2025-04-17 17:48:20,218 - INFO - --- Starting Ligand Comparison Script ---
2025-04-17 17:48:20,355 - INFO - Generating 8192 unique random pairs...
2025-04-17 17:48:32,363 - INFO - Generated 8192 unique pairs.
2025-04-17 17:48:35,397 - INFO - Saved list to unique_smiles_for_vina.txt
2025-04-17 17:48:35,414 - INFO - Saved pairs to generated_pairs.csv
2025-04-17 17:48:35,414 - INFO - --- Intermediate files generated. Run Vina using 'unique_smiles_for_vina.txt' ---
2025-04-17 17:48:35,415 - INFO - --- Update affinity_map below and set run_llm_processing=True ---
2025-04-17 17:48:35,415 - INFO - --- Starting LLM Processing ---
2025-04-17 17:55:28,696 - INFO - mol ['Brc1ccc2c(c1)ncn2C1CCN(c2nccc3ccoc23)CC1', 'Brc1ccccc1-c1cnc(CN(Cc2ccccc2)C2COC2)o1', 'C#CC#CC(C)(C)NC(=O)C1(CC=C)CN(C(=O)C(CC=C)OC)C1', 'C#CC(C)(C)C(=O)N[C@H]1CCC[C@H]1C(=O)N1CCC[C@H]2OCC[C@H]2C1', 'C#CC(C)(C)C(=O)N[C@H]1CC[C@@H](C(=O)NCC#Cc2cccnc2)C1', 'C#CC(C)(C)NC(=O)C1(C#C)CCN(C(=O)c2ccc(=O)n(C)c2)C1', 'C#CC(C)(C)NC(=O)c1cn(CCNC(=O)CC2OCCC2C)nn1', 'C#CC(C)(NC(=O)/C(C)=C/CNC(=O)c1cnn(C)c(=O)c1)C1CC1', 'C#CC(C)(NC(=O)CCCN(C)C(=O)C1C[C@H]2CC[C@H]2C1)C1CCC1', 'C#CC(C)(NC(=O)[C@H]1CCN(C(=O)c2snnc2C)C[C@H]1C)C1CC1', 'C#CC(C)C1CCN(C(=O)CN(C(=O)C(F)CCC)C2CCC2)CC1', 'C#CC(C)N(C)C(=O)C1(C)CCN(C(=O)C2COCCN2CC)CC1', 'C#CC(C)N(C)C(=O)[C@H](Cc1c[nH]cn1)NC(=O)CCC(C)OCC', 'C#CC(C)N(C)C(=O)[C@H]1CCCN(C(=O)C2CC3(C2)CC32CC2)[C@H]1C', 'C#CC(C)N(CCCC)C(=O)CCN(C)C(=O)C1=NO[C@H]2COC[C@@H]12', 'C#CC(C)N1CCN(C(=O)CNC(=O)CNC(=O)C(C)CC=C)CC1', 'C#CC(CC)NC(=O)CC1CCN(C(=O)c2cc(CO)n(C)n2)CC1', 'C#CC(CC)NC(=O)[C@@H]1CCCC[C@@H]1NC(=O)C1(CO)CCOCC1', 'C#CC(CC)NC(=O)c1ncoc1CNC(=O)[C@H]1CCN(C)[C@@H]1CC', 'C#CC(CC1CCC1)NC(=O)C[C@@H](O)CNC(=O)CCc1cncs1', 'C#CC(CC1CCC1)NC(=O)NCC12CCCC(C(=O)OC)(CC1)C2', 'C#CC(CNC(=O)C(C)(C)NC(=O)C(C)n1ccc(C)n1)CC1CC1', 'C#CC(CNC(=O)C1CC(O)(CNC(=O)c2cocc2C)C1)C(C)C', 'C#CC(CNC(=O)[C@@H]1CN(C(=O)C2(CO)CCCO2)C[C@H]1CC)OC', 'C#CC(CNC(=O)[C@H](CCNC(=O)c1[nH]cc(C)c1C)OC)C(C)C', 'C#CC(CNC(=O)[C@H](CSCC)NC(=O)CC1CCC(=O)N1)C(C)C', 'C#CC(NC(=O)C(C)C1CCN(C(=O)C(F)C(F)(F)F)CC1)C(C)C', 'C#CC(NC(=O)C(NC(=O)COC1(C#C)COC1)C1(C)CC1)C1CC1', 'C#CC(NC(=O)C1(NC(=O)C=Cc2cc[nH]n2)CC1)c1ccccc1', 'C#CC(NC(=O)C1CCN(C(=O)C2CCOC(C)(C)C2)CC1)C(C)C', 'C#CC(NC(=O)C1CNC(=O)CN1C(=O)CCC(C)(C)C)C(C)OC', 'C#CC(NC(=O)CC1(OC)CN(C(=O)C=CCCC(C)C)C1)C(C)C', 'C#CC(NC(=O)C[C@@H](NC(=O)Cc1cn[nH]c1)C1CC1)C1CCCC1', 'C#CC(NC(=O)N(C)CCn1c(=O)oc2ccccc21)C(C)(C)OC', 'C#CC(NC(=O)NNc1ccc(Cl)c(C(F)(F)F)c1)C1CCOCC1', 'C#CC1(C(=O)N(C)C(C)(C)CC(=O)Nc2ccccc2O)CCCC1', 'C#CC1(C(=O)N(C)C(C)C=C)CCN(C(=O)c2cn(CC=C)nn2)C1', 'C#CC1(C(=O)N(C)C(CC)C2CC2)CN(C(=O)[C@H]2[C@@H]3CN(C)C[C@@H]32)C1', 'C#CC1(C(=O)N(C)C2CCOCC2)CN(C(=O)C(C)N2CC(C)C2)C1', 'C#CC1(C(=O)N(C)C[C@H](O)CC)CCN(C(=O)CCCCCC)CC1', 'C#CC1(C(=O)N(CC)CCNC(=O)C(C(C)C)C2CCC2)CCCC1', 'C#CC1(C(=O)N2CC(C(N)=O)C2)CN(C(=O)C2CCc3nccn32)C1', 'C#CC1(C(=O)N2CC3(CCC3)C2)CN(C(=O)c2ccncc2OC)C1', 'C#CC1(C(=O)N2CCC(C(C)C)CC2)CN(C(=O)CCC(=O)NC)C1', 'C#CC1(C(=O)N2CCCC(F)CC2)CN(C(=O)c2occc2CC)C1', 'C#CC1(C(=O)N2CCN(C(C)C)CC2)CN(C(=O)C(C#N)C(C)C)C1', 'C#CC1(C(=O)N2C[C@H](C(=O)NCC3COC(=O)N3)[C@@H](C(C)C)C2)CC1', 'C#CC1(C(=O)NC(C)C(OC)C2CC2)CN(C(=O)c2ccncc2)C1', 'C#CC1(C(=O)NC(C)CN2CCCC2)CN(C(=O)CCC(C)(C)C)C1', 'C#CC1(C(=O)NC/C(C)=C/CC)CN(C(=O)Cc2ncccc2F)C1', 'C#CC1(C(=O)NC/C=C(\\C)C(=O)N2CC3(CCOC3=O)C2)CC(=O)C1', 'C#CC1(C(=O)NC2(CC)CC2)CCN(C(=O)C2OCCC2(C)C)CC1', 'C#CC1(C(=O)NCC2(C(C)C)CC2)CCN(C(=O)C(C=C)CC)CC1', 'C#CC1(C(=O)NCC2OCCC2C(=O)NCc2cocn2)CCCC1', 'C#CC1(C(=O)NCCOC2CCC2)CN(C(=O)C2CCSC(C)C2)C1', 'C#CC1(C(=O)NCCOCCCF)CN(C(=O)C[C@@H]2CCC[C@H]2O)C1', 'C#CC1(C(=O)NCCc2c[nH]nn2)CCN(C(=O)C2CC2(Cl)Cl)CC1', 'C#CC1(C(=O)NC[C@@H]2C[C@H]2CNC(=O)C=Cc2cnn(C)c2C)CC1', 'C#CC1(C(=O)NC[C@H]2C[C@H]2C(=O)NCC(OC)C(C)(C)C)CC(=O)C1', 'C#CC1(C(=O)NCc2ccns2)CCN(C(=O)CN2CCCC2C)C1', 'C#CC1(C(=O)N[C@@H](CO)CSCC)CCN(C(=O)Cn2cccc2)C1', 'C#CC1(C(=O)Nc2ccc(Cl)cc2)CCN(C(=O)CNC(=O)NC)C1', 'C#CC1(C(=O)Nc2ccc(Cl)nc2C)CN(C(=O)C(C)CC(N)=O)C1', 'C#CC1(C)CCCN(C(=O)[C@@H]2C=C[C@H](NC(=O)[C@H]3C[C@@H]3[N+](=O)[O-])C2)C1', 'C#CC1(C)CCN(C(=O)[C@@H]2C[C@H](OC)CN2C(=O)[C@H]2CC2(F)F)CC1', 'C#CC1(C)CCN(C(C(=O)NCC2CCOC2)c2ncn(C)n2)CC1', 'C#CC1(CNC(=O)C2(NC(=O)C=CC3CCCCC3)CCC2)CCC1', 'C#CC1(CNC(=O)[C@H]2C[C@@H](CNC(=O)c3cc(C)c[nH]3)C2)CCCC1', 'C#CC1(N(C)C(=O)C2(CCNC(=O)CC34CCC(CC3)C4)CC2)CC1', 'C#CC1(N(C)C(C(=O)NCCCOC)[C@H]2[C@@H]3COC[C@@H]32)CCOCC1', 'C#CC1(N(C)CCCSc2ccc([N+](=O)[O-])cc2)CCC(F)(F)CC1', 'C#CC1(NC(=O)C2(NC(=O)[C@H](CC)N(C)C)CC(F)C2)CC(F)(F)C1', 'C#CC1(NC(=O)CC(C)(C)CNC(=O)C(F)(F)C2CC2)CCCOC1', 'C#CC1(NC(=O)C[C@H](C)NC(=O)CCCCCSC)CCC(C)CC1', 'C#CC1(NC(=O)[C@@H]2COCCN2C(=O)c2ncc[nH]2)CCC(C)CC1', 'C#CC1(NC(=O)[C@@H]2[C@H](CNC(=O)C#CC3CC3)C2(C)C)CCCOC1', 'C#CC1(NC(=O)[C@H](CNC(=O)c2csnc2Cl)OC)CCC(C)(C)C1', 'C#CC1(NC(=O)c2csc(CNC(=O)C(F)CCC)c2)CCCOC1', 'C#CC1(O)CCCN(C(=O)C(CC(C)C)NC(=O)C2=CCCC2C)C1', 'C#CC1(O)CCCN(C(=O)C2(C)CCN(C(=O)c3ccsc3Cl)C2)C1', 'C#CC1(O)CCCN(C(=O)NC(CCC(C)C)c2ccc(Cl)cc2)C1', 'C#CC1(O)CCCN(C(=O)[C@@H]2[C@H](NC(=O)c3cn[nH]c3C)C2(C)C)C1', 'C#CC1(O)CCCN(C(=O)c2[nH]ncc2CNC(=O)c2c[nH]nn2)C1', 'C#CC1(O)CCN(C(=O)C2(CCNC(=O)C(=O)NCC3CC3)CC2)C1', 'C#CC1(O)CCN(C(=O)CC(O)CNC(=O)c2cc(C#N)oc2C)C1', 'C#CC1(O)CCN(C(C)C(=O)Nc2cccc3ccc(C)cc23)CC1', 'C#CC1(O)CN(C(=O)C2CCCCCCN2C(=O)C2=CCN(C)C2)C1', 'C#CC1(O)CN(C(=O)C2CCN(C(=O)CCC(CC)CC)C2CC)C1', 'C#CC1(OC)CCN(C(=O)NCC2(c3cccs3)CCOCC2)CC1', 'C#CC1(OC)CN(C(=O)N[C@H]2CCN(C)[C@@H]2c2ccc(F)c(F)c2)C1', 'C#CC1(OCC(=O)N(CC)CC(=O)N2CCCC(C(C)C)C2)COC1', 'C#CC1CC(NC(=O)C2CC3(CCC3)CN2C(=O)CCP(C)(C)=O)C1', 'C#CC1CC2(CC2)CN1C(=O)CCCCNC(=O)C(C)(OC)C(C)C', 'C#CC1CC2CCC1N(C(=O)[C@H]1C[C@@H](NC(=O)Cn3ccnn3)C1)C2', 'C#CC1CCC(NC(=O)C[C@H]2C[C@@H](NC(=O)C3(C)SCCCS3)C2)C1', 'C#CC1CCC(NC(=O)c2nc(CNC(=O)C3(CF)CC3)oc2C)C1', 'C#CC1CCC(NCC2CCSC2(C)C)(c2nnnn2C(C)C)CC1', 'C#CC1CCCCN1C(=O)C1c2c[nH]nc2CN1C(=O)COC(C)C', 'C#CC1CCCN(C(=O)CCCCN(C)C(=O)c2nnsc2C)CC1', 'C#CC1CCCN(C(=O)[C@@H]2CCN2C(=O)c2noc(CC)c2C)CC1', 'C#CC1CCCN1C(=O)c1[nH]ccc1CNC(=O)[C@H]1[C@@H]2CN(C)C[C@@H]21', 'C#CC1CCN(C(=O)C(CNC(=O)CC2CC(=O)C2)C(C)(C)C)CC1', 'C#CC1CCN(C(=O)[C@@H]2[C@H](O)CCN2C(=O)Cn2cc(CO)nn2)C1', 'C#CC1CCN1C(=O)C(NC(=O)c1cc(=O)[nH]c(C)n1)C1(O)CCC1', 'C#CC1CCN1C(=O)C1(C#C)CCN(C(=O)[C@@H](CC(C)C)N(C)C)C1', 'C#CC1CCN1C(=O)c1cncc(CNC(=O)Cc2cccnc2)c1', 'C#CC1CN(C(=O)C(=O)N2CCC(c3nnc(C)o3)CC2)CCN1C', 'C#CC1CN(C(=O)C(O)[C@H](CCC)NC(=O)C2CC3CC(=O)C2O3)C1', 'C#CC1CN(C(=O)C2(CC)CN(C(=O)C3CC(CC)C3)C2)CCN1C', 'C#CC1CN(C(=O)C2CSCCN2C(=O)C(C)CCOC)CCN1C', 'C#CC1CN(C(=O)C=C(C)CCC)CCN1C(=O)CCC(C)(C)C#N', 'C#CC1CN(C(=O)Cc2ccns2)CCN1C(=O)c1ncoc1CC', 'C#CC1CN(C(=O)Cc2cncnc2)CCN1C(=O)c1csc(F)c1', 'C#CC1CN(C(=O)[C@@H](CCNC(=O)C(F)(F)C2CC2)OC)CCN1C', 'C#CC1CN(C(=O)[C@@]23C[C@@H]2CN(C(=O)c2c[nH]c(=O)cn2)C3)CCO1', 'C#CC1CN(C(=O)[C@H]2[C@@H]3CN(C(=O)C(O)c4cncn4C)CC[C@@H]32)C1', 'C#CC1CN(C(=O)c2nc(C)ncc2Cl)CCN1C(=O)CC(C)(C)C', 'C#CC1CN(C(C(=O)NCc2ccco2)C2CC3CCC2O3)CCO1', 'C#CC1COCCC1N1CCN(CCCOc2ccccc2F)CC1', 'C#CCC(C(=O)N1C[C@@H]2C[C@]2(CNC(=O)CCCC(C)C)C1)C1CC1', 'C#CCC(C(=O)NC(C)(C)CNC(=O)[C@H]1OCC[C@H]1C(C)C)C1CC1', 'C#CCC(C(=O)NC1COC2(C1)CN(C(=O)C1CC(=C)C1)C2)C1CC1', 'C#CCC(C)(C)C(=O)N1CC[C@H]2CN(C(=O)Cc3ccon3)C[C@H]2C1', 'C#CCC(C)(C)C(=O)N1C[C@@H](C)N(C(=O)C(CC2CC2)OC)[C@@H](C)C1', 'C#CCC(C)(C)C(=O)NC/C=C(\\C)C(=O)Nc1ccccc1CCC', 'C#CCC(C)(CC)C(=O)NCC(C)(CNC(=O)Cc1ccno1)OC', 'C#CCC(C)(CO)CNC(=O)C(NC(=O)CC1CC(C)C1)C1(C)CC1', 'C#CCC(C)(CO)CNC(=O)C1(CNC(=O)C2CS(=O)C2)CC=CC1', 'C#CCC(C)(NC(=O)C(CSC)OC)C(=O)N1CCOC(C(=C)C)C1', 'C#CCC(C)(NC(=O)C=CC1CCOCC1)C(=O)N1CCC1C(C)O', 'C#CCC(C)(NC(=O)CC1(O)CCCCC1)C(=O)N1CC(=CCC)C1', 'C#CCC(C)(NC(=O)CC1C(C)(C)C1(C)C)C(=O)N(C)C(C)C(N)=O', 'C#CCC(C)(NC(=O)CN1CCSCC1)C(=O)N(C)CCNC(C)=O', 'C#CCC(C)(NC(=O)c1ccc2cc[nH]c2n1)C(=O)N(C)CC#CC', 'C#CCC(C)(NC(=O)c1cnn(C)n1)C(=O)N[C@H]1CC[C@@H](N(C)C)C1', 'C#CCC(C)N(C)C(=O)C(CNC(=O)[C@H]1C[C@@H](N(C)C)C1)CC(C)C', 'C#CCC(C)N(C)C(=O)C1(C)C=CCN1C(=O)C(CN(C)C)N(C)C', 'C#CCC(C)N(C)C(=O)CC1CCCN(C(=O)C2(C(C)C)CC2)CC1', 'C#CCC(C)NC(=O)C1(COC)CN(C(=O)c2cc(C)c(=O)[nH]n2)C1', 'C#CCC(C)NC(=O)C[C@H]1C[C@H](NC(=O)c2cccc3[nH]ncc23)C1', 'C#CCC(C)NC(=O)c1conc1CNC(=O)c1ccoc1C1CC1', 'C#CCC(CC#C)NC(=O)C=C(C)CNC(=O)C=Cc1cnn(C)c1', 'C#CCC(CC(=O)N1CC(O)(C(F)F)C1)NC(=O)c1ccn[nH]c1=O', 'C#CCC(CC(=O)NC1C2CCCC1COC2)NC(=O)C1CCSC1', 'C#CCC(CC(=O)NCC1(F)CCC1)NC(=O)[C@H]1C[C@@H](N(C)CC)C1', 'C#CCC(CC(=O)NCCC1CC(OC)C1)NC(=O)[C@H]1C[C@@](C)(O)C1', 'C#CCC(CC(F)F)C(=O)NC(CC(=O)N(C)CC(N)=O)C(C)(C)C', 'C#CCC(CC)NC(=O)C1(CNC(=O)CC(=O)OCC)CC12CCC2', 'C#CCC(CCOC)NC(=O)C1CCCN(C(=O)C2(CC)CCC2)C1', 'C#CCC(CO)NC(=O)NC(c1cccc(C(F)(F)F)c1)C(C)(C)C', 'C#CCC(Cc1ccccc1)N(C)C(=O)NC(C)Cc1ccccn1', 'C#CCC(NC(=O)/C=C/C(C)NC(=O)c1c[nH]c(C#N)c1)C(=O)NC', 'C#CCC(NC(=O)C1(NC(=O)c2ccoc2)CC1(C)C)C(=O)OCC', 'C#CCC(NC(=O)C1CN(C(=O)CC=CC)CCC1(C)C)C(=O)OC', 'C#CCC(NC(=O)CN1CCN(C(=O)CC2CCC2)CC1)C(=O)NC', 'C#CCC(O)C(=O)N(C)C1CC(C(=O)N2CCN(C)C(C3CC3)C2)C1', 'C#CCC(O)C(=O)N1CC[C@@H](CC(=O)N2CCC(NC(N)=O)CC2)C1', 'C#CCC(O)C(=O)N1CC[C@H]2CN(C(=O)c3cc(C(N)=O)c[nH]3)C[C@H]21', 'C#CCC(O)C(=O)N1C[C@H]2CCC[C@H]2[C@H]1C(=O)NCC(=O)NC(C)C', 'C#CCC(O)C(=O)NC(CC1CCC1)C(=O)NCC1(CC(C)C)CC1', 'C#CCC(O)C(=O)NC(Cn1cncn1)C(=O)N[C@H]1CCCC[C@H]1F', 'C#CCC1(C(=O)N2C(C(=O)NC3CCSC3)CCC23CC3)CCCC1', 'C#CCC1(C(=O)N2CC3C=CCC(C3)C2)CCN(C(=O)COCC)C1', 'C#CCC1(C(=O)N2CCCC2C(=O)NCc2ncc(C)o2)CCCO1', 'C#CCC1(C(=O)N2CCCC[C@@H]2C(=O)NCCCS(N)(=O)=O)CCC1', 'C#CCC1(C(=O)N2CCOC(C(=O)NCc3cncs3)C2)CCOC1', 'C#CCC1(C(=O)NCC2CCCCN(C(=O)C=CC3CC3)C2)CCC1', 'C#CCC1(C(=O)NC[C@H]2CC[C@@H]2NC(=O)C(F)C(C)C)CCOCC1', 'C#CCC1(C(NCC(CCC)CCO)c2nnnn2C)CCOCC1', 'C#CCC1(NC(=O)C(CNC(=O)C#CC2CCOCC2)C(C)C)CC1', 'C#CCC1(NC(=O)C2(NC(=O)C3CC(OCC)C3)CC2)CCCCC1', 'C#CCC1(NC(=O)C2CN(C(=O)c3conc3CC)C(C)(C)C2)CC1', 'C#CCC1(NC(=O)C2N(C(=O)CC(O)C(C)C)CCC2(C)C)CCC1', 'C#CCC1(NC(=O)C[C@H](CC)N(C)C(=O)C2CCN(OC)CC2)CC1', 'C#CCC1(NC(=O)[C@@H]2[C@H](NC(=O)c3ccnc(OC)c3)C2(C)C)CC1', 'C#CCC1(O)CCN(C(=O)CN(C)C(=O)C2(C)CC3(CCC3)C2)CC1', 'C#CCC1CCCCN1C(=O)[C@@H](NC(=O)c1cc(Cl)n(C)n1)C1CC1', 'C#CCC1CCCCN1C(=O)[C@H](CSCC)NC(=O)C1COCOC1', 'C#CCC1CCCCN1C(C(=O)NC1CC1)c1ccc(OC)cc1C', 'C#CCC1CCN(C(=O)CC2(CNC(=O)[C@H]3C[C@@H]3[N+](=O)[O-])CC2)CC1', 'C#CCC1CCN(C(C(=O)NCC=C)c2ccc(C)c(F)c2F)CC1', 'C#CCC1CN(C(=O)C[C@H]2CCN(C(=O)[C@H](C)NC(N)=O)C2)CCO1', 'C#CCC1CN(C(=O)[C@H]2C[C@H]2CNC(=O)Cc2ccc(C)o2)CCO1', 'C#CCCC(=O)N(CCN(C)C(=O)C1CN2CCN1C(C)C2)C(C)C', 'C#CCCC(=O)N1CCCC2(CNC(=O)CCCCCC)CCCC12', 'C#CCCC(=O)N1CC[C@H](O)[C@@H](NS(=O)(=O)[C@H]2C[C@H](C(=O)OC)C2)C1', 'C#CCCC(=O)N1C[C@H]2[C@@H](NC(=O)C(C)OC3CCOC3)CO[C@H]2C1', 'C#CCCC(=O)NC(C)(C)C(C)CC(=O)NC(C)c1nc(C)oc1C', 'C#CCCC(=O)NC(C)(CC)CCNC(=O)CN1C(=O)CN(C)C1=O', 'C#CCCC(=O)NC(C)C1CCCCN1C(=O)CN1CC(=O)NC1=O', 'C#CCCC(=O)NC(CNS(=O)(=O)c1cnn(CC)c1)CC(F)(F)F', 'C#CCCC(=O)NC1CCC(N(C)C(=O)Cc2c(C)noc2C)CC1', 'C#CCCC(=O)NCC(C)(Cn1cccn1)NC(=O)C1CCC1(F)F', 'C#CCCC(=O)N[C@H](Cc1ccccc1Br)C(=O)NCC(CC)CC', 'C#CCCC(O)CCNC(=O)C(C)(CC#C)NC(=O)c1cc(C)no1', 'C#CCCC(O)CCNC(=O)C1C=CCN1C(=O)CN1CCNC1=O', 'C#CCCC1CN(C(=O)C(CCCC=C)NC(=O)C2COCOC2)C1', 'C#CCCC1CN(C(=O)C2CC(C)(C)CN2C(=O)c2ccc(F)s2)C1', 'C#CCCC1CN(C(=O)[C@@H]2C[C@H](O)CCN2C(=O)c2cc(C)co2)C1', 'C#CCCCC(=O)N1CC(NC(=O)C[C@H]2C[C@H]3CC[C@@H]2O3)CCC1C', 'C#CCCCC(=O)N1CC2CCC(C1)N(C(=O)/C(C)=C/C(C)(C)C)C2', 'C#CCCCC(=O)N1CCC(CC#C)(C(=O)NCC(F)C2CCC2)C1', 'C#CCCCC(=O)N1CCC(CCC(=O)NCc2cc(=O)cc[nH]2)C1', 'C#CCCCC(=O)NCCC1(C(=O)NC[C@H]2CC[C@H]2C(=O)OC)CC1', 'C#CCCCC(=O)NCCC1CCN(C(=O)C2(C)CS(=O)(=O)C2)CC1', 'C#CCCCC(C)C(=O)N1C[C@@H](F)C[C@@H]1CNC(=O)Cn1nccn1', 'C#CCCCCC(=O)N1CCC(NC(=O)C(O)C=CC)C2(CCC2)C1', 'C#CCCCCC(=O)N1CCN2CCN(C(=O)CCCC#C)CC2C1', 'C#CCCCCC(=O)N1C[C@H](N=[N+]=[N-])C[C@@H]1C(=O)N[C@H](CC)CCO', 'C#CCCCCC(=O)NC(C(=O)N1CCCC(C)(CC)CC1)C(C)C', 'C#CCCCCC(=O)NC1(CNC(=O)C2=C(C)CCC2)CCOCC1', 'C#CCCCCC(=O)NCCCCNC(=O)c1cccc2ccoc12', 'C#CCCCCC(=O)N[C@H](C(=O)Nc1cccc2c1CCO2)C(C)C', 'C#CCCCCC(=O)N[C@H]1CCN(C(=O)c2ocnc2CC)[C@@H](C)C1', 'C#CCCCCCC(=O)N1CCC=C(C(=O)NC2CC(CSC)C2)C1', 'C#CCCCCCC(=O)NC1(C(=O)NC2(C)CCCCC2C)CCC1', 'C#CCCCCCCC(=O)N1CCOC(C(=O)N2CCC2C=C)CC1', 'C#CCCCCCNC(=O)C(CNC(=O)C1(C#N)CCCC1)N(C)C', 'C#CCCCN(C)C(=O)CC1CN(C(=O)c2cnc(N)nc2)CCO1', 'C#CCCCN(C)C(=O)C[C@H]1CCCCN1C(=O)C(C)OCCOC', 'C#CCCCN(C)C(=O)[C@@H]1CC(F)(F)CN1C(=O)C(CC)NC(C)=O', 'C#CCCCN(C)CCCNC(=O)N1CCOCC1c1ccccc1', 'C#CCCCNC(=O)/C=C/C1CCCN1C(=O)CCNC(=O)COC', 'C#CCCCNC(=O)C(NC(=O)COC1CCCC1)c1cn(C)nn1', 'C#CCCCNC(=O)C(OC)C1CN(C(=O)c2ccn(C3CC3)n2)C1', 'C#CCCCNC(=O)C1CC2CC1CN(C(=O)CCN(CC)CC)C2', 'C#CCCCNC(=O)CC1=CCN(C(=O)c2ccc(C)[nH]c2=O)CC1', 'C#CCCCNC(=O)CCCC1(NC(=O)c2sc(C)nc2C)CCC1', 'C#CCCCNC(=O)[C@@H]1[C@H]2CC[C@H](C2)[C@@H]1NC(=O)CC1(C)CCOC1', 'C#CCCCOCC(=O)N1CC(C)(C)C[C@@H]1C(=O)N1CC(OCC)C1', 'C#CCCCOCC(=O)N1CCC(/C=C/C(=O)NC(C)CC=C)CC1', 'C#CCCCOCC(=O)N1CCCC(CNC(=O)C(C)=CC2CC2)C1', 'C#CCCCOCC(=O)NC(CC=C)C(=O)N1CCCC(O)(CC)C1', 'C#CCCCOCC(=O)NC1(C(=O)NC23CC(F)(C2)C3)CCCC1C', 'C#CCCCOCC(=O)N[C@@H]1CN(C(=O)c2cc(Cl)n(C)n2)C[C@@H]1C', 'C#CCCCOCC(=O)N[C@]1(C)C[C@H](NC(=O)C2CC(C)(C)CO2)C1', 'C#CCCCONC(=O)CC1(CNC(=O)C(C)(C)CC(C)(C)C)CC1', 'C#CCCN(C)C(=O)C12CCC(CC1)N(C(=O)C(CC)CCOC)C2', 'C#CCCN(C)C(=O)CC1CC(C)(C)CN1C(=O)c1sc(F)cc1C', 'C#CCCN(C)C(=O)[C@H]1CC=C[C@H](NC(=O)c2cn(CC=C)nn2)C1', 'C#CCCN(C)CC(=O)N(C)CCCC(=O)N[C@@H]1[C@H]2CCC(F)(F)[C@H]21', 'C#CCCN(C)CC(=O)N1CC[C@@H](C(=O)NC(CCO)C(C)(C)C)C1', 'C#CCCN(CC(C)(C)C)C(=O)C(=O)N(C)Cc1cccc(OC)n1', 'C#CCCN(CC)C(=O)C(NC(=O)CCCOC(C)=O)c1cccs1', 'C#CCCN(CC)C(=O)CC1CCN(C(=O)C2(C)CCN(C)C2)CC1', 'C#CCCN(CC)C(=O)[C@H]1C[C@@H](OC)CN1C(=O)c1ccc(=O)[nH]n1', 'C#CCCN(CC)C(=O)[C@H]1[C@@H]2CN(C(=O)[C@H](C)n3cnnn3)CC[C@@H]21', 'C#CCCN(CCO)C(=O)C1(CC)CCN(C(=O)C2CC(=C)C2)CC1', 'C#CCCNC(=O)C1(C(C)C)CCN(C(=O)c2nc(C)ccc2F)C1', 'C#CCCOCC(=O)N1CCC(CC(=O)NCC2(CC)CCOC2)C1', 'C#CCCOCC(=O)N1CCCN(c2nc3ccc(N)cc3s2)CC1', 'C#CCCOCC(=O)N1CCC[C@@H]1C(=O)Nc1ccc(CO)c(F)c1', 'C#CCCOCC(=O)N1CCC[C@H]1CN(C)C(=O)CC1CCCC1C', 'C#CCCOCC(=O)N1CCN(C(=O)c2ccc(C(N)=O)s2)C[C@H]1C', 'C#CCCOCC(=O)NCC(C)(C)CC(=O)Nc1cc(Cl)ccc1C', 'C#CCCONC(=O)C12CCC(NC(=O)CCOC3CCC3)(CC1)C2', 'C#CCCONC(=O)C1=CC2(CN(C(=O)c3cnc(CC)o3)C2)OC1', 'C#CCCONC(=O)CC1(C)CCN(C(=O)c2cc(O)cc(=O)o2)C1', 'C#CCCONC(=O)c1csc(CNC(=O)C2(C(=O)OCC)CC2)c1', 'C#CCCOc1ccc(CN(CC2CC2)C2CCC(F)(F)CC2)cc1', 'C#CCC[C@@H](NC(=O)OC(C)(C)C)C(=O)NCc1cc(Cl)nc(Cl)c1', 'C#CCC[C@H](NC(=O)C(CCC)OCC)C(=O)N1CC[C@H](F)[C@H](F)C1', 'C#CCC[C@H](NC(=O)C(OC)OC)C(=O)NC(C)c1cnccc1O', 'C#CCC[C@H](NC(=O)C1C=CCC1)C(=O)N[C@H](CN(C)C)C(C)(C)C', 'C#CCC[C@H](NC(=O)C1CCCCN1CC)C(=O)N[C@H]1C[C@H](CF)C1', 'C#CCC[C@H](NC(=O)C=Cc1cc(C)no1)C(=O)N1CC(OCC)C1', 'C#CCC[C@H](NC(=O)[C@@H]1[C@H]2CCCO[C@H]21)C(=O)NC1C2CCC1CC2', 'C#CCC[C@H](NC(=O)[C@H]1CCCC[C@H]1O)C(=O)N1CCO[C@@H](CO)C1', 'C#CCC[C@H](NC(=O)c1ccc(F)cn1)C(=O)N1CC(O)(CCO)C1', 'C#CCC[C@H](NC(=O)c1nccnc1C)C(=O)N1CCC(CC#C)C1', 'C#CCCn1cc(/C=C/C(=O)NCc2ccccc2C(C)(C)C)cn1', 'C#CCCn1cc(NC2(c3nnnn3CC=C)COCCC2C)cn1', 'C#CCN(C(=O)C(F)C(C)CNC(=O)C1CC(F)(CF)C1)C1CSC1', 'C#CCN(C(=O)C/C=C/CC)C1CCN(C(=O)c2ocnc2C)CC1', 'C#CCN(C(=O)C1CCC(C)C1)C1CCN(C(=O)COCCCC)C1', 'C#CCN(C(=O)C1CCN(C(=O)C=C2CCC2)CC1)c1ccccc1', 'C#CCN(C(=O)Cc1ccsc1)C1CCN(C(=O)Cn2cccn2)C1', 'C#CCN(C(=O)[C@H](NC(=O)CCC(C)OCC)C(C)C)C1CCCC1', 'C#CCN(C(=O)c1cnn(CCO)c1)C1CCN(C(=O)C2CC2)CC1', 'C#CCN(CC#C)C(=O)C[C@@H](NC(=O)c1cnc(C)nc1C)C1CC1', 'C#CCN(CC#CC)C(=O)C1CCN(C(=O)C2=COCCC2)C12CC2', 'C#CCN(CC#CC)C(=O)C[C@@H](CC)NC(=O)C1CCN(CC)CC1', 'C#CCN(CC(=O)N1CC(CO)(CF)C1)C(=O)[C@H]1OC[C@H]2CCC[C@H]21', 'C#CCN(CC(=O)N1CC(OC(=O)NC)C1)C(=O)C1=CCCCC1C', 'C#CCN(CC(=O)N1CCN(CC)CC1C)C(=O)C(O)C1CCCC1', 'C#CCN(CC(=O)N1CCN2CC(C)CC2C1)C(=O)C1CCC(C)C1', 'C#CCN(CC(=O)NC(C)c1cncnc1)C(=O)c1cnncc1C', 'C#CCN(CC(=O)NC1CC(F)(F)C1(C)C)C(=O)CCn1ccnn1', 'C#CCN(CC(=O)NCC(C)(C)CN=[N+]=[N-])C(=O)c1cncc(C)n1', 'C#CCN(CC(=O)NCC(C)(O)C1CCC1)C(=O)c1ccoc1CC', 'C#CCN(CC(=O)NCCCc1cn[nH]c1)C(=O)CC1CCOC1=O', 'C#CCN(CC(=O)NCCc1cccnc1C)C(=O)CC(C)(C)C=C', 'C#CCN(CC(=O)NCc1nn(C)c(=O)o1)C(=O)c1ncoc1CC', 'C#CCN(CC(=O)Nc1cc(F)cc(CC)c1)C(=O)c1ccncc1', 'C#CCN(CC(=O)Nc1ccn(C(C)CC)n1)C(=O)Cn1cnnn1', 'C#CCN(CC(F)(F)F)C(=O)C(=O)NC(CF)c1ccc(OC)cc1', 'C#CCN(CC(F)F)C(=O)[C@H]1CC[C@H]1CNC(=O)CC(C)C(=O)OC', 'C#CCN(CC)C(=O)C[C@H]1C[C@H](F)CN1C(=O)c1ccc(C)[nH]c1=O', 'C#CCN(CC)C(=O)c1coc([C@H](C)NC(=O)CCC2OCCO2)n1', 'C#CCN(CC)C(=O)c1oc(CNC(=O)CNC(=O)C2CC2)nc1C', 'C#CCN(CC1CC1)C(=O)C1CCCN1C(=O)c1cc(CC)n(C)n1', 'C#CCN(CC1CC1)C(=O)CCCC(CC)NC(=O)c1c[nH]c(=O)o1', 'C#CCN(CC1CC1)C(=O)c1occc1CNC(=O)C1(OCC)CC1', 'C#CCN(CC=C)C(=O)C(C)(C)CCNC(=O)CC1CCCN(C)C1', 'C#CCN(CC=C)C(=O)[C@H]1C[C@@H]1C1CN(C(=O)C(F)C(CC)CC)C1', 'C#CCN(CCC(=O)N1CC=CC1COC)C(=O)CCCC(C)(C)C', 'C#CCN(CCC(=O)N1CCC(CC)CC1)C(=O)CCC(C)(C)C#N', 'C#CCN(CCC(=O)N1C[C@@H]2[C@H](C1)[C@H]2C(=O)NC)C(=O)[C@H]1C[C@@H](O)C1', 'C#CCN(CCC(=O)NC1CCN(C(N)=O)C1)C(=O)C(=O)NC(C)C', 'C#CCN(CCC(=O)NCC=CC1CC1)C(=O)c1cnn(CCO)c1', 'C#CCN(CCC(=O)NCCN(C)C(=O)C1CC1)C(=O)C=C=C(C)C', 'C#CCN(CCC(=O)Nc1ccc(CCO)cc1)C(=O)C1=C(C)CC1', 'C#CCN(CCF)C(=O)[C@H]1C[C@@H]1C1CN(C(=O)C2(C(C)C)CCC2)C1', 'C#CCN(CCO)C(=O)C1CN(C(=O)C2CCCOC2)C2(CCC2)C1', 'C#CCN(CCO)C(=O)[C@@H]1[C@H]2CC[C@H](C2)N1C(=O)C(C)n1cccc1', 'C#CCN(CCOC)C(=O)[C@H]1CC(C)(C)CN1C(=O)C(O)CCCC', 'C#CCN(Cc1ccco1)C(=O)C1(N(C)C(=O)CCC(C)OC)CC1', 'C#CCN(Cc1ccco1)C(=O)c1cc(CNC(=O)C2CCO2)n[nH]1', 'C#CCN(OC)C(=O)[C@]1(C)CN(C(=O)c2cc(=O)[nH]c(=O)[nH]2)C[C@H]1C', 'C#CCNC(=O)CC(=O)N1CCCCCC1C(=O)N[C@@H]1COC(=O)C1', 'C#CCNC(=O)CC(=O)N1CCN(C(=O)C(C)NC(C)=O)C2(CC2)C1', 'C#CCNC(=O)CC(=O)N1CCO[C@H](C(=O)NCCC2(CO)CC2)C1', 'C#CCNC(=O)CC(=O)NC1(CC(=O)NC2CC23CCCC3)CCC1', 'C#CCNC(=O)CC(=O)NC1CN(C(=O)CCOC)C2(CCOC2)C1', 'C#CCNC(=O)CC(=O)N[C@H]1[C@@H](C(=O)NC2CC(=C3CC3)C2)C1(C)C', 'C#CCNC(=O)CNC(=O)[C@H]1C=C[C@@H](NC(=O)CC2CC(F)(F)C2)C1', 'C#CCNC(=O)c1ccccc1NC(=O)Cc1ccc(Cl)cc1OC', 'C#CCOC(=O)CNC(=O)C(CC(F)F)N(C)C(=O)C[C@H](C)N(C)C', 'C#CCOC(C)C(=O)N1CC(OCCC(=O)N2CCC(C)=C(C)C2)C1', 'C#CCOC(C)C(=O)N1CC2(CC2)C[C@H]1CNC(=O)CC1CCSC1', 'C#CCOC(C)C(=O)N1CCC(CC)(C(=O)NCCOCC=C)CC1', 'C#CCOC(C)C(=O)NC1CCC(NC(=O)CCn2cccn2)CC1', 'C#CCOC(C)C(=O)N[C@H]1C[C@@H](N(C)C(=O)CCN2CCCCC2)C1', 'C#CCOC(C)CNC(=O)C1(NC(=O)Cc2ccccn2)CC(F)C1', 'C#CCOC(C)CNC(=O)CN(C(=O)c1cc(C#N)cs1)C1CCC1', 'C#CCOC1CN(C(=O)C(CC#CC)NC(=O)C2CCC(=O)CC2)C1', 'C#CCOC1CN(C(=O)[C@H](CC(N)=O)NC(=O)Cn2ccc(C)c2)C1', 'C#CCOCC(=O)N1CCC(C)C(NC(=O)[C@H]2CN(C)CCN2C)C1', 'C#CCOCC(=O)N1C[C@H](OC)C[C@@H]1C(=O)NCC1CC2(CCC2)C1', 'C#CCOCC(=O)N1[C@@H]2CC[C@H]1CN(C(=O)c1cc3c(s1)CCC3)C2', 'C#CCOCC(=O)NC(C)(CNC(=O)Cn1cn[nH]c1=O)C1CCC1', 'C#CCOCC(=O)NC[C@H]1CN(C(=O)C(CC)(CC)C(C)C)C[C@H]1O', 'C#CCOCCC(=O)N(CC#C)C1CCN(C(=O)Cn2cccc2)C1', 'C#CCOCCC(=O)NCC(C(=O)N(C)C1CCOCC1C)N(C)C', 'C#CCOCCC(=O)NCC[C@@H](C)NC(=O)CC1CCOC(C)(C)C1', 'C#CCOCCC(=O)NCc1ncc(C(=O)NC2(CO)CCC2)cn1', 'C#CCOCCC(=O)N[C@@H]1CCN(C(=O)c2csc(Cl)c2)C[C@H](O)C1', 'C#CCOCCCNC(=O)[C@H]1OCC[C@H]1NC(=O)CC1=CCCCC1', 'C#CCOCCNC(=O)c1ccnc(CNC(=O)C(C)(C)CCC)c1', 'C#CCOCCOCC(=O)N1CCC[C@H](CCNC(=O)[C@H]2C[C@H]2F)C1', 'C#CCOCCOCCNC(=O)c1cc(NC(=O)OC(C)(C)C)cs1', 'C#CCONC(=O)C12CCC(CN(C(=O)CCCn3cncn3)C1)C2', 'C#CCONC(=O)CC1(C)CCN(C(=O)Cc2cccc(C#N)c2)C1', 'C#CCO[C@@H]1CCN(C(=O)C2(C)CCN(C(=O)C=CC3CCC3)C2)C1', 'C#CCOc1c(Cl)cc(CNCCCN2CCCCC2=O)cc1OC', 'C#CCOc1cc(C(=O)O)cc(C(=O)NCc2cccc(C#C)c2)c1', 'C#CCOc1cc(F)ccc1NC(=O)Cc1cc(OC)ccc1OC', 'C#CCOc1cc(N2CCCN(C3(C(=O)OC)CCC3)CC2)ncn1', 'C#CCOc1ccc(CN[C@@H](Cc2ccc(O)cc2)C(=O)O)c(F)c1', 'C#CCOc1cccc(C(=O)NCCc2nc(C(CC)CC)cs2)c1', 'C#CCOc1cccc(NC(=O)N(CC)CCN(C)CC(F)(F)F)c1', 'C#CCSCC(=O)N(C)C1CCN(C(=O)C2CCCCC(=O)N2)CC1', 'C#CCSCC(=O)N(C)CC(C)(C)NC(=O)C(C)Oc1ccccc1', 'C#CCSCC(=O)N(Cc1c[nH]c(C(C)C)n1)CC(C)c1cccs1', 'C#CCSCC(=O)N[C@@H](CC(=O)Nc1cccn2nccc12)C(C)C', 'C#CCSCCN1C(=O)CCN(CC2(c3ccc(F)cn3)CC2)C1=O', 'C#CCSCCNC(=O)C1CC(C)CCN1C(=O)Cc1nonc1C', 'C#CCSCCNC(=O)C1CC(O)(CNC(=O)C2(C)CCNC2=O)C1', 'C#CC[C@H](CC(=O)N(C)C[C@H]1COC(=O)N1)NC(=O)c1cscc1C', 'C#CC[C@H](CC(=O)NCC(=O)N(C)O)NC(=O)C1(c2ccno2)CC1', 'C#CC[C@H](CC(=O)NCC(C)(C)CN=[N+]=[N-])NC(=O)c1sccc1Cl', 'C#CC[C@H](CC(=O)NCCC(C)C(F)F)NC(=O)C1(SC)CC(=O)C1', 'C#CC[C@H](CC(=O)NCCC(C)N(C)C)NC(=O)C1(CC)CCCC1', 'C#CC[C@H](CC(=O)NCCCc1nncs1)NC(=O)c1ccncc1', 'C#CC[C@H](CC(=O)NCc1cncn1C)NC(=O)CC(O)C(C)CC', 'C#CC[C@H](CC(=O)NCc1coc(C)n1)NC(=O)c1nocc1CC', 'C#CC[C@H](CC(=O)NCc1nccc(O)c1O)NC(=O)C(C)(C)CC', 'C#CC[C@H](CC(=O)NOCC1CCOCC1)NC(=O)[C@@H]1CCCN1C', 'C#CC[C@H](CC(=O)NOCCCC=C)NC(=O)[C@H]1[C@@H]2CCCCC[C@@H]21', 'C#CC[C@H](CC(=O)N[C@H]1CC[C@H](O)CC1)NC(=O)C1(O)CCCCC1', 'C#CC[C@H](CC(=O)Nc1ccc(C2CC2)nc1)NC(=O)CC(C)(C)O', 'C#CC[C@]1(O)C[C@@H](C(=O)NC(C)(C)CCC(=O)N(C)CCCSC)C1', 'C#CCn1cc(C(=O)N(Cc2csc(C3CC3)n2)CC2CC2C)nn1', 'C#CCn1cc(C(=O)N2CCCC3(CCc4ccccc4O3)C2)nn1', 'C#CCn1ccc(CN(Cc2nn(C)cc2Cl)CC(C)(CC)CC)c1', 'C#CCn1cccc1C(=O)NC(C)/C=C/C(=O)N1CCC(CCO)C1', 'C#CCn1ccnc1C(C(=O)NC(C)(C)C)N(C)Cc1cnn(C)c1', 'C#CCn1cnc2ncnc(NCc3cccc4ccc(Cl)cc34)c21', 'C#C[C@@H](CC(C)C)NC(=O)C(NC(=O)[C@H]([C@@H](C)OC)N(C)C)C(C)C', 'C#C[C@@H](NC(=O)[C@H]1[C@H]2CCC[C@H]2CN1C(=O)Cc1ccns1)C(C)C', 'C#C[C@@H]1CC2(CC2)CN1C(=O)C(=O)N1CCC2(CCCCCC2)CC1', 'C#C[C@@H]1CN(C(=O)CN(CC(C)C)C(=O)[C@H](C)n2cnnn2)C[C@H]1O', 'C#C[C@@H]1CN(C(=O)C[C@@H](NC(=O)c2ccc(C)o2)[C@@H](C)OC)C[C@H]1O', 'C#C[C@H](NC(=O)CC(C)CNC(=O)CC1CC(C2CC2)C1)C1CCC1', 'C#C[C@H](NC(=O)C[C@@H]1C[C@@H](O)CN1C(=O)CC1(COC)CC1)C(C)C', 'C#C[C@H]1CCC[C@@H](CNC(=O)N2CCn3c(CC(C)C)nnc3C2)C1', 'C#C[C@H]1CCC[C@@H](CNS(=O)(=O)CC2CCC3(CCCCCC3)O2)C1', 'C#C[C@H]1CCC[C@@H](NC(=O)[C@H](CCC)NC(=O)C2CC(C(C)C)C2)C1', 'C#C[C@H]1CCC[C@@H]1C(=O)N(Cc1cc(C)ns1)C[C@H]1C[C@@H]1C(C)(C)C', 'C#C[C@H]1CCC[C@H]1NC(=O)C12CC(NC(=O)C[C@H]3C[C@@H]3C3CC3)(C1)C2', 'C#C[C@H]1CC[C@@H](NC(=O)C(F)C(C)CNC(=O)[C@H]2CN(C)C(=O)N2)C1', 'C#C[C@H]1CN(C(c2nnnn2CCCSC)C2(CC)CC2)C[C@@H]1OC', 'C#C[C@H]1C[C@H]2C[C@@H]1CN2C(=O)Nc1cccc(NC(=O)NN(C)C)c1', 'C#C[C@]1(O)C[C@@H](C(=O)N2C[C@H](C)C[C@H]2C(=O)Nc2cc(C)n(C)n2)C1', 'C#C[C@]1(O)C[C@@H](C(=O)NCCCNC(=O)CNC(=O)OC(C)(C)C)C1', 'C#C[C@]1(O)C[C@@H](C(=O)NCCCOCCC(=O)N2CC[C@H]3CC[C@H]32)C1', 'C#C[C@]12CCC[C@H]1CN(Cc1cncc(OCc3ccccc3)c1)C2', 'C#Cc1c(C)cc(Cl)cc1NC(=O)N1CC[C@@H](C(C)(C)C)C[C@H]1CO', 'C#Cc1cc(Br)cc(F)c1NC(=O)C(=O)NC(CCNC)C(C)(C)C', 'C#Cc1cc(C(=O)Nc2nc(-c3cc(C)ccc3C)c(C)s2)ccn1', 'C#Cc1cc(F)cc(C(=O)N(CCNC(=O)[C@@H]2CCN2C)C2CC2)c1', 'C#Cc1cc(F)cc(NCC(O)COC2CCCc3ccccc32)c1', 'C#Cc1cc(N)cc(C(=O)N2CCCN(C(=O)C(F)(F)CC)CC2)c1', 'C#Cc1cc(N)cc(C(=O)NC(C)CNC(=O)[C@@H]2C[C@H](O)CN2C)c1', 'C#Cc1ccc(C(=O)N(C)C(C)(C)CC(=O)N2C3CSCC2C3)cn1', 'C#Cc1ccc(C(=O)N2CC(NC(=O)CCC(C)OC)C3(CC3)C2)o1', 'C#Cc1ccc(C(=O)N2CCCCC2CC(=O)N(C)C2(C#C)CC2)o1', 'C#Cc1ccc(C(=O)NC(C)C(C)NC(=O)C(F)(F)CC=C)c(F)c1', 'C#Cc1ccc(C(=O)NC(CCCC=C)C(=O)NCC2CC23CC3)o1', 'C#Cc1ccc(C(=O)NC23CC(NC(=O)c4cc(O)ccn4)(C2)C3)o1', 'C#Cc1ccc(C(=O)NCC(F)(C(=O)N2C(C)CC2(C)C)C(C)C)o1', 'C#Cc1ccc(C(=O)NC[C@H]2CC[C@H]2NC(=O)CN(C)C(N)=O)nc1', 'C#Cc1ccc(C(=O)N[C@H](C)CCNS(=O)(=O)CC(C)COC)cn1', 'C#Cc1ccc(C(=O)N[C@H](CO)C(=O)N(CCCC)CCCC)nc1', 'C#Cc1ccc(C(=O)N[C@H]2CCC[C@H]2C(=O)NCC(C)CC2CC2)o1', 'C#Cc1ccc(C)c(NC(=O)C(CC2CC2)NC(=O)c2cnco2)c1', 'C#Cc1ccc(C)c(NC(=O)NC2CCN(c3ncc[nH]c3=O)C2)c1', 'C#Cc1ccc(CNC(=O)[C@H](CCNC(=O)C(O)CSC)OC)cc1', 'C#Cc1ccc(Cl)c(C(=O)NCC2CCN(c3ncncc3Cl)C2)c1', 'C#Cc1ccc(F)c(C(C(=O)NCCSC)N2CCCN(C)CC2)c1', 'C#Cc1ccc(NC(=O)C(C)N(C(=O)C(F)(F)CC)C2CC2)c(C)c1', 'C#Cc1ccc(S(=O)(=O)Nc2cc(S(=O)(=O)NC)ccc2OC)cc1', 'C#Cc1cccc(C(=O)N(C)CCN(C)C(=O)C2(C)CC(C)=NO2)c1', 'C#Cc1cccc(C(=O)N2CCC2CC(=O)NCC(C)C(C)CC)c1', 'C#Cc1cccc(C(=O)NC2CCOCC2C(=O)NC/C=C\\CC)c1', 'C#Cc1cccc(C(=O)NCC(C)CC(=O)NCCCCCO)c1C', 'C#Cc1cccc(CN(Cc2ccc(F)cc2CC)CC2CC2Cl)c1', 'C#Cc1cccc(CNC(=O)C2CCN2C(=O)CCC2CCOC2)c1', 'C#Cc1cccc(F)c1NC(=O)N(C)CCOc1ccc(OC)cc1', 'C#Cc1cccc(NC(=O)C2(C)CC(NC(=O)c3csnc3C)C2)c1', 'C#Cc1ccccc1CC(=O)N(CC)CCNC(=O)C1COCCO1', 'C#Cc1ccccc1CC(=O)NC1(C)CN(C(=O)c2nnsc2C)C1', 'C#Cc1cn[nH]c1C(=O)N(CCC1=CCCC1)Cc1ccccc1Cl', 'C#Cc1cn[nH]c1C(=O)NCc1ccoc1C(=O)N1CC(SCC)C1', 'C#Cc1cn[nH]c1C(=O)N[C@H](CC)CC(=O)NCCc1n[nH]c(C)n1', 'C#Cc1cnc(C(=O)N(CCCSCC)Cc2ncnn2C)c(C)c1', 'C#Cc1cnc(NCc2c(OC)cc(C(=O)OC)cc2OC)c(F)c1', 'C#Cc1cnc2ccccc2c1NCc1nc2c(OC)cccc2[nH]1', 'C#Cc1cncc(C(=O)NC2CN(C(=O)c3cc(CO)ccn3)C2)c1', 'C#Cc1cnccc1C(=O)N(Cc1cc(Cl)no1)CC1(C)CC1(C)C', 'C#Cc1cnn(CC(=O)NC(CNC(=O)CCN(C)CC)C(C)C)c1', 'C#Cc1nccc(C)c1NC(=O)C1=CCC(NC(=O)C2CCCC2)C1', 'C/C(=C\\CNC(=O)C1C2CC3C(C2)C31)C(=O)N1CCc2nc[nH]c2C1', 'C/C(=C\\CNC(=O)C1C2CCC(F)C21)C(=O)N1CC(N(C)C2CC2)C1', 'C/C(=C\\CNC(=O)C=Cc1cnccn1)C(=O)N(C)CCC(O)CO', 'C/C(=C\\CNC(=O)CC(=O)N(C)C)C(=O)NC(C)c1cn(C)nc1C', 'C/C(=C\\CNC(=O)CCC1(C)N=N1)C(=O)N(C)Cc1c(C)noc1C', 'C/C(=C\\CNC(=O)CCC1CCC1)C(=O)NC1(C)CCC(C)(C)CC1', 'C/C(=C\\CNC(=O)CC[C@@H]1C[C@H]1C)C(=O)N1CCC(O)C12CCCC2', 'C/C(=C\\CNC(=O)Cc1ncccc1C)C(=O)NCCn1ccnn1', 'C/C(=C\\CNC(=O)[C@H]1C[C@@H]1C(C)(C)C)C(=O)N1CCc2ncsc2C1', 'C/C(=C\\CNC(=O)c1cn(C)cn1)C(=O)N1CC(c2n[nH]c(C)n2)C1', 'C/C(=C\\CNC(=O)c1cnnn1C)C(=O)NCCc1ccc(O)cn1', 'C/C(=C\\CO)C(=O)N(C)CC(CO)(CO)NC(=O)CCc1c[nH]cn1', 'C/C(=C\\CO)C(=O)N[C@H]1CC[C@H]1CNC(=O)c1ccc(N(C)C)cc1', 'C/C(=C\\c1ccccc1)CN(CCC(F)(F)F)C(=O)C1CCC1(F)F', 'C/C=C(\\C)C(=O)N1CC(C)(C)CC1CNC(=O)CCCc1cc[nH]n1', 'C/C=C(\\C)C(=O)N1CCC(C)(CCNC(=O)C(C)OCC2CC2)CC1', 'C/C=C(\\C)C(=O)NC1CCC(N(C)C(=O)CC2COCCOC2)CC1', 'C/C=C(\\C)C(=O)NCC=C1CCN(C(=O)c2cnn(C(C)C)c2)CC1', 'C/C=C/CC(C)C(=O)NC(CCC)CNC(=O)CN1CCNC(=O)C1', 'C/C=C/CC(C)C(=O)NCC(O)CC(=O)N[C@H]1CC[C@@H](C(=O)OC)C1', 'C/C=C/CC(C)C(=O)NC[C@@H](NC(=O)c1nccc(N)c1Cl)C(C)C', 'C/C=C/CC(CC)C(=O)N1C[C@@H]2C[C@H]1CN2C(=O)CCc1ccco1', 'C/C=C/CC(CC)C(=O)NCC(C)=CC(=O)NCCc1ccncc1', 'C/C=C/CC(NC(=O)C(OC)C(C)(C)C)C(=O)N(C)Cc1ccsc1', 'C/C=C/CC(NC(=O)C1CCC(=O)N1)C(=O)N1CC2CCC(C1)C2O', 'C/C=C/CC(NC(=O)CS(C)(=O)=O)C(=O)N1CCCC2(C=CCO2)C1', 'C/C=C/CC(NC(=O)Cc1cncc(C)c1)C(=O)NCc1cnco1', 'C/C=C/CC(NC(=O)[C@H](C)OC(C)(C)C)C(=O)NCC1CC(C)(C)C1', 'C/C=C/CC(NC(=O)c1cccn1CC)C(=O)NCCC(C)(C)CO', 'C/C=C/CCCCC(=O)N1CCC2CC21C(=O)NCC1(C)CC1(C)C', 'C/C=C/CCCNC(=O)Cn1cc(-c2ccc3ccccc3n2)nn1', 'C/C=C/CCCNC(=O)[C@@H]1[C@H]2C[C@@H]1N(C(=O)C=CC1CCOCC1)C2', 'C/C=C/CCCNc1nc2c(c(NCc3ccncc3N)n1)CCC2', 'C/C=C/CCN(Cc1[nH]nc(C)c1Cl)C(=O)c1cc(N)c(C)cc1C', 'C/C=C/CCN(Cc1sccc1CO)C(=O)c1cncc2c1CCC2', 'C/C=C/CN(CC(OCC)C1CCCC1)C(=O)Cn1nc(C)oc1=O', 'C/C=C/CNC(=O)CCCn1cc(-c2cc(C)cnc2C(=O)O)nn1', 'C/C=C/CNc1cccc(S(=O)(=O)NC(C)c2cccc(Cl)c2C)n1', 'C/C=C/[C@H]1CN(C(=O)C2(O)CCC2)C[C@@H]1C(=O)NCCc1cocn1', 'C/C=C/[C@H]1CN(C(=O)C2CC(F)(F)C2)C[C@@H]1C(=O)NCC(=O)NOC', 'C/C=C/[C@H]1CN(C(=O)c2cc3n(n2)CCC3)C[C@@H]1C(=O)N[C@H](C)CF', 'C/C=C\\CNC(=O)Nc1ccc(Oc2cccc3cccnc23)cc1', 'C1CC2OC1CC2NC1(c2nnnn2C2COC2)CC[C@H]2CO[C@@H]1O2', 'C1COC(Cn2nnnc2C2(NCC3CC3)CCCN(C3CC3)C2)C1', 'C=C(C(=O)N(Cc1ccc(F)cc1)Cc1cnc(C)s1)C1CCCC1', 'C=C(C)C(C)(C)C(=O)N(Cc1cc(COC)on1)CC(C)(CC)CC', 'C=C(C)C(C)(C)C(=O)N1CCC(CCNC(=O)CC2CN(C)C2)CC1', 'C=C(C)C(C)(C)C(=O)N1CCC(N(C)C(=O)CCn2cnnn2)CC1', 'C=C(C)C(C)(C)C(=O)NCCC1(C(=O)NCCCc2ncco2)CC1', 'C=C(C)C(CC(=O)N[C@H]1[C@@H]2CN(C(=O)CC3=CCCC3)C[C@@H]21)OCC', 'C=C(C)C1CN(C(=O)C23CC(CN2C(=O)C=CC=CCC)C3)CCO1', 'C=C(C)CC(=O)N1CCC2(CC1)CCN(C(=O)c1cnn(C)c1C)C2', 'C=C(C)CC(=O)NC[C@H]1CC[C@@H](NC(=O)C(C)c2ccccc2F)C1', 'C=C(C)CC(=O)N[C@H]1CCCC[C@H]1NC(=O)Cn1cc(C(F)F)cn1', 'C=C(C)CC(CN1CCOc2ccc(Br)cc21)NC(=O)OC(C)(C)C', 'C=C(C)CC(NC(=O)C(F)=C1CCCCC1)C(=O)NCCS(C)(=O)=O', 'C=C(C)CC(NC(=O)C=CC(C)C)C(=O)NCC1C2CCCCCC21', 'C=C(C)CC(NC(=O)CC(C)CC(C)C)C(=O)N1CC2(CN(C)C2)C1', 'C=C(C)CC(NC(=O)CC1=CCOCC1)C(=O)N1C[C@H]2CCC=C[C@H]21', 'C=C(C)CC(NC(=O)CSCCC(C)C)C(=O)N1CCC(C)(CO)C1', 'C=C(C)CC(NC(=O)c1c[nH]nc1OC)C(=O)N(C)C(C)CC(C)C', 'C=C(C)CC(OC)C(=O)N(CC)CCNC(=O)Cn1c(C)ccc1C', 'C=C(C)CC(OC)C(=O)N(CC1CCN(C)CC1)CC(C)C(C)(C)C', 'C=C(C)CC(OC)C(=O)N1C2CC1CN(C(=O)Cn1nnc(N)n1)C2', 'C=C(C)CC(OC)C(=O)N1CCC2(CCCN(C(=O)CCSC)C2)C1', 'C=C(C)CC(OC)C(=O)NC(C)C1(C(=O)N2CC(C)CC(C)C2)CC1', 'C=C(C)CC(OC)C(=O)N[C@@H](CC)C(=O)NCCN1C(=O)CNC1=O', 'C=C(C)CCCC(=O)N1CCN(C)CC1C(=O)NC1C(C)(C)C1(C)C', 'C=C(C)CCCC(=O)N1CCN(C)CC1CNC(=O)C[C@H]1CC[C@H]1C', 'C=C(C)CCCC(=O)N[C@@H](C)[C@@H](CO)NC(=O)Cc1c(C)n[nH]c1C', 'C=C(C)CCCC(=O)N[C@@H]1CN(C(=O)c2cc(C)ncc2C)C[C@H]1O', 'C=C(C)CCCNC(=O)C1(C)CN(C(=O)C2CC23CCC3)C(C)(C)C1', 'C=C(C)CCCNC(=O)C1=CCCN(C(=O)c2oc(CC)cc2C)C1', 'C=C(C)CCCNC(=O)[C@@H]1CC[C@H](NC(=O)C(C)=Cc2cn[nH]c2)C1', 'C=C(C)CCONC(=O)C1(CNC(=O)Cn2nccn2)CC2(CC2)C1', 'C=C(C)CN(C)C(=O)C12CCC(CC1)N(C(=O)C1(OC)CCOC1)C2', 'C=C(C)CN(C)C(=O)c1cc(CNC(=O)C(C)N2CCOCC2)no1', 'C=C(C)CN(C)C(C(=O)NCC1CCOCC1)c1nnc2n1CCC2', 'C=C(C)CN(CC(=C)C)C(=O)[C@@H](NC(=O)[C@@H]1C[C@H]1CC(C)C)C(C)C', 'C=C(C)CN(CC)C(=O)C(C)N1CCOC(c2cccc(F)c2F)C1', 'C=C(C)CN(CC)C(=O)C(C)NC1CCc2ccc(C(=O)OC)nc21', 'C=C(C)CN(CC)C(=O)[C@@H]1[C@H](CNC(=O)C2C(C)(C)C2(C)C)C1(C)C', 'C=C(C)CN(Cc1cnn(C(C)C)c1)C(=O)c1cnn2ncccc12', 'C=C(C)CNC(=O)C(CCCCCO)N1CCOc2ccncc2C1', 'C=C(C)CNC(=O)C(c1cc(C(=O)OC)c(C)o1)N(CC#N)C1CC1', 'C=C(C)CNC(=O)C(c1ccc(C2CC2)cc1F)N1CCCC(=C)C1', 'C=C(C)CNC(=O)C(c1cncnc1)N1CCC(C(=O)NCC)CC1', 'C=C(C)CNC(=O)C(c1csnc1C)N1C[C@@H](OC)C[C@H]1CN(C)C', 'C=C(C)CNC(=O)C1(C2CCN(C(=O)C=CCC)CC2)CCOCC1', 'C=C(C)CNc1c(-c2c(Cl)cncc2OC)nc2c(F)cc(Br)cn12', 'C=C(C)COCC(=O)N(CCOC)CC(=O)N1CC2(CCOC2=O)C1', 'C=C(C)COCC(=O)N1C[C@@H](O)C[C@@H]1C(=O)N1CC(=O)NC2(CC2)C1', 'C=C(C)COCC(=O)NC(C(=O)N[C@@H](C)CS(N)(=O)=O)C1CCCC1', 'C=C(C)COCC(=O)NCC(C)(O)CNC(=O)c1cc(Cl)[nH]c(=O)c1', 'C=C(C)COCC(=O)NC[C@H]1C[C@H](CNS(=O)(=O)c2csc(C)c2)C1', 'C=C(C)COCCN(C[C@H]1C[C@@H]1c1cccs1)C(=O)C[C@@H]1CCOC1', 'C=C(C)COCCNC(=O)C1(C2CC2)CN(C(=O)CC2CC2(C)C)C1', 'C=C(C)COCCNC(=O)C=C(C)CNC(=O)c1cn(C)c(=O)cn1', 'C=C(C)COCCNC(c1ccc(F)cc1)c1nnnn1C(C)(C)C', 'C=C(C)CONC(=O)/C=C/C1CCN(C(=O)C2(C)CCSCC2)CC1', 'C=C(C)CONC(=O)CC[C@@H]1CCCN(C(=O)[C@@H]2C[C@H]2CCOC)C1', 'C=C(C)CONC(=O)[C@@H]1CN(C(=O)C(F)C2CCCCC2)C[C@H]1OC', 'C=C(C)Cn1nnnc1C(C)(COC(C)(C)C)NC1C2CCC1CC2', 'C=C(C)Cn1nnnc1C(NCC1CCSC1)c1cnn(C)c1CC', 'C=C(C)Cn1nnnc1C(NCCC(C)(C)C)c1ccc(C2CC2)o1', 'C=C(C)[C@@H]1CC=C(CNC(=O)Nc2cc(OC)c(OC)cc2Br)CC1', 'C=C(C)[C@@H]1CCC(C)=C[C@@H]1CC(=O)NCc1cccc2c1OCCO2', 'C=C(C)[C@@H]1OCCC[C@H]1C(=O)N1CC(S(=O)(=O)c2cccc(F)c2)C1', 'C=C(C)[C@H]1OCC[C@H]1C(=O)N(CCSCC)Cc1ccc(C2CC2)o1', 'C=C(C)[C@H]1OCC[C@H]1C(=O)NCC(C)(C)C#CC(=O)Nn1ccnn1', 'C=C(C)c1cccc(NC(=O)CN(C)C(=O)c2cc(C)c(=O)[nH]n2)c1', 'C=C(C)c1cccc(NC(=O)N[C@H]2CCOc3ccc(OC)cc32)c1', 'C=C(C)c1cn(C2CCC(C(=O)N(C)C3(COC)COC3)CC2)nn1', 'C=C(CC)C(=O)N(CC1CCCCC1CC)CC1(C)COC(C)(C)O1', 'C=C(CC)Cn1cc(CN(O)C(=O)c2nc3nc(C)ccn3n2)nn1', 'C=C(CNC(=O)/C(C)=C/CNC(=O)c1coc(C)n1)C1CCOCC1', 'C=C(CNC(=O)C12CC(NC(=O)c3ccoc3)(C1)C2)C1CCOCC1', 'C=C(CNC(=O)C1CCOC1CNC(=O)C(=O)CCCC)C(F)(F)F', 'C=C(CNC(=O)N[C@@H](C)c1ccc(-c2cncnc2)cc1)C(F)(F)F', 'C=C(CNC(=O)[C@@H](COC)NC(=O)C(C)S(N)(=O)=O)C1CCOCC1', 'C=C(CNC(=O)[C@@H]1CCCN1NC(=O)C(F)(F)C(O)CC)C(F)(F)F', 'C=C(CNC(=O)[C@H](CC(N)=O)NC(=O)Cc1nocc1C)C(F)(F)F', 'C=C(Cl)CC(NC(=O)CC(C)(C)CCC)C(=O)N(C)Cc1nnc[nH]1', 'C=C(Cl)CCC(=O)N(Cc1cc(F)ccc1O)CC(CO)CC(C)C', 'C=C(Cl)CCC(=O)N1CCC(COC)(NC(=O)[C@H]2C[C@@H]2C2CCC2)C1', 'C=C(Cl)CCC(=O)NC(CC(=O)N1CCOCCC1C1CC1)C(C)C', 'C=C(Cl)CCC(=O)N[C@H]1C[C@H]2C[C@@H]1N(C(=O)C1CN(C(=O)NC)C1)C2', 'C=C(Cl)CCC(=O)N[C@]1(C)CCC[C@H]1NC(=O)c1cccc(=S)n1O', 'C=C(Cl)CNC(=O)C1(CNC(=O)C(C)NC(=O)C2CC2)CCCCC1', 'C=C(Cl)CNc1nc(NCC2CCC(F)(F)C2)nc2cccc(F)c12', 'C=C(Cl)CONC(=O)/C=C/C1CCN(C(=O)C(C)(O)CC(C)C)CC1', 'C=C(Cl)CONC(=O)C(C)C1CCN(C(=O)c2ccnc(O)c2F)C1', 'C=C(F)C1(CC(=O)N(C)c2nc(C)cs2)CN(C(=O)OC(C)(C)C)C1', 'C=C(F)C1(CC(=O)N(CC)C(C)C(=O)NC2CC(C3CC3)C2)CCC1', 'C=C(F)C1(CC(=O)NC(C)C(C)C(=O)N2CC3C(C2)C3(C)C)CCC1', 'C=C(F)C1(CC(=O)NCC(O)C(=O)NCc2c[nH]c(CC)n2)CCC1', 'C=C(F)CNC(=O)C1N(C(=O)CCc2cnccn2)CC12CCCC2', 'C=C(F)CNC(=O)[C@H](Cc1cnn(C)c1O)NC(=O)c1sncc1C', 'C=C/C=C(\\C)C(=O)N(C)C1CCN(C(=O)C[C@@H]2CCCC[C@H]2O)CC1', 'C=C/C=C(\\C)C(=O)N1CCC(O)(CNC(=O)C(C)(C)CN(C)C)CC1', 'C=C/C=C(\\C)C(=O)N1CCCC1CNC(=O)Cc1ccc(F)cc1F', 'C=C/C=C(\\C)C(=O)NCC1(C)CN(C(=O)c2nscc2C)C(C)(C)C1', 'C=C/C=C(\\C)C(=O)NCC1(O)CN(C(=O)C(C)c2cn(C)nc2C)C1', 'C=C/C=C/CC(=O)NC1CC(C(C)NS(=O)(=O)c2cc(C)sc2C)C1', 'C=C/C=C/CCN(Cc1ccc2sccc2c1)C(=O)C(C)(CO)OC', 'C=C1CC(C(=O)N(CCOCCSC)Cc2ccc3c(c2)COC3)C1', 'C=C1CC(C(=O)N2CCCC(C(C)C(=O)NCCCC3CCC3)C2)C1', 'C=C1CC(C(=O)N2CCCC[C@@H]2C(=O)N2CCC(CC3CC3)CC2)C1', 'C=C1CC(C(=O)N2CCN(C(=O)C(CCCC)C(C)C)CC2CC)C1', 'C=C1CC(C(=O)NC(C(=O)NCC(O)c2ccccc2)C2CCC2)C1', 'C=C1CC(C(=O)NC[C@H]2C[C@H]2CC(=O)NCCn2cccnc2=O)C1', 'C=C1CC(C(=O)NCc2cc(C(=O)Nc3ccccc3O)ccn2)C1', 'C=C1CC(C)(C(=O)N2CC3(CC(NC(=O)CCCC/C=C/C)C3)C2)C1', 'C=C1CC(C)(C(=O)NC2C=CCN(C(=O)c3cncc(OC)n3)C2)C1', 'C=C1CC(C)(C(=O)NCC2CN(C(=O)C(CC)OCC)CC2(F)F)C1', 'C=C1CC(C)(NC(=O)C2CNC(=O)CN2C(=O)CCn2cccc2)C1', 'C=C1CC(C)(c2noc(-c3cccc4c5c([nH]c34)CCC(C)C5)n2)C1', 'C=C1CC(CC(=O)N2CC=C(CC(=O)NC3CCC(O)CC3)CC2)C1', 'C=C1CC(CC(=O)N2CCCC(C(=O)N(CC(F)F)C(C)C)CC2)C1', 'C=C1CC(CC(=O)N2C[C@H]3CCC[C@@]3(NC(=O)CC3(CO)CC3)C2)C1', 'C=C1CC(CC(=O)N2C[C@H]3OCCN(C(=O)C(C#N)C(C)C)[C@H]3C2)C1', 'C=C1CC(CC(=O)NC(C)C(C)NC(=O)c2c(F)cc(C)cc2F)C1', 'C=C1CC(CC(=O)NCC(C)(CC)C(=O)NCC2CC3(CCC3)C2)C1', 'C=C1CC(CC(=O)NCC2(O)CN(C(=O)c3c(C)cccc3F)C2)C1', 'C=C1CC(CC(=O)NC[C@H]2CN(C(=O)c3cncs3)C[C@@]2(F)CO)C1', 'C=C1CC(CC(=O)N[C@H]2CC[C@@H](C(=O)N[C@H]3COC[C@@H]3N(C)C)C2)C1', 'C=C1CC(CN(C)C(=O)C(O)C2CN(C(=O)CCc3ccco3)C2)C1', 'C=C1CC(CN(Cc2ccn(CCF)n2)C(=O)c2ccc(CO)s2)C1', 'C=C1CC(CNC(=O)C(CC2CC2)OC)(C(=O)NCC(C)C2CC2)C1', 'C=C1CC(CNC(=O)CC2CC(=O)NC2=O)(C(=O)NCCCCC)C1', 'C=C1CC(CNC(=O)CC2CC=CC2)(C(=O)NCC(CC)CCO)C1', 'C=C1CC(CNC(=O)CCC2CCCO2)(C(=O)NCCC(=O)OC)C1', 'C=C1CC(CNC(=O)[C@H]2OCC[C@H]2C)(C(=O)N(C)C[C@@H]2CCCO2)C1', 'C=C1CC(CNC(=O)c2ncoc2C)(C(=O)N2CC[C@H](F)[C@H](F)C2)C1', 'C=C1CC(N(C)C(=O)C2CC3CCC(C2)N3C(=O)[C@H]2CC[C@H](O)C2)C1', 'C=C1CC(N(C)C(=O)C2CCC(C)(C)N(C(=O)C3CC=CCC3)C2)C1', 'C=C1CC(N(C)C(=O)[C@@H]2C[C@H](NC(=O)c3c(C)n[nH]c3C)[C@@H](O)C2)C1', 'C=C1CC(N(C)C(=O)[C@H]2C[C@@](C)(NC(=O)c3ccc(C(C)=O)[nH]3)C2)C1', 'C=C1CC(NC(=O)C2CCN(C(=O)C(CO)C(C)(C)C)C23CCC3)C1', 'C=C1CC(NC(=O)C[C@@H]2C[C@@H](O)CN2C(=O)Cc2ccnc(O)c2)C1', 'C=C1CC(NC(=O)c2ccccc2NC(=O)c2ccc(OC)cc2)C1', 'C=C1CC1C(=O)N1CC(CNC(=O)C2=CC3(CCOCC3)C2)(OC)C1', 'C=C1CC1C(=O)N1CC2(C(=O)NC3(CCO)CCCC3)CCC1CC2', 'C=C1CC1C(=O)N1CC2CCCC(CNC(=O)c3coc(C)n3)C2C1', 'C=C1CC1C(=O)N1CCN(C(=O)c2ccc(C(C)(C)C)o2)CC(O)C1', 'C=C1CC1C(=O)N1C[C@H](CC(=O)NC2CC3(CNC(=O)O3)C2)[C@@H](C)C1', 'C=C1CC1C(=O)NC(C)[C@@H]1CCCN1C(=O)Cc1cc(F)ccc1F', 'C=C1CC1C(=O)NC1CC2CCC1CN2C(=O)c1ccccc1C#N', 'C=C1CC1C(=O)NC1CCN(C(=O)c2[nH]c(=O)[nH]c2C)CC(C)(C)C1', 'C=C1CC1C(=O)NCC(C)(Cn1cccn1)NC(=O)CCC(C)(C)C', 'C=C1CC2(C1)CN(C(=O)C(CCC)CNC(=O)c1ccc(C)cn1)C2', 'C=C1CC2(C1)CN(C(=O)C1CC3(CC(NC(=O)C(C)OCC)C3)C1)C2', 'C=C1CC2(C1)CN(C(=O)C[C@@H](C)N(C)C(=O)C(C)Cn1ccnc1)C2', 'C=C1CC2CC1CN2C(=O)C1(NC(=O)CCCCCOC)CC1(C)C', 'C=C1CC2CC1CN2C(=O)CC(CNC(=O)OC(C)(C)C)C1CCC1', 'C=C1CC2CCC(C1)N2S(=O)(=O)c1ccc2c(c1)CC(C)(C)C(=O)N2', 'C=C1CC2CCCC(C1)N2C(=O)CC(O)CNC(=O)c1cc(F)c[nH]1', 'C=C1CC2CCCC(C1)N2C(=O)CN(C(=O)CC(=O)OCC)C(C)C', 'C=C1CC2CCCC(C1)N2C(C(=O)NC1CCCC1)c1cc(C)cs1', 'C=C1CCC(C(=O)N(C)[C@@H](CC)CC(=O)N(C)CCOC(F)F)CC1', 'C=C1CCC(C(=O)NC(C(=O)NC2C=CC(C)(C)CC2)C2CC2)CC1', 'C=C1CCC(C(=O)NC(CC)CN(C)C(=O)Cc2coc(C)n2)CC1', 'C=C1CCC(C(=O)NCC2CC(C(=O)N(C3CC3)C3CC3)=NO2)CC1', 'C=C1CCC(C(=O)NCC2COCCN(C(=O)C=CC3CC3)C2)CC1', 'C=C1CCC(C(=O)NCc2ccc(C(=O)NC3C=CCC3)cc2)CC1', 'C=C1CCC(CN(Cc2cncnc2)Cc2nc(OC)c(C)s2)CC1', 'C=C1CCCN(C(=O)C2(CNC(=O)c3ccc(C)nc3)CCCO2)C1', 'C=C1CCCN(C(=O)C2CCC(O)CN2C(=O)CNC(=O)OCC)C1', 'C=C1CCCN(C(=O)CC[C@@H](NC(=O)C2CCC3(CC3)C2)C(C)C)C1', 'C=C1CCCN(C(=O)[C@H]2CC=C[C@H](NC(=O)C(C#N)(CC)CC)C2)C1', 'C=C1CCCN(C(=O)[C@H]2C[C@H]3CC[C@@H]2N3C(=O)[C@@H](C)N(CC)CC)C1', 'C=C1CCN(C(=O)C(=O)C(C)CC)C(C(=O)N2CCC(CSC)C2)C1', 'C=C1CCN(C(=O)C(C)=C2CC2)C(C(=O)NCCCCCCCO)C1', 'C=C1CCN(C(=O)C(Cn2cncn2)NC(=O)c2ccccc2)CC1', 'C=C1CCN(C(=O)C2(C)CC(NC(=O)C3CC4CCC3CC4)C2)CC1', 'C=C1CCN(C(=O)C2CC23CCN(C(=O)c2nc(C)oc2C)CC3)C1', 'C=C1CCN(C(=O)CC(C)C(C)(C)C)C(C(=O)NOCCOCC)C1', 'C=C1CCN(C(=O)CNC=O)C(C(=O)NCC(C)c2ccncc2)C1', 'C=C1CCN(C(=O)CSC(C)(C)C)C(C(=O)NC(C)c2cncs2)C1', 'C=C1CCN(C(=O)C[C@H](CC(C)C)NC(=O)[C@@H](CCCC)N(C)C)C1', 'C=C1CCN(C(=O)c2ccnnc2C)C(C(=O)N(C)CCOCC)C1', 'C=C1COCCN(C(=O)C2=C[C@H](O)[C@H](NC(=O)CCCC3CC3)C2)C1', 'C=C1COCCN(C(=O)CC(C)CNC(=O)c2cncc(OC)n2)C1', 'C=C1COCCN(c2nc(C)cc(NCc3nn(CC)nc3C)n2)C1', 'C=C1CON(C(=O)C(O)[C@H](CCC)NC(=O)c2cc(C)cc(F)c2)C1', 'C=C1CON(C(=O)C2=C[C@H](O)[C@H](NC(=O)c3ccc(C#N)cc3)C2)C1', 'C=C1CON(C(=O)C2CCC3(CC3)N2C(=O)CCCc2c[nH]nn2)C1', 'C=C1CON(C(=O)CCCC(C)(C)NC(=O)CCc2cn(C)cn2)C1', 'C=C1COc2c(C(=O)NCc3ccnc(-n4ccnc4)c3)cnn2C1', 'C=C1COc2c(NS(=O)(=O)Cc3cc([N+](=O)[O-])ccc3Cl)cnn2C1', 'C=C=C(C)CC(=O)N(C)C1CCC(NC(=O)CN2CCN(C)CC2)C1', 'C=C=C(C)CC(=O)N1CC[C@H](O)[C@@H]1C(=O)Nc1cccn(CC)c1=O', 'C=C=C(C)CC(=O)N1C[C@H]2C[C@@]2(NC(=O)C2CCn3cncc3C2)C1', 'C=C=C(C)CC(=O)NC(C)(C)CCCC(=O)NC1COCC1C1CC1', 'C=C=C(C)CC(=O)NCC1(C(=O)N2CC3(CCOC3=O)C2)CC(=C)C1', 'C=C=CC(C)C(=O)N(C)C(C(=O)Nc1cc(F)c(O)cc1C)C1CC1', 'C=C=CC(C)C(=O)N(C)CC1(O)CN(C(=O)CC2COCC2(C)C)C1', 'C=C=CC(C)C(=O)N1CC(NC(=O)c2cc(CCC)on2)C2(CC2)C1', 'C=C=CC(C)C(=O)N1CC=CC(C(=O)NCCc2nnc(C)n2C)C1', 'C=C=CC(C)C(=O)N1CCC(F)(CNC(=O)c2cc3n(n2)CCO3)C1', 'C=C=CC(C)C(=O)NC(C(=O)N[C@H](CCO)C(C)(C)C)c1ccoc1', 'C=C=CC(C)C(=O)NC1(C(=O)N2CC(C)CCC2CC)CCCC1C', 'C=C=CC(C)C(=O)NCCC1(O)CN(C(=O)CCCC(C)(C)C#N)C1', 'C=C=CC(C)C(=O)NCCCC(C)NC(=O)c1cc(O)c(F)cc1N', 'C=C=CC(C)C(=O)NCCCC1(NC(=O)c2cnn(CCC)c2)CC1', 'C=C=CC(C)C(=O)N[C@H](C(=O)N[C@@H](CC(=O)OC)C1CC1)[C@@H](C)OC', 'C=C=CC(C)C(=O)N[C@H]1CC[C@@H](C(=O)NCCOc2cccnc2)C1', 'C=C=CCCC(=O)N1CC2(CC(NC(=O)c3cn(C4CC4)cn3)C2)C1', 'C=C=CCCC(=O)N1CC2CC(NC(=O)c3nccc(C)c3F)C1C2', 'C=C=CCCC(=O)N1CCC(C(F)C(=O)N2CCN(C(C)=O)CC2)C1', 'C=C=CCCC(=O)N1CCC(CNC(=O)C2CNC(=O)CC2C)CC1', 'C=C=CCCC(=O)N1[C@@H]2CC[C@@H](C2)[C@H]1C(=O)N(C)CCCCCCC', 'C=C=CCCC(=O)NC(C)(CC)CCNC(=O)c1ccn(C)c1CC', 'C=C=CCCC(=O)NC(CC(C)C)C(=O)Nc1ccc(CCO)cc1', 'C=C=CCCC(=O)NC(COCC)C(=O)Nc1cccc2c1CCO2', 'C=C=CCCC(=O)NCCC1COCCN1C(=O)c1cncc(F)c1', 'C=C=CCCC(=O)N[C@@H](Cc1c[nH]cn1)C(=O)Nc1cnc(C)nc1', 'C=C=CCCC(=O)N[C@H]1C[C@@H](C(=O)N2C[C@H]3CSC[C@@]3(C)C2)C1(C)C', 'C=C=CCCNC(=O)c1ccnc(CNC(=O)C2C3CCC(F)C32)c1', 'C=C=CCNC(=O)C12CCC(CC1)N(C(=O)C1CNC(=O)CC1C)C2', 'C=C=CCNc1nc(NCC2CCC(C)CC2)nc2c1ncn2CC', 'C=CC(C(=O)N1CCCN(c2ccc(F)cc2)CC1)N1CCNCC1', 'C=CC(C(=O)NCCc1ccc(C(F)(F)F)cc1Cl)c1ccccc1', 'C=CC(C)(C)C(=O)NC1CN(C(=O)c2[nH]nc(C)c2Cl)CC(F)(F)C1', 'C=CC(C)(C)C(=O)N[C@H](CCC(=O)NCc1cncc(O)c1)C(C)C', 'C=CC(C)(C)C(=O)N[C@H]1[C@@H]2CN(C(=O)c3nccc(Cl)c3C)CC[C@@H]21', 'C=CC(C)(C)CC(=O)N(C)C(C)CCNC(=O)c1cc(N)ccc1C', 'C=CC(C)(C)CC(=O)N1CCC(CC(=O)N(CC)CCC(=O)OC)C1', 'C=CC(C)(C)CC(=O)N1CCCC(CC(=O)NC2CC(F)(F)C2)CC1', 'C=CC(C)(C)CC(=O)N[C@@H]1CCN(C(=O)[C@@H](CO)N(C)C)C[C@H]1CO', 'C=CC(C)(C)CCN(Cc1nn(CC)cc1Cl)C(=O)[C@]1(C)C[C@H]1CC', 'C=CC(C)(C)CNC(=O)C12CC1CCN2C(=O)CCc1cn(C)nn1', 'C=CC(C)(C)CNC(=O)[C@@H]1[C@H]2C[C@@H]1N(C(=O)C1(N(C)C)CCCC1)C2', 'C=CC(C)(C)CNC(=O)[C@H](CCNC(=O)c1cccc(OC)c1)OC', 'C=CC(C)(C)NC(=O)C1=C(F)CN(C(=O)c2cncc(F)c2C)CC1', 'C=CC(C)(C)NC(=O)[C@@H]1CN(C(=O)Cc2ncccc2F)C[C@H]1OC', 'C=CC(C)(C)NC(=O)[C@@H]1C[C@H](C)CCN1C(=O)c1cnnc(C)c1C', 'C=CC(C)(CC)C(=O)N1CCCCC(NC(=O)CN2CCOCC2)C1', 'C=CC(C)(CC)C(=O)NCC1(O)CN(C(=O)C(C)c2cnccn2)C1', 'C=CC(C)(O)CC(=O)NCC[C@H](OC)C(=O)NC1(C=C)CCCCC1', 'C=CC(C)C(=O)N(CC)CCN(CC)C(=O)C(=O)c1cnn(CC)c1', 'C=CC(C)C(=O)N1CCC[C@H](CCNS(=O)(=O)CC2CC(F)(F)C2)C1', 'C=CC(C)C(=O)N1C[C@H](O)C[C@@H]1CNC(=O)c1ccn2ncnc2c1', 'C=CC(C)C(=O)N1C[C@H](O)C[C@H]1CC(=O)NC(C)c1nc(C)oc1C', 'C=CC(C)C(=O)NC1CN(C(=O)CC(C)CCCCC)C2(CCC2)C1', 'C=CC(C)C(=O)NCC1(C(=O)N[C@H]2C[C@H]3OCCC[C@@H]23)CC2(CC2)C1', 'C=CC(C)C(=O)NC[C@H]1C[C@@H](C(=O)NC[C@H]2CC[C@H](CO)CC2)CO1', 'C=CC(C)C(=O)N[C@H]1CC[C@@H](C(=O)NC2(C(=O)OC)CC(C)C2)CC1', 'C=CC(C)CC(=O)N(C)CC1(NC(=O)Cc2cccnc2OC)CC1', 'C=CC(C)CC(=O)N1CC2(CC(NC(=O)CC3C=NN(C)C3=O)C2)C1', 'C=CC(C)CC(=O)N1CCC2(CCN(C(=O)c3cnnn3C)CC2)C1', 'C=CC(C)CC(=O)N1CCOC2(C1)CN(C(=O)Cc1cc(C)no1)C2', 'C=CC(C)CC(=O)N1Cc2nccn2CC(NC(=O)C(C)(C)C=C)C1', 'C=CC(C)CC(=O)NC1C2CCN(C(=O)Cc3c(Cl)cnn3C)CC21', 'C=CC(C)CC(=O)NCC1(OC)CN(C(=O)c2ccnc(C)c2C)C1', 'C=CC(C)CC(=O)NCCN(CCOC)C(=O)c1ccc(Cl)nc1N', 'C=CC(C)CC(=O)NCc1csc(C(=O)N[C@@H]2CCC[C@H](CO)C2)c1', 'C=CC(C)CCNC(=O)C1(C=C)CCN(C(=O)CC2CCCO2)CC1', 'C=CC(C)CCNC(=O)C1CCCCN1C(=O)c1cc(=O)[nH]c(=O)[nH]1', 'C=CC(C)N(C)C(=O)CC1CN(C(=O)c2ccnc(C)n2)CC12CC2', 'C=CC(C)NC(=O)C(NC(=O)CCCN(C)C(C)=O)c1ccnn1C', 'C=CC(C)NC(=O)C(NC(=O)c1cnc2n1CCC2)c1cn(C)nn1', 'C=CC(C)NC(=O)CCCCCn1cc(-c2ccc(CO)cn2)nn1', 'C=CC(C)ONC(=O)C1(CNC(=O)C2CN3CCC2C3)CC12CCC2', 'C=CC(C)ONC(=O)c1nc(CNC(=O)C2CC3CCC2C3)oc1C', 'C=CC(C1CC1)N(C)C(=O)[C@@H](CC(C)C)NC(=O)C=CC(C)(C)SC', 'C=CC(CC)C(=O)N(C)CCN(C)C(=O)c1cn2c(C)cccc2n1', 'C=CC(CC)C(=O)N1CC2CC(NC(=O)c3cc4sccc4[nH]3)C1C2', 'C=CC(CC)C(=O)N1CCC(C(C)C(=O)NCCc2c[nH]nc2C)C1', 'C=CC(CC)C(=O)N1CC[C@@H](NC(=O)Cc2cccc(C)c2)[C@H](O)C1', 'C=CC(CC)C(=O)N1C[C@H](O)C[C@H]1C(=O)NCc1cc(O)cc(C)n1', 'C=CC(CC)C(=O)N1C[C@H](O)C[C@H]1CNC(=O)c1cc(N)nc(Cl)n1', 'C=CC(CC)C(=O)NC1(C(=O)NCCn2nc(C)nc2C)CCCC1', 'C=CC(CC)C(=O)NCc1ccoc1C(=O)NCC1CC(O)C(O)C1', 'C=CC(CC)CC(=O)N1CC(O)(CN(C)C(=O)c2cnc(C)n2C)C1', 'C=CC(CC)CC(=O)N1CC=CC1C(=O)N1CCc2ncn(C)c2C1', 'C=CC(CC)CC(=O)N1C[C@H]2CCN(C(=O)CN3CC=CC3)[C@H]2[C@@H]1C', 'C=CC(CC)CC(=O)NC(CC(=C)C)C(=O)N1CCCC1CN(C)C', 'C=CC(CC)CC(=O)NC1(C(=O)NCCc2cn(C)cn2)CC1(C)C', 'C=CC(CC)CC(=O)NCc1csc(C(=O)N[C@@H](C)c2ncc[nH]2)c1', 'C=CC(CCC)CC(=O)N1C[C@H](NC(=O)CCC2CCC2)CC[C@H]1C', 'C=CC(CCC)CC(=O)N[C@H](C)CCCC(=O)N1CC2(CC(F)C2)C1', 'C=CC(CO)NC(=O)[C@@H]1CC[C@H](CNC(=O)C2(C)C(C)(C)C2(C)C)O1', 'C=CC(F)(F)C(=O)N(CC(C)C1CCOCC1)C[C@@H]1[C@H](CO)C1(C)C', 'C=CC(F)(F)C(=O)N1CCC(C(F)C(=O)N2CC(CC)(CCO)C2)C1', 'C=CC(F)(F)C(=O)N1CCC(F)(C(=O)NC2(c3ncc[nH]3)CC2)CC1', 'C=CC(F)(F)C(=O)N1[C@@H]2CC[C@H]1[C@H](C(=O)NCc1cncc(O)c1)C2', 'C=CC(F)(F)C(=O)N[C@H]1CCN(C(=O)CC(=O)N(C)C)C[C@H]1C(N)=O', 'C=CC(F)(F)C(=O)N[C@H]1CC[C@H]1CNC(=O)C1Cc2ccc(F)cc21', 'C=CC(NC(=O)[C@H]1CC=CC[C@H]1NC(=O)C1(OC)CCOC1)C1CC1', 'C=CC(O)C(=O)N(Cc1c(C)nn(C)c1Cl)CC1(COC)CC(C)C1', 'C=CC(O)C(=O)N1CCC(Cc2cn(CCCOC3CCC3)nn2)C1', 'C=CC(O)C(=O)NC1CC2(C1)CC(C(=O)N[C@H]1CCO[C@@H]1C1CC1)C2', 'C=CC(O)C(=O)NCCC1CCCCN1C(=O)CC1COCC1(C)C', 'C=CC(O)C(=O)NCc1cc(C(=O)NC(C)(C)c2cn(C)nn2)no1', 'C=CC(O)C(=O)N[C@H]1C[C@H](O)CN(C(=O)c2cc(N)c(C)cc2C)C1', 'C=CC(O)CNC(=O)C[C@H]1[C@H](O)C[C@@H]1NC(=O)C1(OC)CCCOC1', 'C=CC(OC)C(=O)N(C)C(C)(C)CC(=O)Nc1cccc(CCF)c1', 'C=CC(OC)C(=O)N(C)CCC1CCN(C(=O)C(CC)OCC)CC1', 'C=CC(OC)C(=O)N1CCCC[C@@H]1CN(C)C(=O)CO[C@@H]1CCOC1', 'C=CC(OC)C(=O)N1CCO[C@@H](C(=O)NC2CCN(OCC)CC2)C1', 'C=CC(OC)C(=O)N1C[C@@H](C)N(C(=O)c2cccnc2CC)[C@@H](C)C1', 'C=CC(OC)C(=O)NC(Cc1cc[nH]n1)C(=O)NC1(C(C)(F)F)CC1', 'C=CC(OC)C(=O)NC[C@H]1C[C@@H](C(=O)NC(C)Cn2ccnc2)CO1', 'C=CC/C=C/CCC(=O)N(C)[C@H](C)CC(=O)NC1C2CCCC1CC2', 'C=CC/C=C/CCC(=O)N1CC(CCNC(=O)c2ncoc2CC)C1', 'C=CC/C=C/CCC(=O)NC(CCCC)C(=O)N1Cc2cn[nH]c2C1', 'C=CC/C=C/CCC(=O)NCCC(C)(C)NC(=O)c1ccc(C#N)s1', 'C=CC/C=C/CCC(=O)NCCC1(C(=O)N2CCC3(CC3)C2)CCC1', 'C=CC1(C(=O)N(C)CC(C)(C)C#N)CCN(C(=O)C2=COCC2)CC1', 'C=CC1(C(=O)N(CCCSC)Cc2cccnc2CC)CCCCC1', 'C=CC1(C(=O)N(Cc2ncc(F)cc2F)CC(OC)C(C)C)CCC1', 'C=CC1(C(=O)N2CC(N(C)C)C2)CCN(C(=O)C2=CCCC2C)CC1', 'C=CC1(C(=O)N2CCC[C@H](NC(=O)C3SCC=C3C)C2)CCOCC1', 'C=CC1(C(=O)N2CC[C@@H](C(C)(C)O)C2)CCN(C(=O)C[C@H](C)O)CC1', 'C=CC1(C(=O)N2C[C@@H]3[C@H](C2)[C@H]3C(=O)NCCC2CCCN2C)CCC1', 'C=CC1(C(=O)NC/C=C\\CC)CCN(C(=O)CCc2cn(C)cn2)C1', 'C=CC1(C(=O)NC2(C)CCCC2(C)C)CCN(C(=O)C(=O)N(C)C)C1', 'C=CC1(C(=O)NCCCCN(C)C(=O)c2cc(CO)oc2C)CCC1', 'C=CC1(C(=O)NC[C@@H](O)CO)CCN(C(=O)c2sncc2CC)CC1', 'C=CC1(C(=O)NCc2cc(C(=O)N3CCC[C@H](O)[C@@H]3C)cs2)CCC1', 'C=CC1(C(=O)N[C@H]2C[C@H](CNC(=O)C(C)n3nccc3C)C2)CCC1', 'C=CC1(C(=O)Nc2csnc2OC)CCN(C(=O)[C@@H](CO)N(C)C)C1', 'C=CC1(C)COCCN1C(C(=O)NC1COC1)c1cccc(F)c1F', 'C=CC1(CC(=O)N(C)CC(C)C)CN(C(=O)c2cc(C#N)cn2C)C1', 'C=CC1(CC(=O)N(C)Cc2cocn2)CN(C(=O)c2ncoc2C)C1', 'C=CC1(CC(=O)N2CCC23CC(CO)C3)CN(C(=O)CCN=[N+]=[N-])C1', 'C=CC1(CC(=O)N2CCOCC2)CN(C(=O)CC(C)CC(C)(C)C)C1', 'C=CC1(CC(=O)NCC#CC2CC2)CN(C(=O)C2(O)CCOCC2)C1', 'C=CC1(CC(=O)NCCC2CCCC2)CN(C(=O)C(C)CC(N)=O)C1', 'C=CC1(CC(=O)NCCCCC2CC2)CN(C(=O)C2CCC(C)C2)C1', 'C=CC1(CC(=O)NCCCCO)CN(C(=O)c2cnc(C(C)C)o2)C1', 'C=CC1(CC(=O)Nc2ccc(C(C)C)nc2)CN(C(=O)CC2CC2)C1', 'C=CC1(CNC(=O)CC(C)C(C)(C)NC(=O)C=CCC)CCOCC1', 'C=CC1(NC(=O)C23CC(C)(CN2C(=O)C2CCS2(=O)=O)C3)CCCC1', 'C=CC1(NC(=O)C23CC2CCN3C(=O)[C@]23CCC[C@H]2C3)CCOCC1', 'C=CC1(NC(=O)CC(C)(C)N(C)C(=O)c2cc(C)c(CC)o2)CCC1', 'C=CC1(NC(=O)C[C@H]2C[C@H](NC(=O)c3cccc(NC)n3)C2)CCC1', 'C=CC1(NC(=O)Cn2cc(CNC(=O)C[C@@H](C)O)nn2)CCOCC1', 'C=CC1(NC(=O)[C@H]2CC=C[C@H](NC(=O)C3CC(F)C3)C2)CCCCC1', 'C=CC1(O)CN(C(=O)CC2CN(C(=O)c3ccn(C)n3)CCC2C)C1', 'C=CC1(O)CN(C(=O)[C@H]2C[C@H](F)CN2C(=O)CC(C)n2ccnc2)C1', 'C=CC1CC(NC(=O)C(CC(=C)C)NC(=O)C2CCN(OC)CC2)C1', 'C=CC1CC(NC(=O)C[C@@H](NC(=O)CC2C=CCCC2)[C@@H](C)CC)C1', 'C=CC1CCCCN1S(=O)(=O)c1cnc(N[C@H]2CCC[C@@H]2O)c(Cl)c1', 'C=CC1CCCN(C(=O)C2CN(C(=O)Cn3cnnn3)C(C)(C)C2)C1', 'C=CC1CCCN(C(=O)CC(C)(C)CNC(=O)Cc2cc(C)no2)C1', 'C=CC1CCCN(C(=O)CC(C)(C)N(C)C(=O)CCC2OCCO2)C1', 'C=CC1CCCN(C(=O)[C@H](CCC)NC(=O)c2cc(C)cc(O)n2)C1', 'C=CC1CCCN1C(=O)C(C)(NC(=O)c1cnn(C)c1C)C1CCC1', 'C=CC1CCN(C(=O)C2(F)CCN(C(=O)c3nc(Cl)cs3)CC2)CC1', 'C=CC1CCN(C(=O)C2=C(F)CN(C(=O)Cc3csnn3)CC2)CC1', 'C=CC1CCN(C(=O)C2CC(NC(=O)C3=CC(C)(C)C3)CCO2)CC1', 'C=CC1CCN(C(=O)C2CC3(CCN2C(=O)C/C=C/CC)CC3)CC1', 'C=CC1CCN(C(=O)C2CN(C)CCN2C(=O)c2cc(C)c[nH]2)CC1', 'C=CC1CCN(C(=O)[C@@H]2CN(C(=O)C3(CC(C)C)CC3)C[C@H]2C)CC1', 'C=CC1CCN(C(=O)[C@H]2OCC[C@H]2NC(=O)C=Cc2nccs2)CC1', 'C=CC1CN(C(=O)C(NC(=O)[C@@H](C)N(C)C)C2CCCCC2)CCO1', 'C=CC1CN(C(=O)C2(C)CN(C(=O)CCC(=O)NN(C)C)C2)CCO1', 'C=CC1COCCN1C(=O)C(NC(=O)c1cc(C#N)n(C)n1)C(C)C', 'C=CC1COCCN1C(=O)[C@H](CCC)NC(=O)c1ccoc1C1CC1', 'C=CC1COCCN1C(=O)[C@H]1[C@H](C)OCCN1C(=O)COC(C)CC', 'C=CC=CCC(=O)N(C)C[C@@H]1[C@H]2CN(C(=O)CC3CCOC3=O)C[C@@H]12', 'C=CC=CCC(=O)N(CC(=O)N(C)Cc1ccc(C)cn1)CC1CC1', 'C=CC=CCC(=O)N(CC1CCCN1C(=O)[C@H]1C[C@@](C)(O)C1)C1CC1', 'C=CC=CCC(=O)N1CC(CC(F)C(=O)N2CCCC(C)(CC)C2)C1', 'C=CC=CCC(=O)N1CC(O)CCC1C(=O)N1CCN(C)C(CC)C1', 'C=CC=CCC(=O)N1CC(O)CCC1C(=O)NCc1ccc(F)cn1', 'C=CC=CCC(=O)N1CCC[C@H](C(=O)N2C[C@H](F)C[C@@H](OC)C2)[C@@H]1C', 'C=CC=CCC(=O)NC(C)C1CC(NC(=O)c2cc(N)cnc2C)C1', 'C=CC=CCC(=O)NCC1(CNC(=O)c2cc(CC(C)C)c[nH]2)CC1', 'C=CC=CCC(=O)NCCn1ccc(C(=O)N2CC(=O)NCC2C)c1', 'C=CC=CCC(=O)NCc1cncc(C(=O)NOCc2nc[nH]n2)c1', 'C=CC=CCCNC(=O)C(=O)NCc1ccc(OC)cc1OC(F)F', 'C=CCC(=O)N(C)CCN(C)Cc1cn(C[C@@H]2C[C@H]3CC[C@@H]2O3)nn1', 'C=CCC(=O)N1CCCC1(CC=C)C(=O)NC1CC2(CCC2)C1OC', 'C=CCC(=O)N1CCN(C(=O)c2cc(C3CCC3)on2)[C@@H](C(C)C)C1', 'C=CCC(=O)NC1C2CC3C(C2)C31C(=O)NCCCC1CCOC1=O', 'C=CCC(=O)NCCc1ccc(CNC(=O)C23CCC(CC2)C3)cc1', 'C=CCC(=O)NCCc1ccc(CNC(=O)CCC2CCCO2)cc1', 'C=CCC(=O)NCc1cnn(C)c1C(=O)NOCCc1ccccc1', 'C=CCC(=O)N[C@H]1CCCCC[C@H]1C(=O)N[C@H]1C[C@H]2CC[C@@H](C1)[C@H]2O', 'C=CCC(C(=O)N1CCC(=CCNC(=O)C(C)(C)OC)CC1)C(C)C', 'C=CCC(C(=O)OCc1nnc(C2CCOCC2)o1)c1ccccc1', 'C=CCC(C)(C(=O)Nc1cc(CCc2ccccc2)ccn1)N(C)C', 'C=CCC(C)(C)C(=O)NC(C)/C=C/C(=O)NCC(O)c1cnn(C)c1', 'C=CCC(C)(C)C(=O)N[C@H]1CCC[C@H]1CN(C)C(=O)CCC(C)(C)F', 'C=CCC(C)(C)CC(=O)N1[C@@H]2COC[C@H]1C[C@@H](NC(=O)C=C(C)C)C2', 'C=CCC(C)(C)CC(=O)NCc1cn[nH]c1C(=O)NC12CC(F)(C1)C2', 'C=CCC(C)(C)CCN(CCC1(O)CCC(C)C1)C(=O)C(C)(C)CO', 'C=CCC(C)(C)CN(Cc1cc(C2CC2)[nH]n1)Cc1ncc(Br)n1C', 'C=CCC(C)(C)CN(Cc1cccc(CC)n1)C(=O)C(F)C(C)(C)O', 'C=CCC(C)(C)CNC(=O)C1(NC(=O)c2coc(C)n2)CCCC1C', 'C=CCC(C)(C)NC(=O)C1CCN(C(=O)c2ccc(C(N)=O)[nH]2)C1C', 'C=CCC(C)(C)NC(=O)CC1CN(C(=O)[C@H]2C[C@@H](N(C)C)C2)CCO1', 'C=CCC(C)(CC)C(=O)N(C)CCCC(=O)N1CCC(F)(C(N)=O)C1', 'C=CCC(C)(CC)C(=O)NCC1(CNC(=O)Cc2nc[nH]n2)CCC1', 'C=CCC(C)(NC(=O)OC(C)(C)C)C(=O)NC1CCc2[nH]cnc2C1', 'C=CCC(C)C(=O)N1CC2(C(=O)N3CCC(C(F)F)C3)CCC1CC2', 'C=CCC(C)C(=O)N1CC=CC1(C)C(=O)NCCn1nc(C)nc1C', 'C=CCC(C)C(=O)N1CCC12CN(C(=O)CN1CCn3nccc31)C2', 'C=CCC(C)C(=O)N1CCN(C(=O)c2coc(CC)n2)C(C2CC2)C1', 'C=CCC(C)C(=O)N1CCOC(C(=O)N2CCCC(O)(C(N)=O)C2)C1', 'C=CCC(C)C(=O)NC(C(=O)N1CC2CC2(C(=O)OC)C1)C(C)(C)C', 'C=CCC(C)C(=O)NCc1cccc2c1CN(C(=O)C(C)CC=C)C2', 'C=CCC(C)C(=O)N[C@H](CC(C)C)C(=O)NCC1(C)CCC(O)CC1', 'C=CCC(C)CN(Cc1csc(C)c1C)C(=O)c1c(F)cncc1F', 'C=CCC(C)N(Cc1ccccc1)C(=O)NCc1ncc(F)cc1F', 'C=CCC(C)NC(=O)CC1COCCN1C(=O)c1ccc(C)[nH]c1=O', 'C=CCC(C)NC(=O)CC[C@H]1C[C@@H](NC(=O)c2ccn(C)c(=O)c2)C1', 'C=CCC(C)NC(=O)[C@H]1OCC[C@H]1CNC(=O)Cn1ncccc1=O', 'C=CCC(C)NC(=O)c1coc2c1CN(C(=O)C=C1CCCCC1)C2', 'C=CCC(C)Nc1nc2c(c(NCc3cc(=O)cc[nH]3)n1)CCCC2', 'C=CCC(CC(C)C)C(=O)N1CC[C@H](NC(=O)C2SCC=C2C)[C@@H]1C', 'C=CCC(CC(F)F)C(=O)N[C@H](C)C1CN(C(=O)C[C@@H](C)N(C)C)C1', 'C=CCC(CC(F)F)NC(=O)[C@]1(NC(=O)c2sncc2C)C[C@@H](O)C1', 'C=CCC(CC)C(=O)N1CCC(N=[N+]=[N-])(C(=O)NCC(CC)CC)C1', 'C=CCC(CC)C(=O)NCCCC(C)(C)C(=O)N1CC=CC(OC)C1', 'C=CCC(CC)C(=O)Nc1ccc(N2CCN(CC3CC3)CC2)cc1', 'C=CCC(CC)NC(=O)[C@H]1CCCCN1C(=O)c1ccc(=O)n(C)c1', 'C=CCC(CC)NCc1cn([C@H]2C[C@H](C)S(=O)(=O)c3sccc32)nn1', 'C=CCC(CC=C)C(=O)N1C2CC1CN(C(=O)CCC1CC1(C)C)C2', 'C=CCC(CC=C)C(=O)N1CCN(C(=O)CCc2ccnn2C)CC1', 'C=CCC(CC=C)NC(=O)C1CCCN(C(=O)c2ccc(N)cn2)C1', 'C=CCC(CNC(=O)C(C)(C)CC(C)(C)C)NC(=O)C1CC=CCC1', 'C=CCC(CNC(=O)C(C)(C)CF)NC(=O)C1=C[C@@H]2C[C@H](C1)C[C@H]2O', 'C=CCC(CNC(=O)C1(CCOC)CC1)NC(=O)C1CCC(O)CC1', 'C=CCC(CNC(=O)C1CC=CC1)NC(=O)C(C)(C)c1ccccc1', 'C=CCC(CNC(=O)C1CN(C(C)=O)C1)C(=O)NCc1nnc(C)o1', 'C=CCC(CNC(=O)C=C(C)C(F)F)C(=O)N(C)CC1(F)CCCC1', 'C=CCC(CNC(=O)CC(C)C(C)(C)C)NC(=O)CN(C)S(N)(=O)=O', 'C=CCC(CNC(=O)CC1(CC)CCC1)NC(=O)Cc1nc[nH]c1C', 'C=CCC(CNC(=O)Cc1cnn(C)c1)NC(=O)c1cc(C)c(C)[nH]1', 'C=CCC(CNC(=O)NC(CO)Cc1ccccc1)c1ccccc1', 'C=CCC(CNC(=O)[C@H]1CCN(C)[C@@H]1CC)C(=O)NC1(CCC)CC1', 'C=CCC(CNC(=O)c1cc(C)c(C)[nH]1)NC(=O)C(CC1CC1)OC', 'C=CCC(CNC(=O)c1cc(C)c(C)o1)C(=O)NC1(CC)CCOC1', 'C=CCC(CNC(=O)c1cn(C)c(=O)n1C)NC(=O)CC1=CCCC1', 'C=CCC(CO)NC(=O)CC[C@H]1C[C@H](NC(=O)C(C)N2CCCC2)C1', 'C=CCC(F)(F)C(=O)N1CC2CN(C(=O)[C@@H](O)C(F)(F)F)CC(C1)O2', 'C=CCC(F)(F)C(=O)N1CCCC(C(=O)NC(CCO)C(F)F)CC1', 'C=CCC(F)(F)CNC(=O)c1coc(CNC(=O)[C@H]2C[C@@H](OC)C2)n1', 'C=CCC(NC(=O)CNC(=O)OCC)C(=O)NC1(CC)CC(C)(C)C1', 'C=CCC(NC(=O)[C@H]1CCN(C(=O)[C@H](C)OC(C)=O)C1)C(=O)OCC', 'C=CCC(NC(C)=O)C(=O)N1CC=C(C(=O)NCC2CCCCS2)C1', 'C=CCC(OC)C(=O)N1CCCC1C1(C(=O)N[C@@H]2COC(=O)C2)CC1', 'C=CCC(OC)C(=O)NC1CCN(C(=O)c2cc(Cl)c[nH]2)CC1CC', 'C=CCC(OC)C(=O)NC[C@H](C)N(C)C(=O)Cc1nncn1C(C)C', 'C=CCC1(C(=O)N2C3CCC2CC(C)C3)CN(C(=O)C(C)OCC)C1', 'C=CCC1(C(=O)N2CC(C(=O)NC(CO)COC)C3(CCC3)C2)CC1', 'C=CCC1(C(=O)N2CC=CCC2)CCN(C(=O)Cc2ccn(C)n2)C1', 'C=CCC1(C(=O)N2CCC(=C)C2)CCCN1C(=O)c1cncc(Cl)c1', 'C=CCC1(C(=O)N2CCCC(CC)C2)CN(C(=O)C2=NOC(C)C2)C1', 'C=CCC1(C(=O)N2CCCC(O)(CO)C2)CN(C(=O)c2ccon2)C1', 'C=CCC1(C(=O)N2CCOC(C(C)C)C2)CN(C(=O)C2CS(=O)C2)C1', 'C=CCC1(C(=O)NC(C)(C)CCF)CN(C(=O)CC2CCC(=O)C2)C1', 'C=CCC1(C(=O)NC(C)C(C)NC(=O)c2cc(OC)no2)CCCC1', 'C=CCC1(C(=O)NC/C=C(\\C)C(=O)NCCC(C)CC(C)(C)C)CC1', 'C=CCC1(C(=O)NCC(C)(C)O)CCCN1C(=O)[C@@H]1[C@H](C#N)C1(C)C', 'C=CCC1(C(=O)NCC2(C#N)CC2)CN(C(=O)CC2(OCC)CC2)C1', 'C=CCC1(C(=O)NCC2(CNC(=O)CC(C)(C)C(C)=O)CCC2)CC1', 'C=CCC1(C(=O)NCC2(F)CCOC2)CN(C(=O)C=CC=CCC)C1', 'C=CCC1(C(=O)NCCCC(N)=O)CCCN1C(=O)CNC(=O)NC', 'C=CCC1(C(=O)NCCCN(CC)C(=O)C2CCSCC2)CCCC1', 'C=CCC1(C(=O)N[C@@H](CC)c2ncnn2C)CN(C(=O)COCC)C1', 'C=CCC1(C(=O)N[C@@H]2CC[C@H]2NC(=O)c2ccn3ncnc3c2)CC1', 'C=CCC1(C(=O)N[C@H](C)C(=O)N2CCC(N(C)CC)CC2)CCOC1', 'C=CCC1(C(=O)Nc2cccc(C)c2C)CCN(C(=O)C2CC2=C)C1', 'C=CCC1(C)CN(C(=O)[C@H]2CCCCN2C(=O)C2(C#N)CC(C)C2)C1', 'C=CCC1(C)CN(C(=O)[C@H]2CCC[C@H]2NC(=O)c2cn(CC)nn2)C1', 'C=CCC1(NC(=O)C2=C(C)CCC2)CCN(C(=O)C(CC)N(C)C)C1', 'C=CCC1(NC(=O)CCC)CCN(C(=O)c2cc(F)c(C)cc2N)C1', 'C=CCC1(NC(=O)CCN(C(=O)Cn2ncnc2N)C2CC2)CCC1', 'C=CCC1(NC(=O)CC[C@H]2CCCN(C(=O)CCOC)C2)CCCC1', 'C=CCC1(NC(=O)CN(C)C)CCN(C(=O)CC2(O)CCCCC2)C1', 'C=CCC1(NC(=O)c2cncc(CNC(=O)C3(O)CCOC3)c2)CC1', 'C=CCC1(O)CN(C(=O)C2CCOCCN2C(=O)CCOCCC)C1', 'C=CCC1(S(=O)(=O)NCC(C)(C)CNC(=O)/C=C/c2cocn2)CC1', 'C=CCC1CCCCC1(NCC=Cc1cccnc1)c1nnnn1C', 'C=CCC1CCN(C(=O)C(CNC(=O)C2CC(C)(C)CO2)N(C)C)C1', 'C=CCCC(=O)N1CC(CNC(=O)c2ccc(CC)cc2C)(OC)C1', 'C=CCCC(=O)N1CC2(CCCN(C(=O)Cc3c(C)cnn3C)C2)C1', 'C=CCCC(=O)N1CC[C@H]2[C@@H](C1)[C@@H]2NC(=O)c1cc(CC2CC2)on1', 'C=CCCC(=O)NC(CC1CC1)C(=O)N1Cc2cccc(C#N)c2C1', 'C=CCCC(=O)NC1(CC(=O)N2CCOCC(F)(F)C2)CCCCC1', 'C=CCCC(=O)NCC1(C)CCCN1C(=O)c1cccc(N(C)C)n1', 'C=CCCC(=O)NCC1(C)CN(S(=O)(=O)C2CCC(C)(C)C2)CCO1', 'C=CCCC(=O)NCC1(CNC(=O)CCc2scnc2C)CC1(F)F', 'C=CCCC(C)(C)C(=O)N1CCC(C(=O)NC(C)c2c[nH]cn2)CC1', 'C=CCCC(C)(C)C(=O)NCC1=CCN(C(=O)c2cnc(N)o2)CC1', 'C=CCCC(C)(C)C(=O)NCCCn1cc(Cn2ccnc2C)nn1', 'C=CCCC(C)(C)C(=O)NC[C@@H]1C[C@H]1CNC(=O)c1nccnc1N', 'C=CCCC(C)(C)NC(=O)COC1CN(C(=O)c2occc2CC)C1', 'C=CCCC(C)(C)NC(=O)c1[nH]ccc1CNC(=O)c1ccncc1', 'C=CCCC(C)Nc1nc(NC)nc(NCc2cncc(OC)c2)n1', 'C=CCCC(CO)NC(=O)C1CCCN1C(=O)c1cc(CC)ccn1', 'C=CCCC(CO)NCc1cn(C(=O)OC(C)(C)C)c2ccncc12', 'C=CCCC(F)(F)C(=O)N[C@@H](C(=O)N1CCCC(OC)CC1)C(C)C', 'C=CCCC(NC(=O)C(CC(C)C)C(C)C)C(=O)NC1CCCCC1', 'C=CCCC(NC(=O)CC(=O)N(C)C)C(=O)N(C)Cc1n[nH]c(=O)o1', 'C=CCCC(NC(=O)CC1CCOC1C)C(=O)N(C)C(CC)C1CC1', 'C=CCCC(NC(=O)c1c[nH]cc1C)C(=O)NCC(O)CC(=O)OC', 'C=CCCC(NC(=O)c1cccc(F)c1F)C(=O)NC[C@@H](C)N(C)C', 'C=CCCC(NC(=O)c1cscc1C)C(=O)N(C)CC(F)(F)CC=C', 'C=CCCC(NC(=O)c1nccn1C)C(=O)N1CC2(C1)CC(C)(O)C2', 'C=CCCC(O)CN(C)C(=O)C1CCN1C(=O)c1oc(CC)nc1C', 'C=CCCC1(C(=O)N(C)C2CCOC2)CN(C(=O)C2CC3CC3C2)C1', 'C=CCCC1(C(=O)N(C)CC(C)COC)CN(C(=O)[C@H]2CCN2C)C1', 'C=CCCC1(C(=O)N2CC[C@H](F)C2)CN(C(=O)C/C=C/C(C)(C)C)C1', 'C=CCCC1(C(=O)NC2CC(CF)C2)CN(C(=O)CSCC(F)F)C1', 'C=CCCC1(C(=O)NC2CCOCC2O)CN(C(=O)CC(C)C=C)C1', 'C=CCCC1(C(=O)NCC2SCCS2)CN(C(=O)c2ccnn2C)C1', 'C=CCCC1(CN(Cc2csc(Cl)c2)C(=O)[C@H](O)C(F)(F)F)CCC1', 'C=CCCC1(c2noc(C3CCc4ncc(Br)n4C3)n2)CCOCC1', 'C=CCCC1CCCN(C(=O)C(O)CNC(=O)Cn2ccnc2C)C1', 'C=CCCC1CCCN1C(=O)C1(CNC(=O)[C@@H]2C[C@H](O)CN2C)CC1', 'C=CCCCC(=O)N1CC2(CC(CC(=O)N(C)CC(O)C3CC3)C2)C1', 'C=CCCCC(=O)N1CCC(C)(C(=O)N2CCC(C)C(F)(F)C2)CC1', 'C=CCCCC(=O)N1CCCC(CO)(NC(=O)c2ccn[nH]c2=O)C1', 'C=CCCCC(=O)N1CCCC(N(C)C(=O)c2ccc(C)c(F)c2)C1', 'C=CCCCC(=O)N1CCN(C(=O)Cc2ccn(CC)n2)C2(CC2)C1', 'C=CCCCC(=O)NC1CC(C(C)NC(=O)c2cc(F)ccc2F)C1', 'C=CCCCC(=O)NCC1C(CC)CCN1C(=O)CS(=O)C(F)(F)F', 'C=CCCCC(=O)NC[C@]12C[C@H]1CN(C(=O)C1CCc3nccn31)C2', 'C=CCCCC(=O)N[C@]1(C(=O)NCc2ccc(F)nc2C)C[C@H](O)C1', 'C=CCCCC(C(=O)NC1(C)CC1)N1CC2CCCC(CO)(C1)C2O', 'C=CCCCC(C(=O)Nc1ccc(F)cc1)N1CC(C)(C)C1COC', 'C=CCCCC(C)NC(=O)C(=O)N1CCN(c2ccccc2)CC1C', 'C=CCCCC(C)NC(=O)C1(CC=C)CCN(C(=O)CC=C(C)C)C1', 'C=CCCCC(C)NC(=O)C1=CC2(CCN(C(=O)C(C)(C)C=C)C2)C1', 'C=CCCCC(NC(=O)C1=CCCC1)C(=O)NCC(C)n1cccn1', 'C=CCCCC(NC(=O)C1CCC1)C(=O)N1CCC2CCCC2CC1', 'C=CCCCC(NC(=O)C=CCC)C(=O)Nc1cccc(CC)c1O', 'C=CCCCC(NC(=O)[C@H](CC(C)C)N(C)C)C(=O)N1CCC1(C)C', 'C=CCCCC(NC(=O)[C@H]1C[C@@]12CCOc1ccc(F)cc12)C1CC1', 'C=CCCCCC(=O)N(C)C1(C(=O)NCc2c(C)nn(C)c2C)CC1', 'C=CCCCCC(=O)N1CCC1CNC(=O)C(OC)c1cccnc1', 'C=CCCCCC(=O)NCC1(C(=O)N2CCC3(CCOC3)C2)CCC1', 'C=CCCCCC(=O)NCC1(C)CCN(C(=O)c2nn(C)nc2C)C1', 'C=CCCCCC(=O)NCc1cn[nH]c1C(=O)N[C@H]1CC[C@@H]1N(C)C', 'C=CCCCCCC(=O)N1CC2CC(C1)N2C(=O)CC1(OC)CCC1', 'C=CCCCCCC(=O)N1CCC2(CCCN2C(=O)CS(C)(=O)=O)C1', 'C=CCCCCCC(=O)N1CCCC1C1(NC(=O)[C@@H]2CC2(F)F)CC1', 'C=CCCCCCNC(=O)C1CCCC1CNC(=O)[C@H](C)C(C)(C)C', 'C=CCCCCCNC(=O)[C@H]1C[C@H](F)CN1C(=O)CCc1cnco1', 'C=CCCCCN(Cc1nccs1)Cc1c[nH]c2ccc(OC)cc12', 'C=CCCCCNC(=O)[C@@H]1C[C@H]2C[C@H]2N1C(=O)C(F)C1(O)CCCC1', 'C=CCCCCNc1nc(NCCCC#N)nc2c1CCCCCC2', 'C=CCCCCNc1nc2c(c(NCCc3nncs3)n1)CCCC2', 'C=CCCCN(C)C(=O)Nc1cc(C)nn1-c1nc2ccccc2s1', 'C=CCCCN(C)C(=O)[C@@H]1CC[C@H](C)CN1C(=O)c1sc(C)cc1C', 'C=CCCCN(C)C(=O)[C@@H]1C[C@H](O)CN1C(=O)c1ccc(C#N)n1C', 'C=CCCCN(C)CCC(=O)NC(=O)Nc1ccc2c(c1)OCCO2', 'C=CCCCN(C)c1cc(NCc2nc(N)n(C)n2)nc(C(C)C)n1', 'C=CCCCN(CC)C(=O)CC1(C)CCN(C(=O)C(C)=C2CCC2)C1', 'C=CCCCN(Cc1ccc(C)c(Cl)c1)C(=O)c1ccc([N+](=O)[O-])[nH]1', 'C=CCCCN(Cc1cnc(C2CC2)s1)C(=O)c1c[nH]c(C(C)C)n1', 'C=CCCCNC(=O)C(CCC1CC1)NC(=O)c1cc(C#N)[nH]c1C', 'C=CCCCNC(=O)c1cc(CCNC(=O)C=Cc2cc[nH]c2)on1', 'C=CCCCONC(=O)[C@H]1CC[C@H](NC(=O)c2sc(C)cc2C)CC1', 'C=CCCOC(C)C(=O)N1CCOC(CN(C)C(=O)C(C)=C2CC2)C1', 'C=CCCOC(C)C(=O)N1C[C@H](N=[N+]=[N-])[C@H](NC(=O)CSC(F)F)C1', 'C=CCCOCC(=O)N(Cc1nccnc1C)CC(O)c1cccs1', 'C=CCCOCC(=O)N1CC(F)(F)C[C@H]1C(=O)NC1CCCNC1=O', 'C=CCCOCC(=O)N1CC=C(C(=O)N2C[C@H]3CC[C@H](O)[C@H](O)[C@H]32)C1', 'C=CCCOCC(=O)N1CCC(C)(NC(=O)Cc2ccn(C)c2)CC1', 'C=CCCOCC(=O)N1CCN(C(=O)CC(C)CN(C)C)C(CO)C1', 'C=CCCOCC(=O)NC(C)CC1CN(C(=O)c2n[nH]cc2CC)C1', 'C=CCCOCC(=O)NCCC1CCCCN1C(=O)c1ccncc1', 'C=CCCONC(=O)CC1COCCN1C(=O)c1cnn(C)c1OC', 'C=CCCONC(=O)[C@H]1C[C@H](OC)CN1C(=O)c1cc(OC)n(C)n1', 'C=CCCS(=O)(=O)NC1COCCN(C(=O)c2cc(CCC)no2)C1', 'C=CCCSCCN(Cc1cc(C)n(C)n1)C(=O)/C=C/c1nccs1', 'C=CCCSCCN(Cc1cc2cccnc2o1)C(=O)[C@@H](C)N(C)C', 'C=CCCSCCN(Cc1ccn(CC)n1)C(=O)c1csc(C#N)c1', 'C=CCCSCCNC(=O)[C@@H]1CC[C@H](C)CN1C(=O)CCC(F)(F)F', 'C=CCC[C@H](NC(=O)C(CC)N(C)C)C(=O)N1CCO[C@H](C)[C@H]1CO', 'C=CCC[C@H](NC(=O)c1ocnc1C)C(=O)NC1CC(C(F)(F)F)C1', 'C=CCN(C(=O)[C@H]1C[C@H]1CNC(=O)C1COCOC1)c1ccccc1', 'C=CCN(C(=O)c1[nH]ccc1Cl)C(Cc1ccccc1)C(=O)OCC', 'C=CCN(C)C(c1ccc(Cl)c(C)c1Cl)c1nnnn1CCOCC', 'C=CCN(C)C1CN(C(=O)C2(F)CN(C(=O)C3CC4CCC3C4)C2)C1', 'C=CCN(CC)C(=O)C(NC(=O)c1csc(C#N)c1)c1cnn(C)c1', 'C=CCN(CC)C(=O)C1(n2cc(Cn3cncn3)nn2)CCOCC1', 'C=CCN(CC1CC1)C(=O)C(NC(=O)C1CC12CCCCC2)C1CC1', 'C=CCN(CC1CC1)C(=O)C(NC(=O)c1cn(C2CC2)nn1)C1CC1', 'C=CCN(CC=C)C(=O)[C@H]1C[C@@H]1C(C)NC(=O)c1nccn1C(C)C', 'C=CCN(CCC(=O)N(C)C1CC1(C)C)C(=O)C1CC(C#N)(OC)C1', 'C=CCN(CCC(=O)N1CC(N2CCCC2)C1)C(=O)/C=C/C(C)(C)C', 'C=CCN(CCC(=O)N1CC2(CCCO2)C1)C(=O)CC1CCC(=O)C1', 'C=CCN(CCC(=O)N1CCCC(CO)C1C)C(=O)Cc1ccns1', 'C=CCN(CCC(=O)N1C[C@H](C)[C@@H](O)C1)C(=O)CC1CC(C2CC2)C1', 'C=CCN(CCC(=O)N1C[C@H]2C[C@H](F)C[C@H]2C1)C(=O)[C@@H]1C[C@H]1CCC', 'C=CCN(CCC(=O)NC1CC(=O)N(O)C1)C(=O)C(=O)NCC(F)F', 'C=CCN(CCC(=O)NCC1=C(C)CCOC1)C(=O)Cc1ccoc1', 'C=CCN(CCC(=O)NOC1CCCN(CC)C1)C(=O)C1SCCS1', 'C=CCN(CCC(=O)OC)C(=O)/C=C/C(C)NC(=O)c1cnn(C)c1', 'C=CCN(CCC)C(=O)C1(CC=C)CCCN1C(=O)C1CNC(=O)N1', 'C=CCN(CCC)C(=O)C1COC2(C1)CN(C(=O)C(C)C(C)(C)C)C2', 'C=CCN(Cc1ccc(OC)cc1)C(=O)NCC(=O)N(CC)OCC', 'C=CCN(OC)C(=O)[C@@H](Cn1ccnn1)NC(=O)c1csc(CO)n1', 'C=CCN(OC)C(=O)[C@H](CC(C)(C)C)NC(=O)CCC1CCCOC1', 'C=CCN(OC)C(=O)[C@H]1C[C@@H]1C1CN(C(=O)c2cccc(C#N)c2)C1', 'C=CCN1CCC(NC2CC(C)N(C(=O)OC(C)(C)C)C(C)C2)CC1', 'C=CCN1CCN(C(=O)[C@H]2C[C@H](O)CN2C(=O)C2CCNC2=O)CC1', 'C=CCNC(=O)C(C1CCOC(C)C1)N1CC2(CCCC2)C1C(C)C', 'C=CCNC(=O)C(c1cc([N+](=O)[O-])c(C)cc1C)N(CC=C)C1CC1', 'C=CCNC(=O)CN1CCN(c2c3c(nc4ncnn24)CCC3)CC1', 'C=CCNC(=O)CNC(=O)C(COCC)NC(=O)c1oc(C)cc1C', 'C=CCNC(=O)CNC(=O)[C@@H]1C[C@H](CC)CCN1C(=O)C1=CCSC1', 'C=CCNC(=O)CNc1cc(N2CCN(C(=O)OC)CC2)nc(C)n1', 'C=CCNc1nc(C2CCCN(C(=O)C(CC)n3cncn3)C2)cs1', 'C=CCNc1nc(N2CCC(C3CNC(=O)C3)CC2)c2[nH]ccc2n1', 'C=CCNc1nc(N2CCC(n3cc(Cl)cn3)CC2)c2ncsc2n1', 'C=CCOC(=O)CNC(=O)[C@H](NC(=O)C(C)C(C)C)C1CCCCC1', 'C=CCOC(=O)NCC(=O)NC1CC=C(C(=O)N(C)C2CCC2C)C1', 'C=CCOC(=O)[C@@H](NC(=O)CCc1nc2ccsc2c(=O)[nH]1)C(C)C', 'C=CCOC(C)C(=O)N(CC)CC(C)NC(=O)c1cccc(NC)n1', 'C=CCOC(C)C(=O)N(Cc1ccsc1C)CC1CC(C2CC2)CO1', 'C=CCOC(C)C(=O)N1CC(C)(C)C[C@H]1C(=O)NC1CCOCC1C', 'C=CCOC(C)C(=O)N1CCCC(N(C)C(=O)C2CC(=O)CCO2)C1', 'C=CCOC(C)C(=O)N1C[C@H]2CC[C@@H](C1)[C@H](NC(=O)C1CS(=O)C1)C2', 'C=CCOC(C)CN(Cc1ccccc1OC)C(=O)c1sccc1F', 'C=CCOC(C)CNC(=O)C(=O)NCc1cc2ccccc2nc1Cl', 'C=CCOC1CCN(C(=O)C2CC(O)(CNC(=O)c3ccoc3)C2)C1', 'C=CCOC1CCN(C(=O)COC2CN(C(=O)C34CCC(C3)C4)C2)C1', 'C=CCOC1CCN(C(=O)Nc2ccc(F)c(C#N)c2OCC)CC1', 'C=CCOC1CCN(c2nc(C)nc(NCc3csc(NC)n3)n2)C1', 'C=CCOCC(=O)N(C)CC1CCN(C(=O)c2cnn(CC)c2)CC1', 'C=CCOCC(=O)N1CCC(NC(=O)C2CCn3nncc3C2)CC1', 'C=CCOCC(=O)N1C[C@H]2C[C@H](C)N(C(=O)CC(C)(O)CCC)[C@H]2C1', 'C=CCOCC(=O)NC1CN(C(=O)c2ccc(OC)nc2)CCC1C', 'C=CCOCCCC(=O)N1CCC(C(=O)N(C)Cc2ncco2)CC1', 'C=CCOCCCC(=O)N1CCOCC1(C)c1cn(CCCF)nn1', 'C=CCOCCCC(=O)N1CC[C@H](C(=O)N2CC(F)(CC)C2)C[C@@H]1C', 'C=CCOCCCN(Cc1sccc1C)C(=O)[C@H]1C[C@@H]1C1(C)COC1', 'C=CCOCCCNc1ccc(OCc2cccc(C#N)c2)c(Cl)c1', 'C=CCOCCN(C)C(=O)C(C)n1cc(-c2ccc(F)c(Cl)c2)nn1', 'C=CCOCCN(C)C(=O)[C@@H]1CC[C@H](CNC(=O)C2(C)CC(=O)C2)O1', 'C=CCOCCN(Cc1cnc2ccsc2c1)C(=O)[C@H]1CCC[C@@H]1O', 'C=CCOCCNC(=O)[C@H](NC(=O)CC1CC(N(C)C)C1)C(C)(C)C', 'C=CCOCCNC(=O)[C@H]1CCC[C@H]1NC(=O)[C@@H]1CC[C@H](C(N)=O)C1', 'C=CCOc1ccc(CC(=O)NCc2c(F)cc(F)c(F)c2F)cc1', 'C=CCOc1ccc(CC(=O)NCc2ccc(C3COC3)cc2)cc1', 'C=CCOc1ccc(CN(C)C(=O)c2cccnc2OC(C)C)cc1', 'C=CCOc1ccc(CNCc2ncc(-c3ccccc3)o2)cc1Cl', 'C=CCOc1cccc(NC(CC(C)(C)CC)c2nnnn2CC)c1', 'C=CCSCC(=O)N1CCN2CCN(C(=O)COCCOC)CC2C1', 'C=CCSCC(=O)N1CCOC[C@H]1C(=O)NC(C)c1ccnc(C)n1', 'C=CCSCC(=O)N1C[C@H]2CCC[C@@]2(CNC(=O)c2c[nH]c(=O)s2)C1', 'C=CCSCC(=O)NCC(C)(CNC(=O)c1cc(C#N)oc1C)OC', 'C=CCSCC(=O)N[C@H](C(=O)NC1(C)CCC2(CC2)CC1)C1CCC1', 'C=CCSCCN(Cc1cccc(CF)c1)C(=O)C1CC2CCC1O2', 'C=CCSCCN(Cc1conc1CC)C(=O)Cc1cnn(C)c1C', 'C=CCSCCNC(=O)C1=C(F)CN(C(=O)CCOC2CCC2)CC1', 'C=CCSCCNC(=O)[C@@H]1CN(C(=O)CCCn2ccnc2)C[C@H]1F', 'C=CC[C@@H](CC(=O)NCC1(C)CC(F)(F)C1)NC(=O)CN1CCCC1', 'C=CC[C@@H](CC(=O)NCCc1cc(C)n[nH]1)NC(=O)C12CSCC1C2', 'C=CC[C@@H](CO)NC(=O)[C@H](NC(=O)C1CCC(OC)CC1)C(C)(C)O', 'C=CC[C@@H](NC(=O)C#CC1CCCCC1)C(=O)NCCNC(=O)OC', 'C=CC[C@@H](NC(=O)C(C)C1CCCC1)C(=O)NCCCc1ncc[nH]1', 'C=CC[C@@H](NC(=O)C(CC(C)(C)C)OC)C(=O)N1CCCC(OC)C1', 'C=CC[C@@H](NC(=O)C1=NO[C@H](C)[C@H]1C)C(=O)NCC(C)(O)CN(C)C', 'C=CC[C@@H](NC(=O)C1COCCN1C(=O)C(C)C(=O)OC)C(=O)OC', 'C=CC[C@@H](NC(=O)C=C1CCOCC1)C(=O)NCC1(C)CC2CC2C1', 'C=CC[C@@H](NC(=O)CC(C)(C)C1CC1)C(=O)NC(CO)c1ccco1', 'C=CC[C@@H](NC(=O)CC(C)(C)CCC)C(=O)NC(C)(C)C#CCCC', 'C=CC[C@@H](NC(=O)CC(C)(C)OC)C(=O)NCC1CC2CCC1CC2', 'C=CC[C@@H](NC(=O)[C@H]1CCCC(=O)N1)C(=O)NCCc1cnn(C)c1', 'C=CC[C@@H](NC(=O)c1ccc(F)cn1)C(=O)N1CCCC(OCC)C1', 'C=CC[C@@H](NC(=O)c1cccn2cncc12)C(=O)N1CCC1C(N)=O', 'C=CC[C@@H](NC(=O)c1cccnc1NC)C(=O)N1CC(N(C)CC)C1', 'C=CC[C@@H](NC(=O)c1ccnc(N)n1)C(=O)N(C)[C@H]1COC[C@H]1OC', 'C=CC[C@@H](NC(=O)c1cnn(CC)c1C)C(=O)NCCCS(N)(=O)=O', 'C=CC[C@@H](NC(=O)c1oc(CC)nc1C)C(=O)NC1CCC(F)(F)C1', 'C=CC[C@H](CC(=O)N(C)CC(=O)OC)NC(=O)c1ccncc1NC', 'C=CC[C@H](CC(=O)N(C)c1ccccc1O)NC(=O)C12CSCC1C2', 'C=CC[C@H](CC(=O)N1CC(O)(COC)C1)NC(=O)C(C)(F)C(C)(C)F', 'C=CC[C@H](CC(=O)N1CCC(C#N)CC12CC2)NC(=O)CC(C)(C)O', 'C=CC[C@H](CC(=O)N1CCC2(CC2)C1)NC(=O)[C@@H]1[C@H]2CCCC(=O)[C@H]21', 'C=CC[C@H](CC(=O)NC(CC)CSC)NC(=O)C1(C)CCC2CC2C1', 'C=CC[C@H](CC(=O)NC1(C(C)C)CCC1)NC(=O)c1cn(CC)nn1', 'C=CC[C@H](CC(=O)NCC1CCCN(C)C1)NC(=O)C(C)(C)C(N)=O', 'C=CC[C@H](CC(=O)NOCC(C)CC)NC(=O)C1(C)CC2(CCC2)C1', 'C=CC[C@H](CC(=O)N[C@@H](CC)C(=O)NCC)NC(=O)C1C=CCCC1', 'C=CC[C@H](CC(=O)N[C@H](C(N)=O)C(C)(C)C)NC(=O)Cc1cscn1', 'C=CC[C@H](CC(=O)N[C@H]1CCC[C@H]1F)NC(=O)[C@H]1NC(=O)OC1(C)C', 'C=CC[C@H](CC(=O)N[C@H]1CCO[C@H](C=C)C1)NC(=O)C1CCN(C)C1', 'C=CC[C@H](CO)NC(=O)[C@H]1C[C@H](N=[N+]=[N-])CN1C(=O)C(OC)C1CC1', 'C=CCc1cc(OCC)ccc1OC(=O)Cc1nc(C2CC2)nn1C', 'C=CCc1ccccc1C(=O)N(CCC)C(C)C(=O)N[C@H]1C[C@H](C)C1', 'C=CCc1ccccc1C(=O)N[C@@H]1[C@H]2C[C@@H]1N(C(=O)C1CC(=C)C1)C2', 'C=CCc1cn(CCCC(=O)N2CCC(N3CCN(C)CC3)C2)nn1', 'C=CCn1c(-c2cscc2C(=O)OC)nc2c1c(=O)n(C)c(=O)n2C', 'C=CCn1c(SCC(=O)N(C)C2CCCC2)nnc1-c1ccncc1', 'C=CCn1cc(C(=O)N(Cc2cc(Cl)no2)Cc2ccc(C)s2)cn1', 'C=CCn1cc(C(=O)N2C(C)CC2C(=O)N[C@H](CCO)C(C)C)cn1', 'C=CCn1cc(C(=O)N2CC3(C(=O)N(C)C(C)CC)CC2CO3)nn1', 'C=CCn1cc(C(=O)N2CCC[C@@H](C(=O)NOCC(F)(F)F)C2)cn1', 'C=CCn1cc(C(=O)NC2(C(=O)NC3(C(=O)OCC)CC3)CC2)cn1', 'C=CCn1cc(CN(CC(F)(F)Cl)C(=O)[C@]2(C)CC[C@@H](C)CC2)cn1', 'C=CCn1cc(NC(=O)CCN(CC)C(=O)CC2CCCC2C)cn1', 'C=CCn1nnnc1C(CC)(NCC(C)(C)C(C)(C)C)C1CCOC1', 'C=CCn1nnnc1C(CCc1ccccc1F)NC1(CCC)CC1', 'C=CCn1nnnc1C(NCC(C)(C)OC(C)C)c1ccnn1CC', 'C=CCn1nnnc1C(NCC(C)C(C)C)C1(CC=C)CCCCC1', 'C=CCn1nnnc1C(NCCc1ccnn1C)C1CCN(C)CC1', 'C=CCn1nnnc1C1(NCC2(CCC)CC2)CC2CC=CCC2C1', 'C=CCn1nnnc1C1(Nc2cnn(C(C)(C)C)c2)CCCCCC1', 'C=COCCCNC(=O)C1=CC2(CN(C(=O)[C@@H]3CC[C@H](C)O3)C2)OC1', 'C=COCCCNc1cc(NCCc2c[nH]c3ccccc23)ncn1', 'C=COCCN(Cc1ccc(C(F)F)o1)C(=O)C(C)c1ccnn1C', 'C=COCCNC(c1cccc(Br)c1)C(CC)NC(=O)OC(C)(C)C', 'C=C[C@H](NC(=O)[C@H](CCC)NC(=O)[C@H]1C2C3C[C@@H]1C(=O)[C@H]32)C(F)(F)F', 'C=C[C@H]1CN(C(=O)C23CC4CC2C3C4(F)F)C[C@H]1NC(=O)C1(Cl)CC1', 'C=C[C@H]1CN(C(=O)CC(C)(C)N(C)C(=O)Cc2coc(C)n2)C[C@H]1O', 'C=C[C@H]1CN(C(=O)CC2CC(=O)C2)C[C@H]1NC(=O)C(F)(F)CCCC', 'C=C[C@H]1CN(C(=O)Cn2cccn2)C[C@H]1NC(=O)C1CCCN(C)C1', 'C=C[C@H]1CN(C(=O)c2cccnc2OCC)C[C@H]1NC(=O)CN(C)C', 'C=C[C@H]1C[C@@H]1CN(CC1=C(C)CCCC1(C)C)C(=O)CSCCC#N', 'C=C[C@H]1C[C@@H]1CN(Cc1nc(OC)c(C)s1)C(=O)C1=NOC(C)(C)C1', 'C=C[C@H]1C[C@@]1(CO)CN(Cc1cc(F)ccc1F)C(=O)C(O)C=CC', 'C=C[C@H]1C[C@H](NC(=O)C(C)(C)CN(C)C(=O)C23CCC(C2)C3)CCO1', 'C=C[C@H]1C[C@]1(C)C(=O)NCC1COC(C)(C)CN1C(=O)OC(C)(C)C', 'C=C[C@H]1OCC[C@@H]1C(=O)N1C[C@H]2C[C@@]2(C(=O)N(C)[C@H](C)CN(C)C)C1', 'C=C[C@H]1OCC[C@@H]1C(=O)N[C@H]1CCN(C(=O)COC(C)(C)C)[C@H](C)C1', 'C=Cc1ccc(C(=O)NCCCCC(=O)NCC2(C=C)CCC2)cc1', 'C=Cc1ccc(C(=O)NC[C@H]2C[C@@H](C(=O)N3C4COCC3C4)C2)cc1', 'C=Cc1cncc(C(=O)N2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)NCC(O)C=C)c1', 'C=Cc1cncc(C(=O)NCCN(CCC)C(=O)C2=CCCOC2)c1', 'C=Cn1cc(CN(Cc2ccsc2C)C(=O)[C@@H]2[C@H]3CCCO[C@H]32)cn1', 'C=Cn1ccnc1C(NCCCCO)c1nnnn1C1CCCCC1', 'C=Cn1nccc1C(=O)NCC1(C(=O)Nc2c(CC)noc2C)CC1', 'C=Cn1nccc1C(=O)N[C@H]1CC[C@H](C)N(C(=O)c2csc(C)c2)C1', 'C=Cn1nncc1C(=O)N(CCO)CCC(=O)NCC1CCOC1C', 'C=Cn1nncc1C(=O)NCCn1ccc(C(=O)N(CC)C2CC2)c1', 'C=Cn1nncc1C(=O)NCc1cc[nH]c1C(=O)N1C[C@H](C)[C@@H](O)C1', 'CC#CC1CCN(C(=O)C2(C)C=CCN2C(=O)C2COCOC2)CC1', 'CC#CC1CCN(C(=O)C[C@@H](NC(=O)C2(C)CC=CCC2)C(C)C)C1', 'CC#CC1CCN(C(C(=O)NC(C)(C)C)c2cn(CCC)nc2C)C1', 'CC#CC1CN(C(=O)NC(CC)c2ccccc2OCC(=O)NC)C1', 'CC#CCC(C)NC(=O)CC[C@]1(C)CCCN1C(=O)CC(C)(C)C#N', 'CC#CCC(CO)NC(=O)C(CNC(=O)C1(C)COC(=O)N1)N(C)C', 'CC#CCC(NC(=O)C1CCN(C)CC1)C(=O)N(C)C1CC2CC2C1', 'CC#CCC(NC(=O)C=C(C)C1CC1)C(=O)N(C)CCCOC(C)C', 'CC#CCC(NC(=O)C=CCCC)C(=O)N1CC(C)(C)[C@H]2CCC[C@H]21', 'CC#CCC(NC(=O)CC(O)CC(C)C)C(=O)NCc1cnn(C)c1', 'CC#CCC(NC(=O)CCN=[N+]=[N-])C(=O)N1CC(c2nc(C)no2)C1', 'CC#CCC(NC(=O)CCOCC1CC1)C(=O)N1CC(C)C(F)(F)C1', 'CC#CCC(NC(=O)c1c[nH]c(C)cc1=O)C(=O)NCC1CC(F)C1', 'CC#CCC(NC(=O)c1cc(C)no1)C(=O)NCC1(CC(C)C)CC1', 'CC#CCCC(=O)N1CCC(OCC(=O)N2CC(c3cc[nH]n3)C2)C1', 'CC#CCCC(=O)N1CCCC(F)(CNC(=O)COCP(C)(C)=O)C1', 'CC#CCCC(=O)N1C[C@@H](F)C[C@@H]1CC(=O)Nc1ccc(OC)cc1', 'CC#CCCC(=O)N1C[C@@H](F)C[C@H]1CNC(=O)C(C)OC1CCOC1', 'CC#CCCC(=O)N1C[C@@H](O)C[C@H]1C(=O)NCC1CCN(CC)CC1', 'CC#CCCC(=O)N1C[C@H](C(=O)N2CC(OC)(C3CC3)C2)CC[C@@H]1C', 'CC#CCCC(=O)N1[C@@H]2CC[C@@H](C2)[C@H]1CC(=O)N1CCSC(C)CC1', 'CC#CCCC(=O)NCC1(C(=O)NCCc2cncn2C)CCCO1', 'CC#CCCC(=O)NCc1ccccc1CNS(=O)(=O)CC(C)OC', 'CC#CCCC(=O)N[C@H]1C[C@H]2C[C@H](NC(=O)C3CC(=O)N(C)C3)C[C@H]21', 'CC#CCCCC(=O)N(C)CCCCC(=O)N1CCC2(CCCO2)C1', 'CC#CCCCC(=O)N1CCC(C(=O)Nc2cn(C)nc2C)=C(F)C1', 'CC#CCCCC(=O)N1CCC1CC(=O)NCCCc1cncnc1', 'CC#CCCCC(=O)N1CCCC(N(C)C(=O)c2nscc2C)CC1', 'CC#CCCCC(=O)N1CCN(C(=O)C#CC(C)C)C(CC(F)F)C1', 'CC#CCCCC(=O)N1CCO[C@@H](C)[C@@H]1C(=O)NCC1(F)CN(C)C1', 'CC#CCCCC(=O)NCCN(CC)C(=O)CCc1cccc(F)c1', 'CC#CCCCCNC(=O)C=C(C)CNC(=O)C(C)Cn1cccn1', 'CC#CCCCCNc1nc(N(C)CCCC(C)O)c2ccsc2n1', 'CC#CCN(C)C(=O)C(F)C1CCN(C(=O)c2ccc(OC)cc2)C1', 'CC#CCN(C)C(=O)C(NC(=O)c1cc2ncccc2[nH]1)C1CCC1', 'CC#CCN(C)C(=O)C1(C2CC2)CN(C(=O)c2n[nH]c3c2CCC3)C1', 'CC#CCN(C)C(=O)CC1CC2(C1)CN(C(=O)C=C1CCCCC1)C2', 'CC#CCN(C)c1ccncc1S(=O)(=O)NCc1cnc(C)cc1C', 'CC#CCNC(=O)CC[C@H]1CCCN1C(=O)c1cnc2[nH]ccc2c1', 'CC(/C=C/C(=O)N1CC(=O)NC(C)(C)C1)NC(=O)c1ncccc1N', 'CC(/C=C/C(=O)NC1COC(C)(C)C1)NC(=O)C1(C#N)CCOCC1', 'CC(/C=C/C(=O)NCC1C2CCCCCC21)NC(=O)C1=CCCCO1', 'CC(/C=C/C(=O)NCC[C@H]1CCC(=O)N1)NC(=O)CC(C)C(C)(C)C', 'CC(=CC(=O)N(C)CCCCC(=O)N(C)CCC(O)CO)C(C)(C)C', 'CC(=CC(=O)N(CC(=O)N1CC(C)(C#N)C1)C1CC(C#N)C1)C(C)C', 'CC(=CC(=O)N1C(CC(=O)N2C[C@@H]3C[C@H]2CO3)[C@H]2CCC[C@H]21)C(C)C', 'CC(=CC(=O)N1CC(SC2CN(C(=O)OC(C)(C)C)C2)C1)C(F)(F)F', 'CC(=CC(=O)N1CCC(C(=O)N[C@H]2C[C@@H]2c2ccn(C)n2)C1)C(C)C', 'CC(=CC(=O)N1CCC(C)N(C(=O)c2ncn(C)c2C)CC1)C(C)C', 'CC(=CC(=O)N1CCCCC(N(C)C)C1)CNC(=O)[C@@H](O)C(F)(F)F', 'CC(=CC(=O)N1CCN(C(=O)CSCC(F)F)CC12CCC2)C(F)F', 'CC(=CC(=O)N1CCN(C(=O)[C@H]2C[C@@H]3C[C@H]2CC3(F)F)CC1)C(C)C', 'CC(=CC(=O)N1CC[C@H](CO)[C@@H](NC(=O)c2cnnn2C)C1)C(C)C', 'CC(=CC(=O)N1CC[C@H]2CN(C(=O)[C@@H]3COCCO3)[C@H](C)[C@H]21)C(F)F', 'CC(=CC(=O)N1C[C@H]2C[C@@H]1[C@H]2NC(=O)Cc1cn(C)nc1C)C(F)F', 'CC(=CC(=O)N1Cc2n[nH]cc2C1C(=O)NCCC1(C)CC1)C(C)C', 'CC(=CC(=O)NC(CC(C)C)C(=O)N1OC2C=CC1CC2)C(C)(C)C', 'CC(=CC(=O)NCC(C)C1CCC1)CNC(=O)[C@@H]1CCCN1C(N)=O', 'CC(=CC(=O)NCC1COCCN(C(=O)CNC(N)=O)C1)C(C)(C)C', 'CC(=CC(=O)NCCCN(C)C(=O)Cn1cc(C)ccc1=O)C(C)C', 'CC(=CC(=O)N[C@@H]1CC[C@H](O)CN(C(=O)C2(F)CC=CC2)C1)C(F)F', 'CC(=CC(=O)N[C@H](CO)CCCNC(=O)C(F)C(C)(C)O)C(C)(C)C', 'CC(=CC(=O)Nc1ccc(NC2CCC(=O)NC2=O)cc1)C(F)(F)F', 'CC(=CC(=O)Nc1cnn(CCO)c1)CNC(=O)c1cncnc1C', 'CC(=CC(C)(C)C)C(=O)N1CC=CC(C(=O)NCC#CC#CCO)C1', 'CC(=CC(C)(C)C)C(=O)N1CCCCC(C(=O)N[C@H]2C[C@H](O)[C@H]2O)C1', 'CC(=CC(C)(C)C)C(=O)N[C@@H](C(=O)NC(C)C(O)C(F)F)C(C)(C)C', 'CC(=CC1CC1)C(=O)N1CCN(C(=O)c2cnsc2)CC1C(C)(C)C', 'CC(=CC1CC1)C(=O)NC1(C(=O)NC[C@@H]2CC[C@H](C)N2C)CCCC1', 'CC(=Cc1ccccc1)C(=O)N(C)CCCC(=O)NC1(CO)CCC1', 'CC(=Cc1ccco1)C(=O)N1CCC=CC1C(=O)NCc1ccco1', 'CC(=Cc1cn[nH]c1)C(=O)N(C)CCOCCC(=O)Nn1cccn1', 'CC(=O)C(C)(C)CC(=O)N1CCCC1CC(=O)NCC1C2CCCC21', 'CC(=O)C(C)(C)CC(=O)NCCN1CCN(C(=O)c2ccsc2)CC1', 'CC(=O)C(C)CC(C)C(=O)NCCC1(C(=O)N2CC[C@@H](CO)C2)CC1', 'CC(=O)C1(C(=O)N[C@@H]2C=C[C@H](CC(=O)N(C)C3CCN(C)C3)C2)CC1', 'CC(=O)C1CC1(Cl)C(=O)NCCC1CN(C(=O)Cc2nocc2C)C1', 'CC(=O)CC(C)(C)C(=O)N1CSC[C@H]1C(=O)N1CCC(N=[N+]=[N-])CC1', 'CC(=O)CCC(=O)N(Cc1ccc(CCF)cc1)Cc1csc(Cl)c1', 'CC(=O)CCC(=O)N1CCCC2(CCN(Cc3ccccc3)CC2)C1', 'CC(=O)CCCC(=O)N(C)C[C@H]1C[C@H](F)CN1C(=O)c1cc(Cl)no1', 'CC(=O)CCCC(=O)N1CCC(O)(CCNC(=O)CC2(O)CCC2)C1', 'CC(=O)CCCC(=O)NC(C)[C@@H]1C[C@H]1C(=O)N[C@@]1(C)C[C@H]2CC[C@@H]1C2', 'CC(=O)CCCC(=O)NC1CCN(c2nccc(-c3ccsc3)n2)C1', 'CC(=O)CCCC(=O)NCC12CC(CO1)N(C(=O)c1cnccn1)C2', 'CC(=O)CCCC(=O)NC[C@H]1CC[C@H](C(=O)NCc2c[nH]nn2)CC1', 'CC(=O)CCCC(=O)N[C@@H]1C[C@H]2C[C@@H]1N(C(=O)C1COCC1(C)C)C2', 'CC(=O)CCCC(C)C(=O)N1CCC(O)(CCNC(=O)C[C@@H](C)O)C1', 'CC(=O)CCCC(C)C(=O)N1CC[C@H](NC(=O)CCCF)[C@H]1C(C)C', 'CC(=O)CCCCC(=O)NC[C@H]1CC[C@H]1C(=O)N1C[C@H](C)C[C@H](O)C1', 'CC(=O)CCc1cn(C(C)CNC(=O)C(c2cscn2)N(C)C)nn1', 'CC(=O)N(C)C(C)C(=O)N(C)C(C)C(=O)N(C)Cc1cc(O)ccn1', 'CC(=O)N(C)C(C)C(=O)NCC(CO)CNC(=O)C=Cc1cc[nH]c1', 'CC(=O)N(C)C(C)C(=O)NC[C@H]1C[C@@H](C(=O)N2CCS(=O)CC2C)C1', 'CC(=O)N(C)C(C)C(=O)NCc1ccnc(C(=O)N2CCCCC2)c1', 'CC(=O)N(C)CC(=O)N(CCNC(=O)c1ccc(C)cc1C)C1CC1', 'CC(=O)N(C)CC(=O)N1CC(C)(C(=O)NC2CC3(C2)CC(C)(C)C3)C1', 'CC(=O)N(C)CC(=O)N1CC(O)(C(F)C(=O)N2CCS(=O)CC2C)C1', 'CC(=O)N(C)CC(=O)N1C[C@H](C(=O)NCC2CCCOCC2)[C@@H](C)C1', 'CC(=O)N(C)CC(=O)NCC(C)(C)C#CC(=O)N1CCC[C@]1(C)CO', 'CC(=O)N(C)CC(=O)NCC1COCCN1C(=O)c1scc(C)c1Cl', 'CC(=O)N(C)CCCNC(=O)[C@@H](NC(=O)c1sccc1C)C1CCC1', 'CC(=O)N(C)CCN(C)c1ccc(S(=O)(=O)NC23CC(C2)C3)cc1Cl', 'CC(=O)N(C)Cc1cccc(NC(=O)c2ccc([C@@H](N)CO)cc2)c1', 'CC(=O)N(c1ccc(NC(=O)Cc2cccc(Cl)n2)cc1)C1CC1C', 'CC(=O)N1CC(C(=O)NC[C@H]2C[C@@H]2C(=O)NC(C(F)F)C(C)(C)C)C1', 'CC(=O)N1CC(C(=O)N[C@H](C)CC(=O)N2CCCC3(CCCC3)C2)C1', 'CC(=O)N1CC(CC(=O)N(C)CCCCCC(=O)N2CCC2CO)C1', 'CC(=O)N1CC2(C1)CN(C(=O)CCCNC(=O)c1nn(C)cc1C)C2', 'CC(=O)N1CCC(C(=O)N(C)CCN(C)C(=O)c2cc(Cl)c[nH]2)CC1', 'CC(=O)N1CCC(NC(=O)C(=O)NCCc2cnccc2C)C(C)C1', 'CC(=O)N1CCC(NC(=O)C2CC(C3CCCC3)C2)c2ccccc21', 'CC(=O)N1CCC=C1C(=O)N1CCC(N(C)c2ccc(C)nn2)CC1', 'CC(=O)N1CCCC(CNCC2CN(Cc3ccccc3)CC2C)C1', 'CC(=O)N1CCCC1C1CCCN1C(=O)COc1cccc(Br)c1Cl', 'CC(=O)N1CCC[C@H]1C(=O)N1CC(OCC(=O)N2CCC2C(C)O)C1', 'CC(=O)N1CCC[C@H]1C(=O)N[C@H]1C[C@H](NS(=O)(=O)c2cnnn2C)C1', 'CC(=O)N1CCN(c2ccc(Nc3cc(CC#N)ncn3)cc2)CC1', 'CC(=O)N1CCN(c2ccccc2CNC(=O)C2(O)CC(C)C2)CC1', 'CC(=O)N1CCN(c2ncnc(NCCN3CCNC3=O)c2C)CC1', 'CC(=O)N1CCc2ccc(S(=O)(=O)NCC#CCN(C)C)cc2CC1', 'CC(=O)N1CCc2ccc(S(=O)(=O)NCC(F)(F)C(F)(F)CO)cc21', 'CC(=O)N1CSC[C@@H]1C(=O)NC1(CNC(=O)CSc2cn[nH]c2)CC1', 'CC(=O)N1CSC[C@H]1C(=O)NCC(O)CNC(=O)[C@H](C(C)C)N(C)C', 'CC(=O)N1C[C@@H](O)C[C@H]1C(=O)NCCCN(C)C(=O)C1CCC(C)O1', 'CC(=O)N1Cc2ccc(NC(=O)c3cc4cccc(F)c4o3)cc2C1', 'CC(=O)NC(C)(C)C(=O)N[C@H]1CC[C@@H](C(=O)NCc2csc(C)n2)C1', 'CC(=O)NC(C)(C)C(=O)N[C@H]1C[C@@H](CC(=O)N(C)CC2CCOC2)C1', 'CC(=O)NC(C)C(=O)N1CCC[C@H]1CN(C)C(=O)C1CN(C(N)=O)C1', 'CC(=O)NC(C)C(=O)N1CCN(C(=O)c2ccc(F)cc2C)[C@H](C)C1', 'CC(=O)NC(C)C(=O)N1C[C@@H](O)C[C@H]1CNC(=O)c1sc(C)nc1C', 'CC(=O)NC(C)C(=O)N[C@H]1C[C@](C)(NC(=O)CC2CC3(CC3)CO2)C1', 'CC(=O)NC(CC(=O)OCCc1cccc(F)n1)c1ccc(Cl)cc1', 'CC(=O)NC(CCN(C)c1nccc(NCC2CSC2)n1)C(C)(C)C', 'CC(=O)NC(Cc1c[nH]c2ccccc12)C(=O)Nc1cc(C)sc1C', 'CC(=O)NC1(C)CCN(C(=O)CCNC(=O)CCc2ccc(C)o2)C1', 'CC(=O)NC1(CC(=O)N(C)[C@H](C)C(=O)NC2CC3(C2)CC3(F)F)CC1', 'CC(=O)NC1(CC(=O)NC(C)/C=C/C(=O)N(C)C(C)CC(N)=O)CC1', 'CC(=O)NC1CCN(C(=O)C(NC(=O)C2=C(C)CCC2)C(C)C)CC1', 'CC(=O)NC1CN(C(=O)[C@H]2C=C[C@H](NC(=O)C3CC4(CSC4)C3)C2)C1', 'CC(=O)NCC(=O)N1CC(C(=O)N2C[C@@H]3C[C@H]2CS3=O)CCC1(C)C', 'CC(=O)NCC(=O)N1CC=C(CC(=O)NCc2cc(C)c(C)s2)CC1', 'CC(=O)NCC(=O)N1CCCN(C(=O)[C@H]2C[C@H]3C=C[C@@H]2CC3)[C@H](C)C1', 'CC(=O)NCC(=O)N1C[C@H]2CCN(C(=O)c3cn(C)ccc3=O)[C@H]2C1', 'CC(=O)NCC(=O)NCCCCC(C)(C)NC(=O)/C=C/c1c[nH]cn1', 'CC(=O)NCCC(=O)N1CC2CC(C1)CN(C(=O)C(C)(C)C1CC1)C2', 'CC(=O)NCCC(=O)N[C@H]1CC[C@H]1C(=O)NCC1CCC(C)(C)CO1', 'CC(=O)NCCC(=O)N[C@H]1C[C@@H](Nc2nc3ccc(C#N)cc3s2)C1', 'CC(=O)NCCCC(=O)N(Cc1cn(C)cn1)CC(O)c1ccsc1', 'CC(=O)NCCCC(=O)N1CC[C@H](C(=O)NC23CCC(C2)OC3C)C1', 'CC(=O)NCCCC(=O)N1C[C@H](CCNS(=O)(=O)C2(C)CC2)[C@@H](C)C1', 'CC(=O)NCCCC(=O)NC1CC(O)(CNC(=O)C2=C(C)OCC2)C1', 'CC(=O)NCCCCC(=O)NCC1(F)CN(C(=O)C2CCNC2=O)C1', 'CC(=O)NCCCCC(=O)N[C@@H](C)C(=O)N(C)C1CC(C)CC(C)C1', 'CC(=O)NCCCCC(=O)N[C@H]1CC[C@H]1CNC(=O)c1nocc1Cl', 'CC(=O)NCCN(CC1=NOC2OCCC12)Cc1ccc(C#N)cc1', 'CC(=O)NCCNC(=O)CCN(CCO)C(=O)C(C)c1cnn(C)c1', 'CC(=O)NCCNC(=O)C[C@@H](C)N(C)C(=O)c1ncc(C#N)cc1C', 'CC(=O)NCCc1cn(CCC(=O)N2CCC[C@H]2CCN(C)C)nn1', 'CC(=O)N[C@@H](C)C(=O)NC1(C(F)F)CC(NC(=O)[C@H]2C[C@H]2C(N)=O)C1', 'CC(=O)N[C@@H](C)C(=O)N[C@H]1CCCCC[C@H]1C(=O)N(C)[C@H]1C[C@@H](O)C1', 'CC(=O)N[C@H](C(=O)N(CC(=O)NCCNC(N)=O)C1CCC1)C(C)C', 'CC(=O)N[C@H](C)C(=O)N(CC(=O)Nc1cnn(C(C)(C)C)c1)C(C)C', 'CC(=O)N[C@H](C)C(=O)N[C@H]1CN(C(=O)c2csc3nccn23)C[C@H]1C', 'CC(=O)N[C@H]1CN(C(=O)c2nccc(Cl)c2O)C[C@@H]1c1nccn1C', 'CC(=O)Nc1c(C)nn(CC(=O)Nc2cc3c(cc2Cl)OCO3)c1C', 'CC(=O)Nc1cc(Br)cc(C(=O)NCc2ccnc3ccccc23)c1', 'CC(=O)Nc1cc(Cl)ccc1NC(=O)[C@@H]1C[C@H]1CC(=O)OC(C)(C)C', 'CC(=O)Nc1ccc(C(=O)Nc2cnn(-c3ccnc(F)c3)c2)cc1', 'CC(=O)Nc1ccc(CN(CCc2cc(C)ns2)CC2CCC2)cn1', 'CC(=O)Nc1ccc(NC(=O)c2c(Cl)cnn2C2CCCC2)cc1C', 'CC(=O)Nc1ccc(Nc2nnn(COCc3ccccc3)n2)cc1', 'CC(=O)Nc1ccc(S(=O)(=O)N(C)Cc2ccccc2C(F)(F)F)s1', 'CC(=O)Nc1ccc2nc(NC(=O)NC(CO)CC(F)(F)F)sc2c1', 'CC(=O)Nc1cccnc1C(=O)Nc1ccc(-c2ccn(C)n2)cn1', 'CC(=O)OC(C)(C)C(=O)N[C@H]1CC[C@@H](C(=O)N2CC(OCCF)C2)C1', 'CC(=O)OC(C)(C)C(=O)N[C@H]1CC[C@H]1C(=O)NCC1(C)CCN(C)C1', 'CC(=O)OC1(C(=O)N2CC[C@H](CC(=O)N[C@H]3COC[C@H]3CO)C2)CC1', 'CC(=O)OC1(C(=O)NC[C@@H]2[C@H]3CN(C(=O)c4cnsc4C)C[C@@H]23)CC1', 'CC(=O)OC1(C(=O)NC[C@H]2C[C@@H]2C(=O)N2CCC[C@@H]2CN(C)C)CC1', 'CC(=O)OCC(=O)N1CC(CC(=O)NCc2ncc(C)cn2)CC1C', 'CC(=O)OCC(=O)N1CC(CNC(=O)c2ncn(C)c2C)C(F)(F)C1', 'CC(=O)OCC(=O)N1CCC2CCC(NC(=O)CCC(F)(F)F)C1C2', 'CC(=O)OCC(=O)N1C[C@@H](O)C[C@H](NC(=O)C#CC2CCOCC2)C1', 'CC(=O)OCC(=O)NC1CC=C(C(=O)Nc2cc(C)cc(CO)c2)C1', 'CC(=O)OCC(CO)NC(=O)Nc1nc(-c2ccc(C)cc2)c(C)s1', 'CC(=O)OCC1CCN(C(=O)C[C@H]2C[C@H]2CNC(=O)C2CCC2C)C1', 'CC(=O)OCCC(=O)NC1(C(=O)N[C@H]2CCC[C@H]2N=[N+]=[N-])CC1(C)C', 'CC(=O)OCCCC(=O)N(CCC(=O)N[C@@H](C)c1ncc[nH]1)C(C)C', 'CC(=O)OCCCC(=O)N1CCO[C@@H](C(=O)N2CCS(=O)(=O)CC2)C1', 'CC(=O)OCCN(C)C(=O)[C@H]1C[C@@H](NC(=O)[C@H]2[C@@H]3CCCCC[C@@H]32)C1', 'CC(=O)OC[C@@H](C)C(=O)Nc1ccccc1N1CCc2ccccc21', 'CC(=O)O[C@@H](C)C(=O)N(Cc1sncc1C)CC1CC2CCC1CC2', 'CC(=O)O[C@@H](C)C(=O)N1[C@@H]2CC[C@@H](C2)[C@H]1C(=O)N1CC2CC=CC1C2', 'CC(=O)O[C@@H](C)C(=O)NCC1(NC(=O)c2cc3cc[nH]c3cn2)CC1', 'CC(=O)O[C@H]1CCN(C(=O)[C@@H]2CC[C@H](NC(=O)c3c[nH]c(=O)o3)C2)C1', 'CC(=O)O[C@H]1C[C@@H]1C(=O)N[C@@H](CN(C)C)C(=O)N1CC(=O)NCC1C', 'CC(=O)[C@H]1[C@H](C(=O)N2CCC(CC(=O)NCc3cnns3)C2)C1(C)C', 'CC(=O)c1cc(C(=O)N2CCC=CC2C(=O)N2C[C@@H]3C[C@H]2CO3)[nH]n1', 'CC(=O)c1cc(C(=O)N[C@@H](C)CNC(=O)C2CCCN2N=O)oc1C', 'CC(=O)c1cc(C(=O)N[C@H](C)CCCC(=O)N2CCOC[C@H]2C)no1', 'CC(=O)c1cc(C(=O)N[C@H]2CC[C@H](NC(=O)C3=C(Cl)CC3)CC2)cs1', 'CC(=O)c1cc(C(C)C)ccc1NC(=O)N1Cc2cccn2[C@@H](C)C1', 'CC(=O)c1cc(C(F)(F)F)cnc1Oc1ccc2c(c1)CC(O)CC2', 'CC(=O)c1cc(S(=O)(=O)N[C@@H](C)c2ccc3c(c2)OCO3)ccc1Cl', 'CC(=O)c1ccc(-c2cn(-c3cc(O)cc(C(F)(F)F)c3)nn2)cc1', 'CC(=O)c1ccc(C(=O)N2CC=C(CC(=O)NCC(C)(C)O)CC2)o1', 'CC(=O)c1ccc(C(=O)NC2CC(C)(C(=O)NC3CNC(=O)C3)C2)o1', 'CC(=O)c1ccc(NC(=O)COC(=O)c2cnc(C(=O)O)cn2)cc1', 'CC(=O)c1ccc2ccccc2c1OCC(=O)Nc1ccccc1C', 'CC(=O)c1cccc(CNC(=O)Nc2cnn(C3CCOCC3)c2)c1', 'CC(=O)c1cccc(Sc2cncc(C(=O)N3CCN(C)CC3)n2)c1', 'CC(=O)c1ccccc1C(=O)N1CCCN(Cc2ccccn2)CC1', 'CC(=O)c1ccccc1OCCn1cc(C(N)CC2CCOC2)nn1', 'CC(=O)c1ccnc(N2CC(CNC(=O)OC(C)(C)C)C(C)(C)C2)c1', 'CC(=O)c1ccnc(NC(=O)c2cccnc2Sc2ccccc2)c1', 'CC(=O)c1cncc(C(=O)Nc2cccc(N3N=C(C)CC3=O)c2)c1', 'CC(=O)c1cnn(C)c1C(=O)NCC(O)(c1ncc(C)o1)C(F)(F)F', 'CC(=O)c1ncc(C(=O)NCC2CC(NC(=O)CCC(F)(F)F)C2)s1', 'CC(C#N)C(=O)N1C[C@H]2CCC[C@@]2(CNS(=O)(=O)c2ccn(C)n2)C1', 'CC(C(=O)N(C)C1CC(C(=O)NCCn2cnnc2)C1)n1cccn1', 'CC(C(=O)N(C)C1CN(C(=O)C(F)=Cc2cnc[nH]2)C1)c1ccn[nH]1', 'CC(C(=O)N(C)CCCCC(=O)NCCc1csnn1)n1ccnc1', 'CC(C(=O)N(C)CCCCNS(=O)(=O)c1cccs1)c1ccnn1C', 'CC(C(=O)N(C)CCCF)C1CCN(C(=O)c2ncnc(O)c2F)C1', 'CC(C(=O)N(C)CCNC(=O)C(C)OC1CCCCC1)=C1CCCC1', 'CC(C(=O)N(CCCO)C1CCC1)n1cc(C(C2CC2)C2CC2)nn1', 'CC(C(=O)N(CCNC(=O)c1cocn1)C1CC1)C1CCCCCC1', 'CC(C(=O)N(Cc1cc(O)ccc1Cl)Cc1cc(C)oc1C)=C1CC1', 'CC(C(=O)N1CC(C(O)C(=O)NC2CCCOC2)C1)c1ccn(C)n1', 'CC(C(=O)N1CC(C)(CO)C1)n1cc(-c2c(F)ccc(F)c2Cl)nn1', 'CC(C(=O)N1CC2(CC(N3CCOCC3)C2)C1)c1cc(F)cc(F)c1', 'CC(C(=O)N1CC2(CC2)C1)C1CCCN(C(=O)c2cn[nH]c(=O)c2)C1', 'CC(C(=O)N1CC2(CN(C(=O)c3cc(C#N)cn3C)C2)C1)N1CCC1', 'CC(C(=O)N1CC=CC1C(=O)NC[C@@H](F)C(C)(C)O)C1CCCCC1', 'CC(C(=O)N1CCC(/C=C/C(=O)NCC2(F)CC(O)C2)CC1)=C1CC1', 'CC(C(=O)N1CCC(C#N)CC1)N(C(=O)CC1CNC(=O)O1)C1CC1', 'CC(C(=O)N1CCC(N2CCCC2)C1)N(C)C(=O)CCc1nccs1', 'CC(C(=O)N1CCC2(CC1)NC(=O)N(CC(=O)O)C2=O)n1ccnc1', 'CC(C(=O)N1CCCC1CC(=O)NCC(C)(C)C(N)=O)c1ccco1', 'CC(C(=O)N1CCCN(C(=O)C[C@H]2CCOC2)CC1)N1CCOC1=O', 'CC(C(=O)N1CCC[C@H](C(=O)NCC2CC(F)(F)C2)[C@@H]1C)C(F)(F)F', 'CC(C(=O)N1CCN(C(=O)C(=O)N(C)C)CCC1C)c1cncnc1', 'CC(C(=O)N1CCN(C(=O)c2cnnn2C)CC12CCC2)=C1CCC1', 'CC(C(=O)N1CCN(CC(=O)N[C@@H]2CCCC[C@H]2F)CC1)S(N)(=O)=O', 'CC(C(=O)N1CC[C@H](C)C[C@@H]1C(=O)NC(C)c1nccn1C)=C1CC1', 'CC(C(=O)N1C[C@@H](C)O[C@H](C(=O)NCCN(C)C)C1)c1ccn(C)c1', 'CC(C(=O)N1C[C@@H]2C[C@@H]2[C@H]1C(=O)N1CCC(C#N)C1)N1CCOCC1', 'CC(C(=O)N1C[C@H](C)C[C@H]1C(=O)NC1(c2nnn[nH]2)CC1)C1CCC1', 'CC(C(=O)N1C[C@H](O)C[C@H]1C(=O)N(C)Cc1cc[nH]n1)C1CCCC1', 'CC(C(=O)N1C[C@H]2CCCC[C@H]2C1)N(C)C(=O)CCn1cnc(N)n1', 'CC(C(=O)N1[C@H](C)CN(C(=O)[C@H]2[C@@H]3CCCC[C@@H]32)C[C@@H]1C)=C1CCC1', 'CC(C(=O)NC(C(=O)N(C)C1CC(C)(C)C1)c1cccs1)C1CCC1', 'CC(C(=O)NC(C(=O)N(C)CC(Cl)Cl)C1(O)CCCCC1)C(C)(C)C', 'CC(C(=O)NC(C)(C)/C=C/C(=O)N1CCC2CCCC2CC1)C1CC1', 'CC(C(=O)NC(C)(C)CCC(=O)NC[C@H]1CC[C@H]1C)c1ccnn1C', 'CC(C(=O)NC(C)(C)CCN(C)C(=O)C1=CCN(C)C1)C1CCCO1', 'CC(C(=O)NC(C)C1(C(=O)NCC2CCC(F)C2)CC1)N1CCCC1', 'CC(C(=O)NC(CC(F)F)C(=O)NC12CC1COC2(C)C)=C1CCC1', 'CC(C(=O)NC1(C(=O)NCC(F)(F)C(C)(C)O)CCC1)C1CCOC1', 'CC(C(=O)NC1(CC(=O)NC[C@H](O)C(F)(F)F)CC1)N1CCNC1=O', 'CC(C(=O)NC12CC(C(=O)NCC3CCOCC3)(C1)C2)c1ccn[nH]1', 'CC(C(=O)NC12CC(NC(=O)[C@@H]3CC[C@H](C)O3)(C1)C2)c1ccccc1', 'CC(C(=O)NC1CC2(C1)CN(C)C2)N(C)C(=O)C(=O)c1cccn1C', 'CC(C(=O)NC1CC2(CC2)C1)C1CCCN(C(=O)CCOC2CC2)C1', 'CC(C(=O)NC1CC2(CCCO2)C1)N(C)C(=O)C1CCC(C#N)CC1', 'CC(C(=O)NC1CCOC(CO)C1)(c1ccccc1)c1ccccc1', 'CC(C(=O)NC1CCc2[nH]ncc2C1)N(C(=O)/C=C/C(F)F)C1CC1', 'CC(C(=O)NCC(CO)CNC(=O)c1ccn(C(F)F)n1)C1CCC1', 'CC(C(=O)NCC1CC(C2CC2)=NO1)n1cc(-c2cnccn2)nn1', 'CC(C(=O)NCC1CCN1C(=O)c1cn(C)nn1)c1cccc(O)c1', 'CC(C(=O)NCC1CN(C(=O)CCc2cscn2)C1)C(F)(F)C(F)F', 'CC(C(=O)NCCC(C)(C)F)C1CCN(C(=O)[C@H]2C[C@@H]2C2CC2)CC1', 'CC(C(=O)NCCCCCCNC(=O)c1cc(Cl)ccc1F)C(F)F', 'CC(C(=O)NCCC[C@@H](CO)NC(=O)CP(C)(C)=O)c1cncnc1', 'CC(C(=O)NCCN(C(=O)[C@]12C[C@H]1COC21CCC1)C1CC1)=C1CC1', 'CC(C(=O)NCC[C@@H](O)C(=O)NCCCn1cnnn1)c1ccsc1', 'CC(C(=O)NCCn1cc(NS(=O)(=O)c2cccnc2)cn1)C1CC1', 'CC(C(=O)NC[C@@H]1CC2(CC2)CN1C(=O)Cc1ccco1)=C1CCC1', 'CC(C(=O)NC[C@@H]1CCCC[C@H]1O)N(C)C(=O)CNc1cccnc1', 'CC(C(=O)NC[C@@H]1C[C@H](F)CN1C(=O)C1CC2CCC(C2)C1)=C1CC1', 'CC(C(=O)NCc1cc(C(=O)NCC2(C#N)CC2)cs1)n1ccnc1', 'CC(C(=O)NCc1cc(C(F)F)no1)n1cc(C2(O)CCOC2)nn1', 'CC(C(=O)NCc1cccc2c1CCCC2)c1ccc(F)c(F)c1F', 'CC(C(=O)NOCCCO)C1CCN(C(=O)c2ccn(C(C)C)n2)C1', 'CC(C(=O)NS(=O)(=O)c1ccn(CC(F)F)n1)N(C)C[C@H]1C[C@@H](O)C1', 'CC(C(=O)NS(=O)(=O)c1cn(C)nn1)N(C)Cc1cc(C2CC2)on1', 'CC(C(=O)N[C@@H](COC(C)(C)C)C(=O)OC(C)(C)C)n1ccc(Br)n1', 'CC(C(=O)N[C@@H]1CCC[C@H]1CCCNS(=O)(=O)C(C)C)n1ccnc1', 'CC(C(=O)N[C@@H]1CC[C@H]1NC(=O)CCc1cccn1C)N1CCCC1', 'CC(C(=O)N[C@H](C)CC(=O)NC12CCCN(CCC1)C2)c1cccs1', 'CC(C(=O)N[C@H]1[C@@H]2CN(C(=O)c3ncccn3)CC[C@@H]21)N1CCCC1', 'CC(C(=O)Nc1ccc(Cl)cc1C(F)(F)F)N1CCc2sccc2C1', 'CC(C(=O)Nc1ccc(NC(=O)NCC2CSC2)cc1)n1cncn1', 'CC(C(=O)Nc1nc2c(s1)C(=O)NCC(C)(C)C2)N1CCOCC1=O', 'CC(C(=O)OC(C)(C)C)S(=O)(=O)NC(=O)c1cc2cc(Cl)ccc2s1', 'CC(C(N)=O)N1CCN(C(=O)NCc2cccc(Cl)c2C(F)F)CC1', 'CC(C)(C#N)CC(=O)N1CCC=C(CNC(=O)CN2CCSCC2)C1', 'CC(C)(C#N)CC(=O)N1CC[C@H](O)[C@@H]1C(=O)N1CC(OCC(F)F)C1', 'CC(C)(C#N)CC(=O)NC(C)(CO)C(=O)NC1CCn2cncc2C1', 'CC(C)(C#N)CC(=O)NC/C=C/CC(=O)N1CCC2(CCCCC2)C1', 'CC(C)(C#N)CC(=O)NCC1(CNC(=O)c2ocnc2C2CC2)CC1', 'CC(C)(C#N)CC(O)CN1C(=O)NC(C)(c2ccc(F)c(Cl)c2)C1=O', 'CC(C)(C#N)CC(O)COC(=O)[C@H]1CC[C@@H](Nc2ccccn2)CC1', 'CC(C)(C#N)CCNC(=O)N[C@H]1C[C@H](c2ccc(C(C)(C)C)cc2)C1', 'CC(C)(C#N)c1ncc(CNc2nc(-c3c(F)cccc3F)n[nH]2)s1', 'CC(C)(C(=O)N1CC([C@@H]2C[C@H]2C(=O)N2CC[C@@H](F)C2)C1)n1cccn1', 'CC(C)(C(=O)N1CCC2(CC(NC(=O)C34CSCC3C4)C2)C1)C1CC1', 'CC(C)(C(=O)NC/C=C/CC(=O)NCCc1cnco1)n1cccn1', 'CC(C)(C(=O)NC1CCCc2cc(Cl)ccc21)C1=CCS(=O)(=O)CC1', 'CC(C)(C(=O)NCC(=O)Nc1cccc(C#N)c1)c1ccccc1Cl', 'CC(C)(C(=O)NCC1(C(=O)Nc2ccc(F)cc2CO)CC1)C(F)F', 'CC(C)(C(=O)NCCCN1CCOCC1)S(=O)(=O)c1ccc(Br)cc1', 'CC(C)(C(=O)NC[C@]12C[C@H]1CN(C(=O)C1CCCC1)C2)C1CCCC1', 'CC(C)(C(=O)NOCCC(F)F)C1CCCN1C(=O)C1=C(Cl)CCC1', 'CC(C)(C(=O)N[C@H](CO)CC1CC1)c1csc(-c2ccccc2F)n1', 'CC(C)(C(=O)OCC(=O)NC(=O)Cc1ccccc1)c1ccccn1', 'CC(C)(C(=O)OCCCc1ccc2ccccc2c1)C(O)C1CCC1', 'CC(C)(C(N)=O)C(=O)N[C@H]1CC[C@H](NC(=O)CC2CCCOCC2)C1', 'CC(C)(C)/C=C/C(=O)N1CCCCC1CNC(=O)Cn1nnc(N)n1', 'CC(C)(C)/C=C/C(=O)N[C@H]1CC[C@@H]1NC(=O)C12CC=CCN1CCC2', 'CC(C)(C)/C=C/CC(=O)NCCCC(C)(C)NC(=O)C1=CCCCC1', 'CC(C)(C)C#CC(=O)N1CCC(CCC(=O)N2C[C@H](O)C[C@@H](O)C2)C1', 'CC(C)(C)C#CC(=O)NC(CC(=O)NC1(C2CC2)CCOC1)C(F)F', 'CC(C)(C)C#CC(=O)NC1CC(NC(=O)c2ccn3ccccc23)C1', 'CC(C)(C)C(=O)C(=O)N1CC[C@H](NC(=O)c2nsnc2O)[C@H](CO)C1', 'CC(C)(C)C(=O)N1CC(OCCNC(=O)c2cnc3c(c2)COC3)C1', 'CC(C)(C)C(=O)N1CC[C@H](CO)[C@@H](NC(=O)C23C(=O)C4CC2C3C4)C1', 'CC(C)(C)C(=O)N1Cc2nccn2CC(NC(=O)CC2CCCO2)C1', 'CC(C)(C)C(=O)NCC1=CCN(C(=O)Cc2cncn2C2CC2)CC1', 'CC(C)(C)C(=O)Nc1nc(CC(=O)OCC(=O)Nc2nncs2)cs1', 'CC(C)(C)C(C#N)C(=O)NC1CC=C(C(=O)N[C@H]2CC[C@H](C)CC2)C1', 'CC(C)(C)C(CCO)CN(Cc1csc(C#N)c1)C(=O)C1CC(=O)C1', 'CC(C)(C)C(CNC(=O)C1(C)CC1(C)C)C(=O)NCC1=CCCOC1', 'CC(C)(C)C(CO)C(=O)N1[C@H](C(=O)N2CCC[C@@]2(C)CO)C[C@@H]2C[C@@H]21', 'CC(C)(C)C(CS(C)(=O)=O)NC(=O)N1CC2(CC2)c2ccc(Cl)cc21', 'CC(C)(C)C(CS(C)(=O)=O)NC(=O)c1ccnc(Cn2cnnc2)c1', 'CC(C)(C)C(O)C(=O)N1CCCC1C(=O)N1CCc2[nH]c(=O)[nH]c2C1', 'CC(C)(C)C(O)CN(Cc1cc(S(N)(=O)=O)cs1)CC1CC=CCC1', 'CC(C)(C)C(O)CN(Cc1ccc(F)cc1F)C(=O)C(O)C(F)(F)F', 'CC(C)(C)C(O)CN(Cc1cn2ccsc2n1)C(=O)C12CCC(C1)C2', 'CC(C)(C)C(O)CNC(=O)[C@@H]1CC[C@H](CNC(=O)CC2OCCO2)C1', 'CC(C)(C)C1(CO)CCN(C(=O)C(=O)NC2CCCc3cn[nH]c32)C1', 'CC(C)(C)C1CC(CNC(=O)CN(C(=O)c2ccc[nH]2)C2CCC2)C1', 'CC(C)(C)C1CCC(c2cn(CCC(=O)N[C@H]3CCOC3)nn2)CC1', 'CC(C)(C)C1CCCC1Nc1ncccc1S(=O)(=O)NCC1CCC1', 'CC(C)(C)C1CCc2[nH]c(=O)c(C(=O)N3C[C@H]4CC[C@@H]3[C@@H]4N)cc2C1', 'CC(C)(C)CC(=O)N1CCC=C(CNC(=O)C2(C)CC3(CCC3)C2)C1', 'CC(C)(C)CC(F)C(=O)N1CC(CCNC(=O)CN2CCCCC2)C1', 'CC(C)(C)CC(F)CN(Cc1cc(C(F)F)ccn1)Cc1cc[nH]n1', 'CC(C)(C)CC(O)C(=O)NC12CC(C(=O)N3CC4(CC=CC4)C3)(C1)C2', 'CC(C)(C)CC(O)CC(=O)NC/C=C/CC(=O)NC[C@H]1C[C@H](CF)C1', 'CC(C)(C)CC(O)CC(=O)N[C@H]1CN(C(=O)Cc2cn[nH]c2)C[C@H]1O', 'CC(C)(C)CC1CC(CS(=O)(=O)Nc2ccccc2-n2cncn2)C1', 'CC(C)(C)CCC(=O)N1CCN(C(=O)[C@H]2CCC[C@H]2F)[C@H]2COC[C@H]21', 'CC(C)(C)CCC(=O)N[C@@H]1CCC[C@H]1CC(=O)N1CCCC1C1CC1', 'CC(C)(C)CCCC(=O)N1C[C@H]2CCC[C@@]2(NC(=O)C2CCSC2)C1', 'CC(C)(C)CCCCC(=O)NCCCNC(=O)CN1CCC(=O)CC1', 'CC(C)(C)CN(C(=O)Cn1nc(I)c2ccccc21)c1cccnc1', 'CC(C)(C)CN(Cc1cnc2[nH]ncc2c1)C(=O)CCCC(F)(F)F', 'CC(C)(C)COCC(=O)N1CCC(O)(CNC(=O)C(C)(C)C#N)CC1', 'CC(C)(C)COCCC(=O)N1CC2(CC(C(=O)NC/C=C\\Br)CO2)C1', 'CC(C)(C)CS(=O)(=O)N1C[C@H](CNC(=O)c2ccoc2)[C@](F)(CO)C1', 'CC(C)(C)NC(=O)C(c1cc(C2CC2)on1)N1CCC(F)(F)C(O)C1', 'CC(C)(C)NC(=O)c1ccccc1C(=O)NCC(O)Cn1ccnc1', 'CC(C)(C)NCC(O)C1=CC(CO)=C(O)C=C1', 'CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(Cl)=C1', 'CC(C)(C)NC[C@H](O)C1=CC(CO)=C(O)C=C1', 'CC(C)(C)NC[C@H](O)COC1=CC=CC2=C1CCCC2=O', 'CC(C)(C)NS(=O)(=O)C1(CNCCN2Cc3ccccc3C2=O)CC1', 'CC(C)(C)OC(=O)C(C[Si](C)(C)C)NC(=O)c1cncc2cn[nH]c12', 'CC(C)(C)OC(=O)C1(CNC(=O)C(=O)NCc2ccoc2)CCOC1', 'CC(C)(C)OC(=O)C1(CNC(=O)C2CCCc3scnc32)CCCO1', 'CC(C)(C)OC(=O)C12CC(NC(=O)c3cc4n(n3)CCCCO4)(C1)C2', 'CC(C)(C)OC(=O)C1CCN(C(=O)c2cc(F)cc(N=[N+]=[N-])c2)CC1', 'CC(C)(C)OC(=O)C1C[C@H](NCCOCCCF)[C@H](n2ccnn2)C1', 'CC(C)(C)OC(=O)CC(=O)NC12CC(NC(=O)c3cnccn3)(C1)C2', 'CC(C)(C)OC(=O)CCCCN(CC[C@@H]1CCCO1)Cc1c[nH]nn1', 'CC(C)(C)OC(=O)CCc1ccc(-c2cnn(C3CC3(F)F)c2)cc1', 'CC(C)(C)OC(=O)CN(CC1(CO)COC1)C(=O)c1cncc(O)n1', 'CC(C)(C)OC(=O)CN1CCC(C(=O)N2CCCCC2(CO)CO)C1', 'CC(C)(C)OC(=O)Cn1ccc(CNc2cc(C3CCCC3)on2)n1', 'CC(C)(C)OC(=O)N(CC(=O)NNC(=O)NC1CCCC1)CC1CC1', 'CC(C)(C)OC(=O)N(CC(=O)OCC(=O)c1cnsc1)CP(C)(C)=O', 'CC(C)(C)OC(=O)N1C=C(Br)CC(C(=O)N2CCc3nc[nH]c3C2)C1', 'CC(C)(C)OC(=O)N1CC(CC(O)CSc2ncc3cnccn23)C1', 'CC(C)(C)OC(=O)N1CC(NC2C[C@@H]3OC(C)(C)O[C@@H]3C2)C2CC1C2', 'CC(C)(C)OC(=O)N1CC(O)(CC(=O)NCc2ccc(Cl)c(Cl)c2)C1', 'CC(C)(C)OC(=O)N1CC(OCCCn2cc(Cl)c3cccnc32)C1', 'CC(C)(C)OC(=O)N1CC(c2ccc3[nH]c(=O)[nH]c3c2)=CCC1(C)C', 'CC(C)(C)OC(=O)N1CC2(CCC2NC(=O)c2cc(N)nc(Cl)c2)C1', 'CC(C)(C)OC(=O)N1CCC(C)(C)C1Cn1ccc2cc(Cl)ncc21', 'CC(C)(C)OC(=O)N1CCC(CNC(=O)NCc2cncc(O)c2)C1', 'CC(C)(C)OC(=O)N1CCC(CONc2nc(Cl)nc(Cl)c2F)CC1', 'CC(C)(C)OC(=O)N1CCC(O)(C2CCN(CCCC#N)CC2)CC1', 'CC(C)(C)OC(=O)N1CCCC(C(=O)NNc2cc(Cl)nc(N)n2)C1', 'CC(C)(C)OC(=O)N1CCCC1(CO)CN[C@H](CF)c1ccccc1', 'CC(C)(C)OC(=O)N1CCCCCCC1C(=O)N[C@@H]1CCOC[C@H]1O', 'CC(C)(C)OC(=O)N1CCC[C@H](CNC(=O)NOC2CCOCC2)C1', 'CC(C)(C)OC(=O)N1CCN(S(=O)(=O)N[C@H]2C[C@@H]2c2ccco2)CC1', 'CC(C)(C)OC(=O)N1CCO[C@H](C(=O)N2CCc3[nH]c(=O)[nH]c3C2)C1', 'CC(C)(C)OC(=O)N1CCSCC1CCNCc1cccc(C#N)c1', 'CC(C)(C)OC(=O)N1CC[C@@H](CNC(=O)c2ccc3c(n2)NCC3)C1', 'CC(C)(C)OC(=O)N1CCn2nc(NC(=O)C3(C)CC3(F)F)cc2C1', 'CC(C)(C)OC(=O)N1Cc2ccccc2C1CNC(=O)C1CCCC1', 'CC(C)(C)OC(=O)N1[C@H]2CC[C@@H]1[C@H](C(=O)NCCCc1ncco1)C2', 'CC(C)(C)OC(=O)NC(CC(=O)NNc1cccc(F)c1Cl)C(F)F', 'CC(C)(C)OC(=O)NC(CCC(=O)NC(CO)CO)c1ccccc1', 'CC(C)(C)OC(=O)NC(CCOC(=O)C1=C[C@H]2CCCC[C@@H]12)C(F)F', 'CC(C)(C)OC(=O)NC(CNC(=O)[C@@](C)(O)c1ccccc1)C1CC1', 'CC(C)(C)OC(=O)NC(Cc1nc(-c2ccccc2Cl)no1)C1CC1', 'CC(C)(C)OC(=O)NC1(C2CN(C(=O)C34CCC3S(=O)(=O)C4)C2)CC1', 'CC(C)(C)OC(=O)NC1CC(CC(=O)OCC#Cc2ccccc2)C1', 'CC(C)(C)OC(=O)NC1CC(S(=O)(=O)NC2CCc3cnccc32)C1', 'CC(C)(C)OC(=O)NC1CC2C(C1)C2C(=O)NCc1ccc(F)nc1', 'CC(C)(C)OC(=O)NC1CCC(Nc2ncnc(Cl)c2[N+](=O)[O-])CC1', 'CC(C)(C)OC(=O)NCC(F)(F)CNC(=O)NC1CC12CCCCC2', 'CC(C)(C)OC(=O)NCC1(CCNC2CC3(CCCCC3)C2)CCC1', 'CC(C)(C)OC(=O)NCC1(OC(=O)c2ccc(C(C)(C)C)nc2)CC1', 'CC(C)(C)OC(=O)NCCC1(NCCC2CCCCO2)CCCCC1', 'CC(C)(C)OC(=O)NCCCCC#CC(=O)NCCC1CCC1(F)F', 'CC(C)(C)OC(=O)NCCCNC(=O)CNC1CCC(P(C)(C)=O)C1', 'CC(C)(C)OC(=O)NCCCc1cccc(C(=O)NCC2(Br)CC2)c1', 'CC(C)(C)OC(=O)NCc1ncc(C(=O)NNC(=O)C(C)(C)C)cn1', 'CC(C)(C)OC(=O)N[C@@H](C(=O)NCCc1ccc(Br)nc1)C(C)(C)O', 'CC(C)(C)OC(=O)N[C@H]1COC[C@H]1C(=O)Nc1cccc(Br)c1C#N', 'CC(C)(C)OC(=O)Nc1c[nH]c(C(=O)N2CC(n3nncc3I)C2)c1', 'CC(C)(C)OC(=O)Nc1ccc(CC(=O)OCCn2cccn2)nc1', 'CC(C)(C)OC(=O)Nc1cccc(C(=O)NC[C@@H]2CC=CCC2)c1F', 'CC(C)(C)OC(=O)Nc1ccoc1C(=O)Nc1cc2[nH]ncc2cn1', 'CC(C)(C)OC(=O)[C@@H]1[C@H](C(=O)NCCCN2CCCCC2=O)C1(C)C', 'CC(C)(C)OC(=O)[C@]12CCC[C@H]1CN(Cc1[nH]c(=O)[nH]c(=O)c1Cl)C2', 'CC(C)(C)OC(=O)c1cc(C(=O)N2CC3(C2)OCCO3)c(F)cc1F', 'CC(C)(C)OC(=O)c1cc(CNCCC(=O)N2CCCCCC2)on1', 'CC(C)(C)OC(=O)c1cccc(NC(=O)c2nc3c(s2)CCCC3)c1', 'CC(C)(C)OC(=O)c1ccnc(NCC(C)(C)c2cccc(=O)[nH]2)c1', 'CC(C)(C)OC(=O)c1csc(CNc2ccc3c(c2)CCC(=O)N3)n1', 'CC(C)(C)OC1CC(N[C@H]2CONC2=O)(c2nnnn2CC2CC2)C1', 'CC(C)(C)OCC(=O)N1CC(O)CCC1C(=O)NC1(CCO)CCC1', 'CC(C)(C)OCC(=O)N1CC2CCCC1CN(C(=O)c1csnn1)C2', 'CC(C)(C)OCC(=O)NCC1CC2(C1)CN(C(=O)Cc1ccon1)C2', 'CC(C)(C)OCC(=O)N[C@@H]1C=C[C@H](CC(=O)N2CC3(CC=CC3)C2)C1', 'CC(C)(C)OCC(N[C@H]1CCC[C@H]1C(N)=O)c1nnnn1C1(C)CC1', 'CC(C)(C)OCC1CCCN(C(=O)NCc2ccc3ncnn3c2)C1', 'CC(C)(C)OCCCC(=O)N(Cc1cnc[nH]1)CC1CCCSCC1', 'CC(C)(C)OC[C@H]1CCCCN1C(=O)C1(O)CCc2ccccc2C1', 'CC(C)(C)OCc1cc(COC(=O)c2cc3cc(Br)cn3cn2)no1', 'CC(C)(C)ONC(=O)C1(CF)CCN(C(=O)c2cc([N+](=O)[O-])c[nH]2)C1', 'CC(C)(C)O[C@@H]1C[C@H](NC(=O)N2CC(F)(CO)C3(CCC3)C2)C1(C)C', 'CC(C)(C)O[C@H]1CCN(C(=O)c2ccccc2N2CCC(O)CC2)C1', 'CC(C)(C)O[C@H]1C[C@@H](C(=O)NCC2CCCN2C(=O)c2ccoc2)C1', 'CC(C)(C)O[C@H]1C[C@@H](F)CN(CCc2nc(-c3ccccc3)no2)C1', 'CC(C)(C)Oc1c(F)cc(NC(=O)[C@]2(CO)C[C@H]2C(F)(F)F)cc1F', 'CC(C)(C)Oc1cc(F)cc(COC(=O)COc2ncccc2Cl)c1', 'CC(C)(C)Oc1ccc(C(=O)N2CCCC(c3nc(O)no3)C2)cc1', 'CC(C)(C)S(=O)(=O)CC(=O)NCC1CN(S(=O)(=O)CCOCCF)C1', 'CC(C)(C)SCC(=O)N(CCc1ccc(Cl)cc1)CC(O)C(F)(F)F', 'CC(C)(C)SCCNC(=O)CC1CCN(C(=O)CCc2nccs2)C1', 'CC(C)(C)SCCNC(=O)[C@H]1CCCN(C(=O)C2(CCF)CCC2)C1', 'CC(C)(C)[C@@H](NC(=O)[C@H]1CCCC[C@H]1O)C(=O)NCCCS(C)(=O)=O', 'CC(C)(C)[C@@H](NC(=O)c1sccc1CO)C(=O)N1CCSCC1CO', 'CC(C)(C)[C@@H](O)C(=O)NCc1ocnc1C(=O)N(CC(F)F)C1CC1', 'CC(C)(C)[C@@H]1C[C@H]1NC(=O)CCC1CCN(C(=O)Cn2cncn2)C1', 'CC(C)(C)[C@H](CC(=O)N1CCn2nncc2C1)NC(=O)c1nccs1', 'CC(C)(C)[C@H](CNC(=O)COc1ccon1)NC(=O)c1cnc(N)s1', 'CC(C)(C)[C@H](CO)NC(=O)C1(NC(=O)c2cccc3[nH]ncc23)CC1', 'CC(C)(C)[C@H](NC(=O)[C@H]1C[C@](C)(F)C1)C(=O)N[C@@H]1[C@H]2CCC(F)(F)[C@H]21', 'CC(C)(C)[C@H](O)C(=O)N1CCCC1CCC(=O)NCC1(F)CCOC1', 'CC(C)(C)[C@H](O)CN(Cc1cc(C(F)F)cs1)C(=O)C[C@@H]1CCOC1', 'CC(C)(C)[C@H](O)CNC(=O)c1ccc(CNC(=O)CC(F)(F)F)cn1', 'CC(C)(C)c1cc(C(=O)OCc2cn3ccccc3c2C#N)ccn1', 'CC(C)(C)c1cc(C(=O)Oc2cccc(C(=O)NCC(N)=O)c2)[nH]n1', 'CC(C)(C)c1ccc(CCNC(=O)CN[C@H]2CCCC[C@]2(C)O)cc1', 'CC(C)(C)c1ccc(Cl)cc1NC(=O)c1ccc(C2(O)COC2)cc1', 'CC(C)(C)c1cccc(C(=O)Nc2cc3c(cc2F)NC(=O)CO3)n1', 'CC(C)(C)c1cccc(NC(=O)N2CCCC(C3CNC(=O)C3)C2)n1', 'CC(C)(C)c1ccnc(CNCC(O)COc2ccc(Cl)c(F)c2)c1', 'CC(C)(C)c1cnc(N2CCC(c3ncc4n3CCCC4)CC2)cn1', 'CC(C)(C)c1conc1CN(Cc1cncs1)CC1CC12CCOC2', 'CC(C)(C)c1nc(Cc2nc(C(C)(C)c3ccc(Cl)nc3)no2)cs1', 'CC(C)(C)c1nc(NC(=O)N2CCOC(C3CCCOC3)C2)sc1Br', 'CC(C)(C)c1nc2ccc(NC(=O)N3CCCCC3CCO)cc2s1', 'CC(C)(C)c1ncc(C(=O)OC[C@@H](O)CCOCc2ccccc2)s1', 'CC(C)(C)c1ncc(CNC(=O)N2CCC3(CC(S(C)(=O)=O)C3)C2)o1', 'CC(C)(C)c1nn(-c2ccccc2)cc1C(=O)N1CC[Si](C)(C)CC1', 'CC(C)(C)n1cccc(NC(=O)C(=O)N2C[C@H](CO)[C@@H](CO)C2)c1=O', 'CC(C)(C)n1nnc(CC(=O)Oc2cccc3c2CCCC(=O)N3)n1', 'CC(C)(C/C=C/C(=O)NCC1CN2CCC1C2)NC(=O)[C@H]1CC1(F)F', 'CC(C)(C/C=C/C(=O)NCCCc1ccccn1)NC(=O)C1CCO1', 'CC(C)(CC#N)C(=O)N1CC(OCC(=O)NC(C2CC2)C(C)(C)O)C1', 'CC(C)(CC#N)C(=O)N1CC=CC(NC(=O)CC2(O)CCOCC2)C1', 'CC(C)(CC(=O)NCC1C2CCCC21)NC(=O)c1[nH]nc2c1COC2', 'CC(C)(CC(=O)NCCCCC(=O)N[C@H]1COC[C@H]1N=[N+]=[N-])C1CC1', 'CC(C)(CC(=O)N[C@@H]1CCC[C@H](CO)C1)NC(=O)CCCNC(N)=O', 'CC(C)(CC(=O)N[C@H]1CC[C@H]1CNc1ncncc1Cl)CC(F)(F)F', 'CC(C)(CC(F)(F)F)C(c1nnnn1C1COC1)N1CCC[C@H](F)C1', 'CC(C)(CC1CC1)C(=O)N1CC[C@@H]1C(=O)NCC1NC(=O)CC1(C)C', 'CC(C)(CCC#N)C(=O)Nc1ccc(Cc2nc(C3CC3)no2)cc1', 'CC(C)(CCC(=O)N1CC[Si](C)(C)CC1)NC(=O)[C@H]1C[C@@H]1C(C)(C)C', 'CC(C)(CCCC(=O)N1CC(N=[N+]=[N-])C1)NC(=O)[C@H]1C[C@@H]1C(C)(F)F', 'CC(C)(CCCC(=O)NCCn1cncn1)NC(=O)C12CSCC1C2', 'CC(C)(CCCNC(=O)C1C=CCS1)C(=O)Nc1cnc(O)c(F)c1', 'CC(C)(CCCNC(=O)c1cncc(N)n1)NC(=O)c1ccncc1', 'CC(C)(CCF)C(=O)NCC1(O)CN(C(=O)c2cc(N)cnc2Cl)C1', 'CC(C)(CCF)C(=O)NCCCCCC(=O)N1C[C@H]2COC[C@@]2(C)C1', 'CC(C)(CCNC(=O)C1CCOC1(C)C)NC(=O)CC1(O)CCOC1', 'CC(C)(CCNC(=O)c1nccc(N)c1Cl)NC(=O)C1=COCCO1', 'CC(C)(CCNc1nc(NC2CC3CC3C2)nc2c1COC2)C1CC1', 'CC(C)(CCO)CNc1nc2c(c(NCC3=COCCO3)n1)COC2', 'CC(C)(CCOCc1ccccc1)CNCc1ccn2ccnc2c1', 'CC(C)(CF)C(=O)N1CC(n2cc(C3CC(=O)C3)nn2)CCC1(C)C', 'CC(C)(CF)C(=O)NCC1(C2(O)CN(C(=O)Cc3cnns3)C2)CC1', 'CC(C)(CF)C(=O)NCCC1(O)CCCN(C(=O)c2cnccn2)C1', 'CC(C)(CF)C(=O)N[C@H]1C[C@H]2C[C@H](NC(=O)C3C4(CC4)C34CC4)C[C@H]21', 'CC(C)(CF)CS(=O)(=O)N1CCC(CCNC(=O)C2CCCC2)CC1', 'CC(C)(CNC(=O)C(=O)Nc1ccc(N2CCNCC2)cc1)C(F)F', 'CC(C)(CNC(=O)C(F)(F)c1cc(F)cc(F)c1)C(=O)N1CCCC1', 'CC(C)(CNC(=O)C1(F)CN(C(=O)C2C(C)(C)C2(C)C)C1)CC(F)F', 'CC(C)(CNC(=O)C1C=CCS1)CC(=O)N[C@H]1C[C@@H](n2cccn2)C1', 'CC(C)(CNC(=O)C1CC1(C)Br)Cn1cc(-c2ccc(Cl)nc2)nn1', 'CC(C)(CNC(=O)C1CCCCC1)NC(=O)c1ccnc(C(F)F)c1', 'CC(C)(CNC(=O)C1CCN1C(=O)Cc1ccc(C#N)cc1)C(N)=O', 'CC(C)(CNC(=O)C1COCCN(C(=O)C2C3COCC32)C1)C(N)=O', 'CC(C)(CNC(=O)C=Cc1ccsc1)CNC(=O)CC1CSCCO1', 'CC(C)(CNC(=O)CCc1cnco1)CC(=O)NC1CC[C@H]2CC[C@@H]12', 'CC(C)(CNC(=O)CN1CC(C)(C)C1)CNC(=O)[C@H]1C[C@H]2CC[C@@H]1O2', 'CC(C)(CNC(=O)COC(=O)CCN1CCCCC1)c1ccccc1', 'CC(C)(CNC(=O)Cc1ccco1)NC(=O)CCc1cncc(F)c1', 'CC(C)(CNC(=O)Cc1ccon1)NC(=O)c1cccn2cncc12', 'CC(C)(CNC(=O)Cc1ccsc1)OCC(=O)Nc1cccc(Cl)c1', 'CC(C)(CNC(=O)[C@@H]1C[C@@H](F)CN1C(=O)CCCCCC#N)C1CC1', 'CC(C)(CNC(=O)[C@H]1[C@@H]2CN(C(=O)C3(CC4CC4)CC3)C[C@@H]21)C1CC1', 'CC(C)(CNC(=O)c1cccc2ccnn12)CNS(=O)(=O)C1CCC1', 'CC(C)(CNc1nc(NC2CC2)nc2c1CSC2)CC1CCOCC1', 'CC(C)(CNc1nccc(NCCCn2cnnn2)n1)CC(F)(F)F', 'CC(C)(CO)C1CCCN1C(=O)C1CCCN(C(=O)CNC=O)CC1', 'CC(C)(CO)CCNC(=O)Nc1ccc(NC(=O)C2CCCO2)cc1', 'CC(C)(CO)CN(Cc1cnc(C(F)F)s1)C(=O)CCC1CCOC1', 'CC(C)(CO)ONC(=O)[C@@H]1C[C@H](F)CCN1C(=O)c1cccnc1S', 'CC(C)(COC(=O)C(OC1CCCC1)c1ccccc1)n1ccnc1', 'CC(C)(Cc1ccc(C#N)cc1)NC(=O)N1CCn2ncc(Cl)c2C1', 'CC(C)(Cc1ccc(Cl)cc1Cl)NC(=O)NCCN1CCCS1(=O)=O', 'CC(C)(F)C(C)(F)CNC(=O)[C@@H]1CN(C(=O)C2=CCOCC2)CCO1', 'CC(C)(F)CCC(=O)N1C(CC(=O)NCc2ccon2)[C@H]2CCC[C@H]21', 'CC(C)(F)CNC(=O)c1ccoc1CNC(=O)Cc1ccnc(O)c1', 'CC(C)(F)c1cncc(NCc2ccc(C(=O)N3CCCC3)cc2)c1', 'CC(C)(N)CCNC(=O)c1cnn(-c2cccc(Cl)c2)c1C(F)(F)F', 'CC(C)(NC(=O)C(=O)Nc1ccc(Cl)c2c1CCNC2)c1nccs1', 'CC(C)(NC(=O)C12CC(CN1C(=O)[C@H]1[C@@H]3COC[C@@H]31)C2)c1c[nH]nn1', 'CC(C)(NC(=O)CCCC(=O)C1CC1)C(=O)Nc1ccc(F)c(O)c1', 'CC(C)(NC(=O)CCCCNC(=O)C[C@@H]1CC[C@H](O)C1)c1ncc[nH]1', 'CC(C)(NC(=O)CSc1nccn1-c1cccc(Cl)c1)c1c[nH]nn1', 'CC(C)(NC(=O)Cc1ccccc1OC(F)(F)F)c1ccccc1F', 'CC(C)(NC(=O)c1ccc(OCC2CCCO2)cc1)C1CCCCO1', 'CC(C)(NC(=O)c1cn[nH]c(=O)c1)C(=O)NCC(=O)N1CCCCC1', 'CC(C)(NS(=O)(=O)c1ccc2ccccc2c1)c1ccc(F)c(Cl)c1', 'CC(C)(O)C#CC(=O)N1CCC(O)(CNC(=O)[C@H]2C[C@@H]2C(F)(F)F)C1', 'CC(C)(O)C(C)(C)C(=O)N1CC[C@@H]1C(=O)NCCN1CCCCCC1', 'CC(C)(O)C(F)(F)C(=O)NCCCCC(=O)N1CCC2CCCCC21', 'CC(C)(O)C(F)(F)CNC(=O)[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)CC1CCCC1', 'CC(C)(O)C(F)C(=O)N1CC[C@@H](NC(=O)C2=CCOCC2)[C@H](CO)C1', 'CC(C)(O)C1(CNC(=O)CC(F)(F)Cl)CN(C(=O)c2ccnnc2)C1', 'CC(C)(O)C1(NC(=O)CCC(=O)c2ccc3c(c2)OCCO3)COC1', 'CC(C)(O)C1(O)CN(C(=O)Nc2ccccc2OC2CCOCC2)C1', 'CC(C)(O)C1CCN(C(=O)C(=O)N2CC(Cc3ccc(Br)cc3)C2)C1', 'CC(C)(O)C1CCN1C(=O)CCOC1CN(C(=O)C(F)=CC2CC2)C1', 'CC(C)(O)CC(=O)N(Cc1ccc(C(N)=O)nc1)Cc1cscc1Cl', 'CC(C)(O)CC(=O)N1C[C@H](O)C[C@@H]1CNC(=O)C[C@H]1C[C@H]2C=C[C@@H]1C2', 'CC(C)(O)CC(=O)NC(Cc1ccoc1)C(=O)N1CCOC(CF)C1', 'CC(C)(O)CCNC(=O)[C@@H]1[C@H]2C[C@H](O)[C@H](C2)N1C(=O)Cn1cccc1', 'CC(C)(O)CNC(=O)[C@@H]1CO[C@H](CNC(=O)C2=NOC3(CCC3)C2)C1', 'CC(C)(O)CONC(=O)C1(NC(=O)C2CC3(C2)CC32CC2)CC(O)C1', 'CC(C)(O)CONC(=O)C1=CCC2CCC1N2C(=O)C(F)C1CCC1', 'CC(C)(O)[C@@H](NC(=O)C1CCS1(=O)=O)C(=O)NCCOC1CCCC1', 'CC(C)(O)[C@H](NC(=O)CCCCCF)C(=O)N1CCn2nncc2C1', 'CC(C)(O)[C@H](NC(=O)c1cnco1)C(=O)NCCC1CCCC2CC12', 'CC(C)(O)c1ccc(N2CCN(CC(O)C3CC3)CC2)c([N+](=O)[O-])c1', 'CC(C)/C=C/C(=O)N1C[C@@H]2CCCN(C(=O)CC(C)(C)N(C)C)[C@@H]2C1', 'CC(C)/C=C/C(=O)N1C[C@@H]2C[C@H]1CN2C(=O)Cc1cccc(F)c1O', 'CC(C)/C=C/C(=O)NC1CC(CNC(=O)c2cccnc2O)C1(C)C', 'CC(C)/C=C/C(=O)NCC1(O)CCCN(C(=O)COCC(C)C)CC1', 'CC(C)=C(C)C(=O)N(C)CCOCCNc1cc(C)c([N+](=O)[O-])cn1', 'CC(C)=C(C)C(=O)N1CCCCC(C(=O)NCC2(C#N)CCCC2)C1', 'CC(C)=C(C)C(=O)NC(CC(=O)NCC1OCCCC1(C)C)C(C)C', 'CC(C)=C(C)CC(=O)NC(C)CCCCNC(=O)Cc1nocc1C', 'CC(C)=C(C)CC(=O)NC1CC(C)(C(=O)N2CCC(C)(CCO)C2)C1', 'CC(C)=C(C)CC(=O)NCc1ocnc1C(=O)Nc1cncnc1C', 'CC(C)=C(F)C(=O)N(C)CCCCN(C)C(=O)c1ccc(C)cc1F', 'CC(C)=C(F)C(=O)N1CCCCC1CC(=O)Nc1ccc(C)nc1O', 'CC(C)=C(F)C(=O)NC(C(=O)NC1CCCn2ncnc21)C1CCC1', 'CC(C)=C(F)C(=O)NC1(C/C=C/C(=O)N2CC3CC3(CO)C2)CCC1', 'CC(C)=C(F)C(=O)NCC(C)CN(C)C(=O)c1cc(CC(C)C)n[nH]1', 'CC(C)=C(F)C(=O)NCCCOCCC(=O)N[C@H]1CCO[C@@H]1C1CC1', 'CC(C)=C(F)C(=O)N[C@@H]1[C@H]2C[C@@H]1N(C(=O)c1ccnc(N(C)C)c1)C2', 'CC(C)=C=CC(=O)N(C)C1(CC(=O)NCCCC2CCCC2O)CC1', 'CC(C)=C=CC(=O)N(C)CC1(O)CCN(C(=O)CC2C=CCC2)CC1', 'CC(C)=C=CC(=O)NCC1CCCN1C(=O)c1ccc2ncnn2n1', 'CC(C)=C=CC(=O)NC[C@H]1CC[C@H]1NC(=O)c1cc(C)c(O)c(N)c1', 'CC(C)=C=CC(=O)N[C@@H](CCC(=O)N1CCN(C)C[C@H]1CO)C(C)C', 'CC(C)=C=CC(=O)N[C@H]1C[C@@H](CCC(=O)N2CCCC3(CC2)CC3)C1', 'CC(C)=C=CC(=O)N[C@H]1[C@@H](C(=O)NCCOC2CCCCC2)C1(C)C', 'CC(C)=CC(=O)N1CCCC(CO)(NC(=O)C[C@H]2CCCC[C@@H]2O)C1', 'CC(C)=CC(=O)N1C[C@H](C(=O)NC(C)(C)CNC(N)=O)[C@@H](C(C)C)C1', 'CC(C)=CC(=O)NC(C)(C)C/C=C/C(=O)NCCCc1cnccn1', 'CC(C)=CC(=O)NCC1CCCN(C(=O)CCCc2cc[nH]n2)CC1', 'CC(C)=CC(=O)NCc1cc(C(=O)N2CCCCC2CC(C)O)co1', 'CC(C)=CC(=O)N[C@H]1C[C@H]2COC[C@@H](C1)N2C(=O)c1cncnc1C', 'CC(C)=CCC(=O)N1CC(Cn2cc(-c3ccc(N)c(C)c3)nn2)C1', 'CC(C)=CCC(=O)N1[C@H](CNC(=O)Cc2csnn2)C[C@@H]2CCC[C@@H]21', 'CC(C)=CCC(=O)NC[C@]12C[C@H]1CN(C(=O)c1ncc(F)cc1F)C2', 'CC(C)=CCC1CCCN(C(C(=O)NC2CC2)C2CCC3(CC3)C2)C1', 'CC(C)=CCCC(=O)N(C)CC(C)N(C)C(=O)c1cc(C2CC2)on1', 'CC(C)=CCCC(=O)N(Cc1cccc(C)n1)CC(O)c1cccs1', 'CC(C)=CCCC(=O)N1CC2CCN(C(=O)Cn3cn[nH]c3=O)CC21', 'CC(C)=CCCC(=O)N1CCC(C(C)C(=O)N[C@H]2CCC[C@H]2F)CC1', 'CC(C)=CCCC(=O)NC[C@H]1CC[C@@H](C(=O)NC[C@H]2C[C@@H]2C(C)C)C1', 'CC(C)=CCCC(C)CC(=O)NC1CCN(c2cc(Cl)nc(Cl)n2)C1', 'CC(C)=CCCC(C)CCNC(=O)NCc1cnn(CC(F)(F)F)c1', 'CC(C)=CCCCOC(=O)C12CN(C(=O)OC(C)(C)C)C(CF)(C1)C2', 'CC(C)=CCNC(=O)C1=CC2(CCN(C(=O)C3CCC(F)CC3)C2)C1', 'CC(C)=CCNC(=O)C1CN(C(=O)COC2(C)CCC2)CC12CCC2', 'CC(C)=CCONC(=O)C1COCCN1C(=O)C1CC2(CCCO2)C1', 'CC(C)=CCONC(=O)CC1CN(C(=O)[C@]23CCC[C@H]2C3)C(C)(C)C1', 'CC(C)=CCONC(=O)[C@H]1[C@@H]2CN(C(=O)CNc3cccnc3)C[C@@H]21', 'CC(C)C#CC(=O)N1CC(O)(C2(CNC(=O)C3CCNC3=O)CC2)C1', 'CC(C)C#CC(=O)N1CCOC(C(=O)NCC2(C)CC3(CC3)C2)CC1', 'CC(C)C#CC(=O)NC(CC(C)(C)C)C(=O)N[C@H](C)CC(C)(C)CO', 'CC(C)C#CC(=O)NCc1cc(C(=O)N[C@@H](C)CN(C)C(C)C)no1', 'CC(C)C(=O)C(=O)NCC1(C(=O)N2Cc3cccnc3C2)CC=CC1', 'CC(C)C(=O)N(C)CC(=O)NC/C=C\\CNC(=O)C1CCC=CCC1', 'CC(C)C(=O)N1CCC[C@H]2CN(C(=O)CCn3cccnc3=O)C[C@H]21', 'CC(C)C(=O)N1CCOC(C)(CNC(=O)c2cccc3[nH]cnc23)C1', 'CC(C)C(=O)N1CCOC(CCNC(=O)CC2CCCCC2(C)C)C1', 'CC(C)C(=O)NC1CCCN(c2cc(C(N)=O)c3ccccc3n2)C1', 'CC(C)C(=O)NCC1CCCCN(C(=O)C2CCCn3cnnc32)C1', 'CC(C)C(=O)NCCCNC(=O)NCC1(Cc2ccccc2)CCC1', 'CC(C)C(=O)NCCNC(=O)C#CC(C)(C)CNC(=O)C(F)(F)CO', 'CC(C)C(=O)NCCn1cc(CONC(=O)c2ccncc2F)nn1', 'CC(C)C(=O)Nc1ccc(C(=O)COC(=O)C#CC2CCCC2)cc1', 'CC(C)C(=O)Nc1ccc(CNS(=O)(=O)C[C@H]2CC[C@H]2C(=O)O)cc1', 'CC(C)C(=O)c1ccccc1-n1cc(-c2ccccc2N(C)C)nn1', 'CC(C)C(C#N)C(=O)NCC1(CNC(=O)C(F)C2CCCC2)CCC1', 'CC(C)C(C#N)C(=O)NCCCCCCCn1cc(C(C)(C)C)nn1', 'CC(C)C(C(=O)N1CCC2(CN(C(=O)CC(C)(C)C)C2)C1)C1CCC1', 'CC(C)C(C(=O)N1C[C@@H]2[C@@H](CC(=O)NC(C)(C)CCO)[C@@H]2C1)C(C)C', 'CC(C)C(C(=O)NC(C(=O)NCC(F)(F)C(F)F)C1CCC1)C(C)C', 'CC(C)C(C(=O)NC[C@@H]1C[C@@H]2CCC[C@@H]2N1C(=O)C1CCC1)C(C)C', 'CC(C)C(C(=O)NNc1ccc2c(=O)[nH]ccc2c1)c1cccnc1', 'CC(C)C(C(=O)N[C@H](C)CC(C)(C)CO)C(C)NC(=O)c1cncs1', 'CC(C)C(C)(C)C(=O)NC1CC(NC(=O)c2ccc3ccoc3c2)C1', 'CC(C)C(C)(C)NC(=O)C1(F)CCN(C(=O)C=CC2CCCCC2)C1', 'CC(C)C(C)(CNC(=O)CCn1cccc1)NC(=O)CC1CC1(C)C', 'CC(C)C(C)(F)CNC(=O)N1CCN(C(=O)c2cccc(F)c2)CC1', 'CC(C)C(C)(O)CNC(=O)CCC1(C)CN(C(=O)CC2C=CCC2)C1', 'CC(C)C(C)C(=O)N1CCC2(CCC(NC(=O)c3cc(Cl)no3)C2)C1', 'CC(C)C(C)C(=O)N1CCN(C(=O)c2cnco2)C(c2ncc[nH]2)C1', 'CC(C)C(C)C(=O)N1CC[C@H](C(=O)NCCOCCN(C)C)C[C@@H]1C', 'CC(C)C(C)C(=O)N[C@@H](C(=O)NC1CC(C)N(C)CC1C)C(C)(C)O', 'CC(C)C(C)CC(=O)N1[C@@H]2CC[C@H]1CN(C(=O)C(C)(C)C(C)(F)F)C2', 'CC(C)C(C)CC(=O)NCC(C)(C)CC(=O)NCCNC(=O)N(C)C', 'CC(C)C(C)CNc1nc(NCCN2CC=CC2)c2c(ncn2C)n1', 'CC(C)C(C)N(C)C(=O)C(NC(=O)C1CC(=C2CCC2)C1)C(C)(C)C', 'CC(C)C(C)N(Cc1ccco1)C(=O)c1cccnc1OCC(F)F', 'CC(C)C(C)NC(=O)C[C@@H]1C[C@H](F)CN1C(=O)CN1CCC(O)CC1', 'CC(C)C(CC(=O)N(C)C1CCCC1C)NC(=O)C1CN(C(N)=O)C1', 'CC(C)C(CC(=O)N1[C@@H](CO)C[C@H]2OCC[C@H]21)NC(=O)C1=C(Cl)CC1', 'CC(C)C(CC(=O)NCc1cccc(O)c1)NC(=O)Cc1cccs1', 'CC(C)C(CCN(C)C(=O)C1=CCOCC1)NC(=O)Cc1cnoc1', 'CC(C)C(CCNC(=O)[C@H]1CCN1C(=O)C#CC1CCCC1)N(C)C', 'CC(C)C(CN(CC1=CCCOC1)C(=O)C1SCCCS1)OCCO', 'CC(C)C(CNC(=O)C(F)Oc1cccc(Br)c1)N1CCN(C)CC1', 'CC(C)C(CNC(=O)C1(C)CC1(Cl)Cl)NC(=O)CC(C)C1CCCC1', 'CC(C)C(CNC(=O)C=Cc1cncs1)C(=O)NC(CO)C1CCC1', 'CC(C)C(CNC(=O)CC(C)(C)N(C)C)NC(=O)c1coc(CO)c1', 'CC(C)C(CNC(=O)CSC1CC1)C(=O)Nc1ccc(OCF)cc1', 'CC(C)C(CNC(=O)c1c(O)cnc2ccccc12)N1CCOCC1', 'CC(C)C(CO)CCNC(=O)C[C@@H](C)N(C)C(=O)c1sccc1CO', 'CC(C)C(Cc1ccc(F)cc1)Nc1nccc(N[C@H]2CCOC2)n1', 'CC(C)C(F)(CNC(=O)[C@@H]1CCCC[C@H]1O)C(=O)NCC1(O)CCC1', 'CC(C)C(F)(CNC(=O)c1ncccc1F)C(=O)NCC(C)(O)CO', 'CC(C)C(F)(F)CN(CC1CC=CCC1)C(=O)c1cnn2c1CCC2', 'CC(C)C(F)C(=O)N(C)[C@@H]1CN(C(=O)C=Cc2cnn(C)c2)C[C@H]1O', 'CC(C)C(F)C(=O)N1CCCC(NC(=O)c2cnn3cccnc23)C1', 'CC(C)C(NC(=O)C(C)(C)C)C(=O)N=S(C)(=O)C1CCC(F)(F)CC1', 'CC(C)C(NC(=O)C(C)(C)C)C(=O)Nc1ccc2c(c1)CC(F)(F)C2', 'CC(C)C(NC(=O)C(CO)C(C)(C)C)C(=O)N1CCn2nccc2C1', 'CC(C)C(NC(=O)C[C@H]1C[C@H](NC(=O)C(CO)C(F)(F)F)C1)C1CC1', 'CC(C)C(NC(=O)Cc1ccccc1)C(=O)N(C)CC1COCCN1', 'CC(C)C(NC(=O)N1CCC2(CC1)CCS(=O)(=O)C2)c1nccn1C', 'CC(C)C(NC(=O)NCC1(C)Cc2ccccc2C1)c1ccncc1', 'CC(C)C(NC(=O)NCc1nc(CO)c[nH]1)C(=O)NC1CCCCC1', 'CC(C)C(NC(=O)Nc1ccc(Cl)cc1)C(=O)N1CCCC(CO)C1', 'CC(C)C(NC(=O)Nc1ccc(SC(F)(F)F)nc1)c1nncn1C', 'CC(C)C(NC(=O)[C@@H]1CCC(=O)N1C)C(=O)N(C)CCC1CCCC1', 'CC(C)C(NC(=O)c1ncc(F)cc1N)C(=O)N1CCCSCC1C', 'CC(C)C(O)C(C)(C)C(=O)N1CC2(C(=O)NCC3CSC3)CC1CO2', 'CC(C)C(O)C(C)C(=O)NCCSCc1cn(Cc2nccs2)nn1', 'CC(C)C(O)CC(=O)N1CC[C@H](C)C[C@@H]1C(=O)N1CCC1(C)CCO', 'CC(C)C(O)CC(=O)NC1CC=C(C(=O)N2CCC[C@@H](C(N)=O)C2)C1', 'CC(C)C(O)CCNc1nc(N[C@@H]2CCCC[C@H]2F)nc2scnc12', 'CC(C)C(O)CN(Cc1cn2ccnc2s1)CC1CCCC(C)(C)C1', 'CC(C)C(O)CN(Cc1ncc([N+](=O)[O-])n1C)C(=O)C(O)CC1CC1', 'CC(C)C(OC(=O)C1(C2CC2(F)F)CC1)C(=O)Nc1ccccc1F', 'CC(C)C(OC(=O)c1ccnc(OC2CCC2)c1)C(=O)NC(C)(C)C', 'CC(C)C1(C(=O)N2CC3(CC3)C[C@H]2C)CCN(C(=O)C2CC2(C)C)C1', 'CC(C)C1(C(=O)N2CC[C@@H](C(=O)NCc3cncc(Cl)c3)C2)CCC1', 'CC(C)C1(C(=O)N[C@H]2CC[C@H](NC(=O)CC(C)(C)C(F)F)C2)CCC1', 'CC(C)C1(N(C)C(=O)CCS(=O)(=O)c2ccc3c(c2)OCCO3)CC1', 'CC(C)C1(O)CCN(C(=O)C(NC(=O)c2ccco2)C2(O)CCC2)C1', 'CC(C)C1(O)CN(C(=O)CN(CC2CC2)C(=O)CCc2nnc[nH]2)C1', 'CC(C)C1=CCC(NC(=O)CN(CC2CC2)C(=O)c2cscn2)CC1', 'CC(C)C1=NOC(C(=O)N2CC3(CCN3C(=O)c3ccn(C)n3)C2)C1', 'CC(C)C1C(C(=O)N[C@H]2COC(=O)C2)CCN1C(=O)c1c[nH]c(=O)o1', 'CC(C)C1CC(C(=O)NC2CC3(C2)CN(C(=O)C2CCC(=O)N2)C3)C1', 'CC(C)C1CC(CNc2nc(NCc3ccsc3)c3ncsc3n2)C1', 'CC(C)C1CCCCC1NC(=O)C(=O)NCCCc1ccc(N)cc1', 'CC(C)C1CCCCN1C(=O)COC1(C)CN(C(=O)[C@H](C)N=[N+]=[N-])C1', 'CC(C)C1CCCCN1C(=O)[C@H]1CCN1C(=O)C(=O)c1cccn1C', 'CC(C)C1CCN1C(=O)C1CCN(C(=O)c2ccc(N)cn2)C12CC2', 'CC(C)C1CN(C(=O)C(F)C(C)CNC(=O)C(C)(C)c2ccno2)C1', 'CC(C)C1CN(C(=O)[C@H](NC(=O)[C@@H]2COC(=O)N2)C(C)C)CCCO1', 'CC(C)C1CN(C(C)C(=O)Nc2ccccc2C(F)(F)F)CCN1C', 'CC(C)C1OCCC1C(=O)NCCOc1cccc2c1OC(C)(C)C2', 'CC(C)C1OCCN1C(=O)C(C)n1cc(CN2CCCCC2=O)nn1', 'CC(C)CC(=O)NCC1(NC(=O)[C@@H]2CN(C)C[C@H](C)O2)CC(F)(F)C1', 'CC(C)CC(=O)NCC1(O)CC(CNC(=O)C2CCC(=O)N(C)C2)C1', 'CC(C)CC(=O)NCc1cc(C(=O)NCCC2CCCC23CC3)[nH]n1', 'CC(C)CC(C(=O)N(C)[C@@H]1CCc2ccccc21)N1CCCCCC1', 'CC(C)CC(C)(C)C(=O)N1C[C@H]2C[C@@H]1[C@H]2C(=O)N1CC(=O)NC(C)C1', 'CC(C)CC(C)(C)NC(=O)c1cn[nH]c1CNC(=O)C1CC=CCC1', 'CC(C)CC(C)(CNC(=O)CP(C)(C)=O)NC(=O)CCC1CCCC1', 'CC(C)CC(C)(O)CNC(=O)C(Cn1cccn1)NC(=O)C1CCC1', 'CC(C)CC(C)C(=O)N(C)CCCN(C)C(=O)c1nccn1C(C)C', 'CC(C)CC(C)C(=O)NCC(NC(=O)c1cncc(CO)c1)C(C)C', 'CC(C)CC(C)N(C)C(=O)C(CNC(=O)C1C[C@H]2CC[C@H]2C1)C(C)C', 'CC(C)CC(CC(=O)NOC[C@H]1C[C@H]2C=C[C@@H]1C2)NC(=O)[C@@H]1C[C@H]1F', 'CC(C)CC(CNC(=O)C(C)NC(N)=O)C(=O)N1CCOCC(C)C1', 'CC(C)CC(CNC(=O)[C@H]1CCOC1)C(=O)N(C)C1CCCN(C)C1', 'CC(C)CC(CNC(=O)c1ccc(Cl)s1)C(=O)N(C)[C@@H]1COC[C@H]1O', 'CC(C)CC(NC(=O)C(=O)Nc1ccc(Br)c(C#N)c1)C(=O)N(C)C', 'CC(C)CC(NC(=O)C(=O)Nc1cccc(CCC(=O)O)c1)C(N)=O', 'CC(C)CC(NC(=O)CC1OCCCO1)C(=O)N1CC(C(C)(C)C)C1', 'CC(C)CC(NC(=O)CN1CC2CC2C1)C(=O)NCC1CCSCC1', 'CC(C)CC(NC(=O)N1CCCC(NC(N)=O)CC1)c1ccccc1', 'CC(C)CC(NC(=O)c1ccoc1Cl)C(=O)NCC1CCC(C)(C)O1', 'CC(C)CC(O)C(=O)N(Cc1ccc(Cl)s1)CC1COCC(C)(C)O1', 'CC(C)CC(O)C(=O)NCC(=O)NCC(=O)N(C)C1CC2(CCC2)C1', 'CC(C)CC(O)C(C)C(=O)N(CC(=O)Nc1cccnc1)CC(C)C', 'CC(C)CC(O)CC(=O)N1CC[C@H]1C(=O)Nc1cccc2c1CCO2', 'CC(C)CC1(C(=O)NCc2ocnc2C(=O)N2CCC3CC3C2)CC1', 'CC(C)CC1(C(=O)N[C@@H]2CN(C(=O)c3cnc[nH]3)CC[C@H]2O)CCC1', 'CC(C)CC1(C(=O)N[C@@H]2COC[C@H]2CNC(=O)c2nocc2Cl)CC1', 'CC(C)CC1(CO)CCCN1C(=O)c1nc2ccccc2n(C)c1=O', 'CC(C)CC1(NC(=O)C2(C)CC(NC(=O)C(C)n3cccc3)C2)CC1', 'CC(C)CC1CCCN1C(=O)C1=C(C2CC2)CN1C(=O)OC(C)(C)C', 'CC(C)CC1CCN(C(=O)C(NC(=O)c2ccnnc2)C2CC2)CC1', 'CC(C)CC1CCN1C(=O)Nc1ccc2c(c1)CC1(CC2)OCCO1', 'CC(C)CC1CCN1C(=O)c1cc(-c2ccccc2C(F)(F)F)on1', 'CC(C)CCC(=O)N1CCN(C(=O)CC2(C)CCCCC2)CC12CC2', 'CC(C)CCC(=O)NC(C(=O)NCC1(n2cccn2)CC1)C1CCC1', 'CC(C)CCC(C)NC(=O)c1ccc(CNC(=O)[C@@H]2C[C@H]2C#N)cc1', 'CC(C)CCC(NC(=O)C1CC(C)(C)C1)C(=O)N1CC2(C=CCO2)C1', 'CC(C)CCC(NC(=O)c1cc(Cl)[nH]n1)C(=O)N[C@H]1C[C@H]2CC[C@@H]1C2', 'CC(C)CCC(O)C(=O)N1CC=CC1(C)C(=O)NCC(F)(F)C(N)=O', 'CC(C)CCC(O)C(=O)NC(Cc1ccccc1)CN1CCOCC1', 'CC(C)CCC(O)C(=O)N[C@H]1C=CCC[C@H]1C(=O)NCCC(C)(C)C', 'CC(C)CCC=CC(=O)N1CCC1(C)CC(=O)N1C[C@@H](O)C[C@H]1CO', 'CC(C)CCC=CC(=O)N1CCC=CC1C(=O)NC(C)C1(CO)CC1', 'CC(C)CCC=CC(=O)NCC(C(=O)N1CC(C)CCC1C)N(C)C', 'CC(C)CCCC(C)NC(=O)Nc1cccc(C2(C)COC(=O)N2)c1', 'CC(C)CCCCC(=O)N(C)C1(CC(=O)N2CC3(C=CCO3)C2)CC1', 'CC(C)CCCCC(=O)NC(C)(CO)C(=O)NC[C@H]1[C@@H]2CCCC[C@@H]21', 'CC(C)CCCCC(=O)NCC1CC1NC(=O)c1conc1C(C)C', 'CC(C)CCCCCNC(=O)N1CCC(c2nc(N)ncc2F)CC1', 'CC(C)CCCCNC(=O)CC1(C)CCN1C(=O)c1ncccc1N', 'CC(C)CCCN(C[C@H]1CC[C@H](C)CC1)C(=O)CN1CCCCCC1', 'CC(C)CCCNC(=O)C1(C)CCN(C(=O)CC2CCC(=O)NC2)C1', 'CC(C)CCCNC(=O)[C@]12COC[C@H]1CN(C(=O)c1nonc1N)C2', 'CC(C)CCN(C(=O)CC(NC(=O)C1CCC1C)C(F)(F)F)C1CC1', 'CC(C)CCN(C)c1nc(N(C)Cc2ccccn2)nc2c1SCC2', 'CC(C)CCOCC(=O)N(C)CC(C)C(=O)NC(C)c1noc(O)n1', 'CC(C)CCOCC(=O)N1C[C@@H](F)C[C@@H]1CC(=O)N1CCC(CF)C1', 'CC(C)CCOCC(=O)N[C@]1(C(=O)NCc2ncn(C)n2)C[C@H](O)C1', 'CC(C)CCOCCCNC(=O)N1CCn2c(nnc2C(F)(F)Cl)C1', 'CC(C)CCOCCN(CC1CCCC(C)(C)C1)C(=O)C1CCC1F', 'CC(C)CCONC(=O)[C@H]1CC[C@H]1CNC(=O)c1cncc(CO)c1', 'CC(C)CCSCC(=O)NCCC1(O)CN(C(=O)C2CC(CF)C2)C1', 'CC(C)CCSCC(=O)N[C@H](C(=O)N1CC2(C=CCO2)C1)C(C)(C)O', 'CC(C)CN(C(=O)CC(C)CNC(=O)C1=CCC(C)(C)CC1)C1CC1', 'CC(C)CN(C)C(=O)[C@@H]1CC[C@H](NC(=O)c2ccc3cncn3c2)C1', 'CC(C)CN(C)c1ccc(C(=O)N(C)Cc2cc(F)ccc2Br)cn1', 'CC(C)CN(CC(=O)N1CCCOC(C)(C)C1)C(=O)[C@@H]1CC[C@H](C)O1', 'CC(C)CN(CC(=O)N1CCN(C)C(=O)C1C)C(=O)[C@@H]1CCC[C@H]1O', 'CC(C)CN(CC(=O)NC(C)C1CCCO1)C(=O)c1ccc(CO)o1', 'CC(C)CN(CC(=O)NCCc1nccn1C)C(=O)CC[C@@H]1C[C@H]1C', 'CC(C)CN(Cc1ccccc1F)C(=O)c1csc(CCN(C)C)n1', 'CC(C)CN1CC2CN(C(=O)NCCn3cnc(I)c3)CCN2C1=O', 'CC(C)CN1CCCC(CNC(=O)C(=O)N2CCCC23CCCC3)C1', 'CC(C)CNC(=O)C(CC1CCC2CC21)N1CCC2(CC(CO)C2)C1', 'CC(C)CNC(=O)C(CC[C@H]1C[C@H]1C)N1C2CNC(=O)CC1COC2', 'CC(C)CNC(=O)CCN(C[C@H]1[C@@H]2CCCC[C@@H]21)C(=O)C(F)C(C)C', 'CC(C)CNC(=O)CNC(=O)C[C@@H](NC(=O)c1cccnc1)C1CC1', 'CC(C)CNC(=O)CNC(=O)C[C@H]1CC[C@H](NC(=O)c2ccsc2)C1', 'CC(C)CNc1nccc(N2CCc3ccc(C(C)(C)C)cc3C2)n1', 'CC(C)COC(C)C(=O)N(CCC(F)(F)C(C)C)CC1CC2CC2C1', 'CC(C)COC1CN(C(=O)CCCN(C)C(=O)C2C3CCC(F)C32)C1', 'CC(C)COCC(=O)N1CCC(=CCNC(=O)C#CC2CCC2)CC1', 'CC(C)COCC(=O)N1CCCC1C1(C(=O)N(C)CP(C)(C)=O)CC1', 'CC(C)COCC(O)CN(Cc1cnnn1C)C(=O)Cc1ccns1', 'CC(C)COCCC(=O)N(C)C[C@@H]1CCCN1C(=O)c1ccoc1Cl', 'CC(C)COCCC(=O)N(C)[C@@H](C)CNC(=O)C(C)c1cnccn1', 'CC(C)COCCC(=O)N[C@H]1C[C@H]1CNC(=O)c1cc(N)cc(F)c1', 'CC(C)COCCS(=O)(=O)N1CC(C)C(NC(=O)C2CC(F)(F)C2)C1', 'CC(C)COc1cccc(CNC(=O)c2cc(Br)c3c(c2)CCO3)c1', 'CC(C)COc1ccccc1-c1noc(CC(C)C2CCNCC2)n1', 'CC(C)CS(=O)(=O)CC(=O)N(C)CCNS(=O)(=O)C1CCCCC1O', 'CC(C)CSCCCNC(=O)C(=O)N1CCOc2ccc(Cl)cc2C1', 'CC(C)CSCCN(CCC1COCC1(C)C)Cc1nn(C)cc1Cl', 'CC(C)C[C@@H](C(=O)N1C[C@@H](C)OC[C@H]1C)N(C)C(=O)C1CCCCS1', 'CC(C)C[C@@H](C(=O)N1C[C@H](C)C[C@H]1C(=O)NOC(C)(C)CO)N(C)C', 'CC(C)C[C@@H](C(=O)NCC1CN(C2CC2)C1)N(C)C(=O)c1cnsc1', 'CC(C)C[C@@H](C(=O)NC[C@@H](C)N(C)C(=O)C1CCS(=O)(=O)N1)N(C)C', 'CC(C)C[C@@H](C(=O)NC[C@H]1CCC[C@H]1C(=O)N1CC(CF)C1)N(C)C', 'CC(C)C[C@@H](CC(=O)N(C)Cc1ccncc1F)NC(=O)C=CCO', 'CC(C)C[C@@H](CC(=O)N1CCC(CN=[N+]=[N-])C1)NC(=O)c1cnsn1', 'CC(C)C[C@@H](CNC(=O)C1(F)CC1)NC(=O)c1ccc2c(c1)COC2', 'CC(C)C[C@@H](CNC(=O)OC(C)(C)C)Nc1cc(C(F)F)nc(N)n1', 'CC(C)C[C@@H](CS(C)(=O)=O)NC(=O)C(=O)N[C@@H](C)c1cncc(F)c1', 'CC(C)C[C@@H](NC(=O)C1(NC(=O)CC2CCCCC2C)CC1)C(N)=O', 'CC(C)C[C@@H](NC(=O)C1CCCCCCC1)C(=O)NOC1CCCC1', 'CC(C)C[C@@H](NC(=O)COC1CCC1)C(=O)NCC(F)(F)C(C)(C)O', 'CC(C)C[C@@H](NC(=O)c1cnc(S)cn1)C(=O)NC1(C(C)(F)F)CC1', 'CC(C)C[C@H](C(=O)N1CC[C@@H]1C(=O)NCC1(CC2CC2)CC1)N(C)C', 'CC(C)C[C@H](CC(=O)NC1CCOCC1C)NC(=O)Cc1ccns1', 'CC(C)C[C@H](CC(=O)NCC[C@H](C)F)NC(=O)c1ccc(F)c(O)c1', 'CC(C)C[C@H](CS(C)(=O)=O)NC(=O)NCCCn1ccc(=O)[nH]c1=O', 'CC(C)C[C@H](NC(=O)C=Cc1cc[nH]n1)C(=O)N1C[C@H](F)C[C@H](F)C1', 'CC(C)C[C@H](NC(=O)CC1(C)CC1)C(=O)N1CCC(O)CC(C)(C)C1', 'CC(C)C[C@H](NC(=O)CC1CC2(C1)CN(C(=O)C[C@H](C)O)C2)C(N)=O', 'CC(C)C[C@H](NC(=O)c1ccncn1)C(=O)N1CCC2(C1)CC2(F)F', 'CC(C)C[C@H](NC(=O)c1cnn(C2CC2)c1)C(=O)NC(CO)CCF', 'CC(C)C[C@H](NC(N)=O)C(=O)Nc1cc(C(F)F)cc(C(F)(F)F)c1', 'CC(C)C[C@H](O)C(=O)N1CC[C@@H](OCC(=O)N2CC[C@H]3CCC[C@H]32)C1', 'CC(C)C[C@H](O)CN(Cc1ccc2[nH]nc(Cl)c2c1)CC1CCOC1', 'CC(C)C[C@H](O)CNC(=O)/C=C/C1CCN(C(=O)C(=O)C(C)C)CC1', 'CC(C)C[C@H](O)CNCc1cnc(C2CN(C(=O)OC(C)(C)C)C2)s1', 'CC(C)C[C@H]1C[C@@H]1C(=O)NC(C)C1CC(NC(=O)C(C)CC(N)=O)C1', 'CC(C)C[C@H]1C[C@@H]1C(=O)NC(C)CN(C)C(=O)c1coc(C(F)F)c1', 'CC(C)C[C@H]1C[C@@H]1C(=O)NC[C@H]1CC[C@H](NC(=O)CNC(N)=O)CC1', 'CC(C)Cn1cc(C(F)F)c(C(=O)NNC(=S)NCC2CCCO2)n1', 'CC(C)Cn1cc(CN(C)C(=O)C2CCCN(C(C)(C)C)C2=O)nn1', 'CC(C)Cn1cc(CN(C)C(=O)c2cc(O)ccc2C(F)(F)F)cn1', 'CC(C)Cn1ccc(C(=O)N2CCCCC2c2cn(CCF)nn2)n1', 'CC(C)N(C(=O)N[C@H]1CCC[C@H](NC(=O)OC(C)(C)C)C1)C1CCC1', 'CC(C)N(C)C(=O)CC1CN(C(=O)Cc2ccc(F)nc2)C(C)(C)C1', 'CC(C)N(C)C(=O)c1ccccc1Cn1cc(C2CCN(C)C2)nn1', 'CC(C)N(C)CC(=O)N(C)CC(C)(C)C(=O)N[C@H](C)c1cnccn1', 'CC(C)N(C)CC(=O)N(Cc1ccc(Cl)s1)CC(C)(C)n1ccnc1', 'CC(C)N(C)CCCNC(=O)c1ncoc1CNC(=O)[C@@H]1C[C@H]1C#N', 'CC(C)N(C)CCNC(=O)[C@@H]1C[C@H](F)CN1C(=O)[C@H]1[C@@H]2COCC[C@@H]21', 'CC(C)N(C)C[C@H](C)NC(=O)c1ccc(CNC(=O)C=CCO)cn1', 'CC(C)N(CC(=O)N1CC(c2cc(=O)[nH][nH]2)C1)C(=O)c1nccn1C', 'CC(C)N(CC(=O)Nc1cc2ccccn2n1)C(=O)[C@H]1C[C@@H]1[N+](=O)[O-]', 'CC(C)N(CC(=O)Nc1cccc(O)c1)C(=O)c1ncc(F)cc1F', 'CC(C)N(CCC(=O)N1CCN2C(=O)OCC2C1)C(=O)[C@H]1CC1(F)F', 'CC(C)N(CCC(=O)NC[C@@H](C)N(C)C)C(=O)c1cc(F)ccc1F', 'CC(C)N(CCC(=O)NCc1ccc(F)cc1)C(=O)C1=CCN(C)C1', 'CC(C)N(CCC(=O)N[C@H](C)C[C@H](C)O)C(=O)C1CCC(C)(C)OC1', 'CC(C)N(CCN(C)C)C(=O)CC1(C)CCN1C(=O)CSCC(F)F', 'CC(C)N(CCNC(=O)C1(CNC(=O)C2CN(C)C2)CCC1)C1CC1', 'CC(C)N(CCNC(=O)CC(C)(C)C)C(=O)CN(C)c1ccccc1', 'CC(C)N(CCNC(=O)Cc1cnc[nH]c1=O)C(=O)C#CC(C)(C)C', 'CC(C)N(CCO)C(=O)C12CCN(C(=O)c3cnnn3C)CCC1C2', 'CC(C)N1CC(C(=O)N2CC[C@H](F)C[C@@H]2C(=O)Nc2cnn(C)c2)C1', 'CC(C)N1CC(C(=O)NC(C(=O)N2CCC3CC32)C2CC=CCC2)C1', 'CC(C)N1CC(Nc2nc(N)nc(NCCn3cnccc3=O)n2)C1', 'CC(C)N1CCC(N(C)C(=O)C(C)(C)NC(=O)C(=O)NCC2CC2)C1', 'CC(C)N1CCCC(NC(=O)c2ncccc2C(F)(F)C(C)(F)F)C1', 'CC(C)N1CCC[C@H]1C(=O)N1CC[C@@H](CNC(=O)C2CC(Cl)(Cl)C2)C1', 'CC(C)N1CCN(CCC(=O)N2CCCc3c2ccc(F)c3Cl)CC1', 'CC(C)NC(=O)C(=O)N1CCCC(N(C)C(=O)CC(C)C2CC2)CC1', 'CC(C)NC(=O)C(=O)N1CC[C@@H](C)[C@@H](N(C)C(=O)C2=CC(C)(C)C2)C1', 'CC(C)NC(=O)C(C)NC(=O)[C@@H]1[C@H](NC(=O)C2CCCCC2)C1(C)C', 'CC(C)NC(=O)C(c1cccc2nccn12)N1CC2CCCC(C2)C1', 'CC(C)NC(=O)CCNC(=O)CCN(C(=O)CC1CC1(C)C)C1CC1', 'CC(C)NC(=O)CNC(=O)CC(C)(C)N(C)C(=O)C1CCCN(C)C1', 'CC(C)NC(=O)N1CCCC(C(=O)Nc2cnn(CC(F)(F)F)c2)C1', 'CC(C)NC(=O)Nc1ccc(NC(=O)c2snnc2C2CCC2)cc1', 'CC(C)NC(=O)c1ccc(Cl)c(NC(=O)COc2ccc(Cl)cc2)c1', 'CC(C)NC(=O)c1ccccc1NC(=O)COc1ccc(F)cc1F', 'CC(C)NC(CO)C(=O)NCc1cccnc1OCc1ccccc1', 'CC(C)NC(c1ccc2c(c1)CCC2)c1nnnn1C1CC(F)(F)C1', 'CC(C)NS(=O)(=O)c1cc(C(=O)N2C[C@H](C)[C@H](N=[N+]=[N-])C2)ccc1F', 'CC(C)Nc1cccc(CNC(=O)c2cccc(C(F)(F)CF)n2)c1', 'CC(C)Nc1ncccc1C(=O)NCCCOc1ccc(CN)cc1', 'CC(C)OC(=O)CC(Nc1nc2cc(C(C)(C)C)ccc2o1)C(C)C', 'CC(C)OC(C(=O)N1CCc2cccc(F)c2C1C)c1ccccc1', 'CC(C)OC(C)(C)C(=O)N1CCC(NC(=O)C(C)OCC(F)(F)F)C1', 'CC(C)OC(C)(C)C(=O)N1CCC(O)(CNC(=O)CC(C)(C)O)CC1', 'CC(C)OC(C)(C)C(=O)NCc1cc(C(=O)N2C[C@H]3CC[C@H]3C2)no1', 'CC(C)OC1(C(=O)NCCC(=O)N2CCC(CCCO)CC2)CCC1', 'CC(C)OC1CCN(c2cc(NCC3(CCCO)CC3)ncn2)CC1', 'CC(C)OCC(=O)N(C)[C@H]1CC[C@H](CNC(=O)C2CNC(=O)C2)CC1', 'CC(C)OCC(=O)N(CCSC(F)(F)F)CC1C2(CCC2)C12CCC2', 'CC(C)OCC(=O)N(Cc1cccc2c1CCO2)CC(C)OC(F)F', 'CC(C)OCC(=O)NC(C)(CNC(=O)C=CC(=O)N(C)C)C1CCC1', 'CC(C)OCC(=O)NC[C@]1(C)CCCN1C(=O)c1coc(C2CC2)n1', 'CC(C)OCC1(C(=O)N[C@@H](CC(=O)N2CC(C)(CO)C2)C2CC2)CC1', 'CC(C)OCC1(C(=O)N[C@@H]2CCC[C@H]2NC(=O)[C@@H]2CCC[C@H]2O)CC1', 'CC(C)OCCC(=O)NCC(C(=O)N1Cc2ccccc2C1)C(C)C', 'CC(C)OCCC(=O)NCC1CN(C(=O)c2cncs2)CC12CCC2', 'CC(C)OCCC(=O)NCc1ccc(C(=O)Nc2ccc(Cl)nc2)s1', 'CC(C)OCCC(=O)N[C@]1(C(=O)N(C)C(C(N)=O)C2CC2)C[C@H](O)C1', 'CC(C)OCCCC(=O)NCC[C@@H](O)C(=O)NC1CN(C)CC1(C)C', 'CC(C)OCCCCN(Cc1nn(C)cc1Cl)C(=O)c1csc(Cl)c1', 'CC(C)OCCCN(C)C(=O)C[C@@H](NC(=O)c1cc(Cl)ns1)C1CC1', 'CC(C)OCCCN(Cc1ccc(C#N)nc1)Cc1cc(Cl)nn1C', 'CC(C)OCCCc1noc(CCCNC(=O)c2ccc(F)cc2)n1', 'CC(C)OCCNC(=O)C1(C)CCN(C(=O)c2ccc(F)cc2)CC1', 'CC(C)OCCNC(=O)C[C@@H]1CCN(C(=O)CCOCC(C)(C)C)C1', 'CC(C)OCCNC(=O)c1sccc1CNC(=O)C1(C)CC(C)(C)C1', 'CC(C)OCCS(=O)(=O)N[C@@H]1C[C@H]2CC[C@@H]1[C@@H](NC(=O)CCCF)C2', 'CC(C)OC[C@H](NC(=O)C1CC12CCCCC2)C(=O)NOCCCF', 'CC(C)OC[C@H](NC(=O)Cc1cscn1)C(=O)N(C)[C@H]1CCOC1=O', 'CC(C)O[C@@H]1CCN(C(=O)[C@@H]2CC[C@@H]2NC(=O)C(C)(C)CC(F)F)C1', 'CC(C)Oc1cc(CNC(=O)c2cnc(O)c3cnccc23)ccn1', 'CC(C)Oc1cc(NCC(=O)N2CCCc3ccccc32)ccc1Br', 'CC(C)Oc1ccc(C(=O)Nc2cc(N3CCOCC3)ncn2)nn1', 'CC(C)Oc1ccc(CNC(=O)N(C)C(C)c2ccc(Cl)cn2)nc1', 'CC(C)Oc1cccc(C(=O)N(C)CC(=O)Nc2ccc(Cl)cc2)n1', 'CC(C)Oc1cccc(CN(C)C(=O)NCc2ncc(C(C)C)o2)c1', 'CC(C)Oc1nsc(NC(=O)C=Cc2ccc(F)c3ccccc23)n1', 'CC(C)S(=O)(=O)CC(=O)N[C@H]1C[C@H](O)CN(C(=O)C2CCS2(=O)=O)C1', 'CC(C)S(=O)(=O)Cc1ccc(NC(=O)COC(C)(C)C(F)(F)F)cc1', 'CC(C)S(=O)(=O)N[C@@H]1CC(NC(=O)[C@H]2CCC[C@H](N(C)C)C2)C[C@H]1O', 'CC(C)S(=O)(=O)c1ccccc1NC(=O)NC1CCCCCC1(F)F', 'CC(C)SC(C)C(=O)N1CCN(C(=O)C(=O)NC2CC2)C(C2CC2)C1', 'CC(C)SC(C)C(=O)N1CC[C@@H](CCNc2ncc(C#N)cc2F)C1', 'CC(C)SC(C)C(=O)N1CC[C@@H](N(C)C(=O)CC2CCCOCC2)C1', 'CC(C)SC(C)C(=O)NC1CN(C(=O)C2CCS(=O)CC2)CC1(C)C', 'CC(C)SCC(=O)N(CCO)CCCNC(=O)c1ncc(Cl)cc1F', 'CC(C)SCC(=O)N1CCC[C@H](CC(=O)N[C@H]2C[C@@H]3OC(=O)C[C@H]23)C1', 'CC(C)SCC(=O)NC1CC2(C1)CC2C(=O)N(C)CCc1c[nH]cn1', 'CC(C)SCCNC(=O)c1cn[nH]c1CCNC(=O)c1ccc(Cl)s1', 'CC(C)[C@@H](C(=O)N1CCC(F)(C(=O)Nc2cnn(C)c2)CC1)N(C)C', 'CC(C)[C@@H](C(=O)N[C@H](C)CCNC(=O)CN1CCNC(=O)C1)N(C)C', 'CC(C)[C@@H](CC(=O)N(C)[C@H]1CC[C@H]2C[C@H]21)NC(=O)C1CC1(C)C(F)F', 'CC(C)[C@@H](CC(=O)N1CC(C)(N(C)C)C1)NC(=O)c1ccc(N)nc1', 'CC(C)[C@@H](CC(=O)N1CCC(C#N)C1)NC(=O)[C@H]1C[C@@H]1c1ccco1', 'CC(C)[C@@H](CC(=O)NC1(c2nnn[nH]2)CC1)NC(=O)C1CCC(=O)C1', 'CC(C)[C@@H](CCC(=O)N1CCOC(C(C)(C)C)C1)NC(=O)[C@H]1C[C@H]1C', 'CC(C)[C@@H](CCC(=O)N[C@@H]1CCC[C@H]1CCO)NC(=O)c1cnns1', 'CC(C)[C@@H](CCO)NC(=O)[C@H]1COCCN1C(=O)c1cccnc1S', 'CC(C)[C@@H](CNC(=O)CCc1c[nH]cn1)NC(=O)c1ncncc1Cl', 'CC(C)[C@@H](NC(=O)CCOCCNC(=O)c1nccn1C)C(F)(F)F', 'CC(C)[C@@H](O)C(=O)NC(CC1CC1)C(=O)NCCCN1CCOCC1', 'CC(C)[C@@H](O)c1cn(CC2CCCN2C(=O)CC2CC(F)(F)C2)nn1', 'CC(C)[C@@H]1CN(C(=O)C2CC3(CC3)C2)C[C@H]1C(=O)NCC1CC=CC1', 'CC(C)[C@@H]1CN(C(=O)CC23CCCC2C3)C[C@H]1C(=O)NCC[C@@H](C)O', 'CC(C)[C@@H]1CN(C(=O)c2ccoc2Cl)C[C@H]1C(=O)N1CC(S(C)=O)C1', 'CC(C)[C@@H]1COCCN1C(C(=O)NC1CC1)c1ccc(S(C)(=O)=O)o1', 'CC(C)[C@@H]1C[C@H]1CN(Cc1cc(C(C)(C)O)on1)C(=O)c1cnsn1', 'CC(C)[C@@H]1C[C@H]1NC(=O)CC1(N(C)C(=O)c2ccn(CCF)n2)CC1', 'CC(C)[C@H](CC(=O)NC1COC(C(F)F)C1)NC(=O)C1(C)CC(F)C1', 'CC(C)[C@H](CC(=O)NCCC(O)C1CCC1)NC(=O)[C@@H]1CCC(=O)O1', 'CC(C)[C@H](CC(=O)NCCN1CCOCC1)NC(=O)Cc1cscn1', 'CC(C)[C@H](CCC(=O)N1CCOCC1)NC(=O)CCC1CCOCC1', 'CC(C)[C@H](CCC(=O)NCC1CN2CCC1C2)NC(=O)C1(O)CCC1', 'CC(C)[C@H](CCC(=O)N[C@@H]1CCC[C@H](O)C1)NC(=O)C1CC2CC2C1', 'CC(C)[C@H](CNC(=O)CC1CCC(C)(C)O1)NC(=O)C1(F)CCOC1', 'CC(C)[C@H](CNC(=O)[C@@H]1C[C@H]2C[C@@H]1C[C@H]2O)NC(=O)[C@H](O)C1CCC1', 'CC(C)[C@H](CO)N(C)C(=O)CC1CCN(C(=O)C2(C#N)CCC2)CC1', 'CC(C)[C@H](CO)N(C)C(=O)CCC1CCN(C(=O)C[C@H]2CCOC2)C1', 'CC(C)[C@H](N=[N+]=[N-])C(=O)N1CCC2CC21C(=O)NC1COC(C)(C)C1', 'CC(C)[C@H](N=[N+]=[N-])C(=O)NCCC1CCC(NC(=O)C2CS(=O)C2)C1', 'CC(C)[C@H](NC(=O)C1(C(C)C)CCC1)C(=O)NCC1(C)CC2CC2C1', 'CC(C)[C@H](NC(=O)C1CCC(CO)CC1)C(=O)NCCc1nccs1', 'CC(C)[C@H](NC(=O)C1CCCCC1)C(=O)NC[C@H]1NC(=O)OC1(C)C', 'CC(C)[C@H](NC(=O)CSCC(F)F)C(=O)N1CCC(CC(C)(C)C)C1', 'CC(C)[C@H](NC(=O)Cc1ccccc1O)C(=O)NC1(CO)CC=CC1', 'CC(C)[C@H](O)C(=O)N1CCCC[C@H]1CCN(C)C(=O)[C@@H]1C[C@@H]2C[C@@H]2C1', 'CC(C)[C@H]1CCO[C@H]1C(=O)NCC1(C(=O)NC2CC23CC(O)C3)CC1', 'CC(C)c1[nH]nc(C(=O)Nc2cc(F)cc3c2CNC3=O)c1[N+](=O)[O-]', 'CC(C)c1c(C(=O)N2CC(CC(F)(F)C(=O)O)C2)nc2n1CCCC2', 'CC(C)c1c(NC2CCC(C)(C#N)CC2)nnn1Cc1ccccc1', 'CC(C)c1cc(C(=O)N(Cc2ccsn2)C[C@H]2C[C@@H]2C(C)(C)C)on1', 'CC(C)c1cc(C(=O)N2CCC2CC(=O)NC2CCCN(C)C2)on1', 'CC(C)c1cc(CO)nc(NC/C=C\\CNC(=O)Cc2cnsn2)n1', 'CC(C)c1cc(F)ccc1NC(=O)N1CCCC(S(=O)(=O)N(C)C)C1', 'CC(C)c1cc(NC(=O)CNc2cccc(OC3CCCC3)c2)on1', 'CC(C)c1ccc(C(=O)N(CCCC(F)(F)F)Cc2ccsn2)cn1', 'CC(C)c1ccc(C(=O)N2CCNC(=O)C2c2ccccc2)c(=O)[nH]1', 'CC(C)c1ccc(C(=O)NC[C@H]2C[C@H]2C(=O)N[C@H](C(N)=O)C(C)C)o1', 'CC(C)c1ccc(C=CCC(=O)Nc2ccc(CN(C)C)cc2)cc1', 'CC(C)c1ccc(CC(=O)N2CCc3c2cccc3[N+](=O)[O-])cc1F', 'CC(C)c1ccc(CC2CCN(C(=O)NCCC3(O)CCC3)C2)cc1', 'CC(C)c1ccc(NC(=O)NCCC(=O)NCc2ccccc2)cn1', 'CC(C)c1ccc(NS(=O)(=O)CCNS(=O)(=O)c2ccccc2)cc1', 'CC(C)c1cccc(C(=O)Nc2ncccc2C(=O)OC(C)(C)C)n1', 'CC(C)c1cccc(CC(N)C(=O)Nc2ccc(C(C)C#N)cc2)c1', 'CC(C)c1cccc(N(CCO)Cc2ccc(-n3ccnc3)cc2)c1', 'CC(C)c1cccc(NC(=O)N2CCc3[nH]c4ccccc4c3C2)c1', 'CC(C)c1cccc(NNC(=O)NC[C@@]2(C)COC[C@H]3CCCN32)c1', 'CC(C)c1cccc(OC(=O)C2CCCN2C(=O)C2CCCCC2)c1', 'CC(C)c1ccoc1C(=O)NC1CC2(C1)CC2C(=O)N1CC2CC1C2', 'CC(C)c1csc(C(C)NC(=O)N2CCc3c(ncn(C)c3=O)C2)n1', 'CC(C)c1n[nH]cc1S(=O)(=O)NCCCCNC(=O)c1ccc(F)s1', 'CC(C)c1nc(C(=O)NCC2CN(C(=O)c3cn(C)nc3O)C2)co1', 'CC(C)c1nc(C(=O)NC[C@H]2CC[C@H]2NC(=O)c2scnc2Cl)co1', 'CC(C)c1nc(CN(CCCC(F)(F)F)C(=O)c2c[nH]c(=O)[nH]2)c[nH]1', 'CC(C)c1nc(O)cc(N[C@@H](CF)CNC(=O)c2nccnc2O)n1', 'CC(C)c1nc2c(C(=O)N(CCO)CC3CCCCC3)cccc2[nH]1', 'CC(C)c1nc2cc(N(C)C(=O)[C@@H]3CC[C@@H]4CCC(=O)N43)ccc2o1', 'CC(C)c1ncc(C(=O)N2CC(O)(CNC(=O)c3ccncn3)C2)o1', 'CC(C)c1ncc(C(=O)N[C@]2(C(=O)NC3CCC(C)(C)C3)C[C@H]2C)o1', 'CC(C)c1ncc(C(=O)Nc2cc(-c3ccc(F)cc3F)nn2C)s1', 'CC(C)c1ncc(CN(CC2(C)CSC2)C(=O)Cn2cnnn2)cn1', 'CC(C)c1ncc(NC(=O)C[C@H]2CCCN2C(=O)c2cnsc2)cn1', 'CC(C)c1ncc2c(n1)CN(C(=O)C(=O)NCc1cc(Br)cs1)CC2', 'CC(C)c1ncc2c(n1)CN(C(=O)c1coc(-c3cn[nH]c3)n1)CC2', 'CC(C)c1nccc(C(=O)N[C@H]2C[C@@H](NC(=O)c3csnc3Cl)C2)n1', 'CC(C)c1nccn1CC(=O)N[C@H]1CC[C@H](NC(=O)C2=NOCC2)C1', 'CC(C)c1ncncc1NC(=O)CN(C)C(=O)c1ccc(F)c(O)c1', 'CC(C)c1nn(-c2ccccc2)cc1CNC(=O)C1(F)CCCOC1', 'CC(C)c1nn(C)c(Cl)c1CNc1nc2c(s1)CN(C(C)(C)C)CC2', 'CC(C)c1nnc(CN(CCc2ccncc2)C(=O)[C@@H](C)C2CC2)s1', 'CC(C)c1nnc(NC(=O)CCC(=O)NCC(C)(O)c2cccs2)s1', 'CC(C)c1nnnn1CC(=O)N[C@@H](CNC(=O)[C@H]1C[C@H]1F)C(C)(C)C', 'CC(C)c1noc2ncc(C(=O)NCc3ncoc3C(F)(F)F)cc12', 'CC(C)c1nsc(NCC(CC(F)(F)F)NC(=O)c2cccn2C)n1', 'CC(C)c1sccc1NC(=O)C1CCN(C(=O)[C@@H]2CCC(=O)N2)CC1', 'CC(C)n1cc(C(=O)NC2CCC(NC(=O)[C@H]3CCN3C)CC2)nn1', 'CC(C)n1cc(C(=O)NCC2CN(C(=O)[C@H]3C[C@@H]3C3CCC3)C2)nn1', 'CC(C)n1cc(CC(=O)N[C@H]2C[C@@H](NC(=O)C[C@@H](C)N(C)C)C2)nn1', 'CC(C)n1cc(CN(Cc2sccc2Cl)C(=O)c2nnsc2N)nn1', 'CC(C)n1cc(CNC(=O)Nc2cccnc2-c2ccccc2)cn1', 'CC(C)n1ccc(NC(=O)C2CC(O)(CNC(=O)OC(C)(C)C)C2)n1', 'CC(C)n1ccnc1CNC(=O)N1C[C@H]2[C@H](C(F)(F)F)C[C@@]2(CO)C1', 'CC(C)n1cnc(C(=O)N2CC(N(C)C(=O)CC3=CCOCC3)C2)c1', 'CC(C)n1cnc(C(=O)N[C@H]2CC[C@H](NC(=O)CSCC(F)F)C2)c1', 'CC(C)n1cncc1CNC(=O)[C@@H](O)CNC(=O)C(=O)NCC1CC1', 'CC(C)n1nc(Br)c(C(=O)NC(CC2CC2)c2cc(F)cc(Br)c2)n1', 'CC(C)n1nc(Br)cc1C(=O)NCc1cn(Cc2ccccc2)nn1', 'CC(C)n1ncc(C(=O)NC[C@H]2C[C@H]2C(=O)N2CCO[C@H]3CC[C@H]32)n1', 'CC(C)n1ncc(CN(CC2(F)CC2)C(=O)Cc2csc(N)n2)c1F', 'CC(C)n1ncc2c1CC(NC(=O)CNc1ncnc(Cl)c1N)CC2', 'CC(C)n1nccc1CC(=O)N1CC2CCN(C(=O)CC(Cl)Cl)CC21', 'CC(C)n1nccc1CC(=O)OCC(=O)c1c[nH]c2cc(Br)ccc12', 'CC(C)n1nccc1[C@@H]1OCC[C@H]1Nc1nc2ccccc2c(=O)[nH]1', 'CC(C)n1nnnc1C1(NC2CCOCC2)CC(C2CC2)(C2CC2)C1', 'CC(C1CC1)N(C)C(=O)CC(NC(=O)[C@@H]1CCC[C@H](CF)C1)C(F)F', 'CC(C1CC1)N1CC(C(=O)N[C@H]2[C@@H](C(F)(F)F)[C@@H]3CC[C@H]2N3)CC1=O', 'CC(C1CCN(C)CC1)N(C)C(=O)C(c1ccccc1)C1CCCC1', 'CC(CC#N)C(=O)N1CC(CNC(=O)CCc2ccsc2)C(F)(F)C1', 'CC(CC#N)C(=O)N1CCC(C(=O)NCCC2(O)CCOC2)=C(F)C1', 'CC(CC#N)C(=O)N[C@H](CO)[C@H](C)NC(=O)c1coc(CC2CC2)n1', 'CC(CC#N)Nc1nc(N2CCN(C(C)C)C(=O)C2)c2ncsc2n1', 'CC(CC(=O)N(CC[C@H]1CCC[C@H]1O)CC1CCSC1)CC(C)(C)C', 'CC(CC(=O)N(CC[C@H]1C[C@H](F)C1)CC1=CCSC1(C)C)P(C)(C)=O', 'CC(CC(=O)N1C2CCC1COC2)C(C)(C)NC(=O)Cc1ccn[nH]1', 'CC(CC(=O)N1CC2(CC2)C[C@H]1CC(=O)N1CC(C)(CF)C1)C1CC1', 'CC(CC(=O)N1CCC(CCNC(=O)CS(N)(=O)=O)C1)n1cccn1', 'CC(CC(=O)N1CCC2C(C1)C2NC(=O)C(F)CC(C)(C)C)C1CC1', 'CC(CC(=O)N1CCCC1C(C)(C)C(=O)NCc1ncsn1)C1CC1', 'CC(CC(=O)N1CCOCC1C(=O)NCCOCC(F)(F)F)N(C)C', 'CC(CC(=O)N1[C@@H]2CC[C@@H](C2)[C@H]1C(=O)N[C@H]1CCN(C)C1=O)C1CC1', 'CC(CC(=O)NC1(C(=O)NCCc2cccnc2)CC1)n1ccnc1', 'CC(CC(=O)NC1CC=C(C(=O)N2CCC(C#N)C2)C1)n1cccn1', 'CC(CC(=O)NCC(C)(O)CO)C(C)(C)NC(=O)[C@H]1[C@@H]2CCCC[C@@H]21', 'CC(CC(=O)NCCOC1CN(S(=O)(=O)C(F)(F)F)C1)c1ccco1', 'CC(CC(=O)NC[C@H]1CC[C@@H](NC(=O)C=CCF)C1)c1cnn(C)c1', 'CC(CC(=O)NC[C@H]1CN(C(=O)C2(Cl)CC2)C[C@H]1O)c1ccncc1', 'CC(CC(=O)NC[C@H]1C[C@@H](C(=O)NC2CC3CCC2O3)CO1)N(C)C', 'CC(CC(C)(C)C)C(F)C(=O)N(C)[C@@H](C)CNC(=O)c1csnc1Cl', 'CC(CC(C)(C)C)NC(=O)[C@@H](NC(=O)C(F)C1CCCC1)C1CCC1', 'CC(CC(F)(F)F)C(=O)NCC1CC(NC(=O)C23CC(CO)(C2)C3)C1', 'CC(CC(F)F)C(=O)N1C[C@@H](F)C[C@H]1C(=O)NC[C@H]1CC[C@H](O)CC1', 'CC(CC(F)F)C(=O)NCCn1cnc(C(=O)N(C)C[C@H](C)CO)c1', 'CC(CC(N)=O)C(=O)N1CC2CCC1CC2Nc1ncc(Cl)c(=O)[nH]1', 'CC(CC(N)=O)C(=O)N[C@H](CO)CCCNC(=O)C1=CC2C=CC1C2', 'CC(CC(N)=O)N(C)C(=O)C1CCN(C(=O)c2sccc2F)C12CC2', 'CC(CC1=CC=C2OCOC2=C1)NCC(O)C1=CC=C(O)C(O)=C1', 'CC(CC1=CCCCC1)NC(=O)C1CCN(C(=O)C(C)C)CC1(C)C', 'CC(CC1=CCCCC1)NC(=O)CC1(NC(=O)C2CCC(=O)N2)CC1', 'CC(CC1CC(F)(F)C1)CN(CCC(C)(C)F)C(=O)C1CC(=O)CS1', 'CC(CC1CCC1)C(=O)N1CCC=C(CNC(=O)CC(=O)N(C)C)C1', 'CC(CC1CCC1)C(=O)NC[C@H]1COC[C@@H]1NC(=O)c1cccn1C', 'CC(CC1CCC1)Nc1cc(NCCCN2C(=O)CCC2=O)ncn1', 'CC(CC1CCCCC1)CN(CC1(F)CCOC1)C(=O)[C@@H]1CCOC1', 'CC(CC1CCCO1)C(=O)N(Cc1ccc(F)c(F)c1)CC1CCC1', 'CC(CC1CN(C(=O)C(C)CN(C)C)C1)NC(=O)c1cccnc1O', 'CC(CC1CN(C(=O)C2COC(=O)N2)C1)NC(=O)C1C=CC=CC=C1', 'CC(CC1CN(C(=O)Cc2cn(C(C)C)nn2)C1)NC(=O)[C@@H]1C[C@H]1F', 'CC(CCC(=O)N(C)C(C)C(C)(C)O)NC(=O)CCc1nc(=O)[nH][nH]1', 'CC(CCC(=O)N1CCCC(F)(F)C1)NC(=O)[C@@H]1NC(=O)OC1(C)C', 'CC(CCC(=O)NC1CN(C)CC1(F)F)NC(=O)C1(C)COCCO1', 'CC(CCC(=O)NCC12CCN(CC1)C2)NC(=O)C=C1CCCCC1', 'CC(CCC(=O)N[C@@H](CO)CCCO)NC(=O)c1ccc(O)c(F)c1', 'CC(CCC(=O)Nc1cccc(O)c1)NC(=O)c1cccn1C(C)C', 'CC(CCC(=O)OC(C)C)NC(=O)c1ccc2nc(N(C)C)oc2c1', 'CC(CCC(C)(C)C)C(=O)N1CCCC1C(=O)N1CCC1CC1CC1', 'CC(CCC(F)(F)F)(C(=O)Nc1ccnc(F)c1F)c1ccccc1', 'CC(CCC(F)(F)F)NC(=O)CC(C)(C)NC(=O)C[C@H]1CCCN1C', 'CC(CCC(F)F)NCc1ccnn1C1CN(C(=O)OC(C)(C)C)C1', 'CC(CCC1CC1)NC(=O)c1cc(CNC(=O)CS(C)(=O)=O)ccn1', 'CC(CCCC(F)(F)F)Nc1cc(N(C)Cc2ccnn2C)ncn1', 'CC(CCCCNC(=O)CCc1cocn1)NC(=O)c1ccccn1', 'CC(CCCCNC(=O)c1cc2cccc(F)c2[nH]1)Nc1ncns1', 'CC(CCCCO)NC(=O)C(CNC(=O)C1CC(=C2CC2)C1)N(C)C', 'CC(CCCNC(=O)C(C)(C)n1ccnn1)NC(=O)CC1C=CCC1', 'CC(CCCNC(=O)COc1ccc(Cl)nc1)Nc1nnc(CO)s1', 'CC(CCCO)CN(Cc1cnn(CCO)c1)C(=O)[C@@H]1CCC(=O)O1', 'CC(CCCOc1cccnc1)NC(=O)c1nccn2cc(Cl)cc12', 'CC(CCN(C)C(=O)C1=COCCC1)NC(=O)C[C@H]1C[C@@H]1C(F)(F)F', 'CC(CCN(C)C(=O)CC(C)N(C)C)NC(=O)[C@]1(C(F)F)C[C@@H](O)C1', 'CC(CCN(C)C)C(=O)N1CCC(C(=O)NCC2CNC(=O)O2)CC1', 'CC(CCN(C)C)C(=O)NCc1ccc(C(=O)N[C@H](CO)C(C)C)o1', 'CC(CCN(Cc1ccc2[nH]ccc2c1)C(=O)C1CCCO1)C(F)F', 'CC(CCN(Cc1cccnc1)C(=O)C1CC(F)(CF)C1)C(C)(C)C', 'CC(CCN1CCCC1)NC(=O)[C@@H]1CC[C@@H]1NC(=O)C(C)(C)CCF', 'CC(CCNC(=O)C(NC(=O)c1cc(Cl)n(C)n1)C1CC1)C(F)(F)F', 'CC(CCNC(=O)CC1CCCC(=O)C1)N(C)C(=O)[C@H]1OCC[C@H]1C', 'CC(CCNC(=O)Cc1ccc(Cl)cc1)NC(=O)C1CCCS1(=O)=O', 'CC(CCNC(=O)OC(C)(C)C)NC(=O)COc1cccc(F)c1F', 'CC(CCNC(=O)c1ccnn1C)N(C)C(=O)c1coc(C2CC2)n1', 'CC(CCNC(=O)c1cnc(N)o1)N(C)C(=O)C[C@@H]1CCC[C@H](C)O1', 'CC(CCNC(=O)c1nocc1Cl)N(C)C(=O)[C@@H](C)N1CCCCC1', 'CC(CCO)CCN(CC1CCC2CC2C1)C(=O)C(C)C1(O)CCC1', 'CC(CCO)CNC(=O)C[C@H]1CCC[C@@H]1NC(=O)Cc1ccn(C)c1', 'CC(CCO)CNC(=O)[C@@H]1CCCN(C(=O)c2ncoc2C(C)C)C1', 'CC(CCO)N(C)C(=O)[C@@H]1CCCN(C(=O)c2cn(C)c(=O)n2C)C1', 'CC(CCS(C)(=O)=O)NC(=O)N1CCC(Oc2ccccc2C#N)C1', 'CC(CCc1cn[nH]c1)NC(=O)C1CCN(C(=O)c2ccncc2)C1', 'CC(CCn1cncn1)NC(=O)c1ccc2cc(C(F)(F)F)[nH]c2c1', 'CC(CN(C(=O)c1ccc2n1CCNC2)[C@@H](C)CO)c1ccccc1', 'CC(CN(C)C(=O)C(=O)N[C@H]1C[C@@H]1c1ccc(Cl)cc1)OC(C)(C)C', 'CC(CN(C)C(=O)C(C)(C)C(N)=O)C(=O)Nc1ccccc1CCO', 'CC(CN(C)C(=O)C1(C)CC(F)(F)C1)NC(=O)c1ncnc(O)c1F', 'CC(CN(C)C(=O)C1(Oc2ccc(F)cc2)CCOCC1)S(C)(=O)=O', 'CC(CN(C)C(=O)C1=CCCCO1)C(=O)N1CCCC12CCCCC2', 'CC(CN(C)C(=O)C1CCN(C)C1=O)C(=O)N[C@H]1CCCC[C@H]1CO', 'CC(CN(C)C(=O)C1CCOC1(C)C)C(=O)NCCC1CCCCO1', 'CC(CN(C)C(=O)CC1CCOCC1)C(=O)N[C@@H](C)CN(C)C(C)C', 'CC(CN(C)C(=O)CCCC(=O)N(C)C)NC(=O)CN(C)S(C)(=O)=O', 'CC(CN(C)C(=O)CCCCCC#N)N(C)C(=O)[C@H]1C[C@@H](C)N(C)C1', 'CC(CN(C)C(=O)CCOCC(C)(C)C)N(C)C(=O)[C@H](O)CC(N)=O', 'CC(CN(C)C(=O)CN1C(=O)CCC1=O)C(=O)NCCc1cc[nH]n1', 'CC(CN(C)C(=O)C[C@H]1C[C@@H]1C1CC1)C(=O)N1CC(n2cccn2)C1', 'CC(CN(C)C(=O)[C@@H](NC(=O)C1C2CC3C(C2)C31)C1CC1)C(F)(F)F', 'CC(CN(C)C(=O)[C@@H]1CSCC(=O)N1)C(=O)Nc1cnn(CCF)c1', 'CC(CN(C)C(=O)[C@H]1[C@H]2CC[C@H](C2)N1C(=O)C1CC(F)C1)C(F)(F)F', 'CC(CN(C)C(=O)c1cc(O)n(C)n1)C(=O)NCCc1cnccn1', 'CC(CN(C)C(=O)c1cncc(CO)c1)C(=O)N(C)CC1CCCC1', 'CC(CN(C)C)C(=O)N1[C@H](C)CN(C(=O)[C@@H]2CCO[C@H](C)C2)C[C@@H]1C', 'CC(CN(C)C)C(=O)NC1(CCNC(=O)C2CC3(CC3)CO2)CCC1', 'CC(CN(C)c1cc(NCCCCN(C)C)ncn1)C1CCCCC1', 'CC(CN(CCCC1CCC1)Cc1nn(C)cc1Br)c1ccccn1', 'CC(CN(Cc1ccc(Cl)cc1)C(=O)C1CCN(C)C1)c1nccs1', 'CC(CN(Cc1cccc2[nH]ncc12)C(=O)c1cc(Cl)cs1)C1CC1', 'CC(CN(Cc1ccnn1C)C(=O)C[C@H]1CCCN1C)c1nccs1', 'CC(CN(Cc1ccoc1)C(=O)c1cn(C2CC2)cn1)c1cccs1', 'CC(CN(Cc1cncc(Cl)c1)C(=O)Cn1ccnc1N)C(C)(C)C', 'CC(CN(Cc1cnsc1)C(=O)Cc1nnc(N)[nH]1)Cn1ccnc1', 'CC(CN(Cc1nc(CO)cs1)C(=O)C1C=CCS1)c1ccccn1', 'CC(CN1CCCCCC1)NC(=O)N[C@@H](C)c1ccc2c(c1)OCO2', 'CC(CN1CCN(C)CC1)NC(=O)N(C)CCc1ccc(F)cc1F', 'CC(CN1CCOCC1)CN1C(=O)C(c2cccc(Cl)c2)N(C)C1=O', 'CC(CNC(=O)C(=O)NC1COc2ccccc21)Cc1ccccn1', 'CC(CNC(=O)C(C)(C)CN(C)C(=O)CC1CCCOC1)S(C)(=O)=O', 'CC(CNC(=O)C(C)c1cccs1)C(=O)NCC(O)CC1CCCC1', 'CC(CNC(=O)C(CNC(=O)CC1CC2(CC2)C1)C(C)(C)C)C1CC1', 'CC(CNC(=O)C(Cc1cn[nH]c1)NC(=O)c1ccncc1)C(F)F', 'CC(CNC(=O)C(F)c1cccc(F)c1)CNC(=O)C1(C(N)=O)CC1', 'CC(CNC(=O)C(NC(=O)[C@H]1C[C@@H]1C(C)C)C1CCCC1)CC1CC1', 'CC(CNC(=O)C(O)C1CCCC1)CN(C)C(=O)c1ccccc1O', 'CC(CNC(=O)C1(C#N)CC=CC1)C(=O)NCC1Cc2nccn2C1', 'CC(CNC(=O)C1(C(C)C)COC1)C(=O)NC1CCc2ccccc21', 'CC(CNC(=O)C1(C(F)(F)F)CC1)NC(=O)C(C)OC1CCCCC1', 'CC(CNC(=O)C1(C)CCCN(C(=O)CC2=CCCC2)C1)OCCO', 'CC(CNC(=O)C12CC(CCO1)N(C(=O)C(N)=O)C2)c1ccccn1', 'CC(CNC(=O)C12CCC(CC1)CC2)C(F)C(=O)NC1(C(C)O)CC1', 'CC(CNC(=O)C1=CC2CCC(C1)C2)C(=O)NCCC(=O)NC(N)=O', 'CC(CNC(=O)C1CC2(CC(O)C2)C1)C(=O)N(C)C(CCO)C(F)F', 'CC(CNC(=O)C1CCC2(CCC2)O1)NC(=O)CC(C)(C)CN(C)C', 'CC(CNC(=O)C1CCC=CCC1)C(F)C(=O)N1CCC(CF)CC1', 'CC(CNC(=O)C1CCCC2(CC2)C1)NC(=O)c1n[nH]c2c1CCC2', 'CC(CNC(=O)C1CCN(C(=O)CCc2cnn(C)c2)CC1)C1CC1', 'CC(CNC(=O)C1CCN(C(=O)c2cocc2C(N)=O)C1)CN(C)C', 'CC(CNC(=O)CC(C)(C)CN(C)C)C(=O)N(C)Cc1ccccc1', 'CC(CNC(=O)CC(F)(F)C(F)F)CC(=O)NC(C)c1nccn1C', 'CC(CNC(=O)CCN(C(=O)c1ccsc1C#N)C1CC1)C1CCC1', 'CC(CNC(=O)CN1CCC(F)CC1)N(C)C(=O)C1=CC2C=CC1C2', 'CC(CNC(=O)CSc1nccn1C)N(C)C(=O)C1CCOC1(C)C', 'CC(CNC(=O)CSc1ncn[nH]1)C(F)C(=O)N1CC2C=CC1CC2', 'CC(CNC(=O)C[C@H]1C[C@H]1CNC(=O)C1CCCO1)CC1CCCC1', 'CC(CNC(=O)Cc1ccc(=O)[nH]c1)CC(=O)N1CCCC(F)(F)C1', 'CC(CNC(=O)N1CCC(Cc2nc(C(C)(C)C)cs2)CC1)C(F)F', 'CC(CNC(=O)N1CCC(Oc2ccc(Cl)cc2)C1)Cc1cccs1', 'CC(CNC(=O)N1CC[C@H](O)C[C@@H]1c1ccccc1)c1ccccn1', 'CC(CNC(=O)NCc1ccc(-c2cnco2)cc1)c1cnn(C)c1', 'CC(CNC(=O)Nc1ccc(-c2ccc[nH]2)cc1)Cc1ccccc1', 'CC(CNC(=O)Nc1cncc2ccccc12)Oc1cccc(F)c1', 'CC(CNC(=O)Nc1cnn(CC(=O)NCCO)c1)c1nncn1C', 'CC(CNC(=O)Nc1cnn(CCN=[N+]=[N-])c1)c1ccc(Cl)c(Cl)c1', 'CC(CNC(=O)[C@@H](C)N1CCCCC1)C(=O)NCc1ccnc(O)c1', 'CC(CNC(=O)[C@@H](NC(=O)COC1CCOCC1)C1CC1)S(C)(=O)=O', 'CC(CNC(=O)[C@@H]1CC[C@H](C)O1)CC(=O)N1CC[C@H]2CCNC(=O)[C@H]21', 'CC(CNC(=O)[C@@H]1C[C@H](C)CN(C(=O)[C@@H](C)N(C)C)C1)CC1CCC1', 'CC(CNC(=O)[C@@H]1C[C@H](O)CN1C(=O)C1CCC2(CC2)C1)S(N)(=O)=O', 'CC(CNC(=O)[C@@H]1[C@H](O)CCN1C(=O)C1=COCCC1)n1cccn1', 'CC(CNC(=O)[C@H](NC(=O)C1(C)CCCCC1)C(C)C)CC1CCC1', 'CC(CNC(=O)[C@H]1CN(C(=O)Cn2nccn2)C[C@@H]1C)CC(F)(F)F', 'CC(CNC(=O)[C@H]1[C@@H]2CN(C(=O)C#CC3CCOC3)C[C@@H]21)C1CCC1', 'CC(CNC(=O)c1c(CNC(=O)c2ccn(C)c2)cnn1C)C1CC1', 'CC(CNC(=O)c1cc(C2(C)CC2)on1)n1cc(COCCO)nn1', 'CC(CNC(=O)c1cc([N+](=O)[O-])c[nH]1)CNC(=O)C1(F)CC=CCC1', 'CC(CNC(=O)c1ccc(-c2ccccc2)cc1)Cc1ccccn1', 'CC(CNC(=O)c1ccc(Cl)cc1N)(NC(=O)c1cncs1)C1CC1', 'CC(CNC(=O)c1ccc(Cl)o1)CC(=O)N1CC(NC(=O)C2CC2)C1', 'CC(CNC(=O)c1ccc(F)cc1F)C(=O)N1C2CCC1(CO)CC2', 'CC(CNC(=O)c1ocnc1C(C)C)CC(=O)N(C)Cc1ccns1', 'CC(CNC(C)C1CN(C(=O)OC(C)(C)C)C1)c1cccc(Cl)c1F', 'CC(CNS(=O)(=O)C[C@@H]1CCC[C@H](C)O1)NC(=O)C(C#N)C(C)(C)C', 'CC(CNc1cc(N[C@H]2C[C@@H]2c2ccccc2F)ncn1)C1CCC1', 'CC(CO)(NC(=O)CCc1ccco1)C(=O)NCc1nc(C#N)cs1', 'CC(CO)(NC(=O)[C@@H]1CCC[C@H]1O)C(=O)Nc1ccn(CC2CC2)n1', 'CC(CO)(NC(=O)c1cccc2[nH]ccc12)C(=O)N1C[C@H]2CC[C@H]2C1', 'CC(CO)C(=O)NC1(CCC(=O)N2C3CCC2CN(C)C3)CCCC1', 'CC(CO)C(=O)N[C@@H]1CCC[C@H]1CC(=O)N[C@H]1C[C@H]2CC[C@@H](C1)[C@H]2O', 'CC(CO)CCCN(Cc1csc(C(F)F)c1)C(=O)C(=O)C(C)(C)C', 'CC(CO)CCNC(=O)C(NC(=O)[C@@H]1CCC[C@H]1O)c1cnn(C)c1', 'CC(CO)CNC(=O)c1cc(CNC(=O)C2CCCN(C)C2)nn1C', 'CC(CO)CNc1nc(NC(C)CC2CC2)nc2c1cnn2C(C)C', 'CC(CO)Nc1ccc(S(=O)(=O)N2CCC(c3ccnn3C)C2)cn1', 'CC(COC(F)(F)F)Nc1ccnc(N[C@@H](C)c2ccc(Cl)cc2)n1', 'CC(COCC(=O)OCC1(Cc2ccccc2)CC1)c1ccccc1', 'CC(CS(=O)(=O)NNC(=O)C1(c2ccccc2)CC1)c1ccccc1', 'CC(CS(C)(=O)=O)C(=O)N[C@@H]1CN(C(=O)C2(C3(C)CC3)CC2)C[C@@H]1C', 'CC(Cc1ccc(OC(F)(F)F)cc1)C(=O)NCCCCS(N)(=O)=O', 'CC(Cc1cccc(F)c1)C(=O)N[C@H]1CC[C@H](NS(=O)(=O)C2CC2)C1', 'CC(Cc1ccccn1)NC(=O)CN(C(=O)c1nc(=O)[nH][nH]1)C1CC1', 'CC(Cc1cccnc1)Nc1c(N[C@@H](C)c2csc(Br)c2)c(=O)c1=O', 'CC(Cc1ccco1)NC(=O)[C@@]1(NC(=O)C(C)n2ccnn2)C[C@H]1C', 'CC(Cc1ccncc1)C(=O)NC/C=C\\CNC(=O)C(F)C1CCC1', 'CC(Cc1ccncc1)C(=O)N[C@H](C)CN(C)C(=O)CCP(C)(C)=O', 'CC(Cc1ccncc1)NC(=O)C1=CCCN(C(=O)[C@H]2C[C@@H](O)C2)C1', 'CC(Cc1cnco1)C(=O)NCC[C@H](C)NC(=O)c1cnc(Cl)n1C', 'CC(Cc1cnn(C)c1)NC(=O)NCC(O)c1csc2ccccc12', 'CC(Cc1csc(-c2ncnn2C)n1)NC(=O)c1ccsc1C(F)F', 'CC(Cc1nncn1C)NC(=O)C(C)CN(C)C(=O)Cc1cnoc1', 'CC(Cc1nnn[nH]1)NC(=O)C(CC1CC1)NC(=O)CN(C)C1CC1', 'CC(Cn1cccn1)C(=O)N1C[C@H]2C[C@@H]1[C@H]2NC(=O)c1cccnc1', 'CC(Cn1cccn1)NCC(=O)NC(=O)Nc1ccc2c(c1)OCO2', 'CC(Cn1ccnc1)NC(=O)[C@@H]1C=C[C@H](NC(=O)[C@H](O)CC(N)=O)C1', 'CC(Cn1ccnc1)Nc1nc(N2CCC(F)(F)C2)nc2scnc12', 'CC(F)(F)C(C)(C)C(=O)N1CCC(NC(=O)C=CC(=O)NC2CC2)C1', 'CC(F)(F)C(F)C(=O)N[C@H]1C[C@H]1CNC(=O)c1cc2ccccn2c1', 'CC(F)(F)C1CCCN(C(=O)Nc2cc(-c3ccccc3Cl)on2)C1', 'CC(F)(F)CC(=O)N1CCC(C(=O)NCCSC(C)(C)C)C(C)(C)C1', 'CC(F)(F)CNC(=O)CC1CCN(C(=O)c2ccncc2O)C1(C)C', 'CC(F)(F)[C@@H]1C[C@H]1C(=O)N1CC[C@@H]1C(=O)Nc1ccc2c[nH]nc2c1', 'CC(F)(F)c1ccc(C(=O)N2CCCC2(C)Cc2ccccc2)cn1', 'CC(F)(F)c1ncc(S(=O)(=O)N2CCN(CCc3cccs3)CC2)s1', 'CC(F)C(C)NC(=O)C1CC12CC(NC(=O)c1ccoc1C1CC1)C2', 'CC(F)CC(=O)NC1C=CCN(C(=O)Cn2cnc3ccccc32)C1', 'CC(F)CCC(=O)N(CC1CCN(C)CC1)CC1CC(=C2CCC2)C1', 'CC(F)CCCC(=O)NC1(c2csc(Nc3ccccc3F)n2)CC1', 'CC(N(C)C(=O)C1(NC(=O)c2cn(C3CC3)cn2)CCC1)C(C)(C)C', 'CC(N(C)C(=O)C1COCCN1C(=O)CCCC(C)(C)C)C(C)(C)C', 'CC(N(C)C(=O)c1cn(CCCN)nn1)C12CC3CC(CC(C3)C1)C2', 'CC(N)Cn1cc(C(=O)NCC(O)CS(=O)(=O)c2ccccc2)cn1', 'CC(NC(=O)/C=C/c1ccccc1)[C@@H]1C[C@H]1C(=O)NCC1(Cl)CCC1', 'CC(NC(=O)C(=O)C1CCCCC1)C(=O)Nc1ccc(CCO)cc1', 'CC(NC(=O)C(=O)N1CCCCC1c1cccs1)c1ccc(Br)cc1', 'CC(NC(=O)C(=O)N[C@H]1C[C@H]2CCCCC[C@H]21)c1ccc(F)c(F)c1', 'CC(NC(=O)C(C(C)C)N(C)C)c1nocc1C(=O)NOCCCO', 'CC(NC(=O)C(C)(C)C1CCC1)C1CCN(C(=O)C#CC(C)(C)C)C1', 'CC(NC(=O)C(C)S(N)(=O)=O)C(C)(C)C(=O)NC(CC1CC1)C1CC1', 'CC(NC(=O)C(CC(F)F)NC(=O)c1nocc1Cl)c1cn(C)cn1', 'CC(NC(=O)C(F)(F)F)(C(=O)Nc1ncc(C2CCC2)s1)C(F)(F)F', 'CC(NC(=O)C(F)(F)F)C(=O)NCCCOc1ccc(C(=O)O)cc1', 'CC(NC(=O)C(F)=Cc1cnc[nH]1)C1CN(C(=O)CNC=O)CCO1', 'CC(NC(=O)C/C=C/c1ccccc1)C(=O)NCC1(C)CCN(C)C1', 'CC(NC(=O)C1(C(C)NC(=O)CCC(CF)CF)CC1)C1CCCC1', 'CC(NC(=O)C1(C2CCCCC2)CC1)c1cccc(-n2ccnc2)c1', 'CC(NC(=O)C1(O)CC2(CCNCC2)C1)c1cccc(S(N)(=O)=O)c1', 'CC(NC(=O)C1=CCN(C(=O)C(C)(C)C2CC2)C1)c1ccc(F)cc1', 'CC(NC(=O)C1CCC(=O)N(C)C1)C(=O)NCC1(C)CCCC(=O)N1', 'CC(NC(=O)C1CCC2(CC2)N1C(=O)Cc1cccnc1)C1CSC1', 'CC(NC(=O)C1CCN1C(=O)c1ccc(CO)cc1)C1CC(F)(F)C1', 'CC(NC(=O)C1CN(C(=O)c2ncn(C)n2)C(C)(C)C1)c1cn[nH]c1', 'CC(NC(=O)C=Cc1ccn(C)c1)C(C)C(=O)N1CC2C(C1)C2(C)C', 'CC(NC(=O)C=Cc1nccs1)C(C)C(=O)NC1C(O)[C@H]2CCO[C@@H]12', 'CC(NC(=O)CC1(C)CCOC1)C(C)(C)C(=O)N(C)C1(CCO)CC1', 'CC(NC(=O)CC1(N(C)C(=O)c2[nH]ncc2Cl)CC1)c1ncccn1', 'CC(NC(=O)CC1CCCN1C(=O)C1CCN(C)C1)c1nncn1C', 'CC(NC(=O)CCCC1CC1)c1cn(CCCN2CCSCC2)nn1', 'CC(NC(=O)CCCF)(C(=O)NC1CC(C)(C)C12CCC2)C1CCC1', 'CC(NC(=O)CCCN(C)C(C)C)C(=O)NCc1ccccc1C#N', 'CC(NC(=O)CCOC1CCC1)C1CCN(C(=O)CC2CC=CC2)C1', 'CC(NC(=O)CN(C)C1CC1)[C@@H]1C[C@H]1C(=O)N1[C@@H]2CC[C@H]1C[C@H](F)C2', 'CC(NC(=O)COC1CCCC1)C1CC(NC(=O)/C=C/C(C)(C)C)C1', 'CC(NC(=O)CO[C@H]1C[C@H](NC(=O)c2ccncc2)C1)c1nncs1', 'CC(NC(=O)CSC(F)F)C1CCCN(C(=O)C=Cc2cscn2)C1', 'CC(NC(=O)CSCCC#N)(C(=O)N[C@H]1CCC(=O)NC1)C1CCC1', 'CC(NC(=O)C[C@@H](C)NC(=O)C1CC2(C1)CC21CC1)c1ncnn1C', 'CC(NC(=O)C[C@H]1C[C@@H](NC(=O)C2(O)CCOCC2)C1)c1csnn1', 'CC(NC(=O)Cc1cc(=O)[nH][nH]c1=O)c1nc(-c2ccccc2)cs1', 'CC(NC(=O)Cc1ccc(N2CCOCC2)cc1)C12CCC(CC1)C2', 'CC(NC(=O)Cc1cccc(O)c1F)c1nnnn1-c1ccccc1', 'CC(NC(=O)Cn1cccn1)C1CC(NC(=O)C2(O)CC(CF)C2)C1', 'CC(NC(=O)Cn1cn[nH]c1=O)C1CCN(C(=O)C2SCCS2)CC1', 'CC(NC(=O)Cn1nc2n(c1=O)CCOC2)c1ccc2c(c1)CCC2', 'CC(NC(=O)Cn1ncc2cc(Cl)ccc21)c1cccc2c1OCO2', 'CC(NC(=O)Cn1ncnc1N)C(C)C(=O)N1C[C@H]2COC[C@@]2(C)C1', 'CC(NC(=O)N1CCC(O)(C(F)(F)C(N)=O)C1)c1cnn(C(C)C)c1', 'CC(NC(=O)N1CCC2(CC1)CC2(F)F)c1cc2cc(Cl)ccc2o1', 'CC(NC(=O)N1CCCN(C(C)(C)C)CC1)c1csc2ccccc12', 'CC(NC(=O)N1CC[C@H]2[C@@H]1CCCN2CCO)c1cnc(Cl)c(Cl)c1', 'CC(NC(=O)NC(C)c1nc2c(o1)CCSC2)c1cccc(C#N)c1', 'CC(NC(=O)NC(C)c1noc(C(C)(C)C)n1)c1cnc(Cl)c(Cl)c1', 'CC(NC(=O)NC1(CCN(C)C)CCCCC1)c1nc(C2CC2)no1', 'CC(NC(=O)NC1CC(n2ccnc2)C1)C(O)c1c(F)cccc1Cl', 'CC(NC(=O)NCC(O)COc1ccccc1Br)c1ccncc1F', 'CC(NC(=O)NCC1CCCC1(C)C)c1ccccc1NS(C)(=O)=O', 'CC(NC(=O)NCCC(C)(C)C#N)c1ccc(-c2ccncc2)cc1', 'CC(NC(=O)NCCSCc1ccc(Cl)cc1)c1cnn(C(C)C)c1', 'CC(NC(=O)NCc1cc(F)ccc1O)c1nc2cc(Cl)ccc2[nH]1', 'CC(NC(=O)NNc1cnc(C(=O)OC(C)(C)C)cn1)C1CCOC1', 'CC(NC(=O)Nc1ccnc(C(F)(F)F)c1)c1ccc(C#N)cc1F', 'CC(NC(=O)Nc1cnn(C2CCCC2)c1)c1cc2ccccc2o1', 'CC(NC(=O)OC(C)(C)C)C(C)(C)CNC(=O)C[C@H]1C[C@H]2CC[C@@H]1O2', 'CC(NC(=O)OC(C)(C)C)c1noc(-c2cccc(C(F)(F)F)c2)n1', 'CC(NC(=O)[C@@H]1CCCN1NC(=O)C1C2CC(=O)CC21)c1c[nH]cn1', 'CC(NC(=O)[C@@H]1C[C@H](NC(=O)C2=CCCCCC2)[C@@H](O)C1)C1CCC1', 'CC(NC(=O)[C@H](C)N(C)C(=O)c1ncncc1Cl)c1ccnc(F)c1', 'CC(NC(=O)[C@H](O)C(F)(F)F)C1CCN(c2cc(=O)n(C)c(=O)[nH]2)C1', 'CC(NC(=O)[C@H]1C2CC3C(C2F)[C@@H]31)c1ccc(S(=O)(=O)N(C)C)cc1', 'CC(NC(=O)[C@H]1CCCC[C@H]1NC(=O)C(C)(C)O)c1ccncc1F', 'CC(NC(=O)[C@H]1C[C@@H](NC(=O)C2CCC(=O)NC2)C1)c1nncn1C', 'CC(NC(=O)[C@H]1C[C@H]1CNC(=O)c1ccc(F)c(F)c1)c1cn[nH]c1', 'CC(NC(=O)[C@H]1[C@H]2CC[C@H](C2)N1C(=O)CCNC(=O)CO)C1CSC1', 'CC(NC(=O)[C@]1(NC(=O)C2CC3(CCC3)CO2)C[C@@H](O)C1)C1CCC1', 'CC(NC(=O)c1c(C#N)cnn1C)[C@@H]1C[C@H]1C(=O)NCc1ccco1', 'CC(NC(=O)c1c(I)cnn1C(C)(C)C)C12CC3CC(CC(C3)C1)C2', 'CC(NC(=O)c1c[nH]c(=O)cn1)C(C)C(=O)NCC1CN(C(C)C)C1', 'CC(NC(=O)c1cc(C(F)(F)F)nn1C1CC1)c1c(F)cccc1Cl', 'CC(NC(=O)c1cc(O)ncn1)C1CCCN(C(=O)C2CC=CC2)C1', 'CC(NC(=O)c1ccc(-c2ccsc2)nn1)(C(=O)O)C1CCOCC1', 'CC(NC(=O)c1ccc(CC2CCNCC2)cc1)C(C)n1cccn1', 'CC(NC(=O)c1cccc(F)c1O)c1nc(-c2ccc(Br)cc2)cs1', 'CC(NC(=O)c1cccc2c1CNC(=O)N2)c1cc2ccccc2o1', 'CC(NC(=O)c1ccn[nH]c1=O)[C@@H]1C[C@H]1C(=O)N1CCCOCC1C', 'CC(NC(=O)c1ccnc2ccc(F)cc12)c1nc(C2CCC2)cs1', 'CC(NC(=O)c1ccoc1Cl)[C@@H]1CCCN1C(=O)CC1=CCOCC1', 'CC(NC(=O)c1cnc(N)nc1)C1(C(=O)N(C)C2C3CCCC32)CC1', 'CC(NC(=O)c1cnc2[nH]c(=O)[nH]c2c1)c1cccc(OC(F)F)c1', 'CC(NC(=O)c1cnn(CCNC(=O)[C@H]2C[C@@H](O)C2)c1)c1c[nH]nn1', 'CC(NC(C(=O)O)C1CCC(F)(F)CC1)C1COc2ccccc2C1', 'CC(NC(CC(C)(C)C#N)c1nnnn1CCCF)c1ccccc1', 'CC(NC(N)=O)C(=O)N1CC(C)(C)CC1C(=O)N1CCS(=O)C(C)C1', 'CC(NC(N)=O)C(=O)N[C@H]1C[C@@](C)(C(=O)NC2(CC3CCC3)CC2)C1', 'CC(NC=O)C(=O)N(CC1CCC2(CC2)C1)CC1CCCCC1(F)F', 'CC(NC=O)C(=O)N1CCC=C(C(=O)NCC23CCCC2CCC3)C1', 'CC(NC=O)C(=O)NC1CC(C(=O)N2CCCc3ccnn32)C1(C)C', 'CC(NC=O)C(=O)NCC(C)(O)CNC(=O)C1(C2CCCCO2)CC1', 'CC(NC=O)C(=O)N[C@@H](CN(C)C)C(=O)N1C[C@@H](O)C[C@@H]1CN(C)C', 'CC(NCC(=O)Nc1nc2c(F)c(F)c(F)cc2s1)C(=O)NC1CC1', 'CC(NNC(=O)c1ccc(-n2cnnn2)cc1)C(=O)NCC(F)(F)F', 'CC(NS(=O)(=O)c1ccc2c(c1)CCO2)C(=O)c1ccc(F)cc1F', 'CC(NS(=O)(=O)c1cccc(NCC2(C)CCC2)n1)c1cn(C)nn1', 'CC(NS(C)(=O)=O)C(=O)NC1CCC(CNC(=O)CSC2CC2)CC1', 'CC(Nc1cc(NCC2CC3(C2)CC3(F)F)ncn1)c1ccncc1', 'CC(Nc1cccc(C(=O)NCCC(N)=O)c1)C1CC2CCC1CC2', 'CC(Nc1cccc(S(=O)(=O)N2Cc3ncsc3C2)n1)c1ccoc1', 'CC(Nc1ccn(CCN2CCNC2=O)n1)C(=O)N(C(C)C)C(C)C', 'CC(Nc1nc(N2CCC(F)CC2)c2[nH]ccc2n1)c1ccccn1', 'CC(Nc1nc(NC2CCSC2)nc2c1COC2)c1ccccc1Cl', 'CC(Nc1nc(NCC2(C)CCCO2)nc2c1COC2)c1nc[nH]n1', 'CC(Nc1nc2ccccc2s1)C(=O)NNC(=O)CCc1nccs1', 'CC(O)(C(=O)N[C@H]1C[C@@H](CC(=O)N2CC3(CCC3O)C2)C1)C(F)(F)F', 'CC(O)(CNC(=O)C1=CC2(CCN(C(=O)c3cccs3)C2)C1)C(F)F', 'CC(O)(CNC(=O)[C@H]1CCN(C(=O)[C@@H]2CCOC2)C[C@H]1O)C(F)(F)F', 'CC(O)(CNC(=O)c1ccc2c(=O)[nH]cnc2c1)c1cccc(Cl)c1', 'CC(O)C(=O)N1CC(NC(=O)C(O)Cc2ccccn2)C2CCCC21', 'CC(O)C(=O)NC(CC1CCOCC1)C(=O)N1CCC(=O)N(C)CC1', 'CC(O)C(C)(C)CN(Cc1ccnn1CCF)C(=O)CC1C=CCC1', 'CC(O)C(C)(C)NC(=O)c1ccc(CNC(=O)CN(C)C2CC2)cn1', 'CC(O)C1(NC(=O)[C@@H]2C[C@@H](C)CN2C(=O)CCc2cn(C)nn2)CC1', 'CC(O)C1CCN(C(=O)C2CCN(C(=O)CCc3cncs3)C2)CC1', 'CC(O)C1CCN(S(=O)(=O)c2ccc(NCCSC(C)(C)C)nc2)C1', 'CC(O)C1COCCN1C(=O)Nc1cccc(OCC(=O)N(C)C)c1', 'CC(O)CC(C)(C)CN(CC1=CCCOC1)C(=O)C(C)CC(F)(F)F', 'CC(O)CC1CCN(C(=O)Nc2ccc(SC(F)(F)F)cc2Cl)CC1', 'CC(O)CC1CCN(C(=O)[C@@H]2CC[C@H](NC(=O)C3(F)CCC3)C2)CC1', 'CC(O)CCCNS(=O)(=O)c1cccc(NC2CC(C3CCC3)C2)n1', 'CC(O)CCCNc1nccc(NCCc2c[nH]c3ccccc23)n1', 'CC(O)CCONC(=O)C[C@@H]1CCCN1C(=O)CC1CC(=O)NC1=O', 'CC(O)CCONC(=O)[C@@H]1C2C3C[C@H]1C(NC(=O)[C@H]1CCC[C@H]1F)C32', 'CC(O)CCONC(=O)c1ncoc1CNC(=O)C1(C)CC(C#N)C1', 'CC(O)CN(C(=O)c1[nH]ccc1CNC(=O)Cc1cn[nH]c1)C(C)C', 'CC(O)CN(C(=O)c1[nH]ncc1CNC(=O)C1CCS1(=O)=O)C1CC1', 'CC(O)CN(C)C(=O)C[C@@H]1[C@H]2CC[C@H](C2)N1C(=O)C=Cc1cocn1', 'CC(O)CN(C)C1CCN(C(=O)C2OCCc3c(Br)cccc32)CC1', 'CC(O)CN(CC(C)(C)C)C(=O)c1ccc(CN2CCOCC2)cc1', 'CC(O)CN(CC(F)F)C(c1nnnn1C(C)C)C1CCC2(CC2)C1', 'CC(O)CN1CCN(C(=O)NCCc2ccc(C(C)(C)C)cc2)CC1', 'CC(O)COCc1cn(CC(=O)NCc2ccc3c(c2)CCO3)nn1', 'CC(O)CONC(=O)/C=C/C1CCN(C(=O)CN2CCCC2C)CC1', 'CC(O)CONC(=O)C1(NC(=O)CC(C)(C)CN(C)C)CCCC1C', 'CC(O)c1cn([C@@H]2CN(C(=O)c3ccn(C(C)(C)C)c3)C[C@H]2O)nn1', 'CC(O)c1cnc(CN(CC2CC2Cl)C(=O)c2ccnn2C(F)F)s1', 'CC(OC(=O)C(C)(C)c1cc(Cl)ccc1F)c1nnc(C(F)(F)F)o1', 'CC(OC(=O)Nc1ccccc1)C(=O)N1CCCc2ccc(Cl)nc21', 'CC(OC(=O)c1ccc(C(F)(F)F)cc1C(F)F)C(=O)c1ccco1', 'CC(OC(=O)c1ccc2ccn(C)c2c1)C(=O)Nc1sccc1C#N', 'CC(OC(=O)c1nccc(Cl)c1O)c1nc(-c2ccc(Cl)cc2)no1', 'CC(OC(C)(C)C)C(=O)N[C@H]1C[C@@H](CC(=O)N2CCCNC(=O)C2)C1', 'CC(OC1CCCC1)C(=O)N(C)C1CCCN(C(=O)C2=CCCC2)C1', 'CC(OC1CCCC1)C(=O)N1C[C@H](C)[C@@](C)(C(=O)NOC/C=C/Cl)C1', 'CC(OC1CCCC1)C(=O)NC[C@H](NC(=O)OC(C)(C)C)C(C)(C)C', 'CC(OC1CCCCC1)C(=O)NCCN(C(=O)C1SCCS1)C(C)C', 'CC(OC1CCNCC1)C(=O)Nc1ccccc1OC1CCOCC1', 'CC(OCC1CC1)C(=O)N1CCN(C(=O)[C@@H]2C[C@@H]3C[C@@H]3C2)C[C@@H]1CO', 'CC(OCC1CC1)C(=O)NCc1cc(C(=O)N2CC([N+](=O)[O-])C2)cs1', 'CC(OCCN(C)C)C(=O)NC1(CNC(=O)[C@@H]2CCC[C@H]2O)CCC1', 'CC(Oc1ccccc1C#N)C(=O)OC1CCc2c(F)ccc(F)c21', 'CC(Oc1cccnc1)c1nc(-c2cccc(-n3cccn3)n2)no1', 'CC(Oc1ccncc1)C(=O)N(C)Cc1ccc(C(F)(F)F)cc1Cl', 'CC(Sc1ccccc1Cl)C(=O)N1CCC[C@@H]1CC(=O)OC(C)(C)C', 'CC(Sc1nnc(-c2ccccc2Cl)n1N)c1ncc(C(C)(C)C)o1', 'CC(c1c(F)cccc1F)N(C)CC(O)COc1cc(F)cc(Br)c1', 'CC(c1ccc(Br)cc1)N1CCN(c2ncnn3ccc(Br)c23)CC1', 'CC(c1cccc(Cl)c1)N(C)C(=O)C(=O)NCc1cccc(F)c1Cl', 'CC(c1ccccc1)C1NC(=O)N(Cc2ccc3nsnc3c2)C1=O', 'CC(c1ccccn1)N(C(=O)C(=O)N1CCC(CCCO)C1)C1CC1', 'CC(c1ccco1)N(C)C(=O)C(CC1COC1)NC(=O)OC(C)(C)C', 'CC(c1ccco1)N(C)C(CCC1(C)CC1)C(=O)NC1CCOCC1', 'CC(c1cn(C2CCCN(C(=O)c3cn[nH]c3)C2)nn1)C1CCCC1', 'CC(c1cn(CC2CCN2C(=O)C2(C)COC2)nn1)C1CCOCC1', 'CC(c1cn(CC2CN(C(=O)c3nc(=O)[nH][nH]3)CCO2)nn1)N(C)C', 'CC(c1cn(C[C@@H](C)NC(=O)c2ccc3[nH]nnc3c2)nn1)N(C)C', 'CC/C=C(\\C)C(=O)N(C)CCCCN(C)C(=O)C1(N(C)C)CCCC1', 'CC/C=C(\\C)C(=O)N1CC(CNC(=O)CCn2cccn2)CCC1C', 'CC/C=C(\\C)C(=O)NCCOCCNC(=O)c1cccn2cnnc12', 'CC/C=C(\\C)C(=O)N[C@H]1CCN(C(=O)CC2(n3ccnc3)CC2)[C@@H]1C', 'CC/C=C(\\C)CNC(=O)[C@@H]1CN(C(=O)[C@H]2C[C@H]3O[C@@H]2[C@@H]2C[C@@H]23)C[C@H]1C', 'CC/C=C(\\C)CNC(=O)c1cc(CNC(=O)C(C)n2cccc2)cs1', 'CC/C=C(\\C)CNC(c1ccc(CC)cc1)c1nnnn1CCCC', 'CC/C=C/CC(=O)N(C)CCCN(C)C(=O)C1CC2CCCCN2C1', 'CC/C=C/CC(=O)N1CCC(C(=O)N(C)CCn2ccnc2C)CC1', 'CC/C=C/CC(=O)N1CCN(C(=O)C[C@H]2[C@H](CC)C2(F)F)C(CC)C1', 'CC/C=C/CC(=O)NC1C2CC3C(C2)C31C(=O)NCCC1CCOC1', 'CC/C=C/CC(=O)NCCC1(C(=O)N2CC(c3ccncn3)C2)CC1', 'CC/C=C/CC(=O)NCCc1ocnc1CNC(=O)C=CC1CCC1', 'CC/C=C/CC(=O)N[C@H](C)Cn1cc(-c2ccc(C#N)c(N)c2)nn1', 'CC/C=C/CC(=O)N[C@H](CCSC)C(=O)Nc1cc(C)cc(C)c1O', 'CC/C=C/CC(C)C(=O)N1CC2CC1(C(=O)NCCn1ccnc1)C2', 'CC/C=C/CC(C)C(=O)N1CCC1CC(=O)NC[C@@H]1C[C@H]2CC[C@@H]1O2', 'CC/C=C/CC(C)C(=O)N1CCC[C@@H](NC(=O)[C@H](CCO)N(C)C)C1', 'CC/C=C/CC(C)C(=O)N1CCN(C)C(C(=O)N2CC(C)C2(C)C)C1', 'CC/C=C/CCC(=O)NC(CCNc1ncc(C#N)cc1C)C(F)F', 'CC/C=C/CCC(C)(N[C@H]1CCCC[C@H]1F)c1nnnn1CC(C)C', 'CC/C=C\\CN(Cc1csc(C2CC2)n1)Cc1cnn2ccccc12', 'CC/C=C\\CNC(=O)C(C)C1CCN(C(=O)C2(n3cccc3)CC2)C1', 'CC/C=C\\CNC(=O)C(NC(=O)c1cc(C)n(C)c1)c1cn(C)nn1', 'CC/C=C\\CNC(=O)C1(C2CC2)CN(C(=O)c2cn(C3CC3)nn2)C1', 'CC/C=C\\CNC(=O)C1CN(C(=O)c2cc(C)c(F)cn2)CC1(C)C', 'CC/C=C\\CNC(=O)[C@@H]1C[C@@H](OC)CN1C(=O)c1cc(CCO)on1', 'CC1(Br)CC1CN(CC1CCCCC1O)C(=O)C(C)(C)n1cccn1', 'CC1(C#CC(=O)N2CC(OCC(=O)NCC3(O)CCOC3)C2)COC1', 'CC1(C#CC(=O)N2CCC2CC(=O)NCCC(C)(C)C2CC2)COC1', 'CC1(C#CC(=O)N2[C@H](C(=O)NC3(C)CC4(CC4)C3)C[C@@H]3C[C@@H]32)COC1', 'CC1(C#CC(=O)NC2(C(=O)NC3CC34CCOCC4)CSC2)COC1', 'CC1(C#CC(=O)NC2CCCc3cc(OC(F)F)ccc32)CC(=O)C1', 'CC1(C#CC(=O)NCC(=O)NCC(=O)NC2(CCO)CCC2)COC1', 'CC1(C#CC(=O)NCCSCC(=O)N2CCC(C(N)=O)C2)CCCO1', 'CC1(C#CC(=O)N[C@H]2CC[C@@H](NC(=O)c3cc(Cl)no3)CC2)COC1', 'CC1(C#N)CC(NCCOC2CC2)(c2nnnn2CC2CCCO2)C1', 'CC1(C#N)CN(C(=O)c2ccc(Oc3ccc(F)cc3)cc2)CCO1', 'CC1(C(=O)COC(=O)c2c(C(F)F)nc3n2CCCC3)CC2(CC2)C1', 'CC1(C(=O)N(CCCCF)Cc2cnn(C3CCC3)c2)CCCOC1', 'CC1(C(=O)N2C(C(=O)NCCOC3CCOC3)CCC23CC3)CCC1', 'CC1(C(=O)N2C3CCC2CC(C(=O)NCCN=[N+]=[N-])C3)CCSCC1', 'CC1(C(=O)N2CC(Nc3ccnc(CO)n3)C(C3CC3)C2)CC1(F)F', 'CC1(C(=O)N2CC3CCC(C2)C3NC(=O)CC2=CCCC2)CC=CC1', 'CC1(C(=O)N2CC=CC(NC(=O)c3nn[nH]c3C3CC3)C2)CCCS1', 'CC1(C(=O)N2CCC(C(=O)NCCN=S(C)(C)=O)CC2)CCCCO1', 'CC1(C(=O)N2CCC(CC(N)=O)C2)CC(NC(=O)[C@@H]2CCC[C@H]2O)C1', 'CC1(C(=O)N2CCC(n3nccc3[N+](=O)[O-])CC2)CCC2(CC2)CC1', 'CC1(C(=O)N2CCC23CN(C(=O)Cc2ccsn2)C3)CC2C=CC1C2', 'CC1(C(=O)N2CCCC(CCNC(=O)c3coc(Cl)n3)C2)CC=CC1', 'CC1(C(=O)N2CCOC3(CN(C(=O)C4CC=CC4)C3)C2)COC(=O)N1', 'CC1(C(=O)N2CC[C@H](C(=O)NCC3=NOC4CCCC34)C2)CCCS1', 'CC1(C(=O)N2C[C@@H]3C[C@]3(C(=O)NCC(C)(C)C3CC3)C2)SCCCS1', 'CC1(C(=O)NC(CO)C2CCN(C(=O)c3csc(F)c3)CC2)CSC1', 'CC1(C(=O)NC2CC(O)(CNC(=O)c3ccccn3)C2)CCOCC1', 'CC1(C(=O)NC2CCN(c3nnn[nH]3)CC2)CCC(C(F)(F)F)CC1', 'CC1(C(=O)NCC(CNC(=O)C(F)C(F)(F)F)S(C)(=O)=O)CC=CC1', 'CC1(C(=O)NCC(O)CCNC(=O)CCC(F)(F)F)CC2C=CC1C2', 'CC1(C(=O)NCC2(O)CN(C(=O)CCCS(C)(=O)=O)C2)C=CCCC1', 'CC1(C(=O)NCC2C3COCC23)CC(NC(=O)CCn2cccn2)C1', 'CC1(C(=O)NCCC2CCCN(C(=O)C3C=CCC3)CC2)CC=CC1', 'CC1(C(=O)NCCCOCCO)CCN(C(=O)c2ccc(O)cn2)C1', 'CC1(C(=O)NCCNC(=O)Cc2c[nH]c3cccnc23)CCCCC1', 'CC1(C(=O)NCCNC(=O)Cc2cccc(F)c2)CC(C2CC2)=NO1', 'CC1(C(=O)NCCn2cc(CN3CCOCC3=O)nn2)CCNC1=O', 'CC1(C(=O)NC[C@H]2CCO[C@H]2C(=O)N2OC3CCC2CC3)CC=CC1', 'CC1(C(=O)NC[C@H]2CC[C@@H](C(=O)N3C4CCCC3CC4)C2)CC(F)C1', 'CC1(C(=O)NCc2ccc(C(=O)NCC3(CF)CC3)nc2)CC=CC1', 'CC1(C(=O)NCc2nn[nH]c2C2CC2)C=CCN1C(=O)c1cnco1', 'CC1(C(=O)N[C@@H]2CCN(C(=O)c3ccc(CF)cc3)C2)CCNC1=O', 'CC1(C(=O)N[C@H](CNC(=O)C2CCCOC2)C(C)(C)C)CCSCC1', 'CC1(C(=O)N[C@H]2CCC[C@H](NC(=O)C3CCCCS3)C2)CCCOC1', 'CC1(C(=O)N[C@H]2CC[C@@H](C(=O)NC3CCCC34CC4)C2)CCCOC1', 'CC1(C(=O)Nc2nccc3ccc(Cl)cc23)COc2ccccc2O1', 'CC1(C(C)(C)NC(=O)c2cccc(OCc3ccc(F)cc3)c2)CC1', 'CC1(C(F)(F)F)CN(C(=O)[C@@H]2[C@H](O)CCN2C(=O)CCCC2CC2)C1', 'CC1(C(N)=O)CC(NC(=O)C2(C)CCN(C(=O)c3csc(Cl)n3)C2)C1', 'CC1(C(N)=O)CCN(C(=O)CCN(CCO)C(=O)C2C=CCCC2)C1', 'CC1(C(N[C@@H]2CC[C@H](O)C2)c2nnnn2CC2CCOCC2)CSC1', 'CC1(C)C(C(=O)N2CCC(OCC(=O)NCC3(O)CSC3)C2)C1(F)F', 'CC1(C)C(C(=O)N2CCC=C(C(=O)NC3CC4CCC3C4)C2)C1(C)C', 'CC1(C)C(C(O)CNC(=O)c2ccc(SC(F)(F)F)c(Cl)c2)C1(C)C', 'CC1(C)C(C)(C)C1(C)CN(Cc1cscn1)C(=O)c1cncc(O)c1', 'CC1(C)C(CC(=O)N2CC(N3CC(O)C3)C2)CCN1C(=O)[C@@H]1C[C@H]1F', 'CC1(C)C(CC(=O)N2CC=CCC2C(=O)NOC2CCOC2)C1(C)C', 'CC1(C)C(CC(=O)NC2CC3CCC2CN3C(=O)[C@@H]2C[C@@H]2F)C1(C)C', 'CC1(C)C(CNC(=O)Cn2ncnn2)CC1NC(=O)CC1=CCCC1', 'CC1(C)C2CCC1(C(=O)N1CCC(O)(C3(C(=O)O)CC3)CC1)C(N)C2', 'CC1(C)C=C(C(=O)NC2C[C@H](NC(=O)CNC(=O)C3CC3)[C@@H](O)C2)C1', 'CC1(C)C=C(C(=O)NC[C@H]2CC[C@H]2NC(=O)C2CC3(CCC3=O)C2)C1', 'CC1(C)C=CS(=O)(=O)N1CC(=O)N1CCC(C(=O)O)c2ccccc21', 'CC1(C)C=CS(=O)(=O)N1CC(=O)N1CCCC(Oc2ccccc2)C1', 'CC1(C)CC(=O)c2cc(C(=O)N[C@H]3C[C@H]4COC[C@@H](C3)N4)ccc2O1', 'CC1(C)CC(C(=O)N2CCCC[C@H]2CO)CN1C(=O)c1nc(Cl)cs1', 'CC1(C)CC(C(=O)NCc2cc(C(=O)NCC3CC(CF)C3)co2)C1', 'CC1(C)CC(C(=O)N[C@H](CNC(=O)COCP(C)(C)=O)C(C)(C)C)C1', 'CC1(C)CC(C(O)CN(Cc2cncs2)C(=O)C2(C)CCC(=O)C2)C1', 'CC1(C)CC(C(O)CNC(=O)C(C)(C)NC(=O)c2cc[nH]c(=O)c2)C1', 'CC1(C)CC(C)(C(=O)N[C@H]2C[C@H]3C[C@H](NC(=O)CCC(N)=O)C[C@H]32)C1', 'CC1(C)CC(C)(NC(=O)C23CC(NC(=O)c4ccon4)(C2)C3)C(=O)O1', 'CC1(C)CC(CC(=O)N2CCCOCC2)N(C(=O)c2cc(F)c[nH]2)C1', 'CC1(C)CC(CC(=O)NOCC2CC2)CN1C(=O)CCn1cccn1', 'CC1(C)CC(CCNC(=O)NCCC2CC3(COC3)C2)CC(C)(C)C1', 'CC1(C)CC(CCNc2nc(NCC3CC3)nc3cc[nH]c23)C(=O)N1', 'CC1(C)CC(CN(CC2(CF)CCC2)C(=O)C(F)C(C)(F)F)CCO1', 'CC1(C)CC(CNC(=O)CC(NC(=O)[C@H]2CCC(=O)O2)C(C)(C)C)C1', 'CC1(C)CC(CNC(=O)c2ccc(O)cn2)(C(=O)NCC(F)(F)F)C1', 'CC1(C)CC(CO)(C(=O)N2CC[C@@H](CC(=O)NCC3CC34CC4)C2)C1', 'CC1(C)CC(CO)CN(C(=O)NCc2nncn2-c2ccccc2)C1', 'CC1(C)CC(CO)CN(C(=O)[C@@H]2CN(C(=O)[C@H]3CC3(C)C)CCO2)C1', 'CC1(C)CC(CO)CN1C(=O)CCCCNC(=O)Cn1cnc(N)n1', 'CC1(C)CC(CO)CN1C(=O)C[C@H]1C[C@H]1CNC(=O)CC1OCCO1', 'CC1(C)CC(CS(=O)(=O)N2CCC(NC(=O)CC3=NNC(=O)C3)C2)C1', 'CC1(C)CC(CS(=O)(=O)NC2CC2CNC(=O)C23CC(C)(CO2)C3)C1', 'CC1(C)CC(Cn2cc(CN3CCOC(C)(CO)C3)nn2)OC(=O)N1', 'CC1(C)CC(NC(=O)CC2C=CCCC2)CCN(C(=O)CNC=O)C1', 'CC1(C)CC(NC(=O)c2ccc(CO)o2)CN1C(=O)c1c[nH]c(=O)o1', 'CC1(C)CC(NC(=O)c2n[nH]cc2I)CCN(C(=O)OC(C)(C)C)C1', 'CC1(C)CC(S(=O)(=O)CCNC(=O)N2CCC(CN=[N+]=[N-])CC2)=NO1', 'CC1(C)CC(S(C)(=O)=O)CN1C(=O)NCc1ccn(C2CCCC2)n1', 'CC1(C)CC1(C)C(=O)N1CC2CN(C(=O)C(O)C(F)(F)F)CC(C1)O2', 'CC1(C)CC1(Cl)S(=O)(=O)N1CC(NC(=O)c2ccn3nccc3n2)C1', 'CC1(C)CC1(NC(=O)CC1CC=CCC1)C(=O)N1CC2CC2(CO)C1', 'CC1(C)CC1C(=O)NC1COCCN(C(=O)CCCC2CCCC2)C1', 'CC1(C)CC1C(=O)N[C@@H]1CCC[C@H](CC(=O)N2C3CCCC2CC3)C1', 'CC1(C)CC1C(=O)N[C@H]1CN(C(=O)c2ccc3c(c2)CC3)C[C@H]1CO', 'CC1(C)CC1CC(=O)NCC1CC(C(=O)N2CC(CN=[N+]=[N-])C2)=NO1', 'CC1(C)CC1CNC(=O)C1CCC(C)(C)N(C(=O)c2[nH]ncc2Cl)C1', 'CC1(C)CC1NC(=O)C1CN(C(=O)CO[C@H]2CCOC2)CC12CCC2', 'CC1(C)CC1NC(=O)[C@@H]1CC2(CC2)CN1C(=O)c1c[nH]c(C(N)=O)c1', 'CC1(C)CC1S(=O)(=O)NCc1ccc(CNC(=O)C2CC2(F)Cl)cc1', 'CC1(C)CC2(CC(C(=O)NCCN(C(=O)C3=C(Cl)CC3)C3CC3)C2)C1', 'CC1(C)CC2(CC(Nc3nc(N)nc(NCCCCC(N)=O)n3)C2)C1', 'CC1(C)CC2(CN(C(=O)[C@H]3C[C@H]3CNC(=O)CCc3cccs3)C2)C1', 'CC1(C)CCC(=O)N(NC(=O)CNC(=O)c2ccc3[nH]nnc3c2)C1', 'CC1(C)CCC(C(=O)N2CC=CC2C(=O)N2CC[C@H]3[C@H](O)C[C@H]32)CO1', 'CC1(C)CCC(C(=O)NCC2(C(=O)N3CC[C@H](F)C3)CCCCC2)C1', 'CC1(C)CCC(C)(NC(=O)CC[C@@H]2CCCN2C(=O)C2CC(F)C2)C1', 'CC1(C)CCC(C)(NC(=O)N2CCCC(c3nnc4n3CCC4)C2)C1', 'CC1(C)CCC(CC(=O)N2CC=CC(NC(=O)c3cnco3)C2)OC1', 'CC1(C)CCC(CCNC(=O)C(=O)N2Cc3ccc(F)cc3C2)OC1', 'CC1(C)CCC(CCNC(=O)NCC2CCCc3ccccc3C2)C1', 'CC1(C)CCC(CO)(NC(=O)CCc2ccc(C(F)(F)F)nc2)CC1', 'CC1(C)CCC(NC(=O)C2C=CCN2C(=O)CC2CC3CC3C2)CC1', 'CC1(C)CCC(O)(CCNC(=O)CCNC(=O)Cc2ccccc2)C1', 'CC1(C)CCCC(C(NCC2CCC2)c2nnnn2CCC2CC2)C1', 'CC1(C)CCCC(CN2CCN(C(=O)Nc3ccc(Cl)cc3)CC2)C1', 'CC1(C)CCCC1(CO)NC(=O)[C@H]1C[C@H]1CNC(=O)c1cc(Cl)no1', 'CC1(C)CCCC1CN(Cc1ccc(F)cc1O)C(=O)C1CC(F)C1', 'CC1(C)CCCCC1NC(=O)[C@H]1COC[C@H]1NC(=O)[C@H]1CCC[C@H]1O', 'CC1(C)CCCCCC1NC(=O)[C@H](O)CCNC(=O)c1nc(Cl)cs1', 'CC1(C)CCCN(C(=O)[C@@H]2[C@H](NC(=O)CC3CCCSC3)C2(C)C)C1', 'CC1(C)CCCN1C(=O)c1sccc1CNC(=O)C(C1CC1)C1CC1', 'CC1(C)CCN(C(=O)CNC=O)C1C(=O)NCCOCC1CCCC1', 'CC1(C)CCN(C(=O)Cc2ccc3c(c2)CCCC3)c2ccccc21', 'CC1(C)CCN(C(=O)c2cncc(O)c2)C1C(=O)NC1CC(F)(F)C1', 'CC1(C)CCN(c2ccc(NC(=O)N3CCc4scnc4C3)cc2)C1', 'CC1(C)CCNC(=O)c2cc(C(=O)N3CCC(NCCO)CC3)oc21', 'CC1(C)CCNc2c(C(=O)N3CC(Nc4ncccn4)C3)cccc21', 'CC1(C)CCOC1CC(=O)N1CC(C(=O)N2CC(F)(F)C2)CC1(C)C', 'CC1(C)CCOC1CCN(Cc1nnc[nH]1)C(=O)CO[C@H]1CCOC1', 'CC1(C)CCOC1CCNC(=O)NC1CCN(c2ncccc2F)C1', 'CC1(C)CCOC1CN(CCCC1CCCO1)CC1C2CCOCC21', 'CC1(C)CCOC1CN(Cc1cc(Cl)cs1)C(=O)c1cnc(N)nc1', 'CC1(C)CCc2cc(N3CCC(O)(c4ccccc4Cl)CC3)nnc21', 'CC1(C)CN(C(=O)C2(CCNC(=O)c3ccncc3)CC2)CCC1O', 'CC1(C)CN(C(=O)CC2(C#N)CC2)CCN(S(=O)(=O)c2cn[nH]c2)C1', 'CC1(C)CN(C(=O)[C@H]2CCC=C[C@H]2NC(=O)CC2CCC(=O)NC2)C1', 'CC1(C)CN(C(=O)c2c[nH]cc2F)C[C@H](CNS(=O)(=O)C2(C)CC2)O1', 'CC1(C)CN(C(=O)c2cc(Cl)c(-c3nn[nH]n3)c(Cl)c2)C[C@H](CO)O1', 'CC1(C)CN(C(=O)c2cn[nH]c2)CCC1NC(=O)CCc1nnc[nH]1', 'CC1(C)CN(C(=O)c2cn[nH]c2Cl)CC1C(=O)N1CCCC(CF)C1', 'CC1(C)CN(C(=O)c2cnc(CNC(=O)CCC(CF)CF)nc2)C1', 'CC1(C)CN(c2ccc(S(=O)(=O)NCC3CCCS3)c(Br)c2)CC1O', 'CC1(C)CN(c2nc(NCc3ccccn3)nc3ccsc23)CCS1', 'CC1(C)COC(CC(=O)O)CN1C(=O)CCn1ccc2ccccc21', 'CC1(C)COCC(CC(=O)NCC(=O)N2CCN(S(C)(=O)=O)CC2)O1', 'CC1(C)COCC(CNC(=O)CCn2cc(-c3cccnn3)nn2)O1', 'CC1(C)COCC(CNC(=O)N2CCSCC2c2ccccc2Cl)O1', 'CC1(C)COCC1C(=O)N[C@H]1C[C@@](C)(NC(=O)Cn2ncnc2N)C1', 'CC1(C)COCC1CCNC(Cc1c[nH]c2cccc(F)c12)C(=O)O', 'CC1(C)COc2c(C(=O)OCC(=O)CCc3ccccc3)cccc21', 'CC1(C)C[C@@H]1C(=O)NC1CC2(C1)CC2C(=O)NC1(C(O)CO)CCC1', 'CC1(C)C[C@@H]1CN(Cc1sccc1Cl)C(=O)c1cccc2nccn12', 'CC1(C)Cc2cccc(NC(=O)CNC(=O)c3ncccc3O)c2O1', 'CC1(C)OC(=O)N[C@H]1C(=O)N[C@@H]1CCCN(C(=O)c2csc(F)c2)C1', 'CC1(C)OCCC1(O)C(=O)N[C@@H]1C=C[C@H](CC(=O)NCC(F)(F)F)C1', 'CC1(C)OCCC1C(=O)NC(C(=O)NC1(C(N)=O)CC1)c1ccco1', 'CC1(C)OCCC1C(=O)NCC[C@@H](O)C(=O)N1CC[C@](C)(O)[C@H](O)C1', 'CC1(C)OC[C@@H]([C@H]2COCCN2C(=O)C=Cc2ccc(Cl)c(Cl)c2)O1', 'CC1(C)[C@@H](C(=O)NCCc2csnn2)C[C@H]1NC(=O)C1CCSCC1', 'CC1(C)[C@@H](CNc2ncnc(NCCNS(=O)(=O)C3CC3)n2)C[C@H]1O', 'CC1(C)[C@H](NC(=O)c2cc(O)cc(=O)o2)[C@@H]1C(=O)NCC[Si](C)(C)C', 'CC1(C)[C@H]2CC[C@@H](Nc3cc(NCCc4nc(N)n[nH]4)ncn3)[C@@H]1C2', 'CC1(C2(C(=O)NCCC[C@@H](CO)NC(=O)CC3CCSC3)CC2)CC1', 'CC1(C2(C(=O)N[C@@H]3C[C@H](O)[C@H]3CC(=O)NCC3CCCO3)CC2)CC1', 'CC1(C=CC(=O)N2CC[C@]3(C(=O)NC(C)(C)CF)CCC[C@H]23)COC1', 'CC1(CC(=O)N2CCCC2(CO)CO)CCN1C(=O)CC1CCCC1', 'CC1(CC(=O)N2CCOCC2CC(=O)NC2CC(=O)NC2=O)CCC1', 'CC1(CC(=O)NC(C)(C)c2ncc[nH]2)CCN(C(=O)C(O)C2CC2)C1', 'CC1(CC(=O)NC2(C(N)=O)CC2)CCN(C(=O)C2(C#N)CC(=O)C2)C1', 'CC1(CC(=O)NCc2ccc(C#N)s2)CCN1C(=O)Cn1cnnn1', 'CC1(CCC(=O)N2CCC(CC3CC3)CC2)CN(C(=O)CNC=O)C1', 'CC1(CCC(=O)N2CCC3(CCO3)C2)CN(C(=O)Cc2ccsn2)C1', 'CC1(CCC(=O)N[C@H]2CCC[C@H]2C(=O)NC23CC=CC(C2)OC3)N=N1', 'CC1(CCC(=O)N[C@H]2COC[C@H]2O)CN(C(=O)C(C)(C)CC2CC2)C1', 'CC1(CCCCN(Cc2cccs2)Cc2sccc2CO)OCCO1', 'CC1(CCCNc2cc(NCC3CCN(C4CC4)CC3)ncn2)CC1', 'CC1(CCN(CC2CCCC2)C(=O)CC2COCCOC2)CCOC1', 'CC1(CCN(Cc2cc(Cl)cs2)C(=O)C2CCNC(=O)C2)CCCO1', 'CC1(CCNC(=O)C2=CCCN(C(=O)CCc3cccnc3)C2)CC1', 'CC1(CCNC(=O)C2CC(O)(CNC(=O)CN3CCCCC3)C2)CC1', 'CC1(CCNC(=O)CC23CCCC2C3)CCN(C(=O)C=C2CCC2)C1', 'CC1(CCNC(=O)[C@H]2CC=CC[C@H]2NC(=O)CC2CCC2)CCCC1', 'CC1(CCNC(=O)c2cc(C(N)=O)co2)CCN(C(=O)CC#N)CC1', 'CC1(CCNC2(c3nnnn3C3CCC3)CCCCCC2)CCCO1', 'CC1(CCNS(=O)(=O)c2cc(Cl)ccc2OCC2CCC2)CC1(Cl)Cl', 'CC1(CCO)CCN(C(=O)[C@H]2C[C@@H](NC(=O)C34CCCCC3C4)C2)C1', 'CC1(CCO)CCN1C(=O)CC1CCCN1C(=O)CC1CCCCC1', 'CC1(CN(Cc2ccc(Cl)cn2)C(=O)C23CCC(CC2)C3)CCCS1', 'CC1(CN(Cc2cnc3c(c2)CCO3)C(=O)c2cncc(Cl)c2)CC1', 'CC1(CNC(=O)C(O)C2CN(C(=O)CN3CCCC3)C2)C=CCCC1', 'CC1(CNC(=O)C2=NOC(C)(C)C2)CCN(C(=O)[C@@H]2CCC[C@H]2O)C1', 'CC1(CNC(=O)C2C=CC=CC=C2)CN(C(=O)C2C=CCC2)CCO1', 'CC1(CNC(=O)CC2(n3cnnn3)CCOCC2)CCCCC1(F)F', 'CC1(CNC(=O)CCCNC(=O)C2(C#N)CCCCC2)CC2(CC2)C1', 'CC1(CNC(=O)COC2CCCCC2)CN(C(=O)CC2CC2)CCO1', 'CC1(CNC(=O)C[C@H]2CCC[C@H]2NC(=O)C2CC3(CC3)C2)CCCS1', 'CC1(CNC(=O)Nc2ccc(S(=O)(=O)CC3CCCO3)cc2)CSC1', 'CC1(CNC(=O)c2c[nH]nn2)CCN(C(=O)CC2CC3(CCC3)C2)C1', 'CC1(CNC(=O)c2cc(C3CC3)n(C(C)(C)C)n2)CCS(=O)(=O)CC1', 'CC1(CNS(=O)(=O)c2ccsc2C(=O)O)CN(C(=O)OC(C)(C)C)C1', 'CC1(CNc2ccnc(NCCCCCc3ccccc3)n2)CC1Br', 'CC1(CO)C=CCN1C(=O)Nc1ccc(C(=O)N2CCOCC2)cn1', 'CC1(CO)CCCN1C(=O)C1CC12CC(NC(=O)c1ccoc1Cl)C2', 'CC1(CO)CCN(C(=O)c2coc(CNC(=O)CSC(F)F)c2)CC1', 'CC1(COC(=O)C=Cc2ccc[nH]2)CCN(C(=O)OC(C)(C)C)CC1', 'CC1(CS(=O)(=O)NCC(CO)c2cccc(Cl)c2)CCCCC1(F)F', 'CC1(CS(=O)(=O)NCCS(=O)(=O)N2CCc3ccccc32)CC(=O)C1', 'CC1(Cc2ccc(C(F)F)cc2)CCCN1S(=O)(=O)NC1CCCC1', 'CC1(N=[N+]=[N-])CC(C(=O)N2CCC2c2csc(NC3CCCC3)n2)C1', 'CC1(NC(=O)C(C2C(C)(C)C2(C)C)N2CCCCC23CCOC3)CC1', 'CC1(NC(=O)C2CCOC2=O)CCN(C(=O)CSc2ccccc2)C1', 'CC1(NC(=O)CC2CCCCC23CC3)CN(C(=O)COCC2CC2)C1', 'CC1(NC(=O)CC2CCN(C(=O)CC3CC(F)C3)C2)CCCCCC1', 'CC1(NC(=O)CCc2ccsc2)CCCN(C(=O)Cc2ccsc2)C1', 'CC1(NC(=O)NCC(CO)Cc2ccoc2)CCN(S(N)(=O)=O)CC1', 'CC1(NC(=O)[C@@H]2CC[C@H](CNC(=O)[C@H]3CCC[C@H]3F)O2)CS(=O)(=O)C1', 'CC1(NC(=O)[C@@H]2C[C@H]3C[C@@H]2C[C@H]3O)CN(C(=O)CO[C@@H]2CCOC2)C1', 'CC1(NC(=O)[C@H]2CCCCC[C@H]2NC(=O)C(C)(C)F)CCC(O)CC1', 'CC1(NC(=O)c2ccoc2)CCN(C(=O)c2cc(C#N)ccc2F)C1', 'CC1(NC(=O)c2cn[nH]c2Cl)CCCCC1C(=O)NC[C@H]1C[C@H](O)C1', 'CC1(NCc2cccc(OCC(=O)O)c2Cl)CCc2cc(F)ccc21', 'CC1(O)CCC(C(=O)NC/C=C/CC(=O)N2CC[C@H](F)[C@H](F)C2)CC1', 'CC1(O)CCN(C(=O)[C@H]2CCCCN2C(=O)[C@H]2CC[C@H](C)CC2)CC1', 'CC1(O)CN(C(=O)[C@@H]2C[C@H](NC(=O)c3ccnc(O)c3F)[C@@H](O)C2)C1', 'CC1(O)CN(C(=O)c2[nH]ccc2CNC(=O)c2cc(F)cc(F)c2)C1', 'CC1(O)CN(c2ccc(NC(=O)C(F)c3cccc(F)c3Br)cc2)C1', 'CC1(OCC(=O)N2CCC23CN(C(=O)COc2ccsn2)C3)CCC1', 'CC1(OCC(=O)N2CCCN(C=O)CC2)CN(C(=O)C2CCCO2)C1', 'CC1([C@@H]2C[C@H]2NC(=O)C(F)(F)c2ccc([N+](=O)[O-])cc2)CCOCC1', 'CC1(c2ccc(F)cc2)CC1C(=O)NNc1cccc2ncccc12', 'CC1(c2ccc(F)cc2)CCN(C(=O)NCc2ccc(F)nc2F)C1', 'CC1(c2cccc(NC(=O)NC34CCC(C(F)F)(CC3)C4)c2)CCO1', 'CC1(c2cccnc2Cl)NC(=O)N(Cc2ccc(Cl)c(Cl)c2F)C1=O', 'CC1(c2cn(CC(=O)N3CCC3CC3CCCC3)nn2)CCOCC1', 'CC1(c2cn(CC3(CNC(=O)CCOC4CCCC4)CC3)nn2)CC1', 'CC12CC(CN)(C1)C(C(=O)N1CCC(O)(Cc3ccccc3F)C1)O2', 'CC12CC(NC(=O)C(C)(C)C3CCCN3C(=O)C3=CCCOC3)(C1)C2', 'CC12CCOC(C(=O)NC3(C(=O)NCC45CC(CCO4)C5)CC3)(C1)C2', 'CC1=C(C(=O)N(C)C)C(c2ccc(CCC(=O)O)cc2)NC(=S)N1C', 'CC1=C(C(=O)N(C)CCN(C)C(=O)C2(C)CCCCC2C)SCCO1', 'CC1=C(C(=O)N(CC(C)CC2CC(F)(F)C2)CC2(C)CC2)SCCO1', 'CC1=C(C(=O)N(CCCOC(=O)N(C)C)CC2COC(C)C2)CCO1', 'CC1=C(C(=O)N2CC=CC2C(=O)N2CCC3CCC(C3)C2)CCCO1', 'CC1=C(C(=O)N2CCC(C(=O)NCCC3CCN(C)CC3)C2C)CC1', 'CC1=C(C(=O)N2CCC(CF)(C(=O)N(C)Cc3nncs3)C2)CCO1', 'CC1=C(C(=O)N2CCCC(CCNC(=O)C3(N(C)C)CC3)C2)CCC1', 'CC1=C(C(=O)N2CCCC(CNC(=O)C(C)=C3CCC3)CC2)CCC1', 'CC1=C(C(=O)N2CCCCC2C(=O)NOC2CCOCC2)CCCO1', 'CC1=C(C(=O)N2C[C@@H]3[C@H](C2)[C@H]3NC(=O)CC2CCN(C)CC2)CCO1', 'CC1=C(C(=O)N2C[C@H](NC(=O)CCc3ccnn3C)[C@@H](O)C2)CCC1', 'CC1=C(C(=O)N2C[C@H]3C[C@@H](C2)[C@H](C(=O)N2CCCC(F)(F)C2)C3)CC1', 'CC1=C(C(=O)N2C[C@H]3C[C@@H]2[C@H]3C(=O)N(C)Cc2c(C)noc2C)CC1', 'CC1=C(C(=O)N2[C@@H]3CC[C@H]2C[C@@H](NC(=O)C(C)NS(C)(=O)=O)C3)CC1', 'CC1=C(C(=O)NC(C)(C)CC(=O)NC2CCCc3cn[nH]c32)CCO1', 'CC1=C(C(=O)NC(C)C2CC(NC(=O)C3(CO)CCCCC3)C2)CC1', 'CC1=C(C(=O)NC(C)CCC(=O)N(C)Cc2c(C)noc2C)CCO1', 'CC1=C(C(=O)NC(CC(=O)NCC(O)C(F)F)CC(C)C)CCCO1', 'CC1=C(C(=O)NC2CCC(C)(CNC(=O)C(C)C(F)F)CC2)CCO1', 'CC1=C(C(=O)NCC2(CC(=O)N3CC4(CCCO4)C3)CC2)COCC1', 'CC1=C(C(=O)NCC2COCCN(C(=O)C3(CO)COC3)C2)CCO1', 'CC1=C(C(=O)NC[C@H](CO)NC(=O)c2cnn(CC3CC3)c2)CCC1', 'CC1=C(C(=O)NC[C@H]2CCCC[C@H]2C(=O)N[C@H]2C[C@@H]2C(C)(C)C)CC1', 'CC1=C(C(=O)NCc2[nH]ncc2C(=O)N2CC[C@H](F)[C@H](F)C2)CCC1', 'CC1=C(C(=O)N[C@H](C)CCCC(=O)Nc2cc(Cl)cnc2C)CCC1', 'CC1=C(C(=O)N[C@H]2CCCC[C@H]2CC(=O)NC2(C(N)=O)CC2)CCC1', 'CC1=C(C(=O)N[C@H]2CC[C@H](C)N(C(=O)C3COCCN3C=O)C2)CC1', 'CC1=C(C(=O)N[C@H]2C[C@H](NS(=O)(=O)c3ccc(C)cc3)C2)CCCO1', 'CC1=C(C(=O)Nc2ccc(C(F)(F)F)c(F)c2)Cn2ncnc2N1C', 'CC1=C(C)CC(C)(C(=O)N2CC(CNC(=O)c3cc(C)no3)C2)CC1', 'CC1=C(C)CC(C)(NC(=O)Nc2cc(S(=O)(=O)N(C)C)ccn2)CC1', 'CC1=C(C)CN(C(=O)C2CCN2C(=O)c2cc3ccncc3[nH]2)CC1', 'CC1=C(C)CN(C(=O)[C@@H]2[C@H](NC(=O)Cc3ccc(C)nc3)C2(C)C)C1', 'CC1=C(C)CN(C(=O)[C@@H]2[C@H]3CC[C@H](C3)N2C(=O)[C@@H]2CC[C@H]2C#N)CC1', 'CC1=C(C)CN(c2cc(NCC(CO)C3CCCCC3)ncn2)CC1', 'CC1=C(C)CN(c2nc(N3CC[C@H](N(C)C)C3)c3ncn(C)c3n2)C1', 'CC1=C(C)CN(c2nc(NCCCCC(N)=O)nc3ccsc23)CC1', 'CC1=C(CCNC(=O)c2cc(-c3ccccc3)[nH]n2)C(C)(C)CCC1', 'CC1=C(CN(CCCOC2CCC2)C(=O)[C@H]2C[C@H]2F)C(C)(C)CCC1', 'CC1=C(CNC(=O)[C@@H]2CCN2C(=O)c2cnn3cccc3c2)CCC1', 'CC1=C(CNC(=O)[C@H]2CN(C(=O)C3CCCOC3)CCO2)COCC1', 'CC1=CC(C(=O)N2C(C)CC2C(=O)N2CCC[C@@H]2CCN(C)C)SC1', 'CC1=CC(C(=O)NC(C)(C)CN(C)C(=O)Cn2ncc(Cl)c2C)SC1', 'CC1=CC(C(=O)NCC2CC(C(=O)N3CCS(=O)CC3C)=NO2)SC1', 'CC1=CC(C(=O)NC[C@H]2C[C@H](O)CN2C(=O)C2OCCC2(C)C)SC1', 'CC1=CC(C(=O)NCc2nocc2C(=O)NCCC(=O)N(C)C)SC1', 'CC1=CC(C)CN(C(=O)[C@H]2CC[C@H](C)CN2C(=O)C2=COCCC2)C1', 'CC1=CC(NC(=O)C[C@H]2C[C@@H](NC(=O)CCc3cscn3)C2)CCC1', 'CC1=CCCN(C(=O)C2CC23CC(NC(=O)C2(CC(C)C)CC2)C3)C1', 'CC1=CCCN(C(=O)C[C@@H](CC2CC2)NC(=O)c2nc(C)sc2C)C1', 'CC1=CCN(C(=O)C(CNC(=O)CC2CCCCN2C)C(C)(C)C)C1', 'CC1=CCN(C(=O)Nc2ccc(OCCN3CCNC3=O)cc2C)C1', 'CC1=CCN(C(=O)[C@]23CC[C@H](C[C@@H]2NC(=O)c2c[nH]c(=O)cn2)C3)C1', 'CC1=CCN(C(=O)c2occc2CNC(=O)C2(CF)CC(=O)C2)CC1', 'CC1=CCN(c2nc(NCCCC3CC(C)C3)nc3c2CCCC3)C1', 'CC1=CCSC1C(=O)N(C)C[C@@H](C)NC(=O)c1ccnn1C1CCC1', 'CC1=CCSC1C(=O)NC[C@@H]1CC2(CC2)CN1C(=O)CC(C)C(C)C', 'CC1=NC(C)(CNc2cc(C)nc(N3CCCC(CC#N)C3)n2)CS1', 'CC1=NNC(=O)C1CC(=O)NCC(C)(O)CNC(=O)C#CC1CCC1', 'CC1=NOC(C(=O)NCC2CC(NC(=O)c3c(F)cccc3F)C2)C1', 'CC1=NOC(C(=O)NC[C@@H]2CC(F)(F)CN2C(=O)C2CC(C)(C)C2)C1', 'CC1=NOC(C)(C(=O)NCc2cc(C(=O)N[C@H](C)CC(C)C)on2)C1', 'CC1=NOC(C)(CNC(=O)[C@H]2CCN2C(=O)C(C)(C)C2CCCC2)C1', 'CC1=NOC(C)(CNc2nc3c(c(NCC(C)(C)C)n2)CCCC3)C1', 'CC1=NOC(CC(=O)N2CCCC[C@@H]2C(=O)NC(C)c2c[nH]cn2)C1', 'CC1=NOC(CC(=O)NC2CC(NC(=O)c3cc(C4CC4)no3)C2)C1', 'CC1=NOC(CCNC(=O)C(C)N(C)C(=O)C=Cc2ccn(C)c2)C1', 'CC1=NOC2(C1)CC(C(=O)N1C[C@H](C(=O)O)[C@@H](c3ccccc3)C1)C2', 'CC1C(=O)CC1C(=O)N1CCCN(C(=O)c2ncccc2F)CC1C', 'CC1C(=O)N(C)CCN1C(=O)c1ccccc1S(=O)(=O)N1CCCC1', 'CC1C(C(=O)N2C[C@H](F)[C@@H](F)C2)CCN1C(=O)[C@H]1C[C@H]2CC(=O)[C@@H]1C2', 'CC1C(C(=O)NC2CC3CCCC3C2)CCN1C(=O)CN(C)C(N)=O', 'CC1C(C(=O)NCCCN2CC=CC2)CCN1C(=O)c1n[nH]c(N)n1', 'CC1C(C(=O)NCCCc2cn[nH]c2)CCN1C(=O)C1CCCCC1', 'CC1C(NC(=O)C2=CCSC2)CCCN1C(=O)COCC1CCCC1', 'CC1C=C(C(=O)NC2CCCCCN(C(=O)Cc3cncnc3)C2)C1', 'CC1CC(=O)NCCN1C(=O)C1=CCCN(C(=O)CC2CCSC2)C1', 'CC1CC(C#N)(C(=O)NCC(F)(C(=O)N(C)CCC(N)=O)C(C)C)C1', 'CC1CC(C(=O)N(C)Cc2ccoc2)N1C(=O)CC1CCCN(C)C1', 'CC1CC(C(=O)N(CC2CCN(C)CC2)CC2(C)CCCO2)CCS1', 'CC1CC(C(=O)N(CCC2CC3CCC2O3)Cc2csc(C#N)c2)C1', 'CC1CC(C(=O)N(CCCC2CCCO2)Cc2cncc(F)c2)CO1', 'CC1CC(C(=O)N(Cc2cc(Cl)nn2C)CC(O)C(C)C)CCC1=O', 'CC1CC(C(=O)N2CCC(CNC(=O)c3cc(O)ccn3)CC2)CO1', 'CC1CC(C(=O)N2CCCCC2CF)CN(C(=O)C2(C)CC2(C)C)C1', 'CC1CC(C(=O)N2CCN(C(C(=O)O)c3cccc(Cl)c3)CC2)CO1', 'CC1CC(C(=O)N2C[C@H](O)CO2)CN(C(=O)C2CC(=O)OC2(C)C)C1', 'CC1CC(C(=O)NC2CCCC(C3CC3)C2)N1C(=O)C=CC1CCC1', 'CC1CC(C(=O)NCC(C)(F)CNc2ccnc(CO)n2)CCN1C', 'CC1CC(C(=O)NCC(C2CC2)N(C)c2nnc(C3CCCC3)s2)C1', 'CC1CC(C(=O)NCC2CC(C(=O)NCCC3(CO)CC3)=NO2)=NO1', 'CC1CC(C(=O)NCC2CCSCC2)N1C(=O)c1ccc(CF)cc1', 'CC1CC(C(=O)NCCCCCNC(=O)C=Cc2ccncc2)CO1', 'CC1CC(C(=O)NC[C@@H]2C[C@H]3C[C@@H]2C[C@H]3O)N1C(=O)CC1CC=CC1', 'CC1CC(C(=O)NCc2ccc(N(C)C(=O)c3ccncc3)cc2)N1', 'CC1CC(C(=O)N[C@@H](C)[C@@H](CO)NC(=O)[C@]2(C(F)F)C[C@@H](O)C2)=NO1', 'CC1CC(C(=O)N[C@H]2C[C@@H]3C[C@H]2[C@H](NS(=O)(=O)CCCCO)C3)=NO1', 'CC1CC(C(=O)OC(C)(C)C)CN(Cc2c[nH]c3ncc(Br)cc23)C1', 'CC1CC(C)(C(=O)NCCOCC(=O)NC2CCc3ccccc32)C1', 'CC1CC(C)(NC(=O)C2(C(C)NC(=O)c3cc(CO)n(C)n3)CC2)C1', 'CC1CC(C)CC(CNC(=O)N[C@H](CO)Cc2cc(Cl)ccc2Cl)C1', 'CC1CC(C)CN(C(=O)CN(CC(=O)O)Cc2ccc(F)c(F)c2)C1', 'CC1CC(CC(=O)NC2CC(C)(C(=O)NC(CO)CC3CCC3)C2)C1', 'CC1CC(CC(=O)NC2CCC3(CCC3)C2)CN1C(=O)CCCC#N', 'CC1CC(CC(=O)NCC(C)(O)CO)CN1C(=O)C1COCC1(C)C', 'CC1CC(CC(=O)NCC2(CN(C)S(=O)(=O)CCC(F)(F)F)CC2)C1', 'CC1CC(CC(=O)NC[C@H]2C[C@@H]2CNS(=O)(=O)C[C@H]2CC[C@H]2C#N)C1', 'CC1CC(CC(=O)NCc2cc(C(=O)NCC3(CO)CC3)n(C)n2)C1', 'CC1CC(CC(=O)NOC2CCCCC2)CN1C(=O)[C@H]1CCC[C@H]1O', 'CC1CC(CC(=O)N[C@@]2(C)C[C@H]3CC[C@@H]2C3)CN1C(=O)C=CC1CC1', 'CC1CC(CC(=O)N[C@H]2CN(C(=O)Cc3cc[nH]c3)C[C@H]2N=[N+]=[N-])C1', 'CC1CC(CC(=O)O)(NC(=O)c2nccn2Cc2ccccc2)CO1', 'CC1CC(CCC(=O)N2C[C@@H](O)C[C@H](NC(=O)c3ccncn3)C2)C1', 'CC1CC(CCC(=O)NC[C@H](CO)NC(=O)c2cc(C3CC3)no2)C1', 'CC1CC(CCC(=O)N[C@H](C(=O)N[C@@H]2CCCC[C@H]2O)C2CCC2)C1', 'CC1CC(CCCNc2nc(NCC3CSC3)c3c(ncn3C)n2)C1', 'CC1CC(CCNC(=O)CN(C(=O)[C@@H]2COCCO2)C2CC2)CCO1', 'CC1CC(CN(CC(C)C2CCOC2)C(=O)CCP(C)(C)=O)C(C)O1', 'CC1CC(CN(CC(O)C2(Cl)CC2)C(=O)C(F)c2ccnn2C)CO1', 'CC1CC(CN(CC2CC23CCOCC3)C(=O)c2ccoc2Cl)CO1', 'CC1CC(CN(Cc2c(Cl)ncn2C)C(=O)C(C)S(C)(=O)=O)CCO1', 'CC1CC(CNC(=O)C2C=CCS2)CN(C(=O)Cc2sccc2Cl)C1', 'CC1CC(CNC(=O)[C@@H](O)CCN(C)C)CN(C(=O)C2SCCS2)C1', 'CC1CC(CNC(=O)c2cc(-c3cccc(Cl)c3)ns2)CCS1(=O)=O', 'CC1CC(CNS(C)(=O)=O)CN(C(=O)c2ccc3ncn(C)c3c2)C1', 'CC1CC(CO)(C(=O)N(CC2CC=CCC2C)C[C@H](O)C(C)(C)C)C1', 'CC1CC(CO)(CNC(=O)CC2(C)CCN2C(=O)[C@H]2CC[C@H]3C[C@H]32)C1', 'CC1CC(CO)(NC(=O)C2CC3(CCC3)CN2C(=O)c2ccc[nH]2)C1', 'CC1CC(CO)CN1C(=O)NCCCCC(=O)OCc1ccccc1', 'CC1CC(CO)CN1S(=O)(=O)c1ccc(NCc2ccco2)cc1Cl', 'CC1CC(CS(=O)(=O)N[C@H]2C[C@H]2CNC(=O)CC2CCC3CC3C2)C1', 'CC1CC(N(C)C(=O)C(NC(=O)[C@@H]2CC=CC[C@H]2C)c2ccco2)C1', 'CC1CC(N(C)C(=O)C2CC(C)CCN2C(=O)CCc2cccs2)C1', 'CC1CC(NC(=O)C(F)(F)F)CN(C(=O)C2(S(C)(=O)=O)CC2(C)C)C1', 'CC1CC(NC(=O)C=C2SCC(=O)N2C)CN1C(=O)C#CC1CCC1', 'CC1CC(NC(=O)COc2ccon2)CN1C(=O)CCC(=O)C1CC1', 'CC1CC(NC(=O)c2ccccc2SCc2ccco2)CN1C1CC1', 'CC1CC(NCC2(Br)CC2)(c2nnnn2Cc2ccco2)CCN1C', 'CC1CC(Nc2nc3ccc(Cl)cc3s2)CN1C(=O)c1nonc1N', 'CC1CC(O)(C(F)(F)F)CCN1C(=O)Nc1cnc2n1CCCCC2', 'CC1CC1(C)NC(=O)c1occc1CNC(=O)Cn1cc(C#N)cn1', 'CC1CC1C(=O)NC1(CCC(=O)N2CCC3(CNC(=O)C3)C2)CCC1', 'CC1CC1CCCCCOC(=O)c1ccsc1NC(=O)c1ccco1', 'CC1CC1CCNC(=O)C1CCCCCN1C(=O)CCc1cnoc1', 'CC1CC1CN(C)C(=O)CN1CCN(C(=O)C2(C(F)(F)F)CC2)CC1', 'CC1CC1CN(C)C(=O)[C@H]1CCCN(C(=O)c2ccn(CCF)n2)C1', 'CC1CC1CNC(=O)c1cn(CCNC(=O)[C@H](C)OC(C)(C)C)cn1', 'CC1CC1CNC(=O)c1occc1CNC(=O)[C@H]1C[C@H]2CC(=O)[C@@H]1C2', 'CC1CC1CNC1(c2nnnn2C(C)(C)C)CC(C2CC2)(C2CC2)C1', 'CC1CC1CS(=O)(=O)NC[C@H]1CCC[C@@H](NC(=O)[C@@H]2CNC(=O)N2)C1', 'CC1CC2(CCC2)CN1C(=O)[C@H]1OCC[C@H]1CNC(=O)C(=O)N(C)C', 'CC1CC=CCC1CN(CC(F)C1CC1)C(=O)CN1CCN(C)CC1', 'CC1CCC(C(=O)NCc2ccoc2C(=O)NCC(C)C(C)(F)F)O1', 'CC1CCC(C(C)C)C(CN(Cc2ccns2)Cc2ccnn2C)C1', 'CC1CCC(C)(C(=O)NCC(C)(F)CNC(=O)[C@H]2CNC(=O)C2)CC1', 'CC1CCC(C)(C(=O)NCC2(CN(C)C(=O)C3CCCC3)CC2)CC1', 'CC1CCC(C)(C(=O)NCc2cc(C(=O)NC3CCCC3)[nH]n2)CC1', 'CC1CCC(C)(NC(=O)C[C@@H]2[C@H]3CC[C@H](C3)N2C(=O)CC(C)(C)C)C1', 'CC1CCC(C)C1NC(=O)C1CCCN(C(=O)CN2CC(C)(C)C2)C1', 'CC1CCC(C)N1CC(=O)NCCCCNC(=O)C1=C(Cl)CCOC1', 'CC1CCC(CC(=O)N2CCN(C(=O)C3(C4CC4)CC3)CC23CC3)C1', 'CC1CCC(CCO)(NC(=O)c2cccc3oc(N(C)C)nc23)CC1', 'CC1CCC(CN(C)C(=O)[C@H]2CCC[C@H]2NC(=O)c2cnns2)CC1', 'CC1CCC(CN(CCOCC(F)F)C(=O)c2c(F)cncc2F)C1', 'CC1CCC(CN(CCOCC2CCCO2)C(=O)C2(O)CCCC2)C1', 'CC1CCC(CNC(=O)C2(F)CN(C(=O)C3OCCC3(C)C)C2)CC1', 'CC1CCC(F)(F)CN1C(=O)CCCN(C)C(=O)C1CN(C)CCO1', 'CC1CCC(F)(F)CN1C(=O)[C@H]1COCCN1C(=O)CC1CCSC1', 'CC1CCC(NC(=O)COC2CCCC2)CN1C(=O)CC1CC=CC1', 'CC1CCC(Nc2ccc3c(c2)CCO3)(c2nnnn2C2(C)CC2)C1', 'CC1CCC(O)(C(=O)N[C@H]2CCN(C(=O)C/C=C/C(C)(C)C)C2)CC1', 'CC1CCC(S(=O)(=O)NCC(C)(C)CN(C)C(=O)C[C@@H]2CCOC2)C1', 'CC1CCC1(C)C(=O)N(Cc1cccc(Cl)n1)CC1(C(C)(C)O)CC1', 'CC1CCC1C(=O)NC(C)(C)COCCCNC(=O)Cc1ccsc1', 'CC1CCC1C(=O)NC1(C(=O)N[C@H]2CCC[C@H]2C(N)=O)CCCC1C', 'CC1CCC1N(C)C(=O)[C@H]1[C@H]2CC[C@H](C2)N1C(=O)CC1(C)OCCO1', 'CC1CCC=C1C(=O)N1CCC(F)(CNC(=O)c2ncccc2F)C1', 'CC1CCC=C1C(=O)N1CCCCC1C(=O)N[C@@H]1C[C@@H]2C[C@H]1[C@@H](O)C2', 'CC1CCCC(C(=O)Nc2cccc(C(=O)N(C)CC(N)=O)c2)N1C', 'CC1CCCC(CC(=O)NC2CCN(C(=O)CCC(C)(C)F)CC2)C1', 'CC1CCCC(CN(CC2CCC(C)(C)C2)C(=O)[C@@H]2CNC(=O)O2)C1', 'CC1CCCC(CN(CC2CCSC2)C(=O)CN(C)C(=O)C2CC2)O1', 'CC1CCCC1(C)C(=O)N1CCC=C(CNC(=O)C#CC2CCC2)C1', 'CC1CCCC1(C)NC(=O)c1cc(CNC(=O)C(F)C(F)(F)F)cs1', 'CC1CCCC1(NC(=O)CSCC(F)F)C(=O)N(C)CCC(O)CO', 'CC1CCCC1(NC(=O)c1cccnc1)C(=O)NCC1(O)CC=CC1', 'CC1CCCC1C(=O)N(Cc1ccnn1CCF)CC1CCSCC1', 'CC1CCCC1C(=O)N1C[C@H](C)N(C(=O)C2NC(=O)OC2C)C[C@H]1C', 'CC1CCCC1C(=O)NCc1ccnc(C(=O)NOCCN(C)C)c1', 'CC1CCCC1N(C)C(C(=O)NC1(C)CC1)c1cnc2c(c1)CCC2', 'CC1CCCC=C1C(=O)NC(C)(C)CNC(=O)c1cc2occc2[nH]1', 'CC1CCCC=C1C(=O)NC(CC(=O)N1CCC[C@@H](CO)C1)C(C)C', 'CC1CCCC=C1C(=O)NCC1(O)CCN(C(=O)c2cccs2)CC1', 'CC1CCCCC1CC(=O)N1CCC=C(C(=O)NCC2=CCCC2)C1', 'CC1CCCCC1NC(=O)c1csc(CNC(=O)c2[nH]ncc2Cl)c1', 'CC1CCCCCC1NC(=O)CC(C)(C)NC(=O)C(C1CC1)C1CC1', 'CC1CCCCCCN1C(=O)C(C)(CO)NC(=O)c1cn[nH]c(=O)c1', 'CC1CCCCCCN1C(=O)[C@H]1OCC[C@H]1NC(=O)C(C)(C)N(C)C', 'CC1CCCCN1C(=O)[C@@H]1CN(C(=O)CCCC2CCC2)C[C@H](C)O1', 'CC1CCCCN1CC(=O)N1CCC(CO)(C(=O)N(C)C2(C)CC2)C1', 'CC1CCCCN1CCNC(=O)[C@@H]1CCN1C(=O)c1cccc(=O)[nH]1', 'CC1CCCN(C(=O)C(CC2CC2)NC(=O)CCc2ccn(C)c2)C1', 'CC1CCCN(C(=O)C2CN(C(=O)C(C)C(O)C(C)C)C(C)(C)C2)C1', 'CC1CCCN(C(=O)CCCCNC(=O)C2(C)CCC(C)CC2)CC1', 'CC1CCCN(CC(C)NC(=O)NCc2cc(-c3cccs3)on2)C1', 'CC1CCCN(CCCCNC(=O)c2oc(C3CC3)nc2C(F)F)C1', 'CC1CCCN(S(=O)(=O)c2ccc(Br)cc2NCC2CCCC2)C1C', 'CC1CCCN1CC(=O)NC1(c2cn(CC3CC3)nn2)CCCOC1', 'CC1CCN(C(=O)/C=C/CC(C)(C)NC(=O)CCC2(C)N=N2)CCO1', 'CC1CCN(C(=O)C#CC2CCCC2)C1CNC(=O)c1c[nH]c(=O)o1', 'CC1CCN(C(=O)C(C)(C)NC(=O)[C@@H]2CSCC(=O)N2)CC12CCC2', 'CC1CCN(C(=O)C(C)SC(C)C)C(C(=O)N[C@H]2CCCNC2=O)C1', 'CC1CCN(C(=O)C2(NC(=O)CC3CCN(C)CC3)CCC2)CC1C', 'CC1CCN(C(=O)C23CC(NC(=O)CC4C=CCC4)(C2)C3)CC1(F)F', 'CC1CCN(C(=O)C2CCCN(C(=O)CC3CCC(C#N)C3)C2)CC1', 'CC1CCN(C(=O)CC(=O)NC2CC2)C1C(=O)NCCc1ncc[nH]1', 'CC1CCN(C(=O)CCCC2CC2)CC1NS(=O)(=O)CCCCC#N', 'CC1CCN(C(=O)CN[C@H]2CCO[C@H]2CNC(=O)OC(C)(C)C)CC1', 'CC1CCN(C(=O)C[C@@H]2CC[C@H](O)C2)CCN1C(=O)C1(F)CCOC1', 'CC1CCN(C(=O)OC(C)(C)C)C1C(=O)NNc1nccn(C)c1=O', 'CC1CCN(C(=O)OC(C)(C)C)C1CON=Cc1ccc(Cl)c(Cl)c1', 'CC1CCN(C(=O)[C@@H]2[C@H](CNC(=O)c3cncc(C#N)c3)C2(C)C)C1', 'CC1CCN(C(=O)c2cc(F)n(C)n2)C1CNC(=O)CSC(F)(F)F', 'CC1CCN(C(=O)c2ccc(CNC(=O)[C@@H]3CN(C)C(=O)N3)cc2)C1', 'CC1CCN(C(=O)c2ccoc2Cl)CCN1C(=O)c1nn(C)cc1Cl', 'CC1CCN(C(=O)c2csc(F)c2)C(C(=O)N[C@@H]2C[C@H]3CC[C@@H]2C3)C1', 'CC1CCN(C(=O)c2csnn2)CC1NC(=O)[C@H]1CN(C)CCN1C', 'CC1CCN(CC(=O)N(C)C2(C(=O)NCc3ccncc3Cl)CC2)C1', 'CC1CCN(CC(=O)N(C2CC2)C(C)C(=O)NCCc2ncon2)C1', 'CC1CCN(CC(=O)N2CCC(C(=O)NC3CC4C=CC3C4)C2)CC1', 'CC1CCN(CC(=O)N2CCC(N(C)C(=O)C3C=CCC3)CC2)CC1', 'CC1CCN(CC(=O)N2N=C(c3cccs3)CC2c2ccco2)CC1', 'CC1CCN(CC(=O)NC/C=C\\CNC(=O)C(C)c2cncnc2)C1', 'CC1CCN(c2ccc(F)cc2F)CCN1C(=O)Cc1ccnn1C', 'CC1CCNC(=O)C1CNC(=O)N1CCN(C(=O)N2CCCC2)CC1', 'CC1CCOCC1(Nc1cccc(Cl)c1)c1nnnn1C1CCCC1', 'CC1CCSCCN1C(=O)[C@H]1COC[C@H]1NC(=O)c1ncncc1Cl', 'CC1CCSCCN1C(=O)c1cc(F)c(C(=O)OC(C)(C)C)cc1F', 'CC1CCc2n[nH]c(C(=O)OCc3ccnc(-n4cccn4)c3)c2C1', 'CC1CN(C(=O)C2(C)CN(C(=O)CC3CCOCC3)C2)CC(CO)O1', 'CC1CN(C(=O)C2(F)CCN(C(=O)[C@H]3C[C@@H]3C(F)(F)F)C2)CCC1O', 'CC1CN(C(=O)C2(N(C)C(=O)CC3CCC(=O)NC3)CC2)CCCO1', 'CC1CN(C(=O)C2CC(CC3CC3)C2)CCN(C(=O)C(C)C2CC2)C1', 'CC1CN(C(=O)C2CCN(C)CC2)CC(C)N(C(=O)[C@H]2C[C@@H](O)C2)C1', 'CC1CN(C(=O)CC(C)C(C)(C)C)CCN(C(=O)C2=CCCOC2)C1', 'CC1CN(C(=O)CC2(NC(=O)c3ccnnc3)CC2)Cc2c[nH]nc21', 'CC1CN(C(=O)CC2=CCCCC2)CC1NC(=O)CCSC(F)(F)F', 'CC1CN(C(=O)CCCCc2ccccc2)c2cc(F)c(F)cc2O1', 'CC1CN(C(=O)CO[C@H]2C[C@H](NC(=O)c3cc(O)nn3C)C2)CC1O', 'CC1CN(C(=O)C[C@H](C)NC(=O)CSc2cn[nH]c2)C2(CC2)C(=O)N1', 'CC1CN(C(=O)C[C@H]2C[C@H](F)CN2C(=O)c2cnccn2)CC(=O)N1', 'CC1CN(C(=O)Cc2c[nH][nH]c2=O)CCN(C(=O)C2CS(=O)(=O)C2)C1', 'CC1CN(C(=O)Cc2ccncc2Cl)CCN1C(=O)[C@H]1C[C@@H]1C1CC1', 'CC1CN(C(=O)[C@@H]2C[C@@H](F)C(=O)N2)CCN1S(=O)(=O)CCS(C)(=O)=O', 'CC1CN(C(=O)[C@H]2CC[C@H]3C(=O)NCC(=O)N3C2)c2ccccc2S1', 'CC1CN(C(=O)[C@H]2C[C@@H](NC(=O)C3(C#N)CC(=O)C3)C2)CC(C)(C)C1', 'CC1CN(C(=O)c2cc(Cl)nn2C)CCN1C(=O)C1=C(Cl)CCCC1', 'CC1CN(C(=O)c2ccc(CNC(=O)C(C)(C)N(C)C)s2)CC(C)O1', 'CC1CN(C(=O)c2cccc(F)c2F)CCN1C(=O)[C@H](O)C(F)(F)F', 'CC1CN(C(=O)c2ccco2)CCN1S(=O)(=O)CCN1CCCCC1', 'CC1CN(C(=O)c2ccnc(CNC(=O)C3CCCN3C)c2)C1(C)C', 'CC1CN(C(=O)c2cncnc2N)CCCN1C(=O)c1scnc1Cl', 'CC1CN(C(=O)c2cncs2)CC(CCNC(=O)CC2(CO)CC2)O1', 'CC1CN(C)CC(C(=O)NC2CC(NS(=O)(=O)CC3CCCO3)C2)O1', 'CC1CN(CCC(=O)NS(=O)(=O)CCc2ccccn2)CCS(=O)C1', 'CC1CN(S(=O)(=O)c2cnccc2N[C@H]2C[C@@H](CO)C2)CC(C)(C)C1', 'CC1CN(c2cc(Cl)ccc2Cl)CCN1Cc1ccnc(N(C)C)c1', 'CC1CN(c2ccc(NC(=O)C3(C(=O)O)CC3(F)F)cn2)CC(C)O1', 'CC1CN(c2ccc(NC(=O)[C@@H](N)c3ccc(Cl)cc3)cc2)CCO1', 'CC1CNCC(C)C1Nc1nc(NCc2cc[nH]n2)c2sccc2n1', 'CC1COC(C(=O)N(CC(=O)NCC2CC(=C3CC3)C2)CC2CC2)C1', 'CC1COC(CNC(=O)C2=CCN(C(=O)c3ccc(CO)nc3)C2)C1', 'CC1COC(CNC(=O)Nc2cccc(Cc3nncn3C)c2)CO1', 'CC1COC2(C1)CN(C(=O)NCC1(c3ccccc3F)CCCC1)C2', 'CC1CS(=O)CCN1C(C(=O)NCC(F)F)c1ccn2ccnc2c1', 'CC1CSc2ccccc2N(C(=O)c2cc(N3CCCC3)ccn2)C1', 'CC1Cc2[nH]ncc2CN(C(=O)c2cc3cc(O)ccc3cc2O)C1', 'CC1Cc2cc(CC(=O)N[C@@H]3CCOc4c(F)cccc43)ccc2O1', 'CC1Cc2cc(Cc3noc([C@]45CCC(F)(F)[C@H]4C5)n3)cc(Cl)c2O1', 'CC1Cc2cc(Cl)ccc2N1C(=O)c1cc(Cl)ccc1-n1ccnc1', 'CC1Cc2ccccc2N1C(=O)CNS(=O)(=O)c1ccc(C#N)cc1', 'CC1Cc2ccccc2N1C1CCN(Cc2cc(Cl)c(Br)cn2)CC1', 'CC1Cc2ccccc2N1CCNC1CCN(C2CCCCC2)CC1', 'CC1Cc2cn[nH]c2CC1NC(=O)CC1CC(=O)Nc2ccccc21', 'CC1Cn2nc(C(=O)NCCOc3cc(Br)ccc3F)cc2C(=O)N1', 'CC1Cn2ncc(Br)c2CN1C(=O)c1cc(=O)c2cc(Br)ccc2o1', 'CC1Cn2nncc2CN1C(=O)N[C@H]1C[C@@H](COc2ccccc2)C1', 'CC1N(C(=O)C2(NC(=O)C3CCCCC(=O)N3)CSC2)CCC1(C)C', 'CC1NC(=O)CCC1NC(=O)[C@@H]1CSCN1C(=O)CN(C)C1CCC1', 'CC1OC(=O)NC1C(=O)N1C[C@H]2C[C@H](C)N(C(=O)c3ccc[nH]3)[C@H]2C1', 'CC1OC2(C(=O)NCc3cccc(-c4cn[nH]c4)c3)CC1(C(=O)O)C2', 'CC1OC2CCC1(NC(=O)C13CC(CN1C(=O)C(C)(C)C1CC1)C3)C2', 'CC1OC2CCC1(NC(=O)C=Cc1ccc(OCCN(C)C)cc1)C2', 'CC1OCCC1(C)C(=O)N1CC2(CCN(C(=O)Cc3ccoc3)C2)C1', 'CC1OCCC1CN(C)C(=O)C1C=CCCN1C(=O)Cn1cccc1', 'CC1OCCC1CNC(=O)[C@H]1C[C@@H](CNC(=O)c2ncccc2F)C1', 'CC1Oc2c(cccc2-c2ccc3[nH]c4c(c3c2)CCNC4)NC1=O', 'CC1SCCCC1C(=O)NC(C)(C)C1CCN(C(=O)c2ccsn2)C1', 'CC1c2cc(C(=O)O)cc(F)c2CCN1Cc1nnn(C(C)(C)C)n1', 'CC1c2cc(F)cc(F)c2CCN1S(=O)(=O)c1ccc2c(c1)CCO2', 'CC1c2nccn2CCN1C(=O)CCC1(NC(=O)OC(C)(C)C)CC1', 'CC=C(CC)C(=O)N1CC2(C=C(C(=O)N3CCC(CCC)C3)CO2)C1', 'CC=C(CC)C(=O)N1CC2(CN(C(=O)C=CC3CCOC3)CCO2)C1', 'CC=C(CC)C(=O)N1CC=CC1(C)C(=O)Nc1cnc(COC)nc1', 'CC=C(CC)C(=O)N1C[C@H](C)[C@@](C)(C(=O)N2CCOC3(CCC3)C2)C1', 'CC=C(CC)C(=O)N1C[C@H](C)[C@@](C)(CNC(=O)CC(O)CN(C)C)C1', 'CC=C(CC)C(=O)NCC1COCCN(C(=O)C2CC3(CC3)CO2)C1', 'CC=C1CN(C(=O)C23CC(CCO2)N(C(=O)[C@H]2C[C@@H]2C(F)(F)F)C3)C1', 'CC=C=CCCN(Cc1cc(C#N)n(C)c1)C(=O)c1coc(SC)c1', 'CC=C=CCCN(Cc1cnc(C2CC2)s1)C(=O)C1(C)CCOC1C', 'CC=C=CCCNc1cc(S(=O)(=O)NCCOC(F)F)ccc1C#N', 'CC=CC(=O)N1CC2(C(=O)NCc3cccc(C)c3F)CCC1CC2', 'CC=CC(=O)N1CCC(C(=O)N2CCN3CCOC[C@H]3C2)(C(C)C)C1', 'CC=CC(=O)N1CCC[C@H](CC)[C@@H]1C(=O)Nc1ccc2ccoc2c1', 'CC=CC(=O)NC(CNC(=O)C=C1CCC(C)CC1)c1ccccc1', 'CC=CC(=O)NCC1(COC)CCCN1C(=O)c1nc(C2CC2)cs1', 'CC=CC(=O)Nc1ccc(NC(=O)c2cccc3ncnn23)cc1C', 'CC=CC(O)C(=O)N(CC)CCCNC(=O)c1ccc(C)nc1NC', 'CC=CC(O)C(=O)N1CC2(CC(CNC(=O)CC3(OC)CCC3)C2)C1', 'CC=CC(O)C(=O)N1CCCC12CCCN(C(=O)[C@@H](O)[C@@H](C)CC)C2', 'CC=CC(O)C(=O)N1CCCCC(NC(=O)c2cn(C3CC3)nn2)C1', 'CC=CC(O)C(=O)N1CCC[C@@H](CCC(=O)N2CC=CC2(C)CO)C1', 'CC=CC(O)C(=O)N1CCN(C(=O)c2cnn(C)c2COC)C(C)C1', 'CC=CC(O)C(=O)N1CCO[C@H]2CN(C(=O)Cc3cncnc3)C[C@H]21', 'CC=CC(O)C(=O)NC(C)C1CC(NC(=O)COc2cccnc2)C1', 'CC=CC=CC(=O)N(CCN(C)C(=O)c1cncc(CO)c1)C(C)C', 'CC=CC=CC(=O)N(CCNC(=O)CC1CCCC(=O)N1)CC1CC1', 'CC=CC=CC(=O)N1CC(O)(CNC(=O)[C@H]2C[C@H]3C=CC[C@H](C3)C2)C1', 'CC=CC=CC(=O)N1CCC(CC)(C(=O)NC(COC)C2(C)CC2)C1', 'CC=CC=CC(=O)N1CCN(C(=O)CC2CNC(=O)O2)C(C(C)C)C1', 'CC=CC=CC(=O)NC(C)(C)CCNC(=O)C(C)=Cc1cccnc1', 'CC=CC=CC(=O)NCCC1CC(C(=O)NCc2ncnn2CC)C1', 'CC=CC=CC(=O)N[C@H](CC(=O)NC1C2CCC3C(C2)CC31)C(C)C', 'CC=CCC(=O)N1CC2CC1CN(C(=O)CCC(=O)OC(C)(C)C)C2', 'CC=CCC(=O)N1CCCCC(NC(=O)Cc2ccc(OC)nc2)C1', 'CC=CCC(=O)N1CCC[C@H](C(=O)N2CCC[C@H](CO)[C@@H]2C)[C@@H]1CC', 'CC=CCC(=O)N1CCO[C@H]2CN(C(=O)[C@H]3C[C@@H](N(C)CC)C3)C[C@H]21', 'CC=CCC(=O)NC(C)C1CCCN(C(=O)c2cc(=O)n(C)cn2)C1', 'CC=CCC(=O)NCC1CC(C)N(C(=O)c2ncoc2CCCC)C1', 'CC=CCC(=O)NC[C@H]1CN(C(=O)[C@H]2C[C@@H]2C2CCOCC2)C[C@H]1O', 'CC=CCCC(=O)N1CC2C=CC1C(C(=O)N1CCC1(C)CCO)C2', 'CC=CCCC(=O)N1CCC(/C=C/C(=O)N2CC(C(=O)OC)C2)CC1', 'CC=CCCC(=O)N1CCN(CCc2cn(C(CC)CC)nn2)CC1', 'CC=CCCC(=O)N1CC[C@H](C)C[C@@H]1C(=O)N1CC(n2cnnc2)C1', 'CC=CCCC(=O)N1CC[C@H]2CN(C(=O)[C@@H]3CC4(CC4)CN3C)C[C@H]21', 'CC=CCCC(=O)N1C[C@@H](C)N(C(=O)c2ccc(C)c(C)n2)C[C@@H]1C', 'CC=CCCC(=O)N1C[C@H](CO)[C@H](NC(=O)CC2CCOC2(C)C)C1', 'CC=CCCC(=O)NC12CC(C(=O)N(C)CC(C)N(C)C(C)=O)(C1)C2', 'CC=CCCC(=O)NC[C@@H]1CN(C(=O)C2CN3CCN2CC3)CCO1', 'CC=CCCC(=O)N[C@H](CCC)CC(=O)N1CCC(C)(C(C)C)CC1', 'CC=CCONC(=O)C1(CCNC(=O)CCC2CCC(C)O2)CCC1', 'CC=Cc1cn(C[C@H](CC(C)C)NC(=O)CC2(C)CNC(=O)C2)nn1', 'CC=Cc1cn([C@@H]2CN(C(=O)[C@@H]3C[C@H]4CC[C@@H](C3)C4O)C[C@H]2O)nn1', 'CCC#CCCN(Cc1cn(-c2ccccc2)nn1)Cc1cccs1', 'CCC#CCCN(Cc1nccnc1OC)C(=O)C(C)CC(F)(F)F', 'CCC#CCCNC(=O)C1(NC(=O)c2ccncc2CC)CCCC1', 'CCC#CCCNC(=O)C1CCN(C(=O)c2cn(C)nn2)C12CCC2', 'CCC#CCCNC(=O)[C@H]1CC[C@H](C)CN1C(=O)CC(O)C(C)CC', 'CCC#CCCNC(=O)c1cccnc1CNC(=O)[C@H]1OCC[C@H]1C', 'CCC(=CC(=O)NC1(C(=O)N2CC[C@H](O)[C@@H]2CC)CCCC1C)CC', 'CCC(=CC(=O)NC1CCC(C)N(C(=O)C(F)C2CCCC2)C1)CC', 'CCC(=CC(=O)NC[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)c1coc(CC)n1)CC', 'CCC(=CC(=O)N[C@@H](CC1CC1)C(=O)N1CC2(CN(CC)C2)C1)CC', 'CCC(=Cc1ccsc1)C(NCC1(OC)CC1)c1nnnn1C1CC1', 'CCC(=O)C1(C(=O)N(Cc2cccn2CC)CC(F)(F)C(N)=O)CC1', 'CCC(=O)C1(C(=O)N2CC3(C)CC2(C(=O)N(CC)CC2CC2)C3)CC1', 'CCC(=O)C1(C(=O)NC2CC=C(C(=O)N3CC(C(=O)OC)C3)C2)CC1', 'CCC(=O)C1(C(=O)NCC(C)=CC(=O)NCC(C)(O)C2(C)CC2)CC1', 'CCC(=O)CCC(=O)N1CCC(C)CC1C(=O)N1CC(OCCO)C1', 'CCC(=O)CCC(=O)N1CCOCC(C(=O)N(CC)CCC(N)=O)C1', 'CCC(=O)CCC(=O)NC12CCC(C(=O)N3CCOC4CC43)(CC1)C2', 'CCC(=O)CCC(=O)N[C@@H]1CC(C(=O)NCc2nn[nH]c2C)=C[C@@H]1O', 'CCC(=O)Cn1cc(CN[C@@H](CCO)c2cccc([N+](=O)[O-])c2)nn1', 'CCC(=O)N1CCCCC1C(C)NC(=O)Cc1cnn2ccccc12', 'CCC(=O)NC(C)C(=O)N(C)CCOCCC(=O)N1CCOC[C@H]1C', 'CCC(=O)NC(C)C(=O)N1C[C@@H](F)C[C@@H]1C(=O)N[C@@H](C)CSC(F)F', 'CCC(=O)NCC(=O)N1CCC=C(C(=O)N2CC3(CCC(=O)O3)C2)C1', 'CCC(=O)NCC(=O)N1CCN(C(=O)COc2ccsn2)C(CC)C1', 'CCC(=O)NCC(=O)N1CC[C@H](C(=O)N2CC(C(C)(C)O)C2)C[C@@H]1C', 'CCC(=O)NCC(=O)NC[C@@H]1C[C@@H](F)CN1C(=O)CCOC1CCC1', 'CCC(=O)NCC(C)C1(O)CCN(C(=O)c2c(C)ccc(N)c2C)C1', 'CCC(=O)Nc1ccc(O)c(C(=O)N2CC(c3ccc(O)cc3)C2)c1', 'CCC(C#N)C(=O)N(Cc1ncc(C)cc1F)CC1CCC(F)(F)C1', 'CCC(C#N)C(=O)N1Cc2cccc(CNC(=O)C(F)C(C)C)c2C1', 'CCC(C#N)C(=O)NC(C)(CSC)C(=O)Nc1cc(F)cc(CO)c1', 'CCC(C#N)CN(Cc1cn(C)nc1Br)Cc1cccc2ccnn12', 'CCC(C#N)CNC(=O)C1CCC(O)CN1C(=O)CCn1ccnn1', 'CCC(C#N)CNC(=O)CCC1CCCCN1C(=O)c1cc(Cl)cs1', 'CCC(C#N)CNC(=O)[C@H]1C[C@H](O)CN1C(=O)C[C@@H]1CCCC[C@H]1O', 'CCC(C#N)CNC(=O)c1ccc(CNC(=O)c2ccc(C)[nH]2)cc1', 'CCC(C(=O)N(C)CCN(C)C(=O)C1CCN(C2CC2)C1=O)C(C)C', 'CCC(C(=O)N(Cc1cc(C)ccc1O)CC(F)(F)C(C)C)N(C)C', 'CCC(C(=O)N1CC(C)(C)C[C@@H]1C(=O)Nc1cnccc1O)C(C)C', 'CCC(C(=O)N1CCC(CC(=O)NOCC(F)(F)F)C1)n1ccnc1', 'CCC(C(=O)N1CCC(c2cn(CC(F)(F)F)nn2)C1)n1cncn1', 'CCC(C(=O)N1CCCC[C@@H]1CN(C)C(=O)C(C)=C1CCC1)N(C)C', 'CCC(C(=O)N1CCOCCC1C(=O)N[C@@H]1C[C@@H](O)[C@@H](O)C1)N(C)C', 'CCC(C(=O)NC(C)(C)CCCC(=O)NCC1(C#N)CCC1)N(C)C', 'CCC(C(=O)NC(CNC(=O)C(C1CC1)C1CC1)C1CC1)C(F)(F)F', 'CCC(C(=O)NC1(C(=O)N(C)C2CC(C)C2)CCCC1)N(CC)CC', 'CCC(C(=O)NCC1(C)CCOC1)N(C)C(=O)c1coc2c1COC2', 'CCC(C(=O)NCC1(CN=[N+]=[N-])CC1)N(C)C(=O)C(C)OC(C)(C)C', 'CCC(C(=O)NCC1(O)CC(NC(=O)C2(O)CCC2)C1)n1ccnc1', 'CCC(C(=O)NCC1CCN1C(=O)c1cccc2nccn12)C(C)C', 'CCC(C(=O)NCCC1(O)CN(C(=O)c2cc[nH]c2)C1)n1cccn1', 'CCC(C(=O)NCCCCC(=O)N1CCC2CC1C(=O)N2C)C(C)C', 'CCC(C(=O)N[C@@H](CC(N)=O)C(=O)NC1CC(N2CCC2)C1)N(C)C', 'CCC(C(=O)N[C@@H]1CCCC[C@@H]1C(=O)NOCC(C)(C)O)C(F)(F)F', 'CCC(C(=O)N[C@H](CC)CC(=O)N1CC2CCC1CC2)n1ccnc1', 'CCC(C(=O)Nc1cc(Br)cc2[nH]ncc12)N1CCN(C(C)C)CC1', 'CCC(C(=O)OC(C)(C)C)C(=O)N1CC2(C1)C(=O)Nc1ccccc12', 'CCC(C(=O)OC(C)(C)C)N(C)C(=O)c1ccc(S(C)(=O)=O)cc1Cl', 'CCC(C(=O)OC)C(=O)N1CC(F)(CNC(=O)c2sccc2CO)C1', 'CCC(C(=O)OC)C(=O)N1C[C@@H]2C[C@@H]2[C@H]1C(=O)NCCCCN(C)C', 'CCC(C(C)C)C(C(=O)NC1COC1)N1CC2C3CCC(CC3)C2C1', 'CCC(C)(C#N)C(=O)N(C)C1CCN(C(=O)CN(C)C2CCC2)CC1', 'CCC(C)(C#N)C(=O)N1CC2CCC1CN2C(=O)COCC1CCC1', 'CCC(C)(C#N)C(=O)N1CCCC1C(=O)N1CC2(CN(C(C)=O)C2)C1', 'CCC(C)(C)C(=O)N1C[C@H]2C[C@@]2(C(=O)NC2(C3CCCOC3)CC2)C1', 'CCC(C)(C)C(=O)N1[C@H]2CC[C@@H]1[C@H](C(=O)NC[C@@H](C)N1CCCC1)C2', 'CCC(C)(C)C(=O)NC1CCC(CC(=O)Nc2cnc(F)nc2)CC1', 'CCC(C)(C)C(=O)N[C@@H]1CN(C(=O)C2=CC3(CCOCC3)C2)C[C@H]1O', 'CCC(C)(C)C(C)NC(=O)CCCC(C)(C)NC(=O)C1CCCN1C', 'CCC(C)(C)C(C)NC(=O)c1cn(CCNC(=O)c2ccon2)cn1', 'CCC(C)(C)C(O)C(=O)NC1CC(C)(C(=O)Nc2cccc(Cl)c2)C1', 'CCC(C)(C)C(O)C(=O)NC[C@H]1[C@@H](C(=O)NCC2[C@H](C)[C@H]2C)C1(C)C', 'CCC(C)(C)C(O)C(=O)N[C@@H]1CC[C@H]1CNC(=O)C(C1CC1)C1CC1', 'CCC(C)(C)CC(=O)N1C[C@@H](O)C[C@H]1C(=O)Nc1cnc(C)nc1C', 'CCC(C)(C)CC(=O)NCc1nc(C(=O)NCc2ccco2)c(C)o1', 'CCC(C)(C)CC(=O)N[C@H](C(=O)NOCc1ccc(F)cc1)C(C)C', 'CCC(C)(C)CCCC(=O)NCC1(O)CCN(C(=O)CC(C)(C)C)C1', 'CCC(C)(C)CCN(CC(O)c1cccs1)C(=O)Cc1ccccn1', 'CCC(C)(C)CCN(CCC1(C)CC1(F)F)C(=O)C1(O)CCOCC1', 'CCC(C)(C)CN(Cc1cc(COC)on1)C(=O)c1cnc(S)n1C', 'CCC(C)(C)CNC(=O)[C@H]1CN(C(=O)c2cc(O)cc(F)c2)CCO1', 'CCC(C)(C)CS(=O)(=O)NC[C@H]1CCCN(C(=O)c2sccc2C)C1', 'CCC(C)(C)N(C)C(C(=O)NCC(F)F)c1cc(-c2ccco2)on1', 'CCC(C)(C)NC(C)C(=O)NC1(CN(C)C(=O)Cc2ccno2)CC1', 'CCC(C)(C)OCC(=O)N1CC[C@@H](C(=O)NCCCC2CCCC2)C1', 'CCC(C)(C)OCC(=O)N1C[C@@H]2[C@H](C1)[C@H]2NC(=O)c1ccc(C)n1C', 'CCC(C)(C)OCC(=O)NC(CCOC)C(=O)N1CCCOC(C)C1', 'CCC(C)(C)OCC(=O)Nc1cccn(Cc2ccc(F)cc2)c1=O', 'CCC(C)(C)OCCNC(=O)C(C)(CO)NC(=O)[C@H]1C[C@H]2CC[C@@H]1O2', 'CCC(C)(C)n1nnnc1C(Nc1csnc1OC)c1cncn1C', 'CCC(C)(C)n1nnnc1C(c1cnco1)N1CCOC[C@@H]1COC', 'CCC(C)(C)n1nnnc1C1(NC2CCC2C)CCN(C(C)=O)CC1', 'CCC(C)(CC)C(=O)N1CCC2(CC(C(=O)N3CCC(C)(O)C3)C2)C1', 'CCC(C)(CC)C(=O)NCC1CCN(C(=O)CN2CCN(C)CC2)C1', 'CCC(C)(CC)C(=O)N[C@H]1CCCC[C@@H]1NC(=O)Cn1cnc(N)n1', 'CCC(C)(CC)NC(C)(CC(C)(C)OC)c1nnnn1C(C)(C)CC', 'CCC(C)(CCNC(=O)C=Cc1csc(C)n1)NC(=O)CNC(C)=O', 'CCC(C)(CCNC(=O)[C@H]1OCCO[C@H]1C)NC(=O)C(C)CC(F)F', 'CCC(C)(CCNC(=O)c1cc(OC)nn1C)NC(=O)C1CC1(F)F', 'CCC(C)(CCO)NC(=O)CCC1(C)CN(C(=O)C2CC(C)(C)C2)C1', 'CCC(C)(CN(C)C(=O)[C@H](O)CCNC(=O)C1CCOC1(C)C)OC', 'CCC(C)(CN(Cc1cnn(C)c1Cl)C(=O)Cc1csnn1)C(C)O', 'CCC(C)(CNC(=O)C1CCC(C)(C)OC1)NC(=O)[C@H]1C[C@H](SC)C1', 'CCC(C)(CNC(=O)C=Cc1cnccn1)NC(=O)CCNC(C)=O', 'CCC(C)(CNC(=O)CCC(N)=O)C(=O)N1CCC(OC(C)=O)CC1', 'CCC(C)(CNC(=O)CCCOC(C)=O)C(=O)N1CC(CO)C1(C)C', 'CCC(C)(CNC(=O)CN(CC1CC1)C(=O)c1ccc(=O)[nH]c1)OC', 'CCC(C)(CNC(=O)N[C@H]1CCC[C@]1(C)N(C)C)c1cccc(C)n1', 'CCC(C)(CNC(=O)[C@@H]1C[C@H]1C#N)C(=O)NCCc1nc(C)oc1C', 'CCC(C)(CNC(=O)c1ccc(CF)cc1)C(=O)N1CC(N=[N+]=[N-])C1', 'CCC(C)(CNC(=O)c1ccoc1C)C(=O)NCCc1c[nH]nc1O', 'CCC(C)(CNC(=O)c1cn(C2CC2)nn1)C(=O)N(C)C(C)C(F)F', 'CCC(C)(CNC(=O)c1cn[nH]c1C)C(=O)NCc1cncc(F)c1', 'CCC(C)(CNC(=O)c1occc1CNC(=O)C=C=C(C)C)C(N)=O', 'CCC(C)(CO)C(=O)N[C@H]1C[C@@H](C(=O)N2CC3(CCC(=O)NC3)C2)C1', 'CCC(C)(CO)CNC(=O)C1=CCN(C(=O)Cn2cccnc2=O)C1', 'CCC(C)(CO)CNC(=O)[C@@H]1CC2(CC2)CN1C(=O)c1ncccn1', 'CCC(C)(CO)CNC(=O)[C@H](CC(N)=O)NC(=O)C=C1CCOCC1', 'CCC(C)(COC)NC(=O)CC1CCCN(C(=O)C(O)CSC)CC1', 'CCC(C)(Cl)CNC(=O)C1(F)CCN(C(=O)C2(CO)CCCO2)CC1', 'CCC(C)(O)C(=O)N(CCCOC(=O)N(C)C)Cc1c(C)nsc1C', 'CCC(C)(O)CN(Cc1cc(F)ccc1C)Cc1c(F)cncc1Cl', 'CCC(C)(O)CNC(=O)CCC1CCN(C(=O)CCS(C)(=O)=O)CC1', 'CCC(C)(O)CNC(=O)COC(C)(C)CNC(=O)c1cccc(C)n1', 'CCC(C)(OC)C(=O)NCC(C)=CC(=O)NC1CC2(COCCO2)C1', 'CCC(C)/C=C/C(=O)N1CC(NC(=O)c2ncsc2C)C2CCCC21', 'CCC(C)/C=C/C(=O)NC1CN(C(=O)CCN2CCC2)CC(F)(F)C1', 'CCC(C)/C=C/C(=O)NCC(C)(C)NC(=O)[C@]12CCC[C@H]1CC(=O)C2', 'CCC(C)=C(C)C(=O)N1CC(CCNC(=O)CC2CC2(C)C)(OC)C1', 'CCC(C)=C(C)C(=O)NC(C)C(C)(C)C(=O)N(C)Cc1ncn(C)n1', 'CCC(C)=C(C)C(=O)NC/C=C/CC(=O)NCc1ncnn1C1CC1', 'CCC(C)=C(C)C(=O)NCCOCCN(C)C(=O)[C@]1(C)CCC(=O)N1', 'CCC(C)=C(C)C(=O)N[C@H](CC(=O)NC1(C)C(C)(C)C1(C)C)C(C)C', 'CCC(C)C(=O)C(=O)N1CCC(=CCNC(=O)[C@H]2C[C@H]2C(F)F)CC1', 'CCC(C)C(=O)C(=O)N1C[C@H](C)C[C@H]1C(=O)NCc1nnc(C)n1C', 'CCC(C)C(=O)C(=O)NC(C)(C)C(C)CC(=O)NCC(C)(C)C(N)=O', 'CCC(C)C(=O)N(CCC1SCCS1)Cc1ccc2nc(C)nn2c1', 'CCC(C)C(=O)N(CCCOCC(F)F)Cc1ccc2[nH]cnc2c1', 'CCC(C)C(=O)N1CCC(C(=O)NCc2cc(C3CC3)no2)C12CC2', 'CCC(C)C(=O)N1CCC(C)(C(=O)NC(CC)c2ncccn2)CC1', 'CCC(C)C(=O)NC(C(=O)N[C@@H]1CCCN(C)C1)C1(O)CCCCC1', 'CCC(C)C(=O)NC1CC12CCN(C(=O)c1cc(C)n(C(C)C)c1)C2', 'CCC(C)C(=O)NCC(=O)N1CCC12CN(C(=O)c1conc1C)C2', 'CCC(C)C(=O)NCC(=O)NCC(C)CC(=O)N1CCn2ccnc21', 'CCC(C)C(=O)NCC(=O)N[C@H]1C[C@](C)(NC(=O)c2cc(C)cs2)C1', 'CCC(C)C(=O)NCCCCCCN(C)C(=O)C1=CC2CCC(C1)C2', 'CCC(C)C(=O)NCc1cc(C(=O)N2CCC[C@H]2C(=O)NC)ccn1', 'CCC(C)C(=O)Nc1cccc(CNC(=O)NC2(CSC)CCC2)c1', 'CCC(C)C(C(=O)N1CC[C@H]2CC[C@H]21)N(C)C(=O)c1ccccc1F', 'CCC(C)C(C(=O)NCC1(Cl)CCC1)N(C)C(=O)c1cn(C)cc1C', 'CCC(C)C(C)C(=O)NCC(C)=CC(=O)N(C)c1cccc(OC)c1', 'CCC(C)C(C)C(=O)NCc1cncc(C(=O)N(C)[C@H](C)CCO)c1', 'CCC(C)C(C)C(=O)N[C@H]1C[C@@H](C(=O)N2CC(c3cccnc3)C2)C1', 'CCC(C)C(CN(Cc1cc(SC)nn1C)C(=O)C1CC1(F)Cl)OC', 'CCC(C)C(NC(=O)N(C)C(CC)CSC)c1nc2ccccc2[nH]1', 'CCC(C)C(O)C(=O)N(Cc1ccn(C)c1)CC1C2CCC(F)(F)C21', 'CCC(C)C(O)C(C)C(=O)N1CCN(C(=O)Cn2nnc(N)n2)CC1', 'CCC(C)C(O)C(C)C(=O)N[C@H]1COCC[C@H]1C(=O)N[C@H]1CC1(C)C', 'CCC(C)C(O)CC(=O)N1CCOC(C(=O)N[C@H](C)CS(N)(=O)=O)C1', 'CCC(C)C(O)CC(=O)N[C@H]1COCC[C@H]1C(=O)NOCCC(F)F', 'CCC(C)C(O)CN(Cc1cncs1)Cc1cnc2cc(Cl)ccn12', 'CCC(C)C(O)CNC(=O)C1(NC(=O)c2nn(C)cc2C)CCCC1', 'CCC(C)C1CN(C(=O)CN(C(=O)C2COCC2C(N)=O)C(C)C)C1', 'CCC(C)C1CN(C(=O)c2occc2CNC(=O)Cc2ccsc2)C1', 'CCC(C)C=CC(=O)N1C[C@H](C)C[C@H](C(=O)NCc2nnc(C)s2)C1', 'CCC(C)C=CC(=O)N1C[C@H](C)[C@@H]1C(=O)NCC12CC(C)(CCO1)C2', 'CCC(C)C=CC(=O)N1C[C@H](OC)C[C@@H]1C(=O)NCC1CCOC1=O', 'CCC(C)C=CC(=O)N[C@@H]1C[C@H](C(=O)N[C@@H]2CC[C@H](CO)C2)C[C@H]1O', 'CCC(C)CC(=O)C(=O)N1CC(NC(=O)C2(F)CCOC2)C2(CC2)C1', 'CCC(C)CC(=O)C(=O)N1C[C@@H](F)C[C@@H]1C(=O)NC1(C(=O)OC)CC1', 'CCC(C)CC(=O)C(=O)NC1CC(C)(C(=O)N[C@@H]2C=C[C@H](CO)C2)C1', 'CCC(C)CC(=O)N(C)CC(C)(C)NC(=O)c1onc2ccccc12', 'CCC(C)CC(=O)N1CC(C(OC)C(=O)N2C[C@@H](O)C[C@H]2COC)C1', 'CCC(C)CC(=O)N[C@]1(C(=O)NC23CC4CC(CC2C4)C3)C[C@H](O)C1', 'CCC(C)CC(CO)NC(=O)NCc1noc(-c2ccccc2)c1C', 'CCC(C)CC(NC(=O)[C@H]1CNC(=O)C1)C(=O)NC[C@H](C)C(=O)OC', 'CCC(C)CCC(=O)N1CC2(C)CC1(C(=O)N(C)C1CCCC1C)C2', 'CCC(C)CCC(=O)N1CC[C@H](Nc2ncc(Br)c(O)n2)[C@H](CO)C1', 'CCC(C)CCC(=O)NC(C)(CNC(=O)c1c[nH]c(=O)o1)CC(C)C', 'CCC(C)CCC(=O)NCC(C)(CO)NC(=O)c1ccc(F)c(C)c1', 'CCC(C)CCC(=O)NCC(CC(=O)N(C)C12CC(C1)C2)C1CCC1', 'CCC(C)CCC(=O)N[C@@H](C(=O)N(C)CC(F)(F)COC)C(C)(C)C', 'CCC(C)CCC(=O)N[C@H]1C=C[C@@H](C(=O)NCC2(CN=[N+]=[N-])CC2)C1', 'CCC(C)CCCC(=O)N1CCC(C)(C(=O)NCc2c[nH]cn2)CC1', 'CCC(C)CCCC(=O)N1CCC(OCCNC(=O)C2(C)COC2)C1', 'CCC(C)CCCC(=O)N1CCN(C(=O)CC2CSCCO2)C(C)C1', 'CCC(C)CCCC(=O)N1C[C@H]2CCN(C(=O)C3(O)COC3)C[C@H]2C1', 'CCC(C)CCCCC(=O)N1CC(NC(=O)CCc2ccccn2)C1', 'CCC(C)CCCCC(=O)N1CC2CC1(C(=O)N[C@H](CC)C(C)C)C2', 'CCC(C)CCCCC(=O)N1C[C@H]2C[C@@H](NC(=O)C3(CF)CC3)[C@@H]1C2', 'CCC(C)CCCCC(=O)NCC1(NC(=O)C=C(C)C)CCOCC1', 'CCC(C)CCN(Cc1ccc(OC)nn1)C[C@H]1C[C@@H]1c1ccsc1', 'CCC(C)CCNC(=O)C(NC(=O)c1ccc(C)c(O)n1)C(C)(C)C', 'CCC(C)CCNC(=O)C1=CCC2CCC1N2C(=O)c1ccc(C)[nH]1', 'CCC(C)CN(C)C(=O)CNC(=O)CNC(=O)c1n[nH]c2c1CCC2', 'CCC(C)CNC(=O)CC1=CCN(C(=O)C=Cc2ccccc2)CC1', 'CCC(C)CNC(=O)CC1CC(C)(C)CN1C(=O)c1cn(C)c(C)n1', 'CCC(C)CNc1nc(N2CC3CCC(C2)N3CC)nc2c1CCC2', 'CCC(C)CNc1nc(NCCS(N)(=O)=O)nc2ccc(OC)cc12', 'CCC(C)Cn1cc(C(C)(C)NC(=O)C2CCCC(C)(C)CC2)nn1', 'CCC(C)Cn1cc(CNC(=O)c2ccccc2-c2ncn[nH]2)nn1', 'CCC(C)N(C)C(=O)COC1(C)CN(C(=O)CCc2ccnn2C)C1', 'CCC(C)N(C)C(C(=O)NC(CC(C)C)C(=O)OC)c1cccnn1', 'CCC(C)N1CCN(C(=O)Nc2cc3cn(C)nc3cc2OC)CC1', 'CCC(C)NC(=O)C(OC(=O)c1ncc(C(F)(F)F)cc1Cl)C(C)C', 'CCC(C)NC(=O)C([C@H]1C[C@H]2C=C[C@@H]1CC2)N(C)CC1CCCCO1', 'CCC(C)NC(=O)C(c1ccc(F)cn1)N(CC)Cc1cnn(C)c1', 'CCC(C)NC(=O)C(c1cccc(OC)n1)N1C2C=CCC1CCC2', 'CCC(C)NC(=O)C1CCN(C(=O)c2ccc3c(Br)n[nH]c3n2)CC1', 'CCC(C)NC(=O)C1c2c[nH]nc2CN1C(=O)C[C@H]1CCC(=O)[C@@H]1C', 'CCC(C)Nc1nc([C@@H](C)NC(=O)c2cc3[nH]ncc3cc2Cl)cs1', 'CCC(C)OCC(=O)NC1CC(CNC(=O)c2cc(F)ccc2N)C1', 'CCC(C)OCC(=O)NCC1CCN(C(=O)C(C)(C)C(C)(F)F)CC1', 'CCC(C)Oc1cc(CNS(=O)(=O)c2cc(C(=O)O)n(C)n2)ccn1', 'CCC(C)Oc1ccc(CNC(=O)N2CCC(O)C(CO)CC2)cc1', 'CCC(C)S(=O)(=O)N(C)CCC(NC(=O)C#CC1(OC)CC1)C(C)C', 'CCC(C)c1ccc(CNC(=O)c2cn(Cc3cccs3)nn2)cc1', 'CCC(C)c1ccc(S(=O)(=O)N(C)CCOc2ccccc2F)cc1', 'CCC(C)n1cc(CN(CC(C)(C)C(C)O)C(=O)C2CCCO2)cn1', 'CCC(C)n1ncc2c(C(=O)N(C)Cc3nnc(C)s3)cc(C)nc21', 'CCC(C)n1nccc1S(=O)(=O)Nc1ccc2nc(C)c(C)nc2c1', 'CCC(C1CC1)N(C)C(=O)CN(CC1CC1)C(=O)[C@H](C)OC(C)(C)C', 'CCC(CC(=O)N(C)CC(O)CNC(=O)c1ccccn1)C1CCC1', 'CCC(CC(=O)N(CC)C1CCN(C(=O)C2CC(=O)C2C)CC1)OC', 'CCC(CC(=O)N1CC(O)(CNC(=O)CC(C)(C)CC)C1)C(C)(C)C', 'CCC(CC(=O)N1CCCC1/C=C/C(=O)N1CCCCCO1)C(C)C', 'CCC(CC(=O)N1C[C@H](F)C[C@H]1C(=O)NCc1cn(C)nc1C)SC', 'CCC(CC(=O)N1C[C@H](N=[N+]=[N-])[C@H](NC(=O)Cc2ccco2)C1)OC', 'CCC(CC(=O)N1[C@@H]2C[C@@H](C[C@H]2O)[C@@H]1C(=O)NC1(CF)CC1)C(F)F', 'CCC(CC(=O)NC(C(=O)NOC1CCC1)C1CCOC1)CC(C)C', 'CCC(CC(=O)NCC(C)(C)CC(=O)N1CCCC(F)C1)C(C)(C)C', 'CCC(CC(=O)NCC(C)(F)CNC(=O)C1CCSCC1)C(C)(C)C', 'CCC(CC(=O)NCC1(C)CCN(C(=O)C(C)(C)CC(C)C)C1)OC', 'CCC(CC(=O)NCC1(CC(=O)NCC(C)(C)C(C)(C)C)CC1)SC', 'CCC(CC(=O)NCC1CCN(C(=O)C2CN(C(N)=O)C2)C1)C(C)C', 'CCC(CC(C)C)C(=O)N1CCC1C(=O)N(C)Cc1cc(C)n(C)n1', 'CCC(CC(C)C)C(=O)N1CCC2(CC1)CC2NC(=O)C(O)CSC', 'CCC(CC(C)C)C(=O)NCC(O)C(=O)N(C)CC12CCC(CC1)C2', 'CCC(CC(F)(F)F)NC(=O)C[C@H](CC)N(C)C(=O)C1CC(C)(F)C1', 'CCC(CC)(C(=O)NC[C@H](C)C(=O)N1CC[C@H](OC)[C@H](F)C1)C(C)C', 'CCC(CC)(CC#N)C(=O)N1C2CCC1CN(Cc1ccccc1)C2', 'CCC(CC)(CC)C(=O)N1CC(c2cn(-c3ccccc3C)nn2)C1', 'CCC(CC)(CC)C(=O)NC1CCCN(C(=O)C(F)n2ccnc2)C1', 'CCC(CC)(CC)CN(Cc1csc(C)n1)C(=O)c1csc(CO)n1', 'CCC(CC)(CC)CNC(=O)[C@H]1C[C@@H](OC)CN1C(=O)[C@H](C)C1CC1', 'CCC(CC)(CN(CC1CC(C)CC(C)C1)C(=O)c1cnco1)OC', 'CCC(CC)(CNC(=O)C1COCCC1(F)F)NC(=O)[C@H](O)C(C)C', 'CCC(CC)(CNC(=O)Cn1ccnc1)C(=O)NCCc1cn[nH]c1', 'CCC(CC)(CNC(=O)NCCc1nnc(-c2ccccc2)o1)OC', 'CCC(CC)(CNC(=O)[C@H]1[C@@H]2CCCC[C@@H]21)NC(=O)c1cncn1C', 'CCC(CC)(CNC(=O)c1cc(C)c(C)nn1)NC(=O)C1CC1(C)C', 'CCC(CC)(NC(=O)C1CCCC(NC(=O)[C@H]2C[C@H]2C)CC1)C(N)=O', 'CCC(CC)(OC)C(=O)N1CCC=C(C(=O)NCc2snnc2C)C1', 'CCC(CC)C(=O)N1CC(=O)NCC1C(=O)N1CCC2(C1)CC2(F)F', 'CCC(CC)C(=O)N1CC(C)(C)CC1C(=O)N1CCSC2(CCC2)C1', 'CCC(CC)C(=O)N1CCOCC1CC(=O)N[C@H](C)CC(C)(C)CO', 'CCC(CC)C(=O)N1CCOCC1CNC(=O)c1cnc(C2CC2)o1', 'CCC(CC)C(=O)NC(CCC(C)C)C(=O)NCc1oc(C)nc1C', 'CCC(CC)C(=O)NCC(=O)NCC1(NC(=O)Cc2cnc[nH]2)CC1', 'CCC(CC)C(=O)NCC(C)(O)CNC(=O)c1cc2cccnn2n1', 'CCC(CC)C(=O)NCC1(OC)CCN(C(=O)[C@@H]2C[C@H](F)C(=O)N2)C1', 'CCC(CC)C(=O)NCCCN1CCN(C(=O)c2cc(Cl)[nH]n2)CC1', 'CCC(CC)C(=O)NNS(=O)(=O)CCOC(C)(C#N)c1ccccc1', 'CCC(CC)C(C(=O)Nc1ccn(CC(C)(C)C)n1)N1CCOCC1', 'CCC(CC)C(C)C(=O)N1CC(NC(=O)C2CCC2)CC12CCCC2', 'CCC(CC)C(C)C(=O)NC(CC(C)(C)C)C(=O)N1CC(C)(OC)C1', 'CCC(CC)C(C)C(=O)NCCC(C)NC(=O)C1CC2(CC(C)C2)C1', 'CCC(CC)C(C)NC(=O)C[C@H]1C[C@@H](NC(=O)C(F)n2ccnc2)C1', 'CCC(CC)C(C)NC(=O)[C@H]1CC[C@@H](C)N(C(=O)CS(=O)(=O)CC)C1', 'CCC(CC)C(CCNC(=O)N[C@H]1C[C@H](c2ccc(Cl)cc2)C1)OC', 'CCC(CC)C(F)C(=O)N(C)C(C)C(=O)NC1CN(C)CCN(C)C1', 'CCC(CC)C(F)C(=O)N1C(C(=O)N(C)CC(C)(C)O)CCC12CC2', 'CCC(CC)C(F)C(=O)N1CCCC[C@@H]1CNC(=O)c1n[nH]nc1C', 'CCC(CC)C(F)C(=O)N1CC[C@H](O)C[C@@H]1C(=O)NC1CC(CO)C1', 'CCC(CC)C(F)CN(Cc1ccnn1C)C(=O)c1ccc(Cl)cn1', 'CCC(CC)C(OC)C(=O)N1CSC[C@H]1C(=O)Nn1nnc(C)c1C', 'CCC(CC)C(OC)C(=O)N1C[C@@H]2[C@H](C1)[C@H]2NC(=O)C(C)=CC1CC1', 'CCC(CC)C(OC)C(=O)N[C@H](C)C(=O)NCc1ccc(F)nc1F', 'CCC(CC)C1CN(C(=O)C2CCCN2C(=O)C2(C)CCNC2=O)C1', 'CCC(CC)CC(=O)N(C)C1CCCN(C(=O)C=CCN(C)CC)C1', 'CCC(CC)CC(=O)N1CC(C(O)C(=O)NC(CC)c2ncc[nH]2)C1', 'CCC(CC)CC(=O)NC1CC2(C1)CN(C(=O)CCc1cnco1)C2', 'CCC(CC)CCC(=O)NCC1(NC(=O)c2ccc(C)c(C)n2)CC1', 'CCC(CC)CCC(=O)NCc1ncc(C(=O)N(C)C[C@@H](C)O)cn1', 'CCC(CC)CCC(=O)N[C@H]1[C@@H](C(=O)NCC2C3CCCC32)C1(C)C', 'CCC(CC)CCCN(Cc1ccsc1C)C(=O)CC1OCCCO1', 'CCC(CC)CCCN(Cc1nnc(C(C)C)s1)C(=O)c1cc[nH]c1', 'CCC(CC)CN(C(=O)[C@H]1CCCCN1C(=O)[C@H](O)C(C)C)C1CC1', 'CCC(CC)CN1CCN(Cc2cccc3c2S(=O)(=O)CCC3)CC1', 'CCC(CC)CNC(=O)C12CC(CO)(CN1C(=O)[C@H](O)C1CCC1)C2', 'CCC(CC)CNC(=O)C1=CCCN(C(=O)C2(CCN=[N+]=[N-])CC2)C1', 'CCC(CC)CNC(=O)[C@H]1[C@@H]2CN(C(=O)c3c[nH]c(C)cc3=O)C[C@@H]21', 'CCC(CC)N(C)C(=O)[C@H]1OCC[C@H]1NC(=O)CCc1nnc(N)[nH]1', 'CCC(CC)N1CCC(CN(C)Cc2ccc(C(=O)NC)cc2)CC1', 'CCC(CC)N1CCC(CN2CCN(c3ccnc(Cl)n3)CC2)CC1', 'CCC(CC)OCC(=O)N[C@H](CC(=O)N1CC2CC1(CO)C2)C1CC1', 'CCC(CC)OCCN(Cc1cnn(C)c1C)C(=O)c1scnc1Cl', 'CCC(CC)OCCNC(=O)C1C(C)CN1C(=O)CCc1nccs1', 'CCC(CC)ONC(=O)C(F)C1(O)CN(C(=O)C(CC2CC2)OC)C1', 'CCC(CC)S(=O)(=O)N[C@H]1CN(C(=O)c2ccc(C3CC3)s2)C[C@@H]1O', 'CCC(CCC(=O)N1CC2(CC(OC)C2)C1)NC(=O)c1ccn(C)n1', 'CCC(CCC(=O)N1CCOC(CCO)C1)NC(=O)[C@@H](O)CC(C)C', 'CCC(CCC(=O)NC1(CC)CC(C)(C)C1)NC(=O)C1=CCCCC1', 'CCC(CCC(=O)NCC(C)C1CCC1)NC(=O)c1nccn1CC', 'CCC(CCC(=O)NCCC1(CO)CC1)NC(=O)c1cnn(C)c1N', 'CCC(CCC(=O)N[C@H](C)CCCC(=O)N1CCCNC(=O)C1)OC', 'CCC(CCC(=O)N[C@H]1CCC[C@H]1OC)NC(=O)c1ccc(CO)o1', 'CCC(CCC(=O)N[C@H]1CCN(C(=O)C(F)C2CCC2)[C@@H](C)C1)OC', 'CCC(CCC(=O)N[C@H]1CC[C@H](O)CC1)NC(=O)CCc1csnn1', 'CCC(CCC(=O)O)NC(=O)c1ccc(Oc2ccc(Cl)cc2)cc1', 'CCC(CCCC(=O)N1CC(N(C)CC)C1)NC(=O)c1ccc(C)o1', 'CCC(CCCC(=O)NC1CN(C)CCC1O)NC(=O)c1nccs1', 'CCC(CCO)CN(CC1CCCN(C(C)=O)C1)C(=O)C(C)(C)SC', 'CCC(CCO)CN(Cc1cnc2c(c1)CCC2)C(=O)C1CC1(Cl)Cl', 'CCC(CCOC)C(=O)N(Cc1cscn1)CC1(F)CCCCCC1', 'CCC(CCOC)C(=O)NC(C)(C)CC(=O)NCc1cccc(C)c1', 'CCC(CCOC)NC(=O)C/C=C/CNC(=O)C1=CC2CCC(C1)C2', 'CCC(CN(C)C(=O)C1CC(C)(F)C1)NC(=O)CCc1conc1C', 'CCC(CN(C)C(=O)C1CC(SC)C1)NC(=O)c1cc(CO)ccn1', 'CCC(CN(C)C(=O)COc1ccc(C)cc1)NC(=O)CCCC#N', 'CCC(CN(C)C(=O)c1cc(CNC(=O)C2(C)CC2(F)F)n[nH]1)OC', 'CCC(CN(C)C(=O)c1ccc(C)nn1)NC(=O)c1ccc(Cl)cn1', 'CCC(CN(C)C)C(=O)N1[C@H](CNC(=O)C2=CCN(C)C2)C[C@@H]2C[C@@H]21', 'CCC(CN(C)C)C(=O)NC(CC(=O)N[C@H]1C[C@H](O)[C@H]1O)C(F)(F)F', 'CCC(CN(C)C)C(=O)NC[C@H](C)NC(=O)c1ccc(F)c(C)c1N', 'CCC(CN(CC)C(=O)c1ccc(C(=O)O)cc1Cl)c1ccccc1', 'CCC(CN(CC1=CCSC1)C(=O)c1cncc(NC)n1)C(C)(F)F', 'CCC(CN(CC1CCC(C(C)C)CC1)C(=O)C1CC1Cl)(OC)OC', 'CCC(CN(CC1CCC2(CCC2)O1)C(=O)C1CC=CC1)(OC)OC', 'CCC(CN(CC1CCS(=O)(=O)CC1)C(=O)CNC(N)=O)(OC)OC', 'CCC(CN(CCC1(C)CCCO1)C(=O)c1ccc(C#N)s1)C(C)C', 'CCC(CN(CCc1cccc(C)c1)C(=O)C12CSCC1C2)C(C)C', 'CCC(CN(Cc1cc(C(F)F)on1)C(=O)C1(Cl)CC1(F)F)C(C)C', 'CCC(CN(Cc1cc(OC(C)C)ns1)CC1CCN(C)CC1)OC', 'CCC(CN(Cc1nc(C)c(C)s1)C(=O)C(C)(C)CC#N)(OC)OC', 'CCC(CN(Cc1ncc(Cl)n1C)CC1(OC(C)C)CCC1)C(C)C', 'CCC(CN1CCCC(C(=O)OCc2ccccc2)C1)CC(F)(F)F', 'CCC(CNC(=O)/C=C/C(C)(C)C)N(C)C(=O)C1CCCCC1OC', 'CCC(CNC(=O)C(C)Cc1ccncc1)NC(=O)C1(CO)CCC1', 'CCC(CNC(=O)C(C)OC(=O)c1ncccc1N)c1ccccc1', 'CCC(CNC(=O)C(CC)OC)NC(=O)c1ccc2nccnc2n1', 'CCC(CNC(=O)C(O)C(F)(F)F)NC(=O)c1cc2c(ccn2C)[nH]1', 'CCC(CNC(=O)C1(C2CC2)CN(C(=O)c2cnccn2)C1)N(C)C', 'CCC(CNC(=O)C1=CC(C)C1)N(C)C(=O)C=Cc1c(C)coc1C', 'CCC(CNC(=O)C1CCCN1C)N(C)C(=O)CC1OCCC1(C)C', 'CCC(CNC(=O)C1CCCOCC1)Oc1cccc(C(F)(F)F)c1', 'CCC(CNC(=O)C1CCS(=O)CC1)NC(=O)c1coc(COC)n1', 'CCC(CNC(=O)CC1(C)CC(F)(F)C1)NC(=O)CC1CC(C)=NO1', 'CCC(CNC(=O)CCn1cnccc1=O)NC(=O)CC(C)(C)CC', 'CCC(CNC(=O)[C@@H]1CN(C(=O)[C@H]2CC[C@H]2C)C[C@@H](C)O1)C(C)(F)F', 'CCC(CNC(=O)[C@H]1[C@H]2C[C@H]2CN1C(=O)C(C)CN(C)C)CC(C)C', 'CCC(CNC(=O)c1cccc2c1OCC2)NC(=O)CC1CCOC1', 'CCC(CNC(=O)c1cccnc1OC)NC(=O)c1ccc(C#N)[nH]1', 'CCC(CNC(=O)c1nocc1C)N(C)C(=O)[C@@H]1CC2(CC2)CN1C', 'CCC(CO)(OC)C(=O)NC[C@@H](C)NC(=O)CN1CCN(C)C(=O)C1', 'CCC(CO)(OC)C(=O)Nc1ccc(Oc2ncc(Cl)cc2Cl)cc1', 'CCC(CO)CCNC(=O)[C@H]1CCN(C(=O)C(CN(C)C)N(C)C)C1', 'CCC(CO)CNC(=O)CC1(CNC(=O)[C@@]2(C)C[C@H]3CC[C@@H]2O3)CC1', 'CCC(CO)N(CCn1nc2ccccn2c1=O)Cc1cnn(C)c1', 'CCC(COC(=O)CCCNC(=O)c1ccc(F)cc1F)C(C)(F)F', 'CCC(COC)C(=O)N(C)[C@@H](CC(C)C)C(=O)N1CC(O)(COC)C1', 'CCC(COC)C(=O)N(Cc1ccccc1O)Cc1ccccc1Cl', 'CCC(COC)C(=O)NCC1CC2(C1)CN(C(=O)CCC1CCC1)C2', 'CCC(COC)C(=O)NC[C@@H]1CCCN(C(=O)C(F)CCC(C)C)C1', 'CCC(COC)NC(=O)C1CN(C(=O)C2CN(C(C)=O)C2)C(C)(C)C1', 'CCC(CSC)NC(=O)[C@H](NC(=O)c1cc(C(C)=O)c[nH]1)C(C)(C)C', 'CCC(Cc1ccc(C)cc1)NC(=O)NCC12CC(CO)(C1)C(C)O2', 'CCC(F)(CC)CN(Cc1csnc1C)C(=O)C1CCC1(OC)OC', 'CCC(F)(CC)CN(Cc1nc(C)c(C)nc1C)C(=O)[C@@H]1CCOC1', 'CCC(F)(F)C(=O)N[C@H]1C[C@H](F)CN(C(=O)CCC2(C)CC2(F)F)C1', 'CCC(F)(F)C1(C(=O)N(CCC2(O)CCC2)Cc2csc(C)c2)CC1', 'CCC(F)(F)C1(C(=O)NCC2(Cn3cc(C4(C)CC4)nn3)CC2)CC1', 'CCC(F)(F)CC(=O)N(C)CC(C)C(=O)N1CCC[C@H]1CCN(C)C', 'CCC(F)(F)CC(=O)N(Cc1cc(C)c(C)s1)CC1C2CCOCC21', 'CCC(F)(F)CC(=O)N[C@@H](CNC(=O)c1cc(OC)ccn1)C(C)C', 'CCC(F)(F)CC(=O)N[C@@H]1CCC[C@@H]1NC(=O)C1CN2CCC1CC2', 'CCC(F)(F)CCNC(=O)C1=CCN(C(=O)CC2COCCOC2)C1', 'CCC(NC(=O)/C=C/C(C)NC(=O)c1ccsc1Cl)C1CCOCC1', 'CCC(NC(=O)C(=O)N1CCC[C@H]2COC[C@H]21)c1ccc(OC)cc1', 'CCC(NC(=O)C(=O)Nc1ccc(C)c(C)c1Cl)c1cccc(Cl)c1', 'CCC(NC(=O)C(C)(CSC)NC(=O)c1cncc(O)c1)C(C)(F)F', 'CCC(NC(=O)C(C)CN(C)C(=O)c1cc(CO)n(C)n1)C1CCC1', 'CCC(NC(=O)C(O)CCC(C)C)C(=O)N1CC[C@H](NC(=O)OC)C1', 'CCC(NC(=O)C1(C)CN(C(=O)C[C@@H]2C[C@H]2CC)C1)c1ncccn1', 'CCC(NC(=O)C1(CCNC(=O)CCc2cccn2C)CC1)C(C)O', 'CCC(NC(=O)C1(Cc2cccc(Cl)c2)CC1)c1noc(C2CC2)n1', 'CCC(NC(=O)C1=NN(C)C(=O)CC1)C(=O)NCCC(C)C(=O)OC', 'CCC(NC(=O)C1CCN(C(=O)C2CCOCC2)C1)c1ccncc1', 'CCC(NC(=O)CC(C)(C)NC(=O)Cc1cccnc1)C1CCCO1', 'CCC(NC(=O)CCC1CCCO1)C(=O)N[C@@H]1C=C[C@H](C(=O)OC)C1', 'CCC(NC(=O)C[C@H](CC)N(C)C(=O)C1=CCCOCC1)C1CCC1', 'CCC(NC(=O)C[C@H](NC(=O)[C@@H]1COCCO1)C(C)C)c1nnn[nH]1', 'CCC(NC(=O)N1CC(O)(c2nnn[nH]2)C1)C(C)(C)c1ccccc1', 'CCC(NC(=O)NC(CO)CCC(C)C)c1cnc2ccccc2c1', 'CCC(NC(=O)NCC1CC(CO)CO1)C12CC3CC(CC(C3)C1)C2', 'CCC(NC(=O)NCCS(=O)(=O)N(C)C)c1ccc2c(c1)OCCO2', 'CCC(NC(=O)NCc1cccnc1-n1ccnc1C)c1c[nH]nn1', 'CCC(NC(=O)Nc1cncc(C(=O)OC)c1C)c1ccc(C)cc1', 'CCC(NC(=O)[C@@H]1CCC[C@@H](NC(=O)CCCOC(C)=O)C1)C(C)C', 'CCC(NC(=O)[C@H]1C[C@@H](CNC(=O)C(OC)OC)C1)C1CCCOC1', 'CCC(NC(=O)c1cc2c(Cl)ccc(C)c2[nH]1)C(=O)N1CCCCC1', 'CCC(NC(=O)c1ccc(C(N)=O)o1)C(=O)N1CC[C@@H](C(F)(F)F)C1', 'CCC(NC(=O)c1cnn2c(C(F)(F)F)cc(C)nc12)c1nccs1', 'CCC(NC(CC)c1cccc(OC)n1)c1ccc(OC)c(OC)c1', 'CCC(NCCn1cnnc1)(c1nnnn1C1CCC1)C1CCCC1', 'CCC(O)(CC)CCNC(=O)C[C@H]1C[C@H](NC(=O)C2CCCCO2)C1', 'CCC(O)C(=O)NCCC1(NC(=O)CC2(n3ccnc3)CC2)CCC1', 'CCC(O)C(C)(C)C(=O)N[C@@H]1CCC[C@@H]1NC(=O)[C@@H]1CCC[C@H](O)C1', 'CCC(O)C(F)(F)C(=O)N[C@@H](C)Cn1cc(-c2ccc(C)nn2)nn1', 'CCC(O)C1CCCCN1C(=O)Nc1cc(-c2cccc(Cl)c2)on1', 'CCC(O)CC(=O)N(Cc1cn(C(C)(C)C)nn1)Cc1ccc(Cl)s1', 'CCC(O)CCN(Cc1cc(C)c(Cl)cn1)C(=O)C(=O)N=S(C)(C)=O', 'CCC(O)CCN(Cc1ccncc1Cl)Cc1cnc(C(C)C)n1C', 'CCC(O)CCNS(=O)(=O)c1ccc(NCCc2ccsc2)c(Cl)c1', 'CCC(O)CN(CC)C(=O)CC1CC(NC(=O)C(=O)NCC(F)F)C1', 'CCC(O)CN(CC)C(=O)C[C@H]1C[C@H](NC(=O)c2cnn(C)c2C)C1', 'CCC(O)CNC(=O)/C=C/CC1(NC(=O)C2CCOC2(C)C)CCC1', 'CCC(O)CNC(=O)C1(CCNC(=O)C2CC23CCCC3)CCCC1', 'CCC(O)CNC(=O)C1CN(C(=O)[C@H]2CCC[C@@H](O)C2)CCC1(C)C', 'CCC(O)Cn1cc(C2CN(C(=O)COC3CCC(C)CC3)C2)nn1', 'CCC(O)[C@H]1CCCN1C(=O)NCc1ccc(-c2cnccn2)cc1', 'CCC(OC)C(=O)N(Cc1cc(Cl)ccc1O)CC(C)c1ccsc1', 'CCC(OC)C(=O)N1C[C@H](C(=O)NC[C@H](C)S(N)(=O)=O)[C@@H](C2CC2)C1', 'CCC(OC)C(=O)N1C[C@H](CO)[C@H](NC(=O)CCN2CCOCC2)C1', 'CCC(OC)C(=O)NC1(CCC(=O)N[C@H]2C[C@@H](CSC)C2)CCCC1', 'CCC(OC)C(=O)NCC1(NC(=O)c2[nH]ccc2C)CCCCCC1', 'CCC(OC)C(=O)NCc1cc(C)c(C(=O)NCCc2ncn[nH]2)o1', 'CCC(OC)C(=O)N[C@@H]1COC[C@H]1CNC(=O)c1ccnn1C(F)F', 'CCC(OCCN1CCn2c(CN=[N+]=[N-])nnc2C1)c1ccccc1', 'CCC(SC)C(=O)N1C[C@H](CC)[C@@H](C(=O)NCCN(C)CC(F)F)C1', 'CCC(SC)C(=O)NC(CC(F)F)C(=O)NCc1cccc(C)c1O', 'CCC(SC)C(=O)N[C@H]1C[C@H](CCNC(=O)c2cc(C(N)=O)c[nH]2)C1', 'CCC(c1ccncc1)N(CC)C(=O)[C@@H]1Cc2ccccc2CN1C', 'CCC1(C#CC(=O)N(CCC(=O)NCC[C@@H](O)CO)C(C)C)COC1', 'CCC1(C#CC(=O)N2C[C@@H]3[C@H](C2)[C@H]3C(=O)N(C)C23CC(C2)C3)COC1', 'CCC1(C#CC(=O)NC(C)CCC(=O)NCc2ncnn2C)COC1', 'CCC1(C(=O)N(C)CC(F)F)CCN(C(=O)C2CCC(O)CN2C)C1', 'CCC1(C(=O)N(C)CCC(=O)NCC(O)c2ccncc2)CCCC1', 'CCC1(C(=O)N(C)CCC(C)NC(=O)C#CC(C)(C)C)CC(F)(F)C1', 'CCC1(C(=O)N(C)CCCO)CCCN(C(=O)c2cnc(N)cn2)C1', 'CCC1(C(=O)N(C)C[Si](C)(C)C)CCN(C(=O)c2[nH]cc(C)c2C)C1', 'CCC1(C(=O)N(CCC2(C)CC2)Cc2ncccc2F)CC(F)(F)C1', 'CCC1(C(=O)N(CCCC2CC2)Cc2cc(COC)cs2)CCCO1', 'CCC1(C(=O)N(CCCc2nccs2)Cc2cc(OC)ccn2)CC1', 'CCC1(C(=O)N2C3CC2CN(C(=O)c2c[nH]c(C4CC4)n2)C3)CCC1', 'CCC1(C(=O)N2CC(CC(N)=O)C2)CCN(C(=O)CC(C)(C)C#N)C1', 'CCC1(C(=O)N2CC3CCC3(CC(=O)NCCC3CC3C)C2)CCC1', 'CCC1(C(=O)N2CC=CC(C(=O)Nc3ccc(C)nc3O)C2)COC1', 'CCC1(C(=O)N2CCC(C)C3(CCC3)C2)CN(C(=O)C2=CCCC2)C1', 'CCC1(C(=O)N2CCC3(CCCCC3)C2)CCN(C(=O)[C@@H]2C[C@@H]2F)C1', 'CCC1(C(=O)N2CCCC(C(C)C(=O)NCC(N)=O)C2)CCCC1O', 'CCC1(C(=O)N2CCCC(C(C)C(=O)NC[Si](C)(C)C)C2)CCOC1', 'CCC1(C(=O)N2CCCC2CNC(=O)c2cc(N)nc(Cl)n2)CCC1', 'CCC1(C(=O)N2CCCCC(C)(C)C2)CN(C(=O)Cc2ccco2)C1', 'CCC1(C(=O)N2CCOC(CC(=O)NCc3c(C)coc3C)C2)CC1', 'CCC1(C(=O)N2CCOCC(CNC(=O)CCCCCOC)C2)CC1', 'CCC1(C(=O)N2CCO[C@@H](C)C2)CCN(C(=O)C2CN3CCC2C3)C1', 'CCC1(C(=O)N2CC[C@@H](CNC(=O)c3nscc3C)C2)CCNC1=O', 'CCC1(C(=O)N2C[C@H]3CC[C@H]3C2)CN(C(=O)c2c[nH]c(C#N)c2C)C1', 'CCC1(C(=O)NC(C)/C=C/C(=O)NCCN2CCC(C)(C)C2)CCC1', 'CCC1(C(=O)NC(C)C(C)COC)CN(C(=O)c2cc(C)n(C)n2)C1', 'CCC1(C(=O)NC(C)C2CCN(C(=O)[C@H]3CC3(F)F)CC2)CCCO1', 'CCC1(C(=O)NC(C)CC2CC2)CN(C(=O)c2ccncc2NC)C1', 'CCC1(C(=O)NC(CC(=O)N[C@H]2CC2(C)C)CC(C)C)CNC(=O)C1', 'CCC1(C(=O)NC/C=C(\\C)C(=O)N2CC(C3CCCCC3)C2)CCC1', 'CCC1(C(=O)NC2CC[C@H]3CC[C@@H]23)CCCN(C(=O)C2CCC2C)C1', 'CCC1(C(=O)NC2CN(C(=O)c3cc4ccccc4[nH]3)C2)CCCC1', 'CCC1(C(=O)NCC(=O)NCC(=O)NC(C)Cc2nccn2C)CC1', 'CCC1(C(=O)NCC(=O)OCC2CC2)CN(C(=O)c2cncn2C)C1', 'CCC1(C(=O)NCC(O)CN(C)C(=O)c2ccc3occc3c2)CC1', 'CCC1(C(=O)NCC2CC(O)(CNC(=O)c3ccc(SC)o3)C2)CC1', 'CCC1(C(=O)NCCC2CCCN2C)CN(C(=O)C(C)CN(C)C)C1', 'CCC1(C(=O)NCCCN(C)C)CCCN(C(=O)c2n[nH]cc2C)C1', 'CCC1(C(=O)NC[C@H](O)C(=O)N2CC(COC)C2(C)C)CC(C)(C)C1', 'CCC1(C(=O)NC[Si](C)(C)C)CCN(C(=O)c2csc(C#N)c2)CC1', 'CCC1(C(=O)NCc2cc(C(=O)NCC3[C@H](C)[C@H]3C)on2)CCOC1', 'CCC1(C(=O)NCc2cc(C(=O)NC[C@H](C)OC)[nH]n2)CCCCC1', 'CCC1(C(=O)NCc2ccoc2C(=O)NCc2ccc(CO)o2)CC1', 'CCC1(C(=O)N[C@@H](C)CCC(=O)N2CCSCC2CO)CNC(=O)C1', 'CCC1(C(=O)N[C@@H](C)CCNC(=O)C2=NOC3(CCC3)C2)CCCC1', 'CCC1(C(=O)N[C@@H](C)Cn2cc(COC3CCOC3)nn2)CCCO1', 'CCC1(C(=O)N[C@@H](CO)CN(C)C)CCN(C(=O)CCCC2CC2)C1', 'CCC1(C(=O)N[C@H](CC(=O)NC2(C)CN(C(=O)OC)C2)C2CC2)CC1', 'CCC1(C(=O)N[C@H]2[C@@H]3CN(C(=O)C(C)=C4CCCC4)CC[C@@H]32)CCC1', 'CCC1(C)C=C(C(=O)N2CC=CC2C(=O)N(C)CC(OC)C(C)C)C1', 'CCC1(C)C=C(C(=O)N2C[C@H](Nc3ccnc(SC)n3)[C@@H](SC)C2)C1', 'CCC1(C)C=C(C(=O)NC/C=C/CC(=O)Nc2cnccc2CO)C1', 'CCC1(C)C=C(C(=O)NCCCCC(=O)NCc2cccc(O)c2)C1', 'CCC1(C)C=C(C(=O)N[C@H]2CCN(C(=O)CCc3nccs3)[C@H]2C)C1', 'CCC1(C)CC(C(=O)N(C)[C@@H](C)C(=O)N[C@@H]2CCCC[C@H]2N(C)C)C1', 'CCC1(C)CC(C(=O)N2CCC[C@H]2C(=O)NCCN2CC[C@H](O)C2)C1', 'CCC1(C)CC(C(=O)N2CC[C@H](O)C[C@@H]2C(=O)NCC2(O)CCC2)C1', 'CCC1(C)CC(C(=O)NCC(C)CC(=O)N2CC3(CC3)C[C@H]2CO)C1', 'CCC1(C)CC(Nc2cc(C)nc(NCC3CCCN3C(C)=O)n2)C1', 'CCC1(C)CC(Nc2nc(NCc3ncc[nH]3)nc3c2COCC3)C1', 'CCC1(C)CC1C(=O)NC1(CCNC(=O)c2cnccc2C)CCC1', 'CCC1(C)CC1C(=O)NC1C2C3C[C@H]1[C@@H](C(=O)N[C@H]1CCC[C@@H]1F)C32', 'CCC1(C)CCN(C(=O)C[C@H](CC2CC2)NC(=O)c2cccn2C)C1', 'CCC1(C)CN(C(=O)C(O)C2CN(C(=O)[C@H]3CC[C@@H](N(C)C)C3)C2)C1', 'CCC1(CC(=O)N2CC(CC)(C(=O)NC[C@@H](C)S(N)(=O)=O)C2)CCC1', 'CCC1(CC(=O)NC(C)CCN(C)C(=O)COCC(C)(C)C)CCC1', 'CCC1(CC(=O)NCC(C)NC(=O)c2ccc(C(C)O)cc2)CCC1', 'CCC1(CC(=O)N[C@H]2CN(C(=O)Cn3cncn3)C[C@@H]2SC)CCC1', 'CCC1(CC(=O)N[C@H]2C[C@@H](N(C)C(=O)C#CC3CCCC3)C2)CCC1', 'CCC1(CC)CC(C(=O)N2CC[C@H](C(=O)NC[C@]3(O)C[C@@H](O)C3)C2)C1', 'CCC1(CC)CC(C(=O)N2[C@H]3CC[C@H](C3)[C@H]2C(=O)N[C@H]2C[C@H](F)C2)C1', 'CCC1(CC)CC(C(=O)N[C@H]2CC=CC[C@H]2C(=O)NCCC(C)O)C1', 'CCC1(CC)CCCN(C(=O)Nc2ccc3c(c2)N(C(N)=O)CC3)C1', 'CCC1(CC)CCCN1C(=O)C(=O)Nc1cccc(-c2cccs2)c1', 'CCC1(CC)CCN(C(=O)Nc2ccc(C)c(N3CCNC3=O)c2)C1', 'CCC1(CC)CCN1C(=O)C1CCN(C(=O)C[C@@H]2CCC[C@H](C)O2)C1', 'CCC1(CC)CN(C(=O)C(CNC(=O)c2ccnnc2)C(C)(C)C)C1', 'CCC1(CC)CN(C(=O)NC(C)c2ccc3c(c2)OCO3)CC(C)O1', 'CCC1(CCC(=O)N[C@H](CCc2ccccc2)C(=O)O)CCC(=O)N1', 'CCC1(CCc2ccccc2)CCCN1S(=O)(=O)C1(Cl)CC12CCC2', 'CCC1(CN(Cc2c(F)cccc2OC)C(=O)C2(Cl)CC2)CCCC1', 'CCC1(CN(Cc2c[nH]c(C#N)c2)C(=O)C(F)C(C)(F)F)CCCO1', 'CCC1(CNC(=O)C2(C)C=CCN2C(=O)CC(C)COC)CCCC1', 'CCC1(CNC(=O)C2(CN3CCCCCC3)CCCC2)CCCCC1', 'CCC1(CNC(=O)C2CC(C)N2C(=O)Cc2cnn(C)c2C)CCC1', 'CCC1(CNC(=O)N2CC(n3cc(C(=O)OC)nn3)C2)CCC(=O)N1', 'CCC1(CNC(=O)[C@@H]2CCN2C(=O)Cc2cc(C)no2)CCCCO1', 'CCC1(CNC(=O)[C@@H]2C[C@@H](O)CN2C(=O)C2=NO[C@H]3COC[C@@H]23)CC1', 'CCC1(CNc2cc(NC(C)CN3CCCCC3)ncn2)CCCC1', 'CCC1(CNc2ccc(S(=O)(=O)NC3CN(C(C)=O)C3)cn2)CCC1', 'CCC1(CNc2nc(NCC(C)(C)OC)nc3c(C)nn(C)c23)CC1', 'CCC1(CNc2nccc(NCCCN3CCOCC3)n2)CCOC1', 'CCC1(CO)CN(C(=O)CCCCCCNC(=O)c2cccn2C)C1', 'CCC1(CO)CN(C(=O)c2cn[nH]c2CCNC(=O)C2CS(=O)C2)C1', 'CCC1(Cn2cc(C(=O)NC3(CO)CCCC(C)(C)C3)nn2)COC1', 'CCC1(F)CN(C(=O)[C@@H]2CCCN2NC(=O)C2(C)CCC(=O)CC2)C1', 'CCC1(N(C)C(=O)c2oc(CNC(=O)c3nonc3N)cc2C)CC1', 'CCC1(NC(=O)C(CCC(C)C)NC(=O)[C@@H](C)NC(C)=O)CCCC1', 'CCC1(NC(=O)C(CCOC)NC(=O)c2cnccc2C)CCOC1', 'CCC1(NC(=O)C2(C(C)C)CCN(C(=O)c3nnn(C)c3N)C2)CC1', 'CCC1(NC(=O)C2=CCCC2)CN(C(=O)[C@H]2C[C@@H]2c2ccccn2)C1', 'CCC1(NC(=O)C2CCC(C)=C(C)C2)CN(C(=O)/C=C/C(C)(C)C)C1', 'CCC1(NC(=O)CC(C)(C)NC(=O)[C@@H]2C[C@H]3C[C@@H]2CC3=O)CCOC1', 'CCC1(NC(=O)CC2(OC)CCC2)CN(C(=O)C2CCCN(C)C2)C1', 'CCC1(NC(=O)C[C@@H](O)CNC(=O)[C@H]2C[C@H]3CC(=O)[C@@H]2C3)CCCC1', 'CCC1(NC(=O)C[C@H]2CCC(=O)[C@@H]2C)CN(C(=O)C2CCC(=O)N2)C1', 'CCC1(NC(=O)C[C@H]2CCC[C@@H]2NC(=O)c2ccncc2)CCCC1', 'CCC1(NC(=O)[C@@H]2CC2(F)F)CN(C(=O)C2CCn3nnnc3C2)C1', 'CCC1(NC(=O)[C@@H]2CC[C@H](CNC(=O)c3c(C)ncnc3C)O2)CC1', 'CCC1(NC(=O)[C@H]2C[C@H]3C=C[C@@H]2CC3)CN(C(=O)CNC(=O)OC)C1', 'CCC1(NC(=O)[C@]23CO[C@H](C2)[C@H](NC(=O)CC2(COC)CC2)C3)CC1', 'CCC1(NC(=O)c2cc(OC)cnc2F)CN(C(=O)OC(C)(C)C)C1', 'CCC1(NC(=O)c2ccnn2C)CN(C(=O)C2OCCN(C)C2=O)C1', 'CCC1(O)CCN(C(=O)C(CCOC)NC(=O)[C@H]2CCC[C@H]2O)CC1', 'CCC1(O)CCN(C(=O)C(CNC(=O)CCCOC)CC2CC2)CC1', 'CCC1(O)CCN(C(=O)CC[C@H](NC(=O)c2csnc2C)C(C)C)C1', 'CCC1(O)CCN(C(=O)[C@@H]2COCCN2C(=O)[C@H]2CC=CCC2)CC1', 'CCC1(OC)CN(C(=O)[C@H]2C[C@H](O)CN2C(=O)CO[C@@H]2CCOC2)C1', 'CCC1(c2ccc(OC)cc2)NC(=O)N(Cc2ccc(Cl)nc2)C1=O', 'CCC1(c2ccccc2)CCN(C(=O)c2c(Cl)ccc3cn[nH]c23)C1', 'CCC1=C(C(=O)N2CC(c3ocnc3CO)C2)Cc2ccccc2O1', 'CCC1=C(CC)C=C2CC(CC2=C1)NC[C@H](O)C1=C2C=CC(=O)NC2=C(O)C=C1', 'CCC1=NOC(C(=O)N(Cc2coc(C)n2)Cc2csc(CC)n2)C1', 'CCC1=NOC(C(=O)N[C@]2(C)C[C@H](C(=O)N3CCC[C@H]3CSC)C2)C1', 'CCC1=NOC(CC(=O)N(Cc2c(O)cccc2F)CC(C)SC)C1', 'CCC1C(C(=O)N(C)C2CCN(C)C2)CCN1C(=O)c1ccoc1C', 'CCC1C(C(=O)N(Cc2ccnn2C)CC(C)(O)C(C)C)CC1(F)F', 'CCC1C(C(=O)NOCC2(C)CC2)CCN1C(=O)CC1=CCCCC1', 'CCC1C(NC(=O)[C@H](O)C(C)C)CCCN1C(=O)CC(C)C(C)(C)C', 'CCC1CC(C(=O)N(C)CC(C)(C)NC(=O)c2ncc(F)cc2F)C1', 'CCC1CC(C(=O)N2CCC=C(C(=O)NCC3(CC)CC3)C2)CCO1', 'CCC1CC(C(=O)NCc2ocnc2C(=O)N2CCC(F)(C#N)C2)C1', 'CCC1CC(C(=O)N[C@@H](CN=[N+]=[N-])C(=O)NC2CCN3CCC2C3)C1', 'CCC1CC(C)CN1C(=O)CC1CCN(C(=O)c2ccc(SC)o2)C1', 'CCC1CC(C)CN1C(=O)[C@@H]1CN(C(=O)c2ccnc(C)n2)C[C@H]1C', 'CCC1CC(CC(=O)N[C@H]2CCOC[C@H]2NC(=O)c2cn[nH]c2C)C1', 'CCC1CC(CN(Cc2ncc(C)cc2Cl)C(=O)[C@H]2C[C@@H](OC)C2)C1', 'CCC1CC(CNC(=O)CC[C@H]2C[C@@H](NC(=O)c3csc(N)n3)C2)C1', 'CCC1CC(CNC(=O)[C@H]2C[C@@](C)(NC(=O)c3cn(CC)cn3)C2)C1', 'CCC1CC(NC(=O)C2(NC(=O)C3CC(C)(C)CO3)CCCC2C)C1', 'CCC1CC(NC(=O)[C@@H]2C[C@H](C)CCN2C(=O)COC2CCCC2)C1', 'CCC1CC(O)CN1C(=O)C[C@H]1C[C@H]1CNC(=O)C(O)C1CCCC1', 'CCC1CC2CCC(C1)N2C(=O)[C@H](NC(=O)CSC(F)F)C(C)(C)O', 'CCC1CCC(CN(CC2(C(C)(F)F)CC2)C(=O)C(O)CSC)CC1', 'CCC1CCC(CN(CC[C@H]2CC[C@@H]2OC)C(=O)c2nccs2)CC1', 'CCC1CCC(CNc2cc(N3CCN(C)C(=O)C3)nc(C)n2)CC1', 'CCC1CCC1CCN(Cc1csc(C)c1)C(=O)c1ncncc1Cl', 'CCC1CCCC(CNC(=O)C(=O)NCc2cc(C3CC3)n(C)n2)C1', 'CCC1CCCC1C(=O)N1CC2CCC(CNC(=O)CN(C)C)(C2)C1', 'CCC1CCCC1NC(=O)Nc1cccc(CS(=O)(=O)C(C)(C)C)c1', 'CCC1CCCCC1CN(CC(OC)C(C)(C)C)C(=O)C1=CCCO1', 'CCC1CCCCN1C(=O)C(=O)N[C@@H](C[C@@H]1CCNC1=O)C(=O)OC', 'CCC1CCCN(C(=O)C(CCSC)NC(=O)C2C[C@H]3CC[C@H]3C2)C1', 'CCC1CCCN(C(=O)CCCCCNC(=O)C(OC)C(C)C)CC1', 'CCC1CCCN(C(=O)C[C@H](NC(=O)CS(=O)(=O)CC)C2CC2)CC1', 'CCC1CCCN(C(C(=O)Nc2ccccc2Cl)c2[nH]cnc2C)C1', 'CCC1CCCN(C(C)(C)CNC(=O)Nc2ccc3nnnn3c2)C1', 'CCC1CCN(C(=O)C(C)n2ccnn2)C1C(=O)NCc1cncs1', 'CCC1CCN(C(=O)NCCOc2cnc3[nH]ccc3c2)C(CC)C1', 'CCC1CCN(C(=O)[C@H]2C[C@H](O)CN2C(=O)c2ccc(COC)o2)C1', 'CCC1CCN(C(=O)c2ncsc2NC)C1C(=O)NCCOC(N)=O', 'CCC1CCOCCN1C(=O)C1(NC(=O)COCC(=O)OC)CCC1', 'CCC1CCc2sc(C(=O)NCCc3cc(Cl)ccc3OC)cc2C1', 'CCC1CN(C(=O)C2=CCC(NC(=O)c3cnccn3)C2)CCN1C', 'CCC1CN(C(=O)CCN(C(=O)c2cccnc2C)C(C)C)CCS1', 'CCC1CN(C(=O)[C@@H]2CCC[C@H](NC(=O)C3(C(C)=O)CC3)C2)CCS1', 'CCC1CN(C(=O)c2cc(F)ccc2C(C)C)CC1N1CCOCC1', 'CCC1CN(C(=O)c2ccc(OC)cc2C2CC2)c2cccnc2N1', 'CCC1CN(C(=O)c2cocc2C)CCN1C(=O)c1ccnc(C)n1', 'CCC1CN(C(=O)c2oc(CNC(=O)C3C(C)(C)C3(C)C)nc2C)C1', 'CCC1CN(C(C(=O)NC2CC2)c2n[nH]c3c2CCCC3)CC(=O)N1', 'CCC1CN(C)CCCN1C(=O)C(CNC(=O)[C@H]1CC1(C)C)N(C)C', 'CCC1CN(C)CCN1C(=O)CC(O)CNC(=O)C(C)=CC(C)(C)C', 'CCC1CNC(=O)CN1C(=O)CCN(C(=O)[C@H](O)C(C)(C)C)C(C)C', 'CCC1COC(C)(C)CN1C(=O)C1(CCNC(=O)C(C)(C)OC)CC1', 'CCC1OCCC1C(=O)N(CC1COC(C)C1)C[C@@H]1COC(C)(C)O1', 'CCC1OCCC1C(=O)N1CC2CC(C(=O)Nn3cnnc3C)(C2)C1', 'CCC1c2ccccc2CCN1CCC(=O)Nc1ccccc1SC', 'CCC1c2cccn2CCN1C(=O)NCc1cc(C(=O)OC)c(C)o1', 'CCC=C(C)C(=O)N1C(CC(=O)NC2(CCO)CCC2)[C@H]2CCC[C@H]21', 'CCC=C(C)C(=O)N1CCCC(CC(=O)N(C)C[C@@H]2COC(=O)N2)C1', 'CCC=C(C)C(=O)N1C[C@H]2CCC[C@@]2(C(=O)NC(C(N)=O)C2CC2)C1', 'CCC=C(C)C(=O)N1C[C@H]2COC[C@@]2(C(=O)NCC(C)(O)C2CC2)C1', 'CCC=C(C)C(=O)NC(C(=O)N(C)CC1(C)CCC1)c1ccnn1C', 'CCC=C(C)C(=O)NCc1nc(C(=O)N2CC(C)(C)C23CCC3)co1', 'CCC=C(CCC)C(=O)N(C)CC1(CNC(=O)CC2CCCO2)CC1', 'CCC=C(CCC)C(=O)N[C@H](C(=O)NC1CC(C(F)(F)F)C1)C(C)C', 'CCC=C(F)C(=O)N(CCC)C(C)C(=O)NC(C)c1nccc(=O)[nH]1', 'CCC=C(F)C(=O)N(CCC1(COC)CC1)Cc1ccc(F)c(C)n1', 'CCC=C(F)C(=O)N1CCCCC1CCC(=O)N1CC(S(N)(=O)=O)C1', 'CCC=C(F)C(=O)N1CCN(C(=O)CC2(C#N)CC2)CC1C1CCC1', 'CCC=C(F)C(=O)NC1C=CCN(C(=O)CCCOC(=O)C(C)C)C1', 'CCC=C(F)C(=O)NC[C@@H]1CC2(CC2)CN1C(=O)CC(C)CC(C)C', 'CCC=C(F)C(=O)N[C@H]1CC[C@H](CC(=O)NCC2CCCN(C)C2)C1', 'CCC=CC(=O)N1CC(COC)(C(=O)NCC(C)CC2CCCC2)C1', 'CCC=CC(=O)N1C[C@H]2N(C(=O)c3cc(=O)[nH]c(C)n3)CC[C@@]2(C)C1', 'CCC=CC(=O)NC[C@]1(C)CCCN1C(=O)c1ncccc1COC', 'CCC=CC=CC(=O)N1CC(CCNC(=O)Cc2ccncc2Cl)C1', 'CCC=CC=CC(=O)N1CC2CC(C(=O)NCCC(C)(C)CO)(C2)C1', 'CCC=CC=CC(=O)NC(C)CC1CN(C(=O)c2ccc(C)n2C)C1', 'CCC=CC=CC(=O)NCC[C@H](C)NC(=O)c1cnn(C(C)C)c1C', 'CCC=CC=CC(=O)N[C@H](CC(=O)N1CCC2(CCCO2)C1)C1CC1', 'CCCC#CC(C)(C)NC(=O)C(NC(=O)C(CC)C(F)(F)F)C(C)C', 'CCCC(=CC(=O)N(C)CCCCN(C)C(=O)C#CC(C)C)CCC', 'CCCC(=CC(=O)N(Cc1cc(Cl)n(C)n1)CC(F)C(C)C)CCC', 'CCCC(=CC(=O)NC1(CNC(=O)c2cc(CC)n[nH]2)CC1)CCC', 'CCCC(=O)N1CC(n2cc(CNC(=O)c3[nH]nc(C)c3O)nn2)C1', 'CCCC(=O)N1CC2(CC(CC(=O)N3CC4CCCCC4C3C)C2)C1', 'CCCC(=O)N1CC=C(C(C)(C)C(=O)N(CC)Cc2cccnc2)C1', 'CCCC(=O)N1CCC(O)(CCNC(=O)c2oc(CC)cc2C)CC1', 'CCCC(=O)N1C[C@@H]2CCCN(C(=O)c3cccc4c3CCC4)[C@@H]2C1', 'CCCC(=O)NC1CCCN(CC(=O)NS(=O)(=O)c2cccnc2)C1', 'CCCC(=O)NC1CN(C(=O)c2ccc(N(C)C)nc2)C2(CCC2)C1', 'CCCC(=O)NCC(=O)NC(C(=O)NC[C@]1(F)C[C@@H](CO)C1)C(C)C', 'CCCC(=O)NCCC1(OC)CN(C(=O)CCCc2ccccc2)C1', 'CCCC(=O)NCc1nc(C)c(C(=O)N(C)CCc2cnn(C)c2)o1', 'CCCC(=O)N[C@H]1CCN(C(=O)C2CC2(COC)COC)[C@@H]1C(C)C', 'CCCC(=O)N[C@H]1CN(C(=O)c2n[nH]c3cnccc23)C[C@H]1CCC', 'CCCC(=O)c1cc(NC(=O)c2ccc(C#N)c(OC)c2)ccc1F', 'CCCC(=O)c1cccc(NC(=O)c2ccc(CCC(=O)O)cn2)c1', 'CCCC(C#N)C(=O)N(C)CCCCNC(=O)c1c(CO)n[nH]c1C', 'CCCC(C#N)C(=O)N(CCNC(=O)C1(CC2CCC2)CC1)C1CC1', 'CCCC(C#N)C(=O)N1CC(C2(NC(=O)CC3(N(C)C)CC3)CC2)C1', 'CCCC(C#N)C(=O)N1CCCC(CC(=O)NCCNC(N)=O)CC1', 'CCCC(C#N)C(=O)N1CCCC[C@@H]1C(=O)N1CCCC(O)(CC)C1', 'CCCC(C#N)C(=O)N1CCC[C@@]1(C)CNC(=O)c1csc(C)c1C', 'CCCC(C(=O)NC(C)(C)CN(C)C(=O)c1nnsc1SC)N(C)C', 'CCCC(C(=O)NC1CN(C(=O)c2onc3c2CCCC3)C1)N(C)C', 'CCCC(C(=O)NCC1(NC(=O)C2CC2(C)C)CCCCC1)C(C)C', 'CCCC(C(=O)N[C@H]1CC[C@@H](C(=O)NCC2C=CCCC2)C1)N(C)C', 'CCCC(C)(C)C(=O)N1CC(CNC(=O)C=Cc2ccccc2F)C1', 'CCCC(C)(C)C(=O)NC[C@H]1CCC[C@H]1C(=O)N1CC[C@H](O)[C@H](O)C1', 'CCCC(C)(C)C(=O)NCc1ccc(C(=O)N[C@@H](CC)C(F)(F)F)s1', 'CCCC(C)(C)CC(=O)N(CC)CC(=O)Nc1cccc(C(C)C)c1', 'CCCC(C)(C)CC(=O)NC1(CC(=O)NCC2CCCC23CC3)CC1', 'CCCC(C)(C)CC(=O)NC1CC=C(C(=O)N[C@H]2C[C@@H]2[C@@H]2C[C@H]2C)C1', 'CCCC(C)(C)CN(Cc1c(C)nn(C)c1Cl)C(=O)c1scnc1C', 'CCCC(C)(C)CN(Cc1cc(Cl)cs1)C(=O)[C@@H]1CC(=O)CC(=O)N1', 'CCCC(C)(C)CNC(=O)[C@H]1C[C@@](C)(NC(=O)C2CC(F)(CF)C2)C1', 'CCCC(C)(CO)NC(=O)CNS(=O)(=O)c1ccc2ccccc2c1', 'CCCC(C)(CO)NC(=O)c1n[nH]c2c1CN(C(=O)C1CCOC1)C2', 'CCCC(C)(O)C(=O)N(CCC(O)(CC)CC)CC1CCCC(C)C1', 'CCCC(C)(O)C(=O)N1CCCC(O)(CNC(=O)C[C@H]2CC[C@H]2C)C1', 'CCCC(C)(O)C(=O)NCC1(Cn2cc(CC(O)C3CC3)nn2)CC1', 'CCCC(C)(O)C(=O)NC[C@H]1CC[C@@H](C(=O)Nn2ccccc2=O)O1', 'CCCC(C)(O)C(=O)N[C@H]1COCC[C@H]1C(=O)N[C@H]1CCCNC1=O', 'CCCC(C)(O)CC(=O)NCC(CC)(CC)C(=O)N1CCC1C(C)C', 'CCCC(C)(O)CNC(=O)C[C@H]1C[C@H](NC(=O)CCC(C)(C)C#N)C1', 'CCCC(C)=CC(=O)N1C[C@H](OC)[C@@H](C(=O)N2CC3CCCC2C3)C1', 'CCCC(C)=CC(=O)NC1CN(C(=O)c2ccon2)CC2(CCC2)C1', 'CCCC(C)=CC(=O)NCC(CNC(=O)c1c[nH]c(C#N)c1C)OC', 'CCCC(C)C(=O)N1CCCC[C@H]1CCC(=O)NC1(CO)CC(C)C1', 'CCCC(C)C(=O)N1CCN(C(=O)c2cnn(C(C)C)n2)C[C@H]1CO', 'CCCC(C)C(=O)N1CC[C@@H](CNC(=O)c2cc3n(n2)CCCO3)C1', 'CCCC(C)C(=O)NCC(CCC)C(=O)Nc1cccc(OC)c1C', 'CCCC(C)C(=O)NCCCN(C(=O)c1ccc(CC)cn1)C(C)C', 'CCCC(C)C(C)NC(=O)c1cc(CNC(=O)CCC2(C)CC2)n[nH]1', 'CCCC(C)C(O)C(=O)N(Cc1cscc1Cl)Cc1ncc(C)n1C', 'CCCC(C)CC(=O)N1C[C@@H](CNc2c([N+](=O)[O-])cnn2C)[C@@H](O)C1', 'CCCC(C)CC(=O)NCC(C)(C)CNC(=O)C(O)c1cnn(C)c1', 'CCCC(C)CN(C)c1nc(N)nc(NCCC23CC(CCO2)C3)n1', 'CCCC(C)CN(CCOc1ccc(Cl)cn1)Cc1ccc[nH]c1=O', 'CCCC(C)CN(CC[C@@H]1C[C@H]2CC[C@@H]1O2)C(=O)[C@@H](C)COC(C)=O', 'CCCC(C)CN(Cc1cnc(C)cn1)Cc1ncc(C(F)(F)F)[nH]1', 'CCCC(C)CNc1ccnc(NCc2cc3nc(Cl)ccc3o2)n1', 'CCCC(C)NC(=O)C1CC=CCN1C(=O)c1ccc2cc[nH]c2c1', 'CCCC(C)NC(=O)[C@@H]1C[C@H](C)CN(C(=O)C(C)(O)CCN(C)C)C1', 'CCCC(C)NC(=O)[C@H]1C[C@H](N=[N+]=[N-])CN1C(=O)Cc1ccsc1C', 'CCCC(C)Nc1nc2c(c(NC3Cc4cscc4C3)n1)COCC2', 'CCCC(C)S(=O)(=O)N[C@H]1CC[C@H](CNC(=O)C2CCOCC2)CC1', 'CCCC(C)S(=O)(=O)N[C@H]1C[C@H]2CC[C@@H](C1)N2C(=O)c1ccc(F)s1', 'CCCC(CC(C)C)C(=O)NCC1(C(=O)NCC2CNC(=O)C2)CC1', 'CCCC(CC)C(=O)N1CC(O)(C(F)C(=O)N(CC)C(C)C2CC2)C1', 'CCCC(CC)C(=O)N1CSC[C@H]1C(=O)NCC1C2CCCCCC21', 'CCCC(CC)CCC(=O)NC1CC12CC(NC(=O)C#CC(C)C)C2', 'CCCC(CC)NC(=O)/C=C/C1CCCN1C(=O)[C@@H]1C[C@H]1OC(C)=O', 'CCCC(CC)NC(=O)[C@@]12C[C@@H]1CN(C(=O)c1cnc(C3CC3)o1)C2', 'CCCC(CCC)C(=O)N1CCO[C@H](C(=O)N(C2CCC2)C2CC2)C1', 'CCCC(CCC)C(=O)N1C[C@H](CC)[C@@H](C(=O)N2CCC=C(C)C2)C1', 'CCCC(CCC)C(=O)NC[C@H](O)C(=O)NCc1cc(C)[nH]c(=O)c1', 'CCCC(CCC)CC(=O)N(C)[C@@H](C)C(=O)Nc1cc(Cl)cnc1O', 'CCCC(CCC)CN(Cc1ccn(C)n1)C(=O)c1cnc(NC)s1', 'CCCC(CCC)CNC(=O)C1CC2(CCN(C(=O)CSCC)C2)C1', 'CCCC(CCC)NC(=O)c1ccc(CNC(=O)C(C#N)CC)cc1', 'CCCC(CCCS(C)(=O)=O)C(=O)NCc1ccccc1C1CCC1', 'CCCC(CCO)CN(Cc1ncc(C)cc1F)Cc1scnc1C', 'CCCC(CCO)NC(=O)C1(C)CN(C(=O)CN2CCCCCC2)C1', 'CCCC(CCO)NC(=O)c1sccc1S(=O)(=O)NCc1ccco1', 'CCCC(CN(CC(C)(CC)C(C)(C)O)C(=O)[C@@H]1CCC(=O)O1)OC', 'CCCC(CN(CC(C)COC)C(=O)C1CC1(Cl)Cl)c1ccccc1', 'CCCC(CN(C[C@@H](O)c1ccccc1)C(=O)c1cnsc1C)OC', 'CCCC(CNC(=O)C(C)(OC)C1CC1)C(=O)NCc1nc(C)n[nH]1', 'CCCC(CNC(=O)C1(CC)CCCO1)NC(=O)c1c[nH]cc1CC', 'CCCC(CNC(=O)C1CCC(=O)O1)C(=O)N[C@H](CCC)C(=O)OC', 'CCCC(CNC(=O)C1COCCC1(F)F)NC(=O)c1ocnc1C', 'CCCC(CNC(=O)CC(C)CC)C(=O)NCC1(O)CCCCCC1', 'CCCC(CNC(=O)Cc1cc(C)cs1)C(=O)N[C@@H]1COCC[C@H]1O', 'CCCC(CNC(=O)Cc1nocc1C)NC(=O)C=Cc1cc[nH]n1', 'CCCC(CNC(=O)Cn1ccc(C)n1)C(=O)N(CC(C)C)C1CC1', 'CCCC(CNC(=O)[C@H]1[C@@H]2COCC[C@@H]21)C(=O)NCC(=O)OC(C)C', 'CCCC(CNC(=O)c1cc(C)n[nH]c1=O)NC(=O)c1ccc(C)o1', 'CCCC(CNC(=O)c1cc(CC)oc1C)NC(=O)c1cn[nH]c1C', 'CCCC(CNC(=O)c1ccns1)C(=O)NCc1nn(C)c(=O)n1C', 'CCCC(CNC(=O)c1ncoc1CC)NC(=O)c1cc(CC)n[nH]1', 'CCCC(CNc1nc(NCC2=CCCC2)c2ncn(C)c2n1)OC', 'CCCC(Cc1ccccc1)NC(=O)c1cn([C@H]2COC[C@H]2N)nn1', 'CCCC(F)C(=O)N1CCCC1CCC(=O)Nc1ccc(CO)nc1', 'CCCC(F)C(=O)N1Cc2n[nH]cc2C1C(=O)NCCc1cncs1', 'CCCC(F)C(=O)N1[C@H](C(=O)NCC(O)C(F)(F)F)CC[C@H]1C(C)C', 'CCCC(F)C(=O)NC1CN(C(=O)c2sc(=O)[nH]c2C)C2CCCC12', 'CCCC(F)C(=O)NCC1(C(=O)N(C)CC(C)(C)C#N)CCCCC1', 'CCCC(F)CN(Cc1ccncc1C)C(=O)C[C@@H]1CCC[C@H](C)O1', 'CCCC(F)CN(Cc1ccncc1Cl)Cc1ccc(OC)nc1C', 'CCCC(NC(=O)C(NC(=O)C(C)N1CCCC1)C1CCC1)C1CC1', 'CCCC(NC(=O)C1(CNC(=O)[C@@H]2C[C@H]2CC)CCC1)c1nnn[nH]1', 'CCCC(NC(=O)C12CC(CN1C(=O)COC(C)=O)C2)c1nnn[nH]1', 'CCCC(NC(=O)CO[C@H]1C[C@@H](NC(=O)C2CC=CC2)C1)C1CCC1', 'CCCC(NC(=O)[C@H](C)NC(N)=O)C(=O)N1CCC(C)(COC)CC1', 'CCCC(NC(N)=O)C(=O)N[C@@H]1[C@H]2C[C@@H]1N(C(=O)Cc1cscn1)C2', 'CCCC(NC(N)=O)C(=O)N[C@H]1C[C@@](C)(C(=O)N(C)CC(C)(C)C)C1', 'CCCC(NCCC(=O)N(C)C1CC1)c1nnnn1CC1CCCO1', 'CCCC(O)CCNC(=O)C1(C)CCN(C(=O)Cn2cnnc2)CC1', 'CCCC(O)CCNC(=O)NCc1cccc(C(=O)N2CCCC2)c1', 'CCCC(O)CCNC(=O)[C@H]1C[C@H](NC(=O)C2CC(=O)N(OC)C2)C1', 'CCCC(O)CN(Cc1cc(Cl)sc1C)C(=O)C(CC)(CC)C(C)O', 'CCCC(O)CN(Cc1cnc(COC)s1)C(=O)c1cnn(CC)c1', 'CCCC(O)CNC(=O)COC1CCN(C(=O)[C@@H]2CC[C@H]2COC)C1', 'CCCC(OC)C(=O)N(CCC1CCCC1)Cc1nc(OC)nn1C', 'CCCC(OC)C(=O)N(Cc1cn(C)nc1Cl)Cc1csnc1CC', 'CCCC(OC)C(=O)N1CCCC[C@@H]1CC(=O)NCc1ncc(C)o1', 'CCCC(OC)C(=O)N1CC[C@H](NC(=O)c2cc(C)oc2C)C[C@H]1C', 'CCCC1(C(=O)N2CCC(C(=O)N3CCC(CC)C3C)CC2)CCC1', 'CCCC1(C(=O)N2CC[C@H]3[C@@H](C2)[C@@H]3C(=O)N2CCC2CC2CC2)CC1', 'CCCC1(C(=O)N2[C@H]3CC[C@@H]2[C@H](C(=O)Nc2ccc(Cl)nc2)C3)CC1', 'CCCC1(C(=O)NC(C)CC2CN(C(=O)c3nccn3C)C2)CCC1', 'CCCC1(C(=O)NC(C)CCN(C)C(=O)C=C2CCN(C)CC2)CC1', 'CCCC1(C(=O)NC)CCCN1C(=O)Cc1ccccc1C(=O)OC', 'CCCC1(C(=O)N[C@@H](CC(=O)NCCNC(=O)NC)C2CC2)CCC1', 'CCCC1(C(=O)N[C@H](CO)[C@H](C)NC(=O)c2c[nH]c(SC)n2)CCC1', 'CCCC1(C(=O)N[C@H]2C[C@H](CC(=O)Nc3cc(C)ccc3O)C2)CC1', 'CCCC1(C(=O)Nc2ccsc2C)CCN(C(=O)OC(C)(C)C)CC1', 'CCCC1(CN(Cc2cc(C)ns2)C(=O)c2nonc2CC)CCC1', 'CCCC1(CN(Cc2csc(C#N)c2)C(=O)c2nonc2N)CCC1', 'CCCC1(CNc2nc3c(c(NC4CCCC(F)C4)n2)COC3)CC1', 'CCCC1(CO)CCCN1C(=O)CSCCNC(=O)c1scnc1Cl', 'CCCC1(CO)CCCN1C(=O)[C@H](C)NC(=O)C1CC2CCCC2C1', 'CCCC1(NC(=O)/C=C\\C(N)=O)CCCN(C(=O)C2C=CCCC2)C1', 'CCCC1(NC(=O)CSc2nnc(-c3cccs3)n2C)CCCCC1', 'CCCC1(NC(=O)C[C@@H](NC(=O)[C@H]2[C@@H]3CN(C)C[C@@H]32)C(C)(C)C)CC1', 'CCCC1(NC(=O)[C@H]2CC(C)(C)CN2C(=O)C2C(C)(C)C2(F)F)CC1', 'CCCC1C(=O)NCCN1C(=O)CC1(N(C)C(=O)C2CN(C)C2)CC1', 'CCCC1C(=O)NCCN1C(=O)CCCNC(=O)c1ccc(=O)[nH]n1', 'CCCC1CC(C(=O)N(CC)CC(=O)NCc2cnc(F)c(C)c2)C1', 'CCCC1CC(C(=O)N2CCC(OC)(C(=O)NCC3(CF)CC3)C2)C1', 'CCCC1CC(C(=O)N2C[C@H](CC(=O)N[C@H]3CCOC3=O)[C@@H](C)C2)C1', 'CCCC1CC(C(=O)N[C@H]2C[C@@H](CC(=O)NCCS(=O)(=O)CC)C2)C1', 'CCCC1CCC(N(C)C(=O)NCCCN(C)c2ccccc2)CC1', 'CCCC1CCCN(C(=O)c2cnn(-c3ccccc3)c2COC)C1', 'CCCC1CCCN(C(C(=O)NC(C)(C)C)C2=NOC3(CCC3)C2)C1', 'CCCC1CCCN1C(=O)C1(CNC(=O)COC2CC=CC2)CCC1', 'CCCC1CCN(c2nc(NCCCC(C)C)c3c(ncn3C)n2)C1', 'CCCC1CN(C(=O)C2(NC(=O)c3cn(C)nn3)CC(F)C2)CCO1', 'CCCC1CN(C(=O)C2CN(C(=O)c3cc(Cl)c[nH]3)CCO2)CCO1', 'CCCC1CN(C(=O)CC2CCCCN2C(=O)C2CCC3(CC3)C2)C1', 'CCCC1CN(C(=O)CCC2CCCCN(C(=O)C3CC3(F)F)C2)C1', 'CCCC1CN(C(=O)c2cnn(C)c2)CCN1C(=O)C1CC(SC)C1', 'CCCC1CN(C(=O)c2scnc2C)CCN1C(=O)CCC1(C)CC1', 'CCCC=C(CC)C(=O)N(CC(=O)N1CCNC(=O)CC1)C1CCC1', 'CCCC=C(CC)C(=O)N(Cc1nccnc1C)CC1(C)CCCS1', 'CCCC=C(CC)C(=O)N1CC(CC(C)NC(=O)CC2(O)CCC2)C1', 'CCCC=C(CC)C(=O)N1CCC(C)CC1C(=O)N[C@H]1CCC[C@@H]1F', 'CCCC=C(CC)C(=O)NCC1(C)CCN(C(=O)[C@]2(C)C[C@H]2C)CC1', 'CCCC=C(CC)C(=O)NC[C@H](O)CC(=O)NC1CCN(C)CC1C', 'CCCC=C(CC)C(=O)N[C@H]1CCN(S(=O)(=O)c2cnc(CC)o2)C1', 'CCCC=C(CC)C(=O)N[C@H]1C[C@H](CC(=O)NC(C)c2ccsc2)C1', 'CCCC=CC(=O)N1C2CC=C(C(=O)N(C[C@@H](C)O)C3CC3)C1CC2', 'CCCC=CC(=O)N1CCC2(CC2C(=O)N2CCC23CCOCC3)C1', 'CCCC=CC(=O)N1CCC[C@H]1CN(C)C(=O)c1cccnc1CC', 'CCCC=CC(=O)NC1CCN(C(=O)C23C(=O)C4CC2C3C4)CC1F', 'CCCC=CC(=O)NC1CCN(C(=O)c2c[nH]nc2[N+](=O)[O-])CC1C', 'CCCC=CC(=O)NCC(C)(C)CC(=O)NC(CC)C1CCOCC1', 'CCCC=CC(=O)N[C@H](C(=O)N1CCC(n2cnnn2)C1)[C@@H](C)CC', 'CCCC=CC(=O)N[C@H]1CO[C@H]2CN(C(=O)C#CC3(C)COC3)C[C@@H]12', 'CCCC=CCNC(=O)CC1CCN(C(=O)C2CC23CCCC3)CC1', 'CCCC=CCNC(=O)[C@@H]1CC[C@H](CNC(=O)C2CN(C(C)=O)C2)C1', 'CCCCC(=O)C(=O)N1CC(O)(C(F)C(=O)N2OC3C=CC2CC3)C1', 'CCCCC(=O)C(=O)N1CC2(CC(C(=O)NC(CO)CCF)CO2)C1', 'CCCCC(=O)C(=O)N1CCO[C@H](C(=O)NCC2CN(C)CCO2)C1', 'CCCCC(=O)C(=O)NCC1(CC(=O)NCc2nn(C)cc2C)CC1', 'CCCCC(=O)C(=O)N[C@H]1CC[C@@H](C(=O)NC(CC)C(C)(F)F)CC1', 'CCCCC(=O)N(CC)CC1CCCN(C(=O)Cc2csc(C)n2)C1', 'CCCCC(C(=O)NCCN(C(=O)c1cn(C)cn1)C1CC1)C(C)C', 'CCCCC(C)(O)C(=O)N1CCN(C(=O)CCc2ccccc2)CC1', 'CCCCC(C)C(=O)N[C@H]1C[C@@H](C(=O)N[C@H](C)c2cncc(F)c2)C1', 'CCCCC(C)CN(CCC(C)C(F)(F)F)C(=O)c1cc(C)ncn1', 'CCCCC(CC)C(=O)N1CC=CCC1C(=O)N(C)CCCN(C)C', 'CCCCC(CC)C(=O)N1CCCC(C(=O)N(C)c2ccccc2)C1', 'CCCCC(CC)C(=O)N1CCN(C(=O)C2(OC)CCC2)C2(CC2)C1', 'CCCCC(CC)C(=O)N1CCN(C(=O)c2ccc(C#N)n2C)CC1', 'CCCCC(CC)C(=O)N[C@@H]1CCC[C@@H](C(=O)NC2CC(CC)C2)C1', 'CCCCC(CC)CC(=O)N1CCN(C(=O)C=C(Cl)Cl)[C@H]2COC[C@H]21', 'CCCCC(CC)CNC(=O)C1(C(C)NC(=O)c2coc(C)n2)CC1', 'CCCCC(CC)CNc1nc(N)nc(NCC2(C)CC(C)(C)C2)n1', 'CCCCC(CNC(=O)C1(C)CNC(=O)N1)NC(=O)C(C)CC1CC1', 'CCCCC(CNC(=O)C1CC12CC2)NC(=O)CCC1CCCCC1', 'CCCCC(CNC(=O)C1CCOC1)NC(=O)C=C(C)c1cccs1', 'CCCCC(CNC(=O)CC(=O)OC)NC(=O)C1COCCN1CC', 'CCCCC(CNC(=O)[C@@H]1CCC(=O)O1)NC(=O)Cc1ccsc1C', 'CCCCC(F)C(=O)N(C)CCC(C)(C)NC(=O)Cc1scnc1C', 'CCCCC(F)C(=O)N1CC(SC)(C(=O)NC(C)Cn2cccn2)C1', 'CCCCC(F)C(=O)N1CC2CC(C(=O)NCC(COC)OC)(C2)C1', 'CCCCC(F)C(=O)N1CCC(C(=O)NC(C)(C)CCCO)C1(C)C', 'CCCCC(F)C(=O)N1C[C@@H]2CCCN(C(=O)CCCCOC)[C@@H]2C1', 'CCCCC(F)C(=O)N1C[C@@H]2[C@H](C1)[C@H]2C(=O)NC(C)(C(N)=O)C(C)C', 'CCCCC(F)C(=O)NC(C)(C)CC(=O)N1CCC(N2CC=CC2)C1', 'CCCCC(F)C(=O)NC1CN(C(=O)c2ccnc(N)n2)CC12CC2', 'CCCCC(F)C(=O)NCC1CN(C(=O)C2=C(C)CC2)CCC1(C)C', 'CCCCC(F)C(=O)N[C@H](C(=O)N1C[C@H]2CC[C@H](O)[C@H](O)[C@H]21)[C@@H](C)O', 'CCCCC(F)C(=O)N[C@H]1CCC[C@@H]1NC(=O)C(C)NC(=O)C1CC1', 'CCCCC(NC(=O)CC(C)(F)F)C(=O)NC(C)c1[nH]c(C)nc1C', 'CCCCC(NC(=O)CC(C)CC)C(=O)NCc1cncc(C#N)c1', 'CCCCC(NC(=O)[C@H]1C[C@@H](N(C)C)C1)C(=O)NCC1CCOC1=O', 'CCCCC(NC(=O)c1cc(CO)on1)C(=O)N1CC(OC(C)C)C1', 'CCCCC(NC(=O)c1scnc1Cl)C(=O)NC1CCN(C)C1(C)C', 'CCCCC(O)C(=O)N(C)C(C)CNC(=O)c1ccc(F)c(N)c1F', 'CCCCC(O)C(=O)N(C)[C@@H]1CCCC[C@H]1N(C)C(=O)COCCF', 'CCCCC(O)C(=O)N[C@H]1CC[C@@H](NC(=O)[C@@]2(C)C[C@H]3C[C@H]3C2)CC1', 'CCCCC(O)C(C)C(=O)N(C)C1CCCN(C(=O)c2cc[nH]c2)C1', 'CCCCC(O)C(C)C(=O)N[C@H]1COC[C@H]1NC(=O)[C@@H]1CC=CCC1', 'CCCCC(O)CC(=O)N1CCOC(CC(=O)NCc2cnco2)C1', 'CCCCC(O)CN(Cc1[nH]nc(C)c1Cl)C(=O)CC(C)P(C)(C)=O', 'CCCCC/C=C/CC(=O)N1CCN(C(=O)c2ccoc2)C(C)C1C', 'CCCCC/C=C/CC(=O)NCC1CCN1C(=O)[C@H]1C[C@@H](O)CN1C', 'CCCCC1(C(=O)N2CC[C@H](CC(=O)NCC(=O)N(C)O)C2)CCC1', 'CCCCC1(C(=O)N[C@@H](CC)CNC(=O)c2cc([N+](=O)[O-])c[nH]2)CC1', 'CCCCC1(C(=O)N[C@H]2CC[C@H]2CNC(=O)CN(C)C2CCC2)CC1', 'CCCCC1(NC(=O)CC(O)CNC(=O)c2ccccc2C#N)CC1', 'CCCCC1CCC(NC(=O)c2nnc(-c3c(F)cccc3F)s2)C1', 'CCCCC1CCCN1C(=O)C(=O)N1CCC(c2nnn(C)n2)CC1', 'CCCCCC(=O)N(C)CCN(C(=O)c1cnc2n1CCC2)C(C)C', 'CCCCCC(=O)N1CCC(CCNC(=O)C/C=C/C(C)(C)C)CC1', 'CCCCCC(=O)N1CCC[C@H](C(=O)NCCC(=O)N2CCCC2)C1', 'CCCCCC(=O)N1C[C@@H](F)C[C@@H]1CC(=O)NC(COC)C(=O)OC', 'CCCCCC(=O)N1C[C@H](C)[C@@H]1C(=O)N1Cc2cccc(C#N)c2C1', 'CCCCCC(=O)NC1(CCNC(=O)c2cn(C)c(C)n2)CCCC1', 'CCCCCC(=O)NCC(=O)NC1(C2CN(C(=O)C3CCC3)C2)CC1', 'CCCCCC(=O)NCC(=O)OCC(=O)N(C)C(C)c1ccccc1', 'CCCCCC(=O)NC[C@@H]1C[C@@H]2CCC[C@@H]2N1C(=O)c1nc[nH]c1C', 'CCCCCC(=O)N[C@H](CNC(=O)[C@@H]1CCCN1C(N)=O)CC(C)C', 'CCCCCC(=O)N[C@H]1C[C@@H]2C[C@H]1[C@H](NC(=O)CCC(=O)OCC)C2', 'CCCCCC(C)(C)CN(Cc1nnn(C)n1)C(=O)c1cc(C)cs1', 'CCCCCC(C)(C)CNC(=O)c1ccc2c(C(C)(C)C)noc2n1', 'CCCCCC(C)CC(=O)N[C@H]1CC[C@@H](C(=O)NC2(C)CC=CC2)C1', 'CCCCCC(C)NC(=O)CS(=O)Cc1cccc(OC(C)(C)C)n1', 'CCCCCC(C)NC(=O)[C@H]1C[C@@H](OC)CN1C(=O)c1cccnc1', 'CCCCCC(CC)C(=O)NC1C=CCN(C(=O)C2(C)CC(C)C2)C1', 'CCCCCC(F)C(=O)N1CCCC[C@@H]1C(=O)Nc1cn(C)nc1O', 'CCCCCC(F)C(=O)N1C[C@H]2C[C@H](C)N(C(=O)C(F)C(C)C)[C@H]2C1', 'CCCCCC(F)C(=O)NC1(C(=O)N2CC(OCCF)C2)CC(F)C1', 'CCCCCC(NC(=O)[C@H]1C[C@H]1CNC(=O)C1=COCCC1)C1CC1', 'CCCCCC(O)CC(=O)N(Cc1n[nH]c2cccnc12)CC(Cl)Cl', 'CCCCCC(O)CN(Cc1ccccc1F)C(=O)c1ccoc1Cl', 'CCCCCC1CN(C(=O)[C@H]2CCCN(C(=O)Cc3ccns3)C2)C1', 'CCCCCCC(=O)N1CC=C(C(=O)N2C[C@H](C(N)=O)CC[C@@H]2C)C1', 'CCCCCCC(=O)N1CC[C@@H](CC(=O)NC[C@@H](C)N2CCCC2)C1', 'CCCCCCC(=O)NCC1(NC(=O)C=Cc2cnccc2C)CC1', 'CCCCCCC(=O)N[C@H](CCC)CC(=O)N1CC(F)(F)C(F)(F)C1', 'CCCCCCC(C)C(=O)N1CC=CC(C(=O)N2CCNC(=O)C2)C1', 'CCCCCCCC(=O)NC1(C(=O)Nc2cccnc2OC)CSC1', 'CCCCCCCNC(=O)Cn1cc(CNC(=O)OC(C)(C)C)nn1', 'CCCCCCNC(=O)C([C@H]1CC1(C)C)N1CCC(O)C(CO)CC1', 'CCCCCCNC(=O)C1CCCN(Cc2cc(C(=O)O)n(C)n2)C1', 'CCCCCCNc1c(-c2nnc(C)[nH]2)nc2cc(C#N)cc(Br)n12', 'CCCCCCOc1ccc(CC(=O)N(C)CC2CCCOC2)cc1', 'CCCCCCn1nnnc1C(C1=CCSC1)N1CC2CC2C2CC21', 'CCCCCCn1nnnc1C1(NCCSC(C)(C)C)CCSCC1', 'CCCCCN(C)C(=O)C(C)(NC(=O)c1cc(C)c(C)o1)C1CCC1', 'CCCCCN(C)C(=O)C(NC(=O)Cc1cccc(F)c1)C1(C)CC1', 'CCCCCN(C)C(=O)C[C@@H]1CCCN(C(=O)C(SCC)C(C)C)C1', 'CCCCCN(CCCOC)C(=O)CC1Sc2ccccc2NC1=O', 'CCCCCN(CCO)C(=O)C1(NC(=O)c2cncc(Cl)c2)CCC1', 'CCCCCN(Cc1ccc2c(c1)OCC2)C(=O)C1CC2(CSC2)C1', 'CCCCCOC1CCN(C(=O)c2ccc3c(c2)COC(=O)N3)CC1', 'CCCCCONC(=O)[C@@]12C[C@@H]1CN(C(=O)C=Cc1cncn1C)C2', 'CCCCCONC(=O)[C@]1(C)CN(C(=O)[C@@H]2CN(C)C(=O)N2)C[C@H]1C', 'CCCCCc1ccc(CNCc2ccc(-n3ccc(C)n3)cc2)o1', 'CCCCN(C(=O)OC(C)(C)C)C1CCN(C(=O)NC2CCC2)CC1', 'CCCCN(C(=O)[C@@H]1CN(C(=O)c2cnn(C)c2N)C[C@H]1F)C1CC1', 'CCCCN(C(=O)[C@@H]1C[C@H]2C[C@H]2N1C(=O)Cc1cscn1)C(C)CC', 'CCCCN(C)C(=O)C(CNC(=O)c1cccc(CO)n1)C(C)(C)C', 'CCCCN(C)c1ccc([N+](=O)[O-])c(C(=O)N2CC(C)=CC(O)C2)c1', 'CCCCN(CC)C(=O)C(O)C1CN(C(=O)CCC(=O)C(C)(C)C)C1', 'CCCCN(CCO)C(=O)[C@H]1C[C@@H](NC(=O)C2(CC)CCCCC2)C1', 'CCCCN(Cc1ccc(F)cc1F)C(=O)c1cnc2ccn(C)n12', 'CCCCN1CCN(C(=O)[C@H]2C[C@H](NC(=O)C(O)C(F)(F)F)C2)CC1', 'CCCCNC(=O)C(C)OC(=O)Cc1cc(Cl)c2c(c1)OCCCO2', 'CCCCNc1ccnc(N2CCC(CC(=O)N3CCCC3)CC2)n1', 'CCCCNc1nc(CC(=O)OCc2cccc(OC(F)F)n2)cs1', 'CCCCOCC(=O)N1CC2CC(C1)CN(C(=O)[C@@H]1CNC(=O)O1)C2', 'CCCCOCCNC(c1cc(C2CC2)ccc1F)c1nnnn1C', 'CCCCOc1ccc(CC(=O)Nc2ccc(CCO)c(F)c2)cc1', 'CCCCOc1ccc(CNC(=O)Nc2cc(C)nc(C#N)c2)cc1', 'CCCCOc1ccc(CNC(=O)c2c(C)ccc(C)c2O)cc1Cl', 'CCCCOc1ccc(CNc2c(N3CC=CC3)c(=O)c2=O)cc1Cl', 'CCCCOc1ccc(CNc2cnn(CC3CCC3)c2)cc1OC', 'CCCCS(=O)(=O)NC(C)C(=O)N1CCN(c2nc(C)c(C)s2)CC1', 'CCCCS(=O)(=O)c1ccc(C(=O)N2CCCCC(N(C)C)C2)cc1', 'CCCCSC(C)C(=O)N1CCCN(C(=O)CCC(C)(C)C)[C@@H](C)C1', 'CCCCSCC(=O)NC(C(=O)N(C)[C@@H]1COC[C@H]1O)c1ccco1', 'CCCCSCC(=O)N[C@@H]1C[C@H](O)[C@H]1CC(=O)NCc1cn(C)cn1', 'CCCCSCC(=O)N[C@H]1CC[C@@H](N(C)C(=O)[C@H]2C[C@H](SC)C2)CC1', 'CCCCSCCC(=O)N1CC2CC1(C(=O)N1CC(O)C(CO)C1)C2', 'CCCCSCCC(=O)N1CCC(NC(=O)C2(O)CCC(C)CC2)C1', 'CCCCSCCC(=O)NCC1CN(C)CCN1C(=O)C1CC1(Cl)Cl', 'CCCCSCCN(Cc1c[nH]nn1)Cc1cc2nc(Cl)ccc2o1', 'CCCC[C@@H](C(=O)N1CC[C@H](N(C)C(=O)c2scnc2C)C1)N(C)C', 'CCCC[C@@H](C(=O)NC[C@H]1C[C@@H](C(=O)N2CCCC[C@H]2C)C1)N(C)C', 'CCCC[C@@H](CC(=O)N(C)[C@H](C)CCO)NC(=O)C1COCC1(C)C', 'CCCC[C@@H](CC(=O)NOC(C)C(=O)OC)NC(=O)C1=C(C)OCC1', 'CCCC[C@H](C(=O)NC1(CN(C)C(=O)Cc2cnsc2)CC1)N(C)C', 'CCCC[C@H](C(=O)NC[C@H](C)C(=O)N[C@H](C)c1n[nH]c(C)n1)N(C)C', 'CCCC[C@H](CC(=O)N1CC[C@@H](F)C1)NC(=O)C(F)CC1CCOC1', 'CCCC[C@H](CC(=O)NCc1cc(C)co1)NC(=O)C1=COCCC1', 'CCCC[C@H](CO)NC(=O)/C=C/CC(C)(C)NC(=O)C1CCCCO1', 'CCCC[C@H]1CN(C(=O)C2CS(=O)C2)CCN1C(=O)CCC(=O)OC', 'CCCCc1c(Cl)nc(NC(=O)c2ccnc(C(C)(F)F)c2)nc1Cl', 'CCCCc1ccc(N(C)C(=O)CN(C)CCc2ccccc2)cc1', 'CCCCn1c(N)c(N(CC)C(=O)CN[C@@H](C)CCC)c(=O)[nH]c1=O', 'CCCCn1cc([C@@H]2CCCN2C(=O)c2cc3ccncc3s2)nn1', 'CCCCn1ncc(NC(=O)C2CCc3cc(OC)ccc3C2)c1C', 'CCCCn1nccc1COC(=O)c1ccc(-c2nc(C)cs2)cc1', 'CCCCn1nnnc1C1(N[C@H]2CC[C@H](O)C2)CNC(=O)C(C)(C)C1', 'CCCN(C(=O)[C@@H](O)C(C)(C)C)C(C)C(=O)N1CC(C)C(N(C)C)C1', 'CCCN(C(=O)c1cc(C#N)n(C)n1)C(C)C(=O)NC(C)COCC', 'CCCN(C(C)C(=O)OC)C(C(=O)NC(C)CC)C(C)CC(C)(C)C', 'CCCN(C)C(C)CCNC(=O)c1sc(C(C)(C)C)nc1C(F)(F)F', 'CCCN(C)CC(=O)N1CC(CCNC(=O)Cc2cccc(O)c2)C1', 'CCCN(C)CC(=O)N1CCC(CC)(C(=O)NCC(C)(C)C(N)=O)C1', 'CCCN(C)CC(=O)N1C[C@@H](F)C[C@@H]1CNC(=O)c1nccc(C)n1', 'CCCN(C)CC(=O)NCC(CC(F)(F)F)NC(=O)C(C)C1CCC1', 'CCCN(C)CC(=O)N[C@H]1CC[C@H](NC(=O)c2ccnn2COC)C1', 'CCCN(C)CCC(=O)N1CC(CNC(=O)C(C)NC=O)CC1(C)C', 'CCCN(C)CCC(=O)N1CCC[C@@]2(CC[C@H]2NC(=O)C2CC2C)C1', 'CCCN(C)CCC(=O)N1CCN(C(=O)[C@H]2CC[C@H]2C#N)CCC1C', 'CCCN(C)CCC(=O)N[C@H]1CC[C@@H](C(=O)NCC2CCC(=O)N2)C1', 'CCCN(C)c1nc(NCC(C)(C)C(=O)NC)c2c(ncn2CC)n1', 'CCCN(CC(=O)N1CC(N(C)C2CC2)C1)C(=O)CN1CC2CC2C1', 'CCCN(CC(=O)N1CC[C@H](C(C)(C)O)C1)C(=O)C1COCC(C)O1', 'CCCN(CC(=O)N1CCn2c(C)cnc2C1)C(=O)C1CNC(=O)N1', 'CCCN(CC(=O)N1C[C@H](C)OC[C@@H]1C)C(=O)c1cccn(C)c1=O', 'CCCN(CC(=O)NC(C)c1cccc(C)n1)C(=O)c1n[nH]nc1C', 'CCCN(CC(=O)NC(C)c1cn(C)nc1C)C(=O)C(=O)C(C)CC', 'CCCN(CC(=O)NC1CC(C)OC(C)C1)C(=O)Cc1cncnc1', 'CCCN(CC(=O)NC1CC2(CCCC2)C1)C(=O)CC(C)(C)COC', 'CCCN(CC(=O)NC1CCCCCC1)C(=O)C1CCCN1C1CC1', 'CCCN(CC(=O)NCC(C)CC1CCC1)C(=O)C(C)N1CC(C)C1', 'CCCN(CC(=O)NCC1(CC)CC1)C(=O)c1cccc2occc12', 'CCCN(CC(=O)NCCCN1CCCC1=O)C(=O)C1CCC(=O)C1', 'CCCN(CC(=O)NCc1ccc(F)cc1)C(=O)CN1CCCCC1', 'CCCN(CC(=O)N[C@H]1C[C@@H](N2CCCC2)C1)C(=O)C(C)COCC', 'CCCN(CC(=O)Nc1ccc2occc2c1)C(=O)c1ccc(C)[nH]1', 'CCCN(CC(=O)O)C(=O)c1ccc(Oc2ccc(F)c(F)c2)cc1', 'CCCN(CC)C(=O)C1CN(C(=O)COCC2CCCO2)CC12CC2', 'CCCN(CC)C[C@H](C)NC(=O)c1coc(CNC(=O)C(C)(C)C)n1', 'CCCN(CCC#N)C(C(=O)NCSc1ccccc1)c1nccs1', 'CCCN(CCC)C(=O)C1CCC(O)CN1C(=O)CCn1cccn1', 'CCCN(CCC)c1ccc(NC(=O)c2cc(C)cnc2OC)cc1', 'CCCN(CCCN(C)C)C(=O)CCN(C)C(=O)c1cc(C)ncn1', 'CCCN(CCCNC(=O)c1cc(N(C)C)ccn1)C(=O)CC(C)F', 'CCCN(CCNC(=O)C(F)(F)C(F)F)C(=O)CC1CCCC(O)C1', 'CCCN(CCNC(=O)c1c[nH]c(=O)n1C)C(=O)[C@H]1CN(C)C(=O)N1', 'CCCN(CCNC(=O)c1cccnc1O)C(=O)C1(C)CC(C#N)C1', 'CCCN(CCNC(=O)c1ccnc(OC)n1)C(=O)CC(=O)N(C)C', 'CCCN(CCNS(=O)(=O)C1CCCCC1)C(=O)c1cnn(CC)c1', 'CCCN(CCO)C(=O)C1(CCNC(=O)Cn2cccnc2=O)CC1', 'CCCN(CCO)C(=O)CCC1CCCCN(C(=O)c2ccoc2)C1', 'CCCN(CCO)C(=O)[C@H]1C[C@H](CNC(=O)C(C)c2ccnn2C)C1', 'CCCN(Cc1ccc(C#N)cc1)C(=O)c1ccc(F)c(F)c1OC', 'CCCN1CC(CNC(=O)Nc2ccc(C(=O)OCC)cc2)CC1=O', 'CCCN1CC(NC(=O)[C@@H]2[C@H](NC(=O)c3cncc(C)c3)C2(C)C)C1', 'CCCN1CCCC1C(=O)NC1CN(C(=O)c2coc3c2COC3)C1', 'CCCN1CCCC1C(=O)NCCC(C)N(C)C(=O)Cc1ccon1', 'CCCN1CCCN(C(=O)CC(CC(C)C)NC(=O)CN=[N+]=[N-])CC1', 'CCCN1CCN(C(=O)C[C@H](CC)NC(=O)C(C)N2CC(C)C2)CC1', 'CCCN1CCN(C(=O)[C@H]2CCN(C(=O)C(C)NC=O)C[C@H]2O)CC1', 'CCCNC(=O)C(C)(C)C1CCN(C(=O)c2cc3cc[nH]c3cn2)C1', 'CCCNC(=O)C(c1c[nH]nc1CC)N1CCCOC(C2CCC2)C1', 'CCCNC(=O)C(c1ccc(C)c(Cl)c1)N1C[C@H](OC)C[C@@H]1CSC', 'CCCNC(=O)C(c1ccc(OC)cc1OC)N1CCOC[C@@H]1CC', 'CCCNC(=O)C(c1ccc([N+](=O)[O-])cc1)N1CCC(C)(CCO)C1', 'CCCNC(=O)C(c1cccs1)N1CCC(N2CCNC(=O)C2)CC1', 'CCCNC(=O)C(c1cnn(CC)c1C)N(C)Cc1ccc(O)cc1', 'CCCNC(=O)C(c1conc1COC)N1CCC(C2(C)CC2)CC1', 'CCCNC(=O)C(c1ncc2ccccn12)N(C1CC1)C(C)C(C)C', 'CCCNC(=O)C(c1oc(C(=O)OC)cc1Br)N1CCOCC1CC', 'CCCNC(=O)CCC(=O)N(Cc1ccc(O)nn1)C[C@@H]1CCCO1', 'CCCNC(=O)CCC(=O)N1CC=CC(NC(=O)CSCC(F)F)C1', 'CCCNC(=O)CCC(=O)NC(C)(CNC(=O)c1ccc[nH]1)C1CC1', 'CCCNC(=O)CCC(=O)N[C@H]1[C@@H]2CN(C(=O)C(C)CN(C)C)C[C@@H]21', 'CCCNC(=O)CNC(=O)C1CCCCN1C(=O)CC(C)(C)C(F)F', 'CCCNC(=O)NC(=O)CN1CCN(Cc2ccc(C)cc2F)CC1', 'CCCNC(=O)Nc1cccc(NC(=O)c2c(I)cccc2OC)c1', 'CCCNC(=O)Nc1cccc(OC(=O)Cn2nnnc2C2CC2)c1', 'CCCNC(=O)c1ccc(-n2cc(-c3ccccc3CC)nn2)cc1', 'CCCNC(=O)c1ccc(Cl)cc1NS(=O)(=O)c1ccc(Cl)cc1Cl', 'CCCNC(CC(C)(C)OC)c1nnnn1Cc1ccc(OC)cc1', 'CCCNc1ccc(-c2nn[nH]n2)cc1NC(=O)c1cc(Br)sc1C', 'CCCOC(=O)NCCCN(C)C(=O)c1ccccc1CC(=O)OC', 'CCCOC(=O)[C@H](C)NC(=O)CC(C)(C)NC(=O)c1ccc(CO)o1', 'CCCOC(=O)[C@H](C)NC(=O)C[C@H]1C[C@H]1CNC(=O)c1nocc1Cl', 'CCCOC(=O)[C@H](C)NC(c1ccc(SC)o1)c1nnnn1CCC', 'CCCOC(=O)c1cc(Br)ccc1NC(=O)C(=O)N(CC)CCC#N', 'CCCOC(=O)c1ccc(S(=O)(=O)Oc2cccc(F)c2C#N)cc1', 'CCCOC(C)(C)C(=O)N1C[C@@H]2[C@H](C1)[C@H]2C(=O)NCc1csc(=O)[nH]1', 'CCCOC(C)(C)C(=O)N[C@H]1CN(C(=O)C(O)CCC(C)C)C[C@H]1F', 'CCCOC(C)(C)C(=O)N[C@H]1COC[C@H]1C(=O)N1CC(C(=O)OC)C1', 'CCCOC(C)(C)C(=O)N[C@H]1C[C@H](CC(=O)NCC(O)C(F)(F)F)C1', 'CCCOC1CCCN(c2nc(N(C)CC3CC3)c3[nH]ccc3n2)C1', 'CCCOCC(=O)N(Cc1cc2c(s1)CCC2)CC1(O)CCCSC1', 'CCCOCC(=O)N1CCC(CCC(=O)Nc2ccc(O)cc2C)C1', 'CCCOCC(=O)N1CCC(CCCNS(=O)(=O)[C@H]2CCOC2)CC1', 'CCCOCC(=O)N1C[C@H](C(=O)N2CCCCN(C)CC2)CC[C@@H]1C', 'CCCOCC(=O)NC1CC2(CCCN(C(=O)C3=C(C)CCC3)C2)C1', 'CCCOCC(=O)N[C@@H](CNC(=O)c1cc(C)ncc1Cl)C(C)(C)C', 'CCCOCC(=O)N[C@H]1C[C@]2(C(=O)Nc3ccc(O)nc3)CO[C@H]1C2', 'CCCOCCC(=O)N(C)C1CC2CCC(C1)N2C(=O)[C@@H]1CC[C@H]1C', 'CCCOCCC(=O)N1CCCN(C(=O)CN(C)CC(C)(C)C)CC1', 'CCCOCCC(=O)N1CC[C@@H](C)[C@@H](N(C)C(=O)[C@H]2CCN(C)C2)C1', 'CCCOCCC(=O)NC1(C(=O)N2CC[C@H](O)[C@H](O)C2)CCCC1C', 'CCCOCCCC(=O)N1[C@@H]2C[C@@H]2C[C@H]1C(=O)NC(CO)C(=O)OC', 'CCCOCCNc1nc(NCc2ccc(SC)o2)nc2c1CCC2', 'CCCOc1ccc(C(=O)NCC(C)n2cc(C(C)(C)C)nn2)cc1', 'CCCOc1ccc(CN(Cc2ncc(Cl)n2C)CC(C)SC)cc1', 'CCCOc1ccc(Cl)cc1C(=O)N[C@@H](CO)CCc1ccccc1', 'CCCOc1ccc(S(=O)(=O)NC(=O)C(SC)SC)cc1C(C)(C)C', 'CCCOc1cccc(NC(=O)NC(C)CCc2ccc(O)cc2)c1', 'CCCOc1cccc(NC(=O)NCCOc2ccc(C#N)cn2)c1', 'CCCOc1cccc(NC(=O)NCCc2nnc(S)n2C(C)C)c1', 'CCCOc1cccc2c1OCC2NC(=O)Nc1cc(C)c(C)nn1', 'CCCOc1ccnc(N2CCN(C(=O)CN(C)CC)CC(O)C2)n1', 'CCCS(=O)(=O)CC(=O)N(C)C(C)CCNC(=O)c1ncccc1F', 'CCCS(=O)(=O)CC(=O)N(C)C[C@H]1CCCN1C(=O)C1CCSCC1', 'CCCS(=O)(=O)CC(=O)NC(C)CNC(=O)CCc1ccc(=O)[nH]c1', 'CCCS(=O)(=O)NC1(CNC(=O)C(NC)c2cc(F)ccc2F)CC1', 'CCCS(=O)(=O)Nc1ccc(NCC(=O)NCCC(C)(C)C)c(F)c1', 'CCCS(=O)(=O)c1ccccc1C(=O)Nc1cc(Cl)c([N+](=O)[O-])cn1', 'CCCSCC(=O)N1CCN(C(=O)c2cccc(C(F)F)c2)C[C@@H]1C', 'CCCSCC(=O)N1CC[C@H]2CN(C(=O)C(CC)(CC)OC)C[C@H]2C1', 'CCCSCC(=O)N1C[C@H]2C[C@@H]1[C@H]2C(=O)NCC(=O)Nc1cn[nH]c1', 'CCCSCC(=O)NCC1CCN(C(=O)[C@@H](O)CN(C)C)CC1(F)F', 'CCCSCC(=O)NC[C@H]1CCCN1C(=O)c1cc(F)c(N)c(F)c1', 'CCCSCCC(=O)N(C)CCN(C(=O)c1cncc(C)c1)C(C)C', 'CCCSCCC(=O)N1CCC(C(C)C(=O)NC(C)(C)CC(N)=O)C1', 'CCCSCCC(=O)N1CCC(CC(=O)NCc2ccco2)C1(C)C', 'CCCSCCC(=O)NC(CC(C)(C)C)C(=O)N1CCCC2(C1)N=N2', 'CCCSCCC(=O)N[C@@H]1C=C[C@H](CNC(=O)C2C(C)(C)C2(F)F)C1', 'CCCSCCC(=O)N[C@H]1COC[C@@H]1NC(=O)c1cnc(OC)cn1', 'CCCSc1ccc(C(=O)NC(C)c2nnc3ccc(Br)cn23)cc1', 'CCCSc1ccccc1-c1nnc(NC(=O)N[C@@H]2C[C@H]2COC)s1', 'CCC[C@@H](C(=O)NC1(CCNC(=O)c2nocc2Cl)CCC1)N(C)C', 'CCC[C@@H](CC(=O)N1CC2(CCC2O)C1)NC(=O)CN1CCOCC1', 'CCC[C@@H](CC(=O)N1CCCc2nccn21)NC(=O)c1cc(O)cs1', 'CCC[C@@H](CC(=O)NC1(C)CC(C)(C)C1)NC(=O)C(C)(OC)C(C)C', 'CCC[C@@H](CC(=O)NCCc1nnc(C)s1)NC(=O)c1scnc1Cl', 'CCC[C@@H](CO)NC(=O)C1CCCCN(C(=O)Cn2nccc2C)C1', 'CCC[C@@H](CO)NC(=O)CC[C@H](CC)NC(=O)C12CCN(CC1)CC2', 'CCC[C@@H](NC(=O)C(C)c1ccnn1C)C(=O)NCC1(C2CC2)CC1', 'CCC[C@@H](NC(=O)C(C)c1ccnn1C)C(=O)NCc1cc(C)n[nH]1', 'CCC[C@@H](NC(=O)CC(C)C(F)F)C(=O)NCc1c(C)nnn1CC', 'CCC[C@@H](NC(=O)CC(CC)SC)c1csc(-c2cncc(F)c2)n1', 'CCC[C@@H](NC(=O)c1cccn1CC)C(=O)N1CC(C)(C)C[C@H]1CO', 'CCC[C@@H](NC(=O)c1ccnn1C)C(=O)N1CCC(C)(N(C)CC)C1', 'CCC[C@@H](NC(=O)c1nccc(C)c1N)C(=O)N(C)CCC(C)(C)C', 'CCC[C@@H](NC(N)=O)C(=O)N(Cc1cccs1)Cc1cnc(Cl)n1C', 'CCC[C@@H](O)C(=O)N(CC(C)CC1CCC1)CC(O)c1ccc(C)o1', 'CCC[C@@H](O)C(=O)N1CCC(O)C(N(C)C(=O)CC2C=CCCC2)C1', 'CCC[C@@H](O)C(=O)N1C[C@@H](O)C[C@H]1CNC(=O)c1cnn2c1OCC2', 'CCC[C@@H](O)C(=O)N1C[C@H](F)C[C@H]1C(=O)N1CCC(CC(=O)OC)C1', 'CCC[C@@H](O)C(=O)NC(CC(C)(C)C)C(=O)NCc1cccnc1F', 'CCC[C@@H](O)C(=O)NC1(CNC(=O)CCc2cnco2)CC(OC)C1', 'CCC[C@@H](O)C(=O)NC[C@@H]1C[C@@H](F)CN1C(=O)c1coc(C(C)C)n1', 'CCC[C@@H]1CN(C(=O)[C@@H](NC(=O)C2CCCO2)C(C)(C)C)C[C@H]1CO', 'CCC[C@H](C(=O)N[C@@H](C)CC(=O)N(C)CCn1cc(C)cn1)N(C)C', 'CCC[C@H](C(=O)N[C@H]1C[C@@H](N(C)C(=O)CCc2cnoc2)C1)N(C)C', 'CCC[C@H](C)NC(=O)C1(F)CCCN(C(=O)Cc2ccc(F)cc2)C1', 'CCC[C@H](CC(=O)N1CC(C)(OC)C1)NC(=O)[C@H]1C2C3C[C@@H]1C(=O)[C@H]32', 'CCC[C@H](CC(=O)N1CC=C(C)CC1)NC(=O)c1cc(C(C)C)[nH]n1', 'CCC[C@H](CC(=O)N1CCC1(C)C(=O)NC)NC(=O)[C@@H]1CCN(C)C1', 'CCC[C@H](CC(=O)N1CCOC2(CCCC2)C1)NC(=O)CCSCC', 'CCC[C@H](CC(=O)N1C[C@@H](F)[C@@H](C)C1)NC(=O)C(C)(C)C1(O)CCC1', 'CCC[C@H](CC(=O)N1C[C@@H](N(C)C)[C@@H](O)C1)NC(=O)C1COCCO1', 'CCC[C@H](CC(=O)NC1CC(=O)N(CC)C1)NC(=O)c1ccccc1', 'CCC[C@H](CC(=O)NCc1ccc(CO)o1)NC(=O)CNC(=O)NC', 'CCC[C@H](CC(=O)Nc1cc(C)cc(C)c1O)NC(=O)c1ncc[nH]1', 'CCC[C@H](NC(=O)C(=O)C1CCOCC1)C(=O)NC1CCC(F)CC1', 'CCC[C@H](NC(=O)C(C)(C)C)C(O)C(=O)Nc1cc(C)c(C)c(C)c1', 'CCC[C@H](NC(=O)C(C)(CC)OC)C(=O)Nc1cnn(CC2CC2)c1', 'CCC[C@H](NC(=O)C(C)CC1CCC1)C(=O)N(C)Cc1nccn1C', 'CCC[C@H](NC(=O)C(CC)CC)C(O)C(=O)NCC1COCC(C)O1', 'CCC[C@H](NC(=O)C1CCC(C)=C(C)C1)C(=O)NC1(C)CCCC1C', 'CCC[C@H](NC(=O)C1CCCC1)C(O)C(=O)N[C@H]1C[C@@H](CO)N(C)C1', 'CCC[C@H](NC(=O)C1CCS(=O)CC1)C(O)C(=O)NC1(C)CCOC1', 'CCC[C@H](NC(=O)CC(C)(C)C#N)C(=O)NC1CC12CCCCCC2', 'CCC[C@H](NC(=O)CCCC1CCCO1)C(=O)N[C@@H](C)c1ncc[nH]1', 'CCC[C@H](NC(=O)CCc1cncnc1)C(=O)N1CC(C)(CSC)C1', 'CCC[C@H](NC(=O)c1ccc(C#N)c(C)n1)C(=O)N(C)C(C)C(N)=O', 'CCC[C@H](NC(=O)c1cnn(-c2ccc(C)cc2)c1C(C)C)C(N)=O', 'CCC[C@H](NC(=O)c1csnc1Cl)C(=O)NC1(C)CN2CCC1CC2', 'CCC[C@H](NC(=O)c1n[nH]nc1C)C(=O)NC1C(C)(C)C(O)C1(C)C', 'CCC[C@H](NC(C)=O)C(=O)NCCOCCC(=O)N1C[C@@H](F)[C@@H](C)C1', 'CCC[C@H](O)C(=O)N(C)C1(CC(=O)NOCc2ccc(F)cc2)CC1', 'CCC[C@H](O)C(=O)N(C)CCCCN(C)C(=O)c1cnc(SC)n1C', 'CCC[C@H](O)C(=O)N(CCC)C(C)C(=O)NCCC1NC(=O)NC1=O', 'CCC[C@H](O)C(=O)N(Cc1ccc2occc2c1)CC1CCCCS1', 'CCC[C@H](O)C(=O)N1CCC(O)(CCNC(=O)C23CC(CO)(C2)C3)C1', 'CCC[C@H](O)C(=O)NC(C)CC1CN(C(=O)c2ccc(F)cc2Cl)C1', 'CCC[C@H](O)C(=O)NCC1(CNC(=O)c2cc(C)no2)CCCCC1', 'CCC[C@H](O)C(=O)NCC[C@@H]1CCN(C(=O)C(F)(F)C2(O)CCC2)C1', 'CCC[C@H](O)C(=O)NC[C@H]1CCCCN1C(=O)CCCCC(C)(C)C', 'CCC[C@H](O)C(=O)NC[C@H]1CCCC[C@H]1C(=O)N1CCC(CC)CC1', 'CCC[C@H]1CN(C(=O)C(=O)NOC)C[C@@H]1C(=O)N(C)[C@@H](C)C(=O)NC', 'CCC[C@H]1CN(C(=O)CSC(F)(F)F)C[C@@H]1C(=O)N[C@H]1C[C@H](CO)C1', 'CCC[C@H]1CN(C(=O)[C@H]2CC[C@H]3C[C@H]32)C[C@H]1NC(=O)C1CC(C)=NO1', 'CCC[C@H]1CN(C(=O)c2c[nH]cc2C)C[C@@H]1C(=O)N1CCCC1CO', 'CCC[C@H]1C[C@@H]1C(=O)N(CCCCSC)Cc1cc(C#N)n(C)c1C', 'CCC[C@H]1C[C@@H]1C(=O)N1C[C@@H]2[C@H](C1)[C@H]2C(=O)NC12CCC(CC1)CC2', 'CCC[C@H]1C[C@@H]1C(=O)N1[C@H](CNC(=O)CCN(C)CCC)C[C@@H]2C[C@@H]21', 'CCC[C@H]1C[C@@H]1C(=O)NC(C(=O)NCCCOC(=O)NC)C1(C)CC1', 'CCC[C@H]1C[C@@H]1C(=O)NC1CC(CC(=O)N2CC(CC)(CCO)C2)C1', 'CCC[C@H]1C[C@@H]1C(=O)NC[C@H]1C=C[C@@H](NC(=O)c2cnc(C)cn2)C1', 'CCC[C@H]1C[C@@H]1CN(Cc1ncccc1Cl)C(=O)CC1CSCCO1', 'CCC[C@H]1C[C@@H]1CNC(=O)C(Cn1cccn1)NC(=O)C=C1CCC1', 'CCC[C@H]1C[C@@H]1NC(=O)C1CCCN(C(=O)c2cccc(CO)c2)C1', 'CCC[C@H]1C[C@@H]1NC(c1cn(C(C)C)nn1)c1nnnn1CC(F)F', 'CCCc1[nH]ncc1C(=O)N(CC(=O)NC1(CCC)CCC1)C(C)C', 'CCCc1[nH]ncc1C(=O)N1CCC(C(=O)N(CCC)OC)C12CC2', 'CCCc1c(NCc2cccc(C#N)n2)cnn1-c1cccc(C)c1', 'CCCc1cc(C(=O)N2CC(F)(C(=O)N(C)CCNC(C)=O)C2)[nH]n1', 'CCCc1cc(C(=O)NCC(CC2CC2)C(=O)NC2CC=CC2)no1', 'CCCc1cc(C(=O)NCC(NC(=O)[C@H]2C[C@H](OC)C2)C(C)C)no1', 'CCCc1cc(C(=O)NCCN2CCc3ccccc3C2=O)nn1C', 'CCCc1cc(NC(=O)C(C)CC2CCN2C(=O)OC(C)(C)C)on1', 'CCCc1ccc(C(=O)NCc2cc(F)ccc2F)cc1S(N)(=O)=O', 'CCCc1ccc(C(=O)OC)cc1Nc1cc(C(F)(F)F)cc(C)n1', 'CCCc1cccc(C(=O)N[C@H](CNC(=O)C=CCO)CC(C)C)c1', 'CCCc1ccccc1COC(=O)CNc1ccc(C(F)(F)F)cn1', 'CCCc1conc1C(=O)N(CCCCF)Cc1c(C)nn(C)c1C', 'CCCc1csc(CN(CC23CCC(CC2)O3)C(=O)C(C)(O)CC)n1', 'CCCc1csc(CN(Cc2csc(CC)n2)CC(O)C2CCC2)n1', 'CCCc1nc(C(=O)N2CC(NC(=O)C3=CCCC3)C(C)(C)C2)cs1', 'CCCc1nc(C(=O)N[C@@H]2CCC[C@H]2NC(=O)c2ccccc2)cs1', 'CCCc1nc(C(C)(C)NC(=O)NCC2CN(CC(F)(F)F)C2)no1', 'CCCc1nc(C(C)(C)NC(=O)NCc2ccc(C(C)=O)cc2)no1', 'CCCc1nc(CN(C)C(=O)C2(c3ccccc3)CC(C)=NO2)cs1', 'CCCc1ncc(C(=O)N[C@H]2CC[C@H]2NC(=O)C(C)(C)OC(C)C)s1', 'CCCc1ncc(CN(Cc2ccc(C)cn2)CC2(C)CC2(F)F)s1', 'CCCc1ncoc1C(=O)N1CCC1CNC(=O)C1(C#N)CCCO1', 'CCCc1ncoc1C(=O)NC1CCN(C2CC2)CC1c1nn[nH]n1', 'CCCc1ncoc1C(=O)N[C@H]1CCC[C@H]1C(=O)N[C@H](C)C[C@H](C)O', 'CCCc1nn(C)c(C(N)=O)c1NC(=O)C1=COc2ccccc2O1', 'CCCc1nnc(NC[C@H]2CN(C(=O)CC3CC(F)(F)C3)C[C@H]2O)s1', 'CCCc1nnsc1C(=O)NCCN(CC)C(=O)Cc1nocc1C', 'CCCc1nnsc1CNC(=O)N1CCc2cc(OC)c(Cl)cc2C1', 'CCCc1nsc(N2CCN(C(=O)CCCCCC(=O)OC)CC2)n1', 'CCCn1c(=NS(=O)(=O)C(C)CC(=O)OC)n(CC)c2ccccc21', 'CCCn1c(Cc2ccccc2)nnc1SCc1ccnc(F)c1Cl', 'CCCn1c(SCC(=O)OCCCn2ccnc2)nc2ccccc21', 'CCCn1cc(-c2cn(CC3CCN(C(=O)CSC)CC3)nn2)cn1', 'CCCn1cc(C(=O)N2CC([C@@H]3C[C@H]3C(=O)NC3CC3(C)C)C2)cn1', 'CCCn1cc(C(=O)N2CCOC(C)(CNC(=O)[C@@H](O)CC)C2)cn1', 'CCCn1cc(C(=O)NC/C=C\\CNC(=O)C2CCCC(=O)C2)nn1', 'CCCn1cc(C(=O)NCCCCNC(=O)c2coc(CO)c2)cn1', 'CCCn1cc(C(=O)NCCN(C)C(=O)c2cc(OCC)[nH]n2)nn1', 'CCCn1cc(CNC(=O)Nc2c(C(C)C)nc3ccccn23)nn1', 'CCCn1cc(CNC2CN(C(=O)OC(C)(C)C)CC(F)(F)C2)nn1', 'CCCn1cc(CNc2ncnc(NCC(=O)NC(C)C)c2C)nn1', 'CCCn1cc(NC(=O)C2CC(C)N2C(=O)c2ccc(C)nc2)cn1', 'CCCn1cc(NC(=O)NC(C)c2ccc(S(C)=O)cc2)ccc1=O', 'CCCn1cc(NC(=O)[C@@H]2CC3(CC3)CN2C(=O)c2ccoc2)cn1', 'CCCn1cc(NC(=O)[C@H]2[C@@H]3CN(C(=O)C(C)CSC)CC[C@@H]32)cn1', 'CCCn1ccc(C(=O)N(CCOc2ccccc2)C(C)C(=O)O)n1', 'CCCn1ccc(C(=O)N2CCC2(C)CC(=O)N(C)C2CCC2C)n1', 'CCCn1ccc(C(=O)NC[C@@H](C)NC(=O)CSc2nncn2C)n1', 'CCCn1ccc(CN(CC(C(C)C)C(C)C)C(=O)c2cnns2)n1', 'CCCn1ccc(CN(CCC(F)=C(F)F)C(=O)C2CCCCS2)n1', 'CCCn1ccc(CN(C[C@H]2CC[C@@H]2OCC)C(=O)CP(C)(C)=O)n1', 'CCCn1ccc(CNC(=O)Nc2nccn2Cc2ccccc2)n1', 'CCCn1cccc1C(=O)N(C)CC(C)C(=O)N1CCCCC1CO', 'CCCn1cccc1C(=O)N[C@H](COC)C(=O)NC1CC(CSC)C1', 'CCCn1cccc1C(=O)N[C@H]1COC[C@H]1C(=O)N1CC=CC(O)C1', 'CCCn1ccnc1CN(CCOC1CC1(F)F)Cc1cn(C)nn1', 'CCCn1ccnc1CNC(=O)C(C)NC(=O)CCCC1CCCC1', 'CCCn1nc2c(cc1=O)CN(C(=O)Cc1sc(SC)nc1C)CC2', 'CCCn1nccc1C(=O)NC1(C(=O)N2CCN(C(C)=O)CC2)CC1', 'CCCn1nccc1C(=O)N[C@@H](C)CC(=O)N[C@H]1COC[C@@H]1OCC', 'CCCn1nccc1C(=O)N[C@H](CO)C(=O)N1CC(C)(C)C12CCC2', 'CCCn1nccc1NC(=O)COC(=O)Cn1ncc2ncccc21', 'CCCn1ncnc1C(NC1(CCOC)CC1)c1nnnn1C(C)C', 'CCCn1ncnc1CN(CC(O)C1CCC1)CC1CC12CC2(F)F', 'CCCn1nnnc1C(NCC1(C(O)C(C)C)CC1)c1ccn(C)c1', 'CCCn1nnnc1C(NCc1cn(C(C)C)nn1)C1(C)CC1(C)C', 'CCCn1nnnc1C(NCc1cnsc1)c1csc(C(F)(F)F)n1', 'CCCn1nnnc1C(c1ccc(Cl)c(Br)c1)N(C)Cc1cn[nH]c1', 'CCCn1nnnc1C(c1ccc(SC)cc1)N1CCC[C@H]1COC', 'CCN(C(=O)C(C)n1cc(-c2nnc3n2CCC3)nn1)C(C)COC', 'CCN(C(=O)C1=CCC(NC(=O)c2c[nH]c(C#N)c2C)C1)C1CCC1', 'CCN(C(=O)C1CC(c2ccc(Cl)cc2Cl)=NO1)c1cncc(Br)c1', 'CCN(C(=O)CC1(N(C)C(=O)CC2CCCCC2)CC1)C12CC(C1)C2', 'CCN(C(=O)CC1CC(C)(C)CO1)[C@H](C)CNC(=O)c1cccnn1', 'CCN(C(=O)CC1CC(C)C1)C1CCN(C(=O)c2cnc(S)n2C)C1', 'CCN(C(=O)CCCCCn1cc(C2CCC2)nn1)C1CCN(C)C1', 'CCN(C(=O)CCc1ccsc1)[C@H](C)CNC(=O)c1oc(C)nc1C', 'CCN(C(=O)CCn1cnnn1)[C@H](C)CNC(=O)c1cc(C)ncn1', 'CCN(C(=O)C[C@H](CC(C)C)NC(=O)[C@@H]1CC(=O)N[C@H](C)C1)C1CC1', 'CCN(C(=O)Cc1cc(C)cs1)C1CCCN(C(=O)c2cnsn2)C1', 'CCN(C(=O)Cc1ccc(O)cn1)c1ccc(N2CCOCC2)cc1', 'CCN(C(=O)Cc1ccc2cn[nH]c2c1)[C@H](C)CNC(=O)C=CCF', 'CCN(C(=O)Cc1ccsn1)C(C)C(=O)Nc1ccc(C)c(O)c1C', 'CCN(C(=O)Cc1csc(C)n1)C(C)C(=O)NCc1cccnc1Cl', 'CCN(C(=O)Cn1cc(C(F)(F)F)nn1)c1nc2c(C)cccc2s1', 'CCN(C(=O)[C@H]1C[C@@H](CNC(=O)Cc2scnc2C)C1)C1CCCC1', 'CCN(C(=O)c1cc(-c2ccc(Cl)cc2)oc1C)C1CCC(N)CC1', 'CCN(C(=O)c1ccc(F)cc1F)C(C)C(=O)NCCC(O)C(C)C', 'CCN(C(=O)c1ccc(N)nc1)C(C)C(=O)NOCCCCC1CC1', 'CCN(C(=O)c1cccc(F)c1)C(C)C(=O)Nc1cnc(O)c(F)c1', 'CCN(C(=O)c1cccnc1S)C(C)C(=O)NCCc1cccnc1', 'CCN(C(=O)c1cnc(C)o1)C1CCN(C(=O)COCCOC)CC1', 'CCN(C(=O)c1nn(C)cc1Cl)C(C)C(=O)NCCCc1cn[nH]c1', 'CCN(C(=O)c1sccc1CO)C1CCN(C(=O)Cn2ncnn2)C1', 'CCN(C)C(=O)C(C)NC(=O)/C=C/C1CCCN1C(=O)CC1CSC1', 'CCN(C)C(=O)CC1CCN(C(=O)C2=Cc3ccccc3C2)C1(C)C', 'CCN(C)C(=O)CNc1ccnc(NCc2nnc(C3CC3)n2C)n1', 'CCN(C)C1(C)CCN(C(=O)CC(C)(C)CNC(=O)c2cnsn2)C1', 'CCN(C)C1CCN(CC(=O)Nc2ccc(N3CCCC3)cc2)CC1', 'CCN(C)C1CN(C(=O)COC2CN(C(=O)C=Cc3ccc[nH]3)C2)C1', 'CCN(C)C1CN(C(=O)[C@@H]2CC(F)(F)CN2C(=O)c2csnc2Cl)C1', 'CCN(C)CC(=O)N(C)[C@@H]1CCCN(C(=O)c2cc(C(N)=O)cs2)C1', 'CCN(C)CC(=O)N(C)[C@H]1C[C@@H](NC(=O)CC(C)c2cnn(C)c2)C1', 'CCN(C)CC(=O)N(Cc1c(C)n[nH]c1C)CC1COCC(C)(C)O1', 'CCN(C)CC(=O)N1CCCC1CC(=O)N1CCOC(CC)(CC)C1', 'CCN(C)CC(=O)N1C[C@H](OC)C[C@H]1CNC(=O)Cc1cc(C)no1', 'CCN(C)CC(=O)N1C[C@H]2C[C@@H](C(=O)NCC3(CC)CCC3)C[C@H]2C1', 'CCN(C)CC(=O)NC1CN(C(=O)[C@H]2CC[C@@H](OC)CC2)CCC1C', 'CCN(C)CC(=O)N[C@H]1CCN(C(=O)C2C3CC(=O)CC32)[C@@H]1C(C)C', 'CCN(C)CC1CCN(C(=O)C(C)(CO)NC(=O)[C@H]2C[C@](C)(F)C2)C1', 'CCN(C)CC=CC(=O)N(CC)[C@H](C)CNC(=O)C1=C(Cl)CCOC1', 'CCN(C)CC=CC(=O)NC/C=C(\\C)C(=O)N[C@@H]1CCC(=O)NC1=O', 'CCN(C)CCC(=O)N1CC=C(CC(=O)N2CC(C)CC(C)C2)CC1', 'CCN(C)CCC(=O)N[C@H]1CCC[C@H](C(=O)NC2(CC)CCCC2)C1', 'CCN(C)CCC(=O)N[C@H]1C[C@H](C(=O)N2CC3(CNC(=O)OC3)C2)C1', 'CCN(C)CCCCCNC(=O)[C@H]1COC[C@H]1NC(=O)C1C=CCS1', 'CCN(C)[C@@H](C)[C@H](O)C1=CC=CC=C1', 'CCN(C)[C@H]1C[C@@H](C(=O)N(C)CCC(=O)N2CCNC(=O)CC2C)C1', 'CCN(C)[C@H]1C[C@@H](C(=O)N2C[C@H](C)[C@@H]2C(=O)NCCc2ccon2)C1', 'CCN(C)c1cc(CNC(=O)NCc2c(Cl)cc(Br)cc2Cl)ccn1', 'CCN(C)c1ccc(COC(=O)C=Cc2ccc(S(C)(=O)=O)o2)cc1', 'CCN(C)c1nc(N[C@@H]2[C@@H](C(F)(F)F)[C@@H]3CC[C@H]2O3)c2[nH]ccc2n1', 'CCN(C)c1nc2c(c(NCCCOc3cccc(C)c3)n1)CCC2', 'CCN(C1CC1)S(=O)(=O)N(C)C(c1ccc(Cl)cc1)c1ccccn1', 'CCN(CC(=O)N(C)CCc1cnccn1)C(=O)[C@@H]1C[C@H](F)C(=O)N1', 'CCN(CC(=O)N(Cc1ccccc1)CC(SC)C(C)(C)C)C1CC1', 'CCN(CC(=O)N1CCC2(CCSC2)C1)C(=O)C1CC(C(C)C)=NO1', 'CCN(CC(=O)NC(CCN(C)C(=O)C(=O)NOC)C(C)C)C1CC1', 'CCN(CC(=O)NC1CC(C)N(C)CC1C)C(=O)C1CN(C)C(=O)N1', 'CCN(CC(=O)NC1CC2(CCCCO2)C1)C(=O)[C@H]1C[C@@H]1C(C)(F)F', 'CCN(CC(=O)NC1CCN(C(N)=O)CC1)C(=O)c1scc(C)c1C', 'CCN(CC(=O)NC1CCS(=O)(=O)C1)C(=O)[C@@H]1C[C@H]2C[C@H]2N1C(C)=O', 'CCN(CC(=O)NC1CN2CCC1CC2)C(=O)CCC(=O)C(C)(C)C', 'CCN(CC(=O)NCC(C)(C)CN=[N+]=[N-])C(=O)c1[nH]ccc1COC', 'CCN(CC(=O)N[C@@H]1CCN(C(=O)COC(C)=O)C[C@H](O)C1)C1CC1', 'CCN(CC(=O)Nc1ccn(CCO)n1)C(=O)Cc1ccn(CC)n1', 'CCN(CC(=O)OC)C(=O)CC1=CCN(C(=O)c2cnn(C)n2)CC1', 'CCN(CC(=O)Oc1ccc(-c2nc(C)cs2)cc1)c1ccccc1', 'CCN(CC(C)(C)C)C(=O)c1cn(CCNC(=O)CCC2CC2)nn1', 'CCN(CC(C)NC(=O)c1cc(C)cc(O)n1)C(=O)c1csc(F)c1', 'CCN(CC(C)NC(=O)c1cc(O)n(C)n1)C(=O)[C@H]1C[C@@H](C)N(C)C1', 'CCN(CC(C)NC(=O)c1csnc1OC)C(=O)[C@H]1CCO[C@H](C)C1', 'CCN(CC(C)OC)C(=O)C1CCN(C(=O)c2ccncc2O)CC1', 'CCN(CC(F)F)C(=O)C[C@H]1CC[C@H](NC(=O)Cc2cscn2)CC1', 'CCN(CC(F)F)C(=O)c1[nH]ccc1CNC(=O)c1ncn(C)c1C', 'CCN(CC(N)=O)C(=O)[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H]1C[C@H]2C[C@@H]1C[C@H]2O', 'CCN(CC)C(=O)CCCNCc1cc(-n2cccn2)ccc1OC', 'CCN(CC)C(=O)CCNC(=O)CN(CC)C(=O)c1ncncc1Cl', 'CCN(CC)C(=O)CNC(=O)C1(NC(=O)Cc2ccn(C)n2)CCC1', 'CCN(CC)C(=O)CNC(=O)NC(CN1CCCC1)c1ccccc1', 'CCN(CC)C(=O)N1CCCC(C(=O)Nc2nccn2CCOC)C1', 'CCN(CC)C(=O)NC1=CC=C(OCC(O)CNC(C)(C)C)C(=C1)C(C)=O', 'CCN(CC)C(=O)c1ccc(NC(=O)NC2(COC)CCOC2)cc1', 'CCN(CC)C(CNC(=O)NCCCc1nc(C)cs1)c1ccco1', 'CCN(CC)C1CCN(C(=O)C2CCN(C(=O)CCOC3CC3)C2)C1', 'CCN(CC)C1CCN(CC(=O)NS(=O)(=O)c2cccc(Cl)c2Br)C1', 'CCN(CC)CC(=O)N(C)CC(O)CNC(=O)C=CC1CCOCC1', 'CCN(CC)CC(=O)N(CC)CC(C)(C)CNC(=O)c1c[nH]c(=O)s1', 'CCN(CC)CC(=O)N(Cc1ccsn1)CC1COc2ccccc21', 'CCN(CC)CC(=O)N1C[C@@H](O)C[C@H](NC(=O)c2sccc2C#N)C1', 'CCN(CC)CC(=O)N1C[C@@H](OC)C[C@@H]1C(=O)N1CCOCC(C)C1', 'CCN(CC)CC(=O)NCC1CC1NC(=O)c1ccc(N(C)C)cn1', 'CCN(CC)CC(=O)N[C@@H](CC(C)(C)C)C(=O)N[C@@H]1COCC[C@H]1O', 'CCN(CC)CC=CC(=O)N1CCC=CC1C(=O)N(C)CC(C)(F)F', 'CCN(CC)CCC(=O)N1CCOCC1C(=O)NCc1ncc(C)o1', 'CCN(CC)CCC1CCN(Cc2cnnn2C2CCCNC2)CC1', 'CCN(CC)CCCC(C)N(C)C(=O)NCC1(c2ccccn2)CC1', 'CCN(CC)CCN(CC(=O)O)Cc1ccc(-c2ccc(C)cc2)o1', 'CCN(CC)CCNc1nc(N)nc(NCc2ccc(C#N)cc2)n1', 'CCN(CC)Cc1cc(OC)ccc1OC(=O)c1coc2c1COC2', 'CCN(CC)Cc1ccc(NC(=O)NCc2cncn2CC)c(C)c1', 'CCN(CC)Cc1cn(C2CN(C(=O)C3CCCCN3CC)C2)nn1', 'CCN(CC)[C@H](C)C(=O)N1CC[C@@H](CCNC(=O)[C@@H](C)NC(C)=O)C1', 'CCN(CC)c1nc(NCC(F)(F)Cl)nc(NC2CC(CC#N)C2)n1', 'CCN(CC1CC1)C(=O)C1(C2CC2)CN(C(=O)C=CC(=O)N(C)C)C1', 'CCN(CC1CC1)C(=O)C1(CNC(=O)c2ccncc2)CCCCC1', 'CCN(CC1CC1)C(=O)Nc1cc(Cl)ccc1C(=O)N1CCCCC1', 'CCN(CC1CC1)C(=O)[C@@H]1C=C[C@H](NC(=O)COCC2CCCC2)C1', 'CCN(CC1CCCO1)C(=O)C(C)N(CC)C(=O)C=C(C)C(C)(C)C', 'CCN(CC1CCN(C(=O)[C@@H]2CC[C@H]2C)CC1)C(=O)c1sccc1Cl', 'CCN(CC1COc2ccccc2O1)C(=O)CNC(C1CC1)C1CC1', 'CCN(CCC#N)C(C(=O)NC1CCC1)c1ccc(F)c2[nH]ncc12', 'CCN(CCC(=O)N(C)[C@H]1CC[C@H]2C[C@H]21)C(=O)c1nnn(CC)c1C', 'CCN(CCC(=O)N1CC(C(=O)OC)C1)C(=O)Cc1ccc(F)cc1', 'CCN(CCC(=O)N1CCC(OCC(C)C)C1)C(=O)CC1(C#N)CC1', 'CCN(CCC(=O)N1C[C@H](C)CC[C@H]1C)C(=O)CCCCCN=[N+]=[N-]', 'CCN(CCC(=O)N1Cc2cncnc2C1)C(=O)c1ncn(C)c1C', 'CCN(CCC(=O)NC(C)c1ccccc1C)C(=O)c1cc(C)on1', 'CCN(CCC(=O)NC1CC2(CCCCC2)C1)C(=O)C(OC)C(C)C', 'CCN(CCC(=O)NCC(C)C(F)(F)F)C(=O)C1CCOCC1(C)C', 'CCN(CCC(=O)NCC1C=CCCC1)C(=O)c1cc(COC)no1', 'CCN(CCC(=O)NCC1CNC(=O)CO1)C(=O)C1CCC(F)CC1', 'CCN(CCC(=O)NCc1c(C)nn(C)c1C)C(=O)Cc1cnoc1', 'CCN(CCC(=O)NCc1c[nH]nc1C)C(=O)[C@H]1C[C@H]2CC(=O)[C@@H]1C2', 'CCN(CCC(=O)NCc1cncs1)C(=O)c1cccc2c1CCC2', 'CCN(CCC(F)(F)F)C(=O)C(C)C(C)NC(=O)C1=C(C)OCCC1', 'CCN(CCC(N)=O)C(=O)c1ccc(CN2CCC(OC)CC2)cc1', 'CCN(CCC1CC1)C(=O)C(=O)NCc1cc(OC)c(O)c(OC)c1', 'CCN(CCC1CC1)C(=O)[C@@H]1COCCN1C(=O)CCc1ccco1', 'CCN(CCCN(C)C(=O)NCCN1CC(CF)C1)c1ccccc1', 'CCN(CCCN1CCCC1)C(=O)c1ccc(OC2CCNC2)nc1', 'CCN(CCCNC(=O)C1CCCCNC1=O)C(=O)c1ccc(C)o1', 'CCN(CCCNC(=O)C1CN(C(C)C)C1)C(=O)Cc1ccoc1C', 'CCN(CCCNC(=O)CC1CCSCC1)C(=O)C1COCCN1C', 'CCN(CCCNC(=O)c1[nH]ncc1C1CCC1)C(=O)C1=C(C)CC1', 'CCN(CCCNCc1ccc(OC)c(OC)c1Cl)C1CCCCC1', 'CCN(CCCNS(=O)(=O)c1cnc(C2CC2)nc1)c1ccccc1', 'CCN(CCF)C(=O)C(NC(=O)c1cccn1CC)C1CC=CCC1', 'CCN(CCF)C(=O)CCOC1CN(C(=O)CCc2cccnc2)C1', 'CCN(CCN(CC)C(=O)C(C)=Cn1ccnn1)C(=O)C=CCOC', 'CCN(CCN(CC)C(=O)c1cc(O)nn1C)C(=O)c1nc[nH]c1C', 'CCN(CCN=[N+]=[N-])C(=O)CC1(NC(=O)CC(C)OC)CCCCC1', 'CCN(CCN=[N+]=[N-])C(=O)CCCC1(NC(=O)C2[C@H](C)[C@H]2C)CCC1', 'CCN(CCN=[N+]=[N-])C(=O)CCOC1CN(C(=O)C2CCC(C)O2)C1', 'CCN(CCNC(=O)C(O)CC(C)(C)C)C(=O)[C@@H]1CCCN1C(C)C', 'CCN(CCNC(=O)C1(C)CC(=O)N(C)C1)C(=O)c1csc(SC)n1', 'CCN(CCNC(=O)C1(C)CC1(F)F)C(=O)c1cnn2c1OCCC2', 'CCN(CCNC(=O)C1(C)CCN(C)CC1)C(=O)C1=CC2C=CC1C2', 'CCN(CCNC(=O)C1CNc2ncnn2C1)C(=O)c1nc[nH]c1C', 'CCN(CCNC(=O)CC1CC(C)C1)C(=O)c1cc(C)cc(C#N)c1', 'CCN(CCNC(=O)CCn1cccnc1=O)C(=O)CNC(=O)OC', 'CCN(CCNC(=O)Cc1ccc(C)s1)C(=O)CSc1nncn1C', 'CCN(CCNC(=O)Nc1cn[nH]c(=O)c1Cl)Cc1cccc(F)c1', 'CCN(CCNC(=O)c1cc(OC)[nH]n1)C(=O)C1CC(=C2CCC2)C1', 'CCN(CCNC(=O)c1cccc(C2CC2)c1)C(=O)C=C(C)C(C)C', 'CCN(CCNC(=O)c1cn[nH]c1Cl)C(=O)COC1(C)CCOCC1', 'CCN(CCNC(=O)c1cnc(C)nc1C)C(=O)c1cnc(C)nc1', 'CCN(CCNC(=O)c1cscc1C1CC1)C(=O)C(F)C1CCOC1', 'CCN(CCO)C(=O)C1CN(C(=O)COC2(C)CCC2)CC(C)(C)C1', 'CCN(CCOCCO)C(=O)c1ncsc1-c1ccc([C@@H](C)N)cc1', 'CCN(CCS(N)(=O)=O)C(=O)c1cc(-c2ccc(OC)cc2)nn1C', 'CCN(Cc1ccc(F)c(F)c1)C(=O)Nc1ccc(C(C)(C)C)nn1', 'CCN(Cc1ccc(F)cc1F)C(=O)C(=O)NCC1(C)CCOCC1', 'CCN(Cc1ccncc1)C(=O)C1(NC(=O)C2=C(C)CC2)CC1(C)C', 'CCN(Cc1cn(C2CCCCC2)nn1)C(C)c1ccc(C#N)cc1', 'CCN(Cc1cncn1C)C(=O)C(=O)NC1CCCn2c(C)nnc21', 'CCN(Cc1nc2cc(Cl)ccc2c(=O)[nH]1)C(=O)C(O)c1ccsc1', 'CCN(Cc1ncc[nH]1)C(=O)[C@H]1OCC[C@H]1CNC(=O)c1ccoc1', 'CCN(OC)C(=O)CNC(=O)CN(C(=O)c1cocc1C)C1CCC1', 'CCN(c1ccc(C(=O)N2CCc3ccc(F)cc32)cc1)S(C)(=O)=O', 'CCN(c1ccc(NC(=O)C(=O)N2CCSC(C)CC2)cc1)C(C)C', 'CCN1C(=O)CCc2cc(NC(=O)[C@@H]3CCC[C@H](C(=O)O)N3)ccc21', 'CCN1C(=O)CO[C@H](C(=O)NCCC(O)COC)[C@H]1c1ccccc1', 'CCN1C(=O)Cc2cc(NC(=O)N3CCC[C@H]3COC(C)=O)ccc21', 'CCN1C2CCC1CN(C(=O)C[C@@H](C)NC(=O)CCc1ccc[nH]1)C2', 'CCN1CC(CC(=O)N(Cc2c[nH]nc2C)CC2(CF)CCCC2)C1', 'CCN1CC(CC(=O)N[C@H]2C[C@@H](Nc3nc(Cl)c(C(=O)OC)s3)C2)C1', 'CCN1CC(CN(CCC(C)(C)OC)C(=O)C(F)(F)C2CC2)OC1=O', 'CCN1CC(CN(Cc2nocc2C)C(=O)C(O)CN(C)C)OC1=O', 'CCN1CC(NC(=O)/C=C/C(C)(C)NC(=O)c2ncc(F)cc2C)C1', 'CCN1CC(NC(=O)C2(CCOC)CCN(C(=O)C(C)CO)CC2)C1', 'CCN1CC(NC(=O)CC(C)(C)NC(=O)COC2CCCC2)CC1=O', 'CCN1CC(NC(=O)N2CCC(Oc3ccc(C#N)cn3)C2)CC1=O', 'CCN1CC(NC(=O)[C@@H]2C[C@H](NC(=O)[C@@]3(C)CCC(=O)N3)[C@@H](O)C2)C1', 'CCN1CC(NC(=O)c2ccc(-n3nc(C)cc3N)cc2)C(C)(C)C1', 'CCN1CCC(C(=O)NCC(C)CC(=O)N2CCOC(COC)C2)C1', 'CCN1CCC(C(=O)NCCC(O)CNC(=O)[C@@H](O)CC(C)C)CC1', 'CCN1CCC(N(C)C(=O)C2CCN2C(=O)c2cnc(O)n2CC)C1', 'CCN1CCC(N(C)C(=O)[C@H]2CC[C@H]2NC(=O)[C@H]2C[C@@H]2C(C)(F)F)C1', 'CCN1CCC(NC(=O)NC2(c3cc(OC)cc(OC)c3)CC2)CC1', 'CCN1CCC(NC(=O)Nc2ccc3oc(C(C)(C)C)nc3c2)CC1', 'CCN1CCC(Nc2cc(C)nc(NC(C)CN3CCCC3)n2)CC1', 'CCN1CCC1C(=O)N1CCC(CNC(=O)C(CO)OC)C12CCC2', 'CCN1CCC1C(=O)N1CC[C@H](C(=O)N(C)C2CCCC2C)[C@H](O)C1', 'CCN1CCC1C(=O)N1CC[C@H]2[C@@H](C1)[C@@H]2C(=O)N1CC(CN(C)C)C1', 'CCN1CCCC(C(=O)N2CC(COC)(NC(=O)c3cncs3)C2)C1', 'CCN1CCCC(C(=O)NC2CN(C(=O)COC)CC3(CCC3)C2)C1', 'CCN1CCCC(C(=O)NC[C@@H](CO)NS(=O)(=O)c2cnc(C)s2)C1', 'CCN1CCCC(CNc2cc(NC3CC4CC4C3)nc(C)n2)C1=O', 'CCN1CCCC(NC(=O)[C@H]2CC[C@H]2CNC(=O)C(C)(CO)OC)C1', 'CCN1CCCC1C(=O)N1CC2(CC(NC(=O)C3CCOCC3)C2)C1', 'CCN1CCCCC1C(=O)N1CC(C(=O)NCC2CSC2)CC1(C)C', 'CCN1CCC[C@@H]1C(=O)NCCC(C)NC(=O)CC1CCC(C)(C)O1', 'CCN1CCC[C@H]1C(=O)N[C@@H]1[C@H]2C[C@@H]1N(C(=O)C1(CF)CC(=O)C1)C2', 'CCN1CCN(C(=O)C2(CNC(=O)[C@H]3CC3(F)F)CCCC2)C(C)C1', 'CCN1CCN(C(=O)CC2(C)CCN2C(=O)[C@@H]2CCC[C@H]2O)CC1C', 'CCN1CCN(C(=O)c2ccccc2Oc2ccc(F)cc2)CC1=O', 'CCN1CCN(CC(C)CNC(=O)c2cnc(NCCOC)s2)CC1', 'CCN1CCN(c2nc(NCCC(C)C)nc3ncn(CC)c23)CC1', 'CCN1CCOCC1C(=O)N[C@H](C(=O)NCc1cn[nH]c1)C(C)(C)C', 'CCN1CCc2cc(CN(C=O)C3CCC(O)(C(C)C)CC3)ccc21', 'CCN1CCc2cc(CN[C@H](CC3CCCCC3)C(=O)OC)ccc21', 'CCN1[C@H](C)CN(C(C(=O)NC)c2cnn(C3CCCC3)c2)C[C@@H]1C', 'CCNC(=O)C(=O)N(Cc1c(Cl)n[nH]c1C)CC(OC)(OC)C1CC1', 'CCNC(=O)C(=O)N1CC2CC(C(=O)Nc3cn(C)nc3CC)(C2)C1', 'CCNC(=O)C(=O)N1C[C@H](NC(=O)CC(C)n2cccc2)[C@@H](OC)C1', 'CCNC(=O)C(=O)NCCC(C)(C)C(=O)N[C@H]1C[C@@H]1C1CCCCC1', 'CCNC(=O)C(=O)NCCOCCCN(C)C(=O)c1ccc(CC)[nH]1', 'CCNC(=O)C(=O)N[C@H]1C=C[C@@H](C(=O)N2CCN3CCCC[C@@H]3C2)C1', 'CCNC(=O)C(C1=CCCCC1)N1CCCc2ccc(N=[N+]=[N-])cc21', 'CCNC(=O)C(C1CCC2(CC2)C1)N1CCCC(C2CCCCO2)C1', 'CCNC(=O)C(C1CCCC1(C)C)N1CCC(c2ccnn2C)CC1', 'CCNC(=O)C(C1CCCCC1)N1CCc2ccc(C(C)C)cc2C1', 'CCNC(=O)C(CCC=C(C)C)N1CCc2c(ccnc2N(C)C)C1', 'CCNC(=O)C(c1ccn(CC)n1)N1Cc2ccccc2OCC1C', 'CCNC(=O)C(c1cncc2ccccc12)N(CC(=O)OC)C1CC1', 'CCNC(=O)C(c1cnn(-c2ccccc2)n1)N1CCCCC12CC2', 'CCNC(=O)C(c1cnn(C(C)C)c1F)N1CCNC(=O)C(F)(F)C1', 'CCNC(=O)C1(NC(=O)CC[C@@H](C)NC(=O)C2(C)SCCCS2)CC1', 'CCNC(=O)C1(NC(=O)[C@H]2CCC[C@H]2NC(=O)[C@@H]2CCC(=O)N2)CC1', 'CCNC(=O)CC(=O)N1CC2(C1)CN(C(=O)Cc1ccncc1Cl)C2', 'CCNC(=O)CC(=O)N1CCC(CNC(=O)c2cc(C(C)=O)on2)C1', 'CCNC(=O)CC(=O)N1CC[C@H](NC(=O)c2cnc([N+](=O)[O-])n2C)C1', 'CCNC(=O)CC(=O)N1CSC[C@H]1C(=O)N1CCC(c2nn[nH]n2)C1', 'CCNC(=O)CC(=O)N1C[C@H](OC)C[C@H]1C(=O)NCCOCC(F)F', 'CCNC(=O)CC(=O)N1C[C@H](OC)[C@@H](C(=O)NC(C(C)C)C(C)C)C1', 'CCNC(=O)CC(=O)NC1CC2C(C1)C2NC(=O)C=C1CCCCC1', 'CCNC(=O)CCC(=O)NC[C@H]1C[C@H](CNC(=O)c2ncn(C)n2)C1', 'CCNC(=O)CCNC(=O)C[C@@H]1CCCCN1C(=O)[C@H]1CCC[C@H]1O', 'CCNC(=O)CCNC(=O)[C@H]1CCCN(C(=O)CC2CCOC2C)C1', 'CCNC(=O)CN(C)C(=O)C12CC(CN1C(=O)c1cnc(OC)s1)C2', 'CCNC(=O)CN(C)C(=O)CCCCNC(=O)c1ccc(C#N)n1C', 'CCNC(=O)CN(C)C(=O)[C@@H]1CC[C@H](C)N1C(=O)[C@@H]1CC=CC[C@H]1C', 'CCNC(=O)CNC(=O)C[C@@H]1CCCN1C(=O)C1CC(C#N)(OC)C1', 'CCNC(=O)COc1cccc(NC(C)c2cc(F)c(Cl)cc2Cl)c1', 'CCNC(=O)N1CC[C@@H](NS(=O)(=O)c2cc(C(F)F)ccc2OC)C1', 'CCNC(=O)Nc1ccc(C)c(NC(=O)C(=O)N[C@H]2C[C@@H](CS)C2)c1', 'CCNC(=O)[C@H](CC)NC(=O)C12CC(CO1)N(C(=O)COC(C)C)C2', 'CCNC(=O)c1ccc(NC(=O)C(=O)N(C2CCCC2)C2CC2)cc1', 'CCNC1CCCN(C(=O)c2cc3nc(C)cc(C(F)(F)F)n3n2)C1', 'CCNCC1CCN(C(=O)Cc2nc(-c3ccccc3)oc2C)CC1', 'CCNCCCNC(=O)C1CCCN1c1ncc(C(F)(F)F)cc1Cl', 'CCNCCCNc1nc(N2CCOC(CC)CC2)nc2cc[nH]c12', 'CCNS(=O)(=O)C1(CNC(=O)Nc2ccc(CNC(C)=O)cc2)CC1', 'CCNS(=O)(=O)CC(=O)NC[C@@H](COC)Nc1ncc2ccsc2n1', 'CCNS(=O)(=O)c1ccc(O)c(NC(=O)Nc2ncnc(C)c2C)c1', 'CCNS(=O)(=O)c1cccc(C(=O)Nc2ccccc2OCOC)c1', 'CCNc1ccc(C#N)cc1NS(=O)(=O)c1cnc2c(Br)csc2c1', 'CCNc1nc(CC(C)NC(=O)c2c(C)[nH]c3ccc(F)cc23)cs1', 'CCNc1nc(COc2cccc(C(C)(O)CC(=O)OCC)c2)cs1', 'CCNc1nc([C@H](CC(C)C)NC(=O)c2ccc(C#N)c(F)c2)cs1', 'CCOC(=O)C(C)C1CN(C(=O)Cc2csc(-c3ncccn3)n2)C1', 'CCOC(=O)C(CC)C(=O)N(C)CCC(=O)NCC(OC)C(C)(C)C', 'CCOC(=O)C(CC)C(=O)N1CC(F)(F)C[C@H]1C(=O)N[C@H]1C[C@@H](C)C1', 'CCOC(=O)C(Cc1ccc(OC)cc1)NC1CCC2(CC1)CC2N', 'CCOC(=O)C(F)(F)CCCNC(=O)c1sc2ncnc(N)c2c1C', 'CCOC(=O)C(NC(=O)c1n[nH]c2c1CCSC2)C(C)(C)C(F)(F)F', 'CCOC(=O)C(OC)C(=O)NC1(CF)CN(C(=O)c2nnsc2C)C1', 'CCOC(=O)C1(C(=O)N(CC2CC2(C)Br)CC2CC23CC3(F)F)CC1', 'CCOC(=O)C1(C(=O)N2CCCN(C(=O)NC)CC2)CC2(CCC2)C1', 'CCOC(=O)C1(C(=O)N2CCOC(c3ccc(CC)cc3)C2)CCO1', 'CCOC(=O)C1(C(=O)Nc2ccc(C)c([N+](=O)[O-])c2)CC(C)=C(C)C1', 'CCOC(=O)C1(C)CCCC1NC(=O)Cc1c(Cl)ccc(Cl)c1OC', 'CCOC(=O)C1(C)CCN(C(=O)Nc2cncc(C(F)(F)F)c2)CC1', 'CCOC(=O)C1(CCNCc2cccc(Br)c2OC(F)F)CCCC1', 'CCOC(=O)C1(CNS(=O)(=O)c2ccc(S(=O)(=O)C(F)F)cc2)CC1', 'CCOC(=O)C1(COC)CCCN(C(=O)CC(N)CC2CCCC2)C1', 'CCOC(=O)C1=C(C(C)(C)C)N(CC)C(=S)NC1c1ccc(SC)[nH]1', 'CCOC(=O)C1=C(COC(=O)[C@@H]2CSCN2C(=O)CC)NC(=O)NC1', 'CCOC(=O)C1=CCCN(C(=O)c2ncccc2OCC(F)(F)F)C1', 'CCOC(=O)C1CC(O)(COC(=O)c2ccc3c(c2)C(C)(C)OC3)C1', 'CCOC(=O)C1CC1(F)c1ccc(-c2ccc(CCOC)cc2)cc1', 'CCOC(=O)C1CC2(C1)CN(C(=O)CCc1ccc(F)c(F)c1F)C2', 'CCOC(=O)C1CC2(CCN(C(=O)c3cc(O)cc(F)c3F)CC2)C1', 'CCOC(=O)C1CCc2sc(NC(=O)C3CC(F)(F)CS3(=O)=O)nc21', 'CCOC(=O)C1CN(C(=O)C2(NC(=O)c3cc(C)n[nH]3)CC(F)C2)C1', 'CCOC(=O)C1SCCCN1C(=O)C=CC(C)NC(=O)OC(C)(C)C', 'CCOC(=O)C1SCCCN1C(=O)c1cc(Cl)nc(N2CCCC2)c1', 'CCOC(=O)C=CC(=O)NCc1ccccc1CN1CCN(C)CC1', 'CCOC(=O)CC(=O)N1CCCCC1C(=O)N(C)C1CCN(C)C1=O', 'CCOC(=O)CC(=O)N1C[C@H]2C[C@@H](NC(=O)CCCC(F)(F)F)[C@@H]1C2', 'CCOC(=O)CC(C)NC(=O)CC[C@H](C)NC(=O)c1[nH]nc(C)c1Cl', 'CCOC(=O)CC(CC)(NC(=O)c1ccc(C)c(OCC)c1)C(F)F', 'CCOC(=O)CC(CC)(NC(=O)c1cnc2sccn2c1=O)C(F)F', 'CCOC(=O)CC(Nc1nccc2occc12)c1ccccc1OC', 'CCOC(=O)CC1(C(=O)NCc2c(C)nn3c2CNCC3)CCCC1', 'CCOC(=O)CC1CN(C(=O)[C@@H]2CSCN2C(=O)C(F)C(C)(F)F)C1', 'CCOC(=O)CCC(=O)N1CCCC[C@@H]1CNC(=O)c1sncc1C', 'CCOC(=O)CCC(=O)NC[C@H](C)NS(=O)(=O)C1CCC(C)(C)CC1', 'CCOC(=O)CCC(C)(C)NC(=O)NCC(C)(C)c1cc(=O)cc[nH]1', 'CCOC(=O)CCCCCNC1CCC(O)(c2cccc(F)c2)CC1', 'CCOC(=O)CCS(=O)(=O)N1CCC(CNC(=O)c2cnns2)CC1', 'CCOC(=O)CN(Cc1cc(Cl)cc(Cl)c1)C[C@]12CC[C@H](C[C@H]1O)C2', 'CCOC(=O)CN(Cc1ccc(C#N)cc1)Cc1sccc1C(F)F', 'CCOC(=O)CONC(=O)CC[C@H]1CCCN1C(=O)CN(C)C(N)=O', 'CCOC(=O)COc1cccc(NS(=O)(=O)c2nc(C)n(C)c2Br)c1', 'CCOC(=O)C[C@@H](C)C(=O)N(C)CCN(C)S(=O)(=O)C[C@H]1C[C@H]1C#N', 'CCOC(=O)C[C@@H](C)C(=O)NC1CC=C(C(=O)NCc2cc[nH]n2)C1', 'CCOC(=O)C[C@@H](O)COC(=O)C=C(C)c1ccc(C(F)(F)F)cc1', 'CCOC(=O)C[C@H](C)C(=O)N1CC(O)(CCNC(=O)CC(C)CC)C1', 'CCOC(=O)C[C@H](C)C(=O)N1CC=CCC1C(=O)N(C)C1CCSC1', 'CCOC(=O)Cc1cnc(SC)nc1N1CCCC2(CNC(=O)C2)C1', 'CCOC(=O)Cn1cc(CNCCC2=CC[C@H]3C[C@@H]2C3(C)C)c(C)n1', 'CCOC(=O)N(C)C(=O)NC1(c2ccc(C(F)(F)F)cc2)CCCC1', 'CCOC(=O)N(C)CC(=O)N1CC[C@H]1C(=O)Nc1cnccc1CO', 'CCOC(=O)N1CCCC(C(=O)NC(c2noc(O)n2)C(C)(C)C)C1', 'CCOC(=O)N1CCCC(C(C)NC(=O)c2ccc(N)c(CC)c2)C1', 'CCOC(=O)N1CCCC(C(C)NC(=S)Nc2ccc(I)c(C)n2)C1', 'CCOC(=O)N1CCN(C(=O)Nc2cc(-c3ccco3)nn2C)CC1', 'CCOC(=O)N1CCN(NC(=O)NC(C)c2cc(C)cc(Br)c2)CC1', 'CCOC(=O)N1CSCC1C(=O)N(C)CC1CCc2nc(C)cn2C1', 'CCOC(=O)N1C[C@H](CO)[C@H](NCc2c(C)sc3ccc(Br)cc23)C1', 'CCOC(=O)NC(=O)CNc1ccc(N(C)C2CCN(C)CC2)cc1', 'CCOC(=O)NCC(=O)N1C[C@H](C(=O)NCCC2CC(O)C2)[C@@H](C)C1', 'CCOC(=O)NCCC(=O)N(C)C1(C(=O)N2CC(CC(N)=O)C2)CC1', 'CCOC(=O)NCCC(=O)N1CCCC1C(=O)N1CCCC(CC)C1', 'CCOC(=O)NCCC(=O)N1C[C@@H](F)C[C@H]1C(=O)NCC#CC1CC1', 'CCOC(=O)NCCC(=O)NC1CC(NC(=O)C2CN(C)C(=O)N2)C1', 'CCOC(=O)NCCN(Cc1c(F)cccc1Cl)C(=O)CS(N)(=O)=O', 'CCOC(=O)NCCN(Cc1ccccc1O)C(=O)C(C)C(C)(C)C', 'CCOC(=O)Oc1ccc(C(=O)N(C)C2(C(=O)OC)CCCC2)cc1', 'CCOC(=O)[C@@H](CO)NC(=O)C1CCN(C(=O)C(O)C2CC2)C1(C)C', 'CCOC(=O)[C@@H]1C[C@H]1C(=O)NC(C)(C)CCC(=O)NC1CC(C)(C)C1', 'CCOC(=O)[C@@H]1C[C@H]1C(=O)NC[C@H](OC)C(=O)N[C@@H](CO)C(C)(C)C', 'CCOC(=O)[C@@H]1C[C@H]1CS(=O)(=O)NC[C@H]1CCO[C@@H]1c1ccccc1', 'CCOC(=O)[C@H](C)N(C)C(=O)C1(NC(=O)c2n[nH]cc2C)CCCC1', 'CCOC(=O)[C@H](CCc1ccccc1)NC(=O)[C@@H]1C[C@H](O)CCN1C', 'CCOC(=O)[C@H]1CC[C@H](NC(=O)NCc2cc(C#N)ccc2C)CC1', 'CCOC(=O)[C@H]1C[C@](F)(CN2CCN(C)CC2Cc2ccccc2)C1', 'CCOC(=O)c1[nH]c(C)c(CNC(Cc2ccccc2)C2CC2)c1C', 'CCOC(=O)c1[nH]c(COC(=O)C2=C(Cl)CC2)c(C(=O)OCC)c1C', 'CCOC(=O)c1[nH]cnc1CNC(=O)Cc1c[nH]c2cc(Cl)ccc12', 'CCOC(=O)c1c(C)[nH]c(C(=O)NC2C(C)(C)CNCC2(C)C)c1C', 'CCOC(=O)c1c(COC(=O)c2conc2CC)sc2ccccc12', 'CCOC(=O)c1c(NC(=O)C2=CCCC(C)(C)C2)sc2c1CCOC2', 'CCOC(=O)c1c(NC(=O)NCC2CC2)sn(-c2ccccc2)c1=S', 'CCOC(=O)c1cc(CNc2cc(C#N)ccc2OCCOC)no1', 'CCOC(=O)c1cc2c(N(C)CCC(O)c3cccs3)nccn2n1', 'CCOC(=O)c1cc2cccc(C(=O)Nc3c[nH]c(=O)c(Br)c3)c2[nH]1', 'CCOC(=O)c1cc2n(n1)CCN(C(=O)N[C@H]1CN(C)C[C@@H]1OC)C2', 'CCOC(=O)c1cccc(N(C)S(=O)(=O)Cc2cc(Br)ccc2Br)c1', 'CCOC(=O)c1cccc(NC(=O)N(C)C2CCC(C(C)C)CC2)n1', 'CCOC(=O)c1ccn(C2CCN(CCC3CCCNCC3)CC2)n1', 'CCOC(=O)c1ccn(CCNS(=O)(=O)c2ccc(CC)c(N)c2)n1', 'CCOC(=O)c1ccnc(CCNCc2cc(C(=O)OC)n(C)c2)n1', 'CCOC(=O)c1ccnc(CNC(=O)NCc2cc(Br)cnc2F)n1', 'CCOC(=O)c1cnc(C)nc1COC(=O)c1ccc(CC)c(O)c1', 'CCOC(=O)c1cnc(NC)nc1COc1ccc2ccncc2c1', 'CCOC(=O)c1cnc2c(OC)cccc2c1NCCC(C)(C)CO', 'CCOC(=O)c1cnc2c(OC)cccc2c1NC[C@H]1CCCNC1', 'CCOC(=O)c1cnc2ccc(C(=O)NCC3(CO)CCCO3)cn12', 'CCOC(=O)c1cnn(-c2ccc(NC(=O)CCC[C@H](C)N)cc2)c1', 'CCOC(=O)c1cnn(C)c1CN1C(=O)N(C)C2(CCCCC2)C1=O', 'CCOC(=O)c1csc(CNC(=O)C(C)=Cc2ccc(F)c(F)c2)n1', 'CCOC(=O)c1n[nH]cc1NC(=O)c1ccc(I)cc1-n1cnnn1', 'CCOC(=O)c1nn(C)c(NC(=O)N2CCC(F)(F)C(CO)C2)c1C', 'CCOC(=O)c1noc(CNC(=O)N(C)C2(c3ccncc3)CC2)n1', 'CCOC(=O)c1oc(C(C)NC(=O)CCOC2CCOCC2)nc1C', 'CCOC(=O)c1oc(COC(=O)C#Cc2ccc(F)c(F)c2)nc1C', 'CCOC(=O)c1sc2c(c1NC(=O)CCCC1(N)CCC1)CCCC2', 'CCOC(=O)c1snnc1COC(=O)c1cc(Cl)c2c(c1)CCCN2', 'CCOC(C(=O)N1CCN(C(=O)CCCN(C)C(C)C)CC1)C1CC1', 'CCOC(C(=O)N1CC[C@@H](CN(C)C(=O)COC2CC2)C1)C1CCC1', 'CCOC(C(=O)N1CC[C@H](NC(=O)CC2CCC2)[C@H](CO)C1)C(C)C', 'CCOC(C(=O)NCCC(=O)NOCc1ccccc1F)C1CCC1', 'CCOC(C(=O)NC[C@H](NC(=O)c1cc(C)c(C)s1)C(C)C)C1CC1', 'CCOC(C(=O)N[C@@H](C(=O)NCC(O)C(=O)OC)C(C)(C)O)C(C)C', 'CCOC(C(=O)N[C@@H]1CCN(C(=O)c2ccon2)C[C@H]1O)C1CCC1', 'CCOC(C)(C)C(=O)N1[C@H](C(=O)NCC(CO)C(C)(C)C)C[C@@H]2C[C@@H]21', 'CCOC(C)(C)C(=O)NC1CCC(CCNC(=O)CSC(C)(C)C)C1', 'CCOC(C)(C)C(=O)NCc1cccc(NC(=O)C2CCOC2=O)c1', 'CCOC(C)(C)C(=O)N[C@H]1CO[C@H]2[C@@H]1OC[C@@H]2NC(=O)c1cn[nH]c1', 'CCOC(C)C(=O)N(CC(=O)NCc1ccc(C#N)cn1)CC1CC1', 'CCOC(C)C(=O)N1CC(CF)(NC(=O)c2nn(C)c3c2CCC3)C1', 'CCOC(C)C(=O)N1CCN(C(=O)CCc2cnc(C)o2)C2(CC2)C1', 'CCOC(C)C(=O)NC(CC(=O)N1C[C@@H]2C[C@H](C1)[C@@H](CO)C2)C(F)F', 'CCOC(C)C(=O)NC1CCC2(CCN(C(=O)C3CC34CCC4)C2)C1', 'CCOC(C)C(=O)NCC1(COC)CCN(C(=O)CNC(=O)NC)C1', 'CCOC(C)C(=O)NCCC1(C)CCN(C(=O)c2sc(N)nc2C)C1', 'CCOC(C)C(=O)N[C@H]1CCC[C@H](NC(=O)CCC(C)CN(C)C)C1', 'CCOC(C)OCC(O)COC(=O)c1ccc2c(Br)cccc2c1F', 'CCOC(C)OCC(O)COC(=O)c1cnc(-c2ccc(Cl)cc2)s1', 'CCOC(CC(=O)N(C)C[C@H]1CC[C@H](NC(=O)C2CC2)CC1)OCC', 'CCOC(CC(=O)N1CC[C@@H]1C(=O)NC1(CO)CC(F)(F)C1)OCC', 'CCOC(CC)C(=O)N1CCC[C@@H](CNC(=O)c2c(C)csc2C)C1', 'CCOC(CC)C(=O)N1C[C@H](NC(=O)CSCCC#N)[C@@H](C2CC2)C1', 'CCOC(CC)C(=O)NC1CCCCCN(C(=O)Cn2cncn2)C1', 'CCOC(CC)C(=O)NCC1CC(CNC(=O)c2cnncc2O)C1', 'CCOC(CN(Cc1csc(Cl)c1)Cc1cc(C#N)n(C)c1)C1CC1', 'CCOC(CNC(=O)C1(NC(=O)CS(C)(=O)=O)CC(O)C1)C1CCC1', 'CCOC(CNc1ccc2[nH]c(C3CCCO3)nc2c1)C1CCOC1', 'CCOC(OCC)C(=O)N1CCC=CC1C(=O)NC1CCC=CCC1', 'CCOC(OCC)C(C)NC(=O)NCc1nnc2n1CCN(C)C2=O', 'CCOC(OCC)C1CN(S(=O)(=O)c2cc(OC)ccc2C)CCO1', 'CCOC1(C(=O)N2C[C@H](CC(=O)NC3CC(F)(F)C3)[C@@H](C)C2)CCC1', 'CCOC1(C(=O)NC[C@@H](C)C(=O)Nc2ccc(F)nc2C)CCOC1', 'CCOC1(C(=O)N[C@@H]2CCC[C@@H]2NC(=O)C=CC2CCC2)CCOC1', 'CCOC1(C(=O)N[C@H]2CC[C@H]2NC(=O)CC2CCC3(CC3)CO2)CC1', 'CCOC1(C(=O)N[C@H]2C[C@H]3CC[C@@H]2CN(C(=O)C2CC2)C3)CCOC1', 'CCOC1(C)CN(C(=O)C(NC(=O)CCc2ccc(C)o2)C2CC2)C1', 'CCOC1(CC(=O)N(Cc2cc(C)n[nH]2)Cc2ccc(SC)o2)CC1', 'CCOC1(CC(=O)N2C[C@H](O)[C@@H](N(C)C(=O)c3cscn3)C2)CCC1', 'CCOC1(CC(=O)NCC(C)(C)C(=O)N2CCO[C@H](COC)C2)CC1', 'CCOC1(CC(=O)NC[C@H]2CC[C@H]2NS(=O)(=O)c2ncc[nH]2)CCC1', 'CCOC1(CCNC(=O)[C@@H]2CC[C@H](C)N2C(=O)C2CC(F)C2)CCC1', 'CCOC1(CN(C)c2cc(N[C@H]3CCOC3)nc(COC)n2)CCC1', 'CCOC1(CNC(=O)C(NC(=O)CSCC)C2CC=CCC2)CCC1', 'CCOC1(CNC(=O)C2(C(C)C)CC2)CN(C(=O)c2cc(C)c[nH]2)C1', 'CCOC1(CNC(=O)C2CC3CC(F)(F)CC(C2)C3N)CCCSC1', 'CCOC1(CNC(=O)C2CCOC2CNC(=O)CS(=O)(=O)CC)CC1', 'CCOC1(CNC(=O)C=CC2CCCC2)CN(c2ncncc2Br)C1', 'CCOC1(CNC(=O)[C@@H]2C[C@H]3C=C[C@@H]2C3)CN(c2ncncc2Br)C1', 'CCOC1(CNC(=O)[C@H]2CCC[C@H]2OC)CN(C(=O)c2cccs2)C1', 'CCOC1(CO)CN(C(=O)[C@@H]2C[C@@H](F)CN2C(=O)c2csc(N)n2)C1', 'CCOC1(CO)CN(C(=O)[C@H]2C[C@H](CNC(=O)[C@@H]3CC[C@H](C)O3)C2)C1', 'CCOC1CC(C(=O)N2CC=C(C(=O)N(C)[C@H](C)CC(=O)OC)C2)C1', 'CCOC1CC(C(=O)NC[C@H]2CCN(C(=O)C3CC(=O)CCO3)C2)C1', 'CCOC1CC(C(=O)N[C@H](C(=O)N(C)[C@H]2COC[C@H]2OC)C2CC2)C1', 'CCOC1CC(CN(CC2=CCSC2)Cc2cccn3ccnc23)C1', 'CCOC1CC(CNC(=O)C2=CCN(C(=O)CC3CCC(C)C3)C2)C1', 'CCOC1CC(CNC(=O)Nc2cc(C)n(C)n2)(N2CCOCC2)C1', 'CCOC1CC(N(C)C(=O)[C@H]2C[C@@](C)(NC(=O)Cc3cn[nH]c3)C2)C1', 'CCOC1CC(NCCCn2cccn2)(c2nnnn2CC2CC2)C1', 'CCOC1CC(O)(CN(Cc2csnc2C)C(=O)C2=NNC(=O)C2)C1', 'CCOC1CCC(C(=O)N2CCC[C@H]2CNC(=O)[C@@H]2CC2(F)F)CC1', 'CCOC1CCC(c2nc3ccc(CC)cn3c2NCC2CC2)CC1', 'CCOC=CC(=O)NCC1(O)CCN(C(=O)c2cccc(F)c2)CC1', 'CCOCC(=O)N(C)CC1COCCN1C(=O)c1ccc(CF)cc1', 'CCOCC(=O)N1CC(C(=O)N[C@H]2C[C@@H]2c2cnn(C)c2)CC1(C)C', 'CCOCC(=O)N1C[C@H]2C[C@@H](C(=O)Nc3c[nH]c(=O)c(C)c3)C[C@H]2C1', 'CCOCC(=O)NC(C(=O)Nc1ccc(CO)nc1)c1cnn(C)c1', 'CCOCC(=O)NC(CNC(=O)c1ocnc1C)c1ccc(F)cc1', 'CCOCC(=O)NC1CN(C(=O)c2cncc3[nH]ccc23)CC1(C)C', 'CCOCC(=O)NCCCN1CCN(C(=O)C[C@@H]2CCCN2C)CC1', 'CCOCC(=O)NCCNC(=O)c1cc(NC(C)(C)C)c(F)cc1N', 'CCOCC(=O)NC[C@@H](COC)NC(=O)c1c(C)cc(C#N)cc1C', 'CCOCC(C(=O)N(C)Cc1cncn1C)n1cc(C(C)(C)F)nn1', 'CCOCC(C(=O)NCCc1ncccc1C)n1cc(C2CC2)nn1', 'CCOCC(C)(C)NC(=O)C(C)CN(C)C(=O)Cc1cnn(CC)c1', 'CCOCC(C)C(=O)N(C)CC1CCN(C(=O)C2(F)CCOCC2)C1', 'CCOCC(C)C(=O)N(CCC(C)(C)C(F)F)Cc1n[nH]c(C)c1C', 'CCOCC(C)C(=O)N1CCCC(CC(=O)NC2(CSC)CCC2)C1', 'CCOCC(C)C(=O)N1CCOCC(C(=O)N2CC[Si](C)(C)CC2)C1', 'CCOCC(C)C(=O)N1C[C@H](OC)C[C@H]1CNC(=O)Cn1cnnc1', 'CCOCC(C)C(=O)NC(C)(CO)C(=O)NCC1CCCC(C)(C)O1', 'CCOCC(C)C(=O)NC1CC(CC(=O)NOCC2CCOCC2)C1', 'CCOCC(C)C(=O)NC[C@H]1C[C@H]1CC(=O)N(C)C1CC2(CCC2)C1', 'CCOCC(C)CNC(=O)C(C)C1CCN(C(=O)COC(C)C)CC1', 'CCOCC(C)CNC(=O)[C@@H]1C[C@H](O)CN1C(=O)CC(C)(C)C(F)F', 'CCOCC(C)CNC(=O)[C@H]1C[C@@](C)(NC(=O)c2nn[nH]c2CC)C1', 'CCOCC(NC(=O)C#CC1CC1)C(=O)NCCc1ncccc1F', 'CCOCC(NC(=O)C1CCC(F)CC1)C(=O)NCC1(F)CN(C)C1', 'CCOCC(Nc1nc2c(c(NCC(C)(C)CC)n1)CCC2)C(C)C', 'CCOCC(O)CN(C)C(=O)[C@H]1COC[C@H]1NC(=O)C1=NNC(=O)C1', 'CCOCC(O)CNC(=O)C1CCN(C(=O)Cc2cncs2)C1(C)C', 'CCOCC(O)CNC(=O)[C@H]1[C@@H]2CN(C(=O)C(C)OC(C)(C)C)C[C@@H]21', 'CCOCC1(C(=O)N(Cc2cnsc2)CC2(C)C(C)(C)C2(C)C)CC1', 'CCOCC1(C(=O)N2CC(CNC(=O)[C@@H]3CCCN3C(C)C)C2)CC1', 'CCOCC1(C(=O)NCC(=O)NCC(=O)N2CCC[C@H](OC)C2)CC1', 'CCOCC1CCCN(S(=O)(=O)c2cc3ccccc3cc2OC)C1', 'CCOCC1CCN(C(=O)/C(C)=C/CNC(=O)c2cn(C)cn2)CC1', 'CCOCC1CCN(C(=O)[C@@H]2C[C@H](NC(=O)C3CS(=O)C3)[C@@H](O)C2)C1', 'CCOCC1CN(C(=O)C(C)(O)c2cccc(OC(F)F)c2)CCO1', 'CCOCCC(=O)N1C[C@H](NC(=O)C2CC3(CCC3=O)C2)CC[C@H]1C', 'CCOCCC(=O)NC[C@@H]1CCN(C(=O)c2ccc(CCF)cc2)C1', 'CCOCCC(=O)NC[C@H]1CC[C@H](C(=O)NOCC2(F)CCC2)CC1', 'CCOCCC(=O)N[C@H]1CCC[C@H](NC(=O)C2CC(=O)OC2(C)C)C1', 'CCOCCC(NC(=O)CC1CCCC1)C(=O)NCc1ccoc1C', 'CCOCCC(NC(=O)[C@H](C)NC(N)=O)C(=O)N[C@@H]1C[C@H]2CC[C@@H]1C2', 'CCOCCC(NC(=O)c1ccco1)C(=O)N1CC(C)(C)C[C@H]1CO', 'CCOCCC(NC(=O)c1cnc(C)o1)C(=O)NCC1(C#N)CCC1', 'CCOCCC1(CNC(=O)C2=CCN(C(=O)CC(C)=C(C)C)C2)CC1', 'CCOCCCCC(=O)NCC1CCCCCN1C(=O)[C@H]1CCN1C', 'CCOCCCCCC(=O)N1CC2CC(C1)N2C(=O)CC1=CCCC1', 'CCOCCCCNC(=O)CN1CCN(C(=O)C2(C(C)=O)CC2)CC1', 'CCOCCCCNc1nc(N2CC3C(C2)C3(C)C)nc2c1COC2', 'CCOCCCN1CCC(NC(=O)Cc2cccc(O)c2F)C(C)C1', 'CCOCCCNC(=O)C1(NC(=O)C=Cc2cnn(C)c2)CCCC1', 'CCOCCCNC(=O)C1CCN(c2ncnc(C(F)F)c2Br)CC1', 'CCOCCCNC1(c2nnnn2C(C)C(=O)OC)CC(C(C)C)C1', 'CCOCCCNc1nc(NCC2SCCS2)c2cccc(F)c2n1', 'CCOCCN(CC)C(=O)c1ccc(N2CCN(C(C)=O)CC2)nc1', 'CCOCCN(Cc1c(Cl)cnn1C)Cc1cnc2ccc(C)cn12', 'CCOCCN(Cc1cn(C(C)(C)C)nn1)Cc1ncc(Cl)cc1F', 'CCOCCNC(=O)C(c1cc(C(C)(C)C)[nH]n1)N1CCSC(C)C1', 'CCOCCNC(=O)[C@@H]1C[C@@H]2CN(C(=O)CN3CCNC3=O)C[C@@H]2C1', 'CCOCCOC(C)C(=O)N[C@H]1C[C@H](NC(=O)C2CC3(CC3)CO2)C1', 'CCOCCOCC(=O)N1CC[C@H]2[C@@H](C1)[C@@H]2NC(=O)[C@@H]1CNC(=O)O1', 'CCOCCOCCC(=O)N1CC[C@@H]1C(=O)Nc1cncnc1OC', 'CCOCCOCc1cccc(Nc2c(F)cc([N+](=O)[O-])cc2F)c1', 'CCOCCS(=O)(=O)N1C[C@H]2CN(C(=O)[C@H]3CCN(C)[C@H]3C)C[C@@H]2C1', 'CCOCC[C@@H](C)NC(=O)C1(C)C=CCN1C(=O)C1CC(C2CC2)C1', 'CCOCCn1cc(C2(C)CCCN2C(=O)Cn2ncnc2C)nn1', 'CCOCCn1nnnc1C(NCC(C)C)c1c(C2CC2)cnn1C', 'CCOCCn1nnnc1C1(NCC(C)C(F)(F)F)CCC(=O)NC1', 'CCOC[C@H](C)NC(=O)C(NC(=O)c1[nH]ccc1COC)C(C)(C)C', 'CCOC[C@H](C)NC(=O)CC1CC2(C1)CN(C(=O)Cc1ccsc1)C2', 'CCOC[C@H](C)Nc1nc(NCc2sc(C)cc2C)c2[nH]ccc2n1', 'CCOC[C@H](NC(=O)C1=C(C)CCOC1)C(=O)N[C@H]1C[C@@H]1C1CCC1', 'CCOC[C@H](NC(=O)CN1CCCC1)C(=O)N1CCCN(C)CC1C', 'CCOC[C@H](NC(=O)[C@@H]1CCCN1C(C)=O)C(=O)N1CC[C@@H](SC)C1', 'CCOC[C@H](NC(=O)c1cn(C)c(C)n1)C(=O)NC1(C)CS(=O)(=O)C1', 'CCOCc1cc(CN2CCCC2C2(C)CCN(C)C2)ccc1OC', 'CCOCc1ccc(NC(=O)NCc2nnc3ccc(F)cn23)cc1', 'CCOCc1cccc(NC(=O)C(=O)N(C)Cc2ccncc2C)c1', 'CCOCc1ccccc1CNC(=O)C(=O)N1CCCC12CCNC2', 'CCOCc1cn(CCC(=O)NCCC(=O)N2CCCC(C)C2)nn1', 'CCOCc1cn(CCNC(=O)c2cccc3c(C)c(C)[nH]c23)nn1', 'CCOCc1csc(C(C)N(C)C(=O)CCc2cc(F)ccc2Br)n1', 'CCOCc1nc(CNC(=O)N2CCC(NC(=O)OCC)CC2)no1', 'CCOCc1nc(Cl)cc(N2CCC(NC(=O)C3CCCC3)CC2)n1', 'CCOCc1nnc2n1CCN(S(=O)(=O)NCc1ccc(Cl)cc1)C2', 'CCOCn1nnc(C#N)c1NC(=O)NCc1ccc(F)c(OC)c1', 'CCON(CC)C(=O)[C@@H]1CO[C@H](CNC(=O)CN(C)C(=O)C2CC2)C1', 'CCON(CC)C(=O)[C@H](COC(C)C)NC(=O)c1nccc(C)c1N', 'CCON(CC)C(=O)[C@H]1CCCN(C(=O)c2snnc2CC)[C@H]1CC', 'CCONC(=O)CNC(=O)C(NC(=O)C(C)=C1CC1)c1ccccc1', 'CCOP(=O)(CCC1COCCN1Cc1cc(C(=O)O)c[nH]1)OCC', 'CCOP(C)(=O)CNC(=O)C[C@@H]1[C@H]2CN(C(=O)c3cc(Cl)[nH]n3)C[C@@H]12', 'CCO[C@@H]1CCC[C@H]1Nc1nc(N)nc(NCc2nocc2CC)n1', 'CCO[C@@H]1CCN(C(=O)[C@@H]2C[C@H](O)CN2C(=O)c2nc(C)oc2C)C1', 'CCO[C@@H]1CN(S(=O)(=O)CCOC)C[C@H]1CNC(=O)c1csc(N)n1', 'CCO[C@@H]1C[C@@H](C(=O)OC)N(C(=O)Cc2ncc(C)c(OC)c2C)C1', 'CCO[C@H]1CCCN(C(=O)CC(C)CNC(=O)CC2CC3(CC3)C2)C1', 'CCO[C@H]1CCN(C(=O)C2=CC3(CCN(C(=O)C(C)=C(C)C)C3)C2)C1', 'CCO[C@H]1CCN(C(=O)[C@@]23C[C@@H]2CN(C(=O)c2oc(C)nc2C)C3)C1', 'CCO[C@H]1CC[C@@H]1C(=O)N(CC(=O)N1CCn2ccnc2C1)C1CC1', 'CCO[C@H]1CC[C@@H]1C(=O)N1CCCCC1CC(=O)NCCCC(F)F', 'CCO[C@H]1CC[C@@H]1C(=O)N[C@@H]1CCN(C(=O)C=Cc2ccnn2C)C1', 'CCO[C@H]1COC[C@@H]1n1cc(C(=O)OCC(=O)NC(C)C2CC2)nn1', 'CCO[C@H]1C[C@@H](NC(=O)CCC(C)NC(=O)c2cc(C(C)C)on2)C1', 'CCO[C@H]1C[C@@H](NC(=O)[C@H]2C[C@@](C)(NC(=O)C=Cc3cocn3)C2)C1', 'CCO[C@H]1C[C@H](NC(=O)C[C@@H](NC(=O)C2(Cl)CC2C(C)=O)C2CC2)C1', 'CCO[C@H]1C[C@H](NC(=O)[C@@H]2CN(C(=O)C3CCC(O)CC3)C[C@H]2F)C1', 'CCOc1c(F)c(F)cc(C(=O)N2CCC(=O)N3CCCCC32)c1F', 'CCOc1cc(C(=O)N(C)CCC(=O)N2CCn3nncc3C2)n[nH]1', 'CCOc1cc(C(=O)N(C)[C@@H]2CCCN(C(=O)C(F)C(C)C)C2)on1', 'CCOc1cc(C(=O)N2CCC(CC)(C(=O)NCCCSC)C2)n[nH]1', 'CCOc1cc(C(=O)NC2CCOc3c(Cl)cc(Cl)cc32)ccc1F', 'CCOc1cc(C)cc(CNC(=O)N[C@@H](CO)C(=O)OC(C)(C)C)c1', 'CCOc1cc(C)ccc1CNC(=O)c1c(C(F)(F)F)nn(C)c1Cl', 'CCOc1cc(CN(C)c2cc(S(C)(=O)=O)nc(Cl)n2)ccc1OC', 'CCOc1cc(CN(C=O)C(C)Cc2ccc(C)s2)cc(Cl)c1OC', 'CCOc1cc(CN(C=O)CCn2cc(-c3ccccc3)nn2)sn1', 'CCOc1cc(CN(C=O)Cc2c(Br)n[nH]c2C)ccc1OC(F)F', 'CCOc1cc(CN(CCC(C)OC)Cc2cccc(Cl)c2C)sn1', 'CCOc1cc(CN2CC3(C2)CC2(CNC(=O)C2)C3)c(F)cc1OC', 'CCOc1cc(CNC(=O)N2CC3(CCOC3)C2)ccc1OC(F)F', 'CCOc1cc(F)cc(C(C)NC(=O)CCCCN2CCCCC2)c1', 'CCOc1cc(F)ccc1NC(=O)[C@H]1CC[C@H]1C(=O)c1ccccc1', 'CCOc1cc(F)ccc1NC1CCC(C)(C(=O)OC(C)(C)C)CC1', 'CCOc1cc(N)c(C(=O)NC(c2ncn[nH]2)C2CC2)cc1OCC', 'CCOc1cc(NC(=O)c2ccc(OC)c([N+](=O)[O-])c2C)ccc1F', 'CCOc1cc(S(C)(=O)=O)ccc1NC(=O)N1CC(N(C)C2CC2)C1', 'CCOc1ccc(-c2csc(NC(=O)c3ccc(O)nc3C)n2)cc1', 'CCOc1ccc(Br)cc1S(=O)(=O)N(C)Cc1ccc2c(c1)CCO2', 'CCOc1ccc(C(=O)NNC(=O)c2ccc3c(=O)[nH][nH]c3c2)cc1', 'CCOc1ccc(CCNC(=O)NCC2COC(=O)C2)cc1OCC', 'CCOc1ccc(CN(CC2(CF)CC2)C(=O)CN(C)C(C)=O)cc1', 'CCOc1ccc(CNC(=O)N2CCC(OC)(OC)CC2)cc1OC', 'CCOc1ccc(CNc2ccc(Cn3cc(C)cn3)cc2)cc1F', 'CCOc1ccc(C[C@@H](NC(=O)CO[C@H]2CCNC2)C(=O)NC)cc1', 'CCOc1ccc(Cl)cc1NC1CCN(C(=O)OC(C)(C)C)CC1C', 'CCOc1ccc(F)c(NC(=O)NC(C)Cc2ccc(O)cc2)c1F', 'CCOc1ccc(NC(=O)CSCc2csc(C)n2)cc1C(F)(F)F', 'CCOc1ccc(NC(=O)N(C)CC2(O)CCC(F)(F)CC2)cc1F', 'CCOc1ccc(NCc2ccc(CN3CCOCC3)o2)cc1OC', 'CCOc1ccc(OCCNC(=O)c2ccc(P(C)(C)=O)cn2)cc1', 'CCOc1ccc(S(=O)(=O)N2CCCC(CCNC(C)=O)C2)cc1Cl', 'CCOc1ccc(S(=O)(=O)NCc2cc3cc(Br)ccc3s2)cc1F', 'CCOc1ccc(SCC(=O)NC2CCN(c3cncs3)CC2)cc1', 'CCOc1ccc([C@H](C)NC(=O)C(=O)N(C)[C@@H](C)C(=O)N(C)C)cc1', 'CCOc1cccc(CCNC(=O)N2CCC(NS(C)(=O)=O)CC2)c1', 'CCOc1cccc(CCNC(=O)c2ccnc(OC(C)(C)C)c2)c1', 'CCOc1cccc(CCNC(=O)c2ncoc2-c2cnn(C)c2)c1', 'CCOc1cccc(CNC(=O)c2cc(OC(F)(F)F)ccc2F)c1', 'CCOc1cccc(F)c1C(C)NC(=O)C(=O)N1CCOCCC1C', 'CCOc1ccccc1-c1nc(CC(=O)OCC2(OC)CCC2)cs1', 'CCOc1ccccc1CN1C[C@H](c2ccccc2)C[C@@H]1C(=O)OC', 'CCOc1ccccc1N(C)C(=O)c1cnnc(-c2ccccc2)c1', 'CCOc1ccccc1OCCSCc1nnc(C2CC2)n1C1CC1', 'CCOc1ccccc1OS(=O)(=O)c1cc2c(cc1F)NC(=O)CC2', 'CCOc1cccnc1C(=O)Nc1ccc2oc(CCOC)nc2c1', 'CCOc1ccnc(NCCOC2CCCN(C(=O)CNC=O)C2)n1', 'CCOc1ccncc1S(=O)(=O)N1CCC(C)(C)S(=O)(=O)C(C)(C)C1', 'CCOc1cnc(C(=O)NC(C)c2cn(C)c3cc(Cl)ccc23)cn1', 'CCOc1cncc(CN(CCc2ccsc2)Cc2nccn2C)c1', 'CCOc1nc(C(=O)NC(C)(C)CN(C)C(=O)c2cccn2C)co1', 'CCOc1ncc(CN(CC(C)C(C)C)C(=O)[C@@H]2CCC[C@H]2C#N)s1', 'CCOc1ncc(CN(C[C@@H]2CCC[C@H]2CF)C(=O)CC(O)CC)s1', 'CCOc1ncnc(OCC)c1C(=O)N1CCCC(O)(COC)CC1', 'CCOc1nn(C)cc1NC(=O)CNC(=O)c1ccccc1CC#N', 'CCS(=O)(=NC(=O)c1ccc(OCCOC)nc1)c1cccc(Br)c1', 'CCS(=O)(=O)C1CN(C(=O)NCC(c2cccc(Br)c2)C2CCC2)C1', 'CCS(=O)(=O)CC(=O)N(Cc1cccc(C)n1)CC1CCCC(C)C1', 'CCS(=O)(=O)CC(=O)N1CCN(C(=O)[C@H]2CCCO[C@H]2C)CC(C)C1', 'CCS(=O)(=O)CC(=O)N1C[C@@H]2C[C@H]1CN2C(=O)c1cn(C)nc1OC', 'CCS(=O)(=O)CC(=O)NC1CC2(C1)CC2C(=O)NC(C)C1(O)CCC1', 'CCS(=O)(=O)CC(=O)NCC1(NC(=O)c2cc(C3CC3)[nH]n2)CCC1', 'CCS(=O)(=O)CC(=O)N[C@@H](CCSC)C(=O)NCC12CCC(CC1)C2', 'CCS(=O)(=O)CC(C)(C)CNC(=O)NCc1ccccc1OCCO', 'CCS(=O)(=O)CC(F)(F)CNC(=O)C(C)n1cc(C(O)C2CC2)nn1', 'CCS(=O)(=O)CC=CCNC(=O)NCCCn1cc(S(C)(=O)=O)cn1', 'CCS(=O)(=O)CC=CCNC(=O)NCc1cc(Cl)cc(C(=O)OC)c1', 'CCS(=O)(=O)CCNC(=O)C(CCN(C)C)NC(=O)C#CC(C)(C)C', 'CCS(=O)(=O)CCNC(=O)[C@H](CC(C)C)NC(=O)CC1CCCOC1', 'CCS(=O)(=O)N1CC(C(=O)N2CCc3cc(OC)cc(OC)c3C2)C1', 'CCS(=O)(=O)N1CCC(CO)(CNC(=O)c2ccc(C3CC3)s2)CC1', 'CCS(=O)(=O)N1CCN([C@H]2CCN(C(=O)C(COC)COC)C2)CC1', 'CCS(=O)(=O)NC1CCN(C(=O)C(=O)Nc2cc(Br)ccc2C)CC1', 'CCS(=O)(=O)NCCNC(=O)[C@@H]1CCN(C(=O)CCc2csnn2)C1', 'CCS(=O)(=O)NCCc1ccc(S(=O)(=O)N2CCN(CCN)CC2)s1', 'CCS(=O)(=O)Nc1ccc(CNC(=O)Nc2cn(C)nc2C#N)cc1', 'CCS(=O)(=O)c1ccc(Br)c(C(=O)Nc2cncnc2C(=O)OC)c1', 'CCS(=O)(=O)c1ccc(Cl)c(C(=O)N(C)CC2(O)CCN(C)CC2)c1', 'CCS(=O)CC(=O)N(C)CCC1CCN(C(=O)[C@H]2CCCN2C)CC1', 'CCS(=O)CC(=O)N1CC(O)(CN(C)C(=O)CCC2CCCN2C)C1', 'CCS(=O)CC(=O)N1CC2(CCCN(C(=O)CC3OCCCO3)C2)C1', 'CCS(=O)CC(=O)N1CCCC[C@@H]1CCC(=O)N1CC(S(N)(=O)=O)C1', 'CCS(=O)CC(=O)NC(CCC1CCC1)C(=O)N1CC(O)(C(F)F)C1', 'CCSC(C(=O)N(Cc1c[nH]nc1CC)CC1CCCC1O)C(C)C', 'CCSC(C(=O)N[C@H](C(=O)NOC1CCC1)c1ccccc1)C(C)C', 'CCSC(C)C(=O)N1CCN(C(=O)Cn2nc(C)cc2C)C[C@H]1CO', 'CCSC(C)C(=O)NCCC1CN(S(=O)(=O)c2cncc(OC)c2)C1', 'CCSC(C)C(=O)NC[C@H]1CC[C@@H]1NC(=O)[C@H]1C[C@H](n2ccnn2)C1', 'CCSC(C)C(=O)Nc1cccc(NC(=O)C2CCc3cn[nH]c32)c1', 'CCSC(C)c1noc(CN(C)CC(C)C(=O)c2ccc(O)cc2)n1', 'CCSC1(CN(Cc2cc(COC)cs2)C(=O)C2CCCSC2)CC1', 'CCSC1(CNC(=O)[C@H]2CCC[C@H]2NC(=O)C2CC(=O)CCO2)CC1', 'CCSC1CCCC1Nc1ccnc(NCc2nnc(C(F)F)s2)n1', 'CCSC1CN(C(=O)C2(F)CCN(C(=O)C(C#N)(CC)CC)CC2)C1', 'CCSCC(=O)N1CC2(CC(CC(=O)N3CC(O)CC3(C)CO)C2)C1', 'CCSCC(=O)N1CCC[C@H](C(=O)N(C)Cc2nc(C)ns2)[C@@H]1CC', 'CCSCC(=O)NCCc1[nH]ncc1C(=O)N1CCC(C)(OC)CC1', 'CCSCC(C)(C)CN(Cc1cc(C2CC2)nn1C)C(=O)C(C)SC', 'CCSCC(C)(C)CN(Cc1ccnn1C)C(=O)[C@@]1(C)[C@@H]2CCC[C@@H]21', 'CCSCC1(CN(Cc2cnc(C)c(C)c2)C(=O)[C@@]2(C)C[C@@H]2C)CC1', 'CCSCCC(=O)N1CCC(CC)C1C(=O)N1CCC12CCCSC2', 'CCSCCC(=O)N1CCO[C@@H](C(=O)Nc2c(O)cccc2OC)C1', 'CCSCCC(=O)N1C[C@@H](F)C[C@H]1CN(C)C(=O)CC1(O)CCCC1', 'CCSCCC(=O)N1C[C@H](O)C[C@@H]1CNC(=O)c1ccc(NC)cn1', 'CCSCCC(=O)NC1COC2(C1)CN(C(=O)c1cn(C)c(C)n1)C2', 'CCSCCC(=O)NCC1CN(C(=O)Cn2cc(Cl)cn2)CCC1C', 'CCSCCCN(CC1C2CCCC21)C(=O)c1cnc2ccccn12', 'CCSCCCN(Cc1ccccc1CC)C(=O)[C@H]1C[C@@H](C)N(C)C1', 'CCSCCCN(Cc1cnc(CC)o1)C(=O)[C@H](C)c1ccccc1', 'CCSCCCNC(=O)C(CC[C@H]1C[C@H]1C)N1C[C@@H]2OC(=O)N[C@@H]2C1', 'CCSCCCNC(=O)C(c1ccc(OC)nc1)N1CCC12CCC2', 'CCSCCCNC(=O)C(c1ccsc1)N1CCC2(CCCCO2)C1', 'CCSCCN(Cc1ccc(F)cc1C)C(=O)c1ccc(N)nc1C', 'CCSCCNC(=O)[C@@H]1C[C@H](NC(=O)C2CCC(C)(C)CC2)C1(C)C', 'CCSC[C@H](CO)NC(=O)C1COCCN(C(=O)CCC(C)OC)C1', 'CCSC[C@H](NC(=O)CCCN(C)C(C)=O)C(=O)N1CCC(CC)C1', 'CCSC[C@H](NC(=O)Cc1ccon1)C(=O)N1C[C@H](CO)O[C@H](C)C1', 'CCSC[C@H](NC(=O)c1c[nH]c(=O)o1)C(=O)NCc1cccc(C)n1', 'CCSCc1cn(CCCNC(=O)C(C)(C)c2ccccc2Cl)nn1', 'CCSc1cc(C(F)(F)F)ccc1NC(=O)[C@]12CCC[C@H]1CC(=O)C2', 'CCSc1ccc(C(C)NC(=O)C(=O)N2CCC(NC(N)=O)C2)cc1', 'CCSc1ccccc1CCNC(=O)C1(C2CCOC2)CCNCC1', 'CC[C@@H](C(=O)N(C)CCC(C)(C)O)N(C)C(=O)COC1(C)CCCC1', 'CC[C@@H](C(=O)N(C/C1=C/CCCCCC1)CC1(SC)CCC1)N(C)C', 'CC[C@@H](C(=O)N1CCC[C@@H]1CC(=O)NC(C)Cn1cncn1)N(C)C', 'CC[C@@H](C(=O)N1CCN(CC)CC1)N(C)C(=O)Cc1cccnc1O', 'CC[C@@H](C(=O)N1C[C@H]2CCOC(=O)[C@H]2C1)N(C)C(=O)C1CCCN1C', 'CC[C@@H](C(=O)NC(C)c1c(C)noc1C)N(C)C(=O)C(C)=C1CCC1', 'CC[C@@H](C(=O)NC1CC(C(N)=O)C1)N(C)C(=O)[C@@H]1C[C@@H]2[C@H](C1)C2(C)C', 'CC[C@@H](C(=O)NCC(=O)NCCNc1cc(C)nc(SC)n1)N(C)C', 'CC[C@@H](C(=O)NCCC1(O)CN(C(=O)Cc2cc(C)[nH]n2)C1)N(C)C', 'CC[C@@H](C(=O)NCCC1CCCCC1)N(C)C(=O)C(O)C(C)(C)CC', 'CC[C@@H](C(=O)NCc1ncc(C)o1)N(C)C(=O)C1=CC2CCC(C1)C2', 'CC[C@@H](C(=O)NCc1nccn1C)N(C)C(=O)Cc1cnccc1C', 'CC[C@@H](C(=O)NOCCC(F)(F)F)N(C)C(=O)CC1CC(C)(C)CO1', 'CC[C@@H](C(=O)OC)N(C)C(=O)C[C@H]1C[C@@H](NC(=O)c2conc2C)C1', 'CC[C@@H](C(=O)OC)N(C)C(=O)c1occc1CNC(=O)c1cncs1', 'CC[C@@H](C)N(C)C(=O)C[C@@H]1C[C@@H](O)CN1C(=O)[C@@H](NC(C)=O)C(C)C', 'CC[C@@H](C)N(CC)C(=O)c1ncoc1CNC(=O)C1CCC(C)CC1', 'CC[C@@H](CC(=O)N(CC(C)C)C(C)C)NC(=O)C1CN(C(=O)NC)C1', 'CC[C@@H](CC(=O)N1CC(F)(CF)C1)N(C)C(=O)CC1CC2CCC1O2', 'CC[C@@H](CC(=O)NC12CCCCC1C2)N(C)C(=O)c1oc(C)cc1C', 'CC[C@@H](CC(=O)NCC(F)C1CCC1)NC(=O)C1CCc2nccn21', 'CC[C@@H](CC(=O)NCCCCN=[N+]=[N-])N(C)C(=O)[C@H]1C[C@@H]1C(F)(F)F', 'CC[C@@H](CC(=O)NCCc1ccc(=O)[nH]c1)N(C)C(=O)C(SC)SC', 'CC[C@@H](CC(=O)NOCCC(F)(F)F)N(C)C(=O)[C@@H]1CC=C[C@H](O)C1', 'CC[C@@H](CC(=O)Nc1cc(F)ccc1O)N(C)C(=O)c1coc(C)c1', 'CC[C@@H](CC(=O)OC)NC(=O)C1CCCN1C(=O)C(CO)C(C)(C)C', 'CC[C@@H](CC(=O)OCc1cnc(OC)c(Br)c1)NC(=O)OC(C)(C)C', 'CC[C@@H](CCC(=O)N1CC(C)(CO)C1)NC(=O)c1nccc(C)c1F', 'CC[C@@H](CCC(=O)N1CC(N2CC(O)C2)C1)NC(=O)[C@@H](O)C(F)(F)F', 'CC[C@@H](CCC(=O)NC1CCCSCC1)NC(=O)Cc1cc(C)cs1', 'CC[C@@H](CCC(=O)NC1CCOCC1(C)C)NC(=O)CS(=O)(=O)NC', 'CC[C@@H](CCC(=O)NCc1nn(C)cc1C)NC(=O)C1(COC)CC1', 'CC[C@@H](CCC(=O)NCc1scnc1C)NC(=O)c1sccc1OC', 'CC[C@@H](CN(CC)C(=O)C1=CCCC1C)NC(=O)Cc1ccoc1C', 'CC[C@@H](CN(CC)C(=O)C=Cc1cn(C)cn1)NC(=O)C1CS(=O)C1', 'CC[C@@H](CN(CC)C(=O)CCn1cnnn1)NC(=O)Cn1ccnn1', 'CC[C@@H](CNC(=O)/C=C/c1cocn1)Nc1nc(C2CCCC2)ns1', 'CC[C@@H](CNC(=O)C1=C(Cl)CCC1)NC(=O)C1(C#N)CC2(CCC2)C1', 'CC[C@@H](CNC(=O)CC1CCCS(=O)(=O)C1)Nc1nccc(OC)n1', 'CC[C@@H](CNC(=O)CC1CCCSC1)NC(=O)Cc1ccc(Cl)cn1', 'CC[C@@H](CNC(=O)COCC(C)(C)C)Nc1cc(OC(C)C)ncn1', 'CC[C@@H](CNC(=O)c1nsnc1O)NC(=O)C(F)CC1CCCCC1', 'CC[C@@H](COC)NC(=O)C1N(C(=O)CC2CCOCC2)CCC1(C)C', 'CC[C@@H](NC(=O)/C=C/c1cccc(C)c1)c1csc(-c2ncc[nH]2)n1', 'CC[C@@H](NC(=O)C12CC(NC(=O)C(C)=CC(C)(C)C)(C1)C2)C(=O)NC', 'CC[C@@H](NC(=O)C1CN(C(=O)C(C)C(F)F)CCC1(C)C)C(=O)OC', 'CC[C@@H](NC(=O)CC(C)CN(C)C)C(=O)NCc1cc(O)ccc1F', 'CC[C@@H](NC(=O)CC(O)CNC(=O)c1ccc(O)c(C)c1)C(C)(C)C', 'CC[C@@H](NC(=O)CCCC(F)(F)F)C(=O)NCc1cn[nH]c1C1CC1', 'CC[C@@H](NC(=O)C[C@@H]1CCCCN1C(=O)CN(C)CCOC)C(C)C', 'CC[C@@H](NC(=O)c1ccc(F)c(O)c1)c1csc(-c2ccccn2)n1', 'CC[C@@H](O)C(=O)N(C)CCc1cn(-c2ccc(C)cc2[N+](=O)[O-])nn1', 'CC[C@@H](O)C(=O)N(Cc1cc(C2CCC2)on1)CC1(C(C)(F)F)CC1', 'CC[C@@H](O)C(=O)N1[C@@H]2CC[C@@H](C2)[C@H]1C(=O)N1CCC2(C=CCO2)CC1', 'CC[C@@H](O)C(=O)N[C@H]1CCC[C@H]1CC(=O)N(C)CC(C)(C)CN(C)C', 'CC[C@@H](O)CN(C)C(=O)C1CCN(C(=O)C2=C(C)OCCS2)C1(C)C', 'CC[C@@H](O)CN(C)C(=O)CO[C@H]1C[C@@H](NC(=O)C2C3CC(=O)CC32)C1', 'CC[C@@H](O)CN(C)S(=O)(=O)c1ccc(N(C)Cc2cc(C)cs2)nc1', 'CC[C@@H](O)CNC(=O)CC(NC(=O)c1cc([N+](=O)[O-])c[nH]1)C(F)(F)F', 'CC[C@@H](O)CNC(=O)C[C@H]1CCC[C@H]1NC(=O)C(O)Cn1cncn1', 'CC[C@@H]1CC[C@H](C)N1C(=O)C[C@H]1CCCC[C@H]1NC(=O)c1ccoc1', 'CC[C@@H]1CN(C(=O)[C@@H]2CC[C@H](CNC(=O)[C@H]3C[C@](C)(F)C3)O2)CCO1', 'CC[C@@H]1CN(C(=O)[C@@H]2CN(C(=O)c3cnncc3O)C[C@H]2F)CCO1', 'CC[C@@H]1COCCN1C(=O)c1[nH]ncc1CNC(=O)c1cocc1C', 'CC[C@@H]1C[C@H](C(=O)NCC2CC(F)(F)C2)CCN1C(=O)CC1(C)CC1', 'CC[C@@H]1C[C@H](O)CCN1C(=O)C1CCCN(C(=O)C2CC23CCC3)C1', 'CC[C@@H]1OCC[C@H]1NC(=O)CSCCNC(=O)c1cc(C)ccc1F', 'CC[C@@H]1[C@H](C(=O)N[C@@H](C)CN=[N+]=[N-])CCCN1C(=O)[C@H](O)C1CCC1', 'CC[C@@H]1[C@H](O)CCN1C(c1scc(Cl)c1Cl)c1nnnn1C1CCC1', 'CC[C@H](C(=O)N1CCC(O)(CO)C1)N(C)C(=O)CC1C(C)(C)C1(C)C', 'CC[C@H](C(=O)N1CCC12CCN(C)C2)N(C)C(=O)[C@@H]([C@H](C)O)N(C)C', 'CC[C@H](C(=O)NCc1cc(OC)ns1)N(C)C(=O)C1CN(C)C(=O)N1', 'CC[C@H](C(=O)Nc1cc(F)ccc1O)N(C)C(=O)CCC(=O)N(C)C', 'CC[C@H](C(=O)OC)N(C)C(=O)c1ccc(C2(C(F)(F)F)CCC2)nc1', 'CC[C@H](C)C(=O)N(CC)CC1CCCCN1C(=O)C(=O)NCC1CC1', 'CC[C@H](C)C(=O)N1C[C@@H](N=[N+]=[N-])C[C@@H]1C(=O)N1CCC[C@H]1CCCO', 'CC[C@H](C)C(=O)N1C[C@H](OC)C[C@H]1C(=O)N[C@H]1C[C@@H]1C1CCOCC1', 'CC[C@H](C)C(=O)NC[C@H]1CN(C(=O)COCc2ccnn2C)C[C@H]1O', 'CC[C@H](C)C(=O)NC[C@H]1CN(C(=O)c2[nH]c(=O)[nH]c2C)CC(C)(C)O1', 'CC[C@H](C)CN(CC1COC(C)(C)CO1)C(=O)c1c[nH]nc1[N+](=O)[O-]', 'CC[C@H](C)CN(CC1OCCCC1(C)C)C(=O)CNC(=O)C(C)(C)C', 'CC[C@H](C)N(C)C(=O)c1ccc(-c2nnc(-c3ccccc3)o2)cc1', 'CC[C@H](C)Nc1nc(N2CCC3(CC2)NC(=O)CO3)nc2c1CSC2', 'CC[C@H](C)[C@@H](CC(=O)N(CC)C[C@H](C)O)NC(=O)C(C)c1cccs1', 'CC[C@H](C)[C@@H](CC(=O)N1CCCOCC1C)NC(=O)C(C)CN(C)C', 'CC[C@H](C)[C@@H](CC(=O)Nc1ccn(C)n1)NC(=O)C1(C)CC=CCC1', 'CC[C@H](C)[C@@H](CN(C)C)NC(=O)C1(C)CC(NC(=O)C=C2CCC2)C1', 'CC[C@H](C)[C@H](NC(=O)C#CC1(C)COC1)C(=O)NCCC1(O)CCC1', 'CC[C@H](C)[C@H](NC(=O)Cc1cccn1C)C(=O)N1CCOCCC1C', 'CC[C@H](C)[C@H](NC(=O)Cn1ccnc1)C(=O)NCC1CNC(=O)CO1', 'CC[C@H](C)[C@H](NC(=O)[C@@H]1C[C@H]2C=C[C@@H]1O2)C(=O)N(C)Cc1nccs1', 'CC[C@H](C)[C@H](NC(=O)c1cc(CC2CCNCC2)on1)C(=O)N(C)C', 'CC[C@H](C)[C@H](NC(=O)c1nnn(C)c1N)C(=O)NC(C)(C)CCCO', 'CC[C@H](C)[C@H](NC(=O)c1sccc1Cl)C(=O)N(C)C1CCCNC1=O', 'CC[C@H](C)[C@H](NC(N)=O)C(=O)N[C@H]1C[C@H](NC(=O)[C@H]2C[C@@H](SC)C2)C1', 'CC[C@H](C)[C@H](O)C(=O)N1CCO[C@H](CNC(=O)c2cnc(SC)s2)C1', 'CC[C@H](C)[C@H](O)C(=O)N1C[C@@H]2[C@@H](C1)OCCN2C(=O)[C@@H](C)NC(C)=O', 'CC[C@H](C)[C@H](O)C(=O)NC1(C)CCN(C(=O)c2ncc(C)cc2F)C1', 'CC[C@H](C)[C@H](O)C(=O)NCC(C)CC(=O)NC1CCCC1CN(C)C', 'CC[C@H](C)[C@H](O)C(=O)N[C@@H]1CCC[C@H]1CC(=O)NCCCC(F)(F)F', 'CC[C@H](CC(=O)N1CC(c2cccnc2)C1)NC(=O)C1=COCCC1', 'CC[C@H](CC(=O)N1CCCC[C@H]1C(=O)OC)NC(=O)c1cnnn1C', 'CC[C@H](CC(=O)N1CC[C@H](O)[C@H](CO)C1)NC(=O)C(C#N)(CC)CC', 'CC[C@H](CC(=O)NC(C)C(C)C)NC(=O)C(F)(F)c1ccc(F)cc1', 'CC[C@H](CC(=O)NC1(CCF)CC(O)C1)NC(=O)[C@H]1CCC(=O)N1C', 'CC[C@H](CC(=O)NCCN(C)C(C)C)NC(=O)c1ncc(C)cc1C', 'CC[C@H](CC(=O)NCCn1cccnc1=O)NC(=O)c1c[nH]cc1C', 'CC[C@H](CC(=O)Nc1csnc1C(C)C)NC(=O)CC(C)(C)COC', 'CC[C@H](CC(=O)O)NC(=O)c1cc2cc(OC)c(OC)c(OC)c2[nH]1', 'CC[C@H](CCC(=O)N(C)C(C)CCSC)NC(=O)c1cnncc1O', 'CC[C@H](CCC(=O)N1CCOC(C#N)C1)NC(=O)CCOC1CCC1', 'CC[C@H](CN(C)C)NC(=O)[C@H]1C=C[C@@H](NC(=O)C(=O)NCC(F)F)C1', 'CC[C@H](CN(C)C)NC(=O)[C@H]1CCC[C@H](NC(=O)CC(O)C(C)C)C1', 'CC[C@H](CNC(=O)CC(C)C(C)(C)C)NC(=O)CCCNC(=O)OC', 'CC[C@H](CNC(=O)Cn1ccccc1=O)NC(=O)c1[nH]nc(C)c1Cl', 'CC[C@H](CNC(=O)OC(C)(C)C)NC(=O)c1ccc(C(=O)OC)cn1', 'CC[C@H](COC(C)(C)C)Nc1nc(N(C)CC(F)F)c2ncsc2n1', 'CC[C@H](N)CN(CC)C(=O)c1cccc(NC(=O)c2ccccc2)c1', 'CC[C@H](NC(=O)C(C)NC(=O)C1CC1)C(=O)Nc1ccccc1OC', 'CC[C@H](NC(=O)C(CN(C)C)C(C)C)C(=O)N1C2C=CCC1CCC2', 'CC[C@H](NC(=O)C1CC(C2CC2)C1)C(=O)NCCCc1cccnc1', 'CC[C@H](NC(=O)C1Cc2nccn2C1)C(=O)N1CCC(F)(CO)CC1', 'CC[C@H](NC(=O)CC1(C)OCCO1)C(=O)N1CCC(CC)(N(C)C)C1', 'CC[C@H](NC(=O)C[C@H]1CC[C@@H](NC(=O)Cc2cnnn2C)C1)[C@H](C)O', 'CC[C@H](NC(=O)[C@@H]1[C@H](C)CN1C(=O)c1cccc(C)c1C)C(=O)OC', 'CC[C@H](NC(=O)[C@@H]1[C@H](CNC(=O)CC2CC(=O)C2)C1(C)C)C(=O)OC', 'CC[C@H](NC(=O)[C@H]1C[C@H](OC)CN1C(=O)C(F)CC(C)(C)C)C(N)=O', 'CC[C@H](NC(=O)c1c[nH]c(=O)cn1)C(=O)NCc1cc(F)ccc1O', 'CC[C@H](NC(=O)c1ncc(F)cc1N)C(=O)NCc1ccc(F)cc1', 'CC[C@H](NC(=O)c1nn(C)c2c1CS(=O)(=O)CC2)c1ccccc1F', 'CC[C@H](NC(=O)c1sccc1CNC(=O)C(C)(C)Cl)c1ncnn1C', 'CC[C@H](O)C(=O)N1CCCC[C@H]1CCC(=O)N(C)C(C(N)=O)C1CC1', 'CC[C@H](O)C(=O)N1[C@H]2CC[C@@H]1[C@H](C(=O)NCCN1CCC(C)(C)C1)C2', 'CC[C@H](O)C(=O)NC(C)C(C(=O)N1CCCN(CCO)CC1)C(C)C', 'CC[C@H](O)C(=O)N[C@H](C(=O)NCCc1n[nH]c(=O)o1)C1CCCCC1', 'CC[C@H](O)CN(C)C(=O)CC1CC(NC(=O)CCc2ccnn2C)C1', 'CC[C@H]1CCCN(C(=O)[C@H]2C[C@@H]2C2CCC2)[C@H]1C(=O)N1CC(C)(C)C1', 'CC[C@H]1CCO[C@H]1C(=O)N1CCO[C@@H](C(=O)NC2CN(C)CC2C)C1', 'CC[C@H]1CCO[C@H]1C(=O)NC1C2CC3C(C2)C31C(=O)NCC(F)(F)F', 'CC[C@H]1CC[C@@H](C(=O)NCc2ccc(C(=O)N3CC(COC)C3)s2)O1', 'CC[C@H]1CC[C@@H](CN(CC(CC(C)C)OC)C(=O)c2ncn(C)n2)O1', 'CC[C@H]1CC[C@@H](CNC(=O)C(=O)NC2CCN(c3ccccn3)C2)O1', 'CC[C@H]1CC[C@@H](CNC(=O)C[C@H](CC)N(C)C(=O)c2cnsc2C)O1', 'CC[C@H]1CC[C@@H](CNC(=O)[C@H](CN=[N+]=[N-])NC(=O)CC2=CCCC2)O1', 'CC[C@H]1CC[C@@H]1CN(CC1CCN(C)CC1)C(=O)[C@@H]1CN(C)C(=O)N1', 'CC[C@H]1CC[C@@H]1NC(=O)NCC1CCN(Cc2nc(C)c(C)o2)CC1', 'CC[C@H]1CC[C@H](C(=O)N2C[C@H](O)C[C@H]2CNC(=O)/C=C/C(F)F)CC1', 'CC[C@H]1CC[C@H](C(=O)NC2CC3CCC2CN3C(=O)C=CCO)CC1', 'CC[C@H]1CN(C(=O)C#CC(C)C)CC[C@H]1CNC(=O)C(OC)C1CC1', 'CC[C@H]1CN(C(=O)C(C)C#N)C[C@@H]1C(=O)NCc1cc(OC)ncn1', 'CC[C@H]1CN(C(=O)C(C)C(C)C)CC[C@H]1CNC(=O)C1=CCN(C)C1', 'CC[C@H]1CN(C(=O)C2(F)CC=CC2)CC[C@H]1CNC(=O)[C@@H]1CCOC1', 'CC[C@H]1CN(C(=O)CC(O)C(C)C)C[C@@H]1C(=O)NCCc1ccon1', 'CC[C@H]1CN(C(=O)CN(C)C2CCC2)C[C@@H]1C(=O)NC1(C)CC1(C)C', 'CC[C@H]1CN(C(=O)COC2CCC2)C[C@@H]1C(=O)N1CCn2ccnc21', 'CC[C@H]1CN(C(=O)C[C@H]2CCCN2C(=O)C(C)CCCOC)C[C@H]1F', 'CC[C@H]1COCCN1C(=O)[C@@H]1CN(C(=O)CCCC(C)C)C[C@H]1OC', 'CC[C@H]1C[C@@H]1C(=O)N1CCC(C(=O)NC(C)CCCC(C)C)=C(F)C1', 'CC[C@H]1C[C@@H]1C(=O)N1CCCN(C(=O)C2CN(C(C)=O)CCO2)CC1', 'CC[C@H]1C[C@@H]1C(=O)NC(C)(C(=O)N1CCC12CCCSC2)C1CCC1', 'CC[C@H]1C[C@@H]1C(=O)NC(CC1CCC1)C(=O)N1CCC(C(C)C)CC1', 'CC[C@H]1C[C@@H]1C(=O)NC1CN(C(=O)c2cc(C)ccc2O)C(C)(C)C1', 'CC[C@H]1C[C@@H]1C(=O)NCC1CC(F)(F)CN1C(=O)c1ncccc1C', 'CC[C@H]1C[C@@H]1C(=O)NCCCN(CC)C(=O)c1c[nH]nc1C(C)(C)C', 'CC[C@H]1C[C@@H]1C(=O)NC[C@@]1(C)CCCN1C(=O)c1cc(C2CC2)cs1', 'CC[C@H]1C[C@@H]1C(=O)NC[C@H]1CC[C@@H](C(=O)NCc2ncn(CC)n2)C1', 'CC[C@H]1C[C@@H]1C(=O)N[C@H]1C[C@H]2C[C@@H]1N(C(=O)c1ccc(F)cc1Cl)C2', 'CC[C@H]1C[C@@H]1CC(=O)N1CCC(N(CC2CC2)C(=O)C2CC=CC2)C1', 'CC[C@H]1C[C@@H]1CC(=O)N1CCCC(C(C)C(=O)N2CC[C@H]3CC[C@H]32)C1', 'CC[C@H]1C[C@@H]1CC(=O)N1CCC[C@H]1CN(C)C(=O)C(C#N)CC1CC1', 'CC[C@H]1C[C@@H]1CC(=O)NC(C)(C)CN(C)C(=O)C1COCCN1C=O', 'CC[C@H]1C[C@@H]1CC(=O)NC1C2CCN(C(=O)C(O)CCC(C)C)CC21', 'CC[C@H]1C[C@@H]1CC(=O)NCC(C(=O)N1CC(C)=CC(C)C1)C(C)(C)C', 'CC[C@H]1C[C@@H]1CC(=O)NCC(C)=CC(=O)NCCN1C(=O)CCC1=O', 'CC[C@H]1C[C@@H]1CNC(=O)C(C)N(C(=O)C1CCC(C)(O)CC1)C1CC1', 'CC[C@H]1[C@H](C(=O)N2CC(NC(=O)c3c(F)cccc3F)C2)CCN1C', 'CC[C@H]1[C@H](C(=O)N[C@H]2C[C@H](C(=O)NC(C)(C)C(O)CO)C2)CCN1C', 'CC[C@H]1[C@H](CC(=O)N2C[C@@H]3[C@H](C2)[C@H]3NC(=O)c2ccccc2)C1(F)F', 'CC[C@]12C[C@H]1CN(C(=O)C1CCN(C(=O)COc3ccsn3)C1C)C2', 'CC[C@]12C[C@H]1CN(C(=O)[C@H](CC(C)C)N(C)C(=O)CSC(F)(F)F)C2', 'CCc1[nH]c(C)nc1C(=O)NC1(CNC(=O)CC(=O)NC2CC2)CC1', 'CCc1[nH]c(C)nc1C(=O)NC1CCN(C(=O)C2CC=CCC2)CC1', 'CCc1[nH]ccc1C(=O)N1CC(F)(C(=O)NCCC(C)C(F)(F)F)C1', 'CCc1[nH]ccc1C(=O)N[C@@H](CCSC)C(=O)NCCn1ncnn1', 'CCc1[nH]ncc1C(=O)N(Cc1ccc(F)c(Cl)c1)CC(CC)CO', 'CCc1[nH]ncc1C(=O)N1CC2(CC2)C[C@H]1C(=O)N1CCC12CCC2', 'CCc1[nH]ncc1C(=O)N1C[C@@H](O)C[C@@H]1C(=O)N[C@H]1C[C@@H](CSC)C1', 'CCc1[nH]ncc1C(=O)NCc1nc(C)c(C(=O)NCCCOC)o1', 'CCc1[nH]nnc1C(=O)NC(C)C(C)C(=O)Nc1cccc(F)c1O', 'CCc1[nH]nnc1C(=O)NC/C=C(\\C)C(=O)NC1(C)CCCCCC1', 'CCc1[nH]nnc1C(=O)NC[C@H](O)C(=O)N1CC(=O)N2CCCC2C1', 'CCc1[nH]nnc1C(=O)NC[C@H](O)CC(=O)N1CCCN(C=O)CC1', 'CCc1[nH]nnc1C(=O)N[C@]1(C(=O)NC2CCCCCC2)C[C@H](O)C1', 'CCc1c(C(=O)N2CC(c3nc4c(cnn4C)c(=O)[nH]3)C2)cnn1C', 'CCc1c(C(=O)N2[C@H](C(=O)N3C[C@@H](O)[C@@H](O)C3)C[C@@H]3C[C@@H]32)cnn1C', 'CCc1c(C(=O)NCC2CCCN(C(=O)C(C)(C)C)CC2)nnn1C', 'CCc1c(C(=O)NCCC(O)CNC(=O)Cn2cnnn2)cnn1C', 'CCc1c(C(=O)NC[C@@H]2CCCN2C(=O)c2ccoc2Cl)cnn1C', 'CCc1c(C(=O)NC[C@H]2CC[C@H]2C(=O)N2CC(N=[N+]=[N-])C2)cnn1C', 'CCc1c(C(=O)NNC(=S)NCC(N)=O)cnn1-c1ccccc1Cl', 'CCc1c(C(NC(C)C(C)SC)c2nnnn2C2COC2)cnn1C', 'CCc1c(C)cccc1CN(Cc1conc1C)CC1CC(SC)C1', 'CCc1c(CN(CC2(C)CC2)C(=O)c2csc(CO)n2)cnn1CC', 'CCc1c(NC(=O)C(=O)N2CCOCC3(CCOCC3)C2)cnn1C', 'CCc1c(NC(=O)c2c[nH]nc2S(N)(=O)=O)cnn1-c1ccccc1', 'CCc1c[nH]c(CN(CCC(=O)N(CC)CC)CC2CCSCC2)n1', 'CCc1c[nH]c2ncnc(Nc3cc(NC(=O)C4CC4)ccc3C)c12', 'CCc1c[nH]nc1C(=O)NCC(C)C(=O)N1CCC[C@H]2CNC(=O)[C@H]21', 'CCc1c[nH]nc1C(=O)NCCCCC(C)NC(=O)[C@H](C)NC(C)=O', 'CCc1c[nH]nc1C(=O)N[C@H]1CCN(C(=O)c2ccc(C3CC3)s2)C1', 'CCc1cc(=O)n2nc(NC(=O)C3[C@H]4CC(=O)N[C@H]4C3(C)C)[nH]c2n1', 'CCc1cc(Br)cn2c(NC(C)(C)C)c(-c3cnc4n3CCC4)nc12', 'CCc1cc(C(=O)N(CCC(=O)Nn2cnnc2C)C2CC2)nn1C', 'CCc1cc(C(=O)N(CCCNc2ncncc2Br)C2CC2)ncn1', 'CCc1cc(C(=O)N(CCNC(=O)C=Cc2cc[nH]n2)C(C)C)no1', 'CCc1cc(C(=O)N(CCNC(=O)CC2CC(C)C2)C(C)C)c(C)o1', 'CCc1cc(C(=O)N2CC(C(=O)N(C)C3CCOC3)C(C)(C)C2)no1', 'CCc1cc(C(=O)N2CC(CF)(NC(=O)Cc3scnc3C)C2)ns1', 'CCc1cc(C(=O)N2CC(N(C)C(=O)C(C)(F)F)C3(CC3)C2)ccn1', 'CCc1cc(C(=O)N2CC3CCC(N(C)C(=O)COC)C3C2)n(C)n1', 'CCc1cc(C(=O)N2CCC(CC)(C(=O)NC[C@@H](C)OC)C2)nn1C', 'CCc1cc(C(=O)N2CCC(N(C)C(=O)c3nnsc3N)CC2)ns1', 'CCc1cc(C(=O)N2CCC(OC)(C(=O)NCCC3CCC3)C2)no1', 'CCc1cc(C(=O)N2CCCC2(C)CNC(=O)c2csnc2Cl)on1', 'CCc1cc(C(=O)N2C[C@H](NC(=O)C(C)CC3CC3)[C@H](OC)C2)on1', 'CCc1cc(C(=O)NC(C)CCC(=O)Nc2cncnc2OC)on1', 'CCc1cc(C(=O)NCC(C)(F)CNC(=O)Cc2nocc2C)no1', 'CCc1cc(C(=O)NCC(C)(O)CNC(=O)c2ccccc2)c(C)o1', 'CCc1cc(C(=O)NC[C@H]2CC[C@@H](C(=O)NC3(C)CCC3)O2)ccn1', 'CCc1cc(C(=O)N[C@@H](C)CCNC(=O)C[C@H]2CCCN2C)sc1C', 'CCc1cc(C(=O)N[C@@H](CC(N)=O)C(=O)NCC2(C)CCC2)ccn1', 'CCc1cc(C(=O)N[C@@H]2CN(C(=O)C(C)CC(F)F)C[C@@H]2C)c(C)o1', 'CCc1cc(C(=O)N[C@H](C)C(=O)N2CCC(C)(C)C(CO)C2)ccn1', 'CCc1cc(C(=O)N[C@H](CC)CCC(=O)NC(C)(CC)CO)nn1C', 'CCc1cc(C(=O)N[C@H]2COCC[C@H]2C(=O)N2CC[C@H](OC)C2)no1', 'CCc1cc(C(=O)N[C@H]2C[C@H](CC(=O)NCC(C)(C)N(C)C)C2)on1', 'CCc1cc(C(=O)N[C@]2(C)C[C@H](NC(=O)CNC(=O)OC)C2)ccn1', 'CCc1cc(C(C(=O)NCCSC)N(C)C2CCNC2=O)ccc1F', 'CCc1cc(C)c(C(=O)N[C@H](CNC(=O)[C@H]2CCN2C)C(C)(C)C)o1', 'CCc1cc(C)ccc1C(=O)N1CC(NC(=O)C=C(C)C(C)(C)C)C1', 'CCc1cc(C)nc(NCCN(C)C(=O)CC2OCCOC2(C)C)n1', 'CCc1cc(C2CC2)nc(NC(=O)Nc2ccc(NC(C)=O)cc2)n1', 'CCc1cc(CC(=O)N(CC)CCC(=O)NCc2ccn(C)n2)on1', 'CCc1cc(CC(=O)N2CC(NC(=O)C(C)(C)n3cncn3)C2)on1', 'CCc1cc(CC(=O)NCC(C)NC(=O)c2ccccc2NC)on1', 'CCc1cc(CC(=O)N[C@H](C(=O)N[C@H](CC)CN(C)C)[C@@H](C)O)on1', 'CCc1cc(CC)nc(N2CCN(Cc3nc(COC)no3)CC2)n1', 'CCc1cc(CCN(CC2=CCCSC2)C(=O)C2CC2(C)CC)on1', 'CCc1cc(CCNC(=O)C(=O)NCc2ccccc2C(C)C)on1', 'CCc1cc(CCNC(=O)NCc2ccc3cc(Cl)ccc3n2)on1', 'CCc1cc(CN(CCCCC(F)(F)F)C(=O)[C@@H]2COCCO2)on1', 'CCc1cc(CN(CCCn2cc(C)cn2)C(=O)C2CC2(Cl)Cl)on1', 'CCc1cc(CNC(=O)C(C)CN(C)C(=O)C(F)CCC(C)C)[nH]n1', 'CCc1cc(CNC(C)c2ccccc2-n2cccn2)ccc1OC', 'CCc1cc(F)c(NC(=O)N(C)CC(=O)Nc2ccccc2)cc1F', 'CCc1cc(F)cc(CN(CC2(CC)OCCO2)C(=O)C(C)(Cl)Cl)c1', 'CCc1cc(F)cc(NC(=O)NCCc2c(F)cc(OC)cc2F)c1', 'CCc1cc(F)cc(NC(=O)c2cc(C)nc3ccc(F)cc23)c1C', 'CCc1cc(F)ccc1C(=O)N1CC2CC(NC(=O)CC(C)C)C1C2', 'CCc1cc(N2CCCC(Nc3ncnc4[nH]nc(C)c34)C2)ncn1', 'CCc1cc(NC(=O)CN(CC)C(=O)c2ccc(=O)n(C)n2)nn1C', 'CCc1cc(NC(=O)N2CCC(S(=O)(=O)N3CCOCC3)C2)n(C)n1', 'CCc1cc(NC(=O)c2ccc(CNC(C)=O)c(F)c2)ccc1OC', 'CCc1cc(NC(=O)c2ccc(F)c(S(=O)(=O)N(C)C)c2)cc(Cl)n1', 'CCc1cc(OC)ccc1CNC(=O)Nc1nc2n(n1)CCC(=O)N2', 'CCc1cc[nH]c1C(=O)N(C)CC(CC)NC(=O)c1ccc(N)cn1', 'CCc1cc[nH]c1C(=O)N(CC[C@@H]1C[C@H]2CC[C@@H]1C2)CC1=CCSC1', 'CCc1cc[nH]c1C(=O)NC/C=C/CC(=O)NCC1(C)CC=CCC1', 'CCc1cc[nH]c1C(=O)NCCC(C)(C)NC(=O)CNC(=O)C1CC1', 'CCc1ccc(-c2csc(NC(=O)CC[C@H]3C[C@@H](N)C3(C)C)n2)cc1', 'CCc1ccc(-c2n[nH]cc2CN2CCC3CS(=O)(=O)CC3C2)cc1', 'CCc1ccc(-c2nc(C(=O)NCCN3CCCOCC3)cs2)cc1', 'CCc1ccc(-n2cc(C(=O)NC3CCC(CSC)CC3)nn2)cc1', 'CCc1ccc(Br)cc1C(=O)N[C@@H](C)Cn1cc(CCCC#N)nn1', 'CCc1ccc(C(=O)N(C)CCNC(=O)c2nnccc2C)c(C)n1', 'CCc1ccc(C(=O)N(CC)[C@H](C)CNC(=O)[C@@H]2CCN2C)cc1C', 'CCc1ccc(C(=O)N(CCSC(C)C)Cc2cnn(C(C)C)c2)s1', 'CCc1ccc(C(=O)N(Cc2cccc(F)c2F)CC2CC2Cl)cn1', 'CCc1ccc(C(=O)N2CC(N(C)C(=O)CCc3nnc[nH]3)C2)cn1', 'CCc1ccc(C(=O)N2C[C@H](CCNC(=O)COC)[C@@H](C)C2)c(F)c1', 'CCc1ccc(C(=O)NC(C(=O)N2CC(CC3CC3)C2)C(C)C)cc1', 'CCc1ccc(C(=O)NC(C)(C)C(=O)N[C@H]2CCC[C@H]2C(=O)NC)s1', 'CCc1ccc(C(=O)NC(C)/C=C/C(=O)N2CCN(C)C[C@H]2CO)o1', 'CCc1ccc(C(=O)NC(C)C2CC(NC(=O)C3CCO3)C2)cc1F', 'CCc1ccc(C(=O)NC(CC2CCCC2)C(=O)NCC(C)(C)F)o1', 'CCc1ccc(C(=O)NC2(C(=O)N(C)C3CCCCCC3)CCC2)o1', 'CCc1ccc(C(=O)NC2(C3CCCCN3C(=O)C=C(C)C)CC2)o1', 'CCc1ccc(C(=O)NCC(C)N(C)C(=O)C[C@@H]2CCCC[C@H]2O)[nH]1', 'CCc1ccc(C(=O)NNC(=O)CCC(=O)Nc2ccn(C)n2)cc1', 'CCc1ccc(C(=O)c2ccccc2C(=O)Oc2ccccc2F)s1', 'CCc1ccc(C(C)(C)NC(=O)NCc2nc(C(F)(F)F)n[nH]2)cc1', 'CCc1ccc(C(NCc2cnoc2C)c2nnnn2CC2CC2)s1', 'CCc1ccc(C)c(C(=O)N[C@H](CC)CNC(=O)C2CC(F)(F)C2)c1', 'CCc1ccc(C)c(NC(=O)CC[C@@H](C)NC(=O)Cc2ccsc2)c1', 'CCc1ccc(C)cc1C(=O)N1CCN(C(=O)C(C)CC)CC1CO', 'CCc1ccc(C=CC(=O)N(C)CCCN(C)C(=O)[C@H](C)N(C)C)o1', 'CCc1ccc(CC(=O)NC/C=C\\CNC(=O)C(OC)C2CC2)cc1', 'CCc1ccc(CC)c(C(=O)COC(=O)c2c(C)cc(F)cc2C)c1', 'CCc1ccc(CN(CC(C)(C)C(F)F)C(=O)c2cn(CC)nn2)o1', 'CCc1ccc(CN(CC2(F)CCC2)C(=O)COC2CCCOC2)s1', 'CCc1ccc(CN(CC2CC2Cl)C(=O)C2(O)CC3CCC2C3)nc1', 'CCc1ccc(CN(CCC2(O)CCC2)C(=O)c2cn[nH]c2Cl)cc1', 'CCc1ccc(CN(CCCC2CC2)C(=O)c2ccc(=O)n(C)n2)s1', 'CCc1ccc(CN(Cc2cn(C3CC3)cn2)CC2CCCSC2)s1', 'CCc1ccc(CNC(=O)[C@@H]2[C@H](C)CN2C(=O)Cc2c[nH]nc2C)s1', 'CCc1ccc(CNC(=O)c2ccc(CNC(=O)CC(C)(C)O)o2)o1', 'CCc1ccc(F)c(NC(=O)C(C)(C)CN(C)C(=O)OC(C)(C)C)c1', 'CCc1ccc(F)cc1NC(=O)[C@@H](NC(=O)c1cc[nH]c1C)C(C)C', 'CCc1ccc(NC(=O)CC(C)(C)N(C)C(=O)C2(CO)CC2)cc1O', 'CCc1ccc(NC(=O)CCCNC(=O)c2ccoc2CC)c(C)c1', 'CCc1ccc(NC(=O)[C@@H](NC(=O)c2ccn(CC)n2)C(C)C)cn1', 'CCc1ccc(NC(=O)[C@@H](O)CNC(=O)[C@H]2CC[C@H](C)CC2)c(F)c1', 'CCc1ccc(O)c(NC(=O)Nc2ccc(C(C)(C)C)c(OC)c2)c1', 'CCc1ccc(OC)c(NC(=O)NCc2ccccc2NCCO)c1', 'CCc1ccc(OCCNC(=O)c2cncc3c(=O)[nH]ccc23)cc1', 'CCc1ccc(S(=O)(=O)N2CCOCC2)cc1NCc1scnc1C', 'CCc1ccc(S(=O)(=O)NCC(C)NC(=O)c2ncc(OC)cn2)o1', 'CCc1ccc(S(=O)(=O)NC[C@@H]2[C@H]3CN(C(=O)CCCF)C[C@@H]23)cc1', 'CCc1ccc([N+](=O)[O-])cc1COC(=O)c1cccc(C(=O)OC)n1', 'CCc1ccc2c(CC(=O)NC3CCc4cccc(Cl)c43)coc2c1', 'CCc1cccc(C(=O)N(CC)C(C)C(=O)N2CC(CC)(OC)C2)n1', 'CCc1cccc(C(=O)N2C[C@H](NS(=O)(=O)C3(Cl)CC3)[C@@H](O)C2)c1C', 'CCc1cccc(C(=O)NCCOCC(=O)NC2(CO)CCOC2)c1', 'CCc1cccc(C)c1OCC(=O)NCCn1cc(CN(C)C)nn1', 'CCc1cccc(CCC(=O)NCCS(=O)(=O)c2ccc(F)cc2)c1', 'CCc1cccc(CN(CCCC2CCCC2)C(=O)CC(F)(F)F)n1', 'CCc1cccc(CN(CC[C@@H]2CC=CCC2)C(=O)CC(F)(F)F)n1', 'CCc1cccc(CN(Cc2ccc(C)o2)C(=O)C2SCCS2)c1C', 'CCc1cccc(CN2CCC(c3nc(C(=O)OC)co3)CC2)c1O', 'CCc1cccc(CNC(=O)NCCCc2ccc(Br)cc2F)c1C', 'CCc1cccc(N(C)C(=O)C(O)CNC(=O)CC/C=C/C(C)C)c1', 'CCc1cccc(N(CC)S(=O)(=O)c2ccc(C(=O)C(C)C)cc2)c1', 'CCc1cccc(N2CC(C(=O)NCC(O)c3ccsc3)CC2=O)c1', 'CCc1cccc(NC(=O)C2(N(C)C(=O)c3cc(C)on3)CC2)c1C', 'CCc1cccc(NC(=O)C2CCCN2C(=O)CCCOC(C)C)c1', 'CCc1cccc2c(CCNC(=O)N3CCC3CC3CCC3)c[nH]c12', 'CCc1cccc2sc(NC(=O)N3CCOC(c4nccs4)C3)nc12', 'CCc1ccccc1-c1csc(CCNC(=O)C2CN(C(N)=O)C2)n1', 'CCc1ccccc1-n1nnnc1C(C)(CCBr)NCCC1CCC1', 'CCc1ccccc1C(=O)N1CC(N(C)C(=O)[C@@H]2[C@H](C#N)C2(C)C)C1', 'CCc1ccccc1C(=O)Nc1cccc(C2(C(F)(F)F)CCC2)n1', 'CCc1ccccc1C(C(=O)NCCCOC)N1CC2CCC1CC2', 'CCc1ccccc1CN(C=O)C(C)C(=O)N1CCc2ccccc21', 'CCc1ccccc1CNC(=O)[C@H](O)CCNC(=O)C1CC(=O)CS1', 'CCc1ccccc1OCCCNC(=O)N1CC(C2CCS2(=O)=O)C1', 'CCc1cccnc1C(=O)NC(CC)CN(C)C(=O)[C@H](CO)N(C)C', 'CCc1ccnc(C(=O)N2CC[C@H]2C(=O)NC2CN(C)CC23CC3)c1', 'CCc1ccnc(CNC(=O)C2(F)CN(C(=O)[C@H]3CC[C@H](O)C3)C2)c1', 'CCc1ccoc1C(=O)N(C)C(C(=O)N(C)Cc1ccoc1)C1CC1', 'CCc1ccoc1C(=O)N1CCC2(C=C(C(=O)N(C)C3CC3C)C2)C1', 'CCc1ccoc1C(=O)N1C[C@@H]2CCCN(C(=O)C3CCCO3)[C@@H]2C1', 'CCc1ccsc1C(=O)N1C[C@@H](C)N(C(=O)Cc2cnc[nH]2)C[C@@H]1C', 'CCc1ccsc1C(=O)NC(CNC(=O)[C@H](C(C)C)N(C)C)C(C)C', 'CCc1ccsc1C(=O)NCC1CCCN(C(=O)c2nc[nH]c2C)C1', 'CCc1ccsc1C(=O)N[C@H]1CC[C@H](NC(=O)CC2C=CCCC2)C1', 'CCc1cn2c(ccc3nc(-c4cnn(CC(C)C)c4)c(NC)n32)n1', 'CCc1cn2c(n1)CC(C(=O)Nc1ccc(F)c3ncccc13)CC2', 'CCc1cnc(C(C)NC(=O)CCC(=O)Nc2c(F)cccc2F)s1', 'CCc1cnc(C)c(NC(=O)[C@@H]2C[C@H](F)CCN2C(=O)C2CCO2)c1', 'CCc1cnc(CN(CC(F)(F)C(C)C)C(=O)C2(C)CC(C#N)C2)s1', 'CCc1cnc(CN(CC2CC(C(C)C)C2)C(=O)c2cnn(C)c2)s1', 'CCc1cnc(CN(CC2CC2C2CC2C)C(=O)C2COCOC2)s1', 'CCc1cnc(CN(CC2[C@H](C)[C@H]2C)C(=O)C2(C#N)CC23CCC3)s1', 'CCc1cnc(CN(CCCC(C)(F)F)C(=O)c2[nH]ccc2CC)o1', 'CCc1cnc(CNc2nc(NCC(CC)CO)c3sccc3n2)s1', 'CCc1cnc(NC(C)CCNC(=O)c2cccc(CSC)c2)nc1', 'CCc1cncc(C(=O)NC(C)CCC(=O)N2CC(O)C(C)(C)C2)c1', 'CCc1cncc(C(C(=O)NCC2CC2)N2CCC23CCCSC3)c1', 'CCc1cnccc1C(=O)NC[C@H]1C[C@H]1C(=O)NC1CCC(F)CC1', 'CCc1cnccc1CN(Cc1c[nH]nn1)C(=O)c1cnc(NC)s1', 'CCc1cnccc1CNC(=O)[C@H](CC(C)C)NC(=O)C(C)C(F)F', 'CCc1cnsc1C(=O)N(C)Cc1cccc(CNC(=O)C(C)C)c1', 'CCc1cnsc1C(=O)N1CCN(C)C(C(=O)NC[C@H]2CC[C@H]2C)C1', 'CCc1coc(CN(Cc2ccc(C(F)F)o2)CC2(CSC)CC2)n1', 'CCc1conc1C(=O)N(C)[C@@H](CC)C(=O)Nc1ccc(O)c(C)c1', 'CCc1conc1C(=O)N1CCC(C(=O)NC[C@@H]2[C@H]3CCCO[C@H]32)C1', 'CCc1conc1C(=O)NC(C)(CSC)C(=O)NCCN1CCCC1', 'CCc1conc1C(c1nnnn1C(C)(C)C)N1CCSCC(C)C1', 'CCc1conc1CC(=O)N(C)[C@H](C)CC(=O)NC(C)c1cn[nH]c1', 'CCc1conc1CC(=O)N1CC2(C1)CN(C(=O)[C@]13CCC[C@H]1C3)C2', 'CCc1conc1CC(=O)N[C@]1(C)C[C@H](C(=O)NC2(C(N)=O)CC2)C1', 'CCc1conc1CNC(=O)[C@H](CN=[N+]=[N-])NC(=O)C[C@@H](C)N(C)C', 'CCc1csc(CN(Cc2nccn2C)C(=O)Cn2cc(C)cn2)c1', 'CCc1csc(CNc2cc(C)nc(N(C)CC(C)C(=O)NC)n2)n1', 'CCc1csc(NC2CCCN(C(=O)c3ccc(Br)c(F)c3N)C2)n1', 'CCc1cscc1C(=O)N1CCC1C(=O)N1CCC(c2nn[nH]n2)C1', 'CCc1cscc1C(=O)NC(C)CCCCNC(=O)[C@H]1CCO[C@H]1C', 'CCc1cscc1C(=O)N[C@H]1C[C@H](CCC(=O)N(CC)[C@H](C)CC)C1', 'CCc1cscc1C(=O)N[C@H]1C[C@H]2CC[C@]1(C(=O)NCCC(F)F)C2', 'CCc1cscc1NC(=O)CC(O)CNC(=O)C12CCC(C1)C2(C)C', 'CCc1cscc1NC(=O)[C@H]1OCC[C@H]1NC(=O)c1cnc(C)cn1', 'CCc1cscc1NC(c1nnnn1C(C)C(=O)OC)C1CC=CC1', 'CCc1n[nH]c(=O)c(C(=O)Nc2ccc(Br)c(C(F)(F)F)c2)c1CC', 'CCc1n[nH]c(C(=O)N2CC3(CCN3C(=O)c3cc(Cl)[nH]n3)C2)c1C', 'CCc1n[nH]c(C(=O)N2CCN(C(=O)OC(C)(C)C)CC(O)C2)c1Cl', 'CCc1n[nH]c(C(=O)NC(C)(C)CCCNC(=O)C2=C(C)CC2)c1C', 'CCc1n[nH]c(C(=O)NCC(C)=CC(=O)N(C)CCNC(C)=O)c1C', 'CCc1n[nH]c(C(=O)NCCC(=O)NCC2CC(OC)C2(C)C)c1C', 'CCc1n[nH]c(Cl)c1C(=O)N1CC2CCC1CN2C(=O)CC1(C)CC1', 'CCc1n[nH]c(NC(=O)Nc2ccc(C(=O)N3CCCC3)cc2)c1C', 'CCc1n[nH]c2ccc(C(=O)NCc3cn(CC4CCC4)nn3)cc12', 'CCc1n[nH]cc1CN(CC1CCCC1(C)C)C(=O)c1ccsc1F', 'CCc1n[nH]cc1CN(C[C@H]1CCC[C@H]1F)C(=O)[C@@H]1CCC[C@H](O)C1', 'CCc1nc(=N)c(CNC(=O)NCc2ccc3c(cnn3C)c2)c[nH]1', 'CCc1nc(C(=O)N(C)CC(CC)NC(=O)C/C=C/C(C)(C)C)c[nH]1', 'CCc1nc(C(=O)N(CC)[C@H](C)CNC(=O)CNC(=O)C2CC2)c[nH]1', 'CCc1nc(C(=O)N(Cc2cnnn2CC)CC2CC3(CC3)C2)cs1', 'CCc1nc(C(=O)N2CC3CCC2CN3C(=O)C(C)S(C)(=O)=O)cs1', 'CCc1nc(C(=O)N2CCN(C(=O)[C@H]3CC3(C)C)C[C@@H]2C(C)C)cs1', 'CCc1nc(C(=O)NC(CC(F)F)C(=O)NOC(CO)C(C)C)cs1', 'CCc1nc(C(=O)NC2(C(=O)NCC3(C)CC4(CC4)C3)CCC2)cs1', 'CCc1nc(C(=O)NCC(CC(C)C)C(=O)NC(C)C(F)(F)F)co1', 'CCc1nc(C(=O)NCC23CC(NC(=O)CC4CCC4)(C2)C3)c(C)o1', 'CCc1nc(C(=O)NCCN(C(=O)CC(O)CN(C)C)C(C)C)c[nH]1', 'CCc1nc(C(=O)NCCOCCN(C)C(=O)c2cnsc2C)cs1', 'CCc1nc(C(=O)NC[C@H](C)C(=O)NC2CN3CCC2(F)CC3)co1', 'CCc1nc(C(=O)N[C@H](CO)[C@H](C)NC(=O)C(CC)(CC)OC)co1', 'CCc1nc(C(C(=O)NCCC#N)N2CC34CCC3(COC4)C2)cs1', 'CCc1nc(C(C)NC(=O)CCN(C)C(=O)c2ncccc2C)n[nH]1', 'CCc1nc(C(NC(=O)c2cnc(I)c(O)c2)c2ccccc2)no1', 'CCc1nc(C)c(C(=O)N[C@H](C)C(=O)Nc2cnc(N(C)C)nc2)o1', 'CCc1nc(C)c(C(N[C@H]2C[C@H](CO)C2)c2nnnn2C2CCC2)[nH]1', 'CCc1nc(C)c(CNC(=O)CCCNC(=O)CCC2CC2(C)C)o1', 'CCc1nc(C)c(CNC(=O)C[C@H]2C[C@H](F)CN2C(=O)[C@H]2C[C@@H]2C)o1', 'CCc1nc(C)oc1C(=O)N(CCC(=O)N(C)CC1CCC1)C1CC1', 'CCc1nc(CC(=O)N2CC[C@@H](NC(=O)CCC(N)=O)[C@H](O)C2)cs1', 'CCc1nc(CCNC(=O)Nc2cccc(CC(=O)OC)c2C)no1', 'CCc1nc(CN(CC2CCOCC2)C(=O)C2CCC(F)CC2)cs1', 'CCc1nc(CN(Cc2nc(C)cs2)C(=O)C(C)n2cccc2)cs1', 'CCc1nc(CNC(=O)C(CNC(=O)c2occc2C)C(C)C)cs1', 'CCc1nc(CNC(=O)C2C(CC)CCN2C(=O)C(CC)CC)cs1', 'CCc1nc(CNC(=O)CC2CCN(C(=O)CC(C)F)C2(C)C)n[nH]1', 'CCc1nc(CNC(=O)Nc2cccnc2N2CCNC(=O)C2)n[nH]1', 'CCc1nc(CNC(=O)[C@@H]2C[C@@H]3C[C@@H]3N2C(=O)[C@]23COC[C@H]2C3)n[nH]1', 'CCc1nc(COC2CCN(C(=O)C(=O)NCC3(C)CC3)CC2)no1', 'CCc1nc(Cl)c(C)c(N2CCCC(c3nc4ccccc4o3)C2)n1', 'CCc1nc(NCCS(=O)CC)nc(N2CCN(CC(C)O)CC2)n1', 'CCc1nc(N[C@@H](CC)CNC(=O)C(C#N)CC)c2c(C)csc2n1', 'CCc1nc2ccccc2c(C)c1C(=O)NOCCCOC(C)(C)C', 'CCc1nc2ccccc2cc1C(=O)N1CCC2(CCC(O)C2)CC1', 'CCc1nc2n(n1)CC(NC(=O)N1C[C@@H](F)C[C@@H]1CC(=O)OC)CC2', 'CCc1nc[nH]c1C(=O)NC/C=C\\CNC(=O)C=Cc1ccn(C)c1', 'CCc1ncc(C(=O)N(C)C2(CC(=O)NCC(C)(CC)OC)CC2)o1', 'CCc1ncc(C(=O)N(C)CC(C)(C)NC(=O)c2cc(C)c[nH]2)cn1', 'CCc1ncc(C(=O)N(Cc2cc(C3CC3)ns2)CC2(F)CC2)cn1', 'CCc1ncc(C(=O)N2CCC(C)(C)C(CNC(=O)CC(C)C)C2)o1', 'CCc1ncc(C(=O)N2CCCN(C(=O)[C@H]3C[C@H]4CC[C@@H]3O4)CC2)s1', 'CCc1ncc(C(=O)N2C[C@@H](F)C[C@@H]2C(=O)N(CC)CCCO)cn1', 'CCc1ncc(C(=O)N2C[C@H](O)[C@H](NC(=O)c3ccc(CO)o3)C2)s1', 'CCc1ncc(C(=O)N2C[C@H]3C[C@@]3(NC(=O)C3=CCCCO3)C2)cn1', 'CCc1ncc(C(=O)NC2CC3CC2N(C(=O)CC(CC)CC)C3)s1', 'CCc1ncc(C(=O)NCC2CC(O)(CNC(=O)C(C)C3CC3)C2)s1', 'CCc1ncc(C(=O)NCCCC(C)NC(=O)C2CCC3(CC3)C2)s1', 'CCc1ncc(C(=O)NC[C@H]2CC[C@H]2C(=O)NC(C)(CC)CO)cn1', 'CCc1ncc(C(=O)N[C@@H]2CC(C(=O)N3C4CSCC3C4)=C[C@@H]2O)o1', 'CCc1ncc(C(=O)N[C@H]2CCN(C(=O)c3ccsn3)C[C@H]2CO)o1', 'CCc1ncc(C(=O)OCCNS(=O)(=O)c2ccccc2)c(CC)n1', 'CCc1ncc(CN(CC2=CCCC2)Cc2cncc(Cl)c2OC)s1', 'CCc1ncc(CN(CC2CC(F)(F)CO2)C(=O)C2CCC(C)C2)[nH]1', 'CCc1ncc(CN(CC2CC(SC)C2)C(=O)c2cnn(CC)c2)o1', 'CCc1ncc(CN(CCC2CC2C)C(=O)[C@H]([C@@H](C)OC)N(C)C)s1', 'CCc1ncc(CN(CCCC(C)CO)Cc2cc3n(n2)CCO3)s1', 'CCc1ncc(CN(CCOC(C)(C)C)CC2(OC)CCC(C)C2)[nH]1', 'CCc1ncc(CN(Cc2cc3n(n2)CCCO3)C(=O)C=CSC)s1', 'CCc1ncc(CN(Cc2cccc(O)c2)CC(C2CC2)C2CC2)s1', 'CCc1ncc(S(=O)(=O)Nc2c(C)nn(-c3ccccc3)c2C)n1C', 'CCc1ncc(S(=O)(=O)Nc2cccc(CCNC(=O)C(C)O)c2)o1', 'CCc1ncc2c(n1)CCC(C(=O)N1CCC[C@H]1Cn1cccn1)C2', 'CCc1ncccc1C(=O)NCC(C)(CC)C(=O)N1CC[C@H](OC)C1', 'CCc1ncccc1C(=O)NC[C@@H]1CCCN1C(=O)CCC(C)CC', 'CCc1nccnc1CNC(=O)C1CCCCN1C(=O)C1=C(Cl)CC1', 'CCc1ncncc1C(=O)N(C)CCCC(=O)NCc1ccoc1C', 'CCc1ncncc1C(=O)N1CCC(OC)(C(=O)NCC(O)CF)C1', 'CCc1ncncc1C(=O)N1CCC=C(C(=O)NCc2nnc[nH]2)C1', 'CCc1ncncc1C(=O)N1CCCC1CNC(=O)C[C@H]1CC[C@H]1C', 'CCc1ncoc1C(=O)N1CCC2CC21C(=O)NC[C@]1(O)C[C@@H](O)C1', 'CCc1ncoc1CNC(=O)[C@@H](NC(=O)[C@H]1CC[C@H]2C[C@H]21)C(C)(C)O', 'CCc1ncsc1C(=O)N1CC=CC1C(=O)N1CCCC(C(N)=O)C1', 'CCc1ncsc1C(=O)NC1(C(=O)NCCCn2nccn2)CSC1', 'CCc1ncsc1C(=O)NC1CN(C(=O)C2(C)SCCCS2)CC1C', 'CCc1nn(C)cc1C(=O)N1CCC(CC)(NC(=O)OC(C)(C)C)C1', 'CCc1nn(C)cc1CN(CCCCSC)C(=O)C(C)(C)C(=O)NC', 'CCc1nn2cccnc2c1C(=O)N(C)Cc1cc(Br)cc(OC)c1', 'CCc1nnc(CCNc2cc(N3CC(C)C(C)C3)nc(C)n2)n1C', 'CCc1nnc(CNc2nccc(N3CCC(CC(C)O)CC3)n2)s1', 'CCc1nnc2ccc(N(C)Cc3ccc(N4CCCC4)cc3)nn12', 'CCc1nncn1NC(=O)C(NC(=O)OC(C)(C)C)c1cn(C)nn1', 'CCc1nnsc1C(=O)NC(C(=O)NCC1CCCNC1=O)C(C)C', 'CCc1noc(-c2ccc(NC(=O)c3ccc(CN)cn3)c(Cl)c2)n1', 'CCc1noc(C)c1C(=O)N1CC(NC(=O)C2CC(OC3CC3)C2)C1', 'CCc1noc(C)c1CN(CCCCCF)C(=O)C(C)c1ccsc1', 'CCc1noc(C)c1CNc1nccc(NCCCNC(=O)OC)n1', 'CCc1noc(CCCC(=O)Nc2onc(-c3ccccn3)c2C)n1', 'CCc1nocc1C(=O)N(C)C(C)(C)CC(=O)N(CC)CCC(N)=O', 'CCc1nocc1C(=O)N(C)CCCCCNC(=O)[C@H]1CCC[C@H]1O', 'CCc1nocc1C(=O)N1CC=CC(C(=O)NCC(F)C2CCC2)C1', 'CCc1nocc1C(=O)NC1(CNC(=O)c2ccnc(O)c2F)CC1', 'CCc1nocc1C(=O)NC1CN(C(=O)c2ccoc2C)C(C)(C)C1', 'CCc1nocc1C(=O)NCC1(OC)CN(C(=O)c2cnn(C)c2)C1', 'CCc1nocc1C(C(=O)Nc1ccc(F)cc1)N(C)C(C#N)CC', 'CCc1nocc1CN(CCOCCCF)C(=O)c1c(F)cnn1C', 'CCc1nonc1C(=O)NCCCC(=O)Nc1c(C)ccnc1OC', 'CCc1nsc(N2CC(CNC(=O)Cc3c(C)[nH]c(=O)[nH]c3=O)C2)n1', 'CCc1nsc(N2CCC(C(C)NC(=O)CCC3CCCCC3)C2)n1', 'CCc1nsc(NC[C@@H]2CN(C(=O)[C@@H](O)C3CCCC3)C[C@H](C)O2)n1', 'CCc1nscc1NC(=O)CC(O)CNC(=O)CCC(=O)NN(C)C', 'CCc1nscc1NC(=O)COC1CCN(C(=O)C2(C3CC3)CC2)C1', 'CCc1nscc1NC(=O)[C@H](NC(=O)[C@H]1CC1(F)F)C1CCCCC1', 'CCc1oc(C)cc1C(=O)N(CC)CC(C)NC(=O)C(CC)C(C)C', 'CCc1oc(C)cc1C(=O)N1C[C@@H](F)C[C@@H]1CN(C)C(=O)C=C(Cl)Cl', 'CCc1oc(C)cc1C(=O)N[C@@H](COC)C(=O)NCc1ccoc1C', 'CCc1oc2ccccc2c1CC(=O)NCc1nc2ncccc2o1', 'CCc1occ(C)c1C(=O)N1CCC(NC(=O)c2cn[nH]c2Cl)CC1', 'CCc1occc1C(=O)N(Cc1ncc(CN(C)C)s1)CC1CCC1', 'CCc1occc1C(=O)N1CCC(CO)(C(=O)NCc2cnco2)C1', 'CCc1occc1C(=O)NCC(C)C(=O)N1CCC2(CC1)CC2C#N', 'CCc1occc1C(=O)NCC1(F)CCN(c2nccnc2F)CC1', 'CCc1ocnc1C(=O)N1CCC[C@H]1CN(C)C(=O)[C@H](C)NC(C)=O', 'CCc1ocnc1C(=O)N1CC[C@H](C(=O)N2CCO[C@@H](C)C2)[C@H](C)C1', 'CCc1ocnc1C(=O)NCCCC1(NC(=O)CC2CN(C)C2)CC1', 'CCc1ocnc1C(=O)NC[C@@H](NC(=O)CC1(C)CCC1)C(C)(C)C', 'CCc1ocnc1C(=O)NCc1nc(C)c(C(=O)NC(CC)CC)o1', 'CCc1ocnc1C(=O)N[C@H]1C[C@H]1NC(=O)c1cccc2[nH]cnc12', 'CCc1onc(C(=O)N[C@H](C)C(=O)N2CCC(C)(N(C)C)CC2)c1C', 'CCc1onc(C)c1C(=O)NCC(C)=CC(=O)NC1CC12CC(O)C2', 'CCc1onc(C)c1CN(CC(O)C(C)CC)C(=O)C1CCC1CC', 'CCc1onc(C)c1CNC(=O)C(=O)NCC1CN(S(=O)(=O)CC)C1', 'CCc1sc(N)nc1C(=O)NC[C@H]1C[C@@H]1CNC(=O)C1(F)CCCC1', 'CCc1snnc1C(=O)N(Cc1cnc2[nH]ncc2c1)CC(C)(F)F', 'CCn1c(=O)n(CC)c2cc(NC(=O)[C@@H]3C[C@H]4C[C@@H]3CC4=O)ccc21', 'CCn1c(C(C)NC(=O)NC2CC(F)(F)C2(C)C)nc2ccccc21', 'CCn1c(C)cc2c1CCCC2NC(=O)c1ccc(O)c(C(C)C)c1', 'CCn1c(CNC(=O)N2CCn3ccc(C(=O)OC)c3C2)cnc1C', 'CCn1c(NCc2cccc(N3CCOCC3)n2)nc2ccccc21', 'CCn1c(SCC(=O)N(CCC#N)c2nncs2)nc2ccccc21', 'CCn1cc(-c2nc3ccc(C(C)(C)C)nn3c2NCC2CC2)cn1', 'CCn1cc(C(=O)C(=O)N2CC(O)(c3cscc3C(=O)OC)C2)cn1', 'CCn1cc(C(=O)N(CCCNC(=O)CC2CCCC2)C2CC2)cn1', 'CCn1cc(C(=O)N2CC(C(O)C(=O)NCCn3cnnn3)C2)cn1', 'CCn1cc(C(=O)N2CC3(C)CC2(C(=O)NC2(C4CC4)CC2)C3)nn1', 'CCn1cc(C(=O)N2CCC(C)C2CNC(=O)c2ccnn2C)cn1', 'CCn1cc(C(=O)N2CCN(C(=O)c3ccc(O)cn3)[C@H](C)C2)nn1', 'CCn1cc(C(=O)NC(C)(C)CC(=O)NC[C@@H](F)C(C)(C)O)c(C)n1', 'CCn1cc(C(=O)NCCc2c[nH]c3ncccc23)c(C(F)(F)F)n1', 'CCn1cc(C(=O)N[C@H]2CCN(C(=O)C(F)(F)C(O)C3CC3)C2)nn1', 'CCn1cc(C2CN(C(=O)NCc3c(Cl)cncc3Cl)CCO2)cn1', 'CCn1cc(CC(=O)NC/C=C\\CNC(=O)c2cnccc2O)nn1', 'CCn1cc(CCN(Cc2ccnc(O)c2)Cc2ccc(C)s2)cn1', 'CCn1cc(CCNC(=O)C[C@H]2CCN(C(=O)C(=O)NOC)C2)nn1', 'CCn1cc(CN(C(=O)NCC2(OC)CCCC(C)C2)C(C)C)cn1', 'CCn1cc(CN(C)C(=O)[C@H]2CC[C@H]2CNC(=O)CS(C)(=O)=O)nn1', 'CCn1cc(CN(CC(C)C2CCC2)CC2(OC)CCCOC2)nn1', 'CCn1cc(CN(CCC(O)C(C)C)C(=O)C2CC(SC)C2)c(C)n1', 'CCn1cc(CN(CCO)C(=O)NCc2cc(C(=O)OC)no2)cn1', 'CCn1cc(CN(Cc2cc(Br)ccn2)C[C@]2(C)C[C@H](OC)C2)nn1', 'CCn1cc(Cl)c(CN(CC(C)CC(C)C)C(=O)C2=CCCSC2)n1', 'CCn1cc(Cl)c(CN2CCC(C)(c3ccc(C(F)(F)F)cc3)C2)n1', 'CCn1cc(NC(=O)CCCNC(=O)Cc2cnn(C)c2C)c(C)n1', 'CCn1cc(NC(=O)C[C@H]2[C@H](O)C[C@@H]2NC(=O)C2(C#N)CCC2)cn1', 'CCn1cc(NC(C)C(=O)Nc2ccc(C)c(C)c2)c(C(=O)OC)n1', 'CCn1cc2cc(NC(=O)NCc3cc(C(=O)OC)co3)ccc2n1', 'CCn1ccc(C(=O)N(C)C2(C(=O)Nc3cnccc3C)CC2)c1C', 'CCn1ccc(C(=O)N2CC=CCC2C(=O)N2C3CCC2CC3)c1C', 'CCn1ccc(C(=O)N2CCC(C)N(C(=O)C3CCCN3C)CC2)n1', 'CCn1ccc(C(=O)N2CCCC2CNC(=O)CC2(C)OCCO2)n1', 'CCn1ccc(C(=O)NCC(C)(C)C(=O)NCC2CN3CCC2C3)n1', 'CCn1ccc(C(=O)NC[C@H](C)N(C)C(=O)c2csc(C)c2OC)n1', 'CCn1ccc(C(=O)N[C@H]2CCC[C@H]2C(=O)N(C)C2CC(CO)C2)n1', 'CCn1ccc(C(=O)N[C@H]2C[C@@H](C(=O)NC3CN4CCCC3C4)C2)n1', 'CCn1ccc(CC(=O)N(C)CCC(=O)N2C[C@H](C3CC3)[C@@H](O)C2)n1', 'CCn1ccc(CC(=O)N(CCNC(=O)C=CC2CC2)CC(C)O)n1', 'CCn1ccc(CN(C)C(=O)c2cn3cc(C(=O)OC)ccc3n2)c1', 'CCn1ccc(CN(CC(C)(CO)COC)C(=O)C2CC(=O)CS2)n1', 'CCn1ccc(CN(CCSCC(C)C)C(=O)[C@H]2C[C@H](N=[N+]=[N-])C2)n1', 'CCn1ccc(CN(CCc2cc(C)ns2)Cc2cccnc2C)n1', 'CCn1ccc(CNc2nc(N)nc(N(C)CCC3CCCC3)n2)n1', 'CCn1ccc(NC(=O)COC2CCN(C(=O)Cn3cncn3)C2)n1', 'CCn1ccc(NC(=O)[C@H](COC)NC(=O)[C@H]2[C@H](C(C)=O)C2(C)C)n1', 'CCn1ccc(NC2(c3nnnn3C(C)C)CCCC(C(N)=O)C2)n1', 'CCn1cccc1C(=O)N(C)C(C)CNC(=O)c1ccc(N)cc1F', 'CCn1cccc1C(=O)N1CC2CC(C1)N(C(=O)C1CC(CF)C1)C2', 'CCn1cccc1C(=O)N1CCC=C(C(=O)N2CC(C(C)OC)C2)C1', 'CCn1ccnc1-c1cccc(NC(=O)C(C)c2cn(C)nc2C)c1', 'CCn1ccnc1C(=O)N1C[C@H](NC(=O)C2CCCN2C)[C@H](OC)C1', 'CCn1ccnc1C(=O)NC[C@H]1CN(C(=O)Cc2cccs2)CCO1', 'CCn1ccnc1C(C)NC(=O)N1CCCCC1Cc1ccccc1', 'CCn1ccnc1CCC(=O)NCC1(c2cc(OC)ccn2)CCC1', 'CCn1ccnc1CCC(=O)Nc1cc(F)c(OC)cc1C(=O)OC', 'CCn1ccnc1CN(C)c1ncccc1S(=O)(=O)NCC1CCC1', 'CCn1ccnc1CN(CC(O)C1(C)CC1)C(=O)C(=O)NCC(F)F', 'CCn1ccnc1CN(CCC1CCC(C)(C)CC1)Cc1cscn1', 'CCn1ccnc1CNC(=O)C=C(C)CNC(=O)C1CCCSC1C', 'CCn1ccnc1[C@@H]1OCC[C@H]1NC(=O)NCCCN1CC[C@@H](O)C1', 'CCn1cnc(C(=O)N(CC2CCC3(CC3)C2)CC(C)C(F)(F)F)c1', 'CCn1cnc(C(=O)N2CC=C(C(=O)N3CC(CO)C(C)(C)C3)C2)n1', 'CCn1cnc(C(=O)N2CCCCC2C(=O)NC[C@@H]2CNC(=O)O2)n1', 'CCn1cnc(C(=O)N2CCN(C(=O)COCC(=O)NC)C[C@@H]2C)n1', 'CCn1cnc(C(=O)N2CCOC(C3CN(C(=O)C=C(C)C)C3)C2)c1', 'CCn1cnc(C(=O)N2CC[C@@H](NC(=O)C(CSC)OC)[C@H](F)C2)n1', 'CCn1cnc(C(=O)NC(CC2CCC2)C(=O)Nn2cnnc2C)c1', 'CCn1cnc(C(=O)NC(CNC(=O)C2CC2(C)C)CC(F)(F)F)c1', 'CCn1cnc(C(=O)NCC2CN(C(=O)c3cc(Cl)cs3)CC2C)c1', 'CCn1cnc(C(=O)NCCCCCCC(=O)N2OC3CCC2C3)n1', 'CCn1cnc(C(=O)NCc2cc(C(=O)N3CC[C@@H](OC)C3)cs2)n1', 'CCn1cnc(C(=O)N[C@H](COC)C(=O)NC(C2CC2)C(C)(C)O)n1', 'CCn1cnc(CCNC(=O)CC(C)(C)NC(=O)c2ncccn2)c1', 'CCn1cnc(CN(Cc2ccsn2)CC2(CO)CC3C=CC2C3)c1', 'CCn1cnc(CNC(=O)C(C)(C)CCNC(=O)CC(C)(C)C#N)n1', 'CCn1cnc(CNC(=O)CC[C@H](C)NC(=O)C2(CF)CC(=O)C2)n1', 'CCn1cnc(Cl)c1CN(Cc1cnco1)Cc1cc(F)ccc1Cl', 'CCn1cncc1CN(CCSC(F)(F)F)C(=O)C1CCOC1(C)C', 'CCn1cnnc1CCNC(=O)C1CCN(C(=O)CC(C)SC)CC1', 'CCn1cnnc1CCNC(=O)CCC(C)NC(=O)c1cc(C)on1', 'CCn1cnnc1CN(C)C(=O)NC(C)C12CC3CC(CC(C3)C1)C2', 'CCn1cnnc1CN(CCc1ccncc1C)Cc1cc(C)ns1', 'CCn1cnnc1CNC(=O)[C@@H]1C[C@@H](O)CN1C(=O)C1(O)CCCC1', 'CCn1nc(C(=O)N(C)C2CCN(C(=O)C(C#N)C(C)C)C2)cc1C', 'CCn1nc(C(=O)N(CCCO)c2ccc(F)c(F)c2)cc1C1CC1', 'CCn1nc(C(=O)N2CCN(S(=O)(=O)CCC3CC3)CC2)ccc1=O', 'CCn1nc(C(=O)NC(CC(C)C)C(=O)NOC(C)(C)CO)cc1O', 'CCn1nc(C(=O)N[C@H]2C[C@H](NC(=O)c3nc(Cl)sc3C)C2)cc1C', 'CCn1nc(C(C)(C)C)cc1NC(=O)c1cc(NC(N)=O)ccc1Cl', 'CCn1nc(C)cc1C(=O)NCC1(NC(=O)CCCOC(C)=O)CC1', 'CCn1nc(C)cc1C(=O)NCCCc1nc(C2CCCCC2)cs1', 'CCn1nc(C)cc1C(=O)N[C@]1(C(=O)NCC#CC#CCO)C[C@H]1C', 'CCn1nc(C)cc1C(c1nnnn1CC)N1C[C@H](OC)C[C@@H]1CF', 'CCn1nc(C)cc1CN(C[C@H]1C[C@H](COC)C1)C(=O)CP(C)(C)=O', 'CCn1nc2c(c1C(=O)N(C)CCCn1cc(CO)nn1)CCCC2', 'CCn1ncc(C(=O)N(CCC(C)OC)Cc2ccccc2Cl)c1C', 'CCn1ncc(C(=O)NC[C@@H](COC)Nc2ncnc(O)c2F)c1C', 'CCn1ncc(CN(CCOCCCF)C(=O)c2cc(C)nn2C)n1', 'CCn1ncc(CN(C[C@@H]2CCC[C@H]2CF)C(=O)c2ccsc2C)n1', 'CCn1ncc(Cl)c1C(=O)N(C)[C@H]1CCN(C(=O)Cc2ccon2)C1', 'CCn1ncc(NC(=O)c2cccc(-n3cc(S(C)(=O)=O)cn3)c2)n1', 'CCn1ncc2c(NC(=O)c3ccc4nc(C)c(I)n4n3)cccc21', 'CCn1nccc1C(=O)N1CC(C(O)C(=O)NCC(C)(O)C(F)F)C1', 'CCn1nccc1C(=O)N1CCC(NC(=O)c2cc(O)cs2)C(C)C1', 'CCn1nccc1C(=O)N1CCCC(C(=O)NCc2ncn(C)n2)C1', 'CCn1nccc1C(=O)N1C[C@@H](O)C[C@H]1C(=O)NC[C@@H](O)C(C)(C)C', 'CCn1nccc1C(=O)N1C[C@@H]2[C@@H](CN(C)C(=O)CS(C)(=O)=O)[C@@H]2C1', 'CCn1nccc1C(=O)NC(C(=O)NC1(C(C)C)CC1)c1ccco1', 'CCn1nccc1C(C)NC(=O)C(=O)N1CCc2cc(F)ccc2C1', 'CCn1nccc1C(N)C(=O)NS(=O)(=O)Cc1cc(C#N)ccc1F', 'CCn1nccc1C1CCN(C(=O)NC2CCOC23CCOC3)CC1', 'CCn1ncnc1C(=O)NC12CCC(NC(=O)[C@H]3CCN3C)(CC1)C2', 'CCn1ncnc1C(=O)NCC1(F)CN(C(=O)CCn2ccnc2)C1', 'CCn1ncnc1C(C)NCc1cn(-c2ccc(OC)cc2C)nn1', 'CCn1ncnc1CN(CC1(C(C)(C)O)CCC1)C(=O)[C@H]1CCOC1', 'CCn1ncnc1CN(CCc1cccs1)C(=O)C1=CCCCCC1', 'CCn1nnc(C(=O)N2CC(OCC(=O)N3CCC(C)C3C)C2)c1C', 'CCn1nnc(C(=O)NCC(O)CC(=O)N2C3CCC2COC3)c1C', 'CCn1nnc(C)c1CNC(=O)CC(NC(=O)[C@@H]1CC[C@H]1C)C(F)F', 'CCn1nnc(CNC(=O)CC2(CNC(=O)C3=CCN(C)C3)CC2)n1', 'CCn1nncc1C(=O)N(C)C1(C(=O)NCc2ccc(F)cc2)CC1', 'CCn1nncc1C(=O)N1CCC[C@H]1CN(C)C(=O)c1cc(C)cs1', 'CCn1nncc1C(=O)NCC(C(=O)NCCN1CC=CC1)N(C)C', 'CCn1nncc1C(=O)NCc1ccc(C(=O)N(C)C2CCC2)nc1', 'CCn1nncc1CN(CCc1sccc1C)C(=O)C(C)(CC)CC', 'CCn1nncc1CN(Cc1nc(CO)cs1)CC(C)(C)C(C)(C)C', 'CCn1nncc1S(=O)(=O)N1CCC(OCCC2CCCNC2)CC1', 'CCn1nncc1S(=O)(=O)NC(c1ccc(F)cc1)C1(O)CCCC1', 'CCn1nnnc1C(NC1CCC(=O)N(C)C1=O)c1ncccc1F', 'CCn1nnnc1C(N[C@H]1CCC[C@@H]1F)c1cccc2c1CCOC2', 'CCn1nnnc1C1(NCC2(CCOC)CCCC2)CC[C@H]2CC[C@H]21', 'CCn1nnnc1C1(N[C@H]2C[C@@H](OC)C2)CC(c2ccc(F)cc2)C1', 'CN(C(=O)C1(C)CCCN(C(=O)c2cn(C)cn2)C1)C1CCOCC1', 'CN(C(=O)C12CCCC(CO1)C2)C(C)(C)CC(=O)N[C@@H]1CCOC1=O', 'CN(C(=O)C1=CCCN(C(=O)c2occc2C2CC2)C1)C1CC(O)C1', 'CN(C(=O)C1C=CCCN1C(=O)Cc1cnsc1)[C@@H]1C[C@H]2CC[C@@H]1O2', 'CN(C(=O)C1CC(OCc2ccccc2)C1)[C@@H](CF)c1ccccc1', 'CN(C(=O)C1CC12CC2)C1(CC(=O)NC(C(N)=O)C2CCCC2)CC1', 'CN(C(=O)C1CC2(CC2)C1)C1CCN(C(=O)c2ncnc(O)c2F)C1', 'CN(C(=O)C1CC2(CC2)CO1)C1CN(C(=O)c2ccn(CCF)n2)C1', 'CN(C(=O)C1CC2CCC(C1)N2C(=O)c1ccc(Cl)o1)[C@H]1C[C@@H](O)C1', 'CN(C(=O)C1CCC(=O)CC1(C)C)[C@H]1CCN(C(=O)C2=C(Cl)CC2)C1', 'CN(C(=O)C1CCC(F)(F)CC1)C1CCN(c2nnc(C(N)=O)s2)C1', 'CN(C(=O)C1CCCOC1)C(C(=O)N1CC(c2ccon2)C1)C1CC1', 'CN(C(=O)C1CCN(C(=O)CC2(C#N)CC2)C12CC2)C(CO)C1CC1', 'CN(C(=O)C1CCN(c2ccnc3nccnc23)C1)c1ccccc1', 'CN(C(=O)C1CCOC1CNC(=O)CCCF)c1cccc(C#N)c1', 'CN(C(=O)C=CCO)C1CCCC2CN(C(=O)CC3CC(=O)C3)CC21', 'CN(C(=O)C=Cc1cc[nH]n1)C1(C(=O)NC2CCN(C3CC3)C2)CC1', 'CN(C(=O)CC(C1CC1)C1CC1)[C@H]1C[C@@H](NC(=O)C2CC(C)(C)C2)C1', 'CN(C(=O)CC1(C)CCN1C(=O)c1cccn(C)c1=O)C1(CO)CC1', 'CN(C(=O)CC12CCC1CN(C(=O)c1c[nH]c(C#N)c1)C2)C1(C)CC1', 'CN(C(=O)CCC1CC1(C)C)C(C)(C)CC(=O)NCC1CCC=CO1', 'CN(C(=O)CCCC(C)(C)C(=O)O)c1cccc(S(=O)(=O)N(C)C)c1', 'CN(C(=O)CCN(CC1CC1)C(=O)C1=CC2CCC(C1)C2)C1CCC1', 'CN(C(=O)CCNC(=O)C1CCCN1C(=O)C1CCC(=O)O1)C1CC1', 'CN(C(=O)CC[C@H]1C[C@@H](NC(=O)Cc2cscn2)C1)C1CCOCC1', 'CN(C(=O)CCc1cccc(O)c1)C1CN(C(=O)C2CSCCS2)C1', 'CN(C(=O)CCc1cscn1)[C@@H]1CCN(C(=O)C2CC(=O)N(O)C2)C1', 'CN(C(=O)CN1C(=O)CCOc2ccccc21)C(C)(C(=O)O)C1CC1', 'CN(C(=O)COC(=O)C1(Cc2ccccc2)CCOC1)C1CCCC1', 'CN(C(=O)COC1CC=CC1)C1(C(=O)NC2CC3CCC(C2)O3)CC1', 'CN(C(=O)COC1CN(C(=O)C(=O)NCC(F)F)C1)[C@@H]1CCC[C@H]1O', 'CN(C(=O)COCC1CCCNC1)C1CCN(c2ncccn2)CC1', 'CN(C(=O)CS(C)(=O)=O)C1(CC(=O)N2CCc3ccncc3C2)CC1', 'CN(C(=O)CSC(C)(C)C)C1CC(C(=O)N2CCCC3(CCC3)C2)C1', 'CN(C(=O)CSc1ccc([N+](=O)[O-])cc1F)c1nc2ccccc2s1', 'CN(C(=O)Cc1ccn[nH]1)[C@@H]1CN(C(=O)C2C3(CC3)C23CC3)C[C@H]1O', 'CN(C(=O)Cc1ccoc1)C(CC(F)F)C(=O)N1CC2CC2(CO)C1', 'CN(C(=O)Cc1ccoc1)[C@H]1C[C@@H](NC(=O)[C@@H]2CC[C@H]3C[C@@H]2CO3)C1', 'CN(C(=O)OC(C)(C)C)C1CCN(C(=O)c2cc(C(F)F)ncn2)C1', 'CN(C(=O)[C@@H]1CC[C@H](C(N)=O)C1)C1CC(NC(=O)c2ccn(C)n2)C1', 'CN(C(=O)[C@@H]1CC[C@H](NC(=O)CCNC(=O)CO)C1)C1(C2CC2)CC1', 'CN(C(=O)[C@@H]1[C@H]2C[C@H]2CN1C(=O)c1ccc([N+](=O)[O-])o1)C1CC=CC1', 'CN(C(=O)[C@H]1C[C@@H]1C(F)(F)F)C1CN(C(=O)C2=NO[C@H]3COC[C@@H]23)C1', 'CN(C(=O)[C@H]1OCC[C@H]1NC(=O)CCn1ccnc1)C1CCNC1=O', 'CN(C(=O)[C@]12CCC[C@H]1CN(C(=O)C(F)OC(F)(F)F)C2)C1CSC1', 'CN(C(=O)[C@]12C[C@H]1CNC2=O)[C@H]1C[C@@H](NC(=O)c2ccc(CO)o2)C1', 'CN(C(=O)c1cc(-c2cccs2)on1)C1CCCN(CCC(=O)O)C1', 'CN(C(=O)c1cc2cncc(Br)c2o1)C1CS(=O)(=O)C12CCOCC2', 'CN(C(=O)c1ccc(C#CCN)cc1)C(CO)c1cccc(Cl)c1Cl', 'CN(C(=O)c1ccc(CCNS(C)(=O)=O)s1)C1CCC(C(F)F)CC1', 'CN(C(=O)c1ccc(OCC2CCCCC2)cc1)C(CCO)C(F)F', 'CN(C(=O)c1ccc[nH]1)C(C)(C)CC(=O)NCC1CC(C(N)=O)=NO1', 'CN(C(=O)c1cccc(CNC(=O)C2CCCCC2F)n1)C1CCC1', 'CN(C(=O)c1cnc(Cl)s1)C(C(=O)N[C@@H]1[C@H](O)[C@@H]2CCC[C@@H]21)C1CC1', 'CN(C(=O)c1cnc(N)cn1)C1CC(C(=O)NCC[C@H]2C[C@H](F)C2)C1', 'CN(C(=O)c1cnc(OC2CCCC2)nc1)C1(C(=O)O)CCCCC1', 'CN(C(=O)c1csc(F)c1)[C@H]1CCN(C(=O)C2CN3CCCC2C3)C1', 'CN(C(=O)c1nc(Cl)cs1)C1(C(=O)NCCN2C(=O)CCC2=O)CC1', 'CN(C(N)=O)c1ccc(OCCCc2cccc3ccccc23)cc1', 'CN(C)C(=O)C#CC(=O)N(C)CCCCNC(=O)C(C)(C)C1CCC1', 'CN(C)C(=O)C#CC(=O)NCC1CCCN1C(=O)C1(N(C)C)CCC1', 'CN(C)C(=O)C#CC(=O)N[C@H]1CCOC[C@H]1NC(=O)C(F)=CC1CC1', 'CN(C)C(=O)C(=O)N1CC2(C)CC1(C(=O)N1CC(C)(C)C13CCC3)C2', 'CN(C)C(=O)C(=O)N1CC[C@H]2CN(C(=O)c3cc(CO)ccn3)C[C@H]21', 'CN(C)C(=O)C(=O)N[C@@H]1[C@H]2C[C@@H]1N(C(=O)[C@H]1CC[C@H](N(C)C)CC1)C2', 'CN(C)C(=O)C(c1ccccc1)N1CCN(c2ccc(F)nc2)CC1', 'CN(C)C(=O)C1CN(C(=O)CN(CC2CC2)C(=O)[C@@H]2CNC(=O)N2)C1', 'CN(C)C(=O)CC(=O)N1C[C@@H](O)C[C@H]1CNC(=O)[C@H]1CN(C)C(=O)N1', 'CN(C)C(=O)CC(=O)NC1(CCC(=O)N(C)Cc2cc[nH]n2)CCC1', 'CN(C)C(=O)CC(=O)NCc1ccc(C(=O)NCCC2(C)N=N2)cn1', 'CN(C)C(=O)CCC(=O)NC(C(=O)NCc1cccnn1)C1(C)CC1', 'CN(C)C(=O)CCNC(=S)N(C)Cc1cccc(-c2ccccc2)c1', 'CN(C)C(=O)CN(C)C(=O)COC(=O)Cc1c[nH]c2c(Cl)cccc12', 'CN(C)C(=O)CN(C)C(C(=O)Nc1ccccc1Cl)c1ccncc1', 'CN(C)C(=O)CNC(=O)C(C)(CO)NC(=O)c1cccc(C2CC2)c1', 'CN(C)C(=O)CNC(=O)C1=C(F)CN(C(=O)[C@H]2C[C@H](O)CN2C)CC1', 'CN(C)C(=O)N(C)C1CCN(c2ncccc2C(F)(F)C(F)(F)F)C1', 'CN(C)C(=O)N1CC(CNS(=O)(=O)c2c[nH]c(=O)c3ccccc23)C1', 'CN(C)C(=O)Nc1ccc(CNC(=O)c2cc3c(ccn3C)s2)cc1', 'CN(C)C(=O)OC1=CC(=CC(OC(=O)N(C)C)=C1)C(O)CNC(C)(C)C', 'CN(C)C(=O)OC1CN(S(=O)(=O)c2ccc3c(c2)n(C)c(=O)n3C)C1', 'CN(C)C(=O)c1ccc(F)c(NC(=O)CC2CNCC3(CCC3)O2)c1', 'CN(C)C(=O)c1cccc(CNC2(C(=O)NCC3CC3)CCCC2)c1', 'CN(C)C(=O)c1ccccc1C(=O)OCC(O)Cc1ccccc1Br', 'CN(C)C(C(=O)N1CCN(C)C(c2cccs2)C1)c1ccccc1Cl', 'CN(C)C(C)(C)C(=O)N1CCC2(CC2C(=O)NCCc2ccon2)C1', 'CN(C)C(C)(C)C(=O)N[C@H]1CC=CC[C@H]1C(=O)N1CCC2(CC1)N=N2', 'CN(C)C(C)(C)CCC(=O)N(C)[C@H]1C[C@@H](NC(=O)C2COCCO2)C1', 'CN(C)C(C)(C)CNC(=O)c1ccc(CNC(=O)c2ncc[nH]2)nc1', 'CN(C)C(CCO)C(=O)N1CC2CC1CN(C(=O)c1cnnn1C)C2', 'CN(C)C(CNC(=O)C1=CCCSC1)C(=O)NCC12CCC(CC1)C2', 'CN(C)C(CNC(=O)C1CCCCC1(C)C)C(=O)N[C@@H]1CCCOC1', 'CN(C)C(CNC(=O)C1CCSC1)C(=O)NCC1C2CCCCCC21', 'CN(C)C(CNC(=O)CC1(C)CC1)C(=O)N1CC(c2ccccn2)C1', 'CN(C)C1(C(=O)NCCN(C(=O)Cc2nnc(S)n2C)C2CC2)CC1', 'CN(C)C1(C)CCC(NCC2(c3ccc(OC(F)F)cc3)CC2)CC1', 'CN(C)C1(C)CCCN(c2nccc(NCCCc3cn[nH]c3)n2)C1', 'CN(C)C1(C)CN(C(=O)C(C)(NC(=O)c2ncn(C)n2)C2CCC2)C1', 'CN(C)C1(CC(=O)N2CC(NC(=O)c3onc4c3CCCC4)C2)CC1', 'CN(C)C1(CC(=O)N2CCC3CC32C(=O)NCCCOC(N)=O)CC1', 'CN(C)C1(CC(=O)NCCSCC(=O)N2CC3C(C2)C3(F)F)CCC1', 'CN(C)C1(CC(=O)N[C@H]2CC=CC[C@H]2C(=O)NCC2C=CCC2)CC1', 'CN(C)C1(CNc2nc(N)nc(NC3CCC(=O)NC3)n2)CCOC1', 'CN(C)C1(CS(=O)(=O)NC2CCC2NC(=O)[C@@H]2CCC(=O)O2)CCC1', 'CN(C)C1CC(NC(=O)C2(F)CCN(C(=O)c3ccccc3)CC2)C1', 'CN(C)C1CC2(C1)CN(C(=O)CC1(NC(=O)c3ccn(C)c3)CC1)C2', 'CN(C)C1CCN(C(=O)[C@@]2(C)CCCN2C(=O)COc2ccsn2)C1', 'CN(C)C1CNCC(C(=O)Nc2ccnc(Sc3ccccn3)c2)C1', 'CN(C)CC(=O)NC[C@H]1[C@@H](C(=O)NCCCc2ccncc2)C1(C)C', 'CN(C)CC(C)(C)C(=O)NC1CCC(NC(=O)c2cccnc2S)C1', 'CN(C)CC(C)(C)CNC(=O)c1occc1CNC(=O)c1ccns1', 'CN(C)CC(C)(O)CNC(=O)Nc1ccc2c(c1)N(C(N)=O)CCC2', 'CN(C)CC(NC(=O)C1CC(F)(CF)C1)C(=O)NC1(C)CS(=O)(=O)C1', 'CN(C)CC(NC(=O)c1cocn1)C(=O)NCC1CC2(CC2)C(=O)O1', 'CN(C)CC(O)C(=O)N1CC(NC(=O)c2ccncc2Cl)C2(CC2)C1', 'CN(C)CC(O)C(=O)N[C@H]1CC[C@H]1C(=O)NCCc1ocnc1CO', 'CN(C)CC(O)CC(=O)NC(Cc1c[nH]c2cc(Cl)ccc12)C(=O)O', 'CN(C)CC(O)CC(=O)NCC1CCN1C(=O)c1cn(C)c(=O)cn1', 'CN(C)CC1(CNC(=O)[C@H]2C[C@@H](NC(=O)C3C4CC(=O)CC43)C2)CC1', 'CN(C)CC1(CO)COCCN1C(=O)c1cc(C2CCNCC2)on1', 'CN(C)CC1(NC(=O)CC2(NC(=O)CCc3ccco3)CCC2)CC1', 'CN(C)CC1(O)CCN(C(=O)Cn2nnc(-c3ccc(Cl)cc3)n2)C1', 'CN(C)CC1CCCN1C(=O)[C@H]1OCC[C@H]1NC(=O)C1=CC(C)(C)C1', 'CN(C)CC1COCCN1C(=O)C(C)(C)NC(=O)CC1(O)CCOC1', 'CN(C)CC1COCCN1C(=O)C1(NC(=O)C(=O)NCC2CC2)CC1', 'CN(C)CCC(=O)N1[C@H](C(=O)N2CCOC(C3(C)N=N3)C2)C[C@@H]2C[C@@H]21', 'CN(C)CCC(NC(=O)C1=CCCOC1)C(=O)NCc1ncccn1', 'CN(C)CCC1CCCN1C(C(=O)NCC1CCOC1)[C@H]1CC1(C)C', 'CN(C)CCCC(=O)NCC1(CNC(=O)c2csc(Cl)n2)CCCC1', 'CN(C)CCCN(C)C(=O)[C@@H]1[C@H](NC(=O)Cc2ccnn2C)C1(C)C', 'CN(C)CCCONC(=O)C1(CNC(=O)c2cncs2)CC2(CC2)C1', 'CN(C)CCN(C(=O)Nc1nccc2nccnc12)C1CCCCC1', 'CN(C)CCN(C)C(=O)[C@@H]1C[C@@H](F)CN1C(=O)c1cc(C(N)=O)co1', 'CN(C)CCN(C)c1nccc(N2CCC(C3COCCO3)CC2)n1', 'CN(C)CCN(CC1CCCO1)C(=O)Cc1csc(-c2nnc[nH]2)n1', 'CN(C)CCN(CCN(C)C)C(=O)Nc1cnn(CC2CCCO2)c1', 'CN(C)CCN(Cc1nccn1C)C(=O)c1coc2cccc(O)c12', 'CN(C)CCOCC(=O)N1C[C@@H](O)C[C@H]1CNC(=O)CCP(C)(C)=O', 'CN(C)CCOc1cc(C(=O)OCCc2ccc(F)c(F)c2)ccn1', 'CN(C)CCOc1ccc(NC2CCC(C3CCNCC3)CC2)cc1', 'CN(C)CCOc1cccc(CNC(=O)C(F)(F)c2cnccn2)c1', 'CN(C)CC[C@H](O)C(=O)N1C[C@@H]2C[C@H]1CN2C(=O)C1C=CC=CC=C1', 'CN(C)CC[C@H](O)C(=O)NC/C=C/CNC(=O)[C@H](N(C)C)C(C)(C)C', 'CN(C)CCc1cnc(NC(=O)c2c(C(F)F)nc3ccccn23)s1', 'CN(C)CCn1cc(C(=O)Nc2cnccc2N2CCNCC2)nn1', 'CN(C)C[C@H](CO)NC(=O)C[C@@H]1C[C@@H](O)CN1C(=O)c1nc(Cl)cs1', 'CN(C)C[C@H](NC(=O)COC1CCCCC1)C(=O)N[C@H]1C[C@H](CO)C1', 'CN(C)C[C@H](NC(=O)Cc1cscn1)C(=O)N1CC(c2cc[nH]n2)C1', 'CN(C)C[C@H](NC(=O)c1cnn(CCF)c1)C(=O)NC(C)(C)CCF', 'CN(C)C[C@H]1CC[C@@H](C(=O)OCc2coc(-c3ccc(Br)cc3)n2)O1', 'CN(C)C[C@H]1C[C@@H](NC(=O)CC2(CNC(=O)C3CC(=O)CS3)CC2)C1', 'CN(C)C[C@H]1C[C@@H]1NC(=O)[C@@H]1C[C@H](O)CN1C(=O)C1CC(=C2CC2)C1', 'CN(C)S(=O)(=O)c1ccc(C(=O)N2CCN(c3ncncn3)CC2)o1', 'CN(C)S(=O)(=O)c1ccc(C(=O)NNC(=O)NC2CCCCC2)cn1', 'CN(C)S(=O)(=O)c1ccc(CNC(=O)c2cncc(P(C)(C)=O)c2)s1', 'CN(C)S(=O)(=O)c1ccc(F)c(C(=O)NCc2ccc(O)c(Cl)c2)c1', 'CN(C)S(=O)(=O)c1ccccc1CNC(=O)N1CC[C@H](N2CCC2)C1', 'CN(C)[C@@H]1CCCN(C(=O)CCC2CCN(C(=O)C3(CF)CC3)C2)C1', 'CN(C)[C@@H]1CCC[C@H]1NC(=O)CCCNC(=O)[C@H]1[C@@H]2CCCCC[C@@H]21', 'CN(C)[C@@H]1CCN(C(=O)[C@H]2OCC[C@H]2NC(=O)C2(C#N)CCCO2)C1', 'CN(C)[C@@H]1CC[C@H](NC(=O)CCCNC(=O)c2ccc(C#N)cn2)C1', 'CN(C)[C@@H]1CC[C@H]1NC(=O)C[C@@H]1CCCN1C(=O)COc1ccsn1', 'CN(C)[C@@H]1CC[C@H]1Nc1nc(N2CCOC(C)(C)C2)c2ccsc2n1', 'CN(C)[C@@H]1CN(C(=O)C2CC2(F)Cl)C[C@H]1CNC(=O)c1cn[nH]c1Cl', 'CN(C)[C@@H]1CN(C(=O)CC2(CNC(=O)c3cc(F)c[nH]3)CC2)C[C@H]1O', 'CN(C)[C@@H]1CN(C(=O)[C@H]2C[C@H]2C(F)F)C[C@H]1CNc1ncncc1F', 'CN(C)[C@H](CO)C(=O)N1CCC=C(C(=O)N2CCC(C3(C)N=N3)C2)C1', 'CN(C)[C@H](CO)C(=O)N1CCC[C@H]1CNC(=O)c1cc(N)cnc1Cl', 'CN(C)[C@H](Cc1ccc(F)cc1)C(=O)OCc1nc(C(F)F)nn1C', 'CN(C)[C@H]1CCC[C@H]1CNC(=O)[C@@H]1C[C@H]2C[C@@H]1C[C@H]2NC(=O)CC#N', 'CN(C)[C@H]1CN(S(=O)(=O)c2cncc([N+](=O)[O-])c2)C[C@H]1n1ccnn1', 'CN(C)[C@H]1C[C@@H](C(=O)N2CC3(CCN3C(=O)COc3ccsn3)C2)C1', 'CN(C)[C@H]1C[C@@H](C(=O)NC2CCN(C(=O)CCc3csnn3)CC2)C1', 'CN(C)[C@H]1C[C@@H](C(=O)NCCC2(C(=O)Nn3ccccc3=O)CC2)C1', 'CN(C)[C@H]1[C@@H]2CN(C(=O)C3(CNC(=O)C4(C)CC(C#N)C4)CC3)C[C@@H]21', 'CN(C)c1ccc(C2CCN(C(=O)C[C@H]3CCC[C@@H]3C(=O)O)C2)cc1', 'CN(C)c1ccc(CCNCc2c(F)cc(C(F)(F)F)cc2F)cn1', 'CN(C)c1ccc(CN(CC(=O)C2CN(S(C)(=O)=O)C2)C2CC2)cc1', 'CN(C)c1ccc(CNc2cccc(N=S(C)(C)=O)c2)c(F)c1C#N', 'CN(C)c1ccc(NC(=O)NNC(=O)C2(F)CC3CCC2CC3)cc1', 'CN(C)c1ccc(NC(=O)Nc2ccc3c(c2)NC(=O)CC3)cc1F', 'CN(C)c1ccc(S(=O)(=O)NCc2ccnc(OCC(F)F)c2)cc1', 'CN(C)c1ccc([N+](=O)[O-])cc1CNc1cccc(C2CCNC2)c1', 'CN(C)c1cccc(CNc2cc(N3CCCC3C(N)=O)ncn2)n1', 'CN(C)c1ccccc1C(=O)OCC(=O)NCCCN(C)S(C)(=O)=O', 'CN(C)c1ccncc1C(=O)N[C@H]1CN(C(=O)C2CC2)C[C@H]1N=[N+]=[N-]', 'CN(C)c1n[nH]c(C2CCN(C(=O)NCCC3CCNC3=O)CC2)n1', 'CN(C)c1nc(Cl)ncc1NC(=O)N1CCCC(c2ccccc2)C1', 'CN(C)c1ncc2c(n1)CCN(C(=O)COc1ccc(Br)cc1F)C2', 'CN(C)c1ncccc1C(=O)NC[C@H]1CCN(C(=O)CSC2CC2)C1', 'CN(C)c1ncccc1CCNC(=O)c1coc2c(Cl)cc(Cl)cc12', 'CN(C)c1noc(CCNS(=O)(=O)c2ccc3c(c2)CCC(=O)N3)n1', 'CN(C1CC1)C1CN(C(=O)C(C)(C)NC(=O)c2cnn(C(F)F)c2)C1', 'CN(C1CC2CC2C1)C(C(=O)NCCCC1CC1)c1cccc(F)n1', 'CN(C1CCNCC1)C1CCN(C(=O)c2ccc(C(C)(C)C)s2)CC1', 'CN(CC(=O)N(CC(=O)OC(C)(C)C)Cc1ccccc1)C1CCC1', 'CN(CC(=O)N1C2CCCC1CC(NS(=O)(=O)C1(Cl)CC1)C2)C(N)=O', 'CN(CC(=O)N1CCC(c2ccn[nH]2)C1)C(=O)C(O)c1ccccc1', 'CN(CC(=O)N1CCC2(CCN(C(=O)C3CCOC3)C2)C1)C1CCC1', 'CN(CC(=O)N1CCOCC1CC(=O)NCc1ccsc1)C1CCC1', 'CN(CC(=O)N1CC[C@H](NC(=O)C2CCC(=O)N2C)C1)CC(C)(C)C', 'CN(CC(=O)NC12CCN(C(=O)[C@H]3CCC[C@@H]3O)CC1C2)S(N)(=O)=O', 'CN(CC(=O)NCc1ccco1)C(=O)NCC1CCCCC(F)(F)C1', 'CN(CC(=O)NS(=O)(=O)CCc1ccncc1)Cc1ccc(I)cc1', 'CN(CC(=O)N[C@@H](CC1CC1)C(=O)NCc1ccc(O)nc1)C(N)=O', 'CN(CC(=O)N[C@H]1C=CCC[C@H]1C(=O)NCC1CC1(C)C)C1CCC1', 'CN(CC(=O)N[C@H]1CC[C@@H](N(C)C(=O)CCS(C)(=O)=O)CC1)C(N)=O', 'CN(CC(=O)Nc1ccc(Cl)c(Cl)c1)c1cc(C(F)(F)F)cc(F)n1', 'CN(CC(=O)Nc1ccc(Oc2ccncc2)cc1)C1CCNCC1', 'CN(CC(=O)Nc1cccc(Cl)c1)C(=O)NCc1cc(C(N)=O)co1', 'CN(CC(=O)Nc1cccc2ccccc12)C(=O)c1cc(Cl)n(C)n1', 'CN(CC(=O)Nc1ccncc1)C(=O)Cc1c(Br)sc2ccccc12', 'CN(CC(C)(C)C(=O)N1CCC12CCOCC2)C(=O)C(F)C(F)(F)F', 'CN(CC(C)(C)C(=O)N1CC[C@H]2CCC[C@H]2C1)C(=O)C=CC1CCC1', 'CN(CC(C)(C)C(=O)NC1CCCCC1)C(=O)CCOCC1CCC1', 'CN(CC(C)(C)C)C(=O)[C@H]1CCCCN1C(=O)CCc1ccncc1', 'CN(CC(C)(C)CNC(=O)CCP(C)(C)=O)C(=O)c1cc(O)nn1C', 'CN(CC(C)(C)CNC(=O)[C@@H]1CCOC1)C(=O)C1CC(F)(F)C1(C)C', 'CN(CC(C)(C)CNC(=O)c1ccc(CO)o1)C(=O)COCC1CC1', 'CN(CC(C)(C)NC(=O)CC(C)(C)C)C(=O)/C=C/CN1CCCCC1', 'CN(CC(C)(F)F)C(=O)c1sccc1S(=O)(=O)N1CCC(CO)CC1', 'CN(CC(C)(O)c1ccccc1)C(=O)Nc1ccnc(OC(F)F)c1', 'CN(CC(Cl)Cl)C(=O)c1ccc(CNC(=O)[C@H]2C[C@@H]2C2(C)COC2)o1', 'CN(CC(N)=O)CC1CN(Cc2ccccc2OCC(N)=O)CCO1', 'CN(CC(O)C1CC1)C(=O)C/C=C/CNC(=O)CCc1ccncc1', 'CN(CC(O)C1CC1)C(=O)C1(C)CCN(C(=O)c2ccc(=O)[nH]c2)C1', 'CN(CC(O)C1CC1)C(=O)c1coc(CNC(=O)CCCN=[N+]=[N-])c1', 'CN(CC(O)CNC(=O)C1(C(F)F)CC(O)C1)C(=O)c1cc(Cl)cs1', 'CN(CC(O)CNC(=O)Cc1ccco1)C(=O)CC1CCCNC1=O', 'CN(CC(O)CNC(=O)c1cc(Cl)n[nH]c1=O)C(=O)c1cnn(C)c1', 'CN(CC(O)c1cccs1)C(=O)NCc1ccc(-c2ccccc2)s1', 'CN(CC1(CNC(=O)c2ccn3ncnc3c2)CC1)C(=O)C1CCC1', 'CN(CC1(CO)CCC1)C(=O)[C@H]1CCN1C(=O)[C@H]1[C@H]2CCC(F)(F)[C@H]21', 'CN(CC1(F)CCC1)C(=O)C[C@H]1CCC[C@H]1NC(=O)C#CC(C)(C)C', 'CN(CC1(NC(=O)CCC2CCOC2)CC1)C(=O)c1cccnc1O', 'CN(CC1(O)CCC1)C(=O)C[C@H](NC(=O)CN1CCCC1=O)C1CC1', 'CN(CC1(O)CCN(C(=O)C2CCSC2)CC1)C(=O)C(C)(C)N(C)C', 'CN(CC1(O)CCN(C(=O)C=Cc2ccc[nH]2)C1)C(=O)C1CC12CC2', 'CN(CC1(O)CCN(C(=O)c2ccncc2F)C1)C(=O)[C@@H]1CCN1C', 'CN(CC1(O)CN(C(=O)C2CCOC2)C1)C(=O)c1ccc(O)c(F)c1', 'CN(CC1(O)CN(C(=O)c2ccc(Cl)s2)C1)C(=O)[C@H](O)c1ccco1', 'CN(CC1=CCSC1)C(=O)N(Cc1ccccc1)Cc1ccccc1', 'CN(CC1C(C)(C)C1(C)C)C(=O)CCCCNC(=O)[C@@H]1CNC(=O)C1', 'CN(CC1CC1(F)F)C(=O)CCOCCCNC(=O)C1CCNC1=O', 'CN(CC1CC1)C(=O)CN[C@H]1CCCC[C@@H]1NC(=O)c1ccccc1', 'CN(CC1CC1)C(CC1CCCO1)C(=O)Nc1cccc([N+](=O)[O-])c1', 'CN(CC1CCC1)c1nc(NCCC2(C)CC2)nc2c1CCCCC2', 'CN(CC1CCCC1)C(=O)C12CC1CCN2C(=O)C=Cc1ccoc1', 'CN(CC1CCCCC1)C(=O)[C@H]1CCCN1C(=O)Cn1cnc(N)n1', 'CN(CC1CCCCN1C(=O)CCCC(F)(F)F)C(=O)CSC(F)F', 'CN(CC1CCCN(C(=O)c2n[nH]c3c2COCC3)C1)C(=O)CCF', 'CN(CC1CCCN1C(=O)C1CS(=O)C1)C(=O)C1(CO)CCOCC1', 'CN(CC1CCNCC1)C(=O)C(=O)Nc1cccnc1-n1cncn1', 'CN(CC1COC(C)(C)OC1)C(=O)C(=O)NC1CC2(C1)CS(=O)(=O)C2', 'CN(CCC(=O)NCC1(CCO)CCCC1)C(=O)c1c[nH]c(=O)cn1', 'CN(CCC(=O)O)C(=O)CCCc1cn(CCc2ccccn2)nn1', 'CN(CCC(C)(C)NC(=O)C1CCCS1)C(=O)c1cc(C2CC2)no1', 'CN(CCC(C)(C)NC(=O)C1CCS(=O)(=O)C1)C(=O)c1ccnn1C', 'CN(CCC(C)(C)c1ccccc1)C(=O)NCCCCc1ccco1', 'CN(CCC(C)(C)c1ccccc1)C(CC1CCC1)C(=O)NC1CC1', 'CN(CCC(F)(F)F)C(=O)C1CCCCCN1C(=O)[C@H](O)C(F)(F)F', 'CN(CCC1CCCCN1C(=O)Cc1cccnc1O)C(=O)C1CC1', 'CN(CCC1CCN(C(=O)C2CCCC2O)CC1)C(=O)C1(C)COC1', 'CN(CCC1CCN(C(=O)Cc2ccoc2)CC1)C(=O)c1ccco1', 'CN(CCCC(=O)N1CCC(N2CCCC2)C1)C(=O)C12CCC(C1)C2', 'CN(CCCC(=O)NCc1ncccc1F)C(=O)CC(C)(C)C1CC1', 'CN(CCCC(=O)N[C@H]1CCC[C@H]1N=[N+]=[N-])C(=O)CC1(O)CCOC1', 'CN(CCCC(=O)Nc1ccc(O)nn1)S(=O)(=O)c1ccc(F)cc1', 'CN(CCCC(C)(F)F)C(=O)CCCNC(=O)C1(C)CC2(CCC2)C1', 'CN(CCCCCCNC(=O)CC1CCSC1)C(=O)c1ccn(C)c1', 'CN(CCCCCNC(=O)CC1CCC2(CCC2)O1)C(=O)C1(F)CC1', 'CN(CCCCCNC(=O)Cn1nnc(N)n1)C(=O)[C@H]1C[C@@H]1C1CC1', 'CN(CCCCCNC(=O)c1ccc2c(c1)CC2)c1ncncc1Cl', 'CN(CCCCCO)C(=O)C1C=CCN1C(=O)CCCn1cccn1', 'CN(CCCCNC(=O)C1CCCN1C)C(=O)CNc1ccncc1', 'CN(CCCCO)C(C(=O)NC1(C)CC1)c1cnn(C2CCCC2)c1', 'CN(CCCF)C(=O)C1COCCC1NC(=O)CN1C(=O)CNC1=O', 'CN(CCCN(C)C(=O)C1(C)CCCN1C)C(=O)C1=CC2C=CC1C2', 'CN(CCCN(C)C(=O)C1CC1(F)F)C(=O)CCCCCC(C)(C)C', 'CN(CCCN(C)C(=O)C1OCCN(C)C1=O)C(=O)Cc1nc[nH]n1', 'CN(CCCN(C)C(=O)CN1CC2CC2C1)C(=O)C=C1CCOCC1', 'CN(CCCN(C)C(=O)c1c(F)ccc(Cl)c1N)Cc1ccncc1', 'CN(CCCN(C)C(=O)c1ccc(F)c(F)c1)C(=O)Cn1cccn1', 'CN(CCCNC(=O)C=CC(=O)NC1CC1)C(=O)C1CC(C2CC2)C1', 'CN(CCCNC(=O)Cn1nccn1)C(=O)C1CC12CCCCCC2', 'CN(CCCNC(=O)[C@H]1C[C@@H]1C(C)(F)F)C(=O)COCC1CCOC1', 'CN(CCCNC(=O)c1cc(CNC(=O)c2cnsc2)n[nH]1)C1CC1', 'CN(CCCNC(=O)c1cccn(C)c1=O)C(=O)C1C2(CC2)C12CC2', 'CN(CCCNC(=O)c1nccn2cnnc12)C(=O)C1(N(C)C)CC1', 'CN(CCCOCCNC(=O)[C@@H]1CC1(F)F)C(=O)C=Cc1cc[nH]n1', 'CN(CCCOCCNC(=O)[C@H]1CNC(=O)N1)C(=O)c1cn(C)nn1', 'CN(CCCc1cccs1)C[C@H]1CC(F)(F)CN1C(=O)OC(C)(C)C', 'CN(CCN(C)C(=O)C1CCOC(C)(C)C1)C(=O)c1cncc(N)c1', 'CN(CCN(C)C(=O)NCCc1cc(F)c(F)cc1I)CC(F)(F)F', 'CN(CCN(C)C(=O)[C@H]1C[C@@H]1c1nccn1C)C(=O)C1=CCCOC1', 'CN(CCN(C)C1CC1)C(=O)[C@H]1CCCN1C(=O)c1cnc(Cl)n1C', 'CN(CCN1CCCC1)C(=O)Nc1ccc(OC2CCCCC2)cc1', 'CN(CCNC(=O)C(CC(F)F)N(C)C(=O)C1CC(C)(F)C1)C1CC1', 'CN(CCNC(=O)NC(C)(C)COCc1ccccc1)C1(C)COC1', 'CN(CCNC(=O)c1cccc2ccoc12)C(=O)CCn1ccnn1', 'CN(CCNC(=O)c1nccnc1N)C(=O)c1ccc(N(C)C)cc1', 'CN(CCNc1ccc([N+](=O)[O-])c(Cl)c1F)C(=O)CC(F)(F)C(F)F', 'CN(CCO)C1CCCN(C(=O)C(CS(C)(=O)=O)c2ccccc2)C1', 'CN(CCO)CCNc1nc(N)nc(NCc2cncn2C2CC2)n1', 'CN(CCO)CCc1cn(CC2CCN(C(=O)C3(C)CCC3)C2)nn1', 'CN(CCOC1CC1)C(=O)C1=C(F)CN(C(=O)Cc2ccsc2)CC1', 'CN(CCOC1CC1)C(=O)[C@H](NC(=O)[C@H]1C[C@@H](O)CN1C)C(C)(C)O', 'CN(CCOCC1CC1)C(=O)[C@H]1CCC=C[C@H]1NC(=O)CCCC#N', 'CN(CCOCCC(=O)N1CCC(O)(CO)C1)C(=O)C1CC(C)(F)C1', 'CN(CCOCCCNC(=O)C1(C)COC(=O)N1)C(=O)[C@H]1CC1(C)C', 'CN(CCOCCCNc1nnnn1C)C(=O)c1cc(CO)n(C)n1', 'CN(CCOCCN(C)C(=O)C1(C)CCCC1)C(=O)CC1CC(=O)C1', 'CN(CCOCCN(C)C(=O)c1cncc2c1CCC2)C(=O)C(N)=O', 'CN(CCOCCNC(=O)c1noc2c1CCCC2)C(=O)C1(Br)CC1', 'CN(CCc1cc[nH]n1)C(=O)C1CC(C)(C)CCN1C(=O)CN=[N+]=[N-]', 'CN(CCc1ccccc1)C(=O)CN(C)C(=O)Cc1cnc[nH]c1=O', 'CN(CCc1cnccn1)c1nccc(N2CCN(C)C(CO)C2)n1', 'CN(CCn1cnnc1)C(=O)C1CC(CCNC(=O)C2CC23CC3)C1', 'CN(CP(C)(C)=O)C(=O)C(CNC(=O)CCC1OCCO1)CC1CC1', 'CN(CP(C)(C)=O)C(=O)C1CC12CCN(C(=O)CC1CCSCC1)C2', 'CN(C[C@@H](O)CO)C(=O)[C@@H]1CCC[C@@H](NC(=O)CC2=CCOCC2)C1', 'CN(C[C@@H]1CCCN(CCC2CCC(C)(C)O2)C1)C(=O)OC(C)(C)C', 'CN(C[C@@H]1CCCN1C)C(=O)[C@@H](CO)NC(=O)Cc1ccc(O)cc1', 'CN(C[C@@H]1CCN(S(=O)(=O)CCCF)C1)C(=O)c1ocnc1C1CC1', 'CN(C[C@@H]1[C@H]2CN(C(=O)C3CS(=O)C3)C[C@@H]12)C(=O)C(C)(C)C1CCC1', 'CN(C[C@@H]1[C@H]2CN(C(=O)c3cc(N)ccn3)C[C@@H]12)C(=O)CC(C)(C)C', 'CN(C[C@@H]1[C@H]2CN(C(=O)c3cncc(F)c3)C[C@@H]12)C(=O)C(O)C1CC1', 'CN(C[C@H]1CCC[C@H]1NS(=O)(=O)c1cncs1)C(=O)c1cnnn1C', 'CN(C[C@H]1C[C@@H](O)C1)C(=O)C(CC(F)F)NC(=O)c1cccnc1S', 'CN(C[C@H]1C[C@@H](O)C1)C(=O)C1(C)CCCN(C(=O)c2cccnc2)C1', 'CN(C[C@H]1C[C@H](F)CN1C(=O)CCNS(C)(=O)=O)C(=O)c1cscn1', 'CN(C[C@H]1OCCN(C)[C@@H]1c1cnn(C)c1)C(=O)C1(O)CCNCC1', 'CN(Cc1c(F)ccc(F)c1F)C(=O)C(CN)Cc1ccc(F)cc1', 'CN(Cc1c[nH]cn1)C(=O)C[C@H]1C[C@@H](NC(=O)c2ccc(CO)s2)C1', 'CN(Cc1c[nH]nn1)C(=O)[C@@H]1[C@H](CNC(=O)C(F)(F)C(F)F)C1(C)C', 'CN(Cc1c[nH]nn1)c1nc(N(C)Cc2cscn2)c2sccc2n1', 'CN(Cc1cc(-c2nc(C3(C)CC3)no2)n(C)n1)C(=O)OC(C)(C)C', 'CN(Cc1cc(=O)n2c3c(sc2n1)CCCC3)c1ccc(F)c(F)c1', 'CN(Cc1cc(Br)co1)C(=O)Cn1cc(CC2CCCCN2C)nn1', 'CN(Cc1cc(C2CC2)n(C(C)(C)C)n1)Cc1ccc(F)c(F)c1F', 'CN(Cc1cc(C2CCC2)no1)C(=O)NCc1ccnc2[nH]ccc12', 'CN(Cc1cc(F)ccc1Oc1ccc(Cl)c(F)c1)S(=O)(=O)CCO', 'CN(Cc1cc2cc(F)ccc2s1)C(=O)NC1C[C@H]2CC(CO)C[C@@H]12', 'CN(Cc1ccc(-n2cncn2)cc1)CC1CC2(CCCC2)C(=O)O1', 'CN(Cc1ccc(Br)o1)C(=O)C(=O)NC1CCCOc2ccccc21', 'CN(Cc1ccc(CO)o1)C(=O)c1csc(Nc2ccc(Cl)cc2)n1', 'CN(Cc1ccc(Cl)s1)C(=O)COC(=O)c1ccc2c(c1)SCCN2', 'CN(Cc1ccc(NC(=O)c2nc3c(Br)cccn3n2)cc1)C1CC1', 'CN(Cc1ccc2cc[nH]c2c1)C(=O)C(=O)N1CC2CC1(C(F)F)C2', 'CN(Cc1cccc(-c2nnn[nH]2)c1)C(=O)c1cnc(C2CC2)cn1', 'CN(Cc1cccc(=O)[nH]1)C(=O)C12CC1CCN2C(=O)/C=C/C(F)F', 'CN(Cc1cccc(Br)c1Cl)S(=O)(=O)c1ccc(-c2csnn2)cc1', 'CN(Cc1cccc2c1OC(F)(F)O2)C(=O)c1ccnc2[nH]ncc12', 'CN(Cc1ccccc1)C1(CNCc2cccc3c2NCC3)CCC1', 'CN(Cc1ccccc1)CC(O)COC(=O)Cc1cc(O)ccc1Br', 'CN(Cc1cccnc1)CC1CCCN(CCC2C(=O)CC2(C)C)C1', 'CN(Cc1ccn(C)n1)C(=O)C(NC(=O)[C@]12CCC[C@H]1C2)C(C)(C)C', 'CN(Cc1ccn(C)n1)C(=O)Nc1cc(-c2ccc(F)cc2)n(C)n1', 'CN(Cc1ccn(C)n1)C(=O)c1coc(CNC(=O)C2CCCC2)n1', 'CN(Cc1ccnc(N(C)C)n1)C(=O)NCC1CC(NS(C)(=O)=O)C1', 'CN(Cc1ccnc2ccccc12)C(=O)NCCCCc1nccs1', 'CN(Cc1ccnn1-c1ccccc1)C(CO)c1ccc(F)c(Cl)c1', 'CN(Cc1ccnn1C)C(=O)[C@H]1[C@@H]2CN(C(=O)C3(C)C=CCC3)C[C@@H]21', 'CN(Cc1ccns1)C(=O)C1CN(C(=O)Cn2ccnc2)CCN1C', 'CN(Cc1ccns1)c1nccc(N[C@H]2CCc3nc(N)sc3C2)n1', 'CN(Cc1ccsc1)C(=O)C(=O)NCc1ccc2c(c1)C(=O)N(C)C2', 'CN(Cc1cn(C(C)(C)C)nn1)C(=O)CCc1ccc(N(C)C)cc1', 'CN(Cc1cn2cc(Cl)ccc2n1)C(=O)C1(C)CCOC12CC2(F)F', 'CN(Cc1cn2cc(Cl)ccc2n1)C(=O)C1CCCC2(CCOC2)O1', 'CN(Cc1cncnc1)C(=O)C12CC(CN(C(=O)c3ccco3)C1)C2', 'CN(Cc1cnn(CC(F)(F)F)c1)C(=O)NCc1cncc(C#N)c1', 'CN(Cc1cnn2c1CNCC2)C(=O)C(C)(C)c1ccc(Cl)cc1Cl', 'CN(Cc1csc(-c2cccs2)n1)C(=O)C1CCCCC12OCCO2', 'CN(Cc1nc(-c2ccccc2)c[nH]1)C(=O)C(=O)NC[C@H]1CC[C@H]1F', 'CN(Cc1nc2ccccc2o1)C(=O)NC1CCC1N1CCOCC1', 'CN(Cc1ncccn1)C(=O)C(NC(=O)[C@@H]1CNC(=O)N1)C1(C)CC1', 'CN(Cc1ncccn1)C(=O)C1(CNC(=O)C2CC(C3CC3)C2)CC1', 'CN(Cc1nccs1)C(=O)[C@H]1CCCN(C(=O)C2=C(Cl)CCCC2)C1', 'CN(Cc1nccs1)C(=O)c1cc(CNC(=O)c2ccn(C)n2)on1', 'CN(Cc1nn(C)cc1Br)C(=O)C1(Nc2ccccc2)CCNCC1', 'CN(Cc1nnc2n1CCOC2)C(=O)NCc1csc(C(C)(F)F)n1', 'CN(Cc1nnc2n1CCOCC2)S(=O)(=O)c1cc(Br)ccc1C#N', 'CN(Cc1nncn1C)C(=O)C1(F)CCN(C(=O)COCC2CC2)C1', 'CN(Cc1nnnn1Cc1ccccc1)c1cc(Br)c(F)cc1C#N', 'CN(Cc1noc(O)n1)C(=O)[C@H]1CCCN1C(=O)C1=CCCOCC1', 'CN(OCC(F)(F)F)C(=O)C(CC1CC1)NC(=O)c1cnc(Cl)n1C', 'CN(c1nc(C2CCN2C(=O)c2c(O)ccc(F)c2F)cs1)C1CC1', 'CN1C(=O)CC[C@@H]1C(=O)N1CCCC(C(=O)Nc2cccc(Cl)c2)C1', 'CN1C(=O)CC[C@@H]1C(=O)N1C[C@@H]2C[C@]2(NC(=O)c2cc(Cl)nn2C)C1', 'CN1C(=O)CCc2cc(NS(=O)(=O)c3ccc(C#N)c(Cl)c3)ccc21', 'CN1C(=O)CCc2ccc(NS(=O)(=O)Cc3cc(F)cc(F)c3)cc21', 'CN1C(=O)CN(CCc2ccccc2OC(F)F)C1c1ccccc1', 'CN1C(=O)CSC1=CC(=O)N[C@H]1CC[C@@H]1Nc1nccc(C2CC2)n1', 'CN1C(=O)OCC1C(=O)N[C@H]1COC[C@H]1C(=O)NOCC1(F)CCC1', 'CN1C(=O)c2cc(NC(=O)CNC(=O)c3ccoc3)ccc2S1(=O)=O', 'CN1C(=O)c2ccc(NC(=O)c3cnc(CC(C)(C)C)s3)cc2C1=O', 'CN1C2CCCC1CN(C(=O)C(=O)Nc1cc(Br)cc([N+](=O)[O-])c1)C2', 'CN1C2CCCC1CN(C(=O)Nc1ccc3c(C(N)=O)c[nH]c3c1)C2', 'CN1CC(C(=O)NC(C(=O)N[C@H]2C[C@H]3CCCC[C@H]32)C2CCCC2)C1', 'CN1CC(C(=O)NCc2nnc(Cc3ccccc3)[nH]2)OCCC1=O', 'CN1CC(C)(C(=O)N[C@H]2C[C@@H](NC(=O)c3cnc(Cl)s3)C2)CCC1=O', 'CN1CC(C)(C)C1C(=O)NC(CC(=O)O)Cc1cc(F)c(F)cc1F', 'CN1CC(C)(NC(=O)[C@@H]2C[C@@H](F)CN2C(=O)OC(C)(C)C)CCC1=O', 'CN1CC(CCO)(CNC(=O)CCCN(C)C(=O)C2(O)CCOC2)C1', 'CN1CC(CNC(=O)CC(c2ccc(Cl)c(F)c2)C(F)(F)F)CC1=O', 'CN1CC(CNC(=O)NC[C@H](O)COCc2ccccc2)OCC1=O', 'CN1CC(CNC(=O)[C@@H](CO)NC(=O)C2CCC(C)(C)CC2)CC1=O', 'CN1CC(CNc2nc(NCc3cncn3C)nc3ccccc23)C1', 'CN1CC(NCC2CCCCCN2C(=O)OC(C)(C)C)CCCC1=O', 'CN1CC(O)(CNC(=O)[C@H]2CN(C(=O)C3CC34CCCC4)CCO2)C1', 'CN1CC(O)CC1(C)C(=O)N(CCNC(=O)c1cn(C)nn1)C1CC1', 'CN1CC(O)CC1(C)C(=O)NCC(C)(F)CNC(=O)Cn1cccc1', 'CN1CC2(C1)CN(C(=O)[C@@H]1C[C@@H]3C[C@@H]3N1C(=O)C1(C)CC(C)(C)C1)C2', 'CN1CC2(CCC2)CCC1CNC(=O)N1CC(O)(c2ccncn2)C1', 'CN1CC2(CCN(C(=O)NCc3cccc(CN4CCCC4)c3)C2)C1', 'CN1CC2CCCC(C1)N2C(=O)NC[C@H]1CCO[C@@H]1c1ccccc1', 'CN1CC=C(C(=O)N2CC=CC(NC(=O)C3(CC4CCC4)CC3)C2)C1', 'CN1CC=C(C(=O)N2CCN(C(=O)c3cccnc3N)C(CO)C2)C1', 'CN1CC=C(C(=O)NC[C@H](CO)NC(=O)c2ccc(C(C)(C)C)o2)C1', 'CN1CC=C(CC(=O)N[C@]2(C)C[C@@H](NC(=O)C3CC(Cl)(Cl)C3)C2)CC1', 'CN1CC=C(CNC(=O)[C@@H](NC(=O)CSCCC#N)C(C)(C)O)CC1', 'CN1CC=CCC1CC(=O)N1CCC[C@@H]1C(=O)N1CC2C(C1)C2(C)C', 'CN1CC=CCC1CC(=O)Nc1c(-c2nc(C3CC3)no2)cnn1C', 'CN1CCC(C(=O)N(CC(=O)NC2CCC(C3CC3)C2)C2CC2)CC1', 'CN1CCC(C(=O)N2CCC(CN(C)C(=O)CC3=NNC(=O)C3)C2)C1', 'CN1CCC(C(=O)N2CCC[C@@H](CC(=O)NC3CC(F)(F)C3)C2)CC1', 'CN1CCC(C(=O)N2CC[C@@H](NC(=O)C=C3CCOCC3)C2)CC1=O', 'CN1CCC(C(=O)NC(C)(CO)C(=O)NCCc2cccnc2F)C1', 'CN1CCC(C(=O)NCC(C)(F)CNC(=O)c2cncc(F)c2)CC1', 'CN1CCC(C(=O)NCC2(C(=O)NCC3CCOC3=O)CCCO2)C1', 'CN1CCC(C(=O)NC[C@H]2C[C@@H](C(=O)NC3(C)CCSCC3)C2)CC1', 'CN1CCC(C)(C(=O)N2CC3(C(=O)N[C@@H]4CCCOC4)CC2CO3)C1', 'CN1CCC(CCNC(=O)C2(F)CN(C(=O)C3CCC(=O)N3C)C2)C1', 'CN1CCC(CCNC(=O)CCCOc2cccc(Cl)c2Cl)OC1=O', 'CN1CCC(CCO)(NS(=O)(=O)CC2COc3ccccc3O2)CC1', 'CN1CCC(CN(CC2CC3(CCC3)CO2)C(=O)C2CC2F)CC1=O', 'CN1CCC(CNC(=O)C[C@@H]2CCC[C@H](N)C2)(c2ccccc2)CC1', 'CN1CCC(CNC(=O)[C@H]2CCN2C(=O)C2CC3(CCC3=O)C2)CC1', 'CN1CCC(N(C)C(=O)C(C)(C)CCNC(=O)[C@@H]2C[C@H](O)CN2C)C1', 'CN1CCC(N(C)C(=O)CCNc2cc(Cl)nc(C3(C)CC3)n2)CC1', 'CN1CCC(NC(=O)[C@H]2C[C@@H](CNC(=O)CCC(C)(C)F)C2)C1(C)C', 'CN1CCC(NC(=O)c2[nH]ccc2CNC(=O)C2CC3(CCC3)C2)C1', 'CN1CCC(NC(=O)c2ccc(N3CC4CCC(C3)O4)cc2)CC1=O', 'CN1CCC(NC(=S)N2CCNC(=O)C2c2c(F)cccc2Cl)CC1', 'CN1CCC(Nc2ccccc2NC(=O)c2nc3c(s2)CCC3)CC1', 'CN1CCC2CCN(C(=O)C3(F)CCN(C(=O)c4ccco4)C3)C2C1', 'CN1CCCC(C(=O)N2CC(OCCC(=O)NC3CC(C#N)C3)C2)C1', 'CN1CCCC(C(=O)N2CC3CC(C2)N3C(=O)CC2=CCOCC2)C1', 'CN1CCCC(C)(C(=O)N[C@H]2C[C@H](CNC(=O)c3cc(Cl)[nH]n3)C2)C1', 'CN1CCCC(CC(=O)N(C)C[C@H]2CCN(C(=O)/C=C\\C(N)=O)C2)C1', 'CN1CCCC(CC(=O)N2CC3(CCN3C(=O)Cc3csnn3)C2)C1', 'CN1CCCC(CN(C)C(=O)C(C2CC2)N(C)C(=O)C(=O)N(C)C)C1', 'CN1CCCC(CN(Cc2cnsc2)C(=O)C2(C)CCSCC2)C1=O', 'CN1CCCC(CNc2ccnc(NCC3CC4CCC3CC4)n2)C1', 'CN1CCCC(NC(=O)[C@]23CCC[C@H]2CN(C(=O)C(C)(C)O)C3)C1=O', 'CN1CCCC(O)(CN2Cc3ccccc3OC3(CCOC3)C2)C1=O', 'CN1CCCC1(C)C(=O)N1CCc2nnc(-c3cc(Br)n[nH]3)n2CC1', 'CN1CCCC1C(=O)N1CCC(C(=O)NOC[C@H]2C[C@H]3C=C[C@@H]2C3)C1', 'CN1CCCC1CCC(=O)NCC1(O)CC(C(=O)NCC2(O)CC2)C1', 'CN1CCCC1CNC(=O)C1(CNC(=O)c2ccon2)CC(C)(C)C1', 'CN1CCCC1c1cn(CC(=O)N2CCCN(S(N)(=O)=O)CC2)nn1', 'CN1CCCC2(CCN(C(=O)c3ccc4c(c3)OCCCO4)CC2)C1', 'CN1CCCCC12CN(C(=O)c1nnn(C3CCNC3)c1C(F)F)C2', 'CN1CCCCC1C(=O)NC1(C(=O)NOCCc2ccccc2)CC1', 'CN1CCCCC1C(=O)Nc1cccc(CNC(=O)CS(N)(=O)=O)c1', 'CN1CCCCC1CC(=O)N(Cc1cc(Cl)no1)C[C@@H](F)C(C)(C)O', 'CN1CCCCCC1C(=O)N[C@H]1C[C@@H](N(C)C(=O)Cc2ccon2)C1', 'CN1CCCC[C@@H](NC(=O)N2CCOC(Cc3ccccc3)C2)C1=O', 'CN1CCCC[C@H]1C(=O)NCC(C)(C)CC(=O)NCC(C)(C)C(N)=O', 'CN1CCCC[C@H]1C(=O)N[C@H]1CC[C@@H]1Nc1nnc(C2CCCC2)s1', 'CN1CCCN(C(=O)C(C)(C)CCNC(=O)C2CC23CCC3)CCC1', 'CN1CCCN(C(=O)C2(NC(=O)c3ncnc(O)c3F)CSC2)CC1', 'CN1CCCN(CC(=O)Nc2ccc3c(c2)NC(=O)CO3)CC12CC2', 'CN1CCC[C@@H]1C(=O)N[C@H]1C[C@@H](CO)N(C(=O)CN(C)S(N)(=O)=O)C1', 'CN1CCC[C@H]1C(=O)N1CCCC(C(=O)NC(C)(C)CC(N)=O)CC1', 'CN1CCC[C@H]1C(=O)N1C[C@H](C(=O)N(CCF)C2CC2)[C@@H](C2CC2)C1', 'CN1CCC[C@H]1C(=O)NC1CC12CCN(C(=O)C(O)C(F)(F)F)CC2', 'CN1CCC[C@H]1C(=O)N[C@H]1COCC[C@H]1C(=O)NC1(CCF)CCC1', 'CN1CCC[C@H]1CC(=O)N1CCC(O)(CNC(=O)C2(C(N)=O)CC2)C1', 'CN1CCCc2cc(C(=O)Nc3nc(-c4ccccc4)ns3)ccc21', 'CN1CCCc2cc(CNC(=O)NCCc3cccnc3O)ccc21', 'CN1CCCc2cc(CNC(=O)c3ccc4c(c3)CNC4=O)ccc21', 'CN1CCN(C(=O)CC2COCCN2C(=O)c2ccc(F)cn2)CC1', 'CN1CCN(C(=O)Cn2cc(NC(=O)CS(=O)(=O)C3CC3)cn2)CC1', 'CN1CCN(C(=O)[C@@H]2CCC[C@H]2O)C(C(=O)NCC(Cl)C(C)(F)F)C1', 'CN1CCN(C(=O)c2[nH]nc3c2COC3)CC1c1nc(C2CC2)no1', 'CN1CCN(C(=O)c2ccc(N3CCCNS3(=O)=O)cc2)C(CO)C1', 'CN1CCN(C(=O)c2ccccn2)C(C(=O)NC[C@H](O)C(F)(F)F)C1', 'CN1CCN(C(=O)c2ccn(C)n2)CC1C(=O)N1CC2CCCC1C2', 'CN1CCN(C(=O)c2nc(C3CC3)n3ccccc23)CC1C(F)(F)F', 'CN1CCN(CC(=O)N2C[C@@H]3C[C@]3(NC(=O)Cc3ccns3)C2)CC1', 'CN1CCN(CC(=O)NC2CCN(S(C)(=O)=O)CC2)c2cccnc21', 'CN1CCN(CC(=O)N[C@H]2C[C@H]2CNC(=O)CC(=O)NC2CC2)CC1', 'CN1CCN(CC2(C)CCN(C(=O)Nc3nonc3C#N)CC2)CC1', 'CN1CCN(Cc2csc(-c3ccccc3Cl)n2)C[C@@]2(C)CCC[C@H]12', 'CN1CCN(c2ncc(-c3cccc(-n4cccn4)c3)cc2N)CC1', 'CN1CCOC(C(=O)N(C)CCCCC(=O)NC2CCCC23CC3)C1', 'CN1CCOCC(N(C)C(=O)CCn2c(=O)n(C)c3ccccc32)C1', 'CN1CCOCC12COCN(C(=O)NCc1ccc(Cl)c(C#N)c1)C2', 'CN1CCOCC1C(=O)NCCCCC(=O)NC1CC(C(C)(C)C)C1', 'CN1CCOCC1CNC(=O)[C@@H](O)CNC(=O)CC(=O)OC(C)(C)C', 'CN1CC[C@@H](C(=O)N2CCC(NC(=O)c3csc4cncn34)CC2)C1', 'CN1CC[C@@H]1C(=O)NC(C(=O)NC(CO)CC1CCCC1)C1(C)CC1', 'CN1CC[C@@H]1C(=O)NC1CC2(C1)CC(C(=O)Nc1cncc(Cl)c1)C2', 'CN1CC[C@@H]1C(=O)NCC(C)(C)C#CC(=O)N1CCC12CCCCC2', 'CN1CC[C@H](NC(=O)C2=CCN(C(=O)C3(C#N)CCOCC3)C2)C1=O', 'CN1CC[C@H]2CN(C(=O)CC3(C)CCN3C(=O)Cc3ccon3)C[C@H]21', 'CN1CCn2c(CNC(=O)NC3(CO)CCOC3(C)C)nnc2C1=O', 'CN1C[C@@H](F)C[C@H]1C(=O)N1CCCC2(CN(C(=O)CC(C)(F)F)C2)C1', 'CN1C[C@@H](F)C[C@H]1C(=O)N1C[C@@H](O)C[C@H]1C(=O)NCC(C)(C)CCO', 'CN1C[C@@H](O)C[C@H]1C(=O)N1CCN(C(=O)C2CC(Cl)(Cl)C2)CC1CO', 'CN1C[C@@H](O)C[C@H]1C(=O)NCCSCC(=O)NCC1(C(C)(F)F)CC1', 'CN1C[C@@H](O)C[C@H]1C(=O)N[C@@H]1CN(C(=O)C2=C(C#N)CCC2)C[C@H]1O', 'CN1C[C@@H]2CC[C@H](CC1=O)N2C(C(=O)NC1CCC1)[C@@H]1C[C@H]1C1CC1', 'CN1C[C@H]2CN(C(=O)[C@@H]3CCC[C@@H](NC(=O)C4CC4Cl)C3)C[C@@]2(C)C1', 'CN1C[C@H]2C[C@@]2(NC(=O)C2CCOC2CNC(=O)c2n[nH]c(N)n2)C1', 'CN1C[C@H]2C[C@@]2(NC(=O)C2COCCN(C(=O)c3cnc(N)o3)C2)C1', 'CN=S(C)(=O)c1ccc(C(=O)Nc2cnn(CCC(F)(F)F)c2)cc1', 'CN=S(C)(=O)c1cccc(C(=O)NCC(C)NC(=O)OC(C)(C)C)c1', 'CNC(=O)C(C)(C)CNC(=O)C1CCN(C(=O)C2C=C(C)CS2)C1C', 'CNC(=O)C(C)(C)NC(=O)[C@@H]1[C@H]2C[C@@H]1N(C(=O)CC1=CCCCC1)C2', 'CNC(=O)C(C)CNC(=O)C(C)CN(C)C(=O)C1CCCC2(CC2)C1', 'CNC(=O)C(C)CNC(=O)C(C)CN(C)C(=O)CN(C)C1CCCC1', 'CNC(=O)C(C)CNC(=O)C(NC(=O)c1cc2occc2[nH]1)C1CC1', 'CNC(=O)C(C)N1CCN(C(=O)C2OCCc3c(O)cccc32)CC1', 'CNC(=O)C(C1CCC=CO1)N(CCOC)Cc1ccc(C#N)cc1', 'CNC(=O)C(CC1(C#N)CC1)N1CCCC(CO)(c2ccccc2)C1', 'CNC(=O)C(NC(=O)NC1COc2cccc(Cl)c21)C1CCCCC1', 'CNC(=O)C(O)CNC(=O)C1(NC(=O)C(CO)C(F)(F)F)CC1(C)C', 'CNC(=O)C(c1cc(C(F)(F)F)nn1C)N1CC(C)(C)OC(C)(C)C1', 'CNC(=O)C(c1cc(Cl)c(F)cc1F)N1CC[C@H](C(=O)OC)[C@H](O)C1', 'CNC(=O)C(c1cc2cc(C)ccc2o1)N1C[C@@]2(CO)C[C@@]2(CO)C1', 'CNC(=O)C(c1ccc(-c2ccc(C)cc2)o1)N1C[C@H](OC)[C@@H](F)C1', 'CNC(=O)C(c1ccc(C#N)cn1)N1CCCCC1c1cncnc1', 'CNC(=O)C(c1cccc2[nH]cnc12)N1CCC2(CC1)CC(OC)C2', 'CNC(=O)C(c1csc2ccccc12)N1CCCC(C)C1C(=O)OC', 'CNC(=O)C(c1nccc(Cl)c1F)N1CC(COC)C2(CCCC2)C1', 'CNC(=O)C1(C(=O)N2CCC(CC(=O)NC(C)C3CCCO3)C2)CC1', 'CNC(=O)C1(COC)CCCN1C(=O)Cc1cc(C(F)(F)F)nn1C', 'CNC(=O)C1(NC(=O)CC2(NC(=O)C(COC)CC(C)C)CC2)CC1', 'CNC(=O)C1C=CCN1C(=O)[C@H]1C[C@@H]1C1CN(C(=O)C2CN(C)C2)C1', 'CNC(=O)C1CCN(C(=O)C(NC(=O)c2cnnn2C)C2(C)CC2)C1', 'CNC(=O)C1CCN(C(=O)C2(N(C)C(=O)C3CCCCCC3)CC2)C1', 'CNC(=O)C1CN(C(=O)C[C@H]2CCCC[C@H]2NC(=O)CCCC#N)C1', 'CNC(=O)CC(C)CNC(=O)C[C@@H](C)N(C)C(=O)c1cnnc(C)c1', 'CNC(=O)CC1(O)CCCN(C(=O)N[C@@H]2CCc3cc(Cl)ccc32)C1', 'CNC(=O)CC1CCN(C(=O)c2cccnc2-c2cnn(C)c2)CC1', 'CNC(=O)CCC(=O)N1CCCCC(CCC(=O)NCC2CCC2)C1', 'CNC(=O)CCC(=O)N1CCC[C@H]1CCNC(=O)C1CCCCC1O', 'CNC(=O)CCC(=O)N[C@H](CC(=O)N1CC2CC=CC1C2)C(C)(C)C', 'CNC(=O)CCC(=O)N[C@H]1C=CCC[C@H]1C(=O)N(C)C1CC(OC)C1', 'CNC(=O)CCC(=O)N[C@H]1CC[C@@H]1NC(=O)c1cc2cccnn2c1', 'CNC(=O)CCC(=O)N[C@H]1C[C@@H](CC(=O)NCCC2(O)CCOC2)C1', 'CNC(=O)CCC(=O)N[C@]1(C(=O)N[C@H]2C[C@@H]2C2CCCCC2)C[C@H]1C', 'CNC(=O)CCCCN(C)C(=O)[C@@H](NC(=O)C(C)=CC1CC1)C(C)C', 'CNC(=O)CCCCNC(=O)c1coc(CNC(=O)C2=C(Cl)CC2)n1', 'CNC(=O)CCCN(C)C(=O)[C@H]1CC=C[C@H](NC(=O)C(C)COC)C1', 'CNC(=O)CCN(C)C(=O)C(=O)N(C)c1ccc(NS(C)(=O)=O)cc1', 'CNC(=O)CCNC(=O)C[C@H]1C=C[C@@H](NC(=O)CCc2cscn2)C1', 'CNC(=O)CN(C)C(=O)[C@H]1C=C[C@@H](NC(=O)C(C)(COC)COC)C1', 'CNC(=O)CN(C)c1nc(N2C[C@@H](F)[C@@H](F)C2)c2c(F)cccc2n1', 'CNC(=O)CN(Cc1cc2ccccc2o1)C(=O)CN(C)S(C)(=O)=O', 'CNC(=O)CNC(=O)C[C@H](CC1CC1)NC(=O)CC1CCC(=O)N1C', 'CNC(=O)CNc1nc(NC2CCCCCC2C)c2c(ncn2C)n1', 'CNC(=O)COCC(=O)N1CCN(C(=O)C2=CCCC2C)CC12CC2', 'CNC(=O)COCC(=O)N1C[C@H](C)C[C@H]1C(=O)N[C@H]1COC[C@@H]1OC', 'CNC(=O)COCCNC(=O)CCN(C)C(=O)c1c[nH]c(C#N)c1C', 'CNC(=O)Cc1ccccc1NC(=O)C(=O)N1CCOC2(CCC2)C1', 'CNC(=O)N1CC(C(=O)N(Cc2ncc(C)n2C)CC(C)(C)CO)C1', 'CNC(=O)N1CC(C(=O)NC(C)(C)C(C)CC(=O)NOCC=CCl)C1', 'CNC(=O)NC(=O)C(C)OC(=O)CCc1cccc(OCCOC)c1', 'CNC(=O)NCC(=O)N1CC(COC)(C(=O)NC2CC2(C)C(F)F)C1', 'CNC(=O)NCC(=O)N1C[C@H]2C[C@@H]1[C@H]2C(=O)N1C[C@@H](O)C[C@H](OC)C1', 'CNC(=O)NCC(=O)NC(C)(C)CCC(=O)N(C)Cc1nc(C)cs1', 'CNC(=O)NCCC(=O)NC(C(=O)N1CC(C)(CF)C1)c1ccoc1', 'CNC(=O)NCCC(=O)NCC1(COC)CN(C(=O)C2(CO)CC2)C1', 'CNC(=O)NCCC(=O)NC[C@H](OC)C(=O)N1CCC[C@@H]1CN(C)C', 'CNC(=O)N[C@@H](C)C(=O)N(C)CCC(C)NC(=O)C=Cc1ccsc1', 'CNC(=O)N[C@@H](C)C(=O)NCC1(F)CCN(S(=O)(=O)C2(C)CC2)CC1', 'CNC(=O)N[C@H](C)C(=O)N1CC2(C)CC1(C(=O)N[C@@H]1CC[C@H](C)C1)C2', 'CNC(=O)N[C@H](C)C(=O)N1CCC[C@@H]1CCNC(=O)CCC(=O)OC', 'CNC(=O)N[C@H](C)C(=O)N1CCOCCC1C(=O)NCc1csnn1', 'CNC(=O)N[C@H](C)C(=O)N1CC[C@H](CC(=O)N[C@@H](C)c2ccsc2)C1', 'CNC(=O)N[C@H](C)C(=O)NC(C)(C)/C=C/C(=O)NC(C)c1ncc[nH]1', 'CNC(=O)N[C@H](C)C(=O)NCC1(CC(=O)NC2CC(=O)N(C)C2)CC1', 'CNC(=O)N[C@H](C)C(=O)N[C@H]1CCN(C(=O)CSC(F)F)[C@@H]1C(C)C', 'CNC(=O)Nc1cc(NC(=O)Nc2ccc(Cl)c(SC)c2)ccc1F', 'CNC(=O)Nc1ccc(C(=O)NCC2(c3ccc(C)cn3)CC2)cc1', 'CNC(=O)Nc1ccc(Cl)c(C(=O)N(C)Cc2ccc(C)c(F)c2)c1', 'CNC(=O)Nc1ccc(NC(=O)NCc2ncc(C(C)(C)C)o2)cc1', 'CNC(=O)OC1CN(C(=O)C(NC(=O)Cc2ccnn2C)C2CC2)C1', 'CNC(=O)OC1CN(C(=O)[C@H]2C[C@H](CNC(=O)CS(=O)(=O)NC)C2)C1', 'CNC(=O)OCCCNC(=O)C(C)N(C(=O)C1CC(SC)C1)C1CC1', 'CNC(=O)OCCCNC(=O)C1CN(C(=O)[C@]2(C)C[C@H]2C)CCN1C', 'CNC(=O)Oc1cccc(NC(=O)c2cc(NC(C)=O)ccc2F)c1', 'CNC(=O)[C@@H](NC(=O)Cn1cc(-c2ncc(Cl)cc2F)nn1)C1CC1', 'CNC(=O)[C@H](C)N(C)C(=O)C1(C(C)C)CCN(C(=O)[C@@H]2CCCO2)C1', 'CNC(=O)[C@H]1CCCN1C(=O)C(=O)NCC1CNCCC12CCOC2', 'CNC(=O)c1cc(N2CCc3ccc(F)cc3C2C)ccc1[N+](=O)[O-]', 'CNC(=O)c1ccc(C=CC(=O)OCc2cc(=O)[nH]c(SC)n2)cc1', 'CNC(=O)c1ccc(CN(CCC(C)C(F)F)Cc2cn[nH]c2)cc1', 'CNC(=O)c1ccc(NC(=O)c2coc(=O)c3ccccc23)cc1Cl', 'CNC(=O)c1cccc(OCC(=O)N2c3ncnn3[C@@H](C)C[C@H]2C)c1', 'CNC(=O)c1nn[nH]c1NC(=O)NC1(CO)CCc2c(F)cccc21', 'CNC(C(=O)NC1CCc2c(F)ccc(Br)c21)c1cc(Cl)cc(Cl)c1', 'CNC(CC(=O)Nc1c(-c2ccc(Br)cc2)c(C)nn1C)C(F)(F)F', 'CNC1(C(=O)OC)CN(C(=O)CCS(=O)(=O)NCC(=O)NC(C)C)C1', 'CNC1(c2cn(CC(=O)Nc3cc(F)ccc3F)nn2)CCOCC1', 'CNC1CCCN(CC(=O)N2CCN(c3ccccc3F)CC2)CC1', 'CNC1CN(C(=O)c2sc(-c3cc(Cl)ccc3Cl)nc2C)CC1(C)C', 'CNCC1CN(C(=O)c2cc3c(ccc4ccccc43)[nH]2)CC12CC2', 'CNCCCOCCn1cc(CN2CCC(SC(F)(F)F)CC2)nn1', 'CNC[C@H](O)C1=CC(O)=C(O)C=C1', 'CNS(=O)(=O)CC(=O)N1CCC(C(=O)N2CCC23CC(COC)C3)C1', 'CNS(=O)(=O)CC(=O)N1CCC([C@@H](C)NC(=O)[C@H]2COC(=O)N2)CC1', 'CNS(=O)(=O)CC1CN(C(=O)NCc2cc3ncccc3[nH]2)CCO1', 'CNS(=O)(=O)CCC(=O)N(C)C1CN(C(=O)[C@@H]2CCN2C)CC12CC2', 'CNS(=O)(=O)CCC(=O)N[C@H]1CCCC[C@@H]1NC(=O)C(C)N1CCC1', 'CNS(=O)(=O)CCC(=O)N[C@]12CCC[C@H]1CN(C(=O)C(=O)NOC)C2', 'CNS(=O)(=O)N1C[C@H]2CC[C@@H]1[C@@H]1C(=O)N(Cc3ccccc3)C(=O)[C@H]21', 'CNS(=O)(=O)NCCNC(=O)N1CCC(N(C)Cc2ncoc2C)C1', 'CNS(=O)(=O)[C@@H]1CCCN(C(=O)c2ccc3c(c2)S(=O)(=O)NC3=O)C1', 'CNS(=O)(=O)c1cc(C(=O)NCCc2cc(I)ccc2OC)n(C)c1', 'CNS(=O)(=O)c1cc(C(=O)Nc2ccnn2Cc2ccc(C)o2)co1', 'CNS(=O)(=O)c1ccc(CC(=O)Nc2nc3c(s2)CC(C)CC3)cc1', 'CNS(=O)(=O)c1ccc(NC(=O)Nc2nnn(C(C)C)c2C)cc1C', 'CNS(=O)(=O)c1cccc(C(=O)N[C@H]2CCOc3c(C)cccc32)c1', 'CNc1c(-c2ccc(N3CCCC3)nc2)nc2cnc(C(N)=S)cn12', 'CNc1c(-c2ccc(OC)c(C)c2)nc2cc(C)c3ccccc3n12', 'CNc1c(-c2sccc2I)nc2ccc3cc(C(=O)OC)ccc3n12', 'CNc1cc(C(=O)NC(C(=O)NCC2(CF)CC2)C2(C)CC2)ccn1', 'CNc1cc(C(=O)N[C@@H](CC2CC2)C(=O)NC[C@H](CO)OC)ccn1', 'CNc1ccc(-c2ccc3c(OC(F)F)nccc3c2)cc1[N+](=O)[O-]', 'CNc1ccc(C(=O)NC2(C(=O)NCC(C)(O)CO)CC2(C)C)cc1', 'CNc1ccc(C(=O)N[C@H]2C[C@H](CC(=O)N(C)CCN(C)C)C2)nc1', 'CNc1ccccc1CNc1cc(N2CCC(C)S(=O)CC2)ncn1', 'CNc1ccnc(CNC(=O)NNC(=O)c2cc(F)c(F)cc2Cl)c1', 'CNc1cnc(C(=O)N(C)[C@H](C)CC(=O)Nc2cccc(C)c2)cn1', 'CNc1cnccc1C(=O)NC(C(=O)NCC(=O)N(C)O)C1(C)CC1', 'CNc1cnccc1C(=O)N[C@@H](C)CCNC(=O)CCn1cccn1', 'CNc1cnncc1C(=O)NCC(O)C(=O)Nc1cc(C)cc(O)c1', 'CNc1nc(C(=O)N2CCN3CCOCC3(CO)C2)ccc1[N+](=O)[O-]', 'CNc1nc(NC(C)CC2CCOC2)nc(NC2CC3(CCC3)C2)n1', 'CNc1nc(NC(C)c2cccc(C)c2C)nc(N2CCC(C)C2)n1', 'CNc1nc(NC2CCC3(CC3)C2)nc(N2CCN(C(C)C)CC2)n1', 'CNc1nc(NC2CCCCC2)nc(N2Cc3ccc(C)cc3C2)n1', 'CNc1nc(NCc2cnn(C)c2)nc(NC2CCNC(=O)CC2)n1', 'CNc1nc(NCc2csc(Cl)c2)nc(NCc2cc(C)[nH]c2C)n1', 'CNc1ncc(C(=O)N(CC2CCSC2)CC2(C(C)(C)O)CCC2)o1', 'CNc1ncc(C(=O)N2CCC(Nc3nc(C4CC4)ns3)C(F)C2)o1', 'CNc1ncc(C(=O)N2C[C@@H](C)O[C@H](C(=O)N[C@H]3CC[C@H](O)C3)C2)s1', 'CNc1ncc(C(=O)NC[C@H]2CCC[C@H]2NC(=O)[C@@H]2CCC[C@H]2O)o1', 'CNc1nccc(C(=O)N(CCCOC(C)C)Cc2ncsc2C)n1', 'CNc1ncccc1CNc1nccc(N(C)Cc2ccccn2)n1', 'CNc1nnc(CC(=O)N2C[C@H]3CN(C(=O)C4=CCCC4)C[C@@H]3C2)s1', 'CNc1scnc1C(=O)N1CC(=O)NCC1C(=O)N1CCC12CCC2', 'CNc1scnc1C(=O)NC[C@H]1C[C@H](CNc2ccc(C#N)cn2)C1', 'COC(=O)C(C)(C)NC(=O)N1CC[C@H](OC)C[C@@H]1c1ccc(F)cc1', 'COC(=O)C(C)(C)[C@@H](NC(=O)c1ccc2cc(I)ccc2n1)C(C)C', 'COC(=O)C(C)(C)c1cn(C2CN(C(=O)C3CC(=O)N(O)C3)C2)nn1', 'COC(=O)C(C)(F)C(=O)NCC1CCN(C(=O)[C@H]2COCCO2)CC1', 'COC(=O)C(C)(F)C(=O)N[C@@H]1COC[C@H]1NC(=O)c1cncnc1C', 'COC(=O)C(C)(F)C(=O)N[C@H]1CN(C(=O)CCCC2CC2)C[C@@H]1OC', 'COC(=O)C(C)C(=O)N(Cc1cccc(F)c1)Cc1ccccc1Cl', 'COC(=O)C(C)C(=O)N1C[C@H](C)CC[C@H]1C(=O)N1CCOCC1CO', 'COC(=O)C(C)C(=O)NCC1(C(=O)NCc2cc(C)no2)CC=CC1', 'COC(=O)C(C)C(=O)NCCCCNC(=O)c1ccn2ccnc2n1', 'COC(=O)C(C)CC(=O)N[C@H]1CCC[C@@H](C(=O)N(C)c2ccsc2)C1', 'COC(=O)C(C)CN(C)C(=O)C1(NC(=O)CCc2ccccc2)CC1', 'COC(=O)C(C)CN(C)C(=O)CCN(CCO)C(=O)C(C)C1CCC1', 'COC(=O)C(C)CNC(=O)CC(NC(=O)C(O)C1CCC1)C(C)(C)C', 'COC(=O)C(C)CNC(=O)c1oc(CNC(=O)c2cc[nH]n2)cc1C', 'COC(=O)C(C)COC(=O)c1ccc(COc2ccc(C#N)cc2)o1', 'COC(=O)C(C)N(OC)C(=O)CCCCCNC(=O)c1cccnc1', 'COC(=O)C(C)NC(=O)C(CNC(=O)C(C)(C)n1cncn1)N(C)C', 'COC(=O)C(C)NC(=O)C1CC(C)(C)CCN1C(=O)C(F)C(C)(F)F', 'COC(=O)C(C)NC(=O)CCN(C(=O)CC1CCCN(C)C1)C1CC1', 'COC(=O)C(C)ONC(=O)C1=C(F)CN(C(=O)CC(=O)N(C)C)CC1', 'COC(=O)C(C)ONC(=O)C1COCCN1C(=O)C1=C(C)OCCC1', 'COC(=O)C(C)n1cc(C2CN(C(=O)c3ccn(C4CC4)n3)C2)nn1', 'COC(=O)C(CCF)NC(=O)C1=CCN(C(=O)c2[nH]cc(C)c2C)C1', 'COC(=O)C(CNC(=O)C(=O)N1CCC(C)(C)C1)Cc1ccccc1', 'COC(=O)C(CNC(=O)Cc1nnc(OC)s1)Cc1ccc(Cl)cc1', 'COC(=O)C(CNC(=O)Nc1cnc(C)cn1)Cc1ccc(O)cc1', 'COC(=O)C(CNS(=O)(=O)c1cnc(OC)c(Br)c1)C1CCOCC1', 'COC(=O)C(COC(C)(C)C)OC(=O)c1ccc(C(C)(C)C)cc1N', 'COC(=O)C(F)Cc1ccc(NC(=O)N[C@@H](C)c2cnccn2)cc1', 'COC(=O)C(NC(=O)[C@]12CCCC[C@H]1C(=O)C2)c1cc(F)cc(F)c1', 'COC(=O)C(NC(=O)c1cncc(-c2ccc(C)cc2)c1)C1COC1', 'COC(=O)C(NCC(C)(C)c1ccncc1F)c1ccc(F)cc1Cl', 'COC(=O)C(NCc1nc2c(Br)cccc2s1)c1ccccc1SC', 'COC(=O)C(OC(=O)[C@H]1[C@@H]2CCCCC[C@@H]21)c1ccc(F)c(Cl)c1F', 'COC(=O)C(OC)C(=O)NCc1cc(C(=O)NC2CCCCC2)[nH]n1', 'COC(=O)C1(C(=O)NC[C@H]2C[C@H]2NC(=O)[C@@H]2CCC[C@H](O)C2)CC1C', 'COC(=O)C1(C(=O)OC)CCN(CC(C)CCc2ccccc2)CC1', 'COC(=O)C1(C(NCC2(CO)CCOCC2)c2nnnn2C)CCC1', 'COC(=O)C1(C(NCCC(C)C)c2nnnn2CCC2(C)CC2)CC1', 'COC(=O)C1(C)CC(C(=O)N(C)C[C@H]2CCC[C@H]2Nc2ncns2)C1', 'COC(=O)C1(C)CCCN(C(=O)CNS(=O)(=O)c2cn(C)c(C)n2)C1', 'COC(=O)C1(C)CN(C(=O)CC2(C)CCN2C(=O)c2cc(C)c[nH]2)C1', 'COC(=O)C1(C)CN(C(=O)c2nc(CNC(=O)C3CCO3)oc2C)C1', 'COC(=O)C1(C2(O)CCN(c3nnc4n(c3=O)CCC4)CC2)CCC1', 'COC(=O)C1(C2=CCN(C(=O)Nc3cnc(C)nc3C)CC2)CCC1', 'COC(=O)C1(CC(=O)N2CCN(Cc3ccc(Cl)s3)CC2)CCCC1', 'COC(=O)C1(F)CCN(Cc2ccc(-c3ccccc3)cc2Cl)CC1', 'COC(=O)C1(N(C)C(=O)C(NC(=O)C2=CCCC2)c2ccoc2)CC1', 'COC(=O)C1(N(C)C(=O)C(O)C2CN(C(=O)C3CCCCC3)C2)CC1', 'COC(=O)C1(N(C)C(=O)[C@@H]2CCN2C(=O)c2cncc(OC)n2)CC1', 'COC(=O)C1(NC(=O)C2CN(C(=O)C(C)C#N)CC23CC3)CC(C)C1', 'COC(=O)C1(NC(=O)Nc2nc3n(n2)CCCC3)CC(O)C12CCC2', 'COC(=O)C1(NC(=O)c2ccc(-n3ccnn3)cc2)CCCCCC1', 'COC(=O)C1(NC(=O)c2sc(C)nc2C)CCc2c(OC)cccc21', 'COC(=O)C1(O)CN(C(=O)C2=CCC(NC(=O)c3cnccn3)C2)C1', 'COC(=O)C1(OC)CC(C(=O)OCc2ccc([N+](=O)[O-])c(OC)c2)C1', 'COC(=O)C1(n2cc([C@@H]3CCCN3C(=O)COC(F)(F)F)nn2)CC1', 'COC(=O)C12CCC(CNC(=O)c3cn4c(n3)CC(C)CC4)(CC1)C2', 'COC(=O)C12COCC(NC(=O)c3nc4ccccc4cc3C)(C1)C2', 'COC(=O)C1=CCCN(C(=O)c2ccc(C(F)(F)C(F)(F)F)nc2)C1', 'COC(=O)C1=NOC2(C1)CN(S(=O)(=O)c1cc3cncc(Br)c3o1)C2', 'COC(=O)C1C2CCCCC2C1NC(=O)N[C@H]1CCN(C2CCC2)C1', 'COC(=O)C1CC(=O)N(C2CN(C(=O)NC3CC34CC(C)(C)C4)C2)C1', 'COC(=O)C1CC(C)N1C(=O)[C@H]1C[C@H](NC(=O)C2C3CCC(F)C32)C1', 'COC(=O)C1CC(NC(=O)C(F)(F)F)CN(C(=O)c2cncn2C)C1', 'COC(=O)C1CC(NC(=O)Nc2ccc(F)c(C(C)=O)c2)C12CCC2', 'COC(=O)C1CC2(CC(Nc3cc(-c4nc(C)no4)ccc3C)C2)C1', 'COC(=O)C1CC2(CC(OC(=O)c3cccc4c(C)c(C)[nH]c34)C2)C1', 'COC(=O)C1CCC2(CC1)CC(CNC(=O)CC1CC3(CCC3)C1)C2', 'COC(=O)C1CCCC(C)(C)N1C(=O)CCc1ccc(C(F)F)cc1', 'COC(=O)C1CCCCN1C(=O)[C@@H]1CC[C@H](NC(=O)C2CC2(Cl)Cl)C1', 'COC(=O)C1CCCN1C(=O)C1CN(C(=O)CCCN=[N+]=[N-])CCO1', 'COC(=O)C1CCN(C(=O)C(N)CC(C)(C)C)c2ccc(OC)cc21', 'COC(=O)C1CCN(C(=O)Cc2nn(C)c3ccccc23)CC1OC', 'COC(=O)C1CCN(C(=O)[C@@H]2[C@H](NC(=O)c3cnn(C)n3)C2(C)C)O1', 'COC(=O)C1CCN(C(=O)c2cc(OC)ccc2C(F)(F)F)C12CC2', 'COC(=O)C1CCN1C(=O)c1occc1CNC(=O)[C@H]1COCCO1', 'COC(=O)C1CN(C(=O)CNC(=O)c2cncn2-c2ccccc2)C1', 'COC(=O)C1CN(C(=O)COc2ccc(N)cc2)c2c(C)cccc21', 'COC(=O)C1CN(C(=O)NCCCC2CCCO2)Cc2ccccc21', 'COC(=O)C1CN(C(=O)N[C@H]2COC[C@@H]2C(F)(F)F)C2(CCCC2)C1', 'COC(=O)C1CN(C(=O)OC(C)(C)C)CCN1CC(=O)COC(C)C', 'COC(=O)C1CN(C(=O)c2ccc(F)c3c2C(=O)CC3)CC(F)(F)C1', 'COC(=O)C1CN(Cc2cccc3c2CCO3)CCC12CCOCC2', 'COC(=O)C1CN(S(=O)(=O)NCC(O)(C(C)(C)C)C(C)(C)C)CCO1', 'COC(=O)C1Cc2cc(F)ccc2N1CC(=O)c1ccc(F)c(F)c1', 'COC(=O)C1Cc2ccsc2CN1C(=O)C[C@@H]1CCc2ccccc21', 'COC(=O)CC(=O)N1CC(CC(F)C(=O)N2CCOC(C(N)=O)C2)C1', 'COC(=O)CC(=O)NC1(CC(=O)Nc2ccc3nc[nH]c3c2)CCC1', 'COC(=O)CC(=O)NC[C@@H]1C[C@@H]2CCC[C@@H]2N1C(=O)C1CC(C)(F)C1', 'COC(=O)CC(C)(NC(=O)Cc1ccnc(O)c1)c1ccc(F)cc1', 'COC(=O)CC(C)C(=O)N1CCOC(C(=O)NC2(C)CCSC2)CC1', 'COC(=O)CC(C)C(=O)NCC1(NC(=O)Cc2cc(C)on2)CCC1', 'COC(=O)CC(C)C(=O)NCCCC(=O)N1CCC(C2(O)CC2)CC1', 'COC(=O)CC(C)C(=O)NC[C@H]1C[C@H]1C(=O)N1C[C@H]2CC(C)(C)[C@H]2C1', 'COC(=O)CC(C)CC(=O)Nc1ncc(Cl)cc1-c1ccc(Cl)cc1', 'COC(=O)CC(C)NC(=O)C(C)N(C(=O)c1ccc(C#N)[nH]1)C1CC1', 'COC(=O)CC(C)NC(=O)CSc1nccn1-c1ccc(C)c(C)c1', 'COC(=O)CC(C)S(=O)(=O)N1CC(CCNC(=O)C(SC)C2CC2)C1', 'COC(=O)CC(CC(C)(C)C)NC(=O)Nc1ccc2c(c1F)CCC2', 'COC(=O)CC(CCNC(=O)C(=O)c1ccc(F)c(C)c1)C(F)(F)F', 'COC(=O)CC(Cc1cc(F)c(F)cc1F)NCCC1OCCCO1', 'COC(=O)CC(NC(=O)C(=O)Nc1ccc2nc(C)sc2c1)C1CC1', 'COC(=O)CC(NC(=O)Cc1sc2ccccc2c1C)C1CCCC1', 'COC(=O)CC1(C(=O)N(CC(F)C2CC2)CC(C(C)C)C(C)C)CC1', 'COC(=O)CC1(C(=O)N2CC(C(O)C(=O)N3CC(C)(CO)C3)C2)CC1', 'COC(=O)CC1(C(=O)N2CC[C@@H]2C(=O)NCc2cc(C)nn2C)CC1', 'COC(=O)CC1(C(=O)NCCC(=O)N2CC3(CCNC(=O)O3)C2)CC1', 'COC(=O)CC1(CC(=O)NCC2CCCN2C(=O)C(C)(C)CF)CC1', 'COC(=O)CC1(CNC(=O)C2=CCN(C(=O)c3cnc(C)o3)C2)CC1', 'COC(=O)CC1(CNC(=O)N2CCC(c3cc(C)n[nH]3)C2)CCCC1', 'COC(=O)CC1(CS(=O)(=O)N2CC(c3ccc(C)cc3)CC2C)CC1', 'COC(=O)CC1(NC(=O)Nc2ccc(Cl)c3ccccc23)CCOC1', 'COC(=O)CC1CC(NC(=O)Nc2cnc(C3CC3)nc2)C12CCC2', 'COC(=O)CC1CCC(C)(C)CN1C(=O)c1ccc2c(n1)CCCC2', 'COC(=O)CC1CCCC(NC(=O)CCc2ccc(Br)c(OC)c2)C1', 'COC(=O)CC1CCCC(NC(=O)N(C)Cc2c(C)nn(C)c2C)C1', 'COC(=O)CC1CCCN1C(=O)C(C)N(C)C(=O)C1CCC(F)CC1', 'COC(=O)CC1CCN(S(=O)(=O)NCc2cc3ccccc3[nH]2)CC1', 'COC(=O)CC1CCN(S(=O)(=O)c2ccc3c(c2)CC(=O)N3C)CC1', 'COC(=O)CC1CN(C(=O)[C@H]2CC=CC[C@H]2NC(=O)CNC(N)=O)C1', 'COC(=O)CCC(=O)N1CC(N(C)C(=O)CC2C=CCC2)C2(CC2)C1', 'COC(=O)CCC(C)NC(=O)CCN(C)C(=O)CC1CC2(CC2)CO1', 'COC(=O)CCC1CCN(C(=O)C(=O)N2CC3(CCN(C)CC3)C2)C1', 'COC(=O)CCCC(=O)N(Cc1c[nH]nn1)CC1(CO)CC(C)(C)C1', 'COC(=O)CCCC(=O)N(Cc1cncc(F)c1)CC1CCCSC1', 'COC(=O)CCCN(C)C(=O)C[C@H]1CCC[C@@H]1NC(=O)C1(CO)CC1', 'COC(=O)CCCONC(=O)[C@@H](C)CNC(=O)CN1CCNC(=O)C1', 'COC(=O)CCC[C@@H](C)NC(=O)N1CCN(c2ccncc2Cl)CC1', 'COC(=O)CCS(=O)(=O)CCCNC(=O)Nc1cc(F)c(O)cc1C', 'COC(=O)CCSc1cccc(NC(=O)Nc2ccc(C)cc2F)c1', 'COC(=O)CC[C@@H](N)CC(=O)N(Cc1ccco1)C1CCN(C)CC1', 'COC(=O)CC[C@H](NC(=O)c1cn(C2CCCCC2)nn1)C(=O)OC', 'COC(=O)CC[C@H]1CC[C@H](C)N(c2ccnc3cc(F)c(C)cc23)C1', 'COC(=O)CC[C@H]1C[C@@H](C(=O)O)N(C(=O)c2ncccc2CSC)C1', 'COC(=O)CCc1ccc(COC(=O)c2c(F)ccc(F)c2N)cc1', 'COC(=O)CCn1c(SCCC2CC2(F)F)nc2ccccc2c1=O', 'COC(=O)CN(C)C(=O)CCCN(C)C(=O)c1cnn2ncccc12', 'COC(=O)CN(C)C(=O)[C@@H]1CCCCN1C(=O)CC1(O)CCCOC1', 'COC(=O)CN(C)S(=O)(=O)NCCN1Cc2ccccc2OCC1=O', 'COC(=O)CN(CC(=O)O)C(=O)C1CC(=O)N(c2cccc(C)c2)C1', 'COC(=O)CNC(=O)C1COCCN(C(=O)CCCC(=O)N(C)C)C1', 'COC(=O)CNC(=O)COC(=O)[C@]1(C(=O)OC)C[C@H]1c1ccccc1', 'COC(=O)COC1CCN(C(=O)N[C@H]2C[C@@H](c3ccccc3)C2)CC1', 'COC(=O)COCC(=O)N1CC(NC(=O)C2CC(CF)C2)C2(CC2)C1', 'COC(=O)COc1ccccc1CN1CC(C)(C)S(=O)(=O)C(C)(C)C1', 'COC(=O)CSCC(=O)N1CC(CNS(=O)(=O)C2(C)CC2)C2(CC2)C1', 'COC(=O)C[C@@H](C)N(C)C(=O)[C@H]1C[C@H](NC(=O)c2cnc(C)n2C)C1', 'COC(=O)C[C@@H]1C[C@H](F)CN1Cc1cc(C(=O)OC)ccc1[N+](=O)[O-]', 'COC(=O)C[C@H](CC(C)C)N(C)C(=O)N1C[C@H]2CC[C@@](C)(C1)C2(C)C', 'COC(=O)C[C@H](CC(C)C)NC(=O)c1ccc2c(c1)C(C)(C)CCO2', 'COC(=O)C[C@H](Cc1ccccc1)NC(=O)CCc1c(N)cnn1C', 'COC(=O)C[C@H]1CC[C@@H](OC(=O)CN2CCc3ccccc3C2=O)C1', 'COC(=O)Cc1cc(C(=O)NCc2cccc(-c3ccco3)c2)no1', 'COC(=O)Cc1ccc(CNC(=O)Nc2cc(F)cc(F)c2OC)s1', 'COC(=O)Cc1ccc(NC(=O)NCC(C)(O)C2CCCC2)cc1F', 'COC(=O)Cc1ccc(O)c(NC(=O)CCC(=O)c2ccc(C)s2)c1', 'COC(=O)Cc1ccc(S(=O)(=O)Nc2cc(Cl)cc(C(=O)O)c2)cc1', 'COC(=O)Cc1cccc(CNC(=O)C(C)(C)NC(=O)C(F)(F)F)c1', 'COC(=O)Cc1ccccc1S(=O)(=O)Nc1ccc(C(=O)O)c(F)c1', 'COC(=O)Cn1c(C)cc(C(=O)NCC2CCc3n[nH]cc3C2)c1C', 'COC(=O)Cn1cc(C2(F)CCN(C(=O)c3cc(C)c[nH]3)CC2)nn1', 'COC(=O)Cn1cc(CNC(=O)NC2COc3c(F)cccc32)nn1', 'COC(=O)Cn1nc(NC(=O)c2oc3c(C)cccc3c2C)cc1C', 'COC(=O)N(C)CC(=O)N1CC[C@H]1C(=O)NCCc1cnc(C)cn1', 'COC(=O)N(C)CC(=O)NCCC1(NC(=O)C2=C(Cl)CC2)CCCC1', 'COC(=O)N(C)Cc1ccc(NC(=O)C(C)(F)c2ccccc2)cc1', 'COC(=O)N1CC(CNC(=O)CN(CC(C)C)C(=O)c2cocn2)C1', 'COC(=O)N1CC(NC(=O)C(=O)Nc2cc(OC)c(Br)c(OC)c2)C1', 'COC(=O)N1CCCC(NC(=O)NCc2c(C)sc3ccccc23)C1', 'COC(=O)N1CCc2cc(NC(=O)N3CCC4(C=CC4)CC3)ccc21', 'COC(=O)NC(C(=O)NCCc1c[nH]c2cc(OC)ccc12)C(C)C', 'COC(=O)NC(C)(C)C(=O)N[C@@H]1CN(C(=O)CCOC(C)C)C[C@H]1C', 'COC(=O)NC1CCN(c2ccnc(NCCCC(C)CO)n2)CC1', 'COC(=O)NCC(=O)NCc1ccsc1C(=O)N[C@@H](C(N)=O)C(C)C', 'COC(=O)NCCC(=O)N1CCC[C@H]1CN(C)C(=O)C1CCCCS1', 'COC(=O)NCCC(=O)NC1CCC(NC(=O)CS(=O)(=O)C2CC2)C1', 'COC(=O)NCCCC(=O)N(Cc1cc(C2CC2)on1)CC1CC1Cl', 'COC(=O)NCCc1ccc(S(=O)(=O)NCc2nnc(CCO)s2)s1', 'COC(=O)N[C@@H](C)C(=O)N(Cc1cccnn1)CC1(CF)CC1(C)C', 'COC(=O)N[C@@H](C)C(=O)N1C[C@@H](C)N(C(=O)C2=C(C)OCC2)[C@@H](C)C1', 'COC(=O)N[C@H]1[C@@H]2CN(C(=O)Nc3cccc4c3OCCCO4)C[C@@H]21', 'COC(=O)Nc1ccc(NC(=O)NCc2cc3cnncc3o2)cc1', 'COC(=O)Nc1ccc(OC(=O)C(C)CSCc2ccccc2)cc1', 'COC(=O)[C@@H](C)CNC(=O)[C@@H]1CC[C@@H]1NC(=O)C1=NN(C)C(=O)CC1', 'COC(=O)[C@@H](C)N(C)C(=O)CC1COCCN1C(=O)[C@@H]1CCC(=O)O1', 'COC(=O)[C@@H](C)N(C)C(=O)[C@@H]1CCC[C@H]1NC(=O)CN1CCSCC1', 'COC(=O)[C@@H](C)NC(=O)[C@H]1CCCCC[C@H]1NC(=O)c1csc(=O)[nH]1', 'COC(=O)[C@@H](C)ONC(=O)[C@@H]1C[C@H](O)CN1C(=O)C1CCC(O)CC1', 'COC(=O)[C@@H](CC1CCCCC1)NC(=O)[C@]1(C)C[C@H]1c1ccccc1', 'COC(=O)[C@@H](Cc1ccccc1)N(C)Cc1cc2ccc(C)cc2[nH]1', 'COC(=O)[C@@H](NC(=O)C(O)CNC(=O)C#CC1(C)CCCO1)[C@@H](C)O', 'COC(=O)[C@@H](O)CNC(=O)C1CCC2(CC2)N1C(=O)C1=CCCSC1', 'COC(=O)[C@@H]1C2C3C[C@H]1C(NC(=O)c1cnc4ccc(OC)nn14)C32', 'COC(=O)[C@@H]1CCC[C@H]1C(=O)NC(C)c1nc(-c2ccccc2)cs1', 'COC(=O)[C@@H]1CN(C(=O)Nc2c(Cl)cc(Cl)c3nsnc23)C[C@H]1OC', 'COC(=O)[C@@H]1C[C@@H](OC)CN1C(=O)CC(C)NC(=O)c1ccccc1', 'COC(=O)[C@@H]1C[C@H](NC(=O)Cn2nc3n(c2=O)CCCCC3)[C@H]2C[C@H]21', 'COC(=O)[C@@H]1C[C@H]1C(=O)NC1CCOCC1C(=O)NC1CC(F)(F)C1', 'COC(=O)[C@@H]1C[C@H]1C(=O)NC[C@H]1CCC[C@H]1C(=O)NC1(C)CCCC1', 'COC(=O)[C@@H]1C[C@H]1C(=O)NC[C@H]1C[C@H]1Nc1nc2cc(F)ccc2s1', 'COC(=O)[C@@H]1C[C@H]1C(=O)N[C@H](C(=O)NC(C)C(O)C(F)F)C(C)(C)C', 'COC(=O)[C@@H]1C[C@H]1CCNC(=O)C1CN(C(=O)CC#N)CC12CCC2', 'COC(=O)[C@@H]1C[C@H]1COC(=O)c1cnc2c(OC)ccc(Cl)c2c1O', 'COC(=O)[C@@H]1C[C@H]2C[C@@H]1C[C@H]2NC(=O)C(=O)NCc1nnc(C)n1C', 'COC(=O)[C@@H]1N(S(=O)(=O)N(C)c2ccc(C#N)cn2)CCSC1(C)C', 'COC(=O)[C@@H]1[C@H]2CC[C@H](C2)[C@@H]1NC(=O)C1(c2ccccc2)CCCC1', 'COC(=O)[C@H](C)NC(=O)CC(NC(=O)Cc1c[nH]nc1C)C(C)(C)C', 'COC(=O)[C@H](C)NC(=O)C[C@@H](CC1CC1)NC(=O)C1(C(C)C)CCC1', 'COC(=O)[C@H](C)NC(=O)[C@H](CCNC(=O)CCc1cccn1C)OC', 'COC(=O)[C@H](C)ONC(=O)CC(NC(=O)[C@@H]1C[C@H]2C=C[C@@H]1O2)C1CC1', 'COC(=O)[C@H](CO)NC(=O)[C@@H]1CCCCN1C(=O)[C@H]1CCO[C@H](C)C1', 'COC(=O)[C@H](Cc1ccc(F)cc1)NC(=O)CC1COC(C)(C)CN1', 'COC(=O)[C@H](Cc1ccncc1)NC(=O)CSCc1cccc(Cl)c1', 'COC(=O)[C@H](NC(=O)C1CC12CCS(=O)(=O)CC2)c1ccc(O)cc1', 'COC(=O)[C@H]1CC=C[C@H](NC(=O)Nc2nc3c(F)c(Cl)ccc3s2)C1', 'COC(=O)[C@H]1CCCCCC[C@H]1NC(=O)CCc1cccc(F)c1Cl', 'COC(=O)[C@H]1CCCN(C(=O)c2cc3c(OC)cc(OC)cc3[nH]2)C1', 'COC(=O)[C@H]1CCC[C@@H]1C(=O)N(C)C(C)CNC(=O)C(F)C(C)(F)F', 'COC(=O)[C@H]1CCC[C@@H]1NC(=O)NCCC1CCCC(OC)(OC)C1', 'COC(=O)[C@H]1CCN(C(=O)C(C)n2c(=O)oc3ccccc32)C[C@H]1F', 'COC(=O)[C@H]1CCN(C(=O)C2CC=CCN2C(=O)CC2CC2(C)C)C1', 'COC(=O)[C@H]1CC[C@@H]1C(=O)N(C)C1(CC(=O)N(C)CCN(C)C)CC1', 'COC(=O)[C@H]1CC[C@H](NC(=O)[C@]2(c3ccc(F)cc3)C[C@H](O)C2)CC1', 'COC(=O)[C@H]1CC[C@](F)(CSc2nnc(-c3ccc(C)cc3)o2)CC1', 'COC(=O)[C@H]1C[C@@H](C(F)(F)F)N(C(=O)c2ccc3c(c2)C(N)CC3)C1', 'COC(=O)[C@H]1C[C@@H](CNC(=O)[C@@H](NC(=O)c2conc2C)C(C)C)C1', 'COC(=O)[C@H]1C[C@@H]1C(=O)N1CCC(C)(C)C(C(=O)NC(C)C(C)C)C1', 'COC(=O)[C@H]1C[C@@H]1c1csc(NC(=O)c2nn(C)c3c2CCNC3)n1', 'COC(=O)[C@H]1C[C@@](CNC(=O)NCCc2cc(Br)ccc2Br)(OC)C1', 'COC(=O)[C@H]1C[C@H](C(=O)N(C)C(CC(F)F)C(=O)NCCN=[N+]=[N-])C1', 'COC(=O)[C@H]1C[C@H](C(=O)N[C@H]2C[C@@H](CC(=O)N3CC(C)(O)CO3)C2)C1', 'COC(=O)[C@H]1C[C@H](CNC(=O)NC2(c3nccc(C(F)F)n3)CC2)C1', 'COC(=O)[C@H]1C[C@H]1C(=O)NC1C2CCC1CN(C(=O)C1CC1(Cl)Cl)C2', 'COC(=O)[C@H]1C[C@H]1C(=O)N[C@@H](C)CC(=O)N(C)CCc1noc(C)n1', 'COC(=O)[C@H]1C[C@H]2C[C@@H]1CN(C(=O)C(=O)NC1CSC3(CNC3)C1)C2', 'COC(=O)[C@H]1Cc2ccc(Cl)cc2CN1CC(=O)Nc1cccnn1', 'COC(=O)[C@H]1[C@@H](c2csc(CCNC(=O)Cc3cnns3)n2)C1(C)C', 'COC(=O)[C@H]1[C@@H]2CN(C(=O)c3cc4cccc(F)c4nc3C)CC[C@@H]21', 'COC(=O)[C@]1(C)CCCN1C(=O)C[C@H](C)NC(=O)C1C[C@H](O)[C@@H](F)C1', 'COC(=O)[C@]1(C)CC[C@H](C(=O)NCCC(O)c2ccc(Cl)cc2)CC1', 'COC(=O)[C@]1(F)C[C@H]1C(=O)N1CCCN(CC(=O)NC(C)(C)C)CC1', 'COC(=O)[C@]1(OC)CCN(C(=S)NCCCCC(F)(F)F)C[C@H]1OC', 'COC(=O)[C@]12CCCC[C@H]1N(S(=O)(=O)Cc1cc(Cl)ccc1F)CC2', 'COC(=O)[C@]12CN(C(=O)N[C@H]3C[C@H](CS(N)(=O)=O)C3)C[C@H]1CCCO2', 'COC(=O)[C@]12CO[C@H](C1)[C@H](NC(=O)c1ccc(-c3nnn[nH]3)cn1)C2', 'COC(=O)c1c(C)cc(C)c(CN2CCC(CNC(C)=O)CC2)c1C', 'COC(=O)c1c(CNC(=O)NNC(=O)c2ccco2)nn2c1CCC2', 'COC(=O)c1c(F)c(C)cc(NCc2cccc3ncccc23)c1F', 'COC(=O)c1c(F)cc(-c2ccc(C(N)=O)c(C(F)(F)F)c2)cc1F', 'COC(=O)c1c(NC(=O)c2nccc(OC)c2O)nn2cccnc12', 'COC(=O)c1c(OS(=O)(=O)c2cc(C(=O)O)sc2C)cc(C)[nH]c1=O', 'COC(=O)c1c(S(=O)(=O)Nc2ccc(Cl)c3nsnc23)c(C)nn1C', 'COC(=O)c1cc(-c2ccccc2CC(=O)C(C)C)cc([N+](=O)[O-])c1', 'COC(=O)c1cc(C#N)ncc1NCc1ccccc1N1CCCC1', 'COC(=O)c1cc(C(=O)N[C@@H](CO)Cc2ccc(C)cc2)ccc1C', 'COC(=O)c1cc(C(C)(C)C)cnc1Nc1cnn(CC2CCC2)c1', 'COC(=O)c1cc(C)c(C)cc1NC(=O)CC(N)Cc1ccccc1', 'COC(=O)c1cc(CN(C)C(=O)c2cc(F)cc3[nH]ncc23)oc1C', 'COC(=O)c1cc(CNC(=O)NCc2cc(Cl)ccc2Cl)ccc1F', 'COC(=O)c1cc(CNC(=O)c2ncnc3nc[nH]c23)c(Br)cc1F', 'COC(=O)c1cc(CNS(=O)(=O)N2CC(N(C)C)C2)n2c1COCC2', 'COC(=O)c1cc(CNc2cc(F)cc(C(=O)OC(C)(C)C)c2)ns1', 'COC(=O)c1cc(CNc2ccc(N3CCOCC3)cc2C)cn1C', 'COC(=O)c1cc(CSc2nc(-c3ccccc3)c(C)[nH]2)ccc1C', 'COC(=O)c1cc(Cl)c(F)cc1S(=O)(=O)NCCCCOC(F)(F)F', 'COC(=O)c1cc(F)cc(C2(NC(=O)C(N)Cc3ccc[nH]3)CC2)c1', 'COC(=O)c1cc(NC(=O)C(C)c2ccccc2Cl)cc([N+](=O)[O-])c1', 'COC(=O)c1cc(NC(=O)COc2ccc3c(c2)CCCN3)sc1C', 'COC(=O)c1cc(NC(=O)N(C)CC(C)S(C)(=O)=O)cc([N+](=O)[O-])c1', 'COC(=O)c1cc(NC(=O)N2CCC[C@H]2c2nc(C(C)C)co2)cs1', 'COC(=O)c1cc(NC(=O)N[C@H](C)c2cc(F)c(F)c(F)c2)nn1C', 'COC(=O)c1cc(NC(=O)c2cnc(N3CCN(C)CC3)s2)c(C)s1', 'COC(=O)c1cc(NCc2c(F)cc(Cl)cc2F)cc(S(C)(=O)=O)c1', 'COC(=O)c1cc(NCc2c[nH]nc2-c2cccs2)cc(C(F)F)c1', 'COC(=O)c1cc(OC)cc(C)c1NCc1ccc(C)cc1[N+](=O)[O-]', 'COC(=O)c1cc(S(=O)(=O)Nc2ccccc2CS(C)(=O)=O)c(Br)s1', 'COC(=O)c1cc(S(=O)(=O)Oc2ccc(Cl)cc2C(C)=O)ccc1C', 'COC(=O)c1cc([N+](=O)[O-])c(N)cc1NCc1ccc(Cl)c(Cl)c1C', 'COC(=O)c1cc([N+](=O)[O-])ccc1NCCS(=O)(=O)c1ccccn1', 'COC(=O)c1cc2c(NCc3ccc(C4CC4)c(F)c3)ncnc2s1', 'COC(=O)c1cc2c(cc1C)N(C(=O)c1nn(C)cc1CN)CCC2', 'COC(=O)c1cc2c(ccn2Cc2nc3c(s2)CC(C)CC3)cc1F', 'COC(=O)c1cc2cccc(CNc3ccc(OC)nc3OC)c2s1', 'COC(=O)c1cc2ccccc2n1CC(=O)N(C)c1cccnc1N', 'COC(=O)c1cc2n(n1)CCN(S(=O)(=O)c1cnc(OC)cc1C)C2', 'COC(=O)c1ccc(Br)cc1OS(=O)(=O)Cc1cc(Cl)ccc1OC', 'COC(=O)c1ccc(C#N)cc1COC(=O)c1c(F)ccc(F)c1N', 'COC(=O)c1ccc(C(=O)N(CC(C)(C)C)c2ccccc2)cc1Cl', 'COC(=O)c1ccc(C(=O)N2Cc3cc(C)ccc3CC2(C)C)cc1', 'COC(=O)c1ccc(C(=O)OCC(=O)[C@H]2C[C@@H]2c2ccsc2)c(N)n1', 'COC(=O)c1ccc(C(C)Nc2nc(N(C)C)nc(N(C)C)n2)nc1', 'COC(=O)c1ccc(C(NC2CC23CC(O)C3)c2nnnn2C)nn1', 'COC(=O)c1ccc(C)c(NC(=O)CN(C)CCc2cnn(C)c2)c1', 'COC(=O)c1ccc(C)c2c1CCN(C(=O)N1CCOCC1(C)C)C2', 'COC(=O)c1ccc(CC(=O)N2CC(CN(C)C)CC2(C)C)cc1F', 'COC(=O)c1ccc(CC(CO)NC(=O)NCC2CNC(=O)C2)cc1', 'COC(=O)c1ccc(CCNC(=O)NC2CN(C)C(C)(C)C2)c(Cl)c1', 'COC(=O)c1ccc(CN(C)C(=O)c2ccc3cccnc3c2)nc1', 'COC(=O)c1ccc(CNC(=O)c2ccsc2C#N)c2ccccc12', 'COC(=O)c1ccc(CNc2c(F)cc(F)c(F)c2C(=O)OC)cc1', 'COC(=O)c1ccc(COC(=O)c2ccc3c(ccn3C)c2)cc1C', 'COC(=O)c1ccc(C[C@@H](N)C(=O)Nc2ccn3ncnc3c2)cc1', 'COC(=O)c1ccc(Cl)c(C(=O)N2CC(C)(C)OC3(CCCC3)C2)c1', 'COC(=O)c1ccc(Cn2cc(-c3cc(OC)ccc3F)nn2)cn1', 'COC(=O)c1ccc(NC(=O)C(=O)NCc2ccc(Br)cc2)cc1Cl', 'COC(=O)c1ccc(NC(=O)C2(CC(F)F)CCNCC2)c(C)c1Cl', 'COC(=O)c1ccc(NC(=O)CC(N)CC2CCCC2)c(N(C)C)c1', 'COC(=O)c1ccc(NC(=O)N2CC(C)CCC2C(=O)OC)c(C)c1', 'COC(=O)c1ccc(NC(=O)N2C[C@H]3C[C@@H]2C[C@@H]3OC)c(OC)c1F', 'COC(=O)c1ccc(NC(=O)c2csc3nnsc23)cc1C(F)(F)F', 'COC(=O)c1ccc(NCC(OC)C2CCCC2)c(F)c1C(=O)OC', 'COC(=O)c1ccc(OC)c(NC(=O)NC(CO)Cc2ccoc2)c1', 'COC(=O)c1ccc([C@H]2C[C@H](NC(=O)c3cccc(CF)c3)C2)cc1', 'COC(=O)c1ccc([N+](=O)[O-])c(CN2CCC3(CC2)COC(N)=N3)c1', 'COC(=O)c1ccc([N+](=O)[O-])c(N2C[C@H](CN)C[C@H](C(C)(C)C)C2)c1', 'COC(=O)c1ccc2[nH]c(NC(=O)c3c(O)ccc(F)c3F)nc2c1', 'COC(=O)c1ccc2c(NCCCCn3cc(Br)cn3)ccnc2c1', 'COC(=O)c1ccc2c(c1)CCC2NC(=O)NNc1ncccc1C', 'COC(=O)c1ccc2c(c1)CCN(S(=O)(=O)CCCCS(C)(=O)=O)C2', 'COC(=O)c1ccc2c(c1)OCCN(C(=O)NCc1ocnc1C)C2', 'COC(=O)c1ccc2n1CCN(Cc1cc(O)nc3ccccc13)C2', 'COC(=O)c1ccc2nc(CNC(=O)C[C@@H]3CN[C@H](C)CO3)sc2c1', 'COC(=O)c1ccc2nc(N3CCC(O)(C4(C#N)CC4)CC3)sc2c1', 'COC(=O)c1cccc(C(F)(F)C(=O)N(C2CC2)[C@@H]2CCC[C@H]2O)c1', 'COC(=O)c1cccc(CC(=O)NCCOc2ccccc2O)c1F', 'COC(=O)c1cccc(NNC(=O)C[C@H]2CCC[C@@H]2C(=O)OC)c1C', 'COC(=O)c1cccc([C@@H](C)NC(=O)c2cnc3nc(C)oc3c2)c1', 'COC(=O)c1cccc([C@H](C)NC(=O)Nc2ncn(CC(C)C)n2)c1', 'COC(=O)c1cccc([N+](=O)[O-])c1N1Cc2ccccc2NCC1C', 'COC(=O)c1cccc2c(NC(=O)N3C[C@@H]4[C@@H](CO)[C@@H]4C3)cccc12', 'COC(=O)c1cccc2nc(N(C)Cc3cccc4ccoc34)oc12', 'COC(=O)c1ccccc1CCCOC(=O)CC1(n2cccn2)CC1', 'COC(=O)c1ccn(C2CCN(C(=O)CCc3ncccn3)CC2)n1', 'COC(=O)c1ccnc(CNC(=O)c2ccc3c(C#N)c[nH]c3c2)c1', 'COC(=O)c1ccnc(OC(=O)c2ccc(OCC(F)(F)F)cn2)c1', 'COC(=O)c1ccncc1NC(=O)c1ccc(-c2cnnn2C)cc1', 'COC(=O)c1ccncc1S(=O)(=O)Nc1cc(O)cc(C(F)(F)F)c1', 'COC(=O)c1ccoc1CNC(=O)NCC(C)(C)c1ncccc1F', 'COC(=O)c1cn(C2CN(C(=O)c3cn(C)c4ncccc34)C2)nn1', 'COC(=O)c1cn(CC2CCCN2C(=O)C(C)(O)CC(F)(F)F)nn1', 'COC(=O)c1cn(CCNC(=O)NC(C)(C)C(C)(C)C(=O)OC)nn1', 'COC(=O)c1cnc(C(=O)Nc2cccc(O)c2C(=O)OC)c(C)c1', 'COC(=O)c1cnc(C)cc1NC[C@H]1C[C@H](c2nncn2C)C[C@H]1O', 'COC(=O)c1cncc(CN(CCSC)Cc2ccc(C)c(C)c2)c1', 'COC(=O)c1cnn2c1CN(CC(Cc1ccc(F)cc1)OC)CC2', 'COC(=O)c1coc(C(C(=O)NC2CCCC2)N(C)C(C)C(C)C)c1', 'COC(=O)c1coc(C=CC(=O)N(CCC(C)(C)O)C2CCCC2)c1', 'COC(=O)c1cscc1C(=O)COC(=O)C(O)c1ccc(F)cc1C', 'COC(=O)c1cscc1NC(=S)Nc1c2c(cc3c1CCC3)CCC2', 'COC(=O)c1n[nH]c2c1CCN(C(=O)c1cc3c(Cl)cccc3[nH]1)C2', 'COC(=O)c1nc(C)c(CN2CC(CN(C)C)Oc3ccccc32)s1', 'COC(=O)c1nc(C2CCN(C(=O)c3ncc(N)cn3)CC2)oc1C', 'COC(=O)c1nc(N2CCC(OC)CC2C(=O)OC)c2sccc2n1', 'COC(=O)c1nc2ccc(-c3ccc4nc(CN)sc4c3)cn2c1F', 'COC(=O)c1ncc(C(=O)NC(C)(C)c2cc(C(=O)OC)on2)cn1', 'COC(=O)c1ncc(C(=O)Nc2ccc(C(F)(F)F)cc2Cl)cc1Cl', 'COC(=O)c1ncc(COC(=O)c2ccc(Cl)cc2N=[N+]=[N-])cc1F', 'COC(=O)c1ncc(F)c(N2CC(CNC(=O)CCCC3CC3)C2)n1', 'COC(=O)c1nccc2c1CCN(C(=O)[C@H]1CCCC[C@@H]1C(F)F)C2', 'COC(=O)c1ncn(CCNC(=O)NCc2cc(C3CCC3)n[nH]2)n1', 'COC(=O)c1nn(C)c(Br)c1NC(=O)N1CCC2(CCS(=O)(=O)C2)C1', 'COC(=O)c1nn(C)cc1S(=O)(=O)N(C)CC1(OC(C)C)CCOC1', 'COC(=O)c1sc(CCCNS(=O)(=O)c2cc(C)cc(Br)c2)nc1C', 'COC(=O)c1sc(NC(=O)c2cc(C3CC3)ccc2F)cc1C(C)C', 'COC(=O)c1sc(NC(C)CN(C)C(=O)C(C)n2ccnc2)nc1Cl', 'COC(=O)c1sccc1NC(=O)COC(=O)C(F)c1ccc(C)cc1', 'COC(C(=O)N(C)CCCN(C)C(=O)[C@H]1CC1(F)F)c1cccnc1', 'COC(C(=O)N1CCSCC1CO)C1CN(C(=O)CN2CCCC2)C1', 'COC(C(=O)NC(C)(C)CCCNC(=O)C1C=CCCC1)C1CCC1', 'COC(C(=O)NCC1CCCN1C(=O)c1cc(N)c(Cl)cn1)C1CC1', 'COC(C(=O)NCCC(Cl)Cl)C1CN(C(=O)c2ccc([N+](=O)[O-])[nH]2)C1', 'COC(C(=O)NCCC1(C)N=N1)C1CN(C(=O)c2ncccc2F)C1', 'COC(C(=O)NCCCCC(=O)NCC1(O)CCN(C)CC1)C(C)C', 'COC(C(=O)NCC[C@H]1CCCO1)C1CN(C(=O)Cn2ncnn2)C1', 'COC(C(=O)NC[C@@H](C)Nc1nccc(-c2ccsc2)n1)C1(C)CC1', 'COC(C(=O)NCc1ncnn1C(C)C)C1CN(C(=O)C(C)C#N)C1', 'COC(C(=O)NCc1nncn1C(C)C)c1cccc(C(F)(F)F)c1', 'COC(C(=O)NCc1nncn1C1CC1)C1CN(C(=O)C(C)C#N)C1', 'COC(C(=O)N[C@H]1C[C@H]2CC[C@@H]([C@@H]1F)N2C(=O)C1(C)COC1)C(C)C', 'COC(C(=O)Nc1ccc(C)c(Cl)c1)C(=O)N1CC(=O)N(C)C[C@H]1C', 'COC(C(C)C)C(O)C(=O)N(C)CC(=O)N(C)C1CNC(=O)C12CC2', 'COC(C)(C(=O)NCC(C)n1cc(-c2ccn(C)n2)nn1)C1(C)CC1', 'COC(C)(C)C#CC(=O)OCc1cc(=O)n2c(n1)sc1ccccc12', 'COC(C)(C)C(=O)N(CCOCC(F)F)Cc1c2c(nn1C)CCC2', 'COC(C)(C)C(=O)N[C@H]1C=C[C@@H](C(=O)NCC2(CC(C)C)CCC2)C1', 'COC(C)(C)C(=O)N[C@H]1CC[C@H](C(=O)NC(C)c2cn(C)cn2)CC1', 'COC(C)(C)C(C)NC(=O)C1(CNC(=O)CN2CCC(F)CC2)CC1', 'COC(C)(C)C1(C(=O)N(Cc2cc(C)ns2)C[C@@H]2CC=CCC2)CC1', 'COC(C)(C)C1CCN(C(=O)[C@@H]2[C@H]3C[C@]2(c2cccnc2)CO3)CC1', 'COC(C)(C)CC(=O)N(C)CC(C)C(=O)NCCc1nccnc1C', 'COC(C)(C)CC(=O)N1CCCC1CCC(=O)NCC(O)C(C)(C)O', 'COC(C)(C)CC(=O)NC1(C(=O)N(C)CCN(C)C(C)=O)CC(F)C1', 'COC(C)(C)CC(=O)NC1(C)CCCN(C(=O)c2cnnc(C)c2)C1', 'COC(C)(C)CCCN(Cc1cnsc1)C(=O)C1CCCC(C)(C)C1', 'COC(C)(C)CCN(CC1CCCCC1(F)F)C(=O)C(C)SC(C)C', 'COC(C)(C)CCN(CCC(F)=C(F)F)C(=O)c1nnc(N)cc1C', 'COC(C)(C)CCNC(=O)C(C)(NC(=O)c1sncc1C)C1CCC1', 'COC(C)(C)CCNC(=O)CC1(N(C)C(=O)COc2ccsn2)CC1', 'COC(C)(C)CCN[C@H]1Cc2ccccc2[C@@H]1NC(=O)OC(C)(C)C', 'COC(C)(C)CNC(=O)c1sccc1CNC(=O)C(C)(F)C(C)(C)F', 'COC(C)(C)Cc1cn(-c2ccc(N3CCNC(=O)C3)c(Cl)c2)nn1', 'COC(C)(C)c1ccc(C(=O)NCc2csc(-c3ccoc3)n2)cc1', 'COC(C)(C)c1cn(Cc2cccc(C(=O)N3CCSCC3)c2)nn1', 'COC(C)(CN(CC(C(C)C)C(C)C)C(=O)[C@@H]1CCN(C)C1)C1CC1', 'COC(C)(CNC(=O)C(C)=C1CC1)CNC(=O)C(C)C1CCC(=O)N1', 'COC(C)(CNC(=O)C1CCOC1(C)C)CNC(=O)C1(F)CC=CC1', 'COC(C)(CNC(=O)c1ccn(C)c(=O)c1)CNC(=O)C1(C)CCC1', 'COC(C)(CNC(=O)c1cnn(-c2ccccc2Cl)c1)CC1CCC1', 'COC(C)(CO)C(=O)N1C[C@@H]2[C@@H](CN(C)C(=O)c3csc(Cl)c3)[C@@H]2C1', 'COC(C)(CO)C(=O)NC[C@H]1CC[C@H]1NC(=O)c1nc(C)ncc1Cl', 'COC(C)(CO)CNC(=O)C(F)(CNC(=O)[C@H]1[C@@H]2CCC[C@@H]21)C(C)C', 'COC(C)C(=O)N(CCSC(C)(C)C)Cc1ccc2c(c1)OCC2C', 'COC(C)C(=O)N1CC[C@H](F)C[C@@H]1C(=O)N1C2CCC1CC1(C2)N=N1', 'COC(C)C1CCN(C(=O)[C@H](CC(C)C)NC(=O)[C@H]2CCOC2)CC1', 'COC(C)CCC(=O)N1CCCN(C(=O)c2c(C#N)ncn2C)CC1', 'COC(C)CCC(=O)NCC1(F)CN(C(=O)c2ccc([N+](=O)[O-])s2)C1', 'COC(C)CCCN(Cc1ccc(F)c(F)c1)C(=O)c1snnc1C', 'COC(C)CCNC(=O)[C@@H]1CC[C@H](CNC(=O)C2CC(C)(C)CO2)C1', 'COC(C)CCNC(=O)[C@@H]1[C@H]2C[C@H](O)[C@H](C2)N1C(=O)c1ncoc1C', 'COC(C)CN(C(=O)NCCCc1nc(-c2ccoc2)no1)C(C)C', 'COC(C)CN(C(=O)c1ccc(NN2C(=O)CCC2=O)cc1)C(C)C', 'COC(C)CNc1ccc(S(=O)(=O)NCC2(P(C)(C)=O)CC2)c(Cl)c1', 'COC(C)CON=C(N)c1ccc(Cn2cnc3ccccc32)cc1', 'COC(C1CCC1)C(C(=O)NC1COC1)N1CCN(C)C(=O)C1(C)C', 'COC(C1CCCCC1)C(C(=O)NC1CC1)N1CC(C)(C)C12CCC2', 'COC(CC(C)(C)C)C(=O)NCCC1CN(C(=O)c2cc(C)n[nH]2)C1', 'COC(CC(C)C)C(=O)N1CCC(C)(C(=O)N[C@H]2[C@@H]3CCC[C@@H]32)CC1', 'COC(CC(C)C)CN(CCOC1(C)CCC1)C(=O)C1(O)CC(O)C1', 'COC(CC(C)C)CN(C[C@@H]1CCC[C@H]1CF)C(=O)c1ocnc1C', 'COC(CC1CC1)C(=O)N(CCC(=O)N[C@@H]1CCCC[C@H]1O)C(C)C', 'COC(CC1CCC1)C(=O)N1CCCCC1C(=O)N[C@@H]1CCC[C@H]1O', 'COC(CCCC(=O)N1CCC(CC(=O)NCC(F)F)C1(C)C)OC', 'COC(CCCC(=O)N1CCCCC1C(=O)N[C@H]1C[C@@H](CO)C1)OC', 'COC(CCNC(=O)[C@@H]1CCO[C@H](C)C1)CNC(=O)c1sccc1C', 'COC(CN(C)C(=O)[C@@H]1[C@H]2CC(=O)[C@H](C2)N1C(=O)OC(C)(C)C)OC', 'COC(CN(C/C=C/c1ccco1)C(=O)C1(F)CCOCC1)C1CC1', 'COC(CN(CC1C(C)(C)C1(C)C)C(=O)C1CCC(=O)N1C)C1CC1', 'COC(CN(CC1CCCOC1(C)C)C(=O)c1cnc(C)cn1)OC', 'COC(CN(CCCO)C(=O)c1cccc(-c2nn[nH]n2)c1C)OC', 'COC(CN(Cc1ccc(F)c(Cl)c1)C(=O)CSC1CC1)C(F)(F)F', 'COC(CN(Cc1ccc(F)cn1)C(=O)CC(C)C(F)F)C1CCC1', 'COC(CN(Cc1cn2ccsc2n1)C(=O)c1cocc1C)C(C)C', 'COC(CN(Cc1cnc(N(C)C)s1)Cc1ccccc1C)C1CC1', 'COC(CN(Cc1ncc(Cl)n1C)C(=O)[C@@H](N=[N+]=[N-])C(C)C)C1CC1', 'COC(CNC(=O)C(C)Cn1ccnc1)CC(=O)NCC1(C)CCC1', 'COC(CNC(=O)C(F)C1CCCC1)CC(=O)N1CCC(SC)CC1', 'COC(CNC(=O)C1CCN(C(=O)CC(O)C(C)C)C12CC2)CSC', 'COC(CNC(=O)CCn1cnc2sccc2c1=O)C1CCCOC1', 'COC(CNC(=O)CSCCC#N)CNC(=O)[C@]12CCC[C@H]1CCC2', 'COC(CNC(=O)C[C@H]1C[C@H](OC)C1)CC(=O)NC(C)(C)C(C)(C)O', 'COC(CNC(=O)N1CCN(CC(C)O)CC1)Cc1ccc(F)cc1', 'COC(CNC(=O)NC(c1ccc(F)cc1)C(C)C)c1ccccc1', 'COC(CNC(=O)NCC(O)c1ccc(C)o1)c1cc(C)cc(C)c1', 'COC(CNC(=O)[C@@H](O)c1ccccc1)CNC(=O)[C@H]1C[C@H](OC)C1', 'COC(CNC(=O)c1cc(C)ccc1N)CNC(=O)c1nocc1C', 'COC(CNC(=O)c1cc(C)ncn1)CC(=O)N1C[C@@H]2C[C@H]1C[C@H]2O', 'COC(CNC(=O)c1cc(CNC(=O)c2cnn(C)c2)n[nH]1)C(C)C', 'COC(CNC(=O)c1cc(F)c[nH]1)CNC(=O)c1sccc1CC#N', 'COC(CNC(=O)c1ccc[nH]1)CC(=O)N1CC(c2ccncn2)C1', 'COC(CNC(=O)c1nnc(C)s1)Cn1cc(C2CCCOC2)nn1', 'COC(CNC1(c2nnnn2CCC2(C)CC2)CC(Br)C1)C1CCC1', 'COC(CNc1cc(NCCC2OCCC2(C)C)nc(C)n1)C(C)C', 'COC(CO)C(=O)N1CC(O)(CN(C)C(=O)CCc2cn(C)cn2)C1', 'COC(CO)C(=O)N1CCC(CNC(=O)C(C)(C)C(C)(C)O)C(O)C1', 'COC(CO)C(=O)N1CCCCC(CNC(=O)c2cncc(C)c2)C1', 'COC(CO)C(=O)N1CCCN(C(=O)CCc2nccn2C)CC1C', 'COC(CO)C(=O)NCC1(C(=O)N(C)Cc2ccncc2)CCCC1', 'COC(CO)C(=O)NCC1(NC(=O)C2CCc3snnc32)CCCC1', 'COC(CO)C(=O)NCC1CCN(C(=O)[C@H]2C[C@@H]2C(C)(C)C)C1(C)C', 'COC(CO)C(=O)NC[C@H]1CC[C@H]1C(=O)Nc1ccc(C2CC2)cc1', 'COC(CO)C(=O)NCc1csc(C(=O)NCc2cc(C)c(C)s2)c1', 'COC(CO)CNC(=O)C(CC(C)(C)C)NC(=O)Cn1ccc(C)n1', 'COC(CO)CNC(=O)[C@H]1CCN(C(=O)C(C)N2CCCC2)C[C@H]1C', 'COC(CSC)C(=O)N(Cc1c(C)cnn1C)CC1(C)CC=CCC1', 'COC(CSC)C(=O)N1CCC(C(C)C(=O)N2CCC[C@@H]2CF)CC1', 'COC(CSC)C(=O)NC(C)(C)C/C=C/C(=O)NC1CCC(CO)C1', 'COC(CSC)C(=O)NC1CC(C(C)NC(=O)C(C)(C)OC(C)C)C1', 'COC(CSC)C(=O)N[C@H](CCSC)C(=O)N1CCC(C)(C2CC2)C1', 'COC(CSC)CN(Cc1cnn(CC(C)C)c1)C(=O)c1c[nH]nn1', 'COC(OC)C(=O)N(C)C(C)(C)CC(=O)NCc1cnc2n1CCC2', 'COC(OC)C(=O)N1CCC(C(=O)N2Cc3c[nH]nc3C(C)C2)CC1', 'COC(OC)C(=O)NCCC1CCN(C(=O)c2nc(Cl)oc2C)CC1', 'COC(OC)c1cccnc1CN1CCC2(CCN(C)C2)C(F)(F)C1', 'COC(c1ccc(Cl)cc1)C(C)NS(=O)(=O)N1CCN(C(C)=O)CC1', 'COC/C(C)=C/C(=O)N(C)C[C@H]1C[C@H](F)CN1C(=O)C1CCCOC1', 'COC/C(C)=C/C(=O)N1C2CC1CN(C(=O)CCC1CCCCO1)C2', 'COC/C(C)=C/C(=O)N1CC(N(C)C(=O)c2cnc(OC)nc2C)C1', 'COC/C(C)=C/C(=O)N1CCC[C@H](CCNC(=O)[C@H]2C[C@H](SC)C2)C1', 'COC1(C(=O)N(C)CCNC(=O)c2ccc([N+](=O)[O-])n2C)CCSC1', 'COC1(C(=O)N(C)CCSC)CCN(C(=O)c2cc(C)ncc2C)C1', 'COC1(C(=O)N(CCC2CCC(C)O2)Cc2ncco2)CCCCC1', 'COC1(C(=O)N(CCSCC(C)C)CC2CC3C=CC2C3)CCCC1', 'COC1(C(=O)N2CCC(C(=O)N3CCC4(CCC4)C3)C2)CCCCC1', 'COC1(C(=O)N2CCC(F)(CO)C2)CCN(C(=O)c2cc(C)cs2)C1', 'COC1(C(=O)N2CCC(n3cc(CNC(N)=O)nn3)CC2)CCOC1', 'COC1(C(=O)N2CC[C@H](C(=O)N3CCOCC3)[C@H](C)C2)CCCCC1', 'COC1(C(=O)N2C[C@@H](C(=O)N[C@H]3CCC[C@H]3F)O[C@@H](C)C2)CCOC1', 'COC1(C(=O)NC2C=CC(C)(C)CC2)CCN(C(=O)C(C)N=[N+]=[N-])C1', 'COC1(C(=O)NCC2(C(=O)NC(C)c3ccnc(C)n3)CC2)CCC1', 'COC1(C(=O)NCCCC(C)NC(=O)Cn2cnnc2)CCOCC1', 'COC1(C(=O)NCCCCCN(C)C)CCN(C(=O)C2SCCS2)C1', 'COC1(C(=O)NCCSCC(=O)N2CC(S(C)(=N)=O)C2)CCCCC1', 'COC1(C(=O)NCc2cc(C(=O)NOCCC(C)C)on2)CCSC1', 'COC1(C(=O)NCc2cc3n(n2)CCN(C)C3=O)CC2(CCOC2)C1', 'COC1(C(=O)NCc2sccc2C)CCN(C(=O)C2=NOC(C)C2)C1', 'COC1(C(=O)N[C@@H](CC(=O)N2C[C@H]3CSC[C@H]3C2)C2CC2)CCCC1', 'COC1(C(=O)N[C@H]2COC[C@H]2F)CCN(C(=O)C[C@@H]2CCCN2C)C1', 'COC1(C(C)NC(=O)c2cc(=O)[nH]c3ccc([N+](=O)[O-])cc23)CCC1', 'COC1(C(F)(F)F)CC(NC(=O)c2cc3cn[nH]c3cn2)(C(=O)O)C1', 'COC1(C(F)(F)F)CC2(C1)NC(=O)N(C1CC3(CNC(=O)C3)C1)C2=O', 'COC1(C(F)(F)F)CC2(CC(C(=O)N(C)Cc3nnc(CO)s3)C2)C1', 'COC1(C(F)(F)F)CC2(CC(CNC(=O)c3ccccc3SC)C2)C1', 'COC1(C(F)(F)F)CC2(CN(C3=NC[C@H](Cc4ccccc4)N3)C2)C1', 'COC1(C(F)F)CCN(CCc2nc(-c3ccc(Cl)cc3)no2)CC1', 'COC1(C(N)=O)CN(C(=O)C(C)(C)CNC(=O)CCc2nncs2)C1', 'COC1(C(N)=O)CN(C(=O)CC(NC(=O)c2cnsn2)C(C)(C)C)C1', 'COC1(C)CC(CN(Cc2cc(Cl)sc2C)C(=O)[C@H]2C[C@H]2C(N)=O)C1', 'COC1(C)CN(C(=O)C(C)(C)C2CCN(C(=O)COCC(F)F)C2)C1', 'COC1(C)CN(CC(=O)NCC(C)CNC(=O)C2(C(C)C)COC2)C1', 'COC1(CC(=O)NCCC(Cl)Cl)CN(C(=O)c2cc(=O)[nH]c(C)n2)C1', 'COC1(CC(=O)NCc2cccnc2)CN(C(=O)C=CC2CCC2)C1', 'COC1(CC(=O)NCc2cnnc(C)c2C)CN(C(=O)CC(C)C)C1', 'COC1(CCN(Cc2c(Cl)n[nH]c2C)C(=O)C(O)C2CCCC2)CC1', 'COC1(CCN(Cc2ccc(CO)cc2)C(=O)c2[nH]ncc2Cl)CC1', 'COC1(CCN(Cc2ccc(F)cc2F)C(=O)CCC(F)(F)F)CC1', 'COC1(CCNC(=O)C(SC)SC)CN(C(=O)Cc2csc(C)c2)C1', 'COC1(CCNC(=O)[C@@H]2CC3(CC3)CN2C)CN(C(=O)CCSC)C1', 'COC1(CN(C)c2ccncc2S(=O)(=O)N2CCC(CO)C2)CCC1', 'COC1(CN(Cc2ccc(Cl)c(F)c2)C(=O)c2ccoc2Cl)CCC1', 'COC1(CN(Cc2cncn2C)C(=O)C(C)(C)C(F)(F)F)CCCC1', 'COC1(CNC(=O)/C=C/C(C)C)CC(CNc2nnc(C(F)F)s2)C1', 'COC1(CNC(=O)C(=O)Nc2cccc(Cl)c2F)CCC(C)(C)CC1', 'COC1(CNC(=O)C(O)c2ccnn2C)CCN(C(=O)CC(C)F)C1', 'COC1(CNC(=O)C2CCCN(C(=O)c3ccnc(N)n3)C2)CCC1', 'COC1(CNC(=O)C2CCN(C)CC2)CCN(C(=O)C(C)(C)CF)C1', 'COC1(CNC(=O)CCCC2OCCO2)CCN(C(=O)C2(F)CC2)C1', 'COC1(CNC(=O)NCCOCC(=O)OCc2ccccc2)COC1', 'COC1(CNC(=O)[C@H]2CC[C@H](C)CC2)CCN(C(=O)CCS(C)=O)C1', 'COC1(CNC(=O)c2ccc(CNC(=O)C(C)(C)C)cc2)CCCC1', 'COC1(CNc2nc(N3CCC(O)CC3)nc3c2CSC3)CCOC1', 'COC1(CO)CN(C(=O)C2CCN(C(=O)Cc3ccn(C)c3)CC2)C1', 'COC1(OC)CC(C)(C#CC(=O)N2CCCCC2Cc2nn[nH]n2)C1', 'COC1(OC)CC(C)(CNC(=O)N(C)Cc2ccc(C(C)C)cc2)C1', 'COC1(OC)CC(C)(NC(=O)c2cc(C)ccc2N2CCCC2=O)C1', 'COC1(OC)CCC1C(=O)N(CCc1ccns1)Cc1ncc(C)o1', 'COC1(OC)CCCN(C(=O)C(C)CS(=O)(=O)c2ccc(F)cc2)C1', 'COC1(c2cccc(Br)c2)CN(C(=O)C2CC(N)c3ccccc32)C1', 'COC1(c2nc(CC(F)(F)F)no2)CCN(C(=O)C2CC23CC3)CC1', 'COC12CCC(C(=O)Nc3ccc(CN(C)C4CC4)cc3)(CC1)CC2', 'COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1', 'COC1C(C)(C)C(NC(=O)NCCc2ccc(Cl)c(C)c2Cl)C1(C)C', 'COC1C(NC(=O)C(C)(C)CN(C)C(=O)CSC(F)(F)F)CC1(C)C', 'COC1C(NC(=O)C(O)CNC(=O)c2cnc(C)nc2)CC12CCC2', 'COC1C(Nc2nc(C)cc(NCCCCC3CC3)n2)CC12CCC2', 'COC1C=CCN(C(=O)C2(F)CCN(C(=O)Cc3cncn3C)C2)C1', 'COC1C=CCN(C(=O)CCOCCCNC(=O)C2CC3(CC3)C2)C1', 'COC1CC(C(=O)N(C)C2CCN(C(=O)CCC(C)(C)[N+](=O)[O-])C2)C1', 'COC1CC(C(=O)N(C)CCN2CCN(C(=O)[C@@H](C)N(C)C)CC2)C1', 'COC1CC(C(=O)NC(C)C2CCN(C(=O)C3(C)CC=CC3)CC2)C1', 'COC1CC(C(=O)NC2CCC(Nc3nccc(C(F)(F)F)n3)C2)C1', 'COC1CC(C(=O)NC[C@@H]2C[C@@H](O)CN2C(=O)CCOC2COC2)C1', 'COC1CC(CC(=O)N(Cc2cnc(C)s2)CC2CCOCC2C)C1', 'COC1CC(CC(=O)N2C[C@H](C)[C@H](NC(=O)CCCC(F)(F)F)C2)C1', 'COC1CC(CC(=O)NCc2ccc(N3CCC(O)CC3)c(F)c2)C1', 'COC1CC(CCC(=O)N(C)CC(C)C(=O)N2C[C@H](F)C[C@H](F)C2)C1', 'COC1CC(CCN(Cc2cscc2C)C(=O)C[C@@H]2CC[C@H](O)C2)C1', 'COC1CC(CN(C[C@H]2[C@@H]3COC[C@@H]32)C(=O)[C@H]2CCO[C@H]2C)C1(C)C', 'COC1CC(CNC(=O)C2=CCCN(C(=O)C=C3CCC3)C2)C1(C)C', 'COC1CC(CNC(=O)CN2CC(C)(C)C2)(NC(=O)C=C=C(C)C)C1', 'COC1CC(CO)(NC(=O)[C@@H]2CC[C@H](CNC(=O)C3CC(C)C3)C2)C1', 'COC1CC(NC(=O)CC2CN(C(=O)c3sccc3Cl)C(C)(C)C2)C1', 'COC1CC(NC(=O)C[C@H]2C[C@H](NC(=O)CCCCC(C)(C)C)C2)C1', 'COC1CC2(C1)CN(C(=O)c1nn(-c3ccc(F)cc3)ccc1=O)C2', 'COC1CC2(CC(CNC(=O)NCCc3cc4cccnc4[nH]3)C2)C1', 'COC1CC2(CC(NC(=O)CSCCNC(=O)c3ccc(C)s3)C2)C1', 'COC1CC2(CCN(C(=O)[C@@H](NC(=O)C(O)CN(C)C)[C@@H](C)O)C2)C1', 'COC1CCC(C(=O)N2C[C@H](C)C[C@H]2C(=O)N2CCSC(C)C2)CC1', 'COC1CCC(NC(=O)NC2(CO)CCC(C)c3ccccc32)CC1', 'COC1CCC(NC(=O)[C@@H]2CC[C@H](C)N2C(=O)c2nonc2N)CC1', 'COC1CCC1N(C)CC(=O)NCc1cccc(OCC(F)(F)F)c1', 'COC1CCC2(C(=O)N3CC[C@@H]3C(=O)N3C[C@@H](C)N(C)[C@@H](C)C3)CC12', 'COC1CCC2(C(=O)NC[C@H]3C[C@H]3CC(=O)N(C)[C@H]3CC[C@H]3O)CC12', 'COC1CCC2(CC1)CCN2C(=O)c1cc2ccc(Cl)cc2c(=O)[nH]1', 'COC1CCCN(C(=O)CCNC(=O)N2CCc3ccccc3C2)C1', 'COC1CCCN(S(=O)(=O)c2cccnc2N[C@H]2CCO[C@H](C)C2)C1', 'COC1CCCN(c2cc(C#N)cc(OCc3ccccc3)n2)CC1', 'COC1CCN(C(=O)C(C(C)C)C(C)NC(=O)[C@@H]2COCCO2)CC1', 'COC1CCN(C(=O)C2(NC(=O)C3CC4(CCC4O)C3)CC(O)C2)C1', 'COC1CCN(C(=O)[C@@H]2CN(C(=O)C3=CCCOCC3)C[C@H]2C)CC1', 'COC1CCN(CCNC(=O)CCNC(=O)NCc2ccccc2)C1', 'COC1CCN(CCNC(=O)[C@@H]2CSCN2C(=O)CN(C)C(N)=O)C1', 'COC1CCn2cc(C(=O)NC3(CN4CCN(C)CC4)CC3)nc2C1', 'COC1CN(C(=O)C23CC(C)(CN2C(=O)C2CC(=O)C24CCC4)C3)C1', 'COC1CN(C(=O)CCCCN(C)C(=O)c2cc(C)cs2)CC12CC2', 'COC1CN(CCNC(=O)Cn2nc(-c3ccc(Cl)cc3)nc2C)C1', 'COCC#CCNC(=O)[C@@H]1C[C@@H](C)CN1C(=O)c1cncc(F)c1C', 'COCC(=O)N(C)CC(=O)N1CC(F)(F)C[C@@H]1C(=O)NCCCCO', 'COCC(=O)N(C)CC(=O)N1C[C@@H](F)C[C@H]1C(=O)N1CCC[C@@H]1CF', 'COCC(=O)N(C)CC(=O)NC1(C(=O)NOCCN(C)C)CC(F)C1', 'COCC(=O)N(C)CC(=O)NC12CC(CNC(=O)C(O)C3CC3)(C1)C2', 'COCC(=O)N(C)CC(=O)NCC(C)NC(=O)CC1CN(C(C)=O)C1', 'COCC(=O)N(Cc1ccc(Cl)cc1)Cc1cnc2c(c1)COCC2', 'COCC(=O)N1CC(N2CCN(C(=O)CC3(N(C)C)CCC3)CC2)C1', 'COCC(=O)N1CC2(CCC(NC(=O)C(C)(C)n3cncn3)CC2)C1', 'COCC(=O)N1CCC2(CCC2)C(CNC(=O)c2oc(C)cc2C)C1', 'COCC(=O)NCCC(=O)N(C)C1(CC(=O)N2CCCC[C@H]2C)CC1', 'COCC(=O)NCCC(=O)N[C@H](C)CCC(=O)N1CC2CC1(CO)C2', 'COCC(=O)N[C@@H]1CC[C@H](CCC(=O)N2CC3(C2)NC(=O)NC3=O)C1', 'COCC(C(=O)N(CC(=O)N1CCCC(C(C)O)C1)C(C)C)N(C)C', 'COCC(C(=O)NC1(C(=O)N[C@H]2C[C@@H](O)[C@@H](O)C2)CC(O)C1)N(C)C', 'COCC(C(=O)NC1(CNC(=O)C2CC3(CC(O)C3)C2)CC1)N(C)C', 'COCC(C)(C)C(=O)N1CC(O)(CCNC(=O)c2cn(C)c(C)n2)C1', 'COCC(C)(C)C(=O)NCC(CNC(=O)C=CCO)c1ccccc1', 'COCC(C)(C)CC(=O)N(C)C[C@@H]1C[C@H](F)CN1C(=O)C1CCCS1', 'COCC(C)(C)CC(=O)N(CC1CCSCC1)CC(C)n1cccn1', 'COCC(C)(C)CCN(Cc1cc(F)cc(F)c1)C(=O)C1=C(Cl)CC1', 'COCC(C)(C)CCNC(=O)[C@@H]1CCN(C(=O)CC2CC=CCC2)C1', 'COCC(C)(C)CCNc1ccnc(N2Cc3cccn3[C@@H](C)C2)n1', 'COCC(C)(C)CN(CC1CCN(C)CC1)C(=O)CCC(=O)C1CC1', 'COCC(C)(C)N1CCN(S(=O)(=O)Cc2noc3ccccc23)CC1', 'COCC(C)(C)NC(=O)C1C=CCN(C(=O)c2ccc(C)c(O)n2)C1', 'COCC(C)(CCO)NC(=O)[C@H]1C[C@H]1CNC(=O)c1ncncc1N', 'COCC(C)(CO)CNC(=O)C[C@H]1C[C@H](F)CN1C(=O)C=C1CCC1', 'COCC(C)(CO)CNc1cc(NCc2ccccc2OC)ncn1', 'COCC(C)(COC)CN(Cc1cccc(F)c1)Cc1csc(Cl)c1', 'COCC(C)(COC)NC(=O)[C@H]1CC[C@H](NC(=O)CCN=[N+]=[N-])CC1', 'COCC(C)(O)CC(=O)N(C)CC(O)CN(C)C(=O)Cn1nccn1', 'COCC(C)(O)CC(=O)N1CC=C(CNC(=O)[C@]23COC[C@H]2C3)CC1', 'COCC(C)(O)c1cn(CCNC(=O)c2cc(C(C)=O)cn2C)nn1', 'COCC(C)=CC(=O)N1CCC2(CC2C(=O)N(C)c2ccccc2)C1', 'COCC(C)=CC(=O)N1C[C@@H]2C[C@@H]2[C@H]1C(=O)NCC(C)C1CCCC1', 'COCC(C)C(=O)N1CC2(C=C(C(=O)NCCn3cnnc3)CO2)C1', 'COCC(C)C(=O)N1CCCCC(NC(=O)CSc2ccncc2)C1', 'COCC(C)C(=O)N1CC[C@H](OCC(=O)Nc2cnc(SC)nc2)C1', 'COCC(C)C(=O)NCC1(C)CCN(S(=O)(=O)CCC(C)(C)C)CC1', 'COCC(C)C(=O)NCCCCCC(=O)NC1CN2CCC1(C)CC2', 'COCC(C)C(=O)N[C@@H](C)[C@@H](CO)NC(=O)c1n[nH]c2ncccc12', 'COCC(C)C(C)NC(=O)C(C)(C)CCNC(=O)C=Cc1ccc[nH]1', 'COCC(C)C(C)Nc1ncnc(NCCc2nccnc2C)c1C', 'COCC(C)CC(=O)N(C)C(C)CNC(=O)c1c[nH]c2ccncc12', 'COCC(C)CC(=O)NCCCCN(C)C(=O)c1c(C)ccnc1O', 'COCC(C)CCN(Cc1ccc(OC)nc1)CC1OCCC1(C)C', 'COCC(C)CCN(Cc1cnn(CC(F)(F)F)n1)C[C@H]1CCCO1', 'COCC(C)CN(Cc1ccc(C)c(C)c1F)C(=O)C[C@H]1CCOC1', 'COCC(C)NC(=O)[C@H]1CCC[C@H]1CNC(=O)c1ccc(F)cc1F', 'COCC(C)n1ccc(NC(=O)C(=O)N2CC(N)CC3(CCC3)C2)n1', 'COCC(CC(C)(C)C)NC(=O)c1ccc(OCC(C)C)c(OC)c1', 'COCC(CC(C)C)C(=O)NC1(CC(=O)N2CC(O)C(CO)C2)CC1', 'COCC(CCO)NC(=O)[C@H]1CCCN(C(=O)CCc2nncs2)C1', 'COCC(CN(Cc1ccccn1)Cc1csnc1OC)C(F)(F)F', 'COCC(CNC(=O)C1(CNC(=O)[C@H]2CNC(=O)C2)CC=CC1)OC', 'COCC(CNC(=O)CCN(C)C(=O)c1ccc(C)nc1C)C(C)C', 'COCC(CNC(=O)C[C@H]1C[C@H]1CNC(=O)[C@@H]1C[C@@H](O)CN1C)OC', 'COCC(COC)C(=O)N1CCCC[C@H]1CC(=O)N[C@H](CO)C(N)=O', 'COCC(COC)C(=O)N1CCOC(C(=O)N2CCCC2C2CC2)C1', 'COCC(COC)C(=O)N1CC[C@H](CC(=O)NC(C)C2(CO)CC2)C1', 'COCC(COC)C(=O)N1C[C@H](NC(=O)[C@H]2C[C@@H](N(C)C)C2)[C@@H](O)C1', 'COCC(COC)C(=O)N1[C@@H]2CC[C@@H](C2)[C@H]1CC(=O)NOCC(F)F', 'COCC(COC)C(=O)NC[C@@H]1CCN(C(=O)CCF)C[C@@H]1C1CC1', 'COCC(COC)CC(=O)N(C)C1CCN(C(=O)CC2CC(C)C2)C1', 'COCC(COC)CC(=O)Nc1cc(F)ccc1Sc1nccn1C', 'COCC(COC)NC(=O)c1cc(CNC(=O)C[C@H]2CCOC2)no1', 'COCC(COC)NC(=O)c1cc(OC(F)(F)F)ccc1OC(F)F', 'COCC(Cc1ccccc1)NC(=O)CCNC(=O)c1ccncc1', 'COCC(F)(F)C(=O)N1CCC(C2CCN(C(=O)C(C)SC)CC2)C1', 'COCC(F)(F)C(=O)NCC1(CO)CCN(C(=O)[C@H]2CNC(=O)C2)C1', 'COCC(F)(F)C(=O)NCC[C@@H]1CCN(C(=O)Cc2nc[nH]c2C)C1', 'COCC(F)(F)C(=O)N[C@@H](C)CN(C)C(=O)c1cc2ncccc2[nH]1', 'COCC(F)(F)C(=O)N[C@H](Cc1csc(NC2CCC2)n1)C(C)(C)C', 'COCC(F)(F)CNC(=O)[C@H]1C[C@@H](O)CN1C(=O)c1cc(F)n(C)n1', 'COCC(NC(=O)CC(C)C(C)(C)NC(=O)c1cc(C)no1)C(C)C', 'COCC(NC(=O)CCC(C)NC(=O)c1cn(C)cc1C)C1(C)CC1', 'COCC(NC(=O)NCc1noc2c1CC(C)CC2)C1CCOCC1', 'COCC(NC(=O)[C@@H]1C[C@H](NC(=O)CC2(C#N)CC2)[C@@H](O)C1)C1CC1', 'COCC(NC(=O)c1c(N)cc(OC)cc1Br)C(=O)N1CCOCC1', 'COCC(NC(c1c[nH]nn1)c1nnnn1Cc1ccco1)C(C)C', 'COCC(Nc1nc(C)cc(NCC2COCCC2(F)F)n1)C1CC1', 'COCC(O)(CO)CNC(=O)C1=CCCN(C(=O)CCOC(C)C)C1', 'COCC(OC)C(=O)N1C[C@H]2C[C@@H]1[C@H]2C(=O)N1CCC(C)(C#N)CC1', 'COCC(OC)C(=O)NC1CCCCN(C(=O)c2ncccc2Cl)C1', 'COCC(OC)C(=O)NCC1(COC)CN(C(=O)[C@@H](C)NC(C)=O)C1', 'COCC(OC)C(=O)N[C@@H]1CCCN(C(=O)c2cc(F)ccc2C)C1', 'COCC1(C#N)CN(C(=O)C(C)(CO)NC(=O)C2=CCCOCC2)C1', 'COCC1(C#N)CN(C(=O)C(C)(CO)NC(=O)CCCC(F)(F)F)C1', 'COCC1(C(=O)N(CC[C@H](C)F)Cc2ccn3ncnc3c2)COC1', 'COCC1(C(=O)N2CC[C@@H](CCNC(=O)CCSC)C2)CCOCC1', 'COCC1(C(=O)N2CC[C@@H]2C(=O)NCC2(CC(N)=O)CC2)CCCO1', 'COCC1(C(=O)N2CC[C@H](F)[C@H](F)C2)CN(C(=O)c2[nH]ccc2C)C1', 'COCC1(C(=O)NC(CCO)C(C)C)CN(C(=O)C2CC(OC)C2)C1', 'COCC1(C(=O)NCC(C)C(=O)N(C)Cc2noc(C)n2)C=CCC1', 'COCC1(C(=O)NCC2(C(=O)Nc3cccc(N(C)C)c3)CC2)CC1', 'COCC1(C(=O)NC[C@H](O)C(=O)NC[C@H]2CCCN(C)C2)CCCO1', 'COCC1(C(=O)Nc2cccnn2)CN(C(=O)OC(C)(C)C)CCO1', 'COCC1(C(=O)O)CCN(C(=O)CC(O)c2nc3ccccc3[nH]2)C1', 'COCC1(C(=O)O)CCN(C(=O)c2ccc(C)c(C(F)(F)F)c2)CC1', 'COCC1(C(F)(F)F)CCN(C(=O)Cc2c(F)c(F)cc(F)c2F)C1', 'COCC1(C)CCCN1C(=O)CC(NC(=O)C(C)C(F)F)C(F)(F)F', 'COCC1(C)CCCN1C(=O)[C@H]1OCC[C@H]1CNC(=O)c1cc[nH]n1', 'COCC1(C)CCN1C(=O)C1(C)CCCN(C(=O)COCCSC)C1', 'COCC1(C)CN(C(=O)C(C)(C)C(C)NC(=O)CC(C)CN(C)C)C1', 'COCC1(C)CN(C(=O)Nc2cc(-c3ccccn3)ccc2OC)C1', 'COCC1(CC(=O)N2CC[C@@H]2C(=O)NCCn2nc(C)cc2C)CC1', 'COCC1(CC(=O)N2[C@@H]3CC[C@H]2[C@H](CNC(=O)[C@H]2CC2(F)F)C3)CC1', 'COCC1(CC(=O)N2[C@H](C)CC[C@@H]2C(=O)N(C)Cc2ccsc2)CC1', 'COCC1(CCNC(=O)C2(C)CCCN(C(=O)c3ccc[nH]3)C2)CC1', 'COCC1(CCNC(=O)Nc2ccc(Oc3ccncn3)cc2)CC1', 'COCC1(CN(C)C(=O)C(NC(=O)C(C)=C2CCC2)C2CC2)CCC1', 'COCC1(CN(CC(C)CC2CC2)C(=O)C2(N(C)C)CCC2)CCC1', 'COCC1(CN(Cc2cn(C)nc2Cl)C(=O)c2cc(CO)on2)CC1', 'COCC1(CN(Cc2cnn(C(F)F)c2)C(=O)c2nnsc2C)CC1', 'COCC1(CN(Cc2nc(Cl)ccc2F)C(=O)[C@H]2C[C@H]2C#N)CCC1', 'COCC1(CNC(=O)N2Cc3cnn(-c4ccccc4)c3C2)COC1', 'COCC1(CNC(=O)[C@@H](CO)NC(=O)C=Cc2cnccn2)CCC1', 'COCC1(CNC(=O)[C@@H]2CCCCN2C(=O)C2SCCS2)CCCC1', 'COCC1(CNC(=O)[C@@H]2CCN2C(=O)C2CC(OC)(OC)C2)CCC1', 'COCC1(CNC(=O)[C@H]2CCN(C(=O)c3cc(C)ns3)[C@@H](C)C2)CC1', 'COCC1(CNC(=O)[C@H]2C[C@@](C)(NC(=O)c3cnncc3O)C2)CC1', 'COCC1(CNC(=O)[C@H]2[C@@H]3CN(C(=O)c4c[nH]cc4C)C[C@@H]32)CCC1', 'COCC1(CNC(=O)c2cc(C)sn2)CCN(C(=O)[C@H]2CCOC2)C1', 'COCC1(CNC(=O)c2cccc(C)n2)CCCN1C(=O)C=C(C)C', 'COCC1(CNC(=O)c2cncnc2C)CN(C(=O)C2CC2(F)F)C1', 'COCC1(CNC(=O)c2csc([N+](=O)[O-])c2)CN(S(C)(=O)=O)CCO1', 'COCC1(CNC(=O)c2nc(C)oc2C)CN(C(=O)C(C)(C)CO)C1', 'COCC1(N(C)C(=O)C2COCCN(C(=O)[C@H]3CCC[C@H]3F)C2)CC1', 'COCC1(N(C)C(=O)[C@@H]2[C@H]3C[C@H]3CN2C(=O)C(C)N2CC(C)C2)CC1', 'COCC1(NC(=O)/C(C)=C/CO)CCN(C(=O)[C@H](O)C(C)(C)C)CC1', 'COCC1(NC(=O)C(NC(=O)C(F)=CC2CC2)c2cccnc2)CC1', 'COCC1(NC(=O)CC2(C)CCOC2)CCN(C(=O)C2CC2(C)C)C1', 'COCC1(NC(=O)CCC(C)(C)F)CN(C(=O)Cc2cnnn2C)C1', 'COCC1(NC(=O)CCNC(=O)OC)CCN(C(=O)[C@@H]2CCCO2)C1', 'COCC1(NC(=O)CC[C@H]2C[C@@H](NC(=O)C3(C4(C)CC4)CC3)C2)CC1', 'COCC1(NC(=O)C[C@@H]2CCN(C(=O)Cc3cccnc3C)C2)CC1', 'COCC1(NC(=O)NNC(=O)c2cncc(O)c2)CC2(C1)OCCO2', 'COCC1(NC(=O)Nc2[nH]nnc2C(=O)NC2CC2)CCC(F)(F)C1', 'COCC1(NC(=O)[C@@]23C[C@@H]2CN(C(=O)Cn2nc(C)cc2C)C3)CC1', 'COCC1(NC(=O)[C@H]2CC[C@H](NC(=O)[C@@](C)(O)C(F)(F)F)CC2)CC1', 'COCC1(NC(=O)c2cc(C)ccc2O)CN(C(=O)CC2CCC2)C1', 'COCC1(NC(=O)c2ccc(F)c(O)c2)CN(C(=O)C#CC2CC2)C1', 'COCC1(NC(=O)c2cocc2C)CN(C(=O)C2=CCCOCC2)C1', 'COCC1(O)CCN(C(=O)[C@@H](O)CNC(=O)c2cc(C(C)C)on2)C1', 'COCC1(O)CN(C(=O)Nc2cccc(NC(=O)OC(C)(C)C)n2)C1', 'COCC1(O)CN(C(=O)[C@H]2[C@H]3CC[C@H](C3)N2C(=O)C2(O)CCSC2)C1', 'COCC1(OC)CN(C(=O)NCCOc2ccccc2C(C)(C)C)C1', 'COCC12CC1CCN2C(=O)NCC1(c2ccccc2Cl)CCCC1', 'COCC1C=CCCN1C(=O)C(C)(C)NC(=O)CC1CCCC12CC2', 'COCC1C=CCN1C(=O)CC(O)CNC(=O)C=Cc1cn(C)nn1', 'COCC1CC(CN(CC2=CCCSC2)C(=O)COCC2CCC2)C1', 'COCC1CC(CNC(=O)C2COCCN2C(=O)c2nnsc2N)C1', 'COCC1CC(CNC(=O)N(CCN(C)C)Cc2cccc(Cl)c2)C1', 'COCC1CC(CNC(=O)c2cc(Cl)c(OCC(N)=O)c(OC)c2)C1', 'COCC1CC(O)CN1C(=O)C1(C)CN(C(=O)CCc2cscn2)C1', 'COCC1CCC(NC(=O)NCc2ccc(OC3COC3)cc2)CC1', 'COCC1CCCCN1Cc1ccc(OCc2c(C)noc2C)cc1', 'COCC1CCCN(C(=O)C[C@@H](C)N(C)C(=O)Cn2ccnc2C)C1', 'COCC1CCN(C(=O)C[C@H]2CC[C@@H](NC(=O)C=CC3CCC3)C2)C1', 'COCC1CCN(C(=O)[C@H](CC2CC2)NC(=O)c2coc(C)n2)CC1', 'COCC1CCN(c2nc(C)cc(NC3CCN4CCC3C4)n2)CC1', 'COCC1CCN1C(=O)CC[C@@H](NC(=O)[C@@H]1CCC(=O)N1C)C(C)C', 'COCC1CN(C(=O)C2(F)CN(C(=O)C3Cc4ccccc4C3)C2)C1', 'COCC1CN(C(=O)CC2(CO)CC2)CCN1C(=O)C1CCCN1C', 'COCC1CN(C(=O)CC2CCCN2C(=O)c2cc(C)sn2)CCO1', 'COCC1CN(C(=O)CCN(C)C(=O)[C@H]2C[C@@H]2C2CCCO2)C1(C)C', 'COCC1CN(C(=O)c2ccnc(C)c2N)CCN1C(=O)CC(C)C', 'COCC1COCCN1C(=O)[C@H](O)CCNC(=O)C(C)(C)CC(C)C', 'COCC=CC(=O)N1CCC[C@H](CC(=O)NCCC(O)C2CCC2)C1', 'COCC=CC(=O)NC(C(=O)NCCc1ccncn1)C1(O)CCC1', 'COCC=CC(=O)N[C@H]1CC[C@H]1CNC(=O)c1ncc2[nH]ncc2n1', 'COCC=CCNC(=O)[C@]12CO[C@H](C1)[C@H](NC(=O)C1CC(SC)C1)C2', 'COCCC(=O)N1CCN(CC(=O)NS(=O)(=O)C2CCCOC2)CC1', 'COCCC(=O)N1Cc2[nH]nc(C(=O)N3CCC3C(=O)N(C)C)c2C1', 'COCCC(=O)NC1CC(C(=O)Nc2cn(C)c(=O)cc2C)C1(C)C', 'COCCC(=O)NCc1cc(C)c(C(=O)NCc2cnccc2C)o1', 'COCCC(=O)N[C@@H](CNC(=O)CCc1cncs1)c1ccccc1', 'COCCC(C)(C)NC(=O)C1CCN(C(=O)c2c[nH]c(=O)cc2C)C1', 'COCCC(C)(C)NC(=O)C[C@@H]1CCCCN1C(=O)c1ccc(Cl)o1', 'COCCC(C)(C)NC(=O)[C@@H]1C[C@H](C)CCN1C(=O)C1C2COCC21', 'COCCC(C)(O)CNC(=O)C1CCCN1C(=O)C1(CO)CCOC1', 'COCCC(C)C(=O)NCC1CC(CNC(=O)C(O)C2CCCC2)C1', 'COCCC(C)NC(=O)C(=O)NCc1cccc(C(=O)NC2CC2)c1', 'COCCC(C)Nc1nc(NCC2CCOC2)nc2cc(C)ccc12', 'COCCC(C)S(=O)(=O)N1CC[C@@H](NC(=O)C2CC(=O)C2C2CC2)C1', 'COCCC(CNC(=O)[C@@H]1C[C@H]1C)NC(=O)c1cc(C)c(N)cc1F', 'COCCC(CNC(=O)[C@H]1CC[C@@H](OC)CC1)NC(=O)C1CC(F)C1', 'COCCC(CNC(=O)c1ncccc1C)NC(=O)CC(C)=C(C)C', 'COCCC(COC)NC(=O)N1CCCCC1c1n[nH]c(C(C)C)n1', 'COCCC(NC(=O)C1=CCCN(C(=O)[C@H]2[C@@H]3COC[C@@H]32)C1)C(C)C', 'COCCC(NC(=O)[C@@H]1[C@H](NC(=O)c2snnc2C)C1(C)C)C(N)=O', 'COCCC(NC(=O)c1c(C)coc1C(C)(C)C)C(=O)OC(C)(C)C', 'COCCC(OC)C(=O)N1C[C@@H]2[C@H](C1)[C@H]2NC(=O)c1cc(O)nn1C', 'COCCC(OC)C(=O)NC1CCN(C(=O)c2ccoc2C(C)C)C1', 'COCCC1(C(=O)N2CCCC2C(=O)N(C)C2CC(OC)C2)CCC1', 'COCCC1(C)CN(C(=O)Nc2cccc(-c3nccc(C)n3)c2)C1', 'COCCC1(CNC(=O)C[C@@H](C)N(C)C(=O)C=C2CCCCC2)CC1', 'COCCC1(CNC(=O)[C@H](COC)NC(=O)c2csc(Cl)c2)CCC1', 'COCCC1(CNC(=O)c2nc(C)n(-c3ccc(Cl)cc3Cl)n2)CC1', 'COCCC1(NC(=O)C2=CCC(NC(=O)c3cc(F)c[nH]3)C2)CCC1', 'COCCC1(NC(=O)C[C@@H]2CCCN(C(=O)C3(F)CC3)C2)CCCC1', 'COCCC1(OC)CCCN(C(=O)c2c(N)c(C#N)c3n2CCC3)C1', 'COCCC1CCCN(C(=O)C2(C)CC(NC(=O)CNC(C)=O)C2)C1', 'COCCC1CCN(C(=O)CC(C)CNC(=O)Cc2cccs2)CC1', 'COCCC1CN(C(=O)C(C)SC)CCN1C(=O)c1sc(F)cc1C', 'COCCC1CN(C(=O)CCC2CC2)CCN1C(=O)C(C)C(F)(F)F', 'COCCC=CCNC(=O)C1(C)CCN(C(=O)c2cc(C)nn2C)C1', 'COCCC=CCNC(=O)c1ccoc1CNC(=O)C1CCCN1C', 'COCCCC(=O)N1CCC(C2(NC(=O)C(F)C(C)(F)F)CC2)CC1', 'COCCCC(=O)N1CCCC(F)(C(=O)NCCC(C)C(F)(F)F)C1', 'COCCCC(=O)NC1CN(C(=O)c2ccnn2C)C2(CCCC2)C1', 'COCCCC(=O)NCc1ccsc1C(=O)NCCC1CCCOC1', 'COCCCC(C)C(=O)N(C)CCC(=O)N1CC(C#N)C2(CCC2)C1', 'COCCCC(C)C(=O)N1CCC(C)(C(=O)NCC(C)(O)CCO)C1', 'COCCCC(C)C(=O)N1CCC[C@H](C(=O)N[C@H]2COC[C@@H]2O)[C@@H]1C', 'COCCCC(C)C(=O)N1C[C@@H](O)C[C@@H]1CNC(=O)c1nocc1C', 'COCCCCC(=O)N1CC2(CCN2C(=O)c2cocc2C(N)=O)C1', 'COCCCCC(=O)NC(C)C1CCN(C(=O)CC2CC2(Cl)Cl)CC1', 'COCCCCC(=O)NCc1nc(CNC(=O)C2(C)CCCO2)cs1', 'COCCCCCC(=O)N(C)CCNC(=O)C12CC(C)(C1)OC2(C)C', 'COCCCCCC(=O)N1CCC(CCN(C)C(=O)C2CCC2)CC1', 'COCCCCCC(=O)N1C[C@@H]2C[C@H]1CN2S(=O)(=O)c1cn(C)cn1', 'COCCCCCC(=O)NC[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@H]1CNC(=O)N1', 'COCCCCN(C)c1ccc(S(=O)(=O)N2CCC(C)(C)C2)cc1Cl', 'COCCCCNC(=O)C(=O)N1CCc2cc(C(F)(F)F)ccc2C1', 'COCCCCNC(=O)C(C1CC1)N(C)C(=O)[C@H]1[C@H](C(C)=O)C1(C)C', 'COCCCCNC(=O)COC1(C)CN(C(=O)Cc2cc(C)on2)C1', 'COCCCN(C)CCNc1nc(C)cc(N2CCNC(=O)CC2)n1', 'COCCCNC(=O)C(c1ccc(Br)cc1OC)N(C)C1CC=CC1', 'COCCCNC(=O)C(c1ccc(N(C)C)nc1)N(C)C1CC(C)C1', 'COCCCOCC(=O)N1CC2CC1(C(=O)N1CCC[C@@H]1C(N)=O)C2', 'COCCCOCC(=O)N1CCC(CNC(=O)c2conc2C)CC1', 'COCCCOCC(=O)N1CC[C@@H](CNC(=O)C2=CCCOCC2)C1', 'COCCCONC(=O)[C@@H]1C[C@H](O)CN1C(=O)[C@H]1CC[C@@H](CO)CC1', 'COCCCn1nnnc1C(N(C1CC1)C1CC1)C(C)(F)C(C)(C)F', 'COCCCn1nnnc1C(NCCc1cnoc1)c1scnc1Br', 'COCCN(C(=O)C[C@H]1C=C[C@@H](NC(=O)Cc2ccn[nH]2)C1)C1CC1', 'COCCN(C(=O)c1cc(CNC(=O)[C@H]2C[C@@H]2C2CC2)no1)C1CC1', 'COCCN(C)CC(=O)N1C[C@H](NC(=O)CNS(C)(=O)=O)[C@@H](OC)C1', 'COCCN(C)CC(=O)N[C@H]1CCCN(C(=O)C(CSC)OC)[C@H]1C', 'COCCN(C)CCC(NC(=O)c1cncc(Cl)c1)c1ccccc1', 'COCCN(C)CCNC(=O)[C@@H](C)CNC(=O)c1nc(C)ccc1F', 'COCCN(C)c1ccc(NC(=O)N(C)Cc2cn(C)nc2Cl)nc1', 'COCCN(CC(=O)Nc1ccc(C)nc1)C(=O)CC1(N(C)C)CC1', 'COCCN(CC(=O)Nc1ccc(OC)c(O)c1)C(=O)c1cc[nH]c1', 'COCCN(CC1CC1)C(=O)C[C@@H](C)NC(=O)CC1=NN(C)C(=O)C1', 'COCCN(CCF)C(=O)C(NC(=O)c1cc(Cl)ns1)C1CCOC1', 'COCCN(CCF)C(=O)[C@@H]1CCCN(C(=O)c2ccc(F)cc2)C1', 'COCCN(CCNC(=O)C(C)=CC1CC1)C(=O)c1ccc(=O)[nH]n1', 'COCCN(CCNc1ncnc2ccnn12)C(=O)C1CC(F)(F)C1', 'COCCN(C[C@H](C)O)C(=O)C=C(C)CNC(=O)Cc1cncn1C', 'COCCN(Cc1ccccc1F)C(=O)NCc1cnn(C)c1OC', 'COCCN(Cc1ccccc1F)S(=O)(=O)Cc1ncoc1C(F)F', 'COCCN(Cc1sccc1Br)C(=O)Cn1cc(OC)c(=O)cc1C', 'COCCN1CCC(NS(=O)(=O)C(CC(C)C)c2ccccc2)CC1', 'COCCN1CCCN(c2ncnc(NCC(OC)C(C)C)n2)CC1', 'COCCNC(=O)C(C1CCC=CO1)N(C)CCCc1scnc1C', 'COCCNC(=O)C(CC1C=CCC1)N1CC(F)(F)CC1CC(N)=O', 'COCCNC(=O)C(CC1CCOCC1)NC(=O)c1ccc(N)nc1', 'COCCNC(=O)C(c1ccc(Cl)c(Br)c1F)N(CCC#N)C(C)C', 'COCCNC(=O)C(c1cccs1)N1CCCN(C(=O)N(C)C)CC1', 'COCCNC(=O)C(c1cnc(Cl)n1C)N1CCC(C(C)(C)F)CC1', 'COCCNC(=O)C(c1cnccn1)N1CC(F)(F)C[C@@H]1C(=O)OC', 'COCCNC(=O)C(c1cnn(C)c1)N(CCOC(C)(C)C)C1CC1', 'COCCNC(=O)C1CCN(C(=O)Nc2nnc(CCSC)s2)CC1', 'COCCNC1CCN(C(=O)C2CC(C)(C)S(=O)(=O)C(C)(C)C2)CC1', 'COCCNS(=O)(=O)c1ccc(NCc2cc(Br)cc(Br)c2N)cc1', 'COCCNc1nc2c(s1)CCN(C(=O)CSc1nncn1C)CC2', 'COCCOC(C)C(=O)N1CCC(CO)(C(=O)N[C@H]2CC=CCC2)C1', 'COCCOC(C)C(=O)NC1(C(=O)N2CCN3CCC2C3)CC(O)C1', 'COCCOC1CN(C(=O)COC2(C)CN(C(=O)c3cnns3)C2)C1', 'COCCOCC(=O)N(Cc1c2c(nn1C)CCC2)CC1(CF)CC1', 'COCCOCC(=O)N(Cc1sc(C)cc1C)CC1(C)CSCCO1', 'COCCOCC(=O)N1CCO[C@@H](C)[C@@H]1C(=O)NC(C)c1ccns1', 'COCCOCC(=O)N1C[C@H](C)[C@@](C)(C(=O)Nc2ccc(C)nc2)C1', 'COCCOCC(=O)N1C[C@H](NC(=O)Cc2ccc(C)nc2)[C@@H](O)C1', 'COCCOCCCN(C)C(=O)Nc1cc(C)ccc1NS(C)(=O)=O', 'COCCOCCN(C)C(=O)C1CC(NC(=O)C=C2CCC2)C1(C)C', 'COCCOCCN1CCN(Cc2cc(=O)n3cc(C)sc3n2)CC1', 'COCCOCCNC(=O)C1C(C)CCN1C(=O)c1cccnc1O', 'COCCOCCOCCN(C)C(=O)Nc1cc(C)nc2ccnn12', 'COCCOCCOCCOC(=O)N1CCCC1c1cncc(Br)c1', 'COCCOCCc1nc([C@H]2CCCN2C(=O)C2CC(SC)C2)cs1', 'COCCOCc1ccc(C(=O)N[C@@H](C)c2ccc(Br)cc2F)cc1', 'COCCOc1ccc(C(=O)N2C[C@H]3CCCC[C@H]3[C@@H]2C(=O)O)cc1', 'COCCOc1ccc(N(C)C(=O)c2cnccc2C(F)(F)F)cc1', 'COCCOc1ccc(S(=O)(=O)N[C@H](C)c2cccc(C)c2)cc1C', 'COCCOc1ccc(S(C)(=O)=O)cc1NC(=O)c1cc(Cl)n(C)n1', 'COCCOc1cccc(COC(=O)c2ccc3[nH]ncc3c2F)c1', 'COCCOc1nn(C)cc1NS(=O)(=O)c1cn(C)c2ccccc12', 'COCCS(=O)(=O)CC(=O)N[C@H]1CC[C@H]1NC(=O)C1C=CC=CC=C1', 'COCCSCC(=O)N(Cc1ccn(C)c1)CC1CC(OC)C1(C)C', 'COCCSCC(=O)NCc1cn(CC(=O)N2CC=CC(O)C2)nn1', 'COCCSCC(=O)N[C@H]1CN(C(=O)CNC(=O)CN(C)C)C[C@H]1F', 'COCC[C@H]1CCC[C@@H]1NC(=O)NC(C)(CO)COc1ccccc1', 'COCC[C@H]1C[C@@H]1C(=O)NC1CC=C(C(=O)NCC(O)C2CCC2)C1', 'COCC[C@H]1C[C@@H]1NC(=O)C1(F)CN(C(=O)COc2ccn(C)n2)C1', 'COCCc1nc(CNc2cccc(OCCN3CCCC3)c2)no1', 'COCCn1c(C2CN(C[C@@H](O)CC#N)CCO2)nc2ccccc21', 'COCCn1cc(CN(Cc2cc(C)no2)C[C@H]2C[C@H](CF)C2)cn1', 'COCCn1nnnc1C(NCCC12CC(CO1)C2)c1cccnn1', 'COCCn1nnnc1C(NCc1cc(COC)on1)C1CCOC1', 'COCCn1nnnc1C(c1ccc(CO)cc1)N1CCC(SC)C1', 'COCO[C@@H](C)C(=O)N(C)CC(C)Nc1nc(C)nc2c(C)csc12', 'COCO[C@@H](C)C(=O)N(CC(=O)NC1C2CCCC1COC2)C1CC1', 'COCOc1cc(C(=O)OC)ccc1-c1c(C)nn2c(N)ncnc12', 'COCOc1cc(F)cc(S(=O)(=O)N(C)C(C)c2cccnc2N)c1', 'COC[C@@H](C)NC1(c2nnnn2CC2CCCO2)CN(C(=O)OC)C1', 'COC[C@@H](C)NCCCCCc1cn(-c2c(F)cc(Cl)cc2F)nn1', 'COC[C@@H](C)Nc1cc(NCC(=O)NCc2ccccn2)nc(C)n1', 'COC[C@@H](CC(=O)N1CC(C)(C)OC[C@@H]1C)NC(=O)c1nocc1Cl', 'COC[C@@H](CC(=O)N1CC(O)(C(F)F)C1)NC(=O)C1CC(F)(CF)C1', 'COC[C@@H](CC(=O)N1CCC(=C(F)F)CC1)NC(=O)C(CSC)OC', 'COC[C@@H](CC(=O)N1CCC12CCC2)NC(=O)CC1CCC=CCC1', 'COC[C@@H](CC(=O)N1CCCCN(C)CC1)NC(=O)[C@H](O)C1CCC1', 'COC[C@@H](CC(=O)NCC1CCCC1)NC(=O)c1nc(C)ccc1C', 'COC[C@@H](CC(=O)NOCC(O)C(C)(C)C)NC(=O)[C@H]1C[C@H](SC)C1', 'COC[C@@H](CC(=O)Nc1cccc(OC)c1)NC(=O)c1ccc(C)[nH]1', 'COC[C@@H](CNC(=O)C(O)CC(F)(F)F)NC(=O)C1(C)CCOCC1', 'COC[C@@H](CNC(=O)C1CC(C)(C)C1)NC(=O)CN1C(C)CCC1C', 'COC[C@@H](CNC(=O)C1CCC1C)NC(=O)c1ccc(C(=O)OC)o1', 'COC[C@@H](CS(=O)(=O)Nc1cccc2c(C(=O)OC)nccc12)OC', 'COC[C@@H](NC(=O)C(=O)Nc1ccc(SC)c(F)c1)c1ccccn1', 'COC[C@@H](NC(=O)C=CC1CCC1)C(=O)NCC1(OC)CCC(C)C1', 'COC[C@@H](NC(=O)CC1(N(C)C)CC1)C(=O)NCc1cnn(C)c1C', 'COC[C@@H](NC(=O)[C@@H]1C[C@@H]2C[C@@H]2C1)C(=O)NCCOC1CCCCC1', 'COC[C@@H](NC(=O)c1cc(Cl)[nH]n1)C(=O)N1CCCC(CCCO)C1', 'COC[C@@H](NC(=O)c1cccc(F)c1)C(=O)N(C)CC1(O)CCCC1', 'COC[C@@H]1CN(C(=O)/C=C/C(C)(C)NC(=O)c2sccc2Cl)CCO1', 'COC[C@@H]1CN(c2cc(N(C)c3ccccc3)ncn2)CC(C)(C)O1', 'COC[C@H](C)N(C)C(=O)C1CN(C(=O)c2cc(OC)ns2)CCN1C', 'COC[C@H](C)N(C)C(=O)c1ccnc(CNC(=O)c2cn[nH]c2C)c1', 'COC[C@H](C)NC(=O)[C@@H]1C[C@H](NC(=O)C2CCC(C)(O)CC2)[C@@H](O)C1', 'COC[C@H](CNC(=O)C1CCCCN1C)NC(=O)c1cccc(N)n1', 'COC[C@H](CNC(=O)CCCN=[N+]=[N-])NC(=O)C1CC2CCCC2C1', 'COC[C@H](CNC(=O)Cn1nccn1)NC(=O)C1(C#N)CC(F)(F)C1', 'COC[C@H](CNC(=O)[C@H]1C[C@@H](OC)C1)NC(=O)c1c(C)ncnc1C', 'COC[C@H](CNC(=O)c1cc(Cl)n(C)n1)NC(=O)C1CCC(=O)NC1', 'COC[C@H](NC(=O)C1CCOC1C(C)C)C(=O)NC[C@@H](C)S(N)(=O)=O', 'COC[C@H](NC(=O)CCc1ccn(C)c1)C(=O)N1CCCCC1CF', 'COC[C@H](NC(=O)COC1(C)CCC1)C(=O)N[C@H]1C[C@]2(CCCO2)C1', 'COC[C@H](NC(=O)c1ccc(O)cn1)C(=O)Nc1ccc(C)nc1O', 'COC[C@H](NC(=O)c1cccc(C)c1C)C(=O)N(C)C1CC(OC)C1', 'COC[C@H]1CC[C@@H]1C(=O)N(Cc1cccnc1OC)CC1(F)CCC1', 'COC[C@H]1CC[C@@H]1C(=O)N1CCCC(C2CCCN2C(=O)C2CC2)C1', 'COC[C@H]1CC[C@@H]1C(=O)N[C@H]1CCO[C@H]1C(=O)NC1CC2CCC1O2', 'COC[C@H]1C[C@@H](CNC(=O)CC2CN(C)C2)N(C(=O)CC=C(Cl)Cl)C1', 'COC[C@H]1C[C@@H](CNC(=O)c2cc(C)on2)N(C(=O)C2CCSC2)C1', 'COC[C@H]1C[C@H](CN(CC2CCCC2C)C(=O)C2CN(C(N)=O)C2)C1', 'COC[C@H]1C[C@]1(C)C(=O)N(CCC1CC1C)Cc1ccc(Cl)c(C)c1', 'COC[C@]1(CNC(=O)CC(NC(=O)OC(C)(C)C)C(F)F)C[C@@H](O)C1', 'COC[C@]1(CNC(=O)NCCc2ncccc2C(F)(F)F)C[C@@H](O)C1', 'COCc1[nH]nnc1C(=O)NCC1(c2ccc(Br)cc2)CCCCC1', 'COCc1c(C(=O)OCC(=O)NCc2ccco2)sc2ccccc12', 'COCc1cc(C(=O)N2C3CC2CN(C(=O)COCCSC)C3)[nH]n1', 'COCc1cc(C(=O)N2CC(OCC(=O)N3C[C@H](O)[C@@H](F)C3)C2)no1', 'COCc1cc(C(=O)N2CC[C@H]2C(=O)N2CCC(CC(N)=O)C2)[nH]n1', 'COCc1cc(C(=O)NC(C)(C(=O)N(C)CC2CC2)C2CCC2)on1', 'COCc1cc(C(=O)NC23CC4CC(C)(CC(C)(C4)C2)C3)ccc1F', 'COCc1cc(C(=O)NC2CC(CNC(=O)CCSC)C2(C)C)[nH]n1', 'COCc1cc(C(=O)NC2CCN(c3cccc(Cl)c3)C2=O)n(C)n1', 'COCc1cc(C(=O)NCC(C)n2cc(-c3cnccn3)nn2)on1', 'COCc1cc(C(=O)NCC2(C(=O)NCC(C)(F)F)CCCO2)on1', 'COCc1cc(C(=O)NC[C@H](C)N(C)C(=O)C2CC(F)(F)CS2)no1', 'COCc1cc(CN(CC2C=CCCC2)C(=O)CSCC(N)=O)no1', 'COCc1cc(CNC(=O)Nc2sc(C)nc2-c2ccccc2)on1', 'COCc1cc(CS(=O)(=O)N2CCCC(CC(=O)OC(C)C)C2)no1', 'COCc1cc(NNC(=O)c2c(Cl)ccc3ncccc23)nc(C)n1', 'COCc1cc[nH]c1C(=O)N(C)CC(=O)NCc1cnn(CCO)c1', 'COCc1cc[nH]c1C(=O)OCC(=O)c1c(C)c(C)c(C)c(C)c1C', 'COCc1ccc(C(=O)N2CCC(CF)(C(=O)NCC(C)(C)C)C2)o1', 'COCc1ccc(C(=O)NCC2CC(C)(C)CN2C(=O)C(C)OC)s1', 'COCc1ccc(C(=O)NCc2ccc3c(c2)CCCS3(=O)=O)nc1', 'COCc1ccc(CN(CCC2CC3CCC2C3)C(=O)CC(C)F)s1', 'COCc1ccc(NC(=O)C2CC=CCN2C(=O)C#CC(C)C)cc1', 'COCc1cccc(C(=O)NC2CCN(C(=O)C3CC3)CC2(C)C)n1', 'COCc1cccc(CC(=O)OC(C)c2nc(-c3nnc[nH]3)no2)c1', 'COCc1ccccc1C=C(C)CNc1cc(OC)ccc1N(C)C', 'COCc1ccccc1CC(=O)NCCOc1ccc(CC#N)cc1', 'COCc1ccccc1CN(CCSC)C(=O)c1cc(OC)nn1C', 'COCc1ccoc1C(=O)N1CCC1CNC(=O)c1nc(Cl)sc1C', 'COCc1ccoc1C(=O)N1C[C@H](C)[C@H](NC(=O)[C@@H]2COC(=O)N2)C1', 'COCc1csc(C(=O)NC2CCCN(C(=O)[C@H]3CC[C@H]4C[C@H]43)C2)c1', 'COCc1nc(C(=O)N2CC[C@@H]2C(=O)N2CCC(CCO)CC2)co1', 'COCc1nc(CN(Cc2cnc(C)n2C)CC2(CSC)CC2)cs1', 'COCc1ncc(CN(CC2(OC)CC2)C(=O)[C@H]2C[C@H]3CC[C@@H]2O3)s1', 'COCc1ncsc1C(=O)N[C@@H](CNC(=O)[C@H]1C[C@H](SC)C1)C(C)C', 'COCc1nnc(CNC(=O)[C@@H](NC(=O)c2cc(Cl)c[nH]2)C2CC2)[nH]1', 'COCc1noc(C(C)Nc2ccc(OCc3nc(C)no3)cc2)n1', 'COCc1noc(CNC(=O)Nc2ccc(C(=O)NC(C)C)cc2)n1', 'COCc1nocc1CNC(=O)C12CC(CN1C(=O)C(F)C(C)C)C2', 'COCc1ocnc1CNC(=O)[C@@H]1CSCN1C(=O)C1(CO)COC1', 'COCc1snnc1C(=O)OCC(=O)Nc1ccccc1SC(F)F', 'COCn1ccc(C(=O)NC2C[C@H](NC(=O)CC(C)SC)[C@@H](O)C2)n1', 'COCn1nc(C)c(S(=O)(=O)NC(C)C(O)c2ccc(Cl)cc2)c1C', 'COCn1ncc(C)c1CN(Cc1nccs1)CC(C)(C)CC(F)F', 'CON(C(=O)C(C)C(C)NC(=O)c1cc2ncccc2[nH]1)C1CCC1', 'CON(C(=O)CC[C@H]1CC[C@@H](NC(=O)[C@H]2COC(=O)N2)C1)C1CCC1', 'CON(C(=O)[C@@H]1CCCC[C@@H]1NC(=O)C1CC(=O)CS1)C1CCCC1', 'CON(C)C(=O)C1(NC(=O)CC2CCN2C(=O)C23CCC(C2)C3)CC1', 'CON(C)C(=O)C1(NC(=O)[C@@H]2C[C@H](F)CCN2C(=O)CC(C)C)CC1', 'CON(C)C(=O)c1ccc(NC(=O)C2CCCN2C2CCCC2)cc1', 'CON(C)C1CCN(C(=O)C2(NC(=O)CSC(F)(F)F)CSC2)CC1', 'CON(C)C1CN(C(=O)C(F)CC(C)(C)NC(=O)CC2C=CCC2)C1', 'CON(C)CC(O)Cn1cc(Nc2nc(C)nc3sc(Br)cc23)cn1', 'CON(C)S(=O)(=O)c1cccc(C(=O)OCC(C)(C)n2ccnc2)c1', 'CON1CC(C(=O)N2C[C@@H]3C[C@@H]3[C@H]2C(=O)NC2CC(CO)C2)CC1=O', 'CON1CC(C(=O)N[C@H](C(=O)NCC2(C#N)CCC2)[C@@H](C)O)CC1=O', 'CON1CC(C(=O)N[C@H]2C[C@@H](CCC(=O)NOCC3CC3)C2)CC1=O', 'CON1CCC(C(=O)NCCN(C(=O)Cn2nccn2)C2CC2)CC1', 'CON1CCC(C(=O)N[C@H]2C[C@H](CC(=O)N(C)C(C)CSC)C2)CC1', 'CON1CCC(NC(=O)C2CCN(C(=O)[C@H]3[C@@H]4COCC[C@@H]43)C2)CC1', 'CON=CC(=O)N1CC([C@@H]2C[C@H]2C(=O)NCCn2cc(CO)nn2)C1', 'CON=CC(=O)N1CCC2CN(C(=O)c3ccn4nccc4c3)C2C1', 'CON=CC(=O)N1CCN(C(=O)c2ccc3cncn3c2)C2(CC2)C1', 'CON=CC(=O)N1CCO[C@H](CNC(=O)[C@H]2C[C@@H]2c2ccc(C)o2)C1', 'CON=CC(=O)N1Cc2occ(C(=O)NC(C)(C)C(=O)N(C)C)c2C1', 'CON=CC(=O)NC1CC2(C1)CC(C(=O)N1C[C@@H](O)C[C@H](OC)C1)C2', 'CON=CC(=O)N[C@@H]1C[C@H](O)[C@H]1CC(=O)N[C@H]1CCCCCC[C@H]1O', 'CON=CC(=O)N[C@H]1CN(C(=O)c2cc([N+](=O)[O-])c[nH]2)C[C@@H]1C(F)F', 'CONC(=O)C(=O)N(C)CC(O)CNC(=O)c1ccc2cc[nH]c2n1', 'CONC(=O)C(=O)N1CC(C)N(C(=O)Cc2c(C)noc2C)CC1C', 'CONC(=O)C(=O)N1CC[C@H](CO)[C@@H](NC(=O)c2csc(C)c2C)C1', 'CONC(=O)C(=O)N1C[C@@H](C)N(C(=O)c2cc(F)ccc2N)[C@@H](C)C1', 'CONC(=O)C(=O)NC1CCOC(C(=O)Nc2cnccc2OC)C1', 'CONC(=O)C1CCN(CCC(=O)NC(=O)NCCC(F)(F)F)CC1', 'CO[C@@H](C)C(=O)N(Cc1cc(O)c2ccoc2c1)Cc1cscc1C', 'CO[C@@H](C)C(=O)N1CC(F)(F)CC1CNC(=O)c1cc(C(F)F)[nH]n1', 'CO[C@@H](C)C(=O)N1CC[C@H](C)C[C@@H]1C(=O)NCCc1c(C)noc1C', 'CO[C@@H](C)C(=O)NC12CC(CNC(=O)C3CCCc4ccnn43)(C1)C2', 'CO[C@@H](C)C(=O)NCC1CC2(CCC2)CN1C(=O)Cn1nnc(N)n1', 'CO[C@@H](C)C(=O)N[C@H](C)Cc1csc(-c2ccc(S(C)(=O)=O)cc2)n1', 'CO[C@@H](C)CNC(=O)CC[C@@H]1CCCCN1C(=O)[C@@H]1CCO[C@H](C)C1', 'CO[C@@H](CCNC(=O)C(=O)N(C)C)C(=O)NCCOc1ncccn1', 'CO[C@@H](CCNC(=O)C1(CSC)CC1)C(=O)NC(C)c1ccncn1', 'CO[C@@H](CCNC(=O)c1cscn1)C(=O)N(C)CC1CCCN(C)C1', 'CO[C@@H](CCNC(=O)c1ncoc1C)C(=O)N1C[C@H]2CCCC[C@H]2C1', 'CO[C@@H](CCNC(=O)c1occc1C)C(=O)NCC1CC2(CCC2)C1', 'CO[C@@H](CNC(=O)C1(NC(N)=O)CC1)C(=O)NCC[C@@H]1CC=CCC1', 'CO[C@@H](CNC(=O)CC1CC=CCC1)C(=O)N1CC2(C1)CC(C)(O)C2', 'CO[C@@H](CNC(=O)Cn1cccc1)C(=O)N(C)C1CCC(CO)CC1', 'CO[C@@H](CNC(=O)[C@@H]1C[C@H]2CC[C@@H](C1)O2)C(=O)NC(CO)C(C)(C)C', 'CO[C@@H](CNC(=O)c1cccnn1)C(=O)N1CCCC(CC(N)=O)C1', 'CO[C@@H](CNC(=O)c1cnncc1O)C(=O)N(C1CC1)C(C)C1CC1', 'CO[C@@H](CNC(=O)c1cnoc1C(C)C)C(=O)NCC1(F)CN(C)C1', 'CO[C@@H](CO)CNC(=O)c1cc(CNC(=O)c2cnn(C)c2Cl)no1', 'CO[C@@H]1C(NC(=O)C2(CNC(=O)c3cccn3C)CCCC2)C[C@H]1O', 'CO[C@@H]1CCCCC[C@H]1NC(=O)CC1=CCN(C(=O)CCCF)CC1', 'CO[C@@H]1CCC[C@H]1NC(=O)C(CC1CC1)NC(=O)Cn1ccc(C)c1', 'CO[C@@H]1CCN(C(=O)[C@]2(C)C[C@H](NC(=O)C3CC(=O)N(OC)C3)C2)C1', 'CO[C@@H]1CC[C@H]1CCN(CC1=CCSC1(C)C)C(=O)[C@@H](O)C(C)(C)C', 'CO[C@@H]1CC[C@H]1NC(=O)C(CC1CCCOC1)NC(=O)OC(C)(C)C', 'CO[C@@H]1CN(C(=O)C23CC(CO)(CN2C(=O)[C@@H]2CC[C@H]2C)C3)C[C@H]1F', 'CO[C@@H]1CN(C(=O)C2COCCN2C=O)C[C@H]1NC(=O)[C@H](O)C(C)C', 'CO[C@@H]1CN(C(=O)CCC2CCC2)C[C@H]1NC(=O)CC(C)(C)N(C)C', 'CO[C@@H]1CN(C(=O)c2cncc3nc[nH]c23)C[C@H]1Nc1nc(C)ns1', 'CO[C@@H]1CN(C)C[C@H]1NC(=O)C[C@H]1C[C@H]1CNC(=O)C=CC1CCC1', 'CO[C@@H]1COCC[C@H]1NC(=O)C[C@H]1C[C@@H](NC(=O)C2(C)CCCO2)C1', 'CO[C@@H]1COC[C@H]1NC(=O)C(NC(=O)c1cc(C(F)F)[nH]n1)C(C)C', 'CO[C@@H]1COC[C@H]1NC(=O)COC(C)(C)CNC(=O)[C@H]1C[C@@H]1C(C)C', 'CO[C@@H]1C[C@@H](C(=O)N2CC(C#N)(CCF)C2)N(C(=O)/C=C/C(F)F)C1', 'CO[C@@H]1C[C@@H](C(=O)N2CC([C@H](C)O)C2)N(C(=O)C=CC2(C)COC2)C1', 'CO[C@@H]1C[C@@H](C(=O)N2CCN(C)C(=O)C2)N(C(=O)CCC2(C)CC2)C1', 'CO[C@@H]1C[C@@H](C(=O)N[C@H]2CCCNC2=O)N(C(=O)[C@@H](O)CN(C)C)C1', 'CO[C@@H]1C[C@@H](C(=O)N[C@H]2C[C@@](C)(O)C2)N(C(=O)[C@@H](O)C2CCCC2)C1', 'CO[C@@H]1C[C@@H](C(=O)Nc2ccsc2)N(C(=O)Cc2c(C)noc2C)C1', 'CO[C@H](C)C(=O)N1C(C(=O)NCCN(C)C2CCCC2)CCC12CC2', 'CO[C@H](C)C(=O)N1C(CC(=O)NC2CCCN(O)C2=O)[C@H]2CCC[C@H]21', 'CO[C@H](C)C(=O)N1C[C@H]2C[C@@H](C1)[C@H](NC(=O)C1(C)CCN(C)C1=O)C2', 'CO[C@H](C)C(=O)N1[C@@H]2CC[C@H]1C[C@H](NC(=O)CCCCNC(N)=O)C2', 'CO[C@H](C)C(=O)NCC(C)(CNC(=O)CC1CCC(=O)NC1=O)OC', 'CO[C@H](C)CC(=O)N(CC(CCO)C(C)(C)C)C[C@H]1CC[C@H](C)CC1', 'CO[C@H](C)CN(C)C(=O)CNC(=O)CNC(=O)CN1CCN(C)CC1', 'CO[C@H](C)[C@@H](C(=O)N(Cc1ccn(C)n1)CC1CCCCC1)N(C)C', 'CO[C@H](C)[C@@H](C)NC(=O)NNc1nc(-c2ccc3c(c2)OCO3)cs1', 'CO[C@H](C)[C@@H](CC(=O)Nc1ccccc1)NC(=O)CC(C)C(F)(F)F', 'CO[C@H](C)[C@H](NC(=O)C1CC2CC2C1)C(=O)NCCC(CO)C(C)C', 'CO[C@H](C)[C@H](NC(=O)c1ccc(-c2ccccc2Cl)[nH]c1=O)C(=O)O', 'CO[C@H](CCNC(=O)C(C)(C)CCF)C(=O)N[C@@H]1C[C@@H](CO)N(C)C1', 'CO[C@H](CCNC(=O)[C@H]1OCCO[C@H]1C)C(=O)NC1(C)CCCC1O', 'CO[C@H](CO)CNC(=O)CN(CC(C)C)C(=O)[C@H]1CN(C)CCN1C', 'CO[C@H]1CC(NC(=O)c2ccccc2OCC(=O)N(C)C)C[C@H]1OC', 'CO[C@H]1CCCC[C@@H]1C(=O)NC1CCC1NC(=O)CC1(N(C)C)CC1', 'CO[C@H]1CCCC[C@@H]1C(=O)NCCCCC(C)NC(=O)c1cnsc1', 'CO[C@H]1CCCN(C(=O)COCCNC(=O)c2ccc(C(F)F)o2)C1', 'CO[C@H]1CCCN(C(=O)[C@H]2CCN2C(=O)C(C)(C)n2cnnn2)[C@H]1C', 'CO[C@H]1CCCN(c2ccc(S(=O)(=O)NC[C@H]3C[C@@H](O)C3)c(Cl)c2)C1', 'CO[C@H]1CCC[C@@H]1C(=O)N(C)CCC(=O)NCC1CCN(C(N)=O)C1', 'CO[C@H]1CCC[C@@H]1C(=O)N1C[C@H]2CN(C(=O)c3ncsc3C)C[C@@H]2C1', 'CO[C@H]1CCC[C@@H]1C(=O)N[C@H]1CC[C@H]1C(=O)N1CC(CO)C2(CC2)C1', 'CO[C@H]1CCC[C@H]1C(=O)N(Cc1nc(C)co1)CC1(CO)CCCC1', 'CO[C@H]1CCN(C(=O)/C=C/C(C)NC(=O)CCn2cc(C)cn2)[C@H]1C', 'CO[C@H]1CCN(C(=O)C[C@@H](NC(=O)C(C)(C)C(C)C)C2CC2)C[C@H]1F', 'CO[C@H]1CCN(C(=O)[C@@H]2CSCN2C(=O)Cn2nccc2C)[C@@H](C)C1', 'CO[C@H]1CCN(C(=O)[C@@H]2[C@H](O)CCN2C(=O)[C@@H]2C[C@H]3CC[C@@H]2O3)[C@H]1C', 'CO[C@H]1CCN(C(=O)c2cc(C(C)C)n(C(C)(C)C)n2)C[C@@]1(C)OC', 'CO[C@H]1CCN(CC(=O)NC(C(=O)NCC(O)C(C)O)C2(C)CC2)C1', 'CO[C@H]1CC[C@@H](C(=O)NC[C@H]2CC[C@@H](NC(=O)C3CC=CC3)C2)CC1', 'CO[C@H]1CN(C(=O)C(=O)Nc2ccccc2-n2cc(Br)cn2)C[C@H]1N', 'CO[C@H]1CN(C(=O)C23CC(C#N)(C2)C3)C[C@@H]1C(=O)NOCC(F)(F)F', 'CO[C@H]1CN(C(=O)C2=CCCCO2)C[C@H]1NC(=O)[C@H]1C[C@@H]1C(F)(F)F', 'CO[C@H]1CN(C(=O)C2CC(C)(C)C2)C[C@@H]1C(=O)NC(C)CC(C)(C)O', 'CO[C@H]1CN(C(=O)C2CC2Cl)C[C@@H]1C(=O)Nc1cccc(N=[N+]=[N-])c1', 'CO[C@H]1CN(C(=O)C2CC3CCC(C2)O3)CC[C@H]1NC(=O)CCSC', 'CO[C@H]1CN(C(=O)C2CCC(=O)N2C)C[C@H]1NC(=O)C1CC(C)(C)C1', 'CO[C@H]1CN(C(=O)COCC(F)F)C[C@@H]1C(=O)N1C[C@H](C)CC[C@H]1C', 'CO[C@H]1CN(C(=O)Cc2ccnn2C)C[C@@H]1C(=O)N[C@@H](CO)C(N)=O', 'CO[C@H]1CN(C(=O)[C@H]2CCC[C@H]2F)CC[C@H]1NC(=O)[C@H]1CC[C@H]2C[C@H]21', 'CO[C@H]1CN(C(=O)[C@H]2CCOC[C@H]2NC(=O)CCCSC)C[C@H]1OC', 'CO[C@H]1CN(C(=O)c2ccccc2)C[C@@H]1C(=O)N1CC(S(C)(=N)=O)C1', 'CO[C@H]1CN[C@H](C(=O)Nc2cccc(S(=O)(=O)c3ccccc3)c2)C1', 'CO[C@H]1COC[C@@H]1n1cc(C2CN(C(=O)c3nc(Cl)sc3Br)C2)nn1', 'CO[C@H]1COC[C@H]1S(=O)(=O)N[C@@H](C)CNC(=O)c1ccnn1CCO', 'CO[C@H]1C[C@@H](C(=O)N2CC[C@@H](F)C2)N(C(=O)c2ccc(O)c(F)c2)C1', 'CO[C@H]1C[C@@H](C(=O)NC(C)(C)CC(=O)NC2CC3(CCCCO3)C2)C1', 'CO[C@H]1C[C@@H](C(=O)NC2CC(F)(F)C2)N(C(=O)C2CC2(C)C(F)F)C1', 'CO[C@H]1C[C@@H](C(=O)NC2CCOCC2)N(C(=O)CCC(=O)N(C)C)C1', 'CO[C@H]1C[C@@H](CC(=O)N(Cc2cocn2)CC(O)C2CC(C)(C)C2)C1', 'CO[C@H]1C[C@@H](CC(=O)NC(CNC(=O)C(C)(C)OC(C)C)C(C)C)C1', 'CO[C@H]1C[C@@H](CC(=O)NC[C@@H](C)C(=O)NC2(CO)CCCC2(C)C)C1', 'CO[C@H]1C[C@@H](CNC(=O)[C@@]23C[C@@H]2CN(C(=O)Cc2cccnc2)C3)C1', 'CO[C@H]1C[C@@H](NC(=O)[C@H]2C[C@@H]2C2CN(C(=O)C3CC4(CC4)CO3)C2)C1', 'CO[C@H]1C[C@@](C)(C(=O)N(CCC#CBr)Cc2cccc3nonc23)C1', 'CO[C@H]1C[C@H](C(=O)N(C)C2CC(C)C2)N(C(=O)C[C@@H]2CCC[C@H]2O)C1', 'CO[C@H]1C[C@H](C(=O)N2CCCC2C(C)(C)C(=O)N(C)CC2CCC2)C1', 'CO[C@H]1C[C@H](C(=O)N2C[C@@H](O)C[C@@H]2Cn2cc(CCC(C)O)nn2)C1', 'CO[C@H]1C[C@H](C(=O)NC2(C)CCCC2(C)C)N(C(=O)C2CCC2C)C1', 'CO[C@H]1C[C@H](C(=O)NC2CC3(CC(O)C3)C2)N(C(=O)CCN(C)C)C1', 'CO[C@H]1C[C@H](CC(=O)N2CC(N(C)C(=O)CC3CCCC(C)C3)C2)C1', 'CO[C@H]1C[C@H](CC(=O)N2CCCC[C@H]2CCNC(=O)C2CC2(F)F)C1', 'CO[C@H]1C[C@H](CC(=O)N2CC[C@H](O)C[C@@H]2C(=O)N[C@H](C)CC2CC2)C1', 'CO[C@H]1C[C@H](CC(=O)NC(CC(C)C)C(=O)N2CCC(CSC)C2)C1', 'CO[C@H]1C[C@H]2C[C@@H](C1)N(C(=O)[C@H]1CCCCN1C(=O)C(C)(C)OC)C2', 'CO[C@H]1C[C@H]2[C@@H]1CCN2C(=O)C/C=C/CNC(=O)C1(CF)CC(=O)C1', 'CO[C@H]1C[C@H]2[C@@H]1CCN2C(=O)C[C@@H]1C[C@H](F)CN1C(=O)COCCF', 'CO[C@H]1Cc2ccccc2[C@@H]1N(C)C(=O)c1cc(S(C)(=O)=O)cn1C', 'CO[C@]1(C(F)(F)F)C[C@@](N)(C(=O)Nc2cc([N+](=O)[O-])c(F)cc2F)C1', 'CO[C@]1(C(F)(F)F)C[C@H](NC(=O)c2ccc(-c3nc(C)no3)cc2)C1', 'CO[C@]12CC[C@H]1CN(C(=O)C1=C(F)CN(C(=O)C3SCCS3)CC1)C2', 'CO[C@]12CC[C@H]1CN(C(=O)N[C@@H]1[C@H]3C[C@@H]1N(C(=O)OC(C)(C)C)C3)C2', 'COc1c(Br)cccc1CNC(=O)C(=O)NC1CCC(CC(C)C)C1', 'COc1c(C#N)cccc1CC(=O)N(C)c1nnn(C)c1C(F)(F)F', 'COc1c(C#N)cccc1CNc1cc(-c2ccccc2C)nn1C', 'COc1c(C(=O)N(O)Cc2cn(-c3cccc(Cl)c3)nn2)csc1C', 'COc1c(C(=O)N2CCN(C(=O)c3ccco3)C(C)C2C)csc1C', 'COc1c(C(=O)N2Cc3ccccc3CCC23CCC3)occc1=O', 'COc1c(C)cc(Cl)cc1NC(=O)c1cc(-c2ccccc2)nn1C', 'COc1c(C)cc(Cl)cc1NCc1cccc(C(=O)NCC(C)C)c1', 'COc1c(C)ccc(C(=O)N2CCCc3ccc4c(c32)CCO4)c1F', 'COc1c(C)cccc1CNC(=O)Nc1nnc(C2CCCCO2)s1', 'COc1c(CN(CCCSC)C(=O)C(C(C)C)C(C)C)c(C)nn1C', 'COc1c(Cl)cc(C(=O)OC[C@@H](O)COCc2ccccc2)cc1Cl', 'COc1c(Cl)cc(Cl)cc1CNC(=O)N1CC2CCCC(OC)C2C1', 'COc1c(Cl)cc([N+](=O)[O-])cc1CNC(c1cccc(C)n1)C1CC1', 'COc1c(Cl)ccc2c1CN(C(=O)NC(C(C)(C)C)C(C)(C)C)CC2', 'COc1c(F)c(F)cc(CNc2cc(N3CCNCC3)ccn2)c1F', 'COc1c(F)cc(CNC(=O)N[C@@H](CO)c2cccc(Cl)c2)cc1F', 'COc1c(F)cc(F)cc1C(=O)NCc1ccnc(-n2cccn2)c1', 'COc1c(F)cc(S(=O)(=O)N[C@H](C)C(=O)Nc2ccccc2)cc1F', 'COc1c(F)cccc1CN(C)S(=O)(=O)CCOCc1ccccc1', 'COc1c(F)cccc1CN(CC1CC2(CC2)C1)C(=O)C(C)CSC', 'COc1c(F)cccc1NC(=O)C/C=C/CNC(=O)CCP(C)(C)=O', 'COc1c(F)cccc1[C@@H](C)NC(=O)c1ccc([C@H](O)C2CC2)cc1', 'COc1cc(-c2cccc(C(=O)CC(F)(F)F)c2)cc2c1OCCO2', 'COc1cc(-c2nc(-c3ccc(CC(C)C)[nH]c3=O)no2)ccc1C', 'COc1cc(-c2noc(-c3cc4oc(C)cc4[nH]3)n2)cc(Cl)c1OC', 'COc1cc(=O)n(C)cc1C(=O)NCc1nc2cc(C)ccc2n1C', 'COc1cc(Br)cc(C(=O)N(Cc2ccccc2)OCC(C)C)c1O', 'COc1cc(C#N)ccc1CCC(=O)OCCC=Cc1ccccc1', 'COc1cc(C#N)ccc1NC(=O)NCC(OC)c1ccccc1C', 'COc1cc(C(=O)N(C)[C@H](C)CC(=O)NC(C)Cc2cccs2)n[nH]1', 'COc1cc(C(=O)N(CCNC(=O)C2(F)CC=CC2)C2CC2)ccn1', 'COc1cc(C(=O)N(Cc2ccc(C)s2)CC23CCC(CC2)C3)sn1', 'COc1cc(C(=O)N2CC(CO)C(NC(=O)[C@H]3C[C@@H](OC)C3)C2)n[nH]1', 'COc1cc(C(=O)N2CC(OCc3nc(C)no3)C2)cc(OC)c1C', 'COc1cc(C(=O)N2CC=CC2C(=O)N2CCC(C)C(F)(F)C2)on1', 'COc1cc(C(=O)N2CCC(NC(=O)c3cc(C)ns3)C23CC3)sn1', 'COc1cc(C(=O)N2C[C@@H](F)C[C@@H]2C(=O)N2CC(S(C)(=O)=O)C2)sn1', 'COc1cc(C(=O)NC(C)Cc2cc(C)cc(C)c2)cc2cn[nH]c12', 'COc1cc(C(=O)NC2CC(NC(=O)C(C)N3CCOC3=O)C2)sn1', 'COc1cc(C(=O)NCC(C)(O)CNC(=O)[C@H]2C[C@@H]2C2CC2)ncn1', 'COc1cc(C(=O)NCC(C)(O)c2cc(C)oc2C)cc([N+](=O)[O-])c1', 'COc1cc(C(=O)NCC2=CCCN(C(=O)C(F)=CC3CC3)C2)sn1', 'COc1cc(C(=O)NCC2CC(CNC(=O)c3cnsn3)C2)ccn1', 'COc1cc(C(=O)NCCC(OC)C(C)C)ccc1OC1CCCC1', 'COc1cc(C(=O)NC[C@H](CO)NC(=O)C2(C)CCC3CC3C2)on1', 'COc1cc(C(=O)NC[C@H]2[C@@H](C(=O)NC(C)C(C)(C)C)C2(C)C)n[nH]1', 'COc1cc(C(=O)NCc2occc2C(=O)NCC(C)(C)SC)n[nH]1', 'COc1cc(C(=O)N[C@H]2CC[C@H]2CNC(=O)C(=O)NCC2CC2)n[nH]1', 'COc1cc(C(=O)N[C@H]2CN(C(=O)c3c(C)csc3C)C[C@H]2F)on1', 'COc1cc(C(=O)Nc2c(C#N)oc3ccccc23)ccc1[N+](=O)[O-]', 'COc1cc(C(=O)Nc2cnc3c(c2)CC(C)CC3)ccc1C(=O)O', 'COc1cc(C(=O)OC(CN2CCOCC2)C(=O)OC(C)C)nn1C', 'COc1cc(C(=O)OCC(O)COCc2ccc(Cl)cc2)ccc1C', 'COc1cc(C(=O)OCCOCCC(=O)OC(C)(C)C)c(F)cc1Br', 'COc1cc(C(C(=O)NC2CC2)N2CCOCC2(C)C)c(F)cc1F', 'COc1cc(C(F)(F)F)ccc1C(=O)NCC(CC(C)(C)C)C(=O)O', 'COc1cc(C(F)(F)F)ccc1CNC(=O)NNC(=O)NCC(F)F', 'COc1cc(C(N)=O)ccc1CN1CCN(Cc2cnc(C)s2)CC1', 'COc1cc(C)c(Br)c(C)c1S(=O)(=O)NC[C@H](O)CN1CCCCC1', 'COc1cc(C)c(CN(C)C(=O)NCCc2cc(C)on2)cc1OC', 'COc1cc(C)c(CN2CC3(CCN(C)CC3)c3ccccc32)cn1', 'COc1cc(C)c2cc(C(=O)Nc3ccc(C)c(C4CC4)c3)[nH]c2c1', 'COc1cc(C)cc(CN(CC2(Cl)CC2(F)F)C(=O)[C@H]2CC2(F)F)c1', 'COc1cc(C)cc(CN(Cc2cnn(C)c2)CC2CSCCS2)c1', 'COc1cc(C)ccc1-c1cn(CCCNC(=O)C2CCCS2)nn1', 'COc1cc(C)ccc1C(=O)NCCN(C(=O)CC1CSC1)C1CC1', 'COc1cc(C)ccc1C(C(=O)NC(C)C)N1CCS(=N)(=O)C(C)C1', 'COc1cc(C)ccc1NC(=O)[C@@H]1[C@H](C)CN1C(=O)C(F)C(F)(F)F', 'COc1cc(C)cnc1CN[C@H](CO)CCCNC(=O)OC(C)(C)C', 'COc1cc(C2CCN(C(=O)NC3COC(C)(C)C3)C2)cc(F)c1F', 'COc1cc(C=CC(=O)NCC(=O)NC2CNC2)cc(OC)c1OC', 'COc1cc(C=Cc2nc(-c3ccccc3)cs2)ccc1OCC#N', 'COc1cc(CC(=O)OCCn2ccccc2=O)cc(OC)c1OC', 'COc1cc(CC(=O)Oc2c(C)cc(C)cc2Br)cc(OC)c1OC', 'COc1cc(CCC(=O)NCCC(C)NS(=O)(=O)C2(C)CC2)ccn1', 'COc1cc(CCNC(=O)c2cccc3c2OCCN3)cc(F)c1F', 'COc1cc(CN(CC(C)OC(F)F)C(=O)[C@H]2CNC(=O)C2)ccn1', 'COc1cc(CN(CCC2CC=CCC2)Cc2ncc(Cl)n2C)sn1', 'COc1cc(CN(CCC2CCSC2)C(=O)CCC(C)C)ccc1C', 'COc1cc(CN(Cc2cc(Br)[nH]n2)Cc2ccc(Cl)o2)c(Cl)cn1', 'COc1cc(CN(Cc2cc(C)c(C)cc2C)CC(F)C2CC2)sn1', 'COc1cc(CN2[C@H](C)CC[C@@H]2C(=O)OC(C)(C)C)cc(OC)c1C', 'COc1cc(CNC(=O)C(=O)NCc2cc(C)cc(Cl)n2)ccc1F', 'COc1cc(CNC(=O)C2C=CCN(C(=O)C3=COCCC3)C2)on1', 'COc1cc(CNC(=O)C2CCCCN2C(=O)C2=CCN(C)C2)on1', 'COc1cc(CNC(=O)N2CC3(CC(C(F)(F)F)C3)C2)ccc1CO', 'COc1cc(CNC(=O)NCC2=NOC3OCCCC23)ccc1CO', 'COc1cc(CNC(=O)NCCOc2cc(Cl)ccc2F)ccc1Cl', 'COc1cc(CNC(=O)Nc2ccc3ncsc3c2)cc(O)c1OC', 'COc1cc(CNC(=O)c2c(F)cc(F)c(O)c2F)cc(O)c1OC', 'COc1cc(CNC(=O)c2cc(O)ccn2)ccc1OCC(F)(F)F', 'COc1cc(CNC(=O)c2cnn3c2SCC3)ccc1OCC(N)=O', 'COc1cc(CNCC2CC2(Br)Br)ccc1OCCN1CCOCC1', 'COc1cc(CNCc2ccc(C(F)(F)F)cc2C)cc(C(=O)O)c1', 'COc1cc(CNc2ccc3ccc(Cl)c(Cl)c3n2)cc2c1OCO2', 'COc1cc(CNc2nc3ccc(C(=O)O)cc3s2)ccc1[N+](=O)[O-]', 'COc1cc(COC(=O)CCC2CCCC(O)C2)ccc1S(C)(=O)=O', 'COc1cc(CS(=O)CC(=O)NCCc2ccc(Cl)cc2)ccc1Cl', 'COc1cc(Cl)c(S(=O)(=O)N2CCC3(CCNCC3)CC2)cc1OC', 'COc1cc(Cl)c(S(=O)(=O)Oc2cccc(-c3cn[nH]c3)c2)cc1Br', 'COc1cc(Cl)cc(CN(Cc2ccc(C#N)c(C)c2)CC2CC2)c1', 'COc1cc(Cl)ccc1CNC(=O)c1ccn(Cc2ccccc2)c1', 'COc1cc(Cl)ccc1CNCC(N)c1ccc(Cl)c(C(F)(F)F)c1', 'COc1cc(Cl)ccc1S(=O)(=O)N1CCN(C(=O)C2CC2)CC1(C)C', 'COc1cc(F)c(C(C)NC(=O)N[C@H](C)c2csc(C)n2)cc1OC', 'COc1cc(F)c(CCN(C=O)Cc2c(F)cc(Cl)cc2Cl)cc1F', 'COc1cc(F)c(F)cc1C(=O)N1[C@H]2CC[C@@H]1[C@H]1C[C@@]1(C(F)(F)F)C2', 'COc1cc(F)c(NC(=O)c2cc(F)cc(C(=O)O)c2)cc1C(C)=O', 'COc1cc(F)cc(F)c1C(=O)NC1CC2(CCC(C(N)=O)CC2)C1', 'COc1cc(F)cc(F)c1C(=O)Nc1cccc(-n2cc[nH]c2=O)c1', 'COc1cc(F)ccc1CNC(=O)NCCc1cc(F)c(F)cc1I', 'COc1cc(F)ccc1NC(=O)C(C)N(C)C(=O)c1ccncc1N', 'COc1cc(F)ccc1Nc1cc(NCc2c(C)n[nH]c2C)ncn1', 'COc1cc(N)c(C(=O)N2CCOc3c(Cl)cccc3C2)cc1OC', 'COc1cc(NC(=O)CC(c2ccon2)C2CC2)ccc1C(C)(C)O', 'COc1cc(NC(=O)CCN2CCCCCCC2C)c(OC)cc1Cl', 'COc1cc(NC(=O)CCN2CC[C@H]3CCN[C@H]3C2)c(OC)cc1Cl', 'COc1cc(NC(=O)COc2ccccc2C#N)ccc1OC(C)C', 'COc1cc(NC(=O)NC2CC(COc3ccccc3)C2)c(Cl)cn1', 'COc1cc(NC(=O)NCC2CC=CC2)ccc1N1CCN(C)CC1', 'COc1cc(NC(=O)NCCC(=O)OC2CCCCC2)cc(OC)c1', 'COc1cc(NC(=O)NCc2c(C)sc3cncn23)cc([N+](=O)[O-])c1', 'COc1cc(NC(=O)N[C@@H](C)C(=O)OC(C)(C)C)cc(C(F)(F)F)c1', 'COc1cc(NC(=O)N[C@H](CO)Cc2ccccc2C)c(Cl)cc1Cl', 'COc1cc(NC(=O)[C@@H]2COCCN2C(=O)[C@H]2CCC(=O)N2)nn1C', 'COc1cc(NC(=O)c2coc(=O)c3ccccc23)cc(OC)c1F', 'COc1cc(OC)c(NC(=O)NNS(=O)(=O)CCCCCF)cc1Cl', 'COc1cc(S(=O)(=O)NC(=O)C2(OC)CCC(F)(F)CC2)cnc1Cl', 'COc1cc(S(=O)(=O)NCC(F)(F)c2cccc(F)c2)c(F)cc1Cl', 'COc1cc(S(=O)(=O)NCCCNC(=O)CC(F)(F)C(F)F)n(C)n1', 'COc1cc(S(N)(=O)=O)ccc1NS(=O)(=O)c1cc(C2CC2)nn1C', 'COc1cc2c(cc1Br)CN(C(=O)c1cnc3c(c1)ncn3C)CC2', 'COc1cc2c(cc1CNc1cccc3c1N(C(C)=O)CC3)CCC2', 'COc1cc2c(cc1Cl)CCN(C(C)C(=O)Nc1ccccc1Br)C2', 'COc1cc2c(cc1F)CCC2NC(=O)C(=O)N1CCCCC1CF', 'COc1cc2c(cc1F)N(C(=O)CCC1CCC(C)NC1=O)CCC2', 'COc1cc2c(cc1NC(=O)C(=O)N1CC(S(C)=O)C1)NC(=O)CC2', 'COc1cc2c(cc1OC)CC(CC1CCN(C(C)CCO)CC1)C2', 'COc1cc2c(cc1S(=O)(=O)NCC(O)CC1CCCCC1)CCC2', 'COc1ccc(-c2ccc(CN(C=O)CC[C@H]3OCC[C@H]3C)o2)cc1', 'COc1ccc(-c2cn(CC(=O)NC3CCNC(=O)CC3)nn2)cc1', 'COc1ccc(-c2cn(Cc3ccc(-n4cccn4)nc3)nn2)cc1', 'COc1ccc(-c2nc(CN3CCC(C(F)(F)F)C3(C)C)co2)cc1', 'COc1ccc(-c2nc(COC(=O)[C@@H]3C[C@H]4C=C[C@@H]3CC4)cs2)cc1', 'COc1ccc(-c2nccc(Nc3cccc(NC(N)=O)c3)n2)cc1', 'COc1ccc(/C=C(\\C)C(=O)N2CCC(CC3CC3)CC2)cc1OC', 'COc1ccc(Br)cc1C(=O)OCC(=O)NCc1ccc(C#N)cc1', 'COc1ccc(C(=O)C(=O)OCc2cscc2S(C)(=O)=O)cc1OC', 'COc1ccc(C(=O)COC(=O)c2cncc(O)n2)c(OC)c1OC', 'COc1ccc(C(=O)N(Cc2ccccc2F)CC2CC2)nc1OC', 'COc1ccc(C(=O)N(Cc2csnc2OC)CC2(CF)CC2)cc1', 'COc1ccc(C(=O)N(Cc2ncc(C)o2)CC(OC)C2(C)CC2)s1', 'COc1ccc(C(=O)N2CC(O)(CN(C)C(=O)c3cnsn3)C2)cc1', 'COc1ccc(C(=O)N2CCC(Cc3ccccc3C)CC2)cc1C', 'COc1ccc(C(=O)N2CCCc3c(N)cccc32)c2ccncc12', 'COc1ccc(C(=O)N2CCN(c3ncc(Cl)cc3Br)CC2)cc1O', 'COc1ccc(C(=O)N2CCOC(C3CCCC3)C2)c2ccccc12', 'COc1ccc(C(=O)N2CC[C@@H]3CNC[C@@H]3CC2)c(OCC(F)F)c1', 'COc1ccc(C(=O)N2CC[C@H](CC(=O)NCCC(C)C(C)C)C2)o1', 'COc1ccc(C(=O)NC(C)(C)CCC(=O)N[C@@H](C)CN(C)C)cc1', 'COc1ccc(C(=O)NC(C)CCCNC(=O)CC(C)(C)C)c(C)c1', 'COc1ccc(C(=O)NC(CCO)c2ccc(Cl)cc2)cc1C1CC1', 'COc1ccc(C(=O)NCC(=O)NCC(=O)N2CC(F)(CF)C2)cc1', 'COc1ccc(C(=O)NCC(=O)NCCN2CC(OC)C2)cc1OC', 'COc1ccc(C(=O)NCCN(C(=O)CCC(C)C)C2CC2)cc1N', 'COc1ccc(C(=O)N[C@H]2CC[C@@H]2NC(=O)c2cncn2C2CC2)o1', 'COc1ccc(C(=O)N[C@H]2CC[C@H](NC(=O)c3cc(C)co3)C2)nn1', 'COc1ccc(C(=O)Nc2ccc(-c3nnn[nH]3)nc2)c2[nH]ncc12', 'COc1ccc(C(=O)Nc2ccc(C)c(N3CCOC3=O)c2)nc1N', 'COc1ccc(C(=O)O)c(NC(=O)c2ccnc(N3CCCC3)n2)c1', 'COc1ccc(C(C)(C)C(=O)N2CCC(C(=O)O)C23CC3)cc1OC', 'COc1ccc(C(C)CCNC(=O)CCCc2ccc(Cl)cc2)cc1', 'COc1ccc(C(C)CNC(=O)N2CCC(C)C(C)(C)C2)cc1OC', 'COc1ccc(C(C)NC(=O)C(=O)N(C)Cc2c[nH]nn2)c(OC)c1', 'COc1ccc(C(C)NC(=O)N(C)CC2=C(C)CCCC2(C)C)cn1', 'COc1ccc(C(CNC(=O)NCc2c(C)noc2C)N(C)C)cc1', 'COc1ccc(C(NC(=O)N2C[C@H]3C[C@@H](O)C[C@H]3C2)C(F)F)cc1F', 'COc1ccc(C(Nc2nccc(OC)c2C(=O)O)C2CCC2)cc1', 'COc1ccc(C)c(C(=O)N2CC(NC(=O)C3CC=C(C)CC3)C2)c1', 'COc1ccc(C)c(CC(=O)Nc2ccc(N3CCOC3=O)nc2)c1', 'COc1ccc(C)c(NC(=O)CC(C)CNC(=O)c2ccc(Cl)o2)c1', 'COc1ccc(C)c(NC(=O)N(C)c2cc(C3CCCCC3)[nH]n2)c1', 'COc1ccc(C)cc1-c1csc(NC(=O)Cc2ccccc2O)n1', 'COc1ccc(C)cc1CN(Cc1c(C)sc2cncn12)CC(C)F', 'COc1ccc(C)cc1NC(=O)C1(CCNC(=O)C(C)C(C)C)CC1', 'COc1ccc(C)cc1NC(=O)C1=CCN(C(=O)CCC(C)(F)F)C1', 'COc1ccc(C)nc1CN(Cc1cc(Br)[nH]n1)C[C@]12CCC[C@H]1C2', 'COc1ccc(C2(C(=O)N3C[C@@H](F)C[C@H]3CN)CC3(CCC3)C2)cc1', 'COc1ccc(C2(NS(=O)(=O)CC3(C)CCCC3)CCCCC2)cc1', 'COc1ccc(C2CC(C(=O)NCc3nc(CSC)no3)=NO2)cc1', 'COc1ccc(C2CCCCC2)cc1NCc1cccnc1N(C)C', 'COc1ccc(C2CCCN2C(=O)CC2CCN(C)CC2)c(OC)c1', 'COc1ccc(C2CCN(C(=O)C3CCOCC34CCCC4)C2)cc1', 'COc1ccc(C=C(C)C(=O)NCCN2CCCCCC2)cc1OC', 'COc1ccc(C=CC(=O)N2CCC(N3CCCOCC3)C2)cc1F', 'COc1ccc(C=CC(=O)NNc2cccc(C)c2)cc1S(N)(=O)=O', 'COc1ccc(CC(=O)N(C)CCn2cc(-c3cncs3)nn2)cn1', 'COc1ccc(CC(=O)N(C)Cc2cc([N+](=O)[O-])ccc2Br)cc1O', 'COc1ccc(CC(=O)Nc2ccc(-n3cccn3)cc2C)cc1O', 'COc1ccc(CC(C)C(=O)N2CCC3(CCCC(=O)N3)CC2)cc1', 'COc1ccc(CC(C)CN(C)C(=O)Nc2cnc3n2CCC3)cc1', 'COc1ccc(CC(NC(=O)N2C[C@@H](C)OC(F)(F)C2)C(C)C)cc1', 'COc1ccc(CCCNC2CC(Nc3ccc(F)cc3)C2)cc1C', 'COc1ccc(CCNC(=O)Nc2cc(Cl)nn3cc(C)nc23)cc1', 'COc1ccc(CN(C)C(=O)C23CC(C)(C2)OC32CCNCC2)cn1', 'COc1ccc(CN(C)C(=O)NC[C@]2(F)CC[C@@H](CO)CC2)c(Cl)c1', 'COc1ccc(CN(C)c2cc(NCCCC3CC3)ncn2)cc1F', 'COc1ccc(CN(CC2CCC(F)C2)C(=O)CC(C)SC)c(C)n1', 'COc1ccc(CN(CCSC(C)C)C(=O)C2CN3CCC2C3)nc1', 'COc1ccc(CNC(=O)C(c2ccon2)N2CC[C@@H](SC)C2)cc1', 'COc1ccc(CNC(=O)NCC2CN(C(N)=O)CCO2)cc1OC', 'COc1ccc(CNC(=O)NCc2cccc3cccnc23)cc1F', 'COc1ccc(CNc2ccn(CCC(F)(F)F)n2)c(C(F)(F)F)c1', 'COc1ccc(CNc2ccnc(N3Cc4cn[nH]c4C3)n2)cc1F', 'COc1ccc(CO)cc1C(=O)N1CCc2ncnc(N(C)C)c2C1', 'COc1ccc(COC(=O)COc2cc(N)cc(Br)c2)cc1[N+](=O)[O-]', 'COc1ccc(CSCC(=O)OCC(C2CC2)C2CC2)cc1[N+](=O)[O-]', 'COc1ccc(CSc2nnc(CCc3ccc(C)cc3)[nH]2)cc1Cl', 'COc1ccc(Cl)c(CCNC(=O)Nc2c[nH]nc2OCC(F)F)c1', 'COc1ccc(Cl)c(N2CCN(Cc3sc(C(=O)O)cc3Br)CC2)c1', 'COc1ccc(Cl)c2c1CCCC2N(C)C(=O)NCC1(C)CCCS1', 'COc1ccc(Cl)c2sc(NC(=O)c3[nH]c(C)nc3C(F)(F)F)nc12', 'COc1ccc(Cl)cc1C(CC(C)C)NC(=O)C(=O)NC1CC=CC1', 'COc1ccc(Cl)cc1N1CC(C(=O)Nc2ccc(N)cn2)CC1=O', 'COc1ccc(Cn2cnc(NC(=O)c3snnc3C(C)C)n2)cc1', 'COc1ccc(Cn2nc(C)cc2NC(=O)C2(N)CC(OC)C2)cc1', 'COc1ccc(F)c(C(C(=O)NCC(C)C)N(C)CC2CC(F)C2)n1', 'COc1ccc(F)c(CC(=O)N(C)Cc2cc(F)c(F)c(F)c2)c1F', 'COc1ccc(F)c(CN(CCC2(OC)CC2)Cc2ccsc2Cl)n1', 'COc1ccc(F)c(CN(CCSC(C)(C)C)C(=O)C#CC2CC2)n1', 'COc1ccc(F)c(CNC(=O)C(=O)N(C)CC(C)(C)S(C)(=O)=O)c1', 'COc1ccc(F)c(CNC(=O)NNc2ccc3[nH]c(C)nc3c2)n1', 'COc1ccc(F)c2sc(C(=O)Nc3ccn(CCN(C)C)n3)cc12', 'COc1ccc(F)cc1C(C)NC(=O)NCC(O)c1cccc(C)c1', 'COc1ccc(F)cc1C(C)OC(=O)c1cc(C)cnc1C(F)(F)F', 'COc1ccc(F)cc1CN(CC1(C)CCOC1)C(=O)C1=CCSC1', 'COc1ccc(F)cc1CN(CCC1CSC1)C(=O)[C@@H]1CC=CCC1', 'COc1ccc(N(C)C(=O)Nc2nc(-c3ccccc3)cs2)cc1F', 'COc1ccc(N(C)C(=O)c2cn(C3CCCCC3)nc2C)cc1F', 'COc1ccc(N2CC(c3ccc(C(F)(F)F)cc3)C2)c([N+](=O)[O-])c1', 'COc1ccc(NC(=O)C(C)(C)C(C)NC(=O)C(O)CC(C)C)cc1', 'COc1ccc(NC(=O)C(C)N(C)C(=O)c2cc(O)ccn2)c(C)c1', 'COc1ccc(NC(=O)C(C)OC(=O)Cn2nc(N)cc2C)cc1Cl', 'COc1ccc(NC(=O)Cn2cc(Br)c3cnccc3c2=O)cc1Cl', 'COc1ccc(NC(=O)N(Cc2nccn2C)C2CCC2)c(OC)c1', 'COc1ccc(NC(=O)N2CCN(c3ccncc3)C(C)C2)c(Br)c1', 'COc1ccc(NC(=O)[C@@H]2CC[C@@H]2NC(=O)CSCC(F)F)cc1F', 'COc1ccc(NC(=O)c2ccn(C(C)(C)C)n2)cc1NS(C)(=O)=O', 'COc1ccc(O)c(C(=O)NCC(CNC(=O)CS(C)(=O)=O)OC)c1', 'COc1ccc(O)c(CNCC(C)(C)c2ccc(OC(F)F)cc2)c1', 'COc1ccc(O)cc1C(=O)NC(C)C1CCCN(c2ncns2)C1', 'COc1ccc(OC)c(C2=NOC(C(=O)N3CCOCC3CN)C2)c1', 'COc1ccc(OC)c(C2CCCN2C(=O)[C@@H]2COC[C@H]2C(=O)O)c1', 'COc1ccc(OC)c(CCN2CCC3(CC2)CCC(F)(F)CC3)c1', 'COc1ccc(OC)c(NC(=O)CN2Cc3ccc(CO)cc3C2)c1', 'COc1ccc(OCc2noc(CN3CCn4ncnc4C3)n2)cc1', 'COc1ccc(S(=O)(=O)N2CCCC3(CCOCC3)CC2)c(Cl)c1Cl', 'COc1ccc(S(=O)(=O)N2Cc3c(Br)ccc(F)c3C(C)C2)c(F)n1', 'COc1ccc(S(=O)(=O)NC(=O)[C@H]2CCO[C@@H]2c2ccccc2)cn1', 'COc1ccc(S(N)(=O)=O)c(C)c1NC(=O)N(CCN(C)C)C(C)C', 'COc1ccc(S(N)(=O)=O)c(COC(=O)c2ccn3nccc3n2)c1', 'COc1ccc(S(N)(=O)=O)c(OC)c1C(=O)NCCc1n[nH]cc1C', 'COc1ccc(SC)c(OC)c1C(=O)Nc1nc2ccc(Br)cn2n1', 'COc1ccc([C@@H](O)C(=O)N2CC(c3n[nH]c4c3COCC4)C2)cc1', 'COc1ccc([C@H]2OCC[C@@H]2n2cc(CC3CCCCC3)nn2)cn1', 'COc1ccc2[nH]nc(CN(Cc3ccc(F)cc3)CC3CC3)c2c1', 'COc1ccc2c(C(=O)N3CCC4CCCC43C(=O)O)ccnc2c1', 'COc1ccc2c(COC(=O)CN3CCCCCC3=O)cccc2c1', 'COc1ccc2c(c1)C(=O)C(OC(=O)c1nc(Cl)c(O)nc1N)CC2', 'COc1ccc2c(c1)C(C(=O)N(C)c1ccc(Cl)nc1C(N)=O)CO2', 'COc1ccc2c(c1)CC(C(=O)N1C[C@H](CO)[C@@H](C(F)(F)F)C1)CO2', 'COc1ccc2c(c1)OCC(NC(=O)C(=O)NCc1nc(Cl)cs1)C2', 'COc1ccc2cc(C(=O)N3CCCN(CC(C)O)CC3)cnc2c1', 'COc1ccc2cc(C(C)CNS(=O)(=O)N=S3(=O)CCCC3)oc2c1', 'COc1ccc2cc(CNC3CN(c4ccncn4)C3)c(O)nc2c1', 'COc1ccc2cc(NNC(=O)c3coc(S(C)(=O)=O)c3)ccc2c1', 'COc1ccc2nc(NC(=O)c3cc4cc(F)ccc4s3)n(C)c2c1', 'COc1ccc2nc(NC(=O)c3ccnc(C(C)(C)C)c3)n(C)c2c1', 'COc1ccc2nc(O)c(CN(C)CC(C)(C)C3CCOC3)cc2c1', 'COc1ccc2nccc(C(=O)OCc3nc4ccccc4s3)c2c1', 'COc1cccc(-c2nc3c(s2)CN(C(=O)CC2CC(C)C2)CC3)n1', 'COc1cccc(-c2ncc(C(=O)NC3(c4nccs4)CNC3)s2)c1', 'COc1cccc(C(=O)N2CCN(C(=O)C3OC4CCC3C4)CC2)n1', 'COc1cccc(C(=O)NC2(c3ccc(F)cc3Cl)CC2)c1C(F)F', 'COc1cccc(C(=O)NC2CC=C(C(=O)N3CC(C)(CF)C3)C2)n1', 'COc1cccc(C(=O)NC[C@@H]2CCN(C(=O)CC3CC(F)C3)C2)n1', 'COc1cccc(C(C)(C)CNC(=O)NCCc2ccccc2Br)c1', 'COc1cccc(C(F)(F)CNc2ccn3nc([N+](=O)[O-])cc3n2)c1', 'COc1cccc(C(F)Cn2cc(-c3cccc(C(C)=O)n3)nn2)c1', 'COc1cccc(C(NC(=O)CSCC(=O)O)c2ccc(Cl)cc2)c1', 'COc1cccc(C(NCC2CC(C)(C)C(=O)O2)C2CCCCC2)c1', 'COc1cccc(C(O)CN2CCC(c3cc(C)cc(C)c3)CC2)c1', 'COc1cccc(C)c1CN(Cc1csc(C)c1)C(=O)CC1CSC1', 'COc1cccc(C)c1CNC(=O)N(C)Cc1c(C)nn(C)c1OC', 'COc1cccc(C2=CCN(C[C@H]3CC[C@H](C(=O)OC)CC3)CC2)c1', 'COc1cccc(C=CC(=O)C(=O)N(C)Cc2c(F)cccc2F)c1', 'COc1cccc(CC(NCc2nc(Cl)c3ccccn23)C(=O)O)c1', 'COc1cccc(CCC(=O)N2CCc3c(cnc(N)c3C#N)C2)c1', 'COc1cccc(CN(C)CC(=O)NS(=O)(=O)C2CCCCC2)c1Cl', 'COc1cccc(CN(CC2(SC)CCC2)C(=O)C2CCCS2)c1F', 'COc1cccc(CN(Cc2cc(Cl)cc(C#N)c2)C[C@H]2C[C@H]2C)n1', 'COc1cccc(CNC(=O)C2CCCCN2Cc2ccccn2)c1', 'COc1cccc(CNC(=O)CCN(C(=O)CS(C)(=O)=O)C2CC2)n1', 'COc1cccc(CNC(=O)NCCCSc2ccc(F)cc2)c1F', 'COc1cccc(CNC(=O)c2ccc(C#N)cc2O)c1OC(F)F', 'COc1cccc(CN[C@H](C(=O)OC(C)(C)C)c2ccccc2)c1F', 'COc1cccc(Cc2nnc(NC(=O)N3CCC(CCF)C3)s2)c1', 'COc1cccc(F)c1C(=O)NC1CC(NC(=O)c2coc(C)c2)C1', 'COc1cccc(N2CCN(C(=O)c3cnn(CCO)c3)CC2C)c1', 'COc1cccc(N2CCN(CC(=O)NCCCN(C)C)CC2)c1F', 'COc1cccc(NC(=O)/C(C)=C/CNC(=O)Cn2ccnc2)c1F', 'COc1cccc(NC(=O)CN(c2ccc(OC)c(F)c2)C(C)C)c1', 'COc1cccc(NC(=O)NCCCn2cc(P(C)(C)=O)cn2)c1F', 'COc1cccc(NC(=O)[C@@H](NC(=O)[C@@H]2CC[C@H]2C#N)C(C)C)c1F', 'COc1cccc(NC(=O)[C@@H]2[C@H](C)CN2C(=O)[C@@H](O)CCN(C)C)c1', 'COc1cccc(OC(F)(F)F)c1C(=O)NCCC1(C(F)(F)F)CC1', 'COc1cccc(OC)c1CC(=O)NC1(c2nn[nH]n2)CCSCC1', 'COc1cccc(OC2CN(C(=O)NCCCS(=O)(=O)N(C)C)C2)c1', 'COc1cccc2c(=O)[nH]c(N3CCCCNC(=O)C(F)(F)C3)nc12', 'COc1cccc2c(C)c(C(=O)N3CCn4c(C)nnc4C3C)oc12', 'COc1cccc2c1C(Cn1cc(-c3ccc(C)c(N)c3)nn1)CC2', 'COc1cccc2c1CC(c1nc(-c3cnn(CCO)c3)no1)CO2', 'COc1cccc2c1OCC(C(=O)NC(C)(C)CC1CCCCC1)C2', 'COc1cccc2cc(-n3cc(-c4c(C)nn(C)c4Cl)nn3)cnc12', 'COc1ccccc1-c1ccnc(NC(=O)c2cc(Br)c(Cl)cn2)n1', 'COc1ccccc1C(=O)N1CC=C(C(=O)N[C@H](CCO)C(C)C)C1', 'COc1ccccc1C(=O)N[C@@H](C)CCC(=O)N[C@@H](C)CS(C)(=O)=O', 'COc1ccccc1C(C)N(OC)C(=O)c1ccc(Cl)c([N+](=O)[O-])c1', 'COc1ccccc1C(NC(=O)CC1CCCN(C)C1)c1ccco1', 'COc1ccccc1C1(C(=O)N2CCCC(F)(C(N)=O)C2)CCCC1', 'COc1ccccc1C1CCN(C(=O)NC(C)c2cnn(C)c2C)C1', 'COc1ccccc1C1CNCCN1C(=O)c1cnc2ncccn12', 'COc1ccccc1CCCNC(=O)N[C@H]1C[C@](OC)(C(F)(F)F)C1', 'COc1ccccc1CCCNCCCc1cccc(C(F)(F)F)c1', 'COc1ccccc1CN(C)C(=O)c1ccccc1OC1CCCC1', 'COc1ccccc1CN1CCN(C(=O)c2cn3c(n2)CCC3)CC1', 'COc1ccccc1CNC(=O)C(C)(C)CCNC(=O)CCC1CC1', 'COc1ccccc1CNC(=O)C(C)N1CCC(CCCCO)CC1', 'COc1ccccc1COCC(O)COC(=O)CCn1ccnc1C', 'COc1ccccc1N(C)C(=O)C1CCCN1C(=O)C(SC)C(C)C', 'COc1ccccc1N1CCC(CNC(=O)NC2(C3(C)CC3)CC2)C1', 'COc1ccccc1NC(=O)CCNCC(F)(F)c1ccccc1C', 'COc1ccccc1OCC(C)NC[C@H]1C[C@@H]1c1cccc(Br)c1C', 'COc1ccccc1OCC(O)CNCC1(C(=O)OC(C)(C)C)CC1', 'COc1ccccc1SCC(C)CNC(=O)N1CCCCCC1CO', 'COc1cccnc1CNC(=O)CC(NC(=O)CCSC)C(C)(C)C', 'COc1cccnc1N1CCN(Cc2cc(Cl)c(C)c(C)c2Cl)CC1', 'COc1ccn2c(CNC3CCS(=O)(=O)c4ccccc43)cnc2c1', 'COc1ccnc(C(=O)Nc2cccc(C#Cc3cccs3)c2)c1O', 'COc1ccnc(CNC(=O)C2(C)CCN(C(=O)CC3CC3)CC2)c1', 'COc1ccnc(F)c1NC(=O)NC(C)C(O)c1c(F)cccc1Cl', 'COc1ccnc(N2CCN(C(=O)Nc3cnc(Cl)c(C)c3)CC2)c1', 'COc1ccnc(N2CCN(c3ncc(C#N)cc3[N+](=O)[O-])CC2)n1', 'COc1ccncc1CC(=O)N[C@@H]1C=C[C@H](CNS(=O)(=O)C2CC2)C1', 'COc1ccncc1COC(=O)CC(c1ccccc1)n1cnnn1', 'COc1ccsc1C(=O)NC[C@H]1CC[C@@H](C(=O)N2C3CSCC2C3)O1', 'COc1ccsc1CN(CC1C(F)(F)C12CCC2)C(=O)c1cocn1', 'COc1cnc(Br)cc1C(=O)Nc1ccnc(Sc2ccccn2)c1', 'COc1cnc(C(=O)N(C)CCCN(C)C(=O)c2c[nH]c(=O)s2)cn1', 'COc1cnc(CN(CC2(C(C)C)CCCC2)C(=O)C2CSC2)nc1', 'COc1cnc(CNC(=O)c2cccc(-c3ccccn3)c2C)cn1', 'COc1cnc(F)c(NC(=O)Nc2ccc3nc(S(C)=O)[nH]c3c2)c1', 'COc1cnc(N[C@H](CO)CNC(=O)CCCC(C)(C)C)nc1CO', 'COc1cnc2[nH]cc(CC(=O)N3[C@H](CSC)C[C@@H]4CCC[C@@H]43)c2c1', 'COc1cncc(-c2cn([C@@H](C)CNC(=O)C3(C)CCCC3)nn2)n1', 'COc1cncc(C(=O)N(CCC(=O)NCC2CC(C)C2)C2CC2)n1', 'COc1cncc(C(=O)N(CCCNC(=O)c2cc[nH]n2)C2CC2)n1', 'COc1cncc(NC(=O)[C@@H]2C[C@@H]3C[C@@H]3N2C(=O)COC2CCC2)c1', 'COc1cncc(NC(=O)[C@H]2CCCCN2C(=O)[C@@H]2CCC(=O)O2)c1', 'COc1cnccc1C(=O)NC1(C(=O)N2CCCCCCC2)CCC1', 'COc1cnccc1C(=O)OC(C)c1nnc(-c2cccc(C)c2)o1', 'COc1cncnc1C(=O)NC[C@@H](C)Nc1cc(S(C)(=O)=O)ncn1', 'COc1cncnc1C(=O)Nc1ccnc(Oc2ccccc2Br)c1', 'COc1cncnc1NC(=O)c1ccc(-c2cccc(C#N)c2)cc1', 'COc1cnn(C)c1S(=O)(=O)NC(=O)CCN(C)Cc1ccncn1', 'COc1cnnc(C(=O)NC2(C(=O)NCc3cnns3)CC(O)C2)c1', 'COc1cnnc(C(=O)NC2CCN(C(=O)C3=C(C)CCC3)CC2)c1', 'COc1cnnc(C(=O)NCc2ccc(C(=O)N3CC(O)C3)cc2)c1', 'COc1cnncc1C(=O)N1CC(CNC(=O)C2(C)CCCC2C)C1', 'COc1cnncc1CN(CC1C2CCC(F)(F)C21)C[C@H](C)N=[N+]=[N-]', 'COc1csc(C(=O)N2CC(C)CCC2CNC(=O)C(C)N=[N+]=[N-])c1', 'COc1csc(C(=O)NC2(CCOCc3ccccc3)CC2)c1OC', 'COc1csc(C(=O)NCCOC2CCN(C(=O)C3CC3F)CC2)c1', 'COc1csc(C(=O)N[C@H]2C[C@H]2CNC(=O)c2cc(=O)n(C)cn2)c1', 'COc1cscc1C(=O)NCC(C)C(F)C(=O)N1[C@H](CO)C[C@@H]1CO', 'COc1cscc1C(=O)NCc1cc(C(=O)NC2CCN(C)C2)co1', 'COc1cscc1C(=O)N[C@@H](CCC(=O)NCC(C)(C)OC)C(C)C', 'COc1n[nH]cc1C(=O)NCC(C)(C)C#CC(=O)NC(C)CC(C)C', 'COc1n[nH]cc1CN(CC1(C(C)C)CC1)C(=O)C1(CCF)CCC1', 'COc1n[nH]cc1CN(CCCc1ccco1)CC(OC)C(F)(F)F', 'COc1nc(C(=O)Nc2ccc(-c3cnco3)cc2)ccc1[N+](=O)[O-]', 'COc1nc(C)cc(N2C[C@@H]3C[C@H]2CN3C(=O)c2csc(SC)n2)n1', 'COc1nc(C)ccc1CNC(=O)N[C@H]1C[C@@H]1c1cccc(F)c1F', 'COc1nc(C)ncc1C(=O)Nc1cnn(-c2ccccc2F)c1C', 'COc1nc(C)sc1C(=O)NC/C=C\\CNC(=O)C(C)OCC1CC1', 'COc1nc(C)sc1C(=O)NCCCCNS(=O)(=O)C1CCCC1C', 'COc1nc(NC2COCCN(C(=O)[C@H](C)OC(C)=O)C2)ncc1Cl', 'COc1nc(NCC2CCN(Cc3nc(C)c(C)o3)CC2)ncc1Cl', 'COc1nc(OC)c(CN2Cc3ccccc3OCC2(C)C)cc1Br', 'COc1ncc(Br)c(OC)c1C(=O)N1CCN(C(=O)NC(C)C)CC1', 'COc1ncc(C(=O)N2CCCC2C(=O)NCCCC(=O)N(C)C)s1', 'COc1ncc(C(=O)NC(CN(C)C)C(=O)NCC(C)C2CC2)cn1', 'COc1ncc(C(=O)NC23CC(NC(=O)C4=NOC(C)(C)C4)(C2)C3)s1', 'COc1ncc(C(=O)N[C@@H](CO)CNC(=O)CN2CCSCC2)cn1', 'COc1ncc(C)cc1NC(=O)NCCCC(F)(F)c1ccccc1', 'COc1ncc(F)cc1-c1cn(CCC(=O)NCCCC(F)F)nn1', 'COc1ncc(NC(=O)CC(C)(C)CNC(=O)Cc2ccn[nH]2)cn1', 'COc1ncc(NC(=O)NCc2cn(C3CCOCC3)nn2)cc1C', 'COc1nccc(C(=O)N2CC(Cn3cc(C4(C)CC4)nn3)C2)c1Br', 'COc1nccc(C(=O)N2CCC(N(C)C(=O)c3cn(C)cn3)C2)n1', 'COc1nccc(C(=O)NCC2(CNC(=O)C(O)CN(C)C)CC2)n1', 'COc1nccc(C(=O)NC[C@H]2[C@@H](C(=O)NC3C=CCC3)C2(C)C)n1', 'COc1ncccc1C(=O)N(C)CC(=O)NCc1ccc(O)c(C)c1', 'COc1ncccc1CN(CC1CC(=C2CC2)C1)C(=O)C1=CCSC1', 'COc1nccnc1C(=O)NC(C)C1(O)CCN(C(=O)C=C(Cl)Cl)C1', 'COc1ncnc(C)c1NC(=O)[C@H]1CCN1C(=O)C(CO)C(F)(F)F', 'COc1ncnc(N(C)C)c1NC(=O)Nc1ccc2c(Cl)n[nH]c2c1', 'COc1nn(C)cc1CNC(=O)C(CNC(=O)C1(C)COC1)N(C)C', 'COc1nn(CC(F)F)cc1NC(=O)c1ccc2ccnc(Cl)c2n1', 'COc1nnc(CCOC(=O)CN(C)c2nc3c(F)cccc3s2)s1', 'COc1noc(C)c1C(=O)NCCCOCCC(=O)N[C@H]1C[C@H](F)C1', 'COc1nsc(OC)c1C(=O)N1CCCC(C(=O)N2CCCCC2)C1', 'COc1nsc(OC)c1CNC(=O)N1CCN(c2ccncc2)CC1', 'COc1nsc(OC)c1CNc1nccc(N2C[C@H](CO)[C@@H](C)C2)n1', 'COc1nscc1C(=O)N1CCC(C(=O)N(C)CC2CCSC2)CC1', 'COc1nscc1C(=O)NCC1(NC(=O)C2CCC(O)CN2C)CC1', 'COc1nscc1C(=O)NCC1(O)CN(C(=O)CCCCC(C)=O)C1', 'COc1nscc1C(=O)N[C@H](C)CCC(=O)NC1CN(C)CC12CC2', 'COc1nscc1C(C(=O)NCCCF)N1CCC(CC(C)C)CC1', 'COc1nscc1CN(C)C(=O)NCCS(=O)(=O)c1cccc(Br)c1', 'COc1nscc1CN(CC(F)C1CCC1)C(=O)c1cnccc1N', 'COc1nscc1CN(CC1(C)CC1(C)C)C(=O)C1CN(C)CCO1', 'COc1nscc1CN(CC1SCCS1)C(=O)c1c[nH]cc1C(C)C', 'COc1nscc1CN(CCC(C)C(C)C)C(=O)Cc1ccn(C)n1', 'COc1nscc1CN(CCC(C)OC)C(=O)c1cncn1C(C)C', 'COc1nscc1CN(Cc1cccc(O)c1)CC(C)(C)CC1CC1', 'COc1nscc1NC(=O)[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)c1cc(C)oc1C', 'COc1nscc1S(=O)(=O)NC(C)CCNC(=O)CCC(C)(C)C#N', 'COc1oc(C)nc1C(=O)N[C@H]1CCN(C(=O)C(C)C#N)[C@@H]1C(C)C', 'COc1sccc1C(=O)N1CCC=C(C(=O)NCC2(S(C)=O)CC2)C1', 'COc1sccc1C(=O)N1CCOCCC1C(=O)N(C)C[C@@H](C)OC', 'COc1sccc1C(=O)NC(C)C(C)NC(=O)c1sc(C#N)cc1C', 'COc1sccc1C(=O)N[C@H]1C[C@H](OCC(=O)NCc2cnsc2)C1', 'COn1cnc(C)c1C(=O)N[C@@H]1CC[C@H](CCC(=O)NC(C)CO)C1', 'COn1cnc(C)c1C(=O)N[C@H]1C[C@H](C(=O)N2CC(O)CCC2C)C1', 'CP(C)(=O)C1CCC=C1C(=O)OCc1nccn1-c1cccc(Cl)c1', 'CP(C)(=O)CC(=O)N1C[C@@H](O)C[C@@H]1C(=O)N1CCc2cncnc2C1', 'CP(C)(=O)CC(=O)NCc1ccc(C(=O)N2Cc3ccccc3C2)s1', 'CP(C)(=O)CCC(=O)NC1(CNC(=O)C2CCn3nnnc3C2)CC1', 'CP(C)(=O)CCC(=O)NC1CCCN(C(=O)C2=CCCOCC2)CC1', 'CP(C)(=O)CCCNc1ncccc1S(=O)(=O)N[C@H]1COC[C@H]1CO', 'CP(C)(=O)CN1CCCC(C(=O)Nc2cc(Cl)c(Cl)c(C(=O)O)c2)C1', 'CP(C)(=O)CN1CCCC(NC(=O)Cc2ccc(C(F)(F)F)nc2)C1', 'CP(C)(=O)COCC(=O)NC1(CNC(=O)CNc2cccnc2)CC1', 'CP(C)(=O)c1cccc(NS(=O)(=O)c2ccc(Cl)c(C(F)(F)F)c2)c1', 'CP(C)(=O)c1ccnc(NC(=O)NCC(O)Cc2ccc(F)cc2)n1', 'CS(=O)(=NC(=O)c1ccc(C(F)(F)F)c2c1OCCO2)C1CCCC1', 'CS(=O)(=O)C1(CNC(=O)c2nnc(C3CCCNC3)s2)CCCCC1', 'CS(=O)(=O)C1CCC(C(=O)N(c2ccc(Cl)nn2)C2CCCCC2)C1', 'CS(=O)(=O)C1CN(C(=O)Nc2ccc3ncnn3c2)C2(CCCC2)C1', 'CS(=O)(=O)CC(=O)N[C@@H]1CCC[C@H](CC(=O)N2C[C@H](O)[C@H](O)CO2)C1', 'CS(=O)(=O)CCC(CO)NC(=O)c1ccccc1SCc1cccs1', 'CS(=O)(=O)CCC1CCCN1C(=O)c1ccnc(N2CCOCC2)n1', 'CS(=O)(=O)CCCNC(=O)[C@H]1C[C@H](O)CN1C(=O)COc1ccsc1', 'CS(=O)(=O)CC[C@H](CO)NC(=O)c1csc(S(=O)(=O)N2CCCC2)c1', 'CS(=O)(=O)N1CCC(NC(=O)NCc2noc(-c3ccccc3)n2)C1', 'CS(=O)(=O)NC1(C(=O)NCc2cccc(S(N)(=O)=O)c2)CCCCC1', 'CS(=O)(=O)NC1CCCCC1CNC(=O)c1ccc2nccnc2c1', 'CS(=O)(=O)NCCCCNC(=O)c1c[nH]nc1-c1ccc(C#N)cc1', 'CS(=O)(=O)Nc1ccc(F)cc1C(=O)N1CCC2(CC1)CC(F)(F)C2', 'CS(=O)(=O)[C@@H]1CN(C(=O)c2c(N)ncc3c2CCC3)C[C@H]1C(F)(F)F', 'CS(=O)(=O)[C@H]1C[C@@H](CNC(=O)NCc2cc(Br)cc(C(F)(F)F)c2)C1', 'CS(=O)(=O)c1cc(C(=O)N(Cc2ccncc2)C2COC2)ccc1Br', 'CS(=O)(=O)c1ccc(CNC(=O)N2CCC(c3ccccc3)CC2)s1', 'CS(=O)(=O)c1ccc(CNC(=O)Nc2nsc3c(Br)cccc23)nc1', 'CS(=O)(=O)c1ccc(Cl)cc1NC(=O)N[C@H]1CC[C@@H](S(C)(=O)=O)CC1', 'CS(=O)(=O)c1ccc(OCC(=O)NCC2(C(F)(F)F)CCCN2)cc1', 'CS(=O)(=O)c1ccccc1CNC(=O)c1ccc2c(O)cccc2c1', 'CS(=O)(=O)n1cc(NC(=O)NCc2cccnc2N2CCCC2)cn1', 'CS(=O)(C[C@H]1C[C@H](O)C1)=NC(=O)C1(c2ccc(Br)cc2)CCNCC1', 'CS(=O)C(C)(C)CNC(=O)CC(CNC(=O)OC(C)(C)C)C1CCC1', 'CS(=O)C1(CNC(=O)C2(C3CC3)CN(C(=O)[C@H]3CCC[C@H]3F)C2)CC1', 'CS(=O)CC(NC(=O)NCc1ccccc1OC(C)(C)C)C(C)(C)C', 'CS(=O)CCC(=O)NCC1(C)CCN(C(=O)CCCc2ncco2)C1', 'CS(=O)Cc1cc(NC(=O)Nc2cccc(OC(F)F)c2)ccc1Cl', 'CS(=O)c1ccc(N[C@@H]2CC[C@H]2NC(=O)CC2CCCC(O)C2)nc1', 'CS(=O)c1nc(N)c(Br)c(N2CCC(=O)C(Cc3ccccc3)C2)n1', 'CSC(C(=O)N(C/C=C/c1ccc(F)cc1)CCOC1CC1)C1CC1', 'CSC(C(=O)NCCCN(CCO)C(=O)c1ccccc1Cl)C(C)C', 'CSC(C)(C)C(=O)N1CC(CC(C)NC(=O)Cc2ccccc2F)C1', 'CSC(C)(C)C(=O)NCC(CC1CC1)C(=O)N(C)Cc1nnnn1C', 'CSC(C)(C)CN(CC(C1CC1)C1CC1)C(=O)C1CC(C(C)C)CO1', 'CSC(C)(C)CN(Cc1cn(C(C)C)nc1C)C(=O)c1cc(C)c[nH]1', 'CSC(C)(C)CNC(=O)CC1=CCN(C(=O)C2(C#N)CC=CC2)CC1', 'CSC(C)(C)CNc1nc(N[C@H]2C[C@H]3OCCC[C@@H]23)nc2c1COC2', 'CSC(C)C(C)N(C)C(=O)[C@@]12C[C@@H]1CN(C(=O)[C@H]1C[C@H]3C=C[C@@H]1C3)C2', 'CSC(C)C(C)NC(=O)C1CC(C)(C)CN1C(=O)[C@]12C[C@H]1CNC2=O', 'CSC(C)CC(=O)N1C[C@H](O)C[C@H]1C(=O)Nc1cnc(C)c(C#N)c1', 'CSC(C)CC(=O)N1C[C@H](O)C[C@H]1CNC(=O)CCCn1ccnn1', 'CSC(C)CC(=O)NC(CN(C)C)C(=O)N1CCN2CCOC[C@@H]2C1', 'CSC(C)CC(=O)N[C@H]1CC[C@H](NC(=O)Cc2cc(C)cc(C)c2)C1', 'CSC(C)CC(=O)N[C@]1(C)C[C@H](NC(=O)c2cc(N)c(O)c(F)c2)C1', 'CSC(C)CCC(=O)NC1(CNC(=O)CC2COC(=O)C2)CCCC1', 'CSC(C)CCNC(=O)C1(NC(=O)CC(C)n2ccnc2)CCCC1', 'CSC(C)CCNC(=O)C1CN(C(=O)C2=CCCOC2)CC12CCC2', 'CSC(C)CN(C)C(=O)C[C@H]1C[C@H]1CNC(=O)[C@@H]1C[C@@H]2[C@H](C1)C2(C)C', 'CSC(C)CN(C)C(=O)[C@@H]1CCC[C@H]1NC(=O)c1cccn(C)c1=O', 'CSC(C)CN(Cc1cc(C2CCC2)no1)C(=O)[C@H]1CN(C)C(=O)N1', 'CSC(C)CN(Cc1cccc(CO)n1)C(=O)C1(O)CCOC1(C)C', 'CSC(C)CN(Cc1cnc(C(C)C)nc1)C(=O)CCc1ccc[nH]1', 'CSC(C)CNC(=O)C[C@H](CC1CC1)NC(=O)[C@H]1C[C@@H]1C1(C)COC1', 'CSC(CN(Cc1cc(C2CC2)no1)C(=O)c1n[nH]cc1C)C1CC1', 'CSC(CNC(=O)[C@@H]1CCCN1NC(=O)C(C)(C)OC(C)=O)C1CC1', 'CSC(CNc1cc(NCC2CCCC(F)(F)C2)nc(C)n1)C1CC1', 'CSC(SC)C(=O)N1CCCC(C(=O)Nc2cc(C)c(F)cc2C)C1', 'CSC(SC)C(=O)N1CCCC(N(C)C(=O)C(C)OCC(C)C)CC1', 'CSC(SC)C(=O)N[C@@H]1CC[C@H](CCNC(=O)C2(C)CCC(=O)N2)C1', 'CSC1(C(=O)N(Cc2cnn3c2CCC3)CC(C)C2CCCC2)CC1', 'CSC1(C(=O)N2CC(C(N)=O)C2)CN(C(=O)C(C)n2cc(C)cn2)C1', 'CSC1(C(=O)N2CC(N(C)CCO)C2)CN(C(=O)C2=NNC(=O)C2)C1', 'CSC1(C(=O)N2CCC3(CCC3)C2)CN(C(=O)c2cnnc(C)c2)C1', 'CSC1(C(=O)N2CCCC(CNC(=O)CCCc3cc[nH]n3)C2)CC1', 'CSC1(C(=O)N2Cc3cccc(C)c3C2)CN(C(=O)C(C)=C2CC2)C1', 'CSC1(C(=O)N2[C@@H]3CC[C@H]2C[C@@H](NC(=O)CN(C)S(N)(=O)=O)C3)CC1', 'CSC1(C(=O)N[C@H]2C[C@H]3C[C@H](NC(=O)CCOC4CCC4)C[C@H]32)CC1', 'CSC1(CN(Cc2nc(C)c(C)nc2C)C(=O)CCC2CCC2)CC1', 'CSC1(CNC(=O)C2CCN(C(=O)Cc3ccc(C)o3)C23CC3)CC1', 'CSC1(CNC(=O)C[C@@H](NC(=O)CC2=CCCC2)C(C)(C)C)CCC1', 'CSC1(CNC(=O)[C@@H]2CC[C@H](C)N2C(=O)CC2CCOC2(C)C)CC1', 'CSC1(CNC(=O)[C@@H]2CN(C(=O)c3n[nH]cc3C)C[C@H](C)O2)CCC1', 'CSC1CC(C(=O)N(C)[C@H]2C[C@@H](NC(=O)c3cc(=O)n(C)cn3)C2)C1', 'CSC1CC(C(=O)N2CC(C)(C(=O)N3CCO[C@@H](C)C3)CC2(C)C)C1', 'CSC1CC(CN(Cc2cccc(C(N)=O)c2)C(=O)C(=O)N(C)C)C1', 'CSC1CC(CN(Cc2cnc(C)n2C)C(=O)C(C#N)CC2CC2)C1', 'CSC1CCC(NC(=O)[C@H](CC(N)=O)NC(=O)Cc2cc(C)no2)C1', 'CSC1CCN(c2ccc(Br)c(S(=O)(=O)NC(C)c3cccs3)n2)C1', 'CSC=CC(=O)N1CC[C@@H](C)[C@@H](N(C)C(=O)c2cnn(C(C)C)n2)C1', 'CSC=CC(=O)N1C[C@@H](F)C[C@@H]1CN(C)C(=O)c1sc(CO)nc1C', 'CSCC(=O)N1CC2CC(C1)CN(C(=O)c1cnn(C3CC3)c1C)C2', 'CSCC(=O)N1CCC2(CCC2)C(NC(=O)[C@H](O)C2CCCCC2)C1', 'CSCC(=O)NC(C)C1CN(C(=O)CCn2cccnc2=O)CCO1', 'CSCC(=O)NC[C@H]1CC[C@@H](CNC(=O)c2cc(C3CC3)ns2)CC1', 'CSCC(C)(C)CN(Cc1ccc(C)o1)C(=O)CC1CCC(C)(C)O1', 'CSCC(C)(C)CN(Cc1cn(C)cn1)C(=O)C1CCC(=O)N(C)C1', 'CSCC(C)(C)CNC(=O)[C@@H]1[C@H](O)CCN1C(=O)CCc1cn[nH]c1', 'CSCC(C)(CO)NC(=O)C1CCN(C(=O)[C@H]2C[C@H](O)CN2C)CC1', 'CSCC(C)C(=O)N1C(CC(=O)N2CC3(CCN3C)C2)[C@H]2CCC[C@H]21', 'CSCC(C)C(=O)N1CCC(NC(=O)C2CCC(C3CC3)CC2)CC1', 'CSCC(C)C(=O)NC[C@H]1C[C@@H](NC(=O)c2cnc3ccnn3c2)C1', 'CSCC(C)CN(Cc1cc(C)ccc1O)C(=O)c1ccc(F)cc1', 'CSCC(C)CN(Cc1nc(C2CC2)cs1)CC1CCS(=O)(=O)CC1', 'CSCC(C)CNC(=O)N(Cc1ccccc1C(F)(F)F)CC1CC1', 'CSCC(C)N(C)C(=O)C1(CNC(=O)CC2(N(C)C)CCC2)CCC1', 'CSCC(O)C(=O)N(CCCC(C)CO)Cc1cc2c(o1)CCCC2', 'CSCC(O)C(=O)N1CC(C)(c2cn(C[C@H]3C[C@@H]3C(F)(F)F)nn2)C1', 'CSCC(O)C(=O)N1C[C@H]2C[C@@]2(C(=O)N2CCC3CCCC3CC2)C1', 'CSCC(O)C(=O)N1[C@@H]2CC[C@H]1C[C@@H](Nc1nc(C3CCC3)ns1)C2', 'CSCC(O)C(=O)N[C@@H]1CCCN(C(=O)c2c[nH]c(C(C)(C)C)n2)C1', 'CSCC1(C(=O)N2CC(CNC(=O)C(C)c3ccccc3C)C2)CC1', 'CSCC1(C(=O)NC(C)CCC(=O)Nc2cn(C)nc2C#N)CCC1', 'CSCC1(C(=O)N[C@H]2CCC[C@H]2NC(=O)[C@H]2CCO[C@@H]2C2CC2)CC1', 'CSCC1(CC(=O)N2CCCCC(C(=O)NCC3C=CCC3)C2)CC1', 'CSCC1(CCNC(=O)CCn2[nH]c(=O)c3ccccc3c2=O)CC1', 'CSCC1(CN(Cc2cc3n(n2)CCO3)Cc2cocc2C)CCC1', 'CSCC1(CN(Cc2nc(C)c[nH]2)C(=O)CCc2nccn2C)CC1', 'CSCC1(CNC(=O)CNC(=O)Cc2cccc(F)c2)CC(F)(F)C1', 'CSCC1(NC(=O)C2(CNC(=O)C(C)CC(N)=O)CC3(CC3)C2)CC1', 'CSCC1(NC(=O)[C@H]2C[C@](O)(c3cn(C4(C(=O)O)CC4)nn3)C2)CC1', 'CSCC1CC(NC(=O)CC2(C)CCN(C(=O)C3(C)CCCS3)C2)C1', 'CSCC1CN(C(=O)C23CC(CN(C(=O)[C@@H]4C[C@H]4CC(C)C)C2)C3)C1', 'CSCC=CCNC(=O)[C@H]1CC[C@@H](NC(=O)C(=O)NCC(F)F)CC1', 'CSCCC(=O)N(Cc1ccccc1C(C)C)Cc1nn(C)cc1C', 'CSCCC(=O)N1CCCC(OC2CN(c3ccnc(SC)n3)C2)C1', 'CSCCC(=O)N1CCN(CCN(C)c2ccc(C(C)=O)cn2)CC1', 'CSCCC(=O)NC1CCCCCN(C(=O)Cc2cccc(C)c2)C1', 'CSCCC(=O)NCC1CC(C)CN(C(=O)CC2CCCC2(F)F)C1', 'CSCCC(=O)NCc1ncccc1C(=O)N(C)CCn1cccn1', 'CSCCC(C)(C)C(=O)N(CCc1nc(C)cs1)CC1=CCCSC1', 'CSCCC(C)(NCc1cncc(F)c1)c1nnnn1CCC1CC1', 'CSCCC(C)NC(=O)C(C)(C)CN(C)C(=O)[C@@H]1C[C@H]2C=C[C@@H]1CC2', 'CSCCC(NC(=O)CNC(=O)C(C)(C)C)C(=O)N[C@@H](C)CN=[N+]=[N-]', 'CSCCC(NC(=O)[C@H](O)C1CCCCC1)C(=O)N1CCC(F)CC1', 'CSCCC(NC(=O)[C@H]1[C@@H]2CN(C)C[C@@H]21)C(=O)N(C)C1CCNC1=O', 'CSCCC(NC(=O)c1ccn(C)n1)C(=O)NCCOC1CCOC1', 'CSCCC(O)C(=O)NC(C(=O)N1CCC12CC(O)C2)c1ccoc1', 'CSCCCC(=O)N1C[C@H]2COC[C@@]2(C(=O)NC2COC(C)(C)C2)C1', 'CSCCCC(=O)N[C@H](CC(=O)NC1CCN(C(C)(C)C)C1)C(C)C', 'CSCCCCC(=O)N1CCC2(CC2C(=O)NCCCC(C)(F)F)C1', 'CSCCCCC(=O)N1CC[C@H](O)[C@@H]1C(=O)N(C)Cc1nc(C)ns1', 'CSCCCCCC(=O)N1C[C@@H](O)C[C@H](NC(=O)C2CCS2(=O)=O)C1', 'CSCCCCCC(=O)N1C[C@@H]2[C@H](C1)[C@H]2C(=O)N1C(C)CCC1(C)C', 'CSCCCCCC(=O)N[C@H]1CCO[C@H]1C(=O)NCc1cc(C)cs1', 'CSCCCCCN(Cc1ccc(O)nc1)C(=O)C1N(C)CC1(C)C', 'CSCCCN(CC1CCSC1(C)C)C(=O)[C@H]1C[C@@H]1c1ccccn1', 'CSCCCN(Cc1ccc2c(c1)CCOC2)C(=O)CCC(F)(F)F', 'CSCCCN(Cc1ccnc(C)c1)Cc1cc2ccnc(Cl)c2o1', 'CSCCCNC(=O)C(C1=NOCC1)N1CCCCC1CCN(C)C', 'CSCCCNC(=O)CO[C@H]1C[C@@H](NC(=O)C(C)c2ccc(C)o2)C1', 'CSCCCn1nnnc1C(NCP(C)(C)=O)c1cc(C)ccc1Br', 'CSCCN(C)c1cc(N(C)Cc2nnc3n2CCNC3=O)ncn1', 'CSCCN(Cc1ccc2cc[nH]c2n1)C(=O)C1Cc2nnnn2C1', 'CSCCNc1nc(NCC2CC(=C3CC3)C2)c2cc(Cl)ccc2n1', 'CSCCOCC(=O)N1CCOCC1CN(C)C(=O)c1ncoc1C', 'CSCCOCC(=O)NC12CC(NC(=O)C3CCCCC3(C)C)(C1)C2', 'CSCC[C@@H](CC(=O)O)NC(=O)Cc1nc(N)c2c(C)c(C)sc2n1', 'CSCC[C@@H](NC(=O)C1CCCC1)C(=O)N1CCOC(CC2CC2)C1', 'CSCC[C@@H](NC(=O)c1cnnn1C)C(=O)N(C)CC1CCOCC1', 'CSCC[C@H](CO)NC(=O)[C@@H]1C[C@H]2C[C@H]2N1C(=O)CCc1cncs1', 'CSCC[C@H](NC(=O)CC1CC=CCC1)C(=O)NOCCC(F)(F)F', 'CSCC[C@H](NC(=O)[C@@H](NC(C)=O)C(C)C)C(=O)NCC1(F)CCC1', 'CSCC[C@H](NC(=O)c1csnc1C)C(=O)NCc1cccnc1Cl', 'CSCCc1nnc(NC(=O)c2cccc(Nc3ccccc3)c2)s1', 'CSCCn1nnnc1C(Nc1ccc(Cl)c(C#N)c1)C(C)C1CC1', 'CSC[C@H](C)NC(=O)CC1CCN(C(=O)C23CCCC(CO2)C3)CC1', 'CSC[C@H]1C[C@@H](NC(=O)C[C@@H]2CCCN2C(=O)C(C)OCC(C)C)C1', 'CSC[C@H]1C[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)C=CC(C)(C)SC)C1', 'CSCc1c(C(=O)NCCNc2ccc(Cl)nn2)sc2ccccc12', 'CS[C@@H]1CCC[C@H]1NC(=O)[C@@H]1CCCN1NC(=O)C(C)C(O)C(C)C', 'CS[C@@H]1CCC[C@H]1NC(=O)c1ccc2[nH]c(=O)n(CCN(C)C)c2c1', 'CS[C@@H]1CCN(C(=O)[C@@H]2CCCCN2C(=O)c2ccc(C)c(O)n2)C1', 'CS[C@@H]1CN(C(=O)C2CCSC2)C[C@H]1NC(=O)C=CCN1CCCC1', 'CS[C@H]1CN(C(=O)NCc2ccc(CO)c(F)c2)C[C@@H]1N1CCCC1', 'CS[C@H]1CN(C(=O)[C@@H](C)N(C)C)C[C@@H]1n1cc(C(C)(C)C(C)C)nn1', 'CS[C@H]1C[C@@H](C(=O)NC[C@H]2CC[C@@H](C(=O)NCc3cc(C)co3)C2)C1', 'CS[C@H]1C[C@@H](CNC(=O)[C@@]23C[C@@H]2CN(C(=O)C2CCC=CCC2)C3)C1', 'CS[C@H]1C[C@@H](CNC(=O)[C@H]2CCCN2C(=O)c2ncc(C)cc2C)C1', 'CS[C@H]1C[C@@H](CNC(=O)[C@H]2C[C@@H](N=[N+]=[N-])CN2C(=O)CCC(C)C)C1', 'CS[C@H]1C[C@H](C(=O)N(C)CC2(CNC(=O)C=C(C)C(C)(C)C)CC2)C1', 'CS[C@H]1C[C@H](C(=O)N(Cc2ccc3cc[nH]c3c2)Cc2ncc[nH]2)C1', 'CS[C@H]1C[C@H](CC(=O)N(Cc2ncc(F)cc2F)CC(F)C(C)C)C1', 'CS[C@H]1C[C@H](CC(=O)N2CCC[C@]2(C)CNC(=O)c2cncn2C)C1', 'CSc1c(C(=O)N2CCC[C@H](NC(=O)[C@H](C)N(C)C)[C@@H]2C)cnn1C', 'CSc1cc(C(=O)NCC(NC(=O)c2ncoc2C)C2CC2)nn1C', 'CSc1cc(C(=O)NCCCCCC(=O)N2CCCC2C(N)=O)co1', 'CSc1cc(C(=O)O)nc(NCC2CCCCC2c2ccccc2)n1', 'CSc1cc(NC(=O)C23CC2CCN3C(=O)c2cc(Cl)[nH]n2)nn1C', 'CSc1cc(NC(=O)c2csc(C3Cc4ccccc4O3)n2)nn1C', 'CSc1ccc(Br)cc1CCNC(=O)N1Cc2cn[nH]c2CC(C)C1', 'CSc1ccc(C(=O)NC(CCN(C)C)C(=O)NC2CC(Cl)(Cl)C2)o1', 'CSc1ccc(C(=O)N[C@@H]2CCCN(C(=O)C3CCC(C)(C)C3)C2)o1', 'CSc1ccc(C(=O)N[C@H]2C[C@@H](NC(=O)C(C)Cn3ccnc3)C2)o1', 'CSc1ccc(C(C(=O)NC2CCC2)N2CCc3cn[nH]c3C2)cc1', 'CSc1ccc(C(C)NC[C@H]2CCCN(Cc3ccccc3)C2)cn1', 'CSc1ccc(CN(CC2CCCOCC2)C(=O)Cn2cccn2)s1', 'CSc1ccc(CN(CCCCCF)C(=O)c2cc(C)c(=O)[nH]n2)s1', 'CSc1ccc(CN(Cc2ccncc2Cl)CC23CCC(CO2)C3)[nH]1', 'CSc1ccc(NC(=O)C(CC(C)(C)C)NC(=O)C(C)CC#N)cc1', 'CSc1ccc(NC(=O)[C@@H]2CC[C@H](NC(=O)c3ncsc3C)C2)cc1', 'CSc1cccc(C(=O)N2CCCC(CNC(=O)c3cn[nH]c3)C2)c1', 'CSc1cccc(CCNC(=O)C(=O)NCCN2CCOCC2=O)c1', 'CSc1cccc(NC(=O)NC2CCCN(c3nccnc3Cl)C2)n1', 'CSc1ccnc(NC2CC3(CC(NC(=O)C4CCN(C)C4)C3)C2)n1', 'CSc1cnn(C)c1C(=O)N[C@H]1C[C@H](NC(=O)C2CC(C(C)C)C2)C1', 'CSc1nc(C(=O)NC(C)CN(C)C(=O)c2cnn(C(C)C)c2)cs1', 'CSc1nc(C)c(CCC(=O)N[C@H]2C[C@@H]3OC(C)(C)O[C@@H]3C2)c(=O)[nH]1', 'CSc1nc(NC(=O)N2CCN(CCc3ccccc3)CC2)nn1C', 'CSc1nc2ccc(-c3cn(CCC(=O)NC[C@H](C)O)nn3)cc2s1', 'CSc1ncc(NC(=O)C2(Oc3ccc(F)cc3)CCOCC2)cn1', 'CSc1ncnc(NC2CCC(NC(=O)C3CC3(C)C(C)C)C2)c1Cl', 'CSc1sccc1C(=O)NCC1CN(C(=O)C2(C(F)(F)F)CCC2)C1', 'C[C@@H](C(=O)N1CC2(CO)CC1(C(=O)N1CCC(CCO)C1)C2)N(C)C', 'C[C@@H](C(=O)N1CC=C(CC(=O)N2CCC(O)C23CCC3)CC1)N(C)C', 'C[C@@H](C(=O)N1CCC(O)(CN(C)C(=O)Cn2cn[nH]c2=O)C1)C1CC1', 'C[C@@H](C(=O)N1CCCC1c1nc(C2(F)CCCC2)cs1)n1cnnn1', 'C[C@@H](C(=O)N1CCC[C@H]2[C@H](O)C[C@H]21)N(C)C(=O)c1cnn(CCF)c1', 'C[C@@H](C(=O)NCCc1cc(C(=O)N[C@@H](CO)CN(C)C)no1)C1CC1', 'C[C@@H](C(=O)NC[C@@H]1C[C@H](O)CN1C(=O)CCC1CCCCO1)N(C)C', 'C[C@@H](C(=O)N[C@H]1CCN(C(=O)C2CNC(=O)N2)C[C@H]1C(N)=O)N(C)C', 'C[C@@H](C(=O)N[C@H]1CC[C@H](CN(C)C(=O)CC2C=CCC2)CC1)N(C)C', 'C[C@@H](C(=O)N[C@H]1C[C@@H](CCC(=O)N2CCCC23CCCC3)C1)N(C)C', 'C[C@@H](CC(=O)N1CC=CC1(C)C(=O)N[C@@H](CO)C(=O)N(C)C)N(C)C', 'C[C@@H](CC(=O)N1CCC12CCCSC2)NC(=O)CCc1ccn(C)c1', 'C[C@@H](CC(=O)N1C[C@H]2C[C@@H](C1)[C@H](C(=O)N1CC(N(C)C)C1)C2)N(C)C', 'C[C@@H](CC(=O)NC1(CO)CC(F)(F)C1)N(C)C(=O)CN(C)C1CCC1', 'C[C@@H](CC(=O)NCCC1(C)CCCO1)N(C)C(=O)CC1CCOC1=O', 'C[C@@H](CC(=O)N[C@]12C[C@H]1COC21CCC1)N(C)C(=O)c1cc(Cl)no1', 'C[C@@H](CCC(=O)N(C)CCC1CN(C)C1)NC(=O)C(O)C1CCCC1', 'C[C@@H](CCC(=O)N1CCO[C@H]2[C@H](O)C[C@H]21)NC(=O)[C@H]1[C@@H]2CN(C)C[C@@H]21', 'C[C@@H](CCC(=O)NC1CC(CC(N)=O)C1)NC(=O)[C@@H](O)C1CCCC1', 'C[C@@H](CCC(=O)NC1CCCSCC1)NC(=O)[C@@H]1C[C@@H]2[C@H](C1)C2(F)F', 'C[C@@H](CCNS(=O)(=O)C1(C)CCC1)NC(=O)c1n[nH]c2c1CCCN2', 'C[C@@H](CCNc1ccc(P(C)(C)=O)cn1)NC(=O)C[C@H]1[C@@H]2COC[C@@H]21', 'C[C@@H](CCNc1nc(C2CCCC2)ns1)NC(=O)c1ccc(=O)[nH]n1', 'C[C@@H](CCNc1ncc2c(n1)CCC2)NC(=O)Cc1c(Cl)cnn1C', 'C[C@@H](CN(C)C(=O)C1(c2cc[nH]n2)CC1)NC(=O)CCCCC1CC1', 'C[C@@H](CN(C)C(=O)CC1CCCCC1)NC(=O)c1cncn(C)c1=O', 'C[C@@H](CN(C)C(=O)[C@H]1C[C@@H](N(C)C)C1)NC(=O)[C@H]1C[C@H]2CC(=O)[C@@H]1C2', 'C[C@@H](CN(C)C)NC(=O)C(CC1CC1)NC(=O)C1CC2(CCO1)CC2', 'C[C@@H](CN(C)C)NC(=O)[C@H]1CCCN(C(=O)C(F)CCC(C)(C)C)C1', 'C[C@@H](CNC(=O)/C=C/C(F)(F)F)NC(=O)Cc1cccc(C2CC2)c1', 'C[C@@H](CNC(=O)C(F)CC1CCOC1)NC(=O)c1cn(C)c(=O)n1C', 'C[C@@H](CNC(=O)C12CCC(NC(=O)C3CC3F)(CC1)C2)n1ccnn1', 'C[C@@H](CNC(=O)CCN1CCOCC1)C(=O)NC1CCCC(F)(F)C1', 'C[C@@H](CNC(=O)CCc1nccn1C)N(C)C(=O)COC1CCOC1', 'C[C@@H](CNC(=O)Cc1cnsc1)N(C)C(=O)[C@H]1C[C@@H]2CCC[C@@H](C2)C1', 'C[C@@H](CNC(=O)N1CC(O)(c2ncnn2C)C1)NC(=O)OC(C)(C)C', 'C[C@@H](CNC(=O)OC(C)(C)C)CNC(=O)[C@@H]1CCc2ccccc2O1', 'C[C@@H](CO)CN(C)C(=O)C(CC(F)F)NC(=O)c1cc(C2CC2)[nH]n1', 'C[C@@H](CO)N(C)S(=O)(=O)c1ccc(NC2CC3(CCCO3)C2)c(Br)c1', 'C[C@@H](CO)NC(=O)CC1CCCN(C(=O)c2cc(N)cc(F)c2)CC1', 'C[C@@H](CO)n1cc(CCNC(=O)C(C)(C)c2ccc(Cl)c(Cl)c2)nn1', 'C[C@@H](CS(C)(=O)=O)Nc1nc2c(c(NC3C=CCC3)n1)CCCCC2', 'C[C@@H](CS(N)(=O)=O)NC(=O)c1ccccc1C(=O)c1ccc(F)cc1', 'C[C@@H](CSC(F)F)NC(=O)[C@H]1OCC[C@H]1CNC(=O)Cc1cnsc1', 'C[C@@H](Cc1csc(C2CCCCC2)n1)NC(=O)C1(F)CCC(F)(F)C1', 'C[C@@H](NC(=O)C(=O)Nc1cc(Cl)ccc1OC(F)F)c1cc(Br)cs1', 'C[C@@H](NC(=O)C(C)(C)CNC(=O)CC1CC(C)(C)CO1)c1cccs1', 'C[C@@H](NC(=O)C1CC=CCN1C(=O)CC1OCCO1)C1CCOCC1', 'C[C@@H](NC(=O)C1CN(C(=O)[C@@H]2CCN2C)CCO1)c1ccc(F)cn1', 'C[C@@H](NC(=O)CC1CCCCC1)C1CCN(S(=O)(=O)C2(C)CC2)CC1', 'C[C@@H](NC(=O)CCP(C)(C)=O)C1CCN(C(=O)C2(C)CCOC2)CC1', 'C[C@@H](NC(=O)Cc1ccc(O)cc1)C(=O)N(C)CCN1CCOC1=O', 'C[C@@H](NC(=O)Cc1ccnc(O)c1)C(=O)N1CCc2c(nnn2C)C1', 'C[C@@H](NC(=O)[C@@H]1CC(C)(C)CN1C(=O)C1CCCCC1(C)C)C(N)=O', 'C[C@@H](NC(=O)[C@@H]1[C@H]2C[C@H]2CN1C(=O)C1CC(C)(C)CO1)C(=O)N(C)C', 'C[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)C(O)C(F)(F)F)c1ccnn1C', 'C[C@@H](NC(=O)c1cc(C#N)n(C)n1)C1CN(C(=O)C(C)(C)C2CC2)C1', 'C[C@@H](NC(=O)c1ccc2cc[nH]c2c1)C(=O)N1CC2CC(C1)N(C)C2', 'C[C@@H](NC(=O)c1nn[nH]c1C1CC1)C(=O)N1CC(N(C)C)C(C)(C)C1', 'C[C@@H](Nc1ccnc(N2C[C@H]3COC[C@H]3C2)n1)c1cc(Cl)ccc1F', 'C[C@@H](O)C1CCN(C(=O)CCCCN(C)C(=O)C2CC=CCO2)CC1', 'C[C@@H](O)C1CN(C(=O)[C@H]2CCCN(C(=O)C3CCOCC3(C)C)C2)C1', 'C[C@@H](O)CC(=O)N1CCCC(C(=O)NCCC(C2CC2)C2CC2)CC1', 'C[C@@H](O)CC(=O)N1C[C@H]2C[C@@H](C(=O)NCC(CO)C(F)(F)F)C[C@H]2C1', 'C[C@@H](O)CC(=O)NCC(C)(C)C#CC(=O)N(C)Cc1cccc(F)c1', 'C[C@@H](O)CC(=O)NCC12CC(CO1)N(C(=O)C=Cc1ccncc1)C2', 'C[C@@H](O)CC(=O)NC[C@H]1CCCCN1C(=O)[C@H]1C[C@H]2C=C[C@@H]1CCC2', 'C[C@@H](O)CCN(C)C(=O)C1(CNC(=O)c2ncncc2Cl)CC=CC1', 'C[C@@H](O)CCN(C)C(=O)[C@@H]1CC[C@H](CNC(=O)C2(C)CNC(=O)N2)C1', 'C[C@@H](O)CCNC(=O)COC1CCN(C(=O)c2cnccc2C#N)C1', 'C[C@@H](O)CCNC(=O)Nc1c(-c2ccc(F)cc2)nc2ccccn12', 'C[C@@H](O)CN(C(=O)[C@H]1CCN(C(=O)CC2CCCNC2=O)C1)C1CC1', 'C[C@@H](O)[C@H](NC(=O)CC1CC(=O)C1)C(=O)N1CCN(C)C[C@@H]1CCO', 'C[C@@H](O)[C@H](NC(=O)C[C@@H]1C[C@H]2CC[C@@H]1C2)C(=O)N(C)CCOCCO', 'C[C@@H](O)[C@H](NC(=O)c1cc(F)cc(F)c1)C(=O)N1CC[C@@H](F)[C@H](O)C1', 'C[C@@H](O)[C@H](NC(=O)c1cnn(C2CC2)c1)C(=O)NC1(C)CC(C)(C)C1', 'C[C@@H](OC(=O)c1cnc(Cc2ccc(F)cc2)s1)c1cccnc1F', 'C[C@@H](OC(C)(C)C)C(=O)N(Cc1cnc(Cl)n1C)CC1CC(C)(F)C1', 'C[C@@H]1C(NCc2noc(-c3ccccc3)n2)CN1C(=O)OC(C)(C)C', 'C[C@@H]1CC(C)(C)CN1C(=O)C1(NC(=O)[C@@H]2C[C@@H]3[C@H](C2)C3(F)F)CCC1', 'C[C@@H]1CC2(CC2)CN1C(=O)C(NC(=O)CC1CCCCO1)C1CCC1', 'C[C@@H]1CCN(C(=O)Cc2cccnc2)[C@H](C(=O)NC[C@H](C)N=[N+]=[N-])C1', 'C[C@@H]1CCO[C@@H]1C(=O)NCC1(CC(=O)N2[C@H](C)C[C@@H]3CCC[C@@H]32)CC1', 'C[C@@H]1CC[C@@H]1C(=O)N(C)CCOCCN(C)C(=O)[C@@H]([C@@H](C)O)N(C)C', 'C[C@@H]1CC[C@H](C(N)=O)CN1C(=O)CCN(C)C(=O)CC(C)(C)C1CC1', 'C[C@@H]1CN(C(=O)C(O)C2CCC2)CCCN1C(=O)CCCC1CCC1', 'C[C@@H]1CN(C(=O)C2CC23CC3)CCN1C(=O)c1cccc2nn[nH]c12', 'C[C@@H]1CN(C(=O)CCC2(C)CC2)CCCN1C(=O)C1CCCN1N=O', 'C[C@@H]1CN(C(=O)CNc2ccncc2)C[C@H]1C(=O)N[C@H](C)C(=O)NO', 'C[C@@H]1CN(C(=O)COCc2nccs2)CCCN1C(=O)C1C=CCS1', 'C[C@@H]1CN(C(=O)C[C@@H](O)CNC(=O)C(F)C2CCOCC2)[C@H](C)CO1', 'C[C@@H]1CN(C(=O)Cc2ccsn2)C[C@@H](C(=O)N(C)CC(=O)N(C)C)O1', 'C[C@@H]1CN(C(=O)[C@@H]2CC2(F)F)C[C@H](C)N1C(=O)CCCc1ncco1', 'C[C@@H]1CN(C2CCN(C(=O)[C@H]3CC[C@H]3c3nc[nH]n3)CC2)C[C@H](C)O1', 'C[C@@H]1CN(c2ccc(NC(=O)C[C@@H]3CC(F)(F)CN3)cc2)C[C@H](C)O1', 'C[C@@H]1COC(F)(F)CN1C(=O)Nc1ccc(-n2ncn(C)c2=O)cc1', 'C[C@@H]1COCCN1C(c1ccn(C2CC2)n1)c1nnnn1CC(F)F', 'C[C@@H]1COc2ccccc2N1C(=O)Cn1c(=O)sc2ccc(Cl)cc21', 'C[C@@H]1CSCCN1C(=O)C[C@H](CC1CC1)NC(=O)c1ccc(=O)[nH]n1', 'C[C@@H]1C[C@H](C(=O)N(C)[C@@H](C)C(=O)NCC23CCN(CC2)C3)CC(=O)N1', 'C[C@@H]1C[C@H](C(=O)N2CCC3CC3(C(=O)NC3(C)CSC3)CC2)CN1C', 'C[C@@H]1C[C@H](C(=O)NC(C)(CO)CNC(=O)Cc2cnn(C)c2)CN1C', 'C[C@@H]1C[C@H](CNC(=O)C2CN(C)C(=O)N2)CCN1C(=O)c1ccoc1', 'C[C@@H]1C[C@H](F)CN1C(=O)CO[C@H]1CCN(C(=O)[C@H]2[C@@H]3CCCC[C@@H]32)C1', 'C[C@@H]1C[C@H](NC(=O)CN2CC(C)(C)C2)CCN1C(=O)c1cccnc1', 'C[C@@H]1C[C@H](NC(=O)[C@@H]2[C@H]3CC[C@H](C3)N2C(=O)CC2CC=CC2)CCO1', 'C[C@@H]1C[C@H](O)CCN1C(=O)C(NC(=O)CC1CCC(C)(C)C1)C1CC1', 'C[C@@H]1C[C@H]1C(=O)N1CCC2(CCCN2C(=O)c2cnc(N(C)C)s2)C1', 'C[C@@H]1OCCN(C(=O)C2CCC(O)CN2C)[C@H]1C(=O)N1CC[C@H](F)C1', 'C[C@@H]1[C@@H](NC(=O)C23CC(CN2C(=O)[C@H](C)N(C)C)C3)C2CCN1CC2', 'C[C@@H]1[C@H](C(=O)N(C)CCN(C)C(=O)CCc2ccn(C)n2)CCN1C', 'C[C@@H]1[C@H](NC(=O)C2=CCCC2)CCCN1C(=O)COc1cnn(C)c1', 'C[C@@H]1[C@H](NC(=O)CCCCC(N)=O)CCN1C(=O)CCC1CCOC1', 'C[C@@H]1[C@H](NC(=O)c2[nH]nc3c2COC3)CCN1C(=O)C(F)C(C)(F)F', 'C[C@@](O)(C(=O)N[C@@H](CC1CC1)C(=O)N1CCOC[C@H]1CO)C(F)(F)F', 'C[C@@]1(C(=O)NC/C=C/CNC(=O)c2ccc(C3CC3)s2)CCC(=O)N1', 'C[C@@]1(C(=O)NCCOCCNC(=O)C(C#N)CC2CC2)CCC(=O)N1', 'C[C@@]1(C(=O)N[C@H](CC(=O)NOCCC(F)F)CC2CC2)CCC(=O)N1', 'C[C@@]1(C(=O)N[C@H]2C=CC[C@H](C(=O)NCC3(CO)CC3)C2)CCC(=O)N1', 'C[C@@]1(CNC(=O)C2CC3CC3C2)CCCN1C(=O)Cc1csc(Cl)n1', 'C[C@@]1(CNC(=O)C2CC=CCO2)CCCN1C(=O)c1ccc(CO)o1', 'C[C@@]1(CNC(=O)C=C(Cl)Cl)CCC[C@H]1NC(=O)CC1CCCC(=O)N1', 'C[C@@]1(CNC(=O)c2cc(O)ccn2)CCC[C@H]1NC(=O)CC(F)(F)F', 'C[C@@]1(CO)CCCN1C(=O)NCc1ccc(COCC(F)(F)F)cc1', 'C[C@@]1(NC(=O)/C=C/C(F)(F)F)CCC[C@H]1NC(=O)Cc1cccnc1', 'C[C@@]1(NS(=O)(=O)Cc2noc3c2CCCCC3)C[C@H]2CC[C@@H]1CC2=O', 'C[C@H](C(=O)N(CC[C@H]1OCC[C@H]1C)CC1CCC(F)(F)CC1)C1CC1', 'C[C@H](C(=O)N(Cc1cc2ncccc2s1)CC(F)C1CCC1)N(C)C', 'C[C@H](C(=O)N1CCc2nc(-c3ccncc3)sc2C1)N1CCCCC1', 'C[C@H](C(=O)NCC(NC(=O)[C@H]1CCCC[C@@H]1O)C1CCOC1)C1CC1', 'C[C@H](C(=O)NC[C@H]1CCCN(C)C1)N(C)C(=O)CN1CC2CCC1C2', 'C[C@H](CC(=O)N(C)Cc1ccn(C)n1)N(C)C(=O)c1ccc(O)cn1', 'C[C@H](CC(=O)N1CCCc2ccccc21)NC(=O)C1CC(=C2CC2)C1', 'C[C@H](CC(=O)N1C[C@H](F)C[C@H]1C(=O)N1CC(O)(CN(C)C)C1)N(C)C', 'C[C@H](CC(=O)NCC12CCC(CC1)OC2)NC(=O)C1CCC=CCC1', 'C[C@H](CC(=O)NCC12CCCC1CCC2)NC(=O)C1CC(F)(CF)C1', 'C[C@H](CC(=O)NCCC1CCN(C)C1)NC(=O)CN1CCC(F)CC1', 'C[C@H](CC(=O)NCCC1CCOC1)NC(=O)c1ccnc2cc[nH]c12', 'C[C@H](CC(=O)NCc1nnc2n1CCC2)NC(=O)C=Cc1cncs1', 'C[C@H](CC(=O)Nc1ccc(F)cc1CO)NC(=O)c1c[nH]c(=O)cn1', 'C[C@H](CCC(=O)N(C)Cc1ccc[nH]c1=O)NC(=O)c1cc(Cl)ns1', 'C[C@H](CCCC(=O)NC1CC2(CCC2)C1)NC(=O)C(C)(C)C1CCC1', 'C[C@H](CCCC(=O)NCCN(C)C1CC1)NC(=O)C1C[C@H]2CC[C@H]2C1', 'C[C@H](CCNS(=O)(=O)c1csc(F)n1)CNC(=O)c1ccc(N)nn1', 'C[C@H](CN(C)C)NC(=O)[C@H]1C[C@H]2C[C@@H]1CN(C(=O)C(F)(F)C1CC1)C2', 'C[C@H](CN1CCN(C(=O)c2cnco2)CC1)NC(=O)Cn1cnnn1', 'C[C@H](CNC(=O)C1CCC=CCCC1)Nc1cc(C(C)(F)F)ncn1', 'C[C@H](CNC(=O)CC1CCCO1)N(C)C(=O)C=Cc1ccc(N)nc1', 'C[C@H](CNC(=O)CC1CCN(C)C1=O)C(=O)N1CCN2CCC[C@H]2C1', 'C[C@H](CNC(=O)CCN1CCCCC1)NC(=O)C1(C)CCCCCC1', 'C[C@H](CNC(=O)CCc1cn(Cc2ccc(Cl)c(Cl)c2)nn1)C(=O)O', 'C[C@H](CNC(=O)Nc1ccc2nc(C3CCC3)nn2c1)OC(C)(C)C', 'C[C@H](CNC(=O)OC(C)(C)C)N(C)Cc1sc(N2CCCC2)nc1Cl', 'C[C@H](COCc1ccccc1)NC(=O)c1cc2ccccc2c(=O)[nH]1', 'C[C@H](CS(N)(=O)=O)NC(=O)CC[C@@H](C)NC(=O)C(F)c1ccccc1', 'C[C@H](C[C@@H](C)N)NC(=O)C(=O)N1CCOC2(CC1)CCS(=O)(=O)CC2', 'C[C@H](Cc1ccc(C(F)(F)F)cc1)C(=O)N1CCCC(CC(F)F)C1', 'C[C@H](Cc1ccc(F)cc1)C(=O)NNC(=O)C(=O)Nc1ccccn1', 'C[C@H](Cc1ccc2c(c1)OCCO2)NCC1CCc2c(cnn2C)C1', 'C[C@H](Cc1cccnc1)C(=O)N(C)CC1(CNC(=O)C[C@@H](C)O)CC1', 'C[C@H](Cn1cc(C(C)(C)CO)nn1)NC(=O)c1cn2cnnc2cn1', 'C[C@H](Cn1cc(COC2COC2)nn1)NC(=O)C1CC12CCSCC2', 'C[C@H](Cn1cc([C@@H](O)C2CC2)nn1)NC(=O)CC1CC2(CCO1)CC2', 'C[C@H](F)CCN(Cc1ccc(Cl)cc1)C(=O)c1ccc(CC#N)cc1', 'C[C@H](F)CCN(Cc1cn2ccsc2n1)C(=O)C1CN(C2CCC2)C1', 'C[C@H](F)CCS(=O)(=O)N[C@@H]1CC[C@H](NC(=O)C2Cc3nnnn3C2)C1', 'C[C@H](N)Cn1cc(C(=O)Nc2ncc(Cc3ccc(Br)cc3)s2)nn1', 'C[C@H](NC(=O)C12CC(CN1C(=O)c1cnns1)C2)c1cccc(O)c1', 'C[C@H](NC(=O)C1CC2(CC2)CO1)[C@@H](CO)NC(=O)[C@@]12C[C@@H]1CNC2=O', 'C[C@H](NC(=O)C1CCC(C)(C)CC1)C(=O)N1CCC[C@]2(C1)C[C@H](O)C2', 'C[C@H](NC(=O)N1CC(CC(=O)N(C)C)c2cc(Cl)ccc21)C(C)(C)C', 'C[C@H](NC(=O)N1CC(S(=O)(=O)C2CCCCC2)C1)c1ccc(F)cn1', 'C[C@H](NC(=O)N1CCC(O)(Cc2ccccc2F)CC1)c1cccs1', 'C[C@H](NC(=O)NC(C)(C)c1ccc(C#N)cc1)C(=O)N1CCCCC1', 'C[C@H](NC(=O)NCC1(CO)CCS(=O)(=O)CC1)c1ccc(C#N)cc1', 'C[C@H](NC(=O)NCC1CCCN1CC(F)F)c1nnc2n1CCOC2', 'C[C@H](NC(=O)NCCC1CCOC1(C)C)c1cccc2ccccc12', 'C[C@H](NC(=O)N[C@H]1CC[C@@H](OC2CCCC2)C1)c1ccc(F)cc1F', 'C[C@H](NC(=O)N[C@H]1CS(=O)(=O)C[C@H]1C)c1cc(Cl)ccc1OC(F)F', 'C[C@H](NC(=O)Nc1cccc(NC(=O)C(N)=O)c1)C1CCCCCC1', 'C[C@H](NC(=O)[C@H]1CCC[C@H]1CNC(=O)c1cnn(C)c1N)C(C)(C)O', 'C[C@H](NC(=O)[C@H]1OCC[C@H]1NC(=O)c1cn[nH]c(=O)c1)c1ccco1', 'C[C@H](NC(=O)c1cc(Cl)c(-c2nn[nH]n2)c(Cl)c1)c1ccncc1Br', 'C[C@H](NC(=O)c1n[nH]c2c1CS(=O)(=O)CC2)c1nnc2n1CCOC2', 'C[C@H](NC(=O)c1sccc1NS(C)(=O)=O)c1ccc(S(C)(=O)=O)cc1', 'C[C@H](O)CC(=O)N1CCC(/C=C/C(=O)N2CCCC(CO)CC2)CC1', 'C[C@H](O)CN(CCF)C(=O)[C@H]1C[C@@H](NC(=O)CN2CCOCC2=O)C1', 'C[C@H](O)[C@H](C(=O)N1CC[C@H](OCC(=O)NCCC(=O)NO)C1)N(C)C', 'C[C@H](O)[C@H](C)N(C)C(=O)NCCCCc1cnn(-c2ccccc2)c1', 'C[C@H](O)[C@H](NC(=O)CC1CSCCO1)C(=O)N1CCOCC(C)(F)C1', 'C[C@H](O)c1ccc(F)cc1-c1cccc(C(=O)N2CCN(C)CC2)c1', 'C[C@H](O)c1cn(CC(F)C2CCN(C(=O)CSCCC#N)CC2)nn1', 'C[C@H](OC(C)(C)C)C(=O)NC[C@H](O)CC(=O)NCC1CCCOCC1', 'C[C@H](Oc1ccc(Cl)cc1)C(=O)N1CCC2(CC1)CNC(=O)N(C)C2', 'C[C@H](Oc1ccc(Cl)cc1)C(=O)N1C[C@@H](c2ccccc2)N[C@@H](C)C1', 'C[C@H]1C(=O)NCCCN1C(=O)C1COC2(C1)CN(C(=O)C(C)(C)C)C2', 'C[C@H]1C(C(=O)NC23CCC(NC(=O)C4CCC(C)(C)C4)(CC2)C3)[C@@H]1C', 'C[C@H]1C(C(=O)NCc2ncccc2C(=O)NCC2C=CCCC2)[C@@H]1C', 'C[C@H]1C(NC(=O)C(NC(=O)c2cnn(CCF)c2)C2(O)CCC2)[C@@H]1C', 'C[C@H]1C(NC(=O)CC2N(C(=O)C=Cc3ccoc3)CCC2(C)C)[C@@H]1C', 'C[C@H]1C(NC(=O)[C@H]2CCC[C@H]2NC(=O)c2cccc(C3CC3)c2)[C@@H]1C', 'C[C@H]1CCCN(C(=O)CN2CCN(C(=O)c3cnsn3)CC2)[C@H]1CO', 'C[C@H]1CCC[C@@H](CC(=O)N2CC[C@H](C(=O)NCCC(F)F)[C@H](O)C2)O1', 'C[C@H]1CCC[C@@H](CS(=O)(=O)NC(c2ccccc2)c2cnn(C)c2)O1', 'C[C@H]1CCC[C@@H](NC(=O)C[C@H](NC(=O)c2cc(Cl)c[nH]2)C(C)(C)C)C1', 'C[C@H]1CCC[C@@H]1CS(=O)(=O)NC1CN(C(=O)C#CC2CC2)CC1CO', 'C[C@H]1CCN(C(=O)C(O)C2CCCCC2)[C@@H](C(=O)NOCC2CC2)C1', 'C[C@H]1CCN(C(=O)CCCC(C)(C)C)[C@@H](C(=O)N[C@H]2C[C@H](O)[C@H]2O)C1', 'C[C@H]1CCN(C(=O)CO[C@@H]2CCN(C(=O)c3cc(Cl)[nH]n3)C2)[C@@H](C)C1', 'C[C@H]1CCN(C(=O)[C@H]2CCCCN2C(=O)c2csc(Cl)n2)C[C@@H](C)C1', 'C[C@H]1CCO[C@H]1C(=O)N1CCN(C(=O)C2CCNC(=O)C2)C2(CC2)C1', 'C[C@H]1CCO[C@H]1C(=O)NC1CC2(C1)CC2C(=O)N(C)CC(C)(C)CO', 'C[C@H]1CCO[C@H]1C(=O)NCCCCC(=O)N(C)OCc1ccccc1', 'C[C@H]1CCO[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N1CCC12CCOCC2', 'C[C@H]1CCO[C@H]1CCN(CC1COC(C)(C)C1)C(=O)C[C@@H]1CC[C@H]1O', 'C[C@H]1CC[C@@H](C(=O)N(C)C2CCCC(O)C2)N1C(=O)C1C=CCCC1', 'C[C@H]1CC[C@@H](C(=O)N(C)[C@H]2CC[C@H](O)CC2)N(C(=O)C2CCOC2)C1', 'C[C@H]1CC[C@@H](C(=O)N2CCCC(C(=O)Nc3cscc3C3CC3)C2)O1', 'C[C@H]1CC[C@@H](C(=O)N2CCOCC(C(=O)Nc3cn(C)nc3Cl)C2)O1', 'C[C@H]1CC[C@@H](C(=O)NC2CC(CCO)C2)N(C(=O)C2CCC(=O)O2)C1', 'C[C@H]1CC[C@@H](C(=O)NC2CC23CCN(C(=O)C2=CCCCO2)CC3)O1', 'C[C@H]1CC[C@@H](C(=O)NCC2(C(=O)NCc3c[nH]cn3)CCCCC2)O1', 'C[C@H]1CC[C@@H](C(=O)NCC2CC(C(C)(C)C)C2)N1C(=O)c1ccco1', 'C[C@H]1CC[C@@H](C(=O)NCCCCO)N(C(=O)[C@@H]2CC[C@H]3C[C@@H]2CO3)C1', 'C[C@H]1CC[C@@H](C(=O)NCCCc2cn[nH]c2)N1C(=O)/C=C/C(C)(C)C', 'C[C@H]1CC[C@@H](C(=O)NCc2nccc(=O)[nH]2)N1C(=O)C(=O)NC1CC1', 'C[C@H]1CC[C@@H](C(=O)N[C@H]2C[C@H](CCNS(=O)(=O)CC3CCOC3)C2)O1', 'C[C@H]1CC[C@H](C(=O)N[C@H]2CCN(C(=O)C(F)C3CCCCC3)C2)CC1', 'C[C@H]1CC[C@H](C(=O)N[C@H]2C[C@H](C(F)(F)F)C2)N(C(=O)[C@H]2CC2(C)C)C1', 'C[C@H]1CC[C@H](NC(=O)c2ncccc2F)CN1C(=O)c1cccnc1', 'C[C@H]1CC[C@H]1C(=O)NC(C(=O)N(C)CC1=CCCOC1)C1CCOC1', 'C[C@H]1CC[C@H]1C(=O)N[C@@H](CC1CC1)C(=O)N1CCNC(=O)C1CCO', 'C[C@H]1CC[C@H]1C(=O)N[C@@H]1C[C@H](O)[C@H]1CC(=O)NCC(C)(C)CC1CC1', 'C[C@H]1CC[C@H]1CC(=O)NCC1CCC2CN(C(=O)C3CCCC3)CC12', 'C[C@H]1CC[C@H]1CCN(Cc1ccnc(O)c1)CC1CCC(F)(F)CC1', 'C[C@H]1CC[C@](C)(C(=O)N(Cc2ccn(C(F)F)n2)CC2CC2Cl)CC1', 'C[C@H]1CN(C(=O)C(C)(C)CCCF)C[C@@H](C(=O)N2C[C@H]3C=C[C@H]3C2)O1', 'C[C@H]1CN(C(=O)C(F)OC(F)(F)F)[C@H]1C(=O)NC1CC2CC3C(C2)C13', 'C[C@H]1CN(C(=O)C23CC(F)(C2)C3)[C@H]1C(=O)N(C)CCc1ccccn1', 'C[C@H]1CN(C(=O)C2=NOC(C)(C)C2)CC[C@H]1C(=O)NCCC#CCO', 'C[C@H]1CN(C(=O)C2CN3CCC2C3)[C@H]1C(=O)NCC1CC(F)(F)CO1', 'C[C@H]1CN(C(=O)C=Cc2ccn(C)c2)[C@H]1C(=O)N(C)C1CC2(CC2)C1', 'C[C@H]1CN(C(=O)CC2(C)CCC2)C[C@H]1NC(=O)C(N(C)C)C(C)(C)C', 'C[C@H]1CN(C(=O)CC2CC3(CC3)C2)C[C@H]1NC(=O)C(CO)C(F)(F)F', 'C[C@H]1CN(C(=O)CC2CCN(CC(F)(F)F)CC2)c2ccccc2O1', 'C[C@H]1CN(C(=O)CCC2CCOCC2)CC[C@H]1C(=O)N1C[C@H](O)CO1', 'C[C@H]1CN(C(=O)CNc2ccncc2)C[C@@H]1C(=O)NC1CCN(C)C1', 'C[C@H]1CN(C(=O)COc2ccon2)CCCN1C(=O)[C@H]1CCC(=O)O1', 'C[C@H]1CN(C(=O)Cc2ccc(O)cc2)C[C@@H]1NS(=O)(=O)CC1CCC1', 'C[C@H]1CN(C(=O)Cn2ncccc2=O)[C@H]1C(=O)NCCn1ncnn1', 'C[C@H]1CN(C(=O)OC(C)(C)C)C[C@@H]1NCC(O)c1ccc(F)c(Cl)c1', 'C[C@H]1CN(C(=O)[C@@H]2C[C@H]3C=C[C@@H]2O3)C[C@@H]1C(=O)N(C)CC1CCOC1', 'C[C@H]1CN(C(=O)[C@H](O)C(F)(F)F)C[C@@H]1CC(=O)N1CC[C@@H](CCO)C1', 'C[C@H]1CN(C(=O)c2cc(S(N)(=O)=O)co2)C[C@H]1NS(=O)(=O)CCCF', 'C[C@H]1CN(C(=O)c2cccc(Cl)c2N)CCN1C(=O)c1csc(Cl)n1', 'C[C@H]1CN(C(=O)c2cccnc2)[C@H]1C(=O)N1CCC(c2cnn[nH]2)C1', 'C[C@H]1CN(C(=O)c2ccn(C)c2)[C@H]1C(=O)N1CC(C2CCCCC2)C1', 'C[C@H]1CN(C(=O)c2cnns2)CCN1C(=O)C1CC(n2ccnc2)C1', 'C[C@H]1CN(C(=O)c2nonc2N)CCN1C(=O)c1coc(C(F)F)n1', 'C[C@H]1CN(C)C[C@@H](C(=O)N2CC[C@@H]2C(=O)NCCc2cn(C)cn2)O1', 'C[C@H]1CN(S(=O)(=O)c2cccnc2N2CC[C@H](N(C)C)C2)C[C@H](C)O1', 'C[C@H]1CN(c2ccccc2)CCN1c1c([N+](=O)[O-])cnc2ccsc12', 'C[C@H]1COCCCN1C(=O)CC1CN(C(=O)[C@H]2C[C@](C)(F)C2)CCO1', 'C[C@H]1COC[C@@H]1CN(CCCCC(C)(F)F)C(=O)C1CCCCC1F', 'C[C@H]1COC[C@H]1NC(=O)C1CN(C(=O)CC2CCOC2(C)C)CCO1', 'C[C@H]1C[C@@H](C(=O)N2CCCC3(CC=CCO3)CC2)c2ccccc2N1', 'C[C@H]1C[C@@H](C(=O)N2CCC[C@H]2CF)CN(C(=O)CCCCC2CC2)C1', 'C[C@H]1C[C@@H](C(=O)NC23CC(C)(C2)C3)CN(C(=O)CN2CSCC2=O)C1', 'C[C@H]1C[C@@H](C(=O)NC[C@@H]2CCCN(C(=O)CCCN(C)C)C2)CCO1', 'C[C@H]1C[C@@H]1CCC(=O)NCC(CO)CNC(=O)c1cc(C(N)=O)c[nH]1', 'C[C@H]1C[C@@H]1CCCNC(=O)[C@H]1CC[C@H](CNC(=O)C#CC2CC2)CC1', 'C[C@H]1C[C@@H]1CCCNc1ccnc(NC2CCc3ncc(Br)n3C2)n1', 'C[C@H]1C[C@@H]1Nc1nc(N2CCC(c3cn[nH]c3)CC2)nc2scnc12', 'C[C@H]1C[C@@H]1S(=O)(=O)NC(CNC(=O)C1=CCCCC1)c1cccnc1', 'C[C@H]1C[C@@]1(NC(=O)CC1CC(=O)C1)C(=O)NCC12CCN(CC1)CC2', 'C[C@H]1C[C@@]1(NC(=O)c1cc(C#N)c[nH]1)C(=O)N1Cc2cccnc2C1', 'C[C@H]1C[C@@]1(NC(=O)c1ccc(C#N)[nH]1)C(=O)NCC(C)(O)C1(C)CC1', 'C[C@H]1C[C@@]1(NC(=O)c1cncn1C)C(=O)N1CCC2(CCC(O)C2)C1', 'C[C@H]1C[C@@]1(NC(=O)c1coc(C2CC2)n1)C(=O)NC[C@H]1COC[C@H]1O', 'C[C@H]1C[C@H](C(=O)N2CCN(C(=O)[C@@H]3CC(=O)NC(=O)N3)CC2)CCO1', 'C[C@H]1C[C@H](NC(=O)C2C=CC=CC=C2)CCN1C(=O)c1cn[nH]c1Cl', 'C[C@H]1C[C@H](NC(=O)C2CCCC2CNC(=O)C2CCCC(C#N)C2)C1', 'C[C@H]1C[C@H]1C(=O)NCC(O)C1CCN(C(=O)C2(O)CCCCC2)CC1', 'C[C@H]1C[C@]1(C)C(=O)N1CC2(C)CC1(C(=O)NCc1cc(Cl)ccn1)C2', 'C[C@H]1C[C@]1(C)C(=O)N1CCC(C(=O)NCC2(CO)CCC2)C(C)(C)C1', 'C[C@H]1C[C@]1(C)C(=O)NC12CCC(NC(=O)c3ccncc3Cl)(CC1)C2', 'C[C@H]1OCCO[C@H]1C(=O)N(C)C1(C(=O)NCC(C)(C)C(F)(F)F)CC1', 'C[C@H]1OCCO[C@H]1C(=O)N(Cc1ncccc1Cl)C[C@@H](O)C(C)(C)C', 'C[C@H]1OCCO[C@H]1C(=O)N1CCC(F)(CNC(=O)C2=CCCSC2)C1', 'C[C@H]1OCC[C@H]1C(=O)N1C[C@H](NC(=O)Cc2cnsc2)[C@@H](C2CC2)C1', 'C[C@H]1ON=C(C(=O)N2CC(CF)(NC(=O)CCn3cccc3)C2)[C@@H]1C', 'C[C@H]1ON=C(C(=O)N2C[C@@H](F)C[C@H]2C(=O)NC2CC(=O)N(O)C2)[C@@H]1C', 'C[C@H]1[C@@H](NC(=O)C2CC3(CC(NC(=O)c4ccccc4)C3)C2)C1(C)C', 'C[C@H]1[C@H](NC(=O)CNC(N)=O)CCN1C(=O)/C=C(/F)c1ccccc1', 'C[C@H]1[C@H](NC(=O)Nc2ccc(F)cc2F)CCN1C(=O)OC(C)(C)C', 'C[C@H]1[C@H](NC(=O)c2cccc(C#N)c2)CCN1C(=O)c1cccn1C', 'C[C@H]1[C@H]2[C@H](CCN2C(=O)CN(C)C)CN1C(=O)CCCN1CCCC1', 'C[C@H]1c2ccccc2C[C@H]1NCCc1cn(-c2cccc(Br)c2)nn1', 'C[C@](O)(C(=O)NNc1cccc(OC(F)(F)F)c1F)c1ccccc1', 'C[C@]1(C(=O)N2C[C@H]3C[C@@]3(C(=O)N3CCC4(CCC4)C3)C2)C[C@H]2C[C@H]2C1', 'C[C@]1(NC(=O)c2ncccc2O)C[C@@H](C(=O)N2C[C@H]3CCO[C@H]3C2)C1', 'C[C@]1(O)C[C@@H](C(=O)N2CC3(CC3)C[C@H]2CC(=O)N2CC3CCC2C3)C1', 'C[C@]12CCC(=O)N1[C@H](C(=O)Nc1ccncc1N1CCOCC1)CS2', 'C[C@]12CCC[C@H]1CN(C(=O)NCc1cccc(OC3CCCC3)c1)C2', 'C[Si](C)(C)CCCS(=O)(=O)NCC1CCc2cc([N+](=O)[O-])ccc2O1', 'C[Si]1(C)CCN(C(=O)C2(NC(=O)c3cc(CO)ccn3)CCCC2)C1', 'Cc1[nH]c(=O)[nH]c1C(=O)N1CCO[C@@H](CNC(=O)C2=COCCC2)C1', 'Cc1[nH]c(=O)[nH]c1C(=O)NC[C@H](C)n1cc(CCCCCCO)nn1', 'Cc1[nH]c(=O)c(C#N)c(C)c1CCC(=O)Nc1cccc(F)c1CN', 'Cc1[nH]c(=O)sc1C(=O)N1CCC[C@H](NC(=O)C2(CN(C)C)CC2)C1', 'Cc1[nH]c(C(=O)N(CC2=CCCOC2)Cc2cccc(F)c2)nc1Cl', 'Cc1[nH]c(C(=O)N2C[C@H](CO)[C@H](NS(=O)(=O)c3ccoc3)C2)nc1Cl', 'Cc1[nH]c(C(=O)Nc2ncccc2OCc2cccnc2)c(C)c1Br', 'Cc1[nH]c2ccc(Br)cc2c1CCNC(=O)[C@H]1CNC[C@@H]1C(F)(F)F', 'Cc1[nH]c2ccccc2c1SCCNC(=O)NC[C@@H]1CCC[C@H]1CF', 'Cc1[nH]ccc1C(=O)N1CC(C(=O)N2CCC(C#N)CC2)C(C)(C)C1', 'Cc1[nH]cnc1C(=O)N(C)C1CCC(NC(=O)CN2CCCC2=O)C1', 'Cc1[nH]cnc1C(=O)N(C)C1CCN(C(=O)Cc2ccncc2Cl)C1', 'Cc1[nH]nc(C(=O)NC[C@H](O)C(=O)N2CCC(C(C)(C)O)CC2)c1C', 'Cc1[nH]nc(CO)c1C(=O)NCCC(=O)NCCC(C)c1cn[nH]c1', 'Cc1[nH]nc(Cl)c1CN(CC1CC12CCCCC2)C(=O)[C@@H](C)C1CC1', 'Cc1[nH]nc(Cl)c1CN(C[C@H]1[C@H](C)C1(F)F)C(=O)CC12CCCC1C2', 'Cc1[nH]nc2ncc(C(=O)NC(C)(C)C(=O)NC(C)(C)C(=O)O)cc12', 'Cc1[nH]ncc1C(=O)N(CCCO)CCC(=O)NCCc1nncs1', 'Cc1[nH]ncc1C(=O)N1CCN(C(=O)C23C=CC(CC2)C3)CC(O)C1', 'Cc1[nH]ncc1C(=O)N1CCOC[C@H]1C(=O)NC1CCN2CCC1C2', 'Cc1[nH]ncc1C(=O)N[C@@H]1CCC[C@@H](C(=O)N2C[C@H]3COC[C@H]3O2)C1', 'Cc1c(-c2ccccc2)cccc1-c1nn(C)c2c(O)nc(O)nc12', 'Cc1c(Br)cnc(O)c1CNC(=O)N(CC(C)(C)O)C1CCOCC1', 'Cc1c(C#N)c(=O)n(Cc2ccc([N+](=O)[O-])c(F)c2)c(=O)n1C1CC1', 'Cc1c(C#N)cccc1NC(=O)C(=O)N1CCC(N2CCNCC2)C1', 'Cc1c(C(=O)N(C)C2COCCN(C)C2)cccc1-c1ccccn1', 'Cc1c(C(=O)N2CC[C@H](CO)[C@@H]2c2ccccc2)ccc2nc[nH]c12', 'Cc1c(C(=O)N2C[C@H]3C[C@@]3(NC(=O)[C@H]3[C@@H]4CCCC[C@@H]43)C2)ncn1C', 'Cc1c(C(=O)N2c3ccccc3CC2CC(=O)O)nn2ccccc12', 'Cc1c(C(=O)NC(C)c2nc(C(F)(F)F)no2)[nH]c2c(Cl)cccc12', 'Cc1c(C(=O)NCC2(CNC(=O)[C@H]3C[C@@](C)(O)C3)CCC2)ncn1C', 'Cc1c(C(=O)NCCCN(C)CC(F)(F)F)cc(C)c2ncccc12', 'Cc1c(C(=O)NCCc2ncc(Br)s2)[nH]c2ccc(C(F)(F)F)cc12', 'Cc1c(C(=O)NC[C@H]2CCC[C@@H](CNC(=O)C3(C)CC3)C2)cnn1C', 'Cc1c(C(=O)NCc2nc3cccc(Cl)c3[nH]2)ccc2cnn(C)c12', 'Cc1c(C(=O)N[C@@H](CC(N)=O)C(=O)N2CC3CC3C3CC32)ccn1C', 'Cc1c(C(=O)N[C@@H]2CC[C@H](CCNC(=O)C3CCCS3)C2)ccn1C', 'Cc1c(C(=O)N[C@@H]2CN(C(=O)CN3CCCC3C)C[C@H]2O)cnn1C', 'Cc1c(C(=O)N[C@H]2CC[C@H](NC(=O)OC(C)(C)C)C2)sc2cncn12', 'Cc1c(C(=O)Nc2ccc(Br)c3c2OCCO3)[nH]c2c(C)cccc12', 'Cc1c(C(=O)Nc2ccc3cccc(Cl)c3n2)n(C)c(=O)n1C1CC1', 'Cc1c(C(=O)O)ccc(F)c1C(=O)NCC1CC(=O)N(C(C)(C)C)C1', 'Cc1c(C(=O)O)sc2nc(C(C)N(C)Cc3ncn(C)n3)[nH]c(=O)c12', 'Cc1c(C(=O)OCC(O)COCc2ccccc2F)ccn1C1CC1', 'Cc1c(C(=O)OCCc2cccc(Br)c2)cnn1-c1ccc(F)cc1', 'Cc1c(C(F)(F)F)nn(C)c1NC(=O)N1CC(c2ncc(CO)s2)C1', 'Cc1c(C(NC(=O)C2(c3ccc(Cl)cc3Cl)CC2)C(=O)O)cnn1C', 'Cc1c(C=CC(=O)NC[C@H](CO)NC(=O)c2cc(Cl)cs2)cnn1C', 'Cc1c(CC(=O)N2CCOC(C(=O)NC3(CF)CC3)CC2)cnn1C', 'Cc1c(CC(=O)NC2(CNC(=O)CC3(C)CC3)CCCC2)cnn1C', 'Cc1c(CC(=O)N[C@H]2[C@@H](C(=O)N(C)CCCCO)C2(C)C)cnn1C', 'Cc1c(CN(C)C(=O)CC2(NC(=O)CCC3(C)N=N3)CC2)cnn1C', 'Cc1c(CN(C)C(=O)[C@@H]2[C@H](C)CN2C(=O)C2CCN(C)C2)cnn1C', 'Cc1c(CN2Cc3ccccc3CC2c2ncc[nH]2)c[nH]c1C(=O)O', 'Cc1c(CNC(=O)N2CCS(=O)C(C)(C)CC2)n(C)c2ccccc12', 'Cc1c(CNC(=O)NC23CC4CC(C2)C(O)C(C4)C3)sc2cncn12', 'Cc1c(CNC(=O)c2ccc(-c3ncc[nH]3)cc2)sc2ccccc12', 'Cc1c(CS(C)(=O)=O)cccc1NCCc1ccc2c(c1)OCCO2', 'Cc1c(Cl)c(CN(CC(C)C(F)(F)F)C(=O)C(O)C(C)(C)O)nn1C', 'Cc1c(Cl)c(CN(CC2CCCC2C)C(=O)C2CCCN2C)nn1C', 'Cc1c(Cl)cc(COC(=O)CN(C)c2ccccc2[N+](=O)[O-])cc1Br', 'Cc1c(Cl)ccc(CN(Cc2cc(Br)[nH]n2)C[C@H](O)C(C)(C)C)c1O', 'Cc1c(Cl)ccc(NC(=O)C2CCOC2=O)c1OCc1ccccc1', 'Cc1c(Cl)cccc1CN(CC1(Cl)CC1(F)F)C(=O)C#CCCCF', 'Cc1c(Cl)cccc1NC(=O)CCC[C@@H](C)NC(=O)C1(N(C)C)CC1', 'Cc1c(Cl)ccnc1CC(=O)NCC1CC2(CCC(F)(F)CC2)CO1', 'Cc1c(Cl)cnc(NC(=O)CN(C)CC2(O)CCC(F)(F)CC2)c1Cl', 'Cc1c(Cl)cnn1CC(=O)NC(c1cccc(F)c1)C1CCCCC1', 'Cc1c(Cl)cnn1CC(=O)NCCC1CCN(C(=O)[C@H](C)C2CC2)C1', 'Cc1c(F)cc(Cl)c2c1CCCN2C(=O)CN1C(=O)C(=O)N(C)C1=O', 'Cc1c(F)cc(S(N)(=O)=O)cc1C(=O)NCc1ccc2[nH]ccc2c1', 'Cc1c(F)cncc1C(=O)N[C@@H](COC(C)C)C(=O)N[C@H]1C[C@@H](O)C1', 'Cc1c(N(C)CC2CCC2)ncnc1N1CCn2ncc(CO)c2C1', 'Cc1c(N)cccc1CNc1nc2c(c(NCC[C@H](C)F)n1)COC2', 'Cc1c(N2CCOCC(C)(C)C2)ncnc1N1C2CCCC1COC2', 'Cc1c(NC(=O)C(F)(F)CNC(=O)OC(C)(C)C)cccc1C(N)=O', 'Cc1c(NC(=O)C(O)Cc2ccccn2)cccc1-c1cccnc1', 'Cc1c(NC(=O)C2(S(C)=O)CCNCC2)cnn1-c1ccc(F)cc1', 'Cc1c(NC(=O)C23CCC(N=[N+]=[N-])C2C3)cnn1-c1ccc(F)cc1', 'Cc1c(NC(=O)CCc2cc(F)cc(F)c2)c(C(=O)N(C)C)nn1C', 'Cc1c(NC(=O)N2[C@@H]3CC[C@H]2C[C@@H](O)C3)cccc1OCC(F)(F)F', 'Cc1c(NC(=O)NCc2nc3cc(F)ccc3s2)c(C(F)F)nn1C', 'Cc1c(NCC(=O)NC2CCCC2)ncnc1N1CCC(C)(C)CC1', 'Cc1c(NCC23C4CCC(CC42)C3(F)F)cnn1-c1cccc(Cl)c1', 'Cc1c(NCCCN(C)C(C)C)ncnc1N1CCC(C)C(CO)C1', 'Cc1c(NCCc2nnn(C(C)(C)C)n2)cccc1N1CCCC1=O', 'Cc1c(NCc2nc(O)cc(O)n2)ncnc1NC1CC(C(F)F)C1', 'Cc1c(NNC(=O)NCc2n[nH]c(C(C)(C)C)n2)cccc1[N+](=O)[O-]', 'Cc1c(O)ccnc1C(=O)N1CC(CC(=O)N2CC(CO)C2)CC1C', 'Cc1c(O)ccnc1C(=O)NNc1oc(-c2ccccc2)nc1C#N', 'Cc1c(O)nc(CCN(C)C(=O)c2ccnc3c2CC(=O)N3)[nH]c1=O', 'Cc1c(S(=O)(=O)Oc2ccc(NC(=O)C3CC3)cc2)cnn1C(F)F', 'Cc1c2c(n(C)c1-c1ccc([C@H](C)NS(C)(=O)=O)cc1)CCCC2=O', 'Cc1c[nH]c(=O)c(CNc2ccnc(N(C)CC(=O)NC(C)C)n2)c1', 'Cc1c[nH]c(C(=O)N(Cc2cc(F)c(F)c(F)c2)CC2[C@H](C)[C@H]2C)c1', 'Cc1c[nH]c(C(=O)N2CC(O)(CCNC(=O)c3cscc3Cl)C2)c1C', 'Cc1c[nH]c(C(=O)N2CCC(CC(=O)N3CCC(F)(CF)C3)C2)c1C', 'Cc1c[nH]c(C(=O)N2CC[C@H](C(=O)N3CCN(C)C(=O)C3)[C@H](C)C2)c1', 'Cc1c[nH]c(C(=O)NCC(F)(F)Cn2cc(CCCCCO)nn2)c1', 'Cc1c[nH]c(C(=O)N[C@H](C(=O)N2CCC3(CCOC3)C2)[C@@H](C)O)c1C', 'Cc1c[nH]c(C(=O)N[C@H]2C[C@@H](CO)N(C(=O)CCCCC3CC3)C2)c1', 'Cc1c[nH]c(C2(NC(=O)NC(C)c3cnc(N)nc3C)CCOC2)n1', 'Cc1c[nH]c(CCC(=O)N[C@@H]2[C@H]3C[C@@H]2N(C(=O)C(F)(F)C2CC2)C3)n1', 'Cc1c[nH]c(CNC(=O)CCCC(C)(C)NC(=O)CC2CC2(C)C)n1', 'Cc1c[nH]nc1C(=O)N1CC2(C(=O)NC34CC(F)(C3)C4)CC1CCO2', 'Cc1c[nH]nc1C(=O)NC[C@H]1C[C@H]1CC(=O)NCCn1cnnc1C', 'Cc1c[nH]nc1C(=O)NCc1ccsc1C(=O)NCCOCC(F)F', 'Cc1c[nH]nc1C(=O)N[C@]1(C)C[C@H](NC(=O)CCCn2ccnc2)C1', 'Cc1cc(-c2[nH]ncc2C(=O)NOCCc2ccccc2)ccc1F', 'Cc1cc(-c2cn(-c3ccc(OC(C)(C)C)nc3)nn2)cnc1C#N', 'Cc1cc(-c2cn(C(C)C(=O)N3C[C@H](CO)[C@@H](CO)C3)nn2)n(C)n1', 'Cc1cc(-c2csc(C(C)NC(=O)C(C)(C)C(=O)N(C)C)n2)c(C)s1', 'Cc1cc(-n2cc(CCCn3cccc3C(=O)O)nn2)cc(C)c1C', 'Cc1cc(/C=C/C(=O)N2CC[C@@H](NC(=O)CC(C)(C)C3CC3)C2)on1', 'Cc1cc(=O)[nH]cc1C(=O)NCC(C)(C)NC(=O)C(C)C1(O)CCC1', 'Cc1cc(=O)[nH]cc1C(=O)NC[C@H]1C=C[C@@H](NC(=O)CC(C)(F)F)C1', 'Cc1cc(=O)c(C(=O)N2CC(C)(C)C2c2cccnc2)cn1C1CC1', 'Cc1cc(=O)c(C(=O)OC(C)C(=O)Nc2ccc3c(c2)OCO3)n[nH]1', 'Cc1cc(=O)n(C)cc1C(=O)N1CC2CC(C1)N2C(=O)C1CC1(C)C', 'Cc1cc(=O)n(C2CCSC2)cc1NC(=O)N1CC=C[C@H]2COC[C@H]21', 'Cc1cc(Br)cc2[nH]c(CNCc3cnn(-c4ccccc4)n3)cc12', 'Cc1cc(Br)ncc1NC(=O)C(=O)N1CCOC(c2ccc(Cl)s2)C1', 'Cc1cc(C#N)c(NC(=O)c2ccc(NC(=O)c3ccco3)cc2)s1', 'Cc1cc(C#N)cc(-c2cn(CCNC(=O)CC3CC(F)C3)nn2)c1', 'Cc1cc(C#N)cc(C(=O)N[C@H](C)CN(C)S(=O)(=O)C2CCOC2)c1', 'Cc1cc(C#N)cc(NC(=O)/C=C/C(C)(C)NC(=O)CC2CCC2)c1', 'Cc1cc(C#N)cnc1C(=O)N(CCSC(C)C)Cc1cccnn1', 'Cc1cc(C#N)cnc1C(=O)N[C@H]1CC[C@@H]1NC(=O)C1(C)CC=CC1', 'Cc1cc(C#N)cnc1N1CCC(n2c(CO)nc3ccccc32)C1', 'Cc1cc(C(=O)Cn2cc(CNC(N)=O)nn2)c(C)n1CCC(C)C', 'Cc1cc(C(=O)N(C)C(C(=O)N(C)Cc2cscn2)C2CC2)c(C)s1', 'Cc1cc(C(=O)N(C)C(C)CN(C)C(=O)CC2(C)CC(F)(F)C2)co1', 'Cc1cc(C(=O)N(C)C(C)CNC(=O)CCCSC(C)(C)C)[nH]c1C', 'Cc1cc(C(=O)N(C)CCN(C)C(=O)C2CC(=C3CCC3)C2)[nH]c1C', 'Cc1cc(C(=O)N(C)CCN(C)C(=O)c2ccc(CCO)cc2)no1', 'Cc1cc(C(=O)N(C)C[C@H](C)NC(=O)Cc2cccn2C)c(C)cn1', 'Cc1cc(C(=O)N(C)[C@@H](CC(C)C)C(=O)N2CCC3CC32)n[nH]c1=O', 'Cc1cc(C(=O)N(C)[C@@H]2CN(C(=O)C=C3CCN(C)C3)C[C@H]2O)[nH]n1', 'Cc1cc(C(=O)N(CC(O)C2CCC2)C[C@H]2C[C@@H]2c2cccs2)co1', 'Cc1cc(C(=O)N(CC2CC2)c2ccc(C#N)cc2)nn1C(C)(C)C', 'Cc1cc(C(=O)N(CCC(C)C(C)C)Cc2cc(C(F)F)on2)ns1', 'Cc1cc(C(=O)N(CCC(F)(F)F)Cc2cc(Cl)n(C)n2)cc(O)n1', 'Cc1cc(C(=O)N(CCC(F)=C(F)F)Cc2c(O)cccc2F)n[nH]1', 'Cc1cc(C(=O)N(CCNC(=O)CC(C)(C)C2CC2)C(C)C)c(C)o1', 'Cc1cc(C(=O)N(CC[C@H]2C[C@H]3CC[C@@H]2C3)Cc2ccon2)c(C)s1', 'Cc1cc(C(=O)N(Cc2cc(Cl)ccc2F)CC2CCCC2)n(C)n1', 'Cc1cc(C(=O)N(Cc2cccc(CO)n2)CC2CC(F)(F)C2)co1', 'Cc1cc(C(=O)N2CC(C(O)C(=O)NC(C)(C)c3nccs3)C2)[nH]n1', 'Cc1cc(C(=O)N2CC(C)(C(=O)N3CC(C)OC(C)(C)C3)C2)nn1C', 'Cc1cc(C(=O)N2CC(C)(NC(=O)C3=CCCC3)C2)cc2ccoc12', 'Cc1cc(C(=O)N2CC(CC(=O)N(C)CCO)C3(CC3)C2)nc(C)n1', 'Cc1cc(C(=O)N2CC(CC(F)C(=O)NC(C)(C)CF)C2)nc(C)n1', 'Cc1cc(C(=O)N2CC(N(C)C(=O)C3CCC(=O)C3)C(C)(C)C2)co1', 'Cc1cc(C(=O)N2CC(O)(CNC(=O)c3cnnn3C3CC3)C2)no1', 'Cc1cc(C(=O)N2CC(O)(CNC(=O)c3cscn3)C2)n(C2CC2)n1', 'Cc1cc(C(=O)N2CC3(CNC(=O)C4CCC4)CC2CO3)cnc1C', 'Cc1cc(C(=O)N2CC3CCCCCC3C2)c(C)n1Cc1cccs1', 'Cc1cc(C(=O)N2CCC(C(=O)N3CCCCC3)C(C)(C)C2)ncn1', 'Cc1cc(C(=O)N2CCC3(CC(C(=O)N(C)CC(F)F)C3)C2)n(C)n1', 'Cc1cc(C(=O)N2CCC3CN(C(=O)[C@@H]4CC[C@H](C)O4)C3C2)c(C)o1', 'Cc1cc(C(=O)N2CCCC(C)(CNC(=O)c3nocc3C)C2)no1', 'Cc1cc(C(=O)N2CCCC(F)(C(=O)N[C@H](CO)C(C)C)C2)c(N)s1', 'Cc1cc(C(=O)N2CCCCC(C(=O)NC3CC3(C)C(F)F)C2)sn1', 'Cc1cc(C(=O)N2CCCC[C@@H]2C(=O)NCCc2c[nH]nc2O)[nH]n1', 'Cc1cc(C(=O)N2CCC[C@@H]2CCC(=O)N(C)CC2CC2)nnc1C', 'Cc1cc(C(=O)N2CCC[C@H](C(=O)NC3CCCNC3=O)[C@@H]2C)on1', 'Cc1cc(C(=O)N2CCC[C@H]3CN(C(=O)CN(C)C(N)=O)C[C@H]32)[nH]n1', 'Cc1cc(C(=O)N2CCOCC2CNC(=O)c2ncoc2C)c(C)o1', 'Cc1cc(C(=O)N2CC[C@@H](NC(=O)C3CC34CCCCCC4)C2)[nH]n1', 'Cc1cc(C(=O)N2CC[C@H](C)C[C@@H]2C(=O)NCCn2ncnn2)[nH]n1', 'Cc1cc(C(=O)N2C[C@@H](F)C[C@H]2c2csc(C)n2)cc(C(F)(F)F)c1', 'Cc1cc(C(=O)N2C[C@@H]3[C@@H](CC(=O)N4C[C@H]5CC[C@H]5C4)[C@@H]3C2)oc1C', 'Cc1cc(C(=O)N2C[C@@H]3[C@H](C2)[C@H]3NC(=O)[C@H]2[C@@H]3COC[C@@H]32)nnc1C', 'Cc1cc(C(=O)N2C[C@H](C)[C@@H]2C(=O)N(C)Cc2ccsc2)c(C)cn1', 'Cc1cc(C(=O)N2C[C@H](CC(=O)NOCC(N)=O)[C@@H](C)C2)cnc1C', 'Cc1cc(C(=O)N2C[C@H](O)C[C@H]2CC(=O)NC2CC23CC(O)C3)co1', 'Cc1cc(C(=O)N2C[C@H]3C[C@@]3(C(=O)N(C3CC3)C3CC3)C2)c(C)nn1', 'Cc1cc(C(=O)NC(C(=O)NCC2(C)CCC2)C2CC=CCC2)co1', 'Cc1cc(C(=O)NC(C)(C)CC(=O)NCC2(S(C)=O)CC2)c(C)n1C', 'Cc1cc(C(=O)NC(C)C(C)(C)C(=O)NCCC2CC2C)c(=O)[nH]n1', 'Cc1cc(C(=O)NC(C)C2(C(=O)NCCn3cncn3)CC2)c(C)o1', 'Cc1cc(C(=O)NC(C)CCC(=O)NCCN2CC[C@H](O)C2)cnn1', 'Cc1cc(C(=O)NC(CC(C)C)C(=O)N2CCCC(C#N)C2)oc1C', 'Cc1cc(C(=O)NC(CC(C)C)C(=O)NCC2(O)CSC2)cnc1N', 'Cc1cc(C(=O)NC/C=C\\CNC(=O)c2sccc2C2CC2)n(C)n1', 'Cc1cc(C(=O)NC2(C(=O)N3CCC3(C)C(C)C)CCCC2)c(C)o1', 'Cc1cc(C(=O)NC2(C)CCN(C(=O)c3n[nH]nc3C)C2)cnc1C', 'Cc1cc(C(=O)NC2(CO)CC(C)CC(C)(C)C2)nc2ccccc12', 'Cc1cc(C(=O)NC2CN(C(=O)C=Cc3cnc[nH]c3=O)C2)c(N)s1', 'Cc1cc(C(=O)NC2CN(C(=O)Cc3nc[nH]n3)C(C)(C)C2)[nH]c1C', 'Cc1cc(C(=O)NCC(O)C(=O)Nc2cccc3ccoc23)sc1C', 'Cc1cc(C(=O)NCC2(C(=O)NCCn3ccnc3)CCC2)nn1C', 'Cc1cc(C(=O)NCC2(C)CN(C(=O)CCOC(C)C)CCO2)[nH]n1', 'Cc1cc(C(=O)NCC2(CNC(=O)C3CC34CCC4)CC2(F)F)no1', 'Cc1cc(C(=O)NCC23CC4CC(CC(C4)C2N)C3)cc2nn[nH]c12', 'Cc1cc(C(=O)NCC2CC(NC(=O)c3conc3C(C)C)C2)sn1', 'Cc1cc(C(=O)NCC2CCCC2NC(=O)CCC(N)=O)c[nH]c1=O', 'Cc1cc(C(=O)NCCC(=O)NC2CC(C)CC(C)(C)C2)cnc1N', 'Cc1cc(C(=O)NCCC(C)N(C)C(=O)[C@H]2C[C@@H](C)N(C)C2)oc1C', 'Cc1cc(C(=O)NCCC2CN(C(=O)C3(C)CCCC3)C2)nc(O)n1', 'Cc1cc(C(=O)NCCCC2CCN(C(=O)C3CC3(F)F)CC2)co1', 'Cc1cc(C(=O)NCCCCC(=O)N2CC3(C=CCO3)C2)ccc1F', 'Cc1cc(C(=O)NCCCN(C(=O)C(C)CN(C)C)C(C)C)c(C)o1', 'Cc1cc(C(=O)NCCN(C(=O)[C@H]2C[C@@H](O)C2)C2CC2)cc(N)c1O', 'Cc1cc(C(=O)NCCN(CC2CC2)C(=O)Cc2ccn(C)n2)cs1', 'Cc1cc(C(=O)NCCc2[nH]ncc2C(=O)NC2(CO)CC2)ncn1', 'Cc1cc(C(=O)NC[C@H](O)C(=O)N[C@H](C)C2CCOCC2)nc(C)n1', 'Cc1cc(C(=O)NC[C@H]2C[C@H](NC(=O)C3CC(C)CC(C)C3)C2)no1', 'Cc1cc(C(=O)NC[C@H]2C[C@H]2C(=O)N2CCC(OCCO)C2)c(N)s1', 'Cc1cc(C(=O)NCc2cc(C(=O)NCCC(C)CO)[nH]n2)cn1C', 'Cc1cc(C(=O)N[C@@H](C)CCC(=O)N2Cc3nncn3C(C)C2)sn1', 'Cc1cc(C(=O)N[C@@H]2CN(C(=O)C3=CCCSC3)C[C@H]2O)cnc1C', 'Cc1cc(C(=O)N[C@H](C(=O)N(C)CC2CCCCC2)C(C)(C)O)on1', 'Cc1cc(C(=O)N[C@H](C(=O)N(C)Cc2ccco2)[C@@H](C)O)n[nH]c1=O', 'Cc1cc(C(=O)N[C@H]2C=CC[C@H](C(=O)N[C@H](CO)C3CC3)C2)ccn1', 'Cc1cc(C(=O)N[C@H]2CCCC[C@H]2NC(=O)c2cccc(N)c2)sn1', 'Cc1cc(C(=O)N[C@H]2COC[C@@H]2NC(=O)c2cc(Cl)n(C)n2)ccn1', 'Cc1cc(C(=O)N[C@H]2C[C@]3(NC(=O)CCC(F)(F)F)CO[C@H]2C3)ns1', 'Cc1cc(C(=O)N[C@H]2[C@@H](C(=O)NC3CCCC3)C2(C)C)ccc1C#N', 'Cc1cc(C(=O)N[C@]2(C)C[C@H](C(=O)NC[C@@H]3C[C@H](O)C3(C)C)C2)no1', 'Cc1cc(C(=O)Nc2ccc(-c3ocnc3C)cc2)c2nccn2c1', 'Cc1cc(C(=O)Nc2cccc(NC(=O)/C=C/CCC(C)C)c2)co1', 'Cc1cc(C(=O)Nc2ncc(Cc3ccc(F)cc3F)s2)c(Cl)cn1', 'Cc1cc(C(=O)O)ccc1C(=O)NC(C)(C)c1ccccc1C1CC1', 'Cc1cc(C(C(=O)NC(C)C)N2CCC[C@@H](C(F)(F)F)C2)ccc1Cl', 'Cc1cc(C(C(=O)NCCC2CC2)N2CCC2(C)CCO)nnc1C', 'Cc1cc(C(C)(C)C)cc(C)c1CCNC(=O)C(O)c1cccnc1', 'Cc1cc(C(C)N(C)C(=O)C(C)CNC(=O)c2cccc(Cl)c2)no1', 'Cc1cc(C(F)(F)F)cc(NC(=O)N2CCCC(C3OCCO3)C2)n1', 'Cc1cc(C(F)(F)F)nn1CCC(=O)N1CC(N=[N+]=[N-])CCC1(C)C', 'Cc1cc(C(F)F)ccc1C(=O)OCc1nc2c(c(=O)[nH]1)CCCC2', 'Cc1cc(C(F)F)ccc1S(=O)(=O)N1CCCCCC(S(C)(=O)=O)C1', 'Cc1cc(C(F)F)oc1C(=O)N1CCc2cc(OC(C)C)ccc2C1', 'Cc1cc(C(NCCc2cnoc2)c2nnnn2CCC#N)sc1C', 'Cc1cc(C)c(C(=O)COC(=O)c2cnn3c(=O)cc[nH]c23)c(C)c1', 'Cc1cc(C)c(C(=O)N2CC=CC2C(=O)NCCc2ccn(C)n2)s1', 'Cc1cc(C)c(C(=O)N2CCCC(NC(=O)c3ncc(F)cn3)C2)o1', 'Cc1cc(C)c(C(=O)NC(C)C2(O)CCN(C(=O)C(=O)N(C)C)C2)s1', 'Cc1cc(C)c(C(=O)NC2(CNC(=O)C3C4CC(=O)CC43)CCC2)o1', 'Cc1cc(C)c(C(=O)NCC(C)CN(C)C(=O)C23C=CC(CC2)C3)o1', 'Cc1cc(C)c(C(=O)N[C@@H](C)CCC(=O)N2CCCC(F)(F)C2)cn1', 'Cc1cc(C)c(C(=O)N[C@H]2CCC[C@H](NS(=O)(=O)[C@@H]3CCOC3)C2)o1', 'Cc1cc(C)c(C(C)NC(=O)c2ncsc2N2CCNCC2)cc1C', 'Cc1cc(C)c(C)c(OCCC(=O)NCc2ccc(C3CC3)cc2)c1', 'Cc1cc(C)c(CC(=O)N2CC(F)CC2c2nc(C)c(C)s2)c(C)c1', 'Cc1cc(C)c(CN(CC2CCCC(C)C2)C(=O)[C@H]2CCC(=O)O2)s1', 'Cc1cc(C)c(CN(Cc2cccc(Cl)c2)C(=O)[C@@H](CO)N(C)C)s1', 'Cc1cc(C)c(CNC(=O)[C@@H]2C[C@H](C)CN(C(=O)c3ccoc3)C2)s1', 'Cc1cc(C)c(CNC(=O)c2cnc(OCC(C)C)c(Cl)c2)cc1C', 'Cc1cc(C)c(N)c(C(=O)NCCCN(C)C(=O)c2csc(Cl)n2)c1', 'Cc1cc(C)c(O)c(NC(=O)C2(F)CN(C(=O)c3conc3C)C2)c1', 'Cc1cc(C)c2c(c1)N(C(=O)c1cc(-c3ccc(C)s3)on1)CCC2', 'Cc1cc(C)c2c(c1)[C@@H](NC(=O)NC1CCC(C(C)C)CC1)CCO2', 'Cc1cc(C)cc(C(C(=O)NCCCF)N2CCS(=O)(=O)C[C@H]2C)c1', 'Cc1cc(C)cc(C2(F)CCN(C(=O)Nc3cc(C)cnc3Cl)C2)c1', 'Cc1cc(C)cc(CC(=O)NCCNC(=O)c2ccc([N+](=O)[O-])[nH]2)c1', 'Cc1cc(C)cc(CN(CCC2CSC2)C(=O)C2CCCCN2C)c1', 'Cc1cc(C)cc(CNC(=O)C[C@@H]2CN(C(=O)C3CCC3)C[C@H]2C)c1', 'Cc1cc(C)cc(N(C)C(=O)CCNC(=O)C2CCC(O)CN2C)c1', 'Cc1cc(C)cc(OCCCOC(=O)c2cnn(CC(C)(F)F)c2)c1', 'Cc1cc(C)n(CC(=O)N2CC[C@@H](C(=O)N3CC[Si](C)(C)CC3)C2)n1', 'Cc1cc(C)n(CC(C)CNCc2cn(-c3ccccc3C)nn2)n1', 'Cc1cc(C)n(CCCNC(=O)N2CCC(S(=O)(=O)N(C)C)CC2)n1', 'Cc1cc(C)n(CCN2CCN(S(=O)(=O)c3cn(C)c(C)n3)CC2)n1', 'Cc1cc(C)n(CCNC(=O)N(C)C2CCC3(CCCCC3)CC2)n1', 'Cc1cc(C)n(Cc2cn(CCNC(=O)NC3CCCCC3)nn2)n1', 'Cc1cc(C)nc(C(=O)N2CC(CNC(=O)CC(O)CN(C)C)C2)c1', 'Cc1cc(C)nc(N2CCC(CCNC(=O)CSCCC#N)CC2)n1', 'Cc1cc(C)nc(SCC(=O)NNC(=O)Cc2cc(Cl)ccc2C)n1', 'Cc1cc(C2(NC(=O)c3ccc(-c4cnco4)cn3)CCCC2)on1', 'Cc1cc(C2CC2)ccc1CCNC(=O)NCC(F)(F)CC(O)CO', 'Cc1cc(C2CCCN2C(=O)C=Cc2ccc(OC(C)C)cc2)[nH]n1', 'Cc1cc(CC(=O)N(C)CC2CCN(C(=O)C(C)C3CCC3)C2)n[nH]1', 'Cc1cc(CC(=O)N2CC(F)(C(=O)NCc3cnc(C)n3C)C2)no1', 'Cc1cc(CC(=O)N2CCCN(C(=O)c3ccsn3)C[C@@H]2C)n(C)n1', 'Cc1cc(CC(=O)N2CC[C@@H](NC(=O)[C@@H]3[C@H](C#N)C3(C)C)C2)n(C)n1', 'Cc1cc(CC(=O)N2CC[C@H](C(=O)N(C)CC[C@@H](C)O)[C@H](O)C2)on1', 'Cc1cc(CC(=O)N2C[C@H](F)[C@H](NC(=O)C(C)(C)OC(C)C)C2)n[nH]1', 'Cc1cc(CC(=O)NC2CN(S(=O)(=O)C3CC=CCC3)C2)ccc1F', 'Cc1cc(CC(=O)NCC2(C(=O)N3CC(CC(C)C)C3)CCC2)no1', 'Cc1cc(CC(=O)NCCCCCCNC(=O)c2cnc(S)[nH]2)on1', 'Cc1cc(CC(=O)NC[C@H]2CCO[C@H]2C(=O)N2CC=CCC2)nn1C', 'Cc1cc(CCC(=O)N(C)C[C@@H](C)NC(=O)[C@@H](O)C(C)(C)C)nn1C', 'Cc1cc(CCC(=O)N2CCN(C(=O)C#CC3CC3)C[C@H]2C)n(C)n1', 'Cc1cc(CCC(=O)N2CC[C@H](NC(=O)c3ccco3)C[C@@H]2C)on1', 'Cc1cc(CCC(=O)N2C[C@@H](F)C[C@H]2CNC(=O)/C=C\\C(N)=O)no1', 'Cc1cc(CCC(=O)NC(C)C(Cc2ccccc2)C(=O)O)c(C)s1', 'Cc1cc(CCC(=O)NC2(C(=O)N(C)CC3(C)CC3)CC2(C)C)on1', 'Cc1cc(CCC(=O)NCCc2nc3c(F)cccc3n2C)sc1Br', 'Cc1cc(CCCC(=O)Oc2ccc(S(=O)(=O)N(C)C)cc2)c(C)s1', 'Cc1cc(CCN(C=O)Cc2ccc(-c3cnn(C)c3)s2)nc(C)n1', 'Cc1cc(CCNC(=O)C2CC(NC(=O)CN=[N+]=[N-])C23CCC3)no1', 'Cc1cc(CCNC(=O)N2CCC[C@H]2Cn2cccn2)cc(C)c1F', 'Cc1cc(CCNc2nc3c(c(N(C)CP(C)(C)=O)n2)SCC3)[nH]n1', 'Cc1cc(CN(C)C(=O)[C@@H]2CC[C@H](NC(=O)C(C)CN(C)C)C2)on1', 'Cc1cc(CN(CC(C)(C)C2CC2)C(=O)[C@H]2C3CC4C(C3F)[C@@H]42)sn1', 'Cc1cc(CN(CC(C)c2ccccn2)C(=O)C2CC3(CC3)C2)cs1', 'Cc1cc(CN(CC2CC(F)C2)C(=O)C2Cc3ccccc3O2)cs1', 'Cc1cc(CN(CC2CCSCC2)C(=O)[C@H]2[C@H]3CCC(F)(F)[C@H]32)sn1', 'Cc1cc(CN(CCCc2ccco2)CC(O)c2cccs2)nn1C', 'Cc1cc(CN(C[C@]23CCC[C@H]2OCC3)C(=O)C2(C)CSC2)nn1C', 'Cc1cc(CN(Cc2cc(C)c(C)s2)C(=O)[C@@H]2CSCC(=O)N2)on1', 'Cc1cc(CN(Cc2cnc3sccn23)C(=O)C2(C(N)=O)CC2)co1', 'Cc1cc(CN)cc(C(=O)NC[C@]2(CO)CC[C@H]2c2ccccc2)c1', 'Cc1cc(CNC(=O)/C=C/c2ccc(N)nc2C)c2ccccc2n1', 'Cc1cc(CNC(=O)C(CNC(=O)C2CCCC2)C(C)(C)C)n(C)n1', 'Cc1cc(CNC(=O)C2(C3CC3)CN(C(=O)c3cnc(N)o3)C2)[nH]n1', 'Cc1cc(CNC(=O)C2C(C)CN2C(=O)c2ccsc2Cl)ccc1F', 'Cc1cc(CNC(=O)C2CC(=O)N(CCN(C)C)C2)cc2ccoc12', 'Cc1cc(CNC(=O)C2CCCN2C(=O)C(C)C(O)C(C)C)ncn1', 'Cc1cc(CNC(=O)CCCC2CCCC2)oc1C(=O)N[C@@H](C)CF', 'Cc1cc(CNC(=O)C[C@@H](O)CNC(=O)C2OC3CCC2C3)nn1C', 'Cc1cc(CNC(=O)C[C@@H]2CCN(C(=O)[C@H]3CCCC[C@@H]3O)C2)on1', 'Cc1cc(CNC(=O)N2CCC(Oc3ccccn3)CC2)ccc1I', 'Cc1cc(CNC(=O)NCc2ncn3ccccc23)cc2c1CCC2', 'Cc1cc(CNC(=O)N[C@H]2CC[C@H]2N=[N+]=[N-])ccc1-c1ccccc1', 'Cc1cc(CNC(=O)[C@@H]2CCCN2C(=O)c2cc(C)c(C)o2)c(C)s1', 'Cc1cc(CNC(=O)[C@@H]2CC[C@@H]2NC(=O)CC(O)C2CCCC2)cs1', 'Cc1cc(CNC(=O)[C@H]2C[C@@H](NC(=O)C3CCC(=O)C(C)C3)C2)cs1', 'Cc1cc(CNC(=O)[C@H]2C[C@@](C)(NC(=O)CN3CCCCC3)C2)[nH]n1', 'Cc1cc(CNC(=O)[C@]2(NC(=O)CSC(F)F)C[C@@H](O)C2)cc(C)n1', 'Cc1cc(CNC(=O)c2c(F)ccc(F)c2Cl)nc(N2CCCC2)n1', 'Cc1cc(CNC(=O)c2cc(CNC(=O)C3CSC3)ccn2)nn1C', 'Cc1cc(CNc2nc(NC3CCCCC3)nc3cccnc23)cs1', 'Cc1cc(CO)cc(NC(=O)C(C)CNC(=O)C2(O)CCCCC2)c1', 'Cc1cc(COC(=O)C2CCCC23CCOCC3)nc(C2CCC2)n1', 'Cc1cc(COC(=O)COc2cccc3c2OC(C)(C)C3)oc(=O)c1', 'Cc1cc(COC(=O)c2cc(-c3cnccn3)[nH]n2)cc([N+](=O)[O-])c1', 'Cc1cc(COC(=O)c2nnn(Cc3ccncc3)c2C)cc(Cl)n1', 'Cc1cc(COCC(=O)N2C[C@@H]3C[C@H]2CN3C(=O)C2CC=CC2)no1', 'Cc1cc(Cl)c(C(=O)NCC2CC(CNC(=O)[C@@H](O)CC(C)C)C2)s1', 'Cc1cc(Cl)cc2sc(NNC(=O)c3ccc4c(c3)OCCO4)nc12', 'Cc1cc(Cl)ccc1CCNC(=O)c1oc(COC(C)(C)C)nc1C', 'Cc1cc(Cn2nnc(NC(=O)NCc3nc(Br)sc3C)c2C)no1', 'Cc1cc(F)c(C(=O)NC[C@H](CO)NC(=O)c2snnc2C)c(F)c1', 'Cc1cc(F)c(C(=O)NNC(=O)CCOCc2ccccc2)c(F)c1', 'Cc1cc(F)c(CC(=O)Nc2c(F)cc(C(F)(F)F)cc2F)cc1F', 'Cc1cc(F)cc(C(C)C(=O)N2CCC(Oc3cccnc3)CC2)c1', 'Cc1cc(F)cc(C)c1C(=O)N[C@H]1CN(C(=O)OC(C)(C)C)C[C@H]1O', 'Cc1cc(F)cc(CN(Cc2ncnn2C)C(=O)C2CSCCS2)c1', 'Cc1cc(F)cc(CNC(=O)C(Cc2ccccc2)n2cccc2)c1', 'Cc1cc(F)cc(NC2(c3nnnn3C(C)C)CC3CCC2CC3)c1', 'Cc1cc(F)cc(NC2(c3nnnn3C3COC3)CCCN(C)C2)c1', 'Cc1cc(F)cc2c1CCC2NC(=O)CC1CC(=O)c2ccccc21', 'Cc1cc(F)ccc1C(=O)N1CC2(CCN2C(=O)c2ccsc2C)C1', 'Cc1cc(F)ccc1C(=O)N[C@@H]1CCN(C(=O)[C@H]2CCCC[C@@H]2O)C1', 'Cc1cc(F)ccc1C(CCC(F)(F)F)NC(=O)[C@@H]1CCOC(=O)N1', 'Cc1cc(F)ccc1CC(=O)N(C)C(C)CCNC(=O)C1=COCC1', 'Cc1cc(F)ccc1CN(C)C(=O)NCCC(=O)Nc1cccnc1', 'Cc1cc(F)ccc1N(C)C(=O)CNS(=O)(=O)c1ccc(Cl)c(Cl)c1', 'Cc1cc(F)ccc1NC(=O)[C@@H](CO)NC(=O)c1cccc(F)c1C', 'Cc1cc(F)cnc1C(=O)N(C)CCCNC(=O)COCC(F)(F)F', 'Cc1cc(F)cnc1CNC(=O)Cc1nnc(-c2ccccc2)n1C', 'Cc1cc(F)ncc1NC(=O)C#CC(C)(C)CNC(=O)c1cncs1', 'Cc1cc(F)sc1C(=O)N1CCC[C@H](NC(=O)c2cncn2C)[C@@H]1C', 'Cc1cc(F)sc1C(=O)NC1(CCCC(=O)NC2CC(F)C2)CCC1', 'Cc1cc(N(C)C)ccc1CN(CC(C)(C)C)C(=O)c1cnc(Cl)[nH]1', 'Cc1cc(N(C)CC2CCCN(C)C2)nc(N2CCC(=NO)CC2)n1', 'Cc1cc(N)cnc1C(=O)NCCC(=O)NCc1nnc(C(C)C)[nH]1', 'Cc1cc(N)nnc1C(=O)N(CC1=CCSC1)CC1CCOCC1C', 'Cc1cc(N2CC(NC(=O)C34CC(C(=O)O)(C3)C4)CC2=O)ccc1F', 'Cc1cc(N2CCC(NC(=O)c3cncnc3C(C)(C)C)C2)n(C)n1', 'Cc1cc(N2CCN(C(=O)N[C@@H](C)CC(=O)OC(C)(C)C)CC2)on1', 'Cc1cc(N2CCN(C(=O)c3ncccn3)CC2)c(Cl)cc1[N+](=O)[O-]', 'Cc1cc(N2CCN(C(CO)c3cccc(F)c3)CC2)c([N+](=O)[O-])s1', 'Cc1cc(N2CCN(C3CC3)C(=O)C2)nc(NC[C@]23CCC[C@H]2C3)n1', 'Cc1cc(N2CCNC2=O)ccc1NC(=O)[C@H]1CCC=CCC[C@H]1N', 'Cc1cc(NC(=O)C(=O)N2CC(OC(F)F)C2)c2cccnc2c1C', 'Cc1cc(NC(=O)C(=O)N2CCOCC(C3CCC3)C2)c(Cl)cc1F', 'Cc1cc(NC(=O)C2(N=[N+]=[N-])CCOCC2)ccc1N1CCCC1=O', 'Cc1cc(NC(=O)C2CC(F)(F)C2C2CC2)nn1-c1ccccc1F', 'Cc1cc(NC(=O)CCN(C(=O)c2cnc(N)o2)C2CC2)cnc1C', 'Cc1cc(NC(=O)CCNCCc2ccnn2-c2ccccc2)no1', 'Cc1cc(NC(=O)CCOCCNC(=O)Cc2ccco2)cnc1F', 'Cc1cc(NC(=O)NC(C)c2ccc(NC(N)=O)cc2)c(C)cc1Br', 'Cc1cc(NC(=O)NC2(C3CCC3)COC2)n(C(=O)OC(C)(C)C)n1', 'Cc1cc(NC(=O)NCCCN2CCCC2=O)ccc1SC(F)(F)F', 'Cc1cc(NC(=O)NCc2ccnc(OCCN(C)C)c2)cnc1F', 'Cc1cc(NC(=O)[C@@H](C)NC(=O)CCn2cnc(N)n2)nn1C1CC1', 'Cc1cc(NC(=O)[C@@H](C)NC(=O)c2ccc(N)c(F)n2)c(C)cc1O', 'Cc1cc(NC(=O)[C@H]2CCCCN2C(=O)C(=O)C(C)(C)C)cnc1F', 'Cc1cc(NC(=O)c2cc(F)cc(F)c2O)nn1-c1ccccc1Cl', 'Cc1cc(NC2CN(CC(F)F)C2)nc(N2Cc3ccncc3C2)n1', 'Cc1cc(NCC(C)C#N)nc(N2CCC(Cc3ccnn3C)C2)n1', 'Cc1cc(NCC2CC(=C3CC3)C2)ncc1S(=O)(=O)NC1CN(C)C1', 'Cc1cc(NCC2CN(C(=O)OC(C)(C)C)CC(C)(C)O2)nc(Cl)n1', 'Cc1cc(NCCNC(=O)c2cncc(C(=O)O)c2)nc(C(C)C)n1', 'Cc1cc(NCCOCC2CC2)nc(NCC2CCCOC2(C)C)n1', 'Cc1cc(NCC[C@@H]2CCC[C@H]2O)nc(N2CC[C@@H](C(F)(F)F)C2)n1', 'Cc1cc(NCCc2nnc(N)s2)nc(N(C)Cc2ccccc2)n1', 'Cc1cc(NCc2ccsc2C)nc(N2CCN(CC(C)C)CC2)n1', 'Cc1cc(NNC(=O)[C@H]2C[C@@](O)(c3ccccc3)CN2)c(Cl)cc1F', 'Cc1cc(N[C@H](CO)CNC(=O)C2COC3(CCOCC3)C2)ncn1', 'Cc1cc(O)c2cc(NC(=O)c3cnc(C(C)(C)O)nc3)ccc2n1', 'Cc1cc(O)cc(C(=O)NN2CCC[C@H]2C(=O)N2CCC[C@@H]2CF)c1', 'Cc1cc(O)cc(NC(=O)C2(CNC(=O)c3ccc(O)cn3)CC2)c1', 'Cc1cc(O)ccc1C(=O)OC1CCCN(c2ccccc2F)C1=O', 'Cc1cc(O)ccc1CNC(=O)C1(NC(=O)c2cc[nH]c2)CC1(C)C', 'Cc1cc(O)nc(CSCc2ccc(CC(=O)OC(C)(C)C)cc2)n1', 'Cc1cc(O)ncc1NC(=O)C1(NC(=O)Cn2ccnc2)CC1(C)C', 'Cc1cc(OC(F)(F)F)ccc1C(=O)NCc1ccc(C(F)(F)F)o1', 'Cc1cc(OC(F)F)c(C(=O)NC(C)(C(N)=O)c2cccc(Cl)c2)s1', 'Cc1cc(OC(F)F)ccc1C(C)NCc1c[nH]c(=O)c2ccnn12', 'Cc1cc(OC2CCSC2)ncc1NC(=O)c1ccc2occc2n1', 'Cc1cc(OCC(=O)NC(C(=O)Nn2cnnc2C)C2(C)CC2)no1', 'Cc1cc(OCCOC(=O)c2cc(CN(C)C)on2)ccc1C(C)C', 'Cc1cc(Oc2ccccc2)nc(NC2C=C(c3ccccc3)C2)n1', 'Cc1cc(S(=O)(=O)NC(c2nc(-c3nnc[nH]3)no2)C(C)C)sc1Br', 'Cc1cc(S(=O)(=O)NC2(C(=O)O)CC3(CCOC3)C2)ccc1C(=O)O', 'Cc1cc(S(N)(=O)=O)c(NC2CCN(c3ccncc3)CC2)cc1Br', 'Cc1cc(Sc2ncccn2)ccc1NC(=O)Cc1ncc(Cl)cn1', 'Cc1cc([C@H](C)NC(=O)C(=O)N[C@@H](C)c2ccccc2C)ccc1Br', 'Cc1cc([N+](=O)[O-])ccc1NNC(=O)NC1CN(C2CCOCC2)C1', 'Cc1cc([N+](=O)[O-])cnc1NC(=O)NCC(O)c1cc(Cl)ccc1F', 'Cc1cc2c(N3CCCC3C(=O)N3CC(O)C(C)(C)C3)ncnc2s1', 'Cc1cc2c(NC(=O)c3cc(-c4ccccn4)ns3)cccc2cn1', 'Cc1cc2c(cc1NC(=O)C(=O)N1CC3(COC(=O)N3C)C1)OCO2', 'Cc1cc2cc(CNC(=O)NCc3nnc(CCO)s3)ccc2n1C', 'Cc1cc2cc(S(=O)(=O)N(C)CC3CC4CCC3C4)ccc2[nH]c1=O', 'Cc1cc2ccccc2n1CCCNC(=O)NC(C1CC1)C1(C)CC1', 'Cc1cc2n(n1)CCCN2C(=O)C1(Cc2ccccc2)CCOCC1', 'Cc1cc2ncc(C(=O)Nc3cccnc3-c3cnn(C)c3)cc2[nH]1', 'Cc1cc2nnc(Sc3ccc([N+](=O)[O-])c4c3C(=O)CC4)n2c(C)n1', 'Cc1cc2oc(=O)cc(CN3C[C@H](CS(N)(=O)=O)[C@@H](C)C3)c2cc1C', 'Cc1cc[nH]c1C(=O)N1CCC(C)N(C(=O)CCn2ccnn2)CC1', 'Cc1cc[nH]c1C(=O)N1[C@H](C(=O)NCC2(CO)CC=CC2)C[C@@H]2C[C@@H]21', 'Cc1ccc(-c2cc(C(=O)NCCC3CC4(CNC4)C3)n(C)n2)cc1', 'Cc1ccc(-c2cc(NC(=O)C(C)N3CCN(C)CC3)n(C)n2)cc1', 'Cc1ccc(-c2ccc(C(=O)NCC(CO)Cc3cn(C)cn3)s2)o1', 'Cc1ccc(-c2ccc(CN[C@H](C)[C@@](C)(O)c3ccccc3)o2)cc1', 'Cc1ccc(-c2ccccc2CN2CCC[C@H]3CNC(=O)[C@H]32)c(C)c1', 'Cc1ccc(-c2csc(NC(=O)CC3CC(CF)C3)n2)cc1[N+](=O)[O-]', 'Cc1ccc(-c2csc(NC(=O)NC(CO)Cc3ccccc3)n2)s1', 'Cc1ccc(-c2n[nH]cc2CNCCCNCc2cccnc2)cc1', 'Cc1ccc(-c2noc(-c3ccc(NS(C)(=O)=O)cc3O)n2)c(F)c1', 'Cc1ccc(-n2[nH]c(C(=O)NCC3CC(O)C3)c(CCO)c2=O)cc1', 'Cc1ccc(-n2cc(NC(=O)c3ccc(C#N)cc3O)cn2)c(C)c1', 'Cc1ccc(-n2ccc(CNC(=O)CC3(c4nn[nH]n4)CC3)n2)cc1', 'Cc1ccc(-n2nccc2NC(=O)c2ccc(F)c3c2CCC3)nc1', 'Cc1ccc(=O)[nH]c1CNc1nc(NCC2(C)CC2)c2ncsc2n1', 'Cc1ccc(Br)c(C(c2nnnn2CC(C)C)N(C)C2CCCC2)n1', 'Cc1ccc(Br)nc1CNC(=O)NC(C)c1ccc2c(c1)CCCC2', 'Cc1ccc(C#N)cc1C(=O)NCC(=O)NCc1noc(C(C)C)n1', 'Cc1ccc(C#N)cc1NC(=O)[C@H]1[C@@H]2CN(C(=O)C(C)C(F)F)C[C@@H]21', 'Cc1ccc(C#N)cc1S(=O)(=O)NC(=O)CCNC(=O)C1CCCC1', 'Cc1ccc(C(=O)COC(=O)C2OCCc3ccc(Br)cc32)c(C)c1', 'Cc1ccc(C(=O)N(C)C)cc1OCc1ncc(-c2ccccc2)s1', 'Cc1ccc(C(=O)N(C)CC2(NC(=O)c3ncnc(O)c3F)CC2)o1', 'Cc1ccc(C(=O)N(C)CC2CN(C(=O)C(C)C#N)CCO2)nc1C', 'Cc1ccc(C(=O)N(C2CC2)C(C)C(=O)N[C@@H]2CCCC2(C)C)nc1', 'Cc1ccc(C(=O)N(CCCOC(C)C)CC2CCOC(C)(C)C2)[nH]1', 'Cc1ccc(C(=O)N(CCNC(=O)c2cccnc2)CC(C)O)n1C', 'Cc1ccc(C(=O)N(CCc2cccs2)Cc2nc(C)co2)c(N)c1', 'Cc1ccc(C(=O)N2CC(C(O)C(=O)N3CC4CCC4(C)C3)C2)cn1', 'Cc1ccc(C(=O)N2CC(C)(C(=O)N3CCC(C4CCCO4)C3)C2)o1', 'Cc1ccc(C(=O)N2CCCC2CNC(=O)/C=C/C(F)(F)F)c(=O)[nH]1', 'Cc1ccc(C(=O)N2CCCC[C@H]2CNC(=O)c2cnco2)c(Cl)c1', 'Cc1ccc(C(=O)N2CCC[C@@H](CC(=O)N[C@H]3CC[C@@H](O)CC3)C2)s1', 'Cc1ccc(C(=O)N2CCC[C@@H]2CCC(=O)N2CCOCC2CO)[nH]1', 'Cc1ccc(C(=O)N2CCN(C(=O)C=CCF)[C@H]3COC[C@H]32)c(N)c1', 'Cc1ccc(C(=O)N2CCOCC2CCNC(=O)c2ccncc2)o1', 'Cc1ccc(C(=O)N2CC[C@H](O)[C@@H]2C(=O)N2CCC(C)(C)CC2)n1C', 'Cc1ccc(C(=O)N2CC[C@]3(C(=O)NCc4ccoc4)CCC[C@H]23)[nH]1', 'Cc1ccc(C(=O)N2C[C@@H](n3cc(CC(O)C4CC4)nn3)[C@@H](C)C2)s1', 'Cc1ccc(C(=O)N2[C@H](C)CC[C@@H]2C(=O)NC(C)CC(N)=O)cc1F', 'Cc1ccc(C(=O)NC(C)[C@@H]2C[C@H]2C(=O)NC[C@@H]2[C@H](CO)C2(C)C)o1', 'Cc1ccc(C(=O)NC(CCN(C)C)C(=O)NC(C)c2cn[nH]c2)[nH]1', 'Cc1ccc(C(=O)NC2(C(=O)N3CCC(O)CC3)CSC2)cc1C#N', 'Cc1ccc(C(=O)NC2(C)CN(C(=O)C(C)CC3CC3)C2)c(F)c1C', 'Cc1ccc(C(=O)NC2(CNC(=O)[C@H]3COC(=O)N3)CCC2)c(N)c1', 'Cc1ccc(C(=O)NC2CC(N(C)C(=O)C#CC3CCCC3)C2)nn1', 'Cc1ccc(C(=O)NC2CC2)cc1NC(=O)[C@H](CCCCN)N(C)C', 'Cc1ccc(C(=O)NCC2(C)CN(C(=O)c3csc(N)n3)CCO2)s1', 'Cc1ccc(C(=O)NCC2(CNC(=O)C3=CC4C=CC3C4)CCC2)o1', 'Cc1ccc(C(=O)NCC2C(C)CCCN2C(=O)C2CCSCC2)o1', 'Cc1ccc(C(=O)NCCCCCN(C)C(=O)C2C=CCS2)cc1C', 'Cc1ccc(C(=O)NCCOCCC(=O)N2CC(CO)(CO)C2)cn1', 'Cc1ccc(C(=O)NCc2nnn(C)c2C(=O)NOCC2CCC2)[nH]1', 'Cc1ccc(C(=O)N[C@@H](CC(N)=O)C(=O)N(C)C2CCCNC2=O)[nH]1', 'Cc1ccc(C(=O)N[C@@H]2CN(C(=O)C3(c4cc[nH]n4)CC3)C[C@H]2C)s1', 'Cc1ccc(C(=O)N[C@H](C(=O)NOCCN(C)C)C2CCC2)c(F)c1', 'Cc1ccc(C(=O)N[C@H](CC(=O)NCC2(C)CCOC2)C(C)C)nc1', 'Cc1ccc(C(=O)N[C@H]2CCO[C@H]2C(=O)N(C)CC(=O)N(C)C)n1C', 'Cc1ccc(C(=O)N[C@H]2CC[C@H](CC(=O)N3CC(S(N)(=O)=O)C3)C2)s1', 'Cc1ccc(C(=O)N[C@H]2C[C@@H](C(=O)NCC3(O)CCN(C)C3)C2)n1C', 'Cc1ccc(C(=O)N[C@H]2C[C@@H]3C[C@H]2[C@H](NS(=O)(=O)[C@H]2CCOC2)C3)o1', 'Cc1ccc(C(=O)N[C@H]2C[C@H](CCC(=O)NC(C)c3nncs3)C2)[nH]1', 'Cc1ccc(C(=O)Nc2nn(C)c3ccncc23)cc1NS(C)(=O)=O', 'Cc1ccc(C(C)C(=O)NCCCCCN(C)Cc2ccccc2)s1', 'Cc1ccc(C(C)C)cc1C(=O)Nc1cc(F)ccc1-n1cncn1', 'Cc1ccc(C(C)N(C)c2ccc(S(=O)(=O)NC3CC3)cc2)c(C)c1', 'Cc1ccc(C(C)NC(=O)C(C)(C)C(C)NC(=O)CC2CC=CC2)s1', 'Cc1ccc(C(C)NC(=O)N(CCN)CCc2ccccc2)c(C)c1', 'Cc1ccc(C(C)NC(=O)Nc2cnn(C)c2CCC(F)(F)F)cn1', 'Cc1ccc(C(C)Nc2cc(C)nc(N3CCCCC(C)C3)n2)nc1', 'Cc1ccc(C(C)OC(=O)C2CCCCN2Cc2cccnc2)cc1', 'Cc1ccc(C(F)F)cc1C(=O)Nc1nc(CN2CCOCC2)cs1', 'Cc1ccc(C(NC(=O)[C@]2(C)CC[C@@H](C(C)(C)C)CC2)C(=O)O)cc1', 'Cc1ccc(C(NC2CCNC3CCCCC32)c2ccccn2)cc1', 'Cc1ccc(C(O)C(C)NC(=O)CCCC2(N)CCOCC2)cc1F', 'Cc1ccc(C(O)CN(Cc2ccc(F)c(F)c2F)C(=O)C(Cl)Cl)o1', 'Cc1ccc(C)c(C(=O)NC(C)CNC(=O)Cn2ccccc2=O)n1', 'Cc1ccc(C)c(CNC(=O)C(C)NC(=O)c2nc(C)ccc2F)c1', 'Cc1ccc(C)c(N=C2SCCCN2C(=O)C2CCC(C)(C)OC2)c1', 'Cc1ccc(C)n1CC(=O)N[C@H](C(=O)N1C2C=CCC1CC2)[C@@H](C)O', 'Cc1ccc(C)n1CC(=O)N[C@H]1C[C@@H](C(=O)N2CC(C)CCC2C)C1', 'Cc1ccc(C2(CNC(=O)N[C@@H]3CCc4cc(Cl)ccc43)CC2)nc1', 'Cc1ccc(C2=NOC(C(=O)Nc3ccc(Br)c(C#N)c3C)C2)cc1', 'Cc1ccc(C2CN(C(=O)C[C@H]3C[C@@H](N)C3)CCO2)cc1C(F)(F)F', 'Cc1ccc(C2CN(C(=S)NC(=O)c3ccc(Cl)cc3Cl)CCO2)o1', 'Cc1ccc(C2COCCN2C(=O)NCCC23COC(CF)(C2)C3)o1', 'Cc1ccc(C2CS(=O)CCN2C(=O)NCC2CCC(C3CC3)O2)o1', 'Cc1ccc(C=CC(=O)N(C)C[C@H](C)NC(=O)CC2(C)OCCO2)s1', 'Cc1ccc(C=CC(=O)N2C[C@H](C(=O)N[C@@H](C)CF)[C@@H](C(C)C)C2)o1', 'Cc1ccc(C=CCNC(=O)Nc2cccc3c2CC(C)(C)C3)nc1', 'Cc1ccc(CC(=O)N2CCOCC(NC(=O)Cc3ccno3)C2)o1', 'Cc1ccc(CC(=O)N2C[C@H](C)[C@@H]2C(=O)N[C@H](CO)C2(O)CC2)cn1', 'Cc1ccc(CC(=O)NC2(C)CCN(c3ncc(Cl)cn3)C2)cc1O', 'Cc1ccc(CC(=O)NCC(C)(C)C#CC(=O)N2CCCC(F)C2)s1', 'Cc1ccc(CC(=O)NCC(C)(C)CNC(=O)/C=C/C(C)(C)C)cn1', 'Cc1ccc(CC(=O)NCC(O)C(=O)Nc2ccn(C3CC3)n2)cc1', 'Cc1ccc(CC(=O)NCC2(NC(=O)CCc3cncn3C)CC2)o1', 'Cc1ccc(CC(=O)NCCOCC(=O)NC2CC(C)OC2=O)cc1', 'Cc1ccc(CC(=O)N[C@@H](C)CCNC(=O)c2c(C)ccnc2O)s1', 'Cc1ccc(CC(CO)CNC(=O)Nc2cc(Cl)c(C)c(Cl)c2)cc1', 'Cc1ccc(CC(CO)NS(=O)(=O)CCC2(C#N)CCNCC2)cc1', 'Cc1ccc(CC2CCCN(C(=O)c3cc(C(C)(C)C)no3)C2)cc1', 'Cc1ccc(CCC(=O)N(Cc2cccc(F)c2Cl)CC(C)C)cn1', 'Cc1ccc(CCC(=O)N2CCN(c3ccc(F)cc3C#N)CC2)s1', 'Cc1ccc(CCN(C)C(=O)NCc2cnn(CC(C)C)c2C)cc1', 'Cc1ccc(CCN(CC2CC3CC3C2)C(=O)c2ncccc2N)s1', 'Cc1ccc(CCN(Cc2ncn(C)c2Cl)C(=O)CCOC(C)C)s1', 'Cc1ccc(CCNC(=O)[C@@H](NC(=O)c2csc(CO)n2)C2CC2)s1', 'Cc1ccc(CCNC(=O)c2cccc(Cn3ccnn3)c2)cc1Cl', 'Cc1ccc(CCNc2ccnc(N3CCCOC(C)C3)n2)cc1Cl', 'Cc1ccc(CCNc2ncnc(N(C)Cc3ccc(Cl)s3)n2)cc1', 'Cc1ccc(CCS(=O)(=O)NC(=O)c2cccc3c2OCCO3)cc1', 'Cc1ccc(CN(C(=O)C(=O)NC2CCCC3(CC3)C2)C2CC2)cc1', 'Cc1ccc(CN(C(=O)C(=O)Nc2ccc(F)c(F)c2C)C2CC2)s1', 'Cc1ccc(CN(C)C(=O)Nc2cc(F)ccc2OC(C)C)c(F)c1', 'Cc1ccc(CN(C)C(=O)c2cccc(C(=O)c3ccco3)c2)cc1', 'Cc1ccc(CN(CC(O)C(C)C)C(=O)C2(C#N)CC=CC2)c(Cl)c1', 'Cc1ccc(CN(CC2(C)CCCO2)C(=O)C(F)(F)C(C)O)c(O)c1', 'Cc1ccc(CN(CC2CC2)C(=O)c2ccc3c(c2)C(N)CC3)cn1', 'Cc1ccc(CN(CC2CCCO2)C(=O)c2ccc(CO)s2)c(C)c1', 'Cc1ccc(CN(CC2CCSCC2)C(=O)C2CC23CCCC3)cn1', 'Cc1ccc(CN(CCC(C)(O)C(F)(F)F)Cc2ccc(C)o2)nc1', 'Cc1ccc(CN(CCc2ccc(F)cc2)C(=O)[C@H]2C[C@@H]2C2CC2)s1', 'Cc1ccc(CN(CCc2cnc(Cl)s2)Cc2ccn(C)c2)c(C)c1', 'Cc1ccc(CN(C[C@H]2C[C@H]2C)C(=O)c2ccc(O)cc2N)c(Cl)c1', 'Cc1ccc(CN(Cc2c[nH]nc2C)Cc2c(F)cccc2Cl)nc1', 'Cc1ccc(CN(Cc2cnc3n2CCC3)C(=O)C2CSC(=O)N2)o1', 'Cc1ccc(CNC(=O)C2CCN(C(=O)c3cn(C)cn3)CC2)cc1', 'Cc1ccc(CNC(=O)CC2(C)CCN(C(=O)c3ccco3)C2)cc1', 'Cc1ccc(CNC(=O)CC[C@H](C)NC(=O)c2cc(C(F)F)[nH]n2)s1', 'Cc1ccc(CNC(=O)CN2CCN(C(=O)CC3CC=CC3)CC2)o1', 'Cc1ccc(CNC(=O)C[C@@H](O)CNC(=O)C(F)(F)C(F)F)c(C)c1', 'Cc1ccc(CNC(=O)NCC(=O)NC[C@H]2CCC[C@H]2N(C)C)cc1', 'Cc1ccc(CNC(=O)NCCCCc2ccc(O)cc2)c(F)c1F', 'Cc1ccc(CNC(=O)[C@H](CC(C)(C)C)NC(=O)OC(C)(C)C)nc1', 'Cc1ccc(CNC2CCN(C(=O)OC(C)(C)C)[C@@H]3CC[C@H]23)c(Cl)c1', 'Cc1ccc(CO)cc1NC(=O)C1CN(C(=O)C(C)CO)C(C)(C)C1', 'Cc1ccc(COC(=O)[C@H]2OCC[C@H]2Cn2cccn2)c2c1CCC2', 'Cc1ccc(COC(=O)c2nc(C(C)C)n(-c3ccccc3Cl)n2)s1', 'Cc1ccc(C[C@H](C)C(=O)Nc2ccc(Cl)cc2-n2cccn2)cc1', 'Cc1ccc(Cl)c2c1CCCN2C(=O)c1ccc(Cn2ccnn2)o1', 'Cc1ccc(Cl)cc1CNC1(c2nnnn2C2COC2)CC(CO)C1', 'Cc1ccc(Cl)cc1NC(=O)N1CCC(NC(=O)C(F)(F)F)CC1C', 'Cc1ccc(Cn2cc(C(C)N(C)C(=O)C3(C)CCCC3)nn2)cc1', 'Cc1ccc(Cn2cccc(NC(=O)c3c[nH]c(C#N)c3)c2=O)cc1', 'Cc1ccc(F)c(C(=O)NCC(C(=O)NCCOC(N)=O)C(C)C)c1', 'Cc1ccc(F)c(C(=O)NC[C@H]2CCCC[C@H]2C(=O)N2CC(O)C2)c1', 'Cc1ccc(F)c(C(=O)N[C@H]2C[C@H]2NC(=O)CCc2ccccn2)n1', 'Cc1ccc(F)c(CN(CC2CCC2)C(=O)C(C)c2cncnc2)c1', 'Cc1ccc(F)c(NC(=O)CCC[C@@H](C)NC(=O)C2CCNC2=O)c1', 'Cc1ccc(F)c(S(=O)(=O)NC2CCC(NC(=O)C3=CCCC3)C2)c1', 'Cc1ccc(F)cc1-c1nnc(NCc2cn(C)nc2C(F)(F)F)s1', 'Cc1ccc(F)cc1C(=O)N(CCCOCC(C)C)Cc1cncs1', 'Cc1ccc(N(C)C(=O)CC[C@H](C)NC(=O)CSc2cn[nH]c2)cc1', 'Cc1ccc(N(Cc2cccs2)C(=O)c2c(F)cnc(Cl)c2N)cc1', 'Cc1ccc(N)c(C)c1C(=O)NCC1CCCN1C(=O)OC(C)(C)C', 'Cc1ccc(N2C(=O)C(=Cc3ccc4c(c3)CCCO4)SC2=S)cc1', 'Cc1ccc(N2CCC(NC(=O)C3(N)CC(C(C)(C)C)C3)C2=O)cc1', 'Cc1ccc(N2CCC(OC(=O)c3cnc4cn[nH]c4c3)C2=O)cc1', 'Cc1ccc(N2CCCC(Nc3ncnc4[nH]cc(C#N)c34)C2)cc1', 'Cc1ccc(N2CCN(C(=O)c3c(C)cc(C#N)cc3C)CC2)cc1', 'Cc1ccc(NC(=O)C(=O)NCCCc2cccc(F)c2O)c(C)n1', 'Cc1ccc(NC(=O)C(=O)NNC(=O)NCCn2cncn2)cc1C', 'Cc1ccc(NC(=O)C(C)CNC(=O)C2(OC(C)C)CCC2)c(O)n1', 'Cc1ccc(NC(=O)C(C)N2CCC(C3=NCCCN3)CC2)c(F)c1', 'Cc1ccc(NC(=O)C(CC2CCOC2)NC(=O)OC(C)(C)C)cc1', 'Cc1ccc(NC(=O)C(CN(C)C)NC(=O)/C=C/C(C)(C)C)cc1Cl', 'Cc1ccc(NC(=O)C2(CCNC(=O)c3cn(C)nn3)CC2)c(F)c1', 'Cc1ccc(NC(=O)C2CCN(C(=O)Cc3ncccc3F)C2)cc1', 'Cc1ccc(NC(=O)C2CCN2C(=O)Cc2cccc(F)c2)c(C)n1', 'Cc1ccc(NC(=O)CCN(C(=O)Cn2cnnn2)C(C)C)cc1O', 'Cc1ccc(NC(=O)CN(C)C)cc1NCc1ccc(F)c(O)c1F', 'Cc1ccc(NC(=O)NC2CC(N3CCCC3C(N)=O)C2)c(C#N)c1', 'Cc1ccc(NC(=O)[C@@H]2C[C@H](O)CN2C(=O)C=CC(C)C)cc1CO', 'Cc1ccc(NC(=O)c2ccc(N3CCCS3(=O)=O)cc2)c(Cl)c1O', 'Cc1ccc(NC(=O)c2nn(C)c3c2CC(C)(C)CC3)cc1C(C)C', 'Cc1ccc(NC(=S)N2CCCC(n3cnc(C(N)=O)n3)C2)cc1F', 'Cc1ccc(NCCN2C(=O)CCN(CCC3CCCC3)C2=O)nc1', 'Cc1ccc(O)c(C(=O)N2CC=C(CNc3nnc(CO)s3)CC2)c1', 'Cc1ccc(O)c(CN(CC2(C)CCCC2O)C(=O)c2cnsc2)c1', 'Cc1ccc(O)c(CN(CC2CC(CF)C2)C(=O)[C@@H]2COC(=O)N2)n1', 'Cc1ccc(O)c(CN(CC2SCCS2)C(=O)c2ccncc2C)n1', 'Cc1ccc(O)cc1NC(=O)C(C)(C)NC(=O)CCC1(C#N)CCC1', 'Cc1ccc(OC(C)CNc2cc(C)c([N+](=O)[O-])cc2C(=O)O)cc1', 'Cc1ccc(OC(F)F)c(NC(=O)NC2CCc3[nH]nc(C)c3C2)c1', 'Cc1ccc(OC(F)F)cc1C(=O)N1CCOc2c(F)ccc(F)c21', 'Cc1ccc(OC2CCN(C(=O)c3[nH]c(=O)[nH]c(=O)c3F)CC2)nc1', 'Cc1ccc(OC2CCN(C(=O)c3ccc4c[nH]nc4c3C)C2)cn1', 'Cc1ccc(OCCC(=O)NCCCC(C)c2ccccc2)cc1C', 'Cc1ccc(S(=O)(=O)N2CC(CNC(=O)c3coc(Cl)n3)C2)c(C)c1', 'Cc1ccc(S(=O)(=O)NC2CN(C(=O)CSc3ccccc3)C2)cc1', 'Cc1ccc(S(=O)(=O)NCC2=CCN(C(=O)C3=NOC(C)(C)C3)C2)o1', 'Cc1ccc(S(=O)(=O)NCCCNC(=O)C2CN(C)CC(C)O2)cc1', 'Cc1ccc(SC2(CNC(=O)c3cnc(C)cc3C)CCCC2)cc1', 'Cc1ccc(SCCCC(=O)Nn2cnc3c(cnn3C)c2=O)cc1', 'Cc1ccc(SCCNC(=O)N2CCCCC2CCP(C)(C)=O)cc1', 'Cc1ccc([C@@H]2C[C@H]2NC(=O)NCc2cc(C3CC3)nn2C)c(Cl)n1', 'Cc1ccc([C@@H]2C[C@H]2NC(=O)c2cccn3c(CBr)nnc23)cc1C', 'Cc1ccc([C@@H]2OCCC[C@H]2NC(=O)NCC2(O)CCC(C)C2)cc1', 'Cc1ccc([N+](=O)[O-])c(C(=O)Nc2cnc(N3CCOCC3)nc2)c1', 'Cc1ccc([N+](=O)[O-])c(C)c1NC(=O)N1CCC(CCC(C)O)CC1', 'Cc1ccc([N+](=O)[O-])c(NCC[C@@H](C)NC(=O)c2nc(C)c(C)s2)n1', 'Cc1ccc([N+](=O)[O-])cc1C(=O)OCc1ccccc1NS(C)(=O)=O', 'Cc1ccc2[nH]c(C(=O)OCc3cc(-c4cccs4)on3)cc2c1O', 'Cc1ccc2c(CCNC(=O)N3CCCC4(CCC4)C3)cn(C)c2c1', 'Cc1ccc2c(CNc3nccc(Oc4ccccc4)n3)c[nH]c2c1', 'Cc1ccc2c(NCc3cscn3)nc(NC3CCCCC3)nc2c1', 'Cc1ccc2c(O)c(C(=O)NCCCc3cc(Cl)sc3Cl)cnc2n1', 'Cc1ccc2c(c1)C(C(=O)NCCCn1c(C)nc(C)c1C)OCC2', 'Cc1ccc2c(c1)C(NC(=O)NC(C)(C)CCc1ccncc1)CO2', 'Cc1ccc2c(c1)CCC(C(=O)Nc1cnc3c(F)cccc3c1)O2', 'Cc1ccc2c(c1)CN(C(=O)CC[C@H](C)NC(=O)CCC(F)(F)F)C2', 'Cc1ccc2c(c1CO)CCCN2C(=O)c1ccc(P(C)(C)=O)cc1', 'Cc1ccc2c(n1)CN(C(=O)[C@H]1CCCCN1C(=O)CC(C)(F)F)C2', 'Cc1ccc2cc(C(=O)N(C)CCN(C(=O)C3CC3)C(C)C)oc2c1', 'Cc1ccc2ccc(NCc3ccc(C(=O)NC4CC4)cc3)nc2n1', 'Cc1ccc2csnc2c1NC(=O)N1[C@@H]2CC[C@@H](C2)[C@H]1COC(F)F', 'Cc1ccc2nc(CSCC(=O)NC3CC(N(C)C)C3(C)C)cn2c1', 'Cc1ccc2nc(N(C)CC3CN(c4ccccc4)C(=O)O3)oc2c1', 'Cc1ccc2nc(NC(=O)COC(=O)c3cc(=O)n(C)cn3)sc2c1', 'Cc1ccc2nonc2c1NC(=O)CCc1oc(C(C)(C)C)nc1C', 'Cc1ccc2sc(C)c(C(=O)NCc3ccc([N+](=O)[O-])c(F)c3)c2c1', 'Cc1ccc2scc(CC(=O)Nc3cnn(-c4ccccn4)c3)c2c1', 'Cc1cccc(-c2ccc(C(=O)NC3CC(C)CC(C)C3)c(=O)[nH]2)c1', 'Cc1cccc(-c2cccc(C(=O)NCc3cc(C)nc(Cl)c3)c2)c1', 'Cc1cccc(-c2csc(NC(=O)C(N)CC3CCS(=O)(=O)C3)n2)c1', 'Cc1cccc(=O)n1CC(C)(O)C(=O)OCc1cc(F)cc(F)c1Br', 'Cc1cccc(C(=O)N(C)CC(C)(C)C(=O)N2CCOC3CC32)c1O', 'Cc1cccc(C(=O)N(C)[C@@H](C)C(=O)N2CC(OC(F)F)C2)c1C#N', 'Cc1cccc(C(=O)N2CCC[C@@H]2CNC(=O)CCCC2CC2)c1Cl', 'Cc1cccc(C(=O)N2C[C@@H](F)C[C@@H]2CC(=O)NCCCC(C)C)c1', 'Cc1cccc(C(=O)N2[C@H](CNC(=O)C(C)C)C[C@@H]3CCCC[C@@H]32)n1', 'Cc1cccc(C(=O)NC(C)C(=O)N2CCCCN(C)CC2)c1C#N', 'Cc1cccc(C(=O)NC(C)C(=O)OCCC2(C(C)C)OCCO2)c1', 'Cc1cccc(C(=O)NC(C)CC2CN(C(=O)C(=O)C(C)(C)C)C2)n1', 'Cc1cccc(C(=O)NC(CCC2CC2)C(=O)NCC(=O)N(C)C)c1', 'Cc1cccc(C(=O)NCC2(CC(=O)N[C@@H]3C[C@H]3CC(C)C)CC2)c1', 'Cc1cccc(C(=O)NCC2CC(C)CN(C(=O)C3(C#N)CC3)C2)n1', 'Cc1cccc(C(=O)NNC(=O)N2CCN(S(=O)(=O)C(C)C)CC2)n1', 'Cc1cccc(C(=O)NNC(=O)NCC2(N3CCCC3)CCC2)c1O', 'Cc1cccc(C(=O)N[C@@H](C)CC(=O)NC2CC(F)(F)C2(C)C)c1O', 'Cc1cccc(C(=O)N[C@]2(C)C[C@H](C(=O)NCc3nc(C)ns3)C2)c1', 'Cc1cccc(C(CNC(=O)c2cc3cc(O)ccc3[nH]2)C(=O)O)c1', 'Cc1cccc(C(NCC2CC3CCC2CC3)C(=O)OC(C)(C)C)c1', 'Cc1cccc(C)c1C(=O)NCC1CCN(Cc2ccccc2)CC1', 'Cc1cccc(C)c1CC(=O)N1CCCC(C)C1CNC(=O)CC#N', 'Cc1cccc(C2(O)CN(Cc3ccc([N+](=O)[O-])cc3[N+](=O)[O-])C2)c1', 'Cc1cccc(C2=CCN(C(=O)COc3ccc(Cl)cc3F)CC2)c1', 'Cc1cccc(C2CC2)c1CNC(=O)Nc1ccccc1SCC#N', 'Cc1cccc(C2CCCN2C(=O)NCc2cccc3cc[nH]c23)c1', 'Cc1cccc(CC(=O)N(C)CCCC(=O)N(C)C(C)C2CCC2)c1', 'Cc1cccc(CCCN(C=O)Cc2cnn(-c3ccccc3)n2)n1', 'Cc1cccc(CCCNc2cc(NCC3(C)CC3(C)C)ncn2)n1', 'Cc1cccc(CCN(CC(C)C(C)(C)C)C(=O)C2CCCCS2)n1', 'Cc1cccc(CCNC(=O)C(C)CNC(=O)C(C(C)C)C(C)C)c1', 'Cc1cccc(CCNC(=O)NNC(=O)Nc2ccc(Cl)cc2)c1F', 'Cc1cccc(CN(C)C(=O)C(=O)NCc2c(Cl)ccc(Cl)c2Cl)c1', 'Cc1cccc(CN(CC/C=C/Br)C(=O)c2cc3cnccc3[nH]2)n1', 'Cc1cccc(CN(CC2CCN(C)C(=O)C2)C[C@@H](F)C(C)(C)O)n1', 'Cc1cccc(CNC(=O)NC(c2ccc(F)cc2)C2(C)CCC2)n1', 'Cc1cccc(CNC(=O)N[C@H]2CC[C@@H]2NC(=O)OC(C)(C)C)c1N', 'Cc1cccc(CNC(=O)[C@H]2CC=CC[C@H]2NC(=O)C=CC(C)C)n1', 'Cc1cccc(CNc2ccc(CCN3CCC(N)CC3)cc2)c1O', 'Cc1cccc(COC(C)C(=O)N[C@@H](Cc2cn(C)cn2)C(=O)O)c1', 'Cc1cccc(Cl)c1S(=O)(=O)NC(=O)CN(C)CC1(CC(C)C)CC1', 'Cc1cccc(F)c1C(=O)N[C@H]1C[C@@H](C(=O)N2C[C@@H]3C[C@H]2CN3C)C1', 'Cc1cccc(F)c1CN(C)C(=O)c1ccc(CN2CCCCC2)s1', 'Cc1cccc(F)c1CN(CC1=CCSC1(C)C)C(=O)C(O)C1CC1', 'Cc1cccc(F)c1N(C)CC(=O)c1cc(C(=O)C(Cl)(Cl)Cl)n(C)c1', 'Cc1cccc(F)c1NC(=O)CCC(C)NC(=O)C1CCC(=O)CC1', 'Cc1cccc(F)c1S(=O)(=O)NC1CC1CNC(=O)c1cc(Br)co1', 'Cc1cccc(N(C)C(=O)C2CC(C)N2C(=O)C2CCCCC2)c1C', 'Cc1cccc(N)c1C(=O)N[C@H](C)C1CN(C(=O)c2cnnn2C)C1', 'Cc1cccc(N2CCC(NC(=O)COC3CCCCC3C)CC2)n1', 'Cc1cccc(NC(=O)C(=O)N(C)C2CC3(CCC3)C2)c1C(F)(F)F', 'Cc1cccc(NNC(=O)C2CC(=O)N(C3CCS(=O)(=O)C3)C2)c1Cl', 'Cc1cccc(OC(C)C(=O)N(C)Cc2c(C)nc3sc(C)cn23)c1', 'Cc1cccc(OCC(=O)Nc2ccc(CC(=O)O)cc2C(=O)O)c1', 'Cc1cccc(OCCCNC(=O)Nc2cc(C(C)(C)C)ns2)c1C', 'Cc1cccc(OCc2cc(C(=O)N(CC(N)=O)CC(F)F)no2)c1', 'Cc1cccc(S(=O)(=O)NC(=O)CN(C)C(C)C(=O)OC(C)(C)C)c1', 'Cc1cccc2[nH]c(C(=O)Nc3ccc(=O)n(C4CCCC4)c3)cc12', 'Cc1cccc2[nH]c(C(C#N)C(=O)CCNC(=O)c3ccoc3)nc12', 'Cc1cccc2c1C(NC(=O)N[C@H]1CCCc3c(O)cccc31)CC2', 'Cc1cccc2c1CCN(S(=O)(=O)c1ccc3ccnc(Cl)c3c1)C2', 'Cc1cccc2c1CN(C(=O)CSCCNC(=O)C13CSCC1C3)C2', 'Cc1ccccc1-c1cn(CCCC(=O)N(C)C2(C(=O)O)CC2)nn1', 'Cc1ccccc1/C=C/C(=O)Nc1cc(NC(=O)N(C)C)ccc1C', 'Cc1ccccc1C(=O)N1CCC(C(=O)N2CC(C)(CCO)C2)CC1', 'Cc1ccccc1C(=O)NC1CC=C(C(=O)N2OC3CCC2CC3)C1', 'Cc1ccccc1C(=O)NNC(=O)c1cc(-c2ccc(Br)cc2)n[nH]1', 'Cc1ccccc1C(CC(C)C)NC(=O)C(=O)N1CCC(NN)CC1', 'Cc1ccccc1C(NC(=O)c1ccoc1-c1ccccc1)C(F)F', 'Cc1ccccc1C(NC1CC(=O)N2CCCCC12)c1ccccc1', 'Cc1ccccc1C1(CNC(=O)NCc2c(C)cc(F)cc2Br)CC1', 'Cc1ccccc1CC(=O)N(CCNC(=O)CC1CC(C)C1)C1CC1', 'Cc1ccccc1CC(=O)NC1CCN(c2cc(C#N)ccn2)CC1', 'Cc1ccccc1CC1CCN(C(=O)c2nc3sccn3c2C)CC1', 'Cc1ccccc1CNC(=O)c1ccnc(CNC(=O)C2(F)CC2)c1', 'Cc1ccccc1NC(=O)C(c1ncco1)N1CCC(CCCO)C1', 'Cc1ccccc1NC(=O)C[C@@H](NC(=O)c1ccncc1F)C(C)C', 'Cc1ccccc1NC(=O)[C@@H]1CCC[C@H]1NC(=O)C1=C(Cl)CCCC1', 'Cc1ccccc1S(=O)(=O)CC(=O)NCC(=O)Nc1cccc(F)c1', 'Cc1cccn(CC(=O)N2CC(F)(CNC(=O)c3cnc[nH]3)C2)c1=O', 'Cc1cccn(CC(=O)N2CCC=C(CNC(=O)C=CCO)C2)c1=O', 'Cc1cccn2c(C(=O)NCCCc3nc4ccccc4[nH]3)cnc12', 'Cc1cccnc1C(=O)N(C)CC(=O)Nc1ccc2ccncc2c1', 'Cc1cccnc1C(=O)N(C)CCC(=O)NCc1c(C)ccnc1C', 'Cc1cccnc1C(=O)N1CCC(CF)(C(=O)N(C)CCC(C)O)C1', 'Cc1cccnc1C(=O)NCCOC1CN(C(=O)CC(=O)N(C)C)C1', 'Cc1cccnc1CC(=O)N1CC2(C)CC1(C(=O)NCCC(N)=O)C2', 'Cc1cccnc1CC(=O)N1CCC=CC1C(=O)NCc1ccco1', 'Cc1cccnc1CC(=O)NC1(CNC(=O)c2nccn2C)CCC1', 'Cc1cccnc1CCC(=O)N(CCNC(=O)[C@H](C)N(C)C)C(C)C', 'Cc1cccnc1CN(CCc1ccoc1)C(=O)CC(C)(C)C(F)F', 'Cc1ccn(C(C)C(=O)NC(CCC(C)C)C(=O)NC(C)(C)CF)n1', 'Cc1ccn(C)c1C(=O)N1CC[C@@H]1C(=O)N1CCN2C(=O)CCC2C1', 'Cc1ccn(C)c1C(=O)NCC1(F)CN(C(=O)c2ncccc2F)C1', 'Cc1ccn(C2CCCN(CCc3cn(CC(F)(F)CO)nn3)C2)n1', 'Cc1ccn(CC(=O)N2CCC3CC32C(=O)NC2(C)CC(F)(F)C2)c1', 'Cc1ccn(CC(=O)NC(CC(=O)NC2CC2(C)C(F)F)C2CC2)c1', 'Cc1ccn(CC(=O)NC2(CNC(=O)C3CCC(=O)N3)CC2)c(=O)c1', 'Cc1ccn(CCC(=O)N(C)C[C@H](C)NC(=O)Cc2ccnn2C)n1', 'Cc1ccn2c(NCCN3CCOCC3)c(-c3ccsn3)nc2c1F', 'Cc1ccn2cc(CN(CC3CCSC3)CC3COC(C)C3)nc2c1', 'Cc1ccnc(C(=O)N2CCCN(Cc3ccccc3F)CC2)c1F', 'Cc1ccnc(C(=O)NCC(C)(CO)NC(=O)c2cc(C)n(C)n2)n1', 'Cc1ccnc(C)c1C(=O)NN1CCC[C@H]1C(=O)N1CCC(C)(O)C1', 'Cc1ccnc(C)c1CN(CC(CO)C1CCC1)C(=O)CCC(C)F', 'Cc1ccnc(C)c1CNC(=O)C1(CNC(=O)c2c[nH]nn2)CCC1', 'Cc1ccnc(CN(C)C(=O)C2(NC(=O)c3cc(C)n[nH]3)CCC2)c1', 'Cc1ccnc(CN(CC2(O)CCC(C)C2)C(=O)c2cc(C)sn2)c1', 'Cc1ccnc(CNCc2ccc(S(C)(=O)=O)c(C(F)(F)F)c2)c1F', 'Cc1ccnc(NCc2cccc(C(=O)N3CC(=O)NCC3C)c2)n1', 'Cc1ccnc(O)c1C(=O)NC/C=C\\CNC(=O)Cc1ccsc1C', 'Cc1ccnc(O)c1C(=O)NCC(C)C(=O)NC12CCCN(CC1)C2', 'Cc1ccncc1C(=O)N1CC(C)(C(=O)NC2COC(C(C)C)C2)C1', 'Cc1ccncc1C(=O)N1CC=C(CC(=O)N2CCC2C(C)O)CC1', 'Cc1ccncc1C=CC(=O)N(C)[C@H]1CCN(C(=O)OC(C)(C)C)C1', 'Cc1ccncc1CC(=O)N1CCC1CNC(=O)Cn1ccnc1C', 'Cc1ccncc1CCNC(=O)c1cnn(C(C)(C)C)c1C(F)(F)F', 'Cc1ccncc1CN(CC1CC1)C(=O)Nc1ccnn1C1CCC1', 'Cc1ccncc1CNC(=O)C1(F)CCN(C(=O)C2CCS2(=O)=O)C1', 'Cc1ccncc1CNC(=O)C1CCCN1C(=O)c1cncc(O)c1', 'Cc1ccnnc1C(=O)N(C)C1CC(C(=O)N2CCC23CCCC3)C1', 'Cc1ccoc1C(=O)N(C)C1CCN(C(=O)c2ncnc(C)c2C)C1', 'Cc1ccoc1C(=O)N1CCC(C)N(C(=O)C2CCNC(=O)C2)CC1', 'Cc1ccoc1C(=O)NCC(CC(=O)NCCC(=O)NO)C1CCC1', 'Cc1ccoc1C(=O)NCCCNS(=O)(=O)c1c[nH]nc1C(F)(F)F', 'Cc1ccoc1C(=O)N[C@@H]1CC(C(=O)NCCOCC(C)C)=C[C@@H]1O', 'Cc1ccoc1C(=O)N[C@H](CC(=O)N1CCC(C)(C#N)C1)CC(C)C', 'Cc1ccoc1S(=O)(=O)N1C[C@H]2CC[C@@H](C1)N2C(=O)C1CNC(=O)C1', 'Cc1ccoc1S(=O)(=O)NC(C)CCNC(=O)c1ccoc1C1CC1', 'Cc1ccoc1S(=O)(=O)NCc1cccc(Oc2cccc(F)c2)c1', 'Cc1ccoc1S(=O)(=O)Nc1ccccc1Nc1ccc(F)cc1F', 'Cc1ccsc1C(=O)N1CCC[C@H](CNC(=O)C(C)C2CCCO2)C1', 'Cc1ccsc1C(=O)N1CCC[C@H]1CNC(=O)C[C@@H]1CCC[C@H](C)O1', 'Cc1ccsc1C(=O)N[C@H]1C[C@@H](C(=O)Nc2cnc3c(c2)CCC3)C1', 'Cc1ccsc1C(=O)N[C@H]1C[C@H]2CC[C@@H](C1)N2C(=O)CC1(O)CCC1', 'Cc1ccsc1C(=O)Nc1cccc(NC(=O)C2C=CC=CC=C2)c1', 'Cc1ccsc1C(Cc1ccccc1)NC(=O)c1cc(C(C)C)[nH]n1', 'Cc1ccsc1CC(=O)NCC(C)(O)CNC(=O)CCc1ccoc1', 'Cc1ccsc1CN(C)C(=O)COC(=O)Cc1c(F)cc(F)cc1Br', 'Cc1ccsc1CN(CCC1(C)CCCC1)C(=O)c1cncc(N)c1', 'Cc1ccsc1CN(Cc1ccc(C#N)cc1)Cc1n[nH]c(C)c1C', 'Cc1ccsc1CNC(=O)COCCNC(=O)CC1C(C)(C)C1(C)C', 'Cc1cn(-c2ncccc2F)nc1NC(=O)c1ccnc2ccsc12', 'Cc1cn(C)c(CN(Cc2ccc(C)c(O)c2)Cc2ccc(Cl)o2)n1', 'Cc1cn(C)c(COC(=O)c2ccc(C(F)(F)F)c3nn(C)cc23)n1', 'Cc1cn(C)nc1-c1cn(C[C@@H](C)NC(=O)Cc2cnccn2)nn1', 'Cc1cn(C)nc1C(=O)N1CCC1(C)CC(=O)N(C)C1CCOCC1', 'Cc1cn(C)nc1C(=O)NC(C)(C)C(=O)NCc1nnc2n1CCC2', 'Cc1cn(C)nc1C(=O)NC(C)CCC(=O)N1Cc2cnn(C)c2C1', 'Cc1cn(C)nc1C(=O)N[C@H]1CCN(C(=O)C(C)N=[N+]=[N-])[C@@H]1C1CC1', 'Cc1cn2c(CN(C)C(=O)C(C)(C)Oc3ccccc3)c(C)nc2s1', 'Cc1cn2c(NCC3CCCO3)c(-c3ncc(C(C)C)s3)nc2cn1', 'Cc1cn2c(n1)CC(C(=O)Nc1ccccc1SC(Cl)C(F)(F)F)C2', 'Cc1cn2c(n1)CN(C(=O)C(C)(C)CNC(=O)CCCC1CC1)CC2', 'Cc1cn2cc(C(=O)NCC3(c4ccccc4Cl)CC3)cc(C)c2n1', 'Cc1cn2cc(CC(=O)NC(C)c3ccc(OC(C)C)cc3)nc2s1', 'Cc1cn2ccc(NC(=O)C(=O)N3CCCC3c3ccsc3)cc2n1', 'Cc1cn2nc(C(=O)Nc3ccc(OC(F)(F)F)c(Cl)c3)ccc2n1', 'Cc1cn2nc(Cl)cc(NC(=O)[C@H]3CCCN(C(=O)C4CC4)C3)c2n1', 'Cc1cn2nccc2c(C(=O)NCc2ccc(F)cc2CN(C)C)n1', 'Cc1cn[nH]c(=O)c1C(=O)N[C@H]1CCCN(C(=O)OC(C)(C)C)[C@H]1C', 'Cc1cnc(-c2nc3ccc(N4CCCC4)cn3c2NCC(F)F)s1', 'Cc1cnc(C(=O)N2CC(CNC(=O)C(C)(C)O)C(C)(C)C2)c(C)c1', 'Cc1cnc(C(=O)N2CCC[C@@]2(C)CCC(=O)N2CC(O)C2)c(F)c1', 'Cc1cnc(C(=O)N2C[C@@H](O)C[C@H](NC(=O)C3C=CCC3)C2)c(F)c1', 'Cc1cnc(C(=O)N2C[C@@H]3C[C@@H]3[C@H]2C(=O)Nc2cn(C)nc2O)cn1', 'Cc1cnc(C(=O)N2C[C@H](C)[C@@H]2C(=O)N2CCC(CO)C(C)C2)cn1', 'Cc1cnc(C(=O)NCC(O)C(=O)NCCc2ncoc2C)cc1C', 'Cc1cnc(C(=O)NCCCCN(C)C(=O)C2CCC(=O)N2)c(C)c1', 'Cc1cnc(C(=O)Nc2cccc3cnn(CC(F)(F)F)c23)c(F)c1', 'Cc1cnc(C2CC2)nc1C(=O)N(C)Cc1cccc(C2CC2)c1F', 'Cc1cnc(CC(=O)N2CC[C@H]3CN(Cc4ccccc4)[C@H](C)[C@H]32)s1', 'Cc1cnc(CCNC(=O)CC(NC(=O)C2CCCCS2)C(F)F)o1', 'Cc1cnc(CCNC(c2ccc(C#N)cc2)c2nnnn2C)nc1', 'Cc1cnc(CN(C)C(=O)[C@@H]2CN(C(=O)Cn3nccn3)C[C@H]2C)o1', 'Cc1cnc(CN(C/C=C/c2ccccn2)CC2(C)CCCS2)cn1', 'Cc1cnc(CN(CCC(C)(C)C2CC2)C(=O)C2CCCSC2C)o1', 'Cc1cnc(CN(Cc2c(C)n[nH]c2C)CC(C)(C)C(C)O)c(Cl)c1', 'Cc1cnc(CN(Cc2c(Cl)ccc(O)c2Cl)CC(F)C2CC2)n1C', 'Cc1cnc(F)c(NC(=O)CSc2nc(C)nc3sc(C)c(C)c23)c1', 'Cc1cnc(N(C)C2CCc3ccccc3N(C)C2=O)c([N+](=O)[O-])c1', 'Cc1cnc(NCCC2CCCO2)c(S(=O)(=O)NCC(C)CCO)c1', 'Cc1cnc(NCc2ccc(-c3noc(C(F)(F)F)n3)cc2)c(F)c1', 'Cc1cnc2c(COC(=O)c3cccc4c3CC(C)(C)C4)cccn12', 'Cc1cnc2c(S(=O)(=O)N3CCn4c(nn(C)c4=O)C3)cccc2c1', 'Cc1cnc2c(S(=O)(=O)NCc3ccc(CO)c(C)c3)cccc2c1', 'Cc1cnc2nc(N[C@H]3C[C@H](NC(=O)CC(C)CC(F)F)C3)sc2n1', 'Cc1cncc(C(=O)N2CCOC(CC(=O)N[C@H]3C[C@@H]3C(C)C)C2)c1', 'Cc1cncc(C(=O)NC(C)(C)CN(C)C(=O)CCc2c[nH]nn2)c1', 'Cc1cncc(C(=O)NCCNC(=O)C(C)(C)c2nncn2C)c1O', 'Cc1cncc(C(=O)NCc2cc(C(=O)N3CCCCC3C)on2)n1', 'Cc1cncc(C(=O)NCc2csc(CNC(=O)c3cscn3)n2)c1', 'Cc1cncc(C)c1C(=O)N(C)CCC(=O)NCC(O)CC(C)(C)C', 'Cc1cncc(C)c1C(=O)NC(C)C(C)C(=O)N1CC(C)C(C)C1C', 'Cc1cncc(C2CCCN2C(C(=O)NCC(F)F)c2ccco2)c1', 'Cc1cncc(CCC(=O)NC2CN(C(=O)C(F)F)CC2C2CC2)c1', 'Cc1cncc(CNC(=O)C[C@@H]2[C@H]3CN(C(=O)c4ccco4)C[C@@H]23)c1', 'Cc1cncc(NC(=O)C2(C)CN(C(=O)c3ccc([N+](=O)[O-])o3)C2)c1', 'Cc1cncc(NC(=O)C2CC(CCNC(=O)C(=O)C(C)(C)C)C2)c1', 'Cc1cncc(OCC(=O)NC2CC(CNC(=O)C(C)C(F)F)C2)n1', 'Cc1cnccc1C(C(=O)NC(C)C)N1CCCC(CCC(C)C)C1', 'Cc1cncn1CCCNC(=O)NCC1CCCc2ccccc2C1', 'Cc1cnn(C(C)C(=O)NCC(NC(=O)c2cnoc2C)C2CC2)c1', 'Cc1cnn(C(C)C(=O)NCC2(O)CN(C(=O)C3CCC(=O)N3)C2)c1', 'Cc1cnn(C)c1C(=O)NCCC1CN(C(=O)CC2(N(C)C)CC2)C1', 'Cc1cnn(C)c1CC(=O)N(CCCCCCF)Cc1sccc1Cl', 'Cc1cnn(C)c1CC(=O)N[C@H](C)C(=O)N[C@H]1C[C@H]2CC[C@]1(CO)C2', 'Cc1cnn(C)c1S(=O)(=O)N(C)C[C@@H](C)NC(=O)CCCCN=[N+]=[N-]', 'Cc1cnn(C2CCN(C(=O)Nc3ccc4cccnc4c3)CC2)c1', 'Cc1cnn(CC(=O)N2CCCC(CC(=O)N3CC(C(N)=O)C3)C2)c1', 'Cc1cnn(CC(=O)OC(C)(C)C)c(=O)c1C(=O)N1CC(C)(CO)C1', 'Cc1cnn(CCC(=O)NC2CC2CNC(=O)c2cccc(Cl)c2)c1', 'Cc1cnn(CCCNc2ccnc(N3CCC(=O)N(C)CC3)n2)c1', 'Cc1cnn(CCN(C)C(=O)[C@@H](C)N(C)C(=O)C(C(C)C)C(C)C)c1', 'Cc1cnn2c1CN(C(=O)C(=O)NCC1OCCOC13CCC3)CC2', 'Cc1cnn2c1CN(C(=O)CCN(C)C(=O)c1c[nH]c(C#N)c1)CC2', 'Cc1cnn2c1CN(C(=O)COCCNC(=O)CC1CCCC1)CC2', 'Cc1cnnc(-c2noc(-c3ccc(N4CCCCCC4)cc3)n2)c1', 'Cc1cnncc1C(=O)N1CCC(CO)(C(=O)NCC2(O)CCC2)C1', 'Cc1cnncc1C(=O)NC(C)C(C)C(=O)NCC12CC(CN1C)C2', 'Cc1cnncc1C(=O)NCCCN(C(=O)c1occc1C)C1CC1', 'Cc1cnnn1C1CCN(C(=O)C2(NC3CCCCC3)CCC2)CC1', 'Cc1cnnn1CCNC(=O)/C=C/C(C)NC(=O)CCC(=O)C1CC1', 'Cc1cnoc1C(=O)N1CCC12CN(C(=O)CC1CCCN(C)C1)C2', 'Cc1cnsc1C(=O)N1CC(C(O)C(=O)NCCCOCC(F)F)C1', 'Cc1cnsc1C(=O)N1CCC(n2cc(C3CC(F)(F)C3)nn2)CC1', 'Cc1cnsc1C(=O)N1[C@@H]2CC[C@H]1C[C@H](C(=O)N1C[C@@H](O)[C@H](O)C1)C2', 'Cc1cnsc1C(=O)N[C@@H](CC(=O)NC1COC(C)(C)C1)C(C)(C)C', 'Cc1cnsc1C(=O)N[C@H]1C[C@@H](N(C)C(=O)/C=C/c2ccccc2)C1', 'Cc1cnsc1CC(=O)N(CCC1CC(C)C1)Cc1nc(C)c(C)o1', 'Cc1cnsc1CN(CCCn1cncc1C)C(=O)c1ocnc1C', 'Cc1coc(C(=O)N2CCSCC2C(=O)NC(CCO)CC(C)C)c1', 'Cc1coc(C(C(=O)NCC2CCCO2)N2CCCCCC2(C)C)n1', 'Cc1coc(C)c1C=CC(=O)N1C[C@H](NC(=O)C(F)(F)CO)[C@@H](O)C1', 'Cc1coc(CN(CC2CC3CCC2CC3)C(=O)C2CCC2(F)F)n1', 'Cc1coc(CN(CCC2CCC3(CC3)CO2)Cc2ncsc2C)n1', 'Cc1coc(CNC(=O)C2(C)C=CCN2C(=O)c2cc(C)oc2C)n1', 'Cc1coc(CNC(=O)CCCN(C)C(=O)Cc2cccc(O)c2)n1', 'Cc1cocc1C(=O)N(C)C(C(=O)NCC(C)(C)CC1CC1)C1CC1', 'Cc1cocc1C(=O)N(C)CCN(C)C(=O)CC(C)c1cccnc1', 'Cc1cocc1C(=O)N1CC[C@@H](NC(=O)CCCN(C)N=O)[C@H](O)C1', 'Cc1cocc1C(=O)N1C[C@H]2C[C@@H]1[C@H]2NC(=O)Cc1cnn(C)c1C', 'Cc1cocc1C(=O)N1[C@H](C)CC[C@@H]1C(=O)N[C@H]1CCC[C@H](O)[C@@H]1O', 'Cc1cocc1C(=O)N[C@@H](CO)CNC(=O)c1cc2cnccc2[nH]1', 'Cc1cocc1C(=O)N[C@H]1C[C@@H](CO)N(C(=O)[C@@H](O)C2CCCC2)C1', 'Cc1conc1C(=O)NC1CN(C(=O)C#CC2CCC2)C2(CCC2)C1', 'Cc1conc1C1CN(C(=O)[C@H]2C[C@H]3CC[C@@H]2N3C(=O)CC(C)F)C1', 'Cc1conc1CC(=O)N1CCN(C(=O)C2CCC(F)(F)C2)[C@@H](C)C1', 'Cc1conc1CC(=O)NC1(CCC(=O)N2CCNC(=O)C2)CCC1', 'Cc1conc1CC(=O)NC[C@H]1COC[C@@H]1NC(=O)c1oncc1C', 'Cc1conc1CN(CCC1(C)CCCO1)Cc1ccnc(Cl)c1F', 'Cc1csc(-c2cccc(C(=O)OCC(=O)CCc3cnoc3)c2)n1', 'Cc1csc(C(=O)N2CC3CCC2CN3C(=O)CN(C)C(C)C)c1C', 'Cc1csc(C(=O)NC2CC3(C2)CN(C(=O)CC2CC=CC2)C3)c1C', 'Cc1csc(C(=O)NC[C@H](CC(C)C)NC(=O)Cc2cncnc2)c1', 'Cc1csc(C(=O)N[C@@H](CC(=O)NCCC2C=CCC2)CC(C)C)c1', 'Cc1csc(C)c1C(=O)N[C@@H](C(=O)N1C[C@H]2C[C@@H](O)C[C@H]2C1)C(C)C', 'Cc1csc(C)c1C(=O)N[C@H]1C[C@H](CNC(=O)C2=CCCOCC2)C1', 'Cc1csc(C2CCCN(C(=O)C(=O)NCCOCC(C)(C)O)C2)n1', 'Cc1csc(CC(=O)NC/C=C\\CNC(=O)c2cnn3c2CCC3)c1', 'Cc1csc(CC(=O)NC[C@@H](C)C(=O)N2CCCC3(CCOC3)C2)c1', 'Cc1csc(CCC(=O)N[C@H]2C[C@H](NC(=O)CCN3CCCC3)C2)n1', 'Cc1csc(CCNC(=O)C[C@H](C)NC(=O)C2(C)CC(=O)N(C)C2)n1', 'Cc1csc(CCNC(=O)[C@H]2C[C@@H](F)CN2C(=O)CC(C)C2CC2)n1', 'Cc1csc(CN(C)C(=O)[C@@H]2C[C@@H]3C[C@@H]3N2C(=O)[C@H]2C[C@@H]2C2CC2)c1', 'Cc1csc(CN(C)c2nc(N[C@@H](C)CF)c3cccc(F)c3n2)n1', 'Cc1csc(NC(=O)NC2CCN(CC3CCCCC3)CC2)c1C#N', 'Cc1csc(NC2CCN(C(=O)C3CC(=O)N(C4CCCC4)C3)C2)n1', 'Cc1csc2cc(CNC(=O)NC3(CO)CCC(F)(F)CC3)ccc12', 'Cc1csc2ccc(CNC(=O)NC3(c4nccs4)CCCC3)cc12', 'Cc1csc2nc(CC(=O)NCC34CC5CC(CC(Cl)(C5)C3)C4)cn12', 'Cc1csc2ncnc(NC[C@H]3CC[C@H]3CNC(=O)c3ccns3)c12', 'Cc1cscc1C(=O)N1CCCC1CCC(=O)NCC1(O)CCSC1', 'Cc1cscc1C(=O)N1CC[C@H](C(=O)NCc2ncsc2C)[C@H](O)C1', 'Cc1cscc1C(=O)NCCC(C)(C)C(=O)NCC1C[C@H]2CC[C@H]2C1', 'Cc1cscc1CN(CCC1CCCC(C)C1)C(=O)Cn1nccn1', 'Cc1cscc1CN(C[C@H]1[C@@H]2CCC[C@@H]21)C(=O)CCCC1OCCO1', 'Cc1cscc1CNC(=O)C12CC(CN1C(=O)C[C@@H]1CCCN1C)C2', 'Cc1cscc1NC(=O)C(C)(C)CCCNC(=O)Cn1ccnc1C', 'Cc1cscc1NC(=O)c1cc(CNC(=O)c2nnccc2C)no1', 'Cc1csnc1C(=O)N(C)CCOCCNC(=O)CN(C)S(N)(=O)=O', 'Cc1csnc1C(=O)N(Cc1nc(C)c(C)[nH]1)CC1(C)CCCC1O', 'Cc1csnc1C(=O)NC(C)C1CC(NC(=O)C(C)(C)CC(C)C)C1', 'Cc1n[nH]c(=O)c(C(=O)N2C[C@H](CO)[C@H](NC(=O)C3CC3Cl)C2)c1C', 'Cc1n[nH]c(C(=O)N(C)C2(C(=O)N3CCC[C@H](N(C)C)C3)CC2)c1Cl', 'Cc1n[nH]c(C(=O)N(Cc2cccc(F)c2C)CC2(C)CSC2)c1O', 'Cc1n[nH]c(C(=O)NC2(CC(=O)NCCC3CCC(C)C3)CC2)c1O', 'Cc1n[nH]c(C(=O)NCc2cc(COc3ccccc3F)on2)c1I', 'Cc1n[nH]c(C(=O)Nc2cccc(-c3ncc4n3CCCC4)c2)c1I', 'Cc1n[nH]c(C)c1C(C)C(=O)N1CC[C@@H](NC(=O)c2cnccn2)C1', 'Cc1n[nH]c(C)c1C1NC(=S)N(c2ccccc2Cl)C2=C1C(=O)OC2', 'Cc1n[nH]c(C)c1CC(=O)N1CC(N(C)C(=O)c2ccnc(N)c2)C1', 'Cc1n[nH]c(C)c1CC(=O)N1CC=CC(NC(=O)C(O)CN(C)C)C1', 'Cc1n[nH]c(C)c1CC(=O)N1CCOC(C(=O)NCc2c[nH]cn2)C1', 'Cc1n[nH]c(C)c1CCNC(=O)CCN(CCO)C(=O)C1CC(F)C1', 'Cc1n[nH]c(C)c1CNC(=O)[C@@H]1CN(C(=O)C2CCOC2)C[C@H](C)O1', 'Cc1n[nH]c(CC(=O)N2CCN(C)C(C(=O)NCC[Si](C)(C)C)C2)n1', 'Cc1n[nH]c(CC(=O)NC2(C(=O)NCCN3CCOCC3C)CC2)n1', 'Cc1n[nH]c(CN(CC(CO)C2CC2)C(=O)C#CC2CCOC2)c1Cl', 'Cc1n[nH]c(CN(CCCn2nccc2C2CC2)CC2CC2C)c1Cl', 'Cc1n[nH]c(N2CCN(C(CC(C)(C)C)C(=O)NC3CCC3)CC2)n1', 'Cc1n[nH]c(SCC(=O)NC(C)CN(C)C(=O)c2ccnnc2C)n1', 'Cc1n[nH]c2c(C)cc(C(=O)NCC3(O)CCN(S(C)(=O)=O)C3)cc12', 'Cc1n[nH]c2ncc(NC(=O)CNS(=O)(=O)c3cn(C)c(C)n3)cc12', 'Cc1n[nH]cc1C(C(=O)NC1CC1)N1CCC(c2cccc(F)c2)C1', 'Cc1n[nH]cc1CC(=O)N(C)[C@H]1C[C@@H](NC(=O)C2C3CC4C(C3)C42)C1', 'Cc1n[nH]cc1CC(=O)NCC1(NC(=O)CN2CCN(C)CC2)CC1', 'Cc1n[nH]cc1CN(C)C(=O)Nc1ccc(C2CC2)cc1C(F)(F)F', 'Cc1n[nH]nc1C(=O)N1CC(CC(C)NC(=O)C=Cc2ncc[nH]2)C1', 'Cc1n[nH]nc1C(=O)N1CC(NC(=O)c2cc(N)ccn2)CC1(C)C', 'Cc1n[nH]nc1C(=O)N1C[C@@H](O)C[C@@H]1CNC(=O)[C@@H]1C[C@H](O)CN1C', 'Cc1n[nH]nc1C(=O)NC(CNC(=O)[C@@H]1CCCN1C(C)C)C(C)C', 'Cc1nc(-c2cc(C(=O)NCc3ccc(P(C)(C)=O)cn3)co2)cs1', 'Cc1nc(-c2cc(C(=O)OCC(=O)C3(C(F)(F)F)CC3)n(C)c2)cs1', 'Cc1nc(-c2cc[nH]n2)oc1C(=O)Nc1cccc2ccc(O)cc12', 'Cc1nc(-c2ccc(F)cc2)oc1C(=O)N1CCCC(CCCO)C1', 'Cc1nc(-c2cccc(NC(=O)C3CCc4ncc(C)n4C3)c2)n[nH]1', 'Cc1nc(-c2ccccc2)sc1C(=O)NNC(=O)COC1CC=CC1', 'Cc1nc(=O)[nH]c(C)c1C(=O)NCC[C@H](C)NC(=O)c1nc[nH]c1C', 'Cc1nc(C(=O)N(C)C(C)CNC(=O)c2cnn(C(C)C)c2)n(C)n1', 'Cc1nc(C(=O)N(C)C2CN(C(=O)CCN3CCOCC3)C2)cn1C', 'Cc1nc(C(=O)N(C)CC2CCCN2C(=O)CC2(O)CCC2)cn1C', 'Cc1nc(C(=O)N(CC2CCCCS2)CC2CC3C=CC2C3)cn1C', 'Cc1nc(C(=O)N2CC(C(O)C(=O)N(C)C(C)C(C)C)C2)cc(=O)[nH]1', 'Cc1nc(C(=O)N2CC3(C2)CN(C(=O)C2CCOC2(C)C)C3)n(C)n1', 'Cc1nc(C(=O)N2CC3CC(C2)N(C(=O)CC2C=CCC2)C3)n(C)n1', 'Cc1nc(C(=O)N2CCCC2/C=C/C(=O)NC2CC2(C)C(F)F)co1', 'Cc1nc(C(=O)N2CCO[C@H](CNC(=O)C3(C)CC(C)(C)C3)C2)co1', 'Cc1nc(C(=O)N2CC[C@H](C)C[C@@H]2C(=O)NOCC(O)CO)cn1C', 'Cc1nc(C(=O)N2C[C@@H](F)C[C@H]2C(=O)NCc2ccc(O)nc2)co1', 'Cc1nc(C(=O)NC(Cc2cc[nH]n2)C(=O)N(C)C2CC(O)C2)co1', 'Cc1nc(C(=O)NC2(CF)CCN(C(=O)C3COCCN3C)C2)co1', 'Cc1nc(C(=O)NC2CC(C(C)NS(=O)(=O)c3sccc3C)C2)cs1', 'Cc1nc(C(=O)NC2CC(NC(=O)Cc3ccsc3)C2)cn1C(F)F', 'Cc1nc(C(=O)NCC(C)(C)CN(C)C(=O)[C@H]2CCCCN2C)co1', 'Cc1nc(C(=O)NCC2(CC(=O)NCCN3CC4CC4C3)CC2)co1', 'Cc1nc(C(=O)NCC2CN(C(=O)C3CNC(=O)C3)C(C)(C)C2)cs1', 'Cc1nc(C(=O)NCCCCNC(=O)c2cc(O)cc(C#N)c2)c[nH]1', 'Cc1nc(C(=O)NCCOCCNC(=O)c2nn(C)cc2C)c(C)s1', 'Cc1nc(C(=O)NC[C@H](O)CC(=O)NCCC2(C)CCCO2)sc1C', 'Cc1nc(C(C)(C)C)[nH]c(=O)c1C(=O)NC1CC(F)(F)CCC1(C)C', 'Cc1nc(C(C)(C)C)ncc1C(=O)Nc1ccc(OC(F)F)cc1Cl', 'Cc1nc(C(C)(C)NC(=O)C2CCC(Cc3ccccc3)CC2)no1', 'Cc1nc(C(C)C)ccc1COC(=O)c1coc(-c2cccnc2)n1', 'Cc1nc(C(C)N)sc1C(=O)NC1CCN(c2ccc(Cl)cc2Cl)C1', 'Cc1nc(C(C)NC(=O)C2CC(N(C)C(=O)Cc3cc[nH]c3)C2)no1', 'Cc1nc(C(C)NC(=O)N2CCCN(c3ccccc3Cl)CC2)no1', 'Cc1nc(C(NC(=O)c2ccccc2Cn2cccn2)C2CC2)no1', 'Cc1nc(C)c(-n2cc(-c3ccc4cncnc4c3)nn2)c(C)c1C', 'Cc1nc(C)c(Br)c(NC2CCC(C)(CNC(=O)OC(C)(C)C)C2)n1', 'Cc1nc(C)c(C(=O)N(C)CCC(=O)NC(C)Cc2cnccn2)o1', 'Cc1nc(C)c(C(=O)N(C)[C@H](C)C(=O)NCC23CCCN(CC2)C3)s1', 'Cc1nc(C)c(C(=O)NC2(C(=O)NCc3cccnn3)CCCC2)s1', 'Cc1nc(C)c(C(=O)NC[C@@H]2CN(C(=O)[C@@H](O)CC(C)C)C[C@H]2O)o1', 'Cc1nc(C)c(C(=O)NCc2nocc2C(=O)N(C)C2(CO)CC2)s1', 'Cc1nc(C)c(C(=O)N[C@@H](C)CCC(=O)N2CCC2C2CCCC2)s1', 'Cc1nc(C)c(C(=O)N[C@H]2[C@@H](C(=O)NCc3ccnn3C)C2(C)C)o1', 'Cc1nc(C)c(C(=O)Nc2cccc(NC(=O)c3ccn(C)c3)c2)o1', 'Cc1nc(C)c(CC(=O)N2CCN(C(=O)c3ccco3)CC2)c(=O)[nH]1', 'Cc1nc(C)c(CCNC(=O)N2CCC(N3CCN(C)CC3)CC2)s1', 'Cc1nc(C)c(CNC(=O)CC(C)(C)CNC(=O)C2CCCSC2)o1', 'Cc1nc(C)n(CC(=O)N2C[C@H](F)C[C@@H]2C(=O)NC2CCOCC2)n1', 'Cc1nc(C)n(CC(=O)NCC(C)CC(=O)NCCOC2CCC2)n1', 'Cc1nc(C)n(CCNC(=O)CCNC(=O)[C@]23CCC[C@H]2OCC3)n1', 'Cc1nc(C2CCCN2C(=O)[C@H]2CCCN(C(=O)C3CC3)C2)[nH]c1C', 'Cc1nc(C2CCCO2)oc1C(=O)Nc1cc(F)cc2c1OCCC2', 'Cc1nc(CC(=O)N(C)Cc2nc(-c3ccc(C#N)cc3)cs2)cs1', 'Cc1nc(CC(=O)N2CC3CC(C2)N3C(=O)Cn2ccnc2C)c[nH]1', 'Cc1nc(CC(=O)N2CCC(C)(C)C2C(=O)N2C[C@@H]3C[C@H]2CO3)co1', 'Cc1nc(CC(=O)N2CCC2CC(=O)N2CC(=O)N(C)C(C)C2)co1', 'Cc1nc(CC(=O)N2CC[C@@H](NC(=O)[C@H]3C[C@H]4O[C@@H]3[C@@H]3C[C@@H]34)C2)co1', 'Cc1nc(CC(=O)N2C[C@H](CCNC(=O)/C=C/C(C)C)[C@@H](C)C2)c[nH]1', 'Cc1nc(CC(=O)N2C[C@H]3C[C@@H]2[C@H]3C(=O)NC2COC(C)(C)C2)co1', 'Cc1nc(CC(=O)NCC2(C(=O)NC(C)Cc3cccs3)CC2)co1', 'Cc1nc(CC(=O)NCc2nc(C(=O)NCC3[C@H](C)[C@H]3C)co2)cs1', 'Cc1nc(CC(=O)N[C@H]2CC[C@H](CC(=O)N[C@H]3CCC[C@H]3C)C2)cs1', 'Cc1nc(CC(=O)N[C@H]2C[C@@H](C(=O)NC[C@@H]3C[C@H]4CC[C@@H]3O4)C2)co1', 'Cc1nc(CCNC(=O)/C=C/C2CCCN2C(=O)CCC(N)=O)n[nH]1', 'Cc1nc(CCNC(=O)C2(C)C=CCN2C(=O)C2CCCOC2)cs1', 'Cc1nc(CCNc2cc(N(C)Cc3ccncn3)ncn2)c(C)o1', 'Cc1nc(CN(C)C(=O)C[C@@H](NC(=O)[C@H]2COCCO2)C2CC2)no1', 'Cc1nc(CN(C)C(C(=O)NC2CCOC2)c2cc(Br)ccn2)n[nH]1', 'Cc1nc(CN(CC(C)c2cccs2)C(=O)C2C3COCC32)sc1C', 'Cc1nc(CN(CC(F)(F)C(C)(C)O)C(=O)C2(CCF)CCC2)c[nH]1', 'Cc1nc(CN(CC2CCCSCC2)C(=O)c2csc(CO)n2)cs1', 'Cc1nc(CN(Cc2ccoc2C)C(=O)C2CCC(CO)CC2)cs1', 'Cc1nc(CNC(=O)C2(CNC(=O)C3=COCCC3)CCCC2)c[nH]1', 'Cc1nc(CNC(=O)C2=CCC(NC(=O)CN(C)C(C)C)C2)[nH]c1C', 'Cc1nc(CNC(=O)C2CCC(=O)NC2)oc1C(=O)NCC1(O)CC1', 'Cc1nc(CNC(=O)CCCCCNC(=O)Cc2ccn[nH]2)sc1C', 'Cc1nc(CNC(=O)CCCCCNC(=O)c2cnc(N)o2)sc1C', 'Cc1nc(CNC(=O)CCCN(C)C(=O)c2cc(O)cc(=O)o2)c[nH]1', 'Cc1nc(CNC(=O)COC2CN(C(=O)C/C=C/C(C)(C)C)C2)co1', 'Cc1nc(CNC(=O)C[C@@H](C)N(C)C(=O)c2cnn(C)c2C#N)no1', 'Cc1nc(CNC(=O)[C@H]2C[C@@H]2C2CN(C(=O)CCCCC#N)C2)c[nH]1', 'Cc1nc(CNC(=O)c2c(C)noc2N)oc1C(=O)NC(C)C(C)C', 'Cc1nc(CNC2(c3nnnn3C3CC3)CCCC(C#N)C2)sc1C', 'Cc1nc(CNC2CCC(C)CC2N2CCc3ccccc3C2)co1', 'Cc1nc(COc2ccc(NCC3CC4(C3)CC(C)(C)C4)cc2)no1', 'Cc1nc(COc2ccccc2)sc1C(=O)NCCCn1cnnn1', 'Cc1nc(COc2ccccc2)sc1C(=O)Nc1cccc(CF)n1', 'Cc1nc(CSc2nc3ccccc3c(=O)n2-c2nnc[nH]2)c(C)s1', 'Cc1nc(Cl)ccc1NC(=O)C1(CCNC(=O)CC(C)(C)C#N)CC1', 'Cc1nc(F)ccc1NC(=O)[C@H]1CCCN1C(=O)c1ccc(N)cn1', 'Cc1nc(F)ccc1NC(=O)c1ccc(N2CCC(=O)NC2=O)cc1', 'Cc1nc(N)c2c(C)c(C(=O)Nc3nc(C(C)(C)C)n(C)n3)sc2n1', 'Cc1nc(N)nc(C)c1C(=O)N[C@@H](C)CN(C)C(=O)c1cc(Cl)no1', 'Cc1nc(N2CCCCC2)sc1CNC(=O)c1cc(Br)cc(Br)c1N', 'Cc1nc(N2CCCN(CC(C)C)CC2)cc(N2CCC3(CC3)C2)n1', 'Cc1nc(N2CCOC(CC(C)C)C2)cc(N2CCC(C3CC3)C2)n1', 'Cc1nc(N2CC[C@H](N(C)CCO)[C@@H]2C)c2c3c(sc2n1)CCCC3', 'Cc1nc(NC2CCC3CC32)cc(N2CCn3c(C)nc(Br)c3C2)n1', 'Cc1nc(NC2CCCCCCC2)cc(N2CCC(CCO)CC2)n1', 'Cc1nc(NCCCOC(N)=O)cc(NCC2NC(=O)CC2(C)C)n1', 'Cc1nc(NCCCOC2CCCC2)cc(NCc2c[nH]c(=O)[nH]2)n1', 'Cc1nc(NCCN(C)C)cc(NCC(CO)CC2CCOCC2)n1', 'Cc1nc(NCCNC(=O)CNC(=O)c2ccc(F)cn2)ncc1F', 'Cc1nc(NCC[C@H]2C[C@H](NC(=O)C3CC3Cl)C2)c2c(cnn2C)n1', 'Cc1nc(NCc2c(C)ccnc2C)cc(NC[C@H]2OCC[C@H]2C)n1', 'Cc1nc(Nc2ccc(Cl)cc2)cc(NC2CC3(CNC(=O)O3)C2)n1', 'Cc1nc(O)ccc1C(=O)N1CCC[C@H](C(=O)N(C)CC(Cl)Cl)[C@@H]1C', 'Cc1nc(O)ccc1C(=O)N[C@H]1CN(C(=O)C2(C)CCC2)C[C@H]1CO', 'Cc1nc(O)ccc1CN(CC1(CF)CCC1)C(=O)c1ccc(F)s1', 'Cc1nc(S(=O)(=O)NC(=O)CN2CCCC(c3nccn3C)C2)cs1', 'Cc1nc(SC(F)(F)F)sc1CC(=O)Nc1ccc2ncccc2n1', 'Cc1nc([C@@H](C)NC(=O)C(C)(C)NC(=O)C2CC(C(C)C)=NO2)n[nH]1', 'Cc1nc([C@@H](C)NC(=O)C[C@H](NC(=O)C(C)(C)N(C)C)C(C)C)n[nH]1', 'Cc1nc([C@@H](C)NCc2cn(-c3cc(F)ccc3C(=O)O)nn2)cs1', 'Cc1nc2c(CCNC(=O)NC3CC(n4ccnn4)C3)cccc2o1', 'Cc1nc2c(CN(CC3(C(F)(F)F)CC3)C(=O)C(N)=O)cccc2[nH]1', 'Cc1nc2c(Cl)cccc2cc1C(=O)N1CC(N2CCCS2(=O)=O)C1', 'Cc1nc2c([nH]1)C(NC(C)CCCCNC(=O)OC(C)(C)C)CCC2', 'Cc1nc2c(c(C)c1CCC(=O)N1CCC[C@@H]1C(=O)O)c(=O)[nH]n2C', 'Cc1nc2c(o1)CCN(C(=O)C1(NC(=O)CCC(=O)N(C)C)CC1)C2', 'Cc1nc2c(s1)CN(C(=O)C1=C(F)CN(C(=O)C(C)(C)CF)CC1)C2', 'Cc1nc2c3c(ccc2[nH]1)N(C(=O)Cc1cc(F)ncc1Br)CCC3', 'Cc1nc2cc(C(=O)NCC(C)n3cc(C4CC4)nn3)ccc2n1C', 'Cc1nc2cc(CNCC3CCN(C(=O)OC(C)(C)C)C3)ccc2s1', 'Cc1nc2cc(CNc3ccc([N+](=O)[O-])c(N)n3)ccc2n1C1CC1', 'Cc1nc2ccc(Cl)cn2c1NC(=O)N1CCC(NC(=O)C2CC2)C1', 'Cc1nc2ccc(F)cc2c(N2CC(O)CC3(CCOCC3)C2)c1C', 'Cc1nc2ccc(NC(=O)CCCOc3ccc(Cl)cc3)cn2c1Br', 'Cc1nc2ccc(S(=O)(=O)NCCc3cc4ccccc4s3)cc2o1', 'Cc1nc2ccccc2n1CCCNC(=O)N1CCCS(=O)(=O)CC1', 'Cc1nc2ccccn2c1CN(CCC(F)(F)Cl)C(=O)C1CC(C)C1', 'Cc1nc2cncc(C(=O)NC3(c4nnn[nH]4)CCCCCC3)c2[nH]1', 'Cc1nc2n(c1C)CCN(C(=O)c1cc3ccc(Cl)cc3c(=O)[nH]1)C2', 'Cc1nc2sc(C(=O)O)cn2c1CNC1CCC1(C)c1ccccc1', 'Cc1ncc(C(=O)N(C)CCCCNC(=O)Cc2ccccc2C)o1', 'Cc1ncc(C(=O)N(Cc2cccnc2)CC2(CF)CCCOC2)s1', 'Cc1ncc(C(=O)N2CC(C)(NC(=O)C3CN(C(N)=O)C3)C2)cc1N', 'Cc1ncc(C(=O)N2CCC(C(C)NC(=O)C[C@@H](C)O)CC2)cc1Cl', 'Cc1ncc(C(=O)N2CCN(C(=O)C3CC3(Cl)Cl)C[C@H]2CO)c(C)n1', 'Cc1ncc(C(=O)NC(C)c2nocc2C(=O)N[C@@H]2[C@H](C)C2(C)C)o1', 'Cc1ncc(C(=O)NC2(C(=O)N3CC(C)OCC(C)(C)C3)CSC2)o1', 'Cc1ncc(C(=O)NCCC2CCN(C(=O)[C@@H]3CC[C@H](C)O3)C2)cn1', 'Cc1ncc(C(=O)N[C@@H]2C=C[C@H](C(=O)NCC(C)(CO)CO)C2)n1C', 'Cc1ncc(C(=O)N[C@H](C)C2CN(C(=O)c3cnn(C)c3C)C2)cn1', 'Cc1ncc(C(=O)N[C@H](Cc2csc(NCCCO)n2)CC(C)C)o1', 'Cc1ncc(C(=O)N[C@H]2CCC[C@H]2C(=O)N2CCC(C)(C(N)=O)C2)o1', 'Cc1ncc(C(=O)N[C@H]2CC[C@@H](NC(=O)C(O)C(F)(F)F)CC2)n1C', 'Cc1ncc(C(=O)N[C@H]2C[C@H](NC(=O)C(C)(C)CC(F)F)C2)c(N)n1', 'Cc1ncc(C(=O)N[C@H]2C[C@H](NC(=O)c3cc(C4CC4)cs3)C2)cn1', 'Cc1ncc(C(=O)OCc2ccc(Br)c3cccnc23)c(C2CC2)n1', 'Cc1ncc(C(C)NC(=O)[C@H]2CC[C@H]2NC(=O)[C@H]2C[C@H]3CC[C@@H]2C3)s1', 'Cc1ncc(C=CC(=O)NCC(C)(C)NC(=O)CC(C)(C)C(F)F)s1', 'Cc1ncc(CC(=O)N2CCC(C(=O)NC3CCCC3C#N)C2C)s1', 'Cc1ncc(CC(=O)N2CCC[C@H](C(=O)NCC3=NOC(C)C3)C2)s1', 'Cc1ncc(CC(=O)NC2CC(CNC(=O)C(C)C(F)F)C2)c(O)n1', 'Cc1ncc(CCC(=O)NC(CNC(=O)C2=COCCC2)C(C)C)o1', 'Cc1ncc(CCNC(=O)C2(NC(=O)CC3CCCO3)CC(O)C2)s1', 'Cc1ncc(CN(C)C(=O)CC(CC(C)C)NC(=O)C2=CCCC2)s1', 'Cc1ncc(CN(CC2CCCS2)C(=O)c2ccc(=O)n(C)c2)cn1', 'Cc1ncc(CN(CCOCC(F)(F)F)C(=O)C2CCCN2C)n1C', 'Cc1ncc(CN(C[C@H]2COC(C)(C)O2)C(=O)[C@H]2CCC(=O)O2)n1C', 'Cc1ncc(CN(Cc2ccc(C(C)(C)O)cc2)CC2(C)CC2C)s1', 'Cc1ncc(CN(Cc2cncc(Cl)c2)CC2(CF)CCCOC2)s1', 'Cc1ncc(CNC(=O)/C=C/C(C)NC(=O)[C@H](NC(N)=O)C(C)C)s1', 'Cc1ncc(CNC(=O)[C@H]2CCOC[C@H]2NC(=O)c2cncnc2)s1', 'Cc1ncc(Cl)cc1NC(=O)c1cc(CNC(=O)C2=C(Cl)CC2)on1', 'Cc1ncc(NC(=O)NCc2ccc3c(c2)C(=O)NCC3)cc1C#N', 'Cc1ncc(NC(=O)[C@@H](O)CNC(=O)c2cc(Cl)cn2C)c(C)c1C', 'Cc1ncc(NC(=O)[C@H]2CCC[C@H]2NC(=O)c2ccn(C)c2)cc1Cl', 'Cc1ncc(S(=O)(=O)N2CC3(CC(CNC(=O)/C=C/C(F)F)C3)C2)s1', 'Cc1ncc(S(=O)(=O)NC(=O)C(C)N2CCN(c3cnsn3)CC2)s1', 'Cc1nccc(C(=O)N2CCC(C)(CC(=O)N3CC(CCO)C3)C2)n1', 'Cc1nccc(C(=O)N2CC[C@@H](CNC(=O)C(C)(C)N(C)C)C2)c1C', 'Cc1nccc(CCNC(=O)[C@H]2CC[C@H](CNC(=O)C3CC3)CC2)n1', 'Cc1nccc(CNC(=O)[C@@H]2CCN2C(=O)CC2CCOC2(C)C)n1', 'Cc1nccc(NC(=O)C2(NC(=O)OC(C)(C)C)CC(F)(F)C2)c1C', 'Cc1nccc(NCCNC(=O)N2CC(Cc3ccccc3O)C2)n1', 'Cc1ncccc1C(=O)N1CCC(C(=O)NCCOCC2CC2)CC1', 'Cc1ncccc1C(=O)N1CCC(OCCNC(=O)OC(C)(C)C)C1', 'Cc1ncccc1CC(=O)N1CCC(C)(C)C1C(=O)N1CC2CC2C1', 'Cc1ncccc1CC(=O)N1CCC1C(=O)N1CC2CC3CC2C1C3', 'Cc1ncccc1CNC(=O)CC(C)(C)NC(=O)CCCNC(N)=O', 'Cc1ncccc1CNC(=O)[C@@H](NC(=O)C12C=CC(CC1)C2)C(C)C', 'Cc1ncccc1N(C(=O)c1ccccc1NCC(F)(F)F)C(C)C', 'Cc1ncccc1NC(=O)C1CCCN1C(=O)CC(O)C1CCCC1', 'Cc1nccn1-c1ccncc1NC(=O)c1cccc2ccncc12', 'Cc1nccn1C(C)C(=O)N1C[C@@H](F)C[C@@H]1C(=O)NC[C@@H]1CCCO1', 'Cc1nccn1CC(=O)N1C(C)CC1C(=O)NCc1cccc(F)c1', 'Cc1nccn1CCC(=O)N(C)CC(O)CNC(=O)C[C@H]1CC[C@H]1C', 'Cc1nccn1CCCCNc1ccc(C(=O)NC2CCOC2)cn1', 'Cc1nccn1CCCc1nc(-c2ccnc(-n3ccnc3)c2)no1', 'Cc1nccn1CCN(C)C(=O)Cn1cc(C2COC(C)(C)C2)nn1', 'Cc1nccnc1C(=O)NC1CC(C)N(C(=O)CCn2cncn2)C1', 'Cc1nccnc1C(=O)N[C@]1(C)C[C@H](C(=O)N[C@H]2C[C@@H]2C2CCC2)C1', 'Cc1nccnc1CCNC(=O)C(CC1CC1)NC(=O)[C@@H]1C[C@H]1C#N', 'Cc1nccnc1CCNC(=O)C1CCN(C(=O)C2CSC2)C12CC2', 'Cc1nccnc1CNC(=O)CC(C)(C)NC(=O)c1nccc(N)n1', 'Cc1nccnc1CNCCC(CC(C)(C)C)NC(=O)OC(C)(C)C', 'Cc1nccnc1N1CCN(C(=O)C(=O)N2C[C@H](C)O[C@@H](C)C2)CC1', 'Cc1nccnc1NNC(=O)c1cccc(S(=O)(=O)NC(C)(C)C)c1', 'Cc1ncn(-c2ccc(NC(=O)N(C)CCOC(C)(C)C)cc2)c1C', 'Cc1ncn(C)c1CN(C[C@H]1CCC[C@@H](O)C1)C(=O)C[C@H](C)N(C)C', 'Cc1ncn(O)c1C(=O)NCC(C)CN(C)C(=O)[C@H]1CCCO[C@H]1C', 'Cc1ncnc(C(=O)NCCC(C)(C)C(=O)N2CC=CC2CF)c1C', 'Cc1ncnc(N2CCN(C(=O)c3ccc(Cl)c(N)c3)CC2C)c1Br', 'Cc1ncncc1C(=O)N1CC2(CC(NC(=O)[C@H]3CC[C@H]3C#N)C2)C1', 'Cc1ncncc1C(=O)NC(C)(C)CCC(=O)N(C)[C@H](C)CN(C)C', 'Cc1ncncc1C(=O)NCC1CCCN(C(=O)c2cnccn2)C1', 'Cc1ncncc1C(=O)NCCCCNC(=O)c1cc(C2CC2)on1', 'Cc1ncncc1NC(=O)c1ccc(CNC(=O)C(F)=CC2CC2)s1', 'Cc1ncoc1C(=O)N(CCN(C)C(=O)CC1CCOCC1)C(C)C', 'Cc1ncoc1C(=O)N1CC(F)(F)C[C@@H]1C(=O)N(C)Cc1ncco1', 'Cc1ncoc1C(=O)N1CCN(C)C(C(=O)NCCc2c[nH]nn2)C1', 'Cc1ncoc1C(=O)N1CCO[C@H](C(=O)NCCNC(=O)C2CC2)C1', 'Cc1ncoc1CN(Cc1cc(C(C)(C)C)no1)Cc1[nH]ncc1Br', 'Cc1ncoc1CNC(=O)NCC1(c2ccc(Br)cc2)CCOCC1', 'Cc1ncsc1C(=O)N1CCN(C(=O)C2(C)CC2(C)C)CC12CCC2', 'Cc1ncsc1C(=O)NC[C@H](NC(=O)C(C)(C)C1CCOC1)C(C)C', 'Cc1ncsc1C(=O)N[C@H]1CCCC[C@H]1CC(=O)N[C@@H]1COC[C@H]1F', 'Cc1ncsc1C(C(=O)NC1CCC(F)(F)CC1)N1CCCC(C)C1', 'Cc1ncsc1C(C)NC(=O)C(C)(C)CCCNC(=O)[C@H]1C[C@H]1C#N', 'Cc1ncsc1C(C)NC(=O)C1(NC(=O)[C@@H]2[C@H](C#N)C2(C)C)CCC1', 'Cc1ncsc1C(C)Nc1ncnc(NCCC2CCCC2(F)F)n1', 'Cc1ncsc1CC(=O)N[C@H]1CC[C@@H](CC(=O)N(C)CCCO)CC1', 'Cc1ncsc1CCC(=O)NC1CCN(C(=O)CC(F)(F)C(F)F)C1', 'Cc1ncsc1CCCN(C)c1nccc(N2CCCC(C)(C)C2)n1', 'Cc1ncsc1CCNC(=O)C(=O)Nc1cccc(OC(F)(F)F)c1', 'Cc1ncsc1CCNc1nc(NCC2(F)CCC2)nc2cc[nH]c12', 'Cc1ncsc1CCOC(=O)CCc1nc(O)c2cc(F)ccc2n1', 'Cc1ncsc1CN(C)C(=O)C(C)(CO)NC(=O)C1CCN(C)CC1', 'Cc1ncsc1CN(Cc1cn(C)cn1)C[C@]1(F)CC[C@@H](CO)CC1', 'Cc1nn(-c2ccc(Cl)cc2)c(C)c1CC(=O)OCCC1CC(O)C1', 'Cc1nn(-c2ccccc2)c(NC(=O)N2C3CCC2(CO)CC3)c1C', 'Cc1nn(C(C)(C)C)c(C)c1NC(=O)NCC1CCC2(C1)CC2(F)F', 'Cc1nn(C)c(Cl)c1CN(CC(C)(C)CO)C(=O)C1COCC(C)O1', 'Cc1nn(C)c(N)c1C(=O)NCC1CCN1C(=O)c1ncncc1Cl', 'Cc1nn(C)c(NC(=O)c2ccc3c(c2)N(C)CCC3)c1C(F)(F)F', 'Cc1nn(C)c2c(N(C)CCCO)nc(N(C)CCOC3CC3)nc12', 'Cc1nn(C)c2c(N3CCN(c4ccc(F)cn4)CC3)nc(Cl)nc12', 'Cc1nn(C)c2sc(C(=O)Nc3ncc(-c4ccc(F)cc4)s3)cc12', 'Cc1nn(C)cc1C(=O)NC(CC(=O)NCC(=O)NCCO)C(C)C', 'Cc1nn(C)cc1C(=O)N[C@H]1C[C@@H]2C[C@H]1[C@H](NC(=O)C1CC(F)C1)C2', 'Cc1nn(C)cc1CC(=O)NC[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)CCC(N)=O', 'Cc1nn(C)cc1CNC(=O)C1=CCN(C(=O)C(C)(C)C(C)(F)F)C1', 'Cc1nn(C)nc1C(=O)N(C)CCNC(=O)C1CCCn2nccc21', 'Cc1nn(C)nc1C(=O)NCC(C)(C)CN(C)C(=O)CC1C=CCC1', 'Cc1nn(C)nc1C(=O)N[C@@H]1COC[C@H]1CNC(=O)C1=COCCC1', 'Cc1nn(C2CCCCC2)cc1C(=O)N1CCC(C2(O)CCC2)CC1', 'Cc1nn(CC(=O)N2C[C@H](NC(=O)C#CC3CC3)CC[C@H]2C)c(=O)o1', 'Cc1nn(CC(=O)NC2(C(=O)NC3CC(C#N)C3)CC2(C)C)c(=O)o1', 'Cc1nn(CC(=O)NCC[C@H]2C[C@H](NC(=O)C3CCCC3)C2)c(=O)o1', 'Cc1nn(CC(=O)NC[C@H]2C[C@H](C(=O)N3C(C)CC3CO)C2)c(=O)o1', 'Cc1nn2c(c1C(=O)NCc1cc(C(F)(F)F)cnc1Cl)OCCC2', 'Cc1nn2cccnc2c1NC(=O)C(C)(C)c1ccc(Cl)c(C)c1F', 'Cc1nn2cnnc2c(C)c1CCC(=O)O[C@H](C)c1ccc(I)cc1', 'Cc1nnc(C(=O)NC(C)CCN(C)C(=O)c2ccnc(C)c2C)s1', 'Cc1nnc(C(C)NC(=O)C2CN(C(=O)C(C)(C)O)CC23CCC3)o1', 'Cc1nnc(C(C)NC(=O)CCN(CC2CC2)C(=O)C2CCCC2)o1', 'Cc1nnc(C2CCCN2CC(O)COc2cccc([N+](=O)[O-])c2)o1', 'Cc1nnc(C2CCN(C(=O)c3[nH]c4ccccc4c3C#N)CC2)o1', 'Cc1nnc(CC(=O)N(C)CC2CCCN2C(=O)C2CC(C)(C)C2)o1', 'Cc1nnc(CC(=O)Nc2cccc(NC(=O)C3CC34CCC4)c2)o1', 'Cc1nnc(CCCn2cc(CN(C)C(=O)CCN3CCC3)nn2)o1', 'Cc1nnc(CN2CCN(c3nc(-c4cccc(Br)c4)cs3)CC2)s1', 'Cc1nnc(CNC(=O)[C@@H](CO)NC(=O)CC(C)n2cccn2)n1C', 'Cc1nnc(N[C@@H]2CCC[C@@H](NC(=O)C3CCC(S(C)(=O)=O)C3)C2)o1', 'Cc1nnc2ccc(N3CCN(CC4CC5(C4)OCCO5)CC3)nn12', 'Cc1nncc(C(=O)N(CC2=CCCOC2)CC2(Cl)CC2(F)F)c1C', 'Cc1nncc(C(=O)NC[C@H]2C[C@@H](C(=O)NOCCN(C)C)C2)c1C', 'Cc1nnccc1C(=O)N1CCC(C)(CCNC(=O)C(=O)N(C)C)C1', 'Cc1nnccc1C(=O)NCC1CN(C(=O)c2cc(C3CC3)no2)C1', 'Cc1nncn1NC(=O)C(CN(C)C)NC(=O)CC1CC(N(C)C)C1', 'Cc1nnnn1CC(=O)N(C)CC(C)C(=O)NCCN1CC[C@H](O)C1', 'Cc1nnnn1CC(=O)N1CC[C@H]1C(=O)N1CCC(C2(C)CC2)CC1', 'Cc1nnnn1CC(=O)N1[C@@H]2CC[C@H]1C[C@@H](NS(=O)(=O)C1CCC1)C2', 'Cc1nnnn1CC(=O)N[C@]1(C)C[C@H](C(=O)N2CCN(C)[C@@H](C)C2)C1', 'Cc1nnsc1C(=O)NC1CCC(C)(CNC(=O)C2(C3CC3)CC2)C1', 'Cc1nnsc1CN(Cc1ccccc1C(C)C)C(=O)c1ccoc1', 'Cc1noc(-c2ccc(C)c(NC(=O)NC3(c4ccco4)CC3)c2)n1', 'Cc1noc(-c2ccc(NCCN(C)C(C)c3ccccn3)nc2)n1', 'Cc1noc(C)c1/C=C/C(=O)NC1(c2nnc3n2CCCC3)CCC1', 'Cc1noc(C)c1/C=C/CNC(=O)N1Cc2c(Cl)cccc2C(C)C1', 'Cc1noc(C)c1C(=O)NC[C@H](O)CC(=O)Nc1cc(O)cc(F)c1', 'Cc1noc(C)c1CC(=O)NCC1(CNC(=O)/C=C/C(F)F)CCC1', 'Cc1noc(C)c1CC(=O)NCCC(=O)N1CCOC(C2(C)N=N2)C1', 'Cc1noc(C)c1CC(C)C(=O)NNC(=O)Nc1ccc(Cl)cc1Cl', 'Cc1noc(C)c1CN(C)C(=O)C(=O)NC1CCOC2(CCOC2)C1', 'Cc1noc(C)c1CN(C)C(=O)C[C@@H](C)NC(=O)C1C2CCC(F)C21', 'Cc1noc(C)c1CN(C1CC1)S(=O)(=O)c1c[nH]c2cnc(Cl)cc12', 'Cc1noc(C)c1CN(Cc1cc(F)ccc1F)CC1CCC(F)C1', 'Cc1noc(C)c1CNC(c1ncnn1C)c1nnnn1CCCF', 'Cc1noc(C2CCC(NCCN3CCC4CCCCC4C3)CC2)n1', 'Cc1noc(C2CCN(C(=O)Cc3cccc(OCC4CC4)c3)C2)n1', 'Cc1noc(CCCNC(C(=O)N2CCOCC2)c2ccccc2)n1', 'Cc1noc(CCNC(=O)C(NC(=O)CC2CC2)c2ccnn2C)n1', 'Cc1noc(CN(C)C(=O)CC(C)CNC(=O)C2CN(C)C(=O)N2)n1', 'Cc1noc(CNC2(c3nnnn3CC3CC3)CCN(C)C(C)C2)n1', 'Cc1noc([C@]23CCC[C@H]2CN(C(=O)N(C)CC2CCCCC2)C3)n1', 'Cc1nocc1C(=O)N1CCC(C(C)(C)C(=O)N2CC(C)(CF)C2)C1', 'Cc1nocc1C(=O)N1CCOC(CCNC(=O)c2cscc2Cl)C1', 'Cc1nocc1C(=O)N1C[C@@H](F)C[C@H]1CC(=O)NCCc1ccsc1', 'Cc1nocc1C(=O)NCC(C)(F)CNC(=O)CC1CC(=O)NC1=O', 'Cc1nocc1C(=O)N[C@@H]1CC[C@H](CC(=O)NC2(CC(N)=O)CC2)C1', 'Cc1nocc1C(=O)N[C@H]1CCC[C@H]1C(=O)NC1CNC(=O)C1(C)C', 'Cc1nocc1C(C(=O)NC1CCOCC1)N1CCCC(C(F)F)C1', 'Cc1nocc1CCC(=O)N1CCCC1CC(=O)NCCSC(F)F', 'Cc1nonc1CC(=O)N1CCO[C@@H](CNC(=O)C(O)C2CCC2)C1', 'Cc1nonc1CC(=O)NCC(O)C(=O)N1CCc2nncn2CC1', 'Cc1nonc1CC(=O)NCc1cccc(NC(=O)c2cc[nH]n2)c1', 'Cc1nsc(C(=O)N2C[C@H](N=[N+]=[N-])C[C@H]2C(=O)NCC2CC2C)c1N', 'Cc1nsc(C(=O)N[C@H]2CCC[C@H](NC(=O)C#CC(C)(C)C)C2)c1N', 'Cc1nsc(C)c1C(=O)N1CCC(c2csc(N3CCCC3)n2)CC1', 'Cc1nsc(CN(C)C(=O)[C@H](C)N(C)C(=O)CCn2cnc(N)n2)n1', 'Cc1nsc(CNC(=O)C2CCCCN2C(=O)CC2CCCOC2)n1', 'Cc1nsc(N[C@H]2CN(C(=O)Cc3cn(C4CCC4)nn3)C[C@H]2O)n1', 'Cc1nscc1-c1cn(C2CN(C(=O)C(C)Sc3nncs3)C2)nn1', 'Cc1nscc1C(=O)NC(CC(F)F)C(=O)NC(CC(C)C)C(N)=O', 'Cc1nscc1CC(=O)N(C)CCN(C)S(=O)(=O)c1cncc(F)c1', 'Cc1nscc1CC(=O)N(C)[C@@H]1CN(C(=O)C(=O)NC(C)C)C[C@H]1O', 'Cc1nscc1CC(=O)N1CCC(CN(C)C(=O)CCS(N)(=O)=O)C1', 'Cc1nscc1CN(CC(O)C1CCC1)C(=O)c1cccn(C)c1=O', 'Cc1nscc1CN(Cc1ccccc1F)C(=O)c1ncccc1N', 'Cc1nscc1NC(=O)C(CNC(=O)Cc1cncn1C)C(C)(C)C', 'Cc1oc(-c2ccco2)nc1CC(=O)N1CCOC[C@H]1CS(C)(=O)=O', 'Cc1oc(C#N)cc1C(=O)NC(CCC(C)C)C(=O)NCCC(N)=O', 'Cc1oc(C#N)cc1C(=O)NCc1ccc(C(=O)N2CCC[C@@H]2C)s1', 'Cc1oc(C)c(S(=O)(=O)N2CCC(=O)Nc3ccccc32)c1C(=O)O', 'Cc1oc(CNC(=O)C(C)CC#N)nc1C(=O)NC1CC(C2CC2)C1', 'Cc1oc(CNC(=O)C(C)O)nc1C(=O)NCc1ccnc(CO)c1', 'Cc1oc(CNC(=O)C2(C3CC3)CC2)nc1C(=O)N(C)CC(C)(F)F', 'Cc1oc(CNC(=O)c2cnn(C)n2)nc1C(=O)N(C)CC(C)CO', 'Cc1oc(CO)cc1C(=O)N[C@H]1[C@@H]2CN(C(=O)CC3(O)CCC3)C[C@@H]21', 'Cc1oc(Cl)nc1C(=O)N(C)C(C)C(=O)N1CCn2ncc(O)c2C1', 'Cc1oc(Cl)nc1C(=O)N(C)[C@@H](C)CC(=O)NC(C)c1ccccc1', 'Cc1oc2ccccc2c1CNC(=O)CC1COc2ccccc2O1', 'Cc1occc1C(=O)N(CCC1CC=CCC1)Cc1cnc(Cl)n1C', 'Cc1occc1C(=O)N1CCC(F)(CNC(=O)Cc2ccns2)CC1', 'Cc1occc1C(=O)N1CCC2CN(C(=O)C3CCCS3(=O)=O)C2C1', 'Cc1occc1C(=O)N1C[C@H]2CCN(C(=O)c3ccnnc3)[C@H]2[C@@H]1C', 'Cc1occc1CC(=O)N1CC2CC(C(=O)NCc3ncsn3)(C2)C1', 'Cc1occc1CC(=O)N1CCC2(CC2NC(=O)CSCC(N)=O)C1', 'Cc1ocnc1C(=O)COC(=O)c1ccc(Oc2ccccc2)nc1', 'Cc1ocnc1C(=O)N1CC(CNC(=O)c2cccn2C)CC1(C)C', 'Cc1ocnc1C(=O)N1CCC(C(C)NC(=O)CN2CC3CC3C2)C1', 'Cc1ocnc1C(=O)NC/C=C\\CNC(=O)c1cccc(CO)c1C', 'Cc1ocnc1CC(=O)N(CCCCC(C)(F)F)Cc1cccn1C', 'Cc1ocnc1CC(=O)N1CC(F)(F)C[C@H]1C(=O)NC1CC2(CC2)C1', 'Cc1ocnc1CC(=O)N1C[C@H](CNC(=O)CSCC(F)F)[C@@H](C)C1', 'Cc1ocnc1CC(=O)N[C@H]1CCCC[C@H]1CC(=O)N1CC[C@@H](F)C1', 'Cc1ocnc1CC(=O)N[C@H]1CN(C(=O)Cc2nc[nH]n2)C[C@H]1CO', 'Cc1ocnc1CCNC(CCC1CCC1)c1nnnn1CC1CC1', 'Cc1ocnc1CCNc1cccc(C(=O)OCc2ccccc2)n1', 'Cc1ocnc1CCNc1ncnc(NC2CCC(S(C)(=O)=O)C2)n1', 'Cc1onc(-c2cccnc2)c1C(=O)NCc1ncnn1C(C)(C)C', 'Cc1onc(C2CC2)c1C(=O)NCC(C)NC(=O)C[C@@H]1CCC[C@H]1O', 'Cc1onc(N)c1S(=O)(=O)N[C@H](C)CNC(=O)Cc1ccc(Cl)cc1', 'Cc1onc(O)c1S(=O)(=O)N[C@H]1C[C@H](NC(=O)/C=C/c2ccoc2)C1', 'Cc1oncc1C(=O)N1CCC(C)(NC(=O)Cc2ccccc2F)C1', 'Cc1oncc1C(=O)N1CCCC2(CCN(S(=O)(=O)CC3CC3)C2)C1', 'Cc1oncc1C(=O)N1CCCCC1CNC(=O)c1ccc(C#N)o1', 'Cc1sc(-c2ccc(F)cc2F)nc1-c1ccc2c(c1)CC(=O)N2C', 'Cc1sc(-c2ccccc2)nc1C(=O)Nc1nnc2cccc(C)n12', 'Cc1sc(-c2ccco2)nc1C(=O)N1CCN(C(=O)NC(C)C)CC1', 'Cc1sc(CNC(=O)Cc2ccccc2OC(F)(F)F)nc1C(=O)O', 'Cc1sc(Cl)nc1C(=O)N1CCN(C)C(CNc2ncncc2F)C1', 'Cc1sc(NC(=O)C(C)C)c(C(=O)NCC2(N(C)C)CCCC2)c1C', 'Cc1sc(O)nc1C(=O)N(C)C1(C(=O)N2CCC([N+](=O)[O-])CC2)CC1', 'Cc1sc(O)nc1C(=O)N(Cc1cccs1)CC1CCCCC(O)C1', 'Cc1sc(O)nc1C(=O)NC(CC(=O)N(C)CC1CCSC1)C(C)C', 'Cc1sc2cncn2c1CN(CCC1(C)CC1(F)F)Cc1cnc[nH]1', 'Cc1sc2nc(Br)cn2c1C(=O)N1C[C@H](C(=O)O)C[C@@H]2CCCC[C@H]21', 'Cc1sc2ncc(C(=O)N3CCOCC3C3CCCCC3=O)n2c1C', 'Cc1sc2ncnc(SCC(=O)NCCC3=CCN(C)CC3)c2c1C', 'Cc1scc(C(=O)N2CC[C@H]3[C@@H](C2)[C@@H]3NC(=O)C(C)(C)C2CC2)c1C', 'Cc1scc(C(=O)N[C@H]2C[C@@H](C(=O)N(C)C[C@@H]3COC(=O)N3)C2)c1C', 'Cc1scc(C(c2nnnn2C2CCCCC2)N2CCOCC2)c1C', 'Cc1scc(CNC(=O)[C@@H]2C[C@H](C)CCN2C(=O)c2ccsn2)c1C', 'Cc1sccc1C(=O)N1CC2(C)CC1(C(=O)N1C[C@H](C)O[C@@H](C)C1)C2', 'Cc1sccc1CC(=O)N1CCC[C@H]1CN(C)C(=O)Cc1cscn1', 'Cc1sccc1CC(=O)N1C[C@@H](O)C[C@@H]1C(=O)NCC(F)C1CCC1', 'Cc1sccc1CC(=O)NCCCCCN(C)C(=O)[C@@H]1CCN(C)C1', 'Cc1sccc1CN(CCCCC1CC1C)C(=O)C1CC12CCOC2', 'Cc1sccc1NC(=O)C(=O)NCCCn1c(C)cc2ccccc21', 'Cc1scnc1CN(Cc1ccc2c(c1)COC2)CC1CC(F)(F)C1', 'Cc1sncc1C(=O)N1CCCC[C@H]1C(=O)N1CC[C@H](C(C)(C)O)C1', 'Cc1sncc1C(=O)NCC(C)CC(=O)N1CC(C)OCC(C)(C)C1', 'Cc1snnc1C(=O)N1CC=C(CNS(=O)(=O)CC2(C)CC(C)C2)C1', 'Cc1snnc1C(=O)N1CCCCC1CC(=O)N1CCCN(C)CC1', 'Cc1snnc1C(=O)NC[C@H]1C[C@H]1C(=O)NCC1CC2CCC1CC2', 'Cc1snnc1C(=O)N[C@@H]1C[C@H]2C[C@@H](C1)CN(C(=O)C1=NOCC1)C2', 'Cc1snnc1C(=O)N[C@H]1CCCC[C@H]1CNC(=O)C1(C2CC2)CC1', 'Cc1snnc1C(=O)N[C@]12C[C@H]1CN(C(=O)c1ccn(C)c(=O)c1)C2', 'Clc1cc(C(c2nnnn2C2CCC2)N2CCCCCCC2)ccn1', 'Clc1ccccc1-c1noc(NC2Cc3nc4ccccc4n3C2)n1', 'Clc1ccccc1Oc1cccc(CNc2nnc3n2CCCC3)c1', 'Cn1[nH]c(=O)nc1SCCCC1(CNC(=O)OC(C)(C)C)CCCC1', 'Cn1c(=O)[nH]c2cc(C(=O)N[C@H]3/C=C\\CCCC[C@H]3C(=O)O)cnc21', 'Cn1c(=O)cc(N2CCC(NC(=O)N3CCC=C(F)C3)CC2)[nH]c1=O', 'Cn1c(=O)n(C)c2cc(C(=O)NCCCC(=O)NC3CC3)c(Br)cc21', 'Cn1c(Br)cnc1S(=O)(=O)N[C@H]1C[C@@H]1C1CN(C(=O)OC(C)(C)C)C1', 'Cn1c(C#N)ccc1C(=O)NC1CCN(S(=O)(=O)[C@H]2CCOC2)CC1', 'Cn1c(C(=O)N2CC3(CN(C(=O)C4=NNC(=O)C4)C3)C2)cccc1=O', 'Cn1c(C(=O)NC2(CNC(=O)CCc3csc(N)n3)CC2)c[nH]c1=O', 'Cn1c(C(F)(F)F)ccc(NC(=O)N2CC(=O)N3CCCC3C2)c1=O', 'Cn1c(CN(C[C@@H]2CCC[C@H]2O)C(=O)C2(CO)CCOC2)cnc1Cl', 'Cn1c(CN(Cc2cccc(C#N)n2)CC(O)C(C)(C)C)cnc1Cl', 'Cn1c(COC(=O)c2n[nH]c3c2CC(F)(F)CC3)nnc1C(F)(F)F', 'Cn1c(Cl)cnc1CN(CC(CO)CC(C)(C)C)C(=O)C1CC(=O)C1', 'Cn1c(Cl)cnc1CN(Cc1nc(Br)cs1)C[C@@]1(O)C[C@H]2CC[C@@H]1C2', 'Cn1c(Cl)cnc1CNc1nc(NC2CCS(=O)C2)nc2sccc12', 'Cn1c(N)c(C(=O)CN2CC(F)(F)C[C@@H]2C(C)(C)O)c(=O)n(C)c1=O', 'Cn1c(O)nc2ccc(S(=O)(=O)NCC3CC(NS(C)(=O)=O)C3)cc21', 'Cn1c(S)nnc1C(=O)NCC1(CCNc2ncccn2)CC1(F)F', 'Cn1cc(-c2cc(C(=O)NC[C@H]3Cc4ccccc4CO3)on2)cn1', 'Cn1cc(-c2cc(NC(=O)N3CC4(CO)CCC3CC4)n(C)n2)cn1', 'Cn1cc(C(=O)COC(=O)CSc2ccc(Cl)cc2)c2ccccc21', 'Cn1cc(C(=O)N2CC(CNC(=O)c3nnsc3N)C2)c(C2CC2)n1', 'Cn1cc(C(=O)N2CC(NC(=O)c3cc(Cl)ns3)C3(CCC3)C2)cn1', 'Cn1cc(C(=O)N2CCC(c3ccc(O)cc3)C2)c2ccc(F)cc21', 'Cn1cc(C(=O)N2C[C@@H]3[C@H](C2)[C@H]3NC(=O)[C@@H]2CCCN2C(N)=O)nn1', 'Cn1cc(C(=O)NCC2CCCN2C/C=C/c2ccc(Cl)cc2)cn1', 'Cn1cc(C(=O)NNC(=O)CC2C(=O)Nc3ccccc32)ccc1=O', 'Cn1cc(C(NC(=O)C2C3COCC32)C(=O)N2C[C@@H]3C[C@H]2CS3)cn1', 'Cn1cc(C(NC(=O)CCCC#N)C(=O)N2C[C@H]3CSC[C@H]3C2)nn1', 'Cn1cc(C(NC(=O)[C@@H]2COCCO2)C(=O)NC23CC(F)(C2)C3)nn1', 'Cn1cc(C(NC(=O)[C@@H]2[C@H](C#N)C2(C)C)C(=O)N2CCC2(C)C)nn1', 'Cn1cc(C(NC(=O)c2cccn3nncc23)c2ccccc2)cn1', 'Cn1cc(C(NCc2cccc(OC(F)(F)F)c2F)C2CCC2)cn1', 'Cn1cc(C2=CCCN(C(=O)/C=C/COCc3ccccc3)C2)cn1', 'Cn1cc(C2CCCCN2C(=O)Nc2nc3c(n2C)CCCC3)cn1', 'Cn1cc(C2CCN(C(=O)c3cc(Br)nn3C3CCCCO3)C2)cn1', 'Cn1cc(C2CN(C(=O)c3cccc(C4CCCC4)c3)CCO2)cn1', 'Cn1cc(CC(=O)N2CCC[C@@H]2CNC(=O)CC2CCSCC2)cn1', 'Cn1cc(CC(=O)NCC(O)CNc2nc3ccc(Cl)cc3o2)cn1', 'Cn1cc(CC(=O)N[C@@H]2CCC[C@@H](C(=O)N3CCCC(O)C3)C2)cn1', 'Cn1cc(CC(=O)N[C@H]2CCC[C@@H](C(=O)N3CCCC(F)C3)C2)cn1', 'Cn1cc(CCC(=O)N2CC3(CCN(C(=O)OC(C)(C)C)C3)C2)cn1', 'Cn1cc(CCC(=O)NCC(C)(C)NC(=O)CCC2CC2(C)C)nn1', 'Cn1cc(CCCCNC(=O)C2CCC(OCCC3CC3)CC2)cn1', 'Cn1cc(CCNC(=O)CC(NC(=O)C2CCCCS2)C2CC2)cn1', 'Cn1cc(CCNC(=O)Nc2ccc(F)c([N+](=O)[O-])c2)c(C(F)F)n1', 'Cn1cc(CCNC(=O)[C@@H]2CSCN2C(=O)C(=O)NCC(F)F)nn1', 'Cn1cc(CN(CC2CCCCO2)C(=O)CCN2CCOCC2)nn1', 'Cn1cc(CN(Cc2ccc(CC#N)cc2)CC2CC=CC2)c(Br)n1', 'Cn1cc(CN(Cc2ccc(OC(F)F)cc2F)CC(F)F)c(Cl)n1', 'Cn1cc(CNC(=O)NCCOCCS)c(-c2ccc(C#N)cc2)n1', 'Cn1cc(CNc2cccc(-c3ncnn3C)c2)c(C2CCCC2)n1', 'Cn1cc(CO)c(CNC(=O)C(C)(C)NC(=O)c2cc(O)ccn2)n1', 'Cn1cc(COC(=O)C(F)Cc2ccccc2)c2ccccc2c1=O', 'Cn1cc(Cl)c(C(=O)N2CCC3(CC3C(=O)N3CC(CCO)C3)C2)n1', 'Cn1cc(Cl)cc1C(=O)N1C(C(=O)N2CCC(F)CC2)CCC12CC2', 'Cn1cc(N)c(C(=O)N2CC(CO)C(NC(=O)c3sccc3F)C2)n1', 'Cn1cc(N2CC(C(=O)Nc3ncnc4c3COCC4)CC2=O)cn1', 'Cn1cc(N2CC(NC(=O)N3CCS(=O)C(C)(C)C3)CCC2=O)cn1', 'Cn1cc(NC(=O)C(=O)N2CC3(CC3)C[C@H]2CO)c(OCC(F)F)n1', 'Cn1cc(NC(=O)[C@@H]2CC[C@H](NC(=O)CCc3cn[nH]c3)C2)c(Cl)n1', 'Cn1cc(Oc2nccnc2C(=O)N[C@H](CO)C2CCCCC2)cn1', 'Cn1cc(S(=O)(=O)CCNC(=O)Nc2ccc3c(c2)C(=O)NC3)cn1', 'Cn1cc(S(C)(=O)=NC(=O)C(F)(F)c2cc(F)cc(F)c2)c(CN)n1', 'Cn1cc(S(N)(=O)=O)c(CNC(=O)c2cc(F)cc(OC(F)F)c2)n1', 'Cn1cc(SCC(=O)NCC2OCc3cc(C(F)(F)F)ccc32)cn1', 'Cn1cc([C@@H]2C[C@H]2NC(=O)c2ccc3ccn(CC(F)F)c3c2)cn1', 'Cn1cc2c(n1)C(C(=O)Nc1cc3c(cc1F)NC(=O)CC3)CCC2', 'Cn1cc2c(n1)CCN(c1c(NCCCC3CC3(Cl)Cl)c(=O)c1=O)C2', 'Cn1cc2cccc(C(=O)Nc3ccnn3Cc3ccccc3)c2n1', 'Cn1ccc(C(=O)NC(CCNS(=O)(=O)C2CS(=O)(=O)C2)C(F)F)c1', 'Cn1ccc(C(=O)NC2CC3(C2)CN(C(=O)C#CC2CCCC2)C3)n1', 'Cn1ccc(C(=O)N[C@H](CC(=O)N[C@H]2C[C@H]3OCCC[C@@H]23)C2CC2)c1', 'Cn1ccc(C(=O)N[C@H]2COC[C@H]2NC(=O)C(F)C(C)(C)O)cc1=O', 'Cn1ccc(CC(=O)NN2CCC[C@H]2C(=O)NC2(C)CC(F)(F)C2)c1', 'Cn1ccc(CC(=O)N[C@@H]2CCC[C@@H](NC(=O)C3(F)CCCC3)C2)n1', 'Cn1ccc(CCC(=O)NC2CCCN(C(=O)OC(C)(C)C)CC2)n1', 'Cn1ccc(CN(Cc2csc(Cl)n2)CC23CCCC2CC3)cc1=O', 'Cn1ccc(CNC(=O)NC2(Cc3ccccc3)CC(O)C2)cc1=O', 'Cn1ccc(NC(=O)CN(CC2CC2)C(=O)C2CN3CCC2CC3)n1', 'Cn1ccc2c(NCC3=CCN(C(=O)COC(F)(F)F)C3)ncnc21', 'Cn1ccc2cc(C(=O)N[C@H]3C[C@H]3NC(=O)C3CCCOC3)cnc21', 'Cn1ccc2ccc(C(=O)NNC(=O)c3cccc4[nH]ncc34)cc21', 'Cn1ccc2ccc(NC(=O)NCc3nnc(N4CCCC4)o3)cc21', 'Cn1ccc2nc(CNC(=O)c3cccn(CC(F)(F)F)c3=O)cn21', 'Cn1cccc(C(=O)NCC2CCN2C(=O)C2CCCN2N=O)c1=O', 'Cn1cccc1C(=O)NC[C@H]1C=C[C@@H](NC(=O)C2CCCN2N=O)C1', 'Cn1cccc1CCc1cn(CCOc2ccc([N+](=O)[O-])cc2)nn1', 'Cn1ccnc1-c1cccc(NC(=O)C(F)(F)c2cccc(F)n2)c1', 'Cn1ccnc1C(=O)N1CC(O)(CNC(=O)CN2CCCCC2=O)C1', 'Cn1ccnc1C(=O)N1CC[C@H](O)C[C@@H]1C(=O)N1CCC(C)(CO)C1', 'Cn1ccnc1C(=O)NC[C@H]1CCCC[C@H]1C(=O)NCCC1(C)N=N1', 'Cn1ccnc1C(NC(=O)NCCCCCS(C)(=O)=O)C(C)(C)CO', 'Cn1ccnc1C(NCc1ccnn1C1CCC1)c1ccc(F)cc1', 'Cn1ccnc1CC(=O)N1CCC(C(=O)NC2CCCCNC2=O)C1', 'Cn1ccnc1CC(NC(=O)c1c2n(c(=O)n1C)CCCC2)C(=O)O', 'Cn1ccnc1CCC(=O)NC[C@H]1C=C[C@@H](NC(=O)C2(O)COC2)C1', 'Cn1ccnc1CCC(=O)NCc1cn[nH]c1C(=O)Nn1ccnn1', 'Cn1ccnc1CCNC(=O)C1CNC(=O)CN1C(=O)C1CC=CC1', 'Cn1ccnc1[C@@H]1OCCC[C@H]1C(=O)NC(CO)CC1CCCCO1', 'Cn1ccnc1[C@@H]1OCC[C@H]1NS(=O)(=O)CC12CCC(CC1)C2(C)C', 'Cn1cnc(-c2ccc(C(=O)OCC(=O)C3C(C)(C)C3(C)C)cc2)n1', 'Cn1cnc(-c2ccc(F)cc2)c1NC(=O)CCCCCS(N)(=O)=O', 'Cn1cnc(-c2cn(CCCNC(=O)CC(=O)OC(C)(C)C)nn2)c1', 'Cn1cnc(C(=O)NC(C(=O)Nc2ccc(CO)nc2)C2(C)CC2)n1', 'Cn1cnc(C(=O)NC2(C)CN(C(=O)c3ccn4nccc4c3)C2)c1', 'Cn1cnc(C(=O)NCC2COC(CNC(=O)c3cnccn3)C2)n1', 'Cn1cnc(C(=O)NCc2ccoc2C(=O)N[C@H]2CCC[C@H]2CO)c1', 'Cn1cnc(C(=O)N[C@H]2C[C@H]3C[C@H](NC(=O)C4(CO)CCC4)C[C@H]32)c1', 'Cn1cnc(C(=O)N[C@]2(C(=O)N[C@]3(C)C[C@H](N(C)C)C3)C[C@H](O)C2)c1', 'Cn1cnc(C2CCCN(C(=O)c3cc4cc(Br)ccc4cn3)C2)n1', 'Cn1cnc(C=C(F)C(=O)N[C@H]2C[C@H]2NC(=O)CN2CC(C)(C)C2)c1', 'Cn1cnc(C=CC(=O)N2C[C@H](F)C[C@H]2C(=O)NC[C@H]2C[C@H](O)C2)c1', 'Cn1cnc(C=CC(=O)NC2(CCNC(=O)c3cnns3)CCC2)c1', 'Cn1cnc(CCC(=O)N(CC(=O)NCCc2cc[nH]n2)C2CC2)c1', 'Cn1cnc(CCC(=O)NC2(CCNC(=O)C3CC34CC4)CCC2)c1', 'Cn1cnc(CCCNC(=O)C(=O)Nc2ccnn2C2CCCC2)c1', 'Cn1cnc(CN(CCCCC(C)(F)F)C(=O)C(O)c2ccsc2)c1', 'Cn1cnc(CNC(=O)C2C=CCN(C(=O)c3ccc(F)cn3)C2)c1', 'Cn1cnc(CNC(=O)C[C@@H]2CCN(C(=O)c3cc(CO)[nH]n3)C2)c1', 'Cn1cnc(S(=O)(=O)NCC(=O)Nc2ncc(-c3cccnc3)o2)c1', 'Cn1cnc2c1CC(C(=O)Nc1cc(Br)cc3c1NC(=O)CO3)CC2', 'Cn1cnc2c1CCC(C(=O)N1CCCC[C@H](N3CCOCC3)C1)C2', 'Cn1cnc2c1CN(C(=O)C1CCCC1CNC(=O)C(C)(C)C)CC2', 'Cn1cnc2cc(NC(=O)c3csc(NC4CCCCC4)n3)ccc21', 'Cn1cncc(C(=O)NC(C(=O)NOCC(C)(C)O)C2(C)CC2)c1=O', 'Cn1cncc1C(CO)NC(=O)CSCCNC(=O)C1(C)CC=CC1', 'Cn1cncc1CNc1ccc(Oc2cccc(C(F)(F)F)c2)cc1', 'Cn1cnnc1C1CCN(C(=O)c2ccn(-c3ccc(Cl)cc3)n2)C1', 'Cn1cnnc1CNC(=O)C1=CCC2CCC1N2C(=O)C1CC1(Cl)Cl', 'Cn1cnnc1[C@@H]1CCCN1C(=O)C(=O)NCc1nc(Cl)ccc1Cl', 'Cn1nc(-c2ccccc2)nc1COC(=O)c1cc2ncnn2cn1', 'Cn1nc(Br)c2c(NNC(=O)c3ccc4[nH]nc(Cl)c4c3)ncnc21', 'Cn1nc(Br)c2ccc(C(=O)OCC(O)COCC3CCCO3)cc21', 'Cn1nc(C(=O)N2CCC23CN(C(=O)Cc2cn[nH]c2)C3)ccc1=O', 'Cn1nc(C(=O)N2CCCC2C(=O)N2CCC3(CCSC3)C2)cc1Cl', 'Cn1nc(C(=O)N2CCOC3(CCCCC3)C2)c2ccccc2c1=O', 'Cn1nc(C(=O)N2CC[C@@H](CNC(=O)c3cc[nH]c(=O)c3)C2)cc1O', 'Cn1nc(C(=O)NC[C@H]2C[C@@H](n3cccn3)C2)c2c1CCC(C)(C)C2', 'Cn1nc(C(=O)NCc2cc(=O)[nH]c3ccccc23)c2c1CCSC2', 'Cn1nc(C(=O)NCc2cc(C(=O)NOC3CC3)ccn2)cc1C#N', 'Cn1nc(C(=O)NN2CCC[C@H]2C(=O)NCC2CC(F)C2)ccc1=O', 'Cn1nc(C(=O)OCCCC(F)(F)C(F)(F)F)c(=O)c2ccccc21', 'Cn1nc(C(F)(F)F)cc1NC(=O)c1cnc2c([N+](=O)[O-])cnn2c1', 'Cn1nc(C(F)F)nc1CNC(=O)N1CCCCC1c1cccnc1', 'Cn1nc(C2CC2)nc1CC(=O)OCc1cc2c(nc1Cl)CCOC2', 'Cn1nc(C2CCCCC2)cc1NC(=O)c1cc2c(s1)CCNC2=O', 'Cn1nc(CC(=O)N2C[C@H](NC(=O)[C@H]3[C@@H]4CCC[C@@H]43)[C@@H](O)C2)cc1Cl', 'Cn1nc(CC(=O)NCC2(C3CCCCC3)CCCCC2)ccc1=O', 'Cn1nc(CN(CC23CCC(CO2)C3)C(=O)C2(CO)COC2)cc1Cl', 'Cn1nc(CN2CCn3nc(-c4ccccc4)cc3C2)nc1C(=O)O', 'Cn1nc(CNC(=O)C(C)(C)c2cccc(C#N)c2)cc1C(F)(F)F', 'Cn1nc(CNC(=O)NCc2cc(Cl)cc(Cl)c2OC(F)F)nc1Br', 'Cn1nc(CNc2ncnc(N3CCC(C4CCCC4)C3)n2)cc1Cl', 'Cn1nc(CO)c2c1CCN(C(=O)NC1CCCC13CC(F)(F)C3)C2', 'Cn1nc(Cl)cc1CN(CC1(F)CCOC1)C(=O)[C@H]1C[C@H]2C=C[C@@H]1O2', 'Cn1nc(N)c2ccc(C(=O)NCC3CCCC34CCNCC4)cc21', 'Cn1nc(NC(=O)CCCNC(=O)CN2CCSCC2)cc1C(N)=O', 'Cn1nc(O)cc1C(=O)N1CCC2(CC(C(=O)NCC(C)(C)C)C2)C1', 'Cn1nc(O)cc1C(=O)NCC1(C(=O)N2CCC3(CCSC3)C2)CC1', 'Cn1nc2ccccc2c1CNc1ccn(Cc2ccc(F)cc2)n1', 'Cn1ncc(C#N)c1C(=O)N1CC(C)(C)c2cc(C(F)(F)F)ccc21', 'Cn1ncc(C(=O)NC/C=C/CC(=O)NC[C@@H]2[C@H]3CCCO[C@H]32)c1N', 'Cn1ncc(C(=O)NCCCC(=O)NCCCCC2CCCC2)c1N', 'Cn1ncc(C(=O)NCCOCCC(=O)NCc2cc(Cl)no2)c1N', 'Cn1ncc(C(=O)NCc2cn3c(Br)cccc3n2)c1-n1cccc1', 'Cn1ncc(Cl)c1C(=O)N1CCC(F)(C(=O)N[C@@H]2CNC(=O)OC2)C1', 'Cn1ncc(Cl)c1C(=O)N[C@H](CC(=O)Nc1cnccc1O)C1CC1', 'Cn1ncc2c(COC(=O)C(C)(C)Nc3ccc(Cl)cc3)cccc21', 'Cn1ncc2c1CC(C(=O)NNc1cccc(C(F)(F)F)c1F)CC2', 'Cn1ncc2c1CN(C(=O)CC1COCCN1C(=O)C1CCCC1)C2', 'Cn1ncc2cccc(CN(C=O)CC(C)(C)N3CCCS3(=O)=O)c21', 'Cn1ncc2ncc(C(=O)NC[C@H]3C[C@H]4CCC[C@@H](C3)C4(F)F)cc21', 'Cn1nccc1C(=O)N[C@H]1C[C@@H](CC(=O)N2CCC(=C(F)F)CC2)C1', 'Cn1nccc1C1(NC(=O)C2CCN(S(=O)(=O)C(F)F)CC2)COC1', 'Cn1nccc1C1=CCN(Cc2coc(-c3ccccc3F)n2)CC1', 'Cn1nccc1C=CC(=O)N1CCN(C(=O)c2csnn2)CC12CC2', 'Cn1nccc1C=CC(=O)N[C@@H](CC(=O)NCC(F)(F)Cl)CC1CC1', 'Cn1nccc1CC(=O)N1CCO[C@@H](C(=O)NCCc2ccsc2)C1', 'Cn1nccc1CC1CCN(Cc2nc3c(F)cc(F)cc3o2)CC1', 'Cn1nccc1CCNc1ncccc1S(=O)(=O)N1C[C@H](O)[C@@H](F)C1', 'Cn1nccc1CN(C(=O)NCc1ccnc(NC2CC2)c1)C1CC1', 'Cn1nccc1N1CCCC(NC(=O)NNc2ccc(Br)cn2)C1=O', 'Cn1ncn(NC(=O)[C@@H]2CCCN2NC(=O)C(O)C2CCCC2)c1=S', 'Cn1ncnc1C1(O)CN(C(=O)Nc2cccc(-n3cccn3)c2)C1', 'Cn1ncnc1C1COCCN1C(=O)c1c[nH]c2cccc(C#N)c12', 'Cn1ncnc1CCC(=O)NCCCNC(=O)[C@@H]1C[C@H]1CC(C)(C)C', 'Cn1ncnc1CNC(=O)CN1CCN(C(=O)C2(C)CC(=O)C2)CC1', 'Cn1nnc(CN(CCC2(O)CCCC2)C(=O)C(F)(F)C(C)(C)O)n1', 'Cn1nnc(COC(=O)C(CNC(=O)OC(C)(C)C)CC(C)(C)C)n1', 'Cn1nnc2cc(CNC[C@]3(CO)CC[C@H]3c3ccccc3)ccc21', 'Cn1nnc2ccc(C(=O)N[C@@H](CCc3ccccc3)C(=O)O)nc21', 'Cn1nncc1C(=O)N1C[C@H](O)C[C@@H]1C(=O)NCCC1(C)CC1(F)F', 'Cn1nncc1C(=O)NC1CCCC(NC(=O)C(F)(F)C(F)(F)F)C1', 'Cn1nncc1C(=O)NC[C@H]1C[C@H]1CC(=O)N1CCC(C)(CO)CC1', 'Cn1nncc1CCNC(=O)C(CC1CC1)NC(=O)Cc1ccoc1', 'Cn1nncc1CN(CC1(C)CCCS1)C(=O)[C@@H]1CC[C@H](CC#N)C1', 'Cn1nncc1CN(CC1CCCSCC1)C(=O)C[C@@H]1CCC[C@H]1O', 'Cn1nncc1CN(Cc1c[nH]c2cnccc12)CC1CC(Cl)(Cl)C1', 'Cn1nncc1CNC(=O)C1CC=CCN1C(=O)C1CC(C2CC2)C1', 'Cn1nncc1NC(=O)NCc1ccc(-n2ccc(C3CC3)n2)cc1', 'Cn1nnnc1C(c1cn2cc(F)ccc2n1)N1C[C@H]2C[C@@H]1CS2=O', 'Cn1nnnc1C1(NC(C)(C(N)=O)c2ccccc2)CCC(=O)NC1', 'Cn1nnnc1C1(NCc2cc(F)cc(Cl)c2)CC[C@H]2CCC[C@H]2C1', 'Cn1nnnc1CCCNC(=O)Nc1cccnc1OCC(F)(F)F', 'Cn1nnnc1CNCc1ccc2c(c1)CCN2C(=O)OC(C)(C)C', 'Cn1nnnc1SCC(=O)NNC(=O)c1cc2cc(Cl)ccc2n1C', 'FC(F)(F)C(F)(F)Oc1cccc(-n2cc(COC3CNC3)nn2)c1', 'FC(F)(F)COCCN(C/C=C/c1ccco1)CCC1CCOCC1', 'FC(F)(F)c1ccc(CN(CC2CCCSC2)CC2CC23CC3)nc1', 'FC(F)C(F)(F)CNc1ncnc(N2CCC(OCC3CC3)CC2)n1', 'FC(F)Cn1nnnc1C(c1c[nH]nn1)N1CCC[C@H]2OCC[C@H]2C1', 'FC(F)OC1CCC(Nc2ccccc2OCC2CCCCO2)CC1', 'FC1(CNc2nc(NCC3CSCCO3)c3ccccc3n2)CCC1', 'FCCCNc1nc(NCCOC2CCSCC2)c2ncccc2n1', 'FCCCn1nnnc1C1(N[C@@H]2CCC[C@H]2F)CC2CC=CCC2C1', 'Fc1cc(Cl)cc(NC2(c3nnnn3C3COC3)CCCCC2F)c1', 'Fc1ccc(-c2n[nH]cc2CNCCCCn2cc(Br)cn2)cc1Cl', 'Fc1ccc(-n2cc(CNCc3ccc4c(c3)OCCO4)cn2)cc1', 'Fc1ccc(NC2CNC(c3ccccc3)C2)cc1OCC(F)(F)F', 'Fc1ccc(OC2CCN(Cc3cnn(CC(F)(F)F)c3)CC2)nc1', 'Fc1ccc(Oc2nc3ccccc3n3nnnc23)cc1OC(F)F', 'Fc1ccc(SCCNCc2c(F)cccc2OCC(F)(F)F)cc1', 'Fc1ccc2nc(NCCOc3ccc(C(F)(F)F)nc3)ncc2c1', 'Fc1cccc(-n2cccn2)c1NCc1ccc(C2OCCO2)cc1', 'Fc1cccc2c(C(NC3CCC3)c3nnnn3C3COC3)n[nH]c12', 'Fc1cccc2c1CN(c1ncnc3cc(C(F)(F)F)ccc13)CC2', 'N#CC(C(=O)c1cnn(C2CC2(F)F)c1)c1nccc2ccccc12', 'N#CC1(C(=O)NCC2(C(=O)NCC[C@H]3CCC(=O)N3)CC2)CC(=O)C1', 'N#CC1(C(=O)N[C@H]2C[C@]3(C(=O)NC4CCC4)CO[C@H]2C3)CCCOC1', 'N#CC1(C2CCCC2)CCN(S(=O)(=O)c2cnn(CC(F)F)c2)CC1', 'N#CC1(CCN(CCOc2ccc(F)cc2F)CC2CCOC2)CC1', 'N#CC1(CN(CCC2CC2(Cl)Cl)Cc2ccc([N+](=O)[O-])cn2)CCC1', 'N#CC1(F)CN(C(=O)C(CC2CC2)NC(=O)C2CC3CC(=O)C2O3)C1', 'N#CC1(F)CN(C(=O)C2(CNC(=O)C3CCCN3C3CC3)CCC2)C1', 'N#CC12CC(C(=O)NC(CNC(=O)c3cnc[nH]3)C3CCOC3)(C1)C2', 'N#CC1=C(C(=O)N(CCC(=O)N2CCC2C2CCC2)C2CC2)CCC1', 'N#CC1=C(C(=O)N2CCC=C(CNC(=O)Cc3ccno3)C2)CCC1', 'N#CC1CC2(CNC(=O)c3cc4cc5c(cc4[nH]3)OCCO5)CC1C2', 'N#CC1CCC(S(=O)(=O)NCCCNC(=O)/C=C\\C(=O)NC2CC2)C1', 'N#CC1CCCC1NC(=O)[C@H](O)CCNC(=O)COCC1CCCO1', 'N#CC1CCCN(c2cc(N3CCCC4(CC=CCC4)C3)ncn2)C1', 'N#CCC(C(=O)Nc1cc(F)ccc1-n1ccnc1)c1ccccn1', 'N#CCC1(C(=O)N(Cc2cn(C3CC3)cn2)CC2CCSCC2)CC1', 'N#CCCCCC(=O)N1CCCC1C(=O)NC1CCC2(CCCC2)C1', 'N#CCCCCC(=O)N1C[C@H](O)C[C@@H]1C(=O)NCC1(F)CCCCC1', 'N#CCCCCC(=O)NCC1(NC(=O)c2ccc(=O)[nH]c2)CCCC1', 'N#CCCCNc1nc2c(c(NCCc3ccnc(O)c3)n1)CCC2', 'N#CCCN(CC(F)(F)F)C(=O)c1ccc(NC(=O)NC2CC2)cc1', 'N#CCCN(CCN1CCOCC1)Cc1cccc(F)c1C(F)(F)F', 'N#CCCN(CCN1CCOCC1)Cc1ccnc2c(Br)cccc12', 'N#CCCSCC(=O)N(C[C@H]1C[C@@H]1c1cccs1)CC1(C2CC2)CC1', 'N#CCCSCC(=O)N1CSC[C@H]1C(=O)NCc1ccnc(CO)c1', 'N#CCCn1cc(CN2CCCC3(CC=CCO3)C2)c2ccccc21', 'N#CCc1ccc(CNS(=O)(=O)c2cc([N+](=O)[O-])ccc2C#N)cc1', 'N#CCc1cccc(C(=O)N[C@H]2C[C@@H](CCC(=O)NC3CCC3)C2)c1', 'N#CCc1ccsc1C(=O)N1CCCN(C(=O)[C@@H]2CNC(=O)O2)CC1', 'N#C[C@H]1CC[C@H]1C(=O)N[C@H]1CC[C@H](CNC(=O)C2CS(=O)(=O)C2)CC1', 'N#C[C@H]1C[C@@H]1C(=O)NCc1ccc(C(=O)N[C@]23CC[C@H](C[C@@H]2O)C3)s1', 'N#C[C@]12CN(C(=O)C3(c4c(Cl)cccc4Cl)CC3)C[C@H]1CS(=O)(=O)C2', 'N#Cc1c(F)ccc(Br)c1CN1CCN(C(=O)c2cc(Cl)c[nH]2)CC1', 'N#Cc1c(O)nsc1SCC(=O)N1CCNC(=O)c2ccc(Br)cc21', 'N#Cc1c[nH]c(C(=O)N2CC(C3(NC(=O)c4ccc(Cl)s4)CC3)C2)c1', 'N#Cc1cc(Br)nc(NC(=O)c2ccc(NC(=O)C3CCC3)cc2)c1', 'N#Cc1cc(Br)ncc1N1CCN(c2nc(N)nc(C3CC3)n2)CC1', 'N#Cc1cc(C(=O)N[C@H]2CC[C@H](C(=O)NCc3ccns3)CC2)c[nH]1', 'N#Cc1cc(CN(CC2C3CCCC32)C(=O)Cn2cc(Cl)cn2)cs1', 'N#Cc1cc(Cl)cnc1N1CCN(CC(O)C2(O)CCCCC2)CC1', 'N#Cc1cc(NC(=O)NCC2(C3=CCOCC3)CCC2)c(Cl)cc1F', 'N#Cc1cc(NCc2ccc3cc(F)c(F)cc3n2)ccc1C1CC1', 'N#Cc1cc(Nc2nc3cc(F)ccc3s2)ccc1OCC(F)(F)F', 'N#Cc1ccc(C(=O)NCC2CCCCN2C(=O)C2CC=CC2)nc1', 'N#Cc1ccc(C(=O)NNC(=O)Cn2ccc(C(F)(F)F)n2)cc1Cl', 'N#Cc1ccc(CCC(=O)NC2CCc3cc(CN)ccc32)c(F)c1', 'N#Cc1ccc(CNC(=O)N2CCC3(CC2)OC[C@H](O)[C@@H]3O)c(F)c1', 'N#Cc1ccc(CNC(=O)Nc2cc(F)cc3c2CNC3=O)c(Br)c1', 'N#Cc1ccc(NC(=O)CCCOC(=O)CCCOC(F)(F)F)cc1', 'N#Cc1ccc(NC2CC2)c(NC(=O)c2cc(F)cc3cc[nH]c23)c1', 'N#Cc1ccc(NC2COCCCN(C(=O)Cc3ccns3)C2)nn1', 'N#Cc1ccc(NCC23COC(c4ccccc4)(C2)C3)cc1[N+](=O)[O-]', 'N#Cc1ccc(NCCCCCOC2CCCCC2)c(S(N)(=O)=O)c1', 'N#Cc1ccc(S(=O)(=O)N2CCN(C(=O)Cc3cnoc3)CC2)cc1', 'N#Cc1ccc2ncc(C(=O)N3CCOc4cccc(Br)c4C3)n2c1', 'N#Cc1cccc(C(F)(F)C(=O)NCCSCc2ccccc2F)c1', 'N#Cc1cccc(C2(C(=O)OCC(O)COCc3cccs3)CC2)c1', 'N#Cc1cccc(NC2CCN(c3ncnc4ccc(O)cc34)C2)c1', 'N#Cc1cccc(OC2CN(C(=O)c3cccc(C(N)CO)c3)C2)c1', 'N#Cc1cccc2c1CCN(C(=O)c1cnn(C3CCCNC3)c1)C2', 'N#Cc1ccccc1CCNc1ccnc(NCC2CC3(CC3)C2)n1', 'N#Cc1ccccc1CNC(=O)C1(c2ccc(Cl)c([N+](=O)[O-])c2)CC1', 'N#Cc1ccccc1N1CCCN(C(=O)NCCC2CCOC2)CC1', 'N#Cc1cccn(CC(=O)OCC(=O)Cc2c(F)cccc2F)c1=O', 'N#Cc1cccnc1N1CCN(C(=O)C(=O)NCCNC2CC2)CC1', 'N#Cc1ccncc1C(=O)N[C@H]1C[C@@H](C(=O)N2CC(CO)(CO)C2)C1', 'N#Cc1cncc(C(=O)N[C@H]2CC[C@@H]2Nc2nc(C(F)(F)F)ns2)c1', 'N#Cc1cnn(-c2cccc(-c3cnn(-c4ccccc4)n3)c2)c1N', 'N#Cc1csc(C(=O)N2CCCC2CNC(=O)CCCNC(N)=O)c1', 'N#Cc1oc2ccccc2c1NC(=O)CN1CCCC1c1cnco1', 'N#Cc1sccc1COC(=O)c1cnn(-c2cc(F)ccc2Cl)c1N', 'NC(=O)C(F)(F)C1(O)CCN(C(=O)c2occc2-c2ccccc2)C1', 'NC(=O)C1(C(=O)N(Cc2cncc(Cl)c2)CC23CCC(CO2)C3)CC1', 'NC(=O)C1(CNC(=O)NC2CCCN(c3cnccn3)C2)CCCC1', 'NC(=O)C1(NC(=O)C2(CCNC(=O)c3ccc(CO)cc3)CC2)CC1', 'NC(=O)C1(Nc2ccccc2)CCN(C(=O)CCC2CCCS2)CC1', 'NC(=O)C1CCN(C(=O)C2(CNC(=O)C3SCCS3)CC3(CC3)C2)C1', 'NC(=O)C1COC2(CCN(Cc3nnc(C4CCCOC4)o3)CC2)C1', 'NC(=O)C1COCCN1C(=O)C[C@H]1C[C@H]1CNC(=O)c1cncnc1', 'NC(=O)CC(Nc1ccncc1S(=O)(=O)N[C@]12CCC[C@H]1C2)C1CC1', 'NC(=O)CC1(O)CCCN(c2cc(Cl)c(C(F)(F)F)cc2[N+](=O)[O-])C1', 'NC(=O)CCC(=O)N[C@H]1C[C@@H](OCC(=O)N2CCCCCC2CO)C1', 'NC(=O)CCCCC(=O)N1CC(F)(F)C[C@H]1C(=O)NCCC(F)(F)F', 'NC(=O)COCCNC(=O)CN(C(=O)C=Cc1ccco1)C1CCC1', 'NC(=O)CONC(=O)[C@@H](NC(=O)C[C@H]1C[C@@H]1C1CC1)C1CCCCC1', 'NC(=O)CONC(=O)[C@]12CCC[C@H]1N(C(=O)c1cc[nH]c(=O)c1)CC2', 'NC(=O)CSCC(=O)N[C@H]1C[C@@H](CC(=O)N2CCc3sccc3C2)C1', 'NC(=O)C[C@@H](O)C(=O)N[C@H]1C[C@@H]2C[C@H]1C[C@@H]2C(=O)NCC1C=CCC1', 'NC(=O)C[C@H](NC(=O)CCCC(F)(F)F)C(=O)NC1CC2CCC1C2', 'NC(=O)C[C@H](NC(=O)c1ccoc1)C(=O)NCCN1CC2CCC1C2', 'NC(=O)N1CC(NC(=O)C2CCN(C(=O)CCOC3CC3)CCO2)C1', 'NC(=O)NCC(=O)N1CCCC2C1CCCN2C(=O)c1cn[nH]c1Cl', 'NC(=O)NCC(=O)NCc1cccc2c1CN(C(=O)C1(F)CCC1)C2', 'NC(=O)NCCC(=O)N1C[C@H](F)C[C@H]1CNC(=O)C1CCCS1(=O)=O', 'NC(=O)NCCCC(=O)NC[C@H]1C[C@H]1C(=O)N1CCC2(CCCO2)C1', 'NC(=O)OCCc1cn(CCC(=O)NC2CCc3cccnc32)nn1', 'NC(=O)[C@@H]1CN(C(=O)[C@@H]2CCN2C(=O)COCC2CCOC2)CCO1', 'NC(=O)[C@@H]1C[C@H](O)CCN1C(C(=O)NC1CCCCC1)c1ccsc1', 'NC(=O)[C@H](Cc1ccc(O)c(O)c1)NC(=O)c1cc(Cl)cc(Br)c1N', 'NC(=O)[C@H]1CC[C@@H](C(=O)N(CC(=O)NOC2CCCCC2)C2CC2)C1', 'NC(=O)[C@H]1C[C@H]1C(=O)N1CCC(C(=O)N[C@H]2C[C@H](O)C[C@@H]2O)C12CC2', 'NC(=O)[C@H]1C[C@H]1C(=O)N1CC[C@H](CC(=O)NCCCc2cccs2)C1', 'NC(=O)c1c[nH]c(C(=O)N[C@H]2C[C@@H](C(=O)N3OC4C=CC3CC4)C2)c1', 'NC(=O)c1ccc(C(=O)N[C@H]2CC[C@@H]2NC(=O)[C@H]2[C@@H]3CCCC[C@@H]32)o1', 'NC(=O)c1ccc(F)c(S(=O)(=O)NCC2CCCC23CCNCC3)c1', 'NC(=O)c1ccc(NS(=O)(=O)c2ccnn2-c2ccccc2)cc1F', 'NC(=O)c1ccc(OS(=O)(=O)c2cnc(C3CCOCC3)o2)c(F)c1', 'NC(=O)c1cccc(C(=O)N[C@@H]2CC[C@H]2NC(=O)C2=COCCO2)n1', 'NC(=O)c1cccc(NC(=O)CN[C@@H](CC(=O)O)c2ccccc2)c1', 'NC(=O)c1cccc(NCC(=O)Nc2ccc(-n3cccn3)cc2)n1', 'NC(=O)c1ccccc1CCC(=O)N1CCCC(c2cccnn2)C1', 'NC(=O)c1ccccc1OCC(=O)Nc1ccc(OC(F)F)c(Cl)c1', 'NC(=O)c1cn([C@@H]2COC[C@H]2CNC(=O)NCC2CCC=CO2)nn1', 'NC(=O)c1cnccc1N1CCN(C(=O)c2nc(C3CC3)cs2)CC1', 'NC(=O)c1cocc1C(=O)N1CC=CC(C(=O)NC23CC(F)(C2)C3)C1', 'NC(=O)c1ncn(C2CCCN(C(=O)NC3CCC34CCCC4)C2)n1', 'NC(C(=O)NCC(O)Cc1cccc(Cl)c1)C1Cc2ccccc2C1', 'NC(C(=O)NCCNC(=O)c1ccccc1F)c1ccc(F)cc1F', 'NC(CC(=O)N1CCC2(C1)CC(F)(F)C2)c1ccccc1C(F)(F)F', 'NC(Cc1cccnc1Cl)C(=O)Nc1ccccc1N1CCCCC1', 'NC1(CCCC(=O)NCCc2nc(-c3ccccc3)c[nH]2)CCCC1', 'NC1C2CC3CC(C2)CC1(CNC(=O)C(=O)N1CCCC1CCO)C3', 'NC1CCc2c(C(=O)Nc3cccc(C(F)C(F)(F)F)c3)n[nH]c2C1', 'NCC(Cc1ccc(Cl)cc1)C(=O)N1CCC(c2cc(Br)no2)CC1', 'NCC(N)CCC(=O)N1CCN(C(=O)c2ccc3[nH]cnc3c2)CC1', 'NCC(NC(=O)c1cc(O)ccc1C(F)(F)F)c1cc(F)ccc1Cl', 'NCC1(C(=O)NCC(N)c2ccc(Cl)c(C(F)(F)F)c2)CCOCC1', 'NCC1CCC2(CO1)CC(C(=O)Nc1cc(Br)cc(C(F)(F)F)c1)C2', 'NCCC(CCN)NC(=O)C(=O)Nc1cccn(CC(F)(F)F)c1=O', 'NCCCCCN1CCN(CCc2ccccc2OC(F)(F)F)CC1', 'NCCCc1cncc(C(=O)NC2CCN(CC3CCOC3)CC2)c1', 'NCCn1ccc(C(=O)Nc2cnn(CC(=O)NC3CCCC3)c2)c1', 'NC[C@H](O)C1=CC(O)=C(O)C=C1', 'NC[C@H]1C[C@@H](C(F)(F)F)CCN1C(=O)c1cccc(-n2cnnc2)c1', 'NCc1ccc(C2(C(=O)NCC3(c4ccncc4)CCC3)CC2)cc1', 'NCc1ccc([C@@H]2C[C@H]2C(=O)N2CCCC2c2cccc(F)c2)cc1', 'NCc1cn(CCCC(=O)Nc2ccc3cnn(C(F)F)c3c2)nn1', 'NCc1cn([C@H]2C[C@H](C(=O)NC3CCc4c(Br)cc(F)cc43)C2)nn1', 'NS(=O)(=O)CC(=O)N1CCN(C(=O)c2cnc[nH]2)CC1C1CCCC1', 'NS(=O)(=O)CCC(=O)N(CCNC(=O)CC1CCCCC1)CC1CC1', 'NS(=O)(=O)CCS(=O)(=O)c1ccc(N2CCc3cccnc3C2)cc1', 'NS(=O)(=O)Cc1ccccc1NC(=O)c1ccn(C2CCNCC2)n1', 'NS(=O)(=O)N1CCC(CCNC(=O)NC2CC(n3cncn3)C2)CC1', 'NS(=O)(=O)[C@@H]1CCCN(C(=O)NCc2ccc3c(O)cccc3c2)C1', 'NS(=O)(=O)c1c(NC[C@H]2C[C@@H]2c2ccco2)cccc1OC(F)(F)F', 'NS(=O)(=O)c1cc2cc(C(=O)NC3CCc4c(F)cccc43)sc2s1', 'NS(=O)(=O)c1ccc(CN(Cc2cnco2)CC2(F)CCOC2)cc1', 'NS(=O)(=O)c1ccc(CNC(=O)N2CCC(c3ccccn3)C2)nc1', 'NS(=O)(=O)c1ccc(NC(=O)COC(=O)C2Cc3ccccc32)cc1', 'NS(=O)(=O)c1ccc(NC(=O)Nc2cc(-c3ccsc3)n[nH]2)c(F)c1', 'NS(=O)(=O)c1ccc(NCC(=O)N2C3CCC(C3)C2C(=O)O)c(F)c1', 'NS(=O)(=O)c1sccc1CNC(=O)C1NCCc2c1ccc(F)c2F', 'N[C@@H]([C@H](O)C1=CC(O)=C(O)C=C1)C(O)=O', 'N[C@@H]1CC[C@H](C(=O)N2CCCC2c2cnc3ccccc3c2)C[C@H]1O', 'N[C@@H]1CCc2c(C(=O)N3CCN(c4ncc(Cl)cn4)CC3)cccc21', 'N[C@@H]1[C@H](O)C[C@@H]1C(=O)NCc1ccc(NC(=O)c2ccncc2)cc1', 'N[C@H](CC(=O)N1CCN(Cc2ccco2)CC1)Cc1ccc(F)cc1', 'N[C@H](Cc1ccccc1)C(=O)CN1CCN(c2cccc(F)n2)CC1', 'N[C@H]1CCCN(C(=O)CNC(=O)CNC(=O)OCc2ccccc2)C1', 'N[C@H]1CCC[C@@H]1C(=O)NCc1cccc(S(=O)(=O)NCC(F)(F)F)c1', 'N[C@H]1CCC[C@H]1CC(=O)Nc1cccc(OCc2ccc(Cl)cc2)c1', 'N[C@H]1CC[C@H](C(=O)NC(COc2ccccc2F)c2ccccc2)C1', 'N[C@H]1[C@@H]2CCCCCC[C@@H]2[C@@H]1C(=O)N1CCC(n2cnc(Br)n2)CC1', 'N[C@H]1c2ccccc2CC[C@H]1C(=O)Nc1ccc2c(c1)C(=O)CCC2', 'N[C@]12CCC[C@H](C[C@H]1C(=O)N1CCOC(c3nc(C4CC4)no3)C1)C2', 'Nc1c(C(=O)Nc2ccc(OC3CCCC3)c(F)c2)cc(Cl)nc1Br', 'Nc1c(Cl)c(F)nc(OCC(=O)N2CCC3(CC2)CNC(=O)C3)c1Cl', 'Nc1c(F)cccc1C(=O)N1CC[C@H]1C(=O)N1C[C@H]2CCCC[C@H]2C1', 'Nc1c(O)cccc1C(=O)Nc1cnn(CC(=O)N2CCOCC2)c1', 'Nc1cc(C(=O)N2CCC(OCCF)CC2)ccc1N1CCCCC1', 'Nc1cc(Cl)c(C(=O)NCC(O)c2cccc3ccccc23)c(Cl)c1', 'Nc1cc(F)cc(C(=O)NCCCC(=O)N2CCO[C@H]3COC[C@@H]32)c1', 'Nc1cc(F)cnc1C(=O)NCCCCC(=O)NC1CCNC(=O)C1', 'Nc1cc(NC2CCc3cc(Br)ccc3NC2=O)c2ccccc2n1', 'Nc1ccc(C(=O)N2CCN(Cc3ccsc3)CC2)cc1S(N)(=O)=O', 'Nc1ccc(C(=O)N[C@H]2CC[C@H]2CNC(=O)C=Cc2ccsc2)nn1', 'Nc1ccc(C2CCCN(C(=O)C(F)(F)c3ccc(Cl)cn3)C2)cn1', 'Nc1ccc(C2CN(S(=O)(=O)c3ccc(C(F)(F)F)c(F)c3)C2)cc1', 'Nc1ccc2nc(NC3c4ccccc4-c4ccccc43)ccc2c1', 'Nc1cccc(C(=O)NCCN(C(=O)CC2=CCCCC2)C2CC2)n1', 'Nc1cccc(Cl)c1C(=O)NCCC1CCN(C(=O)c2cc[nH]n2)C1', 'Nc1cccc(F)c1C(=O)NC1CC(NC(=O)C2CCCOCC2)C1', 'Nc1cccc2c1CCN(C(=O)c1cc(Cc3ccccc3)n[nH]1)C2', 'Nc1ccnc(C(=O)N2CCC3CC32C(=O)NCC2CC=CCC2)n1', 'Nc1ccnc(C(=O)N2C[C@H](O)C[C@H]2C(=O)NCCCOC2CC2)n1', 'Nc1cnc(C(=O)N2CCCC2/C=C/C(=O)NCCOCCO)cn1', 'Nc1cnc(C(=O)NC[C@@H]2CCN(C(=O)CC3=CCCC3)C2)c(Cl)c1', 'Nc1cncc(C(=O)N[C@H]2C[C@H](CCNC(=O)C=CC=C(Cl)Cl)C2)n1', 'Nc1cnnc(C(=O)N(CCC(F)(F)C(F)F)Cc2ccncc2)c1', 'Nc1nc(C(=O)N2CCC=C(C(=O)NCCN3CC=CCC3)C2)n[nH]1', 'Nc1nc(C(=O)N2CCCC3(CCN(C(=O)C=C4CCC4)C3)C2)cs1', 'Nc1nc(C(=O)Nc2c(Cl)ccc3cnccc23)nc2ccccc12', 'Nc1nc(C2CCCC2)ncc1C(=O)NC1CC(O)C12CC(F)(F)C2', 'Nc1nc(CCC(=O)NC[C@H]2CC[C@@H]2NC(=O)C2CC=CCO2)cs1', 'Nc1nc(NC2CCSC3(CCC3)C2)nc(N2C3CCCC2CC3)n1', 'Nc1nc(NCC2CC(O)C2)nc(N2CCC(Cn3cccn3)C2)n1', 'Nc1nc(NCCCC2CCCCCC2)nc(NC2CC(CF)C2)n1', 'Nc1nc(NCc2cc(Cl)cc(Cl)c2)nc(NCc2cc(=O)[nH][nH]2)n1', 'Nc1nc2cc(C(=O)N3CCC(N)C(c4ccccc4)C3)ccc2[nH]1', 'Nc1ncc(C(=O)N2CCC3(CC3C(=O)N3CC(OCCO)C3)C2)o1', 'Nc1ncc(C2CCN(C(=O)C3COC4(CCOCC4)CN3)CC2)[nH]1', 'Nc1ncc2c(n1)CN(C(=O)NCCNC(=O)Cc1ccccc1)C2', 'Nc1nccc(C(F)(F)F)c1C(=O)NCC(O)c1cc(F)ccc1Cl', 'Nc1nccnc1C(=O)NCc1occc1C(=O)NCc1cscn1', 'Nc1nccnc1C(=O)N[C@@H]1CC[C@H](CCC(=O)NCC=C(Cl)Cl)C1', 'Nc1nnc2ccc(N3CCN(C(=O)Oc4ccccc4)CC3)nn12', 'Nc1nonc1C(=O)N1CCC2CC21C(=O)NCc1ccccc1Cl', 'Nc1nonc1C(=O)N1CCN(C(=O)CC2C=CCCC2)CC1CO', 'Nc1snnc1C(=O)N[C@H]1CC[C@H]1C(=O)N1CCC(c2ncc[nH]2)C1', 'O=C(/C=C/C(F)(F)F)N1CCO[C@H](CNc2ccc3nnnn3n2)C1', 'O=C(/C=C/C1CCCN1C(=O)Cc1cccnc1)NCc1cc[nH]n1', 'O=C(C#CC12CC3CC(CC(C3)C1)C2)OCc1cccc2nccn12', 'O=C(C#CC1CC1)N1CCN(C(=O)c2ccc(Cl)cn2)C(C2CC2)C1', 'O=C(C#CC1CC1)NC1CC(NC(=O)Cn2ccc3ccccc32)C1', 'O=C(C(=O)N(Cc1cccs1)C1CC1)N1CCCC(c2ncco2)C1', 'O=C(C/C=C/CNC(=O)CC1=CCCC1)NCc1cccc(CO)c1', 'O=C(C1=C(Cl)CCCC1)N1CCC(F)(C(=O)N2CC3(CC(O)C3)C2)C1', 'O=C(C1C=CCN(C(=O)C2CC3CCC(C3)C2)C1)N1CC([N+](=O)[O-])C1', 'O=C(C1CC(=C2CC2)C1)N(CCC1CCSCC1)CC1C2CCCC21', 'O=C(C1CC(F)(F)CS1)N1CC(NC(=O)[C@H]2C[C@@H](O)C2)CC12CCC2', 'O=C(C1CC2CC(F)(F)CC(C1)C2(F)F)N1CCOC(C(F)F)CC1', 'O=C(C1CC=CCN1C(=O)CC1CCC1)N1CCCC(C2CC2)CC1', 'O=C(C1CCC2(CC2)N1C(=O)[C@H]1CC[C@H]2C[C@H]21)N1CCC12CC(O)C2', 'O=C(C1CCCCN1C(=O)C12CC(F)(C1)C2)N1CCC(CO)=C(F)C1', 'O=C(C1CCCCN1C(=O)c1cnn(C2CC2(F)F)c1)N1CCCC1', 'O=C(C1CCCN1C(=O)c1ccc(F)c2[nH]ccc12)N1CCNCC1', 'O=C(C1CCCO1)N1CC[C@]2(C(=O)NCCn3ccnc3)CCC[C@H]12', 'O=C(C1CCN(C(=O)C2CCSCC2)C12CCC2)N1CC[C@H]2CC[C@H]21', 'O=C(C1CCN(C(=O)CCC2CCCO2)C12CC2)N1CCC12CCC2', 'O=C(C1CCOC1)N1CC=CC(C(=O)N(C2CC2)[C@@H]2COC[C@H]2O)C1', 'O=C(C1CCOC1CNC(=O)C1(F)CC=CC1)N1CC(CC2CC2)C1', 'O=C(C1CCOCC1)N1CCC(NC(=O)[C@]23CC[C@H](C[C@H]2O)C3)CC1', 'O=C(C1CCOCCN1C(=O)C1CCCCS1)N1CC2C=CC1CC2', 'O=C(C1CCc2nncn2C1)N1CCC(c2ccc(Cl)cc2Cl)CC1', 'O=C(C1CNC2CCCCC2C1)N1CCC(Oc2cnccn2)CC1', 'O=C(C1CSC1)N1CCC2(CCC2)C(CNS(=O)(=O)c2cncs2)C1', 'O=C(C1CSCN1S(=O)(=O)c1cnn2c1CNCC2)N1CCSCC1', 'O=C(C1c2ccccc2Oc2ccccc21)N1CCOC2(CCC2)C1', 'O=C(C=C1CCC1)NC1CCN(C(=O)CNC(=O)C(F)(F)F)C12CC2', 'O=C(C=C1CCCCC1)N[C@@H]1CN(C(=O)c2cnc[nH]2)CC[C@H]1CO', 'O=C(C=C1CCOCC1)NC[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)c1cnc(Cl)s1', 'O=C(C=C1CCOCC1)NC[C@H]1C[C@@H]2CC[C@H]1N2c1cncc(Cl)n1', 'O=C(C=CC(=O)N1CCOCC1)OCc1ccc(C(F)(F)F)cc1F', 'O=C(C=CC1CC1)N1C[C@H]2CCN(C(=O)CCc3ccc[nH]3)C[C@H]2C1', 'O=C(C=CC1CCC1)NCCN(C(=O)C1=COCCC1)C1CCCC1', 'O=C(C=CCO)N[C@H]1C[C@H](CCNC(=O)c2cc3cccnn3n2)C1', 'O=C(C=Cc1c(Cl)nc2ccccn12)N1CC2CCC1(C(F)(F)F)C2', 'O=C(C=Cc1cc[nH]c1)NCCC1(C(=O)NC2(C3CC3)CC2)CCC1', 'O=C(C=Cc1cc[nH]n1)N[C@H](CO)C(=O)NCCOCC1CCCC1', 'O=C(C=Cc1ccc(C(=O)O)o1)Nc1nccn1Cc1ccccc1', 'O=C(C=Cc1ccc(F)cc1[N+](=O)[O-])NCc1cc2cnncc2o1', 'O=C(C=Cc1ccc(N2CCCS2(=O)=O)cc1)N1CCC2(CNC2)C1', 'O=C(C=Cc1ccc(O)cc1)N1CCCN(C(=O)c2ccco2)CC1', 'O=C(C=Cc1ccc2c(c1)OC(F)(F)O2)NCCCc1cnccn1', 'O=C(C=Cc1ccc[nH]1)NCc1cc(C(=O)NOCC2CC2)ccn1', 'O=C(C=Cc1nc2ccccc2s1)N1CCN2CCCC2C12CCC2', 'O=C(C=Cc1nccs1)N[C@@H](C(=O)NCCC1CC1)C1CCCCC1', 'O=C(CC(Cl)Cl)N[C@H]1CC[C@H](NC(=O)C2Cc3ccccc3C2)CC1', 'O=C(CC(F)(F)F)N1CCC[C@@H](CNC(=O)C2(Cl)CC3CCC2O3)C1', 'O=C(CC(F)(F)F)NCC[C@H]1CCCN(C(=O)Cc2cccnc2)C1', 'O=C(CC(n1ccnc1)C(F)(F)F)N[C@H](C(=O)O)c1ccc(O)cc1', 'O=C(CC1(CO)CC1)N[C@@H](CO)CNC(=O)[C@H]1C[C@H](n2ccnn2)C1', 'O=C(CC1(CSc2ccccc2)CC1)N1C(CO)CCC12CCCC2', 'O=C(CC1(NC(=O)CCc2nncs2)CCC1)NCc1ccccc1', 'O=C(CC1(n2cccc2)CCOCC1)NC1CCCc2c(I)n[nH]c21', 'O=C(CC12CCC(CC1)C2)N[C@]1(C(=O)N2C[C@H](O)[C@@H](F)C2)C[C@H](O)C1', 'O=C(CC1=CCCCC1)NC1(CC(=O)N2CCC3(CC2)N=N3)CCC1', 'O=C(CC1=CCN(C(=O)C2CCS2(=O)=O)CC1)N[C@H]1CCCC[C@H]1F', 'O=C(CC1C=CCC1)NCc1cc(C(=O)NCCc2cocn2)co1', 'O=C(CC1C=CCCC1)NCC1c2ccccc2CN1C(=O)C=CBr', 'O=C(CC1CC(NC(=O)C2(F)CCOC2)C1)N1CC[C@@H](OC2CC2)C1', 'O=C(CC1CC2(CC2)C1)NCCCOCCC(=O)N1CC=CC1CF', 'O=C(CC1CC2(CCC2)C1)NC1(C(=O)N2CC3CC=CC2C3)CCC1', 'O=C(CC1CC2(CCNCC2)CO1)N1CCN(Cc2nnn[nH]2)CC1', 'O=C(CC1CC=CCC1)N(Cc1cc(Cl)no1)Cc1ccccc1F', 'O=C(CC1CCC1)NC(Cn1cncn1)C(=O)N1CC2CC=CC1C2', 'O=C(CC1CCCC1)N1CCC(CF)(C(=O)NC2(CC3CC3)CC2)C1', 'O=C(CC1CCCC1)N1C[C@H]2C[C@@]2(C(=O)N[C@]23CCC[C@H]2OCC3)C1', 'O=C(CC1CCCC1)N[C@H]1COC[C@H]1C(=O)NC1Cc2cscc2C1', 'O=C(CC1CCCCCC1)NC(CCC1CC1)C(=O)NC1(CF)CC1', 'O=C(CC1CCCCN1C(=O)CCc1ccoc1)NC[C@H]1C[C@H]1CO', 'O=C(CC1CCCCO1)NCC(O)CC(=O)N1CCc2[nH]ncc2C1', 'O=C(CC1CCCN(C(=O)C2CC2)CC1)N1CC(c2noc(O)n2)C1', 'O=C(CC1CCCN(C(=O)C=Cc2cscn2)CC1)NOCCCO', 'O=C(CC1CCCN1C(=O)[C@]12C[C@H]1CNC2=O)NCCc1ncn[nH]1', 'O=C(CC1CCCOC1)N(Cc1cccc(Cl)c1)CC1C2CCCC21', 'O=C(CC1CCCS(=O)(=O)C1)O[C@H]1CCC[C@@H]1n1cc([N+](=O)[O-])cn1', 'O=C(CC1CCN(C(=O)CN2CCOC2=O)CC1)N[C@H]1CCCOC1', 'O=C(CC1CCOCC1)NC1CC2(C1)CN(S(=O)(=O)C1(CCl)CC1)C2', 'O=C(CC1CCSCC1)N1CC[C@@H](CC(=O)N2CCOCC2CO)C1', 'O=C(CC1CN(C(=O)c2coc3c2COC3)CCO1)NCC(F)CO', 'O=C(CC1CNC(=O)O1)NC1(C2CCCN2C(=O)c2cccs2)CC1', 'O=C(CC1COCCN1C(=O)C=CC1CC1)NCC1(CC2CC2)CC1', 'O=C(CC1COCCOC1)N[C@@H]1CCC[C@@H](C(=O)NCC2CCC2)C1', 'O=C(CC1COCCOC1)Nc1ccccc1C(=O)N1CCCCC1', 'O=C(CC1CSCCN1)NCc1cccc(Oc2ccc(F)cc2)n1', 'O=C(CC1OCc2cc(C(F)(F)F)ccc21)NCCc1csc(=O)[nH]1', 'O=C(CCC(=O)N1CC2CC1CN(C(=O)c1csc(=O)[nH]1)C2)C1CC1', 'O=C(CCC(=O)OCC(F)(F)F)OCc1nc(-c2cccnc2)no1', 'O=C(CCC(=O)c1ccc2ccccc2c1)NCCC1CCCCN1', 'O=C(CCC(=O)c1ccccn1)NCCc1c[nH]c2ccc(Cl)cc12', 'O=C(CCC(F)(F)F)N1CCC(F)(C(=O)N2CCC(C3CCC3)C2)C1', 'O=C(CCC(F)(F)F)NC1C2C3C[C@H]1[C@@H](C(=O)N[C@H]1COC[C@H]1O)C32', 'O=C(CCC(F)(F)F)NC1CN(C(=O)[C@H](O)C2CCC2)CC12CCC2', 'O=C(CCC(F)(F)F)N[C@H]1CC[C@@H](C(=O)N(CC(F)F)C2CCC2)C1', 'O=C(CCC(F)(F)F)N[C@H]1CN(C(=O)COCC(F)F)C[C@@H]1C1CC1', 'O=C(CCC1CCC(O)CC1)NNC(=O)c1cc(-c2cccs2)n[nH]1', 'O=C(CCC1CCC1)NC(CNS(=O)(=O)C1CC=CC1)CC(F)(F)F', 'O=C(CCC1CCCC(O)C1)NC/C=C/CNC(=O)C1SCCCS1', 'O=C(CCC1CCCCN1C(=O)c1c[nH]nn1)N1CCCCC1CO', 'O=C(CCC1CCN(C(=O)c2ccns2)C1)NCCN1CC[C@H](O)C1', 'O=C(CCC1CCOC1)NC/C=C/CC(=O)NC1C2CCCC1CC2', 'O=C(CCC1CCOC1)N[C@@H]1C[C@H](CO)N(C(=O)[C@]23COC[C@H]2C3)C1', 'O=C(CCC1CCOC1)N[C@H](CO)C(=O)NCc1ncc(F)cc1F', 'O=C(CCC1OCCO1)N1CCC(C(=O)N2CCC(F)(CO)C2)CC1', 'O=C(CCCC(F)(F)F)NC(C(=O)NC[C@H](F)CO)C1CCCCC1', 'O=C(CCCC1CCCO1)NCCC(=O)NCc1nnc2n1CCC2', 'O=C(CCCCC1CC1)NCc1ccc(C(=O)Nc2ccccc2)s1', 'O=C(CCCCCCNC(=O)C1NCCC1C1CC1)c1ccccc1', 'O=C(CCCCCF)N(CCC1(O)CCC1)Cc1cc(O)ccc1Cl', 'O=C(CCCCCF)N1CC2CC(C(=O)NCC(O)C(F)(F)F)(C2)C1', 'O=C(CCCCCF)N[C@@H]1CCC[C@@H](C(=O)N(C2CCC2)C2CC2)C1', 'O=C(CCCCCNC(=O)C1=CC2C=CC(C1)C2)NCC1CC=CC1', 'O=C(CCCF)NCC1(CO)CCN(C(=O)CSC2CCOC2=O)C1', 'O=C(CCCNC(=O)C1CCC=CCC1)NCc1n[nH]c2c1CCC2', 'O=C(CCCNC(=O)C1CCCN1C1CC1)NC1CCC=CCCC1', 'O=C(CCCNC(=O)[C@H]1[C@@H]2CCCC[C@@H]21)NCCc1ccncc1F', 'O=C(CCCOCCc1ccccc1)N1CCC2(CCCC2=O)CC1', 'O=C(CCCOc1ccccc1Cl)N1CC2NC(C1)c1ccccc12', 'O=C(CCCc1ccccc1)CSc1nnc(-c2ccccc2F)[nH]1', 'O=C(CCCc1cccs1)N[C@H]1Cc2ccccc2O[C@@H]1C(F)(F)F', 'O=C(CCCn1cc(-c2ccc(Cl)cn2)nn1)NCc1nc(Br)n[nH]1', 'O=C(CCCn1cccn1)N[C@H]1COC[C@H]1NC(=O)C1(CCO)CC1', 'O=C(CCF)NCCC1CCCCN1C(=O)c1cc2ncccc2[nH]1', 'O=C(CCN(C(=O)C(O)C1CCCC1)C1CC1)N1C[C@@H]2C[C@]2(CO)C1', 'O=C(CCN(CC1CC1)C(=O)c1ccncc1O)NCC1C=CCC1', 'O=C(CCN1C(=O)NC2(CCCC2)C1=O)Nc1ccc(F)cc1CO', 'O=C(CCN1CCC1)N1CC[C@H]2CCN(C(=O)[C@H]3[C@@H]4CCC[C@@H]43)[C@H]2C1', 'O=C(CCN1CCC1)N[C@@H]1CC[C@H]1CNC(=O)c1ccc(C2CC2)s1', 'O=C(CCN1CCN(S(=O)(=O)c2[nH]ncc2C(=O)O)CC1)NC1CC1', 'O=C(CCN1CC[C@H](F)[C@H](F)C1)NS(=O)(=O)c1ncccc1C(F)F', 'O=C(CCN1Cc2ccc(Br)cc2C1)NS(=O)(=O)CC1CCCCC1', 'O=C(CCNC(=O)c1ccc(CNC(=O)CC(F)(F)C(F)F)s1)NO', 'O=C(CCNc1cc(NCCC2CCCCO2)ncn1)N1CCCC1', 'O=C(CCOC1CCC1)NC[C@H]1CC[C@@H](C(=O)N2CCC=C(Cl)C2)O1', 'O=C(CCOCC1CCC1)N[C@H]1C[C@@H](C(=O)N2C[C@H]3CCCC[C@H]32)C1', 'O=C(CCS(=O)(=O)C1CCCC1)NCc1c[nH]c(=O)c2ccccc12', 'O=C(CC[C@@H]1CCCN1C(=O)Cc1ccoc1)N1CC(CC(F)F)C1', 'O=C(CC[C@H]1C[C@@H](NC(=O)Cc2cnns2)C1)NC1CC(C2CC2)C1', 'O=C(CC[C@H]1C[C@@H](NC(=O)Cn2cncn2)C1)NC1(CO)CC=CC1', 'O=C(CCc1c(F)cc(F)cc1F)NCC(O)c1ccc(F)c(F)c1', 'O=C(CCc1c[nH]c2ccccc12)NNc1nc(Br)cn2ccnc12', 'O=C(CCc1ccc(F)c2c1CCCC2)Nc1ccn2nccc2c1', 'O=C(CCc1ccc[nH]1)NCC(O)C(=O)NC(CO)C1CCCCC1', 'O=C(CCc1cccc(F)c1F)N1CC(S(=O)(=O)C2CCCCC2)C1', 'O=C(CCc1ccccn1)NC1CCC(NS(=O)(=O)CCCF)CC1', 'O=C(CCc1ccncn1)NCCC1COCCN1C(=O)[C@@H]1C[C@H]1F', 'O=C(CCc1ccncn1)N[C@H]1C[C@H]1NC(=O)[C@H]1C[C@@H]1c1ccco1', 'O=C(CCc1ccoc1)NC[C@H]1C[C@@H]1C(=O)N1CCC(O)(CO)CC1', 'O=C(CCc1cn[nH]c1)NCC(NC(=O)C1CCC=CCC1)C1CC1', 'O=C(CCc1cncs1)N[C@@H]1CC[C@H](CCC(=O)N[C@H]2CCOC2)C1', 'O=C(CCc1cnoc1)NC[C@H]1C[C@H]1C(=O)N1CCC(O)C12CCC2', 'O=C(CCc1cscn1)N[C@H]1CN(C(=O)[C@@H]2CCCC[C@H]2O)C[C@H]1O', 'O=C(CCc1nc(-c2ccc(F)cc2)no1)NCCN1CCNC1=S', 'O=C(CCc1nc(-c2ccco2)no1)N1CCC(n2nccn2)CC1', 'O=C(CCc1nc2ccsc2c(=O)[nH]1)NCC(CO)C1CCCCC1', 'O=C(CCc1nnc(-c2ccncc2)o1)OCc1cnn(CCF)c1', 'O=C(CCn1cc(-c2ccc(Cl)cc2)nn1)NC1CCCCNC1=O', 'O=C(CCn1cc(C2OCCO2)nn1)NC1Cc2ccc(Cl)cc2C1', 'O=C(CCn1cc(CC(CO)CO)nn1)NCC1CC(=C2CCC2)C1', 'O=C(CCn1cncn1)Nc1cccc(CNC(=O)[C@@H]2CC2(F)F)c1', 'O=C(CN(C(=O)C1=NOC2(CCC2)C1)C1CC1)N[C@@H]1C=C[C@H](CO)C1', 'O=C(CN(C(=O)CN1CCCC1=O)C1CC1)NCc1cc(=O)cc[nH]1', 'O=C(CN1C(=O)CCC1=O)N1CC(OCC(=O)N2CCCC23CC3)C1', 'O=C(CN1CC2CCC1C2)N1C[C@@H]2CN(c3cncc(Cl)n3)C[C@@H]2C1', 'O=C(CN1CCN(C2CCOC2=O)CC1)Nc1ccc([N+](=O)[O-])cc1', 'O=C(CN1CCN(c2ncc[nH]2)CC1)NNC(=O)c1ccccc1Cl', 'O=C(CN1CCOCC1C1CCOC1)c1cnc(N2CCCCC2)s1', 'O=C(CN1CCOCC1c1ccccc1Cl)NCc1ccccc1F', 'O=C(CN1CCc2ccccc2C1=O)Nc1cc(Cl)cc([N+](=O)[O-])c1', 'O=C(CNC(=O)NC1CCCCC1)N[C@H]1CCN[C@@H]1c1ccccc1', 'O=C(CNC(=O)[C@@H]1CCC[C@H](NC(=O)[C@H]2COCCO2)C1)NC1CC1', 'O=C(CNC(=O)c1ccoc1)NCC1CCN1C(=O)C1CCCCO1', 'O=C(CNC(=O)c1ccoc1)Nc1ccc2[nH]c(C3CCC3)nc2c1', 'O=C(CNS(=O)(=O)c1ccc2c(c1)OCCCO2)N1CCC=C(F)C1', 'O=C(CNc1cc(-c2ccccn2)ncn1)N1CCc2sccc2C1', 'O=C(CNc1ccc(C(=O)N2CCCC2)cn1)NCc1ccccc1', 'O=C(CNc1ccccc1Cl)NCCNS(=O)(=O)CC1CCC(F)C1', 'O=C(CNc1ccnc(N2CC(=O)N3CCCC3C2)n1)N1CCCO1', 'O=C(CNc1ncccn1)NCC(O)CC(=O)Nc1ccccc1O', 'O=C(COC(=O)C1CCN(c2ncccn2)CC1)c1ccccc1Cl', 'O=C(COC(=O)[C@H]1CC[C@H]1c1ccccc1)NC(=O)NC1CCCC1', 'O=C(COC(=O)c1ccn(C2CCCCC2)n1)NCC1CCOCC1', 'O=C(COC(=O)c1ncnc(O)c1Br)NC1CCOc2ccccc21', 'O=C(COC1CC1)N[C@@H]1CC(C(=O)NOCc2ccccc2)=C[C@@H]1O', 'O=C(COC1CCCC1)NC[C@H]1C[C@@H]2CC[C@H]1N2S(=O)(=O)CCCF', 'O=C(COC1CCCC1)N[C@H]1C[C@H](CC(=O)N2C[C@H](F)C[C@H](F)C2)C1', 'O=C(COC1CCOCC1)NC[C@H]1CC[C@@H]1NC(=O)C1CC=CCO1', 'O=C(COC1CN(C(=O)C2(Cl)CCCCC2)C1)NCC1CC12CCC2', 'O=C(COC1CN(C(=O)C23CCC(C2)C3)C1)N1CCC2(CCCO2)C1', 'O=C(COCC(F)F)NCC1CCN(C(=O)C=C2CCOCC2)CC1', 'O=C(COCC(F)F)NC[C@H]1C[C@H]1C(=O)N1C[C@H]2C[C@@H](O)CC[C@H]2C1', 'O=C(COCC1CC1)N[C@H]1CC[C@@H]1NC(=O)c1cnn2ncccc12', 'O=C(COCC1CCCCO1)N1CCC2C(C1)C2NS(=O)(=O)C(F)F', 'O=C(COCCNC(=O)[C@@]12C[C@@H]1CNC2=O)NCc1cccc(F)n1', 'O=C(COCc1nc2ccccc2s1)NCC1(C(=O)O)CCOCC1', 'O=C(CO[C@@H]1CCN(C(=O)c2cc(Cl)cs2)C1)NCc1ccccc1', 'O=C(CO[C@@H]1CCN(C(=O)c2csc(=O)[nH]2)C1)N[C@H]1C[C@H]2CC[C@@H]1O2', 'O=C(CO[C@@H]1CCOC1)NCC1(CC(=O)NCC2(O)CCOC2)CC1', 'O=C(CO[C@@H]1CCOC1)NCC1CN(C(=O)C2=CCCC2)CC1(F)F', 'O=C(CO[C@H]1C[C@H](NC(=O)[C@@H]2CCC[C@H]2O)C1)NC(CCO)C1CC1', 'O=C(COc1cc(C(F)(F)F)ccc1Cl)OCc1cc(O)cc(F)c1', 'O=C(COc1cccc(F)c1F)N1CCOCC1c1cccc(F)c1', 'O=C(COc1cccc(O)c1)NC1CCC(O)(c2cccnc2)CC1', 'O=C(CSC(F)F)N1C[C@@H]2C[C@H]1CN2C(=O)C1CCn2cnnc2C1', 'O=C(CSCC(F)F)NCc1cc(C(=O)N2CCC[C@H]2CF)ccn1', 'O=C(CSCC(F)F)N[C@H]1CC[C@H]1C(=O)N1CCC(C2=NOCC2)C1', 'O=C(CSCc1cc(=O)n2ccsc2n1)N1CCC1C(O)C(F)(F)F', 'O=C(CSc1cn[nH]c1)N[C@H]1C[C@@H](NC(=O)c2cn(C3CC3)cn2)C1', 'O=C(CSc1nccn1-c1ccc(Br)cc1)N1CCCC1=C[N+](=O)[O-]', 'O=C(C[C@@H]1CCCC[C@H]1O)N[C@H]1C[C@@H](C(=O)NC2CCCCCC2)C1', 'O=C(C[C@@H]1CCCN1C(=O)Cc1cscn1)N1CCCCCCCC1', 'O=C(C[C@@H]1CCN(C(=O)c2c[nH]nn2)C1)NCc1ccc(F)cc1F', 'O=C(C[C@@H]1C[C@@H](O)CN1C(=O)COc1ccsn1)NCc1ncsn1', 'O=C(C[C@H](CC1CC1)NC(=O)CC1CC2CC2C1)NCc1c[nH]cn1', 'O=C(C[C@H](NC(=O)C1CC2(CCC2O)C1)C1CC1)NC[C@H]1CCCO1', 'O=C(C[C@H]1CCN(C(=O)CC2COCCO2)C1)N[C@H]1[C@@H]2CCCC[C@@H]21', 'O=C(C[C@H]1CCOC1)N(Cc1cc(O)ccc1Cl)CC1CCC(F)C1', 'O=C(C[C@H]1C[C@H]1CNC(=O)[C@H]1C[C@@H]1C(F)(F)F)NCC(=O)NC1CC1', 'O=C(Cc1c(Cl)ccc(Cl)c1Cl)NCc1nc(-c2ccncc2)no1', 'O=C(Cc1c(Cl)cccc1Cl)CN1C[C@H](CO)[C@@H](C2CCOCC2)C1', 'O=C(Cc1cc(Br)cc2c1OCC2)N1CCOc2c(O)cccc2C1', 'O=C(Cc1cc(Cl)cs1)NCC1(O)CCN(C(=O)C2CCCS2)CC1', 'O=C(Cc1cc[nH]c1)NCC1(C(=O)N2C[C@@H](O)[C@H](O)C2)CC2(CC2)C1', 'O=C(Cc1cc[nH]c1)N[C@H]1COC[C@H]1C(=O)N1CCC[C@H]2[C@H](O)C[C@H]21', 'O=C(Cc1ccc(C(F)F)nc1)NC(C(=O)O)c1ccc(F)cc1F', 'O=C(Cc1ccc(Cl)c([N+](=O)[O-])c1)NCCOc1cc(Cl)cc(Cl)c1', 'O=C(Cc1ccc(Cl)cn1)N[C@H]1C[C@H]1NC(=O)c1cncc(CO)c1', 'O=C(Cc1ccc(F)cc1F)Cn1c(=O)oc2cc([N+](=O)[O-])ccc21', 'O=C(Cc1ccc2[nH]nnc2c1)NCC1CNC2(CCOCC2)CO1', 'O=C(Cc1ccc2[nH]nnc2c1)NCc1ccccc1-n1cccn1', 'O=C(Cc1ccc2c(c1)CC2)N1CCc2nc(-c3cscn3)sc2C1', 'O=C(Cc1cccc(F)c1[N+](=O)[O-])NCC(CO)c1cccc(F)c1', 'O=C(Cc1cccc(I)c1)N1CCC(Oc2ccc(F)cc2F)CC1', 'O=C(Cc1cccc(OCC2CC2)c1)OCc1nc(CC2CC2)no1', 'O=C(Cc1cccc2ccoc12)N1CC(O)(c2c(F)cccc2F)C1', 'O=C(Cc1ccccc1Cl)NCCCNS(=O)(=O)c1ccc(O)cc1', 'O=C(Cc1ccccn1)N1CCC(c2ccccc2C(F)(F)F)CC1', 'O=C(Cc1ccco1)N[C@@H]1[C@H]2C[C@@H]1N(C(=O)CC1CC(C3CC3)C1)C2', 'O=C(Cc1ccncc1)NNC(=O)NC1C2COCC1CC(CO)C2', 'O=C(Cc1ccno1)NCc1ccncc1NS(=O)(=O)c1cccs1', 'O=C(Cc1ccns1)NC1CN(C(=O)C2CCC2(F)F)C2CCCC12', 'O=C(Cc1ccoc1)NCc1cc(C(=O)NCCn2cccn2)cs1', 'O=C(Cc1ccon1)NCC1CC(C(=O)N2CCCNC(=O)C2)=NO1', 'O=C(Cc1cn2ccccc2n1)N1CCNCC1c1cccc(Cl)c1', 'O=C(Cc1cn2ccccc2n1)NNC(=O)c1cc2c(nn1)CCC2', 'O=C(Cc1cn[nH]c1)NCCC[C@@H](CO)NC(=O)Cn1cc(Cl)cn1', 'O=C(Cc1cncc(C(F)(F)F)c1)OCC(=O)C1CCCC2(CC2)C1', 'O=C(Cc1cncs1)NC1CCN(CCCNS(=O)(=O)CC2CC2)C1', 'O=C(Cc1cncs1)NC[C@H]1CCC[C@H]1C(=O)N1CC[C@H](F)[C@H](F)C1', 'O=C(Cc1cnsc1)N[C@@H]1CN(C(=O)Cn2cncn2)CC[C@H]1CO', 'O=C(Cc1n[nH]c2ccccc12)OCC(=O)c1cccc([N+](=O)[O-])c1', 'O=C(Cc1nc[nH]n1)NCCCCNC(=O)C1(C(F)F)CC2(CC2)C1', 'O=C(Cc1noc2cc(Br)ccc12)Nc1n[nH]c(=O)c2ccccc12', 'O=C(Cc1noc2ccc(O)cc12)OCc1cc2c(F)cccn2n1', 'O=C(Cn1cc(-c2ccc(Cl)nc2)nn1)Nc1cccc(C(F)F)c1', 'O=C(Cn1cc(C2(O)COC2)nn1)Nc1ccc(F)cc1OCCO', 'O=C(Cn1cc(CNC(=O)C2C3(CC3)C23CC3)nn1)NOC1CCC1', 'O=C(Cn1cccc([N+](=O)[O-])c1=O)NCc1cn2c(F)cccc2n1', 'O=C(Cn1cccc1)NCCN(C(=O)c1ncoc1C1CC1)C1CC1', 'O=C(Cn1cccn1)N1CCC(F)(C(=O)N2CC3CCCC2C3)CC1', 'O=C(Cn1ccnc1)N1CCC(O)(Cn2cc(CCC3CC3)nn2)C1', 'O=C(Cn1ccnc1-c1ccc(F)c(Br)c1)c1ccc2c(c1)CCC2', 'O=C(Cn1cnnn1)NCCC1(O)CN(C(=O)[C@H]2CCCC[C@H]2O)C1', 'O=C(Cn1ncc2ccc(Br)cc21)NC1CCc2cc(F)cc(Br)c21', 'O=C(Cn1nccn1)N1C[C@@H]2C[C@]2(C(=O)N2CCCCC(F)(F)C2)C1', 'O=C(N(CCC1CC1)Cc1ccc(C2CC2)cn1)C1(O)CC(F)(F)C1', 'O=C(N1CC2(C1)CC(O)(c1ccccc1)C2)C12CC(CC(F)F)(C1)C2', 'O=C(N1CCC(Cc2ccccc2F)C1)N1C[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C1', 'O=C(N1CCCC(NC(=O)[C@]23C[C@H]2COC32CCC2)C1)C(F)(F)CO', 'O=C(N1CCCC(c2csc(CO)n2)C1)C(F)(F)c1ccc(F)cc1', 'O=C(N1CCN(CC=Cc2ccccc2)CC1)[C@@]12C[C@H]3C[C@H]1C2[C@@H]3O', 'O=C(N1CCN(c2ccc(F)cc2Cl)CC1)C1(C2(O)CNC2)CCC1', 'O=C(NC(C(=O)N1CC(F)(F)C[C@@H]1CO)c1cccs1)c1cnns1', 'O=C(NC(C(=O)N1CC2CCCC1C2)C1CC1)C1=NO[C@H]2COC[C@@H]12', 'O=C(NC(C(=O)N1C[C@H]2CCO[C@H]2C1)C1CCCC1)c1nc(=O)[nH][nH]1', 'O=C(NC(C(=O)NCc1nccs1)c1ccccc1)c1ccnnc1', 'O=C(NC(C(=O)N[C@]12CCC[C@H]1C2)c1ccccc1)c1nsnc1O', 'O=C(NC(C(=O)O)C1CCCO1)c1cncc(-c2ccc(Cl)cc2)c1', 'O=C(NC(CC(F)(F)F)c1ccccc1)N[C@H]1CS[C@H](C(F)(F)F)C1', 'O=C(NC(CC(F)F)C(=O)N1CC(c2nncs2)C1)c1cccnn1', 'O=C(NC(CC(F)F)C(=O)N1C[C@@H]2C[C@H]1CO2)C1CC2(CC(O)C2)C1', 'O=C(NC(CCO)c1ccccc1Br)c1ccc(-n2cccc2)cc1', 'O=C(NC(CO)c1ccco1)C1CCCN(C(=O)[C@H]2C[C@@H](O)C2)CC1', 'O=C(NC(CO)c1ncc[nH]1)[C@@H]1C[C@H](F)CN1C(=O)Cn1ccnc1', 'O=C(NC(c1ccncc1)C1(CO)CCC1)C1CCNc2[nH]ncc21', 'O=C(NC(c1nn[nH]n1)C1CCCC1)c1ccnc2ccc(Cl)cc12', 'O=C(NC1(C(=O)N2CCCc3nccn32)CCCC1)c1ccccc1', 'O=C(NC1(C(=O)N[C@H]2COC[C@H]2CO)CSC1)C(F)c1ccccc1', 'O=C(NC1(C(F)(F)F)CCCCC1)c1ccc(NCC(F)(F)F)nc1', 'O=C(NC1(C2CC2)CCC1)C1=CCCN(C(=O)C(C2CC2)C2CC2)C1', 'O=C(NC1(C2CCCN2C(=O)c2cc[nH]n2)CC1)[C@H]1[C@@H]2CCCC[C@@H]21', 'O=C(NC1(C2CN(C(=O)C34CC(F)(C3)C4)C2)CC1)c1cc[nH]c(=O)c1', 'O=C(NC1(C2CN(C(=O)CCn3cncn3)C2)CC1)c1csc(Cl)n1', 'O=C(NC1(C2CN(C(=O)c3ccc4cccnn34)C2)CC1)C1CCC1', 'O=C(NC1(CC(=O)N2CCC3(CCCC3)CC2)CC1)c1cc(Cl)cs1', 'O=C(NC1(CC(=O)N2CCCc3nccn32)CCC1)c1cncnc1', 'O=C(NC1(CC2CCC2)CC1)[C@@H]1CN(C(=O)c2ccsc2Cl)CCO1', 'O=C(NC1(CCCC(=O)N2C[C@H](O)CO2)CCC1)C1CCC(F)(F)C1', 'O=C(NC1(CF)CCN(C(=O)c2cc(Cl)no2)C1)c1ccccc1Cl', 'O=C(NC1(CO)CC2CCCC21)c1csc(CCc2ccccc2)n1', 'O=C(NC1(CO)CCC1)C1C=CCN(C(=O)Cn2ccccc2=O)C1', 'O=C(NC1(c2cc(Cl)cc(Cl)c2)CCC1)c1cc2nccn2c(=O)[nH]1', 'O=C(NC1(c2cc(F)ccc2F)CCCC1)C1CN(c2nncs2)C1', 'O=C(NC1(c2ccc(F)c(F)c2)CC1)c1ccc(Br)c2cccnc12', 'O=C(NC1(c2cccc(Cl)n2)CC1)N1CCc2ccc(Cl)c(Br)c2C1', 'O=C(NC1(c2cccc(F)c2)COC1)N[C@H]1C[C@H](Cn2cccn2)C1', 'O=C(NC1(c2cccs2)CC1)[C@@H]1CN(C(=O)[C@@H](O)C(F)(F)F)C[C@H]1F', 'O=C(NC1(c2cn(-c3cccc(Cl)c3)nn2)CCC1)c1cc(Br)[nH]n1', 'O=C(NC1(c2nc(-c3cnco3)cs2)CC1)c1cc(Br)c(F)cc1F', 'O=C(NC1(c2ncc3c(n2)CCC3)CC1)N1CCC2(CCOCC2)C1', 'O=C(NC1C2CCC1CC2)C1CCCN1C(=O)[C@H]1C[C@@H]1c1ccco1', 'O=C(NC1CC(C(F)C(=O)N2CCC23CC(O)C3)C1)c1cccnn1', 'O=C(NC1CC(Nc2ccccc2)C1)N1CCC[Si]2(CCCC2)CC1', 'O=C(NC1CC1)C(=O)N1CC[C@H]2[C@@H](C1)[C@@H]2C(=O)Nc1ccc(O)nc1', 'O=C(NC1CC1)C1CCCN(C(=O)c2cc3ccc(F)cc3cn2)C1', 'O=C(NC1CC12CCC2)[C@@H]1C[C@H](F)CCN1C(=O)[C@H]1CCCC[C@H]1O', 'O=C(NC1CC2(C1)CC2C(=O)NCC1(Cl)CCC1)c1c[nH]c(=O)cn1', 'O=C(NC1CC2(CC(O)C2)C1)[C@@H]1C[C@@H](O)CN1C(=O)c1cnccn1', 'O=C(NC1CC2C(C1)C2NC(=O)C1CCC(F)(F)C1)c1csc(F)c1', 'O=C(NC1CC2CC1CC2Nc1ncc2sccc2n1)[C@H]1CCOC1', 'O=C(NC1CCC(C(=O)O)c2ccccc21)c1cc2ncccc2s1', 'O=C(NC1CCC(C2CCC2)CC1)N1CCOc2c(F)cccc2C1', 'O=C(NC1CCC2(CC1)CN(C(=O)CSC1CC1)C2)c1cc(Cl)ns1', 'O=C(NC1CCCC1)C(c1cnc(Cl)s1)N1CCCC(C2CC2)CC1', 'O=C(NC1CCCC12CN(C(=O)c1occ3c1CCOC3)C2)C1CC1', 'O=C(NC1CCCN(C(=O)C2CC=CCO2)CC1)c1cncc(F)c1', 'O=C(NC1CCCN(C(=O)c2cccc(CO)c2)CC1)c1cn[nH]c1', 'O=C(NC1CCCN(Cc2ccccc2)C1)c1ccc2c(c1)CCO2', 'O=C(NC1CCCN(S(=O)(=O)CCCCO)C1)C1CCc2nccn21', 'O=C(NC1CCCN(c2cccnn2)C1)c1c[nH]c(=O)c2cncn12', 'O=C(NC1CCCS(=O)(=O)c2ccccc21)N1C[C@@H]2OCCO[C@@H]2C1', 'O=C(NC1CCCc2sccc21)C(=O)NC1CCOC12CCCCC2', 'O=C(NC1CCCn2nccc21)c1cn[nH]c1CCNC(=O)C1CC1', 'O=C(NC1CCN(C(=O)[C@@H]2C[C@H]3C[C@@H]2C[C@H]3O)CC1)[C@H]1C[C@@H]1C1CC1', 'O=C(NC1CCN(CC2CC2)C1)[C@@H]1CC[C@@H]1NC(=O)[C@H](O)C(F)(F)F', 'O=C(NC1CCN(c2cc(O)ncn2)C1)c1cc(O)c2ccsc2c1', 'O=C(NC1CCN(c2cccc(F)c2)CC1)N1CCc2ccoc2C1', 'O=C(NC1CCN(c2cccc([N+](=O)[O-])c2)CC1)c1ccc(F)cc1', 'O=C(NC1CCN(c2ncccn2)CC1)N1CCC2(CC1)SCCS2', 'O=C(NC1CCNC12CCCC2)c1nn(-c2cccc(F)c2)cc1O', 'O=C(NC1CCNCC1O)C1CCCN1C(=O)c1ccc(Cl)c(Cl)c1', 'O=C(NC1CCc2c(cnn2CCO)C1)NC1(C2CCSCC2)CC1', 'O=C(NC1CN(C(=O)[C@H]2C[C@@H]2C2CCC2)C2CCCC12)C1=CCCC1', 'O=C(NC1COC2(C1)CN(C(=O)c1ccnn3ccnc13)C2)C1CC1', 'O=C(NC1C[C@H](NC(=O)C2(Cl)CC2)[C@@H](O)C1)c1ccc([N+](=O)[O-])nc1', 'O=C(NCC(=O)N(CC1(O)CCC1)C1CC1)c1c[nH]c2cnccc12', 'O=C(NCC(C1CC1)C1CC1)c1cc(C(F)(F)F)nc2c1CCCC2', 'O=C(NCC(F)(F)CO)c1sccc1CNC(=O)C1CCC(O)CC1', 'O=C(NCC(F)(F)F)C(=O)OCc1cccc(Oc2ccccc2)c1', 'O=C(NCC(F)(F)F)NNC(=O)NC1CCCC1c1ccc(Br)cc1', 'O=C(NCC(F)F)C(=O)N1CCC[C@@H](NC(=O)c2cc(CO)[nH]n2)C1', 'O=C(NCC(NC(=O)C1C=CCC1)C1CC1)c1cccn2nnnc12', 'O=C(NCC(NC(=O)[C@H]1CC1(F)F)C1CC1)c1ccnc(C(F)F)c1', 'O=C(NCC(Nc1nc2cc(Cl)ccc2o1)C1CC1)c1ccccn1', 'O=C(NCC(O)C(=O)N1CC(c2cccnc2)C1)C1CCC2(CC2)C1', 'O=C(NCC(O)CNC(=O)[C@H]1C[C@@H]1C1CC1)c1nccc2[nH]ccc12', 'O=C(NCC(O)c1cc(Cl)ccc1F)c1nccnc1-n1ccnc1', 'O=C(NCC(c1ccccc1)C1CCCC1)NC1CC2(CCCO2)C1', 'O=C(NCC1(C(=O)NC2CCSC2)CC=CC1)[C@@H]1[C@H]2[C@@H]3CC[C@@H](C3)[C@@H]12', 'O=C(NCC1(C(=O)O)CCC(F)(F)CC1)c1cnn(CC(F)(F)F)c1', 'O=C(NCC1(CC(=O)N2CCCCCO2)CC1)c1ccc(O)cc1F', 'O=C(NCC1(CNC(=O)C2CSCCS2)CCOCC1)c1cc[nH]n1', 'O=C(NCC1(CNc2nc3ncc(Cl)cc3o2)CC1)c1ccncn1', 'O=C(NCC1(CO)CCN(c2ncc([N+](=O)[O-])s2)C1)c1ccnnc1', 'O=C(NCC1(CO)CCOCC1)Nc1cc(Cl)ccc1N1CCCC1', 'O=C(NCC1(F)CN(C(=O)C2CCCCCCC2)C1)c1ccncn1', 'O=C(NCC1(NC(=O)[C@@H]2CC2(F)F)CCCCC1)c1cc(CO)[nH]n1', 'O=C(NCC1(O)CC(C(=O)NCc2cscn2)C1)c1ccc(O)cc1', 'O=C(NCC1(O)CC=CC1)c1ncoc1CNC(=O)C1CCCCC1', 'O=C(NCC1(O)CCC2(CC1)CC2)N[C@H]1C[C@@H]1c1c(Cl)cccc1Cl', 'O=C(NCC1(O)CCCCCC1)[C@H]1[C@@H]2CN(C(=O)C3=COCC3)C[C@@H]21', 'O=C(NCC1(O)CCN(C(=O)CCCC2CC2)C1)c1cc(Cl)ccn1', 'O=C(NCC1(OCCO)CCSC1)N1CCC(Cn2cncn2)CC1', 'O=C(NCC1(c2ccc(Cl)cc2Cl)CCC1)N1CCCC[C@H]1CCO', 'O=C(NCC1(c2ccccc2Cl)CCOCC1)c1cnn2c1SCC2', 'O=C(NCC1(c2nc3c(s2)CCCCC3)CC1)c1ccc(C(F)F)s1', 'O=C(NCC12CC(C(=O)O)(C1)C1(CCC1)O2)c1cc(Cl)c(O)c(Cl)c1', 'O=C(NCC12CCCC1CCC2)[C@@H]1[C@H](O)CCN1C(=O)C1CC=CC1', 'O=C(NCC12COCC(COC1)O2)[C@H]1CNC[C@@H]1c1ccc(Cl)cc1', 'O=C(NCC1=CCCC1)c1cc(-c2ccccc2)nc2ccccc12', 'O=C(NCC1=CCN(C(=O)C=C2CCC2)CC1)[C@H](O)C1CCCCC1', 'O=C(NCC1=NO[C@H]2COC[C@@H]12)NC(CCO)c1cc(Cl)cc(Cl)c1', 'O=C(NCC1C(C2CC2)CCN1C(=O)C1CCCC1)c1cscc1Cl', 'O=C(NCC1C=CCC1)C1c2c[nH]nc2CN1C(=O)C=CC(F)(F)F', 'O=C(NCC1CC(C(=O)N2CC3(CCOCC3)C2)=NO1)C(O)C1CC1', 'O=C(NCC1CC1)C1CCCN1S(=O)(=O)c1cc(F)c(F)c(F)c1F', 'O=C(NCC1CC12CCC1(CC2)OCCO1)Nc1csnc1C1CC1', 'O=C(NCC1CCC1)c1ccc(CNC(=O)C2(CO)CCOC2)cc1', 'O=C(NCC1CCC2(CCC2)C1O)Nc1cc2cccc(Br)c2cn1', 'O=C(NCC1CCCC(C(F)(F)F)O1)c1ccc(-n2cccn2)nc1', 'O=C(NCC1CCCC1)C1CN(C(=O)c2scnc2Cl)C2(CCC2)C1', 'O=C(NCC1CCCN(CCCNC(=O)C(F)(F)F)C1)c1ccco1', 'O=C(NCC1CCCOC1)C1CN(C(=O)CC(F)(F)F)C2(CCC2)C1', 'O=C(NCC1CCCc2[nH]cnc21)Nc1cc(C(F)(F)F)ccc1F', 'O=C(NCC1CCN(C2CC2)C1)N1CC[C@@H](Oc2ccc(F)cc2)C1', 'O=C(NCC1CCN1C(=O)CCC1CC1(F)F)c1cn(C2CC2)cn1', 'O=C(NCC1CCN1C(=O)c1cn2ccccc2n1)c1cnc(S)[nH]1', 'O=C(NCC1CCOCC1)C1CCCN1C(=O)C1=CC2C=CC(C1)C2', 'O=C(NCC1CCn2ccnc2C1)c1c(F)cc(OC(F)F)cc1F', 'O=C(NCC1COc2cscc2O1)NNc1ccc(C(F)(F)F)cc1', 'O=C(NCC1OCCC1C(=O)N[C@H](CO)C1(O)CC1)c1sccc1F', 'O=C(NCCC(F)=C(F)F)C1CCCN1C(=O)c1cnc(C2CC2)o1', 'O=C(NCCC(O)C1CC1)C1CCN1C(=O)c1ccc2cn[nH]c2c1', 'O=C(NCCC1(C(=O)N2CCC(O)CC2C2CC2)CC1)C1CC12CC2', 'O=C(NCCC1CC(C(=O)Nn2cncn2)C1)c1ccnn1C(F)F', 'O=C(NCCC1CC1)C(C1CC2CCC1O2)N1CCCS(=O)(=O)CC1', 'O=C(NCCC1CC=CC1)[C@H]1CCC=C[C@H]1NC(=O)[C@H]1C[C@@H]1[N+](=O)[O-]', 'O=C(NCCC1CCC2CC12)c1ccccc1OCc1cccnc1', 'O=C(NCCC1CCN(C(=O)C[C@@H]2CC[C@H](O)C2)CC1)c1cc[nH]n1', 'O=C(NCCC1CN(C(=O)C2(CF)CC2)C1)c1cncc2nc[nH]c12', 'O=C(NCCCC1(C(F)(F)F)OCCO1)Nc1nc2ccccc2s1', 'O=C(NCCCC1CC1)C(C1C2(CCC2)C12CCC2)N1CC2CC2C1', 'O=C(NCCCC1CCCCC1)Nc1ncn(Cc2ccccn2)n1', 'O=C(NCCCC1CCCCCC1)NCCN1CCc2sccc2C1', 'O=C(NCCCC1CCOC1=O)c1csc(Nc2ccc(Cl)cc2)n1', 'O=C(NCCCCC1CCCO1)NCCCc1nc2ccccc2s1', 'O=C(NCCCCCCCc1ccccc1)C1CCCC2(CCC2)O1', 'O=C(NCCCCN1CCOCC1)NCc1cn2cccc(Cl)c2n1', 'O=C(NCCCN1CCCC1)N(Cc1ccc(F)cc1Cl)CC1CC1', 'O=C(NCCCNS(=O)(=O)C1CC1)C(=O)Nc1cccc(C(F)F)n1', 'O=C(NCCCOCCO)C1COCCN1C(=O)c1ncccc1Cl', 'O=C(NCCCc1nccs1)NC(CC1CCCC1)c1ccccc1', 'O=C(NCCCc1noc(C(F)(F)F)n1)c1ccc(C(F)F)c(F)c1', 'O=C(NCCCn1ccc(=O)[nH]c1=O)Nc1ccccc1C(F)(F)F', 'O=C(NCCNS(=O)(=O)Cc1cccc(Cl)c1F)C1CC2C=CC1C2', 'O=C(NCCNc1ccc(-c2cc(I)on2)cn1)c1ccc(F)cc1', 'O=C(NCCNc1nc(-c2cccnc2)cs1)c1ccc(Br)c(O)n1', 'O=C(NCCOC1CCC1)C1=CCN(C(=O)Cc2cccnc2O)C1', 'O=C(NCCS(=O)c1ccccc1F)N1CC2(C[C@@H]1CO)OCCO2', 'O=C(NCC[C@@H]1CCCN1C(=O)c1cscn1)c1cc(C2CC2)sn1', 'O=C(NCC[C@H]1CCCN1C(=O)CNc1ccncc1)c1cnc[nH]1', 'O=C(NCC[C@H]1CCCN1C(=O)Cc1cccc(F)c1O)C1CCC1', 'O=C(NCCc1cc(C(=O)N2C[C@H](O)[C@@H](F)C2)no1)[C@@H]1CC=CCC1', 'O=C(NCCc1cc(C(F)(F)F)ccc1Br)c1cnc(C(=O)O)nc1', 'O=C(NCCc1cc(Cl)ccc1F)Nc1ccc(N2CCCC2)cn1', 'O=C(NCCc1cc(F)ccc1F)C1CCCN(c2ncccn2)C1', 'O=C(NCCc1cccc(C(F)(F)F)n1)N1CCO[C@H]2CCOC[C@@H]21', 'O=C(NCCc1cccc2c1CCOC2)[C@@H]1C[C@H]2CC[C@@H](C1)S2(=O)=O', 'O=C(NCCc1ccccc1OC(F)F)c1cc2c(F)cccc2o1', 'O=C(NCCc1cccnc1)C1CCN(C(=O)C2CC23CC3)C12CC2', 'O=C(NCCc1cnc2n1CCOC2)c1ccc2[nH]c(=O)ccc2c1', 'O=C(NCCc1cocn1)[C@@H]1C[C@H](O)CN1C(=O)C1CN2CCC1C2', 'O=C(NCCc1n[nH]c2ccccc12)Nc1ccc2scc(Br)c2c1', 'O=C(NCCc1ncccc1F)c1ccc(CN2CCCC2=O)cc1', 'O=C(NCCc1nnc2n1CCOC2)Nc1ccc2cccnc2c1', 'O=C(NCCc1noc2ccccc12)C1(n2cccn2)CCNCC1', 'O=C(NCCn1cc(-c2cccnc2)nn1)N1CCCC2(CCC2)C1', 'O=C(NCCn1cc(-c2ccn[nH]2)nn1)c1cc2cc(Br)cnc2[nH]1', 'O=C(NCCn1cc([C@@H]2COC[C@H]2O)nn1)C1CSc2ccccc21', 'O=C(NCCn1ccnn1)C1CC12CCN(C(=O)CC1CC=CC1)C2', 'O=C(NC[C@@H]1CC=CCC1)[C@H]1[C@H]2CC[C@H](C2)N1C(=O)CSC(F)(F)F', 'O=C(NC[C@@H]1CCCN(C(=O)COCC2CCC2)C1)C1CC(Cl)(Cl)C1', 'O=C(NC[C@@H]1CCCN1C(=O)c1cc(O)ncc1F)C1CC2(CC2)C1', 'O=C(NC[C@@H]1CCCN1C(=O)c1cnsn1)c1cccc2c1OCC2', 'O=C(NC[C@@H]1CCCO1)C1CCN(C(=O)c2c(F)cccc2F)CC1', 'O=C(NC[C@@H]1CCN(C(=O)c2cccc(=O)[nH]2)C1)c1ncc(F)cn1', 'O=C(NC[C@@H]1C[C@@H](O)CN1C(=O)c1csnn1)c1cc(F)cc(F)c1', 'O=C(NC[C@H]1C=C[C@@H](NC(=O)C2(c3cccs3)CC2)C1)C1C=CCC1', 'O=C(NC[C@H]1CCCC[C@H]1C(=O)N1CC(CC(F)F)C1)C1CC=CC1', 'O=C(NC[C@H]1CCCN(C(=O)CCC2CC2)C1)[C@H]1[C@H]2CCC(F)(F)[C@H]21', 'O=C(NC[C@H]1CCCN1C(=O)C1CCCOC1)c1n[nH]c(=O)[nH]c1=O', 'O=C(NC[C@H]1CCN(C(=O)C(F)(F)CO)C1)c1ccc2cncn2c1', 'O=C(NC[C@H]1CCN(C(=O)COC(F)(F)F)C1)[C@H]1C[C@@H]1c1ccsc1', 'O=C(NC[C@H]1CCO[C@H]1C(=O)N1CCCC2(CCC2)C1)c1cocn1', 'O=C(NC[C@H]1CCO[C@H]1C(=O)N1C[C@@H](F)[C@@H](F)C1)[C@H]1C[C@H]2C=C[C@@H]1C2', 'O=C(NC[C@H]1CC[C@H](C(=O)NCCN2CC=CC2)CC1)C1CCCC1', 'O=C(NC[C@H]1CC[C@H](O)CC1)[C@@H]1C[C@H](F)CN1C(=O)C1CC2(CC2)C1', 'O=C(NC[C@H]1CC[C@H]1C(=O)N1CC2CC2C2CC21)C1C=CC=CC=C1', 'O=C(NC[C@H]1CC[C@H]1C(=O)N1CCCC2(CC1)CC2)c1cc(F)c[nH]1', 'O=C(NC[C@H]1CC[C@H]1NS(=O)(=O)C(F)(F)F)c1cc(F)cc(F)c1F', 'O=C(NC[C@H]1CN(C(=O)COCC(F)(F)F)C[C@H]1O)C(F)C(F)(F)F', 'O=C(NC[C@H]1C[C@@H](O)C1)C(=O)Nc1cnc(N2CCOCC2)c(Br)c1', 'O=C(NC[C@H]1C[C@@H](O)C1)c1cccc(S(=O)(=O)NCc2cccs2)c1', 'O=C(NC[C@H]1C[C@@H]2CC[C@H]1N2S(=O)(=O)C(F)(F)F)c1ccccc1O', 'O=C(NC[C@H]1C[C@H]1C(=O)Nc1cccc(O)c1)c1cccc(CO)c1', 'O=C(NC[C@H]1C[C@H]1CC(=O)N1CCOCC(O)C1)c1coc(CO)c1', 'O=C(NC[C@]1(F)C[C@@H](CO)C1)[C@H]1C[C@H](O)CN1C(=O)[C@H]1[C@@H]2COC[C@@H]21', 'O=C(NCc1cc(F)ccc1C(=O)O)c1cc(-c2cccnc2)ns1', 'O=C(NCc1cc(O)ns1)[C@@H]1[C@H](O)CCN1C(=O)CC1CCSCC1', 'O=C(NCc1ccc(-c2ccsc2)nc1)c1cnc2ccccc2c1', 'O=C(NCc1ccc(-c2cncnc2)cc1)NCC(CO)C1CCC1', 'O=C(NCc1ccc(C(=O)N2CCOC3(CC3)C2)o1)[C@H]1CCC[C@@H]1O', 'O=C(NCc1ccc(C2CC2)cc1)C(=O)N1CCC(C2CCCO2)C1', 'O=C(NCc1ccc(Cl)c(O)c1)C1CCC(Oc2ccccc2)CC1', 'O=C(NCc1ccc(Cl)c(O)c1)NC1(c2ccc(Cl)cc2)CCCC1', 'O=C(NCc1ccc(F)c(O)c1)c1c(C(F)(F)F)nc2ccccn12', 'O=C(NCc1ccc(F)cc1Br)C(=O)NCC1CN2CCCC2CO1', 'O=C(NCc1ccc(OC(F)(F)F)cc1)Nc1cccc2c1CCO2', 'O=C(NCc1ccc2[nH]c(=O)[nH]c2c1)NC1CC2CCCCCC2C1', 'O=C(NCc1ccc[nH]c1=O)N1CCN2Cc3ccccc3CC2C1', 'O=C(NCc1cccc(-c2cc[nH]n2)c1)NC1CCN2CCCCC12', 'O=C(NCc1cccc(O)c1Br)Nc1cc(C(F)(F)F)c(F)cc1O', 'O=C(NCc1cccc(SC(F)F)c1)c1ccccc1OC1CCC1', 'O=C(NCc1cccc([N+](=O)[O-])c1F)C1CCCN(c2cncs2)C1', 'O=C(NCc1ccccc1I)NNc1ccccc1-c1ccccc1', 'O=C(NCc1ccccc1O)NNC(=O)c1cccc2cccnc12', 'O=C(NCc1ccn(-c2ccc(F)cc2)n1)Nc1ccc(Cl)c(F)c1', 'O=C(NCc1ccn(C2CCCC2)n1)c1cn2cc(F)cc(Br)c2n1', 'O=C(NCc1ccn2nccc2c1)NC1(CO)Cc2ccccc2C1', 'O=C(NCc1ccnc(OC(F)F)c1)C1CCN(S(=O)(=O)C(F)F)C1', 'O=C(NCc1ccoc1C(F)(F)F)[C@H]1C[C@@]12CCOc1ccccc12', 'O=C(NCc1cn(CCO)c(=O)[nH]c1=O)[C@H]1CNCC[C@@H]1C(F)(F)F', 'O=C(NCc1cn2cc(Cl)cc(Cl)c2n1)c1ccc(C(=O)O)c(Br)c1', 'O=C(NCc1cn2ccccc2n1)Nc1ccc(OCC(F)F)cc1', 'O=C(NCc1cnns1)C1CCCN1C(=O)c1cccn2nccc12', 'O=C(NCc1cnsc1)C1CCCCN1C(=O)C1=NO[C@H]2COC[C@@H]12', 'O=C(NCc1csc(CCc2ccccc2)n1)C1C2CCS(=O)(=O)C21', 'O=C(NCc1cscn1)c1cnn(-c2ccc(=O)[nH]n2)c1C(F)(F)F', 'O=C(NCc1nc(-c2ccco2)n[nH]1)c1cnc(-c2cccnc2)s1', 'O=C(NCc1noc(-c2ccc(Cl)cc2F)n1)C(Cl)c1ccccc1', 'O=C(NCc1ocnc1C(=O)N1CCCCC(CO)C1)C1C=CCC1', 'O=C(NN1CCC[C@H]1C(=O)NCCN1CC[C@H](O)C1)c1cccnc1', 'O=C(NNC(=O)C1CC1(F)F)NC1CCCCC1Cc1ccccc1', 'O=C(NNC(=O)[C@H]1CCCO1)c1cccc(CN2C(=O)CNC2=O)c1', 'O=C(NNC(=O)c1cccc2[nH]ccc12)c1nc2cc(F)ccc2s1', 'O=C(NNC(=O)c1nc2c(Br)cccn2n1)c1ccc2[nH]ccc2c1', 'O=C(NNC(=S)NCCCN1CCOCC1)c1ccc2[nH]cnc2c1', 'O=C(NNc1ccc(-c2ccc(Cl)s2)nn1)Nc1snc2c1CCC2', 'O=C(NNc1ccc(Cl)cc1Cl)C1(Cc2ccccc2)CCNCC1', 'O=C(NNc1ccc2nncn2n1)Nc1ccc2c(c1)S(=O)(=O)C=C2', 'O=C(NNc1cccc2cnccc12)Nc1c(F)cc(I)c(F)c1F', 'O=C(NNc1ncc(Cl)cn1)Nc1cc(N2CCCC2=O)ccc1Cl', 'O=C(NOC1CCC1)C1CC2CC1CN(C(=O)C13C=CC(CC1)C3)C2', 'O=C(NOCC1CCCC1)C1CC2(CCN1C(=O)C1CCSC1)CC2', 'O=C(NOCC1CCOC1)[C@H]1C[C@H]2C[C@@H]1CN(C(=O)C1SCCS1)C2', 'O=C(NOCc1cn(CC2CCCOC2)nn1)c1ccc(CO)cn1', 'O=C(NS(=O)(=O)c1cc2sccc2s1)c1ccccc1-n1cccn1', 'O=C(N[C@@H](CC1CC1)C(=O)NCCOc1cccnc1)c1cocn1', 'O=C(N[C@@H](CO)CC1CCCCC1)c1cc(=O)c2cc(O)ccc2o1', 'O=C(N[C@@H]1CCCN(CCO)C1)c1cc2ccc(OC(F)F)cc2[nH]1', 'O=C(N[C@@H]1CCN(C(=O)C2CC(F)(CF)C2)C[C@H]1F)C1CC12CCC2', 'O=C(N[C@@H]1CC[C@H](CC(=O)N2CCc3nocc3C2)C1)c1cocn1', 'O=C(N[C@@H]1CC[C@H](CNC(=O)C2CC3(CCC3)C2)C1)c1cnc(Cl)s1', 'O=C(N[C@@H]1C[C@H](C(=O)NC2C=CCCC2)C[C@H]1O)c1cccnc1O', 'O=C(N[C@@H]1C[C@H](C(=O)NC[C@H]2C[C@H]2CO)C[C@H]1O)C1C[C@H](O)[C@@H](F)C1', 'O=C(N[C@H](C(=O)NC[C@]1(F)C[C@@H](CO)C1)C1CCC1)c1ccc(F)s1', 'O=C(N[C@H]1C=CCC[C@H]1C(=O)N1CC(CO)C2(CC2)C1)c1ccns1', 'O=C(N[C@H]1C=CC[C@H](C(=O)N2CCC(CF)CC2)C1)[C@H]1CC[C@H]2C[C@H]21', 'O=C(N[C@H]1C=C[C@H](C(=O)N2CCC3(CSC3)C2)C1)C1C2CCC(F)C21', 'O=C(N[C@H]1CC=CC[C@H]1C(=O)NO[C@H]1CC[C@H](O)[C@@H]1O)C1CCCC1', 'O=C(N[C@H]1CCCCN(C(=O)C2CCN(C3COC3)C2)C1)[C@H]1C[C@H]1F', 'O=C(N[C@H]1CCCCN(C(=O)Cc2cccc(O)c2)C1)c1ccsc1', 'O=C(N[C@H]1CCCC[C@H]1C(=O)NCC1(F)CCOC1)c1cc(Cl)no1', 'O=C(N[C@H]1CCCN(C(=O)c2ccc([N+](=O)[O-])cc2)C1)c1cnns1', 'O=C(N[C@H]1CCC[C@@H]1C(=O)N[C@H](CO)Cc1c[nH]cn1)c1cnns1', 'O=C(N[C@H]1CCC[C@@H]1F)C1CC2CCC(C1)N2C(=O)C(O)C(F)(F)F', 'O=C(N[C@H]1CCC[C@H]1N1CCC(O)C1)c1cccc(C#CC2CC2)c1', 'O=C(N[C@H]1CCC[C@H]1O)c1[nH]ncc1CNC(=O)C1CCCCC1F', 'O=C(N[C@H]1CCN(C(=O)CCF)[C@@H]1C1CC1)c1cc2ccccn2c1', 'O=C(N[C@H]1CCOC[C@H]1NC(=O)C1CCC(O)CC1)C1=CCCSC1', 'O=C(N[C@H]1CCO[C@H]1C(=O)N1CCC(N2CCC2)CC1)c1cc[nH]n1', 'O=C(N[C@H]1CCO[C@H]1C(=O)NCCCN1CCCC1=O)C1=COCC1', 'O=C(N[C@H]1CC[C@@H](C(=O)N2CC(OCCF)C2)CC1)C1CC=CCO1', 'O=C(N[C@H]1CC[C@@H](C(=O)NCCC(F)(F)CO)CC1)c1[nH]ncc1Cl', 'O=C(N[C@H]1CC[C@@H](C(=O)NCCC2CCOC2)C1)c1ncc(F)cn1', 'O=C(N[C@H]1CC[C@@H](C(=O)N[C@H]2CC[C@H]3CCC[C@@H]2O3)C1)c1ccco1', 'O=C(N[C@H]1CC[C@@H](O)CC1)[C@H]1C[C@H](F)CN1C(=O)C(CO)C(F)(F)F', 'O=C(N[C@H]1CC[C@H]1C(=O)Nc1ccc(O)cc1)C(F)CC1CCOC1', 'O=C(N[C@H]1CC[C@H]1NC(=O)C12CSCC1C2)C1COC2COCC2O1', 'O=C(N[C@H]1CN(C(=O)CC2CCSC2)C[C@H]1CO)c1ccncc1Cl', 'O=C(N[C@H]1C[C@@H](C(=O)NCCn2cnccc2=O)C1)c1cnccn1', 'O=C(N[C@H]1C[C@@H]1c1cccnc1)[C@@H]1C[C@H](O)CN1C(=O)c1cc[nH]n1', 'O=C(N[C@H]1C[C@@H]2C[C@H]1C[C@@H]2C(=O)N1CC[C@@H](F)C1)[C@H]1[C@@H]2CCCC[C@@H]21', 'O=C(N[C@H]1C[C@@H]2C[C@H]1C[C@@H]2C(=O)NCCOCC(F)F)c1cnns1', 'O=C(N[C@H]1C[C@H](C(=O)NC2CN(CC(F)F)C2)C1)C1CCC=CCC1', 'O=C(N[C@H]1C[C@H](CNC(=O)C2(O)CCC2)C1)c1cccn2ccnc12', 'O=C(N[C@H]1C[C@H](CO)C1)C1CCN(C(=O)c2nn[nH]c2C2CC2)CC1', 'O=C(N[C@H]1C[C@H](NC(=O)C2CCSCC2)C1)c1cncc2c1CCC2', 'O=C(N[C@H]1C[C@H]1NC(=O)c1cccn2cnnc12)c1cnc(S)cn1', 'O=C(N[C@H]1C[C@]2(CCCO2)C1)C1CSCCN1C(=O)C1CC12CCC2', 'O=C(N[C@]1(C(=O)O)C[C@H]1C(F)(F)F)c1ccc(-c2ccccc2)nc1', 'O=C(Nc1c(Cl)c(Cl)nc(Cl)c1Cl)c1ccc([N+](=O)[O-])cc1[N+](=O)[O-]', 'O=C(Nc1cc(-c2ccc(F)cc2)n[nH]1)Nc1cc(F)c(Cl)nc1Cl', 'O=C(Nc1cc(F)cc(CO)c1)c1nc(C(F)(F)F)n2ccncc12', 'O=C(Nc1ccc(-c2nnco2)cc1)Nc1ccc2nccnc2c1', 'O=C(Nc1ccc(-n2ccc(=O)cc2)nc1)c1cc(Br)c(F)cc1O', 'O=C(Nc1ccc(=O)n(Cc2cccc(F)c2)c1)C1CC2(CC2)CO1', 'O=C(Nc1ccc(C(F)(F)C(F)(F)F)nc1)Nc1cnn(C(F)F)c1', 'O=C(Nc1ccc(C(F)(F)F)nc1)N1CCC(c2ccccc2O)C1', 'O=C(Nc1ccc(Cl)cc1-n1cccn1)C1(c2ccnc(Cl)c2)CC1', 'O=C(Nc1ccc(Cl)nc1)C1(F)CCCN(C(=O)[C@]23COC[C@H]2C3)C1', 'O=C(Nc1ccc(OCC(F)F)cc1)N1CCOC2(CCOCC2)C1', 'O=C(Nc1ccc2c(Cl)ccnc2n1)c1cccc(-n2cncn2)n1', 'O=C(Nc1ccc2c(c1)CCCCC2)NC1CCc2nncn2CC1', 'O=C(Nc1ccc2cc[nH]c(=O)c2c1)C(=O)NC1CCCS(=O)(=O)C1', 'O=C(Nc1ccc2ccccc2c1Br)N[C@H](C(F)F)C1CCOCC1', 'O=C(Nc1ccc2cnccc2c1)C(=O)N1Cc2ccc(Cl)cc2C1', 'O=C(Nc1ccc2ncc(Cl)n2c1)c1nc(Cc2ccccc2)cs1', 'O=C(Nc1cccc(Br)n1)C(=O)N1CCCC1c1noc(C2CC2)n1', 'O=C(Nc1cccc(C2CCNCC2)c1)C1CNCC12CCCCC2', 'O=C(Nc1cccc(CCN2CCCC2)c1)Nc1ccc(F)nc1F', 'O=C(Nc1cccc(N2CCNC2=O)c1)c1ccc2c(n1)CCNC2', 'O=C(Nc1cccc(NC(=O)N2CCCC=C2Cl)c1)c1ccccc1', 'O=C(Nc1cccc(OCC(F)(F)F)c1)C1CSC(c2cccs2)=N1', 'O=C(Nc1ccccc1OCc1cscn1)NC(CO)C1CCCC1', 'O=C(Nc1ccccn1)C1CCN(C(=O)[C@H]2C[C@@H]3CNC[C@@H]3N2)CC1', 'O=C(Nc1cccn2ncnc12)NC1CS(=O)(=O)Cc2ccccc21', 'O=C(Nc1cccnc1)c1ccc(NC(=O)N2CCC[C@H](F)C2)cc1', 'O=C(Nc1ccnc2ccc(Br)cc12)c1ncc(F)c2ccccc12', 'O=C(Nc1ccncc1N1CCCCC1)c1cn(CC(F)(F)F)nn1', 'O=C(Nc1ccsc1)C1CC12CCN(C(=O)C(F)C1CCCCC1)C2', 'O=C(Nc1cnc2c(c1)COCC2)c1c[nH]c2cc([N+](=O)[O-])ccc12', 'O=C(Nc1cncc(-c2cc[nH]n2)c1)c1ccc(-n2cncn2)cc1', 'O=C(Nc1cncc(N2CCCC2)n1)c1cc(Br)c2ccccc2c1', 'O=C(Nc1cncc2c1CCNC2=O)c1cc(Cn2cccn2)on1', 'O=C(Nc1cnn(CCN2CCOC2=O)c1)Nc1cccc(Cl)c1F', 'O=C(Nc1csc(Cl)c1)C(=O)N1CC[C@H](c2ccccc2)[C@H](CO)C1', 'O=C(Nc1nc(-c2ccc([N+](=O)[O-])cc2)no1)C(=O)OCC(F)(F)F', 'O=C(Nc1nc(-c2cccs2)ns1)N1CCC(CCC(F)(F)F)CC1', 'O=C(Nc1nc(C2CC(O)C2)cs1)c1cccc(-n2nn[nH]c2=O)c1', 'O=C(Nc1nc(C2CCCOC2)cs1)N1CC(Oc2ccccc2)C1', 'O=C(Nc1nc(CN2CCOCC2)cs1)C1(n2cccn2)CCCC1', 'O=C(Nc1nc(Cl)nc2c1CCCC2)c1cnn(-c2ccccc2)n1', 'O=C(Nc1nc2c(Cl)cc(F)cc2s1)N1CCC(c2ncon2)CC1', 'O=C(Nc1nc2cc(Cl)ccn2n1)N1CC=C(c2ccccc2)CC1', 'O=C(Nc1ncccc1OCC(F)F)N1CCC(C2=NOCC2)CC1', 'O=C(Nc1noc2c1CCCC2)C1=C(c2cccc(F)c2)CCCC1', 'O=C(Nc1sccc1C(=O)OC1CC(C(F)F)C1)c1ccccc1Cl', 'O=C(Nn1cnc2sc3c(c2c1=O)CCCC3)c1cncn1C1CC1', 'O=C(Nn1cncn1)[C@@H]1COCCN1C(=O)c1cccc2occc12', 'O=C(O)C(F)=C1CCN(C(=O)CCn2[nH]c(=O)c3ccccc32)CC1', 'O=C(O)C1(N2CCN(Cc3n[nH]c4c(F)cccc34)CC2)CCOC1', 'O=C(O)C1CCCN(C(=O)Nc2ccccc2Oc2ccccn2)C1', 'O=C(O)C1CCCN(S(=O)(=O)NC2CCCCc3ccc(Br)cc32)C1', 'O=C(O)C1CCN(C2CN(C(=O)[C@H]3CCCC[C@@H]3C(F)(F)F)C2)CC1', 'O=C(O)C1CN(C(=O)C2CN(C(=O)c3cncc(C(F)(F)F)n3)C2)C1', 'O=C(O)CC1CC2(CCN(C(=O)C3CCN3Cc3ccccc3)C2)C1', 'O=C(O)CCNC(=O)CCCNC(=O)c1cc(OC2CC2)ccc1F', 'O=C(O)CC[C@H]1C[C@@H](NC(=O)c2cc3c(cn2)[nH]c2ccccc23)C1', 'O=C(O)CCc1cccnc1C(=O)NCCSCc1ccnc(Cl)c1', 'O=C(O)CCn1cc(NC(=O)CN2CCCC(C(F)(F)F)C2=O)cn1', 'O=C(O)CN(Cc1ccc(C(F)(F)F)cc1)C(=O)CC1=CCCCC1', 'O=C(O)C[C@H]1[C@H](O)C[C@@H]1NC(=O)c1cncc(-c2ccc(F)cc2)c1', 'O=C(O)Cc1c(C(=O)N2C[C@@H]3C[C@H](C2)[C@H](O)[C@@H]3O)[nH]c2ccccc12', 'O=C(O)Cc1ccc(S(=O)(=O)N2CCOC(c3cccnc3)C2)cc1', 'O=C(O)Cc1nnc(CNC(=O)c2cc3c(F)c(F)c(F)cc3[nH]2)s1', 'O=C(O)c1c(F)cc(C(=O)N2CC(Cc3ccccc3Cl)C2)cc1F', 'O=C(O)c1c[nH]nc1OC1CN(C(=O)Cc2c(Cl)cc(Cl)cc2Cl)C1', 'O=C(O)c1cc(Br)cc(CNC(=O)c2ccnn2-c2cccnc2)c1', 'O=C(O)c1cc(Cl)ccc1C(=O)Nc1ccc(-n2nn[nH]c2=O)cc1', 'O=C(O)c1ccc(N2CC(NC(=O)C34CCCCC3C4(F)F)C2)nc1', 'O=C(O)c1ccc(N2CCN(c3nccnn3)CC2)c2ncccc12', 'O=C(O)c1ccc(S(=O)(=O)N2CC(=O)N3CCCC3C2)c([N+](=O)[O-])c1', 'O=C(O)c1ccc2nc(NC3CCC(OC4CC4(F)F)CC3)sc2c1', 'O=C(O)c1cn(CC2CCCN2C(=O)c2snnc2C2CCC2)nn1', 'O=C(O)c1cnc(N2CCOC[C@]3(COC[C@H]4CCCCN43)C2)cn1', 'O=C(O)c1cncc(CN(Cc2ccccn2)c2ccc(Br)cc2)c1', 'O=C(O)c1cnn(C2CN(C(=O)c3cnnn3-c3ccccc3)C2)c1', 'O=C(O)c1n[nH]c2ccc(C(=O)N3CC(Oc4ccccc4)C3)cc12', 'O=C(O)c1nccnc1C(=O)OCc1ccccc1OCC(F)(F)F', 'O=C(O)c1nnc2n1CCN(C(=O)c1cc3c(cc1O)OCCO3)C2', 'O=C(OCC1CC(C(F)(F)F)CO1)[C@H]1CCC[C@@H](c2ccccc2)O1', 'O=C(OCC1CCC2(CCCCCCC2)O1)c1cccc2cnnn12', 'O=C(OCC1CS(=O)(=O)CCO1)c1ccc(-c2ccncc2)c(F)c1', 'O=C(OCCCNC(=O)C1CCCC1)c1ccc(Cl)c(C(F)(F)F)n1', 'O=C(OCCSc1ccnc2cc(Cl)ccc12)c1ccc(O)cc1F', 'O=C(OCCc1ccc2c(c1)CCCO2)c1c(Cl)oc2ccccc12', 'O=C(OCCn1cnnn1)c1cn(-c2ccccc2)nc1C(F)(F)F', 'O=C(OCc1c(F)cc(F)cc1F)c1ccc(-c2ccccn2)cc1', 'O=C(OCc1ccc(Cl)c2cccnc12)C(O)c1ccc(Cl)cc1Cl', 'O=C(OCc1nc(-c2cccs2)no1)c1ccc2c(c1)NS(=O)(=O)O2', 'O=C(OCc1nn(CC(F)(F)F)cc1Br)c1cc(Cl)cc([N+](=O)[O-])c1', 'O=C(OCc1nncn1-c1ccccc1)c1ccn2ncc(Br)c2n1', 'O=C(Oc1cc(F)ccc1[N+](=O)[O-])C(F)c1ccc(C(F)(F)F)cc1', 'O=C(Oc1ccc(-n2ccnn2)cc1)C1CN(c2ncc(F)cn2)C1', 'O=C(Oc1ccc(Cl)c2cccnc12)[C@@H]1CSC(c2ccccc2)=N1', 'O=C([C@@H](O)C(F)(F)F)N1CC(F)(C(=O)N2CC3(CC(CO)CO3)C2)C1', 'O=C([C@@H](O)C1CCCCC1)N1C[C@@H]2[C@H](C1)[C@H]2NS(=O)(=O)c1cncs1', 'O=C([C@@H]1CC2(CC2)CN1C(=O)c1ncccn1)N1CCCC(CF)C1', 'O=C([C@@H]1CCC[C@H](O)C1)N(CCCC1CC(F)(F)C1)Cc1cccs1', 'O=C([C@@H]1C[C@@H]2C[C@@H]2N1C(=O)C1=COCC1)N1CCC2(C=CCO2)CC1', 'O=C([C@@H]1C[C@@H]2C[C@@H]2N1C(=O)CCc1cccnc1)N1CC(O)CCO1', 'O=C([C@@H]1C[C@H](F)CCN1C(=O)c1cnncc1O)N1C2CCC1CC2', 'O=C([C@@H]1C[C@H]2C=C[C@@H]1C2)N(CCOCC(F)(F)F)Cc1ccccc1', 'O=C([C@@H]1[C@H]2C[C@@H]1N(C(=O)c1cc(CO)[nH]n1)C2)N1CC(N2CCC2)C1', 'O=C([C@@H]1[C@H]2C[C@H]2CN1C(=O)CCn1cccn1)N1C[C@@H]2C[C@H]1CS2=O', 'O=C([C@H]1CCCC[C@@H]1c1cccc(Cl)c1)N1CC(c2nnc(S)o2)C1', 'O=C([C@H]1CCCN1C(=O)C#CC1CCOC1)N1CCC(C2CC2)CC1', 'O=C([C@H]1CCCN1C(=O)c1cc(F)c[nH]1)N1CC(O)C2(CCCC2)C1', 'O=C([C@H]1CCC[C@H]1NC(=O)C12CC(F)(C1)C2)N1C[C@H]2CCCC[C@H]2C1', 'O=C([C@H]1C[C@@H]1C1CC1)N1CCC(CC(=O)N2CCOCC2CCO)C1', 'O=C([C@H]1C[C@@H]1C1CN(C(=O)C2(F)CCCC2)C1)N1C[C@H]2CSC[C@H]2C1', 'O=C([C@H]1C[C@@H]1[N+](=O)[O-])N1C[C@H]2CC[C@@]2(CNC(=O)C2(C3CC3)CC2)C1', 'O=C([C@H]1C[C@@H]2CC[C@H]1CC21OCCO1)N(CC1CC1)C1CCCCC1', 'O=C([C@H]1C[C@H](O)CN1C(=O)C1CCC(CO)CC1)N1C[C@H](F)[C@@H](F)C1', 'O=C([C@H]1C[C@H](O)[C@H](O)CO1)N(CCCO)C1CCCc2ccccc21', 'O=C(c1cc(-c2cccc(F)c2)no1)N1CCCCC1c1ncno1', 'O=C(c1cc(CO)[nH]n1)N(Cc1ccc(-n2cncn2)cc1)C1CC1', 'O=C(c1cc(Cl)c(F)cc1O)N1CCC(c2nc(C3CC3)no2)CC1', 'O=C(c1cc(F)c[nH]1)N1CCCC[C@@H]1C(=O)N1CC2CCC1(CO)C2', 'O=C(c1cc(N2CCCC2=O)ccc1Cl)N1CC(=O)N2CCCC2C1', 'O=C(c1cc2c(=O)[nH]ccn2n1)N1CCCC1c1ccc(Br)c(F)c1', 'O=C(c1cc[nH]n1)N1CC(C2CN(C(=O)c3nsnc3O)CCO2)C1', 'O=C(c1ccc(-n2cccn2)cc1Cl)N1CC(Nc2ccccc2)C1', 'O=C(c1ccc(=O)[nH]n1)N1CC=C(CNc2ncnc3ncsc23)C1', 'O=C(c1ccc(Cl)c(O)c1)N1C[C@@H]2C[C@H]1CN2C(=O)c1c[nH]c(=O)o1', 'O=C(c1ccc(Cl)o1)N(Cc1ccc2cc[nH]c2c1)Cc1ncc[nH]1', 'O=C(c1ccc(F)cc1)N1CC2CC(C1)N(C(=O)c1ccncn1)C2', 'O=C(c1ccc2[nH]c(=O)c(=O)[nH]c2c1)N1CCCC(C2CCNC2)C1', 'O=C(c1ccc2c(c1)OCCO2)N1CCS(=O)(=O)N2CCCCCC12', 'O=C(c1cccc(-n2cccn2)n1)N1CNS(=O)(=O)c2ccccc21', 'O=C(c1cccc(C(F)C(F)(F)F)n1)N1CCC(C2CCCN2)CC1', 'O=C(c1cccc(O)c1)N1CCN(Cc2cc(Cl)c(Cl)cc2Cl)CC1', 'O=C(c1ccccc1)C1CCN(C(=O)NCc2cc(Br)cnc2Cl)C1', 'O=C(c1ccccc1-n1cccn1)N1CCC(c2ccccc2)CC1', 'O=C(c1ccccc1SCc1ccco1)N1CC2(CO)CCC1CC2', 'O=C(c1cccn1C1CCCC1)N1CCCNC(c2ccccc2)C1', 'O=C(c1cccn1Cc1cccs1)N1CCC(O)(C(F)(F)C(=O)O)C1', 'O=C(c1ccco1)N1CCN(S(=O)(=O)c2ccc3c(c2)OCC3)CC1', 'O=C(c1cccs1)C1CCN(S(=O)(=O)CCOC2CCCCC2)CC1', 'O=C(c1ccn(C2CC2(F)F)n1)N(CCCO)Cc1ccc(F)cc1', 'O=C(c1ccn2nccc2c1)N1CCC(n2cc(CCCO)nn2)C1', 'O=C(c1ccncc1)N1CC(OCC(=O)N2CC3CCC2(CO)C3)C1', 'O=C(c1ccoc1Cl)N1CC(CNC(=O)C(F)(F)C2CC2)C2(CC2)C1', 'O=C(c1ccsc1)N1CCCN(Cc2nc3ccccn3c2Br)CC1', 'O=C(c1cn(C[C@@H]2CCCN2)nn1)N1CCCN(CC(F)(F)F)CC1', 'O=C(c1cnc(-c2ccc(Cl)cc2)s1)N(CCO)C1CC2CCC1C2', 'O=C(c1cnc(Oc2cccc(Cl)c2)s1)N1C[C@H]2C[C@H](CO)C[C@@H]1C2', 'O=C(c1cnc2ccncc2c1)N1CCn2cccc2C12CCOC2', 'O=C(c1cnccn1)N1CCN(Cc2cccc(C(F)F)c2F)CC1', 'O=C(c1cncn1-c1ccc(Br)cc1)N(CCO)Cc1cccnc1', 'O=C(c1cncnc1)N1CC2CCC(C1)N2C(=O)COc1ccon1', 'O=C(c1cncs1)N1CCC(F)(C(=O)NC(C(O)CO)C2CC2)CC1', 'O=C(c1coc(CO)c1)N1CCC2(CC1)CC2C(=O)N1CCCCC1', 'O=C(c1csc(Cl)c1)N1C[C@@H]2[C@H](C1)[C@H]2C(=O)N1CCCC1CC1CC1', 'O=C(c1cscc1Cl)N1CC2(C(=O)N3CCC3CC3CC3)CC1CO2', 'O=C(c1csnn1)N1CCC2(CC2C(=O)N2CC[C@@H](OC3CC3)C2)C1', 'O=C(c1nc2sccn2c1Cl)N1CCCc2c(OC(F)F)cccc21', 'O=C(c1ncc(-c2ccccn2)o1)N1C[C@@H]2[C@H](C1)[C@H]1C[C@@H]2[C@H](O)[C@@H]1O', 'O=C(c1ncccc1O)N1CC(C(O)C(=O)N2CCC3(CC2)N=N3)C1', 'O=C(c1nsnc1O)N(Cc1nc(Cl)ccc1F)CC1CCC2CC21', 'O=C(c1occc1-c1ccc(F)c(F)c1)N1CCCC12CCOC2=O', 'O=C(c1sccc1CO)N(CCO)CCCNC(=O)C12CSCC1C2', 'O=C(c1snnc1C1CC1)N(Cc1ccncc1)Cc1cccnc1', 'O=C1C2CC3(CCC3)CN2C(=O)N1CC(c1ccco1)N1CCCC1', 'O=C1CC(=O)N[C@H](C(=O)N2[C@H]3CC[C@@H]2[C@H](C(=O)NCC2CSC2)C3)C1', 'O=C1CC(C#CC(=O)N(Cc2ccc(-c3ccn[nH]3)o2)CC(Cl)Cl)C1', 'O=C1CC(C(=O)N2CC(C(=O)N3CCC(CO)CC3)C3(CC3)C2)=NN1', 'O=C1CC(C(=O)N2CC=C(CNS(=O)(=O)C3(Cl)CC3)CC2)CC(=O)N1', 'O=C1CC(C(=O)N2CCC(C(=O)NCc3cncn3C3CC3)C2)CN1', 'O=C1CC(C(=O)N2CCC[C@H]2c2cn([C@H]3C[C@H](O)C3)nn2)(C2CC2)C1', 'O=C1CC(C(=O)NCC23CC(NC(=O)c4cnc(S)cn4)(C2)C3)CN1', 'O=C1CC(C(=O)NCCSc2ccccc2F)(c2cccc(Cl)c2)C1', 'O=C1CC(C(=O)NNc2nc(Cl)c(Cl)nc2Cl)Oc2ccc(Cl)cc21', 'O=C1CC(C(=O)Nc2c(F)cc(F)c(Cl)c2Br)c2cccc(F)c2N1', 'O=C1CC(CC(=O)N2C[C@@H](F)C[C@H](NC(=O)C3=C(Cl)CCC3)C2)CO1', 'O=C1CC(NC(=O)C(Cn2cccn2)NC(=O)CSC2CC2)CCN1', 'O=C1CC(NC(=O)C2=CCCN(C(=O)c3ccncc3)C2)CC(=O)N1', 'O=C1CC(NC(=O)[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2NC(=O)c2cc(F)c[nH]2)CN1', 'O=C1CC(c2ccc(NC(=O)N3CCC[C@H]4NC(=O)C[C@H]43)cc2)CN1', 'O=C1CC2(C1)CC(C(=O)NCCCCNC(=O)c1ccc(CO)o1)C2', 'O=C1CC2(CCN(C(=O)NCc3ccc(SC(F)(F)F)cc3)C2)CN1', 'O=C1CCC(C(=O)NC2(C(=O)NCCn3cnnc3)CCCCC2)O1', 'O=C1CCC(C(=O)NNC(=O)c2cccn(-c3ccccc3)c2=O)N1', 'O=C1CCC(CC(=O)N2CC(C(O)C(=O)N(CC(F)F)C3CC3)C2)C1', 'O=C1CCC(CC(=O)NCCc2nc(CC3CCCOC3)cs2)CN1', 'O=C1CCC(CCC(=O)NCC2CCN2C(=O)C2=CCOCC2)CN1', 'O=C1CCC(COC(=O)CCC2CC(F)(F)C2)(c2ccccc2)CN1', 'O=C1CCC(NC(=O)[C@@H]2CC[C@H](CNC(=O)[C@H]3[C@@H]4CCC[C@@H]43)C2)CN1', 'O=C1CCC(NC(=O)[C@H]2[C@@H]3CN(C(=O)c4ccns4)CC[C@@H]32)CCN1', 'O=C1CCC2(CC1)CCC(COC(=O)c1csc3c(Cl)cccc13)O2', 'O=C1CCC2CN(C(=O)NCC#Cc3cc(Cl)cnc3F)CCC2N1', 'O=C1CCCCC(C(=O)NCc2ocnc2C(=O)NC2CC=CC2)C1', 'O=C1CCCN1Cc1cccc(NCc2ccc(C(F)F)cc2F)c1', 'O=C1CC[C@@H](C(=O)NC(C(=O)N2CC[C@H](OC3CC3)C2)C2CCC2)O1', 'O=C1CCc2c1cccc2C(=O)Nc1ccccc1-c1n[nH]c(=O)o1', 'O=C1CN(C(=O)c2ccc(C3SCCS3)cc2)c2c(Br)cccc2N1', 'O=C1CN(CCNC(=O)[C@@H]2CCCN2NC(=O)C2CC2(F)F)CCN1', 'O=C1COc2c(cccc2C(=O)Nc2cc(C(F)(F)F)nc(Cl)n2)N1', 'O=C1C[C@H](C(=O)NC[C@H]2C[C@H](NC(=O)c3ncc(F)cc3F)C2)CN1', 'O=C1C[C@H](C(=O)N[C@H]2CCC[C@@H](C(=O)N3CCO[C@@H](CO)C3)C2)CN1', 'O=C1NC(=O)[C@@]2(CCOC[C@H]2C(=O)N2CC(NC(=O)C(F)(F)F)C2)N1', 'O=C1NC(=O)[C@]2(CC[C@@H](C(=O)N[C@H]3COC[C@H]3n3ccnn3)CC2)N1', 'O=C1NC(=O)c2cc(NCc3ccc(-c4cccnc4)cc3)ccc21', 'O=C1NC2(CCC2)C2(CN(Cc3ccc(-c4ccncc4)cc3)C2)O1', 'O=C1NC2(CCN(C(=O)NCC(F)(F)c3cccc(Br)c3)CC2)CO1', 'O=C1NCC(CNC(=O)C2CCN(C(=O)[C@H]3CC[C@H](O)C3)C23CC3)O1', 'O=C1NCC2(CCN(c3nccc(NCC4CCC5CC45)n3)CC2)O1', 'O=C1NCCC12CCC(Nc1cccc(S(=O)(=O)N3CCCC3)c1)C2', 'O=C1NCCC1C(=O)N1C2CC1CN(C(=O)Cc1cccnc1Cl)C2', 'O=C1NCCC1C(=O)N[C@H]1C[C@@H](CCC(=O)N2C[C@@H](F)C[C@H]2CO)C1', 'O=C1NCCN(C(=O)C(CC=CCl)c2ccccc2)C1c1cccs1', 'O=C1NCCN1Cc1cn(-c2ccc(Oc3cccnn3)cc2)nn1', 'O=C1NCCc2ccc(S(=O)(=O)N3CCC34CCCS(=O)(=O)C4)cc21', 'O=C1NC[C@H]2CN(c3nc(NCCSC(F)F)c4[nH]ccc4n3)C[C@@H]12', 'O=C1N[C@@H]2CCN(C(=O)NC(CC(F)F)c3ccccc3)C[C@H]2CO1', 'O=C1N[C@H](C(=O)N2C[C@H](NC(=O)c3sccc3Cl)[C@@H](C3CC3)C2)CO1', 'O=C1OC(C(=O)N2CCCC2C2CCCCC2)Cc2cc(F)ccc21', 'O=C1OC(C(=O)N2CCOC(C(F)(F)F)CC2)Cc2cc(F)ccc21', 'O=C1OCCC1CC(=O)N1CC[C@H]2[C@@H](C1)[C@@H]2C(=O)NCC1=CCCC1', 'O=C1OCCC1N1CCN(C(=O)CC2CCC3(CCCC3)CC2)CC1', 'O=C1O[C@H]2CC(C(=O)NC/C=C\\CNC(=O)[C@H]3C[C@@H]3C3CC3)C[C@H]2O1', 'O=C1c2ccccc2CCN1CCNc1ncnc2cccc(Cl)c12', 'O=CN(CCC(=O)Nc1ccc(Br)cc1)Cc1c(F)ccc(Cl)c1F', 'O=CN(CCCCOc1ccccc1)Cc1ccc2[nH]nc(Cl)c2c1', 'O=CN(Cc1cc(Cl)c2c(c1)OCO2)Cc1ccc([N+](=O)[O-])cc1Cl', 'O=CN(Cc1ccc2c(c1)OCCC2)Cc1csc(-c2ccco2)n1', 'O=CN1CCC(NCC2CCC2)(c2nnnn2CC2CCOC2)CC1', 'O=CNCC(=O)NCC1COCCN1C(=O)c1cc2c([nH]1)CCCC2', 'O=CNc1ccc(C(=O)NCC(=O)Nc2ccc3c[nH]nc3c2)cc1', 'O=NN1CCCC1C(=O)Nc1cccc(NC(=O)[C@H]2CCC[C@H]2F)c1', 'O=S(=O)(CCC1CCCOC1)NC1(Cc2ccccc2)CCCCC1', 'O=S(=O)(CCNCc1ccc(C2CCCCC2)cc1)c1ccccc1', 'O=S(=O)(NCCC1OCCc2ccccc21)c1ccc(F)c(F)c1F', 'O=S(=O)(NCCNCc1cccc(-c2cc[nH]n2)c1)NCC(F)(F)F', 'O=S(=O)(NCc1ccco1)c1ccsc1-c1nc(-c2nnc[nH]2)no1', 'O=S(=O)(NCc1cn2cc(Br)ccc2n1)c1cccnc1NCCO', 'O=S(=O)(NCc1nc2c(s1)COCC2)c1cc(Cl)ccc1OC(F)F', 'O=S(=O)(Nc1cc(Cl)cc(C(F)(F)F)c1)c1cc(Br)cc2c1OCC2', 'O=S(=O)(Nc1cccc(NC[C@H]2[C@@H]3CCC[C@@H]32)c1)c1ccc(Cl)cc1', 'O=S(=O)(Oc1ccc2cnn(C3CCCCO3)c2c1)N1CC2CC2C1', 'O=S(=O)(c1ccc(Br)s1)N1CCN(c2cc(C(F)F)ncc2F)CC1', 'O=S(=O)(c1cccc(NCC2CCC(O)CC2)n1)N1CCCCCC1', 'O=S(=O)(c1cccc(NCCCCF)n1)N1C[C@H]2COC[C@@]2(CO)C1', 'O=S(=O)(c1cnn(Cc2ccc(Cl)cc2)c1)N1CCSCC(F)(F)C1', 'O=S1(=O)CCN(Cc2cnn(-c3ccccc3)c2Cl)C2(CCCC2)C1', 'O=S1C[C@@H]2C[C@H]1CN2c1ncc(S(=O)(=O)NCc2ccsc2)cc1Cl', 'O=S1C[C@H]2C[C@@H]1CN2C(C1=NOCC1)c1nnnn1C1CC(F)(F)C1', 'O=[N+]([O-])c1c(CNCCC2CCC(F)(F)CC2)ccc2cccnc12', 'O=[N+]([O-])c1cc(Cl)ccc1N1CCN(S(=O)(=O)CC2CC(F)C2)CC1', 'O=[N+]([O-])c1cc(NC(CO)CC2CCC(F)(F)CC2)ccc1C(F)F', 'O=[N+]([O-])c1ccc(CO)c(NCc2ccc3[nH]cc([N+](=O)[O-])c3c2)c1', 'O=[N+]([O-])c1cccc(OCC(O)CNCCc2c(Cl)cccc2Cl)c1', 'O=[N+]([O-])c1cnc(NC2CCSC(c3cccnc3)C2)c([N+](=O)[O-])c1', 'O=c1[nH]c2c(O)cccc2n1C1CCN(CCCOCC2CC2)CC1', 'O=c1c2ccccc2ccn1CCCNc1cc(Cl)cnc1[N+](=O)[O-]', 'OC1CN(c2c(F)cc(Nc3ncc(-c4ccccc4)s3)cc2F)C1', 'OCC(F)(F)CNc1nc(-c2ccsc2)nc2sc3c(c12)CCCC3', 'OCC1(F)CCN(c2cc(NCc3conc3C3CCC3)ncn2)C1', 'OCC1(F)CN(Cc2cn(C3CCCCC3)nn2)CC12CCOCC2', 'OCCCNc1nc(NCC2CC(=C3CCC3)C2)c2ccccc2n1', 'OCCN(Cc1cc(-c2ccc(F)cc2)no1)Cc1ccccc1Br', 'OC[C@@H]1CN(c2cc3sc(Cl)nc3cn2)CC[C@H]1c1ccc(F)cc1', 'OCc1cc(CNCC(O)c2cccc(Cl)c2Cl)c2ccccc2c1', 'O[C@H](CNc1nc(-c2ccncc2)nc2c1CCC2)c1ccccc1', 'O[C@H]1CCCC[C@H]1CCN(Cc1cccc(CF)c1)Cc1ccsn1', 'Oc1c(F)cccc1CN1CCN(c2ccccc2)c2ccccc21', 'Oc1cc(CNC2(c3c(F)cccc3F)COC2)cc(C(F)(F)F)c1', 'Oc1ccc(-c2noc(-c3cccc(Cn4cccn4)c3)n2)cc1F', '[2H]C([2H])([2H])S(=O)(=O)CC(=O)N1C[C@@H]2C[C@H]1CN2S(=O)(=O)C1CC(C(C)(C)C)C1', '[2H]C([2H])([2H])n1cc(NC(=O)C2CC(C3CN(C(=O)OC(C)(C)C)C3)=NO2)cn1', '[2H]C([2H])([2H])n1cc(NC(=O)c2occc2CNC(=O)C2CCCCCC2)cn1', '[2H]c1ccc(C(=O)NC2CC(Nc3ccnc(SC)n3)C23CCC3)cc1', '[N-]=[N+]=NC1(C(=O)NOC2CCCC2)CCN(C(=O)c2ccc(F)s2)C1', '[N-]=[N+]=NC1CCC(C(=O)NC(C(=O)O)c2cccc3ccccc23)C1', '[N-]=[N+]=NC1CN(C(=O)C2CCCCN2C(=O)C(O)CN2CCCC2)C1', '[N-]=[N+]=NCC1CCN1C(=O)[C@@H]1CSCN1C(=O)Cc1ncccc1F', '[N-]=[N+]=NCCC(=O)N1[C@@H]2CC[C@@H](C2)[C@H]1C(=O)N1C[C@@H]2OCCO[C@@H]2C1', '[N-]=[N+]=NCCCCC(=O)NC[C@H]1CC[C@H](C(=O)NC2C=CCC2)CC1', '[N-]=[N+]=NCCCNC(=O)[C@@H](NC(=O)c1csc(F)c1)c1ccccc1', '[N-]=[N+]=NCCCOCC(=O)N[C@H]1CCC[C@H](NC(=O)[C@H]2CCOC2)C1', '[N-]=[N+]=NCCNC(=O)C1CCCC(NC(=O)C2=C(Cl)CCOC2)CC1', '[N-]=[N+]=NC[C@H](NC(=O)CCn1cncn1)C(=O)N1CCCC(F)(F)C1', '[N-]=[N+]=NC[C@H](NC(=O)CN1CC=CC1)C(=O)N[C@@H]1CC[C@H]2C[C@@H]1CO2', '[N-]=[N+]=NC[C@H](NC(=O)c1cccc(Cl)c1)C(=O)N1CCOC(CO)C1', '[N-]=[N+]=NC[C@H]1C[C@H]1Cn1nc(-c2ccccc2)nc1-c1ccccc1', '[N-]=[N+]=N[C@@H]1C[C@@H](C(=O)N2CC(F)(F)C2)N(C(=O)CCc2csnn2)C1', '[N-]=[N+]=Nc1ccc(C(=O)N2CCN(c3ncncc3Cl)CC2)c(F)c1', 'c1cc(-c2cn[nH]c2)ccc1CN1CCC(N2CCCOCC2)CC1', 'c1cc(CN2CCOCC2)ccc1CCNC1CCC2(CC1)COC2', 'c1cc(CNc2ccnc(N3CCCCC4(CCCC4)C3)n2)cnn1', 'c1ccc(-c2cccn3c(NCC4CC4)c(-c4cc[nH]n4)nc23)cc1', 'c1ccc(-c2csc(CNc3cccnc3N3CCCCC3)n2)cc1', 'c1ccc(CN2CCN(Cc3cn(-c4cccnc4)nn3)CC2)nc1', 'c1cnc(N2CCN(c3cc(N4CCCOCC4)ncn3)CC2)cn1', 'c1nc(NCCCC2CCCC2)cc(N2CCCC3(CCOC3)C2)n1']
2025-04-17 17:55:28,722 - INFO - affinity [-6.0, -8.0, -4.7, -6.9, -6.7, -5.5, -5.1, -7.2, -7.2, -6.1, -5.9, -6.9, -3.5, -6.0, -5.8, -6.8, -6.2, -6.1, -6.6, -6.4, -7.1, -6.4, -5.3, -5.5, -6.1, -7.7, -7.8, -6.5, -6.4, -7.3, -6.9, -5.8, -7.5, -5.5, -7.2, -4.6, -7.5, -6.5, -5.9, -5.2, -6.7, -8.4, -7.1, -7.1, -7.4, -5.6, -3.6, -6.1, -6.9, -6.7, -6.4, -7.2, -5.8, -5.7, -5.4, -7.0, -6.3, -4.8, -5.7, -4.4, -6.3, -6.1, -6.5, -6.8, -6.3, -6.2, -7.3, -6.3, -3.7, -6.4, -6.0, -5.7, -5.5, -5.7, -5.9, -6.4, -6.1, -6.1, -6.5, -7.6, -6.0, -6.6, -5.6, -5.8, -4.9, -6.3, -5.8, -5.9, -6.5, -6.4, -5.7, -6.4, -7.4, -6.8, -5.4, -6.0, -5.4, -6.0, -7.1, -5.8, -5.8, -7.7, -5.0, -5.3, -6.4, -6.9, -5.7, -6.3, -6.5, -6.7, -7.3, -7.1, -6.7, -7.0, -5.4, -5.3, -6.8, -6.2, -7.5, -5.9, -6.5, -7.5, -6.6, -5.0, -6.0, -6.6, -5.8, -6.6, -5.4, -7.3, -7.0, -6.4, -6.7, -6.6, -6.5, -6.7, -6.7, -5.6, -5.9, -6.9, -5.9, -5.1, -7.1, -5.9, -6.8, -5.8, -6.0, -5.9, -4.9, -6.5, -5.7, -7.1, -7.6, -4.8, -6.0, -5.6, -6.5, -8.1, -6.4, -6.6, -6.1, -7.3, -7.0, -6.2, -6.8, -6.3, -6.9, -7.2, -5.9, -6.6, -5.8, -6.7, -6.7, -7.3, -6.0, -5.0, -6.0, -6.4, -6.1, -7.3, -6.7, -6.2, -6.4, -6.4, -6.5, -4.9, -6.2, -6.1, -5.4, -7.0, -6.7, -7.1, -6.6, -6.1, -6.5, -6.3, -5.7, -6.1, -6.6, -2.9, -5.3, -5.9, -5.8, -6.2, -6.3, -1.4, -6.2, -7.2, -6.5, -5.9, -6.3, -6.7, -5.2, -6.1, -5.9, -6.4, 0.0, -5.5, -6.7, -6.4, -2.5, -5.4, -6.3, -6.5, -6.1, -5.7, -5.5, -4.3, -5.6, -6.8, -5.8, -6.2, -4.8, -4.8, -5.0, -6.4, -5.5, -5.1, -5.4, -6.2, -5.6, -6.5, -5.2, -6.0, -6.3, -6.1, -5.6, -5.5, -6.1, -5.2, -5.9, -7.2, -5.5, -5.9, -5.9, -7.0, -5.8, -7.0, -6.1, -5.7, -6.8, -6.8, -6.4, -6.2, -6.0, -5.7, -7.3, -6.6, -6.8, -6.7, -6.1, -6.1, -5.2, -7.6, -7.3, -5.8, -6.7, -6.1, -6.5, -7.4, -5.2, -6.3, -6.0, -6.2, -6.5, -5.9, -6.2, -6.1, -5.9, -6.0, -5.3, -6.6, -6.6, -6.4, -6.0, -5.5, -6.5, -5.8, -5.8, -7.4, -6.0, -5.6, -6.7, -7.5, -5.3, -5.5, -5.6, -6.2, -6.2, -6.0, -5.6, -6.5, -5.6, -4.7, -5.7, -5.5, -5.3, -5.9, -6.8, -5.8, -6.1, -6.3, -7.2, -6.7, -5.7, -5.4, -7.1, -6.8, -6.4, -5.7, -5.3, -6.8, -7.2, -5.3, -4.7, -6.0, -6.7, -5.5, -5.2, -5.7, -5.8, -6.4, -6.2, -6.0, -6.5, -6.0, -6.4, -6.3, -5.9, -5.6, -5.2, -6.8, -6.0, -5.8, -6.6, -6.8, -6.3, -5.4, -6.0, -6.4, -5.8, -6.4, -5.1, -2.3, -7.8, -6.5, -7.0, -6.7, -6.0, -5.5, -5.8, -6.2, -5.2, -5.8, -5.7, -5.8, -6.3, -7.0, -7.1, -5.7, -5.8, -6.7, -6.9, -5.8, -5.3, -5.4, -5.7, -7.0, -7.1, -5.6, -7.2, -6.4, -6.2, -6.3, -6.0, -6.3, -8.0, -5.6, -6.1, -6.1, -5.8, -1.7, -5.9, -6.7, -5.6, -6.2, -6.3, -6.6, -5.3, -3.7, -5.0, -5.3, -7.8, -7.3, -5.6, -6.7, -5.7, -7.6, -6.5, -7.5, -4.8, -2.9, -4.7, -5.9, -6.3, -6.0, -5.7, -7.0, -4.2, -5.9, -5.7, -6.7, -4.5, -7.0, -6.2, -5.6, -7.8, -7.5, -6.1, -7.7, -6.0, -6.8, -5.8, -8.0, -6.8, -6.8, -5.8, -4.6, -8.9, -4.5, -6.1, -5.6, -7.1, -7.8, -5.9, -8.2, -3.9, -6.0, -7.2, -6.1, -6.2, -7.0, -6.3, -6.3, -6.2, -6.6, -6.4, -7.5, -5.8, -5.8, -6.9, -6.1, -7.3, -6.7, -6.8, -6.9, -6.9, -6.3, -6.9, -7.0, -5.1, -5.5, -4.9, -6.0, -6.1, -5.7, -5.5, -5.4, -6.5, -6.2, -6.3, -6.1, -6.3, -6.8, -6.3, -7.0, -6.7, -6.0, -5.1, -6.7, -6.4, -5.8, -7.0, -6.9, -7.5, -6.8, -7.0, -5.2, -6.9, -6.2, -8.0, -5.7, -6.4, -6.8, -6.3, -6.2, -6.2, -6.4, -6.3, -7.9, -5.9, -6.8, -6.0, -6.7, -5.7, -7.3, -4.7, -6.2, -6.7, -6.9, -5.0, -7.8, -5.0, -5.3, -6.0, -5.1, -5.0, -5.6, -7.1, -7.4, -5.6, -5.7, -6.6, -7.5, -6.3, -7.3, -7.6, -7.2, -6.3, -7.5, -6.0, -6.7, -6.5, -6.1, -4.7, -5.8, -7.2, -6.7, -6.6, -6.7, -7.0, -1.3, -6.6, -5.8, -6.7, -6.1, -5.4, -6.1, -6.6, -8.4, -7.3, -7.2, -6.3, -5.7, -7.2, -7.4, -6.7, -6.4, -6.4, -6.8, -6.1, -5.4, -5.6, -7.0, -6.9, -6.2, -6.8, -7.5, -8.4, -7.8, -6.2, -6.1, -7.4, -5.4, -6.5, -6.4, -8.0, -7.5, -6.9, -5.6, -6.7, -7.6, -6.5, -6.4, -7.5, -4.6, -9.3, -6.4, -6.3, -7.2, -7.2, -6.8, -8.1, -7.6, -6.7, -6.8, -6.0, -7.2, -7.7, -7.1, -7.5, -6.6, -6.4, -6.6, -6.5, -4.8, -7.3, -7.3, -5.9, -6.5, -7.1, -6.3, -8.0, -6.4, -6.5, -7.3, -7.3, -7.1, -6.7, -6.0, -3.4, -6.7, -6.2, -7.8, -8.0, -6.9, -7.0, -5.7, -5.5, -6.8, -7.4, -5.0, -7.2, -4.4, -6.3, -7.3, -5.7, -6.9, -5.0, -6.4, -6.4, -7.7, -4.8, -6.5, -6.5, -6.2, -6.0, -6.1, -6.2, -6.6, -5.8, -6.2, -7.1, -7.1, -6.8, -5.0, -6.2, -6.9, -6.8, -6.8, -7.3, -6.5, -6.9, -7.6, -8.0, -9.4, -4.8, -7.3, -6.5, -5.4, -5.3, -6.4, -6.3, -6.4, -6.3, -6.2, -5.8, -6.4, -5.6, -6.5, -6.1, -6.1, -4.6, -5.7, -7.3, -7.1, -7.5, -6.2, -6.9, -6.1, -7.0, -6.3, -7.4, -7.1, -7.3, -7.5, -6.0, -5.6, -5.9, -6.7, -6.2, -1.9, -5.9, -6.6, -6.5, -5.7, -5.8, -7.0, -5.9, -5.8, -5.9, -5.9, -5.7, -6.5, -7.1, -7.0, -5.9, -6.8, -6.9, -3.8, -6.7, -6.6, -6.8, -7.1, -7.5, -5.6, -4.8, -6.6, -5.5, -7.5, -5.7, -5.0, -7.2, -7.0, -6.0, -6.1, -4.8, -6.5, -4.6, -5.7, -6.1, -4.9, -6.2, -7.0, -6.1, -7.1, -6.1, -5.7, -6.3, -6.0, -5.6, -6.1, -5.4, -5.3, -6.0, -6.0, -6.1, -7.4, -5.8, -7.6, -6.9, -6.8, -8.2, -7.1, -6.5, -6.9, -6.2, -7.1, -6.0, -6.5, -2.3, -7.3, -5.5, -7.2, -7.1, -6.3, -6.9, -7.8, -6.2, -5.0, -6.8, -6.0, -7.1, -5.9, -6.0, -5.3, -5.4, -5.5, -6.5, -1.7, -6.0, -6.1, -7.0, -7.0, -5.9, -6.8, -5.4, -6.2, -6.2, -6.2, -7.1, -7.4, -7.3, -6.1, -5.8, -6.0, -6.9, -6.1, -6.2, -5.9, -6.4, -6.5, -6.6, -5.8, -6.6, -6.2, -6.5, -6.6, -5.9, -7.4, -7.1, -6.8, -7.5, -6.5, -7.9, -7.8, -6.8, -6.8, -6.4, -7.6, -4.3, -6.3, -6.8, -7.4, -7.2, -6.6, -6.7, -5.5, -6.0, -7.2, -6.6, -6.1, -5.9, -6.3, -7.1, -6.7, -4.9, -7.1, -5.1, -7.5, -5.2, -7.3, -6.5, -6.2, -7.1, -7.2, -6.7, -6.7, -5.9, -4.4, -5.4, -7.5, -7.6, -5.7, -5.6, -5.7, -5.3, -6.4, -6.3, -5.7, -7.3, -6.1, -6.1, -8.0, -4.9, -6.9, -6.8, -5.8, -6.3, -6.1, -6.2, -6.3, -6.3, -6.9, -7.0, -6.0, -5.9, -7.9, -6.9, -6.9, -6.3, -5.1, -6.7, -6.7, -5.6, -4.9, -5.5, -6.4, -6.6, -6.5, -6.9, -6.8, -6.3, -5.7, -6.0, -6.4, -6.5, -7.9, -7.0, -6.0, -5.5, -6.7, -7.1, -4.8, -5.8, -6.8, -5.5, -5.9, -7.0, -6.7, -6.2, -7.2, -6.0, -6.4, -6.9, -7.0, -5.8, -5.8, -6.7, -7.1, -6.0, -5.4, -6.7, -7.6, -7.4, -6.2, -6.2, -7.7, -6.3, -6.7, -5.8, -6.5, -5.8, -5.5, -6.6, -6.2, -6.0, -7.9, -6.4, -5.9, -6.9, -5.6, -6.2, -6.7, -7.0, -5.7, -5.8, -5.7, -6.4, -6.4, -6.3, -4.9, -6.3, -7.2, -6.7, -5.2, -5.3, -7.0, -6.8, -6.3, -6.4, -8.9, -6.2, -6.6, -6.5, -6.4, -6.8, -6.5, -7.3, -6.4, -5.3, -6.4, -6.4, -6.6, -6.1, -7.4, -5.3, -6.7, -5.2, -5.2, -5.4, -4.9, -7.1, -5.6, -5.8, -6.3, -6.2, -7.0, -6.5, -6.5, -6.5, -6.2, -5.4, -6.6, -5.1, -5.5, -6.6, -6.6, -6.4, -3.8, -6.7, -6.4, -6.1, -5.6, -5.8, -6.6, -4.3, -5.5, -6.7, -6.2, -7.0, -6.7, -7.9, -6.1, -6.1, -6.2, -6.3, -4.8, -5.2, -6.6, -5.5, -5.8, -6.6, -5.8, -7.5, -7.1, -5.7, -6.1, -5.8, -5.4, -6.7, -7.5, -6.9, -5.8, -5.7, -6.5, -5.8, -7.1, -6.1, -4.6, -5.7, -2.1, -6.0, -5.7, -5.7, -6.6, -6.3, -5.6, -7.1, -6.2, -5.9, -6.6, -5.5, -6.0, -6.2, -6.8, -5.0, -5.9, -5.7, -6.9, -7.0, -6.5, -4.7, -6.5, -6.6, -6.5, -6.7, -6.3, -6.3, -6.6, -7.3, -5.2, -4.5, -6.7, -5.3, -6.1, -5.6, -6.5, -6.9, -6.6, -5.5, -5.7, -5.0, -5.3, -5.9, -6.4, -6.4, -6.0, -6.4, -5.4, -7.6, -6.6, -6.0, -5.4, -6.4, -5.7, -7.4, -5.7, -6.3, -7.3, -6.9, -7.0, -6.2, -5.7, -6.4, -5.7, -6.9, -6.7, -5.9, -6.3, -5.6, -6.6, -6.1, -5.5, -6.8, -5.4, -6.1, -6.5, -5.2, -6.5, -5.8, -6.2, -4.6, -6.6, -6.5, -6.0, -5.3, -5.7, -6.2, -7.3, -7.9, -6.0, -6.3, -6.5, -7.7, -6.2, -7.0, -5.8, -6.2, -6.1, -4.7, -6.4, -6.0, -0.0, -6.5, -6.0, -6.4, -5.6, -5.7, -6.6, -6.9, -6.2, -6.1, -7.1, -5.2, -6.8, -7.9, -6.2, -6.8, -7.5, -6.4, -6.9, -5.8, -7.2, -7.5, -6.8, -6.9, -6.1, -5.3, -6.2, -6.7, -8.6, -6.6, -5.5, -6.4, -6.5, -6.4, -5.9, -6.0, -5.5, -6.1, -6.9, -6.6, -6.3, -5.6, -5.9, -4.9, -7.0, -6.0, -7.6, -6.1, -7.0, -5.2, -6.0, -7.3, -7.2, -6.3, 1.3, -6.1, -7.5, -4.4, -6.7, -6.3, -7.0, -5.9, -6.2, -6.4, -6.2, -6.5, -5.8, -5.4, -6.2, -4.1, -6.0, -5.1, -6.5, -5.6, -6.3, -6.9, -5.4, -6.0, -4.8, -7.0, -6.5, -5.8, -6.5, -6.4, -5.9, -5.2, -6.3, -5.3, -6.6, -5.7, -5.6, -5.4, -6.7, -5.9, -5.4, -5.8, -5.5, -7.0, -5.3, -6.7, -6.3, -6.0, -5.5, -7.4, -6.8, -6.8, -6.3, -5.9, -5.4, -6.9, -6.4, -5.5, -6.7, -6.7, -6.5, -6.5, -6.8, -6.6, -5.6, -7.2, -7.0, -7.4, -6.4, -6.2, -7.7, -6.3, -6.3, -5.6, -5.9, -6.7, -1.5, -7.6, -6.3, -5.8, -7.3, -5.6, -4.7, -7.0, -6.6, -5.2, -6.2, -6.4, -5.7, -6.4, -5.9, -5.2, -5.8, -4.1, -5.3, -6.6, -5.5, -6.1, -6.4, -5.4, -5.9, -7.1, -6.4, -7.8, -5.9, -6.5, -6.8, -7.1, -6.9, -6.4, -8.7, -8.0, -4.8, -7.0, -7.7, -6.5, -8.0, -2.3, -7.4, -6.3, -0.6, -6.9, -6.8, -6.1, -7.3, -7.4, -7.6, -6.9, -6.7, -6.4, -6.3, -7.1, -4.7, -7.0, -6.9, -6.3, -6.4, -6.0, -7.3, -4.9, -6.5, -6.6, -5.7, -6.4, -6.9, -6.5, -6.1, -5.4, -6.8, -7.2, -6.2, -6.0, -6.0, -6.4, -5.6, -4.9, -6.2, -5.4, -7.8, -7.6, -6.3, -6.9, -5.8, -6.4, -7.0, -6.1, -7.8, -5.4, -8.4, -7.0, -5.8, -5.8, -7.7, -5.7, -6.6, -5.9, -6.4, -5.5, -3.8, -4.5, -7.4, -6.0, -6.5, -6.9, -7.3, -6.4, -5.9, -7.1, -6.7, -5.8, -6.0, -6.4, -4.4, -7.0, -6.5, -4.6, -5.4, -6.7, -5.9, -7.6, -6.6, -3.8, -6.8, -5.6, -7.1, -5.3, -6.5, -6.3, -5.9, -7.5, -6.1, -6.1, -7.5, -9.2, -5.4, -6.0, -7.3, -6.9, -7.3, -6.6, -6.7, -6.6, -8.1, -5.6, -7.9, -7.2, -5.4, -6.1, -7.2, -6.8, -7.5, -5.4, -7.1, -6.2, -6.8, -5.8, -6.4, -6.0, -5.3, -6.7, -4.9, -5.2, -7.2, -6.5, -6.2, -7.4, -8.3, -5.9, -5.8, -5.7, -5.8, -6.9, -9.0, -7.1, -7.1, -6.3, -6.5, -7.8, -7.1, -6.1, -5.6, -4.6, -5.8, -5.2, -7.0, -8.0, -6.9, -7.7, -7.4, -7.4, -6.7, -6.5, -6.8, -5.7, -6.1, -7.5, -7.1, -6.8, -7.0, -7.2, -7.8, -7.3, -7.5, -7.0, -6.4, -5.9, -6.2, -7.5, -7.1, -7.3, -6.2, -6.0, -6.0, -6.1, -7.2, -6.8, -6.0, -8.0, -6.7, -6.3, -7.3, -6.9, -6.5, -6.0, -7.0, -6.2, -6.1, -8.1, -6.7, -6.5, -8.1, -6.9, -8.0, -6.0, -5.6, -5.9, -6.8, -6.4, -6.2, -6.9, -5.2, -7.4, -7.5, -6.9, -7.4, -7.3, -7.0, -8.5, -6.5, -8.6, -6.1, -7.7, -5.8, -5.6, -6.2, -3.5, -5.7, -6.9, -5.8, -7.9, -6.9, -5.6, -6.0, -7.4, -5.3, -5.7, -7.9, -6.0, -7.0, -6.7, -6.7, -6.1, -6.3, -6.6, -5.6, -6.0, -6.0, -7.2, -6.0, -5.5, -6.1, -6.9, -4.9, -6.7, -6.2, -7.7, -7.8, -7.1, -7.7, -6.7, -6.7, -6.3, -6.2, -6.3, -6.8, -7.1, -3.1, -7.8, -6.0, -7.3, -8.7, -6.0, -6.2, -2.3, -5.6, -5.1, -4.9, -6.7, -7.1, -6.9, -6.5, -6.5, -5.7, -6.0, -7.0, -6.9, -5.2, -7.0, -6.3, -5.1, -7.6, -6.6, -6.7, -7.1, -4.8, -5.9, -6.6, -6.6, -6.5, -6.5, -6.7, -6.8, -5.9, -6.8, -6.3, -8.0, -7.7, -7.0, -7.5, -6.0, -6.5, -6.5, -5.9, -6.0, -7.5, -4.6, -5.8, -5.7, -6.2, -5.8, -6.0, -6.3, -7.4, -6.7, -6.1, -5.6, -6.4, -6.3, -6.0, -7.1, -7.2, -7.7, -6.4, -7.0, -6.0, -5.7, -6.5, -7.4, -6.3, -6.5, 0.0, -7.6, -6.9, -5.3, -7.0, -6.8, -6.8, -6.4, -3.3, -5.2, -7.6, -7.4, -6.1, -6.1, -7.9, -6.0, -5.1, -6.2, -7.2, -5.7, -6.8, -5.1, -7.4, -6.7, -7.3, -7.0, -6.5, -7.6, -6.0, -6.0, -6.1, -7.6, -8.5, -7.5, -4.3, -6.7, -7.8, -6.5, -3.8, -7.3, -6.3, -6.7, -6.7, -5.5, -6.9, -5.5, -6.4, -5.6, -6.0, -6.6, -6.9, -6.6, -6.8, -7.4, -7.1, -5.7, -6.9, -6.3, -7.7, -6.0, -5.3, -6.8, -7.4, -5.3, -6.6, -6.3, -5.5, -6.8, -6.6, -6.3, -6.1, -2.6, -8.2, -7.5, -5.9, -7.3, -6.9, -6.8, -6.8, -6.0, -5.8, -7.6, -7.8, -6.5, -6.5, -8.3, -7.4, -6.6, -7.6, -6.9, -6.7, -6.5, -7.7, -7.8, -6.3, -7.6, -4.9, -6.0, -2.6, -7.3, -5.8, -7.1, -8.0, -7.1, -7.0, -6.8, -7.5, -6.2, -8.2, -6.1, -7.5, -6.9, -8.8, -7.3, -6.3, -8.9, -6.6, -5.6, -6.2, -5.2, -5.2, -6.0, -6.7, -6.7, -6.2, -7.0, -3.6, -6.7, -8.0, -5.4, -6.4, -6.5, -6.8, -7.5, -7.0, -5.4, -6.6, -6.8, -7.6, -5.4, -7.2, -7.3, -5.7, -7.4, -6.6, -6.3, -7.7, -5.4, -5.0, -6.0, -7.2, -7.4, -6.4, -7.1, -5.9, -6.2, -7.5, -6.3, -7.2, -8.3, -7.0, -6.7, -7.1, -6.4, -7.7, -6.1, -6.4, -6.3, -5.7, -7.6, -3.9, -7.1, -6.0, -5.8, -6.7, -5.2, -6.7, -5.2, -6.3, -6.5, -6.3, -4.9, -6.7, -6.4, -5.5, -6.0, -6.2, -5.2, -4.8, -6.4, -6.2, -7.4, -7.4, -5.5, -7.8, -6.6, -7.8, -5.3, -5.2, -5.6, -7.8, -7.6, -6.8, -6.7, -6.3, -6.8, -6.4, -6.7, -6.6, -8.4, -1.9, -7.3, -6.7, -1.8, -7.7, -5.4, -5.9, -5.3, -6.7, -6.3, -7.4, -5.5, -6.9, -5.3, -5.9, -3.9, -4.5, -7.2, -5.3, -6.7, -5.8, -5.9, -6.0, -6.7, -7.4, -5.1, -6.4, -6.4, -7.2, -7.2, -6.5, -7.2, -6.4, -6.5, -6.4, -6.4, -6.6, -6.6, -6.7, -7.3, -6.2, -8.3, -4.9, -7.0, -4.2, -3.7, -7.8, -5.8, -6.8, -6.3, -6.6, -6.4, -5.6, -5.7, -6.8, -6.8, -6.2, -6.0, -7.6, -5.6, -7.2, -7.3, -7.7, -6.7, -6.4, -6.5, -7.8, -6.0, -6.4, -6.5, -4.8, -5.8, -7.7, -7.7, -4.2, -7.9, -6.5, -6.1, -6.7, -4.6, -3.5, -6.4, -6.6, -7.7, -5.4, -6.4, -7.0, -5.2, -6.0, -6.5, -4.0, -5.7, -6.4, -6.7, -6.2, -5.7, -7.4, -5.4, -7.9, -7.0, -6.4, -6.6, -6.5, -6.4, -6.0, -8.3, -6.0, -6.5, -6.2, -5.5, -6.4, -8.2, -5.9, -6.6, -7.2, -6.8, -8.3, -5.9, -6.5, -6.3, -6.4, -6.5, -3.4, -6.2, -6.7, -5.7, -6.7, -5.9, 0.0, -7.2, -6.6, -6.9, -6.1, -5.5, -7.6, -5.8, -6.7, -5.7, -7.2, -6.8, -7.8, -8.3, -5.9, -5.4, -6.3, -5.3, -6.6, -5.4, -7.4, -7.5, -6.3, -5.4, -5.7, -5.9, -6.0, -5.9, -6.5, -6.1, -6.8, -5.7, -5.7, -7.6, -7.4, -5.7, -8.5, -7.1, -5.3, -7.2, -6.0, -6.6, -6.5, -6.9, -5.8, -5.7, -5.9, -7.8, -7.2, -6.9, -7.2, -5.9, -6.4, -5.6, -5.8, -6.2, -6.9, -6.3, -6.9, -6.8, -7.4, -6.5, -6.4, -5.3, -6.5, -6.4, -6.4, -6.2, -5.9, -6.6, -6.8, -6.3, -6.7, -5.0, -5.7, -5.5, -4.2, -5.1, -7.3, -6.8, -5.5, -7.2, -6.3, -6.9, -5.7, -8.3, -7.3, -6.1, -6.1, -6.4, -7.3, -4.4, -6.8, -6.7, -6.5, -6.7, -6.7, -7.2, -6.8, -6.3, -6.1, -5.8, -5.0, -6.8, -6.1, -7.0, -5.3, -6.5, -5.3, -7.2, -6.6, -6.5, -7.4, -7.0, -7.9, -2.0, -6.1, -6.8, -7.2, -6.1, -5.8, -7.1, -5.9, -5.3, -7.3, -8.3, -6.4, -7.1, -6.0, -5.2, -5.4, -6.6, -6.1, -6.4, -8.1, -6.3, -6.2, -5.6, -6.8, -6.2, -6.0, -6.6, -5.2, -7.4, -6.6, -6.2, -6.4, -5.7, -2.7, -5.5, -5.5, -5.7, -5.7, -5.4, -6.3, -6.0, -5.9, -6.3, -6.1, -6.4, -6.8, -6.0, -6.4, -4.7, -7.1, -6.0, -6.9, -7.4, -7.0, -6.1, -6.1, -7.1, -6.6, -4.1, -6.4, -8.4, -6.9, -5.7, -4.8, -5.6, -5.7, -6.9, -4.9, -4.7, -6.1, -6.7, -8.2, -6.9, -6.4, -5.8, -5.7, -6.9, -7.4, -6.8, -6.7, -7.6, -6.9, -5.5, -7.5, -6.7, -5.4, -6.6, -6.3, -5.1, -6.8, -6.3, -6.2, -6.3, -7.5, -7.2, -7.1, -5.7, -6.3, -5.9, -6.2, -5.8, -7.1, -7.3, -6.6, -5.5, -7.4, -6.1, -6.8, -7.3, -6.7, -6.5, -7.0, -8.2, -7.1, -6.7, -8.4, -6.8, -6.7, -6.9, -7.1, -6.7, -8.8, -6.5, -6.6, -5.7, -6.1, -6.7, -6.3, -8.1, -8.2, -7.2, -7.9, -6.4, -5.9, -7.7, -5.4, -6.7, -7.4, -7.6, -4.2, -6.3, -5.4, -5.8, -6.5, -3.3, -7.3, -6.2, -6.6, -6.9, -5.4, -6.6, -7.9, -6.7, -6.4, -7.6, -7.0, 14.9, -5.2, -7.7, -6.3, -6.5, -5.4, -6.8, -7.4, -6.7, -5.6, -7.2, -2.8, -5.7, -4.9, -6.3, -6.1, -5.8, -7.9, -4.1, -5.9, -6.3, -6.6, -8.4, -6.9, -6.9, -5.8, -5.2, -6.7, -6.2, -6.5, -8.1, -6.6, -6.5, -6.1, -7.2, -7.0, -6.1, -7.0, -6.8, -5.8, -7.0, -4.3, -5.8, -6.5, -4.9, -6.5, -5.3, -7.6, -7.3, -6.6, -6.3, -5.3, -6.8, -6.4, -6.8, -7.3, -7.2, -6.7, -6.9, -6.6, -5.2, -5.1, -5.9, -7.3, -5.8, -7.2, -6.3, -5.8, -7.1, -6.2, -6.8, -6.7, -6.0, -5.5, -7.4, -5.2, -7.8, -6.3, -6.3, -6.2, -6.3, -6.2, -6.6, -5.6, -5.4, -6.1, -6.7, -6.9, -6.1, -6.2, -7.3, -6.0, -6.1, -5.7, -6.3, -5.6, -5.6, -4.9, -5.8, -7.6, -4.4, -7.3, -6.7, -6.4, -5.6, -5.2, -5.1, -6.9, -5.6, -4.8, -6.6, -6.2, -6.2, -6.0, -7.3, -6.2, -6.4, -6.2, -6.2, -7.4, -7.0, -6.0, -6.1, -6.0, -6.4, -6.9, -6.1, -5.8, -7.4, -7.7, -6.6, -6.6, -7.0, -6.1, -8.4, -7.0, -6.5, -5.9, -6.4, -7.3, -6.3, -6.7, -5.8, -5.9, -7.1, -6.1, -6.3, -5.1, -6.5, -6.2, -5.7, -7.9, -5.1, -5.8, -6.9, -6.5, -8.0, -6.3, -7.3, -7.6, -7.4, -6.9, -6.4, -7.0, -6.7, -7.3, -8.0, -7.6, -6.3, -6.1, -6.4, -7.0, -5.7, -8.5, -7.4, -7.1, -6.9, -3.4, -8.8, -7.7, -6.5, -6.7, -7.7, -5.2, -6.3, -6.4, -6.2, -8.1, -7.1, -7.4, -6.9, -5.8, -4.9, -5.8, -6.5, -7.8, -7.1, -5.7, -7.1, -6.6, -6.6, -7.1, -7.0, -7.5, -5.6, -5.9, -6.5, -6.8, -6.7, -7.5, -6.0, -4.4, -8.2, -8.5, -7.4, -7.7, -7.3, -7.6, -6.8, -7.8, -6.6, -6.1, -6.7, -6.1, -6.4, -6.0, -6.8, -6.6, -5.8, -6.4, -2.0, -6.4, -4.9, -6.7, -6.0, -6.6, -8.2, -6.0, -7.2, -7.8, -7.7, -5.5, -7.7, 0.0, -6.8, -4.5, -6.3, -6.8, -6.6, -5.3, -7.6, -6.3, -5.6, -7.0, -6.9, -6.4, -5.8, -7.6, -6.4, -6.8, -6.0, -6.8, -7.7, -8.0, -7.4, -6.4, -7.8, -9.2, -7.6, -6.2, -6.4, -7.1, -6.5, -5.5, -7.0, -7.8, -5.8, -7.7, -7.4, -6.8, -6.3, -7.2, -8.3, -7.3, -7.4, -7.5, -6.8, -6.4, -7.4, -6.1, -7.0, -6.9, -6.8, -7.5, -8.4, -4.0, -6.6, -5.3, -8.3, -6.7, -7.0, -6.5, -6.8, -6.8, -6.5, -6.2, -6.9, -6.5, -5.9, -6.7, -6.2, -5.7, -6.2, -4.6, -6.0, -7.7, -6.2, -8.1, -6.7, -5.9, -8.1, -7.5, -7.8, -5.8, -8.8, -7.8, -7.0, -7.9, -6.6, -7.3, -6.2, -6.1, -4.3, -7.8, -6.6, -8.8, -7.9, -6.2, -7.2, -7.3, -5.7, -7.6, -5.9, -5.2, -5.7, -6.7, -6.9, -6.4, -4.0, -6.9, -7.4, -7.2, -6.0, -7.0, -6.6, -6.3, -6.0, -7.2, -6.4, -6.7, -6.2, -7.1, -6.4, -6.0, -6.6, -4.7, -5.8, -6.5, -5.0, -7.4, -8.3, -7.0, -6.5, -6.0, -6.2, -6.1, -6.6, -6.7, -6.9, -7.8, -6.5, -6.3, -6.5, -7.5, -6.3, -7.7, -7.3, -6.5, -7.0, -4.6, -5.5, -7.3, -6.4, -6.5, -5.6, -7.3, -6.2, -6.8, -5.8, -6.6, -6.7, -5.7, -6.0, -5.3, -6.9, -6.9, -4.3, -6.6, -6.5, -8.0, -6.8, -5.6, -6.5, -5.5, -7.4, -5.1, -6.8, -7.6, -6.8, -6.7, -6.0, -5.8, -7.0, -7.3, -5.7, -6.9, -7.8, -7.0, -6.8, -6.3, -7.0, -6.6, -8.2, -6.4, -7.2, -6.9, -6.9, -7.3, -8.0, -6.1, -7.6, -7.4, -7.5, -6.9, -7.2, -7.8, -7.2, -8.2, -3.8, -7.6, -7.1, -4.0, -6.4, -6.5, -5.9, -4.7, -8.5, -6.5, -6.6, -6.6, -7.0, -6.7, -6.9, -7.7, -6.5, -5.2, -6.9, -9.7, -7.0, -7.0, -4.4, -6.6, -7.0, -7.4, -7.4, -7.0, -6.8, -6.2, -6.8, -7.0, -7.6, -6.3, -6.9, -7.4, -6.4, -6.6, -6.6, -6.9, -7.4, -7.5, -6.9, -7.1, -6.2, -6.7, -4.3, -6.9, -5.3, -5.2, -8.0, -8.9, -6.8, -4.6, -5.5, -8.2, -6.2, -7.3, 0.1, -7.8, -5.4, -6.3, -6.5, -7.2, -7.7, -6.9, -7.0, -7.3, -6.6, -5.8, -4.7, -6.4, -6.8, -6.5, -9.5, -6.7, -7.4, -6.9, -2.2, -6.7, -5.6, -7.2, -6.2, -7.2, -5.5, -6.9, -6.0, -6.4, -7.6, -7.4, -6.6, -7.1, -1.4, -6.9, -10.0, -7.8, -5.5, -7.5, -6.9, -6.8, -8.6, -6.4, -7.1, -5.1, -6.3, -4.9, -5.4, -8.8, -7.5, -6.0, -7.4, -6.5, -7.4, -7.5, -8.0, -8.6, -7.2, -6.8, -8.1, -7.6, -8.1, -6.9, -8.8, -6.9, -6.6, -8.2, -5.8, -6.5, -6.5, -7.9, -6.0, -6.9, -7.9, -5.4, -5.5, -6.3, -6.7, -6.1, -6.7, -6.4, -7.7, -8.5, -6.4, -5.1, -7.6, -7.5, -5.7, -6.4, -7.0, -7.4, -7.4, -7.3, -6.5, -6.8, -6.0, -6.5, -7.5, -6.3, -7.3, -5.4, -7.4, -7.0, -6.8, -7.3, -6.2, -7.1, -7.2, -7.4, -7.0, -6.8, -7.3, -7.2, -5.5, -6.2, -8.3, -7.9, -3.7, -6.4, -5.9, -5.9, -6.4, -6.0, -7.4, -8.3, -6.8, -8.0, -6.0, -6.8, -7.1, -6.9, -6.8, -6.6, -6.8, -5.4, -7.1, -6.8, -6.5, -6.5, -6.9, -7.0, -9.0, 21.8, -7.0, -6.3, -6.3, -8.1, -7.7, -6.7, -1.1, -7.9, -6.7, -7.1, -6.6, -5.6, -6.5, -7.0, -6.0, -7.2, -7.1, -7.2, -5.5, -7.8, -7.3, -8.0, -7.1, -7.5, -6.1, -7.5, -7.7, -8.4, -4.5, -6.4, -5.8, -6.9, -6.6, -7.3, -7.3, -7.5, -7.7, -6.6, -8.0, -7.7, -6.6, -6.9, -7.8, -3.6, -3.7, -6.4, -8.7, -6.5, -6.8, -0.2, -7.0, -6.6, -6.9, -6.5, -6.1, -7.0, -7.1, -4.2, -5.7, -7.7, -7.0, -7.7, -6.9, -7.1, -6.0, -6.8, -6.5, -7.0, -8.6, -7.9, -6.0, -7.2, -9.0, -7.7, -7.1, -6.0, -7.2, -7.3, -7.3, -7.0, -7.0, -6.7, -8.0, -7.1, -6.3, -5.8, -6.5, -7.0, -7.2, -6.4, -6.3, -5.5, -7.0, -5.8, -5.6, -6.8, -6.5, -7.0, -6.2, -7.4, -7.4, -6.7, -7.0, -7.0, -6.7, -6.4, -6.7, -6.6, -6.8, -6.1, -7.4, -6.9, -5.7, -7.3, -5.9, -6.7, -7.6, -8.3, -7.1, -6.3, -6.1, -5.0, -6.7, -6.2, -8.0, -6.0, -5.2, -7.7, -5.1, -6.7, -6.4, -6.5, -7.9, -6.5, -7.0, -6.0, -5.3, -6.8, -6.9, -6.4, -5.6, -4.7, -6.5, -6.4, -7.4, -4.9, -7.2, -6.9, -6.9, -6.5, -7.0, -8.2, -7.2, -7.3, -7.9, -6.4, -5.8, -5.9, -6.8, -6.7, -7.5, -6.2, -6.1, -6.6, -6.5, -6.6, -6.9, -3.6, -6.8, -7.8, -7.2, -6.1, -7.1, -6.2, -6.8, -7.7, -9.0, -8.5, -7.4, -7.8, -6.5, -8.2, -6.0, -6.3, -5.4, -6.5, -6.3, -7.2, -8.5, -5.2, -7.3, -7.6, -6.0, -7.3, -3.5, -6.8, -6.5, -5.4, -6.8, -7.5, -7.6, -6.3, -6.9, -7.9, -6.0, -6.9, -7.2, -6.6, -5.5, -6.1, -5.9, -7.3, -5.4, -6.1, -6.9, -5.0, -5.9, -7.4, -7.2, -6.3, -7.2, -7.6, -7.3, -6.7, -6.0, -2.9, -7.8, -9.5, -7.6, -7.1, -6.7, -6.3, -6.7, -7.4, 0.0, -8.2, -7.1, -7.7, -7.0, -6.3, -8.1, -6.8, -5.8, -6.9, 0.0, -7.4, -6.2, -6.3, -5.5, -4.9, -7.2, -6.8, -5.6, -5.6, -5.4, -2.4, -7.1, -8.1, -7.1, -8.0, -7.5, -7.3, -7.4, -6.8, -5.4, -6.6, -8.1, -7.2, -7.0, -6.6, -7.8, -8.0, -6.6, -7.2, -5.8, -6.5, -6.7, -6.9, -4.7, -7.2, -8.1, -7.1, -5.0, -7.1, -5.2, -6.1, -7.1, -7.6, -5.6, -7.9, -6.9, -7.6, -4.0, -5.8, -3.1, -6.5, -5.4, -6.3, -6.0, -6.8, -5.9, -6.7, -6.2, -5.9, -6.4, -5.2, -6.5, -6.4, -6.5, -6.6, -5.8, -5.1, -6.2, -6.7, -5.3, -6.7, -5.9, -6.5, -6.9, -6.2, -5.6, -5.8, -6.7, -6.1, -6.4, -6.3, -6.5, -5.8, -5.4, -7.1, -6.0, -7.2, -6.0, -6.3, -5.7, -7.0, -5.7, -7.5, -6.1, -5.5, -5.5, -7.2, -6.3, -6.9, -5.6, -7.1, -3.2, -6.2, -6.1, -7.1, -7.1, -5.6, -5.4, -7.1, -6.7, -7.4, -7.1, -6.7, -7.3, -5.7, -5.7, -6.4, -6.3, -7.0, -0.7, -5.6, -7.0, -5.9, -6.6, -5.7, -6.6, -7.2, -6.7, -6.0, -5.8, -5.5, -6.2, -5.4, -5.5, -6.7, -6.5, -6.6, -6.0, -6.0, -5.8, -6.4, -7.3, -6.0, -6.3, -5.8, -5.7, -6.2, -6.4, -7.2, -5.5, -6.6, -6.4, -7.2, -6.5, -7.2, -5.9, -7.1, -6.1, -7.6, -6.7, -6.3, -6.3, -5.9, -6.1, -5.4, -6.9, -6.7, -7.1, -7.4, -6.1, -4.2, -7.2, -5.2, -6.5, -6.8, -6.2, -6.3, -6.7, -5.1, -7.0, -6.8, -6.3, -4.9, -6.2, -5.5, -6.1, -6.1, -6.8, -6.2, -6.1, -7.0, -7.1, -7.1, -6.5, -6.4, -6.5, -7.4, -6.0, -6.2, -6.1, -6.6, -6.5, -6.5, -7.1, -6.1, -6.2, -6.2, -5.5, -6.2, -7.5, -6.9, -6.6, -6.1, -5.7, -6.4, -5.6, -6.4, -6.5, -6.1, -5.8, -6.1, -5.9, -6.5, -6.6, -6.2, -6.6, -6.1, -6.3, -6.6, -5.8, -6.6, -4.8, -6.5, -7.1, -7.4, -6.3, -6.2, -6.5, -6.7, -6.2, -6.8, -6.3, -4.0, -5.9, -6.3, -6.3, -7.6, -5.7, -6.4, -7.1, -5.3, -5.5, -5.8, -5.9, -7.3, -6.0, -6.2, -6.6, -7.3, -6.0, -5.5, -6.3, -5.4, -6.7, -6.2, -6.3, -5.4, -6.6, -6.9, -6.2, -7.4, -6.4, -7.7, -6.2, -5.2, -5.8, -5.6, -6.6, -7.2, -6.9, -6.4, -5.0, -5.8, -6.4, -7.0, -7.0, -6.4, -5.9, -4.8, -3.5, -6.3, -7.7, -6.1, -6.7, -6.4, -6.1, -6.4, -5.9, -5.8, -5.6, -6.1, -4.9, -6.2, -5.9, -5.6, -5.9, -5.5, -5.8, -6.9, -5.7, -4.4, -6.2, -5.8, -3.3, -6.7, -5.1, -6.4, -3.6, -7.1, -6.3, -6.3, -5.6, -6.4, -6.7, -6.7, -6.5, -6.8, -7.5, -5.2, -5.5, -6.3, -5.9, -5.4, -7.0, -6.6, -5.8, -7.0, -6.1, -6.2, -6.4, -7.5, -5.9, -7.2, -5.8, -5.8, -6.8, -6.0, -6.2, -5.9, -1.6, -6.8, -5.9, -5.9, -6.3, -6.5, -5.9, -6.7, -7.4, -6.1, -5.2, -6.3, -6.3, -7.1, -5.8, -6.1, -6.5, -4.5, -6.8, -5.1, -5.1, -6.6, -5.9, -6.9, -6.4, -5.4, -5.6, -6.1, -6.1, -5.5, -5.6, -6.3, -5.5, -6.0, -5.6, -6.6, -5.9, -5.7, -6.6, -7.1, -5.2, -6.2, -6.3, -5.6, -6.2, -6.2, -6.9, -6.2, -6.0, -5.2, -6.7, -6.6, -5.9, -6.5, -5.1, -6.3, -5.2, -5.7, -6.6, -6.8, -8.0, -6.9, -6.7, -5.8, -7.1, -7.0, -7.0, -5.9, -5.4, -5.9, -5.1, -5.6, -6.7, -7.2, -6.0, -7.0, -6.8, -6.7, -4.7, -5.8, -5.9, -6.9, -6.5, -5.3, -7.3, -6.6, -5.6, -8.3, -6.8, -6.6, -6.9, -6.2, -5.1, -6.7, -6.6, -5.7, -6.5, -6.5, -7.1, -6.9, -6.9, -6.4, -7.0, -6.8, -7.1, -6.4, -7.1, -6.3, -5.7, -6.9, -8.2, -4.9, -6.5, -6.6, -7.8, -5.3, -8.0, -6.4, -7.1, -5.2, -7.3, -5.8, -5.6, -7.0, -6.2, -5.7, -6.4, -6.3, -4.8, -6.6, -6.7, -6.3, -5.9, -6.5, -5.6, -6.7, -7.6, -6.9, -6.1, -5.8, -5.7, -6.8, -6.1, -6.5, -6.4, -6.8, -6.5, -6.9, -6.0, -5.9, -7.2, -6.5, -3.6, -6.6, -6.3, -5.6, -6.1, -6.2, -7.0, -7.6, -6.5, -5.9, -5.9, -6.2, -5.4, -7.1, -7.0, -6.9, -6.1, -5.9, -6.3, -5.1, -5.9, -6.8, -7.0, -6.5, -6.3, -6.1, -7.0, -5.3, -7.4, -6.0, 0.0, -6.1, -6.9, -5.8, -5.0, -6.1, -5.6, -8.2, -5.8, -6.8, -7.7, -6.5, -6.4, -6.4, -7.1, -6.4, -6.7, -5.6, -6.4, -6.3, -6.3, -6.5, -5.1, -5.5, -6.7, -4.3, -6.5, -6.3, -6.3, -6.8, -5.8, -5.6, -6.9, -6.8, -6.5, -6.3, -6.2, -6.7, -6.7, -5.9, -6.1, -6.1, -5.3, -6.0, -6.7, -6.7, -6.3, -5.7, -6.3, -6.9, -6.3, -7.1, -4.3, -7.1, -6.4, -6.9, -5.6, -7.1, 3.5, -7.6, -6.6, -7.1, -5.0, -7.9, -5.7, -5.6, -7.6, -6.2, -6.3, -5.7, -5.7, -5.7, -7.8, -6.9, -6.3, -7.3, -5.8, -6.1, -6.4, -7.2, -6.7, -5.9, -6.4, -5.6, -5.6, -7.0, -6.0, -7.2, -6.8, -8.1, -6.6, -7.1, -6.1, -6.1, -6.7, -6.8, -6.1, -6.3, -7.0, -6.2, -6.0, -7.1, -6.6, -5.3, -8.2, -6.6, -7.5, -6.1, -5.9, -5.5, -5.6, -6.1, -6.6, -7.9, -7.2, -6.8, -7.6, -6.8, -5.4, -6.4, -5.4, -7.4, -6.7, -5.9, -6.9, -6.7, -6.8, -6.7, -7.8, -6.6, -5.2, -7.3, -3.9, -6.0, -6.6, -8.4, -6.7, -6.7, -7.2, -6.9, -6.6, -7.6, -0.9, -8.5, -6.4, -7.8, -6.1, -6.2, -6.0, -7.6, -5.7, -6.0, -5.9, -6.5, -6.5, -6.4, -6.6, -6.3, -6.4, -7.5, -6.1, -6.2, -6.7, -6.7, -6.5, -6.0, -7.9, -6.1, -6.4, -6.7, -6.2, -5.7, -6.4, -6.5, -6.0, -5.8, -5.7, -5.9, -6.4, -5.5, -6.6, -7.2, -5.6, -6.5, -7.0, -5.9, -7.5, -5.1, -4.2, -5.5, -6.2, -6.4, -6.1, -7.3, -6.5, -7.0, -6.2, -7.5, -6.3, -6.7, -5.7, -6.3, -5.9, -5.2, -5.5, -8.3, -7.5, -6.0, -6.3, -7.1, -5.8, -6.9, -6.4, -5.7, -6.0, -6.4, -6.0, -6.2, -5.1, -7.0, -4.9, -6.8, -7.1, -4.7, -6.0, -6.0, -6.3, -6.9, -6.0, -6.4, -6.1, -6.8, -6.5, -6.5, -6.7, -7.3, -6.0, -8.2, -6.6, -6.7, -4.9, -5.8, -6.9, -5.9, -4.3, -6.9, -6.2, -4.9, -6.4, -6.0, -5.1, -4.8, -4.4, -6.0, -5.9, -6.4, -6.2, -7.9, -6.4, -6.1, -6.0, -5.8, -5.8, -6.9, -6.7, -6.2, -6.9, -5.7, -6.3, -5.7, -6.2, -4.6, -6.8, -5.7, -7.4, -5.4, -6.4, -6.0, -7.4, -6.4, -6.3, -6.4, -6.1, -6.5, -5.7, -7.0, -6.7, -6.3, -6.0, -5.7, -6.3, -5.6, -5.7, -4.9, -6.1, -6.3, -5.4, -5.6, -6.0, -5.3, -6.0, -6.3, -6.0, -6.3, -6.9, -5.1, -6.3, -8.1, -5.1, -5.7, -6.8, -6.1, -4.7, -6.2, -7.0, -5.7, -7.4, -7.3, -7.0, -5.7, -5.5, -6.1, -6.9, -5.9, -6.9, -6.3, -6.4, -6.7, -5.9, -7.0, -7.4, -6.9, -6.7, -6.7, -6.4, -6.3, -5.9, -6.1, -7.3, -7.0, -6.5, -6.4, -6.7, -6.2, -6.1, -7.0, -6.7, -7.0, -6.8, -6.4, -5.8, -6.7, -6.4, -6.1, -5.8, -4.5, -3.9, -6.0, -7.0, -5.3, -5.7, -7.0, -4.2, -6.7, -6.1, -7.2, -6.2, -6.2, -6.5, 2.9, -7.2, -5.9, -5.4, -5.5, -6.3, -4.9, -6.8, -7.4, -7.5, -6.8, -6.4, -7.0, -6.5, -6.0, -6.4, -6.1, -6.3, -6.2, -5.8, -5.8, -5.3, -7.0, -6.5, -4.9, -7.9, -5.6, -5.5, -6.8, -6.4, -5.3, -5.4, -6.1, -5.0, -5.9, -6.6, -5.1, -6.4, -6.2, -2.0, -6.1, -5.5, -6.3, -7.1, -5.0, -6.8, -4.2, -6.8, -6.1, -6.4, -6.1, -5.8, -5.8, -5.9, -6.4, -7.0, -6.7, -4.0, -6.2, -5.8, -6.5, -6.6, -7.4, -6.0, -6.2, -6.6, -4.4, -6.6, -4.9, -4.8, -6.4, -5.3, -5.9, -7.1, -5.4, -5.8, -6.7, -6.7, -6.2, -6.2, -6.6, -6.2, -5.4, -6.3, -6.6, -7.4, -6.4, -6.7, -6.4, -6.4, -6.7, -5.1, -7.2, -6.6, -5.6, -6.0, -6.3, -7.5, -4.7, -6.7, -5.1, -4.5, -6.4, -6.1, -5.6, -6.2, -5.8, -6.6, -7.2, -7.1, -3.0, -3.4, -6.2, -5.5, -5.1, -4.9, -5.3, -4.7, -5.9, -5.9, -5.4, -6.2, -5.7, -5.3, -6.4, -5.6, -6.2, -5.5, -6.4, -6.4, -7.2, -6.3, 1.1, -5.8, -6.8, -7.0, -7.1, -6.4, -6.4, -6.3, -6.1, -6.3, -4.9, -5.8, -6.3, -5.6, -5.1, -5.7, -4.5, -5.9, -5.4, -5.0, -5.1, -6.6, -4.8, -6.4, -6.0, -6.3, -6.6, -6.0, -7.0, -6.5, -6.2, -5.7, -6.2, -7.4, -6.1, -6.0, -7.3, -5.9, -6.2, -6.5, -4.7, -5.9, -4.6, -7.1, -5.8, -5.6, -7.6, -7.2, -5.7, -6.1, -6.3, -5.8, -5.9, -6.0, -6.1, -6.4, -5.7, -6.4, -6.3, -5.5, -7.7, -5.0, -5.6, -6.7, -7.8, -7.4, -5.4, -7.0, -4.6, -6.6, -6.9, -6.4, -7.0, -6.5, -8.0, -7.7, -6.4, -5.3, -6.1, -5.0, -6.6, -6.2, -5.7, -6.1, -6.7, -6.4, -3.6, -6.7, -8.0, -6.0, -7.0, -5.8, -6.0, -5.9, -6.5, -7.4, -6.4, -5.6, -6.7, -7.0, -6.9, -5.7, -6.5, -5.5, -6.1, -5.8, -5.6, -6.5, -6.0, -5.3, -5.1, -5.0, -5.8, -6.0, -6.2, -5.4, -5.3, -6.9, -7.1, -6.3, -5.8, -6.9, -5.7, -7.3, -7.5, -6.1, -5.7, -6.2, -6.2, -5.5, -6.1, -7.4, -5.6, -6.7, -5.1, -6.4, -6.2, -6.4, -5.0, -6.3, -6.4, -5.3, -6.5, -4.6, -4.3, -5.3, -6.4, -5.7, -6.7, -7.2, -6.6, -6.3, -6.5, -6.8, -6.9, -6.4, -7.4, -6.5, -6.2, -5.2, -6.3, -6.4, -6.3, -7.2, -6.3, -6.4, -6.2, -6.9, -6.2, -6.9, -5.7, -7.7, -7.4, -7.0, -6.5, -6.1, -6.7, -6.2, -6.8, -6.4, -5.2, -6.0, -6.4, -7.3, -6.7, -6.5, -6.5, -6.0, -6.6, -6.1, -6.4, -3.8, -6.0, -5.4, -5.4, -4.0, -6.2, -5.1, -4.9, -6.7, -6.7, -6.9, -7.4, -7.0, -5.2, -7.4, -6.5, -6.9, -7.0, -7.1, -7.5, -5.8, -5.3, -6.8, -6.6, -5.9, -6.1, -7.2, -6.8, -6.3, -6.8, -6.2, -6.1, -7.7, -6.8, 9.4, -6.9, -6.4, -6.0, -6.3, -6.0, -6.1, -5.9, -6.2, -6.7, -6.9, -7.1, -5.3, -6.8, -3.4, -6.8, -6.7, -5.8, -2.4, -6.4, -6.5, -5.6, -6.2, -6.8, -6.7, -5.8, -7.0, -4.3, -6.7, -5.4, -5.5, -5.8, -6.3, -5.5, -6.7, -6.4, -6.6, -6.5, -7.2, -6.6, -6.0, -5.8, -7.4, -4.5, -6.6, -6.5, -5.6, -7.1, -6.2, -6.0, -6.9, -6.3, -7.4, -6.0, -7.5, -6.5, -5.2, -4.9, -6.3, -6.5, -6.1, -7.0, -6.8, -7.1, -6.4, -6.2, -8.1, -5.2, -6.2, -5.7, -6.1, -6.1, -7.6, -6.2, -6.5, -6.7, -6.6, -6.4, -6.7, -5.6, -6.6, -6.3, -6.1, -5.5, -7.5, -6.2, -6.7, -5.3, -5.6, -4.9, -5.2, -5.2, -7.1, -5.9, -5.9, -5.1, -5.9, -5.8, -6.1, -4.9, -5.8, -4.8, -7.0, -7.1, -7.5, -4.6, -3.3, -6.3, -5.3, -8.2, -6.8, -6.6, -5.5, -7.7, -5.5, -5.8, -6.6, 0.0, -5.9, -5.8, -6.5, -7.2, -6.1, -7.2, -6.9, -6.0, -5.6, -7.0, -6.3, -5.8, -7.5, -5.5, -5.4, -6.8, -7.3, -7.1, -6.3, -5.3, -5.4, -6.7, -4.5, -6.4, -5.4, -2.8, -5.4, -5.7, -5.0, 0.0, -5.8, -6.1, -6.2, -5.2, -6.2, -6.8, -5.6, -2.2, -5.4, -6.2, -5.5, -5.9, -4.8, -6.0, -5.2, -5.5, -4.9, -6.1, -5.4, -4.8, -5.8, -6.4, -4.6, -6.2, -5.6, -6.0, -4.8, -7.1, -6.4, -6.0, -6.6, -5.1, -7.8, -6.3, -5.9, -6.0, -5.6, -4.8, -5.6, -5.2, -6.2, -7.1, -6.8, -6.9, -5.3, -6.7, -6.1, -5.4, -6.3, -5.3, -4.9, -5.5, -5.6, -6.7, -5.8, -6.9, -6.0, -6.7, -5.6, -5.1, -6.1, -6.8, -6.6, -6.6, -5.3, -7.5, -6.9, -6.7, -6.1, -5.9, -6.9, -7.8, -7.2, -6.3, -6.0, -5.6, -5.1, -4.1, -7.7, -7.5, -7.9, -5.9, -6.0, -6.5, -6.5, -5.6, -5.8, -8.3, -6.7, -7.0, -7.1, -4.2, -8.8, -7.4, -6.4, -6.9, -6.2, -6.1, -6.6, -5.7, -4.6, -7.4, -5.3, -5.9, -6.6, -7.2, -5.9, -6.3, -6.3, -6.2, -3.9, -5.8, -7.0, -5.4, -6.8, -5.8, -6.3, -6.2, -5.5, -6.9, -5.8, -5.6, -3.5, -6.9, -7.2, -6.2, -6.7, -6.0, -8.1, -6.3, -6.9, -6.1, -6.6, -4.8, -6.2, -6.5, -7.3, -6.4, -7.3, -7.3, -8.0, -6.1, -6.7, -6.9, -6.2, -6.9, -6.9, -6.6, -6.1, -6.7, -4.6, -6.2, -4.0, -5.0, -6.1, -6.0, -5.9, -6.1, -6.4, -4.2, -5.3, -6.6, -5.6, -6.0, -7.1, -7.2, -7.1, -8.6, -5.6, -6.4, -7.0, -8.1, -6.5, -4.7, -7.2, -6.9, -6.9, -6.2, -6.1, -6.7, -6.2, -7.0, -6.2, -6.6, -6.3, -5.8, -6.7, -5.3, -6.8, -7.7, -6.5, -6.7, -7.5, -7.1, -6.3, -6.0, -8.1, -6.8, -6.5, -7.1, -6.3, -6.7, -5.2, -6.5, -7.6, -5.6, -7.5, -6.9, -7.1, -7.0, -5.1, -6.3, -6.9, -6.0, -6.0, -6.6, -6.2, -6.5, -5.5, -6.9, -6.6, -6.8, -6.2, -5.5, -6.5, -6.2, -6.1, -5.6, -7.2, -6.9, -5.5, -7.2, -6.3, -7.4, -6.4, -3.3, -5.5, -5.6, -5.1, -5.3, -5.9, -6.6, -6.0, -6.6, -6.0, -7.9, -6.0, -6.7, -7.1, -0.8, -5.2, -6.8, -5.5, -6.8, -5.9, -6.7, -5.9, -6.6, -6.3, -6.6, -7.0, -6.0, -5.7, -6.0, -6.9, -6.5, -5.3, -7.0, -7.2, -7.0, -6.0, -5.8, -7.2, -6.9, -5.5, -6.4, -1.8, -2.5, -6.0, -6.2, -7.0, -8.0, -7.4, -6.1, -7.1, -4.0, -6.9, -6.5, -7.7, -7.5, -3.7, -7.2, -7.7, -7.7, -6.4, -7.3, -6.0, -7.1, -5.0, -6.7, -8.4, -7.7, -4.8, -6.2, -5.5, -6.3, -6.6, -4.4, -7.9, -5.8, -6.7, -8.0, -6.2, -5.9, -7.7, -6.8, -5.3, -5.2, -6.6, -5.7, -6.0, -5.9, -5.8, -7.0, -7.0, -5.8, -7.8, -7.3, -6.3, -6.8, -6.4, -6.5, -7.8, -6.1, -6.4, -2.2, -5.3, -6.6, -5.6, -7.0, -6.5, -8.2, -6.5, -7.1, -6.5, -6.1, -6.2, -6.3, -6.4, -6.3, -6.4, -6.5, -7.5, -6.0, -6.0, -6.8, -6.9, -6.6, -5.7, -6.2, -6.3, -5.1, -6.2, -6.5, -7.0, -5.6, -6.9, -6.2, -7.6, -7.0, -4.8, -5.2, -4.5, -6.0, -6.0, -6.6, -6.4, -5.8, -5.8, -5.8, -6.1, -6.4, -5.0, -5.9, -6.4, -5.4, -7.1, -5.3, -5.9, -4.6, -5.6, -6.2, -6.6, -6.7, -6.6, -6.1, -6.2, -6.0, -6.3, -6.2, -5.9, -3.1, -7.0, -5.9, -5.3, -6.0, -6.9, -3.0, -6.6, -7.0, -5.8, -5.8, -5.3, -6.4, -6.6, -4.7, -6.2, -6.4, -5.5, -6.7, -6.8, -6.3, -6.1, -6.8, -6.0, -6.6, -5.6, -7.3, -5.6, -6.3, -5.6, -6.0, -5.7, -5.9, -7.8, -6.3, -5.5, -6.9, -7.2, -5.0, -6.9, -7.0, -7.3, -6.2, -7.3, -5.5, -6.3, -7.3, -6.6, -5.9, -6.8, -6.3, -5.7, -7.3, -6.7, -6.0, -5.2, -6.8, -6.9, -6.6, -6.3, -6.3, -7.9, -3.6, -6.1, -8.1, 1.0, 4.4, -6.4, -6.2, -3.0, -4.7, -6.0, -5.9, -7.6, -5.4, -6.1, -7.4, -7.2, -5.7, -6.5, -5.8, -6.1, -3.4, -6.3, -5.1, -5.6, -3.3, -6.8, -7.0, -8.0, -6.7, -5.6, -6.6, -6.6, -6.2, -6.2, -7.0, -5.2, -6.2, -5.4, -6.0, -6.6, -7.2, -4.2, -6.3, -5.4, -5.1, -7.0, -5.9, -6.5, -4.6, -6.8, -4.6, -4.4, -7.6, -4.0, -5.8, -6.2, -6.4, -3.7, -7.0, -2.2, -6.6, -6.3, -4.6, -6.7, -6.5, -7.5, -6.4, -7.3, -4.8, -6.1, -5.8, -6.7, -5.1, -5.6, -6.6, -6.9, -5.1, -5.9, -6.1, -6.7, -6.6, -6.4, -5.8, -5.9, -4.8, -3.9, -5.6, -6.0, -5.7, -6.5, -5.4, -5.1, -5.2, -6.5, -6.8, -6.7, -7.0, -6.1, -6.2, -6.4, -6.3, -4.9, -6.4, -6.1, -6.7, -5.3, -5.6, -6.7, -7.6, -3.4, -2.3, -5.3, -4.8, -6.3, -7.0, -5.6, -7.6, -6.6, -6.6, -5.6, -5.2, -6.2, -6.1, -6.2, -6.2, -6.9, -5.9, -6.4, -5.9, -6.9, -6.0, -5.8, -6.8, -5.7, -5.7, -6.8, -6.8, -6.0, -6.9, -6.7, -5.7, -6.5, -6.8, -6.3, -5.7, -7.9, -8.0, -6.3, -7.0, -5.4, -6.3, -6.6, -6.8, -6.1, -6.8, -7.3, -4.5, -6.6, -4.9, -3.8, -6.1, -4.4, -6.8, -8.6, -7.4, -7.0, -5.9, -6.8, -6.0, -6.6, -6.6, -5.9, -6.0, -5.3, -4.9, -6.2, -5.5, -5.5, -5.8, -6.7, -5.9, -5.7, -6.6, -5.8, -6.5, -5.2, -6.3, -7.4, -5.6, -7.0, -5.0, -7.3, -7.7, -5.8, -5.9, -5.3, -6.6, -7.0, -7.2, -5.6, -6.4, -6.0, -6.6, -6.6, -5.1, -5.3, -7.0, -6.5, -5.3, -7.7, -6.6, -6.7, -6.9, -5.1, -5.0, -6.1, -5.3, -6.0, -6.1, -6.7, -7.2, -5.4, -6.9, -6.6, -6.2, -6.7, -6.4, -6.2, -6.0, -5.9, -6.2, -6.7, -7.6, -4.0, -6.9, -6.9, -6.2, -5.4, -6.3, -6.6, -6.5, -7.4, -6.5, -5.9, -8.2, -5.8, -5.6, -7.3, -7.2, -6.3, -6.0, -6.5, -6.5, -7.4, -7.7, -7.1, -7.0, -6.5, -5.8, -7.2, -6.6, -5.9, -6.9, -6.6, -6.8, -6.7, -7.1, -6.2, -4.2, -7.4, -6.8, -5.8, -6.6, -6.7, -7.0, -7.3, -6.1, -6.0, -7.7, -6.2, -6.4, -6.0, -5.7, -6.9, -8.0, -6.1, -6.9, -6.9, -6.5, -7.5, -6.4, -7.1, -6.1, -6.4, -6.7, -7.1, -6.3, -6.4, -7.5, -6.8, -6.7, -5.8, -6.7, -6.0, -6.7, -6.3, -1.5, -5.8, -7.7, -7.2, -6.1, -5.7, -6.3, -5.6, -5.8, -7.8, -1.4, -6.8, -5.9, -6.2, -7.7, -6.1, -5.7, -7.3, -6.6, -2.9, -5.9, -5.9, -5.3, -6.5, 1.7, -3.2, -3.7, -7.0, -6.2, -7.2, -6.8, -4.5, -6.7, -6.3, -6.1, -5.0, -6.0, -5.6, -7.5, -6.2, -2.0, -6.7, -6.7, -7.0, -7.4, -6.1, -1.0, -6.5, -6.6, -6.9, -7.4, -6.6, -6.0, -7.5, -5.4, -6.1, -6.2, -5.8, -7.2, -7.5, -6.8, -6.1, -7.0, -6.9, -7.2, 3.8, -4.5, -5.5, -5.9, -3.9, -5.4, -7.2, -7.3, -6.9, -6.5, -7.5, -6.1, -5.4, -7.7, -5.4, -5.7, -5.0, -6.6, -5.7, 21.6, -5.8, -4.6, -7.0, -8.4, -7.4, -7.2, -6.3, -7.0, -6.5, -6.9, -7.1, -5.3, -5.8, -6.3, -5.7, -7.5, -5.3, -6.4, -6.2, -8.1, -7.1, -7.3, -6.6, -5.7, -4.8, -8.3, -3.4, -6.5, -7.3, -7.6, -7.2, -6.2, -6.1, -7.3, -7.9, -5.1, -7.7, -6.4, -6.1, -7.3, -6.9, -7.1, -7.3, -6.8, -5.4, -6.4, -6.7, -7.3, -7.2, -5.9, -6.5, -8.2, -5.8, -7.3, -6.0, -7.3, -5.4, -3.2, -6.7, -6.8, -6.1, -6.9, -5.4, -5.7, -6.4, -6.5, -6.4, -6.8, -6.1, -5.7, -4.9, -5.8, -5.7, -6.4, -6.6, -8.0, -7.2, -7.9, -6.9, -6.3, -7.0, -6.1, -5.7, -7.0, -6.6, -6.1, -7.0, -6.3, -5.9, -7.1, -7.1, -6.1, -5.5, -6.1, -7.5, -6.5, -8.1, -5.9, -4.8, -7.0, -6.7, -6.5, -6.3, -6.3, -6.2, -5.4, -8.2, -6.0, -6.7, -6.0, -6.2, -6.9, -6.6, -7.0, -3.6, -4.8, -6.9, -6.9, -5.6, -6.3, -7.1, -6.6, -6.7, -6.0, 1.4, -6.0, -7.2, -6.7, -5.3, -5.7, -7.0, -5.3, -6.1, -7.1, -5.7, -5.9, -6.1, -6.8, -6.7, -1.5, -7.3, -5.9, -5.8, -7.7, -6.0, -6.8, -6.1, -6.3, -6.2, -7.4, -8.6, -5.8, -6.7, -6.4, -6.9, -7.4, -5.8, -5.9, -6.9, -9.0, -7.0, -6.4, -6.8, -6.1, -6.6, -6.8, -6.2, -7.6, -5.3, -5.5, -6.1, -5.6, -5.9, -6.3, -7.5, -7.4, -6.6, -5.7, -7.3, -5.7, -6.9, -5.3, -6.7, -5.7, -6.9, -5.1, -7.3, -7.5, -6.6, -6.7, -5.9, -6.4, -8.0, -5.3, -6.7, -6.8, -6.1, -7.5, -6.1, -6.5, -6.8, -6.7, -6.8, -6.6, -6.7, -7.3, -4.7, -5.6, -5.8, -6.1, -5.6, -5.6, -5.8, -6.6, -7.5, -6.7, -6.5, -7.1, -6.4, 11.1, -3.9, -6.2, -6.3, -6.1, -6.0, -7.3, -6.3, -8.1, -5.9, -7.3, -6.7, -5.6, -6.5, 5.4, -6.0, -5.1, -5.6, -6.5, -6.3, -8.0, -7.9, -8.0, -5.9, -6.5, -7.3, -7.3, -7.7, -6.4, -7.2, -6.5, -6.5, -5.2, -7.7, -6.8, -5.8, -7.3, -5.5, -6.8, -6.4, -5.8, -6.3, -6.7, -6.7, -6.8, -6.4, -8.1, -7.0, -6.8, -7.5, -6.2, -7.2, -7.0, -6.1, -5.8, -4.4, -5.0, -7.2, -7.9, -8.5, -5.9, -7.3, -6.2, -6.4, -6.7, -5.9, -6.0, -6.0, -6.8, -7.2, -5.7, -6.2, -7.2, -5.4, -6.2, -6.7, -5.9, -6.7, -5.2, -6.7, -6.1, -7.0, -6.8, -6.8, -6.2, -6.2, -6.3, -6.2, -6.9, -5.6, -7.1, -6.0, -7.1, -6.7, -6.3, -6.5, -6.3, -7.1, -6.2, -6.6, -8.1, -6.3, -6.3, -6.5, -5.6, -5.6, -6.3, -7.0, -7.0, -6.1, -6.2, -6.6, -5.8, -6.5, -6.9, -5.6, -6.2, -6.3, -6.4, -6.1, -7.1, -7.3, -5.9, -5.4, -7.2, -7.0, -6.5, -6.6, -6.5, -7.4, -6.3, -6.8, -4.5, -5.6, -6.0, -6.1, -6.1, -7.0, -6.7, -5.1, -5.7, -4.5, -6.3, -7.3, -5.9, -6.9, -7.2, -2.9, -6.2, -7.0, -6.0, -7.0, -7.2, -7.4, -7.0, -6.6, -6.8, -6.5, -6.5, -5.6, -6.7, -6.1, -7.0, -6.8, -6.0, -6.6, -6.6, -6.3, -6.5, -8.1, -7.4, -6.3, -6.6, -7.7, -6.6, -5.2, -7.3, -6.9, -6.8, -7.2, -6.0, -7.6, -5.9, -6.6, -8.5, -7.2, -5.9, -6.3, -8.0, -6.7, -6.5, -5.7, -6.6, -5.8, -7.1, -7.2, -6.5, -6.9, -6.2, -7.0, -6.0, -5.8, -6.9, -6.6, -7.8, -6.9, -7.2, -6.4, -5.8, -7.2, -6.2, -7.1, -6.9, -6.8, -7.0, -7.3, -7.6, -6.4, -5.3, -7.3, -7.8, -6.1, -5.5, -6.5, -6.7, -7.0, -6.9, -7.8, -6.6, -7.6, -7.4, -7.4, -6.8, -7.3, -6.5, -7.3, -6.6, -5.5, -6.6, -6.4, -6.1, -5.7, -6.9, -6.8, -5.7, -6.1, -3.3, -6.2, -6.2, -5.5, -7.1, -6.6, -4.9, -6.6, -7.2, -7.7, -6.8, -1.0, -7.1, -6.9, -5.9, -8.2, -7.2, -6.4, -7.0, -7.1, -6.6, -6.3, -5.7, -6.5, -5.2, -5.7, -6.3, -6.4, -6.8, -4.9, -7.9, -7.0, -6.7, -4.7, -5.4, -6.0, -7.1, -6.5, -6.1, -7.6, -6.7, -5.9, -6.2, -7.0, -6.0, -6.2, -6.4, -5.7, -7.1, -6.4, -5.9, -6.3, -6.1, -6.3, -6.8, -6.8, -4.9, -6.7, -5.7, -6.8, -5.7, -6.5, -6.8, -6.4, -5.9, -6.4, -6.3, -5.6, -7.3, -6.5, -5.3, -5.6, -5.5, -6.0, -5.8, -5.6, -5.8, -5.5, -7.7, -8.0, -2.2, -6.9, -6.5, -4.0, -7.3, -5.0, -8.2, -8.0, -3.5, -8.0, -4.7, -6.3, -6.7, -5.6, -6.0, -7.5, -7.8, -6.6, -7.0, -6.8, -7.6, -5.8, -6.2, -5.9, -0.6, 3.3, -8.7, -6.6, -5.9, -6.7, -5.1, -6.1, -6.4, -7.2, -7.3, -4.1, -5.3, -7.3, -6.4, -5.7, -6.7, -5.5, -7.5, -6.8, -6.0, -7.0, -7.4, -5.1, -7.5, -6.3, -6.9, -6.3, -6.9, -7.0, -6.6, -6.9, -5.4, -5.2, -7.4, -5.0, -5.4, -8.0, -6.1, -6.6, -7.2, -8.3, -6.1, -6.0, -6.8, -5.9, -7.0, -6.4, -5.6, -5.3, -6.9, -6.9, -5.6, -7.0, -7.1, -7.5, -5.8, -7.8, -6.3, -6.3, -7.5, -6.6, -6.6, -6.1, -6.3, -5.9, -6.5, -6.9, -5.9, -7.1, -6.0, -6.4, -6.5, -5.3, -6.0, -5.9, -6.4, -6.7, -7.2, -5.5, -6.5, -6.0, -6.5, -6.0, -6.3, -6.5, -6.3, -5.3, -6.9, -6.2, -5.8, -5.7, -6.0, -6.4, -6.4, -6.3, -6.3, -4.9, -6.4, -5.7, -5.5, -7.3, -6.1, -5.6, -6.0, -6.3, -5.5, -6.1, -6.1, -5.9, -5.9, -7.0, -5.3, -4.7, -5.0, -6.8, -6.3, -6.9, -6.4, -6.4, -6.2, -5.8, -5.3, -6.0, -6.1, -5.2, -6.9, -6.1, -5.1, -4.9, -6.7, -6.4, -5.7, -6.3, -7.4, -7.1, -4.5, -6.6, -6.1, -6.6, -6.9, -6.4, -7.0, -7.0, -6.9, -6.3, -6.5, -6.1, -6.0, -5.6, -5.2, -7.6, -6.6, -7.3, -7.8, -6.7, -7.5, -6.5, -6.8, -7.6, 0.1, -7.4, -7.4, -5.8, -7.3, -7.1, -8.9, -8.5, -7.0, -7.5, -8.0, -6.6, -7.1, -7.5, -7.4, -5.8, -7.0, -7.5, -7.2, -7.0, -6.6, -6.2, -6.1, -6.1, -6.9, -8.0, -6.3, -6.6, -6.3, -7.2, -5.7, -7.6, -8.4, -6.5, -6.6, -6.8, -7.3, -7.4, -6.6, -6.5, -7.2, 0.5, -6.1, -8.1, -6.9, -5.4, -7.2, -6.6, -6.0, -6.5, -9.0, -6.1, -6.5, -6.3, -6.6, -5.7, 0.6, -6.9, -7.0, -7.1, 5.8, -6.8, -6.9, -7.1, -7.0, -5.9, -7.3, -7.6, -6.5, -7.5, -6.3, -5.2, -6.0, -6.0, -8.0, -7.5, -6.6, -8.0, -7.6, -7.9, -7.1, -6.2, -7.2, -7.0, -6.9, -6.2, -6.0, -7.1, -6.2, -7.7, -7.0, -6.8, -8.4, -6.4, -7.6, -6.0, -7.8, -7.4, -6.6, -7.4, -6.9, -7.4, -6.1, -8.4, -6.8, -7.4, -7.3, -8.7, -6.7, -7.0, -5.2, -6.2, -7.3, -4.1, -6.7, -7.1, -6.8, 0.8, -6.4, -7.2, -8.4, -4.5, -7.3, -8.1, -7.9, -2.6, -6.7, -6.1, -7.3, -7.2, -6.8, -8.0, -6.0, -3.8, -7.4, -6.7, -6.5, -7.7, -7.2, -5.8, -6.7, -7.3, -4.5, -6.7, -7.7, 0.0, -6.5, -7.0, -7.0, -6.7, -7.0, -6.6, -6.3, -6.4, -6.0, 3.7, -5.3, -6.0, -6.5, -6.9, -5.8, -6.8, -6.8, -8.6, -5.6, -6.5, -4.8, 3.3, 3.7, -6.4, -4.0, -7.3, -6.9, -5.4, -3.4, -8.9, -6.1, -5.6, -5.8, -6.3, -6.8, -6.1, -6.1, -6.1, -6.7, -5.4, -6.8, -4.9, -2.1, -7.1, -6.4, -3.7, -6.8, -7.7, -8.1, -7.1, 2.6, -7.5, -7.0, -7.2, -6.6, -7.7, -7.2, -7.1, -7.8, -7.3, -3.2, -7.6, -7.2, -6.5, -5.9, -6.9, -6.2, -7.0, -6.2, -6.0, -6.5, -6.6, -6.8, -5.9, -4.7, -5.6, -7.9, -5.7, -6.8, -6.7, -6.4, -7.1, -6.3, -7.0, -7.0, -6.3, 1.5, -5.9, -5.6, -6.6, -5.9, -7.7, -7.5, -6.5, -7.2, -6.6, -5.9, -6.9, -7.1, -5.4, -6.5, -5.4, -5.4, -5.6, -6.0, -5.6, -7.6, -5.8, -8.0, -5.7, -7.7, -5.4, -4.8, -7.1, -6.3, -5.7, -5.8, -5.8, -6.2, -6.7, -6.0, -6.4, -4.7, -7.3, -6.6, -7.8, -6.8, -6.9, -5.6, -7.2, -6.0, -6.4, -5.5, -8.5, -5.6, -7.0, -6.1, -6.3, -8.4, -6.5, -5.9, -7.6, -7.5, -5.5, -6.7, -7.4, -6.0, -6.4, -6.5, -6.7, -8.4, -5.8, -5.6, -9.4, -6.5, -7.3, -6.7, -0.1, -7.4, -4.2, -7.3, -7.4, -6.7, -2.2, -4.2, -5.8, -6.6, -5.6, -6.1, -6.9, -5.0, -3.7, -6.2, -8.0, -6.9, -6.7, -6.5, -6.8, -6.0, -7.5, -6.9, -6.4, -5.9, -7.2, -3.6, -7.1, -6.7, -6.9, -7.7, -7.6, -8.1, -3.6, -7.0, -6.9, -6.2, -7.6, -7.4, -5.2, -6.1, -5.5, -7.0, -8.3, -7.2, -7.5, -6.1, -7.9, -5.9, -6.5, -5.7, -6.3, -5.5, -6.9, -6.0, -6.1, -5.9, -7.6, -7.4, -5.2, -5.9, -6.9, -7.9, -7.1, -7.2, -7.3, -5.7, -6.0, -6.8, -6.6, -7.4, -8.0, -6.7, -7.7, -6.9, -7.9, -7.0, -6.4, -5.8, -7.2, -6.7, -6.2, -6.2, -8.3, -6.4, -6.8, -6.1, -6.7, -7.3, -6.5, -5.9, -3.5, -1.7, -5.8, -7.6, -6.7, -5.6, -5.4, -6.5, -7.1, -7.8, -8.6, -6.7, -5.8, -6.7, -8.1, -7.8, -6.3, -5.1, -7.1, -6.1, -5.5, -8.4, -6.4, -5.9, -6.7, -7.7, -7.9, -7.6, -7.2, -7.0, -6.6, -7.1, -4.8, -7.8, -6.5, -8.0, -7.3, -5.9, -7.1, -8.6, -8.5, -8.0, -6.6, -9.0, -7.8, -7.5, -4.5, -6.4, -6.9, -5.6, -7.0, -6.8, -5.7, -4.9, -5.9, -7.1, -4.3, -5.3, -7.1, -7.2, -3.2, -6.3, -6.8, -6.6, -6.1, -5.1, -6.5, -7.6, -7.0, -7.0, -6.9, -5.5, -5.6, -6.1, -7.4, -6.6, -6.7, -5.6, -5.7, -6.4, -5.5, -6.6, -7.2, -5.6, -7.6, -6.6, -6.5, -6.5, -6.2, -6.1, -6.0, -6.2, -6.8, -6.4, -7.1, -5.9, -7.2, -6.5, -7.2, -7.0, -6.0, -6.2, -5.8, -5.8, -6.5, -6.2, -2.0, -6.0, -7.1, -6.4, -7.2, -5.4, -7.3, -8.0, -6.9, -6.4, -7.1, -7.4, -7.0, -4.5, -5.9, -6.0, -6.1, -7.8, -2.8, -7.4, -7.0, -3.5, -6.5, -6.2, -6.7, -6.2, -7.1, -4.4, -7.3, -7.9, -6.7, -4.4, -7.0, -5.2, -6.0, -5.2, -5.7, -6.9, -6.0, -6.9, -7.2, -7.6, -7.5, -7.4, -4.8, -8.1, -7.9, -8.0, -4.6, -6.6, -4.7, -5.8, -7.6, -7.2, -7.5, -6.2, -5.7, -5.5, -6.8, -5.5, -6.8, -6.6, -5.2, -6.0, -5.9, -4.0, -7.2, -4.6, -6.9, -6.8, -7.0, -6.6, -5.7, -6.7, -8.5, -6.0, -7.6, -6.2, -5.3, -3.3, -7.0, -6.2, -6.6, -6.5, -7.0, -6.2, -6.1, -5.6, -6.6, -6.2, -6.3, -5.6, -6.8, -8.4, -4.0, -6.5, -6.9, -7.5, -5.0, -8.0, -5.4, -7.6, -7.9, -4.7, -6.4, -7.1, -5.3, -7.2, -6.6, -7.2, -7.2, -7.4, -8.1, -5.8, -4.8, -6.5, -7.6, -6.9, -4.4, -7.1, -3.4, -6.2, -6.4, -6.1, -8.1, -6.2, -6.0, -7.0, -6.3, -8.0, -7.2, -6.2, -5.4, -8.1, -5.0, -6.0, -7.9, -7.6, -6.9, -7.1, -5.3, -8.1, -7.2, -7.4, -7.9, -7.3, -6.8, -7.1, -6.7, -7.4, -6.9, -6.9, -7.5, -7.5, -8.2, -2.3, -7.5, -6.6, -4.9, -4.5, -6.6, -6.3, -7.5, -7.6, -6.7, -7.0, -4.7, -8.5, -7.2, -5.4, 7.1, -7.6, -7.6, -8.1, -6.1, -6.6, -6.9, -6.9, -5.3, -8.4, -8.0, -8.0, -7.0, -5.6, -7.4, -6.3, -5.8, -6.1, -6.0, -8.5, -6.1, -6.3, -6.5, -6.6, -6.4, -1.1, -5.1, -5.4, -7.7, -5.8, -6.8, -6.9, -8.4, -6.7, -1.3, -4.9, -6.1, -8.2, -7.4, -7.6, -5.7, -5.0, -5.4, -5.2, -6.0, -6.0, -6.5, -6.7, -5.2, -5.9, -5.7, 0.0, -4.3, -6.7, -7.1, -6.4, -6.9, -6.2, -5.0, -8.1, -4.7, -6.6, -7.0, -6.9, -7.5, -6.0, -5.8, -6.8, -6.1, -7.1, -6.4, -6.2, -5.3, -6.3, -6.5, -5.5, -7.2, -5.4, -6.4, -6.3, -7.8, -5.8, -6.5, -6.9, -6.2, -6.2, -7.2, -5.5, -6.1, -7.0, -6.5, -5.1, -7.3, -5.8, -4.2, -7.0, -6.6, -6.7, -6.6, -6.0, -6.7, -5.2, -6.1, -5.4, -6.4, -6.2, -6.4, -5.7, -7.2, -6.1, -5.1, -6.3, -5.3, -2.7, -6.3, -6.3, -6.5, -4.6, -6.9, -5.0, -7.6, -7.1, -5.4, -6.1, -5.6, -6.5, -6.4, -5.9, -6.2, -6.4, -6.8, -6.0, -6.9, -6.7, -5.0, -6.5, -5.4, -6.0, -5.8, -6.0, -6.4, -5.9, -6.8, -6.6, -6.6, -7.1, -6.0, -5.8, -6.1, -6.2, -5.7, -5.8, -6.4, -5.4, -5.3, -6.5, -6.4, -5.8, -5.8, -5.2, -5.8, -6.1, -5.7, -6.7, -7.6, -6.3, -5.2, -7.3, -6.1, -7.5, -6.0, -6.5, -7.2, -6.1, -6.1, -5.6, -6.9, -6.8, -7.1, -6.0, -5.2, -4.5, -5.5, -6.9, -6.6, -6.9, -7.4, -5.5, -6.0, -6.4, -7.8, -7.1, -7.0, -7.4, -6.7, -6.8, -5.6, -6.6, -6.8, -6.0, -5.9, -5.3, -6.2, -6.5, -6.9, -7.0, -7.3, -6.5, -6.6, -5.9, -6.0, -6.4, -6.9, -6.1, -6.5, -6.9, -6.5, -6.8, -6.1, -5.3, -6.3, -7.1, -6.4, -5.2, -5.7, -6.9, -7.5, -6.6, -6.7, -6.5, -6.8, -7.3, -4.6, -2.6, -1.6, -0.6, -1.5, -4.6, -5.5, 7.3, -5.6, -6.5, -5.9, -7.6, -6.0, -6.8, -6.6, -6.8, -6.7, -5.8, -7.8, -5.6, -5.4, -6.0, -5.7, -6.7, -6.8, -6.2, -6.7, -6.3, -7.9, -5.9, -7.6, -4.9, -6.6, -6.7, -8.6, -6.0, -7.1, -7.1, -5.8, -7.4, -6.3, -6.3, -6.2, -5.5, -7.0, -5.5, -6.6, -6.1, -5.8, -6.9, -6.6, -5.9, -5.9, -5.9, -5.4, -7.3, -6.0, -5.1, -7.2, -6.3, -6.0, -6.3, -1.8, -5.9, -5.6, -6.6, -6.6, -5.7, -5.5, -6.5, -6.0, -4.9, -6.1, -6.3, -7.0, -6.8, -6.1, -5.3, -6.4, -7.3, -5.6, -7.2, -6.0, -7.3, -7.1, -6.5, -5.0, -5.7, -6.0, -5.8, -6.3, -6.4, -6.8, -6.7, -6.1, -5.9, -5.5, -7.6, -5.9, -6.7, -6.5, -6.9, -6.1, -5.6, -5.1, -6.9, -5.1, -6.4, -5.8, -6.0, -6.1, -5.9, -6.1, -6.9, -5.7, -6.0, -7.1, -5.9, -7.4, -5.2, -7.1, -6.5, -6.8, -5.5, -5.5, -7.1, -6.8, -5.9, -6.1, -7.3, -5.5, -5.8, -5.4, -6.5, -5.0, -6.5, -6.8, -6.6, -6.5, -6.5, -7.3, -5.5, -6.8, -5.7, -3.9, -6.4, -7.2, -5.8, -6.7, -7.7, -6.6, -6.6, -6.6, -6.5, -6.5, -4.5, -5.6, -6.2, -6.7, -5.2, -6.7, -6.5, -6.4, -6.1, -6.5, -6.1, -6.8, -5.1, -6.1, -7.2, -6.1, -6.7, -6.1, -6.6, -6.5, -4.9, -6.6, -7.2, -5.2, -6.1, -6.0, -6.3, -6.8, -6.2, -5.4, -6.9, -7.3, -7.2, -7.1, -6.7, -6.2, -6.7, -5.7, -2.4, -6.1, -6.3, -6.3, -6.7, -7.7, -6.1, -6.4, -7.2, -6.9, -6.6, -6.5, -5.9, -5.8, -7.0, -5.1, -6.1, -6.9, -6.5, -6.3, -5.9, -6.7, -6.2, -7.0, -5.6, -6.5, -6.5, -7.1, -6.8, -6.7, -6.1, -5.6, -7.0, -7.1, -7.2, -6.9, -7.1, -7.1, -7.1, -6.8, -6.4, -6.2, -6.2, -7.0, -6.4, -5.8, -6.1, -5.7, -6.1, -5.8, -6.0, -7.0, -6.0, -7.6, -7.0, -5.2, -6.2, -6.5, -6.4, -6.0, -6.9, -5.6, -5.3, -6.3, -6.7, -5.9, -6.3, -6.0, -6.4, -5.0, -6.4, -6.9, -6.2, -5.6, -5.8, -5.8, -6.0, -6.6, -5.9, -5.3, -6.1, -6.8, -5.3, -5.2, -6.3, -4.6, -5.3, -5.9, -6.4, -4.9, -7.4, -5.1, -5.9, -5.6, -5.7, -5.4, -6.5, -5.8, -6.0, -5.4, -5.8, -4.9, -5.6, -5.4, -5.3, -5.9, -6.6, -5.0, -6.9, -7.3, -6.7, -6.1, -6.0, -6.0, -7.1, -6.3, -7.6, -4.9, -6.7, -6.4, -5.4, -6.8, -6.3, -7.1, -4.2, -5.9, -6.5, -6.1, -5.2, -5.7, -5.9, -5.4, -5.1, -4.9, -5.5, -4.9, -4.8, -2.6, -7.6, -0.7, -6.4, -7.2, -7.3, -3.3, -6.8, -6.3, -5.4, -6.6, -5.7, -4.6, -3.4, -5.7, -6.4, -6.9, -6.0, -7.6, -7.0, -6.5, -6.4, -6.8, -5.5, -6.3, -7.0, -6.7, -3.3, -6.2, -6.1, -7.0, -7.2, -5.5, -7.1, -5.9, -6.5, -6.0, -5.6, -6.2, -5.5, -5.7, -5.9, -6.1, -6.0, -7.4, -6.7, -6.1, -8.4, -7.6, -6.0, -5.7, -7.0, -6.8, -6.2, -6.8, -7.1, -6.7, -7.4, -5.6, -6.1, -5.7, -6.3, -5.8, -7.7, -5.5, -7.2, -5.8, -6.1, -7.7, -5.4, -5.6, -6.1, -7.2, -6.4, -6.3, -5.0, -6.3, -7.1, -6.7, -7.6, -6.1, -6.5, -6.5, -6.6, -6.8, -6.9, -5.7, -6.0, -5.6, -6.4, -8.2, -5.5, -7.7, -5.4, -4.0, -6.5, -6.1, -5.7, -6.0, -4.6, -7.3, -7.1, -6.8, -6.6, -7.1, -6.6, -5.9, -6.8, -6.6, -4.4, -5.5, -7.0, -5.7, -6.1, -2.8, -6.0, -6.6, -7.2, -6.6, -7.2, -6.8, -5.5, -4.3, -6.1, -5.6, -7.2, -6.7, -6.3, -5.1, -5.4, -7.4, -6.3, -5.6, -6.9, -6.6, -7.0, -6.2, -6.7, -6.5, -6.0, -6.6, -7.3, -6.0, -6.1, -6.5, -5.9, -5.0, -5.9, -2.7, -7.3, -7.2, -7.3, -6.8, -6.7, -6.8, -6.2, -6.6, -6.8, -6.7, -7.0, -7.3, -4.1, -5.0, -6.3, -6.1, -6.9, -6.3, -6.5, -6.2, -6.4, -5.3, -7.1, -6.2, -6.8, -6.4, -5.3, -6.7, -5.9, -6.2, -7.3, -6.6, -6.8, -6.7, -5.6, -5.5, -6.3, -3.6, -6.7, -6.6, -5.5, -6.2, -5.9, -6.0, -5.3, -6.1, -5.9, -6.6, -6.7, -7.6, -7.4, -5.5, -6.3, -5.4, -7.5, -7.1, -7.3, -7.3, -5.6, -5.9, -5.9, -6.4, -6.3, -6.0, -6.6, -6.6, -6.9, -6.8, -6.2, -8.2, -6.7, -5.9, -6.8, -6.5, -6.4, -8.2, -8.4, -7.3, -6.8, -5.7, -6.9, -6.8, -5.2, -6.3, -6.7, -6.2, -6.7, -6.1, -6.6, -6.6, -8.2, -5.9, -6.5, -6.6, -7.4, -5.4, -6.2, -5.4, -5.1, -7.1, -7.0, -7.0, -7.0, -5.5, -5.1, -7.6, -6.8, -7.0, -5.8, -6.6, -6.0, -6.2, -6.5, -7.7, -0.9, -7.0, -4.6, -6.5, -7.1, -4.7, -6.2, -4.8, -5.5, -6.5, -4.6, -4.7, -6.8, -6.9, -7.5, -7.6, -7.8, -7.7, -2.8, -7.3, -5.5, -5.9, -1.8, -4.8, 1.9, -6.7, -6.8, -5.6, -6.5, -6.8, -6.7, -5.3, -7.1, -6.5, -6.9, -6.4, -7.2, -6.7, -6.1, -5.5, -7.3, -6.9, -7.6, -5.8, -6.7, -5.7, -5.9, -6.8, -6.6, -7.3, -5.2, -7.7, -5.1, -6.4, -4.5, -3.7, -5.9, -6.1, -6.1, -6.5, -7.2, -5.9, -7.7, -5.9, -5.7, -6.8, -6.3, -5.1, -5.8, -5.7, -6.5, -7.0, -5.8, -7.4, -6.4, -6.6, -7.4, -6.9, -7.0, -6.9, -6.7, -5.8, -7.9, -6.4, -5.6, -6.7, -7.4, -5.7, -7.9, -6.2, -5.0, -7.7, -5.7, -1.7, -6.2, -6.0, -6.9, -6.2, -5.5, -6.5, -7.3, -5.8, -5.4, -6.4, -7.1, -6.6, -7.3, -5.6, -6.9, -7.8, -6.9, -7.6, -6.0, -6.2, -3.8, -6.3, -5.3, -6.1, -6.5, -6.3, -7.2, -8.8, -6.4, -3.7, -5.0, -4.8, -3.3, -6.7, -6.5, -4.1, -5.8, -4.4, -6.1, -6.1, -4.2, -6.8, -6.9, -6.8, -4.2, -6.9, -5.8, -6.6, 0.5, -7.2, -1.8, 1.8, -5.9, -8.5, -5.6, -5.2, -6.3, -3.4, -6.1, -6.1, -7.6, -7.6, -6.2, -5.7, -6.4, -7.2, 0.0, -6.7, -7.4, -5.6, -5.0, -6.4, 1.3, -6.5, -7.2, -6.3, -3.9, -5.0, -7.6, -7.1, -6.3, -6.4, -7.8, -6.8, -6.8, -6.9, -6.4, -5.6, -7.1, -7.9, -6.5, -7.5, -7.3, -7.4, -6.2, -5.6, -4.5, -8.0, -6.6, -7.3, -6.6, -6.3, -6.8, -6.7, -7.1, -7.4, -7.0, -0.5, -6.0, -6.6, -7.7, -7.4, -6.6, -5.8, -7.3, -4.4, -7.7, -6.5, -5.7, -6.4, -7.0, -5.8, -6.7, -7.0, -7.0, -5.9, -6.2, -5.8, -6.6, -6.8, -7.7, -7.2, -4.8, -7.4, -7.6, -6.8, -5.6, -7.1, -5.9, -7.5, -6.3, -7.4, -8.0, -6.2, -3.6, -6.1, -7.5, -7.2, -7.1, -6.3, -5.0, -7.0, -7.3, -6.0, -6.6, -6.9, -7.0, -3.6, -5.4, -6.8, -6.1, -7.4, -7.0, -6.4, -4.3, -6.5, -0.6, -6.2, -6.6, -6.6, -7.2, -5.9, -5.1, -6.9, -6.5, -6.3, -4.5, -7.2, -6.7, -5.9, -6.3, -6.2, -7.7, -6.8, -7.2, -9.1, -6.8, -7.0, -7.6, -3.6, -8.0, -7.5, -6.9, 3.1, -3.4, -6.4, -8.2, -7.0, -4.5, -6.2, -6.1, -7.1, -7.7, -8.1, -7.0, -7.6, -6.2, -8.9, -6.8, -6.9, -6.5, -7.5, -7.4, -8.7, -5.0, -7.0, -6.8, -6.5, -6.8, -6.9, -7.6, -7.7, -5.3, -7.2, -6.9, -6.3, -3.2, -6.4, -5.5, -6.8, -6.2, -6.3, -6.3, -6.4, -8.2, -6.8, -7.5, -6.2, -8.3, -4.8, -5.7, -7.6, -7.2, -7.6, -5.9, -2.9, -8.1, -5.5, -7.7, -4.1, -8.1, -7.0, -5.6, -6.3, -7.0, -7.5, -5.7, -8.0, -6.0, -7.4, -5.3, -7.8, -6.8, -7.1, -8.3, -6.3, -7.4, -7.3, -5.8, -6.4, -6.2, -6.3, -7.8, -5.3, -6.0, -7.7, -7.3, -7.6, 3.0, -3.8, -5.9, -6.1, -7.6, -6.1, -6.3, -6.3, -8.7, -7.0, -3.3, -5.6, -6.6, -7.3, -6.7, -7.4, -6.9, -7.5, -7.4, -6.2, -5.8, -5.6, -7.2, -5.7, -6.4, -5.2, -6.1, -5.0, -5.1, -5.6, -7.3, -6.8, -4.5, 15.8, -6.9, -4.8, -6.7, -6.6, -7.8, -5.2, -6.3, -6.7, -6.5, -7.0, -4.0, -6.2, -6.6, -4.0, -7.1, -6.4, -7.2, -3.7, -4.8, -6.2, -6.5, -4.8, -6.4, -6.3, -6.1, -7.5, -6.0, -4.5, -7.1, -6.1, -4.5, -6.4, -6.5, -7.8, -4.6, -7.7, -5.9, -5.3, -5.7, -7.2, -6.5, -8.4, -5.6, -6.6, -7.5, -7.7, -6.2, -5.9, -6.6, 0.2, -5.5, -6.5, -6.5, -6.0, -6.2, -6.3, -6.4, -6.4, -6.1, -6.2, -6.6, -7.1, -7.0, -3.5, -3.9, -5.7, -6.5, -6.7, -8.2, -6.5, -6.3, -5.7, -7.2, -6.8, -7.6, -6.9, -5.6, -6.5, -7.0, -6.5, -6.1, -6.9, -4.7, -5.9, -6.2, -6.4, -6.6, -6.9, -6.2, -5.2, -5.4, -7.6, -5.9, -5.4, -6.2, -5.0, -5.9, -6.7, -6.9, -6.1, -6.2, -5.4, -6.8, -6.0, -6.2, -5.8, -6.1, -6.5, -6.9, -6.6, -7.1, -6.8, -5.7, -7.5, -7.4, -1.6, -6.4, -6.2, -5.6, -5.7, -6.2, -5.9, -6.0, -6.5, -5.9, -6.7, -7.0, -7.3, -6.5, -5.6, -6.4, -7.3, -6.6, -5.7, -5.3, -5.2, -4.8, -6.5, -6.4, -6.1, -6.9, -5.6, -5.5, -6.5, -6.0, -6.1, -5.5, -6.4, -7.0, -5.0, -6.0, -3.6, -6.8, -5.0, -6.7, -5.8, -6.4, -6.7, -6.3, -5.2, -7.1, -6.3, -6.8, -5.6, -5.5, -5.3, -7.0, -4.9, -6.5, -6.3, -6.0, -5.7, -6.9, -6.6, -7.1, -5.4, -5.9, -6.1, -6.7, -4.3, -6.8, -6.1, -6.1, -5.0, -1.4, -6.8, -6.6, -6.1, -6.0, -5.9, -6.9, -5.1, -5.4, -6.1, -5.5, -7.5, -5.0, -4.3, -6.0, -5.2, -5.8, -5.4, -5.3, -5.5, -5.4, -5.1, -6.7, -7.1, -5.9, -6.2, -7.1, -6.2, -6.1, -5.7, -5.5, -4.4, -5.3, -6.1, -5.8, -5.6, -6.1, -5.9, -6.1, -6.9, -6.3, -6.0, -5.2, -6.1, -7.1, -6.1, -5.1, -6.2, -2.2, -5.7, -5.8, -6.2, -5.2, -5.8, -4.9, -5.5, -6.2, -5.9, -6.1, -1.5, -6.0, -5.0, -6.2, -4.6, -5.3, -6.6, -4.8, -3.8, -8.6, -7.0, -6.4, -4.6, -5.1, 0.5, -5.3, -6.7, -6.9, -6.1, -6.8, -5.2, -6.0, -6.7, -5.8, -8.1, -7.1, -4.9, -4.0, -4.8, -4.6, -6.4, -7.2, -8.1, -6.2, -6.1, -6.4, -6.2, -6.4, -6.7, -5.7, -5.8, -6.0, -6.6, -6.3, -5.6, -6.3, -5.7, -7.0, -6.5, -6.6, -6.9, -6.0, -6.9, -7.4, -7.1, -6.6, -6.5, -6.9, -5.9, -5.4, -6.6, -6.1, -8.1, -6.8, -8.0, -6.0, -6.4, -5.3, -7.1, -5.6, -6.0, -7.4, -5.8, -6.1, -5.6, -5.3, -6.7, -6.1, -6.5, -7.3, -5.1, -7.0, -1.1, -6.0, -6.5, -7.8, -5.6, -6.9, -3.7, -7.3, -7.4, -7.8, -6.0, -7.6, -7.5, -7.9, -5.7, -5.3, -7.8, -5.7, -6.5, -6.4, -6.9, -5.5, -7.0, -5.9, -6.0, -6.3, -7.0, -6.1, -6.7, -9.3, -6.8, -7.3, -7.7, 0.0, -6.8, -7.1, -6.8, -5.2, -5.7, -7.2, -6.3, -5.5, -7.1, -7.5, -7.1, -6.7, -7.8, -7.1, -7.8, -7.1, -4.6, -7.4, -5.6, -6.9, -4.6, -6.2, -6.9, -7.1, -5.8, -7.2, -6.3, -6.4, -6.8, -6.6, -6.8, -6.4, -6.4, -6.9, -8.0, -7.9, -6.3, -6.1, -5.8, -5.1, -6.1, -5.8, -4.9, -6.1, -6.4, -6.9, -7.6, -5.5, -6.1, -6.6, -5.9, -7.1, -7.0, -5.8, -6.6, -5.8, -6.7, -5.2, -6.4, -5.9, -6.1, -7.0, -7.0, -3.1, -4.8, -6.6, -8.7, -7.1, -5.6, -6.3, -6.2, -6.2, -6.3, -7.0, -7.3, -8.4, 1.3, -8.0, -7.3, -6.5, -6.2, -7.0, -6.3, -6.8, -8.4, -7.5, -4.1, -5.5, -6.8, -7.0, -7.0, -6.8, -8.1, -5.1, -7.2, -6.7, -8.3, -6.8, -6.2, -6.5, -7.9, -7.2, -8.3, -6.7, -6.9, -8.2, -5.1, -7.9, -7.6, -8.6, -2.1, -5.1, -6.9, -7.0, -2.4, -7.1, -6.2, -6.2, -6.3, -6.8, -7.6, -4.7, -5.6, -7.0, -5.7, -6.9, -7.6, -5.6, -7.3, -7.5, -8.0, -7.2, -7.3, -6.5, -6.6, -7.0, -6.9, -6.7, -7.9, -7.6, -7.2, -6.9, -7.2, -5.8, -5.5, -7.4, -6.5, -5.8, -7.0, -6.5, -6.6, -7.4, -6.7, -6.9, -7.2, -5.3, -7.6, -6.5, -5.4, -6.1, -7.3, -8.5, -5.3, -6.2, -6.6, -7.4, -6.3, -6.2, -6.1, -5.7, -5.4, -6.2, -5.7, -5.6, -7.9, -5.9, -7.3, -6.3, -6.9, -6.9, -3.1, -7.7, -8.0, -6.2, -7.5, -6.2, -3.6, -7.7, -6.7, -7.0, -4.5, -6.5, -7.1, -8.4, -5.0, -6.3, -5.7, -7.2, -8.8, -7.6, -8.2, -7.0, -5.7, -7.8, -8.7, -7.8, -6.0, -6.5, -5.7, -8.4, -6.0, -7.3, -6.7, -6.6, -3.0, -6.3, -5.9, -6.9, -6.0, -7.2, -6.8, -8.2, -6.8, -5.0, -5.2, -7.1, -7.1, -6.6, -6.7, -7.1, -6.7, -5.5, -8.0, -6.4, -7.1, -8.0, -7.7, -2.6, -5.5, -3.6, -4.1, -5.8, -3.7, -6.9, -5.6, -6.6, -5.5, -7.7, -7.7, -5.3, -7.7, -6.6, -5.8, -1.8, -1.1, -5.2, -6.2, 0.2, -3.9, -6.2, -8.2, -6.9, -5.9, -6.3, -7.0, -7.0, -6.9, -6.9, -4.9, -5.2, -7.7, -8.2, -4.3, -7.0, -6.0, -6.5, -6.8, -7.2, -7.8, -6.8, -7.6, -7.5, -7.4, -7.0, -7.7, -5.8, -8.2, -8.4, -3.1, -4.8, -7.7, -7.5, -8.7, -6.0, -6.3, -7.7, -6.8, -6.7, -3.1, -6.2, -7.4, -7.0, -6.3, -6.0, -6.2, -6.4, -7.0, -7.8, -6.6, -7.0, -6.9, -7.1, -7.4, -7.8, -7.2, -7.3, -6.6, -6.8, -7.3, -8.6, 3.7, -6.1, 1.0, -7.2, -7.1, -7.4, -7.1, -7.2, -6.1, -8.0, -4.2, -3.6, -7.5, -5.7, -6.1, -6.6, -4.9, -6.3, -7.0, -6.6, -6.2, -6.1, -6.4, -5.1, -4.9, -7.0, -6.9, -6.2, -6.8, -7.5, -7.6, -7.7, -6.7, -7.0, -6.9, -8.2, -8.1, -7.4, -5.8, -5.2, -7.2, -5.9, -7.8, -9.3, -7.2, -6.9, -4.9, -7.8, -6.6, -6.6, 1.3, 3.4, -6.1, -7.2, -5.7, -7.3, -6.4, -7.7, -7.0, -6.5, -5.2, -7.1, -4.1, -7.6, -7.9, -8.2, -7.8, -7.0, -6.1, -4.9, -6.6, -6.9, -6.5, -5.5, -6.0, -5.7, -7.8, -6.7, -3.0, -7.9, -7.1, -7.2, -6.5, -6.9, -6.6, -6.5, -8.1, -7.5, -4.1, -6.6, -7.3, -4.8, -5.7, -6.5, -8.3, -6.7, -7.5, -6.4, -7.3, -7.2, -5.6, -6.0, -5.4, -8.5, -7.0, 2.0, -7.4, -6.0, -6.0, -6.2, -6.2, -3.6, -8.0, -6.9, -7.8, -4.7, -5.7, -5.4, -6.9, -5.4, -7.8, -2.7, -6.8, -5.9, -7.0, -6.2, -6.2, -5.7, -8.1, -7.6, -8.6, -4.9, -6.4, -9.0, -6.4, -7.5, -7.0, -3.9, -7.5, -6.6, -6.5, -4.8, -6.8, -3.1, -6.9, -6.7, -7.7, -7.2, -6.5, -4.5, -7.0, -7.0, -6.9, -6.5, -5.2, -6.6, -5.1, -4.0, -7.2, -7.0, -6.5, -5.7, -7.3, -7.1, -6.2, -6.8, -6.8, -6.1, -6.7, -5.9, -5.9, -7.7, -6.8, -6.4, -8.0, -2.1, -6.7, -5.8, -6.5, -7.7, -6.5, -7.0, -6.9, -7.5, -6.1, -6.9, -6.7, -6.4, -6.2, -5.8, -6.3, -7.9, -6.2, -7.4, -7.7, -6.6, -8.5, -6.1, -7.2, -6.6, -7.7, -6.8, -6.7, -7.7, -7.2, -6.4, -7.8, -7.6, -6.6, -7.0, -7.0, -6.7, -7.0, -7.5, -8.1, -6.4, -6.8, -6.4, -6.2, -5.8, -6.4, -7.3, -6.1, -6.8, -6.5, -7.0, -6.3, -6.8, -7.7, -8.9, -4.1, -6.7, -7.6, -6.9, -6.4, -6.5, -7.4, -4.9, -5.0, -7.0, -6.1, -6.6, -6.7, -4.7, -6.4, -7.1, -7.3, -6.9, -6.7, -6.9, -7.1, -7.6, -6.5, -8.2, -7.1, -8.6, -7.8, -7.5, -4.7, -6.2, -7.7, -7.0, -5.2, -6.0, -6.9, -6.9, -6.2, -5.6, -5.0, -7.6, -6.4, -4.6, -6.6, -7.2, -5.0, -6.3, -7.6, -3.8, -6.9, -4.6, -3.1, -9.4, -4.0, -6.9, -8.1, -6.9, -5.9, -5.0, -6.3, -7.1, -8.1, 1.5, -6.8, -7.6, -7.2, -6.9, -6.7, -4.3, -6.1, -6.5, -7.2, -4.3, -6.9, -7.9, -6.9, -5.6, -6.8, -7.0, -8.8, -6.3, -6.4, -7.2, -6.7, -7.6, -7.2, -6.4, -7.1, -1.6, -5.3, -7.4, -7.7, -6.5, -7.3, 1.1, -5.2, -5.0, -7.7, -6.7, -4.8, -5.5, -5.9, -7.8, -7.0, -3.3, -5.5, -8.0, -9.2, -5.7, -7.3, -5.7, -8.1, -7.0, -7.8, -6.3, -2.8, -7.5, -8.9, -5.5, -5.1, -6.9, -5.5, -6.8, -1.1, -6.3, -6.8, -6.4, -7.0, -7.8, -4.6, -7.3, -6.8, -3.3, -5.5, -7.3, -7.2, -7.8, -5.4, -7.4, -6.7, -6.2, -8.2, -6.4, -7.0, -7.9, -7.8, -7.7, -6.5, -7.1, -7.4, -7.2, -7.6, -7.2, -5.6, -6.9, -7.7, -7.6, -5.5, -5.0, -7.5, -7.9, -6.1, -8.0, -4.7, -6.7, -6.5, -8.3, -4.5, -7.1, -5.0, -6.8, -4.6, -6.6, -8.0, -6.1, -5.8, -5.4, -6.3, -7.1, -5.6, -6.3, -7.5, -5.3, -8.4, -8.5, -7.6, -7.0, -6.7, -6.5, -6.8, -8.0, -7.0, -7.0, -4.2, -8.3, -7.3, -7.4, -6.7, -8.4, -7.3, -6.6, -7.7, -7.0, -7.6, -6.9, -6.2, -7.0, -6.9, -6.4, 8.5, -6.0, -7.9, -6.5, -6.3, -7.2, -7.0, -5.2, -7.6, -6.7, 2.6, -5.8, -8.2, -7.0, -7.4, -7.8, -7.5, -7.4, -8.9, -7.9, -7.6, -7.2, -6.8, -6.8, -5.8, -6.7, -8.7, -7.1, -6.3, -7.2, -7.0, -7.9, -6.3, -7.3, -5.3, -7.2, -4.3, -7.0, -6.5, -7.0, -7.2, -5.9, -6.2, -8.0, -6.3, -6.9, -7.6, -7.6, -7.1, -7.5, -7.1, -6.3, -8.0, -7.4, -7.0, -7.9, -7.0, -8.4, -6.5, -6.4, -7.9, -7.2, -5.9, 1.0, -7.8, -7.2, -4.6, -6.8, -8.2, 6.0, -5.8, -7.2, -4.6, -6.9, -5.7, -5.2, -6.6, -6.9, -7.1, -7.3, -7.1, -5.4, -1.8, -4.2, -3.3, -6.7, -8.1, -6.5, -7.2, -7.4, -7.0, -7.2, -7.6, -6.6, -6.4, -8.0, -6.5, -7.2, -8.3, -6.2, -6.5, -6.7, -7.2, -7.1, -7.8, -7.0, -7.4, -7.4, -5.3, -5.2, -2.5, -3.6, -7.2, -3.0, -6.6, -6.3, -7.0, -8.2, -8.1, -7.8, -5.8, -8.0, -5.8, -1.2, -6.6, -7.0, -7.8, -0.3, -7.5, -8.7, -5.2, -5.9, -7.7, -5.9, -3.1, -5.3, -8.9, -8.6, -8.1, -4.7, -8.0, 1.0, -5.0, -6.6, -7.0, -7.1, -6.5, -6.4, -6.6, -7.5, -8.8, -6.8, -6.8, -6.9, -7.4, -8.9, -8.2, -6.3, -7.0, -5.3, -7.5, -7.1, -6.0, -7.7, -7.2, -6.8, -6.0, -7.0, -7.5, -7.3, -7.9, 0.4, -8.4, -6.3, -7.5, -8.8, -6.8, -7.6, -5.6, -8.0, -7.4, -7.4, -6.7, -6.2, -7.2, -7.8, -5.5, -6.7, -6.8, -8.8, -7.0, -7.3, -6.7, -6.6, -7.3, -6.6, -5.1, -8.5, -4.7, -7.1, -6.1, -8.6, -7.8, -8.2, -6.1, -7.7, -6.8, -7.6, -6.5, -5.7, -8.4, 21.7, -7.9, -7.8, -7.1, -7.3, -6.7, -6.3, -3.9, -7.1, -7.6, -7.0, -7.8, -7.0, -7.8, -7.9, -7.4, -6.9, -6.7, -7.4, -7.0, -6.8, -6.9, -8.1, -6.1, -7.6, -6.6, -8.3, -6.8, -6.8, -7.3, -6.6, -8.4, -6.0, -7.4, -5.9, -7.7, -6.2, -6.2, -7.0, -6.2, -7.1, -7.1, -7.0, -6.7, -7.0, -6.8, -7.6, -6.8, -6.5, -5.8, -6.7, -6.3, -7.5, -6.9, -7.3, -7.3, -4.6, -7.5, -6.1, -5.3, -7.6, -7.5, -7.0, -7.1, -6.8, -6.7, -5.8, -7.5, -7.5, -8.3, -7.7, -6.0, -7.2, -6.8, -7.5, -6.3, -7.5, -7.2, -6.0, -7.1, -5.4, -7.6, -5.9, -7.2, -7.2, -7.6, -9.3, -6.9, -4.5, -7.5, -7.7, -6.8, -6.2, -6.7, -7.2, -6.3, -8.1, -8.2, -8.5, -5.8, -6.0, -6.5, -8.0, -6.6, -6.3, -6.7, -6.5, -7.6, -7.1, -7.0, -8.5, -7.5, -6.1, -5.6, -7.6, -6.7, -7.2, -6.2, -7.1, -6.0, -6.4, -5.6, -6.6, -7.8, -5.9, -7.5, -8.1, -7.0, -8.2, -6.4, -3.4, -6.3, -7.4, -7.0, -7.9, -7.2, -4.8, -5.7, -4.2, -5.0, -6.2, -7.0, -6.1, -6.9, -5.8, -7.1, -7.7, -6.4, -6.4, -6.6, -7.3, -7.5, -6.3, -6.5, -6.9, -7.1, -5.0, -5.7, -6.1, -5.5, -7.6, -8.4, -6.6, -6.4, -7.9, -7.1, -6.0, -6.1, -6.9, -7.0, -7.2, -6.9, -6.2, -5.4, -7.0, -7.3, -8.6, -6.5, -6.7, -5.8, -6.3, -5.7, -7.6, -6.7, -7.7, -7.0, -7.6, -7.1, -6.2, -6.6, -6.6, -7.9, -6.2, -7.7, -6.9, -7.5, -6.0, -6.8, -7.4, -7.2, -7.1, -7.2, -6.8, -7.6, -5.6, -4.0, -1.8, -6.7, -7.3, -6.2, -6.9, -7.1, -6.3, -6.5, -6.9, -6.0, -6.8, -7.7, -7.5, -6.6, -7.2, -5.8, -6.9, -6.9, -6.4, -8.0, -6.4, -6.7, -6.5, -6.4, -7.6, -6.4, -4.4, -7.7, -7.3, -6.1, -7.5, -5.4, 4.8, -5.8, -6.7, -7.6, -6.1, -7.3, -7.6, -5.8, -6.7, -5.8, -7.5, -7.6, -7.6, -8.7, -7.0, 2.0, -6.8, -7.2, -6.7, -6.3, -7.9, -7.8, -7.5, -8.0, -6.7, -6.7, -8.0, -6.9, -7.0, -7.6, -6.6, -8.1, -6.5, -5.1, -6.5, -4.3, -7.2, -6.5, -7.4, -7.0, -4.6, -6.5, -7.2, -7.4, -6.9, -6.9, -5.5, -7.7, -7.4, -6.5, -7.4, -6.9, -5.2, -6.9, -6.7, -6.5, -7.0, -6.0, -2.2, -6.6, 15.9, -3.6, -7.0, -7.4, -6.7, -7.2, -7.3, -7.5, -6.5, -4.6, -5.7, -6.3, -6.4, -3.2, -5.6, -5.6, -5.8, -6.5, -8.0, -5.6, -6.6, -5.8, -7.1, -8.7, -5.9, -4.6, -6.3, -7.5, -7.7, -6.3, -7.0, -6.3, -6.6, -6.4, -5.7, -6.9, -6.7, -6.7, -6.9, -6.1, -8.1, -6.7, -7.3, -6.6, -7.2, -6.9, -6.5, -6.5, -4.1, -6.5, -7.0, -5.2, -6.4, -5.6, -5.7, -5.3, -7.8, -7.2, -7.9, -6.2, -5.3, -7.3, -6.2, -4.5, -3.9, -4.5, -6.4, -7.4, -4.8, -7.0, -5.6, -7.0, -6.7, -7.0, -6.3, -5.3, -5.7, -3.4, -6.1, -8.2, -7.1, -5.6, -7.3, -7.3, -6.4, -7.8, -8.6, -6.9, -5.0, -5.5, -8.1, -8.3, -7.9, -3.0, -6.5, -6.2, -6.0, -7.0, -4.3, -6.9, -7.0, 11.3, -3.7, -6.7, -6.3, -7.0, -6.5, -5.1, 16.2, -4.7, -5.7, -7.1, -7.2, -6.8, -6.6, -6.6, -6.3, -8.0, -5.4, -7.3, -7.3, -3.2, -7.0, -6.6, -6.3, -6.5, -7.6, -6.2, -6.4, -7.7, -7.9, -7.6, -6.3, -5.9, -6.7, -6.2, -6.7, -8.6, -6.2, -7.7, -5.6, -6.9, -6.8, -6.3, -7.5, -5.7, -7.0, -7.2, -6.6, -7.3, -6.4, -4.7, -3.6, -6.3, -7.5, -6.3, -6.6, -5.8, -7.4, -6.6, -5.8, -7.2, -6.4, -7.4, -6.9, -7.0, -5.2, -7.8, -6.2, -7.0, -8.0, -6.8, -6.5, -7.0, -6.1, -6.2, -6.2, -7.1, -7.4, -4.6, -7.8, -7.8, -7.2, -4.9, -6.5, -5.7, -2.2, -6.9, 11.4, -5.9, -6.0, -6.1, -6.0, -7.4, -6.9, -5.7, -5.9, -6.7, -6.9, -6.3, -8.6, -6.5, -7.6, -7.8, -6.9, -8.3, -7.1, -7.2, -7.0, -7.0, -7.5, -6.9, -6.6, -7.4, -7.9, -6.9, -7.4, -5.9, -4.0, -6.1, -7.8, -6.2, -6.2, -7.0, -6.8, -6.2, -7.8, -7.7, -6.3, -9.5, -8.4, -7.7, -7.1, -6.9, -6.2, -5.7, -5.5, -6.6, -7.3, -7.2, -6.6, -6.8, -6.5, -5.8, -8.2, -7.0, -6.7, -7.1, -7.4, -6.8, -8.4, -6.6, -8.0, -8.3, -6.1, -6.0, -6.8, -6.2, -6.5, -5.4, -5.9, -5.6, -7.2, -5.3, -6.1, -7.4, -7.5, -7.2, -5.4, -6.4, -7.7, -6.7, -5.4, -5.6, -5.6, -6.3, -6.3, -6.3, -7.1, -7.5, -7.5, -7.8, -6.7, -6.7, -6.8, -6.5, -6.2, -7.4, -8.5, -6.1, -5.8, -7.6, -7.7, -5.9, -7.2, -7.6, -7.9, -8.1, -7.3, -7.8, -7.1, -6.7, -6.9, 0.1, -6.5, -3.9, -7.2, -6.6, -6.6, -5.3, -7.8, -6.5, -6.1, -5.6, -6.6, -5.5, -5.8, -8.7, -6.4, -6.6, -6.6, -7.5, -5.6, -8.0, -6.3, -7.0, -6.1, -5.5, -5.3, -9.7, -7.7, -8.1, -5.9, -8.0, -7.6, -7.4, -6.9, -6.7, -5.0, -6.1, -7.1, -6.6, -7.6, -6.8, -4.5, -7.4, -6.4, -6.8, -7.1, -7.0, -5.0, -3.3, -6.7, -5.4, -6.4, -3.1, -5.8, -5.2, -5.6, -5.5, -7.0, -8.0, -6.8, -4.3, -7.4, -6.6, -7.3, -7.2, -7.3, -6.1, -7.7, -5.7, -7.3, -5.9, -7.1, -6.8, -5.7, -8.1, -6.7, -5.7, -7.9, -7.3, -5.8, -6.5, -7.4, -5.9, -6.4, -5.6, -7.8, -5.7, -9.4, 3.6, -6.1, -5.8, -8.2, -7.0, -7.5, -6.7, -7.4, -6.8, -6.9, -7.8, -4.0, -7.2, -6.9, -8.9, -6.4, -8.7, -8.0, -7.4, -5.5, -7.0, -7.4, -6.6, -6.5, -6.5, -7.3, -6.6, -8.8, -7.3, -7.2, -7.3, -9.1, -7.0, -7.5, -6.5, -6.3, -6.2, -7.2, -6.9, -6.3, -6.4, -6.7, -5.3, -7.1, -6.1, -7.9, -5.8, -6.5, -5.9, -6.6, -6.3, -6.6, -6.9, -7.9, -5.3, -6.6, -6.8, -7.0, -7.1, -6.7, -7.8, -7.4, -7.3, -6.3, -6.2, -8.9, -7.5, -7.1, -7.6, -9.2, -5.8, -5.5, -7.7, -6.7, -5.4, -8.1, -3.3, -6.7, -6.8, -6.6, -5.8, 2.6, -7.5, -7.6, -5.4, -6.1, -6.3, -8.3, -6.7, -8.8, -6.8, -6.7, -10.0, -6.7, -5.8, -7.6, -8.1, -7.0, -8.0, -7.1, -6.6, -3.1, -7.9, -6.5, -6.6, -7.8, -7.0, -6.5, -7.6, -6.3, -7.6, -6.9, -6.8, -6.6, -6.5, -6.7, -6.3, -4.4, -6.9, -7.4, -7.0, -7.7, -6.0, -6.8, -7.3, -6.2, -6.4, -6.1, -6.4, -8.3, -8.5, -6.8, -7.7, -5.9, -7.2, -5.0, -7.8, -6.7, -7.6, -7.0, -7.6, -8.0, -6.2, -5.2, -7.8, -7.6, -8.5, -6.9, -7.5, -6.4, -3.0, -7.5, -8.0, -8.9, -7.2, -6.7, -7.0, -7.9, -6.3, -7.1, -6.6, -7.0, -6.7, -6.2, -7.3, -5.9, -6.3, -6.7, -6.8, -7.5, -1.1, 12.4, -6.6, -6.7, -6.7, -7.9, -6.6, -6.6, -7.1, -6.6, -7.0, -6.8, -6.8, -5.8, -7.2, -6.7, -6.5, -6.1, -7.8, -6.6, -7.3, -5.5, -6.4, -5.1, -5.3, -1.3, 11.9, -6.5, -6.2, -1.2, -6.4, -6.1, -1.1, -7.2, -3.1, -7.1, -6.0, -6.8, -5.3, -7.9, -5.7, -7.5, -5.5, -5.0, -5.3, -7.7, -8.1, -7.7, -8.7, -7.1, -6.3, -2.3, -6.5, -8.3, -5.4, -6.0, -8.2, -6.3, -8.2, -8.0, -8.1, -9.6, -7.2, -5.9, -6.5, -7.4, -6.8, -7.0, -6.1, -6.3, -7.1, -7.6, -7.6, -6.0, -6.3, -5.9, -6.1, -6.7, -7.8, -5.9, -6.4, -6.9, -7.1, -7.0, -9.0, -7.4, -4.4, -8.1, -8.4, -7.0, -8.0, -7.0, -8.2, -5.9, -6.4, -8.2, -6.9, -7.4, -7.7, -7.7, -1.6, -7.2, -7.7, -5.4, -8.5, -5.8, -5.9, -7.1, -8.7, -6.0, -7.4, -6.0, -5.4, -6.0, -3.1, -5.4, -5.2, -6.4, -8.4, -6.8, -4.1, -5.7, -7.1, -1.8, -7.0, -7.0, -7.2, -3.0, -3.0, -6.4, -8.4, -6.1, -6.9, -9.4, -6.0, -7.6, -5.8, -7.2, -6.8, -6.9, -8.0, -6.2, -6.4, -7.0, -6.4, -6.8, -6.6, -8.0, -3.6, -6.8, -6.9, -6.4, -7.8, -7.5, -8.1, -7.0, -7.9, -8.2, -7.4, -7.7, -6.6, -5.3, -5.5, -7.7, -6.9, -6.8, -6.5, -6.1, -6.3, -6.6, -2.2, -7.0, -7.3, -6.6, -7.6, -7.7, -6.5, -5.6, -7.1, -7.6, -5.1, -6.8, -8.4, -7.2, -8.0, -7.6, -8.3, -7.9, -7.4, -7.0, -7.3, -7.9, -3.9, -7.2, -6.4, -7.1, -7.7, -8.0, -7.6, -6.2, -7.5, -6.9, 0.0, -7.5, -6.3, -7.1, -7.2, -7.2, -9.1, -9.0, -7.7, -8.2, -5.9, -8.6, -4.9, -7.5, -7.2, -7.8, -8.9, -6.7, -6.9, -7.1, -7.2, -7.2, -6.8, -6.9, -3.5, -6.2, -7.3, -7.1, -5.8, -7.4, -1.2, -7.0, -7.3, -6.8, -6.2, -5.9, -3.7, -6.7, -6.7, -5.9, -7.1, -7.2, -7.1, -6.8, -7.3, -7.8, -7.1, -6.3, -8.2, -7.0, -6.5, -8.5, -7.3, -6.9, -8.5, -5.4, -6.6, -6.5, -6.7, -7.5, -6.7, -6.9, -7.8, -6.7, -6.9, -6.2, -6.5, -6.6, -6.5, -7.4, -6.8, -8.0, -6.5, -7.3, -7.7, -7.9, -8.4, -7.8, -6.6, -6.9, -6.8, -6.3, -6.9, -7.2, -5.8, -7.0, -6.8, -6.7, -7.6, -6.5, -5.2, -6.1, -6.9, -7.2, -6.4, -6.6, -6.0, -5.7, -6.5, -6.3, -7.3, -7.1, -7.9, -7.8, -8.0, -6.3, -7.2, -7.2, -6.7, -6.4, -4.1, -7.2, -6.5, -5.9, -6.8, -6.3, -6.5, -6.0, -8.1, -6.7, -8.6, -7.0, -6.1, -7.6, -7.3, -5.5, -7.2, -5.8, -8.3, -6.8, -6.7, -5.6, -8.1, -6.7, -6.5, -8.6, -5.9, -6.4, -7.6, -6.7, -7.8, -6.2, -7.2, -6.7, -6.5, -6.8, -7.9, -8.0, -5.7, -7.8, -5.6, -7.1, -6.3, -6.1, -7.4, -7.0, -6.0, -5.0, -4.7, -7.2, -7.1, -8.1, -7.6, -7.0, -7.1, -7.2, -6.4, -6.9, -7.1, -7.6, -6.0, -6.2, -7.8, -6.8, -6.2, -5.7, -6.2, -7.3, -6.6, -6.9, -6.0, -6.9, -7.5, -8.0, -7.3, -7.9, -7.6, -6.2, -8.6, -6.8, -6.1, -3.7, -6.4, -6.0, 0.0, -7.9, -6.3, -6.4, -6.6, -7.0, -6.4, -6.1, -7.0, -6.7, -7.7, -6.6, -6.3, -8.1, -6.5, -7.8, -4.7, -6.1, -5.9, -7.0, -7.5, -8.9, -6.9, -7.6, -7.7, -6.5, -6.9, -7.5, -8.1, -7.5, -7.4, -8.2, -4.9, -7.4, -7.6, -8.0, -5.2, -8.8, -7.3, -4.0, -7.8, -6.2, -7.9, -7.0, -7.0, -7.3, -7.5, -7.3, -7.2, -9.2, -7.4, -6.2, -4.8, -7.1, -7.7, -7.8, -5.8, -7.3, -6.6, -4.7, -7.8, -8.5, -5.0, -7.9, -6.1, -7.8, -5.7, -7.3, -7.4, -6.0, -6.3, -7.4, -7.4, -6.4, -4.3, -7.7, -8.0, -8.3, -8.7, -7.8, -7.3, -8.3, -8.1, -6.3, -7.3, -6.8, -7.3, -7.6, -7.6, -7.1, -7.4, -8.0, -8.2, -8.1, -6.7, -7.2, -2.3, -3.7, -6.8, -7.1, -3.7, -5.9, -8.7, -7.9, -6.9, -3.8, -6.1, -6.6, -3.2, -6.4, -7.2, -6.9, -7.4, -7.4, -4.6, -5.7, 1.0, -6.9, -7.8, -7.8, -6.7, -7.8, -5.8, -8.2, -7.7, -7.9, -5.9, -6.5, -4.8, -5.0, -5.8, -6.3, -7.1, -5.8, -2.8, -2.5, 7.2, -4.8, -6.9, -6.4, -6.6, -7.1, -3.8, -6.7, -7.2, -4.2, -6.7, -6.8, -7.2, -8.1, -6.7, -7.4, -4.1, -6.7, -6.6, -6.6, -7.5, -8.4, -8.4, -6.2, -6.4, -6.8, -5.0, -7.2, -5.9, -3.5, -6.3, -4.7, -6.9, -6.4, -7.3, -8.4, -7.3, -9.0, -5.3, -7.6, -8.7, -6.9, -6.8, -7.5, -6.3, -5.9, -5.4, -9.2, -3.9, -6.7, -6.7, -7.8, -7.5, -6.3, -7.4, -6.1, -8.7, -7.6, -7.6, -6.4, -7.3, -6.1, -5.6, -7.3, -6.2, -6.6, -7.5, -7.1, -6.6, -6.2, -6.3, -7.5, -5.8, -6.0, -6.7, -6.1, -6.2, -7.1, -7.8, -6.4, -7.6, -8.3, -6.7, -7.2, -7.5, -7.3, -7.7, -7.3, -6.8, -4.3, -7.6, -7.2, -5.4, -5.8, -7.1, -7.1, -8.7, -8.2, -8.4, -7.1, -7.3, -6.9, -5.9, -7.4, -8.0, -6.6, -7.9, -7.1, -6.2, -6.9, -7.9, -7.4, -7.4, -7.1, -7.0, -6.9, -7.1, -6.9, -7.9, 0.0, -7.6, -5.8, -7.4, -7.3, -6.7, -7.9, -7.7, -7.6, -6.7, -6.1, -8.0, -7.5, -7.1, 0.2, -6.2, -7.6, -8.0, -6.6, -6.9, -6.1, -8.3, -7.0, -8.1, -8.5, -7.9, -8.7, -9.4, -7.6, -8.6, -9.4, -7.0, -6.4, -6.9, -8.5, -8.8, -3.1, -7.3, -7.1, -3.2, -5.9, -7.5, -7.7, -8.3, -5.4, -8.0, -7.1, -2.3, -7.7, -6.9, -8.4, -6.0, 2.8, -8.2, -2.0, -0.9, -4.1, 0.4, -7.5, -7.9, -6.1, -6.1, -6.3, -4.8, -8.6, -6.9, -8.0, -8.2, -8.0, -7.2, -6.7, -6.8, -8.5, -5.7, -6.9, -6.3, -7.3, -6.4, -6.7, -7.3, -6.6, -6.3, -7.2, -1.4, -6.6, -8.3, -7.8, -4.6, -4.1, -7.0, -6.0, -7.5, -6.4, -7.2, -7.4, -7.3, -4.8, -6.3, -6.5, -6.0, -7.1, -6.9, -7.2, -7.2, -5.6, -4.0, -5.4, -3.2, -4.7, -7.0, -3.8, 2.1, 2.5, -8.7, -7.0, -4.7, -7.1, -6.3, -8.0, -5.4, -2.7, -4.3, -7.2, -4.4, -7.5, -4.1, -7.4, -7.7, -8.1, -7.7, -7.3, -6.7, -8.5, -7.2, -7.7, -3.3, -4.7, -7.6, -6.3, -7.9, -7.5, -3.9, -9.0, -7.7, -4.0, 3.4, -1.0, -5.8, -3.9, -7.4, -9.6, -8.6, -6.3, -7.3, -8.5, -6.1, -7.2, -4.6, -7.0, -7.6, -7.4, -7.5, -6.8, -7.8, -5.1, -5.6, -3.6, -9.4, -7.8, -7.8, -8.1, -5.0, -6.2, -7.5, -4.2, -7.4, -3.2, -1.9, -6.2, -7.1, -7.3, -7.8, -8.1, -6.9, -6.0, -7.0, -7.3, -7.4, -6.4, -6.4, -6.6, -6.6, -7.4, -6.6, -7.0, -6.8, -8.0, -6.7, -6.4, -7.9, -9.1, -8.0, -7.5, -7.1, -6.7, -6.8, -6.2, -7.8, -7.6, -8.2, -7.0, -8.0, -7.4, -8.3, -6.8, -8.0, -8.8, -5.6, -8.4, -7.0, -7.8, -5.9, -8.5, -7.1, -7.4, -4.9, -7.1, -6.9, -5.3, -7.6, -7.8, -8.0, -6.5, -6.6, -6.6, -9.9, -7.3, -5.9, -8.2, -8.8, -7.5, -8.0, -7.6, -7.2, -6.8, -7.4, -7.4, -7.5, -7.8, -6.5, -7.0, -7.1, -7.2, -7.8, -8.5, -6.8, -8.0, -3.5, -7.1, -7.8, -6.0, -5.5, -8.2, -5.4, -7.5, -6.2, -6.9, -7.6, -7.3, -7.0, -7.7, -6.1, -7.1, -7.1, -7.6, -7.1, -6.7, -6.1, -4.7, -7.4, -7.6, -7.6, -4.8, -8.4, -3.5, -7.9, -7.9, -6.4, -6.1, -7.1, -8.5, -7.2, -7.1, -5.8, -6.4, -8.3, -6.8, -6.4, -7.7, -7.0, 0.0, -6.7, -7.5, -8.0, -7.0, -6.7, -7.7, -8.9, -7.8, -3.7, -8.2, -6.7, -7.8, -5.2, -7.6, -8.2, -7.7, -7.9, -6.7, -7.8, -7.7, -5.6, -6.9, -5.0, -8.2, -6.6, -7.7, -5.6, -7.1, -7.8, -3.1, -7.7, -6.4, -6.2, -6.9, -7.4, -6.4, -7.3, -5.2, -7.7, -8.0, -7.8, -6.2, -8.2, -6.5, -8.0, -9.1, -8.1, -6.3, -8.2, -7.9, -7.7, -7.2, -7.2, -5.0, -7.9, -8.9, -8.5, -8.6, -3.8, -7.5, -3.8, -7.7, -6.7, -7.7, -7.2, -7.9, -7.3, -7.4, -6.8, -6.9, -5.7, -6.6, -7.1, -7.3, -7.7, -7.2, -8.6, -8.4, -5.0, -7.7, -5.6, -6.0, -5.8, -5.6, -6.2]
2025-04-17 17:55:28,723 - INFO - Loaded 11295 affinity values.
2025-04-17 17:55:28,839 - INFO - Prepared features for 8192 pairs.
2025-04-17 17:55:28,839 - INFO - Running LLM inference in 512 batches...
2025-04-17 17:55:28,839 - INFO - Processing batch 1/512...
2025-04-17 17:56:15,789 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (378.451 and 349.435 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (85.32) is significantly better than Ligand A (133.91). For a GPCR, lower TPSA is generally preferred for better permeability.
3. **logP:** Ligand A (-2.206) is lower than Ligand B (-0.489), and both are slightly below the optimal 1-3 range. Ligand B is closer to the ideal range, suggesting better membrane permeability.
4. **HBD:** Ligand A (3) is higher than Ligand B (1). Lower HBD is generally preferred for permeability, giving a slight edge to Ligand B.
5. **HBA:** Ligand A (7) is higher than Ligand B (5). Similar to HBD, lower HBA is preferable, favoring Ligand B.
6. **QED:** Ligand B (0.726) has a substantially better QED score than Ligand A (0.387), indicating a more drug-like profile.
7. **DILI:** Ligand B (21.171) has a much lower DILI risk than Ligand A (41.838). This is a significant advantage for Ligand B.
8. **BBB:** Both ligands have relatively low BBB penetration (Ligand A: 35.401, Ligand B: 39.085). Since ADRB2 is a cardiovascular target, BBB penetration is not a primary concern, so this isn't a major differentiating factor.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.507 and -5.316), which is unusual and suggests very poor permeability in this assay. This is a significant concern for both.
10. **Solubility:** Both ligands have very poor aqueous solubility (-1.347 and -1.203). This is a major drawback for both compounds.
11. **hERG:** Ligand A (0.032) has a slightly lower hERG risk than Ligand B (0.196), but both are very low, so the difference is minimal.
12. **Cl_mic:** Ligand B (-20.308) has a much lower (better) microsomal clearance than Ligand A (44.321), indicating greater metabolic stability.
13. **t1/2:** Ligand B (6.768) has a significantly longer in vitro half-life than Ligand A (-51.506). This is a major advantage for Ligand B.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.004 and 0.003).
15. **Binding Affinity:** Ligand A (-7.4) has a substantially stronger binding affinity than Ligand B (-2.6). This is a very significant advantage for Ligand A. A difference of 4.8 kcal/mol is substantial.
**Overall Assessment:**
Ligand A has a much better binding affinity, which is crucial for a drug candidate. However, Ligand B has significantly better ADME properties (QED, DILI, Cl_mic, t1/2, TPSA, HBD, HBA) and is closer to the ideal logP range. The poor Caco-2 and solubility for both are concerning, but the affinity difference is so large that it outweighs the ADME concerns. While optimizing ADME properties is important, a potent ligand provides a better starting point for optimization.
Output:
1
2025-04-17 17:56:15,789 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (365.39 Da) is within the ideal range, while Ligand B (342.443 Da) is also good. No clear advantage here.
2. **TPSA:** Ligand A (130.87) is slightly above the preferred <140 for oral absorption, but still acceptable. Ligand B (97.78) is excellent, well below 140. This favors Ligand B.
3. **logP:** Ligand A (0.56) is a bit low, potentially hindering permeability. Ligand B (2.566) is within the optimal range (1-3). This strongly favors Ligand B.
4. **HBD:** Ligand A (2) and Ligand B (3) are both acceptable.
5. **HBA:** Ligand A (7) and Ligand B (3) are both acceptable.
6. **QED:** Ligand A (0.769) is better than Ligand B (0.45), indicating a more drug-like profile. This favors Ligand A.
7. **DILI:** Ligand A (79.643) has a higher DILI risk than Ligand B (42.303). This favors Ligand B.
8. **BBB:** Ligand A (42.109) is lower than Ligand B (54.13). While ADRB2 isn't exclusively a CNS target, some CNS penetration can be beneficial, and lower Pgp efflux (see below) could make this more relevant. This favors Ligand B.
9. **Caco-2:** Ligand A (-5.27) is very poor, indicating very low intestinal absorption. Ligand B (-4.875) is also poor, but slightly better. This favors Ligand B.
10. **Solubility:** Ligand A (-2.775) is poor, while Ligand B (-4.721) is also poor. No clear advantage.
11. **hERG:** Ligand A (0.263) has a lower hERG risk than Ligand B (0.547). This favors Ligand A.
12. **Cl_mic:** Ligand A (-12.18) has a much lower (better) microsomal clearance than Ligand B (47.555), indicating better metabolic stability. This strongly favors Ligand A.
13. **t1/2:** Ligand A (22.626) has a longer half-life than Ligand B (-15.364). This favors Ligand A.
14. **Pgp:** Ligand A (0.061) has much lower P-gp efflux than Ligand B (0.364), which is a significant advantage for bioavailability and potential CNS exposure. This strongly favors Ligand A.
15. **Affinity:** Ligand A (-8.0) has a better binding affinity than Ligand B (-6.6). This is a substantial difference and outweighs many of the ADME concerns. This strongly favors Ligand A.
**Overall Assessment:**
Ligand A has a significantly better binding affinity and metabolic stability (lower Cl_mic, longer t1/2) and lower Pgp efflux. While Ligand B has better TPSA, logP, and DILI, the substantial advantage in affinity and metabolic properties of Ligand A, combined with its lower Pgp efflux, outweigh the drawbacks. The lower logP and solubility of Ligand A can potentially be addressed through formulation strategies. The GPCR-specific priorities (logP, Pgp, TPSA, affinity) are well-addressed by Ligand A, particularly the affinity.
**Output:**
1
2025-04-17 17:56:15,789 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (344.46 and 347.46 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (66.4) is significantly better than Ligand B (79.26). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand A is well below the 140 threshold, while B is approaching it.
3. **logP:** Ligand A (2.14) is optimal, while Ligand B (0.463) is a bit low. A logP between 1-3 is preferred, and B is bordering on potentially having permeability issues.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer HBDs generally improve membrane permeability.
5. **HBA:** Ligand A (4) is better than Ligand B (5). Similar to HBD, lower HBA is generally better for permeability.
6. **QED:** Ligand A (0.842) is significantly better than Ligand B (0.603), indicating a more drug-like profile.
7. **DILI:** Ligand A (46.3) is significantly better than Ligand B (19.3). Lower DILI risk is crucial. Ligand B is quite low, but A is even lower and more desirable.
8. **BBB:** Ligand A (73.8) is much better than Ligand B (33.7). While ADRB2 isn't necessarily a CNS target, higher BBB penetration is generally favorable, minimizing off-target effects.
9. **Caco-2:** Ligand A (-4.697) is better than Ligand B (-5.194). Both are negative, which is unusual and suggests poor permeability. However, A is slightly less negative.
10. **Solubility:** Ligand A (-2.06) is better than Ligand B (-1.461). Both are quite poor, but A is slightly better.
11. **hERG:** Ligand A (0.451) is better than Ligand B (0.204). Lower hERG inhibition is critical for avoiding cardiotoxicity, a major concern with cardiovascular targets.
12. **Cl_mic:** Ligand A (46.793) is much better than Ligand B (6.847). Lower clearance indicates better metabolic stability, a significant advantage.
13. **t1/2:** Ligand A (0.401) is much better than Ligand B (13.629). A longer half-life is generally preferred.
14. **Pgp:** Ligand A (0.181) is much better than Ligand B (0.015). Lower P-gp efflux is desirable for improved bioavailability.
15. **Binding Affinity:** Ligand A (-6.5) is slightly better than Ligand B (-6.1). While both are good, the slight advantage of A contributes to its overall preference.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across nearly all ADME-Tox properties, and has a slightly better binding affinity. The most significant differences are in DILI risk, metabolic stability (Cl_mic and t1/2), BBB penetration, and P-gp efflux. While both ligands have solubility issues, Ligand A is slightly better. Given the GPCR target class, the balance of properties in Ligand A makes it a much more promising drug candidate.
Output:
1
2025-04-17 17:56:15,790 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (365.543 and 344.39 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (62.3) is better than Ligand B (82.16). ADRB2 is a cardiovascular target, not CNS, but lower TPSA is generally favorable for absorption.
3. **logP:** Both ligands have excellent logP values (3.385 and 3.29) within the optimal 1-3 range.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 5. Both are acceptable, but A is slightly preferred.
6. **QED:** Both ligands have good QED scores (0.768 and 0.833), indicating good drug-like properties.
7. **DILI:** Ligand A (41.179) has a lower DILI risk than Ligand B (60.372). This is a significant advantage for Ligand A.
8. **BBB:** Not a primary concern for a cardiovascular target like ADRB2, but Ligand B (70.88) is slightly better than Ligand A (62.854).
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and requires further investigation. However, the values are similar (-4.967 vs -4.725).
10. **Solubility:** Ligand A (-3.24) is better than Ligand B (-4.391), indicating better aqueous solubility.
11. **hERG:** Ligand A (0.345) has a lower hERG risk than Ligand B (0.557). This is a crucial safety parameter.
12. **Cl_mic:** Ligand B (72.489) has slightly lower microsomal clearance than Ligand A (70.354), suggesting better metabolic stability.
13. **t1/2:** Ligand B (49.793) has a significantly longer in vitro half-life than Ligand A (9.339). This is a major advantage for Ligand B.
14. **Pgp:** Ligand A (0.262) has lower P-gp efflux liability than Ligand B (0.199), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand A (-6.8 kcal/mol) has a slightly better binding affinity than Ligand B (-6.4 kcal/mol). While the difference is not huge, it's a positive for Ligand A.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Both ligands perform well on logP. Ligand A is better on TPSA and Pgp. Ligand B has a better half-life. The affinity difference is small, but favors A. The DILI and hERG risk are significantly better for Ligand A.
**Overall Assessment:**
Ligand A presents a more favorable safety profile (lower DILI and hERG) and slightly better binding affinity and permeability characteristics. While Ligand B has a longer half-life, the safety concerns associated with it are more significant. Given the cardiovascular context, minimizing off-target effects and toxicity is paramount.
Output:
1
2025-04-17 17:56:15,790 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, the priorities are logP, Pgp, TPSA, affinity, and, to a lesser extent, BBB.
Let's break down the comparison:
1. **MW:** Both ligands are within the ideal range (200-500 Da).
2. **TPSA:** Ligand A (58.64) is slightly higher than Ligand B (49.41), but both are well below the 140 threshold for oral absorption.
3. **logP:** Both ligands have good logP values (2.981 and 3.672, respectively), falling within the optimal 1-3 range. Ligand B is slightly higher, which could be a minor concern for solubility, but not a dealbreaker.
4. **HBD/HBA:** Both have acceptable HBD (1) and HBA (3/4) counts.
5. **QED:** Both have good QED scores (0.694 and 0.787), indicating good drug-like properties.
6. **DILI:** Ligand A (6.592) has a significantly lower DILI risk than Ligand B (51.609). This is a substantial advantage.
7. **BBB:** Both have high BBB penetration (81 and 82.784), which isn't critical for a cardiovascular target, but doesn't hurt.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual. This suggests poor permeability.
9. **Solubility:** Both have negative solubility values, which is also unusual. This suggests poor solubility.
10. **hERG:** Both have low hERG inhibition liability (0.694).
11. **Cl_mic:** Ligand B has a lower microsomal clearance (44.765) than Ligand A (70.763), indicating better metabolic stability.
12. **t1/2:** Ligand B has a longer in vitro half-life (10.916) than Ligand A (6.013).
13. **Pgp:** Both have low Pgp efflux liability (0.058 and 0.427).
14. **Affinity:** Ligand B (-6.6 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.2 kcal/mol). This is a 1.4 kcal/mol difference, which is substantial and can outweigh some ADME concerns.
**Overall Assessment:**
The key trade-off is between Ligand A's significantly better DILI profile and Ligand B's superior binding affinity and metabolic stability. Given the cardiovascular target, minimizing potential liver toxicity is paramount. While Ligand B's affinity is attractive, the higher DILI risk is a major concern. The negative Caco-2 and solubility values are concerning for both, but can be addressed with formulation strategies.
Therefore, I favor Ligand A due to its significantly lower DILI risk.
**Output:**
1
2025-04-17 17:56:15,790 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (393.531 Da) is slightly higher than Ligand B (340.467 Da), but both are acceptable.
2. **TPSA:** Ligand A (117.85) is higher than the preferred <140, but still reasonable. Ligand B (58.2) is excellent, well below 140 and suggesting good absorption.
3. **logP:** Ligand A (-0.584) is a bit low, potentially hindering permeability. Ligand B (3.108) is optimal. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (1) and Ligand B (2) are both within the acceptable limit of <=5.
5. **HBA:** Ligand A (5) and Ligand B (2) are both within the acceptable limit of <=10.
6. **QED:** Both ligands have good QED scores (A: 0.621, B: 0.715), indicating drug-likeness. Ligand B is slightly better.
7. **DILI:** Both have low DILI risk (A: 31.718, B: 25.204), which is positive. Ligand B is marginally better.
8. **BBB:** Ligand A (58.511) is lower than Ligand B (64.831). While ADRB2 isn't exclusively a CNS target, some CNS penetration can be beneficial or at least not detrimental.
9. **Caco-2:** Ligand A (-5.501) is very poor, suggesting poor intestinal absorption. Ligand B (-4.572) is also poor, but better than Ligand A.
10. **Solubility:** Ligand A (-1.894) is poor, while Ligand B (-3.453) is even worse. This is a concern for both, but more so for B.
11. **hERG:** Ligand A (0.125) has a very low hERG risk, which is excellent. Ligand B (0.363) is slightly higher, but still relatively low.
12. **Cl_mic:** Ligand A (-1.033) has a negative value, indicating very low clearance and excellent metabolic stability. Ligand B (53.489) is high clearance, suggesting poor metabolic stability. This is a major advantage for Ligand A.
13. **t1/2:** Ligand A (-17.072) is very long, while Ligand B (-3.957) is short. This reinforces the metabolic stability advantage of Ligand A.
14. **Pgp:** Ligand A (0.02) has very low P-gp efflux, which is favorable. Ligand B (0.095) is slightly higher, but still acceptable.
15. **Binding Affinity:** Ligand B (-6.5) is slightly better than Ligand A (-5.6), a difference of 0.9 kcal/mol.
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP and has slightly better affinity. However, Ligand A is superior in TPSA, Pgp, and *significantly* better in metabolic stability (Cl_mic and t1/2). The poor Caco-2 and solubility of both are concerning, but the metabolic stability advantage of Ligand A is crucial for a viable drug candidate. A longer half-life and lower clearance can often be optimized through formulation strategies.
**Conclusion:**
Despite the slightly better affinity of Ligand B, the significantly improved metabolic stability and P-gp properties of Ligand A make it the more promising drug candidate.
Output:
1
2025-04-17 17:56:15,790 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (351.403) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (89.13) is significantly better than Ligand B (51.47), falling well below the 140 threshold and closer to the 90 threshold desirable for GPCRs.
3. **logP:** Ligand A (-0.12) is quite low, potentially hindering membrane permeability. Ligand B (4.435) is high, potentially causing solubility and off-target issues. This is a significant drawback for Ligand B.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable.
5. **HBA:** Ligand A (6) and Ligand B (3) are both acceptable.
6. **QED:** Both ligands have good QED scores (A: 0.645, B: 0.813), indicating good drug-like properties. Ligand B is slightly better here.
7. **DILI:** Ligand A (31.524) has a much lower DILI risk than Ligand B (68.825). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (77.084) has a better BBB penetration score than Ligand A (60.799), but BBB isn't a critical factor for ADRB2, a cardiovascular target.
9. **Caco-2:** Ligand A (-5.038) and Ligand B (-4.565) are both poor, but similar.
10. **Solubility:** Ligand A (-1.508) is better than Ligand B (-5.113).
11. **hERG:** Ligand A (0.211) has a lower hERG risk than Ligand B (0.767).
12. **Cl_mic:** Ligand A (-0.5) has a much lower (better) microsomal clearance than Ligand B (35.943). This suggests better metabolic stability.
13. **t1/2:** Ligand B (38.439) has a significantly longer in vitro half-life than Ligand A (-27.081). This is a positive for Ligand B.
14. **Pgp:** Ligand A (0.005) has a much lower Pgp efflux liability than Ligand B (0.266).
15. **Binding Affinity:** Both ligands have similar binding affinities (-5 kcal/mol and -4 kcal/mol respectively).
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has a poor logP, but excels in TPSA and Pgp. Ligand B has a high logP, which is a significant concern. The affinity is similar for both.
**Overall Assessment:**
While Ligand B has a better half-life and QED, the combination of Ligand A's superior TPSA, lower DILI risk, lower hERG risk, lower Cl_mic, and lower Pgp efflux liability outweigh the slightly lower BBB and half-life. The high logP of Ligand B is a major concern. The poor Caco-2 values for both are concerning, but can be addressed with formulation strategies.
Output:
1
2025-04-17 17:56:15,790 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.471 and 369.872 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (49.85) is better than Ligand B (56.07). Both are below 140, but A is closer to the preferred <90 for potential CNS penetration (though not a primary concern for ADRB2).
3. **logP:** Both ligands have good logP values (2.054 and 3.259), falling within the 1-3 range. Ligand B is slightly higher, which *could* indicate a slightly higher risk of off-target effects, but isn't a major concern.
4. **HBD:** Both have 0 HBD, which is acceptable.
5. **HBA:** Ligand A (3) is better than Ligand B (6). Lower HBA generally improves permeability.
6. **QED:** Both are reasonably good (0.716 and 0.668), indicating drug-like properties.
7. **DILI:** Ligand A (12.214) is significantly better than Ligand B (39.899). This is a crucial advantage, as lower DILI risk is highly desirable.
8. **BBB:** Both have good BBB penetration (76.154 and 77.898). Not a primary concern for ADRB2, but a positive.
9. **Caco-2:** Both have negative Caco-2 values (-4.415 and -4.576). This is unusual and suggests poor permeability. However, these values are on a scale where negative values aren't directly interpretable without knowing the scale's origin. We have to assume they indicate low permeability.
10. **Solubility:** Ligand A (-2.138) is better than Ligand B (-3.3). Better solubility is always preferred.
11. **hERG:** Both have very low hERG inhibition risk (0.371 and 0.65). Excellent.
12. **Cl_mic:** Ligand A (37.244) is significantly better than Ligand B (74.67). Lower clearance means greater metabolic stability, a key advantage.
13. **t1/2:** Ligand A (-10.087) is better than Ligand B (55.188). A negative value is unusual, but assuming this is on a log scale, it suggests a longer half-life.
14. **Pgp:** Ligand A (0.117) is significantly better than Ligand B (0.309). Lower P-gp efflux is beneficial for bioavailability.
15. **Binding Affinity:** Ligand A (-6.9) is slightly better than Ligand B (-6.2). While both are good, the 0.7 kcal/mol difference is noticeable and can outweigh minor ADME drawbacks.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Both ligands perform reasonably well on logP and BBB. Ligand A is better on TPSA, Pgp, and affinity. The significant advantages of Ligand A in DILI risk and metabolic stability (Cl_mic) are also very important.
**Conclusion:**
Ligand A consistently outperforms Ligand B across several critical ADME properties (DILI, Cl_mic, Pgp, solubility) and has a slightly better binding affinity. While the Caco-2 values are concerning for both, the overall profile of Ligand A makes it the more promising drug candidate.
Output:
1
2025-04-17 17:56:15,791 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.503 and 349.391 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (60.85) is significantly better than Ligand B (115.3). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold, while Ligand B is approaching it.
3. **logP:** Ligand A (2.711) is within the optimal 1-3 range. Ligand B (0.817) is slightly below 1, which could potentially hinder permeation. This favors Ligand A.
4. **HBD:** Both ligands have acceptable HBD counts (1 and 2, respectively), well below the limit of 5.
5. **HBA:** Ligand A (3) is preferable to Ligand B (8). Lower HBA is generally better for permeability.
6. **QED:** Ligand A (0.801) has a better QED score than Ligand B (0.644), indicating a more drug-like profile.
7. **DILI:** Ligand A (11.477) has a much lower DILI risk than Ligand B (61.07). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (77.2) has a higher BBB percentile than Ligand B (52.423). While not a primary concern for a cardiovascular target, it's still a positive attribute.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.636 and -4.951), which is unusual and suggests poor permeability. However, the values are very close.
10. **Solubility:** Both ligands have negative solubility values (-2.17 and -2.181), which is also unusual and suggests poor solubility. Again, the values are very close.
11. **hERG:** Both ligands have low hERG inhibition liability (0.508 and 0.152), which is good.
12. **Cl_mic:** Ligand A (42.671) has a higher microsomal clearance than Ligand B (26.108), meaning it's metabolized faster. This favors Ligand B.
13. **t1/2:** Ligand B (19.901) has a significantly longer in vitro half-life than Ligand A (-3.14). This is a substantial advantage for Ligand B.
14. **Pgp:** Ligand A (0.379) has lower P-gp efflux liability than Ligand B (0.07). Lower Pgp is generally preferable.
15. **Binding Affinity:** Ligand A (-6.5 kcal/mol) has a slightly better binding affinity than Ligand B (-6.3 kcal/mol), but the difference is small.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A excels in logP, TPSA, and Pgp, while the affinity difference is minor. Ligand B has a better half-life, but the other ADME properties of Ligand A are more favorable. The lower DILI risk for Ligand A is also a significant factor.
**Overall Assessment:**
Despite Ligand B's better half-life and lower clearance, Ligand A's superior TPSA, logP, QED, lower DILI risk, and slightly better affinity make it the more promising candidate. The negative Caco-2 and solubility values are concerning for both, but the other advantages of Ligand A outweigh this drawback.
Output:
1
2025-04-17 17:56:15,791 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (363.395 Da and 369.506 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (64.41) is significantly better than Ligand A (101.73). ADRB2 is a GPCR, and lower TPSA generally favors better permeability and receptor engagement.
3. **logP:** Ligand B (2.611) is within the optimal 1-3 range, while Ligand A (0.664) is slightly low, potentially hindering membrane permeability. This favors Ligand B.
4. **HBD:** Ligand A (1) is preferable to Ligand B (0). While both are acceptable, a single HBD can contribute to solubility without significantly impacting permeability.
5. **HBA:** Ligand B (4) is better than Ligand A (8). Fewer HBA generally improves permeability.
6. **QED:** Ligand B (0.722) is better than Ligand A (0.476), indicating a more drug-like profile.
7. **DILI:** Ligand B (23.73) is *much* better than Ligand A (69.058). This is a significant advantage for Ligand B, as lower DILI risk is crucial.
8. **BBB:** Ligand B (92.672) is substantially better than Ligand A (36.526). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be beneficial for distribution and off-target effects assessment.
9. **Caco-2:** Both are negative, indicating poor permeability. However, the scale is not provided, so it is difficult to compare.
10. **Solubility:** Ligand B (-3.789) is better than Ligand A (-2.107).
11. **hERG:** Ligand A (0.067) is slightly better than Ligand B (0.659), indicating a lower risk of cardiotoxicity. This is a positive for Ligand A, given ADRB2's cardiovascular involvement.
12. **Cl_mic:** Both are similar (53.664 and 52.713 mL/min/kg), suggesting comparable metabolic stability.
13. **t1/2:** Ligand B (-16.561) is better than Ligand A (-10.786), indicating a longer half-life.
14. **Pgp:** Ligand A (0.111) is better than Ligand B (0.091), indicating lower P-gp efflux.
15. **Affinity:** Ligand A (-6.8 kcal/mol) is slightly better than Ligand B (-6.4 kcal/mol). While a difference of 0.4 kcal/mol isn't huge, it is noticeable.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, and Pgp efflux are important. Ligand B excels in logP and TPSA. While Ligand A has a slightly better affinity and Pgp, the significant advantages of Ligand B in DILI, BBB, solubility, QED, and half-life outweigh these minor differences. The lower DILI risk is particularly important for a cardiovascular target.
**Conclusion:**
Ligand B presents a more balanced and favorable profile overall, particularly regarding safety (DILI) and pharmacokinetic properties (BBB, solubility, half-life). While Ligand A has a slightly better binding affinity, the other advantages of Ligand B make it the more promising drug candidate.
Output:
0
2025-04-17 17:56:15,791 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (366.443) is slightly higher than Ligand B (354.407), but both are acceptable.
2. **TPSA:** Ligand A (91.84) is better than Ligand B (132.7). For a GPCR, keeping TPSA under 140 is good, and lower is generally preferred for better permeability. Ligand B is pushing the upper limit.
3. **logP:** Ligand B (-0.008) is slightly better than Ligand A (0.351). Both are relatively low, but Ligand B is closer to the optimal 1-3 range. Low logP can sometimes hinder permeability, but isn't a dealbreaker.
4. **HBD:** Ligand A (1) is preferable to Ligand B (5). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (6) is preferable to Ligand B (5). Similar to HBD, lower HBA is generally better.
6. **QED:** Ligand A (0.784) is significantly better than Ligand B (0.403). A higher QED suggests a more drug-like profile.
7. **DILI:** Ligand B (29.624) is much better than Ligand A (61.07). Lower DILI risk is crucial. Ligand A is bordering on moderate risk.
8. **BBB:** Ligand A (54.75) is better than Ligand B (30.787). While ADRB2 isn't strictly a CNS target, some CNS penetration can be beneficial for off-target effects assessment and potential peripheral effects mediated through CNS pathways.
9. **Caco-2:** Ligand B (-5.602) is better than Ligand A (-4.583). Higher Caco-2 permeability indicates better intestinal absorption.
10. **Solubility:** Ligand B (-1.093) is better than Ligand A (-1.997). Higher solubility is generally desirable.
11. **hERG:** Both ligands have very low hERG risk (0.118 and 0.113, respectively), which is excellent.
12. **Cl_mic:** Ligand B (1.888) is *much* better than Ligand A (38.267). Lower microsomal clearance indicates greater metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand B (26.947) is significantly better than Ligand A (6.491). A longer half-life is generally preferred.
14. **Pgp:** Both ligands have similar, very low Pgp efflux liability (0.023 and 0.013, respectively).
15. **Binding Affinity:** Ligand B (-7.5) is significantly better than Ligand A (-6.5). A 1.0 kcal/mol difference in binding affinity is substantial and can often outweigh minor ADME drawbacks.
**Overall Assessment:**
Ligand B clearly outperforms Ligand A in several critical areas: DILI risk, metabolic stability (Cl_mic), in vitro half-life, and, most importantly, binding affinity. While Ligand A has a slightly better TPSA and BBB, the advantages of Ligand B are more impactful for overall drug development potential. The superior binding affinity of Ligand B is a major driver for my decision.
Output:
0
2025-04-17 17:56:15,791 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [343.402, 71.09, 2.153, 2, 3, 0.589, 43.583, 80.419, -4.863, -3.41, 0.434, 19.975, 1.49, 0.087, -7.0]
**Ligand B:** [346.431, 84.42, 1.5, 1, 5, 0.873, 43.428, 70.531, -4.701, -2.912, 0.19, 43.862, -13.989, 0.075, -6.3]
Here's a breakdown, considering the guidelines and GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal range (200-500 Da). A is 343.4, B is 346.4 - very similar.
2. **TPSA:** A (71.09) is excellent, well below 140 and good for oral absorption. B (84.42) is still acceptable, but less favorable.
3. **logP:** A (2.153) is optimal. B (1.5) is a bit low, potentially impacting permeability.
4. **HBD:** A (2) and B (1) are both good, within the desired limit.
5. **HBA:** A (3) is good. B (5) is acceptable, but approaching the upper limit.
6. **QED:** A (0.589) is good, above the 0.5 threshold. B (0.873) is even better, indicating a more drug-like profile.
7. **DILI:** Both are very similar and acceptable (around 43.5%).
8. **BBB:** A (80.419) is good, suggesting reasonable potential for some CNS penetration (though not a primary concern for a cardiovascular target). B (70.531) is lower, but still not terrible.
9. **Caco-2:** Both are negative, indicating poor permeability. This is a significant concern for both.
10. **Solubility:** Both are negative, indicating poor solubility. This is a significant concern for both.
11. **hERG:** A (0.434) is very good, low risk of cardiotoxicity. B (0.19) is even better.
12. **Cl_mic:** A (19.975) is better than B (43.862), indicating better metabolic stability.
13. **t1/2:** A (1.49) is poor. B (-13.989) is extremely poor.
14. **Pgp:** A (0.087) is very low, suggesting minimal efflux. B (0.075) is also very low.
15. **Affinity:** A (-7.0) is slightly better than B (-6.3), a difference of 0.7 kcal/mol. This is a meaningful difference, though not enormous.
**Overall Assessment:**
Ligand A has a better balance of properties. While both have poor Caco-2 and solubility, A's superior TPSA, logP, metabolic stability (Cl_mic), and slightly better affinity outweigh B's better QED and hERG. The negative half-life for B is a major red flag. For a GPCR, the slightly better logP and lower TPSA of A are more important than the higher QED of B.
Therefore, I prefer Ligand A.
Output:
1
2025-04-17 17:56:15,791 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
We are targeting ADRB2, a GPCR. Therefore, the priorities are logP, Pgp, TPSA, affinity, and, to a lesser extent, BBB.
Let's break down the comparison:
1. **MW:** Both ligands are within the ideal range (346.43 vs 344.38 Da). No significant difference.
2. **TPSA:** Ligand A (75.71) is significantly better than Ligand B (123.12). Lower TPSA generally favors oral absorption and GPCR penetration.
3. **logP:** Ligand A (1.393) is within the optimal range, while Ligand B (-0.196) is slightly below, potentially impacting permeability.
4. **HBD/HBA:** Ligand B has more HBD (2) and HBA (9) than Ligand A (1 and 4 respectively). While not drastically different, this could slightly hinder permeability.
5. **QED:** Both are similar (0.646 vs 0.635), indicating good drug-likeness.
6. **DILI:** Ligand A (35.13) has a much lower DILI risk than Ligand B (78.17). This is a significant advantage.
7. **BBB:** Ligand A (65.374) has a better BBB percentile than Ligand B (20.512). While ADRB2 isn't necessarily a CNS target, some peripheral ADRB2 activity can be modulated by CNS effects, and higher BBB is generally favorable.
8. **Caco-2:** Ligand A (-4.352) is better than Ligand B (-5.558), indicating better intestinal absorption.
9. **Solubility:** Ligand A (-2.954) is better than Ligand B (-2.54), indicating better aqueous solubility.
10. **hERG:** Both are low (0.314 and 0.076), indicating low cardiotoxicity risk.
11. **Cl_mic:** Ligand B (24.034) has significantly lower microsomal clearance than Ligand A (74.944), suggesting better metabolic stability. This is a strong point for Ligand B.
12. **t1/2:** Ligand B (37.154) has a longer in vitro half-life than Ligand A (-12.232). This is a significant advantage for Ligand B.
13. **Pgp:** Ligand A (0.073) has lower P-gp efflux than Ligand B (0.056), which is favorable for bioavailability.
14. **Affinity:** Ligand B (-6.7 kcal/mol) has a slightly better binding affinity than Ligand A (-5.8 kcal/mol). This is a 0.9 kcal/mol difference, which is substantial and can outweigh some ADME concerns.
**Overall Assessment:**
Ligand B has a superior binding affinity and better metabolic stability (lower Cl_mic and longer t1/2). However, Ligand A has a much better TPSA, logP, DILI risk, BBB, Caco-2 permeability, and solubility. The affinity difference is significant, but the combination of favorable ADME properties in Ligand A, particularly the lower TPSA and DILI risk, makes it the more promising candidate. The lower logP of Ligand B is a concern, and the higher TPSA could hinder its ability to reach the receptor efficiently.
Output:
1
2025-04-17 17:56:15,791 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (353.413) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (53.6) is significantly better than Ligand B (70.25). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (A: 2.626, B: 2.338) falling within the 1-3 range.
4. **HBD:** Both have 2 HBD, which is acceptable.
5. **HBA:** Ligand A (4) is better than Ligand B (5), keeping the total H-bonding capacity reasonable.
6. **QED:** Both ligands have acceptable QED scores (A: 0.874, B: 0.723), indicating good drug-like properties. Ligand A is better.
7. **DILI:** Ligand A (54.866) has a higher DILI risk than Ligand B (42.264), which is a negative for Ligand A.
8. **BBB:** Both are moderate, but Ligand A (63.474) is slightly better than Ligand B (53.16). Not a major factor here.
9. **Caco-2:** Ligand A (-4.862) is better than Ligand B (-5.444), indicating better intestinal absorption.
10. **Solubility:** Both have poor solubility (-3.013 and -3.136 respectively). This is a concern for both, but not a deciding factor.
11. **hERG:** Both ligands have low hERG inhibition liability (A: 0.658, B: 0.565), which is good.
12. **Cl_mic:** Ligand A (-14.264) has a *much* lower (better) microsomal clearance than Ligand B (73.657). This suggests significantly better metabolic stability for Ligand A.
13. **t1/2:** Ligand B (26.476) has a longer in vitro half-life than Ligand A (15.43), which is a positive for Ligand B.
14. **Pgp:** Both have low P-gp efflux liability (A: 0.068, B: 0.108), which is good.
15. **Binding Affinity:** Ligand B (-7.3) has a significantly stronger binding affinity than Ligand A (-6.0). This is a substantial advantage.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, affinity is paramount. The 1.3 kcal/mol difference in binding affinity is significant. While Ligand A has better TPSA and Cl_mic, the improved potency of Ligand B is likely to outweigh these benefits. The DILI score for Ligand B is also better.
**Overall Assessment:**
Ligand B's substantially stronger binding affinity is the key deciding factor. While Ligand A has some favorable ADME properties (lower TPSA, better metabolic stability), the potency advantage of Ligand B is crucial for a GPCR target. The slightly better DILI score of Ligand B is also a plus.
Output:
0
2025-04-17 17:56:15,792 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (353.5 & 348.5 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (53.09) is significantly better than Ligand B (67.43). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have acceptable logP values (1.594 and 2.108, respectively), falling within the 1-3 range. Ligand B is slightly higher, which could potentially lead to distribution issues, but it's not a major concern.
4. **HBD/HBA:** Ligand A (0 HBD, 4 HBA) is preferable to Ligand B (2 HBD, 3 HBA). Fewer hydrogen bond donors generally improve membrane permeability.
5. **QED:** Both ligands have similar QED values (0.705 and 0.66), indicating good drug-likeness.
6. **DILI:** Ligand A (5.312%) has a much lower DILI risk than Ligand B (20.861%). This is a significant advantage for Ligand A.
7. **BBB:** Ligand A (70.027%) has a higher BBB penetration than Ligand B (59.674%). While not critical for a cardiovascular target, it's a positive attribute.
8. **Caco-2:** Both ligands have negative Caco-2 values (-4.535 and -4.779), which is unusual and suggests poor permeability. This is a concern for both.
9. **Solubility:** Ligand A (-0.48) has better solubility than Ligand B (-3.066). Solubility is important for bioavailability.
10. **hERG:** Ligand A (0.565) has a lower hERG inhibition liability than Ligand B (0.225). This is a crucial safety parameter, and Ligand A is better.
11. **Cl_mic:** Ligand A (2.601) has significantly lower microsomal clearance than Ligand B (24.379). This indicates better metabolic stability for Ligand A.
12. **t1/2:** Both ligands have similar in vitro half-lives (7.485 and 7.573 hours).
13. **Pgp:** Ligand A (0.075) has lower P-gp efflux liability than Ligand B (0.046). Lower efflux is generally desirable.
14. **Binding Affinity:** Ligand B (-6.5 kcal/mol) has a slightly better binding affinity than Ligand A (-6.3 kcal/mol). This is a small difference, and other factors are more important.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Both ligands are acceptable in terms of logP and affinity (though B is slightly better on affinity). Ligand A is superior in TPSA, Pgp, and significantly better in DILI and hERG. The improved metabolic stability (lower Cl_mic) of Ligand A is also a significant advantage.
**Conclusion:**
While Ligand B has a marginally better binding affinity, Ligand A demonstrates a significantly more favorable overall profile with lower toxicity (DILI, hERG), better metabolic stability, and improved permeability characteristics (TPSA, Pgp, solubility). These factors outweigh the small difference in binding affinity.
Output:
1
2025-04-17 17:56:15,792 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (343.431 Da) is within the ideal range (200-500). Ligand B (408.252 Da) is also acceptable, but closer to the upper limit.
2. **TPSA:** Both Ligand A (80.12) and Ligand B (78.86) are well below the 140 threshold for good oral absorption and are suitable for a peripherally acting GPCR like ADRB2.
3. **logP:** Ligand A (1.548) is optimal. Ligand B (3.757) is slightly higher, potentially leading to some solubility issues, but still within an acceptable range.
4. **HBD:** Ligand A (1) is good. Ligand B (0) is also good.
5. **HBA:** Ligand A (5) is good. Ligand B (7) is acceptable, but higher.
6. **QED:** Ligand A (0.762) is excellent. Ligand B (0.599) is still acceptable, but lower.
7. **DILI:** Ligand A (47.538) has a lower DILI risk, which is preferable. Ligand B (79.449) is significantly higher, raising a concern.
8. **BBB:** Both Ligand A (74.796) and Ligand B (77.898) have good BBB penetration, but this is less critical for ADRB2 as it's not a CNS target.
9. **Caco-2:** Both Ligand A (-4.861) and Ligand B (-4.933) have similar, poor Caco-2 permeability. This is a potential issue for oral bioavailability.
10. **Solubility:** Both Ligand A (-3.184) and Ligand B (-3.885) have poor aqueous solubility.
11. **hERG:** Ligand A (0.102) has a very low hERG risk, which is excellent. Ligand B (0.325) is slightly higher, but still relatively low.
12. **Cl_mic:** Ligand A (41.966) has lower microsomal clearance, indicating better metabolic stability. Ligand B (81.085) has significantly higher clearance.
13. **t1/2:** Ligand B (62.897) has a significantly longer in vitro half-life than Ligand A (-13.388). This is a major advantage.
14. **Pgp:** Ligand A (0.047) has lower P-gp efflux, which is favorable. Ligand B (0.401) has higher efflux.
15. **Affinity:** Ligand A (-8.0) has a stronger binding affinity than Ligand B (-6.3). This is a substantial difference.
**GPCR-specific priorities:** For ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand A excels in affinity and Pgp, while Ligand B has a better half-life. However, the significantly higher DILI risk and higher clearance of Ligand B are major drawbacks. The stronger binding affinity of Ligand A is a significant advantage that outweighs its shorter half-life, especially given the other favorable properties.
**Conclusion:**
Considering the balance of properties, particularly the strong affinity, lower DILI risk, and better metabolic stability of Ligand A, it is the more promising drug candidate.
Output:
1
2025-04-17 17:56:15,792 - INFO - Batch 1 complete. Total preferences: 16
2025-04-17 17:56:15,792 - INFO - Processing batch 2/512...
2025-04-17 17:57:06,317 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (381.414 and 368.821 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (93.62) is significantly better than Ligand A (129.97). For a GPCR, lower TPSA is generally preferred for better permeability.
3. **logP:** Both ligands have good logP values (2.569 and 1.623), falling within the optimal 1-3 range. Ligand B is slightly lower, which could be beneficial for solubility.
4. **HBD:** Ligand B (1) has fewer HBDs than Ligand A (4), which is preferable for permeability.
5. **HBA:** Ligand A (5) and Ligand B (7) are both acceptable, but Ligand B is slightly higher.
6. **QED:** Ligand B (0.761) has a better QED score than Ligand A (0.553), indicating a more drug-like profile.
7. **DILI:** Ligand B (35.789) has a *much* lower DILI risk than Ligand A (99.38). This is a critical advantage.
8. **BBB:** Ligand B (70.182) has a better BBB penetration score than Ligand A (36.371). While ADRB2 isn't exclusively a CNS target, some CNS exposure can occur, and higher BBB penetration is generally favorable.
9. **Caco-2:** Ligand A (-5.476) and Ligand B (-4.59) are both negative, which is unusual and suggests poor permeability. However, the scale is not specified, so it is difficult to interpret.
10. **Solubility:** Ligand A (-3.991) and Ligand B (-2.723) are both negative, suggesting poor solubility.
11. **hERG:** Both ligands have low hERG inhibition liability (0.389 and 0.345), which is good.
12. **Cl_mic:** Ligand B (31.839) has significantly lower microsomal clearance than Ligand A (4.856), indicating better metabolic stability.
13. **t1/2:** Ligand B (52.438) has a longer in vitro half-life than Ligand A (45.899).
14. **Pgp:** Both ligands have low P-gp efflux liability (0.103 and 0.195).
15. **Binding Affinity:** Both ligands have excellent binding affinity (-6.0 and -6.1 kcal/mol). The difference is negligible.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B excels in TPSA, logP, and has a much better safety profile (DILI). While BBB isn't paramount for ADRB2, the higher value for Ligand B is a bonus. The metabolic stability (Cl_mic and t1/2) is also significantly better for Ligand B.
**Conclusion:**
Ligand B clearly outperforms Ligand A across multiple critical parameters, particularly DILI risk and metabolic stability. The slightly better TPSA and QED scores further support its selection. While both have good affinity, the overall ADME-Tox profile of Ligand B makes it a much more promising drug candidate.
Output:
0
2025-04-17 17:57:06,317 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor (a GPCR).
**Ligand A:** [349.431, 102.66 , 0.741, 2. , 5. , 0.713, 19.426, 48.468, -4.928, -1.204, 0.25 , 6.721, 11.697, 0.015, -6.7 ]
**Ligand B:** [360.523, 53.43 , 4.074, 1. , 4. , 0.733, 25.785, 62.117, -4.855, -3.46 , 0.719, 74.854, 42.315, 0.625, -7.1 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (349.431) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (102.66) is higher than Ligand B (53.43). For a GPCR, lower TPSA is preferred, so Ligand B is better here.
3. **logP:** Ligand A (0.741) is a bit low, potentially hindering permeation. Ligand B (4.074) is higher, approaching the upper limit, but still acceptable. Ligand B is better.
4. **HBD:** Ligand A (2) and Ligand B (1) are both good, within the acceptable limit of 5. Ligand B is slightly better.
5. **HBA:** Ligand A (5) and Ligand B (4) are both good, within the acceptable limit of 10. Ligand B is slightly better.
6. **QED:** Both are similar and good (A: 0.713, B: 0.733), indicating good drug-like properties.
7. **DILI:** Ligand A (19.426) has a significantly lower DILI risk than Ligand B (25.785). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (62.117) has a better BBB penetration percentile than Ligand A (48.468). This is important for a GPCR, though not as crucial for ADRB2 as it would be for a CNS-specific receptor.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. This is concerning for both.
10. **Solubility:** Ligand A (-1.204) has better solubility than Ligand B (-3.46). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.25) has a much lower hERG inhibition liability than Ligand B (0.719). This is a significant safety advantage for Ligand A.
12. **Cl_mic:** Ligand A (6.721) has a lower microsomal clearance, indicating better metabolic stability than Ligand B (74.854).
13. **t1/2:** Ligand B (42.315) has a longer in vitro half-life than Ligand A (11.697). This is a positive for Ligand B.
14. **Pgp:** Ligand A (0.015) has much lower P-gp efflux liability than Ligand B (0.625). This is favorable for bioavailability and potential CNS exposure.
15. **Affinity:** Ligand B (-7.1) has a slightly better binding affinity than Ligand A (-6.7). This is a 1.5 kcal/mol advantage, which is significant.
**Overall Assessment:**
Ligand B has a better binding affinity and longer half-life, and lower TPSA. However, Ligand A demonstrates a much better safety profile (lower DILI and hERG), better solubility, and lower P-gp efflux. The Caco-2 values are poor for both, which is a concern. Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity) and the overall balance of properties, the improved safety profile of Ligand A, coupled with its better solubility and P-gp efflux, outweigh the slightly weaker affinity. The DILI and hERG risks associated with Ligand B are concerning.
Output:
1
2025-04-17 17:57:06,317 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (367.373 and 354.447 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (72.47) is better than Ligand B (85.89). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (2.449) is optimal, while Ligand B (0.928) is slightly low. A logP closer to 1-3 is preferred for good permeability and avoiding off-target effects. Ligand A has a clear advantage.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (4) is preferable to Ligand B (5). Similar to HBD, lower HBA is generally better for permeability.
6. **QED:** Ligand A (0.824) is better than Ligand B (0.664), indicating a more drug-like profile.
7. **DILI:** Ligand B (34.742) is significantly better than Ligand A (82.784). This is a major advantage for Ligand B. DILI risk is a critical factor.
8. **BBB:** Ligand B (71.345) is better than Ligand A (57.193), but as ADRB2 is a cardiovascular target, this isn't a primary concern.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand B (-4.988) is slightly worse than Ligand A (-4.65).
10. **Solubility:** Ligand B (-1.515) is better than Ligand A (-4.445). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.317) is better than Ligand B (0.095). Lower hERG inhibition is crucial for avoiding cardiotoxicity, and Ligand A has a significant advantage.
12. **Cl_mic:** Ligand B (24.104) is much better than Ligand A (59.443). Lower clearance means greater metabolic stability, which is highly desirable.
13. **t1/2:** Ligand A (6.896) is better than Ligand B (3.979). Longer half-life is generally preferred.
14. **Pgp:** Ligand B (0.017) is much better than Ligand A (0.466). Lower P-gp efflux improves bioavailability.
15. **Binding Affinity:** Both ligands have the same binding affinity (-6.2 kcal/mol).
**Overall Assessment:**
Ligand B has significant advantages in DILI risk, metabolic stability (Cl_mic), and P-gp efflux. These are critical factors for drug development. While Ligand A has better TPSA, logP, QED, hERG, and half-life, the DILI and metabolic stability issues with Ligand A are substantial concerns. The solubility advantage of Ligand B also helps offset its slightly lower logP. Given the GPCR-specific priorities, and the importance of minimizing toxicity and maximizing bioavailability, Ligand B is the more promising candidate.
Output:
0
2025-04-17 17:57:06,317 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [346.391, 97.36, 0.328, 0, 7, 0.774, 56.146, 54.634, -5.19, -0.876, 0.076, 39.604, -23.601, 0.017, -4.6]
**Ligand B:** [367.559, 69.22, 3.239, 2, 4, 0.703, 31.601, 42.148, -5.065, -3.433, 0.408, 68.554, -0.438, 0.342, -6.6]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). A is 346.391, B is 367.559. No strong preference here.
2. **TPSA:** A (97.36) is slightly higher than B (69.22). For a cardiovascular GPCR, we don't *need* extremely low TPSA for CNS penetration, but lower is generally better for permeability. B is better.
3. **logP:** A (0.328) is quite low, potentially hindering membrane permeability. B (3.239) is much better, falling within the optimal 1-3 range. B is significantly better.
4. **HBD:** A (0) is ideal. B (2) is acceptable, but A is preferable.
5. **HBA:** A (7) is good. B (4) is also good. No strong preference.
6. **QED:** Both are good (A: 0.774, B: 0.703), indicating drug-like properties. A is slightly better.
7. **DILI:** A (56.146) is higher than B (31.601). B is much better, indicating lower liver injury risk.
8. **BBB:** A (54.634) is higher than B (42.148). While not a CNS target, some level of BBB penetration can be useful for distribution. A is better.
9. **Caco-2:** Both are very negative (-5.19 and -5.065), which is unusual and likely indicates an issue with the scale used. We can't draw strong conclusions from this.
10. **Solubility:** A (-0.876) is better than B (-3.433). Solubility is important for bioavailability. A is better.
11. **hERG:** A (0.076) is much lower than B (0.408), indicating a lower risk of cardiotoxicity. A is much better.
12. **Cl_mic:** A (39.604) is lower than B (68.554), suggesting better metabolic stability. A is better.
13. **t1/2:** A (-23.601) is much better than B (-0.438), indicating a longer half-life. A is significantly better.
14. **Pgp:** A (0.017) is much lower than B (0.342), indicating less P-gp efflux. A is much better.
15. **Affinity:** B (-6.6) is 1.0 kcal/mol stronger than A (-4.6). This is a substantial difference and a major advantage for B.
**Overall Assessment:**
While Ligand A has some advantages (solubility, hERG, metabolic stability, half-life, Pgp efflux), Ligand B's significantly stronger binding affinity (-6.6 vs -4.6 kcal/mol) is a critical factor for a GPCR target. The higher logP of B is also a significant benefit for permeability. The lower DILI risk for B is also a positive. The affinity difference is large enough to outweigh the slightly less favorable TPSA and solubility.
Therefore, I favor Ligand B.
Output:
0
2025-04-17 17:57:06,317 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (348.443 and 366.487 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (76.66) is better than Ligand B (80.48). Both are below the 140 A^2 threshold for good oral absorption, but lower TPSA is generally preferred for GPCRs to facilitate brain penetration even if not a CNS target.
**3. logP:** Both ligands (2.158 and 2.309) are within the optimal 1-3 range. No clear advantage.
**4. H-Bond Donors:** Ligand A (2) is slightly better than Ligand B (1). Both are within the acceptable limit of <=5.
**5. H-Bond Acceptors:** Ligand B (7) is higher than Ligand A (4). While both are under 10, the lower number for A is preferable.
**6. QED:** Both ligands have similar QED values (0.635 and 0.698), indicating good drug-likeness.
**7. DILI:** Ligand A (36.06%) has a significantly lower DILI risk than Ligand B (58.511%). This is a major advantage for Ligand A.
**8. BBB:** Ligand A (55.797%) shows better BBB penetration than Ligand B (36.487%). While ADRB2 is primarily cardiovascular, some CNS side effects are possible with GPCR ligands, and better BBB penetration can sometimes correlate with off-target effects.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.653 and -4.912), which is unusual and suggests poor permeability. This is a significant concern for both.
**10. Aqueous Solubility:** Ligand A (-2.984) is slightly better than Ligand B (-1.86), indicating better solubility.
**11. hERG Inhibition:** Ligand A (0.438) has a lower hERG inhibition liability than Ligand B (0.295), which is a positive.
**12. Microsomal Clearance:** Ligand B (46.646) has lower microsomal clearance than Ligand A (55.788), suggesting better metabolic stability.
**13. In vitro Half-Life:** Ligand B (23.527) has a significantly longer in vitro half-life than Ligand A (-31.029). This is a substantial advantage for Ligand B.
**14. P-gp Efflux:** Ligand A (0.087) has lower P-gp efflux than Ligand B (0.299), which is preferable.
**15. Binding Affinity:** Ligand B (-6.1 kcal/mol) has a slightly better binding affinity than Ligand A (-5.7 kcal/mol). This is a 1.5 kcal/mol advantage.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand B has a slight edge in affinity and metabolic stability. However, Ligand A demonstrates a significantly better safety profile with lower DILI risk and hERG inhibition, better BBB penetration, and lower P-gp efflux. The negative Caco-2 values are concerning for both, but the other advantages of Ligand A, particularly the safety profile, outweigh the slightly weaker affinity. The longer half-life of Ligand B is attractive, but the DILI risk is a major concern.
Output:
1
2025-04-17 17:57:06,318 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
Let's systematically compare Ligand A and Ligand B based on the provided parameters and the guidelines, keeping in mind that ADRB2 is a GPCR, so logP, Pgp, TPSA, and affinity are particularly important.
1. **MW:** Both ligands (363.389 Da and 350.503 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (67.01) is significantly better than Ligand B (78.43). Lower TPSA generally favors better cell permeability, crucial for GPCR targeting.
3. **logP:** Ligand A (4.475) is higher than Ligand B (2.517). While both are within the acceptable range (1-3 is optimal), Ligand A is pushing the upper limit. This could potentially lead to solubility issues, but the benefit of higher binding affinity needs to be considered.
4. **HBD/HBA:** Ligand A has 2 HBD and 5 HBA, while Ligand B has 3 HBD and 3 HBA. Both are within acceptable limits.
5. **QED:** Both ligands have similar QED values (0.634 and 0.66), indicating good drug-likeness.
6. **DILI:** Ligand A (88.484) has a considerably higher DILI risk than Ligand B (24.622). This is a significant negative for Ligand A.
7. **BBB:** Ligand A (66.499) has a better BBB penetration percentile than Ligand B (40.558). While ADRB2 isn't necessarily a CNS target, some peripheral ADRB2 activity can be modulated by CNS effects, and better BBB penetration is generally favorable.
8. **Caco-2:** Both ligands have similar, poor Caco-2 permeability (-4.992 and -4.926).
9. **Solubility:** Ligand A (-5.573) has slightly worse solubility than Ligand B (-3.654).
10. **hERG:** Ligand A (0.766) has a slightly higher hERG risk than Ligand B (0.359), but both are relatively low.
11. **Cl_mic:** Ligand A (86.587) has a higher microsomal clearance than Ligand B (26.961), indicating faster metabolism and potentially lower *in vivo* exposure.
12. **t1/2:** Ligand B (13.641) has a significantly longer *in vitro* half-life than Ligand A (-4.878). This is a strong advantage for Ligand B.
13. **Pgp:** Ligand A (0.48) has a lower P-gp efflux liability than Ligand B (0.282), which is favorable for bioavailability.
14. **Binding Affinity:** Ligand B (-6.7 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.4 kcal/mol). This is a substantial advantage, exceeding the 1.5 kcal/mol threshold.
**Overall Assessment:**
Ligand B is the better candidate. The significantly stronger binding affinity (-6.7 vs -5.4 kcal/mol) is a major driver. While Ligand A has better BBB penetration and Pgp efflux, the substantially lower DILI risk, better metabolic stability (lower Cl_mic and longer t1/2), and comparable TPSA and logP of Ligand B outweigh those advantages. The slightly lower solubility of Ligand A is also a concern. The poor Caco-2 permeability is a shared issue that would need to be addressed regardless of which ligand is chosen.
Output:
0
2025-04-17 17:57:06,318 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (336.355 and 352.475 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (84.5) is significantly lower than Ligand A (114.93). This is a major advantage for Ligand B, as lower TPSA generally correlates with better cell permeability, crucial for GPCR targeting.
3. **logP:** Both ligands have acceptable logP values (1.417 and 2.31), falling within the 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Ligand A has 3 HBD, while Ligand B has 2. Both are within the acceptable limit of 5.
5. **HBA:** Ligand A has 6 HBA, and Ligand B has 4. Both are below the 10 threshold.
6. **QED:** Ligand A (0.63) has a slightly higher QED score than Ligand B (0.467), indicating a more drug-like profile. However, the difference isn't substantial enough to be decisive.
7. **DILI:** Ligand B (30.981) has a much lower DILI risk than Ligand A (85.537). This is a significant advantage for Ligand B, as minimizing liver toxicity is paramount.
8. **BBB:** Ligand B (64.831) has a higher BBB penetration percentile than Ligand A (44.358). While ADRB2 isn't exclusively a CNS target, some cardiovascular effects can be mediated through CNS pathways, and better BBB penetration isn't detrimental.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual. Assuming these are percentile scores, the values suggest poor permeability. Ligand A (-5.574) is slightly worse than Ligand B (-4.799).
10. **Solubility:** Both ligands have very poor solubility scores (-3.379 and -3.052). This is a significant concern for both.
11. **hERG:** Both ligands have low hERG inhibition risk (0.436 and 0.444), which is good.
12. **Cl_mic:** Ligand A (7.29) has a lower microsomal clearance than Ligand B (52.014), indicating better metabolic stability. This is a positive for Ligand A.
13. **t1/2:** Ligand B (-7.331) has a longer in vitro half-life than Ligand A (25.065). This is a significant advantage for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.034 and 0.125).
15. **Binding Affinity:** Ligand B (-6.7 kcal/mol) has a slightly better binding affinity than Ligand A (-6.3 kcal/mol). While the difference is small, it's still a positive for Ligand B.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand B emerges as the more promising candidate. Its lower TPSA, significantly lower DILI risk, higher BBB penetration, and better half-life outweigh Ligand A's slightly better QED and lower microsomal clearance. The solubility is a concern for both, but can potentially be addressed through formulation strategies. The small affinity difference favors Ligand B.
Output:
0
2025-04-17 17:57:06,318 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (379.913 Da) is slightly higher than Ligand B (343.45 Da), but both are acceptable.
2. **TPSA:** Both ligands are reasonably low (A: 53.51, B: 55.63), suggesting good potential for cell permeability. They are both well below the 140 A^2 threshold.
3. **logP:** Both ligands have optimal logP values (A: 3.485, B: 3.594), falling within the 1-3 range. This suggests good partitioning properties.
4. **HBD:** Ligand A has 0 HBD, while Ligand B has 1. Both are acceptable, being less than 5.
5. **HBA:** Ligand A has 3 HBA, Ligand B has 5. Both are acceptable, being less than 10.
6. **QED:** Both ligands have good QED scores (A: 0.74, B: 0.67), indicating a generally drug-like profile.
7. **DILI:** Ligand A (44.009) has a slightly higher DILI risk than Ligand B (36.448), but both are below the concerning threshold of 60.
8. **BBB:** Ligand B (90.617) has significantly better predicted BBB penetration than Ligand A (71.966). While ADRB2 isn't strictly a CNS target, some cardiovascular effects are mediated by central pathways, and better BBB penetration could be beneficial or detrimental depending on the desired effect.
9. **Caco-2:** Ligand A (-4.604) and Ligand B (-5.077) both have negative Caco-2 values, which is unusual and suggests very poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand A (-4.389) and Ligand B (-3.62) both have poor predicted aqueous solubility. This is a major drawback for oral bioavailability.
11. **hERG:** Both ligands have low hERG inhibition risk (A: 0.604, B: 0.599).
12. **Cl_mic:** Ligand A (60.279) and Ligand B (56.253) have similar microsomal clearance values. Both are relatively moderate, suggesting reasonable metabolic stability.
13. **t1/2:** Ligand A (19.605) has a longer in vitro half-life than Ligand B (3.887). This is a significant advantage.
14. **Pgp:** Both ligands have low P-gp efflux liability (A: 0.107, B: 0.519).
15. **Binding Affinity:** Ligand B (-6.8 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.2 kcal/mol). This is a >1.5 kcal/mol difference, a substantial advantage.
**GPCR-Specific Priorities & Overall Assessment:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Both ligands perform similarly on logP, TPSA, and Pgp. However, Ligand B has a much stronger binding affinity, which is the most important factor. While Ligand A has a better half-life, the poor Caco-2 and solubility for both compounds are major concerns. The stronger binding of Ligand B is likely to be more impactful in overcoming these issues during optimization.
**Output:**
0
2025-04-17 17:57:06,318 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, the most important parameters are binding affinity, logP, TPSA, Pgp efflux, and to a lesser extent, BBB.
Let's compare the ligands property by property:
1. **MW:** Both ligands (361.417 & 356.275 Da) are within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (37.61) is significantly better than Ligand B (79.29). A TPSA under 140 is good for oral absorption, and lower is better for GPCRs. Ligand B's TPSA is quite high.
3. **logP:** Both ligands have good logP values (3.549 & 2.782), falling within the optimal 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability.
4. **HBD/HBA:** Ligand A (0 HBD, 5 HBA) is preferable to Ligand B (2 HBD, 3 HBA). Fewer hydrogen bond donors generally improve permeability.
5. **QED:** Both ligands have similar and acceptable QED values (0.716 & 0.78).
6. **DILI:** Both ligands have similar and acceptable DILI risk (78.247 & 79.643).
7. **BBB:** Ligand A (89.415) has a much better BBB percentile than Ligand B (58.007). While ADRB2 is cardiovascular, some CNS penetration can be beneficial for understanding off-target effects and potential side effects.
8. **Caco-2:** Ligand A (-4.25) is better than Ligand B (-5.346). Higher Caco-2 values indicate better absorption.
9. **Solubility:** Ligand A (-4.46) is better than Ligand B (-2.874).
10. **hERG:** Ligand A (0.56) is significantly better than Ligand B (0.039). Lower hERG inhibition is crucial for avoiding cardiotoxicity, a major concern with cardiovascular drugs.
11. **Cl_mic:** Ligand B (-8.568) has a much lower (better) microsomal clearance than Ligand A (50.187). This suggests better metabolic stability.
12. **t1/2:** Ligand B (-14.605) has a much longer in vitro half-life than Ligand A (42.411). This is a significant advantage.
13. **Pgp:** Ligand A (0.727) is better than Ligand B (0.021). Lower P-gp efflux is desirable.
14. **Affinity:** Ligand A (-6.6 kcal/mol) has a slightly better binding affinity than Ligand B (-6.0 kcal/mol), although the difference is not huge.
**Overall Assessment:**
Ligand A excels in TPSA, BBB, Caco-2, solubility, hERG inhibition, and Pgp efflux. Ligand B has a substantial advantage in metabolic stability (Cl_mic and t1/2). However, the higher TPSA and lower hERG safety of Ligand B are major drawbacks for a cardiovascular GPCR target. The slightly better affinity of Ligand A, coupled with its superior ADME properties (especially hERG), makes it the more promising candidate.
**Output:**
1
2025-04-17 17:57:06,318 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (361.833 and 352.475 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (78.74 and 76.66) are below the 140 A^2 threshold for good oral absorption, which is good.
3. **logP:** Ligand A (2.429) is slightly higher than Ligand B (1.629), both are within the optimal 1-3 range.
4. **HBD:** Both ligands have 2 HBD, which is acceptable.
5. **HBA:** Both ligands have 4 HBA, which is acceptable.
6. **QED:** Ligand A (0.881) has a significantly better QED score than Ligand B (0.619), indicating better overall drug-likeness.
7. **DILI:** Ligand A (63.086) has a higher DILI risk than Ligand B (16.479). This is a significant negative for Ligand A.
8. **BBB:** Ligand A (75.107) has a better BBB penetration percentile than Ligand B (52.811). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be beneficial or at least needs to be considered.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability.
10. **Solubility:** Both ligands have negative solubility values, indicating poor solubility.
11. **hERG:** Both ligands have low hERG inhibition risk (0.435 and 0.389), which is good.
12. **Cl_mic:** Ligand A (-0.855) has a *much* lower (better) microsomal clearance than Ligand B (59.931). This suggests significantly improved metabolic stability for Ligand A.
13. **t1/2:** Ligand A (8.19 hours) has a much longer in vitro half-life than Ligand B (3.737 hours). This is a major advantage for Ligand A.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.041 and 0.118).
15. **Binding Affinity:** Ligand A (-8.7 kcal/mol) has a slightly better binding affinity than Ligand B (-7.6 kcal/mol), a difference of 1.1 kcal/mol.
**GPCR-specific priorities:** For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. While both ligands are reasonably good on logP and Pgp, Ligand A has a better affinity. The biggest differentiator is the DILI risk. Ligand B has a much lower DILI risk, which is a critical factor for drug development. The improved metabolic stability and half-life of Ligand A are also very attractive, but the high DILI risk is a major concern.
**Conclusion:**
Despite the slightly better affinity and improved PK properties (Cl_mic, t1/2) of Ligand A, the significantly higher DILI risk associated with Ligand A makes Ligand B the more promising candidate. Safety is paramount, and a lower DILI risk is a substantial advantage.
Output:
0
2025-04-17 17:57:06,318 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (380.491 and 350.503 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (95.5) is slightly higher than Ligand B (78.43). Both are below 140, acceptable for oral absorption, but B is better.
3. **logP:** Both ligands have good logP values (1.727 and 2.375, respectively), falling within the optimal 1-3 range. Ligand B is slightly more favorable.
4. **HBD:** Both ligands have 3 H-bond donors, which is within the acceptable limit of <=5.
5. **HBA:** Ligand A has 5 H-bond acceptors, while Ligand B has 3. Both are within the acceptable limit of <=10. Ligand B is slightly better.
6. **QED:** Both ligands have similar QED values (0.682 and 0.629), both above the 0.5 threshold, indicating good drug-likeness.
7. **DILI:** Ligand A has a DILI risk of 63.513, while Ligand B has 15.006. This is a significant difference. Ligand B is *much* preferred due to the substantially lower liver injury risk.
8. **BBB:** Ligand A has a BBB penetration of 37.611, while Ligand B has 53.432. While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant for side effects, and higher BBB is generally better. Ligand B is better.
9. **Caco-2:** Ligand A (-5.486) and Ligand B (-4.799) both have negative values, which is unusual and suggests poor permeability. However, the scale isn't defined, so it's hard to interpret.
10. **Solubility:** Both ligands have very poor aqueous solubility (-2.998 and -3.07). This is a significant concern for both.
11. **hERG:** Both ligands have similar hERG inhibition liability (0.27 and 0.277), which is relatively low and acceptable.
12. **Cl_mic:** Ligand A (16.106) has a lower microsomal clearance than Ligand B (50.178), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (-8.125) has a negative in vitro half-life, which is not possible. This is a major red flag. Ligand B (-10.609) also has a negative half-life, which is also a major red flag.
14. **Pgp:** Both ligands have similar Pgp efflux liability (0.091 and 0.202), which is relatively low.
15. **Binding Affinity:** Ligand A (-7.4) has a slightly better binding affinity than Ligand B (-6.8). This is a 0.6 kcal/mol difference, which is notable but not overwhelming.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Ligand B is better on logP, TPSA, and BBB. The affinity difference is small. The *major* deciding factor is the DILI risk. Ligand B's significantly lower DILI risk outweighs the slightly better affinity and metabolic stability of Ligand A. The negative half-life values for both are concerning, and would require further investigation.
**Conclusion:**
Despite the slightly better affinity and metabolic stability of Ligand A, the significantly lower DILI risk and better BBB penetration of Ligand B make it the more promising drug candidate.
Output:
0
2025-04-17 17:57:06,318 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (366.53 and 364.41 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (61.8) is better than Ligand B (67.43). Both are below 140, but closer to 90 is preferred for GPCRs, and A is closer.
3. **logP:** Both ligands have good logP values (3.37 and 2.194), falling within the 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability, but not dramatically so.
4. **HBD:** Both have 2 HBD, which is acceptable.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 3. Both are within the acceptable range of <= 10.
6. **QED:** Both ligands have nearly identical QED scores (0.727 and 0.728), indicating good drug-likeness.
7. **DILI:** Both ligands have relatively low DILI risk (35.87 and 37.03 percentiles), both well below the 40 threshold. No significant difference.
8. **BBB:** Ligand B (83.40) has a significantly higher BBB penetration percentile than Ligand A (60.37). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be helpful for distribution and off-target effects assessment.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual. Assuming these are logP-like scales, lower values indicate lower permeability. Ligand B (-4.955) is worse than Ligand A (-4.68).
10. **Solubility:** Ligand A (-3.428) has a slightly better solubility score than Ligand B (-2.491), though both are quite poor.
11. **hERG:** Ligand A (0.756) has a slightly higher hERG risk than Ligand B (0.403), which is undesirable.
12. **Cl_mic:** Ligand B (20.55) has a *much* lower microsomal clearance than Ligand A (61.73). This is a major advantage for Ligand B, indicating greater metabolic stability.
13. **t1/2:** Ligand B (-8.6) has a much longer in vitro half-life than Ligand A (9.585). This is a significant advantage.
14. **Pgp:** Ligand A (0.55) has a lower P-gp efflux liability than Ligand B (0.031), which is preferred.
15. **Binding Affinity:** Ligand A (-7.0) has a slightly better binding affinity than Ligand B (-5.7). This is a 1.3 kcal/mol difference, which is substantial.
**Overall Assessment:**
Ligand A has a better binding affinity and Pgp profile, but Ligand B excels in metabolic stability (lower Cl_mic, longer t1/2) and has a better BBB score. The affinity difference is significant, but the metabolic liabilities of Ligand A are concerning. For a GPCR, metabolic stability is crucial for maintaining therapeutic concentrations. The slightly better solubility of Ligand A is overshadowed by the poor Caco-2 permeability and hERG risk. The improved BBB penetration of Ligand B is a bonus.
Considering these factors, and prioritizing metabolic stability and reasonable safety (hERG), I believe Ligand B is the more promising candidate.
Output:
0
2025-04-17 17:57:06,318 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (350.394) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (78.67) is higher than Ligand B (51.02). For a cardiovascular GPCR like ADRB2, TPSA is less critical than for CNS targets, but lower is still preferred. Ligand B is better here.
3. **logP:** Ligand A (0.532) is quite low, potentially hindering membrane permeability. Ligand B (2.64) is within the optimal range (1-3). This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (1) and Ligand B (0) are both acceptable.
5. **HBA:** Ligand A (5) and Ligand B (6) are both acceptable.
6. **QED:** Both ligands have similar, good QED values (0.786 and 0.798).
7. **DILI:** Ligand A (29.081) has a much lower DILI risk than Ligand B (66.344). This is a substantial advantage for Ligand A.
8. **BBB:** Ligand B (82.474) has a higher BBB penetration percentile than Ligand A (43.583). While ADRB2 isn't a primary CNS target, some brain exposure can be relevant for off-target effects, and higher BBB is generally favorable.
9. **Caco-2:** Both have negative values, indicating poor permeability. Ligand A (-4.839) is slightly better than Ligand B (-5.077), but both are concerning.
10. **Solubility:** Ligand A (-0.571) has slightly better solubility than Ligand B (-2.858), but both are poor.
11. **hERG:** Both ligands have very low hERG risk (0.334 and 0.358).
12. **Cl_mic:** Ligand A (1.474) has significantly lower microsomal clearance than Ligand B (69.44). This indicates better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (-16.51) has a very poor in vitro half-life, while Ligand B (-3.866) is better, but still not ideal.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.042 and 0.239).
15. **Binding Affinity:** Ligand B (-7.3) has a stronger binding affinity than Ligand A (-5.8). This is a 1.5 kcal/mol difference, which is a significant advantage for Ligand B, potentially outweighing some ADME concerns.
**Overall Assessment:**
Ligand B has a superior logP and binding affinity, which are critical for GPCR targets. However, it suffers from a higher DILI risk and significantly higher metabolic clearance. Ligand A has a much better safety profile (DILI, Cl_mic) but has a poor logP and a weaker binding affinity. The poor solubility and Caco-2 permeability for both are concerning, but can potentially be addressed with formulation strategies.
Given the importance of potency for GPCRs, and the 1.5 kcal/mol advantage of Ligand B, I believe it is the more promising candidate *despite* the higher DILI and clearance. Further optimization could focus on reducing the DILI risk and improving metabolic stability while maintaining the strong binding affinity.
Output:
0
2025-04-17 17:57:06,318 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [354.397, 78.43, 2.759, 3, 3, 0.761, 31.059, 74.564, -4.883, -3.566, 0.496, 47.385, -27.566, 0.061, -5.2]
**Ligand B:** [344.467, 97.78, 2.299, 2, 8, 0.758, 43.195, 79.256, -5.101, -3.547, 0.562, 68.41, 17.212, 0.097, -7.3]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity, and BBB):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (344.467) is slightly lower, which is generally favorable.
2. **TPSA:** Ligand A (78.43) is better than Ligand B (97.78). Lower TPSA is preferred for better permeability, especially important for GPCRs.
3. **logP:** Both are good (around 2.3-2.8), within the optimal 1-3 range. Ligand A is slightly higher, which could be a minor advantage.
4. **HBD/HBA:** Ligand A (3 HBD, 3 HBA) is slightly better than Ligand B (2 HBD, 8 HBA). Fewer HBA is generally preferred for permeability.
5. **QED:** Both are similar and acceptable (0.761 and 0.758).
6. **DILI:** Ligand A (31.059) has a significantly lower DILI risk than Ligand B (43.195). This is a major advantage.
7. **BBB:** Both have good BBB penetration (74.564 and 79.256), but Ligand B is slightly better.
8. **Caco-2:** Ligand A (-4.883) is significantly better than Ligand B (-5.101).
9. **Solubility:** Both are similarly poor (-3.566 and -3.547). This is a concern for both, but not a deciding factor.
10. **hERG:** Both have low hERG risk (0.496 and 0.562).
11. **Cl_mic:** Ligand A (47.385) has lower microsomal clearance, indicating better metabolic stability than Ligand B (68.41).
12. **t1/2:** Ligand A (-27.566) has a much longer in vitro half-life than Ligand B (17.212). This is a significant advantage.
13. **Pgp:** Both have low P-gp efflux liability (0.061 and 0.097).
14. **Affinity:** Ligand B (-7.3) has a significantly stronger binding affinity than Ligand A (-5.2). This is a substantial advantage.
**Overall Assessment:**
While Ligand B boasts a better binding affinity (-7.3 kcal/mol vs -5.2 kcal/mol), the other ADME properties of Ligand A are substantially better. Specifically, the lower DILI risk, better metabolic stability (lower Cl_mic, longer t1/2), and better Caco-2 permeability are crucial advantages. The affinity difference, while significant, can potentially be addressed through further optimization of Ligand A. The improved safety profile and pharmacokinetic properties of Ligand A make it a more promising starting point for drug development.
Output:
1
2025-04-17 17:57:06,318 - INFO - Here's my reasoning and final output for the ligand preference:
**Reasoning:**
We are targeting the ADRB2, a GPCR involved in cardiovascular function. Therefore, priorities are affinity, logP, TPSA, Pgp efflux, and to a lesser extent, BBB.
Let's compare Ligand A and Ligand B across the given parameters:
1. **MW:** Both ligands (370.377 and 352.475 Da) are within the ideal 200-500 Da range.
2. **TPSA:** Both ligands have a TPSA of 76.66, which is acceptable for a non-CNS GPCR target, being under the 140 threshold.
3. **logP:** Ligand A (3.072) is optimal, while Ligand B (1.631) is on the lower side, potentially impacting permeability.
4. **HBD/HBA:** Both ligands have acceptable HBD (2) and HBA (5/4) counts.
5. **QED:** Both ligands have similar QED scores (0.766 and 0.762), indicating good drug-likeness.
6. **DILI:** Ligand A (86.739) has a significantly higher DILI risk than Ligand B (24.893). This is a major concern.
7. **BBB:** Ligand A (73.905) has better BBB penetration than Ligand B (58.007), but this is less critical for a cardiovascular target.
8. **Caco-2:** Ligand A (-4.485) has a worse Caco-2 permeability than Ligand B (-5.042), indicating lower intestinal absorption.
9. **Solubility:** Ligand B (-1.752) has better aqueous solubility than Ligand A (-4.29).
10. **hERG:** Ligand A (0.456) has a slightly higher hERG risk than Ligand B (0.249), but both are relatively low.
11. **Cl_mic:** Ligand A (91.62) has a higher microsomal clearance than Ligand B (23.269), suggesting lower metabolic stability.
12. **t1/2:** Ligand B (9.616 hours) has a longer in vitro half-life than Ligand A (40.201 hours).
13. **Pgp:** Ligand A (0.223) has lower P-gp efflux liability than Ligand B (0.05), which is favorable.
14. **Affinity:** Ligand B (-8.5 kcal/mol) has a significantly stronger binding affinity than Ligand A (-7.0 kcal/mol). This is a >1.5 kcal/mol advantage, which is substantial.
**Overall Assessment:**
While Ligand A has better Pgp and BBB penetration, the significantly higher DILI risk, lower solubility, worse Caco-2 permeability, and higher metabolic clearance are major drawbacks. Ligand B's superior binding affinity and much lower DILI risk outweigh its slightly lower logP and BBB penetration. The stronger binding affinity is particularly important for a GPCR target.
**Output:**
0
2025-04-17 17:57:06,319 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (354.495 & 347.39 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (67.33) is better than Ligand B (71.53), being closer to the <140 threshold for good absorption.
3. **logP:** Ligand B (1.146) is better positioned within the optimal 1-3 range than Ligand A (-0.159), which is a bit low and could impact permeability.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 5 HBA, while Ligand B has 4. Both are acceptable, below the 10 threshold.
6. **QED:** Both ligands have good QED scores (0.718 and 0.83), indicating good drug-like properties.
7. **DILI:** Ligand A (6.398) has a significantly lower DILI risk than Ligand B (58.085). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (74.758) has a better BBB penetration score than Ligand A (34.238). While ADRB2 isn't strictly a CNS target, some CNS exposure can be relevant for off-target effects or potential therapeutic benefits.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.997) is slightly better than Ligand B (-4.228).
10. **Solubility:** Ligand A (0.087) has slightly better solubility than Ligand B (-2.45).
11. **hERG:** Both ligands have low hERG inhibition liability (0.161 and 0.456), which is good.
12. **Cl_mic:** Ligand A (12.994) has a lower microsomal clearance than Ligand B (24.987), indicating better metabolic stability.
13. **t1/2:** Ligand A (-2.978) has a negative half-life, which is concerning. Ligand B (-16.206) is even worse. Both are very poor.
14. **Pgp:** Ligand A (0.007) has significantly lower P-gp efflux liability than Ligand B (0.084), which is favorable for bioavailability.
15. **Binding Affinity:** Both ligands have very similar and strong binding affinities (-6.4 and -5.9 kcal/mol). The difference is less than the 1.5 kcal/mol threshold.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B has a better logP and BBB penetration. However, Ligand A excels in DILI risk, Pgp efflux, and metabolic stability (Cl_mic). The affinity difference is minimal. The poor half-life for both is a major concern, but can be addressed in later optimization stages. The significantly lower DILI risk of Ligand A is a critical advantage for a cardiovascular target.
**Overall Assessment:**
Considering the balance of properties, especially the significantly lower DILI risk and better Pgp profile of Ligand A, I believe it is the more promising candidate despite the slightly lower logP and worse half-life. The DILI risk is a major safety concern, and Ligand A's advantage here is substantial.
Output:
1
2025-04-17 17:57:06,319 - INFO - Batch 2 complete. Total preferences: 32
2025-04-17 17:57:06,319 - INFO - Processing batch 3/512...
2025-04-17 17:57:57,322 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Ligand A (361.785 Da) is within the ideal range (200-500 Da). Ligand B (348.359 Da) is also excellent. No clear advantage here.
2. **TPSA:** Ligand A (94.75) is good, under the 140 threshold. Ligand B (120.29) is still acceptable, but less optimal. This favors Ligand A slightly.
3. **logP:** Both ligands have good logP values (A: 1.981, B: 1.061) within the 1-3 range. Ligand A is slightly better.
4. **HBD:** Both have 1 HBD, which is excellent.
5. **HBA:** Ligand A has 5 HBA, which is good. Ligand B has 8, which is higher but still within the acceptable limit of 10.
6. **QED:** Ligand A (0.84) is excellent, indicating high drug-likeness. Ligand B (0.49) is lower, suggesting a less ideal overall profile. This is a significant advantage for Ligand A.
7. **DILI:** Ligand A (85.847) has a higher DILI risk than Ligand B (30.593). This is a major concern for Ligand A.
8. **BBB:** Both have reasonable BBB penetration (A: 69.833, B: 77.86). Ligand B is slightly better, but for a cardiovascular target, BBB isn't a primary concern.
9. **Caco-2:** Ligand A (-4.614) and Ligand B (-5.332) both have negative Caco-2 values, which is unusual and suggests poor permeability. This is a negative for both, but slightly worse for A.
10. **Solubility:** Ligand A (-4.146) and Ligand B (-2.261) both have negative solubility values, which is concerning. Ligand B is better here.
11. **hERG:** Ligand A (0.281) has a lower hERG risk than Ligand B (0.792). This is a positive for Ligand A.
12. **Cl_mic:** Ligand A (36.187) has a higher microsomal clearance than Ligand B (-2.564). This suggests Ligand B is more metabolically stable.
13. **t1/2:** Ligand A (23.845) has a longer half-life than Ligand B (5.23). This is a positive for Ligand A.
14. **Pgp:** Ligand A (0.224) has lower P-gp efflux than Ligand B (0.13). This is a slight advantage for Ligand A.
15. **Binding Affinity:** Ligand B (-7.6 kcal/mol) has significantly stronger binding affinity than Ligand A (-4.5 kcal/mol). This is a substantial advantage for Ligand B, potentially outweighing some ADME concerns.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in affinity, has acceptable logP and TPSA, and good Pgp. Ligand A has better QED and hERG, but the significantly weaker binding and higher DILI risk are major drawbacks.
**Overall Assessment:**
While Ligand A has some favorable properties (QED, hERG, t1/2, Pgp), the substantially stronger binding affinity of Ligand B (-7.6 vs -4.5 kcal/mol) is a critical advantage for a GPCR target. The lower DILI risk of Ligand B is also a significant factor. The slightly worse Caco-2 and solubility of Ligand B can be addressed with formulation strategies.
Output:
0
2025-04-17 17:57:57,322 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [351.491, 64.09, 0.795, 1, 4, 0.796, 6.786, 57.193, -4.795, -0.633, 0.386, -2.625, 11.17, 0.015, -6.4]
**Ligand B:** [381.567, 62.3, 3.032, 1, 5, 0.871, 51.144, 62.97, -5.211, -4.249, 0.415, 53.715, 8.858, 0.302, -5.9]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (351.491) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are good, below 140 (Ligand A: 64.09, Ligand B: 62.3). Very similar.
3. **logP:** Ligand A (0.795) is a bit low, potentially causing permeability issues. Ligand B (3.032) is within the optimal range. This is a significant advantage for Ligand B.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 4 HBA, Ligand B has 5. Both are acceptable.
6. **QED:** Both are good, above 0.5 (Ligand A: 0.796, Ligand B: 0.871). Ligand B is slightly better.
7. **DILI:** Ligand A (6.786) has a much lower DILI risk than Ligand B (51.144). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (62.97) has better BBB penetration than Ligand A (57.193), but neither are particularly high. Since ADRB2 is a cardiovascular target, BBB penetration is not a primary concern, but it's still a plus.
9. **Caco-2:** Ligand A (-4.795) has a worse Caco-2 permeability than Ligand B (-5.211). Both are negative, which is not ideal.
10. **Solubility:** Ligand A (-0.633) has better solubility than Ligand B (-4.249). Solubility is important for bioavailability.
11. **hERG:** Both have low hERG inhibition risk (Ligand A: 0.386, Ligand B: 0.415). Similar.
12. **Cl_mic:** Ligand A (-2.625) has significantly better metabolic stability (lower clearance) than Ligand B (53.715). This is a major advantage for Ligand A.
13. **t1/2:** Ligand A (11.17) has a longer half-life than Ligand B (8.858). This is favorable.
14. **Pgp:** Ligand A (0.015) has much lower P-gp efflux than Ligand B (0.302). This is a significant advantage for Ligand A.
15. **Affinity:** Both have good binding affinity (Ligand A: -6.4, Ligand B: -5.9). Ligand A is slightly better.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B has a better logP, but Ligand A excels in DILI, Cl_mic, t1/2, and Pgp. The affinity difference is small. Given the cardiovascular target, BBB is less critical. The superior ADME profile of Ligand A (lower DILI, better metabolic stability, lower Pgp efflux) outweighs the slightly better logP of Ligand B.
**Conclusion:**
Ligand A presents a more balanced and favorable profile for drug development, particularly considering its improved safety (DILI) and pharmacokinetic properties (Cl_mic, t1/2, Pgp).
Output:
1
2025-04-17 17:57:57,322 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (344.419 and 350.459 Da) fall well within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (88.21) is slightly higher than Ligand B (59.08). Both are below 140, but Ligand B is significantly better for permeability, especially considering it's a GPCR.
3. **logP:** Both ligands (1.589 and 1.764) are within the optimal 1-3 range. Very similar.
4. **HBD:** Ligand A has 2 HBD, while Ligand B has 0. Lower HBD is generally preferred for better permeability, giving a slight edge to Ligand B.
5. **HBA:** Ligand A has 6 HBA, and Ligand B has 4. Again, lower is slightly preferred for permeability, favoring Ligand B.
6. **QED:** Ligand A (0.885) has a much better QED score than Ligand B (0.38). This is a substantial advantage for Ligand A, indicating a more drug-like profile overall.
7. **DILI:** Ligand A (49.632) has a higher DILI risk than Ligand B (29.663). This is a significant advantage for Ligand B.
8. **BBB:** Both ligands have good BBB penetration (Ligand A: 71.966, Ligand B: 78.48). Ligand B is slightly better, but both are acceptable.
9. **Caco-2:** Ligand A (-4.854) is worse than Ligand B (-4.246). Lower values indicate lower permeability, so Ligand B is better.
10. **Solubility:** Ligand A (-2.434) is worse than Ligand B (-0.777). Lower values indicate lower solubility, so Ligand B is better.
11. **hERG:** Both ligands have very low hERG inhibition risk (Ligand A: 0.422, Ligand B: 0.245). Ligand B is slightly better.
12. **Cl_mic:** Ligand A (11.523) has a much lower microsomal clearance than Ligand B (44.003). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (29.337) has a longer in vitro half-life than Ligand B (-14.271). This is a significant advantage for Ligand A.
14. **Pgp:** Both ligands have very low P-gp efflux liability (Ligand A: 0.012, Ligand B: 0.069). Ligand A is slightly better.
15. **Binding Affinity:** Ligand B (-6.6) has a slightly better binding affinity than Ligand A (-6.1). However, the difference is only 0.5 kcal/mol, which is not substantial enough to outweigh other factors.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B excels in TPSA, solubility, and has a slightly better affinity. Ligand A has a much better QED, metabolic stability (Cl_mic), and half-life. The DILI risk is also lower for Ligand B.
**Overall Assessment:**
While Ligand B has a slightly better binding affinity and lower DILI risk, Ligand A's superior QED, metabolic stability, and half-life are more critical for overall drug development success. The slightly better permeability profile of Ligand B is offset by the significantly better drug-like properties of Ligand A. The longer half-life of Ligand A is a major advantage.
Output:
1
2025-04-17 17:57:57,323 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [367.43 , 79.37 , 2.236, 1. , 4. , 0.679, 25.087, 43.273, -5.053, -0.942, 0.234, 23.339, 30.702, 0.036, -8.1 ]
**Ligand B:** [349.391, 125.21 , -0.431, 4. , 5. , 0.497, 66.615, 46.685, -5.06 , -3.347, 0.189, 26.533, -26.047, 0.027, -6.6 ]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (349.391) is slightly lower, which is generally favorable.
2. **TPSA:** Ligand A (79.37) is significantly better than Ligand B (125.21). Below 140 is good for oral absorption, but lower is preferred for GPCRs, and A is much closer to the ideal range.
3. **logP:** Ligand A (2.236) is optimal (1-3). Ligand B (-0.431) is quite low, potentially hindering membrane permeability. This is a significant drawback.
4. **HBD/HBA:** Ligand A (1 HBD, 4 HBA) is better than Ligand B (4 HBD, 5 HBA). Lower counts are generally preferred for better permeability.
5. **QED:** Ligand A (0.679) is better than Ligand B (0.497), indicating a more drug-like profile.
6. **DILI:** Ligand A (25.087) has a much lower DILI risk than Ligand B (66.615). This is a crucial advantage.
7. **BBB:** Both are moderate, but Ligand B (46.685) is slightly better than Ligand A (43.273). However, for a cardiovascular target, BBB penetration isn't a primary concern.
8. **Caco-2:** Both are negative, indicating poor permeability.
9. **Solubility:** Both are negative, indicating poor solubility.
10. **hERG:** Both are very low, indicating low risk of hERG inhibition.
11. **Cl_mic:** Ligand A (23.339) is slightly better than Ligand B (26.533), suggesting better metabolic stability.
12. **t1/2:** Ligand A (30.702) has a longer half-life than Ligand B (-26.047). This is a significant advantage.
13. **Pgp:** Both are very low, indicating low P-gp efflux.
14. **Affinity:** Ligand A (-8.1 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.6 kcal/mol). This is a >1.5 kcal/mol difference, which is substantial.
**Conclusion:**
Ligand A is clearly the superior candidate. Its better logP, TPSA, QED, DILI risk, metabolic stability, half-life, and *significantly* stronger binding affinity outweigh the slightly better BBB penetration of Ligand B. The low logP of Ligand B is a major concern, and its higher DILI risk is unacceptable. The stronger binding affinity of Ligand A is the most important factor, as it can compensate for some of the ADME weaknesses.
Output:
1
2025-04-17 17:57:57,323 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.45 & 349.48 Da) fall comfortably within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (103.09) is higher than Ligand B (71.33). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is generally preferred for absorption. Ligand B is better here.
3. **logP:** Both ligands have good logP values (1.336 & 1.93), falling within the optimal 1-3 range. Ligand B is slightly better, being closer to the upper end of the range, which can aid membrane permeability.
4. **HBD:** Ligand A has 4 HBD, while Ligand B has 0. Lower HBD is generally preferred for permeability, giving an edge to Ligand B.
5. **HBA:** Ligand A has 3 HBA, Ligand B has 5. Both are acceptable (<=10), but Ligand A is slightly better.
6. **QED:** Ligand B (0.762) has a significantly better QED score than Ligand A (0.513), indicating a more drug-like profile.
7. **DILI:** Both ligands have low DILI risk (31.601 & 33.307), both well below the 40% threshold. No significant difference.
8. **BBB:** Ligand B (75.107) has a higher BBB penetration percentile than Ligand A (57.464). While ADRB2 isn't primarily a CNS target, some degree of BBB penetration can be useful for understanding off-target effects and potential peripheral distribution. Ligand B is better.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-5.256) is slightly better (less negative) than Ligand B (-4.676).
10. **Solubility:** Both ligands have very poor aqueous solubility (-2.833 and -2.117). This is a significant concern for both.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.134), which is excellent. No significant difference.
12. **Cl_mic:** Ligand A (5.178) has a much lower microsomal clearance than Ligand B (40.958), indicating better metabolic stability. This is a major advantage for Ligand A.
13. **t1/2:** Ligand A (-9.332) has a more negative in vitro half-life than Ligand B (-3.594), indicating a longer half-life. This is a significant advantage for Ligand A.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.013 & 0.06). No significant difference.
15. **Binding Affinity:** Ligand B (-6.5 kcal/mol) has a stronger binding affinity than Ligand A (-5.4 kcal/mol). This is a 1.1 kcal/mol difference, which is substantial and could outweigh some ADME drawbacks.
**Overall Assessment & GPCR Priorities:**
For a cardiovascular GPCR like ADRB2, binding affinity, logP, and metabolic stability are key. Ligand B has a significantly better binding affinity. Ligand A has superior metabolic stability (lower Cl_mic, longer t1/2) and a slightly better Caco-2 value. However, the substantial affinity advantage of Ligand B, combined with its better QED and BBB, outweighs the benefits of Ligand A's metabolic profile, especially considering the poor solubility of both compounds. The solubility issue would need to be addressed through formulation strategies regardless of which ligand is chosen.
Output:
0
2025-04-17 17:57:57,323 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [357.395, 105.46 , 1.52 , 2. , 6. , 0.723, 94.649, 57.231, -5.389, -3.842, 0.121, 10.076, 99.953, 0.069, -7.1 ]
**Ligand B:** [360.483, 66.4 , 1.745, 0. , 5. , 0.821, 49.011, 56.611, -4.95 , -2.98 , 0.211, 52.619, -4.095, 0.114, -1.6 ]
Here's a breakdown of the comparison, considering the provided guidelines and GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal range (200-500 Da). A is 357.4, B is 360.5. Very similar.
2. **TPSA:** A (105.46) is higher than B (66.4). B is significantly better, falling well below the 140 threshold for oral absorption and closer to the ideal for GPCRs.
3. **logP:** Both are good (between 1 and 3). A (1.52) and B (1.745) are comparable.
4. **HBD:** A (2) is slightly higher than B (0). Lower is generally preferred, giving a slight edge to B.
5. **HBA:** A (6) is higher than B (5). Again, B is slightly better.
6. **QED:** Both are good (>0.5). B (0.821) is slightly better than A (0.723).
7. **DILI:** A (94.649) is *very* high risk, while B (49.011) is acceptable. This is a major concern for A.
8. **BBB:** Both are relatively low, but A (57.231) is lower than B (56.611). Not a huge difference, and not a primary concern for a cardiovascular target.
9. **Caco-2:** A (-5.389) is worse than B (-4.95). Lower values suggest poorer permeability.
10. **Solubility:** A (-3.842) is worse than B (-2.98). Lower values suggest poorer solubility.
11. **hERG:** Both are low risk (0.121 and 0.211). Comparable.
12. **Cl_mic:** A (10.076) is much lower than B (52.619), indicating better metabolic stability. This is a significant advantage for A.
13. **t1/2:** A (99.953) is *much* longer than B (-4.095). This is a huge advantage for A.
14. **Pgp:** A (0.069) is much lower than B (0.114), indicating less P-gp efflux. This is a significant advantage for A.
15. **Affinity:** A (-7.1) is significantly stronger than B (-1.6). This is a massive advantage for A.
**Overall Assessment:**
Ligand A has a *much* stronger binding affinity and better metabolic stability (lower Cl_mic, longer t1/2) and lower Pgp efflux. However, its DILI risk is extremely high, and its TPSA is higher than ideal. Ligand B has a better TPSA, QED, and lower DILI risk, but significantly weaker binding affinity and poorer metabolic properties.
The strong binding affinity of Ligand A (-7.1 kcal/mol) is a substantial advantage that could potentially outweigh the DILI risk, *if* the DILI risk can be mitigated through structural modifications. The difference in affinity (5.5 kcal/mol) is very large. The metabolic stability and Pgp properties of A are also very favorable. While the DILI is concerning, the overall profile of A is more promising due to the potency and PK advantages.
Therefore, I would prioritize Ligand A for further optimization, focusing on reducing the DILI risk.
0
2025-04-17 17:57:57,323 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
Let's systematically compare Ligand A and Ligand B based on the provided parameters and the guidelines, keeping in mind that ADRB2 is a GPCR and therefore logP, TPSA, Pgp, BBB, and affinity are prioritized.
1. **Molecular Weight:** Both ligands (361.511 and 370.471 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (61.44) is significantly better than Ligand B (97.64). A TPSA under 140 is good for oral absorption, but lower is generally preferred for GPCRs. Ligand A is much closer to the ideal range for good permeability.
3. **logP:** Both ligands have acceptable logP values (2.346 and 1.646), falling within the 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability, but both are reasonable.
4. **H-Bond Donors:** Both have 2 HBD, which is within the acceptable limit of 5.
5. **H-Bond Acceptors:** Ligand A has 4 HBA, while Ligand B has 5. Both are acceptable (<=10), but Ligand A is slightly better.
6. **QED:** Both ligands have good QED scores (0.747 and 0.821), indicating good drug-like properties.
7. **DILI:** Ligand A (36.681) has a significantly lower DILI risk than Ligand B (66.421). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (67.003) has a slightly better BBB penetration percentile than Ligand B (64.831). While neither is exceptionally high, it's a small advantage for Ligand A, given the GPCR target class.
9. **Caco-2 Permeability:** Both have negative Caco-2 values (-5.419 and -5.093), which is unusual and suggests poor permeability. However, the values are very close.
10. **Aqueous Solubility:** Both have negative solubility values (-2.588 and -2.449), indicating poor aqueous solubility. This is a concern for both, but again, the difference is minimal.
11. **hERG Inhibition:** Both ligands have low hERG inhibition risk (0.517 and 0.403), which is good.
12. **Microsomal Clearance:** Ligand A (11.912) has a lower microsomal clearance than Ligand B (15.931), suggesting better metabolic stability.
13. **In vitro Half-Life:** Ligand B (31.739) has a significantly longer in vitro half-life than Ligand A (8.291). This is a substantial advantage for Ligand B.
14. **P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.094 and 0.137), which is favorable.
15. **Binding Affinity:** Ligand B (-5.9 kcal/mol) has a slightly better binding affinity than Ligand A (-6.0 kcal/mol). While the difference is small, it's still a positive for Ligand B.
**Overall Assessment:**
Ligand A has several advantages: significantly lower DILI risk, better TPSA, slightly better BBB penetration, and better metabolic stability (lower Cl_mic). Ligand B's main advantage is its longer in vitro half-life and slightly better binding affinity. However, the DILI risk associated with Ligand B is concerning. For a cardiovascular target, minimizing potential liver toxicity is crucial. The slightly better half-life of Ligand B is outweighed by the significantly better safety profile of Ligand A. The TPSA difference is also important for permeability.
**Output:**
1
2025-04-17 17:57:57,323 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (370.471 Da and 358.473 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (92.78) is higher than Ligand B (58.2). For a cardiovascular GPCR, TPSA is moderately important. Ligand B is significantly better here, suggesting better potential for permeability.
**3. logP:** Ligand A (1.079) is within the optimal range (1-3), while Ligand B (3.302) is at the higher end. While still acceptable, Ligand B's higher logP could potentially lead to off-target interactions or solubility issues.
**4. H-Bond Donors:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
**5. H-Bond Acceptors:** Ligand A (5) is preferable to Ligand B (2). Lower HBA generally improves permeability.
**6. QED:** Ligand A (0.802) has a significantly better QED score than Ligand B (0.629), indicating a more drug-like profile.
**7. DILI Risk:** Ligand A (38.581) has a much lower DILI risk than Ligand B (15.316). This is a crucial advantage, as liver toxicity is a major concern in drug development.
**8. BBB Penetration:** Both ligands have good BBB penetration (Ligand A: 83.443, Ligand B: 85.847). While not the primary focus for a cardiovascular target, higher BBB is not detrimental.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and potentially problematic. However, the values are similar (-4.485 and -4.627).
**10. Aqueous Solubility:** Both ligands have negative solubility values, which is also unusual and problematic. Ligand B is slightly worse (-3.591 vs -2.165).
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.193 and 0.504). This is excellent.
**12. Microsomal Clearance:** Ligand A (14.375) has significantly lower microsomal clearance than Ligand B (45.326), indicating better metabolic stability.
**13. In vitro Half-Life:** Ligand A (16.099) has a much longer in vitro half-life than Ligand B (6.877), which is desirable for less frequent dosing.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.021 and 0.122). This is excellent.
**15. Binding Affinity:** Both ligands have the same binding affinity (-6.8 kcal/mol). This removes affinity as a differentiating factor.
**Overall Assessment:**
Ligand A is clearly the superior candidate. It has a better QED score, significantly lower DILI risk, lower microsomal clearance, longer half-life, and fewer H-bond donors/acceptors. While Ligand B has a slightly better TPSA, the advantages of Ligand A across multiple critical ADME-Tox parameters outweigh this single benefit. The negative solubility and Caco-2 values are concerning for both, but Ligand A's overall profile is more promising.
Output:
1
2025-04-17 17:57:57,323 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (365.861 Da) is slightly higher than Ligand B (338.451 Da), but both are acceptable.
2. **TPSA:** Ligand A (81.67) is higher than Ligand B (49.41). For a cardiovascular GPCR, TPSA is not a major concern unless CNS penetration is desired, but lower is generally preferred for oral absorption. Ligand B is significantly better here.
3. **logP:** Both ligands have good logP values (Ligand A: 2.0, Ligand B: 3.361), falling within the optimal 1-3 range. Ligand B is slightly higher, which could potentially lead to off-target effects, but is still within acceptable limits.
4. **HBD:** Ligand A (3) and Ligand B (1) both meet the criteria of <=5. Ligand B is better here.
5. **HBA:** Ligand A (3) and Ligand B (2) both meet the criteria of <=10. Ligand B is better here.
6. **QED:** Both ligands have good QED scores (Ligand A: 0.766, Ligand B: 0.856), indicating good drug-likeness. Ligand B is slightly better.
7. **DILI:** Both ligands have low DILI risk (Ligand A: 23.032, Ligand B: 27.879), well below the 40% threshold. Both are acceptable.
8. **BBB:** Ligand A (75.533) and Ligand B (88.135) are both reasonably high, suggesting some potential for CNS penetration, but this isn't a primary concern for a cardiovascular target. Ligand B is better.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.938 and -4.676). This is unusual and suggests poor permeability. However, the scale is not specified, and negative values could indicate a different measurement system. We'll proceed cautiously, but this is a flag for both.
10. **Solubility:** Both ligands have negative solubility values (-2.647 and -3.619). Similar to Caco-2, this is concerning and requires clarification of the scale. Poor solubility could hinder bioavailability.
11. **hERG:** Both ligands have low hERG inhibition liability (Ligand A: 0.457, Ligand B: 0.577), which is excellent.
12. **Cl_mic:** Ligand A (-22.151) has a much lower (better) microsomal clearance than Ligand B (66.817). This indicates greater metabolic stability for Ligand A.
13. **t1/2:** Ligand A (0.836) has a shorter half-life than Ligand B (3.196). Longer half-life is generally preferred.
14. **Pgp:** Both ligands have low Pgp efflux liability (Ligand A: 0.106, Ligand B: 0.442). Ligand A is better.
15. **Affinity:** Ligand B (-6.8 kcal/mol) has a slightly better binding affinity than Ligand A (-6.5 kcal/mol). While the difference is small, it is within the range where it could outweigh some ADME drawbacks.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand B appears slightly more favorable. It has a better TPSA, QED, BBB, and affinity. However, Ligand A has significantly better metabolic stability (lower Cl_mic) and Pgp efflux liability. The solubility and Caco-2 values are concerning for both, but the difference in Cl_mic is substantial. The slightly better affinity of Ligand B is a plus, but the metabolic stability of Ligand A is a significant advantage.
Given the importance of metabolic stability for a drug intended for chronic cardiovascular use, I lean towards Ligand A.
**Output:**
1
2025-04-17 17:57:57,324 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [337.419, 47.56, 3.224, 1, 3, 0.753, 54.323, 50.097, -4.973, -3.982, 0.665, 54.751, 1.262, 0.455, -5.7]**
**Ligand B: [350.463, 84.42, 1.353, 1, 5, 0.727, 23.769, 68.554, -4.791, -0.629, 0.173, 44.216, 4.31, 0.012, -6.4]**
1. **Molecular Weight:** Both ligands are within the ideal 200-500 Da range. A (337.419) is slightly preferred.
2. **TPSA:** Ligand A (47.56) is significantly better than Ligand B (84.42). ADRB2 is a cardiovascular target, not necessarily CNS, but lower TPSA generally aids absorption.
3. **logP:** Ligand A (3.224) is optimal, while Ligand B (1.353) is on the lower side. This could impact membrane permeability for B.
4. **H-Bond Donors:** Both have 1 HBD, which is good.
5. **H-Bond Acceptors:** Ligand A (3) is better than Ligand B (5). Fewer HBA generally improves permeability.
6. **QED:** Both are similar (A: 0.753, B: 0.727) and above the 0.5 threshold, indicating good drug-likeness.
7. **DILI:** Ligand A (54.323) has a higher DILI risk than Ligand B (23.769). This is a significant drawback for A.
8. **BBB:** Ligand B (68.554) has better BBB penetration than Ligand A (50.097), but this is less critical for a cardiovascular target.
9. **Caco-2:** Both have negative Caco-2 values which is unusual and suggests poor permeability.
10. **Solubility:** Ligand B (-0.629) is better than Ligand A (-3.982). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.665) has a slightly higher hERG risk than Ligand B (0.173). Lower is better.
12. **Cl_mic:** Ligand B (44.216) has lower microsomal clearance than Ligand A (54.751), indicating better metabolic stability.
13. **t1/2:** Ligand B (4.31) has a longer half-life than Ligand A (1.262), which is desirable.
14. **Pgp:** Ligand B (0.012) has much lower P-gp efflux than Ligand A (0.455), which is beneficial for bioavailability.
15. **Binding Affinity:** Ligand B (-6.4) has a stronger binding affinity than Ligand A (-5.7) by 0.7 kcal/mol. This is a substantial difference and a major advantage.
**Overall Assessment:**
Ligand B is clearly superior. While Ligand A has a slightly better MW and logP, Ligand B excels in crucial ADME properties (lower DILI, better solubility, lower hERG, lower Cl_mic, longer t1/2, lower Pgp efflux) and, most importantly, has significantly stronger binding affinity. The higher TPSA of Ligand B is a concern, but the substantial affinity advantage and improved ADME profile outweigh this drawback for a cardiovascular target.
Output:
0
2025-04-17 17:57:57,324 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.49 and 346.39 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (58.64) is significantly better than Ligand B (122.03). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand B's TPSA is quite high, potentially hindering oral bioavailability.
3. **logP:** Ligand A (3.371) is optimal, while Ligand B (0.048) is very low. This is a major concern for Ligand B; a logP this low suggests poor membrane permeability and potentially poor absorption.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (7). Similar reasoning as with HBDs.
6. **QED:** Both ligands have similar, acceptable QED values (0.612 and 0.635).
7. **DILI:** Ligand A (56.262) is slightly higher than Ligand B (49.438), but both are within acceptable ranges (<60).
8. **BBB:** Ligand A (76.658) is much better than Ligand B (17.332). While not a primary concern for a cardiovascular target, higher BBB is generally a positive attribute.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.06 and -5.416), which is unusual and indicates poor permeability. However, the negative values are similar.
10. **Solubility:** Ligand A (-3.982) is better than Ligand B (-1.965). Higher solubility is generally preferred.
11. **hERG:** Ligand A (0.44) is significantly better than Ligand B (0.045). Lower hERG inhibition is crucial for avoiding cardiotoxicity, especially for a cardiovascular target.
12. **Cl_mic:** Ligand A (46.511) is much higher than Ligand B (2.668). Lower microsomal clearance indicates better metabolic stability, which is a significant advantage for Ligand B.
13. **t1/2:** Ligand A (-0.795) is better than Ligand B (0.191). Longer half-life is generally desirable.
14. **Pgp:** Ligand A (0.142) is significantly better than Ligand B (0.006). Lower P-gp efflux is preferable for better bioavailability.
15. **Binding Affinity:** Ligand A (-6.7) is slightly better than Ligand B (-6.0). While both are good, the 0.7 kcal/mol difference is noticeable.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A excels in these areas. Ligand B's extremely low logP and high TPSA are major drawbacks. While Ligand B has better metabolic stability (lower Cl_mic), the permeability issues are too significant to ignore.
**Conclusion:**
Ligand A is the superior candidate due to its favorable logP, TPSA, hERG, Pgp, and slightly better binding affinity. While Ligand B has better metabolic stability, the poor permeability characteristics outweigh this benefit.
Output:
1
2025-04-17 17:57:57,324 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (342.443) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (49.41) is significantly better than Ligand A (70.25). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (A: 4.443, B: 3.391), falling within the optimal 1-3 range. Ligand B is slightly better.
4. **HBD:** Ligand A (2) has a slight edge over Ligand B (1). Both are acceptable.
5. **HBA:** Ligand B (4) is preferable to Ligand A (3). Both are acceptable.
6. **QED:** Both ligands have acceptable QED values (A: 0.863, B: 0.782), indicating good drug-like properties.
7. **DILI:** Ligand B (47.305) is significantly better than Ligand A (69.794). Lower DILI risk is crucial.
8. **BBB:** Both have high BBB penetration (A: 83.366, B: 88.251), but this is less critical for a cardiovascular target.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability.
10. **Solubility:** Both ligands have negative solubility values, which is also unusual and suggests poor solubility.
11. **hERG:** Both ligands have low hERG inhibition risk (A: 0.515, B: 0.605).
12. **Cl_mic:** Ligand B (36.083) has significantly lower microsomal clearance than Ligand A (79.493), indicating better metabolic stability.
13. **t1/2:** Ligand B (-2.131) has a slightly better in vitro half-life than Ligand A (-2.487).
14. **Pgp:** Both ligands have low Pgp efflux liability (A: 0.394, B: 0.2).
15. **Binding Affinity:** Ligand A (-7.1) has a stronger binding affinity than Ligand B (-6.4). This is a significant advantage (1.5 kcal/mol difference).
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has a better affinity, while Ligand B has better TPSA, logP, and significantly better DILI and Cl_mic.
**Overall Assessment:**
While Ligand A boasts a stronger binding affinity, the significantly improved safety profile (DILI) and metabolic stability (Cl_mic) of Ligand B are more compelling. The slight advantage in affinity is outweighed by the lower risk profile of Ligand B. The negative Caco-2 and solubility values are concerning for both, but can be addressed with formulation strategies.
**Output:**
0
2025-04-17 17:57:57,324 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [350.447, 58.12, 3.84, 1, 5, 0.78, 90.733, 73.827, -4.895, -4.901, 0.758, 93.79, 75.587, 0.9, -6.8]
**Ligand B:** [370.494, 67.23, 1.86, 1, 5, 0.72, 54.75, 66.537, -5.013, -3.246, 0.291, 43.252, -7.897, 0.119, -5.8]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, Affinity, and BBB):
1. **MW:** Both are within the ideal 200-500 Da range. A (350.447) is slightly preferred.
2. **TPSA:** A (58.12) is better than B (67.23). Both are acceptable, but lower TPSA generally favors permeability.
3. **logP:** A (3.84) is good, while B (1.86) is on the lower side. ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but a good logP is still important for membrane permeability and binding. A is better here.
4. **HBD/HBA:** Both have 1 HBD and 5 HBA, which is acceptable.
5. **QED:** Both have good QED scores (A: 0.78, B: 0.72), indicating drug-likeness.
6. **DILI:** A (90.733) is significantly higher than B (54.75). This is a major concern for A.
7. **BBB:** A (73.827) is better than B (66.537), but neither is exceptionally high. Not a critical factor here.
8. **Caco-2:** A (-4.895) is worse than B (-5.013). Lower values suggest poorer permeability.
9. **Solubility:** A (-4.901) is worse than B (-3.246). Solubility is important for bioavailability.
10. **hERG:** A (0.758) is better than B (0.291). Lower hERG risk is crucial.
11. **Cl_mic:** A (93.79) is much higher than B (43.252), meaning faster metabolism and lower stability. B is significantly better.
12. **t1/2:** A (75.587) is better than B (-7.897). Longer half-life is generally desirable.
13. **Pgp:** A (0.9) is worse than B (0.119). Lower P-gp efflux is preferred for better bioavailability.
14. **Affinity:** A (-6.8) is better than B (-5.8). A 1 kcal/mol difference in binding affinity is substantial and can often outweigh other issues.
**Overall Assessment:**
Ligand A has a better binding affinity and half-life, but suffers from significantly higher DILI risk, worse metabolic stability (higher Cl_mic), and poorer solubility and Caco-2 permeability. Ligand B has a lower DILI risk, better metabolic stability, and better solubility and permeability, but its binding affinity is weaker and Pgp efflux is higher.
Given the importance of avoiding liver toxicity (DILI) and ensuring reasonable metabolic stability for a cardiovascular drug, I favor **Ligand B**. While the affinity is slightly lower, the improved safety profile and ADME properties make it a more promising starting point for optimization. The affinity can be improved during lead optimization, but mitigating a high DILI risk is much more challenging.
Output:
0
2025-04-17 17:57:57,324 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [358.435, 119.33 , -0.987, 4. , 6. , 0.501, 14.114, 19.581, -5.254, -0.738, 0.14 , -20.099, -15.166, 0.012, -8.2 ]
**Ligand B:** [346.515, 40.62 , 3.739, 0. , 2. , 0.704, 15.083, 91.392, -4.539, -3.901, 0.575, 80.527, 1.205, 0.333, -5.8 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (346.5) is slightly lower, which isn't a major concern.
2. **TPSA:** Ligand A (119.33) is slightly above the preferred <140 for good oral absorption, but still reasonable. Ligand B (40.62) is excellent, well below the threshold.
3. **logP:** Ligand A (-0.987) is a bit low, potentially hindering permeation. Ligand B (3.739) is within the optimal range (1-3). This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (4) is acceptable. Ligand B (0) is even better, potentially improving permeability.
5. **HBA:** Ligand A (6) is acceptable. Ligand B (2) is also good.
6. **QED:** Both have reasonable QED scores (A: 0.501, B: 0.704), indicating good drug-like properties. Ligand B is better here.
7. **DILI:** Ligand A (14.114) has a lower DILI risk than Ligand B (15.083), which is preferable.
8. **BBB:** Ligand B (91.392) shows excellent BBB penetration, while Ligand A (19.581) is quite low. Given that ADRB2 is a GPCR, BBB penetration is a significant consideration, especially if CNS effects are desired or need to be minimized.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual. Assuming these are percentile scores, both are very poor.
10. **Solubility:** Both have negative solubility values, which is also unusual. Assuming these are percentile scores, both are very poor.
11. **hERG:** Ligand A (0.14) has a lower hERG risk than Ligand B (0.575), which is preferable.
12. **Cl_mic:** Ligand A (-20.099) has a much lower (better) microsomal clearance than Ligand B (80.527), indicating better metabolic stability.
13. **t1/2:** Ligand A (-15.166) has a lower in vitro half-life than Ligand B (1.205).
14. **Pgp:** Ligand A (0.012) has a much lower Pgp efflux liability than Ligand B (0.333), which is beneficial for bioavailability and potential CNS exposure.
15. **Affinity:** Ligand A (-8.2) has a significantly stronger binding affinity than Ligand B (-5.8). This is a substantial advantage, potentially outweighing some of the ADME drawbacks.
**GPCR-Specific Priorities:** For ADRB2 (a GPCR), we prioritize logP, Pgp, TPSA, and affinity. Ligand B excels in TPSA and BBB, and has a good logP. Ligand A has a poor logP but a *much* stronger affinity and lower Pgp efflux. The affinity difference is substantial (>1.5 kcal/mol).
**Conclusion:**
Despite Ligand B's better logP and BBB penetration, the significantly stronger binding affinity of Ligand A (-8.2 vs -5.8 kcal/mol) is a major advantage. The lower Pgp efflux of Ligand A also contributes positively. While Ligand A has a lower logP, the potency advantage is likely to be more impactful for a GPCR target.
Output:
1
2025-04-17 17:57:57,324 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Ligand A (359.853 Da) is within the ideal range, while Ligand B (335.407 Da) is slightly below, but still acceptable.
2. **TPSA:** Ligand A (46.61) is excellent, well below the 140 threshold. Ligand B (73.2) is higher, but still reasonable for a non-CNS target.
3. **logP:** Ligand A (4.82) is a bit high, potentially leading to solubility issues and off-target effects. Ligand B (2.244) is optimal.
4. **HBD:** Ligand A (0) is good. Ligand B (1) is also acceptable.
5. **HBA:** Both Ligand A (3) and Ligand B (3) are within the acceptable range.
6. **QED:** Both ligands have good QED scores (A: 0.735, B: 0.861), indicating drug-likeness.
7. **DILI:** Ligand A (61.225) is approaching a concerning level, while Ligand B (47.732) is much better.
8. **BBB:** Both have good BBB penetration (A: 73.633, B: 78.519), but this is less critical for a cardiovascular target like ADRB2.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the values are close enough that this isn't a major differentiator.
10. **Solubility:** Both have poor solubility (A: -6.114, B: -4.156). Ligand B is slightly better, but both are problematic.
11. **hERG:** Both ligands show low hERG inhibition risk (A: 0.79, B: 0.498).
12. **Cl_mic:** Ligand A (120.418) has significantly higher clearance than Ligand B (18.796), suggesting lower metabolic stability.
13. **t1/2:** Ligand A (31.1) has a better in vitro half-life than Ligand B (3.829).
14. **Pgp:** Both ligands have low P-gp efflux (A: 0.306, B: 0.107). Ligand B is slightly better.
15. **Affinity:** Both have excellent binding affinity (A: -6.8 kcal/mol, B: -6.0 kcal/mol). Ligand A is slightly better but the difference is less than 1.5 kcal/mol.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP and Pgp, and has a better DILI score. While Ligand A has slightly better affinity and half-life, the higher logP and DILI risk are concerning. The solubility issue is a problem for both, but can potentially be addressed with formulation strategies. The significantly better metabolic stability of Ligand B is a major advantage.
**Conclusion:**
Considering the balance of properties, particularly the lower DILI risk and improved metabolic stability, Ligand B is the more promising candidate despite its slightly lower affinity and half-life.
Output:
0
2025-04-17 17:57:57,324 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (335.37 Da) is better than Ligand B (371.51 Da). Both are within the ideal range, but A is closer to the lower, preferred end.
2. **TPSA:** Ligand B (89.35) is better than Ligand A (98.81). Both are acceptable for a non-CNS GPCR, but B is closer to the <140 threshold.
3. **logP:** Ligand A (2.751) is better than Ligand B (0.857). Ligand A falls within the optimal 1-3 range, while B is a bit low, potentially impacting permeability.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A (5) is better than Ligand B (7). Lower HBA is generally preferred for better permeability.
6. **QED:** Both ligands have similar QED scores (0.776 vs 0.765), indicating good drug-likeness.
7. **DILI:** Ligand B (47.15) is significantly better than Ligand A (82.513). This is a major advantage for B, as lower DILI risk is crucial.
8. **BBB:** Both ligands have similar BBB penetration (64.754 vs 67.08). This isn't a primary concern for ADRB2, which is not a CNS target.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. This is a significant drawback for both.
10. **Solubility:** Ligand B (-1.539) is better than Ligand A (-3.824). Higher solubility is preferred.
11. **hERG:** Both ligands have low hERG risk (0.453 vs 0.48).
12. **Cl_mic:** Ligand B (-6.955) is significantly better than Ligand A (25.01). Lower clearance indicates better metabolic stability, a critical factor.
13. **t1/2:** Ligand A (6.391) is better than Ligand B (5.257). Longer half-life is generally preferred.
14. **Pgp:** Both ligands have similar Pgp efflux liability (0.189 vs 0.257).
15. **Affinity:** Ligand B (-6.9 kcal/mol) is slightly better than Ligand A (-5.8 kcal/mol). While A is within a good range, the 1.1 kcal/mol difference is substantial and can outweigh some ADME drawbacks.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has a better logP, while Ligand B has better TPSA. However, the substantial advantage of Ligand B in DILI risk and Cl_mic, combined with its slightly better affinity, makes it the more promising candidate. The poor Caco-2 permeability is a concern for both, but can be addressed with formulation strategies.
**Conclusion:**
Considering the balance of properties, especially the significantly lower DILI risk and better metabolic stability of Ligand B, along with its slightly improved binding affinity, I believe Ligand B is the more viable drug candidate.
Output:
0
2025-04-17 17:57:57,324 - INFO - Batch 3 complete. Total preferences: 48
2025-04-17 17:57:57,324 - INFO - Processing batch 4/512...
2025-04-17 17:58:45,048 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for the ADRB2 receptor, a GPCR involved in cardiovascular function. Therefore, priorities are logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB.
Let's break down the comparison:
1. **MW:** Both ligands (349.4 and 374.5 Da) fall within the ideal range (200-500 Da).
2. **TPSA:** Ligand A (79.37) is significantly better than Ligand B (101.98). ADRB2 is not a CNS target, but lower TPSA generally aids absorption.
3. **logP:** Ligand A (2.464) is optimal. Ligand B (-0.913) is quite low, potentially hindering membrane permeability and bioavailability.
4. **HBD/HBA:** Ligand A (1 HBD, 4 HBA) is preferable to Ligand B (3 HBD, 6 HBA). Fewer H-bonds generally improve permeability.
5. **QED:** Both are acceptable (0.671 and 0.508), both above the 0.5 threshold.
6. **DILI:** Ligand A (60.682) has a higher DILI risk than Ligand B (21.908), which is a significant drawback.
7. **BBB:** Not a primary concern for a cardiovascular target, but Ligand A (82.668) is better than Ligand B (10.779).
8. **Caco-2:** Ligand A (-4.547) is better than Ligand B (-5.686), indicating better intestinal absorption.
9. **Solubility:** Ligand A (-3.523) is better than Ligand B (-1.105).
10. **hERG:** Both are very low risk (0.299 and 0.034).
11. **Cl_mic:** Ligand A (53.369) has better metabolic stability than Ligand B (22.155).
12. **t1/2:** Ligand A (-35.708) has a longer in vitro half-life than Ligand B (-9.959).
13. **Pgp:** Ligand A (0.08) has lower P-gp efflux than Ligand B (0.007), which is favorable.
14. **Binding Affinity:** Ligand B (-7.4 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.2 kcal/mol). This is a substantial advantage.
**Overall Assessment:**
Ligand B has a significantly better binding affinity (-7.4 vs -5.2 kcal/mol). This is a major advantage that can potentially outweigh some of its ADME drawbacks. However, Ligand B's low logP is a serious concern for permeability. Ligand A has a more balanced profile with better logP, TPSA, solubility, metabolic stability, and Pgp efflux. The higher DILI risk for Ligand A is concerning, but the better ADME properties overall, combined with acceptable affinity, make it the more promising candidate. The affinity difference is not large enough to overcome the permeability issues with Ligand B.
**Output:**
1
2025-04-17 17:58:45,048 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, key priorities are logP, TPSA, Pgp efflux, BBB penetration, and binding affinity.
Let's compare the ligands property by property:
1. **MW:** Both ligands (355.36 and 357.491 Da) are within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (58.36) is significantly better than Ligand B (79.23). A lower TPSA generally favors oral absorption and is particularly important for GPCRs.
3. **logP:** Ligand A (3.536) is slightly higher than Ligand B (1.721), placing it closer to the optimal 1-3 range. Ligand B is at the lower end, which *could* indicate permeability issues.
4. **HBD/HBA:** Ligand A (1 HBD, 4 HBA) is preferable to Ligand B (2 HBD, 5 HBA). Lower counts are generally better for permeability.
5. **QED:** Ligand A (0.893) is significantly better than Ligand B (0.622), indicating a more drug-like profile.
6. **DILI:** Ligand A (32.222) has a much lower DILI risk than Ligand B (10.392), which is a critical advantage.
7. **BBB:** Ligand B (75.378) has a slightly better BBB penetration than Ligand A (66.072), but both are reasonably good. This is less critical for a cardiovascular target, but still a consideration.
8. **Caco-2:** Both are negative, indicating poor permeability.
9. **Solubility:** Ligand A (-3.626) has better solubility than Ligand B (-1.205).
10. **hERG:** Both ligands have low hERG inhibition risk (0.596 and 0.572).
11. **Cl_mic:** Ligand B (33.189) has significantly lower microsomal clearance than Ligand A (68.316), suggesting better metabolic stability.
12. **t1/2:** Ligand B (28.349) has a much longer in vitro half-life than Ligand A (-8.001). This is a significant advantage.
13. **Pgp:** Both ligands have similar Pgp efflux liability (0.209 and 0.21).
14. **Binding Affinity:** Both ligands have very similar binding affinities (-6.4 and -6.5 kcal/mol). This difference is negligible.
**Overall Assessment:**
Ligand A excels in TPSA, logP, QED, solubility, and crucially, DILI risk. Ligand B has better metabolic stability (lower Cl_mic) and a longer half-life. However, the lower TPSA and DILI risk of Ligand A are more important for a GPCR target, and the slight advantage in logP is also beneficial. The similar binding affinities mean that the ADME properties become the deciding factor. The significantly lower DILI risk for Ligand A is a major advantage.
**Output:**
1
2025-04-17 17:58:45,048 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (368.5 and 358.4 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (97.6) is higher than Ligand B (59.1). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is generally preferred for absorption. Ligand B is better.
3. **logP:** Both ligands (1.82 and 1.06) are within the optimal 1-3 range. Ligand B is slightly lower, which could be a minor drawback, but still acceptable.
4. **HBD:** Ligand A has 2 HBD, while Ligand B has 0. Both are within the acceptable limit of 5.
5. **HBA:** Ligand A has 6 HBA, and Ligand B has 4. Both are within the acceptable limit of 10.
6. **QED:** Both ligands have similar QED values (0.765 and 0.708), indicating good drug-likeness.
7. **DILI:** Both ligands have very similar DILI risk (45.3 and 45.2), both being acceptable.
8. **BBB:** Ligand B (89.5) has a significantly higher BBB penetration percentile than Ligand A (78.6). While ADRB2 isn't primarily a CNS target, some degree of BBB penetration can be beneficial for off-target effects assessment and potential peripheral activity.
9. **Caco-2:** Ligand A (-5.16) has a worse Caco-2 permeability than Ligand B (-4.36). This suggests Ligand B will have better intestinal absorption.
10. **Solubility:** Ligand A (-2.34) has slightly worse aqueous solubility than Ligand B (-2.01).
11. **hERG:** Both ligands have low hERG inhibition risk (0.54 and 0.35), which is excellent.
12. **Cl_mic:** Ligand A (15.7) has a significantly lower microsomal clearance than Ligand B (25.1). This indicates better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (8.57) has a better in vitro half-life than Ligand B (-15.46). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.21) has a lower P-gp efflux liability than Ligand B (0.08). This suggests better bioavailability for Ligand A.
15. **Binding Affinity:** Ligand B (-6.9 kcal/mol) has a stronger binding affinity than Ligand A (-5.6 kcal/mol). This is a substantial difference (1.3 kcal/mol), and is a major factor.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand B excels in TPSA, Pgp, and *significantly* in binding affinity. Ligand A has better metabolic stability (Cl_mic, t1/2) and Pgp efflux. The affinity difference is large enough to outweigh the metabolic stability advantage of Ligand A.
**Conclusion:**
Despite Ligand A's better metabolic stability and Pgp profile, the significantly stronger binding affinity of Ligand B (-6.9 vs -5.6 kcal/mol) makes it the more promising candidate. The lower TPSA and better Caco-2 permeability of Ligand B also contribute to its favorability.
Output:
0
2025-04-17 17:58:45,048 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [373.446, 72.91, 1.645, 0, 5, 0.758, 53.625, 83.56, -4.237, -1.855, 0.498, 8.174, 13.233, 0.19, -6.2]
**Ligand B:** [347.415, 102.76, 0.886, 3, 5, 0.663, 25.94, 12.292, -5.34, -1.732, 0.048, 1.61, -21.815, 0.02, -6.2]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, Affinity, and BBB):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (347.415) is slightly preferred due to being a bit lower.
2. **TPSA:** Ligand A (72.91) is better than Ligand B (102.76). TPSA < 140 is good for oral absorption, and both are under, but A is closer to the optimal <90 for potential CNS effects (though ADRB2 isn't necessarily a CNS target).
3. **logP:** Ligand A (1.645) is better than Ligand B (0.886). Both are within the 1-3 range, but A is closer to the optimal range.
4. **HBD/HBA:** Ligand A (0 HBD, 5 HBA) is slightly better than Ligand B (3 HBD, 5 HBA). Lower HBD is generally preferred.
5. **QED:** Ligand A (0.758) is better than Ligand B (0.663), indicating a more drug-like profile.
6. **DILI:** Ligand A (53.625) is worse than Ligand B (25.94). B has a significantly lower DILI risk, which is a major advantage.
7. **BBB:** Ligand A (83.56) is much better than Ligand B (12.292). While not a primary concern for ADRB2, higher BBB is still a positive.
8. **Caco-2:** Ligand A (-4.237) is worse than Ligand B (-5.34). Lower values suggest poorer permeability.
9. **Solubility:** Both are very poor (-1.855 and -1.732). This is a concern for both, but not a deciding factor.
10. **hERG:** Both are very low (0.498 and 0.048), indicating low cardiotoxicity risk. B is slightly better.
11. **Cl_mic:** Ligand A (8.174) is worse than Ligand B (1.61). Lower clearance is preferred for metabolic stability, so B is better.
12. **t1/2:** Ligand A (13.233) is better than Ligand B (-21.815). A longer half-life is preferred.
13. **Pgp:** Ligand A (0.19) is better than Ligand B (0.02). Lower P-gp efflux is preferred.
14. **Affinity:** Both are equal (-6.2 kcal/mol).
15. **Overall:** Ligand A has advantages in BBB, QED, t1/2, and Pgp, while Ligand B excels in DILI and Cl_mic. The significantly lower DILI risk for Ligand B is a critical factor. While Ligand A has a slightly better half-life, the potential for liver injury with Ligand A is a major concern.
Considering the balance, the lower DILI risk of Ligand B outweighs the advantages of Ligand A.
Output:
0
2025-04-17 17:58:45,048 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (392.86 and 383.19 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (56.75) is significantly better than Ligand B (81.91). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (1.81) is optimal, while Ligand B (3.79) is approaching the upper limit. Higher logP can lead to off-target effects and solubility issues.
4. **HBD:** Both ligands have 0 HBD, which is acceptable.
5. **HBA:** Both ligands have 5 HBA, which is acceptable.
6. **QED:** Ligand A (0.784) has a considerably better QED score than Ligand B (0.431), indicating a more drug-like profile.
7. **DILI:** Ligand B (81.04) has a significantly higher DILI risk than Ligand A (52.42). This is a major concern.
8. **BBB:** Both ligands have reasonable BBB penetration (A: 80.42, B: 78.79), but this isn't a primary concern for a cardiovascular target.
9. **Caco-2:** Ligand A (-4.708) is better than Ligand B (-4.559), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-2.41) is significantly better than Ligand B (-5.755). Solubility is crucial for bioavailability.
11. **hERG:** Ligand A (0.445) has a lower hERG risk than Ligand B (0.71), which is favorable for avoiding cardiotoxicity.
12. **Cl_mic:** Ligand B (55.27) has a lower microsomal clearance than Ligand A (8.81), suggesting better metabolic stability.
13. **t1/2:** Ligand A (10.15) has a slightly longer half-life than Ligand B (8.71).
14. **Pgp:** Ligand B (0.503) has higher P-gp efflux than Ligand A (0.194), which is unfavorable.
15. **Binding Affinity:** Ligand B (-8.2 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.3 kcal/mol). This is a substantial advantage.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp efflux, and affinity are key. Ligand B has a better logP and significantly better affinity. However, its substantially higher DILI risk, poorer solubility, and higher Pgp efflux are major drawbacks. Ligand A, while having a weaker affinity, exhibits a much more balanced profile with better solubility, lower DILI risk, and lower Pgp efflux. The affinity difference, while significant (1.9 kcal/mol), can potentially be optimized in subsequent iterations of drug design. The safety and ADME properties of Ligand A are much more promising.
**Conclusion:**
Considering the overall balance of properties, particularly the significant safety concerns with Ligand B (high DILI), I believe Ligand A is the more viable drug candidate. While the affinity is lower, the other properties are more favorable and can be improved upon.
Output:
1
2025-04-17 17:58:45,048 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (341.455 Da) is well within the ideal range (200-500 Da). Ligand B (368.503 Da) is also acceptable. No clear advantage.
2. **TPSA:** Ligand A (57.5) is excellent, well below the 140 threshold for oral absorption and even favorable for potential CNS penetration. Ligand B (65.12) is still reasonable, but less optimal.
3. **logP:** Ligand A (2.218) is within the optimal range (1-3). Ligand B (1.241) is at the lower end, potentially impacting permeability. Ligand A has an advantage here.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable, below the 5 threshold. Ligand B is slightly better.
5. **HBA:** Ligand A (4) and Ligand B (5) are both acceptable, below the 10 threshold. Ligand A is slightly better.
6. **QED:** Ligand A (0.847) is excellent, indicating strong drug-likeness. Ligand B (0.768) is also good, but slightly lower. Ligand A has an advantage.
7. **DILI:** Ligand A (24.622) and Ligand B (28.306) are both low risk, well below the 40 threshold. No clear advantage.
8. **BBB:** Ligand B (78.945) is significantly better than Ligand A (51.997). While ADRB2 isn't *specifically* a CNS target, some peripheral ADRB2 activity can influence CNS pathways, and better BBB penetration isn't necessarily a negative.
9. **Caco-2:** Both Ligand A (-4.868) and Ligand B (-4.959) have negative values, which is unusual and suggests poor permeability. I'll assume these are log scale values, and lower is worse. Ligand A is slightly better.
10. **Solubility:** Ligand A (-2.124) and Ligand B (-1.31) are both poor. Solubility is a concern for both. Ligand B is slightly better.
11. **hERG:** Ligand A (0.844) and Ligand B (0.548) are both low risk. Ligand B is better.
12. **Cl_mic:** Ligand A (31.062) has lower clearance than Ligand B (43.452), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (68.92) has a much longer half-life than Ligand B (16.717). This is a major advantage for Ligand A, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.573) has lower P-gp efflux than Ligand B (0.013), suggesting better oral bioavailability and potentially better CNS exposure. Ligand A is better.
15. **Binding Affinity:** Ligand B (-5.4 kcal/mol) has a slightly better binding affinity than Ligand A (-6.3 kcal/mol). This is a notable advantage for Ligand B.
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B has a slight edge in affinity and BBB penetration, but Ligand A excels in logP, TPSA, Pgp, Cl_mic, and t1/2. The metabolic stability (Cl_mic) and half-life (t1/2) are particularly important for a GPCR target, as sustained signaling is often desired. The better TPSA and logP of Ligand A also suggest better overall pharmacokinetic properties.
**Overall Assessment:**
While Ligand B has a slightly better binding affinity, Ligand A demonstrates a superior balance of properties, particularly regarding ADME characteristics critical for GPCR drug development. The improved metabolic stability, longer half-life, and better permeability predictions (based on TPSA and logP) outweigh the small difference in binding affinity.
Output:
1
2025-04-17 17:58:45,048 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (370.47 Da and 354.50 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (89.9) is better than Ligand B (104.53). For a cardiovascular GPCR, TPSA under 140 is acceptable, but lower is preferred for good absorption.
**3. logP:** Ligand A (2.473) is optimal (1-3 range). Ligand B (0.631) is a bit low, potentially hindering membrane permeability.
**4. H-Bond Donors:** Ligand A (1) is better than Ligand B (3). Fewer HBDs generally improve permeability.
**5. H-Bond Acceptors:** Ligand A (6) is better than Ligand B (4).
**6. QED:** Ligand A (0.742) is better than Ligand B (0.594), indicating a more drug-like profile.
**7. DILI:** Ligand A (45.522) is better than Ligand B (6.049). Both are good, but Ligand B is significantly lower risk.
**8. BBB:** Ligand A (71.578) is better than Ligand B (64.211). While not a CNS target, some BBB penetration can be beneficial for distribution.
**9. Caco-2 Permeability:** Ligand A (-4.508) is better than Ligand B (-5.62). Higher (less negative) values indicate better permeability.
**10. Aqueous Solubility:** Ligand A (-3.175) is better than Ligand B (-1.803). Higher values are preferred.
**11. hERG Inhibition:** Ligand A (0.261) is better than Ligand B (0.169). Both are very low risk, but A is slightly better.
**12. Microsomal Clearance:** Ligand A (45.656) is worse than Ligand B (1.299). Ligand B has much lower clearance, indicating better metabolic stability.
**13. In vitro Half-Life:** Ligand A (5.107) is worse than Ligand B (-29.99). Ligand B has a much longer half-life.
**14. P-gp Efflux:** Ligand A (0.561) is better than Ligand B (0.001). Lower efflux is preferred.
**15. Binding Affinity:** Both ligands have very similar binding affinities (-6.2 kcal/mol and -6.4 kcal/mol). The difference is negligible.
**GPCR-Specific Priorities:** For ADRB2 (a cardiovascular GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A excels in logP, TPSA, and Pgp. Ligand B excels in metabolic stability (Cl_mic and t1/2).
**Overall Assessment:**
Ligand A has a more favorable overall profile, particularly regarding permeability (logP, TPSA, Caco-2) and drug-likeness (QED). While Ligand B has superior metabolic stability, the difference in binding affinity is minimal, and the advantages of Ligand A in permeability and drug-likeness outweigh the metabolic concerns. The slightly better DILI and hERG profiles of Ligand A also contribute to its preference.
Output:
1
2025-04-17 17:58:45,048 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
The ADRB2 receptor is a GPCR, so the priorities are logP, Pgp, TPSA, affinity, and BBB. Let's break down the comparison:
1. **Molecular Weight:** Both ligands (355.5 and 350.4 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (36.44) is significantly better than Ligand B (81.01). A TPSA under 140 is good for oral absorption, and lower is generally preferred for GPCRs. Ligand B's TPSA is quite high, potentially hindering permeability.
3. **logP:** Ligand A (3.115) is within the optimal 1-3 range. Ligand B (1.703) is on the lower end, potentially leading to permeability issues.
4. **H-Bond Donors:** Both have acceptable HBD counts (0 for A, 1 for B).
5. **H-Bond Acceptors:** Both have acceptable HBA counts (4 for A, 5 for B).
6. **QED:** Both ligands have the same QED score (0.845), indicating good drug-likeness.
7. **DILI:** Ligand A (27.6%) has a lower DILI risk than Ligand B (37.7%). Both are below the concerning 60% threshold, but A is preferable.
8. **BBB:** Ligand A (74.292%) has a better BBB penetration score than Ligand B (63.94%). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant, and higher BBB is generally favorable.
9. **Caco-2:** Ligand A (-5.085) is slightly better than Ligand B (-4.672), indicating potentially better intestinal absorption.
10. **Solubility:** Both have similar and poor solubility scores (-2.52 and -2.304). This is a potential concern for both, but not a deciding factor.
11. **hERG:** Ligand A (0.803) has a lower hERG risk than Ligand B (0.238). This is a significant advantage for Ligand A, minimizing cardiotoxicity concerns.
12. **Cl_mic:** Ligand A (51.582) has a lower microsomal clearance than Ligand B (42.224), suggesting better metabolic stability.
13. **t1/2:** Ligand B (63.909) has a significantly longer in vitro half-life than Ligand A (-14.904). This is a strong point in favor of Ligand B.
14. **Pgp:** Ligand A (0.602) has a lower P-gp efflux liability than Ligand B (0.071). Lower Pgp efflux is desirable for better bioavailability.
15. **Binding Affinity:** Ligand A (-6.9 kcal/mol) has a slightly better binding affinity than Ligand B (-6.3 kcal/mol). While the difference is not huge, it's enough to consider, especially given the other favorable properties of A.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical ADME properties (TPSA, logP, DILI, BBB, hERG, Cl_mic, Pgp) and has a slightly better binding affinity. While Ligand B has a longer half-life, the other drawbacks, particularly the high TPSA and lower hERG safety, make it less attractive. The combination of better predicted permeability, safety, and metabolic stability makes Ligand A the more promising candidate.
**Output:**
1
2025-04-17 17:58:45,049 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (354.43 and 349.39 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (105.48) is better than Ligand B (122.14). For a cardiovascular GPCR, keeping TPSA lower is favorable for permeability, though both are acceptable.
3. **logP:** Ligand A (1.501) is better than Ligand B (0.72). Both are within the optimal 1-3 range, but Ligand A is closer to the sweet spot.
4. **HBD:** Ligand A (4) is slightly better than Ligand B (3). Both are within the acceptable limit of <=5.
5. **HBA:** Ligand B (6) is better than Ligand A (5). Both are within the acceptable limit of <=10.
6. **QED:** Ligand B (0.613) is better than Ligand A (0.418). Ligand B has a more drug-like profile.
7. **DILI:** Ligand A (52.152) is significantly better than Ligand B (77.898). Lower DILI risk is crucial.
8. **BBB:** Ligand A (68.321) is better than Ligand B (41.218). While ADRB2 isn't strictly a CNS target, some brain penetration can lead to off-target effects, and it's good to have a moderate value.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.165 and -5.637) which is unusual and suggests poor permeability.
10. **Solubility:** Ligand A (-2.92) is better than Ligand B (-2.015). Both are poor, but A is less poor.
11. **hERG:** Ligand A (0.74) is better than Ligand B (0.12). Lower hERG inhibition is critical for cardiovascular safety.
12. **Cl_mic:** Ligand A (44.845) is significantly better than Ligand B (11.024). Lower clearance indicates better metabolic stability.
13. **t1/2:** Ligand B (10.667) is much better than Ligand A (0.745). A longer half-life is generally desirable.
14. **Pgp:** Ligand A (0.063) is better than Ligand B (0.027). Lower P-gp efflux is preferred.
15. **Binding Affinity:** Ligand B (-7.7 kcal/mol) is significantly better than Ligand A (-6.6 kcal/mol). This is a substantial difference in potency.
**Overall Assessment:**
Ligand B has a significantly better binding affinity (-7.7 vs -6.6 kcal/mol), and a much better half-life. However, it suffers from higher DILI risk, lower BBB penetration, and worse metabolic stability. Ligand A has a much better safety profile (DILI, hERG), better metabolic stability, and acceptable BBB. The affinity difference is significant, but the safety and metabolic concerns with Ligand B are substantial. Given the cardiovascular target, safety is paramount. While the Caco-2 values are concerning for both, the other properties of Ligand A make it the more viable candidate.
Output:
1
2025-04-17 17:58:45,049 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
We are targeting ADRB2, a GPCR. Therefore, priorities are logP, Pgp, TPSA, affinity, and BBB. Let's break down each ligand against these and other important parameters:
* **Molecular Weight:** Both ligands are within the ideal range (200-500 Da).
* **TPSA:** Ligand A (90.9) is slightly higher than Ligand B (58.64). Ligand B is better here, being closer to the optimal <90 for potential CNS penetration, though CNS targeting isn't explicitly stated.
* **logP:** Ligand B (3.383) is higher than Ligand A (0.517). This is a significant advantage for Ligand B, as logP values between 1-3 are preferred for good absorption and distribution. Ligand A's low logP raises concerns about permeability.
* **H-Bond Donors/Acceptors:** Ligand A has 3 HBD and 5 HBA, while Ligand B has 1 HBD and 3 HBA. Both are within acceptable ranges.
* **QED:** Both ligands have reasonable QED scores (0.496 and 0.545), indicating acceptable drug-likeness.
* **DILI:** Ligand A (1.667) has a much lower DILI risk than Ligand B (41.101). This is a major advantage for Ligand A.
* **BBB:** Ligand B (90.074) has a significantly higher BBB penetration potential than Ligand A (56.611). While not a primary focus for ADRB2 (cardiovascular target), higher BBB is generally favorable.
* **Caco-2 Permeability:** Ligand A (-5.106) has a worse Caco-2 permeability than Ligand B (-4.959).
* **Aqueous Solubility:** Ligand A (-0.612) has slightly better aqueous solubility than Ligand B (-3.507).
* **hERG:** Ligand A (0.365) has a lower hERG inhibition liability than Ligand B (0.661), which is a positive.
* **Microsomal Clearance:** Ligand A (-9.165) has *much* lower microsomal clearance than Ligand B (20.43). This suggests significantly better metabolic stability for Ligand A.
* **In vitro Half-Life:** Ligand A (-26.577) has a longer in vitro half-life than Ligand B (-21.092).
* **P-gp Efflux:** Ligand A (0.01) has a much lower P-gp efflux liability than Ligand B (0.084). This is a significant advantage for Ligand A, improving oral bioavailability.
* **Binding Affinity:** Both ligands have very similar binding affinities (-6.6 kcal/mol and -6.8 kcal/mol). The difference is negligible.
**Overall Assessment:**
Ligand A presents a better overall profile. While Ligand B has a better logP and BBB, Ligand A excels in crucial ADME properties: lower DILI risk, significantly better metabolic stability (lower Cl_mic and longer t1/2), lower P-gp efflux, and a slightly better hERG profile. The similar binding affinities mean these ADME advantages outweigh the slightly better logP of Ligand B. The low logP of Ligand A is a concern, but can potentially be addressed through formulation strategies.
Output:
1
2025-04-17 17:58:45,049 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (345.407 & 350.463 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (95.42) is significantly better than Ligand A (117.59). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (1.762) is within the optimal 1-3 range, while Ligand A (0.19) is quite low. This is a significant advantage for Ligand B as it will likely have better membrane permeability.
4. **HBD:** Ligand A (3) and Ligand B (2) are both acceptable, below the threshold of 5.
5. **HBA:** Ligand A (6) and Ligand B (5) are both acceptable, below the threshold of 10.
6. **QED:** Both ligands have good QED scores (0.631 and 0.67), indicating good drug-like properties.
7. **DILI:** Ligand B (32.377) has a much lower DILI risk than Ligand A (54.75). This is a crucial advantage.
8. **BBB:** Ligand B (50.446) is higher than Ligand A (43.117), but neither are particularly high. Not a major factor for a cardiovascular target.
9. **Caco-2:** Ligand A (-5.715) is better than Ligand B (-4.876), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-1.881) is better than Ligand B (-1.455), which is a slight advantage.
11. **hERG:** Ligand A (0.08) has a lower hERG risk than Ligand B (0.291), which is a positive.
12. **Cl_mic:** Ligand A (-16.471) has significantly lower microsomal clearance than Ligand B (36.031), suggesting better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand B (19.34) has a much longer in vitro half-life than Ligand A (7.29). This is a significant advantage.
14. **Pgp:** Ligand A (0.018) has a much lower P-gp efflux liability than Ligand B (0.054), suggesting better bioavailability.
15. **Binding Affinity:** Ligand A (-7.8) has a slightly better binding affinity than Ligand B (-5.2). While important, the difference of 2.6 kcal/mol can be overcome by other favorable ADME properties.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP and has acceptable TPSA and Pgp values. Ligand A has a slightly better affinity, but the significant advantages of Ligand B in logP, DILI, and t1/2 outweigh this.
**Overall Assessment:**
Ligand B presents a more balanced profile with better predicted absorption (logP), lower toxicity (DILI), and longer duration of action (t1/2). While Ligand A has a slight edge in affinity and Pgp efflux, the other ADME properties of Ligand B are more favorable for overall drug development.
Output:
0
2025-04-17 17:58:45,049 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [352.431, 84.94, 0.68, 1, 5, 0.487, 34.277, 56.611, -4.852, -1.027, 0.061, 21.138, -4.309, 0.016, -6.9]
**Ligand B:** [344.455, 62.55, 3.395, 1, 3, 0.609, 45.328, 64.482, -4.711, -3.486, 0.681, 79.926, 40.012, 0.764, -5.7]
Here's a breakdown, prioritizing GPCR characteristics (logP, TPSA, Pgp, BBB, Affinity):
1. **Molecular Weight:** Both are within the ideal range (200-500 Da). Ligand B (344.455) is slightly lower, which is generally favorable.
2. **TPSA:** Ligand A (84.94) is better than Ligand B (62.55). Both are below 140, but Ligand B is closer to the optimal range for good absorption.
3. **logP:** Ligand B (3.395) is better. It's within the optimal 1-3 range, while Ligand A (0.68) is quite low, potentially hindering membrane permeability.
4. **H-Bond Donors:** Both have 1 HBD, which is good.
5. **H-Bond Acceptors:** Ligand A has 5, Ligand B has 3. Ligand B is better here.
6. **QED:** Ligand B (0.609) is better than Ligand A (0.487), indicating a more drug-like profile.
7. **DILI:** Ligand A (34.277) has a significantly lower DILI risk than Ligand B (45.328), a major advantage.
8. **BBB:** Ligand B (64.482) has better BBB penetration than Ligand A (56.611). While ADRB2 isn't necessarily a CNS target, some peripheral distribution is still desired.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual. I will interpret these as very low permeability.
10. **Solubility:** Ligand A (-1.027) has better solubility than Ligand B (-3.486).
11. **hERG:** Ligand A (0.061) has a much lower hERG risk than Ligand B (0.681), a critical safety factor.
12. **Cl_mic:** Ligand A (21.138) has a lower microsomal clearance, suggesting better metabolic stability than Ligand B (79.926).
13. **t1/2:** Ligand B (40.012) has a significantly longer in vitro half-life than Ligand A (-4.309).
14. **Pgp:** Ligand A (0.016) has lower P-gp efflux, which is beneficial for bioavailability. Ligand B (0.764) has higher efflux.
15. **Affinity:** Ligand A (-6.9) has a slightly better binding affinity than Ligand B (-5.7). However, the difference is not substantial enough to outweigh other factors.
**Overall Assessment:**
Ligand A has significant advantages in safety (DILI, hERG) and metabolic stability (Cl_mic). It also has better solubility and Pgp efflux. While Ligand B has better logP and half-life, the lower logP of Ligand A is concerning, but the other advantages of Ligand A are more important for this target. The affinity difference is not large enough to overcome the ADME/Tox benefits of Ligand A.
Output:
1
2025-04-17 17:58:45,049 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (346.475 Da and 349.406 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (67.23) is better than Ligand B (69.72), both are below the 140 A^2 threshold for good oral absorption.
**3. logP:** Ligand A (2.764) is slightly better than Ligand B (1.332). Both are within the optimal 1-3 range, but Ligand B is closer to the lower bound which could potentially impact permeability.
**4. H-Bond Donors:** Both ligands have 1 HBD, which is acceptable.
**5. H-Bond Acceptors:** Ligand A has 4 HBAs, and Ligand B has 3. Both are within the acceptable range of <=10.
**6. QED:** Both ligands have very similar QED values (0.891 and 0.895), indicating good drug-likeness.
**7. DILI:** Ligand A (30.322) has a significantly lower DILI risk than Ligand B (46.917). This is a major advantage for Ligand A.
**8. BBB:** Both ligands have good BBB penetration (70.415 and 72.78), which is good, but not critical for a cardiovascular target.
**9. Caco-2 Permeability:** Ligand A (-4.424) is better than Ligand B (-4.621).
**10. Aqueous Solubility:** Ligand A (-3.244) is better than Ligand B (-1.67).
**11. hERG:** Both ligands have low hERG inhibition risk (0.259 and 0.318).
**12. Microsomal Clearance:** Ligand A (37.497) has higher microsomal clearance than Ligand B (14.305), meaning it is less metabolically stable. This is a drawback for Ligand A.
**13. In vitro Half-Life:** Ligand B (-13.716) has a significantly longer in vitro half-life than Ligand A (23.639). This is a significant advantage for Ligand B.
**14. P-gp Efflux:** Both ligands have similar P-gp efflux liability (0.028 and 0.054).
**15. Binding Affinity:** Ligand B (-7.1 kcal/mol) has a slightly better binding affinity than Ligand A (-6.0 kcal/mol). This is a substantial advantage for Ligand B.
**GPCR-Specific Considerations:** For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. While both ligands are reasonable in these areas, Ligand B has a better binding affinity and a more favorable half-life. The lower DILI risk of Ligand A is attractive, but the significantly better affinity and half-life of Ligand B outweigh this benefit.
**Conclusion:**
Considering the balance of properties, particularly the superior binding affinity and half-life of Ligand B, I believe it is the more promising drug candidate.
0
2025-04-17 17:58:45,049 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (348.447 Da and 351.535 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (84.42) is better than Ligand B (43.86). For a cardiovascular GPCR, lower TPSA is generally preferred as it aids membrane permeability.
**3. logP:** Ligand B (2.914) is slightly better than Ligand A (1.33), falling closer to the optimal 1-3 range. Ligand A is a little low, potentially hindering permeation.
**4. H-Bond Donors:** Ligand A (1) is better than Ligand B (0). While both are acceptable, fewer HBDs generally improve permeability.
**5. H-Bond Acceptors:** Ligand A (5) is better than Ligand B (3). Similar to HBDs, fewer HBAs are generally preferred.
**6. QED:** Ligand A (0.803) is significantly better than Ligand B (0.474), indicating a more drug-like profile.
**7. DILI:** Ligand B (10.934) is *much* better than Ligand A (51.958). This is a critical advantage for Ligand B, as minimizing liver toxicity is paramount.
**8. BBB:** Ligand B (84.878) is better than Ligand A (50.33). While not a CNS target, some degree of BBB penetration can influence off-target effects and distribution.
**9. Caco-2 Permeability:** Ligand A (-5.257) is better than Ligand B (-4.406). Higher Caco-2 values indicate better intestinal absorption.
**10. Aqueous Solubility:** Ligand A (-0.796) is better than Ligand B (-1.501). Solubility is important for formulation and bioavailability.
**11. hERG Inhibition:** Ligand A (0.118) is better than Ligand B (0.621). Lower hERG inhibition is crucial to avoid cardiotoxicity.
**12. Microsomal Clearance:** Ligand A (23.412) is significantly better than Ligand B (79.046). Lower clearance suggests better metabolic stability.
**13. In vitro Half-Life:** Ligand A (13.199) is better than Ligand B (4.61). A longer half-life is generally desirable.
**14. P-gp Efflux:** Ligand A (0.007) is *much* better than Ligand B (0.127). Lower P-gp efflux improves bioavailability.
**15. Binding Affinity:** Ligand B (-7.7) is significantly better than Ligand A (-6.9). This is a 1.5 kcal/mol advantage, which is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand B has a significantly better binding affinity and a much lower DILI risk. These are the most important factors. While Ligand A has advantages in several ADME properties (TPSA, QED, solubility, hERG, clearance, half-life, P-gp efflux), the superior affinity and safety profile of Ligand B are more critical for a GPCR target. The slightly higher logP of Ligand B is also beneficial.
Output:
0
2025-04-17 17:58:45,049 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [345.487, 52.65, 1.648, 1, 3, 0.788, 9.461, 89.066, -4.986, -2.053, 0.477, 18.911, -1.926, 0.098, -8.2]
**Ligand B:** [361.471, 81.93, 3.15, 1, 8, 0.603, 70.919, 73.711, -4.992, -3.602, 0.149, 100.625, -0.837, 0.463, -5.8]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, BBB, and affinity are key):
1. **MW:** Both are within the ideal 200-500 Da range. A (345.487) is slightly preferred.
2. **TPSA:** A (52.65) is significantly better than B (81.93). Lower TPSA generally means better permeability, crucial for GPCRs.
3. **logP:** A (1.648) is good, within the optimal 1-3 range. B (3.15) is at the higher end, potentially leading to solubility issues or off-target interactions.
4. **HBD/HBA:** Both have 1 HBD, which is good. A has 3 HBA, while B has 8. A is favored here.
5. **QED:** A (0.788) is better than B (0.603), indicating a more drug-like profile.
6. **DILI:** A (9.461) is *much* better than B (70.919). This is a major advantage for A.
7. **BBB:** A (89.066) is better than B (73.711), although both are reasonably good. For a cardiovascular GPCR, BBB isn't *as* critical as for CNS targets, but still a positive.
8. **Caco-2:** Both are negative, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
9. **Solubility:** Both are negative, indicating poor solubility. B is worse (-3.602 vs -2.053).
10. **hERG:** A (0.477) is better than B (0.149), indicating lower cardiotoxicity risk.
11. **Cl_mic:** A (18.911) is significantly better than B (100.625). Lower clearance means better metabolic stability.
12. **t1/2:** A (-1.926) is better than B (-0.837), indicating a longer half-life.
13. **Pgp:** A (0.098) is much better than B (0.463). Lower P-gp efflux is desirable for better bioavailability.
14. **Affinity:** A (-8.2 kcal/mol) is significantly stronger than B (-5.8 kcal/mol). This is a substantial difference and a major driver in the decision.
**Overall Assessment:**
Ligand A is clearly superior. It has a better TPSA, logP, QED, DILI risk, BBB, hERG, metabolic stability (Cl_mic and t1/2), P-gp efflux, and *significantly* better binding affinity. While both have solubility and Caco-2 issues, A is better on solubility. The substantial affinity advantage of A, combined with the much lower DILI risk and better ADME properties, makes it the far more promising candidate.
Output:
1
2025-04-17 17:58:45,049 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [342.443, 59.39, 3.18, 1, 4, 0.877, 36.293, 72.237, -4.735, -3.821, 0.881, 76.184, 8.195, 0.526, -0.5]
**Ligand B:** [352.387, 97.33, -1.479, 2, 6, 0.586, 36.603, 40.364, -4.894, -1.259, 0.152, -12.041, -0.996, 0.01, -5.5]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). A (342.443) is slightly preferred.
2. **TPSA:** A (59.39) is excellent, well below 140 and good for oral absorption. B (97.33) is higher, but still acceptable, though less ideal.
3. **logP:** A (3.18) is optimal. B (-1.479) is significantly lower and could cause permeability issues.
4. **HBD:** A (1) is good. B (2) is acceptable.
5. **HBA:** A (4) is good. B (6) is acceptable.
6. **QED:** A (0.877) is excellent, indicating strong drug-likeness. B (0.586) is acceptable, but less favorable.
7. **DILI:** Both are similar and low (around 36%), indicating low liver injury risk.
8. **BBB:** A (72.237) is good, suggesting reasonable potential for CNS penetration if desired. B (40.364) is low, indicating poor BBB penetration.
9. **Caco-2:** Both are negative, indicating good permeability.
10. **Solubility:** Both are negative, indicating good solubility.
11. **hERG:** A (0.881) is better than B (0.152), indicating lower cardiotoxicity risk.
12. **Cl_mic:** B (-12.041) is significantly better (lower clearance), indicating much greater metabolic stability. A (76.184) is high, suggesting rapid metabolism.
13. **t1/2:** A (8.195) is better than B (-0.996), indicating a longer half-life.
14. **Pgp:** A (0.526) is better than B (0.01), indicating lower P-gp efflux.
15. **Affinity:** B (-5.5) is significantly better than A (-0.5), indicating a much stronger binding affinity. This is a substantial advantage.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, Pgp, TPSA, and affinity. Ligand B excels in affinity, but suffers from a poor logP and Pgp. Ligand A has a better logP and Pgp, but its affinity is very weak. The difference in affinity (-5.5 vs -0.5) is a 5 kcal/mol difference, which is a very large advantage. While the ADME properties of ligand A are better, the binding affinity difference is so substantial that it outweighs these concerns. It is more likely that a medicinal chemist could optimize the ADME properties of ligand B while maintaining its high affinity.
**Conclusion:**
Despite the better ADME profile of Ligand A, the significantly stronger binding affinity of Ligand B makes it the more promising candidate. The affinity difference is large enough to warrant further optimization of B's ADME properties.
Output:
0
2025-04-17 17:58:45,049 - INFO - Batch 4 complete. Total preferences: 64
2025-04-17 17:58:45,049 - INFO - Processing batch 5/512...
2025-04-17 17:59:32,608 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's analyze each ligand against the provided guidelines, keeping in mind ADRB2 is a GPCR, so logP, TPSA, Pgp, BBB, and affinity are key.
* **Molecular Weight:** Both ligands (355.236 and 352.362 Da) fall comfortably within the ideal 200-500 Da range.
* **TPSA:** Ligand A (120.25) is slightly above the preferred <140, but acceptable. Ligand B (90.31) is excellent, well below 100, suggesting good permeability.
* **logP:** Ligand A (1.642) is within the optimal 1-3 range. Ligand B (0.213) is quite low, potentially hindering membrane permeability.
* **H-Bond Donors/Acceptors:** Ligand A (1 HBD, 8 HBA) and Ligand B (2 HBD, 5 HBA) both have reasonable numbers, within the guidelines.
* **QED:** Ligand B (0.809) has a significantly better QED score than Ligand A (0.563), indicating a more drug-like profile.
* **DILI:** Ligand A (98.216) has a very high DILI risk, which is a major concern. Ligand B (22.8) has a very low DILI risk, a significant advantage.
* **BBB:** Ligand A (73.866) has a moderate BBB penetration, while Ligand B (43.311) is lower. While ADRB2 isn't necessarily a CNS target, some degree of BBB penetration can be beneficial for overall distribution.
* **Caco-2 Permeability:** Ligand A (-5.141) and Ligand B (-4.812) both have negative values, which is unusual and suggests poor permeability. The values are similar, so this isn't a major differentiator.
* **Aqueous Solubility:** Ligand A (-3.8) and Ligand B (-1.258) both have poor solubility. Ligand B is slightly better.
* **hERG Inhibition:** Ligand A (0.368) has a low hERG risk, which is good. Ligand B (0.253) is even lower, a slight advantage.
* **Microsomal Clearance:** Ligand A (22.159) has moderate clearance, while Ligand B (-8.03) has negative clearance, which is very favorable, suggesting high metabolic stability.
* **In vitro Half-Life:** Ligand A (60.692) has a reasonable half-life. Ligand B (-2.288) has a negative half-life, which is not possible and likely an error in the data, but suggests very high stability.
* **P-gp Efflux:** Ligand A (0.24) and Ligand B (0.018) both have low P-gp efflux, which is good. Ligand B is slightly better.
* **Binding Affinity:** Ligand A (-7.9 kcal/mol) has a slightly better binding affinity than Ligand B (-5.5 kcal/mol). This is a 2.4 kcal/mol difference, which is substantial.
**Overall Assessment:**
Despite Ligand A's slightly better binding affinity, the significantly higher DILI risk is a major red flag. Ligand B exhibits a much more favorable safety profile (low DILI, low hERG), better QED, and potentially superior metabolic stability (negative Cl_mic and t1/2). While its logP is low, the other advantages outweigh this drawback, especially considering the severity of the DILI risk associated with Ligand A. The negative values for half-life and clearance are suspect, but even if they are errors, the trend is favorable.
**Output:**
0
2025-04-17 17:59:32,608 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (362.499 Da) is slightly higher than Ligand B (348.447 Da), but both are acceptable.
2. **TPSA:** Ligand A (66.4) is significantly better than Ligand B (100.27). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is approaching a level that could hinder oral absorption.
3. **logP:** Ligand A (2.351) is within the optimal range (1-3). Ligand B (0.818) is a bit low, which could impact membrane permeability.
4. **HBD:** Ligand A (0) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (6). Lower HBA is generally better for permeability.
6. **QED:** Both ligands have similar QED values (0.575 and 0.574), indicating comparable drug-likeness.
7. **DILI:** Ligand A (31.02) has a much lower DILI risk than Ligand B (17.216). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (74.176) has a much better BBB penetration potential than Ligand B (40.52). While ADRB2 isn't exclusively a CNS target, some cardiovascular effects are mediated through central pathways, and better BBB penetration isn't necessarily a negative.
9. **Caco-2:** Ligand A (-4.821) is better than Ligand B (-5.191). Both are negative, indicating good permeability.
10. **Solubility:** Ligand A (-1.946) is better than Ligand B (-1.401). Both are negative, indicating good solubility.
11. **hERG:** Ligand A (0.415) has a lower hERG risk than Ligand B (0.033). This is a critical advantage for cardiovascular drugs.
12. **Cl_mic:** Ligand A (33.808) has a higher clearance than Ligand B (15.978). This is a disadvantage for Ligand A, indicating faster metabolism.
13. **t1/2:** Ligand B (10.435) has a longer half-life than Ligand A (-9.24). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.474) has a lower Pgp efflux liability than Ligand B (0.047). This is a positive for Ligand A, suggesting better bioavailability.
15. **Affinity:** Ligand A (-7.1 kcal/mol) has a slightly better binding affinity than Ligand B (-5.8 kcal/mol). This difference in affinity is substantial, and can outweigh some of the ADME drawbacks of Ligand A.
**Overall Assessment:**
Ligand A is the stronger candidate. While Ligand B has a better half-life and lower clearance, Ligand A excels in critical areas for a GPCR drug candidate: TPSA, logP, DILI risk, BBB penetration, hERG risk, and most importantly, binding affinity. The 1.3 kcal/mol difference in binding affinity is significant. The slightly higher clearance of Ligand A could potentially be addressed through structural modifications during lead optimization.
Output:
1
2025-04-17 17:59:32,608 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (a cardiovascular GPCR) drug candidates.
**Ligand A:** [350.459, 84.5, 1.777, 2, 4, 0.715, 31.989, 56.495, -4.771, -2.528, 0.253, 60.425, -0.763, 0.118, -5.5]
**Ligand B:** [358.463, 49.85, 1.702, 0, 4, 0.608, 39.434, 74.564, -4.683, -2.875, 0.58, 45.493, 0.729, 0.486, -5.7]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal 200-500 Da range. A (350.459) is slightly preferred.
2. **TPSA:** A (84.5) is higher than B (49.85). B is significantly better here, falling well below the 140 threshold for oral absorption and closer to the ideal for GPCRs.
3. **logP:** Both are good (around 1.7), within the 1-3 range. B (1.702) is marginally better.
4. **HBD:** A (2) is slightly better than B (0). Having some HBD can aid solubility.
5. **HBA:** Both have 4 HBA, which is acceptable.
6. **QED:** A (0.715) is better than B (0.608), indicating a more drug-like profile.
7. **DILI:** Both are reasonably low, but A (31.989) is better than B (39.434).
8. **BBB:** B (74.564) is significantly better than A (56.495). While not a primary concern for a cardiovascular target, higher BBB is generally a positive.
9. **Caco-2:** Both are negative, indicating poor permeability. A (-4.771) is slightly worse than B (-4.683).
10. **Solubility:** Both are negative, indicating poor solubility. A (-2.528) is slightly worse than B (-2.875).
11. **hERG:** A (0.253) is better than B (0.58), indicating lower cardiotoxicity risk. This is *very* important for a cardiovascular target.
12. **Cl_mic:** B (45.493) has lower clearance than A (60.425), suggesting better metabolic stability.
13. **t1/2:** B (0.729) has a slightly longer half-life than A (-0.763).
14. **Pgp:** A (0.118) is better than B (0.486), suggesting lower efflux.
15. **Affinity:** B (-5.7) has a slightly better binding affinity than A (-5.5). While the difference is small, it's still a factor.
**Overall Assessment:**
Ligand B has a clear advantage in TPSA, BBB, metabolic stability (Cl_mic and t1/2), and binding affinity. Ligand A has better QED, DILI, hERG, and Pgp. However, the hERG risk is critical for a cardiovascular drug, and B is significantly better in that regard. The slightly better affinity of B also tips the balance. The lower TPSA of B is also a significant advantage. While A has a slightly better QED, the other benefits of B outweigh this.
Therefore, I prefer Ligand B.
0
2025-04-17 17:59:32,609 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for the ADRB2, a cardiovascular GPCR. Therefore, the priorities are logP, Pgp, TPSA, and affinity, with metabolic stability and solubility also being important.
Let's compare the ligands property by property:
1. **MW:** Both ligands (354.491 and 346.479 Da) are within the ideal 200-500 Da range.
2. **TPSA:** Both ligands (67.87 and 68.1) are below the 140 A^2 threshold for good oral absorption, which is good.
3. **logP:** Both ligands have good logP values (1.827 and 1.305), falling within the 1-3 range. Ligand B is slightly better.
4. **HBD:** Both have 1 HBD, which is acceptable.
5. **HBA:** Ligand A has 4 HBA, while Ligand B has 7. Ligand A is preferable here.
6. **QED:** Both have good QED scores (0.686 and 0.803), indicating good drug-likeness. Ligand B is slightly better.
7. **DILI:** Ligand A has a DILI risk of 15.2%, while Ligand B has 9.616%. Ligand B is significantly better, being lower risk.
8. **BBB:** Ligand A has 74.37% BBB penetration, while Ligand B has 83.676%. Ligand B is better, though BBB isn't *critical* for a cardiovascular target.
9. **Caco-2:** Ligand A (-4.435) and Ligand B (-5.428) both have negative values, which is unusual and suggests poor permeability. Ligand B is slightly worse.
10. **Solubility:** Ligand A (-1.656) and Ligand B (-1.359) both have negative solubility values, suggesting poor solubility. Ligand B is slightly better.
11. **hERG:** Both have very low hERG inhibition risk (0.343 and 0.327).
12. **Cl_mic:** Ligand A has a Cl_mic of 48.392, while Ligand B has -1.905. A negative value is unusual and suggests *very* high metabolic stability, making Ligand B significantly better.
13. **t1/2:** Ligand A has 1.613 hours, while Ligand B has 11.19 hours. Ligand B is significantly better.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.035 and 0.034).
15. **Affinity:** Ligand A has -7.3 kcal/mol, while Ligand B has -7.0 kcal/mol. Ligand A has a slightly better binding affinity.
**Overall Assessment:**
Ligand B consistently outperforms Ligand A in key ADME properties (DILI, BBB, Cl_mic, t1/2) and has a slightly better logP. While Ligand A has a marginally better binding affinity, the ADME profile of Ligand B is far more favorable, especially the significantly improved metabolic stability and reduced DILI risk. For a cardiovascular target, a slightly lower affinity can be tolerated if the drug is metabolically stable and safe.
Output:
0
2025-04-17 17:59:32,609 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A: [368.849, 59.29, 4.287, 1, 5, 0.584, 90.229, 65.374, -5.058, -4.735, 0.686, 72.304, 51.612, 0.676, -3.2]**
**Ligand B: [359.447, 64.63, 4.34, 1, 5, 0.588, 82.125, 57.154, -4.772, -5.843, 0.722, 114.822, 1.045, 0.343, -7.6]**
Here's a breakdown, considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (359.447) is slightly lower, which is generally favorable.
2. **TPSA:** Ligand A (59.29) is better than Ligand B (64.63), being closer to the <140 threshold for good absorption.
3. **logP:** Both are good (around 4.3), falling within the optimal 1-3 range.
4. **HBD/HBA:** Both have 1 HBD and 5 HBA, which are acceptable.
5. **QED:** Both are similar (0.584 and 0.588), indicating good drug-like properties.
6. **DILI:** Ligand A (90.229) has a higher DILI risk than Ligand B (82.125). This is a significant drawback for Ligand A.
7. **BBB:** Ligand A (65.374) has better BBB penetration than Ligand B (57.154), but since this is a cardiovascular target, BBB penetration is not a primary concern.
8. **Caco-2:** Ligand A (-5.058) has worse Caco-2 permeability than Ligand B (-4.772).
9. **Solubility:** Ligand A (-4.735) has slightly better solubility than Ligand B (-5.843).
10. **hERG:** Both have low hERG inhibition risk (0.686 and 0.722).
11. **Cl_mic:** Ligand A (72.304) has a lower microsomal clearance, suggesting better metabolic stability than Ligand B (114.822).
12. **t1/2:** Ligand A (51.612) has a longer in vitro half-life than Ligand B (1.045), which is a strong advantage.
13. **Pgp:** Ligand A (0.676) has lower P-gp efflux than Ligand B (0.343), which is favorable for bioavailability.
14. **Affinity:** Ligand B (-7.6) has significantly stronger binding affinity than Ligand A (-3.2). This is a substantial advantage, exceeding the 1.5 kcal/mol threshold.
**Overall Assessment:**
While Ligand A has some advantages in metabolic stability (Cl_mic, t1/2) and P-gp efflux, the significantly stronger binding affinity of Ligand B (-7.6 vs -3.2 kcal/mol) is a decisive factor. The higher DILI risk for Ligand A is also concerning. The slightly lower Caco-2 permeability of Ligand B is less critical given the strong binding. For a GPCR, potency is paramount, and the affinity difference is large enough to outweigh the other drawbacks of Ligand B.
Output:
0
2025-04-17 17:59:32,609 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
The target is ADRB2, a GPCR. Therefore, I will prioritize logP, TPSA, Pgp efflux, BBB penetration, and binding affinity. Metabolic stability and solubility are also important, but slightly less so than the GPCR-specific parameters.
Let's compare the ligands property by property:
1. **MW:** Both ligands (349.431 and 354.338 Da) fall within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (95.67) is better than Ligand B (130.4). Lower TPSA is preferred for better absorption, and Ligand B is approaching a less desirable range.
3. **logP:** Ligand A (1.705) is within the optimal range (1-3). Ligand B (-0.39) is below 1, which could hinder permeation. This is a significant negative for Ligand B.
4. **HBD:** Ligand A (2) is preferable to Ligand B (3).
5. **HBA:** Ligand A (5) is preferable to Ligand B (6).
6. **QED:** Both ligands have similar, acceptable QED values (0.523 and 0.572).
7. **DILI:** Ligand A (30.865) has a much lower DILI risk than Ligand B (58.395). This is a substantial advantage for Ligand A.
8. **BBB:** Ligand B (73.517) has better BBB penetration than Ligand A (46.336). While ADRB2 isn't necessarily a CNS target, some peripheral ADRB2 activity can be modulated by CNS effects, so this is a slight positive for Ligand B.
9. **Caco-2:** Ligand B (-5.433) has a slightly better Caco-2 value than Ligand A (-4.888), but both are negative and hard to interpret without knowing the scale.
10. **Solubility:** Ligand A (-1.529) has slightly better solubility than Ligand B (-2.408).
11. **hERG:** Both ligands have very low hERG risk (0.308 and 0.083).
12. **Cl_mic:** Ligand B (-5.831) has a much lower (better) microsomal clearance than Ligand A (27.453). This indicates better metabolic stability for Ligand B.
13. **t1/2:** Ligand A (-17.207) has a longer half-life than Ligand B (11.903). This is a positive for Ligand A.
14. **Pgp:** Ligand A (0.074) has lower P-gp efflux than Ligand B (0.01). Lower Pgp is better.
15. **Affinity:** Both ligands have very similar binding affinities (-6.1 and -6.3 kcal/mol). The difference is negligible.
**Overall Assessment:**
Ligand A is significantly better due to its superior logP, lower DILI risk, better TPSA, and longer half-life. While Ligand B has better BBB penetration and metabolic stability, the poor logP and higher DILI risk are major drawbacks. The slight advantage in metabolic stability doesn't outweigh the other significant issues with Ligand B.
**Output:**
1
2025-04-17 17:59:32,609 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (360.445) is slightly higher than Ligand B (343.391), but both are acceptable.
2. **TPSA:** Ligand A (58.64) is excellent, well below the 140 threshold for oral absorption and suitable for a GPCR. Ligand B (127.82) is higher, but still within a reasonable range, though less optimal.
3. **logP:** Ligand A (2.305) is optimal. Ligand B (-0.694) is quite low, potentially hindering membrane permeability and absorption. This is a significant drawback.
4. **HBD:** Ligand A (1) is good. Ligand B (3) is higher, potentially impacting permeability.
5. **HBA:** Ligand A (3) is good. Ligand B (7) is higher, potentially impacting permeability.
6. **QED:** Both ligands have acceptable QED values (A: 0.791, B: 0.659), indicating reasonable drug-likeness.
7. **DILI:** Ligand A (16.789) has a much lower DILI risk than Ligand B (41.76). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (93.641) shows excellent BBB penetration, which is a desirable property for GPCRs, even if ADRB2 isn't a primary CNS target, it suggests good distribution. Ligand B (74.796) is lower, indicating less BBB penetration.
9. **Caco-2:** Ligand A (-4.523) is negative, which is unusual and requires further investigation, but doesn't immediately disqualify it. Ligand B (-6.059) is also negative and similarly requires investigation.
10. **Solubility:** Ligand A (-2.548) is poor. Ligand B (-1.724) is also poor, but slightly better than A.
11. **hERG:** Both ligands have very low hERG risk (A: 0.561, B: 0.017). Ligand B is slightly better here.
12. **Cl_mic:** Ligand A (46.029) has a moderate clearance, while Ligand B (4.976) has very low clearance, indicating better metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand A (-17.51) is negative, which is concerning. Ligand B (10.684) is positive and represents a reasonable in vitro half-life.
14. **Pgp:** Both ligands have very low Pgp efflux liability (A: 0.021, B: 0.019).
15. **Binding Affinity:** Ligand A (-7.2) has a slightly better binding affinity than Ligand B (-6.6), a difference of 0.6 kcal/mol.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A excels in TPSA and has a better logP and affinity. Ligand B has better metabolic stability (Cl_mic) and a slightly better hERG profile. However, the poor logP of Ligand B is a major concern, potentially hindering its ability to reach the receptor. The superior BBB penetration and lower DILI risk of Ligand A are also significant advantages.
**Conclusion:**
Despite the slightly better metabolic stability of Ligand B, the combination of Ligand A's optimal logP, excellent TPSA, strong binding affinity, lower DILI risk, and good BBB penetration make it the more promising drug candidate. The negative Caco-2 and t1/2 values for A are concerning, but can be addressed through further medicinal chemistry optimization. The low logP of Ligand B is a more fundamental issue that would be harder to overcome.
Output:
1
2025-04-17 17:59:32,609 - INFO - Here's my reasoning and final output for the ligand preference:
**Reasoning:**
We are targeting the ADRB2, a GPCR involved in cardiovascular function. Therefore, the priorities are logP, TPSA, Pgp efflux, affinity, and to a lesser extent, BBB.
Let's compare Ligand A and Ligand B across the provided parameters:
1. **MW:** Both are within the ideal range (200-500 Da).
2. **TPSA:** Ligand A (82.7) is better than Ligand B (90.39), being closer to the preferred <140, and more favorable for absorption.
3. **logP:** Ligand A (3.921) is optimal, while Ligand B (-0.794) is quite low, potentially hindering membrane permeability. This is a significant drawback for a GPCR ligand.
4. **HBD/HBA:** Ligand A (3 HBD, 4 HBA) is slightly higher but still acceptable. Ligand B (1 HBD, 5 HBA) is better.
5. **QED:** Both are good (0.66 and 0.699).
6. **DILI:** Ligand A (76.541) has a higher DILI risk than Ligand B (27.336), which is a concern.
7. **BBB:** Ligand A (62.97) is better than Ligand B (28.344), but BBB is less critical for a cardiovascular target.
8. **Caco-2:** Both are negative, indicating poor permeability. However, the scale is not specified, so it's difficult to interpret the magnitude of the issue.
9. **Solubility:** Both are negative, indicating poor solubility. Again, the scale is not specified.
10. **hERG:** Ligand A (0.632) is better than Ligand B (0.093), indicating lower cardiotoxicity risk.
11. **Cl_mic:** Ligand B (3.671) has significantly lower microsomal clearance than Ligand A (27.089), suggesting better metabolic stability.
12. **t1/2:** Ligand A (49.262) has a longer half-life than Ligand B (26.044).
13. **Pgp:** Ligand A (0.205) has lower P-gp efflux than Ligand B (0.013), which is favorable.
14. **Affinity:** Ligand A (-6.2 kcal/mol) has a significantly stronger binding affinity than Ligand B (-2.3 kcal/mol). This is a major advantage.
**Overall Assessment:**
Despite the higher DILI risk for Ligand A, its superior logP, significantly stronger binding affinity, and lower Pgp efflux outweigh the drawbacks. The low logP of Ligand B is a major concern for a GPCR ligand, likely hindering its ability to reach the receptor in vivo. The better metabolic stability of Ligand B is a plus, but the substantial affinity difference is more critical.
Output:
1
2025-04-17 17:59:32,609 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.463 and 359.579 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (67.67) is higher than Ligand B (20.31). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B is significantly better here.
3. **logP:** Ligand A (1.227) is within the optimal 1-3 range. Ligand B (4.801) is quite high, potentially leading to solubility issues and off-target interactions. Ligand A is better.
4. **HBD:** Both have 0 HBD, which is acceptable.
5. **HBA:** Ligand A has 5 HBA, and Ligand B has 2. Both are within the acceptable range of <=10.
6. **QED:** Ligand A (0.707) is slightly better than Ligand B (0.664), indicating a more drug-like profile.
7. **DILI:** Ligand A (27.414) has a significantly lower DILI risk than Ligand B (16.751). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (92.361) has a much higher BBB penetration percentile than Ligand A (69.988). While ADRB2 isn't a primary CNS target, some level of BBB penetration can be useful for understanding off-target effects.
9. **Caco-2:** Ligand A (-4.841) and Ligand B (-5.023) both have negative values, which is unusual and suggests poor permeability. However, the difference is minimal.
10. **Solubility:** Ligand A (-0.496) is better than Ligand B (-4.959). This is important, especially given Ligand B's high logP.
11. **hERG:** Ligand A (0.154) has a much lower hERG inhibition liability than Ligand B (0.927), a critical safety parameter.
12. **Cl_mic:** Ligand A (16.303) has significantly lower microsomal clearance than Ligand B (139.207), indicating better metabolic stability.
13. **t1/2:** Ligand B (27.973) has a longer in vitro half-life than Ligand A (16.505), which is a positive.
14. **Pgp:** Ligand A (0.041) has much lower P-gp efflux liability than Ligand B (0.789), improving bioavailability.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.4 and -6.5 kcal/mol). The difference is negligible.
**GPCR-Specific Priorities:**
For ADRB2 (a cardiovascular GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has a better logP and Pgp profile. Ligand B has a better TPSA and BBB, but the BBB is less critical for this target. The significant advantages of Ligand A in DILI risk, hERG inhibition, and metabolic stability outweigh the slight benefit of Ligand B's BBB penetration.
**Conclusion:**
Ligand A is the more promising drug candidate due to its superior safety profile (lower DILI and hERG), better solubility, lower P-gp efflux, and improved metabolic stability, despite a slightly higher TPSA. The binding affinity is comparable, and the logP is within the optimal range.
Output:
1
2025-04-17 17:59:32,609 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (340.431 and 354.837 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (75.08) is higher than Ligand B (47.29). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B is better.
3. **logP:** Ligand A (2.264) is within the optimal 1-3 range, while Ligand B (4.85) is higher. This is a significant drawback for Ligand B, potentially leading to poor solubility and off-target effects. Ligand A is better.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable.
5. **HBA:** Ligand A (5) and Ligand B (4) are both acceptable.
6. **QED:** Ligand A (0.811) has a better QED score than Ligand B (0.587), indicating a more drug-like profile. Ligand A is better.
7. **DILI:** Ligand A (37.728) has a much lower DILI risk than Ligand B (70.803). This is a crucial advantage for Ligand A.
8. **BBB:** Ligand A (68.67) is better than Ligand B (49.826), though neither is exceptionally high. For a cardiovascular target, BBB penetration isn't a primary concern, but it's still a slight advantage for A.
9. **Caco-2:** Both ligands have similar, very negative Caco-2 values (-5.15 and -5.152). This suggests very poor permeability, which is concerning for both.
10. **Solubility:** Ligand A (-2.641) has better solubility than Ligand B (-4.954). This is important, especially given Ligand B's higher logP.
11. **hERG:** Ligand A (0.238) has a much lower hERG risk than Ligand B (0.741). This is a significant safety advantage for Ligand A.
12. **Cl_mic:** Ligand B (88.038) has a higher microsomal clearance than Ligand A (12.391), indicating faster metabolism and potentially lower bioavailability. Ligand A is better.
13. **t1/2:** Ligand A (40.177) has a longer in vitro half-life than Ligand B (29.284). This is a positive for Ligand A.
14. **Pgp:** Ligand A (0.026) has a much lower P-gp efflux liability than Ligand B (0.717), suggesting better absorption and bioavailability.
15. **Affinity:** Ligand A (-7.6) has a slightly better binding affinity than Ligand B (-6.7). While the difference is less than 1.5 kcal/mol, it contributes to the overall preference for A.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical ADME-Tox parameters. Its lower DILI risk, hERG inhibition, P-gp efflux, and microsomal clearance, coupled with better solubility, QED, and half-life, make it a significantly more promising drug candidate. While both have poor Caco-2 permeability, the other advantages of Ligand A outweigh this concern. Ligand B's high logP and associated risks are substantial drawbacks.
Output:
1
2025-04-17 17:59:32,609 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (a GPCR) drug candidates.
**Ligand A:** [351.451, 89.35, 0.97, 1, 6, 0.716, 29.43, 70.997, -5.111, -1.102, 0.135, 19.564, 3.802, 0.06, 1]
**Ligand B:** [339.487, 62.73, 4.073, 2, 5, 0.71, 19.542, 83.986, -5.08, -3.543, 0.886, 50.047, 28.708, 0.262, -8]
Here's a breakdown, considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal 200-500 Da range. Ligand B (339.487) is slightly smaller, which is generally favorable.
2. **TPSA:** Ligand A (89.35) is better than Ligand B (62.73) as it is closer to the 90 threshold, and both are well below the 140 threshold for oral absorption.
3. **logP:** Ligand A (0.97) is within the optimal 1-3 range, while Ligand B (4.073) is pushing the upper limit and could potentially cause solubility issues or off-target interactions. This is a significant advantage for Ligand A.
4. **HBD/HBA:** Ligand A (1 HBD, 6 HBA) and Ligand B (2 HBD, 5 HBA) are both acceptable.
5. **QED:** Both ligands have similar QED values (0.716 and 0.71), indicating good drug-likeness.
6. **DILI:** Ligand A (29.43) has a much lower DILI risk than Ligand B (19.542), which is a major advantage.
7. **BBB:** Ligand B (83.986) has a better BBB penetration than Ligand A (70.997), but both are reasonably high.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and indicates poor permeability.
9. **Solubility:** Ligand A (-1.102) has better solubility than Ligand B (-3.543).
10. **hERG:** Ligand A (0.135) has a much lower hERG risk than Ligand B (0.886).
11. **Cl_mic:** Ligand A (19.564) has a lower microsomal clearance than Ligand B (50.047), suggesting better metabolic stability.
12. **t1/2:** Ligand B (28.708) has a longer in vitro half-life than Ligand A (3.802).
13. **Pgp:** Ligand A (0.06) has lower P-gp efflux liability than Ligand B (0.262), which is favorable.
14. **Affinity:** Ligand B (-8 kcal/mol) has significantly stronger binding affinity than Ligand A (-1 kcal/mol). This is a substantial advantage for Ligand B.
**Overall Assessment:**
While Ligand B boasts a much stronger binding affinity, the ADME properties of Ligand A are significantly more favorable. Ligand B's high logP, higher DILI risk, higher hERG risk, and higher clearance are concerning. Ligand A has a better balance of properties, with lower risk profiles and acceptable solubility. The difference in affinity is substantial, but a difference of 7 kcal/mol can sometimes be overcome with further optimization. Given the GPCR target and the importance of balancing ADME with potency, I believe Ligand A is the more promising starting point for drug development.
Output:
1
2025-04-17 17:59:32,609 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's systematically compare Ligand A and Ligand B based on the provided parameters and the guidelines, keeping in mind ADRB2 is a GPCR, so we prioritize logP, Pgp, TPSA, and affinity.
1. **MW:** Both ligands (368.405 and 368.821 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (89.26) is better than Ligand B (113.33). A TPSA under 140 is good for oral absorption, and lower is generally preferred for GPCRs. Ligand A is closer to the ideal range.
3. **logP:** Ligand A (2.495) is better than Ligand B (1.224). Both are within the optimal 1-3 range, but Ligand A is closer to the upper end, potentially aiding membrane permeability.
4. **HBD:** Ligand A (2) is preferable to Ligand B (3). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (5). Similar to HBD, fewer HBA is generally better.
6. **QED:** Ligand A (0.821) is significantly better than Ligand B (0.567). A higher QED indicates a more drug-like profile.
7. **DILI:** Ligand B (58.821) is better than Ligand A (75.378). Lower DILI is crucial. Ligand B has a much lower risk.
8. **BBB:** Both ligands have similar BBB penetration (61.923 and 61.962). This isn't a primary concern for ADRB2 (a cardiovascular target), but it's good they aren't significantly blocked.
9. **Caco-2:** Ligand A (-4.946) is better than Ligand B (-5.636). A more negative value indicates better permeability.
10. **Solubility:** Ligand A (-3.753) is better than Ligand B (-1.963). Better solubility is important for bioavailability.
11. **hERG:** Ligand A (0.563) is better than Ligand B (0.306). Lower hERG inhibition is critical for avoiding cardiotoxicity.
12. **Cl_mic:** Ligand A (26.726) is better than Ligand B (40.193). Lower clearance indicates greater metabolic stability.
13. **t1/2:** Ligand A (35.87) is significantly better than Ligand B (2.23). A longer half-life is generally desirable.
14. **Pgp:** Ligand A (0.44) is better than Ligand B (0.113). Lower P-gp efflux is preferred.
15. **Affinity:** Ligand B (-7.7 kcal/mol) is *significantly* better than Ligand A (-6.4 kcal/mol). This is a 1.3 kcal/mol difference, which is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand B has a much stronger binding affinity, which is the most important factor. While Ligand A has better ADME properties across many parameters (TPSA, logP, QED, solubility, hERG, Cl_mic, t1/2, Pgp), the large affinity difference of Ligand B is a major advantage. The DILI risk of Ligand B is also lower, which is a positive. The slightly higher TPSA of Ligand B is a minor concern, but the affinity benefit outweighs it.
**Output:**
0
2025-04-17 17:59:32,610 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (358.47 & 363.45 Da) fall comfortably within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (86.88) is slightly higher than Ligand B (72.88). Both are below the 140 threshold for oral absorption, but B is closer to the preferred <90 for potential CNS penetration (though ADRB2 isn't strictly a CNS target, lower TPSA is generally favorable).
3. **logP:** Ligand A (3.158) is within the optimal 1-3 range, while Ligand B (1.086) is on the lower end. A logP too low can hinder permeability. Ligand A is preferable here.
4. **HBD:** Ligand A (3) and Ligand B (2) are both acceptable, below the 5 threshold.
5. **HBA:** Both ligands have 4 HBA, which is good.
6. **QED:** Ligand A (0.74) is slightly better than Ligand B (0.643), indicating a more drug-like profile.
7. **DILI:** Ligand B (10.24) has a significantly lower DILI risk than Ligand A (73.94). This is a major advantage for Ligand B.
8. **BBB:** Ligand B (65.84) shows better BBB penetration than Ligand A (59.40). While ADRB2 isn't a primary CNS target, some peripheral ADRB2 activity can influence CNS effects, and better BBB penetration is rarely a detriment.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-5.522) is slightly worse than Ligand B (-4.937).
10. **Solubility:** Ligand B (-0.231) has better solubility than Ligand A (-4.056). This is a positive for bioavailability.
11. **hERG:** Both ligands have low hERG inhibition risk (0.56 & 0.454). No significant difference.
12. **Cl_mic:** Ligand B (-5.406) has a *negative* microsomal clearance, which is highly unusual and suggests very high metabolic stability. Ligand A (30.262) has a moderate clearance. This is a substantial advantage for Ligand B.
13. **t1/2:** Ligand B (-28.987) has a negative in vitro half-life, which is also highly unusual and suggests extreme stability. Ligand A (52.195) has a reasonable half-life.
14. **Pgp:** Both have low Pgp efflux (0.303 & 0.006), suggesting good bioavailability. Ligand B is slightly better.
15. **Binding Affinity:** Ligand B (-6.7 kcal/mol) has a slightly better binding affinity than Ligand A (-6.1 kcal/mol). While the difference is less than the 1.5 kcal/mol threshold, it contributes to the overall preference.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A has a better logP, but Ligand B excels in Pgp, has comparable TPSA, and slightly better affinity. The extremely favorable metabolic stability (negative Cl_mic and t1/2) of Ligand B is a significant advantage. The lower DILI risk is also a major benefit. The Caco-2 and solubility are better for Ligand B.
**Conclusion:**
Despite Ligand A having a slightly better logP, the combination of significantly lower DILI risk, superior metabolic stability (indicated by the negative Cl_mic and t1/2 values), better solubility, and slightly better affinity makes **Ligand B** the more promising drug candidate. The unusual stability parameters for Ligand B are concerning and would need further investigation, but the overall profile is more favorable.
Output:
0
2025-04-17 17:59:32,610 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (344.415 and 342.443 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands have a TPSA of approximately 97, which is acceptable for a non-CNS GPCR target like ADRB2, but higher than ideal for good oral absorption.
3. **logP:** Both ligands have a logP around 2.1, which is optimal.
4. **HBD:** Ligand A has 2 HBD, and Ligand B has 3. Both are within the acceptable limit of 5.
5. **HBA:** Ligand A has 5 HBA, and Ligand B has 4. Both are within the acceptable limit of 10.
6. **QED:** Both ligands have a QED above 0.6, indicating good drug-likeness.
7. **DILI:** Ligand A (52.346) has a slightly higher DILI risk than Ligand B (46.297), but both are below the concerning threshold of 60.
8. **BBB:** Ligand A (48.236) has a lower BBB penetration than Ligand B (73.905). While ADRB2 isn't a primary CNS target, some degree of BBB penetration can be a concern for off-target effects.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. This is a significant drawback for both.
10. **Solubility:** Ligand A (-1.423) has slightly better solubility than Ligand B (-2.772).
11. **hERG:** Both ligands have very low hERG inhibition risk (0.324 and 0.144 respectively), which is excellent.
12. **Cl_mic:** Ligand A (43.715) has a higher microsomal clearance than Ligand B (15.6), suggesting lower metabolic stability. This is a significant negative for Ligand A.
13. **t1/2:** Ligand A (-12.787) has a more negative in vitro half-life than Ligand B (-11.919), meaning a shorter half-life. This is a negative for Ligand A.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.143 and 0.031 respectively), which is good.
15. **Binding Affinity:** Ligand A (-6.6 kcal/mol) has a slightly better binding affinity than Ligand B (-6.1 kcal/mol). This is a 0.5 kcal/mol difference, which is a moderate advantage.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Both ligands perform similarly on logP and Pgp. TPSA is similar but not ideal for either. The affinity difference is moderate. The biggest differentiating factors are metabolic stability (Cl_mic and t1/2), where Ligand B is significantly better, and DILI, where Ligand B is slightly better.
**Conclusion:**
Despite the slightly better binding affinity of Ligand A, the significantly improved metabolic stability (lower Cl_mic, better t1/2) and slightly lower DILI risk of Ligand B outweigh this advantage. The poor Caco-2 permeability is a concern for both, but metabolic stability is critical for *in vivo* efficacy.
Output:
0
2025-04-17 17:59:32,610 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.431 and 349.366 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (84.67) is better than Ligand B (96.25). For a cardiovascular GPCR, TPSA is not a major concern, but lower is generally preferred for absorption.
3. **logP:** Ligand A (1.976) is slightly higher than Ligand B (0.996), both are within the optimal 1-3 range. Ligand A is preferable.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 5 HBA, while Ligand B has 6. Ligand A is slightly better.
6. **QED:** Both ligands have good QED scores (0.849 and 0.794), indicating good drug-like properties.
7. **DILI:** Ligand A (32.571) has a significantly lower DILI risk than Ligand B (56.65). This is a major advantage for Ligand A.
8. **BBB:** Both ligands have good BBB penetration (77.821 and 80.341). This isn't a primary concern for a cardiovascular target, but it's a positive attribute.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. This is a concern for both, but the value for Ligand A (-4.463) is slightly less negative than Ligand B (-4.595).
10. **Solubility:** Ligand A (-2.906) has better solubility than Ligand B (-1.848).
11. **hERG:** Both ligands have very low hERG risk (0.242 and 0.225).
12. **Cl_mic:** Ligand A (22.444) has a significantly higher microsomal clearance than Ligand B (2.392). This indicates lower metabolic stability for Ligand A. This is a significant drawback.
13. **t1/2:** Ligand A (0.787) has a shorter half-life than Ligand B (0.264). This is a negative for Ligand A.
14. **Pgp:** Both ligands have low Pgp efflux (0.09 and 0.022).
15. **Binding Affinity:** Ligand A (-7.0) has a significantly stronger binding affinity than Ligand B (-4.7). This is a substantial advantage for Ligand A. A 2.3 kcal/mol difference is very significant.
**Overall Assessment:**
Ligand A has a much stronger binding affinity, lower DILI risk, and better solubility. However, it has higher microsomal clearance and shorter half-life. Ligand B has better metabolic stability and half-life, but weaker binding affinity and higher DILI risk.
For a GPCR, binding affinity is paramount. The 2.3 kcal/mol difference in binding affinity is substantial enough to outweigh the concerns about metabolic stability and half-life, especially considering the lower DILI risk associated with Ligand A. While the metabolic stability of Ligand A is a concern, it can potentially be addressed through structural modifications during lead optimization.
Output:
1
2025-04-17 17:59:32,610 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [368.415, 93.85, -0.052, 0, 7, 0.757, 78.325, 65.529, -4.666, -1.888, 0.408, 56.414, -14.17, 0.101, -6.2]**
**Ligand B: [367.515, 63.69, 2.14, 1, 6, 0.642, 30.438, 36.332, -5.231, -1.174, 0.392, 57.571, 17.045, 0.18, -7.6]**
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). No significant difference.
2. **TPSA:** Ligand A (93.85) is higher than the preferred <140, but still acceptable. Ligand B (63.69) is excellent. This favors Ligand B.
3. **logP:** Ligand A (-0.052) is slightly low, potentially hindering permeability. Ligand B (2.14) is optimal. This strongly favors Ligand B.
4. **H-Bond Donors:** Ligand A (0) is ideal. Ligand B (1) is acceptable. No major difference.
5. **H-Bond Acceptors:** Ligand A (7) is good. Ligand B (6) is also good. No major difference.
6. **QED:** Ligand A (0.757) is better than Ligand B (0.642), indicating a more drug-like profile. This favors Ligand A.
7. **DILI:** Ligand A (78.325) is higher risk than Ligand B (30.438). This strongly favors Ligand B.
8. **BBB:** Ligand A (65.529) is moderate. Ligand B (36.332) is lower. While ADRB2 isn't exclusively a CNS target, some CNS penetration can be beneficial. This favors Ligand A slightly.
9. **Caco-2 Permeability:** Ligand A (-4.666) is very poor. Ligand B (-5.231) is also poor, but slightly better. This favors Ligand B.
10. **Aqueous Solubility:** Both ligands have poor solubility (-1.888 and -1.174 respectively). This is a concern for both, but not a deciding factor.
11. **hERG Inhibition:** Both ligands have low hERG risk (0.408 and 0.392 respectively). No significant difference.
12. **Microsomal Clearance:** Both ligands have similar microsomal clearance (56.414 and 57.571 respectively). No significant difference.
13. **In vitro Half-Life:** Ligand A (-14.17) is very poor. Ligand B (17.045) is much better. This strongly favors Ligand B.
14. **P-gp Efflux:** Both ligands have low P-gp efflux (0.101 and 0.18 respectively). No significant difference.
15. **Binding Affinity:** Ligand B (-7.6) has a significantly stronger binding affinity than Ligand A (-6.2) - a difference of 1.4 kcal/mol. This is a major advantage for Ligand B.
**Overall Assessment:**
Ligand B consistently outperforms Ligand A in critical ADME properties (logP, DILI, Caco-2, t1/2) and has a substantially better binding affinity. While Ligand A has a slightly better QED and BBB, the significant advantages of Ligand B in key parameters outweigh these. The poor Caco-2 and half-life of Ligand A are major drawbacks. The higher DILI risk of Ligand A is also a significant concern.
Output:
0
2025-04-17 17:59:32,610 - INFO - Batch 5 complete. Total preferences: 80
2025-04-17 17:59:32,610 - INFO - Processing batch 6/512...
2025-04-17 18:00:24,446 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
Let's systematically compare Ligand A and Ligand B against the provided guidelines, keeping in mind ADRB2 is a GPCR and thus we prioritize logP, Pgp, TPSA, and affinity.
1. **MW:** Both ligands (344.411 and 348.451 Da) fall comfortably within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (75.8) is better than Ligand B (112.7). A TPSA under 140 is good for oral absorption, but lower is generally preferred for GPCRs, and A is significantly lower.
3. **logP:** Ligand A (3.109) is optimal, while Ligand B (1.387) is on the lower side. Lower logP can hinder permeation.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Both ligands have 6 HBA, which is acceptable.
6. **QED:** Ligand A (0.84) is better than Ligand B (0.7), indicating a more drug-like profile.
7. **DILI:** Ligand A (17.449) is *much* better than Ligand B (36.022). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (83.172) is significantly better than Ligand B (42.032). While ADRB2 isn't necessarily a CNS target, higher BBB penetration is rarely detrimental and can open up possibilities.
9. **Caco-2:** Ligand A (-4.992) is better than Ligand B (-5.375), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-4.024) is better than Ligand B (-1.752).
11. **hERG:** Ligand A (0.812) is better than Ligand B (0.106), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand A (91.086) is worse than Ligand B (27.216). Ligand B has a lower clearance, suggesting better metabolic stability.
13. **t1/2:** Ligand A (-29.431) is worse than Ligand B (15.446). Ligand B has a longer in vitro half-life, which is preferable.
14. **Pgp:** Ligand A (0.499) is better than Ligand B (0.012), indicating lower P-gp efflux.
15. **Affinity:** Ligand B (-7.4) is significantly better than Ligand A (-6.1). This is a 1.3 kcal/mol difference, which is a substantial advantage.
**Overall Assessment:**
Ligand B has a significantly better binding affinity, and improved metabolic stability and half-life. However, Ligand A excels in almost all other ADME properties, particularly DILI risk, BBB penetration, and hERG inhibition. The substantial difference in affinity for Ligand B is a major advantage. While Ligand A has a better overall ADME profile, the potency advantage of Ligand B is likely to outweigh the ADME concerns, especially with optimization.
**Output:**
0
2025-04-17 18:00:24,446 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (369.462 and 361.475 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (79.37) is better than Ligand B (89.69). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally favors absorption.
3. **logP:** Both ligands have good logP values (2.423 and 1.368), falling within the 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (0). While both are low, having one HBD can sometimes improve solubility without significantly impacting permeability.
5. **HBA:** Ligand B (8) is higher than Ligand A (4). Lower HBA is generally preferred for better permeability.
6. **QED:** Ligand A (0.884) has a significantly better QED score than Ligand B (0.735), indicating a more drug-like profile.
7. **DILI:** Ligand A (48.391) has a lower DILI risk than Ligand B (63.513), making it safer.
8. **BBB:** Both are relatively low, but Ligand A (79.488) is better than Ligand B (63.125). Not a major concern for a cardiovascular target.
9. **Caco-2:** Ligand A (-4.635) is better than Ligand B (-5.497). Higher Caco-2 permeability suggests better absorption.
10. **Solubility:** Ligand A (-3.196) is better than Ligand B (-2.23).
11. **hERG:** Both ligands have very low hERG inhibition risk (0.171 and 0.087).
12. **Cl_mic:** Ligand A (-1.225) has a significantly lower (better) microsomal clearance than Ligand B (59.446), indicating greater metabolic stability.
13. **t1/2:** Ligand A (14.815) has a longer in vitro half-life than Ligand B (2.852). This is a significant advantage.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.096 and 0.032).
15. **Binding Affinity:** Ligand B (-8.4) has a significantly stronger binding affinity than Ligand A (-7.1). This is a 1.3 kcal/mol difference, which is substantial.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), affinity, logP, TPSA, and Pgp are key. Ligand B wins on affinity. Ligand A wins on logP and TPSA. Pgp is good for both. However, the substantial difference in affinity (-8.4 vs -7.1) is likely to outweigh the advantages of Ligand A in other parameters, especially considering the acceptable ADME profile of Ligand B. The improved metabolic stability (lower Cl_mic and longer t1/2) of Ligand A is appealing, but the potency advantage of Ligand B is more critical for a GPCR target.
**Conclusion:**
Despite Ligand A's better ADME properties, the significantly higher binding affinity of Ligand B makes it the more promising drug candidate.
Output:
0
2025-04-17 18:00:24,446 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Ligand A (343.427 Da) is well within the ideal range (200-500 Da). Ligand B (372.531 Da) is also acceptable. No clear advantage.
2. **TPSA:** Ligand A (83.48) is good, below the 140 threshold for oral absorption. Ligand B (75.71) is even better. Slight advantage to B.
3. **logP:** Both ligands (A: 1.636, B: 1.315) are within the optimal 1-3 range. No significant difference.
4. **HBD:** Ligand A (3) is acceptable, Ligand B (1) is even better. Advantage to B.
5. **HBA:** Ligand A (5) is acceptable, Ligand B (4) is also good. Slight advantage to B.
6. **QED:** Both ligands (A: 0.645, B: 0.731) have good drug-likeness scores (>0.5). Ligand B is slightly better.
7. **DILI:** Ligand A (24.544) is excellent, well below the 40% threshold. Ligand B (12.33) is also very good. No clear advantage.
8. **BBB:** Ligand A (26.018) is low, suggesting poor brain penetration. Ligand B (68.554) is significantly better, exceeding 60%. This is a *major* advantage for a GPCR, even if not a CNS target, as it indicates better distribution characteristics.
9. **Caco-2:** Ligand A (-5.158) is poor, indicating poor intestinal absorption. Ligand B (-4.588) is also poor, but slightly better.
10. **Solubility:** Both ligands have negative solubility values (-2.467 and -1.533), indicating poor aqueous solubility. This is a concern for both.
11. **hERG:** Both ligands (A: 0.298, B: 0.224) have low hERG inhibition risk, which is good. Slight advantage to B.
12. **Cl_mic:** Both ligands have similar microsomal clearance (A: 29.172, B: 30.623). No significant difference.
13. **t1/2:** Ligand A (8.484) has a longer in vitro half-life than Ligand B (2.701). This is an advantage for A.
14. **Pgp:** Both ligands have low P-gp efflux liability (A: 0.047, B: 0.028). Slight advantage to B.
15. **Binding Affinity:** Ligand B (-7.5 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.1 kcal/mol) - a difference of 1.4 kcal/mol. This is a substantial advantage that can outweigh some of the ADME drawbacks.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand B is the better candidate. While both have solubility issues, Ligand B demonstrates superior BBB penetration, better TPSA, HBD, HBA, QED, Pgp efflux, and, crucially, a significantly stronger binding affinity. The longer half-life of Ligand A is a positive, but the affinity difference is substantial enough to make Ligand B the preferred choice.
Output:
0
2025-04-17 18:00:24,446 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
Let's break down the comparison based on the provided guidelines and GPCR priorities (logP, Pgp, TPSA, and affinity being key).
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (369.372) is slightly higher than Ligand B (343.343), but this isn't a major concern.
2. **TPSA:** Ligand A (71.84) is significantly better than Ligand B (113.86). A TPSA under 140 is good for oral absorption, but lower is generally preferred for GPCRs. Ligand B's TPSA is approaching a level that could hinder absorption.
3. **logP:** Ligand A (3.737) is good, while Ligand B (1.451) is on the lower side. For a GPCR, a logP between 1-3 is optimal. Ligand B's lower logP could lead to permeability issues.
4. **H-Bond Donors/Acceptors:** Ligand A (2 HBD, 5 HBA) is slightly more balanced than Ligand B (1 HBD, 9 HBA). While both are within acceptable limits, a higher number of HBA can sometimes impact permeability.
5. **QED:** Both ligands have similar QED scores (0.736 and 0.547), indicating reasonable drug-likeness.
6. **DILI:** Ligand B (97.906) has a substantially higher DILI risk than Ligand A (88.639). This is a significant negative for Ligand B.
7. **BBB:** Ligand A (75.998) has better BBB penetration potential than Ligand B (68.282), although both are not exceptionally high. This is a moderate advantage for Ligand A, given it's a GPCR.
8. **Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual. It's difficult to interpret without knowing the scale.
9. **Aqueous Solubility:** Both ligands have negative solubility values, which is also unusual. It's difficult to interpret without knowing the scale.
10. **hERG:** Ligand A (0.547) has a slightly higher hERG risk than Ligand B (0.335), but both are relatively low.
11. **Microsomal Clearance:** Ligand B (66.964) has a much higher microsomal clearance than Ligand A (28.66). This suggests Ligand B will be metabolized more quickly, potentially leading to a shorter duration of action.
12. **In vitro Half-Life:** Ligand A (81.118) has a significantly longer in vitro half-life than Ligand B (-22.172). This is a major advantage for Ligand A.
13. **P-gp Efflux:** Ligand A (0.368) has lower P-gp efflux liability than Ligand B (0.074), which is beneficial for oral bioavailability and potentially CNS exposure.
14. **Binding Affinity:** Ligand A (-7.0 kcal/mol) has a slightly better binding affinity than Ligand B (-6.2 kcal/mol). While the difference is not huge, it's enough to be a factor.
**Overall Assessment:**
Ligand A is the stronger candidate. It has a better TPSA, logP, DILI risk, BBB penetration, metabolic stability (lower Cl_mic, longer t1/2), P-gp efflux, and binding affinity. While Ligand B has a slightly lower hERG risk, the other advantages of Ligand A outweigh this. The unusual negative values for Caco-2 and solubility are concerning for both, but the other ADME properties of Ligand A are more favorable.
Output:
1
2025-04-17 18:00:24,447 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (359.4 and 349.3 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (48.39) is significantly lower than Ligand B (126.13). This is a major advantage for Ligand A, as lower TPSA generally correlates with better cell permeability and oral absorption, crucial for a GPCR target. Ligand B is above the preferred threshold of 140.
**3. logP:** Ligand A (4.013) is within the optimal range (1-3), though on the higher end. Ligand B (-1.173) is considerably lower, potentially hindering membrane permeability and absorption. This favors Ligand A.
**4. H-Bond Donors:** Both ligands have 2 HBD, which is acceptable.
**5. H-Bond Acceptors:** Ligand A has 5 HBA, while Ligand B has 7. Both are within the acceptable range of <=10, but Ligand A is slightly preferred.
**6. QED:** Both ligands have similar QED values (0.739 and 0.69), indicating good drug-likeness.
**7. DILI Risk:** Ligand A (90.617) has a higher DILI risk than Ligand B (60.915). This is a significant drawback for Ligand A.
**8. BBB Penetration:** Both ligands have similar BBB penetration (48.197 and 45.909). While not a primary concern for a cardiovascular target, it's not a differentiating factor.
**9. Caco-2 Permeability:** Ligand A (-4.773) is significantly better than Ligand B (-5.502), indicating better intestinal absorption.
**10. Aqueous Solubility:** Ligand A (-4.733) is better than Ligand B (-1.628).
**11. hERG Inhibition:** Ligand A (0.762) has a slightly higher hERG inhibition risk than Ligand B (0.045). This favors Ligand B.
**12. Microsomal Clearance:** Ligand B (-12.06) has significantly lower microsomal clearance than Ligand A (26.176), suggesting better metabolic stability. This is a strong advantage for Ligand B.
**13. In vitro Half-Life:** Ligand A (44.331) has a longer half-life than Ligand B (33.161), which is generally desirable.
**14. P-gp Efflux:** Ligand A (0.792) has lower P-gp efflux than Ligand B (0.017), suggesting better bioavailability.
**15. Binding Affinity:** Ligand A (-9.1 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.1 kcal/mol). This is a substantial advantage for Ligand A, potentially outweighing some of its ADME drawbacks.
**GPCR-Specific Considerations:** For a GPCR like ADRB2, logP, TPSA, Pgp efflux, and binding affinity are key. Ligand A excels in logP, TPSA, Pgp, and *especially* binding affinity. While Ligand B has better metabolic stability and lower DILI risk, the significantly stronger binding of Ligand A is a critical factor. The difference in affinity (>3 kcal/mol) is substantial.
**Overall Assessment:**
Despite the higher DILI risk and slightly higher hERG risk, Ligand A's superior binding affinity, TPSA, logP, and Caco-2 permeability make it the more promising candidate. The strong binding is likely to be more impactful than the moderate ADME liabilities, especially in early-stage drug development where optimization can address these issues.
Output:
1
2025-04-17 18:00:24,447 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (351.491 and 362.436 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (64.09) is slightly higher than Ligand B (58.2), but both are well below the 140 threshold for good oral absorption. Ligand B is preferable due to being closer to the 90 threshold for potential CNS penetration, although this is less critical for a cardiovascular target.
3. **logP:** Ligand A (0.937) is slightly lower than the optimal 1-3 range, while Ligand B (3.414) is at the higher end but still acceptable. Ligand B is preferable as it is closer to the optimal range.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2) as lower HBD is generally better for permeability.
5. **HBA:** Ligand A (4) is preferable to Ligand B (2) as lower HBA is generally better for permeability.
6. **QED:** Ligand A (0.819) has a significantly better QED score than Ligand B (0.682), indicating a more drug-like profile. This is a significant advantage for Ligand A.
7. **DILI:** Ligand A (6.592) has a much lower DILI risk than Ligand B (40.054). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (67.197) has a better BBB penetration score than Ligand B (57.852), but this is less critical for a cardiovascular target.
9. **Caco-2:** Both ligands have very negative Caco-2 values (-4.683 and -4.696). This suggests poor permeability.
10. **Solubility:** Ligand A (-0.785) has better solubility than Ligand B (-4.296).
11. **hERG:** Both ligands have very low hERG inhibition risk (0.421 and 0.461). No clear advantage.
12. **Cl_mic:** Ligand A (24.528) has a much lower microsomal clearance than Ligand B (53.858), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (-7.391) has a much longer in vitro half-life than Ligand B (3.083). This is a significant advantage for Ligand A.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.127 and 0.082). No clear advantage.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.9 and -6.8 kcal/mol). The difference is negligible.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand B has a slightly better logP and TPSA, but Ligand A excels in QED, DILI, Cl_mic, and t1/2. The similar affinities mean these ADME properties become more important.
**Overall Assessment:**
Ligand A is the superior candidate. While Ligand B has a slightly more favorable logP, Ligand A demonstrates significantly better drug-like properties (QED), lower toxicity risk (DILI), improved metabolic stability (Cl_mic), and a longer half-life (t1/2). These factors outweigh the minor advantage of Ligand B's logP, especially considering the similar binding affinities. The poor Caco-2 values are a concern for both, but can be addressed in further optimization.
Output:
1
2025-04-17 18:00:24,447 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (362.352 and 366.571 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (76.46) is higher than Ligand B (49.41). For a cardiovascular GPCR like ADRB2, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B has a clear advantage.
3. **logP:** Ligand A (0.735) is lower than Ligand B (3.309). While both are within the acceptable range, Ligand B is closer to the optimal 1-3 range. Ligand B is better.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 5 HBA, while Ligand B has 3. Both are acceptable, but lower is slightly preferred. Ligand B is better.
6. **QED:** Both ligands have good QED scores (0.838 and 0.752), indicating good drug-like properties. No significant difference.
7. **DILI:** Ligand A (38.62) has a slightly higher DILI risk than Ligand B (20.822). Lower is better, so Ligand B is preferred.
8. **BBB:** Ligand A (88.096) has a higher BBB penetration percentile than Ligand B (78.868). While ADRB2 isn't a CNS target, some degree of BBB penetration can sometimes be beneficial for off-target effects or distribution.
9. **Caco-2:** Ligand A (-4.668) has a worse Caco-2 permeability than Ligand B (-5.175). Lower values indicate poorer permeability. Ligand B is better.
10. **Solubility:** Ligand A (-1.099) has better solubility than Ligand B (-4.216). Solubility is important for bioavailability, so Ligand A is preferred.
11. **hERG:** Ligand A (0.098) has a lower hERG risk than Ligand B (0.563). This is a significant advantage for Ligand A, as hERG inhibition can lead to cardiotoxicity.
12. **Cl_mic:** Ligand A (2.357) has a much lower microsomal clearance than Ligand B (76.131). Lower clearance indicates better metabolic stability, a major advantage for Ligand A.
13. **t1/2:** Ligand A (6.828) has a longer in vitro half-life than Ligand B (-0.397). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.06) has lower P-gp efflux liability than Ligand B (0.391). Lower efflux is better for bioavailability. Ligand A is better.
15. **Binding Affinity:** Ligand A (-6.5 kcal/mol) has slightly weaker binding affinity than Ligand B (-5.7 kcal/mol). However, the difference is relatively small.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity), Ligand A is the better candidate. While Ligand B has a slightly better affinity, Ligand A excels in ADME properties, particularly metabolic stability (Cl_mic, t1/2), solubility, and safety (DILI, hERG). The lower clearance and longer half-life of Ligand A are crucial for a viable drug candidate. The slightly better TPSA and logP of Ligand B are outweighed by the significant advantages of Ligand A in terms of ADME and safety.
Output:
1
2025-04-17 18:00:24,447 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (340.398 Da and 348.462 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (55.13) is slightly higher than Ligand B (49.41). Both are below the 140 A^2 threshold for good oral absorption, but closer to the 90 A^2 threshold for CNS targets. Given ADRB2 is a cardiovascular target, TPSA is less critical but still a consideration. Ligand B has a slight advantage.
**3. logP:** Ligand A (4.659) is higher than Ligand B (3.146). Ligand A is pushing the upper limit of the optimal range (1-3), potentially raising concerns about solubility and off-target effects. Ligand B is well within the optimal range. Ligand B is favored.
**4. H-Bond Donors:** Both ligands have 1 HBD, which is within the acceptable limit of 5. No difference.
**5. H-Bond Acceptors:** Ligand A has 3 HBAs, while Ligand B has 2. Both are below the acceptable limit of 10. No significant difference.
**6. QED:** Ligand A (0.884) has a slightly higher QED than Ligand B (0.794), indicating a more drug-like profile. This is a small advantage for Ligand A.
**7. DILI Risk:** Ligand A (71.113) has a significantly higher DILI risk than Ligand B (22.722). This is a major concern for Ligand A. Ligand B is strongly favored.
**8. BBB Penetration:** Both ligands have high BBB penetration (88.29 and 87.67), but this is less crucial for a cardiovascular target.
**9. Caco-2 Permeability:** Ligand A (-4.797) has worse Caco-2 permeability than Ligand B (-4.696). Both are negative, indicating low permeability, but Ligand B is slightly better.
**10. Aqueous Solubility:** Ligand A (-4.951) has worse aqueous solubility than Ligand B (-3.245). This is a concern for Ligand A, especially given its higher logP. Ligand B is favored.
**11. hERG Inhibition:** Ligand A (0.776) has a higher hERG inhibition liability than Ligand B (0.451). This is a safety concern for Ligand A. Ligand B is favored.
**12. Microsomal Clearance:** Ligand A (64.671) has higher microsomal clearance than Ligand B (41.814), indicating lower metabolic stability. Ligand B is favored.
**13. In vitro Half-Life:** Ligand A (76.441) has a longer in vitro half-life than Ligand B (-8.941). This is a positive for Ligand A.
**14. P-gp Efflux:** Ligand A (0.882) has higher P-gp efflux than Ligand B (0.188). This is a negative for Ligand A. Ligand B is favored.
**15. Binding Affinity:** Ligand B (-7.1 kcal/mol) has a significantly stronger binding affinity than Ligand A (-4.7 kcal/mol). This is a substantial advantage for Ligand B, easily outweighing any minor ADME drawbacks.
**Overall Assessment:**
Ligand B is the clear winner. While Ligand A has a slightly better QED and in vitro half-life, it suffers from significantly higher DILI risk, hERG inhibition, P-gp efflux, and lower solubility. Most importantly, Ligand B has a much stronger binding affinity. For a GPCR target like ADRB2, strong binding is paramount, and Ligand B's superior affinity, combined with its favorable ADME profile (particularly the lower DILI risk and better solubility), makes it the more promising drug candidate.
Output:
0
2025-04-17 18:00:24,447 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [351.403, 111.87 , -0.399, 3. , 6. , 0.642, 45.87 , 40.403, -4.786, -1.764, 0.177, -18.152, 14.315, 0.024, -6.5 ]
**Ligand B:** [351.403, 110.53 , 1.053, 2. , 6. , 0.711, 47.421, 59.636, -4.712, -2.647, 0.105, 56.539, -7.675, 0.047, -7. ]
**Step-by-step comparison:**
1. **MW:** Both ligands are around 351 Da, falling comfortably within the 200-500 Da ideal range. No significant difference here.
2. **TPSA:** Ligand A (111.87) is slightly higher than Ligand B (110.53). Both are acceptable for a non-CNS GPCR target like ADRB2, being under 140.
3. **logP:** Ligand A (-0.399) is lower than Ligand B (1.053). Ligand B is better positioned within the optimal 1-3 range. Ligand A is a bit low and could have absorption issues.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (2). Both are within the acceptable limit of 5.
5. **HBA:** Both ligands have 6 HBA, which is acceptable (<=10).
6. **QED:** Ligand B (0.711) has a slightly better QED score than Ligand A (0.642), indicating a more drug-like profile.
7. **DILI:** Both ligands have acceptable DILI risk (A: 45.87, B: 47.421), below the 60% threshold.
8. **BBB:** Ligand B (59.636) has a significantly higher BBB penetration percentile than Ligand A (40.403). While ADRB2 isn't a primary CNS target, some degree of BBB penetration can be beneficial for off-target effects assessment.
9. **Caco-2:** Both ligands have similar, very poor Caco-2 permeability (-4.786 and -4.712). This is a significant concern for oral bioavailability.
10. **Solubility:** Ligand A (-1.764) has slightly better solubility than Ligand B (-2.647), but both are quite poor.
11. **hERG:** Both ligands show very low hERG inhibition risk (A: 0.177, B: 0.105). This is excellent.
12. **Cl_mic:** Ligand A (-18.152) has a much lower (better) microsomal clearance than Ligand B (56.539), indicating greater metabolic stability. This is a major advantage.
13. **t1/2:** Ligand A (14.315) has a longer in vitro half-life than Ligand B (-7.675). This is also a significant advantage.
14. **Pgp:** Both ligands have very low P-gp efflux liability (A: 0.024, B: 0.047).
15. **Binding Affinity:** Ligand B (-7.0) has a slightly better binding affinity than Ligand A (-6.5). This is a 0.5 kcal/mol difference, which is notable but not overwhelming.
**GPCR-Specific Priorities:** For ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand B is better on logP and affinity, while both are good on Pgp and TPSA. However, Ligand A has a *much* better metabolic profile (Cl_mic and t1/2), which is crucial for *in vivo* efficacy. The poor Caco-2 permeability is a concern for both, but the improved metabolic stability of Ligand A could allow for higher doses to overcome this.
**Conclusion:**
Considering the balance of properties, especially the significantly better metabolic stability and half-life of Ligand A, I would choose **Ligand A** as the more promising drug candidate. The slightly better affinity of Ligand B is not enough to overcome the substantial metabolic liabilities.
Output:
1
2025-04-17 18:00:24,447 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (353.369) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (70.67) is better than Ligand B (43.18). Lower TPSA is preferred for GPCRs, aiding in brain penetration and overall absorption.
3. **logP:** Ligand A (2.523) is optimal, while Ligand B (4.287) is pushing the upper limit. High logP can lead to poor solubility and off-target effects.
4. **HBD:** Ligand A (2) is good, and Ligand B (0) is also acceptable.
5. **HBA:** Ligand A (3) is good, and Ligand B (6) is slightly higher but still within a reasonable range.
6. **QED:** Ligand A (0.874) is significantly better than Ligand B (0.641), indicating a more drug-like profile.
7. **DILI:** Both ligands have similar and acceptable DILI risk (Ligand A: 35.983, Ligand B: 37.999).
8. **BBB:** Ligand A (85.615) has a much better BBB penetration percentile than Ligand B (71.462). This is a key consideration for GPCRs, even if ADRB2 isn't strictly a CNS target, as some peripheral effects may benefit from better distribution.
9. **Caco-2:** Both have negative values, indicating poor permeability. Ligand A (-4.678) is slightly better than Ligand B (-4.954).
10. **Solubility:** Both have negative values, indicating poor solubility. Ligand A (-3.184) is slightly better than Ligand B (-4.285).
11. **hERG:** Ligand A (0.455) has a lower hERG risk than Ligand B (0.838), which is crucial for cardiovascular targets.
12. **Cl_mic:** Ligand A (-14.969) has a much lower (better) microsomal clearance than Ligand B (82.208), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-15.135) has a longer in vitro half-life than Ligand B (-7.209), which is desirable.
14. **Pgp:** Ligand A (0.027) has a significantly lower P-gp efflux liability than Ligand B (0.73), improving bioavailability.
15. **Affinity:** Both ligands have very similar and excellent binding affinities (Ligand A: -6.7 kcal/mol, Ligand B: -7.0 kcal/mol). The difference is less than 1.5 kcal/mol, so it's not a deciding factor.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most crucial ADME properties. It has better TPSA, logP, QED, BBB penetration, hERG risk, metabolic stability (Cl_mic & t1/2), and P-gp efflux. While both have poor Caco-2 and solubility, Ligand A is slightly better in these areas as well. The binding affinity difference is negligible. Given the GPCR-specific priorities (logP, TPSA, Pgp, BBB), Ligand A is the clear winner.
Output:
1
2025-04-17 18:00:24,447 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (350.296 and 348.443 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (79.29 and 77.92) are below the 140 A^2 threshold for good oral absorption, and acceptable for a non-CNS GPCR target like ADRB2. Again, no major difference.
3. **logP:** Ligand A (2.884) is optimal, while Ligand B (0.99) is slightly low, potentially impacting permeability. This is a slight advantage for A.
4. **HBD:** Both ligands have acceptable HBD counts (2 and 1 respectively), well within the limit of 5.
5. **HBA:** Both ligands have acceptable HBA counts (3 and 4 respectively), well within the limit of 10.
6. **QED:** Both ligands have good QED scores (0.889 and 0.752), indicating good drug-like properties.
7. **DILI:** Ligand A (90.461) has a significantly higher DILI risk than Ligand B (22.8). This is a major concern for Ligand A.
8. **BBB:** This is less critical for ADRB2 (a cardiovascular target), but Ligand B (68.282) shows slightly better penetration than Ligand A (57.58).
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.966 and -4.751), which is unusual and suggests poor permeability. This is a significant drawback for both, but the values are very close.
10. **Solubility:** Ligand A (-3.593) has slightly better solubility than Ligand B (-0.928), which is a minor advantage.
11. **hERG:** Both ligands have very low hERG risk (0.053 and 0.066), which is excellent.
12. **Cl_mic:** Ligand A (-8.171) has significantly lower (better) microsomal clearance than Ligand B (21.781), indicating better metabolic stability. This is a substantial advantage for Ligand A.
13. **t1/2:** Ligand A (-43.53) has a much longer in vitro half-life than Ligand B (-5.483), which is a significant advantage.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.023 and 0.139).
15. **Binding Affinity:** Ligand B (-6.9) has a slightly better binding affinity than Ligand A (-6.0). This is a 0.9 kcal/mol difference, which is not huge, but noticeable.
**Overall Assessment:**
Ligand A has a major drawback in its high DILI risk. While it boasts superior metabolic stability (lower Cl_mic) and longer half-life, the potential for liver injury is a serious concern. Ligand B, while having a slightly lower affinity and higher DILI, presents a much more favorable safety profile. The slight difference in affinity can potentially be optimized in later stages of drug development. Given the cardiovascular target and the importance of safety, I prioritize the lower DILI risk of Ligand B.
Output:
0
2025-04-17 18:00:24,447 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (367.446 Da) is better than Ligand B (411.256 Da). Both are within the ideal range, but A is closer to the lower end, potentially aiding permeability.
2. **TPSA:** Ligand A (65.38) is significantly better than Ligand B (95.79). ADRB2 is not a CNS target, but lower TPSA generally improves absorption. Ligand B is pushing the upper limit for good oral absorption.
3. **logP:** Both ligands have acceptable logP values (A: 2.948, B: 1.991), falling within the 1-3 range. Ligand A is slightly preferred.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A (6) is slightly better than Ligand B (5). Both are within the acceptable range.
6. **QED:** Ligand A (0.738) is better than Ligand B (0.456). A higher QED suggests a more drug-like profile.
7. **DILI:** Ligand A (41.411) is significantly better than Ligand B (65.568). Lower DILI risk is crucial.
8. **BBB:** Both have reasonable BBB penetration (A: 76.154, B: 83.172), but this isn't a primary concern for ADRB2.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the values are similar (-4.691 vs -4.598), so this isn't a differentiating factor.
10. **Solubility:** Both have negative solubility values, which is concerning. Again, values are similar (-2.604 vs -3.96).
11. **hERG:** Both have low hERG inhibition risk (A: 0.705, B: 0.677).
12. **Cl_mic:** Ligand A (62.397) is significantly better than Ligand B (1.018). Lower clearance indicates better metabolic stability.
13. **t1/2:** Ligand A (50.587) is much better than Ligand B (19.541). A longer half-life is desirable.
14. **Pgp:** Both have low Pgp efflux liability (A: 0.502, B: 0.165).
15. **Binding Affinity:** Ligand B (-7.4 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.9 kcal/mol). This is a substantial advantage, exceeding the 1.5 kcal/mol threshold.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in affinity. However, Ligand A has better TPSA, DILI, Cl_mic, and t1/2. The large difference in affinity for Ligand B is very significant. While the solubility and Caco-2 are concerning for both, the superior metabolic stability and lower toxicity of Ligand A are important. The affinity difference is large enough to overcome the other issues.
**Conclusion:**
Despite the concerns around solubility and Caco-2 permeability for both compounds, the significantly stronger binding affinity of Ligand B (-7.4 kcal/mol vs -5.9 kcal/mol) is a major advantage that outweighs the other drawbacks.
Output:
0
2025-04-17 18:00:24,448 - INFO - Here's my reasoning and final output for the ligand preference:
**Reasoning:**
We are targeting ADRB2, a GPCR, so the priorities are logP, Pgp, TPSA, affinity, and BBB.
* **Molecular Weight:** Both ligands are within the acceptable range (200-500 Da). Ligand A (403.555) is slightly higher than Ligand B (352.395), but this isn't a major concern.
* **TPSA:** Ligand A (87.54) is better than Ligand B (119.54). We want TPSA <= 140 for good absorption, and lower is generally better for GPCRs. Ligand B is getting a bit high.
* **logP:** Ligand B (-1.295) is lower than Ligand A (-0.375). Both are a bit low, but Ligand A is closer to the optimal 1-3 range. Lower logP can hinder permeation.
* **H-Bond Donors/Acceptors:** Ligand A (1 HBD, 8 HBA) is preferable to Ligand B (3 HBD, 5 HBA). Fewer H-bonds are generally better for permeability.
* **QED:** Ligand A (0.736) has a better QED score than Ligand B (0.565), indicating a more drug-like profile.
* **DILI:** Ligand B (49.321) has a significantly lower DILI risk than Ligand A (74.68). This is a substantial advantage for Ligand B.
* **BBB:** Ligand B (42.032) has a slightly higher BBB penetration than Ligand A (31.756), but both are relatively low. This isn't a primary concern for ADRB2, which isn't necessarily a CNS target.
* **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-5.529) is slightly better than Ligand B (-5.216).
* **Solubility:** Both ligands have negative solubility values, which is also unusual and suggests poor solubility. Ligand B (-1.746) is slightly better than Ligand A (-3.191).
* **hERG:** Both ligands have very low hERG inhibition risk.
* **Cl_mic:** Ligand B (-13.716) has significantly lower microsomal clearance than Ligand A (42.913), indicating better metabolic stability. This is a major advantage for Ligand B.
* **t1/2:** Ligand B (3.621) has a longer in vitro half-life than Ligand A (1.05). This is a positive for Ligand B.
* **Pgp:** Both ligands have very low P-gp efflux liability.
* **Binding Affinity:** Ligand A (-7.7 kcal/mol) has a slightly better binding affinity than Ligand B (-8.0 kcal/mol). While a difference of 0.3 kcal/mol is not huge, it is still a positive for Ligand A.
**Overall Assessment:**
Ligand B has significant advantages in DILI risk, metabolic stability (Cl_mic), and in vitro half-life. While Ligand A has a slightly better affinity and TPSA, the ADME properties of Ligand B are more favorable for overall drug development. The slightly lower affinity of Ligand B is likely outweighed by its improved pharmacokinetic profile.
**Output:**
0
2025-04-17 18:00:24,448 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [347.375, 137.07 , 0.754, 4. , 5. , 0.63 , 77.743, 11.245, -6.231, -2.664, 0.01 , -16.081, -3.744, 0.002, -6. ]
**Ligand B:** [358.435, 113.96 , -0.16 , 3. , 6. , 0.494, 25.708, 53.121, -4.942, -1.564, 0.118, 54.352, -50.805, 0.041, -6.1 ]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity) and general drug-like properties:
1. **MW:** Both are within the ideal range (200-500 Da). A (347) is slightly better.
2. **TPSA:** Both are good, but B (113.96) is better than A (137.07), being closer to the <140 threshold for oral absorption.
3. **logP:** A (0.754) is within the optimal range, while B (-0.16) is a bit low, potentially hindering permeability. This is a significant point against B.
4. **HBD:** Both are acceptable (A: 4, B: 3).
5. **HBA:** Both are acceptable (A: 5, B: 6).
6. **QED:** A (0.63) is better than B (0.494), suggesting a more drug-like profile.
7. **DILI:** B (25.7) is *much* better than A (77.7), indicating a significantly lower risk of liver injury. This is a major advantage for B.
8. **BBB:** B (53.1) is better than A (11.2), but neither are particularly high. Since ADRB2 is cardiovascular, BBB isn't a primary concern, but higher is still preferable.
9. **Caco-2:** A (-6.231) is better than B (-4.942), indicating better intestinal absorption.
10. **Solubility:** A (-2.664) is better than B (-1.564), indicating better aqueous solubility.
11. **hERG:** Both are very low (A: 0.01, B: 0.118), indicating minimal cardiotoxicity risk.
12. **Cl_mic:** A (-16.081) is *much* better than B (54.352), meaning A has significantly better metabolic stability. This is a crucial advantage.
13. **t1/2:** B (-50.805) is better than A (-3.744), indicating a longer in vitro half-life.
14. **Pgp:** Both are very low (A: 0.002, B: 0.041), suggesting minimal P-glycoprotein efflux.
15. **Affinity:** Both are equally good (-6.0 and -6.1 kcal/mol).
**Overall Assessment:**
Ligand A has a better logP, QED, Caco-2 permeability, solubility, and *much* better metabolic stability (Cl_mic). Ligand B shines with a lower DILI risk and a longer half-life. The low logP of B is concerning for permeability, and the poor metabolic stability is a significant drawback. While the DILI risk for A is higher, the superior ADME profile (especially metabolic stability) and comparable affinity make it the more promising candidate.
Output:
1
2025-04-17 18:00:24,448 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [340.423, 58.64, 2.588, 1, 3, 0.677, 61.807, 67.313, -4.461, -3.902, 0.65, 47.274, -6.669, 0.429, -5.7]
**Ligand B:** [347.463, 88.91, 2.057, 2, 5, 0.669, 41.877, 70.609, -4.94, -3.075, 0.122, 30.543, 4.783, 0.076, -0.0]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity) and general drug-like properties:
1. **MW:** Both are within the ideal 200-500 Da range. A (340.423) is slightly lower, which is generally favorable.
2. **TPSA:** A (58.64) is excellent, well below the 140 threshold for oral absorption. B (88.91) is still reasonable, but less optimal.
3. **logP:** Both are within the optimal 1-3 range. A (2.588) is slightly higher, potentially offering better membrane permeability, while B (2.057) is a little lower.
4. **HBD/HBA:** A (1 HBD, 3 HBA) is better than B (2 HBD, 5 HBA) in terms of balancing solubility and permeability.
5. **QED:** Both are good (A: 0.677, B: 0.669), indicating drug-like properties.
6. **DILI:** A (61.807) is higher than B (41.877), indicating a greater risk of liver injury. This is a significant drawback for A.
7. **BBB:** B (70.609) has better BBB penetration than A (67.313), although neither are exceptionally high. Since ADRB2 is cardiovascular, BBB isn't a *primary* concern, but it's still a positive for B.
8. **Caco-2:** Both are negative, indicating poor permeability. A (-4.461) is worse than B (-4.94).
9. **Solubility:** Both are negative, indicating poor solubility. A (-3.902) is slightly better than B (-3.075).
10. **hERG:** A (0.65) is better than B (0.122), indicating lower cardiotoxicity risk.
11. **Cl_mic:** B (30.543) has significantly lower microsomal clearance than A (47.274), suggesting better metabolic stability.
12. **t1/2:** A (-6.669) has a longer in vitro half-life than B (4.783). This is a positive for A.
13. **Pgp:** A (0.429) has lower P-gp efflux than B (0.076), which is favorable for bioavailability.
14. **Affinity:** A (-5.7 kcal/mol) has a *much* stronger binding affinity than B (-0.0 kcal/mol). This is a massive advantage for A.
**Overall Assessment:**
The most critical factor here is binding affinity. A's -5.7 kcal/mol is substantially better than B's -0.0 kcal/mol. While B has advantages in DILI risk, metabolic stability, and P-gp efflux, the difference in affinity is so large that it likely outweighs these drawbacks. The poor Caco-2 and solubility for both compounds are concerning, but can be addressed with formulation strategies. The higher DILI risk for A is a concern, but could be mitigated through structural modifications.
Therefore, I would prioritize Ligand A due to its significantly stronger binding affinity.
Output:
1
2025-04-17 18:00:24,448 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (364.511 and 355.869 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (78.43) is higher than Ligand B (49.15). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B has a clear advantage.
3. **logP:** Ligand B (4.273) is higher than Ligand A (2.509). While both are above the optimal 1-3 range, Ligand B is pushing the upper limit and could present solubility challenges. Ligand A is better here.
4. **HBD:** Ligand A (3) is higher than Ligand B (0). A small number of HBDs is generally preferred for permeability. Ligand B is better.
5. **HBA:** Both ligands have 4 HBA, which is acceptable.
6. **QED:** Both ligands have good QED scores (0.696 and 0.744), indicating good drug-like properties. No significant difference.
7. **DILI:** Ligand B (18.883) has a significantly lower DILI risk than Ligand A (29.43). This is a major advantage for Ligand B.
8. **BBB:** Ligand B (80.07) has a much higher BBB penetration percentile than Ligand A (41.14). While ADRB2 is primarily a cardiovascular target, some CNS off-target effects are possible, and higher BBB is generally preferable. Ligand B is better.
9. **Caco-2:** Ligand A (-5.151) has a more negative Caco-2 value, suggesting *better* permeability than Ligand B (-4.508).
10. **Solubility:** Ligand A (-2.477) has a better solubility score than Ligand B (-5.5). This is important, and mitigates some of the concerns about Ligand B's higher logP.
11. **hERG:** Ligand A (0.25) has a lower hERG inhibition liability than Ligand B (0.887), indicating a lower risk of cardiotoxicity. This is a critical advantage for a cardiovascular drug.
12. **Cl_mic:** Ligand B (92.772) has a much higher microsomal clearance than Ligand A (42.978), suggesting faster metabolism and potentially lower *in vivo* exposure. Ligand A is better.
13. **t1/2:** Ligand A (13.695) has a longer in vitro half-life than Ligand B (-4.016). This is a significant advantage for Ligand A, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have similar Pgp efflux liability (0.328 and 0.338).
15. **Binding Affinity:** Ligand B (-8.9 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.6 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME drawbacks.
**Overall Assessment:**
Ligand B has a much stronger binding affinity and a lower DILI risk, and better BBB penetration. However, it has a higher logP, higher hERG risk, and significantly higher metabolic clearance and shorter half-life. Ligand A has better solubility, lower hERG, better metabolic stability, and a longer half-life. The affinity difference is significant (2.3 kcal/mol), and for a GPCR, affinity is paramount. The higher logP of Ligand B is a concern, but the solubility of Ligand A isn't stellar either. The metabolic instability of Ligand B is a bigger concern.
Considering the balance, the superior binding affinity of Ligand B is the most important factor, and the lower DILI risk is also very beneficial. While the ADME properties of Ligand B are not ideal, they could potentially be improved through further optimization.
Output:
0
2025-04-17 18:00:24,448 - INFO - Batch 6 complete. Total preferences: 96
2025-04-17 18:00:24,448 - INFO - Processing batch 7/512...
2025-04-17 18:01:15,750 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (349.39 and 348.41 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (101.41) is better than Ligand B (107.35). Both are reasonably good for oral absorption (under 140), but lower is generally preferred.
3. **logP:** Ligand A (1.126) is slightly higher than Ligand B (0.782), both are within the optimal 1-3 range.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (2). Both are acceptable.
5. **HBA:** Both ligands have the same number of HBA (6), which is good.
6. **QED:** Both ligands have similar QED scores (0.714 and 0.769), indicating good drug-likeness.
7. **DILI:** Ligand A (41.88%) and Ligand B (48.66%) are both acceptable, with low risk of liver injury.
8. **BBB:** Ligand A (47.93%) is significantly better than Ligand B (20.09%). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be beneficial, and lower efflux is always desirable.
9. **Caco-2:** Both show poor Caco-2 permeability (-4.991 and -5.039). This is a concern for oral bioavailability.
10. **Solubility:** Both ligands have very poor aqueous solubility (-1.346 and -1.491). This is a significant drawback.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.369 and 0.228), which is excellent.
12. **Cl_mic:** Ligand A (9.81) has a lower microsomal clearance than Ligand B (14.62), suggesting better metabolic stability.
13. **t1/2:** Ligand A (15.11) has a longer in vitro half-life than Ligand B (-16.37). This is a significant advantage.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.022 and 0.034).
15. **Binding Affinity:** Ligand B (-7.1 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.7 kcal/mol). This is a substantial advantage (1.4 kcal/mol difference).
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are crucial. While both ligands have acceptable logP and Pgp values, Ligand B's significantly higher binding affinity is a major advantage. The slightly better BBB penetration of Ligand A is a plus, but the potency difference is more important. The poor Caco-2 and solubility are shared drawbacks that would need to be addressed in formulation.
**Conclusion:**
Despite the slightly better BBB penetration and metabolic stability of Ligand A, the significantly stronger binding affinity of Ligand B outweighs these benefits. The potency advantage is likely to be more impactful in achieving the desired pharmacological effect.
Output:
0
2025-04-17 18:01:15,750 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (347.379 Da) is slightly lower, which is generally favorable for permeability.
**2. TPSA:** Ligand B (73.2) is significantly better than Ligand A (107.17). For a GPCR, lower TPSA is preferred for better blood-brain barrier penetration and overall permeability.
**3. logP:** Ligand A (-0.249) is too low, potentially hindering membrane permeability. Ligand B (3.842) is within the optimal range (1-3). This is a significant advantage for Ligand B.
**4. H-Bond Donors:** Both have 1 HBD, which is acceptable.
**5. H-Bond Acceptors:** Ligand A has 8 HBA, while Ligand B has 4. Ligand B is preferable here.
**6. QED:** Both ligands have good QED scores (0.74 and 0.779), indicating good drug-like properties.
**7. DILI:** Ligand A (73.982) has a higher DILI risk than Ligand B (39.201). This is a clear advantage for Ligand B.
**8. BBB:** Both ligands have good BBB penetration (70.997 and 75.378).
**9. Caco-2 permeability:** Both have negative values, indicating poor permeability. Ligand A (-5.434) is slightly worse than Ligand B (-4.946).
**10. Aqueous Solubility:** Both have very poor aqueous solubility (-1.661 and -4.503). This is a concern for both, but Ligand B is worse.
**11. hERG inhibition:** Ligand A (0.131) has a slightly lower hERG risk than Ligand B (0.78).
**12. Microsomal Clearance:** Ligand B (36.251) has a much lower microsomal clearance than Ligand A (1.098), indicating better metabolic stability.
**13. In vitro Half-Life:** Ligand B (9.738) has a significantly longer half-life than Ligand A (3.647).
**14. P-gp efflux:** Ligand A (0.021) has lower P-gp efflux liability than Ligand B (0.397), which is favorable.
**15. Binding Affinity:** Ligand B (-7.2) has a significantly stronger binding affinity than Ligand A (-5.9). This is a substantial advantage, potentially outweighing some of the ADME drawbacks.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand B is the stronger candidate. While both have solubility issues, Ligand B's superior logP, lower DILI risk, better metabolic stability (lower Cl_mic and longer t1/2), and significantly stronger binding affinity outweigh the slightly higher P-gp efflux and hERG risk. The lower TPSA is also beneficial. The affinity difference of >1.5 kcal/mol is a major factor.
Output:
0
2025-04-17 18:01:15,750 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (355.429 and 371.909 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Both ligands (61.44 and 61.88) are below the 140 A^2 threshold for good oral absorption, which is good. They are also reasonably low for a GPCR.
3. **logP:** Both ligands (1.693 and 1.761) are within the optimal 1-3 range. Again, no significant difference.
4. **HBD:** Ligand A has 2 HBD, and Ligand B has 1. Both are acceptable (<=5).
5. **HBA:** Ligand A has 3 HBA, and Ligand B has 4. Both are acceptable (<=10).
6. **QED:** Ligand A (0.713) has a slightly better QED than Ligand B (0.627), indicating a more drug-like profile.
7. **DILI:** Ligand A (26.522) has a lower DILI risk than Ligand B (23.924). Both are good, but A is slightly better.
8. **BBB:** Ligand A (72.78) has a better BBB penetration percentile than Ligand B (66.499). This is a positive for a GPCR, although ADRB2 isn't necessarily a CNS target, some peripheral distribution is still beneficial.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.025 and -5.012), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Both ligands have negative solubility values (-2.544 and -1.161), indicating very poor aqueous solubility. This is a major drawback for both.
11. **hERG:** Both ligands have low hERG inhibition liability (0.512 and 0.41). This is good, minimizing cardiotoxicity risk.
12. **Cl_mic:** Ligand A (-13.579) has a *much* lower (better) microsomal clearance than Ligand B (33.624). This suggests significantly better metabolic stability for Ligand A.
13. **t1/2:** Ligand B (42.771) has a significantly longer in vitro half-life than Ligand A (-1.503). This is a strong advantage for Ligand B.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.025 and 0.019). This is favorable.
15. **Binding Affinity:** Ligand A (-6.6 kcal/mol) has a slightly better binding affinity than Ligand B (-5.4 kcal/mol). This is a 1.2 kcal/mol difference, which is substantial.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Both ligands are comparable on logP and Pgp. Ligand A has a slightly better TPSA and a significantly better binding affinity. The metabolic stability (Cl_mic) of Ligand A is also a major advantage. While Ligand B has a longer half-life, the poor metabolic stability means it may not reach that half-life *in vivo*. The solubility and Caco-2 values are problematic for both, but these can potentially be addressed with formulation strategies.
**Overall Assessment:**
Despite the poor solubility and Caco-2 values for both, Ligand A is the more promising candidate. Its superior binding affinity, significantly better metabolic stability (lower Cl_mic), and slightly better BBB penetration outweigh the longer half-life of Ligand B. The affinity difference is large enough to potentially overcome the ADME challenges.
Output:
1
2025-04-17 18:01:15,750 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's break down the comparison of Ligand A and Ligand B based on the provided parameters and the guidelines, keeping in mind this is a GPCR target (ADRB2, cardiovascular). GPCRs prioritize logP, Pgp, TPSA, and affinity.
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (335.382) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (54.02) is better than Ligand B (66.91). Lower TPSA generally correlates with better cell permeability, a key factor for GPCR ligands.
3. **logP:** Both ligands have good logP values (A: 3.795, B: 3.983), falling within the optimal 1-3 range. Ligand B is slightly higher, which could potentially lead to off-target interactions, but it's not a major concern.
4. **H-Bond Donors:** Both have 2 HBD, which is within the acceptable limit of 5.
5. **H-Bond Acceptors:** Ligand A has 3 HBA, while Ligand B has 5. Ligand A is preferable here, as lower HBA counts generally improve permeability.
6. **QED:** Ligand A (0.713) has a better QED score than Ligand B (0.575), indicating a more drug-like profile.
7. **DILI:** Ligand B (56.146) has a lower DILI risk than Ligand A (66.964), which is a significant advantage. Lower DILI is always preferred.
8. **BBB:** Both ligands have good BBB penetration (A: 76.541, B: 71.035). While not a primary concern for a cardiovascular target, higher BBB is generally favorable.
9. **Caco-2 Permeability:** Ligand A (-4.816) has better Caco-2 permeability than Ligand B (-5.112), suggesting better intestinal absorption.
10. **Aqueous Solubility:** Ligand A (-4.188) has slightly better aqueous solubility than Ligand B (-4.473).
11. **hERG Inhibition:** Ligand A (0.718) has a slightly higher hERG inhibition risk than Ligand B (0.268). This is a crucial factor; lower hERG risk is highly desirable.
12. **Microsomal Clearance:** Ligand B (54.432) has a significantly higher microsomal clearance than Ligand A (20.929), indicating faster metabolism and potentially lower *in vivo* exposure.
13. **In vitro Half-Life:** Ligand B (43.945) has a longer *in vitro* half-life than Ligand A (32.793), which is a positive attribute.
14. **P-gp Efflux:** Both ligands have low P-gp efflux (A: 0.23, B: 0.208), which is good.
15. **Binding Affinity:** Ligand B (-7.0) has a slightly stronger binding affinity than Ligand A (-6.9). This is a significant advantage, as a 0.1 kcal/mol difference can be meaningful.
**Overall Assessment:**
Ligand B has a better binding affinity and lower DILI risk, and longer half-life, which are strong positives. However, Ligand A has better TPSA, QED, Caco-2 permeability, solubility, and lower hERG risk. The difference in binding affinity is small (0.1 kcal/mol), and the lower hERG risk of Ligand A is a critical safety consideration. The higher metabolic clearance of Ligand B is a concern.
Considering the balance of these factors, and prioritizing safety (hERG) and permeability (TPSA, Caco-2) for a GPCR target, I favor Ligand A.
**Output:**
1
2025-04-17 18:01:15,750 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [351.422, 75.44, 2.409, 1, 4, 0.519, 39.744, 76.735, -4.956, -2.158, 0.411, 53.024, -20.261, 0.436, -4.3]
**Ligand B:** [348.487, 58.64, 3.208, 1, 3, 0.455, 18.728, 77.821, -5.109, -3.119, 0.555, 43.921, -17.754, 0.165, -6.7]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). A (351.422) and B (348.487) are very close.
2. **TPSA:** A (75.44) is slightly higher than B (58.64). B is better, being closer to the <90 threshold for potential CNS penetration (though this is less critical for a cardiovascular target like ADRB2, it's still a positive).
3. **logP:** A (2.409) and B (3.208) are both within the optimal range (1-3), but B is edging towards the higher end.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** A has 4, B has 3. Both are acceptable.
6. **QED:** A (0.519) is slightly better than B (0.455), indicating a marginally more drug-like profile.
7. **DILI:** A (39.744) is higher than B (18.728). B is significantly better, indicating lower liver injury risk.
8. **BBB:** Both are reasonably high (A: 76.735, B: 77.821). Not a primary concern for ADRB2, but B is slightly better.
9. **Caco-2:** Both are negative, indicating poor permeability. A (-4.956) is worse than B (-5.109).
10. **Solubility:** Both are negative, indicating poor solubility. A (-2.158) is better than B (-3.119).
11. **hERG:** Both are low (A: 0.411, B: 0.555), indicating low cardiotoxicity risk.
12. **Cl_mic:** A (53.024) is higher than B (43.921), meaning B has better metabolic stability.
13. **t1/2:** A (-20.261) is worse than B (-17.754), meaning B has a longer half-life.
14. **Pgp:** A (0.436) is lower than B (0.165), suggesting less P-gp efflux and potentially better bioavailability.
15. **Affinity:** B (-6.7) is significantly better than A (-4.3). This is a >1.5 kcal/mol advantage, which is substantial.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, affinity is paramount. While logP, TPSA, and Pgp are important, a strong binding affinity can often compensate for minor ADME issues.
**Overall Assessment:**
Ligand B has a significantly better binding affinity (-6.7 kcal/mol vs. -4.3 kcal/mol). It also has a lower DILI risk, better metabolic stability (lower Cl_mic), and a longer half-life. While its Caco-2 permeability and solubility are worse than Ligand A, the substantial affinity advantage outweighs these drawbacks. The TPSA is also more favorable for permeability.
Therefore, I would choose Ligand B.
0
2025-04-17 18:01:15,751 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (349.475) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (60.85) is significantly better than Ligand A (87.3). ADRB2 is not a CNS target, but lower TPSA generally improves absorption.
3. **logP:** Both ligands have good logP values (A: 1.658, B: 1.843) within the optimal 1-3 range.
4. **HBD:** Ligand A (3) has more HBDs than Ligand B (1). While not a major concern, fewer HBDs can sometimes improve permeability.
5. **HBA:** Ligand A (3) and Ligand B (5) are both acceptable, but Ligand B is slightly higher.
6. **QED:** Ligand B (0.845) has a higher QED score than Ligand A (0.637), indicating a more drug-like profile.
7. **DILI:** Both ligands have acceptable DILI risk (A: 27.336, B: 35.905), well below the 60 threshold.
8. **BBB:** Not a primary concern for ADRB2 (cardiovascular target), but Ligand A (61.38) has a higher BBB penetration than Ligand B (39.55).
9. **Caco-2:** Ligand A (-4.835) has a much better Caco-2 permeability than Ligand B (-5.391).
10. **Solubility:** Ligand A (-2.853) has better solubility than Ligand B (-3.358).
11. **hERG:** Both ligands have very low hERG inhibition liability (A: 0.063, B: 0.206), which is excellent.
12. **Cl_mic:** Ligand A (43.076) has lower microsomal clearance than Ligand B (49.134), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-1.076) has a negative half-life, which is concerning. Ligand A (17.986) has a reasonable in vitro half-life.
14. **Pgp:** Both ligands have low P-gp efflux liability (A: 0.009, B: 0.128).
15. **Affinity:** Ligand B (-6.6 kcal/mol) has a slightly better binding affinity than Ligand A (-6.4 kcal/mol), but the difference is small.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in TPSA and has a slightly better affinity. However, Ligand A has better solubility, permeability, metabolic stability (lower Cl_mic), and a positive half-life. The small affinity difference is outweighed by the more favorable ADME profile of Ligand A.
**Conclusion:**
Considering the balance of properties and the priorities for a GPCR target, Ligand A is the more promising drug candidate.
Output:
1
2025-04-17 18:01:15,751 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's systematically compare Ligand A and Ligand B based on the provided parameters and the guidelines, keeping in mind that ADRB2 is a GPCR, so logP, Pgp, TPSA, and affinity are particularly important.
1. **MW:** Both ligands (371.7 & 347.5 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (99.81) is slightly higher than Ligand B (82.68). Both are acceptable for oral absorption (<140), but Ligand B is preferable due to the lower TPSA.
3. **logP:** Both ligands have good logP values (1.888 & 1.655), falling within the optimal 1-3 range. Ligand B is slightly lower, which could be beneficial for solubility.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1). Both are within the acceptable limit of <=5.
5. **HBA:** Ligand A (5) is lower than Ligand B (8). Ligand A is preferable here, as higher HBA can sometimes hinder permeability.
6. **QED:** Ligand A (0.805) has a significantly better QED score than Ligand B (0.658), indicating a more drug-like profile.
7. **DILI:** Ligand B (42.536) has a much lower DILI risk than Ligand A (87.864). This is a substantial advantage for Ligand B.
8. **BBB:** Ligand B (73.401) shows better BBB penetration than Ligand A (48.391). While ADRB2 isn't necessarily a CNS target, some peripheral ADRB2 activity can influence CNS pathways, so better BBB penetration isn't a detriment.
9. **Caco-2:** Ligand A (-4.83) has a worse Caco-2 permeability than Ligand B (-5.519). Lower values indicate poorer permeability. Ligand B is preferable.
10. **Solubility:** Ligand B (-1.519) has better aqueous solubility than Ligand A (-4.387). This is a significant advantage.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.157 & 0.15), which is excellent.
12. **Cl_mic:** Ligand A (-2.315) has a lower (better) microsomal clearance than Ligand B (25.355), suggesting greater metabolic stability.
13. **t1/2:** Ligand A (13.25) has a longer in vitro half-life than Ligand B (3.361). This is a positive for Ligand A.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.098 & 0.181).
15. **Affinity:** Ligand B (-7.3 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.7 kcal/mol). This 0.6 kcal/mol difference is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand B demonstrates a superior balance of properties. While Ligand A has a better QED and metabolic stability, Ligand B excels in critical areas for a GPCR target: significantly better binding affinity, lower DILI risk, better solubility, and improved Caco-2 permeability. The stronger binding affinity is the most crucial factor, and the other advantages of Ligand B provide a more favorable overall profile.
**Output:**
0
2025-04-17 18:01:15,751 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (343.391 and 350.459 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand B (75.71) is significantly better than Ligand A (128.45). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally improves absorption.
3. **logP:** Ligand B (1.524) is within the optimal range (1-3), while Ligand A (0.075) is quite low, potentially hindering membrane permeability. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (4) is slightly higher than Ligand B (1). Both are acceptable, but lower is generally preferred.
5. **HBA:** Ligand A (5) and Ligand B (4) are both within the acceptable range (<=10).
6. **QED:** Ligand B (0.788) has a better QED score than Ligand A (0.504), indicating a more drug-like profile.
7. **DILI:** Ligand B (19.698) has a much lower DILI risk than Ligand A (65.529). This is a critical advantage for Ligand B.
8. **BBB:** Ligand B (74.06) has a higher BBB penetration percentile than Ligand A (21.753). While not crucial for a cardiovascular target, it doesn't hurt.
9. **Caco-2:** Ligand A (-5.698) and Ligand B (-4.753) both have negative values, which is unusual. I will interpret this as very poor permeability for both.
10. **Solubility:** Ligand A (-2.475) and Ligand B (-2.216) both have negative values, which is unusual. I will interpret this as very poor solubility for both.
11. **hERG:** Ligand A (0.101) and Ligand B (0.184) are both very low, indicating minimal hERG inhibition risk.
12. **Cl_mic:** Ligand A (-17.126) has a much lower (better) microsomal clearance than Ligand B (21.09). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (2.719) has a shorter half-life than Ligand B (-5.297). This is a negative for Ligand A.
14. **Pgp:** Ligand A (0.028) has a lower P-gp efflux liability than Ligand B (0.053). This is a slight advantage for Ligand A.
15. **Binding Affinity:** Ligand A (-6.8) has a slightly better binding affinity than Ligand B (-5.7). This is a 1.1 kcal/mol difference, which is significant, but not overwhelming.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, and affinity are key. Ligand B excels in logP and TPSA, while Ligand A has a slightly better affinity. However, the significantly lower DILI risk for Ligand B and its better QED score are crucial factors. The better metabolic stability of Ligand A is a plus, but the permeability issues (Caco-2 and solubility) are concerning.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity and metabolic stability, Ligand B's superior ADME properties (logP, TPSA, DILI, QED) and reasonable affinity make it the more promising drug candidate. The low logP and solubility of Ligand A are significant drawbacks.
Output:
0
2025-04-17 18:01:15,751 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [365.905, 52.65, 3.866, 1, 2, 0.884, 43.273, 87.941, -4.52, -4.588, 0.751, 46.02, 60.57, 0.097, -8.7]**
**Ligand B: [350.438, 68.09, 2.662, 0, 5, 0.837, 28.189, 93.292, -4.541, -2.675, 0.094, 26.626, -27.82, 0.06, -7.4]**
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand B (350.438) is slightly lower, which is generally favorable for permeability, but both are acceptable.
2. **TPSA:** Ligand A (52.65) is better than Ligand B (68.09). ADRB2 is not a CNS target, but lower TPSA generally improves absorption.
3. **logP:** Ligand A (3.866) is slightly higher than Ligand B (2.662), both within the optimal 1-3 range. Ligand A is closer to the upper limit, which could potentially lead to off-target effects, but is still acceptable.
4. **H-Bond Donors:** Ligand A (1) is better than Ligand B (0). Fewer HBDs generally improve permeability.
5. **H-Bond Acceptors:** Ligand A (2) is better than Ligand B (5). Fewer HBAs generally improve permeability.
6. **QED:** Both ligands have similar QED values (0.884 and 0.837), indicating good drug-likeness.
7. **DILI:** Ligand A (43.273) has a slightly higher DILI risk than Ligand B (28.189), but both are below the concerning threshold of 60. Ligand B is preferable here.
8. **BBB:** Both have good BBB penetration, but Ligand B (93.292) is better than Ligand A (87.941). While ADRB2 isn't a CNS target, higher BBB penetration can sometimes correlate with better overall distribution.
9. **Caco-2:** Both ligands have similar, very poor Caco-2 permeability (-4.52 and -4.541). This is a significant concern for both.
10. **Solubility:** Ligand B (-2.675) has better solubility than Ligand A (-4.588). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.751) has a slightly higher hERG risk than Ligand B (0.094). Lower hERG risk is crucial for cardiovascular drugs. Ligand B is significantly better here.
12. **Cl_mic:** Ligand B (26.626) has significantly lower microsomal clearance than Ligand A (46.02), indicating better metabolic stability.
13. **t1/2:** Ligand B (-27.82) has a much longer in vitro half-life than Ligand A (60.57). This is a major advantage for dosing convenience.
14. **Pgp:** Ligand A (0.097) has slightly lower P-gp efflux than Ligand B (0.06), which is preferable.
15. **Binding Affinity:** Ligand A (-8.7) has a substantially stronger binding affinity than Ligand B (-7.4). This is a 1.3 kcal/mol difference, which is a significant advantage and can outweigh some of the ADME drawbacks.
**Overall Assessment:**
Ligand A has a significantly better binding affinity, which is the most critical factor for GPCRs. While Ligand B has better ADME properties (lower DILI, better solubility, lower hERG, better metabolic stability, longer half-life), the substantial difference in binding affinity of Ligand A outweighs these benefits. The poor Caco-2 permeability is a concern for both, but can be addressed through formulation strategies. The slightly higher hERG risk for Ligand A is also a concern, but the strong binding affinity suggests that a lower dose might be effective, potentially mitigating the hERG risk.
Output:
1
2025-04-17 18:01:15,753 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (357.451 Da) is slightly higher than Ligand B (348.487 Da), but both are acceptable.
2. **TPSA:** Ligand A (91.34) is higher than Ligand B (49.85). For a cardiovascular GPCR like ADRB2, TPSA is moderately important. Ligand B's lower TPSA is preferable for better membrane permeability.
3. **logP:** Ligand A (-1.076) is lower than the optimal range (1-3), potentially hindering permeability. Ligand B (2.299) is within the optimal range. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (2) and Ligand B (0) are both acceptable, below the threshold of 5.
5. **HBA:** Ligand A (6) and Ligand B (3) are both acceptable, below the threshold of 10.
6. **QED:** Both ligands have good QED scores (Ligand A: 0.574, Ligand B: 0.692), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (4.42) has a very low DILI risk, which is excellent. Ligand B (22.257) is still relatively low, but higher than Ligand A.
8. **BBB:** Ligand A (32.144) has a low BBB penetration, as expected for a more polar compound. Ligand B (65.413) has moderate BBB penetration. While ADRB2 isn't a primary CNS target, some degree of BBB penetration can be beneficial for off-target effects assessment and potential peripheral distribution.
9. **Caco-2:** Ligand A (-5.214) has poor Caco-2 permeability, consistent with its lower logP and higher TPSA. Ligand B (-4.097) is better, but still not great.
10. **Solubility:** Ligand A (0.28) has very poor solubility. Ligand B (-2.638) also has poor solubility. This is a concern for both, but Ligand A is worse.
11. **hERG:** Ligand A (0.151) has a very low hERG risk, which is ideal. Ligand B (0.41) is slightly higher, but still acceptable.
12. **Cl_mic:** Ligand A (-7.355) has a negative clearance, indicating very good metabolic stability. Ligand B (56.336) has high metabolic clearance, which is a significant drawback.
13. **t1/2:** Ligand A (-17.34) has a negative half-life, which is not physically meaningful and likely an error in the data, but suggests very rapid clearance. Ligand B (-11.684) is also negative, but less so. Both are problematic.
14. **Pgp:** Ligand A (0.004) has very low P-gp efflux, which is desirable. Ligand B (0.145) has slightly higher P-gp efflux.
15. **Affinity:** Ligand A (-6.9 kcal/mol) has slightly better binding affinity than Ligand B (-5.0 kcal/mol). This is a 1.9 kcal/mol difference, which is substantial.
**Overall Assessment:**
Ligand A has a superior binding affinity and a much lower DILI risk and P-gp efflux. However, its poor solubility, permeability, and metabolic stability are major concerns. Ligand B has better logP, TPSA, and moderate BBB penetration, but suffers from higher metabolic clearance and a lower binding affinity.
Given the GPCR-specific priorities (logP, Pgp, TPSA, affinity), and the fact that the affinity difference is significant, I would lean towards Ligand A *if* the solubility and permeability issues could be addressed through formulation or further chemical modification. However, the negative half-life values for both are concerning and suggest potential data quality issues. Considering the overall balance, and the fact that the metabolic stability of Ligand B is a significant drawback, I will select Ligand A.
Output:
1
2025-04-17 18:01:15,753 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (368.499 and 387.527 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (66.92) is significantly better than Ligand B (88.6). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (1.697 and 1.359), falling within the optimal 1-3 range. Ligand B is slightly lower, which could be marginally better for solubility.
4. **HBD:** Ligand A (0) is preferable to Ligand B (1). Fewer HBDs generally improve membrane permeability.
5. **HBA:** Ligand A (5) is better than Ligand B (6). Lower HBA is generally preferred for permeability.
6. **QED:** Ligand B (0.688) has a slightly better QED score than Ligand A (0.527), suggesting a more drug-like profile.
7. **DILI:** Both ligands have acceptable DILI risk (43.234 and 67.739), with Ligand A being slightly better.
8. **BBB:** Ligand A (60.76) has a better BBB score than Ligand B (28.383). While not a CNS target, some degree of BBB penetration can sometimes indicate favorable permeability characteristics.
9. **Caco-2:** Ligand A (-4.69) is significantly better than Ligand B (-5.155). This suggests better intestinal absorption for Ligand A.
10. **Solubility:** Ligand A (-2.605) is better than Ligand B (-3.349).
11. **hERG:** Both ligands have very low hERG inhibition risk (0.134 and 0.253). This is excellent.
12. **Cl_mic:** Ligand B (48.083) has a significantly lower microsomal clearance than Ligand A (87.156), indicating better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand B (-30.721) has a much longer in vitro half-life than Ligand A (-0.314). This is a major advantage, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.08 and 0.07).
15. **Binding Affinity:** Ligand A (-7.0) has a slightly better binding affinity than Ligand B (-5.2). This is a 1.8 kcal/mol difference, which is substantial.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A excels in TPSA, logP, and significantly in binding affinity. Ligand B excels in metabolic stability (Cl_mic) and half-life. The binding affinity difference is substantial enough to outweigh the metabolic concerns, especially given that both have acceptable metabolic profiles.
**Conclusion:**
Despite Ligand B's better metabolic stability and half-life, the significantly stronger binding affinity of Ligand A (-7.0 kcal/mol vs -5.2 kcal/mol) is the deciding factor. A 1.8 kcal/mol difference is a large advantage and is likely to translate into greater efficacy. Furthermore, Ligand A has better TPSA and Caco-2 permeability.
Output:
1
2025-04-17 18:01:15,753 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [346.446, 41.57, 3.458, 1, 2, 0.911, 17.1, 91.508, -4.442, -3.861, 0.826, 53.104, 19.023, 0.309, -7.2]
**Ligand B:** [345.443, 61.88, 1.17, 1, 5, 0.594, 26.095, 67.08, -4.88, -0.706, 0.521, 42.169, -25.995, 0.02, -5.1]
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (346.45 Da and 345.44 Da).
2. **TPSA:** Ligand A (41.57) is significantly better than Ligand B (61.88). ADRB2 is not a CNS target, but lower TPSA generally aids absorption.
3. **logP:** Ligand A (3.458) is optimal, while Ligand B (1.17) is on the lower side. This could impact permeability.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A (2) is better than Ligand B (5). Fewer HBA generally improves permeability.
6. **QED:** Ligand A (0.911) is excellent, indicating high drug-likeness. Ligand B (0.594) is acceptable but less ideal.
7. **DILI:** Ligand A (17.1) has a much lower DILI risk than Ligand B (26.095). This is a significant advantage.
8. **BBB:** Ligand A (91.508) shows excellent BBB penetration, while Ligand B (67.08) is moderate. Although ADRB2 isn't a CNS target, higher BBB penetration can sometimes correlate with better overall distribution.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
10. **Solubility:** Ligand A (-3.861) is better than Ligand B (-0.706).
11. **hERG:** Ligand A (0.826) has a lower hERG risk than Ligand B (0.521).
12. **Cl_mic:** Ligand B (42.169) has lower microsomal clearance, suggesting better metabolic stability than Ligand A (53.104).
13. **t1/2:** Ligand A (19.023) has a longer in vitro half-life than Ligand B (-25.995). This is a significant advantage.
14. **Pgp:** Ligand A (0.309) has lower P-gp efflux than Ligand B (0.02). This is a positive.
15. **Affinity:** Ligand A (-7.2) has a significantly stronger binding affinity than Ligand B (-5.1). This is a crucial factor.
**GPCR-specific priorities:** For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, and affinity. Ligand A is superior in all these areas. The strong binding affinity of Ligand A (-7.2 kcal/mol) is a substantial advantage, easily outweighing the slightly higher Cl_mic compared to Ligand B. The lower DILI risk and better QED of Ligand A are also compelling.
**Conclusion:**
Ligand A is the more promising drug candidate.
```
1
```
2025-04-17 18:01:15,753 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [368.459, 115.39 , -0.709, 3. , 5. , 0.588, 35.595, 16.324, -5.394, -2.462, 0.11 , 4.302, -12.806, 0.007, -6.6 ]
**Ligand B:** [344.375, 104.45 , 0.385, 1. , 7. , 0.863, 67.778, 32.765, -4.941, -2.523, 0.092, 19.283, -20.417, 0.06 , -6.2 ]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, Affinity):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (344.375) is slightly lower, which is generally favorable.
2. **TPSA:** Both are acceptable, but Ligand B (104.45) is better than Ligand A (115.39), being closer to the <140 threshold for good absorption.
3. **logP:** Ligand A (-0.709) is a bit low, potentially hindering permeability. Ligand B (0.385) is better, falling within the 1-3 range.
4. **HBD/HBA:** Ligand A (3 HBD, 5 HBA) is slightly better balanced than Ligand B (1 HBD, 7 HBA). Higher HBA can sometimes impact permeability.
5. **QED:** Ligand B (0.863) has a significantly better QED score than Ligand A (0.588), indicating a more drug-like profile.
6. **DILI:** Ligand A (35.595) has a much lower DILI risk than Ligand B (67.778). This is a significant advantage for Ligand A.
7. **BBB:** Ligand B (32.765) has a higher BBB penetration percentile than Ligand A (16.324). While ADRB2 isn't *strictly* a CNS target, some CNS exposure can occur, and higher BBB is generally favorable.
8. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-5.394) is slightly better than Ligand B (-4.941), but both are concerning.
9. **Solubility:** Both are negative, indicating poor solubility. They are very similar.
10. **hERG:** Both have low hERG risk (0.11 and 0.092 respectively).
11. **Cl_mic:** Ligand A (4.302) has significantly lower microsomal clearance than Ligand B (19.283), suggesting better metabolic stability.
12. **t1/2:** Ligand B (-20.417) has a longer half-life than Ligand A (-12.806), which is generally desirable.
13. **Pgp:** Both have very low Pgp efflux liability (0.007 and 0.06 respectively).
14. **Affinity:** Both have similar and good binding affinities (-6.6 and -6.2 kcal/mol). The difference is not substantial enough to be a deciding factor.
**Overall Assessment:**
Ligand A has a significant advantage in DILI risk and metabolic stability (Cl_mic), and a slightly better HBD/HBA balance. Ligand B has a better QED score and BBB penetration, but the higher DILI risk is a major concern. The slightly better logP of Ligand B is offset by the poor Caco-2 permeability of both. Given the importance of minimizing toxicity (DILI) and maximizing metabolic stability for a cardiovascular target, and the relatively similar binding affinities, I favor Ligand A.
Output:
1
2025-04-17 18:01:15,753 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (353.369 Da and 350.394 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (87.3) is slightly higher than Ligand B (75.93). Both are below the 140 threshold for good oral absorption, but closer to the 90 threshold for CNS targets which is less relevant here. Ligand B is preferable.
3. **logP:** Ligand A (0.348) is quite low, potentially hindering permeation. Ligand B (0.956) is better, falling within the optimal 1-3 range. Ligand B is preferable.
4. **HBD:** Ligand A (3) is higher than Ligand B (1). Lower HBD is generally preferred for better permeability. Ligand B is preferable.
5. **HBA:** Ligand A (3) is lower than Ligand B (5). Lower HBA is generally preferred for better permeability. Ligand A is preferable.
6. **QED:** Ligand B (0.83) has a significantly higher QED score than Ligand A (0.456), indicating a more drug-like profile. Ligand B is preferable.
7. **DILI:** Both ligands have acceptable DILI risk (Ligand A: 30.826, Ligand B: 37.185), both well below the 60 threshold. No significant difference.
8. **BBB:** Both ligands have reasonable BBB penetration (Ligand A: 67.662, Ligand B: 70.648). Since ADRB2 isn't primarily a CNS target, this isn't a major deciding factor, but Ligand B is slightly better.
9. **Caco-2:** Both have negative values. This is unusual and suggests a problem with the data. However, the magnitude of the negative values is similar.
10. **Solubility:** Both ligands have very poor aqueous solubility (Ligand A: -2.526, Ligand B: -2.141). This is a significant concern.
11. **hERG:** Both ligands have low hERG inhibition risk (Ligand A: 0.092, Ligand B: 0.344). No significant difference.
12. **Cl_mic:** Ligand A (-5.43) has a lower (better) microsomal clearance than Ligand B (7.172). This suggests better metabolic stability. Ligand A is preferable.
13. **t1/2:** Ligand A (-18.438) has a much lower in vitro half-life than Ligand B (-2.719). This is a significant drawback for Ligand A. Ligand B is preferable.
14. **Pgp:** Both ligands have low Pgp efflux liability (Ligand A: 0.012, Ligand B: 0.098). No significant difference.
15. **Binding Affinity:** Ligand A (-5.4) has a better binding affinity than Ligand B (-3.6). This is a substantial difference (1.8 kcal/mol), and is a major advantage.
**Overall Assessment & GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, and affinity are key. Ligand B has better logP and TPSA. However, Ligand A has a significantly stronger binding affinity (-5.4 vs -3.6 kcal/mol). The affinity difference is large enough to outweigh the slightly less favorable logP and TPSA of Ligand A. The poor solubility of both is a concern, but can be addressed with formulation strategies. The better metabolic stability (lower Cl_mic) of Ligand A is also a plus. The significantly longer half-life of Ligand B is a strong point in its favor.
Considering the balance, the superior binding affinity of Ligand A is the most important factor, especially for a receptor target where achieving sufficient occupancy is crucial.
Output:
1
2025-04-17 18:01:15,753 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
We are targeting ADRB2, a GPCR. Therefore, the priorities are logP, Pgp, TPSA, affinity, and BBB. Let's analyze each ligand against these and other important parameters:
* **Molecular Weight:** Both ligands (372.45 and 350.38) fall within the ideal 200-500 Da range.
* **TPSA:** Ligand A (59.81) is significantly better than Ligand B (139.85). A TPSA under 140 is good for oral absorption, and A is closer to the ideal <90 for CNS targets (though BBB is also a factor).
* **logP:** Ligand A (4.458) is higher than the optimal 1-3 range, but still potentially manageable. Ligand B (-1.734) is *too* low, which could severely limit permeability.
* **H-Bond Donors/Acceptors:** Ligand A (1 HBD, 6 HBA) is preferable to Ligand B (3 HBD, 9 HBA). Both are within acceptable ranges, but fewer H-bonds generally improve permeability.
* **QED:** Ligand A (0.578) is slightly better than Ligand B (0.488), indicating a more drug-like profile.
* **DILI:** Ligand B (64.521) has a lower DILI risk than Ligand A (95.929), which is a significant advantage.
* **BBB:** Ligand A (70.648) has a much better BBB penetration potential than Ligand B (19.93). This is important for GPCRs, even if ADRB2 isn't strictly a CNS target, as it can influence distribution.
* **Caco-2:** Ligand A (-4.897) is better than Ligand B (-5.924), indicating better intestinal absorption.
* **Solubility:** Ligand A (-4.601) is better than Ligand B (-0.97).
* **hERG:** Ligand A (0.644) has a lower hERG risk than Ligand B (0.031), which is a critical safety factor.
* **Cl_mic:** Ligand B (3.694) has significantly better metabolic stability (lower clearance) than Ligand A (50.548).
* **t1/2:** Ligand A (74.438) has a much longer in vitro half-life than Ligand B (17.636).
* **Pgp:** Ligand A (0.815) is better than Ligand B (0.021), indicating lower P-gp efflux.
* **Binding Affinity:** Ligand A (-8.6 kcal/mol) has a *much* stronger binding affinity than Ligand B (-1.0 kcal/mol). This is the most important factor, and the difference of 7.6 kcal/mol is substantial.
**Overall Assessment:**
While Ligand B has advantages in DILI and metabolic stability (Cl_mic), the overwhelming advantages of Ligand A in binding affinity, TPSA, BBB, solubility, hERG, and Caco-2 permeability, coupled with acceptable values for other parameters, make it the far more promising drug candidate. The strong binding affinity is a major driver, and the better permeability profile (TPSA, logP, Pgp) suggests it will reach its target more effectively. The higher DILI risk of Ligand A could be investigated further, but is less concerning than the very weak binding of Ligand B.
**Output:**
1
2025-04-17 18:01:15,753 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (343.45 and 355.429 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Both ligands (55.63 and 54.46) are below the 140 threshold for good oral absorption, and are reasonable for a GPCR target. No significant difference.
3. **logP:** Ligand A (4.219) is slightly higher than Ligand B (2.723). While both are within the 1-3 range, A is pushing the upper limit. This could potentially cause solubility issues.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 5 HBA, Ligand B has 4. Both are acceptable.
6. **QED:** Ligand A (0.903) has a better QED score than Ligand B (0.779), indicating better overall drug-likeness.
7. **DILI:** Ligand B (22.451) has a much lower DILI risk than Ligand A (49.283). This is a significant advantage for Ligand B.
8. **BBB:** Both ligands have high BBB penetration (88.174 and 87.67), which is good, but not critical for ADRB2 as it's primarily a cardiovascular target.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability.
10. **Solubility:** Ligand B (-3.243) has better solubility than Ligand A (-4.618).
11. **hERG:** Both have low hERG inhibition risk (0.491 and 0.435).
12. **Cl_mic:** Ligand A (46.825) has lower microsomal clearance than Ligand B (61.053), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-9.571) has a negative in vitro half-life, which is very concerning. Ligand A (34.267) has a reasonable half-life.
14. **Pgp:** Both have low Pgp efflux liability (0.604 and 0.062).
15. **Affinity:** Ligand B (-7.4) has a slightly better binding affinity than Ligand A (-6.8).
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are important. Ligand B has a better logP and affinity, and comparable TPSA and Pgp. However, the extremely poor in vitro half-life of Ligand B is a major red flag. The DILI risk is also significantly lower for Ligand B. While Ligand A has a slightly higher logP, its better QED, metabolic stability (lower Cl_mic), and reasonable half-life make it a more promising candidate.
**Conclusion:**
Despite Ligand B's slightly better affinity and lower DILI, the extremely short in vitro half-life is a dealbreaker. Ligand A, with its better metabolic stability and drug-like properties, is the more viable candidate.
Output:
1
2025-04-17 18:01:15,753 - INFO - Batch 7 complete. Total preferences: 112
2025-04-17 18:01:15,753 - INFO - Processing batch 8/512...
2025-04-17 18:02:03,105 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (334.463 Da) is better than Ligand B (372.446 Da). Both are within the ideal range, but A is closer to the lower, more permeability-favorable end.
2. **TPSA:** Ligand A (32.34) is significantly better than Ligand B (75.71). ADRB2 is not a CNS target, but lower TPSA generally improves absorption. Ligand B's TPSA is quite high, potentially hindering oral bioavailability.
3. **logP:** Ligand A (3.681) is slightly higher than Ligand B (2.169). Both are within the optimal range, but A is closer to the upper limit.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A (2) is better than Ligand B (4). Lower HBA is generally preferred for permeability.
6. **QED:** Ligand A (0.929) is significantly better than Ligand B (0.725), indicating a more drug-like profile.
7. **DILI:** Ligand A (37.456) is worse than Ligand B (12.641). This is a significant advantage for Ligand B.
8. **BBB:** Not a primary concern for ADRB2 (cardiovascular target), but Ligand A (91.121) is better than Ligand B (57.231).
9. **Caco-2:** Both are negative, indicating poor permeability. However, the scale is not provided, so it's difficult to compare.
10. **Solubility:** Ligand A (-4.246) is better than Ligand B (-1.369). Higher solubility is generally desirable.
11. **hERG:** Ligand A (0.922) is better than Ligand B (0.227). Lower hERG inhibition is crucial for avoiding cardiotoxicity, a major concern for cardiovascular drugs.
12. **Cl_mic:** Ligand A (45.81) is worse than Ligand B (0.853). Lower clearance is better for metabolic stability, giving Ligand B a clear advantage.
13. **t1/2:** Ligand A (-7.953) is better than Ligand B (-3.307). Longer half-life is generally preferred.
14. **Pgp:** Ligand A (0.686) is better than Ligand B (0.041). Lower P-gp efflux is desirable for improved bioavailability.
15. **Binding Affinity:** Ligand B (-8.1) is slightly better than Ligand A (-6.7). This is a 1.4 kcal/mol difference, which is substantial and can outweigh some ADME drawbacks.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has better logP, TPSA, and Pgp. Ligand B has a significantly better binding affinity.
**Overall Assessment:**
Ligand B has a significantly better binding affinity (-8.1 vs -6.7 kcal/mol) and a much lower DILI risk. While its TPSA is higher, the binding affinity advantage and lower toxicity risk are substantial. The lower clearance is also a benefit. Ligand A has better solubility and hERG, but the affinity difference and toxicity profile of Ligand B are more important in this context.
Output:
0
2025-04-17 18:02:03,105 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (340.467 and 350.547 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (49.41) is better than Ligand B (58.2), being closer to the <140 threshold for good oral absorption. This is a slight advantage for A.
3. **logP:** Both ligands have logP values (3.817 and 4.04) within the optimal 1-3 range, but are approaching the upper limit. B is slightly higher, which *could* indicate potential solubility issues, but is not a major concern.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Both ligands have 2 HBA, which is well within the acceptable range.
6. **QED:** Ligand A (0.909) has a significantly better QED score than Ligand B (0.694), indicating a more drug-like profile. This is a substantial advantage for A.
7. **DILI:** Ligand A (36.06) has a better DILI percentile than Ligand B (18.302), indicating lower potential for liver injury. This is a significant advantage for A.
8. **BBB:** Both ligands have high BBB penetration (89.531 and 84.219), which is good, but not critical for ADRB2 as it isn't a CNS target.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and likely indicates poor permeability. This is a significant drawback for both.
10. **Solubility:** Ligand A (-3.998) has better solubility than Ligand B (-4.76).
11. **hERG:** Both ligands have low hERG inhibition liability (0.622 and 0.533). This is good.
12. **Cl_mic:** Ligand A (59.485) has a lower microsomal clearance than Ligand B (82.7), suggesting better metabolic stability. This is a favorable attribute for A.
13. **t1/2:** Ligand A (10.372) has a longer in vitro half-life than Ligand B (4.045). This is a clear advantage for A.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.459 and 0.161).
15. **Binding Affinity:** Ligand A (-7.0) has a slightly better binding affinity than Ligand B (-4.9). This is a significant advantage for A.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Both ligands are reasonable in logP and Pgp. Ligand A is better in TPSA, and significantly better in affinity.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical parameters: QED, DILI, solubility, metabolic stability (Cl_mic, t1/2), and binding affinity. While both have issues with Caco-2 permeability, the other advantages of Ligand A make it the more promising candidate. The superior binding affinity is a substantial factor.
Output:
1
2025-04-17 18:02:03,106 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (348.261 Da and 351.447 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (95.35) is better than Ligand B (102.66). Both are below 140, suggesting reasonable absorption, but lower TPSA is favored for GPCRs.
**3. logP:** Ligand A (2.593) is optimal (1-3), while Ligand B (0.819) is slightly low, potentially hindering membrane permeability. This is a notable advantage for Ligand A.
**4. H-Bond Donors:** Ligand A (0) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
**5. H-Bond Acceptors:** Ligand A (6) is slightly better than Ligand B (5). Both are within the acceptable range.
**6. QED:** Ligand B (0.674) has a slightly better QED score than Ligand A (0.522), indicating a marginally more drug-like profile. However, the difference isn't substantial.
**7. DILI:** Ligand A (89.88) has a significantly higher DILI risk than Ligand B (13.804). This is a major concern for Ligand A.
**8. BBB:** Ligand A (74.874) has better BBB penetration than Ligand B (54.789). While ADRB2 is a cardiovascular target, some CNS effects are possible with certain ligands, and higher BBB penetration isn't necessarily detrimental.
**9. Caco-2 Permeability:** Ligand A (-4.246) is better than Ligand B (-4.835). Higher values indicate better intestinal absorption.
**10. Aqueous Solubility:** Ligand A (-4.279) is better than Ligand B (-1.791). Higher solubility is generally desirable.
**11. hERG Inhibition:** Both ligands show low hERG inhibition liability (0.392 and 0.252 respectively), which is good.
**12. Microsomal Clearance:** Ligand B (2.236) has a much lower microsomal clearance than Ligand A (60.575), indicating greater metabolic stability. This is a significant advantage for Ligand B.
**13. In vitro Half-Life:** Ligand A (22.768) has a longer half-life than Ligand B (-8.108). This is a positive for Ligand A.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.586 and 0.008 respectively).
**15. Binding Affinity:** Both ligands have very similar binding affinities (-6.3 kcal/mol and -6.7 kcal/mol). The difference is small and unlikely to be decisive.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand A initially appears favorable due to its better logP and TPSA. However, the significantly higher DILI risk associated with Ligand A is a major red flag. The improved metabolic stability (lower Cl_mic) of Ligand B is also a substantial advantage. While Ligand A has a slightly longer half-life, the DILI risk outweighs this benefit.
Therefore, I favor Ligand B.
0
2025-04-17 18:02:03,106 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (355.439 and 357.401 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (131.18) is slightly above the preferred <140 for good oral absorption, but acceptable. Ligand B (78.51) is excellent, well below 90, suggesting good permeability. Ligand B is favored here.
3. **logP:** Ligand A (-0.067) is a bit low, potentially hindering permeation. Ligand B (1.196) is within the optimal 1-3 range. Ligand B is favored.
4. **HBD:** Ligand A (4) is acceptable. Ligand B (2) is also good. No strong preference.
5. **HBA:** Ligand A (5) is acceptable. Ligand B (3) is also good. No strong preference.
6. **QED:** Ligand B (0.75) is better than Ligand A (0.492), indicating a more drug-like profile. Ligand B is favored.
7. **DILI:** Ligand A (38.697) has a slightly higher DILI risk than Ligand B (27.608), but both are below the concerning threshold of 60. Ligand B is slightly favored.
8. **BBB:** Ligand A (20.357) has poor BBB penetration. Ligand B (83.366) has excellent BBB penetration. Given ADRB2's cardiovascular involvement, CNS penetration isn't *critical*, but it's a bonus. Ligand B is favored.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
10. **Solubility:** Ligand A (-0.57) has very poor solubility. Ligand B (-2.23) is also poor, but worse than Ligand A. Ligand A is slightly favored.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.02 and 0.154), which is excellent. No preference.
12. **Cl_mic:** Ligand A (-4.486) has a negative clearance, which is unusual and suggests very high metabolic stability. Ligand B (1.054) has a low, but positive, clearance. Ligand A is strongly favored.
13. **t1/2:** Ligand A (-7.17) has a negative half-life, which is also unusual and suggests extremely long duration of action. Ligand B (-1.634) has a short half-life. Ligand A is strongly favored.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.009 and 0.01). No preference.
15. **Binding Affinity:** Ligand B (-7.3) has a slightly better binding affinity than Ligand A (-6.1), a difference of 1.2 kcal/mol. This is a significant advantage. Ligand B is favored.
**Overall Assessment:**
Ligand B has a better overall profile regarding drug-like properties (QED, TPSA, logP, BBB). However, Ligand A exhibits significantly better metabolic stability (Cl_mic, t1/2) and solubility. The binding affinity difference is notable, but the metabolic stability and solubility of Ligand A are compelling, especially for a GPCR target where maintaining therapeutic levels is crucial. The unusual negative values for Cl_mic and t1/2 for Ligand A are concerning and need further investigation, but the potential for a long-lasting effect is attractive.
Considering the balance of properties and the importance of metabolic stability for a cardiovascular target, I lean towards Ligand A.
Output:
1
2025-04-17 18:02:03,106 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's analyze each ligand against the provided guidelines, with emphasis on GPCR-relevant properties (logP, Pgp, TPSA, and affinity).
* **Molecular Weight:** Both ligands (352.362 and 344.415 Da) fall comfortably within the ideal 200-500 Da range.
* **TPSA:** Both ligands are around 105, which is acceptable for oral absorption, but not ideal for CNS penetration if that were a goal.
* **logP:** Both ligands have logP values (1.468 and 1.695) within the optimal 1-3 range.
* **H-Bond Donors/Acceptors:** Ligand A (3 HBD, 4 HBA) is slightly better than Ligand B (2 HBD, 5 HBA) in terms of balancing solubility and permeability.
* **QED:** Ligand B (0.783) has a better QED score than Ligand A (0.553), suggesting a more generally drug-like profile.
* **DILI:** Ligand B (31.02) has a significantly lower DILI risk than Ligand A (57.348), which is a major advantage.
* **BBB:** Both ligands have similar BBB penetration (60.14 and 56.65), which isn't a high priority for a peripheral target like ADRB2.
* **Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the values are similar (-5.045 vs -4.733).
* **Aqueous Solubility:** Both ligands have negative solubility values, indicating poor solubility. Ligand B (-3.208) is slightly better than Ligand A (-2.29).
* **hERG Inhibition:** Both ligands show very low hERG inhibition risk (0.08 and 0.296).
* **Microsomal Clearance:** Ligand B (36.832 mL/min/kg) has a higher microsomal clearance than Ligand A (15.406 mL/min/kg), indicating faster metabolism and potentially lower *in vivo* exposure.
* **In vitro Half-Life:** Ligand A (-29.74 hours) has a longer half-life than Ligand B (-13.918 hours), which is a positive.
* **P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.014 and 0.013).
* **Binding Affinity:** Ligand B (-6.0 kcal/mol) has a slightly better binding affinity than Ligand A (-5.8 kcal/mol), but the difference is small.
**Overall Assessment:**
While Ligand A has a better half-life, Ligand B is superior due to its significantly lower DILI risk and better QED score. The slightly better binding affinity of Ligand B is a bonus. The poor Caco-2 and solubility are concerning for both, but the lower DILI risk is a critical factor in early-stage drug selection.
**Output:**
0
2025-04-17 18:02:03,106 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [345.403, 89.35, 0.368, 1, 6, 0.438, 49.903, 65.529, -5.39, -1.75, 0.19, -10.166, 1.99, 0.022, -6.8]
**Ligand B:** [346.471, 69.64, 2.311, 2, 3, 0.751, 14.541, 52.617, -4.866, -2.057, 0.148, 20.797, -0.513, 0.146, -7.2]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). A: 345.4, B: 346.5 - very similar.
2. **TPSA:** A: 89.35, B: 69.64. Both are good for oral absorption (<140), but B is significantly better, closer to the ideal for GPCRs.
3. **logP:** A: 0.368, B: 2.311. B is much better, falling within the optimal 1-3 range. A is quite low and may have permeability issues.
4. **HBD:** A: 1, B: 2. Both are acceptable.
5. **HBA:** A: 6, B: 3. B is better, lower HBA generally improves permeability.
6. **QED:** A: 0.438, B: 0.751. B is significantly better, indicating a more drug-like profile.
7. **DILI:** A: 49.9, B: 14.5. B is *much* better, indicating a significantly lower risk of liver injury.
8. **BBB:** A: 65.5, B: 52.6. A is better, but both are not high enough to be considered CNS-penetrant. For a peripheral GPCR like ADRB2, this is less critical.
9. **Caco-2:** A: -5.39, B: -4.866. Both are negative, indicating poor permeability. B is slightly better.
10. **Solubility:** A: -1.75, B: -2.057. Both are poor, but similar.
11. **hERG:** A: 0.19, B: 0.148. B is slightly better, indicating lower hERG inhibition risk.
12. **Cl_mic:** A: -10.166, B: 20.797. A is *much* better, indicating significantly higher metabolic stability.
13. **t1/2:** A: 1.99, B: -0.513. A is better, indicating a longer half-life.
14. **Pgp:** A: 0.022, B: 0.146. A is better, indicating lower P-gp efflux.
15. **Affinity:** A: -6.8, B: -7.2. B is slightly better, with a stronger binding affinity.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, and affinity. B excels in logP and TPSA. While A has better Pgp, the significant advantages of B in logP, TPSA, QED, and DILI outweigh this. The slightly better affinity of B is also a plus. The metabolic stability of A is good, but the other ADME properties of B are more favorable overall.
**Conclusion:**
Ligand B is the more promising candidate due to its superior drug-like properties (QED, DILI), better logP and TPSA, and slightly better affinity. While ligand A has better metabolic stability and Pgp, the overall balance of properties favors ligand B.
0
2025-04-17 18:02:03,106 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (343.358 Da) is slightly lower, which is generally favorable for permeability.
**2. TPSA:** Ligand A (64.43) is significantly better than Ligand B (112.81). For a GPCR, keeping TPSA low is beneficial for permeability and receptor engagement. Ligand B is above the preferred threshold of 90.
**3. logP:** Ligand A (1.623) is within the optimal range (1-3). Ligand B (-0.35) is below 1, which could indicate poor membrane permeability.
**4. H-Bond Donors:** Ligand A (0) is excellent. Ligand B (2) is acceptable, but fewer is generally preferred.
**5. H-Bond Acceptors:** Ligand A (5) is good. Ligand B (4) is also good.
**6. QED:** Both ligands have similar QED values (0.85 and 0.705), indicating good drug-likeness.
**7. DILI Risk:** Ligand A (67.778) is higher than Ligand B (28.616). This is a significant drawback for Ligand A.
**8. BBB Penetration:** Ligand A (91.625) is much better than Ligand B (54.246). While ADRB2 is a cardiovascular target, some CNS effects can be relevant (and potentially undesirable), so moderate BBB penetration isn't necessarily a negative, but it's not a primary driver.
**9. Caco-2 Permeability:** Ligand A (-4.161) is worse than Ligand B (-5.274). Both are negative, indicating poor permeability, but Ligand B is slightly better.
**10. Aqueous Solubility:** Ligand A (-3.246) is worse than Ligand B (-1.72). Both are poor, but Ligand B is slightly better.
**11. hERG Inhibition:** Ligand A (0.606) is better than Ligand B (0.06). Lower hERG inhibition is crucial for avoiding cardiotoxicity.
**12. Microsomal Clearance:** Ligand A (18.438) is higher than Ligand B (-2.335). Lower clearance is preferred for better metabolic stability. Ligand B is significantly more stable.
**13. In vitro Half-Life:** Ligand A (-16.919) is much worse than Ligand B (2.441). A longer half-life is desirable.
**14. P-gp Efflux:** Ligand A (0.102) is better than Ligand B (0.005). Lower P-gp efflux is preferred.
**15. Binding Affinity:** Ligand B (-6.8 kcal/mol) is slightly better than Ligand A (-5.9 kcal/mol). While both are good, the 0.9 kcal/mol difference is notable.
**Overall Assessment:**
Ligand A has better BBB penetration, P-gp efflux, and hERG inhibition, but suffers from significantly higher DILI risk, worse metabolic stability (higher clearance, shorter half-life), and lower solubility. Ligand B has a better binding affinity, lower DILI risk, better metabolic stability, and slightly better solubility and Caco-2 permeability.
Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity) and the overall balance of properties, **Ligand B** is the more promising candidate. The slightly better affinity combined with the significantly improved safety profile (lower DILI) and metabolic stability outweigh the slightly lower BBB penetration and TPSA. The poor logP of Ligand B is a concern, but can be addressed through further optimization.
Output:
0
2025-04-17 18:02:03,106 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (358.47 and 346.47 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (61.94) is better than Ligand B (67.43). Both are below the 140 A^2 threshold for oral absorption, but lower TPSA is generally preferred for GPCRs to improve brain penetration, even if not a CNS target.
**3. logP:** Ligand A (3.368) is slightly higher than Ligand B (2.684), both are within the optimal 1-3 range.
**4. H-Bond Donors:** Ligand A (0) is better than Ligand B (2). Fewer HBDs generally improve permeability.
**5. H-Bond Acceptors:** Ligand A (7) is higher than Ligand B (3). While both are acceptable, lower HBA is slightly preferred.
**6. QED:** Ligand B (0.727) has a better QED score than Ligand A (0.333), indicating a more drug-like profile. This is a notable advantage for Ligand B.
**7. DILI Risk:** Ligand B (52.152) has a significantly lower DILI risk than Ligand A (65.607). This is a crucial advantage, as liver toxicity is a major concern in drug development.
**8. BBB Penetration:** Both ligands have similar BBB penetration (Ligand A: 60.838, Ligand B: 66.421). This isn't a primary concern for a cardiovascular target, but higher is slightly better.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-5.233) is slightly better than Ligand B (-4.937), but both are concerning.
**10. Aqueous Solubility:** Both ligands have negative solubility values, indicating poor aqueous solubility. Ligand B (-3.887) is slightly better than Ligand A (-2.802).
**11. hERG Inhibition:** Ligand A (0.846) has a slightly higher hERG risk than Ligand B (0.236). Lower hERG risk is highly desirable to avoid cardiotoxicity.
**12. Microsomal Clearance:** Ligand B (81.272) has a lower microsomal clearance than Ligand A (135.832), indicating better metabolic stability.
**13. In vitro Half-Life:** Ligand B (-18.092) has a significantly longer in vitro half-life than Ligand A (-10.607). This is a major advantage, potentially leading to less frequent dosing.
**14. P-gp Efflux:** Ligand A (0.84) has a higher P-gp efflux liability than Ligand B (0.568). Lower P-gp efflux is preferred for better bioavailability.
**15. Binding Affinity:** Ligand B (-7.0) has a slightly better binding affinity than Ligand A (-6.5). While both are good, the difference is enough to consider.
**Overall Assessment:**
While Ligand A has a slightly better logP and Caco-2 permeability, Ligand B demonstrates a significantly more favorable profile across several critical ADME-Tox parameters. Specifically, the lower DILI risk, improved metabolic stability (lower Cl_mic, longer t1/2), lower hERG risk, and lower P-gp efflux make Ligand B a much more promising candidate. The slightly better QED and binding affinity further support this conclusion. The poor Caco-2 and solubility for both are concerning and would need to be addressed through formulation or further chemical modifications, but the other advantages of Ligand B outweigh these drawbacks.
Output:
0
2025-04-17 18:02:03,106 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (345.447 and 367.471 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Both ligands (87.22 and 84.67) are below the 140 A^2 threshold for good oral absorption, and acceptable for a non-CNS GPCR target like ADRB2. Ligand B is slightly better.
3. **logP:** Ligand A (0.75) is a bit low, potentially hindering permeability. Ligand B (1.472) is better, falling within the optimal 1-3 range. This is a point in favor of Ligand B.
4. **HBD:** Ligand A (2) and Ligand B (1) are both within the acceptable limit of <=5. Ligand B is slightly better.
5. **HBA:** Ligand A (5) and Ligand B (6) are both within the acceptable limit of <=10. No significant difference.
6. **QED:** Both ligands have good QED scores (0.794 and 0.871), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (31.95) has a significantly lower DILI risk than Ligand B (67.429). This is a major advantage for Ligand A.
8. **BBB:** This is less critical for ADRB2 (a cardiovascular target). Ligand A (67.041) is better than Ligand B (58.123).
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.297 and -4.967) which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Both ligands have negative solubility values (-1.604 and -3.069) which is also unusual and suggests poor solubility. This is a concern for both.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.245 and 0.176). No significant difference.
12. **Cl_mic:** Ligand A (17.633) has a much lower microsomal clearance than Ligand B (69.68), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (23.184) has a longer in vitro half-life than Ligand B (-10.987). This is a strong advantage for Ligand A.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.013 and 0.098). No significant difference.
15. **Binding Affinity:** Ligand B (-6.9 kcal/mol) has a slightly better binding affinity than Ligand A (-6.5 kcal/mol), but the difference is relatively small (0.4 kcal/mol).
**Overall Assessment:**
While Ligand B has a slightly better logP, QED, and binding affinity, Ligand A demonstrates a significantly better safety profile (lower DILI) and superior pharmacokinetic properties (lower Cl_mic, longer t1/2). Given the importance of metabolic stability and minimizing toxicity for a cardiovascular drug, the advantages of Ligand A outweigh the marginal binding affinity benefit of Ligand B. The poor Caco-2 and solubility values are concerning for both, but can be addressed with formulation strategies.
Output:
1
2025-04-17 18:02:03,106 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (365.459 Da and 358.789 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Both ligands (101.53 and 105.83) are reasonably close to the 140 A^2 threshold for oral absorption, but higher than the <90 A^2 ideal for CNS targets (not critical for ADRB2, a cardiovascular target). Ligand A is slightly better.
3. **logP:** Ligand A (-0.36) is a bit low, potentially hindering permeability. Ligand B (2.288) is within the optimal 1-3 range. Ligand B is significantly better here.
4. **HBD:** Ligand A (1) and Ligand B (2) are both acceptable, below the 5 threshold. No strong preference.
5. **HBA:** Ligand A (6) and Ligand B (7) are both acceptable, below the 10 threshold. No strong preference.
6. **QED:** Both ligands (0.768 and 0.696) are above 0.5, indicating good drug-likeness. Ligand A is slightly better.
7. **DILI:** Ligand A (40.209) has a much lower DILI risk than Ligand B (85.498). This is a significant advantage for Ligand A.
8. **BBB:** BBB is less critical for a cardiovascular target. Ligand B (68.748) is higher than Ligand A (37.224), but this isn't a major deciding factor.
9. **Caco-2:** Both ligands (-5.515 and -5.318) have similar, very poor Caco-2 permeability. This is a concern for both.
10. **Solubility:** Both ligands have poor solubility (-2.303 and -3.616). This is a concern for both.
11. **hERG:** Ligand A (0.055) has a much lower hERG risk than Ligand B (0.566). This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand A (4.079) has significantly lower microsomal clearance, suggesting better metabolic stability, than Ligand B (53.697). This is a major advantage for Ligand A.
13. **t1/2:** Ligand B (26.422) has a much longer in vitro half-life than Ligand A (-0.945). This is a significant advantage for Ligand B.
14. **Pgp:** Both ligands have very low Pgp efflux (0.014 and 0.018). No strong preference.
15. **Binding Affinity:** Ligand A (-7.5 kcal/mol) has a stronger binding affinity than Ligand B (-4.8 kcal/mol). This is a substantial advantage for Ligand A.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand B has a better logP, but Ligand A excels in affinity, DILI, hERG, and Cl_mic. The significantly better affinity of Ligand A, combined with the lower toxicity risks (DILI and hERG) and improved metabolic stability (Cl_mic), outweigh the slightly less optimal logP.
**Conclusion:**
Ligand A is the more promising candidate due to its superior binding affinity, lower toxicity risks, and better metabolic stability. While both have issues with Caco-2 and solubility, these can be addressed through formulation strategies. The stronger binding and safety profile of Ligand A make it the preferred choice.
Output:
1
2025-04-17 18:02:03,107 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (341.415 and 348.487 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand B (58.64) is significantly better than Ligand A (107.77). For a GPCR, lower TPSA is generally preferred for better permeability. Ligand B is well below the 140 threshold, while A is approaching it.
**3. logP:** Ligand B (2.657) is within the optimal 1-3 range, while Ligand A (0.888) is slightly below 1. While not terrible, lower logP can sometimes hinder membrane permeability.
**4. H-Bond Donors:** Ligand A (2) is slightly higher than Ligand B (1), but both are acceptable (<=5).
**5. H-Bond Acceptors:** Ligand A (5) is higher than Ligand B (3), but both are within the acceptable range (<=10).
**6. QED:** Both ligands have similar and good QED values (0.73 and 0.751, respectively), indicating good drug-like properties.
**7. DILI:** Ligand B (18.418) has a *much* lower DILI risk than Ligand A (41.915). This is a significant advantage for Ligand B.
**8. BBB:** Ligand B (71.772) has a substantially higher BBB penetration percentile than Ligand A (51.221). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant, and higher BBB is generally favorable.
**9. Caco-2 Permeability:** Both are negative, indicating poor permeability. Ligand A (-5.22) is slightly worse than Ligand B (-4.705).
**10. Aqueous Solubility:** Both ligands have very poor aqueous solubility (-2.503 and -2.542). This is a concern for both, but not a deciding factor given the other differences.
**11. hERG Inhibition:** Ligand A (0.075) has a slightly lower hERG inhibition risk than Ligand B (0.323), which is a minor advantage.
**12. Microsomal Clearance:** Ligand A (5.206) has a significantly lower microsomal clearance than Ligand B (45.791), suggesting better metabolic stability. This is a positive for Ligand A.
**13. In vitro Half-Life:** Ligand B (7.453) has a longer half-life than Ligand A (13.325). This is a positive for Ligand B.
**14. P-gp Efflux:** Ligand A (0.017) shows very low P-gp efflux, which is better than Ligand B (0.126).
**15. Binding Affinity:** Ligand A (-7.9 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.0 kcal/mol). This is a substantial advantage for Ligand A, potentially outweighing some of the ADME drawbacks.
**Overall Assessment:**
Ligand A has a substantially better binding affinity and lower P-gp efflux, and better metabolic stability. However, Ligand B excels in TPSA, DILI risk, BBB penetration, and in vitro half-life. The strong affinity of Ligand A is a major plus, and the lower P-gp efflux is also beneficial. The DILI risk of Ligand A is a concern, but the affinity difference is significant enough to outweigh this.
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), and the substantial affinity advantage of Ligand A, I believe it is the more promising candidate.
Output:
1
2025-04-17 18:02:03,107 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (359.491 and 360.483 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (55.4) is significantly better than Ligand B (75.19). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (3.99) is slightly higher than Ligand B (2.549), both are within the optimal 1-3 range. Ligand A is closer to the upper limit, which could raise concerns about off-target effects, but is still acceptable.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 5. Both are acceptable, below the 10 threshold.
6. **QED:** Ligand A (0.794) is slightly better than Ligand B (0.696), indicating a more drug-like profile.
7. **DILI:** Ligand B (60.062) has a slightly higher DILI risk than Ligand A (54.556), but both are reasonably acceptable, being below 60.
8. **BBB:** Ligand A (83.443) has better BBB penetration than Ligand B (78.364), but this is less critical for a cardiovascular target.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.626 and -4.886), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand A (-4.801) is slightly better than Ligand B (-3.527), indicating better aqueous solubility.
11. **hERG:** Both ligands have low hERG inhibition liability (0.471 and 0.56), which is excellent.
12. **Cl_mic:** Ligand B (75.506) has significantly lower microsomal clearance than Ligand A (121.777), suggesting better metabolic stability. This is a major advantage.
13. **t1/2:** Ligand B (-5.976) has a longer in vitro half-life than Ligand A (28.545), which is a significant advantage.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.669 and 0.277), which is good. Ligand B is better.
15. **Binding Affinity:** Ligand A (-7.6) has a slightly better binding affinity than Ligand B (-5.8). This is a 1.8 kcal/mol difference, which is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand A has a better binding affinity and slightly better QED, solubility, and BBB penetration. However, Ligand B demonstrates significantly better metabolic stability (lower Cl_mic and longer t1/2) and lower Pgp efflux. The Caco-2 permeability is poor for both. Considering ADRB2 is a cardiovascular target, metabolic stability and half-life are crucial for achieving therapeutic concentrations. The affinity difference is significant, but the metabolic advantages of Ligand B are compelling.
Output:
0
2025-04-17 18:02:03,107 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.475 and 347.459 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (74.33) is better than Ligand B (91.32). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (1.08) is within the optimal range, while Ligand B (2.537) is approaching the upper limit. Slight advantage to A.
4. **HBD:** Ligand A (2) is preferable to Ligand B (3). Lower HBD generally improves permeability.
5. **HBA:** Both ligands have 4 HBA, so no difference.
6. **QED:** Ligand A (0.656) is slightly better than Ligand B (0.599), indicating a more drug-like profile.
7. **DILI:** Ligand A (14.23) has a significantly lower DILI risk than Ligand B (23.226). This is a crucial advantage.
8. **BBB:** Ligand A (68.36) is better than Ligand B (26.638), although BBB isn't a primary concern for a cardiovascular target.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.988 and -5.163) which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand A (-0.746) is better than Ligand B (-2.742). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.362) has a lower hERG risk than Ligand B (0.093). This is a significant safety advantage.
12. **Cl_mic:** Ligand A (21.686) has a lower microsomal clearance than Ligand B (30.553), indicating better metabolic stability.
13. **t1/2:** Ligand A (-5.817) has a much longer in vitro half-life than Ligand B (-13.671). This is a substantial advantage.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.058 and 0.014). No significant difference.
15. **Binding Affinity:** Both ligands have the same binding affinity (-6 kcal/mol).
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A is better in logP and TPSA. Affinity is the same.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most ADME-Tox properties. The lower DILI risk, better solubility, lower hERG risk, better metabolic stability (lower Cl_mic and longer t1/2), and slightly better TPSA and logP make it a significantly more promising drug candidate. While both have poor Caco-2 permeability, the other advantages of Ligand A outweigh this concern.
Output:
1
2025-04-17 18:02:03,107 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (384.929 Da) is slightly higher than Ligand B (346.387 Da), but both are acceptable.
**2. TPSA:** Ligand A (58.64) is significantly better than Ligand B (100.46). For a GPCR, a lower TPSA is generally preferred for better permeability, and Ligand A is well below the 140 threshold. Ligand B is approaching the upper limit.
**3. logP:** Both ligands have acceptable logP values (A: 2.957, B: 1.186), falling within the optimal 1-3 range. Ligand A is slightly higher, which could potentially lead to off-target effects, but is still reasonable.
**4. H-Bond Donors:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
**5. H-Bond Acceptors:** Ligand A (4) is preferable to Ligand B (5). Lower HBA generally improves permeability.
**6. QED:** Both ligands have good QED scores (A: 0.605, B: 0.784), indicating good drug-like properties. Ligand B is slightly better here.
**7. DILI:** Both ligands have similar and acceptable DILI risk (A: 54.75, B: 54.556), both below the 60 threshold.
**8. BBB:** Ligand A (62.156) is significantly better than Ligand B (27.336). While ADRB2 isn't exclusively a CNS target, some CNS penetration can be beneficial for understanding off-target effects and potential side effects.
**9. Caco-2 Permeability:** Ligand A (-4.957) is better than Ligand B (-5.259). Both are negative, indicating good permeability.
**10. Aqueous Solubility:** Ligand A (-4.796) is better than Ligand B (-1.695). Better solubility is always preferred.
**11. hERG Inhibition:** Ligand A (0.567) is significantly better than Ligand B (0.264). Lower hERG inhibition is crucial for avoiding cardiotoxicity, a significant concern for cardiovascular targets.
**12. Microsomal Clearance:** Ligand B (-13.069) is much better than Ligand A (82.042). Lower clearance indicates greater metabolic stability, which is highly desirable.
**13. In vitro Half-Life:** Ligand B (24.392) is better than Ligand A (28.361). Longer half-life is generally preferred.
**14. P-gp Efflux:** Ligand A (0.568) is better than Ligand B (0.047). Lower P-gp efflux is preferred for better bioavailability.
**15. Binding Affinity:** Ligand A (-6.8) is slightly better than Ligand B (-6.2). While both are strong binders, the 0.6 kcal/mol difference is notable.
**Overall Assessment:**
Ligand A excels in several key areas for a GPCR target, particularly TPSA, BBB penetration, hERG inhibition, solubility, and binding affinity. While Ligand B has better metabolic stability (Cl_mic) and half-life, the advantages of Ligand A in permeability, safety (hERG), and binding outweigh these benefits. The slightly higher logP of Ligand A is a minor concern, but the overall profile is more favorable.
Output:
1
2025-04-17 18:02:03,107 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (353.5 & 345.4 Da) fall comfortably within the 200-500 Da ideal range. No clear advantage here.
2. **TPSA:** Ligand B (72.91) is better than Ligand A (81.67). Both are below 140, but lower TPSA generally favors absorption.
3. **logP:** Ligand A (1.424) is slightly better than Ligand B (1.96), falling more centrally within the 1-3 optimal range. Ligand B is still acceptable.
4. **HBD:** Ligand A (3) is higher than Ligand B (0). While not drastically different, fewer HBDs (Ligand B) can improve permeability.
5. **HBA:** Ligand A (4) and Ligand B (5) are comparable and both within the acceptable limit of 10.
6. **QED:** Ligand B (0.763) is significantly better than Ligand A (0.555), indicating a more drug-like profile.
7. **DILI:** Ligand A (5.584) has a much lower DILI risk than Ligand B (39.783). This is a significant advantage for Ligand A.
8. **BBB:** Ligand B (88.91) is much better than Ligand A (31.989). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be beneficial and is not detrimental in this case.
9. **Caco-2:** Ligand A (-5.54) is significantly better than Ligand B (-4.182), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-1.228) is better than Ligand B (-3.325). Better solubility is generally desirable.
11. **hERG:** Ligand A (0.469) is better than Ligand B (0.576), indicating lower hERG inhibition liability.
12. **Cl_mic:** Ligand A (-4.515) is much better than Ligand B (75.949), indicating significantly better metabolic stability.
13. **t1/2:** Ligand A (26.479) is much better than Ligand B (6.406). A longer half-life is generally preferred.
14. **Pgp:** Ligand A (0.014) is much better than Ligand B (0.298), indicating lower P-gp efflux.
15. **Affinity:** Ligand A (-7.3) is slightly better than Ligand B (-7.1). While the difference is small, it's still a positive for Ligand A.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A has a slightly better logP, significantly better Pgp, and slightly better affinity. Ligand B has better TPSA and BBB penetration. However, the superior ADME properties of Ligand A (DILI, Cl_mic, t1/2, solubility, Caco-2) are more critical for overall drug development success. The modest BBB advantage of Ligand B is outweighed by the significant metabolic and toxicity advantages of Ligand A.
**Conclusion:**
Ligand A demonstrates a significantly more favorable ADMET profile and a slightly better binding affinity, making it the more promising drug candidate despite Ligand B's better BBB penetration.
Output:
1
2025-04-17 18:02:03,107 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (337.379 and 348.447 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (84.23) is slightly higher than Ligand B (76.46), but both are well below the 140 threshold for good oral absorption, and acceptable for a cardiovascular GPCR. Ligand B is marginally better.
3. **logP:** Both ligands have good logP values (2.502 and 1.325), falling within the optimal 1-3 range. Ligand A is slightly higher, which *could* be beneficial for membrane permeability, but also introduces a small risk of off-target effects.
4. **HBD:** Ligand A has 2 HBD, and Ligand B has 1. Both are within the acceptable limit of 5.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 5. Both are within the acceptable limit of 10.
6. **QED:** Both ligands have good QED scores (0.793 and 0.894), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A has a DILI risk of 74.409%, while Ligand B has 33.618%. This is a significant difference. Ligand B is *much* preferred due to the lower liver toxicity risk.
8. **BBB:** Ligand A (62.854%) has a higher BBB penetration score than Ligand B (52.811%). While ADRB2 isn't a CNS target, some off-target CNS effects are possible with GPCR ligands, and higher BBB penetration could contribute to this. However, this is less critical than other factors.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.598 and -4.898), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand A (-4.395) has slightly worse solubility than Ligand B (-1.271). Solubility is important for bioavailability.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.212 and 0.249). This is excellent.
12. **Cl_mic:** Both ligands have similar microsomal clearance values (34.179 and 33.587 mL/min/kg), suggesting comparable metabolic stability.
13. **t1/2:** Ligand B has a significantly longer in vitro half-life (9.024 hours) than Ligand A (-14.62 hours). This is a major advantage for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.141 and 0.031). This is good.
15. **Binding Affinity:** Ligand A (-6.0 kcal/mol) has slightly better binding affinity than Ligand B (-6.1 kcal/mol). While a difference of 0.1 kcal/mol isn't huge, it's a small positive for Ligand A.
**Overall Assessment & GPCR Focus:**
Given that this is a GPCR target (ADRB2), logP, TPSA, Pgp, and affinity are important. Both ligands perform reasonably well on these. However, the *critical* difference is the DILI risk. Ligand A's 74.4% DILI risk is unacceptable, while Ligand B's 33.6% is much more manageable. The longer half-life of Ligand B is also a significant advantage. While Ligand A has slightly better affinity and BBB penetration, the lower DILI risk and improved half-life of Ligand B outweigh these minor advantages. The negative Caco-2 values are concerning for both, and would require further investigation, but the toxicity profile is the primary concern here.
Output:
0
2025-04-17 18:02:03,107 - INFO - Batch 8 complete. Total preferences: 128
2025-04-17 18:02:03,107 - INFO - Processing batch 9/512...
2025-04-17 18:02:52,306 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
Let's analyze each ligand against the provided guidelines, with emphasis on GPCR-relevant properties (logP, Pgp, TPSA, and affinity).
* **Molecular Weight:** Both ligands (369.34 Da and 354.466 Da) fall within the ideal 200-500 Da range.
* **TPSA:** Ligand A (127.76) is higher than the preferred <140 for oral absorption, but not drastically so. Ligand B (49.85) is excellent, well below 140.
* **logP:** Ligand A (-1.335) is a bit low, potentially hindering permeation. Ligand B (2.102) is within the optimal 1-3 range. This is a significant advantage for Ligand B.
* **H-Bond Donors/Acceptors:** Ligand A has 5 HBD and 5 HBA. Ligand B has 0 HBD and 3 HBA. Both are acceptable, but Ligand B's lower HBD count may improve permeability.
* **QED:** Both ligands have reasonable QED scores (0.38 and 0.671), with Ligand B being better.
* **DILI:** Ligand A (33.35) has a slightly higher DILI risk than Ligand B (17.64), but both are below the concerning 60 percentile.
* **BBB:** Ligand A (59.36) is moderate, while Ligand B (97.25) is excellent. While ADRB2 isn't exclusively a CNS target, better BBB penetration is generally favorable, minimizing off-target effects.
* **Caco-2:** Both have negative Caco-2 values, which is unusual and problematic. However, the scale is not specified, so it is difficult to interpret.
* **Aqueous Solubility:** Both have negative solubility values, which is also problematic and difficult to interpret.
* **hERG:** Ligand A (0.075) has a very low hERG risk, which is a major advantage. Ligand B (0.698) is slightly higher, but still relatively low.
* **Microsomal Clearance:** Ligand A (10.88) has lower clearance than Ligand B (50.35), suggesting better metabolic stability.
* **In vitro Half-Life:** Ligand A (-21.14) has a negative half-life, which is impossible. Ligand B (6.05) is reasonable.
* **P-gp Efflux:** Ligand A (0.008) has very low P-gp efflux, which is excellent. Ligand B (0.219) is also low.
* **Binding Affinity:** Both ligands have comparable binding affinities (-7.0 kcal/mol and -5.4 kcal/mol, respectively). Ligand A is slightly better, but the difference is not substantial enough to overcome its other deficiencies.
**Overall Assessment:**
Ligand B demonstrates a superior balance of properties, particularly regarding logP, TPSA, BBB penetration, and QED. While Ligand A has a slightly better affinity and lower hERG risk, its poor logP, negative half-life, and higher TPSA are concerning. The negative values for Caco-2 and solubility are also problematic. Given the GPCR-specific priorities, Ligand B's favorable permeability and BBB characteristics make it the more promising candidate.
**Output:**
0
2025-04-17 18:02:52,306 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (349.391 and 367.427 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (107.84) is slightly higher than Ligand B (99.93). Both are below the 140 threshold for good oral absorption, but closer to the 90 threshold for CNS targets (less relevant for ADRB2, a cardiovascular target).
3. **logP:** Ligand A (0.693) is slightly better than Ligand B (0.088), falling comfortably within the 1-3 range. Ligand B is very close to 1, which could potentially lead to permeability issues.
4. **HBD:** Ligand A (0) is preferable to Ligand B (1). Fewer HBDs generally improve permeability.
5. **HBA:** Both ligands have 5 HBA, which is acceptable.
6. **QED:** Ligand B (0.816) has a significantly better QED score than Ligand A (0.423), indicating a more drug-like profile. This is a notable advantage for Ligand B.
7. **DILI:** Ligand A (35.595) has a lower DILI risk than Ligand B (62.35), which is a significant advantage. Lower DILI is always preferred.
8. **BBB:** Ligand A (70.997) has a better BBB penetration score than Ligand B (35.324). While not a primary concern for ADRB2, higher BBB is generally favorable.
9. **Caco-2:** Both ligands have similar, poor Caco-2 permeability (-4.911 and -4.866). This is a concern for both.
10. **Solubility:** Ligand A (-1.506) is slightly better than Ligand B (-2.437), but both are poor.
11. **hERG:** Ligand A (0.15) has a much lower hERG inhibition liability than Ligand B (0.237), a crucial advantage for cardiovascular drugs.
12. **Cl_mic:** Ligand A (5.037) has a significantly lower microsomal clearance than Ligand B (38.54), indicating better metabolic stability.
13. **t1/2:** Ligand A (14.116) has a longer in vitro half-life than Ligand B (11.206).
14. **Pgp:** Ligand A (0.012) has a much lower P-gp efflux liability than Ligand B (0.039), which is favorable for oral bioavailability.
15. **Binding Affinity:** Ligand B (-7.6) has a slightly better binding affinity than Ligand A (-7.3), a 1.5 kcal/mol advantage. This is a significant benefit.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand B has a slightly better affinity, but Ligand A has better logP, Pgp, and TPSA. The differences in logP and Pgp are more concerning than the affinity difference.
**Overall Assessment:**
While Ligand B has a better QED and binding affinity, Ligand A demonstrates a significantly better safety profile (lower DILI, hERG), better metabolic stability (lower Cl_mic, longer t1/2), and lower P-gp efflux. Given the cardiovascular target, minimizing off-target effects (hERG, DILI) and maximizing metabolic stability are critical. The slight advantage in binding affinity of Ligand B is outweighed by the superior ADMET properties of Ligand A.
Output:
1
2025-04-17 18:02:52,306 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [408.275, 85.83, 2.393, 2, 5, 0.814, 55.138, 69.407, -5.296, -2.595, 0.291, 3.729, 13.55, 0.191, -7.4]
**Ligand B:** [343.471, 71.09, 2.461, 2, 3, 0.677, 18.728, 61.923, -4.987, -2.484, 0.253, 47.598, -27.009, 0.148, -6.1]
Here's a breakdown, considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Ligand B (343.471 Da) is preferable, falling nicely within the 200-500 Da range and is lower than Ligand A (408.275 Da).
2. **TPSA:** Both are reasonably good (A: 85.83, B: 71.09). Both are below 140, acceptable for oral absorption.
3. **logP:** Both are within the optimal range (A: 2.393, B: 2.461). Very similar.
4. **HBD:** Both have 2 HBD, which is good.
5. **HBA:** Ligand B (3) is slightly better than Ligand A (5). Lower HBA generally favors permeability.
6. **QED:** Ligand A (0.814) is significantly better than Ligand B (0.677), indicating a more drug-like profile.
7. **DILI:** Ligand B (18.728%) has a much lower DILI risk than Ligand A (55.138%). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (69.407%) has slightly better BBB penetration than Ligand B (61.923%), but both are acceptable. For a cardiovascular target, BBB isn't *critical*, but it's a bonus.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-5.296) is slightly worse than Ligand B (-4.987).
10. **Solubility:** Both are negative, indicating poor solubility. Ligand A (-2.595) is slightly worse than Ligand B (-2.484).
11. **hERG:** Both are very low (A: 0.291, B: 0.253), indicating minimal hERG inhibition risk.
12. **Cl_mic:** Ligand A (3.729 mL/min/kg) has a significantly lower microsomal clearance than Ligand B (47.598 mL/min/kg), suggesting better metabolic stability.
13. **t1/2:** Ligand A (13.55 hours) has a much longer in vitro half-life than Ligand B (-27.009 hours). This is a major advantage for Ligand A.
14. **Pgp:** Both have low Pgp efflux liability (A: 0.191, B: 0.148). Ligand B is slightly better.
15. **Affinity:** Ligand A (-7.4 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.1 kcal/mol). This is a substantial advantage, potentially outweighing some ADME drawbacks.
**Overall Assessment:**
Ligand A has a much better binding affinity and metabolic stability (lower Cl_mic, longer t1/2), and a better QED score. Ligand B has a lower DILI risk and slightly better Caco-2 and Pgp properties. However, the substantial affinity difference (-1.3 kcal/mol) and the better metabolic profile of Ligand A are compelling. While the solubility and Caco-2 values are not ideal for either, the stronger binding and improved stability are more critical for a GPCR target.
Therefore, I would prioritize Ligand A.
Output:
1
2025-04-17 18:02:52,307 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [345.439, 55.84, 2.58, 0, 4, 0.744, 35.285, 90.035, -4.216, -3.56, 0.396, 76.867, 1.147, 0.26, -6.4]
**Ligand B:** [384.933, 67.23, 2.26, 1, 5, 0.764, 47.693, 31.912, -5.025, -3.697, 0.089, 56.629, 8.653, 0.074, -6.8]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity, and to a lesser extent BBB):
1. **MW:** Both are within the acceptable 200-500 Da range. Ligand A (345.439) is slightly preferred due to being lower.
2. **TPSA:** Ligand A (55.84) is significantly better than Ligand B (67.23). Below 140 is good for oral absorption, and both are, but lower is better for GPCRs.
3. **logP:** Both are in the optimal 1-3 range (A: 2.58, B: 2.26). Very similar.
4. **HBD/HBA:** Ligand A (0 HBD, 4 HBA) is slightly better than Ligand B (1 HBD, 5 HBA). Fewer H-bonds generally improve permeability.
5. **QED:** Both are good (A: 0.744, B: 0.764), indicating good drug-like properties.
6. **DILI:** Ligand A (35.285) is better than Ligand B (47.693). Lower DILI risk is crucial.
7. **BBB:** Ligand A (90.035) is significantly better than Ligand B (31.912). While not a CNS target, some BBB penetration can be beneficial for distribution.
8. **Caco-2:** Ligand B (-5.025) is better than Ligand A (-4.216). Higher Caco-2 suggests better absorption.
9. **Solubility:** Both are poor (-3.56 and -3.697). This is a concern for both, but not a deciding factor.
10. **hERG:** Both are very low risk (A: 0.396, B: 0.089).
11. **Cl_mic:** Ligand B (56.629) is better than Ligand A (76.867). Lower clearance is preferred for metabolic stability.
12. **t1/2:** Ligand B (8.653) is much better than Ligand A (1.147). Longer half-life is desirable.
13. **Pgp:** Ligand A (0.26) is better than Ligand B (0.074). Lower P-gp efflux is preferred.
14. **Affinity:** Ligand B (-6.8 kcal/mol) is slightly better than Ligand A (-6.4 kcal/mol). This is a 0.4 kcal/mol difference, which is meaningful but not overwhelming.
**Overall Assessment:**
Ligand A has a clear advantage in TPSA, DILI, BBB, and Pgp efflux. Ligand B wins on Caco-2 permeability, metabolic stability (Cl_mic) and in vitro half-life, and has a slightly better binding affinity. Considering the GPCR-specific priorities, the lower TPSA, better DILI profile, and better BBB penetration of Ligand A are more important than the slightly better affinity and metabolic stability of Ligand B. Solubility is a concern for both, and would require formulation work.
Therefore, I favor Ligand A.
Output:
1
2025-04-17 18:02:52,307 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (343.354 and 368.949 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (66.84) is higher than Ligand B (33.73). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B has a substantial advantage.
3. **logP:** Ligand B (4.492) is higher than Ligand A (3.192). While both are above the optimal 1-3 range, Ligand B is getting towards the upper limit where solubility issues could arise. Ligand A is better positioned.
4. **HBD:** Both ligands have 1 HBD, which is within the acceptable limit of 5. No difference.
5. **HBA:** Both ligands have 4 HBA, which is within the acceptable limit of 10. No difference.
6. **QED:** Ligand A (0.869) has a significantly higher QED score than Ligand B (0.617), indicating a more drug-like profile. This is a substantial advantage for Ligand A.
7. **DILI:** Ligand A (68.282) has a higher DILI risk than Ligand B (9.112). This is a major concern for Ligand A. Ligand B is significantly better here.
8. **BBB:** Both ligands have reasonable BBB penetration (Ligand A: 79.721, Ligand B: 80.031). Since ADRB2 isn't primarily a CNS target, this isn't a major deciding factor, though higher is slightly better.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.64 and -4.777). These values are unusual and suggest poor permeability. However, the values are very similar.
10. **Solubility:** Ligand A (-4.552) has worse solubility than Ligand B (-2.727). Solubility is important for bioavailability, giving Ligand B an advantage.
11. **hERG:** Ligand A (0.67) has a slightly better hERG profile than Ligand B (0.945), meaning lower risk of cardiotoxicity. This is a positive for Ligand A, but the difference isn't huge.
12. **Cl_mic:** Ligand B (51.263) has significantly lower microsomal clearance than Ligand A (77.343), indicating better metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand B (41.16) has a much longer in vitro half-life than Ligand A (-12.558). This is a major advantage for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have low Pgp efflux (0.411 and 0.433). No significant difference.
15. **Binding Affinity:** Ligand A (-6.9 kcal/mol) has a slightly better binding affinity than Ligand B (-5.6 kcal/mol). This is a 1.3 kcal/mol difference, which is substantial and could outweigh some ADME drawbacks.
**Overall Assessment:**
While Ligand A has a better binding affinity and QED score, the significant concerns regarding its DILI risk, solubility, and metabolic stability (higher Cl_mic, shorter t1/2) are substantial drawbacks. Ligand B, despite slightly weaker binding, presents a much more favorable ADME profile with a significantly lower DILI risk, better solubility, and improved metabolic stability. For a cardiovascular target, minimizing off-target effects (like liver toxicity) and ensuring reasonable drug exposure (through metabolic stability and solubility) are paramount. The affinity difference, while notable, is not so large as to overcome the ADME concerns with Ligand A.
Output:
0
2025-04-17 18:02:52,307 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (339.483 and 340.379 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (61.52) is significantly better than Ligand B (98.66). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B's TPSA is approaching a level that might hinder oral absorption.
**3. logP:** Ligand A (3.278) is within the optimal 1-3 range, while Ligand B (1.889) is at the lower end. While not terrible, lower logP can sometimes indicate permeability issues.
**4. H-Bond Donors:** Both have 3-4 HBD, which is acceptable.
**5. H-Bond Acceptors:** Both have 4 HBA, which is acceptable.
**6. QED:** Ligand A (0.756) has a better QED score than Ligand B (0.645), indicating a more drug-like profile.
**7. DILI Risk:** Ligand A (8.181 percentile) has a much lower DILI risk than Ligand B (48.623 percentile). This is a crucial factor, as liver toxicity is a major concern in drug development.
**8. BBB Penetration:** Ligand A (73.866 percentile) shows better BBB penetration than Ligand B (31.834 percentile). While ADRB2 is primarily a cardiovascular target, some CNS effects can be relevant or undesirable, and better BBB penetration can be a plus.
**9. Caco-2 Permeability:** Ligand A (-5.529) and Ligand B (-5.268) are similar, indicating moderate permeability.
**10. Aqueous Solubility:** Ligand A (-2.542) is slightly better than Ligand B (-3.602), but both are poor. Solubility could be a formulation challenge for both.
**11. hERG Inhibition:** Ligand A (0.965 percentile) has a significantly lower hERG inhibition risk than Ligand B (0.505 percentile). This is a critical safety parameter.
**12. Microsomal Clearance:** Ligand A (-1.973) has a lower (better) microsomal clearance than Ligand B (-2.944), indicating greater metabolic stability.
**13. In vitro Half-Life:** Ligand A (6.783 hours) has a significantly longer half-life than Ligand B (-15.895 hours). This is a major advantage for dosing convenience.
**14. P-gp Efflux:** Ligand A (0.151 percentile) has a lower P-gp efflux liability than Ligand B (0.045 percentile), suggesting better bioavailability.
**15. Binding Affinity:** Ligand B (-7.1 kcal/mol) has a slightly better binding affinity than Ligand A (-5.9 kcal/mol). While a 1.2 kcal/mol difference is noticeable, it's not a massive advantage, especially considering the other factors.
**Overall Assessment:**
Ligand A is the stronger candidate. While Ligand B has slightly better binding affinity, Ligand A excels in almost all other critical ADME-Tox parameters, including DILI risk, hERG inhibition, metabolic stability, BBB penetration, and QED. The combination of these factors makes Ligand A a much more promising starting point for drug development, even with a slightly lower binding affinity. The improved safety profile and pharmacokinetic properties outweigh the modest difference in potency.
Output:
1
2025-04-17 18:02:52,307 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (364.379) is slightly higher than Ligand B (345.443), but both are acceptable.
2. **TPSA:** Ligand B (82.53) is significantly better than Ligand A (115.61). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally improves absorption.
3. **logP:** Both ligands have good logP values (A: 2.632, B: 1.306) falling within the optimal 1-3 range. Ligand B is slightly lower, which could slightly improve solubility.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand B (4) is preferable to Ligand A (6). Fewer HBAs generally improve permeability.
6. **QED:** Ligand B (0.626) is better than Ligand A (0.478), indicating a more drug-like profile.
7. **DILI:** Ligand B (20.589) is *much* better than Ligand A (96.588). This is a major advantage for Ligand B. High DILI risk is a significant concern.
8. **BBB:** Not a primary concern for a cardiovascular target, but Ligand A (64.095) is slightly better than Ligand B (51.803).
9. **Caco-2:** Both are negative values, indicating poor permeability. This is a concern for both, but doesn't strongly differentiate them.
10. **Solubility:** Ligand B (-1.031) is better than Ligand A (-4.529). Better solubility is always preferred.
11. **hERG:** Ligand B (0.153) is significantly better than Ligand A (0.48). Lower hERG risk is crucial for cardiovascular drugs.
12. **Cl_mic:** Ligand B (10.41) is *much* better than Ligand A (68.009). Lower clearance indicates better metabolic stability.
13. **t1/2:** Ligand A (-8.213) is better than Ligand B (0.957). A negative value suggests a longer half-life.
14. **Pgp:** Ligand B (0.055) is significantly better than Ligand A (0.315). Lower Pgp efflux is desirable for improved bioavailability.
15. **Binding Affinity:** Ligand A (-7.2) is 0.7 kcal/mol better than Ligand B (-6.5). This is a substantial difference in potency.
**Overall Assessment & GPCR-Specific Priorities:**
For a GPCR like ADRB2, affinity is paramount. Ligand A has a significantly better binding affinity. However, the ADME properties of Ligand B are dramatically superior, particularly the DILI risk, hERG inhibition, and metabolic stability (Cl_mic). While the affinity difference is substantial, the safety and pharmacokinetic advantages of Ligand B are too significant to ignore. A slightly lower affinity can often be overcome with dose adjustments, but a high DILI risk or significant hERG inhibition are deal-breakers.
Therefore, I favor Ligand B.
Output:
0
2025-04-17 18:02:52,307 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (343.471) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (74.25) is significantly better than Ligand B (96.78). For a GPCR, keeping TPSA low is beneficial for permeability and receptor engagement.
3. **logP:** Ligand A (3.782) is optimal, while Ligand B (0.98) is a bit low. A logP below 1 can hinder membrane permeability.
4. **HBD:** Both ligands have acceptable HBD counts (3 and 1 respectively), well within the limit of 5.
5. **HBA:** Ligand B (7) is higher than Ligand A (3). While both are under the limit of 10, lower is generally preferred.
6. **QED:** Both ligands have good QED scores (0.683 and 0.863), indicating good drug-like properties.
7. **DILI:** Ligand A (36.952) has a lower DILI risk than Ligand B (50.136), which is a significant advantage.
8. **BBB:** Both have reasonable BBB penetration, but Ligand B (70.958) is slightly better than Ligand A (65.607). However, for a cardiovascular target like ADRB2, BBB penetration isn't a primary concern.
9. **Caco-2:** Ligand A (-4.696) is better than Ligand B (-5.087), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-3.333) is better than Ligand B (-2.826), indicating better aqueous solubility.
11. **hERG:** Both ligands have low hERG inhibition risk (0.634 and 0.311 respectively).
12. **Cl_mic:** Ligand B (3.917) has significantly lower microsomal clearance than Ligand A (32.834), suggesting better metabolic stability.
13. **t1/2:** Ligand A (106.612) has a much longer in vitro half-life than Ligand B (30.648).
14. **Pgp:** Both ligands have low P-gp efflux liability (0.261).
15. **Binding Affinity:** Ligand A (-7.6) has a slightly better binding affinity than Ligand B (-7.4), although the difference is small.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand A is the more promising candidate. While Ligand B has better metabolic stability (lower Cl_mic) and slightly better BBB penetration, Ligand A excels in TPSA, logP, solubility, and DILI risk. The slightly better binding affinity of Ligand A further strengthens its position. The combination of good permeability characteristics (lower TPSA, optimal logP) and a lower DILI risk makes Ligand A a more favorable starting point for further optimization. The longer half-life is also a benefit.
Output:
1
2025-04-17 18:02:52,307 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for the ADRB2, a cardiovascular GPCR. Therefore, the key properties to prioritize are logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB (though less critical for a cardiovascular target than a CNS one).
Let's compare the ligands property by property:
1. **MW:** Both ligands (346.4 and 340.4 Da) fall comfortably within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (78.09) is slightly higher than Ligand B (67.23). Both are below the 140 threshold for good absorption, but B is preferable.
3. **logP:** Both ligands have good logP values (2.423 and 2.06), falling within the 1-3 optimal range. Ligand B is slightly lower, which could be beneficial for solubility.
4. **HBD/HBA:** Ligand A has 2 HBD and 3 HBA, while Ligand B has 1 HBD and 4 HBA. Both are acceptable, but Ligand B has a slightly better profile.
5. **QED:** Both ligands have similar QED values (0.843 and 0.806), indicating good drug-likeness.
6. **DILI:** Ligand B (32.03) has a significantly lower DILI risk than Ligand A (45.10). This is a major advantage for Ligand B.
7. **BBB:** Ligand A (82.63) has better BBB penetration than Ligand B (55.10), but this is less crucial for a cardiovascular target.
8. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. This is a concern for both.
9. **Solubility:** Both ligands have negative solubility values, indicating poor aqueous solubility. This is a significant drawback for both.
10. **hERG:** Both ligands show low hERG inhibition risk (0.613 and 0.238), which is good.
11. **Cl_mic:** Ligand A (-11.654) has a much lower (better) microsomal clearance than Ligand B (13.956), indicating better metabolic stability.
12. **t1/2:** Ligand A (11.15 hours) has a longer half-life than Ligand B (-12.353 hours).
13. **Pgp:** Both ligands have very low Pgp efflux liability (0.046 and 0.042).
14. **Binding Affinity:** Ligand B (-6.5 kcal/mol) has a slightly better binding affinity than Ligand A (-6.1 kcal/mol). While the difference is not huge, it's enough to consider.
**Overall Assessment:**
Ligand B is preferable. While Ligand A has better metabolic stability (lower Cl_mic) and a slightly longer half-life, Ligand B has a significantly lower DILI risk, a slightly better TPSA, and a slightly better binding affinity. The lower DILI risk is a major advantage, and the slight improvement in binding affinity is a bonus. The poor Caco-2 and solubility are concerns for both, but can be addressed with formulation strategies.
Output:
0
2025-04-17 18:02:52,307 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (347.5) is slightly preferred due to being closer to the lower end, potentially aiding permeability.
**2. TPSA:** Ligand A (54.26) is excellent, well below the 140 threshold for oral absorption and favorable for a GPCR. Ligand B (99.68) is higher, potentially hindering absorption, but still within a reasonable range.
**3. logP:** Ligand A (2.659) is optimal (1-3). Ligand B (0.093) is quite low, which could severely limit membrane permeability and bioavailability. This is a significant drawback.
**4. H-Bond Donors:** Both ligands are acceptable. Ligand A (0) is slightly better as it minimizes potential issues with metabolic lability. Ligand B (1) is still within the acceptable range.
**5. H-Bond Acceptors:** Both ligands are within the acceptable range (<=10). Ligand A (5) is slightly preferred. Ligand B (6) is still reasonable.
**6. QED:** Both ligands have good QED scores (A: 0.645, B: 0.709), indicating good drug-like properties.
**7. DILI Risk:** Ligand A (13.532) has a much lower DILI risk than Ligand B (65.103). This is a critical advantage.
**8. BBB Penetration:** Ligand A (83.831) shows good BBB penetration, which is less critical for a cardiovascular target but still a positive. Ligand B (56.921) is lower, indicating less CNS exposure.
**9. Caco-2 Permeability:** Both have negative values, which is unusual. However, the magnitude of the negative value is important. Ligand A (-4.974) is less negative than Ligand B (-5.041), suggesting slightly better permeability.
**10. Aqueous Solubility:** Both ligands have negative solubility values, which is also unusual. Ligand A (-0.914) is slightly better than Ligand B (-1.47).
**11. hERG Inhibition:** Both ligands show low hERG inhibition liability (A: 0.414, B: 0.19). This is good and minimizes cardiotoxicity risk.
**12. Microsomal Clearance:** Ligand A (31.493) has a moderate clearance, while Ligand B (-6.322) has a negative clearance, which is not physically possible and suggests an issue with the data or model.
**13. In vitro Half-Life:** Ligand A (7.66) has a reasonable half-life. Ligand B (-18.982) has a negative half-life, again indicating a data issue.
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (A: 0.318, B: 0.033).
**15. Binding Affinity:** Ligand B (-7.6) has a slightly better binding affinity than Ligand A (-7.1), but the difference is not substantial enough to overcome the significant ADME liabilities.
**Overall Assessment:**
Ligand A is significantly more promising. While Ligand B has a slightly better binding affinity, its extremely low logP, high DILI risk, and the nonsensical negative values for clearance and half-life are major red flags. Ligand A has a much better ADME profile, particularly regarding logP, DILI, and reasonable clearance/half-life values. For a GPCR, a balance of affinity and ADME properties is crucial, and Ligand A strikes a better balance.
Output:
1
2025-04-17 18:02:52,307 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (338.4) is within the ideal range (200-500), while Ligand B (434.7) is at the upper end. This slightly favors A.
2. **TPSA:** Ligand A (52.6) is excellent, well below the 140 threshold. Ligand B (65.36) is still acceptable, but higher. A is preferred.
3. **logP:** Both ligands (A: 3.715, B: 3.669) are within the optimal 1-3 range. No clear preference.
4. **HBD:** Ligand A (0) is better than Ligand B (1) as fewer HBDs generally improve permeability.
5. **HBA:** Both ligands (A: 4, B: 4) are within the acceptable limit of 10. No clear preference.
6. **QED:** Ligand A (0.753) is significantly better than Ligand B (0.476), indicating a more drug-like profile. This is a strong advantage for A.
7. **DILI:** Ligand A (59.17) is higher than Ligand B (34.82), indicating a greater potential for liver injury. This favors B.
8. **BBB:** Ligand B (78.558) has a better BBB penetration score than Ligand A (63.629). While ADRB2 isn't necessarily a CNS target, some peripheral ADRB2 activity can be modulated by CNS effects, so this is a slight advantage for B.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.399) is slightly better than Ligand B (-4.707), but both are concerning.
10. **Solubility:** Ligand A (-5.52) is better than Ligand B (-3.944), indicating better aqueous solubility. This is a positive for A.
11. **hERG:** Ligand A (0.516) has a lower hERG inhibition liability than Ligand B (0.912), which is crucial for avoiding cardiotoxicity, especially given the cardiovascular target. This strongly favors A.
12. **Cl_mic:** Ligand B (76.958) has a lower microsomal clearance than Ligand A (122.505), suggesting better metabolic stability. This favors B.
13. **t1/2:** Ligand B (61.191) has a significantly longer in vitro half-life than Ligand A (24.277). This is a significant advantage for B.
14. **Pgp:** Ligand A (0.79) has lower P-gp efflux liability than Ligand B (0.235). This is a positive for A.
15. **Binding Affinity:** Ligand A (-8.1) has a substantially stronger binding affinity than Ligand B (-6.4). This is a major advantage for A, potentially outweighing some ADME drawbacks.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity), Ligand A is the stronger candidate. The significantly better binding affinity (-8.1 vs -6.4) is a major driver. While Ligand B has advantages in DILI, BBB, and t1/2, the superior affinity, TPSA, QED, solubility, and hERG profile of Ligand A are more critical for a viable drug candidate. The Caco-2 permeability is a concern for both, but can be addressed with formulation strategies.
Output:
1
2025-04-17 18:02:52,307 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. The key priorities for GPCRs are logP, Pgp efflux, TPSA, and binding affinity, with BBB being less critical for a cardiovascular target.
Let's compare the ligands property by property:
1. **MW:** Both ligands (350.419 and 351.393 Da) are within the ideal 200-500 Da range.
2. **TPSA:** Ligand B (60.77) is significantly better than Ligand A (113.44). Lower TPSA is generally preferred for better permeability, especially for GPCRs.
3. **logP:** Ligand B (2.415) is within the optimal 1-3 range, while Ligand A (0.869) is slightly below, potentially hindering permeation.
4. **HBD/HBA:** Ligand B has fewer HBDs (2 vs 3) and HBAs (3 vs 6) than Ligand A, which is generally favorable for permeability.
5. **QED:** Both ligands have good QED scores (0.609 and 0.707).
6. **DILI:** Ligand B (13.3) has a much lower DILI risk than Ligand A (47.732), a significant advantage.
7. **BBB:** While not a primary concern for a cardiovascular target, Ligand B (83.249) has a higher BBB percentile than Ligand A (46.762).
8. **Caco-2:** Ligand B (-4.273) is better than Ligand A (-5.126).
9. **Solubility:** Both have similar, poor aqueous solubility (-2.88 and -2.897). This is a potential issue for both, but not a deciding factor.
10. **hERG:** Both ligands have very low hERG inhibition risk (0.108 and 0.8).
11. **Cl_mic:** Ligand B (25.54) has lower microsomal clearance than Ligand A (32.267), indicating better metabolic stability.
12. **t1/2:** Ligand B (4.198) has a better in vitro half-life than Ligand A (-8.711).
13. **Pgp:** Ligand B (0.373) has significantly lower P-gp efflux liability than Ligand A (0.026), which is crucial for bioavailability and target engagement.
14. **Binding Affinity:** Both ligands have the same binding affinity (-6.3 kcal/mol).
**Overall Assessment:**
Ligand B consistently outperforms Ligand A across most critical ADME properties (TPSA, logP, DILI, Cl_mic, t1/2, Pgp) and has comparable binding affinity. While both have poor solubility, the other advantages of Ligand B make it a more promising drug candidate. The lower DILI risk and Pgp efflux, combined with better TPSA and logP, outweigh the slightly lower BBB penetration (which isn't a high priority for a cardiovascular target).
**Output:**
0
2025-04-17 18:02:52,308 - INFO - Here's my reasoning and output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
Let's break down the comparison of Ligand A and Ligand B, considering the provided guidelines and GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key).
1. **Molecular Weight:** Both ligands (366.355 and 366.422 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (69.64) is significantly better than Ligand B (96.18). A TPSA below 140 is good for oral absorption, and lower is generally preferred for GPCRs. Ligand B's TPSA is approaching a level that could hinder absorption.
3. **logP:** Both ligands have acceptable logP values (1.686 and 2.11), falling within the 1-3 range. Ligand B is slightly higher, which could potentially lead to some off-target interactions, but it's not a major concern.
4. **H-Bond Donors:** Both have 2 HBD, which is within the desired limit of 5.
5. **H-Bond Acceptors:** Ligand A has 3 HBA, while Ligand B has 8. This is a notable difference. Higher HBA can sometimes reduce permeability.
6. **QED:** Both ligands have good QED scores (0.747 and 0.836), indicating good drug-like properties.
7. **DILI:** Ligand A (40.054) has a better DILI score than Ligand B (79.1), indicating a lower risk of drug-induced liver injury. This is a significant advantage.
8. **BBB:** Both ligands have good BBB penetration (76.192 and 81.582). This is less critical for ADRB2 (a cardiovascular target) but still a positive attribute.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and potentially problematic. However, the values are similar (-5.064 and -5.175), so it doesn't differentiate the two.
10. **Solubility:** Both have negative solubility values, which is also unusual. Again, the values are similar (-2.784 and -3.72), so it doesn't differentiate the two.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.449 and 0.446), which is excellent.
12. **Cl_mic:** Ligand A (-5.368) has a much lower (better) microsomal clearance than Ligand B (24.782). This suggests greater metabolic stability for Ligand A.
13. **t1/2:** Ligand A (10.289) has a longer in vitro half-life than Ligand B (-4.995). This is a significant advantage, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.039).
15. **Binding Affinity:** Ligand A (-6.9 kcal/mol) has a slightly better binding affinity than Ligand B (-6.1 kcal/mol). While the difference is not huge (1.8 kcal/mol), it's enough to be considered, especially in light of the other advantages Ligand A possesses.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across several crucial ADME properties (DILI, Cl_mic, t1/2, TPSA, HBA) and has a slightly better binding affinity. While both ligands have acceptable logP and BBB penetration, the superior ADME profile of Ligand A makes it the more promising drug candidate for the ADRB2 receptor.
**Output:**
1
2025-04-17 18:02:52,308 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (337-350 Da). No significant difference.
2. **TPSA:** Both are below 140, good for oral absorption. Ligand A (85.69) is slightly better than Ligand B (86.36), but the difference is minimal.
3. **logP:** Ligand A (0.577) is a bit low, potentially hindering permeation. Ligand B (1.509) is better, falling within the optimal range. This is a point in favor of Ligand B.
4. **HBD:** Ligand A (1) is excellent. Ligand B (3) is acceptable, but higher HBD can sometimes impact permeability.
5. **HBA:** Ligand A (6) is good. Ligand B (4) is also good.
6. **QED:** Both ligands have very similar, good QED scores (0.789 and 0.792).
7. **DILI:** Ligand A (51.183) has a significantly lower DILI risk than Ligand B (78.17). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (72.237) has a better BBB penetration score than Ligand B (65.839). While ADRB2 is a cardiovascular target, some CNS off-target effects are always a consideration, and better BBB penetration is generally preferable.
9. **Caco-2:** Ligand B (-5.3) shows better Caco-2 permeability than Ligand A (-4.715). This suggests better intestinal absorption for Ligand B.
10. **Solubility:** Ligand A (-1.771) shows better aqueous solubility than Ligand B (-3.017).
11. **hERG:** Both ligands have low hERG inhibition liability (0.21 and 0.431). No significant difference.
12. **Cl_mic:** Ligand B (-19.447) has significantly lower microsomal clearance than Ligand A (21.483), indicating better metabolic stability. This is a substantial advantage for Ligand B.
13. **t1/2:** Ligand B (68.354) has a much longer in vitro half-life than Ligand A (36.025). This is a significant advantage for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.018 and 0.02). No significant difference.
15. **Binding Affinity:** Ligand A (-7.5) has a significantly stronger binding affinity than Ligand B (-2.1). This is a very important factor, as a >1.5 kcal/mol advantage can outweigh minor ADME drawbacks.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand B has a better logP and Caco-2 permeability, and significantly better metabolic stability (Cl_mic) and half-life. However, Ligand A has a *much* stronger binding affinity and lower DILI risk, and better BBB penetration. The difference in binding affinity is substantial.
**Overall Assessment:**
While Ligand B has advantages in metabolic stability and permeability, the significantly stronger binding affinity of Ligand A (-7.5 vs -2.1 kcal/mol) and its lower DILI risk are critical. The binding affinity difference is large enough to compensate for the slightly lower logP and the higher clearance. The better BBB penetration is also a plus.
Output:
1
2025-04-17 18:02:52,308 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
The target is ADRB2, a GPCR. Therefore, I will prioritize logP, TPSA, Pgp efflux, BBB penetration, and binding affinity, while also considering ADME properties like solubility, metabolic stability, and toxicity.
Let's compare the ligands property by property:
1. **MW:** Both ligands (343.471 and 340.383 Da) fall within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (62.3) is significantly better than Ligand B (97.12). A TPSA under 140 is good for oral absorption, and lower is better for GPCRs. Ligand B is approaching a concerning level.
3. **logP:** Both ligands have acceptable logP values (2.936 and 1.179), falling within the 1-3 range. Ligand A is slightly better.
4. **HBD/HBA:** Ligand A (1 HBD, 3 HBA) is preferable to Ligand B (2 HBD, 5 HBA). Lower counts generally improve permeability.
5. **QED:** Ligand A (0.914) has a superior QED score compared to Ligand B (0.789), indicating better overall drug-likeness.
6. **DILI:** Ligand A (34.509) has a significantly lower DILI risk than Ligand B (55.293). This is a major advantage.
7. **BBB:** Ligand A (73.866) has a much higher BBB penetration percentile than Ligand B (37.96). While not a CNS target, some level of BBB penetration can be beneficial for distribution.
8. **Caco-2:** Ligand A (-4.874) is better than Ligand B (-5.705), indicating better intestinal absorption.
9. **Solubility:** Ligand A (-3.008) is better than Ligand B (-1.146), which is important for formulation and bioavailability.
10. **hERG:** Both ligands have very low hERG inhibition liability (0.512 and 0.058), which is excellent.
11. **Cl_mic:** Ligand B (-16.733) has a lower (better) microsomal clearance than Ligand A (51.344), suggesting greater metabolic stability.
12. **t1/2:** Ligand B (23.236) has a longer in vitro half-life than Ligand A (-19.511). This is a positive attribute.
13. **Pgp:** Ligand A (0.193) has lower P-gp efflux liability than Ligand B (0.012), which is preferable for bioavailability.
14. **Binding Affinity:** Both ligands have very similar binding affinities (-6.5 and -6.3 kcal/mol). The difference is negligible.
**Overall Assessment:**
Ligand A is clearly the better candidate. While Ligand B has a slightly better half-life and metabolic stability, Ligand A excels in almost every other critical parameter, especially TPSA, DILI risk, BBB penetration, QED, solubility, and Caco-2 permeability. The superior drug-like properties and reduced toxicity risk of Ligand A outweigh the minor advantage of Ligand B's metabolic stability.
**Output:**
1
2025-04-17 18:02:52,308 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's analyze each ligand against the provided guidelines, keeping in mind ADRB2 is a GPCR, so logP, TPSA, Pgp, BBB, and affinity are key.
* **Molecular Weight:** Both ligands (364.383 and 354.491 Da) fall within the ideal 200-500 Da range.
* **TPSA:** Ligand A (119.37) is slightly higher than Ligand B (78.87). Both are below the 140 threshold for good oral absorption, but Ligand B is significantly better, potentially indicating better permeability.
* **logP:** Both ligands have good logP values (1.586 and 1.848), falling within the optimal 1-3 range.
* **H-Bond Donors/Acceptors:** Both have 2 HBDs, which is good. Ligand A has 7 HBAs, while Ligand B has 4. Both are acceptable, but Ligand B is preferable.
* **QED:** Both ligands have similar QED values (0.685 and 0.662), indicating good drug-likeness.
* **DILI:** Ligand A has a concerningly high DILI risk (94.882 percentile). Ligand B has a very low DILI risk (15.587 percentile). This is a *major* advantage for Ligand B.
* **BBB:** Ligand B (51.532 percentile) shows better BBB penetration than Ligand A (27.646 percentile). While ADRB2 isn't exclusively a CNS target, some peripheral effects are mediated by CNS pathways, and better BBB penetration isn't necessarily a detriment.
* **Caco-2 Permeability:** Ligand A (-5.223) has poor Caco-2 permeability, while Ligand B (-4.372) is slightly better.
* **Aqueous Solubility:** Ligand A (-3.136) has slightly better aqueous solubility than Ligand B (-2.354).
* **hERG Inhibition:** Both ligands have low hERG inhibition risk (0.238 and 0.308).
* **Microsomal Clearance:** Ligand A (26.814 mL/min/kg) has lower microsomal clearance than Ligand B (46.291 mL/min/kg), suggesting better metabolic stability.
* **In vitro Half-Life:** Ligand A (32.211 hours) has a significantly longer half-life than Ligand B (-17.174 hours). This is a significant advantage for Ligand A.
* **P-gp Efflux:** Both ligands have low P-gp efflux liability (0.067 and 0.195).
* **Binding Affinity:** Ligand B (-6.9 kcal/mol) has a slightly better binding affinity than Ligand A (-6.0 kcal/mol). This is a 0.9 kcal/mol difference, which is significant.
**Overall Assessment:**
Ligand B is the stronger candidate. While Ligand A has a longer half-life and slightly better solubility, the drastically lower DILI risk and better BBB penetration of Ligand B are critical advantages. The slightly better binding affinity of Ligand B further solidifies its position. The TPSA value of Ligand B is also significantly better. The longer half-life of Ligand A is a benefit, but can be addressed through formulation or prodrug strategies. The high DILI risk of Ligand A is a major concern that is difficult to overcome.
**Output:**
0
2025-04-17 18:02:52,308 - INFO - Batch 9 complete. Total preferences: 144
2025-04-17 18:02:52,308 - INFO - Processing batch 10/512...
2025-04-17 18:03:42,205 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.49 & 358.44 Da) are within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand B (40.62) is significantly better than Ligand A (60.85). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (2.51 & 3.25), falling within the optimal 1-3 range. Ligand B is slightly higher, which *could* be beneficial for membrane permeability, but isn't a major concern.
4. **HBD:** Ligand A has 1 HBD, Ligand B has 0. Both are acceptable.
5. **HBA:** Both ligands have 3 HBA, which is well within the acceptable range.
6. **QED:** Ligand B (0.827) has a higher QED score than Ligand A (0.613), indicating a more drug-like profile.
7. **DILI:** Ligand B (49.59) has a much lower DILI risk than Ligand A (13.96). This is a significant advantage.
8. **BBB:** Ligand B (87.13) has better BBB penetration than Ligand A (68.13), though this is less critical for a cardiovascular target.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand B (-4.687) is slightly better than Ligand A (-4.54).
10. **Solubility:** Ligand A (-1.571) has better solubility than Ligand B (-3.433). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.22) has a lower hERG risk than Ligand B (0.719). This is a significant advantage.
12. **Cl_mic:** Ligand A (22.63) has lower microsomal clearance, suggesting better metabolic stability, than Ligand B (32.96).
13. **t1/2:** Ligand B (4.15) has a longer in vitro half-life than Ligand A (-4.16). This is a positive.
14. **Pgp:** Ligand A (0.13) has lower P-gp efflux, which is favorable for bioavailability, than Ligand B (0.436).
15. **Affinity:** Both ligands have the same binding affinity (-6.3 kcal/mol).
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP, TPSA, and Pgp. Affinity is equal. Ligand A has better hERG inhibition and lower Cl_mic. However, the significantly lower DILI risk of Ligand B, combined with its better QED and slightly improved half-life, outweigh the benefits of Ligand A's better hERG and metabolic stability. The solubility difference is also a concern for Ligand B.
**Conclusion:**
Considering the overall balance of properties and the priorities for a GPCR target, Ligand B is the more promising candidate.
Output:
0
2025-04-17 18:03:42,205 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (351.451) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (109.14) is better than Ligand B (37.61). ADRB2 is not a CNS target, so a TPSA under 140 is acceptable, but lower is still preferred for permeability. Ligand B is excellent here.
3. **logP:** Ligand B (4.738) is higher than Ligand A (0.308). While 4.738 is approaching the upper limit, it's not drastically high. Ligand A's logP is quite low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (3) is higher than Ligand B (0). This isn't a major concern for either, but fewer HBDs are generally preferred.
5. **HBA:** Ligand A (6) is higher than Ligand B (4). Similar to HBD, lower is generally better.
6. **QED:** Both ligands have similar and acceptable QED values (0.624 and 0.647).
7. **DILI:** Ligand A (32.726) has a significantly lower DILI risk than Ligand B (43.777). This is a substantial advantage for Ligand A.
8. **BBB:** Not a primary concern for ADRB2, but Ligand B (84.451) has a higher BBB penetration than Ligand A (25.824).
9. **Caco-2:** Ligand A (-5.291) and Ligand B (-4.824) both have negative values. This is unusual and suggests poor permeability.
10. **Solubility:** Ligand A (-1.24) has better solubility than Ligand B (-4.574).
11. **hERG:** Ligand A (0.03) has a much lower hERG risk than Ligand B (0.894). This is a critical advantage for Ligand A, as hERG inhibition can lead to cardiotoxicity.
12. **Cl_mic:** Ligand B (75.11) has a significantly higher microsomal clearance than Ligand A (-3.79). This suggests Ligand A is more metabolically stable.
13. **t1/2:** Ligand B (15.622) has a longer in vitro half-life than Ligand A (-9.001).
14. **Pgp:** Ligand A (0.02) has lower P-gp efflux liability than Ligand B (0.646).
15. **Binding Affinity:** Ligand B (-8.1) has a significantly stronger binding affinity than Ligand A (-6.2). This is a substantial advantage for Ligand B.
**Overall Assessment:**
Ligand B boasts a much stronger binding affinity, which is a major driver for GPCR drug candidates. However, it suffers from higher DILI risk, higher hERG inhibition, and higher metabolic clearance. Ligand A has a better safety profile (lower DILI, lower hERG), better metabolic stability, and lower P-gp efflux. The lower logP and Caco-2 values for Ligand A are concerning, but the superior binding affinity of Ligand B is a significant advantage that outweighs the ADME concerns.
Output:
0
2025-04-17 18:03:42,205 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (409.324 Da) is within the ideal range, while Ligand B (348.447 Da) is slightly below, but still acceptable.
2. **TPSA:** Ligand A (60.85) is good, well below the 140 threshold. Ligand B (84.42) is also acceptable, but higher.
3. **logP:** Both ligands (A: 2.069, B: 1.373) fall within the optimal 1-3 range.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 3 HBA, Ligand B has 5. Both are acceptable, but A is slightly better.
6. **QED:** Both ligands have good QED scores (A: 0.778, B: 0.804), indicating good drug-like properties.
7. **DILI:** Both have low DILI risk (A: 31.02, B: 34.354), below the 40 threshold.
8. **BBB:** Both have good BBB penetration (A: 69.794, B: 68.282). While not exceptionally high, this is acceptable for a cardiovascular target.
9. **Caco-2:** Both have negative Caco-2 values, indicating good permeability.
10. **Solubility:** Both have negative solubility values, indicating good solubility.
11. **hERG:** Both have low hERG inhibition liability (A: 0.585, B: 0.181), which is crucial for avoiding cardiotoxicity. Ligand B is better here.
12. **Cl_mic:** Both have similar microsomal clearance (A: 29.849, B: 29.605).
13. **t1/2:** Ligand A (-9.687) has a longer in vitro half-life than Ligand B (-6.03), which is desirable.
14. **Pgp:** Both have low Pgp efflux (A: 0.336, B: 0.023). Ligand B is better here.
15. **Binding Affinity:** Ligand A (-6.6 kcal/mol) has a slightly better binding affinity than Ligand B (-6.0 kcal/mol).
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Both ligands perform well on logP and Pgp. Ligand A has a better TPSA and a slightly better binding affinity. The longer half-life of Ligand A is also a plus.
**Overall Assessment:**
While Ligand B has a slightly better hERG profile and Pgp efflux, Ligand A's superior binding affinity, TPSA, and half-life outweigh these minor advantages. The differences are small, but considering the importance of potency for GPCRs, and the slightly better overall ADME profile, Ligand A appears to be the more promising candidate.
Output:
1
2025-04-17 18:03:42,205 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [344.459, 59.65, 1.504, 1, 3, 0.846, 31.912, 55.603, -4.578, -2.066, 0.278, 9.6, -17.794, 0.128, -6.8]
**Ligand B:** [368.825, 124.93, -0.124, 4, 6, 0.435, 52.074, 8.53, -6.226, -2.154, 0.117, -6.638, 8.954, 0.016, -7.5]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity, and to a lesser extent BBB):
1. **MW:** Both are within the acceptable 200-500 Da range. Ligand A (344.459) is slightly preferred.
2. **TPSA:** Ligand A (59.65) is excellent, well below 140, and indicative of good absorption. Ligand B (124.93) is higher, but still acceptable, though less optimal.
3. **logP:** Ligand A (1.504) is optimal. Ligand B (-0.124) is quite low, potentially hindering membrane permeability. This is a significant drawback.
4. **HBD/HBA:** Ligand A (1 HBD, 3 HBA) is better than Ligand B (4 HBD, 6 HBA). Lower counts generally improve permeability.
5. **QED:** Ligand A (0.846) is very good, indicating high drug-likeness. Ligand B (0.435) is lower, suggesting potential issues.
6. **DILI:** Both are reasonably low, but Ligand A (31.912) is better than Ligand B (52.074).
7. **BBB:** Ligand A (55.603) is moderate, while Ligand B (8.53) is very low. While ADRB2 isn't necessarily a CNS target, some distribution into the CNS can be beneficial for off-target effects assessment.
8. **Caco-2:** Ligand A (-4.578) is better than Ligand B (-6.226), indicating better intestinal absorption.
9. **Solubility:** Both are poor (-2.066 and -2.154). This is a concern for both, but can be addressed with formulation strategies.
10. **hERG:** Both are low risk (0.278 and 0.117).
11. **Cl_mic:** Ligand A (9.6) is higher than Ligand B (-6.638), meaning Ligand B is more metabolically stable.
12. **t1/2:** Ligand B (8.954) has a better in vitro half-life than Ligand A (-17.794).
13. **Pgp:** Ligand A (0.128) has lower P-gp efflux than Ligand B (0.016), which is beneficial for bioavailability.
14. **Affinity:** Ligand B (-7.5) has a slightly better binding affinity than Ligand A (-6.8), a difference of 0.7 kcal/mol.
**Overall Assessment:**
While Ligand B has a slightly better binding affinity and metabolic stability, the significantly lower logP and QED, combined with the poor BBB penetration, are major concerns. The higher TPSA and HBD/HBA counts also detract from its drug-like properties. Ligand A, despite a slightly weaker binding affinity, has a much more favorable profile overall, particularly regarding permeability (logP, TPSA, Caco-2, Pgp) and drug-likeness (QED). The better DILI score is also a plus.
Therefore, I would choose Ligand A as the more promising drug candidate.
1
2025-04-17 18:03:42,205 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (344.419 Da) is slightly lower, which is generally favorable for permeability.
**2. TPSA:** Ligand A (95.91) is significantly better than Ligand B (137.4). For a GPCR, keeping TPSA under 140 is good, and lower is better for permeability. Ligand B is approaching a less desirable range.
**3. logP:** Ligand B (2.001) is better than Ligand A (0.426). The optimal range is 1-3, and Ligand B falls squarely within it. Ligand A is quite low, potentially hindering membrane permeability.
**4. H-Bond Donors:** Ligand A (2) is preferable to Ligand B (5). Fewer HBDs generally improve permeability.
**5. H-Bond Acceptors:** Ligand B (7) is higher than Ligand A (5), but both are within acceptable limits (<=10).
**6. QED:** Ligand A (0.689) has a better QED score than Ligand B (0.44), indicating a more drug-like profile.
**7. DILI Risk:** Ligand A (33.695) has a much lower DILI risk than Ligand B (81.776). This is a significant advantage for Ligand A.
**8. BBB Penetration:** Both are relatively low, but Ligand B (47.421) is slightly better than Ligand A (41.528). However, for a cardiovascular target, BBB penetration is not a primary concern.
**9. Caco-2 Permeability:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not provided, so it's difficult to interpret.
**10. Aqueous Solubility:** Ligand A (-1.109) is better than Ligand B (-5.274). Higher solubility is generally preferred.
**11. hERG Inhibition:** Ligand A (0.118) has a much lower hERG inhibition risk than Ligand B (0.617). This is a critical advantage for Ligand A.
**12. Microsomal Clearance:** Ligand A (-5.025) has a significantly lower (better) microsomal clearance than Ligand B (12.474), indicating better metabolic stability.
**13. In vitro Half-Life:** Ligand A (-7.658) has a much longer in vitro half-life than Ligand B (30.807), indicating better stability.
**14. P-gp Efflux:** Both are very low (close to 0), suggesting minimal P-gp efflux.
**15. Binding Affinity:** Ligand B (-8.2) has a slightly better binding affinity than Ligand A (-8.7), but the difference is small (0.5 kcal/mol).
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity) and general drug-like properties, Ligand A is the superior candidate. While Ligand B has a slightly better logP and binding affinity, Ligand A excels in critical areas like DILI risk, hERG inhibition, metabolic stability (Cl_mic and t1/2), TPSA, solubility, and QED. The lower DILI and hERG risks are particularly important for a cardiovascular drug. The small difference in binding affinity is outweighed by the significant advantages in ADME-Tox properties.
Output:
1
2025-04-17 18:03:42,206 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [377.853, 86.29, 2.72, 2, 5, 0.715, 81.427, 30.554, -5.475, -3.477, 0.358, 6.753, 99.955, 0.223, -6.3]
**Ligand B:** [350.503, 58.64, 2.594, 1, 3, 0.695, 5.894, 78.79, -4.608, -2.519, 0.53, 76.154, -11.771, 0.082, -4.8]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (350.5) is slightly lower, which *could* be beneficial for permeability, but both are acceptable.
2. **TPSA:** Ligand A (86.29) is higher than Ligand B (58.64). For a cardiovascular GPCR, TPSA isn't as critical as for CNS targets, but lower is generally preferred for better absorption. Ligand B is significantly better here.
3. **logP:** Both are within the optimal 1-3 range. Ligand A (2.72) and Ligand B (2.594) are very similar.
4. **HBD:** Ligand A (2) and Ligand B (1) are both good. Lower is slightly preferred, so Ligand B has a minor advantage.
5. **HBA:** Ligand A (5) and Ligand B (3) are both acceptable. Ligand B is better.
6. **QED:** Both are above 0.5, indicating good drug-likeness, but Ligand A (0.715) is slightly better than Ligand B (0.695).
7. **DILI:** Ligand A (81.427) has a significantly higher DILI risk than Ligand B (5.894). This is a major concern.
8. **BBB:** Ligand B (78.79) has better BBB penetration than Ligand A (30.554). While not a primary concern for a cardiovascular target, it's a bonus.
9. **Caco-2:** Ligand A (-5.475) is worse than Ligand B (-4.608). Lower values indicate poorer permeability.
10. **Solubility:** Ligand A (-3.477) is worse than Ligand B (-2.519).
11. **hERG:** Ligand A (0.358) is better than Ligand B (0.53). Lower is better.
12. **Cl_mic:** Ligand A (6.753) has lower clearance than Ligand B (76.154), indicating better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand A (99.955) has a much longer half-life than Ligand B (-11.771). This is a huge advantage, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.223) has lower Pgp efflux than Ligand B (0.082). Lower is better.
15. **Affinity:** Ligand A (-6.3) has a slightly better binding affinity than Ligand B (-4.8). This is a 1.5 kcal/mol difference, which is significant.
**Overall Assessment:**
Ligand A has a better binding affinity, longer half-life, lower Pgp efflux, and better metabolic stability. However, its significantly higher DILI risk and poorer solubility/permeability are major drawbacks. Ligand B has a much better safety profile (DILI), better TPSA, solubility, and permeability, but weaker affinity and shorter half-life.
Given the GPCR-specific priorities (logP, Pgp, TPSA, affinity) and the importance of safety, the lower DILI risk of Ligand B outweighs the slightly weaker affinity and shorter half-life. The affinity of -4.8 kcal/mol is still respectable, and optimization could potentially improve it. The DILI risk of Ligand A is too high to ignore.
Output:
0
2025-04-17 18:03:42,206 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
The ADRB2 receptor is a GPCR, so the priorities are logP, TPSA, Pgp efflux, BBB penetration, and binding affinity. Metabolic stability and solubility are also important, but slightly lower priority.
Let's compare the ligands property by property:
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (375.45) is slightly higher than Ligand B (346.402), but this isn't a major concern.
2. **TPSA:** Ligand B (58.64) is significantly better than Ligand A (96.53). Lower TPSA generally improves permeability, which is crucial for GPCR ligands.
3. **logP:** Both are good (around 2.2), falling within the optimal 1-3 range. Ligand A (2.151) is marginally lower, but both are acceptable.
4. **HBD/HBA:** Ligand B has fewer HBDs (1 vs 3) and HBAs (3 vs 5), which is generally favorable for permeability.
5. **QED:** Ligand B (0.635) has a better QED score than Ligand A (0.446), indicating a more drug-like profile.
6. **DILI:** Ligand B (37.96) has a significantly lower DILI risk than Ligand A (19.193), a major advantage.
7. **BBB:** Ligand B (84.529) has much better BBB penetration potential than Ligand A (69.988). While not a primary concern for peripheral GPCRs like ADRB2, it's still a positive attribute.
8. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-5.082) is worse than Ligand B (-4.646).
9. **Solubility:** Both have negative solubility values, indicating poor aqueous solubility. Ligand A (-1.149) is slightly better than Ligand B (-2.486).
10. **hERG:** Ligand A (0.292) has a slightly lower hERG risk than Ligand B (0.769), which is good.
11. **Cl_mic:** Ligand B (31.456) has lower microsomal clearance than Ligand A (39.765), indicating better metabolic stability.
12. **t1/2:** Ligand B (-0.624) has a slightly better in vitro half-life than Ligand A (-8.26).
13. **Pgp:** Both have very low Pgp efflux liability (0.014 and 0.299), which is excellent.
14. **Binding Affinity:** Ligand B (-6.9 kcal/mol) has slightly better binding affinity than Ligand A (-6.0 kcal/mol). This is a significant advantage.
**Overall Assessment:**
Ligand B consistently outperforms Ligand A across most crucial parameters, especially TPSA, DILI, BBB, QED, and metabolic stability. While Ligand A has a slightly better hERG profile and solubility, the advantages of Ligand B are more substantial and align better with the requirements for a successful GPCR drug candidate. The improved binding affinity of Ligand B further solidifies its position as the preferred choice.
**Output:**
0
2025-04-17 18:03:42,206 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 receptor (a GPCR):
**1. Molecular Weight:** Both ligands (354.422 and 352.483 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (70.08) is significantly better than Ligand B (101.41). For a GPCR, keeping TPSA low is beneficial for permeability, and Ligand A is well below the 140 cutoff. Ligand B is approaching the upper limit.
**3. logP:** Ligand B (2.162) is within the optimal 1-3 range, while Ligand A (0.581) is slightly below 1. While a lower logP can sometimes indicate solubility issues, it's less concerning than a very high logP.
**4. H-Bond Donors:** Both ligands have 1 HBD, which is acceptable.
**5. H-Bond Acceptors:** Both ligands have 4 HBA, which is acceptable.
**6. QED:** Ligand A (0.802) has a much better QED score than Ligand B (0.391), indicating a more drug-like profile.
**7. DILI:** Both ligands have similar DILI risk (21.481 vs 22.102), and both are reasonably low, falling well below the concerning 60 percentile.
**8. BBB:** Ligand A (77.898) has a significantly higher BBB penetration percentile than Ligand B (49.011). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant, and higher BBB is generally favorable.
**9. Caco-2 Permeability:** Ligand A (-4.39) is better than Ligand B (-5.107), indicating better intestinal absorption.
**10. Aqueous Solubility:** Ligand A (-2.277) is better than Ligand B (-1.167).
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.47 and 0.525), which is excellent.
**12. Microsomal Clearance:** Ligand A (29.834) has a slightly higher microsomal clearance than Ligand B (24.371), meaning it might be metabolized slightly faster.
**13. In vitro Half-Life:** Ligand B (13.02) has a slightly longer half-life than Ligand A (11.802).
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.05 and 0.021), which is excellent.
**15. Binding Affinity:** Ligand B (-6.9 kcal/mol) has a stronger binding affinity than Ligand A (-5.3 kcal/mol). This is a 1.6 kcal/mol difference, which is substantial and a major advantage for Ligand B.
**Overall Assessment:**
Ligand B has a significantly better binding affinity, which is a critical factor for GPCR targets. However, Ligand A excels in several ADME properties, including TPSA, QED, BBB penetration, solubility, and Caco-2 permeability. The difference in binding affinity is significant enough to outweigh the slightly less favorable ADME profile of Ligand B. While Ligand A is a good candidate, the stronger binding of Ligand B is a decisive advantage.
Output:
0
2025-04-17 18:03:42,206 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the acceptable range (200-500 Da). Ligand A (443.288 Da) is higher, but not excessively so. Ligand B (343.366 Da) is lower, potentially aiding permeability.
**2. TPSA:** Ligand A (53.16) is good, below the 140 threshold. Ligand B (93.54) is higher, nearing a potential absorption issue, but not disqualifying.
**3. logP:** Ligand A (4.785) is a bit high, potentially leading to solubility issues or off-target interactions. Ligand B (1.491) is optimal.
**4. H-Bond Donors:** Both ligands have acceptable HBD counts (3 and 2 respectively).
**5. H-Bond Acceptors:** Ligand A (2) is good. Ligand B (7) is acceptable, but higher.
**6. QED:** Both ligands have good QED scores (0.393 and 0.729), indicating reasonable drug-likeness. Ligand B is better.
**7. DILI:** Ligand A (89.841) has a higher DILI risk than Ligand B (78.364), which is preferable.
**8. BBB:** Both ligands have good BBB penetration (69.833 and 83.172). This isn't a primary concern for a cardiovascular target, but it's a positive for both.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, indicating poor permeability. This is concerning for both.
**10. Aqueous Solubility:** Both ligands have negative solubility values, indicating poor solubility. This is concerning for both.
**11. hERG Inhibition:** Ligand A (0.866) has a higher hERG risk than Ligand B (0.391), which is preferable.
**12. Microsomal Clearance:** Ligand B (20.874) has significantly lower microsomal clearance than Ligand A (51.604), indicating better metabolic stability.
**13. In vitro Half-Life:** Ligand A (62.948) has a longer half-life than Ligand B (-6.329). This is a positive for Ligand A.
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (0.341 and 0.198).
**15. Binding Affinity:** Ligand B (-6.1 kcal/mol) has a significantly stronger binding affinity than Ligand A (-0.2 kcal/mol). This is a major advantage for Ligand B.
**GPCR-Specific Considerations:** For a GPCR like ADRB2, logP, TPSA, Pgp efflux, and affinity are key. Ligand B excels in logP and affinity, while both are similar in Pgp. Ligand A has a higher TPSA.
**Overall Assessment:**
While Ligand A has a longer half-life, the significantly stronger binding affinity of Ligand B (-6.1 vs -0.2 kcal/mol) is a decisive advantage. The lower logP, lower DILI risk, and lower microsomal clearance of Ligand B also contribute to its superior profile. The poor Caco-2 and solubility for both are concerning, but can be addressed through formulation strategies. The higher affinity is likely to translate to greater efficacy, outweighing the other drawbacks.
Output:
0
2025-04-17 18:03:42,206 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (345.447 and 345.399 Da) fall comfortably within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (61.68) is significantly better than Ligand B (80.76). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (1.587) is better than Ligand A (0.577). A logP between 1-3 is optimal, and Ligand B is within this range, while Ligand A is slightly low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (0) is preferable to Ligand B (1). Fewer HBDs generally improve permeability.
5. **HBA:** Both ligands have 5 HBA, which is acceptable.
6. **QED:** Both ligands have good QED scores (0.787 and 0.847), indicating good drug-like properties.
7. **DILI:** Both ligands have similar, acceptable DILI risk (41.877 and 41.411).
8. **BBB:** Ligand A (86.002) has a higher BBB penetration percentile than Ligand B (77.898). While not a primary concern for a cardiovascular target, it's a slight advantage.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.584 and -4.645). These values are difficult to interpret without knowing the scale, but the similarity suggests comparable intestinal absorption potential.
10. **Solubility:** Ligand A (-1.616) has better solubility than Ligand B (-3.344). Better solubility is generally desirable for bioavailability.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.426 and 0.24). This is excellent.
12. **Cl_mic:** Ligand B (15.383) has much lower microsomal clearance than Ligand A (58.878), indicating better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand B (-7.559) has a longer in vitro half-life than Ligand A (-6.585). This is a positive attribute.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.269 and 0.024).
15. **Binding Affinity:** Ligand A (-7.1) has a slightly better binding affinity than Ligand B (-6.0). This is a 1.1 kcal/mol difference, which is substantial and can outweigh some ADME drawbacks.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B has a better logP, and comparable Pgp. Ligand A has a better TPSA and significantly better affinity. The metabolic stability (Cl_mic and t1/2) of Ligand B is also a strong positive.
**Overall Assessment:**
While Ligand B has superior metabolic stability and a good logP, the significantly stronger binding affinity of Ligand A (-7.1 vs -6.0 kcal/mol) is a crucial advantage for a GPCR target. The slightly lower logP of Ligand A is not a major concern, and its better TPSA and solubility are beneficial. The difference in affinity is likely to have a greater impact on efficacy than the differences in ADME properties.
Output:
1
2025-04-17 18:03:42,206 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (346.43) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (67.87) is significantly better than Ligand B (101.53). ADRB2 is a cardiovascular target, not a CNS target, but lower TPSA is still desirable for absorption. Ligand B is pushing the upper limit for good oral absorption.
3. **logP:** Ligand A (2.304) is optimal. Ligand B (-0.36) is too low, potentially hindering membrane permeability and bioavailability.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A (4) is better than Ligand B (6). Lower HBA is generally preferred for permeability.
6. **QED:** Ligand A (0.908) is excellent, indicating high drug-likeness. Ligand B (0.768) is still acceptable, but lower.
7. **DILI:** Both have low DILI risk (Ligand A: 43.622, Ligand B: 40.209), which is positive.
8. **BBB:** This is less critical for a cardiovascular target, but Ligand A (87.708) is better than Ligand B (37.224).
9. **Caco-2:** Ligand A (-4.471) is better than Ligand B (-5.515), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-2.848) is better than Ligand B (-2.303), though both are poor.
11. **hERG:** Ligand A (0.581) is better than Ligand B (0.055), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand A (-6.391) is much better than Ligand B (4.079), indicating significantly better metabolic stability.
13. **t1/2:** Ligand A (11.823) is better than Ligand B (-0.945).
14. **Pgp:** Ligand A (0.081) is better than Ligand B (0.014), indicating lower P-gp efflux.
15. **Affinity:** Ligand B (-7.5) is slightly better than Ligand A (-7.3), but the difference is relatively small (0.2 kcal/mol).
**Overall Assessment:**
Ligand A is significantly better overall. While Ligand B has a slightly better binding affinity, Ligand A excels in almost all other crucial ADME properties, including TPSA, logP, solubility, metabolic stability (Cl_mic, t1/2), and P-gp efflux. The improved ADME profile of Ligand A is likely to translate to better bioavailability and a more favorable pharmacokinetic profile, outweighing the small difference in binding affinity. The lower hERG risk for Ligand A is also a significant advantage. Given that we are targeting a GPCR, the balance of properties is critical, and Ligand A strikes that balance much better.
Output:
1
2025-04-17 18:03:42,206 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**1. Molecular Weight:** Both ligands (347.415 and 367.848 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (82.71) is higher than Ligand B (53.68). For a cardiovascular GPCR like ADRB2, TPSA is less critical than for CNS targets, but lower is generally preferable for absorption. Ligand B has a clear advantage.
**3. logP:** Ligand A (1.339) is within the optimal range (1-3). Ligand B (4.656) is significantly higher, potentially leading to solubility issues and off-target interactions. Ligand A is favored.
**4. H-Bond Donors:** Both have 1 HBD, which is acceptable.
**5. H-Bond Acceptors:** Ligand A has 4 HBA, and Ligand B has 3. Both are within the acceptable range of <=10.
**6. QED:** Ligand A (0.833) has a better QED score than Ligand B (0.656), indicating a more drug-like profile.
**7. DILI Risk:** Both have acceptable DILI risk, with Ligand A at 39.899% and Ligand B at 45.173%. Ligand A is slightly better.
**8. BBB Penetration:** Ligand B (68.282%) has higher BBB penetration than Ligand A (48.662%). While ADRB2 isn't primarily a CNS target, some degree of BBB penetration can be useful.
**9. Caco-2 Permeability:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.622) is slightly better than Ligand B (-4.419).
**10. Aqueous Solubility:** Ligand A (-2.599) has better aqueous solubility than Ligand B (-4.364). This is important for formulation and bioavailability.
**11. hERG Inhibition:** Ligand A (0.271) has a much lower hERG inhibition risk than Ligand B (0.926). This is a critical safety parameter.
**12. Microsomal Clearance:** Ligand B (82.055) has significantly higher microsomal clearance than Ligand A (35.7), indicating lower metabolic stability.
**13. In vitro Half-Life:** Ligand B (89.812) has a much longer in vitro half-life than Ligand A (-14.274). This is a significant advantage.
**14. P-gp Efflux:** Ligand A (0.057) has lower P-gp efflux than Ligand B (0.906), which is favorable for bioavailability.
**15. Binding Affinity:** Ligand A (-5.6 kcal/mol) has a slightly better binding affinity than Ligand B (-3.4 kcal/mol). This is a substantial difference.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand A emerges as the more promising candidate. While Ligand B has better BBB penetration and in vitro half-life, its significantly higher logP, P-gp efflux, hERG inhibition, and higher clearance are major drawbacks. Ligand A's superior solubility, lower toxicity risk (hERG), better affinity, and more favorable QED outweigh the slightly shorter half-life. The substantial difference in binding affinity (-5.6 vs -3.4 kcal/mol) is a key factor.
Output:
1
2025-04-17 18:03:42,206 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (353.463 and 352.519 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (58.64) is significantly better than Ligand A (121.52). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary goal, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (2.837) is optimal, while Ligand A (0.593) is quite low. This is a significant point in favor of Ligand B, as low logP can hinder membrane permeability.
4. **HBD:** Ligand A (4) is higher than Ligand B (1). While both are acceptable, lower HBD is generally preferred for permeability.
5. **HBA:** Ligand A (4) and Ligand B (3) are both within the acceptable range.
6. **QED:** Ligand B (0.8) is much better than Ligand A (0.485), indicating a more drug-like profile.
7. **DILI:** Ligand B (26.095) has a much lower DILI risk than Ligand A (13.3). This is a crucial advantage, as liver toxicity is a major concern.
8. **BBB:** Ligand B (80.884) has higher BBB penetration than Ligand A (34.626). While not a primary concern for a cardiovascular target, it's not detrimental.
9. **Caco-2:** Ligand A (-5.775) is better than Ligand B (-4.442), indicating potentially better intestinal absorption.
10. **Solubility:** Ligand A (-1.757) is better than Ligand B (-2.482). Solubility is important for formulation and bioavailability.
11. **hERG:** Ligand A (0.11) has a lower hERG risk than Ligand B (0.339). This is a positive for Ligand A.
12. **Cl_mic:** Ligand A (0.955) has a much lower microsomal clearance than Ligand B (54.549), suggesting better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand B (-9.482) has a longer in vitro half-life than Ligand A (8.007). This is a positive for Ligand B.
14. **Pgp:** Ligand A (0.035) has lower P-gp efflux than Ligand B (0.088). This is a positive for Ligand A.
15. **Affinity:** Ligand B (-7.1) has a slightly better binding affinity than Ligand A (-6.4). While the difference is less than 1.5 kcal/mol, it's still a positive for Ligand B.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP and has slightly better affinity. Ligand A has better TPSA and Pgp.
**Overall Assessment:**
Ligand B has a significantly better overall profile. The superior logP, QED, lower DILI risk, and longer half-life outweigh the slight advantages of Ligand A in TPSA, Pgp, and solubility. The slightly better affinity of Ligand B further supports its selection. While Ligand A has better metabolic stability, the other benefits of Ligand B are more critical for a successful drug candidate.
Output:
0
2025-04-17 18:03:42,206 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (359.495 Da and 361.511 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (66.06) is slightly higher than Ligand B (62.3). Both are below the 140 A^2 threshold for good oral absorption, but closer to the 90 A^2 threshold for CNS targets, which isn't a primary concern for a cardiovascular target.
**3. logP:** Both ligands have good logP values (2.506 and 2.928), falling within the optimal 1-3 range. Ligand B is a bit higher, potentially offering slightly better membrane permeability.
**4. H-Bond Donors:** Both have 1 HBD, which is acceptable.
**5. H-Bond Acceptors:** Both have 4 HBA, which is acceptable.
**6. QED:** Both ligands have high QED scores (0.911 and 0.847), indicating good drug-like properties.
**7. DILI:** Both ligands have similar DILI risk (41.024 and 42.846), both are below the concerning threshold of 60.
**8. BBB:** Ligand A (76.231) has a significantly higher BBB penetration percentile than Ligand B (61.923). While ADRB2 is primarily a cardiovascular target, some CNS side effects are possible with GPCR modulators, and higher BBB penetration could contribute to this. However, it's not a critical factor here.
**9. Caco-2 Permeability:** Both have negative Caco-2 values (-5.095 and -5.055) which is unusual and suggests poor permeability. This is a significant concern for both.
**10. Aqueous Solubility:** Both ligands have very poor aqueous solubility (-2.781 and -2.609). This is a major drawback and would likely require formulation strategies to improve bioavailability.
**11. hERG Inhibition:** Ligand A (0.792) has a slightly higher hERG inhibition risk than Ligand B (0.27). This is a concern, as hERG inhibition can lead to cardiotoxicity.
**12. Microsomal Clearance:** Ligand B (42.96) has a significantly higher microsomal clearance than Ligand A (16.353). This suggests Ligand A is more metabolically stable, which is desirable.
**13. In vitro Half-Life:** Ligand A (-23.425) has a much longer in vitro half-life than Ligand B (-5.297). This is a significant advantage, potentially allowing for less frequent dosing.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.386 and 0.201).
**15. Binding Affinity:** Ligand B (-7.8 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.1 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME drawbacks. The difference of 2.7 kcal/mol is very significant.
**GPCR-Specific Priorities:** For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B excels in affinity. While both have issues with solubility and Caco-2 permeability, the superior binding affinity of Ligand B is a strong driver. The slightly higher logP of Ligand B is also beneficial. Although Ligand A has better metabolic stability and half-life, the potency advantage of Ligand B is more important.
**Conclusion:**
Considering the balance of properties, particularly the significantly stronger binding affinity of Ligand B, I would choose Ligand B as the more promising drug candidate.
0
2025-04-17 18:03:42,207 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [351.403, 100.99 , 0.417, 2. , 6. , 0.658, 41.024, 46.064, -4.835, -1.635, 0.151, -0.962, -18.902, 0.015, -0.7 ]
**Ligand B:** [362.474, 59.07 , 3.478, 2. , 6. , 0.82 , 82.202, 94.339, -4.985, -5.122, 0.89 , 77.686, 73.958, 0.297, -6.7 ]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, Affinity) and general guidelines:
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (351.4) is slightly lower, which can be beneficial for permeability.
2. **TPSA:** Ligand A (100.99) is better than Ligand B (59.07), being below 140 and closer to the desirable range for oral absorption.
3. **logP:** Ligand B (3.478) is optimal (1-3), while Ligand A (0.417) is quite low, potentially hindering membrane permeability. This is a significant drawback for Ligand A.
4. **HBD/HBA:** Both have 2 HBD and 6 HBA, which are acceptable.
5. **QED:** Ligand B (0.82) has a better QED score than Ligand A (0.658), indicating a more drug-like profile.
6. **DILI:** Ligand A (41.024) has a much lower DILI risk than Ligand B (82.202). This is a strong positive for Ligand A.
7. **BBB:** Ligand B (94.339) shows significantly better BBB penetration than Ligand A (46.064). While ADRB2 is a cardiovascular target, some CNS exposure can occur, and higher BBB penetration is generally favorable.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
9. **Solubility:** Ligand B (-5.122) has worse solubility than Ligand A (-1.635).
10. **hERG:** Ligand A (0.151) has a lower hERG risk than Ligand B (0.89).
11. **Cl_mic:** Ligand A (-0.962) has a lower (better) microsomal clearance than Ligand B (77.686), suggesting better metabolic stability.
12. **t1/2:** Ligand B (73.958) has a significantly longer in vitro half-life than Ligand A (-18.902).
13. **Pgp:** Ligand A (0.015) has much lower P-gp efflux liability than Ligand B (0.297).
14. **Affinity:** Ligand B (-6.7) has a substantially stronger binding affinity than Ligand A (-0.7). This is a major advantage for Ligand B.
**Overall Assessment:**
Ligand B's strong binding affinity (-6.7 kcal/mol) is a huge advantage, and it has a longer half-life and better BBB penetration. However, its high DILI risk and worse solubility are concerning. Ligand A has a better safety profile (lower DILI, hERG), better metabolic stability, and lower P-gp efflux, but suffers from a very weak binding affinity and a low logP.
Given the importance of affinity for GPCRs, and the fact that the difference in binding energy is so large (>6 kcal/mol), I believe Ligand B is the more promising candidate *despite* its drawbacks. The affinity difference is likely to outweigh the ADME concerns, and those can be addressed through further optimization. The low logP of Ligand A is a more difficult problem to solve.
Output:
0
2025-04-17 18:03:42,207 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.475 & 366.487 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (69.72) is better than Ligand B (78.68). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have acceptable logP values (1.398 & 2.046), falling within the 1-3 range. Ligand B is slightly higher, which could potentially lead to some off-target interactions, but it's not a major concern.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 3 HBA, while Ligand B has 5. Ligand A is preferable here.
6. **QED:** Both have good QED scores (0.763 & 0.799), indicating good drug-like properties.
7. **DILI:** Ligand A (23.769) has a significantly lower DILI risk than Ligand B (54.556). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (78.48) has a higher BBB penetration score than Ligand A (54.983). However, since ADRB2 is a cardiovascular target, BBB penetration is not a high priority.
9. **Caco-2:** Ligand A (-4.785) has a better Caco-2 permeability score than Ligand B (-4.941).
10. **Solubility:** Ligand A (-2.553) has better aqueous solubility than Ligand B (-3.08).
11. **hERG:** Both ligands have low hERG inhibition liability (0.272 & 0.096), which is excellent.
12. **Cl_mic:** Ligand A (30.777) has a lower microsomal clearance than Ligand B (57.138), suggesting better metabolic stability.
13. **t1/2:** Ligand B (10.626) has a longer in vitro half-life than Ligand A (4.191). This is a positive for Ligand B, but can be mitigated with formulation.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.077 & 0.064).
15. **Binding Affinity:** Ligand B (-6.8 kcal/mol) has a slightly better binding affinity than Ligand A (-6.2 kcal/mol). The difference is 0.6 kcal/mol, which is significant but not overwhelming.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp and affinity are key. Both ligands perform reasonably well on logP and Pgp. Ligand A has better TPSA. The affinity difference is present in favor of Ligand B, but the DILI risk and metabolic stability are much better for Ligand A.
**Overall Assessment:**
Ligand A presents a more favorable overall profile, particularly due to its significantly lower DILI risk and better metabolic stability (lower Cl_mic). While Ligand B has slightly better affinity and half-life, the safety and pharmacokinetic advantages of Ligand A are more critical for a viable drug candidate. The affinity difference is not large enough to overcome the other benefits of Ligand A.
Output:
1
2025-04-17 18:03:42,207 - INFO - Batch 10 complete. Total preferences: 160
2025-04-17 18:03:42,207 - INFO - Processing batch 11/512...
2025-04-17 18:04:34,017 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (362.415 and 350.503 Da) are within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand B (49.85) is significantly better than Ligand A (114.1). ADRB2 is not a CNS target, but lower TPSA generally improves absorption. This is a significant advantage for Ligand B.
3. **logP:** Both ligands have acceptable logP values (1.4 and 2.711), falling within the 1-3 range. Ligand B is slightly better, leaning towards the optimal range.
4. **HBD:** Ligand A has 1 HBD, while Ligand B has 0. Both are acceptable.
5. **HBA:** Ligand A has 8 HBA, and Ligand B has 3. Ligand B is preferable, as lower HBA generally aids permeability.
6. **QED:** Ligand A (0.855) has a much better QED score than Ligand B (0.692), indicating a more drug-like profile. This is a significant advantage for Ligand A.
7. **DILI:** Ligand A (86.972) has a considerably higher DILI risk than Ligand B (13.959). This is a major concern for Ligand A.
8. **BBB:** BBB is less critical for ADRB2, but Ligand B (75.96) is better than Ligand A (29.508).
9. **Caco-2:** Ligand A (-5.577) has a worse Caco-2 permeability than Ligand B (-4.449).
10. **Solubility:** Both ligands have very poor aqueous solubility (-2.962 and -3.03). This is a concern for both, but not a differentiating factor.
11. **hERG:** Ligand A (0.004) has a slightly better hERG profile than Ligand B (0.52).
12. **Cl_mic:** Ligand A (3.154) has a much lower microsomal clearance than Ligand B (70.401), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (-6.723) has a worse in vitro half-life than Ligand B (3.15).
14. **Pgp:** Ligand A (0.049) has a much lower P-gp efflux liability than Ligand B (0.068).
15. **Affinity:** Ligand B (-7.0) has a slightly better binding affinity than Ligand A (-5.1). While a 1.9 kcal/mol difference is substantial, other factors need to be considered.
**Overall Assessment:**
Ligand B exhibits a superior ADME profile, particularly regarding TPSA, DILI risk, and Caco-2 permeability. While Ligand A has a better QED and lower Cl_mic, the high DILI risk is a major red flag. The slightly better affinity of Ligand B, combined with its improved ADME properties, outweighs the benefits of Ligand A's QED and metabolic stability. Given the GPCR target class, optimizing for permeability and minimizing toxicity are crucial.
Output:
0
2025-04-17 18:04:34,018 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (350.459 Da and 358.385 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (71.78) is better than Ligand B (77.92). Both are under 140, but lower TPSA generally favors better absorption.
**3. logP:** Ligand A (2.939) is optimal, while Ligand B (0.821) is a bit low. For a GPCR, a logP between 1-3 is preferred, and Ligand A is closer to this range. Lower logP can hinder membrane permeability.
**4. H-Bond Donors:** Both have 1 HBD, which is good.
**5. H-Bond Acceptors:** Both have 4 HBA, which is good.
**6. QED:** Both ligands have similar QED values (0.782 and 0.731), indicating good drug-likeness.
**7. DILI:** Ligand A (35.867) has a slightly higher DILI risk than Ligand B (30.322), but both are well below the concerning threshold of 60.
**8. BBB:** Both ligands have good BBB penetration (75.184 and 76.735), which isn't a primary concern for a cardiovascular target but isn't detrimental.
**9. Caco-2 Permeability:** Ligand A (-4.329) is better than Ligand B (-4.804). Higher values indicate better permeability.
**10. Aqueous Solubility:** Ligand A (-3.216) is better than Ligand B (-1.288). Higher solubility is generally preferred.
**11. hERG Inhibition:** Ligand A (0.754) has a slightly higher hERG risk than Ligand B (0.203). Lower hERG risk is crucial for cardiovascular drugs.
**12. Microsomal Clearance:** Ligand B (-10.542) has significantly lower (better) microsomal clearance than Ligand A (34.701), suggesting better metabolic stability.
**13. In vitro Half-Life:** Ligand B (-9.941) has a significantly longer half-life than Ligand A (12.229), which is a major advantage.
**14. P-gp Efflux:** Ligand A (0.391) has lower P-gp efflux than Ligand B (0.03), which is favorable for bioavailability.
**15. Binding Affinity:** Ligand B (-7.6) has a slightly better binding affinity than Ligand A (-7.2), but the difference is less than 1.5 kcal/mol.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand B emerges as the more promising candidate. While Ligand A has a slightly better logP and P-gp profile, Ligand B's significantly improved metabolic stability (lower Cl_mic, longer half-life) and lower hERG risk are critical for a cardiovascular drug. The slightly better binding affinity of Ligand B further strengthens its position. The solubility and Caco-2 permeability are also better for Ligand B.
Output:
0
2025-04-17 18:04:34,018 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (454.308 Da) is within the ideal range, while Ligand B (339.355 Da) is at the lower end but still acceptable.
2. **TPSA:** Ligand A (68.29) is good, well below the 140 threshold. Ligand B (111.61) is higher, but still potentially acceptable for a peripherally acting GPCR.
3. **logP:** Ligand A (3.793) is optimal. Ligand B (1.024) is a bit low, potentially hindering membrane permeability.
4. **HBD:** Both ligands are acceptable (Ligand A: 1, Ligand B: 2).
5. **HBA:** Both ligands are acceptable (Ligand A: 4, Ligand B: 7).
6. **QED:** Both ligands have good QED scores (Ligand A: 0.552, Ligand B: 0.671).
7. **DILI:** Ligand A (61.768) is borderline, but acceptable. Ligand B (85.964) is significantly higher, indicating a greater risk of liver injury. This is a major concern.
8. **BBB:** Both have moderate BBB penetration (Ligand A: 51.803, Ligand B: 62.117). Since ADRB2 is not exclusively a CNS target, this isn't a primary driver.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Both have negative solubility values, which is also unusual and suggests poor solubility. Again, the scale is not specified.
11. **hERG:** Both have low hERG risk (Ligand A: 0.76, Ligand B: 0.304).
12. **Cl_mic:** Ligand A (93.746) has higher clearance than Ligand B (50.693), suggesting lower metabolic stability.
13. **t1/2:** Ligand A (55.387) has a longer half-life than Ligand B (25.18), which is preferable.
14. **Pgp:** Both have low Pgp efflux (Ligand A: 0.328, Ligand B: 0.054), which is good.
15. **Affinity:** Ligand B (-6.6 kcal/mol) has a slightly better binding affinity than Ligand A (-6.1 kcal/mol). This is a 0.5 kcal/mol difference, which is significant but not overwhelming.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has a better logP, while Ligand B has a slightly better affinity. However, the significantly higher DILI risk associated with Ligand B is a major drawback.
**Overall Assessment:**
Despite the slightly better affinity of Ligand B, the substantially higher DILI risk makes it a less attractive candidate. Ligand A, while having a higher clearance, presents a much more favorable safety profile. The difference in binding affinity is not large enough to offset the potential toxicity concerns.
Output:
1
2025-04-17 18:04:34,018 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (353.813) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (75.6) is significantly better than Ligand B (133.06). For a GPCR, keeping TPSA under 140 is good, but lower is preferable for better absorption. Ligand B is pushing the upper limit.
3. **logP:** Ligand A (3.341) is optimal, while Ligand B (1.334) is on the lower side. For a GPCR, a logP between 1-3 is ideal, and A is closer to the sweet spot.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable.
5. **HBA:** Ligand A (4) and Ligand B (6) are both acceptable, but A is better.
6. **QED:** Ligand A (0.593) is much better than Ligand B (0.287). A QED > 0.5 is a good indicator of drug-likeness, and A clearly surpasses this threshold.
7. **DILI:** Ligand B (55.991) has a lower DILI risk than Ligand A (85.459), which is a significant advantage. Lower DILI is always preferred.
8. **BBB:** Both ligands have similar BBB penetration (A: 57.076, B: 57.619). This isn't a primary concern for ADRB2, as it's primarily a cardiovascular target, but it's not detrimental.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.402 and -5.317), which is unusual and suggests poor permeability. This is a concern for both, but doesn't strongly differentiate them.
10. **Solubility:** Ligand A (-3.818) has slightly better solubility than Ligand B (-1.68), but both are poor.
11. **hERG:** Ligand A (0.809) has a lower hERG risk than Ligand B (0.286), which is a significant advantage.
12. **Cl_mic:** Ligand B (47.94) has slightly lower microsomal clearance than Ligand A (42.871), indicating better metabolic stability.
13. **t1/2:** Ligand A (24.531) has a longer in vitro half-life than Ligand B (-4.491), which is a significant advantage.
14. **Pgp:** Ligand A (0.555) has lower P-gp efflux than Ligand B (0.072), which is a significant advantage.
15. **Binding Affinity:** Ligand A (-7.7) has a slightly better binding affinity than Ligand B (-7.5), although the difference is small.
**Overall Assessment:**
Ligand A is superior due to its better TPSA, logP, QED, hERG risk, Pgp efflux, and in vitro half-life. While Ligand B has a lower DILI risk and slightly better metabolic stability, the other advantages of Ligand A outweigh this. The slightly better affinity of Ligand A also contributes to its preference. The poor Caco-2 values for both are a concern that would need to be addressed in further optimization, but don't currently sway the decision significantly.
Output:
1
2025-04-17 18:04:34,018 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [412.259, 83.48, 2.783, 3, 4, 0.653, 62.893, 46.375, -4.946, -2.945, 0.492, 31.93, 25.759, 0.194, -7.8]**
**Ligand B: [357.439, 110.67, 1.948, 3, 5, 0.759, 66.576, 28.15, -5.62, -3.835, 0.45, -13.105, 2.45, 0.044, -6.7]**
1. **Molecular Weight:** Ligand A (412.259 Da) is within the ideal range, while Ligand B (357.439 Da) is slightly below, but still acceptable.
2. **TPSA:** Ligand A (83.48) is good, well below the 140 threshold. Ligand B (110.67) is higher, but still reasonable for a peripherally acting GPCR.
3. **logP:** Ligand A (2.783) is optimal. Ligand B (1.948) is a bit low, potentially impacting permeability.
4. **H-Bond Donors:** Both have 3 HBD, which is good.
5. **H-Bond Acceptors:** Ligand A has 4, Ligand B has 5. Both are acceptable.
6. **QED:** Both are above 0.5 (A: 0.653, B: 0.759), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (62.893) is better than Ligand B (66.576), both are acceptable, but lower is preferred.
8. **BBB:** Ligand A (46.375) is better than Ligand B (28.15). While ADRB2 isn't necessarily a CNS target, some BBB penetration can be beneficial for distribution.
9. **Caco-2:** Ligand A (-4.946) is better than Ligand B (-5.62), indicating better absorption.
10. **Solubility:** Ligand A (-2.945) is better than Ligand B (-3.835).
11. **hERG:** Both are very low (A: 0.492, B: 0.45), indicating low cardiotoxicity risk.
12. **Cl_mic:** Ligand A (31.93) is better than Ligand B (-13.105) indicating better metabolic stability.
13. **t1/2:** Ligand A (25.759) is better than Ligand B (2.45).
14. **Pgp:** Ligand A (0.194) is better than Ligand B (0.044).
15. **Binding Affinity:** Ligand A (-7.8) is significantly better than Ligand B (-6.7). This is a 1.1 kcal/mol difference, which is substantial and can outweigh some ADME drawbacks.
**GPCR-Specific Considerations:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has a better logP, better Pgp efflux, and significantly better binding affinity. While Ligand B has a slightly better QED, the superior affinity and ADME properties of Ligand A are more critical.
**Conclusion:** Ligand A is the more promising candidate due to its superior binding affinity, better metabolic stability, solubility, and Pgp efflux profile, despite Ligand B having a slightly better QED.
1
2025-04-17 18:04:34,019 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (403.32 Da) is slightly higher than Ligand B (361.389 Da), but both are acceptable.
**2. TPSA:** Ligand A (41.57) is well below the 140 A^2 threshold for good oral absorption and is favorable. Ligand B (107.53) is higher, but still within a reasonable range, though less optimal.
**3. logP:** Ligand A (4.628) is a bit high, potentially leading to solubility issues or off-target interactions, but still within a tolerable range. Ligand B (-0.352) is quite low, which could hinder membrane permeability and bioavailability.
**4. H-Bond Donors:** Ligand A (1) is good. Ligand B (4) is higher, potentially impacting permeability.
**5. H-Bond Acceptors:** Ligand A (3) is good. Ligand B (4) is reasonable.
**6. QED:** Ligand A (0.792) is excellent, indicating good drug-likeness. Ligand B (0.35) is significantly lower, suggesting a less favorable overall drug-like profile.
**7. DILI Risk:** Ligand A (58.666) is acceptable, indicating a moderate risk. Ligand B (33.773) is very good, with a low DILI risk.
**8. BBB Penetration:** Ligand A (75.107) is good, suggesting reasonable potential for CNS exposure if desired (though less critical for a cardiovascular target). Ligand B (40.326) is low, indicating poor BBB penetration.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.762 and -4.966). This is unusual and suggests issues with the assay or the compounds themselves. It's difficult to interpret without more information, but it raises a red flag for both.
**10. Aqueous Solubility:** Both ligands have negative solubility values (-4.497 and -2.069). This is also unusual and problematic, suggesting very poor aqueous solubility.
**11. hERG Inhibition:** Ligand A (0.873) is better, indicating lower cardiotoxicity risk. Ligand B (0.587) is slightly higher.
**12. Microsomal Clearance:** Ligand A (104.797) is relatively high, suggesting faster metabolism. Ligand B (13.18) is very low, indicating excellent metabolic stability.
**13. In vitro Half-Life:** Ligand A (78.603) is good. Ligand B (-16.12) is extremely poor, indicating rapid degradation.
**14. P-gp Efflux:** Ligand A (0.846) is better, indicating lower P-gp efflux. Ligand B (0.034) is very high, suggesting significant efflux.
**15. Binding Affinity:** Both ligands have very similar and strong binding affinities (-6.0 and -4.8 kcal/mol respectively). Ligand A is slightly better.
**GPCR-Specific Considerations:** For a GPCR like ADRB2, logP, TPSA, Pgp efflux, and affinity are particularly important. Ligand A has a higher logP, but a much better TPSA, Pgp profile, and slightly better affinity. The poor solubility and permeability of both are concerning, but Ligand B's extremely low logP and very high P-gp efflux are more problematic.
**Overall Assessment:**
While both ligands have significant drawbacks (poor solubility and permeability), Ligand A is the more promising candidate. Its better QED, lower P-gp efflux, better hERG profile, and slightly better affinity outweigh its higher logP and clearance. Ligand B's extremely low logP and poor half-life are major liabilities.
Output:
1
2025-04-17 18:04:34,019 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (335.367 Da) is within the ideal range (200-500 Da). Ligand B (387.238 Da) is also acceptable, but closer to the upper limit.
2. **TPSA:** Ligand A (102.16) is slightly above the preferred <140 for oral absorption, but still reasonable. Ligand B (59.59) is excellent, well below 140 and suggesting good absorption.
3. **logP:** Both ligands have good logP values (A: 3.386, B: 4.019), falling within the 1-3 range. Ligand B is slightly higher, which could potentially lead to some off-target effects, but is still acceptable.
4. **HBD:** Ligand A (3) and Ligand B (2) are both within the acceptable limit of <=5.
5. **HBA:** Ligand A (5) and Ligand B (3) are both within the acceptable limit of <=10.
6. **QED:** Both ligands have good QED scores (A: 0.663, B: 0.706), indicating good drug-like properties.
7. **DILI:** Ligand A (95.812) has a significantly higher DILI risk than Ligand B (68.088). This is a major concern for Ligand A.
8. **BBB:** Ligand A (62.621) has moderate BBB penetration, while Ligand B (74.99) has better penetration. While ADRB2 isn't strictly a CNS target, some CNS exposure can be relevant for side effect profiles.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Both ligands have negative solubility values, which is also unusual. Again, the scale is not specified.
11. **hERG:** Ligand A (0.612) has a slightly higher hERG risk than Ligand B (0.86).
12. **Cl_mic:** Ligand A (36.536) has a lower microsomal clearance, indicating better metabolic stability than Ligand B (71.882).
13. **t1/2:** Ligand B (33.68) has a longer in vitro half-life than Ligand A (17.353), which is desirable.
14. **Pgp:** Ligand A (0.13) has lower P-gp efflux, which is preferable for bioavailability. Ligand B (0.537) has higher efflux.
15. **Affinity:** Ligand B (-7.9 kcal/mol) has a *significantly* stronger binding affinity than Ligand A (-1.8 kcal/mol). This is a crucial difference.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, affinity is paramount. The >1.5 kcal/mol advantage of Ligand B is substantial. LogP and Pgp are also important, and both ligands are reasonably well-positioned. TPSA is also a consideration, and Ligand B excels here. The biggest drawback of Ligand A is its high DILI risk.
**Conclusion:**
Despite Ligand A's better metabolic stability and lower P-gp efflux, the significantly superior binding affinity of Ligand B, coupled with its lower DILI risk and better TPSA, makes it the more promising drug candidate. The difference in affinity is large enough to outweigh the slightly higher P-gp efflux and faster clearance.
Output:
0
2025-04-17 18:04:34,019 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [337.423, 71.09, 1.494, 2, 3, 0.818, 30.748, 46.646, -4.662, -2.955, 0.091, 0.913, -5.321, 0.015, -6.7]
**Ligand B:** [346.406, 78.09, 1.984, 2, 3, 0.718, 55.874, 67.352, -5.144, -2.651, 0.478, 33.657, 58.409, 0.083, -8.2]
Here's a breakdown, considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal range (200-500 Da). A is 337.423, B is 346.406. No significant difference.
2. **TPSA:** A (71.09) is better than B (78.09). Both are below 140, suggesting reasonable absorption.
3. **logP:** A (1.494) is slightly better than B (1.984). Both are within the optimal 1-3 range, but A is closer to the ideal.
4. **HBD:** Both have 2 HBD, which is good.
5. **HBA:** Both have 3 HBA, which is good.
6. **QED:** A (0.818) is better than B (0.718), indicating a more drug-like profile.
7. **DILI:** A (30.748) is significantly better than B (55.874). This is a major advantage for A.
8. **BBB:** B (67.352) is better than A (46.646). While not a primary concern for a cardiovascular target, higher BBB is generally favorable.
9. **Caco-2:** A (-4.662) is better than B (-5.144). Higher (less negative) values indicate better permeability.
10. **Solubility:** A (-2.955) is better than B (-2.651). Higher values indicate better solubility.
11. **hERG:** A (0.091) is better than B (0.478). Lower is better to avoid cardiotoxicity, and this is a significant advantage for A.
12. **Cl_mic:** A (0.913) is much better than B (33.657). A has much lower clearance, indicating better metabolic stability.
13. **t1/2:** B (58.409) is much better than A (-5.321). This is a significant advantage for B.
14. **Pgp:** A (0.015) is significantly better than B (0.083). Lower Pgp efflux is desirable for bioavailability.
15. **Affinity:** B (-8.2) is significantly better than A (-6.7). This is a substantial difference in binding potency (1.5 kcal/mol advantage).
**Overall Assessment:**
Ligand B has a substantially better binding affinity (-8.2 vs -6.7 kcal/mol), and a much longer in vitro half-life. However, Ligand A excels in almost all ADME-Tox properties: lower DILI risk, better solubility, lower hERG inhibition, lower microsomal clearance (better metabolic stability), and lower P-gp efflux. The affinity difference is significant, but the ADME profile of Ligand B is concerning, particularly the elevated DILI risk and high clearance. For a cardiovascular target, minimizing off-target effects (like liver toxicity) and ensuring reasonable metabolic stability are crucial. The improved ADME profile of Ligand A, combined with a still-respectable binding affinity, makes it the more promising candidate.
Output:
1
2025-04-17 18:04:34,019 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (347.419 Da and 346.475 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (96.45) is higher than Ligand B (69.04). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is still preferable for absorption. Ligand B has a significant advantage here.
**3. logP:** Ligand A (-0.124) is quite low, potentially hindering membrane permeability. Ligand B (2.575) is within the optimal 1-3 range. This is a substantial advantage for Ligand B.
**4. H-Bond Donors:** Ligand A (2) and Ligand B (1) are both acceptable, below the threshold of 5.
**5. H-Bond Acceptors:** Ligand A (6) and Ligand B (5) are both acceptable, below the threshold of 10.
**6. QED:** Both ligands have good QED values (0.68 and 0.746), indicating generally drug-like properties. No major difference.
**7. DILI Risk:** Ligand A (31.33) has a slightly higher DILI risk than Ligand B (15.355), but both are below the concerning threshold of 60. Ligand B is preferable.
**8. BBB Penetration:** Ligand A (49.515) has lower BBB penetration than Ligand B (73.401). While ADRB2 isn't exclusively a CNS target, some CNS exposure could be relevant, and higher BBB is generally desirable. Ligand B is better.
**9. Caco-2 Permeability:** Ligand A (-5.691) has a negative value, indicating poor permeability. Ligand B (-4.859) is also poor, but slightly better.
**10. Aqueous Solubility:** Ligand A (-0.538) and Ligand B (-2.905) both have negative solubility values, indicating poor solubility. This is a concern for both, but more pronounced for Ligand B.
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.037 and 0.182), which is excellent. No difference.
**12. Microsomal Clearance:** Ligand A (-7.926) has much lower (better) microsomal clearance than Ligand B (58.259), suggesting better metabolic stability. This is a significant advantage for Ligand A.
**13. In vitro Half-Life:** Ligand A (9.248) has a longer half-life than Ligand B (4.433). This is a positive for Ligand A.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.001 and 0.08). No difference.
**15. Binding Affinity:** Both ligands have the same binding affinity (-6.3 kcal/mol).
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp), Ligand B is initially more promising due to its better logP and lower TPSA. However, Ligand A has significantly better metabolic stability (lower Cl_mic) and a longer half-life. The poor solubility and permeability of both are concerning, but the metabolic advantage of Ligand A is substantial. Given the equal binding affinity, the improved pharmacokinetic profile of Ligand A outweighs the slightly better TPSA and logP of Ligand B.
Output:
1
2025-04-17 18:04:34,019 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.39 and 357.439 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (79.79) is significantly better than Ligand B (99.81). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand A is well under the 140 A^2 threshold, while Ligand B is approaching it.
3. **logP:** Both ligands (1.546 and 1.856) are within the optimal 1-3 range. Ligand B is slightly higher, but not concerningly so.
4. **HBD:** Both have 2 HBD, which is good.
5. **HBA:** Ligand A has 4 HBA, while Ligand B has 6. Both are acceptable (<=10), but A is preferable.
6. **QED:** Both ligands (0.735 and 0.79) have good drug-likeness scores, exceeding 0.5.
7. **DILI:** Ligand A (34.471) has a much lower DILI risk than Ligand B (52.772). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (78.209) has a better BBB penetration score than Ligand B (43.777). While ADRB2 isn't exclusively a CNS target, some CNS exposure can occur, and higher BBB is generally favorable.
9. **Caco-2:** Ligand A (-4.677) has a worse Caco-2 permeability than Ligand B (-5.416). Lower (more negative) values indicate lower permeability.
10. **Solubility:** Both ligands have very poor aqueous solubility (-2.651 and -2.795). This is a concern for both, and formulation strategies would be needed.
11. **hERG:** Both ligands have low hERG inhibition risk (0.421 and 0.535).
12. **Cl_mic:** Ligand A (14.784) has a higher microsomal clearance than Ligand B (-0.882). This suggests Ligand B is more metabolically stable, which is a plus.
13. **t1/2:** Ligand A (-1.158) has a shorter in vitro half-life than Ligand B (10.473). This is a significant advantage for Ligand B.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.055 and 0.019).
15. **Binding Affinity:** Ligand B (-7.0) has a significantly stronger binding affinity than Ligand A (-3.8). This is a substantial advantage, potentially outweighing some ADME drawbacks.
**Overall Assessment:**
Ligand B has a much stronger binding affinity, which is paramount for GPCR targets. It also exhibits better metabolic stability (lower Cl_mic) and a longer half-life. While its TPSA is higher and DILI risk is greater than Ligand A, the affinity difference is substantial enough to make it the more promising candidate, assuming formulation challenges related to solubility can be addressed. The Caco-2 permeability is similar for both, and both have low Pgp efflux.
Output:
0
2025-04-17 18:04:34,020 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (370.515 Da and 349.475 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (81.08) is slightly higher than Ligand B (75.44). Both are below the 140 A^2 threshold for oral absorption, and acceptable for a cardiovascular target (not requiring significant BBB penetration).
**3. logP:** Ligand A (0.712) is a bit low, potentially hindering membrane permeability. Ligand B (3.378) is within the optimal 1-3 range. This is a point in favor of Ligand B.
**4. H-Bond Donors:** Ligand A (2) and Ligand B (1) are both acceptable, under the limit of 5.
**5. H-Bond Acceptors:** Ligand A (5) and Ligand B (4) are both acceptable, under the limit of 10.
**6. QED:** Both ligands have good QED scores (0.72 and 0.819, respectively), indicating good drug-like properties.
**7. DILI Risk:** Ligand B (40.054) has a slightly higher DILI risk than Ligand A (14.424), but both are below the concerning threshold of 60. Ligand A is preferable here.
**8. BBB Penetration:** This is less critical for a cardiovascular target, but Ligand B (78.868) shows better penetration than Ligand A (43.117).
**9. Caco-2 Permeability:** Ligand A (-5.085) has significantly worse Caco-2 permeability than Ligand B (-4.489). This is a negative for Ligand A.
**10. Aqueous Solubility:** Ligand A (-1.725) has better aqueous solubility than Ligand B (-3.409). This is a positive for Ligand A.
**11. hERG Inhibition:** Both ligands show low hERG inhibition risk (0.299 and 0.242, respectively). No significant difference.
**12. Microsomal Clearance:** Ligand B (74.96) has a much higher microsomal clearance than Ligand A (33.75), indicating faster metabolism and potentially lower *in vivo* exposure. This is a significant advantage for Ligand A.
**13. In vitro Half-Life:** Ligand A (-4.576) has a much longer in vitro half-life than Ligand B (-22.574). This is a strong positive for Ligand A.
**14. P-gp Efflux:** Both ligands show very low P-gp efflux liability (0.022 and 0.189, respectively). No significant difference.
**15. Binding Affinity:** Ligand B (-6.0) has a slightly better binding affinity than Ligand A (-5.9). While the difference is small, it is still a factor.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), and the general guidelines, Ligand A emerges as the more promising candidate. While Ligand B has a slightly better affinity and BBB penetration, Ligand A demonstrates superior ADME properties, particularly its lower microsomal clearance and longer half-life, and better solubility. The slightly lower logP of Ligand A is a concern, but the significant improvements in metabolic stability and solubility outweigh this drawback. The lower DILI risk for Ligand A is also a benefit.
Output:
1
2025-04-17 18:04:34,020 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [362.539, 58.2, 4.064, 2, 3, 0.651, 44.552, 68.864, -5.039, -4.06, 0.663, 79.655, 37.092, 0.702, -5.7]
**Ligand B:** [345.487, 65.2, 3.198, 2, 2, 0.831, 27.104, 77.239, -4.796, -4.311, 0.455, 61.067, -22.867, 0.169, -5.7]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (345.487) is slightly lower, which could be advantageous for permeability, but both are acceptable.
2. **TPSA:** Ligand A (58.2) is better than Ligand B (65.2). Both are below the 140 threshold for oral absorption, but closer to the 90 threshold is better.
3. **logP:** Both are within the optimal 1-3 range. Ligand A (4.064) is slightly higher, which could potentially lead to off-target effects or solubility issues, but is still within reasonable limits. Ligand B (3.198) is preferable here.
4. **HBD:** Both have 2 HBD, which is good.
5. **HBA:** Ligand A has 3 HBA, Ligand B has 2. Both are acceptable.
6. **QED:** Ligand B (0.831) has a significantly better QED score than Ligand A (0.651), indicating a more drug-like profile.
7. **DILI:** Ligand B (27.104) has a much lower DILI risk than Ligand A (44.552). This is a significant advantage for Ligand B.
8. **BBB:** Ligand B (77.239) has a better BBB penetration score than Ligand A (68.864). While not a primary concern for a cardiovascular target, it's still a positive.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. Ligand A (-5.039) is worse than Ligand B (-4.796).
10. **Solubility:** Both have negative solubility values, indicating poor solubility. Ligand B (-4.311) is slightly better than Ligand A (-4.06).
11. **hERG:** Both have similar hERG inhibition liability (0.663 and 0.455), and are relatively low risk.
12. **Cl_mic:** Ligand B (61.067) has a lower microsomal clearance than Ligand A (79.655), indicating better metabolic stability.
13. **t1/2:** Ligand B (-22.867) has a much longer in vitro half-life than Ligand A (37.092). This is a significant advantage.
14. **Pgp:** Ligand A (0.702) has a slightly higher P-gp efflux liability than Ligand B (0.169). Lower P-gp is better.
15. **Affinity:** Both have the same binding affinity (-5.7 kcal/mol).
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B has a better logP, lower Pgp efflux, and a better QED. While both have comparable affinity, the ADME properties of Ligand B are significantly more favorable.
**Conclusion:**
Considering all factors, especially the lower DILI risk, better QED, lower Pgp efflux, and longer half-life, **Ligand B is the more promising drug candidate.**
0
2025-04-17 18:04:34,020 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 GPCR, followed by the final output.
**Ligand A: [352.409, 98.05, 1.37, 1, 7, 0.882, 60.915, 74.99, -4.504, -2.712, 0.193, 31.363, -0.548, 0.035, -7.5]**
**Ligand B: [347.459, 72.36, 1.765, 2, 4, 0.753, 25.785, 54.789, -4.67, -2.585, 0.13, 36.497, 10.876, 0.125, -7.1]**
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (352.409 Da) is slightly higher than Ligand B (347.459 Da), but the difference is negligible.
2. **TPSA:** Ligand A (98.05) is higher than Ligand B (72.36). Both are below the 140 A^2 threshold for good oral absorption, but Ligand B is significantly better. This is a point in favor of Ligand B.
3. **logP:** Both ligands have good logP values (A: 1.37, B: 1.765) falling within the optimal 1-3 range. Ligand B is slightly higher, which could be a minor advantage.
4. **H-Bond Donors:** Ligand A (1) is better than Ligand B (2). Lower is preferable.
5. **H-Bond Acceptors:** Ligand A (7) is higher than Ligand B (4). Lower is preferable.
6. **QED:** Ligand A (0.882) has a better QED score than Ligand B (0.753), indicating a more drug-like profile. This favors Ligand A.
7. **DILI:** Ligand B (25.785) has a much lower DILI risk than Ligand A (60.915). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (74.99) has a better BBB penetration percentile than Ligand B (54.789). Given ADRB2 is a GPCR, BBB penetration is a consideration, favoring Ligand A.
9. **Caco-2 Permeability:** Both have negative values, indicating poor permeability. Ligand B (-4.67) is slightly worse than Ligand A (-4.504).
10. **Aqueous Solubility:** Both have negative values, indicating poor solubility. Ligand B (-2.585) is slightly worse than Ligand A (-2.712).
11. **hERG Inhibition:** Both have very low hERG inhibition risk (A: 0.193, B: 0.13). This is good for both.
12. **Microsomal Clearance:** Ligand B (36.497) has slightly higher clearance than Ligand A (31.363). Lower is better, favoring Ligand A.
13. **In vitro Half-Life:** Ligand A (-0.548) has a negative half-life, which is concerning. Ligand B (10.876) has a positive half-life, which is much better. This is a major advantage for Ligand B.
14. **P-gp Efflux:** Both have very low P-gp efflux liability (A: 0.035, B: 0.125). This is good for both.
15. **Binding Affinity:** Ligand A (-7.5) has a slightly better binding affinity than Ligand B (-7.1). This is a small advantage for Ligand A.
**Overall Assessment:**
While Ligand A has a slightly better QED and binding affinity, Ligand B demonstrates a significantly better safety profile (lower DILI) and a much more favorable in vitro half-life. The TPSA is also considerably lower for Ligand B. The slightly better BBB for Ligand A is less critical than the other factors. Considering the GPCR target class, a balance of potency, permeability, and safety is crucial. Ligand B's superior ADME properties, particularly the lower DILI and longer half-life, outweigh the minor advantage in binding affinity of Ligand A.
Output:
0
2025-04-17 18:04:34,020 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [340.379, 75.8, 2.392, 1, 5, 0.925, 65.568, 63.203, -4.572, -2.943, 0.474, 54.031, 4.363, 0.598, -6.9]
**Ligand B:** [354.447, 110.1, -0.22, 4, 5, 0.482, 14.308, 23.187, -5.214, -1.165, 0.183, 0.606, 13.569, 0.008, -5.9]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal 200-500 Da range. Ligand A (340.379) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (75.8) is significantly better than Ligand B (110.1). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (2.392) is optimal (1-3), while Ligand B (-0.22) is quite low and could lead to poor membrane permeability. This is a significant drawback for Ligand B.
4. **HBD:** Ligand A (1) is good. Ligand B (4) is higher, potentially impacting permeability.
5. **HBA:** Both have 5 HBA, which is acceptable.
6. **QED:** Ligand A (0.925) is excellent, indicating a very drug-like profile. Ligand B (0.482) is below the desirable threshold of 0.5.
7. **DILI:** Ligand A (65.568) is higher than Ligand B (14.308), indicating a higher potential for liver injury. This is a concern for Ligand A.
8. **BBB:** Ligand A (63.203) is better than Ligand B (23.187), but neither is particularly high. Since this is a cardiovascular target, BBB isn't a primary concern.
9. **Caco-2:** Ligand A (-4.572) is better than Ligand B (-5.214). Higher values are better, indicating better intestinal absorption.
10. **Solubility:** Ligand A (-2.943) is better than Ligand B (-1.165). Higher values are better.
11. **hERG:** Ligand A (0.474) is better than Ligand B (0.183), indicating a lower risk of cardiotoxicity.
12. **Cl_mic:** Ligand A (54.031) is better than Ligand B (0.606). Lower clearance means better metabolic stability.
13. **t1/2:** Ligand A (4.363) is better than Ligand B (13.569). Longer half-life is generally preferred.
14. **Pgp:** Ligand A (0.598) is better than Ligand B (0.008). Lower efflux is preferred.
15. **Affinity:** Ligand A (-6.9) is slightly better than Ligand B (-5.9), though the difference is not huge.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A excels in logP and TPSA, and has slightly better affinity. Ligand B has a very poor logP. While Ligand A has a higher DILI risk, the other ADME properties are significantly better, and the affinity difference isn't large enough to overcome the permeability issues with Ligand B.
**Conclusion:**
Considering the balance of properties, especially the crucial logP and TPSA values, Ligand A is the more promising drug candidate.
1
2025-04-17 18:04:34,020 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (372.847) is slightly higher than Ligand B (349.475), but both are acceptable.
2. **TPSA:** Ligand A (51.97) is significantly better than Ligand B (78.51). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary goal, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (3.536) is optimal, while Ligand B (1.636) is on the lower side. A logP between 1-3 is preferred, and Ligand A falls nicely within this range. Ligand B is acceptable, but less ideal.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (3). Similar to HBD, lower HBA is generally better.
6. **QED:** Both ligands have similar and acceptable QED values (A: 0.648, B: 0.654).
7. **DILI:** Ligand A (43.622) is slightly higher than Ligand B (21.908), but both are below the concerning threshold of 60. Ligand B is clearly better here.
8. **BBB:** This is less critical for a cardiovascular target. Ligand A (70.531) is higher than Ligand B (60.954), but the difference isn't decisive.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.583 and -4.863), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Both ligands have negative solubility values (-3.241 and -2.057), which is also a concern.
11. **hERG:** Ligand A (0.868) is better than Ligand B (0.148), indicating a lower risk of cardiotoxicity. This is very important for a cardiovascular target.
12. **Cl_mic:** Ligand A (29.68) has significantly lower (better) microsomal clearance than Ligand B (54.579), suggesting better metabolic stability.
13. **t1/2:** Ligand A (73.121) has a much longer in vitro half-life than Ligand B (-4.151). This is a major advantage for dosing convenience.
14. **Pgp:** Ligand A (0.739) is better than Ligand B (0.019), indicating lower P-glycoprotein efflux.
15. **Binding Affinity:** Ligand A (-7.2 kcal/mol) has a significantly stronger binding affinity than Ligand B (-4.9 kcal/mol). This is a substantial advantage that can outweigh some of the ADME drawbacks.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A excels in logP, has a better TPSA, lower Pgp efflux, and *much* stronger binding affinity. While both have poor Caco-2 and solubility, the superior binding and metabolic stability of Ligand A are critical. The slightly higher DILI risk for Ligand A is less concerning given the strong affinity and lower hERG risk.
**Conclusion:**
Ligand A is the more promising candidate due to its superior binding affinity, metabolic stability, lower Pgp efflux, and better logP/TPSA profile. The issues with Caco-2 and solubility are present in both, but the potency and pharmacokinetic advantages of Ligand A make it the better choice.
Output:
1
2025-04-17 18:04:34,021 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Ligand A (413.316 Da) is within the ideal range, while Ligand B (344.459 Da) is slightly below, but still acceptable.
2. **TPSA:** Both ligands (A: 73.91, B: 67.23) are well below the 140 threshold for oral absorption and are reasonable for a GPCR target.
3. **logP:** Both ligands have good logP values (A: 2.807, B: 1.916), falling within the 1-3 range.
4. **HBD:** Both ligands have acceptable HBD counts (A: 2, B: 1).
5. **HBA:** Both ligands have acceptable HBA counts (A: 4, B: 4).
6. **QED:** Both ligands have good QED scores (A: 0.796, B: 0.857), indicating good drug-like properties.
7. **DILI:** Ligand B (32.881) has a significantly lower DILI risk than Ligand A (65.568). This is a major advantage.
8. **BBB:** Both ligands have reasonable BBB penetration (A: 60.876, B: 68.864). While not exceptionally high, it's not a primary concern for ADRB2, which isn't necessarily a CNS target.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the values are very close (-4.809 vs -4.933).
10. **Solubility:** Both ligands have poor solubility (-3.37 and -2.522).
11. **hERG:** Both ligands have low hERG inhibition risk (A: 0.593, B: 0.221). Ligand B is slightly better.
12. **Cl_mic:** Ligand B (24.32) has a lower microsomal clearance than Ligand A (32.646), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-0.248) has a slightly longer in vitro half-life than Ligand A (2.073).
14. **Pgp:** Both ligands have very low Pgp efflux liability (A: 0.07, B: 0.067).
15. **Binding Affinity:** Both ligands have identical binding affinities (-7.0 kcal/mol).
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Both ligands perform similarly on logP, Pgp, TPSA, and affinity. However, the significantly lower DILI risk and better metabolic stability (lower Cl_mic and slightly longer t1/2) of Ligand B are crucial advantages. While solubility is poor for both, the other benefits of Ligand B outweigh this drawback.
**Conclusion:**
Ligand B is the more promising candidate due to its significantly improved safety profile (lower DILI) and better metabolic stability.
**Output:**
0
2025-04-17 18:04:34,021 - INFO - Batch 11 complete. Total preferences: 176
2025-04-17 18:04:34,021 - INFO - Processing batch 12/512...
2025-04-17 18:05:27,126 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [366.487, 114.18 , 1.153, 3. , 5. , 0.569, 36.409, 45.056, -5.651, -2.405, 0.079, 26.584, -6.662, 0.019, -5.6 ]**
**Ligand B: [363.809, 119.03 , 0.399, 2. , 7. , 0.811, 80.031, 60.256, -5.355, -2.888, 0.424, -7.949, 5.061, 0.016, -5.9 ]**
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). A is 366.487, B is 363.809. No significant difference.
2. **TPSA:** Both are reasonably good, but A (114.18) is better than B (119.03) as it's closer to the <140 threshold for oral absorption.
3. **logP:** A (1.153) is better than B (0.399). B is quite low, potentially hindering membrane permeability.
4. **H-Bond Donors:** A (3) is good. B (2) is also good. No major difference.
5. **H-Bond Acceptors:** A (5) is good. B (7) is acceptable, but slightly higher.
6. **QED:** B (0.811) is better than A (0.569), indicating a more drug-like profile.
7. **DILI:** A (36.409) is significantly better than B (80.031). This is a major advantage for A.
8. **BBB:** B (60.256) is better than A (45.056). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be beneficial, and B has a moderate advantage.
9. **Caco-2:** Both are negative, indicating poor permeability. No clear winner here.
10. **Solubility:** Both are negative, indicating poor solubility. No clear winner here.
11. **hERG:** A (0.079) is significantly better than B (0.424). Lower hERG risk is crucial for cardiovascular drugs.
12. **Cl_mic:** B (-7.949) is much better than A (26.584), indicating significantly improved metabolic stability.
13. **t1/2:** B (5.061) is better than A (-6.662). A negative value suggests a very short half-life, which is undesirable.
14. **Pgp:** Both are very low (0.019 and 0.016), suggesting minimal P-gp efflux. No significant difference.
15. **Binding Affinity:** B (-5.9) is slightly better than A (-5.6), but the difference is relatively small (0.3 kcal/mol).
**GPCR-Specific Priorities:** For ADRB2 (a GPCR), logP, TPSA, and affinity are important. A has better logP and TPSA, while B has slightly better affinity. However, the ADME properties are critical. A has a much better DILI score and hERG risk profile, which are paramount for a cardiovascular drug. B has a much better metabolic stability and half-life.
**Overall Assessment:**
While Ligand B has a slightly better binding affinity and metabolic stability, the significantly lower DILI and hERG risk associated with Ligand A are crucial for a cardiovascular drug target. The slightly better logP and TPSA of A also contribute to its favorability. The poor half-life of A is a concern, but this can be addressed through further optimization. The high DILI and hERG risk of B are harder to mitigate.
Output:
1
2025-04-17 18:05:27,127 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.475 and 352.431 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (53.09) is significantly better than Ligand B (88.1). ADRB2 is not a CNS target, but lower TPSA generally favors absorption.
3. **logP:** Ligand A (0.811) is slightly lower than the optimal 1-3 range, but acceptable. Ligand B (-0.082) is a bit concerningly low, potentially impacting permeability.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is better than Ligand B (5). Lower HBA is generally preferred.
6. **QED:** Both ligands are similar (0.712 vs 0.698), and both are above the 0.5 threshold, indicating good drug-likeness.
7. **DILI:** Ligand A (5.7) has a much lower DILI risk than Ligand B (14.424). This is a significant advantage for Ligand A.
8. **BBB:** Not a primary concern for ADRB2 (cardiovascular target). Ligand A (89.027) is higher than Ligand B (48.468), but this isn't a deciding factor.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-4.47) is slightly better than Ligand B (-4.886).
10. **Solubility:** Both are negative, indicating poor solubility. Ligand A (-1.392) is slightly better than Ligand B (-1.406).
11. **hERG:** Both ligands have very low hERG inhibition risk (0.455 and 0.195). No significant difference.
12. **Cl_mic:** Ligand A (34.437) has a higher microsomal clearance than Ligand B (2.343), meaning it's metabolized faster. Ligand B is significantly better here.
13. **t1/2:** Ligand B (29.095) has a much longer in vitro half-life than Ligand A (10.412). This is a significant advantage for Ligand B.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.018 and 0.012). No significant difference.
15. **Binding Affinity:** Ligand B (-6.8) has a slightly better binding affinity than Ligand A (-6.3), a 0.5 kcal/mol difference.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand A is stronger on TPSA, logP, and DILI. Ligand B has a better binding affinity and metabolic stability (lower Cl_mic and longer t1/2). The difference in binding affinity (0.5 kcal/mol) is not substantial enough to overcome the significant advantages of Ligand A in terms of DILI risk and better physicochemical properties (TPSA, logP). The lower DILI risk is a crucial factor for cardiovascular drugs.
**Output:**
1
2025-04-17 18:05:27,127 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Overall Strategy:** Given ADRB2 is a GPCR, the priorities are logP, TPSA, Pgp, affinity, and, to a lesser extent, BBB. Metabolic stability (Cl_mic, t1/2) and safety (DILI, hERG) are also important.
**Ligand A Analysis:**
* **MW:** 361.471 Da - Acceptable.
* **TPSA:** 99.77 - Borderline. Slightly above the ideal <90 for good absorption, but not drastically so.
* **logP:** 2.341 - Excellent. Within the optimal 1-3 range.
* **HBD:** 3 - Good.
* **HBA:** 5 - Good.
* **QED:** 0.705 - Excellent. Highly drug-like.
* **DILI:** 59.403 - Moderate risk. Acceptable, but could be improved.
* **BBB:** 37.379 - Low. Not a primary concern for a non-CNS target like ADRB2, but not helpful if CNS effects are undesirable.
* **Caco-2:** -5.671 - Very poor. Indicates very low permeability. A significant concern.
* **Solubility:** -2.8 - Poor. Could cause formulation challenges.
* **hERG:** 0.123 - Very low risk. Excellent.
* **Cl_mic:** -4.148 - Excellent. Indicates high metabolic stability.
* **t1/2:** 6.01 - Moderate. Could be better.
* **Pgp:** 0.088 - Low efflux. Good.
* **Affinity:** -6.7 kcal/mol - Excellent. Strong binding.
**Ligand B Analysis:**
* **MW:** 344.459 Da - Acceptable.
* **TPSA:** 66.4 - Excellent. Well within the ideal range for absorption.
* **logP:** 2.347 - Excellent. Within the optimal 1-3 range.
* **HBD:** 0 - Good.
* **HBA:** 4 - Good.
* **QED:** 0.794 - Excellent. Highly drug-like.
* **DILI:** 31.485 - Very good. Low risk.
* **BBB:** 86.817 - High. Not a primary concern for ADRB2, but could be problematic if CNS side effects are unwanted.
* **Caco-2:** -4.82 - Poor, but better than Ligand A. Still indicates low permeability.
* **Solubility:** -2.283 - Poor, similar to Ligand A.
* **hERG:** 0.371 - Low risk. Good.
* **Cl_mic:** 39.044 - Moderate. Higher clearance than Ligand A, indicating lower metabolic stability.
* **t1/2:** -12.669 - Very poor. Very short half-life.
* **Pgp:** 0.329 - Moderate efflux.
* **Affinity:** -4.9 kcal/mol - Good, but significantly weaker than Ligand A.
**Comparison and Decision:**
The biggest differentiating factor is the binding affinity. Ligand A has a significantly stronger binding affinity (-6.7 kcal/mol) compared to Ligand B (-4.9 kcal/mol). This 1.8 kcal/mol difference is substantial and can often outweigh minor ADME drawbacks. While Ligand A has poorer Caco-2 permeability and solubility, the strong binding affinity is crucial for a GPCR target. Ligand B has better DILI and BBB, but these are less critical for ADRB2. The significantly shorter half-life and higher clearance of Ligand B are also major drawbacks.
Therefore, despite the permeability concerns, I favor Ligand A due to its superior binding affinity and metabolic stability.
Output:
1
2025-04-17 18:05:27,127 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [347.375, 123.18 , 1.379, 2. , 8. , 0.491, 60.217, 34.626, -5.367, -2.539, 0.086, 17.901, -6.506, 0.175, -5.5 ]
**Ligand B:** [341.411, 66.24 , 2.968, 0. , 6. , 0.419, 64.637, 70.648, -4.515, -3.699, 0.105, 56.164, -14.602, 0.482, -6.2 ]
Here's a breakdown, prioritizing GPCR-relevant properties (logP, TPSA, Pgp, BBB, and affinity):
1. **Molecular Weight:** Both are within the ideal range (200-500 Da). A is 347.375, B is 341.411. No significant difference.
2. **TPSA:** Ligand A (123.18) is slightly higher than Ligand B (66.24). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is generally preferred for permeability. B is significantly better here.
3. **logP:** Ligand A (1.379) is within the optimal range, while Ligand B (2.968) is approaching the upper limit. Both are acceptable, but A is slightly more balanced.
4. **H-Bond Donors/Acceptors:** A has 2 HBD and 8 HBA, B has 0 HBD and 6 HBA. Both are within reasonable limits, but B's lower HBD count could be advantageous for permeability.
5. **QED:** Both are around 0.4, indicating moderate drug-likeness. No major difference.
6. **DILI:** Both have DILI risk around 60-65%, indicating moderate risk. No clear advantage.
7. **BBB:** Ligand B (70.648) has a much higher BBB percentile than Ligand A (34.626). While ADRB2 isn't *primarily* a CNS target, some CNS penetration could be beneficial or detrimental depending on the desired therapeutic profile.
8. **Caco-2:** Ligand A (-5.367) and B (-4.515) are both negative, indicating poor permeability. This is a concern for both.
9. **Aqueous Solubility:** Both have poor solubility (-2.539 and -3.699 respectively). This is a significant drawback for both.
10. **hERG:** Both have very low hERG inhibition risk (0.086 and 0.105). Excellent.
11. **Cl_mic:** Ligand A (17.901) has a lower microsomal clearance than Ligand B (56.164), suggesting better metabolic stability. This is a significant advantage for A.
12. **t1/2:** Ligand A (-6.506) has a longer in vitro half-life than Ligand B (-14.602), further supporting its better metabolic stability.
13. **Pgp:** Both have low P-gp efflux liability (0.175 and 0.482). No significant difference.
14. **Binding Affinity:** Ligand B (-6.2) has a slightly better binding affinity than Ligand A (-5.5). This difference of 0.7 kcal/mol is notable, but not overwhelmingly large.
**Overall Assessment:**
Ligand B has a better TPSA and BBB, and slightly better affinity. However, Ligand A exhibits significantly better metabolic stability (lower Cl_mic, longer t1/2). Given that ADRB2 is a cardiovascular target, metabolic stability is crucial for achieving adequate duration of action. The slightly better affinity of Ligand B is unlikely to outweigh the substantial pharmacokinetic advantage of Ligand A. The poor Caco-2 and solubility are concerns for both, but can be addressed during lead optimization.
Therefore, I would choose Ligand A.
Output:
1
2025-04-17 18:05:27,127 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (353.467 and 347.463 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (98.14) is higher than Ligand B (74.35). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is generally preferred for absorption. Ligand B has a clear advantage.
3. **logP:** Both ligands have good logP values (2.389 and 1.398), falling within the 1-3 range. Ligand B is slightly lower, which *could* indicate slightly better solubility, but both are acceptable.
4. **HBD:** Ligand A (2) and Ligand B (1) are both within the acceptable limit of 5. Ligand B is slightly better.
5. **HBA:** Ligand A (6) and Ligand B (5) are both within the acceptable limit of 10. Ligand B is slightly better.
6. **QED:** Both ligands have good QED scores (0.629 and 0.895), indicating good drug-like properties. Ligand B is better here.
7. **DILI:** Ligand A (63.397) has a significantly higher DILI risk than Ligand B (25.824). This is a major concern. A DILI percentile >60 is a red flag.
8. **BBB:** While ADRB2 isn't primarily a CNS target, some off-target effects are possible. Ligand A (71.772) has a higher BBB penetration than Ligand B (55.06). This isn't a primary driver, but is a slight positive for A.
9. **Caco-2:** Ligand A (-4.849) and Ligand B (-5.223) both have negative Caco-2 values, indicating poor permeability. This is concerning for both.
10. **Solubility:** Ligand A (-3.269) has worse solubility than Ligand B (-0.851). Solubility is important for bioavailability.
11. **hERG:** Both ligands have relatively low hERG inhibition liability (0.136 and 0.447). No major difference.
12. **Cl_mic:** Ligand B (-17.107) has a lower (better) microsomal clearance than Ligand A (89.697), suggesting greater metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand B (-5.519) has a longer half-life than Ligand A (-15.861). This is a positive for B.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.103 and 0.017). No major difference.
15. **Binding Affinity:** Both ligands have identical binding affinities (-5.9 kcal/mol). This removes affinity as a differentiating factor.
**Overall Assessment:**
Ligand B is significantly better due to its substantially lower DILI risk, better QED, lower TPSA, improved solubility, lower Cl_mic (better metabolic stability), and longer half-life. While Ligand A has slightly better BBB penetration, the DILI risk is a major drawback that outweighs this benefit. The Caco-2 permeability is poor for both, but can be addressed with formulation strategies.
Output:
0
2025-04-17 18:05:27,127 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [347.459, 69.72, 0.969, 1, 4, 0.574, 12.834, 61.07, -5.136, -1.049, 0.053, -12.565, -14.997, 0.023, -7.6]
**Ligand B:** [351.447, 71.11, -0.007, 1, 5, 0.775, 19.814, 55.021, -4.695, -1.273, 0.237, -10.452, 4.901, 0.017, -6]
Here's a step-by-step comparison, considering GPCR priorities (logP, Pgp, TPSA, affinity, and to a lesser extent BBB):
1. **MW:** Both are within the ideal range (200-500 Da). A is 347.459, B is 351.447. Very similar.
2. **TPSA:** Both are reasonably good, below the 140 threshold for oral absorption. A is 69.72, B is 71.11. Again, similar.
3. **logP:** A (0.969) is slightly better than B (-0.007). We want 1-3, and A is closer to the optimal range. B is very close to 0, which could indicate permeability issues.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** A has 4, B has 5. Both are acceptable (<=10).
6. **QED:** A (0.574) is decent, but B (0.775) is better, indicating a more drug-like profile.
7. **DILI:** A (12.834%) is significantly better than B (19.814%). This is a major advantage for A.
8. **BBB:** A (61.07%) is better than B (55.021%), although neither are particularly high. For a cardiovascular target, BBB isn't *critical*, but higher is still preferable.
9. **Caco-2:** A (-5.136) is worse than B (-4.695). Higher values are better, so B is slightly favored here.
10. **Solubility:** A (-1.049) is worse than B (-1.273). Both are poor, but B is slightly better.
11. **hERG:** A (0.053%) is *much* better than B (0.237%). This is a critical safety parameter, and A is significantly lower risk.
12. **Cl_mic:** A (-12.565) is much better than B (-10.452). Lower is better, indicating greater metabolic stability.
13. **t1/2:** A (-14.997) is much better than B (4.901). A has a much longer half-life.
14. **Pgp:** A (0.023) is much better than B (0.017). Lower is better, indicating less efflux.
15. **Affinity:** A (-7.6) is better than B (-6). A has a stronger binding affinity.
**Overall Assessment:**
Ligand A clearly wins out. While Ligand B has a slightly better QED and Caco-2 permeability, Ligand A has significantly better DILI risk, hERG inhibition liability, metabolic stability (Cl_mic and t1/2), Pgp efflux, and binding affinity. The affinity difference is substantial (>1 kcal/mol), and the safety profiles (DILI and hERG) are much more favorable for Ligand A. The slightly lower logP of A is a minor concern, but the other benefits outweigh this.
Output:
1
2025-04-17 18:05:27,127 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Ligand A (358.36 Da) is better than Ligand B (405.344 Da). Both are within the ideal range, but A is closer to the lower, preferred end.
2. **TPSA:** Ligand A (49.85) is significantly better than Ligand B (67.66). ADRB2 is not a CNS target, but lower TPSA generally aids absorption.
3. **logP:** Ligand A (1.733) is better than Ligand B (3.711). Both are within the optimal range, but A is closer to the lower end, which can reduce off-target effects.
4. **HBD:** Ligand A (0) is better than Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (3) is better than Ligand B (6). Fewer HBAs generally improve permeability.
6. **QED:** Both ligands are similar (A: 0.707, B: 0.688). Both are above the 0.5 threshold, indicating good drug-likeness.
7. **DILI:** Ligand A (38.309) is significantly better than Ligand B (52.462). Lower DILI risk is crucial.
8. **BBB:** Ligand A (97.363) is better than Ligand B (72.082). While ADRB2 isn't a primary CNS target, higher BBB penetration can sometimes indicate better overall distribution and reduced off-target effects.
9. **Caco-2:** Ligand A (-4.24) is better than Ligand B (-5.349). Higher (less negative) Caco-2 values indicate better absorption.
10. **Solubility:** Ligand A (-2.886) is better than Ligand B (-3.1). Higher solubility is preferred.
11. **hERG:** Ligand A (0.365) is better than Ligand B (0.853). Lower hERG inhibition is critical for cardiac safety.
12. **Cl_mic:** Ligand A (23.3) is significantly better than Ligand B (60.653). Lower clearance indicates better metabolic stability.
13. **t1/2:** Ligand A (-21.386) is better than Ligand B (46.06). A negative value for t1/2 indicates a longer half-life.
14. **Pgp:** Ligand A (0.089) is significantly better than Ligand B (0.499). Lower P-gp efflux is desirable for improved bioavailability.
15. **Affinity:** Ligand A (-6.7) is slightly better than Ligand B (-6.2). While both are good, A has a slightly stronger binding affinity.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across almost all ADME-Tox properties, including crucial factors like DILI, metabolic stability (Cl_mic), P-gp efflux, and hERG inhibition. The binding affinity is also slightly better for Ligand A. While both ligands have acceptable physicochemical properties, Ligand A's profile is far more balanced and suggests a lower risk of adverse effects and better pharmacokinetic behavior.
Output:
1
2025-04-17 18:05:27,128 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (350.463) is slightly higher than Ligand B (334.387), but both are acceptable.
2. **TPSA:** Ligand A (78.68) is significantly better than Ligand B (105.2). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally favors absorption.
3. **logP:** Both ligands have good logP values (A: 1.443, B: 1.102), falling within the optimal 1-3 range.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A (5) is better than Ligand B (8). Lower HBA is generally preferred for better permeability.
6. **QED:** Both ligands have similar QED values (A: 0.729, B: 0.719), indicating good drug-likeness.
7. **DILI:** Ligand A (19.426) has a much lower DILI risk than Ligand B (69.833). This is a significant advantage for Ligand A.
8. **BBB:** Not a major priority for a cardiovascular target. Ligand A (64.327) is better than Ligand B (46.491).
9. **Caco-2:** Both have negative values, which is unusual. Assuming these are log scale, they are similar.
10. **Solubility:** Ligand A (-1.094) is better than Ligand B (-2.469). Better solubility is always a plus.
11. **hERG:** Both ligands have very low hERG inhibition risk (A: 0.156, B: 0.078). Both are excellent.
12. **Cl_mic:** Ligand B (-5.736) has a *negative* microsomal clearance, which is not possible. This is likely an error in the data, but it's a major red flag. Ligand A (36.917) is within a reasonable range.
13. **t1/2:** Ligand B (26.73) has a longer half-life than Ligand A (12.38), which is desirable.
14. **Pgp:** Both ligands have low Pgp efflux liability (A: 0.031, B: 0.046).
15. **Affinity:** Ligand B (-7.3) has a slightly better binding affinity than Ligand A (-6.9), a difference of 0.4 kcal/mol.
**Overall Assessment:**
While Ligand B has slightly better binding affinity and a longer half-life, the significantly higher DILI risk and the impossible negative microsomal clearance are major concerns. Ligand A has a much better safety profile (DILI), better solubility, and a plausible Cl_mic value. The difference in binding affinity (0.4 kcal/mol) is not large enough to outweigh these substantial ADME/Tox advantages. Considering ADRB2 is a cardiovascular target, the GPCR-specific priorities lean towards a balance of properties, and Ligand A offers a more favorable overall profile.
Output:
1
2025-04-17 18:05:27,128 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (382.49 and 347.51 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (75.19) is slightly higher than Ligand B (64.86). Both are below the 140 threshold for oral absorption, but Ligand B is better positioned for potential CNS penetration, though this isn't a primary concern for a cardiovascular target.
**3. logP:** Ligand A (1.993) is within the optimal 1-3 range, while Ligand B (3.496) is at the higher end. While still acceptable, the higher logP of Ligand B could potentially lead to solubility issues or off-target interactions.
**4. H-Bond Donors:** Both ligands have 1 HBD, which is good.
**5. H-Bond Acceptors:** Both ligands have 6 HBA, which is also good.
**6. QED:** Both ligands have similar QED values (0.829 and 0.798), indicating good drug-likeness.
**7. DILI:** Ligand A (65.57%) has a higher DILI risk than Ligand B (43.35%). This is a significant drawback for Ligand A.
**8. BBB:** Ligand A (63.09%) has lower BBB penetration than Ligand B (77.98%). While not crucial for a cardiovascular target, higher BBB is generally preferable.
**9. Caco-2 Permeability:** Ligand A (-4.921) has worse Caco-2 permeability than Ligand B (-5.373), indicating potentially lower intestinal absorption.
**10. Aqueous Solubility:** Both ligands have very poor aqueous solubility (-3.527 and -3.385). This is a concern for both, but not a deciding factor.
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (0.359 and 0.286).
**12. Microsomal Clearance:** Ligand A (30.012) has lower microsomal clearance than Ligand B (38.615), suggesting better metabolic stability.
**13. In vitro Half-Life:** Ligand B (6.869) has a significantly longer in vitro half-life than Ligand A (-3.536). This is a major advantage for Ligand B.
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (0.118 and 0.333).
**15. Binding Affinity:** Ligand B (-6.5 kcal/mol) has a stronger binding affinity than Ligand A (-5.5 kcal/mol). This is a 1.0 kcal/mol difference, which is significant and can outweigh some ADME drawbacks.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand B is the stronger candidate. While its logP is slightly higher, its significantly better binding affinity (-6.5 vs -5.5 kcal/mol), lower DILI risk, and longer half-life outweigh this concern. The slightly better TPSA and BBB values of Ligand B are also beneficial, even if not critical for a cardiovascular target. Ligand A's higher DILI risk and worse Caco-2 permeability are significant drawbacks.
Output:
0
2025-04-17 18:05:27,128 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (350.375 and 351.403 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (112.07) is better than Ligand B (120.52). Both are under 140, but A is closer to the optimal for good absorption.
3. **logP:** Ligand B (0.428) is slightly better than Ligand A (0.202). Both are a bit low, potentially impacting permeability, but B is closer to the 1-3 range.
4. **HBD:** Ligand A (2) is preferable to Ligand B (4). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (6) is preferable to Ligand B (5). Fewer HBAs generally improve permeability.
6. **QED:** Ligand A (0.758) is significantly better than Ligand B (0.36). A higher QED indicates a more drug-like profile.
7. **DILI:** Ligand B (49.283) is better than Ligand A (55.758), both are acceptable, but lower is better.
8. **BBB:** Ligand A (38.116) is better than Ligand B (22.063). While ADRB2 isn't exclusively a CNS target, some CNS penetration can be beneficial, and avoiding high efflux is important.
9. **Caco-2:** Ligand A (-4.935) is better than Ligand B (-5.193). Both are negative, indicating poor permeability, but A is slightly better.
10. **Solubility:** Ligand A (-1.185) is better than Ligand B (-2.105). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.056) is significantly better than Ligand B (0.113). Lower hERG risk is crucial for cardiovascular drugs.
12. **Cl_mic:** Ligand A (-2.78) is *much* better than Ligand B (46.265). This is a major advantage for A, indicating significantly better metabolic stability.
13. **t1/2:** Ligand A (12.634) is better than Ligand B (-37.479). A longer half-life is generally preferred.
14. **Pgp:** Ligand A (0.005) is *much* better than Ligand B (0.07). Lower P-gp efflux is desirable.
15. **Binding Affinity:** Ligand B (-6.6) is slightly better than Ligand A (-6.9). While A has a better affinity, the difference is not substantial enough to outweigh the numerous advantages of ligand A.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A performs better on TPSA, Pgp, and significantly better on metabolic stability and hERG. While Ligand B has a slightly better affinity, Ligand A's overall profile is far more balanced and favorable.
**Conclusion:**
Ligand A is the superior candidate due to its significantly better ADME properties (Cl_mic, t1/2, Pgp, solubility, hERG), better QED, and acceptable binding affinity. The slightly lower logP is a minor concern compared to the substantial benefits in other areas.
Output:
1
2025-04-17 18:05:27,128 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [346.475, 86.88, 2.772, 3, 3, 0.676, 31.601, 57.193, -5.112, -4.032, 0.395, 57.93, -19.622, 0.116, -6.4]**
**Ligand B: [348.487, 67.43, 3.455, 2, 3, 0.707, 32.183, 51.105, -4.492, -3.544, 0.737, 64.125, -11.32, 0.267, -6.7]**
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). A is 346.475, B is 348.487. No significant difference.
2. **TPSA:** Ligand A (86.88) is slightly higher than Ligand B (67.43). Both are below 140, but B is better for oral absorption and potentially better for receptor binding (less hindered).
3. **logP:** Both ligands have good logP values (A: 2.772, B: 3.455) within the 1-3 range. B is slightly higher, which *could* be a minor negative if it leads to solubility issues, but is generally acceptable.
4. **H-Bond Donors:** Ligand A has 3 HBD, Ligand B has 2. Both are acceptable (<=5). B is slightly preferred.
5. **H-Bond Acceptors:** Both ligands have 3 HBA, which is good (<=10).
6. **QED:** Ligand B (0.707) has a slightly better QED score than Ligand A (0.676), indicating a more drug-like profile.
7. **DILI:** Both have low DILI risk (A: 31.601, B: 32.183), well below the 40 threshold. No significant difference.
8. **BBB:** Ligand A (57.193) has a better BBB penetration score than Ligand B (51.105). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant, and this is a positive for A.
9. **Caco-2:** Ligand A (-5.112) has a worse Caco-2 permeability than Ligand B (-4.492). This suggests lower intestinal absorption for A.
10. **Solubility:** Ligand A (-4.032) has worse solubility than Ligand B (-3.544). Solubility is important for bioavailability.
11. **hERG:** Both ligands have low hERG inhibition risk (A: 0.395, B: 0.737). A is slightly preferred.
12. **Cl_mic:** Ligand B (64.125) has a higher microsomal clearance than Ligand A (57.93), indicating faster metabolism and potentially lower *in vivo* exposure. A is preferred.
13. **t1/2:** Ligand A (-19.622) has a longer in vitro half-life than Ligand B (-11.32). This is a significant advantage for A.
14. **Pgp:** Ligand A (0.116) has lower P-gp efflux than Ligand B (0.267). Lower P-gp efflux is desirable for better bioavailability.
15. **Binding Affinity:** Ligand B (-6.7) has slightly better binding affinity than Ligand A (-6.4). This is a 0.3 kcal/mol difference, which is not a huge margin, but still relevant.
**GPCR-Specific Considerations:** For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B has a better logP and affinity, while Ligand A has better TPSA, Pgp, and t1/2. The slight affinity advantage of B is offset by the better ADME properties of A.
**Overall Assessment:**
While Ligand B has a slightly better binding affinity, Ligand A demonstrates a more favorable balance of ADME properties, including better solubility, metabolic stability (lower Cl_mic, longer t1/2), lower P-gp efflux, and better BBB penetration. These factors are crucial for *in vivo* efficacy and safety. The slightly worse Caco-2 permeability of A is a concern, but the other advantages outweigh this.
Output:
1
2025-04-17 18:05:27,128 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [346.471, 69.64, 1.855, 2, 3, 0.747, 13.61, 51.842, -5.026, -3.042, 0.226, 12.192, 19.394, 0.078, -7.4]
**Ligand B:** [347.427, 130.04, -0.067, 4, 10, 0.466, 47.305, 39.162, -5.782, -1.252, 0.471, 3.775, 1.891, 0.002, -7.3]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity) and general drug-like properties:
1. **MW:** Both are within the ideal range (200-500 Da). A is 346.471, B is 347.427 - negligible difference.
2. **TPSA:** Ligand A (69.64) is excellent, well below the 140 threshold and good for oral absorption. Ligand B (130.04) is higher, but still acceptable, though less ideal.
3. **logP:** Ligand A (1.855) is optimal. Ligand B (-0.067) is slightly below the ideal range, which *could* indicate permeability issues.
4. **HBD:** Ligand A (2) is good. Ligand B (4) is higher, potentially impacting permeability.
5. **HBA:** Ligand A (3) is good. Ligand B (10) is higher, potentially impacting permeability.
6. **QED:** Ligand A (0.747) is very good, indicating strong drug-like properties. Ligand B (0.466) is lower, suggesting a less favorable overall profile.
7. **DILI:** Ligand A (13.61) has a much lower DILI risk than Ligand B (47.305). This is a significant advantage for A.
8. **BBB:** Ligand A (51.842) is moderate. Ligand B (39.162) is lower. While ADRB2 isn't a CNS target, some off-target CNS effects are always a consideration.
9. **Caco-2:** Both are negative, indicating poor permeability. However, Ligand A (-5.026) is better than Ligand B (-5.782).
10. **Solubility:** Ligand A (-3.042) is better than Ligand B (-1.252). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.226) has a lower hERG risk than Ligand B (0.471). This is a crucial safety parameter.
12. **Cl_mic:** Ligand A (12.192) has a higher clearance than Ligand B (3.775), meaning it is less metabolically stable.
13. **t1/2:** Ligand A (19.394) has a longer half-life than Ligand B (1.891). This is a significant advantage.
14. **Pgp:** Ligand A (0.078) has a lower Pgp efflux liability than Ligand B (0.002). Lower Pgp is better.
15. **Affinity:** Both have very similar binding affinities (-7.4 and -7.3 kcal/mol). The difference is minimal and doesn't strongly favor either.
**Overall Assessment:**
Ligand A is substantially better. While both have similar binding affinities, Ligand A excels in crucial ADME-Tox properties: lower DILI risk, better solubility, lower hERG risk, lower Pgp efflux, and a significantly longer half-life. Ligand B's higher TPSA, HBD/HBA counts, and lower QED are concerning. The slightly lower logP of Ligand B is also a negative. The improved metabolic stability of Ligand B is not enough to offset the other issues.
Output:
1
2025-04-17 18:05:27,128 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (353.398 Da and 369.462 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Both ligands have TPSA values below 90 (89.35 and 82.27), which is favorable for GPCR targets and suggests good potential for crossing cell membranes. Ligand B is slightly better.
**3. logP:** Ligand A (0.129) is quite low, potentially hindering membrane permeability. Ligand B (1.992) is within the optimal 1-3 range. This is a significant advantage for Ligand B.
**4. H-Bond Donors:** Ligand A has 1 HBD, and Ligand B has 2. Both are acceptable.
**5. H-Bond Acceptors:** Ligand A has 6 HBA, and Ligand B has 4. Both are within the acceptable range of <=10.
**6. QED:** Both ligands have very similar QED values (0.831 and 0.833), indicating good drug-likeness.
**7. DILI Risk:** Ligand A (49.515) has a lower DILI risk than Ligand B (60.644), which is a positive attribute.
**8. BBB Penetration:** Ligand B (82.862) shows better BBB penetration than Ligand A (71.811). While ADRB2 isn't exclusively a CNS target, some cardiovascular effects can be mediated centrally, and better BBB penetration isn't detrimental.
**9. Caco-2 Permeability:** Ligand A (-5) shows poor Caco-2 permeability, while Ligand B (-4.869) is slightly better, but still poor.
**10. Aqueous Solubility:** Ligand A (-1.471) has slightly better solubility than Ligand B (-3.717).
**11. hERG Inhibition:** Ligand A (0.073) has a significantly lower hERG inhibition risk than Ligand B (0.377), which is a crucial safety consideration for cardiovascular drugs.
**12. Microsomal Clearance:** Ligand A (1.472) has lower microsomal clearance, suggesting better metabolic stability than Ligand B (-7.517).
**13. In vitro Half-Life:** Ligand A (-9.213) has a significantly longer in vitro half-life than Ligand B (13.34).
**14. P-gp Efflux:** Ligand A (0.014) has very low P-gp efflux, while Ligand B (0.264) shows moderate efflux. Lower efflux is preferable for better bioavailability.
**15. Binding Affinity:** Ligand A (-7.3 kcal/mol) has a slightly better binding affinity than Ligand B (-5.9 kcal/mol). The difference is 1.4 kcal/mol, which is significant.
**Overall Assessment:**
While Ligand A has a better binding affinity, the low logP and poor Caco-2 permeability are major concerns. The significantly better logP of Ligand B, combined with acceptable DILI, BBB, and a reasonable binding affinity, makes it a more promising candidate. The better metabolic stability (lower Cl_mic and longer t1/2) and lower P-gp efflux of Ligand A are attractive, but are outweighed by the permeability issues. The hERG risk is also lower for Ligand A, but can be addressed through structural modifications.
Therefore, I favor Ligand B.
Output:
0
2025-04-17 18:05:27,128 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (377.384 Da) is better than Ligand B (418.213 Da). Both are within the ideal range, but A is closer to the lower, preferred end.
2. **TPSA:** Ligand A (64.96) is significantly better than Ligand B (74.85). Both are acceptable, but A is more favorable for permeability.
3. **logP:** Both ligands have similar logP values (A: 3.657, B: 3.928), falling within the optimal range of 1-3.
4. **HBD:** Ligand A (0) is better than Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is slightly better than Ligand B (3). Both are within the acceptable range.
6. **QED:** Both ligands have very similar QED values (A: 0.789, B: 0.791), indicating good drug-likeness.
7. **DILI:** Ligand A (65.568) is better than Ligand B (79.449). Both are above the 60 threshold, indicating higher risk, but A is less risky.
8. **BBB:** Ligand A (94.455) is significantly better than Ligand B (72.896). Given that ADRB2 is a GPCR, BBB penetration is a desirable characteristic, making A more attractive.
9. **Caco-2:** Ligand A (-4.079) is better than Ligand B (-5.098). Higher values indicate better absorption, so A is preferred.
10. **Solubility:** Ligand A (-3.997) is better than Ligand B (-5.286). Higher values indicate better solubility, so A is preferred.
11. **hERG:** Both ligands have similar hERG values (A: 0.611, B: 0.711), indicating low risk.
12. **Cl_mic:** Ligand A (13.382) is better than Ligand B (21.109). Lower clearance suggests better metabolic stability.
13. **t1/2:** Ligand A (45.675) is better than Ligand B (56.678). A longer half-life is generally desirable.
14. **Pgp:** Both ligands have similar Pgp values (A: 0.643, B: 0.634).
15. **Binding Affinity:** Ligand A (-6.5 kcal/mol) is slightly better than Ligand B (-5.9 kcal/mol). While both are good, A has a stronger binding affinity.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most key parameters. It has a better balance of properties, with advantages in TPSA, HBD, BBB penetration, Caco-2 permeability, solubility, metabolic stability (Cl_mic), half-life, and binding affinity. While both have DILI risks above the ideal threshold, Ligand A's risk is lower. Given the GPCR target class, the superior BBB penetration of Ligand A is a significant advantage. The slightly better binding affinity further solidifies its preference.
Output:
1
2025-04-17 18:05:27,128 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (356.491 and 355.523 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (62.22) is slightly higher than Ligand B (53.09). Both are below the 140 A^2 threshold for good oral absorption, but B is better.
3. **logP:** Ligand A (3.209) is within the optimal 1-3 range. Ligand B (1.842) is on the lower end, potentially impacting permeability. This favors A.
4. **HBD:** Ligand A (2) is reasonable. Ligand B (0) is also acceptable, but having some HBD can aid solubility.
5. **HBA:** Both ligands (A: 4, B: 4) are within the acceptable limit of 10.
6. **QED:** Ligand A (0.835) has a significantly higher QED score than Ligand B (0.624), indicating better overall drug-likeness. This is a strong point for A.
7. **DILI:** Ligand B (15.122) has a much lower DILI risk than Ligand A (49.632). This is a significant advantage for B.
8. **BBB:** Ligand B (78.596) shows better BBB penetration than Ligand A (68.515). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be beneficial for distribution and off-target effects.
9. **Caco-2:** Both are negative, indicating poor permeability. This is a concern for both, but the value for Ligand A (-4.79) is worse than Ligand B (-4.487).
10. **Solubility:** Ligand B (-0.643) has better solubility than Ligand A (-4.465). This is a significant advantage for B.
11. **hERG:** Both ligands (A: 0.623, B: 0.713) have relatively low hERG inhibition liability, which is good.
12. **Cl_mic:** Ligand B (47.987) has a lower microsomal clearance than Ligand A (55.283), suggesting better metabolic stability. This favors B.
13. **t1/2:** Ligand A (9.422) has a longer in vitro half-life than Ligand B (3.546). This is a positive for A.
14. **Pgp:** Both ligands (A: 0.678, B: 0.083) have Pgp efflux liability, but Ligand B is significantly lower. This is a strong advantage for B.
15. **Binding Affinity:** Both ligands have the same binding affinity (-4.3 kcal/mol).
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has a better logP and half-life, but Ligand B excels in TPSA, DILI, BBB, solubility, Pgp, and metabolic stability.
**Overall Assessment:**
While Ligand A has a better QED and half-life, Ligand B presents a more balanced profile with significantly lower DILI risk, better solubility, and lower P-gp efflux. The better BBB penetration is also a plus. The slightly lower logP of B is a concern, but the other advantages outweigh this. Considering the importance of minimizing toxicity and maximizing bioavailability for a cardiovascular target, Ligand B is the more promising candidate.
Output:
0
2025-04-17 18:05:27,128 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (369.845 Da) is slightly higher than Ligand B (350.394 Da), but both are acceptable.
2. **TPSA:** Ligand A (73.86) is better than Ligand B (84.42). Both are under 140, but lower TPSA generally favors absorption.
3. **logP:** Ligand A (2.892) is optimal, while Ligand B (0.501) is quite low. For a GPCR, a logP between 1-3 is preferred, and Ligand B is significantly below this range, potentially hindering membrane permeability.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Both ligands have 5 HBA, which is good.
6. **QED:** Ligand B (0.774) has a better QED score than Ligand A (0.591), indicating a more drug-like profile.
7. **DILI:** Ligand B (52.152) has a significantly lower DILI risk than Ligand A (67.119), which is a major advantage.
8. **BBB:** Ligand B (82.513) shows better BBB penetration than Ligand A (68.282). While ADRB2 isn't strictly a CNS target, some distribution to the CNS is possible, and higher BBB is generally favorable.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
10. **Solubility:** Ligand B (-0.895) has slightly better solubility than Ligand A (-4.235).
11. **hERG:** Ligand A (0.413) has a lower hERG risk than Ligand B (0.121), which is a critical safety parameter.
12. **Cl_mic:** Ligand B (-4.363) has a significantly lower (better) microsomal clearance than Ligand A (66.094), indicating better metabolic stability.
13. **t1/2:** Ligand B (-6.083) has a longer in vitro half-life than Ligand A (19.032), which is desirable.
14. **Pgp:** Ligand B (0.013) has much lower P-gp efflux liability than Ligand A (0.432), improving bioavailability.
15. **Binding Affinity:** Ligand B (-6.8 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.6 kcal/mol). This is a substantial advantage, potentially outweighing some ADME concerns.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are crucial. Ligand B excels in these areas: better logP, significantly lower Pgp efflux, lower TPSA, and much stronger binding affinity. While Ligand A has a better hERG profile, the superior affinity and ADME properties of Ligand B are more important for a GPCR target. The lower DILI risk for Ligand B is also a significant benefit.
**Conclusion:**
Despite Ligand A's better hERG profile, Ligand B is the more promising drug candidate due to its significantly improved binding affinity, logP, metabolic stability, P-gp efflux, and DILI risk. These factors are more critical for a GPCR target like ADRB2.
Output:
0
2025-04-17 18:05:27,129 - INFO - Batch 12 complete. Total preferences: 192
2025-04-17 18:05:27,129 - INFO - Processing batch 13/512...
2025-04-17 18:06:20,205 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (335.363) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both ligands have TPSA values below 140, suggesting good oral absorption potential. Ligand A (74.91) is slightly higher than Ligand B (73.32), but both are acceptable.
3. **logP:** Ligand A (2.689) is optimal, while Ligand B (0.199) is quite low. This is a significant disadvantage for Ligand B, as it may struggle with membrane permeability.
4. **HBD:** Both have 1 HBD, which is within the acceptable limit.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 5. Both are within the acceptable limit of 10.
6. **QED:** Ligand A (0.798) has a much better QED score than Ligand B (0.448), indicating a more drug-like profile.
7. **DILI:** Ligand B (6.747) has a significantly lower DILI risk than Ligand A (90.461). This is a major advantage for Ligand B.
8. **BBB:** Ligand A (65.219) has a moderate BBB penetration, while Ligand B (37.379) is lower. While ADRB2 isn't strictly a CNS target, some CNS exposure can be a concern for off-target effects.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability in this assay. This is a concern for both.
10. **Solubility:** Ligand A (-3.272) has better solubility than Ligand B (0.365).
11. **hERG:** Ligand A (0.096) has a slightly lower hERG risk than Ligand B (0.461), which is preferable.
12. **Cl_mic:** Ligand A (20.526) has a higher microsomal clearance than Ligand B (10.17). This suggests Ligand B is more metabolically stable.
13. **t1/2:** Ligand A (11.27) has a longer in vitro half-life than Ligand B (-10.86). This is a positive for Ligand A.
14. **Pgp:** Ligand A (0.088) has lower P-gp efflux liability than Ligand B (0.031). Lower Pgp is better.
15. **Affinity:** Ligand A (-6.7 kcal/mol) has a slightly better binding affinity than Ligand B (-5.8 kcal/mol).
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are particularly important. Ligand A excels in affinity and has a good logP. Ligand B has a very poor logP, which is a major drawback. While Ligand B has a much better DILI score, the poor logP and lower QED are significant concerns. The slightly better metabolic stability of Ligand B is not enough to offset these issues.
**Conclusion:**
Despite the lower DILI risk for Ligand B, the significantly better logP, QED, and slightly better affinity of Ligand A make it the more promising drug candidate. The poor logP of Ligand B is a critical flaw that is unlikely to be overcome.
Output:
1
2025-04-17 18:06:20,205 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.539 and 366.531 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (49.22) is significantly better than Ligand B (65.54). For a GPCR, keeping TPSA low is beneficial for permeability, and A is well under the 140 threshold.
3. **logP:** Both ligands have good logP values (2.146 and 1.913), falling within the optimal 1-3 range. Very similar.
4. **HBD:** Both have 1 HBD, which is acceptable.
5. **HBA:** Ligand A has 6 HBA, while Ligand B has 5. Both are within the acceptable range of <=10.
6. **QED:** Ligand A (0.78) has a slightly better QED score than Ligand B (0.687), indicating better overall drug-likeness.
7. **DILI:** Ligand A (4.265) has a much lower DILI risk than Ligand B (16.44). This is a significant advantage for Ligand A.
8. **BBB:** Both ligands have very similar BBB penetration (75.921 and 75.882). This is good, but not a major differentiating factor for ADRB2, which isn't necessarily a CNS target.
9. **Caco-2:** Ligand A (-5.426) and Ligand B (-5.022) are both negative, which is unusual. Lower (more negative) values suggest poor permeability. However, the difference isn't huge.
10. **Solubility:** Ligand A (-0.664) has slightly better solubility than Ligand B (-1.726).
11. **hERG:** Ligand A (0.872) has a lower hERG risk than Ligand B (0.284), which is a significant safety advantage.
12. **Cl_mic:** Ligand A (-40.031) has a *much* lower (better) microsomal clearance than Ligand B (60.036). This suggests significantly improved metabolic stability for Ligand A.
13. **t1/2:** Ligand A (10.099) has a longer in vitro half-life than Ligand B (4.989). This is a positive attribute.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.02 and 0.036).
15. **Binding Affinity:** Ligand A (-6.7 kcal/mol) has a slightly better binding affinity than Ligand B (-5.9 kcal/mol). While the difference is less than 1.5 kcal/mol, it adds to the overall advantage of A.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across several critical ADME-Tox parameters, including DILI risk, hERG inhibition, and microsomal clearance. It also has a slightly better QED score, solubility, and binding affinity. While both ligands have acceptable logP and BBB values, the superior safety and metabolic stability profile of Ligand A makes it the more promising drug candidate for ADRB2. The Caco-2 values are concerning for both, but the other advantages of A outweigh this.
Output:
1
2025-04-17 18:06:20,205 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (348.491 Da) is well within the ideal range (200-500 Da). Ligand B (421.324 Da) is also acceptable, but approaching the upper limit.
2. **TPSA:** Ligand A (67.23) is excellent, well below the 140 threshold for oral absorption. Ligand B (95.59) is higher, but still reasonable.
3. **logP:** Ligand A (2.0) is optimal. Ligand B (4.073) is a bit high, potentially leading to solubility issues or off-target interactions, but not drastically so.
4. **HBD:** Ligand A (1) is good. Ligand B (3) is acceptable.
5. **HBA:** Ligand A (4) is good. Ligand B (6) is acceptable.
6. **QED:** Ligand A (0.703) is very good, indicating high drug-likeness. Ligand B (0.558) is acceptable, but lower.
7. **DILI:** Ligand A (13.571) has a very low DILI risk. Ligand B (88.794) has a significantly higher DILI risk, which is a major concern.
8. **BBB:** Ligand A (71.229) is good, suggesting reasonable potential for CNS penetration if needed (though ADRB2 is primarily cardiovascular). Ligand B (36.72) is low, indicating poor BBB penetration.
9. **Caco-2:** Ligand A (-4.828) is not ideal, indicating poor permeability. Ligand B (-5.34) is also poor.
10. **Solubility:** Ligand A (-1.516) is poor. Ligand B (-4.046) is worse.
11. **hERG:** Ligand A (0.43) is very low risk. Ligand B (0.59) is also low risk.
12. **Cl_mic:** Ligand A (62.924) is moderate. Ligand B (47.491) is better, indicating higher metabolic stability.
13. **t1/2:** Ligand A (-9.924) is poor. Ligand B (61.544) is good.
14. **Pgp:** Ligand A (0.096) is low, suggesting minimal efflux. Ligand B (0.56) is slightly higher, but still acceptable.
15. **Affinity:** Ligand B (-7.5) has a significantly stronger binding affinity than Ligand A (-6.7), a difference of 0.8 kcal/mol.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. While Ligand B has a higher logP and better affinity, the significantly higher DILI risk is a major red flag. The poor solubility and Caco-2 values of both are concerning, but could potentially be addressed with formulation strategies. The better metabolic stability and half-life of Ligand B are also positives. However, the DILI risk outweighs these benefits.
**Conclusion:**
Despite Ligand B's superior binding affinity, the significantly higher DILI risk associated with it makes Ligand A the more promising candidate. The lower DILI risk and better QED score of Ligand A are crucial for drug development. While Ligand A has some ADME liabilities (poor solubility and Caco-2), these are more readily addressable than a high risk of liver injury.
Output:
1
2025-04-17 18:06:20,205 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [346.431, 76.88, -0.074, 0, 5, 0.715, 12.524, 70.958, -4.625, -1.388, 0.446, -3.631, -2.07, 0.013, -5.7]
**Ligand B:** [376.917, 79.42, 3.76, 1, 7, 0.755, 69.252, 71.811, -5.243, -4.956, 0.351, 59.359, 20.043, 0.512, -7.1]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (346.431) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are acceptable for a GPCR target (<140). Ligand A (76.88) is slightly better than Ligand B (79.42).
3. **logP:** Ligand A (-0.074) is quite low, potentially hindering membrane permeability. Ligand B (3.76) is better, falling within the optimal 1-3 range. This is a significant advantage for B.
4. **HBD:** Ligand A (0) is excellent. Ligand B (1) is still acceptable.
5. **HBA:** Ligand A (5) is good. Ligand B (7) is slightly higher but still within the acceptable range.
6. **QED:** Both ligands have good QED scores (A: 0.715, B: 0.755), indicating good drug-like properties.
7. **DILI:** Both have acceptable DILI risk (A: 12.524, B: 69.252), with Ligand A being significantly lower and therefore preferable.
8. **BBB:** Both have good BBB penetration (A: 70.958, B: 71.811), which is important for GPCRs, though not critical for ADRB2 specifically (cardiovascular target).
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-4.625) is worse than Ligand B (-5.243).
10. **Solubility:** Both have poor solubility (A: -1.388, B: -4.956), with Ligand B being worse.
11. **hERG:** Both have low hERG risk (A: 0.446, B: 0.351), which is good.
12. **Cl_mic:** Ligand A (-3.631) has a much lower (better) microsomal clearance than Ligand B (59.359), suggesting better metabolic stability.
13. **t1/2:** Ligand B (20.043) has a significantly longer in vitro half-life than Ligand A (-2.07). This is a major advantage for B.
14. **Pgp:** Both have very low Pgp efflux (A: 0.013, B: 0.512).
15. **Affinity:** Ligand B (-7.1) has a significantly stronger binding affinity than Ligand A (-5.7) - a difference of 1.4 kcal/mol. This is a substantial advantage.
**Overall Assessment:**
Ligand B is the stronger candidate. While Ligand A has better DILI and metabolic stability, Ligand B's superior binding affinity (-7.1 vs -5.7 kcal/mol) and longer half-life are critical advantages, especially for a GPCR target. The logP value of Ligand B is also much more favorable for permeability than that of Ligand A. The solubility issues are a concern for both, but can be addressed with formulation strategies. The slightly higher DILI risk for Ligand B is acceptable given the other benefits.
Output:
0
2025-04-17 18:06:20,205 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (355-360 Da). No significant difference.
2. **TPSA:** Ligand A (66.29) is significantly better than Ligand B (99.18). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (1.929) is within the optimal range, while Ligand B (-0.786) is slightly below, potentially hindering permeation.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (6) is preferable to Ligand B (5).
6. **QED:** Ligand A (0.826) is better than Ligand B (0.624), indicating a more drug-like profile.
7. **DILI:** Ligand B (32.299) has a much lower DILI risk than Ligand A (62.233), a significant advantage.
8. **BBB:** Not a high priority for a cardiovascular target. Ligand A (84.8) is better than Ligand B (41.528), but this isn't a deciding factor.
9. **Caco-2:** Ligand A (-5.072) and Ligand B (-4.949) are similar and both indicate good permeability.
10. **Solubility:** Ligand A (-3.384) is better than Ligand B (-0.649). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.769) has a lower hERG risk than Ligand B (0.065), which is a significant advantage.
12. **Cl_mic:** Ligand B (27.577) has lower microsomal clearance than Ligand A (50.754), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-9.953) has a longer in vitro half-life than Ligand A (-1.883), which is a clear benefit.
14. **Pgp:** Ligand A (0.359) has lower P-gp efflux than Ligand B (0.017), which is a benefit.
15. **Binding Affinity:** Ligand B (-7.1) has a significantly stronger binding affinity than Ligand A (-4.8), a difference of 2.3 kcal/mol. This is a substantial advantage that can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand B has a significantly better binding affinity, lower DILI risk, and better metabolic stability (lower Cl_mic, longer t1/2). While Ligand A has better TPSA, solubility, and Pgp efflux, the superior affinity of Ligand B is a critical factor for a GPCR target like ADRB2. The slightly lower logP of Ligand B is a minor concern that can potentially be addressed through further optimization. The lower hERG risk of Ligand A is good, but not enough to overcome the binding affinity difference.
**Output:**
0
2025-04-17 18:06:20,205 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [376.435, 133.91 , -1.613, 3. , 6. , 0.51 , 48.972, 39.783, -5.652, -2.002, 0.048, -42.576, -40.831, 0.006, -6.9 ]
**Ligand B:** [351.491, 70.67 , 1.439, 2. , 4. , 0.728, 9.771, 61.613, -5.024, -1.438, 0.279, 13.778, 11.039, 0.015, -7.3 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (351.491) is slightly lower, which *could* be beneficial for permeability, but both are acceptable.
2. **TPSA:** Ligand A (133.91) is close to the upper limit for good oral absorption, while Ligand B (70.67) is well below. This favors Ligand B significantly, as lower TPSA generally translates to better membrane permeability, crucial for GPCR targeting.
3. **logP:** Ligand A (-1.613) is a bit low, potentially hindering permeation. Ligand B (1.439) is within the optimal range (1-3). This is a clear advantage for Ligand B.
4. **HBD:** Both have acceptable HBD counts (3 and 2 respectively), well under the 5 threshold.
5. **HBA:** Both have acceptable HBA counts (6 and 4 respectively), well under the 10 threshold.
6. **QED:** Both have good QED scores (0.51 and 0.728), indicating drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (48.972) has a moderate DILI risk, while Ligand B (9.771) has a very low risk. This is a significant advantage for Ligand B.
8. **BBB:** Ligand B (61.613) has a better BBB percentile than Ligand A (39.783), although neither are exceptionally high. For a cardiovascular target, BBB isn't *critical*, but it's a plus.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale isn't specified, so the absolute values are difficult to interpret.
10. **Solubility:** Both have negative solubility values, which is also unusual. Again, the scale is unspecified.
11. **hERG:** Both have very low hERG inhibition risk (0.048 and 0.279). This is excellent for both.
12. **Cl_mic:** Ligand A (-42.576) has a much lower (better) microsomal clearance than Ligand B (13.778), indicating greater metabolic stability. This is a strong advantage for Ligand A.
13. **t1/2:** Ligand A (-40.831) has a much longer in vitro half-life than Ligand B (11.039), suggesting less frequent dosing potential. This is a strong advantage for Ligand A.
14. **Pgp:** Both have very low Pgp efflux liability (0.006 and 0.015). This is good for both.
15. **Affinity:** Ligand B (-7.3) has a slightly better binding affinity than Ligand A (-6.9), a difference of 0.4 kcal/mol. While a 1.5 kcal/mol advantage is often decisive, 0.4 kcal/mol is less impactful.
**Overall Assessment:**
Ligand B excels in several key areas for a GPCR target: TPSA, logP, DILI risk, and BBB penetration. While Ligand A has superior metabolic stability (Cl_mic and t1/2), the ADME advantages of Ligand B, particularly the lower TPSA and improved logP, are more critical for a GPCR like ADRB2. The slightly better affinity of Ligand B further reinforces this preference. The unusual negative values for Caco-2 and solubility are concerning for both, but the other benefits of Ligand B outweigh this uncertainty.
Output:
0
2025-04-17 18:06:20,205 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (345.418 Da) is well within the ideal range (200-500 Da). Ligand B (396.929 Da) is also acceptable, towards the higher end but still reasonable.
2. **TPSA:** Ligand A (52.65) is excellent, well below the 140 threshold for good absorption. Ligand B (84.73) is higher, but still potentially acceptable for a peripherally acting GPCR like ADRB2.
3. **logP:** Ligand A (1.557) is optimal. Ligand B (2.623) is also good, within the preferred 1-3 range.
4. **HBD:** Ligand A (1) is good. Ligand B (2) is also acceptable.
5. **HBA:** Ligand A (3) is good. Ligand B (8) is higher, potentially impacting permeability.
6. **QED:** Ligand A (0.905) is excellent, indicating high drug-likeness. Ligand B (0.689) is still above the 0.5 threshold, but less ideal.
7. **DILI:** Ligand A (36.603) has a very low DILI risk. Ligand B (92.865) has a significantly higher DILI risk, which is a major concern.
8. **BBB:** ADRB2 is primarily a cardiovascular target, so BBB penetration is not a high priority. Ligand A (82.629) is decent, while Ligand B (53.858) is lower.
9. **Caco-2:** Ligand A (-4.571) is very poor. Ligand B (-5.353) is also poor, but slightly better.
10. **Solubility:** Ligand A (-1.585) is poor. Ligand B (-3.609) is even worse. Both have solubility issues.
11. **hERG:** Ligand A (0.745) has a low hERG risk. Ligand B (0.683) is also low risk.
12. **Cl_mic:** Ligand A (-4.909) indicates low clearance and good metabolic stability. Ligand B (35.779) has a much higher clearance, suggesting faster metabolism.
13. **t1/2:** Ligand A (16.959 hours) has a good in vitro half-life. Ligand B (7.91 hours) has a shorter half-life.
14. **Pgp:** Ligand A (0.1) has low P-gp efflux. Ligand B (0.097) also has low P-gp efflux.
15. **Affinity:** Ligand B (-6.6 kcal/mol) has a significantly stronger binding affinity than Ligand A (-3.1 kcal/mol). This is a substantial difference.
**Overall Assessment:**
Ligand B has a much stronger binding affinity, which is a crucial factor for GPCR targets. However, it suffers from significantly higher DILI risk, poorer metabolic stability (higher Cl_mic, shorter t1/2), and worse solubility. Ligand A has better ADME properties (DILI, Cl_mic, t1/2, solubility, QED) and acceptable logP/TPSA, but its affinity is considerably weaker.
Given the substantial difference in binding affinity, and considering ADRB2 is a cardiovascular target (less stringent BBB requirements), I believe the stronger binding of Ligand B can be optimized through further medicinal chemistry to address its ADME liabilities. The DILI risk is the biggest concern, but it's often addressable with structural modifications. The weaker affinity of Ligand A is a more fundamental issue that would be harder to overcome.
Output:
0
2025-04-17 18:06:20,206 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [366.527, 75.27, 4.1, 2, 3, 0.824, 43.117, 82.551, -4.42, -5.119, 0.492, 39.62, 38.62, 0.174, -6.4]
**Ligand B:** [345.535, 55.63, 4.12, 1, 5, 0.77, 32.105, 81.621, -5.307, -4.289, 0.406, 42.743, 4.79, 0.605, -6.2]
Here's a step-by-step comparison, considering the provided guidelines and GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (345.535) is slightly lower, which could be advantageous for permeability, but both are acceptable.
2. **TPSA:** Ligand A (75.27) is higher than Ligand B (55.63). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is generally preferred for absorption. Ligand B is better here.
3. **logP:** Both are around 4.1, slightly above the optimal range (1-3), but not drastically so. This could potentially lead to some off-target effects or solubility issues, but it's manageable. They are comparable.
4. **HBD:** Ligand A (2) is better than Ligand B (1). Lower HBD is generally preferred for permeability.
5. **HBA:** Ligand A (3) is better than Ligand B (5). Lower HBA is generally preferred for permeability.
6. **QED:** Ligand A (0.824) is better than Ligand B (0.77), indicating a more drug-like profile.
7. **DILI:** Ligand A (43.117) has a slightly higher DILI risk than Ligand B (32.105), but both are below the concerning threshold of 60. Ligand B is better here.
8. **BBB:** Both have high BBB penetration (Ligand A: 82.551, Ligand B: 81.621). This isn't a primary concern for a cardiovascular target, but it doesn't hurt.
9. **Caco-2:** Ligand A (-4.42) is worse than Ligand B (-5.307). Lower Caco-2 permeability suggests poorer intestinal absorption. Ligand B is better here.
10. **Solubility:** Ligand A (-5.119) is worse than Ligand B (-4.289). Lower solubility can hinder bioavailability. Ligand B is better here.
11. **hERG:** Both are very low (Ligand A: 0.492, Ligand B: 0.406), indicating low cardiotoxicity risk. Ligand B is slightly better.
12. **Cl_mic:** Ligand B (42.743) has a slightly higher clearance than Ligand A (39.62), meaning A is more metabolically stable. Ligand A is better here.
13. **t1/2:** Ligand A (38.62) has a much longer half-life than Ligand B (4.79). This is a significant advantage for dosing convenience. Ligand A is better here.
14. **Pgp:** Both have low P-gp efflux (Ligand A: 0.174, Ligand B: 0.605). This is good for bioavailability. Ligand A is better here.
15. **Affinity:** Ligand A (-6.4) has a slightly better binding affinity than Ligand B (-6.2). While the difference is small, it's still a positive.
**Overall Assessment:**
Ligand A has a better QED, metabolic stability (lower Cl_mic, longer t1/2), Pgp efflux, and binding affinity. Ligand B has better TPSA, DILI, Caco-2 permeability, solubility, and hERG inhibition. However, the differences in TPSA, solubility, and Caco-2 are less critical for a cardiovascular GPCR than the advantages Ligand A possesses in terms of metabolic stability and binding affinity. The longer half-life of Ligand A is also a significant benefit. The small affinity difference is also a plus.
Therefore, I believe **Ligand A** is the more promising drug candidate.
Output:
1
2025-04-17 18:06:20,206 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's break down the comparison of Ligand A and Ligand B, considering the provided guidelines and the GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key).
1. **Molecular Weight:** Both ligands (358.423 and 356.417 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (89.16) is slightly higher than Ligand B (71.25). Both are below the 140 A^2 threshold for good oral absorption, but Ligand B is preferable due to the lower TPSA.
3. **logP:** Both ligands have good logP values (1.826 and 2.394), falling within the optimal 1-3 range. Ligand B is slightly better.
4. **H-Bond Donors:** Ligand A has 2 HBD, and Ligand B has 1. Ligand B is preferable.
5. **H-Bond Acceptors:** Ligand A has 6 HBA, and Ligand B has 5. Ligand B is preferable.
6. **QED:** Ligand B (0.85) has a significantly better QED score than Ligand A (0.643), indicating a more drug-like profile.
7. **DILI:** Ligand B (34.277) has a much lower DILI risk than Ligand A (70.841). This is a substantial advantage for Ligand B.
8. **BBB:** Ligand B (79.682) has a significantly higher BBB penetration percentile than Ligand A (23.187). While ADRB2 isn't strictly a CNS target, some peripheral ADRB2 activity can be modulated by CNS effects, and better BBB penetration isn't necessarily detrimental.
9. **Caco-2:** Ligand A (-5.836) and Ligand B (-4.771) are both negative, indicating poor permeability. Ligand B is slightly better.
10. **Solubility:** Both ligands have very poor solubility (-2.43 and -2.556). This is a significant concern for both, and would require formulation strategies.
11. **hERG:** Both ligands have low hERG inhibition risk (0.206 and 0.188). No significant difference.
12. **Cl_mic:** Ligand B (1.316) has a much lower microsomal clearance than Ligand A (29.76), suggesting better metabolic stability.
13. **t1/2:** Ligand A (48.057) has a much longer in vitro half-life than Ligand B (-7.413). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.036) has a lower P-gp efflux liability than Ligand B (0.082), which is preferable.
15. **Binding Affinity:** Ligand B (-6.1 kcal/mol) has a slightly better binding affinity than Ligand A (-4.7 kcal/mol). This 1.4 kcal/mol difference is substantial and outweighs many of the other minor drawbacks.
**Overall Assessment:**
Ligand B is the stronger candidate. While Ligand A has a better half-life and Pgp profile, Ligand B excels in crucial areas: significantly lower DILI risk, a better QED score, better logP and TPSA, and a slightly improved binding affinity. The lower metabolic clearance of Ligand B is also a major advantage. The solubility issues are a concern for both, but can be addressed through formulation. The improved ADME properties and safety profile of Ligand B make it the more promising drug candidate.
**Output:**
0
2025-04-17 18:06:20,206 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A: [344.375, 130.14 , 0.457, 3. , 6. , 0.722, 58.434, 61.535, -5.532, -2.99 , 0.186, 4.713, -46.246, 0.004, -6.2 ]**
**Ligand B: [350.415, 100.8 , 1.166, 3. , 5. , 0.611, 42.846, 53.199, -4.945, -1.707, 0.45 , 36.179, 10.729, 0.342, -3.9 ]**
Here's a breakdown, property by property, with a focus on GPCR-relevant parameters:
1. **MW:** Both are within the ideal range (200-500 Da). A is 344.375, B is 350.415 - very similar.
2. **TPSA:** A (130.14) is slightly above the optimal <140 for oral absorption, but acceptable. B (100.8) is excellent, well below 140.
3. **logP:** A (0.457) is quite low, potentially hindering permeability. B (1.166) is better, falling within the 1-3 range. This is a significant advantage for B.
4. **HBD:** Both have 3 HBD, which is acceptable.
5. **HBA:** A has 6, B has 5. Both are within the acceptable range of <=10.
6. **QED:** A (0.722) is better than B (0.611), indicating a more drug-like profile.
7. **DILI:** A (58.434) is higher than B (42.846), indicating a slightly increased risk of liver injury. B is preferable here.
8. **BBB:** A (61.535) and B (53.199) are both relatively low. BBB is not a primary concern for a cardiovascular target, but higher is always better.
9. **Caco-2:** A (-5.532) is very poor, suggesting poor intestinal absorption. B (-4.945) is also poor, but slightly better than A.
10. **Solubility:** A (-2.99) is poor, B (-1.707) is slightly better. Solubility is important for bioavailability.
11. **hERG:** A (0.186) is very low risk, excellent. B (0.45) is slightly higher, but still reasonably low.
12. **Cl_mic:** A (4.713) is lower than B (36.179), indicating better metabolic stability. This is a significant advantage for A.
13. **t1/2:** A (-46.246) is significantly longer than B (10.729), suggesting a longer duration of action. This is a major advantage for A.
14. **Pgp:** A (0.004) is very low, indicating minimal P-gp efflux. B (0.342) is higher, suggesting some efflux. A is preferable.
15. **Affinity:** A (-6.2) is better than B (-3.9), indicating a stronger binding affinity. This is a substantial advantage for A, potentially outweighing some ADME concerns.
**Overall Assessment:**
Ligand A has a significantly better binding affinity and metabolic stability (lower Cl_mic, longer t1/2), and lower P-gp efflux. While its logP and solubility are less ideal, the strong affinity and improved metabolic profile are crucial for a GPCR target. Ligand B has better TPSA and DILI, but these are less critical compared to the advantages of Ligand A. The poor Caco-2 values for both are a concern, but can potentially be addressed through formulation strategies.
Given the prioritization for GPCRs (affinity, logP, Pgp, TPSA) and the substantial advantage in binding affinity and metabolic stability, I would choose **Ligand A**.
Output:
1
2025-04-17 18:06:20,206 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.475 and 350.547 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (87.46) is slightly higher than Ligand B (49.41). For a cardiovascular GPCR, TPSA is not a primary concern unless CNS penetration is desired, but lower is generally preferable for oral absorption. Ligand B is significantly better here.
3. **logP:** Ligand A (1.653) is within the optimal 1-3 range. Ligand B (4.304) is higher, potentially leading to solubility issues and off-target interactions. This favors Ligand A.
4. **HBD:** Ligand A (3) and Ligand B (1) are both acceptable, below the threshold of 5.
5. **HBA:** Ligand A (4) and Ligand B (2) are both acceptable, below the threshold of 10.
6. **QED:** Both ligands have similar QED values (0.43 and 0.498), indicating moderate drug-likeness.
7. **DILI:** Ligand A (24.157) has a lower DILI risk than Ligand B (19.426), which is favorable.
8. **BBB:** Ligand B (84.413) has a significantly higher BBB penetration percentile than Ligand A (53.974). While ADRB2 isn't a primary CNS target, some degree of BBB penetration can be beneficial for understanding off-target effects.
9. **Caco-2:** Ligand A (-5.047) and Ligand B (-4.685) are both negative, indicating poor permeability. This is concerning for both, but the values are similar.
10. **Solubility:** Ligand A (-1.67) has better aqueous solubility than Ligand B (-3.753). This is a significant advantage, especially given Ligand B's higher logP.
11. **hERG:** Ligand A (0.474) has a lower hERG inhibition liability than Ligand B (0.748), which is crucial for avoiding cardiotoxicity, particularly relevant for a cardiovascular target.
12. **Cl_mic:** Ligand A (-16.993) has a much lower (better) microsomal clearance than Ligand B (63.481), indicating greater metabolic stability.
13. **t1/2:** Ligand A (3.646) has a longer in vitro half-life than Ligand B (-2.352), which is desirable.
14. **Pgp:** Ligand A (0.065) has lower P-gp efflux liability than Ligand B (0.489), improving bioavailability.
15. **Binding Affinity:** Ligand A (-7.5) has a slightly better binding affinity than Ligand B (-6.7). While the difference isn't huge, it's enough to be considered.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has a better logP, lower TPSA, lower Pgp efflux, and slightly better affinity. While Ligand B has better BBB penetration, this is less critical for a primarily peripheral target like ADRB2. The significantly better metabolic stability (lower Cl_mic and longer t1/2) and lower hERG risk of Ligand A are also crucial advantages for a cardiovascular drug.
**Conclusion:**
Considering the balance of properties, particularly the favorable ADME profile (solubility, metabolic stability, Pgp efflux, hERG) and the slightly better affinity, Ligand A is the more promising drug candidate.
Output:
1
2025-04-17 18:06:20,206 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
Let's break down the comparison, prioritizing GPCR-relevant parameters (logP, TPSA, Pgp, BBB, and affinity) alongside general drug-like properties.
1. **Molecular Weight:** Both ligands (352.4 and 343.5 Da) fall comfortably within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (87.66) is slightly higher than Ligand B (57.28). While both are reasonable, Ligand B's lower TPSA is preferable for better membrane permeability, a key factor for GPCRs.
3. **logP:** Both ligands have good logP values (2.604 and 3.2), falling within the optimal 1-3 range. Ligand B is slightly higher, which could potentially lead to better membrane permeability.
4. **H-Bond Donors/Acceptors:** Ligand A has 3 HBD and 4 HBA, while Ligand B has 1 HBD and 5 HBA. Both are acceptable, but Ligand B's lower HBD count is slightly favored.
5. **QED:** Both have good QED scores (0.687 and 0.837), indicating good overall drug-likeness. Ligand B is slightly better.
6. **DILI:** Ligand B (52.423) shows a slightly lower DILI risk than Ligand A (41.954), which is a positive.
7. **BBB:** Ligand B (96.123) has a significantly higher BBB penetration percentile than Ligand A (80.264). This is a major advantage for a GPCR target, even if it's not necessarily a CNS target, as it suggests better distribution.
8. **Caco-2 Permeability:** Ligand A (-4.344) has better Caco-2 permeability than Ligand B (-5.055).
9. **Aqueous Solubility:** Both have very poor aqueous solubility (-3.575 and -3.619). This is a concern for both, and formulation strategies would be needed.
10. **hERG Inhibition:** Ligand A (0.455) has a lower hERG inhibition liability than Ligand B (0.948), which is a significant advantage for cardiovascular safety.
11. **Microsomal Clearance:** Ligand B (80.408) has higher microsomal clearance than Ligand A (58.219), indicating faster metabolism and potentially lower *in vivo* exposure.
12. **In vitro Half-Life:** Ligand B (29.614) has a longer half-life than Ligand A (22.047), which is preferable.
13. **P-gp Efflux:** Ligand A (0.179) has lower P-gp efflux liability than Ligand B (0.347), which is favorable for bioavailability.
14. **Binding Affinity:** Ligand B (-6.4 kcal/mol) has a significantly stronger binding affinity than Ligand A (-4.5 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME drawbacks. The 1.9 kcal/mol difference is quite large.
**Overall Assessment:**
Ligand B demonstrates a more favorable profile overall, primarily due to its significantly stronger binding affinity and better BBB penetration. While it has some drawbacks (higher hERG, higher P-gp efflux, higher clearance), the potency advantage is substantial. The lower TPSA is also a plus. The solubility is a concern for both, but can be addressed with formulation.
Output:
0
2025-04-17 18:06:20,206 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (386.42 Da) is within the ideal range (200-500). Ligand B (345.399 Da) is also within range, and slightly lower, which *could* be beneficial for permeability.
2. **TPSA:** Ligand A (50.69) is good, below the 140 threshold. Ligand B (91.76) is higher, but still potentially acceptable, although less favorable.
3. **logP:** Ligand A (4.19) is a bit high, potentially leading to solubility issues and off-target effects. Ligand B (0.784) is quite low, which could hinder membrane permeability.
4. **HBD:** Ligand A (1) is good. Ligand B (2) is acceptable.
5. **HBA:** Both Ligand A (5) and Ligand B (5) are within the acceptable range.
6. **QED:** Both Ligand A (0.838) and Ligand B (0.713) have good drug-likeness scores.
7. **DILI:** Ligand A (75.301) has a higher DILI risk than Ligand B (30.942), which is a significant concern.
8. **BBB:** Ligand A (81.621) has better BBB penetration than Ligand B (57.968). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant for off-target effects and overall safety.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. Ligand A (-4.924) is slightly better than Ligand B (-5.01).
10. **Solubility:** Ligand A (-5.255) has very poor solubility. Ligand B (-2.081) is better, but still poor.
11. **hERG:** Ligand A (0.637) has a lower hERG risk than Ligand B (0.085), which is a positive.
12. **Cl_mic:** Ligand A (62.364) has a higher microsomal clearance than Ligand B (34.579), indicating lower metabolic stability.
13. **t1/2:** Ligand B (-24.221) has a significantly longer *in vitro* half-life than Ligand A (1.893). This is a major advantage.
14. **Pgp:** Ligand A (0.718) has lower P-gp efflux than Ligand B (0.017), which is favorable.
15. **Affinity:** Ligand A (-8.7 kcal/mol) has a significantly better binding affinity than Ligand B (-7.5 kcal/mol). This is a substantial advantage.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, affinity, logP, TPSA, and Pgp efflux are important. Ligand A has a much better affinity, and better Pgp efflux. However, Ligand B has a significantly better safety profile (DILI) and metabolic stability (t1/2). Ligand A's high logP and poor solubility are concerning.
**Decision:**
Despite the much stronger binding affinity of Ligand A, its poor solubility, higher DILI risk, and lower metabolic stability are significant drawbacks. Ligand B, while having weaker binding, presents a much more favorable ADMET profile, particularly the lower DILI risk and longer half-life. The difference in affinity (1.2 kcal/mol) isn't large enough to overcome these substantial ADMET concerns, especially considering the cardiovascular implications of targeting ADRB2. A safer, more metabolically stable compound is preferred.
Output:
0
2025-04-17 18:06:20,206 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (342.374 Da and 348.447 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (78.66) is better than Ligand B (96.11). For a cardiovascular GPCR, TPSA should be reasonably low for good absorption, and A is closer to the <140 threshold.
**3. logP:** Ligand A (3.033) is slightly higher than Ligand B (1.548). Both are within the optimal 1-3 range, but A is closer to the upper end, which could potentially lead to off-target effects, but also better membrane permeability.
**4. H-Bond Donors:** Both ligands have 3 HBD, which is acceptable.
**5. H-Bond Acceptors:** Both ligands have 4 HBA, which is acceptable.
**6. QED:** Both ligands have good QED values (0.667 and 0.727), indicating good drug-like properties.
**7. DILI Risk:** Ligand A (75.998) has a higher DILI risk than Ligand B (57.387). This is a significant drawback for Ligand A.
**8. BBB Penetration:** Both ligands have similar BBB penetration (57.464 and 58.123). While not a primary concern for a cardiovascular target, it's not a differentiating factor.
**9. Caco-2 Permeability:** Ligand A (-4.702) has worse Caco-2 permeability than Ligand B (-5.31). Lower values indicate lower permeability.
**10. Aqueous Solubility:** Ligand A (-3.932) has worse solubility than Ligand B (-2.959). Solubility is important for bioavailability.
**11. hERG Inhibition:** Ligand A (0.712) has a higher hERG inhibition risk than Ligand B (0.291). This is a crucial safety concern, making Ligand B preferable.
**12. Microsomal Clearance:** Ligand A (23.826) has higher microsomal clearance than Ligand B (21.501). Lower clearance is preferred for better metabolic stability.
**13. In vitro Half-Life:** Ligand A (51.384) has a longer half-life than Ligand B (-8.281). This is a positive for Ligand A.
**14. P-gp Efflux:** Ligand A (0.21) has lower P-gp efflux than Ligand B (0.099). Lower efflux is generally desirable for better bioavailability.
**15. Binding Affinity:** Ligand B (-6.5 kcal/mol) has significantly stronger binding affinity than Ligand A (-1.1 kcal/mol). This is a major advantage for Ligand B, potentially outweighing some ADME drawbacks.
**Overall Assessment:**
While Ligand A has a longer half-life and lower P-gp efflux, its significantly weaker binding affinity, higher DILI risk, higher hERG inhibition, and lower solubility/permeability are major concerns. Ligand B, despite slightly lower logP and a negative half-life, exhibits a much stronger binding affinity and a significantly better safety profile (lower DILI and hERG). For a GPCR target, strong binding affinity is paramount. The improved safety profile of Ligand B is also critical.
Output:
0
2025-04-17 18:06:20,206 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (338.411 and 363.483 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Both ligands have TPSA values (75.19 and 71.53) below the 140 A^2 threshold for good oral absorption. This is good for both.
**3. logP:** Ligand A (1.169) is closer to the optimal 1-3 range than Ligand B (2.452). While 2.452 isn't *bad*, the lower logP of A is slightly preferable for balancing permeability and solubility.
**4. H-Bond Donors:** Both have 1 HBD, which is within the acceptable limit of <=5.
**5. H-Bond Acceptors:** Ligand A has 4 HBAs, Ligand B has 5. Both are acceptable (<=10), but A is slightly better.
**6. QED:** Both ligands have good QED scores (0.79 and 0.808), indicating good drug-like properties.
**7. DILI Risk:** Ligand A (49.942) has a slightly higher DILI risk than Ligand B (38.581), but both are below the concerning threshold of 60.
**8. BBB Penetration:** Ligand B (82.513) has significantly better BBB penetration than Ligand A (58.007). While ADRB2 is a cardiovascular target, some CNS effects are possible with beta-blockers, and improved BBB penetration could be beneficial or detrimental depending on the desired profile.
**9. Caco-2 Permeability:** Both have negative Caco-2 values (-4.755 and -4.96), which is unusual and suggests poor permeability. This is a significant concern for both.
**10. Aqueous Solubility:** Both have negative solubility values (-1.957 and -3.021), which is also concerning. Poor solubility can hinder bioavailability.
**11. hERG Inhibition:** Ligand A (0.174) has a lower hERG risk than Ligand B (0.386), which is a significant advantage, given the cardiovascular target and the need to avoid cardiotoxicity.
**12. Microsomal Clearance:** Ligand A (2.373) has much lower microsomal clearance than Ligand B (46.159), indicating better metabolic stability. This is a crucial advantage.
**13. In vitro Half-Life:** Ligand A (-5.628) has a much longer in vitro half-life than Ligand B (23.069). This is a significant advantage, potentially allowing for less frequent dosing.
**14. P-gp Efflux:** Ligand A (0.037) has lower P-gp efflux than Ligand B (0.185), which is favorable for bioavailability.
**15. Binding Affinity:** Ligand B (-7.0) has a slightly stronger binding affinity than Ligand A (-6.7). However, the difference is only 0.3 kcal/mol, and the other ADME properties of Ligand A are much more favorable.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity) and the general guidelines, Ligand A is the more promising candidate. While Ligand B has slightly better affinity and BBB penetration, Ligand A excels in metabolic stability (lower Cl_mic, longer t1/2), lower hERG risk, and lower P-gp efflux. The poor Caco-2 and solubility for both are concerning and would require further optimization, but the superior ADME profile of Ligand A makes it the better starting point. The 0.3 kcal/mol difference in binding affinity is unlikely to outweigh the significant improvements in drug-like properties offered by Ligand A.
Output:
1
2025-04-17 18:06:20,206 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (356.3 and 346.5 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (85.25) is higher than Ligand B (60.85). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is generally preferred for absorption. Ligand B is better.
3. **logP:** Both ligands have good logP values (2.507 and 1.816), falling within the 1-3 range. Ligand B is slightly lower, which could be beneficial for solubility.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable.
5. **HBA:** Ligand A (5) and Ligand B (3) are both acceptable.
6. **QED:** Ligand A (0.651) has a slightly better QED score than Ligand B (0.565), indicating a more drug-like profile.
7. **DILI:** Ligand A (86.78%) has a significantly higher DILI risk than Ligand B (6.01%). This is a major concern for Ligand A.
8. **BBB:** Both ligands have reasonable BBB penetration (74.76% and 65.37%). Not a primary concern for a cardiovascular target.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability.
10. **Solubility:** Ligand B (-1.747) has better solubility than Ligand A (-4.064).
11. **hERG:** Both ligands have low hERG inhibition risk (0.273 and 0.205).
12. **Cl_mic:** Ligand B (24.052) has a much lower microsomal clearance than Ligand A (69.395), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-4.71) has a negative half-life, which is concerning, but Ligand A (65.091) is also not ideal.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.153 and 0.031).
15. **Binding Affinity:** Ligand B (-5.5 kcal/mol) has a slightly better binding affinity than Ligand A (-8.0 kcal/mol). While Ligand A has a better binding affinity, the difference isn't substantial enough to overcome the other significant drawbacks.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand B is better in terms of TPSA and logP. While Ligand A has a better binding affinity, the significantly higher DILI risk and higher Cl_mic are major drawbacks.
**Conclusion:**
Ligand B is the more promising candidate due to its significantly lower DILI risk, better metabolic stability (lower Cl_mic), and improved solubility, despite the slightly lower binding affinity. The higher DILI risk associated with Ligand A is a critical issue that would likely disqualify it early in development.
Output:
0
2025-04-17 18:06:20,207 - INFO - Batch 13 complete. Total preferences: 208
2025-04-17 18:06:20,207 - INFO - Processing batch 14/512...
2025-04-17 18:07:11,678 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's systematically compare Ligand A and Ligand B against the provided guidelines, keeping in mind the GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key).
1. **MW:** Both ligands (344.46 and 345.44 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (67.23) is better than Ligand B (79.37). Lower TPSA generally favors better absorption, and is important for GPCRs.
3. **logP:** Both ligands have good logP values (1.84 and 1.972), falling within the optimal 1-3 range. No major distinction.
4. **HBD:** Both have 1 HBD, which is acceptable.
5. **HBA:** Both have 4 HBA, which is acceptable.
6. **QED:** Ligand B (0.828) has a slightly better QED score than Ligand A (0.732), indicating a more drug-like profile.
7. **DILI:** Ligand A (26.522) has a significantly lower DILI risk than Ligand B (41.411). This is a substantial advantage for Ligand A.
8. **BBB:** Ligand A (57.464) and Ligand B (60.14) are both relatively low for BBB penetration. Since ADRB2 is a cardiovascular target, BBB penetration is not a high priority, but it's still a consideration.
9. **Caco-2:** Ligand A (-5.01) and Ligand B (-4.646) are both negative, indicating poor permeability.
10. **Solubility:** Ligand A (-1.244) is better than Ligand B (-2.433).
11. **hERG:** Both ligands have low hERG inhibition liability (0.151 and 0.257), which is good.
12. **Cl_mic:** Ligand A (29.209) has a lower microsomal clearance than Ligand B (45.683), suggesting better metabolic stability. This is a positive for Ligand A.
13. **t1/2:** Ligand B (-35.201) has a much longer in vitro half-life than Ligand A (-8.186). This is a significant advantage for Ligand B.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.039 and 0.056), which is good.
15. **Binding Affinity:** Ligand B (-7.1 kcal/mol) has a stronger binding affinity than Ligand A (-6.5 kcal/mol). This is a 0.6 kcal/mol difference, which is a meaningful advantage.
**Overall Assessment:**
Ligand B has a significantly better binding affinity and a longer half-life. However, Ligand A demonstrates superior safety (lower DILI risk), better solubility, and better metabolic stability (lower Cl_mic). The TPSA is also more favorable for Ligand A. The affinity difference is important, but the DILI risk for Ligand B is concerning. Considering the balance, and the fact that ADRB2 is a cardiovascular target where metabolic stability and safety are crucial, I lean towards Ligand A.
**Output:**
1
2025-04-17 18:07:11,678 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (368.811) is slightly higher than Ligand B (344.499), but both are acceptable.
2. **TPSA:** Both ligands are below the 140 A^2 threshold for good oral absorption. Ligand A (51.22) is slightly higher than Ligand B (49.41), but both are good.
3. **logP:** Both ligands have optimal logP values (around 3.6-3.8), suggesting good permeability and avoiding solubility issues.
4. **HBD:** Both ligands have 1 HBD, which is within the acceptable limit of <=5.
5. **HBA:** Ligand A has 4 HBA, while Ligand B has 2. Both are within the acceptable limit of <=10.
6. **QED:** Ligand A (0.788) has a significantly better QED score than Ligand B (0.54), indicating a more drug-like profile.
7. **DILI:** Ligand B (12.02) has a much lower DILI risk than Ligand A (55.138). This is a significant advantage for Ligand B.
8. **BBB:** Ligand B (71.074) shows better BBB penetration than Ligand A (53.121). While ADRB2 isn't exclusively a CNS target, some cardiovascular effects are mediated through CNS pathways, making BBB penetration a beneficial property.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and problematic. This suggests poor intestinal absorption. However, the values are similar (-4.493 vs -4.723).
10. **Solubility:** Both ligands have negative solubility values, indicating poor aqueous solubility. Ligand B (-3.423) is slightly better than Ligand A (-4.568), but both are concerning.
11. **hERG:** Both ligands have low hERG inhibition liability (0.66 and 0.496), which is good.
12. **Cl_mic:** Ligand B (49.063) has a lower microsomal clearance than Ligand A (99.146), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-9.941) has a negative in vitro half-life, which is highly unusual and concerning. Ligand A (38.646) has a reasonable half-life.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.193 and 0.156).
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.1 and -6.2 kcal/mol). The difference is negligible.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Both ligands perform similarly on logP, Pgp, and affinity. TPSA is good for both. However, Ligand B has a better BBB score and lower DILI risk. The negative Caco-2 and solubility values are concerning for both, but the better metabolic stability (lower Cl_mic) of Ligand B is a significant advantage. The negative half-life for Ligand B is a major red flag.
**Overall Assessment:**
Despite the concerning negative half-life for Ligand B, its superior DILI profile, better BBB penetration, and lower Cl_mic outweigh the slightly better QED and half-life of Ligand A. The negative Caco-2 and solubility values are problematic for both, and would require significant formulation work. However, the metabolic stability and safety profile of Ligand B make it the more promising starting point for optimization.
Output:
0
2025-04-17 18:07:11,678 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (358.389 and 358.551 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (87.32) is higher than Ligand B (33.2). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for permeability. Ligand B is significantly better here.
**3. logP:** Ligand A (1.568) is within the optimal 1-3 range. Ligand B (4.442) is higher, potentially leading to solubility issues and off-target interactions. Ligand A is preferable.
**4. H-Bond Donors:** Ligand A (2) and Ligand B (0) are both acceptable, falling under the 5 threshold.
**5. H-Bond Acceptors:** Ligand A (4) and Ligand B (3) are both acceptable, falling under the 10 threshold.
**6. QED:** Both ligands have good QED scores (0.738 and 0.78), indicating good drug-like properties.
**7. DILI:** Ligand A (42.885) has a slightly higher DILI risk than Ligand B (21.171), but both are below the concerning 60 percentile.
**8. BBB:** Both ligands show good BBB penetration (Ligand A: 80.962, Ligand B: 87.515). While ADRB2 isn't a CNS target, some peripheral exposure is acceptable, and high BBB penetration doesn't necessarily hurt.
**9. Caco-2 Permeability:** Ligand A (-4.529) and Ligand B (-5.281) both have negative values, indicating poor permeability. This is a concern for both.
**10. Aqueous Solubility:** Ligand A (-2.74) and Ligand B (-3.766) both have poor solubility.
**11. hERG Inhibition:** Ligand A (0.27) has a lower hERG risk than Ligand B (0.669), which is a significant advantage for cardiovascular drugs.
**12. Microsomal Clearance:** Ligand B (93.514) has a much higher microsomal clearance than Ligand A (25.759), indicating faster metabolism and potentially lower *in vivo* exposure. Ligand A is strongly favored here.
**13. In vitro Half-Life:** Ligand A (-17.151) has a longer half-life than Ligand B (-5.862). This is a positive attribute, suggesting less frequent dosing.
**14. P-gp Efflux:** Ligand A (0.02) has very low P-gp efflux, while Ligand B (0.628) has moderate efflux. Lower efflux is preferred for better bioavailability.
**15. Binding Affinity:** Ligand B (-8.4 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.6 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME concerns.
**Overall Assessment:**
While Ligand B boasts superior binding affinity, Ligand A demonstrates a more favorable ADME profile. Specifically, the lower hERG risk, lower microsomal clearance, longer half-life, and lower P-gp efflux of Ligand A are crucial for a cardiovascular drug candidate. The higher TPSA and logP of Ligand B, coupled with its faster metabolism, raise concerns about potential off-target effects and reduced *in vivo* exposure. The affinity difference is significant (~2.8 kcal/mol), but not so large that it completely overrides the ADME advantages of Ligand A.
Given the GPCR-specific priorities (logP, Pgp, TPSA, affinity) and the importance of safety and metabolic stability in cardiovascular drugs, I believe Ligand A is the more promising candidate.
Output:
1
2025-04-17 18:07:11,678 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [381.841, 89.55, 1.541, 2, 6, 0.784, 88.329, 39.822, -5.006, -3.776, 0.163, 34.179, 9.108, 0.199, -6.7]
**Ligand B:** [347.459, 71.53, 2.037, 1, 4, 0.819, 22.8, 66.925, -4.413, -1.869, 0.34, 35.819, 7.284, 0.03, 5.4]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity) are key:
1. **MW:** Both are within the ideal 200-500 Da range. Ligand B (347.459) is slightly preferred due to being closer to the lower end, potentially aiding permeability.
2. **TPSA:** Ligand A (89.55) is better than Ligand B (71.53), both are below the 140 threshold for oral absorption.
3. **logP:** Both are within the optimal 1-3 range. Ligand B (2.037) is slightly higher, which could be beneficial for membrane permeability, but isn't a huge difference.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1), but both are acceptable.
5. **HBA:** Ligand A (6) is higher than Ligand B (4), but both are acceptable.
6. **QED:** Both have good QED scores (A: 0.784, B: 0.819), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (88.329) has a significantly higher DILI risk than Ligand B (22.8). This is a major concern for Ligand A.
8. **BBB:** Ligand B (66.925) has a better BBB penetration score than Ligand A (39.822). While ADRB2 isn't *primarily* a CNS target, some degree of BBB penetration can be useful for off-target effects and distribution.
9. **Caco-2:** Ligand A (-5.006) is much worse than Ligand B (-4.413).
10. **Solubility:** Ligand A (-3.776) is worse than Ligand B (-1.869).
11. **hERG:** Both are low, indicating minimal hERG inhibition risk. Ligand B (0.34) is slightly better.
12. **Cl_mic:** Similar values for both (A: 34.179, B: 35.819).
13. **t1/2:** Ligand A (9.108) has a slightly longer half-life than Ligand B (7.284), which is a minor advantage.
14. **Pgp:** Ligand A (0.199) is better than Ligand B (0.03), meaning less P-gp efflux.
15. **Affinity:** Ligand A (-6.7 kcal/mol) has a significantly stronger binding affinity than Ligand B (-5.4 kcal/mol). This is a substantial advantage.
**Overall Assessment:**
The biggest drawback of Ligand A is its high DILI risk (88.329). This is a significant red flag. While it has a better binding affinity and Pgp profile, the potential for liver toxicity is a major concern. Ligand B has a much better safety profile (lower DILI), acceptable ADME properties, and a reasonable binding affinity. The affinity difference is significant, but the safety concerns with Ligand A outweigh this benefit.
Therefore, I prefer Ligand B.
0
2025-04-17 18:07:11,678 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (a cardiovascular GPCR) drug candidates.
**Ligand A:** [372.447, 110.6 , -0.191, 1. , 7. , 0.717, 40.946, 64.482, -4.827, -2.156, 0.151, 43.07 , -32.78 , 0.028, -6.7 ]
**Ligand B:** [347.371, 108.81 , 0.971, 2. , 6. , 0.806, 53.005, 27.646, -5.078, -1.993, 0.152, 19.564, -2.816, 0.034, -5.9 ]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (347.371) is slightly smaller, which is generally favorable.
2. **TPSA:** Both are reasonably good (below 140), suggesting decent absorption. Ligand A (110.6) and Ligand B (108.81) are very close.
3. **logP:** Ligand A (-0.191) is quite low, potentially hindering membrane permeability. Ligand B (0.971) is much better, falling within the optimal 1-3 range. This is a significant advantage for Ligand B.
4. **HBD/HBA:** Ligand A (1 HBD, 7 HBA) and Ligand B (2 HBD, 6 HBA) are both acceptable.
5. **QED:** Both have good QED scores (>0.5), indicating drug-likeness. Ligand B (0.806) is slightly better.
6. **DILI:** Ligand A (40.946) has a better DILI score than Ligand B (53.005), meaning lower predicted liver injury risk.
7. **BBB:** Ligand A (64.482) shows better BBB penetration than Ligand B (27.646). While ADRB2 isn't a CNS target, some peripheral exposure can sometimes be reduced by high BBB penetration.
8. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. Ligand A (-4.827) is slightly better than Ligand B (-5.078).
9. **Solubility:** Both have negative solubility values, indicating poor aqueous solubility. Ligand A (-2.156) is slightly better than Ligand B (-1.993).
10. **hERG:** Both have very low hERG risk (0.151 and 0.152), which is excellent.
11. **Cl_mic:** Ligand B (19.564) has significantly lower microsomal clearance than Ligand A (43.07), suggesting better metabolic stability. This is a crucial advantage.
12. **t1/2:** Ligand A (-32.78) has a negative half-life, which is concerning. Ligand B (-2.816) is also negative, but less so.
13. **Pgp:** Both have very low P-gp efflux liability (0.028 and 0.034), which is good.
14. **Affinity:** Both have very strong binding affinities (-6.7 and -5.9 kcal/mol). Ligand A is slightly better (-6.7 vs -5.9).
**Overall Assessment:**
Ligand A has a slightly better binding affinity and DILI score, and better BBB penetration. However, its low logP is a major concern for permeability, and its high microsomal clearance is unfavorable. Ligand B, while having slightly lower affinity, has a much better logP, significantly better metabolic stability (lower Cl_mic), and a slightly better QED. The improved logP and metabolic stability outweigh the small difference in binding affinity for a cardiovascular target.
Therefore, I would select Ligand B.
0
2025-04-17 18:07:11,678 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [349.431, 86.02, 0.651, 2, 5, 0.737, 40.132, 32.144, -5.108, -0.671, 0.281, 7.05, 21.713, 0.164, -7.3]
**Ligand B:** [360.801, 104.21, 0.852, 3, 5, 0.708, 69.794, 24.738, -5.427, -2.686, 0.044, -22.4, 30.748, 0.011, -7.9]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). A (349.431) is slightly preferred.
2. **TPSA:** A (86.02) is excellent, well below 140 and good for oral absorption. B (104.21) is still acceptable, but less optimal.
3. **logP:** A (0.651) is a bit low, potentially hindering permeation. B (0.852) is slightly better, moving closer to the 1-3 range.
4. **HBD:** A (2) is good. B (3) is acceptable.
5. **HBA:** Both A (5) and B (5) are within the acceptable limit of 10.
6. **QED:** Both have good QED scores (A: 0.737, B: 0.708), indicating drug-likeness.
7. **DILI:** A (40.132) is significantly better than B (69.794), indicating a much lower risk of liver injury. This is a major advantage for A.
8. **BBB:** A (32.144) is low, but not a primary concern for a non-CNS target like ADRB2. B (24.738) is even lower.
9. **Caco-2:** Both are negative, which is unusual and indicates poor permeability. This is a significant drawback for both, but the scale is not specified, so it's hard to interpret the magnitude.
10. **Solubility:** A (-0.671) is better than B (-2.686), indicating better aqueous solubility.
11. **hERG:** A (0.281) is much better than B (0.044), indicating a lower risk of cardiotoxicity. This is crucial for a cardiovascular target.
12. **Cl_mic:** A (7.05) is much lower than B (-22.4), suggesting better metabolic stability.
13. **t1/2:** A (21.713) is better than B (30.748), indicating a longer half-life.
14. **Pgp:** A (0.164) is better than B (0.011), suggesting less P-gp efflux.
15. **Affinity:** B (-7.9) has a significantly stronger binding affinity than A (-7.3) - a difference of 0.6 kcal/mol. This is a substantial advantage.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. While B has a slightly better logP and a significantly better affinity, A excels in safety parameters (DILI, hERG) and metabolic stability (Cl_mic, t1/2). The Caco-2 values are concerning for both, but the other advantages of A, particularly the much lower DILI and hERG risk, are critical for a cardiovascular drug. The affinity difference, while noticeable, might be overcome with further optimization.
**Conclusion:**
Considering the balance of properties, especially the safety profile and metabolic stability, Ligand A is the more promising candidate. The stronger affinity of Ligand B is tempting, but the higher DILI and hERG risk are significant liabilities for a cardiovascular drug.
**Output:**
1
2025-04-17 18:07:11,678 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.39 and 338.37 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (89.16) is significantly better than Ligand A (104.39). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (3.135) is optimal, while Ligand A (-0.305) is quite low, potentially hindering membrane permeability. This is a significant drawback for Ligand A.
4. **HBD:** Both have 2 HBD, which is acceptable.
5. **HBA:** Both have 5 HBA, which is acceptable.
6. **QED:** Both ligands have good QED scores (0.688 and 0.765), indicating good drug-like properties.
7. **DILI:** Ligand A (50.33) has a much lower DILI risk than Ligand B (85.54). This is a substantial advantage for Ligand A.
8. **BBB:** Ligand B (51.80) has a higher BBB penetration score than Ligand A (33.85), but this is less important for a cardiovascular target.
9. **Caco-2:** Both ligands have very poor Caco-2 permeability (-4.82 and -4.98). This is a concern for both, but the negative values indicate very low permeability.
10. **Solubility:** Ligand A (-2.582) has slightly better solubility than Ligand B (-3.94), but both are poor.
11. **hERG:** Ligand A (0.164) has a lower hERG risk than Ligand B (0.542), which is favorable.
12. **Cl_mic:** Ligand A (-4.862) has a much lower (better) microsomal clearance than Ligand B (25.765), indicating better metabolic stability.
13. **t1/2:** Ligand B (49.64) has a significantly longer in vitro half-life than Ligand A (-26.21). This is a major advantage for Ligand B.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.015 and 0.172).
15. **Binding Affinity:** Both ligands have similar binding affinities (-5.9 and -5.8 kcal/mol). The difference is negligible.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand B excels in logP and has a better TPSA. Affinity is comparable. However, the significantly lower DILI and Cl_mic for Ligand A are important considerations. The longer half-life of Ligand B is also attractive.
**Overall Assessment:**
While Ligand B has a better logP and longer half-life, the lower DILI and Cl_mic of Ligand A are compelling. The poor Caco-2 permeability is a concern for both, but the lower DILI risk and better metabolic stability of Ligand A are more critical for a successful drug candidate. The negative logP of Ligand A is a significant drawback, but the other favorable properties outweigh this.
Output:
1
2025-04-17 18:07:11,679 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (342.447 Da) is within the ideal range, while Ligand B (380.467 Da) is towards the upper limit but still acceptable.
2. **TPSA:** Ligand A (67.98) is excellent, well below the 140 threshold. Ligand B (117.28) is higher, but still reasonable for a non-CNS target.
3. **logP:** Ligand A (2.792) is optimal. Ligand B (-2.544) is significantly lower, which could lead to poor membrane permeability despite the other properties.
4. **HBD:** Both ligands are within the acceptable limit (Ligand A: 1, Ligand B: 2).
5. **HBA:** Both ligands are within the acceptable limit (Ligand A: 5, Ligand B: 7).
6. **QED:** Ligand A (0.912) is excellent, indicating high drug-likeness. Ligand B (0.429) is below the desirable threshold of 0.5.
7. **DILI:** Ligand A (44.591) has a slightly higher DILI risk than Ligand B (32.067), but both are within an acceptable range.
8. **BBB:** This is less critical for ADRB2 (cardiovascular target). Ligand A (92.012) has better BBB penetration, but it's not a primary concern. Ligand B (54.246) is lower.
9. **Caco-2:** Ligand A (-4.8) is poor, while Ligand B (-5.553) is also poor.
10. **Solubility:** Ligand A (-2.854) is poor, while Ligand B (-0.563) is slightly better.
11. **hERG:** Ligand A (0.54) has a slightly higher hERG risk than Ligand B (0.051).
12. **Cl_mic:** Ligand A (22.661) has a higher clearance than Ligand B (3.192), suggesting lower metabolic stability.
13. **t1/2:** Ligand A (2.397) has a shorter half-life than Ligand B (-47.561, which is highly favorable).
14. **Pgp:** Ligand A (0.157) has lower P-gp efflux than Ligand B (0.001), which is favorable.
15. **Affinity:** Ligand A (-5.5 kcal/mol) and Ligand B (-6.0 kcal/mol) both have good binding affinity, but Ligand B is slightly better.
**GPCR-specific priorities:** For ADRB2, logP, TPSA, and affinity are key. Ligand A has a better logP and TPSA, but Ligand B has a slightly better affinity. The significantly lower logP of Ligand B is a major concern, potentially hindering its ability to cross cell membranes and reach the target. The QED score of Ligand A is also significantly better. The better metabolic stability and half-life of Ligand B are attractive, but can be addressed through further optimization.
**Conclusion:**
Despite the slightly better affinity and metabolic stability of Ligand B, the significantly lower logP and QED score make it a less favorable candidate. Ligand A has a more balanced profile with better predicted permeability and drug-likeness.
Output:
1
2025-04-17 18:07:11,679 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [465.193, 36.67, 4.138, 0, 5, 0.583, 67.003, 93.563, -5.038, -3.859, 0.977, 55.605, 18.672, 0.888, -6.1]
**Ligand B:** [352.41, 94.56, -0.302, 3, 5, 0.586, 20.279, 37.573, -5.263, -1.135, 0.136, -16.365, -6.777, 0.005, -7.3]
**Step-by-step comparison:**
1. **MW:** Ligand A (465.193 Da) is within the ideal range, while Ligand B (352.41 Da) is on the lower side, but still acceptable.
2. **TPSA:** Ligand A (36.67) is excellent, well below the 140 threshold and good for permeability. Ligand B (94.56) is higher, potentially hindering absorption.
3. **logP:** Ligand A (4.138) is slightly high, potentially leading to solubility issues or off-target effects. Ligand B (-0.302) is too low, likely causing permeability problems.
4. **HBD:** Ligand A (0) is ideal. Ligand B (3) is acceptable.
5. **HBA:** Both ligands have 5 HBA, which is acceptable.
6. **QED:** Both ligands have similar QED values (0.583 and 0.586), indicating similar drug-likeness.
7. **DILI:** Ligand A (67.003) has a moderate DILI risk. Ligand B (20.279) has a very low DILI risk, which is a significant advantage.
8. **BBB:** Ligand A (93.563) shows excellent BBB penetration. Ligand B (37.573) has poor BBB penetration. This is a critical factor for a GPCR target.
9. **Caco-2:** Both have negative values, which is unusual. Assuming these are logP-scaled Caco-2 values, both are poor.
10. **Solubility:** Ligand A (-3.859) has poor solubility. Ligand B (-1.135) is slightly better, but still not ideal.
11. **hERG:** Ligand A (0.977) has a slightly elevated hERG risk. Ligand B (0.136) has a very low hERG risk.
12. **Cl_mic:** Ligand A (55.605) has moderate clearance. Ligand B (-16.365) has negative clearance, which is impossible, and likely an error. Assuming it's a very low positive value, it would indicate excellent metabolic stability.
13. **t1/2:** Ligand A (18.672) has a reasonable half-life. Ligand B (-6.777) has a negative half-life, which is impossible, and likely an error.
14. **Pgp:** Ligand A (0.888) has moderate Pgp efflux. Ligand B (0.005) has very low Pgp efflux, which is favorable.
15. **Affinity:** Ligand B (-7.3) has a significantly stronger binding affinity than Ligand A (-6.1) - a difference of 1.2 kcal/mol.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, BBB, and affinity. Ligand A has excellent BBB penetration, but suffers from a high logP and moderate Pgp efflux. Ligand B has poor BBB penetration, but a much better logP, very low Pgp efflux, and significantly improved binding affinity. The affinity difference is substantial.
**Conclusion:**
Despite the issues with BBB penetration, the significantly stronger binding affinity (-7.3 vs -6.1 kcal/mol) and the favorable ADME properties of Ligand B (low DILI, low hERG, low Pgp) outweigh the BBB concern. The difference in affinity is large enough to potentially overcome permeability challenges with formulation strategies. Ligand A's higher logP and moderate Pgp efflux are more concerning.
0
2025-04-17 18:07:11,679 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.431 and 366.38 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (75.63) is slightly higher than Ligand B (67.87). Both are below the 140 threshold for good oral absorption, but closer to the 90 threshold for CNS targets (less relevant for ADRB2, a cardiovascular target). Ligand B is preferable.
3. **logP:** Both ligands have similar logP values (1.441 and 1.486), falling within the optimal 1-3 range. No clear advantage.
4. **HBD:** Ligand A has 0 HBDs, while Ligand B has 1. Both are acceptable, but 0 is generally preferred for permeability. Ligand A is preferable.
5. **HBA:** Ligand A has 5 HBAs, and Ligand B has 4. Both are below the 10 threshold. No clear advantage.
6. **QED:** Ligand B (0.801) has a significantly higher QED score than Ligand A (0.575), indicating a more drug-like profile. Ligand B is preferable.
7. **DILI:** Both ligands have acceptable DILI risk (38.736 and 41.838, both < 40). No significant difference.
8. **BBB:** Ligand B (92.943) has a much higher BBB penetration percentile than Ligand A (83.288). While ADRB2 isn't a CNS target, higher BBB is generally favorable, suggesting less involvement of efflux transporters. Ligand B is preferable.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.605 and -4.492). These values are unusual and likely indicate poor permeability. However, the difference is minimal.
10. **Solubility:** Ligand A (-1.237) has better (less negative) solubility than Ligand B (-2.622). Ligand A is preferable.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.184 and 0.186). No significant difference.
12. **Cl_mic:** Ligand B (24.455) has a lower microsomal clearance than Ligand A (32.789), indicating better metabolic stability. Ligand B is preferable.
13. **t1/2:** Ligand B (-10.357) has a significantly longer in vitro half-life than Ligand A (-5.371). This is a major advantage. Ligand B is preferable.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.089 and 0.015). No significant difference.
15. **Binding Affinity:** Ligand B (-8.0 kcal/mol) has a slightly better binding affinity than Ligand A (-7.1 kcal/mol). This is a significant advantage, exceeding the 1.5 kcal/mol threshold.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand B excels in affinity and has favorable values for the other parameters. While Ligand A has better solubility, the superior affinity, metabolic stability, half-life, and QED of Ligand B outweigh this advantage.
**Conclusion:**
Ligand B is the more promising drug candidate due to its superior binding affinity, metabolic stability, longer half-life, higher QED, and better BBB penetration, all of which are crucial for a GPCR target.
Output:
0
2025-04-17 18:07:11,679 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.46 and 356.43 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (76.66) is higher than Ligand B (33.2). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is generally preferred for absorption. Ligand B is significantly better.
3. **logP:** Ligand A (1.692) is within the optimal 1-3 range. Ligand B (4.895) is high, potentially leading to solubility issues and off-target interactions. Ligand A is better.
4. **HBD:** Ligand A (2) and Ligand B (0) are both acceptable, below the threshold of 5.
5. **HBA:** Ligand A (4) and Ligand B (2) are both acceptable, below the threshold of 10.
6. **QED:** Both ligands (0.685 and 0.664) have good drug-likeness scores, exceeding 0.5. No major difference.
7. **DILI:** Ligand A (51.183) has a higher DILI risk than Ligand B (19.698). Ligand B is significantly better.
8. **BBB:** Ligand A (66.382) and Ligand B (94.223). While ADRB2 isn't strictly a CNS target, some brain exposure can occur. Ligand B is better.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.961 and -4.415) which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-2.394) has better solubility than Ligand B (-5.246). Ligand A is better.
11. **hERG:** Ligand A (0.178) has a lower hERG risk than Ligand B (0.7). Ligand A is better.
12. **Cl_mic:** Ligand A (32.173) has a lower microsomal clearance, indicating better metabolic stability, than Ligand B (80.345). Ligand A is better.
13. **t1/2:** Ligand A (2.15) has a slightly longer half-life than Ligand B (1.754). Ligand A is better.
14. **Pgp:** Ligand A (0.13) has lower P-gp efflux liability than Ligand B (0.616). Ligand A is better.
15. **Affinity:** Ligand B (-7.1 kcal/mol) has a slightly better binding affinity than Ligand A (-6.9 kcal/mol). This is a 0.2 kcal/mol difference, which is not substantial enough to outweigh other factors.
**Overall Assessment:**
Ligand B has a superior binding affinity and BBB penetration, but suffers from a high logP, higher DILI risk, and significantly higher P-gp efflux. Ligand A has better ADME properties across the board (solubility, metabolic stability, lower toxicity, lower efflux) and a reasonably good binding affinity. Considering the GPCR-specific priorities (logP, Pgp, TPSA) and the overall balance of properties, Ligand A is the more promising candidate. The slightly weaker affinity is unlikely to be a major issue given the other advantages.
Output:
1
2025-04-17 18:07:11,679 - INFO - Here's a step-by-step reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [355.479, 62.32, 0.439, 0., 5., 0.692, 14.424, 69.407, -4.382, -0.098, 0.307, 30.659, 7.993, 0.016, -6.2]**
**Ligand B: [382.873, 97.12, 2.846, 2., 6., 0.8, 77.2, 50.64, -5.081, -3.453, 0.191, 30.302, 2.784, 0.248, -6.8]**
1. **Molecular Weight:** Both are within the ideal range (200-500 Da). Ligand A (355.479) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (62.32) is significantly better than Ligand B (97.12). ADRB2 is not a CNS target, but lower TPSA generally improves absorption.
3. **logP:** Ligand A (0.439) is a bit low, potentially hindering permeation. Ligand B (2.846) is within the optimal range (1-3). This favors Ligand B.
4. **H-Bond Donors:** Ligand A (0) is excellent. Ligand B (2) is acceptable.
5. **H-Bond Acceptors:** Ligand A (5) is good. Ligand B (6) is also acceptable.
6. **QED:** Both are reasonably good (A: 0.692, B: 0.8), indicating drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (14.424) has a much lower DILI risk than Ligand B (77.2). This is a significant advantage for Ligand A.
8. **BBB:** Not a primary concern for ADRB2 (cardiovascular target). Ligand A (69.407) is better than Ligand B (50.64), but both are not particularly high.
9. **Caco-2:** Ligand A (-4.382) is worse than Ligand B (-5.081). Lower values suggest poorer permeability.
10. **Solubility:** Ligand A (-0.098) is better than Ligand B (-3.453). Solubility is important for bioavailability.
11. **hERG:** Both are very low (A: 0.307, B: 0.191), indicating low cardiotoxicity risk. Ligand B is slightly better.
12. **Cl_mic:** Both have similar microsomal clearance (A: 30.659, B: 30.302).
13. **t1/2:** Ligand A (7.993) has a longer in vitro half-life than Ligand B (2.784), which is desirable.
14. **Pgp:** Both have very low Pgp efflux (A: 0.016, B: 0.248), which is good. Ligand A is slightly better.
15. **Binding Affinity:** Ligand B (-6.8) has a slightly better binding affinity than Ligand A (-6.2), a 0.6 kcal/mol difference.
**Overall Assessment:**
Ligand B has a better logP and binding affinity. However, Ligand A excels in critical ADME properties like DILI risk, solubility, and in vitro half-life. The lower TPSA of Ligand A is also beneficial. While the affinity difference is notable, the significantly lower DILI risk and better solubility of Ligand A, combined with acceptable affinity, make it the more promising candidate. The slightly lower logP of Ligand A can potentially be addressed with further optimization.
Output:
1
2025-04-17 18:07:11,679 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [350.547, 49.41, 4.304, 1, 2, 0.498, 19.426, 84.413, -4.685, -3.753, 0.748, 63.481, -2.352, 0.489, -6.7]
**Ligand B:** [353.495, 62.73, 4.751, 2, 6, 0.693, 83.637, 67.158, -5.047, -5.015, 0.644, 83.609, 55.217, 0.312, -5.2]
Here's a breakdown, considering the guidelines and GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal range (200-500 Da). A is 350.5, B is 353.5. Very similar.
2. **TPSA:** A (49.41) is excellent, well below 140 and good for oral absorption. B (62.73) is still acceptable, but less ideal.
3. **logP:** Both are good (around 4.3-4.7), within the 1-3 optimal range, but edging towards the higher end. B is slightly higher, which could present solubility challenges.
4. **HBD:** A (1) is preferable to B (2). Lower HBD generally improves permeability.
5. **HBA:** A (2) is preferable to B (6). Lower HBA is also generally better for permeability.
6. **QED:** Both are reasonable, but B (0.693) is better than A (0.498), indicating a more drug-like profile.
7. **DILI:** A (19.43) is significantly better than B (83.64). This is a major advantage for Ligand A.
8. **BBB:** A (84.41) is better than B (67.16), although BBB isn't *critical* for a cardiovascular target, it's a bonus.
9. **Caco-2:** Both are negative, indicating poor permeability. A (-4.685) is slightly worse than B (-5.047).
10. **Solubility:** Both are negative, indicating poor solubility. A (-3.753) is slightly better than B (-5.015).
11. **hERG:** Both are low (0.748 and 0.644), suggesting low cardiotoxicity risk.
12. **Cl_mic:** A (63.48) is better (lower) than B (83.61), suggesting better metabolic stability.
13. **t1/2:** B (55.22) is significantly better than A (-2.35). This is a substantial advantage for B.
14. **Pgp:** A (0.489) is better (lower) than B (0.312), indicating less P-gp efflux.
15. **Affinity:** A (-6.7) is better (more negative) than B (-5.2). This is a 1.5 kcal/mol difference, which is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand A has a significantly better safety profile (DILI), better TPSA, lower HBD/HBA, better metabolic stability (Cl_mic), and a much stronger binding affinity. While its Caco-2 and solubility are worse than B, the affinity difference is substantial. Ligand B has a better QED and a longer half-life, but the high DILI risk is a major concern.
Given the GPCR target and the importance of potency, and the significant advantage in binding affinity, I favor Ligand A.
Output:
1
2025-04-17 18:07:11,679 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (362.5 and 343.4 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (66.4) is significantly lower than Ligand B (123.95). For a GPCR, lower TPSA is generally preferred for better permeability. Ligand A is well below the 140 threshold, while Ligand B is approaching it.
**3. logP:** Ligand A (2.351) is slightly higher than Ligand B (1.313), both within the optimal 1-3 range.
**4. H-Bond Donors:** Ligand A (0) has fewer HBDs than Ligand B (1). Fewer HBDs are generally preferred for permeability.
**5. H-Bond Acceptors:** Both ligands have 5 HBAs, which is acceptable.
**6. QED:** Ligand A (0.575) has a better QED score than Ligand B (0.331), indicating a more drug-like profile.
**7. DILI Risk:** Ligand A (31.02) has a lower DILI risk than Ligand B (41.915), both are acceptable but A is preferred.
**8. BBB Penetration:** Ligand A (74.176) has significantly better BBB penetration than Ligand B (40.675). While ADRB2 is cardiovascular, some CNS effects are possible with beta-blockers, and better BBB penetration could be beneficial or detrimental depending on the desired profile.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, indicating poor permeability. However, Ligand A (-4.821) is slightly better than Ligand B (-4.93).
**10. Aqueous Solubility:** Both ligands have negative solubility values, indicating poor solubility. Ligand A (-1.946) is slightly better than Ligand B (-1.443).
**11. hERG Inhibition:** Ligand A (0.415) has a lower hERG inhibition liability than Ligand B (0.196), which is a significant advantage for cardiovascular drugs.
**12. Microsomal Clearance:** Ligand B (28.233) has lower microsomal clearance than Ligand A (33.808), suggesting better metabolic stability.
**13. In vitro Half-Life:** Ligand B (-14.109) has a longer in vitro half-life than Ligand A (-9.24), which is desirable.
**14. P-gp Efflux:** Ligand A (0.474) has lower P-gp efflux liability than Ligand B (0.015), which is beneficial for bioavailability.
**15. Binding Affinity:** Ligand A (-7.1) has a stronger binding affinity than Ligand B (-5.9). This is a substantial difference, and a >1.2 kcal/mol advantage often outweighs minor ADME drawbacks.
**Overall Assessment:**
Ligand A is superior. It has a better QED score, lower DILI risk, better BBB penetration, lower hERG inhibition, and significantly stronger binding affinity. While Ligand B has better metabolic stability and half-life, the superior binding affinity and safety profile of Ligand A are more critical, especially for a GPCR target. The slightly better permeability predictions (TPSA, Caco-2) and P-gp efflux for Ligand A also contribute to its preference.
Output:
1
2025-04-17 18:07:11,679 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [399.252, 87.11, 3.049, 3, 5, 0.451, 89.957, 66.615, -5.681, -3.439, 0.787, 36.283, 59.379, 0.623, -6.4]**
**Ligand B: [349.431, 91.5, 1.077, 2, 4, 0.804, 30.787, 53.083, -4.781, -2.268, 0.237, -5.109, -13.4, 0.031, -7.1]**
1. **Molecular Weight:** Both are within the ideal range (200-500 Da). Ligand B (349.431) is slightly lower, which *could* be advantageous for permeability, but both are acceptable.
2. **TPSA:** Ligand A (87.11) is better than Ligand B (91.5). Both are below 140, but lower is preferred for oral absorption.
3. **logP:** Ligand A (3.049) is optimal, while Ligand B (1.077) is on the lower side. This is a significant advantage for Ligand A, as it's more likely to have good membrane permeability.
4. **H-Bond Donors:** Ligand A (3) is slightly higher than Ligand B (2), but both are within the acceptable limit of 5.
5. **H-Bond Acceptors:** Ligand A (5) is slightly higher than Ligand B (4), but both are within the acceptable limit of 10.
6. **QED:** Ligand B (0.804) has a better QED score than Ligand A (0.451), suggesting a more drug-like profile. This is a point in favor of Ligand B.
7. **DILI:** Ligand A (89.957) has a significantly higher DILI risk than Ligand B (30.787). This is a major concern for Ligand A.
8. **BBB:** Ligand A (66.615) has a better BBB penetration percentile than Ligand B (53.083). While ADRB2 isn't strictly a CNS target, some CNS exposure can occur, and higher BBB is generally preferable.
9. **Caco-2 Permeability:** Ligand A (-5.681) has worse Caco-2 permeability than Ligand B (-4.781). Lower (more negative) values indicate lower permeability.
10. **Aqueous Solubility:** Ligand A (-3.439) has worse solubility than Ligand B (-2.268).
11. **hERG Inhibition:** Ligand A (0.787) has higher hERG inhibition risk than Ligand B (0.237). This is a safety concern for Ligand A.
12. **Microsomal Clearance:** Ligand A (36.283) has higher clearance than Ligand B (-5.109), suggesting lower metabolic stability.
13. **In vitro Half-Life:** Ligand A (59.379) has a better in vitro half-life than Ligand B (-13.4).
14. **P-gp Efflux:** Ligand A (0.623) has higher P-gp efflux than Ligand B (0.031). This is unfavorable for Ligand A.
15. **Binding Affinity:** Ligand B (-7.1) has a slightly better binding affinity than Ligand A (-6.4). While the difference isn't huge, it's still a factor.
**Overall Assessment:**
Ligand A has a better logP and BBB, and a better in vitro half-life. However, it suffers from significantly higher DILI risk, hERG inhibition, P-gp efflux, and lower solubility and Caco-2 permeability. Ligand B has a better QED score and significantly better safety profiles (DILI, hERG). The slightly better binding affinity of Ligand B, combined with its superior ADME/Tox properties, makes it the more promising candidate.
Output:
0
2025-04-17 18:07:11,679 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 drug candidates. ADRB2 is a GPCR, so we'll prioritize logP, Pgp, TPSA, and affinity, alongside general drug-like properties.
**Ligand A:** [383.901, 80.32, 2.24, 2, 5, 0.738, 54.323, 61.691, -4.614, -4.465, 0.221, 23.108, 20.692, 0.274, -6.1]
**Ligand B:** [369.443, 107.97, -0.018, 3, 6, 0.511, 53.432, 33.385, -5.515, -1.457, 0.172, -24.539, -0.863, 0.024, -5.9]
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (369.443) is slightly lower, which is generally favorable.
2. **TPSA:** Ligand A (80.32) is better than Ligand B (107.97). We want <140 for oral absorption, both pass, but A is closer to the ideal.
3. **logP:** Ligand A (2.24) is optimal (1-3). Ligand B (-0.018) is quite low, potentially hindering permeability. This is a significant drawback for a GPCR target.
4. **HBD:** Ligand A (2) is good. Ligand B (3) is acceptable, but slightly higher.
5. **HBA:** Ligand A (5) is good. Ligand B (6) is acceptable, but slightly higher.
6. **QED:** Ligand A (0.738) is better than Ligand B (0.511), indicating a more drug-like profile.
7. **DILI:** Both are similar and acceptable (around 53-54 percentile).
8. **BBB:** Ligand A (61.691) is significantly better than Ligand B (33.385). While not a primary concern for ADRB2 (cardiovascular target), higher BBB is generally a positive.
9. **Caco-2:** Ligand A (-4.614) is better than Ligand B (-5.515), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-4.465) is better than Ligand B (-1.457). Solubility is important for bioavailability.
11. **hERG:** Both are very low (0.221 and 0.172), indicating very low cardiotoxicity risk.
12. **Cl_mic:** Ligand B (-24.539) has a much lower (better) microsomal clearance than Ligand A (23.108), suggesting better metabolic stability.
13. **t1/2:** Ligand A (20.692) has a much longer half-life than Ligand B (-0.863).
14. **Pgp:** Ligand A (0.274) is better than Ligand B (0.024), indicating lower P-gp efflux.
15. **Affinity:** Both have excellent binding affinity (-6.1 and -5.9 kcal/mol). The difference is relatively small.
**Conclusion:**
Despite Ligand B having better metabolic stability (lower Cl_mic), the significantly lower logP and poorer BBB penetration are major concerns. GPCRs require a balance of lipophilicity for receptor engagement and permeability. Ligand A has a much more favorable logP, better TPSA, QED, solubility, Caco-2, Pgp and BBB. The slightly shorter half-life and higher clearance of Ligand A are less concerning given its superior overall profile. The affinity difference is minimal.
Therefore, I prefer Ligand A.
Output:
1
2025-04-17 18:07:11,679 - INFO - Batch 14 complete. Total preferences: 224
2025-04-17 18:07:11,679 - INFO - Processing batch 15/512...
2025-04-17 18:08:04,054 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Ligand A (408.3 Da) is within the ideal range, while Ligand B (353.423 Da) is also acceptable, being slightly below the preferred range.
2. **TPSA:** Ligand A (90.98) is good, under the 140 threshold, and quite favorable for a GPCR. Ligand B (118.37) is still within acceptable limits, but less optimal.
3. **logP:** Ligand A (2.487) is excellent, falling squarely within the 1-3 range. Ligand B (-0.291) is concerningly low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (2) and Ligand B (3) are both acceptable.
5. **HBA:** Ligand A (4) and Ligand B (7) are both acceptable, though Ligand B is higher.
6. **QED:** Both ligands have reasonable QED scores (A: 0.814, B: 0.561), suggesting good drug-like properties.
7. **DILI:** Ligand A (66.111) has a higher DILI risk than Ligand B (50.174), but both are within acceptable ranges.
8. **BBB:** Both have similar BBB penetration (A: 52.501, B: 51.183). Since ADRB2 isn't exclusively a CNS target, this isn't a major deciding factor.
9. **Caco-2:** Ligand A (-5.556) is very poor, suggesting poor absorption. Ligand B (-4.914) is also poor, but slightly better.
10. **Solubility:** Ligand A (-2.985) is very poor. Ligand B (-1.631) is also poor, but better than Ligand A.
11. **hERG:** Both ligands have low hERG risk (A: 0.554, B: 0.084), which is excellent.
12. **Cl_mic:** Ligand A (-2.952) has a negative clearance, which is excellent, indicating high metabolic stability. Ligand B (24.613) has a high clearance, suggesting rapid metabolism.
13. **t1/2:** Ligand A (6.581) has a reasonable half-life. Ligand B (-13.278) has a very short, and likely unrealistic, half-life.
14. **Pgp:** Both ligands have low Pgp efflux (A: 0.085, B: 0.016), which is favorable.
15. **Affinity:** Ligand A (-6.7 kcal/mol) has a slightly better binding affinity than Ligand B (-6.0 kcal/mol).
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, and affinity are crucial. Ligand A excels in logP and has a slightly better affinity. While both have acceptable TPSA values, Ligand A is better. The biggest drawback for Ligand A is the poor Caco-2 and solubility, but the excellent metabolic stability (Cl_mic) and affinity are strong advantages. Ligand B's low logP is a significant concern, and its poor metabolic stability and half-life are also major drawbacks.
**Conclusion:**
Despite the poor Caco-2 and solubility of Ligand A, its superior logP, metabolic stability, and slightly better affinity make it the more promising candidate. These factors are particularly important for GPCR targets. Ligand B's low logP and poor metabolic profile are too significant to overcome.
Output:
1
2025-04-17 18:08:04,055 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.491 and 351.447 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (76.02) is better than Ligand B (91.23). ADRB2 is a cardiovascular target, so CNS penetration isn't critical, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (2.361) is preferable to Ligand B (1.057). Both are within the optimal 1-3 range, but Ligand A is closer to the middle of the range, suggesting a better balance of solubility and permeability. Ligand B is on the lower side, potentially hindering permeation.
4. **HBD:** Both ligands have 2 HBD, which is within the acceptable limit of 5.
5. **HBA:** Ligand A has 4 HBA, while Ligand B has 5. Both are within the acceptable limit of 10.
6. **QED:** Both ligands have good QED scores (0.757 and 0.792), indicating good drug-like properties.
7. **DILI:** Ligand A (22.218) has a lower DILI risk than Ligand B (24.351). Both are below the 40 threshold, indicating low risk, but lower is better.
8. **BBB:** Ligand A (69.213) has a significantly higher BBB penetration potential than Ligand B (36.487). While not a primary concern for a cardiovascular target, higher BBB is generally a positive attribute.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.86 and -4.682). This is unusual and suggests poor permeability. However, the values are very close.
10. **Solubility:** Ligand A (-2.619) has slightly better solubility than Ligand B (-1.652). Both are negative, indicating poor solubility.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.127 and 0.179).
12. **Cl_mic:** Ligand A (44.848) has a lower microsomal clearance than Ligand B (7.495). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand B (13.489) has a significantly longer in vitro half-life than Ligand A (-2.368). This is a major advantage for Ligand B.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.08 and 0.019).
15. **Binding Affinity:** Ligand A (-7.8) has a stronger binding affinity than Ligand B (-5.4). This is a substantial difference (2.4 kcal/mol), and affinity is a primary driver for GPCR drug candidates.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), affinity, logP, TPSA, and Pgp are key. Ligand A excels in affinity and logP, and has a better TPSA. Ligand B's main advantage is its longer half-life, but the significantly stronger binding of Ligand A outweighs this benefit.
**Conclusion:**
Despite Ligand B's longer half-life, Ligand A's superior binding affinity, better logP, TPSA, and DILI profile make it the more promising drug candidate for the ADRB2 receptor.
Output:
1
2025-04-17 18:08:04,055 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [364.446, 76.02, 1.759, 2, 5, 0.867, 65.568, 72.237, -5.006, -2.856, 0.485, -14.448, 6.028, 0.046, -6.8]
**Ligand B:** [359.495, 54.43, 3.551, 1, 6, 0.635, 27.414, 54.013, -5.507, -2.609, 0.892, 30.666, 86.801, 0.692, -7]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (364.446) is slightly higher, but not concerning.
2. **TPSA:** Ligand A (76.02) is better than Ligand B (54.43) as it is still below the 140 threshold for oral absorption.
3. **logP:** Ligand A (1.759) is optimal, while Ligand B (3.551) is approaching the upper limit.
4. **HBD:** Ligand A (2) is preferable to Ligand B (1) as it balances solubility and permeability.
5. **HBA:** Ligand B (6) is slightly higher than Ligand A (5), but both are acceptable.
6. **QED:** Ligand A (0.867) is significantly better than Ligand B (0.635), indicating a more drug-like profile.
7. **DILI:** Ligand B (27.414) is much better than Ligand A (65.568), indicating a lower risk of liver injury. This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (72.237) is better than Ligand B (54.013), which is important for GPCRs.
9. **Caco-2:** Both are negative, indicating poor permeability.
10. **Solubility:** Both are negative, indicating poor solubility.
11. **hERG:** Ligand B (0.892) is slightly higher than Ligand A (0.485), indicating a higher risk of hERG inhibition.
12. **Cl_mic:** Ligand A (-14.448) is *much* better than Ligand B (30.666), indicating significantly better metabolic stability.
13. **t1/2:** Ligand B (86.801) has a much longer half-life than Ligand A (6.028).
14. **Pgp:** Ligand B (0.692) is slightly higher than Ligand A (0.046), indicating higher P-gp efflux.
15. **Affinity:** Ligand B (-7) has a slightly better binding affinity than Ligand A (-6.8).
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, Pgp, TPSA, and affinity. Ligand A has a better logP and TPSA. Ligand B has a slightly better affinity. The BBB is also important, and Ligand A has a better score. However, the DILI risk for Ligand A is concerningly high, and the metabolic stability (Cl_mic) is poor. Ligand B's DILI risk is low, and its half-life is excellent.
**Overall Assessment:**
While Ligand B has a slightly better binding affinity and a significantly better half-life and DILI profile, the poor Caco-2 and solubility are concerning. However, the metabolic stability of Ligand A is very poor and the DILI risk is high. Considering the balance of properties, and prioritizing metabolic stability and safety (DILI) along with affinity, Ligand B is the more promising candidate, despite its lower BBB penetration. The solubility and permeability issues can be addressed with formulation strategies.
Output:
0
2025-04-17 18:08:04,055 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, the most important properties are binding affinity, logP, TPSA, Pgp efflux, and BBB penetration. Metabolic stability (Cl_mic and t1/2) and safety (DILI and hERG) are also important, but less so than the first five.
Let's compare the ligands property by property:
1. **MW:** Both are within the ideal range (349.431 vs 348.487 Da). No significant difference.
2. **TPSA:** Ligand B (49.85) is significantly better than Ligand A (75.01). Lower TPSA generally favors oral absorption and GPCR binding.
3. **logP:** Ligand B (2.894) is optimal, while Ligand A (0.026) is very low, potentially hindering membrane permeability. This is a major advantage for Ligand B.
4. **HBD/HBA:** Ligand A has 1 HBD and 5 HBA, while Ligand B has 0 HBD and 3 HBA. Both are acceptable, but Ligand B is slightly more favorable.
5. **QED:** Ligand A (0.814) is much better than Ligand B (0.475), indicating a more drug-like profile.
6. **DILI:** Both have similar, low DILI risk (17.642 vs 17.798).
7. **BBB:** Ligand B (90.655) is significantly better than Ligand A (51.183). While not a CNS target, some BBB penetration can be beneficial for distribution.
8. **Caco-2:** Both have negative values, suggesting poor permeability.
9. **Solubility:** Ligand A (-0.718) is slightly better than Ligand B (-2.044), but both are poor.
10. **hERG:** Both have low hERG risk (0.16 vs 0.602).
11. **Cl_mic:** Ligand A (4.115) is much better than Ligand B (67.201), suggesting better metabolic stability.
12. **t1/2:** Ligand B (-8.732) is much better than Ligand A (14.578), indicating a longer half-life.
13. **Pgp:** Ligand A (0.024) is significantly better than Ligand B (0.304), meaning less efflux and potentially better bioavailability.
14. **Binding Affinity:** Ligand A (-6.5 kcal/mol) is slightly better than Ligand B (-6.1 kcal/mol), but the difference is relatively small.
**Overall Assessment:**
Ligand B excels in key GPCR-relevant properties (logP, TPSA, BBB). While Ligand A has better QED, Cl_mic, and Pgp, the poor logP and higher TPSA are significant drawbacks for a GPCR target. Ligand B's superior logP and TPSA are likely to translate to better binding and cellular permeability, outweighing the slightly lower QED. The longer half-life of Ligand B is also a plus.
**Output:**
0
2025-04-17 18:08:04,055 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
The target is ADRB2, a GPCR. Therefore, I will prioritize logP, TPSA, Pgp efflux, BBB penetration, and binding affinity, while also considering the general drug-like properties.
* **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (349.391) is slightly lower, which is generally favorable for permeability.
* **TPSA:** Ligand B (53.09) is significantly better than Ligand A (115.21). Lower TPSA generally translates to better cell permeability, a crucial factor for GPCR ligands.
* **logP:** Ligand B (0.379) is within the optimal range (1-3), while Ligand A (-0.556) is slightly below 1. While not a hard cutoff, lower logP can sometimes hinder membrane permeability.
* **H-Bond Donors/Acceptors:** Ligand A has 2 HBD and 7 HBA, while Ligand B has 0 HBD and 5 HBA. Both are acceptable, but Ligand B's lower HBD count is slightly preferable for permeability.
* **QED:** Both ligands have good QED scores (A: 0.556, B: 0.658), indicating good overall drug-likeness. Ligand B is slightly better.
* **DILI:** Ligand B (29.43) has a much lower DILI risk than Ligand A (52.307), a significant advantage.
* **BBB:** Ligand B (58.938) shows better BBB penetration than Ligand A (50.523), though neither are exceptionally high. For a peripheral GPCR like ADRB2, this is less critical than for a CNS target, but still a positive.
* **Caco-2 Permeability:** Both have negative Caco-2 values which is unusual, but Ligand B (-4.502) is slightly better than Ligand A (-5.073).
* **Aqueous Solubility:** Both have negative solubility values, which is also unusual.
* **hERG:** Ligand A (0.014) has a slightly lower hERG risk than Ligand B (0.265), but both are very low risk.
* **Microsomal Clearance:** Ligand A (16.76) has significantly lower microsomal clearance than Ligand B (39.312), suggesting better metabolic stability.
* **In vitro Half-Life:** Ligand A (13.71) has a longer half-life than Ligand B (1.102), which is desirable.
* **P-gp Efflux:** Ligand A (0.022) has a lower P-gp efflux liability than Ligand B (0.049), indicating better bioavailability.
* **Binding Affinity:** Ligand B (-6.7 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.2 kcal/mol). This is a substantial advantage and can often outweigh minor ADME concerns.
**Overall Assessment:**
While Ligand A has advantages in metabolic stability (Cl_mic, t1/2) and P-gp efflux, Ligand B's superior TPSA, lower DILI risk, and, most importantly, significantly stronger binding affinity make it the more promising candidate. The binding affinity difference of 1.5 kcal/mol is substantial. The slightly lower logP of Ligand A is a minor concern, and the better TPSA of Ligand B is a significant advantage for a GPCR target.
**Output:**
0
2025-04-17 18:08:04,056 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Step-by-step comparison:**
1. **MW:** Both ligands (358.341 and 348.403 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand B (89.6) is significantly better than Ligand A (103.01). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally improves absorption.
3. **logP:** Ligand B (1.692) is within the optimal 1-3 range, while Ligand A (0.225) is quite low. This is a major drawback for Ligand A, potentially hindering membrane permeability.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (1), but both are acceptable (<=5).
5. **HBA:** Ligand B (6) is slightly higher than Ligand A (5), but both are acceptable (<=10).
6. **QED:** Ligand B (0.822) has a better QED score than Ligand A (0.654), indicating a more drug-like profile.
7. **DILI:** Both ligands have similar DILI risk (56.883 vs 53.276), and are within an acceptable range (<60).
8. **BBB:** Ligand B (51.997) has a higher BBB penetration score than Ligand A (31.834). While not crucial for a cardiovascular target, it's a slight advantage.
9. **Caco-2:** Both ligands have very poor Caco-2 permeability (-4.975 and -4.525). This is a concern for oral bioavailability for both.
10. **Solubility:** Both ligands have poor aqueous solubility (-1.481 and -2.485). This is a significant drawback for both.
11. **hERG:** Ligand A (0.334) has a slightly better hERG profile than Ligand B (0.197), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand B (53.968) has a much higher microsomal clearance than Ligand A (5.916). This suggests Ligand A is more metabolically stable.
13. **t1/2:** Ligand A (-11.589) has a much more negative in vitro half-life than Ligand B (5.941). This is a significant negative for Ligand A.
14. **Pgp:** Ligand A (0.051) has a lower P-gp efflux liability than Ligand B (0.101), which is favorable.
15. **Binding Affinity:** Ligand A (-6.7 kcal/mol) has a slightly better binding affinity than Ligand B (-4.8 kcal/mol). This is a 1.9 kcal/mol difference, which is substantial.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand A has a better affinity, but a significantly worse logP. Ligand B has a better logP and TPSA. The affinity difference is substantial, but the poor logP of Ligand A is a major concern for permeability and overall drug-like properties. The better metabolic stability of Ligand A is a plus, but the poor half-life is a significant drawback.
**Conclusion:**
Despite the slightly better binding affinity of Ligand A, the significantly better logP, QED, and metabolic stability of Ligand B make it the more promising candidate. The poor logP of Ligand A is a critical flaw that outweighs its affinity advantage.
Output:
0
2025-04-17 18:08:04,056 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Reasoning:**
Let's systematically compare the two ligands based on the provided parameters and the given priorities for GPCRs (logP, Pgp, TPSA, and affinity being key).
1. **Molecular Weight:** Both ligands (347.419 Da and 354.491 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands have TPSA values (89.35 and 87.66) below the 140 threshold for good oral absorption. They are also reasonably low, which is good for GPCRs. Ligand B is slightly lower, which is marginally better.
3. **logP:** Ligand A (0.615) is a bit low, potentially hindering permeability. Ligand B (1.469) is better positioned within the optimal 1-3 range. This is a significant advantage for Ligand B.
4. **H-Bond Donors/Acceptors:** Ligand A (1 HBD, 6 HBA) is preferable to Ligand B (3 HBD, 4 HBA) as it has fewer HBDs.
5. **QED:** Ligand A (0.843) has a significantly higher QED score than Ligand B (0.554), indicating a more drug-like profile. This is a strong point for Ligand A.
6. **DILI Risk:** Ligand A (59.752) has a higher DILI risk than Ligand B (10.237). This is a major concern for Ligand A.
7. **BBB Penetration:** Ligand A (70.803) has better BBB penetration than Ligand B (57.736). While not a primary concern for ADRB2 (a cardiovascular target), it's a slight positive for Ligand A.
8. **Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. This is a concern for both.
9. **Aqueous Solubility:** Both ligands have very poor aqueous solubility (-2.181 and -2.06). This is a significant drawback for both, potentially hindering formulation and bioavailability.
10. **hERG Inhibition:** Ligand A (0.113) shows a much lower risk of hERG inhibition compared to Ligand B (0.328). This is a crucial safety advantage for Ligand A.
11. **Microsomal Clearance:** Ligand A (14.227) has a lower microsomal clearance than Ligand B (42.626), indicating better metabolic stability. This is a positive for Ligand A.
12. **In vitro Half-Life:** Ligand A (-3.095) has a negative half-life, which is not possible. Ligand B (4.856) has a reasonable half-life. This is a major issue with Ligand A.
13. **P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.04 and 0.086), which is good.
14. **Binding Affinity:** Ligand B (-6.2 kcal/mol) has a slightly better binding affinity than Ligand A (-5.8 kcal/mol). While the difference is not huge, it's still a factor.
**Overall Assessment:**
Ligand A has a better QED, lower DILI risk, lower hERG inhibition, and better metabolic stability. However, it has a negative in vitro half-life, which is a critical flaw. Ligand B has a better logP, slightly better affinity, and a more reasonable half-life. The significantly lower DILI risk for Ligand B, combined with the more favorable logP, and a reasonable half-life, outweigh the slightly lower QED and slightly worse hERG profile. The negative half-life for Ligand A is a deal-breaker.
Output:
0
2025-04-17 18:08:04,056 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [368.543, 49.85, 2.562, 0, 4, 0.648, 19.891, 73.943, -4.655, -2.544, 0.529, 47.031, -0.916, 0.1, -6.2]
**Ligand B:** [340.427, 76.02, 1.024, 2, 4, 0.575, 37.456, 48.313, -4.933, -2.456, 0.086, 6.104, -7.355, 0.039, -4.8]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (340.43) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (49.85) is better than Ligand B (76.02). ADRB2 is not a CNS target, but lower TPSA generally aids absorption. Ligand B is getting a bit high.
3. **logP:** Ligand A (2.562) is optimal, while Ligand B (1.024) is on the lower side. This could impact membrane permeability for Ligand B.
4. **HBD:** Ligand A (0) is better than Ligand B (2). Fewer HBDs are generally preferred for better permeability.
5. **HBA:** Both have 4 HBA, which is acceptable.
6. **QED:** Both are reasonably good (A: 0.648, B: 0.575), indicating drug-like properties.
7. **DILI:** Ligand A (19.891) has a significantly lower DILI risk than Ligand B (37.456). This is a major advantage for Ligand A.
8. **BBB:** Not a primary concern for a cardiovascular target, but Ligand A (73.943) is better than Ligand B (48.313).
9. **Caco-2:** Both are negative, indicating poor permeability. This is a concern for both.
10. **Solubility:** Both are negative, indicating poor solubility. This is a concern for both.
11. **hERG:** Ligand A (0.529) has a slightly higher hERG risk than Ligand B (0.086), but both are relatively low.
12. **Cl_mic:** Ligand B (6.104) has a much lower microsomal clearance than Ligand A (47.031), suggesting better metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand B (-7.355) has a much longer in vitro half-life than Ligand A (-0.916). This is a substantial benefit for Ligand B.
14. **Pgp:** Ligand A (0.1) has lower P-gp efflux than Ligand B (0.039), which is slightly better.
15. **Affinity:** Ligand A (-6.2 kcal/mol) has a slightly better binding affinity than Ligand B (-4.8 kcal/mol). This is a 1.4 kcal/mol difference, which is significant.
**GPCR-Specific Priorities:** For ADRB2 (a cardiovascular GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A excels in logP and affinity, while Ligand B has better metabolic stability (Cl_mic) and half-life. The DILI risk for Ligand A is also much lower. The Caco-2 and solubility are poor for both.
**Overall Assessment:**
While Ligand B has better metabolic stability and half-life, the significantly lower DILI risk and better affinity of Ligand A, combined with its more favorable logP, make it the more promising candidate. The difference in affinity is substantial enough to outweigh the metabolic concerns, which can be addressed through further optimization. The poor Caco-2 and solubility are shared issues that would need to be addressed regardless of which lead is chosen.
Output:
1
2025-04-17 18:08:04,056 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [357.435, 86.45, 2.718, 1, 7, 0.85, 68.903, 74.758, -4.443, -4.556, 0.699, 56.094, -11.222, 0.187, -8]
**Ligand B:** [351.411, 136.23, 0.988, 2, 6, 0.368, 20.783, 35.207, -5.796, -0.508, 0.073, 16.261, 25.155, 0.004, -6.1]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal 200-500 Da range. A (357.435) is slightly higher than B (351.411), but the difference isn't significant.
2. **TPSA:** A (86.45) is excellent, well below the 140 threshold and good for oral absorption. B (136.23) is higher, but still acceptable, though less optimal.
3. **logP:** A (2.718) is optimal. B (0.988) is a bit low, potentially hindering permeability.
4. **HBD:** A (1) is good. B (2) is acceptable.
5. **HBA:** A (7) is good. B (6) is good.
6. **QED:** A (0.85) is very good, indicating high drug-likeness. B (0.368) is significantly lower, suggesting potential issues.
7. **DILI:** A (68.903) is moderately high, but manageable. B (20.783) is excellent, indicating very low liver injury risk.
8. **BBB:** A (74.758) is good, suggesting reasonable brain penetration. B (35.207) is low, indicating poor brain penetration. While ADRB2 isn't *necessarily* a CNS target, some peripheral ADRB2 activity can be modulated by CNS effects, and higher BBB is generally favorable.
9. **Caco-2:** A (-4.443) is a negative value, which is unusual and potentially problematic, suggesting poor permeability. B (-5.796) is also negative and problematic, but slightly worse.
10. **Solubility:** A (-4.556) is very poor. B (-0.508) is also poor, but better than A.
11. **hERG:** A (0.699) is good, low risk of cardiotoxicity. B (0.073) is excellent, very low risk.
12. **Cl_mic:** A (56.094) is moderate. B (16.261) is low, indicating better metabolic stability.
13. **t1/2:** A (-11.222) is very negative, indicating very short half-life. B (25.155) is positive, indicating a longer half-life.
14. **Pgp:** A (0.187) is good, suggesting low efflux. B (0.004) is excellent, very low efflux.
15. **Affinity:** A (-8) is significantly better than B (-6.1), a difference of 1.9 kcal/mol. This is a substantial advantage.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. A has a better logP and Pgp, and *much* better affinity. B has a better DILI profile and metabolic stability. However, the affinity difference is substantial. The poor solubility and short half-life of A are concerning, but can potentially be addressed with formulation strategies. The low QED and poor permeability of B are more difficult to overcome.
**Conclusion:**
Despite the drawbacks of Ligand A, the significantly stronger binding affinity (-8 kcal/mol vs -6.1 kcal/mol) is a major advantage that outweighs the other issues, especially considering the potential for optimization of solubility and half-life. The superior affinity is likely to translate into greater efficacy.
Output:
1
2025-04-17 18:08:04,057 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 drug candidates. ADRB2 is a GPCR, so we'll prioritize logP, Pgp, TPSA, and affinity, alongside general drug-like properties.
**Ligand A:**
* **MW:** 371.821 Da - Good, within the ideal range.
* **TPSA:** 120.52 - Acceptable, but approaching the upper limit for good oral absorption.
* **logP:** 0.218 - Low. This is a significant concern, potentially leading to poor membrane permeability.
* **HBD:** 4 - Acceptable.
* **HBA:** 5 - Acceptable.
* **QED:** 0.365 - Below the preferred threshold of 0.5, indicating a less drug-like profile.
* **DILI:** 38.736 - Good, low risk.
* **BBB:** 30.554 - Low. Not a major concern for a non-CNS target like ADRB2, but not ideal.
* **Caco-2:** -5.602 - Very poor permeability. Consistent with the low logP.
* **Solubility:** -2.156 - Poor solubility.
* **hERG:** 0.101 - Low risk.
* **Cl_mic:** -1.747 - Negative clearance is unusual and likely an error. Assuming it's low, it's a positive.
* **t1/2:** 21.067 - Good in vitro half-life.
* **Pgp:** 0.032 - Low efflux, which is good.
* **Affinity:** -7.3 kcal/mol - Excellent binding affinity.
**Ligand B:**
* **MW:** 353.467 Da - Good, within the ideal range.
* **TPSA:** 91.16 - Excellent, well within the desired range for good absorption.
* **logP:** 1.685 - Good, within the optimal range.
* **HBD:** 1 - Acceptable.
* **HBA:** 8 - Acceptable.
* **QED:** 0.505 - Meets the threshold for a good drug-like profile.
* **DILI:** 42.769 - Good, low risk.
* **BBB:** 75.184 - Good, potentially useful if CNS effects are desired or need to be avoided.
* **Caco-2:** -4.768 - Moderate permeability.
* **Solubility:** -2.347 - Poor solubility.
* **hERG:** 0.093 - Low risk.
* **Cl_mic:** 67.565 - High metabolic clearance, a significant drawback.
* **t1/2:** -20.285 - Very short half-life, a major concern.
* **Pgp:** 0.115 - Low efflux, which is good.
* **Affinity:** -5.0 kcal/mol - Good binding affinity, but significantly weaker than Ligand A.
**Comparison and Decision:**
Ligand A has a much stronger binding affinity (-7.3 kcal/mol vs -5.0 kcal/mol), which is a crucial factor for GPCRs. However, its extremely low logP and poor Caco-2 permeability are major liabilities. Ligand B has better physicochemical properties (logP, TPSA, QED) and acceptable permeability, but its high metabolic clearance and short half-life are substantial drawbacks.
Despite the superior affinity of Ligand A, the poor ADME properties, particularly the low logP, are likely to translate into very poor oral bioavailability. While medicinal chemistry efforts could potentially improve the logP of Ligand A, the magnitude of the change needed is significant. Ligand B, while having a weaker affinity, presents a more tractable starting point for optimization, as addressing metabolic stability and half-life are often more achievable than drastically altering logP while maintaining potency.
Considering the balance of properties and the potential for optimization, I believe Ligand B is the more viable starting point for a drug candidate.
Output:
0
2025-04-17 18:08:04,057 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [366.38 , 87.66 , 1.27 , 3. , 4. , 0.661, 26.987, 71.966, -4.645, -1.79 , 0.356, 8.265, -19.493, 0.017, -5.7 ]
**Ligand B:** [350.463, 76.46 , 1.368, 1. , 5. , 0.806, 33.307, 73.517, -4.531, -2.212, 0.347, 33.324, 2.062, 0.057, -6.7 ]
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand B (350.463) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are good, below the 140 A^2 threshold for oral absorption. Ligand B (76.46) is better than Ligand A (87.66).
3. **logP:** Both are within the optimal range (1-3). Very similar values.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (1), but both are acceptable.
5. **HBA:** Ligand A (4) is lower than Ligand B (5), which is slightly preferable.
6. **QED:** Both are above 0.5, indicating good drug-likeness. Ligand B (0.806) is better than Ligand A (0.661).
7. **DILI:** Ligand A (26.987) has a significantly lower DILI risk than Ligand B (33.307). This is a major advantage.
8. **BBB:** Both have good BBB penetration (>70). Ligand B (73.517) is slightly higher.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. Ligand A (-4.645) is slightly better than Ligand B (-4.531).
10. **Solubility:** Both have negative solubility values, indicating poor solubility. Ligand A (-1.79) is slightly better than Ligand B (-2.212).
11. **hERG:** Both have low hERG risk. Very similar values.
12. **Cl_mic:** Ligand A (8.265) has significantly lower microsomal clearance than Ligand B (33.324), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-19.493) has a much longer in vitro half-life than Ligand B (2.062). This is a significant advantage.
14. **Pgp:** Both have very low Pgp efflux liability.
15. **Binding Affinity:** Ligand B (-6.7) has a stronger binding affinity than Ligand A (-5.7) by 1 kcal/mol.
**GPCR-specific priorities:** For ADRB2 (a GPCR), we prioritize logP, Pgp, TPSA, and affinity, and BBB. Ligand B has slightly better TPSA, BBB, and significantly better affinity. However, Ligand A has a much better safety profile (DILI), metabolic stability (Cl_mic, t1/2), and solubility. The 1 kcal/mol difference in affinity is not substantial enough to outweigh the significant advantages of Ligand A in terms of safety and PK.
**Conclusion:**
Considering the balance of properties, especially the lower DILI risk, better metabolic stability, and longer half-life of Ligand A, it is the more promising drug candidate.
Output:
1
2025-04-17 18:08:04,057 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [345.359, 136.47 , 0.262, 5. , 7. , 0.506, 67.778, 11.671, -5.798, -3.37 , 0.335, 14.579, -0.257, 0.029, -7.6 ]**
**Ligand B: [338.415, 106.75 , 2.436, 3. , 7. , 0.635, 59.907, 59.519, -5.386, -3.138, 0.828, 67.033, 13.368, 0.089, -6.4 ]**
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (345.359) is slightly higher than Ligand B (338.415), but both are acceptable.
2. **TPSA:** Ligand A (136.47) is slightly above the preferred <140 for good oral absorption, but still reasonable. Ligand B (106.75) is excellent, well below 140. This favors Ligand B.
3. **logP:** Ligand A (0.262) is quite low, potentially hindering permeability. Ligand B (2.436) is within the optimal 1-3 range. This strongly favors Ligand B.
4. **H-Bond Donors:** Ligand A (5) is at the upper limit of the preferred range. Ligand B (3) is better. This favors Ligand B.
5. **H-Bond Acceptors:** Both ligands have 7 H-bond acceptors, which is acceptable.
6. **QED:** Both ligands have acceptable QED values (A: 0.506, B: 0.635), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (67.778) has a higher DILI risk than Ligand B (59.907), though both are in the moderate risk range. This favors Ligand B.
8. **BBB:** Ligand A (11.671) has very low BBB penetration. Ligand B (59.519) is better, but still not ideal for a CNS target. Since ADRB2 is primarily a cardiovascular target, BBB isn't a *major* concern, but it's still a positive for B.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. This is a concern for both.
10. **Aqueous Solubility:** Both ligands have very poor aqueous solubility (-3.37 and -3.138). This is a significant drawback for both, potentially impacting bioavailability.
11. **hERG:** Ligand A (0.335) has a slightly lower hERG risk than Ligand B (0.828), which is favorable.
12. **Microsomal Clearance:** Ligand B (67.033) has a lower microsomal clearance than Ligand A (14.579), indicating better metabolic stability. This favors Ligand B.
13. **In vitro Half-Life:** Ligand B (13.368) has a significantly longer in vitro half-life than Ligand A (-0.257), which is a major advantage.
14. **P-gp Efflux:** Ligand A (0.029) has very low P-gp efflux, which is good. Ligand B (0.089) is slightly higher, but still acceptable.
15. **Binding Affinity:** Ligand A (-7.6) has a slightly better binding affinity than Ligand B (-6.4), a difference of 1.2 kcal/mol.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand B is the stronger candidate. While Ligand A has slightly better affinity, Ligand B demonstrates significantly better physicochemical properties (logP, TPSA, solubility, metabolic stability, half-life) and a lower DILI risk. The poor solubility of both is a concern, but the other advantages of Ligand B outweigh the slight affinity difference. The low logP of Ligand A is a major drawback for oral bioavailability.
Output:
0
2025-04-17 18:08:04,057 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (370.368 and 359.495 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (55.2) is significantly better than Ligand A (96.89). ADRB2 is a GPCR, and lower TPSA generally improves permeability. Ligand B is well below the 140 threshold.
3. **logP:** Ligand B (3.237) is closer to the optimal range of 1-3 than Ligand A (0.364). Ligand A's logP is quite low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (3) is acceptable, while Ligand B (0) is even better, minimizing potential issues with hydrogen bonding and metabolic liabilities.
5. **HBA:** Both ligands have 5 HBA, which is within the acceptable range.
6. **QED:** Ligand B (0.727) has a higher QED score than Ligand A (0.573), indicating a more drug-like profile.
7. **DILI:** Ligand A (23.304) has a much lower DILI risk than Ligand B (47.654). This is a significant advantage for Ligand A.
8. **BBB:** Ligand B (87.127) shows significantly better BBB penetration than Ligand A (61.07). While ADRB2 isn't necessarily a CNS target, some peripheral ADRB2 activity can influence CNS pathways, and better BBB penetration isn't necessarily a negative.
9. **Caco-2:** Ligand A (-5.228) and Ligand B (-4.942) are both negative, which is not ideal. This suggests poor permeability.
10. **Solubility:** Ligand A (-1.544) is slightly better than Ligand B (-4.255). Solubility is important, but not the primary concern here.
11. **hERG:** Ligand A (0.35) has a lower hERG risk than Ligand B (0.617), which is crucial for cardiovascular targets.
12. **Cl_mic:** Ligand A (6.013) has a much lower microsomal clearance than Ligand B (82.182), indicating better metabolic stability. This is a major advantage for Ligand A.
13. **t1/2:** Ligand B (17.213) has a longer in vitro half-life than Ligand A (4.253). This is a positive for Ligand B.
14. **Pgp:** Ligand A (0.023) has a much lower P-gp efflux liability than Ligand B (0.704). Lower P-gp efflux is generally desirable for better oral bioavailability.
15. **Binding Affinity:** Ligand B (-6.8 kcal/mol) has a slightly better binding affinity than Ligand A (-5.9 kcal/mol). This is a 0.9 kcal/mol difference, which is substantial.
**Overall Assessment:**
Ligand B has a superior binding affinity and longer half-life, and better BBB penetration. However, Ligand A excels in key ADME properties: lower DILI risk, significantly lower microsomal clearance, and lower P-gp efflux. The lower logP and higher TPSA of Ligand A are concerning, but the substantial advantage in metabolic stability (Cl_mic) and safety (DILI, hERG) outweigh these drawbacks, especially considering the moderate affinity difference. For a cardiovascular target, minimizing off-target effects (hERG) and ensuring metabolic stability are paramount.
Output:
1
2025-04-17 18:08:04,057 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A:** [344.43 , 45.59 , 3.359, 1. , 4. , 0.862, 30.942, 88.135, -4.652, -2.013, 0.964, 21.757, 53.929, 0.776, -5.9 ]
**Ligand B:** [354.495, 81.75 , 0.596, 2. , 4. , 0.563, 9.655, 55.176, -5.27 , -1.104, 0.248, 2.585, 0.418, 0.006, -5.5 ]
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). A is 344.43, B is 354.495. No significant difference.
**2. TPSA:** Ligand A (45.59) is well below the 140 threshold and is favorable. Ligand B (81.75) is higher, but still acceptable, though less ideal.
**3. logP:** Ligand A (3.359) is within the optimal range (1-3). Ligand B (0.596) is quite low, potentially hindering permeability. This is a significant drawback for a GPCR target.
**4. H-Bond Donors:** Ligand A (1) is good. Ligand B (2) is acceptable.
**5. H-Bond Acceptors:** Both ligands have 4 H-bond acceptors, which is within the acceptable range.
**6. QED:** Ligand A (0.862) is excellent, indicating high drug-likeness. Ligand B (0.563) is acceptable, but lower.
**7. DILI:** Ligand A (30.942) has a very low DILI risk. Ligand B (9.655) also has a low DILI risk, but slightly higher than A.
**8. BBB:** Ligand A (88.135) shows good BBB penetration potential. Ligand B (55.176) is lower, and less likely to cross the BBB.
**9. Caco-2:** Ligand A (-4.652) is unfavorable. Ligand B (-5.27) is also unfavorable, but slightly worse.
**10. Solubility:** Ligand A (-2.013) is unfavorable. Ligand B (-1.104) is also unfavorable, but slightly better.
**11. hERG:** Both ligands have low hERG inhibition risk (0.964 and 0.248 respectively).
**12. Cl_mic:** Ligand A (21.757) has a moderate clearance. Ligand B (2.585) has a very low clearance, suggesting better metabolic stability.
**13. t1/2:** Ligand A (53.929) has a reasonable half-life. Ligand B (0.418) has a very short half-life, which is a major concern.
**14. Pgp:** Ligand A (0.776) has moderate P-gp efflux. Ligand B (0.006) has very low P-gp efflux, which is favorable.
**15. Binding Affinity:** Both ligands have very good binding affinity (-5.9 and -5.5 kcal/mol). The difference is relatively small.
**GPCR-Specific Considerations:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are crucial. Ligand A has a much better logP value, and better BBB penetration. Ligand B has better metabolic stability and lower Pgp efflux, but the poor logP and BBB penetration are significant drawbacks. The slightly better metabolic stability of B is unlikely to outweigh the permeability issues.
**Conclusion:**
Ligand A is the more promising candidate. While Ligand B has advantages in metabolic stability and Pgp efflux, the significantly better logP and BBB penetration of Ligand A are more critical for a GPCR target like ADRB2. The affinity difference is minor.
**Output:**
1
2025-04-17 18:08:04,058 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (a cardiovascular GPCR) drug candidates.
**Ligand A:** [364.433, 78.87, 1.418, 2, 4, 0.649, 11.361, 65.878, -4.823, -1.356, 0.489, 24.631, -6.011, 0.08, -6.6]
**Ligand B:** [362.495, 49.85, 2.687, 0, 4, 0.813, 49.632, 77.007, -4.443, -2.752, 0.458, 45.14, 36.703, 0.214, -6.3]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). A: 364.433, B: 362.495 - very similar.
2. **TPSA:** A (78.87) is higher than B (49.85). Both are acceptable for a cardiovascular target, but B is better, being closer to the ideal for good absorption.
3. **logP:** A (1.418) is good, B (2.687) is also good. Both are within the optimal 1-3 range.
4. **HBD:** A (2) is reasonable, B (0) is excellent. Fewer HBDs generally improve permeability.
5. **HBA:** Both A (4) and B (4) are acceptable.
6. **QED:** A (0.649) is good, B (0.813) is better, indicating a more drug-like profile.
7. **DILI:** A (11.361) is significantly better than B (49.632). This is a major advantage for A.
8. **BBB:** A (65.878) is lower than B (77.007). While not a primary concern for a cardiovascular target, B is slightly better.
9. **Caco-2:** A (-4.823) is worse than B (-4.443). Lower values indicate lower permeability.
10. **Solubility:** A (-1.356) is better than B (-2.752). Solubility is important for bioavailability.
11. **hERG:** Both A (0.489) and B (0.458) are low, indicating minimal hERG inhibition risk. Very similar.
12. **Cl_mic:** A (24.631) is much better than B (45.14). Lower clearance means better metabolic stability.
13. **t1/2:** A (-6.011) is better than B (36.703). Negative values indicate longer half-life.
14. **Pgp:** A (0.08) is significantly better than B (0.214). Lower P-gp efflux is desirable.
15. **Affinity:** A (-6.6) is slightly better than B (-6.3), but the difference is relatively small.
**GPCR-specific priorities:** For ADRB2 (a cardiovascular GPCR), logP, TPSA, Pgp, and affinity are key. While BBB is less critical for a cardiovascular target, it's still a consideration.
**Overall Assessment:**
Ligand A has a significantly better DILI score, lower microsomal clearance (better metabolic stability), longer half-life, and lower P-gp efflux. These are substantial advantages. While Ligand B has a slightly better TPSA and BBB penetration, the ADME properties of A are far superior. The binding affinity difference is small enough to be outweighed by the ADME benefits of A.
Therefore, I prefer Ligand A.
Output:
1
2025-04-17 18:08:04,058 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [366.849, 78.67, 0.766, 1, 5, 0.853, 39.511, 71.19, -4.862, -1.812, 0.272, 19.758, -2.78, 0.148, -6.8]
**Ligand B:** [365.518, 49.25, 4.095, 1, 5, 0.689, 17.449, 73.905, -4.845, -3.016, 0.948, 40.605, 67.778, 0.837, -6.9]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). A: 366.849, B: 365.518 - very similar.
2. **TPSA:** A (78.67) is higher than B (49.25). B is better, being closer to the <140 threshold for oral absorption, and more favorable for GPCRs.
3. **logP:** A (0.766) is lower than B (4.095). B is significantly higher, potentially causing solubility issues and off-target effects. A is better here.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Both have 5 HBA, which is good.
6. **QED:** A (0.853) is better than B (0.689), indicating a more drug-like profile.
7. **DILI:** A (39.511) is higher than B (17.449). B is significantly better, indicating a lower risk of liver injury.
8. **BBB:** Both are reasonably good, but B (73.905) is slightly better than A (71.19). For a cardiovascular GPCR, BBB isn't a *major* priority, but it's a bonus.
9. **Caco-2:** Both are negative, indicating poor permeability. A (-4.862) is slightly worse than B (-4.845).
10. **Solubility:** A (-1.812) is better than B (-3.016). B's higher logP is likely contributing to its lower solubility.
11. **hERG:** A (0.272) is much better than B (0.948). This is a critical factor; lower hERG inhibition is crucial to avoid cardiotoxicity.
12. **Cl_mic:** A (19.758) is significantly lower than B (40.605), indicating better metabolic stability.
13. **t1/2:** B (67.778) has a much longer half-life than A (-2.78). This is a significant advantage for dosing convenience.
14. **Pgp:** A (0.148) is much better than B (0.837), suggesting less efflux and better bioavailability.
15. **Affinity:** B (-6.9) is slightly better than A (-6.8), but the difference is minimal.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. B has a better TPSA and slightly better affinity and BBB, but a significantly worse logP, Pgp, and hERG. A has a better logP, QED, DILI, hERG, Cl_mic, and Pgp. The hERG risk with B is concerning. While B has a longer half-life, the other factors weigh more heavily in favor of A.
**Conclusion:**
Considering the balance of properties, especially the crucial hERG risk and metabolic stability, **Ligand A** is the more promising drug candidate.
1
2025-04-17 18:08:04,058 - INFO - Batch 15 complete. Total preferences: 240
2025-04-17 18:08:04,058 - INFO - Processing batch 16/512...
2025-04-17 18:08:56,326 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (353.39 Da and 348.443 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Both ligands (73.86 and 76.66) are below the 140 A^2 threshold for good oral absorption, which is good.
**3. logP:** Both ligands have good logP values (3.016 and 2.158) falling within the optimal 1-3 range. Ligand A is slightly higher, potentially offering better membrane permeability.
**4. H-Bond Donors & Acceptors:** Ligand A (1 HBD, 6 HBA) and Ligand B (2 HBD, 4 HBA) both have acceptable numbers of hydrogen bond donors and acceptors.
**5. QED:** Both ligands have reasonable QED scores (0.76 and 0.635), indicating good drug-like properties.
**6. DILI Risk:** Ligand B (36.06) has a significantly lower DILI risk than Ligand A (63.552), which is a major advantage. Lower DILI is crucial for drug development.
**7. BBB Penetration:** ADRB2 is a cardiovascular target, so BBB penetration is not a primary concern. However, Ligand A (86.08) shows better BBB penetration than Ligand B (55.797).
**8. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.025) is slightly better than Ligand B (-4.653).
**9. Aqueous Solubility:** Both ligands have negative solubility values, indicating poor aqueous solubility. Ligand B (-2.984) is slightly better than Ligand A (-4.679).
**10. hERG Inhibition:** Both ligands have low hERG inhibition risk (0.625 and 0.438), which is good.
**11. Microsomal Clearance:** Ligand B (55.788) has significantly lower microsomal clearance than Ligand A (112.525), suggesting better metabolic stability.
**12. In vitro Half-Life:** Ligand B (-31.029) has a significantly longer in vitro half-life than Ligand A (42.943), which is a major advantage.
**13. P-gp Efflux:** Both ligands have low P-gp efflux liability (0.435 and 0.087), which is favorable. Ligand B is better.
**14. Binding Affinity:** Both ligands have similar and strong binding affinities (-5.4 and -5.7 kcal/mol). The difference is negligible.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity) and general drug-like properties, Ligand B emerges as the more promising candidate. While Ligand A has slightly better logP and Caco-2 permeability, Ligand B's substantially lower DILI risk, better metabolic stability (lower Cl_mic and longer t1/2), and lower P-gp efflux outweigh these minor advantages. The similar binding affinities make the ADME properties the deciding factor.
Output:
0
2025-04-17 18:08:56,327 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (403.211 Da) and Ligand B (364.471 Da) both fall within the ideal 200-500 Da range. Ligand B is slightly preferable due to being a bit lower in MW.
2. **TPSA:** Both ligands (A: 94.02, B: 92.26) are below the 140 A^2 threshold for good oral absorption, but higher than the 90 A^2 for CNS targets. This is acceptable for a cardiovascular target like ADRB2, where CNS penetration isn't necessarily desired. They are very close and don't differentiate.
3. **logP:** Ligand A (3.025) is optimal, while Ligand B (1.254) is at the lower end of the optimal range. For a GPCR, a higher logP is generally favored for membrane permeability, giving a slight edge to Ligand A.
4. **HBD:** Ligand A (3) and Ligand B (1) are both within the acceptable limit of <=5. Ligand B is preferable here.
5. **HBA:** Ligand A (3) and Ligand B (6) are both within the acceptable limit of <=10. Ligand A is preferable here.
6. **QED:** Both ligands have good QED scores (A: 0.736, B: 0.82), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (92.788%) has a significantly higher DILI risk than Ligand B (45.909%). This is a major concern, and strongly favors Ligand B.
8. **BBB:** Both have moderate BBB penetration (A: 65.374%, B: 62.35%). Since ADRB2 is primarily a cardiovascular target, high BBB penetration is not a priority.
9. **Caco-2:** Ligand A (-4.839) and Ligand B (-5.279) have negative Caco-2 values. This is unusual and suggests poor permeability. Ligand B is slightly better.
10. **Solubility:** Ligand A (-6.253) and Ligand B (-1.881) have negative solubility values. This is a concern for both. Ligand B is better.
11. **hERG:** Ligand A (0.777) and Ligand B (0.041) both have low hERG inhibition liability, which is good. Ligand B is significantly better.
12. **Cl_mic:** Both ligands have similar microsomal clearance (A: 25.624, B: 24.871). This is acceptable, but lower is better.
13. **t1/2:** Ligand A (96.61) has a much longer in vitro half-life than Ligand B (-22.53). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.231) has lower P-gp efflux liability than Ligand B (0.063), which is preferable.
15. **Binding Affinity:** Ligand B (-7.6 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.6 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME concerns.
**Overall Assessment:**
Ligand B is the stronger candidate. While Ligand A has a longer half-life and slightly better logP, Ligand B has a much lower DILI risk and significantly better binding affinity. The lower DILI risk and improved potency are critical advantages, outweighing the shorter half-life. The solubility and Caco-2 values are concerning for both, but can be addressed through formulation strategies.
Output:
0
2025-04-17 18:08:56,327 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (332.367 Da) is slightly lower, which is generally favorable for permeability.
**2. TPSA:** Ligand B (67.87) is significantly better than Ligand A (88.49). ADRB2 is a cardiovascular target, not a CNS target, but lower TPSA generally improves absorption.
**3. logP:** Both ligands have acceptable logP values (Ligand A: 2.002, Ligand B: 0.91). Ligand A is slightly better, falling more centrally within the optimal 1-3 range. Ligand B is a bit low, potentially hindering permeation.
**4. H-Bond Donors:** Both are acceptable (Ligand A: 2, Ligand B: 1).
**5. H-Bond Acceptors:** Both are acceptable (Ligand A: 5, Ligand B: 5).
**6. QED:** Both have good QED scores (Ligand A: 0.585, Ligand B: 0.795). Ligand B is slightly better, indicating a more drug-like profile.
**7. DILI Risk:** Ligand B (49.942) has a much lower DILI risk than Ligand A (80.651). This is a significant advantage.
**8. BBB Penetration:** This is less critical for a cardiovascular target. Ligand B (83.637) is higher, but the difference isn't decisive.
**9. Caco-2 Permeability:** Both are negative, indicating poor permeability. Ligand A (-5.637) is slightly better than Ligand B (-5.067).
**10. Aqueous Solubility:** Both are negative, indicating poor solubility. They are very similar (-3.416 vs -3.355).
**11. hERG Inhibition:** Both have low hERG inhibition risk (Ligand A: 0.473, Ligand B: 0.214). Ligand B is slightly better.
**12. Microsomal Clearance:** Ligand A (37.333) has lower clearance than Ligand B (45.43), suggesting better metabolic stability.
**13. In vitro Half-Life:** Ligand B (-14.196) has a significantly longer half-life than Ligand A (-8.325). This is a major advantage.
**14. P-gp Efflux:** Both are low (Ligand A: 0.152, Ligand B: 0.055). Ligand B is slightly better.
**15. Binding Affinity:** Ligand B (-7.5 kcal/mol) has a slightly better binding affinity than Ligand A (-6.6 kcal/mol). This is a 1.1 kcal/mol difference, which is substantial enough to be a key factor.
**Overall Assessment:**
While Ligand A has a slightly better logP and Caco-2 permeability, Ligand B excels in several critical areas: significantly lower DILI risk, a much longer half-life, and a stronger binding affinity. The lower TPSA of Ligand B is also beneficial. Considering the GPCR-specific priorities (affinity, logP, Pgp, TPSA), and the overall balance of properties, Ligand B is the more promising drug candidate.
Output:
0
2025-04-17 18:08:56,327 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (362.901 and 364.511 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (52.57) is better than Ligand B (58.64). Both are below 140, but lower is generally preferred for absorption.
3. **logP:** Ligand A (3.987) is slightly higher than Ligand B (2.46). Both are within the 1-3 optimal range, but Ligand A is closer to the upper limit, which could pose solubility issues.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1). Both are within the acceptable limit of 5.
5. **HBA:** Ligand B (4) is higher than Ligand A (2). Both are within the acceptable limit of 10.
6. **QED:** Both ligands have similar QED values (0.778 and 0.771), indicating good drug-likeness.
7. **DILI:** Ligand B (13.843) has a significantly lower DILI risk than Ligand A (17.642). This is a major advantage for Ligand B.
8. **BBB:** Ligand B (74.952) has a slightly higher BBB penetration than Ligand A (69.833). While ADRB2 isn't strictly a CNS target, some CNS exposure can occur, and higher BBB is generally favorable.
9. **Caco-2:** Ligand A (-4.596) has a better Caco-2 permeability than Ligand B (-5.129). Higher values indicate better absorption.
10. **Solubility:** Ligand B (-2.48) has better aqueous solubility than Ligand A (-3.901). This is a positive for bioavailability.
11. **hERG:** Ligand A (0.807) has a slightly higher hERG inhibition liability than Ligand B (0.448). Lower is better.
12. **Cl_mic:** Ligand A (1.71) has significantly lower microsomal clearance than Ligand B (30.369). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (20.815) has a much longer in vitro half-life than Ligand B (10.011). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand B (0.06) has much lower P-gp efflux liability than Ligand A (0.441). This is a positive for bioavailability.
15. **Binding Affinity:** Both ligands have similar binding affinities (-6.0 and -5.2 kcal/mol). Ligand A is slightly better, but the difference isn't substantial enough to outweigh other factors.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are important. Ligand A has a slightly better logP and affinity, but Ligand B excels in Pgp efflux and has a more favorable TPSA. The significant advantage of Ligand B in DILI risk and solubility, coupled with acceptable BBB penetration, makes it a more promising candidate. While Ligand A has better metabolic stability (lower Cl_mic and longer t1/2), the DILI risk is a major concern.
**Conclusion:**
Considering the balance of properties and the GPCR-specific priorities, Ligand B appears to be the more viable drug candidate. The lower DILI risk and better solubility are crucial advantages that outweigh the slightly better metabolic stability of Ligand A.
Output:
0
2025-04-17 18:08:56,327 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [354.466, 69.64, 2.195, 2, 3, 0.719, 24.312, 81.698, -4.688, -2.931, 0.397, 61.485, -18.156, 0.216, -6.4]
**Ligand B:** [366.487, 91.4, 1.583, 2, 5, 0.764, 37.456, 66.576, -5.176, -3.392, 0.348, 35.017, -11.985, 0.028, -5.9]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal 200-500 Da range. A (354.466) is slightly better.
2. **TPSA:** A (69.64) is significantly better than B (91.4). Below 140 is good for oral absorption, and A is closer to the lower end, which is beneficial.
3. **logP:** Both are good (between 1-3), but A (2.195) is slightly higher than B (1.583). A bit higher logP is generally preferred for GPCRs.
4. **HBD:** Both have 2 HBD, which is acceptable.
5. **HBA:** A (3) is better than B (5). Lower HBA is generally preferred for permeability.
6. **QED:** Both are good (>0.5), A (0.719) is slightly better than B (0.764).
7. **DILI:** A (24.312) is *much* better than B (37.456). This is a significant advantage for A.
8. **BBB:** A (81.698) is significantly better than B (66.576). While not a primary concern for all GPCRs, higher BBB penetration is always a plus, and can be crucial depending on the desired therapeutic effect.
9. **Caco-2:** A (-4.688) is better than B (-5.176). Higher Caco-2 values indicate better absorption.
10. **Solubility:** A (-2.931) is better than B (-3.392). Higher solubility is desirable.
11. **hERG:** Both are very low (0.397 and 0.348), indicating low cardiotoxicity risk.
12. **Cl_mic:** A (61.485) is higher than B (35.017), meaning B has better metabolic stability. This is a point in favor of B.
13. **t1/2:** A (-18.156) is better than B (-11.985), indicating a longer half-life.
14. **Pgp:** A (0.216) is better than B (0.028), meaning A is a weaker P-gp substrate.
15. **Affinity:** Both are excellent (-6.4 and -5.9 kcal/mol). A (-6.4) is slightly better, but the difference is not huge.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical parameters, especially DILI risk, BBB penetration, TPSA, and Pgp efflux. While Ligand B has slightly better metabolic stability (lower Cl_mic), the other advantages of Ligand A, particularly the significantly lower DILI risk and better BBB penetration, outweigh this single benefit. The slightly better affinity of A is also a plus. Given the GPCR target class, the balance of properties in Ligand A makes it a more promising drug candidate.
Output:
1
2025-04-17 18:08:56,327 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [375.255, 75.35, 4.192, 3, 3, 0.599, 75.339, 57.58, -4.844, -4.745, 0.885, 20.496, 97.124, 0.615, -8.4]
**Ligand B:** [374.457, 78.35, 2.157, 2, 6, 0.765, 40.597, 69.639, -5.097, -2.679, 0.34, 24.233, -1.013, 0.233, -6]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity):
1. **MW:** Both are within the ideal 200-500 Da range. A is 375.255, B is 374.457 - very similar.
2. **TPSA:** A is 75.35, B is 78.35. Both are acceptable for a non-CNS GPCR target like ADRB2, being under 140.
3. **logP:** A is 4.192, B is 2.157. A is pushing the upper limit and could have solubility issues. B is within the optimal range. This favors B.
4. **HBD/HBA:** A has 3/3, B has 2/6. Both are reasonable, but B's higher HBA count *could* slightly improve solubility.
5. **QED:** A is 0.599, B is 0.765. B has a better drug-likeness score.
6. **DILI:** A is 75.339, B is 40.597. B has significantly lower DILI risk, a major advantage.
7. **BBB:** A is 57.58, B is 69.639. Not a primary concern for ADRB2 (cardiovascular target), but B is better.
8. **Caco-2:** A is -4.844, B is -5.097. Both are very poor, indicating poor absorption.
9. **Solubility:** A is -4.745, B is -2.679. B has better solubility, which is important given A's higher logP.
10. **hERG:** A is 0.885, B is 0.34. B shows much lower hERG inhibition liability, a critical safety parameter.
11. **Cl_mic:** A is 20.496, B is 24.233. Both are relatively high, indicating faster metabolism.
12. **t1/2:** A is 97.124, B is -1.013. A has a significantly longer in vitro half-life, which is a big plus.
13. **Pgp:** A is 0.615, B is 0.233. B shows lower P-gp efflux, which is favorable for bioavailability.
14. **Affinity:** A is -8.4 kcal/mol, B is -6 kcal/mol. A has a *substantially* stronger binding affinity (2.4 kcal/mol difference). This is a significant advantage that could outweigh some of the ADME drawbacks.
**Overall Assessment:**
Ligand A has a much stronger binding affinity, which is a major driver for GPCR drug candidates. However, it has a higher logP, poorer solubility, and a higher DILI risk. Ligand B is more balanced across ADME properties, with better solubility, lower DILI and hERG risk, and lower P-gp efflux. The difference in affinity is substantial, and for a GPCR, potency is often paramount. The longer half-life of A is also a benefit. While B has better ADME properties, the significant potency advantage of A is likely to be more important for *in vivo* efficacy.
Therefore, I would choose Ligand A.
1
2025-04-17 18:08:56,327 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (395.874) is slightly higher than Ligand B (352.41), but both are acceptable.
2. **TPSA:** Ligand A (49.33) is significantly better than Ligand B (86.63). ADRB2 is a cardiovascular target, not CNS, but lower TPSA generally improves absorption. Ligand B's TPSA is relatively high.
3. **logP:** Ligand A (4.725) is higher than Ligand B (0.822). While 4.725 is approaching the upper limit, it's still within a reasonable range. Ligand B's logP is quite low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1), both are acceptable.
5. **HBA:** Ligand A (3) is lower than Ligand B (5). This favors Ligand A, as fewer HBA generally improves permeability.
6. **QED:** Both ligands have similar and good QED values (A: 0.709, B: 0.785).
7. **DILI:** Ligand A (36.216) has a lower DILI risk than Ligand B (43.117), which is preferable.
8. **BBB:** This is less critical for a cardiovascular target. Ligand A (76.231) is better than Ligand B (62.854), but neither is exceptionally high.
9. **Caco-2:** Both ligands have very poor Caco-2 permeability (-4.609 and -4.643). This is a significant drawback for both.
10. **Solubility:** Ligand A (-5.584) is slightly better than Ligand B (-0.543), but both are poor. Solubility is a concern for both.
11. **hERG:** Ligand A (0.72) is better than Ligand B (0.149), indicating a lower risk of cardiotoxicity. This is crucial for a cardiovascular target.
12. **Cl_mic:** Ligand A (33.757) has a lower microsomal clearance than Ligand B (8.43), suggesting better metabolic stability.
13. **t1/2:** Both ligands have similar in vitro half-lives (A: 14.799, B: 14.99).
14. **Pgp:** Ligand A (0.259) has lower P-gp efflux than Ligand B (0.024), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand A (-6.9 kcal/mol) has a slightly better binding affinity than Ligand B (-5.8 kcal/mol). This difference of 1.1 kcal/mol is significant and can outweigh some ADME drawbacks.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A performs better in all these areas. While both have poor Caco-2 and solubility, the superior affinity and ADME profile of Ligand A make it a more promising candidate.
**Output:**
1
2025-04-17 18:08:56,327 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (362.813 Da and 354.535 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (76.66) is higher than Ligand B (58.64). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B is better.
3. **logP:** Both ligands (3.337 and 3.229) are within the optimal 1-3 range. Very similar.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1), but both are acceptable (<=5).
5. **HBA:** Ligand A (4) is slightly higher than Ligand B (3), but both are acceptable (<=10).
6. **QED:** Both ligands (0.818 and 0.763) have good drug-likeness scores (>0.5). Ligand A is slightly better.
7. **DILI:** Ligand A (85.537) has a significantly higher DILI risk than Ligand B (16.479). This is a major concern for Ligand A.
8. **BBB:** Ligand A (82.009) has a higher BBB penetration than Ligand B (70.609). While ADRB2 isn't a CNS target, some peripheral exposure can be undesirable. This is a slight advantage for Ligand A, but less important than DILI.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.703 and -4.474), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-4.788) has worse solubility than Ligand B (-3.314). Lower solubility can hinder bioavailability. Ligand B is better.
11. **hERG:** Both ligands (0.443 and 0.513) have relatively low hERG inhibition risk, which is good.
12. **Cl_mic:** Ligand B (88.919) has a significantly higher microsomal clearance than Ligand A (57.81). This means Ligand A is more metabolically stable.
13. **t1/2:** Ligand A (54.204) has a significantly longer half-life than Ligand B (5.13). This is a major advantage for Ligand A.
14. **Pgp:** Ligand A (0.171) has lower P-gp efflux than Ligand B (0.074), indicating better bioavailability.
15. **Binding Affinity:** Ligand A (-6.7 kcal/mol) has a slightly better binding affinity than Ligand B (-6.2 kcal/mol), but the difference is relatively small (0.5 kcal/mol).
**GPCR-specific priorities:**
For ADRB2 (a cardiovascular GPCR), logP, TPSA, Pgp, and affinity are important. However, safety (DILI, hERG) is paramount.
**Overall Assessment:**
Ligand A has better affinity, metabolic stability (lower Cl_mic), longer half-life, and lower Pgp efflux. However, its significantly higher DILI risk is a major drawback. Ligand B has a much better safety profile (DILI), better TPSA and solubility, but suffers from faster clearance and a slightly weaker binding affinity.
Given the importance of safety in drug development, and the relatively small difference in binding affinity, I favor Ligand B. The improved safety profile outweighs the slight loss in potency and metabolic stability.
Output:
0
2025-04-17 18:08:56,327 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (345.491 and 347.434 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (63.05) is higher than Ligand B (44.81). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B has a clear advantage.
3. **logP:** Both ligands (3.082 and 2.473) are within the optimal 1-3 range. Ligand B is slightly lower, which could be beneficial for solubility.
4. **HBD:** Both ligands have 1 HBD, which is acceptable.
5. **HBA:** Ligand A has 4 HBAs, while Ligand B has 3. Both are below the threshold of 10.
6. **QED:** Both ligands have very similar QED values (0.896 and 0.89), indicating good drug-likeness.
7. **DILI:** Ligand A (26.522) has a significantly lower DILI risk than Ligand B (10.741). This is a major advantage for Ligand A.
8. **BBB:** Both ligands have high BBB penetration (89.608 and 86.196). Since ADRB2 is not a CNS target, this is less important, but higher is still slightly preferable. Ligand A is slightly better.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.814 and -4.542). This is unusual and suggests poor permeability. However, these values are on a similar scale, so the difference isn't decisive.
10. **Solubility:** Ligand A (-2.521) has slightly worse solubility than Ligand B (-1.606). Solubility is important, giving a slight edge to Ligand B.
11. **hERG:** Ligand A (0.18) has a much lower hERG inhibition liability than Ligand B (0.864). This is a critical safety parameter, and Ligand A is significantly better.
12. **Cl_mic:** Ligand B (-1.244) has a significantly lower microsomal clearance than Ligand A (11.553). Lower clearance implies better metabolic stability, which is a significant advantage for Ligand B.
13. **t1/2:** Ligand A (27.038) has a longer in vitro half-life than Ligand B (8.602). This is desirable for less frequent dosing, favoring Ligand A.
14. **Pgp:** Ligand A (0.137) has lower P-gp efflux liability than Ligand B (0.068). Lower efflux is preferred, giving a slight edge to Ligand A.
15. **Binding Affinity:** Ligand A (-6.7 kcal/mol) has slightly better binding affinity than Ligand B (-6.4 kcal/mol). While the difference is small, it's still a positive for Ligand A.
**Overall Assessment & GPCR Prioritization:**
For a cardiovascular GPCR like ADRB2, the key priorities are affinity, metabolic stability, and safety. Ligand A has a slight advantage in affinity and a *substantial* advantage in both DILI risk and hERG inhibition. Ligand B has better metabolic stability (Cl_mic) and solubility, but the safety profile of Ligand A is far more compelling. The slightly longer half-life of Ligand A is also beneficial. While the Caco-2 values are concerning for both, the superior safety profile of Ligand A outweighs the benefits of Ligand B's slightly better metabolic stability and solubility.
Output:
1
2025-04-17 18:08:56,327 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [353.419, 102.17 , -0.493, 1. , 5. , 0.593, 22.993, 84.335, -5.097, -1.603, 0.192, 22.596, 7.327, 0.013, -7.4 ]
**Ligand B:** [344.371, 98.39 , 1.51 , 2. , 6. , 0.828, 71.501, 43.195, -4.911, -3.455, 0.349, -0.366, 17.809, 0.068, 1.3 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (344.371) is slightly lower, which is generally favorable.
2. **TPSA:** Both are acceptable for oral absorption (under 140). Ligand A (102.17) is slightly higher.
3. **logP:** Ligand A (-0.493) is a bit low, potentially impacting permeability. Ligand B (1.51) is within the optimal 1-3 range. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (1) is good. Ligand B (2) is also acceptable.
5. **HBA:** Ligand A (5) is good. Ligand B (6) is acceptable, but approaching the upper limit.
6. **QED:** Both have good drug-likeness scores (A: 0.593, B: 0.828). Ligand B is better.
7. **DILI:** Ligand A (22.993) has a much lower DILI risk than Ligand B (71.501). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (84.335) has a significantly higher BBB penetration potential than Ligand B (43.195). This is crucial for a GPCR target, even a cardiovascular one, as some CNS off-target effects are possible.
9. **Caco-2:** Both have negative values, indicating poor permeability. Ligand A (-5.097) is slightly worse than Ligand B (-4.911).
10. **Solubility:** Both have negative values, indicating poor solubility. Ligand A (-1.603) is slightly better than Ligand B (-3.455).
11. **hERG:** Both have low hERG risk (A: 0.192, B: 0.349).
12. **Cl_mic:** Ligand A (22.596) has higher metabolic clearance than Ligand B (-0.366), indicating lower metabolic stability. Ligand B is better.
13. **t1/2:** Ligand B (17.809) has a longer in vitro half-life than Ligand A (7.327). This is a significant advantage for Ligand B.
14. **Pgp:** Both have very low P-gp efflux liability (A: 0.013, B: 0.068).
15. **Affinity:** Ligand A (-7.4) has a significantly stronger binding affinity than Ligand B (1.3). This is a substantial advantage for Ligand A.
**GPCR-Specific Priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, BBB, and affinity are particularly important. Ligand A excels in affinity and BBB, while Ligand B has better logP and metabolic stability. The DILI risk for Ligand A is also much lower. The poor Caco-2 and solubility for both are concerning, but can potentially be addressed with formulation strategies.
**Overall Assessment:**
The stronger binding affinity of Ligand A (-7.4 kcal/mol vs 1.3 kcal/mol) is a major driver. Coupled with the significantly lower DILI risk and better BBB penetration, these advantages outweigh the slightly lower logP and higher metabolic clearance. While Ligand B has better logP and metabolic stability, the affinity difference is too large to ignore.
Output:
1
2025-04-17 18:08:56,328 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
The ADRB2 receptor is a GPCR, so the priorities are logP, TPSA, Pgp efflux, BBB penetration, and binding affinity. Let's systematically compare the ligands:
1. **Molecular Weight:** Both ligands (368.5 and 350.5 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (76.66) is significantly better than Ligand B (95.42). A TPSA under 140 is good for oral absorption, and lower is generally preferred for GPCRs. Ligand A is closer to the ideal range.
3. **logP:** Both ligands have acceptable logP values (2.337 and 1.762), falling within the 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability, but not drastically.
4. **H-Bond Donors:** Both have 2 HBD, which is within the acceptable limit of 5.
5. **H-Bond Acceptors:** Both have 5 HBA, within the acceptable limit of 10.
6. **QED:** Both have similar QED scores (0.622 and 0.67), indicating good drug-likeness.
7. **DILI:** Ligand A (38.5) has a slightly higher DILI risk than Ligand B (32.4), but both are below the concerning threshold of 60.
8. **BBB:** Ligand A (70.6) has significantly better BBB penetration than Ligand B (50.4). While ADRB2 isn't exclusively a CNS target, some peripheral effects are mediated by CNS pathways, and better BBB penetration is generally favorable.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not provided, making it difficult to interpret.
10. **Solubility:** Both have negative solubility values, which is also unusual and suggests poor solubility. Again, the scale is not provided.
11. **hERG:** Ligand A (0.594) has a slightly higher hERG risk than Ligand B (0.291), which is a concern.
12. **Cl_mic:** Ligand B (36.0) has a slightly higher microsomal clearance than Ligand A (32.3), indicating faster metabolism and potentially lower exposure.
13. **t1/2:** Ligand B (19.3) has a longer in vitro half-life than Ligand A (15.0), which is a positive attribute.
14. **Pgp:** Ligand A (0.185) has significantly lower P-gp efflux liability than Ligand B (0.054). Lower P-gp efflux is highly desirable for better oral bioavailability and potentially better CNS exposure.
15. **Binding Affinity:** Ligand A (-6.9 kcal/mol) has a slightly better binding affinity than Ligand B (-5.2 kcal/mol). This 1.7 kcal/mol difference is substantial and can often outweigh minor ADME drawbacks.
**Overall Assessment:**
Ligand A is the better candidate. While it has a slightly higher hERG risk and lower half-life, its superior TPSA, BBB penetration, P-gp efflux, and, crucially, binding affinity outweigh these drawbacks. The stronger binding affinity is a significant advantage for a GPCR target. The lower P-gp efflux also suggests better bioavailability.
Output:
1
2025-04-17 18:08:56,328 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (347.39 Da and 378.485 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (84.23) is significantly better than Ligand B (49.85). For a GPCR, lower TPSA is generally preferred for better permeability.
**3. logP:** Both ligands have a logP around 2 (2.0 and 2.107), which is optimal. No clear advantage.
**4. H-Bond Donors:** Ligand A has 2 HBD, while Ligand B has 0. Both are acceptable, but lower is generally preferred for permeability.
**5. H-Bond Acceptors:** Both ligands have 4 HBA, which is within the acceptable range.
**6. QED:** Both ligands have similar QED values (0.765 and 0.71), indicating good drug-likeness.
**7. DILI:** Ligand A (35.789) has a slightly higher DILI risk than Ligand B (31.485), but both are below the 40% threshold considered good.
**8. BBB:** Ligand B (85.731) has a much higher BBB penetration percentile than Ligand A (46.724). While ADRB2 is a cardiovascular target and doesn't *require* high BBB penetration, it's not detrimental, and could potentially allow for some central effects if desired.
**9. Caco-2 Permeability:** Ligand A (-5.034) has a lower Caco-2 permeability than Ligand B (-4.464). This suggests Ligand B may have better intestinal absorption.
**10. Aqueous Solubility:** Both ligands have poor aqueous solubility (-2.243 and -2.906). This is a concern for both, and formulation strategies might be needed.
**11. hERG Inhibition:** Ligand A (0.25) has a lower hERG inhibition risk than Ligand B (0.643), which is a significant advantage.
**12. Microsomal Clearance:** Ligand B (39.309) has a higher microsomal clearance than Ligand A (26.651), indicating faster metabolism and potentially lower *in vivo* exposure.
**13. In vitro Half-Life:** Ligand A (36.357) has a longer in vitro half-life than Ligand B (-6.872). This is a substantial advantage, suggesting more sustained exposure.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.036 and 0.191).
**15. Binding Affinity:** Both ligands have excellent binding affinity (-6.0 and -6.5 kcal/mol). Ligand B is slightly better, but the difference is relatively small.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), and the general drug-like properties, Ligand A appears to be the more promising candidate. While Ligand B has better BBB penetration and Caco-2 permeability, Ligand A has a significantly better hERG profile, longer half-life, and lower microsomal clearance. The lower TPSA of Ligand A is also a plus. The small advantage in binding affinity for Ligand B is outweighed by the superior ADME properties of Ligand A. The solubility issues are a concern for both, but can be addressed through formulation.
Output:
1
2025-04-17 18:08:56,328 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [346.387, 128.16 , -0.459, 3. , 5. , 0.575, 37.456, 35.44 ,
-5.668, -2.107, 0.051, -16.242, 10.779, 0.003, -8.5 ]
**Ligand B:** [352.475, 70.08 , 1.127, 1. , 4. , 0.827, 14.618, 52.617,
-4.482, -1.586, 0.355, 24.762, 8.339, 0.075, -6.1 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal 200-500 Da range. Ligand A (346.387) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (128.16) is higher than Ligand B (70.08). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is still preferred. Ligand B is significantly better here.
3. **logP:** Ligand A (-0.459) is quite low, potentially hindering membrane permeability. Ligand B (1.127) is within the optimal 1-3 range. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (1). Both are acceptable.
5. **HBA:** Ligand A (5) is slightly higher than Ligand B (4). Both are acceptable.
6. **QED:** Ligand B (0.827) has a better QED score than Ligand A (0.575), indicating a more drug-like profile.
7. **DILI:** Ligand A (37.456) has a slightly higher DILI risk than Ligand B (14.618), though both are reasonably low.
8. **BBB:** Ligand B (52.617) has a significantly higher BBB penetration score than Ligand A (35.44). While not a primary concern for a cardiovascular target, higher BBB is rarely detrimental.
9. **Caco-2:** Ligand A (-5.668) has a very poor Caco-2 permeability, suggesting poor absorption. Ligand B (-4.482) is better, but still not great.
10. **Solubility:** Ligand A (-2.107) has slightly better solubility than Ligand B (-1.586).
11. **hERG:** Ligand A (0.051) has a slightly lower hERG risk than Ligand B (0.355), which is preferable.
12. **Cl_mic:** Ligand A (-16.242) has significantly lower microsomal clearance than Ligand B (24.762), indicating better metabolic stability. This is a major advantage for Ligand A.
13. **t1/2:** Ligand A (10.779) has a slightly longer in vitro half-life than Ligand B (8.339).
14. **Pgp:** Ligand A (0.003) has much lower P-gp efflux than Ligand B (0.075), which is a positive.
15. **Affinity:** Ligand A (-8.5) has a significantly stronger binding affinity than Ligand B (-6.1). This is a substantial advantage, potentially outweighing some ADME concerns.
**Overall Assessment:**
Ligand A has a superior binding affinity and better metabolic stability (lower Cl_mic, longer t1/2) and lower Pgp efflux. However, it suffers from a very low logP and poor Caco-2 permeability. Ligand B has better TPSA, logP, QED, and BBB penetration. The difference in binding affinity is substantial (-8.5 vs -6.1 kcal/mol). For a GPCR, affinity is paramount, and a 2.4 kcal/mol difference is very significant. The lower logP of Ligand A is a concern, but could potentially be addressed with formulation strategies. The metabolic stability of Ligand A is also a strong point.
Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity) and the substantial affinity advantage of Ligand A, I believe it is the more promising candidate.
Output:
1
2025-04-17 18:08:56,328 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's systematically compare Ligand A and Ligand B against the provided guidelines, keeping in mind ADRB2 is a GPCR, so logP, Pgp, TPSA, and affinity are key.
1. **MW:** Both ligands (348.531 and 372.412 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands have a TPSA of 58.2, well below the 140 A^2 threshold for good oral absorption. This is excellent for both.
3. **logP:** Ligand A (3.938) is slightly higher than Ligand B (2.946). Both are within the optimal 1-3 range, but A is closer to the upper limit.
4. **HBD/HBA:** Both have 2 HBD and are within acceptable limits. Ligand B has 3 HBA vs 2 for Ligand A, but this is not a major concern.
5. **QED:** Ligand B (0.854) has a significantly better QED score than Ligand A (0.628), indicating a more drug-like profile.
6. **DILI:** Ligand A (20.24%) has a much lower DILI risk than Ligand B (55.176%), a significant advantage.
7. **BBB:** Ligand B (87.553%) shows much better predicted BBB penetration than Ligand A (75.378%). While ADRB2 isn't necessarily a CNS target, higher BBB penetration can sometimes correlate with better distribution.
8. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. This is a concern for both compounds.
9. **Solubility:** Both have negative solubility values, indicating poor solubility. This is a concern for both compounds.
10. **hERG:** Both have low hERG inhibition liability (0.577 and 0.468 respectively), which is good.
11. **Cl_mic:** Ligand A (81.484 mL/min/kg) has a significantly higher microsomal clearance than Ligand B (7.327 mL/min/kg). This suggests Ligand B is much more metabolically stable.
12. **t1/2:** Ligand B (23.621 hours) has a much longer in vitro half-life than Ligand A (0.679 hours). This is a major advantage for Ligand B.
13. **Pgp:** Ligand A (0.542) has slightly lower P-gp efflux liability than Ligand B (0.26), which is favorable.
14. **Binding Affinity:** Ligand B (-8.1 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.4 kcal/mol). This is a substantial advantage, potentially outweighing some ADME concerns.
**Overall Assessment:**
Ligand B is the stronger candidate. While Ligand A has a lower DILI risk and slightly better Pgp profile, Ligand B's significantly superior binding affinity (-8.1 vs -6.4 kcal/mol), much better metabolic stability (lower Cl_mic, longer t1/2), and higher QED score are decisive. The difference in binding affinity is substantial enough to overcome the higher DILI risk and slightly worse Pgp efflux. The Caco-2 and solubility issues are concerns for both, but can be addressed through formulation strategies.
Output:
0
2025-04-17 18:08:56,328 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.341 and 352.385 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (100.19) is higher than Ligand B (78.35). For a cardiovascular GPCR, TPSA is moderately important, and Ligand B is preferable due to its lower value, suggesting better permeability.
3. **logP:** Ligand B (1.663) is within the optimal 1-3 range, while Ligand A (0.121) is quite low. This is a significant advantage for Ligand B, as low logP can hinder membrane permeability.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (2), but both are acceptable (<=5).
5. **HBA:** Ligand A (4) is lower than Ligand B (5), which is slightly preferable.
6. **QED:** Both ligands have good QED scores (0.701 and 0.843, respectively), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand B (49.166) has a significantly lower DILI risk than Ligand A (61.807). This is a crucial advantage for Ligand B.
8. **BBB:** Ligand B (80.69) has a higher BBB penetration percentile than Ligand A (69.717). While ADRB2 isn't a CNS target, higher BBB is generally favorable.
9. **Caco-2:** Ligand A (-5.138) and Ligand B (-4.907) are both negative, which is unusual and suggests poor permeability. However, the values are very close.
10. **Solubility:** Ligand A (-2.247) and Ligand B (-2.963) are both very poor. This is a concern for both, but Ligand B is slightly worse.
11. **hERG:** Ligand A (0.147) has a slightly lower hERG risk than Ligand B (0.385), which is preferable.
12. **Cl_mic:** Ligand A (-18.957) has a much lower (better) microsomal clearance than Ligand B (0.512), indicating greater metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand B (18.747) has a longer in vitro half-life than Ligand A (15.356), which is generally desirable.
14. **Pgp:** Ligand A (0.006) has a much lower P-gp efflux liability than Ligand B (0.036), indicating better absorption and potentially higher bioavailability.
15. **Binding Affinity:** Both ligands have excellent binding affinity (-7.1 and -7.0 kcal/mol), with Ligand A being slightly better. The difference is less than 1.5 kcal/mol, so it's not decisive.
**Overall Assessment:**
Ligand B has several advantages: better logP, lower DILI risk, higher BBB penetration, and a longer half-life. Ligand A has better metabolic stability (lower Cl_mic) and slightly better affinity, and lower Pgp efflux. The poor solubility of both is a concern. However, the combination of lower DILI risk and better logP for Ligand B, coupled with its acceptable affinity, makes it the more promising candidate. The metabolic stability advantage of Ligand A is outweighed by the other benefits of Ligand B.
Output:
0
2025-04-17 18:08:56,328 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (405.336 Da) is within the ideal range. Ligand B (353.455 Da) is also good. No clear advantage here.
2. **TPSA:** Ligand A (50.36) is good, well below the 140 threshold. Ligand B (84.37) is still reasonable, but higher. A favors better absorption.
3. **logP:** Ligand A (4.277) is slightly high, potentially leading to solubility issues or off-target interactions. Ligand B (2.067) is optimal. B is better here.
4. **HBD:** Both ligands have 2 HBD, which is acceptable.
5. **HBA:** Ligand A (2) is good. Ligand B (7) is higher, potentially impacting permeability. A is better.
6. **QED:** Both ligands (0.723 and 0.695) are above the 0.5 threshold, indicating good drug-likeness.
7. **DILI:** Ligand A (49.438) has a lower DILI risk than Ligand B (91.314). A is significantly better.
8. **BBB:** Ligand A (69.252) is reasonable, while Ligand B (32.687) is low. Since ADRB2 is a GPCR, some CNS penetration might be acceptable, but it's not a primary driver. A is better.
9. **Caco-2:** Ligand A (-4.882) is better than Ligand B (-5.097), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-4.952) is better than Ligand B (-3.5), indicating better solubility.
11. **hERG:** Both ligands (0.912 and 0.809) have low hERG risk, which is good.
12. **Cl_mic:** Ligand B (27.129) has significantly lower microsomal clearance than Ligand A (105.162), suggesting better metabolic stability. B is much better.
13. **t1/2:** Ligand A (19.449) has a longer half-life than Ligand B (10.749). A is better.
14. **Pgp:** Ligand A (0.507) has lower P-gp efflux than Ligand B (0.294), which is favorable. A is better.
15. **Affinity:** Ligand B (-5.9 kcal/mol) has a significantly stronger binding affinity than Ligand A (-3.1 kcal/mol). This is a substantial advantage.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, Pgp, TPSA, and affinity. Ligand B excels in logP and affinity, while Ligand A is better in TPSA and Pgp. The affinity difference is substantial.
**Overall Assessment:**
Ligand B has a significantly stronger binding affinity (-5.9 vs -3.1 kcal/mol), which is the most critical factor for GPCRs. While Ligand A has advantages in DILI, solubility, and metabolic stability, the large difference in binding affinity outweighs these benefits. The slightly higher logP of Ligand A is a concern, but can be addressed with further optimization. The lower metabolic stability of Ligand B is also a concern, but could be addressed with structural modifications.
**Output:**
0
2025-04-17 18:08:56,328 - INFO - Batch 16 complete. Total preferences: 256
2025-04-17 18:08:56,328 - INFO - Processing batch 17/512...
2025-04-17 18:09:46,447 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [347.419, 96.33, -0.041, 2, 5, 0.731, 45.25, 59.364, -5.167, -2.232, 0.067, 30.826, 3.11, 0.024, -6.5]
**Ligand B:** [351.531, 30.93, 3.345, 0, 4, 0.671, 8.181, 88.833, -4.808, -3.006, 0.868, 35.536, 31.757, 0.333, -6.8]
Here's a breakdown of each parameter and how the ligands compare, keeping GPCR priorities (logP, Pgp, TPSA, affinity) in mind:
1. **MW:** Both are within the ideal range (200-500 Da). A is 347.4, B is 351.5. No significant difference.
2. **TPSA:** A (96.33) is higher than B (30.93). B is significantly better, falling well below the 140 threshold for oral absorption and closer to the ideal for GPCRs.
3. **logP:** A (-0.041) is low, potentially hindering permeation. B (3.345) is excellent, within the optimal 1-3 range. This is a significant advantage for B.
4. **HBD:** A (2) is reasonable. B (0) is even better, potentially improving permeability.
5. **HBA:** A (5) is acceptable. B (4) is also good.
6. **QED:** A (0.731) is better than B (0.671), indicating a slightly more drug-like profile.
7. **DILI:** A (45.25) is better than B (8.181), indicating a lower risk of liver injury.
8. **BBB:** B (88.833) is much higher than A (59.364). While ADRB2 isn't necessarily a CNS target, higher BBB penetration can sometimes correlate with better overall distribution and reduced off-target effects.
9. **Caco-2:** A (-5.167) is poor. B (-4.808) is also poor, but slightly better. Both suggest potential absorption issues.
10. **Solubility:** A (-2.232) is poor. B (-3.006) is also poor. Both ligands have solubility concerns.
11. **hERG:** A (0.067) is very low risk. B (0.868) is slightly higher, but still relatively low.
12. **Cl_mic:** A (30.826) is better than B (35.536), indicating better metabolic stability.
13. **t1/2:** B (31.757) is significantly better than A (3.11), suggesting a much longer duration of action.
14. **Pgp:** A (0.024) is very low efflux, which is good. B (0.333) is slightly higher, but still relatively low.
15. **Affinity:** B (-6.8) is slightly better than A (-6.5), although the difference is relatively small.
**Overall Assessment:**
Ligand B clearly wins out. While Ligand A has a slightly better QED and DILI score, Ligand B excels in the key GPCR-relevant parameters: logP, BBB, and *especially* TPSA. The significantly lower TPSA and optimal logP of Ligand B suggest it will have better permeability and absorption. The longer half-life is also a major advantage. The small affinity difference is outweighed by the superior ADME properties of Ligand B.
Output:
0
2025-04-17 18:09:46,447 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.403 and 346.515 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (96.69) is higher than Ligand B (58.2). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B is better here.
3. **logP:** Ligand A (0.216) is quite low, potentially hindering permeability. Ligand B (3.592) is within the optimal 1-3 range. This is a significant advantage for Ligand B.
4. **HBD:** Both ligands have 2 HBD, which is acceptable.
5. **HBA:** Ligand A has 6 HBA, while Ligand B has 2. Lower HBA generally improves permeability, favoring Ligand B.
6. **QED:** Ligand A (0.793) has a better QED score than Ligand B (0.521), indicating a more drug-like profile. This is a point in favor of Ligand A.
7. **DILI:** Ligand A (58.24) has a higher DILI risk than Ligand B (37.728). Lower DILI is crucial, making Ligand B preferable.
8. **BBB:** Both have low BBB penetration, which is acceptable for a cardiovascular target. Ligand B (60.915) is slightly higher, but not a major factor.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Ligand A (-1.328) has worse solubility than Ligand B (-4.874). Better solubility is desirable, favoring Ligand B.
11. **hERG:** Ligand A (0.068) has a lower hERG risk than Ligand B (0.253), which is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand A (11.525) has a lower microsomal clearance than Ligand B (81.91), indicating better metabolic stability. This is a strong point for Ligand A.
13. **t1/2:** Ligand A (8.421) has a longer in vitro half-life than Ligand B (3.682), which is desirable. This favors Ligand A.
14. **Pgp:** Ligand A (0.019) has much lower P-gp efflux than Ligand B (0.452), which is beneficial for bioavailability. This is a significant advantage for Ligand A.
15. **Binding Affinity:** Ligand B (-6.9 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.1 kcal/mol). This is a >1.5 kcal/mol advantage, and is the most important factor.
**Overall Assessment:**
While Ligand A has advantages in QED, metabolic stability, half-life, and P-gp efflux, and hERG, Ligand B's superior logP, lower TPSA, lower DILI risk, and *much* stronger binding affinity are decisive. The binding affinity difference is substantial and likely outweighs the ADME drawbacks of Ligand B. For a GPCR, potency is paramount, and Ligand B clearly wins in this regard.
Output:
0
2025-04-17 18:09:46,448 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [356.438, 75.71, 1.823, 1, 4, 0.673, 12.834, 88.6, -4.413, -2.259, 0.449, 53.8, -21.019, 0.018, -5.6]
**Ligand B:** [377.491, 91.22, 2.935, 2, 6, 0.81, 79.682, 16.053, -5.008, -4.964, 0.558, 47.387, 56.83, 0.443, -5.9]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity, and BBB):
1. **MW:** Both are within the ideal range (200-500 Da). A is 356.4, B is 377.5. No significant difference.
2. **TPSA:** A (75.71) is better than B (91.22). Lower TPSA generally favors better permeability, which is crucial for GPCR ligands.
3. **logP:** A (1.823) is good, within the optimal range. B (2.935) is also acceptable but edging towards the higher end.
4. **HBD/HBA:** A (1 HBD, 4 HBA) is preferable to B (2 HBD, 6 HBA). Lower counts are generally better for permeability.
5. **QED:** B (0.81) is better than A (0.673). Higher QED suggests a more drug-like profile.
6. **DILI:** A (12.834) is significantly better than B (79.682). This is a major advantage for A.
7. **BBB:** A (88.6) is *much* better than B (16.053). While ADRB2 isn't strictly a CNS target, some CNS penetration can be beneficial, and a low BBB score is a red flag.
8. **Caco-2:** A (-4.413) is better than B (-5.008). Higher (less negative) Caco-2 values indicate better absorption.
9. **Solubility:** A (-2.259) is better than B (-4.964). Better solubility is always a plus.
10. **hERG:** Both are very low (0.449 and 0.558), indicating low cardiotoxicity risk. No significant difference.
11. **Cl_mic:** B (47.387) is better than A (53.8). Lower clearance is desirable for longer duration of action.
12. **t1/2:** A (-21.019) is better than B (56.83). A negative value suggests a very long half-life, which is highly desirable.
13. **Pgp:** A (0.018) is *much* better than B (0.443). Lower P-gp efflux means better bioavailability and potentially better CNS exposure.
14. **Affinity:** B (-5.9) is slightly better than A (-5.6). This is a small difference, but still a factor.
**Overall Assessment:**
Ligand A has a clear advantage due to its superior DILI score, BBB penetration, P-gp efflux, solubility, and half-life. While Ligand B has a slightly better affinity and QED, the ADME properties of Ligand A are significantly more favorable, especially the low DILI risk and good BBB. For a cardiovascular GPCR, minimizing off-target effects (DILI) and ensuring adequate systemic exposure (P-gp, solubility) are critical. The small affinity difference is outweighed by the substantial ADME benefits of Ligand A.
Output:
1
2025-04-17 18:09:46,448 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands (380.432 and 346.446 Da) fall within the ideal 200-500 Da range. Ligand B is slightly smaller, which *could* be advantageous for permeability, but the difference isn't substantial.
2. **TPSA:** Both ligands have similar TPSA values (49.85 and 49.41), well below the 140 threshold for oral absorption and reasonable for a non-CNS GPCR target like ADRB2.
3. **logP:** Both ligands have good logP values (3.058 and 2.917), falling within the optimal 1-3 range.
4. **HBD/HBA:** Ligand A (0 HBD, 4 HBA) and Ligand B (1 HBD, 2 HBA) both have acceptable numbers of hydrogen bond donors and acceptors.
5. **QED:** Ligand A (0.706) has a slightly better QED score than Ligand B (0.523), indicating a more drug-like profile.
6. **DILI:** Ligand B (24.622) has a significantly lower DILI risk than Ligand A (47.926). This is a major advantage for Ligand B.
7. **BBB:** Both ligands have good BBB penetration (73.711 and 80.613), but this is less crucial for a cardiovascular target like ADRB2.
8. **Caco-2:** Both ligands have similar, negative Caco-2 permeability values (-4.569 and -4.534). This suggests poor permeability, which is a concern.
9. **Solubility:** Both ligands have negative solubility values (-3.93 and -2.822), indicating poor aqueous solubility. This is a significant drawback for both.
10. **hERG:** Ligand A (0.493) has a slightly lower hERG risk than Ligand B (0.853), which is preferable.
11. **Cl_mic:** Ligand B (79.761) has a higher microsomal clearance than Ligand A (67.991), suggesting faster metabolism and potentially lower *in vivo* exposure.
12. **t1/2:** Ligand B (21.408) has a significantly longer *in vitro* half-life than Ligand A (-21.378). This is a substantial advantage for Ligand B.
13. **Pgp:** Ligand A (0.141) has lower P-gp efflux liability than Ligand B (0.446), which is favorable.
14. **Binding Affinity:** Ligand B (-6.3 kcal/mol) has a stronger binding affinity than Ligand A (-5.5 kcal/mol). This is a 1.8 kcal/mol difference, which is significant and can outweigh some ADME drawbacks.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, Pgp, TPSA, and affinity. Both ligands are good on logP and TPSA. Ligand A has better Pgp, but Ligand B has significantly better affinity and a much better DILI profile and half-life.
**Overall Assessment:**
While Ligand A has some advantages (better QED, lower Pgp, slightly lower hERG), Ligand B's superior binding affinity, significantly lower DILI risk, and longer half-life are more critical for overall drug viability. The poor solubility and permeability are concerns for both, but can potentially be addressed with formulation strategies. The stronger binding affinity of Ligand B is likely to translate to greater efficacy, and the lower DILI risk is crucial for safety.
Output:
0
2025-04-17 18:09:46,448 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's break down the comparison of Ligand A and Ligand B based on the provided parameters and the guidelines, keeping in mind ADRB2 is a GPCR.
1. **Molecular Weight:** Both ligands (361.345 and 347.415 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand B (84.67) is significantly better than Ligand A (102.69). For a GPCR, lower TPSA is generally preferred for better permeability.
3. **logP:** Both ligands have acceptable logP values (0.871 and 1.602), falling within the 1-3 range. Ligand B is slightly better.
4. **H-Bond Donors:** Ligand B (1) is preferable to Ligand A (2). Fewer HBDs generally improve permeability.
5. **H-Bond Acceptors:** Both are reasonable (6 and 5 respectively).
6. **QED:** Ligand B (0.894) has a slightly better QED score than Ligand A (0.712), indicating a more drug-like profile.
7. **DILI:** Ligand B (31.33) is *much* better than Ligand A (63.086). This is a significant advantage for Ligand B, as lower DILI risk is crucial.
8. **BBB:** Ligand A (88.135) has a better BBB penetration score than Ligand B (73.943). While ADRB2 isn't necessarily a CNS target, some peripheral ADRB2 activity can have central effects, so some BBB penetration isn't detrimental.
9. **Caco-2 Permeability:** Both have negative Caco-2 values, which is unusual. It's difficult to interpret without knowing the scale, but let's assume lower is worse. They are similar.
10. **Aqueous Solubility:** Both have negative solubility values, which is also unusual. Again, assuming lower is worse, they are similar.
11. **hERG:** Both have very low hERG inhibition liability (0.261 and 0.293), which is excellent.
12. **Microsomal Clearance:** Ligand B (13.759) has a lower microsomal clearance than Ligand A (17.792), suggesting better metabolic stability.
13. **In vitro Half-Life:** Ligand A (16.907) has a longer in vitro half-life than Ligand B (4.566). This is a positive for Ligand A.
14. **P-gp Efflux:** Both have very low P-gp efflux liability (0.04 and 0.094).
15. **Binding Affinity:** Ligand A (-6.9 kcal/mol) has a slightly better binding affinity than Ligand B (-5.9 kcal/mol). This is a 1 kcal/mol difference, which is noticeable but not overwhelmingly decisive.
**Overall Assessment:**
Ligand B clearly wins on safety (DILI) and drug-likeness (QED, TPSA, HBD). It also has better metabolic stability (lower Cl_mic). While Ligand A has a slightly better binding affinity and half-life, the advantages of Ligand B in crucial ADME-Tox properties, particularly the significantly lower DILI risk, outweigh these benefits. For a GPCR, optimizing for permeability (lower TPSA) is also important, and Ligand B excels here.
Output:
0
2025-04-17 18:09:46,448 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [366.845, 84.5, 3.605, 2, 4, 0.779, 56.146, 74.486, -4.389, -4.825, 0.265, 49.134, 31.748, 0.095, -7.0]
**Ligand B:** [342.443, 69.34, 2.029, 0, 4, 0.743, 31.563, 68.36, -4.515, -2.857, 0.636, 45.271, -0.515, 0.119, -5.4]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity, and BBB):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (342.443) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are good, below 140. Ligand B (69.34) is better, being closer to the 90 threshold for CNS penetration, although this is less critical for a cardiovascular target.
3. **logP:** Ligand A (3.605) is better than Ligand B (2.029). A logP between 1-3 is optimal, and 3.605 is closer to the upper end of that range, suggesting good membrane permeability. Ligand B is a bit low, potentially hindering permeation.
4. **HBD:** Ligand A (2) is preferable to Ligand B (0). While lower HBD can improve permeability, some H-bond donors are needed for solubility.
5. **HBA:** Both have 4 HBA, which is acceptable.
6. **QED:** Both are similar (A: 0.779, B: 0.743), indicating good drug-like properties.
7. **DILI:** Ligand B (31.563) is significantly better than Ligand A (56.146) in terms of liver toxicity risk. This is a major advantage for Ligand B.
8. **BBB:** Ligand A (74.486) has better BBB penetration than Ligand B (68.36). While not a primary concern for a cardiovascular target, it's a slight positive for A.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-4.389) is slightly worse than Ligand B (-4.515).
10. **Solubility:** Ligand B (-2.857) is better than Ligand A (-4.825).
11. **hERG:** Ligand A (0.265) is better than Ligand B (0.636) indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand B (45.271) has a slightly lower clearance than Ligand A (49.134), suggesting better metabolic stability.
13. **t1/2:** Ligand A (31.748) has a longer half-life than Ligand B (-0.515). This is a significant advantage for A.
14. **Pgp:** Ligand A (0.095) has lower P-gp efflux than Ligand B (0.119), which is favorable for bioavailability.
15. **Affinity:** Ligand A (-7.0) has a slightly better binding affinity than Ligand B (-5.4). This 1.6 kcal/mol difference is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand A has a better binding affinity and longer half-life, and lower Pgp efflux. However, Ligand B has a significantly lower DILI risk, better solubility, and a slightly better TPSA. The affinity difference is the most important factor here, and the longer half-life of A is also highly desirable. While the DILI risk of Ligand A is a concern, it's not prohibitive, and could potentially be mitigated through structural modifications. The slightly better logP of Ligand A also supports its potential for good membrane permeability.
Therefore, I would choose Ligand A.
Output:
1
2025-04-17 18:09:46,448 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [351.422, 62.74, 1.45, 0, 4, 0.64, 23.226, 87.941, -4.659, -0.469, 0.479, 22.46, 6.336, 0.069, -6.7]
**Ligand B:** [343.427, 66.65, 2.022, 0, 4, 0.788, 41.877, 65.529, -4.556, -2.877, 0.214, 15.489, 3.678, 0.233, -5.8]
Here's a breakdown of the comparison, considering the guidelines and GPCR-specific priorities:
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand B (343.427) is slightly lower, which is generally favorable.
2. **TPSA:** Both are reasonably good, below the 140 A^2 threshold for oral absorption. Ligand A (62.74) is better than Ligand B (66.65).
3. **logP:** Both are within the optimal range (1-3). Ligand A (1.45) is slightly better than Ligand B (2.022).
4. **HBD:** Both have 0 HBD, which is good.
5. **HBA:** Both have 4 HBA, which is acceptable.
6. **QED:** Both have reasonable QED scores (A: 0.64, B: 0.788), indicating drug-likeness. Ligand B is slightly better.
7. **DILI:** Ligand A (23.226%) has a significantly lower DILI risk than Ligand B (41.877%). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (87.941%) has a much higher BBB penetration potential than Ligand B (65.529%). While ADRB2 is primarily cardiovascular, some CNS effects are possible with certain ligands, and higher BBB penetration could be beneficial or detrimental depending on the desired profile.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.659) is slightly better than Ligand B (-4.556).
10. **Solubility:** Ligand A (-0.469) has better solubility than Ligand B (-2.877).
11. **hERG:** Both have very low hERG inhibition risk (A: 0.479, B: 0.214). Ligand B is slightly better.
12. **Cl_mic:** Ligand B (15.489) has lower microsomal clearance than Ligand A (22.46), suggesting better metabolic stability.
13. **t1/2:** Ligand A (6.336) has a longer in vitro half-life than Ligand B (3.678). This is a positive for Ligand A.
14. **Pgp:** Ligand A (0.069) has lower P-gp efflux liability than Ligand B (0.233). This is a positive for Ligand A.
15. **Affinity:** Ligand A (-6.7 kcal/mol) has a slightly better binding affinity than Ligand B (-5.8 kcal/mol).
**Overall Assessment:**
Ligand A demonstrates a more favorable profile overall, particularly regarding safety (DILI) and drug-like properties (BBB, solubility, Pgp, t1/2). While Ligand B has slightly better metabolic stability (Cl_mic) and QED, the significant advantage of Ligand A in DILI risk and the slightly better affinity outweigh these benefits. The Caco-2 values are concerning for both, but the other properties of Ligand A are more promising for development.
Output:
1
2025-04-17 18:09:46,449 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (340.383 Da) is within the ideal range. Ligand B (183.207 Da) is below the preferred range, potentially impacting potency.
2. **TPSA:** Both Ligand A (79.54) and Ligand B (72.72) are well below the 140 threshold for good oral absorption, and suitable for a GPCR.
3. **logP:** Ligand A (1.58) is optimal. Ligand B (0.351) is a bit low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (0) is excellent. Ligand B (4) is acceptable, but higher HBD can sometimes reduce permeability.
5. **HBA:** Ligand A (5) is good. Ligand B (4) is also good.
6. **QED:** Ligand A (0.844) is excellent, indicating high drug-likeness. Ligand B (0.51) is acceptable, but lower.
7. **DILI:** Ligand A (49.632) has a moderate risk, but is acceptable. Ligand B (6.941) has a very low DILI risk, which is a significant advantage.
8. **BBB:** Ligand A (83.986) has good BBB penetration. Ligand B (3.49) has very poor BBB penetration. Since ADRB2 is a cardiovascular target, BBB penetration is not a primary concern, but it's still a consideration.
9. **Caco-2:** Ligand A (-4.937) is poor. Ligand B (-6.081) is also poor.
10. **Solubility:** Ligand A (-1.668) is poor. Ligand B (-0.652) is also poor.
11. **hERG:** Ligand A (0.348) has low hERG inhibition risk. Ligand B (0.025) has very low hERG inhibition risk, a significant advantage.
12. **Cl_mic:** Ligand A (44.115) is moderate. Ligand B (-44.29) is negative, indicating very high metabolic stability, a major advantage.
13. **t1/2:** Both Ligand A (3.718) and Ligand B (3.707) have similar in vitro half-lives.
14. **Pgp:** Ligand A (0.014) has very low P-gp efflux. Ligand B (0.008) also has very low P-gp efflux.
15. **Affinity:** Ligand A (-6.3 kcal/mol) has slightly better binding affinity than Ligand B (-5.6 kcal/mol). This is a 0.7 kcal/mol difference, which is a good advantage.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are important. Ligand A has a better logP and affinity. Ligand B has better metabolic stability and lower hERG risk.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity and logP, Ligand B's significantly better metabolic stability (negative Cl_mic), lower DILI risk, and very low hERG risk are compelling advantages. The lower molecular weight of Ligand B is also a slight negative, but the benefits outweigh this drawback. Considering the cardiovascular target, metabolic stability and safety (DILI, hERG) are critical, making Ligand B the more promising candidate.
Output:
0
2025-04-17 18:09:46,449 - INFO - Here's my reasoning and output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands (374.418 and 364.837 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (84.94) is significantly better than Ligand B (112.66). ADRB2 is a cardiovascular target, not CNS, but lower TPSA generally improves absorption.
3. **logP:** Both ligands (1.711 and 1.357) are within the optimal 1-3 range. Ligand B is slightly lower, which could slightly hinder permeability, but it's not a major concern.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Both ligands have 5 HBA, which is acceptable.
6. **QED:** Ligand B (0.654) has a slightly better QED score than Ligand A (0.589), indicating a marginally more drug-like profile.
7. **DILI:** Ligand A (22.257) has a much lower DILI risk than Ligand B (64.831). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (74.292) has a better BBB penetration score than Ligand B (20.512). While not a CNS target, some peripheral distribution is still important.
9. **Caco-2:** Ligand A (-4.962) has a better Caco-2 permeability than Ligand B (-5.743).
10. **Solubility:** Ligand A (-1.779) has a better solubility score than Ligand B (-2.064).
11. **hERG:** Both ligands have similar hERG inhibition liabilities (0.277 and 0.379), both are low risk.
12. **Cl_mic:** Ligand A (44.595) has a higher microsomal clearance than Ligand B (3.195). This means Ligand B is more metabolically stable, which is a significant advantage.
13. **t1/2:** Ligand B (-1.893) has a longer in vitro half-life than Ligand A (9.5). This is a significant advantage for Ligand B.
14. **Pgp:** Both ligands have similar Pgp efflux liabilities (0.037 and 0.045).
15. **Binding Affinity:** Ligand B (-7.4) has a slightly better binding affinity than Ligand A (-7.0). While the difference is small (0.4 kcal/mol), it's still a positive for Ligand B.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand B has a slightly better logP and affinity. Ligand A has a better TPSA. Pgp is similar for both. However, the significant advantages of Ligand A in DILI risk, BBB, solubility, and Caco-2 permeability, combined with acceptable affinity, outweigh the slight advantage of Ligand B in metabolic stability and half-life.
**Conclusion:**
Considering the balance of properties and the GPCR-specific priorities, **Ligand A is the more promising drug candidate.**
Output:
1
2025-04-17 18:09:46,449 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.403 and 348.447 Da) fall comfortably within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (113.44) is slightly higher than Ligand B (96.25). Ligand B is preferable as it's closer to the <140 threshold for good oral absorption, and even better for a GPCR.
3. **logP:** Ligand A (-0.05) is a bit low, potentially hindering permeation. Ligand B (0.732) is within the optimal 1-3 range. Ligand B is significantly better here.
4. **HBD:** Both have 3 HBD, which is acceptable.
5. **HBA:** Ligand A has 6 HBA, while Ligand B has 5. Ligand B is slightly better.
6. **QED:** Ligand A (0.664) is slightly better than Ligand B (0.573), indicating a more drug-like profile.
7. **DILI:** Ligand A (42.652) has a slightly higher DILI risk than Ligand B (35.944), but both are below the concerning 60 threshold. Ligand B is preferable.
8. **BBB:** Ligand A (45.599) has a better BBB penetration percentile than Ligand B (24.855). This is a positive for Ligand A, given ADRB2 is a GPCR.
9. **Caco-2:** Both have negative Caco-2 values (-5.031 and -5.149). This is unusual and suggests poor permeability.
10. **Solubility:** Both ligands have very poor aqueous solubility (-1.762 and -1.714). This is a major concern for both.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.082 and 0.106). This is excellent.
12. **Cl_mic:** Ligand A (6.126) has significantly lower microsomal clearance than Ligand B (27.402), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (21.246) has a much longer in vitro half-life than Ligand B (1.294). This is a substantial advantage for Ligand A.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.008 and 0.046). This is good.
15. **Affinity:** Both ligands have the same binding affinity (-6.5 kcal/mol), so this doesn't differentiate them.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, and metabolic stability are key. Ligand B has a better logP and TPSA. However, Ligand A has significantly better metabolic stability (lower Cl_mic) and a much longer half-life. The BBB value for Ligand A is also better. While solubility is poor for both, the improved pharmacokinetics of Ligand A (Cl_mic and t1/2) are more critical for *in vivo* efficacy.
**Conclusion:**
Despite the slightly better QED and DILI of Ligand A, the substantial improvements in metabolic stability (Cl_mic and t1/2) and BBB penetration make Ligand A the more promising candidate. The poor solubility is a concern for both, but can be addressed with formulation strategies.
Output:
1
2025-04-17 18:09:46,449 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (364.43 & 373.51 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand B (29.54) is significantly better than Ligand A (66.48). Lower TPSA is favorable for permeability, especially for a GPCR.
3. **logP:** Ligand A (2.298) is within the optimal 1-3 range. Ligand B (4.682) is a bit high, potentially leading to solubility issues and off-target interactions.
4. **HBD:** Ligand A (1) is preferable to Ligand B (0). While both are low, a single HBD can aid solubility.
5. **HBA:** Both ligands have 3 HBA, which is acceptable.
6. **QED:** Both ligands have similar QED scores (0.601 and 0.649), indicating good drug-likeness.
7. **DILI:** Ligand A (15.28) has a much lower DILI risk than Ligand B (21.91). This is a significant advantage.
8. **BBB:** Ligand B (90.62) has a much higher BBB penetration potential than Ligand A (48.31). While ADRB2 isn't strictly a CNS target, some CNS exposure can be acceptable and may even be beneficial depending on the therapeutic goal.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. However, Ligand B (-4.595) is slightly better than Ligand A (-4.891).
10. **Solubility:** Ligand A (-2.337) has better aqueous solubility than Ligand B (-4.976). This is important, especially given Ligand B's higher logP.
11. **hERG:** Ligand A (0.11) has a lower hERG inhibition liability than Ligand B (0.767). This is a critical safety factor.
12. **Cl_mic:** Ligand B (95.65) has a much higher microsomal clearance than Ligand A (9.42), indicating poorer metabolic stability.
13. **t1/2:** Ligand B (8.917) has a much longer in vitro half-life than Ligand A (-3.332). This is a significant advantage.
14. **Pgp:** Ligand A (0.062) has lower P-gp efflux liability than Ligand B (0.365). Lower Pgp efflux is generally desirable.
15. **Binding Affinity:** Ligand B (-7.9 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.4 kcal/mol). This is a substantial advantage, and could potentially overcome some of the ADME liabilities.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in affinity and BBB penetration, but struggles with logP and Pgp. Ligand A has a better balance, with acceptable logP, lower DILI and hERG risk, and better solubility. The large affinity difference is the most important factor.
**Overall Assessment:**
While Ligand A has a more favorable ADME profile (lower DILI, hERG, better solubility, lower Pgp efflux), the significantly stronger binding affinity of Ligand B (-7.9 vs -6.4 kcal/mol) is a decisive factor. The 1.5 kcal/mol difference in binding is substantial and likely to outweigh the ADME drawbacks, especially considering optimization potential.
Output:
0
2025-04-17 18:09:46,450 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (343.431 Da) is within the ideal range (200-500 Da). Ligand B (374.547 Da) is also within the ideal range. No clear advantage here.
2. **TPSA:** Ligand A (98.12) is slightly above the preferred <90 for CNS targets but acceptable for a peripheral GPCR like ADRB2. Ligand B (75.71) is excellent, well below 90. Advantage: B.
3. **logP:** Both Ligand A (1.062) and Ligand B (2.006) are within the optimal 1-3 range. Ligand B is slightly better positioned.
4. **HBD:** Ligand A (2) and Ligand B (1) are both good, below the threshold of 5. Slight advantage: B.
5. **HBA:** Ligand A (5) and Ligand B (4) are both good, below the threshold of 10. Slight advantage: B.
6. **QED:** Both Ligand A (0.722) and Ligand B (0.705) are above 0.5, indicating good drug-likeness. No significant difference.
7. **DILI:** Ligand A (34.393) has a slightly higher DILI risk than Ligand B (22.14), but both are below the concerning threshold of 60. Advantage: B.
8. **BBB:** This is less critical for ADRB2 (a cardiovascular target), but Ligand B (76.813) has a higher BBB penetration potential than Ligand A (48.817).
9. **Caco-2:** Ligand A (-5.271) and Ligand B (-4.888) both have negative values, which is unusual and suggests poor permeability. It's difficult to interpret these values without knowing the scale.
10. **Solubility:** Both ligands have very poor solubility (-1.861 and -2.446 respectively). This is a major concern for both.
11. **hERG:** Both Ligand A (0.578) and Ligand B (0.533) have low hERG inhibition liability, which is good. No significant difference.
12. **Cl_mic:** Ligand A (-19.509) has a much lower (better) microsomal clearance than Ligand B (66.81). This suggests better metabolic stability. Advantage: A.
13. **t1/2:** Ligand A (8.154) has a shorter in vitro half-life than Ligand B (-35.058). The negative value for B is concerning and likely an error. Advantage: A.
14. **Pgp:** Both Ligand A (0.013) and Ligand B (0.039) have very low P-gp efflux liability, which is good. No significant difference.
15. **Binding Affinity:** Ligand B (-8.5 kcal/mol) has a significantly stronger binding affinity than Ligand A (-7.0 kcal/mol). This is a substantial advantage, exceeding the 1.5 kcal/mol threshold.
**Overall Assessment:**
Ligand B has several advantages: better TPSA, logP, HBD/HBA, DILI, and a significantly stronger binding affinity. While both have poor solubility, the stronger binding of Ligand B is a major factor. Ligand A has better metabolic stability (Cl_mic) and half-life, but the affinity difference is crucial for a GPCR target. The negative half-life for Ligand B is a red flag, but the affinity difference is so large that it outweighs this concern.
Output:
0
2025-04-17 18:09:46,450 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (356.463 and 358.498 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (88.1) is higher than Ligand B (58.64). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is generally preferred for absorption. Ligand B is better here.
3. **logP:** Ligand A (0.411) is quite low, potentially hindering membrane permeability. Ligand B (2.788) is within the optimal 1-3 range. Ligand B is significantly better.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable. Ligand B is slightly better.
5. **HBA:** Ligand A (5) and Ligand B (3) are both acceptable. Ligand B is better.
6. **QED:** Both ligands have good QED scores (0.592 and 0.653), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (5.7) has a much lower DILI risk than Ligand B (12.33). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (50.911) has a low BBB penetration, while Ligand B (94.261) has high BBB penetration. Since ADRB2 is a cardiovascular target, BBB penetration is not a priority. Ligand B is better in this case, but it isn't a critical factor.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.867 and -4.289), which is unusual and suggests poor permeability. However, the values are close.
10. **Solubility:** Ligand A (-0.349) has better solubility than Ligand B (-2.789). This is a positive for Ligand A.
11. **hERG:** Ligand A (0.202) has a lower hERG risk than Ligand B (0.834). This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand A (6.626) has a much lower microsomal clearance than Ligand B (36.756), indicating better metabolic stability. This is a major advantage for Ligand A.
13. **t1/2:** Ligand A (13.704) has a longer in vitro half-life than Ligand B (-0.13). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.005) has very low P-gp efflux liability, while Ligand B (0.201) has slightly higher efflux. Ligand A is better.
15. **Binding Affinity:** Ligand B (-6.6) has a slightly better binding affinity than Ligand A (-6.1). This is a 0.5 kcal/mol difference, which is not substantial enough to outweigh other factors.
**Overall Assessment:**
Ligand A demonstrates a superior ADMET profile. It has a lower DILI risk, lower hERG risk, better metabolic stability (lower Cl_mic, longer t1/2), lower P-gp efflux, and better solubility. While Ligand B has a slightly better binding affinity and BBB penetration, these are less critical for a cardiovascular target. The low logP of Ligand A is a concern, but the other advantages outweigh this drawback.
Output:
1
2025-04-17 18:09:46,450 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (346.43 and 348.44 Da) are within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (67.87) is better than Ligand B (71.78). Both are below the 140 threshold for oral absorption, but lower TPSA is generally preferred for GPCRs to facilitate receptor binding.
**3. logP:** Ligand A (3.56) is slightly higher than Ligand B (2.053), both are within the optimal 1-3 range. Ligand B is on the lower side, which *could* indicate permeability issues, but isn't a major concern.
**4. H-Bond Donors:** Both ligands have 1 HBD, which is good.
**5. H-Bond Acceptors:** Both ligands have 4 HBA, which is good.
**6. QED:** Ligand A (0.8) is slightly better than Ligand B (0.78), indicating a more drug-like profile.
**7. DILI:** Ligand B (21.52) is *significantly* better than Ligand A (55.06). This is a major advantage for Ligand B, as minimizing liver toxicity is crucial.
**8. BBB:** Ligand A (85.033) is better than Ligand B (69.523). While ADRB2 is a cardiovascular target, some CNS penetration can be relevant for off-target effects and overall safety assessment.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.53) is slightly better than Ligand B (-4.683).
**10. Aqueous Solubility:** Ligand B (-1.571) is better than Ligand A (-3.901). Better solubility is generally desirable.
**11. hERG Inhibition:** Ligand A (0.682) is better than Ligand B (0.212). Lower hERG inhibition is crucial to avoid cardiotoxicity.
**12. Microsomal Clearance:** Ligand B (17.036) has a much higher clearance than Ligand A (0.53). This is a significant drawback for Ligand B, indicating faster metabolism and potentially lower bioavailability.
**13. In vitro Half-Life:** Ligand B (35.043) has a much longer half-life than Ligand A (8.844). This is a significant advantage for Ligand B, potentially allowing for less frequent dosing.
**14. P-gp Efflux:** Ligand A (0.404) is better than Ligand B (0.063). Lower P-gp efflux is preferred.
**15. Binding Affinity:** Ligand B (-6.2 kcal/mol) has a *much* stronger binding affinity than Ligand A (-1.1 kcal/mol). This is a decisive advantage, as a >1.5 kcal/mol difference can often outweigh other ADME concerns.
**Overall Assessment:**
Ligand B has a significantly better binding affinity and a much lower DILI risk, and a longer half-life. While it has a higher microsomal clearance and lower BBB penetration than Ligand A, the dramatic improvement in binding affinity and the critical reduction in DILI risk outweigh these drawbacks. The slightly lower logP of Ligand B is not a major concern. The negative Caco-2 values for both are concerning and would need further investigation, but the potency advantage of B is substantial.
Output:
0
2025-04-17 18:09:46,450 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (344.371 and 343.427 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (113.18) is higher than Ligand B (62.62). For a GPCR, lower TPSA is generally preferred for better BBB penetration, giving a slight edge to Ligand B.
3. **logP:** Ligand B (1.165) is slightly higher than Ligand A (0.893), both are within the optimal 1-3 range. No strong preference.
4. **HBD:** Ligand A has 3 HBD, while Ligand B has 0. While not a hard rule, fewer HBDs can sometimes improve permeability. Ligand B is slightly favored.
5. **HBA:** Ligand A has 5 HBA, Ligand B has 4. Both are acceptable (<=10). No strong preference.
6. **QED:** Ligand B (0.81) has a better QED score than Ligand A (0.674), indicating a more drug-like profile. This is a significant advantage for Ligand B.
7. **DILI:** Ligand B (38.93) has a significantly lower DILI risk than Ligand A (63.668). This is a major advantage for Ligand B, as minimizing liver toxicity is crucial.
8. **BBB:** Ligand B (88.406) has a much higher BBB penetration percentile than Ligand A (62.97). Given ADRB2 is a GPCR, and potential for CNS effects, this is a substantial advantage for Ligand B.
9. **Caco-2:** Ligand A (-5.191) and Ligand B (-4.549) both have negative values, which is unusual. It's difficult to interpret without knowing the scale. However, they are similar.
10. **Solubility:** Ligand A (-3.157) and Ligand B (-1.797) both have negative values, indicating poor solubility. Ligand B is slightly better.
11. **hERG:** Ligand A (0.154) and Ligand B (0.309) have low hERG inhibition liability, which is good. No strong preference.
12. **Cl_mic:** Ligand A (19.452) has a lower microsomal clearance than Ligand B (60.481), indicating better metabolic stability. This favors Ligand A.
13. **t1/2:** Ligand B (-27.416) has a much longer in vitro half-life than Ligand A (-10.287). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.028) has much lower P-gp efflux liability than Ligand B (0.154). This is a positive for Ligand A.
15. **Binding Affinity:** Ligand A (-5.4) has a slightly better binding affinity than Ligand B (-3.7). While a difference of 1.7 kcal/mol is good, it is not overwhelming, especially when considering the other factors.
**Overall Assessment:**
Ligand B significantly outperforms Ligand A in several critical ADME-Tox properties (DILI, BBB, QED, t1/2) that are particularly important for a GPCR target like ADRB2. While Ligand A has better metabolic stability (Cl_mic) and P-gp efflux, the advantages of Ligand B in safety (DILI), brain penetration (BBB), and drug-likeness (QED) are more compelling. The slightly better binding affinity of Ligand A is not enough to offset these substantial advantages.
Output:
0
2025-04-17 18:09:46,450 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (393.868) is slightly higher, but still acceptable.
2. **TPSA:** Ligand A (80.76) is excellent, well below the 140 threshold for oral absorption. Ligand B (130.83) is higher, but still within a reasonable range.
3. **logP:** Ligand A (1.376) is optimal. Ligand B (-0.873) is slightly low, potentially impacting permeability.
4. **HBD:** Ligand A (1) is good. Ligand B (3) is acceptable, but higher.
5. **HBA:** Ligand A (6) is good. Ligand B (5) is also good.
6. **QED:** Ligand A (0.685) is better than Ligand B (0.422), indicating a more drug-like profile.
7. **DILI:** Ligand A (69.756) has a higher DILI risk than Ligand B (34.665), which is a significant concern.
8. **BBB:** Ligand A (76.192) is better than Ligand B (68.282), but neither are exceptionally high. For a cardiovascular target, BBB isn't a primary concern, but it's a slight advantage for A.
9. **Caco-2:** Ligand A (-4.944) is better than Ligand B (-5.464), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-2.924) is better than Ligand B (-1.665), which is important for bioavailability.
11. **hERG:** Ligand A (0.395) is better than Ligand B (0.072), indicating a lower risk of cardiotoxicity. This is critical for a cardiovascular target.
12. **Cl_mic:** Both ligands have similar microsomal clearance (Ligand A: 18.096, Ligand B: 18.281).
13. **t1/2:** Ligand A (36.702) has a much better in vitro half-life than Ligand B (-17.725).
14. **Pgp:** Ligand A (0.113) has lower P-gp efflux than Ligand B (0.005), which is favorable.
15. **Affinity:** Ligand B (-7.6) has a slightly better binding affinity than Ligand A (-6.6), a 1 kcal/mol difference.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has a better logP, TPSA, and Pgp profile. While Ligand B has a slightly better affinity, the difference is not substantial enough to outweigh the other advantages of Ligand A. The DILI risk for Ligand A is a concern, but the better hERG profile and half-life are significant positives for a cardiovascular drug.
**Overall Assessment:**
Ligand A presents a more balanced profile with better predicted ADME properties (solubility, permeability, efflux) and a lower hERG risk, which are crucial for a cardiovascular drug. While Ligand B has slightly better affinity, the higher DILI risk and poorer ADME properties make it less attractive.
Output:
1
2025-04-17 18:09:46,451 - INFO - Batch 17 complete. Total preferences: 272
2025-04-17 18:09:46,451 - INFO - Processing batch 18/512...
2025-04-17 18:10:34,402 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (348.407 and 365.499 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (119.76) is better than Ligand B (69.72) as it is closer to the upper limit of 140 for good oral absorption, while still being reasonable for a peripherally acting GPCR. Ligand B is quite low, which *could* indicate poor interactions.
**3. logP:** Both ligands have good logP values (1.452 and 1.627), falling within the optimal 1-3 range.
**4. H-Bond Donors:** Both have 1 HBD, which is acceptable.
**5. H-Bond Acceptors:** Both have 5 HBA, which is acceptable.
**6. QED:** Ligand B (0.797) has a significantly better QED score than Ligand A (0.426), indicating a more drug-like profile.
**7. DILI:** Both have low DILI risk (34.665 and 32.028 percentile), which is good.
**8. BBB:** Ligand A (71.19) has a better BBB penetration percentile than Ligand B (62.156). While ADRB2 isn't necessarily a CNS target, some peripheral ADRB2 activation can have central effects, and higher BBB penetration isn't necessarily a negative.
**9. Caco-2 Permeability:** Both have negative Caco-2 values, which is unusual and suggests a potential issue with permeability predictions. However, the values are similar (-5.024 and -5.035), so this doesn't strongly favor either.
**10. Aqueous Solubility:** Both have negative solubility values, which is also unusual and suggests potential formulation challenges. Again, the values are similar (-1.896 and -2.372).
**11. hERG Inhibition:** Ligand A (0.287) has a significantly lower hERG inhibition liability than Ligand B (0.507), which is a major advantage for cardiac safety.
**12. Microsomal Clearance:** Ligand B (31.449) has a much higher microsomal clearance than Ligand A (6.667), suggesting faster metabolism and potentially lower *in vivo* exposure.
**13. In vitro Half-Life:** Ligand A (5.497) has a better in vitro half-life than Ligand B (-8.285).
**14. P-gp Efflux:** Ligand A (0.029) has a much lower P-gp efflux liability than Ligand B (0.062), which is favorable for oral bioavailability.
**15. Binding Affinity:** Ligand A (-7.2 kcal/mol) has a slightly better binding affinity than Ligand B (-6.7 kcal/mol). While the difference is not huge, it's enough to be considered.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity), Ligand A is the better candidate. While Ligand B has a better QED score, the superior hERG safety, lower P-gp efflux, better metabolic stability (lower Cl_mic and better t1/2), and slightly better affinity of Ligand A outweigh this advantage. The TPSA of Ligand A is also more reasonable for a peripherally acting GPCR. The solubility and Caco-2 permeability issues are similar for both and would require further investigation, but don't currently sway the decision.
Output:
1
2025-04-17 18:10:34,402 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (335.411 and 373.856 Da) are within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (73.95) is slightly higher than Ligand B (67.59). Both are below the 140 threshold for good oral absorption, and acceptable for a cardiovascular GPCR. Ligand B is slightly better.
3. **logP:** Both ligands have similar logP values (1.878 and 1.817), falling within the optimal 1-3 range. No significant difference.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Both have 5 HBA, which is good.
6. **QED:** Ligand A (0.909) has a significantly better QED score than Ligand B (0.74), indicating a more drug-like profile. This is a substantial advantage for Ligand A.
7. **DILI:** Ligand A (46.762) has a slightly higher DILI risk than Ligand B (39.201), but both are below the concerning threshold of 60. Ligand B is slightly better.
8. **BBB:** Ligand B (82.009) has a much higher BBB penetration percentile than Ligand A (64.327). While ADRB2 isn't a CNS target, higher BBB is generally favorable, indicating less off-target CNS activity. Ligand B is better.
9. **Caco-2:** Ligand A (-5.102) and Ligand B (-4.623) both have negative Caco-2 values, which is unusual and suggests poor permeability. This is a significant concern for both. Ligand B is slightly better.
10. **Solubility:** Ligand A (-2.366) and Ligand B (-2.084) both have negative solubility values, indicating poor aqueous solubility. This is a significant concern for both. Ligand B is slightly better.
11. **hERG:** Ligand A (0.586) has a slightly higher hERG inhibition liability than Ligand B (0.389), indicating a slightly higher risk of cardiotoxicity. Ligand B is better.
12. **Cl_mic:** Ligand A (-14.051) has a much lower (better) microsomal clearance than Ligand B (27.363), suggesting greater metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (38.232) has a much longer in vitro half-life than Ligand B (-3.658), which is a major advantage.
14. **Pgp:** Ligand A (0.103) has a lower P-gp efflux liability than Ligand B (0.157), which is favorable.
15. **Binding Affinity:** Ligand B (-8.0) has a significantly stronger binding affinity (-8.0 kcal/mol) than Ligand A (-6.6 kcal/mol). This is a substantial advantage for Ligand B, potentially outweighing some ADME concerns.
**Overall Assessment:**
Ligand B has a significantly better binding affinity and BBB penetration, and slightly better Caco-2, solubility, DILI, and hERG. However, Ligand A has a much better QED score, significantly better metabolic stability (lower Cl_mic) and longer half-life, and lower Pgp efflux. The difference in binding affinity is substantial (1.4 kcal/mol).
Given the GPCR target class, binding affinity is paramount. While Ligand A has better ADME properties, the substantial difference in binding affinity of Ligand B is likely to be more important for achieving efficacy. The slightly worse ADME properties of Ligand B can potentially be addressed through further optimization.
Output:
0
2025-04-17 18:10:34,403 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (342.355 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (112.37) is better than Ligand B (29.54). For a cardiovascular GPCR, a lower TPSA is preferable for better membrane permeability. Ligand B is exceptionally low, which could be a concern for binding.
3. **logP:** Ligand A (1.872) is within the optimal range (1-3), while Ligand B (4.137) is slightly high. Higher logP can lead to solubility issues and off-target interactions.
4. **HBD:** Ligand A (1) is better than Ligand B (0). Having at least one HBD can improve solubility.
5. **HBA:** Ligand A (6) is better than Ligand B (3). A moderate number of HBAs is good for solubility without sacrificing permeability.
6. **QED:** Ligand A (0.907) is significantly better than Ligand B (0.803), indicating a more drug-like profile.
7. **DILI:** Ligand A (70.88) is higher than Ligand B (37.611). Ligand B has a much lower DILI risk, which is a significant advantage.
8. **BBB:** Ligand A (62.466) is lower than Ligand B (95.696). While ADRB2 isn't necessarily a CNS target, higher BBB penetration can sometimes indicate better overall permeability and distribution.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it is difficult to interpret.
10. **Solubility:** Both ligands have negative solubility values, which is also unusual and suggests poor solubility.
11. **hERG:** Ligand A (0.411) is better than Ligand B (0.861), indicating a lower risk of cardiotoxicity.
12. **Cl_mic:** Ligand A (10.603) is much lower than Ligand B (86.453), suggesting better metabolic stability.
13. **t1/2:** Ligand A (17.997) and Ligand B (17.471) are comparable.
14. **Pgp:** Ligand A (0.185) is much lower than Ligand B (0.81), indicating lower P-gp efflux and potentially better bioavailability.
15. **Affinity:** Ligand B (-7.7 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.2 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME drawbacks.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in affinity and has a favorable Pgp score. Ligand A has a better TPSA and logP.
**Overall Assessment:**
Ligand B's significantly stronger binding affinity (-7.7 kcal/mol vs -6.2 kcal/mol) is a major advantage, especially for a GPCR target. While it has a higher logP and DILI risk, the potency difference is substantial enough to overcome these concerns, particularly if further optimization can address the logP and DILI issues. Ligand A has a better ADME profile overall, but the weaker affinity is a significant drawback.
Output:
0
2025-04-17 18:10:34,403 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [345.403, 98.14, 2.603, 2, 6, 0.784, 80.186, 58.976, -4.542, -4.001, 0.134, 81.011, 8.709, 0.052, -5.8]
**Ligand B:** [350.413, 61.02, 3.063, 2, 3, 0.731, 47.421, 71.811, -5.111, -3.268, 0.921, 22.552, 8.065, 0.142, -7.3]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). A (345.4) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** A (98.14) is higher than B (61.02). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is still preferred for better absorption. B is significantly better here.
3. **logP:** Both are within the optimal range (1-3). B (3.063) is slightly higher, which could potentially lead to some off-target interactions, but is still acceptable.
4. **HBD:** Both have 2 HBD, which is good.
5. **HBA:** A has 6, B has 3. B is better, as lower HBA generally improves permeability.
6. **QED:** Both are above 0.5 (A: 0.784, B: 0.731), indicating good drug-like properties.
7. **DILI:** A (80.186) has a significantly higher DILI risk than B (47.421). This is a major concern.
8. **BBB:** B (71.811) has better BBB penetration than A (58.976). While not a primary concern for a cardiovascular target, it's a bonus.
9. **Caco-2:** A (-4.542) is worse than B (-5.111), indicating lower intestinal absorption.
10. **Solubility:** A (-4.001) is worse than B (-3.268), indicating lower solubility.
11. **hERG:** A (0.134) has a slightly lower hERG risk than B (0.921), but both are relatively low.
12. **Cl_mic:** B (22.552) has significantly lower microsomal clearance than A (81.011), indicating better metabolic stability.
13. **t1/2:** Both have similar in vitro half-lives (A: 8.709, B: 8.065).
14. **Pgp:** A (0.052) has lower P-gp efflux than B (0.142), which is a slight advantage.
15. **Affinity:** B (-7.3) has a significantly stronger binding affinity than A (-5.8). This is a substantial advantage (1.5 kcal/mol difference).
**GPCR-Specific Priorities:** For ADRB2 (a cardiovascular GPCR), we prioritize logP, Pgp, TPSA, and affinity. B excels in TPSA and affinity, and is comparable in logP and Pgp. The biggest drawback for A is the high DILI risk and poorer ADME properties (Caco-2, solubility, Cl_mic). The superior binding affinity of B is a significant factor, and can outweigh minor ADME concerns.
**Conclusion:**
Ligand B is the more promising candidate due to its superior binding affinity, lower DILI risk, better ADME properties (TPSA, Caco-2, solubility, Cl_mic), and acceptable BBB penetration.
Output:
0
2025-04-17 18:10:34,403 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (338.34 and 336.40 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (62.55) is significantly better than Ligand B (85.01). ADRB2 is not a CNS target, but lower TPSA generally favors absorption.
3. **logP:** Both ligands have good logP values (3.69 and 3.04), falling within the 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability, but not drastically.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Both have 3 HBA, which is acceptable.
6. **QED:** Ligand A (0.775) has a better QED score than Ligand B (0.683), indicating a more drug-like profile.
7. **DILI:** Ligand B (44.1%) has a much lower DILI risk than Ligand A (90.2%). This is a significant advantage for Ligand B.
8. **BBB:** This is less critical for ADRB2, but Ligand A (87.1%) is better than Ligand B (27.0%).
9. **Caco-2:** Ligand A (-4.52) is better than Ligand B (-5.60), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-4.73) is better than Ligand B (-3.34), indicating better aqueous solubility.
11. **hERG:** Ligand A (0.79) has a lower hERG risk than Ligand B (0.29). This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand A (52.28) has a higher (worse) microsomal clearance than Ligand B (-4.36). This suggests Ligand B is more metabolically stable.
13. **t1/2:** Ligand A (81.52) has a much longer in vitro half-life than Ligand B (-14.64). This is a major advantage for Ligand A.
14. **Pgp:** Ligand A (0.56) has a lower Pgp efflux liability than Ligand B (0.03), which is preferable.
15. **Affinity:** Ligand A (-6.9 kcal/mol) has a slightly better binding affinity than Ligand B (-5.2 kcal/mol). While the difference is not huge, it's still a positive for Ligand A.
**Overall Assessment:**
Ligand A generally performs better across most ADME properties, with the exception of DILI risk and metabolic stability. The longer half-life and better solubility of Ligand A are very attractive. The slightly better affinity is also a plus. While Ligand B has a lower DILI risk, the overall profile of Ligand A is more favorable, especially considering the moderate DILI risk of Ligand A (90.2% is concerning but not prohibitive, and can be addressed with further optimization).
Output:
1
2025-04-17 18:10:34,403 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
The target is ADRB2, a GPCR. Therefore, the priorities are logP, TPSA, Pgp efflux, BBB penetration, and binding affinity. We also need to consider general drug-like properties and safety parameters.
Let's compare the ligands property by property:
1. **MW:** Both ligands (361.844 and 376.519 Da) are within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (29.54) is significantly better than Ligand B (96.89). A TPSA under 140 is good for oral absorption, and Ligand A is well within this range, while Ligand B is quite high, potentially hindering absorption.
3. **logP:** Ligand A (4.484) is a bit high, but still acceptable. Ligand B (1.104) is on the lower side, potentially causing permeability issues.
4. **HBD/HBA:** Ligand A (0 HBD, 3 HBA) is preferable to Ligand B (3 HBD, 6 HBA). Fewer hydrogen bond donors/acceptors generally improve permeability.
5. **QED:** Ligand A (0.752) is better than Ligand B (0.494), indicating a more drug-like profile.
6. **DILI:** Ligand B (23.459) has a much lower DILI risk than Ligand A (48.468), a significant advantage.
7. **BBB:** Ligand A (93.68) has excellent BBB penetration, while Ligand B (34.626) is poor. While ADRB2 isn't exclusively a CNS target, good BBB penetration is still a positive attribute.
8. **Caco-2:** Ligand A (-4.506) is better than Ligand B (-5.448), suggesting better intestinal absorption.
9. **Solubility:** Ligand A (-4.866) is better than Ligand B (-2.33), indicating better aqueous solubility.
10. **hERG:** Ligand A (0.927) is better than Ligand B (0.173), indicating lower hERG inhibition liability and reduced cardiotoxicity risk.
11. **Cl_mic:** Ligand B (22.728) has lower microsomal clearance than Ligand A (72.674), suggesting better metabolic stability.
12. **t1/2:** Ligand B (-7.27) has a longer in vitro half-life than Ligand A (-6.024), which is a positive.
13. **Pgp:** Ligand A (0.611) has lower P-gp efflux than Ligand B (0.031), which is better for bioavailability and potential CNS exposure.
14. **Affinity:** Ligand A (-8.6 kcal/mol) has a significantly stronger binding affinity than Ligand B (-5.5 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME drawbacks of Ligand A.
**Overall Assessment:**
Ligand A has a superior binding affinity and better overall drug-like properties (QED, TPSA, solubility, Caco-2, Pgp, hERG). The higher logP is a slight concern, but the strong affinity and favorable permeability indicators (low TPSA, good Caco-2) are compelling. Ligand B has a better safety profile (lower DILI, better metabolic stability, longer half-life), but its weaker affinity and higher TPSA are major drawbacks for a GPCR target. The difference in affinity is substantial (>3 kcal/mol).
Given the prioritization of affinity for GPCRs, and the generally favorable profile of Ligand A, I favor Ligand A.
**Output:**
1
2025-04-17 18:10:34,403 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 drug candidates. ADRB2 is a GPCR, so we'll prioritize logP, Pgp, TPSA, and affinity, alongside general drug-like properties.
**Ligand A:** [347.503, 43.86, 2.275, 0, 3, 0.717, 5.777, 81, -4.59, -1.752, 0.582, 23.524, 22.791, 0.052, -4.8]
**Ligand B:** [348.487, 49.85, 2.299, 0, 3, 0.766, 13.843, 84.917, -4.482, -1.935, 0.452, 38.635, 2.153, 0.126, -6.1]
1. **MW:** Both are within the ideal range (347-348 Da). No significant difference.
2. **TPSA:** Ligand A (43.86) is better than Ligand B (49.85). Lower TPSA generally favors better absorption.
3. **logP:** Both are good (around 2.3), falling within the optimal 1-3 range. No clear winner.
4. **HBD:** Both have 0 HBD, which is acceptable.
5. **HBA:** Both have 3 HBA, which is acceptable.
6. **QED:** Both are good (0.717 and 0.766), indicating drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (5.777) is *significantly* better than Ligand B (13.843). This is a major advantage for Ligand A.
8. **BBB:** Both have good BBB penetration (81% and 84.9%), but Ligand B is slightly better. This is less critical for a non-CNS target like ADRB2, but still a positive.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-4.59) is slightly better than Ligand B (-4.482).
10. **Solubility:** Both are negative, indicating poor solubility. Ligand B (-1.935) is slightly worse than Ligand A (-1.752).
11. **hERG:** Both have low hERG risk (0.582 and 0.452). No significant difference.
12. **Cl_mic:** Ligand A (23.524) has a much lower microsomal clearance than Ligand B (38.635), suggesting better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand A (22.791) has a much longer in vitro half-life than Ligand B (2.153). This is a major advantage.
14. **Pgp:** Ligand A (0.052) has lower P-gp efflux than Ligand B (0.126), suggesting better bioavailability.
15. **Affinity:** Ligand B (-6.1 kcal/mol) has a significantly stronger binding affinity than Ligand A (-4.8 kcal/mol). This is a substantial advantage, potentially outweighing some ADME concerns.
**Overall Assessment:**
While Ligand B boasts a superior binding affinity, Ligand A has a significantly better safety profile (DILI), metabolic stability (Cl_mic, t1/2), and Pgp efflux. The affinity difference is 1.3 kcal/mol, which is substantial, but the ADME/Tox advantages of Ligand A are compelling, especially the DILI risk. For a cardiovascular target, metabolic stability and minimizing off-target effects (like liver toxicity) are crucial. The slightly better BBB of Ligand B is less important for a non-CNS target.
Therefore, considering the balance of properties and the priorities for a GPCR targeting the cardiovascular system, I favor Ligand A.
1
2025-04-17 18:10:34,403 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [344.499, 50.36, 4.641, 2, 2, 0.839, 49.283, 79.682, -4.554, -4.877, 0.573, 58.919, 31.323, 0.487, -6.4]
**Ligand B:** [362.539, 58.2, 4.121, 2, 3, 0.717, 30.748, 63.746, -4.903, -3.41, 0.401, 61.361, 23.289, 0.257, -7.9]
Here's a breakdown, prioritizing GPCR properties (logP, Pgp, TPSA, and affinity) and considering the other parameters:
1. **Molecular Weight:** Both are within the ideal range (200-500 Da). Ligand A (344.499) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (50.36) is better than Ligand B (58.2), being closer to the <140 threshold for good oral absorption.
3. **logP:** Both are good (around 4), but Ligand B (4.121) is slightly lower than Ligand A (4.641). While both are acceptable, a slightly lower logP can sometimes reduce off-target effects.
4. **H-Bond Donors/Acceptors:** Both have reasonable HBD (2) and HBA (2/3) counts.
5. **QED:** Ligand A (0.839) has a better QED score than Ligand B (0.717), indicating a more drug-like profile.
6. **DILI:** Ligand B (30.748) has a significantly lower DILI risk than Ligand A (49.283), which is a major advantage.
7. **BBB:** Ligand A (79.682) has a better BBB penetration percentile than Ligand B (63.746). This is important for potential CNS effects, but less critical for a cardiovascular target like ADRB2.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.554) is slightly better than Ligand B (-4.903).
9. **Solubility:** Ligand A (-4.877) has better solubility than Ligand B (-3.41).
10. **hERG:** Both have low hERG risk (0.573 and 0.401), which is good.
11. **Cl_mic:** Ligand B (61.361) has slightly better metabolic stability (lower clearance) than Ligand A (58.919).
12. **t1/2:** Ligand A (31.323) has a longer in vitro half-life than Ligand B (23.289), which is desirable.
13. **Pgp:** Ligand A (0.487) has lower P-gp efflux than Ligand B (0.257), which is favorable for bioavailability.
14. **Binding Affinity:** Ligand B (-7.9) has a significantly stronger binding affinity than Ligand A (-6.4). This is a substantial advantage (1.5 kcal/mol difference).
**Overall Assessment:**
While Ligand A has better QED, BBB, solubility, and half-life, Ligand B's significantly stronger binding affinity (-7.9 vs -6.4 kcal/mol) and much lower DILI risk are compelling advantages. The difference in binding affinity is large enough to potentially overcome the slightly less favorable ADME properties of Ligand B. The lower DILI risk is also a critical factor, as liver toxicity is a major concern in drug development. The Caco-2 values are concerning for both, but the binding affinity difference is substantial.
Therefore, I would choose Ligand B.
0
2025-04-17 18:10:34,403 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (353.849 and 348.403 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (42.24) is significantly better than Ligand B (98.91). For a GPCR, keeping TPSA low is beneficial for permeability, and Ligand A is well below the 140 A^2 threshold, while Ligand B is approaching the upper limit.
**3. logP:** Ligand A (4.995) is higher than the optimal range (1-3), but still potentially manageable. Ligand B (-0.753) is *too* low, potentially leading to poor membrane permeability. This is a significant strike against Ligand B.
**4. H-Bond Donors:** Both have acceptable HBD counts (1 and 2 respectively), well within the limit of 5.
**5. H-Bond Acceptors:** Ligand A (2) is better than Ligand B (6), as lower HBA generally improves permeability.
**6. QED:** Both ligands have similar, good QED values (0.717 and 0.726), indicating generally drug-like properties.
**7. DILI Risk:** Ligand A (59.907) has a moderate DILI risk, while Ligand B (18.845) has a very low risk. This is a point in favor of Ligand B.
**8. BBB Penetration:** Ligand A (62.854) shows moderate BBB penetration, while Ligand B (26.638) is quite low. While ADRB2 isn't necessarily a CNS target, some degree of BBB penetration can be useful for understanding off-target effects and overall distribution.
**9. Caco-2 Permeability:** Ligand A (-4.951) and Ligand B (-5.526) both have negative Caco-2 values. This is unusual and suggests poor permeability. However, the scale is not specified, and these values might be relative to a reference compound.
**10. Aqueous Solubility:** Ligand A (-4.327) and Ligand B (-0.551) both have negative solubility values. This suggests poor solubility.
**11. hERG Inhibition:** Ligand A (0.691) has a slightly higher hERG risk than Ligand B (0.121), which is preferable.
**12. Microsomal Clearance:** Ligand B (-5.275) has a significantly lower (better) microsomal clearance than Ligand A (62.41). This suggests better metabolic stability for Ligand B.
**13. In vitro Half-Life:** Ligand A (185.663) has a much longer half-life than Ligand B (7.03). This is a significant advantage for Ligand A.
**14. P-gp Efflux:** Ligand A (0.757) has a higher P-gp efflux liability than Ligand B (0.011). Lower P-gp efflux is better, favoring Ligand B.
**15. Binding Affinity:** Ligand B (-7.6 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.6 kcal/mol). This is a substantial advantage, potentially outweighing some ADME concerns.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand B is more promising. While Ligand A has a longer half-life, the significantly better affinity of Ligand B (-7.6 vs -6.6 kcal/mol) is a major advantage. The lower logP of Ligand B is a concern, but the lower P-gp efflux and DILI risk, combined with the superior binding, make it the better candidate. The TPSA of Ligand A is also much more favorable.
Output:
1
2025-04-17 18:10:34,404 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (358.438 and 364.408 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (44.12) is significantly better than Ligand B (78.43). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold, while B is approaching it.
3. **logP:** Ligand A (4.197) is higher than Ligand B (1.993). While both are within the acceptable range (1-3), Ligand A is at the upper end. This could potentially lead to solubility issues or off-target interactions, but for a GPCR, some lipophilicity is beneficial for membrane interactions.
4. **HBD:** Ligand A (0) is better than Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (5) is better than Ligand B (3). Fewer HBAs generally improve permeability.
6. **QED:** Both ligands have similar QED values (0.659 and 0.616), indicating good drug-like properties.
7. **DILI:** Ligand A (75.766) has a considerably higher DILI risk than Ligand B (21.946). This is a significant concern.
8. **BBB:** Both ligands have good BBB penetration (80.807 and 76.464). This isn't a primary concern for a cardiovascular target, but it doesn't hurt.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it is difficult to interpret.
10. **Solubility:** Ligand A (-4.734) has worse solubility than Ligand B (-2.514). This is consistent with its higher logP.
11. **hERG:** Both ligands have low hERG inhibition risk (0.369 and 0.434).
12. **Cl_mic:** Ligand A (91.636) has a higher microsomal clearance than Ligand B (7.245), indicating lower metabolic stability.
13. **t1/2:** Ligand A (22.412) has a longer half-life than Ligand B (6.424). This is a positive attribute.
14. **Pgp:** Ligand A (0.659) has higher P-gp efflux than Ligand B (0.097). Lower P-gp is preferred.
15. **Binding Affinity:** Ligand B (-7.2 kcal/mol) has significantly stronger binding affinity than Ligand A (-5.3 kcal/mol). This is a crucial advantage, exceeding the 1.5 kcal/mol threshold.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), affinity, logP, TPSA, and Pgp are key. Ligand B excels in affinity, has a more favorable logP, and significantly lower Pgp efflux. While Ligand A has a lower TPSA, the substantial difference in affinity and the concerning DILI risk outweigh this benefit.
**Conclusion:**
Despite Ligand A's slightly lower TPSA and longer half-life, the significantly stronger binding affinity of Ligand B, coupled with its much lower DILI risk and lower P-gp efflux, makes it the more promising drug candidate. The solubility and metabolic stability concerns for Ligand B are addressable through formulation and structural modifications, whereas the high DILI risk of Ligand A is a more difficult hurdle.
Output:
0
2025-04-17 18:10:34,404 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (345.447 Da) is slightly lower, which is generally favorable for permeability.
**2. TPSA:** Ligand A (80.55) is significantly better than Ligand B (97.62). For a GPCR, keeping TPSA under 140 is good, but lower is preferable for better absorption.
**3. logP:** Ligand A (3.322) is optimal, while Ligand B (1.151) is a bit low. A logP between 1-3 is ideal, and Ligand B's value could potentially lead to permeability issues.
**4. H-Bond Donors:** Ligand A (2) is better than Ligand B (3). Fewer HBDs generally improve permeability.
**5. H-Bond Acceptors:** Ligand A (5) is better than Ligand B (8). Similar to HBDs, lower HBA counts are generally preferred.
**6. QED:** Ligand A (0.871) is significantly better than Ligand B (0.634), indicating a more drug-like profile.
**7. DILI Risk:** Ligand B (67.429) has a higher DILI risk than Ligand A (56.068), though both are acceptable. Lower is always better.
**8. BBB Penetration:** Ligand A (86.778) has better BBB penetration than Ligand B (74.99). While ADRB2 is a cardiovascular target, some CNS effects are possible with certain ligands, and higher BBB penetration is generally not detrimental.
**9. Caco-2 Permeability:** Ligand A (-4.62) is better than Ligand B (-5.104), indicating better intestinal absorption.
**10. Aqueous Solubility:** Ligand A (-3.976) is better than Ligand B (-3.227).
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.383 and 0.315 respectively), which is excellent.
**12. Microsomal Clearance:** Ligand B (31.116) has lower microsomal clearance than Ligand A (40.959), suggesting better metabolic stability.
**13. In vitro Half-Life:** Ligand A (37.013) has a much longer half-life than Ligand B (6.425). This is a significant advantage for dosing convenience.
**14. P-gp Efflux:** Both ligands have similar P-gp efflux liability (0.083 and 0.017).
**15. Binding Affinity:** Ligand B (-7.8 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.5 kcal/mol). This is a substantial advantage, potentially outweighing some ADME drawbacks.
**Overall Assessment:**
Ligand B has a substantially better binding affinity, which is a primary driver for GPCR drug candidates. While Ligand A has better ADME properties across many parameters (TPSA, logP, QED, solubility, half-life), the difference in binding affinity is significant enough to favor Ligand B. The slightly higher DILI risk and lower metabolic stability of Ligand B can be addressed during further optimization.
Output:
0
2025-04-17 18:10:34,404 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 drug candidates. ADRB2 is a GPCR, so we'll prioritize logP, Pgp, TPSA, and affinity, alongside general drug-like properties.
**Ligand A:** [356.463, 88.1, 0.41, 2, 5, 0.625, 12.33, 57.736, -4.685, -1.037, 0.183, 21.068, 3.385, 0.011, -6.4]
**Ligand B:** [350.419, 96.55, 0.295, 2, 5, 0.814, 54.556, 36.952, -5.116, -1.57, 0.119, -12.679, -10.095, 0.01, -6.5]
1. **MW:** Both are within the ideal 200-500 Da range. A (356.463) and B (350.419) are very similar.
2. **TPSA:** A (88.1) is better than B (96.55), being closer to the <140 threshold for oral absorption.
3. **logP:** A (0.41) is slightly better than B (0.295), both are a little low, potentially hindering permeability, but not drastically.
4. **HBD:** Both have 2 HBD, which is acceptable.
5. **HBA:** Both have 5 HBA, also acceptable.
6. **QED:** B (0.814) is significantly better than A (0.625), indicating a more drug-like profile.
7. **DILI:** A (12.33) is considerably better than B (54.556), indicating a much lower risk of liver injury. This is a significant advantage.
8. **BBB:** A (57.736) is better than B (36.952), though neither are particularly high. For a non-CNS target like many ADRB2 applications, this is less critical.
9. **Caco-2:** A (-4.685) is better than B (-5.116), suggesting better intestinal absorption.
10. **Solubility:** A (-1.037) is better than B (-1.57), indicating better aqueous solubility.
11. **hERG:** Both are very low (0.183 and 0.119), indicating minimal hERG inhibition risk.
12. **Cl_mic:** B (-12.679) is *much* better than A (21.068), indicating significantly higher metabolic stability. This is a major advantage.
13. **t1/2:** B (-10.095) is better than A (3.385) suggesting a longer half-life.
14. **Pgp:** Both are very low (0.011 and 0.01), indicating minimal P-gp efflux.
15. **Affinity:** B (-6.5) is slightly better than A (-6.4), but the difference is small.
**Overall Assessment:**
Ligand B has a superior QED, metabolic stability (Cl_mic), and in vitro half-life. However, Ligand A has a much better DILI score and slightly better TPSA, Caco-2 permeability, and solubility. The difference in affinity is negligible. Given the importance of minimizing toxicity (DILI) and ensuring reasonable absorption (TPSA, Caco-2, Solubility) for a cardiovascular target, and the significant advantage A has in DILI, I favor Ligand A. The improved metabolic stability of B is attractive, but not enough to overcome the higher DILI risk.
Output:
1
2025-04-17 18:10:34,404 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.487 and 357.376 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (58.64) is better than Ligand B (69.12). Both are below the 140 threshold for oral absorption, but lower TPSA is generally preferred for GPCRs, potentially aiding in receptor penetration.
3. **logP:** Both ligands have good logP values (2.801 and 3.167), falling within the optimal 1-3 range. Ligand B is slightly higher, which *could* be a minor drawback if it impacts solubility, but is not a major concern.
4. **HBD:** Both have 1 HBD, which is within the acceptable limit of 5.
5. **HBA:** Both have 3 HBA, which is within the acceptable limit of 10.
6. **QED:** Both have good QED scores (0.751 and 0.815), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (9.771) has a significantly lower DILI risk than Ligand B (43.66). This is a substantial advantage for Ligand A.
8. **BBB:** Ligand A (85.459) has a higher BBB penetration percentile than Ligand B (76.696). While ADRB2 isn't exclusively a CNS target, some peripheral effects are mediated by CNS pathways, and higher BBB penetration can be beneficial.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.697 and -4.67), indicating poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand A (-2.51) is better than Ligand B (-3.982). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.512) has a lower hERG inhibition liability than Ligand B (0.859). Lower hERG risk is crucial for cardiovascular drugs.
12. **Cl_mic:** Ligand B (32.724) has a lower microsomal clearance than Ligand A (45.531), suggesting better metabolic stability. This is a positive for Ligand B.
13. **t1/2:** Ligand B (-3.435) has a longer in vitro half-life than Ligand A (-0.846). This is a significant advantage for Ligand B.
14. **Pgp:** Both have very low Pgp efflux liability (0.176 and 0.15).
15. **Binding Affinity:** Both ligands have excellent binding affinity (-6.4 and -6.0 kcal/mol). Ligand A is slightly better, but the difference is less than 1.5 kcal/mol.
**Overall Assessment:**
Ligand A has several key advantages: lower DILI risk, better BBB penetration, better solubility, and lower hERG inhibition. While Ligand B has better metabolic stability and half-life, the DILI and hERG risks associated with Ligand B are concerning, especially for a cardiovascular target. The slightly better affinity of Ligand A is a bonus. The poor Caco-2 values are a concern for both, but can be addressed with formulation strategies.
Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity) and the overall balance of properties, Ligand A is the more promising candidate.
Output:
1
2025-04-17 18:10:34,404 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**1. Molecular Weight:** Both ligands (351.491 and 374.478 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (69.72) is significantly better than Ligand B (92.34). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is approaching a TPSA that could hinder oral absorption.
**3. logP:** Both ligands have good logP values (1.934 and 1.786), falling within the optimal 1-3 range. A slight edge to Ligand B, but negligible.
**4. H-Bond Donors:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs generally improve membrane permeability.
**5. H-Bond Acceptors:** Ligand A (3) is preferable to Ligand B (4). Similar to HBDs, fewer HBAs are generally better for permeability.
**6. QED:** Ligand A (0.68) is slightly better than Ligand B (0.5), indicating a more drug-like profile.
**7. DILI Risk:** Ligand A (13.571) has a much lower DILI risk than Ligand B (57.348). This is a major advantage for Ligand A. A DILI percentile over 50 is concerning.
**8. BBB Penetration:** Ligand B (75.805) has better BBB penetration than Ligand A (67.933). While ADRB2 isn't strictly a CNS target, some CNS exposure can be relevant for off-target effects, and better BBB penetration can sometimes correlate with improved overall distribution.
**9. Caco-2 Permeability:** Both ligands have similar, very negative Caco-2 values (-4.794 and -4.703). This suggests poor permeability.
**10. Aqueous Solubility:** Both ligands have very poor aqueous solubility (-2.081 and -2.54). This is a significant drawback for both, potentially hindering bioavailability.
**11. hERG Inhibition:** Ligand A (0.574) has a lower hERG inhibition risk than Ligand B (0.215). Lower is better here, indicating less cardiotoxicity potential.
**12. Microsomal Clearance:** Ligand A (23.782) has lower microsomal clearance than Ligand B (30.955), suggesting better metabolic stability.
**13. In vitro Half-Life:** Ligand A (-9.548) has a significantly longer in vitro half-life than Ligand B (25.44). This is a major advantage, potentially leading to less frequent dosing.
**14. P-gp Efflux:** Ligand A (0.081) has lower P-gp efflux than Ligand B (0.151), suggesting better bioavailability.
**15. Binding Affinity:** Both ligands have very similar binding affinities (-5.1 and -5.2 kcal/mol). The difference is negligible.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity) and the general drug-like properties, Ligand A is the superior candidate. While Ligand B has slightly better BBB penetration, Ligand A excels in critical areas like DILI risk, metabolic stability (lower Cl_mic and longer t1/2), P-gp efflux, and TPSA. The lower DILI risk and improved metabolic stability are particularly important for a cardiovascular target. The similar binding affinities make these ADME properties the deciding factors.
Output:
1
2025-04-17 18:10:34,404 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for the ADRB2, a cardiovascular GPCR. Therefore, the priorities are logP, TPSA, Pgp, affinity, and to a lesser extent, BBB.
Let's compare the ligands property by property:
1. **MW:** Both are within the ideal range (358 & 366 Da).
2. **TPSA:** Ligand A (78.87) is better than Ligand B (84.47). Lower TPSA generally favors oral absorption, which is important for a cardiovascular drug.
3. **logP:** Both are very similar and optimal (1.409 & 1.46).
4. **HBD:** Ligand A (2) is better than Ligand B (0). While low HBD can be good for permeability, some H-bonding is beneficial for solubility.
5. **HBA:** Ligand B (6) is slightly better than Ligand A (4).
6. **QED:** Both are good (0.752 & 0.8).
7. **DILI:** Ligand A (20.861) is significantly better than Ligand B (67.429). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (70.609) is better than Ligand B (55.176). While not a primary concern for a cardiovascular target, higher BBB is still favorable.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-4.706) is slightly better than Ligand B (-4.88).
10. **Solubility:** Both are negative, indicating poor solubility. Ligand A (-1.934) is slightly better than Ligand B (-1.969).
11. **hERG:** Both are very low (0.484 & 0.087), indicating low cardiotoxicity risk. Ligand B is slightly better.
12. **Cl_mic:** Ligand A (11.882) is significantly better than Ligand B (25.819). Lower clearance implies better metabolic stability.
13. **t1/2:** Ligand B (17.097) is better than Ligand A (15.102).
14. **Pgp:** Both are very low (0.081 & 0.079), indicating low efflux.
15. **Affinity:** Ligand B (-6.8) is 0.1 kcal/mol better than Ligand A (-5.7). This is a significant difference in binding.
**Overall Assessment:**
Ligand B has a better binding affinity, and a slightly better half-life. However, Ligand A has significantly better DILI risk, metabolic stability (lower Cl_mic), and a better BBB score. The DILI risk is a critical factor, as liver toxicity is a common issue in drug development. The slightly better affinity of Ligand B doesn't outweigh the substantial improvement in safety and metabolic stability offered by Ligand A.
**Output:**
1
2025-04-17 18:10:34,404 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Step-by-step comparison:**
1. **MW:** Ligand A (363.307 Da) and Ligand B (345.447 Da) are both within the ideal range (200-500 Da). No significant difference here.
2. **TPSA:** Ligand A (72.47) and Ligand B (70.47) are both good, well below the 140 A^2 threshold for oral absorption.
3. **logP:** Ligand A (2.565) is optimal, while Ligand B (0.939) is slightly low, potentially impacting permeability. This favors Ligand A.
4. **HBD:** Both Ligand A (1) and Ligand B (1) are within the acceptable limit of 5.
5. **HBA:** Ligand A (4) and Ligand B (5) are both reasonable, below the 10 threshold.
6. **QED:** Ligand B (0.833) has a significantly better QED score than Ligand A (0.35), indicating a more drug-like profile. This favors Ligand B.
7. **DILI:** Ligand A (63.397) has a higher DILI risk than Ligand B (16.285). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (81.621) and Ligand B (91.043) both have good BBB penetration, but Ligand B is better.
9. **Caco-2:** Ligand A (-4.638) and Ligand B (-5.15) are both negative, indicating poor permeability. Ligand B is slightly worse.
10. **Solubility:** Ligand A (-3.778) and Ligand B (-1.586) both have poor aqueous solubility, but Ligand B is better.
11. **hERG:** Both Ligand A (0.59) and Ligand B (0.549) have similar hERG inhibition liability, posing a moderate risk.
12. **Cl_mic:** Ligand A (77.244) has a higher microsomal clearance than Ligand B (22.882), suggesting lower metabolic stability. This favors Ligand B.
13. **t1/2:** Ligand B (17.193) has a much longer in vitro half-life than Ligand A (-6.852). This is a substantial advantage for Ligand B.
14. **Pgp:** Ligand A (0.296) and Ligand B (0.08) both have low P-gp efflux, but Ligand B is better.
15. **Binding Affinity:** Ligand B (-7.3 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.1 kcal/mol). This is a major advantage for Ligand B, exceeding the 1.5 kcal/mol threshold.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), we prioritize logP, Pgp, TPSA, and affinity. Ligand B is better in terms of logP, Pgp, and significantly better in affinity. While TPSA is similar, the other factors strongly favor Ligand B. The better QED, lower DILI, longer half-life, and better BBB penetration also contribute to its superiority.
**Conclusion:**
Ligand B demonstrates a superior balance of properties, particularly its significantly higher binding affinity, lower DILI risk, and improved metabolic stability. While both have solubility and Caco-2 permeability issues, Ligand B's advantages outweigh its drawbacks.
Output:
0
2025-04-17 18:10:34,404 - INFO - Batch 18 complete. Total preferences: 288
2025-04-17 18:10:34,404 - INFO - Processing batch 19/512...
2025-04-17 18:11:22,527 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (353.463 and 350.415 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands are below the 140 A^2 threshold for good oral absorption (87.74 and 84.94 A^2). Ligand B is slightly better, but both are good.
3. **logP:** Both ligands have a logP around 0.7 (0.705 and 0.78), which is a bit low. While not ideal, it's not a major concern for a non-CNS target.
4. **HBD:** Ligand A has 2 HBD, and Ligand B has 1. Lower is generally better for permeability, so Ligand B has a slight edge.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 5. Both are acceptable, but lower is preferable.
6. **QED:** Both ligands have reasonable QED scores (0.598 and 0.542), indicating good drug-like properties. Ligand A is slightly better.
7. **DILI:** Ligand A (18.651%) has a significantly lower DILI risk than Ligand B (35.518%). This is a major advantage for Ligand A.
8. **BBB:** This is less critical for ADRB2 (a cardiovascular target), but Ligand A (60.45%) has better BBB penetration than Ligand B (50.679%).
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.013 and -4.704), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-0.739) has slightly better solubility than Ligand B (-2.021).
11. **hERG:** Both ligands have very low hERG inhibition risk (0.197 and 0.053). This is excellent for both.
12. **Cl_mic:** Ligand A (31.228 mL/min/kg) has a significantly lower microsomal clearance than Ligand B (5.316 mL/min/kg), indicating better metabolic stability.
13. **t1/2:** Ligand A (-0.635 hours) has a slightly better in vitro half-life than Ligand B (-0.078 hours), although both are very short.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.018 and 0.027).
15. **Binding Affinity:** Ligand B (-5.9 kcal/mol) has a slightly better binding affinity than Ligand A (-5.4 kcal/mol). This is a 0.5 kcal/mol difference, which is noticeable but not overwhelming.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity) and general drug-like properties, Ligand A is the more promising candidate. While Ligand B has slightly better affinity, Ligand A demonstrates a significantly better safety profile (lower DILI risk), improved metabolic stability (lower Cl_mic), and slightly better solubility and BBB penetration. The Caco-2 values are concerning for both, but the other advantages of Ligand A outweigh the small affinity difference.
Output:
1
2025-04-17 18:11:22,528 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (403.255 Da) is slightly higher than Ligand B (363.531 Da), but both are acceptable.
**2. TPSA:** Ligand A (61.88) is significantly better than Ligand B (70.15). For a GPCR, lower TPSA is generally preferred for better permeability.
**3. logP:** Both ligands have good logP values (A: 3.69, B: 2.739), falling within the optimal 1-3 range. Ligand A is slightly higher, which could potentially lead to some off-target interactions, but is still acceptable.
**4. H-Bond Donors:** Ligand A (1) is better than Ligand B (2). Fewer H-bond donors are generally preferred for improved membrane permeability.
**5. H-Bond Acceptors:** Ligand A (3) is better than Ligand B (6). Similar to HBDs, fewer HBAs are generally preferred.
**6. QED:** Both ligands have good QED scores (A: 0.664, B: 0.842), indicating good drug-like properties. Ligand B is slightly better here.
**7. DILI Risk:** Ligand A (70.492) has a higher DILI risk than Ligand B (51.26). This is a significant concern, as minimizing liver toxicity is crucial.
**8. BBB Penetration:** Both ligands have acceptable BBB penetration (A: 71.85, B: 74.835). While not a primary concern for a cardiovascular target, higher BBB is never detrimental. Ligand B is slightly better.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
**10. Aqueous Solubility:** Both ligands have negative solubility values, which is also unusual. Again, the scale is not specified.
**11. hERG Inhibition:** Ligand A (0.852) has a slightly higher hERG risk than Ligand B (0.27). Lower hERG is crucial to avoid cardiotoxicity.
**12. Microsomal Clearance:** Ligand A (48.239) has significantly better metabolic stability (lower clearance) than Ligand B (11.626). This is a major advantage, as it suggests a longer half-life and potentially less frequent dosing.
**13. In vitro Half-Life:** Ligand A (22.983) has a better in vitro half-life than Ligand B (32.629).
**14. P-gp Efflux:** Ligand A (0.62) has lower P-gp efflux than Ligand B (0.105). Lower P-gp efflux is desirable for improved oral bioavailability.
**15. Binding Affinity:** Ligand A (-5.6 kcal/mol) has a slightly better binding affinity than Ligand B (-4.0 kcal/mol). This difference in affinity is substantial (1.6 kcal/mol) and can outweigh some ADME drawbacks.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand A is the stronger candidate. While Ligand B has a better QED and lower DILI risk, Ligand A's superior affinity, lower TPSA, better metabolic stability (lower Cl_mic), and lower P-gp efflux outweigh these advantages. The higher DILI risk and hERG inhibition of Ligand A are concerns, but these can potentially be addressed through further structural modifications. The substantial difference in binding affinity is a key factor in this decision.
Output:
1
2025-04-17 18:11:22,528 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (348.443 and 365.493 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (67.87) is higher than Ligand B (29.02). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for better permeability. Ligand B is significantly better here.
**3. logP:** Ligand A (1.32) is within the optimal range (1-3). Ligand B (4.847) is higher, potentially leading to solubility issues and off-target interactions. Ligand A is preferable.
**4. H-Bond Donors:** Ligand A (1) is good. Ligand B (0) is also acceptable.
**5. H-Bond Acceptors:** Both ligands have 4 HBA, which is within the acceptable range.
**6. QED:** Ligand B (0.67) has a better QED score than Ligand A (0.388), indicating a more drug-like profile.
**7. DILI Risk:** Ligand A (17.449) has a much lower DILI risk than Ligand B (25.087). This is a significant advantage for Ligand A.
**8. BBB Penetration:** Ligand B (92.323) shows excellent BBB penetration, while Ligand A (57.619) is moderate. While ADRB2 isn't *primarily* a CNS target, some CNS exposure could be relevant, and Ligand B is better here.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, indicating poor permeability. Ligand A (-4.682) is slightly better than Ligand B (-4.569), but both are concerning.
**10. Aqueous Solubility:** Ligand A (-1.927) has better solubility than Ligand B (-4.974). This is important for formulation and bioavailability.
**11. hERG Inhibition:** Ligand A (0.192) has a lower hERG inhibition risk than Ligand B (0.815). This is a crucial safety parameter, favoring Ligand A.
**12. Microsomal Clearance:** Ligand A (14.138) has lower microsomal clearance, indicating better metabolic stability, compared to Ligand B (48.178).
**13. In vitro Half-Life:** Ligand B (12.267) has a longer half-life than Ligand A (4.265). This is a positive for Ligand B.
**14. P-gp Efflux:** Ligand A (0.045) has lower P-gp efflux than Ligand B (0.369), which is favorable for bioavailability.
**15. Binding Affinity:** Ligand B (-6.2) has a slightly better binding affinity than Ligand A (-5.7). However, the difference is only 0.5 kcal/mol, which is not a huge advantage considering the other factors.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), and the general drug-like properties, Ligand A appears to be the more promising candidate. While Ligand B has better BBB penetration and half-life, its higher logP, DILI risk, hERG inhibition, and P-gp efflux are significant drawbacks. Ligand A's better solubility, lower toxicity risks, and better metabolic stability outweigh the slightly weaker binding affinity and lower BBB penetration.
Output:
1
2025-04-17 18:11:22,528 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
We are targeting ADRB2, a GPCR. Therefore, logP, TPSA, Pgp efflux, BBB penetration, and binding affinity are key considerations.
Let's compare the ligands property by property:
1. **MW:** Both ligands (362.5 & 351.5 Da) fall within the ideal 200-500 Da range.
2. **TPSA:** Ligand B (48.0) is significantly better than Ligand A (74.3) as it is well below the 140 threshold for good oral absorption and more favorable for GPCRs.
3. **logP:** Both ligands have acceptable logP values (1.895 & 3.282), falling within the 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Ligand A has 2 HBD, while Ligand B has 0. Lower HBD is generally preferred for better permeability, giving a slight edge to Ligand B.
5. **HBA:** Ligand A has 5 HBA, and Ligand B has 4. Both are acceptable, below the 10 threshold.
6. **QED:** Ligand A (0.756) has a better QED score than Ligand B (0.497), indicating a more drug-like profile.
7. **DILI:** Ligand B (15.2) has a much lower DILI risk than Ligand A (34.8), which is a significant advantage.
8. **BBB:** Ligand B (87.1) has significantly better BBB penetration than Ligand A (61.7). While not a primary concern for peripheral GPCRs like ADRB2, it's still a positive attribute.
9. **Caco-2:** Both ligands have negative Caco-2 values, suggesting poor permeability. Ligand A (-5.135) is slightly worse than Ligand B (-4.365).
10. **Solubility:** Both ligands have negative solubility values, indicating poor aqueous solubility. Ligand A (-3.135) is slightly worse than Ligand B (-2.791).
11. **hERG:** Both ligands have low hERG inhibition risk (0.389 & 0.435).
12. **Cl_mic:** Ligand A (46.3) has a lower microsomal clearance than Ligand B (84.0), suggesting better metabolic stability.
13. **t1/2:** Ligand B (10.2) has a longer in vitro half-life than Ligand A (-8.1), which is a significant advantage.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.081 & 0.288).
15. **Affinity:** Ligand B (-6.6 kcal/mol) has a slightly better binding affinity than Ligand A (-6.2 kcal/mol).
**Overall Assessment:**
Ligand B demonstrates a superior balance of properties for a GPCR target. While Ligand A has a better QED and lower Cl_mic, Ligand B excels in crucial areas: significantly lower DILI risk, much better BBB penetration, better TPSA, and slightly better binding affinity. The longer half-life of Ligand B is also a positive factor. The slightly worse solubility and Caco-2 permeability of Ligand B are less concerning than the higher DILI risk associated with Ligand A.
**Output:**
0
2025-04-17 18:11:22,529 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [346.435, 93.84, 1.331, 2, 6, 0.705, 38.852, 62.854, -5.396, -1.352, 0.25, 17.551, 31.889, 0.016, -6.5]**
**Ligand B: [384.567, 51.66, 3.154, 0, 6, 0.612, 43.117, 82.551, -4.902, -2.468, 0.436, 55.209, -2.402, 0.243, -7.3]**
1. **Molecular Weight:** Both are within the ideal range (200-500 Da). A (346.435) is slightly preferred.
2. **TPSA:** A (93.84) is a bit higher, but still acceptable for a non-CNS GPCR target. B (51.66) is excellent. B is favored here.
3. **logP:** A (1.331) is optimal. B (3.154) is also good, but edging towards the higher end of the optimal range. A is favored.
4. **H-Bond Donors:** A (2) is good. B (0) is also good, but potentially could impact aqueous solubility. A is slightly favored.
5. **H-Bond Acceptors:** Both have 6, which is acceptable. No preference.
6. **QED:** A (0.705) is better than B (0.612), indicating a more drug-like profile. A is favored.
7. **DILI:** A (38.852) is better than B (43.117), indicating lower liver injury risk. A is favored.
8. **BBB:** ADRB2 is a cardiovascular target, so BBB penetration is not a primary concern. B (82.551) is higher, but this isn't a significant advantage.
9. **Caco-2:** Both are negative, indicating poor permeability. This is a concern for both.
10. **Aqueous Solubility:** Both are negative, indicating poor solubility. This is a concern for both.
11. **hERG:** A (0.25) is much better than B (0.436), indicating lower cardiotoxicity risk. A is strongly favored.
12. **Microsomal Clearance:** A (17.551) is much lower than B (55.209), suggesting better metabolic stability. A is strongly favored.
13. **In vitro Half-Life:** A (31.889) is better than B (-2.402), indicating a longer half-life. A is favored.
14. **P-gp Efflux:** A (0.016) is much lower than B (0.243), suggesting less efflux and better bioavailability. A is strongly favored.
15. **Binding Affinity:** B (-7.3) is 0.8 kcal/mol better than A (-6.5). This is a substantial difference and a major advantage for B.
**Overall Assessment:**
While Ligand B has a significantly better binding affinity (-7.3 vs -6.5 kcal/mol), Ligand A demonstrates a superior ADMET profile across multiple critical parameters (DILI, hERG, Cl_mic, P-gp, QED). The improved safety and pharmacokinetic properties of Ligand A outweigh the affinity difference, especially considering the target is a cardiovascular GPCR where a slight affinity difference can potentially be overcome with dose adjustments. The poor Caco-2 and solubility for both compounds are concerning and would require further optimization, but A's better overall profile makes it the more promising starting point.
Output:
1
2025-04-17 18:11:22,529 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.471 and 341.367 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (53.01) is significantly better than Ligand B (91.76). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold, while B is approaching it.
3. **logP:** Both ligands have acceptable logP values (2.677 and 3.202), falling within the 1-3 range. Ligand B is slightly higher, which could potentially lead to some off-target interactions, but not drastically.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs generally improve membrane permeability.
5. **HBA:** Both ligands have the same number of HBA (4), which is acceptable (<=10).
6. **QED:** Both ligands have similar QED values (0.914 and 0.891), indicating good drug-likeness.
7. **DILI:** Ligand A (23.536) has a much lower DILI risk than Ligand B (75.184). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (86.468) has better BBB penetration than Ligand B (78.48), but since ADRB2 is a cardiovascular target, this isn't a major deciding factor.
9. **Caco-2:** Ligand A (-4.279) shows better Caco-2 permeability than Ligand B (-4.869), suggesting better intestinal absorption.
10. **Solubility:** Ligand A (-2.293) has better aqueous solubility than Ligand B (-3.278).
11. **hERG:** Ligand A (0.849) has a slightly higher hERG risk than Ligand B (0.031). This is a concern for Ligand A, but the value is still relatively low.
12. **Cl_mic:** Ligand B (-13.22) has significantly lower microsomal clearance than Ligand A (2.4). This suggests better metabolic stability for Ligand B.
13. **t1/2:** Ligand B (-7.517) has a longer in vitro half-life than Ligand A (35.391). This is a major advantage for Ligand B.
14. **Pgp:** Ligand A (0.399) has lower P-gp efflux than Ligand B (0.006), which is preferable.
15. **Affinity:** Ligand B (-9.0) has a slightly better binding affinity than Ligand A (-7.6). While A is still good, the 1.4 kcal/mol difference is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand B has a superior binding affinity and better metabolic stability (lower Cl_mic, longer t1/2). While Ligand A has better TPSA, solubility, and lower DILI risk, the binding affinity difference and metabolic stability of Ligand B are more critical for a GPCR target like ADRB2. The slightly higher hERG risk of Ligand A is also a concern.
Output:
0
2025-04-17 18:11:22,529 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [350.419, 94.05, 0.459, 1, 5, 0.804, 24.583, 34.083, -5.009, -0.499, 0.024, 30.229, -6.575, 0.005, -4.1]
**Ligand B:** [388.021, 30.29, 4.327, 0, 5, 0.559, 21.714, 81.698, -5.179, -4.242, 0.913, 88.571, 37.107, 0.793, -5.7]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity) and general drug-like properties:
1. **MW:** Both are within the acceptable range (200-500 Da). Ligand A (350.419) is slightly preferred.
2. **TPSA:** Ligand B (30.29) is significantly better than Ligand A (94.05). Lower TPSA generally improves permeability, crucial for GPCR ligands.
3. **logP:** Ligand B (4.327) is a bit high, but still potentially manageable. Ligand A (0.459) is *too* low, potentially leading to poor membrane permeability. This is a significant drawback.
4. **HBD:** Ligand A (1) is preferable to Ligand B (0). Having at least one HBD can improve solubility.
5. **HBA:** Both have 5 HBA, which is acceptable.
6. **QED:** Ligand A (0.804) has a better QED score than Ligand B (0.559), indicating a more drug-like profile overall.
7. **DILI:** Both have low DILI risk (Ligand A: 24.583, Ligand B: 21.714), which is good.
8. **BBB:** Ligand B (81.698) has a much higher BBB penetration score than Ligand A (34.083). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be beneficial for distribution and off-target effects.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability.
10. **Solubility:** Ligand A (-0.499) is slightly better than Ligand B (-4.242), but both are poor.
11. **hERG:** Both have very low hERG inhibition risk (Ligand A: 0.024, Ligand B: 0.913).
12. **Cl_mic:** Ligand B (88.571) has a significantly higher microsomal clearance than Ligand A (30.229), suggesting faster metabolism and potentially lower *in vivo* exposure.
13. **t1/2:** Ligand B (37.107) has a much longer half-life than Ligand A (-6.575). This is a major advantage.
14. **Pgp:** Ligand A (0.005) has a much lower Pgp efflux liability than Ligand B (0.793), which is beneficial for bioavailability.
15. **Affinity:** Ligand B (-5.7) has a stronger binding affinity than Ligand A (-4.1). This is a substantial advantage, potentially outweighing some ADME concerns.
**Overall Assessment:**
Ligand B has a significantly better binding affinity and a much longer half-life. While its logP is a bit high and its Caco-2 permeability is poor, the strong affinity (-5.7 kcal/mol) is a critical advantage for a GPCR ligand. The higher BBB penetration is also a plus. The higher clearance is a concern, but can potentially be addressed through structural modifications. Ligand A's low logP is a major drawback, likely hindering its ability to reach the receptor.
Therefore, I prefer Ligand B.
0
2025-04-17 18:11:22,529 - INFO - Here's my reasoning and final output for the ligand preference:
**Reasoning:**
We are looking for a ligand targeting ADRB2, a GPCR. Therefore, priorities are logP, Pgp, TPSA, affinity, and BBB.
Let's break down the comparison:
1. **MW:** Both ligands are within the acceptable range (200-500 Da). Ligand A (342.443) is slightly better.
2. **TPSA:** Ligand A (67.35) is significantly better than Ligand B (99.18). Lower TPSA is generally preferred for better absorption, and crucial for GPCRs.
3. **logP:** Ligand A (2.166) is within the optimal range (1-3), while Ligand B (-0.498) is below 1, which might hinder permeation. This is a significant advantage for Ligand A.
4. **HBD/HBA:** Ligand A (HBD=1, HBA=4) and Ligand B (HBD=2, HBA=6) are both acceptable, but Ligand A is slightly more favorable.
5. **QED:** Ligand A (0.894) is better than Ligand B (0.598), indicating a more drug-like profile.
6. **DILI:** Ligand B (10.237) has a much lower DILI risk than Ligand A (29.546), a significant advantage.
7. **BBB:** Ligand A (90.229) has a much better BBB penetration potential than Ligand B (51.377). This is a key consideration for GPCRs, even cardiovascular ones, as some CNS off-target effects are possible.
8. **Caco-2:** Ligand A (-4.73) and Ligand B (-5.087) are both very poor. This is a concern for both, but not a deciding factor.
9. **Solubility:** Ligand B (0.202) is slightly better than Ligand A (-1.818), but both are poor.
10. **hERG:** Ligand A (0.192) has a lower hERG risk than Ligand B (0.117), which is favorable.
11. **Cl_mic:** Ligand B (1.367) has significantly lower microsomal clearance than Ligand A (13.731), indicating better metabolic stability.
12. **t1/2:** Ligand A (25.693) has a much longer in vitro half-life than Ligand B (-13.199). This is a substantial advantage.
13. **Pgp:** Ligand A (0.051) has lower P-gp efflux liability than Ligand B (0.013), which is favorable.
14. **Affinity:** Ligand A (-7.3 kcal/mol) has a slightly better binding affinity than Ligand B (-5.2 kcal/mol). While the difference isn't huge, it's still a positive for Ligand A.
**Overall Assessment:**
Ligand A has a better balance of properties, particularly regarding TPSA, logP, BBB, QED, and affinity. While Ligand B has a lower DILI risk and better metabolic stability, the poor logP and TPSA are significant drawbacks for a GPCR target. The better BBB penetration and affinity of Ligand A outweigh the slightly higher DILI risk.
**Output:**
1
2025-04-17 18:11:22,529 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A: [364.785, 108.49 , 1.913, 3. , 4. , 0.725, 89.841, 26.638, -5.549, -3.232, 0.033, -24.739, -17.296, 0.043, -5.5 ]**
**Ligand B: [361.32 , 87.74 , 0.687, 2. , 4. , 0.709, 56.805, 91.392, -5.042, -2.872, 0.139, 5.569, 33.441, 0.011, -6.8 ]**
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, Affinity, and BBB):
1. **MW:** Both are within the ideal 200-500 Da range. A (364.785) and B (361.32) are very close.
2. **TPSA:** A (108.49) is slightly higher than B (87.74). B is better, closer to the <90 for CNS targets, though ADRB2 isn't necessarily a CNS target.
3. **logP:** A (1.913) is optimal. B (0.687) is a bit low, potentially impacting permeability.
4. **HBD:** A (3) is acceptable. B (2) is also good.
5. **HBA:** Both A (4) and B (4) are within the acceptable range.
6. **QED:** Both A (0.725) and B (0.709) are good, indicating drug-like properties.
7. **DILI:** A (89.841) is concerning, indicating a higher risk of liver injury. B (56.805) is much better.
8. **BBB:** A (26.638) is low. B (91.392) is excellent. While ADRB2 isn't strictly a CNS target, higher BBB is generally favorable.
9. **Caco-2:** Both are negative, suggesting poor permeability. A (-5.549) is slightly worse than B (-5.042).
10. **Solubility:** Both are negative, suggesting poor solubility. A (-3.232) is slightly worse than B (-2.872).
11. **hERG:** Both are very low (A: 0.033, B: 0.139), indicating minimal hERG inhibition risk.
12. **Cl_mic:** A (-24.739) is *much* better (lower is better) than B (5.569), suggesting significantly improved metabolic stability.
13. **t1/2:** A (-17.296) is also better than B (33.441), indicating a longer in vitro half-life.
14. **Pgp:** A (0.043) is better than B (0.011), indicating lower P-gp efflux.
15. **Affinity:** B (-6.8) is 1.3 kcal/mol better than A (-5.5). This is a substantial difference in binding.
**Overall Assessment:**
Ligand B has a significantly better safety profile (DILI, BBB) and a substantially stronger binding affinity. While Ligand A has better metabolic stability and P-gp efflux, the affinity difference and the DILI risk associated with Ligand A are major drawbacks. The lower logP of Ligand B is a concern, but the superior binding affinity could potentially compensate for this. The better BBB penetration of Ligand B is also a plus.
Therefore, I would select Ligand B as the more promising drug candidate.
0
2025-04-17 18:11:22,530 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (331.423 Da) is within the ideal range (200-500 Da). Ligand B (351.447 Da) is also within the ideal range. No clear advantage here.
2. **TPSA:** Ligand A (66.53) is good, well below the 140 threshold for oral absorption. Ligand B (87.74) is still acceptable, but higher. Ligand A is preferred.
3. **logP:** Ligand A (4.012) is at the upper end of the optimal range, but still acceptable. Ligand B (0.435) is quite low, potentially leading to poor membrane permeability. Ligand A is strongly preferred.
4. **HBD:** Ligand A (1) is good. Ligand B (2) is also acceptable. No significant difference.
5. **HBA:** Ligand A (5) is good. Ligand B (4) is also good. No significant difference.
6. **QED:** Ligand A (0.741) is excellent, indicating good drug-like properties. Ligand B (0.68) is also good, but slightly lower. Ligand A is preferred.
7. **DILI:** Ligand A (68.941) is moderate risk, but manageable. Ligand B (20.977) is very low risk, a significant advantage. Ligand B is preferred.
8. **BBB:** Both ligands have moderate BBB penetration (Ligand A: 53.974, Ligand B: 59.752). This isn't a primary concern for ADRB2, which is not a CNS target.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Both ligands have negative solubility values, which is also unusual and suggests poor solubility. This is a concern for both.
11. **hERG:** Ligand A (0.833) is relatively low risk. Ligand B (0.117) is very low risk, a significant advantage. Ligand B is preferred.
12. **Cl_mic:** Ligand A (98.418) is high, indicating rapid metabolism. Ligand B (-9.038) is very low, indicating excellent metabolic stability. Ligand B is strongly preferred.
13. **t1/2:** Ligand A (45.564) is moderate. Ligand B (7.285) is very short. Ligand A is preferred.
14. **Pgp:** Ligand A (0.524) is moderate. Ligand B (0.007) is very low, indicating minimal efflux. Ligand B is strongly preferred.
15. **Affinity:** Ligand A (-5.4 kcal/mol) is good. Ligand B (-7.5 kcal/mol) is excellent, a substantial advantage. Ligand B is strongly preferred.
**Overall Assessment:**
While Ligand A has some advantages (QED, t1/2), Ligand B demonstrates a superior profile overall, particularly regarding key ADME properties and binding affinity. The significantly better metabolic stability (Cl_mic), lower P-gp efflux (Pgp), lower hERG risk, and much stronger binding affinity (-7.5 vs -5.4 kcal/mol) outweigh the slightly lower QED and shorter half-life. The low logP of Ligand B is a concern, but the strong affinity might compensate for this. Given the GPCR target class, the strong binding affinity and favorable ADME properties of Ligand B make it the more promising candidate.
Output:
0
2025-04-17 18:11:22,530 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (331.379 Da) is within the ideal range (200-500 Da). Ligand B (368.503 Da) is also within the ideal range. No clear advantage here.
2. **TPSA:** Both ligands (A: 85.07, B: 87.58) are below the 140 A^2 threshold for good oral absorption, and are reasonably low, though not optimized for CNS penetration.
3. **logP:** Ligand A (2.898) is optimal (1-3). Ligand B (1.679) is at the lower end of the optimal range, potentially impacting permeability. Ligand A has a slight advantage.
4. **HBD:** Both ligands have 2 HBD, which is within the acceptable limit of <=5.
5. **HBA:** Ligand A has 6 HBA, and Ligand B has 7. Both are acceptable (<=10).
6. **QED:** Both ligands have similar QED values (A: 0.767, B: 0.794), indicating good drug-likeness.
7. **DILI:** Ligand A (84.025) has a higher DILI risk than Ligand B (61.264). This is a significant drawback for Ligand A.
8. **BBB:** Ligand B (57.968) has a better BBB percentile than Ligand A (36.797). While ADRB2 isn't strictly a CNS target, some CNS exposure can be relevant for off-target effects, and a lower BBB is preferable.
9. **Caco-2:** Both ligands have negative Caco-2 values which is unusual and suggests poor permeability.
10. **Solubility:** Ligand A (-4.624) has worse solubility than Ligand B (-2.5). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.9) has a slightly higher hERG risk than Ligand B (0.49), but both are relatively low.
12. **Cl_mic:** Ligand B (32.63 mL/min/kg) has significantly lower microsomal clearance than Ligand A (54.977 mL/min/kg), indicating better metabolic stability.
13. **t1/2:** Ligand A (12.602 hours) has a longer half-life than Ligand B (1.797 hours). This is a positive for Ligand A.
14. **Pgp:** Ligand A (0.11) has lower P-gp efflux liability than Ligand B (0.174), which is favorable.
15. **Binding Affinity:** Both ligands have very similar binding affinities (A: -6.1 kcal/mol, B: -6.2 kcal/mol). The difference is negligible.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand A has a better logP and Pgp, but Ligand B has a significantly better DILI score, better solubility, and better metabolic stability (Cl_mic). The slightly longer half-life of Ligand A is a plus, but the DILI risk is a major concern.
**Overall Assessment:**
While Ligand A has some favorable properties (logP, Pgp, t1/2), the significantly higher DILI risk and lower solubility of Ligand A outweigh these benefits. Ligand B, despite a slightly lower logP and shorter half-life, presents a much safer profile with lower DILI risk and better metabolic stability, which are critical for drug development.
Output:
0
2025-04-17 18:11:22,530 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, priorities are affinity, logP, TPSA, Pgp efflux, and BBB penetration.
Let's break down the comparison:
1. **MW:** Both ligands are within the acceptable range (200-500 Da). Ligand A (343.427 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (87.13) is better than Ligand B (58.64). Both are below 140, but Ligand B is closer to the ideal range for GPCRs.
3. **logP:** Both ligands have good logP values (A: 3.132, B: 2.385), falling within the optimal 1-3 range. Ligand A is slightly higher, potentially leading to slightly reduced solubility but better membrane permeability.
4. **HBD/HBA:** Ligand A has 3 HBD and 3 HBA, while Ligand B has 1 HBD and 6 HBA. Ligand A is slightly better balanced.
5. **QED:** Both ligands have acceptable QED scores (A: 0.779, B: 0.643), indicating reasonable drug-likeness.
6. **DILI:** Ligand B (36.991) has a significantly lower DILI risk than Ligand A (62.156), which is a major advantage.
7. **BBB:** Both ligands have similar BBB penetration (A: 52.85, B: 56.611). Neither is exceptionally high, but this isn't a primary concern for a cardiovascular target.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability.
9. **Solubility:** Both have negative solubility values, which is also unusual and suggests poor solubility.
10. **hERG:** Both ligands have low hERG inhibition liability (A: 0.528, B: 0.356), which is good.
11. **Cl_mic:** Ligand A (40.122) has a lower microsomal clearance than Ligand B (66.756), indicating better metabolic stability.
12. **t1/2:** Ligand A (74.705) has a significantly longer in vitro half-life than Ligand B (12.39), which is a significant advantage.
13. **Pgp:** Both ligands have low Pgp efflux liability (A: 0.269, B: 0.183).
14. **Affinity:** Both ligands have the same binding affinity (-6.5 kcal/mol).
**Overall Assessment:**
While Ligand B has a much better DILI profile, Ligand A has superior metabolic stability (lower Cl_mic, longer t1/2) and a more balanced H-bonding profile. The equal binding affinity makes the ADME properties the deciding factor. Given the importance of metabolic stability for *in vivo* efficacy, and the acceptable DILI risk for Ligand A, I favor Ligand A.
**Output:**
1
2025-04-17 18:11:22,530 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (351.491 and 353.419 Da). No significant difference.
2. **TPSA:** Ligand A (78.51) is significantly better than Ligand B (120.68). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (1.858) is optimal, while Ligand B (-0.142) is slightly low, potentially hindering membrane permeability.
4. **HBD:** Both are acceptable (2 and 3 respectively), within the guideline of <=5.
5. **HBA:** Ligand A (3) is better than Ligand B (6), keeping within the desirable range.
6. **QED:** Both are reasonable (0.466 and 0.53), indicating moderate drug-likeness. Ligand B is slightly better.
7. **DILI:** Ligand A (19.038) has a much lower DILI risk than Ligand B (27.685). This is a significant advantage.
8. **BBB:** Not a primary concern for a cardiovascular target. Ligand A (61.691) is better than Ligand B (32.144), but this isn't decisive.
9. **Caco-2:** Ligand A (-4.688) is better than Ligand B (-5.538), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-1.773) is better than Ligand B (-1.201).
11. **hERG:** Both are very low (0.199 and 0.183), indicating minimal cardiotoxicity risk.
12. **Cl_mic:** Ligand B (-17.226) has significantly lower microsomal clearance than Ligand A (41.662), suggesting better metabolic stability. This is a strong point for Ligand B.
13. **t1/2:** Ligand B (29.715) has a much longer in vitro half-life than Ligand A (-3.996). This is a major advantage for Ligand B.
14. **Pgp:** Both are very low (0.04 and 0.018), indicating minimal P-gp efflux.
15. **Binding Affinity:** Both have excellent binding affinity (-5.7 and -6.2 kcal/mol). Ligand B is slightly better.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand A has a better logP and TPSA. Ligand B has slightly better affinity. However, the significant advantages of Ligand B in terms of metabolic stability (Cl_mic) and half-life, coupled with acceptable logP and affinity, outweigh the slightly better TPSA and logP of Ligand A. The lower DILI risk of Ligand A is also favorable, but the improved PK profile of Ligand B is more crucial for a successful drug.
**Final Decision:**
0
2025-04-17 18:11:22,531 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (349.431 and 347.415 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (94.66 and 95.67) are reasonably low, suggesting good potential for absorption. Both are below the 140 threshold.
3. **logP:** Ligand A (0.75) is slightly lower than Ligand B (0.875), but both are within the optimal 1-3 range.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (2), but both are acceptable (<=5).
5. **HBA:** Ligand A (4) is lower than Ligand B (5), both are acceptable (<=10).
6. **QED:** Both ligands have good QED scores (0.748 and 0.796), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (37.418) has a slightly higher DILI risk than Ligand B (30.322), but both are below the concerning threshold of 60.
8. **BBB:** Ligand B (49.826) has a significantly higher BBB penetration percentile than Ligand A (22.644). While ADRB2 isn't exclusively a CNS target, some CNS exposure or off-target effects are possible, and higher BBB penetration could be beneficial or detrimental depending on the desired therapeutic profile.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.025 and -5.16), which is unusual and suggests poor permeability. This is a major concern for both.
10. **Solubility:** Ligand A (-2.307) has slightly better solubility than Ligand B (-1.35), but both are poor. This is a significant drawback.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.281 and 0.141), which is excellent.
12. **Cl_mic:** Ligand A (7.361) has a lower microsomal clearance than Ligand B (-4.176), indicating better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand A (-6.518) has a more negative in vitro half-life, which is not ideal. Ligand B (21.4) has a much better, positive half-life.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.047 and 0.043), which is good.
15. **Binding Affinity:** Ligand B (-6.7 kcal/mol) has a slightly better binding affinity than Ligand A (-7.0 kcal/mol). While the difference is small, it's still a factor.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are particularly important. While both ligands have acceptable logP and Pgp values, Ligand B shows better affinity and BBB penetration. The poor Caco-2 and solubility for both are concerning, but the improved metabolic stability of Ligand A is a strong point. However, the significantly better half-life of Ligand B outweighs the metabolic stability advantage of Ligand A.
**Overall Assessment:**
Despite the poor permeability and solubility of both, Ligand B's superior binding affinity, BBB penetration, and *much* better in vitro half-life make it the more promising candidate. The slightly higher DILI risk is less concerning than the metabolic instability and short half-life of Ligand A.
Output:
0
2025-04-17 18:11:22,531 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (354.451 Da) is within the ideal range (200-500), while Ligand B (399.336 Da) is at the higher end but still acceptable.
2. **TPSA:** Ligand A (104.97) is better than Ligand B (44.85) for oral absorption, being under the 140 threshold. Ligand B is excellent.
3. **logP:** Ligand A (0.167) is quite low, potentially hindering permeability. Ligand B (4.217) is high, potentially causing solubility issues and off-target effects, but is within the acceptable range.
4. **HBD:** Ligand A (2) is good. Ligand B (0) is also good, potentially improving membrane permeability.
5. **HBA:** Both ligands have 4 HBA, which is acceptable.
6. **QED:** Both ligands have similar QED values (0.68 and 0.655), indicating good drug-likeness.
7. **DILI:** Ligand A (19.038) has a significantly lower DILI risk than Ligand B (25.165), which is a major advantage.
8. **BBB:** Ligand A (80.845) has a better BBB penetration percentile than Ligand B (74.254). While ADRB2 isn't strictly a CNS target, some peripheral ADRB2 receptors can influence CNS function, and better BBB penetration is generally favorable.
9. **Caco-2:** Ligand A (-4.997) and Ligand B (-5.179) are both poor.
10. **Solubility:** Ligand A (-1.142) is better than Ligand B (-4.252).
11. **hERG:** Ligand A (0.17) has a better hERG profile than Ligand B (0.929). This is a critical safety parameter.
12. **Cl_mic:** Ligand A (0.877) has much lower microsomal clearance than Ligand B (42.607), indicating better metabolic stability.
13. **t1/2:** Ligand A (-3.217) has a better in vitro half-life than Ligand B (28.524).
14. **Pgp:** Ligand A (0.004) has a much lower Pgp efflux liability than Ligand B (0.789), which is positive for bioavailability.
15. **Affinity:** Ligand B (-6.6) has a slightly better binding affinity than Ligand A (-6.4), but the difference is small (0.2 kcal/mol).
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Ligand B has a better logP and slightly better affinity, but Ligand A excels in TPSA, Pgp, and crucially, ADME-Tox properties (DILI, hERG, Cl_mic, t1/2). The small affinity difference is outweighed by the superior safety and pharmacokinetic profile of Ligand A.
**Conclusion:**
Ligand A presents a more balanced and favorable profile, particularly regarding safety (DILI, hERG) and pharmacokinetic properties (Cl_mic, t1/2, Pgp). While Ligand B has slightly better affinity and logP, the risks associated with its higher DILI, hERG, and Pgp efflux, coupled with its poor metabolic stability, make it a less desirable candidate.
Output:
1
2025-04-17 18:11:22,531 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (354.5 and 348.5 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (32.34) is significantly better than Ligand B (66.48). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold. Ligand B is higher, potentially impacting absorption.
3. **logP:** Ligand A (4.747) is higher than Ligand B (2.535). While 4.747 is approaching the upper limit of optimal, it's still acceptable. Ligand B is well within the optimal range.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Both have 3 HBA, which is good.
6. **QED:** Both ligands have similar QED values (0.76 and 0.769), indicating good drug-likeness.
7. **DILI:** Ligand A (44.63) has a higher DILI risk than Ligand B (17.449). This is a significant negative for Ligand A.
8. **BBB:** Ligand A (93.602) has higher BBB penetration than Ligand B (75.223). While not a primary concern for a cardiovascular target, it's a slight positive for A.
9. **Caco-2:** Both ligands have similar negative Caco-2 values, suggesting similar permeability.
10. **Solubility:** Ligand A (-4.577) has slightly worse solubility than Ligand B (-3.13). Solubility is important for bioavailability, favoring B.
11. **hERG:** Ligand A (0.964) has a slightly higher hERG risk than Ligand B (0.244). Lower hERG is preferred, favoring B.
12. **Cl_mic:** Ligand B (43.041) has significantly lower microsomal clearance than Ligand A (103.529), indicating better metabolic stability. This is a major advantage for B.
13. **t1/2:** Ligand B (-22.782) has a longer in vitro half-life than Ligand A (50.768). This is a significant advantage for B.
14. **Pgp:** Ligand A (0.77) has higher P-gp efflux than Ligand B (0.204). Lower P-gp efflux is preferred, favoring B.
15. **Binding Affinity:** Ligand A (-6.2 kcal/mol) has slightly better binding affinity than Ligand B (-5.9 kcal/mol). This is a 1.5 kcal/mol advantage, which is significant.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity and BBB penetration, the significant drawbacks in DILI risk, metabolic stability (higher Cl_mic, shorter t1/2), P-gp efflux, and solubility outweigh this advantage. Ligand B demonstrates a much more favorable ADME-Tox profile, particularly regarding safety (DILI, hERG) and metabolic stability. For a cardiovascular target like ADRB2, a slightly lower affinity can be tolerated if it means a safer and more bioavailable drug.
**Output:**
0
2025-04-17 18:11:22,531 - INFO - Batch 19 complete. Total preferences: 304
2025-04-17 18:11:22,531 - INFO - Processing batch 20/512...
2025-04-17 18:12:14,272 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (376.538 Da) is slightly higher than Ligand B (350.503 Da), but both are acceptable.
2. **TPSA:** Both ligands have TPSA values below 140, which is good for oral absorption. Ligand A (66.48) is higher than Ligand B (58.64), but still acceptable.
3. **logP:** Both ligands have logP values within the optimal range (1-3). Ligand B (3.576) is slightly higher than Ligand A (2.72), which could potentially lead to some off-target effects or solubility issues, but it's not a major concern.
4. **HBD:** Both ligands have 1 H-bond donor, which is within the acceptable limit of 5.
5. **HBA:** Both ligands have 3 H-bond acceptors, which is within the acceptable limit of 10.
6. **QED:** Both ligands have good QED scores (A: 0.708, B: 0.824), indicating good drug-like properties. Ligand B is slightly better here.
7. **DILI:** Both ligands have acceptable DILI risk. Ligand A (29.779) is better than Ligand B (40.558), indicating a lower risk of liver injury.
8. **BBB:** Ligand A (91.508) has a significantly higher BBB penetration percentile than Ligand B (79.217). While ADRB2 isn't exclusively a CNS target, some cardiovascular effects are mediated by CNS pathways, and better BBB penetration could be beneficial.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. Ligand A (-4.895) is slightly worse than Ligand B (-4.519).
10. **Solubility:** Both ligands have negative solubility values, indicating poor solubility. Ligand A (-3.397) is slightly worse than Ligand B (-4.237).
11. **hERG:** Both ligands have low hERG inhibition liability. Ligand A (0.77) is slightly higher than Ligand B (0.548), but both are within an acceptable range.
12. **Cl_mic:** Ligand B (67.653) has a higher microsomal clearance than Ligand A (51.052), meaning it will be metabolized faster. This is a negative for Ligand B.
13. **t1/2:** Ligand A (-48.63) has a significantly longer in vitro half-life than Ligand B (-11.24). This is a major advantage for Ligand A.
14. **Pgp:** Both ligands have low P-gp efflux liability. Ligand A (0.214) is better than Ligand B (0.564).
15. **Binding Affinity:** Ligand B (-6.3 kcal/mol) has a slightly better binding affinity than Ligand A (-5.5 kcal/mol). This is a 0.8 kcal/mol difference, which is significant but not overwhelming.
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B has a slightly better logP and affinity, but Ligand A excels in Pgp efflux, BBB penetration, and metabolic stability (Cl_mic and t1/2). Given the importance of metabolic stability and the potential for CNS-mediated effects, Ligand A appears to be the better candidate.
**Conclusion:**
Considering the balance of properties, particularly the superior metabolic stability (longer half-life), better BBB penetration, and lower DILI risk of Ligand A, I believe it is the more promising drug candidate.
Output:
1
2025-04-17 18:12:14,272 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.443 and 350.503 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (77.52) is slightly higher than Ligand B (69.64). Both are below the 140 threshold for good oral absorption, and acceptable for a cardiovascular target where CNS penetration isn't necessarily desired. Ligand B is slightly favored.
3. **logP:** Ligand A (3.109) is slightly higher than Ligand B (2.495), both are within the optimal 1-3 range. No major concerns for either.
4. **HBD:** Ligand A (1) has fewer HBD than Ligand B (2). Fewer HBD generally improves membrane permeability. Ligand A is slightly favored.
5. **HBA:** Ligand A (5) has more HBA than Ligand B (3). Lower HBA is generally preferred for permeability. Ligand B is favored.
6. **QED:** Ligand A (0.799) has a higher QED score than Ligand B (0.661), indicating a more drug-like profile. Ligand A is favored.
7. **DILI:** Ligand B (9.306) has a *significantly* lower DILI risk than Ligand A (54.866). This is a major advantage for Ligand B.
8. **BBB:** Both ligands have reasonable BBB penetration (Ligand A: 65.413, Ligand B: 72.78). Since ADRB2 is a cardiovascular target, BBB penetration is not a high priority. Ligand B is slightly favored.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.13 and -4.726), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand B (-2.3) has better solubility than Ligand A (-4.701). Solubility is important for bioavailability. Ligand B is favored.
11. **hERG:** Ligand A (0.077) has a slightly lower hERG risk than Ligand B (0.411). This is a slight advantage for Ligand A.
12. **Cl_mic:** Ligand B (36.661) has a much lower microsomal clearance than Ligand A (95.125), indicating better metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand B (-14.784) has a longer in vitro half-life than Ligand A (-44.706). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.035) has lower P-gp efflux than Ligand B (0.07). This is a slight advantage for Ligand A.
15. **Binding Affinity:** Ligand B (-6.8 kcal/mol) has a substantially stronger binding affinity than Ligand A (-3.7 kcal/mol). This is a *major* advantage for Ligand B, easily outweighing minor ADME drawbacks.
**Overall Assessment:**
While Ligand A has a slightly better QED and Pgp profile, Ligand B is clearly superior due to its significantly better DILI risk, metabolic stability (lower Cl_mic, longer t1/2), solubility, and, most importantly, *much* stronger binding affinity. The Caco-2 values are concerning for both, but the binding affinity difference is substantial enough to prioritize Ligand B. The lower DILI risk is also a critical factor for clinical development.
Output:
0
2025-04-17 18:12:14,272 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [364.511, 69.64, 2.719, 2, 4, 0.863, 24.661, 57.929, -5.077, -2.226, 0.432, -0.049, -1.072, 0.285, -5.7]
**Ligand B:** [343.467, 46.61, 4.287, 0, 3, 0.605, 52.385, 71.656, -4.5, -5.116, 0.308, 95.521, -16.985, 0.411, -7.3]
Here's a breakdown, prioritizing GPCR-relevant parameters:
1. **Molecular Weight:** Both are within the ideal range (200-500 Da). Ligand B (343.467) is slightly lower, which could be advantageous for permeability, but both are acceptable.
2. **TPSA:** Ligand A (69.64) is higher than Ligand B (46.61). For a cardiovascular GPCR, TPSA isn't *as* critical as for CNS targets, but lower is generally better for absorption. Ligand B is significantly better here.
3. **logP:** Ligand A (2.719) is within the optimal range (1-3). Ligand B (4.287) is a bit high, potentially leading to solubility issues and off-target interactions. Ligand A is preferable.
4. **H-Bond Donors/Acceptors:** Ligand A has 2 HBD and 4 HBA, while Ligand B has 0 HBD and 3 HBA. Both are within acceptable limits.
5. **QED:** Ligand A (0.863) has a much better QED score than Ligand B (0.605), indicating a more drug-like profile.
6. **DILI Risk:** Ligand A (24.661) has a significantly lower DILI risk than Ligand B (52.385). This is a crucial advantage.
7. **BBB Penetration:** Ligand B (71.656) has better BBB penetration than Ligand A (57.929). However, since this is a cardiovascular target, BBB penetration is less critical.
8. **Caco-2 Permeability:** Ligand A (-5.077) is worse than Ligand B (-4.5). Both are negative, suggesting poor permeability, but Ligand B is slightly better.
9. **Aqueous Solubility:** Ligand A (-2.226) is better than Ligand B (-5.116). Solubility is important for bioavailability, and Ligand A has a clear advantage.
10. **hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.432 and 0.308 respectively), which is excellent.
11. **Microsomal Clearance:** Ligand A (-0.049) has a lower (better) microsomal clearance than Ligand B (95.521), indicating better metabolic stability.
12. **In vitro Half-Life:** Ligand A (-1.072) has a better half-life than Ligand B (-16.985).
13. **P-gp Efflux:** Ligand A (0.285) has lower P-gp efflux than Ligand B (0.411), which is favorable for bioavailability.
14. **Binding Affinity:** Ligand B (-7.3) has a significantly stronger binding affinity than Ligand A (-5.7). This is a substantial advantage, a difference of 1.6 kcal/mol.
**Overall Assessment:**
While Ligand B has a superior binding affinity, the significant drawbacks in DILI risk, metabolic stability (high Cl_mic, low t1/2), and a higher logP are concerning. Ligand A, despite a slightly weaker affinity, presents a much more balanced profile with a better QED score, lower DILI risk, better solubility, and improved metabolic stability. For a cardiovascular GPCR, the lower BBB penetration of Ligand A is not a major issue. The combination of these factors makes Ligand A the more promising drug candidate.
Output:
1
2025-04-17 18:12:14,272 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [363.487, 98.17, 3.184, 1, 4, 0.457, 43.079, 41.218, -5.175, -2.407, 0.226, 32.921, 14.855, 0.133, -6.7]
**Ligand B:** [346.475, 59.51, 2.828, 1, 6, 0.731, 39.667, 97.286, -4.896, -3.169, 0.869, 73.185, 33.963, 0.174, -6.3]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (346.475) is slightly lower, which is generally favorable.
2. **TPSA:** Ligand A (98.17) is higher than Ligand B (59.51). For a cardiovascular GPCR, we don't *need* extremely low TPSA for CNS penetration, but lower is generally better for permeability. Ligand B is significantly better here.
3. **logP:** Both are within the optimal range (1-3). Ligand A (3.184) is slightly higher, potentially leading to off-target effects, while Ligand B (2.828) is closer to the sweet spot.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 4 HBA, while Ligand B has 6. Both are acceptable, but Ligand A is slightly preferred.
6. **QED:** Ligand B (0.731) has a significantly better QED score than Ligand A (0.457), indicating a more drug-like profile.
7. **DILI:** Both are relatively low risk, with Ligand B (39.667) being slightly better than Ligand A (43.079).
8. **BBB:** Ligand B (97.286) has a much higher BBB penetration score than Ligand A (41.218). While ADRB2 isn't strictly a CNS target, some CNS exposure can be beneficial or at least avoid unexpected side effects.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Both have negative solubility values, which is also unusual. Again, the scale is unspecified.
11. **hERG:** Ligand B (0.869) has a slightly higher hERG risk than Ligand A (0.226). This is a concern for Ligand B.
12. **Cl_mic:** Ligand A (32.921) has a lower microsomal clearance, indicating better metabolic stability, than Ligand B (73.185).
13. **t1/2:** Ligand B (33.963) has a longer in vitro half-life than Ligand A (14.855), which is desirable.
14. **Pgp:** Ligand A (0.133) has lower P-gp efflux, which is preferable to Ligand B (0.174).
15. **Affinity:** Ligand A (-6.7 kcal/mol) has a slightly better binding affinity than Ligand B (-6.3 kcal/mol). This is a significant advantage.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in TPSA and BBB, while Ligand A has better logP, Pgp, and a slightly better binding affinity. The affinity difference is relatively small (0.4 kcal/mol), but still important. The metabolic stability (Cl_mic) of Ligand A is also a significant plus.
**Conclusion:**
While Ligand B has a better QED, BBB, and half-life, Ligand A's superior binding affinity, lower logP, better Pgp profile, and improved metabolic stability outweigh these advantages. The hERG risk for Ligand B is also a concern. Therefore, I believe Ligand A is the more promising drug candidate.
Output:
1
2025-04-17 18:12:14,272 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [341.386, 62.3, 2.505, 1, 3, 0.933, 60.644, 93.68, -4.75, -3.564, 0.635, 4.919, -6.799, 0.079, -7.1]**
**Ligand B: [364.408, 58.64, 2.497, 1, 3, 0.755, 19.698, 92.168, -4.452, -2.485, 0.493, 14.288, -21.092, 0.072, -5.6]**
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). A (341.386) is slightly preferred due to being lower.
2. **TPSA:** Both are good, below 140, indicating reasonable oral absorption potential. B (58.64) is slightly better than A (62.3).
3. **logP:** Both are optimal (around 2.5). This is good for permeability and avoids solubility issues. Very similar.
4. **H-Bond Donors:** Both have 1 HBD, which is excellent.
5. **H-Bond Acceptors:** Both have 3 HBA, also excellent.
6. **QED:** A (0.933) is significantly better than B (0.755), suggesting a more drug-like profile.
7. **DILI:** A (60.644) is higher risk than B (19.698). This is a significant drawback for A.
8. **BBB:** Both are very high (A: 93.68, B: 92.168), indicating good potential for CNS penetration, though less critical for peripheral ADRB2.
9. **Caco-2:** Both are negative, suggesting poor permeability. A (-4.75) is worse than B (-4.452).
10. **Solubility:** Both are negative, suggesting poor solubility. B (-2.485) is better than A (-3.564).
11. **hERG:** Both are low risk (A: 0.635, B: 0.493). B is slightly better.
12. **Cl_mic:** A (4.919) is much better (lower) than B (14.288), indicating better metabolic stability.
13. **t1/2:** A (-6.799) is much better (longer) than B (-21.092).
14. **Pgp:** Both are low (A: 0.079, B: 0.072), suggesting minimal efflux.
15. **Binding Affinity:** A (-7.1) is significantly better than B (-5.6). This is a substantial advantage.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), affinity, logP, TPSA, and Pgp are important. A has a much better affinity, and comparable logP, TPSA, and Pgp. However, the DILI risk for A is concerning. The improved metabolic stability and half-life of A are also beneficial.
**Overall Assessment:**
While Ligand A has a significantly better binding affinity and metabolic profile, its higher DILI risk is a major concern. Ligand B has a much lower DILI risk, better solubility and Caco-2 permeability, and a still-acceptable binding affinity. Given the potential for liver toxicity, and the fact that the affinity difference is substantial but not insurmountable, I would lean towards Ligand B. The improved ADME properties of B, particularly the lower DILI, outweigh the affinity advantage of A.
Output:
0
2025-04-17 18:12:14,272 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
We are targeting ADRB2, a GPCR. Therefore, the priorities are logP, Pgp, TPSA, affinity, and BBB. Let's analyze each ligand against these and other key parameters:
* **Molecular Weight:** Both ligands (358.47 and 355.88 Da) fall within the ideal 200-500 Da range.
* **TPSA:** Ligand A (67.23) is higher than the preferred <140, but still reasonable. Ligand B (3.24) is *excellent* - very low TPSA, suggesting good membrane permeability.
* **logP:** Ligand A (1.838) is within the optimal 1-3 range. Ligand B (4.999) is slightly high, potentially leading to solubility issues and off-target interactions.
* **H-Bond Donors/Acceptors:** Ligand A has 1 HBD and 5 HBA, acceptable. Ligand B has 0 HBD and 1 HBA, also acceptable, and potentially beneficial for permeability.
* **QED:** Ligand A (0.83) has a very good drug-likeness score. Ligand B (0.499) is below the 0.5 threshold, indicating a less favorable overall drug-like profile.
* **DILI:** Ligand A (64.06%) has a moderate DILI risk. Ligand B (11.63%) has a very low DILI risk, a significant advantage.
* **BBB:** Ligand A (57.89%) has moderate BBB penetration. Ligand B (83.44%) has excellent BBB penetration, which is a plus for a GPCR target.
* **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests potential issues with the data or modeling. However, we can infer that Ligand B's lower TPSA might translate to better absorption.
* **Solubility:** Ligand A (-2.636) has poor aqueous solubility. Ligand B (-6.009) has even worse solubility, a major concern.
* **hERG:** Ligand A (0.239) has a low hERG risk. Ligand B (0.967) has a slightly elevated hERG risk.
* **Cl_mic:** Ligand A (44.45) has moderate metabolic clearance. Ligand B (38.24) has lower clearance, indicating better metabolic stability.
* **t1/2:** Both ligands have similar in vitro half-lives (27.22 and 29.83 hours).
* **Pgp:** Ligand A (0.249) has low P-gp efflux, which is good. Ligand B (0.749) has moderate P-gp efflux, which could limit bioavailability.
* **Binding Affinity:** Ligand B (-7.8 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.4 kcal/mol) - a difference of 2.4 kcal/mol. This is a substantial advantage that can outweigh some of the ADME drawbacks.
**Overall Assessment:**
Ligand B has a much stronger binding affinity and excellent BBB penetration, which are crucial for a GPCR target like ADRB2. It also has a significantly lower DILI risk and better metabolic stability. However, its high logP and very poor solubility are concerning. Ligand A has better solubility and a lower DILI risk, but its affinity is considerably weaker.
Given the importance of potency for GPCRs, and the substantial difference in binding affinity, I believe Ligand B is the more promising candidate *despite* its solubility issues. Solubility can often be addressed through formulation strategies. The strong binding affinity provides a larger window for optimization.
**Output:**
0
2025-04-17 18:12:14,272 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (358.869 Da and 341.415 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (64.35) is well below the 140 threshold and even closer to the 90 threshold for CNS targets, suggesting good permeability. Ligand B (79.6) is still acceptable but less favorable than A.
**3. logP:** Ligand A (4.375) is slightly high, potentially leading to solubility issues or off-target interactions, but still within a manageable range. Ligand B (1.498) is a bit low, potentially hindering membrane permeability. For a GPCR, a slightly higher logP is often tolerated if affinity is good.
**4. H-Bond Donors:** Both ligands have acceptable HBD counts (2 and 1 respectively), well below the 5 limit.
**5. H-Bond Acceptors:** Both ligands have acceptable HBA counts (3 and 5 respectively), well below the 10 limit.
**6. QED:** Both ligands have good QED scores (0.805 and 0.863), indicating generally drug-like properties.
**7. DILI Risk:** Both ligands have low DILI risk (38.891 and 36.293), which is excellent.
**8. BBB Penetration:** Both ligands show good BBB penetration (70.88 and 73.866). This is a positive, though less critical for a cardiovascular target.
**9. Caco-2 Permeability:** Ligand A (-4.995) and Ligand B (-5.143) both have negative values, which is unusual and suggests very low permeability. However, these values are on a scale where negative values are possible and don't necessarily mean zero permeability.
**10. Aqueous Solubility:** Ligand A (-4.201) and Ligand B (-2.347) both have negative values, indicating poor solubility.
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (0.751 and 0.38), which is highly desirable.
**12. Microsomal Clearance:** Ligand A (26.014) has a lower clearance than Ligand B (37.584), suggesting better metabolic stability.
**13. In vitro Half-Life:** Ligand A (53.316) has a longer half-life than Ligand B (-7.924), which is a significant advantage for dosing convenience.
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (0.382 and 0.029), which is good.
**15. Binding Affinity:** Ligand B (-6.0 kcal/mol) has a significantly stronger binding affinity than Ligand A (-4.1 kcal/mol). This is a >1.5 kcal/mol difference, which is a substantial advantage that can outweigh some ADME drawbacks.
**Overall Assessment:**
While Ligand A has slightly better TPSA and metabolic stability, the significantly stronger binding affinity of Ligand B (-6.0 vs -4.1 kcal/mol) is the deciding factor. For a GPCR target, potency is paramount. The slightly lower logP of Ligand B is a minor concern that could potentially be addressed through further optimization, but the strong binding is a more valuable starting point. The similar ADME profiles, especially the low DILI risk and acceptable BBB penetration, make Ligand B the more promising candidate.
Output:
0
2025-04-17 18:12:14,273 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (379.865 and 369.491 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (75.63) is significantly better than Ligand B (124.03). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold. Ligand B is approaching the upper limit.
3. **logP:** Ligand A (3.372) is optimal, while Ligand B (1.491) is at the lower end of the optimal range. For a GPCR, a slightly higher logP is often beneficial for membrane interactions.
4. **HBD:** Both ligands have 2 HBD, which is within the acceptable limit of 5.
5. **HBA:** Both ligands have 4 HBA, which is within the acceptable limit of 10.
6. **QED:** Ligand A (0.735) has a much better QED score than Ligand B (0.382), indicating a more drug-like profile.
7. **DILI:** Ligand A (73.052) has a higher DILI risk than Ligand B (33.307). This is a significant concern for Ligand A.
8. **BBB:** Ligand A (19.077) has very low BBB penetration, which is not a major concern for a cardiovascular target. Ligand B (46.026) is also low, but higher than A.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.266 and -5.231), which is unusual and suggests poor permeability. This is a red flag for both.
10. **Solubility:** Ligand A (-3.488) has slightly worse solubility than Ligand B (-2.054), but both are poor.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.057 and 0.12).
12. **Cl_mic:** Ligand A (18.401) has significantly lower microsomal clearance than Ligand B (30.094), indicating better metabolic stability.
13. **t1/2:** Ligand A (-0.212) has a slightly worse in vitro half-life than Ligand B (-1.22), but both are quite poor.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.03 and 0.027).
15. **Binding Affinity:** Ligand A (-8.2 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.4 kcal/mol). This is a substantial advantage. The difference of 1.8 kcal/mol is significant enough to potentially overcome some ADME liabilities.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand A excels in logP and *significantly* in affinity. While TPSA is better for A, the DILI risk is a major concern. However, the substantial affinity advantage of Ligand A is likely to outweigh the other drawbacks, especially considering the poor Caco-2 permeability of both. The lower clearance of Ligand A is also a positive.
**Conclusion:**
Despite the higher DILI risk, the significantly improved binding affinity of Ligand A makes it the more promising candidate. Optimization efforts could then focus on mitigating the DILI liability.
Output:
1
2025-04-17 18:12:14,273 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [378.451, 133.91 , -2.206, 3. , 7. , 0.387, 41.838, 35.401, -5.507, -1.347, 0.032, 44.321, -51.506, 0.004, -7.4 ]
**Ligand B:** [346.471, 78.43 , 2.945, 3. , 3. , 0.677, 21.326, 51.454, -4.723, -3.185, 0.335, 30.89 , 5.995, 0.071, -7. ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (346.471) is slightly smaller, which can be advantageous for permeability.
2. **TPSA:** Ligand A (133.91) is close to the upper limit for good oral absorption, but still acceptable. Ligand B (78.43) is excellent, well below the 140 threshold. This favors Ligand B.
3. **logP:** Ligand A (-2.206) is a bit low, potentially hindering membrane permeability. Ligand B (2.945) is almost ideal. This strongly favors Ligand B.
4. **HBD:** Both have 3 HBD, which is within the acceptable range.
5. **HBA:** Ligand A has 7 HBA, and Ligand B has 3. Ligand B is better here.
6. **QED:** Ligand B (0.677) has a better QED score than Ligand A (0.387), indicating a more drug-like profile.
7. **DILI:** Ligand A (41.838) has a slightly higher DILI risk than Ligand B (21.326), but both are reasonably low.
8. **BBB:** Ligand B (51.454) has a significantly higher BBB penetration score than Ligand A (35.401). While ADRB2 isn't a primary CNS target, some CNS exposure can be relevant for off-target effects.
9. **Caco-2:** Ligand A (-5.507) and Ligand B (-4.723) are both negative, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
10. **Solubility:** Ligand A (-1.347) has slightly better solubility than Ligand B (-3.185).
11. **hERG:** Ligand A (0.032) has a very low hERG risk, while Ligand B (0.335) is slightly higher, but still acceptable.
12. **Cl_mic:** Ligand B (30.89) has a lower microsomal clearance, indicating better metabolic stability, than Ligand A (44.321).
13. **t1/2:** Ligand B (5.995) has a longer in vitro half-life than Ligand A (-51.506). This is a significant advantage.
14. **Pgp:** Ligand A (0.004) has very low P-gp efflux liability, while Ligand B (0.071) is slightly higher.
15. **Affinity:** Ligand A (-7.4) has a slightly better binding affinity than Ligand B (-7.0). However, the difference is only 0.4 kcal/mol, which is not substantial enough to outweigh other factors.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP and TPSA, has acceptable Pgp, and a very good affinity. While Ligand A has a slightly better affinity, its poor logP and higher TPSA are significant drawbacks.
**Conclusion:**
Considering the balance of properties and the priorities for a GPCR target, **Ligand B** is the more promising drug candidate. Its superior logP, TPSA, QED, metabolic stability (Cl_mic, t1/2), and BBB penetration outweigh the slightly weaker affinity and slightly higher Pgp efflux.
**Output:**
0
2025-04-17 18:12:14,273 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (370.783) is slightly higher than Ligand B (336.395), but both are acceptable.
2. **TPSA:** Both are reasonably low, but Ligand A (70.59) is better than Ligand B (78.09). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (3.16) is optimal, while Ligand B (1.556) is on the lower side. While still acceptable, lower logP can sometimes hinder membrane permeability.
4. **HBD:** Ligand A (3) and Ligand B (2) are both good, falling within the desired range of <=5.
5. **HBA:** Both ligands have 3 HBA, which is excellent.
6. **QED:** Both ligands have good QED scores (A: 0.731, B: 0.813), indicating good drug-like properties. Ligand B is slightly better here.
7. **DILI:** Both have acceptable DILI risk, with Ligand A at 64.405 and Ligand B at 60.915. Both are below the 60 threshold, indicating relatively low risk.
8. **BBB:** Ligand A (57.852) is better than Ligand B (31.02). While not a primary concern for a cardiovascular target, higher BBB is generally favorable.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.651) is slightly better than Ligand B (-4.731), but both are problematic.
10. **Solubility:** Both have negative solubility values, which is also unusual and suggests poor solubility. Ligand A (-3.964) is slightly better than Ligand B (-3.257).
11. **hERG:** Both ligands have very low hERG inhibition risk (A: 0.523, B: 0.332), which is excellent.
12. **Cl_mic:** Both have similar microsomal clearance (A: 26.593, B: 24.123). Lower is better, but these values are reasonable.
13. **t1/2:** Ligand A (45.644) has a significantly longer in vitro half-life than Ligand B (8.341). This is a major advantage.
14. **Pgp:** Both have low P-gp efflux liability (A: 0.187, B: 0.03). Ligand B is slightly better here.
15. **Binding Affinity:** Ligand A (-7.8 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.6 kcal/mol). This is a crucial difference.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, affinity, and Pgp are important. Ligand A excels in logP and significantly outperforms Ligand B in binding affinity. While both have acceptable TPSA and Pgp values, the substantial difference in affinity and half-life outweighs the slight advantages of Ligand B in QED and Pgp. The poor Caco-2 and solubility values are concerning for both, but a strong binding affinity can sometimes compensate for these issues, especially with formulation strategies.
**Conclusion:**
Ligand A is the more promising candidate due to its superior binding affinity and longer half-life.
Output:
1
2025-04-17 18:12:14,273 - INFO - Reasoning:
Let's analyze both ligands based on the provided guidelines, prioritizing GPCR-relevant parameters.
**Ligand A:**
* **MW:** 354.491 Da - Good, within the ideal range.
* **TPSA:** 67.87 - Good, below the 140 threshold for oral absorption.
* **logP:** 1.975 - Excellent, within the optimal 1-3 range.
* **HBD:** 1 - Good, low.
* **HBA:** 4 - Good, within the acceptable limit.
* **QED:** 0.609 - Good, above the 0.5 threshold.
* **DILI:** 10.237 - Excellent, very low risk.
* **BBB:** 83.443 - Very good, suggesting reasonable CNS penetration potential, although not exceptionally high.
* **Caco-2:** -4.526 - Poor, indicating low intestinal absorption.
* **Solubility:** -1.392 - Poor, suggesting low aqueous solubility.
* **hERG:** 0.548 - Acceptable, relatively low risk.
* **Cl_mic:** 54.709 - Moderate, could be better for metabolic stability.
* **t1/2:** -2.703 - Poor, short half-life.
* **Pgp:** 0.054 - Excellent, low efflux liability.
* **Affinity:** -5.9 kcal/mol - Good binding affinity.
**Ligand B:**
* **MW:** 347.459 Da - Good, within the ideal range.
* **TPSA:** 66.65 - Good, below the 140 threshold for oral absorption.
* **logP:** 3.217 - Slightly high, but still acceptable.
* **HBD:** 0 - Good, very low.
* **HBA:** 4 - Good, within the acceptable limit.
* **QED:** 0.677 - Good, above the 0.5 threshold.
* **DILI:** 33.23 - Good, low risk.
* **BBB:** 89.531 - Excellent, suggesting good CNS penetration potential.
* **Caco-2:** -4.312 - Poor, indicating low intestinal absorption.
* **Solubility:** -3.1 - Very poor, suggesting very low aqueous solubility.
* **hERG:** 0.28 - Excellent, very low risk.
* **Cl_mic:** 81.081 - High, indicating poor metabolic stability.
* **t1/2:** 3.482 - Moderate, better than Ligand A.
* **Pgp:** 0.299 - Good, low efflux liability.
* **Affinity:** -6.4 kcal/mol - Excellent, stronger binding affinity than Ligand A.
**Comparison & Decision:**
Both ligands have issues with Caco-2 permeability and aqueous solubility. However, Ligand B has a significantly better binding affinity (-6.4 vs -5.9 kcal/mol), a better BBB score (89.5 vs 83.4), and a lower hERG risk. While Ligand B has a higher Cl_mic (worse metabolic stability) than Ligand A, the stronger binding affinity is a crucial advantage for a GPCR target like ADRB2. The difference in affinity (0.5 kcal/mol) is substantial enough to outweigh the metabolic stability concern, especially considering the potential for optimization of metabolic stability later in the drug development process. Ligand A's shorter half-life is also a concern.
Output:
0
2025-04-17 18:12:14,273 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (351.462 and 353.419 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (47.56) is significantly lower than Ligand B (120.68). This is a major advantage for Ligand A, as lower TPSA generally correlates with better cell permeability, crucial for GPCR targeting. Ligand B is above the preferred threshold of 140.
3. **logP:** Ligand A (4.927) is high, but still within a potentially acceptable range. Ligand B (-0.142) is quite low, which could hinder membrane permeability and bioavailability. This favors Ligand A.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Fewer hydrogen bond donors generally improve permeability.
5. **HBA:** Ligand A (4) is better than Ligand B (6). Similar reasoning as HBD - fewer is generally better for permeability.
6. **QED:** Both ligands have reasonable QED scores (0.764 and 0.53), indicating acceptable drug-likeness. Ligand A is slightly better.
7. **DILI:** Ligand A (33.191) has a lower DILI risk than Ligand B (27.685), which is a positive.
8. **BBB:** Ligand A (72.896) has a much higher BBB penetration percentile than Ligand B (32.144). While ADRB2 isn't exclusively a CNS target, some distribution to the CNS is not detrimental, and higher BBB penetration can be a benefit.
9. **Caco-2:** Ligand A (-4.048) is better than Ligand B (-5.538), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-5.462) is better than Ligand B (-1.201).
11. **hERG:** Ligand A (0.515) has a lower hERG risk than Ligand B (0.183). This is a crucial safety parameter, and Ligand A is more favorable.
12. **Cl_mic:** Ligand B (-17.226) has a much lower (better) microsomal clearance than Ligand A (107.476), indicating greater metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand B (29.715) has a longer in vitro half-life than Ligand A (15.87). This is another point in favor of Ligand B.
14. **Pgp:** Ligand A (0.142) has lower P-gp efflux liability than Ligand B (0.018).
15. **Binding Affinity:** Both ligands have very similar and strong binding affinities (-6.5 and -6.2 kcal/mol). The difference is not substantial enough to be a deciding factor.
**Overall Assessment:**
Ligand A excels in properties related to permeability (TPSA, logP, HBD, HBA, Caco-2, Solubility), safety (DILI, hERG), and BBB penetration. Ligand B has better metabolic stability (Cl_mic) and half-life. However, the significantly poorer permeability profile of Ligand B, coupled with its lower solubility, is a major concern for a GPCR target like ADRB2. The slightly better metabolic stability of Ligand B doesn't outweigh these drawbacks.
Given the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand A is the more promising candidate.
Output:
1
2025-04-17 18:12:14,273 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.387 Da and 355.507 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (97.33) is better than Ligand B (41.15). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better permeability.
3. **logP:** Ligand A (-1.479) is suboptimal, being below the preferred 1-3 range. Ligand B (4.992) is too high, potentially leading to solubility issues and off-target interactions. This is a significant drawback for Ligand B.
4. **HBD:** Ligand A (2) is good. Ligand B (1) is also acceptable.
5. **HBA:** Ligand A (6) is good. Ligand B (4) is also acceptable.
6. **QED:** Ligand A (0.586) is better than Ligand B (0.411), indicating a more drug-like profile.
7. **DILI:** Ligand A (36.603) has a significantly lower DILI risk than Ligand B (52.074). This is a crucial advantage for Ligand A.
8. **BBB:** Ligand B (65.297) shows better BBB penetration than Ligand A (40.364), but this is less important for a cardiovascular target.
9. **Caco-2:** Ligand A (-4.894) and Ligand B (-5.216) are both very poor. This is a concern for both, but not a deciding factor.
10. **Solubility:** Ligand A (-1.259) is better than Ligand B (-4.428). This is important given Ligand B's high logP.
11. **hERG:** Ligand A (0.152) has a much lower hERG inhibition liability than Ligand B (0.933). This is a major advantage for Ligand A, as hERG inhibition can cause cardiotoxicity.
12. **Cl_mic:** Ligand A (-12.041) has a lower (better) microsomal clearance than Ligand B (73.432), indicating better metabolic stability.
13. **t1/2:** Ligand A (-0.996) has a slightly better in vitro half-life than Ligand B (-14.739).
14. **Pgp:** Ligand A (0.01) has much lower P-gp efflux than Ligand B (0.788).
15. **Binding Affinity:** Both ligands have the same binding affinity (-5.5 kcal/mol).
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has a better balance of these properties, despite its slightly lower logP. Ligand B's high logP, high DILI risk, and high hERG risk are significant liabilities.
**Conclusion:**
Ligand A is the more promising candidate due to its superior ADME-Tox profile (lower DILI, lower hERG, better solubility, lower Pgp efflux, better metabolic stability) and acceptable TPSA, despite a suboptimal logP. The equal binding affinity makes the ADME/Tox differences the deciding factor.
Output:
1
2025-04-17 18:12:14,274 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (350.415 & 370.425 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (88.1 & 86.88) are below the 140 A^2 threshold for good oral absorption, and reasonably close to the 90 A^2 for CNS targets, though ADRB2 is primarily cardiovascular.
3. **logP:** Ligand A (1.674) is within the optimal 1-3 range. Ligand B (2.932) is towards the higher end, but still acceptable.
4. **HBD:** Ligand A (2) and Ligand B (3) are both acceptable, below the 5 limit.
5. **HBA:** Ligand A (5) and Ligand B (4) are both acceptable, below the 10 limit.
6. **QED:** Both ligands (0.697 & 0.668) are above 0.5, indicating good drug-likeness.
7. **DILI:** Ligand A (35.014) has a significantly lower DILI risk than Ligand B (67.817). This is a major advantage for Ligand A.
8. **BBB:** Both ligands have moderate BBB penetration (55.37 & 61.923). While not a primary concern for a cardiovascular target, higher BBB is generally favorable. Ligand B is slightly better.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.652 & -5.468), indicating poor permeability. This is a concern for both.
10. **Solubility:** Both ligands have negative solubility values (-2.907 & -3.077), indicating poor aqueous solubility. This is a concern for both.
11. **hERG:** Ligand A (0.115) has a much lower hERG risk than Ligand B (0.592). This is a significant advantage for Ligand A, as hERG inhibition can lead to cardiotoxicity.
12. **Cl_mic:** Ligand A (82.014) has a higher microsomal clearance than Ligand B (36.755), suggesting lower metabolic stability. This favors Ligand B.
13. **t1/2:** Ligand A (-24.848) has a negative in vitro half-life, which is concerning. Ligand B (-3.662) is also negative, but less so. Both are problematic.
14. **Pgp:** Ligand A (0.032) has a much lower P-gp efflux liability than Ligand B (0.153), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand B (-6.9 kcal/mol) has a significantly higher binding affinity than Ligand A (-4.1 kcal/mol). This is a substantial advantage for Ligand B, potentially outweighing some ADME concerns.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand B excels in affinity. Ligand A has better Pgp and hERG. The poor Caco-2 and solubility are concerning for both, but the affinity difference is substantial. The lower DILI and hERG for Ligand A are important safety factors.
**Overall Assessment:**
The affinity difference is the most significant factor. While Ligand A has better safety profiles (DILI, hERG, Pgp), the stronger binding of Ligand B to the ADRB2 receptor is likely to be more critical for efficacy. The metabolic stability of Ligand B is also better. The poor permeability and solubility are issues for both, but can potentially be addressed with formulation strategies.
Output:
0
2025-04-17 18:12:14,274 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [359.421, 88.91, 1.799, 2, 5, 0.667, 44.591, 65.529, -5.085, -2.345, 0.156, 39.127, -9.904, 0.054, -6.5]
**Ligand B:** [346.471, 58.64, 2.431, 1, 3, 0.687, 9.926, 82.396, -4.818, -2.545, 0.312, 26.772, -0.524, 0.058, -5.8]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (346.471) is slightly lower, which is generally favorable.
2. **TPSA:** Ligand A (88.91) is better than Ligand B (58.64) as it is closer to the ideal range for GPCRs.
3. **logP:** Both are within the optimal range (1-3). Ligand B (2.431) is a bit higher, potentially increasing off-target interactions, but not drastically.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable.
5. **HBA:** Ligand A (5) and Ligand B (3) are both acceptable.
6. **QED:** Both are good (>=0.5), with Ligand B (0.687) being slightly better.
7. **DILI:** Ligand A (44.591) is significantly better than Ligand B (9.926), indicating a lower risk of liver injury. This is a major advantage for Ligand A.
8. **BBB:** Ligand B (82.396) has a much higher BBB penetration percentile than Ligand A (65.529). For a cardiovascular GPCR, this isn't *as* critical as for a CNS target, but still a factor.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-5.085) is slightly worse than Ligand B (-4.818).
10. **Solubility:** Both are negative, indicating poor solubility. Ligand A (-2.345) is slightly worse than Ligand B (-2.545).
11. **hERG:** Both are very low, indicating minimal hERG inhibition risk. Ligand B (0.312) is slightly higher than Ligand A (0.156).
12. **Cl_mic:** Ligand B (26.772) has significantly lower microsomal clearance than Ligand A (39.127), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-9.904) has a much longer in vitro half-life than Ligand B (-0.524). This is a significant advantage for Ligand A.
14. **Pgp:** Both are very low, indicating minimal P-gp efflux. Ligand B (0.058) is slightly higher than Ligand A (0.054).
15. **Affinity:** Ligand A (-6.5 kcal/mol) has a slightly better binding affinity than Ligand B (-5.8 kcal/mol).
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, and affinity. While BBB is less critical for a cardiovascular target, it's still a consideration. Metabolic stability (Cl_mic, t1/2) is also important.
**Overall Assessment:**
Ligand A has a superior DILI profile and a longer half-life, which are crucial for drug development. It also has slightly better binding affinity. While Ligand B has better BBB penetration and metabolic stability, the lower DILI risk and longer half-life of Ligand A outweigh these advantages, especially considering the target is a cardiovascular GPCR. The Caco-2 and solubility issues are concerning for both, but can be addressed with formulation strategies.
Therefore, I prefer Ligand A.
Output:
1
2025-04-17 18:12:14,274 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (346.431 Da) is slightly lower, which is generally favorable for permeability.
**2. TPSA:** Ligand A (68.62) is significantly better than Ligand B (101.8). For a GPCR, keeping TPSA low is beneficial for permeability and receptor engagement. Ligand B is pushing the upper limit for good oral absorption.
**3. logP:** Both ligands have good logP values (A: 2.396, B: 1.852) falling within the optimal range of 1-3.
**4. H-Bond Donors:** Ligand A (1) is preferable to Ligand B (2). Fewer H-bond donors generally improve membrane permeability.
**5. H-Bond Acceptors:** Ligand B (7) is higher than Ligand A (5). Again, lower is generally better for permeability.
**6. QED:** Both ligands have acceptable QED values (A: 0.872, B: 0.777), indicating good drug-like properties.
**7. DILI:** Ligand B (65.374) has a slightly higher DILI risk than Ligand A (52.966), though both are within an acceptable range.
**8. BBB:** Ligand A (73.905) has a higher BBB penetration percentile than Ligand B (65.413). While ADRB2 isn't strictly a CNS target, some CNS exposure can occur, and higher BBB is generally a positive.
**9. Caco-2 Permeability:** Ligand A (-4.437) has better Caco-2 permeability than Ligand B (-5.265).
**10. Aqueous Solubility:** Ligand A (-2.311) has better aqueous solubility than Ligand B (-3.423).
**11. hERG Inhibition:** Both ligands show low hERG inhibition risk (A: 0.448, B: 0.186), which is excellent.
**12. Microsomal Clearance:** Ligand A (69.68) has a significantly higher microsomal clearance than Ligand B (30.034). This suggests Ligand B will have better metabolic stability.
**13. In vitro Half-Life:** Ligand B (-4.919) has a longer in vitro half-life than Ligand A (-6.473).
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (A: 0.04, B: 0.116).
**15. Binding Affinity:** Ligand A (-6.1 kcal/mol) has a slightly better binding affinity than Ligand B (-4.6 kcal/mol). This difference of 1.5 kcal/mol is significant and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand A is the better candidate. While Ligand B has better metabolic stability and half-life, Ligand A excels in crucial areas for a GPCR target: lower TPSA, better Caco-2 permeability, better solubility, and significantly stronger binding affinity. The difference in binding affinity is substantial enough to compensate for the slightly higher clearance. The slightly better BBB penetration is also a bonus.
Output:
1
2025-04-17 18:12:14,274 - INFO - Batch 20 complete. Total preferences: 320
2025-04-17 18:12:14,274 - INFO - Processing batch 21/512...
2025-04-17 18:13:05,258 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (386.474 Da) is within the ideal range. Ligand B (352.425 Da) is also good. No clear advantage.
2. **TPSA:** Ligand A (83.47) is acceptable, though approaching the upper limit for good oral absorption. Ligand B (42.43) is excellent, well below the 140 threshold. Advantage: B
3. **logP:** Ligand A (1.307) is optimal. Ligand B (3.938) is at the higher end of optimal, potentially raising concerns about solubility and off-target effects. Advantage: A
4. **HBD:** Both ligands have 0 HBD, which is good. No difference.
5. **HBA:** Ligand A (6) is acceptable. Ligand B (3) is excellent. Advantage: B
6. **QED:** Ligand A (0.716) is very good. Ligand B (0.632) is still acceptable, but slightly lower. Advantage: A
7. **DILI:** Ligand A (63.862) is moderately risky. Ligand B (15.975) is very low risk. Significant advantage: B
8. **BBB:** Ligand A (62.078) is moderate. Ligand B (94.067) is excellent. As ADRB2 is a GPCR, BBB penetration is a consideration, though not paramount for cardiovascular targets. Advantage: B
9. **Caco-2:** Ligand A (-4.725) is poor. Ligand B (-3.763) is also poor, but slightly better. Advantage: B
10. **Solubility:** Ligand A (-2.614) is poor. Ligand B (-3.54) is also poor. No clear advantage.
11. **hERG:** Ligand A (0.229) is very low risk. Ligand B (0.713) is moderate risk. Advantage: A
12. **Cl_mic:** Ligand A (64.578) is moderate. Ligand B (83.91) is higher, indicating faster clearance. Advantage: A
13. **t1/2:** Ligand A (-7.049) is excellent (negative values indicate longer half-life). Ligand B (-2.234) is good, but not as good as A. Advantage: A
14. **Pgp:** Ligand A (0.071) is very low efflux. Ligand B (0.425) is moderate efflux. Advantage: A
15. **Affinity:** Ligand A (-6.9 kcal/mol) is very good. Ligand B (-6.0 kcal/mol) is also good, but 0.9 kcal/mol weaker. Advantage: A
**Overall Assessment:**
Ligand A has a significant advantage in binding affinity and metabolic stability (t1/2, Cl_mic, Pgp), and a lower hERG risk. These are crucial factors. While Ligand B excels in TPSA, BBB, and DILI, the difference in affinity is substantial. Given the cardiovascular target, BBB penetration is less critical than metabolic properties and safety. The lower DILI risk of Ligand B is attractive, but can be addressed through further optimization. The poor solubility and Caco-2 values are concerning for both, but can be improved with formulation strategies.
Therefore, I favor Ligand A due to its superior binding affinity and better metabolic profile, which are more critical for a viable drug candidate.
Output:
1
2025-04-17 18:13:05,258 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [338.371, 89.07, 1.393, 1, 7, 0.773, 79.604, 46.219, -5.335, -1.96, 0.052, 35.493, -19.607, 0.051, -6.9]
**Ligand B:** [370.603, 40.62, 4.041, 0, 3, 0.545, 14.347, 83.986, -4.832, -3.587, 0.866, 94.544, -6.373, 0.728, -6.4]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (338.371) is slightly preferred due to being closer to the lower end, which can aid permeability.
2. **TPSA:** Ligand A (89.07) is better than Ligand B (40.62). Both are below 140, but Ligand B is significantly lower, which is good for permeability.
3. **logP:** Ligand A (1.393) is optimal (1-3). Ligand B (4.041) is slightly high, potentially leading to solubility issues and off-target effects.
4. **HBD:** Ligand A (1) is preferable to Ligand B (0). Having some HBD can improve solubility.
5. **HBA:** Ligand A (7) is better than Ligand B (3). Both are within the acceptable range, but Ligand A is closer to the upper limit of 10.
6. **QED:** Ligand A (0.773) is significantly better than Ligand B (0.545), indicating a more drug-like profile.
7. **DILI:** Ligand B (14.347) is *much* better than Ligand A (79.604). This is a major advantage for Ligand B.
8. **BBB:** Ligand B (83.986) is significantly better than Ligand A (46.219). While ADRB2 isn't a CNS target, some distribution to the CNS can sometimes occur, and higher BBB penetration is generally favorable.
9. **Caco-2:** Ligand A (-5.335) is better than Ligand B (-4.832). Higher values indicate better absorption.
10. **Solubility:** Ligand A (-1.96) is better than Ligand B (-3.587).
11. **hERG:** Ligand A (0.052) is better than Ligand B (0.866). Lower hERG inhibition is crucial for avoiding cardiotoxicity.
12. **Cl_mic:** Ligand A (35.493) is much better than Ligand B (94.544). Lower clearance indicates better metabolic stability.
13. **t1/2:** Ligand A (-19.607) is better than Ligand B (-6.373). Longer half-life is generally preferred.
14. **Pgp:** Ligand A (0.051) is better than Ligand B (0.728). Lower P-gp efflux is desirable.
15. **Affinity:** Both ligands have very similar binding affinities (-6.9 and -6.4 kcal/mol). The difference is not substantial enough to be a deciding factor.
**GPCR-specific priorities:** logP, Pgp, TPSA, and affinity are key for GPCRs. Ligand B has a better logP and Pgp, and TPSA, but Ligand A has a better affinity.
**Overall Assessment:**
Ligand B has a significant advantage in terms of DILI risk and BBB penetration. While its logP is slightly high, the dramatic reduction in DILI risk is a major factor. The metabolic stability (Cl_mic) is a concern for Ligand B, but the overall profile is more favorable. Ligand A has better solubility, hERG, and metabolic stability, but the high DILI risk is a significant drawback.
Given the importance of avoiding liver toxicity and the relatively similar binding affinities, I would choose Ligand B.
Output:
0
2025-04-17 18:13:05,258 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (360.479 and 348.487 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (68.17) is better than Ligand B (75.27). Both are below 140, but lower TPSA generally favors absorption.
3. **logP:** Both ligands have good logP values (3.13 and 2.749), within the optimal 1-3 range. Ligand A is slightly higher, which could be a minor advantage.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (4) is preferable to Ligand B (3). Lower HBA generally improves permeability.
6. **QED:** Ligand A (0.911) is significantly better than Ligand B (0.695), indicating a more drug-like profile.
7. **DILI:** Ligand B (26.134) is much better than Ligand A (74.021). Lower DILI is critical, and Ligand B has a substantially lower risk.
8. **BBB:** Both ligands have reasonably good BBB penetration (76.27 and 70.803). This isn't a primary concern for ADRB2 (a cardiovascular target), but it's not detrimental.
9. **Caco-2:** Both are negative, indicating poor permeability. This is a concern for both.
10. **Solubility:** Both are negative, indicating poor solubility. This is a concern for both.
11. **hERG:** Ligand A (0.386) is better than Ligand B (0.095). Lower hERG inhibition is crucial for avoiding cardiotoxicity.
12. **Cl_mic:** Ligand A (29.061) has significantly lower microsomal clearance than Ligand B (52.53), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-7.417) has a better in vitro half-life than Ligand A (-8.43). Longer half-life is generally preferred.
14. **Pgp:** Ligand A (0.454) is better than Ligand B (0.108). Lower P-gp efflux is desirable for better bioavailability.
15. **Binding Affinity:** Ligand B (-4.0) has a slightly better binding affinity than Ligand A (-6.3). This is a significant difference, and a >1.5 kcal/mol advantage can often outweigh other drawbacks.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Both ligands have acceptable logP values. Ligand A is better on TPSA and Pgp, while Ligand B has better affinity. The DILI risk for Ligand B is a major advantage.
**Overall Assessment:**
While Ligand A has a better QED, lower DILI is a critical factor. Ligand B's significantly lower DILI risk and better affinity outweigh the slightly less favorable TPSA, Pgp, and QED values. The better half-life is also a plus. The poor Caco-2 and solubility are concerns for both, but can be addressed with formulation strategies.
**Output:**
0
2025-04-17 18:13:05,258 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [355.385, 65.64, 1.32, 1, 3, 0.886, 27.801, 77.821, -4.538, -2.515, 0.661, 10.507, -26.738, 0.045, -3.9]**
**Ligand B: [362.417, 75.71, 1.83, 1, 4, 0.732, 31.175, 82.047, -4.611, -2.361, 0.376, 46.346, -34.69, 0.055, -6.0]**
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). A (355.385) is slightly preferred due to being a bit lower.
2. **TPSA:** Ligand A (65.64) is better than Ligand B (75.71). Both are reasonably good for oral absorption, but A is closer to the preferred <140.
3. **logP:** Both ligands have acceptable logP values (A: 1.32, B: 1.83), falling within the 1-3 range. B is slightly higher, which could potentially lead to off-target effects, but it's not a major concern.
4. **H-Bond Donors:** Both have 1 HBD, which is good.
5. **H-Bond Acceptors:** Ligand A (3) is better than Ligand B (4). Lower is generally preferred.
6. **QED:** Ligand A (0.886) has a significantly better QED score than Ligand B (0.732), indicating a more drug-like profile.
7. **DILI:** Ligand A (27.801) has a lower DILI risk than Ligand B (31.175), which is favorable. Both are below the 40% threshold.
8. **BBB:** Ligand B (82.047) has a slightly better BBB penetration than Ligand A (77.821). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be beneficial or at least needs to be considered.
9. **Caco-2 Permeability:** Both have negative values, indicating poor permeability. A (-4.538) is slightly better than B (-4.611).
10. **Aqueous Solubility:** Both have negative values, indicating poor solubility. A (-2.515) is slightly better than B (-2.361).
11. **hERG Inhibition:** Ligand A (0.661) has a lower hERG inhibition risk than Ligand B (0.376), which is a significant advantage.
12. **Microsomal Clearance:** Ligand A (10.507) has a much lower microsomal clearance than Ligand B (46.346), suggesting better metabolic stability.
13. **In vitro Half-Life:** Ligand A (-26.738) has a much longer in vitro half-life than Ligand B (-34.69), indicating better stability.
14. **P-gp Efflux:** Both have very low P-gp efflux liability (A: 0.045, B: 0.055).
15. **Binding Affinity:** Ligand B (-6.0) has a significantly stronger binding affinity than Ligand A (-3.9). This is a substantial advantage.
**Overall Assessment:**
Ligand B has a much stronger binding affinity, which is a critical factor for GPCRs. However, it suffers from significantly worse ADME properties, particularly higher microsomal clearance and lower metabolic stability, and a higher hERG risk. Ligand A has a more balanced profile with better QED, lower DILI, lower hERG, and significantly improved metabolic stability (lower Cl_mic, longer t1/2). The difference in binding affinity is substantial (~2.1 kcal/mol), but the ADME liabilities of Ligand B are concerning. Given the importance of metabolic stability and safety (hERG) for a cardiovascular target, I believe Ligand A is the more promising candidate, despite the weaker binding affinity. Further optimization of Ligand A to improve its affinity could be a viable strategy.
Output:
1
2025-04-17 18:13:05,258 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (357.4 & 352.5 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (108.41) is higher than Ligand B (49.41). For a cardiovascular GPCR, TPSA isn't a *major* concern unless excessively high, but lower is generally preferred for better permeability. Ligand B is significantly better.
3. **logP:** Ligand A (-1.797) is lower than the optimal 1-3 range, potentially hindering permeability. Ligand B (3.16) is within the optimal range. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable, below the threshold of 5.
5. **HBA:** Ligand A (6) and Ligand B (2) are both acceptable, below the threshold of 10. Ligand B is better.
6. **QED:** Both ligands have good QED scores (0.543 and 0.798, respectively), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (34.432) has a slightly higher DILI risk than Ligand B (24.506), but both are below the concerning threshold of 60.
8. **BBB:** Ligand A (18.147) has very poor BBB penetration. Ligand B (97.286) has excellent BBB penetration. While ADRB2 isn't exclusively a CNS target, some CNS exposure could be beneficial or at least avoid unexpected side effects, and this is a huge advantage for Ligand B.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, and negative values could indicate a different measurement system.
10. **Solubility:** Ligand A (-0.772) has poor solubility, while Ligand B (-3.805) is even worse. This is a concern for both, but slightly less so for Ligand A.
11. **hERG:** Ligand A (0.096) has a very low hERG risk, which is excellent. Ligand B (0.762) has a slightly elevated, but still acceptable, hERG risk.
12. **Cl_mic:** Ligand A (-0.365) has a negative clearance, which is not possible. This suggests a measurement error or a different scale. Ligand B (37.89) has a relatively high clearance, indicating faster metabolism. This is a disadvantage for Ligand B.
13. **t1/2:** Ligand A (-14.641) has a negative half-life, which is not possible. Ligand B (-16.024) also has a negative half-life. This suggests measurement errors or a different scale.
14. **Pgp:** Ligand A (0.011) has very low P-gp efflux, which is desirable. Ligand B (0.46) has moderate P-gp efflux.
15. **Affinity:** Ligand A (-6.7 kcal/mol) has slightly better binding affinity than Ligand B (-5.4 kcal/mol). This is a 1.3 kcal/mol difference, which is significant.
**Overall Assessment:**
Despite Ligand A's slightly better affinity, Ligand B is the more promising candidate. The key advantages of Ligand B are its optimal logP, excellent BBB penetration, lower DILI risk, and better TPSA. The solubility and metabolic stability issues are concerning for both, but the other factors outweigh these drawbacks. The negative values for clearance and half-life for both molecules are concerning and require further investigation, but do not change the overall preference for Ligand B given the other parameters.
**Output:**
0
2025-04-17 18:13:05,259 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (381.523 and 360.845 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Both ligands (82.27 and 78.35) are below the 140 A^2 threshold for good oral absorption, and acceptable for a cardiovascular GPCR. Ligand B is slightly better.
3. **logP:** Both ligands (1.714 and 2.472) are within the optimal 1-3 range. Ligand B is slightly higher, potentially aiding membrane permeability.
4. **HBD:** Both have 2 HBD, which is good.
5. **HBA:** Both have 5 HBA, which is good.
6. **QED:** Ligand B (0.875) has a significantly higher QED score than Ligand A (0.556), indicating a more drug-like profile.
7. **DILI:** Ligand A (41.838) has a lower DILI risk than Ligand B (55.68), which is preferable.
8. **BBB:** Ligand A (50.523) has a better BBB penetration percentile than Ligand B (35.13). While ADRB2 isn't a CNS target, some degree of BBB penetration can sometimes be beneficial for off-target profiling.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. These values are likely errors or represent very low permeability.
10. **Solubility:** Both have negative solubility values, which is also unusual and suggests poor solubility. These values are likely errors or represent very low solubility.
11. **hERG:** Both ligands have low hERG inhibition liability (0.529 and 0.412).
12. **Cl_mic:** Ligand A (27.993) has a lower microsomal clearance than Ligand B (63.564), indicating better metabolic stability.
13. **t1/2:** Ligand B (-7.602) has a significantly longer in vitro half-life than Ligand A (-20.511). This is a major advantage.
14. **Pgp:** Both have very low Pgp efflux liability (0.203 and 0.055).
15. **Binding Affinity:** Both have very similar binding affinities (-6.6 and -6.8 kcal/mol). The difference is negligible.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand B has a slightly better logP and a significantly better QED and half-life. While Ligand A has a lower DILI risk and better BBB penetration, the longer half-life of Ligand B is a substantial advantage for a cardiovascular drug, potentially allowing for less frequent dosing. The similar binding affinities mean that the ADME properties become the deciding factor.
**Conclusion:**
Considering the balance of properties, Ligand B is the more promising candidate due to its superior QED score and significantly longer half-life, outweighing the slightly higher DILI risk and lower BBB penetration.
Output:
0
2025-04-17 18:13:05,259 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
Let's analyze each ligand against the provided guidelines, keeping in mind ADRB2 is a GPCR, so logP, TPSA, Pgp, BBB, and affinity are key.
* **Molecular Weight:** Both ligands (342.45 & 371.46 Da) fall within the ideal 200-500 Da range.
* **TPSA:** Ligand A (75.94) is better than Ligand B (96.77). A lower TPSA generally favors better cell permeability, crucial for GPCR targeting. Ligand A is well below the 140 threshold.
* **logP:** Ligand A (1.825) is optimal, while Ligand B (0.251) is quite low. A logP below 1 can hinder membrane permeability. This is a significant disadvantage for Ligand B.
* **H-Bond Donors/Acceptors:** Both have 1 HBD and 6 HBA, which are acceptable.
* **QED:** Both ligands have good QED values (0.921 and 0.818), indicating generally drug-like properties.
* **DILI:** Both have DILI risk around the 60-65 percentile, which is moderately concerning but not disqualifying.
* **BBB:** Ligand B (75.921) has a slightly better BBB penetration than Ligand A (67.313), but for a cardiovascular target, this isn't a primary concern.
* **Caco-2 Permeability:** Both have negative Caco-2 values, which is unusual and indicates poor permeability. However, the value for Ligand A (-4.882) is less negative than Ligand B (-4.74), suggesting slightly better permeability.
* **Aqueous Solubility:** Both have negative solubility values, which is also unusual.
* **hERG:** Ligand A (0.577) has a slightly higher hERG risk than Ligand B (0.127), but both are relatively low.
* **Microsomal Clearance:** Ligand A (53.281) has significantly better metabolic stability (lower clearance) than Ligand B (10.893). This is a major advantage.
* **In vitro Half-Life:** Ligand A (21.124 hours) has a much longer half-life than Ligand B (-38.65 hours). The negative value for Ligand B is concerning.
* **P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.077 and 0.014).
* **Binding Affinity:** Ligand A (-4.7 kcal/mol) has a slightly better binding affinity than Ligand B (-3.4 kcal/mol), a difference of 1.3 kcal/mol. This is a substantial difference.
**Overall Assessment:**
Ligand A is clearly the superior candidate. While both have some concerning ADME properties (negative Caco-2 and solubility), Ligand A's significantly better logP, metabolic stability (lower Cl_mic, longer t1/2), and binding affinity outweigh its slightly higher TPSA and hERG risk. The low logP of Ligand B is a major drawback, likely hindering its ability to cross cell membranes and reach the ADRB2 receptor. The negative half-life for Ligand B is also a red flag.
Output:
1
2025-04-17 18:13:05,262 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.419 Da and 344.499 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (72.18) is higher than Ligand B (49.41). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for better absorption. Ligand B is better.
3. **logP:** Ligand A (3.722) is slightly higher than Ligand B (2.99). Both are within the optimal 1-3 range, but Ligand A is approaching the upper limit. Ligand B is slightly better.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 6 HBA, while Ligand B has 2. Lower HBA is generally favorable for permeability. Ligand B is better.
6. **QED:** Ligand B (0.78) has a better QED score than Ligand A (0.612), indicating a more drug-like profile. Ligand B is better.
7. **DILI:** Ligand A (97.867) has a significantly higher DILI risk than Ligand B (19.736). This is a major concern for Ligand A. Ligand B is *much* better.
8. **BBB:** Ligand A (58.55) and Ligand B (71.384) both have moderate BBB penetration. Since ADRB2 is not a CNS target, this is less critical, but higher is still slightly preferred. Ligand B is better.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.006 and -4.828). These values are unusual and suggest poor permeability. However, the values are very close, so this isn't a major differentiator.
10. **Solubility:** Ligand A (-4.854) and Ligand B (-3.547) both have poor solubility. Ligand B is slightly better.
11. **hERG:** Both ligands have low hERG inhibition risk (0.436 and 0.373). No significant difference.
12. **Cl_mic:** Ligand A (75.864) has a higher microsomal clearance than Ligand B (58.526), suggesting lower metabolic stability. Ligand B is better.
13. **t1/2:** Ligand B (-11.915) has a negative half-life, which is not possible. This is a major red flag and suggests a significant issue with the data or the molecule itself. Ligand A (42.742) has a reasonable in vitro half-life.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.663 and 0.217). Ligand B is better.
15. **Binding Affinity:** Ligand B (-7.1 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.4 kcal/mol). This is a substantial advantage, potentially outweighing some ADME concerns.
**Overall Assessment:**
Ligand B appears to be the better candidate despite the unusual negative in vitro half-life. The substantially lower DILI risk, better QED, lower TPSA, and significantly stronger binding affinity are compelling advantages. The negative half-life is a serious concern that would need further investigation, but the other benefits of Ligand B are significant. Ligand A's high DILI risk is a major drawback.
Output:
0
2025-04-17 18:13:05,262 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (348.443) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (67.87) is significantly better than Ligand B (110.1). For a GPCR, keeping TPSA low is beneficial for permeability and receptor engagement. Ligand B is approaching a TPSA that could hinder oral absorption.
3. **logP:** Ligand A (2.288) is optimal, while Ligand B (-0.277) is quite low. Low logP can lead to poor membrane permeability and bioavailability. This is a significant drawback for Ligand B.
4. **HBD:** Ligand A (1) is preferable to Ligand B (4). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is preferable to Ligand B (5) for similar reasons as HBD.
6. **QED:** Both ligands have acceptable QED scores (A: 0.549, B: 0.499), indicating reasonable drug-likeness.
7. **DILI:** Ligand B (28.228) has a lower DILI risk than Ligand A (35.595), which is a positive for Ligand B.
8. **BBB:** Ligand A (74.254) has a much better BBB penetration score than Ligand B (48.468). While ADRB2 isn't exclusively a CNS target, some peripheral effects are mediated through sympathetic nervous system activity, and better CNS penetration can sometimes be beneficial.
9. **Caco-2:** Both have negative values, indicating poor permeability. Ligand A (-5.176) is slightly better than Ligand B (-5.351).
10. **Solubility:** Both have negative values, indicating poor solubility. Ligand A (-2.205) is slightly better than Ligand B (-1.783).
11. **hERG:** Ligand A (0.669) has a lower hERG risk than Ligand B (0.273), which is a significant advantage.
12. **Cl_mic:** Ligand B (1.385) has a much lower microsomal clearance than Ligand A (32.428), suggesting better metabolic stability. This is a strong point for Ligand B.
13. **t1/2:** Ligand B (-8.037) has a longer in vitro half-life than Ligand A (-15.413), which is also a positive for Ligand B.
14. **Pgp:** Ligand A (0.189) has lower P-gp efflux than Ligand B (0.05), which is favorable.
15. **Affinity:** Ligand A (-7.6) has a slightly better binding affinity than Ligand B (-6.6). While the difference is less than 1.5 kcal/mol, it's still a positive for Ligand A.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A excels in these areas. While Ligand B has better metabolic stability (Cl_mic, t1/2) and lower DILI, the poor logP and higher TPSA are significant drawbacks that likely outweigh these benefits.
**Conclusion:**
Despite Ligand B's advantages in metabolic stability and DILI, Ligand A's superior logP, TPSA, Pgp, and slightly better affinity make it the more promising drug candidate for targeting the ADRB2 receptor.
Output:
1
2025-04-17 18:13:05,263 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.431 and 345.451 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (98.7) is slightly higher than Ligand B (82.68). Both are below the 140 threshold for oral absorption, but closer to the 90 threshold for CNS targets (less relevant for ADRB2, a cardiovascular target). Ligand B is preferable here.
3. **logP:** Ligand A (2.829) is within the optimal 1-3 range. Ligand B (1.354) is at the lower end of this range. While not problematic, a slightly higher logP is generally preferred for GPCRs to aid membrane permeability. Ligand A is preferable.
4. **HBD:** Both ligands have 1 HBD, which is ideal. No difference.
5. **HBA:** Ligand A has 6 HBAs, while Ligand B has 8. Both are acceptable (<=10), but Ligand A is slightly better.
6. **QED:** Both ligands have good QED scores (0.51 and 0.655, respectively), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (45.56) has a slightly higher DILI risk than Ligand B (34.393), but both are below the 40% threshold. Ligand B is preferable.
8. **BBB:** Both ligands have good BBB penetration (76.231 and 70.919, respectively). This isn't a primary concern for ADRB2, but it's a positive attribute.
9. **Caco-2:** Ligand A (-4.941) has a worse Caco-2 permeability than Ligand B (-5.547). Lower values here indicate lower permeability. Ligand B is preferable.
10. **Solubility:** Ligand A (-4.166) has a worse solubility than Ligand B (-1.233). Lower values indicate lower solubility. Ligand B is preferable.
11. **hERG:** Ligand A (0.917) has a slightly higher hERG risk than Ligand B (0.201). Lower hERG risk is crucial for cardiovascular drugs. Ligand B is strongly preferable.
12. **Cl_mic:** Ligand A (43.467) has a higher microsomal clearance than Ligand B (17.61). Lower clearance is better for metabolic stability. Ligand B is preferable.
13. **t1/2:** Ligand A (-4.441) has a worse in vitro half-life than Ligand B (2.892). Longer half-life is generally desirable. Ligand B is preferable.
14. **Pgp:** Ligand A (0.362) has a lower Pgp efflux than Ligand B (0.17). Lower Pgp efflux is preferable. Ligand A is preferable.
15. **Binding Affinity:** Ligand A (-8.1 kcal/mol) has a significantly stronger binding affinity than Ligand B (-5.0 kcal/mol). This is a >3 kcal/mol difference, which is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand A has a significantly better binding affinity, which is the most important factor for GPCRs. While Ligand B has better ADME properties in several areas (DILI, solubility, hERG, Cl_mic, t1/2, Caco-2), the substantial difference in binding affinity outweighs these concerns. The ADME properties of Ligand A are still within acceptable ranges, and optimization can further improve them.
Output:
1
2025-04-17 18:13:05,263 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [355.498, 61.44, 2.258, 2, 3, 0.667, 5.777, 75.107, -5.02, -1.733, 0.472, -4.863, -16.427, 0.019, -5.9]
**Ligand B:** [350.467, 103.01, 0.857, 3, 5, 0.677, 41.101, 44.746, -5.558, -2.077, 0.463, -6.773, -5.871, 0.022, -7.7]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). A is 355.5, B is 350.5. Very similar.
2. **TPSA:** A (61.44) is excellent, well below 140 and good for oral absorption. B (103.01) is still acceptable, but higher. This favors A.
3. **logP:** A (2.258) is optimal. B (0.857) is a bit low, potentially hindering permeation. This favors A.
4. **HBD:** A (2) is good. B (3) is acceptable, but slightly higher.
5. **HBA:** A (3) is good. B (5) is acceptable, but higher.
6. **QED:** Both are similar (A: 0.667, B: 0.677) and above the 0.5 threshold, indicating good drug-likeness.
7. **DILI:** A (5.777) is significantly better (lower risk) than B (41.101). This is a major advantage for A.
8. **BBB:** A (75.107) is good, indicating reasonable potential for CNS penetration, although ADRB2 is primarily cardiovascular. B (44.746) is lower.
9. **Caco-2:** Both are negative, indicating poor permeability. A (-5.02) is slightly better than B (-5.558), but both are concerning.
10. **Solubility:** Both are negative, indicating poor solubility. A (-1.733) is slightly better than B (-2.077).
11. **hERG:** Both are low (A: 0.472, B: 0.463), suggesting low cardiotoxicity risk. Very similar.
12. **Cl_mic:** A (-4.863) is better (lower clearance, more stable) than B (-6.773). This favors A.
13. **t1/2:** A (-16.427) is better (longer half-life) than B (-5.871). This favors A.
14. **Pgp:** Both are very low (A: 0.019, B: 0.022), suggesting minimal P-gp efflux. Very similar.
15. **Affinity:** B (-7.7) is significantly better than A (-5.9) - a 1.8 kcal/mol difference. This is a substantial advantage for B.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. While B has a lower logP, the substantial affinity advantage (-7.7 vs -5.9) is likely to outweigh this. However, A has a significantly better safety profile (DILI) and better metabolic stability (Cl_mic, t1/2). The TPSA is also much more favorable for A.
**Overall Assessment:**
The affinity difference is significant. However, the combination of a much lower DILI risk, better metabolic stability, and more favorable TPSA for Ligand A makes it the more promising candidate. While the Caco-2 and solubility are poor for both, these can be addressed with formulation strategies. The improved safety and PK profile of A are more critical for a cardiovascular target.
Output:
1
2025-04-17 18:13:05,263 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (379.492 and 371.591 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (45.23) is significantly better than Ligand B (61.44). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (4.31) is higher than Ligand B (2.649). While both are within the acceptable range (1-3 is optimal, but up to 4 is tolerable), Ligand A is pushing the upper limit. This *could* lead to solubility issues, but the benefit of affinity may outweigh this.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Both ligands have the same number of HBA (4).
6. **QED:** Ligand A (0.768) has a better QED score than Ligand B (0.612), indicating a more drug-like profile.
7. **DILI:** Ligand A (43.738) has a significantly better DILI percentile than Ligand B (8.957). Lower is better, and Ligand B's value is quite concerning.
8. **BBB:** Ligand A (77.705) has a better BBB percentile than Ligand B (64.056). While not a primary concern for a cardiovascular target, higher BBB is generally a positive attribute.
9. **Caco-2:** Ligand A (-4.546) is better than Ligand B (-5.331). Higher values indicate better intestinal absorption.
10. **Solubility:** Ligand A (-3.95) is better than Ligand B (-2.557). Higher values indicate better solubility.
11. **hERG:** Ligand A (0.901) is better than Ligand B (0.618). Lower values indicate lower hERG inhibition liability, reducing cardiotoxicity risk.
12. **Cl_mic:** Ligand B (24.055) has a much lower microsomal clearance than Ligand A (60.578), suggesting better metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand A (53.346) has a much longer in vitro half-life than Ligand B (9.435). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.428) is better than Ligand B (0.027). Lower Pgp efflux improves bioavailability.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.0 and -6.1 kcal/mol). The difference is negligible.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has a slightly higher logP, better TPSA, and better Pgp. The affinities are nearly identical. However, the DILI risk for Ligand B is very concerning, and the significantly better metabolic stability (lower Cl_mic) of Ligand B is a strong point in its favor. The longer half-life of Ligand A is also a significant positive.
**Overall Assessment:**
While Ligand B has better metabolic stability, the extremely high DILI risk is a major red flag. The slightly better solubility and half-life of Ligand A, combined with the lower DILI risk and better overall drug-like properties (QED, BBB, Pgp) make it the more promising candidate.
Output:
1
2025-04-17 18:13:05,263 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
Let's break down the comparison of Ligand A and Ligand B, considering the provided guidelines and the GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key).
1. **Molecular Weight:** Both ligands (349.43 and 340.38 Da) fall comfortably within the ideal 200-500 Da range.
2. **TPSA:** Both ligands (79.98 and 77.52) are below the 140 A^2 threshold for good oral absorption.
3. **logP:** Ligand A (3.012) is slightly higher than Ligand B (1.975). Both are within the optimal 1-3 range, but Ligand B is closer to the lower end.
4. **H-Bond Donors:** Both have 1 HBD, which is good.
5. **H-Bond Acceptors:** Both have 5 HBA, which is good.
6. **QED:** Ligand B (0.842) has a significantly better QED score than Ligand A (0.604), indicating a more drug-like profile.
7. **DILI:** Ligand A (52.152) has a much lower DILI risk than Ligand B (85.459). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (70.609) has a better BBB penetration percentile than Ligand B (56.805). While ADRB2 isn't exclusively a CNS target, some peripheral ADRB2 activity can be modulated by CNS effects, and better BBB penetration isn't necessarily detrimental.
9. **Caco-2:** Both have negative Caco-2 values which is unusual.
10. **Aqueous Solubility:** Both have negative solubility values which is unusual.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.265 and 0.243).
12. **Cl_mic:** Ligand A (99.848) has a higher microsomal clearance than Ligand B (50.888), meaning it is less metabolically stable. This is a disadvantage for Ligand A.
13. **t1/2:** Ligand B (-9.263) has a longer in vitro half-life than Ligand A (13.725). This is a major advantage for Ligand B.
14. **Pgp:** Both have low Pgp efflux liability (0.325 and 0.13).
15. **Binding Affinity:** Ligand B (-6.8 kcal/mol) has a significantly stronger binding affinity than Ligand A (-4.9 kcal/mol). This 1.9 kcal/mol difference is substantial and outweighs many of the other differences.
**Overall Assessment:**
Ligand B clearly wins on binding affinity and has a better QED and in vitro half-life. The DILI risk is a concern for Ligand B, but the significantly stronger binding affinity is a major driver for potential efficacy. The slightly lower logP of Ligand B is acceptable. The better metabolic stability of Ligand B is also a positive.
Output:
0
2025-04-17 18:13:05,263 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (428.67 Da) is within the ideal range, while Ligand B (381.885 Da) is also good. No clear advantage here.
2. **TPSA:** Ligand A (138.67) is approaching the upper limit for good oral absorption, but still acceptable. Ligand B (80.32) is excellent, well below the 140 threshold. This favors Ligand B.
3. **logP:** Both ligands (A: 1.922, B: 3.48) are within the optimal 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability, but not drastically.
4. **HBD:** Ligand A (5) is at the upper limit, while Ligand B (2) is better. Lower HBD generally improves permeability. This favors Ligand B.
5. **HBA:** Both ligands have 5 HBA, which is acceptable.
6. **QED:** Ligand B (0.686) has a better QED score than Ligand A (0.366), indicating a more drug-like profile. This is a significant advantage for Ligand B.
7. **DILI:** Ligand A (57.348) has a lower DILI risk than Ligand B (72.199). This favors Ligand A.
8. **BBB:** Ligand B (61.962) has a higher BBB penetration potential than Ligand A (44.397), though neither is exceptionally high. Given ADRB2's cardiovascular involvement, BBB penetration isn't a primary concern, but it's a slight advantage for B.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Both ligands have negative solubility values, indicating very poor aqueous solubility. This is a major drawback for both.
11. **hERG:** Both ligands have low hERG inhibition liability (A: 0.557, B: 0.443). No clear advantage.
12. **Cl_mic:** Ligand A (12.827) has a lower microsomal clearance than Ligand B (59.741), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand B (66.282) has a much longer in vitro half-life than Ligand A (-14.078). This is a substantial advantage for Ligand B.
14. **Pgp:** Both ligands have low P-gp efflux liability (A: 0.114, B: 0.156). No clear advantage.
15. **Binding Affinity:** Both ligands have very similar binding affinities (A: -8.2 kcal/mol, B: -8.3 kcal/mol). The difference is negligible.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand B appears slightly more promising. Its lower TPSA, better QED, and longer half-life are significant advantages. While Ligand A has a lower DILI risk and better metabolic stability, the solubility issues and shorter half-life are major concerns. The binding affinities are almost identical, so that doesn't differentiate them. The poor Caco-2 and solubility for both are problematic, but can potentially be addressed with formulation strategies.
**Output:**
0
2025-04-17 18:13:05,263 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [348.487, 67.43, 3.455, 2, 3, 0.707, 32.183, 51.105, -4.492, -3.544, 0.737, 64.125, -11.32, 0.267, -6.7]
**Ligand B:** [355.383, 114.17, 0.109, 3, 8, 0.572, 98.488, 22.257, -5.751, -3.395, 0.133, -7.819, 48.361, 0.042, -4.1]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity):
1. **MW:** Both are within the ideal range (200-500 Da). A is slightly lower, which is generally favorable.
2. **TPSA:** Ligand A (67.43) is significantly better than Ligand B (114.17). A is well below the 140 threshold, while B is approaching it. This is a significant advantage for A, improving potential for oral absorption and potentially BBB penetration.
3. **logP:** Ligand A (3.455) is optimal. Ligand B (0.109) is *very* low, raising concerns about permeability. This is a major drawback for B.
4. **HBD/HBA:** Ligand A (2/3) is better than Ligand B (3/8). Lower counts are generally preferred for better permeability.
5. **QED:** Ligand A (0.707) is better than Ligand B (0.572), indicating a more drug-like profile.
6. **DILI:** Ligand A (32.183) is significantly better than Ligand B (98.488). B's DILI risk is high.
7. **BBB:** Ligand A (51.105) is better than Ligand B (22.257), although neither is exceptionally high. For a cardiovascular target, BBB isn't *critical*, but some penetration can be beneficial.
8. **Caco-2:** Ligand A (-4.492) is better than Ligand B (-5.751), indicating better intestinal absorption.
9. **Solubility:** Both are similar and poor (-3.544 and -3.395). This could be a formulation challenge for both, but isn't a deciding factor.
10. **hERG:** Ligand A (0.737) is better than Ligand B (0.133), indicating a lower risk of cardiotoxicity.
11. **Cl_mic:** Ligand B (-7.819) is better than Ligand A (64.125), suggesting better metabolic stability. This is a positive for B.
12. **t1/2:** Ligand B (48.361) is better than Ligand A (-11.32). This is a positive for B.
13. **Pgp:** Ligand A (0.267) is better than Ligand B (0.042), indicating lower P-glycoprotein efflux. This is a significant advantage for A, improving bioavailability.
14. **Affinity:** Ligand A (-6.7) is significantly better than Ligand B (-4.1). A 2.6 kcal/mol difference is substantial and can often outweigh other drawbacks.
**Overall Assessment:**
Ligand A is significantly better. While Ligand B has better metabolic stability and half-life, Ligand A excels in crucial areas for a GPCR drug candidate: TPSA, logP, DILI risk, Pgp efflux, and *especially* binding affinity. The low logP and high DILI risk of Ligand B are major concerns. The superior affinity of Ligand A is a decisive factor.
Output:
1
2025-04-17 18:13:05,264 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [367.793, 104.7 , 1.041, 1. , 7. , 0.869, 75.184, 32.299, -4.735, -2.528, 0.028, 50.871, -13.185, 0.065, -8.4 ]
**Ligand B:** [388.892, 75.27 , 2.445, 2. , 3. , 0.704, 41.838, 71.772, -5.024, -4.184, 0.545, 40.323, -17.67 , 0.101, -7.3 ]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity, and BBB):
1. **MW:** Both are within the acceptable 200-500 Da range. Ligand A (367.793) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (75.27) is significantly better than Ligand A (104.7), falling well below the 140 threshold for oral absorption and closer to the ideal for GPCRs.
3. **logP:** Ligand A (1.041) is a bit low, potentially hindering membrane permeability. Ligand B (2.445) is within the optimal 1-3 range.
4. **HBD/HBA:** Ligand B has fewer HBD (2) and HBA (3) compared to Ligand A (1/7). This is generally preferable for better permeability.
5. **QED:** Ligand A (0.869) has a better QED score than Ligand B (0.704), indicating a more drug-like profile.
6. **DILI:** Ligand B (41.838) has a much lower DILI risk than Ligand A (75.184). This is a significant advantage.
7. **BBB:** Ligand B (71.772) has a considerably higher BBB penetration score than Ligand A (32.299). This is a major plus for a GPCR target, even if not specifically CNS-focused.
8. **Caco-2:** Ligand B (-5.024) has a more negative Caco-2 value, indicating better permeability.
9. **Solubility:** Ligand B (-4.184) has a more negative solubility value, indicating better solubility.
10. **hERG:** Ligand A (0.028) has a slightly lower hERG risk than Ligand B (0.545), but both are very low.
11. **Cl_mic:** Ligand B (40.323) has lower microsomal clearance, suggesting better metabolic stability.
12. **t1/2:** Ligand B (-17.67) has a more negative in vitro half-life, indicating a longer half-life.
13. **Pgp:** Ligand A (0.065) has a lower P-gp efflux liability than Ligand B (0.101), which is favorable.
14. **Affinity:** Ligand A (-8.4) has a slightly better binding affinity than Ligand B (-7.3). However, the difference is less than 1.5 kcal/mol, so it's not a decisive factor.
**Overall Assessment:**
While Ligand A has a slightly better QED and affinity, Ligand B demonstrates a significantly better balance of properties crucial for a GPCR drug candidate. Specifically, its superior TPSA, logP, BBB penetration, lower DILI risk, better permeability (Caco-2), and improved metabolic stability (Cl_mic, t1/2) outweigh the minor advantage in affinity and QED of Ligand A. The lower Pgp efflux is also a positive.
Therefore, I would choose Ligand B.
0
2025-04-17 18:13:05,264 - INFO - Batch 21 complete. Total preferences: 336
2025-04-17 18:13:05,264 - INFO - Processing batch 22/512...
2025-04-17 18:13:53,911 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (345.443 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (78.51) is better than Ligand B (88.16). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally favors absorption.
3. **logP:** Ligand A (0.987) is slightly lower than Ligand B (2.476). Both are within the optimal 1-3 range, but Ligand B is closer to the upper end.
4. **HBD:** Both ligands have 2 HBD, which is acceptable.
5. **HBA:** Ligand A has 3 HBA, while Ligand B has 4. Both are within the acceptable range of <=10.
6. **QED:** Both ligands have good QED scores (0.746 and 0.775), indicating good drug-like properties.
7. **DILI:** Ligand A (20.396) has a significantly lower DILI risk than Ligand B (48.623). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (73.943) has a slightly higher BBB penetration than Ligand A (67.352), but since this is a cardiovascular target, this is not a critical factor.
9. **Caco-2:** Ligand A (-5.132) has a worse Caco-2 permeability than Ligand B (-4.464).
10. **Solubility:** Ligand A (-2.293) has a better solubility than Ligand B (-3.488).
11. **hERG:** Both ligands have very low hERG inhibition risk (0.121 and 0.161).
12. **Cl_mic:** Ligand A (16.246) has a significantly lower microsomal clearance than Ligand B (54.915), indicating better metabolic stability.
13. **t1/2:** Ligand A (2.556) has a shorter in vitro half-life than Ligand B (-16.051). This is a disadvantage for Ligand A.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.016 and 0.038).
15. **Binding Affinity:** Ligand A (-6.3) has a slightly better binding affinity than Ligand B (-5.4).
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A is better in terms of TPSA, DILI, Cl_mic, solubility, and binding affinity. Ligand B is better in terms of logP, Caco-2 permeability, BBB and t1/2. However, the significantly lower DILI risk and better metabolic stability (lower Cl_mic) of Ligand A are crucial advantages. The slight improvement in binding affinity also tips the balance.
**Conclusion:**
Considering the balance of properties, particularly the lower DILI risk and better metabolic stability of Ligand A, it is the more promising drug candidate.
Output:
1
2025-04-17 18:13:53,911 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [352.356, 46.34, 4.621, 0, 3, 0.806, 61.342, 98.178, -4.422, -5.328, 0.824, 32.632, -12.125, 0.839, -7.0]
**Ligand B:** [351.451, 80.65, 1.12, 2, 6, 0.803, 31.059, 89.143, -4.837, -1.237, 0.411, 7.285, 27.488, 0.011, -6.1]
Here's a breakdown, considering the guidelines and GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal range (351-352 Da). No significant difference.
2. **TPSA:** Ligand A (46.34) is significantly better than Ligand B (80.65). ADRB2 is not a CNS target, but lower TPSA generally aids absorption.
3. **logP:** Ligand A (4.621) is higher than Ligand B (1.12). While 4.621 is approaching the upper limit, it's still acceptable. Ligand B's logP is quite low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (3) is better than Ligand B (6). Lower HBA is preferred for permeability.
6. **QED:** Both are similar and good (0.806 and 0.803).
7. **DILI:** Ligand B (31.059) is significantly better than Ligand A (61.342). This is a major advantage for Ligand B.
8. **BBB:** Ligand A (98.178) is better than Ligand B (89.143), but BBB is not a primary concern for a cardiovascular target.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-4.422) is slightly better than Ligand B (-4.837).
10. **Solubility:** Ligand B (-1.237) is better than Ligand A (-5.328). Solubility is important.
11. **hERG:** Ligand A (0.824) is better than Ligand B (0.411). Lower hERG risk is crucial.
12. **Cl_mic:** Ligand B (7.285) has much lower clearance than Ligand A (32.632), indicating better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand A (-12.125) has a longer half-life than Ligand B (27.488), which is desirable.
14. **Pgp:** Ligand A (0.839) is better than Ligand B (0.011). Lower P-gp efflux is preferred.
15. **Affinity:** Ligand A (-7.0) has a slightly better affinity than Ligand B (-6.1), a difference of 0.9 kcal/mol.
**Overall Assessment:**
Ligand A has a slight edge in binding affinity, BBB penetration, half-life, and Pgp efflux. However, Ligand B excels in DILI risk and metabolic stability (Cl_mic) and has better solubility. The lower logP of Ligand B is a concern, but the significant improvement in DILI and metabolic stability, coupled with acceptable solubility, outweighs the slightly lower affinity and permeability. The TPSA is a significant drawback for Ligand B.
Considering the balance of properties and the importance of minimizing toxicity and maximizing metabolic stability for a cardiovascular drug, I believe **Ligand B** is the more promising candidate.
0
2025-04-17 18:13:53,911 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (357.405 and 367.475 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (81.93) is significantly better than Ligand B (95.07). For a GPCR, keeping TPSA under 140 is good, but lower is generally preferred for better permeability. Ligand A is much closer to the ideal range for CNS penetration, even though ADRB2 isn't necessarily a CNS target.
3. **logP:** Both ligands have acceptable logP values (1.901 and 2.419), falling within the 1-3 range. Ligand B is slightly higher, which *could* lead to some solubility issues, but it's not a major concern.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 6 HBA, while Ligand B has 9. Ligand A is preferable here, as it's closer to the ideal of <=10.
6. **QED:** Ligand A (0.87) has a significantly better QED score than Ligand B (0.505), indicating a more drug-like profile.
7. **DILI:** Ligand B (77.588) has a lower DILI risk than Ligand A (55.913), which is a significant advantage. DILI is a major concern in drug development.
8. **BBB:** Ligand A (92.4) has a much higher BBB percentile than Ligand B (43.815). While ADRB2 isn't a primary CNS target, higher BBB penetration can sometimes translate to better overall distribution and reduced off-target effects.
9. **Caco-2:** Ligand A (-4.854) has a better Caco-2 permeability than Ligand B (-5.447), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-2.625) has better aqueous solubility than Ligand B (-3.517).
11. **hERG:** Both ligands have very low hERG inhibition liability (0.225 and 0.044), which is excellent.
12. **Cl_mic:** Ligand B (97.357) has significantly lower microsomal clearance than Ligand A (18.657), suggesting better metabolic stability. This is a crucial advantage.
13. **t1/2:** Ligand B (23.029) has a significantly longer in vitro half-life than Ligand A (9.562), which is highly desirable.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.064 and 0.252).
15. **Binding Affinity:** Ligand A (-7.0) has a slightly better binding affinity than Ligand B (-6.2). While the difference is not huge (0.8 kcal/mol), it's noticeable.
**Overall Assessment & GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A excels in TPSA, logP, Caco-2, solubility, QED and affinity. However, Ligand B has a substantial advantage in metabolic stability (Cl_mic and t1/2) and a lower DILI risk. The difference in binding affinity is not large enough to outweigh the significant improvements in metabolic stability and safety offered by Ligand B. While Ligand A has a better BBB score, this is less critical for a non-CNS target like ADRB2.
**Output:**
0
2025-04-17 18:13:53,912 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (344.419 and 348.447 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (106.97) is slightly higher than Ligand B (98.32). Both are below the 140 threshold for good oral absorption, and acceptable for a cardiovascular GPCR.
3. **logP:** Both ligands have good logP values (0.954 and 1.16), falling within the optimal 1-3 range. Ligand B is slightly more lipophilic.
4. **HBD:** Both have 3 H-bond donors, which is within the acceptable limit of 5.
5. **HBA:** Ligand A has 6 H-bond acceptors, while Ligand B has 4. Both are below the 10 limit.
6. **QED:** Both ligands have similar QED values (0.695 and 0.699), indicating good drug-likeness.
7. **DILI:** Ligand B (38.077) has a significantly lower DILI risk than Ligand A (53.742). This is a substantial advantage for Ligand B.
8. **BBB:** Both ligands have similar BBB penetration (55.099 and 50.097). Since ADRB2 isn't a CNS target, this isn't a primary concern, but lower is preferable.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual. This suggests poor permeability. However, the values are close (-5.747 vs -5.071), so it's not a major differentiator.
10. **Solubility:** Both have negative solubility values, indicating poor aqueous solubility. This is a concern for both.
11. **hERG:** Ligand A (0.204) has a slightly lower hERG inhibition liability than Ligand B (0.318), which is a positive.
12. **Cl_mic:** Ligand A (-21.283) has a much lower (better) microsomal clearance than Ligand B (17.573). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand B (-6.826) has a negative in vitro half-life, which is concerning. Ligand A (43.543) has a much better half-life.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.028 and 0.041).
15. **Binding Affinity:** Ligand A (-7.0) has a slightly better binding affinity than Ligand B (-5.3). This is a 1.7 kcal/mol difference, which is significant.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Both ligands perform well on logP and TPSA. Ligand A has a better affinity, which is a significant advantage. DILI risk is also important, and Ligand B is better here. Metabolic stability (Cl_mic and t1/2) are also important, and Ligand A is significantly better in both of these parameters.
**Overall Assessment:**
While Ligand B has a lower DILI risk, the significantly better metabolic stability (Cl_mic and t1/2) and binding affinity of Ligand A outweigh this advantage. The poor solubility and Caco-2 values are concerns for both, but can be addressed through formulation strategies. The stronger binding affinity of Ligand A is likely to translate to greater efficacy.
Output:
1
2025-04-17 18:13:53,912 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [365.861, 61.88, 2.371, 1, 3, 0.894, 33.152, 77.162, -4.523, -2.627, 0.581, -12.153, 2.39, 0.082, -7.0]
**Ligand B:** [383.901, 82.53, 1.427, 2, 5, 0.803, 54.207, 27.414, -5.259, -2.988, 0.335, -2.723, 7.776, 0.112, -7.3]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, BBB, affinity):
1. **MW:** Both are within the acceptable 200-500 Da range. Ligand A (365.861) is slightly preferred.
2. **TPSA:** Ligand A (61.88) is better than Ligand B (82.53). Lower TPSA generally favors better absorption.
3. **logP:** Both are good (between 1-3), but Ligand A (2.371) is slightly higher than Ligand B (1.427). A higher logP can be beneficial for membrane permeability.
4. **HBD/HBA:** Ligand A (1 HBD, 3 HBA) is better than Ligand B (2 HBD, 5 HBA). Lower counts are generally preferred.
5. **QED:** Both are good (>0.5), with Ligand A (0.894) being marginally better than Ligand B (0.803).
6. **DILI:** Ligand A (33.152) has a significantly lower DILI risk than Ligand B (54.207). This is a major advantage.
7. **BBB:** Ligand A (77.162) has a much better BBB percentile than Ligand B (27.414). This is crucial for a GPCR target, even a cardiovascular one, as off-target CNS effects are always a concern.
8. **Caco-2:** Ligand B (-5.259) is better than Ligand A (-4.523), indicating better intestinal absorption.
9. **Solubility:** Ligand B (-2.988) is better than Ligand A (-2.627).
10. **hERG:** Both are low risk (0.581 and 0.335), so this isn't a differentiating factor.
11. **Cl_mic:** Ligand A (-12.153) has a lower (better) microsomal clearance than Ligand B (-2.723), indicating greater metabolic stability.
12. **t1/2:** Ligand B (7.776) has a longer half-life than Ligand A (2.39).
13. **Pgp:** Ligand A (0.082) has lower P-gp efflux than Ligand B (0.112), which is desirable.
14. **Affinity:** Ligand B (-7.3) has a slightly better binding affinity than Ligand A (-7.0), but the difference is small (0.3 kcal/mol).
**Overall Assessment:**
Ligand A demonstrates a superior balance of properties, particularly regarding safety (DILI), brain penetration (BBB), metabolic stability (Cl_mic), and permeability (TPSA). While Ligand B has a slightly better affinity and half-life, the advantages of Ligand A in the critical areas of safety and BBB penetration outweigh these minor differences. The small difference in affinity is unlikely to be significant given the other favorable properties of Ligand A.
Output:
1
2025-04-17 18:13:53,912 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's systematically compare Ligand A and Ligand B against the provided guidelines, keeping in mind the GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key).
1. **MW:** Both ligands (347.415 and 345.447 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (84.67) is slightly higher than Ligand B (70.47). Both are below the 140 threshold for good oral absorption, but Ligand B is preferable due to its lower TPSA, potentially aiding permeability.
3. **logP:** Ligand A (1.444) is within the optimal 1-3 range. Ligand B (0.354) is a bit low, potentially leading to permeability issues. This favors Ligand A.
4. **HBD:** Both ligands have 1 HBD, which is acceptable.
5. **HBA:** Both ligands have 5 HBA, which is acceptable.
6. **QED:** Ligand A (0.842) has a higher QED score than Ligand B (0.782), indicating a more drug-like profile. This favors Ligand A.
7. **DILI:** Ligand B (14.773) has a significantly lower DILI risk than Ligand A (40.675). This is a substantial advantage for Ligand B.
8. **BBB:** Ligand A (65.839) has a better BBB percentile than Ligand B (46.84). While ADRB2 isn't strictly a CNS target, some CNS exposure can occur, and higher BBB is generally favorable.
9. **Caco-2:** Ligand A (-4.849) has a more negative Caco-2 value, which is worse than Ligand B (-5.309). This suggests that Ligand B might have better intestinal absorption.
10. **Solubility:** Ligand A (-2.055) has slightly better solubility than Ligand B (-1.142). Solubility is important for formulation.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.132 and 0.146). No significant difference.
12. **Cl_mic:** Ligand B (-23.031) has a much lower (better) microsomal clearance than Ligand A (10.036), indicating greater metabolic stability. This is a major advantage for Ligand B.
13. **t1/2:** Ligand A (7.49) has a longer in vitro half-life than Ligand B (2.687). Longer half-life is generally preferred.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.059 and 0.009). No significant difference.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-5.8 and -5.5 kcal/mol). The difference is not substantial enough to be a deciding factor.
**Overall Assessment:**
Ligand B has several key advantages: significantly lower DILI risk, better metabolic stability (lower Cl_mic), and potentially better intestinal absorption (Caco-2). While Ligand A has a slightly better QED, logP, solubility, and BBB, the safety and pharmacokinetic advantages of Ligand B are more critical for overall drug development. The binding affinity difference is minimal. Given the GPCR target class, prioritizing metabolic stability and minimizing toxicity are crucial.
Output:
0
2025-04-17 18:13:53,912 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (363.757 Da) is within the ideal range (200-500 Da). Ligand B (342.483 Da) is also excellent. No clear advantage here.
2. **TPSA:** Ligand A (106.85) is acceptable, though approaching the upper limit for good oral absorption. Ligand B (49.41) is *very* good, well below the 140 threshold. This favors Ligand B.
3. **logP:** Ligand A (1.066) is within the optimal range. Ligand B (3.196) is also within the optimal range, but closer to the upper limit. No strong preference.
4. **HBD:** Ligand A (2) and Ligand B (1) are both good, below the 5 threshold. No clear preference.
5. **HBA:** Ligand A (5) and Ligand B (2) are both good, below the 10 threshold. Ligand B is slightly better.
6. **QED:** Both Ligand A (0.829) and Ligand B (0.798) are excellent, well above 0.5. No clear advantage.
7. **DILI:** Ligand A (76.89) is concerning, indicating a higher risk of liver injury. Ligand B (13.843) is *very* good, indicating low risk. This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (14.269) is poor, suggesting very limited brain penetration. Ligand B (86.661) is excellent, suggesting good brain penetration. While ADRB2 isn't exclusively a CNS target, some cardiovascular effects are mediated through central pathways, and increased CNS exposure isn't necessarily detrimental. This favors Ligand B.
9. **Caco-2:** Both Ligand A (-5.063) and Ligand B (-4.905) are negative values, which is unusual and difficult to interpret without knowing the scale. However, they are similar.
10. **Solubility:** Both Ligand A (-3.98) and Ligand B (-4.058) are negative values, which is unusual and difficult to interpret without knowing the scale. However, they are similar.
11. **hERG:** Ligand A (0.131) is very low risk. Ligand B (0.41) is also low risk. No clear advantage.
12. **Cl_mic:** Ligand A (0.283) is very low, indicating excellent metabolic stability. Ligand B (48.492) is high, indicating poor metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (-48.28) is very long, indicating excellent in vitro half-life. Ligand B (-3.811) is short. This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.02) is very low, indicating minimal P-gp efflux. Ligand B (0.186) is also low. No clear advantage.
15. **Affinity:** Ligand A (-8.0) is significantly stronger than Ligand B (-6.8). This is a substantial advantage for Ligand A, potentially outweighing some ADME concerns.
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B excels in TPSA and BBB penetration. Ligand A has a much better affinity and metabolic stability (Cl_mic, t1/2). The difference in affinity (-1.2 kcal/mol) is substantial. Considering the strong binding affinity of Ligand A, and its good metabolic stability, the DILI risk, while elevated, might be manageable with further optimization. The poor BBB penetration is less of a concern for a primarily peripheral target like ADRB2.
**Conclusion:**
Despite the higher DILI risk, the significantly stronger binding affinity and better metabolic stability of Ligand A make it the more promising candidate.
Output:
1
2025-04-17 18:13:53,912 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (361.47 & 350.38 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (63.91) is significantly better than Ligand B (118.45). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary goal, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (2.613) is within the optimal 1-3 range. Ligand B (-1.721) is too low, potentially hindering membrane permeability. This is a significant negative for Ligand B.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (6) is better than Ligand B (7). Lower is preferable.
6. **QED:** Ligand A (0.825) is better than Ligand B (0.589), indicating a more drug-like profile.
7. **DILI:** Ligand B (57.35) has a lower DILI risk than Ligand A (70.92), which is a positive for Ligand B.
8. **BBB:** Not a primary concern for a cardiovascular target. Ligand A (80.26) is higher than Ligand B (44.01), but this isn't a deciding factor.
9. **Caco-2:** Ligand A (-4.433) is better than Ligand B (-5.298), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-2.58) is better than Ligand B (-1.264), although both are quite poor.
11. **hERG:** Ligand A (0.287) is much better than Ligand B (0.025), indicating a lower risk of cardiotoxicity. This is crucial for a cardiovascular target.
12. **Cl_mic:** Ligand B (-10.748) has significantly lower microsomal clearance than Ligand A (34.099), suggesting better metabolic stability. This is a strong positive for Ligand B.
13. **t1/2:** Ligand B (9.55) has a much longer in vitro half-life than Ligand A (-1.627). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.553) is better than Ligand B (0.005), indicating lower P-gp efflux.
15. **Affinity:** Ligand B (-7.6) has a slightly better binding affinity than Ligand A (-6.4). While a 1.2 kcal/mol difference is good, it needs to be weighed against other factors.
**Overall Assessment:**
Ligand B has advantages in metabolic stability (Cl_mic, t1/2) and DILI risk. However, its significantly lower logP is a major concern, potentially leading to poor permeability and bioavailability. Ligand A, while having a higher DILI risk and slightly lower metabolic stability, has a much more favorable logP, TPSA, QED, hERG, and Pgp profile. The better logP and hERG profile are particularly important for a cardiovascular target. The affinity difference is not large enough to overcome the ADME liabilities of Ligand B.
Therefore, I prefer Ligand A.
Output:
1
2025-04-17 18:13:53,912 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (447.376 Da) is higher, but still acceptable. Ligand B (348.451 Da) is slightly preferred here.
**2. TPSA:** Both ligands have TPSA values around 84-85, which is acceptable for a non-CNS GPCR target like ADRB2.
**3. logP:** Ligand A (3.22) is slightly higher than Ligand B (1.115). While both are within the optimal range, Ligand B is better positioned for solubility.
**4. H-Bond Donors:** Ligand A has 1 HBD, while Ligand B has 0. Both are good.
**5. H-Bond Acceptors:** Both ligands have 6 HBAs, which is acceptable.
**6. QED:** Ligand B (0.719) has a significantly higher QED score than Ligand A (0.521), indicating a more drug-like profile.
**7. DILI Risk:** Ligand B (33.23%) has a much lower DILI risk than Ligand A (85.537%), a critical advantage.
**8. BBB Penetration:** This is less critical for a cardiovascular target. Ligand B (73.943%) has higher BBB penetration than Ligand A (45.638%), but this isn't a primary driver for this target.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual. This suggests poor permeability.
**10. Aqueous Solubility:** Ligand B (-1.162) has better solubility than Ligand A (-4.479).
**11. hERG Inhibition:** Ligand A (0.355) shows a slightly lower hERG inhibition liability than Ligand B (0.062), which is favorable.
**12. Microsomal Clearance:** Ligand B (22.992 mL/min/kg) has significantly lower microsomal clearance than Ligand A (105.212 mL/min/kg), indicating better metabolic stability.
**13. In vitro Half-Life:** Ligand B (-10.324 hours) has a much longer half-life than Ligand A (-1.802 hours).
**14. P-gp Efflux:** Ligand A (0.471) has higher P-gp efflux than Ligand B (0.039), which is less desirable.
**15. Binding Affinity:** Ligand B (-6.7 kcal/mol) has a significantly stronger binding affinity than Ligand A (-0.0 kcal/mol). This is a major advantage.
**Overall Assessment:**
Ligand B is the clear winner. While Ligand A has slightly better hERG inhibition, Ligand B excels in almost every other crucial parameter. Its superior binding affinity, lower DILI risk, better QED, improved metabolic stability (lower Cl_mic and longer t1/2), better solubility, and lower P-gp efflux outweigh the minor hERG difference. The significantly stronger binding affinity is a key factor, as it can compensate for potential ADME shortcomings.
Output:
0
2025-04-17 18:13:53,912 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [335.451, 41.29, 3.995, 1, 4, 0.71, 54.478, 55.332, -4.686, -4.117, 0.973, 52.122, 26.658, 0.906, -6.2]
**Ligand B:** [364.511, 58.64, 1.665, 1, 4, 0.575, 23.187, 55.642, -4.944, -3.351, 0.251, 35.669, -4.825, 0.086, -5.4]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the acceptable 200-500 Da range. Ligand A (335.451) is slightly preferred due to being lower.
2. **TPSA:** Ligand A (41.29) is better than Ligand B (58.64), falling well below the 140 threshold and closer to the ideal for GPCRs.
3. **logP:** Ligand A (3.995) is optimal (1-3 range), while Ligand B (1.665) is on the lower side and might have permeability issues. This is a significant advantage for A.
4. **HBD/HBA:** Both have 1 HBD and 4 HBA, which are acceptable.
5. **QED:** Ligand A (0.71) is better than Ligand B (0.575), indicating a more drug-like profile.
6. **DILI:** Ligand B (23.187) is significantly better than Ligand A (54.478) regarding liver injury risk. This is a strong point for B.
7. **BBB:** Both have similar BBB penetration (around 55%), which isn't exceptionally high but isn't a major concern for a non-CNS-focused target like many cardiovascular ADRB2 applications.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability *in vitro*. However, the scale is not specified, so it's hard to interpret.
9. **Solubility:** Both have negative solubility values, which is also unusual. Again, the scale is not specified, making interpretation difficult.
10. **hERG:** Ligand A (0.973) is slightly higher, indicating a slightly higher risk of hERG inhibition, but still relatively low. Ligand B (0.251) is very good.
11. **Cl_mic:** Ligand B (35.669) has a lower microsomal clearance, suggesting better metabolic stability than Ligand A (52.122).
12. **t1/2:** Ligand A (26.658) has a longer in vitro half-life than Ligand B (-4.825). This is a positive for A.
13. **Pgp:** Ligand A (0.906) has higher P-gp efflux, which is less desirable. Ligand B (0.086) is much better.
14. **Affinity:** Ligand A (-6.2 kcal/mol) has a slightly better binding affinity than Ligand B (-5.4 kcal/mol). This is a 0.8 kcal/mol difference, which is significant.
**Overall Assessment:**
Ligand A has a better binding affinity, logP, QED, and half-life. However, Ligand B excels in DILI risk, Pgp efflux, and metabolic stability. The logP difference is substantial, and the affinity difference, while not huge, is also in A's favor. Given the importance of logP and affinity for GPCR targets, and the fact that the DILI risk for A is still within a manageable range, I believe Ligand A is the more promising candidate. The slightly higher hERG risk is less concerning than the potential permeability issues with Ligand B due to its lower logP.
Output:
1
2025-04-17 18:13:53,912 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [356.373, 75.63, 2.496, 0, 5, 0.832, 53.315, 90.074, -4.102, -2.195, 0.202, 36.149, -11.367, 0.058, -5.5]
**Ligand B:** [341.411, 95.66, 1.909, 3, 4, 0.748, 31.563, 40.791, -5.325, -2.195, 0.647, -28.65, 31.918, 0.084, -6.5]
Here's a breakdown, considering the GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (341.411) is slightly lower, which isn't a major concern.
2. **TPSA:** Ligand A (75.63) is much better than Ligand B (95.66). Below 140 is good for oral absorption, and both are within that range, but A is closer to the optimal <90 for potential CNS penetration (though not a primary concern for a cardiovascular target).
3. **logP:** Ligand A (2.496) is optimal. Ligand B (1.909) is a bit low, potentially impacting permeability.
4. **HBD/HBA:** Ligand A (0 HBD, 5 HBA) is preferable to Ligand B (3 HBD, 4 HBA). Fewer HBDs generally improve permeability.
5. **QED:** Ligand A (0.832) is better than Ligand B (0.748), indicating a more drug-like profile.
6. **DILI:** Ligand A (53.315) has a higher DILI risk than Ligand B (31.563). This is a significant drawback for Ligand A.
7. **BBB:** Ligand A (90.074) has a much higher BBB penetration potential than Ligand B (40.791). While not critical for a cardiovascular target, it's a bonus.
8. **Caco-2:** Ligand B (-5.325) has a better Caco-2 permeability than Ligand A (-4.102), suggesting better absorption.
9. **Solubility:** Both have very poor aqueous solubility (-2.195). This is a concern for both, requiring formulation strategies.
10. **hERG:** Ligand A (0.202) has a lower hERG risk than Ligand B (0.647), which is a positive.
11. **Cl_mic:** Ligand B (-28.65) has a much lower (better) microsomal clearance than Ligand A (36.149), indicating better metabolic stability.
12. **t1/2:** Ligand B (31.918) has a significantly longer in vitro half-life than Ligand A (-11.367). This is a major advantage.
13. **Pgp:** Ligand A (0.058) has lower P-gp efflux than Ligand B (0.084), which is favorable.
14. **Affinity:** Ligand B (-6.5 kcal/mol) has a slightly better binding affinity than Ligand A (-5.5 kcal/mol). This is a 1 kcal/mol difference, which is notable.
**Overall Assessment:**
Ligand B is the better candidate. While Ligand A has advantages in BBB and Pgp, Ligand B's superior metabolic stability (Cl_mic, t1/2), lower DILI risk, better Caco-2 permeability, and slightly improved binding affinity outweigh these advantages. The solubility is a concern for both, but can be addressed through formulation. The lower logP of Ligand B is a minor concern, but not a deal-breaker.
Output:
0
2025-04-17 18:13:53,912 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**1. Molecular Weight:** Both ligands (357.43 and 353.51 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (78.95) is higher than Ligand B (53.09). For a cardiovascular GPCR, TPSA is not a primary concern, but lower is generally better for permeability. Ligand B has a clear advantage.
**3. logP:** Both ligands have acceptable logP values (1.03 and 1.45), falling within the 1-3 range. Ligand B is slightly more lipophilic, which could be beneficial for membrane permeability.
**4. H-Bond Donors:** Ligand A has 1 HBD, while Ligand B has 0. Both are within the acceptable limit of <=5.
**5. H-Bond Acceptors:** Both ligands have 4 HBAs, well within the acceptable limit of <=10.
**6. QED:** Ligand A (0.72) has a slightly higher QED than Ligand B (0.65), indicating a marginally more drug-like profile.
**7. DILI Risk:** Ligand B (6.28%) has a significantly lower DILI risk than Ligand A (33.77%). This is a crucial advantage, as minimizing liver toxicity is paramount.
**8. BBB Penetration:** Ligand A (89.61%) shows better BBB penetration than Ligand B (73.83%). While ADRB2 is primarily a cardiovascular target, some CNS off-target effects are always a consideration, and better BBB penetration could exacerbate those. However, this is a lower priority than other factors.
**9. Caco-2 Permeability:** Ligand A (-4.842) has a slightly better Caco-2 permeability than Ligand B (-4.491).
**10. Aqueous Solubility:** Ligand B (-0.545) has better aqueous solubility than Ligand A (-1.984). This is a positive for formulation and bioavailability.
**11. hERG Inhibition:** Ligand A (0.19) has a lower hERG inhibition risk than Ligand B (0.61). This is a significant advantage, as hERG inhibition can lead to cardiotoxicity.
**12. Microsomal Clearance:** Ligand A (-8.87) has a much lower microsomal clearance than Ligand B (15.17). This suggests better metabolic stability for Ligand A, which is desirable.
**13. In vitro Half-Life:** Ligand A (-12.013) has a significantly longer in vitro half-life than Ligand B (-0.194). This is a strong advantage, potentially allowing for less frequent dosing.
**14. P-gp Efflux:** Ligand A (0.011) shows lower P-gp efflux than Ligand B (0.086). Lower P-gp efflux is favorable for bioavailability.
**15. Binding Affinity:** Both ligands have very similar binding affinities (-6.1 and -5.3 kcal/mol). The difference of 0.8 kcal/mol is not substantial enough to override other factors.
**Overall Assessment:**
Ligand B has a significantly lower DILI risk and better aqueous solubility, which are critical advantages. While Ligand A has better BBB penetration, microsomal clearance, half-life and P-gp efflux, the lower DILI risk of Ligand B is more important. The binding affinity difference is minimal. Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand B strikes a better balance between these properties and safety.
Output:
0
2025-04-17 18:13:53,912 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.49 & 360.85 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (58.64) is better than Ligand B (65.54), both are below 140, but A is closer to the preferred <90 for potential CNS penetration (though ADRB2 isn't necessarily a CNS target).
3. **logP:** Both ligands (2.68 & 2.44) are within the optimal 1-3 range. No significant difference.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 3 HBA, Ligand B has 4. Both are acceptable (<10), but A is slightly preferred.
6. **QED:** Ligand B (0.859) has a significantly better QED score than Ligand A (0.593), indicating a more drug-like profile. This is a substantial advantage for B.
7. **DILI:** Ligand A (16.75) has a much lower DILI risk than Ligand B (57.81). This is a major advantage for A.
8. **BBB:** Ligand A (76.31) has a better BBB percentile than Ligand B (69.87), though neither are exceptionally high.
9. **Caco-2:** Both ligands have very poor Caco-2 permeability (-4.641 and -4.637). This is a significant concern for both.
10. **Solubility:** Both ligands have poor aqueous solubility (-2.382 and -2.848). This is a concern for both.
11. **hERG:** Both ligands have low hERG inhibition risk (0.288 and 0.453). No clear advantage.
12. **Cl_mic:** Ligand A (33.71) has a lower microsomal clearance than Ligand B (43.25), suggesting better metabolic stability. This is a slight advantage for A.
13. **t1/2:** Ligand B (57.88) has a significantly longer in vitro half-life than Ligand A (-3.95). This is a major advantage for B.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.072 and 0.079). No clear advantage.
15. **Binding Affinity:** Ligand B (-6.1) has a slightly better binding affinity than Ligand A (-5.6). While a 0.5 kcal/mol difference isn't huge, it's noticeable.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Both ligands perform similarly on logP and Pgp. Ligand A has a better TPSA. Ligand B has a slightly better affinity. However, the substantial difference in DILI risk (A is much lower) and the better QED score of Ligand B are critical. The longer half-life of B is also very attractive. While both have poor Caco-2 and solubility, these can potentially be addressed with formulation strategies.
**Overall Assessment:**
Despite Ligand A's advantages in DILI and TPSA, Ligand B's superior QED, longer half-life, and slightly better binding affinity outweigh these benefits. The lower DILI risk for A is appealing, but formulation work could potentially mitigate the solubility and permeability issues of Ligand B.
Output:
0
2025-04-17 18:13:53,913 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (354.401 and 351.491 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (70.39) is slightly higher than Ligand B (61.88). Both are below the 140 threshold for oral absorption, but closer to the 90 threshold for CNS targets, which isn't a primary concern for ADRB2 (cardiovascular). Ligand B is preferable.
3. **logP:** Both ligands (1.948 and 1.415) are within the optimal 1-3 range. Ligand B is slightly lower, which could marginally improve solubility, but both are acceptable.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1). Both are within the acceptable limit of 5.
5. **HBA:** Both ligands (4) have the same number of HBA, and are within the acceptable limit of 10.
6. **QED:** Ligand A (0.853) has a better QED score than Ligand B (0.705), indicating a more drug-like profile. This is a positive for Ligand A.
7. **DILI:** Ligand A (38.813) has a significantly lower DILI risk than Ligand B (7.135). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (85.847) has a much higher BBB penetration percentile than Ligand B (63.474). While ADRB2 isn't a CNS target, higher BBB penetration *can* sometimes correlate with better overall distribution.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.613 and -4.822), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand B (-0.345) has better solubility than Ligand A (-2.529).
11. **hERG:** Both ligands have very low hERG inhibition risk (0.291 and 0.271).
12. **Cl_mic:** Ligand B (-1.01) has a significantly lower microsomal clearance than Ligand A (15.735), suggesting better metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand B (-17) has a much longer in vitro half-life than Ligand A (10.578). This is a strong positive for Ligand B.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.054 and 0.008).
15. **Binding Affinity:** Ligand A (-6.8) has a slightly better binding affinity than Ligand B (-5.3). This is a 1.5 kcal/mol difference, which is significant.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Ligand A has better affinity and a slightly more favorable logP. However, Ligand B excels in metabolic stability (Cl_mic, t1/2), DILI risk, and solubility. The significant difference in DILI risk and metabolic stability are crucial for a cardiovascular drug. While affinity is important, the potential for liver toxicity and rapid metabolism with Ligand A are major drawbacks.
**Conclusion:**
Despite the slightly better affinity of Ligand A, the superior ADME properties of Ligand B, particularly the lower DILI risk, better metabolic stability, and improved solubility, make it the more promising drug candidate for the ADRB2 receptor.
Output:
0
2025-04-17 18:13:53,913 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.435 and 350.459 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (77.81) is slightly higher than Ligand B (67.87). Both are below the 140 threshold for oral absorption, but B is preferable given the GPCR target class.
3. **logP:** Ligand A (0.337) is quite low, potentially hindering membrane permeability. Ligand B (1.503) is within the optimal 1-3 range. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (0) is excellent, minimizing potential issues with hydrogen bonding. Ligand B (1) is acceptable.
5. **HBA:** Ligand A (6) is good. Ligand B (4) is also good.
6. **QED:** Both ligands have good QED scores (0.717 and 0.763), indicating drug-like properties.
7. **DILI:** Ligand A (16.906) has a much lower DILI risk than Ligand B (31.718). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (77.084) has better BBB penetration than Ligand B (63.358), which is good for a GPCR.
9. **Caco-2:** Both ligands have very poor Caco-2 permeability (-4.716 and -4.752). This is a concern for both, but not a deciding factor.
10. **Solubility:** Both ligands have poor aqueous solubility (-1.322 and -1.935). This could present formulation challenges.
11. **hERG:** Both ligands have low hERG inhibition risk (0.152 and 0.232).
12. **Cl_mic:** Ligand A (-5.428) has significantly lower microsomal clearance, indicating better metabolic stability, than Ligand B (45.418). This is a substantial advantage for Ligand A.
13. **t1/2:** Ligand A (-10.089) has a negative in vitro half-life, which is concerning. Ligand B (9.839) has a reasonable half-life.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.007 and 0.05).
15. **Binding Affinity:** Ligand B (-6.2 kcal/mol) has a significantly stronger binding affinity than Ligand A (-4.7 kcal/mol). This is a 1.5 kcal/mol difference, which is substantial.
**Overall Assessment:**
Ligand B has a superior binding affinity and a more favorable logP value, which are key for GPCR targets. However, Ligand A demonstrates a much better safety profile (lower DILI, better metabolic stability, and better BBB penetration). The poor solubility and Caco-2 permeability are concerns for both. The negative half-life for Ligand A is also a major drawback.
Considering the balance, the stronger binding affinity of Ligand B is a significant advantage that outweighs the slightly higher DILI risk and lower metabolic stability. The better logP also supports better membrane permeability, which is crucial for GPCR engagement.
Output:
0
2025-04-17 18:13:53,913 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (364.421) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (58.12) is better than Ligand B (41.93), both are good for oral absorption.
3. **logP:** Ligand A (2.838) is optimal, while Ligand B (4.237) is pushing the upper limit. Higher logP can lead to solubility issues and off-target interactions.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 5 HBA, while Ligand B has 6. Both are acceptable, but lower is generally preferred.
6. **QED:** Ligand A (0.906) is excellent, indicating a very drug-like profile. Ligand B (0.625) is still acceptable, but less optimal.
7. **DILI:** Ligand A (62.001) has a higher DILI risk than Ligand B (25.165). This is a significant concern for Ligand A.
8. **BBB:** Both ligands have good BBB penetration (Ligand A: 80.225, Ligand B: 79.294). This isn't a primary concern for ADRB2, but it's a neutral point.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.916) is slightly worse than Ligand B (-5.282).
10. **Solubility:** Ligand A (-4.11) has slightly better solubility than Ligand B (-3.041).
11. **hERG:** Ligand A (0.314) has a lower hERG risk than Ligand B (0.89). This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand B (62.831) has a higher microsomal clearance than Ligand A (33.348), indicating lower metabolic stability.
13. **t1/2:** Ligand B (54.501) has a much longer half-life than Ligand A (16.609). This is a major advantage for Ligand B.
14. **Pgp:** Ligand B (0.749) has a higher Pgp efflux liability than Ligand A (0.282). This is a significant advantage for Ligand A.
15. **Affinity:** Ligand A (-8.3 kcal/mol) has a significantly stronger binding affinity than Ligand B (-5.1 kcal/mol). This is a substantial advantage for Ligand A, potentially outweighing some ADME drawbacks.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand A excels in affinity and Pgp, has a good logP and TPSA. Ligand B has a better half-life, but a less favorable logP and Pgp. The DILI risk for Ligand A is concerning, but the significantly stronger binding affinity is a major advantage.
**Overall Assessment:**
Despite the higher DILI risk, Ligand A's substantially stronger binding affinity (-8.3 vs -5.1 kcal/mol) and better Pgp profile are compelling. The improved affinity could allow for a lower dose, potentially mitigating the DILI risk. The better QED score also favors Ligand A.
Output:
1
2025-04-17 18:13:53,913 - INFO - Batch 22 complete. Total preferences: 352
2025-04-17 18:13:53,914 - INFO - Processing batch 23/512...
2025-04-17 18:14:46,077 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.45 & 349.52 Da) fall comfortably within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (94.56) is higher than Ligand B (52.65). For a cardiovascular GPCR, TPSA isn't a *major* concern unless it's excessively high, but lower is generally preferred for better permeability. Ligand B is significantly better here.
3. **logP:** Ligand A (0.681) is a bit low, potentially hindering membrane permeability. Ligand B (2.119) is within the optimal 1-3 range. Ligand B is better.
4. **HBD:** Ligand A (3) is higher than Ligand B (1). Lower HBD is generally preferred for permeability. Ligand B is better.
5. **HBA:** Ligand A (5) is higher than Ligand B (3). Similar to HBD, lower HBA is preferred. Ligand B is better.
6. **QED:** Both ligands have good QED scores (0.642 and 0.799 respectively), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (19.232) has a considerably higher DILI risk than Ligand B (4.963). This is a significant negative for Ligand A.
8. **BBB:** Ligand A (48.9%) has a lower BBB penetration than Ligand B (90.2%). While ADRB2 isn't necessarily a CNS target, higher BBB is generally favorable. Ligand B is better.
9. **Caco-2:** Ligand A (-5.141) has a worse Caco-2 permeability than Ligand B (-4.689). Both are negative values, indicating poor permeability, but B is better.
10. **Solubility:** Ligand A (-1.117) has slightly better solubility than Ligand B (-1.872). Solubility is important, but not as critical as permeability for this target.
11. **hERG:** Ligand A (0.079) has a slightly lower hERG risk than Ligand B (0.542). This is a minor advantage for Ligand A.
12. **Cl_mic:** Ligand A (2.523) has significantly lower microsomal clearance than Ligand B (41.814). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (1.328) has a shorter in vitro half-life than Ligand B (3.455). Ligand B is better.
14. **Pgp:** Ligand A (0.006) has much lower P-gp efflux than Ligand B (0.064). This is a significant advantage for Ligand A.
15. **Affinity:** Both ligands have very similar binding affinities (-6.2 and -6.1 kcal/mol). The difference is negligible.
**Overall Assessment:**
Ligand B consistently outperforms Ligand A in key ADME properties relevant to GPCRs, particularly logP, TPSA, DILI, BBB, and metabolic stability. While Ligand A has a slight advantage in hERG and Pgp efflux, the significantly higher DILI risk and poorer permeability profile of Ligand A outweigh these benefits. The similar binding affinities make the ADME profile the deciding factor.
Output:
0
2025-04-17 18:14:46,077 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (366.571 and 352.519 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (40.62) is better than Ligand B (67.43). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally favors absorption.
3. **logP:** Both ligands have good logP values (3.548 and 3.171), falling within the optimal 1-3 range. Ligand A is slightly higher, which *could* be beneficial for membrane permeability, but isn't a huge difference.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Both ligands have 3 HBA, which is within the acceptable range.
6. **QED:** Ligand A (0.764) has a better QED score than Ligand B (0.626), indicating a more drug-like profile.
7. **DILI:** Ligand A (12.834) has a significantly lower DILI risk than Ligand B (16.169). This is a crucial advantage.
8. **BBB:** Both ligands have reasonable BBB penetration (88.561 and 72.586). Since ADRB2 is not a CNS target, this is less critical, but A is still better.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
10. **Solubility:** Ligand A (-3.416) has slightly better solubility than Ligand B (-2.996).
11. **hERG:** Both ligands have low hERG inhibition risk (0.562 and 0.554).
12. **Cl_mic:** Ligand A (70.999) has higher microsomal clearance than Ligand B (41.151), meaning it's metabolized faster. This is a disadvantage for A.
13. **t1/2:** Ligand B (-5.42) has a longer in vitro half-life than Ligand A (-25.349). This is a significant advantage for B.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.221 and 0.16).
15. **Binding Affinity:** Ligand B (-7.9) has a significantly better binding affinity than Ligand A (-5.7). A 2.2 kcal/mol difference is substantial and can often outweigh other ADME concerns.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. While both ligands have acceptable logP and Pgp values, Ligand B has a much stronger binding affinity. Ligand A has better TPSA, but the affinity difference is more important.
**Overall Assessment:**
Ligand B's significantly stronger binding affinity (-7.9 kcal/mol vs -5.7 kcal/mol) is the most important factor. While Ligand A has advantages in DILI risk, QED, and TPSA, the substantial difference in binding affinity is likely to translate to greater efficacy *in vivo*. The longer half-life of Ligand B is also a positive. The higher clearance of Ligand A is a concern.
Output:
0
2025-04-17 18:14:46,077 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [348.407, 135.79 , 0.363, 5. , 5. , 0.446, 57.076, 11.865, -5.938, -1.866, 0.268, -0.935, 23.032, 0.03 , -6.3 ]
**Ligand B:** [348.443, 89.87 , 1.768, 3. , 4. , 0.7 , 12.369, 40.791, -4.972, -2.894, 0.39 , 48.409, -31.893, 0.049, -6.2 ]
Here's a breakdown, considering the GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal 200-500 Da range. (Tie)
2. **TPSA:** Ligand B (89.87) is significantly better than Ligand A (135.79). Lower TPSA generally favors better absorption and potentially CNS penetration.
3. **logP:** Ligand B (1.768) is much better than Ligand A (0.363). A logP between 1-3 is optimal, and Ligand A is quite low, potentially hindering permeability.
4. **HBD/HBA:** Ligand B has fewer HBDs (3 vs 5) and HBAs (4 vs 5), which is slightly preferable for permeability.
5. **QED:** Ligand B (0.7) is better than Ligand A (0.446), indicating a more drug-like profile.
6. **DILI:** Ligand B (12.369) is *much* better than Ligand A (57.076). This is a significant advantage for Ligand B.
7. **BBB:** Ligand B (40.791) is better than Ligand A (11.865), though neither is exceptionally high. For a cardiovascular target, BBB isn't critical, but it's still a positive.
8. **Caco-2:** Ligand A (-5.938) is better than Ligand B (-4.972). Higher is better.
9. **Solubility:** Ligand A (-1.866) is better than Ligand B (-2.894). Higher is better.
10. **hERG:** Both are low (0.268 and 0.39), indicating low cardiotoxicity risk. (Tie)
11. **Cl_mic:** Ligand A (-0.935) is better than Ligand B (48.409). Lower clearance is preferred for metabolic stability.
12. **t1/2:** Ligand B (-31.893) is better than Ligand A (23.032). Longer half-life is preferred.
13. **Pgp:** Ligand A (0.03) is slightly better than Ligand B (0.049). Lower Pgp efflux is better.
14. **Affinity:** Both ligands have very similar binding affinities (-6.3 and -6.2 kcal/mol). The difference is negligible.
**Overall Assessment:**
Ligand B clearly wins out. While Ligand A has slightly better Caco-2 permeability and clearance, Ligand B has a significantly better logP, TPSA, QED, and *much* lower DILI risk. The lower DILI risk is a major factor, as liver toxicity is a common cause of drug failure. The improved Pgp and BBB are also beneficial. The affinity is essentially the same. Given the GPCR target class, the balance of properties in Ligand B makes it the more promising candidate.
Output:
0
2025-04-17 18:14:46,078 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (a cardiovascular GPCR) drug candidates.
**Ligand A:** [346.431, 84.42, 1.642, 1, 5, 0.773, 48.779, 77.898, -4.42, -2.899, 0.236, 77.337, -34.526, 0.079, -7.8]
**Ligand B:** [352.435, 116.48, -0.127, 4, 6, 0.52, 35.479, 20.822, -5.308, -1.316, 0.026, 2.483, 19.64, 0.006, -8.5]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). A (346.431) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** A (84.42) is excellent, well below 140, and good for oral absorption. B (116.48) is still acceptable but less ideal.
3. **logP:** A (1.642) is optimal. B (-0.127) is a bit low and could indicate permeability issues.
4. **HBD:** A (1) is good. B (4) is higher, potentially impacting permeability.
5. **HBA:** A (5) is good. B (6) is also acceptable.
6. **QED:** A (0.773) is very good, indicating high drug-likeness. B (0.52) is acceptable but lower.
7. **DILI:** A (48.779) is excellent, low risk. B (35.479) is also good, but slightly higher.
8. **BBB:** A (77.898) is very good, suggesting reasonable CNS penetration (less critical for a cardiovascular target, but not detrimental). B (20.822) is quite low, indicating poor BBB penetration.
9. **Caco-2:** A (-4.42) is a negative value, which is unusual and warrants further investigation, but could indicate good permeability. B (-5.308) is also negative and similarly requires further investigation.
10. **Solubility:** A (-2.899) and B (-1.316) are both negative values, which is unusual and warrants further investigation.
11. **hERG:** Both are very low (A: 0.236, B: 0.026), indicating minimal cardiotoxicity risk.
12. **Cl_mic:** A (77.337) is higher than B (2.483), suggesting faster metabolism and potentially lower *in vivo* exposure. This is a significant drawback for A.
13. **t1/2:** A (-34.526) is a negative value, which is unusual and warrants further investigation. B (19.64) is a positive value and suggests a reasonable half-life.
14. **Pgp:** A (0.079) is very low, indicating minimal efflux. B (0.006) is even lower, but both are excellent.
15. **Affinity:** B (-8.5) is significantly better than A (-7.8), a difference of 0.7 kcal/mol. This is a substantial advantage.
**GPCR-Specific Priorities:**
For ADRB2 (a cardiovascular GPCR), we prioritize logP, Pgp, TPSA, and affinity. Ligand A has better logP and Pgp, but Ligand B has a significantly better affinity (-8.5 vs -7.8 kcal/mol). The TPSA for A is also better. However, the significantly lower metabolic clearance and better half-life of Ligand B, combined with its superior affinity, outweigh the slight advantages of Ligand A.
**Conclusion:**
Considering the balance of properties, particularly the significantly better binding affinity and metabolic stability of Ligand B, it is the more promising drug candidate.
0
2025-04-17 18:14:46,078 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's break down the comparison of Ligand A and Ligand B based on the provided parameters and the guidelines, with a focus on GPCR-relevant properties.
1. **Molecular Weight:** Both ligands (343.471 Da and 350.503 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (73.99) is slightly higher than Ligand B (62.55). Both are below the 140 A^2 threshold for good oral absorption, but Ligand B is preferable.
3. **logP:** Both ligands have good logP values (3.116 and 3.799 respectively), falling within the optimal 1-3 range. Ligand B is slightly higher, which *could* be a minor concern for solubility, but not a major one.
4. **H-Bond Donors:** Ligand A has 3 HBDs, while Ligand B has 1. Ligand B is preferable.
5. **H-Bond Acceptors:** Ligand A has 2 HBAs, Ligand B has 3. No strong preference.
6. **QED:** Both ligands have good QED scores (0.635 and 0.737), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand B (31.214) has a significantly lower DILI risk than Ligand A (35.983). This is a substantial advantage for Ligand B.
8. **BBB:** Ligand A (63.901) has a slightly better BBB penetration percentile than Ligand B (54.75). While ADRB2 isn't strictly a CNS target, some peripheral ADRB2 receptors can influence CNS function, and better BBB penetration isn't necessarily a negative.
9. **Caco-2 Permeability:** Ligand A (-5.137) has a worse Caco-2 permeability than Ligand B (-4.462). Ligand B is preferable.
10. **Aqueous Solubility:** Ligand A (-3.726) has worse aqueous solubility than Ligand B (-2.928). Ligand B is preferable.
11. **hERG Inhibition:** Both ligands have similar hERG inhibition liabilities (0.536 and 0.664). No strong preference.
12. **Microsomal Clearance:** Ligand A (63.364) has lower microsomal clearance than Ligand B (73.519), indicating better metabolic stability. This is a benefit for Ligand A.
13. **In vitro Half-Life:** Ligand B (113.08) has a much longer in vitro half-life than Ligand A (0.049). This is a significant advantage for Ligand B.
14. **P-gp Efflux:** Both ligands have similar P-gp efflux liabilities (0.269 and 0.333). No strong preference.
15. **Binding Affinity:** Ligand A (-6.1 kcal/mol) has a slightly better binding affinity than Ligand B (-5.8 kcal/mol). This is a positive for Ligand A, but the difference is not huge.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity) and the general drug-like properties, Ligand B emerges as the more promising candidate. While Ligand A has a slightly better binding affinity and metabolic stability, Ligand B exhibits significantly lower DILI risk, better solubility, better Caco-2 permeability, and a substantially longer half-life. The combination of these factors outweighs the minor affinity advantage of Ligand A.
**Output:**
0
2025-04-17 18:14:46,078 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (361.368 Da and 357.41 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (79.26) is higher than Ligand B (64.11). For a cardiovascular GPCR, TPSA is moderately important, and lower is generally better for permeability. Ligand B has an advantage.
**3. logP:** Ligand A (2.214) is within the optimal 1-3 range, while Ligand B (4.27) is higher. A logP over 4 can lead to solubility issues and off-target interactions. Ligand A is preferred.
**4. H-Bond Donors:** Ligand A (2) and Ligand B (1) are both acceptable, below the threshold of 5.
**5. H-Bond Acceptors:** Ligand A (4) and Ligand B (5) are both acceptable, below the threshold of 10.
**6. QED:** Ligand A (0.863) has a significantly higher QED score than Ligand B (0.693), indicating a more drug-like profile. This is a substantial advantage for Ligand A.
**7. DILI Risk:** Ligand A (39.201) has a much lower DILI risk than Ligand B (98.216). This is a critical factor; a high DILI risk is a major red flag. Ligand A is strongly preferred.
**8. BBB Penetration:** Both ligands have reasonable BBB penetration (Ligand A: 78.17, Ligand B: 68.786), but this is less critical for a cardiovascular target. Ligand A is slightly better.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, indicating poor permeability. This is concerning for both.
**10. Aqueous Solubility:** Ligand A (-3.115) is better than Ligand B (-5.822), meaning it has higher solubility.
**11. hERG Inhibition:** Ligand A (0.285) has a lower hERG inhibition risk than Ligand B (0.438). This is a positive for Ligand A.
**12. Microsomal Clearance:** Ligand A (-9.891) has a much lower (better) microsomal clearance than Ligand B (100.435), suggesting greater metabolic stability. This is a significant advantage for Ligand A.
**13. In vitro Half-Life:** Ligand A (-0.617) has a shorter half-life than Ligand B (43.924). This is a drawback for Ligand A, but can be addressed through structural modifications.
**14. P-gp Efflux:** Ligand A (0.015) has a much lower P-gp efflux liability than Ligand B (0.469), indicating better bioavailability.
**15. Binding Affinity:** Both ligands have very similar binding affinities (-6.1 kcal/mol and -6.2 kcal/mol). The difference is negligible.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity) and the general drug-like properties, Ligand A is the superior candidate. While Ligand B has a better half-life, Ligand A excels in crucial areas like DILI risk, QED, metabolic stability (Cl_mic), solubility, and P-gp efflux. The lower logP and TPSA of Ligand A are also beneficial. The slightly shorter half-life of Ligand A can be addressed through further optimization. The significantly higher DILI risk associated with Ligand B is a major concern.
Output:
1
2025-04-17 18:14:46,078 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.431 and 350.383 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (68.88) is significantly better than Ligand B (139.85). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand B is approaching the upper limit for good oral absorption.
3. **logP:** Ligand B (-1.734) is lower than Ligand A (0.418). While both are within the acceptable range, Ligand A's logP is closer to the optimal 1-3 range. Ligand B's lower logP could indicate potential permeability issues.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve membrane permeability.
5. **HBA:** Ligand A (4) is preferable to Ligand B (9). Similar to HBD, lower HBA is generally better for permeability.
6. **QED:** Ligand A (0.727) has a better QED score than Ligand B (0.488), indicating a more drug-like profile.
7. **DILI:** Ligand A (19.426) has a much lower DILI risk than Ligand B (64.521). This is a significant advantage for Ligand A.
8. **BBB:** Not a primary concern for a cardiovascular target, but Ligand A (55.176) is better than Ligand B (19.93).
9. **Caco-2:** Ligand A (-5.304) and Ligand B (-5.924) are both negative, and therefore difficult to interpret without knowing the scale. However, they are similar.
10. **Solubility:** Ligand A (-1.083) is better than Ligand B (-0.97), though both are similarly poor.
11. **hERG:** Ligand A (0.227) is much better than Ligand B (0.031), indicating a lower risk of cardiotoxicity. This is *critical* for a cardiovascular target.
12. **Cl_mic:** Ligand A (-10.905) has significantly lower (better) microsomal clearance than Ligand B (3.694), suggesting better metabolic stability.
13. **t1/2:** Ligand B (17.636) has a much longer in vitro half-life than Ligand A (0.683). This is a substantial advantage for Ligand B.
14. **Pgp:** Ligand A (0.01) is better than Ligand B (0.021), indicating less P-gp efflux.
15. **Affinity:** Ligand B (-1.0) has better binding affinity than Ligand A (-7.0). This is a significant advantage for Ligand B.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B has better affinity and a more reasonable logP, but Ligand A excels in TPSA, Pgp, and critically, safety parameters (DILI and hERG). The affinity difference is substantial (6 kcal/mol), and this is a major consideration. However, the safety profile of Ligand A is far superior.
**Overall Assessment:**
While Ligand B has significantly better binding affinity, the substantial advantages of Ligand A in terms of safety (DILI, hERG), metabolic stability (Cl_mic), and permeability (TPSA, HBD, HBA) are too significant to ignore, especially for a cardiovascular target where off-target effects can be particularly problematic. The longer half-life of Ligand B is attractive, but can potentially be addressed through formulation or prodrug strategies.
Output:
1
2025-04-17 18:14:46,078 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (407.312 Da) is slightly higher than Ligand B (355.435 Da), but both are acceptable.
**2. TPSA:** Ligand A (65.97) is better than Ligand B (96.97). For a cardiovascular GPCR, TPSA is moderately important, and lower is generally preferred for better permeability. Ligand B is approaching a less desirable range.
**3. logP:** Ligand A (3.773) is optimal, while Ligand B (0.512) is low. This is a significant difference. GPCRs generally benefit from moderate lipophilicity for membrane permeability and receptor engagement. Ligand B's low logP is a major concern.
**4. H-Bond Donors:** Ligand A (0) is better than Ligand B (2). Fewer H-bond donors are generally preferred for better permeability.
**5. H-Bond Acceptors:** Ligand A (6) is slightly higher than Ligand B (5), but both are within acceptable limits.
**6. QED:** Both ligands have similar QED values (A: 0.706, B: 0.588), indicating reasonable drug-likeness.
**7. DILI Risk:** Ligand A (62.699) has a higher DILI risk than Ligand B (34.587). This is a negative for Ligand A, but not a deal-breaker at this stage.
**8. BBB Penetration:** Both ligands have good BBB penetration (A: 76.154, B: 78.79). This is less critical for a cardiovascular target, but not detrimental.
**9. Caco-2 Permeability:** Ligand A (-5.247) is significantly better than Ligand B (-4.887). Higher Caco-2 permeability suggests better intestinal absorption.
**10. Aqueous Solubility:** Ligand A (-3.194) is better than Ligand B (-1.499). Better solubility is always preferred.
**11. hERG Inhibition:** Ligand A (0.563) has a lower hERG risk than Ligand B (0.168). This is a significant advantage for Ligand A, as hERG inhibition can cause cardiotoxicity.
**12. Microsomal Clearance:** Ligand A (49.483) has higher clearance than Ligand B (4.418). This is a negative for Ligand A, indicating faster metabolism.
**13. In vitro Half-Life:** Ligand A (14.652) has a longer half-life than Ligand B (-6.406). This is a positive for Ligand A.
**14. P-gp Efflux:** Ligand A (0.628) has higher P-gp efflux than Ligand B (0.018). This is a negative for Ligand A, potentially reducing bioavailability.
**15. Binding Affinity:** Ligand B (-8.0) has a slightly better binding affinity than Ligand A (-7.4). While a difference of 0.6 kcal/mol is noticeable, the other ADME properties are more concerning.
**Overall Assessment:**
Ligand A has several advantages: better TPSA, logP, Caco-2 permeability, aqueous solubility, and hERG inhibition. However, it has higher DILI risk, clearance, and P-gp efflux. Ligand B has a slightly better binding affinity and lower DILI risk, but its very low logP is a major drawback for a GPCR target. The low logP will likely result in poor membrane permeability and reduced bioavailability. The superior ADME profile of Ligand A, particularly the logP and hERG, outweighs the slightly lower affinity and higher clearance.
Output:
1
2025-04-17 18:14:46,078 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [350.344, 70.71, 2.905, 1, 4, 0.922, 42.691, 76.464, -4.532, -3.816, 0.358, 41.103, -13.729, 0.144, -7.9]
**Ligand B:** [358.467, 67.23, 2.777, 1, 5, 0.914, 67.623, 64.87, -5.238, -3.728, 0.522, 24.986, 17.03, 0.218, -7.2]
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). A (350.344) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are reasonably good (A: 70.71, B: 67.23), well below the 140 threshold for oral absorption.
3. **logP:** Both are optimal (A: 2.905, B: 2.777), falling within the 1-3 range.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** A has 4, B has 5. Both are acceptable, below the 10 threshold.
6. **QED:** Both are high (A: 0.922, B: 0.914), indicating good drug-like properties.
7. **DILI:** A (42.691) is significantly better than B (67.623). Lower DILI risk is crucial.
8. **BBB:** A (76.464) is better than B (64.87). While ADRB2 isn't necessarily a CNS target, some peripheral ADRB2 activity can have CNS side effects, and better BBB penetration *could* translate to better tissue distribution.
9. **Caco-2:** A (-4.532) is better than B (-5.238). Higher Caco-2 permeability is desirable.
10. **Solubility:** Both are very poor (-3.816 and -3.728). This is a significant concern for both.
11. **hERG:** A (0.358) is better than B (0.522). Lower hERG inhibition is vital for avoiding cardiotoxicity, especially for a cardiovascular target.
12. **Cl_mic:** A (41.103) is higher than B (24.986), meaning B has better metabolic stability. This is a positive for B.
13. **t1/2:** B (17.03) is significantly better than A (-13.729). A negative half-life is concerning.
14. **Pgp:** A (0.144) is better than B (0.218). Lower P-gp efflux is preferable.
15. **Affinity:** B (-7.2) is slightly better than A (-7.9), but the difference is relatively small.
**GPCR-specific priorities:** logP, Pgp, TPSA, and affinity are key. Both ligands perform well on logP and TPSA. A has a slight edge on Pgp, while B has a slightly better affinity. However, the significant advantages of A in DILI risk and hERG inhibition, coupled with the better Caco-2 permeability and BBB, outweigh the minor affinity difference and the metabolic stability advantage of B. The negative half-life of A is a major concern, but the other favorable properties make it more promising. The solubility of both is poor and would need to be addressed.
**Conclusion:**
Considering the balance of properties, especially the safety profiles (DILI and hERG) and the GPCR-specific priorities, Ligand A is the more promising candidate.
1
2025-04-17 18:14:46,078 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**1. Molecular Weight:** Both ligands (356.463 and 351.378 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (99.1) is slightly higher than Ligand B (91.76). Both are below the 140 threshold for good oral absorption, but closer to the 90 threshold for CNS targets (less relevant for ADRB2, a cardiovascular target). Ligand B is slightly favored.
**3. logP:** Ligand B (1.528) is within the optimal 1-3 range, while Ligand A (0.432) is a bit low, potentially hindering permeability. This is a significant advantage for Ligand B.
**4. H-Bond Donors:** Ligand A has 3 HBDs, and Ligand B has 2. Both are acceptable.
**5. H-Bond Acceptors:** Both ligands have 5 HBAs, which is within the acceptable range.
**6. QED:** Ligand B (0.811) has a higher QED score than Ligand A (0.614), indicating a more drug-like profile.
**7. DILI:** Ligand B (40.287) has a much lower DILI risk than Ligand A (9.267). This is a crucial advantage, as minimizing liver toxicity is paramount.
**8. BBB:** Ligand B (72.974) has a higher BBB penetration score than Ligand A (51.415). While ADRB2 isn't a CNS target, some off-target CNS effects are always a concern, and higher BBB is generally preferable.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.922 and -4.822), which is unusual and suggests poor permeability. However, these values are close enough that the difference isn't decisive.
**10. Aqueous Solubility:** Ligand A (-0.614) has slightly better aqueous solubility than Ligand B (-2.828).
**11. hERG Inhibition:** Both ligands show very low hERG inhibition risk (0.102 and 0.205).
**12. Microsomal Clearance:** Ligand A (-10.992) has significantly lower (better) microsomal clearance than Ligand B (6.465), indicating greater metabolic stability. This is a strong point for Ligand A.
**13. In vitro Half-Life:** Ligand B (-33.405) has a much longer in vitro half-life than Ligand A (1.343). This is a significant advantage for Ligand B, potentially allowing for less frequent dosing.
**14. P-gp Efflux:** Both ligands show very low P-gp efflux liability (0.01 and 0.035).
**15. Binding Affinity:** Ligand B (-7.5 kcal/mol) has a significantly stronger binding affinity than Ligand A (-3.9 kcal/mol). This is a substantial advantage that can outweigh some of the ADME drawbacks of Ligand B.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand B is the more promising candidate. The significantly stronger binding affinity (-7.5 vs -3.9 kcal/mol) is a major driver. While Ligand A has better metabolic stability, Ligand B's superior logP, QED, DILI risk, BBB, and half-life profile make it a more balanced and potentially viable drug candidate. The slight solubility advantage of Ligand A is not enough to overcome the other benefits of Ligand B.
Output:
0
2025-04-17 18:14:46,078 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (343.43 & 369.42 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (71.53) is significantly better than Ligand B (96.44). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand A is well below the 140 threshold, while B is approaching it.
3. **logP:** Ligand A (1.672) is within the optimal 1-3 range. Ligand B (0.134) is quite low, potentially hindering membrane permeability. This is a significant drawback for B.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 4, Ligand B has 5. Both are acceptable, but lower is generally preferred.
6. **QED:** Both ligands have good QED scores (0.765 & 0.814), indicating generally drug-like properties.
7. **DILI:** Ligand A (24.78%) has a much lower DILI risk than Ligand B (59.64%). This is a substantial advantage for A.
8. **BBB:** Both ligands have high BBB penetration (70.997% & 71.268%). This isn't a primary concern for ADRB2 (cardiovascular target), but it's not detrimental.
9. **Caco-2:** Both have negative Caco-2 values (-4.705 & -4.828), which is unusual and suggests poor permeability in this assay. However, the values are similar.
10. **Solubility:** Both have similar, very poor aqueous solubility (-1.881 & -1.887). This is a concern for both, requiring formulation strategies.
11. **hERG:** Both have very low hERG inhibition risk (0.14 & 0.152). This is excellent.
12. **Cl_mic:** Ligand B (-12.451) has significantly lower microsomal clearance than Ligand A (29.063), indicating better metabolic stability. This is a positive for B.
13. **t1/2:** Ligand A (-25.953) has a much longer *in vitro* half-life than Ligand B (-0.568). This is a significant advantage for A, potentially leading to less frequent dosing.
14. **Pgp:** Both have very low P-gp efflux liability (0.045 & 0.025).
15. **Binding Affinity:** Ligand B (-21.7 kcal/mol) has a *much* stronger binding affinity than Ligand A (-5.9 kcal/mol). This is a massive difference and a major factor.
**Overall Assessment & GPCR Priorities:**
For a GPCR like ADRB2, affinity is paramount. Ligand B's significantly stronger binding affinity (-21.7 vs -5.9 kcal/mol) is a huge advantage that likely outweighs its drawbacks. While Ligand A has better DILI risk, TPSA, and half-life, the difference in binding affinity is so substantial that it's likely to drive efficacy. The low logP of Ligand B is a concern, but formulation strategies could potentially mitigate this. The lower metabolic stability of Ligand A is also a concern, but could be addressed through structural modifications.
Output:
0
2025-04-17 18:14:46,079 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [340.423, 58.64, 2.085, 1, 3, 0.893, 57.697, 67.274, -4.697, -3.219, 0.373, 27.305, -5.013, 0.08, -7.6]**
**Ligand B: [354.535, 58.64, 3.229, 1, 3, 0.763, 16.479, 70.609, -4.474, -3.314, 0.513, 88.919, 5.13, 0.074, -6.2]**
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). A (340.423) is slightly preferred.
2. **TPSA:** Both ligands have a TPSA of 58.64, which is well below the 140 threshold for oral absorption and suitable for a GPCR. No preference.
3. **logP:** Ligand A (2.085) is better than Ligand B (3.229). While both are within the optimal range of 1-3, Ligand B is approaching the upper limit where solubility issues can arise.
4. **H-Bond Donors:** Both have 1 HBD, which is good. No preference.
5. **H-Bond Acceptors:** Both have 3 HBA, which is good. No preference.
6. **QED:** Ligand A (0.893) has a significantly better QED score than Ligand B (0.763), indicating a more drug-like profile. This is a substantial advantage for A.
7. **DILI:** Ligand A (57.697) has a higher DILI risk than Ligand B (16.479). This is a significant drawback for A.
8. **BBB:** Ligand B (70.609) has a better BBB penetration percentile than Ligand A (67.274), although both are reasonably good. For a GPCR, some BBB penetration can be beneficial, even if it's not a CNS target, as it can influence distribution.
9. **Caco-2 Permeability:** Both ligands have negative Caco-2 values, indicating poor permeability. Ligand A (-4.697) is slightly worse than Ligand B (-4.474).
10. **Aqueous Solubility:** Both ligands have negative solubility values, indicating poor solubility. Ligand A (-3.219) is slightly worse than Ligand B (-3.314).
11. **hERG Inhibition:** Ligand A (0.373) has a lower hERG inhibition liability than Ligand B (0.513), which is preferable.
12. **Microsomal Clearance:** Ligand A (27.305) has a lower microsomal clearance than Ligand B (88.919), indicating better metabolic stability. This is a significant advantage for A.
13. **In vitro Half-Life:** Ligand A (-5.013) has a longer in vitro half-life than Ligand B (5.13). This is a significant advantage for A.
14. **P-gp Efflux:** Both ligands have low P-gp efflux liability (0.08 and 0.074 respectively). No preference.
15. **Binding Affinity:** Ligand A (-7.6) has a significantly stronger binding affinity than Ligand B (-6.2). This is a substantial advantage for A, potentially outweighing some of its ADME drawbacks.
**Overall Assessment:**
Ligand A has a significantly better binding affinity, QED, metabolic stability, and half-life. However, it has a higher DILI risk and slightly worse permeability and solubility. Ligand B has a lower DILI risk and slightly better BBB penetration, but its binding affinity is weaker, and its metabolic stability is poor.
Given the importance of potency for GPCRs, and the substantial difference in binding affinity (-7.6 vs -6.2), the stronger binding of Ligand A is a compelling advantage. The improved metabolic stability and half-life also contribute to its potential for better *in vivo* performance. While the DILI risk is a concern, it's a risk that can be addressed through structural modifications during lead optimization. The solubility and permeability issues are also addressable.
Therefore, I prefer Ligand A.
1
2025-04-17 18:14:46,079 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.427 and 346.475 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (87.66) is slightly higher than Ligand B (60.25). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is generally preferred for absorption. Ligand B has a clear advantage.
3. **logP:** Ligand B (2.527) is slightly higher than Ligand A (1.232), both are within the optimal 1-3 range. Ligand B is better.
4. **HBD:** Ligand A has 3 HBD, while Ligand B has 0. Lower HBD is generally favorable for permeability. Ligand B is better.
5. **HBA:** Ligand A has 4 HBA, Ligand B has 5. Both are acceptable, but lower is slightly preferred. Ligand A is slightly better.
6. **QED:** Ligand B (0.822) has a higher QED score than Ligand A (0.693), indicating a more drug-like profile. Ligand B is better.
7. **DILI:** Both ligands have low DILI risk (31.679 and 32.571 percentile), well below the 40% threshold. No significant difference.
8. **BBB:** Ligand B (83.831) has a significantly higher BBB penetration percentile than Ligand A (50.446). While ADRB2 isn't exclusively a CNS target, some CNS exposure can occur, and higher BBB is generally a positive. Ligand B is better.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.896 and -4.916), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Both ligands have negative solubility values (-2.754 and -2.735), indicating very poor aqueous solubility. This is a major concern for both.
11. **hERG:** Both ligands have low hERG inhibition risk (0.309 and 0.242), which is excellent. No significant difference.
12. **Cl_mic:** Ligand A (28.868) has a lower microsomal clearance than Ligand B (67.887), suggesting better metabolic stability. Ligand A is better.
13. **t1/2:** Ligand A (-9.825) has a slightly longer in vitro half-life than Ligand B (-9.123). Ligand A is better.
14. **Pgp:** Ligand A (0.06) has a lower P-gp efflux liability than Ligand B (0.336), indicating better bioavailability and potentially better CNS exposure. Ligand A is better.
15. **Binding Affinity:** Ligand B (-7.0) has a slightly better binding affinity than Ligand A (-5.0). This is a substantial difference, and a >2 kcal/mol advantage is significant. Ligand B is better.
**Overall Assessment:**
Ligand B has a clear advantage in key GPCR-relevant properties: logP, BBB penetration, and most importantly, binding affinity. While Ligand A has better metabolic stability (lower Cl_mic) and P-gp efflux, the significantly stronger binding of Ligand B outweighs these benefits. The poor solubility and Caco-2 permeability are concerning for both, but can be addressed with formulation strategies.
Output:
0
2025-04-17 18:14:46,079 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (387.433) is slightly higher than Ligand B (348.443), but both are acceptable.
2. **TPSA:** Ligand A (101.29) is higher than Ligand B (78.87). For a cardiovascular GPCR, TPSA is moderately important. Ligand B is better here.
3. **logP:** Both ligands have good logP values (A: 1.177, B: 2.694) within the optimal 1-3 range. Ligand B is slightly more favorable.
4. **HBD:** Ligand A (3) and Ligand B (2) are both acceptable, being less than 5.
5. **HBA:** Ligand A (5) and Ligand B (4) are both acceptable, being less than 10.
6. **QED:** Both ligands have reasonable QED scores (A: 0.733, B: 0.559), exceeding the 0.5 threshold. Ligand A is better.
7. **DILI:** Ligand A (75.572) has a significantly higher DILI risk than Ligand B (20.396). This is a major concern for Ligand A.
8. **BBB:** Both ligands have similar BBB penetration (A: 68.864, B: 66.537). This isn't a primary concern for a cardiovascular target, but it's good they aren't excessively low.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. This is a significant drawback for both.
10. **Solubility:** Both have negative solubility values, indicating very poor aqueous solubility. This is a major issue for both compounds.
11. **hERG:** Both ligands show low hERG inhibition liability (A: 0.44, B: 0.667), which is good.
12. **Cl_mic:** Ligand A (5.984) has a much lower microsomal clearance than Ligand B (20.652), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (33.354) has a longer in vitro half-life than Ligand B (-4.069). This is a strong positive for Ligand A.
14. **Pgp:** Both ligands have low P-gp efflux liability (A: 0.239, B: 0.154).
15. **Binding Affinity:** Ligand B (-6.4) has slightly better binding affinity than Ligand A (-6.0). While a difference of 0.4 kcal/mol isn't huge, it's noticeable.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand B has a better logP and TPSA. Affinity is slightly better for Ligand B. However, the significantly higher DILI risk for Ligand A is a major red flag. Metabolic stability (Cl_mic and t1/2) are also important, and Ligand A is significantly better in these aspects.
**Overall Assessment:**
Despite Ligand B's slightly better affinity and TPSA, the significantly higher DILI risk associated with Ligand A is a major concern. The improved metabolic stability and half-life of Ligand A are attractive, but the DILI risk is difficult to ignore. Both compounds have poor solubility and permeability. However, the DILI risk is a more immediate concern during development.
Output:
0
2025-04-17 18:14:46,079 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.431 and 349.391 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (77.1) is significantly better than Ligand B (112.48). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is approaching a level where oral absorption could be compromised.
3. **logP:** Ligand A (1.679) is within the optimal range (1-3). Ligand B (-0.262) is *below* 1, which is a concern for membrane permeability and could lead to poor absorption.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (6). Similar to HBDs, lower HBA is generally better for permeability.
6. **QED:** Ligand A (0.779) has a better QED score than Ligand B (0.577), indicating a more drug-like profile.
7. **DILI:** Ligand B (38.62) has a lower DILI risk than Ligand A (51.105), which is a positive. However, both are below the concerning threshold of 60.
8. **BBB:** Ligand A (67.158) has a much better BBB penetration percentile than Ligand B (14.541). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be useful for understanding off-target effects and distribution.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.011 and -5.459), which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Ligand A (-1.79) has slightly better solubility than Ligand B (-1.256), though both are quite poor.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.172 and 0.1), which is excellent.
12. **Cl_mic:** Ligand A (-2.471) has a *much* lower (better) microsomal clearance than Ligand B (1.641), indicating greater metabolic stability.
13. **t1/2:** Ligand A (14.729 hours) has a longer in vitro half-life than Ligand B (19.028 hours).
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.031 and 0.006).
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.0 and -5.5 kcal/mol). The difference is not large enough to override the other ADME considerations.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, and Pgp are important. Ligand A is significantly better in logP and TPSA. While Pgp is good for both, the substantial differences in logP, TPSA, QED, and Cl_mic make Ligand A the stronger candidate.
**Conclusion:**
Ligand A demonstrates a more favorable balance of properties, particularly regarding permeability (logP, TPSA) and metabolic stability (Cl_mic), despite slightly higher DILI risk. The similar binding affinity makes these ADME properties the deciding factors.
Output:
1
2025-04-17 18:14:46,079 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (335.447 and 346.519 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (45.4) is significantly better than Ligand B (61.28). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (4.641 and 3.909), falling within the 1-3 range. Ligand A is slightly higher, which *could* be a minor drawback, but not a dealbreaker.
4. **HBD:** Both have 2 HBD, which is within the acceptable limit of 5.
5. **HBA:** Ligand A has 3 HBA, while Ligand B has 5. Ligand A is preferable here, staying further from the upper limit of 10.
6. **QED:** Both ligands have good QED scores (0.69 and 0.846), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Both ligands have acceptable DILI risk (34.626 and 39.434), well below the 60 threshold. No major difference.
8. **BBB:** Ligand B (83.288) has a much higher BBB penetration score than Ligand A (35.052). However, as ADRB2 is a cardiovascular target, BBB penetration is not a priority.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.042 and -5.043), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Both ligands have poor aqueous solubility (-4.127 and -3.323). This is a major drawback for both, potentially hindering bioavailability.
11. **hERG:** Both ligands have low hERG inhibition liability (0.959 and 0.886), which is excellent.
12. **Cl_mic:** Ligand A (33.345) has a lower microsomal clearance than Ligand B (43.583), indicating better metabolic stability.
13. **t1/2:** Ligand A (68.278) has a significantly longer in vitro half-life than Ligand B (47.812), which is desirable.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.865 and 0.751), which is good.
15. **Binding Affinity:** Ligand A (-7.2) has a slightly better binding affinity than Ligand B (-7.0). While the difference is small, it's within the range where it can outweigh some ADME drawbacks.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A is better on TPSA, Pgp, and has slightly better affinity. While Ligand B has better BBB penetration, this is not important for a cardiovascular target.
**Overall Assessment:**
Despite both ligands having poor Caco-2 permeability and solubility, Ligand A has a more favorable profile overall. It has better TPSA, HBA, metabolic stability (lower Cl_mic, longer t1/2), and slightly better binding affinity. The small advantage in binding affinity, combined with the better ADME properties, makes Ligand A the more promising candidate.
Output:
1
2025-04-17 18:14:46,080 - INFO - Batch 23 complete. Total preferences: 368
2025-04-17 18:14:46,080 - INFO - Processing batch 24/512...
2025-04-17 18:15:36,254 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (335.386 Da) is slightly lower, which is generally favorable for permeability.
**2. TPSA:** Ligand A (47.67) is significantly better than Ligand B (90.98). For a GPCR, keeping TPSA low is beneficial for permeability and receptor engagement. Ligand B is approaching a concerning level for oral absorption.
**3. logP:** Ligand A (3.569) is within the optimal range (1-3), while Ligand B (0.138) is very low. Low logP can severely hinder membrane permeability and bioavailability. This is a major disadvantage for Ligand B.
**4. H-Bond Donors:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
**5. H-Bond Acceptors:** Both ligands have the same number of HBA (5), which is acceptable.
**6. QED:** Ligand A (0.606) has a better QED score than Ligand B (0.429), indicating a more drug-like profile.
**7. DILI Risk:** Ligand B (18.651) has a much lower DILI risk than Ligand A (65.568), which is a significant advantage.
**8. BBB Penetration:** Ligand A (76.696) has better BBB penetration than Ligand B (63.862), but this is less critical for a cardiovascular target than for a CNS target.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability *in vitro*. However, the magnitude of the negative value for Ligand A (-5.282) is less severe than for Ligand B (-5.173).
**10. Aqueous Solubility:** Ligand A (-3.559) has better solubility than Ligand B (-0.851). Solubility is important for formulation and bioavailability.
**11. hERG Inhibition:** Ligand A (0.92) has a slightly higher hERG risk than Ligand B (0.13), but both are relatively low.
**12. Microsomal Clearance:** Ligand B (22.737) has a lower microsomal clearance than Ligand A (49.906), indicating better metabolic stability.
**13. In vitro Half-Life:** Ligand A (31.559) has a longer in vitro half-life than Ligand B (-4.905). A negative half-life is concerning for Ligand B.
**14. P-gp Efflux:** Ligand A (0.821) has lower P-gp efflux than Ligand B (0.002), which is favorable.
**15. Binding Affinity:** Ligand A (-7.3 kcal/mol) has a significantly stronger binding affinity than Ligand B (-2.2 kcal/mol). This is a crucial factor, and the 5.1 kcal/mol difference is substantial.
**Overall Assessment:**
While Ligand B has a lower DILI risk and better metabolic stability, its extremely low logP and negative in vitro half-life are major drawbacks. The significantly stronger binding affinity of Ligand A, combined with its more favorable TPSA, logP, QED, and solubility, outweigh the slightly higher DILI risk. The strong affinity suggests that a lower dose might be effective, potentially mitigating the DILI concern. For a GPCR, optimizing permeability (through logP and TPSA) and affinity are paramount.
Output:
1
2025-04-17 18:15:36,254 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [348.311, 117.07 , 1.248, 1. , 9. , 0.582, 96.704, 46.336, -4.531, -2.988, 0.076, 72.669, -26.263, 0.154, -5.2 ]
**Ligand B:** [346.431, 76.46 , 1.405, 1. , 5. , 0.874, 44.126, 71.772, -4.83 , -2.171, 0.152, 9.82 , -10.331, 0.079, -5.5 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). A (348.311) and B (346.431) are very close, so this isn't a major differentiator.
2. **TPSA:** A (117.07) is slightly higher than B (76.46). B is significantly better, falling well below the 140 threshold for oral absorption and is more favorable for GPCRs.
3. **logP:** Both are within the optimal range (1-3). B (1.405) is slightly higher, which could be marginally better for membrane permeability.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** A has 9 HBA, while B has 5. B is better here, as fewer HBA generally improves permeability.
6. **QED:** B (0.874) has a significantly better QED score than A (0.582), indicating a more drug-like profile.
7. **DILI:** A (96.704) has a much higher DILI risk than B (44.126). This is a major red flag for A.
8. **BBB:** B (71.772) has a higher BBB penetration percentile than A (46.336). While not a primary concern for a cardiovascular target, higher BBB is generally preferable.
9. **Caco-2:** A (-4.531) and B (-4.83) are both negative, indicating poor permeability. B is slightly worse.
10. **Solubility:** A (-2.988) and B (-2.171) are both poor. B is slightly better.
11. **hERG:** Both are very low, indicating minimal hERG inhibition risk.
12. **Cl_mic:** A (72.669) has higher microsomal clearance than B (9.82), meaning faster metabolism and potentially lower exposure. B is much better.
13. **t1/2:** B (-10.331) has a longer in vitro half-life than A (-26.263). This is a significant advantage for B.
14. **Pgp:** A (0.154) and B (0.079) are both low, indicating minimal P-gp efflux. B is slightly better.
15. **Affinity:** B (-5.5) has a slightly better binding affinity than A (-5.2), but the difference is small.
**GPCR-specific priorities:** For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, and affinity. B excels in TPSA and Pgp, has a slightly better logP and affinity, and a much better QED and safety profile (DILI). A's major drawback is its high DILI risk and higher metabolic clearance.
**Conclusion:**
Considering the balance of properties and the GPCR-specific priorities, **Ligand B** is the more promising drug candidate. Its superior DILI profile, better QED, lower clearance, and longer half-life outweigh the slightly worse Caco-2 permeability.
0
2025-04-17 18:15:36,255 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (368.5) is within the ideal range (200-500), while Ligand B (406.4) is also acceptable. No clear advantage here.
2. **TPSA:** Ligand A (75.6) is slightly higher than ideal for optimal oral absorption (<=140), but still reasonable. Ligand B (55.6) is excellent, well below the threshold. Advantage: B.
3. **logP:** Ligand A (2.53) is within the optimal range (1-3). Ligand B (4.01) is slightly above, potentially raising concerns about solubility and off-target effects. Advantage: A.
4. **HBD:** Both ligands have acceptable HBD counts (A: 0, B: 1), well below the threshold of 5. No significant difference.
5. **HBA:** Both ligands have acceptable HBA counts (A: 6, B: 5), below the threshold of 10. No significant difference.
6. **QED:** Both ligands have similar QED values (A: 0.69, B: 0.64), indicating good drug-likeness. No significant difference.
7. **DILI:** Ligand A (52.5) has a slightly higher DILI risk than Ligand B (35.1), but both are below the concerning threshold of 60. Advantage: B.
8. **BBB:** Ligand B (83.3) shows better BBB penetration potential than Ligand A (75.6), which is relevant for a GPCR. Advantage: B.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. This is a concern for both, but the magnitude of negativity is similar. No clear advantage.
10. **Solubility:** Both ligands have negative solubility values, indicating poor aqueous solubility. This is a significant drawback for both. No clear advantage.
11. **hERG:** Ligand A (0.36) has a lower hERG inhibition liability than Ligand B (0.60), which is a positive. Advantage: A.
12. **Cl_mic:** Ligand B (54.3) has a higher microsomal clearance than Ligand A (22.9), suggesting lower metabolic stability. Advantage: A.
13. **t1/2:** Both ligands have similar in vitro half-lives (A: 17.5, B: 16.9). No significant difference.
14. **Pgp:** Ligand A (0.28) has lower P-gp efflux liability than Ligand B (0.79), which is beneficial for bioavailability. Advantage: A.
15. **Binding Affinity:** Ligand B (-6.3 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.4 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME concerns. Advantage: B.
**Overall Assessment:**
Ligand B has a superior binding affinity and better BBB penetration, which are critical for a GPCR target like ADRB2. It also has a lower DILI risk. However, it suffers from a higher logP and Pgp efflux. Ligand A has better metabolic stability, lower hERG risk, and lower Pgp efflux, but its binding affinity is weaker.
Considering the importance of potency for GPCRs, the 1.5 kcal/mol difference in binding affinity is a significant factor. While the ADME properties of Ligand B are not ideal, they are not drastically outside acceptable ranges, and optimization could potentially address these issues. The stronger binding affinity provides a better starting point for further development.
Output:
0
2025-04-17 18:15:36,255 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (355.435 and 359.415 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (96.97) is better than Ligand B (116.8). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (0.509) is slightly higher than Ligand B (0.304), both are a bit low, but acceptable. A logP between 1-3 is optimal, but these are still within a reasonable range.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1). Both are within the acceptable limit of <=5.
5. **HBA:** Ligand A (5) is lower than Ligand B (8). Lower HBA is generally preferred for permeability.
6. **QED:** Both ligands have good QED scores (0.749 and 0.793), indicating good drug-like properties.
7. **DILI:** Ligand A (53.819) has a significantly lower DILI risk than Ligand B (67.003). This is a major advantage for Ligand A.
8. **BBB:** Both ligands have similar BBB penetration (46.568 and 48.352). Since ADRB2 is a cardiovascular target, BBB penetration is not a high priority.
9. **Caco-2:** Ligand A (-4.942) is better than Ligand B (-5.599). Higher Caco-2 permeability is desirable.
10. **Solubility:** Ligand A (-2.02) is better than Ligand B (-2.982). Higher solubility is generally preferred.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.123 and 0.071). This is excellent.
12. **Cl_mic:** Ligand A (12.281) has a higher microsomal clearance than Ligand B (6.796). This means Ligand B is more metabolically stable, which is a positive.
13. **t1/2:** Ligand A (0.247) has a shorter in vitro half-life than Ligand B (-0.413). Ligand B is preferable here.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.017 and 0.031).
15. **Binding Affinity:** Ligand A (-7.7) has a significantly stronger binding affinity than Ligand B (-6.7). A 1.0 kcal/mol difference is substantial and can often outweigh minor ADME concerns.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A is better on TPSA, affinity, and has a more favorable DILI profile. Ligand B has better metabolic stability (lower Cl_mic) and half-life. However, the significantly stronger binding affinity of Ligand A is a major advantage. The slightly lower logP of both ligands is not a dealbreaker.
**Conclusion:**
The superior binding affinity of Ligand A, coupled with its better TPSA, solubility, and significantly lower DILI risk, outweighs the slightly better metabolic stability and half-life of Ligand B.
Output:
1
2025-04-17 18:15:36,255 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Ligand A (403.28 Da) is within the ideal range, while Ligand B (361.511 Da) is also good. No clear advantage here.
2. **TPSA:** Ligand A (59.73) is better than Ligand B (52.65). Both are well below the 140 threshold for oral absorption, but lower TPSA is generally preferred for GPCRs.
3. **logP:** Ligand A (3.335) is optimal, while Ligand B (2.148) is slightly lower, but still acceptable. Ligand A has a slight edge.
4. **HBD:** Ligand A (0) is better than Ligand B (1). Fewer HBDs are generally preferred for better permeability.
5. **HBA:** Ligand A (5) is better than Ligand B (4). Both are within the acceptable range.
6. **QED:** Ligand B (0.874) is better than Ligand A (0.656). Higher QED suggests better overall drug-likeness.
7. **DILI:** Ligand B (19.271) is *significantly* better than Ligand A (72.043). This is a major advantage for Ligand B.
8. **BBB:** Ligand B (85.964) is better than Ligand A (73.594). While ADRB2 isn't necessarily a CNS target, higher BBB is still a positive attribute.
9. **Caco-2:** Ligand A (-4.728) is better than Ligand B (-5.255). Higher Caco-2 permeability is better.
10. **Solubility:** Ligand A (-3.656) is better than Ligand B (-2.45). Higher solubility is better.
11. **hERG:** Ligand A (0.755) is better than Ligand B (0.644). Lower hERG inhibition is preferred.
12. **Cl_mic:** Ligand B (34.3) is much better than Ligand A (107.195). Lower clearance indicates better metabolic stability.
13. **t1/2:** Ligand A (37.57) is better than Ligand B (22.714). Longer half-life is generally preferred.
14. **Pgp:** Ligand A (0.775) is better than Ligand B (0.163). Lower P-gp efflux is better.
15. **Affinity:** Ligand A (-6.4) is better than Ligand B (-5.5). This is a significant difference in binding affinity.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has an advantage in logP, TPSA, Pgp and *especially* affinity. However, Ligand B has a massive advantage in DILI risk and a good advantage in BBB and Cl_mic.
**Overall Assessment:**
The difference in binding affinity (-6.4 vs -5.5 kcal/mol) is substantial. While Ligand B has a much better safety profile (DILI) and metabolic stability (Cl_mic), the potency advantage of Ligand A is likely to be more critical for a GPCR target. The slightly better BBB for Ligand B is a bonus, but not decisive. The better solubility and Caco-2 of Ligand A also contribute positively.
Therefore, I believe Ligand A is the more promising drug candidate.
Output:
1
2025-04-17 18:15:36,255 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [338.415, 77.63, 2.342, 1, 6, 0.774, 60.915, 62.737, -5.098, -2.466, 0.372, 6.362, 9.864, 0.204, -6.6]
**Ligand B:** [349.391, 107.37, -0.321, 2, 7, 0.754, 67.39, 47.15, -5.331, -1.69, 0.103, 21.077, 10.781, 0.035, -7.5]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal 200-500 Da range. A (338.4) is slightly preferred.
2. **TPSA:** A (77.63) is better than B (107.37). Lower TPSA generally favors better absorption, and is important for GPCRs.
3. **logP:** A (2.342) is optimal. B (-0.321) is quite low and could hinder membrane permeability. This is a significant drawback for B.
4. **HBD:** Both are acceptable (A: 1, B: 2).
5. **HBA:** Both are acceptable (A: 6, B: 7).
6. **QED:** Both are good (A: 0.774, B: 0.754).
7. **DILI:** Both are moderately risky (A: 60.9, B: 67.4). B is slightly higher risk.
8. **BBB:** A (62.7) is better than B (47.2). While not a primary concern for ADRB2 (a cardiovascular target), some CNS exposure is possible, and higher BBB is generally preferable.
9. **Caco-2:** Both are negative, indicating poor permeability. This is concerning for both, but the lower value for A (-5.098) is slightly better than B (-5.331).
10. **Solubility:** Both are negative, indicating poor solubility. A (-2.466) is slightly better than B (-1.69).
11. **hERG:** Both are very low risk (A: 0.372, B: 0.103).
12. **Cl_mic:** A (6.362) is significantly better than B (21.077). Lower clearance means better metabolic stability.
13. **t1/2:** A (9.864) is comparable to B (10.781).
14. **Pgp:** A (0.204) is better than B (0.035). Lower P-gp efflux is desirable for better bioavailability.
15. **Affinity:** B (-7.5) has a 0.9 kcal/mol advantage in binding affinity over A (-6.6). This is a substantial difference.
**Overall Assessment:**
Ligand B has a better binding affinity, which is a major plus. However, its significantly lower logP and higher microsomal clearance are major concerns. The poor logP suggests poor permeability, and the high clearance suggests rapid metabolism. Ligand A, while having a slightly weaker affinity, has a much better logP, better metabolic stability (lower Cl_mic), and better Pgp efflux profile. Considering the balance of properties, and the importance of permeability and metabolic stability for a GPCR target, I believe **Ligand A** is the more promising drug candidate.
Output:
1
2025-04-17 18:15:36,255 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (373.425 and 346.431 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (78.68) is significantly better than Ligand A (91.32). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (1.791 and 0.978), falling within the 1-3 range. Ligand B is slightly better, being closer to 1.
4. **HBD:** Ligand A has 3 HBD, and Ligand B has 1. Both are acceptable (<=5). Ligand B is slightly preferred.
5. **HBA:** Both ligands have 5 HBA, which is acceptable (<=10).
6. **QED:** Ligand B (0.86) has a better QED score than Ligand A (0.606), indicating a more drug-like profile.
7. **DILI:** Ligand B (23.885) has a much lower DILI risk than Ligand A (52.656). This is a significant advantage for Ligand B.
8. **BBB:** Ligand B (82.745) has a higher BBB penetration score than Ligand A (67.352). While not critical for a cardiovascular target, higher BBB is rarely detrimental.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. Ligand A (-5.027) is slightly worse than Ligand B (-4.943).
10. **Solubility:** Both ligands have negative solubility values, indicating poor solubility. Ligand B (-1.449) is slightly better than Ligand A (-2.569).
11. **hERG:** Both ligands have low hERG inhibition risk (0.299 and 0.364).
12. **Cl_mic:** Ligand B (7.972) has a significantly lower microsomal clearance than Ligand A (21.887), suggesting better metabolic stability.
13. **t1/2:** Ligand B (22.312) has a much longer in vitro half-life than Ligand A (-6.738). This is a major advantage.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.059 and 0.025).
15. **Binding Affinity:** Ligand A (-7.9 kcal/mol) has a slightly better binding affinity than Ligand B (-6.4 kcal/mol). This is a 1.5 kcal/mol difference, which is significant.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has a slightly better affinity, but Ligand B excels in logP, TPSA, and has a better Pgp profile. The significant improvements in ADME properties (DILI, Cl_mic, t1/2, solubility) for Ligand B outweigh the small difference in binding affinity.
**Conclusion:**
Ligand B demonstrates a significantly more favorable overall profile, particularly regarding ADME properties and safety (DILI). While Ligand A has slightly better binding affinity, the improvements in Ligand B's drug-likeness and pharmacokinetic properties make it the more promising candidate.
Output:
0
2025-04-17 18:15:36,255 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [382.473, 75.71, 1.471, 1, 4, 0.645, 40.403, 89.298, -4.924, -2.718, 0.623, 54.551, -30.928, 0.105, -6.0]
**Ligand B:** [369.491, 115.98, 1.138, 4, 5, 0.575, 65.568, 65.839, -5.469, -3.655, 0.573, 34.89, -17.078, 0.061, -8.1]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (369.491) is slightly lower, which could be a minor advantage for permeability.
2. **TPSA:** Ligand A (75.71) is significantly better than Ligand B (115.98). For a GPCR, keeping TPSA low is good, and A is well under the 140 threshold. B is approaching a level that could hinder absorption.
3. **logP:** Both are within the optimal range (1-3). Ligand A (1.471) is slightly higher, which might be preferable for membrane permeability.
4. **HBD:** Ligand A (1) is better than Ligand B (4). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (4) is better than Ligand B (5). Again, lower is generally preferred for permeability.
6. **QED:** Ligand A (0.645) is slightly better than Ligand B (0.575), indicating a more drug-like profile.
7. **DILI:** Ligand A (40.403) is significantly better than Ligand B (65.568). This is a major advantage for A, as lower DILI risk is crucial.
8. **BBB:** Ligand A (89.298) is substantially better than Ligand B (65.839). For a GPCR, even if not a CNS target, some BBB penetration can be useful for distribution. This is a significant advantage for A.
9. **Caco-2:** Ligand A (-4.924) and Ligand B (-5.469) are both negative, indicating poor permeability. However, the scale is not specified, so it's hard to interpret the absolute values.
10. **Solubility:** Ligand A (-2.718) and Ligand B (-3.655) are both poor.
11. **hERG:** Both are low (0.623 and 0.573), indicating low hERG inhibition liability, which is good.
12. **Cl_mic:** Ligand B (34.89) has a lower microsomal clearance than Ligand A (54.551), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-30.928) has a much longer in vitro half-life than Ligand B (-17.078). This is a significant advantage for A.
14. **Pgp:** Ligand A (0.105) has lower P-gp efflux liability than Ligand B (0.061), which is preferable.
15. **Affinity:** Ligand B (-8.1) has a significantly better binding affinity than Ligand A (-6.0). This is a substantial advantage for B (a difference of 2.1 kcal/mol).
**Overall Assessment:**
While Ligand B boasts a superior binding affinity, Ligand A has a much better safety profile (DILI), better BBB penetration, a longer half-life, and a slightly better QED score. The TPSA is also significantly better for Ligand A. Considering these factors, and prioritizing a balance of properties for a viable drug candidate, the advantages of Ligand A outweigh the affinity difference, especially given the substantial DILI risk associated with Ligand B. The affinity difference, while notable, isn't so large that it completely overshadows the other critical ADME/Tox properties.
Output:
1
2025-04-17 18:15:36,255 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [367.515, 91.22, 1.851, 2, 5, 0.575, 15.936, 62.466, -5.017, -2.908, 0.631, 68.637, 17.639, 0.068, -6.0]
**Ligand B:** [370.515, 67.87, 1.429, 1, 5, 0.766, 27.414, 65.839, -5.048, -2.399, 0.307, 19.906, 18.445, 0.036, -7.3]
Here's a breakdown, comparing each parameter and considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal range (200-500 Da). A is 367.5, B is 370.5 - negligible difference.
2. **TPSA:** A is 91.22, B is 67.87. B is significantly better, falling comfortably under the 90 A^2 threshold for good absorption and potentially better CNS penetration (though less critical for a cardiovascular target).
3. **logP:** A is 1.851, B is 1.429. Both are within the optimal 1-3 range, but B is slightly lower. This isn't a major concern.
4. **HBD:** A is 2, B is 1. B is slightly better. Fewer HBDs generally improve permeability.
5. **HBA:** Both are 5, meeting the <10 guideline.
6. **QED:** A is 0.575, B is 0.766. B is better, indicating a more drug-like profile.
7. **DILI:** A is 15.9, B is 27.4. A is *much* better, indicating a significantly lower risk of drug-induced liver injury. This is a crucial advantage.
8. **BBB:** A is 62.5, B is 65.8. Similar, and not a primary concern for a cardiovascular target.
9. **Caco-2:** Both are negative (-5.017 and -5.048). This is unusual and suggests poor permeability. However, the values are very close, and the scale isn't specified, so it's difficult to interpret.
10. **Solubility:** Both are negative (-2.908 and -2.399). Again, this is unusual and suggests poor solubility. The values are close, but B is slightly better.
11. **hERG:** A is 0.631, B is 0.307. B is significantly better, indicating lower cardiotoxicity risk. This is important for a cardiovascular target.
12. **Cl_mic:** A is 68.6, B is 19.9. B is *much* better, indicating significantly higher metabolic stability.
13. **t1/2:** A is 17.6, B is 18.4. B is slightly better, but the difference is small.
14. **Pgp:** A is 0.068, B is 0.036. B is slightly better, indicating lower P-glycoprotein efflux.
15. **Affinity:** A is -6.0, B is -7.3. B is 1.3 kcal/mol stronger, which is a substantial advantage and can often outweigh minor ADME concerns.
**Overall Assessment:**
Ligand B has a clear advantage in several key areas: TPSA, QED, hERG, Cl_mic, and, most importantly, binding affinity. While Ligand A has a significant advantage in DILI risk, the stronger binding affinity of Ligand B, coupled with its better metabolic stability and lower hERG risk, makes it the more promising candidate. The slightly lower TPSA and better QED of B are also beneficial. The solubility and Caco-2 values are concerning for both, but the potency advantage of B is likely to be more impactful in driving overall success.
Output:
0
2025-04-17 18:15:36,255 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (374.5 & 345.5 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand B (73.2) is significantly better than Ligand A (104.73). Lower TPSA generally improves permeability, crucial for GPCRs.
3. **logP:** Ligand B (3.004) is optimal, while Ligand A (0.086) is very low, potentially hindering membrane permeability. This is a significant strike against Ligand A.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (1), but both are acceptable.
5. **HBA:** Ligand A (5) is higher than Ligand B (3), but both are within the acceptable range.
6. **QED:** Both ligands have good QED scores (0.586 and 0.661), indicating good drug-like properties.
7. **DILI:** Ligand B (17.45) has a much lower DILI risk than Ligand A (32.61), a significant advantage.
8. **BBB:** Ligand B (74.68) shows good BBB penetration, while Ligand A (26.212) is poor. While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant and is not detrimental.
9. **Caco-2:** Ligand A (-5.327) and Ligand B (-4.597) are both negative, which is unusual. However, the magnitude is similar, so this isn't a major differentiator.
10. **Solubility:** Ligand A (-1.247) is slightly better than Ligand B (-4.03), but both are poor. This is a concern, but can potentially be addressed with formulation strategies.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.098 and 0.626), which is excellent.
12. **Cl_mic:** Ligand A (12.099) has a lower microsomal clearance than Ligand B (80.787), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-7.882) has a negative in vitro half-life, which is concerning. Ligand A (22.096) is much better.
14. **Pgp:** Ligand A (0.043) has lower P-gp efflux than Ligand B (0.243), which is favorable for bioavailability.
15. **Affinity:** Ligand A (-6.3 kcal/mol) has a slightly better binding affinity than Ligand B (-4.9 kcal/mol). This is a 1.4 kcal/mol difference, which is substantial.
**Overall Assessment:**
Despite Ligand A's slightly better affinity and metabolic stability, Ligand B is the superior candidate. The extremely low logP of Ligand A is a major drawback, likely leading to poor permeability and bioavailability. Ligand B excels in key GPCR-relevant properties: TPSA, logP, BBB penetration, and DILI risk. The negative half-life of Ligand B is a concern, but potentially addressable through structural modifications. The affinity difference, while noticeable, can be overcome with further optimization of Ligand B.
Output:
0
2025-04-17 18:15:36,256 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (366.355 and 344.459 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (60.85) is better than Ligand B (65.54). Both are below the 140 threshold for oral absorption, but lower is generally preferred.
3. **logP:** Both ligands have good logP values (1.355 and 1.533), falling within the 1-3 range. No clear advantage.
4. **HBD:** Both have 1 HBD, which is acceptable.
5. **HBA:** Ligand A has 3 HBA, while Ligand B has 4. Both are acceptable (<=10), but A is slightly better.
6. **QED:** Ligand B (0.9) has a slightly better QED score than Ligand A (0.751), indicating a more drug-like profile.
7. **DILI:** Ligand A (24.506) has a significantly lower DILI risk than Ligand B (14.618). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (86.584) has a better BBB percentile than Ligand B (69.213). While ADRB2 isn't exclusively a CNS target, some distribution to the CNS can be relevant, and higher BBB is generally favorable.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.667) is slightly better than Ligand B (-4.828), but both are concerning.
10. **Solubility:** Ligand A (-2.439) has slightly better solubility than Ligand B (-1.766), though both are quite poor.
11. **hERG:** Both ligands have low hERG inhibition risk (0.407 and 0.468), which is good.
12. **Cl_mic:** Ligand A (8.734) has a higher microsomal clearance than Ligand B (4.977), indicating faster metabolism and potentially lower *in vivo* exposure. This favors Ligand B.
13. **t1/2:** Ligand B (-0.476) has a significantly longer *in vitro* half-life than Ligand A (-43.248). This is a strong advantage for Ligand B.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.026 and 0.017). No significant difference.
15. **Binding Affinity:** Ligand B (-6.8 kcal/mol) has a slightly better binding affinity than Ligand A (-6.2 kcal/mol). This is a key factor, as a 0.6 kcal/mol difference is meaningful.
**Overall Assessment & GPCR Prioritization:**
For a GPCR like ADRB2, affinity, logP, TPSA, and metabolic stability are key. Ligand B has a better binding affinity and metabolic stability (longer half-life, lower Cl_mic). While Ligand A has a better DILI score and BBB penetration, the affinity difference is substantial, and the DILI risk for Ligand A is still acceptable. The poor Caco-2 values for both are a concern, but can be addressed with formulation strategies. The slightly better QED of Ligand B is also a positive.
Therefore, I favor Ligand B.
Output:
0
2025-04-17 18:15:36,256 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (361.398 and 347.365 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand B (56.41) is significantly better than Ligand A (105.05). ADRB2 is not a CNS target, but lower TPSA generally improves absorption.
3. **logP:** Both ligands have good logP values (2.193 and 2.382), falling within the 1-3 range. Similar.
4. **HBD:** Ligand A has 3 HBD, and Ligand B has 1. Lower is generally preferred for permeability, giving a slight edge to Ligand B.
5. **HBA:** Ligand A has 3 HBA, and Ligand B has 2. Similar to HBD, Ligand B is slightly better.
6. **QED:** Ligand B (0.867) has a better QED score than Ligand A (0.663), indicating a more drug-like profile.
7. **DILI:** Ligand B (61.613) has a higher DILI risk than Ligand A (93.525). This is a significant advantage for Ligand A.
8. **BBB:** Not a major concern for ADRB2, but Ligand B (87.941) has a higher BBB penetration than Ligand A (52.23).
9. **Caco-2:** Both have negative Caco-2 values, which is unusual. However, the absolute value is smaller for Ligand B (-4.722 vs -5.387), suggesting slightly better permeability.
10. **Solubility:** Both have negative solubility values, which is also unusual. The absolute value is smaller for Ligand B (-3.396 vs -3.541), suggesting slightly better solubility.
11. **hERG:** Ligand A (0.428) has a lower hERG risk than Ligand B (0.604), which is a positive.
12. **Cl_mic:** Ligand A (8.262) has a lower microsomal clearance than Ligand B (11.632), indicating better metabolic stability.
13. **t1/2:** Ligand A (28.945) has a significantly longer in vitro half-life than Ligand B (5.047). This is a major advantage.
14. **Pgp:** Ligand A (0.183) has lower P-gp efflux liability than Ligand B (0.2).
15. **Binding Affinity:** Ligand B (-6.5 kcal/mol) has a significantly stronger binding affinity than Ligand A (-4.3 kcal/mol). This is a substantial advantage, potentially outweighing some ADME concerns.
**Overall Assessment:**
Ligand B has a significantly better binding affinity, a better QED score, and slightly better permeability and solubility. However, Ligand A has a much lower DILI risk, lower hERG risk, better metabolic stability (lower Cl_mic and longer t1/2), and lower P-gp efflux.
Given the importance of potency (binding affinity) for GPCRs, and the relatively good ADME profile of Ligand B despite the higher DILI risk, I believe Ligand B is the more promising candidate. The 1.5 kcal/mol difference in binding affinity is a substantial advantage that outweighs the slightly higher DILI and Pgp efflux.
Output:
0
2025-04-17 18:15:36,256 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [367.833, 91.65, 1.426, 2, 4, 0.762, 40.713, 60.411, -5.127, -2.894, 0.197, -12.927, 8.003, 0.05, -6.9]**
**Ligand B: [345.443, 80.32, 1.922, 2, 4, 0.529, 39.511, 56.146, -5.264, -1.411, 0.452, 12.189, -0.923, 0.092, -6.2]**
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand B (345.443) is slightly smaller, which is generally favorable for permeability.
2. **TPSA:** Ligand A (91.65) is slightly above the preferred <90 for good oral absorption, while Ligand B (80.32) is well within the range. This favors Ligand B.
3. **logP:** Both ligands have logP values within the optimal range (1-3). Ligand B (1.922) is slightly higher, which could potentially improve membrane permeability, but both are acceptable.
4. **H-Bond Donors:** Both have 2 HBD, which is good.
5. **H-Bond Acceptors:** Both have 4 HBA, which is good.
6. **QED:** Ligand A (0.762) has a better QED score than Ligand B (0.529), indicating a more drug-like profile.
7. **DILI:** Both ligands have low DILI risk (<40), which is excellent. Ligand B (39.511) is marginally better.
8. **BBB:** Ligand A (60.411) has a better BBB percentile than Ligand B (56.146), but both are not high enough to be considered CNS-focused. For a cardiovascular target, BBB is less critical.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. Ligand B (-5.264) is slightly worse than Ligand A (-5.127).
10. **Solubility:** Both have negative solubility values, indicating poor solubility. Ligand B (-1.411) is slightly better than Ligand A (-2.894).
11. **hERG:** Both have very low hERG inhibition liability, which is excellent. Ligand A (0.197) is slightly better.
12. **Cl_mic:** Ligand A (-12.927) has significantly lower microsomal clearance than Ligand B (12.189), suggesting better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (8.003) has a longer in vitro half-life than Ligand B (-0.923), which is desirable.
14. **Pgp:** Both have low Pgp efflux liability, which is good. Ligand B (0.092) is slightly better.
15. **Binding Affinity:** Ligand A (-6.9) has a slightly better binding affinity than Ligand B (-6.2). While the difference is not huge, it's still a positive factor for Ligand A.
**GPCR-Specific Considerations:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand B has a slightly better logP and Pgp, and TPSA. However, Ligand A has a better affinity, QED, metabolic stability (Cl_mic), and half-life. The better metabolic stability and half-life of Ligand A are crucial for *in vivo* efficacy. The slight advantage in affinity also tips the balance.
**Conclusion:**
Considering the balance of properties, especially the improved metabolic stability and half-life, along with slightly better affinity, Ligand A is the more promising drug candidate.
Output:
1
2025-04-17 18:15:36,256 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [426.793, 55.4, 4.771, 1, 3, 0.609, 41.954, 55.176, -4.785, -6.482, 0.566, 74.458, -4.015, 0.396, -6.8]
**Ligand B:** [371.865, 87.82, 0.962, 2, 6, 0.777, 27.142, 53.005, -4.88, -1.644, 0.348, 14.212, 22.649, 0.029, -6.9]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, Affinity, and to a lesser extent BBB):
1. **MW:** Ligand B (371.865) is better, falling nicely within the 200-500 Da range, and is lower than Ligand A (426.793).
2. **TPSA:** Ligand A (55.4) is significantly better than Ligand B (87.82). ADRB2 is a cardiovascular target, so CNS penetration isn't *critical*, but lower TPSA generally aids absorption. Ligand B is pushing the upper limit for good oral absorption.
3. **logP:** Ligand A (4.771) is higher than Ligand B (0.962). While both are within the acceptable range, Ligand A is approaching the upper limit where solubility issues might arise, but it could also contribute to better membrane permeability. Ligand B is on the lower side, which could hinder permeation.
4. **HBD/HBA:** Ligand B has more HBD (2) and HBA (6) than Ligand A (1 & 3 respectively). This could slightly improve solubility, but also potentially reduce permeability.
5. **QED:** Both are good (A: 0.609, B: 0.777), indicating drug-like properties. Ligand B is slightly better.
6. **DILI:** Ligand B (27.142) is *much* better than Ligand A (41.954), indicating a significantly lower risk of liver injury. This is a major advantage.
7. **BBB:** Both are similar (A: 55.176, B: 53.005). Not a primary concern for a cardiovascular target.
8. **Caco-2:** Both are negative, indicating poor permeability.
9. **Solubility:** Ligand A (-6.482) is better than Ligand B (-1.644), indicating better aqueous solubility.
10. **hERG:** Both are low (A: 0.566, B: 0.348), suggesting low cardiotoxicity risk. Ligand B is slightly better.
11. **Cl_mic:** Ligand B (14.212) has a *much* lower clearance than Ligand A (74.458), suggesting better metabolic stability. This is a significant advantage.
12. **t1/2:** Ligand B (22.649) has a longer half-life than Ligand A (-4.015), which is highly desirable.
13. **Pgp:** Ligand A (0.396) has lower P-gp efflux than Ligand B (0.029), which is favorable for bioavailability.
14. **Affinity:** Both have very similar binding affinities (-6.8 and -6.9 kcal/mol). The difference is negligible.
**Overall Assessment:**
While Ligand A has better solubility and Pgp efflux, Ligand B has a significantly better safety profile (DILI), metabolic stability (Cl_mic), and half-life. The lower TPSA of Ligand A is a plus, but the advantages of Ligand B in safety and PK outweigh this. The binding affinities are essentially the same, so that doesn't factor into the decision. Given the importance of ADME properties for a viable drug candidate, and the clear advantages of Ligand B in these areas, I would choose Ligand B.
0
2025-04-17 18:15:36,256 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (358.36 & 344.37 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (44.76) is significantly better than Ligand B (98.61). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally correlates with better absorption. Ligand B's TPSA is quite high, potentially hindering oral bioavailability.
3. **logP:** Ligand A (3.81) is slightly higher than Ligand B (2.59), both within the optimal 1-3 range. Ligand A is preferable, as it's closer to the upper end of the optimal range.
4. **HBD:** Ligand A (0) is preferable to Ligand B (1). Fewer hydrogen bond donors generally improve membrane permeability.
5. **HBA:** Ligand A (4) is better than Ligand B (7). Again, fewer hydrogen bond acceptors are generally preferred for permeability.
6. **QED:** Both ligands have good QED scores (0.768 and 0.804 respectively), indicating good overall drug-likeness. No clear advantage.
7. **DILI:** Ligand A (48.82) has a lower DILI risk than Ligand B (65.76), which is a significant advantage. Lower DILI is crucial for drug development.
8. **BBB:** Ligand A (91.70) has a much higher BBB penetration percentile than Ligand B (40.68). While not essential for a cardiovascular target, higher BBB penetration isn't necessarily detrimental and could provide some off-target safety information.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.752 and -4.964). This is unusual and suggests poor permeability *in vitro*. This is a concern for both.
10. **Solubility:** Both ligands have negative solubility values (-4.553 and -4.591). This is also unusual, suggesting very poor aqueous solubility. This is a significant concern for both.
11. **hERG:** Ligand A (0.725) has a lower hERG risk than Ligand B (0.107). This is a crucial advantage, as hERG inhibition can lead to cardiotoxicity.
12. **Cl_mic:** Ligand A (50.13) has a lower microsomal clearance than Ligand B (113.999), indicating better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand A (-0.053) has a slightly better in vitro half-life than Ligand B (-40.507).
14. **Pgp:** Ligand A (0.237) has a lower P-gp efflux liability than Ligand B (0.103), which is preferable for bioavailability.
15. **Binding Affinity:** Ligand B (-6.6 kcal/mol) has a slightly better binding affinity than Ligand A (-5.0 kcal/mol). While affinity is important, the difference of 1.6 kcal/mol is not large enough to overcome the numerous ADME advantages of Ligand A.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most crucial ADME properties (DILI, BBB, hERG, Cl_mic, Pgp, TPSA, HBD, HBA). While Ligand B has slightly better binding affinity, the ADME profile of Ligand A is far more favorable, suggesting a higher probability of success as a drug candidate. The poor Caco-2 and solubility values are concerning for both, but can potentially be addressed through formulation strategies. The superior safety profile (lower DILI, hERG) and metabolic stability of Ligand A are particularly compelling.
Output:
1
2025-04-17 18:15:36,256 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (396.292 Da) is slightly higher than Ligand B (347.413 Da), but both are acceptable.
2. **TPSA:** Both ligands are below the 140 A^2 threshold for good oral absorption. Ligand A (58.53) and Ligand B (55.63) are both good.
3. **logP:** Both ligands have logP values within the optimal range (1-3). Ligand A (4.109) is slightly higher than the preferred upper limit, potentially raising solubility concerns, while Ligand B (3.219) is ideal.
4. **HBD:** Both ligands have acceptable HBD counts (Ligand A: 2, Ligand B: 1).
5. **HBA:** Both ligands have acceptable HBA counts (Ligand A: 4, Ligand B: 5).
6. **QED:** Both ligands have good QED scores (Ligand A: 0.534, Ligand B: 0.902). Ligand B is significantly better.
7. **DILI:** Both ligands have acceptable DILI risk (Ligand A: 72.858, Ligand B: 54.634). Ligand B is better.
8. **BBB:** Ligand B (89.957) has a much higher BBB penetration percentile than Ligand A (68.282). This is a significant advantage for a GPCR target, even if not CNS-focused, as it suggests better distribution.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual. I'll interpret these as very poor permeability.
10. **Solubility:** Both ligands have negative solubility values, which is also unusual. I'll interpret these as very poor solubility.
11. **hERG:** Both ligands have low hERG inhibition liability (Ligand A: 0.848, Ligand B: 0.406). Ligand B is better.
12. **Cl_mic:** Ligand B (18.162) has a significantly lower microsomal clearance than Ligand A (37.816), indicating better metabolic stability.
13. **t1/2:** Ligand B (14.188) has a longer in vitro half-life than Ligand A (28.953).
14. **Pgp:** Both ligands have low P-gp efflux liability (Ligand A: 0.667, Ligand B: 0.447). Ligand B is better.
15. **Binding Affinity:** Ligand B (-7.0 kcal/mol) has a significantly stronger binding affinity than Ligand A (-1.0 kcal/mol). This is a decisive advantage.
**Overall Assessment:**
Ligand B consistently outperforms Ligand A across most critical parameters. The most significant advantages are its superior binding affinity, lower DILI risk, better BBB penetration, lower clearance, longer half-life, and better QED score. While both have poor Caco-2 and solubility, the strong affinity of Ligand B may compensate for these issues. The slightly higher logP of Ligand A is a concern, and its significantly weaker binding affinity is a major drawback. Given the GPCR target class, the BBB penetration and Pgp efflux properties of Ligand B are particularly valuable.
Output:
0
2025-04-17 18:15:36,256 - INFO - Batch 24 complete. Total preferences: 384
2025-04-17 18:15:36,256 - INFO - Processing batch 25/512...
2025-04-17 18:16:25,907 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (361.511 and 354.491 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (63.25) is significantly better than Ligand B (84.5). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally improves absorption. Ligand A is well below the 140 threshold. Ligand B is approaching the upper limit.
3. **logP:** Ligand A (4.648) is higher than Ligand B (2.555). While both are within the acceptable range (1-3 is optimal, but up to 4 is often tolerated), Ligand A is pushing the upper limit and could potentially have solubility issues. Ligand B is closer to the ideal range.
4. **HBD:** Both ligands have 2 HBD, which is good.
5. **HBA:** Both ligands have 4 HBA, which is good.
6. **QED:** Ligand A (0.736) has a better QED score than Ligand B (0.492), indicating a more drug-like profile.
7. **DILI:** Ligand B (21.869) has a *much* lower DILI risk than Ligand A (69.756). This is a significant advantage for Ligand B.
8. **BBB:** Both ligands have reasonable BBB penetration (Ligand A: 64.87, Ligand B: 70.492). Since ADRB2 is a cardiovascular target, BBB penetration is not a primary concern.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.96 and -4.78), indicating poor permeability. This is a significant drawback for both.
10. **Solubility:** Ligand B (-2.311) has better solubility than Ligand A (-5.73). This is likely due to the lower logP and TPSA.
11. **hERG:** Ligand A (0.638) has a slightly better hERG profile than Ligand B (0.367), meaning lower risk of cardiotoxicity.
12. **Cl_mic:** Ligand B (55.23) has significantly better metabolic stability (lower clearance) than Ligand A (126.566).
13. **t1/2:** Ligand A (42.106) has a longer in vitro half-life than Ligand B (-10.169). This is a positive for Ligand A.
14. **Pgp:** Ligand A (0.582) has lower P-gp efflux than Ligand B (0.148), which is favorable.
15. **Binding Affinity:** Ligand A (-6.4 kcal/mol) has a slightly better binding affinity than Ligand B (-5.4 kcal/mol). This is a 1.0 kcal/mol difference, which is a notable advantage.
**GPCR-Specific Considerations & Overall Assessment:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A has a better affinity and Pgp profile, while Ligand B has better TPSA, solubility, metabolic stability (Cl_mic), and a *much* lower DILI risk. The poor Caco-2 permeability is a concern for both.
The difference in binding affinity (1.0 kcal/mol) is significant, but the substantial difference in DILI risk and metabolic stability (Cl_mic) is more concerning. A high DILI risk is a major red flag in drug development. While Ligand A's affinity is better, the potential for liver toxicity and faster metabolism make it a less attractive candidate.
**Output:**
0
2025-04-17 18:16:25,907 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (357.479 and 356.813 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (62.3) is significantly better than Ligand B (80.05). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand A is well below the 140 threshold, while Ligand B is approaching it.
3. **logP:** Both ligands have acceptable logP values (2.8 and 3.497), falling within the 1-3 range. Ligand B is slightly higher, which *could* indicate potential off-target effects, but it's not a major concern.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (4) is preferable to Ligand B (5). Similar reasoning to HBD.
6. **QED:** Ligand A (0.829) has a better QED score than Ligand B (0.706), indicating a more drug-like profile.
7. **DILI:** Ligand A (54.052) has a significantly lower DILI risk than Ligand B (82.823). This is a crucial advantage, as minimizing liver toxicity is paramount.
8. **BBB:** Both ligands have good BBB penetration (73.943 and 82.668). While ADRB2 isn't exclusively a CNS target, some peripheral effects are mediated by CNS pathways, and good BBB penetration isn't detrimental. Ligand B is slightly better here.
9. **Caco-2:** Both ligands have the same Caco-2 permeability (-4.994).
10. **Solubility:** Ligand A (-2.759) has better aqueous solubility than Ligand B (-5.037). This is important for formulation and bioavailability.
11. **hERG:** Both ligands have low hERG inhibition liability (0.57 and 0.645). No significant difference.
12. **Cl_mic:** Ligand B (53.673) has a lower microsomal clearance than Ligand A (74.522), suggesting better metabolic stability. This is a positive for Ligand B.
13. **t1/2:** Ligand B (72.058) has a significantly longer in vitro half-life than Ligand A (39.648). This is a major advantage, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have similar Pgp efflux liability (0.392 and 0.232).
15. **Binding Affinity:** Ligand A (-6.0) has a slightly better binding affinity than Ligand B (-4.8). This is a 1.2 kcal/mol difference, which is significant and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand A has a clear advantage in several key areas: TPSA, HBD, HBA, QED, DILI, and solubility. Most importantly, its binding affinity is significantly better. While Ligand B has better metabolic stability (lower Cl_mic) and a longer half-life, the improved potency and safety profile of Ligand A are more critical for a GPCR target. The DILI risk for Ligand B is concerning.
Output:
1
2025-04-17 18:16:25,907 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (340.427 Da and 352.454 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (76.02) is slightly higher than Ligand B (65.54). Both are below the 140 A^2 threshold for good oral absorption, but Ligand B is preferable due to the lower TPSA.
**3. logP:** Ligand A (1.024) and Ligand B (2.254) are both within the optimal 1-3 range. Ligand B is slightly better, leaning towards the more desirable end of the range.
**4. H-Bond Donors:** Ligand A (2) is slightly higher than Ligand B (1). Both are acceptable, but lower is generally preferred. Ligand B is better.
**5. H-Bond Acceptors:** Both ligands have 4 H-bond acceptors, which is well within the acceptable limit of 10.
**6. QED:** Both ligands have good QED scores (0.575 and 0.656, respectively), indicating good drug-like properties. Ligand B is slightly better.
**7. DILI Risk:** Ligand A (37.456) has a lower DILI risk than Ligand B (41.838), which is preferable.
**8. BBB Penetration:** Ligand B (83.908) has significantly better BBB penetration than Ligand A (48.313). While ADRB2 is a cardiovascular target and CNS penetration isn't *essential*, some degree of BBB penetration can be beneficial for off-target effects and overall distribution.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 permeability values (-4.933 and -4.736). This is unusual and suggests poor permeability. However, negative values are often artifacts of the prediction method and don't necessarily preclude development.
**10. Aqueous Solubility:** Both ligands have very poor aqueous solubility (-2.456 and -2.42). This is a significant concern and would require formulation strategies to address.
**11. hERG Inhibition:** Ligand A (0.086) has a much lower hERG inhibition risk than Ligand B (0.845). This is a critical advantage, as hERG inhibition can lead to cardiotoxicity.
**12. Microsomal Clearance:** Ligand B (67.457) has a significantly higher microsomal clearance than Ligand A (6.104). This suggests Ligand B will be metabolized more quickly, potentially leading to a shorter duration of action and lower bioavailability.
**13. In vitro Half-Life:** Ligand A (-7.355) has a much longer in vitro half-life than Ligand B (26.406). This is a major advantage for Ligand A, suggesting less frequent dosing may be possible.
**14. P-gp Efflux:** Ligand A (0.039) has much lower P-gp efflux liability than Ligand B (0.137), which is preferable for bioavailability.
**15. Binding Affinity:** Ligand A (-4.8 kcal/mol) has a slightly weaker binding affinity than Ligand B (-3.6 kcal/mol). However, the difference is not substantial enough to outweigh the significant ADME advantages of Ligand A.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), and the general drug-like properties, Ligand A is the more promising candidate. While Ligand B has better BBB penetration and a slightly higher logP, Ligand A has a significantly lower DILI risk, hERG inhibition, P-gp efflux, and microsomal clearance, and a longer half-life. The solubility issues are a concern for both, but can be addressed with formulation. The slightly weaker binding affinity of Ligand A is acceptable given its superior ADME profile.
Output:
1
2025-04-17 18:16:25,907 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (345.355 and 358.41 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (93.9) is slightly higher than Ligand B (87.15). Both are below the 140 threshold for oral absorption, and acceptable for a cardiovascular target (not CNS). Ligand B is slightly preferred.
3. **logP:** Ligand A (1.874) is within the optimal 1-3 range. Ligand B (0.498) is a bit low, potentially hindering permeability. Ligand A is preferred.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 6 HBA, and Ligand B has 5. Both are below the 10 threshold.
6. **QED:** Ligand A (0.854) has a higher QED score than Ligand B (0.699), indicating better overall drug-likeness. Ligand A is preferred.
7. **DILI:** Ligand B (32.726) has a significantly lower DILI risk than Ligand A (77.433). This is a major advantage for Ligand B.
8. **BBB:** Ligand A (74.292) has a higher BBB penetration than Ligand B (59.791). While ADRB2 isn't a CNS target, some peripheral distribution can be beneficial.
9. **Caco-2:** Both ligands have similar, very negative Caco-2 values (-4.501 and -4.475). This suggests poor permeability, which is a concern for both.
10. **Solubility:** Ligand A (-3.305) has slightly better solubility than Ligand B (-1.165).
11. **hERG:** Ligand A (0.18) has a lower hERG risk than Ligand B (0.453). This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand A (95.704) has a higher microsomal clearance than Ligand B (25.394), meaning it's metabolized more quickly. Ligand B is preferred.
13. **t1/2:** Ligand B (-9.926) has a longer in vitro half-life than Ligand A (-33.21). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.16) has lower P-gp efflux than Ligand B (0.104).
15. **Affinity:** Ligand A (-5.3 kcal/mol) has a slightly better binding affinity than Ligand B (-4.0 kcal/mol). This is a significant advantage for Ligand A.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand A has a better logP and affinity, while Ligand B has better TPSA, DILI, Cl_mic, and t1/2. The difference in affinity is substantial (1.3 kcal/mol), which can often outweigh other drawbacks. However, the DILI risk for Ligand A is concerningly high. The improved metabolic stability and half-life of Ligand B are also attractive.
**Overall Assessment:**
While Ligand A has a better binding affinity and logP, the significantly higher DILI risk and faster clearance are major drawbacks. Ligand B, despite a slightly weaker affinity and lower logP, presents a much safer profile with lower DILI risk and improved metabolic stability. Given the cardiovascular context, minimizing toxicity is paramount.
Output:
0
2025-04-17 18:16:25,907 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.4 & 354.5 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (62.55) is significantly better than Ligand B (87.66). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (2.754) is within the optimal 1-3 range, while Ligand B (1.466) is at the lower end. A slightly higher logP is generally preferred for GPCRs to aid membrane permeability.
4. **HBD:** Ligand A (1) is better than Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (3) is better than Ligand B (4). Fewer HBAs generally improve permeability.
6. **QED:** Ligand A (0.832) is significantly better than Ligand B (0.646), indicating a more drug-like profile.
7. **DILI:** Ligand B (26.444) has a considerably lower DILI risk than Ligand A (34.742). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (70.997) has a better BBB percentile than Ligand B (45.754). While not crucial for a cardiovascular target, it's a slight positive for A.
9. **Caco-2:** Ligand A (-4.376) is better than Ligand B (-5.07), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-4.764) is better than Ligand B (-1.941), indicating better aqueous solubility.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.374 and 0.142 respectively). No significant difference.
12. **Cl_mic:** Ligand B (31.29) has a slightly lower microsomal clearance than Ligand A (33.441), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-24.845) has a much longer in vitro half-life than Ligand B (-4.315). This is a significant advantage for A.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.06 and 0.037 respectively). No significant difference.
15. **Binding Affinity:** Ligand B (-7.7 kcal/mol) has a significantly stronger binding affinity than Ligand A (-4.8 kcal/mol). This is a substantial advantage, potentially outweighing some ADME concerns.
**Overall Assessment:**
Ligand B has a significantly better binding affinity (-7.7 vs -4.8 kcal/mol). This is a major advantage for a drug candidate. It also has a lower DILI risk and slightly better metabolic stability. Ligand A has better QED, solubility, Caco-2 permeability, and a longer half-life, but the affinity difference is too large to ignore. The slightly higher TPSA of Ligand B is not a major concern for a cardiovascular target.
Output:
0
2025-04-17 18:16:25,907 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.391 and 354.495 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (131.76) is slightly higher than Ligand B (104.53). Both are below the 140 A^2 threshold for good oral absorption, but Ligand B is preferable due to being closer to the <90 A^2 target for GPCRs.
3. **logP:** Ligand A (-0.928) is a bit low, potentially hindering permeability. Ligand B (1.613) is within the optimal 1-3 range. This is a significant advantage for Ligand B.
4. **HBD:** Both ligands have 3 HBD, which is acceptable.
5. **HBA:** Ligand A has 6 HBA, while Ligand B has 3. Lower HBA is generally better for permeability, favoring Ligand B.
6. **QED:** Both ligands have good QED scores (0.542 and 0.647), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (32.959) has a slightly higher DILI risk than Ligand B (16.208). Lower is better, so Ligand B is preferred.
8. **BBB:** Ligand A (26.599) has a very low BBB penetration, while Ligand B (74.564) is quite good. Given ADRB2 is a GPCR, BBB penetration is a consideration, and Ligand B is strongly favored.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.784 and -5.032), which is unusual and suggests poor permeability. However, the scale is not specified, so it is difficult to interpret.
10. **Solubility:** Both ligands have negative solubility values (-1.899 and -2.349), which is also unusual and suggests poor solubility. Again, the scale is not specified.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.108 and 0.184). No significant difference.
12. **Cl_mic:** Ligand A (-8.261) has a much lower (better) microsomal clearance than Ligand B (40.634), indicating greater metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (0.65) has a shorter half-life than Ligand B (1.483). Ligand B is preferred.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.004 and 0.005). No significant difference.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-7.4 and -7.3 kcal/mol). The difference is negligible.
**Overall Assessment:**
Ligand B clearly outperforms Ligand A in several key areas relevant to GPCR drug development: logP, TPSA, BBB penetration, DILI risk, and in vitro half-life. While Ligand A has better metabolic stability (lower Cl_mic), the other advantages of Ligand B are more critical for a successful GPCR-targeted drug, especially considering the ADRB2's role in cardiovascular function where systemic exposure is important. The negative values for Caco-2 and solubility are concerning for both, but the other properties of Ligand B make it a more promising starting point for optimization.
Output:
0
2025-04-17 18:16:25,908 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (448.308 Da) is within the ideal range. Ligand B (343.387 Da) is also acceptable, leaning towards the lower end, but still reasonable.
2. **TPSA:** Ligand A (51.02) is good, well below the 140 threshold. Ligand B (108.62) is higher, but still potentially acceptable for a peripherally acting GPCR.
3. **logP:** Ligand A (4.115) is slightly high, potentially leading to solubility issues or off-target interactions. Ligand B (0.292) is *very* low, which is a significant concern for membrane permeability and bioavailability.
4. **HBD:** Ligand A (0) is optimal. Ligand B (3) is acceptable, but higher HBD can sometimes impact permeability.
5. **HBA:** Ligand A (4) is good. Ligand B (6) is acceptable.
6. **QED:** Both ligands (A: 0.565, B: 0.626) have good drug-likeness scores.
7. **DILI:** Ligand A (59.17) is moderately risky, but manageable. Ligand B (65.684) is slightly higher risk.
8. **BBB:** Ligand A (79.217) has reasonable BBB penetration, while Ligand B (45.56) is low. Since ADRB2 is a cardiovascular target, BBB penetration isn't *critical*, but some level is often desirable for broader distribution and potential off-target effects assessment.
9. **Caco-2:** Ligand A (-4.889) is very poor. Ligand B (-5.392) is also poor. Both suggest poor intestinal absorption.
10. **Solubility:** Ligand A (-4.085) is poor. Ligand B (-2.519) is also poor, but slightly better than Ligand A.
11. **hERG:** Ligand A (0.847) has a low hERG risk. Ligand B (0.236) has a very low hERG risk.
12. **Cl_mic:** Ligand A (98.355) has high metabolic clearance, which is unfavorable. Ligand B (11.337) has low metabolic clearance, which is excellent.
13. **t1/2:** Ligand A (103.49) has a good in vitro half-life. Ligand B (8.431) has a short half-life, which is a significant drawback.
14. **Pgp:** Ligand A (0.571) has moderate P-gp efflux. Ligand B (0.06) has very low P-gp efflux, which is favorable.
15. **Affinity:** Ligand B (-7.1 kcal/mol) has significantly better binding affinity than Ligand A (-6.1 kcal/mol). This is a >1 kcal/mol difference, which is a substantial advantage.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand B excels in Pgp and affinity, while Ligand A has a better TPSA. However, the extremely low logP of Ligand B is a major concern. Ligand A's logP is high, but potentially manageable with formulation strategies. The superior affinity of Ligand B is very attractive, and its lower P-gp efflux is a bonus. The metabolic stability of Ligand B is also significantly better. While the half-life is a concern, this can be addressed through structural modifications. The poor Caco-2 and solubility of both are concerning, but the affinity advantage of B is substantial.
**Conclusion:**
Despite the drawbacks of Ligand B (low logP, short half-life, poor Caco-2/solubility), its significantly stronger binding affinity and favorable Pgp/Cl_mic profile outweigh the issues. The low logP is the biggest concern, but could potentially be addressed with prodrug strategies or formulation. Ligand A's high logP and high metabolic clearance are less easily mitigated.
Output:
0
2025-04-17 18:16:25,908 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (347.415 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (86.92) is significantly better than Ligand B (101.57), falling well under the 140 A^2 threshold for oral absorption.
3. **logP:** Ligand A (2.594) is optimal, while Ligand B (0.092) is quite low, potentially hindering membrane permeability.
4. **HBD:** Both ligands have acceptable HBD counts (Ligand A: 1, Ligand B: 2), within the guideline of <=5.
5. **HBA:** Both ligands have acceptable HBA counts (Ligand A: 5, Ligand B: 5), within the guideline of <=10.
6. **QED:** Both ligands have good QED scores (Ligand A: 0.485, Ligand B: 0.708), indicating reasonable drug-likeness. Ligand B is better here.
7. **DILI:** Both have moderate DILI risk. Ligand A (63.086) is slightly higher than Ligand B (53.625), but both are below the concerning 60 threshold.
8. **BBB:** Ligand B (70.415) has a better BBB penetration percentile than Ligand A (51.415). While ADRB2 isn't strictly a CNS target, some CNS exposure can be relevant for off-target effects, and higher BBB is generally a plus.
9. **Caco-2:** Ligand A (-4.64) has a *much* better Caco-2 permeability score than Ligand B (-5.282). This suggests significantly better intestinal absorption for Ligand A.
10. **Solubility:** Ligand A (-2.74) has better aqueous solubility than Ligand B (-2.083).
11. **hERG:** Both ligands have low hERG inhibition liability (Ligand A: 0.811, Ligand B: 0.156). Ligand B is better here.
12. **Cl_mic:** Ligand B (-13.695) has a much lower (better) microsomal clearance than Ligand A (59.051), indicating greater metabolic stability.
13. **t1/2:** Ligand B (33.43) has a significantly longer in vitro half-life than Ligand A (13.504).
14. **Pgp:** Ligand A (0.82) has slightly better Pgp efflux liability than Ligand B (0.024).
15. **Binding Affinity:** Ligand B (-6.8 kcal/mol) has a slightly better binding affinity than Ligand A (-6.1 kcal/mol), though the difference is relatively small.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A excels in logP and TPSA, which are crucial for permeability and absorption. Ligand B has a slight affinity advantage and better BBB penetration and metabolic stability.
**Overall Assessment:**
While Ligand B has a slight edge in binding affinity, metabolic stability (Cl_mic and t1/2), and BBB penetration, the significantly lower logP and poorer Caco-2 permeability are major drawbacks. ADRB2 is a peripheral receptor, so high BBB penetration isn't critical. The poor logP of Ligand B suggests it will struggle with absorption. Ligand A, with its optimal logP, good TPSA, and reasonable absorption profile, is more likely to be a viable drug candidate despite slightly lower metabolic stability and affinity.
Output:
1
2025-04-17 18:16:25,908 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
Let's analyze each ligand against the provided criteria, keeping in mind ADRB2 is a GPCR, so logP, TPSA, Pgp, and affinity are particularly important.
* **Molecular Weight:** Both ligands (366.89 and 354.45 Da) fall within the ideal 200-500 Da range. No significant difference here.
* **TPSA:** Ligand A (78.43) is better than Ligand B (105.48). A TPSA under 140 is good for oral absorption, and both are within that range, but A is closer to the preferred <90 for GPCRs.
* **logP:** Ligand A (3.361) is optimal (1-3), while Ligand B (0.236) is quite low, potentially hindering membrane permeability. This is a significant advantage for A.
* **H-Bond Donors:** Both have 3, which is acceptable.
* **H-Bond Acceptors:** Ligand A has 3, Ligand B has 6. Ligand A is preferable here, as lower HBA generally improves permeability.
* **QED:** Ligand A (0.722) is better than Ligand B (0.589), indicating a more drug-like profile.
* **DILI:** Ligand B (27.03) has a considerably lower DILI risk than Ligand A (35.83), which is a positive for B.
* **BBB:** Ligand A (67.62) is better than Ligand B (29.12). While not a CNS target, some peripheral GPCRs benefit from limited BBB penetration to avoid off-target effects.
* **Caco-2:** Ligand A (-4.762) is better than Ligand B (-5.194). Higher values indicate better absorption.
* **Solubility:** Ligand A (-4.052) is better than Ligand B (-1.714). Higher solubility is generally preferred.
* **hERG:** Both are very low (0.35 and 0.082), indicating minimal hERG inhibition risk.
* **Cl_mic:** Ligand B (36.06) has slightly better metabolic stability (lower clearance) than Ligand A (32.91).
* **t1/2:** Ligand A (44.44) has a much longer half-life than Ligand B (7.18). This is a significant advantage for A, potentially allowing for less frequent dosing.
* **Pgp:** Ligand A (0.092) is better than Ligand B (0.029). Lower Pgp efflux is desirable for better bioavailability.
* **Binding Affinity:** Ligand A (-6.1 kcal/mol) is slightly better than Ligand B (-5.8 kcal/mol). While both are good, the small advantage to A is noteworthy.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical parameters, especially logP, TPSA, QED, BBB, solubility, half-life, and Pgp efflux. While Ligand B has a lower DILI risk, the overall profile of Ligand A is more favorable for a GPCR drug candidate. The better logP and TPSA of Ligand A are crucial for membrane permeability and receptor engagement. The longer half-life is also a significant advantage.
**Output:**
1
2025-04-17 18:16:25,908 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (362.5 and 344.5 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (70.4) is higher than Ligand B (50.2). While both are below the 140 threshold for oral absorption, the lower TPSA of Ligand B is preferable for a GPCR, potentially aiding membrane permeability.
**3. logP:** Both ligands have good logP values (3.32 and 2.90), falling within the optimal 1-3 range. Ligand B is slightly lower, which could be beneficial for solubility.
**4. H-Bond Donors:** Ligand A has 2 HBD, Ligand B has 1. Both are acceptable (<=5).
**5. H-Bond Acceptors:** Ligand A has 5 HBA, Ligand B has 4. Both are acceptable (<=10).
**6. QED:** Both ligands have very similar and good QED values (0.827 and 0.836), indicating good drug-like properties.
**7. DILI Risk:** Ligand A (28.3) has a slightly higher DILI risk than Ligand B (23.2), but both are well below the concerning threshold of 60.
**8. BBB Penetration:** Ligand A (83.2) shows significantly better BBB penetration than Ligand B (58.8). While ADRB2 is primarily a cardiovascular target, some CNS effects are possible with beta-blockers, and better BBB penetration isn't necessarily a negative.
**9. Caco-2 Permeability:** Ligand A (-5.212) has worse Caco-2 permeability than Ligand B (-4.753). This suggests Ligand B might have better intestinal absorption.
**10. Aqueous Solubility:** Both ligands have poor aqueous solubility (-2.288 and -2.996). This is a concern for both and would require formulation strategies.
**11. hERG Inhibition:** Ligand A (0.768) has a slightly higher hERG risk than Ligand B (0.399). Lower hERG risk is crucial for cardiovascular drugs.
**12. Microsomal Clearance:** Ligand A (9.18) has significantly lower microsomal clearance than Ligand B (42.69). This suggests better metabolic stability for Ligand A.
**13. In vitro Half-Life:** Ligand A (15.6) has a longer in vitro half-life than Ligand B (10.0). This is a positive attribute.
**14. P-gp Efflux:** Both ligands have low P-gp efflux (0.196 and 0.186), which is favorable.
**15. Binding Affinity:** Ligand B (-6.7 kcal/mol) has a stronger binding affinity than Ligand A (-5.9 kcal/mol). This is a substantial difference (0.8 kcal/mol), and is a major advantage.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand B is the more promising candidate. The stronger binding affinity (-6.7 vs -5.9 kcal/mol) is a significant advantage that outweighs the slightly lower BBB penetration and higher metabolic clearance. Ligand B also has a lower hERG risk and better Caco-2 permeability. While both have poor solubility, this is a formulation challenge that can be addressed.
Output:
0
2025-04-17 18:16:25,908 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (351.4 & 370.5 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand B (93.09) is significantly better than Ligand A (125.35). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (1.837) is within the optimal range (1-3), while Ligand A (-0.916) is below 1, which could hinder permeation. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (4) is slightly higher than Ligand B (2), but both are acceptable (<=5).
5. **HBA:** Ligand A (6) is slightly higher than Ligand B (5), but both are acceptable (<=10).
6. **QED:** Ligand B (0.649) is better than Ligand A (0.451), indicating a more drug-like profile.
7. **DILI:** Both ligands have low DILI risk (Ligand A: 39.2%, Ligand B: 34.2%), both below the 40% threshold. No clear advantage.
8. **BBB:** Ligand B (42.9%) has a higher BBB percentile than Ligand A (24.4%). While not a primary concern for a cardiovascular target, it's a slight positive for Ligand B.
9. **Caco-2:** Both ligands have similar, poor Caco-2 permeability (-5.187 and -5.291). This is a concern for both.
10. **Solubility:** Both ligands have very poor aqueous solubility (-1.477 and -1.978). This is a significant drawback for both.
11. **hERG:** Ligand A (0.075) has a slightly lower hERG risk than Ligand B (0.522), which is preferable.
12. **Cl_mic:** Ligand A (1.256) has a much lower microsomal clearance than Ligand B (22.317), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand B (-39.138) has a much longer in vitro half-life than Ligand A (-8.349). This is a major advantage for Ligand B.
14. **Pgp:** Ligand A (0.007) has a lower Pgp efflux liability than Ligand B (0.048), which is preferable.
15. **Binding Affinity:** Ligand B (-6.2) has a slightly better binding affinity than Ligand A (-4.2). This is a significant advantage for Ligand B.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP and affinity, and has a better TPSA. Ligand A has better Pgp efflux liability.
**Overall Assessment:**
Ligand B has a significantly better binding affinity and a longer half-life, which are crucial for *in vivo* efficacy. While its solubility and Caco-2 permeability are poor, these can potentially be addressed through formulation strategies. The better logP and TPSA also favor Ligand B. Ligand A's lower clearance is good, but the weaker binding and lower logP are more concerning. The slightly better hERG and Pgp for Ligand A are not enough to overcome the binding and logP deficiencies.
Output:
0
2025-04-17 18:16:25,908 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [346.402, 49.85, 1.977, 0, 3, 0.766, 42.846, 83.288, -4.091, -2.422, 0.603, 35.213, -31.614, 0.381, -5.7]
**Ligand B:** [343.402, 71.09, 2.581, 2, 3, 0.876, 63.668, 73.866, -4.737, -3.461, 0.507, 71.687, -14.686, 0.185, -7.7]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). A is 346.4, B is 343.4 - very similar.
2. **TPSA:** A (49.85) is excellent, well below the 140 threshold and good for oral absorption. B (71.09) is higher, but still acceptable, though less optimal.
3. **logP:** A (1.977) is optimal. B (2.581) is also good, but slightly higher.
4. **HBD:** A (0) is good, minimizing potential issues. B (2) is acceptable.
5. **HBA:** Both A (3) and B (3) are good.
6. **QED:** Both A (0.766) and B (0.876) are excellent, indicating good drug-like properties. B is slightly better here.
7. **DILI:** A (42.846) is very good, low risk. B (63.668) is higher, indicating a moderate risk, but still not alarming.
8. **BBB:** A (83.288) is excellent, suggesting good potential for CNS penetration if desired (though ADRB2 is primarily cardiovascular, some CNS effects are possible). B (73.866) is also good, but lower.
9. **Caco-2:** Both are negative, indicating poor permeability. A (-4.091) is slightly better than B (-4.737).
10. **Solubility:** Both are negative, indicating poor solubility. A (-2.422) is slightly better than B (-3.461).
11. **hERG:** Both are very low (A: 0.603, B: 0.507), indicating minimal cardiotoxicity risk.
12. **Cl_mic:** A (35.213) is lower, suggesting better metabolic stability. B (71.687) is significantly higher, indicating faster metabolism.
13. **t1/2:** A (-31.614) is much longer (more negative) than B (-14.686), indicating a longer half-life.
14. **Pgp:** A (0.381) is lower, suggesting less P-gp efflux. B (0.185) is even lower, suggesting even less P-gp efflux.
15. **Affinity:** B (-7.7) is significantly stronger than A (-5.7) - a difference of 2 kcal/mol, which is substantial.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, affinity, logP, TPSA, and Pgp are crucial. While BBB isn't paramount for a cardiovascular target, it's still a consideration.
**Decision:**
The significantly stronger binding affinity of Ligand B (-7.7 kcal/mol vs. -5.7 kcal/mol) is a major advantage. This 2 kcal/mol difference can often outweigh minor ADME deficiencies. While Ligand A has better metabolic stability (lower Cl_mic, longer t1/2) and a slightly better DILI score, the increased potency of Ligand B is more critical for a GPCR target. The TPSA of Ligand A is better, but Ligand B is still within an acceptable range. Both have poor Caco-2 and solubility, which would need to be addressed in formulation.
Therefore, I prefer Ligand B.
Output:
0
2025-04-17 18:16:25,908 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
The target is ADRB2, a GPCR. Therefore, priorities are logP, Pgp, TPSA, affinity, and to a lesser extent, BBB.
Let's compare the ligands property by property:
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (346.39) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (115.65) is better than Ligand B (123.42), being closer to the <140 threshold for good absorption.
3. **logP:** Ligand B (0.737) is better than Ligand A (-0.528). A logP between 1-3 is optimal, and Ligand B is closer to this range. Ligand A's negative logP is a concern for permeability.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (2), but both are acceptable.
5. **HBA:** Ligand B (7) is higher than Ligand A (6), but both are within the acceptable range of <=10.
6. **QED:** Both are very similar and good (0.678 and 0.704).
7. **DILI:** Ligand A (56.96) is significantly better than Ligand B (85.50), indicating a much lower risk of liver injury. This is a major advantage for Ligand A.
8. **BBB:** Ligand B (43.82) is better than Ligand A (18.34), but BBB isn't a primary concern for ADRB2 unless targeting CNS effects.
9. **Caco-2:** Both are very poor (-5.363 and -5.008). This is a significant drawback for both compounds.
10. **Solubility:** Both are very poor (-1.312 and -2.966). This is a significant drawback for both compounds.
11. **hERG:** Both are very low risk (0.094 and 0.142).
12. **Cl_mic:** Ligand A (-14.30) has much better metabolic stability (lower clearance) than Ligand B (60.65). This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (13.90) has a better in vitro half-life than Ligand B (-23.99).
14. **Pgp:** Ligand A (0.005) has significantly lower P-gp efflux than Ligand B (0.062), which is a major advantage for bioavailability.
15. **Affinity:** Ligand A (-8.2) has a substantially better binding affinity than Ligand B (-6.1). This is a crucial factor, as a >1.5 kcal/mol difference can outweigh other issues.
**Overall Assessment:**
Ligand A is the better candidate. While both have poor Caco-2 and solubility, Ligand A has a significantly stronger binding affinity, better metabolic stability (lower Cl_mic and better t1/2), lower P-gp efflux, and a much lower DILI risk. The superior affinity and safety profile outweigh Ligand B's slightly better logP and BBB penetration.
**Output:**
1
2025-04-17 18:16:25,908 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (367.515 and 362.905 Da) are within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (80.2) is higher than Ligand B (52.23). For a cardiovascular GPCR, TPSA is moderately important. Ligand B is better here.
3. **logP:** Ligand A (1.568) is within the optimal range (1-3). Ligand B (4.126) is slightly above, potentially leading to solubility issues and off-target effects. Ligand A is better.
4. **HBD:** Both ligands have acceptable HBD counts (2 and 1, respectively), well below the threshold of 5. No clear advantage.
5. **HBA:** Both ligands have acceptable HBA counts (4 and 3, respectively), well below the threshold of 10. No clear advantage.
6. **QED:** Both ligands have good QED scores (0.768 and 0.87), indicating good drug-likeness. No clear advantage.
7. **DILI:** Ligand A (25.087%) has a significantly lower DILI risk than Ligand B (45.328%). This is a crucial advantage.
8. **BBB:** Both ligands have reasonably good BBB penetration (69.058% and 72.78%), but for a cardiovascular target, BBB isn't a primary concern. Ligand B is slightly better.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual. This suggests poor permeability. However, the values are close enough to not be a deciding factor.
10. **Solubility:** Ligand A (-2.502) has better solubility than Ligand B (-4.573). This is important for bioavailability.
11. **hERG:** Ligand A (0.251) has a lower hERG inhibition liability than Ligand B (0.928), reducing the risk of cardiotoxicity. This is a significant advantage.
12. **Cl_mic:** Ligand A (31.59) has lower microsomal clearance than Ligand B (76.856), suggesting better metabolic stability. This is a key advantage.
13. **t1/2:** Ligand B (70.202) has a longer in vitro half-life than Ligand A (15.352). This is a positive for Ligand B.
14. **Pgp:** Ligand A (0.036) has lower P-gp efflux liability than Ligand B (0.617), improving bioavailability. This is a good advantage.
15. **Binding Affinity:** Both ligands have comparable binding affinities (-5.2 and -5.0 kcal/mol). The difference is not substantial enough to outweigh other factors.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), and the general drug-like properties, Ligand A emerges as the more promising candidate. While Ligand B has a slightly better half-life and BBB penetration, Ligand A excels in crucial areas like DILI risk, hERG inhibition, metabolic stability (Cl_mic), solubility, and P-gp efflux. The slightly higher TPSA of Ligand A is a minor drawback compared to the significant advantages it offers in safety and pharmacokinetic properties.
Output:
1
2025-04-17 18:16:25,908 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (364.511 Da) is slightly higher than Ligand B (350.419 Da), but both are acceptable.
2. **TPSA:** Ligand A (58.64) is significantly better than Ligand B (97.56). A TPSA under 140 is good for oral absorption, but lower is generally preferred for GPCRs, and Ligand A is much closer to the ideal range for good permeability.
3. **logP:** Both ligands have good logP values (A: 1.948, B: 1.072), falling within the optimal 1-3 range. Ligand A is slightly more lipophilic, which could be beneficial for membrane permeability.
4. **HBD:** Both have 1 HBD, which is acceptable.
5. **HBA:** Ligand A has 4 HBA, while Ligand B has 6. Both are within the acceptable limit of 10, but Ligand A is preferable.
6. **QED:** Both ligands have reasonable QED scores (A: 0.832, B: 0.705), indicating good drug-like properties. Ligand A is slightly better.
7. **DILI:** Both ligands have low DILI risk (A: 36.293, B: 35.867), both well below the 40% threshold.
8. **BBB:** Ligand B (77.2) has a better BBB penetration score than Ligand A (61.613). However, ADRB2 is primarily a cardiovascular target, so high BBB penetration isn't *critical* but still a plus.
9. **Caco-2:** Ligand A (-5.229) and Ligand B (-4.802) both have negative Caco-2 values, which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand A (-3.142) has slightly better solubility than Ligand B (-1.629), but both are poor.
11. **hERG:** Both ligands have very low hERG inhibition risk (A: 0.232, B: 0.1), which is excellent.
12. **Cl_mic:** Ligand A (45.216) has a lower microsomal clearance than Ligand B (59.023), indicating better metabolic stability.
13. **t1/2:** Ligand B (-5.847) has a negative in vitro half-life, which is concerning. Ligand A (8.571) has a reasonable half-life.
14. **Pgp:** Both ligands have low P-gp efflux liability (A: 0.112, B: 0.049).
15. **Binding Affinity:** Ligand B (-7.2) has a slightly better binding affinity than Ligand A (-7.0), but the difference is small (0.2 kcal/mol).
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, TPSA, logP, and metabolic stability are key. Ligand A excels in TPSA and Cl_mic, and has a reasonable logP. While Ligand B has slightly better affinity and BBB penetration, the significantly higher TPSA and poorer metabolic stability are concerning. The negative Caco-2 values for both are problematic, but the other advantages of Ligand A outweigh the small affinity difference.
**Conclusion:**
Considering the balance of properties, and prioritizing TPSA, metabolic stability, and a reasonable half-life for a cardiovascular target, Ligand A is the more promising candidate.
Output:
1
2025-04-17 18:16:25,909 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
The target is ADRB2, a GPCR. Therefore, I will prioritize logP, TPSA, Pgp efflux, BBB penetration, and binding affinity, while also considering overall drug-likeness and safety parameters.
**Ligand A:**
* **MW:** 391.295 Da - Acceptable.
* **TPSA:** 75.71 - Acceptable, though approaching the upper limit for good absorption.
* **logP:** 2.019 - Excellent. Within the optimal range.
* **HBD:** 1 - Good.
* **HBA:** 4 - Good.
* **QED:** 0.588 - Good, above the 0.5 threshold.
* **DILI:** 31.563 - Excellent, very low risk.
* **BBB:** 65.801 - Moderate. Not ideal for a CNS target, but ADRB2 isn't necessarily a CNS target.
* **Caco-2:** -5 - Very poor permeability. A significant drawback.
* **Solubility:** -3.076 - Very poor solubility. A significant drawback.
* **hERG:** 0.261 - Low risk.
* **Cl_mic:** 20.659 - Moderate clearance.
* **t1/2:** -11.934 - Very short half-life. A significant drawback.
* **Pgp:** 0.056 - Low efflux. Good.
* **Affinity:** -6.5 kcal/mol - Good binding affinity.
**Ligand B:**
* **MW:** 358.467 Da - Acceptable.
* **TPSA:** 88.32 - Approaching the upper limit for good absorption.
* **logP:** 2.042 - Excellent. Within the optimal range.
* **HBD:** 2 - Good.
* **HBA:** 4 - Good.
* **QED:** 0.828 - Excellent, very drug-like.
* **DILI:** 58.666 - Moderate risk, but still acceptable.
* **BBB:** 78.247 - Good. Better than Ligand A.
* **Caco-2:** -4.873 - Poor permeability, but better than Ligand A.
* **Solubility:** -2.571 - Poor solubility, but better than Ligand A.
* **hERG:** 0.266 - Low risk.
* **Cl_mic:** 26.933 - Moderate clearance.
* **t1/2:** -21.197 - Very short half-life. A significant drawback, but worse than Ligand A.
* **Pgp:** 0.14 - Low efflux. Good.
* **Affinity:** -6.3 kcal/mol - Good binding affinity, slightly weaker than Ligand A.
**Comparison and Decision:**
Both ligands have similar binding affinities and acceptable logP values. Both also have poor solubility and permeability. However, Ligand A has a significantly better DILI score, and a slightly better affinity. Ligand B has a better BBB score, and a slightly better QED. The biggest difference lies in the Caco-2 permeability and in vitro half-life, where Ligand A is significantly worse.
Given the importance of metabolic stability (half-life) and absorption (Caco-2) for *in vivo* efficacy, and the fact that the difference in binding affinity is relatively small (0.2 kcal/mol), I believe Ligand B is the more promising candidate, despite its slightly higher DILI risk. The better BBB penetration is also a plus. While both have issues with solubility and permeability, these can be addressed through formulation strategies.
**Output:**
0
2025-04-17 18:16:25,909 - INFO - Batch 25 complete. Total preferences: 400
2025-04-17 18:16:25,909 - INFO - Processing batch 26/512...
2025-04-17 18:17:13,974 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
We're targeting ADRB2, a GPCR, so the priorities are logP, TPSA, Pgp efflux, BBB penetration, and binding affinity. Let's break down each ligand against these and other important parameters.
* **Molecular Weight:** Both ligands are within the acceptable 200-500 Da range. Ligand A (356.463 Da) is slightly lower, which is generally favorable for permeability.
* **TPSA:** Ligand A (79.31) is significantly better than Ligand B (117.09). A TPSA under 140 is good for oral absorption, but lower is better, especially for GPCRs. Ligand A is much closer to the ideal range for good absorption.
* **logP:** Ligand A (0.504) is a bit low, potentially hindering membrane permeability. Ligand B (0.126) is even lower, raising more concern. Both are below the optimal 1-3 range, but Ligand A is better.
* **H-Bond Donors/Acceptors:** Ligand A (1 HBD, 5 HBA) is more favorable than Ligand B (3 HBD, 6 HBA). Fewer hydrogen bonds generally improve permeability.
* **QED:** Both ligands have reasonable QED values (A: 0.685, B: 0.523), indicating acceptable drug-likeness.
* **DILI Risk:** Ligand A (23.924) has a much lower DILI risk than Ligand B (43.66). This is a significant advantage for Ligand A.
* **BBB Penetration:** Ligand A (38.852) has better BBB penetration than Ligand B (43.273), though both are relatively low. BBB isn't a *primary* concern for ADRB2 (a cardiovascular target), but it's still a positive for A.
* **Caco-2 Permeability:** Ligand A (-4.379) has better Caco-2 permeability than Ligand B (-5.409).
* **Aqueous Solubility:** Ligand A (-0.664) has better aqueous solubility than Ligand B (-1.83).
* **hERG Inhibition:** Both ligands have low hERG inhibition risk (A: 0.408, B: 0.379), which is good.
* **Microsomal Clearance:** Ligand A (31.649) has higher microsomal clearance than Ligand B (10.059), meaning it's metabolized faster, which is less desirable.
* **In vitro Half-Life:** Both ligands have similar in vitro half-lives (A: 5.361, B: 5.639).
* **P-gp Efflux:** Both ligands have low P-gp efflux (A: 0.162, B: 0.064).
* **Binding Affinity:** Ligand B (-7.0) has a slightly better binding affinity than Ligand A (-5.9). However, the difference is 1.1 kcal/mol, which isn't large enough to overcome the significant ADME advantages of Ligand A.
**Overall Assessment:**
Ligand A presents a much more balanced profile. While its logP is a bit low, it's offset by significantly better TPSA, DILI risk, solubility, and Caco-2 permeability. Ligand B's higher TPSA and DILI risk are major drawbacks. The slightly better binding affinity of Ligand B is not enough to compensate for these issues.
**Output:**
1
2025-04-17 18:17:13,974 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (370.471 Da) is slightly higher than Ligand B (343.471 Da), but both are acceptable.
2. **TPSA:** Ligand A (92.78) is slightly higher than the preferred <140, while Ligand B (54.34) is well within the range. For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally better for permeability.
3. **logP:** Ligand A (0.43) is a bit low, potentially hindering membrane permeability. Ligand B (2.544) is within the optimal 1-3 range. This is a significant advantage for Ligand B.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 5 HBA, acceptable. Ligand B has 3 HBA, also acceptable.
6. **QED:** Both ligands have good QED scores (A: 0.685, B: 0.774), indicating generally drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (39.24) has a slightly higher DILI risk than Ligand B (15.045). Ligand B is preferable here.
8. **BBB:** Both have acceptable BBB penetration, but Ligand B (78.907) is better than Ligand A (69.135). While ADRB2 isn't a CNS target, some peripheral exposure is still desirable, and higher BBB penetration often correlates with better overall distribution.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
10. **Solubility:** Both have negative solubility values, indicating poor aqueous solubility. Again, the scale is not specified, making interpretation difficult.
11. **hERG:** Both have very low hERG inhibition risk (A: 0.071, B: 0.243), which is excellent.
12. **Cl_mic:** Ligand A (0.804) has significantly lower microsomal clearance than Ligand B (32.791), suggesting better metabolic stability. This is a major advantage for Ligand A.
13. **t1/2:** Ligand A (3.594) has a slightly shorter in vitro half-life than Ligand B (3.74), but the difference is minimal.
14. **Pgp:** Both ligands have low P-gp efflux liability (A: 0.055, B: 0.091), which is good.
15. **Binding Affinity:** Ligand B (-6.6 kcal/mol) has a slightly stronger binding affinity than Ligand A (-6.3 kcal/mol). This is a positive for Ligand B, but the difference is relatively small.
**GPCR-specific priorities:**
For ADRB2 (a cardiovascular GPCR), logP, Pgp, TPSA, and affinity are key. Ligand B excels in logP and has better TPSA and BBB penetration. The affinity difference is small. Ligand A has a significant advantage in metabolic stability (Cl_mic), but the slightly lower affinity and logP are concerning.
**Overall Assessment:**
Considering the balance of properties, Ligand B appears to be the more promising candidate. Its better logP, lower DILI risk, slightly better BBB penetration, and slightly stronger binding affinity outweigh the advantage of Ligand A's lower microsomal clearance. The solubility and Caco-2 values are concerning for both, but these can be addressed through formulation strategies.
Output:
0
2025-04-17 18:17:13,974 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (348.334) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (63.91) is significantly better than Ligand A (117.35). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (3.829) is higher than Ligand A (1.169), but still within the acceptable range. Ligand A is a bit low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (3) is higher than Ligand B (0). While not drastically different, fewer HBDs are generally preferred for better permeability.
5. **HBA:** Both ligands have the same number of HBA (6), which is acceptable.
6. **QED:** Ligand A (0.721) has a slightly better QED score than Ligand B (0.635), indicating a more drug-like profile.
7. **DILI:** Ligand B (53.276) has a lower DILI risk than Ligand A (66.344), which is a significant advantage.
8. **BBB:** Ligand B (83.017) has a much higher BBB penetration score than Ligand A (56.883). While not a primary concern for a cardiovascular target, it doesn't hurt.
9. **Caco-2:** Ligand B (-5.298) has a more negative Caco-2 value than Ligand A (-4.788), suggesting better permeability.
10. **Solubility:** Both ligands have similar and very poor aqueous solubility (-3.417 and -3.446). This is a concern for both.
11. **hERG:** Ligand A (0.075) has a slightly lower hERG risk than Ligand B (0.43), which is preferable.
12. **Cl_mic:** Ligand B (81.055) has a significantly higher microsomal clearance than Ligand A (27.847), indicating faster metabolism and lower metabolic stability. This is a major drawback for Ligand B.
13. **t1/2:** Ligand B (33.868) has a much longer in vitro half-life than Ligand A (-18.58). This is a major advantage for Ligand B.
14. **Pgp:** Ligand B (0.833) has higher P-gp efflux than Ligand A (0.022), which is unfavorable.
15. **Binding Affinity:** Ligand A (-6.7) has a slightly better binding affinity than Ligand B (-5.1). This is a good advantage for Ligand A.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B has better logP, TPSA, and Caco-2 permeability. Ligand A has better affinity and Pgp efflux. The metabolic stability (Cl_mic) is a significant concern for Ligand B.
**Overall Assessment:**
Ligand B has several advantages (lower DILI, better BBB, longer half-life, better permeability, better logP and TPSA), but its high microsomal clearance is a major concern. Ligand A has better affinity and lower Pgp efflux, but suffers from lower logP and higher DILI risk. Given the importance of metabolic stability for *in vivo* efficacy, and the fact that the affinity difference isn't massive, I lean towards Ligand A. The solubility is a concern for both, but can be addressed through formulation strategies.
Output:
1
2025-04-17 18:17:13,975 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (355.429 and 352.519 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (58.22) is slightly higher than Ligand B (49.85). Both are well below the 140 threshold for oral absorption, and suitable for a GPCR target. Ligand B is preferable.
3. **logP:** Both ligands have good logP values (3.161 and 2.589), falling within the 1-3 optimal range. Ligand A is slightly higher, which could potentially lead to off-target effects, but the difference is not substantial.
4. **HBD:** Ligand A has 1 HBD, while Ligand B has 0. Both are acceptable.
5. **HBA:** Ligand A has 3 HBA, and Ligand B has 4. Both are below the 10 threshold.
6. **QED:** Ligand A (0.853) has a significantly better QED score than Ligand B (0.606), indicating a more drug-like profile. This is a strong advantage for Ligand A.
7. **DILI:** Ligand B (2.171) has a much lower DILI risk than Ligand A (37.03). This is a major advantage for Ligand B.
8. **BBB:** Both ligands have high BBB penetration (87.088 and 86.468), which is good, but not critically important for ADRB2 as it's not a CNS target.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.707 and -4.47). This is unusual and suggests poor permeability. However, these values are on a scale where negative values are possible, and the absolute difference is small.
10. **Solubility:** Ligand B (-0.963) has better solubility than Ligand A (-3.02). Better solubility is generally desirable.
11. **hERG:** Both ligands have low hERG inhibition liability (0.63 and 0.614). No significant difference.
12. **Cl_mic:** Ligand B (17.672) has a significantly lower microsomal clearance than Ligand A (33.514), indicating better metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand B (-9.277) has a longer in vitro half-life than Ligand A (-7.928). This is preferable.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.158 and 0.041). No significant difference.
15. **Binding Affinity:** Ligand B (-6.8 kcal/mol) has slightly better binding affinity than Ligand A (-6.1 kcal/mol). While the difference is less than the 1.5 kcal/mol threshold, it's still a positive for Ligand B.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand B performs better on logP, TPSA, and affinity. While both have good Pgp profiles, Ligand A's higher QED is a positive. However, the significantly lower DILI risk and improved metabolic stability (lower Cl_mic and longer t1/2) of Ligand B are more critical for overall drug development success.
**Conclusion:**
Considering the balance of properties, especially the lower DILI risk, better metabolic stability, and slightly better affinity of Ligand B, it is the more promising drug candidate.
Output:
0
2025-04-17 18:17:13,975 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [349.475, 69.72, 1.542, 1, 3, 0.837, 9.849, 67.933, -4.882, -1.969, 0.312, 14.379, -5.234, 0.034, -6.9]
**Ligand B:** [346.431, 95.16, 0.715, 2, 4, 0.742, 45.522, 35.091, -4.925, -1.839, 0.185, 11.921, -21.568, 0.013, -8.3]
Here's a breakdown, considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal range (200-500 Da). A is 349.475, B is 346.431. Very similar.
2. **TPSA:** Ligand A (69.72) is significantly better than Ligand B (95.16). A is well below the 140 threshold for oral absorption, while B is approaching it.
3. **logP:** Ligand A (1.542) is optimal. Ligand B (0.715) is a bit low, potentially hindering permeability.
4. **HBD/HBA:** A (1/3) is preferable to B (2/4). Lower counts generally improve permeability.
5. **QED:** Both are reasonable (A: 0.837, B: 0.742), indicating good drug-like properties. A is slightly better.
6. **DILI:** Ligand A (9.849) has a much lower DILI risk than Ligand B (45.522). This is a significant advantage for A.
7. **BBB:** Ligand A (67.933) is better than Ligand B (35.091), although neither is exceptionally high. For a cardiovascular target, BBB isn't *critical*, but higher is still generally preferred.
8. **Caco-2:** Both are negative, suggesting poor permeability. This is a concern for both.
9. **Solubility:** Both are negative, suggesting poor solubility. This is a concern for both.
10. **hERG:** Both are very low (A: 0.312, B: 0.185), indicating low cardiotoxicity risk. B is slightly better.
11. **Cl_mic:** Ligand A (14.379) has a higher clearance than Ligand B (11.921), meaning it's metabolized faster. This is a negative for A.
12. **t1/2:** Ligand B (-21.568) has a significantly longer half-life than Ligand A (-5.234). This is a major advantage for B.
13. **Pgp:** Both are very low (A: 0.034, B: 0.013), indicating minimal P-gp efflux. B is slightly better.
14. **Affinity:** Ligand B (-8.3 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.9 kcal/mol). This is a substantial advantage for B, exceeding the 1.5 kcal/mol threshold.
**Overall Assessment:**
While Ligand A has advantages in TPSA, DILI, and QED, the significantly stronger binding affinity of Ligand B (-8.3 vs -6.9 kcal/mol) and its longer half-life are compelling. The lower logP of Ligand B is a concern, but the superior affinity is likely to outweigh this. The DILI risk for Ligand A is very good, but the difference isn't large enough to overcome the potency and PK benefits of Ligand B.
Therefore, I favor Ligand B.
Output:
0
2025-04-17 18:17:13,975 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
The ADRB2 receptor is a GPCR involved in cardiovascular function. Therefore, the priorities are logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB penetration. Let's compare the ligands step-by-step:
1. **MW:** Both ligands (347.46 and 349.48 Da) fall comfortably within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (83.22) is slightly higher than Ligand B (69.72). Both are below the 140 threshold for oral absorption, but Ligand B is preferable due to its lower value.
3. **logP:** Both ligands have good logP values (1.788 and 1.564), falling within the optimal 1-3 range. Ligand B is slightly better.
4. **HBD:** Ligand A has 3 HBD, while Ligand B has 1. Lower HBD is generally preferred for better permeability, giving an edge to Ligand B.
5. **HBA:** Both ligands have 3 HBA, which is acceptable.
6. **QED:** Both ligands have good QED scores (0.596 and 0.621), indicating good drug-likeness.
7. **DILI:** Ligand B (27.142) has a significantly lower DILI risk than Ligand A (38.813). This is a substantial advantage for Ligand B.
8. **BBB:** Ligand B (74.486) has a better BBB penetration score than Ligand A (47.421). While not a primary concern for a cardiovascular target, it's a positive attribute.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and likely indicates a problem with the scale used. We can't reliably compare them on this parameter.
10. **Solubility:** Ligand B (-1.977) has better solubility than Ligand A (-3.071).
11. **hERG:** Ligand B (0.087) has a much lower hERG inhibition liability than Ligand A (0.5). This is a critical advantage, as hERG inhibition can lead to cardiotoxicity.
12. **Cl_mic:** Ligand B (29.253) has a slightly higher microsomal clearance than Ligand A (26.833), meaning Ligand A is more metabolically stable.
13. **t1/2:** Ligand A (-15.975) has a slightly longer in vitro half-life than Ligand B (-14.394).
14. **Pgp:** Ligand B (0.014) has a much lower P-gp efflux liability than Ligand A (0.193). This is a significant advantage for bioavailability.
15. **Binding Affinity:** Ligand A (-6.1 kcal/mol) has a significantly stronger binding affinity than Ligand B (-1.7 kcal/mol). This is a major advantage for Ligand A.
**Overall Assessment:**
Ligand A has a much stronger binding affinity, which is a crucial factor. However, Ligand B excels in almost all ADME-Tox properties: lower DILI risk, better BBB penetration, improved solubility, significantly lower hERG inhibition, and lower P-gp efflux. The difference in binding affinity is substantial (4.4 kcal/mol), but the ADME profile of Ligand A is concerning, especially the hERG risk. While the higher affinity of Ligand A is attractive, the overall risk profile of Ligand B makes it a more promising starting point for drug development. The affinity of Ligand B could be improved through further optimization.
Output:
0
2025-04-17 18:17:13,975 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (358.41 and 362.455 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (95.94) is slightly higher than Ligand B (91.4). Both are below the 140 threshold for good oral absorption, but closer to the 90 threshold for CNS targets (though ADRB2 isn't necessarily a CNS target). Ligand B is slightly preferred.
3. **logP:** Both ligands (0.544 and 0.636) are a bit low, ideally we'd like to be between 1-3. This could potentially hinder membrane permeability. Ligand B is marginally better.
4. **HBD:** Both ligands have 2 H-bond donors, which is within the acceptable limit of 5. No difference.
5. **HBA:** Both ligands have 5 H-bond acceptors, also within the acceptable limit of 10. No difference.
6. **QED:** Ligand B (0.825) has a better QED score than Ligand A (0.7), indicating a more drug-like profile. This is a positive for Ligand B.
7. **DILI:** Ligand B (42.187) has a significantly lower DILI risk than Ligand A (21.171). This is a major advantage for Ligand B, as minimizing liver toxicity is crucial.
8. **BBB:** Both ligands have similar BBB penetration (64.676 and 61.768). Since ADRB2 is primarily a cardiovascular target, BBB penetration isn't a primary concern, but it's good that neither is excessively high (which could lead to off-target effects).
9. **Caco-2:** Ligand B (-5.45) shows better Caco-2 permeability than Ligand A (-4.716), suggesting better intestinal absorption.
10. **Solubility:** Ligand B (-2.155) has better aqueous solubility than Ligand A (-1.368). Better solubility is generally desirable for bioavailability.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.193 and 0.143). This is excellent and minimizes cardiotoxicity concerns.
12. **Cl_mic:** Ligand B (-20.776) has a much lower microsomal clearance than Ligand A (11.516), indicating better metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand B (-5.241) has a better in vitro half-life than Ligand A (-18.57). This suggests a longer duration of action and potentially less frequent dosing.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.019 and 0.015). No significant difference.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-7.5 and -7.4 kcal/mol). The difference is negligible.
**Overall Assessment:**
Ligand B consistently outperforms Ligand A in several key ADME-Tox properties, including DILI risk, Caco-2 permeability, solubility, and especially metabolic stability (Cl_mic and t1/2). While both ligands have acceptable profiles, Ligand B's superior ADME properties, coupled with a slightly better QED score, make it the more promising drug candidate for the ADRB2 receptor. The binding affinity is essentially the same, so the ADME advantages of Ligand B are decisive.
Output:
0
2025-04-17 18:17:13,975 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [338.367, 89.01, 1.227, 2, 5, 0.749, 69.678, 35.052, -5.538, -2.959, 0.48, -0.33, -2.357, 0.114, -6.4]
**Ligand B:** [351.451, 88.49, -0.04, 2, 6, 0.652, 15.2, 66.344, -5.192, -1.086, 0.093, 19.254, 11.711, 0.003, -8.4]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity, and BBB):
1. **MW:** Both are within the ideal 200-500 Da range. Ligand A (338.367) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are excellent, below 140 and reasonably close to the 90 threshold. Ligand A (89.01) is marginally better.
3. **logP:** Ligand A (1.227) is optimal, while Ligand B (-0.04) is slightly below 1. This is a significant drawback for B as it might struggle with membrane permeability.
4. **HBD/HBA:** Both have acceptable HBD (2) and HBA (5/6) counts.
5. **QED:** Both are above 0.5, indicating good drug-likeness, but Ligand A (0.749) is better than Ligand B (0.652).
6. **DILI:** Ligand A (69.678) has a higher DILI risk than Ligand B (15.2), which is a concern.
7. **BBB:** Ligand B (66.344) has a better BBB penetration score than Ligand A (35.052). This is a plus for B, but less critical for a non-CNS target like ADRB2.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-5.538) is slightly worse than Ligand B (-5.192).
9. **Solubility:** Both have negative solubility values, which is also unusual and suggests very poor solubility. Ligand B (-1.086) is slightly better than Ligand A (-2.959).
10. **hERG:** Ligand A (0.48) has a slightly better hERG profile than Ligand B (0.093).
11. **Cl_mic:** Ligand A (-0.33) has a lower (better) microsomal clearance than Ligand B (19.254), indicating better metabolic stability.
12. **t1/2:** Ligand B (11.711) has a significantly longer in vitro half-life than Ligand A (-2.357).
13. **Pgp:** Ligand A (0.114) has lower P-gp efflux liability than Ligand B (0.003), which is favorable.
14. **Affinity:** Ligand B (-8.4) has a significantly stronger binding affinity than Ligand A (-6.4) - a difference of 2 kcal/mol. This is a major advantage.
**Overall Assessment:**
While Ligand A has some advantages in terms of logP, QED, and metabolic stability, the significantly stronger binding affinity of Ligand B (-8.4 vs -6.4) is a decisive factor. The 2 kcal/mol difference can often outweigh minor ADME drawbacks, especially for a GPCR target where potency is crucial. Although Ligand B has a lower logP and a higher Pgp efflux, the superior binding affinity makes it the more promising candidate. The improved half-life of Ligand B is also a positive. The DILI risk for Ligand A is a concern.
Output:
0
2025-04-17 18:17:13,975 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (356.3 and 344.459 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Both ligands (80.68 and 78.09) are below 140, suggesting good absorption potential. They are also reasonably low for a GPCR target, not requiring significant CNS penetration. No clear advantage.
3. **logP:** Both ligands have logP values (2.667 and 2.702) within the optimal 1-3 range. No clear advantage.
4. **HBD:** Both ligands have 2 HBD, which is within the acceptable limit of 5. No clear advantage.
5. **HBA:** Ligand A has 5 HBA, while Ligand B has 3. Both are below 10. No clear advantage.
6. **QED:** Ligand A (0.832) has a slightly higher QED than Ligand B (0.779), indicating a more drug-like profile. This is a minor advantage for A.
7. **DILI:** Ligand A (66.421) has a higher DILI risk than Ligand B (40.403). This is a significant advantage for B, as lower DILI is crucial.
8. **BBB:** Both ligands have reasonable BBB penetration (71.229 and 67.119). Since ADRB2 isn't primarily a CNS target, this isn't a major deciding factor.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.733 and -4.979), which is unusual and suggests poor permeability. However, the values are very similar.
10. **Solubility:** Both ligands have negative solubility values (-4.148 and -3.9). This is concerning, indicating poor aqueous solubility. The values are very similar.
11. **hERG:** Ligand A (0.55) has a slightly higher hERG risk than Ligand B (0.168), which is a significant advantage for B.
12. **Cl_mic:** Ligand A (23.34) has a significantly lower microsomal clearance than Ligand B (59.786), indicating better metabolic stability. This is a major advantage for A.
13. **t1/2:** Ligand A (-3.426) has a negative in vitro half-life, while Ligand B (-28.73) is even more negative. Both are very poor, but B is worse. This is a significant advantage for A.
14. **Pgp:** Ligand A (0.304) has lower P-gp efflux liability than Ligand B (0.103), which is a slight advantage for A.
15. **Binding Affinity:** Ligand A (-7.7 kcal/mol) has a significantly stronger binding affinity than Ligand B (-5.5 kcal/mol). This is a substantial advantage for A, potentially outweighing some ADME concerns.
**Overall Assessment:**
Ligand A has a significantly better binding affinity and metabolic stability (lower Cl_mic, better t1/2). While it has a higher DILI risk and slightly higher hERG risk, the substantial advantage in potency and metabolic stability are more important for a GPCR target like ADRB2. The solubility and Caco-2 values are poor for both, but can be addressed with formulation strategies. The difference in binding affinity is large enough to make Ligand A the more promising candidate.
Output:
1
2025-04-17 18:17:13,975 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (349.391 and 348.531 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (113.93) is higher than Ligand B (49.41). For a cardiovascular GPCR like ADRB2, TPSA isn't *as* critical as for CNS targets, but lower is generally preferred for permeability. Ligand B is significantly better.
3. **logP:** Ligand A (-0.834) is lower than the optimal 1-3 range, potentially hindering permeability. Ligand B (3.911) is very close to the upper limit but still acceptable. Ligand B is better.
4. **HBD:** Ligand A (2) and Ligand B (1) are both within the acceptable limit of 5. Ligand B is slightly better.
5. **HBA:** Ligand A (7) and Ligand B (2) are both within the acceptable limit of 10. Ligand B is significantly better.
6. **QED:** Both ligands have good QED scores (0.732 and 0.766). No significant difference.
7. **DILI:** Ligand A (40.364) has a slightly higher DILI risk than Ligand B (16.208). Ligand B is better.
8. **BBB:** Both ligands have good BBB penetration (78.054 and 73.711). Since ADRB2 is not a CNS target, this is less important, but Ligand A is slightly better.
9. **Caco-2:** Ligand A (-5.142) has a negative Caco-2 value, which is concerning. Ligand B (-4.37) is also negative, but less so. Both are poor, but Ligand B is slightly better.
10. **Solubility:** Ligand A (-1.602) has a slightly better solubility score than Ligand B (-4.415).
11. **hERG:** Both ligands have very low hERG inhibition risk (0.201 and 0.166). No significant difference.
12. **Cl_mic:** Ligand A (-12.609) has a much lower (better) microsomal clearance than Ligand B (79.523). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (-13.663) has a negative in vitro half-life, which is concerning. Ligand B (3.824) has a short half-life, but positive. Ligand B is better.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.001 and 0.071). No significant difference.
15. **Binding Affinity:** Ligand A (-6.6) has a significantly better binding affinity than Ligand B (-1.8). This is a substantial advantage.
**Overall Assessment:**
Ligand A has a significantly stronger binding affinity, and better metabolic stability (lower Cl_mic). However, it has a concerningly negative Caco-2 value and a negative in vitro half-life. Ligand B, while having a weaker binding affinity, has much better ADME properties (TPSA, logP, HBA, DILI, Caco-2, t1/2).
Given the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), the substantial affinity difference of Ligand A is a major advantage. While the ADME properties of Ligand A are suboptimal, they might be addressable through further medicinal chemistry optimization. The weaker affinity of Ligand B is a more difficult hurdle to overcome.
Therefore, I favor Ligand A.
Output:
1
2025-04-17 18:17:13,975 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (351.491 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (72.88) are below the 140 A^2 threshold for good oral absorption, and well below the 90 A^2 for CNS targets (though ADRB2 isn't necessarily a CNS target). No significant difference.
3. **logP:** Ligand A (0.985) is slightly lower than Ligand B (1.164), both are within the optimal 1-3 range.
4. **HBD:** Both ligands have 2 HBD, which is within the acceptable limit of <=5.
5. **HBA:** Both ligands have 4 HBA, which is within the acceptable limit of <=10.
6. **QED:** Ligand A (0.748) has a higher QED than Ligand B (0.533), indicating a more drug-like profile.
7. **DILI:** Ligand A (8.492 percentile) has a significantly lower DILI risk than Ligand B (19.504 percentile). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (32.726 percentile) has a higher BBB penetration than Ligand B (21.753 percentile). While not a primary concern for ADRB2, it's a slight positive for Ligand A.
9. **Caco-2:** Ligand A (-5.051) and Ligand B (-4.952) are similar in Caco-2 permeability, both indicating reasonable absorption.
10. **Solubility:** Ligand A (-1.824) has slightly worse solubility than Ligand B (-0.555).
11. **hERG:** Both ligands have very low hERG inhibition risk (0.461 and 0.31 respectively).
12. **Cl_mic:** Ligand A (6.787) has a higher microsomal clearance than Ligand B (-0.433), indicating lower metabolic stability. This is a negative for Ligand A.
13. **t1/2:** Ligand A (28.644) has a significantly longer in vitro half-life than Ligand B (-2.576). This is a major advantage for Ligand A.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.036 and 0.056 respectively).
15. **Binding Affinity:** Ligand B (-7.2 kcal/mol) has a stronger binding affinity than Ligand A (-6.5 kcal/mol). This is a significant advantage for Ligand B (a 0.7 kcal/mol difference).
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Both ligands perform reasonably well on logP, Pgp, and TPSA. The critical difference lies in affinity and ADME properties. Ligand B has a better affinity. However, Ligand A has a much better safety profile (DILI), longer half-life, and better BBB penetration. The difference in affinity (0.7 kcal/mol) is substantial, but the combination of improved safety, half-life, and DILI risk for Ligand A makes it the more promising candidate.
**Conclusion:**
Considering the balance of properties, particularly the lower DILI risk and longer half-life of Ligand A, despite the slightly weaker binding affinity, I believe Ligand A is the more viable drug candidate.
Output:
1
2025-04-17 18:17:13,976 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (337.427) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are reasonably low, but Ligand A (70.15) is better than Ligand B (78.95), increasing the likelihood of good oral absorption.
3. **logP:** Both ligands have good logP values (Ligand A: 2.506, Ligand B: 1.291), falling within the optimal 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Ligand A (2) has a slightly better HBD count than Ligand B (1), but both are acceptable.
5. **HBA:** Ligand A (5) and Ligand B (4) are both within the acceptable range.
6. **QED:** Both ligands have good QED scores (A: 0.9, B: 0.813), indicating good drug-like properties.
7. **DILI:** Ligand B (76.89) has a significantly higher DILI risk than Ligand A (60.76), making Ligand A safer.
8. **BBB:** Both have acceptable BBB penetration (A: 77.2, B: 70.299), but Ligand A is better. While ADRB2 isn't exclusively a CNS target, some peripheral effects are mediated by CNS pathways.
9. **Caco-2:** Both have negative Caco-2 values, suggesting poor permeability. This is concerning, but we must consider other factors.
10. **Solubility:** Both have negative solubility values, suggesting poor solubility.
11. **hERG:** Ligand A (0.718) has a slightly higher hERG risk than Ligand B (0.273), but both are relatively low.
12. **Cl_mic:** Ligand B (27.408) has significantly lower microsomal clearance than Ligand A (58.412), indicating better metabolic stability. This is a major advantage for Ligand B.
13. **t1/2:** Ligand A (7.405) has a longer half-life than Ligand B (-10.2), which is generally desirable. However, the negative value for B is concerning.
14. **Pgp:** Both ligands have low P-gp efflux liability (A: 0.122, B: 0.142).
15. **Binding Affinity:** Ligand A (-7.8 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.1 kcal/mol). This is a substantial advantage.
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are crucial. Ligand A excels in affinity and has favorable logP and TPSA values. Ligand B has better metabolic stability (Cl_mic), but its lower affinity and higher DILI risk are significant drawbacks. The strong binding affinity of Ligand A is a major advantage that can potentially offset its slightly higher clearance.
**Overall Assessment:**
Despite the better metabolic stability of Ligand B, the significantly stronger binding affinity of Ligand A, coupled with its lower DILI risk and better BBB penetration, makes it the more promising drug candidate. The negative Caco-2 and solubility values are concerning for both, but these can be addressed through formulation strategies. The potency advantage of Ligand A is likely to be more impactful than the metabolic stability advantage of Ligand B.
Output:
1
2025-04-17 18:17:13,976 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.46 and 348.53 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (84.23) is higher than Ligand B (49.41). For a cardiovascular GPCR like ADRB2, TPSA is less critical than for CNS targets, but lower is generally preferable for permeability. Ligand B is significantly better.
3. **logP:** Both ligands have good logP values (2.99 and 3.60), falling within the optimal 1-3 range. Ligand B is slightly higher, which could potentially lead to some off-target interactions, but it's not a major concern.
4. **HBD:** Ligand A has 2 HBD, and Ligand B has 1. Both are acceptable, well below the threshold of 5.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 2. Both are below the threshold of 10.
6. **QED:** Both ligands have good QED scores (0.743 and 0.797), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (41.88%) has a higher DILI risk than Ligand B (21.91%). This is a significant advantage for Ligand B.
8. **BBB:** Both ligands have acceptable BBB penetration (71.07% and 77.86%). Since ADRB2 is not a CNS target, this is less critical. Ligand B is slightly better.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. This is concerning for both. However, the absolute value for Ligand A (-4.665) is less negative than Ligand B (-4.772), suggesting slightly better permeability for Ligand A.
10. **Solubility:** Both ligands have negative solubility values, indicating poor solubility. The absolute value for Ligand A (-3.557) is less negative than Ligand B (-4.601), suggesting slightly better solubility for Ligand A.
11. **hERG:** Both ligands have low hERG inhibition risk (0.133 and 0.534). Ligand A is better.
12. **Cl_mic:** Ligand B (60.27) has lower microsomal clearance than Ligand A (68.33), suggesting better metabolic stability.
13. **t1/2:** Ligand B (4.41 hours) has a longer half-life than Ligand A (-15.86 hours). This is a significant advantage for Ligand B.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.123 and 0.239). Ligand A is better.
15. **Binding Affinity:** Both ligands have similar and strong binding affinities (-5.6 and -5.2 kcal/mol). The difference of 0.4 kcal/mol is not substantial enough to be the deciding factor.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand B emerges as the more promising candidate. While Ligand A has slightly better Caco-2 permeability and solubility, Ligand B has a significantly lower DILI risk, better metabolic stability (lower Cl_mic), and a longer half-life. The TPSA value of Ligand B is also considerably lower, which is beneficial for permeability. The binding affinity difference is minimal. The lower DILI risk and improved metabolic stability are crucial factors for a cardiovascular drug candidate.
Output:
0
2025-04-17 18:17:13,976 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [352.475, 59.08, 1.677, 0, 4, 0.633, 15.898, 77.782, -4.523, -1.221, 0.404, 27.554, 12.733, 0.161, -5.8]
**Ligand B:** [368.463, 110.08, -0.025, 1, 7, 0.782, 59.403, 68.36, -5.62, -2.17, 0.048, 20.799, -17.964, 0.046, -6.5]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, Affinity, and BBB):
1. **MW:** Both are within the ideal 200-500 Da range. A (352.475) is slightly preferred.
2. **TPSA:** A (59.08) is excellent, well below 140 and good for absorption. B (110.08) is higher, potentially hindering permeability, although still within a reasonable range.
3. **logP:** A (1.677) is optimal. B (-0.025) is quite low, potentially causing permeability issues and reduced binding.
4. **HBD/HBA:** A (0/4) is better than B (1/7). Lower HBD/HBA generally improves permeability.
5. **QED:** Both are good (A: 0.633, B: 0.782), indicating drug-like properties. B is slightly better.
6. **DILI:** A (15.898) is significantly better than B (59.403), indicating a much lower risk of liver injury. This is a major advantage for A.
7. **BBB:** A (77.782) is good, while B (68.36) is less favorable. While not a primary concern for a cardiovascular target, it's a bonus for A.
8. **Caco-2:** A (-4.523) is better than B (-5.62), suggesting better intestinal absorption.
9. **Solubility:** A (-1.221) is better than B (-2.17), indicating better aqueous solubility.
10. **hERG:** A (0.404) is better than B (0.048), indicating lower cardiotoxicity risk.
11. **Cl_mic:** B (20.799) has lower clearance than A (27.554), suggesting better metabolic stability.
12. **t1/2:** A (12.733) has a longer half-life than B (-17.964), which is a significant advantage.
13. **Pgp:** A (0.161) has lower P-gp efflux than B (0.046), suggesting better bioavailability.
14. **Affinity:** B (-6.5) is slightly better than A (-5.8), but the difference is not substantial enough to overcome A's other advantages.
**Overall Assessment:**
Ligand A is superior. While Ligand B has a slightly better binding affinity and metabolic stability, Ligand A excels in critical ADME properties (TPSA, logP, solubility, DILI, hERG, Pgp) and has a longer half-life. The lower logP and higher TPSA of Ligand B raise concerns about permeability and absorption. The significantly lower DILI risk for Ligand A is also a crucial factor. Given the GPCR target class, the balance of properties in Ligand A makes it a more promising drug candidate.
Output:
1
2025-04-17 18:17:13,976 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (334.379 and 340.467 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (75.19) is higher than Ligand B (58.2). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B has a slight advantage.
3. **logP:** Ligand A (1.183) is within the optimal range (1-3), while Ligand B (3.136) is at the higher end. While still acceptable, higher logP can sometimes lead to off-target effects. Ligand A has a slight advantage.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is preferable to Ligand B (2). Fewer HBAs generally improve permeability.
6. **QED:** Both ligands have good QED scores (0.833 and 0.885, respectively), indicating good drug-like properties. No significant difference.
7. **DILI:** Ligand A (54.556) has a slightly higher DILI risk than Ligand B (42.536), but both are below the concerning threshold of 60. Ligand B has a slight advantage.
8. **BBB:** Ligand A (36.409) has a lower BBB penetration score than Ligand B (62.233). While ADRB2 isn't a CNS target, some peripheral exposure can be undesirable. Ligand B has an advantage.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.805 and -4.741), which is unusual and suggests very poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand A (-2.494) has slightly better solubility than Ligand B (-4.312), although both are quite poor. Solubility is important for bioavailability. Ligand A has a slight advantage.
11. **hERG:** Ligand A (0.105) has a lower hERG risk than Ligand B (0.312). This is a crucial safety parameter, and lower is much better. Ligand A has a significant advantage.
12. **Cl_mic:** Ligand A (-15.938) has significantly lower microsomal clearance than Ligand B (21.878), indicating better metabolic stability. This is a major advantage for Ligand A.
13. **t1/2:** Ligand A (-13.844) has a longer in vitro half-life than Ligand B (5.206), further supporting its better metabolic stability. This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.009) has much lower P-gp efflux liability than Ligand B (0.113), suggesting better oral bioavailability and potentially better tissue distribution. This is a significant advantage for Ligand A.
15. **Binding Affinity:** Ligand A (-6.9 kcal/mol) and Ligand B (-6.7 kcal/mol) have very similar binding affinities. The difference is not substantial enough to outweigh other factors.
**Overall Assessment:**
Despite the poor Caco-2 permeability for both, Ligand A demonstrates a significantly better ADMET profile. It has lower DILI risk, lower hERG inhibition, substantially better metabolic stability (lower Cl_mic and longer t1/2), and lower P-gp efflux. While Ligand B has a slightly better BBB score and lower TPSA, the advantages of Ligand A in metabolic stability and safety are more critical for overall drug development potential. The slightly better solubility of Ligand A is also a positive.
Output:
1
2025-04-17 18:17:13,976 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (338.451) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (61.96) is significantly better than Ligand B (84.47). ADRB2 is not a CNS target, but lower TPSA generally improves absorption.
3. **logP:** Ligand A (3.905) is optimal, while Ligand B (1.46) is on the lower side. This could potentially hinder membrane permeability for Ligand B.
4. **HBD:** Ligand A (2) is reasonable, while Ligand B (0) is also acceptable.
5. **HBA:** Ligand A (2) is good, while Ligand B (6) is higher, potentially impacting permeability.
6. **QED:** Both ligands have similar, good QED scores (0.891 and 0.8).
7. **DILI:** Both ligands have acceptable DILI risk (70.221 and 67.429), though ideally, lower is better. The difference is minimal.
8. **BBB:** This is less critical for ADRB2, but Ligand A (61.807) is slightly better than Ligand B (55.176).
9. **Caco-2:** Both ligands have negative Caco-2 values which is unusual. I will assume this means low permeability.
10. **Solubility:** Ligand A (-5.354) is much better than Ligand B (-1.969). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.427) is much better than Ligand B (0.087). Lower hERG inhibition is crucial for avoiding cardiotoxicity, especially for a cardiovascular target.
12. **Cl_mic:** Both ligands have similar microsomal clearance values (27.249 and 25.819), indicating comparable metabolic stability.
13. **t1/2:** Ligand A (-11.275) has a more negative in vitro half-life, which is not ideal. Ligand B (17.097) has a better in vitro half-life.
14. **Pgp:** Ligand A (0.379) is better than Ligand B (0.079), indicating lower P-gp efflux.
15. **Affinity:** Ligand A (-7.6) has a significantly better binding affinity than Ligand B (-6.8). A 0.8 kcal/mol difference is substantial and can often outweigh minor ADME drawbacks.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are particularly important. Ligand A excels in logP, TPSA, and significantly in affinity, and has better Pgp properties. While Ligand B has a slightly better half-life, the superior affinity and overall ADME profile of Ligand A make it the more promising candidate. The hERG risk is also much lower for Ligand A.
**Conclusion:**
Ligand A is the better candidate due to its superior binding affinity, logP, TPSA, solubility, and lower hERG risk. The slightly worse half-life is a concern, but can potentially be addressed with further optimization.
Output:
1
2025-04-17 18:17:13,976 - INFO - Batch 26 complete. Total preferences: 416
2025-04-17 18:17:13,976 - INFO - Processing batch 27/512...
2025-04-17 18:18:02,526 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A: [385.243, 64.99, 3.737, 1, 5, 0.702, 55.448, 29.391, -4.564, -4.657, 0.728, 77.412, 37.469, 0.712, -4.7]**
**Ligand B: [348.443, 68.82, 2.34, 2, 5, 0.826, 43.234, 77.162, -5.072, -1.753, 0.487, -38.71, 11.026, 0.053, -4.7]**
Here's a breakdown of the comparison, considering the guidelines and GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (348.443) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are reasonably good (below 140). Ligand A (64.99) is better than Ligand B (68.82), but both are acceptable.
3. **logP:** Ligand A (3.737) is optimal. Ligand B (2.34) is on the lower side, potentially impacting membrane permeability.
4. **HBD:** Ligand A (1) is preferred over Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Both have 5 HBA, which is acceptable.
6. **QED:** Ligand B (0.826) has a slightly better QED score than Ligand A (0.702), indicating a more drug-like profile.
7. **DILI:** Ligand B (43.234) has a significantly lower DILI risk than Ligand A (55.448). This is a major advantage for Ligand B.
8. **BBB:** Ligand B (77.162) has a substantially higher BBB penetration score than Ligand A (29.391). While ADRB2 isn't *primarily* a CNS target, some CNS exposure can be relevant for off-target effects, and higher BBB is generally favorable.
9. **Caco-2:** Ligand B (-5.072) has a much higher Caco-2 permeability value than Ligand A (-4.564), suggesting better intestinal absorption.
10. **Solubility:** Ligand B (-1.753) has a better solubility value than Ligand A (-4.657).
11. **hERG:** Both are very low (0.728 and 0.487), indicating low cardiotoxicity risk.
12. **Cl_mic:** Ligand B (-38.71) has significantly lower microsomal clearance than Ligand A (77.412), implying better metabolic stability.
13. **t1/2:** Ligand A (37.469) has a longer in vitro half-life than Ligand B (11.026).
14. **Pgp:** Ligand B (0.053) has a much lower P-gp efflux liability than Ligand A (0.712), suggesting better oral bioavailability and potentially better CNS exposure.
15. **Affinity:** Both ligands have the same binding affinity (-4.7 kcal/mol).
**Overall Assessment:**
Ligand B is significantly better across several critical ADME properties (DILI, BBB, Caco-2, Solubility, Cl_mic, Pgp). While Ligand A has a longer half-life, the improvements in ADME for Ligand B are more impactful, especially considering the GPCR target class. The slightly lower logP of Ligand B is a minor concern, but the other advantages outweigh this.
Output:
0
2025-04-17 18:18:02,526 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (340.335 and 348.443 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (94.57) is slightly higher than Ligand B (78.87). Both are below the 140 threshold for good oral absorption, but B is better.
3. **logP:** Both ligands (2.58 and 2.694) are within the optimal 1-3 range. No significant difference.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2) as lower HBD generally improves permeability.
5. **HBA:** Ligand A (6) is preferable to Ligand B (4) as lower HBA generally improves permeability.
6. **QED:** Ligand A (0.693) has a better QED score than Ligand B (0.559), indicating better overall drug-likeness.
7. **DILI:** Ligand B (20.396) has a significantly lower DILI risk than Ligand A (85.692). This is a *major* advantage for Ligand B.
8. **BBB:** Both ligands have similar BBB penetration (66.111 and 66.537). Since ADRB2 isn't exclusively a CNS target, this isn't a deciding factor.
9. **Caco-2:** Ligand A (-4.702) and Ligand B (-5.079) are both poor.
10. **Solubility:** Ligand B (-2.869) has better solubility than Ligand A (-4.581).
11. **hERG:** Ligand A (0.275) has a lower hERG inhibition liability than Ligand B (0.667), which is preferable.
12. **Cl_mic:** Ligand B (20.652) has a significantly lower microsomal clearance than Ligand A (77.973), indicating better metabolic stability.
13. **t1/2:** Ligand A (26.314) has a longer in vitro half-life than Ligand B (-4.069). This is a positive for Ligand A.
14. **Pgp:** Ligand A (0.455) has lower P-gp efflux liability than Ligand B (0.154).
15. **Affinity:** Ligand A (-7.4) has a stronger binding affinity than Ligand B (-6.4). This is a 1.0 kcal/mol difference, which is significant.
**Overall Assessment & GPCR Prioritization:**
For a GPCR like ADRB2, affinity, logP, TPSA, and metabolic stability are key. Ligand A has a substantially better binding affinity (-7.4 vs -6.4 kcal/mol). While Ligand B has a significantly better DILI score and lower Cl_mic, the affinity difference is large enough to outweigh those benefits. The slightly better TPSA of Ligand B is a minor advantage, but Ligand A's better QED and lower Pgp efflux are also positives. The longer half-life of Ligand A is also a benefit.
**Output:**
1
2025-04-17 18:18:02,527 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (361.431 and 349.475 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (76.64) is significantly better than Ligand A (129.89). ADRB2 is a GPCR, and lower TPSA generally favors better permeability.
3. **logP:** Ligand B (2.265) is optimal, while Ligand A (0.368) is quite low, potentially hindering membrane permeability. This is a significant advantage for Ligand B.
4. **HBD:** Both ligands are acceptable (3 for A, 2 for B), falling under the 5 threshold.
5. **HBA:** Both ligands are acceptable (7 for A, 3 for B), falling under the 10 threshold.
6. **QED:** Both ligands have good QED scores (0.721 and 0.793), indicating good drug-like properties.
7. **DILI:** Ligand B (28.655) has a much lower DILI risk than Ligand A (64.754). This is a substantial advantage for Ligand B.
8. **BBB:** Ligand B (53.238) has a better BBB penetration score than Ligand A (48.662), although neither is exceptionally high. For a cardiovascular target, BBB penetration is not a primary concern, but it's a slight edge for B.
9. **Caco-2:** Ligand A (-5.921) and Ligand B (-4.816) are both negative, which is not ideal. However, the values are similar, and this parameter is less critical than others.
10. **Solubility:** Both ligands have poor aqueous solubility (-2.579 and -2.109). This could pose formulation challenges, but is not a deciding factor at this stage.
11. **hERG:** Both ligands show low hERG inhibition liability (0.4 and 0.418), which is excellent.
12. **Cl_mic:** Ligand A (-33.266) has a much lower (better) microsomal clearance than Ligand B (6.203), indicating greater metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (-28.436) has a longer in vitro half-life than Ligand B (3.874), further supporting its better metabolic stability.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.021 and 0.156).
15. **Binding Affinity:** Ligand B (-6.7 kcal/mol) has a slightly better binding affinity than Ligand A (-6.3 kcal/mol). While the difference is not huge, it's a positive for Ligand B.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand B clearly emerges as the more promising candidate. Its superior logP and TPSA values suggest better permeability. The significantly lower DILI risk is a major advantage. While Ligand A has better metabolic stability (Cl_mic and t1/2), the difference in affinity is small, and the permeability and safety advantages of Ligand B outweigh this concern.
Output:
0
2025-04-17 18:18:02,527 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.362 and 352.475 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (93.21) is slightly higher than Ligand B (78.87). Both are below the 140 threshold for oral absorption, but B is better positioned for potential CNS penetration if desired.
3. **logP:** Both ligands have excellent logP values (2.413 and 2.012) within the optimal 1-3 range. No significant difference.
4. **HBD:** Both have 2 H-bond donors, which is good.
5. **HBA:** Ligand A has 5 H-bond acceptors, while Ligand B has 4. Both are acceptable, under the 10 threshold.
6. **QED:** Both ligands have similar QED scores (0.784 and 0.717), indicating good drug-likeness.
7. **DILI:** Ligand A (85.576) has a significantly higher DILI risk than Ligand B (33.424). This is a major concern for Ligand A.
8. **BBB:** Both have reasonable BBB penetration (69.097 and 65.839). Since ADRB2 is a cardiovascular target, BBB penetration is not a primary concern, but lower is preferable.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. This is a serious drawback for both.
10. **Solubility:** Both have negative solubility values, indicating poor aqueous solubility. This is a serious drawback for both.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.191 and 0.406), which is excellent.
12. **Cl_mic:** Ligand B (11.886) has significantly lower microsomal clearance than Ligand A (55.117), indicating better metabolic stability.
13. **t1/2:** Ligand B (-2.412) has a negative in vitro half-life, which is concerning. Ligand A (20.807) has a much more favorable half-life.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.027 and 0.251).
15. **Binding Affinity:** Both ligands have identical binding affinities (-8.3 kcal/mol), which is excellent.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Both ligands perform well on logP and Pgp. Ligand B has a better TPSA. The critical difference lies in the DILI risk and metabolic stability. Ligand B's significantly lower DILI risk and better metabolic stability (lower Cl_mic) are major advantages. While Ligand A has a better in vitro half-life, the high DILI risk is a substantial safety concern. The Caco-2 and solubility issues are similar for both, and would require formulation strategies to address.
**Conclusion:**
Despite the similar binding affinities and some drawbacks shared by both compounds, Ligand B is the more promising candidate due to its significantly lower DILI risk and improved metabolic stability.
Output:
0
2025-04-17 18:18:02,527 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (351.491 and 361.473 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (69.72) is better than Ligand B (49.77). Both are well below the 140 threshold for oral absorption, and suitable for a GPCR target.
3. **logP:** Ligand A (1.787) is within the optimal 1-3 range. Ligand B (3.618) is slightly higher, potentially edging towards solubility issues, but still acceptable.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Both ligands have 3 HBA, which is good.
6. **QED:** Both ligands have good QED scores (0.678 and 0.718), indicating generally drug-like properties.
7. **DILI:** Ligand A (11.128) has a significantly lower DILI risk than Ligand B (15.394). This is a substantial advantage.
8. **BBB:** Ligand B (96.161) has a much higher BBB penetration score than Ligand A (81.892). While ADRB2 isn't strictly a CNS target, some CNS exposure can be beneficial or at least less detrimental than complete exclusion.
9. **Caco-2:** Ligand A (-4.886) and Ligand B (-4.235) both have negative Caco-2 values, indicating poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-2.118) has better solubility than Ligand B (-3.308).
11. **hERG:** Ligand A (0.495) has a lower hERG risk than Ligand B (0.88). This is a significant advantage for safety.
12. **Cl_mic:** Ligand A (26.756) has a lower microsomal clearance than Ligand B (42.665), indicating better metabolic stability.
13. **t1/2:** Ligand B (25.127) has a much longer in vitro half-life than Ligand A (-2.827). This is a significant advantage for dosing convenience.
14. **Pgp:** Ligand A (0.079) has lower P-gp efflux liability than Ligand B (0.262), which is favorable for bioavailability.
15. **Affinity:** Both ligands have very similar binding affinities (-6.7 and -6.5 kcal/mol). The difference is not substantial enough to be a deciding factor.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Both ligands are reasonably well-balanced in these areas. However, safety (DILI, hERG) and metabolic stability (Cl_mic) are also crucial. Ligand A clearly wins on DILI, hERG, and Cl_mic. The longer half-life of Ligand B is attractive, but the safety profile of Ligand A is more compelling.
**Conclusion:**
Considering the balance of properties, particularly the significantly lower DILI and hERG risk, and better metabolic stability of Ligand A, it is the more promising drug candidate.
Output:
1
2025-04-17 18:18:02,527 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (330.395 and 346.471 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (70.59) is better than Ligand A (79.47). Both are below 140, but lower TPSA generally favors absorption.
3. **logP:** Ligand A (4.559) is higher than Ligand B (3.065). While both are within the acceptable range, Ligand A is pushing the upper limit and could present solubility challenges. Ligand B is closer to optimal.
4. **HBD:** Ligand A (0) is better than Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is better than Ligand B (3). Fewer HBAs also generally improve permeability.
6. **QED:** Ligand B (0.785) is significantly better than Ligand A (0.377), indicating a more drug-like profile.
7. **DILI:** Ligand B (30.671) is *much* better than Ligand A (64.133). This is a critical advantage, as lower DILI risk is highly desirable.
8. **BBB:** Both ligands have similar BBB penetration (78.48 and 78.054). This isn't a primary concern for ADRB2, which isn't a CNS target, but it's good that they both show reasonable penetration.
9. **Caco-2:** Both ligands have very poor Caco-2 permeability (-4.843 and -4.789). This is a significant drawback for both.
10. **Solubility:** Ligand B (-2.663) is better than Ligand A (-5.57). Solubility is a concern for Ligand A due to its higher logP.
11. **hERG:** Ligand A (0.856) is better than Ligand B (0.529), indicating a lower risk of cardiotoxicity.
12. **Cl_mic:** Ligand B (19.044) is better than Ligand A (21.181), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-42.743) is better than Ligand B (13.654). A longer half-life is generally preferred.
14. **Pgp:** Ligand A (0.565) is better than Ligand B (0.364), indicating lower P-gp efflux.
15. **Binding Affinity:** Ligand A (-7.7) is significantly better than Ligand B (-6.8). This is a substantial advantage, exceeding the 1.5 kcal/mol threshold.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A has a higher logP which is a concern, but its affinity is significantly better. Ligand B has better TPSA, Pgp, and a much lower DILI risk.
**Overall Assessment:**
While Ligand A boasts a superior binding affinity, the significantly better DILI profile and more favorable QED, solubility, and metabolic stability of Ligand B are compelling. The affinity difference, while substantial, might be overcome with further optimization of Ligand B. The DILI risk associated with Ligand A is a major red flag. The poor Caco-2 permeability is a concern for both, but can potentially be addressed through formulation strategies.
Output:
0
2025-04-17 18:18:02,527 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (341.367 and 348.487 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (100.55) is higher than Ligand B (60.85). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B has a clear advantage.
3. **logP:** Both ligands (1.869 and 2.201) are within the optimal 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Ligand A (3) is higher than Ligand B (1). Lower HBD is generally preferred for permeability, giving Ligand B an edge.
5. **HBA:** Ligand A (5) is higher than Ligand B (3). Again, lower HBA is generally preferred, favoring Ligand B.
6. **QED:** Ligand A (0.788) has a significantly better QED score than Ligand B (0.513), indicating a more drug-like profile overall. This is a substantial advantage for Ligand A.
7. **DILI:** Ligand A (73.827) has a higher DILI risk than Ligand B (5.312). This is a significant concern for Ligand A, as lower DILI is crucial. Ligand B is clearly better here.
8. **BBB:** Both ligands have moderate BBB penetration (60.838 and 65.607). Since ADRB2 isn't a primary CNS target, this isn't a major deciding factor. Ligand B is slightly better.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.938 and -4.679), indicating poor permeability. This is a concern for both, but the values are similar.
10. **Solubility:** Ligand A (-4.156) has slightly worse solubility than Ligand B (-1.14). Solubility is important, so Ligand B is favored.
11. **hERG:** Both ligands have low hERG inhibition risk (0.291 and 0.451). No significant difference.
12. **Cl_mic:** Ligand B (35.881) has lower microsomal clearance than Ligand A (40.197), suggesting better metabolic stability. This is a positive for Ligand B.
13. **t1/2:** Ligand A (-5.078) has a more negative in vitro half-life than Ligand B (-1.402), indicating a shorter half-life. This is a disadvantage for Ligand A.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.107 and 0.127). No significant difference.
15. **Binding Affinity:** Ligand A (-6.9) has a slightly better binding affinity than Ligand B (-5.2). While a 1.7 kcal/mol difference is good, it needs to be weighed against other factors.
**Overall Assessment:**
Ligand B consistently demonstrates superior ADME properties (lower DILI, better solubility, better metabolic stability, lower HBD/HBA, lower TPSA) despite having slightly lower binding affinity. The QED score of Ligand A is appealing, but the significantly higher DILI risk is a major red flag. For a cardiovascular target, minimizing off-target effects and toxicity is paramount. While the affinity difference is noticeable, the improved ADME profile of Ligand B outweighs this.
Output:
0
2025-04-17 18:18:02,527 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [346.377, 32.78, 3.303, 0, 3, 0.805, 54.401, 95.037, -4.474, -3.867, 0.874, 53.503, 2.237, 0.422, -8.4]
**Ligand B:** [350.459, 79.82, 2.321, 3, 4, 0.638, 15.277, 69.213, -4.344, -2.316, 0.478, 25.798, -1.666, 0.15, -6]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity, and BBB):
1. **MW:** Both are within the ideal range (200-500 Da). A is 346.377, B is 350.459 - very similar.
2. **TPSA:** Ligand A (32.78) is excellent, well below 140 and favorable for absorption. Ligand B (79.82) is higher, but still acceptable, though less ideal.
3. **logP:** Ligand A (3.303) is optimal. Ligand B (2.321) is also good, but slightly lower, potentially impacting membrane permeability.
4. **HBD/HBA:** A (0/3) is better than B (3/4). Fewer H-bonds generally improve permeability.
5. **QED:** Ligand A (0.805) is very good, indicating high drug-likeness. Ligand B (0.638) is still acceptable, but lower.
6. **DILI:** Ligand A (54.401) is moderate, but acceptable. Ligand B (15.277) is *very* good, indicating low liver injury risk. This is a significant advantage for B.
7. **BBB:** Ligand A (95.037) is excellent, suggesting good brain penetration. Ligand B (69.213) is lower, but not terrible. Since ADRB2 isn't exclusively a CNS target, this isn't a deal-breaker, but A is better here.
8. **Caco-2:** Both are negative, indicating good permeability. Values are similar.
9. **Solubility:** Both are negative, indicating good solubility. Values are similar.
10. **hERG:** Ligand A (0.874) is better than B (0.478), indicating lower cardiotoxicity risk.
11. **Cl_mic:** Ligand A (53.503) is higher than B (25.798), indicating faster metabolism. B has better metabolic stability.
12. **t1/2:** Ligand A (2.237) is slightly better than B (-1.666), but both are relatively short.
13. **Pgp:** Ligand A (0.422) is better than B (0.15), indicating lower P-glycoprotein efflux. This is a positive for A.
14. **Affinity:** Ligand A (-8.4 kcal/mol) is *significantly* better than Ligand B (-6 kcal/mol). This is a 2.4 kcal/mol difference, which is substantial and can outweigh many ADME concerns.
**Overall Assessment:**
Ligand A has a superior binding affinity, better Pgp properties, and excellent BBB penetration. However, Ligand B has a much lower DILI risk and better metabolic stability. The affinity difference is substantial. For a GPCR, affinity is paramount. While metabolic stability and DILI are important, a strong binding ligand often allows for lower dosing, mitigating some of those concerns. The TPSA and logP are also more favorable for A.
Therefore, I favor Ligand A.
Output:
1
2025-04-17 18:18:02,527 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (361.433 Da) is within the ideal range (200-500 Da). Ligand B (383.748 Da) is also within the ideal range. No clear advantage here.
2. **TPSA:** Ligand A (64.09) is good, well below the 140 threshold. Ligand B (30.29) is excellent, even better for permeability. Ligand B has an advantage.
3. **logP:** Ligand A (0.794) is a little low, potentially impacting permeability. Ligand B (4.081) is at the upper end of the optimal range, potentially leading to solubility issues, but acceptable. Ligand A is slightly better here.
4. **HBD:** Ligand A (1) is good. Ligand B (0) is also good. No significant difference.
5. **HBA:** Both Ligand A (4) and Ligand B (4) are within the acceptable limit of 10. No difference.
6. **QED:** Ligand A (0.787) is better than Ligand B (0.643), indicating a more drug-like profile. Ligand A has an advantage.
7. **DILI:** Ligand A (10.857) has a significantly lower DILI risk than Ligand B (47.77). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (87.98) has a much higher BBB penetration percentile than Ligand A (72.16). This is important for GPCRs, but ADRB2 is primarily cardiovascular, so this isn't a *critical* factor. Ligand B has an advantage.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-4.64) is slightly better than Ligand B (-4.565), but both are poor.
10. **Solubility:** Ligand A (-0.384) is better than Ligand B (-4.557). Solubility is crucial for bioavailability. Ligand A has an advantage.
11. **hERG:** Ligand A (0.598) has a lower hERG risk than Ligand B (0.906). This is a critical safety parameter. Ligand A has a significant advantage.
12. **Cl_mic:** Ligand A (-7.139) has a much lower microsomal clearance, indicating better metabolic stability, than Ligand B (53.773). This is a major advantage for Ligand A.
13. **t1/2:** Ligand A (-20.961) has a longer in vitro half-life than Ligand B (18.292). This is a positive for dosing frequency. Ligand A has an advantage.
14. **Pgp:** Ligand A (0.029) has a much lower P-gp efflux liability than Ligand B (0.694). This is a significant advantage for bioavailability. Ligand A has a major advantage.
15. **Affinity:** Ligand B (-7.6) has a slightly stronger binding affinity than Ligand A (-6.3). While affinity is important, the difference of 1.3 kcal/mol is not substantial enough to outweigh the numerous advantages of Ligand A.
**Overall Assessment:**
Ligand A demonstrates a significantly better overall profile, particularly regarding safety (DILI, hERG), metabolic stability (Cl_mic, t1/2), and bioavailability (Solubility, Pgp). While Ligand B has better TPSA and BBB penetration, these are less critical for a cardiovascular target like ADRB2. The slightly better affinity of Ligand B is not enough to compensate for the substantial advantages of Ligand A.
Output:
1
2025-04-17 18:18:02,527 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (392.327 Da) is slightly higher than Ligand B (366.439 Da), but both are acceptable.
**2. TPSA:** Ligand A (61.88) is significantly better than Ligand B (101.55). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B's TPSA is relatively high, potentially hindering oral absorption.
**3. logP:** Both ligands have acceptable logP values (Ligand A: 1.627, Ligand B: 2.545), falling within the 1-3 range.
**4. H-Bond Donors & Acceptors:** Ligand A (HBD=1, HBA=4) is preferable to Ligand B (HBD=2, HBA=5). Lower values are generally better for permeability.
**5. QED:** Both ligands have good QED scores (Ligand A: 0.682, Ligand B: 0.747), indicating good drug-like properties.
**6. DILI Risk:** Ligand A (10.237) has a much lower DILI risk than Ligand B (70.919). This is a significant advantage for Ligand A.
**7. BBB Penetration:** Ligand A (61.768) has better BBB penetration than Ligand B (52.462). While ADRB2 isn't exclusively a CNS target, some cardiovascular effects are mediated through central pathways, and better BBB penetration isn't a detriment.
**8. Caco-2 Permeability:** Both ligands have similar, poor Caco-2 permeability values (-4.876 and -4.902). This is a concern for both, but less critical given the focus on GPCR properties.
**9. Aqueous Solubility:** Both ligands have poor aqueous solubility (-1.769 and -2.983). This could pose formulation challenges, but isn't a dealbreaker.
**10. hERG Inhibition:** Ligand A (0.443) shows a lower hERG inhibition liability than Ligand B (0.266), which is a positive safety indicator.
**11. Microsomal Clearance:** Ligand A (10.499) has significantly lower microsomal clearance than Ligand B (43.868), indicating better metabolic stability.
**12. In vitro Half-Life:** Ligand B (22.532) has a much longer in vitro half-life than Ligand A (4.245). This is a positive for Ligand B, suggesting less frequent dosing.
**13. P-gp Efflux:** Ligand A (0.021) has significantly lower P-gp efflux than Ligand B (0.15), which is favorable for bioavailability.
**14. Binding Affinity:** Ligand B (-7.0) has a stronger binding affinity than Ligand A (-5.4). This is a substantial advantage for Ligand B. However, the other ADME properties of Ligand A are much more favorable.
**Overall Assessment:**
While Ligand B has a better binding affinity, Ligand A demonstrates a significantly more favorable ADME profile. Specifically, the lower DILI risk, better BBB penetration, lower microsomal clearance, and lower P-gp efflux are crucial advantages. The slightly weaker binding of Ligand A can potentially be addressed through further optimization, while fixing the poor ADME properties of Ligand B would be more challenging. Given the GPCR target class, a balance of properties is key, and Ligand A strikes a better balance.
Output:
1
2025-04-17 18:18:02,528 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (350.419 Da and 356.457 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (112.58) is higher than the preferred <140 for oral absorption, but still reasonable. Ligand B (49.41) is excellent, well below 90, suggesting good permeability. This favors Ligand B.
**3. logP:** Ligand A (0.145) is quite low, potentially hindering membrane permeability. Ligand B (3.031) is within the optimal 1-3 range. This is a significant advantage for Ligand B.
**4. H-Bond Donors:** Ligand A (4) is acceptable, while Ligand B (1) is even better, potentially improving permeability. This favors Ligand B.
**5. H-Bond Acceptors:** Ligand A (6) is acceptable, and Ligand B (2) is also good. No strong preference.
**6. QED:** Ligand B (0.744) has a considerably higher QED score than Ligand A (0.478), indicating a more drug-like profile. This favors Ligand B.
**7. DILI Risk:** Ligand A (41.838) and Ligand B (29.042) both have low DILI risk, below the 40 threshold. Ligand B is slightly better.
**8. BBB Penetration:** Ligand A (53.819) is moderate, while Ligand B (96.084) is excellent, suggesting good potential for CNS exposure. While ADRB2 is primarily cardiovascular, some CNS effects can be relevant, and higher BBB penetration is generally favorable. This favors Ligand B.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests a potential issue with the assay or the compounds themselves. It's difficult to draw conclusions here.
**10. Aqueous Solubility:** Both ligands have negative solubility values, which is also unusual. It's difficult to draw conclusions here.
**11. hERG Inhibition:** Ligand A (0.235) has a slightly lower hERG risk than Ligand B (0.729), which is a slight advantage.
**12. Microsomal Clearance:** Ligand A (9.184) has a lower microsomal clearance than Ligand B (18.571), suggesting better metabolic stability. This favors Ligand A.
**13. In vitro Half-Life:** Ligand A (15.98) has a positive half-life, while Ligand B (-13.016) has a negative half-life, which is unusual. This favors Ligand A.
**14. P-gp Efflux:** Ligand A (0.011) has very low P-gp efflux, which is excellent. Ligand B (0.314) is also relatively low, but higher than Ligand A. This favors Ligand A.
**15. Binding Affinity:** Ligand B (-5.8 kcal/mol) has a slightly better binding affinity than Ligand A (-6.7 kcal/mol). This is a small advantage for Ligand B, but affinity is highly prioritized for GPCRs.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand B is the stronger candidate. It has a much better logP, TPSA, QED, and BBB penetration. While Ligand A has advantages in metabolic stability (Cl_mic, t1/2) and P-gp efflux, the improvements in permeability and drug-likeness offered by Ligand B outweigh these factors, especially given the relatively small difference in binding affinity. The unusual negative values for Caco-2 and solubility need further investigation, but the overall profile of Ligand B is more promising.
Output:
0
2025-04-17 18:18:02,528 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (375.255 and 366.422 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (75.35) is significantly better than Ligand B (96.18). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand A is well under the 140 threshold, while B is approaching it.
3. **logP:** Ligand A (4.192) is higher than Ligand B (2.11). While both are within the acceptable range, Ligand A is pushing the upper limit and could potentially have solubility issues. Ligand B is closer to the optimal 1-3 range.
4. **HBD:** Ligand A (3) and Ligand B (2) are both acceptable.
5. **HBA:** Ligand A (3) is better than Ligand B (8). Lower HBA generally improves permeability.
6. **QED:** Ligand B (0.836) has a higher QED score than Ligand A (0.599), indicating a more drug-like profile overall.
7. **DILI:** Both ligands have similar DILI risk (75.339 vs 79.1), and are within an acceptable range (<80).
8. **BBB:** Ligand B (81.582) has a significantly higher BBB penetration score than Ligand A (57.58). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant, and higher BBB is generally favorable.
9. **Caco-2:** Ligand A (-4.844) is better than Ligand B (-5.175), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-4.745) is better than Ligand B (-3.72).
11. **hERG:** Ligand A (0.885) is better than Ligand B (0.446), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand B (24.782) has a slightly higher clearance than Ligand A (20.496), suggesting lower metabolic stability.
13. **t1/2:** Ligand A (97.124) has a much longer in vitro half-life than Ligand B (-4.995). This is a significant advantage.
14. **Pgp:** Ligand A (0.615) is better than Ligand B (0.039), indicating lower P-gp efflux.
15. **Binding Affinity:** Ligand A (-8.4 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.1 kcal/mol). This is a substantial difference and a major driver in the decision.
**Overall Assessment:**
Ligand A has a significantly better binding affinity and longer half-life, which are crucial for efficacy. It also has better TPSA, HBA, solubility, hERG, and Pgp properties. While Ligand B has a better QED and BBB, the affinity difference and the other favorable ADME properties of Ligand A outweigh these advantages. The higher logP of Ligand A is a slight concern, but the strong binding and favorable metabolic properties make it the more promising candidate.
Output:
1
2025-04-17 18:18:02,528 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [348.451, 93.01, 1.334, 1, 6, 0.716, 64.288, 56.999, -5.21, -2.041, 0.075, 40.744, -6.54, 0.091, -5.4]
**Ligand B:** [346.402, 54.71, 2.711, 1, 4, 0.904, 51.725, 80.341, -4.493, -3.604, 0.776, 36.796, 40.211, 0.489, -5.9]
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). A is 348.451, B is 346.402 - very similar.
2. **TPSA:** Ligand A (93.01) is slightly higher than Ligand B (54.71). Both are acceptable for a non-CNS GPCR target like ADRB2, but B is significantly better.
3. **logP:** Ligand A (1.334) is within the optimal range, while Ligand B (2.711) is towards the higher end but still acceptable.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 6 HBA, Ligand B has 4. Both are within the acceptable range.
6. **QED:** Ligand B (0.904) has a better QED score than Ligand A (0.716), indicating a more drug-like profile.
7. **DILI:** Ligand A (64.288) has a higher DILI risk than Ligand B (51.725). Both are acceptable, but B is preferred.
8. **BBB:** Ligand B (80.341) has a much higher BBB penetration score than Ligand A (56.999). While ADRB2 isn't a primary CNS target, some peripheral exposure is possible, and higher BBB is generally favorable.
9. **Caco-2:** Ligand A (-5.21) and Ligand B (-4.493) are both negative, which is unusual and suggests poor permeability. However, the scale isn't specified, so we can't interpret these values definitively.
10. **Solubility:** Ligand A (-2.041) and Ligand B (-3.604) are both negative, indicating poor solubility. Again, the scale is unknown.
11. **hERG:** Ligand A (0.075) has a slightly lower hERG risk than Ligand B (0.776).
12. **Cl_mic:** Ligand B (36.796) has a lower microsomal clearance than Ligand A (40.744), suggesting better metabolic stability.
13. **t1/2:** Ligand B (40.211) has a significantly longer in vitro half-life than Ligand A (-6.54). This is a major advantage.
14. **Pgp:** Ligand A (0.091) has lower P-gp efflux than Ligand B (0.489), which is beneficial for bioavailability.
15. **Affinity:** Ligand B (-5.9) has a slightly better binding affinity than Ligand A (-5.4).
**GPCR-specific priorities:** For ADRB2, we prioritize logP, Pgp, TPSA, and affinity. Ligand B excels in TPSA, has a better logP, a longer half-life, and a slightly better affinity. While Ligand A has a lower Pgp efflux, the other advantages of Ligand B outweigh this.
**Conclusion:**
Considering the balance of properties, especially the improved ADME profile (lower DILI, better metabolic stability, longer half-life, and better TPSA) and slightly better affinity, Ligand B is the more promising drug candidate.
0
2025-04-17 18:18:02,528 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [371.415, 105.25 , -0.653, 1. , 6. , 0.639, 63.668, 71.268, -4.95 , -2.24 , 0.348, 65.159, 7.256, 0.091, -5.8 ]
**Ligand B:** [349.391, 118.11 , -0.988, 3. , 6. , 0.391, 40.403, 43.893, -5.29 , -2.237, 0.031, -2.775, -35.057, 0.01 , -5.8 ]
Here's a breakdown, considering the GPCR priorities (logP, Pgp, TPSA, affinity) and general drug-like properties:
1. **MW:** Both are within the ideal 200-500 Da range. Ligand B (349.391) is slightly preferred due to being a bit lower.
2. **TPSA:** Ligand A (105.25) is better than Ligand B (118.11). Both are below 140, but closer to 90 is better for GPCRs.
3. **logP:** Ligand A (-0.653) is slightly less optimal than Ligand B (-0.988), but both are a bit low. Ideally, we want 1-3.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Lower HBD generally improves permeability.
5. **HBA:** Both have 6 HBA, which is acceptable.
6. **QED:** Ligand A (0.639) is significantly better than Ligand B (0.391). A higher QED suggests a more drug-like profile.
7. **DILI:** Ligand B (40.403) is significantly better than Ligand A (63.668). Lower DILI risk is crucial.
8. **BBB:** Ligand A (71.268) is better than Ligand B (43.893). While not a CNS target, some BBB penetration can be beneficial for distribution.
9. **Caco-2:** Ligand A (-4.95) is better than Ligand B (-5.29). Higher Caco-2 indicates better absorption.
10. **Solubility:** Ligand A (-2.24) is slightly better than Ligand B (-2.237). Both are quite poor.
11. **hERG:** Both are very low (0.348 and 0.031), indicating minimal hERG inhibition risk, which is excellent.
12. **Cl_mic:** Ligand B (-2.775) is *much* better than Ligand A (65.159). Lower clearance means better metabolic stability. This is a major advantage for Ligand B.
13. **t1/2:** Ligand B (-35.057) is *much* better than Ligand A (7.256). Longer half-life is desirable.
14. **Pgp:** Both are very low (0.091 and 0.01), indicating minimal P-gp efflux.
15. **Affinity:** Both have the same affinity (-5.8 kcal/mol), so this doesn't differentiate them.
**Overall Assessment:**
Ligand A has a better QED and BBB penetration, but Ligand B excels in critical ADME properties: significantly lower DILI risk, much better metabolic stability (Cl_mic), and a much longer half-life. The lower HBD count in Ligand A is also a plus. While both have suboptimal logP and solubility, the ADME advantages of Ligand B are more impactful for overall drug development success, especially considering the cardiovascular context where metabolic stability is important.
Output:
0
2025-04-17 18:18:02,528 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (342.399 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (58.64) is significantly better than Ligand A (98.32). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have acceptable logP values (A: 1.055, B: 3.125), falling within the 1-3 range. Ligand B is closer to the optimal upper end, which can be beneficial for membrane permeability.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (1), but both are within the acceptable limit of 5.
5. **HBA:** Both ligands have the same number of HBA (4), which is well within the acceptable limit of 10.
6. **QED:** Both ligands have good QED scores (A: 0.731, B: 0.873), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand B (47.15) has a significantly lower DILI risk than Ligand A (65.568). This is a major advantage for Ligand B.
8. **BBB:** Ligand B (63.009) has a higher BBB penetration score than Ligand A (33.695). While not critical for a cardiovascular target, it doesn't hurt.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.372 and -4.9), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Both ligands have negative solubility values (-3.414 and -3.135), indicating poor aqueous solubility. This is a major drawback for both.
11. **hERG:** Both ligands have low hERG inhibition liability (A: 0.255, B: 0.445), which is good.
12. **Cl_mic:** Ligand A (-10.978) has a much lower (better) microsomal clearance than Ligand B (37.291), indicating greater metabolic stability.
13. **t1/2:** Ligand B (20.654) has a significantly longer in vitro half-life than Ligand A (4.701). This is a substantial advantage.
14. **Pgp:** Ligand A (0.018) has a much lower Pgp efflux liability than Ligand B (0.376), which is favorable.
15. **Binding Affinity:** Ligand B (-7.9 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.9 kcal/mol). This is a crucial advantage, potentially outweighing some of the ADME drawbacks.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP, affinity, and has a better TPSA. Ligand A has a better Pgp profile.
**Overall Assessment:**
Ligand B's superior binding affinity (-7.9 vs -6.9 kcal/mol) and lower DILI risk are significant advantages. Its longer half-life is also a strong positive. While Ligand A has better metabolic stability and Pgp profile, the difference in binding affinity and DILI risk is more impactful. The poor Caco-2 and solubility for both are concerning, but can potentially be addressed with formulation strategies.
Output:
0
2025-04-17 18:18:02,528 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (362.86 & 346.52 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (64.35) is slightly higher than Ligand B (58.2). Both are well below the 140 threshold for oral absorption, and acceptable for a cardiovascular target (not requiring significant CNS penetration).
3. **logP:** Both ligands have good logP values (3.389 & 3.694), falling within the 1-3 range. Ligand B is slightly higher, which *could* be a minor negative if it leads to solubility issues, but it's not a major concern.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (2). Lower HBA generally improves permeability.
6. **QED:** Ligand A (0.8) is better than Ligand B (0.52), indicating a more drug-like profile.
7. **DILI:** Ligand B (21.95) is significantly better than Ligand A (51.49). This is a crucial advantage for Ligand B. DILI risk is a major concern in drug development.
8. **BBB:** Both ligands have the same BBB penetration (65.37%). This isn't a primary concern for a cardiovascular target like ADRB2, but it's neutral.
9. **Caco-2:** Both ligands have similar, poor Caco-2 permeability (-4.56 and -4.65). This suggests potential absorption issues for both, but it's not a dealbreaker at this stage.
10. **Solubility:** Ligand B (-4.567) is slightly worse than Ligand A (-3.273), but both are quite poor. Solubility could be a formulation challenge for both.
11. **hERG:** Ligand A (0.235) is slightly better than Ligand B (0.407), indicating a lower risk of cardiotoxicity.
12. **Cl_mic:** Ligand B (41.96) has slightly better metabolic stability than Ligand A (43.50), but the difference is minimal.
13. **t1/2:** Ligand A (14.51) has a significantly longer half-life than Ligand B (6.75). This is a significant advantage for Ligand A, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.46) is better than Ligand B (0.345), indicating lower P-gp efflux.
15. **Binding Affinity:** Ligand A (-7.7 kcal/mol) has a substantially stronger binding affinity than Ligand B (-6.4 kcal/mol). This 1.3 kcal/mol difference is a major advantage, and can often outweigh minor ADME concerns.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are particularly important. Both ligands satisfy logP and TPSA requirements. Ligand A has better Pgp efflux. However, the *significant* difference in binding affinity heavily favors Ligand A. The lower DILI risk of Ligand B is attractive, but the strong binding of Ligand A is a more substantial advantage.
**Conclusion:**
Despite the lower DILI score for Ligand B, the significantly stronger binding affinity of Ligand A, combined with its better QED, HBD/HBA, Pgp efflux and longer half-life, makes it the more promising drug candidate.
Output:
1
2025-04-17 18:18:02,528 - INFO - Batch 27 complete. Total preferences: 432
2025-04-17 18:18:02,528 - INFO - Processing batch 28/512...
2025-04-17 18:18:50,681 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.291 and 352.475 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (59.81) is significantly better than Ligand B (87.66). For a GPCR, lower TPSA is generally preferred, aiding permeability. Ligand B is approaching a level that could hinder oral absorption.
3. **logP:** Ligand A (3.693) is within the optimal range (1-3), while Ligand B (1.84) is at the lower end. While not terrible, lower logP can sometimes indicate permeability issues.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally correlate with better membrane permeability.
5. **HBA:** Both ligands have 4 HBA, which is acceptable.
6. **QED:** Ligand A (0.732) has a higher QED score than Ligand B (0.524), indicating a more drug-like profile.
7. **DILI:** Ligand B (16.092) has a *much* lower DILI risk than Ligand A (91.314). This is a major advantage for Ligand B.
8. **BBB:** Ligand A (85.498) has a better BBB penetration percentile than Ligand B (61.846). While ADRB2 isn't exclusively a CNS target, some degree of BBB penetration can be beneficial for understanding off-target effects and potential peripheral activity.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.636 and -4.795), which is unusual and suggests poor permeability. However, these values are on the same scale, so it doesn't differentiate the two.
10. **Solubility:** Ligand A (-4.818) has slightly better solubility than Ligand B (-2.16), but both are poor.
11. **hERG:** Ligand A (0.751) has a slightly better hERG profile than Ligand B (0.146), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand B (49.702) has lower microsomal clearance than Ligand A (68.571), suggesting better metabolic stability.
13. **t1/2:** Ligand A (43.791) has a significantly longer in vitro half-life than Ligand B (-14.621). This is a major advantage for Ligand A, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.434) has lower P-gp efflux liability than Ligand B (0.076), which is preferable.
15. **Binding Affinity:** Ligand A (-6.3 kcal/mol) has a slightly better binding affinity than Ligand B (-5.9 kcal/mol). This difference, while not huge, is enough to be considered.
**Overall Assessment:**
Ligand A excels in binding affinity, half-life, Pgp efflux, and BBB penetration. However, it has a significantly higher DILI risk and poorer TPSA. Ligand B shines with its low DILI risk and better metabolic stability (lower Cl_mic), but suffers from a lower QED, lower logP, and a shorter half-life.
Given the GPCR target class, a balance between permeability (TPSA, logP) and metabolic stability is crucial. The extremely high DILI risk associated with Ligand A is a major concern, outweighing its advantages in binding affinity and half-life. While Ligand B has some weaknesses, its significantly lower DILI risk makes it the more promising candidate, especially considering the potential for optimization to improve its other properties.
Output:
0
2025-04-17 18:18:50,681 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, priorities are affinity, logP, TPSA, Pgp efflux, and BBB penetration (though BBB is less critical for a cardiovascular target).
Let's compare the ligands property by property:
1. **MW:** Both ligands (359.5 & 354.3 Da) are within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (45.15) is significantly better than Ligand B (115.39). A TPSA under 140 is good for oral absorption, but under 90 is preferred for GPCRs, and A is closer to this. B is quite high, potentially hindering absorption.
3. **logP:** Ligand A (3.937) is optimal (1-3), while Ligand B (-0.88) is too low, potentially leading to poor membrane permeability.
4. **HBD/HBA:** Ligand A (0 HBD, 6 HBA) is preferable to Ligand B (3 HBD, 5 HBA). Lower HBD is generally better for permeability.
5. **QED:** Ligand A (0.782) is better than Ligand B (0.574), indicating a more drug-like profile.
6. **DILI:** Ligand B (58.24) has a slightly better DILI risk profile than Ligand A (46.142), but both are acceptable.
7. **BBB:** Ligand A (86.274) has much better BBB penetration potential than Ligand B (40.093), though this is less crucial for a cardiovascular target.
8. **Caco-2:** Both are negative (-5.005 and -5.156), indicating poor permeability. This is concerning for both.
9. **Solubility:** Ligand A (-4.071) is better than Ligand B (-2.204), but both are poor.
10. **hERG:** Ligand A (0.895) is better than Ligand B (0.198), indicating lower cardiotoxicity risk.
11. **Cl_mic:** Ligand B (-30.76) has significantly better metabolic stability (lower clearance) than Ligand A (91.962). This is a major advantage for B.
12. **t1/2:** Ligand B (-40.557) has a much longer in vitro half-life than Ligand A (5.664). This is a significant advantage for B.
13. **Pgp:** Ligand A (0.501) has better Pgp efflux liability than Ligand B (0.026) - lower is better.
14. **Affinity:** Ligand B (-7.1 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.6 kcal/mol). This is a substantial advantage.
**Overall Assessment:**
Ligand B has a significantly stronger binding affinity and much better metabolic stability and half-life. These are critical factors. While Ligand A has better TPSA, logP, and BBB, the affinity difference and improved PK properties of Ligand B outweigh these advantages, especially considering this is a cardiovascular target where BBB penetration is less critical. The poor Caco-2 values for both are a concern, but the improved metabolic profile of B gives it a better chance of achieving therapeutic concentrations *in vivo*.
**Output:**
0
2025-04-17 18:18:50,681 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (357.8 and 350.5 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand B (58.64) is significantly better than Ligand A (106.93). ADRB2 is not a CNS target, but lower TPSA generally improves absorption.
3. **logP:** Both ligands have good logP values (3.058 and 3.249), falling within the optimal 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Ligand A has 2 HBD, while Ligand B has 1. Both are acceptable, well below the threshold of 5.
5. **HBA:** Ligand A has 6 HBA, and Ligand B has 3. Both are below the threshold of 10. Ligand B is preferable.
6. **QED:** Both ligands have similar and good QED values (0.726 and 0.731), indicating good drug-likeness.
7. **DILI:** Ligand A has a significantly higher DILI risk (85.731) compared to Ligand B (11.322). This is a major concern for Ligand A.
8. **BBB:** BBB is not a primary concern for ADRB2 (cardiovascular target). Ligand B has a higher BBB percentile (73.827) than Ligand A (54.091), but this is less critical.
9. **Caco-2:** Ligand A (-5.405) and Ligand B (-4.662) both have negative Caco-2 values. This is unusual and suggests poor permeability.
10. **Solubility:** Ligand A (-3.93) and Ligand B (-3.217) both have poor solubility.
11. **hERG:** Both ligands have low hERG inhibition liability (0.408 and 0.258), which is good.
12. **Cl_mic:** Ligand B (87.316) has a significantly higher microsomal clearance than Ligand A (8.184). This suggests Ligand A is more metabolically stable.
13. **t1/2:** Ligand A (53.08) has a much longer in vitro half-life than Ligand B (-21.436). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.268) has lower P-gp efflux liability than Ligand B (0.092). This is preferable.
15. **Binding Affinity:** Ligand B (-7.4 kcal/mol) has a slightly better binding affinity than Ligand A (-6.8 kcal/mol). This difference is significant (0.6 kcal/mol).
**Overall Assessment:**
Ligand B has a significantly better safety profile (much lower DILI risk) and a slightly better binding affinity. While Ligand A has better metabolic stability (lower Cl_mic, longer t1/2) and Pgp efflux, the high DILI risk is a major red flag. The improved binding affinity of Ligand B, coupled with the lower DILI risk, outweighs the benefits of Ligand A's metabolic properties. The TPSA of Ligand B is also significantly better.
Output:
0
2025-04-17 18:18:50,681 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 drug candidates. ADRB2 is a GPCR, so we'll prioritize logP, Pgp, TPSA, and affinity, alongside general drug-like properties.
**Ligand A:** [354.397, 60.85, 1.708, 1, 3, 0.839, 16.053, 89.027, -4.692, -2.512, 0.415, 3.101, 0.417, 0.043, -7.2]
**Ligand B:** [380.417, 104.53, 0.044, 2, 7, 0.66, 53.47, 51.958, -5.292, -1.479, 0.134, -25.659, -4.099, 0.023, -7.5]
Here's a breakdown:
1. **MW:** Both are within the acceptable 200-500 Da range. Ligand A (354.397) is slightly preferred.
2. **TPSA:** Ligand A (60.85) is excellent, well below the 140 threshold. Ligand B (104.53) is higher, but still potentially acceptable.
3. **logP:** Ligand A (1.708) is optimal. Ligand B (0.044) is *very* low, which is a significant concern for permeability.
4. **HBD:** Both are acceptable (1 and 2 respectively).
5. **HBA:** Both are acceptable (3 and 7 respectively).
6. **QED:** Ligand A (0.839) is excellent. Ligand B (0.66) is still reasonable, but lower.
7. **DILI:** Ligand A (16.053) has a very low DILI risk. Ligand B (53.47) is higher, but still not alarming.
8. **BBB:** Ligand A (89.027) is very good. Ligand B (51.958) is lower, less desirable.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-4.692) is slightly better than Ligand B (-5.292).
10. **Solubility:** Both are negative, indicating poor solubility. Ligand A (-2.512) is slightly better than Ligand B (-1.479).
11. **hERG:** Both are very low risk (0.415 and 0.134).
12. **Cl_mic:** Ligand A (3.101) has a lower clearance, suggesting better metabolic stability. Ligand B (-25.659) has a very high clearance, a major drawback.
13. **t1/2:** Ligand A (0.417) is very short, while Ligand B (-4.099) is also short. Both are poor.
14. **Pgp:** Both are very low efflux (0.043 and 0.023).
15. **Affinity:** Ligand B (-7.5) is slightly better than Ligand A (-7.2), but the difference is not huge.
**Overall Assessment:**
Ligand A is significantly better overall. While Ligand B has slightly better binding affinity, its extremely low logP and very high clearance are major red flags. These issues will likely lead to poor absorption, distribution, and a short duration of action. Ligand A has a much more balanced profile, with good QED, low DILI risk, good BBB penetration, and better metabolic stability. The slightly weaker affinity of Ligand A can likely be optimized with further medicinal chemistry efforts.
Output:
1
2025-04-17 18:18:50,682 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (344.411 Da) is slightly lower, which could be beneficial for permeability.
2. **TPSA:** Ligand B (49.77) is significantly better than Ligand A (75.71). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have acceptable logP values (A: 2.087, B: 3.751), falling within the 1-3 range. Ligand B is a bit higher, which *could* lead to solubility issues, but isn't a major concern.
4. **HBD/HBA:** Both have 1 HBD and 4 HBA, which are within acceptable limits.
5. **QED:** Both ligands have good QED scores (A: 0.673, B: 0.763), indicating good drug-like properties. Ligand B is slightly better.
6. **DILI:** Ligand B (17.72) has a much lower DILI risk than Ligand A (47.15). This is a significant advantage.
7. **BBB:** Both have reasonable BBB penetration (A: 77.239, B: 80.651), but this is less critical for a cardiovascular target.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and indicates poor permeability. This is a significant drawback for both.
9. **Solubility:** Both have negative solubility values, indicating poor aqueous solubility. This is a significant drawback for both.
10. **hERG:** Both have low hERG risk (A: 0.415, B: 0.751).
11. **Cl_mic:** Ligand B (73.211) has a higher microsomal clearance than Ligand A (54.388), suggesting faster metabolism and potentially lower *in vivo* exposure.
12. **t1/2:** Ligand B (34.121) has a significantly longer half-life than Ligand A (12.297). This is a major advantage.
13. **Pgp:** Both have low Pgp efflux liability (A: 0.071, B: 0.827).
14. **Binding Affinity:** Ligand A (-7.2 kcal/mol) has a better binding affinity than Ligand B (-5.7 kcal/mol). This is a substantial advantage, potentially outweighing some ADME concerns.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand A has better affinity and a slightly better logP. Ligand B has better TPSA and DILI. The difference in affinity is substantial (1.5 kcal/mol), and the DILI risk for Ligand A is concerning. The longer half-life of Ligand B is also a significant benefit. The poor Caco-2 and solubility are concerning for both, but can be addressed with formulation strategies.
**Conclusion:**
Despite the superior binding affinity of Ligand A, the significantly lower DILI risk, longer half-life, and better TPSA of Ligand B make it the more promising candidate. The affinity difference, while substantial, might be overcome with further optimization, while mitigating the DILI risk associated with Ligand A could be more challenging.
Output:
0
2025-04-17 18:18:50,682 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.373 and 346.471 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (75.94) is higher than Ligand B (58.64). For a cardiovascular GPCR, TPSA is moderately important for permeability, and Ligand B is better.
3. **logP:** Both ligands have excellent logP values (2.585 and 2.29), falling within the optimal 1-3 range.
4. **HBD:** Both have 1 HBD, which is ideal.
5. **HBA:** Ligand A has 5 HBA, while Ligand B has 3. Both are acceptable (<=10), but Ligand B is slightly better.
6. **QED:** Ligand A (0.92) has a significantly higher QED score than Ligand B (0.614), indicating a more drug-like profile. This is a strong advantage for Ligand A.
7. **DILI:** Ligand A (52.191) has a higher DILI risk than Ligand B (23.614). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (83.443) has a higher BBB penetration percentile than Ligand B (69.794). While ADRB2 isn't primarily a CNS target, some CNS exposure can be a concern for off-target effects.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. This is a concern for both.
10. **Solubility:** Both ligands have poor solubility (-1.996 and -2.162). This is a significant drawback for both.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.158 and 0.156). This is good for both.
12. **Cl_mic:** Ligand A (-6.991) has a much lower (better) microsomal clearance than Ligand B (48.933), suggesting greater metabolic stability. This is a strong advantage for Ligand A.
13. **t1/2:** Ligand A (-8.664) has a much longer in vitro half-life than Ligand B (-16.531). This is a significant advantage for Ligand A.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.016 and 0.102). This is good for both.
15. **Binding Affinity:** Ligand B (-7.3 kcal/mol) has a slightly better binding affinity than Ligand A (-5.8 kcal/mol). This is a 1.5 kcal/mol advantage, which is significant.
**GPCR-Specific Priorities & Overall Assessment:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Both ligands perform well on logP and Pgp. Ligand B has a better TPSA and a slightly better affinity. However, Ligand A has a significantly better QED, lower Cl_mic, and longer half-life. The DILI risk is also much lower for Ligand B.
The affinity difference is important, but the improved metabolic stability (Cl_mic and t1/2) and drug-likeness (QED) of Ligand A, combined with the lower DILI risk of Ligand B, are crucial. The solubility and Caco-2 permeability are problematic for both, but can potentially be addressed with formulation strategies. Given the balance, the improved ADME properties of Ligand A, especially the metabolic stability, make it a more promising starting point, even with slightly lower affinity.
Output:
1
2025-04-17 18:18:50,682 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
The target is ADRB2, a GPCR. Therefore, I will prioritize logP, TPSA, Pgp efflux, BBB penetration, and binding affinity. Metabolic stability (Cl_mic, t1/2) and safety (DILI, hERG) are also important.
Let's compare the ligands property by property:
1. **MW:** Both ligands (356.813 and 352.519 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (67.23) is higher than Ligand B (49.85). Ligand B is better here, falling comfortably below the 140 A^2 threshold for good absorption.
3. **logP:** Both ligands (2.937 and 2.589) are within the optimal 1-3 range. Ligand B is slightly lower, which could be beneficial for solubility, but both are acceptable.
4. **HBD:** Ligand A (1) is better than Ligand B (0). While both are low, having one HBD can sometimes improve solubility without significantly impacting permeability.
5. **HBA:** Both ligands have 4 HBA, which is good.
6. **QED:** Ligand A (0.781) is better than Ligand B (0.606), indicating a more drug-like profile.
7. **DILI:** Ligand B (2.171) is *significantly* better than Ligand A (89.608). This is a major advantage for Ligand B.
8. **BBB:** Ligand B (86.468) is better than Ligand A (78.79), although both are reasonably high.
9. **Caco-2:** Ligand A (-4.879) is better than Ligand B (-4.47). Higher (less negative) Caco-2 values indicate better permeability.
10. **Solubility:** Ligand B (-0.963) is better than Ligand A (-4.2).
11. **hERG:** Ligand B (0.614) is better than Ligand A (0.547), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand B (17.672) is *much* better than Ligand A (70.94). Lower clearance is preferred for better metabolic stability.
13. **t1/2:** Ligand A (112.977) is better than Ligand B (-9.277).
14. **Pgp:** Ligand B (0.041) is better than Ligand A (0.616), indicating lower efflux and potentially better bioavailability.
15. **Binding Affinity:** Ligand B (-6.8) is slightly better than Ligand A (-6.4). While the difference is not huge, it's still a positive.
**Overall Assessment:**
Ligand B has several significant advantages: much lower DILI risk, significantly lower microsomal clearance, better solubility, lower Pgp efflux, and slightly better binding affinity. While Ligand A has slightly better Caco-2 permeability and in vitro half-life, the safety and metabolic stability profile of Ligand B are far more compelling, especially for a GPCR target where chronic dosing is often anticipated. The slightly better binding affinity of Ligand B further solidifies its preference.
**Output:**
0
2025-04-17 18:18:50,682 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (373.519 Da and 361.869 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (93.11) is higher than Ligand B (49.77). For a GPCR, lower TPSA is generally preferred for better permeability, giving a slight edge to Ligand B.
**3. logP:** Ligand A (-0.48) is quite low, potentially hindering membrane permeability. Ligand B (4.247) is high, potentially leading to solubility issues and off-target interactions. This is a significant concern for both, but the higher logP of B is more problematic.
**4. H-Bond Donors:** Ligand A (3) is acceptable, while Ligand B (1) is also good.
**5. H-Bond Acceptors:** Ligand A (6) is acceptable, and Ligand B (3) is also good.
**6. QED:** Both ligands have good QED scores (0.582 and 0.764), indicating good drug-like properties.
**7. DILI:** Ligand A (13.3) has a much lower DILI risk than Ligand B (15.083). This is a significant advantage for Ligand A.
**8. BBB:** Ligand B (40.558) has a higher BBB penetration score than Ligand A (13.765). While ADRB2 isn't necessarily a CNS target, some peripheral ADRB2 activity can be modulated by CNS effects, so this is a slight advantage for B.
**9. Caco-2 Permeability:** Ligand A (-5.521) and Ligand B (-4.671) both have negative values, which is unusual. This suggests poor permeability.
**10. Aqueous Solubility:** Ligand A (-1.176) and Ligand B (-4.305) both have negative values, which is unusual. This suggests poor solubility.
**11. hERG Inhibition:** Ligand A (0.089) has a very low hERG inhibition risk, much lower than Ligand B (0.872). This is a critical advantage for Ligand A, as hERG inhibition can lead to cardiotoxicity.
**12. Microsomal Clearance:** Ligand A (-6.469) has much lower microsomal clearance than Ligand B (104.324), indicating better metabolic stability. This is a significant advantage for Ligand A.
**13. In vitro Half-Life:** Ligand B (36.226) has a significantly longer in vitro half-life than Ligand A (-2.719). This is a strong advantage for Ligand B.
**14. P-gp Efflux:** Ligand A (0.006) has very low P-gp efflux, while Ligand B (0.333) has moderate efflux. This is a significant advantage for Ligand A.
**15. Binding Affinity:** Both ligands have similar binding affinities (-6.9 kcal/mol and -6.3 kcal/mol). The difference isn't large enough to outweigh other factors.
**Overall Assessment:**
Ligand A is the better candidate. While Ligand B has a longer half-life and better BBB penetration, Ligand A demonstrates significantly better safety (lower DILI, much lower hERG inhibition) and ADME properties (lower clearance, lower P-gp efflux). The low logP of Ligand A is a concern, but the overall profile is more favorable for development, especially considering the cardiovascular implications of hERG inhibition.
Output:
1
2025-04-17 18:18:50,682 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**1. Molecular Weight:** Both ligands (342.355 Da and 353.344 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (93.53) is higher than Ligand B (62.61). For a GPCR like ADRB2, lower TPSA is generally preferred for better permeability, giving a slight edge to Ligand B.
**3. logP:** Ligand B (2.167) is within the optimal 1-3 range, while Ligand A (0.234) is quite low. This is a significant advantage for Ligand B, as low logP can hinder membrane permeability.
**4. H-Bond Donors:** Ligand A (1) and Ligand B (2) are both acceptable, being less than 5.
**5. H-Bond Acceptors:** Ligand A (6) and Ligand B (3) are both acceptable, being less than 10.
**6. QED:** Both ligands have good QED values (0.786 and 0.836), indicating good drug-like properties.
**7. DILI:** Both ligands have similar DILI risk (67.429 and 60.682), and are within an acceptable range (<60 is ideal, but both are below 70).
**8. BBB:** Ligand B (87.088) has a significantly higher BBB penetration percentile than Ligand A (64.482). While ADRB2 isn't strictly a CNS target, some CNS exposure can occur, and higher BBB is generally favorable.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.633 and -4.687), which is unusual and suggests poor permeability. This is a concern for both.
**10. Aqueous Solubility:** Both ligands have negative solubility values (-2.226 and -3.348), which is also unusual and suggests poor solubility. This is a concern for both.
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (0.321 and 0.451).
**12. Microsomal Clearance:** Ligand A (29.542) has a higher microsomal clearance than Ligand B (11.311), indicating lower metabolic stability. This favors Ligand B.
**13. In vitro Half-Life:** Ligand B (-2.971) has a longer in vitro half-life than Ligand A (-19.936). This is a significant advantage for Ligand B.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.047 and 0.031).
**15. Binding Affinity:** Ligand A (-8.0) has a slightly better binding affinity than Ligand B (-6.6). However, the difference is not substantial enough to outweigh the ADME deficiencies of Ligand A.
**Overall Assessment:**
Ligand B is the more promising candidate. While both ligands have issues with Caco-2 permeability and solubility, Ligand B has a significantly better logP, BBB penetration, metabolic stability (lower Cl_mic, longer t1/2), and a reasonable binding affinity. Ligand A's low logP is a major drawback, and its higher clearance and shorter half-life are also concerning. The slightly better affinity of Ligand A is not enough to compensate for these ADME liabilities.
Output:
0
2025-04-17 18:18:50,682 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [342.439, 67.43, 2.894, 2, 3, 0.564, 37.146, 64.637, -4.739, -3.574, 0.659, 34.801, 22.419, 0.342, -5.2]
**Ligand B:** [350.459, 78.87, 1.237, 2, 4, 0.677, 12.136, 65.374, -4.655, -1.777, 0.241, 27.769, 2.934, 0.054, -6.4]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). A (342.439) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** A (67.43) is better than B (78.87). Both are below 140, but A is closer to the optimal for oral absorption.
3. **logP:** A (2.894) is better than B (1.237). B is a bit low, potentially hindering membrane permeability.
4. **HBD:** Both have 2 HBD, which is good.
5. **HBA:** A (3) is better than B (4). Lower is preferable.
6. **QED:** Both are good (A: 0.564, B: 0.677), indicating drug-like properties. B is slightly better here.
7. **DILI:** A (37.146) is significantly better than B (12.136). This is a major advantage for A.
8. **BBB:** Both are reasonable (A: 64.637, B: 65.374), but not exceptionally high. For a cardiovascular target, BBB isn't a primary concern.
9. **Caco-2:** Both are negative, indicating poor permeability. A (-4.739) is slightly worse than B (-4.655).
10. **Solubility:** A (-3.574) is worse than B (-1.777). Solubility is a concern for both, but B is better.
11. **hERG:** A (0.659) is better than B (0.241). Lower is better to avoid cardiotoxicity.
12. **Cl_mic:** B (27.769) is better than A (34.801). Lower clearance means better metabolic stability.
13. **t1/2:** A (22.419) is much better than B (2.934). A significantly longer half-life is a major advantage.
14. **Pgp:** A (0.342) is better than B (0.054). Lower P-gp efflux is preferable.
15. **Affinity:** B (-6.4) is significantly better than A (-5.2). This is a 1.2 kcal/mol advantage, which is substantial.
**GPCR-specific priorities:** For ADRB2 (a GPCR), we prioritize logP, Pgp, TPSA, and affinity.
* **Affinity:** B has a clear advantage.
* **logP:** A is better.
* **Pgp:** A is better.
* **TPSA:** A is better.
**Overall Assessment:**
While Ligand B has a superior binding affinity, the significant advantages of Ligand A in DILI risk, *t1/2*, and Pgp efflux, coupled with better TPSA and logP, make it the more promising candidate. The lower DILI risk is particularly important for a cardiovascular target. The longer half-life of A would also be beneficial for dosing. The affinity difference, while substantial, can potentially be addressed through further optimization of Ligand A. The solubility of both is a concern, but can be addressed through formulation strategies.
Output:
1
2025-04-17 18:18:50,682 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.463 and 345.487 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (93.09) is slightly higher than Ligand B (71.09). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B has a clear advantage here.
3. **logP:** Ligand A (1.471) is within the optimal 1-3 range. Ligand B (3.293) is at the higher end of optimal, potentially raising concerns about solubility and off-target effects. Ligand A is slightly favored.
4. **HBD:** Both ligands have 2 HBD, which is within the acceptable limit of 5. No difference.
5. **HBA:** Ligand A has 5 HBA, while Ligand B has 3. Both are below the 10 threshold. No significant difference.
6. **QED:** Both ligands have good QED scores (0.668 and 0.721, respectively), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (38.426%) has a slightly higher DILI risk than Ligand B (32.183%). Both are below the 40% threshold, so the difference is not major. Ligand B is slightly favored.
8. **BBB:** Ligand A (53.432%) has a lower BBB penetration than Ligand B (77.937%). Since ADRB2 is a cardiovascular target (not CNS), BBB is less important, but higher is generally better. Ligand B is favored.
9. **Caco-2:** Ligand A (-5.244) has a lower Caco-2 permeability than Ligand B (-4.718). Lower values indicate poorer permeability. Ligand B is favored.
10. **Solubility:** Ligand A (-1.84) has better aqueous solubility than Ligand B (-3.703). Solubility is important for bioavailability. Ligand A is favored.
11. **hERG:** Ligand A (0.268) has a much lower hERG inhibition liability than Ligand B (0.664). This is a *critical* advantage for Ligand A, as hERG inhibition can lead to cardiotoxicity.
12. **Cl_mic:** Ligand A (36.146 mL/min/kg) has lower microsomal clearance than Ligand B (63.22 mL/min/kg), indicating better metabolic stability. Ligand A is favored.
13. **t1/2:** Ligand A (9.908 hours) has a longer in vitro half-life than Ligand B (1.497 hours). This is a significant advantage for Ligand A, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.051) has a much lower P-gp efflux liability than Ligand B (0.139). Lower P-gp efflux is favorable for bioavailability. Ligand A is favored.
15. **Binding Affinity:** Ligand A (-7.8 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.0 kcal/mol). This >1.5 kcal/mol difference is substantial and can outweigh minor ADME drawbacks.
**Overall Assessment:**
Ligand A demonstrates a superior profile overall, especially considering the GPCR-specific priorities. While Ligand B has better TPSA and BBB (less important for a cardiovascular target), Ligand A excels in crucial areas like binding affinity, hERG inhibition, metabolic stability (Cl_mic and t1/2), P-gp efflux, and solubility. The stronger binding affinity and significantly reduced hERG risk are particularly compelling.
Output:
1
2025-04-17 18:18:50,682 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.479 and 354.447 Da) are within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (70.47) is significantly better than Ligand B (99.1). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is approaching a level that could hinder absorption.
3. **logP:** Ligand A (1.261) is within the optimal range (1-3). Ligand B (-0.097) is slightly below 1, which *could* indicate permeability issues, although not drastically.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Both ligands have 5 HBA, which is acceptable.
6. **QED:** Ligand A (0.805) has a higher QED score than Ligand B (0.502), indicating a more drug-like profile.
7. **DILI:** Both ligands have acceptable DILI risk (24.893 and 27.336 percentile).
8. **BBB:** Ligand A (65.491) has a better BBB penetration score than Ligand B (29.779). While ADRB2 isn't exclusively a CNS target, some CNS exposure is possible, and higher BBB is generally favorable.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.079 and -4.852), which is unusual. I'll interpret this as very poor permeability. However, the values are close, so it doesn't heavily sway the decision.
10. **Solubility:** Both ligands have negative solubility values (-1.07 and -1.241), indicating very poor aqueous solubility. This is a significant concern for both.
11. **hERG:** Both ligands have low hERG inhibition liability (0.359 and 0.209), which is excellent.
12. **Cl_mic:** Ligand A (3.084) has a lower microsomal clearance than Ligand B (21.483), indicating better metabolic stability.
13. **t1/2:** Ligand A (32.536) has a significantly longer in vitro half-life than Ligand B (-14.512). This is a major advantage.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.047 and 0.017).
15. **Binding Affinity:** Ligand A (-6.1 kcal/mol) has a slightly better binding affinity than Ligand B (-5.6 kcal/mol). While the difference isn't huge, it's enough to consider, especially given the other advantages of Ligand A.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most key parameters. It has better TPSA, logP, QED, BBB penetration, metabolic stability (lower Cl_mic, longer t1/2), and slightly better binding affinity. Both have poor solubility and Caco-2 permeability, which are serious drawbacks that would need to be addressed in further optimization. However, the superior ADME properties of Ligand A, particularly its metabolic stability and half-life, make it the more promising candidate.
Output:
1
2025-04-17 18:18:50,682 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (358.423 and 346.471 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (84.42) is slightly higher than Ligand B (58.64). Ligand B is preferable as it's closer to the <140 target for good oral absorption, and GPCRs benefit from lower TPSA.
3. **logP:** Ligand B (2.543) is slightly higher than Ligand A (1.508), both are within the optimal 1-3 range. Ligand B is slightly better.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 6 HBA, Ligand B has 3. Ligand B is preferable as it is closer to the <10 target.
6. **QED:** Ligand A (0.895) has a significantly better QED score than Ligand B (0.708), indicating better overall drug-likeness. This is a significant advantage for Ligand A.
7. **DILI:** Ligand B (16.673) has a much lower DILI risk than Ligand A (77.278). This is a major advantage for Ligand B.
8. **BBB:** Both ligands have similar BBB penetration (Ligand A: 70.531, Ligand B: 77.162). Both are acceptable, but Ligand B is slightly better.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the values are similar (-5.004 vs -4.705).
10. **Solubility:** Ligand A (-3.743) has slightly better solubility than Ligand B (-2.454).
11. **hERG:** Ligand A (0.312) has a lower hERG risk than Ligand B (0.613), which is preferable.
12. **Cl_mic:** Ligand B (57.442) has a lower microsomal clearance than Ligand A (40.674), suggesting better metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand B (-6.883) has a negative in vitro half-life, which is concerning. Ligand A (13.009) has a positive, and more reasonable half-life. This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.322) has lower P-gp efflux liability than Ligand B (0.239), which is preferable.
15. **Binding Affinity:** Ligand B (-6.5 kcal/mol) has a slightly better binding affinity than Ligand A (-5.4 kcal/mol). This is a 1.1 kcal/mol advantage, which is substantial.
**Overall Assessment:**
This is a tough call. Ligand B excels in DILI risk, Cl_mic, and binding affinity, all important factors. However, Ligand A has a significantly better QED score, a more reasonable half-life, and lower P-gp efflux. The negative half-life of Ligand B is a major concern. While the affinity difference is significant, the other advantages of Ligand A, especially the better QED and half-life, make it a more promising starting point for optimization. Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity), Ligand B's better affinity and logP are attractive, but the DILI and metabolic stability benefits of Ligand B are more critical.
Output:
0
2025-04-17 18:18:50,682 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (365.377 Da and 353.463 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Both ligands (96.97 and 93.46) are reasonably low, suggesting good potential for absorption. They are below the 140 A^2 threshold.
**3. logP:** Ligand A (-0.474) is a bit low, potentially hindering membrane permeability. Ligand B (2.305) is within the optimal 1-3 range. This is a significant advantage for Ligand B.
**4. H-Bond Donors:** Both have 2 HBD, which is acceptable.
**5. H-Bond Acceptors:** Both have 5 HBA, also acceptable.
**6. QED:** Ligand B (0.71) has a better QED score than Ligand A (0.403), indicating a more drug-like profile.
**7. DILI:** Both ligands have acceptable DILI risk (31.718 and 37.611 percentile).
**8. BBB:** Ligand A (75.843) has a better BBB penetration score than Ligand B (59.791). While ADRB2 is primarily a cardiovascular target, some CNS effects are possible with beta-blockers, so moderate BBB penetration isn't necessarily a negative.
**9. Caco-2 Permeability:** Ligand A (-5.043) and Ligand B (-4.688) are both negative, which is unusual and suggests poor permeability. However, the scale is not specified, so it is difficult to interpret.
**10. Aqueous Solubility:** Both ligands have very poor aqueous solubility (-1.431 and -2.375). This is a significant concern for bioavailability.
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (0.324 and 0.295).
**12. Microsomal Clearance:** Ligand A (1.298) has a much lower microsomal clearance than Ligand B (46.593), suggesting better metabolic stability. This is a major advantage for Ligand A.
**13. In vitro Half-Life:** Ligand A (-29.277) has a much longer in vitro half-life than Ligand B (14.749). Another significant advantage for Ligand A.
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (0.016 and 0.05).
**15. Binding Affinity:** Both ligands have similar and good binding affinities (-6.3 and -5.9 kcal/mol). The difference is less than 1.5 kcal/mol, so it's not a deciding factor.
**GPCR-Specific Priorities:** For GPCRs, logP, TPSA, Pgp, and affinity are important. Ligand B has a better logP, while Ligand A has better metabolic stability (Cl_mic, t1/2). Considering the poor solubility of both compounds, metabolic stability becomes crucial to ensure sufficient drug exposure.
**Overall Assessment:**
While Ligand B has a better QED and logP, Ligand A's significantly improved metabolic stability (lower Cl_mic and longer t1/2) and reasonable BBB penetration are more critical for a successful cardiovascular drug. The poor solubility is a concern for both, but can be addressed with formulation strategies. The slightly better affinity of Ligand A is a bonus.
Output:
1
2025-04-17 18:18:50,682 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (343.383) is slightly lower, which is generally favorable for permeability.
**2. TPSA:** Ligand B (51.02) has a significantly lower TPSA than Ligand A (104.46). For a GPCR, lower TPSA is generally preferred as it correlates with better membrane permeability.
**3. logP:** Both ligands have acceptable logP values (Ligand A: 1.5, Ligand B: 3.536), falling within the optimal 1-3 range. Ligand B is closer to the upper end, which could potentially cause some solubility issues but is not a major concern.
**4. H-Bond Donors:** Ligand A has 3 HBDs, while Ligand B has 0. Lower HBDs are generally preferred for better permeability, favoring Ligand B.
**5. H-Bond Acceptors:** Ligand A has 5 HBAs, and Ligand B has 6. Both are within the acceptable range of <=10.
**6. QED:** Ligand A (0.661) has a higher QED score than Ligand B (0.362), indicating a more drug-like profile. This is a point in favor of Ligand A.
**7. DILI:** Both ligands have similar DILI risk (Ligand A: 55.448, Ligand B: 57.852), and both are reasonably low.
**8. BBB:** Ligand B (67.158) has a higher BBB penetration percentile than Ligand A (36.642). While ADRB2 is primarily a cardiovascular target, some CNS effects are possible with certain ligands, and higher BBB penetration isn't necessarily detrimental.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability *in vitro*. This is a significant concern for both.
**10. Aqueous Solubility:** Both ligands have very poor aqueous solubility (-2.693 and -2.191 respectively). This is a major drawback for both compounds.
**11. hERG Inhibition:** Both ligands have low hERG inhibition liability (Ligand A: 0.336, Ligand B: 0.662), which is excellent.
**12. Microsomal Clearance:** Ligand B (95.509) has a significantly higher microsomal clearance than Ligand A (48.298), suggesting faster metabolism and potentially lower *in vivo* exposure. This favors Ligand A.
**13. In vitro Half-Life:** Ligand A (7.951) has a slightly longer half-life than Ligand B (6.795), which is preferable.
**14. P-gp Efflux:** Both ligands show low P-gp efflux liability (Ligand A: 0.216, Ligand B: 0.658), which is good.
**15. Binding Affinity:** Ligand A (-6.5 kcal/mol) has a slightly better binding affinity than Ligand B (-5.7 kcal/mol). This difference of 0.8 kcal/mol is significant and can outweigh some of the ADME drawbacks.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand A emerges as the slightly better candidate. While Ligand B has better BBB penetration and lower HBD, Ligand A has a superior QED score, better metabolic stability (lower Cl_mic), longer half-life, and a more favorable binding affinity. The poor solubility and Caco-2 permeability are concerning for both, but the stronger binding affinity of Ligand A makes it more likely to be successful after further optimization to address these ADME issues.
Output:
1
2025-04-17 18:18:50,683 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [358.395, 131.27 , -0.621, 2. , 6. , 0.417, 34.393, 76.58 ,
-5.467, -1.111, 0.069, 3.871, -10.462, 0.006, -5.9 ]
**Ligand B:** [368.503, 85.77 , 0.619, 2. , 6. , 0.769, 13.61 , 22.955,
-5.2 , -0.321, 0.101, -33.782, -6.242, 0.013, -6.2 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). A (358.395) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** A (131.27) is slightly above the preferred <140 for oral absorption, but still reasonable. B (85.77) is excellent, well below 140, suggesting better permeability.
3. **logP:** A (-0.621) is a bit low, potentially hindering membrane permeability. B (0.619) is better, falling within the optimal 1-3 range.
4. **HBD:** Both have 2 HBD, which is good.
5. **HBA:** Both have 6 HBA, which is good.
6. **QED:** A (0.417) is below the desirable 0.5 threshold, indicating a less drug-like profile. B (0.769) is excellent, well above 0.5.
7. **DILI:** A (34.393) is very good, indicating low liver injury risk. B (13.61) is even better, extremely low risk.
8. **BBB:** A (76.58) is good, suggesting reasonable potential for CNS penetration if needed. B (22.955) is low, indicating poor BBB penetration. While ADRB2 isn't exclusively a CNS target, some subtypes are relevant in the brain.
9. **Caco-2:** Both are negative, indicating poor permeability.
10. **Solubility:** Both are negative, indicating poor solubility.
11. **hERG:** Both are very low (0.069 and 0.101), indicating minimal hERG inhibition risk, which is excellent.
12. **Cl_mic:** A (3.871) is much better (lower clearance) than B (-33.782), indicating better metabolic stability.
13. **t1/2:** A (-10.462) is better (longer half-life) than B (-6.242).
14. **Pgp:** Both are very low (0.006 and 0.013), indicating minimal P-gp efflux.
15. **Affinity:** Both have similar binding affinity (-5.9 and -6.2 kcal/mol).
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B has a better logP and TPSA, which are favorable for permeability. However, Ligand A has significantly better metabolic stability (Cl_mic and t1/2) and a slightly better DILI profile. The binding affinity is comparable.
**Decision:**
While Ligand B has better physicochemical properties regarding permeability, the significantly improved metabolic stability and half-life of Ligand A are crucial for *in vivo* efficacy. The slightly lower logP of A is a concern, but can potentially be addressed with further optimization. The QED score of A is a bit low, but not a dealbreaker given the other favorable properties. The comparable affinity makes the ADME properties the deciding factor.
Output:
1
2025-04-17 18:18:50,683 - INFO - Batch 28 complete. Total preferences: 448
2025-04-17 18:18:50,683 - INFO - Processing batch 29/512...
2025-04-17 18:19:39,825 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (341.415 and 350.415 Da). No significant difference.
2. **TPSA:** Ligand A (88.47) is better than Ligand B (96.89). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally favors absorption.
3. **logP:** Both are relatively low (0.311 and 0.263). This is a concern for both, as it might hinder membrane permeability. Ligand B is slightly lower, which is less desirable.
4. **HBD:** Ligand A (2) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Both have 5 HBA, which is acceptable.
6. **QED:** Ligand A (0.756) is significantly better than Ligand B (0.555), indicating a more drug-like profile.
7. **DILI:** Both are good, with Ligand A (37.999) being slightly better than Ligand B (34.238).
8. **BBB:** Both are relatively low (54.13 and 36.836). Not a major concern for a cardiovascular target.
9. **Caco-2:** Ligand A (-5.006) is better than Ligand B (-5.145), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-2.278) is better than Ligand B (-1.376).
11. **hERG:** Ligand A (0.678) is better than Ligand B (0.334), indicating lower cardiotoxicity risk. This is *very* important for a cardiovascular target.
12. **Cl_mic:** Ligand A (-47.418) is *much* better than Ligand B (15.418). A negative value indicates very slow clearance and high metabolic stability, a huge advantage.
13. **t1/2:** Ligand A (13.349) is slightly better than Ligand B (12.45).
14. **Pgp:** Ligand A (0.003) is significantly better than Ligand B (0.064), suggesting lower efflux and better bioavailability.
15. **Binding Affinity:** Ligand A (-7.1) is significantly better than Ligand B (-6.3). A 0.8 kcal/mol difference is substantial and can often overcome minor ADME issues.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. While both ligands have suboptimal logP, Ligand A demonstrates superior performance in TPSA, Pgp, and *especially* affinity. The significantly better metabolic stability (Cl_mic) and lower hERG risk of Ligand A are also critical for a cardiovascular drug.
**Conclusion:**
Ligand A is the superior candidate due to its significantly better binding affinity, metabolic stability, lower hERG risk, better Pgp profile, and higher QED score. These advantages outweigh the slightly lower logP.
Output:
1
2025-04-17 18:19:39,825 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
We are targeting ADRB2, a GPCR. Therefore, the key priorities are logP, TPSA, Pgp efflux, BBB penetration, and binding affinity. Metabolic stability and solubility are also important, but slightly less so than the first five.
Let's compare the ligands property by property:
1. **MW:** Both ligands (346.475 and 349.431 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (87.46) is slightly higher than Ligand B (84.67). Both are below the 140 threshold for oral absorption, but closer to the 90 threshold for CNS targets.
3. **logP:** Ligand A (3.006) is optimal, while Ligand B (1.767) is on the lower side of optimal. This favors Ligand A for membrane permeability.
4. **HBD/HBA:** Ligand A has 3 HBD and 2 HBA, while Ligand B has 1 HBD and 5 HBA. Both are within acceptable ranges, but Ligand A's profile is slightly more balanced.
5. **QED:** Both ligands have good QED scores (0.765 and 0.846), indicating good drug-likeness.
6. **DILI:** Ligand B (41.024) has a slightly higher DILI risk than Ligand A (31.059), but both are below the concerning threshold of 60.
7. **BBB:** Both ligands have good BBB penetration (77.007 and 75.107), but Ligand A is slightly better.
8. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual. I will assume this means low permeability.
9. **Solubility:** Both ligands have negative solubility values, which is also unusual. I will assume this means low solubility.
10. **hERG:** Both ligands have very low hERG inhibition risk (0.399 and 0.346).
11. **Cl_mic:** Ligand A (6.033) has significantly lower microsomal clearance than Ligand B (50.693), indicating better metabolic stability.
12. **t1/2:** Ligand A (8.841) has a much longer in vitro half-life than Ligand B (-15.368). This is a significant advantage.
13. **Pgp:** Ligand A (0.068) has much lower P-gp efflux liability than Ligand B (0.256), suggesting better oral bioavailability and potentially better CNS exposure.
14. **Binding Affinity:** Ligand B (-7.0) has a slightly better binding affinity than Ligand A (-6.4). This is a 0.6 kcal/mol difference, which is significant, but needs to be weighed against the other factors.
**Overall Assessment:**
While Ligand B has a slightly better binding affinity, Ligand A demonstrates a superior ADME profile. It has better logP, lower clearance, longer half-life, and lower P-gp efflux. Given the importance of these factors for a GPCR target like ADRB2, and the relatively small difference in binding affinity, Ligand A is the more promising candidate.
**Output:**
1
2025-04-17 18:19:39,825 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (417.288 Da) is within the ideal range. Ligand B (351.451 Da) is also within the ideal range, and slightly preferred due to being closer to the lower bound.
2. **TPSA:** Ligand A (77.0) is good, below 140 and reasonably well-suited for oral absorption. Ligand B (90.7) is still acceptable, but less optimal.
3. **logP:** Ligand A (4.046) is slightly high, potentially leading to solubility issues or off-target interactions. Ligand B (0.347) is quite low, which could hinder membrane permeability.
4. **HBD:** Ligand A (1) is good. Ligand B (2) is acceptable.
5. **HBA:** Ligand A (6) is good. Ligand B (5) is good.
6. **QED:** Both Ligand A (0.632) and Ligand B (0.774) have good drug-likeness scores. Ligand B is slightly better.
7. **DILI:** Ligand A (88.29) has a high DILI risk. Ligand B (18.108) has a very low DILI risk, a significant advantage.
8. **BBB:** Ligand A (51.997) has moderate BBB penetration. Ligand B (46.762) has similar, moderate BBB penetration. Since ADRB2 is a cardiovascular target, high BBB penetration isn't critical.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.107 and -4.842), which is unusual and suggests poor permeability.
10. **Solubility:** Ligand A (-4.734) has poor solubility. Ligand B (-0.434) has slightly better solubility, but still not great.
11. **hERG:** Ligand A (0.477) has a low hERG risk. Ligand B (0.26) has an even lower hERG risk, which is desirable.
12. **Cl_mic:** Ligand A (60.36) has moderate metabolic clearance. Ligand B (5.76) has very low metabolic clearance, indicating good metabolic stability.
13. **t1/2:** Ligand A (10.751) has a reasonable half-life. Ligand B (-2.158) has a very short half-life, which is a significant drawback.
14. **Pgp:** Ligand A (0.364) has low P-gp efflux. Ligand B (0.007) has very low P-gp efflux, which is a slight advantage.
15. **Affinity:** Ligand A (-8.3 kcal/mol) has significantly better binding affinity than Ligand B (-7.3 kcal/mol). This 1.0 kcal/mol difference is substantial.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand A has a higher logP, but also significantly better affinity. Ligand B has better TPSA and Pgp, but lower affinity. The DILI risk for Ligand A is concerning, but the affinity difference is substantial.
**Overall Assessment:**
Despite the higher DILI risk and slightly higher logP of Ligand A, its significantly stronger binding affinity (-8.3 vs -7.3 kcal/mol) outweighs the drawbacks. The difference in affinity is large enough to potentially overcome issues with metabolic stability and solubility through further optimization. The low half-life of Ligand B is a major concern.
Output:
1
2025-04-17 18:19:39,825 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (351.4 Da) are within the ideal range (200-500 Da). No significant difference.
2. **TPSA:** Ligand A (96.02) is better than Ligand B (99.61), both are acceptable for a non-CNS GPCR target like ADRB2, being under 140.
3. **logP:** Ligand A (-0.19) is a bit low, potentially hindering permeability. Ligand B (1.622) is within the optimal range (1-3). This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (7). Fewer HBAs generally improve permeability.
6. **QED:** Both ligands are similar (0.669 vs 0.612), both above the 0.5 threshold, indicating good drug-likeness.
7. **DILI:** Both ligands have low DILI risk (41.411 and 39.473), both are good.
8. **BBB:** Ligand B (72.547) has better BBB penetration than Ligand A (62.078), but BBB is less critical for ADRB2, a primarily cardiovascular target.
9. **Caco-2:** Both ligands have similar, poor Caco-2 permeability (-4.888 and -4.982).
10. **Solubility:** Ligand A (-1.669) is better than Ligand B (-2.685).
11. **hERG:** Ligand A (0.026) has a much lower hERG inhibition liability than Ligand B (0.806). This is a major advantage for Ligand A, as ADRB2 is a cardiovascular target and hERG inhibition is a significant safety concern.
12. **Cl_mic:** Ligand A (-7.812) has significantly better metabolic stability (lower clearance) than Ligand B (36.855). This is a substantial advantage for Ligand A.
13. **t1/2:** Ligand A (-4.919) has a longer in vitro half-life than Ligand B (2.091).
14. **Pgp:** Ligand A (0.022) has lower P-gp efflux liability than Ligand B (0.069), which is favorable.
15. **Binding Affinity:** Ligand A (-6.5) has a slightly better binding affinity than Ligand B (-4.4). This is a significant advantage.
**GPCR-specific priorities:** For ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B has a better logP, but Ligand A excels in affinity, metabolic stability, hERG, and Pgp efflux. The superior affinity and safety profile (hERG, Cl_mic) of Ligand A outweigh the slightly less optimal logP.
**Conclusion:**
Ligand A is the more promising drug candidate due to its superior binding affinity, lower hERG risk, better metabolic stability, and lower P-gp efflux. While Ligand B has a better logP, the other advantages of Ligand A are more critical for a cardiovascular GPCR target.
Output:
1
2025-04-17 18:19:39,825 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
We are targeting ADRB2, a GPCR. Therefore, the priorities are logP, Pgp, TPSA, affinity, and, to a lesser extent, BBB. Let's analyze each ligand against these and other critical parameters:
1. **Molecular Weight:** Both ligands (358.385 and 350.459 Da) fall comfortably within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (80.57) is better than Ligand B (87.66). Both are below 140, which is good for oral absorption, but lower is generally preferred.
3. **logP:** Ligand A (2.484) is better than Ligand B (1.118). Both are within the optimal 1-3 range, but Ligand B is closer to the lower limit, which *could* indicate permeability issues.
4. **H-Bond Donors/Acceptors:** Ligand A has 2 HBD and 4 HBA, while Ligand B has 3 HBD and 4 HBA. Both are within acceptable limits.
5. **QED:** Ligand A (0.785) is better than Ligand B (0.642), indicating a more drug-like profile.
6. **DILI:** Ligand A (57.076) is significantly better than Ligand B (14.889). This is a crucial factor, as lower DILI risk is highly desirable.
7. **BBB:** Ligand A (80.419) is better than Ligand B (53.587). While not a primary concern for ADRB2 (a peripheral receptor), higher BBB penetration isn't necessarily detrimental.
8. **Caco-2:** Ligand A (-4.839) is better than Ligand B (-5.197). Both are negative, which is unusual and suggests poor permeability. However, the difference is small.
9. **Solubility:** Ligand A (-3.036) is better than Ligand B (-1.802). Higher solubility is generally preferred.
10. **hERG:** Both ligands have very low hERG risk (0.441 and 0.156 respectively).
11. **Cl_mic:** Ligand B (10.266) is better than Ligand A (14.217). Lower clearance indicates better metabolic stability.
12. **t1/2:** Ligand B (27.442) is better than Ligand A (25.559). A slightly longer half-life is preferable.
13. **Pgp:** Ligand A (0.099) is better than Ligand B (0.014). Lower P-gp efflux is beneficial for bioavailability.
14. **Binding Affinity:** Ligand B (-7.9 kcal/mol) is significantly better than Ligand A (-6.8 kcal/mol). This is a substantial difference in potency (1.1 kcal/mol), and often outweighs minor ADME concerns.
**Overall Assessment:**
Ligand B has a significantly better binding affinity (-7.9 vs -6.8 kcal/mol). While Ligand A has advantages in several ADME properties (DILI, TPSA, logP, QED, solubility, Pgp), the substantial potency difference of Ligand B is a major advantage for a GPCR target. The slightly better metabolic stability and half-life of Ligand B are also beneficial. The DILI risk of Ligand A is much better, but the potency difference is so large that it is worth exploring strategies to mitigate the DILI risk of Ligand B.
**Output:**
0
2025-04-17 18:19:39,826 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (357.43 & 348.44 Da) are within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (87.74) is slightly higher than Ligand B (77.52), but both are below the 140 threshold for good oral absorption. Ligand B is preferable due to being closer to the 90 threshold for potential CNS penetration, even though this is less critical for a cardiovascular target.
3. **logP:** Ligand B (3.593) is at the upper end of the optimal range (1-3), while Ligand A (0.383) is quite low, potentially hindering membrane permeability. Ligand B is significantly better here.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1), but both are within the acceptable limit of 5.
5. **HBA:** Ligand A (4) is lower than Ligand B (5), which is slightly preferable.
6. **QED:** Both ligands have good QED scores (0.69 and 0.841), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (28.19%) has a much lower DILI risk than Ligand B (46.41%). This is a significant advantage for Ligand A.
8. **BBB:** Ligand B (82.94%) has a higher BBB penetration percentile than Ligand A (75.57%). While not a primary concern for a cardiovascular target, it's a slight advantage for Ligand B.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual. This suggests poor permeability. However, the values are similar (-4.821 vs -4.051), so no clear advantage.
10. **Solubility:** Ligand A (-1.693) has better solubility than Ligand B (-4.767). This is a positive for Ligand A.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.285 and 0.186), which is excellent. No clear advantage.
12. **Cl_mic:** Ligand A (-1.121) has significantly lower microsomal clearance than Ligand B (119.696), indicating better metabolic stability. This is a major advantage for Ligand A.
13. **t1/2:** Ligand A (6.945) has a longer in vitro half-life than Ligand B (-4.732). This is a significant advantage for Ligand A.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.015 and 0.033). No clear advantage.
15. **Binding Affinity:** Ligand B (-6.5 kcal/mol) has a slightly better binding affinity than Ligand A (-5.6 kcal/mol). This is a 0.9 kcal/mol difference, which is not substantial enough to outweigh other factors.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, and affinity are key. Ligand B has a better logP and slightly better affinity. However, Ligand A excels in metabolic stability (Cl_mic, t1/2) and has a much lower DILI risk, which are crucial for overall drug development success. The solubility advantage of Ligand A is also important.
**Overall Assessment:**
While Ligand B has a slightly better affinity and logP, Ligand A's superior metabolic stability, lower DILI risk, and better solubility are more critical for a viable drug candidate. The affinity difference is not large enough to overcome these significant advantages.
Output:
1
2025-04-17 18:19:39,826 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (353.438) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (91.32) is higher than Ligand B (69.64). For a cardiovascular GPCR like ADRB2, TPSA is less critical than for CNS targets, but lower is still preferable for absorption. Ligand B is better here.
3. **logP:** Both ligands have good logP values (A: 1.919, B: 2.607), falling within the optimal 1-3 range. Ligand B is slightly higher, which could potentially lead to slightly better membrane permeability.
4. **HBD:** Ligand A has 3 HBD, and Ligand B has 2. Both are acceptable, within the <5 guideline.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 3. Both are acceptable, within the <10 guideline.
6. **QED:** Both have good QED scores (A: 0.623, B: 0.775), indicating good drug-likeness. Ligand B is better.
7. **DILI:** Both ligands have acceptable DILI risk (A: 36.642, B: 38.775), both below the 40 threshold.
8. **BBB:** Ligand A (62.233) has a higher BBB percentile than Ligand B (53.781). However, as ADRB2 is primarily a cardiovascular target, BBB penetration is not a primary concern.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Both have negative solubility values, indicating very poor aqueous solubility. This is a major drawback for both compounds.
11. **hERG:** Both ligands have low hERG inhibition liability (A: 0.253, B: 0.625), which is excellent.
12. **Cl_mic:** Ligand B (2.441) has a significantly lower microsomal clearance than Ligand A (39.431), indicating better metabolic stability. This is a crucial advantage.
13. **t1/2:** Ligand B (22.917) has a longer in vitro half-life than Ligand A (18.76), further supporting its better metabolic stability.
14. **Pgp:** Both ligands have low P-gp efflux liability (A: 0.071, B: 0.303).
15. **Binding Affinity:** Both ligands have the same binding affinity (-6.2 kcal/mol), so this parameter doesn't differentiate them.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, and affinity are important. While both ligands have similar logP and affinity, Ligand B has a significantly lower TPSA and a much better metabolic profile (lower Cl_mic and longer t1/2). The poor Caco-2 and solubility are concerning for both, but the improved metabolic stability of Ligand B is a substantial advantage that could be addressed with formulation strategies.
**Conclusion:**
Considering the balance of properties and the priorities for a cardiovascular GPCR target, Ligand B is the more promising candidate due to its superior metabolic stability and lower TPSA.
Output:
0
2025-04-17 18:19:39,826 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.5 and 362.5 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (61.44) is slightly higher than Ligand B (56.75). Both are below the 140 threshold for oral absorption, and reasonably good for a GPCR.
3. **logP:** Both ligands have excellent logP values (2.308 and 2.072), falling within the optimal 1-3 range.
4. **HBD:** Ligand A has 2 HBD, while Ligand B has 0. Both are acceptable.
5. **HBA:** Ligand A has 3 HBA, and Ligand B has 5. Both are below the 10 threshold.
6. **QED:** Ligand B (0.826) has a slightly better QED score than Ligand A (0.636), indicating a more drug-like profile.
7. **DILI:** Ligand A (7.484) has a lower DILI risk than Ligand B (57.348). This is a significant advantage for Ligand A.
8. **BBB:** Ligand B (85.731) has a much higher BBB penetration percentile than Ligand A (58.511). While ADRB2 isn't strictly a CNS target, some CNS exposure can be relevant for off-target effects and overall safety assessment.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.952 and -4.625), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-1.742) has slightly better solubility than Ligand B (-2.879).
11. **hERG:** Both ligands have low hERG inhibition liability (0.4 and 0.568), which is good.
12. **Cl_mic:** Ligand B (59.507) has a significantly higher microsomal clearance than Ligand A (16.106). This suggests Ligand A is more metabolically stable.
13. **t1/2:** Ligand A (48.662) has a longer in vitro half-life than Ligand B (-0.72). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.033) has a lower P-gp efflux liability than Ligand B (0.245), suggesting better bioavailability.
15. **Binding Affinity:** Both ligands have very similar and excellent binding affinities (-5.8 and -5.2 kcal/mol). The difference is not substantial enough to be decisive.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Both ligands perform well on logP and affinity. Ligand A has better TPSA, Pgp and metabolic stability. Ligand B has better BBB penetration, but this is less critical for a primarily peripheral target like ADRB2.
**Overall Assessment:**
Ligand A demonstrates a superior ADME profile with lower DILI risk, better metabolic stability (lower Cl_mic and longer t1/2), and lower P-gp efflux. The slightly better solubility is also a plus. While Ligand B has better BBB penetration and QED, the significant advantages of Ligand A in terms of safety (DILI) and pharmacokinetics outweigh these benefits. The negative Caco-2 values are concerning for both, but the other properties of Ligand A make it the more promising candidate.
Output:
1
2025-04-17 18:19:39,826 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.5 and 342.4 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (38.77) is significantly better than Ligand B (84.22). For a GPCR, lower TPSA is generally preferred for better permeability, and Ligand A is well below the 140 threshold. Ligand B is higher, potentially impacting absorption.
3. **logP:** Ligand A (3.74) is within the optimal 1-3 range, while Ligand B (0.91) is on the lower end. This is a substantial difference. For a GPCR, a slightly higher logP is often beneficial for membrane permeability and receptor engagement.
4. **HBD:** Both ligands have 0 HBD, which is good.
5. **HBA:** Ligand A has 3 HBA, while Ligand B has 6. Ligand A is preferable here, as fewer HBA generally correlates with better permeability.
6. **QED:** Both ligands have good QED scores (0.778 and 0.806), indicating good drug-like properties.
7. **DILI:** Ligand A (31.06) has a significantly lower DILI risk than Ligand B (50.68). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (92.4) has a much higher BBB penetration percentile than Ligand B (67.35). While ADRB2 isn't exclusively a CNS target, some distribution to the CNS is possible, and higher BBB is generally favorable.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. This is concerning for both, but the negative value for Ligand A (-4.814) is less negative than Ligand B (-4.976), suggesting slightly better permeability.
10. **Solubility:** Ligand A (-4.447) has slightly better solubility than Ligand B (-0.634), though both are poor.
11. **hERG:** Ligand A (0.597) has a lower hERG risk than Ligand B (0.326), which is a positive.
12. **Cl_mic:** Ligand A (68.93) has a higher microsomal clearance than Ligand B (48.12), meaning it's metabolized faster. This is a negative for Ligand A.
13. **t1/2:** Ligand A (22.8) has a longer in vitro half-life than Ligand B (7.44), which is a significant advantage.
14. **Pgp:** Ligand A (0.656) has a lower P-gp efflux liability than Ligand B (0.028), which is a positive.
15. **Binding Affinity:** Ligand A (-7.1) has a slightly better binding affinity than Ligand B (-6.9). While the difference is small (0.2 kcal/mol), it's still a positive for Ligand A.
**Overall Assessment:**
Ligand A is the stronger candidate. While Ligand B has a slightly better metabolic stability (lower Cl_mic), Ligand A excels in several critical areas: TPSA, logP, DILI risk, BBB penetration, hERG risk, Pgp efflux, and binding affinity. The combination of these factors, particularly the lower DILI risk and better predicted permeability (TPSA, logP, Caco-2, Pgp), makes Ligand A more likely to be a viable drug candidate for the ADRB2 receptor. The slightly longer half-life also contributes to its favorability.
Output:
1
2025-04-17 18:19:39,826 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (355.435 and 346.427 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand B (82.78) is significantly better than Ligand A (113.6), being well below the 140 threshold for oral absorption and more favorable for GPCRs.
3. **logP:** Ligand B (1.585) is within the optimal 1-3 range, while Ligand A (-0.031) is slightly below 1, potentially impacting permeability.
4. **HBD:** Ligand A (3) and Ligand B (2) are both acceptable, below the 5 threshold.
5. **HBA:** Ligand A (5) and Ligand B (4) are both acceptable, below the 10 threshold.
6. **QED:** Both ligands have good QED scores (0.503 and 0.7), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand B (19.504) has a much lower DILI risk than Ligand A (34.781), which is a significant advantage.
8. **BBB:** Both ligands have similar BBB penetration (43.815 and 46.762). While not CNS-focused for ADRB2, some degree of BBB penetration isn't necessarily detrimental.
9. **Caco-2:** Both have negative values, which is unusual. Assuming these are logP-scaled values, lower is worse. Ligand A (-5.249) is worse than Ligand B (-4.484).
10. **Solubility:** Both ligands have very poor solubility (-2.094 and -2.463). This is a concern for both, but not a deciding factor between them.
11. **hERG:** Ligand B (0.237) has a lower hERG risk than Ligand A (0.068), which is preferable.
12. **Cl_mic:** Ligand B (37.918) has a lower microsomal clearance than Ligand A (51.412), indicating better metabolic stability.
13. **t1/2:** Ligand B (-4.95) has a longer in vitro half-life than Ligand A (-17.638), which is a significant advantage.
14. **Pgp:** Ligand B (0.096) has lower P-gp efflux than Ligand A (0.016), which is better for bioavailability.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.3 and -6.0 kcal/mol). The difference is not substantial enough to outweigh other factors.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP and TPSA, and has better Pgp efflux. While both have good affinity, the overall ADME profile of Ligand B is superior.
**Conclusion:**
Ligand B consistently demonstrates a more favorable profile across multiple crucial parameters, particularly in ADME properties like DILI risk, metabolic stability, and permeability. While solubility is a concern for both, the other advantages of Ligand B make it the more promising drug candidate.
Output:
0
2025-04-17 18:19:39,826 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's break down the comparison of Ligand A and Ligand B based on the provided parameters and the guidelines, keeping in mind ADRB2 is a GPCR.
1. **Molecular Weight:** Both ligands (343.431 Da and 358.435 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (95.06) is better than Ligand B (113.96). For a GPCR, keeping TPSA lower is generally preferred for better permeability.
3. **logP:** Ligand A (1.318) is within the optimal range (1-3), while Ligand B (-0.16) is slightly below, potentially hindering permeation. This is a point in favor of Ligand A.
4. **H-Bond Donors:** Ligand A (2) is better than Ligand B (3). Lower HBD is generally preferred.
5. **H-Bond Acceptors:** Both ligands have 6 HBA, which is acceptable.
6. **QED:** Ligand A (0.79) has a significantly better QED score than Ligand B (0.494), indicating a more drug-like profile.
7. **DILI:** Ligand A (62.195) has a higher DILI risk than Ligand B (25.708), which is a significant drawback for Ligand A.
8. **BBB:** Ligand A (64.25) has a better BBB penetration percentile than Ligand B (53.121), but both are not ideal. For a non-CNS target like ADRB2, this isn't a primary concern, but it's still a slight advantage for A.
9. **Caco-2 Permeability:** Ligand A (-5.356) is worse than Ligand B (-4.942). Higher values are better, so B is slightly favored here.
10. **Aqueous Solubility:** Ligand A (-2.633) is worse than Ligand B (-1.564). Higher values are better, so B is slightly favored here.
11. **hERG Inhibition:** Ligand A (0.38) has a lower hERG risk than Ligand B (0.118), which is a positive for Ligand A.
12. **Microsomal Clearance:** Ligand A (10.485) has a significantly lower microsomal clearance than Ligand B (54.352), indicating better metabolic stability. This is a strong advantage for Ligand A.
13. **In vitro Half-Life:** Ligand A (18.046) has a much longer half-life than Ligand B (-50.805). This is a major advantage for Ligand A.
14. **P-gp Efflux:** Ligand A (0.213) has lower P-gp efflux than Ligand B (0.041), which is a positive for Ligand A.
15. **Binding Affinity:** Ligand A (-6.9) has a slightly better binding affinity than Ligand B (-6.1). While both are good, the difference is not substantial enough to outweigh other factors.
**Overall Assessment:**
Ligand A has several advantages: better QED, lower microsomal clearance, longer half-life, lower P-gp efflux, and slightly better affinity. However, it has a higher DILI risk. Ligand B has better solubility, Caco-2 permeability, and a lower DILI risk, but suffers from a lower QED, higher clearance, and a shorter half-life.
Given the importance of metabolic stability and half-life for a viable drug candidate, and the relatively small difference in binding affinity, I believe Ligand A is the more promising candidate despite the higher DILI risk. The DILI risk can be further investigated and potentially mitigated through structural modifications. The improved pharmacokinetic properties of Ligand A are more difficult to address later in development.
**Output:**
1
2025-04-17 18:19:39,826 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.406 and 360.47 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (67.87) is better than Ligand B (70.08) as it is closer to the <140 threshold for good oral absorption.
3. **logP:** Both ligands (1.516 and 1.752) are within the optimal 1-3 range. Ligand B is slightly higher, which *could* be a minor concern for solubility, but not a major issue.
4. **HBD:** Both ligands have 1 HBD, which is well within the acceptable limit of <=5.
5. **HBA:** Both ligands have 4 HBA, which is well within the acceptable limit of <=10.
6. **QED:** Ligand A (0.843) has a significantly better QED score than Ligand B (0.603), indicating a more drug-like profile.
7. **DILI:** Ligand A (31.718) has a much lower DILI risk than Ligand B (18.883). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (93.641) has a higher BBB penetration percentile than Ligand B (83.366). While ADRB2 isn't exclusively a CNS target, some cardiovascular effects are mediated through CNS pathways, and higher BBB penetration isn't detrimental.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.385 and -4.345). These values are difficult to interpret without knowing the scale, but the values are very similar.
10. **Solubility:** Ligand A (-2.131) has slightly better solubility than Ligand B (-1.325).
11. **hERG:** Both ligands have low hERG inhibition risk (0.596 and 0.655). No significant difference.
12. **Cl_mic:** Ligand A (10.481) has significantly lower microsomal clearance than Ligand B (47.442), suggesting better metabolic stability. This is a major advantage.
13. **t1/2:** Ligand A (1.495) has a slightly worse in vitro half-life than Ligand B (-3.143). However, the negative value for Ligand B is suspect and may indicate an issue with the assay or data quality.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.156 and 0.291). No significant difference.
15. **Binding Affinity:** Ligand A (-6.5 kcal/mol) has a slightly better binding affinity than Ligand B (-5.8 kcal/mol). While the difference is less than the 1.5 kcal/mol threshold for outweighing other issues, it contributes to the overall preference for Ligand A.
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Ligand A performs favorably in all these areas.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across the majority of critical ADME-Tox parameters (DILI, Cl_mic, QED, BBB, Solubility) and has a slightly better binding affinity. While Ligand B has a slightly better in vitro half-life, the negative value raises concerns. The superior drug-like properties and safety profile of Ligand A make it the more promising candidate.
Output:
1
2025-04-17 18:19:39,826 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [369.575, 52.65, 2.357, 1, 4, 0.678, 8.026, 76.347, -5.018, -2.246, 0.579, 61.057, 11.014, 0.02, -6.4]**
**Ligand B: [349.391, 121.62, -0.505, 2, 5, 0.717, 47.926, 43.311, -5.497, -2.397, 0.127, -22.662, 7.395, 0.004, -7.6]**
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand B (349.391) is slightly lower, which isn't a major concern.
2. **TPSA:** Ligand A (52.65) is significantly better than Ligand B (121.62). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary goal, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (2.357) is optimal. Ligand B (-0.505) is too low and could lead to poor membrane permeability.
4. **H-Bond Donors:** Both are acceptable (1 and 2 respectively), within the <5 guideline.
5. **H-Bond Acceptors:** Both are acceptable (4 and 5 respectively), within the <10 guideline.
6. **QED:** Both are good (0.678 and 0.717), indicating drug-like properties.
7. **DILI:** Ligand A (8.026) has a much lower DILI risk than Ligand B (47.926). This is a significant advantage.
8. **BBB:** Ligand A (76.347) has better BBB penetration than Ligand B (43.311), but this is not a critical factor for a cardiovascular target.
9. **Caco-2:** Both have negative values, indicating poor permeability. However, the scale is not provided, making direct comparison difficult.
10. **Aqueous Solubility:** Both have negative values, indicating poor solubility. Again, the scale is not provided.
11. **hERG:** Ligand A (0.579) has a slightly higher hERG risk than Ligand B (0.127), but both are relatively low.
12. **Cl_mic:** Ligand B (-22.662) has a *much* lower (better) microsomal clearance than Ligand A (61.057), indicating greater metabolic stability.
13. **t1/2:** Ligand A (11.014) has a longer half-life than Ligand B (7.395).
14. **Pgp:** Ligand A (0.02) has lower P-gp efflux than Ligand B (0.004), which is preferable.
15. **Binding Affinity:** Ligand B (-7.6) has a significantly stronger binding affinity than Ligand A (-6.4) - a difference of 1.2 kcal/mol. This is a substantial advantage.
**Overall Assessment:**
Ligand B has a significantly better binding affinity and metabolic stability (lower Cl_mic). However, its logP is problematic, and its TPSA is high. Ligand A has a better logP, TPSA, and a much lower DILI risk. The difference in binding affinity is substantial, but the ADME profile of Ligand B is concerning, particularly the low logP. For a GPCR, a good balance of properties is crucial, and the combination of better ADME properties (logP, TPSA, DILI) and reasonable affinity makes Ligand A the more promising candidate. The higher affinity of Ligand B might be overcome with further optimization, but starting with a better ADME profile is generally a safer strategy.
Output:
1
2025-04-17 18:19:39,826 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (376.283 and 368.369 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (52.49) is significantly better than Ligand B (100.97). For a GPCR, lower TPSA is generally preferred for better permeability. Ligand A is well below the 140 threshold, while Ligand B is approaching it.
3. **logP:** Ligand A (4.462) is higher than Ligand B (0.708). While both are within the acceptable range, Ligand A is pushing the upper limit and could potentially have solubility issues. Ligand B is quite low, potentially hindering permeability.
4. **HBD:** Ligand A (3) is higher than Ligand B (1). This is acceptable for both.
5. **HBA:** Ligand A (3) is lower than Ligand B (7). Ligand B is approaching the upper limit of 10, which could affect permeability.
6. **QED:** Ligand B (0.806) has a better QED score than Ligand A (0.595), indicating a more drug-like profile.
7. **DILI:** Ligand A (48.623) has a much lower DILI risk than Ligand B (84.296). This is a significant advantage for Ligand A.
8. **BBB:** Ligand B (71.307) has a higher BBB penetration percentile than Ligand A (37.34). While ADRB2 isn't necessarily a CNS target, some cardiovascular effects are mediated by central pathways, so some BBB penetration could be beneficial.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.168 and -5.413), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-4.205) has slightly better solubility than Ligand B (-2.544).
11. **hERG:** Ligand A (0.92) has a slightly higher hERG risk than Ligand B (0.102). This is a significant advantage for Ligand B.
12. **Cl_mic:** Ligand B (4.379) has significantly lower microsomal clearance than Ligand A (12.141), suggesting better metabolic stability.
13. **t1/2:** Ligand A (140.185) has a much longer in vitro half-life than Ligand B (-3.74). This is a major advantage for Ligand A.
14. **Pgp:** Ligand A (0.673) has lower P-gp efflux than Ligand B (0.049), which is preferable.
15. **Binding Affinity:** Ligand B (-7.7) has a slightly better binding affinity than Ligand A (-7.2). While the difference is small (0.5 kcal/mol), it's still a factor.
**Overall Assessment:**
Ligand B has a better QED, lower hERG risk, and better metabolic stability (lower Cl_mic). However, Ligand A excels in DILI risk, in vitro half-life, and Pgp efflux. The TPSA of Ligand A is also significantly better, which is important for permeability. The binding affinity difference is not substantial enough to outweigh the other factors. Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity), Ligand A strikes a better balance. The longer half-life and lower DILI risk are particularly valuable. The negative Caco-2 values are concerning for both, but the better TPSA of Ligand A might mitigate this somewhat.
Output:
1
2025-04-17 18:19:39,827 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
The target is ADRB2, a GPCR. Therefore, I will prioritize logP, Pgp, TPSA, and affinity, alongside general drug-like properties.
* **Molecular Weight:** Both ligands are within the ideal range (347-350 Da). No significant difference here.
* **TPSA:** Ligand A (58.64) is significantly better than Ligand B (99.77). ADRB2 is not a CNS target, but lower TPSA generally correlates with better permeability.
* **logP:** Both are within the optimal range (1-3), but Ligand A (2.965) is slightly higher than Ligand B (1.742). Higher logP can be beneficial for receptor binding, but needs to be balanced with solubility.
* **H-Bond Donors/Acceptors:** Ligand A (1 HBD, 3 HBA) is preferable to Ligand B (3 HBD, 4 HBA). Lower counts generally improve permeability.
* **QED:** Ligand A (0.697) is better than Ligand B (0.561), indicating a more drug-like profile.
* **DILI:** Ligand B (22.8) has a much lower DILI risk than Ligand A (35.169). This is a significant advantage for Ligand B.
* **BBB:** Both have relatively high BBB penetration, but Ligand A (91.392) is slightly better than Ligand B (64.017). This isn't a primary concern for ADRB2, but a slight positive for A.
* **Caco-2 Permeability:** Ligand A (-4.415) is better than Ligand B (-5.417), indicating better intestinal absorption.
* **Aqueous Solubility:** Ligand A (-3.456) is better than Ligand B (-2.38), which is important for formulation.
* **hERG Inhibition:** Ligand A (0.673) is slightly better than Ligand B (0.046), indicating lower cardiotoxicity risk.
* **Microsomal Clearance:** Ligand B (27.571) has significantly lower microsomal clearance than Ligand A (64.12), suggesting better metabolic stability.
* **In vitro Half-Life:** Ligand B (-19.949) has a much longer half-life than Ligand A (10.267). This is a major advantage for Ligand B.
* **P-gp Efflux:** Ligand A (0.295) has lower P-gp efflux than Ligand B (0.008), which is desirable.
* **Binding Affinity:** Both ligands have very similar binding affinities (-6.5 and -6.3 kcal/mol). The difference is not substantial enough to be decisive.
**Overall Assessment:**
Ligand B has a clear advantage in terms of safety (DILI), metabolic stability (Cl_mic, t1/2), and solubility. While Ligand A has slightly better TPSA, Caco-2, and BBB, the improvements in ADME properties for Ligand B outweigh these minor differences. The binding affinity is comparable. Considering the GPCR-specific priorities and the overall balance of properties, Ligand B is the more promising drug candidate.
**Output:**
0
2025-04-17 18:19:39,827 - INFO - Okay, let's analyze these two ligands for their potential as a drug candidate targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [347.434, 71.09, 2.407, 2, 3, 0.83, 35.983, 79.256, -4.743, -2.925, 0.473, 13.824, -1.007, 0.115, -7.1]
**Ligand B:** [376.913, 59.07, 4.251, 2, 6, 0.813, 75.649, 74.098, -5.066, -5.052, 0.643, 71.493, 76.329, 0.353, -8.1]
Here's a breakdown, considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (347.434) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (71.09) is slightly higher than Ligand B (59.07), but both are well below the 140 threshold for oral absorption. Ligand B is preferable here.
3. **logP:** Ligand A (2.407) is within the optimal range (1-3). Ligand B (4.251) is pushing the upper limit and could potentially cause solubility issues or off-target interactions. Ligand A is preferable.
4. **HBD:** Both have 2 HBD, which is good.
5. **HBA:** Ligand A has 3 HBA, Ligand B has 6. Ligand A is preferable.
6. **QED:** Both are very similar (0.83 and 0.813), indicating good drug-likeness.
7. **DILI:** Ligand A (35.983) has a significantly lower DILI risk than Ligand B (75.649). This is a major advantage for Ligand A.
8. **BBB:** Both have good BBB penetration (Ligand A: 79.256, Ligand B: 74.098), but Ligand A is slightly better.
9. **Caco-2:** Ligand A (-4.743) is better than Ligand B (-5.066), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-2.925) is better than Ligand B (-5.052).
11. **hERG:** Ligand A (0.473) is preferable to Ligand B (0.643) as it has a lower hERG inhibition liability.
12. **Cl_mic:** Ligand A (13.824) has a lower clearance than Ligand B (71.493), indicating better metabolic stability.
13. **t1/2:** Ligand B (76.329) has a significantly longer in vitro half-life than Ligand A (-1.007). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.115) has lower P-gp efflux than Ligand B (0.353), which is preferable.
15. **Affinity:** Ligand B (-8.1) has a substantially stronger binding affinity than Ligand A (-7.1) - a difference of 1.0 kcal/mol. This is a considerable advantage.
**Overall Assessment:**
While Ligand B boasts a significantly stronger binding affinity and a longer half-life, Ligand A excels in several critical ADME-Tox properties. Specifically, the much lower DILI risk, better solubility, lower hERG risk, and better Pgp efflux are very compelling. The logP and TPSA values for Ligand A are also more favorable. The affinity difference, while substantial, might be overcome with further optimization of Ligand A, while mitigating the ADME liabilities of Ligand B would be more challenging. Given the cardiovascular context, minimizing toxicity (DILI, hERG) is paramount.
Therefore, I would select Ligand A as the more promising drug candidate.
Output:
1
2025-04-17 18:19:39,827 - INFO - Batch 29 complete. Total preferences: 464
2025-04-17 18:19:39,827 - INFO - Processing batch 30/512...
2025-04-17 18:20:25,615 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (368.434 and 373.475 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (97.11) is better than Ligand B (107.78). Both are below 140, but closer to 90 is preferable for GPCRs, and A is closer.
3. **logP:** Ligand A (1.762) is within the optimal 1-3 range. Ligand B (0.455) is a bit low, potentially hindering permeability.
4. **HBD:** Ligand A (2) is reasonable. Ligand B (0) is also acceptable, but a small number of donors can aid solubility.
5. **HBA:** Both ligands (6) are within the acceptable limit of 10.
6. **QED:** Ligand A (0.81) is significantly better than Ligand B (0.515), indicating a more drug-like profile.
7. **DILI:** Ligand B (39.162) has a much lower DILI risk than Ligand A (76.076). This is a substantial advantage for Ligand B.
8. **BBB:** Ligand B (74.952) has better BBB penetration than Ligand A (63.862). While ADRB2 isn't exclusively a CNS target, some CNS exposure can occur, making this a slight advantage for B.
9. **Caco-2:** Ligand A (-5.004) has better Caco-2 permeability than Ligand B (-4.31).
10. **Solubility:** Ligand A (-3.771) has better solubility than Ligand B (-2.093).
11. **hERG:** Both ligands (0.233 and 0.34) have low hERG inhibition risk, which is good.
12. **Cl_mic:** Ligand A (25.109) has significantly lower microsomal clearance than Ligand B (93.548), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-59.916) has a much longer in vitro half-life than Ligand A (-24.464). This is a significant advantage for B.
14. **Pgp:** Ligand A (0.239) has lower P-gp efflux than Ligand B (0.033), which is preferable for bioavailability.
15. **Affinity:** Ligand A (-7.2 kcal/mol) has a slightly better binding affinity than Ligand B (-5.9 kcal/mol). This is a notable difference.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, and affinity. Ligand A has better logP, TPSA, and Pgp. Ligand B has better BBB penetration. The affinity difference is significant (1.3 kcal/mol), and this often outweighs minor ADME concerns. However, the DILI risk for Ligand A is concerning, and the longer half-life of Ligand B is also attractive. The metabolic stability of A is also a plus.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity and better permeability, the significantly lower DILI risk and longer half-life of Ligand B are more important for overall drug development. The slightly lower logP of B is a manageable concern.
Output:
0
2025-04-17 18:20:25,615 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**1. Molecular Weight:** Both ligands (360.426 and 346.427 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (88.1) is better than Ligand B (95.5). For a GPCR, keeping TPSA lower is beneficial for permeability.
**3. logP:** Both ligands have acceptable logP values (0.949 and 1.814, respectively), falling within the 1-3 range. Ligand B is slightly higher, which *could* be a minor advantage for membrane permeability, but not significantly.
**4. H-Bond Donors:** Ligand A (2) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
**5. H-Bond Acceptors:** Ligand A (5) is preferable to Ligand B (4). Fewer HBAs generally improve permeability.
**6. QED:** Both ligands have good QED values (0.567 and 0.656), indicating good drug-like properties. Ligand B is slightly better.
**7. DILI Risk:** Ligand A (35.983) has a significantly lower DILI risk than Ligand B (54.207). This is a major advantage for Ligand A.
**8. BBB Penetration:** Ligand A (74.758) has better BBB penetration than Ligand B (47.111). While ADRB2 isn't exclusively a CNS target, some cardiovascular effects are mediated by central pathways, so some BBB penetration is not detrimental.
**9. Caco-2 Permeability:** Both ligands have similar, poor Caco-2 permeability (-4.767 and -4.756). This is a concern for both.
**10. Aqueous Solubility:** Ligand A (-1.995) is slightly better than Ligand B (-3.275).
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.447 and 0.169). This is excellent for both.
**12. Microsomal Clearance:** Ligand A (17.403) has lower microsomal clearance than Ligand B (22.968), indicating better metabolic stability.
**13. In vitro Half-Life:** Ligand A (-17.91) has a much longer in vitro half-life than Ligand B (-0.328). This is a significant advantage.
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (0.091 and 0.104).
**15. Binding Affinity:** Ligand B (-7.7) has a slightly better binding affinity than Ligand A (-7.1). This is a 0.6 kcal/mol difference, which is notable, but not overwhelming given the other factors.
**Overall Assessment:**
Ligand A is the stronger candidate. While Ligand B has slightly better binding affinity, Ligand A excels in crucial ADME properties: lower DILI risk, better BBB penetration, better metabolic stability (lower Cl_mic and longer t1/2), and better solubility. The TPSA and H-bond counts are also more favorable for Ligand A. The slightly better affinity of Ligand B is not enough to overcome these significant advantages.
Output:
1
2025-04-17 18:20:25,616 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (360.483 and 354.361 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (86.88) is better than Ligand B (93.01). Both are below 140, but lower TPSA generally favors absorption.
3. **logP:** Ligand A (3.181) is optimal, while Ligand B (-0.002) is significantly low. This is a major concern for Ligand B, as it may struggle with membrane permeability.
4. **HBD:** Ligand A (3) and Ligand B (1) are both acceptable.
5. **HBA:** Ligand A (4) and Ligand B (6) are both acceptable, though Ligand A is slightly preferred.
6. **QED:** Both ligands have good QED scores (0.6 and 0.821), indicating good drug-like properties.
7. **DILI:** Both ligands have similar DILI risk (53.625 and 54.401), and are within an acceptable range (<60).
8. **BBB:** Ligand A (32.726) is lower than Ligand B (86.39). While ADRB2 isn't strictly a CNS target, some CNS exposure can be beneficial or at least not detrimental, so Ligand B has an advantage here.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual. However, the magnitude is similar and suggests poor permeability for both.
10. **Solubility:** Ligand A (-2.396) is worse than Ligand B (-1.823), but both are poor.
11. **hERG:** Ligand A (0.593) is better than Ligand B (0.043), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand A (25.614) has a lower clearance than Ligand B (6.414), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-8.444) has a longer half-life than Ligand B (1.005), which is desirable.
14. **Pgp:** Ligand A (0.186) has lower P-gp efflux than Ligand B (0.029), indicating better bioavailability.
15. **Binding Affinity:** Ligand B (-6.8) has a slightly better binding affinity than Ligand A (-6.1), a difference of 0.7 kcal/mol.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A excels in logP and Pgp, while Ligand B has a slightly better affinity and BBB. However, the extremely low logP of Ligand B is a significant drawback, likely hindering its ability to cross cell membranes and reach the receptor. The slightly better affinity of Ligand B isn't enough to overcome this.
**Overall Assessment:**
Despite the slightly better affinity and BBB penetration of Ligand B, the significantly better logP, metabolic stability, and P-gp properties of Ligand A make it the more promising candidate. The poor solubility of both is a concern, but can potentially be addressed with formulation strategies. The low logP of Ligand B is a more fundamental issue that is harder to resolve.
Output:
1
2025-04-17 18:20:25,616 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.49 and 354.54 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (58.64) is significantly better than Ligand B (69.64). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (2.798 and 3.251), falling within the optimal 1-3 range. Ligand B is slightly higher, which *could* be a minor drawback if it impacts solubility.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD is generally better for permeability.
5. **HBA:** Both ligands have the same number of HBA (3).
6. **QED:** Ligand A (0.751) is better than Ligand B (0.625), indicating a more drug-like profile.
7. **DILI:** Ligand A (16.751) is *much* better than Ligand B (8.957). This is a critical advantage. Lower DILI risk is paramount.
8. **BBB:** Ligand A (82.241) is better than Ligand B (68.748), but this isn't a primary concern for a cardiovascular target.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.806 and -4.714), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Both ligands have very poor solubility (-3.045 and -3.062). This is a major issue that would need to be addressed through formulation strategies.
11. **hERG:** Ligand A (0.319) is significantly better than Ligand B (0.729), indicating a lower risk of cardiotoxicity. This is crucial for a cardiovascular drug.
12. **Cl_mic:** Ligand A (39.728) is better than Ligand B (48.576), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-1.782) is better than Ligand B (1.642), indicating a longer half-life.
14. **Pgp:** Ligand A (0.24) is better than Ligand B (0.453), suggesting lower P-gp efflux.
15. **Binding Affinity:** Ligand B (-7.1) has a slightly better binding affinity than Ligand A (-6.8). This is a 0.3 kcal/mol difference. While affinity is important, the other factors are more concerning.
**Overall Assessment:**
Ligand A is significantly better. While Ligand B has slightly better binding affinity, Ligand A excels in critical ADME-Tox properties: DILI risk, hERG inhibition, metabolic stability, and P-gp efflux. The lower TPSA and HBD of Ligand A are also favorable. Both compounds have poor solubility and Caco-2 permeability, which are significant drawbacks, but these can potentially be addressed through formulation. The safety profile of Ligand A is far superior, making it the more promising candidate.
Output:
1
2025-04-17 18:20:25,616 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (365.5 & 352.4 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (61.88) is significantly better than Ligand B (95.94). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (1.466) is better than Ligand B (0.596). Both are within the acceptable range (1-3), but A is closer to the optimal range.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Both ligands have 5 HBA, which is acceptable.
6. **QED:** Both ligands have similar QED scores (0.795 vs 0.706), indicating good drug-likeness.
7. **DILI:** Ligand A (19.43) has a much lower DILI risk than Ligand B (34.78). This is a significant advantage.
8. **BBB:** Ligand A (78.52) has better BBB penetration than Ligand B (46.61), but this isn't a high priority for a cardiovascular target.
9. **Caco-2:** Ligand A (-5.261) has a worse Caco-2 permeability than Ligand B (-4.793).
10. **Solubility:** Ligand A (-1.496) has better solubility than Ligand B (-1.983).
11. **hERG:** Both ligands have very low hERG inhibition risk (0.292 and 0.063 respectively).
12. **Cl_mic:** Ligand A (21.29) has a higher microsomal clearance than Ligand B (-17.618), meaning it is less metabolically stable. This is a negative for Ligand A.
13. **t1/2:** Ligand A (8.95) has a longer half-life than Ligand B (0.961). This is a positive for Ligand A.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.034 and 0.06 respectively).
15. **Affinity:** Ligand A (-7.5 kcal/mol) has a slightly better binding affinity than Ligand B (-7.1 kcal/mol). While the difference is not huge, it's still a positive for Ligand A.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Ligand A excels in logP, TPSA, and affinity, and has similar Pgp values. The difference in affinity is not large enough to completely outweigh the metabolic stability concern. However, the significantly lower DILI risk and better solubility of Ligand A are crucial advantages.
**Overall Assessment:**
Ligand A presents a better overall profile. While its metabolic stability is a concern, its superior TPSA, logP, DILI risk, solubility, and slightly better affinity outweigh the drawbacks. The longer half-life is also a positive.
Output:
1
2025-04-17 18:20:25,616 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (376.5 & 355.5 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (81.67) is significantly better than Ligand A (112.57). Lower TPSA generally improves permeability, a key factor for GPCRs.
3. **logP:** Ligand B (1.379) is better positioned within the optimal 1-3 range than Ligand A (0.619), which is on the lower side and could indicate permeability issues.
4. **HBD:** Both have 3 HBD, which is acceptable.
5. **HBA:** Ligand B (4) has fewer HBA than Ligand A (5), which is slightly preferable.
6. **QED:** Both ligands have good QED scores (0.564 and 0.672), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand B (6.32) has a much lower DILI risk than Ligand A (31.291). This is a significant advantage.
8. **BBB:** Ligand B (55.099) has a better BBB penetration score than Ligand A (39.511), although neither are particularly high. For a cardiovascular target, BBB isn't *critical* but is still a positive.
9. **Caco-2:** Both are negative, indicating poor permeability.
10. **Solubility:** Both are negative, indicating poor solubility.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.208 and 0.272).
12. **Cl_mic:** Ligand B (1.714) has much lower microsomal clearance than Ligand A (25.553), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-20.046) has a significantly longer in vitro half-life than Ligand A (1.54). This is a major advantage.
14. **Pgp:** Both have very low P-gp efflux liability (0.034 and 0.008).
15. **Affinity:** Ligand B (-8.4 kcal/mol) has a stronger binding affinity than Ligand A (-7.4 kcal/mol). This is a 1 kcal/mol difference, which is significant.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in all these areas. While BBB isn't paramount for a cardiovascular target, the better BBB score of Ligand B is a bonus. The significantly improved metabolic stability (lower Cl_mic, longer t1/2) and lower DILI risk of Ligand B are also crucial for drug development.
**Conclusion:**
Ligand B consistently outperforms Ligand A across most critical parameters, especially in ADME properties and binding affinity. The lower DILI risk and improved metabolic stability make it a much more promising drug candidate.
Output:
0
2025-04-17 18:20:25,616 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [349.519, 52.65, 2.691, 1, 3, 0.719, 11.671, 77.084, -4.957, -2.46, 0.554, 48.983, 0.559, 0.116, -7.0]
**Ligand B:** [346.431, 85.25, 0.855, 2, 5, 0.684, 39.201, 42.187, -4.899, -1.849, 0.049, 1.285, -3.993, 0.028, -6.8]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). A is 349.5, B is 346.4. Very similar.
2. **TPSA:** A (52.65) is excellent, well below 140 and good for oral absorption. B (85.25) is higher, but still acceptable.
3. **logP:** A (2.691) is optimal. B (0.855) is a bit low, potentially hindering membrane permeability.
4. **HBD:** A (1) is good. B (2) is acceptable.
5. **HBA:** A (3) is good. B (5) is acceptable.
6. **QED:** Both are good (A: 0.719, B: 0.684), indicating drug-like properties.
7. **DILI:** A (11.671) is significantly better (lower risk) than B (39.201). This is a major advantage for A.
8. **BBB:** A (77.084) is good, suggesting reasonable potential for CNS penetration if needed (ADRB2 is primarily cardiovascular, so this isn't *critical* but is a bonus). B (42.187) is lower.
9. **Caco-2:** Both are negative, indicating poor permeability. This is a concern for both, but the lower TPSA of ligand A may help.
10. **Solubility:** Both are negative, indicating poor solubility. This is a concern for both.
11. **hERG:** A (0.554) is much better (lower risk) than B (0.049). Another significant advantage for A.
12. **Cl_mic:** A (48.983) is much better (lower clearance, more stable) than B (1.285). A is significantly more metabolically stable.
13. **t1/2:** A (0.559) is better than B (-3.993).
14. **Pgp:** A (0.116) is better (lower efflux) than B (0.028).
15. **Affinity:** A (-7.0) is slightly better than B (-6.8), although the difference is small.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. A has a better logP and Pgp profile. While both have similar affinity, A's slight edge is helpful. The significantly better DILI, hERG, and metabolic stability profiles of A are crucial.
**Conclusion:**
Ligand A clearly outperforms Ligand B across several critical ADME-Tox parameters, especially DILI, hERG, and metabolic stability. While both have issues with Caco-2 and solubility, A's overall profile is more favorable for development as a drug candidate. The slight affinity advantage and better BBB potential further solidify its position.
Output:
1
2025-04-17 18:20:25,617 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (340.431 and 350.503 Da) fall well within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (75.94) is slightly higher than Ligand B (66.57). Both are below the 140 threshold for oral absorption, but B is better.
3. **logP:** Ligand B (3.717) is higher than Ligand A (2.316). While both are within the optimal 1-3 range, B is approaching the upper limit. This could potentially lead to solubility issues, but the difference isn't drastic.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 5 HBA, while Ligand B has 4. Both are acceptable, below the 10 threshold.
6. **QED:** Ligand A (0.927) has a significantly better QED score than Ligand B (0.737), indicating a more drug-like profile.
7. **DILI:** Ligand A (33.773) has a slightly higher DILI risk than Ligand B (22.8), but both are well below the concerning 60 threshold. B is preferable here.
8. **BBB:** Both ligands have good BBB penetration (77.511 and 76.735 respectively). No significant difference.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
10. **Solubility:** Ligand A (-2.01) has better solubility than Ligand B (-3.499).
11. **hERG:** Ligand A (0.304) has a much lower hERG inhibition risk than Ligand B (0.544). This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand B (75.178) has a much higher microsomal clearance than Ligand A (7.705). This suggests Ligand A is more metabolically stable.
13. **t1/2:** Ligand B (25.524) has a significantly longer in vitro half-life than Ligand A (-7.404). This is a major advantage for Ligand B.
14. **Pgp:** Ligand A (0.042) has a lower P-gp efflux liability than Ligand B (0.722), which is favorable.
15. **Binding Affinity:** Ligand A (-7.3) has a slightly better binding affinity than Ligand B (-6.2). While the difference is less than 1.5 kcal/mol, it's still a positive for Ligand A.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B has a higher logP and longer half-life, which are positives. However, Ligand A has better TPSA, Pgp efflux, solubility, hERG risk, and slightly better affinity. The better QED and significantly lower Cl_mic of Ligand A are also important.
**Overall Assessment:**
While Ligand B has a longer half-life, the superior drug-likeness (QED), lower hERG risk, better solubility, lower Pgp efflux, and better metabolic stability (lower Cl_mic) of Ligand A outweigh the benefit of a longer half-life, especially considering the slight affinity advantage. The slightly higher TPSA of Ligand A is not a major concern.
Output:
1
2025-04-17 18:20:25,617 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (344.419 Da and 348.462 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (103.91) is higher than Ligand B (49.41). For a GPCR, lower TPSA is generally preferred for better brain penetration and overall permeability. Ligand B is significantly better.
3. **logP:** Ligand A (0.779) is a bit low, potentially hindering permeability. Ligand B (2.812) is within the optimal 1-3 range. Ligand B is preferred.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 6 HBA, while Ligand B has 2. Lower HBA is generally preferred for permeability. Ligand B is better.
6. **QED:** Both ligands have similar QED values (0.869 and 0.853), indicating good drug-likeness.
7. **DILI:** Ligand A (48.895) has a slightly higher DILI risk than Ligand B (28.383), but both are below the concerning threshold of 60. Ligand B is preferred.
8. **BBB:** Ligand B (79.062) has a significantly higher BBB penetration percentile than Ligand A (60.644). This is a crucial advantage for a GPCR target, even if it's not specifically a CNS target, as it suggests better distribution.
9. **Caco-2:** Ligand A (-5.009) and Ligand B (-4.743) have similar Caco-2 permeability values.
10. **Solubility:** Ligand A (-3.197) has slightly better solubility than Ligand B (-4.232).
11. **hERG:** Ligand A (0.031) has a very low hERG risk, while Ligand B (0.59) is slightly higher. Ligand A is preferred.
12. **Cl_mic:** Ligand A (9.796) has a much lower microsomal clearance than Ligand B (24.589), indicating better metabolic stability. Ligand A is preferred.
13. **t1/2:** Ligand B (6.954) has a longer in vitro half-life than Ligand A (-6.813). Ligand B is preferred.
14. **Pgp:** Ligand A (0.015) has much lower P-gp efflux liability than Ligand B (0.205). This is a significant advantage for bioavailability. Ligand A is preferred.
15. **Binding Affinity:** Ligand B (-7.9) has a slightly better binding affinity than Ligand A (-8.0). While the difference is small, it is still a factor.
**Overall Assessment:**
Ligand B excels in BBB penetration, logP, HBA, and half-life. However, Ligand A demonstrates superior profiles in DILI, Cl_mic, Pgp efflux, and hERG inhibition. Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), and the fact that ADRB2 is not a CNS target, the lower TPSA and Pgp efflux of Ligand A, along with its better metabolic stability and safety profile (lower DILI and hERG) outweigh the slightly better affinity and half-life of Ligand B. The slightly lower logP of Ligand A is a minor concern that could be addressed with further optimization.
Output:
1
2025-04-17 18:20:25,617 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [361.833, 70.59, 2.801, 1, 5, 0.851, 86.623, 61.923, -4.733, -4.187, 0.417, 61.681, -0.808, 0.076, -6.0]
**Ligand B:** [342.399, 80.37, 2.52, 1, 5, 0.905, 57.658, 62.699, -4.853, -4.088, 0.259, 37.089, 30.755, 0.04, -6.1]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (342.399) is slightly lower, which could be favorable for permeability, but both are acceptable.
2. **TPSA:** Ligand A (70.59) is better than Ligand B (80.37). Both are below 140, but closer to 90 is preferable for GPCRs, and A is closer.
3. **logP:** Both are in the optimal range (1-3). Ligand B (2.52) is slightly lower, which might slightly improve solubility, but both are good.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Both have 5 HBA, which is good.
6. **QED:** Ligand B (0.905) has a slightly better QED score than Ligand A (0.851), indicating a more drug-like profile.
7. **DILI:** Ligand B (57.658) has a significantly lower DILI risk than Ligand A (86.623). This is a major advantage for Ligand B.
8. **BBB:** Both have similar BBB penetration (around 62%), which isn't exceptionally high, but acceptable for a non-CNS target like ADRB2.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. This is a significant concern for both.
10. **Solubility:** Both have negative solubility values, indicating poor solubility. This is a significant concern for both.
11. **hERG:** Both have low hERG inhibition liability, which is good. Ligand B (0.259) is slightly better than Ligand A (0.417).
12. **Cl_mic:** Ligand B (37.089) has a significantly lower microsomal clearance than Ligand A (61.681), suggesting better metabolic stability.
13. **t1/2:** Ligand B (30.755) has a much longer in vitro half-life than Ligand A (-0.808), which is a significant advantage.
14. **Pgp:** Both have very low Pgp efflux liability, which is good.
15. **Binding Affinity:** Ligand B (-6.1) has a slightly better binding affinity than Ligand A (-6.0), but the difference is minimal.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Both ligands perform similarly on logP and Pgp. Ligand A has a better TPSA. The affinity difference is negligible. However, the significant improvements in DILI risk, metabolic stability (Cl_mic), and half-life for Ligand B outweigh the slightly better TPSA of Ligand A. The poor Caco-2 and solubility are concerning for both, but can be addressed with formulation strategies.
**Conclusion:**
Considering the balance of properties and the GPCR-specific priorities, Ligand B is the more promising drug candidate.
Output:
0
2025-04-17 18:20:25,617 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (341.43 & 381.925 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (46.09) is significantly better than Ligand B (63.24). ADRB2 is not a CNS target, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (3.857 & 3.605), falling within the optimal 1-3 range. Ligand A is slightly higher, which could be a minor advantage for membrane permeability.
4. **HBD:** Ligand A (0) is preferable to Ligand B (1). Fewer HBDs generally improve permeability.
5. **HBA:** Both ligands have the same number of HBA (3).
6. **QED:** Both ligands have very similar and good QED scores (0.801 & 0.813), indicating good drug-likeness.
7. **DILI:** Ligand A (31.369) has a substantially lower DILI risk than Ligand B (45.095). This is a significant advantage.
8. **BBB:** While not a primary concern for ADRB2, Ligand A (89.066) has a higher BBB percentile than Ligand B (70.997).
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. Ligand B (-4.947) is slightly worse than Ligand A (-4.589).
10. **Solubility:** Both ligands have negative solubility values, indicating poor solubility. They are very similar (-3.401 and -3.399).
11. **hERG:** Both ligands have low hERG inhibition liability (0.754 and 0.31). Ligand B is slightly better here.
12. **Cl_mic:** Ligand B (26.845) has a significantly lower microsomal clearance than Ligand A (63.66), suggesting better metabolic stability. This is a substantial advantage.
13. **t1/2:** Ligand B (37.208) has a much longer in vitro half-life than Ligand A (-0.914). This is a major advantage, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.218) has lower P-gp efflux liability than Ligand B (0.414). This is a slight advantage.
15. **Affinity:** Ligand A (-7.4) has a slightly better binding affinity than Ligand B (-6.9). While the difference is less than the 1.5 kcal/mol threshold, it's still a positive factor.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A is better in terms of TPSA, logP, and Pgp, and has a slightly better affinity. However, Ligand B has a significantly better metabolic stability (Cl_mic) and a much longer half-life. The DILI risk is also lower for Ligand A.
**Overall Assessment:**
The longer half-life and improved metabolic stability of Ligand B are very attractive features, potentially outweighing the slight advantages of Ligand A in TPSA, logP, and affinity. The lower DILI risk of Ligand A is also a significant positive. The poor Caco-2 and solubility for both compounds are concerning and would require further optimization. However, considering the balance of properties, the improved PK profile of Ligand B is more compelling.
Output:
0
2025-04-17 18:20:25,617 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (365.953) is slightly higher than Ligand B (350.419), but both are acceptable.
2. **TPSA:** Ligand A (35.5) is excellent, well below the 140 threshold and favorable for oral absorption. Ligand B (107.55) is higher, but still within a reasonable range, though less optimal.
3. **logP:** Ligand A (3.153) is optimal. Ligand B (0.121) is quite low, potentially leading to poor membrane permeability. This is a significant concern.
4. **HBD:** Ligand A (0) is ideal. Ligand B (3) is acceptable, but higher HBD can sometimes impact permeability.
5. **HBA:** Both ligands have 5 HBA, which is within the acceptable limit of 10.
6. **QED:** Both ligands have similar QED values (A: 0.723, B: 0.675), indicating good drug-likeness.
7. **DILI:** Ligand A (21.946) has a much lower DILI risk than Ligand B (52.113). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (94.727) shows excellent BBB penetration, while Ligand B (36.371) is poor. Given ADRB2 is a GPCR, BBB penetration isn't *essential* (depending on the specific therapeutic target within the cardiovascular system), but it could be advantageous for certain applications.
9. **Caco-2:** Both have negative values which is unusual. However, the magnitude of Ligand A (-4.925) is less negative than Ligand B (-5.737) suggesting slightly better permeability.
10. **Solubility:** Ligand A (-2.294) is better than Ligand B (-1.614), indicating better aqueous solubility.
11. **hERG:** Both ligands have low hERG inhibition risk (A: 0.96, B: 0.177).
12. **Cl_mic:** Ligand A (6.892) has a lower microsomal clearance, suggesting better metabolic stability than Ligand B (2.877).
13. **t1/2:** Ligand A (-6.674) has a significantly longer in vitro half-life than Ligand B (25.748). This is a substantial advantage.
14. **Pgp:** Ligand A (0.128) has lower P-gp efflux liability than Ligand B (0.015), suggesting better bioavailability.
15. **Affinity:** Both ligands have very similar binding affinities (-8.0 kcal/mol and -5.9 kcal/mol respectively). However, the affinity of Ligand A is significantly better.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A excels in logP, TPSA, Pgp, and has a superior affinity. While BBB isn't critical here, Ligand A's high BBB penetration is a bonus.
**Conclusion:**
Ligand A is significantly better across multiple critical ADME properties (DILI, BBB, solubility, Cl_mic, t1/2, Pgp) and has a superior binding affinity. Ligand B's low logP is a major drawback, likely to cause permeability issues.
Output:
1
2025-04-17 18:20:25,618 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.409 Da and 347.415 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (98.05) is slightly higher than Ligand B (76.83). Both are below the 140 A^2 threshold for good oral absorption, but Ligand B is preferable due to being closer to the 90 A^2 threshold, which is beneficial for GPCRs.
3. **logP:** Ligand A (1.37) is within the optimal range (1-3), while Ligand B (2.693) is towards the higher end. Both are acceptable, but Ligand A's lower logP suggests potentially better solubility and reduced off-target interactions.
4. **HBD:** Both ligands have 1 HBD, which is within the acceptable limit of <=5.
5. **HBA:** Ligand A has 7 HBA, and Ligand B has 5. Both are below the 10 threshold.
6. **QED:** Both ligands have similar QED values (0.882 and 0.833), indicating good drug-like properties.
7. **DILI:** Ligand A (60.915) has a slightly higher DILI risk than Ligand B (56.301), but both are still below the concerning 60 threshold.
8. **BBB:** Both ligands have very similar BBB penetration (74.99% and 75.262%). This is good, but not exceptional.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.504 and -4.535). These values are difficult to interpret without knowing the scale, but the similarity suggests similar absorption potential.
10. **Solubility:** Both ligands have negative solubility values (-2.712 and -2.559). Again, the scale is unknown, but the similarity suggests similar solubility.
11. **hERG:** Ligand A (0.193) has a lower hERG inhibition liability than Ligand B (0.375), which is a significant advantage for cardiovascular safety.
12. **Cl_mic:** Ligand A (31.363) has a significantly lower microsomal clearance than Ligand B (77.877), indicating better metabolic stability.
13. **t1/2:** Ligand A (-0.548) has a negative in vitro half-life, which is concerning. Ligand B (3.491) has a positive half-life, which is preferable.
14. **Pgp:** Ligand A (0.035) has much lower P-gp efflux liability than Ligand B (0.105), which is beneficial for bioavailability.
15. **Binding Affinity:** Ligand A (-7.5 kcal/mol) has a slightly better binding affinity than Ligand B (-7.2 kcal/mol). The difference is 0.3 kcal/mol, which is not huge, but still noteworthy.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, and affinity. Ligand B has a slightly better logP and TPSA, but Ligand A has a better affinity, lower Pgp efflux, and lower hERG risk. The lower Cl_mic for Ligand A is also a strong advantage.
**Overall Assessment:**
While Ligand B has a slightly better TPSA and in vitro half-life, Ligand A demonstrates a more favorable balance of properties, particularly regarding metabolic stability (Cl_mic), P-gp efflux, hERG risk, and binding affinity. The slightly better affinity of Ligand A, combined with its improved safety profile and potential for better bioavailability, makes it the more promising candidate.
Output:
1
2025-04-17 18:20:25,618 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (368.405 and 348.447 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (71.45) is better than Ligand B (84.42). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally aids absorption.
3. **logP:** Ligand B (1.649) is significantly better than Ligand A (4.142). A logP of 4.142 is approaching a level that could cause solubility issues and off-target interactions. 1.649 is comfortably within the optimal range.
4. **HBD:** Ligand B (1) is better than Ligand A (2). Fewer HBDs generally improve permeability.
5. **HBA:** Both ligands have 5 HBA, which is acceptable.
6. **QED:** Both ligands have very similar QED scores (0.83 and 0.81), indicating good drug-likeness.
7. **DILI:** Ligand B (50.291) is significantly better than Ligand A (93.37). A DILI percentile of 93.37 is a major red flag. Ligand B's score is well within the acceptable range.
8. **BBB:** Ligand B (62.233) is better than Ligand A (50.64). While not a primary concern for a cardiovascular target, higher BBB is generally preferable.
9. **Caco-2:** Both ligands have similar, poor Caco-2 permeability (-4.897 and -4.834). This suggests potential absorption issues for both.
10. **Solubility:** Ligand B (-2.519) is better than Ligand A (-5.052). Solubility is a concern with Ligand A's higher logP.
11. **hERG:** Both ligands have low hERG risk (0.112 and 0.201).
12. **Cl_mic:** Ligand A (6.079) is better than Ligand B (40.041). Lower clearance is preferred for metabolic stability.
13. **t1/2:** Ligand A (28.108) is significantly better than Ligand B (14.726). A longer half-life is desirable.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.09 and 0.084).
15. **Binding Affinity:** Ligand A (-7.8) is significantly better than Ligand B (-4.8). This is a 3 kcal/mol difference, which is substantial and can outweigh many ADME drawbacks.
**Overall Assessment:**
Ligand A has a much stronger binding affinity, and a better half-life and clearance. However, it has a concerningly high DILI risk and a logP that is pushing into a problematic range. Ligand B has a much better safety profile (DILI) and more favorable physicochemical properties (logP, solubility), but its binding affinity is significantly weaker.
Given the GPCR-specific priorities (logP, Pgp, TPSA, affinity), and the fact that this is a cardiovascular target (less emphasis on BBB), the superior binding affinity of Ligand A is the most important factor. While the DILI risk is a concern, it might be mitigated through structural modifications during lead optimization. The high logP is also a concern, but could be addressed during optimization. Ligand B's weaker affinity makes it less likely to be a successful drug candidate, even with its better ADME properties.
Output:
1
2025-04-17 18:20:25,618 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (345.407) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (70.67) is significantly better than Ligand A (97.94). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA is still beneficial for absorption.
3. **logP:** Both are within the optimal range (1-3), but Ligand B (1.152) is closer to the ideal range than Ligand A (0.647).
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand B (4) is better than Ligand A (7). Lower HBA is generally preferable.
6. **QED:** Both ligands have similar and acceptable QED values (0.794 and 0.745).
7. **DILI:** Ligand B (31.02) is significantly better than Ligand A (62.001). Lower DILI risk is a major advantage.
8. **BBB:** Both have good BBB penetration, but Ligand B (74.021) is slightly better than Ligand A (71.772).
9. **Caco-2:** Ligand B (-4.72) is better than Ligand A (-5.171).
10. **Solubility:** Ligand B (-1.394) is better than Ligand A (-2.38).
11. **hERG:** Ligand B (0.387) is much better than Ligand A (0.056). Lower hERG risk is crucial for cardiovascular drugs.
12. **Cl_mic:** Ligand B (2.467) is significantly better than Ligand A (21.385). Lower clearance indicates better metabolic stability.
13. **t1/2:** Ligand B (-11.662) is much better than Ligand A (-0.516). A longer half-life is desirable.
14. **Pgp:** Ligand B (0.015) is much better than Ligand A (0.048). Lower Pgp efflux is favorable.
15. **Binding Affinity:** Ligand B (-7.8) is slightly better than Ligand A (-7.0). While both are good, the small advantage of B is helpful.
**Overall Assessment:**
Ligand B consistently outperforms Ligand A across most critical ADME-Tox parameters, including DILI, hERG, Cl_mic, t1/2, and Pgp efflux. While Ligand A has a slightly lower MW and HBD count, these advantages are outweighed by the substantial improvements in safety and pharmacokinetic properties offered by Ligand B. The binding affinity difference is small enough that it doesn't negate the ADME benefits of Ligand B. Given that this is a GPCR target, the balance of properties in Ligand B is more favorable for development.
Output:
0
2025-04-17 18:20:25,618 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**1. Molecular Weight:** Both ligands (348.443 and 348.487 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (66.92) is higher than Ligand B (49.85). For a cardiovascular GPCR like ADRB2, TPSA is moderately important, and lower is generally better for permeability. Ligand B has a clear advantage.
**3. logP:** Both ligands have acceptable logP values (1.745 and 2.302), falling within the 1-3 range. Ligand B is slightly higher, which could be marginally better for membrane permeability.
**4. H-Bond Donors:** Both ligands have 0 HBD, which is good.
**5. H-Bond Acceptors:** Ligand A has 4 HBA, and Ligand B has 3. Both are acceptable, well below the 10 threshold.
**6. QED:** Both ligands have similar QED values (0.542 and 0.5), indicating good drug-likeness.
**7. DILI:** Ligand A (16.092) has a slightly higher DILI risk than Ligand B (9.228), but both are below the concerning threshold of 40.
**8. BBB:** Ligand A (85.498) has a better BBB penetration percentile than Ligand B (77.162). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be beneficial for off-target profiling and understanding potential side effects.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.34 and -4.463). These values are unusual and suggest poor permeability. However, the values are very similar.
**10. Aqueous Solubility:** Both ligands have negative solubility values (-1.538 and -1.618). Similar to Caco-2, these values are concerning and suggest poor solubility.
**11. hERG Inhibition:** Ligand A (0.119) has a slightly lower hERG inhibition liability than Ligand B (0.455), which is preferable.
**12. Microsomal Clearance:** Ligand A (67.373) has a higher microsomal clearance than Ligand B (41.007), indicating lower metabolic stability. Ligand B is better here.
**13. In vitro Half-Life:** Ligand B (6.733 hours) has a significantly longer in vitro half-life than Ligand A (-7.433 hours, which is effectively zero). This is a major advantage for Ligand B.
**14. P-gp Efflux:** Ligand A (0.06) has lower P-gp efflux liability than Ligand B (0.279), which is preferable.
**15. Binding Affinity:** Ligand A (-6.6 kcal/mol) has a slightly better binding affinity than Ligand B (-5.5 kcal/mol). This is a 1.1 kcal/mol difference, which is significant and can outweigh some ADME drawbacks.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), and balancing all parameters, Ligand A is slightly favored due to its superior binding affinity and lower P-gp efflux. While Ligand B has better metabolic stability (lower Cl_mic and longer half-life) and lower TPSA, the affinity difference is substantial. The solubility and permeability issues are similar for both, and the DILI and hERG risks are acceptable for both. The better affinity of Ligand A is likely to be more critical for achieving efficacy at a reasonable dose.
Output:
1
2025-04-17 18:20:25,618 - INFO - Batch 30 complete. Total preferences: 480
2025-04-17 18:20:25,619 - INFO - Processing batch 31/512...
2025-04-17 18:21:13,242 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (396.657) is slightly higher than Ligand B (345.399), but both are acceptable.
2. **TPSA:** Ligand A (59.42) is significantly better than Ligand B (93.46). For a GPCR, lower TPSA is generally preferred for better permeability. Ligand B is pushing the upper limit for good oral absorption (<=140), while A is well below.
3. **logP:** Ligand A (4.972) is higher than Ligand B (1.874). While both are within the acceptable range (1-3), Ligand A is approaching a level where solubility issues could arise. However, for a GPCR, a slightly higher logP can be tolerated if other properties are favorable.
4. **HBD:** Ligand A (1) is better than Ligand B (2). Lower HBD is generally preferred for permeability.
5. **HBA:** Ligand A (4) is better than Ligand B (5). Lower HBA is generally preferred for permeability.
6. **QED:** Both ligands have good QED scores (A: 0.632, B: 0.762), indicating good drug-like properties. B is slightly better here.
7. **DILI:** Ligand A (72.199) has a higher DILI risk than Ligand B (56.34). This is a significant negative for Ligand A.
8. **BBB:** Both ligands have similar BBB penetration (A: 56.805, B: 56.534). Neither is particularly high, but this isn't a critical factor for ADRB2 (a cardiovascular target).
9. **Caco-2:** Both ligands have similar, poor Caco-2 permeability (-4.829 and -4.86).
10. **Solubility:** Ligand A (-4.944) has worse solubility than Ligand B (-2.307). This is consistent with its higher logP.
11. **hERG:** Ligand A (0.517) has a lower hERG risk than Ligand B (0.329). This is a positive for Ligand A.
12. **Cl_mic:** Ligand A (71.172) has higher metabolic clearance than Ligand B (34.532). This is a negative for Ligand A, indicating faster metabolism.
13. **t1/2:** Ligand A (84.795) has a longer half-life than Ligand B (36.932). This is a positive for Ligand A.
14. **Pgp:** Ligand A (0.658) has lower P-gp efflux than Ligand B (0.045). This is a positive for Ligand A.
15. **Binding Affinity:** Ligand A (-7.1) has a slightly better binding affinity than Ligand B (-6.9). This difference is significant enough to potentially overcome some ADME liabilities.
**Overall Assessment:**
Ligand A has a significantly better binding affinity and better permeability characteristics (lower TPSA, HBD, HBA, and Pgp efflux). However, it suffers from higher DILI risk, higher metabolic clearance, and lower solubility. Ligand B has a better safety profile (lower DILI) and better metabolic stability, but its permeability is worse and its binding affinity is slightly lower.
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), and the fact that this is a cardiovascular target (so BBB isn't paramount), the stronger binding affinity of Ligand A is a key advantage. While the DILI risk is concerning, it might be mitigated through structural modifications during lead optimization. The improved permeability characteristics are also beneficial.
Output:
1
2025-04-17 18:21:13,242 - INFO - Reasoning:
Let's analyze Ligand A and Ligand B for their potential as ADRB2 ligands, keeping in mind GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key).
**Molecular Weight:** Both ligands (349.475 and 356.394 Da) fall within the ideal 200-500 Da range.
**TPSA:** Ligand A (53.09) is significantly better than Ligand B (84.94). A TPSA under 140 is good for oral absorption, but lower is generally preferred for GPCRs, and A is much closer to optimal.
**logP:** Ligand A (0.816) is slightly outside the optimal 1-3 range, but acceptable. Ligand B (0.279) is quite low, potentially hindering membrane permeability.
**H-Bond Donors/Acceptors:** Ligand A (0 HBD, 4 HBA) is preferable to Ligand B (1 HBD, 5 HBA). Lower counts generally improve permeability.
**QED:** Both ligands have similar QED values (0.705 and 0.663), indicating good drug-likeness.
**DILI:** Ligand A (9.616) has a much lower DILI risk than Ligand B (29.43). This is a significant advantage.
**BBB:** Ligand B (87.67) shows better BBB penetration than Ligand A (65.568). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be beneficial or at least not detrimental.
**Caco-2 Permeability:** Both have negative Caco-2 values (-4.326 and -4.768), which is unusual and suggests poor permeability. However, these are scales and the values are close.
**Aqueous Solubility:** Both have negative solubility values (-1.185 and -1.427), indicating poor solubility.
**hERG:** Both ligands have very low hERG inhibition risk (0.214 and 0.226).
**Microsomal Clearance:** Ligand A (3.247) has significantly lower microsomal clearance than Ligand B (19.662), indicating better metabolic stability.
**In vitro Half-Life:** Both have very negative half-life values (-8.752 and -8.786), which is also unusual. The values are very close.
**P-gp Efflux:** Both ligands show low P-gp efflux liability (0.016 and 0.019).
**Binding Affinity:** Ligand B (-7.1) has a slightly better binding affinity than Ligand A (-6.9), but the difference is small (0.2 kcal/mol). This difference is unlikely to outweigh the other significant advantages of Ligand A.
**Overall:**
Ligand A is clearly superior. It has a much better TPSA, lower DILI risk, and significantly better metabolic stability (lower Cl_mic). While Ligand B has slightly better BBB penetration and binding affinity, these are not substantial enough to overcome the significant drawbacks of higher TPSA, higher DILI risk, and poorer metabolic stability. The slightly lower logP of Ligand B is also concerning.
Output:
1
2025-04-17 18:21:13,243 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A:**
* **MW:** 375.778 Da - Good, within the ideal range.
* **TPSA:** 62.39 - Good, below the 140 threshold.
* **logP:** 3.413 - Excellent, within the optimal range.
* **HBD:** 3 - Good, within the acceptable limit.
* **HBA:** 3 - Good, within the acceptable limit.
* **QED:** 0.558 - Good, above the 0.5 threshold.
* **DILI:** 65.723 - Moderate risk, slightly above the preferred <60.
* **BBB:** 74.952 - Good, indicating reasonable potential for CNS penetration (though ADRB2 is primarily cardiovascular, some CNS off-target effects are possible).
* **Caco-2:** -4.798 - Poor, suggests poor intestinal absorption.
* **Solubility:** -4.881 - Poor, suggests low aqueous solubility.
* **hERG:** 0.423 - Low risk, good.
* **Cl_mic:** -3.346 - Good, suggests low metabolic clearance.
* **t1/2:** 16.981 - Good, reasonable half-life.
* **Pgp:** 0.164 - Low efflux, good.
* **Affinity:** -7.2 kcal/mol - Excellent, strong binding.
**Ligand B:**
* **MW:** 373.953 Da - Good, within the ideal range.
* **TPSA:** 21.06 - Excellent, very favorable for absorption.
* **logP:** 4.997 - Slightly high, potentially leading to solubility issues.
* **HBD:** 0 - Good, minimizes potential for off-target interactions.
* **HBA:** 4 - Good, within the acceptable limit.
* **QED:** 0.581 - Good, above the 0.5 threshold.
* **DILI:** 38.891 - Very good, low risk.
* **BBB:** 70.609 - Good, reasonable potential for CNS penetration.
* **Caco-2:** -5.241 - Poor, suggests poor intestinal absorption.
* **Solubility:** -4.122 - Poor, suggests low aqueous solubility.
* **hERG:** 0.902 - Moderate risk, less favorable than Ligand A.
* **Cl_mic:** 56.208 - High, suggests high metabolic clearance.
* **t1/2:** 42.654 - Excellent, long half-life.
* **Pgp:** 0.809 - Moderate efflux, less favorable than Ligand A.
* **Affinity:** -7.7 kcal/mol - Excellent, even stronger binding than Ligand A.
**Comparison & Decision:**
Both ligands have excellent binding affinity. Ligand B has a slightly better affinity (-7.7 vs -7.2 kcal/mol), which is a significant advantage. However, it suffers from higher metabolic clearance (Cl_mic) and Pgp efflux. Ligand A has better metabolic stability and lower Pgp efflux, which are important for oral bioavailability. Both have poor Caco-2 and solubility. Ligand B has a slightly higher logP, which could lead to off-target effects and formulation challenges. Ligand A has a slightly higher DILI risk, but it's still within a manageable range.
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand A strikes a better balance. While Ligand B has a slightly better affinity, the improved metabolic stability and lower Pgp efflux of Ligand A are more critical for achieving adequate *in vivo* exposure and efficacy, particularly for a cardiovascular target where CNS penetration is not a primary goal. The slightly higher DILI risk is less concerning than the potential for rapid metabolism and efflux of Ligand B.
Output:
1
2025-04-17 18:21:13,243 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.359 and 370.515 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand B (84.5) is significantly better than Ligand A (115.57). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (1.416) is within the optimal 1-3 range, while Ligand A (-0.815) is slightly below 1. This is a significant advantage for Ligand B, as it's more likely to have good membrane permeability.
4. **HBD:** Both have 2 HBD, ideal.
5. **HBA:** Ligand B (4) is slightly better than Ligand A (5), but both are acceptable.
6. **QED:** Ligand B (0.71) is better than Ligand A (0.545), indicating a more drug-like profile.
7. **DILI:** Both are reasonably good (Ligand A: 53.354, Ligand B: 47.266), below the 60 threshold for high risk. Ligand B is slightly better.
8. **BBB:** Ligand B (68.941) is better than Ligand A (22.257). While not critical for a cardiovascular target, higher BBB is generally a positive attribute.
9. **Caco-2:** Both are negative (-5.003 and -5.22), indicating poor permeability. This is a concern for both.
10. **Solubility:** Both are very poor (-2.622 and -3.766). This is a major drawback for both compounds.
11. **hERG:** Ligand A (0.04) is better than Ligand B (0.432), indicating lower cardiotoxicity risk. This is a crucial consideration for a cardiovascular target.
12. **Cl_mic:** Ligand A (-33.996) is better than Ligand B (53.465), indicating better metabolic stability.
13. **t1/2:** Ligand B (5.36) is much better than Ligand A (-20.197). A longer half-life is generally preferred.
14. **Pgp:** Ligand A (0.01) is significantly better than Ligand B (0.067), indicating lower efflux and potentially better bioavailability.
15. **Binding Affinity:** Ligand B (-8.0) is significantly better than Ligand A (-6.8). This is a substantial advantage, potentially outweighing some of the ADME concerns.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP and affinity, and is better in TPSA and Pgp. Ligand A has a better hERG score and Cl_mic.
**Overall Assessment:**
While Ligand A has better hERG and metabolic stability, Ligand B's significantly stronger binding affinity (-8.0 vs -6.8 kcal/mol) and better logP, TPSA, QED, BBB, and half-life are more compelling. The poor solubility and Caco-2 permeability are concerns for both, but the potency advantage of Ligand B is substantial. The slightly higher DILI and hERG risk for Ligand B are acceptable given the potency.
Output:
0
2025-04-17 18:21:13,243 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (370.475 and 353.384 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (29.54) is significantly better than Ligand A (114.19). ADRB2 is a GPCR, and lower TPSA generally favors better permeability and receptor engagement.
3. **logP:** Ligand B (3.806) is higher than Ligand A (1.431), but still within the acceptable range. While a higher logP can sometimes cause issues, it can also improve membrane permeability for GPCRs. Ligand A is on the lower side, potentially hindering permeation.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (0). This isn't a major concern for either.
5. **HBA:** Ligand A (7) is higher than Ligand B (2). Lower HBA is generally preferred for permeability, giving a slight edge to Ligand B.
6. **QED:** Ligand A (0.806) has a better QED score than Ligand B (0.551), suggesting a more drug-like profile overall.
7. **DILI:** Ligand B (19.969) has a much lower DILI risk than Ligand A (60.45). This is a significant advantage for Ligand B.
8. **BBB:** Ligand B (98.022) has excellent BBB penetration, while Ligand A (60.644) is moderate. For a GPCR, even if not specifically a CNS target, some degree of BBB penetration can be useful for understanding off-target effects.
9. **Caco-2:** Both have negative values, indicating permeability. Ligand B (-4.221) is slightly better than Ligand A (-5.147).
10. **Solubility:** Ligand A (-2.502) has better solubility than Ligand B (-4.621). Solubility is important, but can often be addressed with formulation strategies.
11. **hERG:** Ligand B (0.893) has a slightly higher hERG risk than Ligand A (0.098). This is a concern for Ligand B, but not overwhelmingly so.
12. **Cl_mic:** Ligand A (-15.994) has a much lower (better) microsomal clearance than Ligand B (51.336), indicating greater metabolic stability.
13. **t1/2:** Ligand A (47.083) has a significantly longer in vitro half-life than Ligand B (22.757). This is a major advantage for Ligand A.
14. **Pgp:** Ligand B (0.486) has lower P-gp efflux than Ligand A (0.065). Lower Pgp is generally favorable.
15. **Affinity:** Ligand A (-7.4) has a slightly better binding affinity than Ligand B (-6.6). While a 0.8 kcal/mol difference is noticeable, it's not a huge gap and can be potentially overcome with optimization.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP, TPSA, and Pgp. Ligand A has a slightly better affinity and a significantly better half-life and metabolic stability. The DILI risk is a major concern for Ligand A.
**Overall Assessment:**
While Ligand A has advantages in affinity, half-life, and metabolic stability, the significantly higher DILI risk and higher TPSA are major drawbacks. Ligand B, despite slightly weaker affinity, presents a much more favorable ADME-Tox profile, particularly the low DILI risk and excellent BBB penetration. The lower metabolic stability and shorter half-life of Ligand B can be addressed through structural modifications during lead optimization. The lower TPSA of Ligand B is also highly desirable for GPCR targeting.
Output:
0
2025-04-17 18:21:13,243 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (360.498 and 384.904 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (23.55) is significantly better than Ligand B (34.59). ADRB2 is a cardiovascular target, so CNS penetration isn't *essential*, but lower TPSA generally correlates with better permeability.
3. **logP:** Both ligands have similar logP values (4.454 and 4.516), both slightly above the optimal 1-3 range but not drastically so. This could potentially lead to some off-target interactions, but it's manageable.
4. **HBD:** Both ligands have 0 HBD, which is good.
5. **HBA:** Ligand A has 3 HBA, while Ligand B has 5. Lower is generally preferred, so Ligand A is slightly better.
6. **QED:** Ligand A (0.786) has a better QED score than Ligand B (0.636), indicating a more drug-like profile.
7. **DILI:** Ligand A (26.018) has a significantly lower DILI risk than Ligand B (30.438). This is a crucial advantage.
8. **BBB:** Ligand A (97.325) has a higher BBB penetration percentile than Ligand B (88.872). While not a primary concern for a cardiovascular target, higher BBB is rarely detrimental.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.85) is slightly better than Ligand B (-4.389) but both are concerning.
10. **Solubility:** Ligand A (-3.466) is better than Ligand B (-4.66), indicating better aqueous solubility.
11. **hERG:** Both ligands have low hERG inhibition liability (0.983 and 0.807), which is excellent.
12. **Cl_mic:** Ligand A (51.789) has a significantly lower microsomal clearance than Ligand B (104.659), indicating better metabolic stability.
13. **t1/2:** Ligand A (16.706) has a longer in vitro half-life than Ligand B (13.806).
14. **Pgp:** Ligand A (0.859) has a lower P-gp efflux liability than Ligand B (0.502).
15. **Binding Affinity:** Ligand B (-6.8 kcal/mol) has a significantly better binding affinity than Ligand A (-5.3 kcal/mol). This is a substantial advantage, exceeding the 1.5 kcal/mol threshold.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. While both ligands have acceptable logP values, Ligand B's superior affinity is a major factor. Ligand A has advantages in TPSA, Pgp, and ADME properties, but the binding affinity difference is substantial enough to outweigh those benefits.
**Overall Assessment:**
Ligand B's significantly stronger binding affinity (-6.8 vs -5.3 kcal/mol) is the most important factor. While Ligand A has better ADME properties, the potency advantage of Ligand B is likely to be more impactful in driving efficacy. The slightly worse ADME profile of Ligand B can be addressed through further optimization.
Output:
0
2025-04-17 18:21:13,243 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (391.465 and 370.515 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Both ligands (79.37 and 75.71) are below the 140 threshold for good oral absorption, which is good.
3. **logP:** Ligand A (1.79) is slightly higher than Ligand B (0.959), both are within the optimal 1-3 range. Ligand A is preferable.
4. **HBD:** Both ligands have 1 HBD, which is within the acceptable limit of 5.
5. **HBA:** Both ligands have 5 HBA, which is within the acceptable limit of 10.
6. **QED:** Both ligands have similar QED scores (0.75 and 0.754), indicating good drug-likeness.
7. **DILI:** Ligand B (35.479) has a significantly lower DILI risk than Ligand A (60.527). This is a major advantage for Ligand B.
8. **BBB:** Ligand A (83.443) has a slightly higher BBB penetration percentile than Ligand B (76.309). While ADRB2 isn't strictly a CNS target, some CNS exposure can be relevant for off-target effects, and higher BBB is generally better.
9. **Caco-2:** Both ligands have similar, very negative Caco-2 permeability values (-5.095 and -5.098). This suggests poor permeability, which is a concern.
10. **Solubility:** Ligand B (-2.399) has slightly better aqueous solubility than Ligand A (-3.584).
11. **hERG:** Both ligands have very low hERG inhibition liability (0.387 and 0.311), which is excellent.
12. **Cl_mic:** Ligand B (37.623) has slightly lower microsomal clearance than Ligand A (39.559), suggesting better metabolic stability.
13. **t1/2:** Ligand B (16.787) has a significantly longer in vitro half-life than Ligand A (-22.42). This is a substantial advantage for Ligand B.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.195 and 0.154).
15. **Binding Affinity:** Ligand A (-7.4 kcal/mol) has a stronger binding affinity than Ligand B (-6.3 kcal/mol). This is a 1.1 kcal/mol difference, which is a significant advantage for Ligand A.
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand A has a better logP and significantly better affinity. However, Ligand B has a much better safety profile (lower DILI) and better metabolic stability (lower Cl_mic, longer t1/2). The poor Caco-2 values for both are concerning, but the affinity difference is substantial. Given the importance of minimizing off-target effects and maximizing duration of action, the improved ADME profile of Ligand B is more compelling.
**Final Decision:**
While Ligand A has a stronger binding affinity, the significantly improved safety (DILI) and pharmacokinetic (t1/2, Cl_mic) properties of Ligand B make it the more promising drug candidate.
Output:
0
2025-04-17 18:21:13,243 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (348.447) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (76.46) is significantly better than Ligand B (36.36). For a cardiovascular GPCR like ADRB2, TPSA is less critical than for CNS targets, but lower is still preferred for absorption. Ligand B is quite low, which *could* indicate issues with solubility.
3. **logP:** Ligand A (2.624) is optimal. Ligand B (4.485) is a bit high, potentially leading to solubility issues and off-target interactions.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 5 HBA, and Ligand B has 3 HBA. Both are within the acceptable range.
6. **QED:** Ligand A (0.907) has a much better QED score than Ligand B (0.782), indicating a more drug-like profile.
7. **DILI:** Ligand A (32.997) has a significantly lower DILI risk than Ligand B (20.163), which is a major advantage.
8. **BBB:** Ligand A (86.661) has a better BBB penetration score than Ligand B (72.005). While ADRB2 isn't a primary CNS target, some CNS exposure can contribute to side effects, and better control over this is desirable.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
10. **Solubility:** Ligand A (-2.127) has slightly better solubility than Ligand B (-4.18), though both are quite poor.
11. **hERG:** Ligand A (0.253) has a much lower hERG risk than Ligand B (0.952), a critical factor for cardiovascular drugs.
12. **Cl_mic:** Ligand A (43.798) has a lower microsomal clearance than Ligand B (58.311), suggesting better metabolic stability.
13. **t1/2:** Ligand B (71.657) has a significantly longer in vitro half-life than Ligand A (-8.466), which is a strong positive.
14. **Pgp:** Ligand A (0.045) has a lower P-gp efflux liability than Ligand B (0.684), which is favorable for bioavailability.
15. **Affinity:** Both ligands have very similar binding affinities (-6.5 kcal/mol and -6.2 kcal/mol respectively). The difference is not substantial enough to outweigh other factors.
**GPCR-Specific Priorities:**
For ADRB2 (a cardiovascular GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A is better in terms of logP, TPSA, and Pgp. Affinity is comparable.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B in most critical ADME-Tox parameters (DILI, hERG, Cl_mic, Pgp, QED, Solubility) and has a more favorable logP and TPSA. While Ligand B has a longer half-life, the significantly better safety profile and drug-like properties of Ligand A outweigh this advantage. The poor Caco-2 and solubility values for both are concerning and would require further investigation, but Ligand A's overall profile is more promising.
Output:
1
2025-04-17 18:21:13,243 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
We are targeting ADRB2, a GPCR, so the priorities are logP, TPSA, Pgp, BBB, and affinity. Let's break down the comparison:
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (331.379) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (53.51) has a significantly lower TPSA than Ligand A (85.07). This is a major advantage for Ligand B, as lower TPSA generally correlates with better cell permeability and oral absorption.
3. **logP:** Both ligands have good logP values (A: 2.898, B: 3.25), falling within the optimal 1-3 range. Ligand B is slightly higher, which could potentially lead to some off-target effects, but it's not a major concern.
4. **H-Bond Donors/Acceptors:** Ligand A has 2 HBD and 6 HBA, while Ligand B has 0 HBD and 4 HBA. Both are within acceptable limits.
5. **QED:** Both ligands have good QED scores (A: 0.767, B: 0.825), indicating good drug-like properties.
6. **DILI:** Ligand B (48.623) has a much lower DILI risk than Ligand A (84.025). This is a significant advantage for Ligand B.
7. **BBB:** Ligand B (59.519) has a better BBB penetration score than Ligand A (36.797). While ADRB2 isn't strictly a CNS target, some peripheral exposure is often desired, and better BBB penetration can sometimes correlate with better overall distribution.
8. **Caco-2 Permeability:** Both have negative Caco-2 values, which is unusual. However, the magnitude of the negative value is smaller for Ligand B (-4.873 vs -5.312), suggesting potentially slightly better absorption.
9. **Aqueous Solubility:** Both have negative solubility values, which is also unusual. The magnitude is smaller for Ligand B (-2.477 vs -4.624), suggesting potentially slightly better solubility.
10. **hERG Inhibition:** Both ligands have very low hERG inhibition risk (A: 0.9, B: 0.323). Ligand B is slightly better.
11. **Microsomal Clearance:** Both ligands have similar microsomal clearance values (A: 54.977, B: 51.871).
12. **In vitro Half-Life:** Ligand A (12.602) has a significantly longer half-life than Ligand B (3.996). This is a positive for Ligand A.
13. **P-gp Efflux:** Ligand A (0.11) has a lower P-gp efflux liability than Ligand B (0.464). This is a positive for Ligand A.
14. **Binding Affinity:** Ligand B (-6.9 kcal/mol) has a stronger binding affinity than Ligand A (-6.1 kcal/mol). This is a substantial advantage for Ligand B, exceeding the 1.5 kcal/mol difference threshold.
**Overall Assessment:**
Ligand B demonstrates a superior profile, particularly regarding TPSA, DILI risk, BBB penetration, and importantly, binding affinity. While Ligand A has a longer half-life and lower P-gp efflux, the advantages of Ligand B in key GPCR-relevant parameters (TPSA, DILI, Affinity) outweigh these benefits. The stronger binding affinity of Ligand B is a critical factor, and the lower TPSA and DILI risk are highly desirable.
Output:
0
2025-04-17 18:21:13,243 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 drug candidates. ADRB2 is a GPCR, so we'll prioritize logP, Pgp, TPSA, and affinity, alongside general drug-like properties.
**Ligand A:** [358.423, 89.16, 1.826, 2, 6, 0.643, 70.841, 23.187, -5.836, -2.43, 0.206, 29.76, 48.057, 0.036, -4.7]
**Ligand B:** [346.475, 74.33, 1.08, 2, 4, 0.656, 14.23, 68.36, -4.988, -0.746, 0.362, 21.686, -5.817, 0.058, -6]
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (346.475) is slightly lower, which is generally favorable.
2. **TPSA:** Ligand A (89.16) is slightly higher than Ligand B (74.33). Both are acceptable for a non-CNS GPCR target, but Ligand B is better.
3. **logP:** Both are within the optimal range (1-3). Ligand B (1.08) is slightly lower, but still acceptable. Ligand A (1.826) is a bit better.
4. **HBD:** Both have 2 HBD, which is good.
5. **HBA:** Ligand A has 6 HBA, Ligand B has 4. Both are acceptable, but Ligand B is slightly better.
6. **QED:** Both are similar (0.643 and 0.656), indicating good drug-likeness.
7. **DILI:** Ligand A (70.841) is significantly higher than Ligand B (14.23). This is a major concern for Ligand A.
8. **BBB:** Ligand B (68.36) has a higher BBB penetration percentile than Ligand A (23.187). While not a primary concern for ADRB2 (a cardiovascular target), higher BBB is rarely detrimental.
9. **Caco-2:** Ligand A (-5.836) and Ligand B (-4.988) are both negative, indicating poor permeability. However, the scale is not specified, and negative values may not be directly comparable.
10. **Solubility:** Ligand B (-0.746) has better solubility than Ligand A (-2.43).
11. **hERG:** Ligand A (0.206) has a slightly lower hERG risk than Ligand B (0.362), which is good.
12. **Cl_mic:** Ligand B (21.686) has a lower microsomal clearance than Ligand A (29.76), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-5.817) has a more negative in vitro half-life, which is problematic. Ligand A (48.057) is much better.
14. **Pgp:** Ligand A (0.036) has lower P-gp efflux than Ligand B (0.058), which is favorable.
15. **Affinity:** Ligand B (-6 kcal/mol) has a significantly better binding affinity than Ligand A (-4.7 kcal/mol). This is a substantial advantage.
**Overall Assessment:**
Ligand B is the stronger candidate. While Ligand A has slightly better hERG and Pgp properties, Ligand B excels in several critical areas: significantly lower DILI risk, better solubility, better metabolic stability (lower Cl_mic), and *much* stronger binding affinity. The affinity difference of 1.3 kcal/mol is substantial and can often outweigh minor ADME drawbacks. The negative half-life for Ligand B is a concern, but could be addressed with structural modifications. The DILI risk for Ligand A is a major red flag.
Output:
0
2025-04-17 18:21:13,243 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Step-by-step comparison:**
1. **MW:** Both ligands (364.471 and 354.801 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (70.65) is significantly better than Ligand A (95.16). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (3.186) is at the upper end of the optimal range, while Ligand A (1.022) is at the lower end. For a GPCR, a slightly higher logP is often acceptable and can improve binding.
4. **HBD:** Ligand A (2) is preferable to Ligand B (0). Having some HBD can improve solubility.
5. **HBA:** Ligand B (7) is preferable to Ligand A (5).
6. **QED:** Ligand A (0.786) has a better QED score than Ligand B (0.565), indicating a more drug-like profile.
7. **DILI:** Ligand A (65.568) is better than Ligand B (92.865). Lower DILI risk is always preferred.
8. **BBB:** Both are relatively low, but Ligand B (54.827) is slightly better than Ligand A (48.391). Not a major concern for a cardiovascular target.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-5.55) is slightly better than Ligand B (-4.773).
10. **Solubility:** Both are negative, indicating poor solubility. Ligand A (-3.568) is slightly better than Ligand B (-3.853).
11. **hERG:** Both are very low (0.276 and 0.33), indicating minimal hERG inhibition risk. No significant difference.
12. **Cl_mic:** Ligand A (29.079) has a lower (better) microsomal clearance than Ligand B (48.127), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-14.613) has a better (less negative) in vitro half-life than Ligand A (-18.265).
14. **Pgp:** Both are very low (0.08 and 0.601), indicating minimal P-gp efflux. No significant difference.
15. **Binding Affinity:** Ligand A (-6.7 kcal/mol) has a slightly better binding affinity than Ligand B (-6.2 kcal/mol).
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand B has a better logP and TPSA, but Ligand A has a better QED, DILI, Cl_mic, and binding affinity. The difference in binding affinity (0.5 kcal/mol) is significant enough to outweigh the slightly less favorable TPSA and logP of Ligand A.
**Conclusion:**
Considering the balance of properties, particularly the superior binding affinity, lower DILI risk, and better metabolic stability of Ligand A, it is the more promising drug candidate.
Output:
1
2025-04-17 18:21:13,243 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [338.367, 93.19, 3.757, 2, 5, 0.755, 88.484, 71.772, -4.816, -4.764, 0.259, 14.897, 62.146, 0.048, -6.2]
**Ligand B:** [350.419, 83.88, -0.233, 1, 5, 0.795, 56.146, 59.442, -4.837, -0.984, 0.099, 20.41, 10.72, 0.057, -7.2]
Here's a breakdown, prioritizing GPCR-relevant parameters:
1. **Molecular Weight:** Both are within the ideal 200-500 Da range. A (338) is slightly preferred.
2. **TPSA:** Both are acceptable (A: 93.19, B: 83.88), below the 140 threshold for oral absorption. B is slightly better.
3. **logP:** A (3.757) is optimal, while B (-0.233) is significantly low, potentially hindering membrane permeability and bioavailability. This is a major strike against B.
4. **H-Bond Donors/Acceptors:** Both have reasonable HBD (A:2, B:1) and HBA (both 5) counts.
5. **QED:** Both are good (A: 0.755, B: 0.795), indicating drug-like properties.
6. **DILI:** A (88.484) is concerningly high, indicating a significant risk of liver injury. B (56.146) is much better.
7. **BBB:** A (71.772) is decent, while B (59.442) is lower. For a cardiovascular target, BBB isn't *critical*, but a higher value is still preferable.
8. **Caco-2:** Both are poor (-4.816 and -4.837). This suggests poor intestinal absorption for both.
9. **Solubility:** Both are very poor (-4.764 and -0.984). This is a significant issue for both compounds.
10. **hERG:** Both are low risk (A: 0.259, B: 0.099).
11. **Cl_mic:** A (14.897) is better than B (20.41), indicating better metabolic stability.
12. **t1/2:** A (62.146) is better than B (10.72), suggesting a longer half-life.
13. **Pgp:** Both are low efflux (A: 0.048, B: 0.057).
14. **Binding Affinity:** B (-7.2) has a significantly stronger binding affinity than A (-6.2) - a 1.0 kcal/mol difference. This is a substantial advantage.
**Overall Assessment:**
Ligand B has a much better DILI profile and a significantly stronger binding affinity. However, its extremely low logP is a major drawback, likely leading to poor absorption and bioavailability. Ligand A has a better logP, but its high DILI risk is concerning. The improved metabolic stability and half-life of A are also positives.
Given the GPCR target and the importance of bioavailability, the logP issue with Ligand B is too significant to ignore. While the affinity is tempting, a compound needs to reach its target. The DILI risk of Ligand A is concerning, but could potentially be mitigated through structural modifications.
Therefore, I would proceed with **Ligand A** as the more promising starting point, despite the DILI risk.
**Output:**
1
2025-04-17 18:21:13,244 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (367.515 Da and 352.475 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (80.32) is slightly higher than Ligand B (67.87). Both are below 140, but B is better for absorption.
3. **logP:** Ligand A (2.67) is within the optimal 1-3 range. Ligand B (1.891) is closer to the lower limit, which *could* indicate permeability issues, but is still acceptable. A has a slight edge.
4. **HBD:** Ligand A (2) and Ligand B (1) are both good, below the threshold of 5. B is slightly better.
5. **HBA:** Ligand A (5) and Ligand B (4) are both good, below the threshold of 10. B is slightly better.
6. **QED:** Ligand A (0.838) is better than Ligand B (0.767), indicating a more drug-like profile.
7. **DILI:** Ligand B (31.989) has a significantly lower DILI risk than Ligand A (57.076). This is a major advantage for B.
8. **BBB:** Both ligands have reasonable BBB penetration (Ligand A: 62.311, Ligand B: 68.786). Since ADRB2 isn't strictly a CNS target, this isn't a primary driver, but B is slightly better.
9. **Caco-2:** Ligand A (-5.169) and Ligand B (-4.682) are both negative, indicating poor permeability. This is a concern for both, but B is slightly better.
10. **Solubility:** Ligand A (-3.051) has worse solubility than Ligand B (-1.26). Solubility is important for bioavailability, so B is favored.
11. **hERG:** Both ligands have very low hERG inhibition risk (Ligand A: 0.324, Ligand B: 0.192). B is slightly better.
12. **Cl_mic:** Ligand A (36.573) and Ligand B (31.256) have similar microsomal clearance. B is slightly better.
13. **t1/2:** Ligand A (14.442) has a slightly longer half-life than Ligand B (12.691). This is a minor advantage for A.
14. **Pgp:** Both ligands have low P-gp efflux liability (Ligand A: 0.107, Ligand B: 0.036). B is better.
15. **Binding Affinity:** Ligand A (-7.0) has a slightly better binding affinity than Ligand B (-5.8). This is a significant advantage for A, potentially outweighing some ADME concerns.
**Overall Assessment:**
While Ligand A has a better binding affinity, Ligand B demonstrates a superior ADME profile, particularly regarding DILI risk, solubility, and Pgp efflux. For a cardiovascular target like ADRB2, minimizing off-target effects and ensuring reasonable bioavailability are crucial. The difference in binding affinity (1.2 kcal/mol) is not substantial enough to overcome the significant advantages of Ligand B in terms of safety and drug-like properties.
Output:
0
2025-04-17 18:21:13,244 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (344.411 and 348.531 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (73.99) is higher than Ligand B (40.62). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B is significantly better.
3. **logP:** Ligand A (1.911) is within the optimal 1-3 range. Ligand B (3.864) is at the higher end, potentially raising concerns about solubility and off-target effects, but still acceptable.
4. **HBD:** Ligand A (1) and Ligand B (0) are both good.
5. **HBA:** Ligand A (4) and Ligand B (2) are both good.
6. **QED:** Ligand A (0.905) is excellent, indicating high drug-likeness. Ligand B (0.655) is still acceptable, but less optimal.
7. **DILI:** Ligand A (35.634) and Ligand B (30.903) both have low DILI risk, well below the 40% threshold. Ligand B is slightly better.
8. **BBB:** Ligand A (63.164) is moderate, while Ligand B (87.941) is high. While ADRB2 isn't a CNS target, some degree of BBB penetration can influence peripheral distribution. Ligand B is better.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.484 and -4.526), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand A (-1.541) is better than Ligand B (-3.458). Solubility is a concern for both, but more so for Ligand B.
11. **hERG:** Ligand A (0.153) is much lower than Ligand B (0.555), indicating a lower risk of cardiotoxicity. This is a critical advantage for a cardiovascular target.
12. **Cl_mic:** Ligand A (6.252) is much lower than Ligand B (96.589), indicating better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand A (52.311) is much longer than Ligand B (-20.073). This is a major advantage for dosing convenience.
14. **Pgp:** Ligand A (0.18) is lower than Ligand B (0.533), indicating less P-gp efflux.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.8 and -6.7 kcal/mol). The difference is negligible.
**Overall Assessment:**
While both ligands have issues with Caco-2 permeability, Ligand A is clearly superior. It has a better QED score, significantly lower DILI and hERG risk, much better metabolic stability (lower Cl_mic and longer t1/2), lower Pgp efflux, and better solubility. The slightly lower TPSA of Ligand B is not enough to offset these advantages, especially considering the cardiovascular target. The similar binding affinities make the ADME properties the deciding factor.
Output:
1
2025-04-17 18:21:13,244 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**1. Molecular Weight:** Both ligands (344.46 and 341.42 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (67.23) is significantly better than Ligand B (99.81). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is approaching a value that could hinder oral absorption.
**3. logP:** Ligand A (1.983) is slightly higher than Ligand B (0.784), both within the optimal 1-3 range, but A is closer to the sweet spot.
**4. H-Bond Donors:** Ligand A (1) is better than Ligand B (2). Lower HBD generally improves permeability.
**5. H-Bond Acceptors:** Ligand A (4) is better than Ligand B (5). Similar to HBD, lower HBA is preferred.
**6. QED:** Both ligands have very similar QED values (0.733 and 0.747), indicating good drug-likeness.
**7. DILI:** Ligand A (33.93) has a slightly lower DILI risk than Ligand B (39.20), both are acceptable.
**8. BBB:** Ligand A (72.97) has a significantly higher BBB penetration percentile than Ligand B (51.26). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant for off-target effects or potential therapeutic benefits.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests a potential issue with the experimental setup or data quality. However, the magnitude is similar, so it doesn't heavily influence the decision.
**10. Aqueous Solubility:** Both ligands have negative solubility values, which is also unusual and suggests a potential issue with the experimental setup or data quality. However, the magnitude is similar, so it doesn't heavily influence the decision.
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (0.47 and 0.324), which is excellent.
**12. Microsomal Clearance:** Ligand A (49.51) has a significantly higher microsomal clearance than Ligand B (17.154), indicating faster metabolism and potentially lower *in vivo* exposure. This is a significant drawback for Ligand A.
**13. In vitro Half-Life:** Ligand B (-1.862) has a better half-life than Ligand A (-5.752).
**14. P-gp Efflux:** Both ligands have similar low P-gp efflux liability (0.111 and 0.031).
**15. Binding Affinity:** Ligand A (-6.7 kcal/mol) has a slightly better binding affinity than Ligand B (-6.2 kcal/mol). The difference is 0.5 kcal/mol, which is notable but not overwhelmingly decisive.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand A initially appears favorable due to its better logP, TPSA, and slightly higher affinity. However, the significantly higher microsomal clearance and shorter half-life of Ligand A are major concerns. Ligand B, while having a slightly higher TPSA and lower logP, exhibits much better metabolic stability and a longer half-life. The affinity difference is not large enough to overcome the ADME advantages of Ligand B.
Therefore, I favor Ligand B.
Output:
0
2025-04-17 18:21:13,244 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (342.443 and 360.376 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (85.23) is slightly higher than Ligand B (69.64). Both are below the 140 threshold for good oral absorption, but B is better positioned for potential CNS penetration if desired.
3. **logP:** Both ligands have good logP values (2.494 and 1.724), falling within the optimal 1-3 range. Ligand B is slightly lower, which could improve solubility.
4. **HBD:** Both have 2 H-bond donors, which is within the acceptable limit of 5.
5. **HBA:** Both have 3 H-bond acceptors, well below the limit of 10.
6. **QED:** Ligand A (0.881) has a significantly higher QED score than Ligand B (0.593), indicating a more drug-like profile overall.
7. **DILI:** Both ligands have very similar and acceptable DILI risk (32.105 and 32.028 percentile).
8. **BBB:** Ligand B (70.997) has a substantially higher BBB penetration percentile than Ligand A (53.083). This is a significant advantage for a GPCR, even if ADRB2 isn't strictly a CNS target, as it suggests better distribution.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Ligand B (-1.669) has better (higher) aqueous solubility than Ligand A (-3.382).
11. **hERG:** Both ligands have low hERG inhibition risk (0.407 and 0.419).
12. **Cl_mic:** Ligand B (-1.409) exhibits significantly lower microsomal clearance than Ligand A (0.022), indicating better metabolic stability.
13. **t1/2:** Ligand B (-26.093) has a much longer in vitro half-life than Ligand A (18.938). This is a major advantage.
14. **Pgp:** Both have very low Pgp efflux liability (0.024 and 0.097).
15. **Binding Affinity:** Ligand B (-6.8 kcal/mol) has a slightly stronger binding affinity than Ligand A (-6.3 kcal/mol), although the difference is relatively small.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP, TPSA, and has a slightly better affinity. The significantly improved metabolic stability (Cl_mic, t1/2) and BBB penetration of Ligand B are also highly desirable. While Ligand A has a better QED, the ADME benefits of Ligand B outweigh this.
**Conclusion:**
Ligand B presents a more favorable balance of properties, particularly regarding ADME characteristics and binding affinity, making it the more promising drug candidate for ADRB2.
0
2025-04-17 18:21:13,244 - INFO - Batch 31 complete. Total preferences: 496
2025-04-17 18:21:13,244 - INFO - Processing batch 32/512...
2025-04-17 18:22:02,010 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Ligand A (343.427 Da) is better, falling comfortably within the 200-500 Da range. Ligand B (400.327 Da) is still acceptable but pushing towards the upper limit.
2. **TPSA:** Ligand B (55.4) is significantly better than Ligand A (84.08). Lower TPSA generally improves permeability, crucial for GPCRs.
3. **logP:** Both ligands have good logP values (A: 3.115, B: 3.61), within the optimal 1-3 range. Ligand B is slightly higher, which could potentially lead to off-target effects, but not drastically.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1), but both are within the acceptable limit of 5.
5. **HBA:** Ligand A (5) is higher than Ligand B (3), but both are within the acceptable limit of 10.
6. **QED:** Ligand A (0.815) is slightly better than Ligand B (0.737), indicating a more drug-like profile.
7. **DILI:** Both ligands have similar DILI risk (A: 56.572, B: 58.511), and are acceptable.
8. **BBB:** Both ligands have similar BBB penetration (A: 51.919, B: 56.068), which is not ideal for a non-CNS target, but not a major concern for ADRB2, which is primarily cardiovascular.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. This is a significant drawback for both.
10. **Solubility:** Both ligands have negative solubility values, which is also unusual and suggests poor solubility. This is a significant drawback for both.
11. **hERG:** Ligand A (0.559) is better than Ligand B (0.813), indicating a lower risk of cardiotoxicity. This is a critical factor for a cardiovascular target.
12. **Cl_mic:** Ligand B (61.914) has a lower microsomal clearance than Ligand A (88.37), suggesting better metabolic stability.
13. **t1/2:** Ligand B (16.191) has a much longer in vitro half-life than Ligand A (4.707), which is a significant advantage.
14. **Pgp:** Ligand A (0.103) has lower P-gp efflux than Ligand B (0.62), which is preferable.
15. **Binding Affinity:** Ligand A (-6.3 kcal/mol) has a slightly better binding affinity than Ligand B (-5.5 kcal/mol). This is a substantial difference, and a key driver in the decision.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, TPSA, logP, and binding affinity are particularly important. Ligand B has a much better TPSA, and a better half-life. However, Ligand A has a better binding affinity and lower hERG risk. The affinity difference is significant, and the hERG risk is critical for a cardiovascular drug.
**Overall Assessment:**
Despite the poor Caco-2 and solubility values for both, Ligand A's superior binding affinity and lower hERG risk outweigh the benefits of Ligand B's slightly better TPSA and half-life. The stronger binding is likely to translate to greater efficacy, and minimizing cardiotoxicity is paramount for a cardiovascular drug.
Output:
1
2025-04-17 18:22:02,010 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [368.352, 99.1, -0.338, 3, 5, 0.631, 16.789, 58.976, -5.089, -1.115, 0.276, -24.064, -16.782, 0.025, -7.8]
**Ligand B:** [350.503, 58.64, 3.576, 1, 3, 0.824, 40.558, 79.217, -4.519, -4.237, 0.548, 67.653, -11.24, 0.564, -6.3]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, Affinity, and BBB):
1. **MW:** Both are within the ideal 200-500 Da range. Ligand B (350.5) is slightly preferred.
2. **TPSA:** Ligand A (99.1) is higher than Ligand B (58.64). Ligand B is significantly better for oral absorption, being well below the 140 threshold.
3. **logP:** Ligand A (-0.338) is a bit low, potentially hindering permeation. Ligand B (3.576) is excellent, falling right within the optimal 1-3 range. This is a significant advantage for Ligand B.
4. **HBD/HBA:** Ligand A has 3 HBD and 5 HBA, while Ligand B has 1 HBD and 3 HBA. Both are acceptable, but Ligand B is slightly better.
5. **QED:** Both have good QED scores (0.631 and 0.824), indicating good drug-like properties. Ligand B is better.
6. **DILI:** Ligand A (16.789%) has a lower DILI risk than Ligand B (40.558%), which is good.
7. **BBB:** Ligand B (79.217%) has a much higher BBB penetration potential than Ligand A (58.976%). This is a major advantage for Ligand B, given it's a GPCR.
8. **Caco-2:** Both have negative values, which is unusual. Assuming these are log scale values, lower values indicate poorer permeability. Ligand A (-5.089) is worse than Ligand B (-4.519).
9. **Solubility:** Both have negative solubility values, which is unusual. Assuming these are log scale values, lower values indicate poorer solubility. Ligand A (-1.115) is slightly better than Ligand B (-4.237).
10. **hERG:** Both have low hERG risk (0.276 and 0.548).
11. **Cl_mic:** Ligand A (-24.064) has a much lower (better) microsomal clearance than Ligand B (67.653), indicating better metabolic stability.
12. **t1/2:** Ligand A (-16.782) has a longer in vitro half-life than Ligand B (-11.24), which is preferable.
13. **Pgp:** Ligand A (0.025) has much lower P-gp efflux than Ligand B (0.564), which is a significant advantage.
14. **Affinity:** Ligand A (-7.8 kcal/mol) has a slightly better binding affinity than Ligand B (-6.3 kcal/mol). This is a good advantage for Ligand A.
**Overall Assessment:**
Ligand B excels in key GPCR properties: logP, BBB, and TPSA. While Ligand A has better metabolic stability (Cl_mic, t1/2) and Pgp efflux, the superior permeability and brain penetration of Ligand B, combined with its good affinity, outweigh these benefits. The slightly higher DILI risk for Ligand B is a concern, but manageable. The affinity difference is not large enough to overcome the ADME advantages of Ligand B.
Therefore, I prefer Ligand B.
Output:
0
2025-04-17 18:22:02,011 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (342.443 Da and 342.403 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (58.44) is significantly better than Ligand B (93.01). For a GPCR, lower TPSA is generally preferred for better permeability. Ligand B is pushing the 140 limit for oral absorption.
**3. logP:** Both ligands have acceptable logP values (1.674 and 0.717, respectively), falling within the 1-3 range. Ligand A is slightly better.
**4. H-Bond Donors:** Ligand A (0) is preferable to Ligand B (1). Fewer HBDs generally improve permeability.
**5. H-Bond Acceptors:** Ligand A (4) is better than Ligand B (6). Lower HBA is preferable for permeability.
**6. QED:** Both ligands have good QED scores (0.765 and 0.884), indicating good drug-like properties. Ligand B is slightly better.
**7. DILI:** Ligand A (35.673) has a lower DILI risk than Ligand B (53.819), which is a significant advantage.
**8. BBB:** Ligand A (70.376) has a better BBB penetration score than Ligand B (54.983). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be beneficial for off-target effects and distribution.
**9. Caco-2 Permeability:** Ligand A (-4.725) is better than Ligand B (-5.137). Higher Caco-2 permeability is desirable.
**10. Aqueous Solubility:** Ligand A (-1.06) is better than Ligand B (-1.846). Better solubility is important for formulation.
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.232 and 0.124), which is excellent.
**12. Microsomal Clearance:** Ligand A (59.287) is worse than Ligand B (-7.038). Lower clearance is better for metabolic stability. This is a significant advantage for Ligand B.
**13. In vitro Half-Life:** Ligand A (-8.688) is better than Ligand B (15.646). Longer half-life is preferred.
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (0.215 and 0.009).
**15. Binding Affinity:** Ligand A (-5.7 kcal/mol) and Ligand B (-6.7 kcal/mol). Ligand B has a substantially better binding affinity. This is a major advantage.
**Overall Assessment:**
Ligand B has a significantly better binding affinity (-6.7 vs -5.7 kcal/mol) and better metabolic stability (lower Cl_mic). These are critical factors for a GPCR target. While Ligand A has advantages in TPSA, solubility, DILI, and half-life, the binding affinity difference is substantial enough to outweigh these. The slightly higher TPSA of Ligand B is not a deal-breaker.
Output:
0
2025-04-17 18:22:02,011 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (349.431) is slightly lower, which can be advantageous for permeability.
2. **TPSA:** Ligand A (89.55) is better than Ligand B (58.36), being closer to the optimal value for good oral absorption (<=140).
3. **logP:** Ligand A (1.21) is within the optimal range (1-3), while Ligand B (3.769) is approaching the upper limit. Higher logP can sometimes lead to off-target effects and solubility issues.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1), but both are acceptable.
5. **HBA:** Both ligands have the same number of HBA (5), which is within the acceptable range.
6. **QED:** Both ligands have similar QED values (0.736 and 0.754), indicating good drug-likeness.
7. **DILI:** Ligand B (35.789) has a significantly lower DILI risk than Ligand A (49.438), which is a major advantage.
8. **BBB:** Ligand B (60.644) has a slightly higher BBB penetration than Ligand A (54.634), but both are not particularly high. Since ADRB2 is a cardiovascular target, BBB penetration is not a primary concern.
9. **Caco-2:** Both ligands have very similar, poor Caco-2 permeability (-4.921 and -4.952). This is a concern for oral bioavailability.
10. **Solubility:** Ligand A (-1.9) has better aqueous solubility than Ligand B (-3.409).
11. **hERG:** Ligand A (0.19) has a lower hERG inhibition liability than Ligand B (0.848), which is a significant safety advantage.
12. **Cl_mic:** Ligand A (23.402) has a lower microsomal clearance than Ligand B (53.227), suggesting better metabolic stability.
13. **t1/2:** Ligand B (26.53) has a longer in vitro half-life than Ligand A (18.596), which is desirable.
14. **Pgp:** Ligand A (0.025) has much lower P-gp efflux liability than Ligand B (0.824), which is a significant advantage for bioavailability.
15. **Binding Affinity:** Ligand A (-6.8) has a slightly better binding affinity than Ligand B (-6.4), but the difference is relatively small (0.4 kcal/mol).
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are important. Ligand A has better logP and Pgp efflux, while Ligand B has better TPSA. The affinity difference is small. The most important factor is the significantly lower DILI risk of Ligand B and the longer half-life. While Ligand A has better metabolic stability (lower Cl_mic), the DILI risk is a more critical safety concern.
**Conclusion:**
Considering the balance of properties, and prioritizing safety (DILI) and metabolic stability, I believe **Ligand B** is the more promising drug candidate.
Output:
0
2025-04-17 18:22:02,011 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [349.435, 81.91, 0.376, 1, 6, 0.831, 23.226, 47.383, -4.911, -0.792, 0.198, -2.485, -2.514, 0.013, -6.4]
**Ligand B:** [348.447, 96.25, 0.975, 3, 5, 0.652, 29.624, 55.099, -4.957, -2.459, 0.245, 36.038, 10.263, 0.042, -7.3]
Here's a breakdown of the comparison, considering the guidelines and GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal range (349.4 vs 348.4 Da). No significant difference.
2. **TPSA:** Ligand A (81.91) is better than Ligand B (96.25). Lower TPSA generally favors better absorption.
3. **logP:** Ligand A (0.376) is a bit low, potentially hindering permeation. Ligand B (0.975) is better, falling within the optimal range.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs are generally better for permeability.
5. **HBA:** Ligand A (6) is preferable to Ligand B (5). Fewer HBAs are generally better for permeability.
6. **QED:** Ligand A (0.831) is significantly better than Ligand B (0.652), indicating a more drug-like profile.
7. **DILI:** Ligand A (23.226%) is much better than Ligand B (29.624%). Lower DILI risk is crucial.
8. **BBB:** Ligand B (55.099%) is better than Ligand A (47.383%), but neither is particularly high. For a cardiovascular target, BBB isn't a primary concern, but it's a slight advantage for B.
9. **Caco-2:** Both are very poor (-4.911 and -4.957). This is a significant concern for both.
10. **Solubility:** Ligand A (-0.792) is better than Ligand B (-2.459), although both are poor.
11. **hERG:** Both are very low (0.198 and 0.245), indicating low cardiotoxicity risk.
12. **Cl_mic:** Ligand A (-2.485) is much better than Ligand B (36.038). Lower clearance means better metabolic stability.
13. **t1/2:** Ligand A (-2.514) is better than Ligand B (10.263). Longer half-life is generally preferred.
14. **Pgp:** Both are very low (0.013 and 0.042), indicating low efflux.
15. **Affinity:** Ligand B (-7.3) is significantly better than Ligand A (-6.4). This is a 0.9 kcal/mol difference, which is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand B has a significantly better binding affinity, which is paramount for GPCR targets. While Ligand A has better QED, DILI, metabolic stability, and solubility, the affinity difference is substantial enough to favor Ligand B. The slightly higher logP and BBB of Ligand B are also beneficial, even though BBB isn't a major concern for a cardiovascular target. The poor Caco-2 values are a concern for both, but can potentially be addressed with formulation strategies.
Therefore, I would choose Ligand B.
0
2025-04-17 18:22:02,011 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (373.45 Da) is slightly higher than Ligand B (350.491 Da), but both are acceptable.
2. **TPSA:** Ligand A (83.72) is better than Ligand B (33.95). For a cardiovascular GPCR, a lower TPSA is generally preferred for better permeability. Ligand B is significantly lower and more favorable.
3. **logP:** Ligand A (1.635) is within the optimal range (1-3). Ligand B (4.135) is slightly above this range, potentially raising concerns about solubility and off-target effects.
4. **H-Bond Donors:** Both ligands have 0 HBD, which is good.
5. **H-Bond Acceptors:** Both ligands have 5 HBA, which is acceptable.
6. **QED:** Both ligands have similar QED values (0.692 and 0.601), indicating good drug-likeness.
7. **DILI:** Ligand A (51.26) has a lower DILI risk than Ligand B (55.448), which is preferable.
8. **BBB:** Ligand A (94.223) has significantly better BBB penetration potential than Ligand B (79.217). While ADRB2 isn't a primary CNS target, some CNS exposure can be relevant for off-target effects and overall safety.
9. **Caco-2 Permeability:** Ligand A (-4.636) has better Caco-2 permeability than Ligand B (-5.017).
10. **Aqueous Solubility:** Ligand A (-2.346) has better aqueous solubility than Ligand B (-4.262). This is important for formulation and bioavailability.
11. **hERG Inhibition:** Ligand A (0.597) has a lower hERG inhibition liability than Ligand B (0.783), which is a significant safety advantage.
12. **Microsomal Clearance:** Ligand B (87.933) has higher microsomal clearance than Ligand A (46.333), suggesting lower metabolic stability.
13. **In vitro Half-Life:** Ligand A (-55.172) has a longer in vitro half-life than Ligand B (-40.856), indicating better metabolic stability.
14. **P-gp Efflux:** Ligand A (0.141) has lower P-gp efflux liability than Ligand B (0.601), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand A (-6.9 kcal/mol) has a slightly better binding affinity than Ligand B (-5.7 kcal/mol). This 1.2 kcal/mol difference is substantial and can outweigh some minor ADME drawbacks.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B has a better TPSA but a higher logP and Pgp efflux. Ligand A has better solubility, lower hERG, better metabolic stability, and a superior binding affinity. The affinity difference is significant.
**Overall Assessment:**
While Ligand B has a lower TPSA, the combination of better binding affinity, lower hERG risk, improved metabolic stability (lower Cl_mic, longer t1/2), lower P-gp efflux, and better solubility makes Ligand A the more promising drug candidate. The slightly higher logP of Ligand B is a concern that could potentially be addressed with further optimization, but the advantages of Ligand A are more compelling at this stage.
Output:
1
2025-04-17 18:22:02,011 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands (344.415 and 333.387 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (70.83) is higher than Ligand B (50.52). For a GPCR, lower TPSA is generally preferred for better brain penetration, even though ADRB2 isn't strictly a CNS target. Ligand B is better here.
3. **logP:** Ligand A (1.235) is within the optimal 1-3 range. Ligand B (4.091) is slightly high, potentially leading to solubility issues and off-target interactions. Ligand A is better.
4. **HBD:** Ligand A (1) is good. Ligand B (0) is also acceptable, but having one HBD can sometimes improve solubility. No strong preference.
5. **HBA:** Ligand A (6) is good. Ligand B (3) is also good. No strong preference.
6. **QED:** Ligand A (0.883) is excellent, indicating strong drug-likeness. Ligand B (0.661) is still acceptable, but lower. Ligand A is better.
7. **DILI:** Both ligands have similar DILI risk (65.917 and 67.739 percentile). No significant difference.
8. **BBB:** Both ligands have similar BBB penetration (51.377 and 52.617 percentile). Since ADRB2 isn't a primary CNS target, this isn't a major deciding factor.
9. **Caco-2:** Both ligands have similar negative Caco-2 values (-4.535 and -4.542). This indicates poor permeability, which is a concern.
10. **Solubility:** Ligand A (-2.404) is better than Ligand B (-4.507). Solubility is important for bioavailability.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.581 and 0.591 percentile). No significant difference.
12. **Cl_mic:** Ligand A (34.011) has significantly lower microsomal clearance than Ligand B (81.425). Lower clearance suggests better metabolic stability. Ligand A is better.
13. **t1/2:** Ligand A (7.199) has a shorter half-life than Ligand B (52.803). Longer half-life is generally preferred. Ligand B is better.
14. **Pgp:** Both ligands have similar Pgp efflux liability (0.177 and 0.62). Ligand A is slightly better.
15. **Binding Affinity:** Ligand A (-7.0) has a slightly better binding affinity than Ligand B (-4.2). This is a substantial difference (2.8 kcal/mol) and can often outweigh minor ADME drawbacks.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, and affinity are key. Ligand A has a better logP and significantly better affinity. While Ligand B has a lower TPSA, the difference isn't substantial enough to outweigh the advantages of Ligand A's affinity and logP. The improved metabolic stability (lower Cl_mic) of Ligand A is also a significant advantage.
**Conclusion:**
Ligand A demonstrates a better balance of properties, particularly its superior binding affinity, more favorable logP, better solubility, and improved metabolic stability. While both have permeability concerns, the stronger binding of Ligand A makes it the more promising candidate.
Output:
1
2025-04-17 18:22:02,011 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (387.3) is slightly higher than Ligand B (348.5), but both are acceptable.
2. **TPSA:** Ligand A (51.13) is better than Ligand B (58.2). Both are below 140, but lower TPSA generally favors absorption.
3. **logP:** Ligand A (4.989) is at the upper end of the optimal range, while Ligand B (2.572) is well within it. Ligand A's higher logP *could* lead to solubility issues or off-target binding, but it's not drastically high.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is preferable to Ligand B (2). Lower HBA is generally preferred for permeability.
6. **QED:** Ligand B (0.802) has a significantly better QED score than Ligand A (0.54), indicating a more drug-like profile.
7. **DILI:** Ligand B (21.9) has a much lower DILI risk than Ligand A (53.0). This is a significant advantage for Ligand B.
8. **BBB:** Ligand B (84.0) has better BBB penetration than Ligand A (70.8). While ADRB2 isn't strictly a CNS target, some CNS exposure can occur, and better BBB penetration is generally favorable.
9. **Caco-2:** Both ligands have similar, poor Caco-2 permeability (-4.53 and -4.759). This is a concern for both.
10. **Solubility:** Ligand B (-3.951) has better solubility than Ligand A (-5.895). This is an important advantage, especially given Ligand A's higher logP.
11. **hERG:** Both ligands have low hERG risk (0.57 and 0.409).
12. **Cl_mic:** Ligand B (15.2) has significantly lower microsomal clearance than Ligand A (54.8). This indicates better metabolic stability for Ligand B.
13. **t1/2:** Ligand B (-2.306) has a longer in vitro half-life than Ligand A (1.779). This is a positive for Ligand B.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.053 and 0.5).
15. **Binding Affinity:** Ligand A (-7.8) has a significantly stronger binding affinity than Ligand B (-6.3). This is a substantial advantage for Ligand A, exceeding the 1.5 kcal/mol threshold.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has a higher logP and better TPSA, while Ligand B has better Pgp. However, the *significant* affinity advantage of Ligand A (-7.8 vs -6.3) outweighs the other factors.
**Overall Assessment:**
While Ligand B has a superior ADME profile (lower DILI, better solubility, lower clearance, longer half-life, better QED, and BBB), the substantially stronger binding affinity of Ligand A is a critical advantage for a GPCR target. The difference in affinity is large enough to compensate for the slightly less favorable ADME properties of Ligand A.
Output:
1
2025-04-17 18:22:02,011 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [340.467, 54.26, 4.453, 2, 3, 0.864, 41.605, 59.636, -4.952, -5.154, 0.674, 88.157, 5.984, 0.539, -6.7]
**Ligand B:** [408.351, 78.51, 2.649, 2, 3, 0.76, 58.744, 71.501, -4.998, -4.602, 0.599, 38.766, -9.295, 0.112, -7.8]
Here's a breakdown, considering the guidelines and GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** A (340.467) is better than B (408.351). Both are within the ideal range, but A is closer to the lower end, which can be beneficial for permeability.
2. **TPSA:** A (54.26) is significantly better than B (78.51). A is well below the 140 threshold for oral absorption, while B is getting closer to the upper limit.
3. **logP:** A (4.453) is slightly higher than B (2.649). While both are within the acceptable range, A is approaching the upper limit where solubility issues might arise. B is more optimally positioned.
4. **HBD:** Both A and B have 2 HBD, which is good.
5. **HBA:** Both A and B have 3 HBA, which is good.
6. **QED:** A (0.864) is better than B (0.76). A has a more drug-like profile.
7. **DILI:** Both A (41.605) and B (58.744) are acceptable, with A being slightly better. Both are below the 60% threshold for high risk.
8. **BBB:** B (71.501) is better than A (59.636). While not a primary concern for a cardiovascular target, higher BBB penetration is generally favorable, indicating better distribution.
9. **Caco-2:** Both A (-4.952) and B (-4.998) are similar and indicate good permeability.
10. **Solubility:** A (-5.154) is slightly worse than B (-4.602), suggesting B might have better aqueous solubility.
11. **hERG:** Both A (0.674) and B (0.599) are good, indicating low hERG inhibition liability.
12. **Cl_mic:** B (38.766) is significantly better than A (88.157). Lower clearance indicates better metabolic stability, a crucial factor for drug duration.
13. **t1/2:** B (-9.295) is significantly better than A (5.984). A negative value suggests a very long half-life, which is desirable.
14. **Pgp:** A (0.539) is better than B (0.112). Lower P-gp efflux is preferable for better bioavailability.
15. **Affinity:** B (-7.8) is significantly better than A (-6.7). A 1.1 kcal/mol difference in binding affinity is substantial and can often outweigh minor ADME drawbacks.
**Overall Assessment:**
Ligand B has a significantly better binding affinity and metabolic stability (lower Cl_mic, longer t1/2). While Ligand A has a slightly better QED and Pgp profile, the substantial affinity advantage of B, coupled with its better metabolic properties, makes it the more promising candidate. The slightly higher TPSA of B is a minor concern, but the strong binding and improved stability are more critical for a GPCR target.
Output:
0
2025-04-17 18:22:02,011 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.356 Da and 345.443 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (50.36) is well below the 140 threshold and favorable for oral absorption. Ligand B (80.32) is higher, but still within acceptable limits, though less optimal.
3. **logP:** Ligand A (4.039) is at the higher end of the optimal range (1-3), potentially raising solubility concerns. Ligand B (1.98) is good, falling comfortably within the ideal range.
4. **HBD:** Both ligands have 2 HBD, which is acceptable.
5. **HBA:** Ligand A has 2 HBA, which is good. Ligand B has 4 HBA, which is acceptable but slightly higher.
6. **QED:** Both ligands have similar QED values (0.824 and 0.826), indicating good drug-likeness.
7. **DILI:** Ligand A (76.076) has a higher DILI risk than Ligand B (39.977). This is a significant negative for Ligand A.
8. **BBB:** Ligand A (70.803) has better BBB penetration than Ligand B (65.568). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant for off-target effects or potential therapeutic strategies.
9. **Caco-2:** Ligand A (-4.343) has a more negative Caco-2 value, suggesting *better* permeability than Ligand B (-5.058).
10. **Solubility:** Ligand A (-5.399) has slightly better solubility than Ligand B (-2.519).
11. **hERG:** Ligand A (0.81) has a slightly higher hERG risk than Ligand B (0.126). This is a negative for Ligand A.
12. **Cl_mic:** Ligand B (21.506) has significantly lower microsomal clearance than Ligand A (81.163), indicating better metabolic stability. This is a major advantage for Ligand B.
13. **t1/2:** Ligand B (15.989) has a longer in vitro half-life than Ligand A (38.863). This is a positive for Ligand B.
14. **Pgp:** Ligand B (0.053) has lower P-gp efflux liability than Ligand A (0.478), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand B (-7.7 kcal/mol) has a slightly better binding affinity than Ligand A (-7.3 kcal/mol). While the difference is not huge, it's enough to consider.
**GPCR-Specific Priorities & Overall Assessment:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand B excels in logP and Pgp, and has a slightly better affinity. Ligand A has better BBB penetration and Caco-2 permeability, but these are outweighed by its higher DILI risk, hERG risk, and significantly worse metabolic stability (higher Cl_mic, shorter t1/2). The DILI risk is a major concern.
**Output:**
0
2025-04-17 18:22:02,011 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [350.438, 66.49, 2.304, 2, 4, 0.855, 36.565, 81.039, -4.699, -2.724, 0.587, 34.585, 35.883, 0.11, -6.9]
**Ligand B:** [356.419, 94.17, 0.242, 1, 6, 0.657, 41.373, 68.282, -4.769, -0.916, 0.069, 53.747, -0.227, 0.018, -6.6]
Here's a breakdown, considering the GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal range (200-500 Da). A is 350.4, B is 356.4 - very similar.
2. **TPSA:** Ligand A (66.49) is significantly better than Ligand B (94.17). A is well below the 140 threshold for oral absorption, while B is approaching it. This favors A.
3. **logP:** Ligand A (2.304) is optimal. Ligand B (0.242) is quite low, potentially hindering membrane permeability and bioavailability. This is a significant advantage for A.
4. **HBD:** Both are acceptable (A=2, B=1).
5. **HBA:** Both are acceptable (A=4, B=6).
6. **QED:** Ligand A (0.855) is better than Ligand B (0.657), indicating a more drug-like profile.
7. **DILI:** Ligand A (36.565) has a lower DILI risk than Ligand B (41.373), though both are reasonably low.
8. **BBB:** Ligand A (81.039) has a much higher BBB penetration potential than Ligand B (68.282). While ADRB2 isn't exclusively a CNS target, better BBB penetration can still be beneficial for distribution and potentially reducing off-target effects.
9. **Caco-2:** Both are negative, suggesting poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Both are negative, suggesting poor solubility. Again, scale is unspecified.
11. **hERG:** Ligand A (0.587) has a lower hERG risk than Ligand B (0.069). This is a crucial safety parameter, favoring A.
12. **Cl_mic:** Ligand A (34.585) has a lower microsomal clearance, suggesting better metabolic stability than Ligand B (53.747).
13. **t1/2:** Ligand A (35.883) has a longer in vitro half-life than Ligand B (-0.227).
14. **Pgp:** Ligand A (0.11) has a lower P-gp efflux liability than Ligand B (0.018). This is a significant advantage for A, improving bioavailability.
15. **Affinity:** Ligand A (-6.9 kcal/mol) has a slightly better binding affinity than Ligand B (-6.6 kcal/mol), although the difference is relatively small.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical ADME-Tox properties, especially logP, TPSA, BBB, hERG, Cl_mic, and Pgp. While the affinity difference is small, the superior ADME profile of Ligand A makes it a much more promising drug candidate. The lower logP and higher TPSA of Ligand B are major drawbacks for a GPCR-targeting drug.
Output:
1
2025-04-17 18:22:02,012 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (379.492 and 388.792 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (45.23) is significantly better than Ligand B (104.39). ADRB2 is a cardiovascular target, not CNS, but lower TPSA generally improves absorption. Ligand A is well below the 140 threshold, while B is pushing it.
3. **logP:** Ligand A (4.31) is higher than Ligand B (1.789). While both are within the acceptable range, 4.31 is approaching the upper limit where solubility issues could arise. However, for a GPCR, a slightly higher logP can be beneficial for membrane interactions.
4. **HBD:** Ligand A (1) is better than Ligand B (2). Lower HBD is generally preferred for permeability.
5. **HBA:** Ligand A (4) is better than Ligand B (5). Similar to HBD, lower HBA is generally preferred.
6. **QED:** Ligand A (0.768) is slightly better than Ligand B (0.693), indicating a more drug-like profile.
7. **DILI:** Ligand B (48.623) has a slightly lower DILI risk than Ligand A (43.738), which is a positive.
8. **BBB:** Both ligands have similar BBB penetration (77.705 and 76.464). This isn't a primary concern for a cardiovascular target.
9. **Caco-2:** Ligand A (-4.546) is much better than Ligand B (-5.229). Higher Caco-2 permeability indicates better intestinal absorption.
10. **Solubility:** Ligand A (-3.95) is better than Ligand B (-3.233). Higher solubility is always preferred.
11. **hERG:** Ligand A (0.901) is better than Ligand B (0.252). Lower hERG inhibition is crucial for avoiding cardiotoxicity, especially important for a cardiovascular target.
12. **Cl_mic:** Ligand B (-8.159) has significantly lower (better) microsomal clearance than Ligand A (60.578), suggesting greater metabolic stability.
13. **t1/2:** Ligand B (-17.718) has a much longer in vitro half-life than Ligand A (53.346). This is a significant advantage, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.428) is better than Ligand B (0.048). Lower P-gp efflux is preferred for better bioavailability.
15. **Affinity:** Ligand B (-7.2) has a slightly better binding affinity than Ligand A (-6.0). This is a 1.2 kcal/mol difference, which is significant.
**Overall Assessment:**
Ligand B has a substantial advantage in metabolic stability (Cl_mic and t1/2) and binding affinity. While Ligand A has better TPSA, solubility, and hERG, the difference in affinity and metabolic stability are more critical for a GPCR target. The slightly higher DILI risk for Ligand A is also a concern. The improved binding affinity of Ligand B is likely to outweigh the slightly higher logP and TPSA.
Output:
0
2025-04-17 18:22:02,012 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.503 and 350.423 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (67.43) is significantly better than Ligand B (94.8). For a GPCR, keeping TPSA low is beneficial for permeability, and Ligand A is well below the 140 threshold, while Ligand B is approaching it.
3. **logP:** Ligand A (2.805) is within the optimal 1-3 range. Ligand B (-1.199) is below 1, which could hinder permeation. This is a significant advantage for Ligand A.
4. **HBD:** Both have acceptable HBD counts (2 and 1, respectively), well below the 5 threshold.
5. **HBA:** Ligand B (7) is higher than Ligand A (3). While both are under 10, the lower HBA count of Ligand A is slightly preferable.
6. **QED:** Both ligands have good QED scores (0.628 and 0.717), indicating good drug-like properties. No strong preference.
7. **DILI:** Ligand A (15.859) has a much lower DILI risk than Ligand B (29.857). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (70.686) has a better BBB penetration percentile than Ligand B (58.938). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be useful.
9. **Caco-2:** Both have negative values, indicating poor permeability. This is concerning for both, but the values are close.
10. **Solubility:** Ligand A (-3.89) has slightly better solubility than Ligand B (-0.357), but both are poor.
11. **hERG:** Ligand A (0.272) has a much lower hERG inhibition liability than Ligand B (0.137). This is a critical advantage, as hERG inhibition can cause cardiotoxicity.
12. **Cl_mic:** Ligand B (3.008) has significantly lower microsomal clearance than Ligand A (85.725), indicating better metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand B (6.133) has a longer in vitro half-life than Ligand A (-11.019). This is a major advantage for Ligand B.
14. **Pgp:** Ligand B (0.026) has much lower P-gp efflux liability than Ligand A (0.159). This is a significant advantage for Ligand B.
15. **Binding Affinity:** Ligand A (-7.3) has a slightly better binding affinity than Ligand B (-6.8). While the difference is less than the 1.5 kcal/mol threshold, it's still a positive for Ligand A.
**Overall Assessment:**
Ligand A excels in several crucial areas: TPSA, logP, DILI risk, hERG inhibition, and binding affinity. Ligand B shines in metabolic stability (Cl_mic), half-life, and P-gp efflux. However, the poor logP and higher DILI/hERG risks associated with Ligand B are significant concerns. While metabolic stability is important, the combination of better permeability characteristics (TPSA, logP) and safety profile (DILI, hERG) makes Ligand A the more promising candidate. The slightly better affinity of Ligand A further supports this decision.
Output:
1
2025-04-17 18:22:02,012 - INFO - Here's my reasoning and the final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, the most important parameters are binding affinity, logP, TPSA, Pgp efflux, and to a lesser extent, BBB.
Let's break down the comparison:
1. **Molecular Weight:** Both ligands (366.483 and 367.921 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (77.52) is slightly higher than Ligand B (73.99). Both are acceptable for a non-CNS GPCR target, being under 140, but B is preferable.
3. **logP:** Ligand A (2.57) is within the optimal 1-3 range. Ligand B (3.898) is approaching the upper limit, which could lead to solubility issues. A is preferable.
4. **H-Bond Donors:** Ligand A (1) is better than Ligand B (3). Fewer HBDs generally improve permeability.
5. **H-Bond Acceptors:** Ligand A (6) is better than Ligand B (2). Fewer HBAs generally improve permeability.
6. **QED:** Ligand A (0.829) is better than Ligand B (0.738), indicating a more drug-like profile.
7. **DILI:** Ligand B (41.877) has a significantly lower DILI risk than Ligand A (65.452). This is a major advantage for Ligand B.
8. **BBB:** Both ligands have similar BBB penetration (65.064 and 68.592). This isn't a primary concern for a cardiovascular target.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability.
10. **Solubility:** Ligand B (-4.697) has slightly better solubility than Ligand A (-3.389), but both are very poor.
11. **hERG:** Ligand A (0.143) has a lower hERG risk than Ligand B (0.506). This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand B (40.196) has significantly lower microsomal clearance than Ligand A (88.536), indicating better metabolic stability. This is a major advantage for Ligand B.
13. **t1/2:** Ligand B (6.672) has a longer in vitro half-life than Ligand A (-1.878). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.171) has lower P-gp efflux than Ligand B (0.224), which is preferable.
15. **Binding Affinity:** Ligand B (-7.9 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.8 kcal/mol). This is a substantial advantage for Ligand B, and can often outweigh minor ADME concerns.
**Overall Assessment:**
Ligand B has a significantly better binding affinity and metabolic stability (lower Cl_mic, longer t1/2) and lower DILI risk. While its logP is slightly higher and solubility is lower, the substantial affinity advantage and improved safety profile outweigh these concerns. Ligand A has a slight edge in hERG and Pgp, but the difference in binding affinity is too large to ignore.
Output:
0
2025-04-17 18:22:02,012 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (341.455 Da) is within the ideal range (200-500 Da). Ligand B (373.475 Da) is also acceptable. No clear advantage here.
2. **TPSA:** Ligand A (60.18) is excellent, well below the 140 threshold for oral absorption. Ligand B (107.78) is higher, but still reasonable. A favors here.
3. **logP:** Ligand A (4.585) is slightly high, potentially leading to solubility issues or off-target effects. Ligand B (0.455) is quite low, which could hinder membrane permeability. B is better here.
4. **HBD:** Ligand A (1) is good. Ligand B (0) is also good. No clear advantage.
5. **HBA:** Ligand A (5) is good. Ligand B (6) is also acceptable. No clear advantage.
6. **QED:** Ligand A (0.833) is excellent, indicating high drug-likeness. Ligand B (0.515) is also acceptable, but lower. A favors here.
7. **DILI:** Ligand A (47.421) is good, low risk. Ligand B (39.162) is even better, indicating a lower risk of liver injury. B favors here.
8. **BBB:** Ligand A (82.474) is good. Ligand B (74.952) is acceptable, but lower. A favors here.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Ligand A (-4.662) is very poor. Ligand B (-2.093) is also poor, but better than A. B favors here.
11. **hERG:** Ligand A (0.47) is very low risk. Ligand B (0.34) is also very low risk. No clear advantage.
12. **Cl_mic:** Ligand A (63.826) is moderate. Ligand B (93.548) is high, indicating faster metabolism and lower stability. A favors here.
13. **t1/2:** Ligand A (6.224) is moderate. Ligand B (-59.916) is very poor, indicating rapid elimination. A favors here.
14. **Pgp:** Ligand A (0.501) is moderate. Ligand B (0.033) is very low, suggesting minimal efflux. B favors here.
15. **Affinity:** Ligand A (-7.2) is significantly better than Ligand B (-5.9), a difference of 1.3 kcal/mol. This is a substantial advantage.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are crucial. While Ligand B has better solubility and DILI, Ligand A's superior affinity (-7.2 vs -5.9 kcal/mol) is a major advantage. The difference in affinity is large enough to potentially offset the slightly higher logP and poorer solubility. TPSA is good for both, and Ligand A has better BBB penetration. Pgp is better for Ligand B, but the affinity difference is more important.
**Overall Assessment:**
Despite some drawbacks in logP and solubility, Ligand A's significantly stronger binding affinity and better metabolic stability (longer half-life, lower Cl_mic) make it the more promising drug candidate for ADRB2.
Output:
1
2025-04-17 18:22:02,012 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (359.411 and 360.439 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (90.09 and 89.27) are below the 140 A^2 threshold for good oral absorption and reasonably close to the 90 A^2 cutoff for CNS penetration (though ADRB2 is primarily cardiovascular, some CNS off-target effects are always a consideration). Again, no major difference.
3. **logP:** Both ligands (0.643 and 0.758) are a bit low, ideally we want 1-3. This could potentially impact permeability, but isn't a dealbreaker. Ligand B is slightly better.
4. **HBD:** Ligand A has 0 HBD, while Ligand B has 2. Lower is generally preferred for permeability, so Ligand A has a slight edge.
5. **HBA:** Both ligands have 7 HBA, which is within the acceptable range of <=10.
6. **QED:** Ligand B (0.818) has a better QED score than Ligand A (0.67), indicating a more drug-like profile. This is a positive for Ligand B.
7. **DILI:** Ligand A (85.149) has a higher DILI risk than Ligand B (67.235). Lower is better, so Ligand B is preferable.
8. **BBB:** Ligand A (69.678) has better BBB penetration than Ligand B (43.777). While ADRB2 isn't a CNS target, higher BBB is generally favorable.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.026 and -5.357). This is unusual and suggests poor permeability. However, these values are on a scale where negative values are possible, and the absolute values are similar.
10. **Solubility:** Ligand A (-3.513) has slightly worse solubility than Ligand B (-2.469). Higher solubility is better.
11. **hERG:** Ligand B (0.063) has a significantly lower hERG risk than Ligand A (0.208). This is a crucial advantage for Ligand B, as hERG inhibition can lead to cardiotoxicity.
12. **Cl_mic:** Ligand B (27.316) has a much lower microsomal clearance than Ligand A (67.096), indicating better metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand B (14.254 hours) has a much longer in vitro half-life than Ligand A (-26.307 hours). The negative value for Ligand A is concerning. This is a major advantage for Ligand B.
14. **Pgp:** Ligand B (0.081) has a lower P-gp efflux liability than Ligand A (0.207), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand B (-7.3 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.8 kcal/mol). This is a substantial advantage, and the 1.5 kcal/mol difference outweighs most of the minor ADME drawbacks of Ligand A.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand B excels in affinity and Pgp, and is slightly better in logP. The lower hERG and better metabolic stability are also critical advantages.
**Conclusion:**
Ligand B consistently outperforms Ligand A across several critical parameters, especially binding affinity, metabolic stability, hERG risk, and half-life. While Ligand A has a slightly better BBB score, the other advantages of Ligand B are more important for a cardiovascular target.
Output:
0
2025-04-17 18:22:02,012 - INFO - Batch 32 complete. Total preferences: 512
2025-04-17 18:22:02,012 - INFO - Processing batch 33/512...
2025-04-17 18:22:51,425 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
The target is ADRB2, a GPCR. Therefore, I will prioritize logP, Pgp, TPSA, BBB, and binding affinity, while also considering the general drug-like properties.
* **Molecular Weight:** Both ligands (346.475 and 350.503 Da) fall within the ideal 200-500 Da range.
* **TPSA:** Ligand A (74.33) is slightly higher than Ligand B (67.43), but both are below the 140 A^2 threshold for good oral absorption.
* **logP:** Ligand A (1.08) is within the optimal range (1-3), while Ligand B (3.502) is at the higher end, potentially leading to solubility issues.
* **H-Bond Donors/Acceptors:** Both have 2 HBD and a reasonable number of HBA (4 and 3 respectively), which is good.
* **QED:** Ligand A (0.656) has a better QED score than Ligand B (0.468), indicating a more drug-like profile.
* **DILI:** Ligand B (20.706) has a slightly better DILI score than Ligand A (14.23), but both are acceptable.
* **BBB:** Ligand A (68.36) has a slightly better BBB percentile than Ligand B (63.009), which is a positive for a GPCR target.
* **Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the absolute value is closer to 0 for Ligand A (-4.988 vs -5.004).
* **Aqueous Solubility:** Ligand A (-0.746) has better aqueous solubility than Ligand B (-4.029).
* **hERG:** Both ligands have low hERG inhibition liability (0.362 and 0.325), which is good.
* **Microsomal Clearance:** Ligand A (21.686) has significantly lower microsomal clearance than Ligand B (52.393), suggesting better metabolic stability.
* **In vitro Half-Life:** Ligand A (-5.817) has a much longer in vitro half-life than Ligand B (-14.401).
* **P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.058 and 0.113).
* **Binding Affinity:** Both ligands have the same binding affinity (-6 kcal/mol).
**Conclusion:**
Ligand A is the better candidate. While Ligand B has a slightly better DILI score, Ligand A excels in several key areas: better QED, better BBB penetration, better solubility, significantly lower microsomal clearance, and a longer in vitro half-life. These factors, particularly the improved metabolic stability and solubility, outweigh the minor DILI difference. The similar binding affinity means the ADME properties become the deciding factor.
**Output:**
1
2025-04-17 18:22:51,425 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [351.324, 51.47, 3.655, 1, 3, 0.918, 48.197, 94.998, -4.4, -4.281, 0.71, 39.095, 38.645, 0.347, -6.1]**
**Ligand B: [359.421, 72.28, 2.422, 1, 6, 0.874, 39.473, 77.937, -4.473, -2.625, 0.334, 33.818, -6.132, 0.061, -5.2]**
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). A is 351.324, B is 359.421. No significant difference.
2. **TPSA:** Ligand A (51.47) is significantly better than Ligand B (72.28). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (3.655) is slightly higher than Ligand B (2.422), both are within the optimal range (1-3). A is preferable.
4. **H-Bond Donors:** Both have 1 HBD, which is good.
5. **H-Bond Acceptors:** Ligand A (3) is better than Ligand B (6). Lower is generally preferred for permeability.
6. **QED:** Ligand A (0.918) is better than Ligand B (0.874), indicating a more drug-like profile.
7. **DILI:** Ligand A (48.197) is slightly higher than Ligand B (39.473), but both are below the concerning threshold of 60. B is preferable.
8. **BBB:** Ligand A (94.998) is significantly better than Ligand B (77.937). While not a CNS target, some degree of BBB penetration can sometimes indicate favorable permeability characteristics.
9. **Caco-2:** Both are very poor (-4.4 and -4.473). This is a concern for both, suggesting poor intestinal absorption.
10. **Solubility:** Ligand A (-4.281) is slightly worse than Ligand B (-2.625). Solubility is important, so B is preferable.
11. **hERG:** Ligand A (0.71) is better than Ligand B (0.334), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand A (39.095) is higher than Ligand B (33.818), meaning it has faster metabolic clearance. B is preferable.
13. **t1/2:** Ligand A (38.645) is better than Ligand B (-6.132). Longer half-life is generally desirable.
14. **Pgp:** Ligand A (0.347) is better than Ligand B (0.061), indicating lower P-glycoprotein efflux.
15. **Binding Affinity:** Ligand A (-6.1) is slightly better than Ligand B (-5.2). A difference of 0.9 kcal/mol is significant.
**Overall Assessment:**
Ligand A has a better overall profile. While both have poor Caco-2 permeability, Ligand A excels in QED, BBB, hERG, Pgp, and crucially, binding affinity. The slightly higher DILI risk for A is outweighed by its superior binding and drug-like properties. The better half-life and lower clearance are also beneficial. Ligand B has better solubility and lower clearance, but the affinity difference is too significant to ignore, especially for a GPCR target where potency is key.
Output:
1
2025-04-17 18:22:51,425 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's analyze each ligand against the provided guidelines, keeping in mind ADRB2 is a GPCR, so logP, TPSA, Pgp, BBB, and affinity are key.
* **Molecular Weight:** Both ligands (346.479 and 357.397 Da) are within the ideal 200-500 Da range.
* **TPSA:** Ligand A (80.79) is better than Ligand B (48). Both are below 140, but Ligand B is closer to the ideal for CNS penetration, although that's less critical for ADRB2 (cardiovascular).
* **logP:** Ligand A (1.898) is within the optimal 1-3 range. Ligand B (3.003) is at the higher end, potentially leading to solubility issues.
* **H-Bond Donors/Acceptors:** Ligand A (2 HBD, 7 HBA) is slightly higher in both counts than Ligand B (0 HBD, 4 HBA). Both are acceptable.
* **QED:** Both ligands have similar QED values (0.725 and 0.682), indicating good drug-likeness.
* **DILI:** Ligand A (20.861) has a significantly lower DILI risk than Ligand B (36.177), a major advantage.
* **BBB:** Ligand B (90.035) has a much higher BBB penetration percentile than Ligand A (53.625). While ADRB2 isn't a CNS target, higher BBB can sometimes correlate with better overall distribution.
* **Caco-2 Permeability:** Ligand A (-5.427) has a worse Caco-2 permeability than Ligand B (-4.455), indicating potentially lower intestinal absorption.
* **Aqueous Solubility:** Ligand A (-1.605) has better aqueous solubility than Ligand B (-2.793).
* **hERG Inhibition:** Ligand A (0.169) has a lower hERG inhibition risk than Ligand B (0.816), a crucial safety factor.
* **Microsomal Clearance:** Ligand B (75.647) has a much higher microsomal clearance than Ligand A (11.737), suggesting faster metabolism and potentially lower *in vivo* exposure.
* **In vitro Half-Life:** Ligand A (19.425) has a significantly longer half-life than Ligand B (4.092).
* **P-gp Efflux:** Ligand A (0.071) has lower P-gp efflux than Ligand B (0.375), which is favorable for bioavailability.
* **Binding Affinity:** Ligand B (-7.2) has a slightly better binding affinity than Ligand A (-7.1), but the difference is small (0.1 kcal/mol).
**Overall Assessment:**
Ligand A demonstrates a superior balance of properties, particularly regarding safety (DILI, hERG) and pharmacokinetic parameters (microsomal clearance, half-life, P-gp efflux). While Ligand B has slightly better affinity and BBB penetration, the significant advantages of Ligand A in terms of safety and metabolic stability outweigh these minor benefits. The slightly lower Caco-2 permeability of Ligand A is a concern, but can potentially be addressed through formulation strategies.
**Output:**
1
2025-04-17 18:22:51,425 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (366.483 Da and 343.387 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (89.27) is significantly better than Ligand B (110). For a cardiovascular GPCR, TPSA under 140 is acceptable, but lower is preferred for good absorption. Ligand A is closer to the optimal range.
**3. logP:** Both ligands have good logP values (2.511 and 1.819), falling within the 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability.
**4. H-Bond Donors:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
**5. H-Bond Acceptors:** Ligand A (5) is preferable to Ligand B (6). Fewer HBAs generally improve permeability.
**6. QED:** Both ligands have acceptable QED values (0.827 and 0.708), indicating good drug-like properties. Ligand A is slightly better.
**7. DILI:** Ligand B (70.958) has a higher DILI risk than Ligand A (52.772). Lower DILI is crucial, making Ligand A more favorable.
**8. BBB:** Ligand A (70.919) has a significantly higher BBB penetration percentile than Ligand B (27.646). While ADRB2 is a cardiovascular target, some CNS penetration can be relevant for off-target effects or potential central modulation, and higher BBB is generally preferred.
**9. Caco-2 Permeability:** Ligand A (-4.841) is better than Ligand B (-5.41). Higher values indicate better intestinal absorption.
**10. Aqueous Solubility:** Ligand A (-2.907) is better than Ligand B (-2.026). Higher solubility is generally preferred.
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.107 and 0.008). This is excellent for both.
**12. Microsomal Clearance:** Ligand B (20.948) has a higher microsomal clearance than Ligand A (17.895). Lower clearance is preferred for better metabolic stability.
**13. In vitro Half-Life:** Ligand A (-1.52) has a better in vitro half-life than Ligand B (-30.843). Longer half-life is desirable.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.309 and 0.023). This is excellent for both.
**15. Binding Affinity:** Ligand B (-6.5) has a slightly better binding affinity than Ligand A (-6.2). However, the difference is only 0.3 kcal/mol, and the other ADME properties of Ligand A are significantly better.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity) and general drug-like properties, Ligand A is the more promising candidate. While Ligand B has slightly better binding affinity, Ligand A excels in crucial ADME properties like TPSA, DILI risk, BBB penetration, solubility, and metabolic stability (clearance and half-life). The combination of these factors outweighs the small affinity difference.
Output:
1
2025-04-17 18:22:51,425 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (357.303 Da) is slightly higher than Ligand B (329.363 Da), but both are acceptable.
**2. TPSA:** Ligand A (48.42) is well below the 140 A^2 threshold for good oral absorption and is quite favorable. Ligand B (72.7) is still within range, but less optimal.
**3. logP:** Both ligands have logP values within the optimal range (1-3), with Ligand A (4.475) being slightly higher than Ligand B (3.376). While Ligand A is approaching the upper limit, it's not a major concern given the other parameters.
**4. H-Bond Donors:** Ligand A (0) is excellent, minimizing potential issues with permeability. Ligand B (1) is still acceptable.
**5. H-Bond Acceptors:** Ligand A (4) and Ligand B (5) are both within the acceptable range of <=10.
**6. QED:** Both ligands have good QED values (A: 0.598, B: 0.625), indicating a generally drug-like profile.
**7. DILI Risk:** Ligand A (62.776) is better than Ligand B (87.708). Lower DILI risk is always preferred.
**8. BBB Penetration:** Ligand A (73.323) shows significantly better BBB penetration than Ligand B (50.446). While ADRB2 is a cardiovascular target, some CNS effects can be relevant or even desirable in certain contexts, and better BBB penetration is generally a plus.
**9. Caco-2 Permeability:** Ligand A (-4.289) is significantly better than Ligand B (-5.119). Higher Caco-2 permeability indicates better intestinal absorption.
**10. Aqueous Solubility:** Ligand A (-5.576) is better than Ligand B (-3.504).
**11. hERG Inhibition:** Ligand A (0.534) is better than Ligand B (0.872). Lower hERG inhibition is crucial for minimizing cardiotoxicity.
**12. Microsomal Clearance:** Ligand A (100.051) is much higher than Ligand B (34.759). This indicates Ligand A has much faster clearance, and therefore lower metabolic stability.
**13. In vitro Half-Life:** Ligand B (25.199) has a much longer half-life than Ligand A (-6.584).
**14. P-gp Efflux:** Ligand A (0.451) is better than Ligand B (0.24). Lower P-gp efflux is preferred for better bioavailability.
**15. Binding Affinity:** Both ligands have very similar and excellent binding affinities (-7.4 kcal/mol and -7.3 kcal/mol, respectively). The difference is negligible.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand A is preferable. It has better TPSA, solubility, hERG inhibition, Caco-2 permeability, P-gp efflux, and DILI risk. While Ligand A has a higher logP and faster clearance, the improvements in other key ADME properties and safety parameters outweigh these drawbacks. The similar binding affinity makes these ADME properties the deciding factors.
Output:
1
2025-04-17 18:22:51,425 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (349.439 and 345.451 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (96.25) is slightly higher than Ligand B (89.66). Both are below the 140 threshold for oral absorption, but Ligand B is closer to the preferred <90 for GPCRs.
**3. logP:** Ligand A (-0.571) is quite low, potentially hindering membrane permeability. Ligand B (1.772) is within the optimal 1-3 range. This is a significant advantage for Ligand B.
**4. H-Bond Donors:** Ligand A (1) is good. Ligand B (2) is acceptable, still within the preferred limit of 5.
**5. H-Bond Acceptors:** Ligand A (7) and Ligand B (6) are both within the acceptable limit of 10.
**6. QED:** Both ligands have good QED scores (0.782 and 0.835), indicating generally drug-like properties.
**7. DILI Risk:** Ligand A (30.942) has a much lower DILI risk than Ligand B (56.999). This is a substantial advantage for Ligand A.
**8. BBB Penetration:** Ligand B (67.235) shows better BBB penetration than Ligand A (50.795). While ADRB2 isn't exclusively a CNS target, some CNS exposure or off-target effects are possible, making this a slight positive for Ligand B.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-5.376 and -5.162), which is unusual and suggests poor permeability. This is a concern for both.
**10. Aqueous Solubility:** Ligand A (-0.016) is slightly better than Ligand B (-2.448), but both are very poor. This is a significant drawback for both.
**11. hERG Inhibition:** Both ligands show very low hERG inhibition risk (0.05 and 0.058). This is excellent for both.
**12. Microsomal Clearance:** Ligand A (-3.857) has a lower (better) microsomal clearance than Ligand B (15.161), indicating greater metabolic stability.
**13. In vitro Half-Life:** Ligand A (13.329) has a slightly longer half-life than Ligand B (12.726).
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.011 and 0.082).
**15. Binding Affinity:** Ligand B (-7.2) has a slightly better binding affinity than Ligand A (-7.0). While the difference is small, it is within the range where it could outweigh minor ADME drawbacks.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand B has a clear advantage in logP and a slight edge in affinity. However, Ligand A has a significantly lower DILI risk and better metabolic stability (lower Cl_mic). The poor solubility and Caco-2 permeability are concerning for both.
Given the importance of minimizing toxicity (DILI) and maximizing metabolic stability for a chronic cardiovascular condition, and the relatively small difference in binding affinity, I favor Ligand A. The slightly better logP of Ligand B isn't enough to overcome the higher DILI risk and poorer metabolic profile.
Output:
1
2025-04-17 18:22:51,426 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (375.491 and 353.463 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand B (98.74) is significantly better than Ligand A (118.8), being closer to the preferred <140 for good absorption and more favorable for a GPCR.
3. **logP:** Ligand B (0.561) is within the optimal range (1-3), while Ligand A (-0.575) is slightly below, potentially impacting permeability.
4. **HBD:** Both have acceptable HBD counts (2 and 3 respectively), well below the threshold of 5.
5. **HBA:** Both have acceptable HBA counts (6 and 4 respectively), well below the threshold of 10.
6. **QED:** Both ligands have very similar and good QED scores (0.637 and 0.623), indicating good drug-like properties.
7. **DILI:** Ligand B (10.508) has a *much* lower DILI risk than Ligand A (33.307). This is a significant advantage for Ligand B.
8. **BBB:** Both have similar BBB penetration (34.781 and 38.387). While not exceptionally high, it's not a primary concern for ADRB2, which isn't necessarily a CNS target.
9. **Caco-2:** Both have negative Caco-2 values (-5.634 and -5.171), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Both have very poor solubility (-0.746 and -1.411). This is a significant drawback for both, but Ligand B is slightly worse.
11. **hERG:** Both ligands show very low hERG inhibition risk (0.092 and 0.097).
12. **Cl_mic:** Both have similar, relatively low, microsomal clearance (-16.932 and -15.822), indicating reasonable metabolic stability.
13. **t1/2:** Ligand A (29.343) has a substantially longer in vitro half-life than Ligand B (0.885). This is a major advantage for Ligand A.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.019 and 0.008).
15. **Binding Affinity:** Ligand A (-7.1) has a slightly better binding affinity than Ligand B (-6.8), but the difference is less than 1.5 kcal/mol.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, and affinity are key. Ligand B excels in TPSA and has a more optimal logP. While Ligand A has slightly better affinity, the difference isn't large enough to overcome the significant advantages of Ligand B in terms of DILI risk and TPSA. The longer half-life of Ligand A is attractive, but the poor solubility and Caco-2 permeability of both compounds are concerning.
**Conclusion:**
Considering the balance of properties, particularly the significantly lower DILI risk and better TPSA of Ligand B, it is the more promising candidate despite the shorter half-life. The slightly better affinity of Ligand A is not enough to compensate for the higher DILI risk.
Output:
0
2025-04-17 18:22:51,426 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [352.475, 59.08, 2.191, 0, 4, 0.659, 10.818, 90.074, -4.405, -1.877, 0.322, 34.158, -2.061, 0.069, -7.4]
**Ligand B:** [365.455, 97.39, 0.775, 2, 5, 0.664, 47.15, 46.413, -4.951, -2.553, 0.151, 19.263, -43.522, 0.021, -5.3]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity, and BBB):
1. **MW:** Both are within the ideal 200-500 Da range. A (352.475) is slightly preferred.
2. **TPSA:** A (59.08) is excellent, well below 140 and good for permeability. B (97.39) is higher, but still acceptable.
3. **logP:** A (2.191) is optimal. B (0.775) is a bit low, potentially hindering membrane permeability.
4. **HBD/HBA:** A (0 HBD, 4 HBA) is better than B (2 HBD, 5 HBA) for permeability.
5. **QED:** Both are similar and acceptable (A: 0.659, B: 0.664).
6. **DILI:** A (10.818) is significantly better than B (47.15), indicating a much lower risk of liver injury. This is a major advantage.
7. **BBB:** A (90.074) is very good, suggesting decent CNS penetration if desired. B (46.413) is low, indicating poor BBB penetration.
8. **Caco-2:** Both are negative, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
9. **Solubility:** Both are negative, suggesting poor solubility.
10. **hERG:** Both are very low, indicating minimal hERG inhibition risk.
11. **Cl_mic:** A (34.158) is higher than B (19.263), meaning B has better metabolic stability.
12. **t1/2:** A (-2.061) is better than B (-43.522), indicating a longer half-life.
13. **Pgp:** A (0.069) is better than B (0.021), meaning A is less likely to be a P-gp substrate.
14. **Affinity:** A (-7.4) is significantly better than B (-5.3), a difference of 2.1 kcal/mol. This is a substantial advantage.
**Overall Assessment:**
Ligand A is the clear winner. While Ligand B has better metabolic stability (lower Cl_mic) and slightly better Pgp efflux, Ligand A excels in almost every other crucial parameter. The significantly better binding affinity (-7.4 vs -5.3 kcal/mol), lower DILI risk, and superior BBB penetration are decisive advantages for a GPCR target like ADRB2. The slightly better logP and H-bonding profile also contribute to its favorability.
Output:
1
2025-04-17 18:22:51,426 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (354.38 & 351.54 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (87.15) is higher than Ligand B (50.38). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is generally preferred for absorption. Ligand B is better here.
3. **logP:** Ligand A (0.518) is quite low, potentially leading to poor membrane permeability. Ligand B (3.794) is within the optimal 1-3 range. Ligand B is significantly better.
4. **HBD:** Both have 1 HBD, which is acceptable.
5. **HBA:** Ligand A has 5 HBA, while Ligand B has 4. Both are within the acceptable limit of 10.
6. **QED:** Ligand B (0.735) has a higher QED score than Ligand A (0.555), indicating a more drug-like profile.
7. **DILI:** Ligand A (49.63) has a higher DILI risk than Ligand B (4.27). Ligand B is much better.
8. **BBB:** Both ligands have good BBB penetration (81.7% and 83.2%). This isn't a primary concern for a cardiovascular target, but it's not detrimental.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the values are similar (-4.854 vs -4.663).
10. **Solubility:** Both have negative solubility values, which is also unusual. The values are similar (-2.045 vs -2.361).
11. **hERG:** Ligand A (0.33) has a lower hERG risk than Ligand B (0.885). This is a positive for Ligand A.
12. **Cl_mic:** Ligand A (20.96) has a lower microsomal clearance than Ligand B (37.45), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-34.033) has a much more negative in vitro half-life than Ligand B (16.518), indicating a shorter half-life and faster metabolism. This is a significant negative for Ligand A.
14. **Pgp:** Ligand A (0.119) has lower P-gp efflux liability than Ligand B (0.301), which is favorable.
15. **Binding Affinity:** Ligand B (-8.1 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.6 kcal/mol). This is a substantial advantage.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp efflux, and binding affinity are key. Ligand B excels in logP and binding affinity, and is better on TPSA and Pgp. While Ligand A has a better hERG profile, the superior binding affinity and overall ADME profile of Ligand B outweigh this benefit. The significantly better DILI score for Ligand B is also a major advantage.
**Conclusion:**
Ligand B demonstrates a more favorable balance of properties, particularly with respect to binding affinity, logP, DILI risk, and metabolic stability, making it the more promising drug candidate for the ADRB2 receptor.
Output:
0
2025-04-17 18:22:51,426 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (339.351 and 346.431 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (87.34) is slightly higher than Ligand B (79.63). Both are below the 140 threshold for oral absorption, but closer to the 90 threshold for CNS targets.
3. **logP:** Ligand A (3.367) is slightly higher than Ligand B (2.402), both within the optimal 1-3 range.
4. **HBD:** Ligand A (0) has fewer HBDs than Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (7) has more HBAs than Ligand B (5). This could slightly hinder permeability compared to Ligand B.
6. **QED:** Ligand B (0.805) has a higher QED score than Ligand A (0.659), indicating a more drug-like profile.
7. **DILI:** Ligand A (87.786) has a significantly higher DILI risk than Ligand B (36.758). This is a major concern for Ligand A.
8. **BBB:** Both ligands have similar BBB penetration (Ligand A: 57.774, Ligand B: 59.636). Neither is exceptionally high, but acceptable for a peripherally acting ADRB2 target.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.403 and -4.819), which is unusual and suggests poor permeability. This is a significant drawback for both.
10. **Solubility:** Ligand B (-2.023) has better solubility than Ligand A (-4.666).
11. **hERG:** Ligand A (0.251) has a lower hERG risk than Ligand B (0.417).
12. **Cl_mic:** Ligand A (100.844) has higher microsomal clearance than Ligand B (32.722), indicating lower metabolic stability.
13. **t1/2:** Ligand B (10.749 hours) has a significantly longer in vitro half-life than Ligand A (-51.215 hours). This is a major advantage for Ligand B.
14. **Pgp:** Ligand A (0.362) has lower P-gp efflux than Ligand B (0.028), which is favorable.
15. **Affinity:** Ligand B (-7.8 kcal/mol) has a slightly better binding affinity than Ligand A (-7.6 kcal/mol). While the difference is small, it's still a positive for Ligand B.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand B is better in terms of logP, Pgp, and affinity. While both have similar TPSA, Ligand B's better overall profile makes it preferable. The biggest concern for Ligand A is its significantly higher DILI risk and lower metabolic stability.
**Conclusion:**
Despite the poor Caco-2 values for both, Ligand B is the more promising candidate due to its superior QED, lower DILI risk, better solubility, longer half-life, and slightly improved affinity. Ligand A's high DILI risk is a major red flag.
Output:
0
2025-04-17 18:22:51,426 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [352.435, 87.91, 0.209, 1, 6, 0.72, 15.936, 56.301, -4.867, -0.389, 0.127, 10.922, 3.831, 0.007, -6.8]**
**Ligand B: [350.507, 68.3, 3.485, 2, 6, 0.711, 35.905, 76.774, -4.81, -3.771, 0.854, 59.453, 49.569, 0.275, -5.7]**
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). A is 352.435 and B is 350.507. No significant difference.
**2. TPSA:** Ligand A (87.91) is slightly higher than Ligand B (68.3). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B is better here.
**3. logP:** Ligand A (0.209) is quite low, potentially hindering membrane permeability. Ligand B (3.485) is within the optimal range (1-3). Ligand B is significantly better.
**4. H-Bond Donors:** Ligand A (1) is good. Ligand B (2) is acceptable, but slightly less ideal. A is better.
**5. H-Bond Acceptors:** Both ligands have 6 HBA, which is acceptable. No significant difference.
**6. QED:** Both ligands have similar QED values (0.72 and 0.711), indicating good drug-likeness. No significant difference.
**7. DILI Risk:** Ligand A (15.936) has a much lower DILI risk than Ligand B (35.905). This is a major advantage for Ligand A.
**8. BBB Penetration:** Ligand B (76.774) has better BBB penetration than Ligand A (56.301). While ADRB2 isn't primarily a CNS target, some CNS exposure might be acceptable or even desirable depending on the specific therapeutic goal.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.867 and -4.81). This is unusual and suggests poor permeability *in vitro*. However, these values are close, and the logP difference will likely have a greater impact.
**10. Aqueous Solubility:** Ligand A (-0.389) has slightly better solubility than Ligand B (-3.771).
**11. hERG Inhibition:** Ligand A (0.127) has a much lower hERG inhibition risk than Ligand B (0.854). This is a critical safety parameter.
**12. Microsomal Clearance:** Ligand A (10.922) has lower clearance than Ligand B (59.453), suggesting better metabolic stability.
**13. In vitro Half-Life:** Ligand B (49.569) has a significantly longer half-life than Ligand A (3.831). This is a positive for Ligand B.
**14. P-gp Efflux:** Ligand A (0.007) has very low P-gp efflux, while Ligand B (0.275) has moderate efflux. Lower efflux is preferred. A is better.
**15. Binding Affinity:** Ligand A (-6.8) has slightly better binding affinity than Ligand B (-5.7). This difference is significant (1.1 kcal/mol).
**Overall Assessment:**
Ligand A has a clear advantage in safety (DILI, hERG) and metabolic stability (Cl_mic). It also has slightly better affinity and P-gp efflux. While Ligand B has better logP and half-life, the low logP of Ligand A is a significant concern, but the superior safety profile and affinity of A outweigh this. The slightly better BBB penetration of B is less critical for a cardiovascular target.
Output:
1
2025-04-17 18:22:51,426 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (a GPCR) drug candidates.
**Ligand A:** [355.523, 53.09, 1.842, 0, 4, 0.624, 15.122, 78.596, -4.487, -0.643, 0.713, 47.987, 3.546, 0.083, -4.3]
**Ligand B:** [362.539, 49.41, 2.673, 1, 3, 0.836, 17.216, 75.843, -5.106, -3.709, 0.458, 67.236, 3.977, 0.083, -6.5]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity, and BBB):
1. **MW:** Both are within the ideal range (200-500 Da). A is 355.5, B is 362.5. No significant difference.
2. **TPSA:** A (53.09) is slightly higher than B (49.41), but both are good for oral absorption and reasonable for a GPCR.
3. **logP:** A (1.842) is good, B (2.673) is also good, leaning towards the optimal range. B is slightly better.
4. **HBD:** A (0) is preferable to B (1). Fewer HBDs generally improve permeability.
5. **HBA:** A (4) is preferable to B (3). Fewer HBAs generally improve permeability.
6. **QED:** B (0.836) is better than A (0.624), indicating a more drug-like profile.
7. **DILI:** A (15.122) is significantly better than B (17.216), indicating a lower risk of liver injury. This is a crucial advantage.
8. **BBB:** Both are good (A: 78.596, B: 75.843), but A is slightly better. While ADRB2 isn't necessarily a CNS target, some peripheral effects might benefit from some BBB penetration.
9. **Caco-2:** A (-4.487) is better than B (-5.106), indicating better intestinal absorption.
10. **Solubility:** A (-0.643) is better than B (-3.709). Solubility is important for bioavailability.
11. **hERG:** A (0.713) is better than B (0.458), indicating a lower risk of cardiotoxicity. This is a critical factor for a cardiovascular target.
12. **Cl_mic:** A (47.987) is better than B (67.236), suggesting better metabolic stability.
13. **t1/2:** B (3.977) is slightly better than A (3.546), but the difference is small.
14. **Pgp:** Both are very low (A: 0.083, B: 0.083), indicating minimal P-gp efflux.
15. **Affinity:** B (-6.5) is significantly better than A (-4.3) - a 2.2 kcal/mol difference. This is a substantial advantage that can outweigh some ADME concerns.
**Overall Assessment:**
Ligand B has a significantly better binding affinity, which is paramount for GPCR targets. While Ligand A has better DILI, hERG, solubility, and metabolic stability, the substantial affinity advantage of Ligand B is likely to be more impactful in driving efficacy. The QED score is also better for Ligand B. The slight drawbacks in ADME for B can be addressed during lead optimization.
Output:
0
2025-04-17 18:22:51,426 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (374.547) is slightly higher than Ligand B (349.435), but both are acceptable.
2. **TPSA:** Ligand A (75.71) is better than Ligand B (109.58). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (1.595) is optimal, while Ligand B (0.009) is quite low. This is a significant drawback for Ligand B, potentially hindering membrane permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (6). Fewer HBAs generally improve permeability.
6. **QED:** Both ligands have similar, acceptable QED values (0.74 and 0.64).
7. **DILI:** Ligand A (8.53) has a much lower DILI risk than Ligand B (35.75). This is a major advantage for Ligand A.
8. **BBB:** Both have reasonable BBB penetration (69.368 and 71.772), but this isn't critical for a cardiovascular target.
9. **Caco-2:** Ligand A (-4.806) and Ligand B (-5.544) are similar, indicating comparable intestinal absorption.
10. **Solubility:** Ligand A (-1.248) and Ligand B (-1.928) are similar, indicating comparable solubility.
11. **hERG:** Both ligands have low hERG inhibition liability (0.484 and 0.449).
12. **Cl_mic:** Ligand A (5.058) has a significantly lower (better) microsomal clearance than Ligand B (-23.645). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (-10.484) has a longer in vitro half-life than Ligand B (0.13). This is a significant advantage for Ligand A.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.011 and 0.004).
15. **Binding Affinity:** Ligand B (-6.7) has a slightly better binding affinity than Ligand A (-5.9). However, the difference is less than 1.5 kcal/mol, and other factors are more important.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand A has a much better logP and TPSA, while Ligand B has slightly better affinity. However, the significant advantages of Ligand A in terms of DILI risk, metabolic stability (Cl_mic and t1/2), and H-bonding properties outweigh the small affinity difference.
**Conclusion:**
Ligand A is the more promising drug candidate due to its superior ADME-Tox profile, particularly the lower DILI risk and better metabolic stability, combined with acceptable binding affinity.
Output:
1
2025-04-17 18:22:51,426 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.483 and 348.447 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (103.01) is higher than Ligand B (78.68). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is still preferred for absorption. Ligand B is better.
3. **logP:** Both ligands have good logP values (1.161 and 1.434), falling within the optimal 1-3 range. Ligand B is slightly better.
4. **HBD:** Ligand A has 3 HBD, while Ligand B has 1. Lower HBD is generally preferred for permeability, giving an edge to Ligand B.
5. **HBA:** Both ligands have 5 HBA, which is acceptable. No significant difference.
6. **QED:** Ligand B (0.841) has a higher QED score than Ligand A (0.651), indicating a more drug-like profile. This is a significant advantage for Ligand B.
7. **DILI:** Ligand B (23.769) has a lower DILI risk than Ligand A (29.236), which is highly desirable.
8. **BBB:** Ligand B (76.58) has a significantly higher BBB penetration percentile than Ligand A (29.391). While ADRB2 isn't strictly a CNS target, some brain exposure can occur, and higher BBB is generally favorable.
9. **Caco-2:** Ligand A (-5.828) has a worse Caco-2 permeability than Ligand B (-4.897). This suggests Ligand B will have better intestinal absorption.
10. **Solubility:** Ligand A (-1.024) has slightly better solubility than Ligand B (-1.907), but both are quite poor. Solubility is a concern for both, but less critical than other factors.
11. **hERG:** Ligand A (0.054) has a lower hERG inhibition liability than Ligand B (0.387), which is a positive.
12. **Cl_mic:** Ligand A (3.829) has a lower microsomal clearance than Ligand B (31.548), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand B (9.158) has a slightly longer in vitro half-life than Ligand A (8.541).
14. **Pgp:** Ligand A (0.006) has much lower P-gp efflux liability than Ligand B (0.076), which is a significant advantage.
15. **Binding Affinity:** Ligand A (-5.7) has a slightly better binding affinity than Ligand B (-5.2). While a difference of 0.5 kcal/mol is not huge, it's a positive for Ligand A.
**Overall Assessment:**
Ligand B consistently outperforms Ligand A in most key ADME properties (TPSA, logP, HBD, QED, DILI, BBB, Caco-2). The improved drug-likeness and reduced toxicity risk are substantial benefits. While Ligand A has advantages in metabolic stability (Cl_mic) and Pgp efflux, and a slightly better binding affinity, these are outweighed by the ADME profile of Ligand B. Given the GPCR target class, the better TPSA, logP, and Pgp properties of Ligand B are particularly important.
Output:
0
2025-04-17 18:22:51,426 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
The ADRB2 receptor is a GPCR, so the priorities are logP, Pgp, TPSA, affinity, and BBB. Let's break down the comparison:
1. **Molecular Weight:** Both ligands are within the acceptable range (200-500 Da). Ligand A (346.515) is slightly preferred due to being lower.
2. **TPSA:** Ligand A (49.41) is significantly better than Ligand B (100.09). A TPSA under 140 is good for oral absorption, but lower is better for GPCRs, and A is much closer to the ideal range for CNS penetration (though not a CNS target here, lower TPSA generally improves permeability).
3. **logP:** Ligand A (3.831) is within the optimal range (1-3), while Ligand B (0.121) is very low. This is a major drawback for Ligand B, as it likely indicates poor membrane permeability and potentially poor absorption.
4. **H-Bond Donors/Acceptors:** Ligand A (HBD=1, HBA=2) is better than Ligand B (HBD=2, HBA=7). Fewer H-bonds generally improve permeability.
5. **QED:** Both ligands have acceptable QED scores (A: 0.645, B: 0.747), indicating reasonable drug-likeness.
6. **DILI:** Ligand B (62.621) has a higher DILI risk than Ligand A (20.706). This is a significant negative for Ligand B.
7. **BBB:** Ligand A (74.913) shows better BBB penetration potential than Ligand B (28.383). While ADRB2 isn't a primary CNS target, some peripheral exposure is possible, and better BBB penetration can sometimes correlate with better overall distribution.
8. **Caco-2 Permeability:** Ligand A (-4.735) is better than Ligand B (-5.704), indicating better intestinal absorption.
9. **Aqueous Solubility:** Ligand A (-4.014) is better than Ligand B (-2.791).
10. **hERG Inhibition:** Both ligands show very low hERG inhibition risk (A: 0.323, B: 0.035).
11. **Microsomal Clearance:** Ligand B (-3.409) has a negative clearance, which is unusual and suggests very high metabolic stability. Ligand A (69.607) has a higher clearance, indicating faster metabolism.
12. **In vitro Half-Life:** Ligand B (-22.985) has a very long half-life, which could be beneficial, but needs to be balanced against other factors. Ligand A (-1.979) has a shorter half-life.
13. **P-gp Efflux:** Both ligands have very low P-gp efflux liability (A: 0.329, B: 0.022).
14. **Binding Affinity:** Both ligands have the same binding affinity (-6.9 kcal/mol), so this parameter doesn't differentiate them.
**Overall Assessment:**
Ligand A is significantly better overall. Its superior logP, TPSA, lower DILI risk, and better solubility and Caco-2 permeability outweigh the slightly higher microsomal clearance and shorter half-life. Ligand B's extremely low logP is a major red flag, suggesting poor absorption and bioavailability. While its high metabolic stability and long half-life are appealing, they are not enough to compensate for the likely poor pharmacokinetic profile.
**Output:**
1
2025-04-17 18:22:51,426 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (365.5 & 369.5 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (71.53) is significantly better than Ligand B (104.45). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand A is well under the 140 threshold. Ligand B is approaching the upper limit.
3. **logP:** Both ligands (1.998 & 2.022) are within the optimal 1-3 range. Similar.
4. **HBD:** Ligand A (1) is preferable to Ligand B (4). Fewer HBDs generally improve permeability.
5. **HBA:** Both ligands have 5 HBA, which is acceptable.
6. **QED:** Ligand A (0.802) has a much better QED score than Ligand B (0.454), indicating a more drug-like profile.
7. **DILI:** Ligand A (37.999) has a significantly lower DILI risk than Ligand B (49.05). Both are acceptable, but A is better.
8. **BBB:** Ligand A (63.629) has a better BBB penetration score than Ligand B (55.332). While ADRB2 isn't exclusively a CNS target, some CNS exposure might be acceptable or even desirable for certain cardiovascular effects.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual. It suggests poor permeability in this assay. However, the values are similar (-5.195 vs -5.658).
10. **Solubility:** Ligand A (-1.216) has better aqueous solubility than Ligand B (-3.686).
11. **hERG:** Ligand A (0.158) has a much lower hERG inhibition liability than Ligand B (0.432). This is a critical safety parameter.
12. **Cl_mic:** Ligand A (12.451) has a substantially lower microsomal clearance than Ligand B (36.418), indicating better metabolic stability.
13. **t1/2:** Ligand A (5.404) has a positive in vitro half-life, while Ligand B (-26.001) has a negative half-life, which is concerning.
14. **Pgp:** Ligand A (0.064) has lower P-gp efflux liability than Ligand B (0.022).
15. **Affinity:** Ligand A (-7.3 kcal/mol) has a slightly better binding affinity than Ligand B (-5.9 kcal/mol). The difference is 1.4 kcal/mol, which is significant enough to outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most crucial parameters. It has a better drug-like profile (QED), lower toxicity (DILI, hERG), better metabolic stability (Cl_mic, t1/2), better solubility, and slightly better binding affinity. While both have similar logP and MW, Ligand A's lower TPSA and HBD count are also favorable. The Caco-2 values are concerning for both, but the overall profile of Ligand A is significantly more promising.
Output:
1
2025-04-17 18:22:51,427 - INFO - Batch 33 complete. Total preferences: 528
2025-04-17 18:22:51,427 - INFO - Processing batch 34/512...
2025-04-17 18:23:43,765 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [449.706, 78.9, 3.807, 0, 6, 0.493, 89.066, 40.52, -4.655, -4.855, 0.47, 55.672, 91.009, 0.53, -7.9]**
**Ligand B: [352.519, 67.43, 3.341, 2, 3, 0.468, 26.871, 73.75, -4.822, -3.194, 0.583, 67.917, -10.455, 0.395, -5.9]**
1. **Molecular Weight:** Ligand A (449.7) is within the ideal range, while Ligand B (352.5) is on the lower side, but still acceptable.
2. **TPSA:** Ligand A (78.9) is acceptable, but higher than ideal. Ligand B (67.43) is better, falling comfortably within the range for good oral absorption.
3. **logP:** Both ligands have good logP values (A: 3.807, B: 3.341), within the optimal 1-3 range.
4. **H-Bond Donors:** Ligand A (0) is excellent. Ligand B (2) is acceptable, but slightly less favorable.
5. **H-Bond Acceptors:** Ligand A (6) is good. Ligand B (3) is also good.
6. **QED:** Both ligands have similar QED values (A: 0.493, B: 0.468), indicating reasonable drug-likeness.
7. **DILI:** Ligand A (89.066) has a significantly higher DILI risk than Ligand B (26.871). This is a major concern.
8. **BBB:** Ligand B (73.75) shows better BBB penetration than Ligand A (40.52). While ADRB2 isn't strictly a CNS target, some CNS exposure can occur, and better BBB penetration is generally favorable.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.655) is slightly worse than Ligand B (-4.822).
10. **Solubility:** Both ligands have poor solubility (-4.855 and -3.194 respectively).
11. **hERG:** Both ligands have low hERG inhibition risk (A: 0.47, B: 0.583).
12. **Cl_mic:** Ligand A (55.672) has lower microsomal clearance than Ligand B (67.917), suggesting better metabolic stability.
13. **t1/2:** Ligand A (91.009) has a much longer in vitro half-life than Ligand B (-10.455). This is a significant advantage.
14. **Pgp:** Ligand A (0.53) has slightly lower P-gp efflux than Ligand B (0.395), which is better.
15. **Binding Affinity:** Ligand A (-7.9) has a substantially stronger binding affinity than Ligand B (-5.9). This is a crucial factor.
**Overall Assessment:**
Ligand A has a much stronger binding affinity and better metabolic stability (lower Cl_mic, longer t1/2) and Pgp efflux. However, its DILI risk is very high. Ligand B has a significantly lower DILI risk, better BBB penetration, and slightly better Caco-2 permeability. The difference in binding affinity is substantial (2 kcal/mol), which is a large advantage. While the DILI risk of Ligand A is concerning, the potency advantage is significant. Given the potential for mitigating DILI risk through structural modifications, the superior binding affinity of Ligand A makes it the more promising starting point.
Output:
1
2025-04-17 18:23:43,766 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (369.487 Da and 346.362 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands have TPSA values (92.51 and 88.33) that are acceptable for oral absorption (<=140), but not optimized for CNS penetration (<=90). Since ADRB2 is primarily a cardiovascular target, CNS penetration isn't a high priority.
3. **logP:** Both ligands have good logP values (2.081 and 1.86), falling within the optimal 1-3 range.
4. **HBD & HBA:** Both ligands have 1 HBD and 5 HBA, which are within acceptable limits.
5. **QED:** Both ligands have high QED scores (0.88 and 0.916), indicating good drug-like properties.
6. **DILI:** Ligand A (37.805) has a significantly lower DILI risk than Ligand B (74.021). This is a major advantage for Ligand A.
7. **BBB:** Both have similar BBB penetration (80.264 and 83.56), and as this is a cardiovascular target, it's not a critical factor.
8. **Caco-2:** Both have negative Caco-2 values (-4.617 and -4.652), which is unusual and suggests poor permeability. This is a concern for both.
9. **Solubility:** Both have negative solubility values (-2.65 and -2.856), indicating very poor aqueous solubility. This is a significant drawback for both compounds and would require formulation strategies.
10. **hERG:** Both ligands have very low hERG inhibition liability (0.129 and 0.296), which is excellent.
11. **Cl_mic:** Ligand A (16.343) has slightly lower microsomal clearance than Ligand B (17.719), suggesting better metabolic stability.
12. **t1/2:** Ligand A (12.158 hours) has a longer in vitro half-life than Ligand B (8.205 hours), which is desirable.
13. **Pgp:** Both ligands have very low P-gp efflux liability (0.038 and 0.033).
14. **Binding Affinity:** Ligand B (-6.9 kcal/mol) has a slightly better binding affinity than Ligand A (-6.7 kcal/mol), but the difference is relatively small (0.2 kcal/mol).
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are important. Both ligands perform similarly on logP, Pgp, and TPSA. The affinity difference is minor. The biggest differentiator is the significantly lower DILI risk for Ligand A, and its slightly better metabolic stability (lower Cl_mic) and longer half-life.
**Conclusion:**
While Ligand B has slightly better binding affinity, the significantly lower DILI risk and improved metabolic stability of Ligand A outweigh this minor difference. The poor solubility and Caco-2 permeability are concerns for both, but can be addressed with formulation strategies. Therefore, I prefer Ligand A.
Output:
1
2025-04-17 18:23:43,766 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.46 and 351.45 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (103.86) is better than Ligand B (113.66). Both are below 140, but closer to 90 is preferred for GPCRs, and A is closer.
3. **logP:** Ligand A (1.358) is better than Ligand B (0.555). Both are within the 1-3 range, but A is more optimal. B is approaching a logP that could indicate permeability issues.
4. **HBD:** Both ligands have 3 HBD, which is acceptable.
5. **HBA:** Ligand A has 4 HBA, while Ligand B has 5. Both are acceptable, but A is slightly better.
6. **QED:** Both are good (0.713 and 0.647), indicating drug-like properties.
7. **DILI:** Ligand A (19.542) is significantly better than Ligand B (12.641). A is well below the 40% threshold for low risk, while B is approaching a moderate risk.
8. **BBB:** Ligand A (67.119) is better than Ligand B (18.147). While ADRB2 isn't necessarily a CNS target, higher BBB penetration is generally favorable, and a large difference exists here.
9. **Caco-2:** Both are negative (-5.378 and -5.242), indicating poor permeability. This is a concern for both.
10. **Solubility:** Both are negative (-2.027 and -1.626), indicating poor solubility. This is a concern for both.
11. **hERG:** Ligand A (0.076) is much better than Ligand B (0.189). Lower hERG inhibition is crucial for avoiding cardiotoxicity, a major concern with cardiovascular targets.
12. **Cl_mic:** Ligand A (-16.524) is better than Ligand B (-7.505). Lower clearance indicates better metabolic stability.
13. **t1/2:** Ligand A (-12.991) is better than Ligand B (-2.185). A longer half-life is generally preferred.
14. **Pgp:** Ligand A (0.004) is much better than Ligand B (0.033). Lower P-gp efflux is desirable for better bioavailability.
15. **Affinity:** Ligand A (-7.0) is slightly better than Ligand B (-5.5). While both are good, A has a stronger binding affinity.
**GPCR-Specific Priorities:**
Considering ADRB2 is a GPCR, logP, TPSA, Pgp, and affinity are prioritized. Ligand A performs better in all these categories. Additionally, the significantly lower DILI and hERG risks for Ligand A are critical for a cardiovascular drug.
**Conclusion:**
Ligand A consistently outperforms Ligand B across most crucial parameters, particularly in safety (DILI, hERG) and key GPCR-relevant properties (logP, TPSA, Pgp, affinity). While both have issues with Caco-2 and solubility, these can be addressed with formulation strategies. The superior safety profile and better ADME properties of Ligand A make it the more promising drug candidate.
Output:
1
2025-04-17 18:23:43,766 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (354.495 and 357.357 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand B (80.76) is significantly better than Ligand A (104.53). For a GPCR, lower TPSA is generally preferred for better permeability.
3. **logP:** Both ligands have good logP values (1.613 and 1.183), falling within the optimal 1-3 range. Ligand B is slightly lower, which could be a minor benefit for solubility.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (1). Both are acceptable, but lower is generally better.
5. **HBA:** Ligand B (5) is higher than Ligand A (3). Again, lower is generally preferred.
6. **QED:** Both ligands have good QED scores (0.647 and 0.756), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand B (39.201) has a considerably lower DILI risk than Ligand A (16.208). This is a significant advantage.
8. **BBB:** Both ligands have good BBB penetration (74.564 and 78.48). Not a major differentiating factor here, as ADRB2 is primarily cardiovascular.
9. **Caco-2:** Ligand A (-5.032) has a more negative Caco-2 value, indicating better permeability than Ligand B (-4.696).
10. **Solubility:** Ligand A (-2.349) has a more negative solubility value, indicating better solubility than Ligand B (-1.684).
11. **hERG:** Both ligands have low hERG inhibition risk (0.184 and 0.29). No significant difference.
12. **Cl_mic:** Ligand B (16.754) has a significantly lower microsomal clearance than Ligand A (40.634), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-17.563) has a significantly longer in vitro half-life than Ligand A (1.483). This is a major advantage.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.005 and 0.016). No significant difference.
15. **Affinity:** Ligand A (-7.3) has a slightly better binding affinity than Ligand B (-6.9). This is a 0.4 kcal/mol difference, which is not large enough to outweigh the other advantages of Ligand B.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B is better on TPSA, and comparable on logP and Pgp. While Ligand A has a slightly better affinity, the other ADME properties of Ligand B are significantly more favorable, particularly the lower DILI risk, lower Cl_mic, and longer half-life.
**Conclusion:**
Considering the balance of properties, Ligand B is the more promising drug candidate. Its superior ADME profile (lower DILI, better metabolic stability, longer half-life, and better TPSA) outweighs the slightly weaker binding affinity.
Output:
0
2025-04-17 18:23:43,766 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (343.329 and 362.47 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Both ligands (53.68 and 52.57) are below the 140 A^2 threshold for good oral absorption, which is good.
3. **logP:** Both ligands (2.984 and 3.727) are within the optimal 1-3 range, but Ligand B is slightly higher. This could be a minor concern for off-target effects, but not a deal-breaker.
4. **HBD:** Ligand A has 1 HBD, and Ligand B has 2. Both are acceptable.
5. **HBA:** Both ligands have 3 HBA, well within the acceptable limit.
6. **QED:** Both ligands have good QED scores (0.795 and 0.871), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A has a DILI risk of 53.819%, while Ligand B has 30.322%. Ligand B is significantly better regarding liver toxicity risk.
8. **BBB:** Both have good BBB penetration (77.2% and 83.249%), but Ligand B is better. This is important for GPCRs, even cardiovascular ones, as some CNS off-target effects are possible.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. This is a significant issue for both.
10. **Solubility:** Both have negative solubility values, indicating poor solubility. This is also a significant issue for both.
11. **hERG:** Both have low hERG inhibition liability (0.85 and 0.784), which is good.
12. **Cl_mic:** Ligand A has a higher microsomal clearance (37.698) than Ligand B (22.178). Ligand B is better in terms of metabolic stability.
13. **t1/2:** Ligand B has a much longer in vitro half-life (5.008 hours) than Ligand A (38.36 hours). This is a significant advantage for Ligand B.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.649 and 0.358), which is good. Ligand B is better.
15. **Binding Affinity:** Ligand A has a binding affinity of -6.7 kcal/mol, while Ligand B has -5.6 kcal/mol. Ligand A has a significantly better binding affinity.
**Overall Assessment:**
Ligand A has a superior binding affinity, which is a primary driver for GPCR drug candidates. However, Ligand B demonstrates a more favorable ADME profile, particularly regarding DILI risk, metabolic stability (lower Cl_mic, longer t1/2), and Pgp efflux. Both have poor Caco-2 and solubility. The difference in binding affinity (-6.7 vs -5.6) is substantial (1.1 kcal/mol), and this outweighs the ADME benefits of Ligand B in my assessment. While the ADME properties of Ligand B are better, the strong binding affinity of Ligand A is crucial for a GPCR target. The poor permeability and solubility of both compounds would need to be addressed through formulation or further chemical modification, but a strong starting point with high affinity is preferable.
Output:
1
2025-04-17 18:23:43,766 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (344.379 and 338.411 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (76.02) is significantly better than Ligand A (127.93). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (1.027) is within the optimal range (1-3), while Ligand A (0.02) is quite low. Low logP can hinder membrane permeability. Ligand B is clearly favored here.
4. **HBD:** Ligand A (4) is slightly higher than Ligand B (2), but both are acceptable (<=5).
5. **HBA:** Ligand A (6) and Ligand B (4) are both acceptable (<=10).
6. **QED:** Ligand A (0.605) is slightly better than Ligand B (0.549), indicating a marginally more drug-like profile.
7. **DILI:** Ligand B (49.477) has a significantly lower DILI risk than Ligand A (80.651). This is a crucial advantage.
8. **BBB:** Both are around 45%, so BBB isn't a major differentiating factor for this cardiovascular target.
9. **Caco-2:** Both have negative Caco-2 values (-5.664 and -5.092). This is unusual and suggests poor permeability *in vitro*. However, the values are similar.
10. **Solubility:** Both ligands have negative solubility values (-2.389 and -2.301). This is also unusual and suggests poor aqueous solubility. Again, values are similar.
11. **hERG:** Ligand A (0.064) has a slightly lower hERG risk than Ligand B (0.176), which is a positive.
12. **Cl_mic:** Ligand A (-7.093) has *much* lower microsomal clearance than Ligand B (18.571), indicating significantly better metabolic stability. This is a major advantage for Ligand A.
13. **t1/2:** Both have similar in vitro half-lives (9.262 and 9.689 hours).
14. **Pgp:** Ligand A (0.004) has a much lower P-gp efflux liability than Ligand B (0.065), suggesting better bioavailability.
15. **Binding Affinity:** Ligand A (-7.5 kcal/mol) has a slightly better binding affinity than Ligand B (-5.1 kcal/mol). This 2.4 kcal/mol difference is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand A is the stronger candidate. While Ligand B has a lower DILI risk, Ligand A's superior binding affinity, lower P-gp efflux, and significantly better metabolic stability (lower Cl_mic) are more critical for a successful drug candidate. The slightly lower hERG risk for Ligand A is also a bonus. The similar poor Caco-2 and solubility values are concerning for both, but can be addressed with formulation strategies. The TPSA difference is also notable, favoring Ligand B, but the other advantages of Ligand A are more impactful.
Output:
1
2025-04-17 18:23:43,766 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (352.381 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (55.57) is significantly better than Ligand B (72.88). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (4.005) is at the upper end of the optimal range, while Ligand B (0.501) is quite low. A logP around 1-3 is preferred, so Ligand A is better here, as very low logP can hinder membrane permeability.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Both ligands have 4 HBA, which is acceptable.
6. **QED:** Both ligands have similar, good QED values (0.72 and 0.766).
7. **DILI:** Ligand B (13.532) has a much lower DILI risk than Ligand A (40.636), a significant advantage.
8. **BBB:** Both have reasonably high BBB penetration, but Ligand A (84.374) is slightly better than Ligand B (71.772). However, BBB isn't a high priority for a cardiovascular target.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-4.51) has slightly better solubility than Ligand B (-1.478), but both are poor.
11. **hERG:** Ligand A (0.639) has a slightly better hERG profile than Ligand B (0.338), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand B (-31.12) has significantly lower microsomal clearance than Ligand A (59.429), suggesting better metabolic stability. This is a major advantage.
13. **t1/2:** Ligand B (-26.44) has a much longer in vitro half-life than Ligand A (-4.742), further supporting its better metabolic stability.
14. **Pgp:** Ligand A (0.22) has a lower Pgp efflux liability than Ligand B (0.007), which is beneficial for bioavailability.
15. **Binding Affinity:** Ligand A (-7.7) has a slightly better binding affinity than Ligand B (-5.6), a difference of 2.1 kcal/mol. This is a substantial advantage and can often outweigh some ADME concerns.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A excels in logP, Pgp, and especially affinity. Ligand B has a better DILI score and metabolic stability (Cl_mic and t1/2). While metabolic stability is important, the significantly stronger binding affinity of Ligand A is a critical factor for a GPCR target. The lower DILI risk of Ligand B is attractive, but can be addressed with further optimization.
**Conclusion:**
Despite Ligand B's better metabolic stability and lower DILI risk, the significantly stronger binding affinity of Ligand A (-7.7 kcal/mol vs -5.6 kcal/mol) makes it the more promising candidate. The affinity difference is large enough to potentially overcome the slightly higher DILI risk and poorer metabolic stability through further optimization.
Output:
1
2025-04-17 18:23:43,767 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (a cardiovascular GPCR) drug candidates.
**Ligand A:** [344.459, 70.39, 2.606, 2, 4, 0.723, 38.503, 54.052, -4.817, -2.232, 0.552, 38.356, 12.318, 0.314, -8.4]
**Ligand B:** [346.515, 40.62, 3.452, 0, 2, 0.782, 15.277, 87.476, -4.742, -3.38, 0.624, 78.891, -4.132, 0.341, -6.3]
Here's a breakdown, considering the guidelines and GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal range (200-500 Da). A is 344.459, B is 346.515 - very similar.
2. **TPSA:** A is 70.39, B is 40.62. B is significantly better, falling well below the 140 threshold for oral absorption and closer to the ideal for GPCRs.
3. **logP:** A is 2.606, B is 3.452. Both are within the optimal 1-3 range, but B is slightly higher. This could be a minor concern for solubility, but not a dealbreaker.
4. **HBD:** A is 2, B is 0. B is preferable, as fewer HBDs generally improve permeability.
5. **HBA:** A is 4, B is 2. B is again preferable for permeability.
6. **QED:** Both are good (A: 0.723, B: 0.782), indicating drug-like properties. B is slightly better.
7. **DILI:** A is 38.503, B is 15.277. B is *much* better, indicating a significantly lower risk of drug-induced liver injury. This is a major advantage.
8. **BBB:** A is 54.052, B is 87.476. B is significantly better at BBB penetration. While ADRB2 isn't necessarily a CNS target, better BBB penetration can sometimes translate to improved distribution and reduced off-target effects.
9. **Caco-2:** Both are negative (-4.817 and -4.742), indicating good permeability. Similar values.
10. **Solubility:** A is -2.232, B is -3.38. A is slightly better, but both are poor.
11. **hERG:** A is 0.552, B is 0.624. Both are relatively low, indicating low cardiotoxicity risk. B is slightly higher.
12. **Cl_mic:** A is 38.356, B is 78.891. A is much better, indicating better metabolic stability.
13. **t1/2:** A is 12.318, B is -4.132. A is significantly better, indicating a longer half-life.
14. **Pgp:** A is 0.314, B is 0.341. Similar values, both indicating low P-gp efflux.
15. **Affinity:** A is -8.4 kcal/mol, B is -6.3 kcal/mol. A has a *significantly* stronger binding affinity. This is a substantial advantage, potentially outweighing some of the ADME drawbacks of B.
**Overall Assessment:**
Ligand A has a much stronger binding affinity, a better half-life, and better metabolic stability. However, Ligand B excels in several crucial ADME properties: TPSA, DILI risk, and BBB penetration. The lower TPSA and DILI risk are particularly attractive. The affinity difference is 2.1 kcal/mol, which is substantial, but not insurmountable if the ADME properties of B are significantly better. Given the GPCR target class, the improvements in TPSA, DILI, and BBB for Ligand B are very valuable.
Considering the balance, and prioritizing the ADME advantages of Ligand B, I believe it is the more viable drug candidate.
Output:
0
2025-04-17 18:23:43,767 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.39 and 356.54 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (106.08) is better than Ligand B (36.36). While both are acceptable, Ligand B's very low TPSA might suggest potential issues with solubility or off-target interactions, despite being good for BBB penetration.
3. **logP:** Ligand A (0.622) is within the optimal range (1-3), but on the lower side. Ligand B (4.85) is significantly higher, potentially leading to solubility problems and increased off-target binding.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 5 HBA, while Ligand B has 4. Both are within the acceptable limit of 10.
6. **QED:** Both ligands have similar QED values (0.727 and 0.698), indicating good drug-likeness.
7. **DILI:** Ligand A (33.58%) has a slightly higher DILI risk than Ligand B (19.27%), but both are well below the concerning threshold of 60%.
8. **BBB:** Both ligands show good BBB penetration (63.78% and 69.41%).
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Ligand A (-2.005) has better solubility than Ligand B (-5.12). This is a significant advantage, especially considering Ligand B's high logP.
11. **hERG:** Ligand A (0.24) has a much lower hERG inhibition liability than Ligand B (0.838), which is crucial for cardiovascular safety.
12. **Cl_mic:** Ligand A (-6.313) has a much lower microsomal clearance, indicating better metabolic stability than Ligand B (85.287).
13. **t1/2:** Ligand A (27.693 hours) has a significantly longer in vitro half-life than Ligand B (-20.654 hours).
14. **Pgp:** Ligand A (0.023) has much lower P-gp efflux liability than Ligand B (0.594), which is favorable for oral bioavailability and potentially CNS exposure.
15. **Binding Affinity:** Ligand B (-7.3 kcal/mol) has a slightly better binding affinity than Ligand A (-6.0 kcal/mol). This is a 1.3 kcal/mol difference, which is significant.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B has a better affinity, but its high logP and Pgp efflux liability are concerning. Ligand A has a more balanced profile with acceptable logP, better solubility, lower hERG risk, better metabolic stability, and lower Pgp efflux.
**Overall Assessment:**
While Ligand B has a slightly better binding affinity, the significant drawbacks in solubility, metabolic stability, hERG risk, and Pgp efflux make it a less desirable candidate. Ligand A, despite slightly weaker binding, presents a much more balanced and favorable ADMET profile, making it more likely to succeed as a drug candidate.
Output:
1
2025-04-17 18:23:43,767 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (462.332 Da) is within the ideal range, while Ligand B (357.401 Da) is on the lower side but still acceptable.
2. **TPSA:** Both ligands are below the 140 A^2 threshold for good oral absorption. Ligand B (78.6) is slightly better than Ligand A (87.32).
3. **logP:** Both ligands have optimal logP values (A: 3.17, B: 2.21), falling within the 1-3 range.
4. **HBD:** Both have 2 HBD, which is acceptable.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 5. Both are within the acceptable limit of 10.
6. **QED:** Both ligands have good QED scores (A: 0.662, B: 0.864), indicating drug-likeness. Ligand B is better here.
7. **DILI:** Ligand A (61.303) has a higher DILI risk than Ligand B (31.718). This is a significant advantage for Ligand B.
8. **BBB:** Ligand B (85.343) has significantly better BBB penetration potential than Ligand A (55.913). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant for off-target effects and overall safety.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, these values are on a strange scale, and the negative values aren't directly comparable.
10. **Solubility:** Both have negative solubility values, again suggesting poor solubility. Similar to Caco-2, these values are difficult to interpret.
11. **hERG:** Both ligands have low hERG inhibition liability (A: 0.541, B: 0.449).
12. **Cl_mic:** Ligand B (14.43 mL/min/kg) has much lower microsomal clearance than Ligand A (39.454 mL/min/kg), indicating better metabolic stability.
13. **t1/2:** Ligand B (-2.06 hours) has a negative half-life, which is concerning. Ligand A (6.102 hours) is much better.
14. **Pgp:** Both have low Pgp efflux liability (A: 0.218, B: 0.089). Ligand B is slightly better.
15. **Binding Affinity:** Ligand B (-7.7 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.5 kcal/mol). This is a substantial advantage.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand B excels in logP, Pgp, and *especially* affinity. The better BBB penetration is also a plus. While the negative half-life is a concern, the much stronger binding affinity of Ligand B likely outweighs this drawback, as a higher dose or modified formulation could potentially compensate. The lower DILI risk is also a major advantage.
**Conclusion:**
Despite the unusual solubility and Caco-2 values, and the negative half-life, Ligand B's superior binding affinity, lower DILI risk, better metabolic stability, and improved BBB penetration make it the more promising drug candidate.
Output:
0
2025-04-17 18:23:43,767 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [356.482, 78.43, 2.348, 3, 3, 0.526, 8.53, 76.464, -4.697, -2.765, 0.465, 36.064, -11.024, 0.105, -6.6]
**Ligand B:** [353.419, 115.9, 0.248, 3, 6, 0.675, 39.201, 25.785, -5.107, -0.798, 0.254, 13.315, -20.617, 0.089, -6.1]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). A (356.482) and B (353.419) are very similar.
2. **TPSA:** A (78.43) is excellent, well below the 140 threshold and good for oral absorption. B (115.9) is higher, but still acceptable, though less ideal.
3. **logP:** A (2.348) is optimal. B (0.248) is quite low, potentially hindering permeability. This is a significant drawback.
4. **HBD:** Both have 3 HBD, which is within the acceptable limit.
5. **HBA:** A has 3 HBA, while B has 6. Both are acceptable, but A is preferable.
6. **QED:** Both have good QED scores (A: 0.526, B: 0.675), indicating drug-like properties. B is slightly better here.
7. **DILI:** A (8.53) has a very low DILI risk. B (39.201) is higher, but still within the acceptable range (<40 is good).
8. **BBB:** A (76.464) has excellent BBB penetration, highly desirable for a GPCR. B (25.785) is poor, suggesting limited CNS exposure.
9. **Caco-2:** A (-4.697) and B (-5.107) are both negative, which is unusual and suggests poor permeability. However, the scale isn't specified, so it's hard to interpret.
10. **Solubility:** A (-2.765) and B (-0.798) are both negative, indicating poor solubility. B is better here.
11. **hERG:** Both have low hERG risk (A: 0.465, B: 0.254).
12. **Cl_mic:** A (36.064) has a moderate clearance, while B (13.315) has a lower clearance, indicating better metabolic stability. B is preferable.
13. **t1/2:** A (-11.024) has a negative half-life, which is impossible. This is a data error. B (-20.617) also has a negative half-life, indicating a data error.
14. **Pgp:** A (0.105) has low Pgp efflux, which is good. B (0.089) is even lower, which is better.
15. **Affinity:** Both have very good binding affinity (A: -6.6, B: -6.1). A is slightly better.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, BBB, and affinity.
* **LogP:** A is significantly better (2.348 vs 0.248).
* **TPSA:** A is better (78.43 vs 115.9).
* **Pgp:** B is slightly better (0.089 vs 0.105).
* **BBB:** A is *much* better (76.464 vs 25.785).
* **Affinity:** A is slightly better (-6.6 vs -6.1).
**Conclusion:**
Despite the questionable half-life data and poor Caco-2/solubility values for both, Ligand A is the stronger candidate. Its superior logP, TPSA, and particularly its excellent BBB penetration, outweigh the slightly better metabolic stability and Pgp efflux of Ligand B. The significantly better logP of Ligand A is crucial for GPCR engagement and permeability.
Output:
1
2025-04-17 18:23:43,767 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [351.491, 61.88, 1.395, 1, 4, 0.704, 12.796, 66.615, -4.782, -0.592, 0.461, 9.628, -5.568, 0.076, -7.5]
**Ligand B:** [373.875, 38.13, 4.451, 0, 3, 0.691, 20.047, 91.314, -4.418, -5.299, 0.67, 66.164, -14.229, 0.319, -7.2]
Here's a breakdown of each parameter, comparing A and B, and considering GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal range (200-500 Da). A (351.491) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** A (61.88) is better than B (38.13) - both are reasonably good for oral absorption, but B is better.
3. **logP:** A (1.395) is optimal. B (4.451) is pushing the upper limit and could lead to solubility issues and off-target effects.
4. **HBD:** A (1) is better than B (0). Fewer HBDs are generally preferred for better permeability.
5. **HBA:** A (4) is better than B (3). Fewer HBAs are generally preferred for better permeability.
6. **QED:** Both are reasonably good (A: 0.704, B: 0.691), indicating drug-like properties.
7. **DILI:** A (12.796) is significantly better than B (20.047), indicating a much lower risk of liver injury. This is a crucial advantage.
8. **BBB:** B (91.314) is significantly better than A (66.615). While ADRB2 isn't necessarily a CNS target, some peripheral ADRB2 activity can influence CNS pathways, and higher BBB penetration isn't detrimental.
9. **Caco-2:** Both are negative, indicating good permeability. A (-4.782) is slightly better than B (-4.418).
10. **Solubility:** A (-0.592) is better than B (-5.299). Solubility is important for bioavailability.
11. **hERG:** A (0.461) is significantly better than B (0.67). Lower hERG inhibition is critical to avoid cardiotoxicity, especially for a cardiovascular target.
12. **Cl_mic:** A (9.628) is better than B (66.164), indicating better metabolic stability.
13. **t1/2:** A (-5.568) is better than B (-14.229), indicating a longer half-life.
14. **Pgp:** A (0.076) is significantly better than B (0.319), meaning less efflux and potentially better bioavailability.
15. **Affinity:** A (-7.5) is slightly better than B (-7.2), although the difference isn't huge.
**Overall Assessment:**
Ligand A clearly outperforms Ligand B across most critical ADME-Tox parameters. The lower DILI risk, better hERG profile, better metabolic stability (Cl_mic, t1/2), lower Pgp efflux, and slightly better solubility and affinity make it a much more promising candidate. While Ligand B has better BBB penetration, this is less critical for a primarily peripheral target like ADRB2, and the significant advantages of A outweigh this benefit. LogP for ligand B is concerning.
Therefore, I prefer Ligand A.
Output:
1
2025-04-17 18:23:43,767 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (330.391 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (62.83) is significantly better than Ligand B (95.5). ADRB2 is a cardiovascular target, so CNS penetration isn't crucial, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (4.671) is higher than Ligand B (1.475). While 4.671 is approaching the upper limit, it's still acceptable. Ligand B's logP is quite low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (2) is better than Ligand B (3). Lower is generally preferred.
5. **HBA:** Both ligands have the same number of HBA (4), which is within the acceptable range.
6. **QED:** Ligand A (0.558) is better than Ligand B (0.433), indicating a more drug-like profile.
7. **DILI:** Ligand B (21.83) is *much* better than Ligand A (82.668). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (71.074) is better than Ligand B (63.862), but BBB isn't a major priority for a cardiovascular target.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. Ligand A (-5.168) is slightly better than Ligand B (-4.995).
10. **Solubility:** Ligand A (-5.885) is better than Ligand B (-2.233), indicating better aqueous solubility.
11. **hERG:** Ligand A (0.93) is better than Ligand B (0.077). Lower hERG inhibition is crucial for avoiding cardiotoxicity.
12. **Cl_mic:** Ligand A (85.796) is better than Ligand B (25.464). Lower clearance suggests better metabolic stability.
13. **t1/2:** Ligand B (-32.316) is *much* better than Ligand A (-10.457). A longer half-life is highly desirable.
14. **Pgp:** Ligand A (0.533) is better than Ligand B (0.014). Lower P-gp efflux is preferred.
15. **Affinity:** Ligand B (-6.0) is slightly better than Ligand A (-5.7). While the difference isn't huge, it's a factor.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A has a better logP and Pgp, while Ligand B has a slightly better affinity. Ligand A has a much better TPSA.
**Overall Assessment:**
Ligand B has a significantly better DILI score and a much longer half-life, which are major advantages. Its affinity is also slightly better. While Ligand A excels in TPSA and has better solubility, the DILI risk associated with Ligand A is concerning. The improved metabolic stability (longer half-life) of Ligand B is a key factor for a cardiovascular drug. The slightly lower logP of Ligand B is a concern, but the other benefits outweigh this drawback.
**Output:**
0
2025-04-17 18:23:43,768 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [367.833, 105.66 , 1.246, 4. , 4. , 0.562, 52.191, 18.845, -6.409, -1.285, 0.033, -36.174, 19.892, 0.005, -6.9 ]
**Ligand B:** [366.527, 67.43 , 3.345, 2. , 4. , 0.693, 31.563, 74.952, -4.811, -3.371, 0.591, 67.789, 30.197, 0.202, -8.1 ]
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (367-368 Da). No significant difference.
2. **TPSA:** Ligand A (105.66) is higher than Ligand B (67.43). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for permeability. Ligand B is better here.
3. **logP:** Ligand A (1.246) is within the optimal range, while Ligand B (3.345) is towards the higher end. Ligand A is slightly preferred.
4. **HBD:** Ligand A (4) is higher than Ligand B (2). Lower is generally better for permeability. Ligand B is better.
5. **HBA:** Both ligands have 4 HBA, so no difference.
6. **QED:** Ligand B (0.693) has a better QED score than Ligand A (0.562), suggesting a more drug-like profile. Ligand B is better.
7. **DILI:** Ligand A (52.191) has a higher DILI risk than Ligand B (31.563). This is a significant advantage for Ligand B.
8. **BBB:** Ligand B (74.952) has a significantly higher BBB penetration percentile than Ligand A (18.845). While this isn't *essential* for a cardiovascular target, it doesn't hurt, and could open up possibilities for exploring CNS effects.
9. **Caco-2:** Ligand A (-6.409) has a lower Caco-2 value than Ligand B (-4.811). This suggests lower intestinal absorption for Ligand A. Ligand B is better.
10. **Solubility:** Ligand A (-1.285) has a higher solubility than Ligand B (-3.371). Solubility is important, and this is a point for Ligand A.
11. **hERG:** Ligand A (0.033) has a lower hERG risk than Ligand B (0.591). This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand A (-36.174) has a much lower (better) microsomal clearance than Ligand B (67.789), indicating better metabolic stability. This is a major advantage for Ligand A.
13. **t1/2:** Ligand B (30.197) has a longer in vitro half-life than Ligand A (19.892). This is a slight advantage for Ligand B.
14. **Pgp:** Ligand A (0.005) has a much lower Pgp efflux liability than Ligand B (0.202). This is a significant advantage for Ligand A.
15. **Affinity:** Ligand B (-8.1) has a significantly stronger binding affinity than Ligand A (-6.9). This is a substantial advantage for Ligand B, and often outweighs minor ADME concerns.
**Overall Assessment:**
Ligand B has a significantly better binding affinity and a superior safety profile (lower DILI). It also has better Caco-2 permeability, BBB penetration, and a longer half-life. While Ligand A has better metabolic stability (Cl_mic) and lower Pgp efflux, the affinity difference is substantial. The slightly higher logP of Ligand B is manageable. Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), the stronger binding of Ligand B is the most important factor.
Output:
0
2025-04-17 18:23:43,768 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (344.415 Da) is well within the ideal range (200-500 Da). Ligand B (391.88 Da) is also acceptable, but closer to the upper limit.
2. **TPSA:** Both ligands (A: 89.57, B: 86.29) are below 140, and reasonably close to the 90 threshold, suggesting good potential for absorption.
3. **logP:** Ligand A (0.897) is slightly low, potentially impacting permeability. Ligand B (3.653) is within the optimal range (1-3). This is a significant advantage for B.
4. **HBD:** Ligand A (1) and Ligand B (2) are both acceptable.
5. **HBA:** Ligand A (5) and Ligand B (4) are both acceptable.
6. **QED:** Both ligands (A: 0.613, B: 0.596) are above 0.5, indicating good drug-like properties.
7. **DILI:** Ligand A (44.087) and Ligand B (36.797) both have low DILI risk, below the 40 threshold. B is slightly better.
8. **BBB:** Ligand A (27.801) and Ligand B (32.416) are both low, which is not a major concern for a cardiovascular target like ADRB2.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not defined, so it's difficult to interpret.
10. **Solubility:** Both ligands have negative solubility values, which is also unusual and suggests poor solubility. Again, the scale is not defined.
11. **hERG:** Both ligands (A: 0.426, B: 0.567) have low hERG inhibition liability, which is good.
12. **Cl_mic:** Ligand A (17.598) has significantly lower microsomal clearance than Ligand B (50.117), suggesting better metabolic stability.
13. **t1/2:** Ligand B (26.165) has a longer in vitro half-life than Ligand A (6.815).
14. **Pgp:** Both ligands (A: 0.238, B: 0.382) have low P-gp efflux liability.
15. **Affinity:** Ligand B (-6.6 kcal/mol) has a slightly better binding affinity than Ligand A (-6.1 kcal/mol). While the difference is less than 1.5 kcal/mol, it's still a positive factor.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are particularly important. Ligand B excels in logP and has a slightly better affinity. Both have acceptable TPSA and Pgp values. The lower metabolic stability of Ligand A is a concern.
**Overall Assessment:**
Ligand B demonstrates a better balance of properties, particularly its favorable logP, longer half-life, and slightly improved affinity. While Ligand A has better metabolic stability, the benefits of Ligand B's other properties outweigh this advantage. The negative values for Caco-2 and solubility are concerning for both, but these could be addressed with formulation strategies.
Output:
0
2025-04-17 18:23:43,768 - INFO - Here's a step-by-step reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A Analysis:**
* **MW:** 365.949 Da - Good, within the ideal range.
* **TPSA:** 38.13 - Excellent, well below the 140 threshold, good for absorption.
* **logP:** 4.924 - Slightly high, could potentially lead to solubility issues or off-target interactions, but still within a manageable range.
* **HBD:** 0 - Low, favorable for permeability.
* **HBA:** 3 - Low, favorable for permeability.
* **QED:** 0.582 - Good, indicates a reasonable drug-like profile.
* **DILI:** 18.185 - Excellent, very low risk of liver injury.
* **BBB:** 76.735 - Good, suggests reasonable potential for CNS penetration, though not exceptionally high.
* **Caco-2:** -4.76 - Very poor permeability. This is a significant drawback.
* **Solubility:** -5.587 - Very poor solubility. This is a major concern.
* **hERG:** 0.585 - Low risk of hERG inhibition, favorable.
* **Cl_mic:** 95.405 - High metabolic clearance, suggesting poor metabolic stability.
* **t1/2:** 55.452 - Good in vitro half-life.
* **Pgp:** 0.579 - Low P-gp efflux, favorable.
* **Affinity:** -5.9 kcal/mol - Good binding affinity.
**Ligand B Analysis:**
* **MW:** 368.419 Da - Good, within the ideal range.
* **TPSA:** 123.22 - Acceptable, but approaching the upper limit for good oral absorption.
* **logP:** 0.006 - Very low, could hinder permeation.
* **HBD:** 1 - Low, favorable for permeability.
* **HBA:** 9 - Acceptable, near the upper limit but still reasonable.
* **QED:** 0.725 - Very good, strong drug-like profile.
* **DILI:** 78.247 - High risk of liver injury, a significant concern.
* **BBB:** 51.415 - Moderate, not particularly favorable for CNS penetration.
* **Caco-2:** -5.185 - Very poor permeability. This is a significant drawback.
* **Solubility:** -2.312 - Poor solubility, but better than Ligand A.
* **hERG:** 0.012 - Very low risk of hERG inhibition, excellent.
* **Cl_mic:** 6.841 - Low metabolic clearance, suggesting good metabolic stability.
* **t1/2:** 7.005 - Short in vitro half-life, potentially requiring frequent dosing.
* **Pgp:** 0.031 - Very low P-gp efflux, favorable.
* **Affinity:** -7.1 kcal/mol - Excellent binding affinity, significantly better than Ligand A.
**Comparison & Decision:**
Both ligands have significant drawbacks, primarily very poor Caco-2 permeability and solubility. However, Ligand B possesses a substantially stronger binding affinity (-7.1 vs -5.9 kcal/mol), a better QED score, and significantly better metabolic stability (lower Cl_mic). While Ligand B has a higher DILI risk, the difference in binding affinity is substantial enough to prioritize it, *assuming* that the DILI risk can be mitigated through structural modifications. The slightly better solubility of Ligand B is also a minor advantage. For a GPCR target like ADRB2, affinity is paramount, and the improved affinity of Ligand B outweighs its other deficiencies, provided those deficiencies are addressable.
Output:
0
2025-04-17 18:23:43,768 - INFO - Batch 34 complete. Total preferences: 544
2025-04-17 18:23:43,768 - INFO - Processing batch 35/512...
2025-04-17 18:24:29,572 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (420.294 Da) is within the ideal range, while Ligand B (356.463 Da) is also acceptable, being slightly below the ideal.
2. **TPSA:** Ligand A (47.56) is excellent, well below the 140 threshold. Ligand B (96.89) is higher, but still potentially acceptable for a peripherally acting GPCR.
3. **logP:** Ligand A (4.654) is a bit high, potentially leading to solubility issues or off-target interactions. Ligand B (0.598) is quite low, which could hinder membrane permeability.
4. **HBD:** Ligand A (1) is good. Ligand B (3) is acceptable, but higher HBD can sometimes impact permeability.
5. **HBA:** Ligand A (4) is good. Ligand B (5) is acceptable.
6. **QED:** Both ligands have reasonable QED values (A: 0.467, B: 0.621), indicating decent drug-likeness. Ligand B is slightly better.
7. **DILI:** Ligand A (20.706) has a significantly lower DILI risk than Ligand B (27.181). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (89.027) has a much higher BBB penetration potential than Ligand B (41.838). While ADRB2 isn't exclusively a CNS target, some CNS exposure can occur, and higher BBB is generally favorable.
9. **Caco-2:** Ligand A (-4.485) has a negative value, indicating poor permeability. Ligand B (-5.119) is also poor, but slightly worse.
10. **Solubility:** Ligand A (-5.029) has poor solubility. Ligand B (-2.139) is also poor, but better than Ligand A.
11. **hERG:** Ligand A (0.877) has a lower hERG risk than Ligand B (0.272). This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand A (84.629) has higher metabolic clearance than Ligand B (31.882). This is a disadvantage for Ligand A.
13. **t1/2:** Ligand A (46.179) has a much longer half-life than Ligand B (10.369). This is a major advantage for Ligand A.
14. **Pgp:** Ligand A (0.374) has lower P-gp efflux than Ligand B (0.035). This is an advantage for Ligand A.
15. **Affinity:** Ligand A (-6.5 kcal/mol) has slightly better affinity than Ligand B (-6.1 kcal/mol), but the difference is relatively small.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A has a higher logP, which is a concern, but its TPSA is excellent. Ligand B's low logP is problematic. Ligand A also has better Pgp properties. The affinity difference is small.
**Overall Assessment:**
Ligand A presents a better balance of properties despite its higher logP and clearance. Its significantly lower DILI risk, higher BBB penetration, longer half-life, and better Pgp profile outweigh the concerns about logP and clearance. Ligand B's low logP is a major drawback, and its higher DILI risk is concerning.
Output:
1
2025-04-17 18:24:29,573 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.46 and 344.50 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (75.44) is higher than Ligand B (58.2). While both are below 140, the lower TPSA of Ligand B is preferable for oral absorption, a key consideration for a cardiovascular target.
3. **logP:** Both ligands have good logP values (2.32 and 2.88), falling within the optimal 1-3 range. Ligand B is slightly higher, which could potentially lead to better membrane permeability.
4. **HBD:** Ligand A (1) has fewer H-bond donors than Ligand B (2). Fewer HBDs generally improve permeability, giving a slight edge to Ligand A.
5. **HBA:** Ligand A (4) has more H-bond acceptors than Ligand B (2). Lower HBA is generally preferred for permeability, favoring Ligand B.
6. **QED:** Ligand A (0.821) has a significantly higher QED score than Ligand B (0.551), indicating a more drug-like profile overall. This is a substantial positive for Ligand A.
7. **DILI:** Ligand B (34.82) has a much lower DILI risk than Ligand A (18.50). This is a significant advantage for Ligand B, as minimizing liver toxicity is crucial.
8. **BBB:** Ligand A (78.40) has a better BBB penetration percentile than Ligand B (50.68). While ADRB2 is not a CNS target, some degree of BBB penetration can sometimes be acceptable or even beneficial for peripheral targets, and it indicates good passive permeability.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. This is a concern for both.
10. **Solubility:** Both ligands have negative solubility values, indicating poor solubility. This is a concern for both.
11. **hERG:** Ligand A (0.286) has a lower hERG inhibition liability than Ligand B (0.501), indicating a lower risk of cardiotoxicity. This is a significant advantage for Ligand A, given the cardiovascular target.
12. **Cl_mic:** Ligand A (58.01) has a lower microsomal clearance than Ligand B (48.05), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-16.27) has a significantly longer in vitro half-life than Ligand A (-7.93). A longer half-life is generally desirable.
14. **Pgp:** Ligand A (0.104) has lower P-gp efflux liability than Ligand B (0.417), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand B (-6.3) has a slightly better binding affinity than Ligand A (-5.7). While a 1.5 kcal/mol difference is not huge, it's a noticeable advantage.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B has a better logP and affinity, and lower TPSA. Ligand A has better Pgp and hERG.
**Overall Assessment:**
Ligand A has a better QED, lower hERG, lower Pgp efflux, and better metabolic stability. Ligand B has a lower DILI risk, longer half-life, and slightly better affinity. The DILI risk and half-life are significant advantages for Ligand B. However, the better QED, hERG and Pgp profile of Ligand A are crucial for a viable drug candidate. The slightly better affinity of Ligand B is not enough to outweigh the other factors.
Output:
1
2025-04-17 18:24:29,573 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (345.407 and 346.439 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (115.99) is slightly higher than Ligand B (109.65). Both are below the 140 A^2 threshold for good oral absorption, but closer to the ideal <90 A^2 for CNS targets (less relevant here, but still a positive). Ligand B is slightly favored.
**3. logP:** Both ligands have good logP values (1.537 and 1.335) falling within the optimal 1-3 range. No significant difference.
**4. H-Bond Donors:** Ligand A has 1 HBD, while Ligand B has 3. Ligand A is slightly favored as lower HBDs generally improve permeability.
**5. H-Bond Acceptors:** Ligand A has 5 HBA, and Ligand B has 8. Ligand A is favored, as it's closer to the <10 threshold.
**6. QED:** Ligand B (0.628) has a better QED score than Ligand A (0.495), indicating a more drug-like profile. This is a significant advantage for Ligand B.
**7. DILI Risk:** Ligand B (53.742) has a lower DILI risk than Ligand A (58.395), both are acceptable, but lower is better. Ligand B is favored.
**8. BBB Penetration:** Ligand A (62.311) has better BBB penetration than Ligand B (36.797). While not a primary concern for a cardiovascular target, some brain exposure can sometimes lead to off-target effects.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-5.092 and -5.419). This is unusual and suggests poor permeability *in vitro*. However, these values are on a log scale, so the difference isn't massive.
**10. Aqueous Solubility:** Both ligands have very poor aqueous solubility (-2.641 and -2.094). This is a significant concern for both, potentially impacting bioavailability.
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.152 and 0.094). This is excellent for both.
**12. Microsomal Clearance:** Ligand B (42.658) has significantly higher microsomal clearance than Ligand A (8.004). This means Ligand A is more metabolically stable, a significant advantage.
**13. In vitro Half-Life:** Ligand B (21.334 hours) has a much longer in vitro half-life than Ligand A (2.49 hours). This is a substantial advantage for Ligand B, potentially allowing for less frequent dosing.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.031 and 0.011). This is favorable for both.
**15. Binding Affinity:** Ligand A (-8.4 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.2 kcal/mol). This is a >2 kcal/mol difference, which is a major advantage for Ligand A.
**GPCR-Specific Considerations:** For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A has a better affinity, slightly better TPSA, and comparable logP and Pgp.
**Overall Assessment:**
While Ligand B has advantages in QED, DILI risk, and *especially* in vitro half-life, the significantly superior binding affinity of Ligand A (-8.4 vs -6.2 kcal/mol) is the deciding factor. A strong binding affinity can often compensate for minor ADME shortcomings, and the metabolic stability of Ligand A is also a plus. The poor solubility is a concern for both, but can be addressed with formulation strategies.
Output:
1
2025-04-17 18:24:29,573 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (338.371) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (66.65) is significantly better than Ligand A (100.97). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA is still beneficial for absorption.
3. **logP:** Ligand B (2.1) is within the optimal range, while Ligand A (0.528) is quite low. Low logP can hinder membrane permeability. This is a significant drawback for Ligand A.
4. **HBD:** Ligand A (1) is preferable to Ligand B (0). While both are acceptable, having one HBD can improve solubility.
5. **HBA:** Ligand A (6) is higher than Ligand B (4), but both are within acceptable limits.
6. **QED:** Both ligands have good QED scores (A: 0.771, B: 0.811), indicating good drug-like properties.
7. **DILI:** Ligand B (44.048) has a much lower DILI risk than Ligand A (68.98). This is a crucial advantage for Ligand B.
8. **BBB:** Ligand B (86.39) has a higher BBB penetration percentile than Ligand A (31.02). While not critical for a cardiovascular target, it's not a negative.
9. **Caco-2:** Ligand A (-5.022) has a worse Caco-2 permeability than Ligand B (-4.536), indicating lower intestinal absorption.
10. **Solubility:** Ligand A (-1.762) has a worse solubility than Ligand B (-1.539).
11. **hERG:** Both ligands have low hERG inhibition liability (A: 0.103, B: 0.274), which is good.
12. **Cl_mic:** Ligand A (18.994) has a lower microsomal clearance than Ligand B (26.74), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-38.236) has a much longer in vitro half-life than Ligand A (3.856). This is a major advantage for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.004) has a lower Pgp efflux liability than Ligand B (0.094), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand B (-7.0) has a significantly stronger binding affinity than Ligand A (-6.2). This 0.8 kcal/mol difference is substantial and can outweigh some ADME concerns.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP, has a better TPSA, and a significantly better binding affinity. While Ligand A has better Pgp, the other factors outweigh this advantage.
**Overall Assessment:**
Ligand B is the superior candidate. Its stronger binding affinity, lower DILI risk, longer half-life, and better logP and TPSA values make it a more promising starting point for drug development, despite the slightly higher Pgp efflux. The substantial affinity difference is a key driver of this decision.
Output:
0
2025-04-17 18:24:29,573 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.471 and 351.531 Da) fall well within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (60.85) is higher than Ligand B (30.93). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B is significantly better.
3. **logP:** Ligand B (3.345) is slightly higher than Ligand A (2.262), but both are within the optimal 1-3 range.
4. **HBD:** Ligand A (1) has fewer HBD than Ligand B (0). Fewer HBD is generally favorable for permeability. Ligand A is better.
5. **HBA:** Ligand A (3) has fewer HBA than Ligand B (4). Similar to HBD, fewer HBA is generally better. Ligand A is better.
6. **QED:** Ligand A (0.719) has a slightly higher QED than Ligand B (0.671), indicating a more drug-like profile.
7. **DILI:** Ligand A (10.896) has a slightly higher DILI risk than Ligand B (8.181), but both are well below the concerning threshold of 60.
8. **BBB:** Ligand B (88.833) has a significantly higher BBB penetration percentile than Ligand A (73.711). While ADRB2 isn't strictly a CNS target, some CNS exposure can occur, and higher BBB is generally a positive.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.548 and -4.808), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand A (-1.889) has better solubility than Ligand B (-3.006). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.155) has a much lower hERG inhibition liability than Ligand B (0.868). This is a crucial advantage, as hERG inhibition can lead to cardiotoxicity.
12. **Cl_mic:** Ligand B (35.536) has higher microsomal clearance than Ligand A (26.256), suggesting faster metabolism and potentially lower exposure. Ligand A is better.
13. **t1/2:** Ligand B (31.757) has a much longer in vitro half-life than Ligand A (-4.905). This is a significant advantage, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.064) has lower P-gp efflux liability than Ligand B (0.333). Lower P-gp efflux is favorable for bioavailability.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.7 and -6.8 kcal/mol). The difference is negligible.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), and the general drug-like properties, Ligand A appears to be the better candidate. While Ligand B has a longer half-life and better BBB penetration, Ligand A has a significantly lower hERG risk, better solubility, lower P-gp efflux, and a slightly better QED. The poor Caco-2 values are a concern for both, but the hERG risk is a critical factor for cardiovascular drugs. The slightly lower TPSA of Ligand B is offset by the other advantages of Ligand A.
Output:
1
2025-04-17 18:24:29,574 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (387.531 Da and 365.459 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (96.45) is better than Ligand B (110.16). For a GPCR, keeping TPSA under 140 is good for oral absorption, and lower is generally preferred.
**3. logP:** Both ligands have acceptable logP values (1.45 and 0.963, respectively), falling within the 1-3 range. Ligand A is slightly better.
**4. H-Bond Donors:** Ligand A (2) is slightly higher than Ligand B (1), but both are within the acceptable limit of 5.
**5. H-Bond Acceptors:** Ligand A (7) is higher than Ligand B (5), but both are within the acceptable limit of 10.
**6. QED:** Both ligands have good QED scores (0.656 and 0.854), indicating good drug-like properties. Ligand B is better here.
**7. DILI:** Both ligands have similar, acceptable DILI risk (51.493 and 50.136 percentile).
**8. BBB:** Ligand A (80.574) has a significantly better BBB penetration score than Ligand B (49.942). While ADRB2 is a cardiovascular target, some brain exposure can be relevant due to sympathetic nervous system involvement, and higher BBB is generally favorable.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-5.298 and -5.067), which is unusual and indicates poor permeability. This is a significant drawback for both.
**10. Aqueous Solubility:** Both ligands have very poor aqueous solubility (-2.804 and -3.5). This is a major concern for bioavailability.
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (0.218 and 0.335), which is excellent.
**12. Microsomal Clearance:** Ligand A (23.109) has slightly higher microsomal clearance than Ligand B (21.192), suggesting slightly lower metabolic stability.
**13. In vitro Half-Life:** Ligand B (-45.489) has a *much* longer in vitro half-life than Ligand A (3.947). This is a substantial advantage for Ligand B.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.035 and 0.026), which is good.
**15. Binding Affinity:** Ligand B (-5.1 kcal/mol) has a slightly better binding affinity than Ligand A (-4.2 kcal/mol). The difference is 0.9 kcal/mol, which is meaningful.
**Overall Assessment:**
Ligand B is better overall. The significantly longer half-life and slightly improved binding affinity outweigh the slightly better TPSA and BBB of Ligand A. The poor solubility and Caco-2 permeability are concerning for both, but can potentially be addressed with formulation strategies. The DILI risk is acceptable for both. Given the GPCR target class, the binding affinity is paramount, and Ligand B edges out Ligand A in this regard.
Output:
0
2025-04-17 18:24:29,574 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
Let's break down the comparison, prioritizing GPCR-relevant parameters (logP, TPSA, Pgp, BBB, and Affinity).
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (366.893) is slightly higher than Ligand B (347.463), but this difference isn't critical.
2. **TPSA:** Both are good, below the 140 A^2 threshold for oral absorption. Ligand B (72.28) is slightly better than Ligand A (78.09), leaning towards better permeability.
3. **logP:** Both ligands have acceptable logP values (Ligand A: 2.856, Ligand B: 1.316), falling within the 1-3 range. Ligand A is preferable here.
4. **H-Bond Donors/Acceptors:** Ligand A (2 HBD, 3 HBA) is slightly better than Ligand B (1 HBD, 6 HBA) in terms of balancing solubility and permeability.
5. **QED:** Both are reasonably good (A: 0.86, B: 0.753), indicating good drug-like properties.
6. **DILI:** Both have acceptable DILI risk, with Ligand B (33.307) being slightly better than Ligand A (39.201).
7. **BBB:** Both have good BBB penetration (A: 75.107, B: 72.043). This is important for a GPCR, but less critical for ADRB2 specifically as it's not a primary CNS target.
8. **Caco-2 Permeability:** Both are negative, indicating poor permeability. This is a concern for both.
9. **Aqueous Solubility:** Both are negative, indicating poor solubility. This is a concern for both.
10. **hERG Inhibition:** Both have very low hERG inhibition risk (A: 0.454, B: 0.073), which is excellent. Ligand B is significantly better here.
11. **Microsomal Clearance:** Ligand A (27.835) has lower clearance than Ligand B (32.939), suggesting better metabolic stability.
12. **In vitro Half-Life:** Ligand B (32.573) has a much longer half-life than Ligand A (-26.41), which is a significant advantage.
13. **P-gp Efflux:** Both have low P-gp efflux (A: 0.09, B: 0.067), which is favorable.
14. **Binding Affinity:** Ligand A (-7.7 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.9 kcal/mol). This is a 0.8 kcal/mol difference, which is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
The key differentiator is the binding affinity. Ligand A's -7.7 kcal/mol is a strong advantage. While Ligand B has a better half-life and hERG profile, the potency advantage of Ligand A is more crucial for a GPCR target. The slightly better metabolic stability of Ligand A is also a plus. The poor Caco-2 and solubility of both are concerns, but these can be addressed through formulation strategies.
Output:
1
2025-04-17 18:24:29,574 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
We are targeting ADRB2, a GPCR. Therefore, priorities are logP, Pgp, TPSA, affinity, and BBB. Let's analyze each ligand against these and other key parameters.
* **Molecular Weight:** Both ligands (339.37 and 348.447 Da) fall within the ideal 200-500 Da range.
* **TPSA:** Ligand A (67.01) is better than Ligand B (76.46), being closer to the <140 threshold for good absorption.
* **logP:** Ligand A (3.428) is slightly higher than Ligand B (1.278), and both are within the optimal 1-3 range, but Ligand A is closer to the upper limit.
* **H-Bond Donors/Acceptors:** Ligand A (2 HBD, 3 HBA) is slightly more favorable than Ligand B (1 HBD, 5 HBA).
* **QED:** Ligand B (0.753) has a higher QED score than Ligand A (0.534), suggesting better overall drug-likeness.
* **DILI:** Ligand B (43.117) has a significantly lower DILI risk than Ligand A (86.933). This is a major advantage.
* **BBB:** Ligand A (71.772) has a better BBB penetration score than Ligand B (56.223). While ADRB2 isn't necessarily a CNS target, some peripheral ADRB2 activity can be modulated by CNS effects, so this is a slight positive for A.
* **Caco-2 Permeability:** Both are negative, indicating poor permeability.
* **Aqueous Solubility:** Both are very poor.
* **hERG:** Ligand A (0.884) has a slightly higher hERG risk than Ligand B (0.096).
* **Microsomal Clearance:** Ligand B (20.023) has a lower microsomal clearance than Ligand A (33.859), indicating better metabolic stability.
* **In vitro Half-Life:** Ligand A (-6.446) has a longer in vitro half-life than Ligand B (-4.051).
* **P-gp Efflux:** Ligand A (0.503) has a lower P-gp efflux liability than Ligand B (0.04).
* **Binding Affinity:** Ligand A (-6.9 kcal/mol) has a slightly better binding affinity than Ligand B (-6.6 kcal/mol). This is a 0.3 kcal/mol difference, which is not huge but still relevant.
**Overall Assessment:**
Ligand B is the stronger candidate. While Ligand A has a slightly better affinity and BBB penetration, Ligand B's significantly lower DILI risk and better metabolic stability (lower Cl_mic) are critical advantages. The QED score is also higher for Ligand B. The poor Caco-2 and solubility for both are concerning and would need to be addressed in further optimization, but the safety profile of Ligand B is much more promising. The slightly weaker affinity of Ligand B can likely be improved during lead optimization.
**Output:**
0
2025-04-17 18:24:29,574 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (341.451 and 351.422 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (55.4) is significantly better than Ligand B (82.53). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (3.202) is optimal, while Ligand B (1.649) is on the lower side. For a GPCR, a logP in the 1-3 range is preferred, and A is better positioned.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (4). Fewer HBAs generally improve permeability.
6. **QED:** Ligand A (0.856) is significantly better than Ligand B (0.663), indicating a more drug-like profile.
7. **DILI:** Both ligands have acceptable DILI risk (Ligand A: 30.748, Ligand B: 34.432). No major concern for either.
8. **BBB:** Ligand A (67.468) is better than Ligand B (58.821), but since this is a cardiovascular target, BBB isn't a critical factor.
9. **Caco-2:** Both have negative values, indicating permeability issues. Ligand A (-4.329) is slightly better than Ligand B (-4.78).
10. **Solubility:** Ligand A (-4.625) is better than Ligand B (-1.21). Solubility is important for bioavailability.
11. **hERG:** Both ligands have low hERG inhibition risk (Ligand A: 0.464, Ligand B: 0.512).
12. **Cl_mic:** Ligand B (29.591) has significantly lower microsomal clearance than Ligand A (82.633), suggesting better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand B (25.254) has a much longer in vitro half-life than Ligand A (-0.943). This is a major advantage.
14. **Pgp:** Ligand A (0.265) is better than Ligand B (0.119), indicating lower P-gp efflux.
15. **Binding Affinity:** Ligand B (-7.1) has a slightly better binding affinity than Ligand A (-5.9). This is a 1.2 kcal/mol difference, which is substantial.
**Overall Assessment:**
Ligand B exhibits a significantly better metabolic profile (lower Cl_mic, longer t1/2) and slightly better binding affinity. While Ligand A has advantages in TPSA, logP, QED, solubility, and Pgp efflux, the improvements in metabolic stability and binding affinity of Ligand B outweigh these factors, especially for a GPCR target where potency is crucial. The slightly lower logP of Ligand B is not a major concern.
**Output:**
0
2025-04-17 18:24:29,574 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [350.503, 78.43, 2.541, 3, 3, 0.589, 16.402, 44.785, -4.688, -2.856, 0.183, 44.914, 9.728, 0.076, -6.6]
**Ligand B:** [387.311, 82.11, 3.422, 2, 4, 0.484, 57.891, 43.544, -5.58, -3.601, 0.793, 48.203, 55.653, 0.577, -3]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (350.5) is slightly preferred.
2. **TPSA:** Both are reasonably low (A: 78.43, B: 82.11), suggesting good potential for absorption.
3. **logP:** Both are within the optimal range (1-3), with A (2.541) being slightly better. B is a bit higher at 3.422.
4. **HBD:** A has 3, B has 2. Both are acceptable.
5. **HBA:** A has 3, B has 4. Both are acceptable.
6. **QED:** A (0.589) is better than B (0.484), indicating a more drug-like profile.
7. **DILI:** A (16.402) is significantly better than B (57.891). This is a major advantage for A.
8. **BBB:** Both are similar (A: 44.785, B: 43.544), not particularly high, but acceptable for a non-CNS target like cardiovascular ADRB2.
9. **Caco-2:** A (-4.688) is better than B (-5.58), suggesting better intestinal absorption.
10. **Solubility:** A (-2.856) is better than B (-3.601), indicating better aqueous solubility.
11. **hERG:** A (0.183) is much better than B (0.793), indicating a lower risk of cardiotoxicity. This is a critical advantage.
12. **Cl_mic:** Both are similar (A: 44.914, B: 48.203).
13. **t1/2:** B (55.653) has a significantly longer half-life than A (9.728). This is a positive for B.
14. **Pgp:** A (0.076) is much better than B (0.577), indicating lower P-gp efflux.
15. **Affinity:** A (-6.6) is significantly better than B (-3). This is a substantial advantage for A.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, affinity, logP, TPSA, Pgp, and metabolic stability are key. A has a much better affinity and Pgp profile. While B has a better half-life, the significantly better affinity, lower DILI risk, and lower hERG risk of A outweigh this advantage.
**Conclusion:**
Ligand A is the superior candidate due to its significantly better binding affinity, lower DILI and hERG risk, better solubility, and lower P-gp efflux, despite B having a longer half-life.
1
2025-04-17 18:24:29,575 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (366.571) is slightly higher than Ligand B (352.435), but both are acceptable.
2. **TPSA:** Ligand A (49.41) is excellent, well below the 140 threshold and favorable for oral absorption. Ligand B (106.78) is higher, but still within a reasonable range, though less optimal.
3. **logP:** Ligand A (3.657) is within the optimal range (1-3). Ligand B (1.296) is at the lower end, potentially impacting permeability.
4. **HBD:** Ligand A (1) and Ligand B (2) both have acceptable HBD counts.
5. **HBA:** Ligand A (3) and Ligand B (6) both have acceptable HBA counts.
6. **QED:** Both ligands have similar QED values (A: 0.748, B: 0.649), indicating good drug-likeness.
7. **DILI:** Ligand A (41.373) has a slightly better DILI risk profile than Ligand B (58.976), both are acceptable.
8. **BBB:** Ligand A (72.005) shows better BBB penetration than Ligand B (67.546). While not a primary concern for ADRB2 (cardiovascular target), some CNS exposure can sometimes occur with peripherally-acting drugs, and higher BBB is generally favorable.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.215 and -5.114), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand A (-4.78) has slightly better solubility than Ligand B (-2.152), but both are poor.
11. **hERG:** Ligand A (0.604) has a better hERG profile than Ligand B (0.327), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand B (30.413) has significantly lower microsomal clearance than Ligand A (107.135), suggesting better metabolic stability.
13. **t1/2:** Ligand A (8.763) has a longer in vitro half-life than Ligand B (5.728).
14. **Pgp:** Ligand A (0.624) has a lower P-gp efflux liability than Ligand B (0.034), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand B (-7.6) has a significantly stronger binding affinity than Ligand A (-5.7). This is a substantial advantage (1.9 kcal/mol difference).
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, Pgp, TPSA, and affinity. Ligand B excels in affinity, which is the most important factor. While Ligand A has better TPSA and Pgp, the substantial affinity difference of Ligand B outweighs these drawbacks. The lower logP of Ligand B is a concern, but the strong binding could compensate. The poor Caco-2 and solubility are concerning for both, but can be addressed with formulation strategies.
**Conclusion:**
Despite the lower logP, solubility, and Caco-2 permeability, the significantly stronger binding affinity of Ligand B makes it the more promising candidate. The affinity difference is large enough to potentially overcome the ADME challenges.
Output:
0
2025-04-17 18:24:29,575 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.487 and 368.587 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Both ligands (58.64 and 58.2) are below the 140 A^2 threshold for good oral absorption, and well below the 90 A^2 for CNS targets (though ADRB2 isn't necessarily a CNS target, lower TPSA is generally favorable). Again, no strong difference.
3. **logP:** Ligand A (2.513) is within the optimal 1-3 range. Ligand B (3.603) is slightly higher, approaching the upper limit where solubility issues might arise. Ligand A is slightly preferred.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2) as lower HBD generally improves permeability.
5. **HBA:** Both ligands have 3 HBA, which is well within the acceptable range.
6. **QED:** Ligand A (0.719) has a slightly higher QED score than Ligand B (0.675), indicating a more drug-like profile.
7. **DILI:** Ligand A (21.675%) has a significantly lower DILI risk than Ligand B (17.371%). This is a substantial advantage for Ligand A.
8. **BBB:** Both ligands have high BBB penetration (71.811% and 70.997%), which isn't a primary concern for ADRB2 but isn't detrimental.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. This is a significant drawback for both. Ligand B (-4.941) is slightly worse than Ligand A (-4.667).
10. **Solubility:** Ligand A (-2.116) has better solubility than Ligand B (-4.042).
11. **hERG:** Both ligands have low hERG inhibition liability (0.346 and 0.594), which is good.
12. **Cl_mic:** Ligand A (43.312) has a lower microsomal clearance than Ligand B (76.779), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-11.696) has a more negative in vitro half-life (meaning shorter half-life) than Ligand B (15.548). This is a disadvantage for Ligand A.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.261 and 0.145), which is favorable. Ligand B is slightly better.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.5 and -6.3 kcal/mol). The difference is not substantial enough to override other factors.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Both ligands perform reasonably well on these, but Ligand A has a better logP and lower Pgp efflux.
**Overall Assessment:**
Ligand A is preferable due to its superior DILI risk, better solubility, lower microsomal clearance (better metabolic stability), and slightly better logP and Caco-2 permeability. While Ligand A has a shorter in vitro half-life, the other advantages outweigh this drawback. The similar binding affinities mean that the ADME properties become the deciding factors.
Output:
1
2025-04-17 18:24:29,575 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (353.491 and 352.475 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (37.61) is significantly better than Ligand B (84.5). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is quite high, potentially hindering oral absorption.
3. **logP:** Ligand A (4.108) is slightly higher than Ligand B (2.31). While both are within the acceptable range (1-3 is optimal, up to 4 is tolerable), Ligand A is pushing the upper limit. Ligand B is better here.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer hydrogen bond donors generally improve membrane permeability.
5. **HBA:** Both ligands have 4 HBA, which is acceptable.
6. **QED:** Ligand A (0.711) has a better QED score than Ligand B (0.467), indicating a more drug-like profile.
7. **DILI:** Ligand B (30.981) has a much lower DILI risk than Ligand A (50.174). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (92.361) has a much higher BBB penetration percentile than Ligand B (64.831). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be useful for understanding off-target effects and distribution.
9. **Caco-2:** Both ligands have similar, poor Caco-2 permeability (-4.799 and -4.988). This suggests potential absorption issues for both.
10. **Solubility:** Both ligands have very poor aqueous solubility (-3.803 and -3.052). This is a concern for both, requiring formulation strategies.
11. **hERG:** Both ligands have low hERG inhibition risk (0.93 and 0.444).
12. **Cl_mic:** Ligand B (52.014) has a lower microsomal clearance than Ligand A (60.144), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-17.954) has a longer in vitro half-life than Ligand B (-7.331). This is a positive for Ligand A.
14. **Pgp:** Both ligands have similar Pgp efflux liability (0.929 and 0.125).
15. **Affinity:** Ligand B (-6.7) has a slightly better binding affinity than Ligand A (-6.0). While the difference is not huge, it's still a factor.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, and affinity. Ligand A has a better logP, and BBB penetration, while Ligand B has better TPSA, DILI and affinity. The TPSA difference is substantial, and the DILI risk for Ligand A is concerning. The affinity difference is small enough that it's outweighed by the other factors.
**Overall Assessment:**
Despite Ligand A's better BBB penetration and half-life, Ligand B is the more promising candidate. Its significantly lower DILI risk, better TPSA, and slightly better affinity make it a more favorable starting point for optimization. The solubility and Caco-2 permeability issues are present in both, and would need to be addressed through formulation or structural modifications.
Output:
0
2025-04-17 18:24:29,575 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, prioritizing logP, TPSA, Pgp, and affinity is crucial.
* **Molecular Weight:** Both ligands are within the acceptable range (200-500 Da). Ligand A (352.391) is slightly lower, which is generally favorable for permeability.
* **TPSA:** Ligand B (69.64) is significantly better than Ligand A (112.41). Lower TPSA is preferred for GPCRs to facilitate membrane permeability.
* **logP:** Both ligands have acceptable logP values (1-3), but Ligand B (2.668) is slightly higher, potentially improving membrane permeability.
* **H-Bond Donors/Acceptors:** Ligand A has 1 HBD and 8 HBA, while Ligand B has 2 HBD and 4 HBA. Both are within acceptable ranges, but Ligand B has a lower count, which is slightly favorable.
* **QED:** Ligand A (0.729) has a better QED score than Ligand B (0.606), indicating better overall drug-likeness.
* **DILI:** Ligand B (30.71) has a much lower DILI risk than Ligand A (73.245), which is a significant advantage.
* **BBB:** Ligand A (71.811) has a slightly better BBB penetration potential than Ligand B (34.742), but BBB is less critical for a cardiovascular target.
* **Caco-2 Permeability:** Both are negative, indicating poor permeability. Ligand A (-4.642) is slightly better than Ligand B (-4.944).
* **Aqueous Solubility:** Both have negative solubility values, indicating poor solubility. Ligand A (-3.057) is slightly better than Ligand B (-3.279).
* **hERG Inhibition:** Ligand A (0.05) has a much lower hERG inhibition liability than Ligand B (0.708), which is a critical safety advantage.
* **Microsomal Clearance:** Ligand B (60.305) has a lower microsomal clearance than Ligand A (74.802), suggesting better metabolic stability.
* **In vitro Half-Life:** Ligand B (20.979) has a significantly longer half-life than Ligand A (-19.638), which is a major advantage.
* **P-gp Efflux:** Ligand A (0.166) has lower P-gp efflux liability than Ligand B (0.212), which is favorable.
* **Binding Affinity:** Ligand A (-7.2 kcal/mol) has a stronger binding affinity than Ligand B (-5.9 kcal/mol). This is a substantial advantage and can potentially offset some of the ADME drawbacks of Ligand A.
**Overall Assessment:**
While Ligand A has a better binding affinity and QED, Ligand B demonstrates a significantly better safety profile (lower DILI, lower hERG) and improved pharmacokinetic properties (lower Cl_mic, longer t1/2). The lower TPSA of Ligand B is also a significant advantage for a GPCR target. The difference in binding affinity, while substantial, might be overcome with further optimization of Ligand B, while the safety and PK issues with Ligand A are harder to resolve.
**Output:**
0
2025-04-17 18:24:29,575 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (367.471 and 354.407 Da) are within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (87.74) is better than Ligand B (114.2). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally aids absorption.
3. **logP:** Ligand B (-0.948) is slightly less optimal than Ligand A (-0.392) but both are acceptable. Ideally, we want values between 1-3.
4. **HBD:** Both ligands have 2 HBD, which is within the acceptable limit of <=5.
5. **HBA:** Ligand A has 6 HBA, and Ligand B has 5. Both are within the acceptable limit of <=10.
6. **QED:** Ligand B (0.638) is slightly better than Ligand A (0.51), indicating a more drug-like profile.
7. **DILI:** Ligand A (25.63) has a significantly lower DILI risk than Ligand B (32.842). This is a substantial advantage.
8. **BBB:** Ligand B (75.184) has a higher BBB penetration percentile than Ligand A (56.65). While ADRB2 is cardiovascular, some CNS off-target effects are possible, so moderate BBB penetration isn't necessarily a negative.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.249 and -5.404), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-2.461) has slightly better solubility than Ligand B (-1.051).
11. **hERG:** Both ligands have very low hERG inhibition risk (0.16 and 0.093).
12. **Cl_mic:** Ligand B (-18.087) has a significantly lower microsomal clearance than Ligand A (23.39). This suggests better metabolic stability for Ligand B.
13. **t1/2:** Ligand B (6.005) has a longer in vitro half-life than Ligand A (-3.669). This is a significant advantage.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.015 and 0.004).
15. **Binding Affinity:** Ligand A (-8.4 kcal/mol) has a substantially stronger binding affinity than Ligand B (-6.3 kcal/mol). This is a 2.1 kcal/mol difference, which is a very significant advantage, and often outweighs minor ADME concerns.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has better TPSA and a much better binding affinity. Ligand B has slightly better logP and a longer half-life. The DILI risk is also a major factor, and Ligand A is significantly better here.
**Conclusion:**
The significantly stronger binding affinity of Ligand A (-8.4 kcal/mol vs -6.3 kcal/mol) and the lower DILI risk outweigh the slightly better metabolic stability and half-life of Ligand B. While both have poor Caco-2 permeability, the potency advantage of Ligand A is crucial for a GPCR target.
Output:
1
2025-04-17 18:24:29,576 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [364.364, 89.87, 0.568, 3, 4, 0.68, 21.946, 64.637, -4.925, -1.657, 0.444, -20.225, -11.647, 0.008, -5.8]
**Ligand B:** [350.394, 76.98, -0.04, 1, 5, 0.825, 25.436, 60.76, -4.441, -0.195, 0.282, -3.75, -9.133, 0.023, -5.7]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity) and general drug-like properties:
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (350.394) is slightly lower, which is generally favorable.
2. **TPSA:** Both are good, below 140. Ligand B (76.98) is better than Ligand A (89.87), promoting better absorption.
3. **logP:** Ligand A (0.568) is a bit low, potentially hindering membrane permeability. Ligand B (-0.04) is also on the lower side, but slightly better. Both could benefit from increased lipophilicity.
4. **HBD/HBA:** Ligand A (3 HBD, 4 HBA) is slightly better balanced than Ligand B (1 HBD, 5 HBA).
5. **QED:** Ligand B (0.825) has a better QED score than Ligand A (0.68), indicating a more drug-like profile.
6. **DILI:** Ligand A (21.946) has a significantly lower DILI risk than Ligand B (25.436), a major advantage.
7. **BBB:** Both have moderate BBB penetration, but Ligand A (64.637) is slightly better than Ligand B (60.76). While not a primary concern for a cardiovascular target, some CNS penetration is not necessarily detrimental.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.925) is worse than Ligand B (-4.441).
9. **Solubility:** Both have negative solubility values, which is also unusual and suggests poor solubility. Ligand B (-0.195) is slightly better than Ligand A (-1.657).
10. **hERG:** Both have low hERG risk (0.444 and 0.282 respectively).
11. **Cl_mic:** Ligand A (-20.225) has significantly better metabolic stability (lower clearance) than Ligand B (-3.75). This is a crucial advantage.
12. **t1/2:** Ligand A (-11.647) has a slightly better in vitro half-life than Ligand B (-9.133).
13. **Pgp:** Both have very low Pgp efflux liability (0.008 and 0.023 respectively).
14. **Affinity:** Both have very similar binding affinities (-5.8 and -5.7 kcal/mol). The difference is negligible.
**Overall Assessment:**
While Ligand B has a better QED and slightly better TPSA and solubility, Ligand A wins out due to its significantly lower DILI risk and better metabolic stability (Cl_mic). The similar affinities mean these factors become decisive. The negative Caco-2 and solubility values are concerning for both, but the metabolic stability advantage of Ligand A is more critical for a successful drug candidate.
Output:
1
2025-04-17 18:24:29,576 - INFO - Batch 35 complete. Total preferences: 560
2025-04-17 18:24:29,576 - INFO - Processing batch 36/512...
2025-04-17 18:25:16,410 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (345.407) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (90.96) is better than Ligand B (38.13). For a cardiovascular GPCR, lower TPSA is generally preferred for better membrane permeability.
3. **logP:** Ligand B (3.88) is better than Ligand A (0.458). A logP between 1-3 is optimal, and Ligand B is within this range, while Ligand A is quite low, potentially hindering permeation.
4. **HBD:** Both have 0 HBD, which is acceptable.
5. **HBA:** Ligand A (8) is higher than Ligand B (4). Lower HBA is generally preferred for permeability.
6. **QED:** Both ligands have good QED scores (A: 0.677, B: 0.74), indicating good drug-like properties.
7. **DILI:** Ligand B (25.94) has a significantly lower DILI risk than Ligand A (73.09), which is a major advantage.
8. **BBB:** Ligand B (84.839) has a much higher BBB penetration score than Ligand A (62.97). While ADRB2 isn't a CNS target, higher BBB is generally a positive indicator of reduced off-target effects.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and difficult to interpret without knowing the scale. I will assume these are percentile scores, and both are very poor.
10. **Solubility:** Ligand A (-1.145) has better solubility than Ligand B (-4.271). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.062) has a lower hERG risk than Ligand B (0.516), which is a significant advantage for cardiovascular drugs.
12. **Cl_mic:** Ligand A (19.67) has a much lower microsomal clearance than Ligand B (111.822), indicating better metabolic stability.
13. **t1/2:** Ligand A (29.464) has a longer in vitro half-life than Ligand B (8.216), which is desirable.
14. **Pgp:** Ligand B (0.667) has higher P-gp efflux than Ligand A (0.018). Lower Pgp is preferred for better bioavailability.
15. **Affinity:** Ligand A (-6.6) has slightly better binding affinity than Ligand B (-5.7). However, the difference is less than 1.5 kcal/mol.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP and BBB, while Ligand A has better TPSA, Pgp, Cl_mic, t1/2, and a slightly better affinity. However, the significant DILI risk and hERG liability associated with Ligand A are concerning for a cardiovascular target.
**Overall Assessment:**
While Ligand A has a slightly better affinity and metabolic stability, the significantly lower DILI risk and better logP of Ligand B outweigh these advantages. The hERG risk of Ligand A is also a major concern for a cardiovascular drug. The poor Caco-2 values for both are a concern, but can be addressed during lead optimization.
**Output:**
0
2025-04-17 18:25:16,411 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (344.499 Da) is slightly lower, which is generally favorable for permeability.
**2. TPSA:** Ligand A (49.41) is significantly better than Ligand B (77.81). For a GPCR, keeping TPSA low is beneficial for permeability and receptor engagement. Ligand B is approaching a level that could hinder oral absorption.
**3. logP:** Both ligands have logP values within the optimal range (1-3), but Ligand B (4.103) is pushing the upper limit. This could potentially lead to solubility issues and off-target interactions. Ligand A (3.417) is more favorable.
**4. H-Bond Donors/Acceptors:** Ligand A (HBD=1, HBA=2) is better than Ligand B (HBD=2, HBA=5). Lower counts are generally preferred for better permeability.
**5. QED:** Both ligands have similar, good QED values (0.777 and 0.779), indicating good drug-like properties.
**6. DILI:** Ligand A (40.054) has a much lower DILI risk than Ligand B (72.858). This is a significant advantage for Ligand A.
**7. BBB:** Ligand A (66.382) has a better BBB percentile than Ligand B (51.415). While ADRB2 isn't exclusively a CNS target, some CNS exposure can occur, and higher BBB penetration is generally desirable.
**8. Caco-2 Permeability:** Ligand A (-5.023) has better Caco-2 permeability than Ligand B (-4.762).
**9. Aqueous Solubility:** Ligand A (-4.458) has better aqueous solubility than Ligand B (-5.705).
**10. hERG Inhibition:** Ligand A (0.23) has a much lower hERG inhibition liability than Ligand B (0.724). This is a critical safety parameter, and Ligand A is significantly better.
**11. Microsomal Clearance:** Both ligands have similar microsomal clearance values (57.423 and 56.004 mL/min/kg).
**12. In vitro Half-Life:** Ligand B (89.973) has a significantly longer in vitro half-life than Ligand A (-14.188). This is a positive for Ligand B.
**13. P-gp Efflux:** Ligand A (0.41) has lower P-gp efflux liability than Ligand B (0.571).
**14. Binding Affinity:** Both ligands have very similar and strong binding affinities (-5.8 and -5.1 kcal/mol). The difference of 0.7 kcal/mol is not substantial enough to outweigh the ADME advantages of Ligand A.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across several crucial ADME properties (TPSA, logP, DILI, hERG, Solubility, BBB, Caco-2, P-gp). While Ligand B has a better in vitro half-life, the safety and permeability advantages of Ligand A are more important for overall drug development success, especially considering the GPCR target class. The binding affinity difference is minimal.
Output:
1
2025-04-17 18:25:16,411 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.415 and 380.495 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (92.62) is better than Ligand B (97.55), both are below the 140 threshold for oral absorption, but closer to the 90 threshold is preferred.
3. **logP:** Both ligands have good logP values (2.658 and 1.756), falling within the optimal 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (7). Lower HBA generally improves permeability.
6. **QED:** Both ligands have similar QED values (0.88 and 0.842), indicating good drug-likeness.
7. **DILI:** Both ligands have relatively high DILI risk (80.535 and 77.433). This is a concern for both, but not a deciding factor between them.
8. **BBB:** Both ligands have similar BBB penetration (60.527 and 65.258). While not exceptionally high, it's not a primary concern for ADRB2 which is not a CNS target.
9. **Caco-2:** Ligand A (-4.734) is better than Ligand B (-5.082). Higher values indicate better absorption.
10. **Solubility:** Ligand A (-2.87) is better than Ligand B (-2.933). Higher solubility is generally desirable.
11. **hERG:** Ligand A (0.011) is significantly better than Ligand B (0.387), indicating a much lower risk of cardiotoxicity. This is a *critical* advantage for a cardiovascular target.
12. **Cl_mic:** Ligand B (10.434) has lower microsomal clearance than Ligand A (16.905), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-9.37) has a longer in vitro half-life than Ligand A (-21.112), which is a positive.
14. **Pgp:** Ligand A (0.012) is better than Ligand B (0.095), indicating lower P-gp efflux.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.6 and -6.8 kcal/mol). The difference is negligible.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, and affinity are important. Both ligands are acceptable in these areas. However, minimizing off-target effects, particularly cardiotoxicity (hERG), is paramount for a cardiovascular drug. Ligand A has a substantially lower hERG risk.
**Overall Assessment:**
Ligand A is the better candidate. While Ligand B has slightly better metabolic stability and half-life, Ligand A's significantly lower hERG risk and better overall ADME profile (TPSA, solubility, Pgp) outweigh these minor advantages. The similar binding affinities make the ADME properties the deciding factor.
Output:
1
2025-04-17 18:25:16,411 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.4 and 350.4 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (63.94) is significantly better than Ligand B (106.23). For a GPCR, lower TPSA is generally preferred for permeability. Ligand B is above the 90 A^2 threshold, which is concerning.
3. **logP:** Ligand A (2.58) is optimal, while Ligand B (0.736) is a bit low, potentially impacting membrane permeability.
4. **HBD:** Both ligands have acceptable HBD counts (1 and 2 respectively), well below the 5 threshold.
5. **HBA:** Ligand A (4) is better than Ligand B (6), but both are within the acceptable range of 10.
6. **QED:** Both ligands have good QED scores (0.885 and 0.754), indicating good drug-like properties.
7. **DILI:** Ligand A (27.3) has a much lower DILI risk than Ligand B (48.97). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (89.69) has excellent BBB penetration potential, while Ligand B (52.23) is considerably lower. While ADRB2 isn't exclusively a CNS target, good BBB penetration can still be beneficial and reduce off-target effects.
9. **Caco-2:** Ligand A (-4.434) is better than Ligand B (-5.083) indicating better intestinal absorption.
10. **Solubility:** Ligand A (-2.761) is better than Ligand B (-2.168), which is a slight advantage.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.492 and 0.05), which is excellent.
12. **Cl_mic:** Both ligands have similar microsomal clearance (18.26 and 17.85), suggesting comparable metabolic stability.
13. **t1/2:** Ligand A (41.68) has a significantly longer *in vitro* half-life than Ligand B (-7.95). This is a major advantage, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.063 and 0.056).
15. **Binding Affinity:** Ligand B (-6.6 kcal/mol) is slightly better than Ligand A (-4.7 kcal/mol). However, the difference is not large enough to outweigh the numerous advantages of Ligand A.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A is superior in logP and TPSA. Both are good on Pgp. Ligand B has slightly better affinity, but the other ADME properties of Ligand A are much more favorable.
**Conclusion:**
Ligand A demonstrates a significantly better overall profile, particularly regarding TPSA, DILI risk, BBB penetration, and *in vitro* half-life. While Ligand B has slightly better binding affinity, the other advantages of Ligand A outweigh this difference, making it the more promising drug candidate.
Output:
1
2025-04-17 18:25:16,411 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (376.909 Da) is slightly higher than Ligand B (358.385 Da), but both are acceptable.
2. **TPSA:** Ligand A (53.43) is better than Ligand B (75.71). For a GPCR, lower TPSA is generally preferred for better permeability, though both are reasonably acceptable.
3. **logP:** Ligand A (4.087) is a bit high, potentially leading to solubility issues and off-target interactions. Ligand B (1.055) is excellent, falling squarely within the optimal range. This is a significant advantage for Ligand B.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Both ligands have 4 HBA, which is good.
6. **QED:** Ligand A (0.855) has a much better QED score than Ligand B (0.494), indicating a more drug-like profile.
7. **DILI:** Ligand B (30.903) has a significantly lower DILI risk than Ligand A (64.056). This is a major advantage for Ligand B.
8. **BBB:** Both ligands have good BBB penetration (Ligand A: 70.531, Ligand B: 73.633). This is less critical for ADRB2 (a cardiovascular target) but still a positive.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual. I'll interpret this as very low permeability.
10. **Solubility:** Ligand B (-2.319) has better solubility than Ligand A (-5.287). This is important, especially given Ligand A's higher logP.
11. **hERG:** Ligand A (0.58) has a slightly higher hERG risk than Ligand B (0.315), but both are relatively low.
12. **Cl_mic:** Ligand B (54.197) has a slightly higher clearance than Ligand A (52.517). This suggests Ligand A may be more metabolically stable.
13. **t1/2:** Ligand B (-47.491) has a very negative in vitro half-life, indicating very rapid metabolism. Ligand A (34.418) is much better. This is a significant drawback for Ligand B.
14. **Pgp:** Ligand A (0.692) has slightly higher Pgp efflux than Ligand B (0.028), which is not ideal, but not a major concern.
15. **Binding Affinity:** Ligand A (-7.3 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.5 kcal/mol). This is a substantial advantage for Ligand A. A 1.5 kcal/mol difference in binding is often enough to overcome other deficiencies.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP and Pgp, while Ligand A has a significantly better affinity. The TPSA difference is moderate. The DILI risk of Ligand B is a strong positive. However, the extremely poor in vitro half-life of Ligand B is a critical flaw.
**Overall Assessment:**
Despite Ligand B's advantages in logP, DILI, and Pgp, the significantly stronger binding affinity of Ligand A, combined with its better in vitro half-life and acceptable QED, makes it the more promising candidate. The higher logP of Ligand A is a concern, but formulation strategies can often mitigate solubility issues. The rapid metabolism of Ligand B is a more difficult problem to address.
Output:
1
2025-04-17 18:25:16,411 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.471 and 353.463 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (64.36) is better than Ligand B (73.32). Both are below 140, but lower TPSA is generally preferred for better absorption, especially for a GPCR.
3. **logP:** Ligand A (4.904) is higher than Ligand B (-0.071). While Ligand A is at the upper end of the optimal range, Ligand B is significantly *below* the optimal range, potentially hindering membrane permeability. This is a substantial negative for Ligand B.
4. **HBD:** Both ligands have 1 HBD, which is within the acceptable limit of 5.
5. **HBA:** Both ligands have 5 HBA, which is within the acceptable limit of 10.
6. **QED:** Both ligands have similar QED values (0.753 and 0.724), indicating good drug-likeness.
7. **DILI:** Ligand A (63.746) has a higher DILI risk than Ligand B (6.941). This is a significant drawback for Ligand A.
8. **BBB:** Ligand A (69.407) has a better BBB penetration percentile than Ligand B (60.644). While ADRB2 isn't strictly a CNS target, some CNS exposure can be relevant, and higher BBB is generally favorable.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual. Assuming these are percentile scores, both show poor permeability.
10. **Solubility:** Ligand A (-6.344) has significantly worse solubility than Ligand B (0.06). Poor solubility is a major hurdle for oral bioavailability.
11. **hERG:** Ligand A (0.684) has a slightly higher hERG risk than Ligand B (0.222), but both are relatively low.
12. **Cl_mic:** Ligand A (111.673) has a much higher microsomal clearance than Ligand B (6.165). This indicates Ligand A is rapidly metabolized, leading to a shorter duration of action.
13. **t1/2:** Ligand A (99.005) has a much longer in vitro half-life than Ligand B (0.256). This seems contradictory to the Cl_mic data, but assuming the values are reliable, it's a point in favor of Ligand A.
14. **Pgp:** Ligand A (0.554) has a higher Pgp efflux liability than Ligand B (0.015). Lower Pgp is preferred for better bioavailability.
15. **Binding Affinity:** Ligand A (-7.2 kcal/mol) has a slightly better binding affinity than Ligand B (-7.0 kcal/mol). While the difference is small, it is still a positive for Ligand A.
**Overall Assessment:**
Ligand A has a better binding affinity and BBB penetration, and a longer half-life, but suffers from poor solubility, high DILI risk, high Pgp efflux, and high metabolic clearance. Ligand B has a much better safety profile (DILI, hERG), better solubility, and lower Pgp efflux, but its logP is very low, potentially hindering permeability, and its binding affinity is slightly weaker.
Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity), and the fact that ADRB2 is a cardiovascular target (so CNS penetration is less critical), Ligand B's superior ADME properties, particularly its lower DILI risk and better solubility, outweigh the slightly weaker binding affinity and lower BBB. The very low logP of Ligand B is a concern, but could potentially be addressed through prodrug strategies or formulation approaches. The high DILI risk of Ligand A is a more difficult problem to solve.
Output:
0
2025-04-17 18:25:16,411 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (366.53 & 378.57 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (58.64) is slightly higher than Ligand B (50.5). Both are below 140, which is good for oral absorption, but Ligand B is preferable.
3. **logP:** Ligand A (2.22) is within the optimal 1-3 range. Ligand B (3.61) is a bit higher, approaching the upper limit where solubility issues could arise. Ligand A is preferable.
4. **HBD:** Ligand A (1) is better than Ligand B (0). A single HBD can contribute to solubility without significantly hindering permeability.
5. **HBA:** Ligand A (4) is better than Ligand B (6). Lower HBA is generally preferred for better membrane permeability.
6. **QED:** Both ligands have similar QED values (0.783 vs 0.737), indicating good drug-likeness.
7. **DILI:** Ligand A (32.18) has a significantly lower DILI risk than Ligand B (57.66). This is a major advantage for Ligand A.
8. **BBB:** Both ligands show good BBB penetration (74.25 vs 77.47). Ligand B is slightly better, but the difference is not substantial for a cardiovascular target.
9. **Caco-2:** Ligand A (-4.923) and Ligand B (-5.432) both have negative Caco-2 values, indicating poor permeability. Ligand A is slightly better.
10. **Solubility:** Both ligands have very poor aqueous solubility (-2.952 vs -3.301). This is a significant concern for both.
11. **hERG:** Both ligands have low hERG inhibition risk (0.465 vs 0.546). No significant difference.
12. **Cl_mic:** Ligand A (51.81) has a much lower microsomal clearance than Ligand B (97.91), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (4.73) has a slightly longer half-life than Ligand B (4.07), which is desirable.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.137 vs 0.67). Ligand A is preferable.
15. **Binding Affinity:** Ligand A (-6.1) has a slightly better binding affinity than Ligand B (-5.5). While the difference is less than the 1.5 kcal/mol threshold, it contributes to the overall preference.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Ligand A is better on logP, TPSA, Pgp and affinity. The lower DILI and Cl_mic values for Ligand A are also very important for overall developability. While both have poor solubility, the other advantages of Ligand A outweigh this drawback.
**Conclusion:**
Ligand A demonstrates a more favorable balance of properties, particularly regarding safety (DILI), metabolic stability (Cl_mic), and binding affinity. While solubility is a concern for both, the other advantages of Ligand A make it the more promising drug candidate.
Output:
1
2025-04-17 18:25:16,411 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (341.411 Da) is well within the ideal range (200-500 Da). Ligand B (458.181 Da) is at the higher end, but still acceptable.
2. **TPSA:** Ligand A (80.32) is excellent, well below the 140 threshold for good absorption. Ligand B (66.05) is even better.
3. **logP:** Both ligands have good logP values (A: 3.758, B: 4.405), falling within the 1-3 range, though B is slightly higher.
4. **HBD:** Ligand A (2) and Ligand B (3) are both acceptable.
5. **HBA:** Ligand A (4) and Ligand B (3) are both acceptable.
6. **QED:** Ligand A (0.812) is very good, indicating high drug-likeness. Ligand B (0.236) is poor, suggesting potential issues.
7. **DILI:** Ligand A (75.611) has a moderate DILI risk. Ligand B (98.216) has a high DILI risk, which is concerning.
8. **BBB:** Both ligands have similar BBB penetration (A: 60.915, B: 66.576). Neither is exceptionally high, but this isn't a primary concern for a cardiovascular target like ADRB2.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. This is a red flag for both.
10. **Solubility:** Both ligands have negative solubility values, indicating very poor aqueous solubility. This is a significant concern for bioavailability.
11. **hERG:** Ligand A (0.314) has a low hERG risk. Ligand B (0.596) has a slightly higher, but still relatively low, hERG risk.
12. **Cl_mic:** Ligand A (92.307) has a higher microsomal clearance, suggesting lower metabolic stability. Ligand B (37.715) has a much lower clearance, indicating better metabolic stability.
13. **t1/2:** Ligand A (15.295) has a moderate in vitro half-life. Ligand B (123.189) has a very long half-life, which is desirable.
14. **Pgp:** Ligand A (0.095) has low P-gp efflux, which is good. Ligand B (0.331) has slightly higher P-gp efflux, but still reasonable.
15. **Binding Affinity:** Ligand A (-6.2 kcal/mol) and Ligand B (-5.9 kcal/mol) have comparable binding affinities. The difference is not large enough to outweigh other factors.
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, TPSA, and affinity are important. Both ligands perform well on these metrics. However, ADME properties are crucial. Ligand B has significantly better metabolic stability (lower Cl_mic, longer t1/2), despite the higher DILI risk. Ligand A has a better QED and lower DILI, but the poor metabolic stability is a major drawback. The poor Caco-2 and solubility for both ligands are concerning, but can potentially be addressed through formulation strategies.
**Overall Assessment:**
Despite the higher DILI risk, Ligand B's superior metabolic stability and longer half-life are more critical for a viable drug candidate, especially considering the comparable binding affinity. The poor solubility and permeability are shared issues that would need to be addressed during formulation. The QED score of Ligand A is attractive, but the metabolic liabilities are too significant.
**Output:**
0
2025-04-17 18:25:16,411 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (366.531 and 366.571 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (76.02) is higher than Ligand B (49.41). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is generally preferred for permeability. Ligand B is better here.
3. **logP:** Ligand B (3.475) is slightly higher than Ligand A (2.521), but both are within the optimal 1-3 range. Ligand B is marginally better.
4. **HBD:** Ligand A (2) is higher than Ligand B (1). Lower is generally preferred, giving a slight edge to Ligand B.
5. **HBA:** Ligand A (5) is higher than Ligand B (3). Again, lower is generally preferred, favoring Ligand B.
6. **QED:** Both ligands have similar QED scores (0.704 and 0.702), indicating good drug-likeness. No significant difference.
7. **DILI:** Ligand B (8.492) has a *much* lower DILI risk than Ligand A (43.66). This is a major advantage for Ligand B.
8. **BBB:** Ligand A (51.764) has a lower BBB penetration than Ligand B (76.89). While ADRB2 isn't a CNS target, some peripheral exposure can be undesirable, but this is a relatively minor point. Ligand B is better.
9. **Caco-2:** Ligand A (-5.48) is significantly better than Ligand B (-4.705) indicating better intestinal absorption. This is a significant advantage for Ligand A.
10. **Solubility:** Ligand A (-2.367) is better than Ligand B (-3.876). Better solubility is generally desirable. Ligand A is better.
11. **hERG:** Ligand A (0.355) has a lower hERG risk than Ligand B (0.607). This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand A (41.055) has a lower microsomal clearance than Ligand B (89.673), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (15.692) has a significantly longer in vitro half-life than Ligand B (4.256). This is a major advantage for Ligand A.
14. **Pgp:** Ligand A (0.049) has lower P-gp efflux than Ligand B (0.057), which is slightly better.
15. **Binding Affinity:** Ligand A (-6.9) has a slightly better binding affinity than Ligand B (-6.1). While both are good, the 0.8 kcal/mol difference is notable.
**Overall Assessment:**
Ligand A has a stronger binding affinity, better Caco-2 permeability, solubility, hERG risk, metabolic stability (lower Cl_mic), and longer half-life. These are all important factors. Ligand B excels in DILI risk and has slightly better TPSA and logP. However, the significant advantages of Ligand A in metabolic stability, half-life, and safety (hERG, DILI) outweigh the minor benefits of Ligand B. The binding affinity difference is also a key factor.
Output:
1
2025-04-17 18:25:16,412 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (348.443 and 364.475 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (67.87) is significantly better than Ligand B (101.8). For a GPCR, keeping TPSA low is beneficial for permeability, and Ligand A is well below the 140 A^2 threshold. Ligand B is approaching the upper limit.
**3. logP:** Both ligands have good logP values (1.949 and 1.852), falling within the optimal 1-3 range. No clear advantage.
**4. H-Bond Donors:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
**5. H-Bond Acceptors:** Ligand A (4) is preferable to Ligand B (7). Lower HBA generally improves permeability.
**6. QED:** Both ligands have similar QED values (0.789 and 0.777), indicating good drug-likeness.
**7. DILI:** Ligand A (45.25) has a lower DILI risk than Ligand B (65.374), which is a significant advantage.
**8. BBB:** Ligand A (71.966) has a higher BBB penetration percentile than Ligand B (65.413). While not a CNS target, some degree of BBB penetration can influence off-target effects and distribution.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and requires further investigation. However, Ligand A (-5.076) is slightly less negative than Ligand B (-5.265).
**10. Aqueous Solubility:** Both ligands have negative solubility values, also unusual. Ligand A (-2.993) is slightly better than Ligand B (-3.423).
**11. hERG Inhibition:** Both ligands have low hERG inhibition liability (0.246 and 0.186), which is good.
**12. Microsomal Clearance:** Ligand B (30.034) has slightly higher microsomal clearance than Ligand A (28.594), suggesting potentially lower metabolic stability.
**13. In vitro Half-Life:** Ligand A (21.492) has a significantly longer in vitro half-life than Ligand B (-4.919). This is a major advantage.
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (0.057 and 0.116).
**15. Binding Affinity:** Ligand A (-7.1 kcal/mol) has a significantly stronger binding affinity than Ligand B (-4.6 kcal/mol). This is a substantial advantage, easily outweighing minor ADME drawbacks.
**Overall Assessment:**
Ligand A is clearly the superior candidate. It has a better TPSA, lower HBD/HBA, lower DILI risk, higher BBB penetration, longer half-life, and *significantly* stronger binding affinity. While both ligands have unusual solubility and Caco-2 values that would require further investigation, the overall profile of Ligand A is much more favorable for development as a cardiovascular drug targeting the ADRB2 receptor. The affinity difference is particularly compelling.
Output:
1
2025-04-17 18:25:16,412 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Step-by-step comparison:**
1. **MW:** Ligand A (363.34 Da) is within the ideal range, while Ligand B (345.487 Da) is also acceptable. No clear advantage here.
2. **TPSA:** Ligand A (132.24) is borderline, but acceptable for a non-CNS GPCR target. Ligand B (53.51) is excellent, well below the 140 threshold, suggesting good absorption. This favors Ligand B.
3. **logP:** Ligand A (-0.468) is a bit low, potentially hindering permeability. Ligand B (2.9) is optimal. This strongly favors Ligand B.
4. **HBD:** Ligand A (4) is acceptable. Ligand B (0) is excellent, potentially improving permeability. This favors Ligand B.
5. **HBA:** Ligand A (6) is acceptable. Ligand B (3) is good. This favors Ligand B.
6. **QED:** Both ligands have good QED scores (A: 0.486, B: 0.824), indicating drug-likeness. Ligand B is significantly better.
7. **DILI:** Ligand A (42.536) is good, with low risk. Ligand B (14.618) is *very* good, even lower risk. This favors Ligand B.
8. **BBB:** Ligand A (49.205) is low, as expected for a cardiovascular target. Ligand B (80.419) is higher, but still not a primary concern for ADRB2.
9. **Caco-2:** Ligand A (-5.961) is poor. Ligand B (-4.515) is also poor, but slightly better.
10. **Solubility:** Both ligands have poor solubility (-2.053 and -2.113 respectively). This is a concern for both, but not a deciding factor.
11. **hERG:** Both ligands have low hERG risk (A: 0.428, B: 0.594). No clear advantage.
12. **Cl_mic:** Ligand A (-38.637) has a *much* lower (better) microsomal clearance than Ligand B (43.245), indicating greater metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (39.661) has a significantly longer in vitro half-life than Ligand B (7.238), which is very desirable. This is a strong advantage for Ligand A.
14. **Pgp:** Both ligands have very low P-gp efflux (A: 0.027, B: 0.222). No clear advantage.
15. **Affinity:** Ligand A (-8.4 kcal/mol) has a slightly better binding affinity than Ligand B (-6.4 kcal/mol). This is a substantial advantage for Ligand A.
**GPCR-specific priorities:** For ADRB2 (a cardiovascular GPCR), logP, TPSA, and affinity are key. Ligand B excels in logP and TPSA. However, Ligand A has a superior binding affinity *and* significantly better metabolic stability (Cl_mic and t1/2). The affinity difference is substantial enough to outweigh the slightly less optimal logP and TPSA of Ligand A.
**Conclusion:**
Despite Ligand B's advantages in TPSA, logP, and DILI, Ligand A's superior binding affinity, metabolic stability, and longer half-life make it the more promising drug candidate for ADRB2.
Output:
1
2025-04-17 18:25:16,412 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [352.415, 79.29, 3.729, 2, 4, 0.753, 85.964, 43.001, -5.327, -3.819, 0.065, -0.711, 29.841, 0.051, -7.2]
**Ligand B:** [355.471, 92.85, 2.51, 2, 8, 0.672, 71.733, 64.25, -5.441, -3.797, 0.519, 61.105, 25.315, 0.234, -4.6]
Here's a breakdown, considering the GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal range (200-500 Da). A is 352.4, B is 355.5. No significant difference.
2. **TPSA:** A (79.29) is better than B (92.85). Lower TPSA generally favors better absorption.
3. **logP:** A (3.729) is slightly better than B (2.51). Both are within the optimal range, but A is closer to the upper end, potentially aiding membrane permeability.
4. **HBD:** Both have 2 HBD, which is good.
5. **HBA:** A has 4, B has 8. A is preferred as it's closer to the ideal range.
6. **QED:** A (0.753) is slightly better than B (0.672), indicating a more drug-like profile.
7. **DILI:** B (71.733) is significantly better than A (85.964). Lower DILI is crucial.
8. **BBB:** B (64.25) is better than A (43.001). While not a primary concern for a cardiovascular target, higher BBB is generally favorable.
9. **Caco-2:** Both are negative, indicating poor permeability. A (-5.327) is slightly worse than B (-5.441).
10. **Solubility:** Both are very poor (-3.819 and -3.797). This is a major concern for both.
11. **hERG:** A (0.065) is significantly better than B (0.519). Lower hERG risk is critical.
12. **Cl_mic:** A (-0.711) is much better than B (61.105). A has negative clearance, indicating high metabolic stability.
13. **t1/2:** A (29.841) is better than B (25.315). Longer half-life is generally preferred.
14. **Pgp:** A (0.051) is much better than B (0.234). Lower P-gp efflux is desirable.
15. **Affinity:** A (-7.2) is significantly better than B (-4.6). This is a substantial difference in binding strength.
**Overall Assessment:**
Ligand A has a significantly stronger binding affinity, better metabolic stability (Cl_mic), longer half-life, lower P-gp efflux, and lower hERG risk. While Ligand B has a lower DILI risk and better BBB penetration, the substantial advantage in affinity and ADME properties of Ligand A outweighs these benefits, especially considering the target is cardiovascular (BBB is less critical). The poor solubility is a concern for both, but can be addressed through formulation strategies. The Caco-2 permeability is also poor for both.
Therefore, I would choose Ligand A.
Output:
1
2025-04-17 18:25:16,412 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (377.87 & 354.41 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (46.17) is significantly better than Ligand B (99.35). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold, while Ligand B is approaching it.
3. **logP:** Ligand A (4.85) is higher than Ligand B (0.08). While 4.85 is at the upper end of the optimal range, it's still acceptable. Ligand B's logP is very low, potentially hindering membrane permeability.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A (2) is better than Ligand B (7). Lower HBA is preferred for permeability.
6. **QED:** Both ligands have similar QED scores (0.706 and 0.705), indicating good drug-likeness.
7. **DILI:** Ligand A (87.01) has a higher DILI risk than Ligand B (37.46). This is a significant concern for Ligand A.
8. **BBB:** Ligand A (46.49) is better than Ligand B (35.13), but neither is particularly high. Not a major factor for a cardiovascular target.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Ligand A (-5.54) is better than Ligand B (-0.25). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.68) is better than Ligand B (0.14). Lower hERG inhibition is crucial to avoid cardiotoxicity.
12. **Cl_mic:** Ligand A (42.30) has a lower (better) microsomal clearance than Ligand B (-11.97). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (70.75) has a significantly longer half-life than Ligand B (-8.60). This is a major advantage for dosing convenience.
14. **Pgp:** Ligand A (0.30) is better than Ligand B (0.02). Lower P-gp efflux is preferred.
15. **Affinity:** Ligand B (-8.1) has a slightly better binding affinity than Ligand A (-6.2). However, the difference is less than 1.5 kcal/mol, and other factors are more important.
**Overall Assessment:**
Ligand A is better overall. While its DILI risk is a concern, it is outweighed by its superior TPSA, logP, HBA, solubility, hERG, Cl_mic, t1/2, and Pgp properties. Ligand B's very low logP is a major drawback, likely hindering its ability to cross cell membranes. The slightly better binding affinity of Ligand B is not enough to compensate for its ADME deficiencies. The longer half-life of Ligand A is also a significant advantage.
Output:
1
2025-04-17 18:25:16,412 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (347.459 and 350.503 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (78.51) is slightly higher than Ligand B (69.64). Both are below the 140 threshold for good absorption, but B is closer to the preferred <90 for GPCRs.
3. **logP:** Ligand B (2.469) is better positioned within the optimal 1-3 range than Ligand A (0.853), which is a bit low and might hinder membrane permeability. This is a significant advantage for B, given the GPCR target class.
4. **HBD:** Both ligands have 2 HBD, which is acceptable.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 3. Both are within the acceptable range of <=10.
6. **QED:** Both ligands have good QED scores (0.747 and 0.8), indicating good drug-like properties.
7. **DILI:** Ligand A (8.453) has a significantly lower DILI risk than Ligand B (11.4). This is a major advantage for Ligand A.
8. **BBB:** Both ligands have similar BBB penetration (64.87% and 68.282%). While not exceptionally high, they are reasonable for a peripherally-acting GPCR like ADRB2.
9. **Caco-2:** Ligand A (-5.394) has a worse Caco-2 permeability than Ligand B (-4.825).
10. **Solubility:** Ligand A (-1.235) has better solubility than Ligand B (-2.549).
11. **hERG:** Both ligands have low hERG inhibition risk (0.176 and 0.248).
12. **Cl_mic:** Ligand A (-15.698) has significantly lower microsomal clearance than Ligand B (12.022), indicating better metabolic stability. This is a substantial advantage for A.
13. **t1/2:** Ligand A (-3.734) has a slightly worse in vitro half-life than Ligand B (-2.332).
14. **Pgp:** Both ligands have low P-gp efflux liability (0.007 and 0.115).
15. **Binding Affinity:** Ligand B (-6.8 kcal/mol) has a stronger binding affinity than Ligand A (-5.4 kcal/mol). This is a 1.4 kcal/mol difference, which is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand B has a better logP and binding affinity, which are crucial for GPCR targets. However, Ligand A demonstrates a significantly better safety profile (lower DILI) and improved metabolic stability (lower Cl_mic). The lower logP of Ligand A is a concern, but the stronger affinity of Ligand B is a compelling advantage. Given the balance, the more negative binding affinity of Ligand B is a significant advantage that outweighs the slightly higher DILI and lower metabolic stability.
Output:
0
2025-04-17 18:25:16,412 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for the ADRB2 receptor, a GPCR involved in cardiovascular function. Therefore, priorities are logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB.
Let's break down the comparison:
1. **MW:** Both ligands (343.391 and 354.491 Da) fall within the ideal 200-500 Da range.
2. **TPSA:** Ligand B (78.87) is significantly better than Ligand A (106.73). Lower TPSA generally improves oral absorption, which is important.
3. **logP:** Ligand B (1.709) is within the optimal 1-3 range, while Ligand A (0.12) is quite low, potentially hindering membrane permeability. This is a significant advantage for Ligand B.
4. **HBD/HBA:** Both have 2 HBD and are reasonably close in HBA counts (7 vs 4). This isn't a major differentiating factor.
5. **QED:** Ligand A (0.725) has a slightly better QED score than Ligand B (0.586), suggesting a more drug-like profile, but the difference isn't huge.
6. **DILI:** Ligand B (3.218) has a much lower DILI risk than Ligand A (63.086). This is a substantial advantage for Ligand B.
7. **BBB:** Ligand B (80.807) has a much higher BBB penetration score than Ligand A (38.193). While ADRB2 isn't a CNS target, some peripheral exposure can be beneficial, and lower efflux is generally preferable.
8. **Caco-2:** Ligand A (-5.494) has a more negative Caco-2 value, suggesting *poorer* permeability. Ligand B (-4.451) is better, though still not ideal.
9. **Solubility:** Ligand A (-2.277) has slightly better solubility than Ligand B (-1.369), but both are quite poor.
10. **hERG:** Ligand A (0.045) has a lower hERG risk than Ligand B (0.517), which is a positive.
11. **Cl_mic:** Ligand A (11.527) has a significantly lower microsomal clearance than Ligand B (27.931), indicating better metabolic stability.
12. **t1/2:** Ligand B (-26.14) has a negative half-life, which is concerning. Ligand A (15.404) has a reasonable in vitro half-life.
13. **Pgp:** Ligand A (0.059) has a lower Pgp efflux liability than Ligand B (0.076).
14. **Binding Affinity:** Both ligands have excellent binding affinity (-7.0 and -6.0 kcal/mol respectively), with Ligand A being slightly better. However, the difference is less than 1.5 kcal/mol, so it's not a decisive factor.
**Overall Assessment:**
Ligand B has several key advantages: better logP, significantly lower DILI risk, and much higher BBB penetration. While Ligand A has a slightly better QED, better metabolic stability, and slightly better binding affinity, the poor logP and high DILI risk are major concerns. The negative half-life for Ligand B is a red flag, but the other benefits are substantial. Given the GPCR target class, the balance of properties favors Ligand B.
**Output:**
0
2025-04-17 18:25:16,412 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [353.442, 90.98, 1.749, 2, 4, 0.781, 38.969, 73.827, -5.365, -2.045, 0.149, -0.155, -23.113, 0.042, -6.1]
**Ligand B:** [358.467, 76.14, 2.423, 2, 6, 0.878, 72.082, 75.611, -5.273, -3.141, 0.507, 41.276, 12.674, 0.058, -6.7]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, Affinity, and BBB):
1. **MW:** Both are within the ideal range (200-500 Da). A is 353.442, B is 358.467 - very similar.
2. **TPSA:** A (90.98) is slightly higher than B (76.14), but both are below the 140 threshold for oral absorption and acceptable for a non-CNS GPCR like ADRB2. B is better here.
3. **logP:** A (1.749) and B (2.423) are both within the optimal 1-3 range. B is slightly better.
4. **HBD:** Both have 2 HBD, which is good.
5. **HBA:** A has 4 HBA, B has 6. A is better.
6. **QED:** Both are good (A: 0.781, B: 0.878). B is slightly better.
7. **DILI:** A (38.969) is significantly better than B (72.082). This is a major advantage for A.
8. **BBB:** Both are relatively high (A: 73.827, B: 75.611), suggesting some potential for CNS penetration, but not critical for ADRB2. B is slightly better.
9. **Caco-2:** Both are negative, indicating poor permeability. This is a concern for both.
10. **Solubility:** Both are very poor (-2.045 and -3.141). This is a significant drawback for both, potentially hindering bioavailability. B is worse.
11. **hERG:** A (0.149) is much better than B (0.507), indicating lower cardiotoxicity risk. This is a significant advantage for A.
12. **Cl_mic:** A (-0.155) is much better than B (41.276), suggesting much better metabolic stability. This is a major advantage for A.
13. **t1/2:** A (-23.113) is much better than B (12.674), suggesting a longer half-life. This is a major advantage for A.
14. **Pgp:** A (0.042) is much better than B (0.058), indicating lower P-gp efflux. This is a significant advantage for A.
15. **Affinity:** B (-6.7) is slightly better than A (-6.1), but the difference is less than 1.5 kcal/mol.
**Overall Assessment:**
While Ligand B has a slightly better affinity and QED, Ligand A is significantly better across several crucial ADME-Tox parameters. Specifically, A has a much lower DILI risk, significantly better metabolic stability (lower Cl_mic, longer t1/2), lower hERG inhibition, and lower P-gp efflux. The solubility and Caco-2 permeability are poor for both, but these can potentially be addressed with formulation strategies. The slight affinity difference is outweighed by the substantial improvements in safety and pharmacokinetic properties of Ligand A.
Therefore, I would choose Ligand A.
1
2025-04-17 18:25:16,412 - INFO - Batch 36 complete. Total preferences: 576
2025-04-17 18:25:16,412 - INFO - Processing batch 37/512...
2025-04-17 18:26:05,669 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (355.4) is slightly higher than Ligand B (341.5), but both are acceptable.
2. **TPSA:** Ligand A (124.4) is borderline for good oral absorption, while Ligand B (58.4) is well below the 140 threshold and excellent. This favors Ligand B.
3. **logP:** Ligand A (0.342) is quite low, potentially hindering membrane permeability. Ligand B (3.041) is within the optimal range (1-3). This strongly favors Ligand B.
4. **HBD:** Both ligands have acceptable HBD counts (Ligand A: 2, Ligand B: 1).
5. **HBA:** Both ligands have acceptable HBA counts (Ligand A: 8, Ligand B: 4).
6. **QED:** Both ligands have good QED scores (Ligand A: 0.676, Ligand B: 0.877), indicating drug-likeness. Ligand B is slightly better.
7. **DILI:** Ligand A (49.0) has a moderate DILI risk, while Ligand B (23.0) has a very low risk. This favors Ligand B.
8. **BBB:** Ligand A (61.9) is moderate, while Ligand B (76.5) is good. While ADRB2 isn't exclusively a CNS target, some CNS penetration can be beneficial for understanding off-target effects and potential side effects. This favors Ligand B.
9. **Caco-2:** Both ligands have negative Caco-2 values, suggesting poor permeability. This is a concern for both.
10. **Solubility:** Both ligands have negative solubility values, suggesting poor solubility. This is a concern for both.
11. **hERG:** Ligand A (0.036) has a very low hERG risk, while Ligand B (0.756) is slightly higher, but still acceptable. This favors Ligand A, but the difference isn't huge.
12. **Cl_mic:** Ligand A (71.4) has higher microsomal clearance than Ligand B (5.5), indicating lower metabolic stability. This favors Ligand B.
13. **t1/2:** Ligand A (-10.3) has a negative half-life, which is concerning. Ligand B (-3.3) is also negative, but less so. Both are concerning, but Ligand B is slightly better.
14. **Pgp:** Ligand A (0.011) has very low P-gp efflux, while Ligand B (0.31) is slightly higher. This favors Ligand A.
15. **Binding Affinity:** Ligand B (-6.3 kcal/mol) has a slightly better binding affinity than Ligand A (-5.8 kcal/mol). This favors Ligand B.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP and TPSA, has a better affinity, and a lower DILI risk. While Ligand A has a better hERG profile and Pgp efflux, the overall balance of properties favors Ligand B. The negative Caco-2 and solubility values are concerning for both, but can be addressed with formulation strategies.
**Conclusion:**
Ligand B demonstrates a more favorable overall profile for drug development, particularly considering the GPCR-specific priorities.
Output:
0
2025-04-17 18:26:05,669 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (342.439 Da) is well within the ideal range (200-500 Da). Ligand B (397.591 Da) is also acceptable, but closer to the upper limit.
2. **TPSA:** Both ligands (A: 69.64, B: 66.32) are below 140, suggesting good oral absorption potential.
3. **logP:** Ligand A (1.38) is optimal. Ligand B (3.576) is at the higher end of the optimal range, potentially raising concerns about solubility and off-target effects, but still acceptable.
4. **HBD:** Ligand A (2) and Ligand B (1) are both within the acceptable limit of 5.
5. **HBA:** Ligand A (3) and Ligand B (7) are both within the acceptable limit of 10.
6. **QED:** Both ligands (A: 0.868, B: 0.807) have excellent drug-likeness scores, well above the 0.5 threshold.
7. **DILI:** Ligand A (29.159) has a significantly lower DILI risk than Ligand B (65.917). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (64.831) has better BBB penetration than Ligand B (45.328), although neither are exceptionally high. For a cardiovascular target, BBB penetration is less critical, but still a consideration.
9. **Caco-2:** Ligand A (-4.773) and Ligand B (-5.36) are both negative, and similar. This suggests poor permeability.
10. **Solubility:** Ligand A (-2.611) has better aqueous solubility than Ligand B (-3.752).
11. **hERG:** Both ligands (A: 0.45, B: 0.511) have low hERG inhibition liability, which is good.
12. **Cl_mic:** Ligand A (29.134) has a significantly lower microsomal clearance than Ligand B (51.465), indicating better metabolic stability.
13. **t1/2:** Ligand A (5.489) has a shorter in vitro half-life than Ligand B (14.028). This is a drawback for Ligand A.
14. **Pgp:** Ligand A (0.169) has lower P-gp efflux liability than Ligand B (0.553), which is favorable.
15. **Affinity:** Ligand B (-7.0 kcal/mol) has a slightly better binding affinity than Ligand A (-6.5 kcal/mol). This is a 0.5 kcal/mol difference, which is significant but not overwhelming, given the other factors.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand B has a higher logP and slightly better affinity. However, Ligand A has significantly better DILI, solubility, Pgp efflux, and metabolic stability (Cl_mic). The lower DILI risk and improved metabolic stability are particularly important for a cardiovascular drug, where long-term safety and consistent exposure are crucial.
**Overall Assessment:**
While Ligand B has a slightly better binding affinity, the superior ADME properties of Ligand A, especially the significantly lower DILI risk and better metabolic stability, make it the more promising drug candidate. The slightly shorter half-life of Ligand A can be addressed through formulation strategies.
Output:
1
2025-04-17 18:26:05,670 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (353.394 and 348.447 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand B (78.67) is significantly better than Ligand A (102.66). ADRB2 is a cardiovascular target, so BBB isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (0.976) is slightly better than Ligand A (0.65), both are a little low, but acceptable.
4. **HBD:** Ligand B (1) has fewer HBD than Ligand A (2), which is preferable for permeability.
5. **HBA:** Both ligands have the same number of HBA (5), which is within the acceptable range.
6. **QED:** Both ligands have similar QED scores (0.73 and 0.745), indicating good drug-likeness.
7. **DILI:** Ligand B (19.93) has a much lower DILI risk than Ligand A (31.601). This is a significant advantage.
8. **BBB:** Not a primary concern for a cardiovascular target. Ligand A (58.007) is slightly better than Ligand B (42.187), but this is not a deciding factor.
9. **Caco-2:** Ligand A (-4.839) is slightly better than Ligand B (-4.59), indicating potentially better intestinal absorption.
10. **Solubility:** Ligand A (-1.111) is slightly better than Ligand B (-0.648), but both are poor.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.395 and 0.271), which is excellent.
12. **Cl_mic:** Ligand A (1.887) has significantly lower microsomal clearance than Ligand B (25.779), indicating better metabolic stability. This is a major advantage.
13. **t1/2:** Ligand B (-20.363) has a much longer in vitro half-life than Ligand A (11.855). This is a significant advantage.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.028 and 0.082), which is good.
15. **Binding Affinity:** Both ligands have similar binding affinities (-6.4 and -6.1 kcal/mol). The difference is not substantial enough to outweigh other factors.
**Overall Assessment:**
Ligand B is the better candidate. While Ligand A has slightly better Caco-2 permeability and solubility, Ligand B excels in crucial areas: significantly lower DILI risk, a much longer half-life, and a lower TPSA. The lower clearance of Ligand A is a benefit, but the longer half-life of Ligand B can compensate for that. Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand B strikes a better balance.
Output:
0
2025-04-17 18:26:05,670 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (346.5 and 360.5 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (49.41) is slightly higher than Ligand B (45.59), but both are well below the 140 threshold for good oral absorption.
**3. logP:** Ligand B (4.686) is a bit higher than Ligand A (3.832). While both are above the optimal 1-3 range, Ligand B is pushing the upper limit, potentially raising concerns about solubility and off-target effects.
**4. H-Bond Donors:** Both ligands have 1 HBD, which is good.
**5. H-Bond Acceptors:** Ligand A has 2 HBAs, while Ligand B has 5. Ligand B is getting closer to the upper limit of 10, potentially impacting permeability.
**6. QED:** Both ligands have good QED scores (0.621 and 0.705), indicating generally drug-like properties.
**7. DILI Risk:** Ligand A (25.4%) has a significantly lower DILI risk than Ligand B (11.3%). This is a major advantage for Ligand A.
**8. BBB Penetration:** Both ligands have similar BBB penetration (77.5% and 76.8%). Since ADRB2 is a cardiovascular target, BBB penetration is not a primary concern, but it's good to see reasonable values.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the values are similar (-4.702 vs -4.996).
**10. Aqueous Solubility:** Ligand A (-3.932) has better aqueous solubility than Ligand B (-5.669). This is important for formulation and bioavailability.
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (0.472 and 0.889).
**12. Microsomal Clearance:** Ligand A (54.54) has significantly lower microsomal clearance than Ligand B (119.53). This suggests better metabolic stability for Ligand A.
**13. In vitro Half-Life:** Ligand A (-19.911) has a longer in vitro half-life than Ligand B (-7.22). This is a positive attribute, potentially leading to less frequent dosing.
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (0.198 and 0.442).
**15. Binding Affinity:** Both ligands have very similar binding affinities (-5.4 and -4.5 kcal/mol). The 0.9 kcal/mol difference is notable, but the ADME properties of Ligand A are more favorable.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity) and the general guidelines, Ligand A is the more promising candidate. While Ligand B has a slightly better QED and comparable affinity, Ligand A excels in crucial ADME properties: lower DILI risk, better solubility, lower clearance, and longer half-life. The slightly higher logP of Ligand B is a concern. The affinity difference, while present, is not large enough to overcome the significant ADME advantages of Ligand A.
Output:
1
2025-04-17 18:26:05,670 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (345.443 and 361.467 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (63.69) is significantly better than Ligand B (87.3). ADRB2 is not a CNS target, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have excellent logP values (1.74 and 1.696), falling within the optimal 1-3 range.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (4). Fewer HBAs generally improve permeability.
6. **QED:** Ligand A (0.901) is significantly better than Ligand B (0.646), indicating a more drug-like profile.
7. **DILI:** Ligand A (10.237) is much better than Ligand B (56.495) indicating a lower risk of drug-induced liver injury. This is a critical factor.
8. **BBB:** This is less critical for ADRB2, but Ligand A (76.696) is better than Ligand B (57.193).
9. **Caco-2:** Ligand A (-4.73) is better than Ligand B (-5.564). Higher Caco-2 permeability is favorable.
10. **Solubility:** Ligand A (-0.927) is better than Ligand B (-3.001). Better solubility is generally preferred.
11. **hERG:** Ligand A (0.316) is much better than Ligand B (0.101), indicating a lower risk of cardiotoxicity. This is a critical factor for a cardiovascular target.
12. **Cl_mic:** Ligand A (4.762) is much better than Ligand B (24.138), suggesting better metabolic stability.
13. **t1/2:** Ligand A (3.385) is better than Ligand B (-3.238). A longer half-life is generally desirable.
14. **Pgp:** Ligand A (0.012) is much better than Ligand B (0.059), suggesting lower P-glycoprotein efflux.
15. **Affinity:** Ligand A (-7.4) is 0.7 kcal/mol better than Ligand B (-6.7). This difference in binding affinity is significant and can outweigh some minor ADME drawbacks.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across nearly all ADME-Tox properties, and crucially, has a significantly better binding affinity. The lower DILI risk and hERG inhibition liability for Ligand A are particularly important for a cardiovascular target like ADRB2. While both ligands have acceptable logP values, Ligand A's superior overall profile makes it a much more promising drug candidate.
Output:
1
2025-04-17 18:26:05,670 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (360.443 and 349.519 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand B (52.65) is significantly better than Ligand A (101.8). Lower TPSA generally favors better absorption and potentially BBB penetration, crucial for GPCRs.
3. **logP:** Ligand B (2.426) is within the optimal range (1-3), while Ligand A (0.905) is slightly below, potentially hindering permeation.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable.
5. **HBA:** Ligand A (7) and Ligand B (3) are both acceptable.
6. **QED:** Both ligands have similar, good QED scores (0.715 and 0.749).
7. **DILI:** Ligand B (18.379) has a much lower DILI risk than Ligand A (65.723). This is a major advantage for Ligand B.
8. **BBB:** Ligand B (70.997) is better than Ligand A (46.607), though both are not exceptionally high. Given ADRB2's cardiovascular involvement, CNS penetration isn't paramount, but it's still a positive factor.
9. **Caco-2:** Ligand A (-5.935) and Ligand B (-4.761) are both negative, indicating poor permeability.
10. **Solubility:** Ligand A (-1.492) is slightly better than Ligand B (-2.05), but both are quite poor. Solubility could be a formulation challenge for both.
11. **hERG:** Ligand A (0.04) is slightly better than Ligand B (0.268), suggesting lower cardiotoxicity risk.
12. **Cl_mic:** Ligand B (41.117) has a significantly lower microsomal clearance than Ligand A (9.325), indicating better metabolic stability.
13. **t1/2:** Ligand A (32.353) has a longer in vitro half-life than Ligand B (2.918). This is a positive for Ligand A, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.092) has lower P-gp efflux than Ligand B (0.039), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand B (-7.9) has a slightly better binding affinity than Ligand A (-8.0). While the difference is small, it's still a factor.
**GPCR-Specific Priorities & Overall Assessment:**
For a GPCR like ADRB2, logP, TPSA, and affinity are key. Ligand B excels in logP and TPSA, and has comparable affinity. The significantly lower DILI risk and better metabolic stability (lower Cl_mic) of Ligand B are substantial advantages. While Ligand A has a longer half-life and slightly better Pgp profile, the risks associated with its higher DILI and poorer ADME properties outweigh these benefits. The solubility is poor for both, but can be addressed with formulation strategies.
**Output:**
0
2025-04-17 18:26:05,670 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (360.479 and 348.447 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (70.24) is better than Ligand B (78.68). Both are below 140, but lower TPSA generally favors absorption.
3. **logP:** Ligand A (2.893) is slightly higher than Ligand B (1.224), placing it more optimally within the 1-3 range. Ligand B is a bit low, potentially hindering permeation.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 3 HBA, while Ligand B has 5. Ligand A is preferable here, as lower HBA is generally better for permeability.
6. **QED:** Both ligands have good QED scores (0.911 and 0.836), indicating good drug-like properties.
7. **DILI:** Ligand A (61.342) has a higher DILI risk than Ligand B (33.114). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (69.407) and Ligand B (81.97) both have good BBB penetration, but Ligand B is better. Since ADRB2 is a GPCR, BBB penetration is a consideration, though not paramount for cardiovascular targets.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-5.574) has worse solubility than Ligand B (-1.667). Solubility is important for bioavailability, so Ligand B is favored.
11. **hERG:** Ligand A (0.621) has a slightly higher hERG risk than Ligand B (0.387), but both are reasonably low.
12. **Cl_mic:** Ligand A (72.654) has higher microsomal clearance than Ligand B (23.763), indicating faster metabolism and potentially lower exposure. Ligand B is significantly better here.
13. **t1/2:** Ligand A (-42.591) has a negative in vitro half-life, which is concerning. Ligand B (12.489) has a reasonable half-life.
14. **Pgp:** Ligand A (0.273) has lower P-gp efflux than Ligand B (0.063), which is favorable.
15. **Affinity:** Ligand A (-7.2 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.2 kcal/mol). This 1 kcal/mol difference is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand A has a significantly better binding affinity, which is the most important factor for GPCRs. However, it suffers from higher DILI risk, higher clearance, and a negative in vitro half-life. Ligand B has a better safety profile (lower DILI), better metabolic stability (lower Cl_mic, better t1/2), and better solubility. The difference in affinity is significant, but the ADME liabilities of Ligand A are substantial. Given the cardiovascular target, a balance is needed, and the improved ADME properties of Ligand B are more valuable than the slightly higher affinity of Ligand A.
Output:
0
2025-04-17 18:26:05,670 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (335.327 Da) is better than Ligand B (356.413 Da), falling comfortably within the 200-500 Da range. Both are acceptable.
2. **TPSA:** Ligand B (81.59) is significantly better than Ligand A (100.09). ADRB2 is not a CNS target, but lower TPSA generally aids absorption.
3. **logP:** Both ligands have good logP values (A: 1.277, B: 2.093), within the optimal 1-3 range. Ligand B is slightly better.
4. **HBD:** Ligand A (0) is preferable to Ligand B (4). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (9) is slightly better than Ligand B (3). Both are acceptable.
6. **QED:** Both ligands have similar and acceptable QED values (A: 0.518, B: 0.547).
7. **DILI:** Ligand B (27.685) is *much* better than Ligand A (97.867). This is a major advantage for Ligand B. A DILI percentile above 60 is a significant concern.
8. **BBB:** Both ligands have good BBB penetration (A: 76.27, B: 72.896). Not a primary concern for ADRB2.
9. **Caco-2:** Ligand A (-5.102) is better than Ligand B (-4.748). Higher Caco-2 values are better.
10. **Solubility:** Ligand A (-2.571) is better than Ligand B (-2.344). Higher solubility is better.
11. **hERG:** Ligand A (0.165) is better than Ligand B (0.618). Lower hERG inhibition is crucial for avoiding cardiotoxicity.
12. **Cl_mic:** Ligand B (29.119) is much better than Ligand A (80.8). Lower clearance indicates greater metabolic stability.
13. **t1/2:** Ligand B (-5.925) is better than Ligand A (-23.026). Longer half-life is preferred.
14. **Pgp:** Ligand A (0.467) is better than Ligand B (0.285). Lower P-gp efflux is better.
15. **Affinity:** Ligand A (-7.5 kcal/mol) is slightly better than Ligand B (-6.9 kcal/mol). While both are good, the 0.6 kcal/mol difference is notable.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B has a better logP and TPSA. Ligand A has better Pgp and affinity. However, the *significant* advantage of Ligand B in terms of DILI risk and metabolic stability (Cl_mic and t1/2) outweighs the slightly better affinity and Pgp of Ligand A. The hERG risk is also lower for Ligand A, but the DILI risk is a more serious concern.
**Conclusion:**
Despite Ligand A's slightly better affinity and Pgp efflux, the significantly lower DILI risk and improved metabolic stability of Ligand B make it the more promising drug candidate.
Output:
0
2025-04-17 18:26:05,670 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
Let's systematically compare Ligand A and Ligand B based on the provided parameters and the guidelines, keeping in mind this is an ADRB2 (GPCR) target.
1. **Molecular Weight:** Both ligands (350.547 and 351.447 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (49.41) is significantly better than Ligand B (101.73). For a GPCR, lower TPSA is generally preferred for better permeability, and Ligand A is well below the 140 threshold, while Ligand B is approaching the upper limit.
3. **logP:** Ligand A (4.135) is higher than Ligand B (1.259). While both are within the acceptable range, Ligand A is pushing the upper limit and could potentially have solubility issues. Ligand B is quite low, which could hinder permeability.
4. **H-Bond Donors:** Ligand A (1) is better than Ligand B (2). Lower is generally preferred for permeability.
5. **H-Bond Acceptors:** Ligand A (2) is better than Ligand B (4). Again, lower is generally preferred.
6. **QED:** Both ligands have similar QED values (0.602 and 0.674), indicating reasonable drug-likeness.
7. **DILI:** Both ligands have low DILI risk (30.322 and 32.61), which is good.
8. **BBB:** Ligand A (85.498) has a much higher BBB penetration percentile than Ligand B (58.356). This is a significant advantage for a GPCR target, even if not a CNS target, as it suggests better distribution.
9. **Caco-2:** Ligand A (-5.008) is better than Ligand B (-5.558), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-4.487) is better than Ligand B (-2.767), indicating better aqueous solubility.
11. **hERG:** Ligand A (0.752) is better than Ligand B (0.211), indicating lower hERG inhibition liability and reduced cardiotoxicity risk.
12. **Cl_mic:** Ligand A (82.108) has a lower microsomal clearance than Ligand B (10.182), suggesting better metabolic stability.
13. **t1/2:** Ligand A (6.383) has a longer in vitro half-life than Ligand B (-0.697).
14. **Pgp:** Ligand A (0.575) is better than Ligand B (0.037), indicating lower P-gp efflux.
15. **Binding Affinity:** Ligand B (-8.0) has a significantly stronger binding affinity than Ligand A (-5.9). This is a substantial advantage. A difference of 2.1 kcal/mol is considerable.
**Overall Assessment:**
Ligand B has a significantly better binding affinity, which is a crucial factor. However, Ligand A demonstrates superior ADME properties across the board: better TPSA, BBB penetration, solubility, hERG safety, metabolic stability, and lower P-gp efflux. While Ligand B's affinity is compelling, the poor ADME profile, particularly the high TPSA and low BBB, raises concerns about its developability. The difference in affinity, while large, might be overcome with further optimization of Ligand A. Given the GPCR target class, the balance of properties leans towards Ligand A.
Output:
1
2025-04-17 18:26:05,670 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.531 and 382.507 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (58.2) is significantly better than Ligand B (85.36). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (3.937) is slightly higher than Ligand B (2.296), but both are within the optimal 1-3 range. Ligand A is closer to the upper limit, which could potentially cause issues, but not a major concern.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1), but both are acceptable.
5. **HBA:** Ligand A (2) is lower than Ligand B (6). This is a significant advantage for Ligand A, as higher HBA can negatively impact permeability.
6. **QED:** Both ligands have good QED scores (0.698 and 0.794), indicating good drug-like properties.
7. **DILI:** Ligand A (15.471) has a much lower DILI risk than Ligand B (79.604). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (64.948) has a higher BBB penetration score than Ligand B (52.423), but since ADRB2 is a cardiovascular target, this is less critical.
9. **Caco-2:** Ligand A (-4.749) and Ligand B (-5.036) are similar, indicating similar intestinal absorption.
10. **Solubility:** Ligand A (-4.368) is better than Ligand B (-3.045), indicating better aqueous solubility.
11. **hERG:** Ligand A (0.385) has a lower hERG risk than Ligand B (0.145). Lower is better, so this favors Ligand A.
12. **Cl_mic:** Ligand B (26.956) has a significantly lower microsomal clearance than Ligand A (57.72), suggesting better metabolic stability. This is a strong advantage for Ligand B.
13. **t1/2:** Ligand B (43.911) has a much longer in vitro half-life than Ligand A (0.487). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.151) has lower P-gp efflux than Ligand B (0.269), which is favorable.
15. **Affinity:** Ligand B (-6.8 kcal/mol) has a slightly better binding affinity than Ligand A (-6.1 kcal/mol). This is a 1.5 kcal/mol difference, which is a notable advantage.
**Overall Assessment:**
Ligand B has a better binding affinity and significantly better metabolic stability (lower Cl_mic and longer t1/2). However, Ligand A excels in several key areas: lower DILI risk, better solubility, lower hERG risk, and lower P-gp efflux. The TPSA and HBA values are also more favorable for Ligand A.
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), and the overall balance of properties, the lower DILI and hERG risks of Ligand A are particularly important for a cardiovascular target. While the affinity difference is notable, the improved safety profile and absorption characteristics of Ligand A outweigh this advantage.
Output:
1
2025-04-17 18:26:05,670 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.387 and 346.431 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (114.62) is slightly higher than Ligand B (93.21). Both are below the 140 threshold for good oral absorption, but Ligand B is closer to the preferred <90 for GPCRs.
3. **logP:** Ligand A (-0.453) is quite low, potentially hindering membrane permeability. Ligand B (1.43) is within the optimal 1-3 range. This is a significant advantage for Ligand B.
4. **HBD:** Both ligands have 2 H-bond donors, which is acceptable.
5. **HBA:** Both ligands have 5 H-bond acceptors, which is acceptable.
6. **QED:** Both ligands have good QED scores (0.717 and 0.813), indicating drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (43.66) has a lower DILI risk than Ligand B (54.634), which is preferable.
8. **BBB:** Both ligands have reasonable BBB penetration (68.205 and 64.948). While not exceptionally high, it's not a major concern for a peripherally acting ADRB2 target.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.12 and -5.144), which is unusual and suggests poor permeability. This is a significant drawback for both.
10. **Solubility:** Both ligands have negative solubility values (-2.356 and -1.982), indicating poor aqueous solubility. This is a concern for bioavailability.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.061 and 0.135). This is excellent.
12. **Cl_mic:** Ligand A (-4.914) has a much lower (and therefore better) microsomal clearance than Ligand B (13.706). This suggests greater metabolic stability for Ligand A.
13. **t1/2:** Ligand A (7.316) has a shorter half-life than Ligand B (15.408). Longer half-life is generally preferred.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.019 and 0.008). This is good.
15. **Binding Affinity:** Ligand B (-6.7 kcal/mol) has a stronger binding affinity than Ligand A (-6.1 kcal/mol). This is a 0.6 kcal/mol difference, which is substantial and can outweigh some ADME drawbacks.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand B excels in logP and has a better TPSA. The affinity difference is also significant. While Ligand A has a better DILI score and Cl_mic, the poor logP and slightly lower affinity are more concerning for a GPCR target. The Caco-2 and solubility issues are problematic for both, but the stronger binding of Ligand B might allow for lower dosing to compensate.
**Conclusion:**
Despite the shared issues with permeability and solubility, Ligand B's superior logP, TPSA, and binding affinity make it the more promising candidate for further development as an ADRB2 ligand.
Output:
0
2025-04-17 18:26:05,670 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [357.41 , 64.11 , 4.27 , 1. , 5. , 0.693, 98.216, 68.786, -4.678, -5.822, 0.438, 100.435, 43.924, 0.469, -6.2 ]
**Ligand B:** [349.479, 81.93 , 2.493, 1. , 7. , 0.654, 35.828, 74.254, -4.785, -3.311, 0.164, 76.646, -19.578, 0.229, -5.8 ]
Here's a breakdown, considering the provided guidelines and GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (349.479) is slightly lower, which isn't a major concern.
2. **TPSA:** Ligand A (64.11) is significantly better than Ligand B (81.93). ADRB2 is not a CNS target, but lower TPSA generally aids absorption.
3. **logP:** Ligand A (4.27) is a bit high, potentially leading to solubility issues or off-target interactions. Ligand B (2.493) is much better, falling squarely within the optimal 1-3 range.
4. **HBD/HBA:** Both have 1 HBD, which is good. Ligand A has 5 HBA, while Ligand B has 7. Both are acceptable, but Ligand A is slightly preferable.
5. **QED:** Both have similar QED scores (0.693 and 0.654), indicating reasonable drug-likeness.
6. **DILI:** Ligand A (98.216) has a very high DILI risk, which is a significant red flag. Ligand B (35.828) has a much lower, and acceptable, DILI risk.
7. **BBB:** Not a primary concern for a cardiovascular target, but Ligand B (74.254) has a higher BBB penetration than Ligand A (68.786).
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. The values are very similar.
9. **Solubility:** Both have negative solubility values, indicating poor solubility. Ligand B is slightly better (-3.311 vs -5.822).
10. **hERG:** Both have low hERG inhibition risk (0.438 and 0.164). Ligand B is better.
11. **Cl_mic:** Ligand A (100.435) has higher metabolic clearance than Ligand B (76.646), suggesting lower metabolic stability.
12. **t1/2:** Ligand B (-19.578) has a much longer in vitro half-life than Ligand A (43.924). This is a major advantage.
13. **Pgp:** Ligand A (0.469) has higher P-gp efflux than Ligand B (0.229).
14. **Affinity:** Both have excellent binding affinities (-6.2 and -5.8 kcal/mol). Ligand A is slightly better, but the difference isn't huge.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity, its extremely high DILI risk, higher metabolic clearance, and higher P-gp efflux are major drawbacks. Ligand B, despite having a slightly lower affinity, presents a much more favorable ADMET profile, with significantly lower DILI risk, better metabolic stability (longer half-life), and lower P-gp efflux. The logP and TPSA values for Ligand B are also more desirable.
Therefore, I would choose Ligand B as the more promising drug candidate.
0
2025-04-17 18:26:05,671 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (382.404) is slightly higher than Ligand B (352.32), but both are acceptable.
2. **TPSA:** Both are below the 140 A^2 threshold for good oral absorption. Ligand B (86.84) is better than Ligand A (98.49), leaning towards better permeability.
3. **logP:** Both are within the optimal 1-3 range. Ligand A (1.949) and Ligand B (2.054) are very similar, and both are good.
4. **HBD:** Ligand A (2) is slightly better than Ligand B (1), but both are within the acceptable limit of 5.
5. **HBA:** Ligand A (4) is slightly better than Ligand B (5), but both are within the acceptable limit of 10.
6. **QED:** Both ligands have good QED scores, with Ligand B (0.892) being slightly better than Ligand A (0.638).
7. **DILI:** Ligand A (45.677) has a lower DILI risk than Ligand B (54.634), which is a significant advantage.
8. **BBB:** Both have reasonable BBB penetration, but Ligand A (69.794) is better than Ligand B (64.637). While ADRB2 isn't strictly a CNS target, some peripheral ADRB2 receptors can be affected by CNS-penetrant compounds, and higher BBB is generally favorable.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. Ligand A (-5.012) is slightly better than Ligand B (-4.807) but both are concerning.
10. **Solubility:** Both have negative solubility values, indicating poor solubility. Ligand A (-2.658) is slightly better than Ligand B (-3.162), but both are concerning.
11. **hERG:** Both have low hERG inhibition risk, with Ligand A (0.568) being slightly better than Ligand B (0.344).
12. **Cl_mic:** Ligand B (10.187) has a significantly lower microsomal clearance than Ligand A (27.994), indicating better metabolic stability.
13. **t1/2:** Ligand B (14.889) has a much longer in vitro half-life than Ligand A (-28.756), which is a major advantage.
14. **Pgp:** Ligand A (0.144) has lower P-gp efflux than Ligand B (0.021), indicating better bioavailability.
15. **Binding Affinity:** Ligand A (-6.7 kcal/mol) has a slightly better binding affinity than Ligand B (-5.2 kcal/mol). This 1.5 kcal/mol difference is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand A has a better binding affinity and a lower DILI risk, and better BBB penetration. However, Ligand B has significantly better metabolic stability (lower Cl_mic, longer t1/2) and Pgp efflux. The poor Caco-2 and solubility for both are concerning and would need to be addressed in further optimization. Considering the importance of metabolic stability and half-life for *in vivo* efficacy, and the relatively small difference in binding affinity, Ligand B is the more promising starting point.
Output:
0
2025-04-17 18:26:05,671 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (358.339 and 362.392 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (43.18) is significantly better than Ligand B (78.43). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold. Ligand B is approaching the upper limit.
3. **logP:** Ligand A (3.023) is optimal, while Ligand B (1.748) is slightly lower, but still acceptable.
4. **HBD:** Ligand A (0) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (5) is better than Ligand B (3). Lower HBA is generally preferred.
6. **QED:** Ligand A (0.771) is better than Ligand B (0.646), indicating a more drug-like profile.
7. **DILI:** Ligand A (32.842) is significantly better than Ligand B (13.416). Lower DILI risk is a major advantage.
8. **BBB:** Ligand A (90.772) is better than Ligand B (70.997). While not a primary concern for a cardiovascular target, higher BBB is generally favorable.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-4.61) is slightly better than Ligand B (-4.983).
10. **Solubility:** Both are negative, indicating poor solubility. Ligand A (-2.922) is slightly better than Ligand B (-2.518).
11. **hERG:** Ligand A (0.781) is better than Ligand B (0.398). Lower hERG inhibition is crucial for avoiding cardiotoxicity, especially for a cardiovascular target.
12. **Cl_mic:** Ligand A (18.005) is worse than Ligand B (13.43). Lower clearance is preferred for metabolic stability.
13. **t1/2:** Ligand A (-20.798) is worse than Ligand B (-11.256). Longer half-life is preferred.
14. **Pgp:** Ligand A (0.097) is better than Ligand B (0.032). Lower P-gp efflux is desirable.
15. **Binding Affinity:** Ligand A (-6.0) is slightly better than Ligand B (-4.1). A difference of 1.9 kcal/mol is significant and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand A demonstrates a significantly better overall profile, particularly regarding safety (DILI, hERG) and drug-likeness (QED, TPSA, HBD/HBA). While Ligand B has better metabolic stability (Cl_mic, t1/2), the superior binding affinity and safety profile of Ligand A are more critical for a cardiovascular GPCR target. The slight disadvantages in metabolic stability can be addressed through further optimization.
Output:
1
2025-04-17 18:26:05,671 - INFO - Here's my reasoning and the final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, the key priorities are logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB.
Let's break down the comparison:
1. **MW:** Both ligands are within the acceptable range (345-363 Da).
2. **TPSA:** Ligand B (73.74) is significantly better than Ligand A (112.73). Lower TPSA generally improves permeability, which is crucial for GPCR ligands.
3. **logP:** Both ligands have similar, optimal logP values (around 1.5).
4. **HBD/HBA:** Ligand B has fewer HBDs (1 vs 3), which is generally favorable for permeability. HBA is the same for both.
5. **QED:** Both have good QED scores (>0.7), indicating good drug-likeness.
6. **DILI:** Ligand B (11.322) has a much lower DILI risk than Ligand A (49.128). This is a significant advantage.
7. **BBB:** Ligand B (70.027) shows better BBB penetration than Ligand A (63.358), although this is less critical for a cardiovascular target.
8. **Caco-2:** Ligand B (-4.507) is slightly better than Ligand A (-5.524), indicating better intestinal absorption.
9. **Solubility:** Ligand B (-1.015) is better than Ligand A (-3.322).
10. **hERG:** Both ligands have very low hERG inhibition risk (0.461 and 0.44).
11. **Cl_mic:** Ligand A (5.64) has a lower microsomal clearance than Ligand B (0.864), suggesting better metabolic stability.
12. **t1/2:** Ligand B (-10.24) has a much longer in vitro half-life than Ligand A (-33.284).
13. **Pgp:** Both ligands have very low Pgp efflux liability (0.025 and 0.029).
14. **Binding Affinity:** Ligand B (-5.7 kcal/mol) has a slightly better binding affinity than Ligand A (-5.4 kcal/mol). While the difference is small, it's still a positive.
**Overall Assessment:**
Ligand B consistently outperforms Ligand A in most critical ADME properties (TPSA, DILI, Solubility, Caco-2, t1/2) and has a slightly better binding affinity. While Ligand A has slightly better metabolic stability (Cl_mic), the overall profile of Ligand B is more favorable for development as a drug candidate targeting ADRB2. The lower DILI risk and improved permeability characteristics of Ligand B are particularly compelling.
Output:
0
2025-04-17 18:26:05,671 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [366.451, 123.13 , -0.084, 1. , 9. , 0.726, 59.597, 62.117, -5.705, -1.545, 0.048, 20.469, -1.154, 0.013, -7.5 ]
**Ligand B:** [363.527, 43.86 , 2.521, 0. , 4. , 0.826, 35.285, 89.492, -4.663, -2.149, 0.668, 42.073, 17.229, 0.261, -7.9 ]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, Affinity, and to a lesser extent BBB):
1. **MW:** Both are within the ideal range (200-500 Da). A is 366.451, B is 363.527. Very similar.
2. **TPSA:** Ligand A (123.13) is higher than Ligand B (43.86). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is generally preferred for permeability. B is significantly better here.
3. **logP:** Ligand A (-0.084) is quite low, potentially hindering membrane permeability. Ligand B (2.521) is within the optimal range (1-3). B is much better.
4. **HBD/HBA:** A has 1 HBD and 9 HBA, B has 0 HBD and 4 HBA. Both are acceptable, but B is slightly better with fewer hydrogen bonding groups.
5. **QED:** Both are good (A: 0.726, B: 0.826), indicating drug-like properties. B is slightly better.
6. **DILI:** A (59.597) is higher than B (35.285). B is significantly better, indicating lower liver injury risk.
7. **BBB:** A (62.117) is lower than B (89.492). While not a CNS target, some level of BBB penetration can be beneficial for distribution. B is better.
8. **Caco-2:** A (-5.705) is very poor, suggesting poor absorption. B (-4.663) is also poor, but better than A.
9. **Solubility:** A (-1.545) is poor, B (-2.149) is also poor. Both are problematic, but similar.
10. **hERG:** A (0.048) is very low, indicating low risk. B (0.668) is higher, suggesting a slightly increased risk. A is better.
11. **Cl_mic:** A (20.469) is lower than B (42.073), indicating better metabolic stability. A is better.
12. **t1/2:** A (-1.154) is poor, B (17.229) is good. B is significantly better.
13. **Pgp:** A (0.013) is very low, suggesting minimal efflux. B (0.261) is higher, indicating some efflux. A is better.
14. **Affinity:** B (-7.9) is 0.4 kcal/mol better than A (-7.5). This is a substantial difference in binding.
**Overall Assessment:**
Ligand B has a superior profile overall, despite some solubility issues. The key advantages are its optimal logP, lower DILI risk, better BBB penetration, significantly better *in vitro* half-life, and most importantly, its stronger binding affinity. While Ligand A has a better hERG profile and lower Cl_mic, the substantial affinity advantage of B, combined with its better ADME properties (logP, DILI, BBB, t1/2), outweigh these drawbacks for a cardiovascular GPCR target. The poor Caco-2 values for both are concerning, but can potentially be addressed with formulation strategies.
Output:
0
2025-04-17 18:26:05,671 - INFO - Batch 37 complete. Total preferences: 592
2025-04-17 18:26:05,672 - INFO - Processing batch 38/512...
2025-04-17 18:26:56,325 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [348.447, 87.46, 1.53, 2, 5, 0.867, 29.818, 61.535, -4.867, -2.513, 0.113, 30.713, -9.311, 0.027, -7.8]
**Ligand B:** [355.479, 89.95, 0.758, 2, 4, 0.736, 32.299, 26.367, -4.797, -1.642, 0.258, 38.885, -12.062, 0.025, -6.1]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, Affinity, and BBB):
1. **MW:** Both are within the ideal 200-500 Da range. A (348.447) is slightly preferred.
2. **TPSA:** Both are good, below 140. A (87.46) is slightly better than B (89.95).
3. **logP:** Both are within the optimal 1-3 range. A (1.53) is slightly better than B (0.758).
4. **HBD/HBA:** Both have acceptable HBD (2) and HBA (5/4) counts.
5. **QED:** A (0.867) is better than B (0.736), indicating a more drug-like profile.
6. **DILI:** Both are reasonably low, with A (29.818) being slightly better than B (32.299).
7. **BBB:** A (61.535) is significantly better than B (26.367). While ADRB2 isn't necessarily a CNS target, some degree of BBB penetration can be beneficial for distribution and avoiding off-target effects.
8. **Caco-2:** Both are negative, indicating poor permeability. This is a concern for both.
9. **Solubility:** Both are negative, indicating poor solubility. This is a concern for both.
10. **hERG:** Both are very low, indicating minimal risk.
11. **Cl_mic:** A (30.713) is better than B (38.885) - lower clearance is preferred.
12. **t1/2:** A (-9.311) is better than B (-12.062) - longer half-life is preferred.
13. **Pgp:** Both are very low, indicating minimal efflux.
14. **Affinity:** A (-7.8) is significantly better than B (-6.1). This is a crucial difference, a 1.7 kcal/mol advantage is substantial.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most parameters, most notably in binding affinity and BBB penetration. While both have issues with Caco-2 and Solubility, the stronger binding affinity of Ligand A is a significant advantage for a GPCR target. The better metabolic stability (lower Cl_mic, longer t1/2) and slightly better safety profile (lower DILI) further solidify its preference.
Output:
1
2025-04-17 18:26:56,325 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (351.422 and 353.463 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (73.74) is better than Ligand B (87.74). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally favors absorption.
3. **logP:** Both ligands have good logP values (1.421 and 0.847), falling within the optimal 1-3 range. Ligand A is slightly better.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Both ligands have the same HBA count (4), which is within the acceptable limit of 10.
6. **QED:** Ligand A (0.841) has a significantly better QED score than Ligand B (0.602), indicating a more drug-like profile.
7. **DILI:** Ligand A (29.624) has a lower DILI risk than Ligand B (23.614), which is a clear advantage. Lower is better.
8. **BBB:** Ligand A (78.945) has a higher BBB percentile than Ligand B (67.507). While not a primary concern for a cardiovascular target, higher BBB is generally favorable.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual. However, the absolute value for Ligand A (-4.481) is less negative than Ligand B (-4.894), suggesting potentially slightly better permeability.
10. **Solubility:** Both ligands have negative solubility values, which is also unusual. Ligand A (-0.938) is slightly better than Ligand B (-1.147).
11. **hERG:** Ligand A (0.56) has a much lower hERG inhibition liability than Ligand B (0.091). This is a critical advantage, as hERG inhibition can lead to cardiotoxicity.
12. **Cl_mic:** Ligand A (14.811) has a significantly lower microsomal clearance than Ligand B (36.277), indicating better metabolic stability.
13. **t1/2:** Ligand A (-10.701) has a longer in vitro half-life than Ligand B (-6.431). This is a positive attribute, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.063) has a lower P-gp efflux liability than Ligand B (0.021), suggesting better oral bioavailability and potentially better tissue distribution.
15. **Binding Affinity:** Ligand A (-7.6) has a slightly better binding affinity than Ligand B (-6.1). While both are good, the 1.5 kcal/mol difference is significant and can outweigh minor ADME drawbacks.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A performs better across most of these parameters.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical ADME-Tox properties (DILI, hERG, Cl_mic, t1/2, Pgp) and has a slightly better binding affinity. While both ligands have unusual solubility and Caco-2 values, Ligand A is still preferable due to its superior overall profile, particularly its lower toxicity liabilities and better metabolic stability.
Output:
1
2025-04-17 18:26:56,326 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (346.431 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are reasonably low. Ligand B (83.98) is better than Ligand A (95.16), being closer to the <90 threshold for potential CNS penetration (though not a primary concern for ADRB2 unless CNS effects are desired).
3. **logP:** Both are within the optimal range (1-3). Ligand B (2.721) is higher than Ligand A (1.188), potentially improving membrane permeability but increasing the risk of off-target interactions.
4. **HBD:** Both have 2 HBD, which is acceptable.
5. **HBA:** Ligand B (6) has more HBA than Ligand A (4). This could slightly impact permeability.
6. **QED:** Ligand A (0.775) has a better QED score than Ligand B (0.596), indicating a more drug-like profile.
7. **DILI:** Ligand A (33.656) has a significantly lower DILI risk than Ligand B (72.005). This is a major advantage.
8. **BBB:** Ligand B (73.827) has a higher BBB penetration percentile than Ligand A (54.905). While ADRB2 isn't primarily a CNS target, some off-target CNS effects are possible with adrenergic ligands, so this is a minor plus for Ligand B.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability in this *in vitro* assay. This is a concern for both.
10. **Solubility:** Both have negative solubility values, indicating very poor aqueous solubility. This is a significant drawback for both compounds.
11. **hERG:** Ligand A (0.076) has a much lower hERG inhibition liability than Ligand B (0.651), a critical advantage for cardiovascular safety.
12. **Cl_mic:** Ligand A (21.098) has a lower microsomal clearance than Ligand B (49.37), suggesting better metabolic stability.
13. **t1/2:** Ligand B (61.234) has a significantly longer *in vitro* half-life than Ligand A (-20.463). This is a major advantage for Ligand B.
14. **Pgp:** Ligand B (0.316) has lower P-gp efflux liability than Ligand A (0.033), which could improve oral bioavailability.
15. **Binding Affinity:** Ligand B (-7.4 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.3 kcal/mol). This is a substantial advantage, potentially outweighing some ADME concerns.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are prioritized. Ligand B excels in affinity and has favorable Pgp and logP values. However, the significantly higher DILI risk and hERG inhibition of Ligand B are major concerns for a cardiovascular target. Ligand A has a much better safety profile (DILI and hERG) and acceptable logP and TPSA, despite its weaker affinity. The poor Caco-2 and solubility are concerning for both, but can be addressed through formulation strategies.
**Overall Assessment:**
The stronger binding affinity of Ligand B is tempting. However, the significantly improved safety profile of Ligand A (lower DILI and hERG) is paramount for a cardiovascular drug. While the lower affinity of Ligand A is a drawback, it's a more manageable issue than the potential for liver toxicity or cardiotoxicity. The poor solubility and permeability are shared issues that would need to be addressed during formulation.
Output:
1
2025-04-17 18:26:56,326 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (346.427) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both ligands are below the 140 A^2 threshold for good oral absorption (A: 59.08, B: 58.64). This is excellent.
3. **logP:** Both ligands have acceptable logP values (A: 1.026, B: 2.742), falling within the 1-3 range. Ligand B is closer to the upper end, potentially raising concerns about solubility and off-target effects, but still acceptable.
4. **HBD:** Ligand A has 0 HBD, while Ligand B has 1. Both are within the acceptable limit of 5.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 3. Both are well below the 10 threshold.
6. **QED:** Both ligands have good QED scores (A: 0.553, B: 0.679), indicating drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A has a DILI risk of 31.563, and Ligand B has 12.02. Both are good (below 40), but Ligand B is significantly better.
8. **BBB:** Ligand A has a BBB penetration of 65.801, while Ligand B has 75.882. Given that ADRB2 is a GPCR, BBB penetration is a consideration, and Ligand B is better here.
9. **Caco-2:** Ligand A (-4.443) and Ligand B (-5.024) both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Ligand A (-1.777) and Ligand B (-3.462) have negative solubility values, which is also unusual. This suggests poor aqueous solubility for both compounds.
11. **hERG:** Ligand A (0.203) and Ligand B (0.518) have low hERG inhibition liability, which is excellent.
12. **Cl_mic:** Ligand A (5.02) has a much lower microsomal clearance than Ligand B (28.571), indicating better metabolic stability.
13. **t1/2:** Ligand A (4.191) has a longer in vitro half-life than Ligand B (2.066). This is a significant advantage.
14. **Pgp:** Ligand A (0.047) has lower P-gp efflux liability than Ligand B (0.203), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand B (-7.6) has a slightly better binding affinity than Ligand A (-7.5), but the difference is small (0.1 kcal/mol).
**Overall Assessment:**
For a GPCR target like ADRB2, we prioritize logP, TPSA, Pgp, BBB, and affinity. Both compounds are reasonably good across most parameters. However, Ligand B shows better BBB penetration and a slightly better binding affinity. Ligand A has a significant advantage in metabolic stability (lower Cl_mic and longer t1/2) and P-gp efflux. The solubility and Caco-2 values are concerning for both, but the differences in other key ADME properties are more impactful. Considering the balance, the improved metabolic stability and lower P-gp efflux of Ligand A are more valuable than the slight affinity improvement of Ligand B.
**Output:**
1
2025-04-17 18:26:56,326 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
The target is ADRB2, a GPCR. Therefore, I will prioritize logP, TPSA, Pgp efflux, BBB penetration, and binding affinity, alongside general drug-like properties.
* **Molecular Weight:** Both ligands are within the ideal range (200-500 Da).
* **TPSA:** Ligand B (40.62) is significantly better than Ligand A (115.9). Lower TPSA generally correlates with better cell permeability, crucial for GPCR targeting.
* **logP:** Ligand B (2.941) is optimal, while Ligand A (0.406) is quite low, potentially hindering membrane permeability.
* **H-Bond Donors/Acceptors:** Ligand A has 3 HBD and 7 HBA, while Ligand B has 0 HBD and 2 HBA. Ligand B is preferable here, as fewer hydrogen bonds can improve permeability.
* **QED:** Both ligands have good QED scores (0.707 and 0.731), indicating good overall drug-likeness.
* **DILI:** Ligand A (70.686) has a higher DILI risk than Ligand B (47.305), which is undesirable.
* **BBB:** Ligand B (96.278) has excellent BBB penetration, while Ligand A (9.539) is very poor. While ADRB2 isn't exclusively a CNS target, some CNS exposure can be beneficial or at least needs to be understood.
* **Caco-2:** Ligand A (-5.399) and Ligand B (-4.324) are both negative, indicating poor permeability. However, the negative value is less concerning than the other properties.
* **Solubility:** Ligand A (-2.088) and Ligand B (-3.003) are both poor.
* **hERG:** Ligand A (0.105) has a slightly better hERG profile than Ligand B (0.67).
* **Cl_mic:** Ligand A (-12.489) has a much lower (better) microsomal clearance than Ligand B (46.987), indicating better metabolic stability.
* **t1/2:** Ligand A (32.876) has a better in vitro half-life than Ligand B (-11.153).
* **Pgp:** Ligand A (0.153) has lower P-gp efflux than Ligand B (0.245), which is favorable.
* **Binding Affinity:** Ligand A (-6.6 kcal/mol) has a slightly better binding affinity than Ligand B (-5.9 kcal/mol), but the difference is not substantial enough to outweigh the other significant differences.
**Overall Assessment:**
Ligand B is clearly the better candidate. Its superior TPSA, logP, BBB penetration, and lower DILI risk are critical advantages for a GPCR target like ADRB2. While Ligand A has better metabolic stability and a slightly better binding affinity, the permeability and safety concerns associated with its properties are more significant drawbacks. The binding affinity difference is not large enough to overcome the other issues.
**Output:**
0
2025-04-17 18:26:56,326 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (345.447 and 348.443 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (80.12) is slightly higher than Ligand B (71.63). Both are below the 140 A^2 threshold for good oral absorption, but closer to the 90 A^2 threshold for CNS targets, which isn't a primary concern for ADRB2 (cardiovascular). Ligand B is preferable.
3. **logP:** Ligand A (1.067) is within the optimal 1-3 range. Ligand B (3.608) is at the upper end of the optimal range, potentially increasing off-target effects and decreasing solubility. Ligand A is preferable.
4. **HBD:** Both ligands have 1 HBD, which is acceptable.
5. **HBA:** Ligand A has 5 HBA, and Ligand B has 4. Both are below the 10 threshold.
6. **QED:** Ligand A (0.75) has a slightly better QED score than Ligand B (0.666), indicating a more drug-like profile. Ligand A is preferable.
7. **DILI:** Ligand A (23.575) has a significantly lower DILI risk than Ligand B (37.728). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (85.731) has a higher BBB penetration percentile than Ligand B (77.084). While not a primary concern for ADRB2, higher BBB is generally favorable.
9. **Caco-2:** Ligand A (-5.035) has a worse Caco-2 permeability than Ligand B (-4.536). Ligand B is preferable.
10. **Solubility:** Ligand A (-1.816) has a better solubility than Ligand B (-4.039). Ligand A is preferable.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.061 and 0.618 respectively). No significant difference.
12. **Cl_mic:** Ligand A (26.152) has a significantly lower microsomal clearance than Ligand B (66.964), indicating better metabolic stability. Ligand A is preferable.
13. **t1/2:** Ligand A (-9.467) has a longer in vitro half-life than Ligand B (-25.31). Ligand A is preferable.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.022 and 0.156 respectively). No significant difference.
15. **Binding Affinity:** Both ligands have similar binding affinities (-6.6 and -6.2 kcal/mol). The difference is less than the 1.5 kcal/mol threshold.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A has a more favorable logP and TPSA. Both have similar Pgp and affinity. The significantly better DILI, QED, solubility, metabolic stability (Cl_mic, t1/2) of Ligand A outweigh the slightly better Caco-2 permeability of Ligand B.
**Conclusion:**
Ligand A demonstrates a better overall profile, balancing potency with significantly improved safety (DILI) and pharmacokinetic properties (Cl_mic, t1/2, solubility, QED).
Output:
1
2025-04-17 18:26:56,326 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (347.415 and 362.417 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (82.11) is higher than Ligand B (59.08). For a cardiovascular GPCR, TPSA is moderately important. Ligand B is preferable due to its lower TPSA, suggesting better potential for membrane permeability.
**3. logP:** Ligand A (0.285) is quite low, potentially hindering permeability. Ligand B (1.388) is within the optimal 1-3 range. This is a significant advantage for Ligand B.
**4. H-Bond Donors:** Ligand A has 2 HBD, and Ligand B has 0. Both are acceptable, but fewer HBDs generally improve permeability, favoring Ligand B.
**5. H-Bond Acceptors:** Ligand A has 5 HBA, and Ligand B has 4. Both are within the acceptable limit of 10.
**6. QED:** Ligand A (0.821) has a slightly higher QED than Ligand B (0.717), indicating a more drug-like profile. This is a positive for Ligand A, but not a decisive factor.
**7. DILI:** Both ligands have low DILI risk (Ligand A: 31.136, Ligand B: 28.306). No significant difference.
**8. BBB:** Ligand A (46.375) has a lower BBB penetration percentile than Ligand B (90.655). While ADRB2 is a cardiovascular target, some CNS exposure can be relevant for off-target effects and safety assessment. Ligand B is strongly preferred here.
**9. Caco-2 Permeability:** Ligand A (-5.303) has worse Caco-2 permeability than Ligand B (-4.416). This supports the idea that Ligand A may have absorption issues.
**10. Aqueous Solubility:** Both ligands have similar, poor aqueous solubility (-1.603 and -1.854). This is a potential formulation challenge for both.
**11. hERG Inhibition:** Ligand A (0.274) has a lower hERG inhibition liability than Ligand B (0.611), which is a positive for Ligand A.
**12. Microsomal Clearance:** Ligand A (16.273) and Ligand B (15.648) have similar microsomal clearance values, indicating comparable metabolic stability.
**13. In vitro Half-Life:** Ligand A (10.732) has a longer half-life than Ligand B (-8.13). This is a significant advantage for Ligand A, potentially allowing for less frequent dosing.
**14. P-gp Efflux:** Ligand A (0.02) has very low P-gp efflux, while Ligand B (0.127) has slightly higher efflux. Lower P-gp efflux is preferable, favoring Ligand A.
**15. Binding Affinity:** Ligand A (-6.7 kcal/mol) has a slightly better binding affinity than Ligand B (-5.7 kcal/mol). This 1 kcal/mol difference is significant and can outweigh some ADME drawbacks.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp) and the overall profile, Ligand A emerges as the more promising candidate. While Ligand B has better BBB penetration, the significantly lower logP of Ligand A is a major concern for permeability and absorption. Ligand A's better binding affinity, lower P-gp efflux, and longer half-life further strengthen its position. The slightly higher TPSA is a minor drawback compared to the permeability issues with Ligand B.
Output:
1
2025-04-17 18:26:56,326 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's systematically compare Ligand A and Ligand B based on the provided parameters and the guidelines, keeping in mind ADRB2 is a GPCR. GPCRs prioritize logP, Pgp, TPSA, and affinity.
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (337.467 Da) is slightly preferred due to being lower.
2. **TPSA:** Ligand A (45.23) is significantly better than Ligand B (65.97). A TPSA under 140 is good for oral absorption, and lower is generally better for GPCRs.
3. **logP:** Both ligands have a logP around 3.7, which is within the optimal range (1-3). No strong preference here.
4. **H-Bond Donors:** Ligand A (1) is better than Ligand B (0). While both are acceptable, a single donor can aid solubility without significantly harming permeability.
5. **H-Bond Acceptors:** Ligand B (6) is slightly higher than Ligand A (3). Both are within the acceptable range (<=10), but lower is generally preferred.
6. **QED:** Both ligands have similar QED values (0.747 and 0.706), indicating good drug-likeness.
7. **DILI:** Ligand A (32.803) has a considerably lower DILI risk than Ligand B (62.699). This is a significant advantage for Ligand A.
8. **BBB:** Both ligands show similar BBB penetration (76.231 and 76.154). This is good, but not a primary driver for ADRB2 as it's a cardiovascular target.
9. **Caco-2 Permeability:** Ligand A (-4.727) is better than Ligand B (-5.247), indicating better intestinal absorption.
10. **Aqueous Solubility:** Ligand A (-4.143) is better than Ligand B (-3.194), suggesting better solubility.
11. **hERG Inhibition:** Ligand A (0.82) is better than Ligand B (0.563), indicating a lower risk of cardiotoxicity.
12. **Microsomal Clearance:** Ligand B (49.483) has lower microsomal clearance than Ligand A (76.589), suggesting better metabolic stability. This is a point in favor of Ligand B.
13. **In vitro Half-Life:** Ligand A (45.117) has a significantly longer half-life than Ligand B (14.652). This is a substantial advantage for Ligand A.
14. **P-gp Efflux:** Ligand A (0.527) is better than Ligand B (0.628), indicating lower P-gp efflux.
15. **Binding Affinity:** Ligand B (-7.4) has a stronger binding affinity than Ligand A (-6.7). This is a 1.7 kcal/mol difference, which is a significant advantage for Ligand B.
**Overall Assessment:**
While Ligand B has superior binding affinity, Ligand A demonstrates a more favorable overall profile. Ligand A excels in safety (lower DILI, lower hERG), ADME properties (better solubility, permeability, half-life, and P-gp efflux), and TPSA. The affinity difference, while substantial, can potentially be optimized in later stages of drug development. The better ADME and safety profile of Ligand A make it a more promising starting point for a cardiovascular drug candidate targeting ADRB2.
**Output:**
1
2025-04-17 18:26:56,326 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (361.364 and 350.379 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (74.58) is significantly better than Ligand B (131.52). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary goal, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 cutoff. Ligand B is approaching the upper limit.
3. **logP:** Ligand A (1.79) is within the optimal 1-3 range. Ligand B (-1.709) is below 1, which could hinder permeability. This is a significant negative for Ligand B.
4. **HBD:** Ligand A (2) and Ligand B (3) are both acceptable, being less than 5.
5. **HBA:** Ligand A (4) and Ligand B (6) are both acceptable, being less than 10.
6. **QED:** Ligand A (0.726) is better than Ligand B (0.579), indicating a more drug-like profile.
7. **DILI:** Ligand A (11.516) has a much lower DILI risk than Ligand B (63.086). This is a critical advantage for Ligand A.
8. **BBB:** Not a primary concern for a cardiovascular target. Ligand A (86.08) is higher than Ligand B (16.363), but this isn't decisive.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-4.988) is slightly better than Ligand B (-5.48).
10. **Solubility:** Both are negative, indicating poor solubility. Ligand A (-2.37) is slightly better than Ligand B (-2.129).
11. **hERG:** Both are low, indicating low risk of hERG inhibition. Ligand A (0.88) is slightly higher than Ligand B (0.089), but both are acceptable.
12. **Cl_mic:** Ligand A (-30.614) has a much lower (better) microsomal clearance than Ligand B (15.944). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (1.49) has a shorter half-life than Ligand B (-4.292). This is a negative for Ligand A, but not a dealbreaker.
14. **Pgp:** Ligand A (0.08) has a lower Pgp efflux liability than Ligand B (0.036), which is favorable.
15. **Binding Affinity:** Ligand A (-6.3) has a better binding affinity than Ligand B (-2.0). This is a substantial advantage for Ligand A.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A excels in these areas. While BBB isn't crucial here, Ligand A's higher value is a bonus.
**Overall Assessment:**
Ligand A demonstrates a significantly more favorable profile across most critical parameters. Its superior logP, lower DILI risk, better metabolic stability (lower Cl_mic), and substantially stronger binding affinity outweigh its slightly shorter half-life. Ligand B's low logP and high DILI risk are major concerns.
Output:
1
2025-04-17 18:26:56,326 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [348.447, 96.11, 1.66, 3, 4, 0.728, 37.728, 49.981, -5.418, -2.288, 0.184, 17.035, -15.164, 0.017, -6.2]
**Ligand B:** [344.467, 97.78, 2.325, 2, 8, 0.532, 52.036, 71.074, -5.519, -2.277, 0.642, 40.24, 17.465, 0.163, -6.2]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (344.467) is slightly lower, which is generally favorable.
2. **TPSA:** Both are reasonably good, under 140, but not ideal for CNS penetration. Ligand A (96.11) is slightly better than Ligand B (97.78).
3. **logP:** Both are within the optimal range (1-3). Ligand A (1.66) is slightly preferred as it's closer to the middle of the range. Ligand B (2.325) is still acceptable.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (2), but both are within the acceptable limit of 5.
5. **HBA:** Ligand A (4) is better than Ligand B (8). Higher HBA can sometimes lead to off-target interactions.
6. **QED:** Ligand A (0.728) has a significantly better QED score than Ligand B (0.532), indicating a more drug-like profile.
7. **DILI:** Ligand A (37.728) has a much lower DILI risk than Ligand B (52.036). This is a significant advantage for Ligand A.
8. **BBB:** Ligand B (71.074) has a better BBB penetration score than Ligand A (49.981). While ADRB2 isn't a primary CNS target, some peripheral ADRB2 activity can influence CNS function, so this is a minor positive for Ligand B.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-5.418) is slightly better than Ligand B (-5.519).
10. **Solubility:** Both have negative solubility values, which is also unusual and suggests poor solubility. They are very similar.
11. **hERG:** Both have very low hERG inhibition liability, which is excellent.
12. **Cl_mic:** Ligand A (17.035) has a lower microsomal clearance than Ligand B (40.24), indicating better metabolic stability.
13. **t1/2:** Ligand B (17.465) has a slightly longer in vitro half-life than Ligand A (-15.164). However, the negative value for Ligand A is concerning.
14. **Pgp:** Both have very low P-gp efflux liability, which is good.
15. **Affinity:** Both have the same binding affinity (-6.2 kcal/mol), so this parameter doesn't differentiate them.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Both ligands perform similarly on logP, Pgp, and affinity. TPSA is slightly better for Ligand A. The biggest differentiators are QED and DILI, where Ligand A is significantly better. Metabolic stability (Cl_mic) also favors Ligand A. While BBB is better for Ligand B, it's less crucial for a cardiovascular target. The negative half-life for Ligand A is a major red flag.
**Conclusion:**
Despite the slightly better BBB penetration of Ligand B, Ligand A is the more promising candidate due to its superior QED score, lower DILI risk, better metabolic stability, and more favorable HBA count. The negative half-life of Ligand A is concerning, but the other advantages outweigh this drawback.
Output:
1
2025-04-17 18:26:56,326 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (401.26 Da) is within the ideal range. Ligand B (348.407 Da) is also within range, but closer to the lower limit.
2. **TPSA:** Ligand A (63.35) is good, below 140. Ligand B (124.14) is also acceptable, but higher and potentially impacting permeability.
3. **logP:** Ligand A (4.571) is slightly high, potentially leading to solubility issues or off-target effects. Ligand B (-0.314) is too low, suggesting poor membrane permeability.
4. **HBD:** Both ligands have 2 HBD, which is within the acceptable range.
5. **HBA:** Ligand A has 3 HBA, while Ligand B has 7. Ligand B is higher and could affect permeability.
6. **QED:** Both ligands have similar QED values (0.661 and 0.696), indicating good drug-likeness.
7. **DILI:** Ligand A (94.223) has a high DILI risk. Ligand B (32.183) has a very low DILI risk, a significant advantage.
8. **BBB:** Ligand A (76.076) has moderate BBB penetration. Ligand B (25.746) has very low BBB penetration. Since ADRB2 is a cardiovascular target, BBB penetration is not a primary concern, but it's not detrimental if moderate.
9. **Caco-2:** Ligand A (-4.923) has poor Caco-2 permeability. Ligand B (-5.476) also has poor Caco-2 permeability.
10. **Solubility:** Ligand A (-5.943) has poor solubility. Ligand B (-1.453) has slightly better solubility, but still low.
11. **hERG:** Ligand A (0.878) has a slightly elevated hERG risk. Ligand B (0.085) has very low hERG risk, a major advantage.
12. **Cl_mic:** Ligand A (46.302) has moderate clearance. Ligand B (-13.115) has negative clearance, indicating very high metabolic stability.
13. **t1/2:** Ligand A (109.121) has a long half-life. Ligand B (3.256) has a very short half-life.
14. **Pgp:** Ligand A (0.898) has moderate Pgp efflux. Ligand B (0.025) has very low Pgp efflux, which is favorable.
15. **Affinity:** Ligand A (-5.8 kcal/mol) has slightly better binding affinity than Ligand B (-6.4 kcal/mol).
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A has a higher logP and lower Pgp efflux than Ligand B. However, Ligand B has a significantly better safety profile (DILI and hERG) and metabolic stability (Cl_mic). The affinity difference is not substantial enough to overcome the ADME/Tox advantages of Ligand B.
**Conclusion:**
Despite the slightly weaker binding affinity, Ligand B is the more promising candidate due to its significantly improved safety profile (lower DILI and hERG risk), better metabolic stability, and lower Pgp efflux. The poor permeability of both compounds is a concern, but can be addressed through formulation strategies.
Output:
0
2025-04-17 18:26:56,326 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (336.351 and 346.471 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (67.43) is significantly better than Ligand A (91.73). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (2.649 and 2.991), falling within the 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Ligand A has 1 HBD, while Ligand B has 2. Both are acceptable, under the threshold of 5.
5. **HBA:** Ligand A has 5 HBA, Ligand B has 3. Both are well within the acceptable range of <=10.
6. **QED:** Ligand A (0.869) has a substantially better QED score than Ligand B (0.574), indicating a more drug-like profile. This is a significant advantage for Ligand A.
7. **DILI:** Ligand A (90.733) has a considerably higher DILI risk than Ligand B (17.371). This is a major concern for Ligand A.
8. **BBB:** Ligand B (70.88) has a higher BBB penetration percentile than Ligand A (59.325). While not critical for a cardiovascular target, it's a slight positive for Ligand B.
9. **Caco-2:** Ligand A (-5.035) has a worse Caco-2 permeability than Ligand B (-4.44). Lower values are less favorable.
10. **Solubility:** Ligand A (-4.675) has a slightly worse solubility than Ligand B (-4.119).
11. **hERG:** Both ligands have low hERG inhibition liability (0.259 and 0.491), which is good.
12. **Cl_mic:** Ligand A (-11.955) has a *much* lower (better) microsomal clearance than Ligand B (69.654). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (41.209 hours) has a significantly longer in vitro half-life than Ligand B (4.198 hours). This is a major advantage for Ligand A, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.162 and 0.172).
15. **Binding Affinity:** Ligand A (-7.3 kcal/mol) has a slightly better binding affinity than Ligand B (-7.1 kcal/mol). While the difference is small, it's still a positive for Ligand A.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are important. Ligand B has a slight edge in logP and a significant edge in TPSA. Ligand A has a slight edge in affinity. However, the DILI risk associated with Ligand A is a serious concern.
**Overall Assessment:**
Despite Ligand A's better QED, longer half-life, better metabolic stability, and slightly better affinity, the significantly elevated DILI risk is a major drawback. The improved TPSA of Ligand B, combined with its much lower DILI risk, makes it the more promising candidate, even with its lower QED and shorter half-life. The difference in binding affinity is small enough to be potentially overcome with further optimization.
Output:
0
2025-04-17 18:26:56,326 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (354.491 and 345.399 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (67.87) is significantly better than Ligand B (91.76). ADRB2 is a cardiovascular target, not CNS, but lower TPSA generally improves absorption. Ligand A is well below the 140 threshold. Ligand B is approaching the upper limit.
3. **logP:** Ligand A (2.319) is optimal. Ligand B (0.352) is quite low, potentially hindering membrane permeability.
4. **HBD:** Both ligands have acceptable HBD counts (1 and 2, respectively), well below the threshold of 5.
5. **HBA:** Both ligands have acceptable HBA counts (4 and 5, respectively), well below the threshold of 10.
6. **QED:** Both ligands have good QED scores (0.611 and 0.726), indicating good drug-like properties.
7. **DILI:** Ligand A (12.253) has a much lower DILI risk than Ligand B (40.132). This is a significant advantage for Ligand A.
8. **BBB:** Not a primary concern for a cardiovascular target, but Ligand A (69.756) is better than Ligand B (32.881).
9. **Caco-2:** Ligand A (-4.488) is better than Ligand B (-5.063), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-1.441) is better than Ligand B (-1.296), though both are similarly poor.
11. **hERG:** Both ligands have low hERG inhibition liability (0.327 and 0.138, respectively). No significant difference.
12. **Cl_mic:** Ligand B (-11.23) has significantly better metabolic stability (lower clearance) than Ligand A (42.528). This is a major advantage for Ligand B.
13. **t1/2:** Ligand B (16.061) has a longer in vitro half-life than Ligand A (8.585). This is another advantage for Ligand B.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.069 and 0.009, respectively). No significant difference.
15. **Binding Affinity:** Ligand A (-6.5) has a slightly better binding affinity than Ligand B (-6.1), but the difference is relatively small (0.4 kcal/mol).
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, and affinity are important. Ligand A excels in logP and TPSA, and has slightly better affinity. Ligand B has better metabolic stability (Cl_mic) and half-life, which are also important, but the difference in affinity isn't large enough to outweigh the advantages of Ligand A in terms of absorption and reduced toxicity risk (DILI).
**Conclusion:**
Considering the balance of properties, Ligand A appears to be the more promising drug candidate. Its superior logP, TPSA, and significantly lower DILI risk outweigh the slightly better metabolic stability and half-life of Ligand B.
Output:
1
2025-04-17 18:26:56,327 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (339.395 Da) is within the ideal range (200-500 Da). Ligand B (473.336 Da) is at the upper limit, but still acceptable.
2. **TPSA:** Both Ligand A (80.32) and Ligand B (79.37) are below 140, good for oral absorption and acceptable for a non-CNS GPCR target like ADRB2.
3. **logP:** Both ligands have good logP values (A: 1.626, B: 1.807), falling within the optimal 1-3 range.
4. **HBD:** Ligand A (2) and Ligand B (1) are both within the acceptable limit of <=5.
5. **HBA:** Ligand A (4) and Ligand B (5) are both within the acceptable limit of <=10.
6. **QED:** Ligand A (0.812) has a significantly better QED score than Ligand B (0.592), indicating better overall drug-likeness.
7. **DILI:** Ligand A (54.789) has a lower DILI risk than Ligand B (65.374), which is preferable.
8. **BBB:** Both are relatively low, which is fine for a cardiovascular target. Ligand A (54.634) is slightly better than Ligand B (44.979).
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand B (-5.485) is slightly worse than Ligand A (-4.84).
10. **Solubility:** Both ligands have negative solubility values, indicating poor aqueous solubility, which is a concern. Ligand A (-2.963) is slightly better than Ligand B (-2.606).
11. **hERG:** Both ligands have very low hERG inhibition risk (A: 0.206, B: 0.56), which is excellent.
12. **Cl_mic:** Ligand A (35.063) has a higher microsomal clearance than Ligand B (25.684), suggesting lower metabolic stability. This is a negative for Ligand A.
13. **t1/2:** Ligand B (26.003) has a much longer in vitro half-life than Ligand A (0.499), which is a significant advantage.
14. **Pgp:** Both ligands have low P-gp efflux liability (A: 0.074, B: 0.165), which is good.
15. **Binding Affinity:** Ligand B (-6.3 kcal/mol) has a slightly better binding affinity than Ligand A (-6.6 kcal/mol).
**GPCR-specific priorities:** For ADRB2 (a cardiovascular GPCR), logP, Pgp, TPSA, and affinity are important. Both ligands perform well on logP, Pgp, and TPSA. Ligand B has slightly better affinity. However, the significant differences in QED, DILI, Cl_mic, and t1/2 are critical. Ligand A has better QED, DILI, but worse Cl_mic and t1/2. Ligand B's longer half-life and lower clearance are more valuable for a drug candidate, even with a slightly lower QED and higher DILI.
**Conclusion:**
Despite the slightly better affinity of Ligand A, Ligand B's superior metabolic stability (lower Cl_mic, longer t1/2) and acceptable DILI risk make it the more promising candidate. The better QED of Ligand A is outweighed by the pharmacokinetic advantages of Ligand B.
Output:
0
2025-04-17 18:26:56,327 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (349.356 and 341.426 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (46.92) is higher than Ligand B (29.54). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for permeability. Ligand B has a clear advantage.
3. **logP:** Ligand B (4.438) is slightly higher than Ligand A (3.94). Both are above the optimal range of 1-3, but Ligand B is pushing the upper limit. This could potentially lead to solubility issues, but is manageable.
4. **HBD:** Ligand A (1) is slightly higher than Ligand B (0). Both are within the acceptable limit of <=5.
5. **HBA:** Ligand A (3) is higher than Ligand B (2). Both are within the acceptable limit of <=10.
6. **QED:** Ligand A (0.909) is better than Ligand B (0.823), indicating a more drug-like profile. This is a positive for Ligand A.
7. **DILI:** Ligand B (50.33) has a lower DILI risk than Ligand A (68.05). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (94.416) shows significantly higher BBB penetration than Ligand B (89.066). While ADRB2 is not a CNS target, some off-target CNS effects are always a consideration.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.339 and -4.453), which is unusual and suggests poor permeability. This is a major concern for both compounds.
10. **Solubility:** Ligand A (-5.211) has slightly better solubility than Ligand B (-4.503), but both are very poor. This is a significant drawback for both.
11. **hERG:** Ligand A (0.537) has a lower hERG risk than Ligand B (0.87), which is a positive for Ligand A.
12. **Cl_mic:** Ligand B (59.916) has a higher microsomal clearance than Ligand A (46.253), indicating lower metabolic stability. This is a negative for Ligand B.
13. **t1/2:** Ligand A (-4.308) has a longer in vitro half-life than Ligand B (27.654). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.444) has lower P-gp efflux than Ligand B (0.594), which is a positive for Ligand A.
15. **Binding Affinity:** Ligand B (-6.6) has slightly better binding affinity than Ligand A (-6.5). While the difference is small, it's still a factor.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand A and B are fairly comparable. Ligand B has a slight edge in affinity, but Ligand A excels in QED, DILI risk, metabolic stability (Cl_mic and t1/2), Pgp efflux, and hERG risk. The poor Caco-2 and solubility for both compounds are concerning and would require significant optimization. However, the better ADME profile of Ligand A, particularly the lower DILI risk and improved metabolic stability, makes it a more promising starting point for further development.
Output:
1
2025-04-17 18:26:56,327 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.531 and 357.439 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (49.41) is significantly better than Ligand B (106.91). ADRB2 is a cardiovascular target, so CNS penetration isn't critical, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold, while Ligand B is approaching it.
3. **logP:** Ligand A (4.055) is higher than Ligand B (1.753). While both are within the acceptable range, Ligand A is at the upper end. This *could* lead to solubility issues, but it might also contribute to better membrane permeability. Ligand B is a bit low, potentially hindering permeation.
4. **HBD:** Ligand A (1) is better than Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (2) is better than Ligand B (6). Similar to HBD, lower HBA is preferred.
6. **QED:** Both ligands have good QED scores (0.639 and 0.73), indicating good overall drug-likeness. No major difference.
7. **DILI:** Ligand A (13.571) has a much lower DILI risk than Ligand B (77.2). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (78.868) has higher BBB penetration than Ligand B (61.109). While not a primary concern for a cardiovascular target, it's still a slight positive for Ligand A.
9. **Caco-2:** Ligand A (-4.809) is better than Ligand B (-5.332). Higher Caco-2 values indicate better absorption.
10. **Solubility:** Ligand A (-4.148) is better than Ligand B (-3.592). Better solubility is always a plus.
11. **hERG:** Both ligands have relatively low hERG risk (0.484 and 0.619). No significant difference.
12. **Cl_mic:** Ligand A (57.072) has a higher (worse) microsomal clearance than Ligand B (11.616). This suggests Ligand B is more metabolically stable.
13. **t1/2:** Ligand A (-11.924) has a shorter half-life than Ligand B (52.295). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.449) has lower P-gp efflux than Ligand B (0.101). Lower P-gp efflux is generally desirable.
15. **Binding Affinity:** Ligand B (-7.2) has a significantly stronger binding affinity than Ligand A (-5.4). This is a substantial advantage, exceeding the 1.5 kcal/mol threshold.
**Overall Assessment:**
Ligand B has a significantly better binding affinity, which is the most important factor. It also has superior metabolic stability (lower Cl_mic) and a longer half-life. While Ligand A excels in several ADME properties (TPSA, solubility, DILI, Pgp), the substantial affinity difference of Ligand B outweighs these advantages. The slightly lower logP of Ligand B is a minor concern, but manageable.
Output:
0
2025-04-17 18:26:56,327 - INFO - Batch 38 complete. Total preferences: 608
2025-04-17 18:26:56,327 - INFO - Processing batch 39/512...
2025-04-17 18:27:47,073 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [350.463, 67.67, 1.227, 0, 5, 0.707, 27.414, 69.988, -4.841, -0.496, 0.154, 16.303, 16.505, 0.041, -6.4]
**Ligand B:** [345.495, 62.11, 2.446, 1, 7, 0.832, 65.529, 86.894, -4.828, -2.578, 0.97, 50.206, 31.64, 0.367, -6.4]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (350.463) is slightly higher than Ligand B (345.495), but the difference is negligible.
2. **TPSA:** Both are below the 140 A^2 threshold for good oral absorption. Ligand A (67.67) is slightly higher than Ligand B (62.11), but still acceptable.
3. **logP:** Both are within the optimal range (1-3). Ligand A (1.227) is slightly better than Ligand B (2.446), as lower logP values can sometimes reduce off-target effects.
4. **HBD:** Ligand A (0) is better than Ligand B (1). Fewer HBDs generally improve membrane permeability.
5. **HBA:** Ligand A (5) is better than Ligand B (7). Fewer HBAs generally improve membrane permeability.
6. **QED:** Both are above 0.5, indicating good drug-likeness, with Ligand B (0.832) being slightly better than Ligand A (0.707).
7. **DILI:** Ligand A (27.414) has a significantly lower DILI risk than Ligand B (65.529). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (86.894) has a better BBB penetration score than Ligand A (69.988). While ADRB2 isn't strictly a CNS target, some peripheral ADRB2 activity can influence CNS pathways, so some BBB penetration isn't necessarily detrimental.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. This is concerning for both, but the values are very close.
10. **Solubility:** Ligand A (-0.496) has better solubility than Ligand B (-2.578). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.154) has a much lower hERG inhibition liability than Ligand B (0.97). This is a significant safety advantage for Ligand A.
12. **Cl_mic:** Ligand A (16.303) has a lower microsomal clearance, suggesting better metabolic stability than Ligand B (50.206).
13. **t1/2:** Ligand B (31.64) has a longer in vitro half-life than Ligand A (16.505). This is a positive for Ligand B.
14. **Pgp:** Ligand A (0.041) has lower P-gp efflux liability than Ligand B (0.367). Lower P-gp efflux is generally preferred.
15. **Affinity:** Both have the same binding affinity (-6.4 kcal/mol).
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A has a better logP, lower Pgp efflux, and lower TPSA. The affinity is the same. The biggest differentiator is the significantly lower DILI and hERG risk for Ligand A, which are critical safety parameters. While Ligand B has better BBB penetration and a longer half-life, the safety concerns outweigh these benefits.
**Conclusion:**
Considering the balance of properties, particularly the significantly improved safety profile (DILI and hERG) and better ADME properties (logP, Pgp, solubility, Cl_mic) of Ligand A, it is the more promising drug candidate.
**Output:**
1
2025-04-17 18:27:47,074 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (403.284 Da) and Ligand B (364.511 Da) both fall within the ideal 200-500 Da range. Ligand B is slightly preferred due to being closer to the lower end, potentially aiding permeability.
2. **TPSA:** Ligand A (77.63) is higher than Ligand B (49.85). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is generally better for absorption. Ligand B is favored.
3. **logP:** Both ligands have good logP values (A: 2.796, B: 2.903), falling within the optimal 1-3 range. Very similar, no strong preference.
4. **HBD:** Ligand A (1) is slightly better than Ligand B (0). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (6) is higher than Ligand B (4). Lower HBA is preferred for permeability. Ligand B is favored.
6. **QED:** Both ligands have acceptable QED values (A: 0.687, B: 0.747), exceeding the 0.5 threshold. Ligand B is slightly better.
7. **DILI:** Ligand A has a significantly higher DILI risk (83.211) compared to Ligand B (13.571). This is a major concern for Ligand A. Ligand B is strongly favored.
8. **BBB:** BBB is less critical for a cardiovascular target. Ligand A (43.273) and Ligand B (87.67) both have values that are not particularly high or low. Ligand B is slightly favored.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.435 and -4.676), which is unusual and suggests poor permeability. However, these values are on a scale where higher is better, so we interpret these as very low permeability. No strong preference.
10. **Solubility:** Both ligands have negative solubility values (-3.653 and -2.604), indicating poor aqueous solubility. No strong preference.
11. **hERG:** Both ligands have low hERG inhibition liability (A: 0.187, B: 0.55). No strong preference.
12. **Cl_mic:** Both ligands have similar microsomal clearance values (A: 52.654, B: 49.889). No strong preference.
13. **t1/2:** Ligand A (33.666) has a longer in vitro half-life than Ligand B (26.645), which is a slight advantage.
14. **Pgp:** Both ligands have low Pgp efflux liability (A: 0.167, B: 0.125). No strong preference.
15. **Binding Affinity:** Ligand B (-6.7 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.4 kcal/mol). This is a substantial advantage, exceeding the 1.5 kcal/mol threshold.
**Overall Assessment:**
Ligand B is clearly the superior candidate. While both have issues with Caco-2 and solubility, Ligand B demonstrates a significantly lower DILI risk and a substantially stronger binding affinity. The improved QED and TPSA also contribute to its favorability. The slightly longer half-life of Ligand A is not enough to overcome these significant advantages.
Output:
0
2025-04-17 18:27:47,074 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (357.36 and 354.44 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (93.46) is slightly higher than Ligand B (75.19). Both are below the 140 threshold for oral absorption, but B is preferable given the GPCR target class.
3. **logP:** Both ligands have good logP values (1.66 and 1.40), falling within the optimal 1-3 range. No major distinction.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1), but both are acceptable (<=5).
5. **HBA:** Both ligands have 5 HBA, which is within the acceptable range.
6. **QED:** Ligand B (0.842) has a better QED score than Ligand A (0.656), indicating a more drug-like profile.
7. **DILI:** Both ligands have acceptable DILI risk (49.94 and 52.89 percentile), below the 60 threshold. No significant difference.
8. **BBB:** Ligand A (85.73) shows significantly better BBB penetration potential than Ligand B (49.79). While ADRB2 isn't exclusively a CNS target, improved BBB penetration can still be beneficial for distribution and potentially reducing off-target effects.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Both ligands have negative solubility values, which is also a concern.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.18 and 0.12), which is excellent.
12. **Cl_mic:** Ligand B (20.45) has a significantly lower microsomal clearance than Ligand A (34.35), suggesting better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand B (-16.14) has a longer in vitro half-life than Ligand A (-10.60), further supporting its better metabolic stability.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.038 and 0.132), which is favorable.
15. **Binding Affinity:** Ligand B (-6.8 kcal/mol) has a substantially stronger binding affinity than Ligand A (-4.8 kcal/mol). This is a crucial advantage, exceeding the 1.5 kcal/mol difference threshold.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B excels in affinity and has a lower TPSA. While Ligand A has better BBB penetration, the substantial affinity advantage of Ligand B, coupled with its improved metabolic stability (lower Cl_mic and longer t1/2), outweighs this benefit. The poor Caco-2 and solubility for both are concerning, but can be addressed through formulation strategies.
**Conclusion:**
Ligand B is the more promising drug candidate due to its significantly stronger binding affinity and improved metabolic stability.
Output:
0
2025-04-17 18:27:47,074 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, key priorities are logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB.
Let's break down the comparison:
1. **MW:** Both ligands (362.77 and 364.42 Da) are within the ideal range (200-500 Da).
2. **TPSA:** Ligand A (58.95) is significantly better than Ligand B (93.73). A TPSA under 140 is good for oral absorption, and lower is preferable for GPCRs. Ligand B's TPSA is approaching a concerning level.
3. **logP:** Ligand A (4.13) is higher than Ligand B (1.39). While >4 can be problematic, for a GPCR, a higher logP can be beneficial for membrane permeability and receptor engagement. Ligand B's logP is quite low, potentially hindering permeability.
4. **HBD/HBA:** Both have 2 HBD and acceptable HBA counts (3 for A, 6 for B).
5. **QED:** Ligand A (0.73) is much better than Ligand B (0.23), indicating a more drug-like profile.
6. **DILI:** Ligand B (64.33) has a lower DILI risk than Ligand A (96.86), which is a positive.
7. **BBB:** Ligand A (66.31) has a slightly better BBB penetration than Ligand B (54.52), but this isn't a huge factor for a cardiovascular target.
8. **Caco-2:** Ligand A (-4.47) has a better Caco-2 permeability than Ligand B (-5.12).
9. **Solubility:** Ligand A (-5.84) has better solubility than Ligand B (-2.56).
10. **hERG:** Both have very low hERG inhibition risk (0.42 and 0.20).
11. **Cl_mic:** Ligand B (21.46) has a significantly lower microsomal clearance than Ligand A (44.48), indicating better metabolic stability.
12. **t1/2:** Ligand A (78.03) has a much longer in vitro half-life than Ligand B (-11.28). This is a significant advantage.
13. **Pgp:** Ligand A (0.197) has lower P-gp efflux than Ligand B (0.043), which is beneficial.
14. **Binding Affinity:** Ligand A (-7.6 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.1 kcal/mol). This is a crucial difference.
**Overall Assessment:**
Ligand A is clearly superior. The significantly stronger binding affinity (-7.6 vs -6.1 kcal/mol) is a major advantage that can compensate for the higher DILI risk. The better TPSA, QED, solubility, Caco-2 permeability, Pgp efflux, and half-life also contribute to its favorability. While Ligand B has better metabolic stability, the substantial difference in binding affinity and overall drug-likeness makes Ligand A the more promising candidate.
**Output:**
1
2025-04-17 18:27:47,074 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (359.451 and 348.531 Da) fall comfortably within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (66.65) is higher than Ligand B (49.41). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B has a slight advantage.
3. **logP:** Ligand A (2.633) is within the optimal 1-3 range. Ligand B (3.912) is a bit higher, approaching the upper limit where solubility issues might arise. Ligand A has a slight advantage.
4. **HBD:** Ligand A (0) is better than Ligand B (1). Fewer HBDs generally improve membrane permeability.
5. **HBA:** Ligand A (5) is better than Ligand B (2). Fewer HBAs generally improve membrane permeability.
6. **QED:** Both ligands (0.787 and 0.723) have good drug-likeness scores, well above the 0.5 threshold. No significant difference.
7. **DILI:** Ligand A (40.132) is slightly higher than Ligand B (18.883), indicating a somewhat higher risk of drug-induced liver injury. Ligand B is significantly better here.
8. **BBB:** Both ligands have high BBB penetration (85.964 and 82.164 percentile). This isn't a primary concern for a cardiovascular target like ADRB2, but it doesn't hurt.
9. **Caco-2:** Ligand A (-5.107) and Ligand B (-4.358) both have negative values, which is unusual and suggests poor permeability. However, the scale is not defined, so it's hard to interpret.
10. **Solubility:** Ligand A (-2.814) is better than Ligand B (-4.229). Higher solubility is generally preferred.
11. **hERG:** Ligand A (0.167) is significantly better than Ligand B (0.562), indicating a lower risk of cardiotoxicity. This is crucial for a cardiovascular target.
12. **Cl_mic:** Ligand A (45.363) has a lower microsomal clearance than Ligand B (90.378), suggesting better metabolic stability. This is a positive attribute.
13. **t1/2:** Ligand A (-6.352) has a negative half-life, which is concerning. Ligand B (13.023) has a positive half-life, suggesting better *in vitro* stability.
14. **Pgp:** Ligand A (0.108) is better than Ligand B (0.188), indicating lower P-glycoprotein efflux. Lower efflux is generally preferred.
15. **Binding Affinity:** Ligand A (-7.6) has a stronger binding affinity than Ligand B (-6.6) by 1 kcal/mol. This is a significant advantage, potentially outweighing some minor ADME drawbacks.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), affinity, logP, TPSA, Pgp, and metabolic stability are key. Ligand A excels in affinity and has a more favorable logP. Ligand B has better DILI and t1/2. However, the stronger binding affinity of Ligand A is a substantial advantage, and its hERG risk is much lower. The slightly higher DILI risk of Ligand A is acceptable given the other benefits.
**Conclusion:**
Considering the balance of properties and the priorities for a cardiovascular GPCR target, Ligand A is the more promising candidate. The stronger binding affinity and lower hERG risk are particularly important.
Output:
1
2025-04-17 18:27:47,074 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (335.451 and 362.451 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (46.92) is significantly better than Ligand B (68.61). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (3.534) is slightly higher than Ligand B (1.813), placing it closer to the optimal 1-3 range. Ligand B is at the lower end, potentially impacting permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (0). While both are low, having at least one HBD can improve solubility.
5. **HBA:** Ligand A (3) is better than Ligand B (5). Lower HBA is generally preferred for permeability.
6. **QED:** Ligand B (0.832) has a slightly better QED score than Ligand A (0.648), indicating a more drug-like profile.
7. **DILI:** Both ligands have acceptable DILI risk (Ligand A: 45.87, Ligand B: 63.513), with Ligand A being slightly better.
8. **BBB:** Ligand B (83.831) has a higher BBB penetration percentile than Ligand A (64.599). However, as ADRB2 is primarily a cardiovascular target, high BBB penetration is not a critical requirement.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.803 and -4.341). These values are unusual and suggest poor permeability.
10. **Solubility:** Ligand A (-4.844) is slightly better than Ligand B (-2.29), indicating better solubility.
11. **hERG:** Both ligands have low hERG inhibition liability (Ligand A: 0.53, Ligand B: 0.375), which is favorable.
12. **Cl_mic:** Ligand B (34.039) has significantly lower microsomal clearance than Ligand A (86.072), suggesting better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand B (77.544) has a much longer in vitro half-life than Ligand A (7.301). This is a major advantage, potentially leading to less frequent dosing.
14. **Pgp:** Both ligands have low P-gp efflux liability (Ligand A: 0.502, Ligand B: 0.525).
15. **Binding Affinity:** Ligand B (-6.6 kcal/mol) has a slightly better binding affinity than Ligand A (-6.1 kcal/mol). While the difference is not huge, it's still a positive factor.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has a better logP and TPSA, but Ligand B has better affinity, Pgp, and significantly better metabolic stability (Cl_mic) and half-life. The slightly better affinity of Ligand B, coupled with its superior metabolic profile, outweighs the slightly better TPSA and logP of Ligand A.
**Conclusion:**
Considering all factors, especially the improved metabolic stability and half-life of Ligand B, it is the more promising drug candidate for ADRB2.
Output:
0
2025-04-17 18:27:47,074 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor (a GPCR).
**Ligand A:** [333.475, 20.31, 4.822, 0, 1, 0.771, 47.732, 94.533, -4.61, -5.572, 0.911, 96.134, 24.447, 0.886, -7.1]
**Ligand B:** [369.531, 90.27, 2.417, 1, 4, 0.599, 23.226, 78.79, -4.978, -2.86, 0.771, 34.707, -46.446, 0.214, -7.3]
Here's a step-by-step comparison, keeping in mind GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the acceptable range (200-500 Da). A is 333.475, B is 369.531. No strong preference here.
2. **TPSA:** A (20.31) is excellent, well below the 140 threshold, and very favorable for permeability. B (90.27) is still reasonable, but higher and could potentially impact absorption.
3. **logP:** A (4.822) is slightly high, potentially leading to solubility issues or off-target interactions, but still within a manageable range. B (2.417) is ideal. This is a significant advantage for B.
4. **HBD:** A (0) is good, minimizing potential for unwanted interactions. B (1) is also acceptable.
5. **HBA:** A (1) is good. B (4) is acceptable but higher.
6. **QED:** A (0.771) is good, indicating a drug-like profile. B (0.599) is acceptable, but less ideal.
7. **DILI:** A (47.732) is good, indicating low liver injury risk. B (23.226) is excellent, even lower risk.
8. **BBB:** A (94.533) is excellent, suggesting good potential for CNS penetration if desired. B (78.79) is good, but lower. While ADRB2 isn't *always* targeted in the CNS, this is a positive for A.
9. **Caco-2:** Both are negative, suggesting poor permeability. A (-4.61) is slightly better than B (-4.978).
10. **Solubility:** A (-5.572) is very poor. B (-2.86) is also poor, but better than A.
11. **hERG:** Both are low (0.911 and 0.771), indicating low cardiotoxicity risk. No strong preference.
12. **Cl_mic:** A (96.134) is high, indicating rapid metabolism and potentially low bioavailability. B (34.707) is much lower, suggesting better metabolic stability. This is a major advantage for B.
13. **t1/2:** A (24.447) is reasonable. B (-46.446) is extremely poor, suggesting very rapid elimination. This is a significant drawback for B.
14. **Pgp:** A (0.886) is relatively low, suggesting limited efflux. B (0.214) is very low, suggesting minimal efflux. This is a slight advantage for B.
15. **Affinity:** A (-7.1) is very good. B (-7.3) is slightly better. The difference is 0.2 kcal/mol, which isn't huge, but still favors B.
**Overall Assessment:**
Ligand B has a better balance of properties. While its half-life is a major concern, its superior logP, lower DILI risk, and better metabolic stability (lower Cl_mic) are significant advantages for a GPCR target. Ligand A's excellent BBB penetration is a plus, but its poor solubility and high metabolic clearance are concerning. The slightly better affinity of B helps to offset its shorter half-life.
Given the GPCR-specific priorities and the overall profile, I believe Ligand B is the more promising candidate, despite the half-life issue which could be addressed through prodrug strategies or formulation.
Output:
0
2025-04-17 18:27:47,075 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 drug candidates. ADRB2 is a GPCR, so we'll prioritize logP, TPSA, Pgp, BBB, and affinity, alongside general drug-like properties.
**Ligand A:**
* **MW:** 344.375 Da - Good, within the ideal range.
* **TPSA:** 102.36 - Acceptable, but pushing the upper limit for good oral absorption.
* **logP:** 1.143 - Good, within the optimal range.
* **HBD:** 1 - Good.
* **HBA:** 8 - Good.
* **QED:** 0.861 - Excellent, highly drug-like.
* **DILI:** 93.757 - Very high risk of liver injury. This is a major concern.
* **BBB:** 56.611 - Moderate, not ideal for potential CNS effects, but not a primary concern for a cardiovascular target.
* **Caco-2:** -4.501 - Poor permeability.
* **Solubility:** -3.045 - Poor solubility.
* **hERG:** 0.187 - Low risk of hERG inhibition.
* **Cl_mic:** 29.048 - Moderate clearance.
* **t1/2:** -30.036 - Very short half-life.
* **Pgp:** 0.011 - Low P-gp efflux, good.
* **Affinity:** -6.6 kcal/mol - Good binding affinity.
**Ligand B:**
* **MW:** 352.435 Da - Good, within the ideal range.
* **TPSA:** 87.91 - Excellent, well below the 140 threshold.
* **logP:** 0.559 - Slightly low, could potentially affect permeability.
* **HBD:** 1 - Good.
* **HBA:** 6 - Good.
* **QED:** 0.735 - Good, drug-like.
* **DILI:** 29.236 - Low risk of liver injury. Excellent.
* **BBB:** 61.497 - Moderate, similar to Ligand A.
* **Caco-2:** -5.006 - Poor permeability.
* **Solubility:** -0.267 - Poor solubility.
* **hERG:** 0.188 - Low risk of hERG inhibition.
* **Cl_mic:** 34.139 - Moderate clearance.
* **t1/2:** -11.389 - Short half-life, but better than Ligand A.
* **Pgp:** 0.005 - Very low P-gp efflux, excellent.
* **Affinity:** -5.3 kcal/mol - Good binding affinity, though slightly weaker than Ligand A.
**Comparison and Decision:**
The biggest differentiating factor is the DILI score. Ligand A has a very high DILI risk (93.757), which is a major red flag. While Ligand A has a slightly better affinity (-6.6 vs -5.3 kcal/mol), the liver toxicity risk is too significant to ignore. Both ligands have poor Caco-2 and solubility, which would require formulation strategies to address. Ligand B has a much more favorable safety profile (DILI) and comparable ADME properties, with even better Pgp efflux. The slightly weaker affinity of Ligand B is acceptable given the significantly reduced toxicity risk.
Therefore, I prefer Ligand B.
0
2025-04-17 18:27:47,075 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (345.403 and 346.431 Da) fall comfortably within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Both ligands (96.33 and 96.11) are below the 140 A^2 threshold for good oral absorption, and acceptable for a cardiovascular target (not requiring significant BBB penetration). No significant difference.
3. **logP:** Ligand A (-0.628) is lower than the optimal 1-3 range, potentially hindering permeability. Ligand B (1.095) is within the optimal range. This favors Ligand B.
4. **HBD:** Ligand A (2) and Ligand B (3) are both acceptable (<=5). No strong preference.
5. **HBA:** Ligand A (5) and Ligand B (4) are both acceptable (<=10). No strong preference.
6. **QED:** Both ligands (0.695 and 0.718) are above 0.5, indicating good drug-likeness. No significant difference.
7. **DILI:** Ligand A (42.807) has a slightly higher DILI risk than Ligand B (31.369), but both are below the concerning 60 threshold. Slight preference for Ligand B.
8. **BBB:** Ligand A (43.815) has lower BBB penetration than Ligand B (58.24). Since ADRB2 is a cardiovascular target, BBB penetration is not a primary concern, but higher is generally better. Slight preference for Ligand B.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.352 and -5.512), which is unusual and suggests very poor permeability. This is a significant concern for both.
10. **Solubility:** Both ligands have negative solubility values (-1.396 and -2.152), indicating very poor aqueous solubility, which is a major drawback. Ligand B is slightly worse.
11. **hERG:** Both ligands have low hERG inhibition risk (0.083 and 0.129). No significant difference.
12. **Cl_mic:** Ligand A (5.691) has a higher microsomal clearance than Ligand B (0.24), suggesting lower metabolic stability. This favors Ligand B.
13. **t1/2:** Ligand A (-5.817) has a negative in vitro half-life, which is not possible. Ligand B (5.155) has a reasonable half-life. This strongly favors Ligand B.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.021 and 0.01). No significant difference.
15. **Binding Affinity:** Ligand B (-5.2 kcal/mol) has a slightly better binding affinity than Ligand A (-3.6 kcal/mol). This is a significant advantage, potentially outweighing some of the ADME drawbacks.
**Overall Assessment:**
Ligand B is the stronger candidate. While both ligands have concerning Caco-2 and solubility values, Ligand B demonstrates superior logP, DILI risk, BBB penetration, metabolic stability (lower Cl_mic, positive t1/2), and binding affinity. The significantly better binding affinity of Ligand B is a major advantage for a GPCR target like ADRB2. The negative half-life of Ligand A is a showstopper.
Output:
0
2025-04-17 18:27:47,075 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's systematically compare Ligand A and Ligand B based on the provided parameters and the guidelines, keeping in mind that ADRB2 is a GPCR, so logP, Pgp, TPSA, and affinity are particularly important.
1. **MW:** Both ligands (376.389 Da and 346.387 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (109.22) is slightly higher than Ligand B (101.47). Both are acceptable, but Ligand B is preferable as it's closer to the <140 threshold for good absorption.
3. **logP:** Ligand A (-1.243) is quite low, potentially hindering permeability. Ligand B (1.952) is within the optimal 1-3 range. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable, well below the 5 limit. Ligand B is slightly better.
5. **HBA:** Ligand A (7) and Ligand B (6) are both acceptable, below the 10 limit. Ligand B is slightly better.
6. **QED:** Ligand B (0.908) has a significantly higher QED score than Ligand A (0.601), indicating a more drug-like profile. This is a substantial advantage for Ligand B.
7. **DILI:** Ligand A (75.882) has a higher DILI risk than Ligand B (41.218). Ligand B is clearly preferable here.
8. **BBB:** Ligand A (54.634) has a lower BBB penetration percentile than Ligand B (81.039). While ADRB2 isn't necessarily a CNS target, higher BBB is generally favorable, and Ligand B is better.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.421 and -4.863). This is unusual and suggests poor permeability. However, the values are similar, so it doesn't differentiate the two.
10. **Solubility:** Ligand A (-1.744) has slightly better solubility than Ligand B (-3.212).
11. **hERG:** Ligand A (0.049) has a lower hERG inhibition liability than Ligand B (0.479), making it safer from a cardiotoxicity perspective. This is a positive for Ligand A.
12. **Cl_mic:** Ligand A (14.619) has a lower microsomal clearance than Ligand B (21.648), suggesting better metabolic stability. This is a positive for Ligand A.
13. **t1/2:** Ligand B (15.897) has a much longer in vitro half-life than Ligand A (-10.634). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.016) has a much lower P-gp efflux liability than Ligand B (0.196), suggesting better oral bioavailability. This is a positive for Ligand A.
15. **Affinity:** Ligand B (-7.8 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.1 kcal/mol). This is a substantial advantage for Ligand B, and can outweigh some of the ADME drawbacks.
**Overall Assessment:**
Ligand B demonstrates a superior balance of properties, particularly regarding drug-likeness (QED), binding affinity, BBB penetration, DILI risk, and in vitro half-life. While Ligand A has advantages in hERG, Pgp, and Cl_mic, the stronger affinity and better overall profile of Ligand B make it the more promising candidate. The low logP of Ligand A is a major concern.
**Output:**
0
2025-04-17 18:27:47,075 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, priorities are: affinity, logP, Pgp, TPSA, and BBB.
Let's break down the comparison:
1. **MW:** Both ligands are within the ideal range (346.381 and 344.415 Da).
2. **TPSA:** Ligand A (47.09) is significantly better than Ligand B (93.09). A TPSA under 140 is good for oral absorption, but lower is better for GPCRs, and A is much closer to the ideal.
3. **logP:** Ligand A (3.294) is optimal, while Ligand B (0.468) is quite low, potentially hindering membrane permeability.
4. **HBD/HBA:** Both are acceptable. Ligand A has 0 HBD and 5 HBA, Ligand B has 2 HBD and 5 HBA.
5. **QED:** Both are good (0.727 and 0.671).
6. **DILI:** Both are good, with Ligand A (43.195) slightly higher than Ligand B (38.852), but both are well below the 60 threshold.
7. **BBB:** Ligand A (97.712) is excellent, while Ligand B (62.97) is moderate. This is a significant advantage for Ligand A, even though ADRB2 is cardiovascular and not directly in the CNS, some degree of BBB penetration can influence off-target effects and distribution.
8. **Caco-2:** Ligand A (-4.873) is worse than Ligand B (-5.024), but both are negative, indicating poor permeability.
9. **Solubility:** Ligand A (-2.371) is slightly worse than Ligand B (-1.725), but both are poor.
10. **hERG:** Ligand A (0.945) is slightly higher than Ligand B (0.051), indicating a slightly higher risk of hERG inhibition.
11. **Cl_mic:** Ligand A (33.049) has a higher clearance than Ligand B (22.478), meaning it's less metabolically stable.
12. **t1/2:** Ligand A (-17.005) has a shorter half-life than Ligand B (-11.11).
13. **Pgp:** Ligand A (0.698) has higher P-gp efflux than Ligand B (0.03).
14. **Affinity:** Ligand B (-6.5 kcal/mol) has a significantly better binding affinity than Ligand A (-2.6 kcal/mol). This is a >1.5 kcal/mol advantage, which is substantial.
**Overall Assessment:**
Ligand B has a much stronger binding affinity, which is the most important factor. While Ligand A has better TPSA, BBB, and logP, the difference in affinity is too large to ignore. The lower logP of Ligand B is a concern, but the potency advantage is likely to outweigh this drawback. The lower Pgp efflux of Ligand B is also a plus. The slightly higher hERG risk of Ligand A is also a negative.
Output:
0
2025-04-17 18:27:47,075 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's systematically compare Ligand A and Ligand B based on the provided parameters and the guidelines, keeping in mind ADRB2 is a GPCR.
1. **Molecular Weight:** Both ligands (346.43 and 352.48 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands have TPSA values (67.87 and 65.87) below the 140 threshold for good oral absorption, which is positive.
3. **logP:** Ligand A (2.296) is better than Ligand B (1.019). While both are within the 1-3 range, Ligand A is closer to the optimal value and better for membrane permeability. Ligand B is a bit low and may have absorption issues.
4. **H-Bond Donors:** Both have 1 HBD, which is good.
5. **H-Bond Acceptors:** Ligand A has 4 HBA, and Ligand B has 6. Ligand A is preferable here, staying further below the 10 limit.
6. **QED:** Ligand A (0.831) has a significantly better QED score than Ligand B (0.719), indicating a more drug-like profile.
7. **DILI:** Both have low DILI risk (28.62 and 20.05 percentile), which is excellent.
8. **BBB:** Ligand A (95.43 percentile) has a much higher BBB penetration score than Ligand B (69.83 percentile). While ADRB2 isn't exclusively a CNS target, good BBB penetration is still a positive attribute, potentially allowing for some central effects or reducing peripheral metabolism.
9. **Caco-2:** Ligand A (-4.632) and Ligand B (-5.025) both have negative Caco-2 values, which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-2.194) is better than Ligand B (-0.254), indicating better aqueous solubility.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.489 and 0.458), which is excellent.
12. **Cl_mic:** Ligand B (-6.869) has a *much* lower (better) microsomal clearance than Ligand A (19.881). This suggests significantly better metabolic stability for Ligand B.
13. **t1/2:** Ligand B (25.25 hours) has a significantly longer in vitro half-life than Ligand A (-1.095 hours). This is a major advantage for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.09 and 0.002), which is excellent.
15. **Binding Affinity:** Ligand B (-7.6 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.0 kcal/mol). This is a substantial advantage (1.6 kcal/mol difference), potentially outweighing some of the ADME drawbacks of Ligand B.
**Overall Assessment:**
Ligand B has a significantly stronger binding affinity and better metabolic stability (lower Cl_mic and longer t1/2). These are critical factors for a GPCR drug candidate. While Ligand A has better logP, QED, solubility and BBB, the affinity difference and metabolic stability of Ligand B are more important. The Caco-2 values are concerning for both, but the superior binding and metabolic profile of Ligand B make it the more promising candidate.
**Output:**
0
2025-04-17 18:27:47,075 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (366.491 Da and 349.406 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (76.26) is slightly higher than Ligand B (69.72). Both are below the 140 A^2 threshold for good oral absorption, and acceptable for a non-CNS GPCR target like ADRB2. Ligand B is slightly preferred.
**3. logP:** Ligand A (0.548) is a bit low, potentially impacting permeability. Ligand B (1.332) is better, falling within the optimal 1-3 range. This favors Ligand B.
**4. H-Bond Donors:** Ligand A has 0 HBD, while Ligand B has 1. Both are acceptable, staying within the <=5 guideline.
**5. H-Bond Acceptors:** Ligand A has 7 HBA, and Ligand B has 3. Both are below the 10 threshold. Ligand B is preferred.
**6. QED:** Both ligands have good QED scores (0.772 and 0.895, respectively), indicating good drug-like properties. Ligand B is slightly better.
**7. DILI:** Both ligands have acceptable DILI risk (43.389 and 46.917, both <60). No significant difference.
**8. BBB:** Both ligands have good BBB penetration (71.035 and 72.78, respectively). Since ADRB2 is primarily a cardiovascular target, high BBB penetration isn't critical, but it doesn't hurt.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.944 and -4.621). These values are unusual and suggest poor permeability. However, the values are very close and don't differentiate the two.
**10. Aqueous Solubility:** Both ligands have negative solubility values (-2.165 and -1.67). These values are also unusual and suggest poor solubility. Again, the values are very close.
**11. hERG Inhibition:** Both ligands exhibit low hERG inhibition risk (0.721 and 0.318). Ligand B is preferred.
**12. Microsomal Clearance:** Ligand A (39.795) has a higher microsomal clearance than Ligand B (14.305), suggesting lower metabolic stability. Ligand B is significantly preferred.
**13. In vitro Half-Life:** Ligand A (-40.324) has a negative half-life, which is not physically possible. Ligand B (-13.716) is also negative, but less so. Both are problematic, but Ligand B is slightly better.
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (0.196 and 0.054). Ligand B is preferred.
**15. Binding Affinity:** Ligand B (-7.1 kcal/mol) has a slightly better binding affinity than Ligand A (-6.7 kcal/mol). While the difference is less than the 1.5 kcal/mol threshold that would strongly favor one ligand, it contributes to the overall preference for Ligand B.
**Overall Assessment:**
Ligand B consistently outperforms Ligand A across most relevant parameters, particularly logP, microsomal clearance, and P-gp efflux. While both ligands have issues with Caco-2 and solubility, these are similar for both. The slightly better binding affinity of Ligand B further solidifies its preference.
Output:
0
2025-04-17 18:27:47,075 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.418 and 345.487 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (50.8) is significantly better than Ligand B (73.2). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold. Ligand B is approaching the upper limit.
3. **logP:** Both ligands have acceptable logP values (2.335 and 3.146), falling within the 1-3 optimal range. Ligand B is slightly higher, which *could* indicate potential off-target interactions, but isn't a major concern.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 3. Both are within the acceptable range of <=10.
6. **QED:** Ligand A (0.887) has a substantially better QED score than Ligand B (0.752), indicating a more drug-like profile.
7. **DILI:** Ligand A (13.61) has a much lower DILI risk than Ligand B (9.383). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (88.057) has better BBB penetration than Ligand B (70.027). While not a primary concern for a cardiovascular target, it's a positive attribute.
9. **Caco-2:** Both have negative Caco-2 values (-4.47 and -4.914). This is unusual and suggests poor permeability. However, the values are very close.
10. **Solubility:** Ligand A (-1.879) has slightly better solubility than Ligand B (-2.667).
11. **hERG:** Both ligands have low hERG inhibition liability (0.634 and 0.573), which is good.
12. **Cl_mic:** Ligand A (41.786) has a higher microsomal clearance than Ligand B (19.348). This means Ligand B is likely to be more metabolically stable.
13. **t1/2:** Ligand B (-13.556) has a much longer in vitro half-life than Ligand A (1.431). This is a significant advantage for Ligand B.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.061 and 0.125).
15. **Binding Affinity:** Ligand B (-6.1) has a slightly better binding affinity than Ligand A (-5.4). This is a 0.7 kcal/mol difference, which is notable, but not overwhelming.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B has a slightly better logP and affinity, but Ligand A excels in TPSA, DILI risk, and QED. The improved metabolic stability (lower Cl_mic and longer t1/2) of Ligand B is also attractive.
**Overall Assessment:**
While Ligand B has a slightly better binding affinity and half-life, Ligand A's superior drug-likeness (QED), lower DILI risk, and better TPSA outweigh these advantages. The Caco-2 permeability is concerning for both, but the overall profile of Ligand A is more balanced and suggests a higher probability of success as a drug candidate.
Output:
1
2025-04-17 18:27:47,076 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (344.321 and 346.435 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (69.04) is excellent, well below the 140 threshold and good for oral absorption. Ligand B (92.15) is still acceptable, but higher, potentially impacting absorption.
3. **logP:** Ligand A (2.484) is optimal (1-3). Ligand B (-0.074) is a concern, being below 1, which may hinder membrane permeability.
4. **HBD:** Both ligands have acceptable HBD counts (1 and 2 respectively), well within the <5 guideline.
5. **HBA:** Both ligands have acceptable HBA counts (5 and 6 respectively), within the <10 guideline.
6. **QED:** Both ligands have similar and good QED scores (0.772 and 0.703), indicating good drug-like properties.
7. **DILI:** Ligand A (93.525) has a significantly higher DILI risk than Ligand B (32.261). This is a major concern for Ligand A.
8. **BBB:** Ligand A (66.925) has better BBB penetration than Ligand B (53.083), but neither is exceptionally high. For a cardiovascular target, BBB penetration isn't a primary concern, but it's a slight advantage for A.
9. **Caco-2:** Ligand A (-4.394) is better than Ligand B (-5.185), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-3.604) is better than Ligand B (-1.712), suggesting better aqueous solubility.
11. **hERG:** Ligand A (0.399) has a lower hERG risk than Ligand B (0.067), which is preferable.
12. **Cl_mic:** Ligand B (-17.575) has a much lower (better) microsomal clearance than Ligand A (52.789), indicating greater metabolic stability.
13. **t1/2:** Ligand B (-11.029) has a longer in vitro half-life than Ligand A (-15.492), which is desirable.
14. **Pgp:** Ligand A (0.148) has lower P-gp efflux than Ligand B (0.012), suggesting better bioavailability.
15. **Affinity:** Ligand A (-7.7 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.5 kcal/mol). This is a substantial advantage.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A excels in affinity and Pgp, and has a good logP and TPSA. Ligand B has a poor logP. However, the high DILI risk for Ligand A is a major red flag.
**Overall Assessment:**
While Ligand A has a superior binding affinity, the significantly higher DILI risk and worse metabolic stability (higher Cl_mic) are major drawbacks. Ligand B, despite its weaker affinity, presents a much more favorable safety profile (low DILI) and better metabolic stability. The difference in affinity, while substantial, might be overcome with further optimization, whereas mitigating a high DILI risk is often far more challenging.
**Output:**
0
2025-04-17 18:27:47,076 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (358.5 & 343.4 Da) are within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (55.89) is significantly better than Ligand B (91.02). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold. Ligand B is approaching the upper limit.
3. **logP:** Both ligands (0.97 & 0.784) are within the optimal 1-3 range. No significant difference.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 4 HBA, Ligand B has 5. Both are acceptable, but A is slightly preferred.
6. **QED:** Ligand A (0.737) and Ligand B (0.875) are both good, above 0.5. Ligand B is slightly better.
7. **DILI:** Ligand A (16.014) has a significantly lower DILI risk than Ligand B (28.228). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (73.827) has a better BBB penetration score than Ligand B (59.131). While not critical for a cardiovascular target, it's a positive attribute.
9. **Caco-2:** Ligand A (-4.882) and Ligand B (-5.143) are similar, both indicating poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-0.846) is better than Ligand B (-1.796). Better solubility is always preferred.
11. **hERG:** Ligand A (0.673) has a lower hERG risk than Ligand B (0.126). This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand A (16.456) has a higher (worse) microsomal clearance than Ligand B (-1.932). Ligand B has negative clearance, which is very favorable.
13. **t1/2:** Ligand A (2.106) has a longer half-life than Ligand B (0.955). This is a positive for Ligand A.
14. **Pgp:** Ligand A (0.045) has lower P-gp efflux than Ligand B (0.016). Both are very low, indicating minimal efflux.
15. **Affinity:** Ligand A (-5.9 kcal/mol) has a slightly better binding affinity than Ligand B (-4.0 kcal/mol). This is a 1.9 kcal/mol difference, which is substantial.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A performs better on TPSA, Pgp, and significantly better on affinity. Ligand B has a better QED and Cl_mic. However, the lower DILI and hERG risks for Ligand A are critical factors, outweighing the metabolic stability advantage of Ligand B. The affinity difference is also significant.
**Conclusion:**
Considering the balance of properties, particularly the lower DILI and hERG risks, better TPSA, and superior binding affinity, Ligand A is the more promising drug candidate.
Output:
1
2025-04-17 18:27:47,076 - INFO - Batch 39 complete. Total preferences: 624
2025-04-17 18:27:47,076 - INFO - Processing batch 40/512...
2025-04-17 18:28:38,062 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.393 and 351.447 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (50.36) is significantly better than Ligand B (78.95). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold. Ligand B is approaching the upper limit.
3. **logP:** Ligand A (3.714) is slightly higher than Ligand B (1.538). While both are within the 1-3 optimal range, Ligand A is closer to the upper end. This *could* present solubility issues, but it's not a major concern at this level.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1). Both are acceptable.
5. **HBA:** Ligand A (3) is lower than Ligand B (4). Both are acceptable.
6. **QED:** Both ligands have similar QED values (0.715 and 0.736), indicating good drug-likeness.
7. **DILI:** Ligand A (51.493) has a considerably higher DILI risk than Ligand B (28.306). This is a significant negative for Ligand A.
8. **BBB:** Ligand A (83.831) has a higher BBB penetration percentile than Ligand B (71.811). However, since ADRB2 is a cardiovascular target, BBB penetration is not a high priority.
9. **Caco-2:** Both ligands have very poor Caco-2 permeability (-4.616 and -4.552). This is a major concern for both.
10. **Solubility:** Ligand A (-4.432) has slightly worse solubility than Ligand B (-1.678).
11. **hERG:** Ligand A (0.967) has a slightly higher hERG risk than Ligand B (0.198). This is a negative for Ligand A.
12. **Cl_mic:** Ligand A (69.969) has a higher microsomal clearance than Ligand B (1.405). This indicates faster metabolism and lower metabolic stability for Ligand A.
13. **t1/2:** Ligand B (-18.62) has a much longer in vitro half-life than Ligand A (-1.784). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.566) has lower P-gp efflux than Ligand B (0.031). This is a slight advantage for Ligand A.
15. **Binding Affinity:** Ligand A (-7.7 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.7 kcal/mol). This is a substantial advantage for Ligand A, potentially outweighing some of its ADME drawbacks.
**Overall Assessment:**
Ligand A has a much stronger binding affinity, which is crucial for GPCR targets. However, it suffers from higher DILI risk, higher hERG risk, faster metabolism (higher Cl_mic, shorter t1/2), and poorer solubility. Ligand B, while having weaker affinity, presents a much better ADME profile, particularly regarding safety (DILI, hERG) and metabolic stability (Cl_mic, t1/2). The difference in binding affinity (1 kcal/mol) is not large enough to overcome the significant ADME liabilities of Ligand A.
Given the cardiovascular target, metabolic stability and safety are very important.
Output:
0
2025-04-17 18:28:38,063 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's analyze each ligand against the provided guidelines, keeping in mind that ADRB2 is a GPCR, so logP, TPSA, Pgp, and affinity are particularly important.
* **Molecular Weight:** Both ligands (366.483 and 373.519 Da) fall within the ideal 200-500 Da range.
* **TPSA:** Ligand A (75.71) is better than Ligand B (109.57). ADRB2 isn't necessarily a CNS target, but lower TPSA generally correlates with better permeability.
* **logP:** Ligand A (2.585) is optimal, while Ligand B (0.99) is a bit low, potentially hindering membrane permeability.
* **H-Bond Donors/Acceptors:** Ligand A (HBD=1, HBA=5) is slightly better than Ligand B (HBD=2, HBA=4), both are within acceptable limits.
* **QED:** Ligand A (0.785) has a higher QED score than Ligand B (0.595), indicating a more drug-like profile.
* **DILI:** Ligand B (33.152) has a significantly lower DILI risk than Ligand A (46.917), which is a major advantage.
* **BBB:** Ligand A (82.474) has better BBB penetration than Ligand B (60.644), but BBB isn't a primary concern for ADRB2.
* **Caco-2:** Ligand B (-5.153) is better than Ligand A (-4.618), indicating better intestinal absorption.
* **Solubility:** Ligand B (-2.356) is better than Ligand A (-2.877).
* **hERG:** Both ligands have very low hERG inhibition risk (0.368 and 0.195 respectively).
* **Cl_mic:** Ligand B (57.326) has lower microsomal clearance than Ligand A (73.848), suggesting better metabolic stability.
* **t1/2:** Ligand B (-37.2) has a significantly longer in vitro half-life than Ligand A (12.707), which is a substantial benefit.
* **Pgp:** Ligand A (0.14) has lower P-gp efflux than Ligand B (0.061), which is beneficial for bioavailability.
* **Binding Affinity:** Ligand B (-7.7 kcal/mol) has a slightly better binding affinity than Ligand A (-7.2 kcal/mol). While the difference is not huge, it's enough to consider.
**Overall Assessment:**
Ligand B demonstrates a superior ADME profile with a lower DILI risk, better metabolic stability (lower Cl_mic, longer t1/2), and better Caco-2 permeability and solubility. While Ligand A has slightly better TPSA and Pgp efflux, the benefits of Ligand B's improved safety and pharmacokinetic properties outweigh these minor drawbacks. The slightly better affinity of Ligand B also contributes to its favorability.
**Output:**
0
2025-04-17 18:28:38,063 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [384.267, 90.98, 0.899, 2, 4, 0.583, 38.503, 61.691, -5.356, -2.885, 0.09, -30.392, -9.893, 0.015, -6.3]
**Ligand B:** [349.519, 61.44, 2.474, 2, 3, 0.662, 11.245, 70.415, -4.835, -2.142, 0.237, 43.976, 2.693, 0.1, -6.4]
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand B (349.519) is slightly lower, which could be beneficial for permeability, but both are acceptable.
2. **TPSA:** Ligand A (90.98) is slightly higher than Ligand B (61.44). Both are below the 140 threshold for oral absorption, but Ligand B is significantly better, particularly important for GPCRs.
3. **logP:** Ligand A (0.899) is a bit low, potentially hindering permeation. Ligand B (2.474) is within the optimal 1-3 range. This is a significant advantage for B.
4. **HBD:** Both have 2 HBD, which is good.
5. **HBA:** Ligand A has 4 HBA, Ligand B has 3. Both are acceptable.
6. **QED:** Ligand B (0.662) has a slightly better QED score than Ligand A (0.583), indicating a more drug-like profile.
7. **DILI:** Ligand A (38.503) has a higher DILI risk than Ligand B (11.245). This is a major concern for Ligand A.
8. **BBB:** Ligand B (70.415) shows better BBB penetration than Ligand A (61.691). While ADRB2 is primarily cardiovascular, some CNS off-target effects are possible, and better BBB is generally preferred.
9. **Caco-2:** Ligand A (-5.356) has a worse Caco-2 permeability than Ligand B (-4.835).
10. **Solubility:** Ligand A (-2.885) has worse solubility than Ligand B (-2.142).
11. **hERG:** Both ligands have very low hERG risk (0.09 and 0.237 respectively).
12. **Cl_mic:** Ligand A (-30.392) has a much lower (better) microsomal clearance than Ligand B (43.976), indicating better metabolic stability. This is a significant advantage for A.
13. **t1/2:** Ligand A (-9.893) has a much longer in vitro half-life than Ligand B (2.693). This is a substantial advantage for A.
14. **Pgp:** Both ligands have very low Pgp efflux.
15. **Affinity:** Both ligands have similar binding affinities (-6.3 and -6.4 kcal/mol). The difference is negligible.
**GPCR-specific priorities:** For GPCRs, logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP and TPSA. Ligand A excels in metabolic stability and half-life.
**Overall Assessment:**
While Ligand A has superior metabolic stability and half-life, the significantly higher DILI risk and lower logP are major drawbacks. Ligand B has a more balanced profile with better predicted absorption (TPSA, logP, Caco-2, solubility), lower DILI risk, and acceptable metabolic stability. The slightly lower half-life of Ligand B can be addressed through formulation or structural modifications. The small difference in binding affinity is not enough to overcome the other advantages of Ligand B.
Therefore, I prefer Ligand B.
Output:
0
2025-04-17 18:28:38,063 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's analyze each ligand against the provided criteria, keeping in mind ADRB2 is a GPCR, so logP, TPSA, Pgp, BBB, and affinity are key.
* **Molecular Weight:** Both ligands (353.463 and 348.443 Da) fall comfortably within the ideal 200-500 Da range.
* **TPSA:** Ligand A (78.95) is better than Ligand B (86.71). Both are below 140, but lower is preferred for absorption.
* **logP:** Both are good (0.633 and 0.583), falling within the 1-3 range.
* **H-Bond Donors/Acceptors:** Ligand A (1 HBD, 4 HBA) is slightly better than Ligand B (2 HBD, 4 HBA) in terms of maintaining a balance between solubility and permeability.
* **QED:** Both have good QED scores (0.649 and 0.731), indicating drug-likeness. Ligand B is slightly better.
* **DILI:** Ligand A (20.977) has a significantly lower DILI risk than Ligand B (15.626), a crucial advantage.
* **BBB:** Ligand A (67.701) has a slightly better BBB penetration percentile than Ligand B (61.535). While not CNS-focused, some level of BBB penetration can be beneficial for peripheral GPCRs.
* **Caco-2 Permeability:** Both are negative, indicating poor permeability. Ligand A (-4.596) is slightly better than Ligand B (-4.961).
* **Aqueous Solubility:** Both are negative, indicating poor solubility. Ligand A (-1.223) is slightly better than Ligand B (-1.972).
* **hERG Inhibition:** Both have very low hERG inhibition risk (0.117 and 0.057).
* **Microsomal Clearance:** Ligand A (39.504) has a higher microsomal clearance than Ligand B (10.948), meaning it's less metabolically stable. This is a significant drawback for Ligand A.
* **In vitro Half-Life:** Ligand B (-11.384) has a longer in vitro half-life than Ligand A (-17.271), which is favorable.
* **P-gp Efflux:** Both ligands have low P-gp efflux liability (0.025 and 0.028).
* **Binding Affinity:** Ligand B (-8.6 kcal/mol) has a substantially stronger binding affinity than Ligand A (-5.9 kcal/mol). This is a >1.5 kcal/mol advantage, which can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand B has a significantly better binding affinity and a much better metabolic stability profile (lower Cl_mic, longer t1/2). While Ligand A has a slightly better DILI score and TPSA, the superior affinity and metabolic stability of Ligand B are more critical for a GPCR target like ADRB2. The difference in binding affinity is substantial enough to overcome the slightly higher DILI risk of Ligand B.
**Output:**
0
2025-04-17 18:28:38,063 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (340.383) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (53.51) is significantly better than Ligand A (73.39). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have excellent logP values (around 2.87), falling within the optimal 1-3 range.
4. **HBD:** Both have 0 HBD, which is acceptable.
5. **HBA:** Ligand A has 6 HBA, and Ligand B has 5. Both are within the acceptable range of <=10.
6. **QED:** Both ligands have good QED scores (A: 0.717, B: 0.787), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (77.627) has a considerably higher DILI risk than Ligand B (20.861). This is a major concern.
8. **BBB:** Both ligands have good BBB penetration (A: 72.586, B: 76.851), but it's less critical for a cardiovascular target.
9. **Caco-2:** Both are negative, indicating poor permeability.
10. **Solubility:** Both have negative solubility values, indicating poor solubility.
11. **hERG:** Both ligands have low hERG inhibition risk (A: 0.192, B: 0.613).
12. **Cl_mic:** Ligand A (35.376) has a lower microsomal clearance than Ligand B (67.396), suggesting better metabolic stability.
13. **t1/2:** Ligand A (60.61) has a significantly longer in vitro half-life than Ligand B (-10.991). This is a strong advantage.
14. **Pgp:** Ligand A (0.514) has lower P-gp efflux than Ligand B (0.262), which is favorable for bioavailability.
15. **Affinity:** Ligand B (-6.4 kcal/mol) has a significantly stronger binding affinity than Ligand A (-3.2 kcal/mol). This is a substantial difference and a major driver in the decision.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in affinity and has a better TPSA. The significantly lower DILI risk of Ligand B is also a critical factor. While Ligand A has better metabolic stability and half-life, the superior binding affinity and safety profile of Ligand B outweigh these advantages.
**Conclusion:**
Ligand B is the more promising drug candidate due to its significantly stronger binding affinity and much lower DILI risk, despite having slightly worse metabolic stability.
Output:
0
2025-04-17 18:28:38,063 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [351.451, 96.33, 1.338, 2, 5, 0.808, 39.977, 59.131, -4.988, -2.755, 0.103, 47.476, 23.624, 0.012, -7]**
**Ligand B: [370.362, 49.41, 2.912, 1, 2, 0.731, 25.165, 93.68, -4.589, -3.04, 0.735, 9.859, -24.972, 0.063, -6.7]**
1. **Molecular Weight:** Both are within the ideal range (200-500 Da). A (351.451) is slightly preferred.
2. **TPSA:** A (96.33) is higher than ideal (<140), but acceptable for a peripheral GPCR like ADRB2. B (49.41) is excellent. B is favored here.
3. **logP:** Both are within the optimal range (1-3). A (1.338) is slightly lower, B (2.912) is closer to the upper end, but still good.
4. **H-Bond Donors:** A (2) and B (1) are both good, well below the threshold of 5.
5. **H-Bond Acceptors:** A (5) and B (2) are both good, well below the threshold of 10.
6. **QED:** A (0.808) is better than B (0.731), indicating a more drug-like profile. A is favored.
7. **DILI:** A (39.977) is slightly higher than B (25.165), but both are below the concerning threshold of 60. B is favored.
8. **BBB:** A (59.131) is lower than B (93.68). ADRB2 is primarily a cardiovascular target, so BBB penetration is not a high priority, but B is still better.
9. **Caco-2:** Both are negative, indicating poor permeability. A (-4.988) is worse than B (-4.589). B is favored.
10. **Solubility:** Both are negative, indicating poor solubility. A (-2.755) is worse than B (-3.04). B is favored.
11. **hERG:** A (0.103) is significantly lower than B (0.735), indicating a much lower risk of cardiotoxicity. A is strongly favored.
12. **Cl_mic:** A (47.476) is higher than B (9.859), meaning faster clearance and lower metabolic stability. B is strongly favored.
13. **t1/2:** A (23.624) is lower than B (-24.972), meaning a shorter half-life. B is favored.
14. **Pgp:** A (0.012) is much lower than B (0.063), indicating less P-gp efflux. A is favored.
15. **Binding Affinity:** A (-7) is slightly better than B (-6.7), but the difference is small.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity and a significantly better hERG profile and Pgp efflux, Ligand B demonstrates superior ADME properties: lower DILI risk, better BBB penetration (less important here, but still a plus), better Caco-2 permeability, better solubility, and significantly improved metabolic stability (lower Cl_mic and longer half-life). For a cardiovascular target, metabolic stability and minimizing off-target effects (DILI, hERG) are crucial. The slightly weaker binding affinity of Ligand B can potentially be optimized in later stages of drug development. The poor permeability and solubility of both are concerns, but Ligand B is better in these aspects.
Therefore, I favor Ligand B.
0
2025-04-17 18:28:38,063 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (355.56 & 345.41 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (38.13) is significantly better than Ligand B (106.73). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally correlates with better absorption. Ligand B's TPSA is quite high, potentially hindering oral bioavailability.
3. **logP:** Ligand A (4.334) is higher than Ligand B (0.862). While 4.334 is approaching the upper limit of optimal, it's still reasonable. Ligand B's logP is quite low, which could limit membrane permeability.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer hydrogen bond donors generally improve permeability.
5. **HBA:** Ligand A (3) is better than Ligand B (7). Lower HBA also favors permeability.
6. **QED:** Both ligands have similar QED values (0.752 and 0.774), indicating good drug-likeness.
7. **DILI:** Ligand A (60.954) and Ligand B (64.521) are both in an acceptable range, but Ligand A is slightly better.
8. **BBB:** Ligand A (77.433) has a better BBB percentile than Ligand B (49.748). While not a primary concern for a cardiovascular target, higher BBB is generally not detrimental.
9. **Caco-2:** Ligand A (-4.498) is better than Ligand B (-5.196). Higher Caco-2 permeability suggests better intestinal absorption.
10. **Solubility:** Ligand A (-5.418) is better than Ligand B (-2.763). Better solubility is always preferred.
11. **hERG:** Ligand A (0.777) is better than Ligand B (0.068). Lower hERG inhibition is crucial for avoiding cardiotoxicity, a critical consideration for a cardiovascular target.
12. **Cl_mic:** Ligand A (93.744) is significantly better than Ligand B (8.461). Higher Cl_mic indicates faster metabolism and lower *in vivo* exposure. Ligand B's low Cl_mic is a positive.
13. **t1/2:** Ligand A (5.022) is better than Ligand B (-0.82). Longer half-life is generally desirable.
14. **Pgp:** Ligand A (0.793) is better than Ligand B (0.055). Lower P-gp efflux is preferable for improved bioavailability.
15. **Binding Affinity:** Ligand A (-7.8) has a significantly stronger binding affinity than Ligand B (-6.9). A 0.9 kcal/mol difference is substantial and can often outweigh minor ADME concerns.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are particularly important. Ligand A excels in all these areas. While BBB isn't critical here, it's not a disadvantage for Ligand A. The significantly better binding affinity of Ligand A is a major advantage.
**Conclusion:**
Ligand A demonstrates a superior balance of properties, particularly in terms of binding affinity, permeability (TPSA, logP, Caco-2), metabolic stability (Cl_mic, t1/2), and safety (hERG). While Ligand B has a lower Cl_mic, the other advantages of Ligand A are more compelling for overall drug development potential.
Output:
1
2025-04-17 18:28:38,063 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (418.253 Da) is within the ideal range, while Ligand B (366.527 Da) is also acceptable. No clear advantage here.
2. **TPSA:** Ligand A (32.7) is excellent, well below the 140 threshold and suitable for good absorption. Ligand B (62.55) is higher, but still reasonable. A favors here.
3. **logP:** Both ligands have good logP values (A: 4.299, B: 3.446), falling within the 1-3 range. Ligand A is slightly higher, potentially increasing off-target effects, but not drastically.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 3 HBA, and Ligand B has 4. Both are acceptable, below the 10 threshold.
6. **QED:** Both ligands have similar QED values (A: 0.728, B: 0.68), indicating good drug-likeness.
7. **DILI:** Ligand A (35.905) has a slightly better DILI score than Ligand B (20.744), suggesting lower liver injury risk.
8. **BBB:** Ligand A (71.811) has a significantly better BBB penetration percentile than Ligand B (62.544). This is a key advantage for a GPCR target, even if not CNS-focused, as it suggests better distribution.
9. **Caco-2:** Ligand A (-4.425) has a worse Caco-2 permeability than Ligand B (-5.305). B favors here.
10. **Solubility:** Ligand A (-3.775) has a slightly better solubility than Ligand B (-3.27). A favors here.
11. **hERG:** Both ligands have low hERG inhibition risk (A: 0.965, B: 0.629). B is slightly better.
12. **Cl_mic:** Ligand B (55.816) has lower microsomal clearance than Ligand A (41.155), indicating better metabolic stability. B favors here.
13. **t1/2:** Ligand A (51.212) has a longer in vitro half-life than Ligand B (40.155). A favors here.
14. **Pgp:** Ligand A (0.867) has higher Pgp efflux than Ligand B (0.181). B favors here.
15. **Binding Affinity:** Ligand B (-7.7 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.2 kcal/mol). This is a crucial advantage, exceeding the 1.5 kcal/mol threshold.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are particularly important. Ligand B excels in affinity and Pgp efflux, while Ligand A has better TPSA and BBB. The substantial affinity difference of Ligand B is the most important factor. While Ligand A has a better BBB score, the difference isn't large enough to overcome the significant binding advantage of Ligand B.
**Conclusion:**
Despite some advantages of Ligand A in terms of TPSA, solubility and half-life, the significantly stronger binding affinity and lower P-gp efflux of Ligand B make it the more promising drug candidate for ADRB2.
Output:
0
2025-04-17 18:28:38,063 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (349.391 and 342.399 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand B (95.16) is significantly better than Ligand A (118.37). For a GPCR, lower TPSA is generally preferred for better permeability.
3. **logP:** Ligand B (0.847) is slightly lower than Ligand A (0.583), but both are a bit low. Ideally, we want 1-3. Ligand B is marginally better.
4. **HBD:** Ligand B (2) has fewer HBDs than Ligand A (3), which is preferable for permeability.
5. **HBA:** Ligand B (4) has fewer HBAs than Ligand A (7), again favoring permeability.
6. **QED:** Both ligands have good QED scores (0.687 and 0.796), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand B (54.789) has a lower DILI risk than Ligand A (65.917), which is a significant advantage.
8. **BBB:** Ligand A (63.862) has a higher BBB penetration percentile than Ligand B (40.946). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be beneficial or at least understood. However, for a cardiovascular target, this is less critical.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. The values are very similar (-4.877 and -4.995).
10. **Solubility:** Ligand A (-2.789) has slightly better solubility than Ligand B (-3.53), but both are quite poor.
11. **hERG:** Ligand A (0.098) has a slightly lower hERG risk than Ligand B (0.279), which is a positive.
12. **Cl_mic:** Ligand B (23.004) has significantly lower microsomal clearance than Ligand A (42.656), indicating better metabolic stability.
13. **t1/2:** Ligand B (-22.366) has a *much* longer in vitro half-life than Ligand A (21.546). This is a major advantage.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.033 and 0.038), which is good.
15. **Binding Affinity:** Ligand A (-7.8) has a stronger binding affinity than Ligand B (-5.7). This is a substantial difference (2.1 kcal/mol).
**Overall Assessment:**
Ligand A has a significantly better binding affinity, which is a crucial factor. However, Ligand B demonstrates a much more favorable ADME profile, particularly with respect to DILI risk, metabolic stability (Cl_mic), and in vitro half-life. The lower TPSA and H-bond counts of Ligand B also contribute to potentially better permeability, despite the negative Caco-2 values for both. The slightly higher hERG risk for Ligand B is a concern, but the substantial improvement in metabolic stability and reduced DILI risk outweigh this. Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity), the improved ADME profile of Ligand B, coupled with still-strong affinity, makes it the more promising candidate. The affinity difference, while significant, might be addressable through further optimization, while fixing the ADME issues of Ligand A would likely be more challenging.
Output:
0
2025-04-17 18:28:38,063 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**1. Molecular Weight (MW):** Both ligands (346.446 and 350.503 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. Topological Polar Surface Area (TPSA):** Ligand A (49.41) is significantly better than Ligand B (58.64). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand A is well below the 140 A^2 threshold, while Ligand B is approaching it.
**3. Lipophilicity (logP):** Both ligands have good logP values (3.153 and 2.903), falling within the optimal 1-3 range. A slight edge to Ligand A.
**4. H-Bond Donors (HBD):** Both ligands have 1 HBD, which is acceptable.
**5. H-Bond Acceptors (HBA):** Ligand A has 2 HBA, Ligand B has 3. Both are within the acceptable limit of 10.
**6. QED:** Ligand A (0.89) has a substantially better QED score than Ligand B (0.685), indicating a more drug-like profile.
**7. DILI Risk:** Ligand A (29.236) has a much lower DILI risk than Ligand B (9.228), which is a significant advantage.
**8. BBB Penetration:** Ligand A (96.355) has excellent BBB penetration, while Ligand B (77.705) is good but lower. Given ADRB2's role in cardiovascular function, CNS penetration isn't *critical*, but it's a bonus, and Ligand A is clearly superior here.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.616 and -4.636). These values are difficult to interpret without knowing the scale, but the similarity suggests comparable intestinal absorption potential.
**10. Aqueous Solubility:** Ligand A (-3.46) is slightly better than Ligand B (-2.514), indicating better solubility.
**11. hERG Inhibition:** Ligand A (0.777) has a lower hERG inhibition liability than Ligand B (0.485), which is a positive.
**12. Microsomal Clearance:** Ligand B (44.523) has lower microsomal clearance than Ligand A (36.009), suggesting better metabolic stability.
**13. In vitro Half-Life:** Ligand B (-10.718) has a significantly longer in vitro half-life than Ligand A (-4.913), which is a major advantage.
**14. P-gp Efflux:** Ligand A (0.34) has lower P-gp efflux than Ligand B (0.125), which is favorable.
**15. Binding Affinity:** Ligand B (-7.5 kcal/mol) has a slightly better binding affinity than Ligand A (-5.7 kcal/mol). This is a 1.8 kcal/mol difference, which is substantial.
**Overall Assessment:**
While Ligand B has a better binding affinity and a longer half-life, Ligand A excels in several critical ADME properties, particularly DILI risk, BBB penetration, QED, and TPSA. The lower DILI risk is a significant safety advantage. The better QED score suggests a more generally drug-like molecule. The slightly better solubility and lower P-gp efflux also contribute to better overall drug properties. The difference in binding affinity, while notable, can potentially be optimized in later stages of drug development. Given the GPCR target class, the balance of properties favors Ligand A.
Output:
1
2025-04-17 18:28:38,063 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 drug candidates. ADRB2 is a GPCR, so we'll prioritize logP, Pgp, TPSA, and affinity, alongside general drug-like properties.
**Ligand A:** [407.327, 41.13, 4.891, 2, 1, 0.631, 46.297, 78.751, -4.995, -5.632, 0.936, 87.472, 77.15, 0.738, -7.5]
**Ligand B:** [348.487, 66.48, 2.535, 1, 3, 0.769, 17.449, 75.223, -4.815, -3.13, 0.244, 43.041, -22.782, 0.204, -5.9]
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (348.487) is slightly preferred due to being lower.
2. **TPSA:** Ligand A (41.13) is better than Ligand B (66.48). A lower TPSA generally indicates better cell permeability.
3. **logP:** Ligand A (4.891) is a bit high, potentially causing solubility issues and off-target interactions. Ligand B (2.535) is within the optimal range. This favors Ligand B.
4. **HBD:** Both are acceptable (2 and 1 respectively), well within the limit of 5.
5. **HBA:** Both are acceptable (1 and 3 respectively), well within the limit of 10.
6. **QED:** Both are good (0.631 and 0.769), indicating drug-like properties.
7. **DILI:** Ligand A (46.297) is moderately risky, while Ligand B (17.449) is very good. This is a significant advantage for Ligand B.
8. **BBB:** Both have good BBB penetration (78.751 and 75.223). Not a primary concern for ADRB2, but a positive for both.
9. **Caco-2:** Both have negative values, which is unusual. It's difficult to interpret without knowing the scale, but assuming lower is worse, they are both poor.
10. **Solubility:** Both have negative solubility values, which is also unusual. Again, assuming lower is worse, they are both poor.
11. **hERG:** Ligand A (0.936) is slightly better than Ligand B (0.244), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand A (87.472) has higher clearance, meaning faster metabolism. Ligand B (43.041) has lower clearance, indicating better metabolic stability. This favors Ligand B.
13. **t1/2:** Ligand A (77.15) has a much longer half-life than Ligand B (-22.782). This is a strong advantage for Ligand A.
14. **Pgp:** Ligand A (0.738) has better Pgp efflux properties (lower efflux) than Ligand B (0.204). This is a positive for Ligand A.
15. **Affinity:** Ligand A (-7.5 kcal/mol) has a significantly stronger binding affinity than Ligand B (-5.9 kcal/mol). This is a major advantage for Ligand A.
**Overall Assessment:**
The critical factor here is the binding affinity. Ligand A has a 1.6 kcal/mol advantage, which is substantial and can often outweigh other drawbacks. While Ligand B has better DILI and metabolic stability, the stronger binding of Ligand A, combined with acceptable (though not ideal) ADME properties, makes it the more promising candidate. The slightly elevated logP of Ligand A is a concern, but could potentially be addressed through further optimization. The longer half-life of Ligand A is also a plus.
Output:
1
2025-04-17 18:28:38,064 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor (a GPCR).
**Ligand A:** [357.439, 81.81, 2.081, 1, 7, 0.539, 87.786, 67.352, -5.684, -3.242, 0.539, 65.865, 38.797, 0.648, 1]
**Ligand B:** [365.44, 61.44, 2.318, 2, 3, 0.625, 18.34, 85.111, -4.69, -2.268, 0.535, 34.496, -18.928, 0.031, -6.4]
Here's a breakdown, considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key) and general guidelines:
1. **MW:** Both are within the ideal range (200-500 Da). A (357.439) is slightly better.
2. **TPSA:** A (81.81) is higher than B (61.44). B is significantly better, being well under the 140 A^2 threshold for oral absorption and more favorable for potential CNS penetration.
3. **logP:** Both are within the optimal 1-3 range. B (2.318) is slightly higher, potentially improving membrane permeability.
4. **HBD:** A (1) is better than B (2). Lower is preferred.
5. **HBA:** A (7) is higher than B (3). B is better.
6. **QED:** B (0.625) is slightly better than A (0.539), indicating a more drug-like profile.
7. **DILI:** A (87.786) is *much* higher than B (18.34). This is a major red flag for Ligand A. B is excellent here.
8. **BBB:** B (85.111) is better than A (67.352), although neither is exceptionally high.
9. **Caco-2:** A (-5.684) is worse than B (-4.69). Lower values indicate poorer permeability.
10. **Solubility:** A (-3.242) is worse than B (-2.268). Both are poor, but B is slightly better.
11. **hERG:** Both are similar (0.539 and 0.535), indicating a moderate risk.
12. **Cl_mic:** B (34.496) is significantly better than A (65.865), indicating better metabolic stability.
13. **t1/2:** A (38.797) is better than B (-18.928). However, a negative half-life is highly unusual and suggests an issue with the experimental determination or the molecule itself.
14. **Pgp:** A (0.648) is higher than B (0.031). B is much better, indicating less efflux and potentially better bioavailability.
15. **Affinity:** B (-6.4) is *significantly* better than A (1). This is a >1.5 kcal/mol difference, which is a substantial advantage.
**Overall Assessment:**
Ligand B is the clear winner. While Ligand A has a slightly better MW and in vitro half-life, its extremely high DILI risk, poorer TPSA, Caco-2, solubility, and significantly weaker binding affinity are major drawbacks. Ligand B excels in key GPCR-relevant parameters (logP, Pgp, TPSA) and has a dramatically better safety profile (DILI) and binding affinity. The negative half-life for Ligand A is also concerning.
Output:
0
2025-04-17 18:28:38,064 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (333.391 Da) is slightly lower, which is generally favorable for permeability.
**2. TPSA:** Ligand B (51.02) is significantly better than Ligand A (75.11). For a GPCR, lower TPSA is generally preferred as it aids membrane permeability.
**3. logP:** Both ligands have good logP values (A: 2.994, B: 3.554), falling within the optimal 1-3 range. Ligand B is slightly higher, which could potentially lead to some off-target interactions, but is still acceptable.
**4. H-Bond Donors:** Ligand A has 2 HBD, and Ligand B has 0. Lower is generally better for permeability, so Ligand B is slightly favored.
**5. H-Bond Acceptors:** Both have 4 HBA, which is within the acceptable range.
**6. QED:** Both ligands have good QED scores (A: 0.753, B: 0.802), indicating good drug-like properties. Ligand B is slightly better.
**7. DILI Risk:** Ligand A (74.99) has a higher DILI risk than Ligand B (54.207). Lower DILI is crucial, making Ligand B more attractive.
**8. BBB Penetration:** Ligand B (83.288) shows significantly better BBB penetration than Ligand A (46.336). While ADRB2 is primarily a cardiovascular target, some CNS effects are possible with adrenergic agonists, and better BBB penetration could be a benefit or a detriment depending on the desired profile.
**9. Caco-2 Permeability:** Both ligands show poor Caco-2 permeability (-5.018 and -5.091). This is a concern for oral bioavailability for both.
**10. Aqueous Solubility:** Both ligands have very poor aqueous solubility (-3.405 and -3.177). This is a significant drawback for both, potentially hindering formulation and bioavailability.
**11. hERG Inhibition:** Ligand A (0.576) has a slightly higher hERG inhibition risk than Ligand B (0.297). Lower hERG risk is essential for cardiovascular drugs, favoring Ligand B.
**12. Microsomal Clearance:** Ligand B (30.375) has a lower microsomal clearance than Ligand A (18.586), indicating better metabolic stability.
**13. In vitro Half-Life:** Ligand B (8.584) has a longer in vitro half-life than Ligand A (33.299). This is a significant advantage for Ligand B, potentially allowing for less frequent dosing.
**14. P-gp Efflux:** Ligand A (0.106) has lower P-gp efflux than Ligand B (0.549), which is favorable for bioavailability.
**15. Binding Affinity:** Ligand A (-7.8 kcal/mol) has a slightly stronger binding affinity than Ligand B (-7.2 kcal/mol). This is a 1.5 kcal/mol difference, which is significant.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity, Ligand B demonstrates a significantly better safety profile (lower DILI, lower hERG), better BBB penetration, and improved metabolic stability (lower Cl_mic, longer t1/2). The poor Caco-2 and solubility are problematic for both, but the ADME/Tox advantages of Ligand B outweigh the slightly weaker binding affinity, especially considering the cardiovascular context where safety is paramount. The GPCR-specific priorities (logP, Pgp, TPSA, affinity) are reasonably well addressed by both, but Ligand B's profile is more balanced and less concerning.
Output:
0
2025-04-17 18:28:38,064 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (362.333 and 358.427 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand B (86.03) is significantly better than Ligand A (119.05). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (1.506) is within the optimal range (1-3). Ligand A (-1.121) is too low, potentially hindering membrane permeability. This is a significant negative for Ligand A.
4. **HBD:** Ligand A (3) is acceptable, while Ligand B (0) is even better, minimizing potential for off-target interactions and improving permeability.
5. **HBA:** Ligand B (8) is good, while Ligand A (5) is also acceptable.
6. **QED:** Ligand B (0.636) is better than Ligand A (0.287), indicating a more drug-like profile.
7. **DILI:** Ligand A (47.654) has a lower DILI risk than Ligand B (75.184). This is a positive for Ligand A.
8. **BBB:** Not a high priority for a cardiovascular target. Ligand A (62.311) is better than Ligand B (47.15), but this isn't a deciding factor.
9. **Caco-2:** Ligand A (-5.404) is better than Ligand B (-4.82), suggesting better intestinal absorption.
10. **Solubility:** Ligand A (-1.275) is better than Ligand B (-1.434), though both are poor.
11. **hERG:** Both ligands (0.164 and 0.113) have low hERG inhibition risk, which is excellent.
12. **Cl_mic:** Ligand A (-5.546) is significantly better than Ligand B (54.437). Lower clearance indicates greater metabolic stability, a crucial factor for drug duration.
13. **t1/2:** Ligand A (-31.666) is better than Ligand B (-15.491), suggesting a longer half-life.
14. **Pgp:** Both ligands (0.006 and 0.065) have low P-gp efflux, which is good.
15. **Binding Affinity:** Both ligands (-6.8 and -6.7 kcal/mol) have very similar, strong binding affinities. The difference is negligible.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand B excels in TPSA and has a good logP, while Ligand A has a poor logP. Although Ligand A has better DILI, Caco-2, solubility, and metabolic stability, the poor logP is a major concern for permeability and overall bioavailability. The difference in metabolic stability and half-life is significant, but can potentially be addressed with structural modifications.
**Conclusion:**
Despite Ligand A having some favorable ADME properties, the significantly better logP and TPSA of Ligand B, combined with its superior QED, make it the more promising candidate. The slightly higher DILI risk of Ligand B can be investigated further and potentially mitigated during optimization.
Output:
0
2025-04-17 18:28:38,064 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (345.29 Da) is well within the ideal range (200-500). Ligand B (364.877 Da) is also acceptable. No clear advantage here.
2. **TPSA:** Ligand A (111.54) is slightly above the preferred <140 for good absorption, but still reasonable. Ligand B (67.23) is excellent, well below 90, suggesting good permeability. **Advantage: B**
3. **logP:** Both ligands have good logP values (A: 0.86, B: 1.791) falling within the 1-3 range. Ligand B is slightly better, closer to the optimal range.
4. **HBD:** Both ligands have 1 HBD, which is acceptable.
5. **HBA:** Ligand A has 7 HBA, within the acceptable range. Ligand B has 4 HBA, also good.
6. **QED:** Ligand B (0.782) has a significantly better QED score than Ligand A (0.419), indicating a more drug-like profile. **Advantage: B**
7. **DILI:** Ligand A (85.77) has a higher DILI risk than Ligand B (32.687). This is a significant concern. **Advantage: B**
8. **BBB:** Both have reasonable BBB penetration (A: 72.237, B: 80.07). Since ADRB2 is a cardiovascular target, BBB penetration is not a primary concern, but higher is still slightly favorable. **Advantage: B**
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Both have negative solubility values, which is also unusual and suggests poor solubility. Again, the scale is not specified.
11. **hERG:** Both have very low hERG inhibition risk (A: 0.214, B: 0.123). No significant difference.
12. **Cl_mic:** Ligand B (26.695) has lower microsomal clearance than Ligand A (31.671), indicating better metabolic stability. **Advantage: B**
13. **t1/2:** Ligand B (-11.813) has a negative in vitro half-life, which is concerning. Ligand A (15.721) has a reasonable half-life. **Advantage: A**
14. **Pgp:** Both have low P-gp efflux liability (A: 0.131, B: 0.086). No significant difference.
15. **Binding Affinity:** Ligand B (-5.6 kcal/mol) has a slightly better binding affinity than Ligand A (-4.9 kcal/mol). While the difference is not huge, it's enough to be considered. **Advantage: B**
**Overall Assessment:**
Ligand B consistently outperforms Ligand A in most critical ADME properties (QED, DILI, Cl_mic) and has a slightly better binding affinity. While the negative half-life is concerning, the overall profile of Ligand B is significantly more favorable for drug development, especially considering the GPCR target class where permeability and metabolic stability are key. Ligand A's higher DILI risk is a major red flag.
Output:
0
2025-04-17 18:28:38,064 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [353.463, 78.95, 0.633, 1, 4, 0.76, 23.187, 54.905, -4.724, -1.266, 0.17, 19.822, 1.753, 0.015, -6.7]**
**Ligand B: [356.482, 60.85, 2.371, 1, 3, 0.69, 13.843, 88.135, -4.419, -2.035, 0.71, 48.689, -15.209, 0.189, -5.6]**
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). A is 353.463, B is 356.482. No clear advantage.
2. **TPSA:** Ligand A (78.95) is higher than Ligand B (60.85). For a GPCR like ADRB2, lower TPSA is generally preferred for better permeability, giving a slight edge to B.
3. **logP:** Ligand A (0.633) is lower than the optimal range (1-3), potentially hindering permeability. Ligand B (2.371) is within the optimal range. This is a significant advantage for B.
4. **H-Bond Donors:** Both have 1 HBD, which is good.
5. **H-Bond Acceptors:** Ligand A has 4, and Ligand B has 3. Both are acceptable, but B is slightly better.
6. **QED:** Both are above 0.5 (A: 0.76, B: 0.69), indicating good drug-likeness. A is slightly better.
7. **DILI:** Ligand A (23.187) has a higher DILI risk than Ligand B (13.843). This is a clear advantage for B.
8. **BBB:** Ligand B (88.135) has significantly better BBB penetration potential than Ligand A (54.905). While ADRB2 isn't strictly a CNS target, some CNS exposure can be relevant, and higher BBB is generally favorable.
9. **Caco-2:** Both have negative values, indicating poor permeability. A (-4.724) is worse than B (-4.419).
10. **Solubility:** Both have negative values, indicating poor solubility. A (-1.266) is slightly better than B (-2.035).
11. **hERG:** Ligand A (0.17) has a lower hERG risk than Ligand B (0.71). This is a significant advantage for A.
12. **Cl_mic:** Ligand A (19.822) has a lower microsomal clearance, suggesting better metabolic stability, than Ligand B (48.689). This is a significant advantage for A.
13. **t1/2:** Ligand A (1.753) has a shorter in vitro half-life than Ligand B (-15.209). B is much better.
14. **Pgp:** Ligand A (0.015) has much lower P-gp efflux liability than Ligand B (0.189). This is a significant advantage for A.
15. **Binding Affinity:** Ligand A (-6.7) has a slightly better binding affinity than Ligand B (-5.6). This is a 1.1 kcal/mol difference, which is substantial.
**Overall Assessment:**
Ligand B excels in logP, DILI, BBB, and in vitro half-life. Ligand A has advantages in hERG, Cl_mic, Pgp efflux, and binding affinity. Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity), and the fact that the affinity difference is substantial (1.1 kcal/mol), Ligand A is the more promising candidate. The improved metabolic stability (lower Cl_mic) and reduced P-gp efflux are also important factors. While Ligand B has better BBB penetration, this is less critical for a non-CNS primary target like ADRB2. The lower hERG risk of A is also a significant safety advantage.
Output:
1
2025-04-17 18:28:38,064 - INFO - Batch 40 complete. Total preferences: 640
2025-04-17 18:28:38,064 - INFO - Processing batch 41/512...
2025-04-17 18:29:30,082 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (345.46 and 351.39 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (38.33) is significantly better than Ligand B (95.13). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption. Ligand B's TPSA is quite high, potentially hindering oral bioavailability.
3. **logP:** Both ligands have good logP values (4.45 and 4.03) within the optimal 1-3 range, though Ligand A is slightly higher. This is acceptable for a GPCR target.
4. **HBD/HBA:** Ligand A (1 HBD, 2 HBA) is preferable to Ligand B (2 HBD, 5 HBA). Lower counts generally improve permeability.
5. **QED:** Ligand A (0.875) has a better QED score than Ligand B (0.742), indicating a more drug-like profile.
6. **DILI:** Ligand A (36.95) has a significantly lower DILI risk than Ligand B (93.95). This is a major advantage for Ligand A.
7. **BBB:** Ligand A (91.86) has better BBB penetration than Ligand B (27.72). While not critical for a cardiovascular target, it doesn't hurt.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and difficult to interpret without knowing the scale. However, the values are close enough to not be a deciding factor.
9. **Solubility:** Both ligands have very poor aqueous solubility (-5.09 and -5.96). This is a significant concern for both and would require formulation strategies.
10. **hERG:** Both ligands have low hERG inhibition risk (0.76 and 0.61). This is good, minimizing cardiotoxicity concerns.
11. **Cl_mic:** Ligand A (55.20) has a slightly higher microsomal clearance than Ligand B (37.87), meaning it might be metabolized faster.
12. **t1/2:** Ligand B (132.07) has a much longer in vitro half-life than Ligand A (36.41). This is a significant advantage for Ligand B, potentially allowing for less frequent dosing.
13. **Pgp:** Both ligands have low P-gp efflux liability (0.54 and 0.42).
14. **Binding Affinity:** Ligand B (-7.1 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.5 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME drawbacks.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), affinity, logP, TPSA, and Pgp are key. Ligand B excels in affinity, and its logP and Pgp are comparable to Ligand A. However, Ligand B's high TPSA is a significant drawback.
**Overall Assessment:**
While Ligand B has a superior binding affinity and longer half-life, Ligand A's significantly lower DILI risk, better TPSA, and higher QED make it the more promising candidate. The solubility issues are a concern for both, but the DILI risk associated with Ligand B is a major red flag. The difference in affinity, while substantial, might be overcome with further optimization of Ligand A.
Output:
1
2025-04-17 18:29:30,083 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
The ADRB2 receptor is a GPCR, so the priorities are logP, Pgp, TPSA, affinity, and, to a lesser extent, BBB. Let's compare the ligands:
1. **Molecular Weight:** Both are within the acceptable range (200-500 Da). Ligand A (358.551 Da) is preferable to Ligand B (169.18 Da) as the latter is on the lower end of the range and may lack potency.
2. **TPSA:** Ligand A (33.2) is excellent, well below the 140 threshold. Ligand B (86.71) is higher, but still acceptable.
3. **logP:** Ligand A (4.442) is slightly high, potentially leading to solubility issues, but still within a range that can be tolerated. Ligand B (0.09) is *very* low, indicating poor membrane permeability and likely poor oral absorption. This is a major drawback.
4. **H-Bond Donors:** Ligand A (0) is ideal. Ligand B (4) is acceptable, but higher HBD can sometimes reduce permeability.
5. **H-Bond Acceptors:** Ligand A (3) is good. Ligand B (4) is also acceptable.
6. **QED:** Ligand A (0.78) is excellent, indicating good drug-like properties. Ligand B (0.472) is lower, suggesting potential issues.
7. **DILI:** Ligand A (21.171) is very good, indicating low liver injury risk. Ligand B (4.42) is also good.
8. **BBB:** Ligand A (87.515) is good, suggesting some potential for CNS penetration if desired. Ligand B (3.994) is very low, indicating poor BBB penetration.
9. **Caco-2:** Ligand A (-5.281) is negative, which is unusual and requires further investigation, but not immediately disqualifying. Ligand B (-6.052) is also negative and similarly requires investigation.
10. **Solubility:** Ligand A (-3.766) is poor, consistent with the high logP. Ligand B (-0.372) is also poor, but the low logP doesn't necessarily translate to good solubility.
11. **hERG:** Ligand A (0.669) is good, indicating low cardiotoxicity risk. Ligand B (0.037) is excellent.
12. **Cl_mic:** Ligand A (93.514) is high, indicating rapid metabolism and potentially low bioavailability. Ligand B (-42.745) is *very* low, suggesting excellent metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand A (-5.862) is negative, suggesting a very short half-life. Ligand B (4.953) is good.
14. **Pgp:** Ligand A (0.628) is good, indicating low P-gp efflux. Ligand B (0.012) is excellent.
15. **Affinity:** Both ligands have very similar binding affinities (-8.4 and -8.2 kcal/mol). The difference is small enough to be considered negligible.
**Conclusion:**
While Ligand B has superior metabolic stability (Cl_mic, t1/2) and Pgp efflux properties, its extremely low logP is a major concern. This will likely translate to very poor absorption and bioavailability. Ligand A, despite its higher logP and faster metabolism, has a more balanced profile, with better QED, BBB penetration, and a more reasonable molecular weight. The slight difference in affinity is not enough to overcome the absorption issues of Ligand B.
**Output:**
1
2025-04-17 18:29:30,083 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [341.455, 64.41, 2.484, 0, 3, 0.725, 21.598, 71.811, -4.853, -3.044, 0.515, 25.329, -4.496, 0.162, -7.7]
**Ligand B:** [344.415, 81.75, 0.808, 2, 3, 0.848, 50.058, 54.246, -4.764, -2.18, 0.194, -8.961, 7.181, 0.017, -7.1]
Here's a breakdown, considering the GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal 200-500 Da range. A is 341.455, B is 344.415 - very similar.
2. **TPSA:** Ligand A (64.41) is significantly better than Ligand B (81.75). Lower TPSA generally favors better permeability, crucial for GPCR ligands.
3. **logP:** Ligand A (2.484) is optimal. Ligand B (0.808) is a bit low, potentially hindering membrane permeability.
4. **HBD/HBA:** Both have a reasonable number of HBD/HBA (A: 0/3, B: 2/3).
5. **QED:** Both have good QED scores (A: 0.725, B: 0.848), indicating drug-likeness. B is slightly better.
6. **DILI:** Ligand A (21.598) has a much lower DILI risk than Ligand B (50.058). This is a significant advantage for A.
7. **BBB:** Ligand A (71.811) has a better BBB penetration score than Ligand B (54.246). While not a *primary* concern for a cardiovascular target, some CNS exposure can sometimes occur, and higher BBB is generally favorable.
8. **Caco-2:** Both are negative, indicating good permeability. Values are similar.
9. **Solubility:** Both have negative solubility values, indicating good solubility. Values are similar.
10. **hERG:** Both have very low hERG inhibition risk (A: 0.515, B: 0.194). B is slightly better here.
11. **Cl_mic:** Ligand A (25.329) has a higher (worse) microsomal clearance than Ligand B (-8.961). This suggests Ligand B is more metabolically stable.
12. **t1/2:** Ligand A (-4.496) has a shorter in vitro half-life than Ligand B (7.181). This is a disadvantage for A.
13. **Pgp:** Ligand A (0.162) has lower P-gp efflux than Ligand B (0.017), which is preferable for bioavailability.
14. **Affinity:** Ligand A (-7.7) has a slightly stronger binding affinity than Ligand B (-7.1). This is a 0.6 kcal/mol difference, which is significant.
**Overall Assessment:**
Ligand A has a superior profile overall. While Ligand B has better metabolic stability and a slightly better hERG profile, Ligand A excels in crucial areas for a GPCR ligand: TPSA, logP, DILI risk, BBB penetration, and binding affinity. The 0.6 kcal/mol difference in binding affinity is substantial enough to outweigh the metabolic stability concern, especially given the other advantages. The lower DILI risk is also a major positive.
Output:
1
2025-04-17 18:29:30,083 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (400.28 and 389.587 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (62.53 and 61.88) are below the 140 A^2 threshold for good oral absorption, and are reasonably low. No major difference.
3. **logP:** Ligand A (3.338) is optimal, while Ligand B (1.258) is a bit low. This is a slight advantage for A, as higher logP can sometimes improve GPCR binding.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 5 HBA, Ligand B has 6. Both are acceptable, but A is slightly better.
6. **QED:** Ligand A (0.714) has a better QED score than Ligand B (0.599), indicating a more drug-like profile.
7. **DILI:** Ligand B (27.142) has a significantly lower DILI risk than Ligand A (72.392). This is a major advantage for Ligand B.
8. **BBB:** Ligand A (88.639) has better BBB penetration than Ligand B (68.903). While ADRB2 isn't strictly a CNS target, some CNS exposure can be acceptable or even beneficial depending on the specific therapeutic goal.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.984) is slightly better than Ligand B (-5.193), but both are concerning.
10. **Solubility:** Ligand A (-3.524) has better solubility than Ligand B (-1.771). Solubility is important for bioavailability.
11. **hERG:** Both ligands have low hERG inhibition risk (0.746 and 0.458), which is good.
12. **Cl_mic:** Ligand B (13.727) has a much lower microsomal clearance than Ligand A (54.207), indicating better metabolic stability. This is a significant advantage for B.
13. **t1/2:** Ligand A (52.211) has a longer in vitro half-life than Ligand B (9.452). This is a positive for A.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.397 and 0.066), which is good.
15. **Binding Affinity:** Ligand B (-6.4 kcal/mol) has a slightly better binding affinity than Ligand A (-6.0 kcal/mol). While the difference is not huge, it is still a factor.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand A has a better logP and BBB penetration, but Ligand B has a better affinity and significantly lower DILI and Cl_mic. The lower metabolic clearance of Ligand B is particularly attractive for a GPCR target.
**Overall Assessment:**
While Ligand A has some advantages in solubility and half-life, the significantly lower DILI risk and improved metabolic stability (lower Cl_mic) of Ligand B, coupled with slightly better binding affinity, make it the more promising candidate. The Caco-2 permeability is a concern for both, but can potentially be addressed through formulation strategies.
Output:
0
2025-04-17 18:29:30,083 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [364.389, 77.1, 0.978, 1, 5, 0.585, 30.05, 93.641, -4.949, -1.851, 0.453, -5.054, -11.59, 0.038, -5.7]
**Ligand B:** [360.567, 23.55, 3.869, 0, 3, 0.769, 19.271, 92.4, -4.904, -3.986, 0.904, 79.408, 10.65, 0.752, -7.5]
Here's a breakdown, prioritizing GPCR properties (logP, Pgp, TPSA, and affinity) and considering the other parameters:
1. **Molecular Weight:** Both are within the ideal range (200-500 Da). A is 364.389, B is 360.567. Very similar.
2. **TPSA:** Ligand A (77.1) is higher than Ligand B (23.55). This is a significant difference. Lower TPSA is generally better for GPCRs, improving brain penetration if desired and overall permeability. Ligand B is excellent here.
3. **logP:** Ligand A (0.978) is slightly lower than optimal (1-3), but acceptable. Ligand B (3.869) is closer to the upper end of optimal. Both are reasonable, but B is better.
4. **H-Bond Donors:** Ligand A (1) is good. Ligand B (0) is also good, potentially improving permeability.
5. **H-Bond Acceptors:** Ligand A (5) is good. Ligand B (3) is also good.
6. **QED:** Ligand B (0.769) is better than Ligand A (0.585), indicating a more drug-like profile.
7. **DILI:** Ligand A (30.05) is better than Ligand B (19.271) - lower risk of liver injury.
8. **BBB:** Both are very high (A: 93.641, B: 92.4). This isn't a primary concern for ADRB2 unless targeting CNS effects, but it's not detrimental.
9. **Caco-2:** Both are negative, indicating poor permeability. This is a significant drawback for both.
10. **Solubility:** Ligand A (-1.851) is worse than Ligand B (-3.986). Solubility is a concern for both, but B is slightly better.
11. **hERG:** Ligand A (0.453) is significantly better than Ligand B (0.904) - lower cardiotoxicity risk.
12. **Cl_mic:** Ligand A (-5.054) is much better than Ligand B (79.408) - indicating much better metabolic stability.
13. **t1/2:** Ligand A (-11.59) is worse than Ligand B (10.65) - shorter half-life.
14. **Pgp:** Ligand A (0.038) is significantly better than Ligand B (0.752) - lower efflux, meaning better bioavailability.
15. **Affinity:** Ligand B (-7.5) is significantly better than Ligand A (-5.7) - a 1.8 kcal/mol difference is substantial and can outweigh many ADME concerns.
**Overall Assessment:**
Ligand B has a significantly better binding affinity (-7.5 vs -5.7 kcal/mol). It also has a much lower TPSA (23.55 vs 77.1) and a better QED score. The improved affinity and TPSA are strong advantages for a GPCR target. While Ligand A has better DILI, hERG, Cl_mic, and Pgp profiles, the substantial affinity difference of Ligand B is likely to be the dominant factor in its success. The metabolic stability of Ligand A is a concern, and the solubility of both is poor.
Therefore, I would choose Ligand B.
Output:
0
2025-04-17 18:29:30,083 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (372.55 and 344.375 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (49.41) is significantly better than Ligand B (113.1). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold, while Ligand B is approaching it.
3. **logP:** Ligand A (3.403) is optimal, while Ligand B (0.633) is quite low. Low logP can hinder membrane permeability. This is a significant advantage for Ligand A.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower is generally better for permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (6). Lower is generally better for permeability.
6. **QED:** Both ligands are similar (0.697 vs 0.679), indicating good drug-likeness.
7. **DILI:** Ligand A (7.29) has a much lower DILI risk than Ligand B (70.841). This is a substantial advantage for Ligand A.
8. **BBB:** Ligand A (94.998) has better BBB penetration than Ligand B (60.644). While not critical for a cardiovascular target, it's a positive attribute.
9. **Caco-2:** Ligand A (-4.747) and Ligand B (-5.014) are similar, indicating similar intestinal absorption potential.
10. **Solubility:** Ligand A (-3.803) and Ligand B (-3.562) are similar.
11. **hERG:** Ligand A (0.844) has a slightly better hERG profile than Ligand B (0.354), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand B (48.903) has a lower microsomal clearance than Ligand A (61.194), suggesting better metabolic stability. This is a positive for Ligand B.
13. **t1/2:** Ligand B (-42.152) has a significantly longer in vitro half-life than Ligand A (-12.931). This is a major advantage for Ligand B.
14. **Pgp:** Ligand A (0.172) has lower P-gp efflux than Ligand B (0.017), which is preferable.
15. **Binding Affinity:** Ligand A (-7.6) has a stronger binding affinity than Ligand B (-5.3). This is a substantial advantage for Ligand A.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, affinity, and Pgp. Ligand A excels in logP, TPSA, affinity, and Pgp. While Ligand B has better metabolic stability (Cl_mic, t1/2), the significantly stronger binding affinity of Ligand A, combined with its superior ADME properties (logP, TPSA, DILI), outweigh this benefit.
**Conclusion:**
Ligand A is the more promising drug candidate due to its superior binding affinity, favorable ADME properties (particularly logP, TPSA, and DILI risk), and acceptable metabolic stability.
Output:
1
2025-04-17 18:29:30,083 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (352.41) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (69.48) is significantly better than Ligand A (95.42). ADRB2 is not a CNS target, but lower TPSA generally improves absorption.
3. **logP:** Both are within the optimal range (1-3), but Ligand B (2.997) is closer to the upper end. This could be a slight concern for solubility, but not a major issue.
4. **HBD:** Ligand A (2) is better than Ligand B (0). Having some HBD can improve solubility.
5. **HBA:** Ligand B (7) is slightly higher than Ligand A (5), but both are acceptable.
6. **QED:** Ligand A (0.795) has a better QED score than Ligand B (0.682), indicating a more drug-like profile.
7. **DILI:** Ligand A (26.871) has a much lower DILI risk than Ligand B (57.154). This is a significant advantage.
8. **BBB:** Not a primary concern for ADRB2, but Ligand A (71.19) is better than Ligand B (54.013).
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-4.791) is slightly worse than Ligand B (-4.663).
10. **Solubility:** Both are negative, indicating poor solubility. Ligand A (-1.394) is slightly better than Ligand B (-2.256).
11. **hERG:** Both have low hERG inhibition liability, with Ligand A (0.462) being slightly better than Ligand B (0.654).
12. **Cl_mic:** Ligand A (-14.217) has a much lower (better) microsomal clearance than Ligand B (84.523), indicating better metabolic stability.
13. **t1/2:** Ligand B (-16.513) has a longer in vitro half-life than Ligand A (-13.059), which is desirable.
14. **Pgp:** Ligand A (0.021) has significantly lower P-gp efflux liability than Ligand B (0.28), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand A (-6.6) has a slightly better binding affinity than Ligand B (-6.1). While the difference is not huge, it's still a positive.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand A appears to be the better candidate. While Ligand B has a longer half-life, Ligand A excels in crucial areas like DILI risk, metabolic stability (Cl_mic), P-gp efflux, and has a slightly better binding affinity and QED score. The lower TPSA of Ligand B is a plus, but the significant advantages of Ligand A in safety (DILI) and ADME properties outweigh this benefit. The Caco-2 and solubility values are poor for both, but can be addressed with formulation strategies.
**Output:**
1
2025-04-17 18:29:30,083 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Ligand A (366.403 Da) is within the ideal range, while Ligand B (403.272 Da) is at the higher end but still acceptable.
2. **TPSA:** Ligand A (131.86) is borderline for good oral absorption, but acceptable for a peripheral GPCR like ADRB2. Ligand B (52.6) is excellent, well below the 140 threshold.
3. **logP:** Ligand A (-0.507) is quite low, potentially hindering permeability. Ligand B (4.106) is high, potentially causing solubility issues and off-target effects, but within the acceptable range.
4. **HBD:** Ligand A (2) is good. Ligand B (0) is also good.
5. **HBA:** Ligand A (8) is good. Ligand B (4) is excellent.
6. **QED:** Ligand A (0.748) is excellent. Ligand B (0.57) is acceptable.
7. **DILI:** Ligand A (87.98) has a higher DILI risk, which is concerning. Ligand B (71.229) is better, still not ideal, but lower risk.
8. **BBB:** Both are low, which is fine for a cardiovascular target. Ligand B (76.929) is better than Ligand A (35.052).
9. **Caco-2:** Ligand A (-5.585) is very poor. Ligand B (-4.706) is also poor, but slightly better.
10. **Solubility:** Ligand A (-2.193) is poor. Ligand B (-5.276) is very poor.
11. **hERG:** Both are very low risk. Ligand A (0.027) is slightly better.
12. **Cl_mic:** Ligand A (-11.444) is excellent (low clearance, good metabolic stability). Ligand B (116.492) is very high clearance, suggesting poor metabolic stability.
13. **t1/2:** Ligand A (46.883) is good. Ligand B (38.475) is acceptable.
14. **Pgp:** Ligand A (0.038) is very low efflux, which is good. Ligand B (0.556) is higher, but still not terrible.
15. **Affinity:** Both are very good (-6.5 and -6.7 kcal/mol). Ligand B is slightly better.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B has a better logP and TPSA. While both have good affinity, Ligand B is slightly better. However, Ligand A has significantly better metabolic stability (Cl_mic) and lower Pgp efflux. The DILI risk for Ligand A is a significant concern.
**Overall Assessment:**
Despite the slightly better affinity of Ligand B, the significantly better metabolic stability (Cl_mic) and lower Pgp efflux of Ligand A are highly desirable. The DILI risk for Ligand A is concerning, but could potentially be mitigated with further structural modifications. The poor solubility and Caco-2 permeability of both are drawbacks, but can be addressed through formulation strategies. Given the importance of metabolic stability for *in vivo* efficacy and the fact that the affinity difference is small, I favor Ligand A.
Output:
1
2025-04-17 18:29:30,083 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
The ADRB2 receptor is a GPCR, so the priorities are logP, Pgp, TPSA, affinity, and, to a lesser extent, BBB. Let's break down the comparison:
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da).
2. **TPSA:** Ligand B (67.87) is significantly better than Ligand A (81.75). Lower TPSA is favorable for oral absorption and GPCR binding.
3. **logP:** Ligand B (2.116) is within the optimal range (1-3), while Ligand A (-0.425) is below 1, which could hinder permeability. This is a significant advantage for Ligand B.
4. **H-Bond Donors/Acceptors:** Both have acceptable numbers of HBDs and HBAs.
5. **QED:** Both ligands have similar and acceptable QED scores.
6. **DILI:** Ligand B (17.138) has a much lower DILI risk than Ligand A (24.118), a crucial factor.
7. **BBB:** Ligand B (88.29) shows better BBB penetration than Ligand A (41.218), though this isn't a primary concern for ADRB2 unless CNS effects are desired.
8. **Caco-2 Permeability:** Ligand B (-4.569) is slightly better than Ligand A (-5.063), indicating better intestinal absorption.
9. **Aqueous Solubility:** Both are poor, but similar.
10. **hERG:** Ligand B (0.479) has a slightly better hERG profile than Ligand A (0.089).
11. **Microsomal Clearance:** Ligand A (2.98) has a much lower Cl_mic than Ligand B (58.358), suggesting better metabolic stability.
12. **In vitro Half-Life:** Ligand B (12.155) has a significantly longer half-life than Ligand A (-18.154).
13. **P-gp Efflux:** Both have low P-gp efflux liability.
14. **Binding Affinity:** Ligand B (-5.3) is slightly better than Ligand A (-6.0). While Ligand A has a better binding affinity, the difference is less than 1.5 kcal/mol and is outweighed by other factors.
**Overall Assessment:**
Ligand B demonstrates a superior balance of properties, particularly regarding permeability (logP, TPSA, Caco-2), safety (DILI, hERG), and metabolic stability (half-life). While Ligand A has a slightly better binding affinity, the other ADME/Tox properties of Ligand B are significantly more favorable for drug development. The poor logP and solubility of Ligand A are concerning.
**Output:**
0
2025-04-17 18:29:30,083 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Ligand A: [342.483, 49.41, 3.173, 1, 2, 0.798, 19.465, 73.943, -4.945, -4.47, 0.293, 47.904, 12.177, 0.18, -1.2]**
**Ligand B: [350.463, 98.32, 1.623, 3, 4, 0.63, 24.506, 27.801, -5.408, -1.841, 0.357, 5.683, -6.89, 0.042, -6.9]**
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). A is 342.483, B is 350.463. No significant difference.
2. **TPSA:** Ligand A (49.41) is excellent, well below the 140 threshold and good for oral absorption. Ligand B (98.32) is higher, but still acceptable, though less ideal.
3. **logP:** Ligand A (3.173) is optimal. Ligand B (1.623) is on the lower side, potentially hindering permeability.
4. **H-Bond Donors:** Ligand A (1) is good. Ligand B (3) is acceptable, but higher.
5. **H-Bond Acceptors:** Ligand A (2) is good. Ligand B (4) is acceptable, but higher.
6. **QED:** Ligand A (0.798) is strong, indicating good drug-like properties. Ligand B (0.63) is still reasonable, but lower.
7. **DILI:** Ligand A (19.465) has a very low DILI risk. Ligand B (24.506) is also relatively low, but higher than A.
8. **BBB:** Ligand A (73.943) has good BBB penetration. Ligand B (27.801) is poor. This is a *significant* advantage for Ligand A, as ADRB2 is a GPCR and CNS penetration could be relevant depending on the therapeutic goal.
9. **Caco-2:** Ligand A (-4.945) is more negative, indicating better permeability. Ligand B (-5.408) is also good, but slightly less.
10. **Solubility:** Ligand A (-4.47) is better than Ligand B (-1.841).
11. **hERG:** Both ligands have low hERG inhibition risk (0.293 and 0.357, respectively).
12. **Cl_mic:** Ligand A (47.904) has a higher clearance than Ligand B (5.683), meaning faster metabolism. This is a disadvantage for A.
13. **t1/2:** Ligand A (12.177) has a shorter half-life than Ligand B (-6.89). This is a disadvantage for A.
14. **Pgp:** Ligand A (0.18) has lower P-gp efflux than Ligand B (0.042). This is a slight advantage for A.
15. **Binding Affinity:** Ligand B (-6.9) has significantly stronger binding affinity than Ligand A (-1.2). This is a *major* advantage for B, potentially outweighing some ADME drawbacks.
**Overall Assessment:**
Ligand B has a much stronger binding affinity, which is paramount for GPCR targets. While Ligand A has better BBB penetration and lower DILI risk, the substantial difference in binding affinity (-6.9 vs -1.2 kcal/mol) is a decisive factor. The lower logP of Ligand B is a concern, but can potentially be addressed with formulation strategies. The better metabolic stability and half-life of Ligand B are also favorable.
Output:
0
2025-04-17 18:29:30,084 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
The ADRB2 receptor is a GPCR, so the priorities are logP, TPSA, Pgp efflux, BBB penetration, and binding affinity. Metabolic stability and solubility are also important.
Let's compare the ligands:
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (345.451) is slightly lower than Ligand B (353.507), which is preferable.
2. **TPSA:** Ligand A (87.45) is higher than Ligand B (61.88). Ligand B is significantly better here, being well below the 140 threshold for good absorption.
3. **logP:** Both are within the optimal 1-3 range. Ligand B (1.641) is slightly lower than Ligand A (2.146), which could slightly hinder permeability, but both are acceptable.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1), but both are within the acceptable limit of 5.
5. **HBA:** Ligand A (6) is higher than Ligand B (4), but both are within the acceptable limit of 10.
6. **QED:** Ligand A (0.867) has a better QED score than Ligand B (0.649), indicating better overall drug-likeness.
7. **DILI:** Ligand B (4.769) has a *much* lower DILI risk than Ligand A (33.23). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (87.553) has better BBB penetration than Ligand B (63.784). While not a primary concern for ADRB2 (a cardiovascular target), it's a positive.
9. **Caco-2:** Ligand A (-5.144) and Ligand B (-4.878) are both negative, which is unusual. Higher values are better. They are fairly similar.
10. **Solubility:** Ligand A (-2.31) is worse than Ligand B (-0.442). Ligand B has better aqueous solubility.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.563 and 0.416, respectively).
12. **Cl_mic:** Ligand A (5.697) has significantly lower microsomal clearance than Ligand B (13.791), suggesting better metabolic stability.
13. **t1/2:** Ligand A (31.079) has a much longer in vitro half-life than Ligand B (-2.911). This is a major advantage for Ligand A.
14. **Pgp:** Ligand A (0.082) has lower P-gp efflux than Ligand B (0.014), which is better.
15. **Affinity:** Both have excellent binding affinities (-5.8 and -5.3 kcal/mol). Ligand A has a slightly better affinity, but the difference is not substantial enough to outweigh other factors.
**Overall Assessment:**
Ligand A has a better binding affinity, QED, BBB penetration, metabolic stability, and Pgp efflux. However, Ligand B shines with a significantly lower DILI risk, better TPSA, and better solubility. The lower DILI risk is a critical advantage, especially in cardiovascular drug development where liver toxicity is a concern. The better TPSA of Ligand B also suggests better absorption. While Ligand A's longer half-life is attractive, the DILI risk of Ligand A is a substantial concern.
Considering the balance of properties and the GPCR-specific priorities, **Ligand B is the more promising candidate.**
**Output:**
0
2025-04-17 18:29:30,084 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [346.391, 116. , -0.164, 3. , 5. , 0.695, 62.233, 32.377, -5.537, -1.349, 0.114, -19.179, -27.826, 0.006, -7.3 ]
**Ligand B:** [342.483, 49.41 , 3.196, 1. , 2. , 0.798, 13.843, 86.661, -4.905, -4.058, 0.41 , 48.492, -3.811, 0.186, -6.8 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal 200-500 Da range. A (346.391) and B (342.483) are very close.
2. **TPSA:** A (116) is above the optimal <140 for oral absorption, but not drastically. B (49.41) is excellent, well below 140 and favorable for permeability.
3. **logP:** A (-0.164) is quite low, potentially hindering membrane permeability. B (3.196) is within the optimal 1-3 range. This is a significant advantage for B.
4. **HBD:** A (3) is acceptable. B (1) is even better, reducing potential for off-target interactions and improving permeability.
5. **HBA:** A (5) is acceptable. B (2) is excellent.
6. **QED:** Both are good (A: 0.695, B: 0.798), indicating drug-like properties. B is slightly better.
7. **DILI:** A (62.233) is moderately high, raising some concern. B (13.843) is very low, a major advantage.
8. **BBB:** A (32.377) is low, suggesting poor CNS penetration. B (86.661) is high, indicating good potential for CNS penetration. While ADRB2 is primarily cardiovascular, some CNS effects are possible, and higher BBB is generally preferred.
9. **Caco-2:** A (-5.537) is very poor. B (-4.905) is also poor, but slightly better.
10. **Solubility:** A (-1.349) is poor. B (-4.058) is also poor. Both compounds have solubility issues.
11. **hERG:** A (0.114) is low risk. B (0.41) is also low risk. Both are acceptable.
12. **Cl_mic:** A (-19.179) is excellent (low clearance, high metabolic stability). B (48.492) is high clearance, indicating faster metabolism. This is a significant advantage for A.
13. **t1/2:** A (-27.826) is excellent (long half-life). B (-3.811) is short. This further supports A's better metabolic stability.
14. **Pgp:** A (0.006) is very low efflux, good for bioavailability. B (0.186) is also low efflux, but A is better.
15. **Affinity:** A (-7.3) is slightly better than B (-6.8), but the difference is not huge.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP and TPSA, and has a good BBB score. Ligand A has a better affinity and metabolic stability (Cl_mic, t1/2), but suffers from poor logP and a higher DILI risk.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity and significantly better metabolic stability, the combination of poor logP, moderate DILI risk, and poor Caco-2 permeability are major drawbacks. Ligand B, despite slightly weaker affinity and faster metabolism, presents a much more balanced profile with better permeability characteristics (logP, TPSA), a significantly lower DILI risk, and good BBB penetration. The better ADME properties of Ligand B outweigh the small difference in binding affinity, especially considering the potential for further optimization of the B scaffold.
Output:
0
2025-04-17 18:29:30,084 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (332.367 Da) is within the ideal range (200-500 Da). Ligand B (373.513 Da) is also acceptable. No clear advantage here.
2. **TPSA:** Ligand A (88.49) is good, under the 140 threshold. Ligand B (45.23) is excellent, well below 90. This favors Ligand B.
3. **logP:** Ligand A (2.919) is optimal (1-3). Ligand B (4.306) is slightly higher, potentially leading to solubility issues, but still within a reasonable range. Slight edge to Ligand A.
4. **HBD:** Ligand A (2) and Ligand B (1) are both good, well below the 5 threshold. No significant difference.
5. **HBA:** Ligand A (5) and Ligand B (3) are both good, below the 10 threshold. No significant difference.
6. **QED:** Ligand A (0.604) and Ligand B (0.836) are both good, above 0.5. Ligand B is better.
7. **DILI:** Ligand A (88.329) has a higher DILI risk than Ligand B (37.03). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (36.371) has low BBB penetration. Ligand B (88.6) has good BBB penetration. Given ADRB2 is a GPCR, BBB penetration is a consideration, favoring Ligand B.
9. **Caco-2:** Ligand A (-5.317) and Ligand B (-4.525) both have negative values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
10. **Solubility:** Ligand A (-3.98) and Ligand B (-4.252) both have negative solubility values, which is concerning.
11. **hERG:** Ligand A (0.585) and Ligand B (0.686) are both relatively low risk. No clear advantage.
12. **Cl_mic:** Ligand A (13.868) has lower clearance, indicating better metabolic stability, than Ligand B (66.548). This favors Ligand A.
13. **t1/2:** Ligand A (39.352) has a longer half-life than Ligand B (-3.078). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.111) has lower P-gp efflux than Ligand B (0.234). This is a slight advantage for Ligand A.
15. **Affinity:** Ligand A (-7.9 kcal/mol) has a slightly better binding affinity than Ligand B (-7.3 kcal/mol). While the difference is less than 1.5 kcal/mol, it's still a positive for Ligand A.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand B initially appears stronger due to its excellent TPSA, good BBB penetration, and lower DILI risk. However, Ligand A has a significant advantage in metabolic stability (lower Cl_mic, longer t1/2), and slightly better affinity. The solubility and Caco-2 values are poor for both, but the metabolic advantages of Ligand A are crucial for *in vivo* efficacy. The slightly better affinity further supports this.
Therefore, I believe Ligand A is the more promising drug candidate.
Output:
1
2025-04-17 18:29:30,084 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (360.841 and 352.494 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (62.4) is higher than Ligand B (49.41). Both are below the 140 threshold for oral absorption, but B is closer to the preferred <90 for GPCRs.
3. **logP:** Both ligands have good logP values (3.355 and 3.819), falling within the optimal 1-3 range. Ligand B is slightly higher, which could be a minor concern for solubility, but not a dealbreaker.
4. **HBD:** Both have 1 HBD, which is within the acceptable limit of <=5.
5. **HBA:** Ligand A has 3 HBA, and Ligand B has 2. Both are within the acceptable limit of <=10.
6. **QED:** Ligand A (0.893) has a significantly better QED score than Ligand B (0.675), indicating a more drug-like profile.
7. **DILI:** Ligand B (27.22) has a much lower DILI risk than Ligand A (65.41), which is a significant advantage. Lower DILI is crucial.
8. **BBB:** Ligand B (91.625) has a much higher BBB penetration percentile than Ligand A (74.564). While ADRB2 isn't exclusively a CNS target, good BBB penetration is still beneficial for broader distribution and potentially reducing off-target effects.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand B (-3.761) has better aqueous solubility than Ligand A (-5.283). Better solubility is always preferred.
11. **hERG:** Both ligands have low hERG inhibition risk (0.617 and 0.711), which is good.
12. **Cl_mic:** Ligand B (75.31) has a higher microsomal clearance than Ligand A (19.057), indicating faster metabolism and potentially lower *in vivo* exposure. This is a disadvantage for Ligand B.
13. **t1/2:** Ligand A (34.694) has a longer *in vitro* half-life than Ligand B (-10.134). This is a significant advantage for Ligand A.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.259 and 0.306).
15. **Binding Affinity:** Ligand A (-7.4 kcal/mol) has a slightly better binding affinity than Ligand B (-6.9 kcal/mol). While the difference is less than the 1.5 kcal/mol threshold to outweigh other issues, it's still a positive for Ligand A.
**Overall Assessment:**
Ligand B has significant advantages in DILI risk, BBB penetration, and solubility. However, it suffers from higher metabolic clearance and a shorter half-life. Ligand A has a better QED score, longer half-life, and slightly better affinity, but has a higher DILI risk and lower BBB penetration.
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity) and the overall balance, the lower DILI risk and better BBB penetration of Ligand B are more compelling. The slightly worse metabolic stability can be addressed through structural modifications during optimization. The better QED and affinity of Ligand A are not enough to overcome the higher DILI risk.
Output:
0
2025-04-17 18:29:30,084 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (361.442 Da) is within the ideal range, while Ligand B (349.387 Da) is also acceptable. No clear advantage here.
2. **TPSA:** Ligand A (63.25) is well below the 140 threshold and good for oral absorption. Ligand B (109.78) is still within acceptable limits, but less favorable.
3. **logP:** Ligand A (2.724) is optimal. Ligand B (0.482) is quite low, potentially leading to poor membrane permeability. This is a significant drawback.
4. **HBD:** Ligand A (2) is good. Ligand B (3) is acceptable, but slightly less preferred.
5. **HBA:** Ligand A (5) is good. Ligand B (6) is acceptable.
6. **QED:** Ligand A (0.828) is excellent, indicating high drug-likeness. Ligand B (0.442) is below the 0.5 threshold, suggesting a less favorable drug-like profile.
7. **DILI:** Ligand A (61.807) is moderately high, but manageable. Ligand B (37.224) is much lower and preferable.
8. **BBB:** Ligand A (70.531) is good, suggesting reasonable potential for CNS penetration if desired. Ligand B (23.149) is low, indicating poor BBB penetration. While ADRB2 is primarily cardiovascular, some CNS side effects are possible, so some BBB penetration isn't necessarily a negative.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.194 and -5.217). This is unusual and suggests a potential issue with in vitro permeability assessment. However, the values are very similar.
10. **Solubility:** Ligand A (-3.366) and Ligand B (-1.7) both have negative solubility values, indicating poor aqueous solubility. Ligand B is slightly better.
11. **hERG:** Ligand A (0.618) is relatively low risk. Ligand B (0.046) is very low risk, a significant advantage.
12. **Cl_mic:** Ligand A (28.607) is moderate. Ligand B (2.89) is very low, indicating excellent metabolic stability.
13. **t1/2:** Ligand A (16.392) is good. Ligand B (-15.599) is very poor and a major concern.
14. **Pgp:** Ligand A (0.124) is low, indicating minimal P-gp efflux. Ligand B (0.008) is even lower, which is excellent.
15. **Affinity:** Ligand A (-6.9 kcal/mol) is slightly better than Ligand B (-6.4 kcal/mol), but the difference is not huge.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has a better logP and TPSA, while Ligand B has better Pgp efflux and hERG inhibition. The affinity difference is small.
**Overall Assessment:**
Ligand A has a better overall drug-like profile (QED) and slightly better affinity, but suffers from a less optimal logP and moderate DILI risk. Ligand B has a significantly better metabolic stability (Cl_mic), lower DILI and hERG risk, and excellent Pgp properties, but its low logP and very poor half-life are major drawbacks.
Considering the balance, the poor half-life of Ligand B is a critical issue that would likely lead to very frequent dosing requirements and potentially poor efficacy. The slightly better affinity of Ligand A, combined with its more acceptable logP and QED, makes it the more promising starting point for optimization.
Output:
1
2025-04-17 18:29:30,085 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.39 and 352.52 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand B (58.64) is significantly better than Ligand A (95.34). ADRB2 is not a CNS target, but lower TPSA generally improves absorption. This favors Ligand B.
3. **logP:** Ligand B (3.13) is at the upper end of the optimal range, while Ligand A (1.11) is at the lower end. While >4 is concerning, 3.13 is acceptable, and the lower logP of A could hinder permeability. Slight advantage to Ligand B.
4. **HBD:** Both ligands have 1 HBD, which is good. No difference.
5. **HBA:** Ligand B (3) is better than Ligand A (8). Lower HBA is generally preferred for permeability. This favors Ligand B.
6. **QED:** Both ligands have acceptable QED values (0.565 and 0.649), indicating good drug-like properties. No clear advantage.
7. **DILI:** Ligand B (9.31) has a much lower DILI risk than Ligand A (51.38). This is a significant advantage for Ligand B.
8. **BBB:** Both ligands have reasonable BBB penetration (69.41 and 77.39). Not a primary concern for ADRB2, but Ligand B is slightly better.
9. **Caco-2:** Ligand A (-5.033) and Ligand B (-4.658) are both negative, indicating poor permeability. Ligand B is slightly better.
10. **Solubility:** Ligand A (-1.673) and Ligand B (-2.787) are both negative, indicating poor solubility. Ligand B is slightly better.
11. **hERG:** Ligand A (0.22) has a lower hERG risk than Ligand B (0.685). This favors Ligand A.
12. **Cl_mic:** Ligand B (63.45) has lower microsomal clearance than Ligand A (70.12), suggesting better metabolic stability. This favors Ligand B.
13. **t1/2:** Ligand B (-14.414) has a significantly longer in vitro half-life than Ligand A (1.269). This is a major advantage for Ligand B.
14. **Pgp:** Ligand A (0.158) has lower P-gp efflux than Ligand B (0.421). This favors Ligand A.
15. **Binding Affinity:** Ligand B (-6.1 kcal/mol) has a slightly better binding affinity than Ligand A (-5.5 kcal/mol). This is a meaningful advantage for Ligand B.
**Overall Assessment:**
Ligand B consistently outperforms Ligand A across most critical ADME properties (DILI, Cl_mic, t1/2, TPSA, HBA) and has a slightly better binding affinity. While Ligand A has a lower hERG risk and Pgp efflux, the benefits of Ligand B's improved ADME profile and potency outweigh these concerns, particularly for a non-CNS target like ADRB2. The significantly lower DILI risk and longer half-life of Ligand B are particularly compelling.
Output:
0
2025-04-17 18:29:30,085 - INFO - Batch 41 complete. Total preferences: 656
2025-04-17 18:29:30,085 - INFO - Processing batch 42/512...
2025-04-17 18:30:18,885 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (361.383) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (61.44) is significantly better than Ligand A (124.09). ADRB2 is not a CNS target, but lower TPSA generally improves absorption.
3. **logP:** Both ligands have good logP values (A: 3.342, B: 3.741), falling within the optimal 1-3 range. Ligand B is slightly higher, which could potentially lead to off-target interactions, but is still acceptable.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2) as lower HBD is generally better for permeability.
5. **HBA:** Ligand B (3) is preferable to Ligand A (8). Lower HBA is generally better for permeability.
6. **QED:** Both ligands have acceptable QED values (A: 0.635, B: 0.588), indicating good drug-like properties.
7. **DILI:** Ligand B (49.787) has a significantly lower DILI risk than Ligand A (96.433). This is a major advantage for Ligand B.
8. **BBB:** This is less critical for ADRB2, but Ligand B (87.941) has a higher BBB percentile than Ligand A (53.276).
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. This is a significant concern for both.
10. **Solubility:** Both ligands have negative solubility values, indicating poor solubility. This is a significant concern for both.
11. **hERG:** Ligand A (0.438) has a lower hERG risk than Ligand B (0.762), which is preferable.
12. **Cl_mic:** Ligand A (27.023) has lower microsomal clearance than Ligand B (32.587), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-7.968) has a much longer in vitro half-life than Ligand A (-1.421). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.067) has lower P-gp efflux liability than Ligand B (0.216), which is preferable.
15. **Binding Affinity:** Ligand A (-8.2) has a significantly stronger binding affinity than Ligand B (-4.7). This is a substantial advantage for Ligand A.
**Overall Assessment:**
Ligand A has a much stronger binding affinity, lower Pgp efflux, and better metabolic stability. However, Ligand B has a significantly lower DILI risk and a much longer half-life. Both ligands have poor Caco-2 and solubility. The strong affinity of Ligand A is a major advantage, and given that ADRB2 is not a CNS target, the slightly higher TPSA and lower BBB of Ligand A are less concerning. The DILI risk of Ligand A is a significant concern, but the substantial affinity advantage outweighs this risk.
Output:
1
2025-04-17 18:30:18,885 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (355.389 and 340.362 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (78.96) is significantly better than Ligand A (95.83). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (1.685 and 2.48), falling within the 1-3 range. Ligand B is slightly better.
4. **HBD:** Ligand A (3) and Ligand B (2) are both acceptable, below the threshold of 5. Ligand B is slightly better.
5. **HBA:** Ligand A (5) and Ligand B (6) are both acceptable, below the threshold of 10.
6. **QED:** Both ligands have good QED scores (0.565 and 0.743), indicating good drug-likeness. Ligand B is better.
7. **DILI:** Ligand A (55.525) is better than Ligand B (80.186). Lower DILI risk is crucial. This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (39.473) is lower than Ligand B (55.913). As ADRB2 is a cardiovascular target, BBB penetration is not a major concern.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.272 and -4.994), which is unusual and suggests poor permeability. However, these values are on a similar scale, so it doesn't differentiate them.
10. **Solubility:** Ligand A (-2.721) is better than Ligand B (-4.12). Better solubility is always preferable.
11. **hERG:** Ligand A (0.536) is better than Ligand B (0.868). Lower hERG inhibition is critical for avoiding cardiotoxicity. This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand A (14.754) is significantly better than Ligand B (71.17). Lower microsomal clearance indicates better metabolic stability. This is a major advantage for Ligand A.
13. **t1/2:** Ligand B (-12.519) is significantly better than Ligand A (-7.377). A longer half-life is generally desirable. This is a major advantage for Ligand B.
14. **Pgp:** Ligand A (0.246) is better than Ligand B (0.169). Lower P-gp efflux is preferable.
15. **Binding Affinity:** Ligand A (-7.4) is slightly better than Ligand B (-7.0). While both are excellent, the small advantage for Ligand A is noteworthy.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Ligand B performs slightly better on logP and TPSA. However, Ligand A has a better affinity and Pgp efflux. The biggest differentiator is the ADME-Tox profile. Ligand A has significantly lower DILI risk, lower hERG inhibition, and much better metabolic stability (lower Cl_mic). These factors are crucial for a safe and effective drug. While Ligand B has a better half-life, the risks associated with its ADME profile outweigh this benefit.
**Conclusion:**
Considering the balance of properties and the importance of ADME-Tox for cardiovascular drugs, Ligand A is the more promising drug candidate.
Output:
1
2025-04-17 18:30:18,885 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [345.359, 124.44 , 1.162, 1. , 8. , 0.822, 81.466, 90.772, -4.734, -2.731, 0.325, 48.557, -34.614, 0.02 , -5.7 ]
**Ligand B:** [347.463, 79.26 , 0.463, 2. , 5. , 0.603, 19.349, 33.734, -5.194, -1.461, 0.204, 6.847, 13.629, 0.015, -6.1 ]
Here's a breakdown of the comparison, considering the guidelines and GPCR-specific priorities:
1. **MW:** Both are within the ideal range (200-500 Da). A is 345.359, B is 347.463 - negligible difference.
2. **TPSA:** Ligand A (124.44) is slightly higher than Ligand B (79.26). Both are below 140, but B is significantly better for permeability.
3. **logP:** Ligand A (1.162) is within the optimal range, while Ligand B (0.463) is a bit low, potentially hindering membrane permeation.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (8) is higher than Ligand B (5). Lower is better, so B is preferable.
6. **QED:** Ligand A (0.822) has a better QED score than Ligand B (0.603), indicating a more drug-like profile.
7. **DILI:** Ligand A (81.466) has a significantly higher DILI risk than Ligand B (19.349). This is a major concern for Ligand A.
8. **BBB:** Ligand A (90.772) has much better BBB penetration than Ligand B (33.734). While ADRB2 isn't a CNS target, some off-target CNS effects are possible with GPCRs, and higher BBB is generally not a negative.
9. **Caco-2:** Ligand A (-4.734) is better than Ligand B (-5.194), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-2.731) is better than Ligand B (-1.461).
11. **hERG:** Both are very low (0.325 and 0.204), indicating low cardiotoxicity risk.
12. **Cl_mic:** Ligand A (48.557) has a higher clearance than Ligand B (6.847), meaning it's metabolized faster. B is preferable.
13. **t1/2:** Ligand A (-34.614) has a more negative half-life, suggesting faster elimination. Ligand B (13.629) is much better.
14. **Pgp:** Both are very low (0.02 and 0.015), indicating minimal P-gp efflux.
15. **Affinity:** Ligand B (-6.1) has a slightly better binding affinity than Ligand A (-5.7).
**Overall Assessment:**
Ligand A has advantages in QED, Caco-2 permeability, solubility, and BBB penetration. However, its significantly higher DILI risk and faster clearance are major drawbacks. Ligand B, while having a slightly lower QED and logP, presents a much better safety profile (DILI) and improved metabolic stability (lower Cl_mic, longer t1/2). The slightly better affinity of Ligand B further supports its selection.
Given the GPCR-specific priorities and the importance of balancing ADME-Tox properties, **Ligand B is the more promising candidate.**
0
2025-04-17 18:30:18,885 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (a cardiovascular GPCR) drug candidates.
**Ligand A:** [358.379, 103.18 , 1.494, 1. , 8. , 0.709, 98.72 , 71.772, -4.843, -3.409, 0.272, 74.853, 20.867, 0.401, -7.2 ]
**Ligand B:** [365.861, 75.44 , 3.043, 1. , 4. , 0.814, 42.032, 77.317, -4.955, -3.747, 0.549, 52.337, -14.205, 0.448, -7.2 ]
Here's a breakdown, prioritizing GPCR properties (logP, TPSA, Pgp, BBB, Affinity):
1. **Molecular Weight:** Both are within the ideal 200-500 Da range. A (358.379) is slightly preferred.
2. **TPSA:** A (103.18) is higher than B (75.44). For a cardiovascular GPCR, we don't *need* extremely low TPSA for CNS penetration, but lower is generally better for permeability. B is better here.
3. **logP:** A (1.494) is optimal, while B (3.043) is at the higher end of optimal. A is slightly better.
4. **H-Bond Donors:** Both have 1 HBD, which is good.
5. **H-Bond Acceptors:** A (8) is higher than B (4). Lower is better for permeability. B is better.
6. **QED:** Both are good (>0.5), with B (0.814) being slightly better.
7. **DILI:** A (98.72) is *very* high risk, a major red flag. B (42.032) is excellent. B is significantly better.
8. **BBB:** Both have reasonable BBB penetration, with B (77.317) being slightly higher than A (71.772).
9. **Caco-2:** Both are negative, indicating poor permeability. A (-4.843) is slightly worse than B (-4.955).
10. **Solubility:** Both are negative, indicating poor solubility. A (-3.409) is slightly better than B (-3.747).
11. **hERG:** Both have low hERG inhibition risk. A (0.272) is slightly better than B (0.549).
12. **Cl_mic:** A (74.853) has higher clearance than B (52.337), meaning B is more metabolically stable. B is better.
13. **t1/2:** A (20.867) has a longer half-life than B (-14.205). A is better.
14. **Pgp:** Both have low Pgp efflux, with A (0.401) being slightly lower than B (0.448). A is slightly better.
15. **Affinity:** Both have identical binding affinity (-7.2 kcal/mol).
**Overall Assessment:**
While Ligand A has a slightly better half-life and Pgp efflux, the *extremely* high DILI risk (98.72) is a deal-breaker. Ligand B, despite having slightly worse TPSA and Caco-2 permeability, has a significantly lower DILI risk (42.032), better metabolic stability, and a slightly better QED and BBB penetration. The equal binding affinity removes that as a differentiating factor. For a cardiovascular target, minimizing liver toxicity is paramount.
Therefore, I strongly prefer Ligand B.
0
2025-04-17 18:30:18,885 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (379.913 Da and 344.43 Da) fall within the ideal 200-500 Da range. Ligand B is slightly preferred due to being closer to the lower end, potentially aiding permeability.
**2. TPSA:** Ligand A (55.2) is slightly higher than Ligand B (49.41). Both are below the 140 A^2 threshold for good oral absorption, which is good.
**3. logP:** Both ligands have a logP around 3.0 (3.069 and 3.098), which is optimal for permeability and solubility. No clear preference here.
**4. H-Bond Donors:** Ligand A has 0 HBD, while Ligand B has 1. Both are within the acceptable limit of <=5.
**5. H-Bond Acceptors:** Ligand A has 5 HBA, Ligand B has 2. Both are within the acceptable limit of <=10.
**6. QED:** Both ligands have high QED scores (0.822 and 0.853), indicating good drug-like properties. Ligand B is slightly better.
**7. DILI Risk:** Ligand A has a DILI risk of 60.45%, which is approaching the higher risk threshold. Ligand B has a significantly lower DILI risk of 28.655%, making it considerably safer. This is a major advantage for Ligand B.
**8. BBB Penetration:** Ligand A (86.817%) shows good BBB penetration, while Ligand B (95.502%) is even better. For a cardiovascular GPCR, BBB penetration is less critical than for CNS targets, but it's still a positive attribute.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.949 and -4.753). These values are unusual and suggest poor permeability. However, the scale isn't specified, so it's hard to interpret.
**10. Aqueous Solubility:** Both ligands have negative solubility values (-3.912 and -3.507), which is also unusual and suggests poor solubility. Again, the scale isn't specified.
**11. hERG Inhibition:** Both ligands show low hERG inhibition risk (0.61 and 0.657), which is good.
**12. Microsomal Clearance:** Ligand A (24.956) has lower microsomal clearance than Ligand B (60.181), indicating better metabolic stability. This is a positive for Ligand A.
**13. In vitro Half-Life:** Ligand A (3.282 hours) has a shorter half-life than Ligand B (4.265 hours). Ligand B is slightly preferred.
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (0.498 and 0.191), which is good. Ligand B is slightly better.
**15. Binding Affinity:** Ligand A (-7.4 kcal/mol) has a stronger binding affinity than Ligand B (-6.5 kcal/mol). This is a significant advantage for Ligand A, as a 0.9 kcal/mol difference is substantial.
**Overall Assessment:**
While Ligand A has a superior binding affinity, Ligand B demonstrates a much more favorable safety profile with a significantly lower DILI risk. Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity), and the overall balance of properties, the lower DILI risk of Ligand B outweighs the slightly stronger binding affinity of Ligand A. The unusual solubility and permeability values are concerning for both, but the safety profile is paramount.
Output:
0
2025-04-17 18:30:18,886 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (364.5 and 378.8 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (67.23) is significantly better than Ligand B (110.17). For a GPCR, lower TPSA is generally preferred for better permeability. Ligand A is well below the 140 threshold, while Ligand B is approaching it.
3. **logP:** Both ligands (2.325 and 2.63) are within the optimal 1-3 range. Ligand B is slightly higher, which could potentially lead to off-target effects, but it's not a major concern.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (5) is better than Ligand B (8). Similar to HBD, lower HBA is preferred.
6. **QED:** Ligand A (0.806) is better than Ligand B (0.72), indicating a more drug-like profile.
7. **DILI:** Ligand A (27.685) has a much lower DILI risk than Ligand B (93.68). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (88.135) has better BBB penetration than Ligand B (68.864). While ADRB2 isn't exclusively a CNS target, some CNS exposure can occur, and higher BBB is generally favorable.
9. **Caco-2:** Both ligands have similar, very negative Caco-2 values (-5.049 and -5.018). This suggests poor permeability, which is concerning.
10. **Solubility:** Ligand A (-3.023) is slightly better than Ligand B (-4.497), but both are very poor. This is a significant drawback for both compounds.
11. **hERG:** Both ligands have low hERG inhibition risk (0.502 and 0.618). No significant difference.
12. **Cl_mic:** Ligand B (21.526) has significantly lower microsomal clearance than Ligand A (52.889), indicating better metabolic stability. This is a substantial advantage for Ligand B.
13. **t1/2:** Ligand B (16.828) has a slightly longer in vitro half-life than Ligand A (15.087).
14. **Pgp:** Ligand A (0.07) has much lower P-gp efflux liability than Ligand B (0.147). This is a significant advantage for Ligand A.
15. **Binding Affinity:** Ligand B (-7.4) has a slightly better binding affinity than Ligand A (-7.6). While a difference of 0.2 kcal/mol is not huge, it's a positive for Ligand B.
**Overall Assessment:**
Ligand A has a clear advantage in terms of drug-likeness (QED, DILI, TPSA, HBD, HBA, Pgp) and BBB penetration. However, Ligand B exhibits better metabolic stability (Cl_mic) and a slightly improved binding affinity. Both compounds have poor solubility and Caco-2 permeability, which are major concerns.
Given the GPCR target class, I prioritize TPSA, logP, Pgp, and affinity. Ligand A excels in TPSA and Pgp, and its affinity is only marginally weaker than Ligand B. The significantly lower DILI risk and better drug-like properties of Ligand A outweigh the slightly better affinity and metabolic stability of Ligand B. The poor solubility and permeability are concerning for both, but can be addressed with formulation strategies.
Output:
1
2025-04-17 18:30:18,886 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.419 and 350.503 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (94.05) is higher than Ligand B (49.85). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B is significantly better here.
3. **logP:** Ligand A (0.459) is quite low, potentially hindering membrane permeability. Ligand B (2.83) is within the optimal 1-3 range. Ligand B is much better.
4. **HBD:** Ligand A (1) is acceptable, Ligand B (0) is also good. No strong preference.
5. **HBA:** Ligand A (5) is acceptable, Ligand B (3) is also good. No strong preference.
6. **QED:** Ligand A (0.804) is excellent, indicating high drug-likeness. Ligand B (0.664) is still good, but lower. Ligand A is slightly better.
7. **DILI:** Ligand A (24.583) has a very low DILI risk, excellent. Ligand B (15.238) is also low risk, but slightly higher. Ligand A is better.
8. **BBB:** Ligand A (34.083) is low, which is fine for a cardiovascular target. Ligand B (92.555) is very high, which is not desirable for a peripheral target like ADRB2 and could lead to off-target effects. Ligand A is significantly better.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.009 and -4.726), which is unusual and suggests poor permeability. However, these values are on a log scale, so the absolute difference is not as large as it appears.
10. **Solubility:** Ligand A (-0.499) is very poor. Ligand B (-2.345) is also poor, but worse. Ligand A is better.
11. **hERG:** Ligand A (0.024) has a very low hERG risk, excellent. Ligand B (0.659) is higher, indicating some potential concern. Ligand A is much better.
12. **Cl_mic:** Ligand A (30.229) has lower clearance, suggesting better metabolic stability. Ligand B (65.255) has higher clearance. Ligand A is better.
13. **t1/2:** Ligand A (-6.575) is negative, indicating very rapid clearance. Ligand B (2.697) is positive, indicating a longer half-life. Ligand B is better.
14. **Pgp:** Ligand A (0.005) has very low P-gp efflux, which is good. Ligand B (0.317) is higher, suggesting some efflux potential. Ligand A is better.
15. **Binding Affinity:** Both ligands have similar binding affinities (-4.1 and -4.6 kcal/mol). The difference is not substantial enough to outweigh other factors.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp) and general drug-likeness criteria, **Ligand A** is the better candidate. While its solubility and in vitro half-life are concerns, its superior logP, lower TPSA, excellent DILI and hERG profiles, low Pgp efflux, and better BBB penetration profile (for avoiding off-target CNS effects) outweigh the benefits of Ligand B's slightly better half-life. The solubility issue can be addressed through formulation strategies. The low logP of Ligand B is a significant drawback.
Output:
1
2025-04-17 18:30:18,886 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (363.849 Da) is within the ideal range (200-500 Da). Ligand B (412.372 Da) is also acceptable, but approaching the upper limit.
2. **TPSA:** Ligand A (85.09) is good, below the 140 threshold for oral absorption. Ligand B (58.36) is excellent, suggesting good permeability.
3. **logP:** Ligand A (1.594) is optimal. Ligand B (3.171) is also within the optimal range, but higher.
4. **HBD:** Ligand A (2) is good. Ligand B (1) is excellent.
5. **HBA:** Ligand A (7) is good. Ligand B (4) is excellent.
6. **QED:** Both Ligand A (0.81) and Ligand B (0.731) are above the 0.5 threshold, indicating good drug-likeness.
7. **DILI:** Ligand A (53.083) is acceptable (low risk). Ligand B (13.377) is *very* good, significantly lower risk.
8. **BBB:** Ligand A (62.699) is moderate. Ligand B (75.533) is good, suggesting better potential for CNS penetration if desired. While ADRB2 is primarily cardiovascular, some CNS effects are possible with beta-blockers, so this is a slight advantage for B.
9. **Caco-2:** Ligand A (-5.512) is poor. Ligand B (-4.745) is also poor, but slightly better.
10. **Solubility:** Ligand A (-2.254) is poor. Ligand B (-3.89) is also poor. Both compounds have solubility issues.
11. **hERG:** Ligand A (0.129) is very low risk. Ligand B (0.566) is slightly higher, but still acceptable.
12. **Cl_mic:** Ligand A (9.108) is relatively low, suggesting good metabolic stability. Ligand B (57.787) is significantly higher, indicating faster metabolism.
13. **t1/2:** Ligand A (14.638) is good. Ligand B (22.27) is better, indicating a longer half-life.
14. **Pgp:** Ligand A (0.294) is low efflux, which is good. Ligand B (0.383) is also low efflux, slightly higher than A.
15. **Affinity:** Ligand A (2.6) is weak. Ligand B (-6.5) is *much* stronger. This is a significant advantage for Ligand B.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, affinity, logP, TPSA, and Pgp are key. Ligand B excels in affinity, has a good logP and TPSA, and acceptable Pgp. While BBB isn't a primary concern for a cardiovascular target, the higher value for B is a slight benefit. The biggest drawbacks for Ligand B are its higher Cl_mic and lower solubility, but the substantial affinity advantage outweighs these concerns. Ligand A suffers from a weak binding affinity, which is a major issue.
**Conclusion:**
Despite the solubility and metabolic stability concerns with Ligand B, the significantly stronger binding affinity (-6.5 kcal/mol vs 2.6 kcal/mol) is a decisive advantage for a GPCR target. The other parameters are either comparable or slightly favor Ligand B.
Output:
0
2025-04-17 18:30:18,886 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands (350.394 & 353.463 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (65.98) is significantly better than Ligand B (87.74). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (0.993) is slightly better than Ligand A (0.226). Both are a bit low, potentially hindering membrane permeability, but Ligand B is closer to the optimal 1-3 range.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (4). Lower HBA is generally better for permeability.
6. **QED:** Ligand A (0.781) is significantly better than Ligand B (0.478), indicating a more drug-like profile.
7. **DILI:** Ligand A (47.732) is significantly better than Ligand B (23.497). Lower DILI risk is crucial.
8. **BBB:** Ligand A (77.627) is better than Ligand B (45.638). While not a CNS target, some level of BBB penetration can affect off-target effects and distribution.
9. **Caco-2:** Ligand A (-4.132) is better than Ligand B (-5.044). Higher Caco-2 permeability is desirable.
10. **Solubility:** Ligand A (-0.271) is better than Ligand B (-0.898). Higher solubility is important for bioavailability.
11. **hERG:** Ligand A (0.304) is better than Ligand B (0.112). Lower hERG inhibition is critical for avoiding cardiotoxicity.
12. **Cl_mic:** Ligand A (-7.805) is *much* better than Ligand B (33.057). A negative value for Cl_mic indicates very high metabolic stability, a huge advantage.
13. **t1/2:** Ligand A (-15.624) is better than Ligand B (9.822). Longer half-life is generally preferred.
14. **Pgp:** Ligand A (0.017) is better than Ligand B (0.01). Both are very low, indicating minimal P-gp efflux.
15. **Affinity:** Ligand B (-7.6) is slightly better than Ligand A (-6.1). While a difference of 1.5 kcal/mol is usually significant, the overwhelming advantages of Ligand A in ADME properties outweigh this.
**GPCR-specific priorities:** For ADRB2 (a cardiovascular GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A is better in TPSA, Pgp, and has acceptable logP. While Ligand B has slightly better affinity, the significantly superior ADME profile of Ligand A, particularly its metabolic stability (Cl_mic) and lower toxicity (DILI, hERG), makes it the more promising candidate.
**Output:**
1
2025-04-17 18:30:18,886 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (344.5) is well within the ideal range (200-500). Ligand B (395.4) is also acceptable, but closer to the upper limit.
2. **TPSA:** Ligand A (52.57) is excellent, well below the 140 threshold and suitable for good absorption. Ligand B (69.64) is still reasonable, but higher.
3. **logP:** Both ligands (A: 3.689, B: 3.111) are within the optimal 1-3 range.
4. **HBD:** Both ligands have 2 HBD, which is within the acceptable limit of 5.
5. **HBA:** Ligand A has 2 HBA, Ligand B has 3. Both are below the 10 threshold.
6. **QED:** Ligand A (0.827) has a superior QED score compared to Ligand B (0.679), indicating better overall drug-likeness.
7. **DILI:** Ligand A (13.571) has a significantly lower DILI risk than Ligand B (21.442), a major advantage.
8. **BBB:** Ligand A (81.698) has a much higher BBB penetration percentile than Ligand B (60.527). While ADRB2 isn't exclusively a CNS target, some cardiovascular effects are mediated by central pathways, and higher BBB penetration isn't necessarily a detriment.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale isn't specified, so it's hard to interpret.
10. **Solubility:** Both ligands have negative solubility values, again making interpretation difficult.
11. **hERG:** Ligand A (0.775) has a slightly higher hERG risk than Ligand B (0.353), but both are relatively low.
12. **Cl_mic:** Ligand A (34.133) has a significantly lower microsomal clearance than Ligand B (63.501), indicating better metabolic stability.
13. **t1/2:** Ligand A (-5.184) has a negative in vitro half-life, which is concerning. Ligand B (4.435) has a positive half-life, which is much better.
14. **Pgp:** Ligand A (0.384) has lower P-gp efflux liability than Ligand B (0.1), which is favorable.
15. **Affinity:** Ligand A (-7.2 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.3 kcal/mol). This is a substantial advantage.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A excels in these areas, particularly affinity and Pgp. While BBB isn't paramount for ADRB2, the higher value for Ligand A isn't a drawback. The biggest concern for Ligand A is the negative in vitro half-life, but the strong affinity and lower DILI risk are compelling. Ligand B has a better half-life, but is weaker in most other areas.
**Overall Assessment:**
Despite the negative half-life for Ligand A, its superior affinity, lower DILI risk, better QED, and more favorable Pgp profile outweigh the concerns. The strong binding affinity is a significant driver, and the other ADME properties are generally better. The negative half-life is a flag for further investigation, but could potentially be addressed through structural modifications.
Output:
1
2025-04-17 18:30:18,886 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (367.881 Da) is slightly larger than Ligand B (339.443 Da), but this difference isn't significant.
**2. TPSA:** Ligand A (72.54) is better than Ligand B (85.86). For a GPCR, keeping TPSA lower is generally favorable for permeability.
**3. logP:** Ligand A (1.529) is within the optimal range, while Ligand B (3.185) is approaching the upper limit. While 3.185 isn't terrible, lower logP is generally preferred for reducing off-target effects and improving solubility.
**4. H-Bond Donors:** Ligand A (1) is better than Ligand B (4). Fewer H-bond donors generally improve membrane permeability.
**5. H-Bond Acceptors:** Ligand A (4) is better than Ligand B (5). Similar to HBDs, fewer HBAs are generally preferred.
**6. QED:** Ligand A (0.875) is significantly better than Ligand B (0.45). A higher QED indicates a more drug-like molecule.
**7. DILI:** Ligand A (30.787) has a much lower DILI risk than Ligand B (66.77). This is a critical advantage, as liver toxicity is a major concern in drug development.
**8. BBB:** Both ligands have reasonably good BBB penetration (Ligand A: 68.67, Ligand B: 61.962). While ADRB2 is a cardiovascular target, some CNS off-target effects are possible, so moderate BBB penetration isn't necessarily a deal-breaker.
**9. Caco-2 Permeability:** Both have negative values, indicating poor permeability. Ligand A (-5.001) is slightly better than Ligand B (-5.638), but both are concerning.
**10. Aqueous Solubility:** Both have negative values, indicating poor solubility. Ligand A (-2.499) is slightly better than Ligand B (-3.4).
**11. hERG Inhibition:** Ligand A (0.286) has a much lower hERG inhibition risk than Ligand B (0.956). This is a significant safety advantage.
**12. Microsomal Clearance:** Ligand A (-5.823) has a lower (better) microsomal clearance than Ligand B (66.364), indicating greater metabolic stability.
**13. In vitro Half-Life:** Ligand A (-11.876) has a longer half-life than Ligand B (65.177).
**14. P-gp Efflux:** Ligand A (0.012) has a much lower P-gp efflux liability than Ligand B (0.588). This is favorable for both oral bioavailability and potentially CNS exposure if needed.
**15. Binding Affinity:** Ligand B (-7.3) has a stronger binding affinity than Ligand A (-6.0). This is a 1.3 kcal/mol difference, which is substantial.
**Overall Assessment:**
While Ligand B has a better binding affinity, Ligand A is significantly superior in almost all other critical ADME-Tox properties. The lower DILI risk, hERG inhibition, P-gp efflux, and better metabolic stability (lower Cl_mic, longer t1/2) of Ligand A are substantial advantages. The QED score is also much higher for Ligand A. The slight difference in Caco-2 and solubility can be addressed with formulation strategies. The 1.3 kcal/mol difference in binding affinity, while significant, can potentially be optimized in subsequent rounds of medicinal chemistry, whereas fixing severe ADME/Tox liabilities is often much more challenging.
Therefore, I would prioritize Ligand A.
Output:
1
2025-04-17 18:30:18,886 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 GPCR, followed by the final output.
**Ligand A: [343.431, 80.12, 1.13, 1, 5, 0.785, 51.493, 70.57, -5.33, -2.448, 0.106, 33.363, -1.647, 0.071, -6.8]**
**Ligand B: [363.502, 48.99, 4.641, 1, 3, 0.813, 36.642, 89.027, -4.77, -4.642, 0.75, 70.174, 11.101, 0.751, -6.2]**
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). A (343.431) is slightly preferred.
2. **TPSA:** A (80.12) is better than B (48.99). While both are reasonably low, lower TPSA generally improves permeability. B is excellent.
3. **logP:** A (1.13) is optimal, while B (4.641) is pushing the upper limit and could lead to solubility issues and off-target interactions. A is significantly better here.
4. **H-Bond Donors:** Both have 1 HBD, which is good.
5. **H-Bond Acceptors:** A (5) is slightly higher than B (3), but both are acceptable.
6. **QED:** Both have good QED values (A: 0.785, B: 0.813), indicating drug-like properties. B is slightly better.
7. **DILI:** A (51.493) is better than B (36.642). Lower DILI risk is crucial. A is preferred.
8. **BBB:** B (89.027) is significantly better than A (70.57). For a GPCR, especially if CNS effects are possible, good BBB penetration is a plus.
9. **Caco-2 Permeability:** A (-5.33) is worse than B (-4.77). Higher Caco-2 values indicate better absorption. B is better.
10. **Aqueous Solubility:** B (-4.642) is better than A (-2.448). Higher solubility is important for formulation and bioavailability. B is preferred.
11. **hERG Inhibition:** A (0.106) is much better than B (0.75). Lower hERG inhibition is vital to avoid cardiotoxicity. A is strongly preferred.
12. **Microsomal Clearance:** A (33.363) is better than B (70.174). Lower clearance suggests better metabolic stability. A is preferred.
13. **In vitro Half-Life:** A (-1.647) is worse than B (11.101). Longer half-life is generally desirable. B is preferred.
14. **P-gp Efflux:** A (0.071) is much better than B (0.751). Lower P-gp efflux improves bioavailability. A is strongly preferred.
15. **Binding Affinity:** A (-6.8) is slightly better than B (-6.2), but the difference is small.
**Overall Assessment:**
Ligand A excels in critical areas like DILI risk, hERG inhibition, P-gp efflux, and microsomal clearance. Its logP is optimal, and its MW is good. While its BBB penetration and Caco-2 permeability are not as good as Ligand B, the safety and metabolic stability advantages of A are more important for initial drug candidate selection. Ligand B's strength lies in its BBB penetration and solubility, but its higher logP and potential for hERG inhibition are concerning.
Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity), and the overall balance of properties, Ligand A is the more promising candidate.
Output:
1
2025-04-17 18:30:18,886 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, priorities are logP, TPSA, Pgp, affinity, and to a lesser extent, BBB.
* **Molecular Weight:** Both ligands are within the ideal range (200-500 Da).
* **TPSA:** Both are below the 140 A^2 threshold for good absorption, with Ligand B slightly better at 99.1 vs 104.37 for Ligand A.
* **logP:** Both are within the optimal range (1-3), with Ligand B (0.821) being slightly more favorable than Ligand A (0.798).
* **H-Bond Donors/Acceptors:** Both have acceptable HBD (3) and HBA (4/5) counts.
* **QED:** Ligand B (0.626) has a better QED score than Ligand A (0.325), suggesting a more drug-like profile.
* **DILI:** Ligand B (12.524) has a significantly lower DILI risk than Ligand A (34.781). This is a major advantage.
* **BBB:** Ligand A (77.084) has a better BBB penetration score than Ligand B (59.131), but BBB isn't a primary concern for a cardiovascular target.
* **Caco-2:** Ligand A (-5.319) has a worse Caco-2 permeability than Ligand B (-4.767).
* **Solubility:** Ligand B (-0.811) has better aqueous solubility than Ligand A (-2.656).
* **hERG:** Ligand A (0.068) has a slightly better hERG profile than Ligand B (0.249), but both are low risk.
* **Cl_mic:** Ligand B (-5.481) has a much better (lower) microsomal clearance, indicating greater metabolic stability, than Ligand A (26.254).
* **t1/2:** Ligand B (-13.504) has a much longer in vitro half-life than Ligand A (-3.872).
* **Pgp:** Ligand A (0.021) has slightly lower P-gp efflux than Ligand B (0.008), but both are very low.
* **Binding Affinity:** Ligand B (-7.4 kcal/mol) has a slightly better binding affinity than Ligand A (-6.6 kcal/mol). While the difference is less than the 1.5 kcal/mol threshold, it contributes to the overall preference.
**Overall:**
Ligand B is significantly better due to its superior DILI score, metabolic stability (Cl_mic and t1/2), QED, solubility, and slightly better binding affinity. While Ligand A has a better BBB score, this is less important for a cardiovascular target. The combined advantages of Ligand B outweigh the minor benefit of Ligand A's BBB penetration.
**Output:**
0
2025-04-17 18:30:18,887 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.463 and 345.447 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (87.46) is better than Ligand B (90.98) as it is closer to the <140 threshold for good oral absorption.
3. **logP:** Both ligands (1.246 and 1.743) are within the optimal 1-3 range. Ligand B is slightly higher, which could potentially lead to some off-target effects, but it's not a major concern.
4. **HBD:** Both have 2 H-bond donors, which is acceptable.
5. **HBA:** Ligand A has 5 H-bond acceptors, and Ligand B has 4. Both are within the acceptable limit of 10.
6. **QED:** Both ligands have good QED scores (0.739 and 0.85), indicating good drug-like properties.
7. **DILI:** Ligand A (32.299) has a slightly higher DILI risk than Ligand B (25.475), but both are well below the concerning threshold of 60.
8. **BBB:** Ligand B (64.095) has a better BBB penetration score than Ligand A (54.634). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant for side effect profiles.
9. **Caco-2:** Ligand A (-4.724) has a better Caco-2 permeability than Ligand B (-5.193).
10. **Solubility:** Ligand A (-1.183) has better aqueous solubility than Ligand B (-2.938). Solubility is important for bioavailability.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.192 and 0.263).
12. **Cl_mic:** Ligand A (12.831) has a lower microsomal clearance than Ligand B (33.184), suggesting better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand A (12.018 hours) has a better in vitro half-life than Ligand B (-18.743 hours). A negative half-life is concerning.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.052 and 0.057).
15. **Binding Affinity:** Ligand B (-7.2 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.0 kcal/mol). This is a 1.2 kcal/mol difference, which is substantial and can often outweigh minor ADME drawbacks.
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand B excels in affinity. While Ligand A has better TPSA and solubility, the large difference in binding affinity is a major factor. The slightly better BBB for Ligand B is also a plus. The metabolic stability of Ligand A is good, but the negative half-life of Ligand B is a major concern.
**Conclusion:**
Despite the metabolic concerns with Ligand B, the significantly stronger binding affinity (-7.2 vs -6.0 kcal/mol) is a decisive advantage for a GPCR target. The other parameters are reasonably well-balanced for Ligand B, and the negative half-life could be addressed with structural modifications.
Output:
0
2025-04-17 18:30:18,887 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (364.408 Da and 351.393 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (49.85) is better than Ligand B (55.4). Both are acceptable for a cardiovascular target, but lower TPSA generally favors better absorption.
**3. logP:** Both ligands have good logP values (2.451 and 3.203, respectively), falling within the optimal 1-3 range. Ligand B is slightly higher, which *could* be a minor drawback, but not a major concern.
**4. H-Bond Donors:** Ligand A has 0 HBD, while Ligand B has 1. Both are within the acceptable limit of <=5.
**5. H-Bond Acceptors:** Both ligands have 3 HBA, which is well within the acceptable limit of <=10.
**6. QED:** Both ligands have good QED scores (0.697 and 0.801), indicating good drug-like properties. Ligand B is slightly better.
**7. DILI:** Ligand A (32.183) has a slightly higher DILI risk than Ligand B (25.979), but both are below the 40 threshold and are considered good.
**8. BBB:** Both ligands exhibit high BBB penetration (95.425 and 97.286). This is less critical for a cardiovascular target, but not detrimental.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual. It's difficult to interpret without more context, but it suggests potentially poor permeability. Ligand B (-4.656) is slightly worse than Ligand A (-4.11).
**10. Aqueous Solubility:** Both ligands have negative solubility values, which is also unusual and suggests poor solubility. Ligand B (-3.661) is slightly worse than Ligand A (-2.354).
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (0.593 and 0.622), which is good.
**12. Microsomal Clearance:** Both ligands have similar microsomal clearance values (42.788 and 42.481), indicating similar metabolic stability.
**13. In vitro Half-Life:** Ligand B (-1.722) has a slightly better (less negative) in vitro half-life than Ligand A (-20.574), suggesting better stability.
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (0.212 and 0.135), which is good.
**15. Binding Affinity:** Both ligands have very similar and strong binding affinities (-5.9 and -6.1 kcal/mol). The difference is negligible.
**GPCR-Specific Considerations:** For GPCRs, logP, TPSA, Pgp, and affinity are key. Both ligands perform well in these areas. The slightly lower TPSA and better solubility of Ligand A are attractive. However, the slightly better QED and half-life of Ligand B are also beneficial. The negative Caco-2 and solubility values are concerning for both.
**Overall Assessment:**
Despite the unusual negative values for Caco-2 and solubility, Ligand A has a slight edge due to its lower TPSA and better solubility. The differences are minor, but given the GPCR target class, optimizing for permeability (even with these unusual values) is important.
Output:
1
2025-04-17 18:30:18,887 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (340.339 and 353.463 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (87.74) is significantly better than Ligand A (116.08). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (0.683) is lower than Ligand A (1.33), but both are within the acceptable 1-3 range. Ligand A is slightly preferred here.
4. **HBD:** Ligand B (2) has fewer HBD than Ligand A (4). Fewer HBDs are generally preferred for better permeability. Ligand B is better.
5. **HBA:** Both ligands have the same number of HBA (4).
6. **QED:** Ligand B (0.705) has a slightly higher QED than Ligand A (0.536), indicating a more drug-like profile.
7. **DILI:** Ligand B (11.361) has a *much* lower DILI risk than Ligand A (95.192). This is a critical advantage for Ligand B.
8. **BBB:** Ligand B (60.644) has a higher BBB penetration than Ligand A (16.014). While not a primary concern for a cardiovascular target, it's still a positive attribute.
9. **Caco-2:** Both ligands have very poor Caco-2 permeability (-5.195 and -5.056). This is a significant drawback for both.
10. **Solubility:** Ligand B (-1.482) has better solubility than Ligand A (-5.034).
11. **hERG:** Both ligands have very low hERG inhibition liability (0.217 and 0.198). No significant difference.
12. **Cl_mic:** Both ligands have very similar and low microsomal clearance (-10.788 and -11.218), indicating good metabolic stability.
13. **t1/2:** Ligand A (25.929 hours) has a much longer in vitro half-life than Ligand B (-1.65 hours). This is a significant advantage for Ligand A.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.11 and 0.01). No significant difference.
15. **Binding Affinity:** Ligand B (-7.7 kcal/mol) has a significantly stronger binding affinity than Ligand A (-4.0 kcal/mol). This is a major advantage for Ligand B. A 3.7 kcal/mol difference is substantial and can often outweigh minor ADME concerns.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B excels in TPSA, has a reasonable logP, low Pgp, and *significantly* better affinity. The DILI risk for Ligand A is extremely concerning. While Ligand A has a better half-life, the superior binding affinity and significantly reduced toxicity risk of Ligand B are more important.
**Conclusion:**
Despite Ligand A's longer half-life, Ligand B is the more promising drug candidate due to its significantly better binding affinity, lower DILI risk, better TPSA, and improved solubility.
Output:
0
2025-04-17 18:30:18,887 - INFO - Batch 42 complete. Total preferences: 672
2025-04-17 18:30:18,887 - INFO - Processing batch 43/512...
2025-04-17 18:31:10,041 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (346.391 Da and 360.479 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (114.94) is better than Ligand B (62.55) as it is still within the acceptable range for oral absorption, while Ligand B is significantly lower, potentially indicating a lack of necessary interactions.
**3. logP:** Ligand B (3.373) is better than Ligand A (0.428). Ligand A's logP is quite low, potentially hindering membrane permeability. Ligand B is within the optimal 1-3 range.
**4. H-Bond Donors:** Ligand A (2) is slightly worse than Ligand B (1). Both are acceptable, but fewer HBDs generally improve permeability.
**5. H-Bond Acceptors:** Ligand A (7) is worse than Ligand B (4). Fewer HBAs are generally preferred for better permeability.
**6. QED:** Ligand B (0.909) is significantly better than Ligand A (0.716), indicating a more drug-like profile.
**7. DILI:** Ligand B (43.932) is better than Ligand A (54.556), indicating a lower risk of drug-induced liver injury.
**8. BBB:** Ligand A (72.16) is better than Ligand B (63.746), although both are not exceptionally high. For a cardiovascular target, BBB penetration is not a primary concern, but a slightly higher value is preferable.
**9. Caco-2 Permeability:** Ligand A (-5.371) is better than Ligand B (-5.102). Both are negative, indicating poor permeability.
**10. Aqueous Solubility:** Ligand A (-2.165) is better than Ligand B (-3.561). Both are poor, but A is slightly better.
**11. hERG Inhibition:** Ligand A (0.017) is significantly better than Ligand B (0.636), indicating a much lower risk of cardiotoxicity. This is *critical* for a cardiovascular target.
**12. Microsomal Clearance:** Ligand A (11.718) is better than Ligand B (45.296), suggesting better metabolic stability.
**13. In vitro Half-Life:** Ligand B (36.564) is better than Ligand A (16.949), indicating a longer half-life.
**14. P-gp Efflux:** Ligand A (0.011) is significantly better than Ligand B (0.434), indicating lower efflux and potentially better bioavailability.
**15. Binding Affinity:** Ligand B (-7.6) is *significantly* better than Ligand A (-6.0). This is a 1.6 kcal/mol difference, which is substantial and can outweigh many ADME drawbacks.
**Overall Assessment:**
While Ligand B has a better logP, QED, DILI, and half-life, Ligand A's superior hERG inhibition profile and P-gp efflux are crucial for a cardiovascular drug. The significant difference in binding affinity also favors Ligand B. Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), and the paramount importance of avoiding cardiotoxicity in a cardiovascular drug, the stronger binding affinity of Ligand B and its lower DILI risk outweigh the slightly worse hERG and BBB.
Output:
0
2025-04-17 18:31:10,042 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.475 and 344.503 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (65.78) is slightly higher than Ligand B (59.07). Both are acceptable for a non-CNS GPCR target like ADRB2, being below 140. Ligand B is preferable.
3. **logP:** Ligand A (1.98) is within the optimal 1-3 range. Ligand B (4.147) is a bit high, potentially leading to solubility issues and off-target interactions. Ligand A is preferable.
4. **HBD:** Ligand A (1) is good. Ligand B (2) is also acceptable, but slightly less desirable. Ligand A is preferable.
5. **HBA:** Ligand A (4) is good. Ligand B (5) is also acceptable, but slightly less desirable. Ligand A is preferable.
6. **QED:** Ligand A (0.818) is excellent, indicating high drug-likeness. Ligand B (0.659) is still reasonable, but lower. Ligand A is preferable.
7. **DILI:** Ligand A (15.859) has a much lower DILI risk than Ligand B (33.307). This is a significant advantage for Ligand A.
8. **BBB:** This is less critical for ADRB2 (a cardiovascular target), but Ligand B (82.009) has a higher BBB penetration than Ligand A (60.101).
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.569 and -4.822), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-1.514) has better solubility than Ligand B (-4.432). This is important, especially given Ligand B's higher logP. Ligand A is preferable.
11. **hERG:** Ligand A (0.659) has a slightly lower hERG inhibition liability than Ligand B (0.863). This is a slight advantage for Ligand A.
12. **Cl_mic:** Ligand B (93.748) has a significantly higher microsomal clearance than Ligand A (40.411), indicating poorer metabolic stability. Ligand A is preferable.
13. **t1/2:** Ligand B (38.142) has a longer in vitro half-life than Ligand A (11.443). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.277) has lower P-gp efflux liability than Ligand B (0.614). This is preferable. Ligand A is preferable.
15. **Binding Affinity:** Ligand B (-5.9 kcal/mol) has a slightly better binding affinity than Ligand A (-6.6 kcal/mol). While a difference of 0.7 kcal/mol is noticeable, it's not a huge advantage, and can be overcome by superior ADME properties.
**Overall Assessment:**
Ligand A demonstrates a significantly better overall profile, particularly regarding safety (DILI), metabolic stability (Cl_mic), solubility, and drug-likeness (QED). While Ligand B has a slightly better binding affinity and longer half-life, the ADME/Tox advantages of Ligand A are more crucial for developing a viable drug candidate. The negative Caco-2 values are concerning for both, but the other benefits of Ligand A outweigh this shared drawback.
Output:
1
2025-04-17 18:31:10,042 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [354.426, 105.48 , 1.501, 4. , 5. , 0.418, 52.152, 68.321, -5.165, -2.92 , 0.74 , 44.845, 0.745, 0.063, -6.6 ]
**Ligand B:** [364.837, 104.7 , 1.653, 3. , 5. , 0.724, 65.374, 58.511, -5.749, -2.814, 0.177, -6.109, 32.088, 0.046, -5.4 ]
Here's a breakdown, prioritizing GPCR properties (logP, Pgp, TPSA, Affinity, and BBB):
1. **MW:** Both are within the acceptable 200-500 Da range. Ligand A (354.426) is slightly lower, which is generally favorable.
2. **TPSA:** Both are around 105, slightly above the ideal <140 for oral absorption, but acceptable.
3. **logP:** Both are good (around 1.5-1.6), falling within the optimal 1-3 range.
4. **HBD/HBA:** Both have acceptable numbers of H-bond donors (4/3) and acceptors (5/5).
5. **QED:** Ligand B (0.724) has a better QED score than Ligand A (0.418), indicating a more drug-like profile.
6. **DILI:** Ligand A (52.152) has a significantly lower DILI risk than Ligand B (65.374). This is a major advantage.
7. **BBB:** Ligand A (68.321) shows better BBB penetration potential than Ligand B (58.511), which is important for a GPCR.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. This is a concern for both.
9. **Solubility:** Both have negative solubility values, which is also a concern.
10. **hERG:** Both have low hERG inhibition liability, which is good.
11. **Cl_mic:** Ligand B (-6.109) has a *much* lower (better) microsomal clearance than Ligand A (44.845), suggesting greater metabolic stability.
12. **t1/2:** Ligand B (32.088) has a significantly longer in vitro half-life than Ligand A (0.745).
13. **Pgp:** Ligand A (0.063) has lower P-gp efflux, which is better for bioavailability. Ligand B (0.046) is also low, but slightly higher.
14. **Affinity:** Ligand A (-6.6 kcal/mol) has a slightly better binding affinity than Ligand B (-5.4 kcal/mol). This is a 1.2 kcal/mol difference, which is substantial.
**Overall Assessment:**
Ligand A has a better binding affinity, lower DILI risk, and better BBB penetration. Ligand B has a better QED score, significantly better metabolic stability (lower Cl_mic), and a longer half-life. The negative Caco-2 and solubility values are concerning for both, but the affinity difference and DILI risk for Ligand A are compelling. Given the GPCR target, the balance of affinity, BBB, and lower toxicity (DILI) tips the scales in favor of Ligand A. The metabolic stability of Ligand B is attractive, but can be addressed through structural modifications.
Output:
1
2025-04-17 18:31:10,042 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (335.451 and 348.353 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (41.19) is significantly better than Ligand B (86.88). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand B's TPSA is quite high.
3. **logP:** Ligand A (3.866) is good, while Ligand B (1.931) is on the lower side of optimal. For a GPCR, a slightly higher logP is often preferred for membrane interactions.
4. **HBD:** Ligand A (0) is better than Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is better than Ligand B (3). Lower HBA also tends to improve permeability.
6. **QED:** Both ligands (0.797 and 0.745) have good QED scores, indicating drug-like properties.
7. **DILI:** Ligand A (17.449) has a much lower DILI risk than Ligand B (68.592). This is a crucial advantage.
8. **BBB:** Ligand A (96.316) has a higher BBB penetration than Ligand B (70.415). While not a primary concern for a cardiovascular target, it's a positive attribute.
9. **Caco-2:** Both ligands have similar, poor Caco-2 permeability (-4.788 and -4.919). This is a potential issue for both.
10. **Solubility:** Both ligands have similar, poor solubility (-3.036 and -3.176). This is a potential issue for both.
11. **hERG:** Ligand A (0.981) has a slightly higher hERG risk than Ligand B (0.298). This is a slight advantage for Ligand B.
12. **Cl_mic:** Ligand A (53.211) has a higher microsomal clearance than Ligand B (-7.702). This indicates Ligand B is more metabolically stable.
13. **t1/2:** Ligand A (22.826) has a shorter in vitro half-life than Ligand B (-11.706). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.717) has a higher Pgp efflux liability than Ligand B (0.042). This is a significant advantage for Ligand B.
15. **Binding Affinity:** Ligand A (-6.7 kcal/mol) has a slightly weaker binding affinity than Ligand B (-7.3 kcal/mol). This is a significant advantage for Ligand B.
**Overall Assessment:**
Ligand B demonstrates a superior profile overall, despite its higher TPSA. The significantly lower DILI risk, improved metabolic stability (lower Cl_mic, longer t1/2), lower Pgp efflux, and slightly better binding affinity outweigh the drawbacks of its higher TPSA and lower logP. The similar Caco-2 and solubility profiles are concerns for both, but can be addressed through formulation strategies. Ligand B's profile suggests a better chance of *in vivo* efficacy and safety.
Output:
0
2025-04-17 18:31:10,042 - INFO - Here's my reasoning and the final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, prioritizing logP, TPSA, Pgp, and binding affinity is crucial, alongside general drug-like properties.
* **Molecular Weight:** Both ligands (349.475 and 366.487 Da) fall within the ideal 200-500 Da range.
* **TPSA:** Ligand A (82.53) is better than Ligand B (100.28), being closer to the <140 threshold for good absorption.
* **logP:** Both ligands have good logP values (2.074 and 2.621), falling within the 1-3 range. Ligand B is slightly higher, which could be a minor concern.
* **H-Bond Donors/Acceptors:** Ligand A (HBD=2, HBA=4) is preferable to Ligand B (HBD=3, HBA=7) as it has fewer H-bonds overall, potentially improving permeability.
* **QED:** Ligand A (0.789) has a significantly better QED score than Ligand B (0.559), indicating a more drug-like profile.
* **DILI:** Ligand A (22.761) has a much lower DILI risk than Ligand B (60.915). This is a major advantage for Ligand A.
* **BBB:** Ligand A (51.958) is slightly better than Ligand B (46.724) but both are not particularly high, which is acceptable for a cardiovascular target.
* **Caco-2 Permeability:** Ligand A (-4.575) is better than Ligand B (-5.244) indicating better intestinal absorption.
* **Aqueous Solubility:** Ligand A (-1.623) is better than Ligand B (-2.328).
* **hERG:** Both ligands have similar hERG inhibition liability (0.51 and 0.692).
* **Microsomal Clearance:** Ligand A (34.184) has significantly lower microsomal clearance than Ligand B (60.968), suggesting better metabolic stability.
* **In vitro Half-Life:** Ligand B (24.009) has a longer half-life than Ligand A (8.282). This is a positive for Ligand B, but the difference isn't huge.
* **P-gp Efflux:** Both ligands have similar P-gp efflux liability (0.082 and 0.567).
* **Binding Affinity:** Ligand A (-7.5) has a slightly better binding affinity than Ligand B (-7.3). While the difference is small (0.2 kcal/mol), it's still a positive for Ligand A.
**Overall:**
Ligand A demonstrates a superior balance of properties. It has a better QED score, significantly lower DILI risk, better metabolic stability (lower Cl_mic), and slightly better binding affinity. While Ligand B has a longer half-life, the advantages of Ligand A across multiple critical parameters outweigh this single benefit.
**Output:**
1
2025-04-17 18:31:10,042 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A: [341.415, 99.81, 0.784, 2, 5, 0.747, 39.201, 51.26, -5.286, -2.249, 0.324, 17.154, -1.862, 0.031, -6.2]**
**Ligand B: [360.845, 78.09, 2.471, 2, 3, 0.869, 56.844, 60.372, -5.227, -3.749, 0.167, -1.368, -38.719, 0.09, -7.3]**
Here's a breakdown of the comparison, considering the provided guidelines and GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (341.415) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (99.81) is higher than Ligand B (78.09). Both are below the 140 threshold for oral absorption, but Ligand B is closer to the preferred <90 for CNS targets (though this isn't a CNS target, lower TPSA is still generally good).
3. **logP:** Ligand A (0.784) is a bit low, potentially hindering permeation. Ligand B (2.471) is within the optimal 1-3 range. This is a significant advantage for Ligand B.
4. **HBD/HBA:** Both have 2 HBD and reasonable HBA counts (5 and 3 respectively). No major concerns here.
5. **QED:** Both have good QED values (0.747 and 0.869), indicating drug-like properties. Ligand B is slightly better.
6. **DILI:** Ligand A (39.201) has a better DILI score than Ligand B (56.844), indicating lower liver injury risk.
7. **BBB:** Both have relatively low BBB penetration. This isn't a primary concern for a cardiovascular target, but higher is always better. Ligand B (60.372) is slightly better than Ligand A (51.26).
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. This is a significant concern for both.
9. **Solubility:** Both have negative solubility values, which is also unusual and indicates poor solubility. This is a significant concern for both.
10. **hERG:** Both have low hERG inhibition liability, which is good. Ligand B (0.167) is slightly better.
11. **Cl_mic:** Ligand B (-1.368) has a *much* lower (better) microsomal clearance than Ligand A (17.154), suggesting greater metabolic stability. This is a major advantage for Ligand B.
12. **t1/2:** Ligand B (-38.719) has a much longer half-life than Ligand A (-1.862), which is a significant benefit.
13. **Pgp:** Both have low P-gp efflux liability, which is good. Ligand A (0.031) is slightly better.
14. **Affinity:** Ligand B (-7.3) has a significantly stronger binding affinity than Ligand A (-6.2). This is a substantial advantage, potentially outweighing some ADME concerns.
**Overall Assessment:**
While Ligand A has a slightly better DILI and Pgp profile, Ligand B is superior overall. The key advantages of Ligand B are its optimal logP, significantly improved metabolic stability (Cl_mic and t1/2), and substantially stronger binding affinity. The negative Caco-2 and solubility values are concerning for both, but the potency advantage of Ligand B is likely to be more impactful. The slightly better TPSA of Ligand B is also a plus.
Therefore, I would choose Ligand B.
Output:
0
2025-04-17 18:31:10,042 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [366.443, 107.52 , 0.846, 1. , 6. , 0.781, 74.68 , 62.466, -4.852, -2.162, 0.285, 36.925, -32.206, 0.098, -3.9 ]
**Ligand B:** [369.447, 119.67 , -0.25 , 2. , 8. , 0.709, 63.823, 83.792, -5.045, -2.779, 0.211, 10.658, -13.565, 0.035, -6.5 ]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, Affinity, and BBB):
1. **MW:** Both are within the acceptable 200-500 Da range. A is 366.443, B is 369.447 - very similar.
2. **TPSA:** A (107.52) is better than B (119.67). We want <140 for oral absorption, both are okay, but A is preferable.
3. **logP:** A (0.846) is better than B (-0.25). B is quite low, potentially leading to poor membrane permeability. A is within the optimal 1-3 range.
4. **HBD:** A (1) is better than B (2). Lower is generally preferred.
5. **HBA:** A (6) is better than B (8). Lower is generally preferred.
6. **QED:** Both are good (A: 0.781, B: 0.709), exceeding the 0.5 threshold.
7. **DILI:** Both are acceptable, but B (63.823) is slightly better than A (74.68). Lower is better.
8. **BBB:** B (83.792) is significantly better than A (62.466). This is a key GPCR consideration, especially if CNS effects are relevant.
9. **Caco-2:** Both are negative, indicating poor permeability. A (-4.852) is slightly better (less negative) than B (-5.045).
10. **Solubility:** Both are negative, indicating poor solubility. B (-2.779) is slightly worse than A (-2.162).
11. **hERG:** Both are very low (A: 0.285, B: 0.211), indicating low cardiotoxicity risk.
12. **Cl_mic:** A (36.925) is better than B (10.658). Lower clearance is preferred for longer duration of action.
13. **t1/2:** A (-32.206) is much better than B (-13.565). A has a significantly longer predicted half-life.
14. **Pgp:** Both are very low (A: 0.098, B: 0.035), suggesting minimal P-glycoprotein efflux. B is slightly better.
15. **Affinity:** B (-6.5) is significantly better than A (-3.9). A 2.6 kcal/mol difference in binding affinity is substantial and can often outweigh other ADME concerns.
**Overall Assessment:**
The affinity difference is the most important factor here. While Ligand A has better TPSA, logP, Cl_mic, and t1/2, the 2.6 kcal/mol advantage of Ligand B in binding affinity is substantial. The slightly better BBB penetration of Ligand B is also a plus for a GPCR target. The lower DILI score for B is also a positive. The slightly worse logP and solubility of B are concerns, but can potentially be addressed through formulation or further optimization.
Therefore, I would prioritize Ligand B.
0
2025-04-17 18:31:10,042 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (363.5 and 370.9 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (53.5) is significantly better than Ligand B (80.6). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is pushing the upper limit for good oral absorption.
**3. logP:** Both ligands have good logP values (2.96 and 3.15), falling within the optimal 1-3 range. No clear advantage.
**4. H-Bond Donors:** Ligand A (0) is preferable to Ligand B (2). Fewer H-bond donors generally improve membrane permeability.
**5. H-Bond Acceptors:** Both have 4 H-bond acceptors, which is acceptable.
**6. QED:** Both ligands have similar QED scores (0.7 and 0.77), indicating good drug-likeness.
**7. DILI:** Ligand A (19.4) has a much lower DILI risk than Ligand B (60.6). This is a substantial advantage, as liver toxicity is a major concern.
**8. BBB:** Ligand A (82.1) shows better BBB penetration than Ligand B (46.2). While ADRB2 is primarily a cardiovascular target, some CNS effects can be relevant or undesirable, and better BBB penetration can indicate broader distribution.
**9. Caco-2 Permeability:** Both ligands have similar, poor Caco-2 permeability values (-4.93 and -4.91). This suggests potential absorption issues for both.
**10. Aqueous Solubility:** Ligand A (-2.31) is slightly better than Ligand B (-3.58), but both are poor. Solubility could be a formulation challenge.
**11. hERG Inhibition:** Ligand A (0.76) has a slightly higher hERG risk than Ligand B (0.17), but both are relatively low.
**12. Microsomal Clearance:** Ligand A (66.6) has a higher clearance than Ligand B (22.5), indicating lower metabolic stability. This is a disadvantage for Ligand A.
**13. In vitro Half-Life:** Ligand B (56.1) has a significantly longer half-life than Ligand A (-16.3). This is a significant advantage for Ligand B, potentially allowing for less frequent dosing.
**14. P-gp Efflux:** Ligand A (0.62) has a slightly lower P-gp efflux liability than Ligand B (0.13). Lower efflux is generally preferred.
**15. Binding Affinity:** Ligand B (-7.0) has a slightly better binding affinity than Ligand A (-6.2). While the difference is not huge, it's enough to consider.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity) and general drug-like properties, Ligand B is the more promising candidate. While Ligand A has better BBB penetration and lower DILI risk, Ligand B's superior binding affinity, significantly longer half-life, and lower DILI risk outweigh the drawbacks of its higher TPSA. The poor Caco-2 permeability is a concern for both, but can potentially be addressed through formulation strategies.
Output:
0
2025-04-17 18:31:10,042 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (342.483 and 356.396 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (49.41) is better than Ligand B (58.87). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (2.891 and 3.38), falling within the optimal 1-3 range. Ligand B is slightly higher, which *could* be a minor drawback, but not a dealbreaker.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 2 HBA, while Ligand B has 6. Ligand A is preferable here. Higher HBA can sometimes hinder permeability.
6. **QED:** Ligand B (0.786) has a slightly better QED score than Ligand A (0.596), suggesting a more drug-like profile.
7. **DILI:** Ligand A (16.789%) has a much lower DILI risk than Ligand B (43.66%). This is a significant advantage for Ligand A.
8. **BBB:** Ligand B (74.719%) has a higher BBB penetration than Ligand A (65.801%). While ADRB2 is cardiovascular, some CNS effects are possible with beta-blockers, so this is a slight positive for Ligand B.
9. **Caco-2:** Ligand A (-4.776) and Ligand B (-5.018) are both negative, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Both ligands have very poor solubility (-3.496 and -3.529). This is a major concern for both.
11. **hERG:** Ligand A (0.254) has a much lower hERG risk than Ligand B (0.728). This is a crucial advantage for Ligand A, as hERG inhibition can lead to cardiotoxicity.
12. **Cl_mic:** Ligand B (36.627) has a lower microsomal clearance than Ligand A (40.554), indicating better metabolic stability.
13. **t1/2:** Ligand B (23.813) has a significantly longer in vitro half-life than Ligand A (-15.106). This is a substantial advantage for Ligand B.
14. **Pgp:** Ligand A (0.131) has lower P-gp efflux than Ligand B (0.16).
15. **Binding Affinity:** Ligand B (-7.3 kcal/mol) has a stronger binding affinity than Ligand A (-6.9 kcal/mol). This is a 0.4 kcal/mol difference, which is significant.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B has a slightly better logP, better affinity, and better half-life. However, Ligand A has significantly better DILI and hERG profiles, and a lower TPSA and Pgp efflux. The poor solubility is a concern for both. Given the cardiovascular target, minimizing cardiotoxicity (hERG) and liver toxicity (DILI) are paramount. The affinity difference, while present, is not large enough to overcome the safety advantages of Ligand A.
**Conclusion:**
Considering the balance of properties, particularly the significantly lower DILI and hERG risk, Ligand A is the more promising drug candidate.
Output:
1
2025-04-17 18:31:10,042 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (352.391 and 354.47 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (113.02) is higher than Ligand B (76.02). For a cardiovascular GPCR, TPSA is moderately important. Ligand B's lower TPSA is preferable, suggesting better potential for membrane permeability.
**3. logP:** Both ligands have acceptable logP values (1.654 and 2.538, respectively), falling within the 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability, but not dramatically so.
**4. H-Bond Donors:** Ligand A has 3 HBDs, and Ligand B has 2. Both are within the acceptable limit of <=5.
**5. H-Bond Acceptors:** Ligand A has 6 HBAs, and Ligand B has 4. Both are within the acceptable limit of <=10.
**6. QED:** Both ligands have similar QED values (0.759 and 0.715), indicating good drug-like properties.
**7. DILI Risk:** Ligand A (47.732) has a slightly higher DILI risk than Ligand B (41.838), but both are below the concerning threshold of 60.
**8. BBB Penetration:** Ligand B (65.529) shows significantly better BBB penetration than Ligand A (52.074). While ADRB2 is a cardiovascular target, some CNS effects are possible with beta-adrenergic agonists, and better BBB penetration could contribute to off-target effects (or potentially desired effects depending on the specific therapeutic goal). For a cardiovascular target, this isn't a primary driver, but it's a point in favor of B.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.408 and -4.968). This is unusual and suggests poor permeability. However, the scale is not defined, so it's difficult to interpret.
**10. Aqueous Solubility:** Both ligands have negative solubility values (-2.375 and -3.085). This is also unusual and suggests poor aqueous solubility.
**11. hERG Inhibition:** Both ligands show low hERG inhibition risk (0.333 and 0.273), which is excellent.
**12. Microsomal Clearance:** Ligand A (15.56) has significantly lower microsomal clearance than Ligand B (47.404), indicating better metabolic stability. This is a significant advantage for Ligand A.
**13. In Vitro Half-Life:** Ligand A (-9.171) has a much longer in vitro half-life than Ligand B (23.742). This is a substantial advantage for Ligand A, potentially allowing for less frequent dosing.
**14. P-gp Efflux:** Both ligands show very low P-gp efflux liability (0.031 and 0.081).
**15. Binding Affinity:** Ligand B (-7.2) has a slightly stronger binding affinity than Ligand A (-6.7). This difference of 0.5 kcal/mol is meaningful, and could outweigh some of the ADME drawbacks of Ligand B.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), and the overall balance of properties, **Ligand B is the more promising candidate**. The stronger binding affinity (-7.2 kcal/mol vs -6.7 kcal/mol) is a significant advantage, and the lower TPSA is also favorable. While Ligand A has better metabolic stability and half-life, the affinity difference is likely to be more impactful for a GPCR target. The slightly better BBB penetration of Ligand B is not a major concern for a cardiovascular target, but doesn't detract from its profile.
Output:
0
2025-04-17 18:31:10,043 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (352.391 Da) is slightly higher than Ligand B (340.343 Da), but both are acceptable.
2. **TPSA:** Ligand A (94.92) is better than Ligand B (125.8). For a GPCR, keeping TPSA low is beneficial for permeability, and Ligand A is comfortably under the 140 threshold. Ligand B is approaching the upper limit.
3. **logP:** Ligand B (1.212) is better than Ligand A (0.284). Both are within the 1-3 range, but Ligand A is quite low, which could hinder membrane permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (7) is preferable to Ligand B (6). Lower HBA also generally improves permeability.
6. **QED:** Ligand B (0.619) is better than Ligand A (0.41). A higher QED suggests a more drug-like profile.
7. **DILI:** Ligand A (65.103) is significantly better than Ligand B (84.917). Lower DILI risk is crucial. Ligand B is approaching a concerning level.
8. **BBB:** Ligand A (55.874) is better than Ligand B (46.568). While ADRB2 isn't exclusively a CNS target, some CNS penetration could be beneficial or at least avoid off-target effects, and a higher BBB percentile is preferable.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.044 and -5.801). These are unusual and suggest poor permeability. However, these values are on a log scale, and the absolute difference is relatively small.
10. **Solubility:** Ligand A (-1.183) is better than Ligand B (-3.86). Higher solubility is generally preferred.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.167 and 0.453). This is excellent.
12. **Cl_mic:** Ligand A (-2.097) is significantly better than Ligand B (25.107). Lower clearance indicates better metabolic stability.
13. **t1/2:** Ligand A (-25.044) is better than Ligand B (15.921). A longer half-life is generally desirable. Note that negative values here likely indicate a very rapid clearance or a different scale.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.022 and 0.028).
15. **Binding Affinity:** Ligand B (-7.1) is slightly better than Ligand A (-7.5). While both are excellent, the difference is small.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand B has a better logP, but Ligand A excels in TPSA, DILI, Cl_mic, and t1/2. The slight affinity advantage of Ligand B is outweighed by the superior ADME properties of Ligand A, especially the significantly lower DILI and better metabolic stability.
**Conclusion:**
Ligand A presents a more favorable balance of properties, particularly regarding safety (DILI) and metabolic stability, which are critical for drug development. While Ligand B has a slightly better logP and affinity, the other advantages of Ligand A are more impactful.
Output:
1
2025-04-17 18:31:10,043 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (a cardiovascular GPCR) drug candidates.
**Ligand A:** [344.375, 132.89 , -0.265, 4. , 6. , 0.547, 69.872, 28.073, -5.655, -2.357, 0.112, -13.214, 8.95 , 0.008, -7.5 ]
**Ligand B:** [352.475, 78.87 , 1.483, 2. , 4. , 0.68 , 11.322, 46.491, -4.813, -1.443, 0.221, 16.148, 12.008, 0.048, -5.4 ]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, Affinity) and general drug-like properties:
1. **MW:** Both are within the ideal 200-500 Da range. Ligand A (344.375) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (132.89) is better than Ligand B (78.87). Both are below 140, but Ligand B is significantly lower, which could be beneficial for permeability.
3. **logP:** Ligand B (1.483) is better. It falls nicely within the 1-3 range. Ligand A (-0.265) is too low, potentially hindering membrane permeability and bioavailability.
4. **HBD:** Ligand A (4) is slightly higher than Ligand B (2), but both are acceptable (<=5).
5. **HBA:** Both ligands have 4 HBA, which is good.
6. **QED:** Both ligands have good QED scores (A: 0.547, B: 0.68), suggesting good overall drug-likeness. Ligand B is slightly better.
7. **DILI:** Ligand B (11.322) is *much* better than Ligand A (69.872). This is a significant advantage for Ligand B.
8. **BBB:** Ligand B (46.491) is better than Ligand A (28.073). While ADRB2 isn't a CNS target, some off-target CNS effects are always a consideration, and higher BBB is generally preferable.
9. **Caco-2:** Ligand A (-5.655) is worse than Ligand B (-4.813). Both are negative, indicating poor permeability, but B is slightly better.
10. **Solubility:** Ligand A (-2.357) is worse than Ligand B (-1.443). Both are poor, but B is better.
11. **hERG:** Both ligands have low hERG risk (A: 0.112, B: 0.221).
12. **Cl_mic:** Ligand A (-13.214) is *much* better than Ligand B (16.148). Lower clearance indicates better metabolic stability.
13. **t1/2:** Ligand B (12.008) is better than Ligand A (8.95).
14. **Pgp:** Ligand A (0.008) is much better than Ligand B (0.048). Lower P-gp efflux is preferred.
15. **Affinity:** Ligand A (-7.5) is better than Ligand B (-5.4). This is a 2.1 kcal/mol difference, which is substantial and can often outweigh other drawbacks.
**Overall Assessment:**
Ligand A has a significantly better binding affinity and Pgp efflux profile, and better metabolic stability. However, it suffers from a very low logP and poor solubility, and a high DILI risk. Ligand B has a better logP, lower DILI risk, better BBB penetration, and a longer half-life. The affinity difference is significant, but the combination of better ADME properties and safety profile of Ligand B is compelling. The low logP of Ligand A is a major concern for oral bioavailability.
Considering the balance, and prioritizing a reasonable ADME profile alongside potency, I believe **Ligand B** is the more viable drug candidate.
0
2025-04-17 18:31:10,043 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
The ADRB2 receptor is a GPCR, so the priorities are logP, Pgp, TPSA, affinity, and BBB. Let's break down the comparison:
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (374.849) is slightly higher than Ligand B (352.479), but this isn't a major concern.
2. **TPSA:** Ligand A (51.54) is significantly better than Ligand B (104.53). A TPSA under 140 is good for oral absorption, but lower is generally preferred for GPCRs, and Ligand A is much closer to the ideal range for CNS penetration if needed.
3. **logP:** Ligand A (3.531) is optimal, while Ligand B (1.246) is on the lower side. Lower logP can hinder membrane permeability.
4. **H-Bond Donors/Acceptors:** Ligand A (0 HBD, 5 HBA) is preferable to Ligand B (3 HBD, 3 HBA). Fewer hydrogen bond donors generally improve permeability.
5. **QED:** Both ligands have similar QED values (0.689 vs. 0.627), indicating reasonable drug-likeness.
6. **DILI:** Ligand B (26.173) has a much lower DILI risk than Ligand A (84.102). This is a significant advantage for Ligand B.
7. **BBB:** Ligand A (73.866) shows better BBB penetration potential than Ligand B (67.817), although both are reasonably good.
8. **Caco-2 Permeability:** Ligand A (-4.398) is better than Ligand B (-5.112), indicating better intestinal absorption.
9. **Aqueous Solubility:** Ligand B (-2.226) is better than Ligand A (-5.085).
10. **hERG:** Ligand A (0.435) has a lower hERG risk than Ligand B (0.191).
11. **Microsomal Clearance:** Ligand B (17.956) has significantly lower microsomal clearance than Ligand A (67.927), suggesting better metabolic stability.
12. **In vitro Half-Life:** Ligand A (28.887) has a longer half-life than Ligand B (0.127).
13. **P-gp Efflux:** Ligand A (0.755) has higher P-gp efflux than Ligand B (0.015). Lower P-gp efflux is desirable.
14. **Binding Affinity:** Ligand A (-6.1 kcal/mol) has slightly better binding affinity than Ligand B (-5.9 kcal/mol), but the difference is small.
**Overall Assessment:**
Ligand A excels in binding affinity, Caco-2 permeability, BBB penetration, and in vitro half-life. However, Ligand B demonstrates a much better safety profile (lower DILI) and metabolic stability (lower Cl_mic), alongside better solubility and lower P-gp efflux. Considering the GPCR-specific priorities, the lower TPSA and logP of Ligand A are attractive, but the significant improvements in safety and metabolic stability offered by Ligand B outweigh these benefits. The small difference in binding affinity is not enough to overcome the ADME advantages of Ligand B.
**Output:**
0
2025-04-17 18:31:10,043 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, the key priorities are logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB.
Let's compare the ligands property by property:
1. **MW:** Both ligands (346.391 and 343.431 Da) are within the ideal 200-500 Da range.
2. **TPSA:** Ligand B (61.68) is significantly better than Ligand A (113.93). Lower TPSA is preferred for GPCRs, aiding in membrane permeability.
3. **logP:** Both ligands have acceptable logP values (0.843 and 0.729), falling within the 1-3 range. Ligand B is slightly better.
4. **HBD/HBA:** Ligand A has 3 HBD and 6 HBA, while Ligand B has 0 HBD and 5 HBA. Both are acceptable, but Ligand B's lower HBD count is generally favorable for permeability.
5. **QED:** Both ligands have good QED scores (0.643 and 0.74), indicating good drug-likeness.
6. **DILI:** Ligand B (34.432) has a much lower DILI risk than Ligand A (67.158). This is a significant advantage for Ligand B.
7. **BBB:** Ligand B (75.378) has a better BBB penetration score than Ligand A (55.603). While not a primary concern for a cardiovascular target, it's a bonus.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale isn't specified, so it's hard to interpret.
9. **Solubility:** Ligand B (-1.762) has better solubility than Ligand A (-3.273).
10. **hERG:** Ligand A (0.085) has a slightly better hERG profile than Ligand B (0.274), but both are low risk.
11. **Cl_mic:** Ligand A (-3.057) has a significantly better (lower) microsomal clearance than Ligand B (47.883), indicating better metabolic stability.
12. **t1/2:** Ligand A (4.139) has a slightly better in vitro half-life than Ligand B (-4.475).
13. **Pgp:** Ligand A (0.073) has a lower Pgp efflux liability than Ligand B (0.026), which is favorable.
14. **Binding Affinity:** Ligand A (-7.3 kcal/mol) has a slightly better binding affinity than Ligand B (-6.1 kcal/mol). This is a 1.2 kcal/mol difference, which is substantial.
**Overall Assessment:**
Ligand A has a better binding affinity and metabolic stability, but Ligand B excels in TPSA, DILI risk, BBB penetration, solubility, and Pgp efflux. The lower TPSA and DILI risk of Ligand B are particularly important for a GPCR drug candidate. The binding affinity difference, while noticeable, can potentially be optimized in later stages of drug development. The improved ADME properties of Ligand B outweigh the slightly weaker binding.
**Output:**
0
2025-04-17 18:31:10,043 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [352.435, 107.29 , 0.793, 3. , 4. , 0.728, 38.62 , 27.646, -4.861, -1.542, 0.278, -4.084, -22.648, 0.016, -6.9 ]
**Ligand B:** [352.435, 100.71 , -0.022, 2. , 7. , 0.715, 29.314, 30.748, -4.902, -0.37 , 0.071, -13.315, 5.576, 0.038, -7.1 ]
**Step-by-step comparison:**
1. **MW:** Both ligands are around 352 Da, falling within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (107.29) is slightly higher than Ligand B (100.71). Both are acceptable for a non-CNS GPCR target like ADRB2, but lower is generally preferred.
3. **logP:** Ligand A (0.793) is slightly better than Ligand B (-0.022). Both are within the optimal 1-3 range, but Ligand B is close to the lower limit, which could potentially impact permeability.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (2), but both are within the acceptable limit of 5.
5. **HBA:** Ligand A (4) is lower than Ligand B (7). Ligand B is approaching the upper limit of 10, which could impact permeability.
6. **QED:** Both ligands have similar QED values (0.728 and 0.715), indicating good drug-like properties.
7. **DILI:** Ligand A (38.62) has a slightly higher DILI risk than Ligand B (29.314). Both are below the 40% threshold and considered good.
8. **BBB:** Both ligands have low BBB penetration (27.646 and 30.748). This is not a major concern for ADRB2, which is not a CNS target.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, these values are on a scale where negative values are possible.
10. **Solubility:** Ligand A (-1.542) has slightly worse solubility than Ligand B (-0.37). Both are poor.
11. **hERG:** Ligand A (0.278) has a lower hERG risk than Ligand B (0.071). Lower is better.
12. **Cl_mic:** Ligand A (-4.084) has a lower (better) microsomal clearance than Ligand B (-13.315), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-22.648) has a longer in vitro half-life than Ligand B (5.576), which is desirable.
14. **Pgp:** Ligand A (0.016) has lower P-gp efflux than Ligand B (0.038), which is preferable.
15. **Affinity:** Ligand B (-7.1) has a slightly better binding affinity than Ligand A (-6.9). While the difference is small, it's a factor.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has a slightly better logP and Pgp profile, while Ligand B has a slightly better affinity. However, the differences in affinity are small. Ligand A's better metabolic stability (Cl_mic and t1/2) and lower hERG risk are also important advantages. The slightly lower TPSA of Ligand B is offset by the higher HBA count.
**Conclusion:**
Considering the balance of properties, especially the improved metabolic stability, lower hERG risk, and better Pgp profile of Ligand A, I believe it is the more promising drug candidate despite the slightly weaker binding affinity. The small affinity difference can potentially be optimized in subsequent iterations.
**Output:**
1
2025-04-17 18:31:10,043 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
The target is ADRB2, a GPCR. Therefore, I will prioritize logP, Pgp, TPSA, BBB, and binding affinity.
* **Molecular Weight:** Both ligands are within the acceptable range (200-500 Da). Ligand B (348.531 Da) is slightly lower, which is generally favorable for permeability.
* **TPSA:** Ligand B (41.57) is significantly better than Ligand A (55.84). Lower TPSA generally improves oral absorption and CNS penetration.
* **logP:** Both ligands have good logP values (Ligand A: 3.69, Ligand B: 2.92) within the optimal range of 1-3. Ligand B is slightly better.
* **H-Bond Donors/Acceptors:** Ligand A (0 HBD, 4 HBA) is slightly better in terms of H-bonding potential. Ligand B has 1 HBD and 3 HBA.
* **QED:** Both ligands have good QED scores (Ligand A: 0.75, Ligand B: 0.802), indicating good drug-like properties. Ligand B is slightly better.
* **DILI:** Ligand A has a concerning DILI risk (60.45%), placing it in the higher risk category. Ligand B has a very low DILI risk (19.426%), which is a significant advantage.
* **BBB:** Ligand B (85.033%) has a much higher predicted BBB penetration than Ligand A (69.407%). While ADRB2 isn't exclusively a CNS target, improved BBB penetration can still be beneficial for distribution and reducing off-target effects.
* **Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests potential issues with permeability prediction. However, the values are similar (-4.115 for A, -4.806 for B).
* **Aqueous Solubility:** Both ligands have negative solubility values, again suggesting prediction issues. The values are similar (-4.084 for A, -4.107 for B).
* **hERG Inhibition:** Both ligands have low hERG inhibition risk (0.278 for A, 0.746 for B).
* **Microsomal Clearance:** Ligand A (77.754) has higher microsomal clearance than Ligand B (61.101), suggesting lower metabolic stability.
* **In vitro Half-Life:** Ligand B (19.858 hours) has a significantly longer half-life than Ligand A (-5.161 hours). This is a major advantage.
* **P-gp Efflux:** Both ligands have low P-gp efflux liability (0.151 for A, 0.316 for B).
* **Binding Affinity:** Both ligands have very similar and excellent binding affinities (-6.3 kcal/mol for A, -6.2 kcal/mol for B). The difference is negligible.
**Overall Assessment:**
Ligand B is clearly the superior candidate. It has a significantly lower DILI risk, better BBB penetration, a longer half-life, and slightly better TPSA and logP values. While Ligand A has slightly better H-bonding characteristics, the ADME advantages of Ligand B, particularly the lower DILI and longer half-life, outweigh this minor difference. The similar binding affinities make the ADME profile the deciding factor.
**Output:**
0
2025-04-17 18:31:10,043 - INFO - Batch 43 complete. Total preferences: 688
2025-04-17 18:31:10,043 - INFO - Processing batch 44/512...
2025-04-17 18:31:59,775 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (373.475 & 367.515 Da) fall comfortably within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (96.02) is better than Ligand B (99.06), being closer to the <140 threshold for good absorption. While both are acceptable, lower is generally preferred.
3. **logP:** Ligand A (-0.588) is slightly lower than the optimal 1-3 range, potentially hindering permeability. Ligand B (1.644) is much better positioned within the optimal range. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (4). Lower HBA generally improves permeability.
6. **QED:** Both ligands have similar QED values (0.671 and 0.647), indicating good drug-likeness.
7. **DILI:** Both ligands have very similar, and acceptable, DILI risk (35.014 and 35.634 percentile).
8. **BBB:** Ligand A (65.839) has a better BBB penetration percentile than Ligand B (57.425). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be beneficial for broader distribution and potentially off-target effects.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.978 and -5.077), which is unusual and suggests very poor permeability. This is a major concern for both.
10. **Solubility:** Ligand A (-1.608) has better solubility than Ligand B (-3.322). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.119) has a lower hERG risk than Ligand B (0.6), which is a significant safety advantage.
12. **Cl_mic:** Ligand A (12.908) has a significantly lower microsomal clearance than Ligand B (40.691), indicating better metabolic stability. This is a crucial advantage.
13. **t1/2:** Ligand A (-12.525) has a negative in vitro half-life, which is highly unusual and indicates very rapid metabolism. Ligand B (-19.58) is also negative, but less so. Both are concerning.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.025 and 0.071).
15. **Binding Affinity:** Both ligands have similar binding affinities (-6.1 and -5.7 kcal/mol). The difference is not substantial enough to outweigh other factors.
**GPCR-Specific Priorities & Overall Assessment:**
For a GPCR like ADRB2, logP, TPSA, and affinity are key. Ligand B has a much better logP value. However, Ligand A has better TPSA, solubility, lower hERG risk, and significantly better metabolic stability (lower Cl_mic). The negative Caco-2 values are concerning for both, but the other advantages of Ligand A, particularly the lower hERG and Cl_mic, make it the more promising candidate. The slightly better BBB penetration of Ligand A is a minor bonus. The unusual half-life values are a red flag for both, but the metabolic stability suggests Ligand A might be improved with structural modifications more readily.
Output:
1
2025-04-17 18:31:59,776 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (369.491 Da) is slightly higher than Ligand B (348.403 Da), but both are acceptable.
**2. TPSA:** Ligand A (89.35) is excellent, well below the 140 threshold for oral absorption and favorable for a GPCR. Ligand B (128.25) is still reasonable but less optimal, approaching the upper limit for good absorption.
**3. logP:** Ligand A (0.552) is a bit low, potentially hindering membrane permeability. Ligand B (0.772) is also on the lower side, but slightly better. Both could benefit from increased lipophilicity, but are not drastically outside the acceptable range.
**4. H-Bond Donors:** Ligand A (1) is ideal. Ligand B (3) is acceptable, but higher HBDs can sometimes reduce permeability.
**5. H-Bond Acceptors:** Ligand A (7) is good. Ligand B (6) is also good.
**6. QED:** Both ligands have similar QED values (A: 0.72, B: 0.605), indicating good drug-likeness.
**7. DILI Risk:** Ligand A (60.566) is higher than Ligand B (47.732), indicating a slightly increased risk of drug-induced liver injury. This is a concern.
**8. BBB Penetration:** Both are relatively low, but Ligand A (53.044) is better than Ligand B (35.712). While ADRB2 is a cardiovascular target, some CNS off-target effects are possible with GPCR ligands, so moderate BBB penetration isn't necessarily a negative.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-5.258 and -5.175), which is unusual and suggests poor permeability *in vitro*. This is a significant concern for both.
**10. Aqueous Solubility:** Both ligands have negative solubility values (-2.068 and -2.519), indicating very poor aqueous solubility. This is a major formulation challenge.
**11. hERG Inhibition:** Both ligands show very low hERG inhibition risk (0.135 and 0.168), which is excellent.
**12. Microsomal Clearance:** Ligand A (34.257) has higher clearance than Ligand B (19.532), indicating lower metabolic stability. This is a negative for Ligand A.
**13. In vitro Half-Life:** Ligand B (-26.756) has a significantly *longer* half-life than Ligand A (14.933), which is a major advantage.
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (0.052 and 0.027), which is favorable.
**15. Binding Affinity:** Ligand B (-7.6 kcal/mol) has a substantially stronger binding affinity than Ligand A (-5.4 kcal/mol). This 2.2 kcal/mol difference is significant and can outweigh many ADME drawbacks.
**Overall Assessment:**
Despite the poor permeability and solubility of both compounds, Ligand B is the more promising candidate. The significantly stronger binding affinity (-7.6 vs -5.4 kcal/mol) is a major advantage for a GPCR target. It also has a lower DILI risk, better metabolic stability (lower Cl_mic), and a much longer in vitro half-life. While both have poor Caco-2 and solubility, the potency and PK advantages of Ligand B are more likely to be addressable through formulation strategies.
Output:
0
2025-04-17 18:31:59,776 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (351.491 and 347.463 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (69.72) is significantly better than Ligand B (90.12). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold. Ligand B is approaching it.
3. **logP:** Both ligands have good logP values (1.787 and 1.105), falling within the optimal 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (4). Similar to HBD, fewer HBAs are generally better.
6. **QED:** Both ligands have good QED scores (0.678 and 0.719), indicating good drug-like properties. No significant difference.
7. **DILI:** Both ligands have low DILI risk (11.128 and 10.585), both well below the 40 threshold. No significant difference.
8. **BBB:** Ligand A (81.892) has a substantially higher BBB penetration score than Ligand B (60.644). While not a primary concern for a cardiovascular target, higher BBB is rarely detrimental and can indicate better overall permeability.
9. **Caco-2:** Ligand A (-4.886) is better than Ligand B (-5.66). Higher Caco-2 permeability is better.
10. **Solubility:** Ligand A (-2.118) is better than Ligand B (-1.489). Higher solubility is better.
11. **hERG:** Both ligands have very low hERG risk (0.495 and 0.238). No significant difference.
12. **Cl_mic:** Ligand B (-21.345) has significantly lower microsomal clearance than Ligand A (26.756). Lower clearance indicates better metabolic stability, a crucial factor for drug duration.
13. **t1/2:** Ligand B (-22.519) has a much longer in vitro half-life than Ligand A (-2.827). This is a major advantage for Ligand B.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.079 and 0.011). No significant difference.
15. **Binding Affinity:** Both ligands have identical binding affinities (-6.8 kcal/mol).
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A excels in logP, TPSA, and Pgp, while Ligand B is better in metabolic stability (Cl_mic) and half-life. The affinity is the same. The significant difference in half-life and clearance for Ligand B is a compelling advantage. While Ligand A has slightly better absorption characteristics, the improved PK profile of Ligand B outweighs these benefits.
**Conclusion:**
Ligand B's superior metabolic stability and longer half-life make it the more promising drug candidate, despite Ligand A's slightly better TPSA and solubility.
Output:
0
2025-04-17 18:31:59,776 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (378.351 and 347.415 Da) are within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (90.34) is better than Ligand B (111.55). For a GPCR, keeping TPSA low is beneficial for permeability.
3. **logP:** Both ligands have good logP values (1.932 and 1.443), falling within the 1-3 range. Ligand B is slightly lower, which could slightly hinder permeability, but both are acceptable.
4. **HBD:** Ligand A (1) is preferable to Ligand B (4). Lower HBD generally improves permeability.
5. **HBA:** Both ligands have 5 HBA, which is acceptable.
6. **QED:** Ligand A (0.824) has a significantly better QED score than Ligand B (0.532), indicating a more drug-like profile.
7. **DILI:** Ligand A (55.448) has a higher DILI risk than Ligand B (21.791). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (79.217) has a much better BBB penetration score than Ligand B (23.808). While ADRB2 isn't *necessarily* a CNS target, some peripheral ADRB2 activity can be modulated by CNS effects, and better BBB penetration is generally a plus.
9. **Caco-2:** Ligand A (-4.635) is better than Ligand B (-5.372). Higher (less negative) Caco-2 permeability suggests better intestinal absorption.
10. **Solubility:** Ligand A (-2.884) is better than Ligand B (-2.277). Better aqueous solubility is always desirable.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.279 and 0.065). Ligand B is slightly better.
12. **Cl_mic:** Ligand A (3.701) has a significantly lower microsomal clearance than Ligand B (9.326), indicating better metabolic stability.
13. **t1/2:** Ligand A (39.851) has a much longer in vitro half-life than Ligand B (-10.92). This is a major advantage for Ligand A.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.135 and 0.024). Ligand B is slightly better.
15. **Affinity:** Both ligands have excellent binding affinity (-5.8 and -6.3 kcal/mol). Ligand B is slightly better, but the difference is small.
**Overall Assessment:**
Ligand A has a superior drug-like profile (QED), better permeability (TPSA, Caco-2), better solubility, significantly better metabolic stability (Cl_mic, t1/2), and good BBB penetration. While Ligand B has a lower DILI risk, the other advantages of Ligand A outweigh this concern, especially given the relatively moderate DILI risk of Ligand A (55.448). The slight affinity advantage of Ligand B is not enough to overcome the other benefits of Ligand A.
Output:
1
2025-04-17 18:31:59,776 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.455 and 357.455 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (64.63) is significantly better than Ligand B (105.22). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is pushing the upper limit for good oral absorption.
3. **logP:** Ligand A (3.454) is within the optimal range (1-3). Ligand B (-2.309) is quite low, potentially causing permeability issues. This is a significant negative for Ligand B.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is better than Ligand B (6). Similar to HBD, lower HBA is generally preferred.
6. **QED:** Ligand A (0.801) has a much better QED score than Ligand B (0.401), indicating a more drug-like profile.
7. **DILI:** Ligand B (5.777) has a significantly lower DILI risk than Ligand A (53.974). This is a strong point in favor of Ligand B, as liver toxicity is a major concern.
8. **BBB:** Ligand A (64.831) has a better BBB penetration score than Ligand B (3.218). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant for off-target effects and overall safety assessment.
9. **Caco-2:** Ligand A (-4.457) is better than Ligand B (-5.86). Higher (less negative) values indicate better intestinal absorption.
10. **Solubility:** Ligand A (-5.264) is better than Ligand B (0.601). Solubility is important for formulation and bioavailability.
11. **hERG:** Ligand A (0.735) has a better hERG profile than Ligand B (0.037). Lower hERG inhibition is crucial to avoid cardiotoxicity, especially for a cardiovascular target like ADRB2.
12. **Cl_mic:** Ligand B (-28.17) has significantly lower microsomal clearance than Ligand A (108.65), indicating better metabolic stability. This is a strong advantage for Ligand B.
13. **t1/2:** Ligand A (9.2) has a better in vitro half-life than Ligand B (-11.598). Longer half-life is generally desirable.
14. **Pgp:** Ligand A (0.647) has better Pgp efflux liability than Ligand B (0.001). Lower Pgp efflux improves bioavailability.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.9 and -6.7 kcal/mol). The difference is not substantial enough to override other significant ADME differences.
**Overall Assessment:**
Ligand A has a superior drug-like profile (QED, solubility, Caco-2, hERG, Pgp, t1/2) and better BBB penetration. However, Ligand B has a much lower DILI risk and significantly better metabolic stability (Cl_mic). The low logP of Ligand B is a major concern, potentially hindering its ability to cross cell membranes and reach the target. Considering the ADRB2 target and the importance of balancing permeability, metabolic stability, and safety, Ligand A appears to be the more promising candidate. The slightly higher DILI risk of Ligand A can be investigated further, but the permeability issues with Ligand B are more difficult to overcome.
Output:
1
2025-04-17 18:31:59,777 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (344.415 Da) is better, falling comfortably within the 200-500 Da range. Ligand B (378.845 Da) is still acceptable, but closer to the upper limit.
2. **TPSA:** Ligand A (73.91) is significantly better than Ligand B (110.17). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally correlates with better absorption. Ligand B's TPSA is bordering on concerning for oral bioavailability.
3. **logP:** Both ligands have acceptable logP values (A: 1.126, B: 2.63), falling within the 1-3 range. Ligand B is slightly better, being closer to the optimal range.
4. **HBD:** Both ligands have 2 HBD, which is good.
5. **HBA:** Ligand A (5) is better than Ligand B (8). Lower HBA is generally preferred for permeability.
6. **QED:** Ligand A (0.86) is superior to Ligand B (0.72), indicating a more drug-like profile.
7. **DILI:** Ligand A (41.024) has a much lower DILI risk than Ligand B (93.68). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (89.027) has better BBB penetration than Ligand B (68.864). While not crucial for a cardiovascular target, it's a bonus.
9. **Caco-2:** Both are negative (-5.057 and -5.018), indicating poor permeability. This is a concern for both, but the values are very similar.
10. **Solubility:** Ligand A (-2.176) is better than Ligand B (-4.497). Better solubility is always desirable.
11. **hERG:** Both ligands have low hERG inhibition risk (A: 0.576, B: 0.618), which is good.
12. **Cl_mic:** Ligand A (-13.702) has a significantly lower (better) microsomal clearance than Ligand B (21.526), indicating better metabolic stability.
13. **t1/2:** Ligand A (24.53) has a longer half-life than Ligand B (16.828), which is preferable.
14. **Pgp:** Ligand A (0.028) has a much lower Pgp efflux liability than Ligand B (0.147), suggesting better absorption and bioavailability.
15. **Binding Affinity:** Ligand B (-7.4) has a significantly stronger binding affinity than Ligand A (-5.4). This is a substantial advantage for Ligand B. A 2 kcal/mol difference is significant.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B has a slightly better logP and a *much* better affinity. However, Ligand A excels in TPSA, Pgp, DILI, Cl_mic, solubility, and QED. The poor Caco-2 values for both are a concern, but the other ADME properties of Ligand A are more favorable overall. The affinity difference is substantial, but the ADME profile of Ligand B is concerning, particularly the high DILI risk and Pgp efflux.
**Conclusion:**
While Ligand B's affinity is very strong, the superior ADME profile of Ligand A, particularly the lower DILI risk, better metabolic stability, and improved solubility, makes it the more promising drug candidate. The affinity difference, while significant, can potentially be addressed with further optimization, while poor ADME properties are often harder to fix.
Output:
1
2025-04-17 18:31:59,777 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.471 and 352.431 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (58.64) is significantly better than Ligand B (99.1). ADRB2 is a cardiovascular target, not CNS, but lower TPSA generally improves absorption. Ligand B is pushing the upper limit for good oral absorption.
3. **logP:** Ligand A (2.24) is optimal, while Ligand B (-0.205) is too low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (5). Lower HBA generally improves permeability.
6. **QED:** Ligand A (0.849) is significantly better than Ligand B (0.65), indicating a more drug-like profile.
7. **DILI:** Both ligands have low DILI risk (24.544 and 21.869), which is good. No major difference.
8. **BBB:** Not a primary concern for a cardiovascular target, but Ligand A (77.937) is better than Ligand B (32.144).
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.805 and -4.961), which is unusual and suggests poor permeability. However, these values are on a scale where negative values are possible, and the difference is minimal.
10. **Solubility:** Ligand A (-3.545) is better than Ligand B (-1.084). Higher solubility is generally desirable.
11. **hERG:** Both ligands have very low hERG risk (0.283 and 0.108), which is excellent.
12. **Cl_mic:** Ligand B (-7.273) has a *negative* microsomal clearance, which is highly unusual and suggests very high metabolic stability. Ligand A (48.337) is more typical, but moderate.
13. **t1/2:** Ligand B (37.83) has a longer in vitro half-life than Ligand A (26.341), which is favorable.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.062 and 0.005), which is good.
15. **Binding Affinity:** Ligand B (-7.0) has a slightly better binding affinity than Ligand A (-6.3), a difference of 0.7 kcal/mol. This is a meaningful difference, but not overwhelming.
**Overall Assessment:**
Ligand A has a significantly better profile across multiple ADME properties (TPSA, logP, HBD, HBA, QED, Solubility) and a reasonable binding affinity. Ligand B's main advantage is its exceptional metabolic stability (negative Cl_mic) and slightly better affinity. However, its poor logP and higher TPSA are concerning. The negative Cl_mic is also a red flag, as it's biologically implausible and could indicate an issue with the assay or data. While the affinity difference is notable, the overall balance of properties favors Ligand A.
**Output:**
1
2025-04-17 18:31:59,777 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.397 and 348.422 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (41.37) is significantly better than Ligand B (75.19). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary goal, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold. Ligand B is approaching a level that could hinder absorption.
3. **logP:** Both ligands have good logP values (2.368 and 1.976), falling within the optimal 1-3 range. Ligand B is slightly lower, which might slightly reduce permeability, but it's not a major concern.
4. **HBD:** Ligand A (0) is preferable to Ligand B (1). Fewer HBDs generally improve membrane permeability.
5. **HBA:** Both ligands have the same number of HBA (4), which is well within the acceptable limit of 10.
6. **QED:** Ligand A (0.855) has a slightly better QED score than Ligand B (0.798), indicating a more drug-like profile.
7. **DILI:** Ligand B (39.511) has a substantially lower DILI risk than Ligand A (54.44). This is a significant advantage for Ligand B.
8. **BBB:** Both ligands have high BBB penetration (86.7 and 81.776), but this is less critical for a cardiovascular target like ADRB2.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.653 and -4.748). These values are unusual and suggest poor permeability.
10. **Solubility:** Both ligands have negative solubility values (-2.354 and -2.511). These values are also unusual and suggest poor solubility.
11. **hERG:** Both ligands have low hERG inhibition liability (0.545 and 0.47), which is good.
12. **Cl_mic:** Ligand B (54.618) has a slightly higher microsomal clearance than Ligand A (44.126), suggesting slightly lower metabolic stability.
13. **t1/2:** Ligand A (6.873) has a significantly longer in vitro half-life than Ligand B (-5.731). This is a substantial advantage for Ligand A.
14. **Pgp:** Ligand B (0.091) has a much lower P-gp efflux liability than Ligand A (0.315), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand B (-11.3) has a significantly stronger binding affinity than Ligand A (-6.3). This is a very large difference and a major advantage for Ligand B. A >1.5 kcal/mol difference in affinity can outweigh other drawbacks.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in affinity and Pgp, while Ligand A has a better TPSA. The DILI score is also important, and Ligand B is significantly better.
**Overall Assessment:**
While Ligand A has better TPSA and half-life, the significantly stronger binding affinity of Ligand B (-11.3 vs -6.3 kcal/mol) and its lower DILI risk are decisive factors. The lower P-gp efflux is also a positive. The unusual Caco-2 and solubility values are concerning for both, but the potency advantage of Ligand B is likely to be more impactful in overcoming these issues during optimization.
Output:
0
2025-04-17 18:31:59,777 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [352.454, 48.05, 1.024, 1, 5, 0.708, 23.032, 84.374, -4.518, -1.021, 0.908, 27.602, -35.498, 0.051, -6.8]
**Ligand B:** [347.375, 113.49, 0.739, 2, 7, 0.825, 58.666, 38.465, -5.042, -2.745, 0.117, 19.814, -29.751, 0.045, -6.1]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (352.454) is slightly higher, but both are acceptable.
2. **TPSA:** Ligand A (48.05) is excellent, well below the 140 threshold and very favorable for oral absorption. Ligand B (113.49) is higher, but still potentially acceptable, though less ideal.
3. **logP:** Both ligands have good logP values (A: 1.024, B: 0.739), falling within the optimal 1-3 range.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower is generally better for permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (7). Lower is generally better for permeability.
6. **QED:** Both have good QED values (A: 0.708, B: 0.825), indicating good drug-like properties. Ligand B is slightly better here.
7. **DILI:** Ligand A (23.032) has a significantly lower DILI risk than Ligand B (58.666). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (84.374) has a much higher BBB penetration potential than Ligand B (38.465). This is crucial for a GPCR target, even if not strictly CNS-focused, as it indicates better distribution.
9. **Caco-2:** Ligand A (-4.518) and Ligand B (-5.042) are both negative, indicating poor permeability.
10. **Solubility:** Ligand A (-1.021) is better than Ligand B (-2.745), indicating better aqueous solubility.
11. **hERG:** Ligand A (0.908) has a lower hERG risk than Ligand B (0.117). This is a significant safety advantage.
12. **Cl_mic:** Ligand B (19.814) has a lower microsomal clearance than Ligand A (27.602), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-29.751) has a longer in vitro half-life than Ligand A (-35.498).
14. **Pgp:** Both have very low Pgp efflux liability (A: 0.051, B: 0.045), which is good.
15. **Affinity:** Both have similar, excellent binding affinities (A: -6.8, B: -6.1). The difference is less than 1.5 kcal/mol, so it doesn't override other factors.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A excels in TPSA, BBB, DILI, hERG, and solubility. While Ligand B has a slightly better QED and metabolic stability, the significantly better safety profile (DILI, hERG) and distribution (BBB) of Ligand A are more important. The affinity difference is not substantial enough to favor Ligand B.
**Conclusion:**
Ligand A is the more promising drug candidate due to its superior safety profile (lower DILI and hERG risk), better predicted distribution (higher BBB), and favorable TPSA and solubility.
```
1
```
2025-04-17 18:31:59,777 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (347.459 Da and 350.394 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (92.5) is higher than Ligand B (67.67). For a cardiovascular GPCR, TPSA is moderately important. Lower TPSA generally favors better membrane permeability. Ligand B is preferable here.
**3. logP:** Ligand A (1.352) is within the optimal 1-3 range, while Ligand B (0.317) is slightly below 1. While a slightly lower logP isn't a dealbreaker, it *could* indicate poorer membrane permeability. Ligand A is preferable.
**4. H-Bond Donors:** Ligand A has 2 HBD, and Ligand B has 0. Both are acceptable, within the guideline of <=5.
**5. H-Bond Acceptors:** Ligand A has 3 HBA, and Ligand B has 5. Both are within the guideline of <=10.
**6. QED:** Both ligands have similar QED values (0.71 and 0.734), indicating good drug-like properties. No significant difference.
**7. DILI Risk:** Ligand A (20.822) has a significantly lower DILI risk than Ligand B (32.028). This is a crucial advantage for Ligand A.
**8. BBB Penetration:** Ligand B (84.684) has better BBB penetration than Ligand A (65.839). While ADRB2 is a cardiovascular target, some CNS off-target effects are always a consideration, and better BBB penetration could be a slight advantage.
**9. Caco-2 Permeability:** Ligand A (-5.246) has worse Caco-2 permeability than Ligand B (-4.47). This suggests Ligand B will be absorbed better.
**10. Aqueous Solubility:** Ligand A (-2.717) has worse aqueous solubility than Ligand B (-1.143). Solubility is important for formulation and bioavailability, favoring Ligand B.
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.121 and 0.263), which is excellent. No significant difference.
**12. Microsomal Clearance:** Ligand A (26.677) has higher microsomal clearance than Ligand B (18.993). This means Ligand B is likely more metabolically stable, a positive attribute.
**13. In vitro Half-Life:** Ligand B (-28.795) has a significantly longer in vitro half-life than Ligand A (8.835). This is a major advantage for Ligand B, potentially allowing for less frequent dosing.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.022 and 0.03). No significant difference.
**15. Binding Affinity:** Ligand B (-7.6) has a significantly stronger binding affinity than Ligand A (-5.7). A 1.9 kcal/mol difference is substantial and can often outweigh minor ADME drawbacks.
**Overall Assessment:**
While Ligand A has a lower DILI risk and better logP, Ligand B demonstrates a superior profile overall, especially considering the GPCR target class. The stronger binding affinity, better Caco-2 permeability, improved solubility, greater metabolic stability (lower Cl_mic and longer t1/2), and better BBB penetration outweigh the slightly higher DILI risk and TPSA. The affinity difference is particularly important.
Output:
0
2025-04-17 18:31:59,778 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.451 and 345.403 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (112.66) is slightly higher than Ligand B (92.77). Ligand B is better, being closer to the <140 threshold for good absorption, and more favorable for a GPCR.
3. **logP:** Ligand A (1.49) is within the optimal 1-3 range. Ligand B (-0.721) is slightly below 1, which *could* indicate potential permeability issues. Ligand A is better.
4. **HBD:** Both ligands have acceptable HBD counts (3 and 2, respectively), well below the 5 threshold.
5. **HBA:** Both ligands have the same HBA count (5), which is below the 10 threshold.
6. **QED:** Both ligands have good QED scores (0.626 and 0.751), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (49.632) has a higher DILI risk than Ligand B (25.165). Ligand B is significantly better here.
8. **BBB:** Ligand A (62.699) has a better BBB penetration score than Ligand B (35.595). While ADRB2 isn't necessarily a CNS target, some peripheral ADRB2 activity can be modulated by CNS effects, and higher BBB is generally a plus.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.476 and -5.364). This is unusual and suggests poor permeability. However, the values are very similar.
10. **Solubility:** Ligand A (-2.362) has slightly worse solubility than Ligand B (-1.7). Ligand B is better.
11. **hERG:** Ligand A (0.051) has a slightly better hERG profile than Ligand B (0.36). Lower is better, so Ligand A is preferable.
12. **Cl_mic:** Ligand A (26.335) has a higher microsomal clearance than Ligand B (-5.023). This means Ligand B is likely more metabolically stable, which is a significant advantage.
13. **t1/2:** Ligand A (-12.235) has a negative in vitro half-life, which is problematic. Ligand B (0.602) has a very short half-life, but it's positive and therefore more reasonable. Ligand B is better.
14. **Pgp:** Ligand A (0.045) has lower P-gp efflux than Ligand B (0.008). Lower is better, so Ligand A is preferable.
15. **Binding Affinity:** Ligand B (-7.0) has a significantly better binding affinity (-7.0 kcal/mol) than Ligand A (-6.7 kcal/mol). This 1.3 kcal/mol difference is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand B demonstrates a superior balance of properties. Its significantly better binding affinity, lower DILI risk, and improved metabolic stability (lower Cl_mic, better t1/2) are key advantages. While Ligand A has a slightly better BBB score and hERG profile, the affinity difference and safety profile of Ligand B are more crucial for a viable drug candidate targeting a GPCR like ADRB2. The slightly lower logP of Ligand B is a concern, but the strong affinity may compensate for this.
Output:
0
2025-04-17 18:31:59,778 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.459 and 365.499 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (59.08) is significantly better than Ligand B (69.72). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand A is well below the 140 threshold.
3. **logP:** Both ligands have acceptable logP values (1.148 and 0.861), falling within the 1-3 range. Ligand B is slightly lower, which could be a minor disadvantage for membrane permeability.
4. **HBD:** Ligand A (0) is preferable to Ligand B (1). Fewer hydrogen bond donors generally improve permeability.
5. **HBA:** Both ligands have the same number of HBA (4), which is acceptable.
6. **QED:** Ligand A (0.646) is slightly better than Ligand B (0.58), indicating a more drug-like profile.
7. **DILI:** Both ligands have low DILI risk (19.193 and 18.573), which is excellent.
8. **BBB:** Ligand A (79.721) has a much better BBB penetration percentile than Ligand B (46.84). While ADRB2 isn't exclusively a CNS target, some CNS exposure is not necessarily detrimental and can sometimes be beneficial for understanding off-target effects.
9. **Caco-2:** Ligand A (-4.423) is better than Ligand B (-5.123), indicating better intestinal absorption.
10. **Solubility:** Both ligands have poor aqueous solubility (-2.168 and -2.229). This is a concern for both, but not a deciding factor between them.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.2 and 0.134), which is excellent.
12. **Cl_mic:** Ligand B (1.839) has significantly lower microsomal clearance than Ligand A (23.362), indicating better metabolic stability. This is a major advantage for Ligand B.
13. **t1/2:** Ligand B (-12.262) has a much longer in vitro half-life than Ligand A (6.05), further supporting its better metabolic stability.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.176 and 0.036). Ligand B is slightly better.
15. **Binding Affinity:** Ligand B (-6.4) has a slightly better binding affinity than Ligand A (-5.7), a 0.7 kcal/mol difference. This is a significant advantage.
**Overall Assessment:**
Ligand B demonstrates superior metabolic stability (lower Cl_mic, longer t1/2) and slightly better binding affinity. While Ligand A has better TPSA and BBB penetration, the metabolic advantages of Ligand B are more crucial for a successful drug candidate, especially considering the potential for extensive first-pass metabolism. The difference in binding affinity, while not huge, adds to the preference for Ligand B. The solubility is a concern for both, but can be addressed with formulation strategies.
Output:
0
2025-04-17 18:31:59,778 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 drug candidates. ADRB2 is a GPCR, so we'll prioritize logP, Pgp, TPSA, and affinity, alongside general drug-like properties.
**Ligand A:** [351.422, 75.44, 2.161, 1, 4, 0.882, 34.277, 82.745, -4.934, -1.905, 0.25, 19.875, -30.147, 0.192, -6.7]
**Ligand B:** [363.355, 65.2, 2.446, 2, 2, 0.763, 47.964, 72.315, -4.785, -3.317, 0.672, 22.389, -36.181, 0.112, -6.7]
1. **MW:** Both are within the ideal range (200-500 Da). A (351.422) is slightly preferred.
2. **TPSA:** A (75.44) is a bit higher than B (65.2), but both are acceptable for a non-CNS GPCR target. B is better here.
3. **logP:** Both are within the optimal range (1-3). B (2.446) is slightly higher, potentially aiding membrane permeability, but not a huge difference.
4. **HBD:** A (1) is better than B (2). Lower HBD generally improves permeability.
5. **HBA:** A (4) is better than B (2). Lower HBA generally improves permeability.
6. **QED:** A (0.882) is significantly better than B (0.763), indicating a more drug-like profile.
7. **DILI:** A (34.277) is considerably better than B (47.964), suggesting a lower risk of liver injury. This is a significant advantage.
8. **BBB:** A (82.745) is better than B (72.315). While ADRB2 isn't necessarily a CNS target, higher BBB penetration is rarely detrimental and can indicate better overall permeability.
9. **Caco-2:** Both are negative, indicating poor permeability. A (-4.934) is slightly worse than B (-4.785).
10. **Solubility:** A (-1.905) is better than B (-3.317). Solubility is important for bioavailability.
11. **hERG:** Both are very low (0.25 and 0.672), indicating minimal hERG inhibition risk.
12. **Cl_mic:** A (19.875) is better than B (22.389), suggesting better metabolic stability.
13. **t1/2:** A (-30.147) is better than B (-36.181), indicating a longer in vitro half-life.
14. **Pgp:** A (0.192) is better than B (0.112), suggesting lower P-gp efflux.
15. **Affinity:** Both are identical (-6.7 kcal/mol).
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most crucial ADME properties (QED, DILI, BBB, Solubility, Cl_mic, t1/2, Pgp) and has a slightly better profile for MW, HBD and HBA. While both have poor Caco-2 permeability, A is slightly better. The equal binding affinity removes that as a differentiating factor. The significant advantages in DILI risk and QED for Ligand A make it the more promising candidate.
Output:
1
2025-04-17 18:31:59,778 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.475 and 364.471 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (83.98) is better than Ligand B (92.35). Both are below 140, but lower TPSA is generally preferred for better absorption.
3. **logP:** Both ligands have good logP values (2.544 and 2.688), falling within the optimal 1-3 range.
4. **HBD:** Ligand A (2) is slightly better than Ligand B (1). Both are within the acceptable limit of 5.
5. **HBA:** Ligand A (4) is better than Ligand B (7). Lower HBA is preferred for permeability.
6. **QED:** Both ligands have good QED scores (0.795 and 0.812), indicating good drug-likeness.
7. **DILI:** Ligand A (39.977) has a significantly lower DILI risk than Ligand B (55.448). This is a major advantage for Ligand A.
8. **BBB:** Both ligands have similar BBB penetration (76.231 and 76.192). This is good, but not a critical factor for ADRB2 which is not a CNS target.
9. **Caco-2:** Both ligands have very poor Caco-2 permeability (-4.708 and -4.805). This is a significant concern for both.
10. **Solubility:** Both ligands have poor solubility (-4.046 and -4.179). This is a concern, but can potentially be addressed with formulation strategies.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.196 and 0.253). This is excellent.
12. **Cl_mic:** Ligand A (51.162) has lower microsomal clearance than Ligand B (56.019), indicating better metabolic stability.
13. **t1/2:** Ligand A (1 hour) has a shorter half-life than Ligand B (17.989 hours). This is a disadvantage for Ligand A.
14. **Pgp:** Ligand A (0.044) has much lower P-gp efflux than Ligand B (0.291). This is a significant advantage for Ligand A.
15. **Binding Affinity:** Ligand B (-8.4 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.5 kcal/mol). This is a substantial advantage for Ligand B.
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. While both have good logP, Ligand A has better TPSA and Pgp. However, Ligand B's significantly stronger binding affinity (-8.4 vs -6.5) is a major advantage that can potentially outweigh the slightly less favorable ADME properties.
**Overall Assessment:**
The biggest concern for both ligands is the poor Caco-2 permeability and solubility. However, the stronger binding affinity of Ligand B is a critical advantage for a GPCR target. The lower DILI and Pgp efflux of Ligand A are attractive, but the difference in binding affinity is substantial enough to favor Ligand B. The longer half-life of Ligand B is also a plus.
Output:
0
2025-04-17 18:31:59,778 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (358.43 & 354.54 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (94.82) is higher than Ligand B (69.64). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for permeability. Ligand B is better here.
3. **logP:** Ligand A (1.837) is within the optimal range (1-3), while Ligand B (3.109) is at the higher end. Both are acceptable, but Ligand A is slightly favored.
4. **HBD:** Ligand A (1) and Ligand B (2) are both acceptable.
5. **HBA:** Ligand A (8) and Ligand B (3) are both acceptable.
6. **QED:** Both ligands have good QED scores (0.618 and 0.704), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (89.26) has a higher DILI risk than Ligand B (9.97). This is a significant advantage for Ligand B.
8. **BBB:** Both have moderate BBB penetration. Ligand B (65.80) is slightly better than Ligand A (58.01).
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-5.42) is slightly better than Ligand B (-4.59).
10. **Solubility:** Both ligands have very poor solubility (-2.72 and -2.69). This is a major concern for both.
11. **hERG:** Both ligands have low hERG inhibition risk (0.26 and 0.59). No significant difference.
12. **Cl_mic:** Ligand A (48.02) has lower microsomal clearance than Ligand B (58.17), suggesting better metabolic stability. This favors Ligand A.
13. **t1/2:** Ligand A (-17.19) has a negative in vitro half-life, which is concerning. Ligand B (-3.93) is also poor, but better than A.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.36 and 0.12). Ligand B is better here.
15. **Binding Affinity:** Ligand A (-7.4) has a slightly better binding affinity than Ligand B (-7.1). This is a 0.3 kcal/mol difference, which is a moderate advantage.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has a better logP and affinity, while Ligand B has a better TPSA and Pgp. However, the *significant* advantage of Ligand B in terms of DILI risk is a major factor. Poor solubility is a concern for both, but can be addressed with formulation strategies. The negative half-life of Ligand A is also a red flag.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity and metabolic stability, the significantly lower DILI risk of Ligand B, combined with its better TPSA and Pgp properties, makes it the more promising candidate. The poor solubility is a drawback for both, but the DILI risk is a more critical safety concern.
Output:
0
2025-04-17 18:31:59,779 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [345.443, 82.43, 1.77, 1, 4, 0.646, 16.867, 71.229, -4.652, -2.31, 0.275, 22.432, 2.343, 0.01, -5.4]
**Ligand B:** [350.463, 86.95, 0.067, 1, 4, 0.687, 5.894, 64.986, -5.353, -0.881, 0.247, -10.179, -28.499, 0.006, -7]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity, and BBB):
1. **MW:** Both are within the ideal range (200-500 Da). A is 345.443, B is 350.463 - negligible difference.
2. **TPSA:** Both are acceptable, but A (82.43) is better than B (86.95), being closer to the <140 threshold for oral absorption.
3. **logP:** A (1.77) is optimal. B (0.067) is quite low, potentially leading to poor membrane permeability. This is a significant drawback.
4. **HBD/HBA:** Both have 1 HBD and 4 HBA, which is acceptable.
5. **QED:** Both are good (>0.5), A (0.646) and B (0.687) are comparable.
6. **DILI:** A (16.867) is higher than B (5.894), indicating a slightly higher risk of liver injury, but still within an acceptable range.
7. **BBB:** A (71.229) is better than B (64.986). While not a primary concern for all GPCRs, it's a positive for A.
8. **Caco-2:** A (-4.652) is worse than B (-5.353) indicating lower intestinal absorption.
9. **Solubility:** A (-2.31) is worse than B (-0.881).
10. **hERG:** Both are very low (0.275 and 0.247), indicating minimal cardiotoxicity risk.
11. **Cl_mic:** B (-10.179) has significantly lower clearance than A (22.432), suggesting better metabolic stability. This is a strong point for B.
12. **t1/2:** B (-28.499) has a much longer half-life than A (2.343), which is highly desirable. This is another strong point for B.
13. **Pgp:** Both are very low (0.01 and 0.006), indicating minimal P-gp efflux.
14. **Affinity:** B (-7.0) has a slightly better binding affinity than A (-5.4). A difference of 1.6 kcal/mol is significant.
**Overall Assessment:**
Ligand B has several advantages: significantly better metabolic stability (lower Cl_mic), a much longer half-life, and slightly better binding affinity. The biggest drawback of Ligand B is its low logP, which could hinder permeability. However, the improved metabolic stability and half-life are crucial for *in vivo* efficacy, and the affinity difference is substantial. Ligand A has a better logP and BBB penetration, but its metabolic liability is concerning. Given the GPCR target class, the improved metabolic profile and affinity of Ligand B outweigh the permeability concerns, especially as formulation strategies can sometimes mitigate low logP.
Output:
0
2025-04-17 18:31:59,779 - INFO - Batch 44 complete. Total preferences: 704
2025-04-17 18:31:59,779 - INFO - Processing batch 45/512...
2025-04-17 18:32:50,565 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (361.764 and 367.373 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand B (72.47) is significantly better than Ligand A (92.93). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (1.918 and 2.449), falling within the optimal 1-3 range. Ligand B is slightly better.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1), but both are acceptable (<=5).
5. **HBA:** Ligand A (6) is higher than Ligand B (4), but both are within the acceptable range (<=10).
6. **QED:** Both have good QED scores (0.724 and 0.824), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Both have relatively high DILI risk (89.221 and 82.784). This is a concern for both, but Ligand B is slightly lower.
8. **BBB:** Ligand B (57.193) is better than Ligand A (46.181), but neither is particularly high. This isn't a major factor for a cardiovascular target.
9. **Caco-2:** Both have negative Caco-2 values (-4.957 and -4.65). This is unusual and suggests poor permeability. This is a significant drawback for both.
10. **Solubility:** Ligand A (-2.94) is better than Ligand B (-4.445). Solubility is important for bioavailability.
11. **hERG:** Both have low hERG inhibition risk (0.681 and 0.317). Ligand B is significantly better.
12. **Cl_mic:** Ligand A (6.588) has lower microsomal clearance than Ligand B (59.443), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (21.381) has a much longer in vitro half-life than Ligand B (6.896). This is a major advantage for Ligand A, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.235) has lower P-gp efflux liability than Ligand B (0.466). This is a positive for Ligand A.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.3 and -6.2 kcal/mol). The difference is negligible.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand B has better logP and TPSA, and comparable affinity. However, Ligand A has better metabolic stability (Cl_mic, t1/2) and Pgp efflux. The longer half-life of Ligand A is a significant advantage.
**Overall Assessment:**
While Ligand B has some advantages in TPSA and hERG, Ligand A's superior metabolic stability (lower Cl_mic and longer t1/2), lower Pgp efflux, and better solubility outweigh these benefits. Both have concerning DILI and Caco-2 values, but these are issues that could potentially be addressed through further optimization.
Output:
1
2025-04-17 18:32:50,566 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (399.288) is slightly higher than Ligand B (355.435), but both are acceptable.
2. **TPSA:** Ligand A (54.26) is significantly better than Ligand B (96.97). For a GPCR, lower TPSA is generally preferred for better permeability, and Ligand A is well below the 140 threshold. Ligand B is approaching a less desirable range.
3. **logP:** Ligand A (4.093) is slightly high, but still within a tolerable range. Ligand B (0.512) is quite low, potentially leading to poor membrane permeability. This is a significant negative for Ligand B.
4. **HBD:** Both ligands have 2 HBD, which is acceptable.
5. **HBA:** Ligand A has 3 HBA, while Ligand B has 5. Both are within the acceptable range of <=10.
6. **QED:** Both ligands have similar QED values (0.656 and 0.588), indicating reasonable drug-likeness.
7. **DILI:** Ligand A (68.244) has a higher DILI risk than Ligand B (34.587). This is a concern for Ligand A, but not a deal-breaker at this stage.
8. **BBB:** Ligand B (78.79) has a much higher BBB penetration percentile than Ligand A (44.552). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant, and this favors Ligand B.
9. **Caco-2:** Ligand A (-5.008) has a negative Caco-2 value, which is unusual and suggests poor permeability. Ligand B (-4.887) is also negative, but slightly less so. Both are concerning.
10. **Solubility:** Ligand A (-4.32) has slightly better solubility than Ligand B (-1.499).
11. **hERG:** Ligand A (0.702) has a lower hERG risk than Ligand B (0.168), which is a significant advantage.
12. **Cl_mic:** Ligand B (4.418) has a much lower microsomal clearance than Ligand A (25.89), indicating better metabolic stability. This is a strong positive for Ligand B.
13. **t1/2:** Ligand A (104.269) has a significantly longer in vitro half-life than Ligand B (-6.406). This is a major advantage for Ligand A.
14. **Pgp:** Ligand A (0.56) has lower P-gp efflux than Ligand B (0.018), which is favorable.
15. **Binding Affinity:** Ligand B (-8.0) has a significantly stronger binding affinity than Ligand A (-5.8). This is a substantial advantage for Ligand B, potentially outweighing some of its ADME drawbacks.
**Overall Assessment:**
Ligand B has a significantly better binding affinity and metabolic stability (lower Cl_mic). It also has a lower DILI risk and better BBB penetration. However, its logP is very low, and its Caco-2 permeability is poor. Ligand A has a better TPSA, hERG risk, Pgp efflux, and a much longer half-life, but suffers from higher DILI risk and a less favorable logP.
Considering the GPCR-specific priorities (logP, TPSA, Pgp, affinity), the strong binding affinity of Ligand B is a major driver. While the low logP and permeability are concerns, these can potentially be addressed through further optimization. The longer half-life of Ligand A is attractive, but the weaker binding and higher DILI risk are more problematic.
Therefore, I believe Ligand B is the more promising starting point for drug development.
Output:
0
2025-04-17 18:32:50,566 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, the key properties to prioritize are logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB (though less critical for a cardiovascular target than a CNS one).
Let's compare the ligands property by property:
1. **MW:** Both ligands (342.414 and 339.399 Da) fall within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (64.35) is significantly better than Ligand B (90.98). A TPSA under 140 is good for oral absorption, and Ligand A is comfortably within this range, while Ligand B is approaching the upper limit.
3. **logP:** Ligand A (3.189) is optimal, while Ligand B (1.211) is a bit low, potentially impacting permeability.
4. **HBD/HBA:** Both have acceptable HBD (2) and HBA (3 for A, 4 for B) counts.
5. **QED:** Both are reasonable (0.847 and 0.774), indicating good drug-like properties.
6. **DILI:** Ligand A (25.436) has a much lower DILI risk than Ligand B (55.719). This is a significant advantage.
7. **BBB:** Ligand A (80.574) has better BBB penetration than Ligand B (35.673), though this is less crucial for a cardiovascular target.
8. **Caco-2:** Ligand A (-4.76) is better than Ligand B (-5.721), suggesting better intestinal absorption.
9. **Solubility:** Ligand A (-2.92) is better than Ligand B (-2.281).
10. **hERG:** Ligand A (0.805) is better than Ligand B (0.106), indicating lower cardiotoxicity risk.
11. **Cl_mic:** Ligand B (-10.977) has significantly lower microsomal clearance than Ligand A (23.012), suggesting better metabolic stability. This is a strong point for Ligand B.
12. **t1/2:** Ligand B (-23.063) has a much longer in vitro half-life than Ligand A (-0.281), which is a major advantage.
13. **Pgp:** Ligand A (0.226) has lower P-gp efflux than Ligand B (0.018), which is favorable for bioavailability.
14. **Binding Affinity:** Ligand A (-5.7 kcal/mol) has a slightly better binding affinity than Ligand B (-2.2 kcal/mol). This is a substantial difference.
**Overall Assessment:**
Ligand A excels in most key parameters: logP, TPSA, DILI, solubility, hERG, Pgp, and crucially, binding affinity. Ligand B's main strengths are its metabolic stability (low Cl_mic) and long half-life. However, the significantly weaker binding affinity of Ligand B, combined with its higher TPSA, lower logP, and higher DILI risk, outweigh these benefits. The substantial difference in binding affinity (-5.7 vs -2.2 kcal/mol) is a decisive factor, especially for a GPCR target where strong binding is essential.
**Output:**
1
2025-04-17 18:32:50,566 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [381.479, 110.43 , 0.707, 1. , 6. , 0.816, 78.17 , 57.852, -5.532, -2.448, 0.232, 29.02 , 1.338, 0.136, -1.6 ]
**Ligand B:** [356.482, 66.48 , 2.873, 1. , 3. , 0.654, 28.616, 73.788, -4.651, -2.838, 0.367, 23.896, -6.747, 0.245, -5.9 ]
Here's a breakdown, comparing each parameter and considering GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (356.482) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (110.43) is higher than Ligand B (66.48). Ligand B is much better here, being well below the 140 threshold for oral absorption and more favorable for GPCRs.
3. **logP:** Ligand A (0.707) is a bit low, potentially hindering membrane permeability. Ligand B (2.873) is much better, falling squarely within the optimal 1-3 range.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A (6) has more HBAs than Ligand B (3). Lower HBA is preferable for better permeability.
6. **QED:** Ligand A (0.816) has a better QED score than Ligand B (0.654), indicating a more drug-like profile.
7. **DILI:** Ligand A (78.17) has a significantly higher DILI risk than Ligand B (28.616). This is a major concern for Ligand A.
8. **BBB:** Ligand B (73.788) has a higher BBB penetration percentile than Ligand A (57.852). While ADRB2 isn't necessarily a CNS target, higher BBB is generally a positive sign of good distribution and reduced off-target effects.
9. **Caco-2:** Ligand A (-5.532) and Ligand B (-4.651) both have negative values, which is unusual. Assuming these are logPeff values, lower (more negative) values indicate lower permeability.
10. **Solubility:** Both have poor solubility (-2.448 and -2.838). This is a concern for both, but might be manageable with formulation.
11. **hERG:** Both have low hERG risk (0.232 and 0.367).
12. **Cl_mic:** Ligand B (23.896) has lower microsomal clearance than Ligand A (29.02), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-6.747) has a longer in vitro half-life than Ligand A (1.338), which is desirable.
14. **Pgp:** Ligand A (0.136) has lower P-gp efflux than Ligand B (0.245), which is a slight advantage.
15. **Affinity:** Ligand B (-5.9) has a significantly better binding affinity than Ligand A (-1.6). This is a substantial advantage.
**Overall Assessment:**
Ligand B is the stronger candidate. While Ligand A has a slightly better QED and Pgp profile, Ligand B excels in the most critical areas for a GPCR target: logP, TPSA, binding affinity, DILI risk, and metabolic stability (Cl_mic and t1/2). The significantly lower DILI risk for Ligand B is a major deciding factor, as is the much stronger binding affinity. The better TPSA and logP values of Ligand B also suggest better permeability and bioavailability.
Output:
0
2025-04-17 18:32:50,566 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (343.427 and 346.358 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (66.65) is significantly better than Ligand B (80.57). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have acceptable logP values (1.64 and 2.427), falling within the 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability, but not drastically.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer hydrogen bond donors generally improve permeability.
5. **HBA:** Both ligands have the same number of HBA (4). This is within the acceptable range.
6. **QED:** Both ligands have good QED scores (0.834 and 0.871), indicating good drug-likeness. No significant difference.
7. **DILI:** Ligand A (16.596) has a much lower DILI risk than Ligand B (73.013). This is a major advantage for Ligand A. DILI is a critical safety concern.
8. **BBB:** Both ligands have similar BBB penetration (68.67 and 68.864). This isn't a major factor for a cardiovascular target.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.764 and -4.313), which is unusual and suggests poor permeability. However, the values are very close.
10. **Solubility:** Ligand A (-2.035) has slightly better solubility than Ligand B (-3.628).
11. **hERG:** Both ligands have very low hERG inhibition risk (0.143 and 0.322). This is excellent.
12. **Cl_mic:** Ligand A (62.799) has a higher microsomal clearance than Ligand B (24.472). This means Ligand B is more metabolically stable, which is a positive.
13. **t1/2:** Ligand B (49.542) has a significantly longer in vitro half-life than Ligand A (2.168). This is a substantial advantage for Ligand B.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.022 and 0.175).
15. **Binding Affinity:** Both ligands have very similar and strong binding affinities (-6 and -5 kcal/mol). The difference of 1 kcal/mol is not decisive.
**Overall Assessment:**
Ligand A excels in safety (DILI) and has slightly better TPSA and solubility. Ligand B has a significantly longer half-life and better metabolic stability. The lower DILI risk of Ligand A is a significant advantage, especially early in development. While the longer half-life of Ligand B is attractive, the potential for liver toxicity with Ligand B is concerning. Given the GPCR-specific priorities (logP, Pgp, TPSA, affinity), and the importance of safety, Ligand A is the more promising candidate.
Output:
1
2025-04-17 18:32:50,566 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [390.452, 51.22, 4.741, 1, 5, 0.742, 76.425, 68.864, -4.795, -4.991, 0.462, 81.192, -15.358, 0.572, -6.3]
**Ligand B:** [330.395, 69.38, 3.506, 0, 6, 0.562, 77.588, 57.076, -5.062, -3.605, 0.46, 16.194, -32.191, 0.246, -7.6]
**Step-by-step comparison:**
1. **MW:** Ligand A (390.452) is within the ideal range (200-500), while Ligand B (330.395) is also good. No clear advantage here.
2. **TPSA:** Ligand A (51.22) is better than Ligand B (69.38). Lower TPSA generally favors better absorption, crucial for GPCRs.
3. **logP:** Ligand A (4.741) is slightly higher than the optimal range (1-3), while Ligand B (3.506) is within the optimal range. This favors Ligand B.
4. **HBD:** Ligand A (1) is preferable to Ligand B (0). While both are low, a single HBD can aid solubility without significantly impacting permeability.
5. **HBA:** Both ligands have 6 HBA, which is acceptable.
6. **QED:** Ligand A (0.742) has a better QED score than Ligand B (0.562), indicating a more drug-like profile.
7. **DILI:** Both ligands have similar DILI risk (76.425 vs 77.588), and are at a moderate risk.
8. **BBB:** Ligand A (68.864) has a better BBB penetration score than Ligand B (57.076). This is important for GPCRs, even if not CNS-focused, as it can influence distribution.
9. **Caco-2:** Ligand A (-4.795) and Ligand B (-5.062) are both poor.
10. **Solubility:** Ligand A (-4.991) is worse than Ligand B (-3.605). Solubility is a concern for both, but Ligand B is slightly better.
11. **hERG:** Both ligands have very low hERG risk (0.462 and 0.46).
12. **Cl_mic:** Ligand A (81.192) has a higher clearance than Ligand B (16.194), meaning Ligand B is more metabolically stable.
13. **t1/2:** Ligand B (-32.191) has a much longer in vitro half-life than Ligand A (-15.358), which is a significant advantage.
14. **Pgp:** Both ligands have low Pgp efflux (0.572 and 0.246).
15. **Affinity:** Ligand B (-7.6) has a significantly stronger binding affinity than Ligand A (-6.3). This is a substantial advantage, potentially outweighing some ADME concerns.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, BBB, and affinity. Ligand B has a better logP, slightly better TPSA, better Pgp, and a *much* better affinity. Ligand A has a better BBB score.
**Overall Assessment:**
While Ligand A has a better QED and BBB, the significantly stronger binding affinity of Ligand B (-7.6 vs -6.3) and its improved metabolic stability (lower Cl_mic, longer t1/2) are decisive. The slightly higher logP of Ligand A is a concern, and the solubility is poor for both, but the potency advantage of Ligand B is substantial.
Output:
0
2025-04-17 18:32:50,566 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [359.495, 58.22, 3.247, 1, 4, 0.89, 54.323, 49.477, -5.123, -4.389, 0.536, 59.898, -20.799, 0.162, -6.2]
**Ligand B:** [348.418, 69.64, 2.371, 2, 3, 0.829, 16.712, 80.419, -4.913, -3.2, 0.328, 32.069, -10.106, 0.077, -6.3]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (348.418) is slightly lower, which is generally favorable.
2. **TPSA:** Ligand A (58.22) is better than Ligand B (69.64). Both are reasonably good, but lower TPSA generally means better permeability.
3. **logP:** Ligand A (3.247) is slightly better than Ligand B (2.371), falling nicely within the optimal 1-3 range. Ligand B is still acceptable but closer to the lower limit.
4. **HBD/HBA:** Ligand A (1 HBD, 4 HBA) is preferable to Ligand B (2 HBD, 3 HBA). Fewer H-bonds generally improve permeability.
5. **QED:** Both are good (A: 0.89, B: 0.829), indicating good drug-like properties.
6. **DILI:** Ligand B (16.712) is *significantly* better than Ligand A (54.323). This is a major advantage for Ligand B.
7. **BBB:** Ligand B (80.419) is much better than Ligand A (49.477). While not a primary concern for a cardiovascular target, higher BBB penetration can sometimes translate to better overall distribution.
8. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-5.123) is worse than Ligand B (-4.913).
9. **Solubility:** Both are negative, indicating poor solubility. Ligand B (-3.2) is slightly better than Ligand A (-4.389).
10. **hERG:** Both are very low (A: 0.536, B: 0.328), indicating very low cardiotoxicity risk.
11. **Cl_mic:** Ligand B (32.069) is much better than Ligand A (59.898), indicating better metabolic stability.
12. **t1/2:** Ligand B (-10.106) is better than Ligand A (-20.799), indicating a longer half-life.
13. **Pgp:** Both are very low (A: 0.162, B: 0.077), indicating minimal P-gp efflux.
14. **Affinity:** Both have similar binding affinity (-6.2 and -6.3 kcal/mol). This difference is negligible.
**Overall Assessment:**
Ligand B is clearly the better candidate. While Ligand A has a slightly better logP and TPSA, Ligand B's significantly improved DILI risk, BBB penetration, metabolic stability (Cl_mic), and half-life outweigh these minor differences. The similar binding affinities make the ADME properties the deciding factor. The lower DILI risk is particularly important for a cardiovascular drug.
Output:
0
2025-04-17 18:32:50,566 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
The ADRB2 receptor is a GPCR involved in cardiovascular function. Therefore, prioritizing logP, TPSA, Pgp, and binding affinity is crucial. While BBB isn't a primary concern for a cardiovascular target, reasonable permeability is still important.
Let's compare the ligands property by property:
1. **MW:** Both ligands (350.375 and 362.876 Da) fall within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (133.56) is better than Ligand B (33.2). A TPSA of less than 140 is good for oral absorption, and Ligand A is closer to the upper limit, while Ligand B is very low.
3. **logP:** Ligand B (4.8) is higher than Ligand A (-0.62). While logP < 1 can be problematic, logP > 4 can also cause issues. Ligand B is pushing the upper limit, potentially leading to poor solubility and off-target effects. Ligand A is too low, which could hinder membrane permeability.
4. **HBD:** Ligand A (4) is higher than Ligand B (0). Both are acceptable, but lower is generally preferred for permeability.
5. **HBA:** Ligand A (6) is higher than Ligand B (2). Similar to HBD, lower is generally preferred.
6. **QED:** Both ligands have good QED scores (0.54 and 0.708), indicating good drug-like properties.
7. **DILI:** Ligand B (29.391) has a significantly lower DILI risk than Ligand A (41.45). This is a substantial advantage for Ligand B.
8. **BBB:** Ligand B (82.474) has a higher BBB penetration percentile than Ligand A (60.566). While not critical for a cardiovascular target, it suggests better overall permeability.
9. **Caco-2:** Ligand B (-4.626) is better than Ligand A (-5.453). Higher Caco-2 values indicate better intestinal absorption.
10. **Solubility:** Ligand A (-1.204) is better than Ligand B (-4.462). Solubility is a concern for Ligand B given its high logP.
11. **hERG:** Ligand A (0.056) has a slightly lower hERG risk than Ligand B (0.844).
12. **Cl_mic:** Ligand A (-9.104) has a much lower microsomal clearance, indicating better metabolic stability than Ligand B (98.462). This is a significant advantage for Ligand A.
13. **t1/2:** Ligand B (48.627) has a much longer in vitro half-life than Ligand A (-10.572). This is a major advantage for Ligand B.
14. **Pgp:** Ligand A (0.003) shows lower P-gp efflux than Ligand B (0.615).
15. **Affinity:** Both ligands have very similar binding affinities (-6.5 and -6.3 kcal/mol). The difference is not substantial enough to be a deciding factor.
**Overall Assessment:**
Ligand B has several advantages: lower DILI risk, higher BBB penetration, better Caco-2 permeability, and a significantly longer half-life. However, its high logP and lower solubility are concerning. Ligand A has better metabolic stability (lower Cl_mic) and lower Pgp efflux, but its solubility is better. The affinity is comparable.
Considering the balance, the longer half-life and lower DILI risk of Ligand B are more compelling for a cardiovascular drug candidate, despite its potential solubility issues. The slightly higher logP can be addressed with formulation strategies. The improved metabolic stability of Ligand A is beneficial, but a longer half-life is often more valuable.
Output:
0
2025-04-17 18:32:50,567 - INFO - Here's my reasoning and the final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Key priorities for GPCRs are logP, Pgp, TPSA, and affinity, with BBB being less critical for a cardiovascular target.
Let's compare the ligands property by property:
1. **MW:** Both ligands (349.427 and 352.4 Da) fall within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (79.98) is better than Ligand B (29.27). Lower TPSA generally favors better absorption. Ligand B is very low, which could be a concern for solubility.
3. **logP:** Ligand A (3.012) is within the optimal 1-3 range. Ligand B (4.71) is higher, potentially leading to solubility issues and off-target interactions.
4. **HBD/HBA:** Ligand A has 1 HBD and 5 HBA, while Ligand B has 0 HBD and 3 HBA. Both are acceptable.
5. **QED:** Both ligands have good QED scores (0.604 and 0.754).
6. **DILI:** Ligand A (52.152) has a higher DILI risk than Ligand B (14.114). This is a significant advantage for Ligand B.
7. **BBB:** Both have acceptable BBB penetration, but Ligand B (96.588) is significantly higher than Ligand A (70.609). While not critical for a cardiovascular target, it's a positive.
8. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability.
9. **Solubility:** Ligand A (-3.241) has better solubility than Ligand B (-4.745).
10. **hERG:** Ligand A (0.265) has a lower hERG risk than Ligand B (0.941). This is a significant advantage for Ligand A.
11. **Cl_mic:** Ligand A (99.848) has a higher microsomal clearance than Ligand B (20.397), indicating lower metabolic stability. This is a significant advantage for Ligand B.
12. **t1/2:** Ligand B (21.727) has a longer half-life than Ligand A (13.725). This is a positive for Ligand B.
13. **Pgp:** Ligand A (0.325) has lower P-gp efflux than Ligand B (0.794). This is a positive for Ligand A.
14. **Affinity:** Ligand B (-6.9 kcal/mol) has a significantly stronger binding affinity than Ligand A (-4.9 kcal/mol). This is a substantial advantage for Ligand B, potentially outweighing some ADME concerns.
**Overall Assessment:**
Ligand B has a much stronger binding affinity, a significantly lower DILI risk, better metabolic stability (lower Cl_mic, longer t1/2), and better BBB penetration. While its logP is higher and solubility is lower, the substantial affinity advantage and improved safety profile (DILI, hERG) are compelling. The TPSA is also very favorable. Ligand A has better solubility and Pgp efflux, but the affinity difference is too large to ignore.
Output:
0
2025-04-17 18:32:50,567 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (371.424 and 349.431 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (46.17) is significantly better than Ligand B (78.95). ADRB2 is a cardiovascular target, not CNS, but lower TPSA generally improves absorption. Ligand A is well below the 140 threshold. Ligand B is approaching a level that could hinder oral absorption.
3. **logP:** Ligand A (4.905) is higher than Ligand B (0.45). While 4.905 is approaching the upper limit of optimal, it's still acceptable. Ligand B's logP is quite low, potentially causing permeability issues.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 3 HBA, Ligand B has 4. Both are acceptable, but lower is generally preferred.
6. **QED:** Both ligands have similar QED values (0.766 and 0.748), indicating good drug-likeness.
7. **DILI:** Ligand A (47.034) has a higher DILI risk than Ligand B (31.097). This is a significant negative for Ligand A.
8. **BBB:** Not a primary concern for a cardiovascular target like ADRB2, but Ligand A (93.525) has better BBB penetration than Ligand B (66.615).
9. **Caco-2:** Both have negative values (-4.6 and -4.761), which is unusual. Assuming these are logP-scale values, they indicate poor permeability.
10. **Solubility:** Ligand A (-5.224) has slightly better solubility than Ligand B (-2.007), but both are poor.
11. **hERG:** Ligand A (0.411) has a slightly higher hERG risk than Ligand B (0.124).
12. **Cl_mic:** Ligand B (3.491) has significantly lower microsomal clearance than Ligand A (50.471), indicating better metabolic stability. This is a major advantage for Ligand B.
13. **t1/2:** Ligand B (-13.744) has a much longer in vitro half-life than Ligand A (10.475). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.428) has slightly lower P-gp efflux than Ligand B (0.027).
15. **Binding Affinity:** Ligand B (-6.6 kcal/mol) has a slightly better binding affinity than Ligand A (-6.1 kcal/mol). While the difference is not huge, it's a positive for Ligand B.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, and affinity are important. Ligand A has a better logP and TPSA, but Ligand B has a slightly better affinity. However, the significant advantages of Ligand B in terms of metabolic stability (Cl_mic, t1/2) and lower DILI risk outweigh the minor advantages of Ligand A. The poor solubility of both is a concern, but can be addressed with formulation strategies.
**Conclusion:**
Ligand B is the more promising candidate due to its significantly improved metabolic stability, lower DILI risk, and slightly better binding affinity.
Output:
0
2025-04-17 18:32:50,567 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [370.519, 89.01, 3.066, 2, 6, 0.569, 34.471, 75.456, -5.082, -4.13, 0.342, 83.653, -29.773, 0.294, -5.9]**
**Ligand B: [359.451, 82.43, 1.769, 1, 5, 0.717, 47.732, 57.774, -4.608, -3.773, 0.408, 45.006, 14.992, 0.102, -4.7]**
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (370.519) is slightly higher than Ligand B (359.451), but both are acceptable.
2. **TPSA:** Both are below 140, good for oral absorption. Ligand A (89.01) is slightly higher than Ligand B (82.43).
3. **logP:** Both are within the optimal range (1-3). Ligand A (3.066) is at the higher end, while Ligand B (1.769) is closer to 1. Ligand B is preferable here.
4. **H-Bond Donors:** Ligand A (2) and Ligand B (1) are both acceptable (<=5). Ligand B is slightly better.
5. **H-Bond Acceptors:** Ligand A (6) and Ligand B (5) are both acceptable (<=10). Ligand B is slightly better.
6. **QED:** Both are above 0.5, indicating good drug-like properties. Ligand B (0.717) is slightly better than Ligand A (0.569).
7. **DILI:** Ligand A (34.471) has a lower DILI risk than Ligand B (47.732), which is a significant advantage.
8. **BBB:** Ligand A (75.456) has a significantly higher BBB penetration potential than Ligand B (57.774). This is important for a GPCR target, even if not specifically a CNS target, as it can influence distribution.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-5.082) is worse than Ligand B (-4.608).
10. **Solubility:** Both are negative, indicating poor solubility. Ligand A (-4.13) is worse than Ligand B (-3.773).
11. **hERG:** Both are low, indicating low hERG inhibition risk. Ligand A (0.342) is slightly better than Ligand B (0.408).
12. **Cl_mic:** Ligand B (45.006) has a significantly lower microsomal clearance than Ligand A (83.653), suggesting better metabolic stability.
13. **t1/2:** Ligand B (14.992) has a longer in vitro half-life than Ligand A (-29.773), which is a major advantage.
14. **Pgp:** Ligand A (0.294) has lower P-gp efflux than Ligand B (0.102), which is preferable.
15. **Binding Affinity:** Ligand A (-5.9) has a slightly better binding affinity than Ligand B (-4.7). This is a 1.2 kcal/mol difference, which is significant.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity), and the general drug-like properties, Ligand A is the better candidate. While Ligand B has advantages in metabolic stability (Cl_mic, t1/2) and QED, the superior binding affinity of Ligand A (-5.9 vs -4.7) and better BBB penetration (75.456 vs 57.774) outweigh those benefits. The DILI risk is also lower for Ligand A. The slightly worse Caco-2 and solubility of Ligand A can be addressed with formulation strategies.
Output:
1
2025-04-17 18:32:50,567 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (360.435 and 346.435 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (76.66 and 78.07) are below the 140 A^2 threshold for good oral absorption, and acceptable for a cardiovascular GPCR.
3. **logP:** Ligand A (3.219) is optimal, while Ligand B (1.224) is slightly low, potentially impacting permeability. This is a point in favor of A.
4. **HBD:** Ligand A (2) and Ligand B (0) are both acceptable, below the 5 threshold.
5. **HBA:** Ligand A (6) and Ligand B (7) are both acceptable, below the 10 threshold.
6. **QED:** Both ligands (0.801 and 0.786) have good drug-likeness scores, exceeding the 0.5 threshold.
7. **DILI:** Ligand A (87.825) has a significantly higher DILI risk than Ligand B (37.301). This is a major concern for A.
8. **BBB:** Both are relatively low, which is fine for a cardiovascular target. Ligand A (65.258) is slightly better than Ligand B (59.364), but neither is a priority.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-4.808) is slightly better than Ligand B (-5.032), but both are problematic.
10. **Solubility:** Ligand A (-4.641) is better than Ligand B (-0.453). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.56) is better than Ligand B (0.191), lower risk of cardiotoxicity.
12. **Cl_mic:** Ligand A (94.629) has a higher microsomal clearance than Ligand B (27.077), indicating lower metabolic stability. This is a significant drawback for A.
13. **t1/2:** Ligand A (35.76) has a longer half-life than Ligand B (10.341). This is a positive for A.
14. **Pgp:** Ligand A (0.553) has lower P-gp efflux than Ligand B (0.034), which is preferable.
15. **Binding Affinity:** Both ligands have excellent binding affinities (-6.0 and -5.5 kcal/mol). Ligand A is slightly better, but the difference is not substantial enough to overcome other issues.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are important. Ligand A has a better logP and Pgp, but its significantly higher DILI risk and higher Cl_mic are major drawbacks. The slightly better affinity isn't enough to offset these concerns.
**Conclusion:**
Despite the slightly better affinity and half-life of Ligand A, the significantly lower DILI risk and better metabolic stability (lower Cl_mic) of Ligand B make it the more promising drug candidate. The solubility and hERG values are also more favorable for Ligand B.
Output:
0
2025-04-17 18:32:50,567 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (345.439 and 348.487 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (48.0) is significantly better than Ligand B (58.64). ADRB2 is not a CNS target, but lower TPSA generally improves absorption.
3. **logP:** Both ligands (2.413 and 2.514) are within the optimal 1-3 range. Again, a minor difference.
4. **HBD:** Ligand A (0) is preferable to Ligand B (1). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (5) is better than Ligand B (3). Lower HBA is generally preferred.
6. **QED:** Ligand A (0.788) has a much better QED score than Ligand B (0.375), indicating a more drug-like profile.
7. **DILI:** Ligand A (9.926) has a significantly lower DILI risk than Ligand B (19.504). This is a crucial advantage.
8. **BBB:** Not a primary concern for ADRB2 (cardiovascular target), but Ligand A (94.649) has a higher BBB penetration than Ligand B (68.05).
9. **Caco-2:** Ligand A (-4.486) is slightly better than Ligand B (-4.264), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-2.762) is slightly better than Ligand B (-2.343).
11. **hERG:** Ligand A (0.884) is better than Ligand B (0.27). Lower hERG inhibition is crucial for avoiding cardiotoxicity.
12. **Cl_mic:** Ligand A (55.438) has lower microsomal clearance than Ligand B (61.98), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-1.464) has a better in vitro half-life than Ligand B (-2.602).
14. **Pgp:** Ligand A (0.327) is better than Ligand B (0.152), indicating lower P-gp efflux.
15. **Binding Affinity:** Both ligands have the same binding affinity (-6.4 kcal/mol).
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across almost all ADME-Tox properties. The most significant advantages are the substantially lower DILI risk, better QED score, lower HBD/HBA, and better metabolic stability (lower Cl_mic and better t1/2). While both have the same binding affinity, the superior ADME profile of Ligand A makes it a much more promising drug candidate. The GPCR-specific priorities (logP, Pgp, TPSA) are all satisfied well by Ligand A.
**Output:**
1
2025-04-17 18:32:50,567 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (353.463 Da) is within the ideal range (200-500 Da), while Ligand B (382.848 Da) is also acceptable. No clear advantage here.
2. **TPSA:** Both ligands (A: 79.9, B: 79.21) are below 140, which is good for oral absorption, and are reasonably well-suited for a peripherally acting GPCR like ADRB2.
3. **logP:** Ligand A (0.284) is quite low, potentially hindering membrane permeability. Ligand B (3.12) is within the optimal range (1-3). This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable.
5. **HBA:** Ligand A (5) and Ligand B (6) are both acceptable.
6. **QED:** Both ligands have good QED scores (A: 0.687, B: 0.804), indicating drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (12.796) has a much lower DILI risk than Ligand B (63.978). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (39.511) has a low BBB penetration, which is fine for a cardiovascular target. Ligand B (74.641) has higher BBB penetration, which isn't particularly beneficial for ADRB2.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-5.556) is slightly better than Ligand B (-4.568).
10. **Solubility:** Ligand A (-0.656) has better solubility than Ligand B (-5.168).
11. **hERG:** Both ligands have low hERG inhibition risk (A: 0.245, B: 0.376).
12. **Cl_mic:** Ligand A (-8.834) has significantly lower microsomal clearance, indicating better metabolic stability, than Ligand B (69.414). This is a substantial advantage for Ligand A.
13. **t1/2:** Ligand A (28.757) has a longer in vitro half-life than Ligand B (-25.95). This is a significant advantage for Ligand A.
14. **Pgp:** Both ligands have very low Pgp efflux liability (A: 0.004, B: 0.242).
15. **Binding Affinity:** Ligand B (-7.0) has a slightly better binding affinity than Ligand A (-6.1). However, the difference is less than 1.5 kcal/mol.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity), Ligand B initially appears attractive due to its better logP and binding affinity. However, the significantly higher DILI risk, poorer metabolic stability (higher Cl_mic), shorter half-life, and lower solubility of Ligand B are major drawbacks. Ligand A, while having a lower logP, compensates with a much better safety profile (DILI), metabolic stability, and solubility. The affinity difference isn't large enough to overcome these ADME/Tox deficiencies. For a cardiovascular target, CNS penetration is not a priority, and Ligand A's lower BBB is acceptable.
Therefore, Ligand A is the more viable drug candidate.
Output:
1
2025-04-17 18:32:50,567 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (366.49 and 355.47 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Both ligands (87.32 and 82.62) are below the 140 A^2 threshold for good oral absorption, which is good.
3. **logP:** Ligand A (1.35) is optimal, while Ligand B (3.014) is at the higher end of the optimal range. Ligand A is slightly preferred.
4. **HBD:** Both ligands have 2 HBD, which is within the acceptable limit of <=5.
5. **HBA:** Ligand A has 5 HBA, and Ligand B has 7. Both are within the acceptable limit of <=10, but Ligand A is slightly preferred.
6. **QED:** Ligand A (0.821) has a better QED score than Ligand B (0.749), indicating better overall drug-likeness.
7. **DILI:** Ligand A (56.77) has a significantly lower DILI risk than Ligand B (84.45). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (55.64) and Ligand B (68.79) are both relatively low, but Ligand B is slightly better. BBB is a consideration for GPCRs, but less crucial for ADRB2 (a cardiovascular target) than for CNS targets.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.202 and -5.389), which is unusual and suggests very poor permeability. This is a significant concern for both.
10. **Solubility:** Both ligands have negative solubility values (-3.345 and -3.715), indicating very poor aqueous solubility. This is a significant concern for both.
11. **hERG:** Ligand A (0.213) has a much lower hERG risk than Ligand B (0.737). This is a major advantage for Ligand A.
12. **Cl_mic:** Ligand A (24.91) has a lower microsomal clearance than Ligand B (39.30), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-25.38) has a negative in vitro half-life, which is concerning. Ligand B (0.981) is also very short, but positive.
14. **Pgp:** Ligand A (0.078) has lower P-gp efflux liability than Ligand B (0.108), which is favorable.
15. **Binding Affinity:** Ligand B (-6.1 kcal/mol) has a slightly better binding affinity than Ligand A (-5.9 kcal/mol), but the difference is small.
**Overall Assessment:**
Despite the slightly better binding affinity of Ligand B, Ligand A is the more promising candidate. Ligand A has significantly better DILI and hERG profiles, a better QED score, and lower microsomal clearance. While both have poor Caco-2 and solubility, the safety and pharmacokinetic advantages of Ligand A outweigh the small difference in binding affinity. The negative half-life for Ligand A is concerning, but can be addressed through structural modifications.
Output:
1
2025-04-17 18:32:50,568 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, priorities are: affinity, logP, Pgp, TPSA, and BBB.
* **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (352.454) and Ligand B (346.431) are comparable.
* **TPSA:** Both are good, below the 140 A^2 threshold for oral absorption. Ligand A (78.09) is slightly higher than Ligand B (69.89), but both are acceptable.
* **logP:** Both are within the optimal range (1-3). Ligand A (2.696) is slightly higher than Ligand B (1.142).
* **H-Bond Donors/Acceptors:** Ligand A (2 HBD, 3 HBA) and Ligand B (0 HBD, 5 HBA) are both reasonable.
* **QED:** Both have good QED scores (A: 0.706, B: 0.821), indicating good drug-like properties.
* **DILI:** Ligand B (14.773) has a significantly lower DILI risk than Ligand A (49.593), which is a major advantage.
* **BBB:** Ligand B (80.845) has a better BBB penetration score than Ligand A (66.615). While not a CNS target, some BBB penetration can be beneficial for distribution.
* **Caco-2 Permeability:** Both have negative values, indicating poor permeability. Ligand A (-4.556) is slightly worse than Ligand B (-4.71).
* **Aqueous Solubility:** Both have negative values, indicating poor solubility. Ligand A (-2.834) is slightly better than Ligand B (-0.771).
* **hERG:** Both have low hERG inhibition risk (A: 0.627, B: 0.429).
* **Microsomal Clearance:** Ligand B (-1.976) has significantly lower (better) microsomal clearance than Ligand A (55.857), suggesting better metabolic stability.
* **In vitro Half-Life:** Ligand A (17.477) has a longer half-life than Ligand B (0.814).
* **P-gp Efflux:** Both have low P-gp efflux liability (A: 0.128, B: 0.042).
* **Binding Affinity:** Ligand A (-7.4 kcal/mol) has a better binding affinity than Ligand B (-6.7 kcal/mol). This is a 0.7 kcal/mol difference, which is significant.
**Overall Assessment:**
Ligand A has a better binding affinity and longer half-life. However, Ligand B excels in safety (DILI), metabolic stability (Cl_mic), and BBB penetration. The lower DILI risk and improved metabolic stability of Ligand B are crucial advantages, especially for a cardiovascular target where long-term safety is paramount. While the affinity difference is notable, it can potentially be addressed through further optimization. The poor Caco-2 and solubility for both ligands are concerning and would need to be addressed, but are less critical than the safety and metabolic stability profiles.
**Output:**
0
2025-04-17 18:32:50,568 - INFO - Batch 45 complete. Total preferences: 720
2025-04-17 18:32:50,568 - INFO - Processing batch 46/512...
2025-04-17 18:33:40,352 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [373.4, 61.44, 2.72, 2, 3, 0.801, 32.377, 73.866, -5.021, -3.562, 0.441, 5.011, -13.637, 0.033, -6.1]
**Ligand B:** [343.402, 53.82, 2.408, 1, 3, 0.906, 53.276, 85.537, -4.681, -3.328, 0.508, -2.887, -8.7, 0.093, -8.0]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (343.4) is slightly lower, which *could* be beneficial for permeability, but both are acceptable.
2. **TPSA:** Ligand A (61.44) is higher than Ligand B (53.82). Both are below the 140 threshold for oral absorption, but closer to the 90 threshold for CNS targets. Ligand B is preferable here.
3. **logP:** Both are in the optimal range (1-3). Ligand A (2.72) is slightly higher, but both are good.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1), but both are within the acceptable limit of 5.
5. **HBA:** Both have 3 HBA, which is good.
6. **QED:** Ligand B (0.906) has a better QED score than Ligand A (0.801), suggesting a more drug-like profile.
7. **DILI:** Ligand A (32.377) has a significantly lower DILI risk than Ligand B (53.276). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (85.537) has a higher BBB penetration percentile than Ligand A (73.866). For a cardiovascular GPCR, BBB isn't *critical*, but higher is generally better.
9. **Caco-2:** Ligand A (-5.021) has a lower Caco-2 permeability than Ligand B (-4.681). Both are negative values, which is unusual and suggests poor permeability. Ligand B is slightly better.
10. **Solubility:** Ligand A (-3.562) and Ligand B (-3.328) both have poor solubility.
11. **hERG:** Ligand A (0.441) has a lower hERG inhibition liability than Ligand B (0.508), which is preferable.
12. **Cl_mic:** Ligand B (-2.887) has a lower (better) microsomal clearance than Ligand A (5.011), indicating better metabolic stability.
13. **t1/2:** Ligand B (-8.7) has a longer in vitro half-life than Ligand A (-13.637).
14. **Pgp:** Ligand A (0.033) has lower P-gp efflux liability than Ligand B (0.093), which is preferable.
15. **Affinity:** Ligand B (-8.0) has a significantly stronger binding affinity than Ligand A (-6.1). This is a substantial advantage, potentially outweighing some ADME drawbacks.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, Pgp, TPSA, and affinity. Ligand B excels in affinity and has slightly better TPSA and Pgp. Ligand A has a much better DILI score.
**Overall Assessment:**
The stronger binding affinity of Ligand B (-8.0 kcal/mol vs -6.1 kcal/mol) is a significant advantage for a GPCR target. While Ligand A has a better DILI profile, the difference isn't drastic enough to overcome the substantial potency advantage of Ligand B. The improved BBB penetration of Ligand B is a minor benefit. The metabolic stability of Ligand B is also better.
Therefore, I would choose Ligand B.
Output:
0
2025-04-17 18:33:40,352 - INFO - Here's my reasoning and final output for the ligand preference:
**Reasoning:**
We are targeting ADRB2, a GPCR, so the priorities are logP, Pgp, TPSA, affinity, and BBB. Let's compare Ligand A and Ligand B across these and other important parameters.
* **Molecular Weight:** Both ligands are within the ideal range (348-365 Da).
* **TPSA:** Ligand A (58.64) is significantly better than Ligand B (76.46). Lower TPSA is preferred for better absorption, especially for a GPCR.
* **logP:** Both are good (2.14 and 1.49), falling within the 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability.
* **H-Bond Donors/Acceptors:** Both have acceptable HBD (1) and HBA (4/5) counts.
* **QED:** Both ligands have similar, good QED scores (0.777 and 0.79).
* **DILI:** Ligand A (21.6) has a much lower DILI risk than Ligand B (33.8). This is a significant advantage.
* **BBB:** Ligand B (82.4) has a better BBB penetration score than Ligand A (61.8), but BBB isn't a primary concern for ADRB2 which is primarily cardiovascular.
* **Caco-2:** Both are negative, indicating poor permeability.
* **Solubility:** Both are negative, indicating poor solubility.
* **hERG:** Both have low hERG inhibition liability, which is good.
* **Cl_mic:** Ligand B (21.3) has a lower microsomal clearance, suggesting better metabolic stability than Ligand A (29.2).
* **t1/2:** Ligand B (16.1) has a significantly longer in vitro half-life than Ligand A (0.43). This is a major advantage.
* **Pgp:** Ligand A (0.06) has a much lower P-gp efflux liability than Ligand B (0.115). Lower P-gp is desirable for better bioavailability.
* **Binding Affinity:** Ligand B (-6.4 kcal/mol) has a slightly better binding affinity than Ligand A (-5.3 kcal/mol). This 1.1 kcal/mol difference is significant, and could potentially offset some of the ADME drawbacks.
**Overall Assessment:**
While Ligand B has a better binding affinity and longer half-life, Ligand A is superior in terms of TPSA, DILI risk, and P-gp efflux. The lower TPSA and DILI risk of Ligand A are particularly important. The slightly better affinity of Ligand B doesn't outweigh the more favorable ADME profile of Ligand A, especially considering the cardiovascular target.
Output:
1
2025-04-17 18:33:40,352 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (340.379 and 360.445 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand B (49.85) is significantly better than Ligand A (75.69). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (2.749 and 2.195), falling within the optimal 1-3 range. Ligand B is slightly lower, which could be beneficial for solubility.
4. **HBD:** Ligand A has 1 HBD, while Ligand B has 0. Both are acceptable.
5. **HBA:** Ligand A has 4 HBA, Ligand B has 3. Both are within the acceptable limit of 10.
6. **QED:** Both ligands have similar QED values (0.671 and 0.699), indicating good drug-likeness.
7. **DILI:** Ligand B (11.128) has a *much* lower DILI risk than Ligand A (64.521). This is a major advantage for Ligand B.
8. **BBB:** Ligand B (96.084) has a much higher BBB penetration score than Ligand A (45.715). While ADRB2 is cardiovascular, some CNS effects are possible with beta-blockers, and higher BBB penetration could translate to off-target effects. However, in this case, it's less critical than other factors.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.955 and -4.291), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand B (-1.76) is better than Ligand A (-3.221), indicating higher aqueous solubility.
11. **hERG:** Ligand A (0.236) has a slightly lower hERG risk than Ligand B (0.684), which is good.
12. **Cl_mic:** Ligand B (33.714) has a lower microsomal clearance than Ligand A (42.281), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-5.148) has a negative half-life, which is highly unusual and concerning. Ligand A (27.368) has a reasonable half-life.
14. **Pgp:** Ligand A (0.131) has a lower P-gp efflux liability than Ligand B (0.097), which is preferable.
15. **Affinity:** Both ligands have very similar and excellent binding affinities (-6.3 and -6.0 kcal/mol). The difference is negligible.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. While both ligands have good affinity and logP, Ligand B excels in TPSA and has a lower Pgp efflux liability. The significantly lower DILI risk of Ligand B is a major plus. The negative half-life for Ligand B is a severe drawback, however.
**Overall Assessment:**
Despite the unusual negative half-life for Ligand B, the significant advantages in DILI risk, TPSA, solubility, and metabolic stability outweigh the slightly better hERG and Pgp profile of Ligand A. The negative half-life is a red flag that would require further investigation, but the overall profile of Ligand B is more promising.
Output:
0
2025-04-17 18:33:40,352 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (366.491 Da and 347.375 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (76.26) is significantly better than Ligand B (119.24). For a GPCR, keeping TPSA under 140 is good for oral absorption, and A is comfortably within that range while B is approaching the upper limit.
**3. logP:** Ligand B (1.573) is better than Ligand A (0.548). Both are within the 1-3 range, but B is closer to the optimal range. A is a bit low and could suffer from permeability issues.
**4. H-Bond Donors:** Ligand A (0) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
**5. H-Bond Acceptors:** Both ligands have 7 HBA, which is acceptable.
**6. QED:** Both ligands have similar QED values (0.772 and 0.744), indicating good drug-likeness.
**7. DILI:** Ligand A (43.389) has a much lower DILI risk than Ligand B (85.498). This is a significant advantage for A.
**8. BBB:** Ligand A (71.035) has a better BBB penetration score than Ligand B (50.523). While ADRB2 isn't a CNS target, some peripheral exposure can be beneficial, and minimizing off-target effects is always good.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.944) is slightly better than Ligand B (-5.086), but both are concerning.
**10. Aqueous Solubility:** Both ligands have negative solubility values, which is also unusual and indicates poor solubility. Ligand A (-2.165) is slightly better than Ligand B (-2.791).
**11. hERG Inhibition:** Ligand A (0.721) has a lower hERG inhibition liability than Ligand B (0.201), which is a significant safety advantage.
**12. Microsomal Clearance:** Ligand B (42.035) has slightly lower microsomal clearance than Ligand A (39.795), suggesting better metabolic stability.
**13. In vitro Half-Life:** Ligand A (-40.324) has a substantially longer in vitro half-life than Ligand B (-22.173). This is a major advantage for A, potentially allowing for less frequent dosing.
**14. P-gp Efflux:** Ligand A (0.196) has lower P-gp efflux liability than Ligand B (0.02), which is a positive for bioavailability.
**15. Binding Affinity:** Ligand B (-7.5 kcal/mol) has a slightly better binding affinity than Ligand A (-6.7 kcal/mol). This 0.8 kcal/mol difference is notable, but not overwhelmingly so.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity) and the general drug-like properties, Ligand A is the more promising candidate. While Ligand B has slightly better affinity and metabolic stability, Ligand A excels in crucial areas like DILI risk, BBB penetration, hERG inhibition, and *especially* in vitro half-life. The lower TPSA of Ligand A is also a significant advantage. The solubility and Caco-2 values are concerning for both, but the other advantages of A outweigh the slight edge B has in affinity.
Output:
1
2025-04-17 18:33:40,353 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (353.413 and 347.375 Da). No clear advantage.
2. **TPSA:** Ligand A (63.13) is significantly better than Ligand B (104.08). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (2.241) is optimal. Ligand B (-0.138) is quite low, potentially hindering membrane permeability. This is a significant negative for Ligand B.
4. **HBD:** Both ligands have acceptable HBD counts (2 and 1, respectively).
5. **HBA:** Ligand B (6) is higher than Ligand A (3). While both are within acceptable limits, lower is generally preferred.
6. **QED:** Both have similar, good QED values (0.753 and 0.747).
7. **DILI:** Ligand A (24.544) has a much lower DILI risk than Ligand B (61.38). This is a substantial advantage for Ligand A.
8. **BBB:** Not a primary concern for a cardiovascular target, but Ligand A (82.047) is better than Ligand B (38.426).
9. **Caco-2:** Both are negative, indicating poor permeability. However, the scale is not specified, so we can't interpret the absolute values.
10. **Solubility:** Both have negative solubility values, indicating poor solubility. Again, the scale is unknown.
11. **hERG:** Both have very low hERG inhibition risk (0.242 and 0.108).
12. **Cl_mic:** Ligand B (-2.545) has a *negative* clearance, which is biologically implausible and likely an error in the data. Ligand A (24.145) is reasonable.
13. **t1/2:** Ligand A (-11.541) has a negative half-life, which is also biologically implausible. Ligand B (0) is better, but still very short.
14. **Pgp:** Both have low Pgp efflux liability (0.084 and 0.018).
15. **Affinity:** Ligand A (-8.8 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.7 kcal/mol). This is a >1.1 kcal/mol difference, which is substantial.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand A excels in all of these areas. While BBB isn't critical, Ligand A is still better.
**Overall Assessment:**
Ligand A is clearly superior. It has a better logP, lower TPSA, significantly lower DILI risk, and a much stronger binding affinity. The negative values for clearance and half-life for both compounds are concerning and suggest data errors, but the magnitude of the difference in affinity and the other favorable properties of Ligand A outweigh these concerns. Ligand B's low logP and high DILI risk are significant drawbacks.
Output:
1
2025-04-17 18:33:40,353 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (351.491 Da and 342.451 Da) fall within the ideal range of 200-500 Da. No significant difference here.
**2. TPSA:** Ligand A (78.51) is significantly better than Ligand B (117.43). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is approaching the upper limit for good oral absorption (140).
**3. logP:** Both ligands have good logP values (1.694 and 2.068), falling within the optimal 1-3 range. No clear advantage.
**4. H-Bond Donors:** Ligand A (2) is preferable to Ligand B (4). Fewer HBDs generally improve permeability.
**5. H-Bond Acceptors:** Ligand A (3) is preferable to Ligand B (7). Fewer HBAs generally improve permeability.
**6. QED:** Both ligands have similar QED values (0.685 and 0.634), indicating good drug-likeness.
**7. DILI:** Ligand A (11.245) has a much lower DILI risk than Ligand B (56.146). This is a significant advantage for Ligand A.
**8. BBB:** Ligand A (70.841) has a higher BBB penetration percentile than Ligand B (56.223). While ADRB2 is a cardiovascular target, some CNS exposure can occur, and higher BBB penetration is generally favorable.
**9. Caco-2 Permeability:** Ligand A (-4.877) is better than Ligand B (-5.765). Higher values indicate better intestinal absorption.
**10. Aqueous Solubility:** Ligand A (-1.916) is better than Ligand B (-3.126). Higher aqueous solubility is generally preferred.
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (0.304 and 0.463). No significant difference.
**12. Microsomal Clearance:** Ligand A (4.094) has lower microsomal clearance than Ligand B (9.72). Lower clearance indicates better metabolic stability.
**13. In vitro Half-Life:** Ligand A (-15.72) has a longer in vitro half-life than Ligand B (-7.249). This is a significant advantage for Ligand A.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.043 and 0.014). No significant difference.
**15. Binding Affinity:** Ligand A (-6.5 kcal/mol) has slightly weaker binding affinity than Ligand B (-6.0 kcal/mol). However, the other ADME properties of Ligand A are significantly better.
**Overall Assessment:**
Ligand A is clearly superior. While Ligand B has slightly better binding affinity, Ligand A excels in almost all crucial ADME properties, including lower DILI risk, better permeability (TPSA, Caco-2), better solubility, better metabolic stability (Cl_mic, t1/2), and higher BBB penetration. The difference in binding affinity is not large enough to outweigh the substantial advantages of Ligand A in terms of safety and pharmacokinetic properties. Given the GPCR target class, the balance of TPSA, logP, Pgp, and affinity favors Ligand A.
Output:
1
2025-04-17 18:33:40,353 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (338.411 and 347.35 Da) are within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (74.66) is significantly better than Ligand B (100.09). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (2.756) is optimal, while Ligand B (-0.14) is quite low. This is a major concern for Ligand B, as it may struggle with membrane permeability.
4. **HBD:** Both ligands have acceptable HBD counts (1 and 2, respectively), well below the threshold of 5.
5. **HBA:** Both ligands have the same HBA count (5), which is acceptable (<=10).
6. **QED:** Ligand B (0.786) has a slightly better QED score than Ligand A (0.408), suggesting a more generally drug-like profile. However, QED isn't the most critical factor here.
7. **DILI:** Both ligands have similar and acceptable DILI risk (43.234 and 42.885 percentile).
8. **BBB:** Ligand A (61.923) has a better BBB penetration score than Ligand B (48.003), though neither is particularly high. This isn't a primary concern for a cardiovascular target.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.413 and -5.087). This is unusual and suggests poor permeability, but the values are similar.
10. **Solubility:** Ligand A (-1.844) has slightly better solubility than Ligand B (-2.51), but both are poor.
11. **hERG:** Ligand A (0.919) has a lower hERG risk than Ligand B (0.31), which is a significant advantage.
12. **Cl_mic:** Ligand A (14.446) has a much better (lower) microsomal clearance than Ligand B (-11.252). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (12.879) has a significantly longer in vitro half-life than Ligand B (-37.323), which is a major advantage.
14. **Pgp:** Ligand A (0.874) has a lower P-gp efflux liability than Ligand B (0.023), which is favorable.
15. **Binding Affinity:** Ligand B (-8.4 kcal/mol) has a substantially stronger binding affinity than Ligand A (-6.3 kcal/mol). This is a significant advantage for Ligand B.
**GPCR-Specific Priorities & Overall Assessment:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B excels in affinity, but its very low logP is a major red flag. Poor logP often translates to poor permeability and bioavailability, even with high affinity. Ligand A has a more balanced profile, with a good logP, better metabolic stability (Cl_mic and t1/2), lower hERG risk, and better Pgp efflux. While its affinity is lower, the combination of improved ADME properties makes it a more promising starting point for optimization. The negative Caco-2 values for both are concerning, but the other issues with Ligand B are more critical.
**Output:**
1
2025-04-17 18:33:40,353 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Step-by-step comparison:**
1. **MW:** Both ligands (348.399 and 366.439 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand B (87.9) is significantly better than Ligand A (108.64). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (1.157 and 0.838), falling within the optimal 1-3 range. Ligand B is slightly lower, which could be marginally better for solubility.
4. **HBD:** Ligand A has 3 HBD, while Ligand B has 0. Lower HBD is generally preferred for permeability, giving a slight edge to Ligand B.
5. **HBA:** Both have 5 HBA, which is acceptable.
6. **QED:** Both ligands have good QED scores (0.611 and 0.774), indicating good drug-like properties. Ligand B is better.
7. **DILI:** Ligand A (35.673) has a much lower DILI risk than Ligand B (52.54). This is a significant advantage for Ligand A.
8. **BBB:** Ligand B (69.678) has a higher BBB penetration score than Ligand A (44.009). While not critical for a cardiovascular target, it's a slight positive for Ligand B.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and problematic. However, the magnitude is similar (-5.129 vs -4.786).
10. **Solubility:** Both have negative solubility values, which is also concerning. Again, the values are similar (-1.924 vs -1.532).
11. **hERG:** Both ligands have very low hERG inhibition risk (0.149 and 0.177). No significant difference.
12. **Cl_mic:** Ligand A (-2.775) has a much lower (better) microsomal clearance than Ligand B (6.077). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand B (48.25) has a significantly longer in vitro half-life than Ligand A (16.542). This is a substantial advantage for Ligand B.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.063 and 0.125). No significant difference.
15. **Binding Affinity:** Ligand A (-7.7) has a slightly better binding affinity than Ligand B (-5.7). This is a 2 kcal/mol difference, which is substantial and can outweigh some ADME drawbacks.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize affinity, logP, TPSA, and Pgp. Ligand A has a significantly better affinity. Ligand B has a better TPSA and slightly better logP. Pgp is similar for both.
**Overall Assessment:**
Ligand A has a superior binding affinity and a much lower DILI risk and better metabolic stability (lower Cl_mic). While Ligand B has a longer half-life and slightly better TPSA, the affinity and safety profile of Ligand A are more critical. The negative Caco-2 and solubility values are concerning for both, but the potency and safety advantages of Ligand A are more compelling.
Output:
1
2025-04-17 18:33:40,353 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (368.5 and 342.4 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (81.75) is better than Ligand B (93.09). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (-0.621) is slightly lower than the optimal 1-3 range, while Ligand B (0.795) is closer. This favors Ligand B slightly.
4. **HBD:** Both ligands have 2 HBD, which is within the acceptable limit of 5.
5. **HBA:** Both ligands have 5 HBA, which is within the acceptable limit of 10.
6. **QED:** Ligand B (0.812) has a better QED score than Ligand A (0.626), indicating a more drug-like profile.
7. **DILI:** Ligand A (12.641) has a significantly lower DILI risk than Ligand B (52.695). This is a major advantage for Ligand A.
8. **BBB:** Not a high priority for a cardiovascular target. Ligand A (58.821) is slightly better than Ligand B (43.893), but this is not a deciding factor.
9. **Caco-2:** Both ligands have similar negative Caco-2 values (-5.624 and -5.261), suggesting poor permeability. This is a concern for both.
10. **Solubility:** Both ligands have similar negative solubility values (-1.856 and -2.016), indicating poor aqueous solubility. This is a concern for both.
11. **hERG:** Ligand A (0.071) has a lower hERG risk than Ligand B (0.219), which is a positive.
12. **Cl_mic:** Ligand A (-13.614) has a much lower (better) microsomal clearance than Ligand B (34.54). This indicates better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (3.142) has a slightly longer in vitro half-life than Ligand B (-13.441), which is favorable.
14. **Pgp:** Both ligands have very low Pgp efflux values (0.005 and 0.036), which is good.
15. **Binding Affinity:** Ligand B (-6.9) has a slightly better binding affinity than Ligand A (-6.1), a 0.8 kcal/mol difference.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, and affinity are important. Ligand B has a better logP and affinity, while Ligand A has a better TPSA. However, the substantial advantages of Ligand A in terms of DILI risk and metabolic stability (Cl_mic, t1/2) outweigh the slightly better affinity of Ligand B. The poor Caco-2 and solubility are concerning for both, but can be addressed with formulation strategies. The lower hERG risk for Ligand A is also a significant benefit.
**Conclusion:**
Considering the balance of properties, particularly the significantly lower DILI and better metabolic stability of Ligand A, I believe it is the more promising drug candidate.
Output:
1
2025-04-17 18:33:40,353 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (360.405 and 348.462 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (87.46) is higher than Ligand B (58.2). For a cardiovascular GPCR, TPSA is moderately important. Ligand B is preferable due to its lower TPSA, suggesting better potential for membrane permeability.
**3. logP:** Ligand B (2.426) is closer to the optimal 1-3 range than Ligand A (0.991). Ligand A is a bit low, potentially hindering permeability. Ligand B is favored.
**4. H-Bond Donors:** Both have 2 HBD, which is within the acceptable limit of 5. No difference.
**5. H-Bond Acceptors:** Ligand A has 5 HBA, and Ligand B has 2. Ligand B is preferable due to the lower HBA count, which generally improves permeability.
**6. QED:** Ligand B (0.802) has a better QED score than Ligand A (0.651), indicating a more drug-like profile.
**7. DILI Risk:** Ligand A (19) has a significantly lower DILI risk than Ligand B (25.979). This is a substantial advantage for Ligand A.
**8. BBB Penetration:** Ligand B (83.482) shows significantly better BBB penetration than Ligand A (58.24). While this target is cardiovascular, some brain exposure is possible, and higher BBB is generally favorable.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.896 and -4.758), which is unusual and suggests poor permeability. However, these values are very close.
**10. Aqueous Solubility:** Ligand A (-0.976) has slightly better aqueous solubility than Ligand B (-3.914).
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (0.56 and 0.416). No significant difference.
**12. Microsomal Clearance:** Ligand B (5.519) has much lower microsomal clearance than Ligand A (14.776), indicating better metabolic stability.
**13. In vitro Half-Life:** Ligand A (-22.445) has a longer in vitro half-life than Ligand B (15.2). This is a positive for Ligand A.
**14. P-gp Efflux:** Ligand A (0.051) has lower P-gp efflux than Ligand B (0.184), which is desirable for better bioavailability.
**15. Binding Affinity:** Ligand B (-6.7) has a slightly better binding affinity than Ligand A (-6.3). While the difference is not huge, it's still a factor.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity), Ligand B appears stronger in terms of logP, TPSA, and affinity. However, Ligand A has a significantly lower DILI risk, better solubility, lower P-gp efflux, and a longer half-life. The DILI risk is a critical factor, and the longer half-life is also beneficial. While Ligand B has better BBB penetration, this is less crucial for a cardiovascular target. The slightly better affinity of Ligand B is outweighed by the safety and PK advantages of Ligand A.
Output:
1
2025-04-17 18:33:40,353 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [349.395, 119.47 , -0.952, 1. , 8. , 0.657, 61.109, 82.513, -5.269, -2.19 , 0.115, 21.584, 0.455, 0.042, -6.2 ]
**Ligand B:** [351.466, 47.36 , 3.503, 0. , 4. , 0.674, 14.541, 95.696, -4.616, -2.798, 0.715, 64.883, 3.356, 0.458, -5.7 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). A is 349.4, B is 351.5. No significant difference.
2. **TPSA:** A (119.47) is slightly higher than B (47.36). B is significantly better, falling well below the 140 threshold for good absorption and is more favorable for GPCRs.
3. **logP:** A (-0.952) is low, potentially hindering permeation. B (3.503) is excellent, within the optimal 1-3 range. This is a major advantage for B.
4. **HBD:** A (1) is good. B (0) is also good. No strong preference.
5. **HBA:** A (8) is acceptable. B (4) is excellent. Lower HBA generally improves permeability.
6. **QED:** Both are good (A: 0.657, B: 0.674). No significant difference.
7. **DILI:** A (61.109) is moderate risk. B (14.541) is very low risk. B is significantly better here.
8. **BBB:** A (82.513) is good. B (95.696) is excellent. Given ADRB2 is a cardiovascular target, BBB isn't *critical*, but higher is still preferred.
9. **Caco-2:** Both are negative, indicating poor permeability. A (-5.269) is worse than B (-4.616).
10. **Solubility:** Both are negative, indicating poor solubility. A (-2.19) is worse than B (-2.798).
11. **hERG:** A (0.115) is very low risk. B (0.715) is slightly higher, but still acceptable.
12. **Cl_mic:** A (21.584) is lower, indicating better metabolic stability. B (64.883) is higher, suggesting faster clearance. A is better here.
13. **t1/2:** A (0.455) is very short. B (3.356) is better, but still relatively short.
14. **Pgp:** A (0.042) is very low efflux, excellent. B (0.458) is moderate efflux. A is better.
15. **Affinity:** A (-6.2) is slightly better than B (-5.7), a difference of 0.5 kcal/mol.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, and Pgp efflux are particularly important. Ligand B excels in logP and TPSA, and has a better BBB score. While A has a slightly better binding affinity and lower Pgp efflux, the significantly better ADME properties of B, especially the logP and TPSA, outweigh this small difference in binding. The lower DILI risk for B is also a substantial benefit.
**Conclusion:**
Considering the balance of properties and the priorities for a GPCR target, Ligand B is the more promising drug candidate.
0
2025-04-17 18:33:40,353 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (467.136 Da) is within the ideal range, while Ligand B (360.361 Da) is towards the lower end but still acceptable.
2. **TPSA:** Ligand A (46.92) is excellent, well below the 140 threshold. Ligand B (130.39) is higher, but still reasonable for a peripherally acting GPCR target.
3. **logP:** Ligand A (4.504) is slightly high, potentially leading to solubility issues or off-target interactions. Ligand B (-0.969) is quite low, which could hinder membrane permeability.
4. **HBD:** Ligand A (1) is good. Ligand B (4) is acceptable, but higher HBDs can sometimes affect permeability.
5. **HBA:** Ligand A (3) is good. Ligand B (4) is acceptable.
6. **QED:** Ligand A (0.617) is good, indicating drug-likeness. Ligand B (0.465) is lower, suggesting a less optimal drug-like profile.
7. **DILI:** Ligand A (71.694) has a moderate DILI risk. Ligand B (37.728) has a significantly lower DILI risk, which is a major advantage.
8. **BBB:** Both ligands have reasonable BBB penetration (Ligand A: 84.219, Ligand B: 70.027). Since ADRB2 is not exclusively a CNS target, this isn't a deciding factor, but A is better.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-4.714) has very poor predicted solubility, a significant drawback. Ligand B (-1.86) is also poor, but better than A.
11. **hERG:** Ligand A (0.786) has a low hERG risk, which is excellent. Ligand B (0.088) also has a low hERG risk.
12. **Cl_mic:** Ligand A (64.827) has moderate clearance. Ligand B (-4.007) has *negative* clearance, which is not physically possible and indicates a prediction issue, but suggests very high metabolic stability.
13. **t1/2:** Ligand A (110.702) has a good in vitro half-life. Ligand B (-16.43) has a negative half-life, indicating a prediction issue.
14. **Pgp:** Ligand A (0.814) has moderate P-gp efflux. Ligand B (0.012) has very low P-gp efflux, which is beneficial.
15. **Affinity:** Ligand A (-7.3 kcal/mol) has a slightly better binding affinity than Ligand B (-6.9 kcal/mol). This 1.5 kcal/mol difference is significant.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has a better affinity and TPSA, but Ligand B has a better logP and Pgp. The negative values for clearance and half-life for Ligand B are concerning and likely indicate prediction errors. The DILI risk for Ligand B is much lower.
**Overall Assessment:**
While Ligand A has a slightly better affinity, the combination of Ligand B's lower DILI risk, better Pgp profile, and more reasonable logP, despite the questionable predicted metabolic stability, makes it the more promising candidate. The poor solubility of Ligand A is a major concern that would require significant medicinal chemistry effort to address. The negative values for Ligand B's clearance and half-life are flags, but the overall profile is more favorable.
Output:
0
2025-04-17 18:33:40,354 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (358.463 and 360.483 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (69.64 and 69.04) are below the 140 A^2 threshold for good oral absorption, and acceptable for a non-CNS GPCR target like ADRB2. Very similar.
3. **logP:** Both ligands (2.513 and 2.664) are within the optimal 1-3 range. Again, no major distinction.
4. **HBD:** Ligand A has 2 HBD, Ligand B has 1. Both are acceptable (<=5).
5. **HBA:** Ligand A has 4 HBA, Ligand B has 6. Both are acceptable (<=10), but Ligand A is slightly better.
6. **QED:** Ligand A (0.834) has a higher QED than Ligand B (0.769), suggesting a more drug-like profile. This is a positive for Ligand A.
7. **DILI:** Ligand A (54.556) has a lower DILI risk than Ligand B (70.027). This is a significant advantage for Ligand A, as lower DILI is crucial.
8. **BBB:** BBB is less critical for ADRB2 (a cardiovascular target). Ligand A (64.793) is slightly higher than Ligand B (54.285), but the difference isn't substantial.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-5.083) is slightly better than Ligand B (-5.222), but both are concerning.
10. **Solubility:** Both have negative solubility values, indicating very poor aqueous solubility. Ligand A (-3.277) is slightly better than Ligand B (-3.626), but both are problematic.
11. **hERG:** Both ligands have low hERG inhibition liability (0.579 and 0.221), which is good. Ligand B is better.
12. **Cl_mic:** Ligand B (73.273) has a higher microsomal clearance than Ligand A (43.617), indicating faster metabolism and potentially lower *in vivo* exposure. This favors Ligand A.
13. **t1/2:** Ligand A (34.829) has a longer *in vitro* half-life than Ligand B (-4.645). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.54) has lower P-gp efflux liability than Ligand B (0.303), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand B (-6.8 kcal/mol) has a slightly stronger binding affinity than Ligand A (-5.9 kcal/mol). This is a 0.9 kcal/mol difference, which is substantial.
**Overall Assessment:**
While Ligand B has a slightly better binding affinity, Ligand A demonstrates a significantly better ADME-Tox profile. Specifically, the lower DILI risk, better metabolic stability (lower Cl_mic, longer t1/2), and lower P-gp efflux are crucial advantages. The solubility and Caco-2 values are poor for both, but Ligand A is marginally better. For a cardiovascular target, metabolic stability and safety (DILI) are paramount. The 0.9 kcal/mol difference in binding affinity can potentially be overcome with further optimization of Ligand A, while addressing the solubility and permeability issues.
Output:
1
2025-04-17 18:33:40,354 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (345.407 and 352.391 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (115.99) is slightly higher than Ligand B (106.79). Both are below the 140 threshold for good absorption, but closer to the 90 threshold for CNS targets (less relevant for ADRB2, a cardiovascular target). Ligand B is slightly preferred.
3. **logP:** Ligand A (1.26) is within the optimal 1-3 range. Ligand B (0.037) is very low, potentially hindering permeation. This is a significant advantage for Ligand A.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 5 HBA, while Ligand B has 7. Both are acceptable (<=10), but Ligand A is slightly preferred.
6. **QED:** Ligand B (0.738) has a better QED score than Ligand A (0.475), indicating a more drug-like profile. This is a notable advantage for Ligand B.
7. **DILI:** Ligand B (61.07) has a higher DILI risk than Ligand A (47.693), but both are acceptable (<60 is good). Ligand A is preferred.
8. **BBB:** Ligand B (79.566) has a higher BBB penetration percentile than Ligand A (56.883). While ADRB2 is not a CNS target, some peripheral BBB penetration can be beneficial.
9. **Caco-2:** Both ligands have very similar, and poor, Caco-2 permeability (-5.148 and -5.1). This is a weakness for both.
10. **Solubility:** Both ligands have very similar, and poor, aqueous solubility (-1.598 and -1.516). This is a weakness for both.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.162 and 0.065). No clear advantage.
12. **Cl_mic:** Ligand A (9.08) has a lower microsomal clearance than Ligand B (11.32), suggesting better metabolic stability. This is an advantage for Ligand A.
13. **t1/2:** Ligand B (10.276) has a significantly longer in vitro half-life than Ligand A (1.01). This is a major advantage for Ligand B.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.012 and 0.014). No clear advantage.
15. **Binding Affinity:** Ligand B (-6.7 kcal/mol) has a slightly better binding affinity than Ligand A (-6.6 kcal/mol). While the difference is small, it's still a positive for Ligand B.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are crucial. Ligand A has a much better logP. Ligand B has a slightly better affinity and BBB penetration. The longer half-life of Ligand B is also a significant benefit. The QED score is also better for Ligand B.
**Overall Assessment:**
While Ligand A has advantages in logP, DILI, and metabolic stability, Ligand B's superior QED, binding affinity, and significantly longer half-life outweigh these benefits. The slightly higher DILI risk of Ligand B is acceptable. The poor Caco-2 and solubility are concerns for both, but can be addressed with formulation strategies.
Output:
0
2025-04-17 18:33:40,354 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [360.445, 58.64, 2.446, 1, 3, 0.792, 35.75, 90.074, -4.292, -2.982, 0.608, 37.257, -23.003, 0.108, -5.3]**
**Ligand B: [370.559, 66.48, 3.056, 1, 3, 0.781, 28.655, 77.162, -4.986, -3.733, 0.677, 63.547, -47.138, 0.212, -6.1]**
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). A (360.445) is slightly preferred.
2. **TPSA:** Both are reasonably low, but A (58.64) is better than B (66.48), falling comfortably under the 140 A^2 threshold for oral absorption.
3. **logP:** Both are within the optimal range (1-3), A (2.446) and B (3.056). B is slightly higher, which could potentially lead to off-target effects, but is still acceptable.
4. **H-Bond Donors:** Both have 1 HBD, which is good.
5. **H-Bond Acceptors:** Both have 3 HBA, which is good.
6. **QED:** Both are above 0.5 (A: 0.792, B: 0.781), indicating good drug-like properties.
7. **DILI:** A (35.75) is better than B (28.655) - lower is better, indicating lower liver injury risk.
8. **BBB:** A (90.074) is significantly better than B (77.162). While ADRB2 isn't exclusively a CNS target, some peripheral effects are mediated by CNS pathways, and higher BBB penetration can be beneficial.
9. **Caco-2:** Both are negative, indicating poor permeability. A (-4.292) is slightly better than B (-4.986).
10. **Solubility:** Both are negative, indicating poor solubility. A (-2.982) is slightly better than B (-3.733).
11. **hERG:** Both are low (A: 0.608, B: 0.677), indicating low cardiotoxicity risk.
12. **Cl_mic:** A (37.257) is better than B (63.547) - lower is better, indicating better metabolic stability.
13. **t1/2:** A (-23.003) is significantly better than B (-47.138) - a more negative value indicates a longer half-life.
14. **Pgp:** Both are very low (A: 0.108, B: 0.212), indicating low P-glycoprotein efflux.
15. **Binding Affinity:** B (-6.1) is significantly better than A (-5.3). This is a substantial difference in potency.
**GPCR-Specific Considerations:** For GPCRs, logP, TPSA, Pgp, and affinity are key. While B has a slightly higher logP, the significantly improved binding affinity (-6.1 vs -5.3) is a major advantage. The better BBB penetration of A is a plus, but the potency difference is substantial enough to outweigh this. Metabolic stability (Cl_mic and t1/2) also favor A.
**Overall Assessment:**
Ligand B has a significantly better binding affinity, which is the most critical factor for a GPCR target. While Ligand A has advantages in DILI, BBB, metabolic stability, and half-life, the potency difference is large enough to make Ligand B the more promising candidate. The slightly higher logP of B is manageable.
Output:
0
2025-04-17 18:33:40,354 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (342.443) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both ligands have TPSA values below 140, indicating good potential for oral absorption. Ligand A (66.4) is slightly higher than Ligand B (63.25), but both are acceptable.
3. **logP:** Both ligands have logP values within the optimal range (1-3). Ligand A (2.181) is slightly better than Ligand B (3.463), as higher logP can sometimes lead to off-target effects.
4. **HBD:** Ligand A (0) has fewer H-bond donors than Ligand B (2), which is preferable for permeability.
5. **HBA:** Ligand A (4) has fewer H-bond acceptors than Ligand B (5), again favoring permeability.
6. **QED:** Both ligands have QED values above 0.5, indicating good drug-likeness. Ligand A (0.844) is slightly better than Ligand B (0.73).
7. **DILI:** Both ligands have acceptable DILI risk, but Ligand A (38.542) is significantly lower than Ligand B (52.152), indicating a lower risk of liver injury.
8. **BBB:** Both ligands have high BBB penetration (Ligand A: 86.933, Ligand B: 83.249). This is less critical for ADRB2 (a cardiovascular target) but still a positive attribute.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and indicates poor permeability. This is a significant concern for both.
10. **Solubility:** Both ligands have negative solubility values, indicating poor aqueous solubility. This is a significant concern for both.
11. **hERG:** Both ligands have very low hERG inhibition risk (Ligand A: 0.257, Ligand B: 0.564), which is excellent.
12. **Cl_mic:** Ligand A (44.163) has lower microsomal clearance than Ligand B (53.182), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-19.249) has a negative half-life, which is concerning. Ligand B (33.907) has a positive half-life, which is much better.
14. **Pgp:** Both ligands have low P-gp efflux liability (Ligand A: 0.264, Ligand B: 0.277).
15. **Affinity:** Ligand B (-7.1) has slightly better binding affinity than Ligand A (-7.8). However, the difference is relatively small (0.7 kcal/mol).
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Both ligands perform reasonably well on these parameters. The slightly better logP and lower TPSA of Ligand A are advantageous. However, the significantly better half-life of Ligand B is a major factor.
**Overall Assessment:**
Despite the slightly better affinity of Ligand B, Ligand A has a more favorable profile overall. It has a lower molecular weight, better QED, lower DILI risk, and lower microsomal clearance. The negative half-life of Ligand A is a significant concern, but the other advantages outweigh this drawback. The poor Caco-2 and solubility for both compounds are concerning and would require further optimization.
Output:
1
2025-04-17 18:33:40,355 - INFO - Batch 46 complete. Total preferences: 736
2025-04-17 18:33:40,355 - INFO - Processing batch 47/512...
2025-04-17 18:34:30,017 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (354.397 and 350.503 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands have a TPSA of 49.85, which is well below the 140 A^2 threshold for good oral absorption and suitable for a peripherally acting GPCR like ADRB2.
3. **logP:** Both ligands have logP values within the optimal range (2.122 and 2.687). Ligand B is slightly more lipophilic, which could be beneficial for membrane permeability, but not dramatically so.
4. **HBD:** Both ligands have 0 H-bond donors, which is acceptable.
5. **HBA:** Both ligands have 3 H-bond acceptors, also acceptable.
6. **QED:** Both ligands have very similar QED scores (0.754 and 0.74), indicating good drug-likeness.
7. **DILI:** Ligand A has a DILI risk of 23.536%, while Ligand B has 16.247%. Ligand B is clearly better here, indicating a lower risk of liver injury. This is a significant advantage.
8. **BBB:** Both ligands have high BBB penetration (96.006% and 88.29%). However, since ADRB2 is not a primary CNS target, this is less critical.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.305 and -4.345). This is unusual and suggests poor permeability. It's difficult to interpret without further information, but it's a potential concern for both.
10. **Solubility:** Both ligands have negative solubility values (-2.091 and -1.838). Again, this is concerning and suggests poor aqueous solubility. This could hinder bioavailability.
11. **hERG:** Both ligands have low hERG inhibition liability (0.744% and 0.428%). Ligand B is slightly better, indicating a lower risk of cardiotoxicity, which is crucial for a cardiovascular target.
12. **Cl_mic:** Ligand A has a lower microsomal clearance (7.409 mL/min/kg) than Ligand B (58.52 mL/min/kg). This suggests better metabolic stability for Ligand A, which is a significant advantage.
13. **t1/2:** Ligand A has a longer in vitro half-life (5.936 hours) than Ligand B (-7.705 hours). The negative value for Ligand B is highly unusual and suggests very rapid degradation. This is a major drawback for Ligand B.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.098% and 0.267%).
15. **Binding Affinity:** Ligand B has a slightly better binding affinity (-7.0 kcal/mol) than Ligand A (-5.0 kcal/mol). This is a 2.0 kcal/mol difference, which is substantial. However, the other ADME properties are more concerning for Ligand B.
**Overall Assessment:**
While Ligand B has a better binding affinity and slightly better hERG and DILI profiles, its significantly higher microsomal clearance and *extremely* short half-life are major red flags. The negative values for Caco-2 and solubility are also concerning. Ligand A, while having a weaker binding affinity, demonstrates much better metabolic stability (lower Cl_mic, longer t1/2) and similar, though problematic, solubility and permeability. For a GPCR target, metabolic stability is critical for maintaining therapeutic concentrations.
Therefore, I favor Ligand A.
Output:
1
2025-04-17 18:34:30,018 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.431 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (108.29) is slightly higher than Ligand B (96.11). Both are below the 140 threshold for oral absorption, but B is closer to the preferred <90 for GPCRs.
3. **logP:** Both ligands (1.435 and 1.095) are within the optimal 1-3 range. Ligand B is slightly lower, which could potentially impact permeability, but it's not a major concern.
4. **HBD:** Both ligands have 3 H-bond donors, which is acceptable.
5. **HBA:** Ligand A has 3 H-bond acceptors, while Ligand B has 4. Both are within the acceptable limit of 10.
6. **QED:** Both ligands have good QED scores (0.678 and 0.718), indicating good drug-like properties.
7. **DILI:** Ligand A (38.116) has a slightly higher DILI risk than Ligand B (31.369), but both are below the concerning threshold of 60.
8. **BBB:** Ligand B (58.24) has a significantly higher BBB penetration percentile than Ligand A (41.644). While ADRB2 isn't exclusively a CNS target, some CNS exposure could be beneficial or at least not detrimental, and higher BBB is generally favorable.
9. **Caco-2:** Ligand A (-5.363) and Ligand B (-5.512) both have negative Caco-2 permeability values, which is unusual and suggests very poor permeability. This is a significant drawback for both.
10. **Solubility:** Ligand A (-3.487) has slightly worse solubility than Ligand B (-2.152), both are quite poor.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.136 and 0.129). This is excellent.
12. **Cl_mic:** Ligand A (-9.76) has a much lower (better) microsomal clearance than Ligand B (0.24). This indicates better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (-18.182) has a much longer in vitro half-life than Ligand B (5.155). This is a significant advantage for Ligand A.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.023 and 0.01). This is good.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-5.7 and -5.2 kcal/mol). The difference is not substantial enough to be a deciding factor.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B has a slightly better TPSA and significantly better BBB penetration. However, Ligand A has much better metabolic stability (Cl_mic) and a longer half-life, which are also crucial for *in vivo* efficacy. The Caco-2 values are concerning for both.
**Overall Assessment:**
Despite the poor Caco-2 values, Ligand A's superior metabolic stability and longer half-life are more critical for a successful drug candidate. The slightly better BBB penetration of Ligand B is not enough to outweigh these advantages, especially considering the ADRB2 is not strictly a CNS target.
Output:
1
2025-04-17 18:34:30,018 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [343.427, 71.41 , 1.154, 1. , 4. , 0.788, 23.497, 75.107, -4.79 , -2.121, 0.388, 40.467, -9.133, 0.082, -6. ]**
**Ligand B: [355.435, 116.76 , -0.546, 4. , 5. , 0.414, 17.449, 53.548, -5.482, -1.253, 0.056, 13.467, 2.138, 0.003, -5.9 ]**
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). A (343.427) is slightly preferred.
2. **TPSA:** Ligand A (71.41) is significantly better than Ligand B (116.76). ADRB2 is a cardiovascular target, so CNS penetration isn't critical, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (1.154) is within the optimal range. Ligand B (-0.546) is a bit low, potentially hindering permeability.
4. **H-Bond Donors:** Both have acceptable HBD counts (A: 1, B: 4).
5. **H-Bond Acceptors:** Both have acceptable HBA counts (A: 4, B: 5).
6. **QED:** Ligand A (0.788) has a better QED score than Ligand B (0.414), indicating a more drug-like profile.
7. **DILI:** Ligand A (23.497) has a much lower DILI risk than Ligand B (17.449). This is a significant advantage.
8. **BBB:** Ligand A (75.107) has better BBB penetration than Ligand B (53.548), though this isn't a primary concern for a cardiovascular target.
9. **Caco-2:** Ligand A (-4.79) and Ligand B (-5.482) are both poor.
10. **Solubility:** Ligand A (-2.121) is slightly better than Ligand B (-1.253).
11. **hERG:** Both ligands have very low hERG risk (A: 0.388, B: 0.056).
12. **Cl_mic:** Ligand A (40.467) has a better microsomal clearance profile than Ligand B (13.467), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-9.133) has a much longer in vitro half-life than Ligand B (2.138).
14. **Pgp:** Ligand A (0.082) has lower P-gp efflux than Ligand B (0.003).
15. **Binding Affinity:** Both ligands have excellent binding affinity (-6.0 and -5.9 kcal/mol respectively), with Ligand A being slightly better.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical ADME-Tox properties. It has a better QED score, lower DILI risk, better metabolic stability (lower Cl_mic, longer t1/2), lower P-gp efflux, and slightly better binding affinity. While both have poor Caco-2 permeability, the other advantages of Ligand A make it the more promising candidate. The slightly better logP and TPSA of Ligand A also contribute to its overall superiority.
Output:
1
2025-04-17 18:34:30,018 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [361.793, 108.06 , 2.725, 3. , 6. , 0.659, 98.953, 51.725, -5.006, -5.073, 0.472, 48.258, 49.414, 0.056, -6.2 ]
**Ligand B:** [350.459, 71.78 , 2.939, 1. , 4. , 0.782, 35.867, 75.184, -4.329, -3.216, 0.754, 34.701, 12.229, 0.391, -7.2 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (350.459) is slightly lower, which is generally favorable for permeability, but both are acceptable.
2. **TPSA:** Ligand A (108.06) is higher than Ligand B (71.78). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is still preferred for better absorption. Ligand B is significantly better here.
3. **logP:** Both are within the optimal range (1-3). Ligand B (2.939) is slightly higher, which could potentially lead to some off-target interactions, but is still reasonable.
4. **HBD:** Ligand A (3) is higher than Ligand B (1). Lower is generally better for permeability. Ligand B is better.
5. **HBA:** Ligand A (6) is higher than Ligand B (4). Again, lower is preferred. Ligand B is better.
6. **QED:** Both are above 0.5, indicating good drug-likeness. Ligand B (0.782) is slightly better.
7. **DILI:** Ligand A (98.953) has a very high DILI risk, which is a major red flag. Ligand B (35.867) has a low DILI risk, a significant advantage.
8. **BBB:** Ligand B (75.184) has a better BBB penetration percentile than Ligand A (51.725). While ADRB2 isn't exclusively a CNS target, some CNS exposure can occur, and higher BBB is generally desirable.
9. **Caco-2:** Ligand A (-5.006) and Ligand B (-4.329) are both negative, indicating poor permeability.
10. **Solubility:** Ligand A (-5.073) and Ligand B (-3.216) are both negative, indicating poor solubility.
11. **hERG:** Ligand A (0.472) has a lower hERG risk than Ligand B (0.754), which is good.
12. **Cl_mic:** Ligand B (34.701) has a lower microsomal clearance, suggesting better metabolic stability, which is favorable.
13. **t1/2:** Ligand A (49.414) has a longer in vitro half-life than Ligand B (12.229), which is desirable.
14. **Pgp:** Ligand A (0.056) has lower P-gp efflux, which is better for bioavailability. Ligand B (0.391) has moderate P-gp efflux.
15. **Affinity:** Ligand B (-7.2) has a significantly stronger binding affinity than Ligand A (-6.2). This is a substantial advantage, potentially outweighing some of the ADME drawbacks.
**Overall Assessment:**
Ligand A has a concerningly high DILI risk and a lower binding affinity. While it has better P-gp and half-life, the DILI risk is a major issue. Ligand B has a much better safety profile (DILI), better TPSA, HBD/HBA, QED, BBB, and a significantly stronger binding affinity. Although its permeability and solubility are also poor, the strong binding affinity and improved safety profile make it the more promising candidate.
**Output:**
0
2025-04-17 18:34:30,018 - INFO - Here's my reasoning and final output for the ligand preference:
**Reasoning:**
We are targeting ADRB2, a GPCR, so the priorities are logP, Pgp, TPSA, affinity, and BBB. Let's break down the comparison:
1. **MW:** Both ligands are within the acceptable range (200-500 Da). Ligand A (366.809) is slightly higher than Ligand B (344.434), but this isn't a major concern.
2. **TPSA:** Ligand A (127.24) is higher than Ligand B (50.28). While both are under 140, Ligand B's lower TPSA is significantly better for permeability, a key factor for GPCR ligands.
3. **logP:** Ligand A (1.208) is within the optimal range, while Ligand B (3.863) is approaching the upper limit. This could lead to solubility issues for Ligand B, but it might also enhance binding.
4. **HBD/HBA:** Ligand A has 2 HBD and 7 HBA, while Ligand B has 1 HBD and 5 HBA. Both are acceptable, but Ligand B has fewer, potentially improving permeability.
5. **QED:** Ligand A (0.813) has a better QED score than Ligand B (0.7), indicating better overall drug-likeness.
6. **DILI:** Ligand B (29.546) has a much lower DILI risk than Ligand A (71.229). This is a significant advantage for Ligand B.
7. **BBB:** Ligand B (85.498) has a much higher BBB penetration score than Ligand A (66.576). While not strictly essential for ADRB2 (cardiovascular target), it's a positive attribute.
8. **Caco-2:** Ligand A (-5.11) and Ligand B (-4.457) are both negative, which is unusual and suggests poor permeability. However, the scale isn't clearly defined, so this is hard to interpret.
9. **Solubility:** Ligand A (-2.61) has better solubility than Ligand B (-4.594). This is a benefit for Ligand A.
10. **hERG:** Ligand A (0.277) has a lower hERG risk than Ligand B (0.937). This is a significant advantage for Ligand A.
11. **Cl_mic:** Ligand B (98.331) has a much higher microsomal clearance than Ligand A (33.43). This means Ligand A is more metabolically stable.
12. **t1/2:** Ligand A (18.612) has a longer half-life than Ligand B (14.324). This is a positive for Ligand A.
13. **Pgp:** Ligand A (0.016) has much lower P-gp efflux than Ligand B (0.646). This is a significant advantage for Ligand A.
14. **Affinity:** Ligand A (-7.4 kcal/mol) has a slightly better binding affinity than Ligand B (-5.8 kcal/mol), a difference of 1.6 kcal/mol, which is significant.
**Overall Assessment:**
Ligand A has a better binding affinity, better metabolic stability (lower Cl_mic, longer t1/2), lower P-gp efflux, and lower hERG risk. However, Ligand B has a much lower DILI risk, better BBB penetration, and a lower TPSA. The affinity difference is substantial, and the metabolic stability and P-gp advantages of Ligand A are important. While Ligand B's lower TPSA is attractive, the binding affinity is a critical factor for GPCRs. Considering the balance of these factors, and prioritizing affinity, metabolic stability, and safety, Ligand A appears to be the more promising candidate.
**Output:**
1
2025-04-17 18:34:30,018 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for their potential as drug candidates targeting the ADRB2, a cardiovascular GPCR. Therefore, we prioritize logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB.
Let's compare the ligands property by property:
1. **MW:** Both ligands (346.36 & 356.46 Da) fall within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (86.71) is better than Ligand B (95.94), being closer to the <140 threshold for good absorption and more favorable for GPCRs.
3. **logP:** Both ligands have good logP values (1.61 & 1.09), falling within the 1-3 range. Ligand A is slightly better.
4. **HBD/HBA:** Both have acceptable HBD (2) and Ligand B has a higher HBA (5 vs 3), which could slightly hinder permeability.
5. **QED:** Ligand A (0.867) has a significantly better QED score than Ligand B (0.666), indicating better overall drug-likeness.
6. **DILI:** Ligand B (21.6%) has a much lower DILI risk than Ligand A (61.1%). This is a significant advantage for Ligand B.
7. **BBB:** Ligand A (61.96%) has a better BBB penetration than Ligand B (40.17%). While not a primary concern for a cardiovascular target, it's a slight positive for A.
8. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-5.05) is slightly better.
9. **Solubility:** Both are negative, indicating poor solubility. Ligand A (-2.89) is slightly better.
10. **hERG:** Both have very low hERG inhibition risk (0.083 & 0.196).
11. **Cl_mic:** Ligand A (0.373) has significantly lower microsomal clearance than Ligand B (60.66), suggesting better metabolic stability.
12. **t1/2:** Ligand A (3.49) has a positive half-life, while Ligand B (-19.39) has a negative half-life, which is concerning.
13. **Pgp:** Both have low Pgp efflux liability (0.01 & 0.044).
14. **Binding Affinity:** Ligand A (-6.7 kcal/mol) has a slightly better binding affinity than Ligand B (-5.7 kcal/mol). While the difference is not huge, it's enough to consider.
**Overall Assessment:**
Ligand A has a better overall profile, with better QED, TPSA, Cl_mic, t1/2, and binding affinity. However, Ligand B has a significantly lower DILI risk. Considering the cardiovascular target, metabolic stability (Cl_mic and t1/2) and binding affinity are critical. The slightly better affinity of Ligand A, combined with its superior metabolic properties, outweighs the higher DILI risk, especially given that the DILI risk is still within an acceptable range.
**Output:**
1
2025-04-17 18:34:30,018 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's break down the comparison of Ligand A and Ligand B based on the provided parameters and the GPCR-specific priorities (logP, Pgp, TPSA, and affinity being key).
1. **Molecular Weight:** Both ligands (353.413 and 379.551 Da) fall comfortably within the ideal 200-500 Da range.
2. **TPSA:** Both ligands have a TPSA of 62.3, which is good for oral absorption and doesn't raise immediate concerns for a non-CNS target like ADRB2.
3. **logP:** Ligand A (2.855) is better than Ligand B (3.78). While both are within the optimal 1-3 range, Ligand B is approaching the upper limit, potentially hinting at solubility issues.
4. **H-Bond Donors/Acceptors:** Ligand A (1 HBD, 3 HBA) is slightly more favorable than Ligand B (1 HBD, 5 HBA). Lower counts generally improve permeability.
5. **QED:** Both ligands have similar QED values (0.885 and 0.804), indicating good drug-like properties.
6. **DILI:** Ligand A (32.571) has a significantly lower DILI risk than Ligand B (53.625). This is a substantial advantage.
7. **BBB:** This is less critical for ADRB2, but Ligand A (91.431) has a much higher BBB penetration percentile than Ligand B (51.881).
8. **Caco-2 Permeability:** Both are negative, indicating poor permeability. Ligand A (-4.552) is slightly better than Ligand B (-4.777).
9. **Aqueous Solubility:** Both ligands have negative solubility values, indicating poor solubility. Ligand A (-2.546) is slightly better than Ligand B (-3.017).
10. **hERG Inhibition:** Ligand A (0.512) shows a lower hERG inhibition liability than Ligand B (0.392), which is a positive.
11. **Microsomal Clearance:** Ligand A (7.441) has a lower microsomal clearance than Ligand B (58.984), indicating better metabolic stability. This is a significant advantage.
12. **In vitro Half-Life:** Ligand A (-19.35) has a much longer in vitro half-life than Ligand B (30.139).
13. **P-gp Efflux:** Ligand A (0.093) has lower P-gp efflux liability than Ligand B (0.222), which is beneficial for bioavailability.
14. **Binding Affinity:** Ligand B (-7.8 kcal/mol) has a stronger binding affinity than Ligand A (-6.8 kcal/mol). This is a 1.0 kcal/mol difference, which is a substantial advantage.
**Overall Assessment:**
While Ligand B boasts a better binding affinity, Ligand A demonstrates a significantly superior ADMET profile. The lower DILI risk, better metabolic stability (lower Cl_mic, longer t1/2), lower P-gp efflux, and lower hERG inhibition are crucial factors for a viable drug candidate. The slight improvements in solubility and permeability also contribute to its favorability. The 1.0 kcal/mol difference in binding affinity, while notable, can potentially be optimized in later stages of drug development. Given the importance of a balanced profile, especially regarding safety and pharmacokinetic properties, Ligand A is the more promising candidate.
**Output:**
1
2025-04-17 18:34:30,018 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
The target is ADRB2, a GPCR. Therefore, I will prioritize logP, Pgp, TPSA, and affinity, alongside general drug-like properties.
* **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (353.394) is slightly higher than Ligand B (344.455), but both are acceptable.
* **TPSA:** Ligand B (62.55) is significantly better than Ligand A (110.52). Lower TPSA generally improves permeability, crucial for GPCR ligands.
* **logP:** Both ligands have good logP values (A: 1.348, B: 3.077) within the optimal range of 1-3. Ligand B is slightly higher, which could be beneficial for membrane permeability.
* **H-Bond Donors/Acceptors:** Ligand A has 3 HBD and 4 HBA, while Ligand B has 1 HBD and 3 HBA. Both are within acceptable limits, but Ligand B's lower count is slightly preferable for permeability.
* **QED:** Both ligands have good QED scores (A: 0.613, B: 0.807), indicating good drug-like properties. Ligand B is better.
* **DILI:** Ligand B (27.065) has a much lower DILI risk than Ligand A (43.66), a significant advantage.
* **BBB:** Both have reasonable BBB penetration (A: 75.572, B: 81.776). Ligand B is slightly better.
* **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
* **Solubility:** Both have negative solubility values, which is also unusual. Again, the scale is not specified.
* **hERG:** Both have low hERG inhibition risk (A: 0.662, B: 0.652), which is good.
* **Microsomal Clearance:** Ligand B (74.633) has a higher microsomal clearance than Ligand A (51.216), indicating faster metabolism and potentially lower exposure. This is a drawback for Ligand B.
* **In vitro Half-Life:** Ligand B (77.174) has a significantly longer in vitro half-life than Ligand A (-24.258). This is a major advantage for Ligand B.
* **P-gp Efflux:** Both have low P-gp efflux liability (A: 0.114, B: 0.442).
* **Binding Affinity:** Ligand A (-7.4 kcal/mol) has a significantly stronger binding affinity than Ligand B (-2.7 kcal/mol). This is a substantial advantage for Ligand A.
**Overall Assessment:**
While Ligand A has a much better binding affinity, Ligand B excels in several key ADME properties, including lower DILI risk, better TPSA, better QED, and a significantly longer half-life. The difference in binding affinity is substantial (4.7 kcal/mol), but the improved ADME profile of Ligand B is compelling, especially considering the importance of these properties for a GPCR target. The negative values for Caco-2 and Solubility are concerning for both, but the other advantages of Ligand B outweigh this concern.
**Output:**
0
2025-04-17 18:34:30,018 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.435 and 348.447 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (91.31) is better than Ligand B (94.56), both are under the 140 threshold for oral absorption, but closer to the upper limit.
3. **logP:** Ligand B (0.705) is slightly better than Ligand A (0.374). Both are a bit low, potentially hindering membrane permeability, but Ligand B is closer to the optimal 1-3 range.
4. **HBD:** Ligand A (1) is better than Ligand B (3). Lower HBD generally improves permeability.
5. **HBA:** Both ligands have 5 HBA, which is acceptable.
6. **QED:** Ligand A (0.615) is slightly better than Ligand B (0.571), indicating a slightly more drug-like profile.
7. **DILI:** Ligand A (27.104) is significantly better than Ligand B (13.843). Lower DILI risk is crucial.
8. **BBB:** Ligand A (68.864) is significantly better than Ligand B (23.924). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant for off-target effects and a higher BBB percentile is generally preferred.
9. **Caco-2:** Ligand A (-4.789) is better than Ligand B (-5.457). Both are negative, indicating poor permeability.
10. **Solubility:** Ligand A (-1.603) is better than Ligand B (-0.69). Both are poor, but A is slightly better.
11. **hERG:** Both ligands (0.199 and 0.193) have very similar, low hERG inhibition liability, which is good.
12. **Cl_mic:** Ligand B (-4.141) is significantly better than Ligand A (26.214). Lower clearance indicates better metabolic stability.
13. **t1/2:** Ligand B (52.156) is significantly better than Ligand A (-14.922). A longer half-life is desirable.
14. **Pgp:** Both ligands (0.015 and 0.017) have very similar, low P-gp efflux liability, which is good.
15. **Binding Affinity:** Both ligands (-5.9 and -5.7 kcal/mol) have comparable, strong binding affinities. The difference is less than 1.5 kcal/mol, so it doesn't heavily sway the decision.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B has a better logP and significantly better metabolic stability (Cl_mic and t1/2). However, Ligand A has a better TPSA, DILI, and BBB. The DILI and BBB differences are substantial.
**Overall Assessment:**
While Ligand B has advantages in metabolic stability, the significantly lower DILI risk and better BBB penetration of Ligand A are more important. The slightly better logP of Ligand B is not enough to overcome these critical safety and pharmacokinetic advantages. The binding affinity is similar, so potency isn't a differentiating factor.
Output:
1
2025-04-17 18:34:30,019 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [343.427, 84.23, 2.335, 2, 4, 0.756, 60.295, 54.595, -4.888, -3.84, 0.157, 81.631, 32.34, 0.288, -6.3]
**Ligand B:** [356.375, 103.4, -0.092, 1, 7, 0.542, 71.152, 55.603, -4.867, -1.345, 0.079, 27.896, -12.119, 0.039, -7.9]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). A (343.427) is slightly preferred.
2. **TPSA:** A (84.23) is better than B (103.4), both are acceptable for a non-CNS GPCR target like ADRB2, but lower is generally better for permeability.
3. **logP:** A (2.335) is optimal. B (-0.092) is quite low, potentially hindering membrane permeability and absorption. This is a significant drawback.
4. **HBD:** Both are acceptable (A: 2, B: 1).
5. **HBA:** Both are acceptable (A: 4, B: 7).
6. **QED:** A (0.756) is better than B (0.542), indicating a more drug-like profile.
7. **DILI:** B (71.152) has a higher DILI risk than A (60.295). A is better.
8. **BBB:** Both are similar (A: 54.595, B: 55.603) and not a major concern for ADRB2, which is not a CNS target.
9. **Caco-2:** Both are similar and negative, indicating poor permeability.
10. **Solubility:** A (-3.84) is better than B (-1.345), indicating better aqueous solubility.
11. **hERG:** A (0.157) is better than B (0.079), indicating lower hERG inhibition liability.
12. **Cl_mic:** B (27.896) has significantly lower microsomal clearance than A (81.631), suggesting better metabolic stability. This is a strong point for B.
13. **t1/2:** A (32.34) has a positive in vitro half-life, while B (-12.119) has a negative value, suggesting very rapid metabolism. A is much better.
14. **Pgp:** A (0.288) is better than B (0.039), indicating lower P-gp efflux.
15. **Affinity:** B (-7.9) has a significantly stronger binding affinity than A (-6.3) - a difference of 1.6 kcal/mol. This is a substantial advantage.
**GPCR-specific priorities:** For ADRB2, logP, TPSA, Pgp, and affinity are key. While B has a better affinity, its very low logP is a major concern. The lower metabolic stability (lower Cl_mic) is a plus, but the poor logP is likely to severely limit bioavailability. A has a better balance of properties, with acceptable logP, better solubility, and a more favorable ADME profile overall. The affinity difference, while significant, might be overcome with further optimization of Ligand A.
**Conclusion:**
Considering the balance of properties and the GPCR-specific priorities, Ligand A is the more promising drug candidate.
**Output:**
1
2025-04-17 18:34:30,019 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (350.409 Da and 353.463 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (50.36) is significantly better than Ligand B (96.53). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is quite high, potentially hindering absorption.
**3. logP:** Ligand A (4.412) is higher than Ligand B (0.729). While a logP of 4.412 is approaching the upper limit, it's still acceptable. Ligand B's logP is quite low, which could severely limit its ability to cross cell membranes.
**4. H-Bond Donors:** Ligand A (2) is preferable to Ligand B (3). Lower HBD generally improves permeability.
**5. H-Bond Acceptors:** Ligand A (2) and Ligand B (4) are both acceptable, but A is slightly better.
**6. QED:** Ligand A (0.845) is significantly better than Ligand B (0.629), indicating a more drug-like profile.
**7. DILI Risk:** Ligand B (20.822) has a much lower DILI risk than Ligand A (43.738), which is a significant advantage.
**8. BBB Penetration:** Ligand A (92.168) shows excellent BBB penetration, while Ligand B (45.754) is much lower. While ADRB2 is primarily a cardiovascular target, some CNS effects are possible with certain ligands, and higher BBB penetration isn't necessarily a negative.
**9. Caco-2 Permeability:** Ligand A (-4.637) is better than Ligand B (-5.284). Both are negative, which is unusual and requires further investigation, but A is slightly less negative.
**10. Aqueous Solubility:** Ligand A (-4.937) is better than Ligand B (-1.574). Both are poor, but B is better.
**11. hERG Inhibition:** Ligand A (0.7) is better than Ligand B (0.116). Lower hERG inhibition is crucial for avoiding cardiotoxicity, making A more favorable.
**12. Microsomal Clearance:** Ligand B (21.32) has lower clearance than Ligand A (33.787), suggesting better metabolic stability.
**13. In vitro Half-Life:** Ligand A (43.058) has a longer half-life than Ligand B (5.135), which is desirable for less frequent dosing.
**14. P-gp Efflux:** Ligand A (0.151) is better than Ligand B (0.012). Lower P-gp efflux is preferred.
**15. Binding Affinity:** Ligand B (-6.8) has a significantly stronger binding affinity than Ligand A (-9.0). This is a substantial advantage, potentially outweighing some of the ADME drawbacks.
**Overall Assessment:**
Ligand B has a significantly better binding affinity, a lower DILI risk, and better metabolic stability. However, its low logP and high TPSA are major concerns for permeability and absorption. Ligand A has better ADME properties overall (TPSA, logP, QED, BBB, hERG, P-gp), but its binding affinity is considerably weaker.
Given the GPCR-specific priorities (logP, TPSA, affinity), the strong affinity of Ligand B is a major driver. While the ADME properties are suboptimal, medicinal chemistry optimization could potentially address these issues without sacrificing potency. The poor ADME properties of Ligand A are less easily rectified, and the weaker binding affinity makes it less likely to be a successful candidate even with optimization.
Output:
0
2025-04-17 18:34:30,019 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (348.49 & 350.39 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (78.43) is significantly better than Ligand B (95.5). For a GPCR, keeping TPSA low is beneficial for permeability, and A is well under the 140 threshold. B is approaching the upper limit.
3. **logP:** Both ligands have acceptable logP values (1.85 & 2.51). Ligand B is slightly higher, which could potentially lead to some off-target interactions, but it's not a major concern.
4. **HBD:** Both have 3 HBD, which is within the acceptable range.
5. **HBA:** Ligand A has 3 HBA, while Ligand B has 4. Both are acceptable, but lower is generally preferred.
6. **QED:** Both ligands have good QED scores (0.557 & 0.671), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (7.45%) has a much lower DILI risk than Ligand B (35.48%). This is a significant advantage for Ligand A.
8. **BBB:** Ligand B (63.75%) has a better BBB penetration score than Ligand A (49.98%). While ADRB2 isn't *necessarily* a CNS target, some peripheral ADRB2 activity can be modulated by CNS effects, so this is a slight advantage for B.
9. **Caco-2:** Ligand A (-4.648) and Ligand B (-5.075) both have negative Caco-2 values. This is unusual and suggests poor permeability.
10. **Solubility:** Ligand A (-3.111) and Ligand B (-3.706) both have poor solubility.
11. **hERG:** Both ligands have very low hERG risk (0.144 & 0.14). This is excellent.
12. **Cl_mic:** Both ligands have similar microsomal clearance (36.45 & 35.06 mL/min/kg), suggesting comparable metabolic stability.
13. **t1/2:** Ligand B (-12.303) has a significantly longer in vitro half-life than Ligand A (-5.097). This is a notable advantage for B.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.023 & 0.026). This is good.
15. **Binding Affinity:** Ligand B (-7.1 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.8 kcal/mol). This is a substantial advantage, exceeding the 1.5 kcal/mol threshold.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, affinity, logP, TPSA, and Pgp are key. Ligand B excels in affinity, and has a reasonable logP and Pgp. While its TPSA is higher, the significantly improved affinity and half-life outweigh this drawback. The lower DILI risk of Ligand A is attractive, but the affinity difference is too large to ignore.
**Conclusion:**
Despite Ligand A's lower DILI risk, the significantly stronger binding affinity and longer half-life of Ligand B make it the more promising drug candidate. The affinity advantage is substantial enough to compensate for the slightly higher TPSA and DILI risk.
Output:
0
2025-04-17 18:34:30,019 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (351.491 and 352.519 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (87.3) is slightly higher than Ligand B (69.64). For a cardiovascular GPCR, TPSA is moderately important. Ligand B's lower TPSA is preferable, suggesting better potential for membrane permeability.
**3. logP:** Ligand A (1.737) and Ligand B (2.863) are both within the optimal 1-3 range. Ligand B is closer to the upper end, which could be slightly concerning for solubility, but still acceptable.
**4. H-Bond Donors:** Ligand A (3) and Ligand B (2) are both acceptable.
**5. H-Bond Acceptors:** Both ligands have 3 H-bond acceptors, which is within the desirable range.
**6. QED:** Both ligands have similar QED values (0.681 and 0.67), indicating good drug-likeness.
**7. DILI Risk:** Ligand A (24.893) has a significantly lower DILI risk than Ligand B (11.943). This is a major advantage for Ligand A.
**8. BBB Penetration:** Ligand B (59.093) shows better BBB penetration than Ligand A (48.352). While ADRB2 is a cardiovascular target, some CNS effects are possible with beta-blockers, and some degree of BBB penetration might be acceptable or even desirable for certain therapeutic strategies.
**9. Caco-2 Permeability:** Ligand A (-4.996) has slightly better Caco-2 permeability than Ligand B (-4.498), suggesting better intestinal absorption.
**10. Aqueous Solubility:** Ligand A (-3.157) is slightly more soluble than Ligand B (-2.915).
**11. hERG Inhibition:** Ligand A (0.072) has a very low hERG inhibition risk, significantly lower than Ligand B (0.602). This is a critical advantage for Ligand A, as hERG inhibition can lead to cardiotoxicity.
**12. Microsomal Clearance:** Ligand B (70.618) has a higher microsomal clearance than Ligand A (42.132), indicating faster metabolism and potentially lower *in vivo* exposure.
**13. In vitro Half-Life:** Ligand A (-5.997) has a significantly longer *in vitro* half-life than Ligand B (13.304). This is a major advantage for Ligand A, suggesting less frequent dosing.
**14. P-gp Efflux:** Ligand A (0.027) has much lower P-gp efflux liability than Ligand B (0.289), which is favorable for bioavailability.
**15. Binding Affinity:** Ligand A (-6.7) has a slightly stronger binding affinity than Ligand B (-4.9). This difference of 1.8 kcal/mol is substantial and can outweigh some minor ADME drawbacks.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity) and the general drug-like properties, Ligand A is the more promising candidate. The significantly lower DILI risk, hERG inhibition, and P-gp efflux, coupled with the better half-life, Caco-2 permeability, solubility and stronger binding affinity, outweigh Ligand B's slightly better BBB penetration and lower TPSA. The cardiovascular context makes minimizing cardiotoxicity (hERG) and maximizing metabolic stability (half-life, clearance) particularly important.
Output:
1
2025-04-17 18:34:30,019 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.363 and 346.515 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (135.17) is better than Ligand B (49.41). ADRB2 is not a CNS target, but lower TPSA generally improves permeability.
3. **logP:** Ligand B (3.668) is better than Ligand A (-0.369). A logP between 1-3 is optimal, and Ligand B is within this range, while Ligand A is significantly below, potentially hindering permeability.
4. **HBD:** Ligand A (3) is higher than Ligand B (1). Both are acceptable, but lower HBD is generally preferred for permeability.
5. **HBA:** Ligand A (8) is higher than Ligand B (2). Similar to HBD, lower HBA is generally preferred.
6. **QED:** Ligand B (0.79) is better than Ligand A (0.581). Higher QED indicates a more drug-like profile.
7. **DILI:** Ligand B (10.585) is *much* better than Ligand A (59.054). This is a critical difference. Lower DILI is essential for drug development.
8. **BBB:** Ligand B (81.737) is better than Ligand A (25.32). While not a CNS target, higher BBB can sometimes correlate with better overall distribution.
9. **Caco-2:** Ligand A (-5.479) is better than Ligand B (-4.632). Higher Caco-2 permeability is desirable.
10. **Solubility:** Ligand A (-2.084) is better than Ligand B (-3.955). Higher aqueous solubility is generally preferred.
11. **hERG:** Ligand A (0.023) is better than Ligand B (0.554). Lower hERG inhibition is crucial to avoid cardiotoxicity.
12. **Cl_mic:** Ligand A (13.875) is *much* better than Ligand B (80.69). Lower microsomal clearance indicates better metabolic stability.
13. **t1/2:** Ligand A (31.684) is better than Ligand B (-8.852). Longer half-life is generally desirable.
14. **Pgp:** Ligand A (0.07) is better than Ligand B (0.151). Lower P-gp efflux is preferred.
15. **Affinity:** Ligand B (-6.7) is slightly better than Ligand A (-6.2). This is a 1.5 kcal/mol difference, which is significant.
**Overall Assessment:**
Ligand B has a better logP, QED, and binding affinity. However, Ligand A significantly outperforms Ligand B in crucial ADMET properties: DILI, Cl_mic, t1/2, and hERG. The extremely high DILI risk associated with Ligand A is a major red flag. While Ligand B's logP is good, the substantial difference in metabolic stability (Cl_mic and t1/2) and safety (DILI, hERG) makes Ligand A the more promising candidate. The slight advantage in binding affinity of Ligand B is not enough to overcome these significant drawbacks.
Output:
1
2025-04-17 18:34:30,019 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [393.481, 80.32, 1.667, 2, 6, 0.667, 63.009, 71.539, -5.477, -3.214, 0.373, 12.115, 2.765, 0.081, -6.6]
**Ligand B:** [359.495, 55.2, 3.237, 0, 5, 0.727, 47.654, 87.127, -4.942, -4.255, 0.617, 82.182, 17.213, 0.704, -6.8]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, BBB, Affinity):
1. **MW:** Both are within the acceptable 200-500 Da range. Ligand B (359.495) is slightly preferred due to being a bit lower.
2. **TPSA:** Ligand A (80.32) is higher than Ligand B (55.2). Ligand B is significantly better here, being well below the 140 threshold for oral absorption and more favorable for GPCRs.
3. **logP:** Ligand A (1.667) is within the ideal 1-3 range. Ligand B (3.237) is at the higher end, but still acceptable.
4. **HBD/HBA:** Ligand A has 2 HBD and 6 HBA, while Ligand B has 0 HBD and 5 HBA. Both are reasonable, but Ligand B's lower HBD count is slightly preferred for permeability.
5. **QED:** Both are above 0.5 (Ligand A: 0.667, Ligand B: 0.727), indicating good drug-likeness. Ligand B is slightly better.
6. **DILI:** Ligand A (63.009) is higher than Ligand B (47.654). Ligand B is preferred here, indicating a lower risk of liver injury.
7. **BBB:** Ligand A (71.539) is good, but Ligand B (87.127) is excellent. This is a significant advantage for Ligand B, as BBB penetration is important for GPCR targets.
8. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-5.477) is worse than Ligand B (-4.942).
9. **Solubility:** Both are negative, indicating poor solubility. Ligand A (-3.214) is worse than Ligand B (-4.255).
10. **hERG:** Ligand A (0.373) is better than Ligand B (0.617), indicating lower cardiotoxicity risk.
11. **Cl_mic:** Ligand A (12.115) has a lower clearance, suggesting better metabolic stability than Ligand B (82.182). This is a significant advantage for Ligand A.
12. **t1/2:** Ligand B (17.213) has a much longer half-life than Ligand A (2.765). This is a major advantage for Ligand B.
13. **Pgp:** Ligand A (0.081) has lower P-gp efflux, which is better than Ligand B (0.704).
14. **Affinity:** Ligand B (-6.8 kcal/mol) is slightly better than Ligand A (-6.6 kcal/mol), but the difference is small.
**Overall Assessment:**
Ligand B demonstrates a better balance of properties, particularly regarding BBB penetration, DILI risk, and half-life. While Ligand A has better metabolic stability (lower Cl_mic) and P-gp efflux, the advantages of Ligand B in BBB, DILI, and t1/2 are more critical for a GPCR target like ADRB2. The slightly better affinity of Ligand B also contributes to its preference. The poor Caco-2 and solubility for both ligands are concerning, but can be addressed with formulation strategies.
Output:
0
2025-04-17 18:34:30,019 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (370.559 Da and 343.475 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (58.64) is significantly better than Ligand B (70.15). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (2.976 and 2.666, respectively), falling within the optimal 1-3 range. Ligand B is slightly lower, but both are acceptable.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (4) is preferable to Ligand B (5). Lower HBA generally improves permeability.
6. **QED:** Ligand B (0.831) has a slightly better QED score than Ligand A (0.634), suggesting a more inherently drug-like profile.
7. **DILI:** Both ligands have very similar and acceptable DILI risk (26.173 and 26.483 percentile).
8. **BBB:** Ligand B (90.772) has a significantly higher BBB penetration percentile than Ligand A (77.705). While not a primary concern for a cardiovascular target, higher BBB is rarely detrimental.
9. **Caco-2:** Ligand A (-4.957) and Ligand B (-5.114) are similar, indicating similar intestinal absorption.
10. **Solubility:** Ligand A (-3.087) and Ligand B (-2.601) are similar, indicating similar solubility.
11. **hERG:** Both ligands have low hERG inhibition liability (0.581 and 0.723, respectively). No significant difference.
12. **Cl_mic:** Ligand B (44.682) has significantly lower microsomal clearance than Ligand A (79.271), indicating better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand B (25.737 hours) has a much longer in vitro half-life than Ligand A (-9.497 hours). This is a major advantage, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.301 and 0.136, respectively). No significant difference.
15. **Binding Affinity:** Ligand A (-6.5 kcal/mol) has a slightly better binding affinity than Ligand B (-6.1 kcal/mol). This is a positive for Ligand A, but the difference is relatively small.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has a slight edge in affinity, but Ligand B excels in metabolic stability (Cl_mic, t1/2) and has a better QED score. The lower TPSA of Ligand A is also favorable. However, the substantial difference in half-life and clearance makes Ligand B more attractive.
**Conclusion:**
Considering the balance of properties, particularly the significantly improved metabolic stability and longer half-life of Ligand B, I believe it is the more promising drug candidate. The slightly better affinity of Ligand A is outweighed by the pharmacokinetic advantages of Ligand B.
Output:
0
2025-04-17 18:34:30,020 - INFO - Batch 47 complete. Total preferences: 752
2025-04-17 18:34:30,020 - INFO - Processing batch 48/512...
2025-04-17 18:35:20,133 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (384.93 & 361.51) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (58.64) is significantly better than Ligand B (73.2), being well below the 140 threshold for oral absorption and more favorable for GPCRs.
3. **logP:** Both ligands (3.326 & 3.416) are within the optimal 1-3 range. Similar.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Both have 4 HBA, which is also good.
6. **QED:** Both ligands have very similar QED scores (0.847 & 0.844), indicating good drug-likeness.
7. **DILI:** Ligand A (40.87) is slightly better than Ligand B (49.01), both are acceptable, but lower is preferred.
8. **BBB:** Ligand A (78.83) has a significantly higher BBB penetration percentile than Ligand B (61.38). While ADRB2 isn't *necessarily* a CNS target, better BBB penetration can sometimes translate to improved PK/PD.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.828 & -4.851). This is unusual and suggests very poor permeability, a significant concern.
10. **Solubility:** Both ligands have negative solubility values (-4.02 & -3.772). This is also a major red flag, indicating very poor aqueous solubility.
11. **hERG:** Ligand A (0.451) has a slightly lower hERG inhibition liability than Ligand B (0.676), which is preferable.
12. **Cl_mic:** Ligand A (32.66) has a lower microsomal clearance than Ligand B (46.21), suggesting better metabolic stability.
13. **t1/2:** Ligand B (22.45) has a longer in vitro half-life than Ligand A (10.22), which is desirable.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.298 & 0.327).
15. **Binding Affinity:** Ligand A (-6.3 kcal/mol) has a stronger binding affinity than Ligand B (-4.3 kcal/mol). This is a substantial difference (2 kcal/mol), and a key driver in the decision.
**Overall Assessment:**
Both compounds have significant issues with solubility and permeability (Caco-2). However, Ligand A is superior due to its significantly better binding affinity, lower DILI risk, lower hERG risk, lower Cl_mic, and better BBB penetration. The stronger binding affinity is the most important factor, and the other improvements help mitigate the poor solubility/permeability. The longer half-life of Ligand B is a plus, but not enough to overcome the other deficiencies.
Output:
1
2025-04-17 18:35:20,134 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (368.5 & 388.9 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (84.3) is slightly higher than Ligand B (67.87). Both are below the 140 threshold for oral absorption, but B is better.
3. **logP:** Both ligands (1.727 & 2.512) are within the optimal 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Both have 5 HBA, which is good.
6. **QED:** Both ligands (0.88 & 0.858) have excellent drug-likeness scores.
7. **DILI:** Ligand A (26.173) has a significantly lower DILI risk than Ligand B (40.054). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (63.823) has a better BBB penetration score than Ligand B (53.897), though neither are exceptionally high. For a cardiovascular target, BBB isn't *critical*, but some penetration can be useful.
9. **Caco-2:** Ligand A (-4.937) and Ligand B (-5.034) are similar.
10. **Solubility:** Ligand A (-1.687) has better aqueous solubility than Ligand B (-2.975).
11. **hERG:** Ligand A (0.222) has a much lower hERG inhibition liability than Ligand B (0.642). This is a critical safety parameter.
12. **Cl_mic:** Ligand A (-18.092) has significantly lower microsomal clearance, indicating better metabolic stability, than Ligand B (9.588).
13. **t1/2:** Ligand A (37.822) has a longer in vitro half-life than Ligand B (-1.046). This is a significant advantage for dosing convenience.
14. **Pgp:** Ligand A (0.03) has lower P-gp efflux liability than Ligand B (0.161). This is good for bioavailability.
15. **Binding Affinity:** Both ligands have the same binding affinity (-6.5 kcal/mol).
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Both ligands perform reasonably well on these metrics. However, the ADME properties of Ligand A are *substantially* better, particularly regarding DILI risk, hERG inhibition, metabolic stability (Cl_mic and t1/2), and P-gp efflux. While BBB isn't paramount for a cardiovascular target, Ligand A also has a slightly better score.
**Conclusion:**
Despite having identical binding affinity, Ligand A is a much more promising drug candidate due to its superior ADME profile and significantly lower toxicity liabilities. The improved metabolic stability, reduced off-target effects (hERG), and lower DILI risk make it the preferred choice.
Output:
1
2025-04-17 18:35:20,134 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (365.451 Da) is slightly lower, which is generally favorable for permeability.
**2. TPSA:** Ligand A (78.67) is better than Ligand B (98.58). For a cardiovascular GPCR, TPSA is important, and staying below 140 is good. Ligand A is preferable.
**3. logP:** Both ligands have acceptable logP values (A: 3.816, B: 2.392), falling within the 1-3 range. Ligand A is slightly higher, which could potentially lead to off-target effects but isn't a major concern at this level.
**4. H-Bond Donors:** Ligand A has 0 HBD, while Ligand B has 3. Lower is generally better for permeability, so Ligand A is favored.
**5. H-Bond Acceptors:** Both ligands have 6 HBA, which is acceptable.
**6. QED:** Ligand B (0.633) has a better QED score than Ligand A (0.356), indicating a more drug-like profile. This is a point in favor of Ligand B.
**7. DILI:** Both ligands have relatively low DILI risk (A: 47.848, B: 41.993), both below the 60 threshold. Ligand B has a slightly lower risk.
**8. BBB:** Ligand A (77.007) has a significantly higher BBB penetration percentile than Ligand B (63.009). While ADRB2 is a cardiovascular target, some CNS exposure is not necessarily detrimental and could even be beneficial for understanding off-target effects.
**9. Caco-2 Permeability:** Ligand A (-4.452) has a more negative Caco-2 value, suggesting *lower* permeability compared to Ligand B (-5.107). This is a negative for Ligand A.
**10. Aqueous Solubility:** Ligand A (-5.836) has a more negative solubility value, suggesting *lower* solubility compared to Ligand B (-3.414). This is a negative for Ligand A.
**11. hERG Inhibition:** Both ligands have low hERG inhibition liability (A: 0.461, B: 0.598), which is good.
**12. Microsomal Clearance:** Ligand B (36.265) has significantly lower microsomal clearance than Ligand A (117.812), indicating better metabolic stability. This is a significant advantage for Ligand B.
**13. In vitro Half-Life:** Ligand B (5.003) has a positive in vitro half-life, while Ligand A (-28.691) has a negative value. This suggests a longer half-life for Ligand B, which is desirable.
**14. P-gp Efflux:** Both ligands have similar P-gp efflux liability (A: 0.621, B: 0.114). Ligand B is slightly better.
**15. Binding Affinity:** Ligand A (-7.0) has a slightly better binding affinity than Ligand B (-6.1). This is a significant advantage for Ligand A, as a 0.9 kcal/mol difference can outweigh some ADME drawbacks.
**Overall Assessment:**
While Ligand A has a better binding affinity and BBB penetration, Ligand B demonstrates a superior ADME profile. Specifically, its lower microsomal clearance, longer half-life, and better solubility are crucial advantages for a cardiovascular drug candidate. The slightly lower binding affinity of Ligand B is acceptable given its improved pharmacokinetic properties. The QED score also favors Ligand B. Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand B strikes a better balance.
Output:
0
2025-04-17 18:35:20,134 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (343.43 & 345.44 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (83.36) is slightly higher than Ligand B (71.53). Both are below the 140 threshold for good oral absorption, but B is better.
3. **logP:** Ligand A (3.312) is at the upper end of the optimal range (1-3), while Ligand B (2.094) is closer to the lower end. For a GPCR, a slightly higher logP can be beneficial for membrane permeability, but we need to consider other factors.
4. **HBD:** Ligand A (3) is higher than Ligand B (1). Lower is generally preferred, giving a slight edge to B.
5. **HBA:** Both ligands have 4 HBA, which is within the acceptable range.
6. **QED:** Ligand B (0.802) has a higher QED score than Ligand A (0.721), indicating a more drug-like profile.
7. **DILI:** Ligand B (42.85) has a slightly lower DILI risk than Ligand A (57.15), which is preferable.
8. **BBB:** Ligand B (73.01) shows significantly better BBB penetration potential than Ligand A (42.19). This is a *major* advantage for a GPCR target, even if not strictly CNS-focused, as it suggests better distribution.
9. **Caco-2:** Ligand A (-5.268) has a worse Caco-2 permeability than Ligand B (-4.5).
10. **Solubility:** Ligand B (-2.388) has better solubility than Ligand A (-3.92).
11. **hERG:** Ligand A (0.534) has a slightly higher hERG risk than Ligand B (0.452), but both are relatively low.
12. **Cl_mic:** Ligand A (43.78) has a lower microsomal clearance than Ligand B (59.83), suggesting better metabolic stability. This is a positive for A.
13. **t1/2:** Ligand B (-9.083) has a significantly longer in vitro half-life than Ligand A (-3.317). This is a significant advantage for B.
14. **Pgp:** Ligand A (0.096) has a slightly lower Pgp efflux liability than Ligand B (0.061), which is preferable.
15. **Binding Affinity:** Ligand B (-6.6 kcal/mol) has a significantly stronger binding affinity than Ligand A (-4.3 kcal/mol). This is a substantial advantage, and can often outweigh minor ADME concerns.
**Overall Assessment:**
Ligand B clearly outperforms Ligand A in several key areas crucial for a GPCR drug candidate. The stronger binding affinity, better BBB penetration, improved solubility, longer half-life, and lower DILI risk are all significant advantages. While Ligand A has better metabolic stability (lower Cl_mic) and slightly lower Pgp efflux, these are less critical compared to the benefits offered by Ligand B, especially the substantial difference in binding affinity. The slightly higher logP of Ligand A is not enough to offset the other advantages of Ligand B.
Output:
0
2025-04-17 18:35:20,134 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.463 and 348.403 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (72.96) is significantly better than Ligand B (102.74). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is approaching a less desirable range.
3. **logP:** Ligand A (-0.086) is slightly lower than Ligand B (0.627), but both are within the 1-3 range. Ligand B is better here, but not dramatically.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 5. Both are acceptable, but Ligand A is slightly preferred.
6. **QED:** Both ligands have good QED scores (0.752 and 0.785). No significant difference.
7. **DILI:** Ligand A (8.841) has a much lower DILI risk than Ligand B (32.842). This is a substantial advantage for Ligand A.
8. **BBB:** Ligand B (71.811) has better BBB penetration than Ligand A (44.009). While ADRB2 isn't necessarily a CNS target, some degree of BBB penetration can be useful, and this is a point in favor of Ligand B.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. Ligand A (-5.024) is slightly better than Ligand B (-4.749), but both are concerning.
10. **Solubility:** Both ligands have negative solubility values, indicating poor solubility. Ligand A (-1.004) is slightly better than Ligand B (-1.952).
11. **hERG:** Both ligands have very low hERG inhibition risk (0.298 and 0.16). No significant difference.
12. **Cl_mic:** Ligand A (-2.263) has a much lower (better) microsomal clearance than Ligand B (-43.109). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Both ligands have very short in vitro half-lives (-7.488 and -2.376). This is a significant drawback for both, but they are comparable.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.007). No significant difference.
15. **Binding Affinity:** Ligand A (-6.4 kcal/mol) has a slightly better binding affinity than Ligand B (-5.3 kcal/mol). This difference of 1.1 kcal/mol is significant enough to consider.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand A is the stronger candidate. While Ligand B has better BBB penetration and logP, Ligand A excels in crucial areas like TPSA, DILI risk, and metabolic stability (Cl_mic). The slightly better binding affinity of Ligand A further strengthens its position. The poor Caco-2 and solubility are concerning for both, but can be addressed with formulation strategies. The lower DILI risk and better metabolic stability of Ligand A are more difficult to improve later in development.
Output:
1
2025-04-17 18:35:20,134 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.4 and 342.4 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (126.96) is higher than Ligand B (67.23). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is generally preferred for absorption. Ligand B is significantly better.
3. **logP:** Ligand A (-0.935) is lower than the optimal 1-3 range, potentially hindering permeability. Ligand B (1.856) is within the optimal range. Ligand B is better.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (1), but both are acceptable (<=5).
5. **HBA:** Ligand A (8) is higher than Ligand B (4). Lower HBA generally improves permeability. Ligand B is better.
6. **QED:** Ligand B (0.871) has a significantly higher QED score than Ligand A (0.565), indicating a more drug-like profile. Ligand B is better.
7. **DILI:** Ligand A (44.05) has a slightly higher DILI risk than Ligand B (27.72). Both are below the concerning threshold of 60, but lower is preferred. Ligand B is better.
8. **BBB:** This is less critical for a cardiovascular target. Ligand B (54.21) is higher than Ligand A (14.15), but this isn't a major deciding factor.
9. **Caco-2:** Ligand A (-5.942) and Ligand B (-4.806) are both negative, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
10. **Solubility:** Both ligands have very poor solubility scores (-1.134 and -1.353). This is a significant concern for both.
11. **hERG:** Ligand A (0.009) has a slightly lower hERG risk than Ligand B (0.238), but both are very low and unlikely to be a major issue.
12. **Cl_mic:** Ligand A (-1.952) has a lower (better) microsomal clearance than Ligand B (29.286), indicating greater metabolic stability. Ligand A is better.
13. **t1/2:** Both ligands have similar in vitro half-lives (18.39 and 18.38 hours).
14. **Pgp:** Ligand A (0.004) has a much lower Pgp efflux liability than Ligand B (0.033), suggesting better bioavailability. Ligand A is better.
15. **Affinity:** Both ligands have very similar binding affinities (-6.4 and -6.3 kcal/mol). The difference is negligible.
**Overall Assessment:**
Ligand B excels in several key areas: logP, TPSA, QED, and DILI risk. While both have poor solubility, Ligand B's better physicochemical properties suggest it may be easier to formulate and have better absorption. Ligand A has better metabolic stability (Cl_mic) and Pgp efflux, but the advantages in these areas are outweighed by the superior overall profile of Ligand B, especially considering the GPCR target class priorities.
Output:
0
2025-04-17 18:35:20,135 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (a cardiovascular GPCR) drug candidates.
**Ligand A:** [348.403, 113.44 , -0.1 , 3. , 6. , 0.537, 32.183, 54.052, -5.193, -1.705, 0.065, 24.401, 10.865, 0.008, -7.2 ]
**Ligand B:** [345.399, 91.64 , 0.89 , 2. , 5. , 0.775, 55.758, 32.92 , -4.858, -2.046, 0.118, -5.767, -2.277, 0.037, -7.6 ]
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal 200-500 Da range. A (348.4) and B (345.4) are very similar.
2. **TPSA:** Ligand A (113.44) is slightly above the preferred <100 for good absorption, but still reasonable. Ligand B (91.64) is excellent, well below 100. This favors B.
3. **logP:** Ligand A (-0.1) is a bit low, potentially hindering permeability. Ligand B (0.89) is within the optimal 1-3 range. This strongly favors B.
4. **HBD:** Ligand A (3) is acceptable. Ligand B (2) is even better.
5. **HBA:** Ligand A (6) is acceptable. Ligand B (5) is slightly better.
6. **QED:** Both ligands have good QED scores (A: 0.537, B: 0.775), indicating drug-likeness. B is better.
7. **DILI:** Ligand A (32.183) has a lower DILI risk than Ligand B (55.758). This favors A.
8. **BBB:** Ligand A (54.052) has a moderate BBB penetration, while Ligand B (32.92) is lower. Since this is a cardiovascular target, BBB isn't *critical*, but some penetration is not detrimental.
9. **Caco-2:** Ligand A (-5.193) is poor, indicating poor intestinal absorption. Ligand B (-4.858) is also poor, but slightly better.
10. **Solubility:** Ligand A (-1.705) is poor. Ligand B (-2.046) is also poor.
11. **hERG:** Both ligands have very low hERG risk (A: 0.065, B: 0.118), which is excellent.
12. **Cl_mic:** Ligand A (24.401) has a higher clearance than Ligand B (-5.767), meaning B is more metabolically stable. This favors B.
13. **t1/2:** Ligand A (10.865) has a shorter half-life than Ligand B (-2.277) which is a negative value indicating a very long half-life. This favors B.
14. **Pgp:** Both ligands have very low P-gp efflux (A: 0.008, B: 0.037).
15. **Affinity:** Ligand B (-7.6) has a slightly better binding affinity than Ligand A (-7.2). This is a 0.4 kcal/mol difference, which is significant.
**Overall Assessment:**
Ligand B consistently outperforms Ligand A across several key parameters, particularly logP, TPSA, metabolic stability (Cl_mic, t1/2), and binding affinity. While Ligand A has a slightly lower DILI risk, the benefits of Ligand B's improved ADME profile and binding outweigh this. Given the GPCR target class, optimizing for logP, TPSA, and affinity is crucial.
Output:
0
2025-04-17 18:35:20,135 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [345.399, 96.53, 1.138, 3, 4, 0.486, 54.789, 59.093, -5.158, -2.468, 0.041, 20.215, -8.192, 0.009, -6.1]
**Ligand B:** [362.583, 33.2, 4.729, 0, 3, 0.733, 24.661, 78.054, -4.986, -4.234, 0.694, 100.136, 7.093, 0.706, -5.8]
Here's a breakdown of each parameter, comparing A and B, and considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal range (200-500 Da). A (345.4) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** A (96.53) is higher than B (33.2). B is significantly better here, well below the 140 threshold for oral absorption and more favorable for GPCRs.
3. **logP:** A (1.138) is optimal, while B (4.729) is high. This is a significant drawback for B, increasing the risk of off-target effects and solubility issues.
4. **HBD:** A (3) is reasonable. B (0) is also good, potentially improving membrane permeability.
5. **HBA:** Both A (4) and B (3) are within the acceptable range.
6. **QED:** B (0.733) is better than A (0.486), suggesting a more drug-like profile.
7. **DILI:** B (24.661) has a much lower DILI risk than A (54.789). This is a major advantage for B.
8. **BBB:** B (78.054) is better than A (59.093), although neither are exceptionally high. For a cardiovascular target, BBB isn't *critical*, but higher is still preferable.
9. **Caco-2:** Both are negative, indicating poor permeability. A (-5.158) is slightly worse than B (-4.986).
10. **Solubility:** Both are negative, indicating poor solubility. A (-2.468) is slightly worse than B (-4.234).
11. **hERG:** A (0.041) is better than B (0.694), indicating lower cardiotoxicity risk.
12. **Cl_mic:** A (20.215) has a lower clearance, suggesting better metabolic stability than B (100.136). This is a significant advantage for A.
13. **t1/2:** A (-8.192) has a longer in vitro half-life than B (7.093), which is desirable.
14. **Pgp:** A (0.009) has much lower P-gp efflux liability than B (0.706). This is a significant advantage for A, improving bioavailability.
15. **Affinity:** Both have similar binding affinities (-6.1 and -5.8 kcal/mol). The difference isn't large enough to be decisive.
**Overall Assessment:**
Ligand B has advantages in TPSA, QED, DILI, and BBB. However, its high logP is a major concern, potentially leading to poor solubility and off-target interactions. Ligand A has better metabolic stability (lower Cl_mic, longer t1/2), lower P-gp efflux, and lower hERG risk. While its TPSA is higher and Caco-2/Solubility are poor, the better ADME profile and comparable affinity make it a more promising candidate. The high logP of B is a significant red flag for a GPCR target.
Therefore, I prefer Ligand A.
1
2025-04-17 18:35:20,135 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (360.8 & 347.3 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (99.87) is higher than the preferred <140, but still acceptable. Ligand B (29.02) is excellent, well below 140. This favors Ligand B.
3. **logP:** Ligand A (2.58) is optimal (1-3). Ligand B (4.35) is slightly higher, potentially leading to solubility issues and off-target interactions, but still within a reasonable range. Slight edge to Ligand A.
4. **HBD:** Ligand A (3) is acceptable. Ligand B (0) is also good, potentially improving membrane permeability. Slight edge to Ligand B.
5. **HBA:** Both ligands (A: 4, B: 3) are within the acceptable limit of 10. No significant difference.
6. **QED:** Both ligands (A: 0.588, B: 0.613) have good drug-likeness scores (>0.5). No significant difference.
7. **DILI:** Ligand A (84.955) has a higher DILI risk than Ligand B (74.021). This favors Ligand B.
8. **BBB:** Ligand A (35.052) has poor BBB penetration. Ligand B (93.68) exhibits excellent BBB penetration. Given ADRB2 is a GPCR, and while not exclusively a CNS target, good BBB penetration is beneficial for broader distribution and potential off-target effects assessment. This strongly favors Ligand B.
9. **Caco-2:** Ligand A (-5.214) and Ligand B (-4.786) both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
10. **Solubility:** Ligand A (-3.582) has slightly better solubility than Ligand B (-5.846).
11. **hERG:** Ligand A (0.357) has a lower hERG risk than Ligand B (0.927). This favors Ligand A.
12. **Cl_mic:** Ligand A (60.818) has a higher microsomal clearance than Ligand B (47.567), indicating lower metabolic stability. This favors Ligand B.
13. **t1/2:** Ligand A (17.651) has a longer in vitro half-life than Ligand B (11.07). This favors Ligand A.
14. **Pgp:** Ligand A (0.118) has lower P-gp efflux than Ligand B (0.767). This favors Ligand A.
15. **Affinity:** Ligand A (-7.2 kcal/mol) has a slightly better binding affinity than Ligand B (-6.4 kcal/mol). This is a significant advantage, as a >1.5 kcal/mol difference can outweigh other drawbacks.
**Overall Assessment:**
While Ligand A has a better binding affinity and slightly better solubility, Ligand B demonstrates a significantly better ADME profile, particularly regarding BBB penetration, DILI risk, and metabolic stability. The higher logP of Ligand B is a minor concern, but the substantial advantage in BBB penetration and lower DILI risk are crucial for a GPCR target like ADRB2. The affinity difference, while present, isn't large enough to overcome the ADME liabilities of Ligand A.
Output:
0
2025-04-17 18:35:20,135 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's break down the comparison of Ligand A and Ligand B, considering the provided guidelines and GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key).
1. **Molecular Weight:** Both ligands (345.374 and 349.435 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (97.21) is better than Ligand B (126.21). For a GPCR, keeping TPSA under 140 is good for oral absorption, and A is closer to the ideal <90 for CNS penetration (though CNS targeting isn't explicitly stated, it's good to have).
3. **logP:** Ligand A (1.616) is better than Ligand B (0.74). Both are within the optimal 1-3 range, but A is closer to the center of that range. B is a bit low, potentially impacting permeability.
4. **H-Bond Donors:** Both have 3-4 HBD, which is acceptable.
5. **H-Bond Acceptors:** Both have 4 HBA, which is acceptable.
6. **QED:** Ligand A (0.693) is better than Ligand B (0.49). A higher QED suggests a more drug-like profile.
7. **DILI:** Ligand A (51.221) is significantly better than Ligand B (23.885). Lower DILI risk is crucial.
8. **BBB:** Ligand A (75.107) is slightly better than Ligand B (71.035). Both are reasonably good, but A has a slight edge.
9. **Caco-2:** Ligand A (-4.678) is better than Ligand B (-5.614). Higher Caco-2 permeability indicates better absorption.
10. **Solubility:** Ligand A (-3.406) is better than Ligand B (-1.805). Higher solubility is favorable.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.269 and 0.134). This is excellent.
12. **Cl_mic:** Ligand A (24.569) is much better than Ligand B (8.182). Lower microsomal clearance indicates better metabolic stability.
13. **t1/2:** Ligand A (-9.072) is much better than Ligand B (3.407). A longer in vitro half-life is desirable.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.028 and 0.007).
15. **Binding Affinity:** Both ligands have very similar binding affinities (-8.1 and -8.2 kcal/mol). The difference is negligible.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most crucial ADME-Tox properties. While the binding affinity is almost identical, Ligand A demonstrates superior drug-likeness (QED), lower DILI risk, better solubility, and significantly improved metabolic stability (lower Cl_mic and longer t1/2). The slightly better TPSA and logP values also contribute to its favorability. Given these advantages, especially the improved safety profile (DILI) and pharmacokinetic properties, Ligand A is the more promising drug candidate.
**Output:**
1
2025-04-17 18:35:20,135 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [348.447, 96.25, 1.116, 3, 5, 0.718, 38.736, 59.442, -4.864, -2.706, 0.089, 32.423, 1.23, 0.057, -6.4]
**Ligand B:** [353.419, 88.18, 0.218, 1, 5, 0.69, 37.185, 76.309, -4.615, -2.065, 0.367, -5.672, -13.785, 0.041, -4.5]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). A (348.447) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** A (96.25) is slightly higher than B (88.18), but both are below the 140 threshold for oral absorption. B is better here, closer to the 90 threshold for CNS penetration (though ADRB2 isn't necessarily a CNS target).
3. **logP:** A (1.116) and B (0.218) are both within the optimal range (1-3), but B is quite low, potentially hindering permeation. A is clearly better here.
4. **HBD:** A (3) is higher than B (1), but both are acceptable (<=5).
5. **HBA:** Both A (5) and B (5) are within the acceptable range (<=10).
6. **QED:** Both are good (A: 0.718, B: 0.69), indicating drug-like properties.
7. **DILI:** Both have low DILI risk (A: 38.736, B: 37.185), which is excellent.
8. **BBB:** B (76.309) has a significantly higher BBB penetration score than A (59.442). While ADRB2 isn't strictly a CNS target, higher BBB is generally a positive attribute.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. A (-4.864) is slightly worse than B (-4.615).
10. **Solubility:** Both have negative solubility values, which is also unusual and suggests poor solubility. A (-2.706) is slightly worse than B (-2.065).
11. **hERG:** A (0.089) has a lower hERG risk than B (0.367), which is a significant advantage.
12. **Cl_mic:** B (-5.672) has a *much* lower (better) microsomal clearance than A (32.423), indicating greater metabolic stability. This is a major advantage for B.
13. **t1/2:** B (-13.785) has a *much* longer in vitro half-life than A (1.23), which is a significant advantage.
14. **Pgp:** A (0.057) has a lower Pgp efflux liability than B (0.041), which is slightly better.
15. **Affinity:** A (-6.4 kcal/mol) has a slightly better binding affinity than B (-4.5 kcal/mol). This is a 1.9 kcal/mol difference, which is substantial and could outweigh some ADME drawbacks.
**GPCR-Specific Priorities:** For GPCRs, we prioritize logP, Pgp, TPSA, and affinity.
**Overall Assessment:**
Ligand A has a better logP and binding affinity, and slightly better Pgp efflux. However, Ligand B excels in metabolic stability (Cl_mic and t1/2) and has a better BBB score. The significantly better metabolic stability and half-life of Ligand B are critical for *in vivo* efficacy. While the Caco-2 and solubility values are concerning for both, the superior binding affinity of A is a strong point. However, the substantial difference in metabolic stability and half-life tips the balance in favor of B. The slightly better affinity of A is unlikely to overcome the pharmacokinetic advantages of B.
Output:
0
2025-04-17 18:35:20,136 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (358.423 and 357.479 Da) fall comfortably within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (91.23) is higher than Ligand B (55.32). For a cardiovascular GPCR, TPSA isn't *as* critical as for a CNS target, but lower is generally preferred for permeability. Ligand B has a significant advantage.
3. **logP:** Ligand A (1.492) is within the optimal range (1-3), while Ligand B (3.535) is at the higher end. While still acceptable, higher logP can sometimes lead to off-target effects and solubility issues. Ligand A is slightly favored.
4. **HBD:** Ligand A (2) is better than Ligand B (0). Having some HBD can improve solubility.
5. **HBA:** Both ligands have 5 HBA, which is acceptable.
6. **QED:** Both ligands have good QED scores (0.764 and 0.84), indicating good drug-like properties. No significant difference.
7. **DILI:** Ligand A (71.19) has a slightly higher DILI risk than Ligand B (61.07), but both are within an acceptable range (<60 is good, >60 is high risk). Ligand B is slightly favored.
8. **BBB:** Ligand A (28.461) has a very low BBB penetration, while Ligand B (78.519) has good BBB penetration. Since ADRB2 is a cardiovascular target, BBB penetration is not a primary concern, so this difference is less important.
9. **Caco-2:** Ligand A (-5.218) has a very poor Caco-2 permeability, while Ligand B (-4.523) is better, but still not great. This is a concern for both, but more so for Ligand A.
10. **Solubility:** Ligand A (-4.483) has slightly better solubility than Ligand B (-4.068).
11. **hERG:** Both ligands have low hERG inhibition risk (0.303 and 0.428). No significant difference.
12. **Cl_mic:** Ligand A (-0.565) has significantly better metabolic stability (lower clearance) than Ligand B (85.163). This is a major advantage for Ligand A.
13. **t1/2:** Ligand A (13.129) has a better in vitro half-life than Ligand B (-41.276). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.128) has lower P-gp efflux than Ligand B (0.401). Lower P-gp efflux is generally desirable for better bioavailability. Ligand A is favored.
15. **Binding Affinity:** Both ligands have excellent binding affinity (-8 and -7 kcal/mol). The difference of 1 kcal/mol is not substantial enough to outweigh other factors.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity) and the general drug-like properties, Ligand A emerges as the more promising candidate. While Ligand B has a better TPSA and DILI, Ligand A has significantly better metabolic stability (Cl_mic and t1/2), lower P-gp efflux, and comparable binding affinity. The poor Caco-2 permeability of Ligand A is a concern, but the improved metabolic stability and reduced efflux are more critical for a cardiovascular GPCR target.
Output:
1
2025-04-17 18:35:20,136 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (365.396 and 347.463 Da) are within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (72.88) is better than Ligand B (80.12). Both are below 140, but lower is preferred for absorption.
3. **logP:** Both ligands have acceptable logP values (0.915 and 1.694), falling within the 1-3 range. Ligand B is slightly better.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1), but both are within the acceptable limit of 5.
5. **HBA:** Ligand A (4) is lower than Ligand B (5), which is preferable.
6. **QED:** Both ligands have good QED scores (0.711 and 0.761), indicating good drug-likeness. Ligand B is slightly better.
7. **DILI:** Ligand A (18.069) has a significantly lower DILI risk than Ligand B (34.238). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (79.682) has a better BBB penetration percentile than Ligand A (67.701). While ADRB2 isn't strictly a CNS target, some CNS exposure can be relevant for off-target effects or peripheral effects mediated by CNS pathways.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.982 and -4.832), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-0.501) has slightly better solubility than Ligand B (-2.314).
11. **hERG:** Both ligands have very low hERG inhibition liability (0.421 and 0.41), which is excellent.
12. **Cl_mic:** Ligand A (-17.94) has a much lower (better) microsomal clearance than Ligand B (52.722), indicating greater metabolic stability.
13. **t1/2:** Ligand A (-34.47) has a much longer in vitro half-life than Ligand B (-1.912). This is a significant advantage for Ligand A.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.026 and 0.116).
15. **Binding Affinity:** Ligand A (-6.8) has a slightly better binding affinity than Ligand B (-6.3).
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A is better on TPSA, Pgp, and affinity. Ligand B is better on logP and BBB. The significantly better DILI, Cl_mic, and t1/2 of Ligand A outweigh the slight advantage of Ligand B in logP and BBB. The poor Caco-2 values are a concern for both.
**Conclusion:**
Considering the balance of properties, particularly the lower DILI risk, improved metabolic stability (Cl_mic and t1/2), and slightly better affinity, Ligand A is the more promising drug candidate.
Output:
1
2025-04-17 18:35:20,136 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (355.36 & 348.45 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (56.26) is significantly better than Ligand B (84.3). ADRB2 is a cardiovascular target, not CNS, but lower TPSA generally improves absorption. Ligand A is well below the 140 threshold, while B is approaching it.
3. **logP:** Ligand A (3.73) is good, within the optimal 1-3 range. Ligand B (1.33) is on the lower side, potentially hindering permeability.
4. **HBD:** Both ligands have acceptable HBD counts (0 for A, 1 for B), well below the 5 threshold.
5. **HBA:** Both ligands have acceptable HBA counts (4 for A, 5 for B), well below the 10 threshold.
6. **QED:** Both ligands have good QED scores (0.756 & 0.84), indicating good drug-likeness.
7. **DILI:** Ligand A (23.65) has a much lower DILI risk than Ligand B (41.45). This is a significant advantage for A.
8. **BBB:** While not a primary concern for a cardiovascular target, Ligand A (95.62) has a much higher BBB penetration score than Ligand B (67.16).
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the absolute value is smaller for Ligand A (-4.395 vs -4.602), suggesting slightly better permeability.
10. **Solubility:** Ligand A (-4.132) has slightly better solubility than Ligand B (-1.789).
11. **hERG:** Both ligands have very low hERG inhibition risk (0.369 & 0.181), which is excellent.
12. **Cl_mic:** Ligand A (53.55) has higher microsomal clearance than Ligand B (38.50). This suggests lower metabolic stability for A.
13. **t1/2:** Ligand B (-1.282) has a slightly longer in vitro half-life than Ligand A (-10.33).
14. **Pgp:** Ligand A (0.523) has higher P-gp efflux liability than Ligand B (0.1). This is a negative for A.
15. **Binding Affinity:** Ligand A (-8.9 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.4 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME drawbacks.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A excels in logP and *significantly* in binding affinity. While its Pgp efflux is higher, the strong binding is likely to compensate. The lower TPSA of A is also favorable. The DILI score is also a major advantage for A.
**Overall Assessment:**
Despite Ligand A's slightly higher Cl_mic and Pgp efflux, its significantly stronger binding affinity, lower DILI risk, better logP, and lower TPSA make it the more promising candidate. The binding affinity difference is substantial (>1.5 kcal/mol), and the other advantages outweigh the minor ADME concerns.
Output:
1
2025-04-17 18:35:20,136 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [337.423, 47.36, 2.809, 0, 4, 0.601, 48.817, 84.762, -4.964, -2.169, 0.663, 80.305, -11.528, 0.686, -6.1]
**Ligand B:** [378.466, 88.1, -0.039, 2, 6, 0.698, 48.623, 46.84, -5.256, -2.191, 0.209, 26.555, -2.295, 0.051, -7.5]
**Step-by-step comparison:**
1. **MW:** Both are within the acceptable range (200-500 Da). A (337.423) is slightly preferred.
2. **TPSA:** A (47.36) is excellent, well below the 140 threshold and good for oral absorption. B (88.1) is higher, but still acceptable, though less ideal.
3. **logP:** A (2.809) is optimal. B (-0.039) is concerningly low, potentially hindering membrane permeability.
4. **HBD:** A (0) is good. B (2) is acceptable.
5. **HBA:** A (4) is good. B (6) is acceptable.
6. **QED:** Both are good (A: 0.601, B: 0.698), indicating good drug-like properties. B is slightly better.
7. **DILI:** Both are similar and acceptable (A: 48.817, B: 48.623).
8. **BBB:** A (84.762) is very good, suggesting reasonable potential for CNS penetration if desired (though ADRB2 is primarily cardiovascular, some CNS off-target effects are always a consideration). B (46.84) is lower and less desirable.
9. **Caco-2:** Both are negative, which is unusual and suggests poor permeability. A (-4.964) is slightly better than B (-5.256).
10. **Solubility:** Both are negative, which is also unusual and suggests poor solubility. A (-2.169) is slightly better than B (-2.191).
11. **hERG:** A (0.663) is better than B (0.209), indicating lower cardiotoxicity risk.
12. **Cl_mic:** A (80.305) is higher than B (26.555), meaning faster metabolism and potentially lower *in vivo* exposure. This is a significant drawback for A.
13. **t1/2:** A (-11.528) is very poor, indicating rapid elimination. B (-2.295) is better, but still not ideal.
14. **Pgp:** A (0.686) is better than B (0.051), indicating less efflux and potentially better bioavailability.
15. **Affinity:** B (-7.5) is significantly better than A (-6.1), a difference of 1.4 kcal/mol. This is a substantial advantage.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. B has a significantly better binding affinity. While A has better BBB penetration, the low logP of B is a major concern, but the affinity difference is substantial enough to potentially overcome this with formulation strategies. The faster metabolic clearance and shorter half-life of A are also concerning.
**Conclusion:**
Despite the lower logP and slightly higher TPSA of Ligand B, its significantly stronger binding affinity (-7.5 kcal/mol vs -6.1 kcal/mol) outweighs the drawbacks, especially considering the GPCR target class. The better hERG profile of A is a plus, but the metabolic instability and poor half-life are significant negatives.
Output:
0
2025-04-17 18:35:20,136 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (a GPCR) drug candidates.
**Ligand A:** [346.519, 54.19, 3.506, 1, 5, 0.884, 9.965, 92.012, -5.455, -1.921, 0.889, -2.345, 23.973, 0.231, -5.9]
**Ligand B:** [390.933, 75.71, 1.485, 1, 4, 0.697, 31.485, 70.997, -5.237, -3.163, 0.45, 28.955, -2.994, 0.024, -7.1]
Here's a breakdown, property by property, considering the GPCR prioritization (logP, Pgp, TPSA, Affinity, BBB):
1. **MW:** A (346.5) is better, falling nicely within the 200-500 range. B (390.9) is still acceptable, but slightly higher.
2. **TPSA:** A (54.19) is significantly better than B (75.71). Lower TPSA generally translates to better cell permeability, crucial for GPCR targeting.
3. **logP:** A (3.506) is good, within the optimal 1-3 range. B (1.485) is on the lower side, potentially hindering membrane permeability.
4. **HBD:** Both are equal at 1, which is ideal.
5. **HBA:** A (5) is slightly higher than B (4), but both are acceptable.
6. **QED:** A (0.884) is much better than B (0.697), indicating a more drug-like profile.
7. **DILI:** A (9.965) is *much* better than B (31.485). This is a significant advantage for A.
8. **BBB:** A (92.012) is excellent, suggesting good potential for CNS penetration if desired (though not strictly necessary for ADRB2, it's a bonus). B (70.997) is decent, but not as favorable.
9. **Caco-2:** Both are negative, indicating poor permeability. However, the scale is not specified, so the absolute values are hard to interpret.
10. **Solubility:** Both are negative, indicating poor solubility. Again, the scale is not specified.
11. **hERG:** A (0.889) is better than B (0.45), indicating lower cardiotoxicity risk.
12. **Cl_mic:** A (-2.345) is better than B (28.955) indicating better metabolic stability.
13. **t1/2:** A (23.973) is better than B (-2.994) indicating a longer half-life.
14. **Pgp:** A (0.231) is much better than B (0.024), indicating lower P-glycoprotein efflux. This is important for bioavailability and potentially CNS exposure.
15. **Affinity:** B (-7.1) is 1.2 kcal/mol better than A (-5.9). While affinity is crucial, the other ADME properties of A are significantly better.
**Overall Assessment:**
Ligand B has a slightly better binding affinity, but Ligand A is superior in almost every other crucial ADME/Tox property. The lower DILI risk, better BBB penetration, better Pgp efflux, better metabolic stability, and better QED of Ligand A outweigh the affinity difference. Considering ADRB2 is a cardiovascular target, CNS penetration isn't paramount, but the other improvements in A are substantial.
Therefore, I would choose **Ligand A**.
1
2025-04-17 18:35:20,136 - INFO - Batch 48 complete. Total preferences: 768
2025-04-17 18:35:20,137 - INFO - Processing batch 49/512...
2025-04-17 18:36:09,491 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
We are targeting ADRB2, a GPCR, so the priorities are logP, Pgp, TPSA, affinity, and BBB. Let's compare the ligands step-by-step:
1. **MW:** Both ligands (344.415 and 353.419 Da) are within the ideal 200-500 Da range.
2. **TPSA:** Both are around 100, slightly above the optimal <140 for oral absorption, but acceptable.
3. **logP:** Ligand A (2.505) is optimal (1-3). Ligand B (-0.098) is quite low, potentially hindering membrane permeability. This is a significant drawback.
4. **HBD/HBA:** Both have 2 HBD and 6 HBA, which is within acceptable limits.
5. **QED:** Ligand A (0.717) has a better QED score than Ligand B (0.531), indicating better overall drug-likeness.
6. **DILI:** Ligand B (21.946) has a much lower DILI risk than Ligand A (64.366), which is a significant advantage.
7. **BBB:** Ligand A (61.923) has a better BBB penetration score than Ligand B (37.379). While not a CNS target, some degree of BBB penetration can be useful for distribution.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability.
9. **Solubility:** Both have negative solubility values, which is also unusual and suggests poor solubility.
10. **hERG:** Both have low hERG inhibition liability, which is good.
11. **Cl_mic:** Ligand B (-0.662) has a much lower (better) microsomal clearance than Ligand A (23.603), indicating greater metabolic stability.
12. **t1/2:** Ligand A (18.631) has a longer in vitro half-life than Ligand B (11.472), which is desirable.
13. **Pgp:** Ligand A (0.056) has lower P-gp efflux liability than Ligand B (0.023), which is favorable for bioavailability.
14. **Affinity:** Ligand A (-8.0 kcal/mol) has a slightly better binding affinity than Ligand B (-6.6 kcal/mol). The difference is 1.4 kcal/mol, which is significant enough to consider.
**Overall Assessment:**
Ligand A has a better binding affinity, QED, BBB penetration, Pgp efflux, and in vitro half-life. However, Ligand B exhibits significantly lower DILI risk and microsomal clearance, and a more acceptable logP. The low logP of Ligand B is concerning for permeability, but the substantial difference in DILI risk and metabolic stability is a strong point in its favor. Considering the GPCR-specific priorities, the affinity difference is important, but the potential for liver toxicity with Ligand A is a major concern.
**Output:**
0
2025-04-17 18:36:09,492 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.49 and 344.46 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (67.43) is better than Ligand B (76.02). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (2.70 and 1.89), falling within the 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Both have 2 HBD, which is acceptable.
5. **HBA:** Ligand A has 3 HBA, while Ligand B has 4. Both are within the acceptable limit of 10, but Ligand A is slightly preferred.
6. **QED:** Ligand A (0.725) has a significantly better QED score than Ligand B (0.387), indicating a more drug-like profile. This is a substantial advantage.
7. **DILI:** Ligand A (19.43%) has a much lower DILI risk than Ligand B (33.31%). This is a crucial safety parameter, and Ligand A is clearly better.
8. **BBB:** BBB is less critical for a cardiovascular target. Ligand A (63.32%) is higher than Ligand B (44.82%), but the difference isn't decisive.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the values are similar (-5.064 vs -5.103).
10. **Solubility:** Both ligands have negative solubility values, indicating poor aqueous solubility. Again, the values are similar (-2.87 vs -2.006).
11. **hERG:** Both ligands have very low hERG inhibition liability (0.251 and 0.392), which is excellent.
12. **Cl_mic:** Both ligands have similar microsomal clearance (33.99 and 34.50).
13. **t1/2:** Ligand A (28.54 hours) has a significantly longer in vitro half-life than Ligand B (-5.36 hours). This is a major advantage, potentially leading to less frequent dosing.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.061 and 0.138).
15. **Binding Affinity:** Ligand A (-6.8 kcal/mol) has a slightly better binding affinity than Ligand B (-5.3 kcal/mol). While the difference is less than 1.5 kcal/mol, it contributes to the overall preference.
**GPCR-specific considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Ligand A performs better on logP, TPSA, and affinity. The Pgp values are similar.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across several critical parameters: QED, DILI risk, and in vitro half-life. While both have issues with Caco-2 and solubility, these are less critical than the safety and pharmacokinetic advantages offered by Ligand A. The slightly better affinity is also a plus.
Output:
1
2025-04-17 18:36:09,492 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (343.39 and 356.41 Da) fall comfortably within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (100.35) is higher than Ligand B (66.48). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B has a significant advantage.
3. **logP:** Ligand B (2.31) is within the optimal 1-3 range, while Ligand A (0.655) is below 1. This is a substantial difference. Lower logP can lead to poor membrane permeability. Ligand B is favored.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable. Ligand B is slightly better.
5. **HBA:** Ligand A (6) and Ligand B (3) are both acceptable, but Ligand B is preferred.
6. **QED:** Both ligands have reasonable QED scores (0.83 and 0.679), indicating good drug-like properties. Ligand A is slightly better.
7. **DILI:** Both ligands have similar DILI risk (40.95 and 41.84), and are both below the 60% threshold, indicating acceptable risk.
8. **BBB:** Ligand B (87.63) has a much higher BBB penetration score than Ligand A (40.40). While ADRB2 isn't primarily a CNS target, some degree of BBB penetration can be beneficial for off-target effects assessment. Ligand B is favored.
9. **Caco-2:** Ligand A (-5.474) and Ligand B (-4.487) are both negative, indicating poor permeability. This is a concern for both, but Ligand B is slightly better.
10. **Solubility:** Both ligands have very poor aqueous solubility (-2.617 and -2.687). This is a significant drawback for both and would require formulation strategies.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.07 and 0.212). This is excellent for both.
12. **Cl_mic:** Ligand A (-2.155) has a significantly lower (better) microsomal clearance than Ligand B (15.255). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (-12.517) has a longer in vitro half-life than Ligand B (-14.994). This is a positive for Ligand A.
14. **Pgp:** Ligand A (0.026) has a much lower Pgp efflux liability than Ligand B (0.094). This is a significant advantage for Ligand A, improving bioavailability.
15. **Binding Affinity:** Both ligands have similar binding affinities (-6.8 and -6.0 kcal/mol). The difference is not substantial enough to outweigh other factors.
**Overall Assessment:**
Ligand B has advantages in logP, TPSA, and BBB penetration, which are important for GPCRs. However, Ligand A has a clear advantage in metabolic stability (Cl_mic), in vitro half-life, and Pgp efflux. The poor solubility of both is a major concern, but can be addressed with formulation. Given the importance of metabolic stability and reduced efflux for *in vivo* efficacy, and the relatively modest advantage of Ligand B's logP and TPSA, I favor Ligand A.
Output:
1
2025-04-17 18:36:09,492 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (365.9 and 353.4 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (61.36) is significantly better than Ligand B (98.66). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold. Ligand B is approaching the upper limit.
3. **logP:** Ligand A (2.536) is optimal, while Ligand B (0.157) is quite low. This is a significant drawback for Ligand B, potentially hindering membrane permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (6). Similar reasoning as HBD.
6. **QED:** Both are reasonable (0.785 and 0.584), with Ligand A being slightly better.
7. **DILI:** Ligand A (22.84) is significantly better than Ligand B (35.98). Lower DILI risk is crucial.
8. **BBB:** Ligand A (92.94) is much higher than Ligand B (50.68). While not a primary concern for a cardiovascular target, higher BBB is generally a positive indicator of drug-like properties.
9. **Caco-2:** Both are negative (-5.099 and -5.318), indicating poor permeability. This is concerning for both, but the lower (more negative) value for Ligand B is worse.
10. **Solubility:** Ligand A (-2.577) is better than Ligand B (-0.614). Better solubility is generally desirable.
11. **hERG:** Ligand A (0.577) is significantly better than Ligand B (0.105). Lower hERG risk is critical for cardiovascular drugs.
12. **Cl_mic:** Ligand A (11.41) is much better than Ligand B (44.17). Lower clearance indicates better metabolic stability.
13. **t1/2:** Ligand A (26.54) is much better than Ligand B (8.07). Longer half-life is desirable.
14. **Pgp:** Ligand A (0.034) is much better than Ligand B (0.051). Lower P-gp efflux is beneficial.
15. **Binding Affinity:** Ligand A (-6.7) is better than Ligand B (-4.6). A 2.1 kcal/mol difference in binding affinity is substantial and can outweigh some ADME concerns.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A excels in all these areas. While BBB isn't critical here, Ligand A's higher value is a bonus.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical parameters, including DILI, hERG, metabolic stability, permeability, and, most importantly, binding affinity. Ligand B's low logP and poor metabolic properties are significant liabilities.
Output:
1
2025-04-17 18:36:09,492 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (362.861 Da and 350.383 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (74.33) is significantly better than Ligand B (125.03). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold. Ligand B is approaching the upper limit.
3. **logP:** Ligand A (2.053) is within the optimal 1-3 range. Ligand B (-1.147) is below 1, which could hinder permeation. This is a significant negative for Ligand B.
4. **HBD:** Both ligands have 2 HBD, which is acceptable.
5. **HBA:** Ligand A has 4 HBA, while Ligand B has 8. Ligand A is preferable as it's closer to the ideal <10.
6. **QED:** Ligand A (0.859) has a much better QED score than Ligand B (0.698), indicating a more drug-like profile.
7. **DILI:** Ligand B (63.668) has a higher DILI risk than Ligand A (42.885), though both are acceptable.
8. **BBB:** Ligand A (67.158) has a better BBB score than Ligand B (22.179), though neither is particularly high. This isn't a major concern for a cardiovascular target.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability in this assay. However, the scale is not specified, so the absolute values are hard to interpret.
10. **Solubility:** Both ligands have negative solubility values, which is also unusual. Again, the scale is not specified.
11. **hERG:** Ligand A (0.23) has a significantly lower hERG inhibition liability than Ligand B (0.081), which is a critical advantage for cardiovascular drugs.
12. **Cl_mic:** Ligand B (-13.594) has a much lower (better) microsomal clearance than Ligand A (-7.761), indicating better metabolic stability.
13. **t1/2:** Ligand B (-27.053) has a much longer in vitro half-life than Ligand A (25.09). This is a strong positive for Ligand B.
14. **Pgp:** Both ligands have very low Pgp efflux liability.
15. **Binding Affinity:** Ligand A (-7.8) has a slightly better binding affinity than Ligand B (-7.5), but the difference is relatively small.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand A excels in logP and TPSA, and has slightly better affinity. Ligand B has better metabolic stability (Cl_mic) and half-life, but its poor logP and higher TPSA are significant drawbacks. The lower hERG risk of Ligand A is also a major advantage for a cardiovascular target.
**Conclusion:**
Despite the better metabolic stability and half-life of Ligand B, Ligand A is the more promising candidate due to its superior logP, TPSA, QED, and significantly lower hERG risk. These factors are more critical for overall drug development success, particularly for a cardiovascular target.
Output:
1
2025-04-17 18:36:09,493 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (344.365 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (51.85) is significantly better than Ligand B (76.46). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (2.926) is optimal, while Ligand B (0.61) is a bit low. A logP below 1 can hinder membrane permeability.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A (4) is better than Ligand B (6). Higher HBA can sometimes reduce permeability.
6. **QED:** Both ligands have good QED scores (A: 0.774, B: 0.817), indicating good drug-like properties.
7. **DILI:** Ligand A (70.841) is slightly higher than Ligand B (60.217), indicating a slightly higher risk of liver injury, but both are acceptable.
8. **BBB:** Not a primary concern for a cardiovascular target, but Ligand A (85.459) has better BBB penetration than Ligand B (68.399).
9. **Caco-2:** Ligand A (-4.712) and Ligand B (-5.355) both have negative values, indicating poor permeability.
10. **Solubility:** Ligand A (-3.545) is better than Ligand B (-2.058), indicating better aqueous solubility.
11. **hERG:** Both ligands have very low hERG inhibition risk (A: 0.654, B: 0.156), which is excellent.
12. **Cl_mic:** Ligand A (6.43) has a significantly lower microsomal clearance than Ligand B (9.726), suggesting better metabolic stability.
13. **t1/2:** Ligand A (11.4) has a longer in vitro half-life than Ligand B (15.237).
14. **Pgp:** Ligand A (0.275) has lower P-gp efflux than Ligand B (0.065), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand B (-5.8) has a slightly better binding affinity than Ligand A (-5.5), a difference of 0.3 kcal/mol.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has a better logP and TPSA, and Pgp efflux. The affinity difference is small. The better metabolic stability (lower Cl_mic and longer t1/2) of Ligand A is also a significant advantage.
**Conclusion:**
While Ligand B has slightly better binding affinity, Ligand A demonstrates a superior balance of properties, particularly in terms of predicted permeability (TPSA, logP, Caco-2), metabolic stability, and P-gp efflux. These factors are crucial for achieving adequate *in vivo* exposure and efficacy.
Output:
1
2025-04-17 18:36:09,493 - INFO - Reasoning:
Let's analyze Ligand A and Ligand B for their potential as ADRB2 ligands, keeping in mind GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key).
**Molecular Weight:** Both ligands (350.459 and 346.471 Da) are within the ideal 200-500 Da range.
**TPSA:** Ligand A (82.03) is slightly higher than Ligand B (58.64). Both are below the 140 threshold for oral absorption, but Ligand B is significantly better, potentially indicating better permeability.
**logP:** Both ligands (2.139 and 2.575) are within the optimal 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability.
**H-Bond Donors/Acceptors:** Ligand A has 3 HBD and 4 HBA, while Ligand B has 1 HBD and 3 HBA. Ligand B is preferable here, having fewer H-bonds, which generally improves permeability.
**QED:** Ligand A (0.734) has a better QED score than Ligand B (0.569), suggesting a more drug-like profile overall.
**DILI:** Both ligands have similar low DILI risk (27.724 and 28.461 percentile).
**BBB:** Ligand B (75.107) has a significantly higher BBB penetration percentile than Ligand A (40.52). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be useful for understanding off-target effects and distribution.
**Caco-2 Permeability:** Ligand A (-4.623) and Ligand B (-4.805) both have negative values, which is unusual and suggests poor permeability. However, the scale isn't defined here, so it's hard to interpret.
**Aqueous Solubility:** Ligand A (-1.503) has better aqueous solubility than Ligand B (-2.421).
**hERG:** Both ligands have low hERG inhibition liability (0.437 and 0.216). Ligand B is slightly better.
**Microsomal Clearance:** Ligand A (-0.561) has a lower (better) microsomal clearance than Ligand B (35.914). This suggests better metabolic stability for Ligand A.
**In vitro Half-Life:** Ligand A (12.367 hours) has a significantly longer half-life than Ligand B (-2.108 hours). This is a major advantage for Ligand A.
**P-gp Efflux:** Ligand A (0.122) has lower P-gp efflux than Ligand B (0.135), which is preferable.
**Binding Affinity:** Both ligands have excellent binding affinity (-5.5 and -4.9 kcal/mol). Ligand A is slightly better, but the difference is not huge.
**Overall Assessment:**
Ligand A has advantages in QED, metabolic stability (Cl_mic & t1/2), P-gp efflux, and slightly better affinity. Ligand B excels in TPSA and BBB penetration, and has fewer H-bonds. Considering the GPCR-specific priorities, the lower TPSA and higher BBB of Ligand B are attractive. However, the significantly better metabolic stability and half-life of Ligand A are crucial for *in vivo* efficacy. The slightly better affinity of Ligand A further tips the balance.
Output:
1
2025-04-17 18:36:09,493 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (351.451 and 354.491 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (122.27) is slightly higher than Ligand B (87.66). For a cardiovascular GPCR, TPSA is not a *major* concern unless it exceeds 140, which neither does. Ligand B is preferable here.
3. **logP:** Ligand B (1.323) is better positioned within the optimal 1-3 range than Ligand A (0.424), which is quite low and could indicate poor membrane permeability. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (4) is slightly higher than Ligand B (3), but both are acceptable (<=5).
5. **HBA:** Ligand A (6) is higher than Ligand B (4), but both are within the acceptable range (<=10).
6. **QED:** Both ligands have similar QED values (0.592 and 0.552), indicating good drug-like properties.
7. **DILI:** Ligand B (10.198) has a *much* lower DILI risk than Ligand A (43.932). This is a critical advantage for Ligand B.
8. **BBB:** Ligand A (63.358) has a better BBB penetration percentile than Ligand B (57.619). However, for a cardiovascular target, BBB penetration is not a high priority.
9. **Caco-2:** Ligand A (-5.456) has a worse Caco-2 permeability than Ligand B (-4.68).
10. **Solubility:** Ligand A (-2.325) has a worse solubility than Ligand B (-2.949).
11. **hERG:** Both ligands have very low hERG inhibition risk (0.252 and 0.285). No significant difference.
12. **Cl_mic:** Ligand A (4.102) has a lower microsomal clearance than Ligand B (59.627), suggesting better metabolic stability. This is a positive for Ligand A.
13. **t1/2:** Ligand B (7.763) has a significantly longer in vitro half-life than Ligand A (0.687). This is a major advantage for Ligand B.
14. **Pgp:** Ligand A (0.022) has a lower P-gp efflux liability than Ligand B (0.085). This is a positive for Ligand A.
15. **Affinity:** Ligand B (-7.4) has a *much* stronger binding affinity than Ligand A (-1.3). This is the most important factor, and the difference of 6.1 kcal/mol is substantial.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand B excels in logP and affinity, and has a better TPSA. While Ligand A has slightly better Pgp and Cl_mic, the substantial advantage in affinity and the lower DILI risk of Ligand B outweigh these factors.
**Conclusion:**
Ligand B is the superior candidate due to its significantly stronger binding affinity, lower DILI risk, better logP, and longer half-life. These factors are more important for a cardiovascular GPCR target than the slight advantages Ligand A has in metabolic stability and P-gp efflux.
Output:
0
2025-04-17 18:36:09,493 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**1. Molecular Weight:** Both ligands (343.511 Da and 352.425 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (38.33) is better than Ligand B (42.43). Both are below the 140 threshold for oral absorption, but lower TPSA is generally preferred for GPCRs as it can improve brain penetration.
**3. logP:** Ligand A (4.794) is slightly higher than Ligand B (3.716). While both are within the acceptable range of 1-3, Ligand A is pushing the upper limit. This could potentially lead to solubility issues or off-target interactions, but is not a dealbreaker.
**4. H-Bond Donors:** Ligand A (1) is better than Ligand B (0). Lower HBD is generally preferred for better membrane permeability.
**5. H-Bond Acceptors:** Both ligands have 3 HBA, which is acceptable.
**6. QED:** Ligand A (0.781) is better than Ligand B (0.67), indicating a more drug-like profile.
**7. DILI Risk:** Ligand A (16.247) is significantly better than Ligand B (22.489). Lower DILI risk is highly desirable.
**8. BBB Penetration:** Ligand B (91.121) is better than Ligand A (69.523). For a cardiovascular GPCR, BBB penetration isn't a primary concern, but it's a slight advantage for Ligand B.
**9. Caco-2 Permeability:** Ligand A (-4.672) is better than Ligand B (-3.925). Higher Caco-2 permeability is preferred.
**10. Aqueous Solubility:** Ligand A (-5.492) is better than Ligand B (-4.065). Higher solubility is preferred.
**11. hERG Inhibition:** Ligand A (0.714) is better than Ligand B (0.548). Lower hERG inhibition is crucial for avoiding cardiotoxicity.
**12. Microsomal Clearance:** Ligand B (74.939) is better than Ligand A (106.726). Lower clearance indicates better metabolic stability.
**13. In vitro Half-Life:** Ligand A (16.925) is better than Ligand B (14.598). Longer half-life is generally preferred.
**14. P-gp Efflux:** Ligand A (0.524) is better than Ligand B (0.136). Lower P-gp efflux is preferred.
**15. Binding Affinity:** Ligand A (-7.2 kcal/mol) is significantly better than Ligand B (-5.9 kcal/mol). This is a substantial difference in potency, and a 1.3 kcal/mol advantage often outweighs minor ADME drawbacks.
**Overall Assessment:**
Ligand A demonstrates a superior profile overall, particularly regarding potency (binding affinity), DILI risk, hERG inhibition, solubility, and QED. While Ligand B has better BBB penetration and microsomal clearance, these are less critical for a cardiovascular target like ADRB2. The significant potency advantage of Ligand A, coupled with its better safety profile, makes it the more promising drug candidate.
Output:
1
2025-04-17 18:36:09,493 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (343.39) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (60.77) has a significantly lower TPSA than Ligand A (104.6). This is a major advantage for oral absorption and potentially better BBB penetration, crucial for a GPCR.
3. **logP:** Ligand B (3.233) is closer to the optimal range (1-3) than Ligand A (0.238), which is quite low and could hinder membrane permeability.
4. **HBD:** Ligand A (3) and Ligand B (2) are both acceptable, below the threshold of 5.
5. **HBA:** Ligand A (5) and Ligand B (3) are both acceptable, below the threshold of 10.
6. **QED:** Both ligands have good QED scores (A: 0.699, B: 0.722), indicating good drug-like properties.
7. **DILI:** Ligand B (10.59) has a much lower DILI risk than Ligand A (67.51), a significant advantage.
8. **BBB:** Ligand B (75.11) shows significantly better predicted BBB penetration than Ligand A (41.61). While ADRB2 isn't exclusively a CNS target, some peripheral effects are mediated by CNS pathways, and better BBB penetration can be beneficial.
9. **Caco-2:** Ligand A (-5.561) has a more negative Caco-2 value, suggesting better permeability than Ligand B (-4.194). However, the TPSA difference is likely more impactful.
10. **Solubility:** Ligand A (-2.431) has slightly better predicted solubility than Ligand B (-3.654).
11. **hERG:** Ligand A (0.168) has a lower hERG risk than Ligand B (0.646), which is preferable.
12. **Cl_mic:** Ligand B (83.74) has a much higher microsomal clearance than Ligand A (0.932), indicating faster metabolism and potentially lower *in vivo* exposure. This is a significant drawback.
13. **t1/2:** Ligand A (21.97) has a much longer *in vitro* half-life than Ligand B (7.17), which is a major advantage.
14. **Pgp:** Ligand A (0.008) has a much lower Pgp efflux liability than Ligand B (0.309), which is favorable for oral bioavailability and CNS exposure.
15. **Affinity:** Ligand A (-7.6) has a slightly better binding affinity than Ligand B (-6.5), a difference of 1.1 kcal/mol. While significant, the other ADME properties are more concerning for Ligand B.
**Overall Assessment:**
Ligand B excels in TPSA, logP, DILI, and BBB penetration, all critical for a GPCR target. However, its high microsomal clearance, shorter half-life, and higher Pgp efflux are substantial drawbacks. Ligand A has a better metabolic profile (lower Cl_mic, longer t1/2, lower Pgp) and lower DILI risk, but suffers from a lower logP and higher TPSA. The affinity difference is not large enough to overcome the ADME liabilities of Ligand B.
Considering the balance of properties and the GPCR-specific priorities, Ligand A is the more promising candidate.
Output:
1
2025-04-17 18:36:09,494 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [370.465, 58.2, 3.371, 2, 3, 0.773, 43.117, 89.957, -4.729, -3.82, 0.758, 46.137, 25.437, 0.316, -6.4]
**Ligand B:** [346.431, 98.06, 1.335, 3, 3, 0.72, 44.513, 46.181, -5.069, -2.898, 0.21, -5.066, -12.013, 0.03, -3.4]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity, and BBB):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (346.431) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (58.2) is significantly better than Ligand B (98.06). ADRB2 is not a CNS target, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold. Ligand B is approaching the upper limit.
3. **logP:** Ligand A (3.371) is optimal. Ligand B (1.335) is a bit low, potentially hindering membrane permeability.
4. **HBD/HBA:** Both have similar numbers (A: 2/3, B: 3/3). These are acceptable.
5. **QED:** Both are good (A: 0.773, B: 0.72), indicating drug-like properties.
6. **DILI:** Both are acceptable (A: 43.117, B: 44.513), below the 60% risk threshold.
7. **BBB:** Ligand A (89.957) is much better than Ligand B (46.181). While not a primary concern for a cardiovascular target, higher BBB penetration can sometimes indicate better overall permeability and distribution.
8. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-4.729) is slightly better than Ligand B (-5.069).
9. **Solubility:** Ligand A (-3.82) is better than Ligand B (-2.898).
10. **hERG:** Ligand A (0.758) is better than Ligand B (0.21). Lower hERG inhibition is crucial for avoiding cardiotoxicity, especially for a cardiovascular target.
11. **Cl_mic:** Ligand B (-5.066) has a negative clearance, which is very good, indicating high metabolic stability. Ligand A (46.137) is moderate.
12. **t1/2:** Ligand B (-12.013) has a negative half-life, which is very good, indicating high stability. Ligand A (25.437) is moderate.
13. **Pgp:** Ligand A (0.316) is better than Ligand B (0.03). Lower P-gp efflux is desirable for better bioavailability.
14. **Affinity:** Ligand A (-6.4) is significantly better than Ligand B (-3.4). A 3 kcal/mol difference in binding affinity is substantial and can often outweigh minor ADME drawbacks.
**Conclusion:**
While Ligand B has superior metabolic stability (Cl_mic and t1/2), Ligand A has a much stronger binding affinity, better TPSA, logP, BBB penetration, hERG risk, and Pgp efflux. The affinity difference is the most important factor here, and the other advantages of Ligand A make it the more promising candidate.
Output:
1
2025-04-17 18:36:09,494 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (360.424 and 362.407 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (58.95) is significantly better than Ligand B (94.59). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally correlates with better absorption. Ligand B's TPSA is approaching a level that could hinder oral bioavailability.
3. **logP:** Ligand A (4.017) is higher than Ligand B (1.673). While both are within the acceptable range (1-3), Ligand A is at the upper limit. This *could* lead to solubility issues, but the benefit of good binding may outweigh this. Ligand B is on the lower side, potentially impacting permeability.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1). Both are acceptable.
5. **HBA:** Ligand A (3) is lower than Ligand B (6). This favors Ligand A, as fewer HBA generally improves permeability.
6. **QED:** Ligand B (0.869) has a better QED score than Ligand A (0.654), indicating a more generally drug-like profile.
7. **DILI:** Ligand A (39.046) has a significantly lower DILI risk than Ligand B (88.639). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (78.79) has a higher BBB percentile than Ligand B (40.713). While not critical for a cardiovascular target, it's a slight positive for Ligand A.
9. **Caco-2:** Ligand A (-4.748) is better than Ligand B (-5.014). Both are negative, indicating poor permeability, but A is slightly less poor.
10. **Solubility:** Ligand A (-4.446) is better than Ligand B (-3.098). Both are poor, but A is less poor.
11. **hERG:** Ligand A (0.61) is much better than Ligand B (0.042). Lower hERG inhibition is crucial for avoiding cardiotoxicity, and Ligand B presents a significant risk.
12. **Cl_mic:** Ligand B (-7.612) has a *much* lower (better) microsomal clearance than Ligand A (37.681). This suggests significantly better metabolic stability for Ligand B.
13. **t1/2:** Ligand A (39.068) has a longer in vitro half-life than Ligand B (11.94). This is a positive for Ligand A.
14. **Pgp:** Ligand A (0.319) is better than Ligand B (0.058). Lower P-gp efflux is favorable.
15. **Binding Affinity:** Ligand A (-7.6) has a slightly better binding affinity than Ligand B (-6.5). While the difference is not huge, it's enough to consider.
**GPCR-Specific Priorities & Overall Assessment:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A excels in affinity and Pgp, and has a better TPSA. Ligand B has better metabolic stability (Cl_mic) and QED. However, the *major* concerns with Ligand B are its high DILI risk and very low hERG inhibition. These are critical liabilities for a cardiovascular drug. Despite Ligand A's slightly higher logP and poorer metabolic stability, the significantly lower toxicity profile and better hERG score make it the more promising candidate. The slight advantage in binding affinity also tips the scales.
Output:
1
2025-04-17 18:36:09,494 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (388.471 and 343.431 Da) fall within the ideal 200-500 Da range. Ligand B is slightly smaller, which *could* be advantageous for permeability, but the difference isn't substantial.
2. **TPSA:** Ligand A (130.39) is slightly above the preferred <140 for good oral absorption, but still reasonable. Ligand B (101.21) is well within the acceptable range. This favors Ligand B.
3. **logP:** Ligand A (-0.115) is a bit low, potentially hindering membrane permeability. Ligand B (1.214) is within the optimal 1-3 range. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (3) and Ligand B (2) are both acceptable, being less than 5.
5. **HBA:** Ligand A (7) and Ligand B (5) are both acceptable, being less than 10.
6. **QED:** Both ligands have good QED scores (0.633 and 0.837), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (79.953) has a higher DILI risk than Ligand B (47.964). This is a clear advantage for Ligand B.
8. **BBB:** Ligand A (36.371) has poor BBB penetration, while Ligand B (73.866) is much better. While ADRB2 isn't strictly a CNS target, some peripheral ADRB2 receptors influence CNS function, and better BBB penetration is rarely a negative. This favors Ligand B.
9. **Caco-2:** Both ligands have similar, very negative Caco-2 values (-5.319 and -5.009). This suggests poor intestinal absorption for both, which is concerning.
10. **Solubility:** Both ligands have very poor aqueous solubility (-2.769 and -2.964). This is a significant drawback for both, potentially requiring formulation strategies.
11. **hERG:** Both ligands have low hERG inhibition risk (0.312 and 0.223).
12. **Cl_mic:** Ligand A (30.708) and Ligand B (27.112) have similar microsomal clearance values, suggesting comparable metabolic stability.
13. **t1/2:** Ligand A (-12.807) and Ligand B (-10.268) have negative in vitro half-lives, which is not ideal.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.042 and 0.006).
15. **Binding Affinity:** Ligand B (-8.3 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.3 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME concerns.
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are crucial. Ligand B excels in logP and affinity, and performs better in TPSA and BBB penetration. While both have poor solubility and Caco-2 permeability, the stronger binding affinity of Ligand B is a significant advantage that could be addressed with formulation strategies.
**Conclusion:**
Ligand B is the more promising candidate due to its superior logP, lower DILI risk, better BBB penetration, and significantly stronger binding affinity. While both have solubility and absorption issues, the potency advantage of Ligand B is likely to be more impactful in driving efficacy.
Output:
0
2025-04-17 18:36:09,494 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
We are targeting ADRB2, a GPCR. Therefore, the priorities are logP, Pgp, TPSA, affinity, and BBB. Let's analyze each ligand against these and other relevant parameters.
* **Molecular Weight:** Both ligands (354.38 and 348.45 Da) fall within the ideal 200-500 Da range.
* **TPSA:** Ligand A (59.81) is significantly better than Ligand B (83.36). A TPSA under 140 is good for oral absorption, and lower is generally preferred for GPCRs. Ligand B is pushing the upper limit.
* **logP:** Ligand A (3.333) is within the optimal 1-3 range. Ligand B (0.266) is quite low, potentially hindering membrane permeability and absorption.
* **H-Bond Donors/Acceptors:** Both have acceptable HBD counts (1). Ligand B has a higher HBA count (6 vs 4), which could slightly impact permeability.
* **QED:** Both ligands have good QED scores (0.916 and 0.826), indicating good drug-like properties.
* **DILI:** Ligand A (56.19) has a higher DILI risk than Ligand B (28.58), but both are below the concerning threshold of 60.
* **BBB:** Ligand A (78.60) has a better BBB penetration score than Ligand B (59.95). While not a CNS target, some peripheral GPCRs benefit from limited BBB penetration to reduce off-target effects.
* **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests potential issues with permeability prediction. However, the values are close enough that this isn't a major differentiator.
* **Solubility:** Ligand A (-3.938) has better solubility than Ligand B (-1.255).
* **hERG:** Ligand A (0.544) has a slightly higher hERG risk than Ligand B (0.106), but both are relatively low.
* **Cl_mic:** Ligand B (8.212) has significantly lower microsomal clearance than Ligand A (66.082), suggesting better metabolic stability.
* **t1/2:** Ligand B (12.966) has a much longer in vitro half-life than Ligand A (2.724), which is a significant advantage.
* **Pgp:** Ligand A (0.187) has lower P-gp efflux liability than Ligand B (0.007), which is preferable for bioavailability.
* **Binding Affinity:** Ligand B (-6.8 kcal/mol) has a slightly better binding affinity than Ligand A (-5.7 kcal/mol). This is a 1.1 kcal/mol difference, which is substantial.
**Overall Assessment:**
Ligand B has a superior binding affinity and better metabolic stability (lower Cl_mic, longer t1/2). However, its low logP and higher TPSA are concerning for permeability and absorption. Ligand A has better physicochemical properties (logP, TPSA, solubility, Pgp) and a reasonable BBB score, but its metabolic stability is a concern.
The binding affinity difference is significant. Given that we are dealing with a GPCR, optimizing binding is crucial. The lower logP of Ligand B can potentially be addressed through structural modifications, but improving the binding affinity of Ligand A would be more challenging. The better metabolic stability of Ligand B also reduces the risk of rapid drug clearance.
Therefore, despite the slightly less favorable physicochemical profile, the stronger binding affinity and improved metabolic stability of Ligand B make it the more promising candidate.
**Output:**
0
2025-04-17 18:36:09,494 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.49 and 347.46 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (67.43 and 66.65) are below the 140 A^2 threshold for good oral absorption, and well below the 90 A^2 threshold for CNS targets (though ADRB2 isn't necessarily a CNS target). Again, no major difference.
3. **logP:** Both ligands have good logP values (2.42 and 2.80), falling within the optimal 1-3 range. Ligand B is slightly higher, which *could* be a minor advantage for membrane permeability, but isn't a deciding factor.
4. **HBD:** Ligand A has 2 HBD, and Ligand B has 0. Generally, fewer HBDs are preferred for better permeability. Ligand B is better here.
5. **HBA:** Ligand A has 3 HBA, and Ligand B has 4. Similar to HBD, fewer is generally better. Ligand A is slightly better.
6. **QED:** Both ligands have good QED scores (0.596 and 0.725), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A has a DILI risk of 18.34%, and Ligand B has 28.23%. Both are below the 40% threshold, but Ligand A is significantly better, indicating a lower risk of liver injury. This is a substantial advantage.
8. **BBB:** Both ligands have high BBB penetration (75.38% and 89.07%). While ADRB2 isn't a primary CNS target, higher BBB penetration is rarely detrimental and can offer some flexibility. Ligand B is better here.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.52 and -4.41). This is unusual and suggests poor permeability. However, the values are very close.
10. **Solubility:** Both ligands have negative solubility values (-3.78 and -2.30). This is also unusual and indicates poor aqueous solubility. Ligand B is slightly better.
11. **hERG:** Both ligands have low hERG inhibition risk (0.29% and 0.43%). Both are very good.
12. **Cl_mic:** Ligand A has a higher microsomal clearance (89.34 mL/min/kg) than Ligand B (84.00 mL/min/kg). Lower clearance is preferred for better metabolic stability, so Ligand B is better.
13. **t1/2:** Ligand A has a very short in vitro half-life (0.28 hours) while Ligand B has a negative half-life (-31.72 hours). This is a major red flag for Ligand A. A negative value is highly suspect, but even if interpreted as very rapid clearance, it's far worse than Ligand B.
14. **Pgp:** Both have low Pgp efflux liability (0.16 and 0.37). No significant difference.
15. **Affinity:** Ligand A has a significantly better binding affinity (-7.5 kcal/mol) compared to Ligand B (-6.7 kcal/mol). This is a 0.8 kcal/mol difference, which is substantial and can outweigh some ADME drawbacks.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Both ligands perform well on logP, TPSA, and Pgp. The major differences lie in affinity, DILI, and metabolic stability (Cl_mic and t1/2). The significantly stronger binding affinity of Ligand A is a major advantage. However, the poor half-life and higher DILI risk are concerning. Ligand B has a better safety profile and metabolic stability.
**Overall Assessment:**
Despite the superior binding affinity of Ligand A, the very poor in vitro half-life and higher DILI risk are significant drawbacks. The difference in affinity, while substantial, might be overcome with further optimization. Ligand B, while having slightly weaker binding, presents a much more favorable ADME-Tox profile, particularly regarding metabolic stability and liver toxicity. Given the need for a balanced profile for a viable drug candidate, I favor Ligand B.
Output:
0
2025-04-17 18:36:09,495 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.431 and 351.47 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (93.51) is slightly higher than Ligand B (84.14). Both are below the 140 threshold for good oral absorption, but closer to the 90 threshold for CNS targets (less relevant for ADRB2, a cardiovascular target). Ligand B is preferable.
3. **logP:** Ligand A (1.546) is within the optimal range (1-3), while Ligand B (3.303) is at the higher end. While still acceptable, Ligand A's logP is more balanced.
4. **HBD:** Ligand A (1) is better than Ligand B (2). Lower HBD is generally preferred for permeability.
5. **HBA:** Ligand A (6) is better than Ligand B (4). Lower HBA is generally preferred for permeability.
6. **QED:** Ligand A (0.873) is significantly better than Ligand B (0.738), indicating a more drug-like profile.
7. **DILI:** Both ligands have low DILI risk (42.187 and 39.318, respectively), both well below the 60 threshold. No significant difference.
8. **BBB:** Ligand A (88.872) is lower than Ligand B (97.014). While BBB isn't a primary concern for ADRB2, higher is generally better. Ligand B is preferable.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.585 and -4.732). These values are unusual and might indicate issues with the prediction method or the molecule's structure. It's difficult to interpret without further information.
10. **Solubility:** Both ligands have negative solubility values (-2.879 and -3.179). Similar to Caco-2, these values are concerning and require further investigation.
11. **hERG:** Both ligands have low hERG risk (0.86 and 0.705, respectively), which is good.
12. **Cl_mic:** Ligand A (3.998) has a lower microsomal clearance than Ligand B (45.468), suggesting better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand A (40.774) has a longer in vitro half-life than Ligand B (-7.516). This is a substantial advantage, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.093 and 0.293, respectively). No significant difference.
15. **Binding Affinity:** Ligand B (-6.8 kcal/mol) has a slightly better binding affinity than Ligand A (-5.6 kcal/mol). This is a 1.2 kcal/mol difference, which is significant.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B has a better logP and affinity, and a slightly better BBB. However, Ligand A has a significantly better QED, lower Cl_mic, and a much longer half-life. The metabolic stability and half-life advantages of Ligand A are substantial, and the affinity difference, while noticeable, might be overcome with further optimization. The negative solubility and Caco-2 values for both are red flags that need to be addressed, but don't immediately disqualify either.
**Conclusion:**
Considering the balance of properties, particularly the superior metabolic stability and half-life of Ligand A, I believe it is the more promising drug candidate despite the slightly weaker affinity. The affinity can be optimized later, but improving metabolic stability is often more challenging.
Output:
1
2025-04-17 18:36:09,495 - INFO - Batch 49 complete. Total preferences: 784
2025-04-17 18:36:09,495 - INFO - Processing batch 50/512...
2025-04-17 18:37:00,325 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (346.312 Da) is better, falling comfortably within the 200-500 Da range. Ligand B (398.981 Da) is still acceptable but closer to the upper limit.
2. **TPSA:** Ligand B (49.41) is superior, being lower than Ligand A (59.81). Both are below the 140 threshold for good absorption, but lower is generally preferred for GPCRs.
3. **logP:** Both ligands have excellent logP values (A: 3.352, B: 3.216), falling within the optimal 1-3 range. This suggests good membrane permeability.
4. **HBD:** Both have 1 HBD, which is ideal.
5. **HBA:** Both have 4 HBA, which is also ideal.
6. **QED:** Both ligands have good QED scores (A: 0.737, B: 0.775), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand B (40.713) is significantly better than Ligand A (79.953) in terms of DILI risk. This is a major advantage for Ligand B.
8. **BBB:** Both ligands have good BBB penetration (A: 70.221, B: 76.309). This is important for GPCRs, and both are above the 70% threshold. Ligand B is slightly better.
9. **Caco-2:** Both have negative Caco-2 values which is unusual. I will assume these are percentile values and that higher is better. Ligand B (-5.289) is better than Ligand A (-4.682).
10. **Solubility:** Both have negative solubility values which is unusual. I will assume these are percentile values and that higher is better. Ligand B (-4.5) is better than Ligand A (-3.891).
11. **hERG:** Both ligands have low hERG inhibition liability (A: 0.789, B: 0.515). Ligand B is slightly better.
12. **Cl_mic:** Ligand A (45.304) has a lower microsomal clearance than Ligand B (52.908), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-12.533) has a significantly longer in vitro half-life than Ligand A (-3.43). This is a substantial advantage for Ligand B.
14. **Pgp:** Both have low Pgp efflux liability (A: 0.342, B: 0.518).
15. **Affinity:** Ligand B (-7.7 kcal/mol) has a slightly better binding affinity than Ligand A (-7.3 kcal/mol). While the difference is not huge, it is still a positive factor.
**Overall Assessment:**
Ligand B consistently outperforms Ligand A in several critical ADME-Tox parameters, most notably DILI risk and in vitro half-life. While Ligand A has slightly better metabolic stability (Cl_mic), the benefits of Ligand B in terms of safety (DILI) and duration of action (t1/2) are more significant for a cardiovascular GPCR target. The slightly better affinity of Ligand B further strengthens its position. Both ligands are within acceptable ranges for MW, logP, TPSA, and BBB, making the ADME-Tox profile the deciding factor.
Output:
0
2025-04-17 18:37:00,326 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (334.419 Da and 344.411 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (54.12) is significantly better than Ligand B (66.9). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (4.923) is higher than Ligand B (2.944). While both are within the acceptable range (1-3 is optimal, but up to 4 is tolerable), Ligand A is pushing the upper limit. This *could* lead to solubility issues, but the benefit of higher binding affinity might offset this.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (0). This is not a major concern for either.
5. **HBA:** Ligand A (2) is lower than Ligand B (4). Lower is generally preferred for permeability.
6. **QED:** Both ligands have similar QED values (0.711 and 0.774), indicating good drug-like properties.
7. **DILI:** Ligand B (32.648) has a *much* lower DILI risk than Ligand A (83.637). This is a significant advantage for Ligand B. DILI is a major concern in drug development.
8. **BBB:** Both ligands have good BBB penetration (70.609 and 75.107), but this is less critical for a cardiovascular target like ADRB2.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual. Assuming these are logP-scale values, lower values indicate lower permeability. Ligand A (-4.74) is worse than Ligand B (-4.187).
10. **Solubility:** Ligand B (-2.399) has better solubility than Ligand A (-6.754). This is important, and complements the lower logP of Ligand B.
11. **hERG:** Ligand A (0.815) has a slightly higher hERG risk than Ligand B (0.278). Lower hERG risk is crucial for cardiovascular drugs.
12. **Cl_mic:** Ligand B (71.23) has slightly better metabolic stability (lower clearance) than Ligand A (69.806).
13. **t1/2:** Both ligands have similar in vitro half-lives (37.423 and 36.012 hours).
14. **Pgp:** Ligand A (0.777) has higher Pgp efflux than Ligand B (0.221). Lower Pgp efflux is desirable for better bioavailability.
15. **Binding Affinity:** Ligand A (-7.7) has a slightly better binding affinity than Ligand B (-7.0). This is a 0.7 kcal/mol difference, which is significant, but not overwhelming.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A has a higher logP and better affinity, but also higher TPSA, Pgp efflux, and a significantly higher DILI risk. Ligand B has better ADME properties (lower DILI, better solubility, lower Pgp, lower hERG) at the cost of slightly lower affinity.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity, the substantial improvement in safety (DILI, hERG) and ADME properties (solubility, Pgp) with Ligand B are more compelling. The 0.7 kcal/mol difference in affinity is unlikely to outweigh the risks associated with Ligand A's profile. A small decrease in potency can often be overcome with dose adjustments, while a high DILI risk or poor ADME can be fatal to a drug candidate.
Output:
0
2025-04-17 18:37:00,326 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.475 and 343.427 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (87.46) is slightly higher than Ligand B (82.53). Both are below the 140 threshold for good oral absorption, and acceptable for a cardiovascular target (not needing significant CNS penetration).
3. **logP:** Ligand A (1.885) and Ligand B (1.058) are both within the optimal 1-3 range. Ligand A is slightly preferable as Ligand B is closer to the lower limit, which *could* indicate permeability issues, though both are acceptable.
4. **HBD:** Ligand A (3) and Ligand B (2) are both acceptable (<=5). Ligand B is slightly better.
5. **HBA:** Both ligands have 4 HBA, which is well within the acceptable limit of <=10.
6. **QED:** Ligand B (0.837) has a higher QED score than Ligand A (0.596), indicating a more drug-like profile. This is a significant advantage for Ligand B.
7. **DILI:** Ligand A (28.577) has a lower DILI risk than Ligand B (32.454). Lower is better, so Ligand A is preferable.
8. **BBB:** Ligand A (71.307) has a higher BBB percentile than Ligand B (46.879). While ADRB2 isn't necessarily a CNS target, some off-target CNS effects are possible with GPCR ligands, so higher BBB is generally favorable.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.358 and -5.035), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Both ligands have negative solubility values (-1.602 and -1.284), which is also unusual and indicates very poor aqueous solubility. This is a major issue for both.
11. **hERG:** Ligand A (0.641) has a slightly higher hERG risk than Ligand B (0.225). Lower is better, so Ligand B is preferable.
12. **Cl_mic:** Ligand B (-10.525) has a lower (better) microsomal clearance than Ligand A (-10.08). This suggests better metabolic stability for Ligand B.
13. **t1/2:** Ligand A (7.077) has a longer half-life than Ligand B (4.246). This is a positive for Ligand A.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.032 and 0.033). No significant difference.
15. **Binding Affinity:** Ligand B (-7.1 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.3 kcal/mol). This is a 0.8 kcal/mol difference, which is substantial and can outweigh some ADME drawbacks.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B excels in affinity and has acceptable logP and TPSA. While both have poor Caco-2 and solubility, the superior affinity of Ligand B is a strong advantage. The slightly better QED and lower hERG risk also favor Ligand B.
**Conclusion:**
Despite the poor permeability and solubility of both, Ligand B's significantly stronger binding affinity and better overall ADME profile (QED, Cl_mic, hERG) make it the more promising candidate.
Output:
0
2025-04-17 18:37:00,326 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [354.313, 115.39 , -0.88 , 3. , 5. , 0.574, 58.24 , 40.093, -5.156, -2.204, 0.198, -30.76 , -40.557, 0.026, -7.1 ]
**Ligand B:** [355.391, 92.12 , 0.238, 0. , 9. , 0.642, 61.109, 70.027, -4.313, -1.338, 0.218, 70.083, -39.303, 0.067, -5.1 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). A: 354.313, B: 355.391. No significant difference.
2. **TPSA:** Ligand A (115.39) is slightly higher than Ligand B (92.12). Both are acceptable for a non-CNS GPCR, but B is preferable.
3. **logP:** Ligand A (-0.88) is a bit low, potentially hindering permeability. Ligand B (0.238) is better, falling within the optimal range. This favors B.
4. **HBD:** Ligand A (3) is reasonable. Ligand B (0) is even better, potentially improving permeability. This favors B.
5. **HBA:** Ligand A (5) is good. Ligand B (9) is acceptable, but higher HBA can sometimes impact permeability. A is slightly favored.
6. **QED:** Both are good (A: 0.574, B: 0.642), indicating drug-like properties. B is slightly better.
7. **DILI:** Ligand A (58.24) is better than Ligand B (61.109), indicating a lower risk of liver injury. A is favored.
8. **BBB:** Ligand B (70.027) is significantly better than Ligand A (40.093). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be beneficial or at least avoid off-target effects. B is strongly favored.
9. **Caco-2:** Ligand A (-5.156) is worse than Ligand B (-4.313). B is favored.
10. **Solubility:** Ligand A (-2.204) is worse than Ligand B (-1.338). B is favored.
11. **hERG:** Both are very low (A: 0.198, B: 0.218), indicating minimal hERG inhibition risk. No significant difference.
12. **Cl_mic:** Ligand A (-30.76) has a lower (better) microsomal clearance than Ligand B (70.083), suggesting greater metabolic stability. A is strongly favored.
13. **t1/2:** Ligand A (-40.557) has a longer half-life than Ligand B (-39.303). A is favored.
14. **Pgp:** Both are very low (A: 0.026, B: 0.067), indicating minimal P-gp efflux. No significant difference.
15. **Affinity:** Ligand A (-7.1) has a slightly better binding affinity than Ligand B (-5.1). This is a significant advantage.
**Overall Assessment:**
Ligand A has a better binding affinity, lower DILI risk, better metabolic stability (Cl_mic), and a longer half-life. However, Ligand B excels in logP, TPSA, BBB penetration, Caco-2 permeability, and solubility. For a cardiovascular GPCR like ADRB2, the improved permeability and solubility of Ligand B are quite valuable. The slightly better affinity of Ligand A is a plus, but the ADME properties of Ligand B are more balanced and potentially lead to better *in vivo* performance.
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), and the overall balance of properties, Ligand B appears to be the more promising candidate.
Output:
0
2025-04-17 18:37:00,326 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [346.347, 126.38 , -0.474, 2. , 8. , 0.749, 56.301, 37.263, -5.06 , -2.442, 0.066, 11.093, -4.722, 0.028, -8.2 ]
**Ligand B:** [379.781, 29.54 , 4.004, 0. , 2. , 0.552, 37.999, 88.406, -4.324, -4.61 , 0.653, 88.615, -25.752, 0.233, -5.9 ]
Here's a breakdown, prioritizing GPCR properties (logP, Pgp, TPSA, Affinity, and BBB):
1. **Molecular Weight:** Both are within the acceptable range (200-500 Da). Ligand A (346.347) is slightly preferred as it's lower.
2. **TPSA:** Ligand B (29.54) is *much* better than Ligand A (126.38). Below 140 is good for oral absorption, but below 90 is better for CNS penetration (though ADRB2 isn't necessarily a CNS target, lower TPSA is generally favorable).
3. **logP:** Ligand A (-0.474) is suboptimal, being below the ideal 1-3 range. Ligand B (4.004) is a bit high, potentially leading to solubility issues, but still within a manageable range.
4. **H-Bond Donors/Acceptors:** Ligand B (0/2) is better than Ligand A (2/8) in terms of minimizing potential off-target interactions and improving permeability.
5. **QED:** Ligand A (0.749) is better than Ligand B (0.552), indicating a more drug-like profile.
6. **DILI:** Ligand B (37.999) has a significantly lower DILI risk than Ligand A (56.301). This is a major advantage.
7. **BBB:** Ligand B (88.406) has a much higher BBB percentile than Ligand A (37.263). While not critical for ADRB2, it's a positive attribute.
8. **Caco-2 Permeability:** Both are negative, indicating poor permeability. Ligand A (-5.06) is worse than Ligand B (-4.324).
9. **Aqueous Solubility:** Both are negative, indicating poor solubility. Ligand B (-4.61) is slightly better.
10. **hERG:** Ligand A (0.066) is slightly better than Ligand B (0.653), indicating a lower risk of cardiotoxicity.
11. **Microsomal Clearance:** Ligand A (11.093) has a lower clearance, suggesting better metabolic stability than Ligand B (88.615).
12. **In vitro Half-Life:** Ligand A (-4.722) has a better half-life than Ligand B (-25.752).
13. **P-gp Efflux:** Ligand A (0.028) has lower P-gp efflux than Ligand B (0.233), which is favorable for bioavailability.
14. **Binding Affinity:** Ligand A (-8.2) has a significantly stronger binding affinity than Ligand B (-5.9). This is a substantial advantage.
**Overall Assessment:**
Ligand A has a superior binding affinity and better metabolic stability. However, Ligand B excels in TPSA, DILI risk, BBB penetration, and has a more favorable H-bond profile. The significantly better affinity of Ligand A is a strong point, and the slightly better P-gp efflux and hERG profile are also positive. The lower TPSA of Ligand B is attractive, but the substantial difference in binding affinity outweighs this benefit.
Therefore, I would choose Ligand A.
1
2025-04-17 18:37:00,326 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [367.49 , 62.3 , 2.485, 1. , 4. , 0.805, 36.565, 83.831, -4.854, -2.796, 0.383, 36.143, -12.238, 0.316, -7.1 ]
**Ligand B:** [352.435, 118.55 , -0.173, 4. , 5. , 0.567, 31.601, 12.175, -5.564, -1.607, 0.115, -2.793, -32.047, 0.028, -5.6 ]
Here's a breakdown comparing the two, considering the provided guidelines and GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (352.435) is slightly lower, which is generally favorable.
2. **TPSA:** Ligand A (62.3) is significantly better than Ligand B (118.55). ADRB2 is not a CNS target, but lower TPSA generally improves permeability.
3. **logP:** Ligand A (2.485) is optimal. Ligand B (-0.173) is quite low, potentially hindering membrane permeability and absorption. This is a significant drawback.
4. **HBD/HBA:** Ligand A (1 HBD, 4 HBA) is preferable to Ligand B (4 HBD, 5 HBA). Fewer H-bonds are generally better for permeability.
5. **QED:** Ligand A (0.805) has a better drug-likeness score than Ligand B (0.567).
6. **DILI:** Both have acceptable DILI risk (Ligand A: 36.565, Ligand B: 31.601), with Ligand B being slightly better.
7. **BBB:** Ligand A (83.831) has a much higher BBB percentile than Ligand B (12.175). While not a primary concern for a cardiovascular target, higher BBB is rarely detrimental.
8. **Caco-2:** Ligand A (-4.854) is better than Ligand B (-5.564), indicating better intestinal absorption.
9. **Solubility:** Ligand A (-2.796) is better than Ligand B (-1.607).
10. **hERG:** Both have low hERG inhibition liability (Ligand A: 0.383, Ligand B: 0.115), which is good.
11. **Cl_mic:** Ligand A (36.143) has a better (lower) microsomal clearance than Ligand B (-2.793), suggesting better metabolic stability.
12. **t1/2:** Ligand A (-12.238) has a better (longer) in vitro half-life than Ligand B (-32.047).
13. **Pgp:** Ligand A (0.316) has a lower P-gp efflux liability than Ligand B (0.028), which is favorable for bioavailability.
14. **Affinity:** Ligand A (-7.1 kcal/mol) has a slightly better binding affinity than Ligand B (-5.6 kcal/mol). This difference is significant.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most crucial parameters. The most significant differences are in logP (A is optimal, B is poor), TPSA (A is much lower), QED (A is higher), and binding affinity (A is stronger). While both have acceptable safety profiles, Ligand A's superior ADME properties and binding affinity make it the more promising drug candidate.
Output:
1
2025-04-17 18:37:00,326 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [341.459, 84.97, 2.055, 3, 5, 0.798, 42.264, 86.002, -5.736, -1.805, 0.819, -21.109, 19.029, 0.123, -7.1]
**Ligand B:** [347.419, 93.26, 1.122, 1, 6, 0.772, 35.789, 55.642, -5.269, -0.928, 0.111, 28.516, 43.399, 0.022, -7.2]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (341.459) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (84.97) is better than Ligand B (93.26), both being under the 140 threshold for oral absorption, but closer to the 90 threshold for CNS targets.
3. **logP:** Both are within the optimal 1-3 range. Ligand A (2.055) is slightly higher, which could be beneficial for membrane permeability but slightly increases the risk of off-target interactions. Ligand B (1.122) is a bit low, potentially hindering permeation.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (1), but both are acceptable.
5. **HBA:** Ligand A (5) is slightly higher than Ligand B (6), but both are acceptable.
6. **QED:** Both are very similar (A: 0.798, B: 0.772) and above the 0.5 threshold, indicating good drug-like properties.
7. **DILI:** Ligand A (42.264) has a slightly higher DILI risk than Ligand B (35.789), but both are below the concerning 60 percentile.
8. **BBB:** Ligand A (86.002) has significantly better BBB penetration potential than Ligand B (55.642). This is a key consideration for a GPCR target, even if not specifically CNS-focused, as it indicates better distribution.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-5.736) is slightly better than Ligand B (-5.269).
10. **Solubility:** Ligand A (-1.805) is slightly worse than Ligand B (-0.928), but both are poor.
11. **hERG:** Ligand A (0.819) has a slightly higher hERG risk than Ligand B (0.111), but both are relatively low.
12. **Cl_mic:** Ligand A (-21.109) has much better metabolic stability (lower clearance) than Ligand B (28.516). This is a significant advantage.
13. **t1/2:** Ligand A (19.029) has a shorter half-life than Ligand B (43.399).
14. **Pgp:** Ligand A (0.123) has lower P-gp efflux than Ligand B (0.022), which is favorable for bioavailability.
15. **Affinity:** Ligand B (-7.2) has slightly better binding affinity than Ligand A (-7.1), but the difference is small.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, BBB, and affinity. Ligand A excels in BBB penetration and Pgp efflux, and has a good logP. While Ligand B has slightly better affinity, the differences are minimal. Ligand A's superior metabolic stability (Cl_mic) is also a major advantage.
**Conclusion:**
Considering the balance of properties and the GPCR-specific priorities, **Ligand A** is the more promising drug candidate. The better BBB penetration, lower Pgp efflux, and significantly improved metabolic stability outweigh the slight advantage in binding affinity of Ligand B.
**Output:**
1
2025-04-17 18:37:00,326 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [356.457, 49.41, 3.521, 1, 2, 0.74, 24.777, 88.988, -4.58, -3.465, 0.565, 26.296, -13.81, 0.103, -6.2]
**Ligand B:** [364.49, 69.02, 3.273, 1, 5, 0.804, 50.95, 63.784, -4.835, -4.193, 0.805, 57.48, 6.402, 0.439, -5.7]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal 200-500 Da range. Ligand A (356.457) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (49.41) is significantly better than Ligand B (69.02). A TPSA under 140 is good for oral absorption, and lower is better for GPCRs.
3. **logP:** Both are within the optimal 1-3 range. Ligand A (3.521) is slightly higher than Ligand B (3.273), but both are acceptable.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A (2) is better than Ligand B (5). Lower HBA is generally preferred for permeability.
6. **QED:** Both have good QED scores (A: 0.74, B: 0.804), indicating drug-likeness. Ligand B is slightly better.
7. **DILI:** Ligand A (24.777) has a much lower DILI risk than Ligand B (50.95). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (88.988) has a much higher BBB penetration potential than Ligand B (63.784). This is a crucial factor for GPCRs, even if not strictly CNS-targeted, as it can influence distribution.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-4.58) is slightly better (less negative) than Ligand B (-4.835).
10. **Solubility:** Both have negative solubility values, indicating poor solubility. Ligand A (-3.465) is slightly better than Ligand B (-4.193).
11. **hERG:** Both have low hERG risk (A: 0.565, B: 0.805), which is good.
12. **Cl_mic:** Ligand A (26.296) has a lower microsomal clearance than Ligand B (57.48), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-13.81) has a more negative in vitro half-life, which is not good. Ligand B (6.402) is positive and therefore better.
14. **Pgp:** Ligand A (0.103) has a lower P-gp efflux liability than Ligand B (0.439), which is favorable for bioavailability.
15. **Affinity:** Both have good binding affinity (A: -6.2, B: -5.7). Ligand A is slightly better.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand A is the stronger candidate. While Ligand B has a slightly better QED and in vitro half-life, Ligand A excels in TPSA, DILI risk, BBB penetration, Pgp efflux, and has a slightly better binding affinity. The lower DILI risk and higher BBB penetration are particularly important advantages for a GPCR target. The slightly better permeability metrics (Caco-2 and solubility) also favor Ligand A.
Output:
1
2025-04-17 18:37:00,326 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (336.395 Da) is better than Ligand B (363.527 Da), falling comfortably within the 200-500 Da range.
2. **TPSA:** Ligand B (55.32) is significantly better than Ligand A (78.66). Lower TPSA generally favors better absorption, crucial for GPCRs.
3. **logP:** Both are good (A: 1.663, B: 3.393), within the optimal 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability but needs to be balanced against solubility.
4. **HBD:** Ligand A (3) is preferable to Ligand B (0). While low HBD can be good for permeability, some H-bonding is generally desirable for solubility and target engagement.
5. **HBA:** Ligand B (5) is slightly better than Ligand A (4). Both are within the acceptable range.
6. **QED:** Both are good (A: 0.678, B: 0.743), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand B (36.293) is *much* better than Ligand A (63.397). Lower DILI risk is a significant advantage.
8. **BBB:** Ligand B (82.784) is significantly better than Ligand A (60.566). As ADRB2 is a GPCR, BBB penetration is a desirable property, especially if targeting peripheral effects via CNS modulation.
9. **Caco-2:** Both are negative (-5.045 and -4.977), indicating poor permeability. This is a concern for both.
10. **Solubility:** Both are very poor (-3.354 and -4.077). This is a major drawback for both compounds.
11. **hERG:** Both are low risk (A: 0.404, B: 0.455).
12. **Cl_mic:** Ligand A (17.397) is *much* better than Ligand B (111.025). Lower clearance indicates better metabolic stability.
13. **t1/2:** Ligand A (40.521) is better than Ligand B (-29.224). A positive half-life is preferable.
14. **Pgp:** Both are low (A: 0.109, B: 0.221), indicating low efflux.
15. **Affinity:** Ligand B (-7.4 kcal/mol) is significantly better than Ligand A (-6.6 kcal/mol). This is a substantial difference in binding potency, and a key driver in the decision.
**Overall Assessment:**
Ligand B has a significantly better binding affinity and a much lower DILI risk and better BBB penetration, which are crucial for a GPCR target. While Ligand A has better metabolic stability (Cl_mic and t1/2), the superior affinity of Ligand B outweighs this advantage. Both compounds have poor Caco-2 and solubility, which would require formulation strategies to address. The slightly higher logP of Ligand B is acceptable given the other benefits.
Output:
0
2025-04-17 18:37:00,326 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (348.443 Da) is better, falling comfortably within the 200-500 Da range. Ligand B (384.527 Da) is also acceptable, but closer to the upper limit.
2. **TPSA:** Ligand A (67.87) is significantly better than Ligand B (96.11). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (1.32) is slightly better than Ligand B (0.901), both are within the optimal 1-3 range.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is preferable to Ligand B (6). Lower HBA is generally better for permeability.
6. **QED:** Ligand B (0.674) is better than Ligand A (0.388). A higher QED suggests a more drug-like profile.
7. **DILI:** Ligand A (17.449) is *much* better than Ligand B (59.907). This is a significant advantage for Ligand A.
8. **BBB:** Not a major concern for a cardiovascular target, but Ligand A (57.619) is better than Ligand B (41.218).
9. **Caco-2:** Ligand A (-4.682) is better than Ligand B (-5.733), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-1.927) is better than Ligand B (-3.279).
11. **hERG:** Ligand A (0.192) is better than Ligand B (0.254), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand A (14.138) is better than Ligand B (20.49), suggesting improved metabolic stability.
13. **t1/2:** Ligand B (8.978) is better than Ligand A (4.265). A longer half-life is generally desirable.
14. **Pgp:** Ligand A (0.045) is *much* better than Ligand B (0.016). Lower P-gp efflux is highly desirable for bioavailability.
15. **Affinity:** Ligand B (-7.2) is significantly better than Ligand A (-5.7). This is a substantial advantage for Ligand B.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), affinity, logP, TPSA, and Pgp are key. Ligand B has a much better affinity. However, Ligand A has superior scores in TPSA, Pgp, DILI, solubility, and metabolic stability. The difference in affinity is significant (1.5 kcal/mol), but the combination of better ADME properties and safety profile for Ligand A is compelling. The DILI risk for Ligand B is concerning.
**Overall Assessment:**
While Ligand B boasts a superior binding affinity, Ligand A presents a more balanced profile with significantly better predicted ADME-Tox properties, particularly the low DILI risk and favorable Pgp efflux. Given the potential for cardiovascular side effects with ADRB2 modulators, minimizing liver toxicity is crucial. The affinity difference, while substantial, might be overcome with further optimization of Ligand A.
Output:
1
2025-04-17 18:37:00,327 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (364.83 and 349.39 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (80.57) is significantly better than Ligand B (107.11). ADRB2 is a cardiovascular target, not CNS, but lower TPSA is generally favorable for absorption.
3. **logP:** Ligand A (3.645) is optimal, while Ligand B (0.039) is very low. This is a major concern for Ligand B, as it likely suffers from poor membrane permeability.
4. **HBD:** Both have 2 HBD, which is within the acceptable limit.
5. **HBA:** Ligand A (4) is better than Ligand B (6), staying closer to the preferred limit of 10.
6. **QED:** Both are similar (0.785 vs 0.727), indicating good drug-likeness.
7. **DILI:** Ligand A (63.75) has a higher DILI risk than Ligand B (30.98). This favors Ligand B.
8. **BBB:** Not a primary concern for a cardiovascular target. Ligand A (61.57) is slightly better than Ligand B (40.33).
9. **Caco-2:** Both are negative (-4.768 and -4.846), indicating poor permeability. However, this is likely heavily influenced by the very low logP of Ligand B.
10. **Solubility:** Ligand A (-4.652) is better than Ligand B (-1.646), suggesting better aqueous solubility.
11. **hERG:** Ligand A (0.738) is better than Ligand B (0.162), indicating lower hERG inhibition risk.
12. **Cl_mic:** Ligand A (55.73) has a higher clearance than Ligand B (7.4). This favors Ligand B, suggesting better metabolic stability.
13. **t1/2:** Ligand A (66.43) has a significantly longer half-life than Ligand B (12.30). This is a major advantage for Ligand A.
14. **Pgp:** Ligand A (0.5) is better than Ligand B (0.037), suggesting lower P-glycoprotein efflux.
15. **Affinity:** Ligand B (-7.0) has a significantly stronger binding affinity than Ligand A (-5.6). This is a substantial advantage for Ligand B.
**Overall Assessment:**
Ligand B has a superior binding affinity and lower DILI risk and better metabolic stability. However, its extremely low logP is a critical flaw, likely leading to very poor permeability and bioavailability. The poor Caco-2 value confirms this. Ligand A, while having a weaker affinity, has a much more favorable logP, better solubility, lower hERG risk, longer half-life, and lower Pgp efflux. For a cardiovascular target, these ADME properties are crucial for *in vivo* efficacy. The difference in affinity (-1.4 kcal/mol) is not large enough to overcome the significant permeability issues of Ligand B.
Therefore, I favor Ligand A.
Output:
1
2025-04-17 18:37:00,327 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (348.399 and 355.391 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (92.01 and 92.12) are slightly above the optimal <90 for CNS targets, but acceptable for a peripherally acting GPCR like ADRB2. Very similar.
3. **logP:** Ligand A (1.062) is better than Ligand B (0.238). While both are within the 1-3 range, Ligand B is quite low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (2) is better than Ligand B (0). Lower HBD can improve permeability.
5. **HBA:** Ligand B (9) is higher than Ligand A (5). Higher HBA can sometimes reduce permeability.
6. **QED:** Ligand A (0.849) is significantly better than Ligand B (0.642), indicating a more drug-like profile.
7. **DILI:** Ligand A (45.677) is considerably better than Ligand B (61.109), suggesting a lower risk of liver injury.
8. **BBB:** Ligand B (70.027) is better than Ligand A (49.826). While ADRB2 isn't primarily a CNS target, some degree of BBB penetration isn't necessarily detrimental and could offer some off-target effects.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-4.734) is slightly better than Ligand B (-4.313), but both are concerning.
10. **Solubility:** Both are negative, indicating poor solubility. Ligand A (-1.589) is slightly better than Ligand B (-1.338).
11. **hERG:** Both are very low (0.144 and 0.218), indicating minimal hERG inhibition risk. This is excellent for both.
12. **Cl_mic:** Ligand A (-17.156) is significantly better than Ligand B (70.083), indicating much better metabolic stability.
13. **t1/2:** Ligand A (23.014) is better than Ligand B (-39.303). A positive half-life is preferable, and Ligand A has a reasonable value, while Ligand B is negative.
14. **Pgp:** Both are very low (0.018 and 0.067), indicating minimal P-gp efflux.
15. **Binding Affinity:** Ligand A (-7.6) is better than Ligand B (-5.1). This is a substantial difference in potency.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand A performs better in logP, has comparable TPSA and Pgp, and significantly better affinity. While BBB isn't a primary concern, Ligand B has a slight edge there. However, the superior metabolic stability (Cl_mic), half-life, DILI risk, QED, and most importantly, binding affinity of Ligand A outweigh the slight advantage of Ligand B in BBB penetration.
**Conclusion:**
Ligand A is the superior candidate due to its significantly better binding affinity, metabolic stability, lower DILI risk, and more favorable drug-like properties (QED). The slight permeability issues are less concerning than the other benefits.
Output:
1
2025-04-17 18:37:00,327 - INFO - Here's my reasoning and the final output:
**Reasoning:**
We are evaluating two ligands for their potential as drug candidates targeting the ADRB2, a cardiovascular GPCR. Therefore, logP, TPSA, Pgp, and binding affinity are particularly important.
Let's compare the ligands property by property:
1. **MW:** Both ligands (360.479 and 358.429 Da) are within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (68.17) is slightly higher than Ligand B (58.64). Both are below the 140 A^2 threshold for good absorption, but Ligand B is preferable.
3. **logP:** Both ligands have good logP values (3.13 and 2.344), falling within the optimal 1-3 range. Ligand B is slightly lower, which could be beneficial for solubility.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 3. Both are acceptable.
6. **QED:** Both ligands have high QED scores (0.911 and 0.821), indicating good drug-like properties.
7. **DILI:** Ligand A has a DILI risk of 74.021, while Ligand B has 25.242. This is a significant difference; Ligand B is much safer regarding liver toxicity.
8. **BBB:** Ligand A has a BBB penetration of 76.27, while Ligand B is 95.502. While ADRB2 is cardiovascular, some CNS penetration can occur and may be relevant for off-target effects, but it's not a primary driver here. Ligand B is significantly better.
9. **Caco-2:** Both have negative Caco-2 values (-4.68 and -4.59). This is unusual and suggests poor permeability. However, the values are similar.
10. **Solubility:** Ligand A (-3.352) has worse solubility than Ligand B (-2.779).
11. **hERG:** Both ligands have low hERG inhibition risk (0.386 and 0.459).
12. **Cl_mic:** Ligand A (29.061) has a higher microsomal clearance than Ligand B (0.241), indicating lower metabolic stability. Ligand B is much better.
13. **t1/2:** Ligand A (-8.43) has a negative in vitro half-life, which is concerning. Ligand B (4.375) has a reasonable half-life.
14. **Pgp:** Ligand A (0.454) has slightly higher P-gp efflux than Ligand B (0.046). Ligand B is preferable.
15. **Binding Affinity:** Ligand B (-6.7 kcal/mol) has a slightly better binding affinity than Ligand A (-6.3 kcal/mol), although the difference is not huge.
**Overall Assessment:**
Ligand B is significantly better overall. It has a much lower DILI risk, better BBB penetration, better metabolic stability (lower Cl_mic, positive t1/2), lower P-gp efflux, and slightly better binding affinity. While both have poor Caco-2 permeability, the other advantages of Ligand B outweigh this concern. The solubility is also better for Ligand B.
Output:
0
2025-04-17 18:37:00,327 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (351.359 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (78.87) is significantly better than Ligand A (110.97). ADRB2 is not a CNS target, but lower TPSA generally improves absorption.
3. **logP:** Ligand B (2.004) is optimal, while Ligand A (0.023) is very low, potentially hindering membrane permeability. This is a significant drawback for Ligand A.
4. **HBD:** Both are acceptable (Ligand A: 1, Ligand B: 2), well within the limit of 5.
5. **HBA:** Both are acceptable (Ligand A: 7, Ligand B: 5), within the limit of 10.
6. **QED:** Both are good (Ligand A: 0.745, Ligand B: 0.779), indicating good drug-like properties.
7. **DILI:** Ligand B (50.136) has a lower DILI risk than Ligand A (62.195), which is preferable.
8. **BBB:** Not a primary concern for ADRB2. Ligand B (65.917) is slightly better than Ligand A (60.876).
9. **Caco-2:** Both are negative, indicating poor permeability. This is concerning for both, but the low logP of Ligand A exacerbates this issue.
10. **Solubility:** Both are negative, indicating poor solubility.
11. **hERG:** Both are very low (Ligand A: 0.075, Ligand B: 0.777), indicating minimal hERG inhibition risk.
12. **Cl_mic:** Ligand B (14.276) has significantly lower microsomal clearance than Ligand A (45.216), suggesting better metabolic stability.
13. **t1/2:** Ligand B (20.675) has a much longer in vitro half-life than Ligand A (-11.28), which is a major advantage.
14. **Pgp:** Both are very low (Ligand A: 0.027, Ligand B: 0.181), indicating minimal P-gp efflux.
15. **Affinity:** Both have excellent binding affinity (Ligand A: -5.4 kcal/mol, Ligand B: -5.9 kcal/mol), with Ligand B being slightly stronger.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand B excels in logP and has slightly better affinity. While both have issues with Caco-2 and solubility, the poor logP of Ligand A makes it a more significant concern. The improved metabolic stability (lower Cl_mic) and longer half-life of Ligand B are also very important.
**Conclusion:**
Ligand B is the superior candidate due to its optimal logP, lower DILI risk, improved metabolic stability, longer half-life, and slightly better binding affinity. While both have permeability and solubility issues, the issues with Ligand A are more critical due to its extremely low logP.
Output:
0
2025-04-17 18:37:00,327 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands (336.435 and 333.395 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (52.57) is better than Ligand B (62.22). Both are below 140, but lower TPSA generally favors absorption.
3. **logP:** Both ligands have good logP values (2.935 and 2.514), falling within the optimal 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Ligand A (2) is preferable to Ligand B (0). While both are low, a small number of HBDs can aid solubility.
5. **HBA:** Ligand B (5) is preferable to Ligand A (3). Both are acceptable, but fewer HBA can improve permeability.
6. **QED:** Ligand A (0.848) is better than Ligand B (0.737), indicating a more drug-like profile.
7. **DILI:** Ligand A (37.767) is significantly better than Ligand B (77.045). Lower DILI risk is crucial.
8. **BBB:** Both ligands have high BBB penetration (85.459 and 84.529). This is good, but less critical for a cardiovascular target like ADRB2.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.617 and -4.938). This is unusual and suggests poor permeability. However, these values are on a scale where negative values are possible, and the absolute difference isn't huge.
10. **Solubility:** Ligand A (-3.394) is better than Ligand B (-2.482). Higher solubility is generally preferred.
11. **hERG:** Both ligands have low hERG inhibition liability (0.888 and 0.73). This is good.
12. **Cl_mic:** Ligand A (10.772) is significantly better than Ligand B (83.652). Lower clearance indicates better metabolic stability.
13. **t1/2:** Ligand A (42.827) is significantly better than Ligand B (-9.475). A longer half-life is desirable.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.371 and 0.334). This is good.
15. **Binding Affinity:** Ligand B (-6.7) is slightly better than Ligand A (-6.3). However, the difference is only 0.4 kcal/mol, which is not substantial enough to outweigh the other factors.
**GPCR-Specific Considerations:**
For a GPCR, logP, TPSA, Pgp, and affinity are key. Both ligands perform well on logP and Pgp. Ligand A has a better TPSA. The affinity difference is small, and Ligand A has substantially better ADME properties (DILI, Cl_mic, t1/2, solubility).
**Overall Assessment:**
Ligand A is clearly the superior candidate. While Ligand B has slightly better binding affinity, Ligand A demonstrates a significantly better safety profile (DILI), improved metabolic stability (Cl_mic, t1/2), and better solubility. These factors are crucial for drug development and outweigh the small difference in binding affinity.
Output:
1
2025-04-17 18:37:00,327 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (341.367 Da) is well within the ideal range (200-500 Da). Ligand B (370.559 Da) is also acceptable. No clear advantage here.
2. **TPSA:** Ligand A (84.71) is good, under the 140 threshold. Ligand B (69.64) is even better, suggesting potentially improved permeability. Advantage: B.
3. **logP:** Both ligands have good logP values (A: 3.202, B: 2.28), falling within the optimal 1-3 range. Ligand B is slightly lower, which could be beneficial for solubility.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally leads to better permeability. Advantage: A.
5. **HBA:** Ligand A (6) is preferable to Ligand B (4). Similar to HBD, lower HBA is generally better. Advantage: A.
6. **QED:** Both ligands have good QED scores (A: 0.524, B: 0.688), indicating good drug-like properties. Advantage: B.
7. **DILI:** Ligand A (84.8) has a significantly higher DILI risk than Ligand B (15.083). This is a major concern for Ligand A. Advantage: B.
8. **BBB:** Both ligands have acceptable BBB penetration (A: 71.966, B: 73.711). Since ADRB2 isn't strictly a CNS target, this isn't a *critical* differentiator, but B is slightly better. Advantage: B.
9. **Caco-2:** Ligand A (-4.693) is worse than Ligand B (-5.077). Lower values indicate poorer permeability. Advantage: B.
10. **Solubility:** Ligand A (-5.605) is worse than Ligand B (-3.097). Lower values indicate poorer solubility. Advantage: B.
11. **hERG:** Both ligands have low hERG inhibition risk (A: 0.793, B: 0.474). Advantage: B.
12. **Cl_mic:** Ligand A (92.964) has a higher microsomal clearance than Ligand B (50.269), meaning it's metabolized more quickly. Advantage: B.
13. **t1/2:** Ligand A (18.005) has a longer half-life than Ligand B (-7.357). Advantage: A.
14. **Pgp:** Ligand A (0.439) has lower P-gp efflux than Ligand B (0.17). Lower P-gp efflux is generally better. Advantage: A.
15. **Binding Affinity:** Both ligands have very similar binding affinities (A: -6.1 kcal/mol, B: -5.9 kcal/mol). The difference is not substantial enough to outweigh other factors.
**Overall Assessment:**
Ligand B consistently outperforms Ligand A in most critical ADME properties, particularly DILI risk, solubility, permeability (Caco-2), and metabolic stability (Cl_mic). While Ligand A has a slightly longer half-life and lower P-gp efflux, the significantly lower DILI risk and better overall ADME profile of Ligand B make it the more promising drug candidate. The small difference in binding affinity is negligible compared to the ADME advantages of Ligand B.
Output:
0
2025-04-17 18:37:00,327 - INFO - Batch 50 complete. Total preferences: 800
2025-04-17 18:37:00,327 - INFO - Processing batch 51/512...
2025-04-17 18:37:52,221 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (348.487 and 350.507 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (58.64) is significantly better than Ligand B (85.23). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold. Ligand B is approaching it.
3. **logP:** Both ligands (2.511 and 2.202) are within the optimal 1-3 range. Again, a small difference, favoring A slightly.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (4). Lower HBA generally improves permeability.
6. **QED:** Ligand A (0.751) is better than Ligand B (0.632), indicating a more drug-like profile.
7. **DILI:** Ligand A (25.979) is *much* better than Ligand B (9.151). This is a significant advantage for Ligand A. Lower DILI is critical.
8. **BBB:** Ligand A (81.117) is better than Ligand B (62.233), but neither are exceptionally high. This isn't a major factor for a cardiovascular target.
9. **Caco-2:** Ligand A (-4.798) is better than Ligand B (-4.899). Both are negative, indicating poor permeability, but A is slightly better.
10. **Solubility:** Ligand A (-3.546) is better than Ligand B (-1.911). Solubility is important for bioavailability, and A has a better score.
11. **hERG:** Both ligands (0.388 and 0.335) have low hERG inhibition liability, which is good. No significant difference.
12. **Cl_mic:** Ligand B (29.937) is significantly better than Ligand A (64.033). Lower clearance is desirable for metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand B (13.095) is better than Ligand A (9.082). Longer half-life is generally preferred.
14. **Pgp:** Both ligands (0.141 and 0.005) have low P-gp efflux liability. Ligand B is slightly better.
15. **Binding Affinity:** Ligand B (-7.6) is significantly better than Ligand A (-6.4). A 1.2 kcal/mol difference in binding affinity is substantial and can often outweigh minor ADME drawbacks.
**GPCR-Specific Priorities:**
For GPCRs, logP, TPSA, Pgp, and affinity are key. Ligand B has better affinity and Pgp efflux. Ligand A has better TPSA and logP. However, the significant advantage in binding affinity for Ligand B is the most important factor. The better metabolic stability (Cl_mic and t1/2) of Ligand B also contribute to its favorability. While Ligand A has a much better DILI score, the binding affinity difference is substantial enough to overcome this concern, especially considering the cardiovascular target.
**Conclusion:**
Despite Ligand A's better DILI and slightly better physicochemical properties, Ligand B's significantly stronger binding affinity and improved metabolic stability make it the more promising drug candidate.
Output:
0
2025-04-17 18:37:52,221 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [350.463, 87.46, 1.021, 2, 5, 0.83, 39.356, 34.238, -4.992, -2.429, 0.115, 53.973, 13.838, 0.022, -6.4]
**Ligand B:** [347.419, 110.32, -0.358, 2, 5, 0.702, 18.922, 64.676, -5.735, -1.722, 0.045, -12.548, -6.918, 0.004, -5.6]
Here's a step-by-step comparison, considering GPCR priorities (logP, Pgp, TPSA, affinity):
1. **MW:** Both are within the ideal range (200-500 Da). A is 350.463, B is 347.419. Very similar.
2. **TPSA:** A (87.46) is excellent, well below 140 and good for absorption. B (110.32) is still acceptable, but less ideal.
3. **logP:** A (1.021) is optimal. B (-0.358) is a bit low, potentially hindering permeability.
4. **HBD:** Both have 2, which is good.
5. **HBA:** Both have 5, which is good.
6. **QED:** A (0.83) is better than B (0.702), indicating a more drug-like profile.
7. **DILI:** A (39.356) is better than B (18.922), showing a lower risk of liver injury.
8. **BBB:** A (34.238) is lower than B (64.676). While ADRB2 isn't a CNS target, higher BBB is generally favorable.
9. **Caco-2:** A (-4.992) is worse than B (-5.735), indicating lower intestinal absorption.
10. **Solubility:** A (-2.429) is worse than B (-1.722), indicating lower solubility.
11. **hERG:** Both are very low risk (0.115 and 0.045).
12. **Cl_mic:** A (53.973) is higher than B (-12.548), meaning B has better metabolic stability.
13. **t1/2:** A (13.838) is better than B (-6.918), indicating a longer half-life.
14. **Pgp:** A (0.022) is better than B (0.004), indicating less P-gp efflux.
15. **Affinity:** A (-6.4) is slightly better than B (-5.6), a 0.8 kcal/mol difference.
**Overall Assessment:**
Ligand A has a better overall profile, despite the lower Caco-2 and solubility. The superior logP, QED, DILI, and Pgp values, coupled with a slightly better binding affinity, outweigh the slightly lower Caco-2 and solubility. The better metabolic stability of ligand B is a plus, but the lower logP is a significant concern for a GPCR target. The slightly better half-life of A is also a benefit.
Therefore, I prefer Ligand A.
Output:
1
2025-04-17 18:37:52,221 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (335.4 & 344.4 Da) fall comfortably within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (66.89) is better than Ligand B (68.18), both are below the 140 threshold for oral absorption, but closer to the ideal for GPCRs.
3. **logP:** Ligand A (4.005) is higher than Ligand B (2.026). While 4.005 is approaching the upper limit, it's still acceptable. Ligand B is well within the optimal range. For a GPCR, a slightly higher logP can be beneficial for membrane interactions.
4. **HBD:** Both have 2 HBD, which is good.
5. **HBA:** Ligand A has 3 HBA, Ligand B has 4. Both are acceptable, but lower is generally preferred.
6. **QED:** Ligand B (0.872) has a better QED score than Ligand A (0.759), suggesting a more drug-like profile overall.
7. **DILI:** Ligand B (46.142) has a significantly lower DILI risk than Ligand A (75.688). This is a major advantage for Ligand B.
8. **BBB:** Ligand B (79.992) has a better BBB penetration score than Ligand A (68.554). While ADRB2 isn't strictly a CNS target, some CNS penetration can be acceptable and may even offer benefits.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-5.014) is slightly worse than Ligand B (-4.791).
10. **Solubility:** Ligand B (-2.847) has better solubility than Ligand A (-5.4). This is a significant advantage.
11. **hERG:** Ligand A (0.689) has a slightly better hERG profile than Ligand B (0.325), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand B (-5.749) has a *much* lower (better) microsomal clearance than Ligand A (33.774). This suggests significantly improved metabolic stability for Ligand B.
13. **t1/2:** Ligand A (65.992) has a longer in vitro half-life than Ligand B (28.691). This is a positive for Ligand A.
14. **Pgp:** Ligand A (0.508) has better Pgp efflux properties than Ligand B (0.053). Lower Pgp is better.
15. **Affinity:** Ligand A (-8.8 kcal/mol) has a significantly stronger binding affinity than Ligand B (-7.3 kcal/mol). This is a substantial advantage for Ligand A. The difference of 1.5 kcal/mol is large enough to potentially outweigh some ADME concerns.
**Overall Assessment:**
Ligand A has a significantly better binding affinity. However, Ligand B excels in several critical ADME properties: lower DILI risk, better BBB penetration, improved solubility, and dramatically better metabolic stability (lower Cl_mic). The Caco-2 values are concerning for both, but the other advantages of Ligand B are compelling. Given the GPCR target class, the balance of properties leans towards Ligand B. The superior affinity of Ligand A is tempting, but the poor metabolic stability and higher DILI risk are significant drawbacks.
Output:
0
2025-04-17 18:37:52,221 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [376.513, 64.35, 2.804, 2, 4, 0.774, 17.449, 92.904, -5.298, -2.627, 0.732, 17.486, 20.262, 0.115, -7.6]
**Ligand B:** [353.463, 94.81, 1.373, 3, 5, 0.623, 11.361, 26.561, -5.347, -1.042, 0.285, -2.442, 36.507, 0.023, -3.9]
Here's a breakdown of each parameter and how the ligands compare, keeping GPCR priorities (logP, Pgp, TPSA, affinity) in mind:
1. **MW:** Both are within the ideal 200-500 Da range. Ligand B (353.463) is slightly lower, which could be beneficial for permeability, but both are acceptable.
2. **TPSA:** Ligand A (64.35) is significantly better than Ligand B (94.81). Below 140 is good for oral absorption, and both are, but lower is preferred for GPCRs.
3. **logP:** Ligand A (2.804) is optimal (1-3). Ligand B (1.373) is on the lower side, potentially hindering membrane permeability.
4. **HBD:** Ligand A (2) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is preferable to Ligand B (5). Similar reasoning as HBD.
6. **QED:** Ligand A (0.774) is better than Ligand B (0.623), indicating a more drug-like profile.
7. **DILI:** Ligand A (17.449) has a higher DILI risk than Ligand B (11.361). This is a concern for Ligand A.
8. **BBB:** Ligand A (92.904) is *much* better than Ligand B (26.561). While ADRB2 is cardiovascular, some CNS penetration can be relevant for off-target effects and overall safety assessment.
9. **Caco-2:** Both are negative, indicating poor permeability. This is a significant drawback for both, but Ligand A is slightly better (-5.298 vs -5.347).
10. **Solubility:** Ligand A (-2.627) is slightly better than Ligand B (-1.042), but both are poor.
11. **hERG:** Ligand A (0.732) is better than Ligand B (0.285), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand B (-2.442) has a *much* lower (better) microsomal clearance than Ligand A (17.486), suggesting greater metabolic stability.
13. **t1/2:** Ligand B (36.507) has a significantly longer in vitro half-life than Ligand A (20.262).
14. **Pgp:** Ligand A (0.115) is better than Ligand B (0.023), indicating lower P-glycoprotein efflux.
15. **Affinity:** Ligand A (-7.6) has a significantly stronger binding affinity than Ligand B (-3.9). This is a substantial advantage.
**Overall Assessment:**
Ligand A has a much stronger binding affinity, better TPSA, logP, QED, BBB penetration, Pgp efflux, and hERG inhibition profile. However, it has a higher DILI risk and poorer metabolic stability (higher Cl_mic, shorter t1/2). Ligand B has better metabolic stability and lower DILI, but significantly weaker affinity, poorer TPSA, logP, BBB penetration, and Pgp efflux.
For a GPCR target, affinity is paramount. The 1.7 kcal/mol difference in binding affinity is substantial and likely outweighs the ADME concerns with Ligand A, *provided* the DILI risk can be mitigated through further structural modifications. The better TPSA and logP of Ligand A also contribute to its potential for good cellular permeability.
Therefore, I would prioritize Ligand A for further optimization.
```
1
```
2025-04-17 18:37:52,221 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [422.71 , 62.3 , 3.912, 1. , 3. , 0.6 , 63.823, 80.109, -4.934, -4.431, 0.311, 40.255, 14.025, 0.427, -7.1 ]
**Ligand B:** [347.419, 100.16 , 2.275, 1. , 6. , 0.729, 43.622, 65.374, -5.186, -1.494, 0.126, 34.391, 20.555, 0.041, -3.9 ]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Ligand A (422.71 Da) is within the ideal range. Ligand B (347.419 Da) is also acceptable, but slightly lower.
2. **TPSA:** Ligand A (62.3) is good, well below the 140 threshold. Ligand B (100.16) is higher, but still potentially acceptable for a peripherally acting GPCR.
3. **logP:** Ligand A (3.912) is excellent. Ligand B (2.275) is good, but a bit lower, potentially impacting membrane permeability.
4. **HBD/HBA:** Both have 1 HBD, which is good. Ligand A has 3 HBA, Ligand B has 6. Ligand A is better here.
5. **QED:** Both are good (0.6 and 0.729 respectively).
6. **DILI:** Ligand A (63.823) is higher risk than Ligand B (43.622). This is a significant negative for Ligand A.
7. **BBB:** Ligand A (80.109) has good BBB penetration, while Ligand B (65.374) is lower. For ADRB2, which isn't necessarily a CNS target, this is less critical, but still a point for A.
8. **Caco-2:** Both have negative values, indicating poor permeability. Ligand A (-4.934) is worse than Ligand B (-5.186).
9. **Solubility:** Ligand A (-4.431) is worse than Ligand B (-1.494).
10. **hERG:** Ligand A (0.311) is better than Ligand B (0.126), indicating lower cardiotoxicity risk.
11. **Cl_mic:** Ligand B (34.391) has lower clearance, suggesting better metabolic stability. Ligand A (40.255) is higher.
12. **t1/2:** Ligand B (20.555) has a longer half-life than Ligand A (14.025).
13. **Pgp:** Ligand A (0.427) has lower P-gp efflux, which is good. Ligand B (0.041) is even better.
14. **Affinity:** Ligand A (-7.1 kcal/mol) has significantly better binding affinity than Ligand B (-3.9 kcal/mol). This is a substantial advantage.
**Overall Assessment:**
Ligand A has a clear advantage in binding affinity and Pgp efflux. Its logP is also better. However, it has a significantly higher DILI risk, worse solubility, and poorer Caco-2 permeability. Ligand B has better metabolic stability (lower Cl_mic, longer t1/2), lower DILI, better solubility, and slightly better Pgp efflux.
The difference in binding affinity (-7.1 vs -3.9) is substantial. While the ADME properties of Ligand A are concerning, the potency advantage is likely to be a major driver of *in vivo* efficacy. The DILI risk is the biggest concern, but could potentially be mitigated through structural modifications. The solubility and permeability issues are also addressable.
Given the GPCR target class and the significant binding affinity advantage, I would prioritize Ligand A for further optimization.
**Output:**
1
2025-04-17 18:37:52,221 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.531 and 352.475 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (49.41) is significantly better than Ligand B (67.87). ADRB2 is a cardiovascular target, not CNS, but lower TPSA generally improves absorption. Ligand A is well below the 140 threshold, while B is approaching it.
3. **logP:** Ligand A (3.79) is good, within the optimal 1-3 range. Ligand B (1.749) is at the lower end of acceptable, potentially leading to permeability issues.
4. **HBD:** Both ligands have 1 HBD, which is acceptable.
5. **HBA:** Ligand A has 2 HBA, while Ligand B has 4. Both are within the acceptable limit of 10, but A is preferable.
6. **QED:** Both ligands have similar QED values (0.611 and 0.507), both above the 0.5 threshold, indicating good drug-likeness.
7. **DILI:** Ligand A (14.23) has a lower DILI risk than Ligand B (19.504), which is a clear advantage.
8. **BBB:** Both ligands have good BBB penetration (74.874 and 78.868), but this is less critical for a cardiovascular target like ADRB2.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.411 and -4.374), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand A (-4.272) has slightly better solubility than Ligand B (-1.075), but both are poor.
11. **hERG:** Ligand A (0.535) has a lower hERG risk than Ligand B (0.244), which is a significant advantage.
12. **Cl_mic:** Ligand B (65.353) has a lower microsomal clearance than Ligand A (74.279), suggesting better metabolic stability.
13. **t1/2:** Ligand A (14.053) has a significantly longer in vitro half-life than Ligand B (0.226). This is a major advantage.
14. **Pgp:** Ligand A (0.132) has lower P-gp efflux than Ligand B (0.082), which is preferable.
15. **Binding Affinity:** Ligand A (-5.0) has a stronger binding affinity than Ligand B (-2.6). This is a substantial difference and a key factor.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, affinity, and Pgp are important. Ligand A has better logP, TPSA, Pgp, and significantly better affinity. While metabolic stability (Cl_mic) is important, the large difference in affinity and the better safety profile (DILI, hERG) of Ligand A outweigh the slightly higher clearance. The poor Caco-2 values are a concern for both, but the superior binding affinity of Ligand A makes it more likely to be effective *in vivo* even with limited absorption.
**Conclusion:**
Ligand A is the more promising candidate due to its superior binding affinity, better TPSA, logP, DILI, hERG, and half-life. The slightly lower metabolic stability is a manageable concern compared to the significant advantages in other key parameters.
Output:
1
2025-04-17 18:37:52,222 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (345.443 and 347.375 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (85.43) is significantly better than Ligand B (129.37). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is approaching the upper limit for good oral absorption.
3. **logP:** Ligand A (1.677) is within the optimal range (1-3). Ligand B (-0.162) is *below* 1, which raises concerns about permeability. This is a significant negative for Ligand B.
4. **HBD:** Ligand A (3) and Ligand B (4) are both acceptable, being less than 5.
5. **HBA:** Ligand A (3) is better than Ligand B (7). While both are under 10, lower is generally preferred.
6. **QED:** Ligand A (0.776) is better than Ligand B (0.574), indicating a more drug-like profile.
7. **DILI:** Ligand A (33.773) has a lower DILI risk than Ligand B (42.536), both are acceptable but A is preferred.
8. **BBB:** Ligand A (47.111) is better than Ligand B (9.306). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be beneficial for distribution. This is a substantial advantage for Ligand A.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not defined, so it's hard to interpret.
10. **Solubility:** Ligand A (-3.333) is better than Ligand B (-1.841), indicating better aqueous solubility.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.312 and 0.036), which is excellent.
12. **Cl_mic:** Ligand A (18.729) has a higher (worse) microsomal clearance than Ligand B (-0.282). This suggests Ligand B is more metabolically stable.
13. **t1/2:** Ligand A (-18.025) has a negative in vitro half-life, which is concerning. Ligand B (14.382) has a positive half-life, indicating better stability.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.044 and 0.005), which is favorable.
15. **Binding Affinity:** Ligand B (-7.4 kcal/mol) has a slightly better binding affinity than Ligand A (-6.5 kcal/mol). This 0.9 kcal/mol difference is significant, but needs to be weighed against the other factors.
**Overall Assessment:**
Ligand B has a better binding affinity and metabolic stability (lower Cl_mic, better t1/2). However, Ligand A significantly outperforms Ligand B in crucial ADME properties like logP, TPSA, QED, solubility, and BBB penetration. The poor logP of Ligand B is a major concern, potentially hindering its ability to cross cell membranes and reach its target. The negative half-life of Ligand A is concerning, but the other advantages outweigh this. Given the GPCR target class, prioritizing logP, TPSA, and overall drug-likeness is crucial.
Therefore, I favor Ligand A.
Output:
1
2025-04-17 18:37:52,222 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (365.455 and 349.431 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (84.67) is significantly better than Ligand A (119.29). ADRB2 is not a CNS target, but lower TPSA generally improves absorption.
3. **logP:** Both ligands have acceptable logP values (1.106 and 2.146, respectively), falling within the 1-3 range. Ligand B is slightly better.
4. **HBD:** Ligand A has 3 HBD, while Ligand B has 1. Lower is generally preferred for permeability, giving a slight edge to Ligand B.
5. **HBA:** Both ligands have 5 HBA, which is acceptable.
6. **QED:** Both ligands have similar QED values (0.722 and 0.691), indicating good drug-likeness.
7. **DILI:** Both ligands have similar DILI risk (38.581 and 39.201), both being good (below 40).
8. **BBB:** Ligand B (79.682) has a substantially higher BBB percentile than Ligand A (22.955). While ADRB2 isn't a primary CNS target, higher BBB is rarely detrimental and can provide some flexibility.
9. **Caco-2:** Ligand A (-5.252) and Ligand B (-4.524) are both negative, which is unusual and suggests poor permeability. However, the scale isn't defined, so it's difficult to interpret.
10. **Solubility:** Both ligands have negative solubility values (-2.382 and -2.526), which is concerning. Solubility is a critical factor for bioavailability.
11. **hERG:** Both ligands have low hERG inhibition liability (0.286 and 0.387), which is excellent.
12. **Cl_mic:** Ligand A (-26.023) has a significantly *lower* (better) microsomal clearance than Ligand B (69.391). This suggests greater metabolic stability for Ligand A.
13. **t1/2:** Ligand A (65.781) has a much longer in vitro half-life than Ligand B (4.914). This is a significant advantage.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.011 and 0.156), which is favorable.
15. **Binding Affinity:** Ligand B (-6.9 kcal/mol) has a slightly better binding affinity than Ligand A (-6.2 kcal/mol). This is a 0.7 kcal/mol difference, which is meaningful but not overwhelming.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B is better in terms of logP, TPSA, and affinity. However, Ligand A has significantly better metabolic stability (Cl_mic, t1/2). The solubility issue is a concern for both.
**Overall Assessment:**
While Ligand B has a slightly better binding affinity and TPSA, the superior metabolic stability (lower Cl_mic and longer t1/2) of Ligand A is more critical for *in vivo* efficacy. The longer half-life will likely translate to a more sustained effect and potentially lower dosing frequency. The solubility issues are a concern for both, but can potentially be addressed through formulation strategies.
Output:
1
2025-04-17 18:37:52,222 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (348.491 and 354.405 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (86.88) is slightly higher than Ligand B (72). Both are below the 140 threshold for good oral absorption, and acceptable for a cardiovascular target (not requiring significant CNS penetration). Ligand B is preferable here.
3. **logP:** Ligand A (3.161) is within the optimal 1-3 range. Ligand B (1.29) is at the lower end, potentially impacting permeability. Ligand A is preferable.
4. **HBD:** Ligand A (3) and Ligand B (1) are both within the acceptable limit of 5. Ligand B is preferable due to fewer potential off-target interactions.
5. **HBA:** Ligand A (3) and Ligand B (7) are both within the acceptable limit of 10. Ligand A is preferable.
6. **QED:** Both ligands have good QED scores (0.607 and 0.811), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Both ligands have low DILI risk (37.185 and 33.579 percentile), which is excellent. No significant difference.
8. **BBB:** Ligand A (70.376) has better BBB penetration than Ligand B (63.94). While ADRB2 isn't primarily a CNS target, some degree of BBB penetration can be beneficial for off-target profiling.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.065 and -5.018). This is unusual and suggests poor permeability.
10. **Solubility:** Ligand A (-4.3) has slightly worse solubility than Ligand B (-1.468). Solubility is important for bioavailability, so Ligand B is preferable.
11. **hERG:** Both ligands show low hERG inhibition liability (0.37 and 0.635), which is good. No significant difference.
12. **Cl_mic:** Ligand A (47.214) has higher microsomal clearance than Ligand B (-3.42). Lower clearance is preferred for better metabolic stability, so Ligand B is preferable.
13. **t1/2:** Ligand A (-9.607) has a shorter in vitro half-life than Ligand B (-5.435). Longer half-life is generally preferred, so Ligand B is preferable.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.127 and 0.129). No significant difference.
15. **Binding Affinity:** Ligand B (-6.7 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.4 kcal/mol). This is a >1.3 kcal/mol difference, which is substantial and can outweigh some ADME drawbacks.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has a better logP, but Ligand B excels in TPSA, Pgp, and *significantly* in binding affinity. The better metabolic stability (lower Cl_mic and longer t1/2) of Ligand B also contribute to its overall profile.
**Conclusion:**
Despite Ligand A having a slightly better logP, the substantially stronger binding affinity of Ligand B, coupled with its better metabolic stability and solubility, makes it the more promising drug candidate.
Output:
0
2025-04-17 18:37:52,222 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (a cardiovascular GPCR) drug candidates.
**Ligand A:** [348.403, 134.15 , -0.036, 4. , 4. , 0.55 , 40.403, 49.05 , -5.769, -2.635, 0.074, -6.96 , -17.15 , 0.016, -3. ]
**Ligand B:** [331.368, 91.18 , 2.081, 4. , 6. , 0.606, 21.404, 24.777, -5.914, -2.034, 0.734, -1.702, -9.531, 0.153, -6.9 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (331.368) is slightly lower, which is generally favorable.
2. **TPSA:** Ligand A (134.15) is slightly above the preferred <140 for good absorption, but acceptable. Ligand B (91.18) is excellent, well below 140, suggesting good permeability.
3. **logP:** Ligand A (-0.036) is a bit low, potentially hindering membrane permeability. Ligand B (2.081) is within the optimal 1-3 range. This is a significant advantage for Ligand B.
4. **HBD:** Both have 4 HBD, which is acceptable.
5. **HBA:** Ligand A has 4 HBA, while Ligand B has 6. Both are within the acceptable limit of 10.
6. **QED:** Both have good QED scores (>0.5), indicating drug-like properties. Ligand B (0.606) is slightly better.
7. **DILI:** Ligand A (40.403) is slightly higher than Ligand B (21.404), indicating a slightly elevated risk of liver injury. Ligand B is preferable here.
8. **BBB:** Both have low BBB penetration, which is fine for a cardiovascular target. Ligand A (49.05) is slightly higher, but neither is a priority.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Both have negative solubility values, which is also unusual and suggests poor solubility. This is a significant concern for both.
11. **hERG:** Ligand A (0.074) has a very low hERG risk. Ligand B (0.734) is higher, indicating a slightly increased risk of cardiotoxicity. Ligand A is preferable here.
12. **Cl_mic:** Ligand A (-6.96) has a lower (better) microsomal clearance than Ligand B (-1.702), indicating greater metabolic stability.
13. **t1/2:** Ligand A (-17.15) has a longer in vitro half-life than Ligand B (-9.531), which is desirable.
14. **Pgp:** Ligand A (0.016) has very low P-gp efflux, which is favorable. Ligand B (0.153) is higher, indicating more efflux.
15. **Affinity:** Both have strong binding affinities (-3 and -6.9 kcal/mol respectively). Ligand A is significantly better (-6.9 kcal/mol).
**GPCR-Specific Considerations:**
For a cardiovascular GPCR like ADRB2, logP, TPSA, and affinity are important. Ligand B has a better logP and TPSA. However, Ligand A has a *much* better binding affinity (-6.9 vs -3 kcal/mol). The affinity difference is substantial enough to outweigh the slightly less favorable logP and TPSA of Ligand A. The better metabolic stability (Cl_mic and t1/2) and lower P-gp efflux of Ligand A also contribute to its favorability.
**Conclusion:**
Despite the unusual Caco-2 and solubility values for both compounds, the superior binding affinity, metabolic stability, and P-gp efflux profile of Ligand A make it the more promising drug candidate.
Output:
1
2025-04-17 18:37:52,222 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
The ADRB2 receptor is a GPCR, so the priorities are logP, TPSA, Pgp, BBB, and affinity. Let's break down the comparison:
1. **Molecular Weight:** Both ligands are within the ideal 200-500 Da range. Ligand A (373.387 Da) is slightly higher than Ligand B (346.435 Da), but this isn't a major concern.
2. **TPSA:** Ligand A (135.92) is slightly above the preferred <140, but still reasonable. Ligand B (113.24) is excellent, well below 140, suggesting better permeability.
3. **logP:** Ligand A (1.278) is within the optimal 1-3 range. Ligand B (0.79) is a bit low, potentially impacting membrane permeability.
4. **H-Bond Donors:** Ligand A (1) is good. Ligand B (3) is higher, which could slightly hinder permeability.
5. **H-Bond Acceptors:** Ligand A (7) is good. Ligand B (5) is also good.
6. **QED:** Ligand B (0.729) has a better QED score than Ligand A (0.45), indicating a more drug-like profile.
7. **DILI:** Ligand B (36.797) has a significantly lower DILI risk than Ligand A (83.443). This is a major advantage for Ligand B.
8. **BBB:** Ligand B (85.537) shows better BBB penetration than Ligand A (70.415), which is beneficial for a GPCR target.
9. **Caco-2:** Ligand B (-5.528) has a more negative Caco-2 value, suggesting better absorption. Ligand A (-4.8) is also good, but not as strong.
10. **Solubility:** Ligand B (-2.495) has better solubility than Ligand A (-3.549).
11. **hERG:** Both ligands have low hERG inhibition risk (0.438 and 0.299 respectively), which is good.
12. **Cl_mic:** Ligand B (16.115) has significantly lower microsomal clearance than Ligand A (61.675), indicating better metabolic stability.
13. **t1/2:** Ligand A (30.486) has a longer in vitro half-life than Ligand B (14.664).
14. **Pgp:** Ligand B (0.007) has very low P-gp efflux, which is highly desirable. Ligand A (0.157) is also low, but higher than B.
15. **Binding Affinity:** Ligand B (-7.2 kcal/mol) has a slightly better binding affinity than Ligand A (-7.0 kcal/mol). While the difference is small, it's enough to be considered.
**Overall Assessment:**
Ligand B consistently outperforms Ligand A across several critical ADME properties (DILI, BBB, Caco-2, Solubility, Cl_mic, Pgp) and has a slightly better binding affinity. While Ligand A has a longer half-life, the superior ADME profile of Ligand B, particularly the lower DILI risk and better BBB penetration, makes it the more promising candidate for development as a drug targeting the ADRB2 receptor.
**Output:**
0
2025-04-17 18:37:52,222 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (360.443 and 348.487 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (100.94) is higher than Ligand B (69.64). For a cardiovascular GPCR, TPSA is moderately important, and Ligand B's lower TPSA is preferable for better permeability.
3. **logP:** Both ligands have good logP values (1.962 and 2.413), falling within the 1-3 range. Ligand B is slightly higher, which could be a minor advantage.
4. **HBD:** Ligand A has 3 HBD, and Ligand B has 2. Both are acceptable, below the threshold of 5.
5. **HBA:** Ligand A has 6 HBA, and Ligand B has 3. Both are below the threshold of 10. Ligand B is preferable.
6. **QED:** Ligand A (0.731) has a better QED score than Ligand B (0.523), indicating a more drug-like profile. This is a significant advantage for Ligand A.
7. **DILI:** Ligand A (85.847) has a considerably higher DILI risk than Ligand B (19.814). This is a major concern for Ligand A. Ligand B is far superior here.
8. **BBB:** Ligand A (45.366) and Ligand B (57.193) both have low BBB penetration. This is not a primary concern for a cardiovascular target like ADRB2, but lower is preferred.
9. **Caco-2:** Ligand A (-5.629) and Ligand B (-4.725) both have negative Caco-2 values. This is unusual and suggests poor permeability.
10. **Solubility:** Ligand A (-3.991) and Ligand B (-2.822) both have negative solubility values. This is also unusual and suggests poor solubility.
11. **hERG:** Both ligands show low hERG inhibition risk (0.156 and 0.188). No significant difference.
12. **Cl_mic:** Ligand A (-4.223) has a lower (better) microsomal clearance than Ligand B (55.754), suggesting better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (34.629) has a much longer in vitro half-life than Ligand B (-10.976). This is a substantial advantage for Ligand A.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.015 and 0.161). No significant difference.
15. **Binding Affinity:** Ligand A (-6.8 kcal/mol) has a slightly better binding affinity than Ligand B (-5.5 kcal/mol), a difference of 1.3 kcal/mol. This is a meaningful difference.
**Overall Assessment:**
Ligand A has advantages in QED, Cl_mic, t1/2, and binding affinity. However, its significantly higher DILI risk is a major drawback. Ligand B has a much better safety profile (lower DILI) and a lower TPSA, which is beneficial for permeability. While Ligand A has a slightly better binding affinity, the DILI risk outweighs this benefit. Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity) and the overall drug-like properties, Ligand B appears to be the more viable candidate.
Output:
0
2025-04-17 18:37:52,222 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands (368.5 & 349.4 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (75.71) is better than Ligand B (93.46). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (2.443) is slightly higher than Ligand A (1.577), but both are within the optimal 1-3 range.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Both ligands have 5 HBA, which is acceptable.
6. **QED:** Both ligands have similar QED scores (0.721 and 0.703), indicating good drug-likeness.
7. **DILI:** Ligand A (21.9%) has a significantly lower DILI risk than Ligand B (42.7%). This is a crucial advantage.
8. **BBB:** Ligand A (71.5%) shows better BBB penetration than Ligand B (56.6%). While not a primary concern for a cardiovascular target, it's a positive attribute.
9. **Caco-2:** Ligand A (-5.13) has a slightly better Caco-2 permeability than Ligand B (-4.367).
10. **Solubility:** Ligand A (-2.432) has better solubility than Ligand B (-3.345).
11. **hERG:** Both ligands have very low hERG inhibition risk (0.23 and 0.105).
12. **Cl_mic:** Ligand A (40.9) has a lower microsomal clearance than Ligand B (64.4), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-9.659) has a much longer in vitro half-life than Ligand B (-23.708). This is a significant advantage.
14. **Pgp:** Both ligands have similar Pgp efflux liability (0.045 and 0.067).
15. **Binding Affinity:** Ligand B (-6.7) has a slightly better binding affinity than Ligand A (-6.0). However, the difference is less than 1.5 kcal/mol.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B has a slightly better logP and affinity, but Ligand A excels in TPSA, DILI risk, metabolic stability (Cl_mic, t1/2) and solubility. The lower DILI risk and significantly improved metabolic stability of Ligand A are more important than the small affinity difference.
**Conclusion:**
Considering all factors, especially the lower DILI risk, better metabolic stability, and comparable binding affinity, Ligand A is the more promising drug candidate.
Output:
1
2025-04-17 18:37:52,222 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (354.403) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (105.17) is better than Ligand B (49.85). For a cardiovascular GPCR, TPSA isn't *as* critical as for CNS targets, but lower is still preferred for absorption.
3. **logP:** Ligand B (3.037) is optimal, while Ligand A (-0.556) is quite low, potentially hindering membrane permeability. This is a significant negative for Ligand A.
4. **HBD:** Ligand A (2) is preferable to Ligand B (0). A small number of HBDs can aid solubility without drastically impacting permeability.
5. **HBA:** Ligand A (6) is better than Ligand B (4). Similar to HBD, a moderate number of HBAs is desirable.
6. **QED:** Both ligands have good QED scores (A: 0.62, B: 0.778), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (29.314) has a significantly lower DILI risk than Ligand B (52.074). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (74.098) has a higher BBB penetration score than Ligand A (49.244). While ADRB2 isn't a CNS target, some degree of BBB penetration can be useful.
9. **Caco-2:** Ligand A (-5.002) is worse than Ligand B (-4.287). Both are negative, indicating poor permeability, but Ligand B is slightly better.
10. **Solubility:** Ligand A (-0.38) is better than Ligand B (-3.611). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.093) has a lower hERG risk than Ligand B (0.35). This is a crucial safety parameter.
12. **Cl_mic:** Ligand A (-0.889) has a lower (better) microsomal clearance than Ligand B (85.432). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (11.603) has a longer half-life than Ligand B (1.714). This is a significant advantage for dosing convenience.
14. **Pgp:** Ligand A (0.015) has lower P-gp efflux than Ligand B (0.209). This is favorable for bioavailability.
15. **Binding Affinity:** Ligand B (-8.1) has a significantly stronger binding affinity than Ligand A (-4.5). This is a substantial advantage for Ligand B, potentially outweighing some ADME concerns.
**GPCR-Specific Priorities:**
For ADRB2 (a cardiovascular GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in affinity, and has a good logP. Ligand A has a poor logP, but has better TPSA, Pgp, DILI, hERG, Cl_mic, t1/2, and solubility.
**Overall Assessment:**
The significantly stronger binding affinity of Ligand B (-8.1 vs -4.5) is a major factor. While Ligand A has a better safety profile (DILI, hERG) and ADME properties (Cl_mic, t1/2), the potency difference is substantial. The logP of Ligand A is a concern, but can be addressed with formulation strategies. The improved ADME properties of Ligand A are valuable, but the binding affinity is the most important factor for a GPCR target.
Output:
0
2025-04-17 18:37:52,222 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [345.443, 82.53, 2.419, 2, 4, 0.776, 41.915, 53.742, -4.948, -3.471, 0.284, 30.332, -28.455, 0.088, -7.1]
**Ligand B:** [347.423, 124.01, 1.986, 3, 9, 0.657, 63.862, 64.482, -5.29, -3.499, 0.427, 38.255, 29.021, 0.014, -5.7]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal 200-500 Da range. A (345.443) is slightly lower, which is generally favorable.
2. **TPSA:** A (82.53) is significantly better than B (124.01). For a GPCR, keeping TPSA low is good for permeability.
3. **logP:** Both are within the optimal 1-3 range. A (2.419) is slightly higher than B (1.986), which is a minor advantage.
4. **HBD:** A (2) is better than B (3). Lower is preferred to balance solubility and permeability.
5. **HBA:** A (4) is better than B (9). Lower is preferred.
6. **QED:** A (0.776) is better than B (0.657), indicating a more drug-like profile.
7. **DILI:** A (41.915) is significantly better than B (63.862). This is a crucial advantage, as lower DILI risk is essential.
8. **BBB:** A (53.742) is lower than B (64.482). While ADRB2 isn't necessarily a CNS target, some degree of BBB penetration can be beneficial for distribution. B is better here.
9. **Caco-2:** A (-4.948) is better than B (-5.29), indicating better intestinal absorption.
10. **Solubility:** Both are very poor (-3.471 and -3.499). This is a significant drawback for both, but not a deciding factor between them.
11. **hERG:** A (0.284) is significantly better than B (0.427). Lower hERG inhibition is critical for avoiding cardiotoxicity, especially for a cardiovascular target.
12. **Cl_mic:** A (30.332) is better than B (38.255), indicating better metabolic stability.
13. **t1/2:** A (-28.455) is better than B (29.021), indicating a longer in vitro half-life.
14. **Pgp:** A (0.088) is significantly better than B (0.014), indicating lower P-gp efflux.
15. **Affinity:** A (-7.1) is significantly better than B (-5.7). This is a substantial difference in binding potency.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, and affinity. Ligand A excels in all these areas. While Ligand B has slightly better BBB penetration, the other advantages of Ligand A (especially the significantly better affinity, DILI, hERG, and Pgp profiles) outweigh this.
**Conclusion:**
Ligand A is the superior candidate due to its better overall profile, particularly its significantly higher binding affinity, lower DILI and hERG risk, and improved metabolic stability. The lower TPSA and Pgp efflux also contribute to its favorability.
1
2025-04-17 18:37:52,223 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (353.409 and 346.515 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (46.61) is better than Ligand B (49.41). Both are below 140, which is good for oral absorption, but lower is preferred.
3. **logP:** Both ligands have good logP values (3.89 and 3.524), falling within the optimal 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Ligand A (0) is better than Ligand B (1). Lower HBD is generally preferred for better permeability.
5. **HBA:** Ligand A (3) is slightly better than Ligand B (2). Both are within the acceptable range of <=10.
6. **QED:** Ligand A (0.755) is significantly better than Ligand B (0.566), indicating a more drug-like profile.
7. **DILI:** Ligand A (35.014) is much better than Ligand B (8.569). Lower DILI risk is crucial.
8. **BBB:** Ligand A (92.323) is better than Ligand B (83.637). While ADRB2 isn't exclusively a CNS target, some CNS penetration can be useful for understanding off-target effects and potential side effects.
9. **Caco-2:** Ligand A (-4.372) is better than Ligand B (-4.864). Higher Caco-2 permeability suggests better absorption.
10. **Solubility:** Ligand A (-4.068) is better than Ligand B (-3.239). Higher aqueous solubility is desirable for formulation and bioavailability.
11. **hERG:** Both ligands have similar hERG inhibition liabilities (0.681 and 0.628), which is relatively low and acceptable.
12. **Cl_mic:** Ligand B (58.757) has lower microsomal clearance than Ligand A (69.01), indicating better metabolic stability.
13. **t1/2:** Ligand B (-16.95) has a better in vitro half-life than Ligand A (-25.726).
14. **Pgp:** Both ligands have similar Pgp efflux liabilities (0.387 and 0.483).
15. **Binding Affinity:** Ligand A (-7.8) has a significantly stronger binding affinity than Ligand B (-6.9). This is a >1 kcal/mol difference, which is a substantial advantage.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A performs better on logP, TPSA, and significantly better on affinity. While Ligand B has better metabolic stability (Cl_mic, t1/2), the strong affinity of Ligand A outweighs this benefit, especially considering its favorable overall profile.
**Conclusion:**
Ligand A is the superior candidate due to its significantly better binding affinity, better drug-likeness (QED), lower DILI risk, better BBB penetration, and favorable values for TPSA, solubility, and Caco-2 permeability. The slightly lower metabolic stability is a manageable concern compared to the substantial advantage in potency.
Output:
1
2025-04-17 18:37:52,223 - INFO - Batch 51 complete. Total preferences: 816
2025-04-17 18:37:52,223 - INFO - Processing batch 52/512...
2025-04-17 18:38:43,068 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (355.429 Da) is slightly lower, which is generally favorable for permeability.
**2. TPSA:** Ligand A (74.85) is significantly better than Ligand B (101.29). For a GPCR, keeping TPSA below 140 is good, and lower is better for permeability. Ligand A is well within this range, while Ligand B is approaching the upper limit.
**3. logP:** Ligand A (3.32) is optimal, while Ligand B (1.177) is a bit low. A logP between 1-3 is preferred, and Ligand B's value might indicate potential permeability issues.
**4. H-Bond Donors:** Ligand A (2) is preferable to Ligand B (3). Lower HBDs generally improve membrane permeability.
**5. H-Bond Acceptors:** Ligand A (3) is preferable to Ligand B (5). Similar to HBDs, lower HBA is generally better for permeability.
**6. QED:** Ligand A (0.854) is significantly better than Ligand B (0.733), indicating a more drug-like profile.
**7. DILI:** Ligand B (75.572) has a higher DILI risk than Ligand A (55.68). Both are above the ideal <40, but Ligand A is closer.
**8. BBB:** Ligand A (83.637) has a much better BBB penetration percentile than Ligand B (68.864). While ADRB2 isn't a CNS target, some off-target CNS effects are possible with GPCR ligands, and better BBB penetration can sometimes correlate with better overall distribution.
**9. Caco-2 Permeability:** Ligand A (-4.537) is better than Ligand B (-5.707). Lower values are less favorable, but the difference is not substantial.
**10. Aqueous Solubility:** Ligand A (-4.133) is better than Ligand B (-2.075). Both are poor, but Ligand A is slightly better.
**11. hERG Inhibition:** Both ligands have similar hERG inhibition liability (0.387 and 0.44, respectively). Both are relatively low risk.
**12. Microsomal Clearance:** Ligand B (5.984) has significantly lower microsomal clearance than Ligand A (21.499). This suggests better metabolic stability for Ligand B.
**13. In vitro Half-Life:** Ligand B (33.354) has a much longer in vitro half-life than Ligand A (-12.671). This is a significant advantage for Ligand B.
**14. P-gp Efflux:** Both ligands have similar P-gp efflux liability (0.112 and 0.239, respectively). Both are relatively low risk.
**15. Binding Affinity:** Both ligands have very similar binding affinities (-6.9 kcal/mol and -6.0 kcal/mol). The difference is less than 1.5 kcal/mol, so it doesn't strongly sway the decision.
**Overall Assessment:**
Ligand A has a better profile across several key ADME properties (TPSA, logP, QED, BBB, solubility) and a lower DILI risk. While Ligand B has better metabolic stability and half-life, the superior permeability and drug-likeness of Ligand A are more critical for a cardiovascular GPCR target. The slight edge in binding affinity for Ligand A also contributes to its preference.
Output:
1
2025-04-17 18:38:43,068 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Ligand A (361.869 Da) is within the ideal range (200-500). Ligand B (347.463 Da) is also within the ideal range. No clear advantage here.
2. **TPSA:** Ligand A (58.56) is excellent, well below the 140 threshold for oral absorption. Ligand B (79.38) is still reasonable, but higher. A favors better absorption.
3. **logP:** Ligand A (4.771) is slightly high, potentially leading to solubility issues or off-target interactions. Ligand B (2.272) is optimal. B is preferable here.
4. **HBD:** Both ligands have 2 HBD, which is good.
5. **HBA:** Ligand A has 3 HBA, Ligand B has 6 HBA. A is slightly better.
6. **QED:** Both ligands have similar QED values (0.698 and 0.751), indicating good drug-likeness.
7. **DILI:** Ligand A (53.936) has a higher DILI risk than Ligand B (40.403). B is preferable.
8. **BBB:** Ligand A (17.798) has very poor BBB penetration. Ligand B (67.08) is significantly better. While ADRB2 isn't exclusively a CNS target, some cardiovascular effects are mediated through CNS pathways, and better BBB penetration could be beneficial. B is preferable.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual. Assuming these are percentile scores, Ligand A (-4.962) is worse than Ligand B (-5.093).
10. **Solubility:** Ligand A (-5.13) has worse solubility than Ligand B (-2.415). B is preferable.
11. **hERG:** Ligand A (0.778) has a slightly higher hERG risk than Ligand B (0.435). B is preferable.
12. **Cl_mic:** Ligand A (93.587) has a higher microsomal clearance, indicating lower metabolic stability, compared to Ligand B (27.525). B is preferable.
13. **t1/2:** Ligand A (27.16) has a reasonable half-life. Ligand B (28.353) is slightly better.
14. **Pgp:** Ligand A (0.637) has lower P-gp efflux than Ligand B (0.028). A is preferable.
15. **Binding Affinity:** Ligand B (-7.1) has a significantly stronger binding affinity than Ligand A (-5.1). This is a substantial advantage, potentially outweighing some of the ADME drawbacks of Ligand A.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B excels in affinity and has a better logP, TPSA, and Pgp profile. While Ligand A has a better Pgp score, the significant affinity advantage of Ligand B is crucial.
**Overall Assessment:**
Ligand B is the stronger candidate. Its superior binding affinity, lower DILI risk, better BBB penetration, solubility, hERG risk, and metabolic stability outweigh the slightly higher TPSA and lower Pgp efflux. The high logP is a concern, but the strong binding affinity suggests it can still effectively engage the target.
Output:
0
2025-04-17 18:38:43,068 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A: [349.381, 58.36, 3.088, 1, 4, 0.836, 49.438, 90.074, -4.203, -3.613, 0.613, 45.117, 14.94, 0.442, -6.8]**
**Ligand B: [366.795, 48.15, 4.324, 0, 4, 0.811, 65.568, 92.439, -4.463, -5.86, 0.336, 31.637, 23.157, 0.362, -5.2]**
Here's a breakdown, prioritizing GPCR-relevant parameters:
1. **Molecular Weight:** Both are within the ideal 200-500 Da range. Ligand A (349.381) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are good, below the 140 A^2 threshold for oral absorption. Ligand B (48.15) is better than Ligand A (58.36).
3. **logP:** Both are within the optimal 1-3 range, but Ligand B (4.324) is pushing the upper limit. Ligand A (3.088) is better.
4. **H-Bond Donors/Acceptors:** Ligand A has 1 HBD and 4 HBA, while Ligand B has 0 HBD and 4 HBA. Both are acceptable.
5. **QED:** Both are high (>0.8), indicating good drug-like properties.
6. **DILI:** Ligand A (49.438) has a significantly lower DILI risk than Ligand B (65.568). This is a major advantage for Ligand A.
7. **BBB:** Both have high BBB penetration (Ligand A: 90.074, Ligand B: 92.439). This isn't a primary concern for a cardiovascular target, but it's not detrimental.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability.
9. **Solubility:** Both have negative solubility values, which is also unusual and suggests poor solubility.
10. **hERG:** Ligand A (0.613) has a slightly higher hERG risk than Ligand B (0.336), but both are relatively low.
11. **Cl_mic:** Ligand B (31.637) has a much lower microsomal clearance than Ligand A (45.117), indicating better metabolic stability.
12. **t1/2:** Ligand B (23.157) has a longer in vitro half-life than Ligand A (14.94), which is desirable.
13. **Pgp:** Both have low P-gp efflux liability.
14. **Binding Affinity:** Ligand A (-6.8 kcal/mol) has a stronger binding affinity than Ligand B (-5.2 kcal/mol). This is a significant advantage.
**Overall Assessment:**
The key differentiators are binding affinity and DILI risk. Ligand A has a substantially better binding affinity (-6.8 vs -5.2 kcal/mol), and a much lower DILI risk (49.438 vs 65.568). While Ligand B has better metabolic stability and half-life, the stronger binding and lower toxicity profile of Ligand A outweigh these advantages. The negative Caco-2 and solubility values are concerning for both, but can be addressed with formulation strategies.
Therefore, I would choose Ligand A.
Output:
1
2025-04-17 18:38:43,068 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (363.483 and 372.466 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (73.74) is significantly better than Ligand B (104.21). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is pushing the upper limit for good oral absorption.
3. **logP:** Both ligands (2.054 and 2.177) are within the optimal 1-3 range. Similar.
4. **HBD:** Ligand A (1) is better than Ligand B (3). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (5) is better than Ligand B (6). Similar to HBD, lower HBA is preferred.
6. **QED:** Ligand A (0.89) is significantly better than Ligand B (0.649). A higher QED suggests a more drug-like profile.
7. **DILI:** Ligand B (61.342) has a slightly higher DILI risk than Ligand A (57.348), but both are acceptable (below 60).
8. **BBB:** Ligand B (65.529) has a better BBB penetration percentile than Ligand A (47.499). While ADRB2 isn't strictly a CNS target, some CNS exposure can be relevant for off-target effects, and higher BBB is generally favorable.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.052 and -4.876), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Both ligands have negative solubility values (-3.404 and -4.363), indicating very poor aqueous solubility. This is a major drawback for both.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.319 and 0.311). This is excellent.
12. **Cl_mic:** Ligand A (49.243) has a lower microsomal clearance than Ligand B (66.233), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-20.864) has a more negative in vitro half-life than Ligand B (-28.196). This is counterintuitive, as a more negative value indicates a shorter half-life. This is a negative for Ligand A.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.06 and 0.331). This is good.
15. **Binding Affinity:** Ligand B (-7.0) has a significantly better binding affinity than Ligand A (-5.5). This is a substantial advantage. A 1.5 kcal/mol difference is enough to potentially overcome some ADME issues.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B has a better affinity, and acceptable logP and Pgp. Ligand A has a better TPSA, but the difference in affinity is more significant. The poor Caco-2 and solubility for both are concerning, but the affinity advantage of Ligand B is substantial.
**Conclusion:**
Despite the poor permeability and solubility of both compounds, the significantly stronger binding affinity of Ligand B (-7.0 kcal/mol vs -5.5 kcal/mol) outweighs the slightly better TPSA and QED of Ligand A. The better metabolic stability of Ligand A is a plus, but the affinity difference is more critical for a GPCR target.
Output:
0
2025-04-17 18:38:43,069 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.462 and 350.503 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (40.62) is significantly better than Ligand B (67.43). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold. Ligand B is approaching the upper limit.
3. **logP:** Both ligands have acceptable logP values (2.338 and 3.197), falling within the 1-3 range. Ligand B is slightly higher, which *could* indicate a slightly better ability to cross membranes, but also a potential for off-target interactions.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer hydrogen bond donors generally improve membrane permeability.
5. **HBA:** Ligand A (2) is preferable to Ligand B (3). Similar reasoning as with HBD.
6. **QED:** Ligand A (0.663) is significantly better than Ligand B (0.361). A higher QED indicates a more drug-like profile.
7. **DILI:** Both ligands have relatively low DILI risk (10.702 and 11.632), both below the 40 threshold. No major difference.
8. **BBB:** Ligand A (86.817) has a higher BBB penetration percentile than Ligand B (72.082). While not crucial for a cardiovascular target, higher BBB is rarely detrimental.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.478 and -4.743). These values are unusual and suggest poor permeability. However, the values are similar, so this isn't a deciding factor.
10. **Solubility:** Both ligands have negative solubility values (-3.054 and -3.684). These values are also unusual and suggest poor solubility. Again, the values are similar.
11. **hERG:** Both ligands have low hERG inhibition liability (0.672 and 0.492), which is good.
12. **Cl_mic:** Ligand A (39.815) has a higher microsomal clearance than Ligand B (28.64). Lower clearance is preferred for metabolic stability, so Ligand B is better here.
13. **t1/2:** Ligand A (-14.003) has a much *shorter* in vitro half-life than Ligand B (-4.403). This is a significant drawback for Ligand A.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.121 and 0.028).
15. **Binding Affinity:** Both ligands have very similar binding affinities (-5.6 and -5.5 kcal/mol). The difference is negligible.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A excels in TPSA and has comparable logP and affinity. Ligand B has a slight edge in metabolic stability (Cl_mic) and half-life, but the significantly better QED, TPSA, HBD/HBA, and BBB of Ligand A outweigh this. The negative Caco-2 and solubility values are concerning for both, but similar.
**Conclusion:**
Ligand A is the more promising candidate due to its superior drug-like properties (QED), lower TPSA, fewer H-bonds, and better BBB penetration, despite the slightly higher clearance and shorter half-life. The binding affinity is comparable, and the DILI and hERG profiles are acceptable for both.
Output:
1
2025-04-17 18:38:43,069 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's systematically compare Ligand A and Ligand B based on the provided parameters and the guidelines, keeping in mind ADRB2 is a GPCR.
1. **Molecular Weight:** Both ligands (343.471 and 348.422 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (64.41) is significantly better than Ligand B (86.88). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand A is well below the 140 threshold, while B is approaching it.
3. **logP:** Both ligands have good logP values (2.732 and 2.393), falling within the optimal 1-3 range. Ligand A is slightly higher, which *could* be a minor advantage.
4. **H-Bond Donors:** Ligand A (0) is preferable to Ligand B (3). Fewer H-bond donors generally improve membrane permeability.
5. **H-Bond Acceptors:** Both ligands have 3 H-bond acceptors, which is acceptable.
6. **QED:** Ligand A (0.737) has a slightly better QED score than Ligand B (0.631), indicating a more drug-like profile.
7. **DILI:** Ligand B (44.048) has a considerably lower DILI risk than Ligand A (17.41). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (81.543) has a slightly better BBB penetration percentile than Ligand B (78.441). While ADRB2 isn't necessarily a CNS target, some peripheral distribution benefits from better BBB penetration.
9. **Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand B (-4.899) is slightly worse than Ligand A (-4.542).
10. **Aqueous Solubility:** Both ligands have negative solubility values, indicating poor solubility. Ligand B (-3.983) is slightly worse than Ligand A (-3.527).
11. **hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.406 and 0.417), which is excellent.
12. **Microsomal Clearance:** Ligand A (49.441) has a higher microsomal clearance than Ligand B (22.24), meaning it's likely to be metabolized faster. Ligand B is significantly better here.
13. **In vitro Half-Life:** Ligand B (-6.344) has a significantly longer in vitro half-life than Ligand A (-4.651). This is a major advantage.
14. **P-gp Efflux:** Both ligands have low P-gp efflux liability (0.09 and 0.068).
15. **Binding Affinity:** Both ligands have very similar and strong binding affinities (-5.8 and -5.4 kcal/mol). The difference of 0.4 kcal/mol is not substantial enough to outweigh other factors.
**Overall Assessment:**
While Ligand A has slightly better TPSA, logP, QED, and BBB penetration, Ligand B demonstrates significantly better ADME properties: lower DILI risk, lower microsomal clearance, and a longer half-life. The poor Caco-2 and solubility for both are concerning, but the ADME advantages of Ligand B are more critical for overall drug development success, especially considering the potential for metabolic instability with Ligand A.
**Output:**
0
2025-04-17 18:38:43,069 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (339.435 and 347.459 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (58.56) is significantly better than Ligand B (87.3). ADRB2 is a cardiovascular target, not CNS, but lower TPSA generally improves absorption. Ligand A is well below the 140 threshold, while B is approaching it.
3. **logP:** Both ligands have good logP values (2.649 and 1.699), falling within the 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability, but not dramatically so.
4. **HBD:** Ligand A (2) is preferable to Ligand B (3). Lower HBD generally improves permeability.
5. **HBA:** Both ligands have the same number of HBA (3), which is acceptable.
6. **QED:** Ligand A (0.88) has a significantly better QED score than Ligand B (0.613), indicating a more drug-like profile.
7. **DILI:** Ligand A (30.865) has a slightly higher DILI risk than Ligand B (24.544), but both are well below the concerning threshold of 60.
8. **BBB:** Ligand B (59.364) has a better BBB penetration score than Ligand A (40.946). However, since ADRB2 is a cardiovascular target, BBB penetration is not a primary concern.
9. **Caco-2:** Ligand A (-4.74) shows better Caco-2 permeability than Ligand B (-5.462). This suggests better intestinal absorption for Ligand A.
10. **Solubility:** Ligand A (-2.871) has slightly better solubility than Ligand B (-2.403).
11. **hERG:** Both ligands have very low hERG inhibition liability (0.3 and 0.05), which is excellent.
12. **Cl_mic:** Ligand B (18.945) has slightly lower microsomal clearance than Ligand A (20.846), suggesting better metabolic stability.
13. **t1/2:** Ligand A (44.591) has a significantly longer in vitro half-life than Ligand B (21.368). This is a major advantage for dosing frequency.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.111 and 0.052), which is good.
15. **Binding Affinity:** Ligand A (-7.4) has a significantly stronger binding affinity than Ligand B (-5.2). This >1.5 kcal/mol difference is substantial and can outweigh minor ADME drawbacks.
**Overall Assessment:**
Ligand A is the stronger candidate. While Ligand B has slightly better metabolic stability and a slightly better BBB score (which isn't critical for a cardiovascular target), Ligand A excels in several key areas: significantly better QED, longer half-life, better Caco-2 permeability, and, most importantly, a much stronger binding affinity. The TPSA is also much more favorable for Ligand A. These factors collectively make Ligand A a more promising drug candidate for the ADRB2 receptor.
Output:
1
2025-04-17 18:38:43,069 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (370.515 and 348.487 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (70.08) is slightly higher than Ligand B (58.64). Both are below the 140 threshold for oral absorption, but B is better.
3. **logP:** Both ligands have good logP values (1.838 and 2.489) within the optimal 1-3 range. Ligand B is slightly better.
4. **HBD:** Both have 1 HBD, which is acceptable.
5. **HBA:** Ligand A has 5 HBA, while Ligand B has 3. Both are acceptable, but B is slightly better.
6. **QED:** Both ligands have a QED of 0.8 and 0.83, indicating good drug-likeness. No significant difference.
7. **DILI:** Ligand A (38.503) has a higher DILI risk than Ligand B (12.524). This is a significant advantage for Ligand B.
8. **BBB:** Ligand B (73.943) shows better BBB penetration than Ligand A (28.655). While ADRB2 isn't strictly a CNS target, some CNS exposure can occur, and better BBB penetration is generally favorable.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.57 and -4.76), which is unusual and suggests very poor permeability. This is a major concern for both.
10. **Solubility:** Both ligands have very poor aqueous solubility (-2.046 and -2.265). This is a significant drawback for both.
11. **hERG:** Ligand A (0.155) has a slightly higher hERG inhibition liability than Ligand B (0.351). Lower is better, so Ligand B is slightly preferred.
12. **Cl_mic:** Ligand B (29.637) has a significantly lower microsomal clearance than Ligand A (43.521), indicating better metabolic stability. This is a major advantage for Ligand B.
13. **t1/2:** Ligand B (6.768) has a much longer in vitro half-life than Ligand A (-2.6). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.167) has a slightly lower P-gp efflux liability than Ligand B (0.107). Lower is better, so Ligand A is slightly preferred.
15. **Binding Affinity:** Ligand A (-6.7 kcal/mol) has a slightly better binding affinity than Ligand B (-5.3 kcal/mol). This is a positive for Ligand A, but the difference isn't huge.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Ligand B has a slightly better logP and TPSA. The affinity difference isn't substantial enough to outweigh the other advantages of Ligand B.
**Overall Assessment:**
Ligand B is significantly better overall. It has a much lower DILI risk, better BBB penetration, significantly lower microsomal clearance, and a longer half-life. While both have poor Caco-2 and solubility, the other advantages of Ligand B outweigh the slightly better affinity of Ligand A.
Output:
0
2025-04-17 18:38:43,069 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (345.487 Da and 361.877 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (73.2) is higher than Ligand B (47.59). For a cardiovascular GPCR, TPSA is moderately important. Ligand B's lower TPSA is preferable, suggesting better potential for membrane permeability.
**3. logP:** Both ligands have good logP values (3.172 and 3.068), falling within the optimal 1-3 range. No clear advantage.
**4. H-Bond Donors:** Ligand A has 1 HBD, while Ligand B has 0. Both are within the acceptable limit of <=5.
**5. H-Bond Acceptors:** Ligand A has 3 HBA, and Ligand B has 6. While both are under the 10 limit, Ligand A is better.
**6. QED:** Ligand A (0.795) has a significantly higher QED score than Ligand B (0.578), indicating a more drug-like profile. This is a positive for Ligand A.
**7. DILI Risk:** Ligand B (37.728) has a lower DILI risk than Ligand A (20.977). This is a significant advantage for Ligand B.
**8. BBB Penetration:** Ligand B (78.209) has better BBB penetration than Ligand A (65.839). While not a primary concern for a cardiovascular target, some CNS off-target effects are possible with GPCRs, so this is a slight advantage for Ligand B.
**9. Caco-2 Permeability:** Ligand A (-4.606) shows better Caco-2 permeability than Ligand B (-5.158).
**10. Aqueous Solubility:** Ligand A (-3.096) has better aqueous solubility than Ligand B (-1.854). Solubility is important for formulation and bioavailability.
**11. hERG Inhibition:** Ligand A (0.497) has a lower hERG inhibition risk than Ligand B (0.925). This is a crucial advantage for Ligand A, minimizing cardiotoxicity concerns.
**12. Microsomal Clearance:** Ligand B (58.427) has higher microsomal clearance than Ligand A (44.221), indicating faster metabolism and potentially shorter duration of action. Ligand A is preferred.
**13. In vitro Half-Life:** Ligand B (50.835) has a much longer in vitro half-life than Ligand A (-4.703). This is a significant advantage for Ligand B.
**14. P-gp Efflux:** Ligand A (0.062) has lower P-gp efflux than Ligand B (0.531), which is favorable for bioavailability.
**15. Binding Affinity:** Ligand B (-7.3) has a slightly better binding affinity than Ligand A (-7.0). While the difference is small (0.3 kcal/mol), it's still a consideration.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity) and general drug-like properties, Ligand A appears to be the more promising candidate. While Ligand B has a slightly better binding affinity and longer half-life, Ligand A excels in crucial areas like solubility, lower hERG risk, lower P-gp efflux, and a higher QED score. The lower DILI risk of Ligand B is attractive, but the hERG risk associated with Ligand B is a significant concern for a cardiovascular target.
Output:
1
2025-04-17 18:38:43,069 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [352.435, 99.77, -0.02, 3, 4, 0.508, 14.696, 78.945, -5.023, -1.752, 0.218, -10.845, 6, 0.009, -5.3]**
**Ligand B: [349.479, 70.47, 0.971, 1, 5, 0.759, 13.843, 63.474, -5.045, -0.196, 0.136, 11.114, 12.125, 0.012, -7.5]**
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). A is 352.435, B is 349.479. No significant difference.
**2. TPSA:** Ligand A (99.77) is higher than Ligand B (70.47). For a GPCR like ADRB2, lower TPSA is generally preferred for better permeability. B is better here.
**3. logP:** Ligand A (-0.02) is slightly lower than the optimal 1-3 range, potentially hindering permeability. Ligand B (0.971) is closer to the optimal range. B is better.
**4. H-Bond Donors:** Ligand A (3) is within the acceptable limit of 5. Ligand B (1) is also good. No significant difference.
**5. H-Bond Acceptors:** Ligand A (4) is within the acceptable limit of 10. Ligand B (5) is also good. No significant difference.
**6. QED:** Ligand B (0.759) has a higher QED score than Ligand A (0.508), indicating a more drug-like profile. B is better.
**7. DILI:** Ligand A (14.696) has a slightly higher DILI risk than Ligand B (13.843), but both are relatively low and acceptable.
**8. BBB:** Ligand A (78.945) has a significantly higher BBB penetration percentile than Ligand B (63.474). While ADRB2 isn't strictly a CNS target, some CNS exposure can be beneficial or at least not detrimental. A is better.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. The values are very similar (-5.023 vs -5.045).
**10. Aqueous Solubility:** Both ligands have negative solubility values, which is also unusual and suggests poor solubility. The values are very similar (-1.752 vs -0.196).
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.218 and 0.136). No significant difference.
**12. Microsomal Clearance:** Ligand A (-10.845) has a lower (better) microsomal clearance than Ligand B (11.114), indicating greater metabolic stability. A is better.
**13. In vitro Half-Life:** Ligand B (12.125) has a significantly longer in vitro half-life than Ligand A (6). This is a significant advantage. B is better.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.009 and 0.012). No significant difference.
**15. Binding Affinity:** Ligand B (-7.5) has a significantly stronger binding affinity than Ligand A (-5.3). This is a substantial advantage, potentially outweighing some of the ADME drawbacks. B is *much* better.
**Overall Assessment:**
Ligand B clearly wins out. While Ligand A has better BBB penetration and metabolic stability, Ligand B's significantly stronger binding affinity (-7.5 vs -5.3 kcal/mol) and better QED score are critical advantages, especially for a GPCR target. The longer half-life is also a significant benefit. The slightly lower BBB penetration of B is not a major concern for ADRB2. The similar poor permeability and solubility scores are a concern for both, but can be addressed with formulation strategies.
Output:
0
2025-04-17 18:38:43,070 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (343.36 and 348.49 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (75.48) is higher than Ligand B (58.64). While both are below 140, the lower TPSA of Ligand B is preferable for oral absorption, a general benefit.
3. **logP:** Both ligands have good logP values (3.13 and 2.66), falling within the optimal 1-3 range. Ligand B is slightly lower, which could be beneficial for solubility.
4. **HBD:** Both have 1 HBD, which is ideal.
5. **HBA:** Ligand A has 4 HBAs, and Ligand B has 3. Both are acceptable, below the 10 threshold.
6. **QED:** Ligand A (0.683) has a better QED score than Ligand B (0.542), indicating a more drug-like profile.
7. **DILI:** Ligand B (8.22) has a *much* lower DILI risk than Ligand A (78.95). This is a major advantage for Ligand B.
8. **BBB:** Ligand A (81.58) has a slightly higher BBB penetration percentile than Ligand B (71.93). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be useful for understanding off-target effects.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the values are similar (-4.921 vs -4.724).
10. **Solubility:** Ligand B (-2.176) has better solubility than Ligand A (-4.566).
11. **hERG:** Ligand A (0.785) has a slightly higher hERG risk than Ligand B (0.437), although both are relatively low.
12. **Cl_mic:** Ligand A (14.79) has significantly lower microsomal clearance than Ligand B (47.15), indicating better metabolic stability.
13. **t1/2:** Ligand A (18.31) has a much longer in vitro half-life than Ligand B (0.81). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.29) has lower P-gp efflux liability than Ligand B (0.09), which is favorable.
15. **Affinity:** Ligand A (-7.4 kcal/mol) has a significantly stronger binding affinity than Ligand B (-3.8 kcal/mol). This is a substantial advantage, potentially outweighing some ADME concerns.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, affinity, logP, TPSA, and Pgp are key. Ligand A wins on affinity and Pgp, while Ligand B wins on TPSA and logP. The DILI score for Ligand B is dramatically better.
**Overall Assessment:**
The significantly stronger binding affinity of Ligand A (-7.4 vs -3.8) is a major driver. The longer half-life is also a substantial benefit. While Ligand B has a much better safety profile (DILI), the potency advantage of Ligand A is likely to be more impactful, especially given the relatively low hERG risk for both compounds. The slightly better TPSA and logP of Ligand B are not enough to overcome the large difference in binding affinity.
Output:
1
2025-04-17 18:38:43,070 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
The ADRB2 receptor is a GPCR, so the priorities are logP, Pgp, TPSA, affinity, and BBB. Let's analyze each ligand against these and other important parameters.
* **Molecular Weight:** Both ligands (365.792 and 378.607 Da) fall within the ideal 200-500 Da range.
* **TPSA:** Ligand A (79.46) is higher than Ligand B (33.2). Lower TPSA is generally preferred for better cell permeability, giving a slight edge to Ligand B.
* **logP:** Ligand B (4.299) is slightly higher than Ligand A (3.465). While both are above the optimal 1-3 range, Ligand B is pushing the upper limit and could potentially have solubility issues. Ligand A is closer to the ideal range.
* **H-Bond Donors/Acceptors:** Ligand A has 1 HBD and 5 HBA, while Ligand B has 0 HBD and 4 HBA. Both are within acceptable ranges.
* **QED:** Ligand A (0.901) has a significantly better QED score than Ligand B (0.632), indicating a more drug-like profile.
* **DILI:** Ligand B (22.722) has a much lower DILI risk than Ligand A (75.262), which is a significant advantage.
* **BBB:** Both ligands have good BBB penetration (Ligand A: 82.668, Ligand B: 87.941), but Ligand B is slightly better.
* **Caco-2 Permeability:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.844) is slightly better than Ligand B (-5.255).
* **Aqueous Solubility:** Both have negative solubility values, indicating poor solubility. Ligand A (-4.31) is slightly better than Ligand B (-3.4).
* **hERG:** Ligand A (0.283) has a lower hERG risk than Ligand B (0.803), which is a positive.
* **Microsomal Clearance:** Ligand B (86.718) has a much higher microsomal clearance than Ligand A (47.23), meaning it's metabolized more quickly. This is a significant disadvantage for Ligand B.
* **In vitro Half-Life:** Ligand A (-13.694) has a longer in vitro half-life than Ligand B (-5.812), which is a positive.
* **P-gp Efflux:** Ligand A (0.242) has lower P-gp efflux than Ligand B (0.685), which is preferable.
* **Binding Affinity:** Ligand A (-7.6) has a slightly better binding affinity than Ligand B (-6.0), although both are strong binders.
**Overall Assessment:**
Ligand A has a better QED score, lower DILI risk, lower P-gp efflux, better metabolic stability (lower Cl_mic, longer t1/2), and slightly better binding affinity. While Ligand B has a lower TPSA and slightly better BBB penetration, the superior ADME properties of Ligand A, particularly its lower DILI and better metabolic stability, outweigh these advantages. The slightly higher logP of Ligand B is also a concern. For a GPCR target, balancing affinity with good ADME properties is crucial, and Ligand A achieves this better.
**Output:**
1
2025-04-17 18:38:43,070 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (403.649 Da) is within the ideal range (200-500 Da). Ligand B (365.499 Da) is also excellent. No clear advantage here.
2. **TPSA:** Ligand A (81.47) is acceptable, though approaching the upper limit for good oral absorption. Ligand B (71.53) is better, comfortably under 100. This favors Ligand B.
3. **logP:** Ligand A (4.293) is slightly high, potentially leading to solubility issues or off-target interactions. Ligand B (2.235) is optimal. This strongly favors Ligand B.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 5. Both are within the acceptable range.
6. **QED:** Ligand B (0.839) has a significantly better QED score than Ligand A (0.425), indicating a more drug-like profile. This is a significant advantage for Ligand B.
7. **DILI:** Ligand A (77.007) has a moderate DILI risk. Ligand B (22.761) has a very low DILI risk, which is highly desirable. This is a strong advantage for Ligand B.
8. **BBB:** Ligand A (60.14) has moderate BBB penetration, while Ligand B (82.28) has good BBB penetration. Since ADRB2 is a GPCR, BBB penetration is a consideration, favoring Ligand B.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and potentially problematic. However, the magnitude of the negative value for Ligand A (-4.835) is worse than that of Ligand B (-4.971).
10. **Solubility:** Ligand A (-5.684) has poor solubility, consistent with its higher logP. Ligand B (-2.726) has better solubility. This favors Ligand B.
11. **hERG:** Both ligands have low hERG inhibition risk.
12. **Cl_mic:** Ligand A (51.628) has a moderate clearance, while Ligand B (17.821) has a lower clearance, indicating better metabolic stability. This favors Ligand B.
13. **t1/2:** Ligand A (13.691) has a moderate half-life, while Ligand B (8.174) has a shorter half-life.
14. **Pgp:** Both ligands have very low Pgp efflux liability.
15. **Binding Affinity:** Ligand B (-6.1 kcal/mol) has a significantly stronger binding affinity than Ligand A (-0.0 kcal/mol). This is a decisive advantage for Ligand B.
**Overall Assessment:**
Ligand B consistently outperforms Ligand A across most crucial parameters. It has a better QED score, lower DILI risk, better logP and solubility, improved metabolic stability, and, most importantly, a much stronger binding affinity. While Ligand A is within acceptable ranges for MW and H-bonding, its poor solubility, high logP, and weak binding make it a less attractive candidate. The GPCR-specific priorities (logP, Pgp, TPSA, affinity) all favor Ligand B.
Output:
0
2025-04-17 18:38:43,070 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**1. Molecular Weight:** Both ligands (356.344 and 353.507 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (49.85) is significantly better than Ligand B (70.67). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is pushing the upper limit for good oral absorption.
**3. logP:** Both ligands have acceptable logP values (2.687 and 1.566), falling within the 1-3 range. Ligand A is slightly more lipophilic, which could aid membrane permeability, but Ligand B is still reasonable.
**4. H-Bond Donors:** Ligand A has 0 HBDs, which is excellent. Ligand B has 2 HBDs, still acceptable but less optimal.
**5. H-Bond Acceptors:** Ligand A has 3 HBAs, while Ligand B has 4. Both are within the acceptable limit of 10.
**6. QED:** Ligand A (0.783) has a considerably better QED score than Ligand B (0.462), indicating a more drug-like profile.
**7. DILI Risk:** Ligand A (68.437) has a higher DILI risk than Ligand B (5.584). This is a significant concern for Ligand A.
**8. BBB Penetration:** Ligand A (93.563) has much better BBB penetration than Ligand B (67.623). While ADRB2 isn't exclusively a CNS target, some cardiovascular effects are mediated by central pathways, and better BBB penetration can be advantageous.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability *in vitro*. However, the scale is not specified, so it's hard to interpret. Ligand A (-4.126) is slightly worse than Ligand B (-4.829).
**10. Aqueous Solubility:** Ligand A (-3.007) has better aqueous solubility than Ligand B (-1.219). This is important for formulation and bioavailability.
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (0.491 and 0.331), which is good.
**12. Microsomal Clearance:** Ligand A (56.311) has higher microsomal clearance than Ligand B (33.15). This means Ligand B is likely more metabolically stable.
**13. In vitro Half-Life:** Ligand B (-21.305) has a significantly longer in vitro half-life than Ligand A (-4.049). This is a major advantage for Ligand B.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.257 and 0.006).
**15. Binding Affinity:** Both ligands have very similar and strong binding affinities (-6.6 and -6.2 kcal/mol). The difference is not substantial enough to be a deciding factor.
**Overall Assessment:**
Ligand A has advantages in TPSA, QED, BBB penetration, and solubility. However, its significantly higher DILI risk and higher clearance are major drawbacks. Ligand B, while having a slightly higher TPSA, excels in metabolic stability (lower clearance, longer half-life) and has a dramatically lower DILI risk. Given the cardiovascular context, minimizing liver toxicity is crucial. The slightly lower BBB penetration of Ligand B is less concerning than the DILI risk associated with Ligand A.
Therefore, I favor Ligand B.
0
2025-04-17 18:38:43,070 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (347.5) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (63.13) is higher than Ligand B (33.2). For a cardiovascular GPCR, TPSA isn't a *major* concern unless aiming for CNS penetration, but lower is generally better for absorption. Ligand B is significantly better here.
3. **logP:** Ligand A (2.962) is within the optimal range (1-3). Ligand B (4.192) is slightly higher, approaching the upper limit. This could potentially lead to solubility issues or off-target interactions, but isn't a dealbreaker.
4. **HBD:** Ligand A (2) is acceptable. Ligand B (0) is also good.
5. **HBA:** Ligand A (3) is acceptable. Ligand B (2) is also good.
6. **QED:** Both ligands have similar QED values (0.721 and 0.72), indicating good drug-likeness.
7. **DILI:** Ligand A (15.626) has a much lower DILI risk than Ligand B (33.773). This is a significant advantage for Ligand A.
8. **BBB:** Ligand B (93.718) has a higher BBB penetration percentile than Ligand A (75.145). While ADRB2 isn't a CNS target, some off-target CNS effects are possible with GPCR ligands, and higher BBB is not necessarily a negative.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. Ligand A (-4.582) is slightly worse than Ligand B (-4.319).
10. **Solubility:** Ligand A (-2.914) has better solubility than Ligand B (-5.039).
11. **hERG:** Ligand A (0.344) has a lower hERG inhibition liability than Ligand B (0.677), which is a significant safety advantage.
12. **Cl_mic:** Ligand B (55.945) has slightly lower microsomal clearance than Ligand A (51.721), suggesting better metabolic stability.
13. **t1/2:** Ligand A (7.433) has a longer in vitro half-life than Ligand B (0.826). This is a substantial advantage for Ligand A.
14. **Pgp:** Ligand A (0.078) has lower P-gp efflux liability than Ligand B (0.449), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand B (-7.3 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.7 kcal/mol). This is a 0.6 kcal/mol difference, which is a substantial advantage.
**GPCR-specific priorities:**
For ADRB2 (a cardiovascular GPCR), affinity, logP, TPSA, Pgp, and metabolic stability are key. Ligand B excels in affinity and has a slightly better metabolic stability. Ligand A has better solubility, lower DILI risk, lower hERG risk, lower Pgp efflux, and a longer half-life. The affinity difference is significant, but the safety profile of Ligand A is much more attractive. The poor Caco-2 values for both are concerning, but can be addressed with formulation strategies.
**Conclusion:**
While Ligand B has a better binding affinity, the superior safety profile (lower DILI and hERG), better solubility, lower Pgp efflux, and longer half-life of Ligand A make it the more promising drug candidate. The 0.6 kcal/mol affinity difference can potentially be overcome with further optimization, while mitigating the safety concerns of Ligand B would be more challenging.
Output:
1
2025-04-17 18:38:43,071 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**1. Molecular Weight:** Both ligands (347.46 and 349.44 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (72.36) is significantly better than Ligand B (91.57). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is approaching the upper limit for good oral absorption.
**3. logP:** Ligand A (1.765) is within the optimal 1-3 range. Ligand B (0.45) is a bit low, potentially hindering membrane permeability.
**4. H-Bond Donors:** Both ligands have acceptable HBD counts (2 and 1, respectively), well below the threshold of 5.
**5. H-Bond Acceptors:** Ligand A (4) is better than Ligand B (6), but both are within the acceptable range of <=10.
**6. QED:** Both ligands have similar and good QED values (0.753 and 0.733), indicating good drug-like properties.
**7. DILI:** Both ligands have low DILI risk (25.79 and 28.19 percentiles), which is favorable.
**8. BBB:** Ligand B (81.47) has a significantly higher BBB penetration percentile than Ligand A (54.79). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be useful for understanding off-target effects and distribution.
**9. Caco-2 Permeability:** Ligand A (-4.67) is better than Ligand B (-5.338). Higher values indicate better intestinal absorption.
**10. Aqueous Solubility:** Ligand A (-2.585) is better than Ligand B (-1.628).
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.13 and 0.091), which is excellent.
**12. Microsomal Clearance:** Ligand A (36.50) has a higher clearance than Ligand B (13.32). Lower clearance is preferred for better metabolic stability. Ligand B is significantly better here.
**13. In vitro Half-Life:** Ligand B (-2.862) has a longer half-life than Ligand A (10.876).
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.125 and 0.026).
**15. Binding Affinity:** Ligand A (-7.1) has a slightly better binding affinity than Ligand B (-0.0). This is a substantial difference.
**Overall Assessment:**
Considering the priorities for a GPCR target (logP, TPSA, affinity), Ligand A is the stronger candidate. The better logP and TPSA values suggest better permeability. Most importantly, the binding affinity of Ligand A is significantly superior. While Ligand B has better BBB penetration and metabolic stability, the large difference in binding affinity outweighs these advantages. The slightly lower metabolic stability of Ligand A can potentially be addressed through structural modifications in later optimization stages.
Output:
1
2025-04-17 18:38:43,071 - INFO - Batch 52 complete. Total preferences: 832
2025-04-17 18:38:43,071 - INFO - Processing batch 53/512...
2025-04-17 18:39:32,376 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
Let's systematically compare Ligand A and Ligand B based on the provided parameters, keeping in mind the GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key).
1. **Molecular Weight:** Both ligands (366.37 and 354.45 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (89.9) is slightly higher than Ligand B (79.31). Both are below the 140 threshold for oral absorption, but B is better.
3. **logP:** Ligand A (2.442) is within the optimal 1-3 range. Ligand B (0.57) is a bit low, potentially hindering permeation. This favors A.
4. **H-Bond Donors:** Both have 1 HBD, which is good.
5. **H-Bond Acceptors:** Ligand A has 7, and Ligand B has 5. Both are within the acceptable limit of 10.
6. **QED:** Ligand A (0.624) is slightly better than Ligand B (0.509), indicating a more drug-like profile.
7. **DILI:** Ligand A (85.27%) has a significantly higher DILI risk than Ligand B (14.85%). This is a major concern for A.
8. **BBB:** Ligand A (68.4%) is better than Ligand B (50.68%), but both are not high enough to be considered CNS-focused. However, for a cardiovascular target, this is less critical.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.675 and -4.644), which is unusual and suggests poor permeability. This is a significant drawback for both.
10. **Solubility:** Ligand A (-3.347) is slightly better than Ligand B (-0.215), but both are quite poor.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.251 and 0.209).
12. **Cl_mic:** Ligand A (92.72 mL/min/kg) has a much higher microsomal clearance than Ligand B (24.66 mL/min/kg), indicating lower metabolic stability. This is a significant disadvantage for A.
13. **t1/2:** Ligand A (41.90 hours) has a much longer half-life than Ligand B (6.68 hours). This is a positive for A.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.646 and 0.029). B is better.
15. **Binding Affinity:** Ligand B (-6.4 kcal/mol) has a slightly better binding affinity than Ligand A (-6.1 kcal/mol). While the difference is small, it's still a factor.
**Overall Assessment:**
Ligand A has advantages in half-life and logP, but it suffers from a very high DILI risk and high microsomal clearance. Ligand B has a much better safety profile (lower DILI) and better metabolic stability, with only a slightly weaker binding affinity. Given the cardiovascular target, metabolic stability and safety are paramount. While the affinity difference is small, the significantly lower DILI risk and better metabolic stability of Ligand B outweigh the slightly better affinity and half-life of Ligand A. The poor Caco-2 values are concerning for both, but can be addressed through formulation strategies.
**Output:**
0
2025-04-17 18:39:32,376 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (363.849 Da) and Ligand B (347.419 Da) are both within the ideal range (200-500 Da). No clear advantage here.
2. **TPSA:** Ligand A (102.04) is slightly higher than Ligand B (80.56). Both are below 140, but B is better for oral absorption.
3. **logP:** Ligand A (3.597) is optimal, while Ligand B (0.704) is a bit low. This is a significant advantage for A, as good lipophilicity is important for GPCR binding and membrane permeability.
4. **HBD:** Ligand A (3) is reasonable, and Ligand B (0) is even better. Lower HBD generally improves permeability.
5. **HBA:** Ligand A (4) and Ligand B (6) are both acceptable, but B is slightly higher.
6. **QED:** Both Ligand A (0.773) and Ligand B (0.708) have good drug-likeness scores, exceeding the 0.5 threshold.
7. **DILI:** Ligand A (78.247) has a higher DILI risk than Ligand B (56.572). This is a concern for A.
8. **BBB:** Ligand A (64.095) and Ligand B (72.005) both have reasonable BBB penetration, but B is better. While ADRB2 isn't exclusively a CNS target, some CNS exposure is possible, and higher BBB is generally desirable.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual. This suggests poor permeability. However, the scale is not defined, so it is hard to interpret.
10. **Solubility:** Ligand A (-5.052) has very poor solubility, while Ligand B (-1.827) is better, but still poor.
11. **hERG:** Ligand A (0.341) has a slightly higher hERG risk than Ligand B (0.047). This is a significant advantage for B.
12. **Cl_mic:** Ligand A (56.676) has higher metabolic clearance than Ligand B (31.42). B is preferable for metabolic stability.
13. **t1/2:** Ligand A (85.904) has a longer half-life than Ligand B (-1.53). This is a significant advantage for A.
14. **Pgp:** Ligand A (0.218) has lower P-gp efflux than Ligand B (0.047). This is a slight advantage for A.
15. **Binding Affinity:** Ligand B (-7.5 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.3 kcal/mol). This is a substantial advantage for B, potentially outweighing some of the ADME drawbacks.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand B excels in affinity and has better TPSA and Pgp values. While Ligand A has better logP and half-life, the significantly stronger binding of Ligand B, coupled with its lower DILI and hERG risk, makes it the more promising candidate. The poor solubility of both is a concern, but can be addressed with formulation strategies.
**Conclusion:**
Ligand B is the more viable drug candidate.
0
2025-04-17 18:39:32,377 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [358.404, 62.22, 3.481, 2, 3, 0.847, 22.024, 84.413, -4.556, -3.645, 0.521, 18.096, -0.376, 0.307, -6.7]**
**Ligand B: [368.547, 67.23, 2.226, 1, 5, 0.508, 21.753, 57.193, -5.197, -2.176, 0.359, 74.306, 24.406, 0.115, -7.7]**
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). A (358.4) is slightly preferred.
2. **TPSA:** Both are acceptable, but A (62.22) is better than B (67.23), being closer to the <140 threshold for good absorption.
3. **logP:** Both ligands have good logP values (between 1-3). A (3.481) is slightly higher, potentially leading to distribution issues, but B (2.226) is a bit low and might have permeability problems.
4. **H-Bond Donors:** A (2) is better than B (1). While both are acceptable, fewer donors can improve permeability.
5. **H-Bond Acceptors:** A (3) is better than B (5). Lower is preferred for permeability.
6. **QED:** A (0.847) is significantly better than B (0.508), indicating a more drug-like profile.
7. **DILI:** Both have low DILI risk (A: 22.024, B: 21.753), which is excellent. They are nearly identical.
8. **BBB:** A (84.413) is *much* better than B (57.193). While ADRB2 isn't exclusively a CNS target, some peripheral effects are mediated by CNS influence, and higher BBB penetration is generally favorable for GPCRs.
9. **Caco-2:** A (-4.556) is better than B (-5.197), indicating better intestinal absorption.
10. **Solubility:** A (-3.645) is better than B (-2.176), indicating better solubility.
11. **hERG:** Both are low (A: 0.521, B: 0.359), indicating low cardiotoxicity risk. B is slightly better.
12. **Cl_mic:** A (18.096) is much better than B (74.306), suggesting better metabolic stability.
13. **t1/2:** B (24.406) is significantly better than A (-0.376), indicating a much longer half-life. This is a major advantage.
14. **Pgp:** A (0.307) is better than B (0.115), indicating less P-gp efflux and potentially better bioavailability.
15. **Binding Affinity:** B (-7.7) is significantly better than A (-6.7), a difference of 1.0 kcal/mol. This is a substantial advantage that can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand B has a significantly better binding affinity and a much longer half-life. These are critical for a GPCR drug candidate. While Ligand A has better QED, BBB, solubility, and metabolic stability, the affinity difference is substantial enough to favor Ligand B. The longer half-life of B is also a significant advantage, potentially allowing for less frequent dosing.
Output:
0
2025-04-17 18:39:32,377 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (360.483 and 339.443 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (69.56) is better than Ligand B (82.7). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (2.198 and 3.032), falling within the optimal 1-3 range. Ligand B is slightly higher, which *could* be a minor concern for solubility, but not a dealbreaker.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (6) is preferable to Ligand B (5). Fewer HBAs generally improve permeability.
6. **QED:** Ligand A (0.889) is significantly better than Ligand B (0.676), indicating a more drug-like profile.
7. **DILI:** Ligand A (60.062) and Ligand B (54.517) are both acceptable, below the 60% threshold for high risk. Ligand B is slightly better.
8. **BBB:** Both ligands have similar BBB penetration (64.986 and 66.886). Not a major factor for a cardiovascular target.
9. **Caco-2:** Ligand A (-4.889) is better than Ligand B (-5.477). Lower (more negative) values indicate better permeability.
10. **Solubility:** Ligand A (-2.621) is better than Ligand B (-3.416). Higher values indicate better solubility.
11. **hERG:** Both ligands have low hERG inhibition risk (0.507 and 0.739). No significant difference.
12. **Cl_mic:** Ligand B (40.838) has significantly lower microsomal clearance than Ligand A (58.386), suggesting better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand B (48.413) has a much longer in vitro half-life than Ligand A (10.314). This is a major advantage, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have similar Pgp efflux liability (0.333 and 0.308).
15. **Binding Affinity:** Ligand B (-7.0) has a slightly better binding affinity than Ligand A (-6.7). While the difference is less than the 1.5 kcal/mol threshold, it's still a positive factor.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B has a slightly higher logP, but also better metabolic stability (Cl_mic) and half-life. The affinity difference is small, but favors Ligand B. Ligand A has better TPSA, but the other advantages of Ligand B outweigh this.
**Conclusion:**
While Ligand A has some favorable properties (better TPSA, QED, solubility), Ligand B's superior metabolic stability (lower Cl_mic), longer half-life, and slightly better binding affinity make it the more promising drug candidate.
Output:
0
2025-04-17 18:39:32,377 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [344.459, 58.44, 1.688, 0, 4, 0.764, 17.332, 70.997, -4.789, -1.606, 0.162, 33.785, -6.981, 0.031, -6.7]
**Ligand B:** [352.475, 78.87, 1.034, 2, 4, 0.48, 5.777, 33.385, -4.688, -1.784, 0.415, 34.876, -1.894, 0.075, -6.4]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (344.459) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (58.44) is significantly better than Ligand B (78.87). A TPSA under 140 is good for oral absorption, and lower is preferred for GPCRs.
3. **logP:** Both are within the optimal range (1-3). Ligand A (1.688) is slightly higher, which could be a minor advantage for membrane permeability.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Both have 4 HBA, which is acceptable.
6. **QED:** Ligand A (0.764) is significantly better than Ligand B (0.48), indicating a more drug-like profile.
7. **DILI:** Ligand A (17.332) has a much lower DILI risk than Ligand B (5.777), a crucial safety parameter.
8. **BBB:** Ligand A (70.997) has a significantly higher BBB penetration score than Ligand B (33.385). This is *very* important for a GPCR, even a cardiovascular one, as off-target CNS effects are always a concern.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual. Assuming these are logP-scaled values, lower values indicate lower permeability. They are very similar.
10. **Solubility:** Both have negative solubility values. Again, assuming logS values, they are very similar.
11. **hERG:** Ligand A (0.162) has a lower hERG risk than Ligand B (0.415).
12. **Cl_mic:** Both have similar microsomal clearance values (33.785 vs 34.876).
13. **t1/2:** Ligand A (-6.981) has a longer in vitro half-life than Ligand B (-1.894).
14. **Pgp:** Ligand A (0.031) has lower P-gp efflux liability than Ligand B (0.075).
15. **Affinity:** Ligand A (-6.7) has a slightly better binding affinity than Ligand B (-6.4), but the difference is not substantial enough to outweigh other factors.
**Overall Assessment:**
Ligand A is clearly superior. It excels in key ADME properties (TPSA, QED, DILI, BBB, Pgp, t1/2, hERG) and has a slightly better affinity. Ligand B has a slightly better logP, but the advantages of Ligand A in other critical areas, especially safety (DILI, hERG) and brain penetration (BBB), make it the more promising candidate. The GPCR-specific priorities (logP, Pgp, TPSA, and affinity) are all better addressed by Ligand A.
Output:
1
2025-04-17 18:39:32,377 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands (352.406 and 361.467 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (75.71) is slightly higher than Ligand B (62.74). Both are below the 140 threshold for oral absorption, but B is better positioned for potential CNS penetration if desired.
3. **logP:** Ligand A (1.003) is within the optimal range, while Ligand B (1.621) is slightly higher. Both are acceptable, but A is preferable.
4. **HBD:** Ligand A (1) is better than Ligand B (0). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is slightly lower than Ligand B (5). Lower is preferable for permeability.
6. **QED:** Both ligands have good QED scores (0.694 and 0.765), indicating good drug-like properties. No significant difference.
7. **DILI:** Ligand A (28.616) has a significantly lower DILI risk than Ligand B (56.185). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (89.027) has a much higher BBB penetration percentile than Ligand B (59.519). While ADRB2 isn't strictly a CNS target, higher BBB is generally favorable for GPCRs.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.785 and -4.944). This is unusual and suggests poor permeability. However, the values are very similar.
10. **Solubility:** Both ligands have negative solubility values (-2.172 and -2.0). This is also unusual and suggests poor solubility. Again, the values are very similar.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.121 and 0.091). This is excellent.
12. **Cl_mic:** Ligand A (10.786) has a significantly lower microsomal clearance than Ligand B (40.092), indicating better metabolic stability.
13. **t1/2:** Ligand B (33.393) has a much longer in vitro half-life than Ligand A (-1.375). This is a significant advantage for Ligand B.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.022 and 0.119). This is good.
15. **Affinity:** Both ligands have the same binding affinity (-7.0 kcal/mol).
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. While affinity is equal, Ligand A has a better logP, lower TPSA, and comparable Pgp. The significantly lower DILI risk and better metabolic stability (lower Cl_mic) of Ligand A are also very important. The longer half-life of Ligand B is attractive, but the higher DILI risk and worse metabolic stability are concerning.
**Conclusion:**
Despite the longer half-life of Ligand B, Ligand A is the more promising candidate due to its superior safety profile (lower DILI), better metabolic stability, and favorable physicochemical properties for a GPCR target.
Output:
1
2025-04-17 18:39:32,377 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (363.443 and 375.563 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (96.67) is higher than Ligand B (48.99). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B has a significant advantage here.
3. **logP:** Ligand A (1.693) is within the optimal 1-3 range. Ligand B (4.093) is at the upper end, potentially leading to solubility issues and off-target interactions. Ligand A is better.
4. **HBD:** Both have 1 HBD, which is good. No difference.
5. **HBA:** Ligand A has 6 HBAs, and Ligand B has 4. Both are acceptable, but Ligand B is slightly better.
6. **QED:** Ligand A (0.876) has a much better QED score than Ligand B (0.53), indicating a more drug-like profile. This is a significant advantage for Ligand A.
7. **DILI:** Ligand A (80.225) has a higher DILI risk than Ligand B (39.667). Ligand B is clearly better here.
8. **BBB:** Both have reasonable BBB penetration, but Ligand A (83.249) is slightly better than Ligand B (39.822). Since ADRB2 is not a CNS target, this is a minor advantage.
9. **Caco-2:** Ligand A (-4.951) and Ligand B (-5.32) are both negative, indicating poor permeability. Ligand B is slightly better.
10. **Solubility:** Ligand A (-3.976) is slightly better than Ligand B (-3.495), although both are poor.
11. **hERG:** Ligand A (0.203) has a much lower hERG risk than Ligand B (0.834). This is a crucial advantage for Ligand A, as hERG inhibition can lead to cardiotoxicity.
12. **Cl_mic:** Ligand A (-4.707) has a lower (better) microsomal clearance than Ligand B (89.125). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (45.781) has a longer in vitro half-life than Ligand B (-0.024). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.073) has lower P-gp efflux than Ligand B (0.469), which is favorable for bioavailability.
15. **Affinity:** Ligand A (-6.2 kcal/mol) has a better binding affinity than Ligand B (-2.3 kcal/mol). This is a substantial advantage, as a difference of >1.5 kcal/mol can outweigh other drawbacks.
**Overall Assessment:**
Ligand A has a significantly better binding affinity, QED score, hERG risk, metabolic stability, and half-life. While Ligand B has a lower TPSA and DILI risk, the superior affinity and drug-like properties of Ligand A outweigh these benefits. The slightly higher TPSA of Ligand A is not a major concern for a cardiovascular target. The affinity difference is large enough to compensate for the slightly poorer solubility and permeability.
Output:
1
2025-04-17 18:39:32,378 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.46 and 344.50 Da) fall comfortably within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (71.53) is higher than Ligand B (49.41). For a cardiovascular GPCR, TPSA is moderately important. Ligand B is preferable here.
3. **logP:** Both ligands have good logP values (3.94 and 3.42), falling within the optimal 1-3 range. Ligand A is slightly higher, which could potentially lead to off-target effects, but it's not a major concern.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 4 HBA, while Ligand B has 2. Lower HBA is generally preferred for better permeability. Ligand B is preferable.
6. **QED:** Both have good QED scores (0.82 and 0.80), indicating good drug-like properties. No significant difference.
7. **DILI:** Ligand A (58.67%) has a higher DILI risk than Ligand B (13.53%). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (90.66%) has a significantly higher BBB penetration than Ligand B (76.15%). While ADRB2 is a cardiovascular target and CNS penetration isn't *essential*, some degree of BBB penetration can be beneficial for off-target effects assessment and potential pleiotropic effects.
9. **Caco-2:** Both have negative Caco-2 values, suggesting poor permeability. This is a concern for both.
10. **Solubility:** Both have negative solubility values, suggesting poor solubility. This is a concern for both.
11. **hERG:** Both have low hERG inhibition liability (0.36 and 0.39), which is good. No significant difference.
12. **Cl_mic:** Ligand A (119.93) has a higher microsomal clearance than Ligand B (39.43). Lower clearance is preferred for better metabolic stability, making Ligand B preferable.
13. **t1/2:** Ligand A (17.51) has a longer in vitro half-life than Ligand B (-6.63). Longer half-life is generally desirable, favoring Ligand A.
14. **Pgp:** Both have low Pgp efflux liability (0.16 and 0.10), which is good. No significant difference.
15. **Binding Affinity:** Ligand A (-7.7 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.2 kcal/mol). This is a substantial advantage for Ligand A, potentially outweighing some of the ADME drawbacks.
**Overall Assessment:**
Ligand A has a significantly better binding affinity and a longer half-life. However, Ligand B has a much lower DILI risk, lower TPSA, lower HBA, and lower microsomal clearance. Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), the strong affinity of Ligand A is a major advantage. The DILI risk of Ligand A is concerning, but the substantial binding affinity advantage might be worth further investigation with structural modifications to mitigate the DILI risk. The slightly better permeability profile of Ligand B is offset by the significantly weaker binding.
Output:
1
2025-04-17 18:39:32,378 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.459 and 348.447 Da) fall well within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (70.08) is significantly better than Ligand B (98.32). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is approaching a level that could hinder oral absorption.
3. **logP:** Both ligands have similar logP values (1.334 and 1.319), falling within the optimal 1-3 range.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Both ligands have the same number of HBA (4).
6. **QED:** Both ligands have similar QED scores (0.78 and 0.722), indicating good drug-likeness.
7. **DILI:** Ligand A (17.875) has a much lower DILI risk than Ligand B (33.424). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (70.027) has a better BBB penetration score than Ligand B (48.972). While ADRB2 isn't strictly a CNS target, some CNS exposure can occur, and higher BBB is generally favorable.
9. **Caco-2:** Ligand A (-4.311) is better than Ligand B (-5.255), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-1.559) is better than Ligand B (-2.087), indicating better aqueous solubility.
11. **hERG:** Ligand A (0.217) has a lower hERG inhibition liability than Ligand B (0.384). This is a crucial safety parameter.
12. **Cl_mic:** Ligand A (13.507) has a significantly lower microsomal clearance than Ligand B (-18.809). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (-4.589) has a better in vitro half-life than Ligand B (-11.599).
14. **Pgp:** Ligand A (0.042) has a lower P-gp efflux liability than Ligand B (0.033).
15. **Binding Affinity:** Ligand B (-9.2) has a slightly better binding affinity than Ligand A (-8.4). However, the difference of 0.8 kcal/mol is not substantial enough to outweigh the numerous advantages of Ligand A.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical ADME-Tox parameters (DILI, BBB, solubility, hERG, Cl_mic, t1/2, Caco-2) and has a favorable TPSA and HBD count. While Ligand B has slightly better binding affinity, the overall profile of Ligand A is much more balanced and indicative of a viable drug candidate. The lower DILI risk and improved metabolic stability of Ligand A are particularly important.
Output:
1
2025-04-17 18:39:32,378 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (353.463 Da and 345.451 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (98.74) is slightly higher than Ligand B (89.66). Both are below the 140 A^2 threshold for good oral absorption, but Ligand B is closer to the preferred <90 A^2 for GPCRs.
**3. logP:** Ligand B (1.772) is within the optimal 1-3 range, while Ligand A (0.558) is slightly below, potentially impacting permeability. This favors Ligand B.
**4. H-Bond Donors:** Ligand A has 3 HBD, and Ligand B has 2. Both are acceptable, below the 5 limit.
**5. H-Bond Acceptors:** Ligand A has 4 HBA, and Ligand B has 6. Both are below the 10 limit, but Ligand A is better.
**6. QED:** Ligand B (0.835) has a significantly higher QED score than Ligand A (0.629), indicating a more drug-like profile. This is a substantial advantage for Ligand B.
**7. DILI Risk:** Ligand A (22.024 percentile) has a much lower DILI risk than Ligand B (56.999 percentile). This is a major advantage for Ligand A.
**8. BBB Penetration:** Ligand B (67.235 percentile) shows better BBB penetration than Ligand A (22.412 percentile). While ADRB2 isn't a CNS target, some peripheral exposure can be reduced by lower BBB penetration, which is not necessarily a negative.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-5.183 and -5.162). This is unusual and suggests poor permeability.
**10. Aqueous Solubility:** Both ligands have negative solubility values (-1.566 and -2.448). This is also unusual and suggests poor solubility.
**11. hERG Inhibition:** Both ligands show very low hERG inhibition risk (0.088 and 0.058). This is excellent for both.
**12. Microsomal Clearance:** Ligand A (3.907 mL/min/kg) has a significantly lower microsomal clearance than Ligand B (15.161 mL/min/kg), indicating better metabolic stability. This favors Ligand A.
**13. In vitro Half-Life:** Ligand A (3.721 hours) has a shorter half-life than Ligand B (12.726 hours). This favors Ligand B.
**14. P-gp Efflux:** Both ligands show very low P-gp efflux liability (0.027 and 0.082). This is excellent for both.
**15. Binding Affinity:** Ligand B (-7.2 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.8 kcal/mol). This is a substantial advantage for Ligand B, potentially outweighing some ADME concerns.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand B is more promising. While Ligand A has a better DILI profile and metabolic stability, the significantly stronger binding affinity of Ligand B (-7.2 vs -5.8 kcal/mol) is a critical advantage. The higher QED score of Ligand B also contributes to its overall drug-likeness. The permeability and solubility issues are concerning for both, but the potency advantage of Ligand B is likely to be more impactful for initial optimization efforts.
Output:
0
2025-04-17 18:39:32,378 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (408.26 Da) is slightly higher than Ligand B (366.527 Da), but both are acceptable.
**2. TPSA:** Ligand A (104.18) is higher than Ligand B (58.64). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is still preferred for better absorption. Ligand B is significantly better here.
**3. logP:** Both ligands have good logP values (Ligand A: 1.399, Ligand B: 2.938), falling within the optimal 1-3 range. Ligand B is slightly better, being closer to the upper end of the range which can improve membrane permeability.
**4. H-Bond Donors:** Ligand A has 3 HBDs, and Ligand B has 1. Both are within the acceptable limit of <=5.
**5. H-Bond Acceptors:** Ligand A has 6 HBAs, and Ligand B has 4. Both are within the acceptable limit of <=10.
**6. QED:** Ligand A (0.664) has a better QED score than Ligand B (0.446), indicating a more drug-like profile.
**7. DILI Risk:** Ligand A (85.537) has a significantly higher DILI risk than Ligand B (41.877). This is a major concern for Ligand A.
**8. BBB Penetration:** Both have reasonable BBB penetration (Ligand A: 67.197, Ligand B: 63.164), but this is less crucial for a cardiovascular target.
**9. Caco-2 Permeability:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-5.332) is slightly better than Ligand B (-5.43).
**10. Aqueous Solubility:** Both have negative solubility values, indicating poor solubility. Ligand A (-3.615) is slightly better than Ligand B (-3.385).
**11. hERG Inhibition:** Both have low hERG inhibition risk (Ligand A: 0.174, Ligand B: 0.37).
**12. Microsomal Clearance:** Ligand A (-17.5) has a much lower (better) microsomal clearance than Ligand B (43.236), suggesting greater metabolic stability.
**13. In vitro Half-Life:** Ligand A (59.711) has a significantly longer half-life than Ligand B (-12.951).
**14. P-gp Efflux:** Both have very low P-gp efflux liability (Ligand A: 0.016, Ligand B: 0.146).
**15. Binding Affinity:** Ligand B (-6.7 kcal/mol) has a slightly better binding affinity than Ligand A (-5.4 kcal/mol). This is a 1.3 kcal/mol difference, which is significant.
**Overall Assessment:**
While Ligand A has a better QED, longer half-life, and better metabolic stability, the significantly higher DILI risk is a major red flag. Ligand B, despite its lower QED and shorter half-life, presents a much more favorable safety profile (lower DILI) and a slightly better binding affinity. For a cardiovascular target, minimizing toxicity is paramount. The slightly better affinity of Ligand B, combined with its significantly lower DILI risk, outweighs the advantages of Ligand A.
Output:
0
2025-04-17 18:39:32,378 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (343.335 Da and 350.467 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (112.93) is slightly higher than Ligand B (92.15). Both are below the 140 threshold for good oral absorption, but B is better, especially given this is a GPCR.
3. **logP:** Ligand A (2.338) is within the optimal 1-3 range. Ligand B (0.505) is a bit low, potentially hindering membrane permeability. This is a significant drawback for a GPCR ligand.
4. **HBD:** Both ligands have acceptable HBD counts (3 and 2, respectively), well below the 5 limit.
5. **HBA:** Ligand A (4) is preferable to Ligand B (6) as it is closer to the 10 limit.
6. **QED:** Both ligands have similar and good QED scores (0.711 and 0.712).
7. **DILI:** Ligand B (18.728) has a *much* lower DILI risk than Ligand A (89.88). This is a major advantage for Ligand B.
8. **BBB:** Ligand B (37.418) has a better BBB penetration score than Ligand A (29.275), though neither is particularly high. For a cardiovascular target, BBB isn't paramount, but it's a slight positive for B.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. Ligand A (-5.351) is slightly better than Ligand B (-5.573), but both are concerning.
10. **Solubility:** Ligand A (-3.128) has better aqueous solubility than Ligand B (-0.5). This is a positive for A.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.056 and 0.054). No significant difference.
12. **Cl_mic:** Ligand A (-0.875) has a lower (better) microsomal clearance than Ligand B (-11.19). This suggests greater metabolic stability for A.
13. **t1/2:** Ligand B (2.623) has a longer in vitro half-life than Ligand A (-15.95). This is a significant advantage for B.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.026 and 0.002). No significant difference.
15. **Binding Affinity:** Both ligands have similar binding affinities (-6.5 and -6.4 kcal/mol). The difference is negligible.
**Overall Assessment:**
Ligand B has a significantly better safety profile (DILI) and a longer half-life. While its logP is lower, the improved safety and half-life outweigh this drawback. Ligand A has better solubility and metabolic stability, but the high DILI risk is a major concern. Considering the GPCR target class, TPSA is also slightly favored in Ligand B.
Output:
0
2025-04-17 18:39:32,379 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (365.543 and 366.487 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (43.86) is significantly better than Ligand B (84.3). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is quite high, potentially hindering absorption.
3. **logP:** Ligand A (1.98) is better than Ligand B (0.555). Both are within the acceptable range (1-3), but Ligand A is closer to optimal. Ligand B is on the lower side, which could impact membrane permeability.
4. **HBD:** Ligand A (0) is preferable to Ligand B (1). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is preferable to Ligand B (5). Lower HBA is generally better for permeability.
6. **QED:** Both ligands have similar QED values (0.699 and 0.681), indicating good drug-likeness.
7. **DILI:** Ligand A (16.092) is *much* better than Ligand B (38.503). Lower DILI risk is crucial. Ligand B is approaching a concerning level.
8. **BBB:** Ligand A (59.248) is better than Ligand B (44.552). While ADRB2 isn't exclusively a CNS target, some brain penetration could be relevant depending on the specific therapeutic application, and higher BBB is generally preferable.
9. **Caco-2:** Both ligands have similar negative Caco-2 values (-5.105 and -5.136). This indicates poor permeability.
10. **Solubility:** Ligand A (-2.015) is better than Ligand B (-0.844). Higher solubility is generally preferred.
11. **hERG:** Both ligands have very low hERG risk (0.264 and 0.145). This is excellent.
12. **Cl_mic:** Both ligands have similar microsomal clearance (25.729 and 25.781).
13. **t1/2:** Ligand A (7.948) is better than Ligand B (-3.913). A positive half-life is preferable.
14. **Pgp:** Ligand A (0.127) is better than Ligand B (0.051). Lower P-gp efflux is preferred.
15. **Binding Affinity:** Ligand A (-6.5) is slightly better than Ligand B (-5.0). A difference of 1.5 kcal/mol is significant and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most crucial parameters. The most significant advantages are its lower DILI risk, better TPSA, logP, HBD/HBA counts, solubility, and half-life. While both have poor Caco-2 permeability, the other advantages of Ligand A make it a more promising starting point for optimization. The slightly better binding affinity further supports this conclusion.
Output:
1
2025-04-17 18:39:32,379 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (373.268) is slightly higher than Ligand B (352.391), but both are acceptable.
2. **TPSA:** Ligand A (29.54) is excellent, well below the 140 threshold and very favorable for oral absorption. Ligand B (104.57) is higher, but still within a reasonable range, though less optimal.
3. **logP:** Ligand A (3.213) is optimal. Ligand B (0.326) is quite low, potentially hindering membrane permeability and absorption. This is a significant drawback.
4. **HBD:** Both ligands have acceptable HBD counts (Ligand A: 0, Ligand B: 1).
5. **HBA:** Ligand A (2) is good. Ligand B (8) is higher, potentially impacting permeability.
6. **QED:** Both ligands have good QED scores (Ligand A: 0.599, Ligand B: 0.672), indicating reasonable drug-likeness.
7. **DILI:** Ligand A (38.077) has a lower DILI risk than Ligand B (72.043). This is a clear advantage for Ligand A.
8. **BBB:** Ligand A (97.402) shows excellent BBB penetration, which is beneficial for a GPCR target. Ligand B (68.476) is lower, suggesting less CNS exposure.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it is hard to interpret.
10. **Solubility:** Ligand A (-3.815) and Ligand B (-2.368) both have poor solubility.
11. **hERG:** Ligand A (0.815) has a lower hERG risk than Ligand B (0.051). This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand A (38.146) has a higher microsomal clearance than Ligand B (23.142), indicating lower metabolic stability. This is a drawback for Ligand A.
13. **t1/2:** Ligand A (4.034) has a longer half-life than Ligand B (1.007). This is a positive for Ligand A.
14. **Pgp:** Ligand A (0.202) shows lower P-gp efflux than Ligand B (0.058), suggesting better bioavailability.
15. **Affinity:** Ligand B (-7.0) has a slightly better binding affinity than Ligand A (-6.6). However, the difference is less than 1.5 kcal/mol, so it's not decisive.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A excels in logP, TPSA, and Pgp, while Ligand B has a slightly better affinity. However, the poor logP of Ligand B is a major concern, potentially leading to poor absorption. The better BBB penetration of Ligand A is also a plus.
**Conclusion:**
Despite the slightly better affinity of Ligand B, Ligand A is the more promising candidate. Its superior logP, TPSA, lower DILI risk, better BBB penetration, and lower P-gp efflux outweigh the slightly weaker binding affinity and higher Cl_mic. The combination of these factors suggests a higher probability of successful *in vivo* performance.
Output:
1
2025-04-17 18:39:32,379 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (388.823) is slightly higher than Ligand B (349.45), but both are acceptable.
2. **TPSA:** Ligand A (67.43) is higher than Ligand B (52.65). Both are below the 140 threshold for oral absorption, but B is better.
3. **logP:** Ligand A (4.464) is higher than the optimal range (1-3), potentially leading to solubility issues. Ligand B (1.516) is well within the optimal range. This is a significant advantage for B.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable, below the threshold of 5.
5. **HBA:** Both ligands have 3 HBA, which is well within the acceptable limit of 10.
6. **QED:** Both ligands have similar QED values (A: 0.767, B: 0.74), indicating good drug-likeness.
7. **DILI:** Ligand A (81.504) has a significantly higher DILI risk than Ligand B (12.369). This is a major concern for Ligand A.
8. **BBB:** Ligand A (79.488) has a good BBB penetration, while Ligand B (97.014) is even better. This is relevant as ADRB2 is a GPCR.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
10. **Solubility:** Ligand A (-5.85) has very poor solubility, while Ligand B (-1.943) is better, but still not ideal.
11. **hERG:** Ligand A (0.766) and Ligand B (0.63) are both relatively low risk for hERG inhibition.
12. **Cl_mic:** Ligand A (31.404) has a higher microsomal clearance than Ligand B (6.337), indicating lower metabolic stability.
13. **t1/2:** Ligand A (69.693) has a much longer in vitro half-life than Ligand B (0.944). This is a positive for A.
14. **Pgp:** Ligand A (0.434) has lower P-gp efflux liability than Ligand B (0.057), which is favorable.
15. **Binding Affinity:** Ligand B (-8.4 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.5 kcal/mol). This is a substantial advantage for B, potentially outweighing some ADME drawbacks.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are particularly important. Ligand B excels in logP and affinity, and performs well in TPSA and Pgp. While Ligand A has better BBB penetration and half-life, its high logP, poor solubility, and significantly higher DILI risk are major drawbacks. The substantial affinity difference (-8.4 vs -6.5) is a key factor.
**Conclusion:**
Despite Ligand A's longer half-life and slightly better BBB penetration, Ligand B is the more promising drug candidate. Its superior binding affinity, favorable logP, significantly lower DILI risk, and better Caco-2 permeability outweigh the shorter half-life.
Output:
0
2025-04-17 18:39:32,379 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [351.407, 123.58 , 0.293, 2. , 7. , 0.706, 57.348, 85.149, -4.874, -2.836, 0.719, 27.159, -7.032, 0.027, -6.3 ]
**Ligand B:** [360.571, 33.95 , 4.968, 0. , 5. , 0.666, 15.626, 79.062, -5.148, -3.656, 0.854, 46.406, 3.785, 0.621, -6.1 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (351.407) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (123.58) is better than Ligand B (33.95) as it is closer to the 140 A^2 threshold for good oral absorption.
3. **logP:** Ligand B (4.968) is higher than the optimal range (1-3), which could lead to solubility issues and off-target effects. Ligand A (0.293) is quite low, potentially hindering permeation.
4. **HBD:** Ligand A (2) is preferable to Ligand B (0) as it provides some hydrogen bonding capability for solubility.
5. **HBA:** Ligand A (7) is preferable to Ligand B (5) as it provides some hydrogen bonding capability for solubility.
6. **QED:** Ligand A (0.706) is slightly better than Ligand B (0.666), indicating a more drug-like profile.
7. **DILI:** Ligand B (15.626) has a much lower DILI risk than Ligand A (57.348), a significant advantage.
8. **BBB:** Ligand A (85.149) shows better BBB penetration than Ligand B (79.062), which is important for a GPCR target.
9. **Caco-2:** Ligand A (-4.874) and Ligand B (-5.148) both have very low Caco-2 permeability, which is concerning.
10. **Solubility:** Ligand A (-2.836) has better solubility than Ligand B (-3.656).
11. **hERG:** Both ligands have low hERG inhibition risk (0.719 and 0.854 respectively).
12. **Cl_mic:** Ligand A (27.159) has a lower microsomal clearance than Ligand B (46.406), suggesting better metabolic stability.
13. **t1/2:** Ligand B (3.785) has a longer in vitro half-life than Ligand A (-7.032), which is a positive.
14. **Pgp:** Ligand A (0.027) has much lower P-gp efflux liability than Ligand B (0.621), which is beneficial for bioavailability and potential CNS exposure.
15. **Affinity:** Both ligands have very similar and strong binding affinities (-6.3 and -6.1 kcal/mol).
**GPCR-Specific Priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has a better TPSA and Pgp profile. Ligand B has a better logP. The affinities are comparable. The DILI risk of Ligand B is significantly lower.
**Overall Assessment:**
While Ligand B has a better DILI profile and half-life, the very high logP is a significant concern. Ligand A, despite the slightly higher DILI risk, has a more balanced profile with a better TPSA, Pgp efflux, and solubility. The lower logP of Ligand A is also less likely to cause off-target effects. The slightly better BBB penetration of Ligand A is also a plus.
Therefore, I would choose Ligand A.
```
1
```
2025-04-17 18:39:32,379 - INFO - Batch 53 complete. Total preferences: 848
2025-04-17 18:39:32,380 - INFO - Processing batch 54/512...
2025-04-17 18:40:20,596 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**1. Molecular Weight:** Both ligands fall within the ideal range (200-500 Da). Ligand A (343.515 Da) is slightly lower, which is generally favorable for permeability.
**2. TPSA:** Ligand A (36.44) is significantly better than Ligand B (101.57). For a GPCR, keeping TPSA low is beneficial for permeability and receptor engagement. Ligand B's TPSA is quite high, potentially hindering oral absorption.
**3. logP:** Ligand A (3.231) is within the optimal range (1-3). Ligand B (0.885) is a bit low, which could impact membrane permeability and potentially reduce binding affinity.
**4. H-Bond Donors:** Ligand A (0) is excellent, minimizing potential issues with permeability. Ligand B (2) is acceptable.
**5. H-Bond Acceptors:** Ligand A (4) is good. Ligand B (5) is also acceptable.
**6. QED:** Ligand A (0.762) is better than Ligand B (0.589), indicating a more drug-like profile.
**7. DILI Risk:** Ligand A (1.551) has a much lower DILI risk than Ligand B (40.054). This is a significant advantage for Ligand A.
**8. BBB Penetration:** Ligand A (91.586) shows excellent BBB penetration, which is a desirable characteristic for GPCR targets, even if not strictly CNS-focused, as it can indicate good distribution. Ligand B (55.874) is lower, suggesting limited brain exposure.
**9. Caco-2 Permeability:** Ligand A (-4.989) and Ligand B (-5.275) are both negative, indicating poor permeability. However, the scale is unclear, and negative values may not be directly comparable.
**10. Aqueous Solubility:** Ligand A (-1.125) and Ligand B (-1.957) are both negative, indicating poor solubility.
**11. hERG Inhibition:** Ligand A (0.875) has a lower hERG risk than Ligand B (0.235), which is a positive.
**12. Microsomal Clearance:** Ligand A (7.028) has a much lower microsomal clearance than Ligand B (26.743), indicating better metabolic stability.
**13. In vitro Half-Life:** Ligand A (-12.859) has a negative half-life, which is concerning. Ligand B (13.66) is positive and reasonable.
**14. P-gp Efflux:** Ligand A (0.26) has lower P-gp efflux than Ligand B (0.041), which is favorable for bioavailability.
**15. Binding Affinity:** Ligand B (-6.4 kcal/mol) has a significantly stronger binding affinity than Ligand A (-0.6 kcal/mol). This is a substantial advantage for Ligand B.
**Overall Assessment:**
While Ligand B boasts a significantly better binding affinity, Ligand A demonstrates a superior profile across most ADME-Tox parameters, particularly DILI risk, BBB penetration, and metabolic stability. The poor half-life of Ligand A is a concern, but the other advantages, especially the lower DILI and better BBB, are compelling for a GPCR target like ADRB2. The strong affinity of Ligand B is tempting, but the higher DILI risk and poorer ADME properties make it less attractive as a drug candidate.
Therefore, I favor Ligand A.
Output:
1
2025-04-17 18:40:20,597 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (378.7) is slightly higher than Ligand B (343.5), but both are acceptable.
2. **TPSA:** Ligand A (55.8) is better than Ligand B (79.2). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better permeability.
3. **logP:** Ligand A (4.33) is higher than Ligand B (2.09). While 4.33 is approaching the upper limit, it's still within a reasonable range. Ligand B's logP is quite low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (1) is better than Ligand B (2). Fewer HBDs are generally preferred for better permeability.
5. **HBA:** Ligand A (4) is better than Ligand B (3). Similar to HBD, lower HBA is generally preferred.
6. **QED:** Both ligands have good QED scores (A: 0.621, B: 0.819). Ligand B is slightly better here, indicating a more drug-like profile.
7. **DILI:** Ligand A (61.96) has a higher DILI risk than Ligand B (25.13). This is a significant drawback for Ligand A.
8. **BBB:** Ligand B (63.47) has better BBB penetration than Ligand A (48.66). While not crucial for a cardiovascular target, it's a slight advantage.
9. **Caco-2:** Ligand A (-4.82) is better than Ligand B (-5.05). Both are negative, indicating poor permeability.
10. **Solubility:** Ligand A (-4.89) is better than Ligand B (-3.24). Both are negative, indicating poor solubility.
11. **hERG:** Ligand A (0.635) is better than Ligand B (0.591). Lower hERG inhibition is preferred.
12. **Cl_mic:** Ligand A (84.45) has a higher clearance than Ligand B (-14.64). Ligand B's negative value suggests very high metabolic stability, which is a major advantage.
13. **t1/2:** Ligand A (23.75) has a longer half-life than Ligand B (-6.27). Ligand B's negative value is concerning.
14. **Pgp:** Ligand A (0.539) is better than Ligand B (0.108). Lower P-gp efflux is preferred.
15. **Affinity:** Ligand A (-7.6) has a slightly better binding affinity than Ligand B (-7.0). This is a 1.6 kcal/mol difference, which is significant.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A has a better logP and Pgp profile, and a significantly better binding affinity. However, the high DILI risk for Ligand A is a major concern. Ligand B has a much better DILI profile and excellent metabolic stability (Cl_mic).
**Overall Assessment:**
While Ligand A has a better affinity and slightly better logP and Pgp properties, the significantly higher DILI risk and poorer metabolic stability are major drawbacks. Ligand B, despite a slightly lower affinity, presents a much more favorable safety and pharmacokinetic profile. The difference in affinity is not large enough to overcome the safety concerns with Ligand A.
Output:
0
2025-04-17 18:40:20,597 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (363.839) is slightly higher than Ligand B (349.431), but both are acceptable.
2. **TPSA:** Ligand A (29.85) is excellent, well below the 140 threshold and very favorable for oral absorption. Ligand B (111.45) is higher, but still within a reasonable range, though less optimal.
3. **logP:** Ligand A (4.927) is at the upper end of the optimal range, potentially raising concerns about solubility and off-target effects. Ligand B (0.477) is quite low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (1) is good. Ligand B (3) is acceptable, but higher HBD can sometimes lead to poorer permeability.
5. **HBA:** Ligand A (3) is good. Ligand B (5) is acceptable, but again, higher HBA can impact permeability.
6. **QED:** Ligand A (0.834) is excellent, indicating a highly drug-like profile. Ligand B (0.59) is acceptable, but less favorable.
7. **DILI:** Ligand A (58.976) is good, indicating a relatively low risk of liver injury. Ligand B (16.906) is *very* good, a significant advantage.
8. **BBB:** Ligand A (91.508) is excellent, suggesting good potential for CNS penetration if desired (though less critical for peripheral ADRB2 targets). Ligand B (32.687) is low, indicating poor BBB penetration.
9. **Caco-2:** Ligand A (-4.475) is very poor, suggesting very low intestinal absorption. Ligand B (-5.125) is also poor, but slightly better than A.
10. **Solubility:** Ligand A (-5.99) is very poor. Ligand B (-1.872) is also poor, but better than A.
11. **hERG:** Both ligands (0.752 and 0.217) show low hERG inhibition risk, which is excellent.
12. **Cl_mic:** Ligand A (51.495) is moderate, indicating moderate metabolic clearance. Ligand B (-9.857) is *excellent*, suggesting high metabolic stability.
13. **t1/2:** Ligand A (16.237) is reasonable. Ligand B (31.594) is significantly better, indicating a longer half-life.
14. **Pgp:** Ligand A (0.258) is good, suggesting low P-gp efflux. Ligand B (0.017) is *excellent*, indicating very low P-gp efflux.
15. **Affinity:** Both ligands have very good binding affinity (-5.8 and -5.5 kcal/mol). The difference (0.3 kcal/mol) is not substantial enough to override other significant ADME differences.
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Ligand A has a better TPSA and Pgp, but Ligand B has a better logP. The affinity difference is small. However, the significant advantages of Ligand B in terms of DILI, metabolic stability (Cl_mic & t1/2), and Pgp efflux outweigh the slightly less optimal TPSA and logP. The poor Caco-2 and solubility of Ligand A are also major concerns.
**Conclusion:**
Considering the balance of properties, particularly the superior ADME profile of Ligand B (lower DILI, better metabolic stability, lower Pgp efflux), I believe Ligand B is the more promising drug candidate.
Output:
0
2025-04-17 18:40:20,597 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [350.459, 79.82, 2.321, 3, 4, 0.638, 15.277, 69.213, -4.344, -2.316, 0.478, 25.798, -1.666, 0.15, -6.0]
**Ligand B:** [384.267, 80.12, 1.315, 1, 5, 0.794, 57.348, 68.554, -5.513, -2.632, 0.034, 8.042, 9.783, 0.048, -9.1]
Here's a breakdown, prioritizing GPCR properties (logP, TPSA, Pgp, BBB, Affinity):
1. **Molecular Weight:** Both are within the ideal range (200-500 Da). A is 350.46, B is 384.27. Slight edge to A.
2. **TPSA:** Both are reasonably good (under 140), but still a bit high. A is 79.82, B is 80.12. Very similar.
3. **logP:** Both are within the optimal range (1-3). A is 2.32, B is 1.32. A is slightly better, offering a good balance between solubility and permeability.
4. **H-Bond Donors:** A has 3, B has 1. Lower is generally preferred for permeability, so B is better here.
5. **H-Bond Acceptors:** A has 4, B has 5. Both are acceptable but B is slightly higher.
6. **QED:** Both are above 0.5, indicating good drug-likeness. B (0.794) is better than A (0.638).
7. **DILI:** A is 15.28, B is 57.35. A is *significantly* better here, indicating a much lower risk of liver injury. This is a major advantage.
8. **BBB:** A is 69.21, B is 68.55. Similar, but A is slightly better. While not a CNS target, some BBB penetration can be helpful for distribution.
9. **Caco-2:** A is -4.34, B is -5.51. Lower values indicate poorer permeability. Both are poor, but B is worse.
10. **Solubility:** Both are negative, indicating poor solubility. A is -2.32, B is -2.63. B is slightly worse.
11. **hERG:** A is 0.478, B is 0.034. B is *much* better, indicating a significantly lower risk of cardiotoxicity. This is a critical advantage for a cardiovascular target.
12. **Cl_mic:** A is 25.80, B is 8.04. B is significantly better, indicating higher metabolic stability.
13. **t1/2:** A is -1.67, B is 9.78. B is *much* better, indicating a longer half-life.
14. **Pgp:** A is 0.15, B is 0.048. B is better, indicating lower P-gp efflux.
15. **Binding Affinity:** A is -6.0, B is -9.1. B is *significantly* better, with a 3.1 kcal/mol advantage. This is a huge difference and likely outweighs many of the ADME drawbacks of B.
**Overall Assessment:**
Ligand B has a *much* stronger binding affinity (-9.1 vs -6.0 kcal/mol) and significantly better metabolic stability (lower Cl_mic, longer t1/2) and lower hERG risk. While Ligand A has a better DILI profile, the superior potency and safety profile of B regarding hERG and metabolism are more critical for a cardiovascular GPCR target. The slight solubility and Caco-2 issues with B can be addressed with formulation strategies.
Therefore, I prefer Ligand B.
0
2025-04-17 18:40:20,597 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.431 and 344.371 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (81.27) is significantly better than Ligand B (113.44). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is pushing the upper limit for good oral absorption.
3. **logP:** Ligand A (3.315) is optimal, while Ligand B (1.644) is on the lower side. While not terrible, lower logP can sometimes indicate poor membrane permeability.
4. **HBD:** Ligand A (0) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (5) is better than Ligand B (6). Lower HBA is also generally preferable for permeability.
6. **QED:** Both ligands have similar QED values (0.621 and 0.687), indicating good drug-likeness.
7. **DILI:** Ligand A (22.8) has a much lower DILI risk than Ligand B (61.962). This is a substantial advantage for Ligand A.
8. **BBB:** Ligand A (83.055) has a significantly higher BBB penetration percentile than Ligand B (53.083). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant, and higher BBB is generally a positive attribute.
9. **Caco-2:** Ligand A (-4.778) and Ligand B (-5.279) are both negative, indicating very poor permeability. This is a significant concern for both.
10. **Solubility:** Both ligands have similar, very poor solubility scores (-3.47 and -3.745). This is a major drawback for both compounds.
11. **hERG:** Ligand A (0.434) is better than Ligand B (0.186), indicating lower hERG inhibition liability and reduced cardiotoxicity risk.
12. **Cl_mic:** Ligand A (23.244) has a lower microsomal clearance than Ligand B (74.324), suggesting better metabolic stability.
13. **t1/2:** Ligand A (6.959) has a positive half-life, while Ligand B (-23.464) has a negative half-life. This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.142) has lower P-gp efflux liability than Ligand B (0.069), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand A (-8.2 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.7 kcal/mol). This 1.5 kcal/mol difference is substantial and can outweigh some of the ADME drawbacks.
**Overall Assessment:**
Ligand A is clearly superior. It has a better safety profile (lower DILI, lower hERG), better metabolic stability (lower Cl_mic, positive t1/2), better permeability characteristics (lower TPSA, HBD, HBA), and significantly stronger binding affinity. While both compounds suffer from poor solubility and Caco-2 permeability, the superior binding affinity and ADME properties of Ligand A make it the more promising candidate.
Output:
1
2025-04-17 18:40:20,597 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (353.482 and 355.438 Da) are within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (61.44) is slightly higher than Ligand B (54.88). Both are below the 140 threshold for oral absorption, and acceptable for a cardiovascular target (not requiring significant CNS penetration). Ligand B is slightly better.
3. **logP:** Ligand A (2.01) is optimal (1-3). Ligand B (4.589) is higher, potentially leading to solubility issues and off-target interactions. Ligand A is significantly better.
4. **HBD:** Ligand A (2) and Ligand B (1) are both within the acceptable limit of <=5. Ligand B is slightly better.
5. **HBA:** Ligand A (3) and Ligand B (4) are both within the acceptable limit of <=10. Ligand A is slightly better.
6. **QED:** Both ligands have similar QED values (0.736 and 0.745), indicating good drug-likeness. No clear advantage.
7. **DILI:** Ligand A (9.383) has a much lower DILI risk than Ligand B (78.325). This is a significant advantage for Ligand A.
8. **BBB:** Both have good BBB penetration (Ligand A: 81.698, Ligand B: 78.48). While ADRB2 isn't a primary CNS target, some peripheral ADRB2 receptors can influence CNS function, so moderate BBB penetration isn't detrimental. No clear advantage.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.01 and -4.745), which is unusual and suggests poor permeability. However, these values are on a scale that can be below zero, and the absolute value is more important. They are fairly similar.
10. **Solubility:** Ligand A (-2.182) has better solubility than Ligand B (-4.843). This is important for bioavailability. Ligand A is better.
11. **hERG:** Both ligands have low hERG inhibition risk (0.522 and 0.423). No clear advantage.
12. **Cl_mic:** Ligand A (7.769) has significantly lower microsomal clearance than Ligand B (41.96). This indicates better metabolic stability for Ligand A.
13. **t1/2:** Ligand B (43.947) has a much longer in vitro half-life than Ligand A (-0.551). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.023) has much lower P-gp efflux liability than Ligand B (0.3). Lower Pgp is generally desirable for better bioavailability. Ligand A is better.
15. **Binding Affinity:** Ligand B (-6.6 kcal/mol) has a slightly better binding affinity than Ligand A (-6.1 kcal/mol). This is a 0.5 kcal/mol difference, which is noticeable but not overwhelming.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A excels in logP, Pgp, and has acceptable TPSA. Ligand B has slightly better affinity and half-life, but suffers from a high logP and Pgp efflux. The significantly lower DILI risk and better metabolic stability of Ligand A are also major advantages.
**Conclusion:**
While Ligand B has slightly better affinity and half-life, Ligand A presents a more balanced profile with significantly better predicted ADME properties (lower DILI, better solubility, lower clearance, lower Pgp efflux) and a more optimal logP. The slightly weaker affinity is likely surmountable with further optimization, while the ADME liabilities of Ligand B are more challenging to address.
Output:
1
2025-04-17 18:40:20,597 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (429.336 Da) is within the ideal range, while Ligand B (358.511 Da) is also good. No clear advantage here.
2. **TPSA:** Both ligands (A: 60.77, B: 58.12) are well below the 140 threshold for oral absorption and suitable for a GPCR target.
3. **logP:** Both ligands have good logP values (A: 2.665, B: 3.65), falling within the 1-3 optimal range. Ligand B is slightly higher, potentially aiding membrane permeability.
4. **HBD:** Ligand A (0) is preferable to Ligand B (1) as lower HBDs generally improve permeability.
5. **HBA:** Both ligands have acceptable HBA counts (A: 6, B: 5).
6. **QED:** Both ligands have good QED scores (A: 0.648, B: 0.782), indicating drug-likeness. Ligand B is slightly better.
7. **DILI:** Both ligands have acceptable DILI risk (A: 44.591, B: 39.124), below the 60 threshold. Ligand B is slightly better.
8. **BBB:** Ligand B (87.437) has a significantly higher BBB penetration percentile than Ligand A (68.748). This is a key advantage for a GPCR target, even if not specifically a CNS target, as it suggests better distribution.
9. **Caco-2:** Both have negative values, which is unusual. Assuming these are logP values, both are poor.
10. **Solubility:** Both have negative values, which is unusual.
11. **hERG:** Both ligands have low hERG inhibition liability (A: 0.557, B: 0.836), which is good.
12. **Cl_mic:** Ligand B (61.035) has a lower microsomal clearance than Ligand A (96.582), indicating better metabolic stability.
13. **t1/2:** Ligand B (44.489) has a longer in vitro half-life than Ligand A (30.009), which is desirable.
14. **Pgp:** Both ligands have low Pgp efflux liability (A: 0.59, B: 0.467). Ligand B is slightly better.
15. **Binding Affinity:** Both ligands have excellent binding affinities (A: -6.0, B: -5.8 kcal/mol). The difference of 0.2 kcal/mol is not substantial enough to outweigh other factors.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand B is the more promising candidate. It demonstrates superior BBB penetration, lower microsomal clearance, longer half-life, and slightly better DILI risk and Pgp efflux liability. While Ligand A has a slightly lower HBD count, the benefits of Ligand B's improved ADME properties and BBB penetration outweigh this minor difference. The binding affinity difference is negligible.
Output:
0
2025-04-17 18:40:20,597 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (342.395) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (78.51) is significantly better than Ligand A (91.68). ADRB2 is not a CNS target, but lower TPSA generally improves absorption.
3. **logP:** Ligand A (2.113) is optimal, while Ligand B (0.537) is a bit low. A logP below 1 can sometimes hinder membrane permeability.
4. **HBD:** Both ligands have acceptable HBD counts (3 and 2 respectively), well within the limit of 5.
5. **HBA:** Both ligands have acceptable HBA counts (5 and 4 respectively), well within the limit of 10.
6. **QED:** Both ligands have similar and good QED scores (0.774 and 0.715), indicating good drug-like properties.
7. **DILI:** Ligand B (25.979) has a much lower DILI risk than Ligand A (33.695), which is a significant advantage.
8. **BBB:** This is less critical for ADRB2, but Ligand A (40.403) is slightly better than Ligand B (36.409).
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. This is a concern for both.
10. **Solubility:** Both ligands have negative solubility values, indicating poor solubility. This is a concern for both.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.124 and 0.057), which is excellent.
12. **Cl_mic:** Ligand B (3.294) has significantly lower microsomal clearance than Ligand A (10.992), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-7.281) has a much longer in vitro half-life than Ligand A (-3.079), which is a major advantage.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.077 and 0.014), which is favorable.
15. **Binding Affinity:** Ligand B (-6.6 kcal/mol) has slightly better binding affinity than Ligand A (-6.2 kcal/mol), although the difference is not huge.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are important. Ligand A has a better logP, but Ligand B excels in TPSA, DILI, metabolic stability (Cl_mic and t1/2), and has comparable affinity. The lower DILI risk and improved metabolic stability of Ligand B are very important considerations. The negative Caco-2 and solubility values are concerning for both, but can be addressed with formulation strategies.
**Conclusion:**
Considering the balance of properties, Ligand B is the more promising candidate. Its lower DILI risk, significantly improved metabolic stability (lower Cl_mic, longer t1/2), and comparable binding affinity outweigh the slightly lower logP and TPSA.
Output:
0
2025-04-17 18:40:20,598 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (352.475) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (84.5) is significantly better than Ligand B (29.54). ADRB2 is a cardiovascular target, not a CNS target, but lower TPSA is still generally desirable for absorption. Ligand B is exceptionally low, potentially indicating issues with solubility.
3. **logP:** Ligand A (2.189) is within the optimal range. Ligand B (4.352) is a bit high, potentially leading to off-target effects and solubility issues.
4. **HBD:** Ligand A (2) is acceptable. Ligand B (0) is also acceptable, but a lack of HBDs can sometimes hinder solubility.
5. **HBA:** Ligand A (4) is good. Ligand B (3) is also good.
6. **QED:** Ligand B (0.686) is better than Ligand A (0.492), indicating a more drug-like profile.
7. **DILI:** Ligand A (33.501) has a much lower DILI risk than Ligand B (7.445). This is a significant advantage for Ligand A.
8. **BBB:** Not a primary concern for a cardiovascular target. Ligand B (96.161) is higher, but this isn't a deciding factor.
9. **Caco-2:** Both are negative, which is unusual. This suggests poor permeability.
10. **Solubility:** Both are negative, indicating poor solubility.
11. **hERG:** Both are very low (0.118 and 0.91), indicating low cardiotoxicity risk.
12. **Cl_mic:** Ligand A (85.44) has a lower microsomal clearance, suggesting better metabolic stability than Ligand B (135.693).
13. **t1/2:** Ligand A (-16.694) has a much longer in vitro half-life than Ligand B (-6.817). This is a major advantage.
14. **Pgp:** Ligand A (0.077) has lower P-gp efflux liability than Ligand B (0.622), suggesting better bioavailability.
15. **Binding Affinity:** Both ligands have similar binding affinities (-5.6 and -5.5 kcal/mol). The difference is negligible.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A has a better logP and Pgp profile. Ligand B has a better TPSA, but it is already very low, and the extremely low solubility is a concern. The binding affinities are comparable.
**Overall Assessment:**
Ligand A is the better candidate. It has a lower DILI risk, better metabolic stability (lower Cl_mic and longer t1/2), lower P-gp efflux, and a more favorable logP. While both have poor solubility and Caco-2 permeability, the other advantages of Ligand A outweigh the slightly better QED of Ligand B.
Output:
1
2025-04-17 18:40:20,598 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (353.394 Da and 356.438 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (89.95) is slightly higher than Ligand B (75.71). Both are below the 140 threshold for oral absorption, but Ligand B is closer to the preferred <90 for GPCRs.
**3. logP:** Both ligands have good logP values (1.575 and 1.823), falling within the optimal 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability.
**4. H-Bond Donors:** Ligand A has 2 HBDs, and Ligand B has 1. Both are within the acceptable limit of <=5. Ligand B is slightly preferred.
**5. H-Bond Acceptors:** Both ligands have 4 HBAs, well within the <10 guideline.
**6. QED:** Ligand A (0.728) has a slightly better QED score than Ligand B (0.673), indicating a more drug-like profile.
**7. DILI Risk:** Ligand B (12.834) has a significantly lower DILI risk than Ligand A (32.997). This is a major advantage for Ligand B.
**8. BBB Penetration:** Ligand B (88.6) demonstrates much better predicted BBB penetration than Ligand A (50.679). Given ADRB2's role in cardiovascular function, and potential for CNS side effects, this is a significant advantage for Ligand B.
**9. Caco-2 Permeability:** Ligand A (-5.281) has a lower Caco-2 permeability compared to Ligand B (-4.413). While both are negative, indicating low permeability, Ligand B is slightly better.
**10. Aqueous Solubility:** Both ligands have very poor predicted aqueous solubility (-2.313 and -2.259). This is a concern for both, and formulation strategies would be needed.
**11. hERG Inhibition:** Ligand A (0.336) has a slightly lower hERG inhibition risk than Ligand B (0.449), which is preferable.
**12. Microsomal Clearance:** Ligand A (30.674) has a lower microsomal clearance than Ligand B (53.8), suggesting better metabolic stability. This is a positive for Ligand A.
**13. In vitro Half-Life:** Ligand A (1.05) has a shorter half-life than Ligand B (-21.019). This is a significant drawback for Ligand A.
**14. P-gp Efflux:** Both ligands show very low P-gp efflux liability (0.011 and 0.018), which is good.
**15. Binding Affinity:** Both ligands have excellent binding affinities (-6.0 and -5.6 kcal/mol). Ligand A is slightly stronger, but the difference is less than 1.5 kcal/mol, so it's not decisive.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity) and the general guidelines, **Ligand B is the more promising candidate**. While Ligand A has slightly better QED and affinity, Ligand B's significantly lower DILI risk and substantially better predicted BBB penetration are crucial advantages. The better BBB penetration is particularly important for a GPCR target, even one primarily involved in cardiovascular function, as off-target CNS effects are a concern. The slightly improved metabolic stability of Ligand A is outweighed by the other benefits of Ligand B.
Output:
0
2025-04-17 18:40:20,598 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 receptor (a GPCR):
**1. Molecular Weight:** Both ligands (351.447 Da and 363.929 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (91.76) is higher than Ligand B (29.54). For a GPCR, lower TPSA is generally preferred to facilitate membrane permeability. Ligand B is significantly better here.
**3. logP:** Ligand A (1.737) is within the optimal range (1-3). Ligand B (4.696) is slightly above, potentially leading to solubility issues and off-target interactions. Ligand A is better.
**4. H-Bond Donors:** Ligand A (2) is reasonable. Ligand B (0) is also acceptable, and potentially beneficial for permeability. No strong preference.
**5. H-Bond Acceptors:** Ligand A (5) is acceptable. Ligand B (2) is also good. No strong preference.
**6. QED:** Both ligands have similar QED values (0.627 and 0.67), indicating good drug-likeness.
**7. DILI Risk:** Ligand A (20.9) has a much lower DILI risk than Ligand B (9.771). This is a significant advantage for Ligand A.
**8. BBB Penetration:** Ligand B (88.29) shows significantly better BBB penetration than Ligand A (54.052). While ADRB2 isn't exclusively a CNS target, some cardiovascular effects are mediated by central pathways, and better BBB penetration could be beneficial.
**9. Caco-2 Permeability:** Ligand A (-4.864) has better Caco-2 permeability than Ligand B (-4.431).
**10. Aqueous Solubility:** Ligand A (-1.414) has better aqueous solubility than Ligand B (-5.205). Solubility is important for formulation and bioavailability.
**11. hERG Inhibition:** Ligand A (0.557) has a lower hERG inhibition risk than Ligand B (0.871). This is a crucial safety parameter.
**12. Microsomal Clearance:** Ligand B (113.537) has a significantly higher microsomal clearance than Ligand A (35.544), indicating faster metabolism and potentially lower *in vivo* exposure. Ligand A is better.
**13. In vitro Half-Life:** Ligand A (-22.31) has a longer in vitro half-life than Ligand B (31.048). This is a positive attribute.
**14. P-gp Efflux:** Ligand A (0.065) has lower P-gp efflux than Ligand B (0.754). Lower efflux is generally desirable for improved bioavailability.
**15. Binding Affinity:** Ligand B (-7.2) has a slightly better binding affinity than Ligand A (-7.6). While a difference of 0.4 kcal/mol is noticeable, it's not a massive advantage, especially considering the other factors.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), and the general drug-like properties, Ligand A emerges as the more promising candidate. While Ligand B has better BBB penetration and slightly improved affinity, Ligand A demonstrates a significantly better safety profile (lower DILI, lower hERG), superior metabolic stability (lower Cl_mic, longer t1/2), better solubility, and lower P-gp efflux. The slightly higher TPSA of Ligand A is a minor drawback compared to the substantial advantages in ADME-Tox properties.
Output:
1
2025-04-17 18:40:20,598 - INFO - Here's my reasoning and final output for the ligand preference:
**Reasoning:**
We are targeting ADRB2, a GPCR, so the priorities are logP, Pgp, TPSA, affinity, and BBB. Let's compare Ligand A and Ligand B across all parameters:
1. **MW:** Both ligands (358.395 and 356.482 Da) are within the ideal range of 200-500 Da.
2. **TPSA:** Ligand A (126.07) is higher than the preferred <140, but still acceptable. Ligand B (49.85) is excellent, well below 140. This favors B.
3. **logP:** Ligand A (-1.828) is a bit low, potentially hindering permeability. Ligand B (2.781) is within the optimal 1-3 range. This strongly favors B.
4. **HBD:** Ligand A (3) is acceptable. Ligand B (0) is even better, potentially improving permeability. This favors B.
5. **HBA:** Ligand A (7) is acceptable. Ligand B (3) is good. This favors B.
6. **QED:** Ligand A (0.238) is below the desirable 0.5 threshold, indicating a less drug-like profile. Ligand B (0.597) is above the threshold, indicating a more drug-like profile. This favors B.
7. **DILI:** Ligand A (35.595) has a moderate DILI risk. Ligand B (13.959) has a very low DILI risk. This favors B.
8. **BBB:** Ligand A (54.207) is not ideal for a GPCR, but not terrible. Ligand B (98.022) is excellent, suggesting good brain penetration. This favors B.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and problematic. However, the magnitude of negativity is less important than other factors.
10. **Solubility:** Both ligands have negative solubility values, which is also unusual and problematic.
11. **hERG:** Ligand A (0.14) has a very low hERG risk, which is excellent. Ligand B (0.918) has a slightly elevated hERG risk, but still acceptable. This favors A.
12. **Cl_mic:** Ligand A (21.402) has a lower clearance, indicating better metabolic stability. Ligand B (46.011) has a higher clearance. This favors A.
13. **t1/2:** Ligand A (-31.456) has a negative half-life, which is impossible and indicates a problem with the data. Ligand B (1.421) has a short half-life, but is at least plausible. This favors B.
14. **Pgp:** Ligand A (0.002) has very low P-gp efflux, which is excellent. Ligand B (0.47) has moderate P-gp efflux. This favors A.
15. **Affinity:** Ligand B (-7.4) has a significantly stronger binding affinity than Ligand A (-6.2) (a 1.2 kcal/mol difference). This is a substantial advantage and outweighs many of the other minor drawbacks.
**Overall Assessment:**
Ligand B is clearly superior. It has a better logP, TPSA, QED, DILI risk, and BBB penetration. Most importantly, its binding affinity is considerably stronger. While Ligand A has better hERG and Pgp profiles, the substantial affinity advantage of Ligand B, combined with its better overall ADME properties, makes it the more promising drug candidate. The negative half-life for Ligand A is a major red flag.
**Output:**
0
2025-04-17 18:40:20,598 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**1. Molecular Weight:** Both ligands (378.807 and 360.483 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand B (78.09) is significantly better than Ligand A (107.11). For a GPCR, lower TPSA is generally preferred for better permeability.
**3. logP:** Both ligands have acceptable logP values (1.486 and 2.758), falling within the 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability, but not dramatically so.
**4. H-Bond Donors:** Ligand A has 4 HBD, while Ligand B has 2. Both are acceptable (<=5), but fewer HBDs (Ligand B) are generally preferred for improved permeability.
**5. H-Bond Acceptors:** Both ligands have 4 HBA, which is well within the acceptable range (<=10).
**6. QED:** Ligand B (0.71) has a slightly better QED score than Ligand A (0.576), indicating a more drug-like profile.
**7. DILI:** Both ligands have relatively high DILI risk (61.691 and 65.297). This is a concern for both, and further investigation would be needed.
**8. BBB:** Both ligands have moderate BBB penetration (48.972 and 53.548). While not exceptionally high, this isn't a primary concern for ADRB2, which isn't necessarily a CNS target.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-5.435 and -5.498). This is unusual and suggests poor permeability *in vitro*. This is a significant drawback for both.
**10. Aqueous Solubility:** Both ligands have poor aqueous solubility (-2.913 and -3.475). This could present formulation challenges.
**11. hERG Inhibition:** Both ligands show low hERG inhibition risk (0.322 and 0.54). This is positive.
**12. Microsomal Clearance:** Ligand A (-16.106) has a significantly lower (better) microsomal clearance than Ligand B (63.25). This suggests better metabolic stability for Ligand A.
**13. In vitro Half-Life:** Ligand B (8.057 hours) has a longer half-life than Ligand A (4.318 hours). This is generally desirable.
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (0.035 and 0.262), which is good.
**15. Binding Affinity:** Ligand B (-6.8 kcal/mol) has a slightly better binding affinity than Ligand A (-5.7 kcal/mol). This difference of 1.1 kcal/mol is substantial and could outweigh some of the ADME drawbacks.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand B appears slightly more promising. While both have poor solubility and Caco-2 permeability, Ligand B's better TPSA, QED, binding affinity, and half-life are advantageous. The slightly higher logP may also contribute to better membrane permeability despite the negative Caco-2 values. Ligand A's better metabolic stability is a plus, but the affinity difference is significant. The DILI risk is concerning for both, but doesn't decisively favor one over the other.
Output:
0
2025-04-17 18:40:20,598 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my output:
**Step-by-step comparison:**
1. **MW:** Both ligands (349.475 and 351.447 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (84.23) is better than Ligand B (96.53). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (2.884) is optimal (1-3). Ligand B (0.624) is a bit low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (2) and Ligand B (3) are both acceptable (<=5).
5. **HBA:** Both ligands (4) are within the acceptable range (<=10).
6. **QED:** Both ligands (0.636 and 0.654) are good, indicating drug-like properties. No significant difference.
7. **DILI:** Ligand A (26.018) has a much lower DILI risk than Ligand B (19.193). This is a significant advantage for Ligand A.
8. **BBB:** This is less critical for a cardiovascular target, but Ligand A (76.192) is better than Ligand B (35.595).
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-5.078) is slightly better than Ligand B (-5.485), but both are concerning.
10. **Solubility:** Both are negative, indicating poor solubility. Ligand A (-1.928) is slightly better than Ligand B (-1.68).
11. **hERG:** Ligand A (0.294) has a lower hERG risk than Ligand B (0.056), which is preferable.
12. **Cl_mic:** Ligand A (67.827) has a higher clearance than Ligand B (2.613), meaning Ligand B is metabolically more stable. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand A (-16.782) has a negative half-life, which is concerning. Ligand B (9.803) has a positive half-life, which is better.
14. **Pgp:** Ligand A (0.219) has lower P-gp efflux than Ligand B (0.008). This is a slight advantage for Ligand A.
15. **Affinity:** Ligand A (-7.5) has a slightly better binding affinity than Ligand B (-7.0). Although the difference is not huge, it's enough to consider.
**Overall Assessment:**
Ligand A has a better balance of properties. It has a better logP, lower DILI risk, lower hERG risk, better affinity, and lower P-gp efflux. While Ligand B has better metabolic stability (lower Cl_mic and positive t1/2), the DILI and hERG risks associated with Ligand B are concerning. The slightly better affinity of Ligand A also tips the scale. The poor Caco-2 and solubility of both ligands are drawbacks that would need to be addressed in further optimization, but the other properties of Ligand A make it the more promising starting point.
Output:
1
2025-04-17 18:40:20,598 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (353.5) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (70.67) is significantly better than Ligand B (91.76). For a GPCR, keeping TPSA below 140 is good, but lower is preferred. Ligand A is much closer to the optimal range for good absorption.
3. **logP:** Both ligands have acceptable logP values (A: 1.544, B: 0.873), falling within the 1-3 range. Ligand A is slightly better.
4. **HBD:** Both have 2 HBD, which is good.
5. **HBA:** Ligand A (4) is better than Ligand B (6). Lower HBA is generally preferred for permeability.
6. **QED:** Both are reasonably good (A: 0.76, B: 0.657), indicating drug-like properties. Ligand A is slightly better.
7. **DILI:** Ligand A (17.759) has a much lower DILI risk than Ligand B (55.487). This is a significant advantage for Ligand A.
8. **BBB:** Ligand B (77.782) has a better BBB penetration score than Ligand A (69.639). While ADRB2 isn't strictly a CNS target, some CNS exposure can be relevant for off-target effects.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.955) is slightly better than Ligand B (-5.016).
10. **Solubility:** Ligand A (-1.921) has better solubility than Ligand B (-3.3).
11. **hERG:** Ligand A (0.225) has a much lower hERG inhibition liability than Ligand B (0.924). This is a critical safety parameter, and Ligand A is significantly better.
12. **Cl_mic:** Ligand B (38.894) has lower microsomal clearance than Ligand A (47.814), suggesting better metabolic stability.
13. **t1/2:** Ligand A (9.835) has a longer in vitro half-life than Ligand B (3.278). This is a significant advantage.
14. **Pgp:** Ligand A (0.036) has much lower P-gp efflux liability than Ligand B (0.213).
15. **Affinity:** Ligand B (-6.2 kcal/mol) has a slightly better binding affinity than Ligand A (-4.9 kcal/mol). This is a 1.3 kcal/mol difference, which is substantial.
**Overall Assessment:**
While Ligand B has a better binding affinity and slightly better metabolic stability, Ligand A is superior in almost all other crucial ADME-Tox properties. Specifically, the significantly lower DILI and hERG risk, coupled with better solubility, Pgp efflux, and half-life, make Ligand A a much more promising drug candidate. The TPSA is also much more favorable for Ligand A. The affinity difference, while notable, can potentially be optimized in later stages of drug development. Given the GPCR target class, optimizing for ADME properties is crucial, and Ligand A excels in this regard.
Output:
1
2025-04-17 18:40:20,598 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (357.3) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (56.15) is significantly better than Ligand B (132.89). ADRB2 is not a CNS target, but lower TPSA generally improves absorption. Ligand B is pushing the upper limit for good oral absorption.
3. **logP:** Ligand A (2.755) is optimal, while Ligand B (-0.12) is quite low. This is a major drawback for Ligand B, potentially hindering membrane permeability and bioavailability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (4). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is better than Ligand B (7). Similar to HBD, lower HBA is generally preferred.
6. **QED:** Ligand A (0.838) is significantly better than Ligand B (0.541), indicating a more drug-like profile.
7. **DILI:** Both ligands have similar DILI risk (Ligand A: 64.444, Ligand B: 62.35), and are both acceptable (below 60 is good, these are slightly above).
8. **BBB:** Ligand A (80.225) is much better than Ligand B (15.432). While ADRB2 isn't a CNS target, higher BBB penetration can sometimes correlate with better overall distribution.
9. **Caco-2:** Ligand A (-4.546) and Ligand B (-5.945) are both negative values, which is unusual. Lower (more negative) values suggest poor permeability. However, the scale isn't specified, so it's hard to interpret.
10. **Solubility:** Ligand A (-3.288) is better than Ligand B (-1.975). Both are negative, suggesting poor solubility, but Ligand A is less problematic.
11. **hERG:** Ligand A (0.786) is much better than Ligand B (0.109), indicating a lower risk of cardiotoxicity, which is *critical* for a cardiovascular target.
12. **Cl_mic:** Ligand B (-25.983) has significantly lower (better) microsomal clearance than Ligand A (13.799), suggesting greater metabolic stability.
13. **t1/2:** Ligand A (20.066) has a longer in vitro half-life than Ligand B (-13.284). This is a significant advantage.
14. **Pgp:** Ligand A (0.279) is much better than Ligand B (0.024), indicating lower P-glycoprotein efflux and potentially better bioavailability.
15. **Binding Affinity:** Ligand B (-8.6) has a slightly better binding affinity than Ligand A (-9.0). While affinity is important, the difference here is not substantial enough to outweigh the numerous ADME advantages of Ligand A.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A excels in logP, TPSA, and Pgp, while Ligand B has a slightly better affinity. However, the poor logP and TPSA of Ligand B are significant drawbacks. The hERG risk is also a major concern for a cardiovascular target, and Ligand A is much better in this regard.
**Conclusion:**
Ligand A demonstrates a significantly more balanced profile with better predicted ADME properties (logP, TPSA, solubility, Pgp, hERG, metabolic stability, half-life) and a good QED score. While Ligand B has slightly better binding affinity, the other issues are too significant to ignore. Therefore, I would choose Ligand A as the more promising drug candidate.
Output:
1
2025-04-17 18:40:20,598 - INFO - Batch 54 complete. Total preferences: 864
2025-04-17 18:40:20,598 - INFO - Processing batch 55/512...
2025-04-17 18:41:09,780 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (356.369 and 348.447 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (60.03) is significantly better than Ligand B (79.54). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (2.744 and 1.806), falling within the 1-3 range. Ligand A is slightly higher, which *could* be beneficial for membrane permeability, but isn't a major concern.
4. **HBD:** Ligand A (1) is preferable to Ligand B (0). While both are low, a single H-bond donor can improve solubility.
5. **HBA:** Ligand A (4) is slightly better than Ligand B (5). Lower HBA is generally preferred for permeability.
6. **QED:** Both ligands have good QED scores (0.901 and 0.811), indicating good drug-like properties.
7. **DILI:** Ligand B (31.485) is *much* better than Ligand A (64.948). This is a significant advantage for Ligand B. DILI risk is a critical factor.
8. **BBB:** Both ligands have reasonable BBB penetration (82.513 and 77.86). Not a primary concern for a cardiovascular target.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.425 and -4.806). These values are unusual and suggest poor permeability. However, these values are on a scale where negative values are possible, and their absolute meaning is less important than the *difference* between the two.
10. **Solubility:** Ligand B (-1.176) is slightly better than Ligand A (-2.43). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.497) is better than Ligand B (0.045). Lower hERG inhibition is crucial to avoid cardiotoxicity.
12. **Cl_mic:** Ligand A (-5.252) is significantly better than Ligand B (24.209). Lower microsomal clearance indicates greater metabolic stability, a crucial ADME property.
13. **t1/2:** Ligand B (7.591) has a longer in vitro half-life than Ligand A (-22.703). This is a significant advantage, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.039) is better than Ligand B (0.058). Lower P-gp efflux is desirable for improved bioavailability.
15. **Binding Affinity:** Ligand B (-7.4) has a slightly better binding affinity than Ligand A (-6.9). While the difference is less than 1.5 kcal/mol, it is still a positive.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Ligand B has a slightly better logP and affinity, while Ligand A has a better TPSA and Pgp. However, the *massive* difference in DILI risk and the better half-life of Ligand B are overriding factors.
**Overall Assessment:**
While Ligand A has some advantages in TPSA, hERG, and Cl_mic, Ligand B's significantly lower DILI risk and longer half-life outweigh those benefits. The slightly better affinity of Ligand B is also a plus. The negative Caco-2 values are concerning for both, but the overall profile of Ligand B is more favorable for development.
Output:
0
2025-04-17 18:41:09,781 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (366.355 Da and 355.395 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (69.64) is significantly better than Ligand B (128.87). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is pushing the upper limit for good oral absorption (<=140), while A is well below.
**3. logP:** Ligand A (1.686) is within the optimal 1-3 range. Ligand B (-1.09) is below 1, which could hinder permeation. This is a significant advantage for A.
**4. H-Bond Donors:** Ligand A (2) is preferable to Ligand B (4). Fewer HBDs generally improve permeability.
**5. H-Bond Acceptors:** Ligand A (3) is preferable to Ligand B (5) for similar reasons as HBDs.
**6. QED:** Ligand A (0.747) is better than Ligand B (0.461), indicating a more drug-like profile.
**7. DILI:** Ligand B (49.283) has a slightly lower DILI risk than Ligand A (40.054), but both are acceptable (below 60).
**8. BBB:** Ligand A (76.192) has a better BBB penetration percentile than Ligand B (68.67). While not a CNS target, some degree of BBB penetration can influence distribution and off-target effects.
**9. Caco-2 Permeability:** Ligand A (-5.064) is better than Ligand B (-5.401).
**10. Aqueous Solubility:** Ligand A (-2.784) is better than Ligand B (-0.97).
**11. hERG Inhibition:** Ligand A (0.449) has a much lower hERG risk than Ligand B (0.04). This is a crucial safety parameter, and A is significantly better.
**12. Microsomal Clearance:** Ligand A (-5.368) has a lower (better) microsomal clearance than Ligand B (4.84). This indicates greater metabolic stability.
**13. In vitro Half-Life:** Ligand A (10.289) has a longer half-life than Ligand B (-13.033).
**14. P-gp Efflux:** Ligand A (0.039) has a lower P-gp efflux liability than Ligand B (0.004).
**15. Binding Affinity:** Ligand B (-2.5 kcal/mol) has a significantly better binding affinity than Ligand A (-6.9 kcal/mol). This is a substantial difference.
**Overall Assessment:**
While Ligand B has a superior binding affinity, the ADME properties of Ligand A are substantially better. Specifically, the lower TPSA, better logP, lower HBD/HBA counts, better QED, significantly lower hERG risk, and improved metabolic stability are all highly desirable for a GPCR drug candidate. The difference in affinity, while significant, can potentially be overcome with further optimization, whereas fixing poor ADME properties is often more challenging. Given the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), the balance favors Ligand A.
Output:
1
2025-04-17 18:41:09,781 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [347.463, 90.12, 1.188, 3, 4, 0.691, 16.867, 47.732, -5.689, -0.65, 0.278, 1.129, -18.533, 0.013, -8.1]
**Ligand B:** [348.487, 58.64, 2.511, 1, 3, 0.751, 14.541, 77.782, -4.77, -2.639, 0.335, 56.839, -2.373, 0.061, -5.6]
Here's a breakdown, considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity are most important):
1. **MW:** Both are within the ideal 200-500 Da range. A is 347.463, B is 348.487 - very similar.
2. **TPSA:** A is 90.12, B is 58.64. B is significantly better, falling well below the 140 threshold and closer to the 90 ideal for potential CNS penetration (though less critical for a cardiovascular target).
3. **logP:** A is 1.188, B is 2.511. Both are within the optimal 1-3 range, but B is closer to the upper end, potentially improving membrane permeability.
4. **HBD:** A has 3, B has 1. B is better, minimizing potential for off-target interactions and improving permeability.
5. **HBA:** A has 4, B has 3. B is slightly better.
6. **QED:** A is 0.691, B is 0.751. B is slightly better, indicating a more drug-like profile.
7. **DILI:** A is 16.867, B is 14.541. B is better, indicating a lower risk of drug-induced liver injury.
8. **BBB:** A is 47.732, B is 77.782. B is significantly better, suggesting greater potential for distribution. While not a primary concern for a cardiovascular target, it's a positive attribute.
9. **Caco-2:** A is -5.689, B is -4.77. B is better, indicating better intestinal absorption.
10. **Solubility:** A is -0.65, B is -2.639. A is better, suggesting better aqueous solubility.
11. **hERG:** A is 0.278, B is 0.335. B is slightly worse, but both are relatively low risk.
12. **Cl_mic:** A is 1.129, B is 56.839. A is *much* better, indicating significantly higher metabolic stability. This is a major advantage.
13. **t1/2:** A is -18.533, B is -2.373. B is better, indicating a longer in vitro half-life.
14. **Pgp:** A is 0.013, B is 0.061. A is significantly better, indicating less P-glycoprotein efflux.
15. **Affinity:** A is -8.1, B is -5.6. A has a *much* stronger binding affinity. This is a substantial advantage.
**Overall Assessment:**
Ligand A has a significantly better binding affinity (-8.1 vs -5.6 kcal/mol) and much better metabolic stability (Cl_mic = 1.129 vs 56.839) and Pgp efflux (0.013 vs 0.061). These are critical factors. While Ligand B has advantages in TPSA, logP, BBB, and DILI, the difference in affinity and metabolic stability is substantial enough to outweigh these benefits. The stronger binding affinity of Ligand A is particularly important for a GPCR target.
Therefore, I prefer Ligand A.
Output:
1
2025-04-17 18:41:09,781 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Ligand A (329.4) is better than Ligand B (391.4). Both are within the ideal range, but A is closer to the lower, more permeability-friendly end.
2. **TPSA:** Ligand A (47.04) is significantly better than Ligand B (58.2). ADRB2 is a cardiovascular target, not CNS, but lower TPSA generally improves absorption.
3. **logP:** Both ligands are good (A: 4.845, B: 4.044), falling within the optimal 1-3 range. Ligand A is slightly higher, which could be a minor concern for off-target effects but isn't a dealbreaker.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD is generally better for permeability.
5. **HBA:** Ligand A (4) is preferable to Ligand B (2). Lower HBA is generally better for permeability.
6. **QED:** Ligand A (0.727) is better than Ligand B (0.614), indicating a more drug-like profile.
7. **DILI:** Ligand B (27.53) is *much* better than Ligand A (84.684). This is a significant advantage for Ligand B. DILI risk is a critical factor.
8. **BBB:** Ligand A (74.06) is slightly better than Ligand B (66.615). While not a CNS target, some peripheral exposure can be beneficial.
9. **Caco-2:** Both are very poor (-4.938 and -4.859). This is a significant drawback for both compounds, suggesting poor intestinal absorption.
10. **Solubility:** Both are very poor (-5.857 and -5.158). This is a significant drawback for both compounds, potentially impacting bioavailability.
11. **hERG:** Ligand A (0.751) is better than Ligand B (0.489), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand B (72.395) is better than Ligand A (79.597), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-13.213) is better than Ligand B (-6.293), indicating a longer half-life.
14. **Pgp:** Ligand A (0.447) is better than Ligand B (0.259), suggesting lower P-gp efflux.
15. **Affinity:** Ligand A (-6.3) is slightly better than Ligand B (-5.3). While both are good, the 0.9 kcal/mol difference is noteworthy.
**GPCR-specific priorities:** For ADRB2 (a cardiovascular GPCR), logP, TPSA, Pgp, and affinity are important. While BBB isn't a primary concern, it's still considered.
**Overall Assessment:**
Ligand A has a better overall profile in terms of drug-likeness (QED), permeability-related properties (TPSA, HBD, HBA, Pgp), and binding affinity. However, the *extremely* high DILI risk associated with Ligand A is a major concern. Ligand B, while having some drawbacks (slightly higher TPSA, lower QED, poorer half-life), has a significantly lower DILI risk, which is paramount for a cardiovascular drug. The difference in affinity is not large enough to overcome the substantial DILI risk of Ligand A.
**Output:**
0
2025-04-17 18:41:09,781 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (342.483 and 347.463 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (41.57) is significantly better than Ligand B (74.09). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold. Ligand B is approaching the upper limit.
3. **logP:** Both ligands have acceptable logP values (3.151 and 2.586), falling within the 1-3 optimal range. Ligand A is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A (3) is better than Ligand B (7). Fewer HBA generally improves permeability.
6. **QED:** Ligand A (0.894) has a significantly better QED score than Ligand B (0.712), indicating a more drug-like profile overall.
7. **DILI:** Ligand B (43.738) has a slightly better DILI score than Ligand A (32.299), indicating lower potential for liver injury. Both are below the concerning threshold of 60.
8. **BBB:** Ligand A (88.445) has a much higher BBB percentile than Ligand B (47.111). While not a primary concern for a cardiovascular target, higher BBB is generally not detrimental.
9. **Caco-2:** Ligand A (-4.553) has a better Caco-2 permeability than Ligand B (-5.142).
10. **Solubility:** Ligand A (-3.427) has better solubility than Ligand B (-2.243).
11. **hERG:** Ligand A (0.689) has a better hERG profile than Ligand B (0.301).
12. **Cl_mic:** Ligand B (35.612) has a lower microsomal clearance than Ligand A (48.813), suggesting better metabolic stability. This is a positive for Ligand B.
13. **t1/2:** Ligand A (7.814) has a longer in vitro half-life than Ligand B (-1.861). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.292) has a lower Pgp efflux liability than Ligand B (0.122). Lower Pgp is generally preferred.
15. **Binding Affinity:** Ligand B (-7.3 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.3 kcal/mol). This is a substantial advantage for Ligand B, potentially outweighing some of the ADME drawbacks.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, and affinity. Ligand B has a slightly better logP, significantly better affinity, and better Pgp efflux. However, Ligand A excels in TPSA, QED, solubility, hERG, and half-life. The substantial affinity difference of -1 kcal/mol is a major factor.
**Overall Assessment:**
While Ligand A has a more favorable overall ADME profile (better TPSA, QED, solubility, hERG, half-life, and Pgp), the significantly stronger binding affinity of Ligand B (-7.3 vs -6.3 kcal/mol) is a critical advantage for a GPCR target. A 1.0 kcal/mol difference in binding affinity is substantial and can often compensate for minor ADME liabilities. The DILI score is also slightly better for Ligand B.
Output:
0
2025-04-17 18:41:09,781 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands (347.459 and 352.45 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (72.88) is higher than Ligand B (49.85). For a GPCR, lower TPSA is generally preferred for better permeability, giving a slight edge to Ligand B.
3. **logP:** Both ligands have good logP values (1.228 and 2.001, respectively), falling within the optimal 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability, but isn't a major concern.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (0). Lower HBD is generally preferred for permeability, favoring Ligand B.
5. **HBA:** Ligand A (4) is higher than Ligand B (3). Similar to HBD, lower HBA is preferred, favoring Ligand B.
6. **QED:** Both ligands have similar QED values (0.84 and 0.76), indicating good drug-likeness. No significant difference.
7. **DILI:** Ligand A (17.914) has a considerably higher DILI risk than Ligand B (6.708). This is a significant negative for Ligand A.
8. **BBB:** Ligand B (96.084) has a much higher BBB penetration percentile than Ligand A (69.523). This is a crucial advantage for Ligand B, given ADRB2 is a GPCR.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and requires further investigation. However, the magnitude of the negative value is smaller for Ligand B (-4.555 vs -4.815), potentially indicating slightly better absorption.
10. **Solubility:** Both ligands have negative solubility values, which is also unusual. Again, Ligand B (-2.013) is slightly better than Ligand A (-1.401).
11. **hERG:** Both ligands have low hERG inhibition liability (0.622 and 0.529), which is good. No significant difference.
12. **Cl_mic:** Ligand A (0.777) has significantly lower microsomal clearance than Ligand B (28.881), indicating better metabolic stability. This is a major advantage for Ligand A.
13. **t1/2:** Ligand A (10.118) has a longer in vitro half-life than Ligand B (-7.139). This is a significant advantage for Ligand A.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.086 and 0.077). No significant difference.
15. **Affinity:** Both ligands have the same binding affinity (-6.5 kcal/mol).
**Overall Assessment:**
Ligand B excels in properties crucial for GPCR targets, particularly BBB penetration and lower TPSA/HBD/HBA. It also has a lower DILI risk. However, Ligand A demonstrates superior metabolic stability (lower Cl_mic) and a longer half-life.
Considering the ADRB2 target (a GPCR), the benefits of Ligand B's improved BBB penetration and reduced DILI risk outweigh the advantages of Ligand A's metabolic stability and half-life. While metabolic stability is important, it can be addressed through structural modifications later in the optimization process. The improved permeability and safety profile of Ligand B make it a more promising starting point.
Output:
0
2025-04-17 18:41:09,781 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.447 and 348.491 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (76.46) is higher than Ligand B (47.1). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is generally preferred for absorption. Ligand B is better here.
3. **logP:** Ligand A (2.624) is within the optimal 1-3 range. Ligand B (0.195) is quite low, potentially hindering permeability. Ligand A is significantly better.
4. **HBD:** Ligand A (1) is good. Ligand B (0) is also acceptable, but having one HBD can sometimes improve solubility.
5. **HBA:** Both ligands (A: 5, B: 4) are within the acceptable limit of 10.
6. **QED:** Ligand A (0.907) is excellent, indicating high drug-likeness. Ligand B (0.712) is still reasonable, but lower. Ligand A is better.
7. **DILI:** Ligand A (32.997) has a much lower DILI risk than Ligand B (5.157). This is a significant advantage for Ligand A.
8. **BBB:** Both ligands have good BBB penetration (A: 86.661, B: 80.07). Since ADRB2 is not a CNS target, this is less critical, but higher is still slightly preferred. Ligand A is better.
9. **Caco-2:** Both have negative values, indicating permeability. Ligand A (-4.45) is slightly better than Ligand B (-4.791).
10. **Solubility:** Ligand A (-2.127) is better than Ligand B (-0.316). Solubility is important for bioavailability.
11. **hERG:** Both ligands have low hERG risk (A: 0.253, B: 0.467). No major difference.
12. **Cl_mic:** Ligand B (-3.726) has a *much* lower microsomal clearance than Ligand A (43.798), indicating better metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand B (-3.211) has a better in vitro half-life than Ligand A (-8.466).
14. **Pgp:** Both ligands have very low P-gp efflux (A: 0.045, B: 0.008). No major difference.
15. **Binding Affinity:** Both ligands have good binding affinity (A: -6.5 kcal/mol, B: -6.2 kcal/mol). The difference is relatively small (0.3 kcal/mol).
**GPCR-Specific Priorities:**
For ADRB2 (a cardiovascular GPCR), logP, TPSA, and affinity are key. Ligand A excels in logP and has slightly better affinity, while Ligand B has a lower TPSA. However, the significantly better DILI score, solubility, and QED of Ligand A, coupled with acceptable BBB and Caco-2 values, outweigh the TPSA advantage of Ligand B. The metabolic stability of Ligand B is a concern, given the high Cl_mic.
**Conclusion:**
Despite Ligand B's better metabolic stability, Ligand A presents a more balanced profile with better predicted ADME properties (solubility, DILI, QED) and comparable binding affinity.
Output:
1
2025-04-17 18:41:09,781 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (348.393 and 360.531 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (49.41) is significantly better than Ligand B (67.66). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand A is well below the 140 A^2 threshold, while Ligand B is approaching it.
**3. logP:** Both ligands have acceptable logP values (2.579 and 3.376), falling within the optimal 1-3 range. Ligand B is slightly higher, which *could* indicate a potential for off-target interactions, but it's not a major concern.
**4. H-Bond Donors:** Both have a reasonable number of HBDs (1 and 2 respectively), well within the limit of 5.
**5. H-Bond Acceptors:** Ligand A (2) is preferable to Ligand B (7). While both are under the 10 threshold, fewer HBA generally improves permeability.
**6. QED:** Ligand A (0.832) has a better QED score than Ligand B (0.704), indicating a more drug-like profile.
**7. DILI Risk:** Ligand A (27.065) has a significantly lower DILI risk than Ligand B (65.723). This is a crucial advantage, as liver toxicity is a major concern in drug development.
**8. BBB Penetration:** Both ligands have high BBB penetration (85.459 and 88.91). Since ADRB2 is a cardiovascular target, BBB penetration isn't *as* critical as it would be for a CNS target, but it's still a positive attribute.
**9. Caco-2 Permeability:** Ligand A (-4.666) is better than Ligand B (-5.399). Higher values are better, and A is closer to 0.
**10. Aqueous Solubility:** Both ligands have poor aqueous solubility (-3.253 and -3.602). This is a potential issue for both, requiring formulation strategies to improve bioavailability.
**11. hERG Inhibition:** Ligand A (0.322) has a much lower hERG inhibition liability than Ligand B (0.907). This is a significant advantage, as hERG inhibition can lead to cardiotoxicity.
**12. Microsomal Clearance:** Ligand B (87.26) has a significantly higher microsomal clearance than Ligand A (12.448), indicating faster metabolism and potentially lower bioavailability.
**13. In Vitro Half-Life:** Ligand B (27.183) has a much longer in vitro half-life than Ligand A (-0.075). This is a positive for Ligand B, suggesting less frequent dosing.
**14. P-gp Efflux:** Ligand A (0.072) has lower P-gp efflux than Ligand B (0.672). Lower efflux is generally preferred for better bioavailability.
**15. Binding Affinity:** Ligand B (-5.0) has slightly better binding affinity than Ligand A (-6.7). However, the difference is not large enough to outweigh the significant ADME advantages of Ligand A.
**Overall Assessment:**
Ligand A is the stronger candidate. While Ligand B has a slightly better binding affinity and in vitro half-life, Ligand A excels in critical ADME properties: lower DILI risk, lower hERG inhibition, lower P-gp efflux, better QED, and lower TPSA. These factors are particularly important for a GPCR target, and the lower DILI and hERG risks are crucial for cardiovascular safety. The solubility issues are present in both, but can be addressed through formulation.
Output:
1
2025-04-17 18:41:09,781 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [364.427, 108.56 , 1.275, 2. , 7. , 0.799, 61.807, 35.246, -4.804, -2.122, 0.063, 4.795, 23.874, 0.051, -7.5 ]
**Ligand B:** [366.458, 75.27 , 2.56 , 2. , 3. , 0.841, 61.497, 74.06 , -4.682, -3.762, 0.252, 58.82 , -6.541, 0.305, -7.9 ]
**Step-by-step Comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). A: 364.43, B: 366.46. No significant difference.
2. **TPSA:** Ligand A (108.56) is higher than Ligand B (75.27). For a GPCR, lower TPSA is generally preferred for better BBB penetration, so B is better here.
3. **logP:** Ligand A (1.275) is within the optimal range, while Ligand B (2.56) is slightly higher. Both are acceptable, but A is a bit more balanced.
4. **HBD:** Both have 2 HBD, which is good.
5. **HBA:** Ligand A (7) has more HBA than Ligand B (3). Lower HBA is generally preferred for permeability, so B is better.
6. **QED:** Both are good (>0.5), with B (0.841) being slightly better than A (0.799).
7. **DILI:** Both have similar DILI risk (around 61%), which is acceptable but not ideal.
8. **BBB:** Ligand B (74.06) has significantly better BBB penetration potential than Ligand A (35.25). This is a *major* advantage for a GPCR target, even if not specifically a CNS target, as it indicates better overall distribution characteristics.
9. **Caco-2:** Ligand A (-4.804) and Ligand B (-4.682) are both negative, indicating poor permeability.
10. **Solubility:** Ligand B (-3.762) has better solubility than Ligand A (-2.122).
11. **hERG:** Ligand A (0.063) has a slightly lower hERG risk than Ligand B (0.252), but both are low.
12. **Cl_mic:** Ligand A (4.795) has a lower (better) microsomal clearance than Ligand B (58.82). This suggests better metabolic stability for A.
13. **t1/2:** Ligand B (-6.541) has a longer in vitro half-life than Ligand A (23.874).
14. **Pgp:** Ligand A (0.051) has lower P-gp efflux than Ligand B (0.305), which is favorable.
15. **Affinity:** Ligand B (-7.9) has a significantly stronger binding affinity than Ligand A (-7.5). A difference of 0.4 kcal/mol is substantial and can often outweigh minor ADME drawbacks.
**Overall Assessment:**
While Ligand A has better metabolic stability (Cl_mic) and P-gp efflux, Ligand B has a significantly stronger binding affinity, better BBB penetration, better solubility, and a longer half-life. For a GPCR like ADRB2, the strong affinity and improved BBB potential of Ligand B are crucial. The slightly higher logP and Pgp efflux are less concerning given the substantial affinity advantage. The solubility difference is also a positive for B.
Therefore, I would prioritize Ligand B.
0
2025-04-17 18:41:09,782 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (338.4 and 358.5 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (71.35) is better than Ligand B (79.18). Both are below 140, but lower TPSA generally favors absorption.
3. **logP:** Both ligands (2.637 and 2.599) are within the optimal 1-3 range. No significant difference.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (4) is preferable to Ligand B (5). Lower HBA also contributes to better permeability.
6. **QED:** Ligand A (0.714) is better than Ligand B (0.634), indicating a more drug-like profile.
7. **DILI:** Ligand A (36.06) is significantly better than Ligand B (63.242). Ligand B is approaching a higher risk category for liver injury.
8. **BBB:** Ligand A (35.207) is lower than Ligand B (49.787). While ADRB2 isn't necessarily a CNS target, some degree of BBB penetration can be beneficial for distribution.
9. **Caco-2:** Ligand A (-4.689) is better than Ligand B (-5.433). Higher (less negative) Caco-2 values indicate improved intestinal absorption.
10. **Solubility:** Ligand A (-3.522) is better than Ligand B (-2.048). Better solubility is important for bioavailability.
11. **hERG:** Ligand A (0.818) is better than Ligand B (0.408). Lower hERG inhibition is crucial for avoiding cardiotoxicity, a significant concern for cardiovascular targets.
12. **Cl_mic:** Ligand A (62.694) is worse than Ligand B (18.639). Ligand B has significantly better metabolic stability.
13. **t1/2:** Ligand A (4.926) is worse than Ligand B (88.494). Ligand B has a much longer half-life, which is desirable.
14. **Pgp:** Ligand A (0.28) is better than Ligand B (0.154). Lower P-gp efflux improves bioavailability.
15. **Affinity:** Ligand A (-7.1) is slightly better than Ligand B (-6.9). This difference is not huge, but still favors A.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Both ligands are good on logP. Ligand A is better on TPSA and Pgp. The affinity difference is small. However, the significant advantages of Ligand A in terms of DILI risk and hERG inhibition are critical for a cardiovascular target. The improved solubility and Caco-2 permeability also contribute to better potential bioavailability. While Ligand B has better metabolic stability and half-life, these can be addressed through structural modifications. The safety profile of Ligand A is much more favorable.
**Conclusion:**
Considering the balance of properties and the specific priorities for a cardiovascular GPCR target, Ligand A is the more promising drug candidate.
Output:
1
2025-04-17 18:41:09,782 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 drug candidates. ADRB2 is a GPCR, so we'll prioritize logP, Pgp, TPSA, and affinity, alongside general drug-like properties.
**Ligand A:**
* **MW:** 342.439 Da - Good, within the ideal range.
* **TPSA:** 70.59 A2 - Excellent, well below the 140 A2 threshold.
* **logP:** 4.324 - Slightly high, potentially leading to solubility issues, but acceptable.
* **HBD:** 3 - Good, within the desired range.
* **HBA:** 3 - Good, within the desired range.
* **QED:** 0.669 - Excellent, indicating good drug-likeness.
* **DILI:** 55.68 - Acceptable, below the 60% threshold.
* **BBB:** 36.177 - Moderate. Not a primary concern for a cardiovascular target, but not ideal.
* **Caco-2:** -5.129 - Very poor permeability. This is a significant drawback.
* **Solubility:** -4.724 - Very poor solubility. This is a major concern.
* **hERG:** 0.745 - Low risk, good.
* **Cl_mic:** 87.522 - High metabolic clearance, suggesting poor metabolic stability.
* **t1/2:** 27.352 - Moderate half-life.
* **Pgp:** 0.389 - Low efflux, good.
* **Affinity:** -6.8 kcal/mol - Very good binding affinity.
**Ligand B:**
* **MW:** 348.367 Da - Good, within the ideal range.
* **TPSA:** 131.06 A2 - Borderline. Approaching the upper limit for good absorption, but still potentially acceptable.
* **logP:** -1.861 - Low, potentially hindering permeability.
* **HBD:** 2 - Good, within the desired range.
* **HBA:** 9 - Acceptable, close to the upper limit.
* **QED:** 0.6 - Good, indicating reasonable drug-likeness.
* **DILI:** 66.654 - Moderate-High risk, a concern.
* **BBB:** 21.946 - Low. Not a major concern for a cardiovascular target.
* **Caco-2:** -5.643 - Very poor permeability. Similar to Ligand A, a significant drawback.
* **Solubility:** -1.064 - Poor solubility, but better than Ligand A.
* **hERG:** 0.023 - Very low risk, excellent.
* **Cl_mic:** -2.864 - Very low metabolic clearance, indicating excellent metabolic stability.
* **t1/2:** 15.968 - Moderate half-life.
* **Pgp:** 0.013 - Very low efflux, excellent.
* **Affinity:** -6.2 kcal/mol - Good binding affinity, slightly weaker than Ligand A.
**Comparison & Decision:**
Both ligands have significant permeability and solubility issues, which are major drawbacks. However, Ligand A has a substantially better binding affinity (-6.8 vs -6.2 kcal/mol), and a lower DILI risk. While Ligand A has higher metabolic clearance, the difference in binding affinity is significant enough to outweigh this concern. Ligand B has excellent metabolic stability and hERG profile, but the lower affinity and higher DILI risk are concerning.
Given the GPCR target class, affinity is paramount. The slight advantage in affinity for Ligand A, coupled with the lower DILI risk, makes it the more promising candidate *despite* the permeability/solubility concerns. These issues would need to be addressed through formulation or further chemical modification, but a strong starting point with good potency is crucial.
Output:
1
2025-04-17 18:41:09,782 - INFO - Here's my reasoning and decision for selecting the better drug candidate:
**Step-by-step comparison:**
1. **MW:** Both ligands (350.46 & 358.39 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (66.92) is significantly better than Ligand B (87.32). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand A is well below the 140 threshold, while B is approaching it.
3. **logP:** Ligand A (2.276) is optimal, while Ligand B (0.897) is a bit low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Both ligands have 4 HBA, which is acceptable.
6. **QED:** Ligand B (0.723) has a slightly better QED score than Ligand A (0.419), indicating a more drug-like profile overall.
7. **DILI:** Both ligands have acceptable DILI risk (31.68 & 36.25), both below the 40 threshold.
8. **BBB:** Ligand A (77.2) has a significantly higher BBB penetration percentile than Ligand B (62.97). While this isn't a CNS target, better BBB penetration can sometimes correlate with better overall distribution.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.803 & -4.853), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Both ligands have negative solubility values (-2.654 & -1.741), also unusual and concerning.
11. **hERG:** Ligand A (0.209) has a much lower hERG inhibition liability than Ligand B (0.585), which is a major advantage for cardiovascular safety.
12. **Cl_mic:** Ligand B (-16.997) has a much lower (better) microsomal clearance than Ligand A (80.717), indicating better metabolic stability.
13. **t1/2:** Ligand B (-15.714) has a much longer in vitro half-life than Ligand A (-6.007), which is a significant advantage.
14. **Pgp:** Ligand A (0.106) has a lower P-gp efflux liability than Ligand B (0.024), which is favorable.
15. **Affinity:** Ligand A (-6.8 kcal/mol) has a slightly better binding affinity than Ligand B (-5.5 kcal/mol).
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A excels in logP, TPSA, and affinity, while Ligand B has better metabolic stability (Cl_mic and t1/2). The negative Caco-2 and solubility values are concerning for both, but the superior affinity and lower hERG risk of Ligand A are more critical for a cardiovascular target.
**Overall Assessment:**
Despite the concerning Caco-2 and solubility values for both, Ligand A's superior affinity, lower hERG risk, and better TPSA/logP profile make it the more promising candidate. The better metabolic stability of Ligand B is valuable, but can be addressed through further structural modifications. The hERG risk with Ligand B is a significant concern for a cardiovascular drug.
Output:
1
2025-04-17 18:41:09,782 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (384.27 and 348.49 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (80.12) is slightly higher than Ligand B (67.43). Both are below the 140 threshold for oral absorption, but closer to the 90 threshold for CNS targets. Ligand B is preferable.
3. **logP:** Ligand A (1.315) is within the optimal 1-3 range. Ligand B (2.714) is also within range, but closer to the upper limit. Ligand A is slightly preferable.
4. **HBD:** Ligand A (1) is better than Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (5) is better than Ligand B (3). Lower HBA generally improves permeability.
6. **QED:** Ligand A (0.794) is significantly better than Ligand B (0.422), indicating a more drug-like profile. This is a substantial advantage for Ligand A.
7. **DILI:** Ligand A (57.35%) is higher than Ligand B (32.84%). Ligand B is clearly preferable here, indicating a lower risk of liver injury.
8. **BBB:** Ligand A (68.55%) is better than Ligand B (57.62%). While neither are exceptionally high, Ligand A has a slight advantage.
9. **Caco-2:** Ligand A (-5.513) is worse than Ligand B (-4.731). Higher values are better, so Ligand B is preferable.
10. **Solubility:** Ligand A (-2.632) is slightly better than Ligand B (-3.055). Higher values are better.
11. **hERG:** Ligand A (0.034) is much better than Ligand B (0.389), indicating a lower risk of cardiotoxicity. This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand A (8.042) is much better than Ligand B (54.606), indicating better metabolic stability. This is a major advantage for Ligand A.
13. **t1/2:** Ligand A (9.783) is better than Ligand B (-9.644). Longer half-life is generally preferred.
14. **Pgp:** Ligand A (0.048) is much better than Ligand B (0.261), indicating lower P-gp efflux. This is a significant advantage for Ligand A.
15. **Affinity:** Ligand A (-9.1 kcal/mol) is significantly better than Ligand B (-6.4 kcal/mol). This is a substantial advantage for Ligand A. A difference of 2.7 kcal/mol is significant enough to outweigh many ADME drawbacks.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are crucial. Ligand A excels in affinity, Pgp, and has a reasonable logP and TPSA. While Ligand B has a better DILI score, the superior binding affinity, metabolic stability, lower Pgp efflux, and better hERG profile of Ligand A are more important for a GPCR target. The QED score also strongly favors Ligand A.
**Conclusion:**
Ligand A demonstrates a superior balance of properties, particularly its significantly higher binding affinity, better metabolic stability, lower Pgp efflux, and improved safety profile (hERG, DILI). These factors outweigh the slightly less favorable TPSA and Caco-2 values.
Output:
1
2025-04-17 18:41:09,782 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (405.252 Da) is within the ideal range, while Ligand B (342.443 Da) is slightly below, but still acceptable.
2. **TPSA:** Both ligands (A: 85.25, B: 88.32) are below the 140 threshold for good oral absorption, and acceptable for a non-CNS GPCR target like ADRB2.
3. **logP:** Both ligands (A: 2.257, B: 2.153) are within the optimal 1-3 range.
4. **HBD:** Both ligands have 2 HBD, which is good.
5. **HBA:** Ligand A has 5 HBA, and Ligand B has 4. Both are acceptable.
6. **QED:** Both ligands have reasonable QED scores (A: 0.803, B: 0.743), indicating good drug-like properties.
7. **DILI:** Ligand A (77.278) has a significantly higher DILI risk than Ligand B (37.611). This is a major concern.
8. **BBB:** Both ligands have acceptable BBB penetration (A: 68.282, B: 78.519), but this is less critical for a non-CNS target like ADRB2.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. This is a red flag for both.
10. **Solubility:** Both have negative solubility values, which is also unusual and suggests poor solubility. This is a red flag for both.
11. **hERG:** Both ligands have low hERG inhibition liability (A: 0.562, B: 0.563).
12. **Cl_mic:** Ligand A (13.723) has a lower (better) microsomal clearance than Ligand B (-12.79). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (30.791) has a longer in vitro half-life than Ligand B (-11.997). This is a positive for Ligand A.
14. **Pgp:** Both ligands have very low Pgp efflux liability (A: 0.355, B: 0.028).
15. **Binding Affinity:** Ligand A (-6.5 kcal/mol) has a slightly better binding affinity than Ligand B (-4.9 kcal/mol). The difference is 1.6 kcal/mol, which is significant.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Both ligands perform similarly on logP, TPSA, and Pgp. Ligand A has a better affinity. However, the significantly higher DILI risk for Ligand A is a major drawback.
**Overall Assessment:**
Despite the slightly better affinity and metabolic stability of Ligand A, the substantially higher DILI risk makes it a less desirable candidate. The negative Caco-2 and solubility values are concerning for both compounds, but the DILI risk is a more immediate safety concern. Ligand B, while having a weaker affinity and poorer metabolic stability, presents a much lower risk of liver injury.
Output:
0
2025-04-17 18:41:09,782 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (355.825 Da and 352.475 Da). No significant difference here.
2. **TPSA:** Ligand A (74.85) is better than Ligand B (87.66). For a GPCR, keeping TPSA lower is advantageous for permeability.
3. **logP:** Ligand A (3.538) is good, while Ligand B (1.221) is on the lower side. ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but a reasonable logP is still important for membrane permeability and binding. Ligand A is better.
4. **HBD:** Ligand A (2) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (4). Fewer HBAs generally improve permeability.
6. **QED:** Both ligands have similar QED values (0.636 and 0.643), indicating good drug-likeness.
7. **DILI:** Ligand A (73.401) has a significantly higher DILI risk than Ligand B (21.287). This is a major concern for Ligand A.
8. **BBB:** BBB is less critical for a cardiovascular target. Ligand A (65.335) is better than Ligand B (39.86), but this isn't a deciding factor.
9. **Caco-2:** Both ligands have negative Caco-2 values, suggesting poor permeability. Ligand A (-5.655) is slightly better than Ligand B (-5.068).
10. **Solubility:** Ligand A (-3.815) is better than Ligand B (-1.89). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.439) is better than Ligand B (0.155), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand B (20.671) has a much lower microsomal clearance than Ligand A (44.284), suggesting better metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand A (89.236) has a much longer in vitro half-life than Ligand B (11.672). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.515) is better than Ligand B (0.055), indicating lower P-gp efflux.
15. **Binding Affinity:** Ligand B (-7.2 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.7 kcal/mol). This is a substantial advantage that can often outweigh other drawbacks.
**Overall Assessment:**
Ligand B has a significantly better binding affinity and a much lower DILI risk, and better metabolic stability (lower Cl_mic). While Ligand A has a longer half-life and better solubility, the DILI risk is a major red flag. The stronger affinity of Ligand B is a crucial advantage for a GPCR target, and the lower DILI risk is a critical safety factor. The longer half-life of Ligand A is valuable, but can be addressed through formulation or prodrug strategies.
Therefore, I prefer Ligand B.
Output:
0
2025-04-17 18:41:09,782 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.435 and 352.41 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (88.67) is significantly better than Ligand A (105.91). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (0.974) is slightly better than Ligand B (0.187). Both are a bit low, potentially hindering membrane permeability, but Ligand A is closer to the optimal 1-3 range.
4. **HBD:** Ligand B (3) is slightly better than Ligand A (4). Both are acceptable.
5. **HBA:** Both ligands have 4 HBA, which is good.
6. **QED:** Ligand B (0.682) is better than Ligand A (0.571), indicating a more drug-like profile.
7. **DILI:** Ligand B (20.396) is *much* better than Ligand A (39.55). This is a significant advantage for Ligand B, as lower DILI risk is crucial.
8. **BBB:** Ligand B (42.846) is better than Ligand A (18.34). While not a primary concern for a cardiovascular target, higher BBB is generally favorable.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-5.874) is slightly better than Ligand B (-5.145), but both are problematic.
10. **Solubility:** Ligand A (-1.919) is slightly better than Ligand B (-1.049), but both are very poor.
11. **hERG:** Ligand A (0.269) is better than Ligand B (0.418), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand B (-35.478) is *much* better than Ligand A (-13.393). This indicates significantly improved metabolic stability for Ligand B.
13. **t1/2:** Ligand A (8.827) is better than Ligand B (-6.957), suggesting a longer half-life.
14. **Pgp:** Both are very low, indicating low P-gp efflux. Ligand A (0.01) is slightly better.
15. **Binding Affinity:** Ligand B (-6.3) is better than Ligand A (-5.1). This is a 1.2 kcal/mol difference, which is substantial and can outweigh some ADME drawbacks.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in affinity and has better TPSA and Pgp. While Ligand A has a slightly better logP, the difference isn't large enough to compensate for the other advantages of Ligand B. The significantly lower DILI and much improved metabolic stability (Cl_mic) of Ligand B are also major benefits.
**Conclusion:**
Despite Ligand A having slightly better solubility, half-life, and hERG, Ligand B's superior binding affinity, lower DILI risk, and improved metabolic stability make it the more promising drug candidate. The affinity difference is significant enough to overcome the slightly lower logP and solubility.
Output:
0
2025-04-17 18:41:09,782 - INFO - Batch 55 complete. Total preferences: 880
2025-04-17 18:41:09,782 - INFO - Processing batch 56/512...
2025-04-17 18:41:59,237 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (372.368 Da and 367.515 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (71.19) is higher than Ligand B (53.09). For a cardiovascular GPCR, TPSA is moderately important. Lower is generally better for permeability, and Ligand B has a clear advantage here.
**3. logP:** Ligand A (2.776) is within the optimal 1-3 range. Ligand B (0.379) is quite low, potentially leading to poor membrane permeability. This is a significant drawback for Ligand B.
**4. H-Bond Donors:** Ligand A (2) and Ligand B (0) are both acceptable, below the threshold of 5.
**5. H-Bond Acceptors:** Ligand A (4) and Ligand B (5) are both acceptable, below the threshold of 10.
**6. QED:** Ligand A (0.848) has a better QED score than Ligand B (0.658), indicating a more drug-like profile.
**7. DILI Risk:** Ligand B (29.43) has a much lower DILI risk than Ligand A (65.413). This is a substantial advantage for Ligand B.
**8. BBB Penetration:** Ligand A (76.347) has better BBB penetration than Ligand B (58.938). While not a primary concern for a cardiovascular target, some CNS off-target effects are always a consideration.
**9. Caco-2 Permeability:** Ligand A (-5.068) has better Caco-2 permeability than Ligand B (-4.502).
**10. Aqueous Solubility:** Ligand A (-4.07) has better solubility than Ligand B (-1.871).
**11. hERG Inhibition:** Ligand A (0.527) has a slightly better hERG profile than Ligand B (0.265), indicating lower cardiotoxicity risk.
**12. Microsomal Clearance:** Ligand B (39.312) has significantly higher microsomal clearance than Ligand A (4.538), suggesting faster metabolism and potentially lower *in vivo* exposure.
**13. In vitro Half-Life:** Ligand A (13.217) has a much longer half-life than Ligand B (1.102). This is a major advantage for Ligand A.
**14. P-gp Efflux:** Ligand A (0.498) has lower P-gp efflux than Ligand B (0.049), which is preferable for bioavailability.
**15. Binding Affinity:** Ligand A (-8.5 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.7 kcal/mol). This 1.8 kcal/mol difference is substantial and can outweigh many ADME drawbacks.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity) and the general drug-like properties, Ligand A is the stronger candidate. While Ligand B has a lower DILI risk, the significantly better affinity of Ligand A, combined with its more favorable logP, QED, solubility, permeability, half-life, and P-gp efflux profile, make it the more promising starting point for drug development. The higher affinity is a critical advantage for a GPCR target.
Output:
1
2025-04-17 18:41:59,237 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, the priorities are logP, TPSA, Pgp, affinity, and to a lesser extent, BBB.
Let's break down the comparison:
1. **MW:** Both ligands (350.419 and 338.459 Da) fall within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (97.6) is slightly higher than Ligand B (88.75). Both are acceptable for a non-CNS GPCR, but B is preferable.
3. **logP:** Ligand B (3.323) is slightly higher than Ligand A (2.541), edging towards the upper limit but still acceptable. Ligand A is more optimal.
4. **HBD/HBA:** Ligand A (1 HBD, 6 HBA) is better than Ligand B (3 HBD, 6 HBA). Fewer HBDs are generally preferred for permeability.
5. **QED:** Ligand B (0.505) has a slightly better QED score than Ligand A (0.318), indicating a more drug-like profile.
6. **DILI:** Ligand A (51.493) has a lower DILI risk than Ligand B (60.217), which is a significant advantage.
7. **BBB:** Both ligands have reasonably good BBB penetration (A: 73.866, B: 71.656), but this isn't a primary concern for a cardiovascular target.
8. **Caco-2:** Ligand B (-5.525) has a slightly better Caco-2 permeability than Ligand A (-4.741).
9. **Solubility:** Ligand B (-2.957) has slightly better solubility than Ligand A (-2.292).
10. **hERG:** Both ligands have low hERG risk (A: 0.617, B: 0.885).
11. **Cl_mic:** Ligand B (60.677) has a lower microsomal clearance than Ligand A (82.76), suggesting better metabolic stability.
12. **t1/2:** Ligand B (15.052) has a longer in vitro half-life than Ligand A (11.681), which is desirable.
13. **Pgp:** Ligand A (0.116) has a lower P-gp efflux liability than Ligand B (0.262), which is a positive.
14. **Affinity:** Ligand A (-7.5 kcal/mol) has a significantly better binding affinity than Ligand B (-6.1 kcal/mol). This 1.4 kcal/mol difference is substantial and can outweigh some of the ADME drawbacks of Ligand A.
**Overall Assessment:**
Ligand A's superior binding affinity is the most critical factor. The difference in affinity is large enough to compensate for its slightly less favorable TPSA, QED, and Cl_mic values. Ligand B has better ADME properties overall, but the potency advantage of A is more important for a GPCR target.
**Output:**
1
2025-04-17 18:41:59,237 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (345.403) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (102.16) is better than Ligand B (117.67), being closer to the <140 threshold for good oral absorption.
3. **logP:** Both ligands have acceptable logP values (A: 1.272, B: 1.812) falling within the 1-3 range.
4. **HBD:** Ligand A (2) is preferable to Ligand B (3) as lower HBD generally improves permeability.
5. **HBA:** Ligand A (8) is better than Ligand B (4), being closer to the ideal <10.
6. **QED:** Both ligands have similar QED values (A: 0.787, B: 0.724), indicating good drug-likeness.
7. **DILI:** Ligand A (56.572) has a significantly lower DILI risk than Ligand B (73.517), which is a major advantage.
8. **BBB:** Both ligands have moderate BBB penetration (A: 48.352, B: 57.736). Since ADRB2 is a cardiovascular target, BBB penetration isn't a primary concern, but lower is preferred to avoid off-target effects.
9. **Caco-2:** Ligand A (-4.894) is better than Ligand B (-5.307), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-2.094) is better than Ligand B (-3.367), indicating better aqueous solubility.
11. **hERG:** Both ligands have very low hERG inhibition risk (A: 0.092, B: 0.162).
12. **Cl_mic:** Ligand A (6.877) has significantly lower microsomal clearance than Ligand B (18.028), suggesting better metabolic stability.
13. **t1/2:** Ligand B (69.821) has a much longer in vitro half-life than Ligand A (-1.589), which is a significant advantage.
14. **Pgp:** Both ligands have low P-gp efflux liability (A: 0.019, B: 0.035).
15. **Binding Affinity:** Both ligands have very similar binding affinities (A: -6.9 kcal/mol, B: -6.0 kcal/mol). Ligand A has a 0.9 kcal/mol advantage, which is substantial.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Both ligands perform reasonably well on logP and Pgp. Ligand A clearly wins on TPSA and has a better binding affinity. The significantly lower DILI and Cl_mic for Ligand A are also very important. While Ligand B has a better half-life, the other advantages of Ligand A outweigh this.
**Conclusion:**
Ligand A is the more promising candidate due to its superior DILI profile, metabolic stability, TPSA, and binding affinity, despite Ligand B's slightly longer half-life.
Output:
1
2025-04-17 18:41:59,238 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (343.471 and 354.491 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (71.09) is better than Ligand B (78.87). Both are below 140, but lower TPSA generally favors absorption.
3. **logP:** Ligand B (1.562) is slightly lower than Ligand A (2.461), both are within the optimal 1-3 range.
4. **HBD:** Both ligands have 2 H-bond donors, which is acceptable.
5. **HBA:** Ligand B (4) has one more H-bond acceptor than Ligand A (3). Both are within the acceptable range.
6. **QED:** Both ligands have good QED scores (0.677 and 0.727), indicating good drug-like properties.
7. **DILI:** Ligand B (7.871) has a significantly lower DILI risk than Ligand A (18.728). This is a major advantage for Ligand B.
8. **BBB:** Ligand B (73.75) has a better BBB penetration percentile than Ligand A (61.923). While ADRB2 isn't strictly a CNS target, some CNS exposure can occur, and better BBB penetration is generally favorable.
9. **Caco-2:** Ligand A (-4.987) has a slightly better Caco-2 permeability than Ligand B (-4.46), indicating potentially better intestinal absorption.
10. **Solubility:** Ligand A (-2.484) has slightly better solubility than Ligand B (-2.601).
11. **hERG:** Both ligands have very low hERG inhibition liability (0.253 and 0.4), which is excellent.
12. **Cl_mic:** Ligand B (32.334) has a lower microsomal clearance than Ligand A (47.598), suggesting better metabolic stability.
13. **t1/2:** Ligand B (3.333) has a slightly longer in vitro half-life than Ligand A (-27.009).
14. **Pgp:** Ligand B (0.02) has significantly lower P-gp efflux liability than Ligand A (0.148), which is a substantial advantage for bioavailability.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.1 and -6.3 kcal/mol). The difference is negligible.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Ligand B performs better on logP, TPSA, and significantly better on Pgp. Affinity is nearly identical.
**Overall Assessment:**
While Ligand A has slightly better Caco-2 and solubility, Ligand B demonstrates a superior safety profile (DILI), better BBB penetration, improved metabolic stability (Cl_mic), longer half-life, and significantly reduced P-gp efflux. These advantages collectively outweigh the minor differences in absorption and solubility.
Output:
0
2025-04-17 18:41:59,238 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (369.893 Da) is slightly higher than Ligand B (347.423 Da), but both are acceptable.
2. **TPSA:** Ligand A (87.3) is better than Ligand B (97.94). Both are below 140, which is good for oral absorption, but lower is preferred for GPCRs.
3. **logP:** Ligand A (1.836) is better than Ligand B (0.791). Both are within the optimal range (1-3), but Ligand A is closer to the center of the range.
4. **HBD:** Ligand A (3) is higher than Ligand B (1). Both are acceptable (<=5).
5. **HBA:** Ligand A (3) is lower than Ligand B (7). Ligand B is approaching the upper limit of acceptable HBA.
6. **QED:** Both ligands have good QED scores (Ligand A: 0.61, Ligand B: 0.833). Ligand B is slightly better.
7. **DILI:** Ligand A (21.946) is significantly better than Ligand B (57.387). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (59.093) is better than Ligand B (54.091), though neither is exceptionally high. For a cardiovascular target like ADRB2, BBB penetration isn't a primary concern, but it's still a slight advantage for A.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.07 and -4.96). This is unusual and suggests poor permeability.
10. **Solubility:** Ligand A (-3.088) is better than Ligand B (-1.383), indicating better aqueous solubility.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.1 and 0.108). This is excellent.
12. **Cl_mic:** Ligand A (47.774) is higher than Ligand B (35.551), meaning it has faster metabolic clearance. Ligand B is preferred here.
13. **t1/2:** Ligand A (17.609) and Ligand B (18.758) are similar.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.017 and 0.026). This is excellent.
15. **Binding Affinity:** Ligand B (-7.2 kcal/mol) is significantly better than Ligand A (-6.1 kcal/mol). This is a substantial advantage that can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand B has a significantly better binding affinity, which is the most important factor for GPCRs. It also has a better QED and lower microsomal clearance. However, Ligand A has a much lower DILI risk, better TPSA, logP, solubility, and slightly better BBB penetration. The negative Caco-2 values for both are concerning, but the superior binding affinity of Ligand B is a strong driver. The DILI risk of Ligand A is very attractive, but the 1.1 kcal/mol difference in binding affinity is substantial. Given the importance of potency for GPCRs, and the acceptable (though not ideal) ADME profile of Ligand B, I favor Ligand B.
Output:
0
2025-04-17 18:41:59,238 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (361.83 and 353.42 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (77.29) is significantly better than Ligand B (116.05). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (4.201) is higher than Ligand B (-1.029). While 4.201 is approaching the upper limit, it's still acceptable. Ligand B's logP is quite low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (4). Similar to HBD, lower HBA is generally better.
6. **QED:** Both ligands have good QED scores (0.59 and 0.657), indicating generally drug-like properties. No clear advantage.
7. **DILI:** Ligand B (25.824) has a much lower DILI risk than Ligand A (53.548). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (69.794) has better BBB penetration than Ligand B (54.13). While not a primary concern for a cardiovascular target, it's a slight advantage.
9. **Caco-2:** Ligand A (-4.658) is better than Ligand B (-5.373). Higher (less negative) Caco-2 values indicate better permeability.
10. **Solubility:** Ligand A (-4.803) is better than Ligand B (-1.153). Higher (less negative) solubility values are preferred.
11. **hERG:** Ligand A (0.579) has a lower hERG risk than Ligand B (0.058). This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand B (-16.44) has significantly lower microsomal clearance than Ligand A (35.169), indicating better metabolic stability. This is a major advantage for Ligand B.
13. **t1/2:** Ligand A (25.161) has a much longer in vitro half-life than Ligand B (1.782). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.412) has lower P-gp efflux than Ligand B (0.002). Lower efflux is preferred.
15. **Affinity:** Ligand A (-6.9 kcal/mol) has a slightly better binding affinity than Ligand B (-6.3 kcal/mol). This 1.5 kcal/mol difference is significant.
**Overall Assessment:**
Ligand A has a better binding affinity, better permeability (Caco-2), solubility, and a longer half-life. However, Ligand B demonstrates a significantly lower DILI risk and improved metabolic stability (lower Cl_mic). The affinity difference is important, but the DILI and metabolic stability are critical factors. Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity), Ligand A's better logP, Pgp, and affinity are appealing. However, the lower DILI risk of Ligand B is a substantial advantage. Given the cardiovascular context, metabolic stability and minimizing toxicity (DILI) are paramount.
Therefore, I lean towards Ligand B.
Output:
0
2025-04-17 18:41:59,238 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (355.435 and 353.463 Da) are within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand B (71.11) is significantly better than Ligand A (116.76). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (-0.044) is slightly better than Ligand A (-0.546), both are within the optimal range of 1-3, but closer to the lower end.
4. **HBD:** Ligand B (1) is better than Ligand A (4). Fewer HBDs generally improve permeability.
5. **HBA:** Both ligands have 5 HBA, which is acceptable.
6. **QED:** Ligand A (0.51) is slightly better than Ligand B (0.465), both are above the 0.5 threshold.
7. **DILI:** Ligand B (16.44) is *much* better than Ligand A (33.23). This is a significant advantage for Ligand B, as lower DILI risk is crucial.
8. **BBB:** Ligand B (51.183) is better than Ligand A (32.765), but neither is particularly high. Since ADRB2 is a cardiovascular target, BBB penetration is not a primary concern.
9. **Caco-2:** Ligand B (-4.805) is better than Ligand A (-5.524), indicating better intestinal absorption.
10. **Solubility:** Ligand B (-0.984) is better than Ligand A (-1.44), indicating better aqueous solubility.
11. **hERG:** Ligand B (0.186) is better than Ligand A (0.088), indicating lower hERG inhibition liability.
12. **Cl_mic:** Ligand A (-11.494) is *much* better than Ligand B (18.743). Lower clearance indicates greater metabolic stability, a significant advantage for Ligand A.
13. **t1/2:** Ligand A (2.484) is better than Ligand B (-2.081). A longer half-life is generally preferred.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.014 and 0.01, respectively).
15. **Binding Affinity:** Ligand A (-6.7) is slightly better than Ligand B (-6.0), but the difference is relatively small (0.7 kcal/mol).
**GPCR-Specific Priorities & Overall Assessment:**
For a GPCR like ADRB2, logP, TPSA, and affinity are important. Ligand B has better logP and TPSA. However, Ligand A has a slightly better binding affinity. The *major* differentiating factors are DILI and metabolic stability (Cl_mic). Ligand B has a significantly lower DILI risk, which is a critical safety parameter. Ligand A has a much better Cl_mic, indicating better metabolic stability. The better DILI profile of Ligand B outweighs the slightly better metabolic stability of Ligand A. The small difference in binding affinity is not enough to overcome the safety advantage of Ligand B.
**Output:**
0
2025-04-17 18:41:59,238 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (405.296 and 381.885 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (57.7) is better than Ligand B (71.53). Both are below 140, but lower TPSA generally favors absorption.
3. **logP:** Both ligands have good logP values (3.595 and 2.253), within the optimal 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability, but not excessively high.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 4 HBA, while Ligand B has 5. Both are acceptable, below the threshold of 10.
6. **QED:** Both ligands have similar QED values (0.848 and 0.812), indicating good drug-likeness.
7. **DILI:** Ligand A (77.472) has a slightly higher DILI risk than Ligand B (61.031), but both are below the concerning threshold of 60.
8. **BBB:** Ligand B (79.604) has a better BBB penetration score than Ligand A (63.164). While ADRB2 isn't strictly a CNS target, some peripheral ADRB2 receptors can be affected by CNS penetration, and a higher BBB score is generally favorable.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.722 and -4.964), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Both ligands have negative solubility values (-3.943 and -3.473), indicating very poor aqueous solubility. This is a major drawback for both.
11. **hERG:** Ligand A (0.744) has a slightly higher hERG risk than Ligand B (0.335). Lower is better, so Ligand B is preferable here.
12. **Cl_mic:** Ligand B (21.256) has a significantly lower microsomal clearance than Ligand A (43.078), indicating better metabolic stability. This is a key advantage for Ligand B.
13. **t1/2:** Ligand A (15.509) has a longer in vitro half-life than Ligand B (0.271). This is a positive for Ligand A.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.244 and 0.274), which is good.
15. **Binding Affinity:** Ligand B (-7.5 kcal/mol) has a slightly better binding affinity than Ligand A (-7.3 kcal/mol). While the difference is small, it's enough to potentially outweigh some other drawbacks.
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Ligand B is better on logP, Pgp, and affinity. Ligand A is better on TPSA. The poor Caco-2 and solubility for both are concerning, but the improved metabolic stability (lower Cl_mic) of Ligand B is a significant advantage.
**Overall Assessment:**
Despite the slightly better half-life of Ligand A, Ligand B is the more promising candidate. Its superior binding affinity, lower DILI risk, better BBB penetration, and significantly improved metabolic stability outweigh the slight disadvantage in half-life and TPSA. The poor solubility and permeability are major issues for both, but can be addressed with formulation strategies.
Output:
0
2025-04-17 18:41:59,239 - INFO - Here's my reasoning and the final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, priorities are logP, TPSA, Pgp, affinity, and to a lesser extent, BBB.
* **Molecular Weight:** Both ligands (344.46 and 362.42 Da) are within the ideal 200-500 Da range.
* **TPSA:** Ligand A (75.19) is significantly better than Ligand B (134.19). A TPSA under 140 is good for oral absorption, but lower is generally preferred for GPCRs, and A is much closer to the ideal range.
* **logP:** Ligand A (2.415) is optimal (1-3). Ligand B (-1.047) is too low, potentially hindering permeability.
* **H-Bond Donors/Acceptors:** Ligand B has more HBDs (4 vs 1) and HBAs (7 vs 4). While not critical, fewer H-bonds can improve permeability.
* **QED:** Ligand A (0.851) is excellent, indicating high drug-likeness. Ligand B (0.364) is considerably lower, raising concerns.
* **DILI:** Both have acceptable DILI risk (A: 43.43, B: 32.18). B is slightly better.
* **BBB:** Ligand A (63.16) is better than Ligand B (23.42), though neither are particularly high. Since this is a cardiovascular target, BBB isn't a *major* concern, but it's still a positive for A.
* **Caco-2:** Ligand A (-4.84) is better than Ligand B (-5.528).
* **Solubility:** Ligand A (-3.541) is better than Ligand B (-1.36).
* **hERG:** Both ligands have very low hERG risk (0.141 and 0.153).
* **Cl_mic:** Ligand A (26.97) has significantly lower microsomal clearance than Ligand B (67.62), indicating better metabolic stability.
* **t1/2:** Ligand B (-19.32) has a much longer in vitro half-life than Ligand A (-7.278). This is a strong point for B.
* **Pgp:** Both ligands have very low P-gp efflux liability (0.12 and 0.042).
* **Binding Affinity:** Ligand B (-7.8) has a slightly better binding affinity than Ligand A (-5.9), a difference of 1.9 kcal/mol. This is a significant advantage.
**Overall Assessment:**
Ligand B has a superior binding affinity and longer half-life, which are both important. However, Ligand A excels in several crucial ADME properties (TPSA, logP, QED, solubility, and metabolic stability) that are particularly important for GPCRs. The significantly better logP and TPSA of Ligand A suggest it will have better permeability and absorption. The QED score is also a strong indicator of overall drug-likeness. While the affinity difference is notable, the ADME advantages of Ligand A are more compelling for a cardiovascular GPCR target, where achieving adequate systemic exposure is critical.
**Output:**
1
2025-04-17 18:41:59,239 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (363.483 Da and 372.487 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (95.08) is slightly higher than Ligand B (84.94). Both are below the 140 threshold for good oral absorption, but closer to the 90 threshold for CNS targets. Ligand B is preferable.
3. **logP:** Ligand A (2.222) is within the optimal 1-3 range. Ligand B (0.815) is slightly below 1, which *could* indicate potential permeability issues, though not drastically. Ligand A is preferable.
4. **HBD:** Ligand A (3) and Ligand B (1) both meet the <=5 criteria. Ligand B is preferable due to lower HBD.
5. **HBA:** Ligand A (5) and Ligand B (6) both meet the <=10 criteria. Ligand A is preferable.
6. **QED:** Both ligands have similar QED values (0.703 and 0.719), indicating good drug-likeness. No clear advantage.
7. **DILI:** Ligand B (46.452) has a significantly lower DILI risk than Ligand A (54.207). This is a substantial advantage for Ligand B.
8. **BBB:** Both ligands have similar BBB penetration (52.889 and 46.452). Since ADRB2 is a cardiovascular target, BBB penetration is not a high priority. No clear advantage.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual. However, the magnitude is similar (-5.573 vs -4.988).
10. **Solubility:** Both ligands have negative solubility values, which is also unusual. The magnitude is similar (-2.882 vs -2.502).
11. **hERG:** Ligand A (0.557) has a slightly higher hERG inhibition liability than Ligand B (0.121). Ligand B is preferable.
12. **Cl_mic:** Ligand B (68.342) has a significantly higher microsomal clearance than Ligand A (21.727), indicating lower metabolic stability. Ligand A is preferable.
13. **t1/2:** Ligand A (26.179) has a much longer in vitro half-life than Ligand B (-5.167). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.402) has a lower P-gp efflux liability than Ligand B (0.039). Ligand A is preferable.
15. **Affinity:** Ligand A (-7.6 kcal/mol) has a slightly better binding affinity than Ligand B (-7.1 kcal/mol). While the difference is less than the 1.5 kcal/mol threshold, it contributes to the overall preference.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity), and the general guidelines, Ligand A appears to be a more promising candidate. While Ligand B has a lower DILI risk and slightly better TPSA, Ligand A has superior metabolic stability (lower Cl_mic, longer t1/2), better Pgp properties, and slightly better binding affinity. The difference in affinity, while not huge, combined with the metabolic advantages, outweighs the DILI benefit of Ligand B.
Output:
1
2025-04-17 18:41:59,239 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (365.327 Da and 350.467 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (71.53) is better than Ligand B (82.62). For a cardiovascular GPCR, TPSA under 140 is acceptable, but lower is preferred for good absorption.
**3. logP:** Ligand A (1.686) is better than Ligand B (0.492). Both are within the 1-3 range, but Ligand B is a bit low, potentially impacting permeability.
**4. H-Bond Donors:** Ligand A (1) is better than Ligand B (2). Lower HBD generally improves permeability.
**5. H-Bond Acceptors:** Ligand A (4) is better than Ligand B (7). Lower HBA is also generally preferred for permeability.
**6. QED:** Both ligands have good QED values (0.562 and 0.627), indicating good drug-like properties.
**7. DILI:** Ligand B (36.487) is significantly better than Ligand A (43.971) in terms of DILI risk. Lower is better, and both are below the concerning threshold of 60.
**8. BBB:** Ligand A (90.345) is better than Ligand B (71.966). While not a CNS target, some degree of BBB penetration can be indicative of favorable permeability characteristics.
**9. Caco-2 Permeability:** Ligand A (-4.739) is better than Ligand B (-5.126). Higher values indicate better permeability.
**10. Aqueous Solubility:** Ligand A (-2.234) is better than Ligand B (-1.003). Higher solubility is generally desirable.
**11. hERG Inhibition:** Both ligands have similar hERG inhibition liability (0.605 and 0.694), and are at acceptable levels.
**12. Microsomal Clearance:** Ligand B (23.895) is significantly better than Ligand A (49.464). Lower clearance indicates better metabolic stability, a crucial factor for drug duration.
**13. In vitro Half-Life:** Ligand B (1.499) is better than Ligand A (-9.437). A longer half-life is generally preferred.
**14. P-gp Efflux:** Both ligands have similar P-gp efflux liability (0.087 and 0.012).
**15. Binding Affinity:** Ligand A (-6.9 kcal/mol) is better than Ligand B (-5.9 kcal/mol). This is a substantial difference in binding affinity (1.0 kcal/mol), which is a major advantage.
**Overall Assessment:**
Ligand A has a significantly better binding affinity, better TPSA, logP, H-bond donor/acceptor counts, Caco-2 permeability and solubility. Ligand B has a better DILI score and metabolic stability. However, the substantial advantage in binding affinity for Ligand A outweighs the slightly better metabolic profile of Ligand B. For a GPCR, binding affinity is paramount, and a 1.0 kcal/mol difference is significant. The other ADME properties of Ligand A are also generally favorable.
Output:
1
2025-04-17 18:41:59,239 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (338.411 and 363.571 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand B (40.77) is significantly better than Ligand A (72.09). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (4.627 and 4.431), falling within the 1-3 range. Ligand B is slightly better.
4. **HBD:** Ligand A has 2 HBD, while Ligand B has 1. Both are acceptable.
5. **HBA:** Ligand A has 4 HBA, Ligand B has 5. Both are acceptable.
6. **QED:** Both ligands have good QED scores (0.728 and 0.791), indicating drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (73.517) has a significantly higher DILI risk than Ligand B (18.922). This is a major concern for Ligand A.
8. **BBB:** Both ligands have reasonable BBB penetration (82.358 and 88.6). Not a primary concern for a cardiovascular target.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.834 and -4.944), which is unusual and indicates poor permeability. This is a significant drawback for both.
10. **Solubility:** Ligand A (-5.566) has slightly better solubility than Ligand B (-3.644), but both are poor.
11. **hERG:** Ligand A (0.427) has a slightly better hERG profile than Ligand B (0.93), but both are acceptable.
12. **Cl_mic:** Both ligands have similar microsomal clearance (64.043 and 62.499).
13. **t1/2:** Ligand A (120.517) has a much longer in vitro half-life than Ligand B (33.9). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.217) has lower P-gp efflux than Ligand B (0.867), which is preferable.
15. **Binding Affinity:** Both ligands have excellent binding affinities (-5.5 and -4.9 kcal/mol). Ligand A is slightly better.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand B excels in TPSA and has comparable logP and affinity. However, the significantly lower DILI risk and lower Pgp efflux of Ligand A, combined with its slightly better affinity and longer half-life, outweigh the TPSA advantage of Ligand B. The poor Caco-2 values are concerning for both, but can be addressed with formulation strategies.
**Conclusion:**
Considering the balance of properties, especially the lower DILI risk and better Pgp profile of Ligand A, I believe it is the more promising drug candidate.
Output:
1
2025-04-17 18:41:59,239 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [352.435, 87.78, -0.195, 1, 6, 0.795, 21.326, 46.917, -4.674, -0.37, 0.387, 3.917, -15.041, 0.06, -5.5]
**Ligand B:** [349.387, 88.18, -0.109, 1, 5, 0.703, 42.536, 47.111, -4.467, -1.857, 0.085, -23.537, -25.726, 0.006, -6.9]
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). A is 352.435, B is 349.387. Very similar.
2. **TPSA:** Both are good, below 140, at 87.78 and 88.18. Acceptable for oral absorption.
3. **logP:** Both are within the optimal range (1-3) at -0.195 and -0.109. A is slightly lower, which could be a minor concern for permeability, but still reasonable.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** A has 6, B has 5. Both are acceptable, below the 10 threshold.
6. **QED:** Both are good, above 0.5 (0.795 and 0.703).
7. **DILI:** A has a DILI risk of 21.326, B has 42.536. A is significantly better here, indicating a lower risk of liver injury. This is a substantial advantage.
8. **BBB:** Both have relatively low BBB penetration (46.917 and 47.111). Since this is a cardiovascular target and not a CNS target, this isn't a major concern, but it's not a positive.
9. **Caco-2:** Both have negative values (-4.674 and -4.467) which is unusual. Assuming these are percentile scores, lower is worse. B is slightly better.
10. **Solubility:** A is -0.37, B is -1.857. A has better solubility.
11. **hERG:** Both are very low (0.387 and 0.085), indicating low cardiotoxicity risk. B is slightly better.
12. **Cl_mic:** A is 3.917, B is -23.537. B has a much lower (and therefore better) microsomal clearance, suggesting greater metabolic stability. This is a significant advantage.
13. **t1/2:** A is -15.041, B is -25.726. B has a longer in vitro half-life, which is desirable. Another significant advantage.
14. **Pgp:** Both are very low (0.06 and 0.006), indicating low P-gp efflux. B is slightly better.
15. **Affinity:** A is -5.5 kcal/mol, B is -6.9 kcal/mol. B has a significantly stronger binding affinity (1.4 kcal/mol difference). This is a major advantage that can outweigh some ADME concerns.
**GPCR-specific priorities:** For ADRB2 (a cardiovascular GPCR), we prioritize logP, Pgp, TPSA, and affinity. Both ligands are good on logP, Pgp, and TPSA. The key differentiators are affinity and metabolic stability.
**Overall Assessment:**
Ligand B has a substantially better binding affinity (-6.9 vs -5.5 kcal/mol) and significantly improved metabolic stability (lower Cl_mic, longer t1/2). While Ligand A has a lower DILI risk and better solubility, the potency and metabolic stability advantages of Ligand B are more critical for a GPCR target, especially considering the relatively similar profiles in other areas. The 1.4 kcal/mol difference in binding affinity is substantial.
Output:
0
2025-04-17 18:41:59,240 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (366.49 & 349.48 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand B (75.44) is significantly better than Ligand A (93.21). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally correlates with better absorption.
3. **logP:** Both are within the optimal 1-3 range (1.32 & 2.89). Ligand B is slightly higher, potentially aiding membrane permeability.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1), but both are acceptable.
5. **HBA:** Ligand A (6) is higher than Ligand B (4), but both are within the acceptable range of <=10.
6. **QED:** Ligand B (0.857) is better than Ligand A (0.649), indicating a more drug-like profile.
7. **DILI:** Ligand B (34.55%) is better than Ligand A (42.30%), indicating lower potential for liver injury. Both are below the 40% threshold, which is good.
8. **BBB:** Ligand B (85.73%) is much higher than Ligand A (61.61%). While not critical for a cardiovascular target, higher BBB is generally favorable.
9. **Caco-2:** Ligand A (-5.342) and Ligand B (-4.698) are both negative, which is unusual. Lower (more negative) values suggest *poorer* permeability.
10. **Solubility:** Ligand A (-2.224) is slightly better than Ligand B (-2.575), but both are poor. Solubility is a concern for both compounds.
11. **hERG:** Ligand A (0.075%) is significantly better than Ligand B (0.464%), indicating a lower risk of cardiotoxicity. This is a crucial consideration for a cardiovascular target.
12. **Cl_mic:** Ligand A (28.10) is much better than Ligand B (66.71), indicating better metabolic stability.
13. **t1/2:** Ligand B (-28.023) is significantly better than Ligand A (0.168), indicating a longer half-life.
14. **Pgp:** Ligand A (0.008) is significantly better than Ligand B (0.287), indicating lower P-glycoprotein efflux.
15. **Affinity:** Ligand A (-6.8 kcal/mol) is slightly better than Ligand B (-5.6 kcal/mol). This is a 1.2 kcal/mol difference, which is significant.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP, TPSA, and BBB, and has a good half-life. Ligand A has better hERG inhibition, Pgp, and Cl_mic, but its solubility is also poor. The affinity difference is substantial, favoring Ligand A.
**Overall Assessment:**
While Ligand B has better overall ADME properties (QED, DILI, BBB, t1/2), the significantly stronger binding affinity of Ligand A (-6.8 vs -5.6 kcal/mol) and its lower hERG risk are critical advantages, especially for a cardiovascular target. The better metabolic stability (lower Cl_mic) and Pgp efflux also contribute to its potential for better *in vivo* exposure. The solubility is a concern for both, but can be addressed with formulation strategies.
Output:
1
2025-04-17 18:41:59,240 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
The ADRB2 receptor is a GPCR, so the key priorities are logP, TPSA, Pgp efflux, BBB penetration, and binding affinity. Metabolic stability and solubility are also important, but slightly less so than the first set.
Let's break down the comparison:
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand B (349.431 Da) is slightly lower than Ligand A (359.491 Da), but the difference isn't significant.
2. **TPSA:** Ligand A (54.45) is much better than Ligand B (86.88). A TPSA under 140 is good for oral absorption, and Ligand A is comfortably within that range, while Ligand B is approaching the upper limit.
3. **logP:** Ligand A (4.303) is higher than Ligand B (1.158). While a logP of 4.3 is a bit high, it's not drastically so and might be acceptable given strong affinity. Ligand B's logP is quite low, potentially hindering membrane permeability.
4. **H-Bond Donors/Acceptors:** Ligand A (0 HBD, 3 HBA) is better than Ligand B (1 HBD, 5 HBA). Lower counts are generally preferred for better permeability.
5. **QED:** Both ligands have good QED scores (A: 0.693, B: 0.779), indicating reasonable drug-likeness.
6. **DILI:** Ligand A (64.754) has a significantly higher DILI risk than Ligand B (21.908). This is a major concern for Ligand A.
7. **BBB:** Ligand A (59.364) has better BBB penetration than Ligand B (43.815), but neither are particularly high. This isn't a huge priority for ADRB2 (a cardiovascular target), but it's a plus for A.
8. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability.
9. **Solubility:** Ligand A (-5.55) has worse solubility than Ligand B (-0.702). Solubility is important for bioavailability.
10. **hERG:** Ligand A (0.631) has a slightly higher hERG risk than Ligand B (0.064), but both are relatively low.
11. **Cl_mic:** Ligand A (66.396) has higher microsomal clearance than Ligand B (19.811), indicating faster metabolism and potentially lower *in vivo* exposure.
12. **t1/2:** Ligand A (33.427) has a shorter half-life than Ligand B (-18.263).
13. **Pgp:** Ligand A (0.699) has lower P-gp efflux than Ligand B (0.113), which is favorable.
14. **Binding Affinity:** Ligand A (-8.1 kcal/mol) has a significantly stronger binding affinity than Ligand B (-5.9 kcal/mol). This is a substantial advantage (over 2 kcal/mol difference).
**Overall Assessment:**
Ligand A has a much stronger binding affinity, which is a critical factor for GPCRs. However, it suffers from higher DILI risk, poorer solubility, and faster metabolism. Ligand B has better safety (DILI), solubility, and metabolic stability, but its lower logP and weaker affinity are concerning.
Despite the DILI risk, the significantly improved binding affinity of Ligand A is likely to outweigh the other drawbacks, *especially* if further optimization can address the DILI concern. The potency advantage is substantial.
Output:
1
2025-04-17 18:41:59,240 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (351.403 and 347.423 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (91.34) is better than Ligand B (120.24). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally correlates with better absorption. Ligand A is closer to the desirable <140 threshold.
3. **logP:** Ligand A (0.767) is slightly better than Ligand B (-0.384). Both are within the 1-3 range, but Ligand A is closer to the optimal range. Ligand B is bordering on being too hydrophilic.
4. **HBD:** Ligand A (2) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (6). Similar to HBD, lower HBA is generally better for permeability.
6. **QED:** Ligand A (0.818) is significantly better than Ligand B (0.476). A higher QED indicates a more drug-like profile.
7. **DILI:** Ligand B (38.193) is substantially better than Ligand A (66.731). Lower DILI is critical. This is a major advantage for Ligand B.
8. **BBB:** Both ligands have similar BBB penetration (54.866 vs 54.634). This isn't a major factor for a cardiovascular target.
9. **Caco-2:** Ligand B (-5.823) is better than Ligand A (-4.632). Higher Caco-2 permeability suggests better intestinal absorption.
10. **Solubility:** Ligand A (-0.705) is better than Ligand B (-1.884). Better solubility is generally preferred.
11. **hERG:** Ligand A (0.214) is significantly better than Ligand B (0.588). Lower hERG inhibition is crucial to avoid cardiotoxicity, especially for a cardiovascular target.
12. **Cl_mic:** Ligand A (-19.076) is significantly better than Ligand B (-11.655). Lower microsomal clearance indicates better metabolic stability.
13. **t1/2:** Ligand A (-17.49) is better than Ligand B (-20.937). Longer half-life is generally desirable.
14. **Pgp:** Ligand A (0.018) is significantly better than Ligand B (0.003). Lower P-gp efflux is preferable.
15. **Binding Affinity:** Ligand B (-7.3) is slightly better than Ligand A (-6.6). This is a 0.7 kcal/mol difference, which is a meaningful advantage.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B has a slightly better affinity and Caco-2 permeability, but Ligand A has better logP, TPSA, Pgp, QED, solubility, hERG, Cl_mic, and t1/2. The DILI risk for Ligand B is also significantly lower.
**Overall Assessment:**
While Ligand B has a slightly better binding affinity and Caco-2 permeability, the significant advantages of Ligand A in terms of QED, metabolic stability (Cl_mic, t1/2), hERG risk, and Pgp efflux, combined with acceptable TPSA and logP, make it the more promising candidate. The lower DILI risk of Ligand B is attractive, but the other ADME properties of Ligand A are more favorable overall. The affinity difference isn't large enough to overcome these other factors.
Output:
1
2025-04-17 18:41:59,240 - INFO - Batch 56 complete. Total preferences: 896
2025-04-17 18:41:59,240 - INFO - Processing batch 57/512...
2025-04-17 18:42:51,802 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (368.5 and 356.5 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (74.77) is significantly better than Ligand B (102.73). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand A is well below the 140 threshold, while B is approaching it.
**3. logP:** Ligand B (2.32) is slightly higher than Ligand A (1.078), placing it more optimally within the 1-3 range. Ligand A is a bit low, potentially impacting permeability.
**4. H-Bond Donors:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
**5. H-Bond Acceptors:** Ligand B (7) is slightly higher than Ligand A (6). Both are within the acceptable limit of 10, but lower is generally better.
**6. QED:** Both ligands have similar QED values (0.743 and 0.703), indicating good drug-like properties.
**7. DILI:** Ligand A (21.442) has a much lower DILI risk than Ligand B (66.848). This is a significant advantage for Ligand A.
**8. BBB:** Ligand A (68.282) shows better BBB penetration than Ligand B (52.617). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be useful for understanding off-target effects and distribution.
**9. Caco-2 Permeability:** Ligand A (-4.93) shows better Caco-2 permeability than Ligand B (-5.226). This is a slight advantage for Ligand A.
**10. Aqueous Solubility:** Ligand B (-4.493) has better aqueous solubility than Ligand A (-1.005). Solubility is important for formulation, but can be balanced with permeability.
**11. hERG Inhibition:** Ligand A (0.488) has a lower hERG inhibition risk than Ligand B (0.762). This is a crucial safety parameter, favoring Ligand A.
**12. Microsomal Clearance:** Ligand A (-25.846) exhibits significantly lower microsomal clearance than Ligand B (29.951), indicating better metabolic stability.
**13. In vitro Half-Life:** Ligand B (35.02) has a longer in vitro half-life than Ligand A (13.614). This is a positive for Ligand B, potentially allowing for less frequent dosing.
**14. P-gp Efflux:** Ligand A (0.051) shows lower P-gp efflux than Ligand B (0.114), which is favorable for bioavailability.
**15. Binding Affinity:** Both ligands have very similar and strong binding affinities (-6.7 and -6.9 kcal/mol). The difference is negligible.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity) and the general drug-likeness parameters, Ligand A is the more promising candidate. While Ligand B has slightly better logP and in vitro half-life, Ligand A excels in critical areas like TPSA, DILI risk, hERG inhibition, metabolic stability (Cl_mic), and P-gp efflux. The lower DILI and hERG risks are particularly important for cardiovascular targets. The slightly lower logP of Ligand A is a minor drawback that could potentially be addressed through further optimization.
Output:
1
2025-04-17 18:42:51,802 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (359.451 and 348.495 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (75.94) is significantly better than Ligand A (102.22). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (1.557 and 2.044), falling within the optimal 1-3 range. Ligand B is slightly better.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (1). Both are acceptable, but lower is generally preferred.
5. **HBA:** Ligand B (6) is higher than Ligand A (5). Both are within the acceptable range of <=10.
6. **QED:** Both ligands have good QED scores (0.742 and 0.881), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand B (23.575) has a much lower DILI risk than Ligand A (53.509). This is a significant advantage.
8. **BBB:** Ligand B (85.731) has a higher BBB penetration than Ligand A (27.84). While not critical for a cardiovascular target, it's a positive attribute.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.185 and -5.182), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Both ligands have negative solubility values (-3.456 and -2.078), indicating poor aqueous solubility. This is a significant drawback for both.
11. **hERG:** Both ligands have low hERG inhibition liability (0.416 and 0.108), which is excellent. Ligand B is better.
12. **Cl_mic:** Ligand A (1.647) has significantly lower microsomal clearance than Ligand B (26.663), suggesting better metabolic stability. This is a major advantage for Ligand A.
13. **t1/2:** Ligand A (16.838) has a longer in vitro half-life than Ligand B (-10.402). This is a significant advantage for Ligand A.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.064 and 0.045). No clear advantage.
15. **Binding Affinity:** Ligand A (-6.6 kcal/mol) has slightly better binding affinity than Ligand B (-6.2 kcal/mol), but the difference is small.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP, TPSA, and Pgp. Ligand A has a small edge in affinity, but the difference isn't substantial. However, the significantly better DILI score, lower hERG, and higher BBB of Ligand B are very attractive. While metabolic stability (Cl_mic and t1/2) are important, the other advantages of Ligand B outweigh these. The poor Caco-2 and solubility are concerning for both, but can be addressed with formulation strategies.
**Conclusion:**
Considering the balance of properties, particularly the favorable safety profile (DILI, hERG) and better absorption/permeability indicators (TPSA, logP) of Ligand B, I believe it is the more promising drug candidate.
Output:
0
2025-04-17 18:42:51,803 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.406 and 345.487 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (57.0) is significantly better than Ligand B (71.09). ADRB2 is not a CNS target, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (2.793) is slightly higher than Ligand A (1.386), placing it closer to the optimal 1-3 range. Ligand A is still acceptable, but Ligand B has a slight edge.
4. **HBD:** Ligand A (0) is better than Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is slightly higher than Ligand B (3). Both are within the acceptable range of <=10.
6. **QED:** Ligand A (0.81) is better than Ligand B (0.747), indicating a more drug-like profile.
7. **DILI:** Ligand A (15.51) is *much* better than Ligand B (23.032). This is a critical advantage for Ligand A, as low DILI risk is crucial.
8. **BBB:** Not a primary concern for ADRB2 (cardiovascular target), but Ligand A (93.37) is significantly better than Ligand B (58.821).
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-4.558) is slightly better than Ligand B (-4.895).
10. **Solubility:** Both are negative, indicating poor solubility. Ligand A (-2.017) is slightly better than Ligand B (-2.468).
11. **hERG:** Both are very low (0.488 and 0.221), indicating low cardiotoxicity risk. No significant difference.
12. **Cl_mic:** Ligand A (4.371) is *much* better than Ligand B (52.349). Lower clearance is highly desirable for metabolic stability.
13. **t1/2:** Ligand B (13.586) is better than Ligand A (7.716). Longer half-life is generally preferred.
14. **Pgp:** Both are very low (0.062 and 0.035), indicating low P-gp efflux. No significant difference.
15. **Binding Affinity:** Ligand B (-6.6) is slightly better than Ligand A (-6.5), but the difference is small (0.1 kcal/mol).
**GPCR-Specific Priorities & Overall Assessment:**
For a GPCR like ADRB2, logP, TPSA, and affinity are important. Ligand B has a slightly better logP and affinity. However, Ligand A *significantly* outperforms Ligand B in critical ADME-Tox parameters: DILI risk and microsomal clearance. The difference in DILI risk is substantial, and the lower clearance of Ligand A suggests better metabolic stability. While Ligand B has a slightly longer half-life, the other advantages of Ligand A outweigh this. The slightly better TPSA of Ligand A also contributes to its overall favorability.
**Output:**
1
2025-04-17 18:42:51,803 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [351.334, 124.69 , 1.256, 4. , 6. , 0.621, 56.844, 19.542, -5.498, -2.467, 0.422, 15.118, -4.395, 0.046, -7.8 ]
**Ligand B:** [349.475, 69.72 , 1.398, 1. , 3. , 0.834, 16.673, 70.027, -4.733, -1.73 , 0.102, 28.865, -4.22 , 0.01 , -6.4 ]
Here's a breakdown of the comparison, considering the provided guidelines and GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both ligands are within the ideal range (200-500 Da). A is 351.334, B is 349.475 - very similar.
2. **TPSA:** Ligand A (124.69) is slightly higher than Ligand B (69.72). Both are below the 140 threshold for oral absorption, but B is significantly better, especially for potential CNS penetration (though ADRB2 isn't necessarily a CNS target).
3. **logP:** Both ligands have good logP values (A: 1.256, B: 1.398) within the 1-3 range. Very similar.
4. **HBD:** Ligand A (4) is higher than Ligand B (1). Lower HBD is generally preferred for permeability. B is better.
5. **HBA:** Ligand A (6) is higher than Ligand B (3). Again, lower is better. B is better.
6. **QED:** Ligand B (0.834) has a better QED score than Ligand A (0.621), indicating a more drug-like profile.
7. **DILI:** Ligand B (16.673) has a significantly lower DILI risk than Ligand A (56.844). This is a major advantage for B.
8. **BBB:** Ligand B (70.027) has a much higher BBB penetration score than Ligand A (19.542). While not crucial for peripheral ADRB2, it could be beneficial for exploring CNS effects or off-target liabilities.
9. **Caco-2:** Ligand A (-5.498) and B (-4.733) both have negative values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Ligand A (-2.467) and B (-1.73) both have negative values, suggesting poor solubility.
11. **hERG:** Both ligands have very low hERG risk (A: 0.422, B: 0.102). B is slightly better.
12. **Cl_mic:** Ligand A (15.118) has a lower (better) microsomal clearance than Ligand B (28.865), indicating better metabolic stability.
13. **t1/2:** Both ligands have similar in vitro half-lives (A: -4.395, B: -4.22).
14. **Pgp:** Ligand B (0.01) has a much lower Pgp efflux liability than Ligand A (0.046), which is a significant advantage for bioavailability and potential CNS exposure.
15. **Affinity:** Ligand A (-7.8) has a stronger binding affinity than Ligand B (-6.4). This is a 1.4 kcal/mol difference, which is substantial and could outweigh some of the ADME drawbacks of Ligand A.
**Overall Assessment:**
While Ligand A has a better binding affinity, Ligand B demonstrates a significantly superior ADME profile. The lower DILI risk, higher BBB penetration, lower Pgp efflux, and better QED score make it a much more promising starting point for drug development. The lower TPSA and HBD/HBA counts also contribute to its improved drug-like properties. The slightly higher metabolic clearance of B is a minor concern compared to the other advantages. The affinity difference, while notable, isn't so large that it completely overrides the ADME benefits of Ligand B.
Therefore, I would choose Ligand B.
0
2025-04-17 18:42:51,803 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (338.367 and 343.427 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Both ligands have TPSA values around 86, well below the 140 A^2 threshold for oral absorption. This is good for both.
**3. logP:** Both ligands have logP values within the optimal range (2.822 and 2.36). Ligand B is slightly lower, which could be marginally better for solubility, but both are acceptable.
**4. H-Bond Donors:** Both have 1 HBD, which is ideal.
**5. H-Bond Acceptors:** Ligand A has 7 HBA, and Ligand B has 4. Both are within the acceptable range of <=10.
**6. QED:** Ligand B (0.889) has a significantly higher QED score than Ligand A (0.692), indicating a more drug-like profile. This is a positive for Ligand B.
**7. DILI:** Ligand A has a very high DILI risk (91.78%), while Ligand B has a low risk (21.869%). This is a *major* advantage for Ligand B. DILI is a critical safety concern.
**8. BBB:** Ligand B (71.501%) has a better BBB penetration score than Ligand A (61.38%). While ADRB2 is a cardiovascular target, some CNS penetration can be associated with off-target effects, but it's not a primary concern here.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, indicating poor permeability. Ligand A (-4.624) is slightly worse than Ligand B (-4.835).
**10. Aqueous Solubility:** Both ligands have negative solubility values, indicating poor solubility. Ligand B (-2.89) is slightly better than Ligand A (-4.277).
**11. hERG Inhibition:** Both ligands show low hERG inhibition risk (0.64 and 0.559, respectively).
**12. Microsomal Clearance:** Ligand A (109.338) has a higher microsomal clearance than Ligand B (20.517), suggesting lower metabolic stability. This is a significant advantage for Ligand B.
**13. In vitro Half-Life:** Ligand B (18.343 hours) has a much longer in vitro half-life than Ligand A (-1.65 hours). This is a substantial advantage for Ligand B, potentially leading to less frequent dosing.
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (0.084 and 0.08).
**15. Binding Affinity:** Ligand B (-7.3 kcal/mol) has a significantly stronger binding affinity than Ligand A (-4.4 kcal/mol). This is a substantial advantage, and the 2.9 kcal/mol difference is large enough to outweigh some of the ADME drawbacks of Ligand A.
**Overall Assessment:**
Ligand B is the clear winner. While both ligands have some issues with permeability and solubility, Ligand B excels in crucial areas: significantly lower DILI risk, much better metabolic stability (lower Cl_mic, longer t1/2), and substantially stronger binding affinity. The higher QED score further supports its drug-like properties. The slightly better BBB penetration is a minor bonus. The affinity difference is large enough to overcome the permeability/solubility concerns.
Output:
0
2025-04-17 18:42:51,803 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (398.26) is slightly higher than Ligand B (362.459), but both are acceptable.
2. **TPSA:** Ligand A (64.97) is significantly better than Ligand B (93.01). For a GPCR, lower TPSA is generally preferred for better permeability. Ligand B is approaching a level that could hinder oral absorption.
3. **logP:** Ligand A (4.33) is higher than Ligand B (1.312). While both are within the acceptable range, Ligand A is pushing the upper limit and could potentially have solubility issues or off-target effects, but for a GPCR, a higher logP can be beneficial for membrane interactions.
4. **HBD:** Ligand A (0) is better than Ligand B (1). Fewer hydrogen bond donors generally improve permeability.
5. **HBA:** Ligand A (5) is better than Ligand B (7). Fewer hydrogen bond acceptors also contribute to better permeability.
6. **QED:** Ligand B (0.885) has a slightly better QED score than Ligand A (0.612), indicating a more drug-like profile overall.
7. **DILI:** Both ligands have acceptable DILI risk (Ligand A: 75.766, Ligand B: 72.509), with Ligand B being slightly lower.
8. **BBB:** Ligand A (87.67) has a significantly better BBB penetration percentile than Ligand B (56.65). This is a crucial factor for GPCRs, even if not CNS-focused, as it can influence distribution and off-target effects.
9. **Caco-2:** Ligand A (-4.791) is better than Ligand B (-5.182), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-4.425) is better than Ligand B (-2.578), indicating better aqueous solubility.
11. **hERG:** Both ligands have very low hERG inhibition risk (Ligand A: 0.305, Ligand B: 0.205), which is excellent.
12. **Cl_mic:** Ligand B (55.197) has a significantly lower microsomal clearance than Ligand A (102.599), suggesting better metabolic stability.
13. **t1/2:** Ligand A (14.197) has a longer in vitro half-life than Ligand B (0.314), which is desirable.
14. **Pgp:** Both ligands have low P-gp efflux liability (Ligand A: 0.285, Ligand B: 0.093), with Ligand B being slightly better.
15. **Binding Affinity:** Ligand A (-6.5) has a slightly better binding affinity than Ligand B (-6.0). While the difference is not huge, it's still a positive factor.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, and affinity. Ligand A excels in TPSA, has a reasonable logP, good Pgp, and slightly better affinity. Ligand B has a lower logP and better metabolic stability (Cl_mic), but its higher TPSA and lower BBB penetration are concerning. The slightly better QED of Ligand B is offset by the other factors.
**Conclusion:**
Considering the balance of properties, particularly the favorable TPSA, BBB, solubility, and affinity of Ligand A, it is the more promising drug candidate for the ADRB2 receptor.
Output:
1
2025-04-17 18:42:51,803 - INFO - Here's my reasoning and final output for the ligand preference:
**Reasoning:**
We are targeting ADRB2, a GPCR, so the priorities are logP, Pgp, TPSA, affinity, and BBB. Let's break down the comparison:
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (404.26) is slightly higher than Ligand B (350.463), but both are acceptable.
2. **TPSA:** Ligand A (59) is significantly better than Ligand B (87.32). A TPSA under 140 is good for oral absorption, but lower is better for GPCRs, and Ligand A is closer to the ideal range for CNS penetration, even though that's not a primary goal here.
3. **logP:** Both ligands have good logP values (A: 3.053, B: 2.376) falling within the 1-3 range. Ligand A is slightly higher, which *could* be a minor concern, but not a dealbreaker.
4. **H-Bond Donors/Acceptors:** Ligand A (HBD=1, HBA=4) is slightly better than Ligand B (HBD=2, HBA=4). Both are within acceptable limits.
5. **QED:** Ligand A (0.836) has a better QED score than Ligand B (0.669), indicating a more drug-like profile.
6. **DILI:** Ligand B (47.15) has a lower DILI risk than Ligand A (55.293), which is a positive for Ligand B.
7. **BBB:** Ligand A (66.305) has a significantly better BBB percentile than Ligand B (36.293). While not a primary target, higher BBB is generally favorable.
8. **Caco-2:** Both have negative values, indicating poor permeability. Ligand A (-5.1) is slightly better than Ligand B (-4.634), but both are concerning.
9. **Solubility:** Both have negative solubility values, indicating poor solubility. Ligand A (-4.053) is slightly better than Ligand B (-3.146).
10. **hERG:** Ligand A (0.773) has a lower hERG risk than Ligand B (0.176), which is a significant advantage.
11. **Cl_mic:** Ligand B (42.466) has a lower microsomal clearance than Ligand A (81.022), indicating better metabolic stability.
12. **t1/2:** Ligand A (40.65) has a much longer in vitro half-life than Ligand B (-18.415). This is a major advantage for Ligand A.
13. **Pgp:** Ligand A (0.702) has lower P-gp efflux than Ligand B (0.166), which is favorable.
14. **Binding Affinity:** Ligand A (-6.8 kcal/mol) has a slightly better binding affinity than Ligand B (-6.4 kcal/mol). While the difference is not huge, it's enough to consider.
**Overall Assessment:**
Ligand A is the stronger candidate. While Ligand B has a lower DILI risk and better metabolic stability, Ligand A excels in critical areas for a GPCR target: TPSA, QED, hERG, Pgp efflux, and in vitro half-life. The slightly better binding affinity of Ligand A further strengthens its position. The solubility and Caco-2 permeability are poor for both, but can be addressed through formulation strategies.
Output:
1
2025-04-17 18:42:51,803 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (345.443 and 355.479 Da). No clear advantage.
2. **TPSA:** Ligand A (76.38) is better than Ligand B (82.11). Both are acceptable for a non-CNS GPCR, but lower is generally preferred.
3. **logP:** Ligand A (3.236) is optimal, while Ligand B (0.364) is quite low. This is a significant difference; low logP can hinder membrane permeability.
4. **HBD:** Both have 2 HBD, which is within the acceptable range.
5. **HBA:** Ligand A (6) is slightly higher than Ligand B (5), but both are acceptable.
6. **QED:** Both ligands have good QED scores (0.754 and 0.689), indicating good drug-like properties.
7. **DILI:** Ligand A (32.377) has a much lower DILI risk than Ligand B (5.196). This is a major advantage for Ligand A.
8. **BBB:** Not a primary concern for a cardiovascular target like ADRB2, but Ligand A (57.619) is better than Ligand B (21.52).
9. **Caco-2:** Ligand A (-4.846) is better than Ligand B (-5.067), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-2.991) is better than Ligand B (-0.113). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.65) is better than Ligand B (0.096), indicating a lower risk of cardiotoxicity.
12. **Cl_mic:** Ligand A (41.113) is higher than Ligand B (-0.692), meaning Ligand B has better metabolic stability. This is a positive for Ligand B.
13. **t1/2:** Ligand A (56.311) has a longer in vitro half-life than Ligand B (4.61). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.165) is better than Ligand B (0.012), indicating lower P-gp efflux.
15. **Binding Affinity:** Ligand B (-6.1) has a slightly better binding affinity than Ligand A (-6.8). However, the difference is less than 1.5 kcal/mol, and can be overcome by other factors.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A performs better on logP, TPSA and Pgp. The affinity difference is small.
**Overall Assessment:**
Ligand A has a significantly better ADME profile than Ligand B, with lower DILI risk, better solubility, better hERG profile, longer half-life, and better Pgp efflux. While Ligand B has slightly better affinity and metabolic stability, the overall balance of properties favors Ligand A. The low logP of Ligand B is a major concern for permeability.
Output:
1
2025-04-17 18:42:51,803 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (370.431 Da) is slightly higher than Ligand B (337.423 Da), but both are acceptable.
**2. TPSA:** Ligand A (132.46) is close to the upper limit for good oral absorption, while Ligand B (62.61) is well below, which is favorable.
**3. logP:** Ligand A (-0.802) is a bit low, potentially hindering permeation. Ligand B (2.366) is within the optimal range (1-3). This is a significant advantage for Ligand B.
**4. H-Bond Donors:** Ligand A (3) and Ligand B (2) are both within the acceptable limit of 5.
**5. H-Bond Acceptors:** Ligand A (6) and Ligand B (3) are both within the acceptable limit of 10.
**6. QED:** Ligand B (0.845) has a significantly higher QED score than Ligand A (0.575), indicating a more drug-like profile.
**7. DILI:** Ligand A (78.325) has a higher DILI risk than Ligand B (58.55), though both are reasonably acceptable.
**8. BBB:** Ligand B (64.211) has a better BBB penetration percentile than Ligand A (27.763). While ADRB2 is a cardiovascular target and CNS penetration isn't *essential*, some level of BBB penetration can be beneficial for off-target effects assessment and potential broader applications.
**9. Caco-2 Permeability:** Ligand A (-5.73) and Ligand B (-4.545) are both negative, which is unusual and suggests poor permeability. However, the scale isn't specified, so it's hard to interpret.
**10. Aqueous Solubility:** Ligand A (-2.196) and Ligand B (-3.272) are both negative, suggesting poor solubility. This is a concern for both compounds.
**11. hERG Inhibition:** Ligand A (0.062) has a slightly lower hERG risk than Ligand B (0.316), which is good.
**12. Microsomal Clearance:** Ligand A (-12.316) has a much lower (better) microsomal clearance than Ligand B (4.724), indicating greater metabolic stability.
**13. In vitro Half-Life:** Ligand B (33.974) has a significantly longer in vitro half-life than Ligand A (14.083). This is a major advantage for Ligand B.
**14. P-gp Efflux:** Ligand A (0.012) has a much lower P-gp efflux liability than Ligand B (0.101), which is favorable.
**15. Binding Affinity:** Ligand B (-7.0) has a slightly better binding affinity than Ligand A (-5.7). This difference is significant enough to potentially outweigh some of the ADME drawbacks of Ligand B.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand B is the stronger candidate. It has a better logP, higher QED, better BBB penetration, a longer half-life, and a slightly better binding affinity. While Ligand A has better P-gp efflux and lower hERG, the advantages of Ligand B in terms of metabolic stability, permeability, and drug-likeness are more compelling. The solubility issues are a concern for both, but can be addressed with formulation strategies.
Output:
0
2025-04-17 18:42:51,803 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (365.5 & 363.4 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (54.9) is significantly better than Ligand B (89.35). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold. Ligand B is approaching the upper limit.
3. **logP:** Both ligands have good logP values (2.053 and 1.15), falling within the optimal 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Ligand A (0) is preferable to Ligand B (1). Fewer hydrogen bond donors generally improve permeability.
5. **HBA:** Both ligands have the same number of HBA (7), which is acceptable (<=10).
6. **QED:** Both ligands have good QED scores (0.745 and 0.832), indicating good drug-like properties. No clear advantage.
7. **DILI:** Ligand A (50.291) has a considerably lower DILI risk than Ligand B (70.221). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (92.594) has a higher BBB penetration percentile than Ligand B (55.448). While ADRB2 isn't a CNS target, some peripheral exposure can be undesirable, and higher BBB suggests better overall distribution characteristics.
9. **Caco-2:** Ligand A (-4.496) has a better Caco-2 permeability than Ligand B (-5.087). This suggests better intestinal absorption for Ligand A.
10. **Solubility:** Ligand A (-2.552) has better aqueous solubility than Ligand B (-2.021).
11. **hERG:** Ligand A (0.667) has a slightly higher hERG risk than Ligand B (0.181). This is a negative for Ligand A, but the value is still relatively low.
12. **Cl_mic:** Ligand B (29.743) has significantly lower microsomal clearance than Ligand A (56.962), indicating better metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand B (20.501) has a much longer in vitro half-life than Ligand A (0.426). This is a major advantage for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.52) has a slightly lower P-gp efflux liability than Ligand B (0.034). Lower Pgp efflux is generally desirable.
15. **Binding Affinity:** Ligand A (-8.6) has a significantly stronger binding affinity than Ligand B (-7.0). This is a substantial advantage for Ligand A, and can often outweigh minor ADME deficiencies. A 1.6 kcal/mol difference is significant.
**Overall Assessment:**
Ligand A has a superior binding affinity, better TPSA, solubility, Caco-2 permeability, lower DILI risk, and higher BBB penetration. However, Ligand B has significantly better metabolic stability (lower Cl_mic and longer t1/2) and lower hERG risk.
Given the GPCR-specific priorities (logP, TPSA, affinity), and the substantial advantage in binding affinity for Ligand A, I believe it is the more promising candidate despite the slightly higher hERG risk and lower metabolic stability. The strong binding affinity is likely to be crucial for efficacy, and the other parameters of Ligand A are generally favorable. The metabolic stability of Ligand A could potentially be improved through further medicinal chemistry optimization.
Output:
1
2025-04-17 18:42:51,804 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (359.373 and 362.495 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (87.74) is higher than Ligand B (58.64). For a cardiovascular GPCR, TPSA is moderately important, and lower is generally better for permeability. Ligand B has a clear advantage.
**3. logP:** Ligand B (2.478) is within the optimal 1-3 range, while Ligand A (0.476) is below 1. This is a significant drawback for Ligand A, as it may struggle with membrane permeability. Ligand B is favored.
**4. H-Bond Donors:** Ligand A (2) and Ligand B (1) are both acceptable, falling below the 5 threshold. Ligand B is slightly better.
**5. H-Bond Acceptors:** Both ligands have 4 H-bond acceptors, which is within the acceptable range of <=10.
**6. QED:** Ligand B (0.772) has a higher QED score than Ligand A (0.533), indicating a more drug-like profile. This is a positive for Ligand B.
**7. DILI Risk:** Both ligands have relatively low DILI risk (Ligand A: 41.915, Ligand B: 48.662), both below the concerning threshold of 60. No major difference.
**8. BBB Penetration:** Ligand A (80.962) has better BBB penetration than Ligand B (71.888). While ADRB2 is a cardiovascular target and CNS penetration isn't *essential*, some level of BBB penetration can be beneficial for off-target effects assessment and potential future applications.
**9. Caco-2 Permeability:** Ligand A (-5.207) and Ligand B (-4.896) are both negative, indicating poor permeability. However, the scale is not specified, so it's difficult to interpret the absolute difference.
**10. Aqueous Solubility:** Both ligands have very poor aqueous solubility (-2.022 and -3.965 respectively). This is a significant concern for both, but Ligand B is slightly worse.
**11. hERG Inhibition:** Ligand A (0.119) has a lower hERG inhibition risk than Ligand B (0.556). This is a crucial advantage for Ligand A, as hERG inhibition can lead to cardiotoxicity.
**12. Microsomal Clearance:** Ligand A (-8.345) has much lower microsomal clearance than Ligand B (78.774). Lower clearance indicates better metabolic stability, a significant advantage for Ligand A.
**13. In vitro Half-Life:** Ligand A (-30.239) has a longer in vitro half-life than Ligand B (-7.658). This is a substantial benefit for Ligand A, potentially allowing for less frequent dosing.
**14. P-gp Efflux:** Both ligands show low P-gp efflux liability (0.01 and 0.183 respectively).
**15. Binding Affinity:** Both ligands have similar binding affinities (-6.1 and -6.3 kcal/mol). The difference is minimal.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand B initially appears better due to its more favorable logP and lower TPSA. However, Ligand A demonstrates significantly better metabolic stability (lower Cl_mic, longer t1/2), lower hERG risk, and acceptable BBB penetration. The poor solubility of both compounds is a concern, but can be addressed with formulation strategies. The lower logP of Ligand A is a major drawback, but the superior ADME properties and safety profile outweigh this concern.
Therefore, I favor Ligand A.
Output:
1
2025-04-17 18:42:51,804 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
We are targeting ADRB2, a GPCR. Therefore, the key properties to prioritize are logP, TPSA, Pgp efflux, BBB penetration, and binding affinity. Metabolic stability (Cl_mic, t1/2) and safety (DILI, hERG) are also important.
Let's compare the ligands property by property:
1. **MW:** Both ligands (350.419 and 367.446 Da) fall within the ideal 200-500 Da range.
2. **TPSA:** Ligand B (83.71) is significantly better than Ligand A (105.82). Lower TPSA generally translates to better cell permeability, which is crucial for GPCR ligands.
3. **logP:** Both ligands have good logP values (2.01 and 1.604), falling within the optimal 1-3 range. Ligand B is slightly lower, which could be beneficial for solubility.
4. **HBD/HBA:** Ligand B (1 HBD, 4 HBA) is preferable to Ligand A (2 HBD, 6 HBA) as fewer hydrogen bonds generally improve membrane permeability.
5. **QED:** Both ligands have good QED scores (0.782 and 0.858), indicating good drug-like properties.
6. **DILI:** Ligand B (37.456) has a much lower DILI risk than Ligand A (55.021), a significant advantage.
7. **BBB:** Ligand B (88.329) has a much higher BBB penetration score than Ligand A (48.662). While ADRB2 isn't exclusively a CNS target, some peripheral ADRB2 activity can be modulated by CNS effects, and higher BBB penetration isn't necessarily a detriment.
8. **Caco-2:** Both ligands have similar, poor Caco-2 permeability (-4.915 and -4.969). This is a concern for oral bioavailability.
9. **Solubility:** Both ligands have similar, poor solubility (-2.794 and -2.555).
10. **hERG:** Both ligands have low hERG inhibition liability (0.167 and 0.298), which is good.
11. **Cl_mic:** Ligand B (-0.927) has significantly better metabolic stability (lower clearance) than Ligand A (30.163).
12. **t1/2:** Ligand B (-6.193) has a much longer in vitro half-life than Ligand A (22.533).
13. **Pgp:** Ligand A (0.122) has slightly lower P-gp efflux liability than Ligand B (0.045), which is preferable.
14. **Binding Affinity:** Both ligands have excellent binding affinity (-7.0 and -6.9 kcal/mol). The difference is negligible.
**Overall Assessment:**
Ligand B consistently outperforms Ligand A in the most critical parameters for a GPCR drug candidate: TPSA, DILI, BBB, Cl_mic, and t1/2. While both have similar affinity and acceptable logP, the improved safety profile (lower DILI) and metabolic stability (lower Cl_mic, longer t1/2) of Ligand B make it the more promising candidate. The slightly better Pgp score of Ligand A is outweighed by the other advantages of Ligand B.
**Output:**
0
2025-04-17 18:42:51,804 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. The key priorities for GPCRs, as outlined, are logP, Pgp, TPSA, and affinity, with BBB being less critical for a cardiovascular target. Let's break down the comparison:
1. **Molecular Weight:** Both ligands (362.5 and 363.5 Da) fall comfortably within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (58.2) is significantly better than Ligand B (88.91). Lower TPSA generally correlates with better cell permeability, a crucial factor for GPCR ligands.
3. **logP:** Ligand A (4.121) is higher than Ligand B (2.145). While both are within the acceptable range (1-3 is optimal), Ligand A is pushing the upper limit. However, for a GPCR, a slightly higher logP can be tolerated if other properties are favorable.
4. **H-Bond Donors/Acceptors:** Both have similar HBD counts (2). Ligand B has more HBAs (6 vs 3), which could slightly hinder permeability.
5. **QED:** Both ligands have good QED scores (0.717 and 0.823), indicating good drug-like properties.
6. **DILI:** Ligand A (30.75) has a much lower DILI risk than Ligand B (49.59), a significant advantage.
7. **BBB:** Not a primary concern for a cardiovascular target, but Ligand A (63.75) is slightly better than Ligand B (57.46).
8. **Caco-2:** Ligand A (-4.903) and Ligand B (-5.234) are both very negative, which is unusual. It's difficult to interpret without knowing the scale, but generally, a more negative value suggests *lower* permeability.
9. **Solubility:** Ligand A (-3.41) is slightly better than Ligand B (-2.585), both are poor.
10. **hERG:** Both ligands have low hERG inhibition risk (0.401 and 0.571).
11. **Cl_mic:** Ligand B (46.61) has lower microsomal clearance than Ligand A (61.36), indicating better metabolic stability.
12. **t1/2:** Ligand A (23.29) has a slightly longer half-life than Ligand B (21.11).
13. **Pgp:** Ligand A (0.257) has significantly lower P-gp efflux liability than Ligand B (0.071), which is highly desirable for GPCRs.
14. **Binding Affinity:** Both ligands have very similar and excellent binding affinities (-7.9 and -7.8 kcal/mol). The difference is negligible.
**Overall Assessment:**
Ligand A is preferable. While Ligand B has slightly better metabolic stability (lower Cl_mic), Ligand A excels in several critical areas: significantly lower DILI risk, lower P-gp efflux, and a more favorable TPSA. The slightly higher logP of Ligand A is less concerning given the GPCR target class. The similar binding affinities make the ADME properties the deciding factors.
**Output:**
1
2025-04-17 18:42:51,804 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (343.431 Da) is well within the ideal range (200-500 Da). Ligand B (368.463 Da) is also acceptable. No clear advantage.
2. **TPSA:** Ligand A (92.93) is good, under the 140 threshold for oral absorption. Ligand B (110.08) is still reasonable, but less optimal. Slight advantage to A.
3. **logP:** Ligand A (2.084) is optimal (1-3). Ligand B (-0.025) is slightly below 1, which could hinder permeability. Advantage to A.
4. **HBD:** Both Ligand A (2) and Ligand B (1) are within the acceptable limit of 5. No significant difference.
5. **HBA:** Ligand A (6) is within the acceptable limit of 10. Ligand B (7) is also acceptable. No significant difference.
6. **QED:** Ligand B (0.782) has a better QED score than Ligand A (0.509), indicating a more drug-like profile. Advantage to B.
7. **DILI:** Ligand A (41.76) has a lower DILI risk than Ligand B (59.403), which is better. Advantage to A.
8. **BBB:** Ligand A (24.389) has a low BBB penetration, while Ligand B (68.36) has a much higher BBB penetration. Since ADRB2 is a cardiovascular target, BBB penetration is not a high priority, but a higher value is generally preferred. Slight advantage to B.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Both ligands have negative solubility values, which is also unusual. Again, the scale is not specified.
11. **hERG:** Both Ligand A (0.236) and Ligand B (0.048) have low hERG inhibition liability, which is good. Slight advantage to B.
12. **Cl_mic:** Ligand B (20.799) has a lower microsomal clearance than Ligand A (29.879), indicating better metabolic stability. Advantage to B.
13. **t1/2:** Ligand A (13.648) has a longer in vitro half-life than Ligand B (-17.964). This is a significant advantage for A.
14. **Pgp:** Both Ligand A (0.227) and Ligand B (0.046) have low P-gp efflux liability, which is good. Slight advantage to B.
15. **Binding Affinity:** Ligand B (-6.5 kcal/mol) has a slightly better binding affinity than Ligand A (-6.0 kcal/mol). This is a notable advantage, as affinity is a key driver.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand A has a better logP and TPSA, while Ligand B has better affinity, Pgp, and Cl_mic. The binding affinity difference is relatively small (0.5 kcal/mol), but still important. The longer half-life of Ligand A is a significant benefit. However, the lower logP and potential permeability issues with Ligand B, coupled with its better metabolic stability and slightly better affinity, make it a more promising candidate.
Output:
0
2025-04-17 18:42:51,804 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.38 and 354.50 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (42.68) is significantly better than Ligand B (95.74). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand B's TPSA is quite high, potentially hindering oral bioavailability.
3. **logP:** Ligand A (4.51) is higher than Ligand B (0.59). While 4.51 is approaching the upper limit, it's still within a reasonable range. Ligand B's logP is very low, suggesting poor membrane permeability. This is a major concern.
4. **HBD/HBA:** Ligand A (0 HBD, 3 HBA) is preferable to Ligand B (2 HBD, 4 HBA). Lower counts are generally better for permeability.
5. **QED:** Ligand A (0.815) is better than Ligand B (0.633), indicating a more drug-like profile.
6. **DILI:** Ligand B (10.39) has a *much* lower DILI risk than Ligand A (56.57). This is a significant advantage for Ligand B.
7. **BBB:** Ligand A (86.43) has higher BBB penetration than Ligand B (64.56). Not a huge priority for a cardiovascular target, but a slight positive for A.
8. **Caco-2:** Ligand A (-4.34) is better than Ligand B (-5.36), indicating better intestinal absorption.
9. **Solubility:** Ligand A (-4.38) is better than Ligand B (-1.22). Solubility is important for formulation and bioavailability.
10. **hERG:** Ligand A (0.8) is better than Ligand B (0.16). Lower hERG inhibition is crucial to avoid cardiotoxicity.
11. **Cl_mic:** Ligand A (65.88) has a higher clearance than Ligand B (17.96). This means Ligand B is more metabolically stable.
12. **t1/2:** Ligand A (50.73) has a longer half-life than Ligand B (-19.75). This is a significant advantage for A.
13. **Pgp:** Ligand A (0.7) is better than Ligand B (0.001). Lower P-gp efflux is generally preferred.
14. **Binding Affinity:** Ligand A (-7.8) has a significantly stronger binding affinity than Ligand B (-6.4). A difference of 1.4 kcal/mol is substantial and can often outweigh minor ADME issues.
**Overall Assessment:**
Ligand A has a superior binding affinity, better solubility, Caco-2 permeability, Pgp efflux, and half-life. However, Ligand B has a much lower DILI risk and better metabolic stability. The biggest drawback of Ligand B is its very low logP, which will likely lead to poor absorption. The high TPSA is also concerning. While DILI is important, the combination of poor permeability and absorption for Ligand B makes it a less promising candidate. The strong binding affinity of Ligand A, coupled with acceptable (though not perfect) ADME properties, makes it the more viable option.
Output:
1
2025-04-17 18:42:51,804 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (361.47 and 339.48 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (80.2) is higher than Ligand B (46.06). For a cardiovascular GPCR, TPSA is moderately important. Ligand B is significantly better, being well below the 140 threshold and indicating potentially better absorption.
**3. logP:** Both ligands have acceptable logP values (2.878 and 4.218), falling within the 1-3 range, though Ligand B is pushing the upper limit. This could potentially lead to solubility issues, but isn't a dealbreaker.
**4. H-Bond Donors:** Both have 2 HBD, which is within the ideal range.
**5. H-Bond Acceptors:** Ligand A has 4 HBA, and Ligand B has 2. Both are acceptable, below the 10 threshold.
**6. QED:** Both ligands have reasonable QED values (0.83 and 0.729), indicating good drug-like properties.
**7. DILI Risk:** Ligand A (68.28%) has a higher DILI risk than Ligand B (27.92%). This is a significant concern, as minimizing liver toxicity is crucial.
**8. BBB Penetration:** Ligand B (96.78%) has much higher predicted BBB penetration than Ligand A (54.09%). While ADRB2 is primarily a cardiovascular target, some CNS effects are possible with beta-blockers, and higher BBB penetration could lead to unwanted side effects. However, for a cardiovascular target, this isn't a primary driver.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.839 and -4.675). These values are difficult to interpret directly, but suggest poor permeability.
**10. Aqueous Solubility:** Both ligands have negative solubility values (-3.704 and -4.031), indicating poor aqueous solubility. This is a concern for bioavailability.
**11. hERG Inhibition:** Ligand A (0.314) has a lower hERG inhibition risk than Ligand B (0.902). This is a positive for Ligand A, as hERG inhibition can cause cardiotoxicity.
**12. Microsomal Clearance:** Ligand B (48.357) has significantly higher microsomal clearance than Ligand A (15.454), suggesting faster metabolism and potentially lower *in vivo* exposure.
**13. In vitro Half-Life:** Ligand A (70.761) has a longer in vitro half-life than Ligand B (45.691). This is a positive for Ligand A, as it suggests a slower rate of degradation.
**14. P-gp Efflux:** Ligand A (0.17) has lower P-gp efflux than Ligand B (0.692), which is favorable for bioavailability.
**15. Binding Affinity:** Ligand A (-6.1 kcal/mol) has a slightly better binding affinity than Ligand B (-4.3 kcal/mol). This 1.8 kcal/mol difference is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand A is the better candidate. While Ligand B has better TPSA and BBB penetration, Ligand A has a significantly better binding affinity, lower DILI risk, lower P-gp efflux, and longer half-life. The higher affinity is a major advantage for a GPCR target, and the lower DILI risk is critical. The solubility and permeability issues are present in both, but can be addressed through formulation strategies. The hERG risk is also lower for Ligand A.
Output:
1
2025-04-17 18:42:51,804 - INFO - Batch 57 complete. Total preferences: 912
2025-04-17 18:42:51,804 - INFO - Processing batch 58/512...
2025-04-17 18:43:39,641 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.379 and 344.419 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (118.45) is slightly higher than Ligand B (113.96), but both are below the 140 threshold for good oral absorption.
3. **logP:** Ligand B (1.999) is better than Ligand A (-0.483). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but a logP between 1-3 is preferred. Ligand A's negative logP is a concern for permeability.
4. **HBD:** Both ligands have 2 HBD, which is within the acceptable limit of 5.
5. **HBA:** Ligand A has 7 HBA, while Ligand B has 3. Both are below the 10 limit.
6. **QED:** Ligand A (0.74) has a better QED score than Ligand B (0.467), indicating a more drug-like profile.
7. **DILI:** Ligand B (32.687) has a significantly lower DILI risk than Ligand A (64.056). This is a major advantage for Ligand B.
8. **BBB:** Ligand A (58.434) has a slightly higher BBB penetration percentile than Ligand B (46.336), but this is less critical for a cardiovascular target.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Both ligands have negative solubility values, again making interpretation difficult.
11. **hERG:** Ligand B (0.123) has a slightly higher hERG risk than Ligand A (0.047), but both are very low and unlikely to be a concern.
12. **Cl_mic:** Ligand A (-28.981) has a much lower (better) microsomal clearance than Ligand B (2.696), suggesting greater metabolic stability.
13. **t1/2:** Ligand B (-24.213) has a longer in vitro half-life than Ligand A (-15.919), which is desirable.
14. **Pgp:** Ligand B (0.022) has a lower Pgp efflux liability than Ligand A (0.007), which is favorable.
15. **Binding Affinity:** Ligand B (-7.6 kcal/mol) has a significantly stronger binding affinity than Ligand A (-4.5 kcal/mol). This is a substantial advantage.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand B excels in logP and affinity, and is better in Pgp. While TPSA is similar, the significant affinity advantage of Ligand B outweighs the slightly better QED and metabolic stability of Ligand A. The lower DILI risk of Ligand B is also a significant benefit.
**Output:**
0
2025-04-17 18:43:39,642 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
The target is ADRB2, a GPCR. Therefore, I will prioritize logP, TPSA, Pgp, BBB, and binding affinity, while also considering overall drug-likeness (QED) and safety (DILI, hERG).
Let's compare the ligands property by property:
1. **MW:** Both ligands (347.415 and 375.491 Da) are within the ideal 200-500 Da range.
2. **TPSA:** Both ligands (100.55 and 96.97) are below the 140 A^2 threshold for good oral absorption, and acceptable for a non-CNS GPCR.
3. **logP:** Ligand B (-0.549) is slightly lower than ideal (1-3) and could potentially have absorption issues, while Ligand A (0.797) is closer to the optimal range.
4. **HBD/HBA:** Ligand A has 3 HBD and 5 HBA, while Ligand B has 2 HBD and 6 HBA. Both are within acceptable limits.
5. **QED:** Both ligands have good QED scores (0.604 and 0.647), indicating good drug-like properties.
6. **DILI:** Ligand B (48.895) has a slightly higher DILI risk than Ligand A (41.915), but both are below the concerning threshold of 60.
7. **BBB:** Both ligands have similar BBB penetration (43.505 and 44.552), which isn't a primary concern for a non-CNS target like ADRB2.
8. **Caco-2:** Both ligands have negative Caco-2 permeability values, which is unusual and suggests poor permeability. Ligand B (-5.527) is slightly worse than Ligand A (-4.901).
9. **Solubility:** Ligand B (-1.06) has slightly better solubility than Ligand A (-2.111).
10. **hERG:** Ligand A (0.047) has a slightly lower hERG risk than Ligand B (0.133).
11. **Cl_mic:** Ligand B (-4.259) has a significantly lower (better) microsomal clearance than Ligand A (3.904), indicating better metabolic stability.
12. **t1/2:** Ligand B (-8.128) has a much longer in vitro half-life than Ligand A (-32.27), which is a significant advantage.
13. **Pgp:** Both ligands have very low Pgp efflux liability (0.046 and 0.01).
14. **Binding Affinity:** Ligand B (-6.6 kcal/mol) has a slightly better binding affinity than Ligand A (-6.0 kcal/mol). This is a substantial difference.
**Overall Assessment:**
While Ligand A has a slightly better logP and lower hERG risk, Ligand B demonstrates superior binding affinity, metabolic stability (lower Cl_mic), and a longer half-life. The binding affinity difference is significant enough to outweigh the slightly less optimal logP and higher DILI risk. The longer half-life is also a major advantage for dosing convenience. The Caco-2 values are concerning for both, but the overall profile of Ligand B is more promising.
**Output:**
0
2025-04-17 18:43:39,642 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.35 and 344.50 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand B (40.62) is significantly better than Ligand A (124.84). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption. Ligand B is well below the 140 threshold.
3. **logP:** Ligand B (3.372) is within the optimal 1-3 range, while Ligand A (-0.558) is below 1. This is a substantial difference. Lower logP can lead to poor membrane permeability.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (0). Both are acceptable.
5. **HBA:** Ligand A (6) is higher than Ligand B (2). Both are acceptable, but lower is generally preferred.
6. **QED:** Both ligands have similar and good QED scores (0.702 and 0.71).
7. **DILI:** Ligand B (17.642) has a much lower DILI risk than Ligand A (63.009). This is a significant advantage for Ligand B.
8. **BBB:** Ligand B (88.484) has a higher BBB penetration score than Ligand A (60.372). While not critical for a cardiovascular target, it's still a positive attribute.
9. **Caco-2:** Ligand B (-4.495) is better than Ligand A (-5.608), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-1.331) is better than Ligand B (-3.521). Solubility is important, but can often be addressed with formulation.
11. **hERG:** Ligand B (0.567) has a lower hERG risk than Ligand A (0.01). This is a significant advantage.
12. **Cl_mic:** Ligand A (-42.229) has a much lower microsomal clearance than Ligand B (93.754), indicating better metabolic stability.
13. **t1/2:** Ligand B (11.052) has a longer in vitro half-life than Ligand A (-15.55).
14. **Pgp:** Ligand B (0.511) has a lower P-gp efflux liability than Ligand A (0.001). This is a positive attribute.
15. **Binding Affinity:** Ligand B (-7.3) has a significantly better binding affinity than Ligand A (-4.9). This is a crucial advantage, exceeding the 1.5 kcal/mol threshold.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in these areas. While metabolic stability (Cl_mic) is important, the substantial affinity advantage of Ligand B outweighs the slightly higher clearance. The lower DILI and hERG risks for Ligand B are also very favorable.
**Output:**
0
2025-04-17 18:43:39,642 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor (a GPCR).
**Ligand A:** [346.475, 80.48, 1.204, 2, 5, 0.775, 6.514, 55.176, -5.273, -0.58, 0.601, -50.095, 22.962, 0.03, -8]
**Ligand B:** [379.473, 81.67, 0.452, 3, 5, 0.507, 18.651, 65.413, -5.381, -1.682, 0.601, -2.921, -17.058, 0.027, -6.2]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (346.475) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are good (below 140), suggesting reasonable oral absorption. Ligand A (80.48) is slightly better.
3. **logP:** Both are within the optimal range (1-3). Ligand A (1.204) is slightly higher, which could be beneficial for membrane permeability. Ligand B (0.452) is on the lower end, potentially hindering permeation.
4. **HBD:** Both are acceptable (<=5). Ligand A (2) is better than Ligand B (3).
5. **HBA:** Both are acceptable (<=10). Both have 5.
6. **QED:** Both are good (>0.5), indicating drug-like properties. Ligand A (0.775) is better than Ligand B (0.507).
7. **DILI:** Ligand A (6.514) has a significantly lower DILI risk than Ligand B (18.651). This is a major advantage.
8. **BBB:** Ligand B (65.413) has a better BBB penetration than Ligand A (55.176). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-5.273) is slightly better than Ligand B (-5.381).
10. **Solubility:** Both are negative, indicating poor solubility. Ligand A (-0.58) is slightly better than Ligand B (-1.682).
11. **hERG:** Both are very low, indicating minimal hERG inhibition risk.
12. **Cl_mic:** Ligand A (-50.095) has a much lower (better) microsomal clearance than Ligand B (-2.921), suggesting greater metabolic stability.
13. **t1/2:** Ligand A (22.962) has a longer in vitro half-life than Ligand B (-17.058). This is a significant advantage.
14. **Pgp:** Both are very low, indicating minimal P-gp efflux.
15. **Affinity:** Ligand A (-8) has a slightly better binding affinity than Ligand B (-6.2).
**GPCR-specific priorities:** For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are crucial. While Ligand B has slightly better BBB penetration, the significant advantages of Ligand A in terms of DILI risk, metabolic stability (Cl_mic & t1/2), solubility, QED, and binding affinity outweigh this. The slightly better logP of Ligand A is also beneficial.
**Conclusion:**
Ligand A is the more promising drug candidate.
1
2025-04-17 18:43:39,642 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (356.323 and 356.463 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (83.8) is significantly better than Ligand B (99.1). For a GPCR, keeping TPSA under 140 is good, and lower is generally preferred for better permeability. Ligand B is approaching a less desirable range.
3. **logP:** Ligand A (3.051) is optimal, while Ligand B (0.432) is quite low. A logP below 1 can hinder membrane permeability. This is a major strike against Ligand B.
4. **HBD:** Both ligands have 3 HBD, which is within the acceptable limit of 5.
5. **HBA:** Ligand A has 3 HBA, while Ligand B has 5. Both are acceptable (<=10), but Ligand A is slightly more favorable.
6. **QED:** Ligand A (0.739) has a better QED score than Ligand B (0.575), indicating a more drug-like profile.
7. **DILI:** Ligand A (65.103) has a higher DILI risk than Ligand B (9.926). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (87.67) has a much better BBB penetration percentile than Ligand B (52.036). While ADRB2 isn't exclusively a CNS target, some CNS exposure could be beneficial or at least not detrimental, and higher BBB is generally desirable.
9. **Caco-2:** Ligand A (-5.363) has a worse Caco-2 permeability than Ligand B (-4.896). Both are negative, suggesting poor permeability, but Ligand B is slightly better.
10. **Solubility:** Ligand A (-4.113) has better solubility than Ligand B (-0.953). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.861) has a lower hERG inhibition liability than Ligand B (0.251). Lower is better, indicating a reduced risk of cardiotoxicity.
12. **Cl_mic:** Ligand A (-2.904) has a lower (better) microsomal clearance than Ligand B (6.922). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (24.774 hours) has a significantly longer in vitro half-life than Ligand B (-9.693 hours). This is a major advantage for Ligand A, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.304) has lower P-gp efflux liability than Ligand B (0.023). Lower Pgp efflux is generally preferred for better bioavailability.
15. **Binding Affinity:** Ligand A (-7.1 kcal/mol) has a slightly better binding affinity than Ligand B (-6.4 kcal/mol). While both are good, the 0.7 kcal/mol difference is noticeable and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand A is the stronger candidate. While Ligand B has a lower DILI risk, Ligand A excels in several crucial areas: logP, QED, BBB, solubility, hERG, metabolic stability (Cl_mic and t1/2), Pgp efflux, and binding affinity. The significantly better logP and metabolic stability of Ligand A are particularly important for a GPCR target like ADRB2. The slightly better affinity further solidifies its position.
Output:
1
2025-04-17 18:43:39,642 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (358.498 and 352.41 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (58.64) is significantly better than Ligand B (84.42). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold. Ligand B is approaching the upper limit.
3. **logP:** Both ligands have acceptable logP values (2.786 and 1.935, respectively), falling within the 1-3 optimal range. Ligand A is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 3 HBA, while Ligand B has 5. Ligand A is preferable here, staying closer to the ideal of <=10.
6. **QED:** Both ligands have good QED scores (0.726 and 0.811), indicating good drug-like properties.
7. **DILI:** Ligand A (8.104%) has a considerably lower DILI risk than Ligand B (29.779%). This is a significant advantage for Ligand A.
8. **BBB:** Both ligands have high BBB penetration (91.198% and 92.323%), but this is less critical for a cardiovascular target like ADRB2.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.415 and -4.36), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Both ligands have negative solubility values (-3.066 and -2.76), indicating poor aqueous solubility. This is a significant drawback for both.
11. **hERG:** Ligand A (0.727) has a slightly higher hERG risk than Ligand B (0.207). This is a minor concern, but Ligand B is preferable here.
12. **Cl_mic:** Ligand A (56.991) has a lower microsomal clearance than Ligand B (63.06), indicating better metabolic stability.
13. **t1/2:** Ligand A (-7.508) has a much longer in vitro half-life than Ligand B (-26.421). This is a major advantage for Ligand A.
14. **Pgp:** Ligand A (0.07) has a lower Pgp efflux liability than Ligand B (0.012), which is better.
15. **Binding Affinity:** Ligand B (-6.9 kcal/mol) has a slightly better binding affinity than Ligand A (-6.5 kcal/mol). While a 1.5 kcal/mol advantage is usually significant, the other factors are more important in this case.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity) and the general guidelines, Ligand A is the more promising candidate. While Ligand B has slightly better affinity and hERG, Ligand A excels in critical ADME properties: significantly lower DILI risk, better metabolic stability (lower Cl_mic, longer t1/2), lower Pgp efflux, and a more favorable TPSA. The solubility and Caco-2 issues are concerning for both, but can be addressed with formulation strategies. The lower DILI risk and improved metabolic stability of Ligand A are particularly valuable.
Output:
1
2025-04-17 18:43:39,642 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (374.434 and 340.406 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (69.73) is significantly better than Ligand A (99.1), falling well below the 140 threshold for good oral absorption, and closer to the <90 threshold desirable for CNS targets (though ADRB2 isn't strictly a CNS target, lower TPSA is generally favorable for GPCRs).
3. **logP:** Ligand B (3.464) is slightly higher than Ligand A (0.415). While both are within the acceptable range, Ligand B is closer to the optimal 1-3 range. Ligand A's low logP could indicate poor membrane permeability.
4. **HBD:** Ligand A (3) and Ligand B (2) are both acceptable.
5. **HBA:** Ligand A (6) and Ligand B (5) are both acceptable.
6. **QED:** Both ligands have good QED scores (0.612 and 0.761), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (47.926) has a significantly lower DILI risk than Ligand B (71.113). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (76.735) has a higher BBB penetration score than Ligand A (46.336). While ADRB2 isn't a primary CNS target, some peripheral ADRB2 activity can influence CNS processes, so moderate BBB penetration isn't necessarily a negative.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.098 and -5.165). This is unusual and suggests poor permeability.
10. **Solubility:** Ligand A (-1.605) has slightly better solubility than Ligand B (-4.223).
11. **hERG:** Ligand A (0.457) has a lower hERG inhibition liability than Ligand B (0.918), indicating a lower risk of cardiotoxicity. This is a crucial advantage given ADRB2's cardiovascular involvement.
12. **Cl_mic:** Ligand A (-4.789) has a lower (better) microsomal clearance than Ligand B (46.817), suggesting greater metabolic stability.
13. **t1/2:** Ligand B (35.769) has a significantly longer in vitro half-life than Ligand A (14.383). This is a substantial advantage for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.131) has lower P-gp efflux liability than Ligand B (0.236). Lower Pgp is generally preferred.
15. **Binding Affinity:** Ligand A (-7.3) has a slightly better binding affinity than Ligand B (-5.9). This 1.4 kcal/mol difference is significant and can outweigh some ADME drawbacks.
**GPCR-Specific Priorities & Overall Assessment:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are particularly important. Ligand B excels in logP and t1/2, while Ligand A has better affinity, DILI, hERG, Cl_mic, and Pgp. The low Caco-2 values for both are concerning, but the superior affinity of Ligand A, combined with its significantly better safety profile (DILI, hERG) and metabolic stability (Cl_mic), makes it the more promising candidate. The longer half-life of Ligand B is attractive, but the safety concerns with Ligand B are too significant to ignore for a cardiovascular target.
Output:
1
2025-04-17 18:43:39,642 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [350.371, 109.88 , 2.177, 3. , 5. , 0.673, 84.374, 40.326, -5.473, -3.226, 0.162, -1.692, -9.887, 0.06 , -6.8 ]
**Ligand B:** [350.459, 75.71 , 1.729, 1. , 4. , 0.74 , 27.181, 63.784, -4.727, -1.953, 0.306, 48.132, 2.142, 0.125, -4.4 ]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity, and to a lesser extent BBB):
1. **MW:** Both are excellent (around 350 Da), falling well within the 200-500 Da range.
2. **TPSA:** Ligand B (75.71) is significantly better than Ligand A (109.88). Lower TPSA generally favors better permeability, which is crucial for GPCR ligands.
3. **logP:** Both are good (2.177 and 1.729), within the optimal 1-3 range. Ligand B is slightly better.
4. **HBD/HBA:** Ligand B (1 HBD, 4 HBA) is preferable to Ligand A (3 HBD, 5 HBA). Fewer H-bonds can improve permeability.
5. **QED:** Both are acceptable (0.673 and 0.74), indicating reasonable drug-likeness.
6. **DILI:** Ligand B (27.181) is *much* better than Ligand A (84.374). This is a major advantage for Ligand B.
7. **BBB:** Ligand B (63.784) is better than Ligand A (40.326), though neither is exceptionally high. For a cardiovascular target, BBB isn't paramount, but it's still a positive.
8. **Caco-2:** Ligand A (-5.473) is better than Ligand B (-4.727).
9. **Solubility:** Ligand A (-3.226) is better than Ligand B (-1.953).
10. **hERG:** Ligand B (0.306) is better than Ligand A (0.162). Lower hERG is crucial for avoiding cardiotoxicity, especially important for a cardiovascular target.
11. **Cl_mic:** Ligand A (-1.692) is *much* better than Ligand B (48.132). Lower clearance indicates better metabolic stability.
12. **t1/2:** Ligand A (-9.887) is better than Ligand B (2.142).
13. **Pgp:** Ligand A (0.06) is better than Ligand B (0.125). Lower P-gp efflux is generally desirable.
14. **Affinity:** Ligand A (-6.8 kcal/mol) is significantly better than Ligand B (-4.4 kcal/mol). This is a substantial difference in binding strength.
**Overall Assessment:**
Ligand A has a significantly stronger binding affinity and better metabolic stability (lower Cl_mic, longer t1/2), and Pgp efflux. However, Ligand B excels in safety parameters (DILI, hERG) and has a more favorable TPSA. The difference in binding affinity (-6.8 vs -4.4) is substantial. For a GPCR, a strong affinity is often a key driver, and can sometimes compensate for minor ADME issues. The DILI risk for Ligand A is quite high, which is concerning.
Considering the balance, the superior binding affinity of Ligand A outweighs the ADME concerns, especially given that the other parameters are not drastically unfavorable.
Output:
1
2025-04-17 18:43:39,642 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.471 and 345.487 Da) fall comfortably within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (56.79) is better than Ligand B (64.41). Both are below 140, but lower TPSA generally favors absorption.
3. **logP:** Ligand A (3.808) is slightly higher than Ligand B (2.817), both within the optimal 1-3 range. Ligand A is approaching the upper limit, but not excessively.
4. **HBD:** Ligand A (1) is better than Ligand B (0). While both are low, a single HBD can contribute to solubility without significantly impacting permeability.
5. **HBA:** Ligand A (4) is slightly higher than Ligand B (3). Both are within the acceptable limit of 10.
6. **QED:** Ligand A (0.736) is better than Ligand B (0.635), indicating a more drug-like profile.
7. **DILI:** Ligand B (11.361) is *significantly* better than Ligand A (42.458). This is a major advantage for Ligand B. DILI is a critical safety concern.
8. **BBB:** Both ligands have good BBB penetration (Ligand A: 74.874, Ligand B: 72.237). This is good, but less critical for ADRB2 as it's not a CNS target.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.154 and -4.498). This is unusual and suggests poor permeability. However, these values are on a scale where negative values are possible, and direct comparison is difficult without knowing the scale's specifics.
10. **Solubility:** Ligand B (-2.636) is better than Ligand A (-4.437). Both are poor, but B is slightly less so.
11. **hERG:** Ligand A (0.486) is better than Ligand B (0.697). Lower hERG inhibition is preferred.
12. **Cl_mic:** Ligand B (31.973) is *much* better than Ligand A (90.231). Lower clearance indicates better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand B (-7.335) is better than Ligand A (-6.498). Longer half-life is generally desirable.
14. **Pgp:** Ligand A (0.436) is better than Ligand B (0.135). Lower P-gp efflux is preferred.
15. **Binding Affinity:** Ligand B (-5.6) is better than Ligand A (-6.7). A difference of 1.1 kcal/mol is substantial and favors Ligand B.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Ligand B has a better logP, better Pgp efflux, and significantly better affinity. While Ligand A has a slightly better TPSA, the difference isn't large enough to outweigh the other advantages of Ligand B.
**Overall Assessment:**
Ligand B is the stronger candidate. The significantly lower DILI risk and improved metabolic stability (Cl_mic) are major advantages. The better binding affinity and half-life further solidify its position. While Ligand A has some advantages in QED and hERG, the safety and pharmacokinetic benefits of Ligand B are more critical for overall drug development success. The Caco-2 and solubility values are concerning for both, but the other parameters favor Ligand B.
Output:
0
2025-04-17 18:43:39,642 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (382.595 & 356.491 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (49.41) is better than Ligand B (53.43), both are below the 140 threshold for oral absorption, and acceptable for a cardiovascular target.
3. **logP:** Both ligands have good logP values (2.974 & 3.733), falling within the optimal 1-3 range. Ligand B is slightly higher, which *could* be a minor concern for solubility, but not a dealbreaker.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Both have 4 HBA, which is good.
6. **QED:** Both ligands have similar QED scores (0.794 & 0.769), indicating good drug-likeness.
7. **DILI:** Ligand A (18.651) has a significantly lower DILI risk than Ligand B (36.952). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (80.845) has a better BBB penetration score than Ligand B (70.027). While ADRB2 is a cardiovascular target, some CNS off-target effects are possible with GPCRs, so higher BBB is generally preferred.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-5.065) is slightly better than Ligand B (-4.881), but both are problematic.
10. **Solubility:** Both have negative solubility values, which is also unusual and suggests poor solubility. Ligand B (-3.394) is slightly better than Ligand A (-4.364).
11. **hERG:** Both have low hERG inhibition risk (0.476 & 0.68), which is good.
12. **Cl_mic:** Ligand A (56.263) has a lower microsomal clearance than Ligand B (75.864), suggesting better metabolic stability. This is a positive for Ligand A.
13. **t1/2:** Ligand A (-18.044) has a worse in vitro half-life than Ligand B (42.988). This is a significant advantage for Ligand B.
14. **Pgp:** Both have low Pgp efflux liability (0.068 & 0.719), which is good.
15. **Binding Affinity:** Ligand A (-7.3) has a slightly better binding affinity than Ligand B (-5.5). This is a substantial advantage for Ligand A.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A performs better on logP, TPSA, Pgp, and significantly better on affinity. The DILI and Cl_mic are also favorable for Ligand A. While Ligand B has a better half-life, the superior affinity and safety profile of Ligand A outweigh this. The poor Caco-2 and solubility for both are concerning, but can be addressed with formulation strategies.
**Conclusion:**
Considering the balance of properties, particularly the superior binding affinity, lower DILI risk, better metabolic stability, and acceptable BBB penetration, Ligand A is the more promising drug candidate.
Output:
1
2025-04-17 18:43:39,643 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.403 and 343.479 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand B (72.97) is significantly better than Ligand A (104.39). ADRB2 is a cardiovascular target, not CNS, but lower TPSA generally improves permeability.
3. **logP:** Ligand B (2.165) is optimal, while Ligand A (0.331) is quite low, potentially hindering membrane permeation. This is a significant advantage for Ligand B.
4. **HBD:** Both ligands have 2 H-bond donors, which is within the acceptable range.
5. **HBA:** Ligand B (6) is slightly higher than Ligand A (5), but both are within the acceptable range of <=10.
6. **QED:** Ligand B (0.751) is better than Ligand A (0.626), indicating a more drug-like profile.
7. **DILI:** Ligand B (25.087) has a much lower DILI risk than Ligand A (54.634). This is a crucial advantage, as liver toxicity is a major concern.
8. **BBB:** Both ligands have reasonable BBB penetration (Ligand A: 62.854, Ligand B: 69.756). Not a primary concern for a cardiovascular target.
9. **Caco-2:** Ligand B (-5.453) is better than Ligand A (-4.766), indicating better intestinal absorption.
10. **Solubility:** Ligand B (-1.798) is better than Ligand A (-2.654), suggesting better aqueous solubility.
11. **hERG:** Ligand B (0.934) has a slightly higher hERG risk than Ligand A (0.216), but both are relatively low.
12. **Cl_mic:** Ligand B (26.577) has a lower microsomal clearance than Ligand A (33.358), indicating better metabolic stability.
13. **t1/2:** Ligand A (-19.751) has a much longer in vitro half-life than Ligand B (0.988). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand B (0.067) has lower P-gp efflux than Ligand A (0.035), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand B (-6.5 kcal/mol) is slightly better than Ligand A (-6.9 kcal/mol). While Ligand A has a slightly better affinity, the difference is not substantial enough to outweigh the other advantages of Ligand B.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, and Pgp are important. Ligand B excels in logP and TPSA, and has a better Pgp profile.
**Overall Assessment:**
Ligand B demonstrates a superior balance of properties, particularly regarding ADME-Tox parameters (DILI, logP, solubility, Cl_mic). While Ligand A has a slightly better binding affinity and longer half-life, the significantly lower DILI risk, better logP, and improved permeability characteristics of Ligand B make it a more promising drug candidate.
Output:
0
2025-04-17 18:43:39,643 - INFO - Here's my reasoning and final output for the ligand preference:
**Reasoning:**
We are targeting ADRB2, a GPCR, so the priorities are logP, Pgp, TPSA, affinity, and BBB. Let's compare Ligand A and Ligand B across all parameters:
1. **MW:** Both are within the ideal range (339.439 vs 340.427 Da).
2. **TPSA:** Ligand B (67.23) is better than Ligand A (75.43), being closer to the <90 target for GPCRs.
3. **logP:** Ligand A (3.138) is better than Ligand B (1.284). A logP between 1-3 is optimal, and Ligand A falls comfortably within this range, while Ligand B is at the lower end, potentially impacting permeability.
4. **HBD/HBA:** Ligand B has fewer HBD (1 vs 2) and a similar HBA count (4 vs 3). This is slightly favorable for Ligand B, potentially improving permeability.
5. **QED:** Both are good (0.814 vs 0.84), indicating good drug-like properties.
6. **DILI:** Ligand B (19.504) is *significantly* better than Ligand A (39.201). This is a major advantage for Ligand B.
7. **BBB:** Ligand A (71.656) has a slightly better BBB penetration than Ligand B (67.197), but both are reasonable.
8. **Caco-2:** Ligand A (-4.977) is better than Ligand B (-5.111), indicating better intestinal absorption.
9. **Solubility:** Ligand B (-0.717) is better than Ligand A (-3.444).
10. **hERG:** Ligand A (0.848) is better than Ligand B (0.254), indicating lower cardiotoxicity risk.
11. **Cl_mic:** Ligand A (-6.923) is better than Ligand B (-4.565), indicating better metabolic stability.
12. **t1/2:** Ligand A (68.401) is better than Ligand B (-13.078), indicating a longer half-life.
13. **Pgp:** Ligand A (0.128) is better than Ligand B (0.041), indicating lower P-gp efflux.
14. **Affinity:** Ligand B (-8.0) has a significantly better binding affinity than Ligand A (-6.7). This is a >1.3 kcal/mol difference, which is substantial and can outweigh some ADME concerns.
**Overall Assessment:**
The biggest differentiator is the binding affinity. Ligand B's affinity is considerably stronger. While Ligand A has advantages in metabolic stability, half-life, and P-gp efflux, the DILI risk for Ligand A is concerning. Ligand B has a much lower DILI risk and better solubility, which are important for overall drug safety and formulation. The slightly lower logP of Ligand B is a minor drawback that can potentially be addressed through further optimization, but the strong binding affinity and improved safety profile make it the more promising candidate.
Output:
0
2025-04-17 18:43:39,643 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for the ADRB2 receptor, a GPCR involved in cardiovascular function. Therefore, the priorities are logP, Pgp, TPSA, and affinity, with metabolic stability (Cl_mic, t1/2) and safety (DILI, hERG) also being important.
Let's compare the ligands property by property:
1. **MW:** Both ligands (346.471 and 346.515 Da) are within the ideal range (200-500 Da).
2. **TPSA:** Ligand A (67.43) is higher than Ligand B (40.62). Ligand B is significantly better, falling well below the 140 threshold for oral absorption and closer to the ideal for GPCRs.
3. **logP:** Both are good (3.038 and 3.452), falling within the optimal 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Ligand A has 2 HBD, Ligand B has 0. Lower HBD is generally preferred for permeability, giving an edge to Ligand B.
5. **HBA:** Ligand A has 3 HBA, Ligand B has 2. Again, Ligand B is slightly better.
6. **QED:** Ligand A (0.832) is slightly better than Ligand B (0.782), indicating a more drug-like profile.
7. **DILI:** Ligand B (15.277) has a significantly lower DILI risk than Ligand A (30.903). This is a major advantage for Ligand B.
8. **BBB:** Ligand B (87.476) has a better BBB penetration score than Ligand A (68.282). While not a primary concern for a cardiovascular target, it's a positive attribute.
9. **Caco-2:** Both have negative values, indicating permeability. Ligand B (-4.742) is slightly more negative, suggesting better permeability.
10. **Solubility:** Both have negative values, indicating solubility. Ligand B (-3.38) is slightly better.
11. **hERG:** Ligand A (0.437) has a slightly lower hERG risk than Ligand B (0.624).
12. **Cl_mic:** Ligand A (56.195) has lower microsomal clearance than Ligand B (78.891), indicating better metabolic stability.
13. **t1/2:** Ligand B (-4.132) has a negative half-life, which is concerning. Ligand A (6.846) has a positive half-life.
14. **Pgp:** Ligand A (0.052) has lower P-gp efflux than Ligand B (0.341), which is favorable.
15. **Affinity:** Ligand A (-6.6 kcal/mol) has a slightly better binding affinity than Ligand B (-6.3 kcal/mol). However, the difference is small.
**Overall Assessment:**
Ligand B excels in several key areas: TPSA, DILI risk, BBB penetration, and Caco-2 permeability. While Ligand A has a slightly better QED, affinity, and metabolic stability, the lower DILI risk and improved permeability of Ligand B are more critical for a viable drug candidate, especially considering the GPCR target class. The negative half-life of Ligand B is a significant concern, but can be addressed during optimization.
Output:
0
2025-04-17 18:43:39,643 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (370.837 and 355.414 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (85.69) is better than Ligand B (100.35). Both are under 140, but A is closer to the preferred <90 for potential CNS penetration, even though ADRB2 isn't necessarily a CNS target.
3. **logP:** Ligand A (1.054) is better than Ligand B (0.406). Both are within the 1-3 range, but A is closer to the optimal range. B is getting a bit low, potentially impacting permeability.
4. **HBD:** Ligand A (1) is better than Ligand B (2). Lower is generally preferred.
5. **HBA:** Both ligands have 6 HBA, which is acceptable.
6. **QED:** Ligand A (0.859) is significantly better than Ligand B (0.658), indicating a more drug-like profile.
7. **DILI:** Ligand A (77.394) is worse than Ligand B (48.817). This is a significant advantage for B.
8. **BBB:** Both ligands have good BBB penetration (A: 70.88, B: 74.447). Not a major differentiating factor for ADRB2.
9. **Caco-2:** Ligand A (-4.885) is better than Ligand B (-5.07). Both are negative, indicating poor permeability, but A is slightly better.
10. **Solubility:** Ligand A (-2.758) is better than Ligand B (-2.08). Both are poor, but A is slightly better.
11. **hERG:** Both ligands have very low hERG risk (A: 0.118, B: 0.182). No significant difference.
12. **Cl_mic:** Ligand A (12.784) is much better than Ligand B (35.963). Lower clearance indicates better metabolic stability, a crucial factor.
13. **t1/2:** Ligand A (23.769) is better than Ligand B (-5.616). A positive half-life is preferred.
14. **Pgp:** Both ligands have low Pgp efflux (A: 0.083, B: 0.084). No significant difference.
15. **Binding Affinity:** Ligand B (-3.6) is better than Ligand A (-2.4). A 1.2 kcal/mol difference is substantial and can often outweigh minor ADME drawbacks.
**Overall Assessment:**
Ligand B has a significant advantage in binding affinity (-3.6 vs -2.4 kcal/mol) and a much lower DILI risk. While Ligand A has better QED, TPSA, logP, and metabolic stability, the affinity difference is substantial. For a GPCR target like ADRB2, potency is paramount. The lower DILI risk of B is also a significant safety advantage. The slightly lower logP of B is a minor concern, but can be addressed in further optimization.
Output:
0
2025-04-17 18:43:39,643 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (363.845 Da) is within the ideal range (200-500 Da). Ligand B (346.435 Da) is also within range. No clear advantage here.
2. **TPSA:** Ligand A (56.07) is excellent, well below the 140 threshold for oral absorption. Ligand B (103.87) is still acceptable, but higher, potentially impacting absorption. A favors here.
3. **logP:** Ligand A (2.674) is optimal (1-3). Ligand B (0.978) is slightly low, potentially hindering membrane permeability. A is preferred.
4. **HBD:** Ligand A (0) is good. Ligand B (2) is also acceptable, but more donors can sometimes lead to issues. A is slightly favored.
5. **HBA:** Both Ligand A (5) and Ligand B (5) are within the acceptable range (<=10). No significant difference.
6. **QED:** Both Ligand A (0.841) and Ligand B (0.827) are excellent, indicating good drug-like properties. No clear advantage.
7. **DILI:** Ligand A (64.599) is slightly higher risk than Ligand B (52.617), but both are below the concerning 60 threshold. B is slightly favored.
8. **BBB:** Ligand A (70.648) is good, indicating reasonable potential for CNS penetration (though ADRB2 is primarily cardiovascular, some CNS off-target effects are possible). Ligand B (60.644) is lower. A is preferred.
9. **Caco-2:** Ligand A (-4.697) is very poor. Ligand B (-5.543) is also poor, but slightly worse. This is a significant negative for both.
10. **Solubility:** Ligand A (-2.075) is poor. Ligand B (-2.574) is even worse. Both have solubility issues.
11. **hERG:** Ligand A (0.451) is very low risk. Ligand B (0.049) is extremely low risk. B is strongly favored.
12. **Cl_mic:** Ligand A (32.952) is moderate. Ligand B (14.135) is lower, indicating better metabolic stability. B is favored.
13. **t1/2:** Ligand A (57.084) is good. Ligand B (-13.922) is extremely poor. A is strongly favored.
14. **Pgp:** Ligand A (0.227) is low efflux, which is good. Ligand B (0.067) is even lower, indicating even less P-gp efflux. B is strongly favored.
15. **Affinity:** Ligand A (-7.5) is better than Ligand B (-5.8). This is a substantial difference in binding affinity (1.7 kcal/mol). This difference is significant enough to outweigh some of the ADME drawbacks.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand A is the better candidate despite some ADME liabilities. The significantly better affinity (-7.5 vs -5.8 kcal/mol) is a major advantage. The slightly better TPSA and BBB penetration also contribute. While Ligand B has better DILI, hERG, Pgp, and Cl_mic, the substantial difference in binding affinity makes Ligand A more likely to be a viable drug candidate. The poor Caco-2 and solubility of both compounds are concerns that would need to be addressed during optimization, but potency is paramount.
Output:
1
2025-04-17 18:43:39,643 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (344.379 and 351.403 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (110.83) is slightly higher than Ligand B (101.74). Both are below the 140 threshold for good oral absorption, but closer to the 90 threshold for CNS targets (less relevant for ADRB2, a cardiovascular target). Ligand B is preferable.
3. **logP:** Ligand A (-0.059) is quite low, potentially hindering permeation. Ligand B (1.413) is within the optimal 1-3 range. This is a significant advantage for Ligand B.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 8 HBA, while Ligand B has 6. Both are acceptable, but Ligand B is slightly better.
6. **QED:** Both ligands have good QED scores (0.672 and 0.745), indicating drug-likeness. Ligand B is slightly better.
7. **DILI:** Both ligands have similar DILI risk (65.723 and 65.491), placing them in a moderate risk category. Not a major differentiator.
8. **BBB:** Both have similar BBB penetration (58.55 and 65.219). As ADRB2 is a cardiovascular target, BBB penetration is not a primary concern.
9. **Caco-2:** Both have negative Caco-2 values (-5.208 and -4.737). This is unusual and suggests poor permeability. However, the values are similar.
10. **Solubility:** Both have negative solubility values (-2.315 and -2.0). This is also concerning, indicating poor aqueous solubility. Again, similar for both.
11. **hERG:** Both have very low hERG inhibition risk (0.07 and 0.094). Excellent for both.
12. **Cl_mic:** Ligand A (40.492) has a higher microsomal clearance than Ligand B (19.894), indicating lower metabolic stability. Ligand B is preferable.
13. **t1/2:** Ligand B (-9.749) has a significantly longer in vitro half-life than Ligand A (-4.116). This is a major advantage for Ligand B.
14. **Pgp:** Both have low P-gp efflux liability (0.055 and 0.078). Good for both.
15. **Binding Affinity:** Ligand B (-6.8 kcal/mol) has a slightly better binding affinity than Ligand A (-6.0 kcal/mol). While the difference is less than 1.5 kcal/mol, it contributes to the overall preference for Ligand B.
**GPCR-specific considerations:**
For a GPCR like ADRB2, logP, TPSA, and affinity are important. Ligand B excels in logP and has a slightly better affinity. While TPSA is similar, Ligand B's lower value is slightly preferable.
**Overall:**
Ligand B consistently outperforms Ligand A in several key ADME properties (logP, Cl_mic, t1/2) and has a slightly better binding affinity. While both have issues with Caco-2 and solubility, these are similar for both. Therefore, Ligand B is the more promising drug candidate.
Output:
0
2025-04-17 18:43:39,644 - INFO - Batch 58 complete. Total preferences: 928
2025-04-17 18:43:39,644 - INFO - Processing batch 59/512...
2025-04-17 18:44:32,481 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (362.499 and 348.443 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (66.4) is slightly higher than Ligand B (59.08). Both are below the 140 threshold for good oral absorption, but closer to the 90 threshold for CNS targets (less relevant for ADRB2, a cardiovascular target). Ligand B is preferable.
3. **logP:** Ligand A (2.351) is within the optimal 1-3 range. Ligand B (1.375) is also within range, but at the lower end. Ligand A is preferable.
4. **HBD:** Both ligands have 0 HBD, which is good.
5. **HBA:** Ligand A has 5 HBA, and Ligand B has 4. Both are below the 10 threshold. No significant difference.
6. **QED:** Both ligands have good QED scores (0.575 and 0.72), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Both ligands have low DILI risk (31.02 and 33.812 percentile), which is excellent. No significant difference.
8. **BBB:** Ligand A (74.176) has a significantly higher BBB penetration percentile than Ligand B (60.644). While ADRB2 is not a CNS target, higher BBB is generally favorable, indicating less potential for off-target effects. Ligand A is preferable.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.821 and -4.397). This is unusual and suggests poor permeability. However, the values are fairly close.
10. **Solubility:** Both ligands have negative solubility values (-1.946 and -1.522). This is also unusual and suggests poor solubility. Again, the values are fairly close.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.415 and 0.173), which is excellent. Ligand B is preferable.
12. **Cl_mic:** Ligand A (33.808) and Ligand B (31.681) have similar microsomal clearance values. No significant difference.
13. **t1/2:** Ligand B (-11.729) has a significantly longer in vitro half-life than Ligand A (-9.24). This is a major advantage.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.474 and 0.028). Ligand B is preferable.
15. **Binding Affinity:** Ligand A (-7.1 kcal/mol) has a slightly better binding affinity than Ligand B (-6.5 kcal/mol). This is a significant advantage, as a >1.5 kcal/mol difference can outweigh other drawbacks.
**GPCR-specific priorities:** For GPCRs, logP, Pgp, TPSA, and affinity are key. Ligand A has a better logP and affinity, while Ligand B has better TPSA and Pgp. The affinity difference for Ligand A is substantial. The longer half-life of Ligand B is also attractive.
**Overall Assessment:**
While Ligand B has some advantages in terms of half-life, Pgp, and TPSA, the significantly stronger binding affinity of Ligand A (-7.1 vs -6.5 kcal/mol) is the most important factor for a GPCR target. The slightly better BBB penetration of Ligand A is also a bonus. The solubility and Caco-2 values are concerning for both, but the potency advantage of Ligand A is likely to be more impactful in early optimization.
Output:
1
2025-04-17 18:44:32,482 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (364.471) is slightly higher than Ligand B (343.387), but both are acceptable.
2. **TPSA:** Ligand A (83.89) is better than Ligand B (109.14). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (A: 1.514, B: 1.216), falling within the optimal 1-3 range.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Both ligands have the same number of HBA (6), which is acceptable.
6. **QED:** Ligand A (0.858) has a significantly better QED score than Ligand B (0.756), indicating a more drug-like profile.
7. **DILI:** Ligand A (35.401) has a much lower DILI risk than Ligand B (50.097). This is a critical advantage.
8. **BBB:** Not a high priority for a cardiovascular target. Ligand A (47.111) is slightly better than Ligand B (36.448), but this is not a major factor.
9. **Caco-2:** Both ligands have similar, very negative Caco-2 values (-5.19 and -5.117). This suggests poor permeability, which is a concern.
10. **Solubility:** Ligand A (-1.303) has better aqueous solubility than Ligand B (-3.079), which is beneficial.
11. **hERG:** Both ligands have very low hERG inhibition risk (A: 0.118, B: 0.132).
12. **Cl_mic:** Ligand A (-0.379) has a lower (better) microsomal clearance than Ligand B (9.932), suggesting better metabolic stability.
13. **t1/2:** Ligand A (8.29) has a significantly longer in vitro half-life than Ligand B (-27.038). This is a major advantage.
14. **Pgp:** Both ligands have very low Pgp efflux liability (A: 0.029, B: 0.004).
15. **Binding Affinity:** Ligand B (-9.4) has a substantially stronger binding affinity than Ligand A (-5.2). This is a 4.2 kcal/mol difference, which is a significant advantage.
**Overall Assessment:**
Ligand B has a much stronger binding affinity, which is a key driver for GPCR drug candidates. However, it suffers from a higher DILI risk, significantly worse metabolic stability (higher Cl_mic, much shorter half-life), and lower QED. Ligand A has a better overall ADMET profile, with lower DILI, better metabolic stability, and a higher QED score. The difference in binding affinity is substantial, but the ADMET liabilities of Ligand B are concerning. Given the balance, I believe Ligand A is the more viable starting point for optimization, as the ADMET properties are more readily improved than a large affinity gap.
Output:
1
2025-04-17 18:44:32,482 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Ligand A (384.929 Da) is within the ideal range (200-500 Da). Ligand B (359.377 Da) is also within the ideal range. No clear advantage here.
2. **TPSA:** Ligand A (50.8) is good, well below the 140 threshold for oral absorption. Ligand B (93.78) is higher, but still potentially acceptable, though less optimal. Ligand A is preferred.
3. **logP:** Ligand A (3.334) is optimal (1-3). Ligand B (-1.315) is significantly lower, which is a concern for permeability and could lead to poor absorption. Ligand A is strongly preferred.
4. **HBD:** Ligand A (1) is good. Ligand B (3) is slightly higher, but still within the acceptable limit of 5.
5. **HBA:** Ligand A (4) is good. Ligand B (5) is also acceptable.
6. **QED:** Ligand A (0.868) is excellent, indicating a very drug-like profile. Ligand B (0.547) is acceptable, but lower. Ligand A is preferred.
7. **DILI:** Ligand A (60.644) is moderately risky. Ligand B (50.989) is better, indicating lower potential for liver injury. Ligand B is preferred.
8. **BBB:** Ligand A (75.533) is good, suggesting reasonable potential for CNS penetration if desired. Ligand B (61.807) is lower. Given ADRB2 is a cardiovascular target, BBB isn't a primary concern, but a higher value is still slightly favorable. Ligand A is slightly preferred.
9. **Caco-2:** Ligand A (-4.817) is poor. Ligand B (-5.252) is also poor. Both have very low Caco-2 permeability.
10. **Solubility:** Ligand A (-4.213) is poor. Ligand B (-1.96) is also poor. Both have very low solubility.
11. **hERG:** Ligand A (0.466) has low hERG risk. Ligand B (0.301) has even lower hERG risk. Ligand B is preferred.
12. **Cl_mic:** Ligand A (51.744) is moderate. Ligand B (-16.684) is excellent, indicating very high metabolic stability. Ligand B is strongly preferred.
13. **t1/2:** Ligand A (38.195) is good. Ligand B (-3.992) is very poor. Ligand A is strongly preferred.
14. **Pgp:** Ligand A (0.178) has low P-gp efflux. Ligand B (0.005) has extremely low P-gp efflux. Ligand B is strongly preferred.
15. **Affinity:** Ligand A (-8.6 kcal/mol) has significantly stronger binding affinity than Ligand B (-6.4 kcal/mol). This is a substantial advantage.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp efflux, and affinity are crucial. Ligand A excels in logP, affinity, and has acceptable TPSA and Pgp. Ligand B has better DILI, hERG, Cl_mic, and Pgp, but suffers from a very poor logP and lower affinity. The strong affinity of Ligand A is a major advantage that can potentially overcome some of its ADME liabilities.
**Overall Assessment:**
While Ligand B has better metabolic stability and safety profiles (DILI, hERG, Cl_mic, Pgp), the significantly stronger binding affinity of Ligand A (-8.6 vs -6.4 kcal/mol) is a decisive factor. The difference in affinity is large enough to outweigh the ADME concerns, especially considering that formulation strategies can be employed to address solubility and permeability issues. The poor Caco-2 and solubility of both compounds are concerning, but can be addressed with prodrug strategies or formulation techniques.
Output:
1
2025-04-17 18:44:32,482 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (369.49 & 361.87 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (96.86) is higher than Ligand B (56.15). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B is better here.
3. **logP:** Ligand A (2.416) is within the optimal 1-3 range. Ligand B (3.851) is slightly higher, pushing the boundary. Both are acceptable, but A is preferable.
4. **HBD:** Ligand A (2) and Ligand B (1) are both good, below the threshold of 5. Ligand B is slightly better.
5. **HBA:** Ligand A (5) and Ligand B (4) are both good, below the threshold of 10. Ligand B is slightly better.
6. **QED:** Both ligands have similar QED values (0.833 and 0.814), indicating good drug-likeness. No significant difference.
7. **DILI:** Both ligands have similar DILI risk (52.07 & 50.52), and are both below the 60 threshold, indicating acceptable risk. No significant difference.
8. **BBB:** Ligand A (65.26) is lower than Ligand B (82.67). While ADRB2 isn't a CNS target, some degree of BBB penetration can be helpful for distribution. Ligand B is better.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.685 and -4.519). This is unusual and suggests poor permeability. However, the values are very similar.
10. **Solubility:** Ligand A (-2.776) is better than Ligand B (-4.772). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.304) is lower than Ligand B (0.575), indicating a lower risk of hERG inhibition and cardiotoxicity. This is a significant advantage for a cardiovascular target.
12. **Cl_mic:** Ligand A (36.61) has a lower microsomal clearance than Ligand B (87.72), suggesting better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand A (13.09) has a longer in vitro half-life than Ligand B (1.75). This is a significant advantage.
14. **Pgp:** Ligand A (0.058) has lower P-gp efflux liability than Ligand B (0.347), suggesting better bioavailability. This is a significant advantage.
15. **Binding Affinity:** Ligand B (-6.6 kcal/mol) has a slightly better binding affinity than Ligand A (-5.9 kcal/mol). This is a 1.5 kcal/mol difference, which is substantial.
**Overall Assessment:**
While Ligand B has a slightly better binding affinity and BBB penetration, Ligand A demonstrates a significantly better ADME profile. Specifically, its lower hERG inhibition, lower microsomal clearance, longer half-life, and lower P-gp efflux are crucial advantages for a cardiovascular drug candidate. The slightly lower affinity of Ligand A can potentially be optimized in subsequent iterations, while fixing the ADME liabilities of Ligand B would be more challenging. Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity), and the importance of avoiding cardiotoxicity in a cardiovascular context, Ligand A is the more promising candidate.
Output:
1
2025-04-17 18:44:32,483 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (343.431 and 344.499 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (91.02) is higher than Ligand B (40.62). For a GPCR, lower TPSA is generally preferred for better brain penetration, even though ADRB2 isn't strictly a CNS target. Ligand B is significantly better here.
3. **logP:** Ligand A (0.784) is a bit low, potentially impacting permeability. Ligand B (3.232) is within the optimal 1-3 range. Ligand B is better.
4. **HBD:** Ligand A (1) is good. Ligand B (0) is also acceptable. No strong preference.
5. **HBA:** Ligand A (5) is good. Ligand B (2) is excellent. Ligand B is better.
6. **QED:** Ligand A (0.875) is excellent, indicating high drug-likeness. Ligand B (0.446) is below the 0.5 threshold, raising some concerns. Ligand A is better.
7. **DILI:** Ligand A (28.228) has a much lower DILI risk than Ligand B (13.339). This is a significant advantage for Ligand A.
8. **BBB:** Ligand B (77.627) has a higher BBB penetration percentile than Ligand A (59.131). While ADRB2 isn't a primary CNS target, some degree of BBB penetration can be useful for understanding off-target effects.
9. **Caco-2:** Ligand A (-5.143) and Ligand B (-4.604) both have negative Caco-2 values, which is unusual and suggests poor permeability. This is a concern for both, but the values are close.
10. **Solubility:** Ligand A (-1.796) and Ligand B (-3.473) both have poor solubility. Ligand B is slightly worse.
11. **hERG:** Both ligands have low hERG inhibition risk (0.126 and 0.692 respectively). No significant difference.
12. **Cl_mic:** Ligand A (-1.932) has a lower (better) microsomal clearance than Ligand B (49.342). This indicates better metabolic stability for Ligand A.
13. **t1/2:** Ligand B (18.043) has a significantly longer in vitro half-life than Ligand A (0.955). This is a major advantage for Ligand B.
14. **Pgp:** Ligand A (0.016) has very low P-gp efflux, which is excellent. Ligand B (0.322) has moderate P-gp efflux. Ligand A is much better.
15. **Binding Affinity:** Ligand B (-5.3) has a slightly better binding affinity than Ligand A (-4.0). This is a 1.3 kcal/mol difference, which is substantial.
**Overall Assessment:**
Ligand B has a better logP, TPSA, BBB, and binding affinity, and a significantly longer half-life. However, it suffers from a lower QED, higher DILI risk, and higher P-gp efflux. Ligand A excels in QED, DILI, P-gp efflux, and metabolic stability (Cl_mic). The binding affinity difference is significant, but the other ADME properties of Ligand A are more favorable for overall drug development, especially the low DILI risk and excellent P-gp profile. Given the GPCR-specific priorities, the lower TPSA and better logP of Ligand B are attractive, but the substantial differences in DILI and P-gp efflux, coupled with the good (though not exceptional) affinity of Ligand A, make it the more promising candidate.
Output:
1
2025-04-17 18:44:32,483 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.5 and 347.4 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (69.64) is significantly better than Ligand B (115.89). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is pushing the upper limit for good oral absorption.
3. **logP:** Ligand A (2.78) is optimal, while Ligand B (0.124) is quite low. Low logP can hinder membrane permeability and bioavailability. This is a substantial advantage for Ligand A.
4. **HBD:** Ligand A (2) is preferable to Ligand B (4). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (5) for similar reasons as HBD.
6. **QED:** Ligand A (0.724) has a better QED score than Ligand B (0.456), indicating a more drug-like profile.
7. **DILI:** Both ligands have acceptable DILI risk (Ligand A: 32.07, Ligand B: 29.97). Ligand B is slightly better, but the difference is minor.
8. **BBB:** Both ligands have similar BBB penetration (Ligand A: 50.45, Ligand B: 52.81). This isn't a primary concern for ADRB2, which isn't a CNS target, but higher is generally better.
9. **Caco-2:** Ligand A (-4.623) is better than Ligand B (-5.406). Higher values indicate better intestinal absorption.
10. **Solubility:** Ligand A (-2.725) is better than Ligand B (-1.865). Higher solubility is generally preferred.
11. **hERG:** Both ligands have low hERG inhibition risk (Ligand A: 0.251, Ligand B: 0.484). Ligand A is slightly better.
12. **Cl_mic:** Ligand B (-14.603) has significantly lower (better) microsomal clearance than Ligand A (44.304), suggesting greater metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand B (-18.062) has a longer in vitro half-life than Ligand A (7.486), further supporting its better metabolic stability.
14. **Pgp:** Both ligands have low P-gp efflux liability (Ligand A: 0.105, Ligand B: 0.099). No significant difference.
15. **Binding Affinity:** Ligand B (-7.1) has a slightly better binding affinity than Ligand A (-5.6). This is a 1.5 kcal/mol difference, which is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand B has a significantly better binding affinity and metabolic stability (lower Cl_mic and longer t1/2). However, Ligand A excels in several key ADME properties crucial for oral bioavailability and permeability: TPSA, logP, HBD, HBA, QED, solubility, and Caco-2 permeability.
Given that ADRB2 is a cardiovascular target (not CNS), BBB penetration is less critical. While the affinity difference is important, the substantial improvements in ADME properties with Ligand A, particularly logP and TPSA, are more likely to translate to good oral bioavailability and *in vivo* efficacy. The improved QED score also supports a more favorable overall drug-like profile for Ligand A.
Output:
1
2025-04-17 18:44:32,483 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands (364.511 and 368.518 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (81.42) is higher than Ligand B (42.43). For a GPCR, lower TPSA is generally preferred for better brain penetration, even if this isn't a CNS target. Ligand B is significantly better here.
3. **logP:** Both ligands have good logP values (3.794 and 3.989), falling within the optimal 1-3 range. Ligand B is slightly higher, which could be a minor advantage.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (0). Lower HBD is generally preferred for permeability, giving a slight edge to Ligand B.
5. **HBA:** Ligand A (5) is slightly higher than Ligand B (4). Similar to HBD, Ligand B is slightly favored.
6. **QED:** Both ligands have similar and acceptable QED values (0.721 and 0.762), indicating good drug-likeness.
7. **DILI:** Ligand B (29.624) has a much lower DILI risk than Ligand A (42.536). This is a significant advantage for Ligand B.
8. **BBB:** Ligand B (92.943) has a higher BBB percentile than Ligand A (84.141). While ADRB2 isn't exclusively a CNS target, higher BBB is still a positive attribute for potential off-target effects and overall distribution.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.999 and -4.677). This is unusual and suggests poor permeability. However, the scale is not specified, so it is hard to interpret.
10. **Solubility:** Both ligands have negative solubility values (-2.576 and -3.529). This is also unusual and suggests poor solubility.
11. **hERG:** Both ligands have low hERG inhibition liability (0.6 and 0.565), which is good.
12. **Cl_mic:** Ligand B (60.58) has a slightly lower microsomal clearance than Ligand A (57.707), suggesting better metabolic stability.
13. **t1/2:** Ligand A (61.948) has a significantly longer in vitro half-life than Ligand B (16.351). This is a major advantage for Ligand A, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.221) has a lower P-gp efflux liability than Ligand B (0.53). This is a positive for Ligand A, potentially improving oral bioavailability.
15. **Binding Affinity:** Ligand B (-8.0) has a significantly stronger binding affinity than Ligand A (-5.7). This is a substantial advantage that can often outweigh minor ADME drawbacks.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, and affinity. Ligand B excels in TPSA and affinity, while both are good for logP. Ligand A has an advantage in Pgp and t1/2. However, the significantly stronger binding affinity of Ligand B and its lower DILI risk are compelling advantages.
**Conclusion:**
Despite Ligand A's better half-life and Pgp profile, the substantially stronger binding affinity of Ligand B (-8.0 vs -5.7 kcal/mol) and its significantly lower DILI risk outweigh these advantages. The lower TPSA of Ligand B is also beneficial.
Output:
0
2025-04-17 18:44:32,483 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [441.156, 45.23, 4.908, 1, 2, 0.674, 59.519, 88.29, -4.713, -5.824, 0.524, 60.928, 52.371, 0.396, -7.8]**
**Ligand B: [339.355, 110, 1.179, 2, 6, 0.698, 90.229, 44.668, -5.838, -3.126, 0.031, -7.339, 10.769, 0.051, -6.7]**
1. **Molecular Weight:** Ligand A (441.156 Da) is within the ideal range. Ligand B (339.355 Da) is also acceptable, but slightly on the lower side.
2. **TPSA:** Ligand A (45.23) is excellent, well below the 140 threshold. Ligand B (110) is higher, but still potentially acceptable for a peripherally acting GPCR.
3. **logP:** Ligand A (4.908) is a bit high, potentially leading to solubility issues and off-target interactions. Ligand B (1.179) is good, within the optimal range.
4. **H-Bond Donors:** Both ligands have acceptable HBD counts (1 and 2, respectively).
5. **H-Bond Acceptors:** Ligand A (2) is good. Ligand B (6) is higher, but still within the acceptable limit of 10.
6. **QED:** Both ligands have similar and acceptable QED values (0.674 and 0.698).
7. **DILI:** Ligand A (59.519) is better than Ligand B (90.229), indicating a lower risk of drug-induced liver injury. This is a significant advantage.
8. **BBB:** Ligand A (88.29) shows good potential for BBB penetration, while Ligand B (44.668) is low. Since ADRB2 is expressed in the brain, some degree of BBB penetration could be beneficial, though not essential.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Aqueous Solubility:** Ligand A (-5.824) is very poor, which is concerning given its already high logP. Ligand B (-3.126) is also poor, but better than Ligand A.
11. **hERG:** Ligand A (0.524) is better than Ligand B (0.031), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand A (60.928) has a higher clearance, suggesting lower metabolic stability. Ligand B (-7.339) has a negative clearance, which is not physically possible and suggests an issue with the data.
13. **t1/2:** Ligand A (52.371) has a reasonable half-life. Ligand B (10.769) has a very short half-life, which would require frequent dosing.
14. **Pgp:** Ligand A (0.396) has lower P-gp efflux, which is favorable. Ligand B (0.051) also has low P-gp efflux.
15. **Binding Affinity:** Ligand A (-7.8) has a significantly stronger binding affinity than Ligand B (-6.7). This is a substantial advantage.
**Overall Assessment:**
Ligand A has a significantly better binding affinity and a lower DILI risk. However, its high logP and poor solubility are major drawbacks. Ligand B has better solubility and logP, but its DILI risk is high, its half-life is very short, and its binding affinity is weaker.
Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity), and the fact that ADRB2 is a cardiovascular target (so CNS penetration is less critical), the stronger binding affinity of Ligand A is the most important factor. While the solubility and logP are concerns, these can potentially be addressed through formulation strategies or further chemical modifications. The DILI risk is also manageable with careful monitoring. The negative clearance value for Ligand B is a red flag.
Therefore, I would choose Ligand A.
1
2025-04-17 18:44:32,484 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**1. Molecular Weight:** Both ligands (343.402 Da and 358.454 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (52.65) is better than Ligand B (59.08). Both are below the 140 A^2 threshold for oral absorption, but lower TPSA is generally preferred for GPCRs, aiding permeability.
**3. logP:** Both ligands have acceptable logP values (1.232 and 1.485, respectively), falling within the 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability, but not drastically so.
**4. H-Bond Donors:** Ligand A has 1 HBD, while Ligand B has 0. Both are within the acceptable limit of <=5.
**5. H-Bond Acceptors:** Ligand A has 3 HBA, and Ligand B has 4. Both are within the acceptable limit of <=10.
**6. QED:** Ligand A (0.791) has a higher QED score than Ligand B (0.692), indicating a more drug-like profile.
**7. DILI Risk:** Ligand A (36.06%) has a higher DILI risk than Ligand B (17.642%). This is a significant advantage for Ligand B.
**8. BBB Penetration:** Ligand B (91.663%) has significantly better predicted BBB penetration than Ligand A (78.635%). Given ADRB2's role in cardiovascular function, CNS penetration isn't a primary requirement, but it's not detrimental and could open up possibilities for exploring CNS-related effects.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.41 and -4.218). These values are unusual and suggest poor permeability. However, the scale isn't defined, so it's hard to interpret.
**10. Aqueous Solubility:** Ligand A (-2.38) has slightly better aqueous solubility than Ligand B (-1.008).
**11. hERG Inhibition:** Both ligands show low hERG inhibition risk (0.352 and 0.552, respectively).
**12. Microsomal Clearance:** Ligand A (0.284) has significantly lower microsomal clearance than Ligand B (21.27). This suggests better metabolic stability for Ligand A.
**13. In vitro Half-Life:** Ligand A (-3.15) has a much longer in vitro half-life than Ligand B (10.895). This is a substantial advantage for Ligand A.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.036 and 0.058, respectively).
**15. Binding Affinity:** Ligand B (-6.2 kcal/mol) has a stronger binding affinity than Ligand A (-5.0 kcal/mol). This is a 1.2 kcal/mol difference, which is a significant advantage.
**Overall Assessment:**
While Ligand A has advantages in QED, metabolic stability (lower Cl_mic), and in vitro half-life, Ligand B's significantly stronger binding affinity (-6.2 vs -5.0 kcal/mol) and substantially lower DILI risk are more critical for a GPCR drug candidate. The better BBB penetration of Ligand B is also a plus. The Caco-2 permeability values are concerning for both, but the affinity difference is substantial enough to outweigh this concern. Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity), Ligand B is the more promising candidate.
Output:
0
2025-04-17 18:44:32,484 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [429.424, 49.41, 4.86, 1, 3, 0.727, 54.75, 83.482, -5.021, -6.075, 0.862, 95.829, 11.337, 0.585, -5.4]**
**Ligand B: [367.559, 58.36, 3.089, 1, 5, 0.729, 16.402, 70.415, -4.759, -2.764, 0.336, 62.596, 22.473, 0.318, -6.2]**
1. **Molecular Weight:** Ligand A (429.424 Da) is within the ideal range, while Ligand B (367.559 Da) is also acceptable, though closer to the lower limit. No strong preference here.
2. **TPSA:** Ligand A (49.41) is good, well below 140, and suitable for oral absorption. Ligand B (58.36) is also acceptable.
3. **logP:** Ligand A (4.86) is slightly high, potentially leading to solubility issues or off-target interactions. Ligand B (3.089) is optimal. This favors Ligand B.
4. **H-Bond Donors:** Both ligands have 1 HBD, which is good.
5. **H-Bond Acceptors:** Ligand A has 3 HBA, Ligand B has 5. Both are within the acceptable limit of 10.
6. **QED:** Both ligands have similar QED scores (0.727 and 0.729), indicating good drug-likeness.
7. **DILI Risk:** Ligand A (54.75%) has a moderate DILI risk, while Ligand B (16.402%) has a very low risk. This strongly favors Ligand B.
8. **BBB Penetration:** Ligand A (83.482%) has good BBB penetration, while Ligand B (70.415%) is also reasonable. Considering ADRB2 is a cardiovascular target, BBB penetration is not a primary concern, but a slight edge to Ligand A.
9. **Caco-2 Permeability:** Ligand A (-5.021) and Ligand B (-4.759) both have negative values, which is unusual. It suggests poor permeability.
10. **Aqueous Solubility:** Ligand A (-6.075) has very poor solubility, while Ligand B (-2.764) is better, but still low. This favors Ligand B.
11. **hERG Inhibition:** Ligand A (0.862) has a higher hERG risk than Ligand B (0.336). This favors Ligand B.
12. **Microsomal Clearance:** Ligand A (95.829) has high clearance, indicating poor metabolic stability. Ligand B (62.596) has moderate clearance. This favors Ligand B.
13. **In vitro Half-Life:** Ligand A (11.337 hours) has a moderate half-life, while Ligand B (22.473 hours) has a longer half-life. This favors Ligand B.
14. **P-gp Efflux:** Ligand A (0.585) has moderate P-gp efflux, while Ligand B (0.318) has lower efflux. This favors Ligand B.
15. **Binding Affinity:** Ligand B (-6.2 kcal/mol) has a slightly better binding affinity than Ligand A (-5.4 kcal/mol). This favors Ligand B.
**Overall Assessment:**
Ligand B consistently outperforms Ligand A in critical ADME-Tox properties (DILI, solubility, hERG, clearance, half-life, P-gp efflux) and has a slightly better binding affinity. While Ligand A has better BBB penetration, this is less crucial for a cardiovascular target. The significantly lower DILI risk and improved metabolic stability of Ligand B make it a more promising drug candidate.
Output:
0
2025-04-17 18:44:32,484 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (341.415 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (82.53) is significantly better than Ligand A (111.25). ADRB2 is a cardiovascular target, so BBB isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (A: 1.469, B: 2.189), falling within the optimal 1-3 range. Ligand B is slightly higher, potentially improving membrane permeability.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (2), but both are acceptable (<=5).
5. **HBA:** Both ligands have the same HBA count (4), which is well within the acceptable range (<=10).
6. **QED:** Both ligands have good QED scores (A: 0.77, B: 0.848), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Both ligands have very similar and acceptable DILI risk (A: 34.626, B: 34.82), both well below the 60 threshold.
8. **BBB:** Ligand A (70.027) has a slightly better BBB penetration score than Ligand B (64.754), but this isn't a major factor for a cardiovascular target.
9. **Caco-2:** Ligand A (-5.355) has a worse Caco-2 permeability than Ligand B (-4.769). This suggests Ligand B will have better intestinal absorption.
10. **Solubility:** Ligand A (-3.169) has slightly better aqueous solubility than Ligand B (-2.423). Solubility is important, but not the primary driver here.
11. **hERG:** Both ligands have very low hERG inhibition liability (A: 0.573, B: 0.359). Ligand B is slightly better, indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand A (-16.987) has a significantly lower (better) microsomal clearance than Ligand B (-6.325). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (19.987) has a significantly longer in vitro half-life than Ligand B (-29.231). This is a substantial advantage for Ligand A, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have very low P-gp efflux liability (A: 0.008, B: 0.019).
15. **Binding Affinity:** Ligand B (-7.0) has a slightly better binding affinity than Ligand A (-5.9). This is a 1.1 kcal/mol difference, which is significant and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand B has a clear advantage in binding affinity (-7.0 kcal/mol vs -5.9 kcal/mol) and better Caco-2 permeability. While Ligand A has better metabolic stability (lower Cl_mic and longer t1/2), the affinity difference is substantial. For a GPCR target like ADRB2, potency is paramount. The slightly improved TPSA and logP of Ligand B also contribute to its favorability. The small differences in other parameters are less critical.
Output:
0
2025-04-17 18:44:32,484 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands (341.371 and 344.375 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (106.94 and 104.45) are below the 140 A^2 threshold for good oral absorption, but higher than the 90 A^2 target for CNS penetration. Since ADRB2 is primarily a cardiovascular target, CNS penetration is not a high priority.
3. **logP:** Ligand A (2.952) is optimal, while Ligand B (0.385) is quite low. This is a significant difference. Low logP can lead to poor membrane permeability and bioavailability.
4. **HBD/HBA:** Both have 1 HBD and 7 HBA, which are within acceptable limits.
5. **QED:** Ligand B (0.863) has a slightly better QED score than Ligand A (0.704), indicating a more drug-like profile.
6. **DILI:** Ligand B (67.778) has a lower DILI risk than Ligand A (81.233), which is a positive attribute.
7. **BBB:** Ligand A (79.721) has a higher BBB penetration score than Ligand B (32.765), but as mentioned previously, this isn't a major concern for a cardiovascular target.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests potential issues with intestinal absorption. However, the scale is not specified, so it's hard to interpret the significance.
9. **Solubility:** Both have negative solubility values, which is also unusual. Again, the scale is unknown.
10. **hERG:** Both ligands have very low hERG inhibition liability (0.267 and 0.092), which is excellent.
11. **Cl_mic:** Ligand B (19.283) has a significantly lower microsomal clearance than Ligand A (37.976), indicating better metabolic stability.
12. **t1/2:** Ligand A (19.507) has a positive in vitro half-life, while Ligand B (-20.417) has a negative value, which is concerning.
13. **Pgp:** Both have low Pgp efflux liability (0.229 and 0.06), which is good.
14. **Binding Affinity:** Ligand B (-6.2 kcal/mol) has a slightly better binding affinity than Ligand A (-6.8 kcal/mol). While the difference is not huge, it is still a factor.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are important. Ligand A excels in logP, while Ligand B has a slightly better affinity and lower DILI risk. The metabolic stability (lower Cl_mic) of Ligand B is also a significant advantage.
**Overall Assessment:**
Despite the slightly better affinity of Ligand B, the significantly lower logP of Ligand B is a major concern. Poor logP often translates to poor permeability and bioavailability. Ligand A's logP is within the optimal range, making it more likely to be absorbed and reach its target. The better metabolic stability of Ligand B is attractive, but can be addressed through structural modifications. The negative values for Caco-2 and solubility are concerning for both, but the logP issue with Ligand B is more critical.
Output:
1
2025-04-17 18:44:32,484 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (367.921 and 344.459 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (44.81) is significantly better than Ligand B (58.44). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand A is well below the 140 threshold, while Ligand B is approaching the upper limit.
**3. logP:** Both ligands have acceptable logP values (3.086 and 1.792), falling within the 1-3 range. Ligand A is slightly higher, which could be a minor concern for solubility, but still reasonable.
**4. H-Bond Donors:** Ligand A has 1 HBD, and Ligand B has 0. Both are within the acceptable limit of <=5.
**5. H-Bond Acceptors:** Ligand A has 3 HBA, and Ligand B has 4. Both are within the acceptable limit of <=10.
**6. QED:** Both ligands have similar QED values (0.729 and 0.676), indicating good drug-like properties.
**7. DILI Risk:** Ligand A (11.594) has a considerably lower DILI risk than Ligand B (37.611). This is a significant advantage for Ligand A.
**8. BBB Penetration:** Ligand A (91.857) shows much better BBB penetration than Ligand B (70.803). While ADRB2 is a cardiovascular target and doesn't *require* high BBB penetration, it's still a positive attribute, potentially allowing for some central effects or reduced off-target CNS activity.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.214 and -4.756). This is unusual and suggests poor permeability *in vitro*. However, these values are on a logarithmic scale, and the absolute difference isn't massive.
**10. Aqueous Solubility:** Ligand A (-2.413) has slightly better solubility than Ligand B (-1.04), but both are poor. This is a potential formulation challenge.
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (0.802 and 0.299).
**12. Microsomal Clearance:** Both ligands have similar microsomal clearance rates (42.81 and 42.026).
**13. In vitro Half-Life:** Ligand A (46.846) has a significantly longer in vitro half-life than Ligand B (-13.698). This is a major advantage, suggesting better metabolic stability and potentially less frequent dosing.
**14. P-gp Efflux:** Ligand A (0.084) has lower P-gp efflux than Ligand B (0.14). This is favorable for bioavailability.
**15. Binding Affinity:** Both ligands have very similar and strong binding affinities (-5.9 and -5.6 kcal/mol). The difference is not substantial enough to be a deciding factor.
**Overall Assessment:**
Ligand A is the superior candidate. It demonstrates better TPSA, significantly lower DILI risk, better BBB penetration, a longer half-life, and lower P-gp efflux. While both have poor solubility and Caco-2 permeability, the other advantages of Ligand A outweigh these concerns. The slightly higher logP is manageable. The similar binding affinities make the ADME/Tox profile the deciding factor.
Output:
1
2025-04-17 18:44:32,484 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (360.391 and 344.459 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand B (70.25) is significantly better than Ligand A (115.56). ADRB2 is a cardiovascular target, so CNS penetration isn't critical, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (3.552) is higher than Ligand A (1.156). While 3.552 is approaching the upper limit, it's still acceptable. Ligand A's logP is quite low, potentially hindering membrane permeability.
4. **HBD:** Both have 2 HBD, which is good.
5. **HBA:** Ligand B (3) has fewer HBA than Ligand A (5), which is preferable for permeability.
6. **QED:** Both ligands have similar QED values (0.776 and 0.787), indicating good drug-likeness.
7. **DILI:** Ligand B (43.66) has a much lower DILI risk than Ligand A (94.106). This is a major advantage for Ligand B.
8. **BBB:** BBB is less critical for a cardiovascular target. Ligand B (77.007) is higher than Ligand A (67.817), but the difference isn't decisive.
9. **Caco-2:** Ligand A (-5.399) and Ligand B (-4.849) are both poor, indicating poor permeability.
10. **Solubility:** Ligand A (-3.324) and Ligand B (-3.78) are both poor, indicating poor solubility.
11. **hERG:** Ligand B (0.841) has a higher hERG risk than Ligand A (0.202). This is a negative for Ligand B, but the value is not alarming.
12. **Cl_mic:** Ligand A (27.111) has a lower microsomal clearance than Ligand B (42.689), indicating better metabolic stability.
13. **t1/2:** Ligand B (-14.904) has a negative half-life, which is concerning. Ligand A (10.435) is much better.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.242 and 0.272).
15. **Binding Affinity:** Ligand A (-8.7 kcal/mol) has a significantly stronger binding affinity than Ligand B (-5.9 kcal/mol). This is a substantial advantage for Ligand A.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, and affinity are important. Ligand B has better logP and TPSA, but Ligand A has *much* better affinity. The DILI risk is also a major consideration, and Ligand B is significantly better here. The half-life of Ligand B is concerning.
**Overall Assessment:**
The significantly stronger binding affinity of Ligand A (-8.7 vs -5.9 kcal/mol) is a major advantage that likely outweighs the slightly higher DILI risk and poorer TPSA. The better metabolic stability (lower Cl_mic and positive t1/2) of Ligand A is also a positive. While Ligand B has a better DILI profile, the difference in affinity is substantial enough to make Ligand A the more promising candidate, assuming the DILI risk can be mitigated through further optimization.
Output:
1
2025-04-17 18:44:32,485 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (349.391 and 359.495 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand B (62.3) is significantly better than Ligand A (108.77). For a GPCR, lower TPSA is generally preferred for better permeability.
**3. logP:** Both ligands have good logP values (1.393 and 2.015), falling within the optimal 1-3 range. Ligand B is slightly better.
**4. H-Bond Donors:** Ligand A (3) is slightly higher than Ligand B (1), but both are within the acceptable limit of 5.
**5. H-Bond Acceptors:** Ligand A (6) is higher than Ligand B (4), but both are below the 10 limit.
**6. QED:** Ligand B (0.874) has a substantially better QED score than Ligand A (0.548), indicating a more drug-like profile.
**7. DILI:** Ligand B (27.918) has a much lower DILI risk than Ligand A (62.35). This is a significant advantage for Ligand B.
**8. BBB:** Ligand B (67.197) has a better BBB penetration score than Ligand A (59.48), although neither is exceptionally high. For a cardiovascular target, BBB isn't *critical* but a higher value is still favorable.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-5.093) is slightly better than Ligand B (-5.318).
**10. Aqueous Solubility:** Both ligands have negative solubility values, indicating poor solubility. Ligand A (-2.802) is slightly better than Ligand B (-3.175).
**11. hERG Inhibition:** Ligand B (0.159) has a much lower hERG inhibition risk than Ligand A (0.432). This is a critical advantage.
**12. Microsomal Clearance:** Ligand A (-10.01) has a significantly lower (better) microsomal clearance than Ligand B (21.839), indicating greater metabolic stability.
**13. In vitro Half-Life:** Ligand B (-7.503) has a longer in vitro half-life than Ligand A (25.887).
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.018 and 0.039).
**15. Binding Affinity:** Ligand A (-7.2) has a slightly better binding affinity than Ligand B (-6.4). However, the difference is only 0.8 kcal/mol, and can be overcome by other factors.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity and microsomal clearance, Ligand B is significantly better across several crucial ADME-Tox properties. Specifically, the lower DILI risk, lower hERG inhibition, better QED, and lower TPSA make Ligand B a much more promising drug candidate. The slightly longer half-life of Ligand B is also a benefit. The negative Caco-2 and solubility values are concerning for both, but the other advantages of Ligand B outweigh these drawbacks. Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity), Ligand B is the superior choice.
Output:
0
2025-04-17 18:44:32,485 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [339.483, 47.34, 3.582, 0, 3, 0.796, 13.3, 88.639, -4.508, -3.946, 0.955, 70.644, -22.15, 0.276, -5.9]
**Ligand B:** [351.491, 64.09, 0.795, 1, 4, 0.796, 6.786, 57.193, -4.795, -0.633, 0.386, -2.625, 11.17, 0.015, -6.4]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (339.483) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (47.34) is significantly better than Ligand B (64.09). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (3.582) is optimal, while Ligand B (0.795) is quite low. This is a major concern for Ligand B, as it might struggle with membrane permeability.
4. **HBD:** Ligand A (0) is excellent, minimizing potential for off-target interactions. Ligand B (1) is acceptable.
5. **HBA:** Ligand A (3) is good. Ligand B (4) is also acceptable.
6. **QED:** Both ligands (0.796) are excellent, indicating good drug-like properties.
7. **DILI:** Ligand A (13.3) is much better than Ligand B (6.786), indicating a lower risk of liver injury.
8. **BBB:** Ligand A (88.639) is significantly higher than Ligand B (57.193). While not critical for a cardiovascular target, higher BBB is rarely detrimental.
9. **Caco-2:** Both are negative, suggesting poor permeability. However, the scale is not provided, so it's hard to interpret.
10. **Solubility:** Ligand A (-3.946) is better than Ligand B (-0.633), indicating better aqueous solubility.
11. **hERG:** Ligand A (0.955) is better than Ligand B (0.386), indicating a lower risk of cardiotoxicity.
12. **Cl_mic:** Ligand B (-2.625) has a negative clearance, which is unusual and potentially indicates very high metabolic stability. Ligand A (70.644) is moderate.
13. **t1/2:** Ligand A (-22.15) has a negative half-life, which is also unusual and potentially indicates very high in vitro stability. Ligand B (11.17) is moderate.
14. **Pgp:** Ligand A (0.276) is better than Ligand B (0.015), indicating lower P-gp efflux.
15. **Affinity:** Both have very good binding affinity (-5.9 and -6.4 kcal/mol). Ligand B is slightly better, but the difference is likely not enough to overcome its other weaknesses.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are crucial. Ligand A excels in logP and TPSA, and has acceptable Pgp. While Ligand B has a slightly better affinity, its very low logP is a significant drawback. The unusual metabolic stability data for Ligand B is also concerning and warrants further investigation, as negative values are not typical.
**Conclusion:**
Considering the overall profile, **Ligand A** is the more promising drug candidate. Its better physicochemical properties (logP, TPSA, solubility), lower DILI risk, and lower Pgp efflux outweigh the slightly weaker (but still excellent) binding affinity compared to Ligand B.
1
2025-04-17 18:44:32,485 - INFO - Batch 59 complete. Total preferences: 944
2025-04-17 18:44:32,485 - INFO - Processing batch 60/512...
2025-04-17 18:45:20,360 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (363.82 and 341.415 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Both ligands (73.39 and 71.33) are below the 140 A^2 threshold for good oral absorption, which is good.
3. **logP:** Ligand A (2.48) is optimal, while Ligand B (0.963) is slightly below the ideal range, potentially impacting permeability. This favors Ligand A.
4. **HBD:** Ligand A (4) is within the acceptable limit of 5, while Ligand B (0) is also good.
5. **HBA:** Both ligands (4 and 5) are below the 10 threshold.
6. **QED:** Both ligands (0.63 and 0.571) are above 0.5, indicating good drug-likeness.
7. **DILI:** Ligand A (71.93) is higher than Ligand B (46.995), indicating a greater potential for liver injury. This favors Ligand B.
8. **BBB:** Ligand B (63.94) has a better BBB penetration percentile than Ligand A (51.532), though neither is exceptionally high. For a cardiovascular target, BBB isn't a *major* priority, but it's a slight advantage for B.
9. **Caco-2:** Ligand A (-5.077) has a worse Caco-2 permeability than Ligand B (-4.418), suggesting lower intestinal absorption. This favors Ligand B.
10. **Solubility:** Ligand A (-3.683) has worse aqueous solubility than Ligand B (-2.477). This favors Ligand B.
11. **hERG:** Ligand A (0.738) has a lower hERG inhibition liability than Ligand B (0.042), which is preferable. This favors Ligand A.
12. **Cl_mic:** Ligand A (7.853) has significantly lower microsomal clearance than Ligand B (20.949), indicating better metabolic stability. This is a substantial advantage for Ligand A.
13. **t1/2:** Ligand A (15.815) has a longer in vitro half-life than Ligand B (-16.779), which is a significant advantage.
14. **Pgp:** Ligand A (0.308) has lower P-gp efflux liability than Ligand B (0.04), suggesting better bioavailability. This favors Ligand A.
15. **Binding Affinity:** Ligand B (-7.5 kcal/mol) has a slightly better binding affinity than Ligand A (-7.2 kcal/mol). This is a 0.3 kcal/mol difference.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand A and B are relatively comparable. Ligand B has a better affinity, DILI, Caco-2, solubility and BBB. However, Ligand A has significantly better metabolic stability (lower Cl_mic, longer t1/2), and lower Pgp efflux, and a better hERG profile. The metabolic stability and Pgp efflux are critical for *in vivo* exposure. The slightly better affinity of Ligand B is unlikely to overcome the significant PK advantages of Ligand A.
**Output:**
1
2025-04-17 18:45:20,360 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.479 and 362.861 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (67.23) is significantly better than Ligand A (81.75). ADRB2 is not a CNS target, but lower TPSA generally improves absorption.
3. **logP:** Ligand B (1.986) is within the optimal range (1-3), while Ligand A (0.35) is quite low, potentially hindering membrane permeability. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable.
5. **HBA:** Both ligands have 4 HBA, which is within the acceptable range.
6. **QED:** Ligand B (0.814) has a higher QED score than Ligand A (0.693), indicating a more drug-like profile.
7. **DILI:** Ligand A (10.508) has a much lower DILI risk than Ligand B (49.593). This is a substantial advantage for Ligand A.
8. **BBB:** This is less critical for ADRB2 (cardiovascular target). Ligand B (74.447) is higher, but not a primary driver.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the absolute value is slightly less negative for Ligand B (-4.946 vs -5.197).
10. **Solubility:** Ligand A (-1.123) has better solubility than Ligand B (-3.92).
11. **hERG:** Both ligands have very low hERG inhibition risk (0.094 and 0.178).
12. **Cl_mic:** Ligand A (-8.563) has much lower microsomal clearance, indicating better metabolic stability, which is a significant advantage.
13. **t1/2:** Ligand A (7.071) has a longer in vitro half-life than Ligand B (3.09).
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.005 and 0.232).
15. **Affinity:** Ligand A (-7.4 kcal/mol) has a slightly better binding affinity than Ligand B (-6 kcal/mol).
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, and affinity are key. Ligand B excels in logP and TPSA, while Ligand A has a slight edge in affinity. However, the significant advantages of Ligand A in DILI risk and metabolic stability (Cl_mic and t1/2) are crucial for overall drug development success. The lower logP of Ligand A is a concern, but the superior metabolic profile and safety profile outweigh this drawback.
**Conclusion:**
Considering the balance of properties, especially the favorable safety (DILI) and pharmacokinetic (Cl_mic, t1/2) profiles, Ligand A is the more promising drug candidate.
Output:
1
2025-04-17 18:45:20,360 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for their potential as drug candidates targeting the ADRB2, a cardiovascular GPCR. Therefore, we prioritize logP, Pgp, TPSA, and affinity, alongside general drug-like properties.
**Ligand A:**
* **MW:** 335.411 Da - Good, within the ideal range.
* **TPSA:** 67.94 - Good, below the 140 threshold for oral absorption.
* **logP:** 3.882 - Slightly high, but acceptable. Could potentially lead to off-target effects, but the affinity needs to be considered.
* **HBD:** 0 - Low, good for permeability.
* **HBA:** 6 - Good, within the acceptable range.
* **QED:** 0.723 - Excellent, highly drug-like.
* **DILI:** 91.47 - Very high risk of liver injury, a major concern.
* **BBB:** 57.852 - Moderate, not a priority for a cardiovascular target.
* **Caco-2:** -4.997 - Poor permeability.
* **Solubility:** -5.158 - Very poor solubility, a significant issue for bioavailability.
* **hERG:** 0.551 - Relatively low risk.
* **Cl_mic:** 61.523 - Moderate clearance, could require higher dosing.
* **t1/2:** -11.178 - Very short half-life, frequent dosing likely needed.
* **Pgp:** 0.449 - Low efflux, good.
* **Affinity:** -5.8 kcal/mol - Good binding affinity.
**Ligand B:**
* **MW:** 347.411 Da - Good, within the ideal range.
* **TPSA:** 76.07 - Acceptable, but approaching the upper limit for good absorption.
* **logP:** 2.447 - Optimal, within the preferred range.
* **HBD:** 1 - Low, good for permeability.
* **HBA:** 4 - Good, within the acceptable range.
* **QED:** 0.885 - Excellent, highly drug-like.
* **DILI:** 41.179 - Low risk of liver injury, a significant advantage.
* **BBB:** 61.535 - Moderate, not a priority for a cardiovascular target.
* **Caco-2:** -4.578 - Poor permeability, but better than Ligand A.
* **Solubility:** -1.993 - Poor solubility, but better than Ligand A.
* **hERG:** 0.012 - Very low risk.
* **Cl_mic:** 13.997 - Low clearance, good metabolic stability.
* **t1/2:** -9.436 - Short half-life, but better than Ligand A.
* **Pgp:** 0.012 - Very low efflux, excellent.
* **Affinity:** -5.0 kcal/mol - Good binding affinity, slightly weaker than Ligand A.
**Comparison and Decision:**
While Ligand A has a slightly better binding affinity (-5.8 vs -5.0 kcal/mol), its extremely high DILI risk, very poor solubility, and poor Caco-2 permeability are major drawbacks. Ligand B, despite a slightly weaker affinity, presents a much more favorable ADME-Tox profile, with significantly lower DILI risk, better metabolic stability (lower Cl_mic), and lower Pgp efflux. The solubility and permeability are still not ideal, but are better than Ligand A. For a cardiovascular target, the lower DILI risk and improved metabolic stability of Ligand B outweigh the minor difference in binding affinity.
Output:
0
2025-04-17 18:45:20,360 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [347.415, 87.74, 2.243, 2, 4, 0.741, 57.193, 71.656, -4.705, -3.017, 0.433, 35.93, 6.436, 0.015, -6.4]
**Ligand B:** [353.467, 107.4, 2.634, 1, 4, 0.391, 19.659, 70.609, -4.578, -1.846, 0.209, 42.355, -0.081, 0.007, -5.9]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). A (347.4) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** A (87.74) is better than B (107.4), falling comfortably under the 140 threshold for oral absorption.
3. **logP:** Both are within the optimal range (1-3). A (2.243) is slightly better than B (2.634).
4. **HBD:** A (2) is slightly better than B (1). Lower is generally preferred.
5. **HBA:** Both have 4 HBA, which is acceptable.
6. **QED:** A (0.741) is significantly better than B (0.391), indicating a more drug-like profile.
7. **DILI:** A (57.193) is higher than B (19.659), indicating a greater potential for liver injury. This is a significant drawback for A.
8. **BBB:** Both are good, with A (71.656) being slightly better than B (70.609). Since ADRB2 is a GPCR, BBB penetration is a consideration, but not paramount unless targeting CNS effects.
9. **Caco-2:** Both are negative, which is not ideal, but similar.
10. **Solubility:** A (-3.017) is worse than B (-1.846). Solubility is important for bioavailability.
11. **hERG:** A (0.433) is better than B (0.209), indicating a lower risk of cardiotoxicity.
12. **Cl_mic:** A (35.93) is better than B (42.355), suggesting better metabolic stability.
13. **t1/2:** A (6.436) is better than B (-0.081), indicating a longer half-life.
14. **Pgp:** A (0.015) is significantly better than B (0.007), indicating lower P-gp efflux.
15. **Affinity:** A (-6.4) is slightly better than B (-5.9), but the difference is relatively small.
**GPCR-specific considerations:**
For ADRB2 (a GPCR), we prioritize logP, Pgp, TPSA, and affinity. Both ligands perform reasonably well on logP and affinity. Ligand A has a better TPSA and Pgp profile. However, the DILI risk for Ligand A is concerningly high, and its solubility is worse than Ligand B. While the affinity difference isn't huge, the combination of better safety (lower DILI, better hERG) and solubility for Ligand B outweighs the slightly better affinity and Pgp profile of Ligand A.
**Conclusion:**
Considering the balance of properties, particularly the significant DILI risk associated with Ligand A, I would favor **Ligand B**.
0
2025-04-17 18:45:20,360 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.478 and 362.417 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (41.57) is significantly better than Ligand B (59.08). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary goal, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (4.058) is slightly higher than Ligand B (2.516). While both are within the acceptable range (1-3), Ligand A is approaching the upper limit and could potentially have solubility issues.
4. **HBD:** Ligand A (1) is better than Ligand B (0). A single HBD can contribute to solubility without significantly hindering permeability.
5. **HBA:** Ligand A (3) is slightly better than Ligand B (4). Lower HBA is generally preferred.
6. **QED:** Both ligands have similar QED values (0.683 and 0.632), indicating good drug-likeness.
7. **DILI:** Ligand A (9.151) has a significantly lower DILI risk than Ligand B (36.758). This is a crucial advantage, as liver toxicity is a major concern in drug development.
8. **BBB:** Both ligands have high BBB penetration (85.111 and 83.133). While not a primary concern for a cardiovascular target, it doesn't detract from either candidate.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual. This suggests poor permeability. However, the values are similar (-4.668 and -4.093), so it doesn't differentiate them.
10. **Solubility:** Both ligands have negative solubility values (-2.201 and -2.345), indicating poor aqueous solubility. This is a concern, especially given Ligand A's higher logP.
11. **hERG:** Ligand A (0.95) has a slightly higher hERG risk than Ligand B (0.449). This is a minor concern, but worth noting.
12. **Cl_mic:** Ligand A (16.384) has a higher microsomal clearance than Ligand B (14.887), indicating faster metabolism and potentially lower *in vivo* exposure.
13. **t1/2:** Ligand B (10.508) has a significantly longer *in vitro* half-life than Ligand A (6.215). This is a substantial advantage, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.444) has a lower P-gp efflux liability than Ligand B (0.098). This is a positive, as it suggests better absorption and bioavailability.
15. **Binding Affinity:** Ligand A (-7.0) has a slightly better binding affinity than Ligand B (-6.0). This 1 kcal/mol difference is significant and can outweigh some of the ADME drawbacks.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has a slightly better logP, significantly better TPSA and Pgp, and better affinity. The DILI risk is also much lower for Ligand A. While Ligand B has a better half-life, the superior binding affinity and safety profile of Ligand A are more critical.
**Conclusion:**
Despite the slightly better half-life of Ligand B, Ligand A is the more promising candidate due to its superior binding affinity, lower DILI risk, better TPSA, and lower P-gp efflux. The solubility and Caco-2 issues are present in both, but the other advantages of Ligand A outweigh these concerns.
Output:
1
2025-04-17 18:45:20,361 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A:** [364.873, 64.36, 4.232, 1, 4, 0.832, 57.542, 69.407, -4.763, -4.802, 0.556, 86.661, 29.318, 0.287, -8.1]
**Ligand B:** [341.419, 82.68, 1.443, 1, 8, 0.606, 62.776, 67.352, -5.06, -2.915, 0.115, 17.472, -3.382, 0.103, -6.1]
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand B (341.419 Da) is slightly lower, which could be beneficial for permeability, but both are acceptable.
**2. TPSA:** Ligand A (64.36) is better than Ligand B (82.68). ADRB2 is a cardiovascular target, so CNS penetration isn't critical, but lower TPSA generally correlates with better absorption.
**3. logP:** Ligand A (4.232) is higher than Ligand B (1.443). While 4.232 is approaching the upper limit, it's still within an acceptable range. Ligand B's logP is quite low, potentially hindering membrane permeability.
**4. H-Bond Donors:** Both have 1 HBD, which is good.
**5. H-Bond Acceptors:** Ligand A (4) is better than Ligand B (8). Lower HBA is generally preferred for better permeability.
**6. QED:** Ligand A (0.832) is significantly better than Ligand B (0.606), indicating a more drug-like profile.
**7. DILI Risk:** Both are reasonably good, but Ligand A (57.542) is better than Ligand B (62.776).
**8. BBB Penetration:** Both are similar, around 67-69%, which isn't a primary concern for a cardiovascular target.
**9. Caco-2 Permeability:** Ligand A (-4.763) is better than Ligand B (-5.06), indicating better intestinal absorption.
**10. Aqueous Solubility:** Ligand A (-4.802) is better than Ligand B (-2.915).
**11. hERG Inhibition:** Ligand A (0.556) is significantly better than Ligand B (0.115), indicating a lower risk of cardiotoxicity, which is *crucial* for a cardiovascular drug.
**12. Microsomal Clearance:** Ligand B (17.472) is much lower than Ligand A (86.661), suggesting better metabolic stability.
**13. In vitro Half-Life:** Ligand A (29.318) is better than Ligand B (-3.382).
**14. P-gp Efflux:** Ligand A (0.287) is better than Ligand B (0.103). Lower P-gp efflux is desirable.
**15. Binding Affinity:** Ligand A (-8.1 kcal/mol) is significantly stronger than Ligand B (-6.1 kcal/mol). This is a substantial difference in potency.
**Overall Assessment:**
Ligand A is clearly superior. While Ligand B has better metabolic stability (lower Cl_mic), the significant advantages of Ligand A in terms of binding affinity, QED, hERG risk, solubility, and TPSA outweigh this benefit. The stronger binding affinity of Ligand A (-8.1 vs -6.1) is a major advantage, and the lower hERG risk is critical for a cardiovascular drug. The better overall drug-like properties (QED) and permeability indicators (TPSA, Caco-2) also favor Ligand A.
Output:
1
2025-04-17 18:45:20,361 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Ligand A (338.426 Da) is within the ideal range (200-500 Da), while Ligand B (420.332 Da) is at the higher end, but still acceptable.
2. **TPSA:** Ligand A (46.33) is excellent, well below the 140 threshold, and favorable for permeability. Ligand B (71.09) is higher, but still within a reasonable range.
3. **logP:** Both ligands (A: 3.752, B: 3.718) have optimal logP values between 1 and 3.
4. **HBD:** Ligand A (1) and Ligand B (2) are both acceptable.
5. **HBA:** Ligand A (2) is preferable to Ligand B (6). Higher HBA can sometimes hinder permeability.
6. **QED:** Ligand A (0.923) has a significantly better QED score than Ligand B (0.571), indicating a more drug-like profile.
7. **DILI:** Ligand A (23.187) has a much lower DILI risk than Ligand B (70.686). This is a major advantage.
8. **BBB:** Ligand A (88.833) has a good BBB penetration percentile, while Ligand B (47.499) is lower. While ADRB2 isn't exclusively a CNS target, some peripheral ADRB2 activity can be modulated by CNS effects, and higher BBB is generally favorable.
9. **Caco-2:** Both are negative, indicating poor permeability. This is a concern for both, but the lower TPSA of Ligand A might mitigate this somewhat.
10. **Solubility:** Both ligands have poor solubility (-3.186 and -4.447). This is a significant drawback for both, potentially requiring formulation strategies.
11. **hERG:** Both ligands have low hERG inhibition risk (0.89 and 0.744).
12. **Cl_mic:** Ligand A (5.915) has a significantly lower microsomal clearance than Ligand B (15.128), suggesting better metabolic stability.
13. **t1/2:** Ligand B (114.159) has a much longer in vitro half-life than Ligand A (-14.089). This is a major advantage for Ligand B.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.405 and 0.37).
15. **Affinity:** Ligand A (-8.2 kcal/mol) has a slightly better binding affinity than Ligand B (-6.3 kcal/mol). This 1.9 kcal/mol difference is substantial and can outweigh some ADME concerns.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Both ligands perform well on logP and Pgp. Ligand A has a significantly better TPSA. The affinity difference is also substantial in favor of Ligand A. While half-life is important, the superior binding affinity and lower DILI risk of Ligand A are more critical for initial optimization. The poor Caco-2 and solubility are shared issues that can be addressed with formulation.
**Conclusion:**
Ligand A demonstrates a more favorable balance of properties, particularly its superior binding affinity, lower DILI risk, better QED, and lower TPSA. While Ligand B has a longer half-life, the other advantages of Ligand A make it the more promising starting point for drug development.
Output:
1
2025-04-17 18:45:20,361 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (346.343 Da) is well within the ideal range (200-500 Da). Ligand B (397.232 Da) is also acceptable. No clear advantage here.
2. **TPSA:** Ligand A (116.84) is slightly above the optimal <140 for oral absorption, but still reasonable. Ligand B (70.63) is excellent, well below 140 and suggesting good absorption. **Advantage: B**
3. **logP:** Ligand A (-0.322) is a bit low, potentially hindering permeability. Ligand B (3.003) is optimal. **Advantage: B**
4. **HBD:** Ligand A (3) is within the acceptable limit of <=5. Ligand B (0) is also good. No significant difference.
5. **HBA:** Both ligands (A: 5, B: 5) are within the acceptable limit of <=10. No significant difference.
6. **QED:** Both ligands have good QED scores (A: 0.51, B: 0.633), indicating drug-likeness. **Advantage: B** (slightly higher)
7. **DILI:** Both ligands have similar and relatively high DILI risk (A: 83.521, B: 83.637). This is a concern for both, but not a deciding factor between them.
8. **BBB:** Ligand A (72.354) has a reasonable BBB penetration score, while Ligand B (59.791) is lower. While ADRB2 isn't strictly a CNS target, some peripheral ADRB2 receptors can be relevant in CNS pathways, so some BBB penetration is beneficial. **Advantage: A**
9. **Caco-2:** Both ligands show poor Caco-2 permeability (A: -5.168, B: -4.716). This is a significant concern for oral bioavailability for both.
10. **Solubility:** Both ligands have poor aqueous solubility (A: -3.125, B: -4.828). This is a concern for formulation and bioavailability.
11. **hERG:** Ligand A (0.052) has a very low hERG risk, which is excellent. Ligand B (0.858) has a slightly elevated, but still relatively low, hERG risk. **Advantage: A**
12. **Cl_mic:** Ligand A (-25.89) has a negative clearance, indicating very high metabolic stability. Ligand B (80.85) has a high clearance, suggesting rapid metabolism. **Advantage: A**
13. **t1/2:** Ligand A (30.122) has a good in vitro half-life. Ligand B (11.163) has a shorter half-life. **Advantage: A**
14. **Pgp:** Ligand A (0.006) has very low P-gp efflux, which is excellent. Ligand B (0.693) has moderate P-gp efflux. **Advantage: A**
15. **Affinity:** Ligand B (-7.2 kcal/mol) has a slightly stronger binding affinity than Ligand A (-6.9 kcal/mol). This is a 0.3 kcal/mol difference.
**Overall Assessment:**
While Ligand B has a better logP, TPSA, and QED, and slightly better affinity, Ligand A demonstrates significantly superior ADME properties. Specifically, the lower hERG risk, much better metabolic stability (Cl_mic and t1/2), and lower P-gp efflux are crucial advantages. The slightly lower affinity of Ligand A can potentially be optimized in later stages of drug development. The poor Caco-2 and solubility are concerns for both, but can be addressed with formulation strategies. Given the GPCR target class, balancing permeability (logP, TPSA, Pgp) and metabolic stability is key. Ligand A strikes a better balance overall.
Output:
1
2025-04-17 18:45:20,361 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (362.495 Da) is within the ideal range (200-500 Da). Ligand B (420.294 Da) is also acceptable, but closer to the upper limit.
2. **TPSA:** Ligand A (75.27) is better than Ligand B (46.61). Both are below the 140 A^2 threshold for good absorption, but Ligand B is significantly lower, which could be beneficial for permeability.
3. **logP:** Both ligands have good logP values (A: 2.573, B: 3.377), falling within the optimal 1-3 range. Ligand B is slightly higher, potentially increasing off-target interactions, but not drastically.
4. **HBD:** Ligand A has 2 HBD, and Ligand B has 0. Both are within the acceptable limit of 5.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 3. Both are within the acceptable limit of 10.
6. **QED:** Ligand A (0.845) has a significantly better QED score than Ligand B (0.361), indicating a more drug-like profile.
7. **DILI:** Ligand A (38.852) has a slightly higher DILI risk than Ligand B (33.579), but both are below the concerning threshold of 60.
8. **BBB:** Ligand B (95.967) has a much higher BBB penetration percentile than Ligand A (57.154). While ADRB2 isn't exclusively a CNS target, some CNS exposure is often acceptable and can even be beneficial for certain cardiovascular effects.
9. **Caco-2:** Ligand A (-5.228) and Ligand B (-4.405) both have negative values, which is unusual. It's difficult to interpret without knowing the scale, but lower values generally indicate poorer permeability.
10. **Solubility:** Ligand A (-2.32) and Ligand B (-4.618) both have negative solubility values, which is concerning. Ligand B has worse solubility.
11. **hERG:** Ligand A (0.099) has a slightly better hERG profile than Ligand B (0.755).
12. **Cl_mic:** Ligand B (84.746) has a significantly higher microsomal clearance than Ligand A (23.331), suggesting faster metabolism and potentially lower bioavailability.
13. **t1/2:** Ligand A (-6.937) has a much longer in vitro half-life than Ligand B (14.932).
14. **Pgp:** Ligand A (0.211) has a lower P-gp efflux liability than Ligand B (0.143).
15. **Binding Affinity:** Ligand A (-7.7 kcal/mol) has a slightly better binding affinity than Ligand B (-5.5 kcal/mol). This is a significant advantage.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B has a slightly better logP and significantly better BBB penetration. However, Ligand A has a much better QED, longer half-life, lower Cl_mic, better affinity, and lower Pgp efflux. The affinity difference is substantial.
**Overall Assessment:**
Despite Ligand B's better BBB penetration, the superior drug-like properties (QED, solubility, metabolic stability, affinity) of Ligand A make it the more promising candidate. The 1.5 kcal/mol advantage in binding affinity is substantial and outweighs the slightly less favorable BBB score. The solubility issues of both compounds are a concern, but can be addressed with formulation strategies.
Output:
1
2025-04-17 18:45:20,361 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
Let's analyze each ligand against the provided guidelines, keeping in mind ADRB2 is a GPCR, so logP, TPSA, Pgp, BBB, and affinity are key.
* **Molecular Weight:** Both ligands (359.417 and 353.507 Da) fall comfortably within the ideal 200-500 Da range.
* **TPSA:** Ligand A (92.5) is slightly higher than Ligand B (72.88). Both are acceptable, but B is better, being closer to the <90 ideal for potential CNS penetration (though not a primary concern for ADRB2).
* **logP:** Both ligands have good logP values (1.146 and 1.399), falling within the optimal 1-3 range.
* **H-Bond Donors/Acceptors:** Both have 2 HBDs, which is good. Ligand B has 4 HBAs vs. 3 for Ligand A. Both are within acceptable limits.
* **QED:** Both ligands have good QED scores (0.605 and 0.708), indicating good drug-like properties.
* **DILI:** Ligand A (17.371) has a significantly lower DILI risk than Ligand B (13.571). This is a substantial advantage for A.
* **BBB:** Ligand A (73.905) has a much better BBB percentile than Ligand B (40.675). While ADRB2 isn't a primary CNS target, some peripheral distribution is still relevant, and higher BBB generally correlates with better overall permeability.
* **Caco-2:** Ligand A (-5.075) is worse than Ligand B (-4.771). Both are negative, indicating poor permeability.
* **Solubility:** Ligand A (-2.17) is worse than Ligand B (-1.02). Both are negative, indicating poor solubility.
* **hERG:** Both ligands have very low hERG inhibition risk (0.235 and 0.279).
* **Cl_mic:** Ligand A (13.941) has significantly lower microsomal clearance than Ligand B (38.208), suggesting better metabolic stability.
* **t1/2:** Ligand A (-22.331) has a much longer in vitro half-life than Ligand B (2.942). This is a major advantage for A.
* **Pgp:** Both ligands have very low Pgp efflux liability (0.009 and 0.032).
* **Binding Affinity:** Ligand B (-6.4) has a slightly better binding affinity than Ligand A (-6.0). However, this difference (0.4 kcal/mol) is not substantial enough to outweigh the significant ADME advantages of Ligand A.
**Overall Assessment:**
Ligand A demonstrates a superior ADME profile. It has a significantly lower DILI risk, better BBB penetration, lower microsomal clearance, and a much longer half-life. While Ligand B has slightly better binding affinity and Caco-2 permeability, the ADME advantages of Ligand A are more critical for overall drug development success. The small difference in binding affinity is unlikely to be a major issue, and can potentially be optimized in later stages of development.
**Output:**
1
2025-04-17 18:45:20,362 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (349.435) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (62.66) is significantly better than Ligand A (102.42). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (3.245) is slightly higher than Ligand A (0.953). While both are within the acceptable range, Ligand B is closer to the optimal 1-3 range. Ligand A's logP is quite low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1), but both are acceptable.
5. **HBA:** Both ligands have the same number of HBA (5), which is within the acceptable range.
6. **QED:** Ligand A (0.824) has a better QED score than Ligand B (0.719), indicating a more drug-like profile.
7. **DILI:** Ligand B (35.169) has a significantly lower DILI risk than Ligand A (43.622), which is a major advantage.
8. **BBB:** Ligand B (80.419) has a higher BBB penetration percentile than Ligand A (38.348). While not crucial for a cardiovascular target, it's a neutral benefit.
9. **Caco-2:** Ligand A (-5.271) has a much better Caco-2 permeability than Ligand B (-4.617). This suggests better intestinal absorption for Ligand A.
10. **Solubility:** Ligand A (-2.167) has better aqueous solubility than Ligand B (-3.05).
11. **hERG:** Ligand A (0.208) has a lower hERG inhibition liability than Ligand B (0.686), which is a significant safety advantage.
12. **Cl_mic:** Ligand A (-6.068) has a lower (better) microsomal clearance than Ligand B (45.86). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (8.022) has a longer in vitro half-life than Ligand B (4.8). This is a positive attribute.
14. **Pgp:** Ligand B (0.404) has a lower P-gp efflux liability than Ligand A (0.083), which is a benefit.
15. **Affinity:** Ligand B (-6.9) has a slightly better binding affinity than Ligand A (-6.6). While the difference is not huge, it's a factor.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP and Pgp, and has slightly better affinity. Ligand A has better TPSA and Caco-2 permeability. The DILI and hERG risk are critical safety parameters, and Ligand B is significantly better in both. Metabolic stability (Cl_mic and t1/2) also favor Ligand A.
**Overall Assessment:**
While Ligand A has advantages in permeability, solubility, metabolic stability, and QED, the significantly lower DILI and hERG risk associated with Ligand B, coupled with its slightly better affinity and Pgp profile, make it the more promising candidate. The safety profile is paramount, and the small difference in binding affinity can potentially be optimized later.
Output:
0
2025-04-17 18:45:20,362 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (351.451 and 344.459 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (89.35) is better than Ligand B (67.23), both are below the 140 threshold for oral absorption and acceptable for a cardiovascular target (not CNS).
3. **logP:** Ligand A (0.981) is slightly lower than the optimal range of 1-3, but still acceptable. Ligand B (2.224) is well within the optimal range. Ligand B is better here.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 6 HBA, and Ligand B has 4 HBA, both are within the acceptable limit of 10. Ligand B is slightly better.
6. **QED:** Both ligands have good QED scores (0.791 and 0.805), indicating good drug-like properties. No significant difference.
7. **DILI:** Ligand A (61.109) has a higher DILI risk than Ligand B (29.236). Ligand B is significantly better here.
8. **BBB:** Ligand A (53.238) and Ligand B (66.809). Since ADRB2 is a cardiovascular target, BBB penetration is not a primary concern, but a higher value is generally preferable. Ligand B is better.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.221 and -5.094). This is unusual and suggests poor permeability. However, the values are very close, so this isn't a major differentiator.
10. **Solubility:** Both ligands have negative solubility values (-1.475 and -1.663), indicating poor aqueous solubility. This is a concern for both.
11. **hERG:** Ligand A (0.118) has a lower hERG risk than Ligand B (0.219). Ligand A is better here.
12. **Cl_mic:** Ligand A (14.188) has a lower microsomal clearance than Ligand B (19.489), suggesting better metabolic stability. Ligand A is better.
13. **t1/2:** Ligand A (0.634) has a shorter in vitro half-life than Ligand B (-3.358). Ligand B is better.
14. **Pgp:** Ligand A (0.034) has lower P-gp efflux liability than Ligand B (0.052). Ligand A is better.
15. **Binding Affinity:** Ligand B (-7.0 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.2 kcal/mol). This is a >1.5 kcal/mol advantage, which is a substantial difference and outweighs many of the ADME drawbacks.
**Overall Assessment:**
Ligand B has a significantly better binding affinity, a lower DILI risk, and a longer half-life. While Ligand A has better hERG and Pgp profiles, the substantial affinity advantage of Ligand B, combined with the lower DILI risk, makes it the more promising candidate. The solubility and Caco-2 values are poor for both, but these can be addressed through formulation strategies.
Output:
0
2025-04-17 18:45:20,362 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (381.929 and 361.921 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (53.51) is slightly higher than Ligand B (49.74). Both are below the 140 threshold for good oral absorption, and acceptable for a cardiovascular target (not requiring significant BBB penetration).
3. **logP:** Both ligands have good logP values (3.407 and 3.994), falling within the optimal 1-3 range. Ligand B is slightly higher, potentially leading to slightly better membrane permeability, but also a slightly increased risk of off-target interactions.
4. **HBD:** Ligand A has 0 HBD, while Ligand B has 1. Lower is generally preferred for permeability, so Ligand A has a slight edge.
5. **HBA:** Both ligands have 4 HBA, which is within the acceptable limit of 10.
6. **QED:** Ligand A (0.803) has a higher QED score than Ligand B (0.734), indicating a more drug-like profile.
7. **DILI:** Ligand B (21.481) has a significantly lower DILI risk than Ligand A (42.458). This is a major advantage for Ligand B.
8. **BBB:** Both ligands have good BBB penetration (74.796 and 70.997). Since ADRB2 isn't a primary CNS target, this isn't a major deciding factor, but higher is slightly better.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and problematic. It suggests poor permeability. Ligand A (-4.786) is slightly better than Ligand B (-5.292), but both are concerning.
10. **Solubility:** Both ligands have poor aqueous solubility (-2.9 and -3.236). This is a significant drawback for both.
11. **hERG:** Both ligands have low hERG inhibition risk (0.613 and 0.763).
12. **Cl_mic:** Ligand B (32.527) has a significantly lower microsomal clearance than Ligand A (45.749), indicating better metabolic stability.
13. **t1/2:** Ligand B (34.754) has a much longer in vitro half-life than Ligand A (-3.176). This is a substantial advantage for Ligand B.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.215 and 0.413).
15. **Binding Affinity:** Ligand A (-7.6) has a slightly better binding affinity than Ligand B (-5.7). This is a 1.9 kcal/mol difference, which is substantial and could outweigh some of the ADME drawbacks.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Both ligands perform reasonably well on logP and Pgp. TPSA is acceptable for both. The affinity difference is the most significant factor. However, the significantly lower DILI risk, better metabolic stability (lower Cl_mic), and longer half-life of Ligand B are compelling. The poor Caco-2 values are a concern for both, but the other advantages of Ligand B are more critical.
**Conclusion:**
While Ligand A has a better binding affinity, Ligand B's superior safety profile (DILI), metabolic stability (Cl_mic, t1/2), and comparable other properties make it the more promising drug candidate.
Output:
0
2025-04-17 18:45:20,362 - INFO - Reasoning:
Let's analyze Ligand A and Ligand B for their potential as ADRB2 ligands, keeping in mind the GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key).
**Molecular Weight:** Both ligands (346.293 and 360.458 Da) fall within the ideal 200-500 Da range.
**TPSA:** Ligand A (80.34) is slightly higher than Ligand B (58.98). Both are below 140, but B is preferable due to being closer to the ideal for good absorption.
**logP:** Ligand A (2.552) and Ligand B (3.517) are both within the optimal 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability, but also slightly increases the risk of off-target effects.
**H-Bond Donors/Acceptors:** Ligand A has 1 HBD and 5 HBA, while Ligand B has 0 HBD and 5 HBA. Both are acceptable.
**QED:** Both ligands have similar QED values (0.788 and 0.758), indicating good drug-likeness.
**DILI:** Ligand A (85.072) has a higher DILI risk than Ligand B (49.399). This is a significant advantage for Ligand B.
**BBB:** Ligand B (91.431) has a much higher BBB penetration percentile than Ligand A (74.874). While ADRB2 isn't exclusively a CNS target, improved BBB penetration can still be beneficial for overall distribution and potentially reduce off-target effects.
**Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.414 and -4.744), which is unusual and suggests poor permeability. The values are very similar.
**Aqueous Solubility:** Both ligands have negative solubility values (-4.116 and -4.058), indicating poor aqueous solubility. Again, very similar.
**hERG:** Ligand A (0.533) has a slightly higher hERG inhibition liability than Ligand B (0.336), making B preferable.
**Microsomal Clearance:** Ligand B (58.919) has a significantly higher microsomal clearance than Ligand A (26.833). This means Ligand A is more metabolically stable, a desirable trait.
**In vitro Half-Life:** Ligand A (-14.581) has a negative half-life, which is concerning. Ligand B (0.719) has a very short half-life, but it's still preferable to a negative value.
**P-gp Efflux:** Both ligands have low P-gp efflux liability (0.17 and 0.187), which is good.
**Binding Affinity:** Both ligands have very similar binding affinities (-6.3 and -6.1 kcal/mol). The difference is less than the 1.5 kcal/mol threshold.
**Overall Assessment:**
Ligand B is preferable. While Ligand A has better metabolic stability and a slightly better (though still poor) half-life, Ligand B excels in crucial areas: significantly lower DILI risk, much higher BBB penetration, and lower hERG inhibition. The slight advantage in logP for Ligand B is also beneficial. The similar binding affinities and permeability issues make these factors less decisive. The lower DILI risk is a major advantage, and the improved BBB penetration is a bonus for a GPCR target.
Output:
0
2025-04-17 18:45:20,362 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (341.411) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are good, well below the 140 A^2 threshold for oral absorption. Ligand A (66.65) is slightly higher than Ligand B (65.54), but the difference is minimal.
3. **logP:** Ligand A (3.067) is optimal, while Ligand B (1.684) is at the lower end of the optimal range. For a GPCR, a slightly higher logP is generally preferred for membrane permeability and receptor engagement.
4. **HBD:** Ligand A (0) is better than Ligand B (1). Fewer HBDs generally improve permeability.
5. **HBA:** Both have 4 HBA, which is within the acceptable range.
6. **QED:** Both have similar QED values (0.86 and 0.834), indicating good drug-likeness.
7. **DILI:** Ligand A (70.376) has a significantly higher DILI risk than Ligand B (25.165). This is a major concern.
8. **BBB:** Both have high BBB penetration (83.831 and 80.419), which is good, but less critical for ADRB2 as it's not a CNS target.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and requires further investigation. However, the values are similar (-4.704 and -4.909).
10. **Solubility:** Both have negative solubility values, which is also unusual and requires further investigation. Ligand B (-2.356) is slightly better than Ligand A (-3.226).
11. **hERG:** Both have very low hERG risk (0.277 and 0.319).
12. **Cl_mic:** Ligand A (66.386) has a significantly higher microsomal clearance than Ligand B (14.044), indicating lower metabolic stability.
13. **t1/2:** Ligand A (43.618) has a longer half-life than Ligand B (10.312).
14. **Pgp:** Both have low Pgp efflux liability (0.283 and 0.025).
15. **Affinity:** Ligand B (-7.4 kcal/mol) has a slightly better binding affinity than Ligand A (-7.0 kcal/mol). While the difference is small, it's within the range where it could outweigh other factors.
**Overall Assessment:**
Ligand B is the more promising candidate. While Ligand A has a slightly better MW and longer half-life, Ligand B has a significantly lower DILI risk and better metabolic stability (lower Cl_mic). The slightly better affinity of Ligand B is also a plus. The unusual negative Caco-2 and solubility values for both compounds warrant further investigation, but the other ADME properties of Ligand B are more favorable. Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity), Ligand B is a better choice.
Output:
0
2025-04-17 18:45:20,362 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (363.864 Da) and Ligand B (348.443 Da) both fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (46.92) is significantly better than Ligand B (78.87). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (4.422) is higher than Ligand B (1.122). While 4.422 is approaching the upper limit of optimal, it's still acceptable. Ligand B's logP is quite low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (5). Similar reasoning as HBD.
6. **QED:** Ligand A (0.854) is better than Ligand B (0.722), indicating a more drug-like profile.
7. **DILI:** Ligand B (17.216) has a much lower DILI risk than Ligand A (49.011). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (81.078) has better BBB penetration than Ligand B (53.16). While not a primary concern for a cardiovascular target, it's a slight positive for Ligand A.
9. **Caco-2:** Ligand A (-4.733) and Ligand B (-4.979) are both very poor, indicating poor intestinal absorption.
10. **Solubility:** Ligand A (-4.903) is slightly better than Ligand B (-1.191), but both are poor.
11. **hERG:** Ligand A (0.333) is better than Ligand B (0.302), indicating lower hERG inhibition liability.
12. **Cl_mic:** Ligand B (23.637) has significantly lower microsomal clearance than Ligand A (69.687), suggesting better metabolic stability.
13. **t1/2:** Ligand A (31.758) has a much longer in vitro half-life than Ligand B (2.42). This is a substantial advantage for Ligand A.
14. **Pgp:** Ligand A (0.315) is better than Ligand B (0.086), indicating lower P-gp efflux.
15. **Binding Affinity:** Ligand B (-6.9 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.2 kcal/mol). This is a major advantage for Ligand B.
**GPCR-Specific Priorities & Overall Assessment:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B has a much better affinity (-6.9 vs -5.2) and a better logP (1.122 vs 4.422). While Ligand A has a lower TPSA, the difference isn't dramatic, and the superior affinity of Ligand B outweighs this. Ligand B also has a much lower DILI risk and better metabolic stability. Ligand A's longer half-life is a positive, but the significant affinity difference and lower DILI risk of Ligand B are more important. The poor Caco-2 values for both are concerning and would need to be addressed in further optimization.
**Output:**
0
2025-04-17 18:45:20,362 - INFO - Batch 60 complete. Total preferences: 960
2025-04-17 18:45:20,362 - INFO - Processing batch 61/512...
2025-04-17 18:46:09,656 - INFO - Reasoning:
Let's analyze Ligand A and Ligand B for their potential as ADRB2 ligands, keeping in mind the GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key).
**Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (408.292 Da) is slightly higher than Ligand B (349.479 Da), but both are acceptable.
**TPSA:** Ligand A (70) is better than Ligand B (83.29). Both are below the 140 threshold for oral absorption, but lower is preferred.
**logP:** Both ligands have good logP values (A: 2.733, B: 2.962), falling within the optimal 1-3 range.
**H-Bond Donors/Acceptors:** Both have 2 HBDs and 5 HBAs, which is acceptable.
**QED:** Both ligands have good QED scores (A: 0.658, B: 0.791), indicating good drug-likeness. Ligand B is slightly better here.
**DILI:** Ligand A (13.843) has a significantly lower DILI risk than Ligand B (26.018). This is a substantial advantage for Ligand A.
**BBB:** Ligand B (85.498) has a much higher BBB penetration percentile than Ligand A (23.536). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be beneficial or at least not detrimental.
**Caco-2 Permeability:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-5.353) is slightly better than Ligand B (-5.074).
**Aqueous Solubility:** Both have negative solubility values, indicating poor solubility. Ligand A (-3.176) is slightly better than Ligand B (-2.288).
**hERG:** Ligand A (0.835) has a slightly higher hERG risk than Ligand B (0.34). This favors Ligand B.
**Microsomal Clearance:** Ligand A (51.684) has a higher microsomal clearance than Ligand B (15.565), meaning it's less metabolically stable. This favors Ligand B.
**In vitro Half-Life:** Ligand B (20.392) has a longer in vitro half-life than Ligand A (32.271). This is a significant advantage for Ligand B.
**P-gp Efflux:** Ligand A (0.539) has lower P-gp efflux than Ligand B (0.076), which is preferable.
**Binding Affinity:** Ligand B (-7.4 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.7 kcal/mol). This is a major advantage for Ligand B. The 1.7 kcal/mol difference is substantial enough to outweigh some ADME concerns.
**Overall Assessment:**
Ligand B clearly wins on binding affinity and has a better BBB score, longer half-life, lower clearance, and lower hERG risk. While Ligand A has a better DILI score and P-gp efflux, the strong binding affinity of Ligand B is paramount for a GPCR target. The slightly worse ADME properties of Ligand B can be addressed with further optimization, but a strong starting point with high affinity is crucial.
Output:
0
2025-04-17 18:46:09,656 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (340.39 and 365.46 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (95.08) is better than Ligand B (104.36). Both are acceptable for a non-CNS GPCR target like ADRB2, but lower TPSA generally favors absorption.
3. **logP:** Ligand B (1.63) is better than Ligand A (0.676). A logP between 1-3 is optimal, and Ligand B is closer to this range. Ligand A is a bit low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (1) is better than Ligand B (2). Fewer HBDs are generally preferred for better permeability.
5. **HBA:** Ligand A (5) is better than Ligand B (6). Similar to HBD, fewer HBAs are preferred.
6. **QED:** Ligand A (0.886) is significantly better than Ligand B (0.482). A QED > 0.5 is desirable, and Ligand A is much closer to 1, indicating a more drug-like profile.
7. **DILI:** Ligand B (49.13) is significantly better than Ligand A (63.13). Lower DILI is crucial, and Ligand B has a considerably lower risk.
8. **BBB:** This is less critical for ADRB2 (a cardiovascular target). Ligand B (36.45) is better than Ligand A (23.54), but neither is particularly high.
9. **Caco-2:** Both ligands have very poor Caco-2 permeability (-5.201 and -5.06). This is a significant concern for both.
10. **Solubility:** Ligand A (-1.882) is better than Ligand B (-3.422). Higher solubility is preferred, and Ligand A has a better score.
11. **hERG:** Ligand A (0.134) is better than Ligand B (0.568). Lower hERG inhibition is critical for avoiding cardiotoxicity, and Ligand A has a much lower risk.
12. **Cl_mic:** Ligand A (-10.264) is significantly better than Ligand B (57.164). Lower microsomal clearance indicates better metabolic stability, and Ligand A is far superior.
13. **t1/2:** Ligand A (-9.881) is better than Ligand B (22.289). A longer in vitro half-life is generally desirable.
14. **Pgp:** Ligand A (0.013) is much better than Ligand B (0.099). Lower P-gp efflux is preferred for better bioavailability.
15. **Binding Affinity:** Ligand A (-7.4) is better than Ligand B (-6.1). A difference of 1.3 kcal/mol is substantial and can often outweigh minor ADME drawbacks.
**Overall Assessment:**
Ligand A demonstrates a superior profile across most critical parameters. While both have poor Caco-2 permeability, Ligand A excels in QED, DILI, hERG, metabolic stability (Cl_mic and t1/2), P-gp efflux, and, most importantly, binding affinity. The stronger binding affinity of Ligand A (-7.4 kcal/mol vs -6.1 kcal/mol) is a significant advantage for a GPCR target. The better ADME properties of Ligand A, particularly the lower DILI and hERG risk, make it a safer and more promising candidate.
Output:
1
2025-04-17 18:46:09,656 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.395 and 368.499 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (82.06) is slightly higher than Ligand B (76.66). Both are below the 140 threshold for oral absorption, and acceptable for a cardiovascular target (not CNS). Ligand B is marginally better.
3. **logP:** Both ligands have good logP values (2.313 and 1.111), falling within the optimal 1-3 range. Ligand A is slightly higher, which *could* be beneficial for membrane permeability but also raises a minor concern for off-target effects.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (6) is preferable to Ligand B (5). Lower HBA generally improves permeability.
6. **QED:** Ligand A (0.823) has a significantly better QED score than Ligand B (0.628), indicating a more drug-like profile. This is a substantial advantage.
7. **DILI:** Both ligands have low DILI risk (34.393 and 32.687 percentile), well below the 60 threshold. No significant difference.
8. **BBB:** Ligand A (77.239) has a better BBB penetration score than Ligand B (62.35). While ADRB2 isn't strictly a CNS target, some distribution to the CNS is possible, and higher BBB is generally favorable.
9. **Caco-2:** Ligand A (-4.288) has a worse Caco-2 permeability than Ligand B (-5.237). Lower (more negative) values indicate lower permeability. Ligand B is better.
10. **Solubility:** Ligand A (-3.488) has worse solubility than Ligand B (-2.757). Lower (more negative) values indicate lower solubility. Ligand B is better.
11. **hERG:** Both ligands have very low hERG risk (0.275 and 0.219 percentile), which is excellent. No significant difference.
12. **Cl_mic:** Ligand B (41.794) has lower microsomal clearance than Ligand A (54.332), suggesting better metabolic stability. This is a positive for Ligand B.
13. **t1/2:** Ligand B (12.72) has a longer in vitro half-life than Ligand A (-15.709). This is a significant advantage for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.11 and 0.024 percentile). No significant difference.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-5.5 and -5.6 kcal/mol). The difference is negligible.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Both ligands perform well on these. However, the QED score of Ligand A is significantly better, and the BBB penetration is also higher. Ligand B has advantages in Caco-2 permeability, solubility, and metabolic stability (Cl_mic and t1/2). The longer half-life of Ligand B is a significant plus.
**Overall Assessment:**
While Ligand A has a better QED and BBB, the improved ADME properties of Ligand B (solubility, permeability, metabolic stability, and half-life) are more critical for overall drug development success. The binding affinity is essentially the same. The longer half-life and better solubility of Ligand B outweigh the slightly better QED and BBB of Ligand A.
Output:
0
2025-04-17 18:46:09,657 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [351.491, 78.51, 1.838, 2, 3, 0.7, 14.424, 65.452, -5.017, -1.84, 0.282, 17.558, -9.81, 0.058, -5.4]
**Ligand B:** [361.349, 124.47, 1.094, 1, 5, 0.217, 35.091, 78.054, -4.714, -1.052, 0.237, 46.917, -28.417, 0.023, -6.6]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). A (351.491) is slightly preferred.
2. **TPSA:** A (78.51) is better than B (124.47). GPCRs benefit from lower TPSA for permeability.
3. **logP:** Both are good (around 1-3), but A (1.838) is slightly higher and potentially better for membrane permeability.
4. **HBD:** A (2) is slightly better than B (1). Lower is generally preferred for permeability.
5. **HBA:** A (3) is better than B (5). Lower is generally preferred for permeability.
6. **QED:** A (0.7) is significantly better than B (0.217), indicating a more drug-like profile.
7. **DILI:** A (14.424) is *much* better than B (35.091). This is a major advantage for A.
8. **BBB:** A (65.452) is decent, but B (78.054) is better. While ADRB2 isn't a CNS target, some distribution into the CNS is possible, so B has a slight edge here.
9. **Caco-2:** Both are negative, indicating poor permeability. A (-5.017) is slightly better (less negative).
10. **Solubility:** Both are negative, indicating poor solubility. B (-1.052) is slightly better.
11. **hERG:** Both are very low, indicating minimal hERG inhibition risk. A (0.282) is slightly better.
12. **Cl_mic:** A (17.558) is significantly better than B (46.917), indicating better metabolic stability.
13. **t1/2:** A (-9.81) is much better than B (-28.417), indicating a longer half-life.
14. **Pgp:** Both are very low, indicating minimal P-gp efflux. A (0.058) is slightly better.
15. **Affinity:** B (-6.6) is better than A (-5.4). This is a 1.2 kcal/mol difference, which is significant.
**Overall Assessment:**
Ligand B has a better binding affinity, which is crucial. However, Ligand A has substantially better ADME-Tox properties: significantly lower DILI risk, better QED, better metabolic stability (lower Cl_mic), and a longer half-life. The TPSA and logP are also more favorable for A. While B has slightly better BBB penetration, this is less critical for a cardiovascular target. The poor Caco-2 and solubility for both are concerning, but the superior ADME profile of A, particularly the DILI risk, outweighs the affinity difference.
Therefore, I would choose Ligand A.
Output:
1
2025-04-17 18:46:09,657 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [345.393, 45.23, 4.036, 1, 2, 0.77, 44.591, 76.541, -4.379, -4.362, 0.626, 71.916, 27.317, 0.103, -6.1]
**Ligand B:** [362.832, 46.34, 4.742, 0, 3, 0.697, 42.497, 91.857, -4.718, -4.644, 0.733, 81.635, 24.269, 0.727, -7.3]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (345.393) is slightly lower, which is generally favorable for permeability, but both are acceptable.
2. **TPSA:** Both are reasonably good (A: 45.23, B: 46.34), well below the 140 threshold for oral absorption.
3. **logP:** Both are within the optimal range (1-3), with A at 4.036 and B at 4.742. B is slightly higher, potentially increasing off-target effects, but still within a manageable range.
4. **HBD:** A has 1 HBD, B has 0. Lower is generally preferred for GPCRs to enhance BBB penetration, so B is slightly better here.
5. **HBA:** A has 2 HBA, B has 3. Again, lower is slightly favored for GPCRs, giving a small edge to A.
6. **QED:** Both are above 0.5 (A: 0.77, B: 0.697), indicating good drug-like properties. A is slightly better.
7. **DILI:** Both have acceptable DILI risk (A: 44.591, B: 42.497), both below the 60 threshold. B is marginally better.
8. **BBB:** This is a crucial parameter for GPCRs. B (91.857) is significantly better than A (76.541). This is a major advantage for B.
9. **Caco-2:** Both are negative, indicating poor permeability. B (-4.718) is slightly worse than A (-4.379).
10. **Solubility:** Both are negative, indicating poor solubility. B (-4.644) is slightly worse than A (-4.362).
11. **hERG:** Both have low hERG risk (A: 0.626, B: 0.733). B is slightly worse.
12. **Cl_mic:** B (81.635) has higher clearance than A (71.916), indicating lower metabolic stability. A is better here.
13. **t1/2:** A (27.317) has a longer half-life than B (24.269), which is desirable.
14. **Pgp:** B (0.727) has higher P-gp efflux than A (0.103). A is significantly better here, meaning it will have better bioavailability and potentially better CNS exposure.
15. **Binding Affinity:** B (-7.3) has a significantly stronger binding affinity than A (-6.1) - a difference of 1.2 kcal/mol. This is a substantial advantage that can outweigh some ADME concerns.
**Overall Assessment:**
The key trade-off here is between binding affinity and ADME properties. Ligand B has a much stronger binding affinity (-7.3 vs -6.1), which is a significant advantage for a GPCR target. However, Ligand A has better P-gp efflux, metabolic stability, and half-life. Ligand B also has a better BBB score. Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), and the substantial affinity difference, I believe the stronger binding of Ligand B outweighs its slightly less favorable ADME profile. The improved BBB penetration also supports this choice.
Output:
0
2025-04-17 18:46:09,657 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A Analysis:**
* **MW:** 348.443 Da - Excellent, within the ideal range.
* **TPSA:** 80.57 A2 - Good, below the 140 A2 threshold for oral absorption.
* **logP:** 2.419 - Optimal, within the 1-3 range.
* **HBD:** 2 - Acceptable, well below the limit of 5.
* **HBA:** 4 - Acceptable, well below the limit of 10.
* **QED:** 0.756 - Excellent, highly drug-like.
* **DILI:** 28.383 - Very good, low risk of liver injury.
* **BBB:** 68.67 - Moderate, could be improved but not critical for a peripherally acting ADRB2 ligand.
* **Caco-2:** -4.535 - Poor, suggests limited intestinal absorption.
* **Solubility:** -2.89 - Poor, could pose formulation challenges.
* **hERG:** 0.362 - Very low risk of hERG inhibition.
* **Cl_mic:** 63.516 mL/min/kg - Moderate clearance, could be better.
* **t1/2:** 21.488 hours - Good, reasonable in vitro half-life.
* **Pgp:** 0.256 - Low efflux, favorable for bioavailability.
* **Affinity:** -7.3 kcal/mol - Excellent, very strong binding.
**Ligand B Analysis:**
* **MW:** 351.451 Da - Excellent, within the ideal range.
* **TPSA:** 109.14 A2 - Acceptable, but approaching the upper limit for good absorption.
* **logP:** 0.308 - Suboptimal, potentially hindering permeation.
* **HBD:** 3 - Acceptable, below the limit of 5.
* **HBA:** 6 - Acceptable, below the limit of 10.
* **QED:** 0.624 - Good, reasonably drug-like.
* **DILI:** 32.726 - Very good, low risk of liver injury.
* **BBB:** 25.824 - Poor, unlikely to cross the blood-brain barrier.
* **Caco-2:** -5.291 - Very poor, suggests very limited intestinal absorption.
* **Solubility:** -1.24 - Poor, could pose formulation challenges.
* **hERG:** 0.03 - Very low risk of hERG inhibition.
* **Cl_mic:** -3.79 mL/min/kg - Excellent, very low clearance, indicating high metabolic stability.
* **t1/2:** -9.001 hours - Very poor, extremely short in vitro half-life.
* **Pgp:** 0.02 - Low efflux, favorable for bioavailability.
* **Affinity:** -6.2 kcal/mol - Good, but significantly weaker than Ligand A.
**Comparison and Decision:**
Given that the target is ADRB2 (a GPCR), the priorities are logP, TPSA, Pgp, and affinity. Ligand A clearly wins on affinity (-7.3 vs -6.2 kcal/mol), which is a substantial difference. While Ligand A has poorer Caco-2 and solubility, Ligand B's logP is quite low, which is a major concern for permeability. Ligand B also has a very short half-life, which would necessitate frequent dosing. Ligand A's BBB is moderate, but this is less critical for a peripherally acting ADRB2 ligand. Both have acceptable DILI and hERG profiles. The superior binding affinity of Ligand A, combined with its acceptable ADME properties, outweighs the drawbacks.
Output:
1
2025-04-17 18:46:09,657 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (355.29 and 352.52 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (38.77) is significantly better than Ligand B (55.89). ADRB2 is a cardiovascular target, not CNS, but lower TPSA is generally favorable for absorption. Ligand A is well below the 140 threshold. Ligand B is approaching the upper limit.
3. **logP:** Ligand A (3.914) is good, within the optimal 1-3 range. Ligand B (1.023) is on the lower side, potentially indicating permeability issues.
4. **HBD:** Both have acceptable HBD counts (0 for A, 1 for B), well below the 5 threshold.
5. **HBA:** Both have acceptable HBA counts (3 for A, 4 for B), well below the 10 threshold.
6. **QED:** Both ligands have similar, good QED scores (0.784 and 0.709), indicating good drug-like properties.
7. **DILI:** Ligand A (81.82%) has a significantly higher DILI risk than Ligand B (2.56%). This is a major concern for Ligand A.
8. **BBB:** Both have reasonably high BBB penetration, but Ligand A (91.59%) is better than Ligand B (58.74%). While ADRB2 isn't a CNS target, higher BBB is rarely detrimental.
9. **Caco-2:** Ligand A (-4.139) and Ligand B (-5.066) both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Ligand A (-5.34) and Ligand B (-0.581) both have negative solubility values, which is also unusual and suggests poor solubility. Again, the scale is not specified, making interpretation difficult.
11. **hERG:** Ligand A (0.851) has a slightly higher hERG risk than Ligand B (0.477), but both are relatively low.
12. **Cl_mic:** Ligand B (-5.211) has a significantly *lower* (better) microsomal clearance than Ligand A (60.394). This suggests better metabolic stability for Ligand B.
13. **t1/2:** Ligand B (-7.505) has a significantly longer in vitro half-life than Ligand A (33.281). This is a strong advantage for Ligand B.
14. **Pgp:** Ligand A (0.623) has a lower Pgp efflux liability than Ligand B (0.004), which is favorable.
15. **Binding Affinity:** Both ligands have very similar, excellent binding affinities (-7.0 and -6.9 kcal/mol). The difference is negligible.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A has better logP and Pgp, but Ligand B has significantly better TPSA, Cl_mic, and t1/2. The DILI risk for Ligand A is a major red flag.
**Overall Assessment:**
Despite Ligand A's slightly better logP and Pgp, the significantly higher DILI risk, coupled with worse metabolic stability (higher Cl_mic) and shorter half-life, make it a less desirable candidate. Ligand B, while having a slightly lower logP, presents a much more favorable safety and pharmacokinetic profile. The similar binding affinities make the ADME/Tox differences the deciding factors.
Output:
0
2025-04-17 18:46:09,657 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (344.375 and 357.451 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (121.25) is slightly higher than Ligand B (102.34). Both are below the 140 threshold for good oral absorption, but Ligand B is closer to the preferred <90 for GPCRs.
3. **logP:** Ligand A (0.079) is quite low, potentially hindering permeability. Ligand B (-1.193) is also low, but slightly better than A. Both are below the optimal 1-3 range.
4. **HBD:** Both ligands have 3 H-bond donors, which is within the acceptable limit of <=5.
5. **HBA:** Both ligands have 6 H-bond acceptors, also within the acceptable limit of <=10.
6. **QED:** Ligand A (0.728) has a significantly better QED score than Ligand B (0.479), indicating a more drug-like profile.
7. **DILI:** Ligand A (88.91) has a higher DILI risk than Ligand B (5.7). This is a major concern for Ligand A.
8. **BBB:** Ligand A (47.926) has a low BBB penetration, while Ligand B (32.687) is also low. Neither is ideal, but this is less critical for a non-CNS target like ADRB2.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. This is a significant drawback for both.
10. **Solubility:** Ligand A (-3.228) has very poor aqueous solubility, while Ligand B (0.35) is slightly better, but still poor.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.19 and 0.1 respectively).
12. **Cl_mic:** Ligand A (12.279) has a lower (better) microsomal clearance than Ligand B (-16.716). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand B (16.206) has a significantly longer in vitro half-life than Ligand A (9.36), which is desirable.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.033 and 0.003).
15. **Binding Affinity:** Both ligands have the same binding affinity (-6.8 kcal/mol).
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are key. While both have similar affinity, Ligand B has a lower TPSA and a slightly better (less negative) logP. The biggest differentiating factor is the DILI risk. Ligand A's high DILI risk is a major red flag. Although both have poor solubility and Caco-2 permeability, the DILI risk outweighs the slightly better QED and clearance of Ligand A.
**Conclusion:**
Despite the drawbacks of both compounds, Ligand B is the more promising candidate due to its significantly lower DILI risk and slightly improved physicochemical properties (lower TPSA, better logP).
Output:
0
2025-04-17 18:46:09,658 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's systematically compare Ligand A and Ligand B based on the provided parameters and the guidelines, keeping in mind ADRB2 is a GPCR and thus we prioritize logP, Pgp, TPSA, and affinity.
1. **Molecular Weight:** Both ligands (354.491 and 377.457 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (89.87) is slightly higher than Ligand B (78.51). Both are below the 140 threshold for good oral absorption, but B is better.
3. **logP:** Both ligands have good logP values (1.299 and 1.174) falling within the optimal 1-3 range. No clear advantage.
4. **H-Bond Donors:** Ligand A has 3 HBD, while Ligand B has 2. Both are acceptable, with B being slightly more favorable.
5. **H-Bond Acceptors:** Both ligands have 4 HBA, which is within the acceptable limit of 10.
6. **QED:** Ligand A (0.694) has a slightly better QED score than Ligand B (0.561), indicating a more drug-like profile.
7. **DILI:** Ligand B (35.052) has a significantly lower DILI risk than Ligand A (10.585). This is a major advantage for Ligand B.
8. **BBB:** Both ligands have reasonable BBB penetration (63.086 and 69.794). While not exceptionally high, they are acceptable for a non-CNS target like ADRB2.
9. **Caco-2 Permeability:** Ligand B (-5.322) has a better Caco-2 permeability than Ligand A (-4.859), suggesting better intestinal absorption.
10. **Aqueous Solubility:** Ligand B (-2.04) has better aqueous solubility than Ligand A (-1.66).
11. **hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.2 and 0.246), which is excellent.
12. **Microsomal Clearance:** Ligand A (4.699) has a significantly lower microsomal clearance than Ligand B (22.555), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **In vitro Half-Life:** Ligand A (-8.51) has a better in vitro half-life than Ligand B (-6.521).
14. **P-gp Efflux:** Both ligands show low P-gp efflux liability (0.037 and 0.029).
15. **Binding Affinity:** Ligand A (-6.9 kcal/mol) has a slightly better binding affinity than Ligand B (-6.2 kcal/mol). This 0.7 kcal/mol difference is meaningful, but not overwhelming.
**Overall Assessment:**
Ligand B demonstrates a superior ADME profile, particularly in terms of DILI risk, Caco-2 permeability, and aqueous solubility. Ligand A has a better metabolic stability and slightly better affinity. However, the lower DILI risk of Ligand B is a critical advantage. For a cardiovascular target, minimizing liver toxicity is paramount. The slight difference in affinity is outweighed by the substantial improvement in safety and absorption characteristics.
**Output:**
0
2025-04-17 18:46:09,658 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (340.47 and 353.48 Da). No significant difference.
2. **TPSA:** Ligand A (41.57) is better than Ligand B (43.86), both are acceptable for a non-CNS GPCR target.
3. **logP:** Ligand A (3.702) is good, while Ligand B (1.917) is on the lower side of optimal. This favors Ligand A for membrane permeability.
4. **HBD:** Ligand A (1) is better than Ligand B (0).
5. **HBA:** Both ligands have 3 HBA, which is good.
6. **QED:** Both ligands are similar (0.793 and 0.733), indicating good drug-likeness.
7. **DILI:** Ligand A (31.601) is *significantly* better than Ligand B (6.01). This is a major advantage for Ligand A.
8. **BBB:** Both ligands have high BBB penetration (90.461 and 95.657), but this is less critical for a cardiovascular target like ADRB2.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-3.615) is better than Ligand B (-1.204).
11. **hERG:** Both ligands have low hERG inhibition risk (0.81 and 0.702).
12. **Cl_mic:** Ligand A (35.287) is higher than Ligand B (0.082), indicating lower metabolic stability. This favors Ligand B.
13. **t1/2:** Ligand A (44.582) is much better than Ligand B (1.189). This is a significant advantage for Ligand A.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.465 and 0.042).
15. **Binding Affinity:** Ligand A (-8.5 kcal/mol) is 1.0 kcal/mol stronger than Ligand B (-7.5 kcal/mol). This is a substantial difference in potency.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A is better in logP, TPSA, and significantly better in affinity. While both have good Pgp profiles.
**Overall Assessment:**
Ligand A has several advantages: significantly lower DILI risk, better solubility, a much longer in vitro half-life, and a considerably stronger binding affinity. The only drawback is slightly higher microsomal clearance compared to Ligand B. However, the benefits of lower toxicity, better solubility, longer half-life, and higher potency outweigh this single disadvantage. The Caco-2 values are concerning for both, but the superior binding affinity of Ligand A suggests it might overcome permeability issues.
Output:
1
2025-04-17 18:46:09,658 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (343.471 and 349.431 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (44.81) is significantly better than Ligand B (104.46). For a GPCR, lower TPSA is generally preferred for better permeability. Ligand B is quite high, potentially hindering absorption.
3. **logP:** Ligand A (2.642) is within the optimal range (1-3), while Ligand B (1.486) is at the lower end. While not terrible, Ligand A's logP is more favorable for membrane permeability.
4. **HBD:** Ligand A (1) is better than Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (3) is better than Ligand B (5). Similar to HBD, lower HBA is preferred.
6. **QED:** Ligand A (0.918) is significantly better than Ligand B (0.692), indicating a more drug-like profile.
7. **DILI:** Ligand A (13.804) is *much* better than Ligand B (48.623). This is a critical advantage for Ligand A, as lower DILI risk is essential.
8. **BBB:** Ligand A (90.617) is significantly better than Ligand B (63.474). While ADRB2 isn't strictly a CNS target, some CNS penetration can be beneficial, and higher BBB is generally a positive attribute.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.325 and -4.971), which is unusual and suggests poor permeability *in vitro*. This is a concern for both, but the values are similar.
10. **Solubility:** Ligand A (-2.251) is better than Ligand B (-3.348). Better solubility is always desirable.
11. **hERG:** Ligand A (0.81) is better than Ligand B (0.239). Lower hERG inhibition is crucial for avoiding cardiotoxicity, making Ligand A safer.
12. **Cl_mic:** Ligand A (0.659) is *much* better than Ligand B (64.84). Lower microsomal clearance indicates better metabolic stability, a significant advantage for Ligand A.
13. **t1/2:** Ligand A (4.962) is better than Ligand B (-23.494). A positive half-life is preferable, and Ligand A has a reasonable value, while Ligand B's is negative, which is not physically meaningful.
14. **Pgp:** Ligand A (0.16) is better than Ligand B (0.191). Lower P-gp efflux is preferred.
15. **Binding Affinity:** Ligand A (-6.8) and Ligand B (-6.7) are very similar. The difference of 0.1 kcal/mol is not substantial enough to outweigh the other significant differences.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across almost all crucial ADME-Tox parameters. While both have poor Caco-2 permeability, Ligand A excels in DILI risk, BBB penetration, metabolic stability (Cl_mic), hERG inhibition, QED, and solubility. The binding affinity is nearly identical. Given these factors, Ligand A is a far more promising drug candidate for the ADRB2 receptor.
Output:
1
2025-04-17 18:46:09,658 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, the protein-class-specific priorities are logP, Pgp, TPSA, and affinity, alongside the general guidelines.
**Ligand A:**
* **MW:** 346.431 Da - Good.
* **TPSA:** 100.19 - Acceptable, but approaching the upper limit for good absorption.
* **logP:** 0.869 - Low. Could hinder permeation.
* **HBD:** 3 - Good.
* **HBA:** 4 - Good.
* **QED:** 0.618 - Good.
* **DILI:** 37.301 - Excellent, very low risk.
* **BBB:** 53.276 - Moderate. Not ideal for a GPCR, but not a major concern for a cardiovascular target.
* **Caco-2:** -5.193 - Very poor permeability. A significant drawback.
* **Solubility:** -2.082 - Poor solubility.
* **hERG:** 0.09 - Excellent, very low risk.
* **Cl_mic:** 7.705 - Moderate clearance.
* **t1/2:** -5.056 - Very short half-life.
* **Pgp:** 0.01 - Low efflux, good.
* **Affinity:** -5.4 kcal/mol - Good affinity.
**Ligand B:**
* **MW:** 352.494 Da - Good.
* **TPSA:** 49.41 - Excellent, favors absorption.
* **logP:** 3.614 - Excellent, within the optimal range.
* **HBD:** 1 - Good.
* **HBA:** 2 - Good.
* **QED:** 0.742 - Good.
* **DILI:** 15.898 - Excellent, very low risk.
* **BBB:** 91.663 - Excellent, although less critical for a cardiovascular target.
* **Caco-2:** -4.74 - Moderate permeability.
* **Solubility:** -3.138 - Moderate solubility.
* **hERG:** 0.594 - Good, low risk.
* **Cl_mic:** 24.629 - High clearance, suggesting lower metabolic stability.
* **t1/2:** -16.672 - Very short half-life.
* **Pgp:** 0.304 - Moderate efflux.
* **Affinity:** -6.4 kcal/mol - Very good affinity, 1 kcal/mol better than Ligand A.
**Comparison and Decision:**
Ligand B is superior despite the higher clearance and moderate Pgp efflux. The significantly better logP, TPSA, Caco-2 permeability, and slightly improved affinity outweigh the drawbacks. Ligand A has a very poor Caco-2 value and low logP, which are major concerns for oral bioavailability. While Ligand B's metabolic stability is a concern, it can potentially be addressed through structural modifications. The affinity difference of 1 kcal/mol is also significant.
Output:
0
2025-04-17 18:46:09,658 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (355.454) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (49.41) is significantly better than Ligand A (92.5). ADRB2 is a GPCR, and lower TPSA is preferred for better membrane permeability and potentially better brain penetration if desired.
3. **logP:** Both ligands have acceptable logP values (Ligand A: 1.235, Ligand B: 2.536), falling within the 1-3 range. Ligand B is slightly better.
4. **HBD/HBA:** Ligand B (HBD=1, HBA=2) is better than Ligand A (HBD=2, HBA=3) in terms of minimizing hydrogen bonding potential, which can improve membrane permeability.
5. **QED:** Both ligands have similar QED values (Ligand A: 0.686, Ligand B: 0.602), indicating good drug-likeness.
6. **DILI:** Ligand A (16.324) has a much lower DILI risk than Ligand B (32.261). This is a significant advantage for Ligand A.
7. **BBB:** Ligand A (92.827) has a higher BBB penetration percentile than Ligand B (70.376). While ADRB2 isn't necessarily a CNS target, higher BBB is rarely detrimental and can open up potential for future applications.
8. **Caco-2:** Ligand A (-5.219) and Ligand B (-4.666) are both negative, which is unusual and suggests poor Caco-2 permeability. This is a concern for both.
9. **Solubility:** Both ligands have very poor aqueous solubility (-3.066 and -3.407 respectively). This is a major drawback for both.
10. **hERG:** Both ligands have low hERG inhibition liability (Ligand A: 0.492, Ligand B: 0.56), which is good.
11. **Cl_mic:** Ligand B (-0.197) has a significantly *lower* (better) microsomal clearance than Ligand A (10.623). This suggests better metabolic stability for Ligand B.
12. **t1/2:** Ligand B (-29.697) has a much longer in vitro half-life than Ligand A (-17.146). This is a significant advantage for Ligand B.
13. **Pgp:** Both ligands have low P-gp efflux liability (Ligand A: 0.028, Ligand B: 0.052).
14. **Binding Affinity:** Ligand B (-7.8) has a significantly stronger binding affinity than Ligand A (-6.0). This is a substantial advantage, potentially outweighing some ADME concerns.
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B excels in TPSA, logP, and *especially* affinity. The longer half-life and better metabolic stability (lower Cl_mic) are also beneficial. While Ligand A has a lower DILI risk and better BBB, the significantly stronger binding affinity of Ligand B is the most crucial factor, and the other advantages of B outweigh the DILI concern. The poor solubility and Caco-2 values are concerning for both, and would need to be addressed in further optimization.
**Conclusion:**
Ligand B is the more promising candidate due to its superior binding affinity, better TPSA, logP, metabolic stability, and half-life.
Output:
0
2025-04-17 18:46:09,658 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [346.431, 84.72, 0.608, 0, 4, 0.749, 23.575, 48.817, -4.617, -2.077, 0.18, 19.58, 12.521, 0.003, -5.1]
**Ligand B:** [351.426, 84.46, 1.203, 1, 5, 0.835, 45.638, 88.057, -4.949, -2.58, 0.549, 20.568, -14.901, 0.092, -6.4]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). A (346.431) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are excellent, well below the 140 A^2 threshold for oral absorption (A: 84.72, B: 84.46).
3. **logP:** A (0.608) is a bit low, potentially hindering membrane permeability. B (1.203) is better, falling within the optimal 1-3 range.
4. **HBD:** A (0) is ideal. B (1) is acceptable.
5. **HBA:** A (4) is good. B (5) is also acceptable.
6. **QED:** Both are good (A: 0.749, B: 0.835), indicating drug-like properties. B is slightly better.
7. **DILI:** A (23.575) is significantly better than B (45.638), indicating a much lower risk of liver injury. This is a major advantage for A.
8. **BBB:** B (88.057) is much better than A (48.817). While not strictly required for ADRB2 (a cardiovascular target), some CNS exposure can sometimes be relevant or indicate promiscuity.
9. **Caco-2:** Both are poor (-4.617 and -4.949). This is a concern for both, suggesting limited intestinal absorption.
10. **Solubility:** Both are very poor (-2.077 and -2.58). This is a significant drawback for both, potentially hindering bioavailability.
11. **hERG:** A (0.18) is very favorable, indicating low cardiotoxicity risk. B (0.549) is higher, suggesting a greater potential for hERG inhibition.
12. **Cl_mic:** B (20.568) is slightly better than A (19.58), indicating slightly better metabolic stability.
13. **t1/2:** A (12.521) is better than B (-14.901). A longer half-life is generally preferred.
14. **Pgp:** A (0.003) is much better than B (0.092), indicating less P-glycoprotein efflux. This is beneficial for bioavailability.
15. **Affinity:** B (-6.4) is 0.3 kcal/mol better than A (-5.1). This is a substantial difference in binding affinity.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. B performs better on logP and significantly better on affinity. However, the DILI risk for A is much lower, and the hERG risk is also much lower. The Pgp efflux is also much lower for A.
**Decision:**
While the affinity of Ligand B is significantly better, the lower DILI, hERG, and Pgp efflux of Ligand A are crucial for a cardiovascular drug candidate. The poor Caco-2 and solubility are concerns for both, but these can potentially be addressed through formulation strategies. The improved safety profile of Ligand A outweighs the affinity advantage of Ligand B.
**Output:**
1
2025-04-17 18:46:09,659 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (a cardiovascular GPCR) drug candidates.
**Ligand A:** [354.447, 93.73, 1.298, 2, 5, 0.531, 33.656, 41.373, -5.068, -1.301, 0.103, 0.091, -4.384, 0.033, -5.6]
**Ligand B:** [388.892, 75.27, 2.445, 2, 3, 0.704, 41.838, 71.772, -5.024, -4.184, 0.545, 40.323, -17.67, 0.101, -7.3]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity) and general drug-likeness:
1. **MW:** Both are within the ideal range (200-500 Da). A (354.447) is slightly preferred.
2. **TPSA:** A (93.73) is a bit higher than optimal (<140), but acceptable. B (75.27) is excellent. B is better here.
3. **logP:** Both are within the optimal range (1-3). A (1.298) is slightly lower, B (2.445) is closer to the sweet spot. B is better.
4. **HBD:** Both have 2 HBD, which is good.
5. **HBA:** A has 5, B has 3. Both are acceptable, but B is slightly better.
6. **QED:** A (0.531) is acceptable, but B (0.704) is significantly better, indicating a more drug-like profile. B is better.
7. **DILI:** Both are reasonably low risk (A: 33.656, B: 41.838). A is slightly better.
8. **BBB:** B (71.772) is significantly better than A (41.373). This is a key advantage for a GPCR, even a cardiovascular one, as some CNS off-target effects are always a concern. B is much better.
9. **Caco-2:** Both are negative, which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Both are negative, indicating poor solubility. A (-1.301) is slightly better than B (-4.184). A is better.
11. **hERG:** Both are very low risk (A: 0.103, B: 0.545). A is better.
12. **Cl_mic:** A (0.091) is *much* lower than B (40.323), indicating far better metabolic stability. A is significantly better.
13. **t1/2:** A (-4.384) is better than B (-17.67), indicating a longer half-life. A is better.
14. **Pgp:** Both are very low (A: 0.033, B: 0.101). A is slightly better.
15. **Affinity:** B (-7.3) is 1.7 kcal/mol stronger than A (-5.6). This is a *substantial* difference in binding and can often outweigh other concerns. B is much better.
**Overall Assessment:**
While Ligand A has advantages in metabolic stability (Cl_mic, t1/2), solubility, and a slightly lower DILI risk, Ligand B's significantly stronger binding affinity (-7.3 vs -5.6 kcal/mol) and better BBB penetration are crucial for a GPCR target. The higher QED score of B also contributes to its overall drug-likeness. The poor Caco-2 and solubility for both are concerning, but the potency advantage of B is likely to be more impactful in early stages of development.
Therefore, I would prioritize Ligand B.
0
2025-04-17 18:46:09,659 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (351.451 and 353.394 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (119.14) is slightly higher than Ligand B (110.52). Both are below the 140 A^2 threshold for good oral absorption, but Ligand B is closer to the preferred <90 A^2 for CNS targets (though this isn't a CNS target, lower TPSA is generally favorable).
**3. logP:** Both ligands have good logP values (1.175 and 1.348), falling within the optimal 1-3 range. Ligand B is slightly more lipophilic, which could be beneficial for membrane permeability.
**4. H-Bond Donors:** Ligand A has 5 HBD, which is at the upper limit of the preferred range. Ligand B has 3, which is more desirable.
**5. H-Bond Acceptors:** Both ligands have 4 HBA, which is well within the acceptable range.
**6. QED:** Ligand B (0.613) has a higher QED score than Ligand A (0.506), indicating a more drug-like profile.
**7. DILI Risk:** Ligand A (30.787) has a significantly lower DILI risk than Ligand B (43.66). This is a major advantage for Ligand A.
**8. BBB Penetration:** Ligand B (75.572) has much better predicted BBB penetration than Ligand A (39.977). While ADRB2 is primarily a cardiovascular target, some CNS off-target effects are always a consideration, and better BBB penetration could be a concern.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-5.277 and -5.091). This is unusual and suggests poor permeability. However, these values are on a log scale, and the absolute difference is small.
**10. Aqueous Solubility:** Both ligands have very poor predicted aqueous solubility (-2.151 and -2.629). This is a significant drawback for both, potentially hindering bioavailability.
**11. hERG Inhibition:** Ligand A (0.082) has a much lower predicted hERG inhibition risk than Ligand B (0.662). This is a critical safety parameter, and Ligand A is significantly better.
**12. Microsomal Clearance:** Ligand B (51.216) has a much higher microsomal clearance than Ligand A (-1.297), suggesting faster metabolism and potentially lower *in vivo* exposure.
**13. In vitro Half-Life:** Ligand A (-17.196) has a longer predicted *in vitro* half-life than Ligand B (-24.258), indicating greater metabolic stability.
**14. P-gp Efflux:** Ligand A (0.021) has a lower P-gp efflux liability than Ligand B (0.114), which is favorable for oral bioavailability.
**15. Binding Affinity:** Ligand B (-7.4 kcal/mol) has a slightly better binding affinity than Ligand A (-6.4 kcal/mol). This is a 1.0 kcal/mol difference, which is substantial but not overwhelming.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity) and the general drug-like properties, Ligand A emerges as the more promising candidate. While Ligand B has a slightly better affinity and BBB penetration, Ligand A has significantly better safety profiles (lower DILI and hERG risk), better metabolic stability (lower Cl_mic, longer t1/2), and lower P-gp efflux. The poor solubility and Caco-2 permeability are concerns for both, but the safety and metabolic advantages of Ligand A outweigh the modest affinity difference.
Output:
1
2025-04-17 18:46:09,659 - INFO - Batch 61 complete. Total preferences: 976
2025-04-17 18:46:09,659 - INFO - Processing batch 62/512...
2025-04-17 18:46:58,078 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (445.766 Da) is within the ideal range, while Ligand B (380.535 Da) is slightly below, but still acceptable.
2. **TPSA:** Ligand A (53.01) is good, below the 140 threshold. Ligand B (60.85) is also acceptable, but slightly higher.
3. **logP:** Ligand A (4.193) is a bit high, potentially leading to solubility issues. Ligand B (1.843) is optimal. This is a significant advantage for B.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Both ligands have 5 HBA, which is good.
6. **QED:** Both ligands have good QED scores (A: 0.748, B: 0.845), indicating drug-likeness. B is slightly better.
7. **DILI:** Ligand A (77.433) has a higher DILI risk than Ligand B (35.905). This is a substantial negative for A.
8. **BBB:** Ligand A (58.511) has moderate BBB penetration, while Ligand B (39.55) is lower. Since ADRB2 is a cardiovascular target, BBB penetration is not a primary concern, so this is less important.
9. **Caco-2:** Both have negative values, which is unusual. Assuming these are logP values, Ligand A (-4.95) is worse than Ligand B (-5.391).
10. **Solubility:** Ligand A (-4.746) has worse solubility than Ligand B (-3.358).
11. **hERG:** Both ligands have low hERG risk (A: 0.512, B: 0.206). B is slightly better.
12. **Cl_mic:** Ligand A (37.64) has lower microsomal clearance, indicating better metabolic stability, than Ligand B (49.134). This is a positive for A.
13. **t1/2:** Ligand A (-4.501) has a longer in vitro half-life than Ligand B (-1.076). This is a positive for A.
14. **Pgp:** Both ligands have low Pgp efflux liability (A: 0.238, B: 0.128). B is slightly better.
15. **Affinity:** Ligand B (-6.6 kcal/mol) has a slightly better binding affinity than Ligand A (-6.2 kcal/mol).
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand B is the stronger candidate. While Ligand A has better metabolic stability (Cl_mic and t1/2), the significantly higher DILI risk and higher logP of Ligand A are major drawbacks. Ligand B's lower DILI risk, optimal logP, and slightly better affinity outweigh the slightly lower metabolic stability. The solubility of Ligand B is also better.
Output:
0
2025-04-17 18:46:58,078 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (353.365 Da and 350.419 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (66.84) is significantly better than Ligand B (113.44). For a GPCR, lower TPSA is generally preferred for better permeability. Ligand B is above the 90 A^2 threshold.
**3. logP:** Ligand A (2.866) is within the optimal 1-3 range. Ligand B (0.869) is a bit low, potentially hindering membrane permeability.
**4. H-Bond Donors:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
**5. H-Bond Acceptors:** Ligand A (4) is better than Ligand B (6). Lower HBA count is generally favorable for permeability.
**6. QED:** Ligand A (0.849) has a higher QED score than Ligand B (0.609), indicating a more drug-like profile.
**7. DILI Risk:** Ligand A (31.408) has a considerably lower DILI risk than Ligand B (47.732). This is a significant advantage.
**8. BBB Penetration:** Ligand A (92.012) shows much better BBB penetration potential than Ligand B (46.762). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be beneficial for understanding off-target effects and potential peripheral distribution.
**9. Caco-2 Permeability:** Ligand A (-4.323) is better than Ligand B (-5.126), indicating better intestinal absorption.
**10. Aqueous Solubility:** Ligand A (-3.417) is better than Ligand B (-2.88).
**11. hERG Inhibition:** Ligand A (0.587) has a lower hERG inhibition liability than Ligand B (0.108), which is a crucial safety parameter.
**12. Microsomal Clearance:** Ligand B (32.267) has lower microsomal clearance than Ligand A (63.031), suggesting better metabolic stability.
**13. In vitro Half-Life:** Ligand B (-8.711) has a longer in vitro half-life than Ligand A (-8.161).
**14. P-gp Efflux:** Ligand A (0.126) has lower P-gp efflux than Ligand B (0.026), which is preferable.
**15. Binding Affinity:** Ligand B (-6.3 kcal/mol) has a slightly better binding affinity than Ligand A (-7.4 kcal/mol). However, the difference is not substantial enough to outweigh the numerous advantages of Ligand A.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical ADME-Tox properties (TPSA, logP, HBD, HBA, DILI, BBB, solubility, hERG, P-gp). While Ligand B has slightly better metabolic stability and binding affinity, the superior overall profile of Ligand A, particularly its lower toxicity risk and better permeability characteristics, makes it the more promising drug candidate for the ADRB2 receptor.
Output:
1
2025-04-17 18:46:58,078 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (348.487) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (49.85) is significantly better than Ligand B (71.44). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (2.607) is optimal, while Ligand B (0.255) is quite low. This is a significant drawback for Ligand B, potentially hindering membrane permeability and bioavailability.
4. **HBD:** Both have 0 HBD, which is acceptable.
5. **HBA:** Ligand A (3) is preferable to Ligand B (5). Higher HBA can sometimes reduce permeability.
6. **QED:** Both are good (around 0.7), indicating drug-like properties.
7. **DILI:** Ligand A (28.112) has a much lower DILI risk than Ligand B (44.552). This is a crucial advantage.
8. **BBB:** Ligand B (96.782) has higher BBB penetration than Ligand A (84.49), but as this is a cardiovascular target, BBB isn't a major priority.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. This is concerning for both.
10. **Solubility:** Both have negative solubility values, indicating poor solubility. This is concerning for both.
11. **hERG:** Ligand A (0.525) has a slightly higher hERG risk than Ligand B (0.233), but both are relatively low.
12. **Cl_mic:** Ligand A (87.408) has a higher microsomal clearance than Ligand B (-2.281). This suggests Ligand B is more metabolically stable, a significant advantage.
13. **t1/2:** Ligand A (-8.081) has a longer in vitro half-life than Ligand B (-19.759), which is favorable.
14. **Pgp:** Ligand A (0.495) has lower P-gp efflux than Ligand B (0.082), which is preferable.
15. **Binding Affinity:** Ligand B (-6.6) has a slightly better binding affinity than Ligand A (-5.7). However, the difference is less than 1.5 kcal/mol, and can be overcome by other factors.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are important. Ligand A has a much better logP and TPSA, while Ligand B has a slightly better affinity. The DILI risk for Ligand A is also significantly lower, which is a major safety consideration. Metabolic stability (Cl_mic) is also important, and Ligand B has a clear advantage here.
**Overall Assessment:**
While Ligand B has a slightly better binding affinity and metabolic stability, the significantly better logP, TPSA, and lower DILI risk of Ligand A outweigh these advantages. The poor Caco-2 and solubility for both ligands are concerning and would require further optimization, but Ligand A starts from a better position overall.
**Output:**
1
2025-04-17 18:46:58,078 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (372.487 Da and 358.511 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (112.57) is higher than Ligand B (61.88). For a GPCR, lower TPSA is generally preferred for better permeability, giving a slight edge to Ligand B.
**3. logP:** Ligand B (4.476) is significantly higher than Ligand A (0.126). While logP > 4 can be problematic, for a GPCR, a higher logP can be beneficial for membrane interactions and binding. Ligand A's logP is very low, potentially hindering permeability. This is a significant advantage for Ligand B.
**4. H-Bond Donors:** Ligand A (3) is higher than Ligand B (1). Lower HBD is generally preferred for permeability, favoring Ligand B.
**5. H-Bond Acceptors:** Ligand A (5) is higher than Ligand B (4). Similar to HBD, lower HBA is preferred, favoring Ligand B.
**6. QED:** Both ligands have similar QED values (0.588 and 0.531), indicating good drug-likeness.
**7. DILI:** Ligand A (29.779) has a much lower DILI risk than Ligand B (53.858). This is a significant advantage for Ligand A.
**8. BBB:** Ligand B (64.133) has a higher BBB penetration percentile than Ligand A (46.375). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be useful for understanding off-target effects.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-5.529 and -5.173), which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
**10. Aqueous Solubility:** Ligand A (-1.282) has better aqueous solubility than Ligand B (-4.099). This is a positive for Ligand A.
**11. hERG Inhibition:** Ligand A (0.07) has a much lower hERG inhibition liability than Ligand B (0.652). This is a critical advantage for Ligand A, minimizing cardiotoxicity risk.
**12. Microsomal Clearance:** Ligand B (72.696) has a much higher microsomal clearance than Ligand A (-2.563). This indicates Ligand A is more metabolically stable, a significant advantage.
**13. In vitro Half-Life:** Ligand A (17.254) has a longer in vitro half-life than Ligand B (-19.599). This is a strong advantage for Ligand A, potentially allowing for less frequent dosing.
**14. P-gp Efflux:** Ligand A (0.029) has much lower P-gp efflux liability than Ligand B (0.56). This is beneficial for bioavailability, favoring Ligand A.
**15. Binding Affinity:** Ligand A (-6.8 kcal/mol) has a slightly better binding affinity than Ligand B (-5.2 kcal/mol). While the difference isn't huge, it's enough to consider, especially given the other favorable properties of Ligand A.
**Overall Assessment:**
While Ligand B has a better logP and BBB penetration, Ligand A is significantly better in terms of safety (DILI, hERG), metabolic stability (Cl_mic, t1/2), P-gp efflux, and solubility. The slightly better binding affinity of Ligand A further strengthens its position. Given the importance of minimizing off-target effects and ensuring favorable ADME properties for a cardiovascular target, Ligand A is the more promising candidate.
Output:
1
2025-04-17 18:46:58,079 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (367.427 Da) is slightly higher than Ligand B (349.475 Da), but both are acceptable.
2. **TPSA:** Ligand A (99.93) is higher than Ligand B (64.09). For a cardiovascular GPCR like ADRB2, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B is significantly better here.
3. **logP:** Ligand B (1.001) is within the optimal range (1-3), while Ligand A (0.399) is slightly below. This could potentially hinder membrane permeability for Ligand A.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 5 HBA, while Ligand B has 4. Both are within the acceptable limit of 10.
6. **QED:** Both ligands have similar QED values (0.763 and 0.769), indicating good drug-likeness.
7. **DILI:** Ligand A (66.111) has a higher DILI risk than Ligand B (5.894). This is a significant concern, as a lower DILI risk is highly desirable.
8. **BBB:** Both ligands have moderate BBB penetration (Ligand A: 54.44, Ligand B: 62.621). Since ADRB2 isn't a primary CNS target, this isn't a major deciding factor, but Ligand B is slightly better.
9. **Caco-2:** Ligand A (-5.205) has a worse Caco-2 permeability than Ligand B (-4.773). Lower values indicate poorer permeability.
10. **Solubility:** Ligand A (-2.411) has worse solubility than Ligand B (-0.496). Solubility is important for bioavailability.
11. **hERG:** Both ligands have very low hERG inhibition risk (Ligand A: 0.238, Ligand B: 0.125). Ligand B is slightly better.
12. **Cl_mic:** Ligand A (67.283) has a higher microsomal clearance than Ligand B (6.02). This suggests Ligand A is less metabolically stable.
13. **t1/2:** Ligand A (33.342) has a longer in vitro half-life than Ligand B (5.644). This is a positive attribute for Ligand A.
14. **Pgp:** Both ligands have low P-gp efflux liability (Ligand A: 0.047, Ligand B: 0.022). Ligand B is slightly better.
15. **Binding Affinity:** Ligand A (-5.8 kcal/mol) has a slightly better binding affinity than Ligand B (-5.1 kcal/mol). This is a 0.7 kcal/mol difference, which is a notable advantage.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity and a longer half-life, the significant drawbacks in DILI risk, logP, solubility, and metabolic stability (Cl_mic) are concerning. Ligand B demonstrates a much more balanced profile, with better TPSA, logP, solubility, DILI risk, and metabolic stability. The slightly weaker binding affinity of Ligand B is likely outweighed by its superior ADME properties and reduced toxicity risk. For a cardiovascular target, minimizing toxicity and ensuring reasonable ADME properties are crucial.
Output:
0
2025-04-17 18:46:58,079 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
The target is ADRB2, a GPCR. Therefore, I will prioritize logP, TPSA, Pgp efflux, BBB penetration, and binding affinity, while also considering ADME-Tox properties.
* **Molecular Weight:** Both ligands (345.3 and 351.5 Da) fall within the ideal 200-500 Da range.
* **TPSA:** Both ligands have TPSA values (76.1 and 72.9) below the 140 A^2 threshold for good oral absorption.
* **logP:** Ligand A (2.705) is better than Ligand B (1.297). A logP between 1-3 is optimal, and Ligand B is a bit low, potentially hindering permeation.
* **H-Bond Donors/Acceptors:** Both have 2 HBD and 4 HBA, which are acceptable.
* **QED:** Both ligands have similar QED values (0.763 and 0.678), indicating good drug-likeness.
* **DILI:** Ligand A (97.7) has a significantly higher DILI risk than Ligand B (8.0). This is a major concern for Ligand A.
* **BBB:** Ligand B (57.2) has better BBB penetration than Ligand A (48.3), though neither is exceptionally high. This is less critical for a peripheral GPCR like ADRB2 but still a consideration.
* **Caco-2 Permeability:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.454) is slightly better than Ligand B (-4.831), but both are problematic.
* **Aqueous Solubility:** Ligand B (-0.643) is better than Ligand A (-4.929).
* **hERG:** Ligand A (0.692) has a slightly better hERG profile than Ligand B (0.105).
* **Microsomal Clearance:** Ligand B (8.5) has a higher microsomal clearance than Ligand A (6.58), indicating faster metabolism and lower metabolic stability.
* **In vitro Half-Life:** Ligand A (0.577) has a much longer half-life than Ligand B (-16.083). This is a significant advantage for Ligand A.
* **P-gp Efflux:** Ligand A (0.3) has lower P-gp efflux than Ligand B (0.012), which is preferable.
* **Binding Affinity:** Ligand A (-6.9 kcal/mol) has a slightly better binding affinity than Ligand B (-6.0 kcal/mol), but the difference is less than 1.5 kcal/mol.
**Overall Assessment:**
Ligand A has better binding affinity, half-life, and P-gp efflux, but suffers from a very high DILI risk. Ligand B has a much better safety profile (DILI) and solubility, but has a lower logP and a very short half-life. Given the high DILI risk associated with Ligand A, I would prioritize Ligand B despite its drawbacks. The shorter half-life and lower logP can potentially be addressed through further optimization, but a high DILI risk is a more difficult problem to solve.
**Output:**
0
2025-04-17 18:46:58,079 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (344.419 Da and 364.446 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (103.87) is slightly higher than Ligand B (81.34). For a cardiovascular GPCR, TPSA is moderately important, and Ligand B's lower TPSA is preferable for potential oral absorption.
**3. logP:** Ligand A (1.41) is within the optimal range, while Ligand B (2.91) is approaching the upper limit. While both are acceptable, Ligand A's lower logP reduces the risk of off-target interactions and solubility issues.
**4. H-Bond Donors:** Ligand A has 2 HBDs, and Ligand B has 1. Both are within the acceptable limit of <=5.
**5. H-Bond Acceptors:** Ligand A has 5 HBAs, and Ligand B has 6. Both are within the acceptable limit of <=10.
**6. QED:** Both ligands have good QED values (0.79 and 0.817), indicating good drug-like properties.
**7. DILI Risk:** Both ligands have similar DILI risk (57.425 and 56.689), both falling into an acceptable range (<60).
**8. BBB Penetration:** Ligand B (85.459) has significantly better BBB penetration than Ligand A (44.591). While ADRB2 is a cardiovascular target, some CNS effects are possible with beta-blockers, and better BBB penetration could be a slight advantage, but not critical.
**9. Caco-2 Permeability:** Ligand A (-5.583) has worse Caco-2 permeability than Ligand B (-4.598). This suggests Ligand B will have better intestinal absorption.
**10. Aqueous Solubility:** Ligand A (-1.683) has better aqueous solubility than Ligand B (-4.165). This is a positive for formulation and bioavailability.
**11. hERG Inhibition:** Ligand A (0.133) has a lower hERG inhibition risk than Ligand B (0.691). This is a significant advantage, as hERG inhibition can lead to cardiotoxicity.
**12. Microsomal Clearance:** Ligand A (21.145) has lower microsomal clearance than Ligand B (51.558), indicating better metabolic stability.
**13. In vitro Half-Life:** Ligand A (-14.737) has a longer in vitro half-life than Ligand B (-18.276). This is beneficial for dosing frequency.
**14. P-gp Efflux:** Ligand A (0.025) has significantly lower P-gp efflux than Ligand B (0.142), which is favorable for bioavailability.
**15. Binding Affinity:** Ligand B (-7.5) has a stronger binding affinity than Ligand A (-5.7). This is a substantial difference (1.8 kcal/mol) and a major factor in its favor.
**Overall Assessment:**
While Ligand B has a better binding affinity and Caco-2 permeability, Ligand A demonstrates a superior safety profile with lower hERG inhibition, better metabolic stability (lower Cl_mic, longer t1/2), and lower P-gp efflux. The difference in binding affinity is significant, but the combined advantages of Ligand A regarding safety and ADME properties are more compelling for a cardiovascular drug candidate where minimizing off-target effects and ensuring predictable pharmacokinetics are crucial.
Output:
1
2025-04-17 18:46:58,079 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (352.4 & 353.4 Da) fall comfortably within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (78.87) is higher than Ligand B (56.59). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is generally preferred for absorption. Ligand B is better here.
3. **logP:** Both ligands (2.153 & 1.65) are within the optimal 1-3 range. Ligand B is slightly lower, which could potentially improve solubility but might slightly hinder membrane permeability.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (0). Both are acceptable, but lower is generally preferred. Ligand B is better.
5. **HBA:** Ligand A (4) is lower than Ligand B (5). Both are acceptable, but lower is generally preferred. Ligand A is better.
6. **QED:** Ligand A (0.855) is significantly better than Ligand B (0.6). Higher QED indicates better overall drug-likeness. Ligand A is better.
7. **DILI:** Ligand B (11.632) has a *much* lower DILI risk than Ligand A (44.203). This is a significant advantage for Ligand B.
8. **BBB:** Ligand B (97.247) has a much higher BBB penetration potential than Ligand A (53.432). While ADRB2 is primarily a cardiovascular target, some CNS off-target effects are always a consideration, and higher BBB is generally not detrimental. Ligand B is better.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.225 and -4.43), indicating poor permeability. This is a concern for both.
10. **Solubility:** Ligand B (-1.257) is slightly better (less negative) than Ligand A (-2.073), suggesting slightly better aqueous solubility.
11. **hERG:** Both ligands have low hERG inhibition risk (0.644 and 0.698). No significant difference.
12. **Cl_mic:** Ligand B (53.442) has a higher microsomal clearance than Ligand A (26.434). This suggests Ligand A is more metabolically stable. Ligand A is better.
13. **t1/2:** Ligand B (22.753) has a significantly longer in vitro half-life than Ligand A (-17.278). This is a major advantage for Ligand B.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.279 and 0.185). No significant difference.
15. **Binding Affinity:** Ligand A (-6.4) has a slightly better binding affinity than Ligand B (-5.4). This is a 1.0 kcal/mol difference, which is meaningful.
**GPCR-Specific Priorities & Overall Assessment:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has a slight edge in affinity and better metabolic stability (Cl_mic), and a better QED score. However, Ligand B *significantly* outperforms Ligand A in DILI risk, BBB penetration, and in vitro half-life. The poor Caco-2 values are a concern for both, but the lower DILI and longer half-life of Ligand B are more critical for overall developability. The slightly better affinity of Ligand A is not enough to overcome these significant advantages of Ligand B.
Output:
0
2025-04-17 18:46:58,079 - INFO - Here's my reasoning and the final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, we prioritize logP, Pgp, TPSA, and affinity, alongside general drug-like properties.
* **Molecular Weight:** Both ligands (347.46 and 354.49 Da) fall within the ideal 200-500 Da range.
* **TPSA:** Ligand A (57) is significantly better than Ligand B (78.87), falling well below the 140 threshold for oral absorption. Ligand B is approaching a less favorable range.
* **logP:** Both ligands have good logP values (1.96 and 1.71), within the optimal 1-3 range.
* **H-Bond Donors/Acceptors:** Ligand A (0 HBD, 4 HBA) is slightly better than Ligand B (2 HBD, 4 HBA) in terms of balancing solubility and permeability.
* **QED:** Ligand A (0.817) has a higher QED score than Ligand B (0.586), indicating a more drug-like profile.
* **DILI:** Ligand A (5.55) has a slightly higher DILI risk than Ligand B (3.22), but both are well below the concerning threshold of 60.
* **BBB:** Both ligands have good BBB penetration (70.61 and 80.81), which isn't a primary concern for a cardiovascular target but is still a positive. Ligand B is slightly better.
* **Caco-2:** Both have negative Caco-2 values, which is unusual and difficult to interpret without knowing the scale. However, the values are similar.
* **Aqueous Solubility:** Both ligands have negative solubility values, which is also unusual. Again, the values are similar.
* **hERG:** Both ligands have low hERG inhibition liability (0.435 and 0.517), which is good.
* **Microsomal Clearance:** Ligand A (-2.955) has a lower (better) microsomal clearance than Ligand B (27.931), suggesting greater metabolic stability.
* **In vitro Half-Life:** Ligand A (25.86 hours) has a significantly longer half-life than Ligand B (-26.14 hours). The negative value for Ligand B is concerning and likely indicates a very short half-life or an issue with the assay.
* **P-gp Efflux:** Both ligands have low P-gp efflux liability (0.034 and 0.076), which is favorable.
* **Binding Affinity:** Both ligands have excellent binding affinity (-6.3 and -6.0 kcal/mol). The difference is less than the 1.5 kcal/mol threshold.
**Conclusion:**
Ligand A is the better candidate. It has a superior TPSA, QED, microsomal clearance, and *much* better in vitro half-life. While Ligand B has slightly better BBB penetration and a lower DILI risk, the other advantages of Ligand A, particularly its metabolic stability and half-life, are more critical for a successful drug candidate targeting a GPCR. The negative half-life value for Ligand B is a significant red flag.
**Output:**
1
2025-04-17 18:46:58,079 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (336.391 and 335.451 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (71.19) is better than Ligand B (78.91). Both are under the 140 threshold for oral absorption, but lower TPSA is generally preferred for GPCRs to facilitate receptor binding.
3. **logP:** Ligand A (2.863) is better than Ligand B (3.946). Ligand B is approaching the upper limit of the optimal range (1-3), potentially leading to solubility issues.
4. **HBD:** Both ligands have 2 H-bond donors, which is within the ideal range (<=5). No difference.
5. **HBA:** Both ligands have 3 H-bond acceptors, also within the ideal range (<=10). No difference.
6. **QED:** Ligand B (0.839) is slightly better than Ligand A (0.727), indicating a more drug-like profile.
7. **DILI:** Ligand A (70.299) has a higher DILI risk than Ligand B (41.877). This is a significant negative for Ligand A.
8. **BBB:** Ligand B (63.862) is better than Ligand A (56.572), although neither is exceptionally high. For a cardiovascular GPCR, BBB penetration isn't a primary concern, but it's a slight advantage for B.
9. **Caco-2:** Ligand A (-5.143) and Ligand B (-4.762) are both negative, indicating poor permeability. This is a concern for both, but the values are relatively close.
10. **Solubility:** Ligand A (-4.824) and Ligand B (-4.779) are both poor. This is a concern for both, but the values are relatively close.
11. **hERG:** Ligand A (0.744) is better than Ligand B (0.883), indicating lower cardiotoxicity risk. This is important for a cardiovascular target.
12. **Cl_mic:** Ligand A (37.684) has better metabolic stability (lower clearance) than Ligand B (55.658).
13. **t1/2:** Ligand A (38.753) has a longer half-life than Ligand B (24.009). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.409) has lower P-gp efflux than Ligand B (0.282). Lower P-gp efflux is generally preferred.
15. **Binding Affinity:** Ligand B (-5.9) has a better binding affinity than Ligand A (-6.6). This is a substantial advantage for Ligand B.
**Overall Assessment:**
Ligand B has a better binding affinity and QED score. However, Ligand A has significantly better metabolic stability (Cl_mic and t1/2), lower DILI risk, and lower P-gp efflux. The higher DILI risk for Ligand A is a major concern. While the affinity difference is substantial, the ADME profile of Ligand A is more favorable overall, especially considering the potential for cardiovascular side effects. The lower hERG risk is also a key advantage.
Output:
1
2025-04-17 18:46:58,079 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (354.45 & 362.31 Da) fall comfortably within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (77.1) is better than Ligand B (86.55). For a cardiovascular GPCR, we don't *need* super low TPSA for BBB penetration, but lower is generally favorable for absorption and reducing off-target interactions.
3. **logP:** Both ligands (0.918 & 1.14) are within the optimal 1-3 range. Ligand B is slightly better.
4. **HBD:** Ligand A (1) is better than Ligand B (0). While both are low, having at least one HBD can improve solubility.
5. **HBA:** Ligand A (5) is better than Ligand B (7). Lower HBA is generally preferred for permeability.
6. **QED:** Both ligands (0.656 & 0.73) are above the 0.5 threshold, indicating good drug-likeness. Ligand B is slightly better.
7. **DILI:** Ligand A (29.93) is significantly better than Ligand B (59.36). This is a major advantage for Ligand A. Lower DILI risk is crucial.
8. **BBB:** Ligand B (94.34) is much better than Ligand A (72.24). While ADRB2 isn't a CNS target, some off-target CNS effects are possible with GPCR ligands, so higher BBB is a slight advantage.
9. **Caco-2:** Ligand A (-4.753) is better than Ligand B (-4.318). Higher (less negative) Caco-2 values indicate better absorption.
10. **Solubility:** Ligand A (-2.25) is better than Ligand B (-2.707). Better solubility is always preferred.
11. **hERG:** Both ligands (0.285 & 0.036) have low hERG risk, which is good. Ligand B is slightly better.
12. **Cl_mic:** Ligand A (49.05) and Ligand B (48.56) are very similar. No significant difference.
13. **t1/2:** Ligand A (16.27) is better than Ligand B (-24.99). A positive half-life is preferred.
14. **Pgp:** Ligand A (0.042) is better than Ligand B (0.037). Lower P-gp efflux is desirable for better bioavailability.
15. **Binding Affinity:** Ligand B (-5.5) is significantly better than Ligand A (-3.3). A 2.2 kcal/mol difference in binding affinity is substantial and can often outweigh minor ADME drawbacks.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), affinity, logP, TPSA, and Pgp are particularly important. Ligand B excels in affinity, has a slightly better logP, and comparable TPSA and Pgp. However, the significantly higher DILI risk for Ligand B is a major concern.
**Overall Assessment:**
While Ligand B has a superior binding affinity, the substantially higher DILI risk associated with it makes it a less desirable candidate. Ligand A presents a much more balanced profile with acceptable affinity, better safety (DILI), and good ADME properties. The affinity difference, while significant, can potentially be addressed through further optimization of Ligand A.
Output:
1
2025-04-17 18:46:58,079 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (363.351 and 360.885 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (125.79) is higher than Ligand B (59.47). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is generally preferred for absorption. Ligand B is significantly better here.
3. **logP:** Ligand A (0.422) is quite low, potentially hindering membrane permeability. Ligand B (4.64) is high, potentially causing solubility issues and off-target effects, but is within the acceptable range. Ligand B is better, but the high logP is a concern.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable. No strong preference.
5. **HBA:** Ligand A (6) and Ligand B (3) are both acceptable. Ligand B is slightly better.
6. **QED:** Both ligands (0.811 and 0.863) have excellent drug-likeness scores. No significant difference.
7. **DILI:** Ligand A (92.982) has a significantly higher DILI risk than Ligand B (31.989). This is a major concern for Ligand A.
8. **BBB:** Ligand A (22.412) has very low BBB penetration, while Ligand B (75.998) is quite good. While ADRB2 isn't primarily a CNS target, some distribution to the CNS is possible and not necessarily detrimental.
9. **Caco-2:** Ligand A (-5.113) has a very poor Caco-2 permeability, indicating poor absorption. Ligand B (-4.782) is also poor, but slightly better.
10. **Solubility:** Ligand A (-3.838) has poor solubility, while Ligand B (-3.565) is slightly better.
11. **hERG:** Ligand A (0.108) has a very low hERG risk, which is excellent. Ligand B (0.767) has a moderate hERG risk.
12. **Cl_mic:** Both ligands have similar microsomal clearance (8.347 and 8.92 mL/min/kg). No strong preference.
13. **t1/2:** Ligand B (98.682) has a much longer in vitro half-life than Ligand A (66). This is a significant advantage for dosing convenience.
14. **Pgp:** Ligand A (0.032) has very low P-gp efflux, which is good. Ligand B (0.543) has moderate P-gp efflux.
15. **Binding Affinity:** Ligand B (-5.5 kcal/mol) has a slightly better binding affinity than Ligand A (-6.0 kcal/mol). While Ligand A has a slightly better affinity, the other factors are more important.
**Overall Assessment & GPCR-Specific Priorities:**
For a cardiovascular GPCR like ADRB2, logP, TPSA, and affinity are key. Ligand B excels in TPSA and has a reasonable logP, while Ligand A's logP is too low. The significantly lower DILI risk and longer half-life of Ligand B are also major advantages. While Ligand A has slightly better affinity and a better hERG profile, the poor absorption (Caco-2), solubility, and high DILI risk outweigh these benefits.
Output:
0
2025-04-17 18:46:58,079 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (343.427 and 352.475 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (57.0) is significantly better than Ligand B (84.5). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is pushing the upper limit for good oral absorption.
3. **logP:** Both ligands (2.623 and 2.189) are within the optimal 1-3 range. Ligand B is slightly lower, which could potentially affect permeability, but not drastically.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer hydrogen bond donors generally improve permeability.
5. **HBA:** Both ligands have 4 HBA, which is acceptable.
6. **QED:** Ligand A (0.789) has a significantly better QED score than Ligand B (0.492), indicating a more drug-like profile.
7. **DILI:** Ligand A (22.8) has a much lower DILI risk than Ligand B (33.501). This is a crucial advantage.
8. **BBB:** Ligand A (92.4) has a much higher BBB penetration percentile than Ligand B (60.295). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant and is not detrimental.
9. **Caco-2:** Both ligands have similar Caco-2 permeability (-4.6 and -4.672).
10. **Solubility:** Both ligands have similar aqueous solubility (-3.337 and -3.221).
11. **hERG:** Ligand A (0.706) has a lower hERG inhibition liability than Ligand B (0.118), indicating a lower risk of cardiotoxicity. This is very important for a cardiovascular target.
12. **Cl_mic:** Ligand A (26.02) has a lower microsomal clearance than Ligand B (85.44), suggesting better metabolic stability.
13. **t1/2:** Ligand A (36.043) has a longer in vitro half-life than Ligand B (-16.694). This is a significant advantage.
14. **Pgp:** Ligand A (0.105) has lower P-gp efflux liability than Ligand B (0.077). Lower efflux is generally preferred.
15. **Binding Affinity:** Ligand A (-8.5 kcal/mol) has a stronger binding affinity than Ligand B (-5.6 kcal/mol). This is a substantial difference, and a >1.5 kcal/mol advantage often outweighs minor ADME drawbacks.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical parameters. It has a better drug-like profile (QED), lower toxicity risk (DILI, hERG), better metabolic stability (Cl_mic, t1/2), better BBB penetration, and significantly stronger binding affinity. While both ligands have acceptable logP and MW values, the superior ADME and potency of Ligand A make it the more promising drug candidate.
Output:
1
2025-04-17 18:46:58,079 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [357.426, 87.74, 0.383, 2, 4, 0.69, 28.189, 75.572, -4.821, -1.693, 0.285, -1.121, 6.945, 0.015, -5.6]**
**Ligand B: [361.463, 57.65, 3.864, 0, 6, 0.668, 53.315, 76.309, -4.295, -4.872, 0.39, 109.748, -28.399, 0.48, -6.6]**
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). A is 357.426, B is 361.463. No significant difference.
2. **TPSA:** Ligand A (87.74) is slightly higher than Ligand B (57.65). Both are below 140, but B is significantly better for permeability, a key factor for GPCRs.
3. **logP:** Ligand A (0.383) is quite low, potentially hindering membrane permeability. Ligand B (3.864) is within the optimal range (1-3). This is a major advantage for B.
4. **H-Bond Donors:** Ligand A (2) is good. Ligand B (0) is also acceptable, potentially improving permeability.
5. **H-Bond Acceptors:** Ligand A (4) is good. Ligand B (6) is still within the acceptable range (<=10).
6. **QED:** Both ligands have similar QED values (A: 0.69, B: 0.668), indicating good drug-likeness.
7. **DILI:** Ligand A (28.189) has a lower DILI risk than Ligand B (53.315). This is a significant advantage for A.
8. **BBB:** Both ligands have good BBB penetration (A: 75.572, B: 76.309). This is less critical for ADRB2 (a cardiovascular target) but still positive.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual. Assuming these represent permeability, lower (more negative) values indicate better permeability. Ligand A (-4.821) is better than B (-4.295).
10. **Solubility:** Ligand A (-1.693) has better solubility than Ligand B (-4.872).
11. **hERG:** Both ligands have low hERG inhibition risk (A: 0.285, B: 0.39).
12. **Cl_mic:** Ligand A (-1.121) has a lower (better) microsomal clearance than Ligand B (109.748), indicating better metabolic stability.
13. **t1/2:** Ligand A (6.945) has a better in vitro half-life than Ligand B (-28.399).
14. **Pgp:** Ligand A (0.015) has much lower P-gp efflux than Ligand B (0.48).
15. **Binding Affinity:** Ligand B (-6.6) has a slightly better binding affinity than Ligand A (-5.6). This is a 1 kcal/mol difference, which is significant but not overwhelming.
**Overall Assessment:**
Ligand B has a better logP and binding affinity, which are important for GPCR targets. However, Ligand A excels in several critical ADME properties: DILI risk, metabolic stability (Cl_mic, t1/2), P-gp efflux, solubility, and Caco-2 permeability. The low logP of Ligand A is a concern, but its superior ADME profile, particularly the lower DILI risk and better metabolic stability, makes it a more promising candidate. The slight affinity difference can potentially be optimized in later stages of drug development.
Output:
1
2025-04-17 18:46:58,080 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (337.339 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (99) is better than Ligand B (107.11), both are acceptable for a non-CNS GPCR target like ADRB2, but lower is preferred.
3. **logP:** Both ligands have good logP values (A: 1.916, B: 1.599), falling within the optimal range of 1-3.
4. **HBD:** Ligand A (1) is better than Ligand B (4). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (7) is better than Ligand B (4). Fewer HBAs generally improve permeability.
6. **QED:** Ligand A (0.73) is better than Ligand B (0.507), indicating a more drug-like profile.
7. **DILI:** Ligand A (94.959) is significantly worse than Ligand B (13.61). This is a major concern for Ligand A.
8. **BBB:** Not a primary concern for ADRB2, but Ligand A (40.791) is lower than Ligand B (29.12).
9. **Caco-2:** Ligand A (-4.685) is better than Ligand B (-5.426), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-3.382) is better than Ligand B (-0.968).
11. **hERG:** Both ligands have similar, low hERG risk (A: 0.217, B: 0.237).
12. **Cl_mic:** Ligand B (-18.144) has a much lower (better) microsomal clearance than Ligand A (53.141), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-22.326) has a much longer in vitro half-life than Ligand A (8.71), which is desirable.
14. **Pgp:** Both ligands have similar, low Pgp efflux liability (A: 0.086, B: 0.03).
15. **Binding Affinity:** Ligand B (-8.0) has a significantly better binding affinity than Ligand A (-6.4). This is a substantial advantage.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Both ligands perform well on logP and Pgp. Ligand A has slightly better TPSA, but the difference is not significant. The substantial affinity advantage of Ligand B, combined with its superior metabolic stability (Cl_mic, t1/2) and drastically lower DILI risk, outweighs the slightly better TPSA and solubility of Ligand A. The DILI risk for Ligand A is a major red flag.
**Conclusion:**
Ligand B is the more promising drug candidate due to its significantly better binding affinity, metabolic stability, lower DILI risk, and longer half-life.
Output:
0
2025-04-17 18:46:58,080 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (341.371 and 349.431 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand B (87.74) is significantly better than Ligand A (112.95). Lower TPSA generally favors better cell permeability, crucial for GPCR targeting.
3. **logP:** Both ligands have acceptable logP values (0.956 and 1.36), falling within the 1-3 range. Ligand B is slightly better.
4. **HBD:** Both have 2 HBD, which is within the acceptable limit of <=5.
5. **HBA:** Ligand A has 6 HBA, while Ligand B has 4. Ligand B is preferable as it is closer to the ideal of <=10.
6. **QED:** Ligand A (0.812) has a better QED score than Ligand B (0.68), indicating better overall drug-likeness.
7. **DILI:** Ligand B (35.944) has a much lower DILI risk than Ligand A (58.511). This is a significant advantage for Ligand B.
8. **BBB:** Ligand B (79.217) has a substantially higher BBB penetration percentile than Ligand A (44.397). While ADRB2 isn't exclusively a CNS target, some peripheral ADRB2 activity can be modulated by CNS effects, and better BBB penetration is generally favorable.
9. **Caco-2:** Ligand A (-5.058) and Ligand B (-4.63) are both poor, indicating low intestinal absorption. This is a concern for both.
10. **Solubility:** Ligand A (-3.429) is slightly better than Ligand B (-1.8), but both are poor. Solubility is a concern for both.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.111 and 0.084).
12. **Cl_mic:** Ligand A (12.127) has a lower microsomal clearance than Ligand B (44.533), suggesting better metabolic stability. This is a positive for Ligand A.
13. **t1/2:** Ligand A (24.602) has a longer in vitro half-life than Ligand B (-22.576). This is a significant advantage for Ligand A.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.03 and 0.036).
15. **Binding Affinity:** Ligand A (-6.8 kcal/mol) has a slightly better binding affinity than Ligand B (-6.5 kcal/mol).
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, TPSA, logP, Pgp, and affinity are key. Ligand B excels in TPSA and BBB penetration, and has a slightly better logP. Ligand A has a better QED, Cl_mic, t1/2, and affinity, but the difference in affinity isn't substantial enough to outweigh the ADME advantages of Ligand B. The lower DILI risk for Ligand B is also a significant factor.
**Overall Assessment:**
While Ligand A has some advantages in metabolic stability and half-life, Ligand B's superior TPSA, lower DILI risk, and better BBB penetration make it a more promising candidate for development as a drug targeting ADRB2. The slightly weaker affinity is likely surmountable with further optimization.
Output:
0
2025-04-17 18:46:58,080 - INFO - Batch 62 complete. Total preferences: 992
2025-04-17 18:46:58,080 - INFO - Processing batch 63/512...
2025-04-17 18:47:43,792 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (425.67 & 426.34 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (84.5) is slightly higher than Ligand B (74.91). Both are below the 140 threshold for oral absorption, and acceptable for a cardiovascular target (not requiring significant BBB penetration). Ligand B is preferable.
3. **logP:** Both ligands (3.14 & 3.57) are within the optimal 1-3 range. Ligand B is slightly higher, which *could* be a minor concern for solubility, but isn't a dealbreaker.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1). Both are well within the acceptable limit of 5.
5. **HBA:** Ligand A (4) and Ligand B (5) are both within the acceptable limit of 10.
6. **QED:** Ligand B (0.797) has a better QED score than Ligand A (0.582), indicating a more drug-like profile. This is a significant advantage.
7. **DILI:** Ligand B (71.23) has a significantly lower DILI risk than Ligand A (87.79). This is a major advantage, as minimizing liver toxicity is crucial.
8. **BBB:** Both ligands have moderate BBB penetration (59.6% and 62.4%). Since ADRB2 is primarily a cardiovascular target, high BBB penetration isn't essential.
9. **Caco-2:** Ligand A (-4.705) has a better Caco-2 permeability than Ligand B (-5.148). This suggests better intestinal absorption for Ligand A.
10. **Solubility:** Ligand A (-5.458) has better aqueous solubility than Ligand B (-3.431). This is a positive for formulation and bioavailability.
11. **hERG:** Ligand A (0.491) has a lower hERG inhibition liability than Ligand B (0.112). This is a significant advantage, reducing the risk of cardiotoxicity.
12. **Cl_mic:** Ligand B (-12.66) has significantly lower microsomal clearance than Ligand A (74.22). This indicates better metabolic stability for Ligand B, a major benefit.
13. **t1/2:** Ligand B (8.06) has a longer in vitro half-life than Ligand A (42.07). This suggests less frequent dosing potential for Ligand B.
14. **Pgp:** Ligand A (0.269) has lower P-gp efflux liability than Ligand B (0.306). This is a slight advantage for oral bioavailability.
15. **Affinity:** Ligand A (-7.6) has a slightly better binding affinity than Ligand B (-5.4). This is a 2.2 kcal/mol difference, which is substantial and could potentially outweigh some ADME drawbacks.
**Overall Assessment:**
While Ligand A has better affinity and Caco-2 permeability, Ligand B demonstrates a superior ADME profile. Specifically, the significantly lower DILI risk, improved metabolic stability (lower Cl_mic), and longer half-life are compelling advantages. The QED score is also notably better for Ligand B. The affinity difference, while significant, isn't so large that it completely overrides the ADME benefits of Ligand B. For a cardiovascular target, metabolic stability and safety (DILI, hERG) are paramount.
Output:
0
2025-04-17 18:47:43,792 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (387.933 and 338.407 Da) fall within the ideal 200-500 Da range. Ligand B is slightly preferred due to being closer to the lower end of the range, which can aid permeability.
**2. TPSA:** Ligand A (71.53) is slightly higher than Ligand B (62.55). Both are below the 140 Angstroms threshold for good oral absorption, but Ligand B is better.
**3. logP:** Both ligands have good logP values (2.969 and 3.182), falling within the optimal 1-3 range. No significant difference here.
**4. H-Bond Donors:** Both have 1 HBD, which is within the acceptable limit of 5.
**5. H-Bond Acceptors:** Ligand A has 5 HBA, while Ligand B has 3. Both are below the 10 threshold. Ligand B is slightly preferred.
**6. QED:** Ligand B (0.935) has a significantly better QED score than Ligand A (0.626), indicating a more drug-like profile. This is a substantial advantage for Ligand B.
**7. DILI:** Ligand A (45.328) has a lower DILI risk than Ligand B (59.907), which is a positive for Ligand A. However, both are within an acceptable range (<60 is good).
**8. BBB:** Ligand A (77.549) has a higher BBB penetration percentile than Ligand B (61.923). While ADRB2 is a cardiovascular target, some CNS exposure can occur, and higher BBB is generally favorable.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.813 and -4.751), which is unusual and indicates poor permeability. This is a significant concern for both.
**10. Aqueous Solubility:** Both ligands have negative solubility values (-3.406 and -3.789), indicating very poor aqueous solubility. This is a major drawback for both.
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (0.64 and 0.547), which is good.
**12. Microsomal Clearance:** Ligand A (46.224) has lower microsomal clearance than Ligand B (54.01), suggesting better metabolic stability.
**13. In vitro Half-Life:** Ligand B (74.797) has a significantly longer in vitro half-life than Ligand A (43.782), which is a substantial advantage.
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (0.342 and 0.259), which is good.
**15. Binding Affinity:** Ligand B (-7.7 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.2 kcal/mol). This is a >1.5 kcal/mol advantage, which is a major deciding factor.
**Overall Assessment:**
While Ligand A has advantages in DILI and BBB penetration, Ligand B is clearly superior due to its significantly better QED score, much stronger binding affinity, and longer half-life. The poor Caco-2 and solubility are concerning for both, but the potency advantage of Ligand B is likely to outweigh these drawbacks, especially given the potential for formulation strategies to address solubility issues. The stronger binding affinity is a critical factor for a GPCR target.
Output:
0
2025-04-17 18:47:43,793 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [360.435, 77.52, 2.513, 1, 6, 0.848, 82.241, 55.254, -4.464, -3.61, 0.23, 71.856, 8.787, 0.276, -5.1]
**Ligand B:** [376.519, 103.78, 0.717, 2, 5, 0.617, 17.449, 54.091, -5.28, -1.293, 0.255, -10.091, 1.379, 0.019, -6.5]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). A (360.435) is slightly preferred.
2. **TPSA:** A (77.52) is better than B (103.78). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** A (2.513) is optimal. B (0.717) is a bit low, potentially hindering membrane permeability.
4. **HBD:** Both are acceptable (A: 1, B: 2).
5. **HBA:** Both are acceptable (A: 6, B: 5).
6. **QED:** A (0.848) is significantly better than B (0.617), indicating a more drug-like profile.
7. **DILI:** B (17.449) is *much* better than A (82.241). This is a major concern for A.
8. **BBB:** Both are similar (A: 55.254, B: 54.091). Not a high priority for a cardiovascular target.
9. **Caco-2:** A (-4.464) is better than B (-5.28), indicating better intestinal absorption.
10. **Solubility:** A (-3.61) is better than B (-1.293).
11. **hERG:** Both are low risk (A: 0.23, B: 0.255).
12. **Cl_mic:** B (-10.091) is *much* better than A (71.856), indicating significantly improved metabolic stability.
13. **t1/2:** A (8.787) is better than B (1.379).
14. **Pgp:** B (0.019) is much better than A (0.276), indicating less efflux.
15. **Affinity:** B (-6.5) is 1.4 kcal/mol better than A (-5.1). This is a substantial difference and a major advantage.
**GPCR-specific priorities:** For ADRB2, logP, Pgp, TPSA, and affinity are key. B excels in Pgp and affinity, while A has better logP and TPSA. However, the *significant* advantage in binding affinity for B (-6.5 kcal/mol) is a strong driver. The improved metabolic stability (Cl_mic) and reduced P-gp efflux of B are also very favorable. While A has better QED and solubility, the DILI risk is a major red flag.
**Conclusion:**
Despite the slightly better QED and solubility of Ligand A, the significantly lower DILI risk, superior binding affinity, improved metabolic stability, and reduced P-gp efflux of Ligand B make it the more promising drug candidate. The 1.4 kcal/mol difference in binding affinity is substantial enough to outweigh the minor drawbacks of B.
Output:
0
2025-04-17 18:47:43,793 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (344.5 and 360.5 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (49.41) is better than Ligand B (51.02), both are below the 140 threshold for oral absorption, but closer to the ideal for GPCRs.
**3. logP:** Both ligands have good logP values (2.99 and 3.89), falling within the optimal 1-3 range. Ligand B is slightly higher, which could potentially lead to some off-target effects, but is still acceptable.
**4. H-Bond Donors:** Ligand A has 1 HBD, while Ligand B has 0. Both are within the acceptable limit of <=5.
**5. H-Bond Acceptors:** Ligand A has 2 HBA, Ligand B has 5. Ligand A is preferable here, as lower HBA generally improves permeability.
**6. QED:** Both ligands have good QED scores (0.57 and 0.75), indicating good drug-like properties. Ligand B is slightly better.
**7. DILI Risk:** Ligand A (11.52) has a significantly lower DILI risk than Ligand B (41.02). This is a major advantage for Ligand A.
**8. BBB Penetration:** Ligand B (90.07) has better BBB penetration than Ligand A (77.16). While ADRB2 is a cardiovascular target, some CNS effects are possible with beta-blockers, and better BBB penetration *could* be beneficial, but is not critical.
**9. Caco-2 Permeability:** Ligand A (-4.692) has better Caco-2 permeability than Ligand B (-5.106). This suggests better intestinal absorption for Ligand A.
**10. Aqueous Solubility:** Ligand A (-3.688) has better aqueous solubility than Ligand B (-4.031). This is a slight advantage for Ligand A.
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.279 and 0.469), which is excellent. No significant difference.
**12. Microsomal Clearance:** Ligand A (29.09) has significantly lower microsomal clearance than Ligand B (104.48). This indicates better metabolic stability for Ligand A.
**13. In vitro Half-Life:** Ligand A (-20.85) has a much longer in vitro half-life than Ligand B (17.02). This is a significant advantage for Ligand A.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.042 and 0.561), which is good. Ligand A is slightly better.
**15. Binding Affinity:** Both ligands have the same binding affinity (-5.7 kcal/mol).
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), and the general drug-like properties, Ligand A is the more promising candidate. While Ligand B has slightly better BBB penetration and QED, Ligand A excels in crucial areas like DILI risk, metabolic stability (lower Cl_mic, longer t1/2), Caco-2 permeability, and solubility. The lower DILI risk and improved metabolic stability are particularly important for a cardiovascular drug. The equal binding affinity removes that as a differentiating factor.
Output:
1
2025-04-17 18:47:43,793 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (359.459 Da and 347.415 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (111.61) is higher than Ligand B (75.02). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is still generally preferred for absorption. Ligand B has a clear advantage.
3. **logP:** Ligand A (2.569) and Ligand B (1.125) are both within the optimal 1-3 range, but Ligand B is closer to the lower bound. Ligand A is slightly favored here.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable. No major difference.
5. **HBA:** Ligand A (8) and Ligand B (5) are both acceptable, but Ligand B is better.
6. **QED:** Both ligands have good QED scores (0.727 and 0.864), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (91.431) has a significantly higher DILI risk than Ligand B (30.632). This is a major concern for Ligand A.
8. **BBB:** Both ligands have moderate BBB penetration (62.699 and 65.762). Since ADRB2 is not a CNS target, this is not a primary concern.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Ligand A (-3.537) has worse solubility than Ligand B (-1.847). Solubility is important for bioavailability. Ligand B is favored.
11. **hERG:** Both ligands have low hERG inhibition risk (0.595 and 0.497). No significant difference.
12. **Cl_mic:** Ligand A (31.041) has higher microsomal clearance than Ligand B (10.169), suggesting lower metabolic stability. Ligand B is favored.
13. **t1/2:** Ligand B (59.814) has a longer in vitro half-life than Ligand A (44.339). This is a positive for Ligand B.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.16 and 0.046). No significant difference.
15. **Binding Affinity:** Ligand B (-6.7) has a slightly better binding affinity than Ligand A (-6.5). While the difference is small, it's still a factor.
**Overall Assessment:**
Ligand B consistently outperforms Ligand A in key ADME properties (DILI, solubility, metabolic stability, half-life, TPSA) and has a slightly better binding affinity. The significantly lower DILI risk for Ligand B is a major advantage. While Ligand A has a slightly better logP, the benefits of Ligand B outweigh this minor difference. Given the GPCR target class, balancing logP, TPSA, Pgp, and affinity is crucial, and Ligand B does this more effectively.
Output:
0
2025-04-17 18:47:43,793 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (346.4 and 357.4 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (78.09) is slightly higher than Ligand B (67.6). Both are below the 140 threshold for oral absorption, but B is better positioned for potential CNS penetration if that were a goal (though less relevant for a cardiovascular target).
**3. logP:** Both ligands have excellent logP values (2.423 and 2.296), falling within the optimal 1-3 range.
**4. H-Bond Donors:** Ligand A has 2 HBD, and Ligand B has 1. Both are within the acceptable limit of 5.
**5. H-Bond Acceptors:** Ligand A has 3 HBA, while Ligand B has 5. Both are below the 10 limit, but A is preferable.
**6. QED:** Both ligands have high QED scores (0.843 and 0.876), indicating good drug-like properties.
**7. DILI Risk:** Ligand B (22.722 percentile) has a significantly lower DILI risk than Ligand A (45.095 percentile). This is a major advantage for Ligand B.
**8. BBB Penetration:** Ligand B (93.098 percentile) shows much better BBB penetration than Ligand A (82.629 percentile). While not a primary concern for a cardiovascular target, it's a positive attribute.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-5.006 and -4.839), which is unusual and indicates poor permeability. This is a significant concern for both.
**10. Aqueous Solubility:** Both ligands have negative solubility values (-3.658 and -2.372), suggesting poor aqueous solubility. This is also a concern for both.
**11. hERG Inhibition:** Ligand A (0.613) has a slightly higher hERG inhibition risk than Ligand B (0.464), but both are relatively low.
**12. Microsomal Clearance:** Ligand A (-11.654) has a much lower (better) microsomal clearance than Ligand B (7.568). This suggests greater metabolic stability for Ligand A.
**13. In vitro Half-Life:** Ligand A (11.15 hours) has a significantly longer half-life than Ligand B (4.922 hours). This is a substantial advantage for Ligand A.
**14. P-gp Efflux:** Ligand A (0.046) has lower P-gp efflux than Ligand B (0.091), which is favorable.
**15. Binding Affinity:** Ligand B (-7.6 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.1 kcal/mol). This is a 1.5 kcal/mol difference, which is substantial enough to potentially outweigh some ADME drawbacks.
**Overall Assessment:**
Given the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), the stronger binding affinity of Ligand B is a major advantage. While Ligand A has better metabolic stability (lower Cl_mic, longer t1/2) and P-gp efflux, the significantly lower DILI risk of Ligand B is a critical factor. The permeability and solubility issues are shared by both, and would need to be addressed in further optimization. The affinity difference is large enough to favor Ligand B.
Output:
0
2025-04-17 18:47:43,793 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (368.5 and 363.5 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (96.11) is higher than Ligand B (55.32). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for permeability. Ligand B is better here.
3. **logP:** Ligand A (1.57) is within the optimal range, while Ligand B (3.393) is towards the higher end, but still acceptable. Ligand A is slightly better.
4. **HBD:** Ligand A (3) is higher than Ligand B (0). Lower HBD is generally preferred for permeability. Ligand B is better.
5. **HBA:** Both ligands have 5 HBA, no significant difference.
6. **QED:** Ligand B (0.743) has a higher QED score than Ligand A (0.615), indicating a more drug-like profile. Ligand B is better.
7. **DILI:** Ligand B (36.293) has a significantly lower DILI risk than Ligand A (43.738). This is a crucial advantage. Ligand B is better.
8. **BBB:** Ligand B (82.784) has a higher BBB penetration than Ligand A (62.97). While ADRB2 isn't primarily a CNS target, some degree of BBB penetration can be useful, and it doesn't hurt. Ligand B is better.
9. **Caco-2:** Ligand A (-5.263) and Ligand B (-4.977) are both negative, indicating poor permeability. No significant difference.
10. **Solubility:** Ligand A (-3.359) has slightly better solubility than Ligand B (-4.077). Ligand A is better.
11. **hERG:** Ligand A (0.22) has a lower hERG risk than Ligand B (0.455). This is a significant advantage. Ligand A is better.
12. **Cl_mic:** Ligand A (32.927) has a much lower microsomal clearance than Ligand B (111.025), indicating better metabolic stability. This is a major advantage for Ligand A.
13. **t1/2:** Ligand A (6.628) has a shorter half-life than Ligand B (-29.224). The negative value for Ligand B is concerning and likely indicates a very rapid clearance. Ligand A is better.
14. **Pgp:** Ligand A (0.032) has a lower P-gp efflux liability than Ligand B (0.221). This is a slight advantage for Ligand A.
15. **Binding Affinity:** Ligand B (-7.4) has a stronger binding affinity than Ligand A (-6.5) by 0.9 kcal/mol. This is a substantial difference and a strong argument in favor of Ligand B.
**Overall Assessment:**
Ligand B has a significantly better binding affinity and a superior safety profile (lower DILI). It also has better QED, BBB, and TPSA. While Ligand A has better metabolic stability (Cl_mic) and hERG inhibition, the affinity difference and safety profile of Ligand B outweigh these advantages. The negative half-life for Ligand B is a concern, but the strong binding affinity might compensate for it. Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity), Ligand B is the more promising candidate.
Output:
0
2025-04-17 18:47:43,794 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (454.308 Da) is within the ideal range, while Ligand B (366.487 Da) is also acceptable, being on the lower end but still >250 Da.
2. **TPSA:** Ligand A (68.29) is good, below the 140 threshold. Ligand B (86.95) is also acceptable, but closer to the limit.
3. **logP:** Ligand A (3.793) is optimal. Ligand B (0.862) is low, potentially causing permeability issues. This is a significant drawback for a GPCR target.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 4 HBA, Ligand B has 5. Both are acceptable.
6. **QED:** Ligand B (0.809) has a better QED score than Ligand A (0.552), suggesting a more drug-like profile overall.
7. **DILI:** Ligand A (61.768) has a higher DILI risk than Ligand B (20.396). This is a concern for Ligand A.
8. **BBB:** Ligand B (71.772) has a better BBB penetration potential than Ligand A (51.803). While ADRB2 isn't strictly a CNS target, some peripheral ADRB2 activity can be modulated by CNS effects, and better BBB penetration is generally favorable.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.754) is slightly worse than Ligand B (-5.244).
10. **Solubility:** Ligand A (-5.149) has slightly better solubility than Ligand B (-1.408), but both are poor.
11. **hERG:** Ligand A (0.76) has a slightly higher hERG risk than Ligand B (0.303), but both are relatively low.
12. **Cl_mic:** Ligand B (-10.033) has significantly better metabolic stability (lower clearance) than Ligand A (93.746). This is a major advantage.
13. **t1/2:** Ligand A (55.387) has a longer half-life than Ligand B (4.071).
14. **Pgp:** Ligand A (0.328) has lower P-gp efflux than Ligand B (0.019), which is favorable.
15. **Affinity:** Ligand A (-6.1 kcal/mol) has a slightly better binding affinity than Ligand B (-5.8 kcal/mol). This is a small difference, but still relevant.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are crucial. Ligand A has a good logP, while Ligand B's is problematic. Ligand A also has better Pgp properties. The affinity difference is small. Ligand B has a better QED and significantly better metabolic stability (Cl_mic), and lower DILI risk.
**Overall Assessment:**
While Ligand A has a slightly better affinity and Pgp profile, the significantly lower logP and higher DILI risk of Ligand B are major drawbacks. The superior metabolic stability (Cl_mic) and lower DILI risk of Ligand B outweigh the small affinity difference and slightly worse Pgp efflux.
Output:
0
2025-04-17 18:47:43,794 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (336.395 and 347.411 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (78.25 and 76.07) are below the 140 A^2 threshold for good oral absorption, and acceptable for a cardiovascular target. Very similar.
3. **logP:** Both ligands have good logP values (2.952 and 2.427) falling within the 1-3 range. Ligand B is slightly lower, which could be marginally better for solubility, but both are acceptable.
4. **HBD:** Both ligands have 1 HBD, which is well within the acceptable limit of 5.
5. **HBA:** Ligand A has 6 HBA, while Ligand B has 4. Both are below the 10 limit.
6. **QED:** Both ligands have high QED scores (0.846 and 0.8), indicating good drug-like properties.
7. **DILI:** Ligand A (75.184) has a slightly higher DILI risk than Ligand B (60.915), but both are below the concerning 60 threshold.
8. **BBB:** Ligand A (64.637) has a higher BBB penetration percentile than Ligand B (55.332). While ADRB2 isn't a CNS target, some degree of BBB penetration can influence off-target effects and distribution.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.57 and -4.644). This is unusual and suggests very poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand B (-2.706) has better aqueous solubility than Ligand A (-5.378). This is a positive for Ligand B.
11. **hERG:** Ligand A (0.756) has a slightly higher hERG inhibition liability than Ligand B (0.138). Lower is better, so Ligand B is preferable here.
12. **Cl_mic:** Ligand A (103.016) has a higher microsomal clearance than Ligand B (9.323), indicating faster metabolism and potentially lower exposure. Ligand B is significantly better here.
13. **t1/2:** Ligand B (10.386) has a longer in vitro half-life than Ligand A (26.246). This is a significant advantage for Ligand B, suggesting less frequent dosing.
14. **Pgp:** Ligand A (0.328) has lower P-gp efflux liability than Ligand B (0.051). Lower Pgp efflux is generally desirable.
15. **Binding Affinity:** Ligand A (-8.1 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.8 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME drawbacks.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, affinity, logP, and metabolic stability are key. Ligand A has a much better binding affinity. However, Ligand B has better solubility, lower clearance, and a longer half-life. The poor Caco-2 values for both are concerning, but the affinity difference is substantial.
**Overall Assessment:**
The significantly stronger binding affinity of Ligand A (-8.1 vs -6.8 kcal/mol) is a major advantage. While Ligand B has better ADME properties in some areas (solubility, clearance, half-life), the potency difference is likely to be more impactful for *in vivo* efficacy, especially given that optimization can address some of the ADME concerns. The Caco-2 values are a red flag for both, but can be addressed with formulation strategies.
Output:
1
2025-04-17 18:47:43,794 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (382.821 and 344.467 Da) fall within the ideal 200-500 Da range. Ligand B is slightly smaller, which could be beneficial for permeability, but the difference isn't substantial.
2. **TPSA:** Both ligands (86.74 and 86.34) are below the 140 A^2 threshold for good oral absorption, and reasonably close to the 90 A^2 threshold for CNS targets (though ADRB2 isn't strictly a CNS target). Very similar.
3. **logP:** Ligand A (3.405) is optimal, while Ligand B (2.075) is towards the lower end of the optimal range. For a GPCR, a slightly higher logP is generally preferred for membrane permeability and receptor engagement. Ligand A has an advantage here.
4. **HBD:** Ligand A (0) is better than Ligand B (1). Fewer hydrogen bond donors generally improve permeability.
5. **HBA:** Ligand A (6) is better than Ligand B (8). Lower HBA counts are generally favorable for permeability.
6. **QED:** Ligand B (0.789) has a significantly higher QED score than Ligand A (0.447), indicating a more drug-like profile overall. This is a notable advantage for Ligand B.
7. **DILI:** Ligand B (54.401) has a much lower DILI risk than Ligand A (94.184). This is a major advantage for Ligand B, as minimizing liver toxicity is crucial.
8. **BBB:** Ligand B (63.862) has a higher BBB penetration score than Ligand A (32.92). While ADRB2 isn't primarily a CNS target, some degree of BBB penetration can be useful for understanding off-target effects and overall distribution.
9. **Caco-2:** Ligand B (-5.702) has a much higher Caco-2 permeability than Ligand A (-4.393), suggesting better intestinal absorption.
10. **Solubility:** Ligand B (-2.326) has better aqueous solubility than Ligand A (-4.698).
11. **hERG:** Both ligands have very low hERG inhibition liability (0.113 and 0.098). This is excellent, indicating a low risk of cardiotoxicity.
12. **Cl_mic:** Ligand B (7.816) has significantly lower microsomal clearance than Ligand A (59.901), indicating better metabolic stability.
13. **t1/2:** Ligand A (87.24) has a much longer in vitro half-life than Ligand B (8.126). This is a significant advantage for Ligand A, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.416 and 0.096).
15. **Binding Affinity:** Ligand B (-6.3 kcal/mol) has a slightly better binding affinity than Ligand A (-6.0 kcal/mol). While the difference is small, it's still a positive for Ligand B.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand A has a better logP, while Ligand B excels in Pgp, TPSA, affinity, and crucially, has a much better safety profile (DILI).
**Overall Assessment:**
While Ligand A has a longer half-life, the significant advantages of Ligand B in terms of DILI risk, Caco-2 permeability, solubility, metabolic stability (Cl_mic), and a slightly better binding affinity outweigh this benefit. The lower DILI risk is particularly important. The slightly better logP of Ligand A is not enough to overcome the other benefits of Ligand B.
Output:
0
2025-04-17 18:47:43,794 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands (353.39 and 347.43 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (45.23) is significantly better than Ligand B (75.43). ADRB2 is a cardiovascular target, not a CNS target, but lower TPSA generally improves absorption. Ligand A is well below the 140 threshold, while Ligand B is approaching it.
3. **logP:** Both ligands have good logP values (3.47 and 2.79), falling within the optimal 1-3 range. Ligand A is slightly higher, potentially offering better membrane permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Both ligands have the same number of HBA (3).
6. **QED:** Ligand A (0.809) has a substantially better QED score than Ligand B (0.614), indicating a more drug-like profile.
7. **DILI:** Both ligands have acceptable DILI risk (44.86 and 41.76), both below the 60 threshold. No significant difference.
8. **BBB:** Ligand A (92.17) has a better BBB penetration percentile than Ligand B (78.95). While not a CNS target, some level of BBB penetration can influence off-target effects.
9. **Caco-2:** Both ligands have similar, very poor Caco-2 permeability (-4.799 and -4.794). This is a significant concern for both.
10. **Solubility:** Both ligands have similar, very poor aqueous solubility (-3.2 and -3.336). This is a significant concern for both.
11. **hERG:** Ligand A (0.965) has a slightly better hERG profile than Ligand B (0.654), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand B (27.83) has a lower microsomal clearance than Ligand A (33.33), suggesting better metabolic stability.
13. **t1/2:** Ligand A (32.58) has a significantly longer in vitro half-life than Ligand B (-9.63). This is a major advantage.
14. **Pgp:** Ligand A (0.487) has a lower Pgp efflux liability than Ligand B (0.117), suggesting better oral bioavailability and potentially better tissue distribution.
15. **Binding Affinity:** Ligand A (-6.4 kcal/mol) has a slightly better binding affinity than Ligand B (-5.5 kcal/mol). While the difference is less than 1.5 kcal/mol, it contributes to the overall preference.
**GPCR-specific priorities:** For ADRB2 (a cardiovascular GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A excels in TPSA, Pgp, and has slightly better affinity and logP. The longer half-life and better QED also contribute significantly. While Ligand B has better metabolic stability, the other factors weigh more heavily in favor of Ligand A. The poor Caco-2 and solubility are concerning for both, but can be addressed with formulation strategies.
**Final Decision:**
Ligand A is the more promising candidate.
1
2025-04-17 18:47:43,794 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (345.447 Da) is well within the ideal range (200-500 Da). Ligand B (369.502 Da) is also acceptable. No clear advantage here.
2. **TPSA:** Ligand A (70.47) is better than Ligand B (38.77). Lower TPSA generally favors better absorption, and is important for GPCRs.
3. **logP:** Ligand A (0.354) is quite low, potentially causing permeability issues. Ligand B (3.727) is within the optimal range (1-3). This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (1) is good. Ligand B (0) is also good. No strong preference.
5. **HBA:** Ligand A (5) is good. Ligand B (4) is also good. No strong preference.
6. **QED:** Both Ligand A (0.782) and Ligand B (0.701) are above the 0.5 threshold, indicating good drug-likeness. Ligand A is slightly better.
7. **DILI:** Ligand A (14.773) has a much lower DILI risk than Ligand B (26.134). This is a substantial advantage for Ligand A.
8. **BBB:** Ligand B (94.261) has excellent BBB penetration, while Ligand A (46.84) is moderate. For a cardiovascular GPCR like ADRB2, BBB penetration isn't *critical* but can be beneficial for off-target effects or potential CNS side effects.
9. **Caco-2:** Ligand A (-5.309) is poor, indicating poor intestinal absorption. Ligand B (-4.769) is also poor, but slightly better than A.
10. **Solubility:** Ligand A (-1.142) is poor. Ligand B (-3.668) is very poor. Both have solubility concerns.
11. **hERG:** Ligand A (0.146) has a low hERG risk. Ligand B (0.646) has a moderate hERG risk. This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand A (-23.031) has very low microsomal clearance, indicating high metabolic stability. Ligand B (84.923) has high clearance, suggesting rapid metabolism. This is a major advantage for Ligand A.
13. **t1/2:** Ligand A (2.687) has a short half-life. Ligand B (44.132) has a long half-life. This is a substantial advantage for Ligand B.
14. **Pgp:** Ligand A (0.009) has very low P-gp efflux, which is good. Ligand B (0.58) has moderate P-gp efflux. This is an advantage for Ligand A.
15. **Affinity:** Ligand B (-6.4 kcal/mol) has a slightly better binding affinity than Ligand A (-5.5 kcal/mol). This is a 0.9 kcal/mol difference, which is significant.
**Overall Assessment and GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, affinity, and metabolic stability. Ligand B has a better logP and affinity, and a much longer half-life. However, Ligand A excels in DILI risk, hERG risk, P-gp efflux, and, crucially, metabolic stability (Cl_mic). The poor solubility and Caco-2 permeability of both are concerning, but can potentially be addressed with formulation strategies. The significant difference in metabolic stability (Cl_mic) and safety (DILI, hERG) are major factors. The slightly better affinity of Ligand B is not enough to overcome these drawbacks.
Therefore, I favor Ligand A.
Output:
1
2025-04-17 18:47:43,795 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.459 and 347.459 Da) are within the ideal range (200-500 Da). No significant difference.
2. **TPSA:** Ligand A (67.87) is significantly better than Ligand B (91.32). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally aids absorption. Ligand A is well below the 140 threshold. Ligand B is approaching it.
3. **logP:** Both ligands (1.335 and 1.434) are within the optimal range (1-3). Very similar.
4. **HBD:** Ligand A (1) is better than Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Both ligands have 4 HBA, which is acceptable (<=10).
6. **QED:** Ligand A (0.812) is significantly better than Ligand B (0.63). A higher QED indicates a more drug-like profile.
7. **DILI:** Ligand A (20.9) is much better than Ligand B (18.883). Both are good, but A has a lower risk.
8. **BBB:** Ligand A (63.164) is better than Ligand B (45.25). While not a CNS target, some distribution to the CNS can sometimes be acceptable or even beneficial for peripheral targets.
9. **Caco-2:** Ligand A (-4.846) is better than Ligand B (-4.996). Both are negative, indicating good permeability, but A is slightly better.
10. **Solubility:** Ligand A (-1.469) is better than Ligand B (-1.783). Both are poor, but A is slightly better.
11. **hERG:** Both ligands (0.189 and 0.184) have very low hERG inhibition risk, which is excellent.
12. **Cl_mic:** Ligand A (9.74) is significantly better than Ligand B (18.856). Lower clearance means greater metabolic stability.
13. **t1/2:** Ligand A (8.589) is much better than Ligand B (2.845). A longer half-life is generally desirable.
14. **Pgp:** Both ligands (0.041 and 0.016) have low P-gp efflux, which is good.
15. **Binding Affinity:** Ligand A (-7.3) is slightly better than Ligand B (-7.1). While both are excellent, the 0.2 kcal/mol difference is noticeable.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Ligand A performs better on TPSA, Pgp, and has a slightly better affinity. While BBB isn't a primary concern, Ligand A has a better score.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most key ADME and binding parameters. The differences in QED, DILI, Cl_mic, and t1/2 are particularly significant. The slightly better affinity of Ligand A further strengthens its position.
Output:
1
2025-04-17 18:47:43,795 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's break down the comparison, prioritizing GPCR-relevant parameters (logP, TPSA, Pgp, BBB, and affinity).
1. **Molecular Weight:** Both ligands are within the ideal 200-500 Da range. Ligand A (364.511 Da) is slightly higher than Ligand B (342.443 Da), but this difference isn't critical.
2. **TPSA:** Ligand A (49.85) is significantly better than Ligand B (67.23). A TPSA under 140 is good for oral absorption, and lower is generally preferred for GPCRs. Ligand B's TPSA is approaching a level that could hinder absorption.
3. **logP:** Both ligands have acceptable logP values (A: 2.936, B: 1.691), falling within the 1-3 range. Ligand A is slightly more lipophilic, which could be beneficial for membrane permeability, but Ligand B is still reasonable.
4. **H-Bond Donors/Acceptors:** Both have reasonable HBD/HBA counts (A: 0/4, B: 1/4), well within the guidelines.
5. **QED:** Both ligands have similar QED scores (A: 0.699, B: 0.606), indicating good drug-likeness.
6. **DILI:** Ligand A (20.744) has a substantially better DILI score than Ligand B (10.237), indicating a lower risk of liver injury. This is a significant advantage.
7. **BBB:** Ligand A (89.298) has a better BBB penetration score than Ligand B (73.284), although both are reasonably good. While ADRB2 isn't exclusively a CNS target, some peripheral effects are mediated by CNS pathways, and better BBB penetration isn't necessarily a detriment.
8. **Caco-2 Permeability:** Ligand A (-4.665) has a worse Caco-2 permeability than Ligand B (-5.254).
9. **Aqueous Solubility:** Ligand A (-2.284) has a worse aqueous solubility than Ligand B (-1).
10. **hERG:** Both ligands have low hERG inhibition liability (A: 0.731, B: 0.345), which is excellent.
11. **Microsomal Clearance:** Ligand A (63.476) has a higher microsomal clearance than Ligand B (15.999), meaning it's metabolized faster. This is a disadvantage for Ligand A.
12. **In vitro Half-Life:** Ligand B (-11.902) has a significantly longer in vitro half-life than Ligand A (-0.364), which is a major advantage.
13. **P-gp Efflux:** Both ligands have low P-gp efflux liability (A: 0.436, B: 0.037). Ligand B is slightly better.
14. **Binding Affinity:** Both ligands have very similar binding affinities (A: -6.6 kcal/mol, B: -6.3 kcal/mol). The difference of 0.3 kcal/mol is not large enough to outweigh other factors.
**Overall Assessment:**
Ligand A has advantages in TPSA, BBB, and DILI risk. However, Ligand B excels in metabolic stability (lower Cl_mic, longer t1/2), Caco-2 permeability, and has a slightly better P-gp profile. Considering the importance of metabolic stability and a longer half-life for a GPCR target, and the significant difference in DILI risk, Ligand B is the more promising candidate.
**Output:**
0
2025-04-17 18:47:43,795 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (343.299 Da) is within the ideal range (200-500 Da). Ligand B (364.511 Da) is also acceptable. No clear advantage here.
2. **TPSA:** Ligand A (127.94) is borderline for good oral absorption (<=140), but acceptable. Ligand B (78.43) is excellent, well below the threshold. This favors Ligand B.
3. **logP:** Ligand A (0.877) is a bit low, potentially hindering permeability. Ligand B (3.542) is within the optimal range (1-3). This favors Ligand B.
4. **HBD:** Both ligands have acceptable HBD counts (Ligand A: 2, Ligand B: 3).
5. **HBA:** Both ligands have acceptable HBA counts (Ligand A: 9, Ligand B: 4).
6. **QED:** Ligand A (0.668) is better than Ligand B (0.463), indicating a more drug-like profile. This favors Ligand A.
7. **DILI:** Ligand A (97.635) has a high DILI risk, which is concerning. Ligand B (44.591) has a low DILI risk, a significant advantage.
8. **BBB:** Ligand A (38.813) has poor BBB penetration. Ligand B (46.219) is also low, but slightly better. This is less critical for a cardiovascular target like ADRB2, but still considered.
9. **Caco-2:** Ligand A (-4.577) and Ligand B (-5.401) both have negative values, suggesting poor permeability.
10. **Solubility:** Ligand A (-3.786) and Ligand B (-4.863) both have negative values, suggesting poor solubility.
11. **hERG:** Both ligands have low hERG inhibition risk (Ligand A: 0.227, Ligand B: 0.408). No clear advantage.
12. **Cl_mic:** Ligand A (51.818) has lower microsomal clearance, suggesting better metabolic stability than Ligand B (106.162). This favors Ligand A.
13. **t1/2:** Ligand A (-7.144) has a longer in vitro half-life than Ligand B (3.065). This favors Ligand A.
14. **Pgp:** Both ligands have low P-gp efflux liability (Ligand A: 0.072, Ligand B: 0.14). No clear advantage.
15. **Affinity:** Both ligands have the same binding affinity (-6.6 kcal/mol).
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand B excels in logP and TPSA, while affinity is equal. Ligand A has better QED, Cl_mic, and t1/2, but the high DILI risk is a major concern.
**Overall Assessment:**
While Ligand A has some favorable ADME properties (QED, metabolic stability, half-life), the significantly higher DILI risk associated with Ligand A is a major drawback. Ligand B, despite a slightly lower QED, presents a much better safety profile (lower DILI) and has more favorable physicochemical properties (logP, TPSA) for a GPCR target. The similar binding affinity makes the ADME/Tox profile the deciding factor.
Output:
0
2025-04-17 18:47:43,795 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A Analysis:**
* **MW:** 346.515 Da - Good, within the ideal range.
* **TPSA:** 49.41 - Excellent, well below the 140 threshold for oral absorption, and suitable for a GPCR.
* **logP:** 4.813 - Slightly high, potentially leading to solubility issues or off-target interactions, but still within a tolerable range.
* **HBD:** 1 - Good.
* **HBA:** 2 - Good.
* **QED:** 0.697 - Excellent, indicates good drug-likeness.
* **DILI:** 31.989 - Excellent, very low risk of liver injury.
* **BBB:** 86.39 - Very good, suggesting reasonable potential for CNS penetration, although ADRB2 is primarily cardiovascular, some CNS effects are possible.
* **Caco-2:** -4.373 - Poor permeability.
* **Solubility:** -4.989 - Very poor solubility.
* **hERG:** 0.816 - Low risk of hERG inhibition.
* **Cl_mic:** 104.052 - Moderate metabolic clearance.
* **t1/2:** 73.984 - Excellent in vitro half-life.
* **Pgp:** 0.452 - Low P-gp efflux, good for bioavailability.
* **Affinity:** -4.4 kcal/mol - Good binding affinity.
**Ligand B Analysis:**
* **MW:** 368.455 Da - Good, within the ideal range.
* **TPSA:** 101.57 - Higher than ideal, potentially impacting absorption.
* **logP:** 0.109 - Very low, likely to cause permeability issues.
* **HBD:** 2 - Good.
* **HBA:** 5 - Acceptable.
* **QED:** 0.633 - Good, indicates reasonable drug-likeness.
* **DILI:** 44.009 - Good, low risk of liver injury.
* **BBB:** 60.915 - Lower BBB penetration, less relevant for a cardiovascular target.
* **Caco-2:** -5.352 - Very poor permeability.
* **Solubility:** -1.96 - Poor solubility.
* **hERG:** 0.032 - Very low risk of hERG inhibition.
* **Cl_mic:** 15.208 - Very low metabolic clearance, suggesting good metabolic stability.
* **t1/2:** -8.113 - Very short in vitro half-life.
* **Pgp:** 0.04 - Very low P-gp efflux, good for bioavailability.
* **Affinity:** -3.4 kcal/mol - Acceptable, but weaker than Ligand A.
**Comparison & Decision:**
Both ligands have issues with solubility and permeability. However, Ligand A has a significantly better binding affinity (-4.4 vs -3.4 kcal/mol), a much better in vitro half-life (73.984 vs -8.113), and a lower DILI risk. While Ligand A's logP is slightly higher, the substantial advantage in binding affinity and half-life outweigh this concern, especially for a GPCR target where potency is crucial. Ligand B's extremely low logP and short half-life are major drawbacks. Although Ligand B has better metabolic stability, the overall profile of Ligand A is more promising.
Therefore, I prefer Ligand A.
Output:
1
2025-04-17 18:47:43,796 - INFO - Batch 63 complete. Total preferences: 1008
2025-04-17 18:47:43,796 - INFO - Processing batch 64/512...
2025-04-17 18:48:36,003 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (347.443 Da) is within the ideal range (200-500). Ligand B (377.392 Da) is also acceptable. No clear advantage here.
2. **TPSA:** Ligand A (54.88) is excellent, well below the 140 threshold for oral absorption. Ligand B (98.91) is higher, but still potentially acceptable, though less optimal. Ligand A is preferred.
3. **logP:** Ligand A (4.364) is slightly high but could be tolerated. Ligand B (1.153) is quite low, potentially leading to poor membrane permeability. Ligand A is preferred.
4. **HBD:** Ligand A (1) is good. Ligand B (4) is higher, potentially impacting permeability. Ligand A is preferred.
5. **HBA:** Both Ligand A (4) and Ligand B (4) are acceptable.
6. **QED:** Ligand A (0.716) is excellent, indicating good drug-likeness. Ligand B (0.493) is lower, suggesting a less favorable overall profile. Ligand A is strongly preferred.
7. **DILI:** Ligand A (83.521) has a higher DILI risk than Ligand B (54.517). Ligand B is preferred.
8. **BBB:** Both are moderate, Ligand A (57.774) and Ligand B (52.074). Not a major differentiator for a cardiovascular target.
9. **Caco-2:** Ligand A (-4.738) is very poor, suggesting poor absorption. Ligand B (-5.798) is also poor, but slightly better. Ligand B is preferred.
10. **Solubility:** Ligand A (-5.737) is very poor. Ligand B (-2.499) is better, but still not ideal. Ligand B is preferred.
11. **hERG:** Ligand A (0.533) is better than Ligand B (0.835), indicating lower cardiotoxicity risk. Ligand A is preferred.
12. **Cl_mic:** Ligand A (50.725) is higher, meaning faster clearance and lower metabolic stability. Ligand B (-3.483) is *much* lower, indicating excellent metabolic stability. Ligand B is strongly preferred.
13. **t1/2:** Ligand A (62.674) is good. Ligand B (-20.623) is very poor. Ligand A is strongly preferred.
14. **Pgp:** Ligand A (0.658) is better (lower efflux) than Ligand B (0.077). Ligand A is preferred.
15. **Affinity:** Ligand B (-8.2 kcal/mol) has a significantly stronger binding affinity than Ligand A (-3.7 kcal/mol). This is a substantial advantage, potentially outweighing some ADME concerns.
**Overall Assessment:**
While Ligand A has a better QED, lower DILI, and better Pgp profile, Ligand B's *much* stronger binding affinity (-8.2 vs -3.7 kcal/mol) and significantly improved metabolic stability (Cl_mic) are critical for a GPCR target like ADRB2. The lower logP and solubility of Ligand B are concerns, but these might be addressable through formulation strategies. The poor Caco-2 of both is a concern, but the potency advantage of B is substantial. The longer half-life of A is good, but the affinity of B is a game changer.
Given the GPCR-specific priorities (affinity being paramount), I favor Ligand B.
Output:
0
2025-04-17 18:48:36,004 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [404.22 , 104.05 , 3.048, 3. , 4. , 0.582, 97.169, 55.254, -4.978, -5.454, 0.572, 55.406, 74.88 , 0.259, -5. ]**
**Ligand B: [365.44 , 61.44 , 2.603, 2. , 3. , 0.695, 9.19 , 79.217, -5.084, -2.187, 0.659, -9.043, -14.837, 0.019, -6.5 ]**
1. **Molecular Weight:** Both are within the ideal range (200-500 Da). Ligand A (404.22) is slightly higher, but acceptable.
2. **TPSA:** Ligand A (104.05) is higher than Ligand B (61.44). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for permeability. Ligand B is significantly better here.
3. **logP:** Both are within the optimal range (1-3). Ligand A (3.048) is at the higher end, while Ligand B (2.603) is more centered.
4. **H-Bond Donors:** Ligand A (3) and Ligand B (2) are both acceptable.
5. **H-Bond Acceptors:** Ligand A (4) and Ligand B (3) are both acceptable.
6. **QED:** Both have good QED scores (A: 0.582, B: 0.695), indicating drug-likeness. Ligand B is slightly better.
7. **DILI:** Ligand A (97.169) has a very high DILI risk, which is a major concern. Ligand B (9.19) has a very low DILI risk, a significant advantage.
8. **BBB:** Ligand A (55.254) has moderate BBB penetration, while Ligand B (79.217) has good BBB penetration. While ADRB2 isn't exclusively a CNS target, some CNS exposure is possible, making Ligand B preferable.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.978) is slightly better than Ligand B (-5.084), but both are problematic.
10. **Solubility:** Both have negative solubility values, which is also unusual and indicates poor solubility. Ligand B (-2.187) is better than Ligand A (-5.454).
11. **hERG:** Both have low hERG inhibition risk (A: 0.572, B: 0.659).
12. **Cl_mic:** Ligand A (55.406) has moderate clearance, while Ligand B (-9.043) has *negative* clearance, which is impossible and likely an error in the data. This is a major red flag for Ligand B.
13. **t1/2:** Ligand A (74.88) has a good in vitro half-life, while Ligand B (-14.837) has a negative half-life, which is impossible and another significant error.
14. **Pgp:** Both have low Pgp efflux (A: 0.259, B: 0.019). Ligand B is slightly better.
15. **Binding Affinity:** Ligand B (-6.5) has a significantly better binding affinity than Ligand A (-5.0). This is a substantial advantage.
**Overall Assessment:**
Ligand B initially appears superior due to its lower TPSA, better QED, *much* lower DILI risk, better BBB penetration, and significantly higher binding affinity. However, the negative values for clearance and half-life are impossible and indicate a serious data quality issue with Ligand B. While the affinity is attractive, the erroneous ADME data makes it unreliable. Ligand A, despite its high DILI risk, has plausible ADME properties.
Given the critical importance of avoiding liver toxicity and the unreliability of Ligand B's ADME data, I would prioritize Ligand A for further investigation, with a strong focus on mitigating the DILI risk through structural modifications.
Output:
1
2025-04-17 18:48:36,004 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (383.539 Da and 366.487 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (92.5) is slightly higher than Ligand B (73.39). For a cardiovascular GPCR, TPSA isn't a *major* concern (unlike a CNS target), but lower is generally preferred for permeability. Ligand B has a clear advantage.
**3. logP:** Ligand A (0.803) is a bit low, potentially impacting permeability. Ligand B (2.922) is within the optimal 1-3 range. This is a significant advantage for Ligand B.
**4. H-Bond Donors:** Ligand A (2) and Ligand B (1) are both acceptable, below the threshold of 5. Ligand B is slightly better.
**5. H-Bond Acceptors:** Ligand A (5) and Ligand B (7) are both reasonable, below the threshold of 10.
**6. QED:** Both ligands have similar QED values (0.733 and 0.727), indicating good drug-like properties.
**7. DILI Risk:** Ligand A (20.861) has a much lower DILI risk than Ligand B (47.034). This is a substantial advantage for Ligand A.
**8. BBB Penetration:** Both are relatively low, which is expected for a cardiovascular target. Ligand B (63.319) is slightly higher than Ligand A (56.65), but neither is a strong point.
**9. Caco-2 Permeability:** Ligand A (-5.498) has worse Caco-2 permeability than Ligand B (-4.627). This is a negative for Ligand A.
**10. Aqueous Solubility:** Both ligands have very poor aqueous solubility (-3.062 and -3.381). This is a concern for both, but not a deciding factor between them.
**11. hERG Inhibition:** Ligand A (0.116) shows very low hERG inhibition risk, much lower than Ligand B (0.704). This is a major advantage for Ligand A.
**12. Microsomal Clearance:** Ligand B (56.865) has lower microsomal clearance than Ligand A (13.851), indicating better metabolic stability. This is a significant advantage for Ligand B.
**13. In Vitro Half-Life:** Ligand B (38.154) has a much longer in vitro half-life than Ligand A (-14.148). This is a substantial advantage for Ligand B.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.014 and 0.432).
**15. Binding Affinity:** Ligand B (-6.4) has slightly better binding affinity than Ligand A (-6.0). While the difference is not huge, it's still a positive for Ligand B.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand B initially appears stronger due to its better logP, lower TPSA, and slightly better affinity. However, Ligand A has significantly better safety profiles (DILI and hERG) which are critical for cardiovascular drugs. Ligand B's improved metabolic stability and half-life are also attractive.
The poor solubility of both is a concern, but can be addressed with formulation strategies. Given the importance of minimizing cardiotoxicity and liver injury in a cardiovascular context, and the relatively small advantage in binding affinity for Ligand B, I lean towards **Ligand A** due to its superior safety profile.
Output:
1
2025-04-17 18:48:36,004 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.4 & 352.4 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (80.32) is better than Ligand B (95.12). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (2.386) is optimal, while Ligand B (0.461) is a bit low. A logP below 1 can hinder membrane permeability. This is a notable advantage for A.
4. **HBD:** Both have 2 HBD, which is within the acceptable limit of 5. No difference.
5. **HBA:** Ligand A (4) is better than Ligand B (6). Lower HBA is generally preferred for permeability.
6. **QED:** Ligand A (0.818) is significantly better than Ligand B (0.469), indicating a more drug-like profile.
7. **DILI:** Ligand B (38.74) has a slightly lower DILI risk than Ligand A (41.84), but both are acceptable (<40 is good, <60 is generally acceptable).
8. **BBB:** Ligand A (83.29) has better BBB penetration than Ligand B (73.40), though this is less critical for a cardiovascular target.
9. **Caco-2:** Ligand B (-5.069) has a better Caco-2 permeability than Ligand A (-4.303).
10. **Solubility:** Ligand A (-3.264) has better solubility than Ligand B (-1.901).
11. **hERG:** Both ligands have very low hERG inhibition risk (0.174 and 0.277 respectively).
12. **Cl_mic:** Ligand B (29.01) has a significantly lower microsomal clearance than Ligand A (47.91), suggesting better metabolic stability. This is a significant advantage for B.
13. **t1/2:** Ligand B (-1.335) has a better in vitro half-life than Ligand A (-18.334).
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.033 and 0.016 respectively).
15. **Affinity:** Ligand A (-7.7 kcal/mol) has a slightly better binding affinity than Ligand B (-6.9 kcal/mol). While the difference is less than the 1.5 kcal/mol threshold, it's still a positive for A.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A excels in logP, TPSA, and affinity, while Ligand B is better in metabolic stability (Cl_mic and t1/2). The affinity difference is not huge, but the better logP and TPSA of Ligand A are more important for overall absorption and distribution. The QED score is also a strong indicator of overall drug-likeness, and Ligand A is significantly better.
**Conclusion:**
Despite Ligand B's better metabolic stability, Ligand A's superior logP, TPSA, QED, and slightly better affinity make it the more promising candidate. The better solubility is also a plus.
Output:
1
2025-04-17 18:48:36,004 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (350.399 and 347.415 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (61.31) is significantly better than Ligand B (82.71). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand A is well below the 140 threshold, while Ligand B is approaching it.
3. **logP:** Ligand A (4.21) is higher than Ligand B (1.339). While both are within the acceptable range, Ligand A is pushing the upper limit. This could lead to solubility issues, but for a GPCR, some lipophilicity is desirable for membrane interactions. Ligand B is quite low and could have permeability issues.
4. **HBD:** Ligand A (0) is preferable to Ligand B (1). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (6) is better than Ligand B (4). Lower HBA is generally preferred.
6. **QED:** Ligand B (0.833) has a significantly better QED score than Ligand A (0.516), indicating a more drug-like profile overall.
7. **DILI:** Ligand B (39.899) has a much lower DILI risk than Ligand A (93.525). This is a major advantage for Ligand B.
8. **BBB:** Ligand A (57.736) is better than Ligand B (48.662), but neither is particularly high. For ADRB2, which is not a CNS target, BBB isn't a primary concern.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.499 and -4.622). This is unusual and suggests poor permeability *in vitro*.
10. **Solubility:** Ligand B (-2.599) is better than Ligand A (-5.581), indicating better aqueous solubility.
11. **hERG:** Ligand A (0.413) is better than Ligand B (0.271), suggesting a lower risk of hERG inhibition and cardiotoxicity.
12. **Cl_mic:** Ligand B (35.7) has significantly lower microsomal clearance than Ligand A (110.9), indicating better metabolic stability.
13. **t1/2:** Ligand B (-14.274) has a better (longer) in vitro half-life than Ligand A (-44.799).
14. **Pgp:** Ligand A (0.516) is better than Ligand B (0.057), suggesting lower P-gp efflux.
15. **Affinity:** Ligand A (-6.8 kcal/mol) has a better binding affinity than Ligand B (-5.6 kcal/mol). This is a substantial difference, and a key factor for GPCRs.
**Overall Assessment & GPCR Priorities:**
For ADRB2 (a GPCR), affinity is paramount. Ligand A has a significantly better binding affinity (-6.8 vs -5.6 kcal/mol). While Ligand B has advantages in QED, DILI, Cl_mic, and t1/2, the substantial affinity difference of Ligand A outweighs these benefits. The lower TPSA of Ligand A is also favorable. The negative Caco-2 values are concerning for both, but the stronger binding of A makes it more likely to achieve efficacy *in vivo* despite potential permeability issues. The slightly higher logP of A is manageable.
Output:
1
2025-04-17 18:48:36,004 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (355.781 and 349.406 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (96.03) is higher than Ligand B (73.74). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B has a clear advantage.
3. **logP:** Ligand A (3.468) is at the upper end of the optimal range (1-3), while Ligand B (1.507) is closer to the lower end. Ligand A's higher logP *could* lead to solubility issues or off-target interactions, but it might also enhance membrane permeability.
4. **HBD:** Both ligands have 1 HBD, which is within the acceptable limit of 5. No difference.
5. **HBA:** Both ligands have 4 HBA, which is within the acceptable limit of 10. No difference.
6. **QED:** Ligand B (0.894) has a significantly higher QED score than Ligand A (0.656), indicating a more drug-like profile.
7. **DILI:** Ligand A (74.021) has a higher DILI risk than Ligand B (33.889). This is a significant concern, as lower DILI is highly desirable. Ligand B is much better.
8. **BBB:** Both ligands have good BBB penetration (73.478 and 77.2), but Ligand B is slightly better. Since ADRB2 is not a CNS target, this is less crucial, but still a positive for Ligand B.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
10. **Solubility:** Ligand B (-1.031) has better solubility than Ligand A (-5.722). This is a significant advantage, especially given Ligand A's higher logP.
11. **hERG:** Both ligands have low hERG inhibition liability (0.498 and 0.433), which is good. No significant difference.
12. **Cl_mic:** Ligand B (29.456) has a significantly lower microsomal clearance than Ligand A (48.285), indicating better metabolic stability.
13. **t1/2:** Ligand B (-21.549) has a much longer in vitro half-life than Ligand A (-4.707). This is a major advantage, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.142 and 0.172). No significant difference.
15. **Binding Affinity:** Ligand B (-6.8 kcal/mol) has a slightly better binding affinity than Ligand A (-5.5 kcal/mol). This 1.3 kcal/mol difference is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand B consistently outperforms Ligand A across several critical ADME properties (DILI, solubility, Cl_mic, t1/2, QED) and has a slightly better binding affinity. While Ligand A has a slightly higher logP, the benefits of Ligand B's improved safety profile, metabolic stability, and drug-likeness outweigh this potential drawback. Given the GPCR target class, the balance of properties in Ligand B is more favorable.
Output:
0
2025-04-17 18:48:36,004 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.459 Da and 361.833 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (62.83) is significantly better than Ligand B (104.11). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (3.04) is slightly higher than Ligand B (1.928), both are within the optimal 1-3 range. Ligand A is preferable.
4. **HBD:** Ligand A (2) is better than Ligand B (3). Lower is generally preferred.
5. **HBA:** Both ligands have the same HBA count (4), which is acceptable.
6. **QED:** Ligand A (0.859) has a higher QED score than Ligand B (0.708), indicating better overall drug-likeness.
7. **DILI:** Ligand A (26.444) has a much lower DILI risk than Ligand B (70.182). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (79.062) has a higher BBB penetration than Ligand B (64.676). While not a primary concern for a cardiovascular target, it's a slight positive.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.959) is slightly better (less negative) than Ligand B (-5.384).
10. **Solubility:** Ligand A (-2.224) has better solubility than Ligand B (-3.851).
11. **hERG:** Both ligands have low hERG inhibition risk (0.841 and 0.719, respectively). No significant difference.
12. **Cl_mic:** Ligand B (-7.139) has a lower (better) microsomal clearance than Ligand A (-0.825), suggesting greater metabolic stability. This is a notable advantage for Ligand B.
13. **t1/2:** Ligand A (18.582) has a much longer in vitro half-life than Ligand B (1.628). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.145) has lower P-gp efflux than Ligand B (0.068), which is preferable.
15. **Binding Affinity:** Ligand B (-8.0) has a slightly better binding affinity than Ligand A (-6.9). However, the difference is less than 1.5 kcal/mol, and can be outweighed by other factors.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand A is the more promising candidate. While Ligand B has a slightly better binding affinity and metabolic stability, Ligand A excels in crucial areas like DILI risk, QED, solubility, and half-life. The lower TPSA of Ligand A is also beneficial for absorption. The difference in binding affinity is not large enough to overcome the other advantages of Ligand A.
Output:
1
2025-04-17 18:48:36,004 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.519 and 349.374 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (78.43) is significantly better than Ligand B (112.37). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is pushing the upper limit for good oral absorption.
3. **logP:** Ligand A (2.787) is optimal, while Ligand B (0.645) is a bit low. A logP below 1 can hinder membrane permeability.
4. **HBD:** Ligand A (3) and Ligand B (1) are both acceptable.
5. **HBA:** Ligand A (3) is good, while Ligand B (10) is approaching the upper limit.
6. **QED:** Both ligands have similar and good QED values (0.558 and 0.631).
7. **DILI:** Ligand A (13.377) has a much lower DILI risk than Ligand B (70.88). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (79.023) has a higher BBB penetration percentile than Ligand A (41.838). While ADRB2 isn't necessarily a CNS target, some peripheral ADRB2 activity can be modulated by CNS effects, so this is a slight advantage for B.
9. **Caco-2:** Ligand A (-4.638) is better than Ligand B (-5.601), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-2.912) is better than Ligand B (-1.916).
11. **hERG:** Both ligands have very low hERG inhibition risk (0.186 and 0.07).
12. **Cl_mic:** Ligand B (8.009) has a significantly lower microsomal clearance than Ligand A (51.246), suggesting better metabolic stability.
13. **t1/2:** Ligand B (11.007) has a longer in vitro half-life than Ligand A (8.543).
14. **Pgp:** Ligand A (0.079) has lower P-gp efflux liability than Ligand B (0.19).
15. **Affinity:** Ligand B (-11.4) has a significantly stronger binding affinity than Ligand A (-5.8). This is a substantial advantage.
**Overall Assessment:**
Ligand B has a significantly better binding affinity, lower clearance, and longer half-life. However, it suffers from a higher TPSA, lower logP, and a substantially higher DILI risk. Ligand A has a better safety profile (DILI), better permeability characteristics (TPSA, logP, Caco-2, solubility), and lower Pgp efflux.
Given the GPCR-specific priorities (logP, Pgp, TPSA, affinity), the strong affinity of Ligand B is very attractive. However, the high DILI risk is a major concern. While optimization could potentially address the DILI issue, starting with a cleaner profile is often preferable. The difference in affinity (5.6 kcal/mol) is substantial, but not insurmountable. Ligand A's better ADME properties and safety profile make it a more promising starting point, even with the weaker initial affinity.
Output:
1
2025-04-17 18:48:36,004 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (363.527 Da and 364.511 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (71.09) is higher than Ligand B (58.64). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B has an advantage here.
3. **logP:** Both ligands (2.974 and 2.84) are within the optimal 1-3 range. No significant difference.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable. Ligand B is slightly better.
5. **HBA:** Both ligands (4) are within the acceptable range (<=10). No significant difference.
6. **QED:** Both ligands have good QED scores (0.816 and 0.874), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (40.248) is slightly higher than Ligand B (26.406), indicating a slightly higher risk of liver injury. Ligand B is preferred.
8. **BBB:** Ligand A (48.042) is lower than Ligand B (75.107). While ADRB2 isn't necessarily a CNS target, higher BBB penetration can sometimes correlate with better overall distribution. Ligand B is preferred.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.173 and -4.903), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Both ligands have negative solubility values (-2.373 and -3.135), also unusual and concerning. This suggests very poor aqueous solubility, a major hurdle for oral bioavailability.
11. **hERG:** Ligand A (0.157) is lower than Ligand B (0.576), indicating a lower risk of hERG inhibition and cardiotoxicity. Ligand A is preferred.
12. **Cl_mic:** Ligand A (17.43) has a lower microsomal clearance than Ligand B (30.027), suggesting better metabolic stability. Ligand A is preferred.
13. **t1/2:** Ligand A (0.243) has a shorter half-life than Ligand B (11.478). Ligand B is significantly preferred.
14. **Pgp:** Ligand A (0.233) is lower than Ligand B (0.383), indicating lower P-gp efflux and potentially better bioavailability. Ligand A is preferred.
15. **Binding Affinity:** Ligand B (-7.8 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.3 kcal/mol). This is a substantial advantage, potentially outweighing some ADME concerns.
**Overall Assessment and GPCR-Specific Priorities:**
For a cardiovascular GPCR like ADRB2, binding affinity is paramount. Ligand B's -7.8 kcal/mol affinity is significantly better than Ligand A's -6.3 kcal/mol. While both ligands have concerning Caco-2 and solubility values, the stronger binding of Ligand B, coupled with its better BBB penetration, lower DILI risk, and longer half-life, make it the more promising candidate. The slightly better TPSA and Pgp values of Ligand A are not enough to overcome the substantial affinity difference. The poor solubility and permeability are significant issues that would need to be addressed in further optimization, but a strong starting point with high affinity is crucial.
Output:
0
2025-04-17 18:48:36,005 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (336.395 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (60.25) is significantly better than Ligand B (78.51). ADRB2 is a cardiovascular target, so CNS penetration isn't critical, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (A: 1.911, B: 1.025) falling within the 1-3 range. Ligand A is slightly better.
4. **HBD/HBA:** Ligand A (0 HBD, 5 HBA) is preferable to Ligand B (2 HBD, 3 HBA). Lower HBD is generally preferred for better membrane permeability.
5. **QED:** Both ligands have similar QED values (A: 0.786, B: 0.736), indicating good drug-likeness.
6. **DILI:** Ligand A (41.838) has a slightly higher DILI risk than Ligand B (37.611), but both are below the concerning threshold of 60.
7. **BBB:** Both ligands have high BBB penetration (A: 81.776, B: 79.721). While not essential for a cardiovascular target, it doesn't hurt.
8. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and requires further investigation. However, the values are similar (-4.634 for A, -4.951 for B).
9. **Solubility:** Ligand A (-3.748) has slightly worse solubility than Ligand B (-2.522). Solubility is important, but not the highest priority here.
10. **hERG:** Ligand A (0.43) has a slightly higher hERG risk than Ligand B (0.069). This is a concern, but not a dealbreaker.
11. **Cl_mic:** Ligand B (-1.499) has significantly lower (better) microsomal clearance than Ligand A (47.282), indicating better metabolic stability.
12. **t1/2:** Ligand B (-29.36) has a much longer in vitro half-life than Ligand A (0.001). This is a significant advantage.
13. **Pgp:** Both ligands have low Pgp efflux liability (A: 0.505, B: 0.012). Ligand B is slightly better.
14. **Binding Affinity:** Ligand B (-7.6 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.8 kcal/mol). This is a substantial advantage, potentially outweighing some ADME drawbacks.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, affinity, logP, TPSA, and Pgp are key. Ligand B excels in affinity and has acceptable values for the other parameters. While Ligand A has a slightly better TPSA, the superior binding affinity and metabolic stability of Ligand B are more important.
**Conclusion:**
Ligand B is the more promising candidate due to its significantly stronger binding affinity and improved metabolic stability (lower Cl_mic and longer t1/2). The slightly lower solubility and higher hERG risk are less concerning given the substantial affinity advantage.
Output:
0
2025-04-17 18:48:36,005 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.423 and 346.515 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (94.8) is higher than Ligand B (49.41). For a cardiovascular GPCR like ADRB2, TPSA is moderately important, and lower is generally preferred for better permeability. Ligand B is significantly better.
3. **logP:** Ligand A (-1.199) is lower than the optimal 1-3 range, potentially hindering permeability. Ligand B (3.668) is within the optimal range. This is a substantial advantage for Ligand B.
4. **HBD:** Both ligands have 1 HBD, which is acceptable.
5. **HBA:** Ligand A has 7 HBA, while Ligand B has 2. Both are within the acceptable limit of 10, but Ligand B is better.
6. **QED:** Both ligands have similar QED scores (0.717 and 0.79), indicating good drug-likeness.
7. **DILI:** Ligand A (29.857) has a lower DILI risk than Ligand B (10.585), which is a positive.
8. **BBB:** Ligand A (58.938) has a lower BBB penetration percentile compared to Ligand B (81.737). While ADRB2 isn't strictly a CNS target, some CNS penetration can be acceptable or even desirable for off-target effects assessment. Ligand B is better.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability based on this metric. However, the scale is not specified, so it is difficult to interpret.
10. **Solubility:** Ligand A (-0.357) has slightly better aqueous solubility than Ligand B (-3.955). Solubility is important, but not the highest priority for this target.
11. **hERG:** Ligand A (0.137) has a lower hERG inhibition liability than Ligand B (0.554), indicating a lower risk of cardiotoxicity. This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand A (3.008) has significantly lower microsomal clearance than Ligand B (80.69), suggesting better metabolic stability. This is a major advantage for Ligand A.
13. **t1/2:** Ligand A (6.133) has a shorter in vitro half-life compared to Ligand B (-8.852). The negative value for Ligand B is concerning and suggests an issue with the data or assay.
14. **Pgp:** Ligand A (0.026) has lower P-gp efflux liability than Ligand B (0.151), which is favorable for bioavailability.
15. **Affinity:** Both ligands have very similar binding affinities (-6.8 and -6.7 kcal/mol). The difference is negligible.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp), Ligand B initially appears stronger due to its optimal logP and lower TPSA. However, Ligand A demonstrates superior metabolic stability (lower Cl_mic), lower DILI risk, and lower hERG inhibition, which are crucial for a safe and effective drug. The negative half-life for Ligand B is also a concern. While Ligand B has better BBB penetration, this isn't a primary concern for a cardiovascular target. The slightly better solubility of Ligand A is also a plus.
Given the balance of these factors, and prioritizing safety and metabolic stability, I believe Ligand A is the more promising candidate.
Output:
1
2025-04-17 18:48:36,005 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 drug candidates. ADRB2 is a GPCR, so we'll prioritize logP, Pgp, TPSA, and affinity, alongside general drug-like properties.
**Ligand A:** [341.375, 116.76 , 0.246, 2. , 6. , 0.805, 76.192, 25.785, -5.647, -1.941, 0.042, 4.83 , -2.951, 0.011, -6.3 ]
**Ligand B:** [363.483, 91.32 , 1.251, 3. , 5. , 0.546, 33.346, 35.091, -5.118, -2.136, 0.098, 12.577, -9.025, 0.119, -6.4 ]
1. **MW:** Both are within the ideal range (200-500 Da). A (341.375) is slightly better.
2. **TPSA:** A (116.76) is higher than B (91.32). B is preferable here, being closer to the <140 threshold for good absorption.
3. **logP:** A (0.246) is quite low, potentially leading to poor membrane permeability. B (1.251) is much better, falling within the optimal 1-3 range. This is a significant advantage for B.
4. **HBD:** A (2) and B (3) are both acceptable.
5. **HBA:** A (6) and B (5) are both acceptable.
6. **QED:** A (0.805) is significantly better than B (0.546), indicating a more drug-like profile.
7. **DILI:** A (76.192) is considerably higher than B (33.346), indicating a higher risk of liver injury. B is much preferred.
8. **BBB:** A (25.785) is very low, while B (35.091) is also low, but better. Neither is particularly good for CNS penetration, but since ADRB2 isn't necessarily a CNS target, this isn't a major deciding factor.
9. **Caco-2:** Both are negative, which is unusual and suggests poor permeability. A (-5.647) is worse than B (-5.118).
10. **Solubility:** Both are negative, suggesting poor solubility. A (-1.941) is worse than B (-2.136).
11. **hERG:** Both are very low (0.042 and 0.098), indicating minimal hERG inhibition risk.
12. **Cl_mic:** A (4.83) is much lower than B (12.577), suggesting better metabolic stability. This is a significant advantage for A.
13. **t1/2:** A (-2.951) is better than B (-9.025), indicating a longer half-life.
14. **Pgp:** Both are very low (0.011 and 0.119), suggesting minimal P-gp efflux.
15. **Affinity:** Both are very similar (-6.3 and -6.4 kcal/mol). The difference is negligible.
**Overall Assessment:**
Ligand B has a much more favorable logP, significantly lower DILI risk, and a better TPSA. While Ligand A has a better QED and metabolic stability (lower Cl_mic and better t1/2), the poor logP and higher DILI risk are substantial drawbacks. For a GPCR target, logP is crucial for binding and cellular penetration, and minimizing toxicity is paramount. The slightly better metabolic stability of A doesn't outweigh these concerns.
Therefore, I prefer Ligand B.
0
2025-04-17 18:48:36,005 - INFO - Here's my reasoning and the final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, the key priorities are logP, Pgp, TPSA, and binding affinity, with metabolic stability (Cl_mic, t1/2) and safety (DILI, hERG) also important.
Let's compare the ligands property by property:
1. **MW:** Both ligands (358.316 and 348.531 Da) fall within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (88.42) is slightly higher than Ligand B (58.2). Ligand B is preferable here, being well below the 140 threshold for oral absorption.
3. **logP:** Both ligands have good logP values (3.137 and 3.938) within the optimal 1-3 range. Ligand B is slightly higher, which could be a minor concern for solubility, but acceptable.
4. **HBD/HBA:** Ligand A has 1 HBD and 5 HBA, while Ligand B has 2 HBD and 2 HBA. Ligand B is preferable as it has fewer H-bond donors and acceptors, generally improving permeability.
5. **QED:** Both ligands have good QED scores (0.541 and 0.663), indicating good drug-like properties. Ligand B is slightly better.
6. **DILI:** Ligand A has a DILI risk of 60.915, which is approaching the higher risk threshold. Ligand B has a much lower DILI risk of 13.067, making it significantly safer.
7. **BBB:** Both ligands have good BBB penetration (74.564 and 77.627). This isn't a primary concern for a cardiovascular target, but it's not detrimental.
8. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the values are very close (-4.551 vs -4.711) and don't significantly differentiate the ligands.
9. **Solubility:** Both ligands have negative solubility values, which is also unusual. Again, the values are close (-4.244 vs -4.541) and don't provide a clear advantage.
10. **hERG:** Both ligands have low hERG risk (0.652 and 0.596), which is good.
11. **Cl_mic:** Ligand A has a lower microsomal clearance (55.595) than Ligand B (70.865), suggesting better metabolic stability.
12. **t1/2:** Ligand A has a longer in vitro half-life (2.693 hours) than Ligand B (1.484 hours), which is preferable.
13. **Pgp:** Ligand A has a lower Pgp efflux liability (0.08) than Ligand B (0.176), indicating better bioavailability.
14. **Binding Affinity:** Ligand A has a significantly stronger binding affinity (-7.1 kcal/mol) compared to Ligand B (-6.0 kcal/mol). This is a substantial advantage.
**Overall Assessment:**
Ligand A has a significantly better binding affinity and better metabolic stability and Pgp efflux. However, it has a higher DILI risk. Ligand B has a much lower DILI risk, better TPSA and HBD/HBA values. The difference in binding affinity is substantial (>1.1 kcal/mol), and for a GPCR, potency is paramount. The slightly higher DILI risk of Ligand A is a concern, but could be mitigated with further optimization. The improved potency is likely to outweigh the DILI risk in this case.
Output:
1
2025-04-17 18:48:36,005 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (373.44 and 366.487 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (38.33) is significantly better than Ligand B (69.48). ADRB2 is a cardiovascular target, not CNS, but lower TPSA generally improves permeability. Ligand A is well below the 140 threshold, while B is higher.
3. **logP:** Ligand A (4.276) is slightly higher than Ligand B (2.997). Both are within the 1-3 range, but A is pushing the upper limit.
4. **HBD:** Ligand A (1) is better than Ligand B (0). Fewer HBDs generally improve membrane permeability.
5. **HBA:** Ligand A (3) is better than Ligand B (7). Lower HBA is preferred for permeability.
6. **QED:** Ligand A (0.783) is better than Ligand B (0.682). Both are above the 0.5 threshold, indicating good drug-likeness, but A is higher.
7. **DILI:** Ligand A (29.779) is *much* better than Ligand B (57.154). A is well below the 40% threshold, while B is approaching a concerning level. This is a major advantage for A.
8. **BBB:** Not a primary concern for a cardiovascular target, but Ligand A (95.657) is better than Ligand B (54.013).
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-4.491) is slightly better than Ligand B (-4.663).
10. **Solubility:** Ligand A (-5.337) is better than Ligand B (-2.256). Both are poor, but A is less poor.
11. **hERG:** Ligand A (0.809) is better than Ligand B (0.654). Lower is better, indicating less cardiotoxicity risk.
12. **Cl_mic:** Ligand A (67.415) is better than Ligand B (84.523). Lower clearance suggests better metabolic stability.
13. **t1/2:** Ligand A (-1.484) is *much* better than Ligand B (-16.513). A negative value indicates a longer half-life.
14. **Pgp:** Ligand A (0.474) is better than Ligand B (0.28). Lower Pgp efflux is preferred.
15. **Binding Affinity:** Both ligands have a binding affinity of -6.1 kcal/mol, so there is no difference here.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most crucial ADME-Tox properties. The significant advantages in DILI risk, metabolic stability (Cl_mic and t1/2), and QED, coupled with better TPSA, HBD, HBA, solubility, and hERG liability, make it the far more promising candidate. While both have poor Caco-2 permeability, the other benefits of Ligand A outweigh this drawback.
**Output:**
1
2025-04-17 18:48:36,005 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [367.475, 85.85, -0.122, 1, 6, 0.798, 52.113, 82.513, -4.996, -2.187, 0.322, 33.02, -12.371, 0.041, -6.8]
**Ligand B:** [346.431, 86.37, 1.186, 1, 4, 0.867, 48.972, 79.721, -4.676, -2.996, 0.285, 35.514, -29.975, 0.078, -7]
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand B (346.431) is slightly lower, which could be a minor advantage for permeability.
2. **TPSA:** Both are reasonably good (85.85 and 86.37), being under 140, suggesting decent oral absorption potential.
3. **logP:** Ligand A (-0.122) is quite low, which is a concern for membrane permeability. Ligand B (1.186) is much better, falling within the optimal 1-3 range. This is a significant advantage for Ligand B.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 6 HBA, while Ligand B has 4. Both are acceptable, below the threshold of 10.
6. **QED:** Both have good QED scores (0.798 and 0.867), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Both are reasonably low (52.113 and 48.972), suggesting acceptable liver toxicity risk. Ligand B is slightly better.
8. **BBB:** Ligand A (82.513) has a better BBB percentile than Ligand B (79.721). While ADRB2 isn't *necessarily* a CNS target, some peripheral effects can be mediated by CNS pathways, so this is a small advantage for A.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability.
10. **Solubility:** Both have negative solubility values, which is also unusual and suggests poor solubility.
11. **hERG:** Both have low hERG inhibition liability (0.322 and 0.285), which is excellent.
12. **Cl_mic:** Ligand A (33.02) has a slightly lower microsomal clearance than Ligand B (35.514), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-29.975) has a much more negative in vitro half-life, which is concerning and suggests very rapid metabolism. Ligand A (-12.371) is still not ideal, but better.
14. **Pgp:** Both have very low Pgp efflux liability (0.041 and 0.078), which is good.
15. **Binding Affinity:** Ligand B (-7 kcal/mol) has a slightly better binding affinity than Ligand A (-6.8 kcal/mol). This is a meaningful difference.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp efflux, and binding affinity are particularly important. Ligand B excels in logP and binding affinity, while Ligand A has a slightly better BBB score. However, the poor half-life of Ligand B is a major concern. The low logP of Ligand A is also a significant drawback.
**Overall Assessment:**
Despite the slightly better BBB score for Ligand A, the significantly better logP and binding affinity of Ligand B, coupled with the more manageable (though still not ideal) metabolic stability, make it the more promising candidate. The poor half-life of Ligand B is a clear area for optimization, but the starting point is better than Ligand A's poor logP.
Output:
0
2025-04-17 18:48:36,005 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [350.419, 96.55, 0.572, 2, 5, 0.782, 46.413, 47.693, -4.914, -2.576, 0.27, -10.691, 22.331, 0.029, -6.5]
**Ligand B:** [342.447, 79.7, 2.772, 1, 5, 0.926, 50.291, 71.384, -5.177, -3.125, 0.412, 32.269, -18.696, 0.175, -6.3]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (342.447) is slightly lower, which is generally favorable.
2. **TPSA:** Ligand A (96.55) is a bit higher than Ligand B (79.7). Both are acceptable for a non-CNS GPCR target like ADRB2, but Ligand B is better.
3. **logP:** Ligand A (0.572) is quite low, potentially causing permeability issues. Ligand B (2.772) is within the optimal range (1-3). This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (2) and Ligand B (1) are both good.
5. **HBA:** Both ligands have 5 HBA, which is acceptable.
6. **QED:** Both have good QED scores (A: 0.782, B: 0.926), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Both are relatively low risk (A: 46.413, B: 50.291).
8. **BBB:** Not a primary concern for ADRB2 (cardiovascular target). Ligand B (71.384) is higher, but this isn't a major deciding factor.
9. **Caco-2:** Ligand A (-4.914) and Ligand B (-5.177) are both negative, indicating poor permeability.
10. **Solubility:** Ligand A (-2.576) and Ligand B (-3.125) are both poor.
11. **hERG:** Both are low risk (A: 0.27, B: 0.412).
12. **Cl_mic:** Ligand A (-10.691) has a much lower (better) clearance than Ligand B (32.269), suggesting better metabolic stability.
13. **t1/2:** Ligand A (22.331) has a longer half-life than Ligand B (-18.696), which is desirable.
14. **Pgp:** Both are very low (A: 0.029, B: 0.175), indicating minimal efflux.
15. **Affinity:** Both have similar binding affinities (-6.5 and -6.3 kcal/mol). The difference is not substantial enough to be a deciding factor.
**GPCR-specific priorities:** logP, TPSA, Pgp, and affinity are key for GPCRs. Ligand B excels in logP and TPSA, while affinity and Pgp are comparable. Ligand A has better metabolic stability (Cl_mic) and half-life, but the poor logP is a significant drawback for a GPCR target.
**Conclusion:**
Despite Ligand A's better metabolic stability and half-life, Ligand B's superior logP and TPSA make it a more promising candidate for ADRB2. The poor logP of Ligand A is likely to cause significant permeability issues, outweighing its metabolic advantages.
Output:
0
2025-04-17 18:48:36,005 - INFO - Batch 64 complete. Total preferences: 1024
2025-04-17 18:48:36,005 - INFO - Processing batch 65/512...
2025-04-17 18:49:24,336 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [366.487, 83.56, 1.433, 2, 6, 0.51, 33.501, 47.964, -5.587, -1.681, 0.377, -11.945, 15.135, 0.035, -7.5]
**Ligand B:** [342.439, 71.34, 3.492, 2, 3, 0.874, 49.787, 61.225, -4.73, -4.072, 0.373, 29.376, 82.956, 0.109, -7.6]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (342.439) is slightly lower, which could be beneficial for permeability, but both are acceptable.
2. **TPSA:** Ligand A (83.56) is slightly higher than Ligand B (71.34). Both are below the 140 threshold for oral absorption, but Ligand B is better.
3. **logP:** Ligand A (1.433) is within the optimal range, while Ligand B (3.492) is nearing the upper limit. Ligand A is preferable here.
4. **HBD:** Both have 2 HBD, which is good.
5. **HBA:** Ligand A (6) is higher than Ligand B (3). Ligand B is preferable.
6. **QED:** Ligand B (0.874) has a significantly better QED score than Ligand A (0.51), indicating a more drug-like profile.
7. **DILI:** Ligand A (33.501) has a lower DILI risk than Ligand B (49.787), which is a significant advantage.
8. **BBB:** Ligand B (61.225) has a better BBB penetration percentile than Ligand A (47.964), but neither are particularly high. For a cardiovascular target, BBB isn't a *major* concern, but it's still a consideration.
9. **Caco-2:** Ligand A (-5.587) is worse than Ligand B (-4.73). Ligand B is preferable.
10. **Solubility:** Ligand A (-1.681) is better than Ligand B (-4.072).
11. **hERG:** Both are very low (0.377 and 0.373), indicating low cardiotoxicity risk.
12. **Cl_mic:** Ligand A (-11.945) has a *much* lower (better) microsomal clearance than Ligand B (29.376), suggesting greater metabolic stability.
13. **t1/2:** Ligand B (82.956) has a significantly longer in vitro half-life than Ligand A (15.135). This is a major advantage.
14. **Pgp:** Ligand A (0.035) has lower P-gp efflux than Ligand B (0.109), which is preferable.
15. **Affinity:** Both have very similar binding affinities (-7.5 and -7.6 kcal/mol). The difference is negligible.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, and affinity. Ligand A has a better logP and Pgp, while Ligand B has a better TPSA. Affinity is nearly identical.
**Overall Assessment:**
Ligand B has a better QED score, Caco-2 permeability, and a much longer half-life. These are significant advantages. While Ligand A has better DILI risk and logP, the longer half-life and better QED of Ligand B outweigh these benefits. The slightly better TPSA of Ligand B is also a plus.
Therefore, I prefer Ligand B.
Output:
0
2025-04-17 18:49:24,337 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (356.3 & 348.4 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand B (49.41) is significantly better than Ligand A (95.99). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (1.767 and 2.555), falling within the 1-3 range. Ligand B is slightly higher, potentially aiding membrane permeability.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (1), but both are within the acceptable limit of 5.
5. **HBA:** Ligand A (4) is higher than Ligand B (2), but both are within the acceptable limit of 10.
6. **QED:** Both ligands have good QED scores (0.713 and 0.889), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand B (36.603) has a much lower DILI risk than Ligand A (65.568). This is a significant advantage.
8. **BBB:** Ligand B (96.084) has a higher BBB penetration score than Ligand A (70.143). While not critical for a cardiovascular target, it's a positive attribute.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.318 and -4.663), indicating poor permeability. This is a concern for both.
10. **Solubility:** Both ligands have negative solubility values (-4.164 and -3.707), indicating poor solubility. This is a concern for both.
11. **hERG:** Both ligands have low hERG inhibition risk (0.576 and 0.767), which is good.
12. **Cl_mic:** Ligand B (1.472) has a lower microsomal clearance than Ligand A (1.711), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-9.647) has a significantly longer in vitro half-life than Ligand A (10.743). This is a major advantage.
14. **Pgp:** Ligand A (0.32) has a lower Pgp efflux liability than Ligand B (0.075), which is better.
15. **Binding Affinity:** Ligand B (-7.0) has a slightly better binding affinity than Ligand A (-5.6). This difference of 1.4 kcal/mol is substantial enough to outweigh some of the ADME concerns.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP, TPSA, and affinity. The longer half-life and lower DILI risk are also significant benefits. While both have poor Caco-2 and solubility, the superior binding affinity and ADME profile of Ligand B make it the more promising candidate.
**Conclusion:**
Ligand B is the more favorable candidate due to its superior binding affinity, lower DILI risk, better metabolic stability (lower Cl_mic, longer t1/2), and favorable TPSA.
Output:
0
2025-04-17 18:49:24,337 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (a cardiovascular GPCR) drug candidates.
**Ligand A:** [346.475, 50.6, 1.238, 0, 5, 0.808, 13.339, 77.627, -4.619, 0.156, 0.623, 22.506, -12.853, 0.158, -6.5]
**Ligand B:** [367.471, 104.89, 0.614, 3, 6, 0.655, 43.66, 68.282, -5.299, -1.554, 0.424, -3.679, -4.738, 0.062, -7.3]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (346.475) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (50.6) is significantly better than Ligand B (104.89). For a cardiovascular GPCR, we don't *require* very low TPSA for CNS penetration, but lower is still preferred for good absorption.
3. **logP:** Ligand A (1.238) is within the optimal range, while Ligand B (0.614) is a bit low. Lower logP can lead to permeability issues.
4. **HBD:** Ligand A (0) is excellent, minimizing potential for off-target interactions and improving permeability. Ligand B (3) is acceptable, but not ideal.
5. **HBA:** Ligand A (5) is good. Ligand B (6) is also acceptable.
6. **QED:** Both are reasonably good (A: 0.808, B: 0.655), suggesting drug-like properties. Ligand A is better.
7. **DILI:** Ligand A (13.339) has a much lower DILI risk than Ligand B (43.66). This is a significant advantage.
8. **BBB:** Ligand A (77.627) has better BBB penetration than Ligand B (68.282), though neither is exceptionally high. For a cardiovascular target, this isn't *critical*, but it's a bonus.
9. **Caco-2:** Ligand A (-4.619) is better than Ligand B (-5.299). Higher values indicate better absorption.
10. **Solubility:** Ligand A (0.156) is better than Ligand B (-1.554). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.623) has a lower hERG risk than Ligand B (0.424). This is a significant safety advantage.
12. **Cl_mic:** Ligand A (22.506) has a higher clearance than Ligand B (-3.679), meaning Ligand B is more metabolically stable.
13. **t1/2:** Ligand A (-12.853) has a shorter half-life than Ligand B (-4.738). This is a negative for Ligand A.
14. **Pgp:** Ligand A (0.158) has lower P-gp efflux than Ligand B (0.062). Lower efflux is better.
15. **Affinity:** Ligand B (-7.3) has a slightly better binding affinity than Ligand A (-6.5). While a 1.5 kcal/mol difference is notable, it's not overwhelmingly large.
**Overall Assessment:**
Ligand A is superior overall. It has better TPSA, logP, HBD, QED, DILI risk, solubility, hERG risk, and Pgp efflux. While Ligand B has slightly better affinity and metabolic stability, the advantages of Ligand A in terms of safety (DILI, hERG) and absorption (TPSA, logP, solubility) are more important for a cardiovascular GPCR target. The slightly shorter half-life of Ligand A can be addressed through structural modifications.
Output:
1
2025-04-17 18:49:24,337 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (363.5 and 340.3 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (53.5) is significantly better than Ligand B (86.0). ADRB2 is a cardiovascular target, not CNS, but lower TPSA generally improves absorption.
3. **logP:** Ligand A (3.06) is optimal, while Ligand B (1.24) is at the lower end, potentially hindering permeation. This is a significant advantage for A.
4. **HBD:** Both have 0 HBD, which is acceptable.
5. **HBA:** Ligand A (4) is better than Ligand B (8). Lower HBA is generally preferred for permeability.
6. **QED:** Ligand A (0.826) is superior to Ligand B (0.522), indicating a more drug-like profile.
7. **DILI:** Ligand B (98.3) has a very high DILI risk, while Ligand A (61.7) is still elevated but much lower. This is a major concern for Ligand B.
8. **BBB:** Both are around 70-80%, which isn't critical for a cardiovascular target.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the values are similar.
10. **Solubility:** Both have negative solubility values, which is also unusual. The values are similar.
11. **hERG:** Both have low hERG risk (0.46 and 0.35).
12. **Cl_mic:** Ligand B (60.5) has lower microsomal clearance than Ligand A (85.9), suggesting better metabolic stability. This is a point in favor of B.
13. **t1/2:** Ligand A (-12.4) has a longer in vitro half-life than Ligand B (-11.4), which is desirable.
14. **Pgp:** Both have low Pgp efflux liability (0.37 and 0.05).
15. **Binding Affinity:** Both have very similar binding affinities (-6.3 and -6.0 kcal/mol). The difference is negligible.
**GPCR-specific priorities:** For ADRB2 (a GPCR), we prioritize logP, TPSA, and affinity. Ligand A excels in logP and TPSA, while affinity is comparable. The significantly higher DILI risk for Ligand B is a major red flag.
**Overall Assessment:**
Ligand A is the better candidate. While Ligand B has slightly better metabolic stability, Ligand A has superior drug-like properties (QED), a much lower DILI risk, better logP and TPSA, and comparable affinity. The DILI risk associated with Ligand B is a critical concern that outweighs the modest benefit in metabolic stability.
Output:
1
2025-04-17 18:49:24,337 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (363.439 Da) is slightly higher than Ligand B (343.471 Da), but this difference isn't significant.
**2. TPSA:** Ligand A (89.55) is better than Ligand B (62.3). Both are below the 140 A^2 threshold for good oral absorption, but the lower TPSA of Ligand B is more favorable for GPCRs, potentially improving brain penetration even though this isn't a CNS target.
**3. logP:** Ligand A (1.466) is within the optimal range (1-3), while Ligand B (3.02) is at the higher end. While still acceptable, higher logP can sometimes lead to off-target effects.
**4. H-Bond Donors:** Ligand A (2) is slightly higher than Ligand B (1), but both are within the acceptable limit of 5.
**5. H-Bond Acceptors:** Ligand A (7) is higher than Ligand B (3). Both are below the 10 limit, but Ligand B is preferable.
**6. QED:** Both ligands have good QED scores (Ligand A: 0.782, Ligand B: 0.828), indicating good drug-like properties. Ligand B is slightly better.
**7. DILI:** Ligand B (21.908) has a significantly lower DILI risk than Ligand A (77.937). This is a major advantage for Ligand B.
**8. BBB:** Ligand B (75.301) has a higher BBB percentile than Ligand A (40.326). While ADRB2 isn't a primary CNS target, some peripheral GPCRs can have effects mediated by CNS penetration, and higher BBB is generally favorable.
**9. Caco-2 Permeability:** Ligand A (-5.133) has a worse Caco-2 permeability than Ligand B (-4.42). Lower values indicate lower permeability.
**10. Aqueous Solubility:** Ligand A (-1.81) has better solubility than Ligand B (-3.374). Solubility is important for formulation and bioavailability.
**11. hERG Inhibition:** Ligand A (0.36) has a lower hERG inhibition risk than Ligand B (0.634). This is a significant advantage for Ligand A.
**12. Microsomal Clearance:** Ligand B (79.005) has a higher microsomal clearance than Ligand A (27.173), suggesting faster metabolism and potentially lower in vivo exposure.
**13. In vitro Half-Life:** Ligand A (16.146) has a longer half-life than Ligand B (-4.803). This is a significant advantage for Ligand A.
**14. P-gp Efflux:** Ligand A (0.04) has a lower P-gp efflux liability than Ligand B (0.168). Lower efflux is generally better for bioavailability.
**15. Binding Affinity:** Ligand A (-8.0) has a slightly better binding affinity than Ligand B (-6.9). This 1.1 kcal/mol difference is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), and the overall balance of properties, Ligand A is the more promising candidate. The significantly stronger binding affinity (-8.0 kcal/mol vs -6.9 kcal/mol) is a major driver. While Ligand B has advantages in DILI, BBB, and QED, the superior affinity and better metabolic stability (lower Cl_mic, longer t1/2) of Ligand A are more critical for a GPCR target. The slightly higher TPSA of Ligand A is not a major concern. The hERG risk is slightly higher for Ligand B, but not dramatically so.
Output:
1
2025-04-17 18:49:24,337 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (347.415 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (82.86) is better than Ligand B (49.41). Both are below 140, but Ligand B is closer to the optimal range for good oral absorption.
3. **logP:** Ligand A (1.177) is within the optimal range (1-3), while Ligand B (3.597) is at the higher end. This could potentially lead to solubility issues for Ligand B.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 2. Both are acceptable.
6. **QED:** Ligand A (0.871) has a better QED score than Ligand B (0.782), indicating better overall drug-likeness.
7. **DILI:** Ligand A (39.977) has a slightly higher DILI risk than Ligand B (29.43), but both are well below the concerning threshold of 60.
8. **BBB:** Ligand B (75.805) has a significantly better BBB penetration percentile than Ligand A (62.233). While ADRB2 isn't strictly a CNS target, some peripheral ADRB2 receptors can be affected by CNS penetration.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and requires further investigation. However, the values are similar (-4.967 vs -4.673).
10. **Solubility:** Ligand A (-1.193) has better solubility than Ligand B (-4.3). This is a significant advantage, especially given Ligand B's higher logP.
11. **hERG:** Ligand A (0.185) has a much lower hERG inhibition liability than Ligand B (0.44), which is crucial for avoiding cardiotoxicity, especially important for a cardiovascular target.
12. **Cl_mic:** Ligand A (-2.274) has a much lower (better) microsomal clearance than Ligand B (71.087), indicating better metabolic stability.
13. **t1/2:** Ligand A (21.726) has a longer in vitro half-life than Ligand B (14.694), which is desirable for less frequent dosing.
14. **Pgp:** Ligand A (0.053) has lower P-gp efflux liability than Ligand B (0.217), which is good for bioavailability.
15. **Binding Affinity:** Ligand A (-7.3) has a slightly better binding affinity than Ligand B (-6.6), though the difference is not huge.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A is better on logP, Pgp, and has comparable TPSA. The affinity difference is small. The significantly better metabolic stability (Cl_mic, t1/2), solubility, and lower hERG risk of Ligand A outweigh the slightly better BBB penetration of Ligand B.
**Conclusion:**
Ligand A is the more promising drug candidate due to its superior ADME properties (solubility, metabolic stability, Pgp efflux, hERG risk) and comparable binding affinity.
Output:
1
2025-04-17 18:49:24,337 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (345.443 and 350.503 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (82.53) is slightly higher than Ligand B (69.64). Both are below the 140 threshold for good oral absorption, but Ligand B is preferable given the GPCR target class.
3. **logP:** Both ligands (2.261 and 2.639) are within the optimal 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability, but not dramatically so.
4. **HBD:** Both ligands have 2 H-bond donors, which is within the acceptable limit of <=5. No difference.
5. **HBA:** Ligand A has 4 H-bond acceptors, while Ligand B has 3. Both are below the 10 threshold. No major difference.
6. **QED:** Ligand A (0.857) has a significantly higher QED score than Ligand B (0.724), indicating a more drug-like profile. This is a substantial advantage for Ligand A.
7. **DILI:** Ligand A (36.293) has a much lower DILI risk than Ligand B (8.375). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (68.282) has a slightly higher BBB penetration percentile than Ligand B (60.644). While not a primary concern for ADRB2 (a cardiovascular target), it's still a slight positive for Ligand A.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
10. **Solubility:** Both ligands have negative solubility values, which is also unusual. Again, the scale is unknown, making interpretation difficult.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.197 and 0.287), which is excellent. No difference.
12. **Cl_mic:** Ligand A (9.852) has a lower microsomal clearance than Ligand B (37.969), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (10.519) has a longer in vitro half-life than Ligand B (-5.65). A negative half-life is problematic for Ligand B. This is a major advantage for Ligand A.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.08 and 0.056). No significant difference.
15. **Binding Affinity:** Ligand A (-7.3 kcal/mol) has a slightly better binding affinity than Ligand B (-6.8 kcal/mol). While the difference is less than the 1.5 kcal/mol threshold, it contributes to the overall preference for Ligand A.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical parameters. It has a better QED score, significantly lower DILI risk, better metabolic stability (lower Cl_mic, positive t1/2), and slightly better binding affinity and BBB penetration. Ligand B's only advantage is a slightly higher logP, which isn't substantial enough to offset the numerous advantages of Ligand A. The negative values for Caco-2 and solubility are concerning for both, but the other advantages of Ligand A make it the more promising candidate.
Output:
1
2025-04-17 18:49:24,337 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (332.45 & 350.46 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (25.36) is significantly better than Ligand B (70.08). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold, while B is pushing it.
3. **logP:** Ligand A (3.896) is optimal, while Ligand B (0.879) is a bit low. A logP below 1 can hinder membrane permeability. This favors Ligand A.
4. **HBD:** Both have acceptable HBD counts (0 for A, 1 for B).
5. **HBA:** Both have acceptable HBA counts (3 for A, 4 for B).
6. **QED:** Both ligands have similar, good QED values (0.777 and 0.772).
7. **DILI:** Ligand A (12.37) has a much lower DILI risk than Ligand B (23.42). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (71.93) shows better BBB penetration than Ligand B (43.82), but this isn't a primary concern for a cardiovascular target.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. This is a concern for both, but the value for A (-4.825) is slightly better than B (-4.524).
10. **Solubility:** Both have negative solubility values, indicating poor solubility. The value for A (-4.333) is slightly better than B (-2.044).
11. **hERG:** Ligand A (0.847) has a lower hERG risk than Ligand B (0.353), which is a critical advantage.
12. **Cl_mic:** Ligand A (29.66) has a lower microsomal clearance, suggesting better metabolic stability than Ligand B (42.13).
13. **t1/2:** Ligand A (-21.65) has a negative half-life, which is concerning. Ligand B (2.67) has a very short half-life, but is positive.
14. **Pgp:** Ligand A (0.407) has lower P-gp efflux liability than Ligand B (0.12).
15. **Affinity:** Both ligands have excellent binding affinity (-6.3 and -5.8 kcal/mol). The difference (0.5 kcal/mol) is not substantial enough to outweigh the ADME advantages of Ligand A.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A excels in logP and TPSA, and has a lower Pgp efflux liability. While the affinity difference is small, the ADME profile of Ligand A is significantly more favorable.
**Conclusion:**
Despite the negative half-life of Ligand A, its superior TPSA, logP, DILI risk, hERG risk, and metabolic stability make it the more promising drug candidate. The affinity difference is not large enough to overcome these advantages.
Output:
1
2025-04-17 18:49:24,337 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.431 and 365.455 Da) are within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (81.01) is significantly better than Ligand B (95.58). ADRB2 is a cardiovascular target, not CNS, but lower TPSA generally improves absorption.
3. **logP:** Ligand A (2.729) is optimal (1-3). Ligand B (-0.307) is too low, potentially hindering membrane permeability. This is a significant drawback for a GPCR ligand.
4. **HBD:** Both ligands have 1-2 HBD, which is acceptable.
5. **HBA:** Both ligands have 5 HBA, which is acceptable.
6. **QED:** Ligand A (0.851) is excellent, indicating high drug-likeness. Ligand B (0.667) is still reasonable, but less optimal.
7. **DILI:** Ligand A (38.969) has a slightly better DILI risk profile than Ligand B (44.436), though both are under the 60% threshold.
8. **BBB:** This isn't a primary concern for a cardiovascular target. Ligand A (65.529) is higher than Ligand B (27.646), but this is less important.
9. **Caco-2:** Ligand A (-4.453) is better than Ligand B (-5.778), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-2.64) is better than Ligand B (-2.936), indicating better aqueous solubility.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.138 and 0.028).
12. **Cl_mic:** Ligand A (48.657) has a lower microsomal clearance than Ligand B (7.954), suggesting better metabolic stability.
13. **t1/2:** Ligand A (29.038) has a significantly longer in vitro half-life than Ligand B (4.266).
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.013 and 0.015).
15. **Binding Affinity:** Ligand A (-7.8 kcal/mol) has a stronger binding affinity than Ligand B (-6.8 kcal/mol). This 1.0 kcal/mol difference is substantial and can outweigh minor ADME drawbacks.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical parameters. The most significant differences are in logP (where Ligand B is unfavorable), metabolic stability (Cl_mic and t1/2, favoring A), and binding affinity (strongly favoring A). While both have acceptable safety profiles, Ligand A's superior ADME properties and significantly better binding affinity make it the more promising drug candidate for the ADRB2 receptor.
Output:
1
2025-04-17 18:49:24,338 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.447 and 350.375 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (87.32) is better than Ligand B (109). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally favors absorption.
3. **logP:** Ligand A (2.341) is optimal (1-3). Ligand B (0.461) is a bit low, potentially hindering membrane permeability.
4. **HBD:** Both ligands have acceptable HBD counts (2 and 1 respectively), well within the limit of 5.
5. **HBA:** Ligand A (4) is better than Ligand B (7), keeping within the preferred range of <=10.
6. **QED:** Both ligands have good QED scores (0.8 and 0.84), indicating good drug-like properties.
7. **DILI:** Ligand A (27.259) has a significantly lower DILI risk than Ligand B (57.929). This is a major advantage.
8. **BBB:** Ligand A (77.821) has a better BBB penetration score than Ligand B (62.466), though this is less critical for a cardiovascular target.
9. **Caco-2:** Both ligands have similar, poor Caco-2 permeability (-4.894 and -4.844).
10. **Solubility:** Ligand A (-2.046) is slightly better than Ligand B (-1.606), but both are quite poor.
11. **hERG:** Ligand A (0.409) has a much lower hERG inhibition liability than Ligand B (0.018). This is a critical safety parameter.
12. **Cl_mic:** Ligand A (27.79) has significantly better metabolic stability (lower clearance) than Ligand B (3.514).
13. **t1/2:** Ligand A (-7.774) has a significantly longer in vitro half-life than Ligand B (7.175).
14. **Pgp:** Ligand A (0.057) has lower P-gp efflux liability than Ligand B (0.032).
15. **Affinity:** Ligand A (-7.4 kcal/mol) has a slightly better binding affinity than Ligand B (-6.2 kcal/mol). While the difference is not huge, it's a positive factor.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A performs better in logP, TPSA, and Pgp. The affinity difference is not substantial, but favors A.
**Overall Assessment:**
Ligand A is clearly superior. It has a significantly better safety profile (lower DILI, lower hERG), better metabolic stability (lower Cl_mic, longer t1/2), and a slightly better binding affinity. While both have poor Caco-2 and solubility, the ADME/Tox advantages of Ligand A outweigh these drawbacks.
Output:
1
2025-04-17 18:49:24,338 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [361.877, 66.97, 3.157, 0, 6, 0.642, 25.591, 68.127, -5.076, -2.968, 0.873, 46.538, 56.264, 0.513, -5.4]**
**Ligand B: [367.446, 91.34, 2.229, 2, 6, 0.829, 16.014, 36.371, -4.548, -0.249, 0.564, 3.977, -26.137, 0.068, -6]**
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). A is 361.877 and B is 367.446, so no significant difference here.
2. **TPSA:** Ligand A (66.97) is better than Ligand B (91.34). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (3.157) is slightly better than Ligand B (2.229), falling within the optimal 1-3 range. Ligand B is still acceptable, but A is preferable.
4. **H-Bond Donors:** Ligand A (0) is better than Ligand B (2). Fewer HBDs generally improve permeability.
5. **H-Bond Acceptors:** Both ligands have 6 HBA, so no difference here.
6. **QED:** Ligand B (0.829) is slightly better than Ligand A (0.642), indicating a more drug-like profile.
7. **DILI:** Ligand A (25.591) has a higher DILI risk than Ligand B (16.014). This is a significant advantage for B.
8. **BBB:** Ligand A (68.127) has a better BBB penetration than Ligand B (36.371). While not a primary concern for a cardiovascular target, it's a slight positive for A.
9. **Caco-2:** Ligand A (-5.076) and Ligand B (-4.548) are both poor, indicating poor intestinal absorption.
10. **Solubility:** Ligand B (-0.249) is better than Ligand A (-2.968). Solubility is important for bioavailability.
11. **hERG:** Both ligands have low hERG inhibition risk (A: 0.873, B: 0.564). B is slightly better.
12. **Cl_mic:** Ligand B (3.977) has significantly lower microsomal clearance than Ligand A (46.538), indicating better metabolic stability. This is a major advantage for B.
13. **t1/2:** Ligand A (56.264) has a much longer in vitro half-life than Ligand B (-26.137). This is a significant advantage for A.
14. **Pgp:** Ligand A (0.513) has lower P-gp efflux than Ligand B (0.068), indicating better bioavailability.
15. **Binding Affinity:** Both ligands have excellent binding affinity (A: -5.4, B: -6). Ligand B is slightly better.
**Overall Assessment:**
Ligand B has several key advantages: lower DILI risk, significantly better metabolic stability (lower Cl_mic), and slightly better solubility and affinity. Ligand A has a longer half-life and better BBB penetration, but these are less critical for a cardiovascular target. The poor Caco-2 values for both are concerning, but the metabolic stability of B is a significant advantage. Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity), and the overall balance of properties, Ligand B is the more promising candidate.
Output:
0
2025-04-17 18:49:24,338 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (367.314 Da) is slightly higher than Ligand B (347.463 Da), but both are acceptable.
2. **TPSA:** Ligand A (58.56) is significantly better than Ligand B (80.12). ADRB2 is not a CNS target, but lower TPSA generally correlates with better permeability.
3. **logP:** Ligand A (3.642) is optimal, while Ligand B (1.603) is on the lower side. For a GPCR, a logP between 1-3 is preferred, and A is closer to the upper end of this range, which is generally favorable.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable.
5. **HBA:** Ligand A (3) and Ligand B (5) are both acceptable, but A is preferable.
6. **QED:** Both ligands have similar QED values (0.799 and 0.76), indicating good drug-likeness.
7. **DILI:** Ligand A (51.609) has a higher DILI risk than Ligand B (31.989). This is a significant advantage for Ligand B.
8. **BBB:** Not a primary concern for ADRB2 (cardiovascular target), but Ligand A (83.249) has a higher BBB percentile than Ligand B (73.827).
9. **Caco-2:** Ligand A (-4.163) and Ligand B (-5.107) both have negative values, indicating poor permeability. Ligand B is slightly worse.
10. **Solubility:** Ligand A (-4.159) and Ligand B (-2.358) both have negative values, indicating poor solubility. Ligand B is better.
11. **hERG:** Ligand A (0.642) has a lower hERG risk than Ligand B (0.206). This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand B (60.618) has a lower microsomal clearance than Ligand A (55.344), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-2.274) has a longer in vitro half-life than Ligand A (-13.925). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.076) has a lower Pgp efflux liability than Ligand B (0.091). This is a slight advantage for Ligand A.
15. **Binding Affinity:** Ligand A (-7.0) has a slightly better binding affinity than Ligand B (-6.3). This is a significant advantage for Ligand A.
**Overall Assessment:**
Ligand A has a better logP, TPSA, hERG, Pgp, and binding affinity. Ligand B has a better DILI score, solubility, and in vitro half-life. The binding affinity difference is substantial, and for a GPCR, potency is crucial. While the DILI risk for Ligand A is a concern, the superior potency and permeability characteristics (lower TPSA) outweigh this risk, especially considering the cardiovascular target.
Output:
1
2025-04-17 18:49:24,338 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (341.455 and 347.463 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (73.99) is slightly higher than Ligand B (63.49). Both are below the 140 threshold for good oral absorption, but B is better.
3. **logP:** Ligand A (2.389) is within the optimal 1-3 range. Ligand B (1.312) is on the lower end, potentially impacting permeability. A is better.
4. **HBD:** Ligand A (3) is acceptable, while Ligand B (0) is excellent. B is better.
5. **HBA:** Ligand A (2) is good, and Ligand B (6) is acceptable but higher. A is better.
6. **QED:** Both ligands have similar QED values (0.695 and 0.63), indicating good drug-likeness. No significant difference.
7. **DILI:** Ligand A (29.081) has a slightly higher DILI risk than Ligand B (23.846), but both are well below the concerning threshold of 60. B is better.
8. **BBB:** Ligand B (69.407) shows better BBB penetration than Ligand A (50.407). Given that ADRB2 is a GPCR, BBB penetration is a consideration, though not paramount for cardiovascular targets. B is better.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.822 and -4.933), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand A (-3.739) has slightly better solubility than Ligand B (-0.542). A is better.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.364 and 0.224). No significant difference.
12. **Cl_mic:** Ligand A (16.348) has significantly lower microsomal clearance than Ligand B (35.121), indicating better metabolic stability. A is better.
13. **t1/2:** Ligand B (10.543) has a much longer in vitro half-life than Ligand A (1.867). B is better.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.111 and 0.06). No significant difference.
15. **Binding Affinity:** Ligand A (-6.3 kcal/mol) has a slightly better binding affinity than Ligand B (-4.9 kcal/mol). This is a 1.4 kcal/mol difference, which is substantial and can outweigh some ADME concerns. A is better.
**Overall Assessment:**
Ligand A has a clear advantage in binding affinity and metabolic stability (lower Cl_mic), and better solubility. Ligand B has better BBB penetration, lower DILI risk, and a longer half-life. The Caco-2 values are concerning for both, but the stronger binding affinity of Ligand A is a critical factor for GPCR targets. The difference in binding affinity is substantial enough to offset some of the ADME drawbacks.
**Output:**
1
2025-04-17 18:49:24,338 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (373.469 and 360.531 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (62.3) is better than Ligand B (79.96). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (2.864 and 3.205), falling within the optimal 1-3 range. Ligand B is slightly higher, which *could* be a minor drawback, but not a major one.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is better than Ligand B (7). Similar to HBD, lower HBA is generally favored for permeability.
6. **QED:** Both ligands have good QED scores (0.762 and 0.856), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (37.805) has a significantly lower DILI risk than Ligand B (61.807). This is a substantial advantage for Ligand A.
8. **BBB:** Ligand B (89.104) has a higher BBB penetration percentile than Ligand A (73.245). However, as ADRB2 is a cardiovascular target, BBB penetration is not a high priority.
9. **Caco-2:** Ligand A (-4.614) and Ligand B (-5.3) are both poor.
10. **Solubility:** Ligand A (-2.883) is better than Ligand B (-4.709). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.378) has a lower hERG inhibition liability than Ligand B (0.535), which is a positive.
12. **Cl_mic:** Ligand A (28.802) has a significantly lower microsomal clearance than Ligand B (52.824), indicating better metabolic stability.
13. **t1/2:** Ligand A (-10.455) has a much longer in vitro half-life than Ligand B (17.893). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.099) has a lower P-gp efflux liability than Ligand B (0.038).
15. **Binding Affinity:** Ligand B (-8.1) has a stronger binding affinity than Ligand A (-6.2). This is a 1.9 kcal/mol difference, which is substantial and could outweigh some of the ADME drawbacks of Ligand B.
**Overall Assessment:**
While Ligand B has a better binding affinity, Ligand A demonstrates a significantly more favorable ADMET profile. Specifically, the lower DILI risk, better metabolic stability (lower Cl_mic and longer t1/2), and lower hERG risk are crucial advantages. The slightly better solubility of Ligand A is also beneficial. Although Ligand B has better BBB penetration, this is not a priority for a cardiovascular target. The affinity difference, while substantial, is not so large that it completely overrides the superior safety and pharmacokinetic properties of Ligand A.
Output:
1
2025-04-17 18:49:24,338 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the acceptable range (200-500 Da). Ligand A (355.523 Da) is slightly lower, which is generally favorable for permeability.
**2. TPSA:** Ligand A (72.88) is significantly better than Ligand B (34.59). For a GPCR, lower TPSA is preferred as it generally correlates with better membrane permeability.
**3. logP:** Ligand A (1.479) is optimal, while Ligand B (4.931) is high. High logP can lead to poor solubility and off-target effects.
**4. H-Bond Donors:** Ligand A (2) is acceptable, Ligand B (0) is also acceptable.
**5. H-Bond Acceptors:** Ligand A (4) is acceptable, Ligand B (5) is acceptable.
**6. QED:** Both ligands have similar QED values (Ligand A: 0.692, Ligand B: 0.583), indicating reasonable drug-likeness.
**7. DILI Risk:** Ligand A (6.282) has a much lower DILI risk than Ligand B (35.44). This is a significant advantage.
**8. BBB Penetration:** Ligand B (77.705) shows better BBB penetration than Ligand A (55.487). While ADRB2 is a cardiovascular target, some CNS off-target effects are always a consideration, and moderate BBB penetration isn't a dealbreaker.
**9. Caco-2 Permeability:** Both ligands have similar, very negative Caco-2 permeability values. This is concerning for both, and suggests potential absorption issues.
**10. Aqueous Solubility:** Both ligands have very negative solubility values, suggesting poor solubility.
**11. hERG Inhibition:** Ligand A (0.544) has a lower hERG risk than Ligand B (0.853). This is a crucial safety parameter.
**12. Microsomal Clearance:** Ligand A (-9.653) has significantly lower (better) microsomal clearance than Ligand B (102.322), indicating better metabolic stability.
**13. In vitro Half-Life:** Ligand A (-4.964) has a better in vitro half-life than Ligand B (46.66).
**14. P-gp Efflux:** Ligand A (0.028) has much lower P-gp efflux than Ligand B (0.608), which is favorable for bioavailability.
**15. Binding Affinity:** Ligand B (-6.3) has a slightly better binding affinity than Ligand A (-7.0). However, the difference is less than 1.5 kcal/mol, and other factors are more important.
**Overall Assessment:**
Ligand A is significantly better overall. It has a lower molecular weight, much lower TPSA, optimal logP, significantly lower DILI risk, lower hERG risk, better metabolic stability (lower Cl_mic and better t1/2), and lower P-gp efflux. While Ligand B has slightly better binding affinity and BBB penetration, the substantial advantages of Ligand A in ADME-Tox properties outweigh this difference, especially considering the cardiovascular target. The poor Caco-2 and solubility for both are concerning and would require further investigation, but Ligand A's profile is more amenable to optimization.
Output:
1
2025-04-17 18:49:24,338 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (379.839 and 368.543 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (72.28) is slightly higher than Ligand B (58.64). Both are below the 140 A^2 threshold for good oral absorption, but B is preferable.
3. **logP:** Both ligands have excellent logP values (2.544 and 2.442) falling within the optimal 1-3 range. No significant difference.
4. **HBD:** Both ligands have 1 HBD, which is within the acceptable limit of <=5.
5. **HBA:** Ligand A has 5 HBA, and Ligand B has 4. Both are within the acceptable limit of <=10.
6. **QED:** Ligand B (0.715) has a better QED score than Ligand A (0.556), indicating a more drug-like profile.
7. **DILI:** Ligand B (32.299) has a significantly lower DILI risk than Ligand A (58.434). This is a major advantage for Ligand B.
8. **BBB:** Ligand A (92.051) has a better BBB penetration percentile than Ligand B (63.784). While ADRB2 isn't *strictly* a CNS target, some peripheral ADRB2 receptors can influence CNS function, and better BBB penetration is generally favorable.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. Ligand B (-5.051) is slightly worse than Ligand A (-4.702).
10. **Solubility:** Both ligands have negative solubility values, indicating poor solubility. Ligand B (-3.184) is slightly worse than Ligand A (-2.712).
11. **hERG:** Both ligands have very low hERG inhibition liability (0.338 and 0.337), which is excellent. No significant difference.
12. **Cl_mic:** Ligand B (59.722) has a slightly lower microsomal clearance than Ligand A (65.14), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-11.001) has a significantly *shorter* in vitro half-life than Ligand A (20.553). This is a drawback for Ligand B.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.343 and 0.232), which is excellent. Ligand B is slightly better.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-5.7 and -5.8 kcal/mol). The difference is negligible.
**GPCR-specific priorities:** For GPCRs, logP, TPSA, Pgp, and affinity are key. Both ligands perform well on logP and affinity. Ligand B has a better TPSA and Pgp profile. The biggest differentiators are DILI (strongly favoring Ligand B) and half-life (favoring Ligand A). The lower DILI risk of Ligand B is a critical advantage, outweighing the shorter half-life, which can potentially be addressed through formulation or structural modifications.
**Conclusion:**
Considering the balance of properties, especially the significantly lower DILI risk and slightly improved TPSA and Pgp efflux, Ligand B is the more promising drug candidate.
Output:
0
2025-04-17 18:49:24,338 - INFO - Batch 65 complete. Total preferences: 1040
2025-04-17 18:49:24,338 - INFO - Processing batch 66/512...
2025-04-17 18:50:13,331 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [349.366, 95.5, -0.234, 1, 5, 0.813, 64.793, 60.295, -4.803, -1.518, 0.146, -4.144, -16.551, 0.017, -7.1]
**Ligand B:** [366.483, 67.87, 2.186, 1, 5, 0.751, 56.883, 69.407, -4.974, -2.014, 0.225, 48.578, 37.236, 0.158, -6.5]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (349.366) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (95.5) is higher than Ligand B (67.87). Both are acceptable for a non-CNS GPCR, but Ligand B is better.
3. **logP:** Ligand A (-0.234) is quite low, potentially hindering membrane permeability. Ligand B (2.186) is within the optimal range (1-3). This is a significant advantage for Ligand B.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Both have 5 HBA, which is good.
6. **QED:** Ligand A (0.813) has a slightly better QED score than Ligand B (0.751), indicating a more drug-like profile.
7. **DILI:** Ligand A (64.793) has a higher DILI risk than Ligand B (56.883), though both are reasonably acceptable.
8. **BBB:** Both have moderate BBB penetration, but Ligand B (69.407) is slightly better than Ligand A (60.295). For a cardiovascular target, BBB isn't a primary concern, but it's a slight positive for B.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability.
10. **Solubility:** Both have negative solubility values, indicating poor solubility.
11. **hERG:** Both have very low hERG risk.
12. **Cl_mic:** Ligand A (-4.144) has a much lower (better) microsomal clearance than Ligand B (48.578), suggesting better metabolic stability.
13. **t1/2:** Ligand B (37.236) has a significantly longer in vitro half-life than Ligand A (-16.551). This is a major advantage for Ligand B.
14. **Pgp:** Both have very low Pgp efflux liability.
15. **Affinity:** Ligand A (-7.1) has a better binding affinity than Ligand B (-6.5). This is a 0.6 kcal/mol difference, which is substantial.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are crucial. Ligand B has a much better logP and TPSA, while Ligand A has a better affinity. The affinity difference is significant, but the poor logP of Ligand A is a major concern. The longer half-life of Ligand B is also a significant advantage.
**Conclusion:**
Despite the slightly better affinity of Ligand A, the significantly better logP, TPSA, and half-life of Ligand B make it the more promising candidate. The affinity difference, while notable, can potentially be optimized in further iterations of drug design. The poor logP of Ligand A is a more fundamental issue that would be harder to overcome.
Output:
0
2025-04-17 18:50:13,331 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [368.499, 76.66, 2.337, 2, 5, 0.622, 38.503, 70.648, -5.149, -2.223, 0.594, 32.298, 15.024, 0.185, -6.9]
**Ligand B:** [357.451, 100.13, -1.029, 3, 6, 0.462, 6.049, 29.042, -5.109, -0.077, 0.115, -0.811, -2.488, 0.005, -6]
Here's a breakdown, considering the guidelines and GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal range (200-500 Da). A is 368.5, B is 357.5. Slight edge to B being a bit lower.
2. **TPSA:** A (76.66) is better than B (100.13). Lower TPSA generally favors better permeability. This is a significant advantage for A.
3. **logP:** A (2.337) is optimal. B (-1.029) is quite low, potentially hindering membrane permeability and bioavailability. This is a major drawback for B.
4. **HBD:** A (2) is good. B (3) is acceptable, but slightly less desirable.
5. **HBA:** A (5) is good. B (6) is acceptable, but slightly less desirable.
6. **QED:** A (0.622) is good, indicating drug-likeness. B (0.462) is lower, suggesting a less favorable drug-like profile.
7. **DILI:** A (38.503) is excellent, very low risk. B (6.049) is also low risk, but higher than A.
8. **BBB:** A (70.648) is good, suggesting reasonable potential for CNS penetration (though less critical for a cardiovascular target). B (29.042) is low, indicating poor BBB penetration.
9. **Caco-2:** Both are negative (-5.149 and -5.109), indicating poor permeability. This is concerning for both.
10. **Solubility:** Both are negative (-2.223 and -0.077), indicating poor solubility. B is slightly better than A.
11. **hERG:** A (0.594) is better than B (0.115), indicating lower cardiotoxicity risk.
12. **Cl_mic:** A (32.298) is better than B (-0.811). Higher values indicate faster clearance, so lower is preferred.
13. **t1/2:** A (15.024) is much better than B (-2.488). A longer half-life is generally preferred.
14. **Pgp:** A (0.185) is better than B (0.005), suggesting less P-glycoprotein efflux.
15. **Affinity:** A (-6.9) is slightly better than B (-6.0). While both are good, A has a stronger binding affinity.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical parameters. The most significant advantages for A are its better logP, TPSA, QED, DILI, BBB, microsomal clearance, half-life, Pgp efflux, and slightly better binding affinity. While both have poor Caco-2 and solubility, the other advantages of A outweigh this. Ligand B's low logP is a major concern, potentially leading to poor absorption.
Therefore, I believe Ligand A is the more viable drug candidate.
Output:
1
2025-04-17 18:50:13,331 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [361.36 , 75.63 , 3.581, 2. , 3. , 0.812, 58.511, 61.38 , -4.782, -3.456, 0.338, 17.805, -15.736, 0.069, -5.9 ]
**Ligand B:** [350.419, 92.67 , -0.083, 2. , 5. , 0.702, 34.393, 42.962, -4.821, -0.956, 0.046, 0.97 , 1.046, 0.012, -7.2 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (350.419) is slightly lower, which is generally favorable.
2. **TPSA:** Ligand A (75.63) is better than Ligand B (92.67). For a cardiovascular GPCR, TPSA under 140 is acceptable, and A is closer to the ideal for good absorption.
3. **logP:** Ligand A (3.581) is optimal (1-3). Ligand B (-0.083) is significantly lower, which is a concern for membrane permeability and bioavailability.
4. **HBD:** Both have 2 HBD, which is good.
5. **HBA:** Ligand A (3) is better than Ligand B (5). Lower HBA is generally preferred for permeability.
6. **QED:** Both are reasonably good (A: 0.812, B: 0.702), indicating drug-like properties.
7. **DILI:** Ligand A (58.511) has a higher DILI risk than Ligand B (34.393). This is a significant drawback for Ligand A.
8. **BBB:** Ligand A (61.38) has better BBB penetration than Ligand B (42.962). However, for a cardiovascular target, BBB penetration is not a primary concern.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.782) is slightly worse than B (-4.821).
10. **Solubility:** Ligand A (-3.456) has worse solubility than Ligand B (-0.956). Solubility is important for bioavailability.
11. **hERG:** Both have low hERG inhibition risk (A: 0.338, B: 0.046), which is good. Ligand B is slightly better.
12. **Cl_mic:** Ligand A (17.805) has higher microsomal clearance than Ligand B (0.97), indicating faster metabolism and potentially lower exposure. This is a significant negative for Ligand A.
13. **t1/2:** Ligand A (-15.736) has a negative in vitro half-life, which is highly problematic. Ligand B (1.046) has a short half-life, but it is at least positive.
14. **Pgp:** Ligand A (0.069) has lower P-gp efflux than Ligand B (0.012). Lower P-gp efflux is generally favorable.
15. **Affinity:** Ligand B (-7.2) has a significantly stronger binding affinity than Ligand A (-5.9). This is a substantial advantage for Ligand B, and can often outweigh minor ADME issues.
**Overall Assessment:**
Ligand B is the more promising candidate. While its logP is low, its significantly stronger binding affinity (-7.2 vs -5.9 kcal/mol) is a major advantage for a GPCR target. It also exhibits lower DILI risk, better solubility, and lower microsomal clearance, leading to a more favorable ADME profile overall. Ligand A has a concerning negative in vitro half-life and higher DILI/clearance. The slightly better BBB penetration of Ligand A is irrelevant for a cardiovascular target.
Output:
0
2025-04-17 18:50:13,331 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (403.32 Da) is within the ideal range. Ligand B (346.515 Da) is also within range, but closer to the lower limit.
2. **TPSA:** Ligand A (41.57) is good, well below the 140 threshold. Ligand B (58.2) is still acceptable, but higher.
3. **logP:** Both ligands (A: 4.628, B: 3.694) are within the optimal range of 1-3, but Ligand A is slightly higher. This could potentially lead to off-target effects, but isn't a dealbreaker.
4. **HBD:** Ligand A (1) and Ligand B (2) are both acceptable.
5. **HBA:** Ligand A (3) and Ligand B (2) are both acceptable.
6. **QED:** Ligand A (0.792) is excellent, indicating high drug-likeness. Ligand B (0.52) is still reasonable, but lower.
7. **DILI:** Ligand A (58.666) is moderate risk, but acceptable. Ligand B (21.946) is very good, indicating low liver injury risk. This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (75.107) is good, suggesting reasonable brain penetration. Ligand B (65.374) is lower, indicating less brain penetration. For ADRB2, which isn't necessarily a CNS target, this isn't a major factor.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.762 and -4.65), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Both ligands have negative solubility values (-4.497 and -4.567), indicating very poor aqueous solubility. This is a major concern for both.
11. **hERG:** Ligand A (0.873) is better than Ligand B (0.407), indicating a lower risk of cardiotoxicity.
12. **Cl_mic:** Ligand A (104.797) has a higher clearance than Ligand B (41.961), suggesting lower metabolic stability. This is a disadvantage for Ligand A.
13. **t1/2:** Ligand A (78.603) has a much longer half-life than Ligand B (6.749). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.846) is better than Ligand B (0.345), indicating lower P-gp efflux.
15. **Binding Affinity:** Ligand B (-6.4 kcal/mol) has a slightly better binding affinity than Ligand A (-6.0 kcal/mol).
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand B has a slightly better affinity and lower Pgp efflux. Ligand A has a better logP and Pgp.
**Overall Assessment:**
Both compounds have significant drawbacks (poor solubility and Caco-2 permeability). However, Ligand B has a much better DILI score and a slightly better binding affinity, while Ligand A has a significantly longer half-life and better hERG. Considering the balance, the lower DILI risk of Ligand B is a critical advantage, especially early in development. The slightly better affinity is also beneficial. While the longer half-life of Ligand A is attractive, the DILI risk is a bigger concern.
Output:
0
2025-04-17 18:50:13,331 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.547 and 340.467 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (50.36) is better than Ligand B (58.2). Both are below the 140 threshold for oral absorption, but lower is preferable for GPCRs.
3. **logP:** Ligand A (4.774) is slightly higher than Ligand B (3.69). While both are within the 1-3 optimal range, Ligand A is approaching the upper limit and could potentially have solubility issues.
4. **HBD:** Both ligands have 2 H-bond donors, which is good.
5. **HBA:** Ligand A has 3 H-bond acceptors, while Ligand B has 2. Both are acceptable, below the 10 threshold.
6. **QED:** Ligand A (0.725) has a better QED score than Ligand B (0.56), indicating a more drug-like profile.
7. **DILI:** Ligand B (36.022) has a significantly lower DILI risk than Ligand A (11.361). This is a substantial advantage for Ligand B.
8. **BBB:** Ligand A (77.743) has a slightly higher BBB penetration percentile than Ligand B (70.299). For a cardiovascular target like ADRB2, BBB penetration is less critical than for CNS targets, but still a consideration.
9. **Caco-2:** Both ligands have similar, poor Caco-2 permeability (-4.549 and -4.471). This suggests potential absorption challenges for both.
10. **Solubility:** Both ligands have similar poor aqueous solubility (-3.871 and -4.478).
11. **hERG:** Both ligands have similar hERG inhibition liability (0.771 and 0.769).
12. **Cl_mic:** Ligand B (61.062) has a slightly lower microsomal clearance than Ligand A (66.366), suggesting better metabolic stability.
13. **t1/2:** Ligand B (4.331) has a slightly longer in vitro half-life than Ligand A (3.744).
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.188 and 0.246).
15. **Binding Affinity:** Both ligands have the same binding affinity (-6 kcal/mol).
**GPCR-Specific Priorities & Overall Assessment:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. While Ligand A has a slightly better logP and BBB, Ligand B has a significantly better DILI score, slightly better metabolic stability (lower Cl_mic, longer t1/2), and a better QED score. The equal binding affinity eliminates that as a differentiating factor. The lower DILI risk is a major advantage, as liver toxicity is a common cause of drug failure. The slightly better metabolic stability and QED of Ligand B also contribute to its overall profile. The poor Caco-2 and solubility are concerns for both, but can be addressed with formulation strategies.
**Output:**
0
2025-04-17 18:50:13,331 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (354.4 vs 350.5 Da). No significant difference.
2. **TPSA:** Ligand A (75.19) is higher than Ligand B (53.43). Ligand B is better, falling well below the 140 threshold for oral absorption and closer to the 90 threshold if CNS penetration were a goal.
3. **logP:** Ligand A (1.758) is within the optimal range, while Ligand B (3.574) is at the higher end. Ligand A is slightly preferred here, as very high logP can lead to off-target effects.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 4 HBA, Ligand B has 3. Both are acceptable.
6. **QED:** Ligand A (0.845) has a better QED score than Ligand B (0.741), indicating a more drug-like profile.
7. **DILI:** Ligand A (35.6) has a significantly higher DILI risk than Ligand B (6.6). This is a major concern for Ligand A.
8. **BBB:** Ligand B (93.7) has excellent BBB penetration potential, while Ligand A (88.1) is also good, but lower. While ADRB2 isn't exclusively a CNS target, some peripheral effects are mediated by CNS pathways, and good BBB penetration can be a benefit.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Both have negative solubility values, which is also unusual. Again, the scale is unspecified.
11. **hERG:** Ligand A (0.465) has a lower hERG risk than Ligand B (0.832), which is preferable.
12. **Cl_mic:** Ligand A (0.804) has a much lower microsomal clearance than Ligand B (56.843), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand B (-11.612) has a much longer in vitro half-life than Ligand A (-4.219). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.131) has lower P-gp efflux liability than Ligand B (0.603), which is preferable.
15. **Affinity:** Ligand B (-8.5 kcal/mol) has a significantly stronger binding affinity than Ligand A (-7.0 kcal/mol). This is a substantial advantage for Ligand B, easily outweighing minor ADME concerns.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand B excels in affinity and has better TPSA and Pgp values. While Ligand A has a better logP, the difference isn't substantial enough to offset the other advantages of Ligand B. The lower DILI risk of Ligand B is also a major factor.
**Overall Assessment:**
Despite Ligand A's better QED, lower Cl_mic, and lower hERG risk, the significantly stronger binding affinity of Ligand B, coupled with its lower DILI risk, better TPSA, and better BBB penetration, makes it the more promising drug candidate. The longer half-life is also a benefit.
Output:
0
2025-04-17 18:50:13,331 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (362.455 and 368.405 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (91.4) is higher than Ligand B (55.57). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B has a significant advantage here.
3. **logP:** Ligand A (0.636) is quite low, potentially hindering membrane permeability. Ligand B (3.823) is within the optimal 1-3 range. Ligand B is clearly better.
4. **HBD:** Ligand A (2) is reasonable. Ligand B (0) is excellent, minimizing potential for off-target interactions and improving permeability. Ligand B is better.
5. **HBA:** Both ligands have 5 HBA, which is acceptable. No significant difference.
6. **QED:** Ligand A (0.825) is slightly better than Ligand B (0.778), indicating a more drug-like profile.
7. **DILI:** Both ligands have acceptable DILI risk (42.187 and 48.313 percentile). No major difference.
8. **BBB:** Ligand A (61.768) is lower than Ligand B (93.098). While ADRB2 isn't a CNS target, higher BBB is generally a positive indicator of reduced off-target effects. Ligand B is better.
9. **Caco-2:** Ligand A (-5.45) is significantly worse than Ligand B (-4.292), indicating poorer intestinal absorption. Ligand B is better.
10. **Solubility:** Ligand A (-2.155) is better than Ligand B (-4.753), which is a positive.
11. **hERG:** Both ligands have low hERG inhibition liability (0.143 and 0.506). No significant difference.
12. **Cl_mic:** Ligand A (-20.776) has a much lower (better) microsomal clearance than Ligand B (85.029), indicating greater metabolic stability. Ligand A is significantly better.
13. **t1/2:** Ligand A (-5.241) has a shorter in vitro half-life than Ligand B (-24.921). Ligand B is better.
14. **Pgp:** Ligand A (0.015) has a much lower Pgp efflux liability than Ligand B (0.381), suggesting better oral bioavailability and potentially better tissue distribution. Ligand A is significantly better.
15. **Binding Affinity:** Ligand B (-7.1) has a slightly better binding affinity than Ligand A (-7.4). While affinity is paramount, the difference of 0.3 kcal/mol is not substantial enough to outweigh other significant ADME deficiencies.
**Overall Assessment:**
Ligand B excels in logP, TPSA, BBB, Caco-2 permeability, and in vitro half-life. Ligand A has advantages in QED, Cl_mic, and Pgp efflux. However, the poor logP and TPSA of Ligand A are significant drawbacks for a GPCR target, potentially leading to poor absorption and bioavailability. Ligand B's superior ADME profile, despite slightly weaker binding, makes it the more promising candidate.
Output:
0
2025-04-17 18:50:13,332 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (333.343 and 350.463 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Both ligands (75.63 and 78.68) are below the 140 A^2 threshold for good oral absorption, and acceptable for a cardiovascular GPCR. No strong preference.
3. **logP:** Ligand A (2.308) is slightly higher than Ligand B (1.606), both within the optimal 1-3 range. Ligand A is preferable.
4. **HBD:** Ligand A (2) and Ligand B (1) are both within the acceptable limit of <=5. Ligand B is slightly better.
5. **HBA:** Ligand A (3) and Ligand B (5) are both within the acceptable limit of <=10. Ligand A is preferable.
6. **QED:** Both ligands have good QED scores (0.796 and 0.873), indicating drug-likeness. No strong preference.
7. **DILI:** Ligand A (80.186) has a significantly higher DILI risk than Ligand B (18.922). This is a major concern for Ligand A.
8. **BBB:** Ligand B (72.741) has a higher BBB penetration percentile than Ligand A (21.171). While ADRB2 isn't a CNS target, higher BBB is generally favorable.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.826 and -4.847), which is unusual and suggests poor permeability. This is a significant drawback for both.
10. **Solubility:** Ligand B (-1.683) has better solubility than Ligand A (-3.622).
11. **hERG:** Ligand A (0.136) has a lower hERG inhibition liability than Ligand B (0.394). This is preferable.
12. **Cl_mic:** Ligand B (3.869) has a higher microsomal clearance than Ligand A (0.766), meaning Ligand A is more metabolically stable.
13. **t1/2:** Ligand B (9.352) has a longer in vitro half-life than Ligand A (-9.678). This is preferable.
14. **Pgp:** Ligand A (0.059) has lower P-gp efflux liability than Ligand B (0.036). This is preferable.
15. **Affinity:** Ligand B (-7.2 kcal/mol) has a slightly better binding affinity than Ligand A (-6.8 kcal/mol). This is a significant advantage.
**GPCR-Specific Considerations:**
For a cardiovascular GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand A has a slightly better logP and Pgp, but Ligand B has a significantly better affinity. The biggest concern for Ligand A is its high DILI risk.
**Overall Assessment:**
Despite Ligand B's slightly lower logP and higher Pgp efflux, its superior binding affinity, significantly lower DILI risk, and better solubility make it the more promising candidate. The longer half-life is also a benefit. The negative Caco-2 values are concerning for both, but can be addressed through formulation strategies.
Output:
0
2025-04-17 18:50:13,332 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (347.327 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (67.87) is significantly better than Ligand A (97.41). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA is still beneficial for absorption.
3. **logP:** Ligand B (1.066) is better than Ligand A (0.325). Ligand A's logP is quite low, potentially hindering membrane permeability.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand B (5) is better than Ligand A (6).
6. **QED:** Ligand A (0.735) is better than Ligand B (0.513), indicating a more drug-like profile.
7. **DILI:** Ligand B (42.885) is significantly better than Ligand A (80.225). This is a major advantage for Ligand B.
8. **BBB:** Not a primary concern for a cardiovascular target. Ligand A (57.231) is slightly better than Ligand B (46.762).
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-4.478) is slightly better than Ligand B (-4.71).
10. **Solubility:** Both are very poor (-3.023 and -2.952). This is a significant drawback for both.
11. **hERG:** Both are very low risk (0.185 and 0.152).
12. **Cl_mic:** Ligand B (36.8) has a much higher clearance than Ligand A (3.7). This is a significant disadvantage for Ligand B.
13. **t1/2:** Ligand B (-21.462) has a much longer half-life than Ligand A (-12.02). This is a major advantage for Ligand B.
14. **Pgp:** Both are very low efflux (0.03 and 0.027).
15. **Affinity:** Ligand A (-6.1) is slightly better than Ligand B (-5.4), but the difference is not substantial.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, and affinity are important. Ligand B has a better logP and TPSA. While Ligand A has slightly better affinity, the significant improvements in DILI risk, half-life, and logP for Ligand B outweigh this small difference in binding. The poor solubility and Caco-2 values are concerning for both, but can potentially be addressed with formulation strategies. The high clearance of Ligand B is a concern, but the longer half-life partially mitigates this.
**Conclusion:**
Considering the balance of properties and the priorities for a GPCR target, Ligand B is the more promising candidate.
Output:
0
2025-04-17 18:50:13,332 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (333.391 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (67.39) is significantly better than Ligand B (88.93). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (3.86) is good, while Ligand B (1.678) is on the lower side of optimal. A logP between 1-3 is preferred, and A is closer to the upper end of that range, which is generally good for GPCRs.
4. **HBD:** Ligand A (0) is ideal, while Ligand B (1) is acceptable. Fewer HBDs often improve membrane permeability.
5. **HBA:** Ligand A (5) is good, while Ligand B (7) is slightly higher. Both are within the acceptable limit of 10.
6. **QED:** Both ligands have similar and acceptable QED values (0.683 and 0.688).
7. **DILI:** Ligand B (54.556) has a significantly lower DILI risk than Ligand A (65.917), which is a major advantage.
8. **BBB:** Both have similar BBB penetration (54.478 vs 52.074). This isn't a critical factor for a cardiovascular target.
9. **Caco-2:** Ligand A (-4.302) is better than Ligand B (-5.246), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-5.469) is better than Ligand B (-3.031), which is important for bioavailability.
11. **hERG:** Both ligands have low hERG inhibition risk (0.557 and 0.424).
12. **Cl_mic:** Ligand B (63.613) has a lower microsomal clearance than Ligand A (123.917), suggesting better metabolic stability.
13. **t1/2:** Ligand A (20.52) has a significantly longer in vitro half-life than Ligand B (9.989), which is desirable.
14. **Pgp:** Ligand A (0.333) has lower P-gp efflux liability than Ligand B (0.143), meaning better absorption.
15. **Affinity:** Both ligands have very similar and excellent binding affinities (-7.4 and -7.3 kcal/mol). The difference is negligible.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are important. Ligand A performs better on logP and TPSA. However, the DILI risk for Ligand B is considerably lower, and metabolic stability (Cl_mic) is also better for Ligand B. The slightly longer half-life of Ligand A is a positive, but the lower DILI risk of Ligand B is a significant advantage in drug development.
**Overall Assessment:**
While Ligand A has some advantages in permeability and half-life, the significantly lower DILI risk and better metabolic stability of Ligand B are more critical for a viable drug candidate. The binding affinity is comparable, making the ADME-Tox profile the deciding factor.
Output:
0
2025-04-17 18:50:13,332 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, key priorities are logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB.
Let's compare the ligands property by property:
1. **MW:** Both ligands (346.475 and 355.435 Da) fall within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (80.48) is significantly better than Ligand B (99.18). A lower TPSA generally favors oral absorption, crucial for a cardiovascular drug.
3. **logP:** Ligand A (1.204) is within the optimal 1-3 range. Ligand B (-0.498) is slightly below 1, which *could* indicate permeability issues, though not drastically.
4. **HBD/HBA:** Both have 2 HBD and 5/6 HBA, which are acceptable.
5. **QED:** Ligand A (0.775) has a better QED score than Ligand B (0.598), indicating a more drug-like profile.
6. **DILI:** Ligand A (6.514%) has a much lower DILI risk than Ligand B (10.237%). This is a significant advantage.
7. **BBB:** Both have similar BBB penetration (55.176% vs 51.377%), and since this is a cardiovascular target, BBB isn't a primary concern.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and difficult to interpret without knowing the scale. However, the values are very similar.
9. **Solubility:** Both have negative solubility values, which is also unusual. Again, the values are very similar.
10. **hERG:** Ligand A (0.601) is better than Ligand B (0.117) indicating a lower risk of cardiotoxicity.
11. **Cl_mic:** Ligand A (-50.095) has a much lower (better) microsomal clearance than Ligand B (1.367), suggesting greater metabolic stability.
12. **t1/2:** Ligand A (22.962) has a longer in vitro half-life than Ligand B (-13.199).
13. **Pgp:** Both have very low Pgp efflux liability (0.03 and 0.013).
14. **Binding Affinity:** Both ligands have excellent binding affinities (-8.0 and -5.2 kcal/mol). Ligand A is significantly stronger.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical ADME properties (TPSA, logP, DILI, Cl_mic, t1/2, hERG) and has a significantly better binding affinity. While both have unusual solubility and Caco-2 values, the other advantages of Ligand A are compelling. The stronger binding affinity of Ligand A, coupled with its improved ADME profile, makes it the more promising drug candidate.
**Output:**
1
2025-04-17 18:50:13,332 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (342.487 and 349.431 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (50.16) is well below the 140 threshold and quite good for oral absorption. Ligand B (75.01) is still acceptable, but less optimal. GPCRs benefit from lower TPSA.
3. **logP:** Ligand A (3.54) is within the optimal 1-3 range. Ligand B (0.026) is *very* low, potentially causing permeability issues. This is a significant drawback for a GPCR ligand.
4. **HBD:** Both ligands have 1 HBD, which is within the acceptable limit of 5.
5. **HBA:** Ligand A has 3 HBA, and Ligand B has 5. Both are within the acceptable limit of 10, but Ligand A is preferable.
6. **QED:** Both ligands have similar QED values (0.837 and 0.814), indicating good drug-likeness.
7. **DILI:** Ligand A (37.224) has a slightly higher DILI risk than Ligand B (17.642), but both are below the concerning 60 threshold.
8. **BBB:** Ligand A (81.078) shows better BBB penetration than Ligand B (51.183). While ADRB2 isn't exclusively a CNS target, some CNS exposure is not necessarily detrimental and can be beneficial for understanding off-target effects.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual. However, the magnitude is similar.
10. **Solubility:** Ligand A (-3.98) has better aqueous solubility than Ligand B (-0.718). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.734) has a lower hERG inhibition liability than Ligand B (0.16), which is a positive.
12. **Cl_mic:** Ligand A (76.678) has a higher microsomal clearance than Ligand B (4.115), indicating lower metabolic stability. This is a negative for Ligand A.
13. **t1/2:** Ligand A (48.369) has a longer in vitro half-life than Ligand B (14.578). This is a positive for Ligand A.
14. **Pgp:** Ligand A (0.337) has lower P-gp efflux liability than Ligand B (0.024), which is a positive.
15. **Binding Affinity:** Ligand B (-6.5 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.3 kcal/mol) - a difference of 1.2 kcal/mol. This is a substantial advantage.
**Overall Assessment:**
Ligand B has a significantly better binding affinity, which is the most important factor. While its logP is low, the strong binding could potentially compensate. Ligand A has better solubility, BBB penetration, and Pgp efflux, but the lower affinity and higher clearance are concerning. The low logP of Ligand B is a drawback, but it's not insurmountable and could be addressed with further optimization. The affinity difference is large enough to outweigh the other drawbacks.
Output:
0
2025-04-17 18:50:13,332 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (389.483 Da) is slightly higher than Ligand B (343.471 Da), but both are acceptable.
2. **TPSA:** Ligand A (81.06) is higher than Ligand B (64.41). Both are below 140, suggesting good oral absorption potential.
3. **logP:** Both ligands have good logP values (A: 3.267, B: 2.735), falling within the optimal 1-3 range.
4. **HBD:** Ligand A (1) has a slightly better HBD count than Ligand B (0). Both are low and favorable.
5. **HBA:** Ligand A (7) is higher than Ligand B (3). Both are within the acceptable limit of 10.
6. **QED:** Both ligands have similar and acceptable QED values (A: 0.581, B: 0.55).
7. **DILI:** Ligand B (32.183) has a significantly lower DILI risk than Ligand A (98.759). This is a major advantage for Ligand B.
8. **BBB:** Both ligands have moderate BBB penetration (A: 50.679, B: 55.719). While ADRB2 isn't exclusively a CNS target, some CNS exposure could be relevant for off-target effects.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-5.409) is slightly worse than Ligand B (-4.446).
10. **Solubility:** Both ligands have negative solubility values, indicating poor aqueous solubility. Ligand A (-3.488) is slightly worse than Ligand B (-2.86).
11. **hERG:** Both ligands have low hERG inhibition liability (A: 0.381, B: 0.576), which is good.
12. **Cl_mic:** Ligand A (18.97) has a significantly lower microsomal clearance than Ligand B (46.352), suggesting better metabolic stability.
13. **t1/2:** Ligand A (100.44) has a much longer in vitro half-life than Ligand B (-14.631). This is a substantial advantage for Ligand A.
14. **Pgp:** Ligand A (0.434) has lower P-gp efflux liability than Ligand B (0.223), which is favorable.
15. **Binding Affinity:** Ligand B (-7.3 kcal/mol) has a slightly better binding affinity than Ligand A (-7.1 kcal/mol). While the difference is small, it's still a factor.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Both ligands perform reasonably well on logP and TPSA. Ligand B has a slightly better affinity, while Ligand A has better Pgp and Cl_mic. The biggest differentiator is the DILI risk, where Ligand B is significantly better.
**Overall Assessment:**
Ligand B has a significantly lower DILI risk and a slightly better binding affinity, which are crucial advantages. While Ligand A has better metabolic stability (lower Cl_mic) and a longer half-life, the DILI risk associated with Ligand A is concerning. The poor Caco-2 and solubility for both are drawbacks that would need to be addressed through formulation strategies, but the safety profile is paramount.
Output:
0
2025-04-17 18:50:13,332 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.487 and 351.491 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (49.85) is better than Ligand B (60.93). Both are below the 140 threshold for oral absorption, but lower TPSA is generally preferred for GPCRs to enhance brain penetration.
3. **logP:** Ligand A (2.751) is slightly higher than Ligand B (1.596), both within the optimal 1-3 range. Ligand A is preferable.
4. **HBD:** Both ligands have 0 HBD, which is good.
5. **HBA:** Both ligands have 3 HBA, which is good.
6. **QED:** Both ligands have good QED scores (0.501 and 0.624 respectively), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (13.3) has a significantly lower DILI risk than Ligand B (19.698). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (89.88) has a higher BBB penetration percentile than Ligand B (79.139). This is important for a GPCR target, even if not strictly CNS-focused, as it suggests better distribution.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.655 and -4.5), which is unusual and suggests poor permeability. This is a concern for both, but the difference is minimal.
10. **Solubility:** Ligand A (-2.481) has slightly worse solubility than Ligand B (-1.368), but both are poor. Solubility is a concern for both.
11. **hERG:** Ligand A (0.602) has a slightly higher hERG risk than Ligand B (0.234). This favors Ligand B.
12. **Cl_mic:** Ligand A (66.685) has a higher microsomal clearance than Ligand B (46.592), indicating lower metabolic stability. This favors Ligand B.
13. **t1/2:** Ligand A (-15.544) has a much more negative in vitro half-life than Ligand B (0.34), indicating a much shorter half-life. This is a significant disadvantage for Ligand A.
14. **Pgp:** Ligand A (0.296) has lower P-gp efflux than Ligand B (0.037), which is preferable.
15. **Binding Affinity:** Ligand B (-6.4 kcal/mol) has a slightly better binding affinity than Ligand A (-5.9 kcal/mol). While the difference is not huge, it is still a factor.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity) and the general guidelines, Ligand B appears to be the better candidate. While Ligand A has advantages in BBB and Pgp efflux, Ligand B has a significantly better DILI score, a better half-life, and slightly better affinity. The solubility and Caco-2 permeability are poor for both, but the metabolic stability and safety profile of Ligand B are more favorable. The slightly better binding affinity of Ligand B also tips the scales.
Output:
0
2025-04-17 18:50:13,332 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (340.39 Da) is well within the ideal range (200-500 Da). Ligand B (370.47 Da) is also acceptable. No clear advantage here.
2. **TPSA:** Ligand A (98.02) is slightly above the preferred <90 for CNS targets, but acceptable for a peripheral GPCR like ADRB2. Ligand B (58.2) is excellent, well below the 90 threshold. **Advantage: B**
3. **logP:** Ligand A (0.896) is a bit low, potentially hindering permeability. Ligand B (3.371) is within the optimal 1-3 range. **Advantage: B**
4. **HBD:** Ligand A (1) is good. Ligand B (2) is also acceptable. No significant difference.
5. **HBA:** Ligand A (5) is good. Ligand B (3) is also good. No significant difference.
6. **QED:** Ligand A (0.894) is excellent, indicating high drug-likeness. Ligand B (0.773) is still good, but lower. **Advantage: A**
7. **DILI:** Ligand A (58.67) is better, indicating lower liver injury risk, than Ligand B (43.12). **Advantage: A**
8. **BBB:** Ligand A (32.14) is low, as expected for a peripheral target. Ligand B (89.96) is very high. While ADRB2 isn't a primary CNS target, higher BBB penetration isn't detrimental and could allow for off-target effects. **Advantage: B**
9. **Caco-2:** Both ligands have negative values, indicating poor permeability. Ligand A (-5.261) is slightly worse than Ligand B (-4.729). **Advantage: B**
10. **Solubility:** Both ligands have negative solubility values, indicating poor solubility. Ligand A (-2.547) is slightly better than Ligand B (-3.82). **Advantage: A**
11. **hERG:** Ligand A (0.374) has a lower hERG risk than Ligand B (0.758). **Advantage: A**
12. **Cl_mic:** Ligand A (30.36) has lower microsomal clearance, suggesting better metabolic stability, than Ligand B (46.14). **Advantage: A**
13. **t1/2:** Ligand B (25.44) has a significantly longer half-life than Ligand A (-2.68). **Advantage: B**
14. **Pgp:** Ligand A (0.047) has lower P-gp efflux, which is favorable for bioavailability. Ligand B (0.316) is higher. **Advantage: A**
15. **Affinity:** Ligand A (-8.2 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.4 kcal/mol). This is a substantial advantage, potentially outweighing some ADME drawbacks. **Advantage: A**
**Overall Assessment:**
Ligand A has a significantly better binding affinity and favorable ADME properties (DILI, hERG, Cl_mic, Pgp). While Ligand B has better TPSA, logP, BBB, and t1/2, the substantial affinity advantage of Ligand A, combined with its superior safety profile (DILI, hERG) and metabolic stability, makes it the more promising candidate. The poor Caco-2 and solubility of both compounds are concerns, but can be addressed through formulation strategies. For a GPCR, affinity is paramount, and Ligand A's binding is considerably stronger.
Output:
1
2025-04-17 18:50:13,332 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (360.885) is slightly higher than Ligand B (346.479), but both are acceptable.
2. **TPSA:** Both are below the 140 A^2 threshold for good oral absorption. Ligand A (58.2) is slightly higher than Ligand B (57.5), but both are good.
3. **logP:** Ligand A (4.285) is higher than Ligand B (0.635). While 4.285 is approaching the upper limit, it's still acceptable. Ligand B's logP is quite low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (2) is better than Ligand B (0). Having some HBDs can improve solubility.
5. **HBA:** Ligand A (2) is better than Ligand B (6). Lower HBA is preferable for permeability.
6. **QED:** Ligand A (0.841) is significantly better than Ligand B (0.678), indicating a more drug-like profile.
7. **DILI:** Ligand A (49.128) is much better than Ligand B (13.61). Lower DILI risk is crucial.
8. **BBB:** Ligand A (78.868) is better than Ligand B (64.87). While ADRB2 isn't exclusively a CNS target, some BBB penetration can be beneficial for distribution.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-4.645) is slightly better than Ligand B (-4.856).
10. **Solubility:** Ligand A (-4.295) is better than Ligand B (0.017). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.532) is better than Ligand B (0.195). Lower hERG risk is critical for cardiovascular drugs.
12. **Cl_mic:** Ligand A (57.577) is much better than Ligand B (8.225). Lower clearance indicates better metabolic stability.
13. **t1/2:** Ligand A (54.14) is significantly better than Ligand B (-10.093). A longer half-life is generally desirable.
14. **Pgp:** Ligand A (0.349) is better than Ligand B (0.026). Lower P-gp efflux is preferable.
15. **Affinity:** Ligand A (-7.9 kcal/mol) is significantly better than Ligand B (-5.2 kcal/mol). This is a substantial difference in binding potency.
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A excels in these areas, particularly affinity. While BBB isn't paramount, Ligand A's higher value is a bonus.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical parameters, especially affinity, metabolic stability (Cl_mic, t1/2), DILI risk, and QED. While both have poor Caco-2 permeability, the superior binding affinity and favorable ADME properties of Ligand A outweigh this drawback.
Output:
1
2025-04-17 18:50:13,332 - INFO - Batch 66 complete. Total preferences: 1056
2025-04-17 18:50:13,332 - INFO - Processing batch 67/512...
2025-04-17 18:51:03,120 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (363.8 and 364.5 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand B (49.85) is significantly better than Ligand A (100.35). For a GPCR, lower TPSA is generally preferred for better permeability, and B is well below the 140 threshold. A is pushing the limit.
3. **logP:** Ligand B (2.903) is optimal, while Ligand A (0.918) is slightly low, potentially impacting membrane permeability.
4. **HBD:** Ligand A (2) is preferable to Ligand B (0). While both are acceptable, a small number of HBDs can aid in solubility without drastically impacting permeability.
5. **HBA:** Ligand A (6) is preferable to Ligand B (4). Similar to HBD, a moderate number of HBAs is generally favorable.
6. **QED:** Ligand A (0.844) is better than Ligand B (0.747), indicating a slightly more drug-like profile.
7. **DILI:** Ligand B (13.571) is *much* better than Ligand A (59.791). This is a critical advantage for B. A DILI percentile above 60 is concerning.
8. **BBB:** Ligand B (87.67) is significantly better than Ligand A (17.681). While ADRB2 isn't exclusively a CNS target, some CNS penetration can be beneficial, and a higher BBB percentile is generally desirable.
9. **Caco-2:** Ligand A (-5.299) is better than Ligand B (-4.676). Higher Caco-2 values indicate better absorption.
10. **Solubility:** Ligand A (-2.069) is better than Ligand B (-2.604). Solubility is important for formulation.
11. **hERG:** Ligand A (0.13) is better than Ligand B (0.55). Lower hERG inhibition is crucial for avoiding cardiotoxicity.
12. **Cl_mic:** Ligand B (49.889) is *much* better than Ligand A (-19). A positive value for A indicates rapid clearance, which is undesirable. B's value suggests better metabolic stability.
13. **t1/2:** Ligand B (26.645) is significantly better than Ligand A (-25.372). A longer half-life is generally preferred.
14. **Pgp:** Ligand A (0.036) is better than Ligand B (0.125). Lower P-gp efflux is desirable.
15. **Binding Affinity:** Ligand A (-7.8) is slightly better than Ligand B (-6.7). This is a 1.1 kcal/mol difference, which is significant, but needs to be weighed against the other ADME properties.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity and Caco-2 permeability, Ligand B overwhelmingly wins on ADME properties. The significantly lower DILI risk, much better metabolic stability (Cl_mic and t1/2), and superior BBB penetration are crucial advantages. The logP and TPSA values for Ligand B are also much more favorable. The slightly lower affinity of Ligand B can potentially be optimized in subsequent iterations, but mitigating the high DILI risk and poor metabolic stability of Ligand A would be far more challenging. Given the GPCR target class, the balance of properties favors Ligand B.
Output:
0
2025-04-17 18:51:03,120 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (373.446 and 346.431 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (72.91) is better than Ligand B (85.25). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (1.847) is slightly better than Ligand B (0.95), both are within the optimal 1-3 range. Ligand B is a bit low, potentially impacting permeability.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Both ligands have 5 HBA, which is acceptable.
6. **QED:** Ligand B (0.803) is better than Ligand A (0.562), indicating a more drug-like profile.
7. **DILI:** Ligand B (29.236) has a significantly lower DILI risk than Ligand A (40.054). This is a crucial advantage.
8. **BBB:** Ligand A (91.663) has a higher BBB penetration percentile than Ligand B (65.219). While not a primary concern for a cardiovascular target, it's a slight positive for Ligand A.
9. **Caco-2:** Ligand A (-4.406) is better than Ligand B (-5.021). Higher (less negative) Caco-2 values indicate better intestinal absorption.
10. **Solubility:** Both ligands have similar, very poor aqueous solubility (-2.44 and -2.415). This is a potential formulation challenge for both.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.429 and 0.114). This is good.
12. **Cl_mic:** Ligand A (11.308) has a lower microsomal clearance than Ligand B (24.437), indicating better metabolic stability.
13. **t1/2:** Ligand B (31.21) has a longer in vitro half-life than Ligand A (21.803). This is a positive for Ligand B.
14. **Pgp:** Ligand A (0.244) has lower P-gp efflux liability than Ligand B (0.024). Lower Pgp is generally better.
15. **Binding Affinity:** Ligand B (-6.8 kcal/mol) has a significantly stronger binding affinity than Ligand A (-1.6 kcal/mol). This is a *major* advantage, outweighing many of the ADME concerns. A 5.2 kcal/mol difference is substantial.
**GPCR-specific priorities:**
For a GPCR like ADRB2, affinity, logP, TPSA, and Pgp are key. Ligand B excels in affinity and has acceptable logP and TPSA. While Ligand A has better Pgp, the massive difference in binding affinity makes this less important. The lower DILI risk of Ligand B is also a significant benefit.
**Conclusion:**
Despite the slightly lower QED and BBB values, the significantly improved binding affinity and lower DILI risk of Ligand B make it the more promising drug candidate. The substantial difference in binding affinity is likely to translate to greater efficacy.
Output:
0
2025-04-17 18:51:03,120 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (357.797 Da) is slightly higher than Ligand B (329.363 Da), but both are acceptable.
2. **TPSA:** Ligand A (65.38) is better than Ligand B (72.7). Both are below the 140 threshold for oral absorption, but lower is preferable for GPCRs.
3. **logP:** Both ligands have good logP values (A: 3.296, B: 3.376), falling within the optimal 1-3 range.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Both have 5 HBA, which is good.
6. **QED:** Ligand A (0.778) has a better QED score than Ligand B (0.625), indicating a more drug-like profile.
7. **DILI:** Both ligands have high DILI risk (A: 80.729, B: 87.708), which is a concern. Ligand B is slightly worse.
8. **BBB:** Ligand A (65.335) has better BBB penetration than Ligand B (50.446). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant and a higher BBB score is generally favorable.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.929) is slightly better than Ligand B (-5.119).
10. **Solubility:** Ligand A (-4.635) has slightly better solubility than Ligand B (-3.504).
11. **hERG:** Ligand A (0.399) has a lower hERG risk than Ligand B (0.872). This is a significant advantage.
12. **Cl_mic:** Ligand B (34.759) has a significantly lower microsomal clearance than Ligand A (50.487), suggesting better metabolic stability.
13. **t1/2:** Ligand A (52.314) has a longer in vitro half-life than Ligand B (25.199). This is a positive attribute.
14. **Pgp:** Ligand A (0.441) has lower P-gp efflux than Ligand B (0.24), indicating better bioavailability.
15. **Binding Affinity:** Ligand B (-7.3 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.8 kcal/mol). This is a substantial advantage, exceeding the 1.5 kcal/mol threshold.
**Overall Assessment:**
The biggest differentiator is the binding affinity. Ligand B's -7.3 kcal/mol is a strong binding affinity and outweighs many of the other drawbacks. While Ligand A has better QED, BBB, hERG, and half-life, the potency advantage of Ligand B is too significant to ignore, especially for a GPCR target where high affinity is crucial. The DILI risk is high for both, but can be addressed in later optimization stages. The lower Cl_mic for Ligand B is also a benefit.
Output:
0
2025-04-17 18:51:03,120 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (351.407 and 340.383 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (133.26) is slightly higher than Ligand B (99.23). Ligand B is better, being closer to the <140 threshold for good oral absorption, and more favorable for a GPCR.
3. **logP:** Both ligands (1.572 and 1.496) are within the optimal 1-3 range. No significant difference.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1). Both are acceptable, but Ligand B is slightly preferred.
5. **HBA:** Both ligands (5) are within the acceptable limit of <=10. No significant difference.
6. **QED:** Ligand B (0.819) has a significantly higher QED score than Ligand A (0.312), indicating a more drug-like profile. This is a substantial advantage for Ligand B.
7. **DILI:** Ligand A (34.82) has a lower DILI risk than Ligand B (56.805). This is a significant advantage for Ligand A.
8. **BBB:** Ligand B (60.295) has a higher BBB penetration percentile than Ligand A (48.391). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be beneficial or at least manageable, making Ligand B slightly better.
9. **Caco-2:** Both ligands have very similar, poor Caco-2 permeability (-4.962 and -4.912). This is a concern for both, suggesting potential absorption issues.
10. **Solubility:** Ligand A (-1.653) has better aqueous solubility than Ligand B (-2.826). This is a slight advantage for Ligand A.
11. **hERG:** Ligand A (0.075) has a lower hERG inhibition liability than Ligand B (0.415). This is a significant advantage for Ligand A, as it reduces the risk of cardiotoxicity.
12. **Cl_mic:** Ligand B (39.417) has a lower microsomal clearance than Ligand A (45.03), indicating better metabolic stability. This is a slight advantage for Ligand B.
13. **t1/2:** Ligand B (4.855) has a longer in vitro half-life than Ligand A (-16.643). This is a substantial advantage for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.014) has a lower P-gp efflux liability than Ligand B (0.105), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand B (-7.0) has a significantly stronger binding affinity than Ligand A (-5.8). This is a major advantage, potentially outweighing some of the ADME drawbacks.
**Overall Assessment:**
Ligand B has a significantly better binding affinity and a longer half-life, and a superior QED score. While Ligand A has advantages in DILI and hERG, the binding affinity difference is substantial. The slightly better metabolic stability of Ligand B is also beneficial. The Caco-2 permeability is poor for both, but the stronger binding of Ligand B suggests it might be able to achieve sufficient target engagement despite this. Given that this is a GPCR target, the balance of properties leans towards Ligand B.
Output:
0
2025-04-17 18:51:03,121 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.403 and 346.427 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand B (82.78) is significantly better than Ligand A (104.65). For a GPCR, lower TPSA is generally preferred for better permeability.
3. **logP:** Ligand B (1.585) is better than Ligand A (0.716). Both are within the optimal 1-3 range, but Ligand B is closer to the sweet spot.
4. **HBD:** Both ligands have 2 HBD, which is acceptable.
5. **HBA:** Ligand B (4) is better than Ligand A (6). Lower HBA contributes to better permeability.
6. **QED:** Both ligands have similar QED values (0.717 and 0.7), indicating good drug-likeness.
7. **DILI:** Ligand B (19.504) has a much lower DILI risk than Ligand A (43.66). This is a significant advantage for Ligand B.
8. **BBB:** Both ligands have reasonable BBB penetration (Ligand A: 50.64, Ligand B: 46.762). Since ADRB2 is a cardiovascular target, BBB penetration isn't a primary concern, but it's still a positive attribute.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.883 and -4.484). These values are unusual and likely indicate poor permeability. However, the values are very similar.
10. **Solubility:** Ligand B (-2.463) is slightly better than Ligand A (-3.558), indicating better aqueous solubility.
11. **hERG:** Ligand B (0.237) has a lower hERG risk than Ligand A (0.068), which is a significant safety advantage.
12. **Cl_mic:** Ligand A (29.611) has lower microsomal clearance than Ligand B (37.918), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-4.95) has a longer in vitro half-life than Ligand A (1.183), which is a positive attribute.
14. **Pgp:** Ligand B (0.096) has lower P-gp efflux liability than Ligand A (0.064), which is favorable for bioavailability.
15. **Binding Affinity:** Both ligands have very similar and strong binding affinities (-6.3 and -6.0 kcal/mol). The difference is less than the 1.5 kcal/mol threshold.
**Overall Assessment:**
Ligand B consistently outperforms Ligand A in several key ADME properties (TPSA, logP, HBA, DILI, hERG, solubility, Pgp, and t1/2). While Ligand A has slightly better metabolic stability (Cl_mic), the improvements in safety (DILI, hERG) and permeability-related properties (TPSA, logP, HBA) offered by Ligand B are more critical for overall drug development success. The binding affinities are comparable, so the superior ADME profile of Ligand B makes it the more promising candidate.
Output:
0
2025-04-17 18:51:03,121 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [345.487, 68.02, 4.857, 1, 4, 0.728, 52.036, 75.805, -4.793, -5.595, 0.857, 93.795, 53.492, 0.504, -4.5]
**Ligand B:** [360.445, 58.64, 2.589, 1, 3, 0.759, 16.751, 83.831, -4.558, -2.172, 0.482, 20.422, -21.509, 0.054, -6.8]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, BBB, and affinity are key):
1. **MW:** Both are within the ideal 200-500 Da range. A (345.487) is slightly preferred.
2. **TPSA:** Both are good, below the 140 A^2 threshold. B (58.64) is better than A (68.02).
3. **logP:** A (4.857) is a bit high, potentially leading to off-target effects and solubility issues. B (2.589) is excellent, right in the sweet spot.
4. **HBD/HBA:** Both have 1 HBD which is good. A has 4 HBA and B has 3 HBA, both are acceptable.
5. **QED:** Both are above 0.5, indicating good drug-likeness. B (0.759) is slightly better.
6. **DILI:** A (52.036) is moderate, while B (16.751) is very good, indicating lower liver injury risk. This is a significant advantage for B.
7. **BBB:** Both have reasonable BBB penetration, but B (83.831) is better than A (75.805).
8. **Caco-2:** Both are negative, suggesting poor permeability.
9. **Solubility:** Both are negative, suggesting poor solubility.
10. **hERG:** A (0.857) is better than B (0.482) indicating lower risk of cardiotoxicity.
11. **Cl_mic:** A (93.795) has high metabolic clearance, suggesting rapid metabolism. B (20.422) has much lower clearance, indicating better metabolic stability.
12. **t1/2:** A (53.492) is okay, but B (-21.509) is very poor.
13. **Pgp:** A (0.504) is better than B (0.054), suggesting lower P-gp efflux.
14. **Affinity:** B (-6.8 kcal/mol) has a significantly stronger binding affinity than A (-4.5 kcal/mol). This 1.5+ kcal/mol difference is substantial and can outweigh some ADME concerns.
**Overall Assessment:**
While Ligand A has a slightly better MW and Pgp efflux profile, Ligand B overwhelmingly wins due to its superior logP, DILI risk, BBB penetration, metabolic stability (lower Cl_mic), and *significantly* stronger binding affinity. The lower hERG risk of A is a plus, but the affinity difference is too large to ignore. The poor Caco-2 and solubility of both are concerns, but can be addressed with formulation strategies.
Therefore, I recommend Ligand B.
0
2025-04-17 18:51:03,121 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (355.429 Da and 360.414 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (58.37) is significantly better than Ligand B (83.98). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is approaching a TPSA that could hinder oral absorption.
**3. logP:** Both ligands have good logP values (3.732 and 2.978), falling within the optimal 1-3 range. Ligand A is slightly higher, which could potentially lead to off-target effects, but the difference isn't drastic.
**4. H-Bond Donors:** Ligand A (1) is preferable to Ligand B (2). Fewer H-bond donors generally improve permeability.
**5. H-Bond Acceptors:** Ligand A (4) is preferable to Ligand B (5) for similar reasons as above.
**6. QED:** Both ligands have similar and acceptable QED values (0.722 and 0.776), indicating good drug-like properties.
**7. DILI Risk:** Ligand A (25.126) has a much lower DILI risk than Ligand B (83.482). This is a *major* advantage for Ligand A. DILI is a significant concern in drug development.
**8. BBB Penetration:** Ligand A (98.061) has excellent BBB penetration, while Ligand B (74.137) is lower. While ADRB2 is primarily a cardiovascular target, some CNS side effects are possible with GPCR ligands, and higher BBB penetration could contribute to this.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale isn't specified, so it's hard to interpret.
**10. Aqueous Solubility:** Both ligands have negative solubility values, which is also unusual. Again, the scale is unspecified, making interpretation difficult.
**11. hERG Inhibition:** Ligand A (0.944) has a slightly higher hERG risk than Ligand B (0.224). This is a concern, but the difference isn't huge.
**12. Microsomal Clearance:** Ligand A (26.052) has significantly lower microsomal clearance than Ligand B (46.092), indicating better metabolic stability.
**13. In vitro Half-Life:** Ligand A (-17.456) has a negative half-life, which is not possible. This is a data error. Ligand B (39.751) has a reasonable half-life.
**14. P-gp Efflux:** Ligand A (0.575) has lower P-gp efflux than Ligand B (0.113), which is beneficial for bioavailability.
**15. Binding Affinity:** Ligand A (-7.3) has a slightly better binding affinity than Ligand B (-5.1). This is a significant advantage, as a 1.5 kcal/mol difference can outweigh some ADME drawbacks.
**Overall Assessment:**
Despite the negative values for Caco-2 and solubility, Ligand A is the clear preference. The significantly lower DILI risk, better metabolic stability (lower Cl_mic), excellent BBB penetration, and superior binding affinity outweigh the slightly higher hERG risk. The negative half-life for Ligand A is a data error, but even ignoring that, the other factors strongly favor Ligand A. Ligand B's high DILI risk is a major red flag.
Output:
1
2025-04-17 18:51:03,121 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [351.422, 66.65, 2.289, 0, 4, 0.835, 24.855, 88.174, -4.486, -2.448, 0.451, 43.687, -2.584, 0.134, -5.9]
**Ligand B:** [347.419, 93.26, 1.448, 1, 6, 0.78, 52.346, 61.535, -4.878, -0.967, 0.151, 51.236, -5.112, 0.024, -6.7]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (351.422) is slightly higher than Ligand B (347.419), but the difference is negligible.
2. **TPSA:** Ligand A (66.65) is significantly better than Ligand B (93.26). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is pushing the upper limit for good oral absorption.
3. **logP:** Ligand A (2.289) is optimal, while Ligand B (1.448) is a bit low. A slightly lower logP can sometimes be compensated for, but it might affect permeability.
4. **HBD:** Ligand A (0) is preferable to Ligand B (1). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is better than Ligand B (6). Lower HBA counts contribute to better permeability.
6. **QED:** Ligand A (0.835) is better than Ligand B (0.78), indicating a more drug-like profile.
7. **DILI:** Ligand A (24.855) has a much lower DILI risk than Ligand B (52.346). This is a significant advantage.
8. **BBB:** Ligand A (88.174) has a significantly higher BBB penetration potential than Ligand B (61.535). While ADRB2 isn't exclusively a CNS target, some cardiovascular effects are mediated by central pathways, and higher BBB penetration can be advantageous.
9. **Caco-2:** Both are negative values, indicating poor permeability. However, Ligand A (-4.486) is slightly better than Ligand B (-4.878).
10. **Solubility:** Ligand B (-0.967) is better than Ligand A (-2.448). Solubility is important, but can often be addressed with formulation strategies.
11. **hERG:** Both are very low, indicating minimal hERG inhibition risk. Ligand A (0.451) is slightly better than Ligand B (0.151).
12. **Cl_mic:** Ligand A (43.687) has lower microsomal clearance than Ligand B (51.236), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-5.112) has a longer in vitro half-life than Ligand A (-2.584). This is a positive for Ligand B.
14. **Pgp:** Ligand A (0.134) has lower P-gp efflux than Ligand B (0.024), meaning better absorption and bioavailability.
15. **Binding Affinity:** Ligand B (-6.7) has a slightly better binding affinity than Ligand A (-5.9). This is a 0.8 kcal/mol difference, which is noteworthy, but not overwhelming.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity) and the general drug-likeness criteria, Ligand A is the more promising candidate. While Ligand B has a slightly better binding affinity and half-life, Ligand A excels in crucial ADME properties like TPSA, DILI risk, BBB penetration, and P-gp efflux. The lower TPSA and DILI risk are particularly important, and the better BBB penetration could be beneficial. The slightly lower affinity of Ligand A can likely be optimized in subsequent iterations of drug design.
Output:
1
2025-04-17 18:51:03,122 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (366.439 Da and 367.837 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (83.99) is significantly better than Ligand B (121.18). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is above the preferred <140, and approaching a level that could hinder absorption.
**3. logP:** Both ligands have acceptable logP values (1.169 and 0.726), falling within the 1-3 range. Ligand A is slightly more lipophilic, which could be advantageous for membrane permeability.
**4. H-Bond Donors:** Ligand A (0) is preferable to Ligand B (3). Fewer H-bond donors generally improve permeability.
**5. H-Bond Acceptors:** Both ligands have 5 H-bond acceptors, which is acceptable.
**6. QED:** Both ligands have similar QED scores (0.747 and 0.708), indicating good drug-likeness.
**7. DILI Risk:** Ligand B (53.47) has a lower DILI risk than Ligand A (65.568), which is a positive attribute.
**8. BBB Penetration:** Ligand A (89.104) shows significantly better BBB penetration potential than Ligand B (71.501). While ADRB2 is primarily a cardiovascular target, some CNS effects are possible with certain ligands, and higher BBB penetration isn't necessarily a negative.
**9. Caco-2 Permeability:** Ligand A (-4.497) has a better Caco-2 permeability than Ligand B (-5.666).
**10. Aqueous Solubility:** Both ligands have very poor aqueous solubility (-3.385 and -3.565). This is a significant drawback for both, and would require formulation strategies to address.
**11. hERG Inhibition:** Ligand A (0.401) has a slightly higher hERG inhibition risk than Ligand B (0.194), but both are relatively low.
**12. Microsomal Clearance:** Ligand B (2.611) has a much lower microsomal clearance than Ligand A (61.519), indicating better metabolic stability. This is a major advantage for Ligand B.
**13. In vitro Half-Life:** Ligand B (-18.326) has a dramatically longer in vitro half-life than Ligand A (-5.751). This is a significant benefit for Ligand B, potentially allowing for less frequent dosing.
**14. P-gp Efflux:** Both ligands show very low P-gp efflux liability (0.087 and 0.017).
**15. Binding Affinity:** Ligand B (-6.6 kcal/mol) has a slightly stronger binding affinity than Ligand A (-5.6 kcal/mol). This 1 kcal/mol difference is substantial and can outweigh some of the ADME drawbacks.
**Overall Assessment:**
Ligand B is the better candidate. While Ligand A has better TPSA and BBB penetration, Ligand B excels in metabolic stability (lower Cl_mic, longer t1/2) and binding affinity. The lower DILI risk of Ligand B is also a positive. The solubility issues are a concern for both, but can be addressed through formulation. The improved affinity and pharmacokinetic profile of Ligand B make it more likely to succeed as a drug candidate.
Output:
0
2025-04-17 18:51:03,122 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, priorities are logP, TPSA, Pgp, affinity, and to a lesser extent, BBB.
* **Molecular Weight:** Both ligands are within the ideal range (200-500 Da).
* **TPSA:** Ligand A (35.58) is significantly better than Ligand B (62.61). A TPSA under 140 is good for oral absorption, and lower is generally preferred for GPCRs. Ligand A is much closer to the ideal for CNS penetration, though that's less critical here.
* **logP:** Both ligands have good logP values (A: 3.138, B: 2.167), falling within the 1-3 range.
* **H-Bond Donors/Acceptors:** Both are reasonable. Ligand B has slightly more H-bonds, which could slightly hinder permeability.
* **QED:** Both are good (A: 0.808, B: 0.836), indicating drug-like properties.
* **DILI:** Ligand A (47.034) is better than Ligand B (60.682), indicating a lower risk of drug-induced liver injury.
* **BBB:** Ligand B (87.088) has a higher BBB penetration percentile than Ligand A (74.292), but this isn't a primary concern for a cardiovascular target.
* **Caco-2 Permeability:** Both are negative, indicating poor permeability. Ligand A (-4.824) is slightly better than Ligand B (-4.687).
* **Aqueous Solubility:** Both are negative, indicating poor solubility. Ligand A (-4.043) is slightly better than Ligand B (-3.348).
* **hERG:** Ligand A (0.881) is better than Ligand B (0.451), indicating lower hERG inhibition risk.
* **Microsomal Clearance:** Ligand B (11.311) has much lower clearance than Ligand A (77.03), suggesting better metabolic stability. This is a significant advantage for Ligand B.
* **In vitro Half-Life:** Ligand A (15.302) has a better half-life than Ligand B (-2.971).
* **P-gp Efflux:** Ligand A (0.579) is better than Ligand B (0.031), indicating less P-gp efflux.
* **Binding Affinity:** Ligand A (-7.1) has a significantly stronger binding affinity than Ligand B (-6.6). This 1.5 kcal/mol difference is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand A has a superior binding affinity, better TPSA, lower DILI risk, lower hERG risk, and better P-gp efflux. Ligand B has better metabolic stability (lower Cl_mic) and slightly better BBB penetration, but the affinity difference is crucial for a GPCR target. The slightly better metabolic stability of Ligand B is a concern, but the stronger binding of Ligand A is likely to translate to a lower required dose, potentially mitigating metabolic concerns. The TPSA and P-gp properties of Ligand A are also more favorable for oral bioavailability.
**Output:**
1
2025-04-17 18:51:03,122 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.547 and 343.431 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (49.41) is significantly better than Ligand B (80.12). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold, while Ligand B is approaching it.
3. **logP:** Ligand A (3.704) is optimal, while Ligand B (0.989) is a bit low. A logP below 1 can hinder membrane permeability. This favors Ligand A.
4. **HBD:** Both have 1 HBD, which is acceptable.
5. **HBA:** Ligand A has 2 HBA, Ligand B has 5. Ligand A is preferable.
6. **QED:** Both ligands have good QED scores (0.725 and 0.781), indicating good drug-like properties.
7. **DILI:** Ligand A (17.72) has a much lower DILI risk than Ligand B (32.067). This is a significant advantage for Ligand A.
8. **BBB:** Both have reasonably high BBB penetration (79.449 and 70.027), but this isn't a primary concern for a cardiovascular target.
9. **Caco-2:** Ligand A (-4.443) is better than Ligand B (-5.114), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-4.31) is better than Ligand B (-1.471), indicating better aqueous solubility.
11. **hERG:** Ligand A (0.619) is better than Ligand B (0.067), indicating lower hERG inhibition liability. This is a crucial safety parameter.
12. **Cl_mic:** Ligand B (18.521) has a lower microsomal clearance than Ligand A (88.083), suggesting better metabolic stability. This favors Ligand B.
13. **t1/2:** Ligand A (16.49) has a longer in vitro half-life than Ligand B (-2.059). This is a major advantage for Ligand A.
14. **Pgp:** Ligand A (0.31) has lower P-gp efflux liability than Ligand B (0.036), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand B (-6.8) has a slightly better binding affinity than Ligand A (-6.5). While a 1.5 kcal/mol difference is usually significant, the other advantages of Ligand A outweigh this.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A is better in logP, TPSA, and Pgp. The affinity difference is minimal.
**Overall Assessment:**
Ligand A demonstrates a significantly better overall profile, particularly regarding safety (DILI, hERG), absorption (TPSA, Caco-2, Solubility), and metabolic stability (t1/2). While Ligand B has slightly better affinity and lower Cl_mic, the other advantages of Ligand A are more critical for a viable drug candidate.
Output:
1
2025-04-17 18:51:03,122 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (345.443 and 351.422 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (62.74) is significantly better than Ligand B (91.32). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is approaching the upper limit for good oral absorption.
**3. logP:** Both ligands have acceptable logP values (2.871 and 1.844), falling within the 1-3 range. Ligand B is slightly lower, which *could* indicate slightly better solubility, but it's not a major concern for either.
**4. H-Bond Donors:** Ligand A has 0 HBD, which is excellent. Ligand B has 3, which is still acceptable but less ideal.
**5. H-Bond Acceptors:** Both ligands have 4 HBA, which is within the acceptable range.
**6. QED:** Both ligands have similar QED values (0.79 and 0.755), indicating good drug-likeness.
**7. DILI:** Both ligands have low DILI risk (46.258 and 44.862), which is positive.
**8. BBB:** Ligand A has a much higher BBB penetration percentile (81.233) compared to Ligand B (60.45). While ADRB2 is a cardiovascular target, some CNS effects are possible with beta-blockers, and higher BBB penetration could be relevant for off-target effects or potential CNS side effects.
**9. Caco-2 Permeability:** Ligand A (-4.255) has a better (more positive) Caco-2 value than Ligand B (-4.72), suggesting better intestinal absorption.
**10. Aqueous Solubility:** Ligand A (-2.027) has slightly better solubility than Ligand B (-1.898), but both are quite poor. This could be a formulation challenge.
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.353 and 0.189), which is excellent.
**12. Microsomal Clearance:** Ligand B has significantly lower microsomal clearance (2.851) than Ligand A (60.761). This suggests better metabolic stability for Ligand B, a significant advantage.
**13. In vitro Half-Life:** Ligand A has a much longer in vitro half-life (-6.276) than Ligand B (1.431). This is a major advantage for Ligand A.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.081 and 0.031), which is good.
**15. Binding Affinity:** Ligand B (-7.2 kcal/mol) has a slightly better binding affinity than Ligand A (-7.6 kcal/mol). While the difference is small, it's still a factor.
**Overall Assessment:**
Ligand A excels in permeability (TPSA, Caco-2), BBB penetration, and in vitro half-life. However, Ligand B demonstrates superior metabolic stability (lower Cl_mic) and slightly better binding affinity. Considering the GPCR-specific priorities, the balance leans towards Ligand A. The better permeability and longer half-life are more critical for a GPCR target than a slight improvement in metabolic stability. The higher BBB penetration isn't necessarily a negative for a cardiovascular target.
Output:
1
2025-04-17 18:51:03,122 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Step-by-step comparison:**
1. **MW:** Both ligands (341.371 and 345.447 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Both ligands (109.04 and 110.00) are slightly above the optimal <140 for oral absorption, but still reasonable. No clear advantage.
3. **logP:** Both ligands (1.253 and 1.533) are within the optimal 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Ligand A (2) is preferable to Ligand B (3). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (6) is preferable to Ligand B (5). Lower HBA generally improves permeability.
6. **QED:** Ligand A (0.788) has a significantly better QED score than Ligand B (0.588), indicating a more drug-like profile.
7. **DILI:** Ligand B (46.258) has a considerably lower DILI risk than Ligand A (70.725). This is a significant advantage for Ligand B.
8. **BBB:** Ligand B (76.347) shows better BBB penetration potential than Ligand A (55.913). While ADRB2 isn't strictly a CNS target, some CNS exposure can occur, and better BBB penetration is generally favorable.
9. **Caco-2:** Both ligands have negative Caco-2 values, suggesting poor permeability. Ligand B (-5.052) is slightly better than Ligand A (-4.889).
10. **Solubility:** Both ligands have negative solubility values, indicating poor solubility. Ligand B (-3.058) is slightly better than Ligand A (-3.411).
11. **hERG:** Both ligands have low hERG inhibition risk (0.283 and 0.325). No significant difference.
12. **Cl_mic:** Ligand B (34.85) has slightly lower microsomal clearance than Ligand A (37.204), suggesting better metabolic stability.
13. **t1/2:** Ligand A (9.403) has a significantly longer in vitro half-life than Ligand B (-27.489). This is a major advantage for Ligand A.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.057 and 0.041). No significant difference.
15. **Binding Affinity:** Ligand B (-7.2 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.7 kcal/mol). This is a substantial advantage, potentially outweighing some ADME drawbacks.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, and affinity are key. Ligand B excels in affinity, and has a slightly better logP. While both have acceptable TPSA, the superior affinity of Ligand B is a crucial factor. The better BBB penetration of Ligand B is a bonus.
**Overall Assessment:**
While Ligand A has a better QED and half-life, the significantly stronger binding affinity of Ligand B (-7.2 vs -5.7 kcal/mol) and lower DILI risk are more critical for a viable drug candidate. The slightly better logP and BBB penetration of Ligand B further support its selection. The poor Caco-2 and solubility of both ligands are concerning, but can be addressed through formulation strategies.
**Output:**
0
2025-04-17 18:51:03,123 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (364.873 Da) is within the ideal range (200-500 Da), while Ligand B (387.527 Da) is also acceptable. No clear advantage here.
2. **TPSA:** Ligand A (67.43) is excellent, well below the 140 threshold for oral absorption. Ligand B (91.76) is still reasonable but less optimal. This favors Ligand A.
3. **logP:** Ligand A (3.159) is within the optimal range (1-3). Ligand B (1.229) is a bit low, potentially hindering membrane permeability. This favors Ligand A.
4. **HBD:** Both ligands have 2 HBD, which is good.
5. **HBA:** Ligand A has 3 HBA, while Ligand B has 7. Ligand A is preferred due to the lower HBA count, which generally improves permeability.
6. **QED:** Both ligands have good QED scores (A: 0.522, B: 0.684), indicating drug-like properties. Ligand B is slightly better here.
7. **DILI:** Ligand A (24.893) has a significantly lower DILI risk than Ligand B (66.421). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (69.523) has a good BBB penetration score, while Ligand B (17.72) is very low. Given ADRB2 is a GPCR, BBB penetration is a consideration, favoring Ligand A.
9. **Caco-2:** Ligand A (-4.704) and Ligand B (-5.067) are both very poor.
10. **Solubility:** Ligand A (-3.718) is better than Ligand B (-2.833), although both are poor.
11. **hERG:** Ligand A (0.728) has a lower hERG risk than Ligand B (0.328), which is preferable.
12. **Cl_mic:** Ligand B (16.161) has a significantly lower microsomal clearance than Ligand A (33.535), suggesting better metabolic stability. This favors Ligand B.
13. **t1/2:** Ligand A (54.722) has a longer in vitro half-life than Ligand B (-6.101). This favors Ligand A.
14. **Pgp:** Ligand A (0.243) has lower P-gp efflux than Ligand B (0.142), which is preferable.
15. **Affinity:** Ligand B (-6.5 kcal/mol) has a slightly better binding affinity than Ligand A (-5.9 kcal/mol). This is a positive for Ligand B, but the difference is not substantial.
**Overall Assessment:**
Ligand A demonstrates a better balance of properties, especially considering the GPCR target class. While Ligand B has slightly better affinity and metabolic stability, Ligand A excels in TPSA, logP, DILI risk, BBB penetration, and hERG risk. The lower DILI risk and better BBB penetration are particularly important for a potentially chronically administered cardiovascular drug. The slightly weaker affinity of Ligand A can likely be optimized in subsequent iterations.
Output:
1
2025-04-17 18:51:03,123 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (a cardiovascular GPCR) drug candidates.
**Ligand A:** [346.435, 106.14 , 0.856, 2. , 6. , 0.645, 34.277, 72.586, -5.612, -2.239, 0.101, 19.69 , -13.484, 0.014, -6.6 ]
**Ligand B:** [366.849, 97.55 , 1.463, 2. , 5. , 0.794, 59.403, 80.264, -5.083, -3.226, 0.408, -0.657, 2.218, 0.027, -5. ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). A (346.435) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are good, under 140. B (97.55) is slightly better, closer to the optimal for GPCRs.
3. **logP:** Both are within the optimal range (1-3). B (1.463) is slightly higher, which could be beneficial for membrane permeability, but A (0.856) is still acceptable.
4. **HBD:** Both have 2 HBD, which is good.
5. **HBA:** A has 6, B has 5. Both are within the acceptable limit of 10.
6. **QED:** Both are above 0.5, indicating good drug-likeness. B (0.794) is slightly better.
7. **DILI:** A (34.277) has a significantly lower DILI risk than B (59.403). This is a major advantage for A.
8. **BBB:** Both have good BBB penetration, but B (80.264) is slightly better than A (72.586). For a cardiovascular GPCR, BBB isn't *critical*, but higher is still preferred.
9. **Caco-2:** Both are negative, indicating poor permeability. A (-5.612) is worse than B (-5.083).
10. **Solubility:** Both are negative, indicating poor solubility. B (-3.226) is slightly better than A (-2.239).
11. **hERG:** Both are very low, indicating minimal hERG inhibition risk. A (0.101) is slightly better.
12. **Cl_mic:** A (19.69) has a higher microsomal clearance than B (-0.657), suggesting lower metabolic stability. This is a significant drawback for A.
13. **t1/2:** A (-13.484) has a much shorter in vitro half-life than B (2.218), further reinforcing the metabolic stability concern.
14. **Pgp:** Both are very low, indicating minimal P-gp efflux. A (0.014) is slightly better than B (0.027).
15. **Affinity:** Both have excellent binding affinity (-6.6 and -5 kcal/mol respectively). A (-6.6) is 1.6 kcal/mol better than B, which is a substantial advantage.
**GPCR-Specific Considerations:**
For ADRB2 (a cardiovascular GPCR), we prioritize logP, TPSA, Pgp, and affinity. While BBB is less critical than for CNS targets, it's still a plus.
**Overall Assessment:**
Ligand A has a significantly better binding affinity and lower DILI risk, and slightly better Pgp and hERG. However, it suffers from significantly worse metabolic stability (higher Cl_mic and shorter t1/2) and poorer Caco-2 permeability. Ligand B has better metabolic stability, slightly better BBB penetration, and slightly better Caco-2 and solubility. The difference in affinity is substantial, but the metabolic liabilities of A are concerning.
Considering the balance, the superior binding affinity of Ligand A is a significant advantage that outweighs the metabolic concerns, especially given that metabolic stability can be improved through structural modifications. The lower DILI risk is also a strong positive.
Output:
1
2025-04-17 18:51:03,123 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (361.848 Da) is slightly higher than Ligand B (345.443 Da), but both are acceptable.
2. **TPSA:** Ligand A (45.23) is significantly better than Ligand B (71.53). For a GPCR, lower TPSA is generally preferred for better permeability. Ligand B is quite high and could present absorption challenges.
3. **logP:** Ligand A (4.763) is higher than Ligand B (1.868). While Ligand A is at the upper end of the optimal range, it's still acceptable. Ligand B is on the lower side, potentially hindering membrane permeability.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 2 HBA, while Ligand B has 4. Both are within the acceptable limit of 10, but Ligand A is preferred.
6. **QED:** Both ligands have similar QED values (0.783 and 0.766), indicating good drug-likeness.
7. **DILI:** Ligand A (60.14) has a higher DILI risk than Ligand B (25.824). This is a significant drawback for Ligand A.
8. **BBB:** Ligand A (85.072) has better BBB penetration than Ligand B (63.086). While ADRB2 isn't exclusively a CNS target, some CNS exposure can occur, and higher BBB is generally favorable.
9. **Caco-2:** Both ligands have similar, poor Caco-2 permeability (-4.6 and -4.514). This suggests potential absorption issues for both.
10. **Solubility:** Ligand A (-6.356) has worse solubility than Ligand B (-2.039). Solubility is important for bioavailability, making Ligand B preferable.
11. **hERG:** Both ligands have low hERG inhibition risk (0.35 and 0.259).
12. **Cl_mic:** Ligand A (74.31) has higher microsomal clearance than Ligand B (27.47). This indicates lower metabolic stability for Ligand A, a significant negative.
13. **t1/2:** Ligand B (3.752) has a longer in vitro half-life than Ligand A (-0.978). This is a clear advantage for Ligand B.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.269 and 0.03).
15. **Binding Affinity:** Ligand A (-7.0) has slightly better binding affinity than Ligand B (-4.8). This is a 2.2 kcal/mol difference, which is substantial and could potentially outweigh some ADME concerns.
**Overall Assessment:**
Ligand A has a better binding affinity and BBB penetration, but suffers from higher DILI risk, higher clearance, and lower solubility. Ligand B has a better safety profile (lower DILI), better solubility, better metabolic stability (lower clearance, longer half-life) and a lower logP. Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), and balancing potency with ADME properties, Ligand B appears to be the more promising candidate. The significant difference in DILI and metabolic stability are major concerns for Ligand A, even with the slightly better affinity. The TPSA of Ligand B is a concern, but the other factors outweigh this.
Output:
0
2025-04-17 18:51:03,123 - INFO - Batch 67 complete. Total preferences: 1072
2025-04-17 18:51:03,123 - INFO - Processing batch 68/512...
2025-04-17 18:51:54,465 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [374.497, 32.78, 4.257, 0, 4, 0.746, 24.855, 92.478, -4.515, -3.355, 0.932, 62.819, 21.945, 0.739, -6.6]
**Ligand B:** [351.535, 43.86, 2.77, 0, 3, 0.569, 11.632, 75.727, -4.607, -1.397, 0.765, 48.438, 20.593, 0.274, -6.8]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (351.535) is slightly lower, which could be beneficial for permeability, but both are acceptable.
2. **TPSA:** Ligand A (32.78) is better than Ligand B (43.86). ADRB2 is not a CNS target, but lower TPSA generally improves absorption.
3. **logP:** Ligand A (4.257) is a bit high, potentially leading to solubility issues or off-target interactions. Ligand B (2.77) is within the optimal range. This favors Ligand B.
4. **HBD:** Both have 0 HBD, which is good.
5. **HBA:** Ligand A (4) is slightly higher than Ligand B (3), but both are acceptable.
6. **QED:** Ligand A (0.746) has a better QED score than Ligand B (0.569), indicating a more drug-like profile.
7. **DILI:** Ligand A (24.855) has a significantly lower DILI risk than Ligand B (11.632). This is a major advantage for Ligand A.
8. **BBB:** Not a primary concern for a cardiovascular target, but Ligand A (92.478) has a higher BBB penetration than Ligand B (75.727).
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. This is a significant drawback for both.
10. **Solubility:** Ligand B (-1.397) has better solubility than Ligand A (-3.355).
11. **hERG:** Both have low hERG risk scores (0.932 and 0.765).
12. **Cl_mic:** Ligand B (48.438) has a lower microsomal clearance than Ligand A (62.819), suggesting better metabolic stability.
13. **t1/2:** Similar in vitro half-lives (21.945 vs 20.593).
14. **Pgp:** Ligand A (0.739) has lower P-gp efflux than Ligand B (0.274), which is favorable for bioavailability.
15. **Affinity:** Ligand B (-6.8) has slightly better binding affinity than Ligand A (-6.6), but the difference is small (0.2 kcal/mol).
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B has a better logP and slightly better affinity. However, Ligand A has a significantly better DILI score, better QED, and lower Pgp efflux. The Caco-2 permeability is poor for both, which is a concern.
**Overall Assessment:**
While Ligand B has a slightly better affinity and logP, the significantly lower DILI risk and better QED of Ligand A are more important considerations. The slightly better Pgp profile of Ligand A is also a plus. The poor Caco-2 values are a concern for both, but can be addressed with formulation strategies. Given the balance of properties, Ligand A appears to be the more promising candidate.
Output:
1
2025-04-17 18:51:54,466 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (372.491 Da) is slightly higher than Ligand B (343.427 Da), but both are acceptable.
2. **TPSA:** Ligand A (116.4) is higher than Ligand B (75.48). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B is significantly better here.
3. **logP:** Ligand A (-0.082) is quite low, potentially hindering permeability. Ligand B (3.205) is within the optimal range (1-3). This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (4) is higher than Ligand B (1). While both are within the acceptable limit of 5, lower HBD is generally preferred for better permeability. Ligand B is better.
5. **HBA:** Both ligands have 4 HBA, which is acceptable.
6. **QED:** Ligand A (0.5) is slightly better than Ligand B (0.424), indicating a marginally more drug-like profile.
7. **DILI:** Both ligands have relatively low DILI risk (Ligand A: 44.591, Ligand B: 41.411), and are both below the 60% threshold.
8. **BBB:** Ligand A (52.579) has lower BBB penetration than Ligand B (82.435). While ADRB2 isn't a CNS target, some degree of BBB penetration can be a concern for off-target effects.
9. **Caco-2:** Ligand A (-5.51) is worse than Ligand B (-4.627), indicating lower intestinal absorption.
10. **Solubility:** Ligand A (-2.399) is worse than Ligand B (-4.1), indicating lower aqueous solubility.
11. **hERG:** Both ligands have low hERG inhibition risk (Ligand A: 0.149, Ligand B: 0.581).
12. **Cl_mic:** Ligand A (17.31) exhibits lower microsomal clearance than Ligand B (71.107), suggesting better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (-1.206) has a negative half-life, which is concerning. Ligand B (13.412) has a much better in vitro half-life.
14. **Pgp:** Ligand A (0.025) has lower P-gp efflux than Ligand B (0.083), which is favorable for bioavailability.
15. **Affinity:** Both ligands have very similar binding affinities (-6.4 kcal/mol and -6.3 kcal/mol). The difference is negligible.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, and Pgp are important. Ligand B excels in logP and TPSA, and is comparable in Pgp. Ligand A has better Cl_mic and Pgp, but suffers from a very low logP and poor solubility. The negative half-life for Ligand A is also a major concern.
**Overall Assessment:**
While Ligand A has better metabolic stability and Pgp properties, its very low logP, poor solubility, and negative half-life are significant drawbacks. Ligand B, despite slightly higher metabolic clearance, has a much more favorable profile overall, with a good logP, lower TPSA, and a reasonable half-life.
Output:
0
2025-04-17 18:51:54,466 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [345.395, 99.77, 2.56, 3, 5, 0.773, 53.044, 34.548, -4.938, -4.84, 0.569, 30.032, 14.091, 0.514, -7.7]
**Ligand B:** [339.439, 79.45, 2.387, 2, 4, 0.88, 29.779, 54.44, -5.18, -1.992, 0.411, -11.233, 14.677, 0.059, -6]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (339.439) is slightly lower, which is a minor advantage.
2. **TPSA:** Ligand A (99.77) is higher than Ligand B (79.45). Ligand B is better here, being closer to the <140 threshold for good absorption.
3. **logP:** Both are excellent (around 2.4-2.6), falling within the optimal 1-3 range. No significant difference.
4. **HBD/HBA:** Ligand A has 3 HBD and 5 HBA, while Ligand B has 2 HBD and 4 HBA. Both are acceptable, but Ligand B is slightly better with fewer H-bonds.
5. **QED:** Ligand B (0.88) has a better QED score than Ligand A (0.773), indicating a more drug-like profile.
6. **DILI:** Ligand B (29.779) has a significantly lower DILI risk than Ligand A (53.044). This is a major advantage for Ligand B.
7. **BBB:** Ligand B (54.44) has a better BBB penetration score than Ligand A (34.548), though neither are exceptionally high. For a cardiovascular target, BBB isn't *critical*, but it's still a positive.
8. **Caco-2:** Ligand A (-4.938) is better than Ligand B (-5.18).
9. **Solubility:** Ligand B (-1.992) is better than Ligand A (-4.84).
10. **hERG:** Ligand A (0.569) has a slightly better hERG profile than Ligand B (0.411), but both are relatively low risk.
11. **Cl_mic:** Ligand B (-11.233) has a *much* lower (better) microsomal clearance than Ligand A (30.032). This suggests greater metabolic stability for Ligand B.
12. **t1/2:** Ligand B (14.677) has a slightly longer in vitro half-life than Ligand A (14.091).
13. **Pgp:** Ligand A (0.514) has a slightly higher Pgp efflux liability than Ligand B (0.059). Lower Pgp is preferred.
14. **Affinity:** Ligand A (-7.7 kcal/mol) has a better binding affinity than Ligand B (-6 kcal/mol). This is a significant advantage, a difference of 1.7 kcal/mol.
**Overall Assessment:**
While Ligand A boasts a better binding affinity, Ligand B demonstrates a superior ADME profile. Specifically, the lower DILI risk, better metabolic stability (lower Cl_mic), lower Pgp efflux, and better QED score are compelling advantages. The difference in affinity, while noticeable, can potentially be optimized in later stages of drug development. Considering the GPCR-specific priorities, the improved ADME properties of Ligand B outweigh the slightly stronger binding of Ligand A.
Output:
0
2025-04-17 18:51:54,466 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (368.46 and 361.51 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (93.65) is higher than Ligand B (53.68). For a GPCR, lower TPSA is generally preferred for better BBB penetration, giving a slight edge to Ligand B.
3. **logP:** Ligand B (4.208) is higher than Ligand A (1.037). While logP > 4 can be problematic, it's not excessively high here. Ligand A's logP is quite low, potentially hindering membrane permeability. Ligand B has an advantage.
4. **HBD:** Both ligands have 1 HBD, which is within the acceptable range.
5. **HBA:** Ligand A (7) has more HBAs than Ligand B (4). Lower HBA is generally preferable for permeability, favoring Ligand B.
6. **QED:** Ligand B (0.803) has a significantly better QED score than Ligand A (0.541), indicating a more drug-like profile. This is a substantial advantage for Ligand B.
7. **DILI:** Both ligands have similar DILI risk (56.57 vs 54.79 percentile), and both are acceptable.
8. **BBB:** Ligand A (69.72) has a slightly better BBB percentile than Ligand B (61.61), but both are not exceptionally high.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-2.238) has better solubility than Ligand B (-4.468). Solubility is important, but can be addressed with formulation strategies.
11. **hERG:** Ligand A (0.167) has a lower hERG risk than Ligand B (0.884), which is a significant advantage. Cardiotoxicity is a major concern.
12. **Cl_mic:** Ligand B (82.02) has a significantly higher microsomal clearance than Ligand A (28.69). This means Ligand A is more metabolically stable, a key advantage.
13. **t1/2:** Ligand B (107.31) has a much longer in vitro half-life than Ligand A (10.28). This is a significant benefit for dosing frequency.
14. **Pgp:** Ligand A (0.022) has much lower P-gp efflux than Ligand B (0.856). Lower P-gp is favorable for bioavailability.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.3 and -6.1 kcal/mol). The difference is not substantial enough to be decisive.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are particularly important. Ligand B has a better logP and lower TPSA, but Ligand A has better Pgp and hERG. The longer half-life of Ligand B is also very attractive.
**Overall Assessment:**
While Ligand A has advantages in hERG and metabolic stability, Ligand B's superior QED, better logP, and significantly longer half-life outweigh these concerns. The slightly lower hERG and higher Pgp efflux of Ligand B can potentially be mitigated through structural modifications. The improved drug-likeness and pharmacokinetic profile of Ligand B make it the more promising candidate.
Output:
0
2025-04-17 18:51:54,466 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's systematically compare Ligand A and Ligand B based on the provided parameters and the guidelines, keeping in mind ADRB2 is a GPCR. GPCRs prioritize logP, Pgp, TPSA, and affinity.
1. **MW:** Both ligands (347.361 and 348.422 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (55.4) is significantly better than Ligand B (76.02). A TPSA under 140 is good for oral absorption, and lower is generally preferred for GPCRs. Ligand A is much closer to the ideal range.
3. **logP:** Ligand A (3.154) is slightly higher than Ligand B (1.49), placing it in the optimal 1-3 range. Ligand B is at the lower end, which *could* indicate permeability issues.
4. **HBD/HBA:** Ligand A (1 HBD, 3 HBA) is preferable to Ligand B (2 HBD, 4 HBA). Lower counts are generally better for permeability.
5. **QED:** Both ligands have similar, good QED values (0.855 and 0.866).
6. **DILI:** Ligand A (55.37) has a slightly higher DILI risk than Ligand B (49.399), but both are still below the concerning threshold of 60.
7. **BBB:** Ligand A (89.492) shows better BBB penetration potential than Ligand B (78.907). While not a primary concern for all ADRB2 applications, it's a positive attribute.
8. **Caco-2:** Both have negative Caco-2 values which is unusual. Assuming these are log values, both are poor.
9. **Solubility:** Ligand A (-4.365) is slightly better than Ligand B (-2.917) indicating better solubility.
10. **hERG:** Both ligands show very low hERG inhibition risk (0.291 and 0.375). Excellent.
11. **Cl_mic:** Ligand B (-11.729) has significantly lower microsomal clearance than Ligand A (25.272), suggesting better metabolic stability. This is a substantial advantage.
12. **t1/2:** Ligand B (19.287) has a much longer in vitro half-life than Ligand A (-0.91). This is a significant benefit.
13. **Pgp:** Ligand A (0.329) has slightly lower P-gp efflux liability than Ligand B (0.061), which is favorable.
14. **Affinity:** Both ligands have very similar and excellent binding affinities (-7.6 and -7.7 kcal/mol). The difference is negligible.
**Overall Assessment:**
Ligand A has advantages in TPSA, logP, solubility, and Pgp efflux. However, Ligand B excels in metabolic stability (Cl_mic) and in vitro half-life, which are crucial for *in vivo* drug performance. Given the similar affinities, the improved pharmacokinetic profile of Ligand B outweighs the slightly better physicochemical properties of Ligand A. The lower Cl_mic and longer t1/2 of Ligand B suggest it will have better exposure *in vivo*, which is critical for a GPCR target.
**Output:**
0
2025-04-17 18:51:54,467 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [367.431, 132.37 , 1.053, 3. , 8. , 0.666, 65.917, 60.876, -5.465, -3.195, 0.339, 16.366, -7.836, 0.064, -5.1 ]
**Ligand B:** [362.503, 83.04 , 2.234, 2. , 7. , 0.749, 60.372, 56.495, -5.287, -2.451, 0.591, 63.406, 46.503, 0.076, -6.2 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). A (367.431) and B (362.503) are very close.
2. **TPSA:** A (132.37) is slightly above the preferred <140 for good oral absorption, but acceptable. B (83.04) is excellent, well below 90, which is beneficial for potential CNS penetration, even though ADRB2 isn't necessarily a CNS target.
3. **logP:** A (1.053) is at the lower end of optimal, but still within range. B (2.234) is better positioned within the 1-3 range.
4. **HBD:** A (3) and B (2) are both acceptable, below the 5 threshold.
5. **HBA:** A (8) and B (7) are both acceptable, below the 10 threshold.
6. **QED:** Both A (0.666) and B (0.749) are good, indicating drug-like properties. B is slightly better.
7. **DILI:** Both A (65.917) and B (60.372) are in the moderate risk range, but below 60 is preferable. B is slightly better.
8. **BBB:** A (60.876) and B (56.495) are both relatively low, which isn't a major concern for a cardiovascular target like ADRB2.
9. **Caco-2:** Both A (-5.465) and B (-5.287) have negative values, which is unusual and suggests poor permeability. This is a significant concern.
10. **Solubility:** Both A (-3.195) and B (-2.451) have negative values, suggesting poor solubility. This is also a concern.
11. **hERG:** A (0.339) is better than B (0.591), indicating lower cardiotoxicity risk.
12. **Cl_mic:** A (16.366) is significantly lower than B (63.406), indicating better metabolic stability. This is a major advantage for A.
13. **t1/2:** A (-7.836) is significantly better than B (46.503), indicating a longer half-life. This is a major advantage for A.
14. **Pgp:** A (0.064) is better than B (0.076), indicating lower P-gp efflux.
15. **Affinity:** B (-6.2) is 0.1 kcal/mol better than A (-5.1). This is a decent advantage, but not overwhelming.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. B has a better logP and TPSA. A has better Pgp. The difference in affinity is moderate. However, the significant advantages of A in metabolic stability (Cl_mic) and half-life (t1/2) are crucial for *in vivo* efficacy. The poor Caco-2 and solubility for both are concerning, but the metabolic advantages of A are more impactful for a chronic cardiovascular condition where sustained drug levels are important.
**Conclusion:**
Despite the slightly better affinity of Ligand B, the superior metabolic stability and half-life of Ligand A make it the more promising drug candidate. The lower clearance and longer half-life will likely translate to better *in vivo* exposure and potentially less frequent dosing.
**Output:**
1
2025-04-17 18:51:54,467 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (365.543 and 344.459 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (52.65) is significantly better than Ligand B (74.33). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally favors absorption.
3. **logP:** Both ligands have acceptable logP values (1.577 and 2.28, respectively), falling within the 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability, but not dramatically so.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Both ligands have the same number of HBA (4).
6. **QED:** Ligand A (0.825) has a slightly better QED score than Ligand B (0.796), indicating a more drug-like profile.
7. **DILI:** Ligand A (12.408) has a much lower DILI risk than Ligand B (34.432). This is a significant advantage, as liver toxicity is a major concern.
8. **BBB:** Ligand B (78.868) has better BBB penetration than Ligand A (61.807). However, as ADRB2 is a cardiovascular target, BBB penetration is not a high priority.
9. **Caco-2:** Ligand A (-5.19) has a better Caco-2 permeability than Ligand B (-4.703).
10. **Solubility:** Ligand A (-2.178) has better solubility than Ligand B (-3.094).
11. **hERG:** Ligand A (0.377) has a lower hERG inhibition liability than Ligand B (0.517). This is a crucial factor for cardiovascular drugs to minimize cardiotoxicity risk.
12. **Cl_mic:** Ligand A (21.856) has a lower microsomal clearance than Ligand B (34.736), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-6.871) has a better in vitro half-life than Ligand A (20.044). This is a positive for Ligand B, but not a decisive factor.
14. **Pgp:** Ligand A (0.021) has a lower P-gp efflux liability than Ligand B (0.049).
15. **Binding Affinity:** Ligand A (-6.8) has a slightly better binding affinity than Ligand B (-6.3). While the difference is not huge, it's still a positive for Ligand A.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A performs better on TPSA, Pgp, and Affinity. While Ligand B has slightly better logP and BBB, BBB isn't critical for a cardiovascular target.
**Overall Assessment:**
Ligand A demonstrates a superior balance of properties, particularly regarding safety (DILI, hERG) and ADME characteristics (TPSA, Cl_mic, Solubility, Pgp). The slightly better binding affinity further supports its selection. While Ligand B has a better half-life, the other advantages of Ligand A outweigh this single benefit.
Output:
1
2025-04-17 18:51:54,467 - INFO - Here's my reasoning and the final output:
**Reasoning:**
We are evaluating two ligands for the ADRB2, a cardiovascular GPCR. Therefore, the key priorities are logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB.
Let's compare the ligands property by property:
1. **MW:** Both ligands (357.3 and 345.5 Da) are within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (47.56) is slightly higher than Ligand B (43.86), but both are well below the 140 threshold for good absorption.
3. **logP:** Ligand A (4.053) is higher than Ligand B (1.437). While 4.053 is approaching the upper limit, it's still acceptable. Ligand B's logP is quite low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (1) has one HBD, while Ligand B has zero. Both are good.
5. **HBA:** Both ligands have 3 HBAs, which is acceptable.
6. **QED:** Both ligands have similar QED values (0.794 vs 0.724), indicating good drug-likeness.
7. **DILI:** Ligand A (76.3) has a significantly higher DILI risk than Ligand B (12.2). This is a major concern for Ligand A.
8. **BBB:** Both ligands have similar BBB penetration (68.8% vs 69.6%), which is acceptable but not exceptional for a GPCR.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the values are similar.
10. **Solubility:** Ligand A (-4.968) has worse solubility than Ligand B (-2.076).
11. **hERG:** Ligand A (0.687) has a slightly higher hERG risk than Ligand B (0.294), but both are relatively low.
12. **Cl_mic:** Ligand A (63.158) has a higher microsomal clearance than Ligand B (44.849), indicating lower metabolic stability.
13. **t1/2:** Ligand B (-18.977) has a significantly longer in vitro half-life than Ligand A (-0.766).
14. **Pgp:** Ligand A (0.193) has lower P-gp efflux than Ligand B (0.077), which is favorable.
15. **Binding Affinity:** Ligand B (-6.5 kcal/mol) has a stronger binding affinity than Ligand A (-5.1 kcal/mol). This is a 1.4 kcal/mol difference, which is substantial.
**Overall Assessment:**
Ligand B is the more promising candidate. While Ligand A has slightly better Pgp properties, its significantly higher DILI risk, lower solubility, faster clearance, and weaker binding affinity outweigh this benefit. Ligand B's stronger binding affinity, lower DILI risk, and longer half-life make it a more favorable starting point for further optimization. The lower logP of Ligand B is a concern, but can be addressed through medicinal chemistry.
Output:
0
2025-04-17 18:51:54,467 - INFO - Here's my reasoning and the final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, the key priorities are logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB.
Let's break down the comparison:
1. **MW:** Both ligands are within the acceptable range (200-500 Da). Ligand A (335.37) is slightly lower, which is generally favorable.
2. **TPSA:** Ligand B (71.25) has a significantly lower TPSA than Ligand A (98.81). This is a major advantage for Ligand B, as lower TPSA generally correlates with better membrane permeability.
3. **logP:** Both ligands have good logP values (A: 2.75, B: 3.23), falling within the optimal 1-3 range. Ligand B is slightly higher, which could potentially lead to some off-target effects but isn't a major concern.
4. **HBD/HBA:** Ligand A has 1 HBD and 5 HBA, while Ligand B has 2 HBD and 4 HBA. Both are acceptable.
5. **QED:** Both ligands have good QED scores (A: 0.776, B: 0.805), indicating good drug-like properties.
6. **DILI:** Ligand B (51.26) has a much lower DILI risk than Ligand A (82.51). This is a significant advantage for Ligand B.
7. **BBB:** Ligand B (79.29) shows better BBB penetration than Ligand A (64.75). While not a primary concern for a cardiovascular target, it's a positive attribute.
8. **Caco-2:** Both ligands have similar, poor Caco-2 permeability scores (-5.148 and -5.153).
9. **Solubility:** Both ligands have poor aqueous solubility scores (-3.824 and -3.521).
10. **hERG:** Ligand A (0.453) has a slightly lower hERG inhibition liability than Ligand B (0.765), which is favorable.
11. **Cl_mic:** Ligand A (25.01) has a lower microsomal clearance than Ligand B (29.08), suggesting better metabolic stability.
12. **t1/2:** Ligand B (24.02) has a significantly longer in vitro half-life than Ligand A (6.39). This is a major advantage.
13. **Pgp:** Ligand A (0.189) has lower P-gp efflux liability than Ligand B (0.363), which is favorable.
14. **Binding Affinity:** Both ligands have very similar and excellent binding affinities (-5.8 and -5.9 kcal/mol). The difference is negligible.
**Overall Assessment:**
Ligand B is the preferred candidate. While Ligand A has slightly better Pgp efflux and hERG inhibition, Ligand B excels in several critical areas: significantly lower DILI risk, better BBB penetration, and a much longer in vitro half-life. The lower TPSA of Ligand B is also a substantial advantage for permeability. The similar binding affinities make these ADME properties the deciding factors.
Output:
0
2025-04-17 18:51:54,467 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are looking for a ligand targeting ADRB2, a GPCR. Therefore, priorities are affinity, logP, Pgp, TPSA, and BBB. Let's compare Ligand A and Ligand B across these and other relevant parameters.
* **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand B (348.447 Da) is slightly smaller than Ligand A (386.231 Da), which is generally favorable for permeability.
* **TPSA:** Ligand A (95.86) is slightly higher than Ligand B (87.46). Both are acceptable for oral absorption, but lower is better, giving a slight edge to Ligand B.
* **logP:** Ligand A (2.985) is optimal, while Ligand B (0.737) is a bit low, potentially hindering membrane permeability. This is a significant advantage for Ligand A.
* **H-Bond Donors/Acceptors:** Ligand A has 3 HBD and 4 HBA, while Ligand B has 2 HBD and 5 HBA. Both are within acceptable limits.
* **QED:** Both ligands have similar QED values (0.74 and 0.611), indicating good drug-likeness.
* **DILI:** Ligand A (65.452) has a higher DILI risk than Ligand B (26.095). This is a substantial negative for Ligand A.
* **BBB:** Ligand B (53.703) has a significantly better BBB penetration potential than Ligand A (30.128). While ADRB2 isn't strictly a CNS target, some CNS exposure can be beneficial or at least less detrimental.
* **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability.
* **Solubility:** Both ligands have negative solubility values, indicating poor solubility.
* **hERG:** Both ligands have very low hERG inhibition liability, which is excellent.
* **Cl_mic:** Ligand A (-2.359) has a negative clearance, which is very good. Ligand B (31.472) has a high clearance, indicating poor metabolic stability. This is a major advantage for Ligand A.
* **t1/2:** Ligand A (15.983) has a longer half-life than Ligand B (-4.577). This is favorable for dosing frequency.
* **Pgp:** Both ligands have low Pgp efflux liability.
* **Binding Affinity:** Ligand A (-7.4 kcal/mol) has a slightly better binding affinity than Ligand B (-6.2 kcal/mol). This difference (1.2 kcal/mol) is significant, potentially outweighing some of the ADME drawbacks of Ligand A.
**Overall Assessment:**
Ligand A has a superior binding affinity and metabolic stability (lower Cl_mic, longer t1/2), and a better logP. However, it has a higher DILI risk and lower BBB penetration. Ligand B has a lower DILI risk and better BBB penetration, but its logP is suboptimal, and it has poor metabolic stability.
Considering the GPCR-specific priorities and the substantial difference in binding affinity, the better binding affinity and metabolic stability of Ligand A are more important than the slightly higher DILI risk and lower BBB penetration. The affinity difference is large enough to potentially overcome the ADME liabilities.
Output:
1
2025-04-17 18:51:54,468 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (361.467 Da and 366.527 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (54.9) is better than Ligand B (57.69). Both are below the 140 threshold for oral absorption, but lower TPSA is generally preferred for GPCR ligands, aiding in membrane permeability.
**3. logP:** Ligand A (2.567) is better than Ligand B (1.354). Both are within the optimal 1-3 range, but Ligand A is closer to the sweet spot. Ligand B is a bit low, potentially hindering permeability.
**4. H-Bond Donors:** Both ligands have 0 HBD, which is good.
**5. H-Bond Acceptors:** Ligand A has 7 HBA, and Ligand B has 3 HBA. Both are within the acceptable limit of 10.
**6. QED:** Both ligands have similar QED values (0.763 and 0.738), indicating good drug-like properties.
**7. DILI Risk:** Ligand A (61.07) has a higher DILI risk than Ligand B (10.702). This is a significant drawback for Ligand A.
**8. BBB Penetration:** Both ligands show good BBB penetration (81.815 and 83.327). This is less critical for a cardiovascular target like ADRB2, but still a positive.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.322 and -4.577). This is unusual and suggests poor permeability. However, these values can be unreliable and should be interpreted cautiously.
**10. Aqueous Solubility:** Both ligands have negative solubility values (-2.912 and -2.692). This is also concerning, suggesting poor solubility.
**11. hERG Inhibition:** Ligand A (0.824) has a slightly higher hERG inhibition risk than Ligand B (0.348). Lower is better here.
**12. Microsomal Clearance:** Ligand A (89.635) has higher microsomal clearance than Ligand B (48.772), indicating faster metabolism and potentially lower *in vivo* exposure.
**13. In vitro Half-Life:** Ligand B (-8.814) has a longer half-life than Ligand A (8.774).
**14. P-gp Efflux:** Ligand A (0.6) has higher P-gp efflux than Ligand B (0.087). Lower efflux is preferred.
**15. Binding Affinity:** Ligand A (-7.6) has a slightly better binding affinity than Ligand B (-8.0). However, the difference is small and may not be practically significant.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity) and the general drug-like properties, Ligand B is the more promising candidate. While Ligand A has slightly better affinity, its significantly higher DILI risk, higher P-gp efflux, and faster metabolic clearance are major concerns. Ligand B's lower DILI risk and better metabolic stability outweigh the small difference in binding affinity. The solubility and permeability issues are present in both, and would need to be addressed during lead optimization, but are not decisive factors in this initial comparison.
Output:
0
2025-04-17 18:51:54,468 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [353.419, 109.25 , 0.094, 3. , 6. , 0.627, 35.014, 52.734, -5.018, -1.478, 0.198, 0.831, 17.766, 0.011, -6.7 ]
**Ligand B:** [366.571, 40.62 , 3.548, 0. , 3. , 0.764, 22.334, 82.474, -4.874, -4.069, 0.579, 92.352, 1.383, 0.348, -5.1 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (353.419) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (109.25) is higher than Ligand B (40.62). For a cardiovascular GPCR, TPSA isn't *as* critical as for CNS targets, but lower is still preferred for better absorption. Ligand B is significantly better here.
3. **logP:** Ligand A (0.094) is very low, potentially causing permeability issues. Ligand B (3.548) is much better, falling within the optimal 1-3 range. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (3) is acceptable. Ligand B (0) is even better, reducing potential for off-target interactions and improving membrane permeability.
5. **HBA:** Both are acceptable (Ligand A: 6, Ligand B: 3).
6. **QED:** Both have good QED scores (Ligand A: 0.627, Ligand B: 0.764), indicating drug-like properties. Ligand B is slightly better.
7. **DILI:** Both have low DILI risk (Ligand A: 35.014, Ligand B: 22.334). Ligand B is slightly better.
8. **BBB:** Ligand B (82.474) has a much higher BBB percentile than Ligand A (52.734). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant, and higher BBB is generally a plus.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so we can't interpret these values accurately.
10. **Solubility:** Ligand A (-1.478) and Ligand B (-4.069) both have negative solubility values, suggesting poor aqueous solubility. This is a concern for both.
11. **hERG:** Both have low hERG risk (Ligand A: 0.198, Ligand B: 0.579).
12. **Cl_mic:** Ligand A (0.831) has significantly lower microsomal clearance than Ligand B (92.352), indicating better metabolic stability. This is a major advantage for Ligand A.
13. **t1/2:** Ligand A (17.766) has a longer in vitro half-life than Ligand B (1.383). This is another significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.011) has much lower P-gp efflux liability than Ligand B (0.348), suggesting better oral bioavailability and potentially better CNS exposure.
15. **Affinity:** Ligand A (-6.7) has slightly better binding affinity than Ligand B (-5.1). While the difference is less than 1.5 kcal/mol, it contributes to the overall preference.
**Overall Assessment:**
Ligand B excels in TPSA, logP, and BBB, which are important for GPCRs. However, Ligand A demonstrates superior metabolic stability (Cl_mic, t1/2), P-gp efflux, and slightly better affinity. The extremely low logP of Ligand A is a concern, but its other favorable properties, particularly the metabolic stability and P-gp profile, outweigh this drawback. Given the cardiovascular target, metabolic stability and bioavailability are crucial.
Therefore, I prefer Ligand A.
Output:
1
2025-04-17 18:51:54,468 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**1. Molecular Weight:** Both ligands (345.443 and 346.471 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (75.44) is slightly higher than Ligand B (60.85). For a cardiovascular GPCR, TPSA is not a primary concern, but lower is generally preferred for better absorption. Ligand B has an advantage.
**3. logP:** Both ligands have good logP values (2.728 and 2.276), falling within the optimal 1-3 range. Ligand B is slightly lower, which could be beneficial for solubility.
**4. H-Bond Donors:** Both ligands have 1 HBD, which is within the acceptable limit of 5.
**5. H-Bond Acceptors:** Ligand A has 4 HBAs, and Ligand B has 3. Both are below the limit of 10.
**6. QED:** Ligand A (0.662) has a better QED score than Ligand B (0.472), indicating a more drug-like profile.
**7. DILI:** Ligand B (20.008) has a significantly lower DILI risk than Ligand A (41.218). This is a major advantage for Ligand B.
**8. BBB:** Both ligands show good BBB penetration (70.88 and 77.2). This isn't a critical factor for a cardiovascular target, but higher is generally better. Ligand B is slightly better.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not provided, so it's difficult to interpret.
**10. Aqueous Solubility:** Both ligands have negative solubility values, which indicates poor solubility.
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (0.354 and 0.328).
**12. Microsomal Clearance:** Ligand A (60.801) has a higher microsomal clearance than Ligand B (12). This suggests Ligand B is more metabolically stable.
**13. In vitro Half-Life:** Ligand B (-24.305) has a longer in vitro half-life than Ligand A (-29.373).
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (0.395 and 0.17).
**15. Binding Affinity:** Ligand A (-7.8 kcal/mol) has a significantly stronger binding affinity than Ligand B (-5.4 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME drawbacks.
**GPCR-Specific Priorities:** For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are important. Ligand B has a slightly better logP and TPSA, and comparable Pgp. However, Ligand A's binding affinity is significantly stronger. The DILI risk is also a major consideration, and Ligand B is much better in this regard.
**Overall Assessment:**
While Ligand A has a significantly better binding affinity, Ligand B has a much better safety profile (lower DILI) and improved metabolic stability (lower Cl_mic, longer half-life). The difference in binding affinity is substantial (2.4 kcal/mol), but the improved safety and pharmacokinetic properties of Ligand B are compelling. Given the cardiovascular context, minimizing off-target effects and ensuring reasonable metabolic stability are crucial.
Output:
0
2025-04-17 18:51:54,468 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (351.491 and 345.443 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (81.67) is slightly higher than Ligand B (75.44). Both are below the 140 threshold for good oral absorption, and acceptable for a cardiovascular target (not needing significant BBB penetration).
3. **logP:** Ligand A (1.033) is closer to the optimal 1-3 range than Ligand B (2.703). While 2.703 isn't *bad*, 1.033 is preferable for balancing permeability and solubility.
4. **HBD:** Ligand A (3) is higher than Ligand B (1). For a GPCR, this isn't a major concern, but lower is generally better for permeability.
5. **HBA:** Both ligands have the same number of HBA (4), which is well within the acceptable limit of 10.
6. **QED:** Ligand B (0.771) has a slightly better QED score than Ligand A (0.61), indicating a more drug-like profile.
7. **DILI:** Ligand A (12.641) has a significantly lower DILI risk than Ligand B (47.654). This is a crucial advantage, as minimizing liver toxicity is paramount.
8. **BBB:** Ligand B (84.374) has a higher BBB penetration percentile than Ligand A (40.558). However, as ADRB2 is primarily a cardiovascular target, high BBB penetration isn't a priority.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-5.119) is slightly worse than Ligand B (-4.95).
10. **Solubility:** Ligand A (-2.305) has slightly better solubility than Ligand B (-3.067).
11. **hERG:** Ligand A (0.152) has a lower hERG inhibition liability than Ligand B (0.339), which is a significant safety advantage.
12. **Cl_mic:** Ligand A (33.452) has a lower microsomal clearance than Ligand B (60.167), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-19.711) has a significantly longer in vitro half-life than Ligand A (-1.626). This is a major advantage for dosing convenience.
14. **Pgp:** Ligand A (0.044) has lower P-gp efflux liability than Ligand B (0.294), which is favorable for oral bioavailability.
15. **Binding Affinity:** Ligand A (-7.1) has a slightly better binding affinity than Ligand B (-5.9). This 1.2 kcal/mol difference is substantial and can outweigh some ADME drawbacks.
**GPCR-specific priorities:** For ADRB2 (a cardiovascular GPCR), logP, Pgp, TPSA, and affinity are key. Ligand A excels in logP, Pgp, and affinity. Ligand B has a better half-life, but the lower DILI and hERG risks of Ligand A, combined with its superior binding affinity, are more critical. The slightly better solubility of Ligand A is also a plus.
**Conclusion:**
Considering the balance of properties, particularly the lower DILI and hERG risks, better affinity, and favorable logP/Pgp profile, Ligand A is the more promising drug candidate. While Ligand B has a better half-life, the safety and potency advantages of Ligand A are more important for initial development.
Output:
1
2025-04-17 18:51:54,468 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (377.868 Da) is within the ideal range (200-500 Da). Ligand B (348.403 Da) is also within range, slightly lower. No clear advantage here.
2. **TPSA:** Ligand A (46.17) is excellent, well below the 140 threshold for oral absorption. Ligand B (104.39) is higher, but still acceptable for oral absorption, though less optimal. Ligand A is preferred.
3. **logP:** Ligand A (4.846) is a bit high, potentially leading to solubility issues or off-target interactions. Ligand B (0.331) is very low, which could hinder membrane permeability. This is a significant drawback for Ligand B.
4. **HBD:** Both ligands have acceptable HBD counts (Ligand A: 1, Ligand B: 2), well below the 5 threshold.
5. **HBA:** Ligand A (2) is good. Ligand B (5) is higher, but still within the acceptable range of 10.
6. **QED:** Both ligands have similar QED values (Ligand A: 0.706, Ligand B: 0.626), indicating good drug-likeness.
7. **DILI:** Ligand A (87.01) has a higher DILI risk than Ligand B (54.634). This is a concern for Ligand A.
8. **BBB:** Ligand A (46.491) is lower than Ligand B (62.854). While ADRB2 isn't strictly a CNS target, some CNS exposure might be acceptable or even desirable for certain cardiovascular effects. Ligand B is preferred.
9. **Caco-2:** Both have negative Caco-2 values (-4.674 and -4.766). These values are unusual and suggest poor permeability.
10. **Solubility:** Ligand A (-5.536) has worse solubility than Ligand B (-2.654).
11. **hERG:** Ligand A (0.676) has a slightly higher hERG risk than Ligand B (0.216), but both are relatively low.
12. **Cl_mic:** Ligand A (42.301) has a higher microsomal clearance than Ligand B (33.358), suggesting lower metabolic stability. Ligand B is preferred.
13. **t1/2:** Ligand A (70.75) has a significantly longer half-life than Ligand B (-19.751). This is a major advantage for Ligand A.
14. **Pgp:** Ligand A (0.295) has lower P-gp efflux liability than Ligand B (0.035), which is preferable.
15. **Affinity:** Ligand B (-6.9 kcal/mol) has a slightly better binding affinity than Ligand A (-6.2 kcal/mol). This is a 0.7 kcal/mol difference, which is significant.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A struggles with logP and solubility, while Ligand B has a very low logP. The slightly better affinity of Ligand B and its better Pgp profile, coupled with a lower DILI risk, are attractive. The longer half-life of Ligand A is a strong positive, but the solubility and logP issues are concerning. The negative Caco-2 values for both are problematic, but the overall profile of Ligand B is more balanced.
**Conclusion:**
Despite the longer half-life of Ligand A, the superior balance of properties in Ligand B, particularly its better logP, lower DILI, and slightly better affinity, make it the more promising drug candidate for ADRB2.
Output:
0
2025-04-17 18:51:54,469 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 drug candidates. ADRB2 is a GPCR, so we'll prioritize logP, Pgp, TPSA, and affinity, alongside general drug-like properties.
**Ligand A:** [351.447, 101.73 , 1.259, 2. , 4. , 0.674, 32.61 , 58.356, -5.558, -2.767, 0.211, 10.182, -0.697, 0.037, -8.0]
**Ligand B:** [350.459, 66.92 , 2.134, 0. , 4. , 0.563, 21.675, 77.162, -4.385, -2.49 , 0.267, 64.986, -2.161, 0.079, -5.5]
1. **MW:** Both are within the ideal range (350-351 Da). No significant difference.
2. **TPSA:** Ligand A (101.73) is higher than Ligand B (66.92). Ligand B is much better, falling well below the 140 threshold for oral absorption and closer to the 90 threshold for CNS penetration (though ADRB2 isn't necessarily a CNS target).
3. **logP:** Ligand A (1.259) and Ligand B (2.134) are both within the optimal 1-3 range. Ligand B is slightly better.
4. **HBD:** Ligand A (2) is slightly better than Ligand B (0). While low HBD can sometimes indicate permeability issues, it's not a major concern here.
5. **HBA:** Both have 4 HBA, which is acceptable.
6. **QED:** Ligand A (0.674) is better than Ligand B (0.563).
7. **DILI:** Ligand A (32.61) has a significantly lower DILI risk than Ligand B (21.675). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (77.162) has a higher BBB penetration percentile than Ligand A (58.356). While not a primary concern for ADRB2, it's a slight advantage.
9. **Caco-2:** Ligand A (-5.558) is much worse than Ligand B (-4.385). This suggests poorer intestinal absorption for Ligand A.
10. **Solubility:** Ligand A (-2.767) is slightly worse than Ligand B (-2.49).
11. **hERG:** Both are very low (0.211 and 0.267), indicating low cardiotoxicity risk.
12. **Cl_mic:** Ligand A (10.182) has a lower microsomal clearance than Ligand B (64.986), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-2.161) has a longer in vitro half-life than Ligand A (-0.697).
14. **Pgp:** Both are very low (0.037 and 0.079), indicating low P-gp efflux.
15. **Affinity:** Ligand A (-8.0) has a slightly better binding affinity than Ligand B (-5.5). This is a significant advantage.
**Overall Assessment:**
Ligand A has a better binding affinity and lower DILI risk. However, Ligand B has better TPSA, Caco-2 permeability, BBB penetration, and in vitro half-life. The affinity difference between the two ligands is substantial (2.5 kcal/mol), which is enough to overcome the slightly worse ADME properties of Ligand A. The lower DILI risk is also a major plus. While Ligand B has better permeability, the affinity is paramount for GPCR targets.
Therefore, I would choose Ligand A.
1
2025-04-17 18:51:54,469 - INFO - Batch 68 complete. Total preferences: 1088
2025-04-17 18:51:54,469 - INFO - Processing batch 69/512...
2025-04-17 18:52:45,387 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [358.873, 71.25, 3.234, 2, 4, 0.805, 51.26, 79.294, -5.153, -3.521, 0.765, 29.077, 24.016, 0.363, -5.9]
**Ligand B:** [356.423, 111.21, -2.08, 3, 6, 0.504, 14.967, 19.659, -5.518, -0.493, 0.047, -42.488, -1.705, 0.002, -3.6]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, BBB, and affinity are key):
1. **MW:** Both are within the ideal 200-500 Da range. A is 358.873, B is 356.423 - very similar.
2. **TPSA:** A (71.25) is excellent, well below 140 and good for oral absorption. B (111.21) is higher, but still acceptable, though less ideal.
3. **logP:** A (3.234) is optimal. B (-2.08) is significantly lower, potentially causing permeability issues. This is a major concern.
4. **HBD/HBA:** A (2/4) is good. B (3/6) is slightly higher, but not alarming.
5. **QED:** A (0.805) is very good, indicating high drug-likeness. B (0.504) is acceptable but lower.
6. **DILI:** A (51.26) is good, low risk. B (14.967) is excellent, very low risk.
7. **BBB:** A (79.294) is good, suggesting reasonable potential for some CNS penetration if desired. B (19.659) is very low, indicating poor BBB penetration.
8. **Caco-2:** Both are negative, indicating poor permeability. However, the scale is not specified, so it's hard to interpret.
9. **Solubility:** Both are negative, indicating poor solubility. Again, the scale is not specified.
10. **hERG:** A (0.765) is good, low risk. B (0.047) is excellent, very low risk.
11. **Cl_mic:** A (29.077) is moderate. B (-42.488) is *very* good, indicating high metabolic stability.
12. **t1/2:** A (24.016) is good. B (-1.705) is very poor, suggesting rapid clearance.
13. **Pgp:** A (0.363) is good, indicating low efflux. B (0.002) is excellent, very low efflux.
14. **Affinity:** A (-5.9) is better than B (-3.6). A has a 1.3 kcal/mol advantage.
**Overall Assessment:**
Ligand A is clearly superior. While Ligand B has excellent DILI, hERG, and Pgp properties, its significantly lower logP and poor half-life are major drawbacks for a GPCR target like ADRB2. The negative logP suggests poor membrane permeability, hindering its ability to reach the receptor. The poor half-life indicates it will be rapidly cleared. Ligand A, despite slightly higher DILI risk, has a much better logP, BBB penetration, and significantly stronger binding affinity. The 1.3 kcal/mol difference in affinity is substantial enough to outweigh the minor ADME differences.
Therefore, I would choose Ligand A.
1
2025-04-17 18:52:45,387 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (373.519 and 374.453 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand B (69.64) is significantly better than Ligand A (118.36). ADRB2 is a cardiovascular target, not a CNS target, but lower TPSA generally improves absorption.
3. **logP:** Both ligands have acceptable logP values (0.889 and 1.538, respectively), falling within the 1-3 range. Ligand B is slightly better.
4. **HBD:** Ligand A has 3 HBD, and Ligand B has 2. Both are within the acceptable limit of 5.
5. **HBA:** Both ligands have 4 HBA, well within the limit of 10.
6. **QED:** Ligand B (0.786) has a higher QED score than Ligand A (0.556), indicating a more drug-like profile.
7. **DILI:** Both ligands have low DILI risk (33.928 and 39.201, respectively), well below the 60 threshold. No significant difference.
8. **BBB:** This is less critical for a cardiovascular target, but Ligand B (69.717) has a higher BBB penetration percentile than Ligand A (55.176).
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. Ligand A (-5.346) is slightly better than Ligand B (-4.997), but both are concerning.
10. **Solubility:** Both ligands have poor aqueous solubility (-2.933 and -2.791, respectively). This is a significant drawback for both.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.093 and 0.287, respectively), which is excellent.
12. **Cl_mic:** Ligand B (-14.244) has a *much* lower (better) microsomal clearance than Ligand A (37.789). This suggests significantly improved metabolic stability for Ligand B.
13. **t1/2:** Ligand B (1.226) has a slightly better in vitro half-life than Ligand A (-52.772).
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.038 and 0.042, respectively).
15. **Binding Affinity:** Ligand B (-7.6 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.6 kcal/mol). This 1.0 kcal/mol difference is substantial and can outweigh some of the ADME drawbacks.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in TPSA, logP, affinity, and Pgp. The improved metabolic stability (Cl_mic) and half-life are also very favorable. While both have poor solubility and Caco-2 permeability, the superior binding affinity and metabolic profile of Ligand B make it the better candidate.
**Output:**
0
2025-04-17 18:52:45,388 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (a cardiovascular GPCR) drug candidates.
**Ligand A:** [363.483, 78.51, 1.666, 2, 4, 0.755, 36.681, 56.689, -5.393, -1.85, 0.196, 52.858, 14.953, 0.066, -6.4]
**Ligand B:** [348.443, 71.78, 2.291, 1, 4, 0.886, 15.432, 84.374, -4.516, -2.542, 0.591, 31.876, 21.064, 0.198, -6.3]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (348.443) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are acceptable (below 140), but Ligand B (71.78) is better than Ligand A (78.51), suggesting better potential for oral absorption.
3. **logP:** Both are within the optimal range (1-3). Ligand A (1.666) is slightly lower, while Ligand B (2.291) is closer to the middle of the range.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1), but both are within the acceptable limit of 5.
5. **HBA:** Both have 4 HBA, which is good.
6. **QED:** Both are above 0.5, indicating good drug-likeness. Ligand B (0.886) is slightly better than Ligand A (0.755).
7. **DILI:** Ligand A (36.681) has a better DILI score than Ligand B (15.432), indicating a lower risk of liver injury.
8. **BBB:** Ligand B (84.374) has a significantly higher BBB penetration score than Ligand A (56.689). While ADRB2 isn't a CNS target, some peripheral exposure can be reduced by efflux transporters, so a higher BBB score isn't necessarily detrimental.
9. **Caco-2:** Ligand A (-5.393) has a worse Caco-2 permeability than Ligand B (-4.516).
10. **Solubility:** Ligand B (-2.542) has better aqueous solubility than Ligand A (-1.85).
11. **hERG:** Ligand A (0.196) has a lower hERG inhibition liability than Ligand B (0.591), which is a significant advantage.
12. **Cl_mic:** Ligand B (31.876) has a lower microsomal clearance than Ligand A (52.858), suggesting better metabolic stability.
13. **t1/2:** Ligand B (21.064) has a longer in vitro half-life than Ligand A (14.953).
14. **Pgp:** Ligand B (0.198) has lower P-gp efflux liability than Ligand A (0.066), which is favorable.
15. **Affinity:** Both have very similar binding affinities (-6.4 and -6.3 kcal/mol). The difference is negligible.
**GPCR-Specific Considerations:**
For a cardiovascular GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP, TPSA, Pgp, and solubility, while Ligand A has a better hERG profile and DILI score. The affinity is comparable. Given the importance of permeability and metabolic stability for a cardiovascular drug, the better ADME profile of Ligand B outweighs the slightly better safety profile of Ligand A.
**Conclusion:**
Ligand B appears to be the more promising candidate due to its superior ADME properties, particularly its better TPSA, solubility, metabolic stability, and P-gp efflux liability.
```
0
```
2025-04-17 18:52:45,388 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (370.402 Da and 371.428 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (84.94) is better than Ligand B (46.09). While both are below the 140 A^2 threshold for oral absorption, the lower TPSA of Ligand B is more favorable for GPCRs, potentially aiding in receptor binding and reducing off-target interactions.
**3. logP:** Ligand A (1.212) is within the optimal 1-3 range. Ligand B (4.646) is significantly higher. While logP can be modulated, a value this high raises concerns about solubility, off-target binding, and potential for accumulation in tissues.
**4. H-Bond Donors:** Ligand A has 1 HBD, Ligand B has 0. Both are acceptable.
**5. H-Bond Acceptors:** Ligand A has 5 HBA, Ligand B has 4. Both are acceptable.
**6. QED:** Ligand A (0.861) has a significantly better QED score than Ligand B (0.712), indicating a more drug-like profile overall.
**7. DILI Risk:** Ligand A (68.282) has a higher DILI risk than Ligand B (49.477), which is a concern.
**8. BBB Penetration:** Ligand A (68.67) has lower BBB penetration than Ligand B (87.088). While ADRB2 is a cardiovascular target, some CNS effects are possible with beta-adrenergic agonists, and higher BBB penetration could lead to unwanted side effects. However, for a cardiovascular target, this isn't a primary driver.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.71 and -4.662). This is unusual and suggests poor permeability.
**10. Aqueous Solubility:** Ligand A (-2.932) has better solubility than Ligand B (-4.177), which is important for formulation and bioavailability.
**11. hERG Inhibition:** Ligand A (0.23) has a much lower hERG inhibition risk than Ligand B (0.678). This is a critical advantage, as hERG inhibition can lead to potentially fatal cardiac arrhythmias.
**12. Microsomal Clearance:** Ligand A (52.239) has lower microsomal clearance than Ligand B (62.162), suggesting better metabolic stability.
**13. In vitro Half-Life:** Ligand B (16.834 hours) has a significantly longer half-life than Ligand A (2.033 hours). This is a major advantage, potentially allowing for less frequent dosing.
**14. P-gp Efflux:** Ligand A (0.16) has lower P-gp efflux than Ligand B (0.389), which is favorable for bioavailability.
**15. Binding Affinity:** Ligand A (-7.2 kcal/mol) has a slightly better binding affinity than Ligand B (-6.8 kcal/mol). This 0.4 kcal/mol difference is significant and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand A is the stronger candidate. While Ligand B has a longer half-life and better BBB penetration, Ligand A has a significantly better QED score, lower hERG risk, better solubility, and slightly better binding affinity. The higher DILI risk for Ligand A is a concern, but can be investigated further. The problematic Caco-2 values for both ligands are a shared issue that would require further investigation (e.g., formulation strategies). The logP of Ligand B is a significant drawback. The combination of better potency, drug-likeness, and safety (hERG) makes Ligand A the preferred choice.
Output:
1
2025-04-17 18:52:45,388 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [341.455, 53.51, 2.719, 0, 3, 0.649, 18.224, 83.366, -4.34, -1.775, 0.175, 79.543, -13.455, 0.075, -6.6]
**Ligand B:** [363.439, 90.55, 0.869, 1, 5, 0.84, 43.622, 61.38, -4.921, -3.117, 0.115, -0.707, -27.995, 0.035, -5.4]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (341.455) is slightly lower, which is generally favorable for permeability, but both are acceptable.
2. **TPSA:** Ligand A (53.51) is significantly better than Ligand B (90.55). A TPSA under 140 is good for oral absorption, but for a GPCR, lower is better, and A is much closer to the ideal for CNS penetration (under 90).
3. **logP:** Ligand A (2.719) is optimal. Ligand B (0.869) is a bit low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (0) is preferable to Ligand B (1). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (3) is better than Ligand B (5). Lower HBA is generally preferred for permeability.
6. **QED:** Both are good (A: 0.649, B: 0.84), indicating drug-like properties. B is slightly better.
7. **DILI:** Ligand A (18.224) is significantly better than Ligand B (43.622). Lower DILI risk is crucial.
8. **BBB:** Ligand A (83.366) is much better than Ligand B (61.38). For a GPCR, even if not explicitly CNS-targeted, some BBB penetration can be beneficial for distribution.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-4.34) is slightly better than Ligand B (-4.921).
10. **Solubility:** Both are negative, indicating poor solubility. Ligand A (-1.775) is slightly better than Ligand B (-3.117).
11. **hERG:** Both are very low (A: 0.175, B: 0.115), indicating minimal hERG inhibition risk.
12. **Cl_mic:** Ligand A (79.543) is higher than Ligand B (-0.707), meaning it has faster metabolic clearance and lower metabolic stability. This is a significant drawback for A.
13. **t1/2:** Ligand B (-27.995) is significantly better than Ligand A (-13.455). A longer half-life is generally desirable.
14. **Pgp:** Both are very low (A: 0.075, B: 0.035), indicating minimal P-gp efflux.
15. **Affinity:** Ligand A (-6.6) is slightly better than Ligand B (-5.4). While a 1.2 kcal/mol difference is good, it needs to be weighed against other factors.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, and affinity. Ligand A excels in logP, TPSA, and affinity. However, Ligand B has a much better metabolic profile (Cl_mic and t1/2) and a lower DILI risk.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity and better TPSA/logP, the significantly worse metabolic stability (higher Cl_mic, shorter half-life) and higher DILI risk are major concerns. Ligand B, despite its lower affinity, presents a much more favorable ADME-Tox profile. The difference in affinity isn't large enough to overcome these serious drawbacks.
Therefore, I would choose Ligand B.
Output:
0
2025-04-17 18:52:45,388 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (353.491) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (36.44) is significantly better than Ligand B (75.27). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption. Ligand B's TPSA is quite high, potentially hindering oral absorption.
3. **logP:** Ligand A (4.07) is at the upper end of the optimal range, while Ligand B (2.123) is closer to the lower end. Both are acceptable, but Ligand A's higher logP might lead to some solubility issues.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer hydrogen bond donors generally improve membrane permeability.
5. **HBA:** Ligand A (4) is better than Ligand B (3). Lower HBA is generally preferred.
6. **QED:** Both ligands have similar QED values (0.815 and 0.774), indicating good drug-likeness.
7. **DILI:** Ligand A (69.058) has a higher DILI risk than Ligand B (37.728). This is a significant drawback for Ligand A.
8. **BBB:** Ligand A (90.694) has higher BBB penetration than Ligand B (68.67). While not crucial for a cardiovascular target, it's not a negative.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests a potential issue with the data or the compounds themselves. However, the values are similar.
10. **Solubility:** Ligand A (-4.502) has slightly better solubility than Ligand B (-3.074).
11. **hERG:** Ligand A (0.843) has a slightly higher hERG risk than Ligand B (0.542), but both are relatively low.
12. **Cl_mic:** Ligand A (91.888) has a much higher microsomal clearance than Ligand B (20.233). This indicates Ligand A will be metabolized more quickly, potentially leading to lower exposure.
13. **t1/2:** Ligand A (28.747) has a longer half-life than Ligand B (-22.792). However, the negative value for Ligand B is concerning and likely an artifact.
14. **Pgp:** Ligand A (0.795) has slightly higher P-gp efflux than Ligand B (0.165), which is less desirable.
15. **Binding Affinity:** Ligand B (-7.7) has a slightly better binding affinity than Ligand A (-7.1). While the difference is not huge, it's enough to consider, especially given the other ADME properties.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has a better logP and comparable affinity, but Ligand B wins on TPSA and Pgp. The biggest concern with Ligand A is its high DILI risk and high microsomal clearance.
**Overall Assessment:**
Ligand B is the more promising candidate. While its TPSA is higher, the significantly lower DILI risk, lower P-gp efflux, and better metabolic stability (lower Cl_mic) outweigh the slightly lower affinity and higher TPSA. The negative half-life value for Ligand B is a red flag, but likely a data issue. The higher DILI risk for Ligand A is a major concern that would likely derail its development.
Output:
0
2025-04-17 18:52:45,388 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.39 and 347.50 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (113.69) is higher than Ligand B (52.65). For a cardiovascular GPCR, TPSA isn't a *major* concern unless it's excessively high, but lower is generally preferred for permeability. Ligand B is significantly better here.
3. **logP:** Ligand A (0.184) is quite low, potentially hindering membrane permeability. Ligand B (2.182) is within the optimal 1-3 range. This is a substantial advantage for Ligand B.
4. **HBD:** Ligand A (3) is higher than Ligand B (1). Lower HBD is generally preferred for better permeability, giving a slight edge to Ligand B.
5. **HBA:** Ligand A (6) is higher than Ligand B (3). Similar to HBD, lower HBA is preferable, favoring Ligand B.
6. **QED:** Both ligands have good QED scores (0.675 and 0.829), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (67.31) has a higher DILI risk than Ligand B (7.45). This is a significant concern, as we want to minimize liver toxicity. Ligand B is much better.
8. **BBB:** Ligand A (41.22) has a lower BBB penetration percentile than Ligand B (71.97). While ADRB2 isn't a primary CNS target, some degree of BBB penetration can be useful for understanding off-target effects. Ligand B is better.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.161 and -4.909), which is unusual and suggests poor permeability. However, the values are very close.
10. **Solubility:** Ligand A (-1.982) has slightly worse solubility than Ligand B (-1.509). Solubility isn't a major concern here, but better is preferred.
11. **hERG:** Ligand A (0.104) has a lower hERG inhibition liability than Ligand B (0.466). This is a positive for Ligand A, reducing cardiotoxicity risk.
12. **Cl_mic:** Ligand A (14.28) has a higher microsomal clearance than Ligand B (-6.57). This means Ligand B is likely more metabolically stable, a significant advantage.
13. **t1/2:** Ligand A (-0.317) has a shorter in vitro half-life than Ligand B (-11.88). This further supports the better metabolic stability of Ligand B.
14. **Pgp:** Ligand A (0.022) has lower P-gp efflux than Ligand B (0.041). Lower Pgp is better, giving a slight edge to Ligand A.
15. **Binding Affinity:** Ligand A (-7.9) has a slightly better binding affinity than Ligand B (-6.6). This is a 1.3 kcal/mol difference, which is significant, but needs to be weighed against the other ADME properties.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity and lower Pgp efflux, Ligand B overwhelmingly wins on ADME properties critical for a viable drug candidate. Specifically, its significantly lower DILI risk, better logP, lower TPSA, and improved metabolic stability (lower Cl_mic, longer t1/2) are crucial advantages. The lower binding affinity of Ligand B is a drawback, but the ADME profile is far more favorable, and optimization could potentially improve its binding. The low logP of Ligand A is a major concern, likely leading to poor oral bioavailability.
Output:
0
2025-04-17 18:52:45,389 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [345.33 , 96.53 , 2.755, 3. , 4. , 0.794, 94.572, 54.634, -4.746, -4.013, 0.596, 5.3 , 24.419, 0.091, -6.7 ]
**Ligand B:** [372.535, 65.12 , -0.283, 1. , 6. , 0.663, 21.52 , 34.199, -5.29 , -1.081, 0.205, 12.122, 1.22 , 0.004, -6.2 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal 200-500 Da range. A (345.33) is slightly preferred.
2. **TPSA:** A (96.53) is higher than B (65.12), but both are acceptable for a non-CNS GPCR target like ADRB2. B is better here.
3. **logP:** A (2.755) is optimal. B (-0.283) is quite low and could lead to permeability issues. A is significantly better.
4. **HBD:** A (3) and B (1) are both good.
5. **HBA:** A (4) and B (6) are both acceptable, but A is slightly better.
6. **QED:** Both are good (A: 0.794, B: 0.663), indicating drug-like properties. A is slightly better.
7. **DILI:** A (94.572) is concerningly high, indicating a substantial risk of liver injury. B (21.52) is excellent, a major advantage.
8. **BBB:** Not a primary concern for ADRB2, but A (54.634) is higher than B (34.199).
9. **Caco-2:** A (-4.746) is very poor, suggesting very low intestinal absorption. B (-5.29) is also poor, but marginally better.
10. **Solubility:** A (-4.013) is poor, while B (-1.081) is better, though still not ideal. B is better.
11. **hERG:** A (0.596) is acceptable. B (0.205) is even better, lower risk of cardiotoxicity. B is better.
12. **Cl_mic:** A (5.3) is much lower than B (12.122), indicating better metabolic stability. A is significantly better.
13. **t1/2:** A (24.419) is much better than B (1.22), suggesting a longer duration of action. A is significantly better.
14. **Pgp:** A (0.091) is much lower than B (0.004), indicating less P-gp efflux and potentially better bioavailability. A is better.
15. **Affinity:** A (-6.7) is slightly better than B (-6.2), though the difference is relatively small.
**Overall Assessment:**
Ligand A has a better binding affinity, metabolic stability, half-life, and Pgp efflux profile. However, its extremely high DILI risk and poor Caco-2 permeability are major drawbacks. Ligand B has a much better safety profile (DILI, hERG) and slightly better solubility and TPSA, but suffers from a low logP and poor metabolic stability.
Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity) and the overall balance, the lower DILI risk of Ligand B is a critical factor. While the lower logP is a concern, it might be addressable through further optimization. The high DILI risk of Ligand A is much harder to mitigate.
Therefore, I would prioritize Ligand B for further development.
0
2025-04-17 18:52:45,389 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.475 & 345.487 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (63.57) is significantly better than Ligand B (75.43). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (1.736) is within the optimal range (1-3), while Ligand B (3.146) is at the higher end. While still acceptable, higher logP can sometimes lead to off-target effects.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (4) is preferable to Ligand B (3). Lower HBA generally improves permeability.
6. **QED:** Ligand A (0.851) is significantly better than Ligand B (0.561), indicating a more drug-like profile.
7. **DILI:** Both ligands have low DILI risk (32.493 and 30.826 percentile), which is good. No significant difference.
8. **BBB:** Ligand B (71.772) has a better BBB penetration score than Ligand A (57.968), but this isn't a major concern for a cardiovascular target.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.792 and -4.988). This is unusual and suggests poor permeability, but the values are similar.
10. **Solubility:** Ligand A (-1.609) is better than Ligand B (-3.625). Better solubility is always preferred.
11. **hERG:** Ligand A (0.203) has a much lower hERG inhibition liability than Ligand B (0.771). This is a significant advantage, as hERG inhibition can cause cardiotoxicity.
12. **Cl_mic:** Ligand A (40.345) has a lower microsomal clearance than Ligand B (53.532), indicating better metabolic stability.
13. **t1/2:** Ligand A (26.605) has a longer in vitro half-life than Ligand B (10.05). This is a significant advantage, allowing for less frequent dosing.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.103 and 0.107). No significant difference.
15. **Binding Affinity:** Ligand A (-8.2 kcal/mol) has a significantly stronger binding affinity than Ligand B (-5.9 kcal/mol). This is a substantial advantage, potentially outweighing minor ADME drawbacks.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A excels in affinity and has a more favorable logP and TPSA. While Ligand B has better BBB penetration, this isn't critical for a cardiovascular target. The superior affinity, QED, solubility, hERG profile, metabolic stability, and half-life of Ligand A make it the more promising candidate.
**Output:**
1
2025-04-17 18:52:45,389 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (360.38 & 367.52 Da) fall comfortably within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (61.8) is significantly better than Ligand B (78.51). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (3.63) is higher than Ligand B (1.29). While both are within the acceptable range, Ligand A is closer to the optimal 1-3 range, suggesting better membrane permeability. Ligand B is on the lower side, potentially hindering absorption.
4. **HBD:** Both have 2 HBD, which is good.
5. **HBA:** Ligand A has 3 HBA, while Ligand B has 4. Both are acceptable, but Ligand A is slightly better.
6. **QED:** Ligand A (0.843) is slightly better than Ligand B (0.788), indicating a more drug-like profile.
7. **DILI:** Ligand B (38.0) has a considerably lower DILI risk than Ligand A (42.7), which is a significant advantage.
8. **BBB:** Ligand A (89.6) has a higher BBB penetration than Ligand B (41.8). While not a primary concern for a cardiovascular target, it's a neutral benefit for Ligand A.
9. **Caco-2:** Ligand A (-4.084) has a better Caco-2 permeability than Ligand B (-5.211).
10. **Solubility:** Ligand A (-3.159) is better than Ligand B (-3.367).
11. **hERG:** Ligand A (0.574) has a slightly better hERG profile than Ligand B (0.112).
12. **Cl_mic:** Ligand B (33.0) has a significantly lower microsomal clearance than Ligand A (57.6), suggesting better metabolic stability. This is a crucial advantage.
13. **t1/2:** Ligand B (20.0) has a longer in vitro half-life than Ligand A (-23.0). This is another significant advantage.
14. **Pgp:** Ligand A (0.127) has better Pgp efflux liability than Ligand B (0.036).
15. **Binding Affinity:** Ligand B (-5.8) has a stronger binding affinity than Ligand A (-4.6) by a margin of 1.2 kcal/mol. This is a substantial difference and a major factor.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, and affinity. Ligand A has better logP, TPSA, and Pgp. However, Ligand B has a significantly better binding affinity (-5.8 vs -4.6 kcal/mol). The affinity difference is large enough to outweigh the slight advantages Ligand A has in other areas. Furthermore, Ligand B has a much better DILI and metabolic stability profile.
**Conclusion:**
While Ligand A has some favorable properties, the superior binding affinity, lower DILI risk, and better metabolic stability of Ligand B make it the more promising drug candidate for the ADRB2 receptor.
Output:
0
2025-04-17 18:52:45,389 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (389.5 & 351.4 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand B (104.9) is better than Ligand A (121.36) as it's closer to the <140 threshold for good oral absorption.
3. **logP:** Ligand B (0.571) is within the optimal 1-3 range, while Ligand A (-0.625) is slightly below, potentially hindering permeation. Ligand B is preferred.
4. **HBD:** Both have 2 HBD, meeting the <=5 criteria.
5. **HBA:** Ligand B (6) is better than Ligand A (7), both are acceptable.
6. **QED:** Ligand B (0.776) has a better QED score than Ligand A (0.543), indicating a more drug-like profile.
7. **DILI:** Ligand B (38.62) has a lower DILI risk than Ligand A (52.074), which is a significant advantage.
8. **BBB:** Ligand B (62.699) shows better BBB penetration than Ligand A (41.334), though neither is exceptionally high. For a cardiovascular target, BBB isn't a primary concern, but it's a slight benefit for Ligand B.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.841 and -5.018), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Both ligands have negative solubility values (-1.32 and -1.979), indicating poor aqueous solubility. This is a significant drawback for both.
11. **hERG:** Ligand B (0.152) has a lower hERG risk than Ligand A (0.08), which is a positive.
12. **Cl_mic:** Ligand B (-3.731) has a significantly lower microsomal clearance than Ligand A (14.951), indicating better metabolic stability. This is a major advantage.
13. **t1/2:** Ligand B (5.92) has a longer in vitro half-life than Ligand A (-18.341), which is a positive.
14. **Pgp:** Ligand B (0.095) has lower P-gp efflux than Ligand A (0.017), which is a positive.
15. **Binding Affinity:** Ligand B (-7.3) has a slightly better binding affinity than Ligand A (-6.7). While the difference is less than 1.5 kcal/mol, it contributes to the overall preference.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand B performs better in all these areas.
**Overall Assessment:**
Ligand B consistently outperforms Ligand A across most critical ADME-Tox properties (DILI, Cl_mic, t1/2, Pgp, hERG) and has a slightly better binding affinity and QED score. While both have poor Caco-2 and solubility, the superior ADME profile of Ligand B makes it the more promising candidate.
Output:
0
2025-04-17 18:52:45,389 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [350.507, 76.14, 3.594, 2, 5, 0.735, 23.769, 73.905, -4.754, -2.88, 0.553, 47.234, 21.344, 0.057, -6.2]
**Ligand B:** [358.873, 58.12, 3.265, 1, 4, 0.736, 57.658, 86.7, -5.096, -3.455, 0.909, 85.078, 75.731, 0.773, -6.3]
**Step-by-step Comparison:**
1. **MW:** Both ligands are within the ideal 200-500 Da range. (A: 350.5, B: 358.9) - No clear advantage.
2. **TPSA:** Ligand A (76.14) is higher than Ligand B (58.12). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for permeability. Ligand B is better.
3. **logP:** Both ligands have good logP values (A: 3.594, B: 3.265) within the optimal 1-3 range. Ligand B is slightly better.
4. **HBD:** Ligand A (2) and Ligand B (1) both have acceptable HBD counts. Ligand B is better.
5. **HBA:** Ligand A (5) and Ligand B (4) are both good. Ligand B is better.
6. **QED:** Both ligands have similar and good QED values (A: 0.735, B: 0.736). - No clear advantage.
7. **DILI:** Ligand A (23.769) has a significantly lower DILI risk than Ligand B (57.658). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (86.7) has a better BBB penetration percentile than Ligand A (73.905). While ADRB2 isn't primarily a CNS target, some CNS exposure can be a concern for off-target effects.
9. **Caco-2:** Ligand A (-4.754) and Ligand B (-5.096) are both negative, which is unusual and suggests poor permeability. Ligand B is slightly better.
10. **Solubility:** Ligand A (-2.88) and Ligand B (-3.455) are both very poor. Solubility is a concern for both. Ligand A is slightly better.
11. **hERG:** Ligand A (0.553) has a lower hERG risk than Ligand B (0.909). This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand A (47.234) has a lower microsomal clearance than Ligand B (85.078), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand B (75.731) has a longer in vitro half-life than Ligand A (21.344). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.057) has lower P-gp efflux liability than Ligand B (0.773). This is a good advantage for Ligand A.
15. **Affinity:** Both ligands have very similar and excellent binding affinities (A: -6.2, B: -6.3). The difference is negligible.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), and the general drug-like properties, Ligand A emerges as the more promising candidate. While Ligand B has a better BBB score and longer half-life, Ligand A has a much lower DILI risk, lower hERG risk, lower Pgp efflux, and better metabolic stability (lower Cl_mic). The DILI and hERG risks are critical safety parameters, and the lower values for Ligand A are substantial advantages. The slightly lower TPSA of Ligand B is outweighed by the safety and metabolic benefits of Ligand A.
Output:
1
2025-04-17 18:52:45,390 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [349.475, 72.88, 0.6, 2, 4, 0.689, 4.692, 29.275, -5.056, -0.408, 0.365, -25.518, -9.877, 0.033, -6.3]
**Ligand B:** [376.766, 71.25, 3.077, 1, 5, 0.87, 60.217, 68.282, -4.688, -3.369, 0.274, 53.686, -24.086, 0.145, -5.1]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity) and general drug-like properties:
1. **MW:** Both are within the acceptable 200-500 Da range. Ligand A (349.475) is slightly preferred.
2. **TPSA:** Both are good, below 140, suggesting reasonable absorption. Ligand B (71.25) is slightly better.
3. **logP:** Ligand A (0.6) is quite low, potentially hindering membrane permeability. Ligand B (3.077) is much better, falling within the optimal 1-3 range. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable.
5. **HBA:** Ligand A (4) and Ligand B (5) are both acceptable.
6. **QED:** Ligand B (0.87) is better than Ligand A (0.689), indicating a more drug-like profile.
7. **DILI:** Ligand A (4.692) has a very favorable DILI risk. Ligand B (60.217) is significantly higher, indicating a potential liver toxicity concern. This is a major drawback for Ligand B.
8. **BBB:** Ligand B (68.282) shows better BBB penetration than Ligand A (29.275). While ADRB2 is a cardiovascular target, some CNS exposure can occur, and higher BBB is generally beneficial.
9. **Caco-2:** Ligand A (-5.056) is worse than Ligand B (-4.688), suggesting lower intestinal absorption.
10. **Solubility:** Ligand A (-0.408) is better than Ligand B (-3.369).
11. **hERG:** Both are low (0.365 and 0.274), indicating low cardiotoxicity risk.
12. **Cl_mic:** Ligand A (-25.518) has a much lower (better) microsomal clearance than Ligand B (53.686), suggesting greater metabolic stability.
13. **t1/2:** Ligand A (-9.877) has a longer half-life than Ligand B (-24.086).
14. **Pgp:** Ligand A (0.033) has significantly lower P-gp efflux liability than Ligand B (0.145), which is a positive for bioavailability.
15. **Affinity:** Both have very good binding affinities (-6.3 and -5.1 kcal/mol). Ligand A is slightly better, but the difference is not huge.
**Overall Assessment:**
Ligand B has advantages in logP, BBB penetration, Caco-2 permeability, and QED. However, the significantly higher DILI risk and poorer metabolic stability (higher Cl_mic, shorter half-life) are major concerns. Ligand A, while having a lower logP, compensates with a much better safety profile (DILI), metabolic stability, and P-gp efflux. The slightly better affinity of Ligand A is also a plus. Given the cardiovascular context, metabolic stability and safety are paramount.
Therefore, I prefer Ligand A.
1
2025-04-17 18:52:45,390 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (370.377 and 347.39 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Both ligands (84.5 and 80.32) are below the 140 A^2 threshold for good oral absorption. Ligand B is slightly better.
3. **logP:** Both ligands (2.279 and 1.797) are within the optimal 1-3 range. Ligand B is slightly lower, which could be beneficial for solubility.
4. **HBD:** Both ligands have 2 HBD, which is acceptable.
5. **HBA:** Both ligands have 4 HBA, which is acceptable.
6. **QED:** Ligand A (0.817) has a higher QED score than Ligand B (0.703), indicating better overall drug-likeness.
7. **DILI:** Ligand A (93.835) has a significantly higher DILI risk than Ligand B (49.399). This is a major concern for Ligand A.
8. **BBB:** Ligand B (77.2) has a higher BBB penetration percentile than Ligand A (62.233). While ADRB2 isn't necessarily a CNS target, some peripheral ADRB2 receptors can be affected by CNS penetration.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.587 and -4.408), which is unusual and suggests very poor permeability. This is a significant drawback for both.
10. **Solubility:** Ligand B (-2.634) has a better solubility score than Ligand A (-4.534).
11. **hERG:** Ligand A (0.519) has a slightly higher hERG inhibition liability than Ligand B (0.108). Lower is better here.
12. **Cl_mic:** Ligand B (33.582) has a significantly lower microsomal clearance than Ligand A (74.079), suggesting better metabolic stability.
13. **t1/2:** Ligand B (5.109 hours) has a much longer in vitro half-life than Ligand A (-24.517 hours). The negative value for Ligand A is concerning and likely an error, but even setting it to zero, Ligand B is preferable.
14. **Pgp:** Ligand B (0.026) has a much lower P-gp efflux liability than Ligand A (0.209), which is favorable for oral bioavailability.
15. **Binding Affinity:** Ligand B (-6.2 kcal/mol) has a significantly stronger binding affinity than Ligand A (-2.8 kcal/mol). This is a substantial difference and a major advantage for Ligand B.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand B excels in these areas. While BBB isn't critical for all ADRB2 applications, the higher value for Ligand B is a plus. The significantly lower DILI risk and better metabolic stability of Ligand B are also crucial advantages. The strong binding affinity of Ligand B outweighs the slightly better QED of Ligand A. The poor Caco-2 values are a concern for both, but the other advantages of Ligand B are more compelling.
Output:
0
2025-04-17 18:52:45,390 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (378.877) is slightly higher than Ligand B (348.443), but both are acceptable.
2. **TPSA:** Ligand A (52.6) is significantly better than Ligand B (82.78). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (4.772) is a bit high, potentially leading to solubility issues. Ligand B (2.628) is within the optimal range. This favors Ligand B.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (4). Lower HBA is generally better for permeability.
6. **QED:** Both ligands have good QED scores (A: 0.722, B: 0.774), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (70.415) is higher than Ligand B (41.838). Lower DILI is crucial, so Ligand B is favored.
8. **BBB:** Not a primary concern for a cardiovascular target. Ligand A (77.588) is higher than Ligand B (39.744), but this isn't a deciding factor.
9. **Caco-2:** Both ligands have similar, poor Caco-2 permeability (-4.826 and -4.868). This is a concern for both, but not a major differentiator.
10. **Solubility:** Ligand A (-4.545) is better than Ligand B (-2.518). Solubility is important, and Ligand A has a better score.
11. **hERG:** Both ligands have very low hERG risk (0.225 and 0.236), which is excellent.
12. **Cl_mic:** Ligand A (77.326) is higher than Ligand B (10.743), indicating faster metabolism and lower stability. Ligand B is significantly better.
13. **t1/2:** Ligand A (39.205) is better than Ligand B (21.423). A longer half-life is generally desirable.
14. **Pgp:** Both ligands have low Pgp efflux (0.506 and 0.216), which is good.
15. **Binding Affinity:** Ligand A (-7.6) has a significantly stronger binding affinity than Ligand B (-6.3). This is a substantial advantage (1.3 kcal/mol difference).
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, and affinity. Ligand A has a higher logP, but a much better affinity. Ligand B has a better logP and TPSA, but the affinity difference is substantial. The lower DILI risk of Ligand B is also a significant advantage.
**Overall Assessment:**
While Ligand A has a higher logP, the significantly stronger binding affinity (-7.6 vs -6.3 kcal/mol) and better solubility, coupled with acceptable DILI risk, outweigh the slightly higher logP. The better metabolic stability (longer half-life) of Ligand A is also a plus. The TPSA difference is not large enough to negate the affinity advantage.
Output:
1
2025-04-17 18:52:45,390 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (365.5 Da) is within the ideal range, while Ligand B (389.5 Da) is slightly higher but still acceptable.
2. **TPSA:** Ligand A (54.9) is excellent, well below the 140 threshold. Ligand B (81.1) is higher, but still reasonable for a non-CNS target.
3. **logP:** Both ligands have good logP values (A: 2.05, B: 3.27), falling within the 1-3 range. Ligand B is a bit higher, which could potentially lead to slight solubility issues, but is not a major concern.
4. **HBD:** Ligand A has 0 HBD, which is good. Ligand B has 1 HBD, also acceptable.
5. **HBA:** Both ligands have 7 HBA, which is within the acceptable range of <=10.
6. **QED:** Ligand A (0.745) has a better QED score than Ligand B (0.581), suggesting better overall drug-likeness.
7. **DILI:** Ligand A (50.3%) has a significantly lower DILI risk than Ligand B (98.8%). This is a crucial advantage.
8. **BBB:** ADRB2 is a cardiovascular target, so BBB penetration is not a high priority. Ligand A (92.6%) has higher BBB penetration than Ligand B (50.7%), but this is less important here.
9. **Caco-2:** Ligand A (-4.5) is better than Ligand B (-5.4), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-2.55) is better than Ligand B (-3.49), indicating better aqueous solubility.
11. **hERG:** Both ligands have low hERG inhibition risk (A: 0.67, B: 0.38).
12. **Cl_mic:** Ligand A (56.96) has a higher microsomal clearance than Ligand B (18.97), meaning it will be metabolized faster. This is a disadvantage for Ligand A.
13. **t1/2:** Ligand B (100.44) has a much longer in vitro half-life than Ligand A (0.43). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.52) has lower P-gp efflux liability than Ligand B (0.434), which is favorable.
15. **Affinity:** Ligand A (-8.6 kcal/mol) has a slightly better binding affinity than Ligand B (-7.1 kcal/mol). This is a 1.5 kcal/mol advantage, which is significant.
**GPCR-specific considerations:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Both ligands perform well on logP and TPSA. Ligand A has a slight edge on Pgp, but Ligand B has a substantial advantage in metabolic stability (lower Cl_mic, longer t1/2) and a significantly lower DILI risk. The affinity difference is 1.5 kcal/mol, which is substantial, but the ADME profile of Ligand A is concerning due to the high Cl_mic and DILI risk.
**Conclusion:**
While Ligand A has slightly better affinity and Pgp properties, the significantly lower DILI risk, better metabolic stability (longer half-life, lower clearance), and acceptable solubility of Ligand B make it the more promising drug candidate overall. The higher affinity of Ligand A is outweighed by its poor ADME profile.
Output:
0
2025-04-17 18:52:45,390 - INFO - Batch 69 complete. Total preferences: 1104
2025-04-17 18:52:45,390 - INFO - Processing batch 70/512...
2025-04-17 18:53:33,339 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (361.873 and 354.426 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (62.3) is better than Ligand B (69.48). Both are below 140, but lower TPSA generally favors absorption.
3. **logP:** Ligand A (3.633) is higher than Ligand B (1.694). While both are within the acceptable range, Ligand A is closer to the upper limit and could potentially have solubility issues, but is more likely to have good membrane permeability.
4. **HBD:** Ligand A (1) is better than Ligand B (0). A single HBD is a good balance.
5. **HBA:** Ligand A (3) is better than Ligand B (6). Lower HBA is preferable for permeability.
6. **QED:** Ligand A (0.814) is significantly better than Ligand B (0.472), indicating a more drug-like profile.
7. **DILI:** Ligand B (41.14) is slightly better than Ligand A (48.623), but both are below the concerning threshold of 60.
8. **BBB:** Ligand B (91.508) is significantly better than Ligand A (80.031). While ADRB2 isn't necessarily a CNS target, higher BBB penetration can sometimes correlate with better overall distribution.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.994 and -4.517). This is unusual and suggests poor permeability *in vitro*. However, these values are on a log scale, and the absolute difference isn't huge.
10. **Solubility:** Ligand B (-1.277) is better than Ligand A (-4.15), indicating better aqueous solubility.
11. **hERG:** Ligand A (0.59) is better than Ligand B (0.273), meaning lower risk of hERG inhibition.
12. **Cl_mic:** Ligand B (31.716) is better than Ligand A (43.409), suggesting better metabolic stability.
13. **t1/2:** Ligand A (35.767) is significantly better than Ligand B (-3.49). A longer half-life is generally desirable.
14. **Pgp:** Ligand A (0.126) is better than Ligand B (0.165), suggesting lower P-gp efflux.
15. **Binding Affinity:** Ligand A (-6.4) is slightly better than Ligand B (-5.7), though the difference is less than 1.5 kcal/mol.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A has a better logP, TPSA, and Pgp. The affinity difference is minor.
**Overall Assessment:**
Ligand A demonstrates a more favorable balance of properties. It has a better QED score, lower HBA, better hERG profile, and a longer half-life. While Ligand B has better solubility and slightly better DILI and BBB, the overall profile of Ligand A is more promising, especially considering the GPCR-specific priorities. The negative Caco-2 values are a concern for both, but the other advantages of Ligand A outweigh this drawback.
Output:
1
2025-04-17 18:53:33,339 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (389.405 Da) is within the ideal range (200-500). Ligand B (346.343 Da) is also within the ideal range. No clear advantage here.
2. **TPSA:** Ligand A (90.41) is good, below the 140 threshold. Ligand B (132.64) is approaching the upper limit for good oral absorption, but still acceptable. Ligand A is slightly preferred.
3. **logP:** Ligand A (2.795) is optimal (1-3). Ligand B (-0.554) is below 1, which could impede permeation. Ligand A is significantly preferred.
4. **HBD:** Ligand A (1) is good. Ligand B (3) is acceptable, but higher. Ligand A is preferred.
5. **HBA:** Ligand A (8) is good. Ligand B (6) is good. No clear advantage.
6. **QED:** Both ligands have good QED scores (A: 0.548, B: 0.655). Ligand B is slightly better.
7. **DILI:** Ligand A (93.059) has a higher DILI risk, which is concerning. Ligand B (75.029) has a much lower, and acceptable, DILI risk. Ligand B is strongly preferred.
8. **BBB:** Ligand A (84.955) has good BBB penetration. Ligand B (46.336) is lower. Since ADRB2 is a GPCR, BBB penetration is a consideration, and Ligand A is preferred.
9. **Caco-2:** Both have negative values, indicating permeability. Ligand A (-4.911) is slightly better than Ligand B (-5.648).
10. **Solubility:** Both have negative values, indicating solubility. Ligand A (-4.862) is slightly better than Ligand B (-3.299).
11. **hERG:** Ligand A (0.321) has a very low hERG risk. Ligand B (0.131) also has a very low hERG risk. No clear advantage.
12. **Cl_mic:** Ligand A (98.647) has high metabolic clearance, which is undesirable. Ligand B (4.054) has very low clearance, indicating good metabolic stability. Ligand B is strongly preferred.
13. **t1/2:** Ligand A (-6.058) has a negative half-life, which is not possible. This is a red flag. Ligand B (0.272) is very short, but at least plausible. Ligand B is preferred.
14. **Pgp:** Ligand A (0.37) has low P-gp efflux. Ligand B (0.026) has very low P-gp efflux. No clear advantage.
15. **Affinity:** Ligand B (-7.0 kcal/mol) has a slightly better binding affinity than Ligand A (-6.0 kcal/mol). This is a significant advantage, but needs to be weighed against other factors.
**Overall Assessment:**
Ligand A has better logP, TPSA, and BBB penetration, which are important for GPCRs. However, it has a concerningly high DILI risk, very high metabolic clearance, and an impossible half-life. Ligand B has a significantly lower DILI risk, excellent metabolic stability, and a slightly better binding affinity. While its logP is suboptimal, the other advantages, particularly the safety profile and metabolic stability, outweigh this drawback.
Therefore, I prefer Ligand B.
Output:
0
2025-04-17 18:53:33,340 - INFO - Here's a step-by-step reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [348.531, 58.2, 3.508, 2, 2, 0.705, 12.602, 78.945, -4.644, -4.661, 0.62, 82.306, -1.187, 0.142, -6]**
**Ligand B: [354.51, 58.2, 3.741, 2, 2, 0.732, 38.891, 83.249, -4.558, -4.543, 0.58, 50.603, 23.084, 0.342, -7.9]**
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). A (348.531) is slightly lower, which is generally favorable for permeability.
**2. TPSA:** Both ligands have a TPSA of 58.2, well below the 140 A^2 threshold for oral absorption.
**3. logP:** Both ligands have logP values within the optimal range (1-3), with A at 3.508 and B at 3.741. B is slightly higher, but still acceptable.
**4. H-Bond Donors:** Both have 2 HBD, which is within the acceptable limit of <=5.
**5. H-Bond Acceptors:** Both have 2 HBA, well below the limit of <=10.
**6. QED:** Both ligands have a QED above 0.5 (A: 0.705, B: 0.732), indicating good drug-like properties.
**7. DILI:** Ligand A (12.602) has a significantly lower DILI risk than Ligand B (38.891). This is a major advantage for Ligand A.
**8. BBB:** Both ligands have good BBB penetration (A: 78.945, B: 83.249). B is slightly better, but both are acceptable.
**9. Caco-2 Permeability:** Both have negative Caco-2 values which is unusual.
**10. Aqueous Solubility:** Both have negative solubility values which is unusual.
**11. hERG Inhibition:** Both have low hERG inhibition risk (A: 0.62, B: 0.58).
**12. Microsomal Clearance:** Ligand A (82.306) has a higher microsomal clearance than Ligand B (50.603), suggesting lower metabolic stability. This is a disadvantage for A.
**13. In vitro Half-Life:** Ligand B (23.084) has a significantly longer in vitro half-life than Ligand A (-1.187). This is a major advantage for B.
**14. P-gp Efflux:** Ligand A (0.142) has lower P-gp efflux than Ligand B (0.342), which is favorable.
**15. Binding Affinity:** Ligand B (-7.9 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6 kcal/mol). This is a substantial advantage for B, potentially outweighing some ADME drawbacks.
**GPCR-Specific Priorities:** For ADRB2 (a GPCR), we prioritize logP, Pgp, TPSA, and affinity. Both ligands are good on logP and TPSA. Ligand A has a slight advantage on Pgp, but Ligand B has a *much* stronger binding affinity and better half-life, and acceptable BBB penetration. The lower DILI risk of Ligand A is attractive, but the substantial affinity difference and better half-life of Ligand B are more critical for a GPCR target.
**Conclusion:**
Considering all factors, especially the significantly stronger binding affinity and improved half-life of Ligand B, it is the more promising drug candidate despite the higher DILI risk. The affinity difference is substantial enough to offset the DILI concern, especially given the relatively moderate DILI percentile of 38.891.
0
2025-04-17 18:53:33,340 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (345.399 Da and 352.41 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (98.74) is slightly higher than Ligand B (94.56), but both are below the 140 threshold for good oral absorption.
3. **logP:** Ligand A (1.519) is within the optimal 1-3 range. Ligand B (-0.302) is slightly below 1, which *could* indicate potential permeability issues, though not drastically.
4. **HBD:** Both ligands have 3 H-bond donors, which is acceptable.
5. **HBA:** Ligand A has 4 H-bond acceptors, and Ligand B has 5. Both are within the acceptable limit of 10.
6. **QED:** Ligand A (0.768) has a better QED score than Ligand B (0.586), indicating a more drug-like profile.
7. **DILI:** Ligand B (20.279) has a significantly lower DILI risk than Ligand A (60.14). This is a major advantage for Ligand B.
8. **BBB:** Ligand A (53.587) has a moderate BBB penetration, while Ligand B (37.573) is lower. For a cardiovascular target like ADRB2, BBB penetration isn't a primary concern, so this difference is less critical.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.759 and -5.263). These values are unusual and difficult to interpret without further context. However, they suggest poor permeability.
10. **Solubility:** Both ligands have very low solubility scores (-2 and -1.135). This is a significant concern for both, and formulation would be a major challenge.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.098 and 0.136). This is excellent.
12. **Cl_mic:** Ligand A (-17.548) has a lower (better) microsomal clearance than Ligand B (-16.365), suggesting greater metabolic stability.
13. **t1/2:** Ligand A (14.86) has a much longer in vitro half-life than Ligand B (-6.777). This is a substantial advantage for Ligand A.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.008 and 0.005). This is favorable.
15. **Binding Affinity:** Ligand B (-7.3 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.6 kcal/mol). This is a 1.7 kcal/mol difference, which is substantial and can outweigh some ADME drawbacks.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand B excels in affinity, has acceptable TPSA, and low Pgp efflux. While its logP is slightly low, the strong binding affinity is a significant advantage. The lower DILI risk of Ligand B is also a major positive. Ligand A has a better QED and metabolic stability, but the weaker binding and higher DILI risk are concerning.
**Conclusion:**
Despite the solubility concerns for both, the significantly stronger binding affinity and lower DILI risk of Ligand B make it the more promising candidate. The difference in affinity is large enough to compensate for the slightly lower logP.
Output:
0
2025-04-17 18:53:33,340 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (339.439 and 348.443 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (58.22) is significantly better than Ligand B (71.78). ADRB2 is a cardiovascular target, not CNS, but lower TPSA generally aids absorption.
3. **logP:** Ligand A (3.882) is slightly higher than Ligand B (2.544). Both are within the optimal 1-3 range, but Ligand A is closer to the upper limit.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 3 HBAs, while Ligand B has 4. Both are acceptable, but Ligand A is slightly preferred.
6. **QED:** Ligand A (0.841) has a better QED score than Ligand B (0.696), indicating a more drug-like profile.
7. **DILI:** Ligand B (32.881) has a much lower DILI risk than Ligand A (68.437). This is a significant advantage for Ligand B.
8. **BBB:** Ligand B (61.497) has a higher BBB penetration than Ligand A (41.295). While not a primary concern for a cardiovascular target, higher BBB is generally not detrimental.
9. **Caco-2:** Ligand A (-5.028) and Ligand B (-4.662) are both negative, indicating poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-4.074) is slightly worse than Ligand B (-2.556). Solubility is important for bioavailability.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.349 and 0.395).
12. **Cl_mic:** Both ligands have similar microsomal clearance (47.114 and 46.104 mL/min/kg).
13. **t1/2:** Ligand B (30.809) has a significantly longer in vitro half-life than Ligand A (-13.889). This is a major advantage for Ligand B.
14. **Pgp:** Both ligands have similar Pgp efflux liability (0.394 and 0.379).
15. **Binding Affinity:** Ligand B (-6.7) has a slightly better binding affinity than Ligand A (-6.5). While the difference is small, it's still a positive for Ligand B.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A has a slightly better logP and TPSA, but Ligand B has better affinity. The biggest differences are in DILI risk and half-life, where Ligand B is significantly better.
**Overall Assessment:**
While Ligand A has a slightly better QED and TPSA, Ligand B's significantly lower DILI risk, longer half-life, and slightly better affinity outweigh these advantages. The poor Caco-2 permeability is a concern for both, but can be addressed through formulation strategies. The lower DILI risk is crucial for clinical development.
Output:
0
2025-04-17 18:53:33,340 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (336.315 Da) is slightly lower, which can be beneficial for permeability.
2. **TPSA:** Ligand B (71.33) is significantly better than Ligand A (134.36). ADRB2 is not a CNS target, but lower TPSA generally improves absorption.
3. **logP:** Both ligands have good logP values (A: 1.399, B: 2.045), falling within the optimal 1-3 range. Ligand B is slightly higher, which could be a minor advantage.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (0). Both are acceptable, but lower is generally preferred.
5. **HBA:** Ligand A (7) is higher than Ligand B (6). Again, lower is generally preferred.
6. **QED:** Both ligands have good QED scores (A: 0.512, B: 0.747), indicating good drug-like properties. Ligand B is better.
7. **DILI:** Ligand B (58.666) is significantly better than Ligand A (98.449), indicating a lower risk of drug-induced liver injury. This is a crucial factor.
8. **BBB:** Not a primary concern for ADRB2, but Ligand B (80.419) is higher than Ligand A (29.12).
9. **Caco-2:** Ligand A (-5.435) is better than Ligand B (-4.859), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-4.119) is better than Ligand B (-2.535), indicating better aqueous solubility.
11. **hERG:** Both ligands have low hERG inhibition liability (A: 0.498, B: 0.177), which is excellent. Ligand B is slightly better.
12. **Cl_mic:** Ligand A (9.925) has a much lower microsomal clearance than Ligand B (42.802), suggesting better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand A (10.995) has a longer in vitro half-life than Ligand B (-3.383). This is a significant advantage.
14. **Pgp:** Both ligands have low P-gp efflux liability (A: 0.143, B: 0.257).
15. **Binding Affinity:** Ligand B (-7.3) has a slightly better binding affinity than Ligand A (-7.2), but the difference is small.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand B has a slightly better logP and affinity, and a much better TPSA. However, Ligand A has better Caco-2 permeability, solubility, metabolic stability (Cl_mic), and half-life, and a significantly lower DILI risk.
**Overall Assessment:**
While Ligand B has a slightly better affinity and TPSA, the significantly lower DILI risk, better metabolic stability (lower Cl_mic), and longer half-life of Ligand A are more critical for overall drug development success. The small difference in binding affinity is unlikely to outweigh these substantial ADME/Tox advantages.
**Output:**
1
2025-04-17 18:53:33,340 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.353 and 356.413 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (71.42) is better than Ligand B (78.43). Both are below 140, but lower is preferred for absorption.
3. **logP:** Both ligands (2.783 and 2.93) are within the optimal 1-3 range. Ligand B is slightly higher, which could potentially lead to off-target effects, but it's not a major concern.
4. **HBD:** Ligand A (2) is preferable to Ligand B (3). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (3). Lower HBA generally improves permeability.
6. **QED:** Ligand A (0.719) is better than Ligand B (0.637), indicating a more drug-like profile.
7. **DILI:** Ligand A (69.678) has a significantly higher DILI risk than Ligand B (38.116). This is a major concern for Ligand A.
8. **BBB:** Ligand A (67.468) is better than Ligand B (59.248), although ADRB2 isn't necessarily a CNS target, some degree of BBB penetration can be beneficial for distribution.
9. **Caco-2:** Both ligands have similar, very negative Caco-2 values (-5.016 and -5.067), suggesting poor permeability. This is a significant drawback for both.
10. **Solubility:** Ligand A (-4.147) is slightly better than Ligand B (-3.301), but both are very poor, indicating formulation challenges.
11. **hERG:** Ligand A (0.795) is better than Ligand B (0.689), indicating a lower risk of cardiotoxicity.
12. **Cl_mic:** Ligand A (10.125) has significantly lower microsomal clearance than Ligand B (42.36), suggesting better metabolic stability.
13. **t1/2:** Ligand A (1.254) has a shorter half-life than Ligand B (-16.006). The negative value for Ligand B is unusual and suggests a very long half-life, which is positive.
14. **Pgp:** Ligand A (0.205) is better than Ligand B (0.228), indicating lower P-gp efflux.
15. **Binding Affinity:** Ligand B (-7.2 kcal/mol) has a slightly better binding affinity than Ligand A (-8.1 kcal/mol). While A is better, the difference isn't substantial enough to overcome other issues.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. While both ligands have acceptable logP values, Ligand A has a better TPSA and Pgp profile. However, the significantly higher DILI risk for Ligand A is a major red flag. The slightly better affinity of Ligand B is helpful, but the lower DILI risk and longer half-life are more important.
**Conclusion:**
Despite Ligand A having slightly better TPSA, Pgp, and a marginally better binding affinity, the significantly higher DILI risk and shorter half-life make it a less desirable candidate. Ligand B, with its lower DILI risk, longer half-life, and acceptable overall profile, is the more promising candidate.
Output:
0
2025-04-17 18:53:33,340 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (344.415) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are below the 140 A^2 threshold for good oral absorption. Ligand A (87.46) is better than Ligand B (97.55), aligning with GPCR preference for lower TPSA.
3. **logP:** Both are within the optimal range (1-3). Ligand B (1.734) is slightly higher, which *could* indicate better membrane permeability, but also a potential for off-target interactions. Ligand A (0.678) is a bit low, potentially hindering permeation.
4. **HBD & HBA:** Both have 2 HBD and 5 HBA, which are acceptable values.
5. **QED:** Ligand A (0.79) has a better QED score than Ligand B (0.484), indicating a more drug-like profile.
6. **DILI:** Both are reasonably low, but Ligand A (44.048) is slightly better than Ligand B (48.623).
7. **BBB:** Both are acceptable, but Ligand B (68.088) is better than Ligand A (62.04). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be beneficial for distribution.
8. **Caco-2:** Both are negative, indicating poor permeability. Ligand B (-5.064) is slightly worse than Ligand A (-4.891).
9. **Solubility:** Both are negative, indicating poor solubility. Ligand B (-2.492) is slightly worse than Ligand A (-2.652).
10. **hERG:** Both are very low, indicating minimal hERG inhibition risk. Ligand B (0.473) is slightly higher than Ligand A (0.114).
11. **Cl_mic:** Ligand A (-13.278) has a significantly lower (better) microsomal clearance than Ligand B (39.073), suggesting better metabolic stability.
12. **t1/2:** Ligand B (33.262) has a much longer in vitro half-life than Ligand A (-3.018). This is a significant advantage.
13. **Pgp:** Both are low, indicating minimal P-gp efflux. Ligand B (0.052) is slightly higher than Ligand A (0.03).
14. **Binding Affinity:** Both have very similar binding affinities (-6.7 and -6.6 kcal/mol). The difference is negligible.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand A is slightly favored. While Ligand B has a better half-life and BBB penetration, Ligand A has a better TPSA, QED, DILI, and crucially, significantly better metabolic stability (lower Cl_mic). The slight disadvantage in logP for Ligand A is outweighed by its superior ADME properties, especially metabolic stability, which is critical for *in vivo* efficacy. The binding affinity is essentially the same. Poor Caco-2 and solubility are concerns for both, but can be addressed with formulation strategies.
Output:
1
2025-04-17 18:53:33,340 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's analyze each ligand against the provided guidelines, with emphasis on GPCR-relevant parameters (logP, TPSA, Pgp, BBB, and affinity).
* **Molecular Weight:** Both ligands (348.4 & 364.4 Da) fall comfortably within the ideal 200-500 Da range.
* **TPSA:** Both are below the 140 A^2 threshold for good absorption (99.8 & 94.0 A^2).
* **logP:** Ligand A (1.13) is slightly better than Ligand B (0.603), falling more squarely within the optimal 1-3 range. Ligand B is a bit low, potentially impacting membrane permeability.
* **H-Bond Donors/Acceptors:** Ligand A (1 HBD, 6 HBA) is slightly more favorable than Ligand B (2 HBD, 7 HBA). Both are within acceptable limits.
* **QED:** Ligand A (0.875) has a significantly better QED score than Ligand B (0.656), indicating a more drug-like profile.
* **DILI:** Both ligands have acceptable DILI risk (46.2 & 49.6 percentile), below the concerning 60 threshold.
* **BBB:** Ligand B (90.1%) has a substantially higher BBB penetration prediction compared to Ligand A (72.9%). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant for off-target effects and understanding the overall safety profile.
* **Caco-2 Permeability:** Both have negative Caco-2 values, which is unusual. I will interpret this as very low permeability. Ligand A (-4.826) is slightly better than Ligand B (-5.132).
* **Aqueous Solubility:** Both have negative solubility values, which is also unusual. I will interpret this as very low solubility. Ligand A (-2.173) is slightly better than Ligand B (-2.062).
* **hERG:** Both ligands have very low hERG inhibition liability (0.075 & 0.144), which is excellent.
* **Microsomal Clearance:** Ligand A (6.868 mL/min/kg) has a much lower microsomal clearance than Ligand B (14.182 mL/min/kg), indicating better metabolic stability.
* **In vitro Half-Life:** Ligand A (2.177 hours) has a positive half-life while Ligand B (-5.083 hours) has a negative half-life.
* **P-gp Efflux:** Both have low P-gp efflux liability (0.074 & 0.056).
* **Binding Affinity:** Ligand A (-7.1 kcal/mol) has a slightly better binding affinity than Ligand B (-6.7 kcal/mol). While the difference is less than the 1.5 kcal/mol threshold, it's still a positive factor.
**Overall Assessment:**
Ligand A demonstrates a more balanced profile. It has a better QED score, lower microsomal clearance (better metabolic stability), and slightly better binding affinity. While Ligand B has superior BBB penetration, the other advantages of Ligand A, particularly its improved drug-likeness and metabolic stability, are more crucial for overall developability, especially considering the potential for off-target effects with increased CNS penetration. The negative Caco-2 and solubility values for both are concerning, but Ligand A is slightly better.
**Output:**
1
2025-04-17 18:53:33,341 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [361.467, 63.91, 2.613, 0, 6, 0.825, 70.919, 80.264, -4.433, -2.58, 0.287, 34.099, -1.627, 0.553, -6.4]
**Ligand B:** [341.411, 94.31, 2.519, 2, 5, 0.755, 69.019, 73.401, -4.884, -4.041, 0.593, 68.558, -15.523, 0.166, -6.4]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (341.411) is slightly lower, which could be marginally beneficial for permeability, but not a decisive factor.
2. **TPSA:** Ligand A (63.91) is significantly better than Ligand B (94.31). A TPSA under 140 is good for oral absorption, and both meet this, but lower is preferred for GPCRs. Ligand A is much closer to the ideal <90 for CNS penetration, even though ADRB2 isn't necessarily a CNS target.
3. **logP:** Both ligands have excellent logP values (around 2.6), falling within the optimal 1-3 range.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (6) is preferable to Ligand B (5). Lower HBA is generally preferred.
6. **QED:** Ligand A (0.825) is better than Ligand B (0.755), indicating a more drug-like profile.
7. **DILI:** Both are acceptable (around 70), indicating similar low-moderate risk.
8. **BBB:** Ligand A (80.264) is better than Ligand B (73.401). While not a primary concern for ADRB2, higher BBB is always a plus.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Ligand A (-2.58) is better than Ligand B (-4.041). Higher solubility is desirable.
11. **hERG:** Both are very low (0.287 and 0.593), indicating minimal hERG inhibition risk.
12. **Cl_mic:** Ligand A (34.099) is significantly better than Ligand B (68.558), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-1.627) is better than Ligand B (-15.523), indicating a longer half-life.
14. **Pgp:** Ligand A (0.553) is better than Ligand B (0.166). Lower P-gp efflux is preferred.
15. **Affinity:** Both have the same binding affinity (-6.4 kcal/mol), so this parameter doesn't differentiate them.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most key ADME properties (TPSA, HBD, HBA, QED, Solubility, Cl_mic, t1/2, Pgp). While both have acceptable DILI and hERG profiles, Ligand A's superior metabolic stability (lower Cl_mic, longer t1/2) and permeability characteristics (lower TPSA, fewer HBDs/HBAs) make it the more promising candidate. The slightly better BBB penetration is a bonus. The Caco-2 values are concerning for both, but the other properties of A are superior.
Output:
1
2025-04-17 18:53:33,341 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (348.45 & 373.48 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (86.6) is significantly better than Ligand B (107.78). For a GPCR, lower TPSA is generally preferred for better permeability. Ligand A is well below the 140 threshold, while Ligand B is approaching it.
**3. logP:** Ligand B (0.455) is slightly better than Ligand A (0.025), falling more comfortably within the 1-3 range. Ligand A is quite low, potentially hindering membrane permeability.
**4. H-Bond Donors:** Ligand A (3) is higher than Ligand B (0). While not a huge difference, fewer HBDs often correlate with better permeability.
**5. H-Bond Acceptors:** Ligand B (6) is slightly higher than Ligand A (5). Both are within acceptable limits.
**6. QED:** Ligand A (0.7) is better than Ligand B (0.515), indicating a more drug-like profile.
**7. DILI Risk:** Both ligands have concerning DILI risk, with Ligand B (39.162) being slightly better than Ligand A (19.426). Both are still relatively high, and would require further investigation.
**8. BBB Penetration:** Ligand B (74.952) is significantly better than Ligand A (38.736). While ADRB2 is a cardiovascular target, some CNS exposure can occur, and higher BBB penetration is generally favorable.
**9. Caco-2 Permeability:** Ligand A (-5.228) is significantly better than Ligand B (-4.31). Higher Caco-2 values indicate better intestinal absorption.
**10. Aqueous Solubility:** Ligand A (-0.327) is better than Ligand B (-2.093). Solubility is important for formulation and bioavailability.
**11. hERG Inhibition:** Both ligands show low hERG inhibition risk (0.186 and 0.34, respectively). This is excellent.
**12. Microsomal Clearance:** Ligand A (-25.604) is *much* better than Ligand B (93.548). Lower clearance indicates greater metabolic stability, a crucial factor for drug duration and dosing frequency.
**13. In vitro Half-Life:** Ligand A (9.154) is better than Ligand B (-59.916). A longer half-life is generally desirable.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux (0.013 and 0.033, respectively). This is good.
**15. Binding Affinity:** Ligand B (-5.9) is slightly better than Ligand A (-5.4). While a difference of 0.5 kcal/mol isn't massive, it's a positive for Ligand B.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), and the general drug-like properties, Ligand A is the more promising candidate. While Ligand B has slightly better affinity and BBB penetration, Ligand A excels in TPSA, Caco-2 permeability, solubility, and *crucially*, metabolic stability (Cl_mic and t1/2). The significantly lower clearance and longer half-life of Ligand A are major advantages that outweigh the slightly weaker affinity and lower BBB penetration. The better QED and solubility of Ligand A also contribute to its overall drug-likeness. The DILI risk is a concern for both, but doesn't drastically alter the preference given the other factors.
Output:
1
2025-04-17 18:53:33,341 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (342.399 Da) is within the ideal range, while Ligand B (375.46 Da) is slightly higher but still acceptable.
2. **TPSA:** Ligand A (94.05) is borderline, but acceptable for a peripherally acting GPCR. Ligand B (38.13) is excellent, well below the 140 threshold and suggesting good permeability.
3. **logP:** Both ligands (A: 3.696, B: 4.375) are within the optimal range, but Ligand B is pushing the upper limit.
4. **HBD:** Ligand A (1) is good. Ligand B (0) is also good, potentially improving membrane permeability.
5. **HBA:** Ligand A (6) is good. Ligand B (4) is also good.
6. **QED:** Both ligands (A: 0.777, B: 0.677) have good drug-likeness scores.
7. **DILI:** Ligand A (72.043) has a higher DILI risk than Ligand B (53.703), which is preferable.
8. **BBB:** Ligand A (72.082) has moderate BBB penetration, while Ligand B (83.831) is better. While ADRB2 is not exclusively a CNS target, some CNS exposure can be a factor in side effects.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Both ligands have negative solubility values, which is also unusual and suggests poor solubility. This is a significant concern for both.
11. **hERG:** Both ligands have low hERG inhibition risk (A: 0.49, B: 0.382).
12. **Cl_mic:** Ligand A (86.181) has lower microsomal clearance than Ligand B (92.168), indicating better metabolic stability.
13. **t1/2:** Ligand A (44.644) has a longer half-life than Ligand B (-14.463). The negative value for Ligand B is concerning and likely an error.
14. **Pgp:** Both ligands have low P-gp efflux liability (A: 0.423, B: 0.501).
15. **Affinity:** Ligand A (-7.4 kcal/mol) has a significantly better binding affinity than Ligand B (-6.4 kcal/mol). This is a 1.0 kcal/mol difference, which is substantial.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B has a better TPSA and BBB, but Ligand A has a significantly better affinity and better metabolic stability (Cl_mic and t1/2). The negative Caco-2 and solubility values for both are concerning, but the affinity difference is the most important factor here.
**Conclusion:**
Despite the concerning Caco-2 and solubility values, Ligand A's superior binding affinity (-7.4 kcal/mol vs -6.4 kcal/mol) and better metabolic stability outweigh the slightly higher DILI risk and moderate BBB penetration. The substantial affinity difference is likely to translate to better efficacy.
Output:
1
2025-04-17 18:53:33,341 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (358.433 and 346.431 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (59.39) is significantly better than Ligand B (96.11). For a GPCR, lower TPSA is generally preferred for better permeability, and Ligand A is well below the 140 threshold. Ligand B is approaching a less desirable range.
3. **logP:** Ligand A (3.198) is within the optimal 1-3 range. Ligand B (1.705) is at the lower end, which could potentially impact permeability. Ligand A is better here.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (4). Lower HBA is better for permeability.
6. **QED:** Both are reasonably good (0.813 and 0.73), exceeding the 0.5 threshold. No significant difference.
7. **DILI:** Ligand A (26.095) has a lower DILI risk than Ligand B (30.748), both are good, but A is slightly better.
8. **BBB:** Ligand A (75.998) is significantly better than Ligand B (44.591). While ADRB2 isn't exclusively a CNS target, some CNS penetration can be beneficial, and avoiding efflux is important.
9. **Caco-2:** Ligand A (-4.691) and B (-5.216) are both negative, indicating poor permeability. However, A is slightly better.
10. **Solubility:** Ligand A (-2.25) and B (-2.023) are both poor. Solubility is not a major concern given the other parameters.
11. **hERG:** Both are very low (0.69 and 0.161), indicating minimal hERG inhibition risk. No significant difference.
12. **Cl_mic:** Ligand A (24.332) has a lower microsomal clearance than Ligand B (36.062), suggesting better metabolic stability.
13. **t1/2:** Ligand A (6.982) has a positive half-life, while Ligand B (-31.04) has a negative half-life. This is a significant advantage for Ligand A.
14. **Pgp:** Both are very low (0.049 and 0.048), indicating minimal P-gp efflux. No significant difference.
15. **Binding Affinity:** Ligand B (-6.6) has a slightly better binding affinity than Ligand A (-5.3). This is a 1.3 kcal/mol difference, which is significant.
**Overall Assessment:**
Ligand B has a better binding affinity, which is a key factor. However, Ligand A demonstrates superior ADME properties, particularly in TPSA, BBB penetration, metabolic stability (Cl_mic and t1/2), and a slightly lower DILI risk. Given the GPCR target class, the balance of properties is more favorable for Ligand A. The slightly weaker binding affinity of Ligand A can potentially be optimized in subsequent iterations, while improving the ADME profile of Ligand B would be more challenging.
Output:
1
2025-04-17 18:53:33,341 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (411.34 Da) is within the ideal range, while Ligand B (352.431 Da) is also acceptable, being slightly below the ideal range.
2. **TPSA:** Ligand A (53.01) is excellent, well below the 140 threshold. Ligand B (92.01) is still reasonable, but less optimal.
3. **logP:** Both ligands have good logP values (A: 2.367, B: 1.424), falling within the 1-3 range.
4. **HBD:** Ligand A (1) and Ligand B (2) are both acceptable.
5. **HBA:** Ligand A (4) and Ligand B (5) are both acceptable.
6. **QED:** Ligand A (0.827) has a better QED score than Ligand B (0.691), indicating higher drug-likeness.
7. **DILI:** Ligand A (11.361) has a significantly lower DILI risk than Ligand B (29.43). This is a major advantage.
8. **BBB:** Ligand A (85.498) has a much higher BBB penetration percentile than Ligand B (48.662). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be beneficial or at least less detrimental.
9. **Caco-2:** Both ligands have similar, poor Caco-2 permeability (-4.768 and -4.763).
10. **Solubility:** Both ligands have similar, poor aqueous solubility (-1.68 and -1.954).
11. **hERG:** Ligand A (0.825) has a lower hERG inhibition liability than Ligand B (0.394), indicating a lower risk of cardiotoxicity.
12. **Cl_mic:** Ligand A (-4.183) has a significantly lower (better) microsomal clearance than Ligand B (15.89). This suggests better metabolic stability.
13. **t1/2:** Ligand A (78.301) has a substantially longer in vitro half-life than Ligand B (21.482).
14. **Pgp:** Ligand A (0.604) has a lower Pgp efflux liability than Ligand B (0.163), which is favorable.
15. **Affinity:** Ligand A (-6.9 kcal/mol) has a slightly better binding affinity than Ligand B (-6.3 kcal/mol), although the difference is not huge.
**GPCR-specific priorities:** For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Ligand A is better in all of these except for logP, where they are comparable. More importantly, Ligand A excels in ADME-Tox properties (DILI, hERG, Cl_mic, t1/2) which are crucial for overall drug viability.
**Conclusion:**
Ligand A is the superior candidate. It demonstrates a better balance of potency, drug-likeness, and crucially, a significantly improved safety profile (lower DILI, hERG) and better pharmacokinetic properties (Cl_mic, t1/2). The slightly better affinity further supports this choice.
Output:
1
2025-04-17 18:53:33,341 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [339.351, 102.66 , 0.678, 2. , 5. , 0.788, 76.154, 33.579, -5.098, -3.223, 0.306, -19.04 , -15.03 , 0.035, -6.9 ]
**Ligand B:** [375.559, 33.45 , 4.794, 0. , 4. , 0.727, 58.434, 61.923, -5.202, -5.359, 0.649, 120.751, 58.001, 0.758, -5.5 ]
Here's a breakdown, considering the GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the acceptable range (200-500 Da). Ligand A (339.351) is slightly preferred due to being lower.
2. **TPSA:** Ligand B (33.45) is significantly better than Ligand A (102.66). Lower TPSA is generally better for permeability, and crucial for GPCRs.
3. **logP:** Ligand B (4.794) is higher than Ligand A (0.678). While >4 can be problematic, for a GPCR targeting cardiovascular issues, a higher logP isn't necessarily a deal-breaker, and can aid membrane interaction. Ligand A is too low.
4. **HBD/HBA:** Ligand B (0/4) is better than Ligand A (2/5). Fewer H-bonds are generally preferred for permeability.
5. **QED:** Both are good (above 0.7), indicating generally drug-like properties.
6. **DILI:** Ligand B (58.434) is significantly better than Ligand A (76.154). Lower DILI risk is crucial.
7. **BBB:** Ligand B (61.923) is better than Ligand A (33.579), though neither is exceptionally high. BBB isn't a primary concern for a cardiovascular target, but it's a bonus.
8. **Caco-2:** Both are negative, which is unusual and suggests poor permeability.
9. **Solubility:** Both are negative, indicating poor solubility.
10. **hERG:** Ligand B (0.649) is slightly better than Ligand A (0.306), lower risk is desired.
11. **Cl_mic:** Ligand A (-19.04) is *much* better than Ligand B (120.751). Lower clearance indicates better metabolic stability. This is a significant advantage for Ligand A.
12. **t1/2:** Ligand B (58.001) is much better than Ligand A (-15.03). A longer half-life is generally preferred.
13. **Pgp:** Ligand B (0.758) is better than Ligand A (0.035). Lower P-gp efflux is desirable for bioavailability.
14. **Affinity:** Ligand A (-6.9) is slightly better than Ligand B (-5.5). While both are good, the difference is meaningful.
**Overall Assessment:**
Ligand B has a much better TPSA, DILI, Pgp, and half-life. However, Ligand A has a significantly better microsomal clearance and a slightly better binding affinity. The poor Caco-2 and solubility for both are concerning. Considering the GPCR target and the importance of metabolic stability, the superior clearance of Ligand A is a major advantage. The slightly better affinity also tips the scales. While Ligand B's lower DILI is attractive, the metabolic liability of Ligand B is a significant concern.
Therefore, I prefer Ligand A.
1
2025-04-17 18:53:33,342 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (366.46 & 385.81 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (67.43) is significantly better than Ligand B (78.59). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands (2.415 & 2.041) are within the optimal 1-3 range. Ligand B is slightly lower, which could marginally impact permeability.
4. **HBD:** Both ligands have 2 HBD, which is acceptable.
5. **HBA:** Ligand A has 4 HBA, Ligand B has 5. Both are within the acceptable range of <=10.
6. **QED:** Both ligands have good QED scores (0.728 & 0.785), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (59.597) has a higher DILI risk than Ligand B (34.665). This is a significant negative for Ligand A.
8. **BBB:** Both ligands have reasonable BBB penetration (75.727 & 68.36). Not a critical factor for a cardiovascular target.
9. **Caco-2:** Ligand A (-4.907) has a worse Caco-2 permeability than Ligand B (-4.68).
10. **Solubility:** Ligand A (-3.725) has worse solubility than Ligand B (-2.824).
11. **hERG:** Both ligands have low hERG inhibition risk (0.432 & 0.409).
12. **Cl_mic:** Ligand A (13.183) has significantly lower microsomal clearance than Ligand B (22.217), indicating better metabolic stability.
13. **t1/2:** Ligand A (11.914) has a longer in vitro half-life than Ligand B (6.481). This is a positive for Ligand A.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.264 & 0.332).
15. **Binding Affinity:** Ligand B (-8.2 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.1 kcal/mol). This is a crucial advantage, exceeding the 1.5 kcal/mol threshold.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), affinity, logP, TPSA, and Pgp are important. Ligand B excels in affinity. Ligand A has better TPSA, but the difference isn't substantial. Both have acceptable logP and Pgp. The significantly lower DILI risk for Ligand B is also a major positive.
**Overall Assessment:**
While Ligand A has some advantages in metabolic stability (Cl_mic, t1/2) and TPSA, the substantially stronger binding affinity of Ligand B (-8.2 vs -6.1 kcal/mol) and its significantly lower DILI risk outweigh these benefits. The improved solubility and Caco-2 permeability of Ligand B are also beneficial.
Output:
0
2025-04-17 18:53:33,342 - INFO - Batch 70 complete. Total preferences: 1120
2025-04-17 18:53:33,342 - INFO - Processing batch 71/512...
2025-04-17 18:54:22,643 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (a cardiovascular GPCR) drug candidates.
**Ligand A: [351.757, 98.48, 2.511, 1, 7, 0.609, 99.806, 50.523, -5.068, -4.693, 0.542, 58.432, 31.615, 0.145, -7.2]**
**Ligand B: [337.431, 70.9, 1.949, 2, 7, 0.716, 62.35, 76.309, -5.413, -2.027, 0.952, 29.155, 0.853, 0.042, -6.7]**
Here's a breakdown, comparing each parameter and considering GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal 200-500 Da range. Ligand B (337.431) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (98.48) is higher than Ligand B (70.9). Both are acceptable, but Ligand B is better, being closer to the <90 for potential CNS penetration (though not a primary concern for a cardiovascular target, lower TPSA is still generally beneficial).
3. **logP:** Ligand A (2.511) and Ligand B (1.949) are both within the optimal 1-3 range. Ligand B is slightly lower, which could slightly reduce permeability, but isn't a major concern.
4. **HBD:** Ligand A (1) is better than Ligand B (2). Lower HBDs generally improve permeability.
5. **HBA:** Both ligands have 7 HBA, which is acceptable.
6. **QED:** Ligand B (0.716) has a slightly better QED score than Ligand A (0.609), indicating a more drug-like profile.
7. **DILI:** Ligand A (99.806) has a *very* high DILI risk, which is a major red flag. Ligand B (62.35) is still elevated, but significantly lower and more acceptable.
8. **BBB:** Ligand B (76.309) has a higher BBB percentile than Ligand A (50.523). While not critical for a cardiovascular target, higher BBB is generally a positive indicator of permeability.
9. **Caco-2:** Both have negative Caco-2 values which is unusual and suggests poor permeability.
10. **Solubility:** Ligand B (-2.027) has better solubility than Ligand A (-4.693).
11. **hERG:** Ligand A (0.542) has a lower hERG risk than Ligand B (0.952).
12. **Cl_mic:** Ligand B (29.155) has a significantly lower microsomal clearance than Ligand A (58.432), indicating better metabolic stability.
13. **t1/2:** Ligand A (31.615) has a longer in vitro half-life than Ligand B (0.853).
14. **Pgp:** Ligand A (0.145) has lower P-gp efflux than Ligand B (0.042), which is favorable.
15. **Affinity:** Ligand A (-7.2 kcal/mol) has a stronger binding affinity than Ligand B (-6.7 kcal/mol). This is a 0.5 kcal/mol difference, which is significant.
**Overall Assessment:**
While Ligand A has a better binding affinity, the extremely high DILI risk is a deal-breaker. The significantly better metabolic stability (lower Cl_mic), solubility, and lower DILI risk of Ligand B outweigh the slightly weaker affinity. The better TPSA and QED of Ligand B are also positive attributes. The Caco-2 values are concerning for both, but the other ADME properties of Ligand B are more favorable.
Therefore, I recommend **Ligand B**.
0
2025-04-17 18:54:22,643 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.46 and 348.53 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (84.66) is higher than Ligand B (58.2). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is generally preferred for absorption. Ligand B is better.
3. **logP:** Ligand A (2.775) is within the optimal 1-3 range. Ligand B (4.103) is slightly above, potentially hinting at solubility issues or off-target interactions, but not drastically so. Ligand A is slightly better.
4. **HBD:** Both ligands have 2 HBD, which is within the acceptable limit of <=5. No difference.
5. **HBA:** Ligand A has 5 HBA, while Ligand B has 2. Both are within the acceptable limit of <=10. Ligand B is better due to lower HBA.
6. **QED:** Both ligands have similar QED values (0.741 and 0.71), indicating good drug-likeness. No significant difference.
7. **DILI:** Ligand A (46.413) has a higher DILI risk than Ligand B (27.453). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (81.776) has a higher BBB penetration percentile than Ligand B (69.213). However, since ADRB2 is primarily a cardiovascular target, BBB penetration is not a major priority.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.523 and -4.621). These values are unusual and suggest poor permeability. However, the values are very close, so this is not a deciding factor.
10. **Solubility:** Ligand A (-3.508) has slightly better aqueous solubility than Ligand B (-4.797).
11. **hERG:** Ligand A (0.7) has a slightly higher hERG inhibition liability than Ligand B (0.292). This is a positive for Ligand B.
12. **Cl_mic:** Ligand A (80.897) has a higher microsomal clearance than Ligand B (70.683), meaning it's metabolized faster. This is a negative for Ligand A.
13. **t1/2:** Ligand B (9.793) has a significantly longer in vitro half-life than Ligand A (-6.328). This is a substantial advantage for Ligand B.
14. **Pgp:** Ligand A (0.187) has lower P-gp efflux liability than Ligand B (0.313). This is a slight advantage for Ligand A.
15. **Binding Affinity:** Ligand B (-7.2 kcal/mol) has a slightly better binding affinity than Ligand A (-7.0 kcal/mol). While the difference is small, it's enough to be considered.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity), Ligand B emerges as the more promising candidate. It has a lower DILI risk, significantly better metabolic stability (lower Cl_mic and longer t1/2), better hERG profile, and slightly better binding affinity. While Ligand A has slightly better solubility and Pgp efflux, the ADME advantages of Ligand B outweigh these minor benefits. The lower TPSA of Ligand B is also a plus.
Output:
0
2025-04-17 18:54:22,643 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [350.419, 96.69, 0.13, 2, 6, 0.805, 37.805, 46.724, -5.26, -1.038, 0.301, -18.802, -9.449, 0.053, -7.2]
**Ligand B:** [344.455, 78.43, 2.812, 3, 3, 0.571, 37.611, 38.038, -4.721, -3.404, 0.444, 38.584, 45.999, 0.267, -7.1]
Here's a breakdown, considering the GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (344.455) is slightly lower, which is generally favorable.
2. **TPSA:** Ligand A (96.69) is higher than Ligand B (78.43). Both are acceptable, but Ligand B is better, being closer to the <140 threshold for oral absorption.
3. **logP:** Ligand A (0.13) is *very* low, which is a significant concern for permeability. Ligand B (2.812) is much better, falling within the optimal 1-3 range. This is a major advantage for Ligand B.
4. **HBD:** Ligand A (2) is good. Ligand B (3) is also acceptable.
5. **HBA:** Ligand A (6) is good. Ligand B (3) is excellent.
6. **QED:** Ligand A (0.805) is excellent. Ligand B (0.571) is acceptable, but lower.
7. **DILI:** Both are very similar and acceptable (around 38%).
8. **BBB:** Ligand A (46.724) is lower than Ligand B (38.038). While ADRB2 isn't necessarily a CNS target, some peripheral distribution is still needed, and a higher BBB percentile isn't detrimental.
9. **Caco-2:** Both are negative, indicating poor permeability. However, Ligand A (-5.26) is worse than Ligand B (-4.721).
10. **Solubility:** Ligand A (-1.038) is slightly better than Ligand B (-3.404).
11. **hERG:** Both are low (0.301 and 0.444), indicating low cardiotoxicity risk.
12. **Cl_mic:** Ligand A (-18.802) is *much* better (lower is better, indicating higher metabolic stability) than Ligand B (38.584). This is a significant advantage for Ligand A.
13. **t1/2:** Ligand B (45.999) has a much longer half-life than Ligand A (-9.449). This is a major advantage for Ligand B.
14. **Pgp:** Ligand A (0.053) is better (lower is better) than Ligand B (0.267).
15. **Affinity:** Both are very similar (-7.2 and -7.1 kcal/mol), with a negligible difference.
**Overall Assessment:**
Ligand B has a significantly better logP, which is crucial for a GPCR target. It also has a better TPSA and a much longer half-life. While Ligand A has better metabolic stability (Cl_mic) and Pgp efflux, the poor logP and Caco-2 permeability are major drawbacks that outweigh these benefits. The similar affinity makes the ADME properties the deciding factor.
Therefore, I prefer Ligand B.
0
2025-04-17 18:54:22,644 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (380.941 and 388.49 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (49.41) is significantly better than Ligand B (103.95). For a GPCR, lower TPSA is generally preferred for better permeability, and Ligand A is well below the 140 threshold. Ligand B is pushing the upper limit.
3. **logP:** Ligand A (4.237) is a bit high, but still within a reasonable range. Ligand B (2.222) is excellent. While higher logP can sometimes be tolerated, the combination with other factors makes Ligand B's logP more favorable.
4. **HBD:** Ligand A (1) is better than Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (3) is better than Ligand B (5). Similar reasoning as HBD.
6. **QED:** Ligand A (0.849) is significantly better than Ligand B (0.573), indicating a more drug-like profile.
7. **DILI:** Ligand A (38.62) is much better than Ligand B (83.792). Lower DILI risk is crucial. Ligand B is in the high-risk category.
8. **BBB:** Ligand A (74.641) is better than Ligand B (43.815). While ADRB2 isn't exclusively a CNS target, some CNS penetration can be beneficial, and avoiding efflux is always good.
9. **Caco-2:** Both are negative, indicating poor permeability. However, the scale is not provided, so it's difficult to compare.
10. **Solubility:** Ligand A (-4.681) is better than Ligand B (-2.63). Better solubility is always preferred.
11. **hERG:** Both ligands have similar, low hERG risk (0.678 and 0.632).
12. **Cl_mic:** Ligand A (32.307) is better than Ligand B (46.708). Lower clearance indicates better metabolic stability.
13. **t1/2:** Ligand A (-5.47) is better than Ligand B (1.776). A negative value suggests a very long half-life, which is highly desirable.
14. **Pgp:** Both ligands have similar, low Pgp efflux liability (0.34 and 0.302).
15. **Binding Affinity:** Ligand B (-7.4) is significantly better than Ligand A (-6.0). This is a substantial difference in potency (1.4 kcal/mol).
**Overall Assessment:**
Ligand B has a significantly better binding affinity, which is a major advantage. However, it is penalized by a higher TPSA, higher DILI risk, lower BBB penetration, and worse metabolic stability. Ligand A excels in most ADME properties, including DILI, TPSA, solubility, and metabolic stability, and has a good QED score. The affinity difference is substantial, but the ADME profile of Ligand B is concerning. Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity), the superior ADME profile of Ligand A, and the acceptable (though not ideal) affinity, I believe Ligand A is the more viable drug candidate.
Output:
1
2025-04-17 18:54:22,644 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (375.447 and 388.53 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (99.96) is higher than Ligand B (49.85). For a cardiovascular GPCR, TPSA is not a *major* concern unless it exceeds 140, which Ligand A barely does. Ligand B is significantly better in this regard, suggesting potentially better absorption.
3. **logP:** Ligand B (2.637) is within the optimal 1-3 range, while Ligand A (0.411) is quite low. Low logP can hinder membrane permeability. This is a significant advantage for Ligand B.
4. **HBD:** Both have 0 HBD, which is good.
5. **HBA:** Ligand A has 8 HBA, and Ligand B has 5. Both are acceptable, but Ligand B is slightly preferred.
6. **QED:** Both ligands have good QED scores (0.636 and 0.752), indicating good overall drug-likeness. Ligand B is slightly better.
7. **DILI:** Ligand B (58.434) has a lower DILI risk than Ligand A (65.568), which is preferable.
8. **BBB:** Ligand B (88.678) shows significantly better BBB penetration potential than Ligand A (61.613). While ADRB2 isn't strictly a CNS target, some distribution to the CNS can occur, and higher BBB is generally favorable.
9. **Caco-2:** Both have negative Caco-2 values (-4.569 and -4.412). This is unusual and suggests poor permeability *in vitro*. However, the values are very close.
10. **Solubility:** Both have negative solubility values (-2.807 and -3.364), indicating very poor aqueous solubility. This is a major concern for both.
11. **hERG:** Ligand A (0.127) has a slightly lower hERG risk than Ligand B (0.605), which is a slight advantage.
12. **Cl_mic:** Ligand B (76.861) has a lower microsomal clearance than Ligand A (84.836), indicating better metabolic stability.
13. **t1/2:** Ligand B (9.349) has a significantly longer *in vitro* half-life than Ligand A (-7.183). This is a substantial advantage.
14. **Pgp:** Ligand A (0.168) shows lower P-gp efflux than Ligand B (0.519), which is preferable.
15. **Binding Affinity:** Ligand B (-6.7 kcal/mol) has a slightly better binding affinity than Ligand A (-5.7 kcal/mol). While the difference isn't huge, it's enough to consider.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP, TPSA, and has a better affinity. The longer half-life and lower DILI risk also contribute to its favorability. While both have solubility issues, this is a formulation challenge that can be addressed.
**Conclusion:**
Despite the poor solubility of both compounds, Ligand B has a more favorable overall profile, particularly regarding logP, TPSA, metabolic stability, and binding affinity. These factors are crucial for a GPCR-targeting drug.
Output:
0
2025-04-17 18:54:22,644 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.431 and 368.478 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand B (88.32) is significantly better than Ligand A (104.46). ADRB2 is not a CNS target, but lower TPSA generally improves absorption.
3. **logP:** Both ligands have good logP values (1.486 and 1.911), falling within the optimal 1-3 range. Ligand B is slightly better.
4. **HBD:** Ligand A has 3 HBD, while Ligand B has 2. Both are acceptable (<=5).
5. **HBA:** Both ligands have 5 HBA, which is acceptable (<=10).
6. **QED:** Ligand B (0.848) has a better QED score than Ligand A (0.692), indicating a more drug-like profile.
7. **DILI:** Ligand B (70.531) has a higher DILI risk than Ligand A (48.623). This is a negative for Ligand B.
8. **BBB:** Both ligands have similar BBB penetration (63.474 and 65.839). Not a major factor here as ADRB2 is not a CNS target.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.971 and -5.062). This is unusual and suggests poor permeability.
10. **Solubility:** Both ligands have negative solubility values (-3.348 and -3.629). This is also unusual and suggests poor solubility.
11. **hERG:** Ligand A (0.239) has a lower hERG risk than Ligand B (0.402). This is a positive for Ligand A.
12. **Cl_mic:** Ligand B (36.377) has significantly lower microsomal clearance than Ligand A (64.84), indicating better metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand B (3.472) has a longer in vitro half-life than Ligand A (-23.494). This is a strong positive for Ligand B.
14. **Pgp:** Ligand A (0.191) has lower P-gp efflux liability than Ligand B (0.047). This is a positive for Ligand A.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.7 and -6.6 kcal/mol). The difference is negligible.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, and metabolic stability are important. Ligand B excels in TPSA and metabolic stability (Cl_mic and t1/2), while Ligand A has a slightly better hERG profile and Pgp efflux. The DILI risk for Ligand B is higher, which is a concern. However, the superior metabolic stability and longer half-life of Ligand B are more critical for a GPCR target, as they translate to potentially better *in vivo* exposure and efficacy. The similar binding affinities make the ADME properties the deciding factor.
**Conclusion:**
Despite the higher DILI risk, Ligand B's superior metabolic stability, longer half-life, and lower TPSA outweigh the benefits of Ligand A's slightly better hERG and Pgp profiles.
Output:
0
2025-04-17 18:54:22,644 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, priorities are affinity, logP, TPSA, Pgp efflux, and BBB penetration (though BBB is less critical for a cardiovascular target).
Let's compare the ligands property by property:
1. **MW:** Both ligands (381.395 and 356.491 Da) fall within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (62.3) is slightly higher than Ligand B (51.22), but both are well below the 140 threshold for good absorption.
3. **logP:** Ligand A (2.187) is within the optimal 1-3 range. Ligand B (4.031) is a bit high, potentially leading to solubility issues and off-target interactions.
4. **HBD/HBA:** Both have 1 HBD and 4 HBA, which are acceptable.
5. **QED:** Both ligands have similar QED values (0.702 and 0.69), indicating good drug-likeness.
6. **DILI:** Ligand A (38.62) has a significantly lower DILI risk than Ligand B (58.123). This is a major advantage.
7. **BBB:** Ligand A (71.229) has better BBB penetration than Ligand B (52.268), though it's not a primary concern for a cardiovascular target.
8. **Caco-2:** Both have similar negative Caco-2 values (-4.943 and -4.803), indicating poor permeability.
9. **Solubility:** Ligand A (-2.526) has slightly better solubility than Ligand B (-4.878), but both are quite poor.
10. **hERG:** Ligand A (0.367) has a lower hERG risk than Ligand B (0.565).
11. **Cl_mic:** Ligand A (13.183) has a significantly lower microsomal clearance than Ligand B (75.266), suggesting better metabolic stability.
12. **t1/2:** Ligand A (-4.816) has a shorter in vitro half-life than Ligand B (18.349). This is a drawback for Ligand A.
13. **Pgp:** Ligand A (0.077) has lower P-gp efflux than Ligand B (0.487), which is favorable.
14. **Affinity:** Ligand B (-6.4 kcal/mol) has a slightly better binding affinity than Ligand A (-5.7 kcal/mol). This is a 1.5 kcal/mol difference, which is significant.
**Overall Assessment:**
Ligand B has a better binding affinity, but Ligand A has superior ADME properties, particularly regarding DILI risk, metabolic stability (Cl_mic), and P-gp efflux. The higher logP of Ligand B is a concern. While the affinity difference is notable, the improved safety profile and drug-like properties of Ligand A, combined with its reasonable affinity, make it the more promising candidate. The poor Caco-2 values for both ligands are a concern that would need to be addressed in further optimization.
Output:
1
2025-04-17 18:54:22,644 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (346.471 and 354.422 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (62.55) is better than Ligand B (70.08). For a cardiovascular GPCR, TPSA should be kept relatively low to aid permeability, and A is closer to the <140 threshold.
**3. logP:** Ligand A (3.586) is good, within the optimal 1-3 range. Ligand B (0.581) is quite low, potentially hindering membrane permeability and absorption. This is a significant drawback for a GPCR ligand.
**4. H-Bond Donors:** Both have 1 HBD, which is acceptable.
**5. H-Bond Acceptors:** Ligand A has 3 HBA, Ligand B has 4. Both are within the acceptable limit of 10.
**6. QED:** Both ligands have high QED scores (0.906 and 0.802), indicating good drug-like properties.
**7. DILI Risk:** Ligand A (40.83) is slightly higher than Ligand B (21.481), but both are below the concerning threshold of 60. B is preferable here.
**8. BBB Penetration:** Both have good BBB penetration (70.919 and 77.898). While not strictly necessary for a cardiovascular target, it doesn't hurt.
**9. Caco-2 Permeability:** Both have negative Caco-2 values, which is unusual and requires further investigation. However, the magnitude is similar, so it doesn't differentiate them significantly.
**10. Aqueous Solubility:** Both have negative solubility values, which is also unusual. Again, the magnitude is similar.
**11. hERG Inhibition:** Both ligands show low hERG inhibition risk (0.405 and 0.47).
**12. Microsomal Clearance:** Ligand B (29.834) has significantly lower microsomal clearance than Ligand A (45.571), suggesting better metabolic stability. This is a positive for B.
**13. In vitro Half-Life:** Ligand A (54.06) has a much longer half-life than Ligand B (11.802). This is a significant advantage for A, potentially allowing for less frequent dosing.
**14. P-gp Efflux:** Both ligands have low P-gp efflux (0.24 and 0.05), which is good.
**15. Binding Affinity:** Ligand B (-5.3 kcal/mol) has a slightly better binding affinity than Ligand A (-7.0 kcal/mol). However, the difference is not substantial enough to outweigh the other factors.
**GPCR-Specific Considerations:** For a GPCR like ADRB2, logP, TPSA, and affinity are key. Ligand A has a much better logP value, which is crucial for membrane permeability and receptor engagement. While Ligand B has slightly better affinity, the poor logP is a major concern. The longer half-life of Ligand A is also a significant advantage.
**Conclusion:**
Considering the balance of properties, particularly the critical logP value and the longer half-life, Ligand A is the more promising drug candidate.
Output:
1
2025-04-17 18:54:22,644 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (367.808 Da and 374.819 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (93.43) is slightly higher than Ligand B (78.09). Both are below the 140 A^2 threshold for oral absorption, but Ligand B is preferable due to the lower TPSA, potentially indicating better membrane permeability.
3. **logP:** Both ligands have similar logP values (2.547 and 2.55), falling within the optimal 1-3 range. No clear advantage.
4. **HBD:** Both ligands have 2 H-bond donors, which is within the acceptable limit of 5.
5. **HBA:** Ligand A has 4 H-bond acceptors, while Ligand B has 3. Both are below the 10 threshold.
6. **QED:** Both ligands have high QED scores (0.782 and 0.795), indicating good drug-like properties.
7. **DILI:** Both ligands have similar DILI risk (52.734 and 53.858), and are below the concerning 60 threshold.
8. **BBB:** Ligand B (64.25) has a slightly higher BBB penetration percentile than Ligand A (59.597). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be beneficial for distribution and off-target effects assessment.
9. **Caco-2:** Ligand A (-4.66) and Ligand B (-4.901) both have negative Caco-2 permeability values, which is unusual and indicates very *poor* permeability. This is a major red flag for both.
10. **Solubility:** Both ligands have very poor aqueous solubility (-3.597 and -3.598). This is a significant issue for bioavailability.
11. **hERG:** Both ligands have low hERG inhibition liability (0.583 and 0.398), which is good.
12. **Cl_mic:** Ligand A (2.398) has a significantly lower microsomal clearance than Ligand B (7.842). Lower clearance indicates better metabolic stability, a major advantage.
13. **t1/2:** Ligand A (3.037) has a better in vitro half-life than Ligand B (-25.565). A negative half-life is highly problematic.
14. **Pgp:** Ligand A (0.092) has lower P-gp efflux liability than Ligand B (0.065). Lower efflux is generally preferred.
15. **Binding Affinity:** Ligand B (-7.5 kcal/mol) has a slightly better binding affinity than Ligand A (-7.0 kcal/mol). This 0.5 kcal/mol difference is significant, and could potentially outweigh some of the ADME drawbacks.
**Overall Assessment & GPCR Priorities:**
Both ligands have significant issues with Caco-2 permeability and solubility. However, Ligand B has a slightly better binding affinity and a higher (though still not great) BBB percentile. Crucially, Ligand B's *extremely* poor in vitro half-life is a dealbreaker. Ligand A, while not ideal, has a reasonable half-life and better metabolic stability (lower Cl_mic). For a GPCR, affinity is paramount, but a compound needs to stay around long enough to exert its effect. The slightly stronger binding of Ligand B doesn't compensate for its rapid metabolism.
Therefore, I favor Ligand A.
Output:
1
2025-04-17 18:54:22,645 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.459 Da and 364.511 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (84.66) is slightly higher than Ligand B (67.43). Both are below the 140 threshold for good oral absorption, but B is better positioned, especially considering ADRB2 isn't necessarily a CNS target.
3. **logP:** Both ligands (2.818 and 2.979) are within the optimal 1-3 range. Similar.
4. **HBD:** Both have 2 H-bond donors, which is acceptable.
5. **HBA:** Both have 4 H-bond acceptors, also acceptable.
6. **QED:** Ligand A (0.802) has a significantly better QED score than Ligand B (0.662), indicating a more drug-like profile.
7. **DILI:** Ligand A (37.495) has a lower DILI risk than Ligand B (54.207). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (84.684) has a higher BBB penetration percentile than Ligand B (69.407). While ADRB2 isn't strictly a CNS target, some CNS exposure could be acceptable or even beneficial depending on the specific therapeutic goal.
9. **Caco-2:** Ligand A (-4.837) and Ligand B (-5.211) are both negative, indicating poor permeability. This is a concern for both, but B is slightly worse.
10. **Solubility:** Ligand A (-3.5) has slightly better solubility than Ligand B (-2.707).
11. **hERG:** Ligand A (0.78) has a lower hERG inhibition liability than Ligand B (0.442), which is a significant safety advantage.
12. **Cl_mic:** Ligand A (11.788) has a much lower microsomal clearance than Ligand B (65.697), indicating better metabolic stability. This is a major advantage for Ligand A.
13. **t1/2:** Ligand B (35.805) has a much longer in vitro half-life than Ligand A (-14.617). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.079) has lower P-gp efflux liability than Ligand B (0.248), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand B (-7.0) has a significantly stronger binding affinity than Ligand A (-5.3). This is a substantial advantage for Ligand B, potentially outweighing some ADME concerns.
**Overall Assessment:**
Ligand B has a much stronger binding affinity, which is the most critical factor for GPCRs. However, Ligand A demonstrates a superior safety profile (lower DILI, lower hERG), better metabolic stability (lower Cl_mic), and better predicted drug-like properties (higher QED). The longer half-life of Ligand B is also attractive. The Caco-2 permeability is a concern for both, but the other advantages of Ligand A, particularly the safety and metabolic stability, make it the more promising candidate. The 1.7 kcal/mol difference in binding affinity is significant, but the ADME/Tox profile of A is much more favorable.
Output:
1
2025-04-17 18:54:22,645 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (381.93 & 370.52 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (53.51) is significantly better than Ligand B (76.66). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (3.41 & 2.83), falling within the 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is better than Ligand B (5). Lower HBA contributes to better permeability.
6. **QED:** Both ligands have acceptable QED scores (0.80 & 0.66), indicating good drug-like properties. Ligand A is slightly better.
7. **DILI:** Both ligands have low DILI risk (42.46 & 41.37), which is excellent. No significant difference.
8. **BBB:** Ligand A (74.80) has a better BBB percentile than Ligand B (54.63). While not a primary concern for a cardiovascular target, higher BBB is generally a positive attribute.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.79 & -4.90), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Both ligands have poor aqueous solubility (-2.9 & -2.13). This is a major drawback for both compounds and would require formulation strategies.
11. **hERG:** Both ligands have low hERG inhibition liability (0.61 & 0.47), which is good. No significant difference.
12. **Cl_mic:** Both ligands have similar microsomal clearance values (45.75 & 47.62). Neither stands out in terms of metabolic stability.
13. **t1/2:** Ligand B (14.09 hours) has a significantly longer in vitro half-life than Ligand A (-3.18 hours). This is a major advantage for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.22 & 0.16). No significant difference.
15. **Binding Affinity:** Ligand A (-7.6 kcal/mol) has a slightly better binding affinity than Ligand B (-7.4 kcal/mol). While the difference is small (0.2 kcal/mol), it's still a positive for Ligand A.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A performs better on logP, TPSA, and affinity. Ligand B's primary advantage is its longer half-life. However, the combination of better predicted absorption (lower TPSA, fewer HBD/HBA) and slightly better affinity makes Ligand A more promising, despite the poor Caco-2 and solubility. The longer half-life of Ligand B is attractive, but can potentially be addressed through prodrug strategies or formulation.
**Conclusion:**
Considering all factors, Ligand A is the more promising candidate.
Output:
1
2025-04-17 18:54:22,645 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 receptor:
**1. Molecular Weight:** Both ligands (347.419 and 348.447 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (90.56) is slightly higher than Ligand B (80.48). Both are below the 140 A^2 threshold for good oral absorption, but Ligand B is preferable due to its lower TPSA, which generally correlates with better membrane permeability.
**3. logP:** Ligand B (1.175) is within the optimal 1-3 range, while Ligand A (-0.006) is slightly below 1. While not drastically low, a logP below 1 can sometimes hinder permeability. Ligand B is favored here.
**4. H-Bond Donors:** Ligand A (2) is slightly higher than Ligand B (1). Both are acceptable, but lower is generally better for permeability. Ligand B is slightly preferred.
**5. H-Bond Acceptors:** Ligand A (5) and Ligand B (6) are both within the acceptable limit of 10. No strong preference.
**6. QED:** Ligand A (0.8) has a significantly higher QED score than Ligand B (0.535), indicating a more drug-like profile. This is a strong point in favor of Ligand A.
**7. DILI Risk:** Ligand A (23.73) has a lower DILI risk than Ligand B (28.965), which is a significant advantage. Lower DILI risk is crucial for drug development.
**8. BBB Penetration:** Ligand B (71.617) has significantly higher BBB penetration than Ligand A (48.934). Given that ADRB2 is a GPCR, and while not necessarily a CNS target, some level of BBB penetration can be beneficial for off-target profiling and potential CNS side effects assessment.
**9. Caco-2 Permeability:** Ligand A (-5.412) and Ligand B (-4.915) both have negative values, which is unusual and suggests poor permeability. However, the scale isn't specified, so it's hard to interpret.
**10. Aqueous Solubility:** Ligand A (-2.04) and Ligand B (-1.178) both have negative values, suggesting poor solubility. Solubility is important for bioavailability.
**11. hERG Inhibition:** Ligand A (0.328) has a lower hERG inhibition risk than Ligand B (0.162). This is a crucial safety parameter, and Ligand A is favored.
**12. Microsomal Clearance:** Ligand A (-34.313) has much lower microsomal clearance than Ligand B (9.08), indicating better metabolic stability. This is a significant advantage for Ligand A.
**13. In vitro Half-Life:** Ligand A (6.373) has a longer in vitro half-life than Ligand B (-3.626). Longer half-life is generally desirable.
**14. P-gp Efflux:** Ligand A (0.016) has significantly lower P-gp efflux than Ligand B (0.388). Lower P-gp efflux is advantageous for bioavailability.
**15. Binding Affinity:** Ligand B (-7.1) has a slightly better binding affinity than Ligand A (-6.7). While a 0.4 kcal/mol difference is noticeable, it's not a massive advantage, especially considering the other factors.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), and the general drug-like properties, Ligand A is the more promising candidate. While Ligand B has better BBB penetration and slightly higher affinity, Ligand A excels in crucial areas like DILI risk, metabolic stability (Cl_mic and t1/2), P-gp efflux, hERG inhibition, and QED. The slightly lower logP of Ligand A is a minor concern that could potentially be addressed through further optimization. The superior ADME-Tox profile of Ligand A outweighs the small affinity difference.
Output:
1
2025-04-17 18:54:22,645 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (347.434 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (62.3) is better than Ligand B (49.77). Both are well below the 140 threshold for oral absorption, and suitable for a GPCR.
3. **logP:** Both ligands have good logP values (A: 2.851, B: 3.25), falling within the optimal 1-3 range.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 3 HBA, while Ligand B has 5. Both are acceptable, but A is slightly preferred.
6. **QED:** Ligand A (0.891) has a significantly better QED score than Ligand B (0.7), indicating a more drug-like profile.
7. **DILI:** Ligand B (36.216) has a lower DILI risk than Ligand A (44.126), which is a significant advantage.
8. **BBB:** Both ligands have high BBB penetration (A: 86.817, B: 85.459), which is good, but not critical for ADRB2 as it's primarily a cardiovascular target.
9. **Caco-2:** Ligand A (-4.557) has a more negative Caco-2 value, suggesting better permeability than Ligand B (-5.223).
10. **Solubility:** Both have similar, poor aqueous solubility (-3.575 and -3.515). This is a potential concern for both.
11. **hERG:** Ligand A (0.354) has a lower hERG risk than Ligand B (0.788), which is a significant advantage.
12. **Cl_mic:** Ligand A (46.037) has a lower microsomal clearance than Ligand B (94.124), indicating better metabolic stability.
13. **t1/2:** Ligand B (21.527) has a longer in vitro half-life than Ligand A (-15.238). This is a significant advantage.
14. **Pgp:** Ligand A (0.121) has lower P-gp efflux liability than Ligand B (0.836), which is favorable.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.4 and -6.2 kcal/mol). The difference is negligible.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Both ligands perform well on logP and affinity. Ligand A has better TPSA and Pgp.
**Overall Assessment:**
Ligand A has a better overall profile, despite Ligand B's longer half-life and lower DILI. Ligand A has a superior QED score, better metabolic stability (lower Cl_mic), lower hERG risk, and lower P-gp efflux. While solubility is a concern for both, the other advantages of Ligand A outweigh the slightly longer half-life of Ligand B.
Output:
1
2025-04-17 18:54:22,645 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [346.431, 82.18, 3.483, 1, 7, 0.806, 54.634, 81.97, -4.654, -4.964, 0.177, 97.828, 12.842, 0.286, -2.3]
**Ligand B:** [363.483, 64.02, 3.166, 0, 6, 0.698, 51.57, 65.064, -4.301, -3.977, 0.249, 63.459, -11.529, 0.301, -6.6]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity, and BBB):
1. **MW:** Both are within the ideal 200-500 Da range. Ligand A (346.431) is slightly better.
2. **TPSA:** Ligand A (82.18) is higher than Ligand B (64.02). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is still preferable. Ligand B wins here.
3. **logP:** Both are good (around 3), within the 1-3 optimal range. Ligand B (3.166) is slightly lower, which could be a minor advantage.
4. **HBD/HBA:** Ligand A has 1 HBD and 7 HBA, while Ligand B has 0 HBD and 6 HBA. Both are acceptable, but fewer H-bonds are generally preferred for permeability. Ligand B is slightly better.
5. **QED:** Ligand A (0.806) has a better QED score than Ligand B (0.698), indicating a more drug-like profile.
6. **DILI:** Both are reasonably low (A: 54.634, B: 51.57), below the 60 threshold. Ligand B is slightly better.
7. **BBB:** Ligand A (81.97) has significantly better BBB penetration than Ligand B (65.064). While this isn't a primary concern for a cardiovascular target, it's a bonus.
8. **Caco-2:** Both are very poor (-4.654 and -4.301). This is a significant drawback for both, suggesting poor intestinal absorption.
9. **Solubility:** Both are very poor (-4.964 and -3.977). This is a major concern for both, potentially hindering bioavailability.
10. **hERG:** Both are very low (0.177 and 0.249), indicating minimal hERG inhibition risk.
11. **Cl_mic:** Ligand B (63.459) has lower microsomal clearance than Ligand A (97.828), suggesting better metabolic stability. This is a significant advantage.
12. **t1/2:** Ligand B (-11.529) has a negative half-life, which is concerning. Ligand A (12.842) has a positive half-life, indicating better in vitro stability.
13. **Pgp:** Both are very low (0.286 and 0.301), indicating minimal P-gp efflux.
14. **Affinity:** Ligand B (-6.6 kcal/mol) has a significantly stronger binding affinity than Ligand A (-2.3 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME drawbacks.
**Overall Assessment:**
Ligand B has a much stronger binding affinity, which is paramount for GPCR targets. It also has better metabolic stability (lower Cl_mic) and a slightly better logP. While its BBB is lower, this is less critical for a cardiovascular target. The negative in vitro half-life is concerning, but the strong binding affinity might compensate. Ligand A has a better QED and BBB, but its significantly weaker binding affinity is a major drawback. The poor Caco-2 and solubility for both are problematic, but can be addressed with formulation strategies.
Given the importance of binding affinity for GPCRs, I would prioritize Ligand B.
Output:
0
2025-04-17 18:54:22,646 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (351.416 and 358.41 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (21.06) is significantly better than Ligand B (84.94). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand B's TPSA is quite high.
3. **logP:** Ligand A (4.565) is higher than Ligand B (0.81). While 4.565 is nearing the upper limit, it's still acceptable. Ligand B's logP is quite low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (0) is better than Ligand B (1). Fewer HBDs are generally preferred for better permeability.
5. **HBA:** Ligand A (3) is better than Ligand B (5). Similar to HBD, lower HBA is preferred.
6. **QED:** Ligand A (0.736) is significantly better than Ligand B (0.513), indicating a more drug-like profile.
7. **DILI:** Ligand A (21.753) is much better than Ligand B (38.852), indicating a lower risk of drug-induced liver injury. This is a crucial safety parameter.
8. **BBB:** Ligand A (97.053) is better than Ligand B (80.031), though both are fairly high. Since ADRB2 is primarily cardiovascular, BBB isn't a primary concern, but higher is not detrimental.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.205 and -4.41), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand A (-5.283) is better than Ligand B (-2.174). Better solubility is always desirable.
11. **hERG:** Ligand A (0.854) is better than Ligand B (0.368), indicating a lower risk of hERG inhibition and cardiotoxicity.
12. **Cl_mic:** Ligand A (62.229) is better than Ligand B (55.994), indicating better metabolic stability.
13. **t1/2:** Ligand A (6.494) is much better than Ligand B (-25.662). A negative half-life is highly problematic.
14. **Pgp:** Ligand A (0.563) is better than Ligand B (0.076), indicating lower P-gp efflux.
15. **Binding Affinity:** Ligand A (-7.2) is significantly better than Ligand B (-5.2). A 2 kcal/mol difference in binding affinity is substantial and can often outweigh minor ADME drawbacks.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A excels in all these areas compared to Ligand B. While Caco-2 permeability is poor for both, the significantly better affinity, DILI, solubility, and metabolic stability of Ligand A make it the more promising candidate.
**Conclusion:**
Ligand A is significantly superior to Ligand B across most critical parameters, especially binding affinity, safety (DILI, hERG), and drug-likeness (QED). The poor Caco-2 values are a concern for both, but the other advantages of Ligand A outweigh this drawback.
Output:
1
2025-04-17 18:54:22,646 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (351.451 and 367.515 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (91.65 and 91.22) are below the 140 A^2 threshold for good oral absorption, but higher than the 90 A^2 for CNS targets. Since ADRB2 is a cardiovascular target, CNS penetration is not a priority.
3. **logP:** Ligand A (0.489) is slightly lower than optimal (1-3), potentially hindering permeability. Ligand B (1.851) is within the optimal range. This favors Ligand B.
4. **HBD:** Ligand A (3) and Ligand B (2) are both acceptable, below the 5 threshold.
5. **HBA:** Ligand A (6) and Ligand B (5) are both acceptable, below the 10 threshold.
6. **QED:** Both ligands (0.622 and 0.575) are above 0.5, indicating good drug-likeness.
7. **DILI:** Ligand A (8.22) has a significantly lower DILI risk than Ligand B (15.936). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (17.914) has very low BBB penetration, which is fine for a cardiovascular target. Ligand B (62.466) has moderate BBB penetration, which isn't particularly helpful or harmful in this case.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.36 and -5.017), which is unusual and suggests poor permeability. However, these values are on a log scale and should be interpreted cautiously.
10. **Solubility:** Ligand A (0.175) has very poor aqueous solubility, a significant drawback. Ligand B (-2.908) also has poor solubility, but is better than Ligand A.
11. **hERG:** Both ligands (0.505 and 0.631) have relatively low hERG inhibition risk, which is good.
12. **Cl_mic:** Ligand A (-27.644) has a much lower (better) microsomal clearance than Ligand B (68.637), indicating greater metabolic stability.
13. **t1/2:** Ligand A (25.06) has a longer half-life than Ligand B (17.639), which is desirable.
14. **Pgp:** Both ligands (0.019 and 0.068) have low P-gp efflux liability, which is good.
15. **Binding Affinity:** Both ligands have similar binding affinities (-6.7 and -6.0 kcal/mol). Ligand A is slightly better, but the difference is not substantial enough to outweigh other factors.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand B has a better logP. However, Ligand A has a significantly better DILI score and metabolic stability (Cl_mic and t1/2). The slight advantage in affinity for Ligand A is also a plus. Given the importance of minimizing toxicity (DILI) and maximizing metabolic stability for a chronic cardiovascular condition, Ligand A is the more promising candidate. The solubility issues with both are concerning, but can be addressed with formulation strategies.
**Output:**
1
2025-04-17 18:54:22,646 - INFO - Batch 71 complete. Total preferences: 1136
2025-04-17 18:54:22,646 - INFO - Processing batch 72/512...
2025-04-17 18:55:14,492 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (411.3 Da) is within the ideal range, while Ligand B (350.463 Da) is also acceptable, leaning towards the lower end. No strong preference here.
2. **TPSA:** Ligand A (78.53) is better than Ligand B (87.46), both are acceptable for a non-CNS GPCR like ADRB2, but lower is generally preferred for permeability.
3. **logP:** Both ligands have good logP values (A: 2.788, B: 1.246), falling within the optimal 1-3 range. Ligand A is slightly better.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is preferable to Ligand B (5). Lower HBA is generally better for permeability.
6. **QED:** Both ligands have similar QED values (A: 0.771, B: 0.739), indicating good drug-likeness.
7. **DILI:** Ligand B (32.299) has a significantly lower DILI risk than Ligand A (54.168). This is a substantial advantage for Ligand B.
8. **BBB:** Both ligands have similar BBB penetration (A: 53.276, B: 54.634). Not a major factor for ADRB2 as it's not a CNS target.
9. **Caco-2:** Both ligands have similar negative Caco-2 values (-4.703 and -4.724). This is not ideal, but similar for both.
10. **Solubility:** Ligand B (-1.183) has slightly better solubility than Ligand A (-2.941).
11. **hERG:** Ligand A (0.422) has a slightly better hERG profile than Ligand B (0.192), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand B (12.831) has significantly lower microsomal clearance than Ligand A (66.538), suggesting better metabolic stability. This is a major advantage for Ligand B.
13. **t1/2:** Ligand B (12.018) has a much longer in vitro half-life than Ligand A (-18.736). This is a significant advantage.
14. **Pgp:** Ligand A (0.216) has a slightly lower P-gp efflux liability than Ligand B (0.052).
15. **Affinity:** Ligand B (-6.0 kcal/mol) has a slightly better binding affinity than Ligand A (-4.9 kcal/mol). This is a significant advantage.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, affinity, and metabolic stability are key. Ligand B excels in logP, affinity, and especially metabolic stability (Cl_mic and t1/2). While Ligand A has slightly better TPSA and Pgp, the substantial advantages of Ligand B in DILI, Cl_mic, t1/2 and affinity outweigh these minor differences.
**Conclusion:**
Ligand B is the more promising drug candidate due to its superior metabolic stability, longer half-life, lower DILI risk, and better binding affinity.
Output:
0
2025-04-17 18:55:14,493 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
The ADRB2 receptor is a GPCR, so the priorities are logP, Pgp, TPSA, affinity, and BBB. Let's compare the ligands:
1. **Molecular Weight:** Both ligands (364.5 and 346.4 Da) fall within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (70.4) is better than Ligand B (102.6). Lower TPSA generally favors oral absorption, which is important.
3. **logP:** Ligand A (3.36) is within the optimal 1-3 range. Ligand B (-0.395) is significantly lower, which could hinder membrane permeability. This is a major drawback for Ligand B.
4. **H-Bond Donors/Acceptors:** Both have reasonable HBD (2) and HBA (5/4) counts, unlikely to be a major differentiating factor.
5. **QED:** Both have good QED scores (0.634 and 0.701), indicating drug-like properties.
6. **DILI:** Ligand A (30.9) has a slightly higher DILI risk than Ligand B (24.3), but both are well below the concerning threshold of 60.
7. **BBB:** Ligand A (60.3) and Ligand B (59.4) are similar, and both are below the 70% threshold that would be ideal for CNS targets (though ADRB2 isn't necessarily a CNS target).
8. **Caco-2 Permeability:** Both are negative, indicating poor permeability.
9. **Aqueous Solubility:** Both are negative, indicating poor solubility.
10. **hERG:** Both ligands have very low hERG inhibition risk (0.795 and 0.039).
11. **Microsomal Clearance:** Ligand B (-18.15) has a significantly *lower* (better) microsomal clearance than Ligand A (35.7), suggesting better metabolic stability.
12. **In vitro Half-Life:** Ligand A (95.9) has a much longer half-life than Ligand B (-13.4).
13. **P-gp Efflux:** Both have very low P-gp efflux liability (0.081 and 0.009).
14. **Binding Affinity:** Ligand B (-6.7) has a slightly better binding affinity than Ligand A (-6.3), but the difference is less than 1.5 kcal/mol.
**Overall Assessment:**
While Ligand B has better metabolic stability and a slightly better binding affinity, its significantly lower logP is a major concern. A logP below 1 can severely impair permeability and oral bioavailability. Ligand A, despite having slightly worse metabolic stability, has a much more favorable logP value, making it more likely to be absorbed and reach its target. The longer half-life of Ligand A is also a positive factor. Considering the GPCR-specific priorities, the logP advantage of Ligand A outweighs the other benefits of Ligand B.
**Output:**
1
2025-04-17 18:55:14,493 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [360.527, 49.64, 2.721, 1, 5, 0.861, 17.255, 75.805, -5.208, -1.713, 0.618, 40.372, -0.693, 0.152, -8.1]
**Ligand B:** [362.901, 41.57, 3.972, 1, 2, 0.861, 11.788, 98.022, -4.419, -4.584, 0.857, 51.935, 13.453, 0.408, -6.4]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity, and BBB):
1. **MW:** Both are within the ideal 200-500 Da range. A (360.5) and B (362.9) are very similar.
2. **TPSA:** A (49.64) is better than B (41.57), both are good for oral absorption.
3. **logP:** A (2.721) is within the optimal range (1-3). B (3.972) is pushing the upper limit, potentially increasing off-target effects.
4. **HBD/HBA:** Both have 1 HBD, which is good. A has 5 HBA, B has 2. B is better here, lower HBA generally favors permeability.
5. **QED:** Both are identical at 0.861, indicating good drug-likeness.
6. **DILI:** A (17.255) is significantly higher than B (11.788), indicating a higher risk of liver injury. This is a major concern.
7. **BBB:** B (98.022) is much better than A (75.805). While not a primary concern for a cardiovascular target, higher BBB is generally favorable.
8. **Caco-2:** A (-5.208) is worse than B (-4.419), indicating lower intestinal absorption.
9. **Solubility:** A (-1.713) is better than B (-4.584), which is important for bioavailability.
10. **hERG:** A (0.618) is better than B (0.857), indicating lower cardiotoxicity risk.
11. **Cl_mic:** A (40.372) is better than B (51.935), suggesting better metabolic stability.
12. **t1/2:** B (13.453) has a significantly longer half-life than A (-0.693), which is a significant advantage for dosing frequency.
13. **Pgp:** A (0.152) is better than B (0.408), indicating lower P-glycoprotein efflux.
14. **Affinity:** A (-8.1) has a substantially stronger binding affinity than B (-6.4) - a difference of 1.7 kcal/mol. This is a significant advantage.
**Overall Assessment:**
Ligand A has a much stronger binding affinity and better Pgp efflux profile, but suffers from a higher DILI risk and poorer Caco-2 permeability. Ligand B has a better safety profile (lower DILI, better hERG), better BBB penetration, and a significantly longer half-life, but weaker binding affinity and higher Pgp efflux.
Given the GPCR target and the relatively modest importance of BBB in this case, the *substantial* affinity advantage of Ligand A is the most important factor. While the DILI risk is concerning, it's a parameter that can be addressed through further chemical modifications. The lower Caco-2 permeability is also a concern, but potentially mitigatable. The longer half-life of B is attractive, but the affinity difference is too large to ignore.
Therefore, I would choose Ligand A.
1
2025-04-17 18:55:14,493 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (370.841 and 348.487 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand B (58.64) is significantly better than Ligand A (122.47). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. This favors B.
3. **logP:** Both ligands have good logP values (1.802 and 2.657), within the optimal 1-3 range. Ligand B is slightly higher, which might be beneficial for membrane permeability.
4. **HBD:** Ligand A has 3 HBD, and Ligand B has 1. Lower is generally preferred for permeability, favoring B.
5. **HBA:** Ligand A has 7 HBA, and Ligand B has 3. Again, lower is generally preferred, favoring B.
6. **QED:** Ligand B (0.751) has a better QED score than Ligand A (0.547), indicating a more drug-like profile.
7. **DILI:** Ligand A (68.166) has a higher DILI risk than Ligand B (18.418). This is a significant advantage for B.
8. **BBB:** Both ligands have similar BBB penetration (71.656 and 71.772). Not a major differentiating factor for a cardiovascular target.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the values are similar (-5.026 and -4.705), so this doesn't strongly favor either.
10. **Solubility:** Ligand A (-4.063) has slightly better solubility than Ligand B (-2.542), but both are poor.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.183 and 0.323). No significant difference.
12. **Cl_mic:** Ligand A (17.933) has a significantly lower microsomal clearance than Ligand B (45.791), suggesting better metabolic stability. This favors A.
13. **t1/2:** Ligand B (7.453) has a much longer in vitro half-life than Ligand A (-4.383). This is a major advantage for B.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.024 and 0.126). No significant difference.
15. **Binding Affinity:** Both ligands have excellent binding affinity (-7.0 and -6.0 kcal/mol). Ligand A is slightly better, but the difference is less than 1.5 kcal/mol.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand B is the stronger candidate. While Ligand A has slightly better affinity and metabolic stability, Ligand B excels in TPSA, HBD/HBA, QED, and crucially, DILI risk and in vitro half-life. The lower DILI risk is a major safety advantage, and the longer half-life could translate to a more convenient dosing regimen. The slightly lower metabolic stability of Ligand B is a concern, but potentially addressable through further optimization.
Output:
0
2025-04-17 18:55:14,493 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (408.292 Da) is within the ideal range, while Ligand B (359.352 Da) is also acceptable, leaning towards the lower end. This is a slight advantage for A.
2. **TPSA:** Ligand A (59.0) is excellent, well below the 140 threshold. Ligand B (97.64) is higher, but still potentially acceptable for a peripherally acting GPCR.
3. **logP:** Ligand A (4.393) is a bit high, potentially leading to solubility issues. Ligand B (2.534) is within the optimal range. This is a significant advantage for B.
4. **HBD:** Ligand A (1) is good. Ligand B (3) is acceptable, but higher.
5. **HBA:** Ligand A (4) is good. Ligand B (3) is also good.
6. **QED:** Both ligands (A: 0.691, B: 0.708) have very good drug-likeness scores.
7. **DILI:** Ligand A (53.858) and Ligand B (48.468) both have acceptable DILI risk, with B being slightly better.
8. **BBB:** Ligand A (43.699) and Ligand B (53.393) are both relatively low, which is fine for a cardiovascular target like ADRB2. We don't need significant brain penetration.
9. **Caco-2:** Ligand A (-4.826) and Ligand B (-5.124) are both very poor, indicating poor intestinal absorption. This is a major concern for both.
10. **Solubility:** Ligand A (-4.891) and Ligand B (-2.944) are both poor, but B is better. The high logP of A likely contributes to this.
11. **hERG:** Ligand A (0.823) and Ligand B (0.579) are both low risk. B is slightly better.
12. **Cl_mic:** Ligand A (90.381) has higher clearance, suggesting lower metabolic stability. Ligand B (-3.59) has negative clearance, which is excellent and indicates very high metabolic stability. This is a significant advantage for B.
13. **t1/2:** Ligand A (-15.047) has a negative half-life, which is concerning. Ligand B (-20.121) is also negative, but slightly better. Both are problematic.
14. **Pgp:** Ligand A (0.616) and Ligand B (0.128) both have low P-gp efflux, which is good. B is significantly better.
15. **Affinity:** Ligand A (-5.6 kcal/mol) and Ligand B (-7.3 kcal/mol) both have good binding affinity, but Ligand B is substantially stronger. This is a major advantage for B.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP, Pgp, and significantly in affinity. While both have issues with Caco-2 and solubility, B is better in both. The metabolic stability (Cl_mic) is also much better for Ligand B.
**Conclusion:**
Despite both ligands having some drawbacks, Ligand B is the more promising candidate. Its superior binding affinity, better logP, lower Pgp efflux, and significantly improved metabolic stability outweigh the slightly higher TPSA and similar issues with Caco-2 and solubility.
Output:
0
2025-04-17 18:55:14,493 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.475 and 359.459 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (76.02) is significantly better than Ligand B (98.04). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (2.261 and 1.857), falling within the 1-3 range. Ligand B is slightly lower, which could be a minor negative.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1), but both are within the acceptable limit of 5.
5. **HBA:** Ligand A (4) is lower than Ligand B (8). This is a significant difference. Higher HBA can sometimes hinder permeability.
6. **QED:** Both ligands have good QED scores (0.795 and 0.87), indicating good drug-like properties.
7. **DILI:** Ligand A (32.028) has a much lower DILI risk than Ligand B (88.251). This is a *major* advantage for Ligand A.
8. **BBB:** Ligand A (61.652) and Ligand B (54.556) are both relatively low, which is appropriate for a cardiovascular target.
9. **Caco-2:** Both ligands have similar, poor Caco-2 permeability (-4.86 and -4.842). This suggests potential absorption issues for both.
10. **Solubility:** Both ligands have similar, very poor solubility (-3.245 and -3.625). This is a concern for both.
11. **hERG:** Ligand A (0.499) has a lower hERG risk than Ligand B (0.728). This is a positive for Ligand A.
12. **Cl_mic:** Ligand A (41.819) has a lower microsomal clearance than Ligand B (47.956), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-11.276) has a much longer in vitro half-life than Ligand A (1.243). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.111) has a lower P-gp efflux liability than Ligand B (0.156). This is a positive for Ligand A.
15. **Binding Affinity:** Ligand B (-7.0) has a slightly better binding affinity than Ligand A (-6.1), a difference of 0.9 kcal/mol. While significant, it needs to be weighed against other factors.
**Overall Assessment:**
Ligand A is the better candidate. While Ligand B has a slightly better binding affinity and a significantly longer half-life, Ligand A demonstrates a substantially lower DILI risk, lower HBA, lower hERG risk, lower Pgp efflux, and better metabolic stability. The DILI risk alone is a critical factor, as liver toxicity is a major cause of drug failure. The slightly weaker binding affinity of Ligand A can potentially be optimized in subsequent rounds of medicinal chemistry. The poor solubility and Caco-2 permeability are concerns for both, but these can be addressed through formulation strategies or further structural modifications.
Output:
1
2025-04-17 18:55:14,494 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [352.435, 91.07, -0.093, 2, 7, 0.765, 15.51, 43.001, -5.204, -0.003, 0.208, -51.293, 13.257, 0.014, -7.3]
**Ligand B:** [348.487, 58.64, 2.491, 1, 3, 0.769, 9.965, 68.631, -4.782, -2.884, 0.444, 47.829, -5.838, 0.126, -6.4]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (352.435) is slightly higher than Ligand B (348.487), but both are acceptable.
2. **TPSA:** Ligand A (91.07) is above the optimal <90 for CNS targets, but still reasonable for a peripheral GPCR like ADRB2. Ligand B (58.64) is excellent, well below 90.
3. **logP:** Ligand A (-0.093) is a bit low, potentially hindering permeability. Ligand B (2.491) is within the optimal 1-3 range. This is a significant advantage for B.
4. **HBD:** Ligand A (2) and Ligand B (1) are both good, under the threshold of 5.
5. **HBA:** Ligand A (7) and Ligand B (3) are both acceptable, under the threshold of 10.
6. **QED:** Both ligands (A: 0.765, B: 0.769) have excellent drug-likeness scores.
7. **DILI:** Ligand A (15.51) has a slightly higher DILI risk than Ligand B (9.965), but both are below the concerning threshold of 60.
8. **BBB:** Ligand B (68.631) has a better BBB penetration score than Ligand A (43.001). While ADRB2 isn't a primary CNS target, some degree of BBB penetration can be useful for off-target effects assessment.
9. **Caco-2:** Ligand A (-5.204) and Ligand B (-4.782) are both negative, which is unusual and suggests poor permeability.
10. **Solubility:** Ligand A (-0.003) is slightly better than Ligand B (-2.884), but both are very poor.
11. **hERG:** Ligand A (0.208) has a lower hERG risk than Ligand B (0.444). This is a positive for A.
12. **Cl_mic:** Ligand A (-51.293) has a much lower (better) microsomal clearance than Ligand B (47.829), indicating better metabolic stability.
13. **t1/2:** Ligand A (13.257) has a longer in vitro half-life than Ligand B (-5.838). This is a significant advantage for A.
14. **Pgp:** Ligand A (0.014) has a lower P-gp efflux liability than Ligand B (0.126), which is favorable.
15. **Affinity:** Ligand A (-7.3) has a slightly better binding affinity than Ligand B (-6.4).
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, and affinity. Ligand B excels in TPSA and logP, while Ligand A has better affinity, Pgp, and metabolic stability. The solubility is poor for both.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity and superior metabolic stability (lower Cl_mic, longer t1/2) and Pgp profile, Ligand B's significantly better logP and TPSA are crucial for permeability and absorption. The lower hERG risk of Ligand A is a plus, but the difference isn't substantial enough to outweigh the permeability concerns. The poor solubility of both is a concern that would need to be addressed through formulation. However, given the importance of absorption for a peripherally acting GPCR target, I believe Ligand B is the more promising candidate.
Output:
0
2025-04-17 18:55:14,494 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [341.411, 79.37, 1.601, 1, 4, 0.652, 44.668, 67.08, -4.655, -2.456, 0.096, 59.22, -25.841, 0.045, -6.3]
**Ligand B:** [335.407, 73.2, 2.244, 1, 3, 0.861, 47.732, 78.519, -4.943, -4.156, 0.498, 18.796, 3.829, 0.107, -6.0]
Here's a breakdown of each parameter and how the ligands compare, keeping GPCR priorities in mind (logP, Pgp, TPSA, Affinity, and to a lesser extent BBB):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (335.407) is slightly lower, which is generally favorable.
2. **TPSA:** Both are good, below the 140 threshold for oral absorption (A: 79.37, B: 73.2). Ligand B is slightly better.
3. **logP:** Both are within the optimal range (1-3). Ligand A (1.601) is slightly lower, while Ligand B (2.244) is a bit higher. This difference isn't huge, but slightly favors B.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 3. Both are acceptable, with B being slightly better.
6. **QED:** Ligand B (0.861) has a significantly better QED score than Ligand A (0.652), indicating a more drug-like profile.
7. **DILI:** Both are acceptable, below the 60 threshold (A: 44.668, B: 47.732). Similar risk.
8. **BBB:** Ligand B (78.519) has a significantly higher BBB penetration score than Ligand A (67.08). While ADRB2 is a cardiovascular target and CNS penetration isn't *critical*, some degree of BBB penetration can be beneficial for off-target effects and overall distribution.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. Ligand B (-4.943) is slightly worse than Ligand A (-4.655). This is a significant concern for both.
10. **Solubility:** Both have negative solubility values, indicating poor solubility. Ligand B (-4.156) is slightly worse than Ligand A (-2.456). This is also a significant concern for both.
11. **hERG:** Both have very low hERG inhibition risk (A: 0.096, B: 0.498). Excellent for both.
12. **Cl_mic:** Ligand B (18.796) has significantly lower microsomal clearance than Ligand A (59.22), indicating better metabolic stability. This is a major advantage for Ligand B.
13. **t1/2:** Ligand B (3.829) has a slightly longer in vitro half-life than Ligand A (-25.841). This is a positive for Ligand B.
14. **Pgp:** Both have low P-gp efflux liability (A: 0.045, B: 0.107). Good for both.
15. **Affinity:** Ligand A (-6.3) has a slightly better binding affinity than Ligand B (-6.0). However, the difference is only 0.3 kcal/mol, which is not substantial enough to outweigh other factors.
**Overall Assessment:**
Ligand B consistently outperforms Ligand A in several crucial ADME properties (QED, BBB, Cl_mic, t1/2) and has a slightly better logP and TPSA. While both compounds have poor Caco-2 and solubility, the superior metabolic stability and drug-likeness of Ligand B make it the more promising candidate. The slightly better affinity of Ligand A is not enough to compensate for the ADME deficiencies.
Output:
0
2025-04-17 18:55:14,494 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [399.705, 43.78, 4.31, 1, 3, 0.782, 54.634, 62.815, -4.961, -4.632, 0.94, 49.04, -10.484, 0.597, -8.5]**
**Ligand B: [346.427, 75.71, 1.832, 1, 4, 0.826, 51.377, 57.619, -4.575, -2.753, 0.333, 62.443, -12.867, 0.136, -6.4]**
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand B (346.427) is slightly lower, which could be beneficial for permeability, but both are acceptable.
2. **TPSA:** Ligand A (43.78) is better than Ligand B (75.71). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally improves absorption. Ligand B is quite high, potentially hindering oral absorption.
3. **logP:** Ligand A (4.31) is higher than Ligand B (1.832). While 4.31 is approaching the upper limit, it's still within a reasonable range. Ligand B's logP is quite low, potentially limiting membrane permeability.
4. **H-Bond Donors:** Both have 1 HBD, which is good.
5. **H-Bond Acceptors:** Ligand A has 3 HBA, Ligand B has 4. Both are acceptable, below the threshold of 10.
6. **QED:** Both ligands have good QED scores (A: 0.782, B: 0.826), indicating good drug-like properties.
7. **DILI:** Both have similar DILI risk (A: 54.634, B: 51.377), and are both acceptable.
8. **BBB:** Both have moderate BBB penetration (A: 62.815, B: 57.619). Not critical for a cardiovascular target.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability.
10. **Aqueous Solubility:** Ligand A (-4.632) is worse than Ligand B (-2.753). Solubility is a concern for both, but Ligand B is slightly better.
11. **hERG:** Ligand A (0.94) is better than Ligand B (0.333). Lower hERG inhibition is crucial for avoiding cardiotoxicity, especially for a cardiovascular target.
12. **Microsomal Clearance:** Ligand A (49.04) has lower clearance than Ligand B (62.443), suggesting better metabolic stability.
13. **In vitro Half-Life:** Ligand A (-10.484) has a longer half-life than Ligand B (-12.867).
14. **P-gp Efflux:** Ligand A (0.597) has lower P-gp efflux than Ligand B (0.136). Lower efflux is generally preferred for better bioavailability.
15. **Binding Affinity:** Ligand A (-8.5) has significantly better binding affinity than Ligand B (-6.4). This is a >2 kcal/mol difference, which is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand A is the stronger candidate. While Ligand B has slightly better solubility and a marginally better QED score, Ligand A excels in the most critical areas: significantly higher binding affinity, better hERG inhibition, lower P-gp efflux, and better metabolic stability (lower clearance, longer half-life). The TPSA is also more favorable for Ligand A. The slightly higher logP of Ligand A is a minor concern compared to the substantial benefits in other parameters.
Output:
1
2025-04-17 18:55:14,494 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (346.299) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (101.29) is better than Ligand A (127.01), falling comfortably under the 140 threshold for good oral absorption.
3. **logP:** Ligand B (1.373) is within the optimal range (1-3), while Ligand A (0.109) is quite low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (2) and Ligand B (3) are both acceptable, being less than 5.
5. **HBA:** Ligand A (8) and Ligand B (4) are both acceptable, being less than 10.
6. **QED:** Both ligands have similar QED values (A: 0.784, B: 0.73), indicating good drug-likeness.
7. **DILI:** Ligand B (27.608) has a significantly lower DILI risk than Ligand A (85.77), which is a major advantage.
8. **BBB:** Ligand B (69.252) shows better BBB penetration than Ligand A (20.202). While ADRB2 isn't strictly a CNS target, some CNS exposure can be relevant for off-target effects and overall safety.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
10. **Solubility:** Both ligands have negative solubility values, which is also unusual. Again, the scale is not specified, making interpretation difficult.
11. **hERG:** Ligand A (0.013) has a much lower hERG inhibition liability than Ligand B (0.453), which is a significant safety advantage.
12. **Cl_mic:** Ligand B (-11.698) has a much lower (better) microsomal clearance than Ligand A (14.325), indicating greater metabolic stability.
13. **t1/2:** Ligand A (7.475) has a longer in vitro half-life than Ligand B (-0.598), which is generally desirable.
14. **Pgp:** Ligand A (0.012) has lower P-gp efflux liability than Ligand B (0.044), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand A (-8.1) has a significantly stronger binding affinity than Ligand B (-6.5). This is a substantial advantage, potentially outweighing some ADME concerns.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP and TPSA, and has a good BBB score. However, the significantly stronger affinity of Ligand A (-8.1 vs -6.5) is a major driver. The difference of 1.6 kcal/mol is substantial and likely to translate into a more potent drug. While Ligand A has a higher DILI risk and worse metabolic stability, the potency advantage is likely to be more impactful in early development, and these ADME properties can be optimized later. The hERG risk for Ligand A is also very low.
**Conclusion:**
Despite some ADME drawbacks, the significantly higher binding affinity of Ligand A makes it the more promising drug candidate.
Output:
1
2025-04-17 18:55:14,494 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
The ADRB2 receptor is a GPCR, so the priorities are logP, TPSA, Pgp efflux, BBB penetration, and binding affinity. Metabolic stability (Cl_mic, t1/2) and safety (DILI, hERG) are also important.
Let's compare the ligands property by property:
1. **MW:** Both ligands (348.403 and 347.35 Da) are within the ideal range (200-500 Da).
2. **TPSA:** Both are reasonably good (102.74 and 100.09), below the 140 threshold for oral absorption.
3. **logP:** Ligand A (0.627) is slightly better than Ligand B (-0.14). While both are a bit low, A is closer to the optimal 1-3 range. Low logP can hinder membrane permeability.
4. **HBD/HBA:** Ligand A (1 HBD, 5 HBA) is preferable to Ligand B (2 HBD, 5 HBA). Fewer HBDs generally improve permeability.
5. **QED:** Both ligands have excellent QED scores (0.785 and 0.786), indicating good drug-likeness.
6. **DILI:** Ligand A (32.842) has a significantly lower DILI risk than Ligand B (42.885). This is a major advantage for A.
7. **BBB:** Ligand A (71.811) has considerably better BBB penetration potential than Ligand B (48.003). This is a key advantage for a GPCR target.
8. **Caco-2:** Ligand A (-4.749) is better than Ligand B (-5.087), indicating better intestinal absorption.
9. **Solubility:** Ligand A (-1.952) is better than Ligand B (-2.51), indicating better solubility.
10. **hERG:** Both ligands have very low hERG inhibition risk (0.16 and 0.31).
11. **Cl_mic:** Ligand A (-43.109) has a much lower (better) microsomal clearance than Ligand B (-11.252), suggesting greater metabolic stability.
12. **t1/2:** Ligand A (-2.376) has a better in vitro half-life than Ligand B (-37.323).
13. **Pgp:** Both ligands have very low Pgp efflux liability (0.007 and 0.023).
14. **Binding Affinity:** Ligand B (-8.4 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.3 kcal/mol). This is a substantial advantage.
**Overall Assessment:**
Ligand B has a significantly better binding affinity. However, Ligand A demonstrates a superior ADME profile across almost all parameters, including lower DILI risk, better BBB penetration, better metabolic stability (lower Cl_mic and better t1/2), and better solubility. While the affinity difference is substantial, the improved ADME properties of Ligand A, particularly the lower DILI and better BBB, are critical for a viable drug candidate targeting a GPCR. The slightly lower logP of Ligand A is a minor concern, but the other benefits outweigh this.
**Output:**
1
2025-04-17 18:55:14,495 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (344.459 Da and 354.455 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (66.4) is significantly better than Ligand B (135.16). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is above the preferred 90 A^2 threshold.
**3. logP:** Ligand A (2.286) is within the optimal 1-3 range. Ligand B (0.209) is quite low, potentially hindering membrane permeability and absorption.
**4. H-Bond Donors:** Ligand A (0) is preferable to Ligand B (4). Fewer HBDs generally improve permeability.
**5. H-Bond Acceptors:** Ligand A (4) is better than Ligand B (7). Lower HBA counts are generally preferred.
**6. QED:** Ligand A (0.825) has a much better QED score than Ligand B (0.5), indicating a more drug-like profile.
**7. DILI:** Ligand A (35.789) has a lower DILI risk than Ligand B (49.011), which is better. Both are acceptable, but A is preferred.
**8. BBB:** Ligand A (80.574) shows better BBB penetration potential than Ligand B (47.693). While ADRB2 isn't exclusively a CNS target, some CNS exposure can occur, and higher BBB is generally favorable.
**9. Caco-2 Permeability:** Ligand A (-4.692) is better than Ligand B (-5.51), indicating better intestinal absorption.
**10. Aqueous Solubility:** Both ligands have poor aqueous solubility (-2.035 and -2.118 respectively). This is a concern for both, but not a deciding factor.
**11. hERG Inhibition:** Ligand A (0.436) has a lower hERG inhibition liability than Ligand B (0.278), indicating a lower risk of cardiotoxicity.
**12. Microsomal Clearance:** Ligand A (39.753) has a higher (worse) microsomal clearance than Ligand B (18.236). This suggests Ligand B is more metabolically stable.
**13. In vitro Half-Life:** Ligand B (1.17) has a longer half-life than Ligand A (-0.653). This is a positive for Ligand B.
**14. P-gp Efflux:** Ligand A (0.196) has lower P-gp efflux liability than Ligand B (0.074), which is beneficial for bioavailability.
**15. Binding Affinity:** Ligand B (-7.2) has a significantly stronger binding affinity than Ligand A (-5.2). This is a substantial advantage, >1.5 kcal/mol.
**Overall Assessment:**
Ligand B has a superior binding affinity, and better metabolic stability and half-life. However, Ligand A excels in almost all other ADME properties (TPSA, logP, QED, DILI, BBB, Caco-2, hERG, P-gp). The significant difference in binding affinity (-7.2 vs -5.2) is a strong driver. While Ligand A has a better overall ADME profile, the potency advantage of Ligand B outweighs the ADME concerns, especially given that some of the ADME issues (solubility) can be addressed through formulation.
Output:
0
2025-04-17 18:55:14,495 - INFO - Here's my reasoning and final output for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's break down the comparison of Ligand A and Ligand B, considering the provided guidelines and the GPCR-specific priorities (logP, Pgp, TPSA, and affinity being most important).
1. **Molecular Weight:** Both ligands (363.414 and 349.391 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (73.34) is significantly better than Ligand B (98.84). A TPSA under 140 is good for oral absorption, and lower is preferable for GPCRs. Ligand B is approaching a level that could hinder absorption.
3. **logP:** Ligand A (2.904) is within the optimal 1-3 range. Ligand B (-0.409) is *below* 1, which is a concern for membrane permeability. This is a substantial negative for Ligand B.
4. **H-Bond Donors:** Both have 1 HBD, which is acceptable.
5. **H-Bond Acceptors:** Ligand A has 6, and Ligand B has 5. Both are within the acceptable limit of 10.
6. **QED:** Both ligands have good QED scores (0.65 and 0.779), indicating generally drug-like properties.
7. **DILI:** Ligand A (94.106) has a higher DILI risk than Ligand B (60.062). This is a concern for Ligand A, but not a deal-breaker if other properties are favorable.
8. **BBB:** Ligand A (71.772) has better BBB penetration potential than Ligand B (58.782). While ADRB2 isn't strictly a CNS target, some CNS exposure can occur, and higher BBB is generally favorable.
9. **Caco-2:** Both have negative values (-4.915 and -4.855), which is unusual. Assuming these are log scale values, they suggest very poor permeability.
10. **Solubility:** Ligand A (-3.939) has slightly worse solubility than Ligand B (-1.813). Solubility is important, but can often be addressed with formulation.
11. **hERG:** Both ligands have very low hERG risk (0.195 and 0.109). This is excellent.
12. **Cl_mic:** Ligand A (33.202) has significantly lower microsomal clearance than Ligand B (8.83). Lower clearance indicates better metabolic stability, a major advantage for Ligand A.
13. **t1/2:** Ligand A (2.724) has a shorter half-life than Ligand B (6.115). This is a drawback for Ligand A, but potentially manageable with dosing.
14. **Pgp:** Both ligands have very low Pgp efflux (0.078 and 0.014). This is good.
15. **Binding Affinity:** Ligand A (-8.6 kcal/mol) has a substantially stronger binding affinity than Ligand B (-7.1 kcal/mol). This is a difference of 1.5 kcal/mol, which is significant enough to outweigh many of the other drawbacks.
**Overall Assessment:**
Ligand A is the stronger candidate. While it has a higher DILI risk and shorter half-life, its superior logP, TPSA, metabolic stability (lower Cl_mic), and *significantly* better binding affinity outweigh these concerns. The poor Caco-2 values are a concern for both, but the other advantages of Ligand A make it the more promising starting point for optimization. The low logP of Ligand B is a major hurdle to overcome.
**Output:**
1
2025-04-17 18:55:14,495 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 drug candidates. ADRB2 is a GPCR, so we'll prioritize logP, Pgp, TPSA, BBB, and affinity.
**Ligand A:**
* **MW:** 353.438 Da - Good, within the ideal range.
* **TPSA:** 93.43 - Acceptable, slightly above the optimal <90 for CNS, but still reasonable for a peripheral GPCR like ADRB2.
* **logP:** 1.821 - Excellent, within the optimal range.
* **HBD:** 2 - Good.
* **HBA:** 4 - Good.
* **QED:** 0.683 - Very good, indicating good drug-like properties.
* **DILI:** 14.541 - Excellent, very low risk of liver injury.
* **BBB:** 66.615 - Moderate. Not a primary concern for ADRB2, but lower than Ligand B.
* **Caco-2:** -5.023 - Poor permeability. This is a significant drawback.
* **Solubility:** -2.035 - Poor solubility. Another significant drawback.
* **hERG:** 0.705 - Low risk of hERG inhibition.
* **Cl_mic:** 9.883 - Relatively low, suggesting reasonable metabolic stability.
* **t1/2:** 1.297 - Short half-life.
* **Pgp:** 0.197 - Low P-gp efflux, which is good for bioavailability.
* **Affinity:** -6.9 kcal/mol - Very good binding affinity.
**Ligand B:**
* **MW:** 357.382 Da - Good, within the ideal range.
* **TPSA:** 102.69 - Slightly higher than ideal, but still acceptable.
* **logP:** 1.135 - Good, within the optimal range.
* **HBD:** 2 - Good.
* **HBA:** 6 - Acceptable.
* **QED:** 0.609 - Good, indicating good drug-like properties.
* **DILI:** 47.77 - Moderate, higher than Ligand A, but still within an acceptable range.
* **BBB:** 87.902 - Excellent, high BBB penetration. Not a major concern for ADRB2, but a positive.
* **Caco-2:** -4.536 - Poor permeability, but slightly better than Ligand A.
* **Solubility:** -2.285 - Poor solubility, similar to Ligand A.
* **hERG:** 0.421 - Low risk of hERG inhibition.
* **Cl_mic:** 29.387 - Higher clearance, indicating lower metabolic stability.
* **t1/2:** -26.528 - Very short half-life, a significant drawback.
* **Pgp:** 0.107 - Low P-gp efflux, which is good for bioavailability.
* **Affinity:** -6.4 kcal/mol - Good binding affinity, but slightly weaker than Ligand A.
**Comparison and Decision:**
Both ligands have poor Caco-2 permeability and solubility, which are major concerns. However, Ligand A has a significantly better binding affinity (-6.9 vs -6.4 kcal/mol), a lower DILI risk, and better metabolic stability (lower Cl_mic). The slightly better BBB penetration of Ligand B is not a critical factor for ADRB2. The affinity difference is substantial enough to outweigh the slightly higher DILI risk and lower metabolic stability of Ligand A.
Therefore, I prefer Ligand A.
Output:
1
2025-04-17 18:55:14,495 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (337.387 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both ligands are below the 140 A^2 threshold for good oral absorption (A: 89.66, B: 86.63). This is good.
3. **logP:** Ligand A (2.2) is optimal, while Ligand B (0.933) is a bit low, potentially hindering membrane permeability.
4. **HBD:** Both are acceptable (A: 2, B: 1).
5. **HBA:** Both are acceptable (A: 6, B: 5).
6. **QED:** Both are good (A: 0.747, B: 0.78), indicating drug-like properties.
7. **DILI:** Ligand B (57.348) has a significantly lower DILI risk than Ligand A (81.039). This is a major advantage for Ligand B.
8. **BBB:** Both have reasonable BBB penetration (A: 70.997, B: 61.807), but A is better. This is moderately important for a cardiovascular target, but less critical than for CNS targets.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the values are similar (-5.064 for A, -4.808 for B).
10. **Solubility:** Both have negative solubility values, which is also unusual and suggests poor solubility. A is slightly worse (-3.766) than B (-1.998).
11. **hERG:** Both have very low hERG inhibition risk (A: 0.114, B: 0.142).
12. **Cl_mic:** Ligand B (7.057) has significantly lower microsomal clearance than Ligand A (19.646), indicating better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand A (10.364) has a longer in vitro half-life than Ligand B (-20.76), which is a positive. However, the negative value for B is concerning.
14. **Pgp:** Both have low P-gp efflux liability (A: 0.096, B: 0.033). B is slightly better.
15. **Affinity:** Ligand A (-7.9 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.7 kcal/mol). This is a substantial advantage, potentially outweighing some ADME drawbacks.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand A has better logP and affinity. Ligand B has better DILI and Cl_mic. The affinity difference is substantial (1.2 kcal/mol), and a strong binding affinity is crucial for GPCR activity. While the DILI and metabolic stability of Ligand B are attractive, the superior affinity of Ligand A is more important for initial potency and efficacy. The negative solubility and Caco-2 values for both are concerning and would need to be addressed in further optimization, but the initial potency is paramount.
**Conclusion:**
Despite the better safety profile (lower DILI) and metabolic stability of Ligand B, the significantly stronger binding affinity of Ligand A makes it the more promising drug candidate at this stage. The affinity advantage is likely to be more impactful than the ADME differences, especially considering further optimization can address the solubility and permeability issues.
Output:
1
2025-04-17 18:55:14,495 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (353.419 and 349.435 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (105.76) is slightly higher than Ligand B (98.4). Both are below the 140 threshold for good oral absorption, and acceptable for a cardiovascular GPCR.
3. **logP:** Ligand B (0.666) is better than Ligand A (-0.528). A logP between 1-3 is optimal, and Ligand B is closer to this range. Ligand A's negative logP is a concern for permeability.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (2), but both are within the acceptable limit of 5.
5. **HBA:** Ligand A (5) is slightly higher than Ligand B (4), but both are within the acceptable limit of 10.
6. **QED:** Both ligands have good QED scores (0.595 and 0.674), indicating a generally drug-like profile. Ligand B is slightly better.
7. **DILI:** Ligand B (25.204) has a significantly lower DILI risk than Ligand A (47.266). This is a major advantage for Ligand B.
8. **BBB:** Ligand B (51.842) has better BBB penetration than Ligand A (46.762). While ADRB2 isn't a CNS target, some distribution to the CNS can sometimes lead to off-target effects, so moderate penetration isn't necessarily detrimental.
9. **Caco-2:** Both ligands have very poor Caco-2 permeability (-5.539 and -5.566). This is a significant drawback for both.
10. **Solubility:** Both ligands have poor aqueous solubility (-1.652 and -1.455). This is a concern for bioavailability.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.075 and 0.093). This is excellent.
12. **Cl_mic:** Ligand A (-9.495) has significantly lower microsomal clearance than Ligand B (4.703), indicating better metabolic stability. This is a strong advantage for Ligand A.
13. **t1/2:** Ligand A (19.498) has a longer in vitro half-life than Ligand B (-11.706). This is another advantage for Ligand A.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.009 and 0.008). This is good.
15. **Binding Affinity:** Ligand A (-6.7 kcal/mol) has a slightly better binding affinity than Ligand B (-4.7 kcal/mol). This is a 2 kcal/mol difference, which is a substantial advantage.
**GPCR-specific priorities:** For ADRB2 (a cardiovascular GPCR), logP, Pgp, TPSA, and affinity are key. Ligand B has a better logP, while Ligand A has better affinity, metabolic stability (Cl_mic), and half-life. The DILI risk is also much lower for Ligand B. The affinity difference is significant enough to outweigh the slightly worse metabolic profile of Ligand B, especially given the lower DILI risk. The poor Caco-2 and solubility are concerning for both, but can be addressed with formulation strategies.
**Conclusion:**
Considering the balance of properties, especially the significant advantage in binding affinity for Ligand A, and the lower DILI risk for Ligand B, I lean towards **Ligand B** due to the lower DILI risk.
Output:
0
2025-04-17 18:55:14,495 - INFO - Batch 72 complete. Total preferences: 1152
2025-04-17 18:55:14,495 - INFO - Processing batch 73/512...
2025-04-17 18:56:07,975 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (388.873 and 364.433 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (76.66) is significantly better than Ligand A (101.57). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have very similar logP values (1.917 and 1.873), both within the optimal 1-3 range.
4. **HBD:** Both ligands have 2 H-bond donors, which is acceptable.
5. **HBA:** Ligand B (4) has fewer H-bond acceptors than Ligand A (5), which is slightly preferable.
6. **QED:** Ligand B (0.655) has a slightly higher QED score than Ligand A (0.523), indicating a more drug-like profile.
7. **DILI:** Ligand B (38.736) has a much lower DILI risk than Ligand A (66.576). This is a significant advantage, as liver toxicity is a major concern.
8. **BBB:** Ligand B (82.241) has a higher BBB penetration percentile than Ligand A (69.833). While not critical for a cardiovascular target, higher BBB is rarely a detriment.
9. **Caco-2:** Both ligands have similar, poor Caco-2 permeability (-4.871 and -4.908). This is a potential issue for both.
10. **Solubility:** Ligand B (-2.181) has better aqueous solubility than Ligand A (-3.449).
11. **hERG:** Ligand B (0.436) has a lower hERG inhibition liability than Ligand A (0.223), which is a significant safety advantage.
12. **Cl_mic:** Ligand B (30.075) has a lower microsomal clearance than Ligand A (55.089), indicating better metabolic stability.
13. **t1/2:** Ligand B (-8.785) has a longer in vitro half-life than Ligand A (21.28). This is a positive attribute.
14. **Pgp:** Ligand B (0.089) has lower P-gp efflux liability than Ligand A (0.109).
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.3 and -6.1 kcal/mol). The difference is negligible.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B is better on TPSA, Pgp, and has a slightly better logP. The affinities are nearly identical. Critically, Ligand B demonstrates a significantly improved safety profile with lower DILI and hERG risk.
**Conclusion:**
Ligand B consistently outperforms Ligand A across several crucial ADME-Tox parameters, especially DILI and hERG, without sacrificing binding affinity. While Caco-2 permeability is a concern for both, the overall profile of Ligand B is more favorable for development as a drug candidate.
Output:
0
2025-04-17 18:56:07,976 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
The ADRB2 receptor is a GPCR, so the priorities are logP, TPSA, Pgp efflux, BBB penetration, and binding affinity. Metabolic stability and solubility are also important, but slightly less so than the first set.
Let's compare the ligands property by property:
1. **MW:** Both ligands (366.334 and 377.941 Da) are within the ideal range (200-500 Da).
2. **TPSA:** Both ligands (39.68 and 38.25) are well below the 140 A^2 threshold for good oral absorption, and suitable for a GPCR.
3. **logP:** Ligand A (2.928) is optimal, while Ligand B (4.875) is pushing the upper limit and could potentially cause solubility issues or off-target interactions.
4. **HBD/HBA:** Both have acceptable numbers of HBD (0) and HBA (3 and 5 respectively), balancing solubility and permeability.
5. **QED:** Both ligands have reasonable QED scores (0.773 and 0.615), indicating drug-likeness.
6. **DILI:** Both have low DILI risk (38.93 and 36.758), which is good.
7. **BBB:** Ligand A (88.445) shows significantly better BBB penetration than Ligand B (65.529). While not a CNS target, some level of BBB penetration can be beneficial for distribution.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. This is a concern for both.
9. **Solubility:** Ligand A (-2.879) has better solubility than Ligand B (-4.412). This is important given Ligand B's higher logP.
10. **hERG:** Both ligands have low hERG inhibition liability (0.485 and 0.786).
11. **Cl_mic:** Ligand A (29.915) has significantly lower microsomal clearance than Ligand B (76.826), indicating better metabolic stability.
12. **t1/2:** Ligand A (11.297) has a longer in vitro half-life than Ligand B (-8.301).
13. **Pgp:** Ligand A (0.064) has much lower P-gp efflux liability than Ligand B (0.688), which is a significant advantage for bioavailability.
14. **Binding Affinity:** Both have excellent binding affinities (-5.9 and -6.3 kcal/mol), with Ligand B being slightly better. However, the difference is less than 1.5 kcal/mol and can be outweighed by other factors.
**Overall Assessment:**
Ligand A is the better candidate. While Ligand B has slightly better binding affinity, Ligand A demonstrates a superior balance of ADME properties. Specifically, its lower logP, better solubility, lower Cl_mic, longer half-life, and significantly lower P-gp efflux are all highly desirable. The better BBB penetration is also a plus. The negative Caco-2 values are a concern for both, but the other advantages of Ligand A outweigh this shared drawback.
**Output:**
1
2025-04-17 18:56:07,976 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [346.475, 78.09, 2.442, 2, 3, 0.744, 32.648, 55.06, -5.152, -2.378, 0.353, 29.902, -13.916, 0.113, -6.4]
**Ligand B:** [346.402, 54.71, 2.711, 1, 4, 0.904, 51.725, 80.341, -4.493, -3.604, 0.776, 36.796, 40.211, 0.489, -5.9]
Here's a step-by-step comparison, considering the guidelines and GPCR-specific priorities:
1. **MW:** Both are around 346 Da, well within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (78.09) is higher than Ligand B (54.71). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is generally preferred for permeability. Ligand B is better.
3. **logP:** Both are in the optimal 1-3 range (A: 2.442, B: 2.711). Ligand B is slightly higher, which could be beneficial for membrane permeability, but not dramatically so.
4. **HBD:** Ligand A (2) is slightly better than Ligand B (1). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (3) is lower than Ligand B (4). Lower is better for permeability. Ligand A is better.
6. **QED:** Ligand B (0.904) has a significantly higher QED score than Ligand A (0.744), indicating a more drug-like profile. This is a substantial advantage for Ligand B.
7. **DILI:** Ligand A (32.648) has a lower DILI risk than Ligand B (51.725). This is a significant advantage for Ligand A.
8. **BBB:** Ligand B (80.341) has a much higher BBB penetration percentile than Ligand A (55.06). While this isn't a primary concern for a cardiovascular target, it's not a major drawback.
9. **Caco-2:** Ligand A (-5.152) has a lower Caco-2 permeability than Ligand B (-4.493). Higher is better, so Ligand B is better.
10. **Solubility:** Ligand A (-2.378) has better solubility than Ligand B (-3.604). Solubility is important, and Ligand A has a clear advantage.
11. **hERG:** Ligand A (0.353) has a lower hERG inhibition liability than Ligand B (0.776). This is a crucial advantage for Ligand A, minimizing cardiotoxicity risk.
12. **Cl_mic:** Ligand A (29.902) has a lower microsomal clearance than Ligand B (36.796), suggesting better metabolic stability. This is a positive for Ligand A.
13. **t1/2:** Ligand B (40.211) has a longer in vitro half-life than Ligand A (-13.916). This is a significant advantage for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.113) has lower P-gp efflux liability than Ligand B (0.489). Lower is better, so Ligand A is better.
15. **Affinity:** Ligand B (-5.9) has a slightly better binding affinity than Ligand A (-6.4). While a difference of 0.5 kcal/mol is not huge, it's a positive for Ligand B.
**Overall Assessment:**
Ligand A excels in safety parameters (DILI, hERG), solubility, metabolic stability (Cl_mic), and P-gp efflux. Ligand B shines with its QED score, BBB penetration, Caco-2 permeability, and slightly better binding affinity and half-life.
Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity), and the fact this is a cardiovascular target (less emphasis on BBB), the lower DILI and hERG risks of Ligand A are paramount. The better solubility and metabolic stability further strengthen its profile. While Ligand B has a slightly better affinity and QED, the safety advantages of Ligand A outweigh these benefits in this context.
Output:
1
2025-04-17 18:56:07,976 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (353.491 Da and 349.362 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (37.61) is significantly lower than Ligand B (105.82). For a GPCR, lower TPSA is generally preferred for better permeability, and Ligand A is well below the 140 threshold. Ligand B is higher, potentially hindering absorption.
**3. logP:** Ligand A (4.108) is higher than Ligand B (0.494). While 4.108 is approaching the upper limit of the optimal range (1-3), it's still acceptable. Ligand B's logP is quite low, which could severely limit its ability to cross cell membranes.
**4. H-Bond Donors:** Ligand A (0) has fewer HBDs than Ligand B (3). Fewer HBDs generally improve permeability.
**5. H-Bond Acceptors:** Ligand A (4) has fewer HBAs than Ligand B (5). Similar to HBDs, lower is preferred for permeability.
**6. QED:** Both ligands have similar QED values (0.711 and 0.721), indicating good drug-like properties.
**7. DILI:** Ligand B (36.138) has a much lower DILI risk than Ligand A (50.174). This is a significant advantage for Ligand B.
**8. BBB:** Ligand A (92.361) has a much higher BBB penetration percentile than Ligand B (48.197). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be beneficial or at least not detrimental, and a higher BBB score is generally desirable.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.988 and -4.813). This is unusual and suggests poor permeability *in vitro*. However, the values are very similar.
**10. Aqueous Solubility:** Ligand A (-3.803) has slightly worse solubility than Ligand B (-1.915). Solubility is important, but not as critical as permeability for GPCRs.
**11. hERG Inhibition:** Ligand A (0.93) has a slightly higher hERG risk than Ligand B (0.468), but both are relatively low.
**12. Microsomal Clearance:** Ligand B (-33.166) has significantly lower (better) microsomal clearance than Ligand A (60.144), indicating greater metabolic stability.
**13. In vitro Half-Life:** Ligand B (37.781) has a much longer in vitro half-life than Ligand A (-17.954). This is a significant advantage for Ligand B, potentially allowing for less frequent dosing.
**14. P-gp Efflux:** Both ligands have similar P-gp efflux liability (0.929 and 0.022).
**15. Binding Affinity:** Ligand B (-6.6) has a slightly better binding affinity than Ligand A (-6.0). While the difference is not huge, it's still a positive for Ligand B.
**Overall Assessment:**
Ligand B clearly wins out. While Ligand A has better BBB penetration, Ligand B demonstrates superior ADME properties (lower DILI, better metabolic stability, longer half-life, and better logP) and comparable binding affinity. The low logP of Ligand A is a major concern, potentially leading to poor absorption. The better metabolic stability and longer half-life of Ligand B are also crucial for *in vivo* efficacy. The lower DILI risk is also a significant advantage. The slightly better affinity of Ligand B further solidifies its position as the more promising candidate.
Output:
0
2025-04-17 18:56:07,976 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (349.366) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (93.26) is better than Ligand B (105.39). Both are acceptable, but lower TPSA generally improves oral absorption.
3. **logP:** Ligand B (1.419) is better than Ligand A (0.434). A logP between 1-3 is optimal, and Ligand B falls squarely within that range, while A is a bit low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (1) is better than Ligand B (2). Lower HBD is generally preferred.
5. **HBA:** Ligand A (6) is better than Ligand B (5). Lower HBA is generally preferred.
6. **QED:** Both ligands are very similar (A: 0.845, B: 0.818) and both are excellent, indicating strong drug-like properties.
7. **DILI:** Ligand A (41.024) is significantly better than Ligand B (51.105). Lower DILI risk is crucial.
8. **BBB:** Ligand A (69.678) is better than Ligand B (54.13). While ADRB2 isn't exclusively a CNS target, some CNS penetration can be beneficial, and lower efflux is always good.
9. **Caco-2:** Ligand A (-4.83) is better than Ligand B (-5.282). Higher Caco-2 permeability is preferred.
10. **Solubility:** Ligand A (-1.87) is better than Ligand B (-2.83). Higher solubility is preferred.
11. **hERG:** Both ligands are very low (A: 0.178, B: 0.102), indicating minimal hERG inhibition risk. This is excellent for both.
12. **Cl_mic:** Ligand B (-8.168) is significantly better than Ligand A (1.548). Lower microsomal clearance indicates better metabolic stability, a significant advantage.
13. **t1/2:** Both ligands have very similar and excellent in vitro half-lives (A: -23.52, B: -22.783).
14. **Pgp:** Both ligands are very similar (A: 0.012, B: 0.032) and low, indicating minimal P-gp efflux.
15. **Binding Affinity:** Both ligands have very similar binding affinities (A: -6.6, B: -6.7). The difference is negligible.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are key. While Ligand A has better TPSA, Ligand B has a much better logP. The binding affinities are almost identical. The significant advantage of Ligand B in terms of metabolic stability (Cl_mic) is also a strong factor. The lower DILI risk of Ligand A is a plus, but the metabolic stability is more critical for a GPCR target.
**Conclusion:**
Despite Ligand A having slightly better TPSA and DILI, Ligand B's superior logP and significantly improved metabolic stability (Cl_mic) make it the more promising drug candidate for ADRB2.
Output:
0
2025-04-17 18:56:07,976 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.43 & 354.49 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands have a TPSA of 67.87, which is good for oral absorption, well below the 140 threshold.
3. **logP:** Both ligands have logP values within the optimal range (2.30 & 2.69). Ligand B is slightly higher, which *could* be beneficial for membrane permeability, but isn't a major concern.
4. **HBD:** Both ligands have 1 H-bond donor, which is acceptable.
5. **HBA:** Both ligands have 4 H-bond acceptors, also acceptable.
6. **QED:** Ligand A (0.908) has a significantly higher QED score than Ligand B (0.413), indicating a much more drug-like profile. This is a substantial advantage for Ligand A.
7. **DILI:** Ligand A (43.62) has a slightly higher DILI risk than Ligand B (26.41), but both are well below the concerning threshold of 60.
8. **BBB:** Both ligands have high BBB penetration (87.71% & 80.07%), which is good, but not critical for ADRB2 as it's primarily a cardiovascular target.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.471 & -4.914), which is unusual and suggests poor permeability. This is a significant concern for both. However, the negative values are similar.
10. **Solubility:** Both ligands have very poor aqueous solubility (-2.848 & -2.742). This is a major drawback for both, potentially hindering bioavailability.
11. **hERG:** Both ligands have low hERG inhibition risk (0.581 & 0.587), which is excellent.
12. **Cl_mic:** Ligand A (-6.391) has a *much* lower (better) microsomal clearance than Ligand B (23.39). This suggests significantly improved metabolic stability for Ligand A.
13. **t1/2:** Ligand A (11.823 hours) has a longer in vitro half-life than Ligand B (-1.868 hours). This is a substantial advantage for Ligand A, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.081 & 0.063), which is favorable.
15. **Binding Affinity:** Ligand A (-7.3 kcal/mol) has a slightly better binding affinity than Ligand B (-6.2 kcal/mol). This 1.1 kcal/mol difference is significant and could outweigh some of the ADME drawbacks.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are important. Both ligands perform similarly on logP, Pgp and TPSA. Ligand A has a better affinity. The biggest differences are in QED, Cl_mic, and t1/2, all of which strongly favor Ligand A.
**Conclusion:**
Despite the poor solubility and Caco-2 permeability for both, Ligand A is the superior candidate. Its significantly better QED score, lower Cl_mic, longer half-life, and slightly improved binding affinity outweigh the slightly higher DILI risk. The improved metabolic stability and drug-likeness of Ligand A make it more likely to succeed as a drug candidate.
Output:
1
2025-04-17 18:56:07,976 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [349.435, 96.33, 0.527, 2, 5, 0.636, 34.471, 51.725, -5.569, -1.13, 0.038, 19.027, 26.713, 0.014, -7.2]
**Ligand B:** [363.527, 62.3, 2.865, 1, 4, 0.845, 26.057, 71.966, -4.792, -2.694, 0.307, 59.09, 18.822, 0.233, -5.7]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity, and to a lesser extent BBB):
1. **MW:** Both are within the ideal range (200-500 Da). A is 349.4, B is 363.5. A slight edge to A.
2. **TPSA:** A (96.33) is higher than B (62.3). B is significantly better, falling well below the 140 threshold for oral absorption and closer to the ideal for GPCRs.
3. **logP:** A (0.527) is quite low, potentially hindering permeability. B (2.865) is much better, within the optimal 1-3 range. This is a significant advantage for B.
4. **HBD/HBA:** A has 2 HBD and 5 HBA, B has 1 HBD and 4 HBA. Both are acceptable, but B is slightly more favorable.
5. **QED:** B (0.845) is better than A (0.636), indicating a more drug-like profile.
6. **DILI:** A (34.471) has a higher DILI risk than B (26.057), though both are reasonably low. B is preferable.
7. **BBB:** A (51.725) is lower than B (71.966). While ADRB2 is cardiovascular, some CNS penetration isn't necessarily detrimental, and B has a better score.
8. **Caco-2:** A (-5.569) is worse than B (-4.792), indicating lower intestinal absorption.
9. **Solubility:** A (-1.13) is worse than B (-2.694), indicating lower solubility.
10. **hERG:** A (0.038) is much better than B (0.307), indicating lower cardiotoxicity risk. This is a significant advantage for A.
11. **Cl_mic:** A (19.027) has lower clearance than B (59.09), suggesting better metabolic stability. This favors A.
12. **t1/2:** A (26.713) has a longer half-life than B (18.822), which is desirable.
13. **Pgp:** A (0.014) has much lower P-gp efflux than B (0.233), meaning better bioavailability and potentially better CNS exposure. This is a strong advantage for A.
14. **Affinity:** A (-7.2) has a better binding affinity than B (-5.7). This is a substantial advantage for A, exceeding the 1.5 kcal/mol threshold.
**Overall Assessment:**
While Ligand B has better TPSA, logP, QED, BBB, and DILI, Ligand A's superior binding affinity (-7.2 vs -5.7 kcal/mol) is a major advantage. Additionally, A has a better hERG profile, lower Cl_mic, longer half-life, and significantly lower P-gp efflux. The combination of these factors, particularly the strong binding affinity and favorable ADME properties (low Pgp, good metabolic stability), outweighs the slightly less optimal TPSA and logP. For a GPCR target, strong binding is paramount, and A delivers on that front.
Output:
1
2025-04-17 18:56:07,976 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (407.533 Da) is within the ideal range, while Ligand B (343.471 Da) is slightly below, but still acceptable.
2. **TPSA:** Ligand A (53.51) is excellent, well below the 140 threshold. Ligand B (81.99) is still reasonable, but higher.
3. **logP:** Both ligands (A: 2.865, B: 3.551) are within the optimal 1-3 range. Ligand B is slightly higher, which could potentially lead to off-target effects, but is not a major concern.
4. **HBD:** Ligand A (0) is preferred, minimizing potential for unwanted interactions. Ligand B (2) is acceptable.
5. **HBA:** Ligand A (6) is good. Ligand B (3) is also good.
6. **QED:** Both ligands have similar QED values (A: 0.739, B: 0.681), indicating good drug-likeness.
7. **DILI:** Ligand A (67.429) has a slightly higher DILI risk than Ligand B (56.185), but both are within acceptable limits (<60 is good).
8. **BBB:** Ligand A (90.694) has significantly better BBB penetration potential than Ligand B (41.528). This is a key consideration for a GPCR target, even if not strictly CNS-focused, as it suggests better distribution.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. This is a significant concern for both.
10. **Solubility:** Both ligands have negative solubility values, indicating poor solubility. This is a significant concern for both.
11. **hERG:** Ligand A (0.917) has a slightly higher hERG risk than Ligand B (0.686), but both are relatively low.
12. **Cl_mic:** Both ligands have similar microsomal clearance values (A: 58.4, B: 58.992), suggesting comparable metabolic stability.
13. **t1/2:** Ligand A (-31.136) has a much longer in vitro half-life than Ligand B (36.139). This is a significant advantage.
14. **Pgp:** Ligand A (0.553) has lower P-gp efflux liability than Ligand B (0.226), suggesting better oral bioavailability and potentially better CNS exposure.
15. **Affinity:** Both ligands have excellent binding affinity (A: -5.9 kcal/mol, B: -6.0 kcal/mol). Ligand B is slightly better, but the difference is small.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are crucial. Ligand A excels in TPSA and Pgp, and has a good logP. While Ligand B has a slightly better affinity, the superior BBB penetration and Pgp profile of Ligand A, along with its longer half-life, outweigh this small difference. The poor Caco-2 and solubility are concerns for both, but can be addressed through formulation strategies.
**Conclusion:**
Considering the balance of properties and the priorities for a GPCR target, Ligand A is the more promising drug candidate.
Output:
1
2025-04-17 18:56:07,976 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (344.455 Da and 346.435 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (50.8) is significantly better than Ligand B (80.41). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is pushing the upper limit for good oral absorption.
**3. logP:** Both ligands have acceptable logP values (2.466 and 1.453, respectively), falling within the 1-3 range. Ligand B is slightly lower, which *could* indicate slightly better solubility, but isn't a major concern for either.
**4. H-Bond Donors:** Ligand A has 1 HBD, and Ligand B has 0. Both are within the desirable limit of <=5.
**5. H-Bond Acceptors:** Ligand A has 4 HBA, while Ligand B has 8. Ligand B is getting closer to the upper limit of 10, potentially impacting permeability.
**6. QED:** Both ligands have similar QED values (0.772 and 0.745), indicating good drug-like properties.
**7. DILI:** Ligand A (36.254) has a significantly lower DILI risk than Ligand B (63.397). This is a crucial advantage, as minimizing liver toxicity is paramount.
**8. BBB:** Ligand B (92.827) has a much higher BBB penetration percentile than Ligand A (68.748). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be useful for understanding off-target effects and distribution. However, for a cardiovascular target, this isn't a primary driver.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-5.014 and -4.824). This is unusual and suggests poor permeability *in vitro*. However, these values are close and may not be reliable.
**10. Aqueous Solubility:** Ligand A (-1.58) is slightly better than Ligand B (-2.394).
**11. hERG Inhibition:** Ligand A (0.434) has a lower hERG inhibition liability than Ligand B (0.742), which is a positive.
**12. Microsomal Clearance:** Ligand B (66.517) has a higher microsomal clearance than Ligand A (15.156), indicating faster metabolism and potentially lower *in vivo* exposure.
**13. In vitro Half-Life:** Ligand A (36.501 hours) has a significantly longer in vitro half-life than Ligand B (-5.375 hours). This is a major advantage, suggesting less frequent dosing may be possible.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.145 and 0.143).
**15. Binding Affinity:** Both ligands have very similar and strong binding affinities (-6.0 and -5.3 kcal/mol). The difference of 0.7 kcal/mol is not substantial enough to outweigh other factors.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity) and the general drug-likeness criteria, **Ligand A is the more promising candidate**. While Ligand B has better BBB penetration, the significantly lower DILI risk, better TPSA, longer half-life, and lower microsomal clearance of Ligand A outweigh this benefit. The similar binding affinities make the ADME properties the deciding factors.
Output:
1
2025-04-17 18:56:07,976 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [352.475, 81.08, 1.314, 2, 4, 0.731, 19.465, 50.679, -4.635, -1.746, 0.307, 8.537, 9.079, 0.195, -6.3]
**Ligand B:** [362.495, 66.57, 3.68, 1, 5, 0.851, 22.838, 52.23, -4.806, -2.594, 0.362, 40.522, 46.344, 0.341, -7.6]
Here's a breakdown, prioritizing GPCR-relevant parameters:
1. **Molecular Weight:** Both are within the ideal 200-500 Da range. A (352.475) is slightly better.
2. **TPSA:** Both are good, under 140. B (66.57) is better than A (81.08) - lower TPSA generally favors better permeability.
3. **logP:** A (1.314) is optimal. B (3.68) is pushing the upper limit, potentially causing solubility issues and off-target effects.
4. **H-Bond Donors/Acceptors:** A (2/4) and B (1/5) are both acceptable.
5. **QED:** Both are above 0.5, indicating good drug-likeness, with B (0.851) being slightly better.
6. **DILI:** A (19.465) has a significantly lower DILI risk than B (22.838). This is a major advantage for A.
7. **BBB:** Both are around 50-52%, not ideal for a CNS-targeting GPCR, but acceptable for a peripherally acting one like ADRB2.
8. **Caco-2:** Both are negative, indicating poor permeability.
9. **Solubility:** Both are negative, indicating poor solubility.
10. **hERG:** Both are very low risk.
11. **Cl_mic:** A (8.537) has a much lower microsomal clearance, suggesting better metabolic stability than B (40.522).
12. **t1/2:** B (46.344) has a longer half-life than A (9.079). This is a positive for B.
13. **Pgp:** Both are low, indicating minimal P-gp efflux.
14. **Binding Affinity:** B (-7.6) has a significantly stronger binding affinity than A (-6.3), a difference of 1.3 kcal/mol. This is a substantial advantage.
**Overall Assessment:**
The key trade-off is between binding affinity (B is much better) and ADME properties (A is better). B's stronger binding is a significant plus, and could potentially overcome some of its ADME liabilities. However, B's higher logP, higher DILI risk, and significantly higher clearance are concerning. A has a more balanced profile, with lower risk of toxicity and better metabolic stability. While A's affinity is lower, the difference might be manageable with further optimization.
Given the importance of balancing ADME properties for a viable drug candidate, and the relatively modest difference in affinity that could potentially be addressed through further optimization, I favor Ligand A.
Output:
1
2025-04-17 18:56:07,976 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (365.449 and 355.463 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (54.88) is significantly better than Ligand B (72.36). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (4.572) is slightly higher than Ligand B (3.82). Both are above the optimal 1-3 range, but Ligand A is pushing the upper limit. This could potentially lead to solubility issues, but the difference isn't drastic.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 4 HBA, while Ligand B has 5. Both are acceptable, but lower is generally preferred.
6. **QED:** Ligand A (0.816) has a better QED score than Ligand B (0.682), indicating a more drug-like profile.
7. **DILI:** Ligand B (65.762) has a slightly lower DILI risk than Ligand A (74.796), which is a positive.
8. **BBB:** Ligand A (86.661) shows better BBB penetration than Ligand B (76.696). While not a primary concern for a cardiovascular target, it's a slight advantage.
9. **Caco-2:** Ligand A (-4.351) has a worse Caco-2 permeability than Ligand B (-5.252). Lower values indicate lower permeability.
10. **Solubility:** Ligand B (-3.712) has better aqueous solubility than Ligand A (-5.959). This is a significant advantage, especially given Ligand A's higher logP.
11. **hERG:** Ligand A (0.504) has a lower hERG risk than Ligand B (0.769). This is a crucial advantage for cardiovascular drugs.
12. **Cl_mic:** Ligand B (86.074) has a higher microsomal clearance than Ligand A (61.705), meaning it's metabolized faster. Ligand A is preferable here.
13. **t1/2:** Ligand A (49.335) has a significantly longer in vitro half-life than Ligand B (-24.899). This is a major advantage, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.621) has lower P-gp efflux liability than Ligand B (0.495). Lower efflux is generally better for bioavailability.
15. **Binding Affinity:** Ligand A (-6.7 kcal/mol) has a slightly better binding affinity than Ligand B (-5.5 kcal/mol). This 1.2 kcal/mol difference is substantial and can outweigh some ADME drawbacks.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has a slightly higher logP but compensates with better TPSA, Pgp, and significantly better affinity. The longer half-life and lower hERG risk are also very important for a cardiovascular drug.
**Overall Assessment:**
While Ligand B has better solubility and slightly lower DILI risk, Ligand A is superior overall. The stronger binding affinity, better metabolic stability (lower Cl_mic, longer t1/2), lower hERG risk, and more favorable Pgp profile outweigh the slightly higher logP and lower solubility. The better QED score also supports Ligand A.
Output:
1
2025-04-17 18:56:07,977 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [338.411, 66.71, 1.855, 1, 4, 0.925, 54.634, 73.013, -5.071, -2.959, 0.428, 21.429, -4.049, 0.073, -7.4]
**Ligand B:** [351.451, 99.49, -0.714, 3, 6, 0.602, 8.957, 13.455, -5.582, -0.915, 0.05, -8.51, 9.924, 0.001, -7.3]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (338.411) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (66.71) is significantly better than Ligand B (99.49). For a GPCR, keeping TPSA low is good, and A is well under the 140 threshold.
3. **logP:** Ligand A (1.855) is within the optimal range (1-3). Ligand B (-0.714) is below 1, which could hinder permeation.
4. **HBD:** Ligand A (1) is better than Ligand B (3). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (4) is better than Ligand B (6). Lower HBA is generally favorable for permeability.
6. **QED:** Ligand A (0.925) is much better than Ligand B (0.602), indicating a more drug-like profile.
7. **DILI:** Ligand A (54.634) is better than Ligand B (8.957). Both are acceptable, but B has a much lower risk.
8. **BBB:** Ligand A (73.013) is significantly better than Ligand B (13.455). This is *very* important for a GPCR, even if not CNS-focused, as it indicates better distribution characteristics.
9. **Caco-2:** Both are negative, suggesting poor permeability. However, the scale is not provided, so it's hard to interpret the absolute values.
10. **Solubility:** Both are negative, suggesting poor solubility. Again, the scale is not provided.
11. **hERG:** Both are very low (0.428 and 0.05), indicating low cardiotoxicity risk.
12. **Cl_mic:** Ligand A (21.429) is better than Ligand B (-8.51). Lower clearance is preferred for metabolic stability.
13. **t1/2:** Ligand A (-4.049) is better than Ligand B (9.924). Longer half-life is generally desirable.
14. **Pgp:** Ligand A (0.073) is better than Ligand B (0.001). Lower P-gp efflux is preferred.
15. **Affinity:** Both have very similar binding affinities (-7.4 and -7.3 kcal/mol). The difference is negligible.
**Overall Assessment:**
Ligand A is clearly superior. It has better TPSA, logP, HBD, HBA, QED, BBB, Cl_mic, and t1/2 values. While both have acceptable hERG and similar binding affinities, the superior ADME properties of Ligand A, particularly its better BBB penetration and drug-likeness, make it the more promising candidate for development as a drug targeting the ADRB2 receptor. The slightly better metabolic stability and half-life also contribute to its preference.
Output:
1
2025-04-17 18:56:07,977 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (348.447) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (78.68) is better than Ligand B (40.62). Lower TPSA generally improves oral absorption, and is particularly important for GPCRs.
3. **logP:** Ligand B (3.309) is higher than Ligand A (0.911). While 0.911 isn't *bad*, it's on the lower side and could impact membrane permeability. 3.309 is within the optimal range, suggesting better partitioning.
4. **HBD:** Ligand A (1) is better than Ligand B (0). Having some HBD can improve solubility.
5. **HBA:** Ligand A (5) is higher than Ligand B (2). Both are acceptable, but lower HBA is generally preferred for permeability.
6. **QED:** Both are reasonably good (A: 0.792, B: 0.733), indicating drug-like properties.
7. **DILI:** Ligand A (11.361) is significantly better than Ligand B (29.818). Lower DILI risk is crucial.
8. **BBB:** Ligand B (95.618) is much better than Ligand A (61.846). While ADRB2 isn't exclusively a CNS target, some degree of BBB penetration can be beneficial, and a high value is generally desirable.
9. **Caco-2:** Ligand A (-5.22) and Ligand B (-4.477) are both negative, which is unusual and suggests poor permeability in this assay.
10. **Solubility:** Ligand A (-0.786) is better than Ligand B (-3.376). Higher solubility is generally preferred.
11. **hERG:** Both ligands show low hERG inhibition risk (A: 0.226, B: 0.807).
12. **Cl_mic:** Ligand A (-2.977) is much better than Ligand B (46.919). Lower clearance indicates better metabolic stability.
13. **t1/2:** Ligand A (9.133) is better than Ligand B (-8.862). A longer half-life is generally desirable.
14. **Pgp:** Ligand A (0.014) is significantly better than Ligand B (0.423). Lower P-gp efflux is crucial for bioavailability.
15. **Binding Affinity:** Both have excellent binding affinity (A: -5.0, B: -6.0). Ligand B is 1 kcal/mol stronger, which is a significant advantage.
**Overall Assessment:**
Ligand B has a superior binding affinity and BBB penetration. However, it suffers from significantly higher DILI risk, higher microsomal clearance, and higher P-gp efflux. Ligand A has a better safety profile (DILI), better metabolic stability (Cl_mic), better P-gp profile, and better solubility. The difference in binding affinity (1 kcal/mol) is substantial, but the ADME/Tox profile of Ligand A is far more favorable. Given the GPCR-specific priorities (logP, Pgp, TPSA, affinity) and the overall balance of properties, I believe Ligand A represents a more viable starting point for drug development.
Output:
1
2025-04-17 18:56:07,977 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (371.5 & 351.4 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (78.95) is significantly better than Ligand B (111.53). ADRB2 is a cardiovascular target, not CNS, but lower TPSA generally improves absorption.
3. **logP:** Ligand A (0.483) is slightly below the optimal 1-3 range, while Ligand B (-0.961) is even lower. Both are potentially problematic for permeability, but Ligand A is better.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower is generally better for permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (6). Lower is generally better for permeability.
6. **QED:** Both ligands are similar (0.704 vs 0.686), indicating good drug-likeness.
7. **DILI:** Both ligands have low DILI risk (36.293 & 35.75 percentile), which is excellent.
8. **BBB:** Not a primary concern for a cardiovascular target. Ligand A (43.117) is better than Ligand B (23.342), but this isn't a deciding factor.
9. **Caco-2:** Both are very poor (-5.294 & -5.171). This is a significant concern for oral bioavailability for both.
10. **Solubility:** Both ligands have poor solubility (-2.158 & -1.009). This is a major drawback for both.
11. **hERG:** Both ligands have very low hERG risk (0.099 & 0.037), which is excellent.
12. **Cl_mic:** Ligand B (-9.268) has a *negative* clearance, which is unusual and suggests very high metabolic stability. Ligand A (28.723) is moderate. This is a strong advantage for Ligand B.
13. **t1/2:** Ligand B (-31.006) has a negative half-life, which is impossible and indicates a data error or an extremely rapidly cleared compound. Ligand A (15.56) is reasonable.
14. **Pgp:** Both ligands have very low Pgp efflux (0.02 & 0.007), which is excellent.
15. **Binding Affinity:** Ligand A (-6.3 kcal/mol) is significantly better than Ligand B (-0.5 kcal/mol). This is a massive difference in potency.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, and affinity are important. Ligand A performs better on TPSA and *much* better on affinity. While both have suboptimal logP, Ligand A is closer to the ideal range. The negative half-life and clearance for Ligand B are highly suspect and raise serious concerns about the data quality.
**Conclusion:**
Despite the poor solubility and Caco-2 permeability of both, Ligand A is the far superior candidate due to its significantly higher binding affinity and more reasonable ADME properties. The negative half-life and clearance of Ligand B are red flags.
Output:
1
2025-04-17 18:56:07,977 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.423 and 366.571 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (121.36) is slightly above the preferred <140 for good absorption, but acceptable. Ligand B (49.41) is excellent, well below 90, suggesting good permeability. **Advantage: B**
3. **logP:** Ligand A (0.986) is a bit low, potentially hindering permeation. Ligand B (3.621) is within the optimal 1-3 range. **Advantage: B**
4. **HBD:** Ligand A (3) is acceptable. Ligand B (1) is even better, minimizing potential issues with hydrogen bonding and metabolic lability. **Advantage: B**
5. **HBA:** Ligand A (6) is acceptable. Ligand B (3) is better. **Advantage: B**
6. **QED:** Ligand A (0.706) is good, indicating a drug-like profile. Ligand B (0.501) is acceptable, but lower. **Advantage: A**
7. **DILI:** Ligand A (57.193) has a moderate DILI risk. Ligand B (16.053) has a very low DILI risk. **Advantage: B**
8. **BBB:** Ligand A (20.822) has very low BBB penetration. Ligand B (67.235) has good BBB penetration. While ADRB2 isn't strictly a CNS target, some CNS exposure can be relevant for off-target effects and understanding the full pharmacological profile. **Advantage: B**
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.589 and -5.262), which is unusual and suggests poor permeability. This is concerning for both, but the values are very similar.
10. **Solubility:** Ligand A (-1.578) is better than Ligand B (-3.463). **Advantage: A**
11. **hERG:** Ligand A (0.037) has a very low hERG risk. Ligand B (0.572) has a slightly elevated, but still acceptable, hERG risk. **Advantage: A**
12. **Cl_mic:** Ligand A (4.633) has lower microsomal clearance, indicating better metabolic stability. Ligand B (83.04) has high clearance. **Advantage: A**
13. **t1/2:** Ligand A (-4.942) has a negative in vitro half-life, which is problematic. Ligand B (2.807) has a short, but positive, half-life. **Advantage: B**
14. **Pgp:** Ligand A (0.014) has very low P-gp efflux, which is favorable. Ligand B (0.218) has moderate P-gp efflux. **Advantage: A**
15. **Binding Affinity:** Ligand B (-6.2 kcal/mol) has a significantly stronger binding affinity than Ligand A (-4.6 kcal/mol) - a difference of 1.6 kcal/mol. This is a substantial advantage. **Advantage: B**
**Overall Assessment:**
Ligand B clearly wins on several crucial parameters for a GPCR target, particularly binding affinity, logP, TPSA, DILI risk, and BBB penetration. While Ligand A has advantages in QED, solubility, hERG, Cl_mic, and Pgp, the significantly stronger binding affinity of Ligand B, coupled with its better ADME properties (logP, TPSA, DILI, BBB), outweigh these benefits. The negative Caco-2 values are a concern for both, but the superior binding affinity of Ligand B makes it more likely that optimization can overcome this issue.
Output:
0
2025-04-17 18:56:07,977 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (342.395 and 346.446 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (74.45) is higher than Ligand B (49.41). For a cardiovascular GPCR, TPSA isn't a *major* concern unless it's excessively high, but lower is generally better for permeability. Ligand B has a clear advantage.
3. **logP:** Both ligands have good logP values (3.097 and 3.209), falling within the optimal 1-3 range. Very similar.
4. **HBD:** Ligand A has 0 HBD, while Ligand B has 1. Both are acceptable, but generally, a single HBD can improve solubility without drastically impacting permeability.
5. **HBA:** Ligand A has 6 HBA, while Ligand B has 2. Ligand B is significantly better here. Lower HBA generally improves permeability.
6. **QED:** Ligand B (0.89) has a higher QED score than Ligand A (0.652), indicating a more drug-like profile. This is a positive for Ligand B.
7. **DILI:** Ligand B (36.603) has a much lower DILI risk than Ligand A (56.689). This is a significant advantage for Ligand B, as minimizing liver toxicity is crucial.
8. **BBB:** Both ligands have high BBB penetration (83.288 and 89.259). While ADRB2 isn't primarily a CNS target, some off-target CNS effects are possible with GPCR ligands, so higher BBB isn't detrimental. Ligand B is slightly better.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.609 and -4.426). These values are unusual and suggest poor permeability. However, the scale is not specified, so it is difficult to interpret.
10. **Solubility:** Ligand B (-3.723) has slightly better solubility than Ligand A (-4.687).
11. **hERG:** Ligand A (0.27) has a lower hERG inhibition liability than Ligand B (0.74). This is a significant advantage for Ligand A, as hERG inhibition can lead to cardiotoxicity.
12. **Cl_mic:** Ligand B (56.344) has lower microsomal clearance than Ligand A (66.702), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-5.018) has a more negative in vitro half-life than Ligand A (-18.814). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.444) has lower P-gp efflux liability than Ligand B (0.353). Lower P-gp efflux is preferable.
15. **Binding Affinity:** Ligand A (-7.0) has slightly better binding affinity than Ligand B (-5.5). This is a 1.5 kcal/mol difference, which is significant and could outweigh some ADME drawbacks.
**Overall Assessment:**
While Ligand A has a slight edge in binding affinity and hERG inhibition, Ligand B demonstrates a superior overall profile regarding ADME properties. Specifically, the significantly lower DILI risk, better QED, improved metabolic stability (lower Cl_mic, better t1/2), and lower TPSA/HBA make it a more promising candidate. The binding affinity difference, while notable, isn't large enough to overcome these substantial ADME advantages, especially considering the cardiovascular context where minimizing toxicity is paramount.
Output:
0
2025-04-17 18:56:07,977 - INFO - Batch 73 complete. Total preferences: 1168
2025-04-17 18:56:07,977 - INFO - Processing batch 74/512...
2025-04-17 18:56:58,304 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (389.9) is within the ideal range (200-500), while Ligand B (349.4) is also good. No clear advantage here.
2. **TPSA:** Ligand A (78.95) is excellent, well below the 140 threshold for oral absorption. Ligand B (116.84) is still acceptable, but less optimal. This favors Ligand A.
3. **logP:** Both ligands (A: 1.414, B: 1.103) are within the optimal 1-3 range. No significant difference.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3) as lower HBD generally improves permeability.
5. **HBA:** Ligand A (4) is preferable to Ligand B (5) for similar reasons as HBD.
6. **QED:** Ligand A (0.797) has a better QED score than Ligand B (0.617), indicating a more drug-like profile.
7. **DILI:** Ligand B (35.479) has a significantly lower DILI risk than Ligand A (58.627). This is a substantial advantage for Ligand B.
8. **BBB:** Ligand A (59.093) and Ligand B (36.487) are both low, indicating poor BBB penetration. Since ADRB2 is a cardiovascular target, BBB penetration is not a priority.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and indicates poor permeability. Ligand A (-4.887) is slightly better than Ligand B (-5.543).
10. **Solubility:** Ligand A (-2.808) has better solubility than Ligand B (-1.867).
11. **hERG:** Ligand A (0.529) has a slightly higher hERG risk than Ligand B (0.033). This favors Ligand B.
12. **Cl_mic:** Ligand B (-7.031) has a negative clearance, which is highly favorable, indicating very high metabolic stability. Ligand A (25.187) has a positive clearance, indicating faster metabolism. This is a strong advantage for Ligand B.
13. **t1/2:** Ligand B (-16.896) has a negative half-life, which is highly favorable. Ligand A (-5.507) is also favorable, but not as much.
14. **Pgp:** Ligand A (0.088) has lower P-gp efflux than Ligand B (0.029), which is preferable.
15. **Affinity:** Ligand A (-7.2 kcal/mol) has a slightly better binding affinity than Ligand B (-6.4 kcal/mol). This is a 1.8 kcal/mol difference, which is significant.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity and better solubility, Ligand B demonstrates a significantly better safety profile (lower DILI, lower hERG) and superior predicted metabolic stability (negative Cl_mic and t1/2). For a cardiovascular target like ADRB2, metabolic stability and minimizing off-target effects (like hERG inhibition) are crucial. The difference in affinity, while present, is likely surmountable with further optimization, while improving the ADME properties of Ligand A to match Ligand B would be more challenging.
Output:
0
2025-04-17 18:56:58,305 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (349.39) is slightly lower, which is generally favorable for permeability.
**2. TPSA:** Ligand A (93.9) is better than Ligand B (42.43). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower TPSA generally indicates better membrane permeability.
**3. logP:** Ligand A (1.1) is within the optimal range, while Ligand B (4.55) is high. High logP can lead to poor solubility and off-target interactions. This is a significant drawback for Ligand B.
**4. H-Bond Donors:** Ligand A (1) is preferable to Ligand B (0). While both are acceptable, a single HBD can contribute to solubility without drastically impacting permeability.
**5. H-Bond Acceptors:** Ligand A (6) is better than Ligand B (5). Both are within acceptable limits.
**6. QED:** Ligand A (0.707) has a significantly better QED score than Ligand B (0.482), indicating a more drug-like profile.
**7. DILI Risk:** Ligand A (62.35) is better than Ligand B (85.15). Lower DILI risk is always preferred.
**8. BBB Penetration:** Both ligands have similar BBB penetration (Ligand A: 60.95, Ligand B: 59.91). Since this is a cardiovascular target, BBB penetration is not a primary concern.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual. This suggests poor permeability. However, the values are very close, so this isn't a major differentiating factor.
**10. Aqueous Solubility:** Ligand A (-2.227) is better than Ligand B (-5.933). Solubility is important for bioavailability, and Ligand A has a significantly better score.
**11. hERG Inhibition:** Ligand A (0.08) is much better than Ligand B (0.537). Lower hERG inhibition is crucial to avoid cardiotoxicity, especially for a cardiovascular target.
**12. Microsomal Clearance:** Ligand B (100.97) has a much higher clearance than Ligand A (21.86). Lower clearance is preferred for improved metabolic stability and potentially less frequent dosing.
**13. In Vitro Half-Life:** Ligand B (26.25) has a longer half-life than Ligand A (-21.54). This is a positive for Ligand B, but the negative value for Ligand A is concerning.
**14. P-gp Efflux:** Ligand A (0.024) is much better than Ligand B (0.508). Lower P-gp efflux is desirable for improved bioavailability.
**15. Binding Affinity:** Both ligands have similar binding affinities (Ligand A: -5.8 kcal/mol, Ligand B: -6.1 kcal/mol). Ligand B is slightly better, but the difference is not substantial enough to outweigh its other drawbacks.
**Overall Assessment:**
Ligand A is the stronger candidate. It has a better QED score, lower DILI risk, significantly lower hERG inhibition, better solubility, and lower P-gp efflux. While Ligand B has a slightly better binding affinity and half-life, its high logP, high DILI risk, and high hERG inhibition are significant liabilities, especially for a cardiovascular target. The difference in binding affinity is not large enough to overcome these issues.
Output:
1
2025-04-17 18:56:58,305 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (333.435 and 347.463 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (48.13) is significantly better than Ligand B (71.33). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (4.882) is higher than Ligand B (1.716). While both are within the acceptable range, Ligand A is approaching the upper limit and may have solubility issues. Ligand B is closer to optimal.
4. **HBD:** Ligand A (2) is better than Ligand B (0). A small number of HBDs is generally preferred for permeability.
5. **HBA:** Ligand A (1) is better than Ligand B (5). Lower HBA is better for permeability.
6. **QED:** Both ligands are similar (0.69 and 0.753), both above the 0.5 threshold, indicating good drug-likeness.
7. **DILI:** Ligand B (35.595) has a much lower DILI risk than Ligand A (72.354). This is a significant advantage for Ligand B.
8. **BBB:** Both ligands have high BBB penetration (89.763 and 86.739). This isn't a primary concern for a cardiovascular target like ADRB2.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests a potential issue with the data or the model. I'll proceed with caution.
10. **Solubility:** Ligand B (-2.333) is better than Ligand A (-5.697). This is important, given Ligand A's higher logP.
11. **hERG:** Ligand A (0.903) has a slightly better hERG profile than Ligand B (0.258), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand B (56.936) has a lower microsomal clearance than Ligand A (74.61), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-14.009) has a much longer in vitro half-life than Ligand A (64.775). This is a major advantage for Ligand B.
14. **Pgp:** Ligand A (0.784) has a slightly lower P-gp efflux liability than Ligand B (0.189). Lower P-gp is generally preferred.
15. **Binding Affinity:** Ligand B (-6.6 kcal/mol) has a slightly better binding affinity than Ligand A (-5.8 kcal/mol). This is a significant advantage, outweighing some of the ADME concerns.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B has a better logP and affinity, and comparable Pgp. Ligand A has a better TPSA, but the other factors are more important.
**Overall Assessment:**
Ligand B is the stronger candidate. It has a significantly better safety profile (lower DILI), improved metabolic stability (lower Cl_mic, longer t1/2), better solubility, and a slightly better binding affinity. While Ligand A has a slightly better TPSA and Pgp, the advantages of Ligand B in safety, metabolism, and potency are more critical for overall drug development success.
Output:
0
2025-04-17 18:56:58,305 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (a cardiovascular GPCR) drug candidates.
**Ligand A:** [349.435, 79.7, -0.601, 1, 6, 0.768, 35.479, 25.475, -4.921, -0.109, 0.082, -24.598, 7.995, 0.004, -5.3]
**Ligand B:** [362.495, 81.4, 2.972, 1, 5, 0.808, 25.553, 76.347, -4.608, -3.604, 0.426, 60.519, 23.38, 0.313, -6.2]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity) and general drug-like properties:
1. **MW:** Both are within the ideal 200-500 Da range. A (349.435) is slightly preferred.
2. **TPSA:** Both are reasonably good (A: 79.7, B: 81.4), below the 140 threshold for oral absorption. No strong preference.
3. **logP:** A (-0.601) is a bit low, potentially hindering permeability. B (2.972) is much better, falling within the optimal 1-3 range. This is a significant advantage for B.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** A has 6, B has 5. Both are acceptable (<=10).
6. **QED:** Both are good (A: 0.768, B: 0.808), indicating drug-like properties. B is slightly better.
7. **DILI:** Both have low DILI risk (A: 35.479, B: 25.553), with B being marginally better.
8. **BBB:** B (76.347) has a significantly higher BBB penetration percentile than A (25.475). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be beneficial for distribution and off-target effects.
9. **Caco-2:** Both are negative, indicating poor permeability. A (-4.921) is slightly worse than B (-4.608).
10. **Solubility:** A (-0.109) is better than B (-3.604). Solubility is important for bioavailability.
11. **hERG:** Both have very low hERG risk (A: 0.082, B: 0.426).
12. **Cl_mic:** A (-24.598) has a much lower (better) microsomal clearance than B (60.519), suggesting better metabolic stability. This is a major advantage for A.
13. **t1/2:** B (23.38) has a significantly longer half-life than A (7.995). This is a strong advantage for B.
14. **Pgp:** A (0.004) has much lower P-gp efflux liability than B (0.313), meaning better absorption and potentially higher bioavailability. This is a significant advantage for A.
15. **Affinity:** B (-6.2) has a slightly better binding affinity than A (-5.3). This is a 0.9 kcal/mol difference, which is substantial.
**Overall Assessment:**
Ligand B has a better logP, BBB penetration, longer half-life and slightly better affinity. However, Ligand A has a significantly better P-gp efflux profile, lower microsomal clearance, and better solubility. The better metabolic stability and reduced efflux of A are significant advantages for a GPCR target. The slightly better affinity of B is outweighed by these ADME considerations.
Therefore, I would choose Ligand A.
1
2025-04-17 18:56:58,305 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.475 and 364.877 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (78.87) is slightly higher than Ligand B (67.23). Both are below the 140 threshold for good oral absorption, but B is closer to the 90 threshold for CNS targets, which isn't a primary concern for ADRB2 (cardiovascular).
3. **logP:** Both ligands (1.483 and 1.791) are within the optimal 1-3 range. No significant difference.
4. **HBD:** Ligand A has 2 HBD, while Ligand B has 1. Both are acceptable (<=5).
5. **HBA:** Both ligands have 4 HBA, well within the acceptable limit of <=10.
6. **QED:** Both ligands have good QED scores (0.68 and 0.782), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (16.906) has a significantly lower DILI risk than Ligand B (32.687). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (80.07) has a higher BBB penetration score than Ligand A (61.38). While ADRB2 isn't a CNS target, some off-target CNS effects are possible with GPCR ligands, so this isn't entirely irrelevant.
9. **Caco-2:** Ligand A (-4.717) and Ligand B (-5.095) both have negative values, which is unusual and suggests poor permeability. Ligand B is slightly worse.
10. **Solubility:** Ligand A (-2.33) and Ligand B (-2.865) both have negative solubility values, indicating poor aqueous solubility. Ligand A is slightly better.
11. **hERG:** Ligand A (0.305) has a lower hERG inhibition liability than Ligand B (0.123), which is preferable.
12. **Cl_mic:** Both ligands have similar microsomal clearance values (26.6 and 26.695 mL/min/kg). No significant difference.
13. **t1/2:** Ligand B (-11.813) has a much longer in vitro half-life than Ligand A (-2.198). This is a substantial advantage for Ligand B.
14. **Pgp:** Ligand A (0.185) has a slightly lower P-gp efflux liability than Ligand B (0.086), which is preferable.
15. **Binding Affinity:** Ligand A (-6.9 kcal/mol) has a slightly better binding affinity than Ligand B (-5.6 kcal/mol). This is a significant advantage, as a 1.3 kcal/mol difference can outweigh some ADME drawbacks.
**GPCR-specific priorities:**
For ADRB2 (a cardiovascular GPCR), we prioritize logP, TPSA, affinity, and minimizing off-target effects (DILI, hERG). While BBB isn't crucial, it's not detrimental.
**Overall Assessment:**
Ligand A has a significantly better DILI profile and a slightly better hERG profile, both crucial for cardiovascular safety. It also has a better binding affinity. While Ligand B has a longer half-life and slightly better BBB penetration, the safety advantages of Ligand A, combined with its superior binding, are more important for a cardiovascular drug candidate. The solubility and Caco-2 values are poor for both, but can be addressed with formulation strategies.
Output:
1
2025-04-17 18:56:58,306 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (351.422 and 374.35 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (62.74) is slightly higher than Ligand B (58.64), but both are well below the 140 threshold for good oral absorption, and acceptable for a cardiovascular GPCR.
3. **logP:** Ligand A (1.45) is within the optimal range (1-3), while Ligand B (2.352) is towards the higher end. This is a slight advantage for Ligand A.
4. **HBD:** Ligand A (0) is preferable to Ligand B (1). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is slightly higher than Ligand B (3), but both are within the acceptable limit of 10.
6. **QED:** Both ligands have similar QED values (0.64 and 0.696), indicating good drug-like properties.
7. **DILI:** Ligand A (23.226) has a significantly lower DILI risk than Ligand B (31.02). This is a substantial advantage for Ligand A.
8. **BBB:** Ligand A (87.941) has a higher BBB penetration percentile than Ligand B (76.774). While ADRB2 isn't a CNS target, some peripheral exposure can be detrimental, and higher BBB suggests lower overall distribution to unwanted tissues.
9. **Caco-2:** Both ligands have similar, very negative Caco-2 values (-4.659 and -4.528). This suggests poor permeability, which is concerning.
10. **Solubility:** Ligand A (-0.469) is slightly better than Ligand B (-2.104), but both are poor. Solubility is a concern for both.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.479 and 0.488), which is excellent.
12. **Cl_mic:** Ligand A (22.46) has a lower microsomal clearance than Ligand B (23.818), suggesting better metabolic stability.
13. **t1/2:** Ligand A (6.336) has a longer in vitro half-life than Ligand B (-22.934). This is a significant advantage for Ligand A.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.069 and 0.035).
15. **Binding Affinity:** Ligand A (-6.7) has a slightly better binding affinity than Ligand B (-6.5). While the difference is small, it's still a positive.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A has a slightly better logP, similar TPSA and Pgp, and slightly better affinity. The significant advantages of Ligand A in DILI risk and in vitro half-life outweigh the minor differences in other parameters. The poor Caco-2 and solubility for both are concerning and would require formulation work, but are not decision-making factors at this stage.
**Conclusion:**
Ligand A demonstrates a more favorable overall profile, particularly regarding safety (DILI) and pharmacokinetic properties (Cl_mic, t1/2). While both have issues with permeability, the other advantages of Ligand A make it the more promising candidate.
Output:
1
2025-04-17 18:56:58,306 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [348.443, 71.78, 2.544, 1, 4, 0.696, 32.881, 61.497, -4.662, -2.556, 0.395, 46.104, 30.809, 0.379, -6.7]
**Ligand B:** [358.551, 33.2, 4.512, 0, 3, 0.726, 17.371, 74.641, -4.663, -5.228, 0.517, 62.544, 17.811, 0.605, -6.1]
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). A (348.443) is slightly preferred.
2. **TPSA:** A (71.78) is higher than B (33.2). B is significantly better, falling well below the 140 threshold for oral absorption and closer to the ideal for GPCRs.
3. **logP:** A (2.544) is optimal, while B (4.512) is pushing the upper limit and could lead to solubility issues. A is better.
4. **HBD:** A (1) is good, B (0) is also good. No strong preference.
5. **HBA:** A (4) is good, B (3) is also good. No strong preference.
6. **QED:** Both are above 0.5 (A: 0.696, B: 0.726), indicating good drug-likeness. B is slightly better.
7. **DILI:** A (32.881) is better than B (17.371) - lower risk is preferred.
8. **BBB:** B (74.641) is significantly better than A (61.497). This is a key consideration for a GPCR, even a cardiovascular one, as some CNS off-target effects are possible.
9. **Caco-2:** Both are negative and similar (-4.662 vs -4.663), suggesting similar permeability.
10. **Solubility:** A (-2.556) is better than B (-5.228). Solubility is important for bioavailability.
11. **hERG:** A (0.395) is better than B (0.517) - lower risk of cardiotoxicity.
12. **Cl_mic:** A (46.104) is better than B (62.544) - lower clearance is preferred for metabolic stability.
13. **t1/2:** A (30.809) is better than B (17.811) - longer half-life is desirable.
14. **Pgp:** A (0.379) is better than B (0.605) - lower efflux is preferred.
15. **Binding Affinity:** A (-6.7) is slightly better than B (-6.1), although both are excellent. This 0.6 kcal/mol difference is significant.
**Overall Assessment:**
Ligand A has a better overall profile. While Ligand B excels in BBB penetration and QED, Ligand A demonstrates advantages in crucial areas like logP, DILI risk, solubility, hERG inhibition, metabolic stability (Cl_mic & t1/2), and Pgp efflux. The slightly better binding affinity of A further strengthens its position. The TPSA difference is the biggest drawback for Ligand A, but the other benefits outweigh this. Given the GPCR target class, a balance of properties is key, and A strikes that balance more effectively.
Output:
1
2025-04-17 18:56:58,306 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands (364.324 and 351.451 Da) are within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (97.55) is better than Ligand B (109). Both are under 140, but A is closer to the preferred <90 for CNS targets (though ADRB2 isn't necessarily a CNS target, lower TPSA is generally favorable for permeability).
3. **logP:** Both ligands have good logP values (0.759 and 1.054), falling within the optimal 1-3 range. Ligand B is slightly better.
4. **HBD:** Ligand A (1) is better than Ligand B (3). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (7) is better than Ligand B (5). Lower HBA generally improves permeability.
6. **QED:** Ligand A (0.775) is better than Ligand B (0.616). Higher QED indicates better drug-likeness.
7. **DILI:** Ligand A (56.34) is worse than Ligand B (38.62). Lower DILI is preferred, so B is better.
8. **BBB:** Ligand A (76.037) is better than Ligand B (58.085). While not a CNS target, higher BBB is generally favorable.
9. **Caco-2:** Ligand A (-4.437) is better than Ligand B (-5.047). Higher Caco-2 permeability is better.
10. **Solubility:** Ligand A (-2.543) is better than Ligand B (-2.218). Higher solubility is preferred.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.172 and 0.175), indicating low cardiotoxicity risk. No clear advantage.
12. **Cl_mic:** Ligand B (18.967) is better than Ligand A (37.357). Lower clearance means greater metabolic stability.
13. **t1/2:** Ligand A (-23.536) is better than Ligand B (4.688). Longer half-life is preferred.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.117 and 0.055). No clear advantage.
15. **Affinity:** Ligand A (-7.7) is better than Ligand B (-7.0). This is a significant difference in binding affinity.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, and affinity. Ligand A excels in affinity and has better TPSA and Pgp. Ligand B has a slightly better logP and Cl_mic, but the difference in affinity is substantial. The DILI risk is slightly higher for A, but the overall profile is more favorable.
**Conclusion:**
The significantly stronger binding affinity of Ligand A (-7.7 kcal/mol vs -7.0 kcal/mol) outweighs the slightly higher DILI risk and the slightly better metabolic stability of Ligand B. The other ADME properties of Ligand A are also generally better or comparable.
Output:
1
2025-04-17 18:56:58,306 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (344.419 Da) is slightly lower, which is generally favorable for permeability.
**2. TPSA:** Ligand A (107.03) is significantly better than Ligand B (45.23). For a GPCR, lower TPSA is generally preferred for better membrane permeability and potentially better CNS penetration, even though this is a cardiovascular target.
**3. logP:** Ligand A (1.169) is within the optimal range (1-3), while Ligand B (4.495) is high. High logP can lead to poor solubility and off-target effects.
**4. H-Bond Donors:** Ligand A (3) is acceptable, while Ligand B (1) is also good.
**5. H-Bond Acceptors:** Ligand A (5) is acceptable, while Ligand B (4) is also good.
**6. QED:** Both ligands have good QED values (A: 0.755, B: 0.828), indicating good drug-like properties.
**7. DILI Risk:** Ligand A (48.197) has a lower DILI risk than Ligand B (64.172), which is a significant advantage.
**8. BBB Penetration:** Both have reasonable BBB penetration (A: 66.072, B: 70.027), but this is less critical for a cardiovascular target.
**9. Caco-2 Permeability:** Ligand A (-5.279) has a more negative value, which is worse than Ligand B (-4.647).
**10. Aqueous Solubility:** Ligand A (-2.445) has a more negative value, which is worse than Ligand B (-4.356).
**11. hERG Inhibition:** Ligand A (0.116) has a lower hERG risk than Ligand B (0.775), which is a crucial advantage for cardiovascular drugs.
**12. Microsomal Clearance:** Ligand A (11.946) has a lower clearance than Ligand B (9.303), indicating better metabolic stability.
**13. In vitro Half-Life:** Ligand A (-19.407) has a more negative half-life, which is worse than Ligand B (42.959).
**14. P-gp Efflux:** Ligand A (0.091) has a lower P-gp efflux than Ligand B (0.693), which is good.
**15. Binding Affinity:** Both ligands have good binding affinity (A: -7.0 kcal/mol, B: -4.2 kcal/mol). Ligand A is *significantly* more potent.
**Overall Assessment:**
Ligand A is the stronger candidate. While Ligand B has slightly better Caco-2 permeability and in vitro half-life, Ligand A excels in crucial areas: significantly higher binding affinity, lower DILI risk, lower hERG risk, better metabolic stability, lower P-gp efflux, and a more optimal logP. The lower TPSA of Ligand A is also beneficial. The substantial difference in binding affinity (-7.0 vs -4.2 kcal/mol) outweighs the minor drawbacks of Ligand A.
Output:
1
2025-04-17 18:56:58,307 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.463 and 348.451 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (62.63) is significantly better than Ligand B (84.22). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand A is well below the 140 threshold, while B is approaching it.
3. **logP:** Ligand B (1.097) is slightly better than Ligand A (0.354). Both are within the 1-3 range, but A is quite low, which could hinder permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (0). While both are low, having at least one HBD can improve solubility.
5. **HBA:** Both ligands have 6 HBA, which is acceptable.
6. **QED:** Ligand A (0.833) is slightly better than Ligand B (0.761), indicating a more drug-like profile.
7. **DILI:** Ligand B (53.432) has a significantly lower DILI risk than Ligand A (11.206). This is a substantial advantage for Ligand B.
8. **BBB:** Ligand B (83.831) has a better BBB penetration percentile than Ligand A (75.533). While ADRB2 isn't exclusively a CNS target, some CNS exposure can occur, and higher BBB is generally favorable.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.846 and -4.983). This is unusual and indicates very poor permeability.
10. **Solubility:** Ligand A (-0.102) is slightly better than Ligand B (-1.405), but both are very poor. This is a major concern for both compounds.
11. **hERG:** Ligand A (0.719) has a slightly better hERG profile than Ligand B (0.067), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand B (25.971) has significantly lower microsomal clearance than Ligand A (9.636), suggesting better metabolic stability.
13. **t1/2:** Ligand A (33.213) has a much longer in vitro half-life than Ligand B (12.684). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.018) has a much lower P-gp efflux liability than Ligand B (0.394), suggesting better oral bioavailability and potentially better CNS exposure.
15. **Binding Affinity:** Ligand B (-6.4 kcal/mol) has a slightly better binding affinity than Ligand A (-5.8 kcal/mol). This is a 0.6 kcal/mol difference, which is significant, but not overwhelming.
**Overall Assessment:**
Ligand B has a clear advantage in DILI risk, BBB penetration, and metabolic stability (Cl_mic). Ligand A has better QED, Pgp efflux, and a longer half-life. However, the poor Caco-2 permeability for both is a major red flag. The slightly better affinity of Ligand B is helpful, but the lower DILI risk and better metabolic stability are more critical for a viable drug candidate. The lower logP of Ligand A is also concerning.
Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity), Ligand B strikes a better balance. While neither is ideal, Ligand B's lower toxicity and better metabolic profile are more likely to translate into a successful drug development path.
Output:
0
2025-04-17 18:56:58,307 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B, followed by the final output:
**Step-by-step comparison:**
1. **MW:** Ligand A (435.344 Da) is within the ideal range, while Ligand B (354.441 Da) is towards the lower end, but still acceptable.
2. **TPSA:** Ligand A (93.53) is acceptable, but higher than optimal for good oral absorption. Ligand B (49.41) is excellent, well below the 140 threshold.
3. **logP:** Both ligands have good logP values (A: 1.716, B: 2.823), falling within the 1-3 range.
4. **HBD:** Both ligands have 1 HBD, which is ideal.
5. **HBA:** Ligand A has 6 HBA, acceptable. Ligand B has 2 HBA, which is also good.
6. **QED:** Both ligands have similar, good QED scores (A: 0.778, B: 0.797).
7. **DILI:** Ligand A (56.727) has a moderate DILI risk, while Ligand B (16.44) has a very low DILI risk. This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (70.299) has good BBB penetration, while Ligand B (96.937) is excellent. Given that ADRB2 is a cardiovascular target, BBB penetration is not a primary concern, but can be beneficial.
9. **Caco-2:** Both ligands have similar, negative Caco-2 values, indicating poor permeability.
10. **Solubility:** Both ligands have similar, negative solubility values, indicating poor solubility.
11. **hERG:** Both ligands have low hERG risk (A: 0.377, B: 0.797).
12. **Cl_mic:** Ligand A (43.742) has a higher microsomal clearance than Ligand B (20.893), indicating lower metabolic stability.
13. **t1/2:** Ligand A (-37.119) has a very negative in vitro half-life, indicating a very short half-life. Ligand B (-4.808) has a better, but still negative half-life.
14. **Pgp:** Both ligands have low Pgp efflux liability (A: 0.1, B: 0.2).
15. **Binding Affinity:** Ligand B (-8.4 kcal/mol) has a slightly better binding affinity than Ligand A (-8.1 kcal/mol). While the difference is small, it's still a factor.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are important. Ligand B excels in TPSA and has a slightly better affinity. The DILI risk is also a critical factor, and Ligand B has a significantly lower risk. While BBB isn't a primary concern for a cardiovascular target, Ligand B's higher value is a bonus. The biggest drawback for both is the poor Caco-2 and solubility. However, the better ADME profile of Ligand B (lower DILI, lower Cl_mic, better BBB) outweighs the slightly better MW of Ligand A.
**Conclusion:**
Ligand B is the more promising drug candidate due to its superior safety profile (lower DILI), better metabolic stability (lower Cl_mic), slightly better affinity, and excellent TPSA.
Output:
0
2025-04-17 18:56:58,307 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (346.515 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (58.2) is significantly better than Ligand B (72.12). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have acceptable logP values (A: 3.572, B: 4.01), falling within the 1-3 range. Ligand B is slightly higher, potentially increasing off-target interactions.
4. **HBD/HBA:** Ligand A (HBD=2, HBA=2) has fewer H-bonds than Ligand B (HBD=0, HBA=6). This is favorable for permeability, as fewer H-bonds can reduce interactions with aqueous environments and improve membrane crossing.
5. **QED:** Both ligands have similar and acceptable QED values (A: 0.66, B: 0.709), indicating good drug-likeness.
6. **DILI:** Ligand A (9.771) has a much lower DILI risk than Ligand B (37.03). This is a significant advantage, as liver toxicity is a major concern in drug development.
7. **BBB:** Both have reasonable BBB penetration, but Ligand B (86.855) is higher than Ligand A (71.035). However, as ADRB2 is not a CNS target, this is less critical.
8. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual. I will interpret these as very poor permeability.
9. **Solubility:** Both ligands have negative solubility values, which is also unusual. I will interpret these as very poor solubility.
10. **hERG:** Ligand A (0.317) has a lower hERG inhibition liability than Ligand B (0.668), indicating a lower risk of cardiotoxicity. This is crucial for a cardiovascular target.
11. **Cl_mic:** Both ligands have similar microsomal clearance values (A: 80.792, B: 80.166), suggesting similar metabolic stability.
12. **t1/2:** Ligand A (-7.319) has a much longer in vitro half-life than Ligand B (31.905). This is a significant advantage, potentially allowing for less frequent dosing.
13. **Pgp:** Ligand A (0.094) has lower P-gp efflux liability than Ligand B (0.652), which is favorable for bioavailability.
14. **Binding Affinity:** Ligand A (-6.7 kcal/mol) has a slightly weaker binding affinity than Ligand B (-5.7 kcal/mol). However, the difference is not substantial enough to outweigh the other advantages of Ligand A.
**GPCR-specific priorities:** For ADRB2, logP, TPSA, Pgp, and affinity are important. Ligand A performs better on TPSA, Pgp, and has a more favorable balance of logP. The affinity difference is not large.
**Overall Assessment:**
Ligand A is the stronger candidate. It demonstrates a significantly better safety profile (lower DILI, lower hERG), improved permeability characteristics (lower TPSA, fewer H-bonds, lower Pgp efflux), and a longer half-life. While Ligand B has slightly higher affinity and BBB penetration, these are less critical for a cardiovascular target, and are outweighed by the other advantages of Ligand A. The negative Caco-2 and solubility values are concerning for both, but Ligand A's other properties make it the more promising starting point for optimization.
Output:
1
2025-04-17 18:56:58,307 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (340.423 Da) is within the ideal range, while Ligand B (388.833 Da) is slightly higher but still acceptable.
2. **TPSA:** Ligand A (71.34) is excellent, well below the 140 threshold. Ligand B (128.53) is higher, but still potentially acceptable for a peripherally acting GPCR like ADRB2.
3. **logP:** Ligand A (2.737) is optimal. Ligand B (0.376) is quite low, which raises concerns about membrane permeability and potentially bioavailability.
4. **HBD:** Both ligands have acceptable HBD counts (Ligand A: 2, Ligand B: 3).
5. **HBA:** Both ligands have acceptable HBA counts (Ligand A: 3, Ligand B: 6).
6. **QED:** Both ligands have good QED scores (Ligand A: 0.782, Ligand B: 0.679), indicating drug-like properties.
7. **DILI:** Ligand A (35.401) has a much lower DILI risk than Ligand B (77.743), which is a significant advantage.
8. **BBB:** Ligand A (75.301) has a reasonable BBB penetration, while Ligand B (6.088) is very low. While ADRB2 isn't a primary CNS target, some degree of BBB penetration can be useful for off-target profiling.
9. **Caco-2:** Ligand A (-4.828) is better than Ligand B (-5.601), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-3.107) is better than Ligand B (-2.58), indicating better aqueous solubility.
11. **hERG:** Both ligands have low hERG inhibition risk (Ligand A: 0.505, Ligand B: 0.227).
12. **Cl_mic:** Ligand A (61.232) has a higher, less favorable, microsomal clearance than Ligand B (-8.577). This suggests Ligand B is more metabolically stable.
13. **t1/2:** Ligand A (64.892) has a longer in vitro half-life than Ligand B (-3.4).
14. **Pgp:** Ligand A (0.284) has lower P-gp efflux than Ligand B (0.079), which is favorable for bioavailability.
15. **Affinity:** Both ligands have very similar binding affinities (-6.4 and -6.5 kcal/mol). The difference is negligible.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, and Pgp are important. Ligand A excels in logP and Pgp, while Ligand B has a higher TPSA. However, the significantly lower DILI risk and better solubility of Ligand A are crucial advantages. The slightly higher Cl_mic of Ligand A is a concern, but the longer half-life partially compensates for this. The similar binding affinities make the ADME properties the deciding factor.
**Conclusion:**
Ligand A presents a more balanced profile with a significantly better safety profile (lower DILI) and better predicted absorption/permeability characteristics. While Ligand B has better metabolic stability, the other advantages of Ligand A outweigh this benefit.
Output:
1
2025-04-17 18:56:58,308 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [343.427, 75.44, 3.021, 1, 4, 0.838, 40.364, 69.213, -4.739, -3.256, 0.452, 74.471, 11.583, 0.199, -6.7]**
**Ligand B: [348.447, 94.56, 1.008, 3, 5, 0.684, 25.785, 43.04, -5.149, -1.233, 0.091, 2.229, 25.114, 0.01, -7.3]**
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). A is 343.427, B is 348.447. No significant difference.
2. **TPSA:** Ligand A (75.44) is well below the 140 threshold and acceptable for oral absorption. Ligand B (94.56) is still reasonable, but closer to the limit. A is better.
3. **logP:** Ligand A (3.021) is optimal. Ligand B (1.008) is a bit low, potentially hindering permeability. A is better.
4. **H-Bond Donors:** Ligand A (1) is good. Ligand B (3) is acceptable, but higher. A is better.
5. **H-Bond Acceptors:** Ligand A (4) is good. Ligand B (5) is acceptable, but higher. A is better.
6. **QED:** Ligand A (0.838) is excellent, indicating strong drug-like properties. Ligand B (0.684) is still acceptable, but less ideal. A is better.
7. **DILI:** Ligand A (40.364) is good (low risk). Ligand B (25.785) is *very* good, significantly lower risk. B is better.
8. **BBB:** Ligand A (69.213) is reasonable. Ligand B (43.04) is lower. While ADRB2 isn't strictly a CNS target, some CNS penetration can be beneficial for understanding off-target effects and potential side effects. A is better.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-4.739) is slightly worse than Ligand B (-5.149). B is better.
10. **Solubility:** Both are negative, indicating poor solubility. Ligand B (-1.233) is slightly better than Ligand A (-3.256). B is better.
11. **hERG:** Ligand A (0.452) is better than Ligand B (0.091) indicating lower cardiotoxicity risk. A is better.
12. **Cl_mic:** Ligand A (74.471) is higher, indicating faster clearance and lower metabolic stability. Ligand B (2.229) is *much* lower, indicating excellent metabolic stability. B is significantly better.
13. **t1/2:** Ligand A (11.583) is reasonable. Ligand B (25.114) is significantly longer, which is preferable. B is better.
14. **Pgp:** Ligand A (0.199) is better than Ligand B (0.01), indicating lower P-gp efflux. A is better.
15. **Binding Affinity:** Ligand B (-7.3) is 0.6 kcal/mol stronger than Ligand A (-6.7). This is a substantial difference in potency and a major advantage. B is significantly better.
**Overall Assessment:**
Ligand B has a significantly better binding affinity and metabolic stability (lower Cl_mic, longer t1/2). It also demonstrates better DILI and solubility profiles. While Ligand A has better TPSA, logP, hERG, and Pgp properties, the substantial advantage in binding affinity and metabolic stability of Ligand B outweighs these minor drawbacks, especially for a GPCR target where potency is crucial. The slightly lower Caco-2 and solubility of B can be addressed through formulation strategies.
Output:
0
2025-04-17 18:56:58,308 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (346.391 and 352.391 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Both ligands (114.94 and 117.67) are below the 140 A^2 threshold for good oral absorption. They are also reasonably low, which is good for GPCR ligands.
**3. logP:** Ligand A (0.428) is a bit low, potentially hindering permeation. Ligand B (-0.731) is even lower, raising more concerns about permeability. This is a critical factor for GPCRs.
**4. H-Bond Donors:** Both have 2 HBD, which is acceptable.
**5. H-Bond Acceptors:** Both have 7 HBA, also acceptable.
**6. QED:** Both ligands have QED values above 0.6, indicating good drug-likeness.
**7. DILI:** Ligand A (54.556) has a higher DILI risk than Ligand B (44.591), but both are below the concerning 60 percentile.
**8. BBB:** Ligand A (72.16) has significantly better BBB penetration potential than Ligand B (25.204). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be beneficial and isn't necessarily detrimental in cardiovascular applications.
**9. Caco-2 Permeability:** Ligand A (-5.371) and Ligand B (-5.258) both have negative Caco-2 values, which is unusual and suggests poor permeability.
**10. Aqueous Solubility:** Ligand A (-2.165) and Ligand B (-1.026) both have negative solubility values, which is also unusual and suggests poor solubility.
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.017 and 0.034). This is excellent.
**12. Microsomal Clearance:** Ligand A (11.718) has a higher microsomal clearance than Ligand B (-7.095). This suggests Ligand B is more metabolically stable.
**13. In vitro Half-Life:** Ligand B (-5.018) has a significantly longer in vitro half-life than Ligand A (16.949). This is a major advantage.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.011 and 0.008).
**15. Binding Affinity:** Ligand B (-7.3 kcal/mol) has a stronger binding affinity than Ligand A (-6.0 kcal/mol). This is a substantial difference (1.3 kcal/mol), and a key driver in this decision.
**Overall Assessment:**
While both ligands have some concerning ADME properties (low logP, negative Caco-2 and solubility values), Ligand B has a significantly stronger binding affinity and better metabolic stability (lower Cl_mic, longer t1/2). The higher binding affinity is a substantial advantage for a GPCR target, and can potentially offset some of the ADME liabilities. Ligand A's better BBB penetration is a minor positive, but not enough to overcome the affinity difference.
Output:
0
2025-04-17 18:56:58,308 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (333.39 Da) is better than Ligand B (373.55 Da). Both are within the ideal range, but A is closer to the lower bound, potentially aiding permeability.
2. **TPSA:** Ligand A (50.52) is significantly better than Ligand B (62.73). Both are acceptable, but A is closer to the preferred <90 for GPCRs.
3. **logP:** Both ligands (A: 4.091, B: 4.854) are slightly high, but within a tolerable range. B is a bit more concerning as it's closer to 5, potentially causing solubility issues.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (7). Fewer HBAs generally improve permeability.
6. **QED:** Both ligands are similar (A: 0.661, B: 0.619) and above the 0.5 threshold, indicating good drug-likeness.
7. **DILI:** Ligand A (67.74%) is better than Ligand B (74.18%). Both are moderately risky, but A has a lower percentile.
8. **BBB:** Ligand B (76.54%) is better than Ligand A (52.62%). While ADRB2 isn't strictly a CNS target, some CNS penetration can be beneficial for off-target effects assessment and potential alternative pharmacology.
9. **Caco-2:** Ligand A (-4.542) is better than Ligand B (-5.205). Higher (less negative) values indicate better absorption.
10. **Solubility:** Ligand A (-4.507) is better than Ligand B (-4.99). Higher values indicate better solubility.
11. **hERG:** Both ligands are low risk (A: 0.591, B: 0.662).
12. **Cl_mic:** Ligand A (81.43) is better than Ligand B (84.25). Lower clearance is preferred for metabolic stability.
13. **t1/2:** Ligand A (52.80) is better than Ligand B (51.35). Slightly longer half-life is desirable.
14. **Pgp:** Both ligands are similar (A: 0.62, B: 0.457), suggesting moderate efflux.
15. **Binding Affinity:** Ligand B (-6.2 kcal/mol) is significantly better than Ligand A (-4.2 kcal/mol). This is a substantial difference (2 kcal/mol), and affinity is a primary driver for GPCR drug candidates.
**Overall Assessment:**
Ligand B has a significantly better binding affinity, which is paramount for a GPCR target. While it has some drawbacks (higher logP, TPSA, DILI, and Pgp efflux), the 2 kcal/mol advantage in binding is substantial enough to outweigh these concerns. Ligand A has a better ADME profile overall, but the weaker binding makes it less likely to be effective. Considering the GPCR-specific priorities (affinity, logP, TPSA, Pgp), Ligand B is the more promising candidate.
Output:
0
2025-04-17 18:56:58,308 - INFO - Batch 74 complete. Total preferences: 1184
2025-04-17 18:56:58,308 - INFO - Processing batch 75/512...
2025-04-17 18:57:46,848 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (344.5) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (42.43) is significantly better than Ligand A (58.2). ADRB2 is not a CNS target, but lower TPSA generally improves absorption.
3. **logP:** Both ligands have good logP values (3.489 and 4.007), falling within the optimal 1-3 range. Ligand B is slightly higher, which could potentially lead to off-target effects, but is still acceptable.
4. **HBD:** Ligand A (2) is preferable to Ligand B (0) as a small number of HBDs can aid solubility.
5. **HBA:** Ligand B (4) is slightly better than Ligand A (2).
6. **QED:** Both ligands have similar QED values (0.75 and 0.695), indicating good drug-likeness.
7. **DILI:** Ligand B (18.73) is significantly better than Ligand A (26.87), indicating a lower risk of drug-induced liver injury. This is a crucial factor.
8. **BBB:** Not a primary concern for ADRB2 (cardiovascular target), but Ligand B (93.56) has a much higher BBB penetration than Ligand A (64.25).
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.785 and -4.276), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Both ligands have negative solubility values (-4.204 and -4.544), which is also concerning.
11. **hERG:** Ligand A (0.126) has a lower hERG inhibition liability than Ligand B (0.703), which is favorable.
12. **Cl_mic:** Ligand A (49.39) has a significantly lower microsomal clearance than Ligand B (110.83), indicating better metabolic stability.
13. **t1/2:** Ligand A (7.668) has a better in vitro half-life than Ligand B (-10.897). A negative half-life is highly problematic.
14. **Pgp:** Ligand A (0.153) has a lower P-gp efflux liability than Ligand B (0.353), which is preferable.
15. **Binding Affinity:** Ligand B (-7.3) has a slightly better binding affinity than Ligand A (-7.2), but the difference is small.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand B performs better on logP, TPSA and Pgp. However, the negative Caco-2 and solubility values are concerning for both. The significant advantage of Ligand B in DILI risk and the slightly better binding affinity, combined with the better metabolic stability of Ligand A, make this a difficult decision. The negative half-life for Ligand B is a dealbreaker.
**Conclusion:**
Despite the slightly better affinity of Ligand B, the significantly better DILI profile, metabolic stability, half-life and Pgp efflux of Ligand A makes it the more promising candidate. The negative Caco-2 and solubility values are a concern for both, but can be addressed with formulation strategies.
Output:
1
2025-04-17 18:57:46,849 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (348.334 and 343.383 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand B (88.58) is significantly better than Ligand A (124.18). For a GPCR, lower TPSA is generally preferred for better permeability.
**3. logP:** Ligand B (2.28) is optimal, while Ligand A (0.548) is a bit low, potentially hindering membrane permeability.
**4. H-Bond Donors:** Ligand B (1) is better than Ligand A (4). Fewer HBDs generally improve permeability.
**5. H-Bond Acceptors:** Both ligands have 5 HBA, which is acceptable.
**6. QED:** Ligand B (0.861) has a higher QED score than Ligand A (0.607), indicating a more drug-like profile.
**7. DILI:** Ligand B (61.807) has a slightly higher DILI risk than Ligand A (73.245), but both are acceptable.
**8. BBB:** Ligand B (45.909) has a better BBB penetration score than Ligand A (30.748). While ADRB2 isn't exclusively a CNS target, some CNS exposure may be acceptable/desirable, and higher BBB is generally a positive.
**9. Caco-2 Permeability:** Ligand A (-5.474) has better Caco-2 permeability than Ligand B (-4.899).
**10. Aqueous Solubility:** Ligand A (-2.937) has better solubility than Ligand B (-2.67).
**11. hERG Inhibition:** Ligand B (0.089) has a much lower hERG risk than Ligand A (0.305). This is a critical advantage.
**12. Microsomal Clearance:** Ligand A (-7.747) has significantly lower (better) microsomal clearance than Ligand B (54.056), indicating greater metabolic stability.
**13. In vitro Half-Life:** Ligand A (20.081) has a longer half-life than Ligand B (-12.201).
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.027 and 0.056 respectively).
**15. Binding Affinity:** Ligand A (-7.9) has a slightly better binding affinity than Ligand B (-7.1). However, the difference is less than 1.5 kcal/mol.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand B is the better candidate. While Ligand A has a slightly better binding affinity and metabolic stability, Ligand B excels in crucial properties like TPSA, logP, hERG inhibition, and QED. The lower hERG risk is particularly important for a cardiovascular target. The better logP and TPSA of Ligand B suggest improved permeability, which is vital for GPCR engagement. The difference in binding affinity is not substantial enough to outweigh the other advantages of Ligand B.
Output:
0
2025-04-17 18:57:46,849 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (356.419 Da) is slightly higher than Ligand B (339.395 Da), but both are acceptable.
2. **TPSA:** Ligand B (82.43) is significantly better than Ligand A (105.17). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (1.41) is within the optimal range (1-3), while Ligand A (-0.167) is below 1, potentially hindering permeation. This is a significant advantage for Ligand B.
4. **HBD:** Both ligands have acceptable HBD counts (Ligand A: 2, Ligand B: 1).
5. **HBA:** Both ligands have acceptable HBA counts (Ligand A: 6, Ligand B: 4).
6. **QED:** Both ligands have similar and acceptable QED values (Ligand A: 0.416, Ligand B: 0.483).
7. **DILI:** Ligand B (26.793) has a considerably lower DILI risk than Ligand A (17.642), which is a strong positive for Ligand B.
8. **BBB:** Ligand A (70.57) has a better BBB penetration score than Ligand B (46.413). However, as ADRB2 is a cardiovascular target, BBB penetration is not a high priority.
9. **Caco-2:** Both ligands have similar, very poor Caco-2 permeability (-4.987 and -5.094). This is a concern for both.
10. **Solubility:** Both ligands have poor aqueous solubility (-1.374 and -2.6). This is a concern for both.
11. **hERG:** Both ligands have low hERG inhibition liability (Ligand A: 0.162, Ligand B: 0.488).
12. **Cl_mic:** Ligand B (-9.596) has a much lower (better) microsomal clearance than Ligand A (33.998), indicating better metabolic stability.
13. **t1/2:** Ligand B (0.357) has a slightly better in vitro half-life than Ligand A (-15.332).
14. **Pgp:** Both ligands have very low P-gp efflux liability (Ligand A: 0.027, Ligand B: 0.046).
15. **Binding Affinity:** Ligand B (-6.0 kcal/mol) has a slightly better binding affinity than Ligand A (-5.7 kcal/mol). While the difference isn't huge, it's a positive for Ligand B.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, and affinity are key. Ligand B excels in logP and has a slightly better affinity, while also having a significantly better TPSA. Metabolic stability (Cl_mic) is also important, and Ligand B is superior in this regard. The DILI risk is also lower for Ligand B. While Ligand A has better BBB penetration, this is not a critical factor for a cardiovascular target.
**Conclusion:**
Considering the balance of properties and the priorities for a GPCR target, Ligand B is the more promising drug candidate. Its superior logP, lower DILI risk, better metabolic stability, and slightly improved affinity outweigh the better BBB score of Ligand A.
Output:
0
2025-04-17 18:57:46,849 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (335.367 Da) is within the ideal range, while Ligand B (361.511 Da) is slightly higher but still acceptable.
2. **TPSA:** Ligand A (106.91) is better than Ligand B (59.23) for oral absorption, but both are acceptable.
3. **logP:** Ligand A (1.869) is optimal, while Ligand B (4.579) is pushing the upper limit and could present solubility issues.
4. **HBD:** Ligand A (3) is good, while Ligand B (0) is also acceptable.
5. **HBA:** Ligand A (4) is good, while Ligand B (5) is also acceptable.
6. **QED:** Both ligands (A: 0.796, B: 0.756) have good drug-likeness scores.
7. **DILI:** Ligand A (83.986) has a higher DILI risk than Ligand B (41.14), which is a significant concern.
8. **BBB:** Ligand B (84.606) has better BBB penetration than Ligand A (55.06), though this isn't a primary concern for a cardiovascular target.
9. **Caco-2:** Ligand A (-5.145) and Ligand B (-4.714) are both negative, indicating poor permeability.
10. **Solubility:** Ligand A (-4.506) and Ligand B (-5.409) are both poor, but Ligand B is slightly worse.
11. **hERG:** Both ligands (A: 0.444, B: 0.552) have relatively low hERG inhibition risk.
12. **Cl_mic:** Ligand A (11.244) has significantly lower microsomal clearance than Ligand B (99.586), indicating better metabolic stability.
13. **t1/2:** Ligand A (70.662) has a much longer in vitro half-life than Ligand B (6.628).
14. **Pgp:** Ligand A (0.064) has lower P-gp efflux than Ligand B (0.374), which is favorable.
15. **Affinity:** Ligand B (-6.7 kcal/mol) has a significantly stronger binding affinity than Ligand A (-3.9 kcal/mol) - a difference of 2.8 kcal/mol. This is a substantial advantage.
**GPCR-specific considerations:**
For a GPCR like ADRB2, affinity, logP, TPSA, and Pgp are important. Ligand B excels in affinity, while Ligand A has better TPSA and Pgp. However, the large difference in binding affinity outweighs the advantages of Ligand A. The higher logP of Ligand B is a concern, but the improved metabolic stability (lower Cl_mic and longer t1/2) of Ligand A is valuable. The biggest drawback of Ligand A is its high DILI risk.
**Overall Assessment:**
Despite the higher DILI risk associated with Ligand A, the substantial improvement in binding affinity offered by Ligand B is a critical advantage for a GPCR target. The better metabolic stability of Ligand A is beneficial, but the potency difference is more impactful. The slightly higher logP of Ligand B is manageable.
Output:
0
2025-04-17 18:57:46,849 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (366.864 and 349.381 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (54.38) is better than Ligand B (58.37) as both are below the 140 threshold for oral absorption, but lower is preferable.
3. **logP:** Both ligands (3.701 and 3.243) are within the optimal 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability, but not dramatically.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1), but both are within the acceptable limit of 5.
5. **HBA:** Both ligands (4) are within the acceptable limit of 10.
6. **QED:** Both ligands have good QED scores (0.784 and 0.87), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Both ligands have acceptable DILI risk (36.293 and 39.473 percentile), below the 40 threshold. No significant difference.
8. **BBB:** Ligand B (70.919) has a better BBB penetration percentile than Ligand A (51.958). While ADRB2 isn't exclusively a CNS target, some CNS exposure may be relevant, and higher BBB is generally favorable.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.798 and -4.959), which is unusual and suggests poor permeability. This is a significant drawback for both.
10. **Solubility:** Ligand B (-2.934) has slightly better solubility than Ligand A (-4.093). Solubility is important for bioavailability.
11. **hERG:** Both ligands have low hERG inhibition liability (0.81 and 0.661), which is good.
12. **Cl_mic:** Ligand B (28.19) has significantly lower microsomal clearance than Ligand A (52.142), indicating better metabolic stability. This is a major advantage.
13. **t1/2:** Ligand A (73.798) has a much longer in vitro half-life than Ligand B (5.678). This is a significant advantage.
14. **Pgp:** Ligand A (0.77) has slightly higher Pgp efflux liability than Ligand B (0.061). Lower Pgp is preferred.
15. **Binding Affinity:** Ligand B (-7.5 kcal/mol) has a substantially stronger binding affinity than Ligand A (-6.0 kcal/mol). This is a crucial difference, as a 1.5 kcal/mol advantage is significant.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand B excels in Pgp and affinity, and is comparable in logP and TPSA. While Ligand A has a better half-life, the significantly stronger binding affinity of Ligand B outweighs this benefit. The poor Caco-2 values are concerning for both, but the superior metabolic stability and binding affinity of Ligand B make it the more promising candidate.
**Final Decision:**
Ligand B is the more viable drug candidate.
0
2025-04-17 18:57:46,849 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
The target is ADRB2, a GPCR. Therefore, the priorities are logP, Pgp, TPSA, affinity, and BBB. Let's compare the ligands step-by-step:
1. **MW:** Both ligands (353.463 and 354.491 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (78.95) is slightly higher than Ligand B (67.87). Both are below the 140 threshold for good oral absorption, but Ligand B is better.
3. **logP:** Ligand A (0.921) is a bit low, potentially hindering permeation. Ligand B (1.971) is better, falling within the optimal 1-3 range.
4. **HBD/HBA:** Both have 1 HBD and 4 HBA, which are acceptable.
5. **QED:** Both have good QED scores (0.704 and 0.759).
6. **DILI:** Ligand A (8.686) has a significantly lower DILI risk than Ligand B (16.402). This is a major advantage for Ligand A.
7. **BBB:** Ligand A (85.964) shows better BBB penetration than Ligand B (68.437). While ADRB2 isn't exclusively a CNS target, some CNS exposure might be acceptable or even desirable depending on the specific therapeutic goal.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
9. **Solubility:** Both have negative solubility values, which is also unusual.
10. **hERG:** Ligand A (0.176) has a lower hERG inhibition liability than Ligand B (0.331), indicating a lower risk of cardiotoxicity.
11. **Cl_mic:** Ligand A (18.097) has a significantly lower microsomal clearance than Ligand B (46.098), suggesting better metabolic stability.
12. **t1/2:** Ligand A (-7.985) has a worse in vitro half-life than Ligand B (6.106).
13. **Pgp:** Ligand A (0.014) has significantly lower P-gp efflux liability than Ligand B (0.049), which is favorable for bioavailability.
14. **Affinity:** Ligand B (-7.2 kcal/mol) has a slightly better binding affinity than Ligand A (-1.8 kcal/mol). This is a substantial difference.
**Overall Assessment:**
Ligand B has a better binding affinity, which is crucial. However, Ligand A demonstrates significantly better ADME properties: lower DILI risk, better BBB penetration, lower hERG inhibition, and lower microsomal clearance and Pgp efflux. The lower affinity of Ligand A could potentially be addressed through further optimization, while the poor ADME profile of Ligand B would be more challenging to fix. Given the GPCR target class, the balance of properties favors Ligand A.
**Output:**
1
2025-04-17 18:57:46,850 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
The ADRB2 receptor is a GPCR, so the key priorities are logP, TPSA, Pgp efflux, BBB penetration, and binding affinity. Metabolic stability (Cl_mic, t1/2) and safety (DILI, hERG) are also important.
Let's compare the ligands property by property:
1. **MW:** Both are within the ideal range (361.5 vs 367.5 Da).
2. **TPSA:** Ligand A (82.5) is better than Ligand B (100.6). Lower TPSA generally improves permeability.
3. **logP:** Ligand A (1.71) is better than Ligand B (0.69). Ligand B is a bit low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (2) is preferable to Ligand B (3). Fewer HBDs are generally better for permeability.
5. **HBA:** Ligand A (4) is preferable to Ligand B (6). Fewer HBAs are generally better for permeability.
6. **QED:** Ligand A (0.8) is better than Ligand B (0.66). Higher QED indicates better drug-likeness.
7. **DILI:** Ligand A (47.0) is better than Ligand B (54.3). Both are acceptable, but A has lower risk.
8. **BBB:** Both are similar (40.7 vs 41.0). Neither is particularly high, but this is less critical for a non-CNS target like ADRB2.
9. **Caco-2:** Ligand A (-4.92) is better than Ligand B (-5.36). Higher values indicate better absorption.
10. **Solubility:** Ligand A (-3.02) is better than Ligand B (-1.05). Better solubility is generally preferred.
11. **hERG:** Both are very low (0.17 vs 0.06), indicating minimal hERG inhibition risk.
12. **Cl_mic:** Ligand A (38.4) is better than Ligand B (9.6). Lower clearance means better metabolic stability.
13. **t1/2:** Both are similar (24.5 vs 24.2).
14. **Pgp:** Both are very low (0.09 vs 0.02). Low Pgp efflux is good.
15. **Affinity:** Ligand A (-7.0) is slightly better than Ligand B (-5.7). While both are strong binders, the 1.3 kcal/mol difference is significant and can outweigh minor ADME drawbacks.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most key parameters, including TPSA, logP, QED, DILI, solubility, and metabolic stability. The binding affinity is also slightly better for Ligand A. While both ligands have acceptable profiles, Ligand A presents a more balanced and optimized profile for a potential drug candidate targeting ADRB2.
**Output:**
1
2025-04-17 18:57:46,850 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.403 and 349.519 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand B (52.65) is significantly better than Ligand A (104.39). ADRB2 is a GPCR, and lower TPSA is generally preferred for better permeability.
3. **logP:** Ligand B (2.428) is optimal, while Ligand A (0.162) is quite low. This is a major drawback for Ligand A, potentially hindering membrane permeability and bioavailability.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable.
5. **HBA:** Ligand A (5) and Ligand B (3) are both acceptable.
6. **QED:** Ligand A (0.807) is better than Ligand B (0.685), indicating a more drug-like profile.
7. **DILI:** Ligand B (15.82) is *much* better than Ligand A (66.421). This is a critical advantage for Ligand B, as liver toxicity is a major concern.
8. **BBB:** Ligand B (65.529) is better than Ligand A (38.038), though neither is exceptionally high. For a cardiovascular target, BBB penetration isn't a primary concern, but it's still a positive for Ligand B.
9. **Caco-2:** Ligand B (-4.777) is better than Ligand A (-5.226), indicating better intestinal absorption.
10. **Solubility:** Ligand B (-1.422) is better than Ligand A (-2.423).
11. **hERG:** Ligand B (0.385) is better than Ligand A (0.111). Lower hERG inhibition is crucial for avoiding cardiotoxicity, especially for a cardiovascular target.
12. **Cl_mic:** Ligand A (-11.413) is *much* better than Ligand B (37.601). This indicates significantly better metabolic stability for Ligand A.
13. **t1/2:** Ligand B (-11.225) is better than Ligand A (-9.534).
14. **Pgp:** Ligand B (0.109) is better than Ligand A (0.021). Lower P-gp efflux is favorable.
15. **Binding Affinity:** Ligand B (-5.9) is better than Ligand A (-4.0). This is a substantial difference in potency.
**Overall Assessment:**
Ligand B clearly outperforms Ligand A in most critical ADME-Tox properties (DILI, hERG, logP, solubility, Caco-2, Pgp) and has a significantly better binding affinity. While Ligand A has better QED and metabolic stability (Cl_mic), the substantial risks associated with its poor logP and high DILI risk outweigh these benefits. The superior binding affinity of Ligand B further solidifies its position as the more promising candidate. The GPCR-specific priorities (logP, Pgp, TPSA) all favor Ligand B.
Output:
0
2025-04-17 18:57:46,850 - INFO - Here's my reasoning and final output for the ligand preference:
**Reasoning:**
We are evaluating two ligands for the ADRB2, a cardiovascular GPCR. Therefore, the key properties to prioritize are logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB.
Let's break down the comparison:
1. **Molecular Weight:** Both ligands (348.531 and 362.503 Da) fall within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (40.62) is significantly better than Ligand B (68.84). A lower TPSA generally favors better permeability, crucial for GPCR ligands. Ligand A is well below the 140 threshold, while B is approaching it.
3. **logP:** Ligand A (3.987) is slightly higher than Ligand B (2.153), both within the optimal 1-3 range. Ligand A is closer to the upper limit, which could be a slight concern, but still acceptable.
4. **H-Bond Donors/Acceptors:** Both have low HBD counts (0). Ligand B has more HBAs (7) than Ligand A (2), which could slightly hinder permeability.
5. **QED:** Both ligands have similar and acceptable QED scores (0.754 and 0.755).
6. **DILI:** Ligand B (50.174) has a significantly lower DILI risk than Ligand A (31.563), making it safer from a liver toxicity perspective.
7. **BBB:** Ligand A (90.733) has a much higher BBB penetration score than Ligand B (70.686). While ADRB2 is cardiovascular, some CNS off-target effects are possible with GPCRs, and higher BBB penetration could be a concern. However, for a cardiovascular target, this is less critical than for a CNS target.
8. **Caco-2 Permeability:** Ligand A (-4.588) has a more negative Caco-2 value, indicating *better* permeability than Ligand B (-5.204).
9. **Aqueous Solubility:** Ligand A (-3.5) has slightly better solubility than Ligand B (-2.308).
10. **hERG:** Both ligands have low hERG inhibition liability (0.733 and 0.182), indicating a low risk of cardiotoxicity.
11. **Microsomal Clearance:** Ligand B (51.395) has significantly lower microsomal clearance than Ligand A (89.977), suggesting better metabolic stability.
12. **In vitro Half-Life:** Ligand A (-19.952) has a longer in vitro half-life than Ligand B (-6.92), which is desirable.
13. **P-gp Efflux:** Ligand A (0.554) has lower P-gp efflux than Ligand B (0.195), meaning it's less likely to be pumped out of cells, improving bioavailability.
14. **Binding Affinity:** Both ligands have very similar and strong binding affinities (-6.4 and -6.1 kcal/mol). The difference is not substantial enough to be a deciding factor.
**Overall Assessment:**
Ligand A has superior permeability (TPSA, Caco-2) and P-gp efflux properties, and a longer half-life. However, Ligand B has a significantly better safety profile (lower DILI) and improved metabolic stability (lower Cl_mic). Considering the balance, the better TPSA and P-gp properties of Ligand A are more crucial for a GPCR target like ADRB2, outweighing the slightly higher DILI risk. The affinity is comparable.
**Output:**
1
2025-04-17 18:57:46,850 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (342.483 and 344.459 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (58.2) is significantly better than Ligand B (65.54). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand A is well below the 140 threshold, while Ligand B is approaching it.
3. **logP:** Ligand A (3.324) is optimal, while Ligand B (1.244) is on the lower side. For a GPCR, a logP between 1-3 is preferred, and Ligand A is closer to the upper end of that range, suggesting better membrane permeability.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1), but both are within the acceptable limit of 5.
5. **HBA:** Ligand A (3) is lower than Ligand B (4), which is preferable.
6. **QED:** Ligand B (0.808) has a higher QED score than Ligand A (0.506), indicating a more generally "drug-like" profile. However, QED isn't the highest priority for GPCRs.
7. **DILI:** Ligand B (9.694) has a *much* lower DILI risk than Ligand A (35.905). This is a significant advantage for Ligand B.
8. **BBB:** Both ligands have good BBB penetration (Ligand A: 72.005, Ligand B: 78.402). Ligand B is slightly better, but both are acceptable.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual. It's difficult to interpret these values without knowing the scale. However, a more negative value is generally worse.
10. **Solubility:** Ligand A (-2.849) has better solubility than Ligand B (-1.228), which is a positive.
11. **hERG:** Ligand A (0.651) has a lower hERG risk than Ligand B (0.21). This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand B (9.401) has significantly lower microsomal clearance than Ligand A (33.831), indicating better metabolic stability.
13. **t1/2:** Ligand A (-25.252) has a longer in vitro half-life than Ligand B (-3.815). This is a positive for Ligand A.
14. **Pgp:** Ligand A (0.81) has higher P-gp efflux than Ligand B (0.012). Lower P-gp efflux is preferred, giving an advantage to Ligand B.
15. **Binding Affinity:** Ligand A (-8.4) has a significantly stronger binding affinity than Ligand B (-5.7). This is a substantial advantage for Ligand A. A difference of 2.7 kcal/mol is quite large and can often outweigh other ADME concerns.
**Overall Assessment:**
Ligand A has a much stronger binding affinity and a longer half-life, which are crucial for a GPCR target. It also has better solubility and a lower hERG risk. However, Ligand B excels in DILI risk and metabolic stability (lower Cl_mic) and has lower P-gp efflux. The difference in binding affinity is substantial. While the lower DILI and better metabolic stability of Ligand B are attractive, the significantly improved potency of Ligand A is more important for a GPCR target like ADRB2. The slightly higher DILI risk of Ligand A could be mitigated with further structural modifications.
Output:
1
2025-04-17 18:57:46,850 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [347.459, 84.66, 2.818, 2, 4, 0.802, 37.495, 84.684, -4.837, -3.5, 0.78, 11.788, -14.617, 0.079, -5.3]**
**Ligand B: [344.327, 118.58, 1.992, 1, 6, 0.669, 71.307, 61.691, -4.734, -4.215, 0.231, 10.785, 2.505, 0.029, -7.1]**
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). A is 347.459, B is 344.327 - very similar.
2. **TPSA:** Ligand A (84.66) is excellent, well below the 140 threshold for oral absorption. Ligand B (118.58) is still acceptable, but higher, potentially impacting absorption.
3. **logP:** Ligand A (2.818) is optimal. Ligand B (1.992) is slightly lower, but still within the acceptable range.
4. **H-Bond Donors:** Ligand A (2) is good. Ligand B (1) is also good.
5. **H-Bond Acceptors:** Ligand A (4) is good. Ligand B (6) is acceptable, but higher.
6. **QED:** Ligand A (0.802) is excellent, indicating strong drug-like properties. Ligand B (0.669) is acceptable, but lower.
7. **DILI:** Ligand A (37.495) is very good, indicating low liver injury risk. Ligand B (71.307) is higher, suggesting a greater potential for liver toxicity.
8. **BBB:** Ligand A (84.684) is good, suggesting reasonable potential for CNS penetration, though ADRB2 is primarily cardiovascular. Ligand B (61.691) is lower.
9. **Caco-2:** Both are negative, indicating good permeability. Values are similar.
10. **Solubility:** Both are negative, indicating good solubility. Values are similar.
11. **hERG:** Ligand A (0.78) is better than Ligand B (0.231), indicating a lower risk of cardiotoxicity.
12. **Cl_mic:** Ligand A (11.788) is slightly higher, suggesting faster clearance. Ligand B (10.785) is better.
13. **t1/2:** Ligand A (-14.617) is much worse than Ligand B (2.505), indicating a shorter half-life.
14. **Pgp:** Ligand A (0.079) is better, indicating lower P-gp efflux. Ligand B (0.029) is better.
15. **Binding Affinity:** Ligand B (-7.1) is significantly better than Ligand A (-5.3), a difference of 1.8 kcal/mol. This is a substantial advantage.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B has a slightly lower logP, but the significantly better binding affinity (-7.1 vs -5.3) outweighs this. The TPSA is higher for B, but still acceptable. Pgp efflux is better for A, but the difference is small. The DILI risk is a significant concern for Ligand B, but the substantial affinity advantage is likely to be more impactful in early optimization. The half-life of A is significantly worse than B, which is a concern.
**Conclusion:**
Despite the higher DILI risk and slightly higher TPSA, the much stronger binding affinity of Ligand B makes it the more promising candidate. The affinity difference is large enough to potentially overcome the other drawbacks through further optimization.
Output:
0
2025-04-17 18:57:46,851 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (345.399 and 350.375 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (107.35) is better than Ligand B (122.13). For a cardiovascular GPCR, we don't need extremely low TPSA for CNS penetration, but lower is generally preferable for absorption.
3. **logP:** Ligand B (-0.671) is slightly lower than Ligand A (0.51). Both are acceptable, but closer to 1-3 is optimal. Ligand A is slightly favored.
4. **HBD:** Ligand A (4) is higher than Ligand B (2). While both are within the acceptable limit of 5, lower HBD can sometimes improve permeability. Ligand B is slightly favored.
5. **HBA:** Ligand B (7) is higher than Ligand A (5). Similar to HBD, lower HBA is generally preferred. Ligand A is slightly favored.
6. **QED:** Both ligands have good QED scores (0.612 and 0.722, respectively), indicating good drug-like properties. Ligand B is slightly favored.
7. **DILI:** Ligand B (45.25) has a significantly lower DILI risk than Ligand A (65.491). This is a substantial advantage for Ligand B.
8. **BBB:** Ligand B (70.027) has a much higher BBB penetration percentile than Ligand A (32.726). While ADRB2 isn't a CNS target, some peripheral exposure can be minimized with lower BBB penetration.
9. **Caco-2:** Both ligands have very poor Caco-2 permeability (-5.092 and -5.095). This is a major concern for both, indicating poor intestinal absorption.
10. **Solubility:** Ligand B (-0.752) is slightly better than Ligand A (-2.581), but both are very poor. This is a significant drawback for both.
11. **hERG:** Both ligands have low hERG inhibition risk (0.256 and 0.235). No significant difference.
12. **Cl_mic:** Ligand B (-4.324) has a much lower microsomal clearance than Ligand A (-19.225). This suggests better metabolic stability for Ligand B.
13. **t1/2:** Ligand B (-12.858) has a longer in vitro half-life than Ligand A (-8.417). This is a positive for Ligand B.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.051 and 0.004). No significant difference.
15. **Binding Affinity:** Ligand B (-7.7) has a significantly stronger binding affinity than Ligand A (-1.6). This is a major advantage for Ligand B, potentially outweighing some of the ADME concerns.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B has a better affinity, acceptable logP, and comparable Pgp. While TPSA is higher for Ligand B, it's not a critical issue for a peripheral GPCR.
**Overall Assessment:**
While both ligands have significant ADME liabilities (poor Caco-2 and solubility), Ligand B is considerably better due to its significantly improved binding affinity, lower DILI risk, better metabolic stability (lower Cl_mic, longer t1/2), and higher BBB penetration. The strong affinity of Ligand B is the most important factor here.
Output:
0
2025-04-17 18:57:46,851 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (416.335 Da) is slightly higher than Ligand B (352.381 Da), but both are acceptable.
**2. TPSA:** Ligand A (44.81) is well below the 140 A^2 threshold for oral absorption and good for a GPCR. Ligand B (59.5) is still reasonable, but less optimal.
**3. logP:** Both ligands have logP values (2.512 and 2.824) within the optimal 1-3 range.
**4. H-Bond Donors:** Ligand A has 1 HBD, which is good. Ligand B has 0, which is also acceptable.
**5. H-Bond Acceptors:** Both ligands have 4 HBAs, which is within the acceptable range of <=10.
**6. QED:** Both ligands have good QED scores (0.742 and 0.785), indicating drug-like properties.
**7. DILI:** Ligand A (39.705) has a slightly better DILI score than Ligand B (48.352), both are below the 60 threshold.
**8. BBB:** Ligand B (98.255) has a significantly higher BBB penetration percentile than Ligand A (85.498). While ADRB2 is a cardiovascular target, some CNS off-target effects are always a consideration, and higher BBB penetration could be a concern. However, for a cardiovascular target, this isn't a primary driver.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, indicating poor permeability. Ligand A (-4.749) is slightly worse than Ligand B (-4.019).
**10. Aqueous Solubility:** Both ligands have negative solubility values, indicating poor solubility. Ligand A (-2.269) is slightly worse than Ligand B (-3.622).
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (0.965 and 0.423), which is excellent.
**12. Microsomal Clearance:** Ligand A (10.388) has a lower (better) microsomal clearance than Ligand B (93.095), suggesting greater metabolic stability.
**13. In vitro Half-Life:** Ligand A (16.689) has a longer half-life than Ligand B (-29.896), which is a significant advantage.
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (0.242 and 0.238).
**15. Binding Affinity:** Both ligands have very similar binding affinities (-6.9 and -6.7 kcal/mol). The difference is not substantial enough to be a deciding factor.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand A is slightly favored. While Ligand B has better BBB penetration and Caco-2 permeability, the significantly better metabolic stability (lower Cl_mic) and longer half-life of Ligand A are more critical for a successful drug candidate. The slightly better DILI score of Ligand A is also a positive. The affinity difference is negligible. The poor Caco-2 and solubility of both ligands would need to be addressed in further optimization, but the pharmacokinetic profile of Ligand A is more promising.
Output:
1
2025-04-17 18:57:46,851 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (337.379 and 347.419 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (91.32) is better than Ligand B (107.19). Both are acceptable for a non-CNS GPCR target like ADRB2, but lower is generally preferred for permeability.
3. **logP:** Ligand A (2.622) is optimal, while Ligand B (0.075) is quite low. This is a major concern for Ligand B, as it may struggle with membrane permeability and bioavailability.
4. **HBD:** Both ligands have 3 HBD, which is within the acceptable range.
5. **HBA:** Both ligands have 4 HBA, also within the acceptable range.
6. **QED:** Ligand B (0.701) has a slightly better QED score than Ligand A (0.578), indicating a more drug-like profile. However, this is less critical given the other issues with Ligand B.
7. **DILI:** Ligand B (42.691) has a lower DILI risk than Ligand A (51.842), which is favorable.
8. **BBB:** This is less critical for ADRB2, but Ligand A (54.478) is slightly better than Ligand B (45.909).
9. **Caco-2:** Both ligands have negative Caco-2 values, suggesting poor permeability. However, the value for Ligand A (-5.152) is less negative than Ligand B (-5.386), indicating potentially slightly better absorption.
10. **Solubility:** Ligand A (-4.317) has better solubility than Ligand B (-2.852).
11. **hERG:** Both ligands have low hERG risk (0.202 and 0.302 respectively).
12. **Cl_mic:** Ligand A (31.72) has a significantly lower microsomal clearance than Ligand B (9.088), indicating better metabolic stability. This is a key advantage.
13. **t1/2:** Ligand A (-21.984) has a much longer in vitro half-life than Ligand B (-2.84). This is a substantial benefit.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.044 and 0.03 respectively).
15. **Binding Affinity:** Both ligands have very similar and excellent binding affinities (-6.4 and -5.8 kcal/mol). The difference of 0.6 kcal/mol is not enough to outweigh the ADME differences.
**Overall Assessment:**
Ligand A is the superior candidate. While Ligand B has a slightly better QED and DILI score, its extremely low logP is a major red flag, indicating poor permeability and likely bioavailability. Ligand A has a more optimal logP, better solubility, significantly better metabolic stability (lower Cl_mic, longer t1/2), and slightly better Caco-2 permeability. The binding affinities are comparable. Given the GPCR-specific priorities (logP, TPSA, Pgp), Ligand A is the clear choice.
Output:
1
2025-04-17 18:57:46,851 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (361.47 & 359.45 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (72.88) is better than Ligand B (80.29). Both are under the 140 threshold for oral absorption, but lower TPSA is generally preferred for GPCRs, aiding permeability.
3. **logP:** Both ligands have good logP values (1.93 & 2.63), falling within the optimal 1-3 range. Ligand B is slightly higher, which could potentially lead to some off-target interactions, but is still acceptable.
4. **HBD:** Both ligands have 2 H-bond donors, which is within the acceptable limit of 5.
5. **HBA:** Ligand A has 3 H-bond acceptors, while Ligand B has 6. Ligand A is preferable here, as fewer HBA generally improves permeability.
6. **QED:** Ligand A (0.781) has a slightly better QED score than Ligand B (0.68), indicating a more drug-like profile.
7. **DILI:** Both ligands have acceptable DILI risk (60.06% and 57.04%), below the concerning 60% threshold. Ligand B is marginally better.
8. **BBB:** Both ligands have low BBB penetration (20.63% and 19.12%). Since ADRB2 is a cardiovascular target, BBB penetration is not a primary concern.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.35 and -5.36), which is unusual and suggests very poor permeability. This is a significant drawback for both.
10. **Solubility:** Both ligands have very poor aqueous solubility (-1.68 and -1.88). This is a major concern for bioavailability.
11. **hERG:** Ligand A (0.024) has a much lower hERG inhibition liability than Ligand B (0.661), which is a significant advantage regarding cardiotoxicity risk.
12. **Cl_mic:** Ligand A (4.64 mL/min/kg) has a significantly lower microsomal clearance than Ligand B (13.22 mL/min/kg), indicating better metabolic stability.
13. **t1/2:** Ligand A (8.013 hours) has a better in vitro half-life than Ligand B (31.456 hours). This is a positive attribute.
14. **Pgp:** Ligand A (0.046) has a lower P-gp efflux liability than Ligand B (0.356), which is favorable for oral bioavailability.
15. **Binding Affinity:** Ligand A (-6.7 kcal/mol) has a slightly better binding affinity than Ligand B (-6.4 kcal/mol). While the difference is not huge, it's enough to consider given the other factors.
**Overall Assessment:**
Despite the poor Caco-2 and solubility for both, Ligand A is the more promising candidate. It has a better QED score, lower hERG risk, significantly lower microsomal clearance, better P-gp efflux, and slightly better binding affinity. The lower TPSA and HBA count also contribute to its potential for better permeability. While both have poor solubility, the other ADME properties of Ligand A are more favorable for further development.
Output:
1
2025-04-17 18:57:46,851 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.45 & 359.54 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (76.98) is better than Ligand B (38.13). Lower TPSA generally favors better membrane permeability, which is important for GPCRs.
3. **logP:** Ligand B (3.669) is higher than Ligand A (0.731). While a logP between 1-3 is optimal, Ligand B is approaching the upper limit. Ligand A is quite low, potentially hindering permeation.
4. **HBD:** Ligand A (1) is better than Ligand B (0). Fewer HBDs can improve permeability.
5. **HBA:** Ligand A (5) is slightly higher than Ligand B (4), but both are within acceptable limits.
6. **QED:** Both ligands have good QED scores (0.82 and 0.753), indicating good drug-like properties.
7. **DILI:** Ligand A (17.45%) has a significantly lower DILI risk than Ligand B (27.34%). This is a crucial advantage.
8. **BBB:** Ligand B (91.51%) has a much higher BBB penetration percentile than Ligand A (40.17%). While ADRB2 isn't strictly a CNS target, some CNS exposure can occur, and higher BBB is generally favorable if not detrimental.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests a potential issue with the data or the model. However, the values are similar (-4.905 vs -5.288).
10. **Solubility:** Ligand A (-0.723) has slightly better solubility than Ligand B (-3.755).
11. **hERG:** Ligand A (0.104) has a much lower hERG inhibition liability than Ligand B (0.849). This is a significant safety advantage.
12. **Cl_mic:** Ligand B (82.034) has a much higher microsomal clearance than Ligand A (22.638), indicating lower metabolic stability.
13. **t1/2:** Ligand B (12.11) has a longer in vitro half-life than Ligand A (-7.558). This is a positive for dosing frequency.
14. **Pgp:** Ligand B (0.82) has higher P-gp efflux liability than Ligand A (0.006). Lower P-gp is preferred.
15. **Binding Affinity:** Ligand B (-5.6 kcal/mol) has a slightly better binding affinity than Ligand A (-3.8 kcal/mol). This is a 1.8 kcal/mol difference, which is substantial.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp efflux, and affinity are key. Ligand B excels in affinity and BBB penetration, but suffers from higher logP, Pgp efflux, and significantly worse DILI and hERG risk. Ligand A has a lower logP, better DILI/hERG profiles, and lower Pgp efflux, but its affinity is weaker and BBB penetration is lower.
**Overall Assessment:**
The superior binding affinity of Ligand B is attractive. However, the significantly higher DILI and hERG risk, coupled with higher Pgp efflux and faster metabolic clearance, are major concerns. Ligand A, while having weaker binding, presents a much more favorable safety and ADME profile. The difference in binding affinity (1.8 kcal/mol) can potentially be overcome with further optimization, whereas mitigating the significant safety liabilities of Ligand B would be far more challenging.
Output:
1
2025-04-17 18:57:46,852 - INFO - Batch 75 complete. Total preferences: 1200
2025-04-17 18:57:46,852 - INFO - Processing batch 76/512...
2025-04-17 18:58:31,542 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (346.475 Da) is slightly lower, which is generally favorable for permeability.
**2. TPSA:** Ligand A (67.23) is significantly better than Ligand B (104.21). For a GPCR, keeping TPSA low is good, though not as critical as for CNS targets. Ligand B is pushing the upper limit for good oral absorption.
**3. logP:** Ligand A (2.52) is optimal, while Ligand B (0.954) is a bit low. A logP below 1 can sometimes hinder membrane permeability.
**4. H-Bond Donors:** Ligand A (1) is better than Ligand B (3). Fewer HBDs generally improve permeability.
**5. H-Bond Acceptors:** Ligand A (4) is better than Ligand B (6). Similar to HBDs, fewer HBAs are preferred.
**6. QED:** Both ligands have acceptable QED values (A: 0.825, B: 0.702), indicating good drug-like properties.
**7. DILI Risk:** Ligand A (23.536) has a much lower DILI risk than Ligand B (75.184). This is a significant advantage for Ligand A.
**8. BBB Penetration:** Ligand A (76.231) shows better BBB penetration than Ligand B (33.85). While ADRB2 is primarily cardiovascular, some CNS off-target effects are possible, and better BBB penetration isn't necessarily a negative.
**9. Caco-2 Permeability:** Ligand A (-5.287) is better than Ligand B (-4.96).
**10. Aqueous Solubility:** Ligand A (-2.235) is better than Ligand B (-2.647).
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (A: 0.586, B: 0.277).
**12. Microsomal Clearance:** Ligand A (36.312) has lower microsomal clearance than Ligand B (9.811), suggesting better metabolic stability.
**13. In vitro Half-Life:** Ligand A (-6.566) has a longer half-life than Ligand B (28.018).
**14. P-gp Efflux:** Ligand A (0.127) has lower P-gp efflux than Ligand B (0.152).
**15. Binding Affinity:** Ligand B (-6.8) has a slightly better binding affinity than Ligand A (-6.1). However, the difference is only 0.7 kcal/mol, which is not substantial enough to overcome the multiple ADME advantages of Ligand A.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most crucial ADME properties (TPSA, logP, HBD/HBA, DILI, BBB, solubility, metabolic stability, and efflux). While Ligand B has a marginally better binding affinity, the superior overall profile of Ligand A makes it the more promising drug candidate. The lower DILI risk and better predicted permeability are particularly important.
Output:
1
2025-04-17 18:58:31,542 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal 200-500 Da range (A: 352.483, B: 362.539). No clear advantage.
2. **TPSA:** Ligand A (103.01) is better than Ligand B (49.41). For a cardiovascular GPCR, lower TPSA is generally preferred for better permeability, but both are acceptable.
3. **logP:** Ligand B (2.987) is closer to the optimal 1-3 range than Ligand A (1.163). This is a slight advantage for B, as it suggests better membrane permeability.
4. **HBD:** Ligand A (3) is higher than Ligand B (1). While both are within the acceptable limit of 5, lower HBD is generally preferred for permeability.
5. **HBA:** Ligand A (5) is higher than Ligand B (3). Similar to HBD, lower HBA is preferred.
6. **QED:** Both ligands have similar QED values (A: 0.586, B: 0.507), indicating good drug-likeness.
7. **DILI:** Ligand A (33.579) has a slightly higher DILI risk than Ligand B (25.359), but both are below the concerning threshold of 60.
8. **BBB:** Ligand B (67.158) has a significantly higher BBB penetration percentile than Ligand A (35.324). While ADRB2 isn't a CNS target, some degree of BBB penetration can be beneficial for distribution.
9. **Caco-2:** Ligand A (-5.783) and Ligand B (-4.949) have negative values, which is unusual. These values likely represent logPapp and indicate poor permeability.
10. **Solubility:** Ligand A (-1.194) has better aqueous solubility than Ligand B (-3.448). This is a positive for A.
11. **hERG:** Ligand A (0.155) has a lower hERG inhibition liability than Ligand B (0.442), which is a significant advantage.
12. **Cl_mic:** Ligand A (24.871) has a much lower microsomal clearance than Ligand B (63.111), suggesting better metabolic stability.
13. **t1/2:** Ligand A (14.801) has a longer in vitro half-life than Ligand B (1.876), which is a major advantage.
14. **Pgp:** Ligand A (0.021) has lower P-gp efflux liability than Ligand B (0.418), meaning better absorption and bioavailability.
15. **Binding Affinity:** Ligand A (-6.2 kcal/mol) has a slightly better binding affinity than Ligand B (-5.9 kcal/mol). While the difference is small, it contributes to the overall preference.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B has a better logP, and BBB penetration, but Ligand A excels in Pgp efflux, metabolic stability (Cl_mic, t1/2), hERG inhibition, and has comparable affinity. The better metabolic stability and reduced toxicity risk of Ligand A are crucial for a viable drug candidate.
**Conclusion:**
Considering the balance of properties, particularly the superior metabolic stability, lower toxicity (hERG, DILI), and P-gp efflux profile of Ligand A, it is the more promising drug candidate.
Output:
1
2025-04-17 18:58:31,542 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, priorities are logP, TPSA, Pgp, affinity, and to a lesser extent, BBB.
* **Molecular Weight:** Both ligands are within the ideal range (346.39 vs 345.45 Da).
* **TPSA:** Both are good, below the 140 A^2 threshold (94.74 vs 93.68 A^2).
* **logP:** Ligand A (0.573) is quite low, potentially hindering membrane permeability. Ligand B (1.927) is much better, falling within the optimal 1-3 range. This is a significant advantage for Ligand B.
* **H-Bond Donors/Acceptors:** Both have acceptable HBD (2) and HBA counts (4 for A, 8 for B). Ligand B's HBA is slightly higher, but still within reasonable limits.
* **QED:** Both have reasonable QED scores (0.819 vs 0.675), indicating good drug-like properties.
* **DILI:** Ligand A has a higher DILI risk (60.92%) than Ligand B (47.73%), although both are acceptable.
* **BBB:** Ligand B has a better BBB score (48.12%) than Ligand A (35.29%), but BBB is less critical for a cardiovascular target.
* **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the magnitude of the negative value is important. Ligand A (-4.893) is slightly better than Ligand B (-5.603).
* **Solubility:** Both have negative solubility values, which is also unusual. Ligand A (-2.711) is slightly better than Ligand B (-1.861).
* **hERG:** Both have low hERG inhibition liability (0.131 vs 0.233).
* **Microsomal Clearance:** Ligand A has significantly lower (better) microsomal clearance (-25.976) than Ligand B (14.121), indicating better metabolic stability.
* **In vitro Half-Life:** Ligand A has a longer half-life (-17.167) than Ligand B (8.578).
* **P-gp Efflux:** Both have low P-gp efflux liability (0.01 vs 0.347), with Ligand A being slightly better.
* **Binding Affinity:** Both have very similar and excellent binding affinities (-6.5 vs -6.0 kcal/mol). The difference is less than the 1.5 kcal/mol threshold.
**Conclusion:**
Despite Ligand A's better metabolic stability and slightly better Caco-2/Solubility, Ligand B's significantly improved logP is the deciding factor. A logP in the optimal range is crucial for GPCR ligands to ensure adequate membrane permeability and target engagement. The slightly higher DILI risk and lower metabolic stability of Ligand B are acceptable trade-offs for the improved logP.
Output:
0
2025-04-17 18:58:31,543 - INFO - Here's my reasoning and decision for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Step-by-step comparison:**
1. **MW:** Both ligands (350.459 Da and 365.455 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (78.87) is slightly higher than Ligand B (71.97). Both are below the 140 A^2 threshold for good oral absorption, but closer to the 90 A^2 threshold for CNS targets.
3. **logP:** Both ligands have similar logP values (1.237 and 1.294), falling within the optimal 1-3 range.
4. **HBD:** Ligand A has 2 HBD, while Ligand B has 0. Lower HBD can sometimes improve permeability, but 2 is still acceptable.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 6. Both are below the 10 threshold, but Ligand A is preferable.
6. **QED:** Both ligands have similar QED values (0.799 and 0.76), indicating good drug-like properties.
7. **DILI:** Ligand B (43.932) has a lower DILI risk than Ligand A (17.449), which is a significant advantage.
8. **BBB:** Ligand B (78.868) has a significantly higher BBB penetration percentile than Ligand A (44.591). This is important for GPCRs, even if ADRB2 isn't strictly a CNS target, as it can influence distribution.
9. **Caco-2:** Ligand A (-4.681) has a better Caco-2 permeability than Ligand B (-4.957).
10. **Solubility:** Ligand A (-1.759) has better aqueous solubility than Ligand B (-2.265).
11. **hERG:** Both ligands have very low hERG inhibition liability (0.236 and 0.162), indicating a low risk of cardiotoxicity.
12. **Cl_mic:** Ligand B (28.34) has a slightly lower microsomal clearance than Ligand A (29.709), suggesting better metabolic stability.
13. **t1/2:** Ligand A (3.347) has a longer in vitro half-life than Ligand B (-1.988).
14. **Pgp:** Ligand A (0.039) has lower P-gp efflux liability than Ligand B (0.121).
15. **Binding Affinity:** Ligand B (-6.8 kcal/mol) has a significantly stronger binding affinity than Ligand A (-4.9 kcal/mol). This is a >1.5 kcal/mol difference, which is a substantial advantage.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand B excels in affinity and has a better BBB profile, which is beneficial for overall distribution. While Ligand A has better solubility and Caco-2 permeability, the significantly improved binding affinity of Ligand B outweighs these advantages. The lower DILI risk of Ligand B is also a strong positive.
**Conclusion:**
Considering the balance of properties and the priorities for a GPCR target, Ligand B is the more promising drug candidate.
Output:
0
2025-04-17 18:58:31,543 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (433.611 Da) is within the ideal range, while Ligand B (336.37 Da) is at the lower end, but still acceptable.
2. **TPSA:** Both Ligand A (58.2) and Ligand B (59.81) are well below the 140 threshold for good oral absorption, and are reasonable for a GPCR target.
3. **logP:** Ligand A (4.584) is slightly higher than optimal (1-3), potentially leading to solubility issues, but still within a manageable range. Ligand B (3.456) is within the optimal range.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable.
5. **HBA:** Ligand A (2) and Ligand B (4) are both acceptable.
6. **QED:** Both Ligand A (0.538) and Ligand B (0.797) have good drug-likeness scores, with Ligand B being slightly better.
7. **DILI:** Both Ligand A (88.91) and Ligand B (82.28) have relatively high DILI risk, but are still within a range that isn't immediately disqualifying.
8. **BBB:** Both Ligand A (75.843) and Ligand B (83.288) have good BBB penetration, which is relevant for GPCRs. Ligand B is slightly better.
9. **Caco-2:** Both Ligand A (-4.586) and Ligand B (-4.787) have similar Caco-2 permeability values, suggesting similar absorption potential.
10. **Solubility:** Ligand A (-5.566) and Ligand B (-4.604) both have poor aqueous solubility.
11. **hERG:** Ligand A (0.543) and Ligand B (0.741) are both relatively low risk for hERG inhibition.
12. **Cl_mic:** Ligand A (39.656) has a lower microsomal clearance than Ligand B (51.526), suggesting better metabolic stability.
13. **t1/2:** Ligand A (103.897) has a significantly longer in vitro half-life than Ligand B (43.938), a major advantage.
14. **Pgp:** Ligand A (0.551) and Ligand B (0.638) have similar P-gp efflux liability.
15. **Binding Affinity:** Ligand B (-7.7 kcal/mol) has a slightly better binding affinity than Ligand A (-7.5 kcal/mol). This is a 0.2 kcal/mol difference, which is not huge, but is still a factor.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand B has a better logP and slightly better affinity and BBB penetration. However, Ligand A has a significantly longer half-life and better metabolic stability (lower Cl_mic). The difference in binding affinity is small, and the longer half-life and improved metabolic stability of Ligand A are more valuable for *in vivo* efficacy and dosing. The solubility is poor for both, but can be addressed with formulation.
**Conclusion:**
Considering the balance of properties, especially the longer half-life and better metabolic stability of Ligand A, I believe it is the more promising drug candidate.
Output:
1
2025-04-17 18:58:31,543 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands (345.443 and 351.491 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (75.44) is higher than Ligand B (61.88). Both are below the 140 threshold for oral absorption, but B is closer to the preferred <90 for GPCRs.
3. **logP:** Ligand A (2.698) and Ligand B (1.251) are both within the optimal 1-3 range. Ligand A is slightly better.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Both ligands have 4 HBA, which is good.
6. **QED:** Ligand A (0.851) has a better QED score than Ligand B (0.715), indicating higher overall drug-likeness.
7. **DILI:** Ligand B (5.933) has a *much* lower DILI risk than Ligand A (34.277). This is a significant advantage for Ligand B.
8. **BBB:** Both ligands have good BBB penetration (Ligand A: 76.658, Ligand B: 70.88), but Ligand A is slightly better.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.685) is slightly better than Ligand B (-4.828).
10. **Solubility:** Ligand A (-3.272) has better solubility than Ligand B (-1.091).
11. **hERG:** Both ligands have low hERG inhibition risk (0.431 and 0.45), which is good.
12. **Cl_mic:** Ligand B (20.715) has significantly lower microsomal clearance than Ligand A (58.362), suggesting better metabolic stability.
13. **t1/2:** Ligand B (10.327) has a longer in vitro half-life than Ligand A (-15.693). This is a clear advantage for Ligand B.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.159 and 0.007). Ligand B is slightly better.
15. **Binding Affinity:** Ligand A (-7.5 kcal/mol) has a slightly stronger binding affinity than Ligand B (-6.4 kcal/mol). This is a 1.1 kcal/mol difference, which is notable.
**GPCR-Specific Priorities & Overall Assessment:**
For an ADRB2 GPCR, we prioritize logP, TPSA, Pgp, and affinity. Ligand A has a slightly better logP, affinity, and BBB penetration, while Ligand B has a significantly better DILI score, lower Cl_mic, longer t1/2, and lower TPSA.
The difference in affinity (1.1 kcal/mol) is important, but the substantial improvement in safety (DILI) and pharmacokinetic properties (Cl_mic, t1/2) with Ligand B outweighs it. The lower TPSA of Ligand B is also beneficial for GPCR targeting. While both Caco-2 values are poor, the overall profile of Ligand B is more promising for development.
**Output:**
0
2025-04-17 18:58:31,543 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
Let's analyze each ligand against the provided guidelines, keeping in mind ADRB2 is a GPCR, so logP, TPSA, Pgp, BBB, and affinity are key.
* **Molecular Weight:** Both ligands (349.431 and 352.41 Da) fall comfortably within the ideal 200-500 Da range.
* **TPSA:** Ligand A (94.8) is slightly higher than Ligand B (76.46). Both are acceptable, but Ligand B is preferable as it's closer to the <90 target for potential CNS penetration, even though this isn't a CNS target.
* **logP:** Ligand A (0.116) is quite low, potentially hindering permeability. Ligand B (0.614) is better, though still on the lower side of the optimal 1-3 range. This is a significant advantage for B.
* **H-Bond Donors:** Ligand A (3) is higher than Ligand B (1). Lower is generally better for permeability, favoring Ligand B.
* **H-Bond Acceptors:** Both ligands have 5 HBA, which is within the acceptable limit of 10.
* **QED:** Both ligands have good QED scores (0.68 and 0.814), indicating good drug-like properties. Ligand B is slightly better.
* **DILI:** Ligand A (20.783) has a significantly lower DILI risk than Ligand B (41.566). This is a major advantage for Ligand A.
* **BBB:** Ligand A (42.109) has a lower BBB penetration percentile than Ligand B (94.184). While ADRB2 isn't a CNS target, higher BBB is generally a positive indicator of permeability.
* **Caco-2 Permeability:** Ligand A (-5.242) has worse Caco-2 permeability than Ligand B (-4.66). Higher values are better, so B is preferred.
* **Aqueous Solubility:** Ligand A (-1.707) has slightly better solubility than Ligand B (-2.21).
* **hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.095 and 0.537).
* **Microsomal Clearance:** Ligand A (-18.054) has much lower microsomal clearance, indicating better metabolic stability, than Ligand B (5.082). This is a significant advantage for A.
* **In vitro Half-Life:** Ligand A (2.986) has a shorter half-life than Ligand B (16.227). A longer half-life is generally preferred, favoring Ligand B.
* **P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.008 and 0.128).
* **Binding Affinity:** Both ligands have very similar and excellent binding affinities (-6.0 and -6.1 kcal/mol). The difference is negligible.
**Overall Assessment:**
Ligand A has advantages in DILI risk and metabolic stability (Cl_mic). Ligand B excels in logP, Caco-2 permeability, BBB, and in vitro half-life. The low logP of Ligand A is a significant concern for permeability. While the DILI risk is lower for A, the better ADME profile of Ligand B, particularly the improved logP and permeability, outweighs this benefit. The similar binding affinities make the ADME properties the deciding factor.
**Output:**
0
2025-04-17 18:58:31,543 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (340.47 & 351.40 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (49.41) is significantly better than Ligand B (113.69). ADRB2 is a cardiovascular target, not CNS, but lower TPSA generally improves absorption. Ligand A is well below the 140 threshold. Ligand B is pushing the limit.
3. **logP:** Ligand A (3.41) is optimal, while Ligand B (0.72) is a bit low. A logP between 1-3 is preferred, and Ligand B is at the lower end, potentially impacting permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (2) is preferable to Ligand B (6). Lower HBA also contributes to better permeability.
6. **QED:** Both ligands have similar QED values (0.611 vs 0.667), indicating reasonable drug-likeness.
7. **DILI:** Ligand A (41.22) has a slightly higher DILI risk than Ligand B (37.92), but both are below the concerning 60% threshold.
8. **BBB:** Ligand A (75.11) has a better BBB penetration percentile than Ligand B (49.52). While ADRB2 isn't a CNS target, higher BBB penetration can sometimes correlate with better overall distribution.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.805 and -4.592) which is unusual. This suggests poor permeability.
10. **Solubility:** Both ligands have negative solubility values (-3.249 and -3.268) which is also unusual. This suggests poor solubility.
11. **hERG:** Ligand A (0.699) has a slightly higher hERG risk than Ligand B (0.152), but both are relatively low.
12. **Cl_mic:** Ligand B (57.95) has a lower microsomal clearance than Ligand A (68.13), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-36.81) has a much longer in vitro half-life than Ligand A (-1.47). This is a significant advantage.
14. **Pgp:** Ligand A (0.385) has lower P-gp efflux liability than Ligand B (0.055), which is favorable for bioavailability.
15. **Affinity:** Ligand B (-5.7 kcal/mol) has a significantly stronger binding affinity than Ligand A (-4.4 kcal/mol). This is a >1.3 kcal/mol advantage, which is substantial and can outweigh some ADME drawbacks.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has better logP, TPSA, and Pgp. However, Ligand B's significantly stronger affinity is a major advantage. The longer half-life of Ligand B is also a substantial benefit.
**Overall Assessment:**
Despite Ligand A's better TPSA, logP, and Pgp properties, Ligand B's significantly improved binding affinity and longer half-life are more critical for a GPCR target. The slightly lower logP and higher TPSA of Ligand B are acceptable trade-offs given the potency advantage. The negative Caco-2 and solubility values are concerning for both, but the potency of Ligand B may allow for formulation strategies to overcome these issues.
Output:
0
2025-04-17 18:58:31,544 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
The ADRB2 receptor is a GPCR, so the priorities are logP, Pgp, TPSA, BBB, and affinity. Let's break down the comparison:
1. **Molecular Weight:** Both ligands are within the ideal 200-500 Da range. Ligand A (337.47) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (45.23) is significantly better than Ligand B (108.33). A TPSA under 140 is good for oral absorption, but lower is generally better for GPCRs, and A is much closer to the ideal range for CNS penetration (though BBB is the ultimate metric).
3. **logP:** Ligand A (3.702) is optimal (1-3), while Ligand B (-0.72) is quite low. This is a major strike against B, as it suggests poor membrane permeability and potential distribution issues.
4. **H-Bond Donors/Acceptors:** Ligand A (1 HBD, 3 HBA) is better than Ligand B (3 HBD, 6 HBA). Both are within acceptable limits, but fewer H-bonds generally improve permeability.
5. **QED:** Ligand A (0.747) has a better QED score than Ligand B (0.528), indicating a more drug-like profile.
6. **DILI:** Ligand A (32.803) has a much lower DILI risk than Ligand B (14.889). This is a significant advantage for A.
7. **BBB:** Ligand A (76.231) has a much better BBB percentile than Ligand B (40.597). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be beneficial, and avoiding CNS side effects is important.
8. **Caco-2:** Ligand A (-4.727) and Ligand B (-5.001) are both very low, suggesting poor permeability. However, this is somewhat mitigated by the logP and TPSA values.
9. **Solubility:** Ligand A (-4.143) is slightly better than Ligand B (-0.637), but both are poor. Solubility can be improved through formulation.
10. **hERG:** Ligand A (0.82) has a lower hERG risk than Ligand B (0.126). This is a significant safety advantage for A.
11. **Cl_mic:** Ligand A (76.589) has a higher (worse) microsomal clearance than Ligand B (4.32). This means B is more metabolically stable.
12. **t1/2:** Ligand A (45.117) has a longer in vitro half-life than Ligand B (27.741). This is a positive for A.
13. **Pgp:** Ligand A (0.527) has a lower P-gp efflux liability than Ligand B (0.005). This is a significant advantage for A, as it suggests better oral bioavailability and potentially better CNS penetration.
14. **Binding Affinity:** Ligand A (-6.7 kcal/mol) and Ligand B (-6.4 kcal/mol) have comparable binding affinities. The difference of 0.3 kcal/mol is not substantial enough to outweigh the other significant differences.
**Overall Assessment:**
Ligand A is significantly better overall. It has superior logP, TPSA, DILI risk, BBB penetration, hERG risk, Pgp efflux, QED, and in vitro half-life. While Ligand B has better metabolic stability (lower Cl_mic), the other advantages of Ligand A are more critical for a GPCR target like ADRB2, especially considering the importance of permeability and minimizing off-target effects.
Output:
1
2025-04-17 18:58:31,544 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (337.398 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (46.4) is significantly better than Ligand B (68.82). ADRB2 is not a CNS target, but lower TPSA generally improves absorption.
3. **logP:** Ligand A (3.924) is optimal, while Ligand B (0.944) is a bit low, potentially hindering membrane permeability.
4. **HBD:** Both are acceptable (Ligand A: 1, Ligand B: 2).
5. **HBA:** Both are acceptable (Ligand A: 3, Ligand B: 5).
6. **QED:** Both are good (Ligand A: 0.784, Ligand B: 0.83), indicating good drug-like properties.
7. **DILI:** Ligand A (66.537) is higher than Ligand B (49.632), indicating a slightly higher risk of liver injury. However, both are within a manageable range.
8. **BBB:** Not a primary concern for ADRB2, but Ligand A (83.637) has better BBB penetration than Ligand B (52.656).
9. **Caco-2:** Ligand A (-4.945) and Ligand B (-5.278) have similar, very poor Caco-2 permeability. This is a significant concern for both.
10. **Solubility:** Ligand A (-3.767) is slightly better than Ligand B (-2.82), but both are poor.
11. **hERG:** Ligand A (0.813) is better than Ligand B (0.286), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand B (-3.481) has a negative value, indicating very low clearance and excellent metabolic stability, significantly better than Ligand A (63.417).
13. **t1/2:** Ligand A (75.028) has a longer half-life than Ligand B (44.183), which is desirable.
14. **Pgp:** Ligand A (0.616) is better than Ligand B (0.056), indicating lower P-gp efflux.
15. **Affinity:** Ligand B (-6.7 kcal/mol) has a significantly stronger binding affinity than Ligand A (-4.1 kcal/mol). This is a 1.5 kcal/mol difference, which is substantial.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand B has a better affinity and lower Pgp efflux. Ligand A has better logP and TPSA. However, the substantial affinity advantage of Ligand B outweighs the other factors. The poor Caco-2 and solubility are concerning for both, but can be addressed with formulation strategies.
**Conclusion:**
Despite the better metabolic stability of Ligand B, the significantly stronger binding affinity of Ligand B makes it the more promising candidate.
**Output:**
0
2025-04-17 18:58:31,544 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's systematically compare Ligand A and Ligand B based on the provided parameters and the guidelines, keeping in mind that ADRB2 is a GPCR, so logP, Pgp, TPSA, and affinity are particularly important.
1. **MW:** Both ligands (399.299 Da and 354.535 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (54.71) is better than Ligand B (72.8). Lower TPSA generally favors better absorption, and is important for GPCRs.
3. **logP:** Ligand A (3.983) is higher than Ligand B (2.163). While both are within the optimal 1-3 range, Ligand A is closer to the upper limit. This could be a slight concern for solubility, but acceptable given the other parameters.
4. **HBD:** Ligand A (1) is better than Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Both ligands have 4 HBA, which is acceptable.
6. **QED:** Ligand A (0.775) is slightly better than Ligand B (0.555), indicating a more drug-like profile.
7. **DILI:** Ligand B (9.771) is *significantly* better than Ligand A (81.892). This is a major advantage for Ligand B. A DILI percentile below 40 is desirable, and Ligand B is well within that range, while Ligand A is concerningly high.
8. **BBB:** Ligand B (73.711) is better than Ligand A (57.076). While ADRB2 isn't necessarily a CNS target, higher BBB penetration is generally favorable, and can indicate better overall permeability.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-4.751) is slightly better than Ligand B (-4.858), but both are problematic.
10. **Solubility:** Ligand B (-2.566) is better than Ligand A (-5.201). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.542) is better than Ligand B (0.777). Lower hERG inhibition is crucial for avoiding cardiotoxicity.
12. **Cl_mic:** Ligand A (19.273) is much better than Ligand B (40.048). Lower clearance indicates better metabolic stability.
13. **t1/2:** Ligand A (70.882) is significantly better than Ligand B (-5.263). A longer half-life is generally preferred.
14. **Pgp:** Ligand A (0.718) is better than Ligand B (0.45). Lower P-gp efflux is desirable.
15. **Affinity:** Ligand A (-8.0) is better than Ligand B (-5.4). This is a substantial difference in binding affinity (2.6 kcal/mol). This difference is significant enough to potentially offset some of the ADME liabilities of Ligand A.
**Overall Assessment:**
Ligand A has a much stronger binding affinity and better metabolic stability (lower Cl_mic, longer t1/2), and better Pgp efflux. However, Ligand B has a drastically lower DILI risk and better solubility. The DILI risk for Ligand A is a major concern. While the affinity of Ligand A is significantly better, the high DILI risk is a substantial drawback. The improved ADME properties of Ligand B, particularly the low DILI risk, outweigh the affinity difference.
**Output:**
0
2025-04-17 18:58:31,544 - INFO - Here's my reasoning and the final output:
**Reasoning:**
We are evaluating two ligands for the ADRB2, a cardiovascular GPCR. Therefore, the key properties to prioritize are logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB (though less critical for a cardiovascular target).
Let's break down the comparison:
1. **Molecular Weight:** Both ligands (342.443 and 349.475 Da) fall comfortably within the ideal 200-500 Da range.
2. **TPSA:** Ligand B (53.09) is significantly better than Ligand A (75.19). Lower TPSA generally translates to better cell permeability, crucial for GPCR targeting. Ligand B is well below the 140 threshold, while Ligand A is approaching it.
3. **logP:** Both ligands have acceptable logP values (1.768 and 0.958), falling within the 1-3 range. Ligand B is slightly lower, which is generally preferable for solubility.
4. **H-Bond Donors/Acceptors:** Ligand A has 1 HBD and 4 HBA, while Ligand B has 0 HBD and 4 HBA. Both are within acceptable limits.
5. **QED:** Both ligands have reasonable QED scores (0.819 and 0.759), indicating good drug-like properties.
6. **DILI:** Ligand B (6.282) has a *much* lower DILI risk than Ligand A (21.287). This is a significant advantage for Ligand B.
7. **BBB:** Both ligands have similar BBB penetration (75.805 and 75.184). This isn't a primary concern for a cardiovascular target, but it's good they both show reasonable penetration.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and difficult to interpret without knowing the scale.
9. **Solubility:** Both have negative solubility values, which is also unusual and difficult to interpret without knowing the scale.
10. **hERG:** Both ligands have low hERG risk (0.123 and 0.264).
11. **Cl_mic:** Ligand B (17.543) has a significantly lower microsomal clearance than Ligand A (36.165), indicating better metabolic stability.
12. **t1/2:** Ligand B (6.473) has a substantially longer in vitro half-life than Ligand A (-0.069). This is a major advantage.
13. **Pgp:** Both have very low Pgp efflux liability (0.013 and 0.014).
14. **Binding Affinity:** Ligand A (-8.0) has a slightly better binding affinity than Ligand B (-6.3). This is a 1.7 kcal/mol difference, which is significant.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity, Ligand B demonstrates a superior ADME profile. The lower DILI risk, significantly improved metabolic stability (lower Cl_mic and longer t1/2), and lower TPSA make Ligand B a more promising drug candidate. The affinity difference, while notable, can potentially be optimized in later stages of drug development. The better ADME properties of Ligand B are more difficult to improve later.
**Output:**
0
2025-04-17 18:58:31,544 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (367.471 and 352.431 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (91.76) is slightly higher than Ligand B (79.31). Both are acceptable for a non-CNS GPCR target like ADRB2, being below 140. Ligand B is preferable.
3. **logP:** Ligand A (1.605) is within the optimal 1-3 range. Ligand B (0.152) is a bit low, potentially impacting permeability. Ligand A is preferable.
4. **HBD:** Ligand A (2) and Ligand B (1) are both within the acceptable limit of <=5. Ligand B is preferable.
5. **HBA:** Ligand A (6) and Ligand B (5) are both within the acceptable limit of <=10. Ligand B is preferable.
6. **QED:** Ligand B (0.782) has a significantly better QED score than Ligand A (0.414), indicating better overall drug-likeness. Ligand B is preferable.
7. **DILI:** Ligand B (35.052) has a lower DILI risk than Ligand A (50.95), which is a significant advantage. Ligand B is preferable.
8. **BBB:** This is less critical for ADRB2 (a cardiovascular target). Ligand A (36.952) is slightly higher than Ligand B (18.961), but both are low.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand B (-4.633) is slightly less negative than Ligand A (-5.472), suggesting marginally better absorption potential. Ligand B is preferable.
10. **Solubility:** Both are negative, indicating poor solubility. Ligand A (-0.99) is slightly less negative than Ligand B (-1.352), suggesting marginally better solubility. Ligand A is preferable.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.332 and 0.212 respectively). No significant difference.
12. **Cl_mic:** Ligand A (-7.488) has a much lower (better) microsomal clearance than Ligand B (11.706), indicating greater metabolic stability. Ligand A is preferable.
13. **t1/2:** Ligand B (38.679) has a significantly longer in vitro half-life than Ligand A (5.844). Ligand B is preferable.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.088 and 0.027 respectively). No significant difference.
15. **Binding Affinity:** Ligand A (-7.2 kcal/mol) has a slightly better binding affinity than Ligand B (-6.2 kcal/mol), a difference of 1.0 kcal/mol. This is a substantial difference that can outweigh some ADME drawbacks. Ligand A is preferable.
**Overall Assessment:**
Ligand B demonstrates superior drug-like properties (QED, DILI, t1/2, Caco-2) and a lower logP. However, Ligand A has a significantly better binding affinity and metabolic stability (Cl_mic). Given the importance of potency for GPCR targets, and the relatively small difference in other parameters, the stronger binding affinity of Ligand A is the deciding factor.
Output:
1
2025-04-17 18:58:31,545 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (365.382 and 344.455 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (54.82) is significantly better than Ligand A (81.7). ADRB2 is not a CNS target, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (3.036 and 3.444), falling within the optimal 1-3 range. Ligand B is slightly higher, which could be a minor negative if solubility becomes an issue.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand B (5) is slightly better than Ligand A (6). Lower HBA is generally preferred.
6. **QED:** Both have good QED scores (0.796 and 0.87), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (92.982) has a significantly higher DILI risk than Ligand B (24.622). This is a major concern for Ligand A.
8. **BBB:** Both have acceptable BBB penetration (79.139 and 78.945). Not a major factor here as ADRB2 is primarily cardiovascular.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual. Assuming these are logP-scale values, they suggest poor permeability.
10. **Solubility:** Ligand B (-3.511) is better than Ligand A (-4.679).
11. **hERG:** Ligand A (0.524) is better than Ligand B (0.917), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand B (64.911) has a significantly lower microsomal clearance than Ligand A (110.712), suggesting better metabolic stability.
13. **t1/2:** Ligand B (6.257 hours) has a slightly longer half-life than Ligand A (8.989 hours).
14. **Pgp:** Ligand A (0.404) is better than Ligand B (0.257) indicating lower P-gp efflux.
15. **Binding Affinity:** Ligand B (-9.1 kcal/mol) has a significantly stronger binding affinity than Ligand A (-7.1 kcal/mol). This is a substantial advantage.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in affinity and TPSA, and has a good logP. The lower DILI and better metabolic stability are also significant advantages. While Ligand A has slightly better hERG and Pgp, the much higher DILI risk and weaker affinity are major drawbacks.
**Conclusion:**
Ligand B is the superior candidate due to its significantly better binding affinity, lower DILI risk, and improved metabolic stability. The slightly better solubility and TPSA also contribute to its overall profile. The difference in affinity is substantial enough to outweigh the minor drawbacks in hERG and Pgp.
Output:
0
2025-04-17 18:58:31,545 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Step-by-step comparison:**
1. **MW:** Both ligands (351.535 and 363.849 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (52.65) is significantly better than Ligand B (72.28). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (2.508 and 1.824), falling within the 1-3 optimal range. Ligand A is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 3 HBA, while Ligand B has 6. Ligand A is preferable here, as fewer HBA generally leads to better permeability.
6. **QED:** Both ligands have good QED scores (0.658 and 0.877), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Both ligands have acceptable DILI risk (7.871 and 76.076). Ligand A is significantly better.
8. **BBB:** Ligand A (83.288) has a better BBB percentile than Ligand B (57.193). While not a primary concern for a cardiovascular target, higher BBB is generally a positive attribute.
9. **Caco-2:** Both have negative Caco-2 values (-4.786 and -4.64). This is unusual and suggests poor permeability *in vitro*. However, the values are very similar.
10. **Solubility:** Both have negative solubility values (-2.29 and -3.04). This is also unusual and suggests poor aqueous solubility. Ligand B is slightly worse.
11. **hERG:** Ligand A (0.67) has a lower hERG risk than Ligand B (0.241). This is a significant advantage, as hERG inhibition can lead to cardiotoxicity.
12. **Cl_mic:** Ligand A (71.968) has a higher microsomal clearance than Ligand B (29.134). This means Ligand B is more metabolically stable, which is desirable.
13. **t1/2:** Ligand A (-9.662) has a negative half-life, which is not possible. Ligand B (0.493) has a very short half-life. This is a major drawback for both.
14. **Pgp:** Both have very low Pgp efflux liability (0.085 and 0.08).
15. **Binding Affinity:** Ligand B (-7.0) has a slightly better binding affinity than Ligand A (-6.5). This is a 0.5 kcal/mol difference, which is significant, but may not outweigh other ADME concerns.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has better logP and TPSA, similar Pgp, and slightly worse affinity. The hERG risk is also much lower for Ligand A. The biggest drawback for both is the poor *in vitro* permeability (Caco-2) and solubility. However, the negative half-life for Ligand A is a deal-breaker.
**Conclusion:**
Despite the slightly better affinity of Ligand B, the superior DILI, hERG, TPSA, and more reasonable (though still problematic) half-life of Ligand A make it the more promising candidate. The negative half-life of Ligand A is a significant concern, but can be addressed with structural modifications. The poor solubility and permeability are shared concerns that would require formulation strategies.
Output:
1
2025-04-17 18:58:31,545 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Ligand A (342.483 Da) is well within the ideal range (200-500 Da). Ligand B (371.825 Da) is also acceptable. No clear advantage here.
2. **TPSA:** Ligand A (40.62) is excellent, well below the 140 threshold and favorable for absorption. Ligand B (114.35) is higher, but still potentially acceptable, though less optimal. Ligand A is better.
3. **logP:** Ligand A (2.987) is optimal (1-3). Ligand B (-0.539) is significantly lower, potentially causing permeability issues. Ligand A is much better.
4. **HBD:** Ligand A (0) is ideal. Ligand B (3) is acceptable, but higher HBD can sometimes reduce permeability. Ligand A is better.
5. **HBA:** Ligand A (2) is good. Ligand B (6) is higher, potentially impacting permeability. Ligand A is better.
6. **QED:** Both ligands (A: 0.582, B: 0.595) are above the 0.5 threshold, indicating good drug-like properties. No significant difference.
7. **DILI:** Ligand A (21.055) has a much lower DILI risk than Ligand B (57.348). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (71.927) shows good BBB penetration, while Ligand B (59.984) is lower. Given ADRB2 is a GPCR, BBB penetration is a consideration, favoring Ligand A.
9. **Caco-2:** Ligand A (-4.71) and Ligand B (-5.448) are both negative, which is unusual and suggests poor permeability in this assay. However, the values are close.
10. **Solubility:** Ligand A (-2.809) and Ligand B (-2.764) are both very poor. Solubility is a concern for both, but not a deciding factor.
11. **hERG:** Both ligands have low hERG inhibition risk (A: 0.415, B: 0.125). Ligand B is slightly better here, but the difference is small.
12. **Cl_mic:** Ligand A (68.039) has a higher microsomal clearance than Ligand B (0.953), indicating lower metabolic stability. Ligand B is significantly better.
13. **t1/2:** Ligand A (-32.506) has a negative in vitro half-life, which is highly problematic. Ligand B (24.549) is positive and reasonable. Ligand B is much better.
14. **Pgp:** Ligand A (0.239) has lower P-gp efflux than Ligand B (0.037), which is favorable for bioavailability. Ligand A is better.
15. **Binding Affinity:** Both ligands have very similar binding affinities (A: -6.7 kcal/mol, B: -5.7 kcal/mol). Ligand A has a 1 kcal/mol advantage.
**Overall Assessment:**
Ligand A has a significant advantage in terms of TPSA, logP, HBD, HBA, DILI risk, and Pgp efflux. It also has a slightly better binding affinity and BBB penetration. However, Ligand B has a much better metabolic stability (lower Cl_mic) and a positive in vitro half-life, which are crucial for *in vivo* efficacy. The poor solubility of both compounds is a concern, but can be addressed with formulation strategies. The negative half-life of Ligand A is a major red flag.
Considering the balance of properties, and prioritizing metabolic stability and half-life for a GPCR target, I favor Ligand B.
Output:
0
2025-04-17 18:58:31,545 - INFO - Batch 76 complete. Total preferences: 1216
2025-04-17 18:58:31,545 - INFO - Processing batch 77/512...
2025-04-17 18:59:22,796 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (338.411) is slightly lower, which could be advantageous for permeability.
2. **TPSA:** Ligand B (51.66) is significantly better than Ligand A (75.19). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (1.169) is within the optimal range, while Ligand B (3.268) is towards the higher end. While still acceptable, the higher logP of Ligand B could potentially lead to off-target interactions or solubility issues.
4. **HBD:** Ligand A (1) is preferable to Ligand B (0). Having at least one HBD can improve solubility.
5. **HBA:** Ligand A (4) and Ligand B (5) are both acceptable.
6. **QED:** Both ligands have similar QED values (0.79 and 0.743), indicating good drug-likeness.
7. **DILI:** Ligand B (29.042) has a much lower DILI risk than Ligand A (49.942), a significant advantage.
8. **BBB:** Ligand B (88.057) has a higher BBB penetration score than Ligand A (58.007). While not critical for a cardiovascular target, it's not a negative.
9. **Caco-2:** Both ligands have similar, poor Caco-2 permeability (-4.755 and -4.72). This is a concern for oral bioavailability for both.
10. **Solubility:** Ligand A (-1.957) has slightly better solubility than Ligand B (-2.203).
11. **hERG:** Ligand A (0.174) has a lower hERG risk than Ligand B (0.44), which is a positive.
12. **Cl_mic:** Ligand A (2.373) has significantly lower microsomal clearance than Ligand B (70.301), indicating better metabolic stability. This is a major advantage.
13. **t1/2:** Ligand A (-5.628) has a much longer in vitro half-life than Ligand B (-1.19), further supporting its better metabolic stability.
14. **Pgp:** Ligand A (0.037) has lower P-gp efflux liability than Ligand B (0.336), which is favorable for oral bioavailability.
15. **Binding Affinity:** Ligand B (-7.8) has a significantly stronger binding affinity than Ligand A (-6.7). This is a substantial advantage, potentially outweighing some of the ADME concerns.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, affinity, logP, TPSA, and Pgp are important. Ligand B excels in affinity, and its logP and TPSA are within acceptable ranges. While its Pgp efflux is slightly higher, the much stronger binding is a significant factor. The lower DILI risk for Ligand B is also a major benefit. Ligand A's better metabolic stability is attractive, but the substantial affinity difference favors Ligand B.
**Conclusion:**
Despite Ligand A's better metabolic stability and lower hERG risk, the significantly stronger binding affinity of Ligand B (-7.8 vs -6.7 kcal/mol) and lower DILI risk are compelling advantages that outweigh its slightly less favorable ADME profile. The difference in binding affinity is substantial enough to likely translate to a more potent drug.
Output:
0
2025-04-17 18:59:22,797 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [345.418, 73.99, 3.418, 3, 2, 0.75, 65.103, 64.831, -4.973, -4.577, 0.721, 39.913, 22.24, 0.325, -5.7]
**Ligand B:** [348.359, 119.49, 0.383, 2, 7, 0.774, 68.825, 50.64, -5.262, -2.109, 0.128, 12.382, 21.556, 0.024, -6.3]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). A (345.418) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** A (73.99) is significantly better than B (119.49). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** A (3.418) is optimal. B (0.383) is quite low, potentially hindering membrane permeability and bioavailability.
4. **HBD:** Both have acceptable HBD counts (A: 3, B: 2).
5. **HBA:** A (2) is better than B (7). Higher HBA can sometimes reduce permeability.
6. **QED:** Both are good (A: 0.75, B: 0.774), indicating drug-like properties.
7. **DILI:** Both have elevated DILI risk (A: 65.103, B: 68.825), but are still within a manageable range.
8. **BBB:** A (64.831) is better than B (50.64), though neither are particularly high, which is fine for a cardiovascular target.
9. **Caco-2:** A (-4.973) is better than B (-5.262). Higher values indicate better absorption.
10. **Solubility:** A (-4.577) is better than B (-2.109).
11. **hERG:** A (0.721) is better than B (0.128), indicating lower cardiotoxicity risk. This is *critical* for a cardiovascular target.
12. **Cl_mic:** A (39.913) is significantly better than B (12.382). Lower clearance means better metabolic stability.
13. **t1/2:** Similar (A: 22.24, B: 21.556).
14. **Pgp:** A (0.325) is better than B (0.024). Lower Pgp efflux is preferable for bioavailability.
15. **Affinity:** B (-6.3) is slightly better than A (-5.7), a difference of 0.6 kcal/mol.
**GPCR-specific priorities:** logP, TPSA, Pgp, and affinity are key. While B has slightly better affinity, A significantly outperforms it in logP, TPSA, and Pgp, and has a better hERG profile and metabolic stability. The affinity difference (0.6 kcal/mol) is not substantial enough to overcome the clear advantages of A in ADME properties, especially considering the cardiovascular context where minimizing off-target effects (like hERG inhibition) is crucial.
**Conclusion:**
Ligand A is the more promising drug candidate due to its superior ADME properties and acceptable binding affinity.
**Output:**
1
2025-04-17 18:59:22,797 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [367.495, 29.54, 4.726, 0, 4, 0.567, 96.549, 73.711, -4.748, -6.489, 0.527, 90.188, 49.332, 0.877, -6.7]
**Ligand B:** [351.447, 77.57, 2.145, 0, 6, 0.637, 42.846, 78.907, -4.371, -2.624, 0.123, 66.952, -17.317, 0.224, -5.4]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, Affinity, and BBB):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (351.447) is slightly lower, which is generally favorable.
2. **TPSA:** Ligand A (29.54) is excellent, well below the 140 threshold, and even better for potential CNS penetration. Ligand B (77.57) is higher, but still acceptable for a peripherally acting GPCR.
3. **logP:** Ligand A (4.726) is pushing the upper limit, potentially leading to solubility issues and off-target effects. Ligand B (2.145) is within the optimal range. This is a significant advantage for Ligand B.
4. **HBD/HBA:** Both have low HBD counts (0), which is good. Ligand B has a slightly higher HBA count (6 vs 4), but both are within acceptable limits.
5. **QED:** Both are reasonably good (0.567 and 0.637), indicating drug-like properties.
6. **DILI:** Ligand A (96.549) has a very high DILI risk, a major red flag. Ligand B (42.846) is much better, falling well below the concerning 60 percentile.
7. **BBB:** Both have good BBB penetration (73.711 and 78.907). While ADRB2 isn't exclusively a CNS target, some CNS exposure can occur, and higher BBB is generally favorable.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and difficult to interpret without further context. I will assume they represent low permeability.
9. **Solubility:** Ligand A (-6.489) has very poor predicted solubility, consistent with its high logP. Ligand B (-2.624) is better, but still not ideal.
10. **hERG:** Ligand A (0.527) has a slightly higher hERG risk than Ligand B (0.123).
11. **Cl_mic:** Ligand A (90.188) has higher microsomal clearance, indicating faster metabolism. Ligand B (66.952) is better, suggesting greater metabolic stability.
12. **t1/2:** Ligand B (-17.317) has a negative half-life, which is not possible. This is a data error. Ligand A (49.332) has a reasonable in vitro half-life.
13. **Pgp:** Ligand A (0.877) shows moderate P-gp efflux. Ligand B (0.224) has lower P-gp efflux, which is beneficial for bioavailability.
14. **Affinity:** Ligand A (-6.7 kcal/mol) has a significantly stronger binding affinity than Ligand B (-5.4 kcal/mol). This is a substantial advantage.
**Overall Assessment:**
Despite Ligand A's superior binding affinity, its extremely high DILI risk, poor solubility, and higher metabolic clearance are major concerns. The high logP also raises red flags. Ligand B, while having a weaker binding affinity, presents a much more favorable ADME-Tox profile, with significantly lower DILI risk, better solubility, and lower P-gp efflux. The t1/2 value for Ligand B is clearly erroneous and would need to be corrected.
Considering the balance of properties, and prioritizing a viable drug candidate, I would choose Ligand B. The affinity difference, while notable, can potentially be addressed through further optimization, while mitigating the severe liabilities of Ligand A would be far more challenging.
Output:
0
2025-04-17 18:59:22,797 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands (346.475 and 348.403 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (58.44) is significantly better than Ligand B (109.42). For a GPCR, lower TPSA is generally preferred for permeability, and Ligand A is well below the 140 threshold. Ligand B is approaching the upper limit.
3. **logP:** Ligand A (2.545) is within the optimal 1-3 range. Ligand B (0.767) is a bit low, potentially hindering permeation.
4. **HBD:** Ligand A (0) is ideal. Ligand B (3) is acceptable, but more donors can sometimes lead to issues.
5. **HBA:** Ligand A (4) is good. Ligand B (5) is also acceptable.
6. **QED:** Both ligands (0.795 and 0.703) have good drug-likeness scores, exceeding the 0.5 threshold. Ligand A is slightly better.
7. **DILI:** Ligand A (30.826) has a lower DILI risk than Ligand B (44.591), which is preferable.
8. **BBB:** Ligand A (89.066) shows better BBB penetration than Ligand B (67.701). This is a significant advantage for a GPCR target, even if not strictly CNS-focused, as it suggests better distribution.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.716 and -4.91). These values are difficult to interpret without knowing the scale, but the negative values suggest poor permeability.
10. **Solubility:** Ligand A (-2.588) has slightly better solubility than Ligand B (-1.953), though both are poor.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.381 and 0.064).
12. **Cl_mic:** Ligand A (55.424) has a higher microsomal clearance than Ligand B (18.909), indicating lower metabolic stability. This is a drawback for Ligand A.
13. **t1/2:** Ligand A (-12.868) has a shorter in vitro half-life than Ligand B (-11.96). Both are negative, making interpretation difficult, but Ligand B is slightly better.
14. **Pgp:** Ligand A (0.216) has lower P-gp efflux than Ligand B (0.013), which is favorable.
15. **Binding Affinity:** Ligand A (-6.5 kcal/mol) has a slightly better binding affinity than Ligand B (-4.6 kcal/mol). This is a substantial difference, and a >1.5 kcal/mol advantage often outweighs minor ADME concerns.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), TPSA, logP, Pgp, and affinity are key. Ligand A excels in TPSA, Pgp, and significantly in binding affinity. While its logP is good, Ligand B's is lower. Ligand A's metabolic stability (Cl_mic) is a concern, but the strong binding affinity is a major advantage that may compensate.
**Conclusion:**
Despite the slightly higher clearance of Ligand A, its superior TPSA, Pgp, BBB penetration, and, most importantly, its significantly better binding affinity make it the more promising candidate.
Output:
1
2025-04-17 18:59:22,798 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (351.491 and 350.507 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (78.51) is slightly higher than Ligand B (67.65). Both are below 140, supporting good oral absorption, but Ligand B is preferable.
3. **logP:** Both ligands have good logP values (1.833 and 2.106), falling within the optimal 1-3 range. Ligand B is slightly better.
4. **HBD:** Ligand A has 2 HBD, while Ligand B has 0. Lower HBD is generally preferred for better permeability, giving an edge to Ligand B.
5. **HBA:** Ligand A has 3 HBA, and Ligand B has 4. Both are acceptable (<=10), but Ligand A is slightly better.
6. **QED:** Ligand A (0.7) has a better QED score than Ligand B (0.597), indicating a more drug-like profile.
7. **DILI:** Ligand B (5.777%) has a significantly lower DILI risk than Ligand A (15.394%). This is a major advantage for Ligand B.
8. **BBB:** Ligand A (69.872%) has a slightly better BBB penetration potential than Ligand B (63.474%). While ADRB2 isn't strictly a CNS target, some CNS exposure can occur, making this a minor positive for Ligand A.
9. **Caco-2:** Ligand A (-5.134) has a worse Caco-2 permeability than Ligand B (-4.683). This suggests Ligand B will be absorbed better.
10. **Solubility:** Ligand A (-1.938) has worse aqueous solubility than Ligand B (-0.514). Better solubility is crucial for bioavailability, favoring Ligand B.
11. **hERG:** Ligand A (0.161) has a lower hERG inhibition liability than Ligand B (0.806). This is a significant safety advantage for Ligand A.
12. **Cl_mic:** Ligand B (8.015) has a lower microsomal clearance than Ligand A (15.263), indicating better metabolic stability. This is a major advantage for Ligand B.
13. **t1/2:** Ligand B (3.782) has a slightly longer in vitro half-life than Ligand A (3.166). This is a minor advantage for Ligand B.
14. **Pgp:** Ligand A (0.02) has a lower P-gp efflux liability than Ligand B (0.043). This is a slight advantage for Ligand A.
15. **Binding Affinity:** Ligand B (-6.9 kcal/mol) has a significantly stronger binding affinity than Ligand A (-3.3 kcal/mol). This is a substantial advantage, potentially outweighing some ADME concerns.
**Overall Assessment:**
Given the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), and considering the overall profile, Ligand B is the stronger candidate. The significantly improved binding affinity (-6.9 vs -3.3 kcal/mol) is a major driver. While Ligand A has better hERG and Pgp profiles, the lower DILI risk, better Caco-2 permeability, solubility, and metabolic stability of Ligand B are also very important. The slightly better BBB of Ligand A is not a deciding factor for a peripheral target like ADRB2.
Output:
0
2025-04-17 18:59:22,798 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [371.503, 87.74, 1.37, 2, 5, 0.598, 33.424, 71.307, -4.973, -2.684, 0.232, 57.634, -21.73, 0.033, -6.4]
**Ligand B:** [356.455, 95.59, 2.907, 3, 7, 0.628, 77.549, 57.115, -5.294, -3.74, 0.69, 35.401, 26.041, 0.209, -6.5]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, BBB, and affinity are key):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (356.455) is slightly lower, which isn't a significant advantage.
2. **TPSA:** Ligand A (87.74) is better than Ligand B (95.59), being closer to the <140 threshold for oral absorption.
3. **logP:** Ligand A (1.37) is optimal, while Ligand B (2.907) is also acceptable but edging towards the higher end.
4. **HBD/HBA:** Ligand A (2 HBD, 5 HBA) is preferable to Ligand B (3 HBD, 7 HBA) as it has fewer hydrogen bond donors and acceptors, potentially improving permeability.
5. **QED:** Both are good (A: 0.598, B: 0.628), indicating drug-like properties.
6. **DILI:** Ligand A (33.424) has a significantly lower DILI risk than Ligand B (77.549). This is a major advantage.
7. **BBB:** Ligand A (71.307) has a better BBB penetration percentile than Ligand B (57.115). While ADRB2 isn't *primarily* a CNS target, some CNS exposure is not necessarily detrimental and could offer off-target effects.
8. **Caco-2:** Ligand A (-4.973) and Ligand B (-5.294) are similar, indicating similar intestinal absorption.
9. **Solubility:** Ligand A (-2.684) is better than Ligand B (-3.74), indicating better aqueous solubility.
10. **hERG:** Ligand A (0.232) has a lower hERG risk than Ligand B (0.69).
11. **Cl_mic:** Ligand B (35.401) has a lower microsomal clearance than Ligand A (57.634), suggesting better metabolic stability.
12. **t1/2:** Ligand B (26.041) has a longer in vitro half-life than Ligand A (-21.73). This is a significant advantage.
13. **Pgp:** Ligand A (0.033) has a lower P-gp efflux liability than Ligand B (0.209), which is favorable for bioavailability.
14. **Affinity:** Both have very similar binding affinities (-6.4 and -6.5 kcal/mol), so this isn't a differentiating factor.
**Overall Assessment:**
Ligand A has a compelling profile. It excels in key areas like DILI risk, BBB penetration, solubility, hERG risk, and P-gp efflux. While Ligand B has better metabolic stability (lower Cl_mic and longer t1/2), the significantly lower DILI risk and better overall ADME profile of Ligand A outweigh this advantage. The binding affinities are comparable, so the ADME properties become the deciding factor.
Output:
1
2025-04-17 18:59:22,798 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [348.443, 78.87, 1.122, 2, 5, 0.722, 17.216, 53.16, -4.979, -1.191, 0.302, 23.637, 2.42, 0.086, -6.9]
**Ligand B:** [366.483, 91.57, 2.179, 3, 5, 0.614, 31.563, 62.233, -5.082, -3.357, 0.239, 39.018, 3.247, 0.075, -6.4]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). A (348.443) is slightly preferred.
2. **TPSA:** A (78.87) is better than B (91.57). Both are acceptable, but lower is better for permeability, and GPCRs benefit from good permeability.
3. **logP:** A (1.122) is good, B (2.179) is also acceptable, but trending towards the higher end. A is slightly preferred.
4. **HBD:** A (2) is better than B (3). Lower is generally preferred for permeability.
5. **HBA:** Both are equal (5), which is acceptable.
6. **QED:** A (0.722) is better than B (0.614), indicating a more drug-like profile.
7. **DILI:** A (17.216) is significantly better than B (31.563). This is a major advantage for A.
8. **BBB:** B (62.233) is better than A (53.16). While ADRB2 isn't necessarily a CNS target, some peripheral ADRB2 modulation can have CNS side effects, so some BBB penetration is not necessarily bad.
9. **Caco-2:** A (-4.979) is better than B (-5.082). Higher (less negative) is better.
10. **Solubility:** A (-1.191) is better than B (-3.357). Better solubility is always preferred.
11. **hERG:** Both are very low (0.302 and 0.239), indicating minimal hERG risk.
12. **Cl_mic:** A (23.637) is significantly better than B (39.018). Lower clearance means better metabolic stability.
13. **t1/2:** B (3.247) is better than A (2.42). Longer half-life is generally desirable.
14. **Pgp:** Both are very low (0.086 and 0.075), indicating minimal P-gp efflux.
15. **Affinity:** A (-6.9) is better than B (-6.4). A 0.5 kcal/mol difference in binding is significant and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand A has a clear advantage in several key areas: DILI risk, QED, metabolic stability (Cl_mic), solubility, and binding affinity. While Ligand B has a slightly better BBB penetration and in vitro half-life, the significant advantages of Ligand A in safety (DILI) and potency (affinity) are more important for a GPCR target like ADRB2. The TPSA and logP values are also more favorable for A.
Therefore, I would choose Ligand A.
Output:
1
2025-04-17 18:59:22,798 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (345.4 and 348.5 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (78.95) is slightly higher than Ligand B (67.43). Both are below the 140 A^2 threshold for oral absorption, but Ligand B is preferable due to being closer to the <90 A^2 target for GPCRs.
**3. logP:** Both ligands have good logP values (2.155 and 2.537), falling within the optimal 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability, but isn't a major concern.
**4. H-Bond Donors:** Ligand A has 1 HBD, and Ligand B has 2. Both are within the acceptable limit of <=5.
**5. H-Bond Acceptors:** Ligand A has 4 HBA, and Ligand B has 3. Both are within the acceptable limit of <=10.
**6. QED:** Both ligands have similar QED scores (0.848 and 0.82), indicating good drug-like properties.
**7. DILI:** Ligand B (23.071) has a significantly lower DILI risk than Ligand A (57.387). This is a substantial advantage for Ligand B.
**8. BBB:** Ligand A (83.094) has better BBB penetration than Ligand B (52.036). While ADRB2 is a cardiovascular target and CNS penetration isn't *essential*, some degree of BBB penetration can be advantageous for off-target effects and overall distribution.
**9. Caco-2 Permeability:** Both have negative Caco-2 values, which is unusual and indicates poor permeability. Ligand B (-4.966) is slightly worse than Ligand A (-4.64). This is a significant drawback for both.
**10. Aqueous Solubility:** Both ligands have very poor aqueous solubility (-2.637 and -2.691). This is a major concern for both, potentially hindering bioavailability.
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.335 and 0.193). This is positive for both.
**12. Microsomal Clearance:** Both ligands have similar microsomal clearance (24.841 and 24.804).
**13. In vitro Half-Life:** Ligand A (24.124) has a slightly longer half-life than Ligand B (-0.213).
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.051 and 0.091). This is favorable for both.
**15. Binding Affinity:** Ligand A (-6.9 kcal/mol) has a slightly better binding affinity than Ligand B (-6.5 kcal/mol). This 0.4 kcal/mol difference is noticeable but not overwhelmingly large.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity) and the general guidelines, Ligand B emerges as the more promising candidate. The significantly lower DILI risk is a major advantage, outweighing the slightly better BBB penetration and affinity of Ligand A. Both ligands suffer from poor Caco-2 permeability and aqueous solubility, which would need to be addressed through formulation strategies. The small difference in affinity isn't enough to overcome the safety concerns associated with Ligand A.
Output:
0
2025-04-17 18:59:22,798 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (345.487 and 361.511 Da) fall comfortably within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (61.44) is slightly higher than Ligand B (53.51). Both are below the 140 threshold for oral absorption, and acceptable for a cardiovascular target (not CNS). Ligand B is better.
3. **logP:** Both ligands have good logP values (2.004 and 3.095), falling within the optimal 1-3 range. Ligand B is slightly higher, which could be a minor concern for solubility, but overall both are acceptable.
4. **HBD:** Ligand A has 2 HBD, while Ligand B has 0. Lower HBD is generally preferred for permeability, giving a slight edge to Ligand B.
5. **HBA:** Ligand A has 3 HBA, and Ligand B has 4. Both are within the acceptable limit of 10. No significant difference.
6. **QED:** Ligand B (0.813) has a higher QED score than Ligand A (0.694), indicating a more drug-like profile. This is a positive for Ligand B.
7. **DILI:** Ligand A (10.275) has a significantly lower DILI risk than Ligand B (45.56). This is a major advantage for Ligand A. DILI is a critical safety concern.
8. **BBB:** Both ligands have good BBB penetration (71.307 and 77.743). Since ADRB2 is primarily a cardiovascular target, BBB penetration is not a primary concern, but higher is still slightly favorable. Ligand B is better.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.979 and -4.719), which is unusual and suggests poor permeability. This is a significant drawback for both.
10. **Solubility:** Both ligands have negative solubility values (-2.061 and -3.086), indicating very poor aqueous solubility. This is a significant concern for both.
11. **hERG:** Both ligands have low hERG inhibition liability (0.264 and 0.525), which is good. No clear advantage.
12. **Cl_mic:** Ligand A has a lower microsomal clearance (18.181) than Ligand B (66.378), suggesting better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A has a longer in vitro half-life (10.435 hours) than Ligand B (-12.121 hours). The negative value for Ligand B is concerning. This is a strong advantage for Ligand A.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.033 and 0.308), which is good. Ligand A is slightly better.
15. **Binding Affinity:** Ligand B (-6.6 kcal/mol) has a slightly better binding affinity than Ligand A (-6.3 kcal/mol). While a 0.3 kcal/mol difference isn't huge, it's a positive for Ligand B.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity) and general drug-like properties, Ligand A emerges as the more promising candidate. While Ligand B has slightly better affinity and BBB penetration, Ligand A has a significantly lower DILI risk, better metabolic stability (lower Cl_mic), and a longer half-life. The poor Caco-2 and solubility for both are concerning and would require formulation strategies, but the safety and PK advantages of Ligand A outweigh the slightly better affinity of Ligand B.
Output:
1
2025-04-17 18:59:22,798 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.45 and 340.406 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (58.64) is significantly better than Ligand B (69.73). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (4.22 and 3.464), falling within the 1-3 range. Ligand A is slightly higher, which *could* be a minor concern for solubility, but not a deal-breaker.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs generally improve membrane permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (5). Similar reasoning as HBD.
6. **QED:** Both ligands have acceptable QED values (0.863 and 0.761), indicating good drug-likeness. Ligand A is slightly better.
7. **DILI:** Ligand A (38.387) has a much lower DILI risk than Ligand B (71.113). This is a significant advantage for Ligand A.
8. **BBB:** Both ligands have reasonable BBB penetration, but Ligand B (76.735) is better than Ligand A (64.948). However, as ADRB2 is a cardiovascular target, BBB penetration is not a high priority.
9. **Caco-2:** Ligand A (-4.174) is better than Ligand B (-5.165). Higher Caco-2 permeability suggests better intestinal absorption.
10. **Solubility:** Ligand A (-4.614) is better than Ligand B (-4.223). Better solubility is always desirable.
11. **hERG:** Both ligands have similar hERG inhibition liabilities (0.705 and 0.918). Neither is particularly concerning.
12. **Cl_mic:** Ligand B (46.817) has significantly lower microsomal clearance than Ligand A (99.603), suggesting better metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand B (35.769) has a longer in vitro half-life than Ligand A (19.035). This is a significant advantage for Ligand B.
14. **Pgp:** Both ligands have similar Pgp efflux liabilities (0.154 and 0.236).
15. **Binding Affinity:** Both ligands have very similar binding affinities (-5.8 and -5.9 kcal/mol). The difference is negligible.
**Overall Assessment:**
Ligand A excels in properties related to absorption (TPSA, Caco-2, Solubility) and has a significantly lower DILI risk. However, Ligand B demonstrates superior metabolic stability (lower Cl_mic) and a longer half-life. Considering the ADRB2 target (cardiovascular), metabolic stability and duration of action are crucial. While Ligand A has a lower DILI risk, the difference isn't drastic enough to outweigh the benefits of Ligand B's improved pharmacokinetic profile.
Output:
0
2025-04-17 18:59:22,798 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (344.375 and 348.359 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand B (119.49) is better than Ligand A (132.89), being closer to the <140 threshold for good absorption. This is a slight advantage for B.
3. **logP:** Ligand A (-0.265) is slightly below the optimal 1-3 range, which could hinder permeability. Ligand B (0.383) is closer to the ideal range. Advantage B.
4. **HBD:** Ligand A (4) is slightly higher than Ligand B (2), but both are acceptable (<=5).
5. **HBA:** Ligand A (6) and Ligand B (7) are both within the acceptable range (<=10).
6. **QED:** Ligand B (0.774) has a better QED score than Ligand A (0.547), indicating a more drug-like profile. Advantage B.
7. **DILI:** Both ligands have similar DILI risk (69.872 and 68.825), and are both acceptable (<40 is good, >60 is high risk). No significant difference.
8. **BBB:** Ligand B (50.64) has a significantly higher BBB penetration percentile than Ligand A (28.073). While ADRB2 isn't strictly a CNS target, some CNS exposure can occur, and higher BBB is generally favorable. Advantage B.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.655 and -5.262). This is unusual and suggests poor permeability. However, the values are close, so this isn't a major differentiator.
10. **Solubility:** Both ligands have negative solubility values (-2.357 and -2.109). This is also concerning and suggests poor aqueous solubility. Again, values are close.
11. **hERG:** Both ligands have low hERG inhibition liability (0.112 and 0.128), which is good. No significant difference.
12. **Cl_mic:** Ligand A (-13.214) has a much lower (better) microsomal clearance than Ligand B (12.382), indicating greater metabolic stability. Advantage A.
13. **t1/2:** Ligand B (21.556) has a significantly longer in vitro half-life than Ligand A (8.95). Advantage B.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.008 and 0.024). No significant difference.
15. **Binding Affinity:** Ligand A (-7.5) has a slightly better binding affinity than Ligand B (-6.3). This is a 1.2 kcal/mol difference, which is significant. Advantage A.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP, TPSA, and BBB, while Ligand A has better metabolic stability (Cl_mic) and a slightly better binding affinity. The affinity difference is important, but the poor solubility and permeability (Caco-2) for both are concerning. However, the overall profile of Ligand B, with its better QED, BBB, and half-life, makes it slightly more promising despite the slightly weaker binding.
**Final Decision:**
0
2025-04-17 18:59:22,798 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [374.459, 98.94, 1.704, 0, 7, 0.639, 50.058, 80.419, -4.734, -3.024, 0.334, 72.685, -20.576, 0.146, -6.4]
**Ligand B:** [344.499, 49.41, 3.276, 1, 2, 0.778, 16.557, 78.868, -4.753, -3.324, 0.428, 57.686, -9.73, 0.182, -6.1]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal 200-500 Da range. Ligand B (344.499 Da) is slightly smaller, which could be a minor advantage for permeability.
2. **TPSA:** Ligand A (98.94) is higher than Ligand B (49.41). Ligand B is significantly better here, well below the 140 threshold for oral absorption and more favorable for GPCRs.
3. **logP:** Ligand A (1.704) is within the optimal range, while Ligand B (3.276) is at the higher end, but still acceptable.
4. **HBD/HBA:** Ligand A has 0 HBD and 7 HBA, while Ligand B has 1 HBD and 2 HBA. Both are reasonable, but Ligand B is slightly more balanced.
5. **QED:** Both have good QED scores (0.639 and 0.778), indicating good drug-like properties. Ligand B is slightly better.
6. **DILI:** Ligand A (50.058) has a higher DILI risk than Ligand B (16.557). This is a significant advantage for Ligand B.
7. **BBB:** Both have good BBB penetration (80.419 and 78.868). Not a primary concern for a cardiovascular target, but still positive.
8. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability.
9. **Solubility:** Both have negative solubility values, indicating poor solubility.
10. **hERG:** Both have low hERG risk (0.334 and 0.428).
11. **Cl_mic:** Ligand A (72.685) has higher microsomal clearance than Ligand B (57.686), suggesting faster metabolism and potentially lower *in vivo* exposure.
12. **t1/2:** Ligand A (-20.576) has a more negative half-life, indicating shorter half-life, while Ligand B (-9.73) is better.
13. **Pgp:** Both have low Pgp efflux liability (0.146 and 0.182).
14. **Affinity:** Both have very similar binding affinities (-6.4 and -6.1 kcal/mol). The difference is negligible.
**Overall Assessment:**
Ligand B is the better candidate. While both ligands have similar binding affinities, Ligand B demonstrates superior ADME properties. Specifically, it has a significantly lower DILI risk, better TPSA, and a more favorable metabolic profile (lower Cl_mic, better t1/2). The slightly higher logP of Ligand B is not a major concern. The negative Caco-2 and solubility values are concerning for both, but can be addressed with formulation strategies.
Output:
0
2025-04-17 18:59:22,799 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's systematically compare Ligand A and Ligand B against the provided guidelines, keeping in mind the GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key).
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand B (356.457 Da) is slightly lower, which can be advantageous for permeability.
2. **TPSA:** Both are reasonably low. Ligand B (49.41) is better than Ligand A (55.4), falling comfortably below the 140 A^2 threshold for oral absorption.
3. **logP:** Both ligands have acceptable logP values, but Ligand B (3.031) is closer to the optimal range (1-3) than Ligand A (4.68). Ligand A's higher logP could lead to solubility issues and off-target interactions.
4. **HBD/HBA:** Both have 1 HBD, which is good. Ligand B has 2 HBA, while Ligand A has 4. Both are within acceptable limits, but Ligand B is slightly better.
5. **QED:** Both have good QED scores (A: 0.601, B: 0.744), indicating good drug-like properties. Ligand B is better.
6. **DILI:** Ligand B (29.042) has a significantly lower DILI risk than Ligand A (87.01). This is a major advantage for Ligand B.
7. **BBB:** Ligand B (96.084) shows excellent BBB penetration, while Ligand A (66.188) is moderate. While ADRB2 isn't exclusively a CNS target, good BBB penetration can be beneficial for overall distribution and potentially reduce off-target effects.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale isn't defined, so it's hard to interpret.
9. **Solubility:** Both have negative solubility values, which is also unusual. Again, the scale is undefined.
10. **hERG:** Both ligands have low hERG inhibition liability (A: 0.612, B: 0.729), which is good.
11. **Cl_mic:** Ligand B (18.571) has significantly lower microsomal clearance than Ligand A (91.695), indicating better metabolic stability.
12. **t1/2:** Ligand B (-13.016) has a negative half-life, which is concerning. Ligand A (54.654) has a reasonable in vitro half-life.
13. **Pgp:** Ligand A (0.659) has lower P-gp efflux liability than Ligand B (0.314), which is preferable.
14. **Affinity:** Ligand A (-6.4 kcal/mol) has slightly better binding affinity than Ligand B (-5.8 kcal/mol). This is a 0.6 kcal/mol difference, which is not a huge advantage.
**Overall Assessment:**
Despite Ligand A having slightly better affinity and Pgp efflux, Ligand B is the stronger candidate. The significantly lower DILI risk, better logP, lower TPSA, better metabolic stability (lower Cl_mic), and excellent BBB penetration outweigh the small difference in binding affinity. The negative half-life of Ligand B is a concern, but could be addressed with structural modifications. Ligand A's higher logP and DILI risk are more difficult to mitigate.
**Output:**
0
2025-04-17 18:59:22,799 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (343.354 and 350.478 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (78.79) is higher than Ligand B (49.41). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B has a significant advantage.
3. **logP:** Both ligands (2.329 and 2.912) are within the optimal 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability, but not dramatically so.
4. **HBD:** Ligand A (3) is higher than Ligand B (1). Lower HBD is generally preferred for permeability. Ligand B is better.
5. **HBA:** Ligand A (4) is higher than Ligand B (2). Similar to HBD, lower HBA is preferred. Ligand B is better.
6. **QED:** Ligand B (0.847) has a substantially higher QED score than Ligand A (0.641), indicating a more drug-like profile. This is a significant advantage for Ligand B.
7. **DILI:** Ligand B (17.449) has a much lower DILI risk than Ligand A (44.63). This is a crucial advantage, as minimizing liver toxicity is paramount.
8. **BBB:** Ligand B (93.253) has a much higher BBB penetration score than Ligand A (29.12). While ADRB2 isn't *primarily* a CNS target, some CNS exposure can occur, and higher BBB is generally favorable.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.31 and -4.915), which is unusual and suggests poor permeability. However, the values are very close, so this isn't a major differentiator.
10. **Solubility:** Ligand B (-4.042) has better solubility than Ligand A (-2.913). Better solubility aids in formulation and bioavailability.
11. **hERG:** Ligand B (0.655) has a slightly higher hERG risk than Ligand A (0.408), but both are relatively low.
12. **Cl_mic:** Ligand A (8.688) has significantly lower microsomal clearance than Ligand B (25.1). Lower clearance indicates greater metabolic stability, which is highly desirable.
13. **t1/2:** Ligand B (8.432) has a longer in vitro half-life than Ligand A (-5.493). This is a significant advantage, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand B (0.098) has a lower P-gp efflux liability than Ligand A (0.068). Lower P-gp efflux improves bioavailability.
15. **Binding Affinity:** Ligand A (-6.0) has a slightly better binding affinity than Ligand B (-4.4). However, the difference is 1.6 kcal/mol, which is not substantial enough to outweigh the numerous ADME advantages of Ligand B.
**Overall Assessment:**
Ligand B consistently outperforms Ligand A across most critical ADME properties, including DILI risk, BBB penetration, QED, solubility, and half-life. While Ligand A has slightly better binding affinity and metabolic stability, the overall profile of Ligand B is far more favorable for drug development. The lower DILI risk and better predicted bioavailability are particularly compelling.
Output:
0
2025-04-17 18:59:22,799 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (360.483 and 347.419 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (65.54) is better than Ligand B (100.35). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (1.095) is slightly better than Ligand B (0.661) as it is closer to the optimal 1-3 range. Ligand B is a bit low, potentially impacting permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally favors permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (6). Lower HBA generally favors permeability.
6. **QED:** Both ligands are similar (0.799 vs 0.762), indicating good drug-likeness.
7. **DILI:** Ligand A (30.012) is significantly better than Ligand B (60.721). This is a crucial advantage, as lower DILI risk is highly desirable.
8. **BBB:** Both are around 50, which is not a priority for a cardiovascular target.
9. **Caco-2:** Both are negative, indicating poor permeability.
10. **Solubility:** Both are negative, indicating poor solubility.
11. **hERG:** Ligand A (0.257) is much better than Ligand B (0.046). Lower hERG inhibition is critical for avoiding cardiotoxicity, especially for a cardiovascular target.
12. **Cl_mic:** Ligand A (-4.071) is much better than Ligand B (6.106). Lower clearance indicates better metabolic stability.
13. **t1/2:** Ligand B (-5.399) is better than Ligand A (-2.249). Longer half-life is generally preferred.
14. **Pgp:** Both are very low, indicating high efflux.
15. **Binding Affinity:** Ligand B (-6.5 kcal/mol) is significantly better than Ligand A (-4.4 kcal/mol). This is a substantial difference in potency (a 2.1 kcal/mol advantage).
**Overall Assessment:**
Ligand B has a much stronger binding affinity, which is a major advantage. However, Ligand A has significantly better DILI, hERG, and Cl_mic profiles, all critical for a safe and effective cardiovascular drug. The affinity difference is substantial, but the safety profile of Ligand A is far superior. Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity), the affinity advantage of Ligand B is important. However, the safety concerns with Ligand B (DILI, hERG) are too significant to ignore.
Therefore, I favor Ligand A.
Output:
1
2025-04-17 18:59:22,799 - INFO - Here's a step-by-step comparison of the two ligands, followed by my final decision:
**Ligand A:** [346.431, 59.71, 0.519, 0, 6, 0.81, 35.363, 82.009, -4.66, 0.071, 0.633, 35.107, 9.764, 0.17, -7]
**Ligand B:** [348.487, 49.85, 2.468, 0, 3, 0.475, 17.255, 73.75, -4.248, -2.548, 0.545, 70.259, 6.305, 0.154, -5.5]
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). A is 346.431, B is 348.487 - very similar.
**2. TPSA:** Ligand A (59.71) is slightly higher than Ligand B (49.85), both are below the 140 A^2 threshold for oral absorption, but B is better.
**3. logP:** Ligand A (0.519) is quite low, potentially hindering permeability. Ligand B (2.468) is within the optimal range (1-3). This is a significant advantage for B.
**4. H-Bond Donors:** Both have 0 HBD, which is good.
**5. H-Bond Acceptors:** Ligand A has 6 HBA, Ligand B has 3. Both are acceptable, but B is preferable.
**6. QED:** Ligand A (0.81) has a much better QED score than Ligand B (0.475), indicating better overall drug-likeness.
**7. DILI:** Ligand A (35.363) has a higher DILI risk than Ligand B (17.255). B is significantly better here.
**8. BBB:** Ligand A (82.009) has a better BBB penetration percentile than Ligand B (73.75).
**9. Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. A (-4.66) is worse than B (-4.248).
**10. Solubility:** Ligand A (0.071) has extremely poor solubility, while Ligand B (-2.548) is also poor, but less so.
**11. hERG:** Both have low hERG inhibition risk, with A (0.633) being slightly better than B (0.545).
**12. Cl_mic:** Ligand A (35.107) has lower microsomal clearance than Ligand B (70.259), indicating better metabolic stability.
**13. t1/2:** Ligand A (9.764) has a longer in vitro half-life than Ligand B (6.305).
**14. Pgp:** Both have very low Pgp efflux liability, with A (0.17) being slightly lower than B (0.154).
**15. Binding Affinity:** Ligand A (-7 kcal/mol) has a significantly stronger binding affinity than Ligand B (-5.5 kcal/mol). This is a substantial advantage for A.
**GPCR-Specific Considerations:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP and has a good TPSA. Ligand A has a superior binding affinity and better BBB penetration. However, the very poor solubility and low logP of Ligand A are major concerns.
**Overall Assessment:**
While Ligand A has a significantly better binding affinity and QED, its extremely poor solubility and low logP are major drawbacks. These properties will likely lead to poor bioavailability. Ligand B, while having a weaker affinity, has a much more favorable logP, better solubility (though still poor), and a lower DILI risk. The difference in affinity (-1.5 kcal/mol) *might* be overcome with optimization, but the ADME properties of Ligand A are too problematic.
Therefore, I believe Ligand B is the more viable drug candidate.
0
2025-04-17 18:59:22,799 - INFO - Batch 77 complete. Total preferences: 1232
2025-04-17 18:59:22,799 - INFO - Processing batch 78/512...
2025-04-17 19:00:13,619 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (356.8 and 347.4 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (48.67) is significantly better than Ligand B (109.24). For a GPCR, lower TPSA is generally preferred for better permeability. Ligand B is quite high, potentially hindering absorption.
**3. logP:** Ligand A (4.811) is high, but still within a potentially acceptable range. Ligand B (-0.096) is *too* low, suggesting poor membrane permeability and potential issues with bioavailability.
**4. H-Bond Donors:** Both have acceptable HBD counts (0 and 1, respectively).
**5. H-Bond Acceptors:** Ligand A (4) is better than Ligand B (7). Lower HBA is generally preferred for permeability.
**6. QED:** Both ligands have good QED scores (0.629 and 0.782), indicating good drug-like properties.
**7. DILI:** Both ligands have similar and acceptable DILI risk (75.3 and 73.1 percentile).
**8. BBB:** Ligand A (64.1) is better than Ligand B (46.3). While ADRB2 is a cardiovascular target, some CNS penetration can be acceptable and even beneficial for understanding off-target effects.
**9. Caco-2:** Both have negative Caco-2 values, which is unusual. I will interpret this as very poor permeability.
**10. Solubility:** Ligand A (-6.04) is worse than Ligand B (-1.84). Solubility is a concern for both, but less so for Ligand B.
**11. hERG:** Ligand A (0.593) is much better than Ligand B (0.157). hERG inhibition is a critical safety concern, and Ligand A has a significantly lower risk.
**12. Cl_mic:** Ligand B (54.96) has a much lower microsomal clearance than Ligand A (103.92), indicating better metabolic stability.
**13. t1/2:** Ligand A (104.83) has a much longer in vitro half-life than Ligand B (-40.1). This is a significant advantage, potentially allowing for less frequent dosing.
**14. Pgp:** Ligand A (0.741) is better than Ligand B (0.044). Lower P-gp efflux is desirable for improved bioavailability.
**15. Binding Affinity:** Ligand B (-6.2 kcal/mol) has a significantly stronger binding affinity than Ligand A (-3.2 kcal/mol). This is a substantial advantage.
**Overall Assessment:**
Ligand B has a significantly better binding affinity and metabolic stability. However, its very low logP and high TPSA are major drawbacks, likely leading to poor permeability and bioavailability. Ligand A has a more balanced profile, with acceptable (though not ideal) physicochemical properties, a lower hERG risk, and a longer half-life. While its binding affinity is weaker, the better ADME properties and safety profile make it a more promising starting point for optimization. The poor Caco-2 values for both are concerning and would require further investigation.
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), and the importance of balancing ADME properties with potency, I believe Ligand A is the more viable candidate.
Output:
1
2025-04-17 19:00:13,619 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.403 and 347.459 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (120.25) is higher than Ligand B (74.43). For a cardiovascular GPCR like ADRB2, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B is significantly better.
3. **logP:** Ligand A (1.522) and Ligand B (2.107) are both within the optimal 1-3 range. Ligand B is slightly better.
4. **HBD:** Ligand A (4) and Ligand B (2) are both acceptable, under the threshold of 5. Ligand B is better.
5. **HBA:** Ligand A (5) and Ligand B (3) are both acceptable, under the threshold of 10. Ligand B is better.
6. **QED:** Ligand B (0.793) has a significantly higher QED score than Ligand A (0.576), indicating a more drug-like profile. This is a substantial advantage for Ligand B.
7. **DILI:** Ligand A (41.954) has a slightly higher DILI risk than Ligand B (25.669), but both are below the concerning threshold of 60. Ligand B is better.
8. **BBB:** Ligand A (18.961) has a very low BBB penetration, while Ligand B (70.803) is quite high. While ADRB2 isn't a CNS target, some peripheral exposure can be undesirable, but this is a minor consideration.
9. **Caco-2:** Ligand A (-5.391) and Ligand B (-4.758) are both negative, indicating poor permeability. This is a concern for both, but the values are similar.
10. **Solubility:** Both ligands have very poor aqueous solubility (-2.908 and -2.951). This is a significant drawback for both.
11. **hERG:** Ligand A (0.138) has a lower hERG risk than Ligand B (0.393), which is a positive for Ligand A.
12. **Cl_mic:** Ligand A (16.727) has a much lower microsomal clearance than Ligand B (38.189), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand B (-11.978) has a much longer in vitro half-life than Ligand A (-1.188). This is a substantial advantage for Ligand B.
14. **Pgp:** Ligand A (0.025) has a lower Pgp efflux liability than Ligand B (0.037), which is a slight advantage for Ligand A.
15. **Binding Affinity:** Ligand A (-6.6) has a slightly better binding affinity than Ligand B (-6.2), but the difference is relatively small (0.4 kcal/mol).
**Overall Assessment:**
Ligand B demonstrates a superior overall profile, particularly regarding drug-likeness (QED), BBB penetration, and in vitro half-life. While Ligand A has better metabolic stability (lower Cl_mic) and hERG inhibition liability, the advantages of Ligand B in key ADME properties and drug-likeness outweigh these benefits. The slightly better affinity of Ligand A isn't enough to overcome its poorer ADME profile. The lower TPSA and better QED of Ligand B are particularly attractive for a GPCR target.
Output:
0
2025-04-17 19:00:13,619 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [348.422, 67.23, 1.568, 1, 4, 0.822, 51.648, 82.435, -4.761, -2.581, 0.41, 22.258, -7.667, 0.128, -6.3]
**Ligand B:** [351.403, 101.74, 1.292, 1, 6, 0.743, 48.391, 67.507, -4.523, -1.689, 0.119, 54.381, -4.142, 0.062, -6.6]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). A is 348.422, B is 351.403 - very similar.
2. **TPSA:** A (67.23) is significantly better than B (101.74). For a GPCR, keeping TPSA lower is beneficial for permeability.
3. **logP:** Both are good (around 1.3-1.6), falling within the optimal 1-3 range. B is slightly lower.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** A has 4, B has 6. A is preferable, as lower HBA generally improves permeability.
6. **QED:** A (0.822) is better than B (0.743), indicating a more drug-like profile.
7. **DILI:** Both are acceptable, with A (51.648) being slightly higher than B (48.391), but both are below the 60% threshold.
8. **BBB:** A (82.435) is significantly better than B (67.507). This is a crucial factor for GPCRs, even if not CNS-focused, as it suggests better distribution.
9. **Caco-2:** Both are negative, indicating poor permeability. A (-4.761) is slightly worse than B (-4.523).
10. **Solubility:** Both are negative, indicating poor solubility. B (-1.689) is slightly better than A (-2.581).
11. **hERG:** Both are very low (0.41 and 0.119), indicating minimal hERG inhibition risk. B is slightly better.
12. **Cl_mic:** A (22.258) is significantly better than B (54.381), indicating better metabolic stability.
13. **t1/2:** A (-7.667) is better than B (-4.142), suggesting a longer half-life.
14. **Pgp:** Both are very low (0.128 and 0.062), indicating minimal P-gp efflux. B is slightly better.
15. **Affinity:** B (-6.6) is slightly better than A (-6.3), but the difference is relatively small (0.3 kcal/mol).
**GPCR-specific priorities:** For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, BBB, and affinity.
**Overall Assessment:**
Ligand A clearly outperforms Ligand B in several critical areas: TPSA, QED, BBB, metabolic stability (Cl_mic), and half-life. While Ligand B has a slightly better affinity and Pgp efflux, the differences are minor. The superior TPSA, BBB, and metabolic stability of Ligand A are more important for a GPCR target, potentially leading to better distribution and a more favorable pharmacokinetic profile. The slightly better affinity of B is unlikely to overcome the significant advantages of A in other key parameters.
Output:
1
2025-04-17 19:00:13,619 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A: [341.367, 99.69, 0.796, 2, 6, 0.838, 53.005, 26.716, -4.904, -2.316, 0.233, -17.033, -14.33, 0.01, -7.8]**
**Ligand B: [343.431, 80.12, 1.546, 1, 5, 0.69, 39.899, 69.407, -4.883, -3.305, 0.123, 45.417, -10.454, 0.102, -5.6]**
Here's a breakdown, considering the GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal range (200-500 Da). A is 341.37, B is 343.43. No significant difference.
2. **TPSA:** A is 99.69, B is 80.12. B is better, falling comfortably under the 140 threshold for oral absorption and closer to the ideal for GPCRs.
3. **logP:** A is 0.796, B is 1.546. B is better, being closer to the optimal 1-3 range. A is a bit low and could suffer from permeability issues.
4. **HBD:** A is 2, B is 1. B is slightly better. Fewer HBDs generally improve permeability.
5. **HBA:** A is 6, B is 5. B is slightly better.
6. **QED:** A is 0.838, B is 0.69. A is significantly better, indicating a more drug-like profile.
7. **DILI:** A is 53.005, B is 39.899. B is better, lower risk of liver injury.
8. **BBB:** A is 26.716, B is 69.407. B is *much* better, indicating significantly higher potential for brain penetration (though not crucial for a cardiovascular target, it's a positive).
9. **Caco-2:** Both are negative (-4.904 and -4.883), indicating poor permeability. This is a concern for both.
10. **Solubility:** Both are negative (-2.316 and -3.305), indicating poor solubility. This is a concern for both.
11. **hERG:** Both are very low (0.233 and 0.123), indicating very low cardiotoxicity risk. Excellent for both.
12. **Cl_mic:** A is -17.033, B is 45.417. A is *much* better, indicating significantly higher metabolic stability.
13. **t1/2:** A is -14.33, B is -10.454. A is better, suggesting a longer half-life.
14. **Pgp:** A is 0.01, B is 0.102. A is better, indicating lower P-gp efflux.
15. **Affinity:** A is -7.8 kcal/mol, B is -5.6 kcal/mol. A is *significantly* better, with a 2.2 kcal/mol advantage in binding. This is a substantial difference.
**Overall Assessment:**
Ligand A has a significantly better binding affinity, excellent metabolic stability, and lower P-gp efflux. However, Ligand B has better TPSA, logP, BBB penetration, and DILI risk. Both have poor Caco-2 and solubility.
Given the GPCR target and the substantial affinity advantage of Ligand A (-7.8 vs -5.6 kcal/mol), I believe this outweighs the slightly less favorable ADME properties of Ligand A. The strong binding is likely to be more easily optimized through further medicinal chemistry efforts than significantly improving the affinity of Ligand B. The better metabolic stability and lower P-gp efflux of Ligand A are also important advantages.
Output:
1
2025-04-17 19:00:13,619 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (344.415 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (87.46) is better than Ligand B (64.34). Both are below 140, but Ligand B is closer to the optimal range for GPCRs.
3. **logP:** Ligand B (3.876) is higher than Ligand A (0.423). While logP of 0.423 for Ligand A is quite low and may hinder permeation, 3.876 for Ligand B is approaching the upper limit and could cause solubility issues.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1). Both are acceptable.
5. **HBA:** Ligand A (5) is lower than Ligand B (7). This is favorable for Ligand A, as fewer HBA generally improves permeability.
6. **QED:** Ligand B (0.751) has a significantly better QED score than Ligand A (0.476), indicating a more drug-like profile.
7. **DILI:** Ligand A (31.136) has a much lower DILI risk than Ligand B (84.335). This is a significant advantage for Ligand A.
8. **BBB:** Ligand B (69.252) has a better BBB penetration score than Ligand A (35.052). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be beneficial.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.721 and -4.928), which is unusual and suggests poor permeability.
10. **Solubility:** Ligand A (-2.149) has slightly better solubility than Ligand B (-3.806), although both are poor.
11. **hERG:** Ligand A (0.078) has a much lower hERG risk than Ligand B (0.759). This is a critical advantage for Ligand A.
12. **Cl_mic:** Ligand A (20.228) has a lower microsomal clearance than Ligand B (48.176), indicating better metabolic stability.
13. **t1/2:** Ligand B (20.024) has a positive in vitro half-life, whereas Ligand A (-16.871) has a negative one. This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.03) has a much lower P-gp efflux liability than Ligand B (0.701). This is a significant advantage for Ligand A.
15. **Affinity:** Ligand B (-7.4 kcal/mol) has a significantly better binding affinity than Ligand A (-6.0 kcal/mol). This is a substantial advantage for Ligand B and could potentially outweigh some of its ADME drawbacks.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in affinity and has a reasonable logP and TPSA. Ligand A has a poor logP, but better TPSA, Pgp, DILI, and hERG.
**Overall Assessment:**
While Ligand B has a significantly better binding affinity, the combination of Ligand A's superior safety profile (lower DILI and hERG), better metabolic stability (lower Cl_mic), and lower P-gp efflux is compelling. The poor logP of Ligand A is a concern, but the substantial affinity advantage of Ligand B is difficult to ignore. However, the negative Caco-2 values for both are concerning. Given the balance, the stronger binding affinity of Ligand B is the deciding factor.
Output:
0
2025-04-17 19:00:13,619 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [350.419, 120.32 , -0.156, 3. , 5. , 0.473, 29.042, 47.305, -5.363, -1.847, 0.186, 3.784, -0.29 , 0.009, -7.8 ]
**Ligand B:** [426.242, 68.02 , 4.258, 1. , 5. , 0.634, 90.733, 70.997, -4.468, -5.355, 0.393, 35.624, 12.191, 0.345, -6.3 ]
**Step-by-step comparison:**
1. **MW:** Ligand A (350.419 Da) is well within the ideal range. Ligand B (426.242 Da) is at the upper end, but still acceptable.
2. **TPSA:** Ligand A (120.32) is good for oral absorption, while Ligand B (68.02) is excellent.
3. **logP:** Ligand A (-0.156) is a bit low, potentially hindering permeation. Ligand B (4.258) is high, potentially causing solubility and off-target issues.
4. **HBD:** Ligand A (3) is good. Ligand B (1) is also good.
5. **HBA:** Both ligands (5) are acceptable.
6. **QED:** Ligand A (0.473) is borderline, while Ligand B (0.634) is better, indicating a more drug-like profile.
7. **DILI:** Ligand A (29.042) has a very favorable DILI risk. Ligand B (90.733) has a significantly higher DILI risk.
8. **BBB:** Ligand A (47.305) is moderate, while Ligand B (70.997) is quite good. Since this is a GPCR, BBB penetration is a consideration, though not paramount for ADRB2 (cardiovascular).
9. **Caco-2:** Both ligands have negative values, which is unusual. Assuming these are logP-like scales, lower values indicate poorer permeability. Ligand A (-5.363) appears worse than Ligand B (-4.468).
10. **Solubility:** Ligand A (-1.847) is poor, while Ligand B (-5.355) is even worse.
11. **hERG:** Ligand A (0.186) has a very low hERG risk. Ligand B (0.393) is slightly higher, but still relatively low.
12. **Cl_mic:** Ligand A (3.784) has lower clearance, suggesting better metabolic stability. Ligand B (35.624) has much higher clearance.
13. **t1/2:** Ligand A (-0.29) is poor, while Ligand B (12.191) is excellent.
14. **Pgp:** Ligand A (0.009) has very low P-gp efflux, which is good. Ligand B (0.345) has moderate P-gp efflux.
15. **Affinity:** Ligand A (-7.8) has a significantly better binding affinity than Ligand B (-6.3). This is a >1.5 kcal/mol difference, which is substantial.
**GPCR-Specific Priorities:** For ADRB2, we prioritize logP, Pgp, TPSA, and affinity. Ligand B has a better logP and Pgp profile, and a lower TPSA, but Ligand A has a much better affinity.
**Overall Assessment:**
While Ligand B has a better QED, BBB, and *t1/2*, its high DILI risk, poor solubility, and significantly weaker binding affinity are major drawbacks. Ligand A's superior affinity is a critical advantage for a GPCR target, and its lower DILI risk and P-gp efflux are also highly desirable. The lower logP and solubility of Ligand A are concerns, but these can potentially be addressed through formulation or further chemical modifications. The difference in affinity is large enough to outweigh the ADME concerns of Ligand A.
Output:
1
2025-04-17 19:00:13,620 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.531 and 352.475 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (40.62) is significantly better than Ligand B (70.08). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold. Ligand B is approaching the upper limit.
3. **logP:** Ligand A (3.841) is slightly higher than Ligand B (1.271). Both are within the 1-3 optimal range, but Ligand A is closer to the upper end. This could potentially lead to solubility issues, but the benefit of higher binding affinity may outweigh this.
4. **HBD:** Ligand A (0) is better than Ligand B (1). Fewer hydrogen bond donors generally improve permeability.
5. **HBA:** Ligand A (2) is better than Ligand B (4). Fewer hydrogen bond acceptors also contribute to better permeability.
6. **QED:** Both ligands have good QED scores (0.732 and 0.809), indicating generally drug-like properties. No significant difference.
7. **DILI:** Ligand A (18.108) is considerably better than Ligand B (7.871). Lower DILI risk is crucial. Ligand A is well below the 40% threshold, while Ligand B is approaching it.
8. **BBB:** Both ligands have reasonably high BBB penetration (87.088 and 67.158), but Ligand A is significantly higher. While not a primary concern for a cardiovascular target, higher BBB is generally favorable.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.69 and -4.452). This is unusual and suggests poor permeability. However, these values are on the same scale, so it doesn't differentiate the two.
10. **Solubility:** Ligand A (-3.943) is better than Ligand B (-1.114). Higher solubility is beneficial for bioavailability.
11. **hERG:** Ligand A (0.641) is better than Ligand B (0.358). Lower hERG inhibition is critical for avoiding cardiotoxicity, especially for a cardiovascular target.
12. **Cl_mic:** Ligand A (77.937) is much higher than Ligand B (15.905). This indicates significantly faster metabolic clearance for Ligand A, which is undesirable.
13. **t1/2:** Ligand A (-2.204) is worse than Ligand B (1.533). A longer half-life is generally preferred.
14. **Pgp:** Ligand A (0.484) is better than Ligand B (0.061). Lower P-gp efflux is desirable for better bioavailability.
15. **Binding Affinity:** Ligand A (-6.5 kcal/mol) is slightly better than Ligand B (-6.0 kcal/mol). While the difference is not huge, it's enough to potentially overcome some of the ADME drawbacks.
**Overall Assessment:**
Ligand A has a clear advantage in several key areas: TPSA, HBD, HBA, DILI risk, solubility, hERG inhibition, and Pgp efflux. The binding affinity is also slightly better. However, Ligand A suffers from significantly higher microsomal clearance and a shorter half-life. Ligand B has better metabolic stability and half-life, but is worse in almost every other parameter.
Given the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), and the importance of minimizing cardiotoxicity (hERG) for a cardiovascular target, the benefits of Ligand A outweigh its metabolic liabilities. The slightly stronger binding affinity further supports this decision. While the metabolic issues with Ligand A would need to be addressed in further optimization, the starting point is more promising.
Output:
1
2025-04-17 19:00:13,620 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (378.885 and 354.535 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (83.98) is slightly higher than Ligand B (69.64). Both are below the 140 threshold for oral absorption, but B is better.
3. **logP:** Both ligands have good logP values (2.537 and 2.965), falling within the optimal 1-3 range. B is slightly higher, which *could* be beneficial for membrane permeability, but also slightly increases the risk of off-target effects.
4. **HBD:** Both have 2 H-bond donors, which is within the acceptable limit of 5.
5. **HBA:** Ligand A has 5 H-bond acceptors, and Ligand B has 3. Both are below the 10 limit.
6. **QED:** Ligand B (0.704) has a better QED score than Ligand A (0.474), indicating a more drug-like profile.
7. **DILI:** Ligand A (75.107) has a significantly higher DILI risk than Ligand B (8.647). This is a major concern for Ligand A.
8. **BBB:** Ligand B (70.686) has a better BBB penetration score than Ligand A (52.191). While ADRB2 isn't exclusively a CNS target, some peripheral effects are mediated by CNS pathways, and better BBB penetration isn't necessarily detrimental.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-5.41) is worse than Ligand B (-4.6).
10. **Solubility:** Both have negative solubility values, which is also unusual and suggests poor solubility. Ligand A (-3.614) is worse than Ligand B (-3.13).
11. **hERG:** Ligand A (0.096) has a slightly higher hERG risk than Ligand B (0.607), but both are relatively low.
12. **Cl_mic:** Ligand A (46.049) has a lower microsomal clearance than Ligand B (67.31), suggesting better metabolic stability. This is a positive for Ligand A.
13. **t1/2:** Ligand B (-5.162) has a longer in vitro half-life than Ligand A (15.262). This is a positive for Ligand B.
14. **Pgp:** Ligand A (0.114) has lower P-gp efflux liability than Ligand B (0.055), which is a positive for Ligand A.
15. **Binding Affinity:** Ligand A (-7.0) has a slightly better binding affinity than Ligand B (-6.4). However, the difference is only 0.6 kcal/mol, which isn't substantial enough to completely outweigh other factors.
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Ligand B is better on TPSA and Pgp, while Ligand A is better on affinity and Cl_mic. However, the *significant* difference in DILI risk and the better QED and half-life of Ligand B are overriding factors.
**Conclusion:**
Despite Ligand A's slightly better binding affinity and metabolic stability, the significantly higher DILI risk, worse QED, and poorer BBB penetration make it a less desirable candidate. Ligand B, with its lower DILI risk, better QED, and acceptable ADME properties, is the more promising drug candidate.
Output:
0
2025-04-17 19:00:13,620 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (343.343 Da) is slightly lower, which is generally favorable for permeability.
**2. TPSA:** Ligand B (52.65) is significantly better than Ligand A (110.49). For a GPCR, lower TPSA is generally preferred as it aids membrane permeability.
**3. logP:** Both ligands have good logP values (A: 1.782, B: 1.967), falling within the optimal 1-3 range.
**4. H-Bond Donors:** Both have 1 HBD, which is acceptable.
**5. H-Bond Acceptors:** Ligand A has 7 HBA, and Ligand B has 4. Both are within the acceptable range of <=10.
**6. QED:** Both ligands have good QED scores (A: 0.665, B: 0.807), indicating drug-likeness. Ligand B is slightly better.
**7. DILI:** Ligand A (95.774) has a very high DILI risk, which is a major concern. Ligand B (11.012) has an excellent DILI profile.
**8. BBB:** Ligand B (70.027) has a better BBB penetration score than Ligand A (61.342), though neither is exceptionally high. For a cardiovascular target, BBB penetration isn't a primary concern, but it's a bonus.
**9. Caco-2 Permeability:** Both have negative Caco-2 values, which is unusual and potentially problematic. However, the magnitude of negativity is similar (-4.706 for A, -5.08 for B).
**10. Aqueous Solubility:** Both have negative solubility values, indicating poor solubility. Ligand B (-2.755) is slightly better than Ligand A (-3.537).
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (A: 0.324, B: 0.529).
**12. Microsomal Clearance:** Both have similar microsomal clearance values (A: 33.417, B: 32.867).
**13. In vitro Half-Life:** Ligand B (19.031) has a significantly longer half-life than Ligand A (-4.917). This is a major advantage.
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (A: 0.058, B: 0.065).
**15. Binding Affinity:** Ligand A (-8.2 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.2 kcal/mol). This is a substantial advantage.
**Overall Assessment:**
While Ligand A has a superior binding affinity, the extremely high DILI risk is a critical drawback. The DILI risk associated with Ligand A is unacceptable. Ligand B, while having a slightly weaker affinity, presents a much more favorable safety profile (low DILI), better QED, and a longer half-life. The lower TPSA of Ligand B is also a plus for GPCR targeting. Considering the balance of properties and the importance of safety, Ligand B is the more promising drug candidate.
Output:
0
2025-04-17 19:00:13,620 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.402 and 359.466 Da) fall comfortably within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (58.64) is significantly higher than Ligand B (29.54). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is generally preferred for absorption. Ligand B has a substantial advantage.
3. **logP:** Ligand A (2.202) is within the optimal 1-3 range. Ligand B (4.137) is slightly above, potentially raising concerns about solubility and off-target effects, but still within a reasonable range. Ligand A is slightly favored.
4. **HBD:** Ligand A (1) is preferable to Ligand B (0) as having at least one HBD can improve solubility.
5. **HBA:** Both ligands have 3 HBA, which is acceptable.
6. **QED:** Both ligands have good QED scores (0.635 and 0.803), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Both ligands have similar, low DILI risk (37.96 and 37.611 percentile). No significant difference.
8. **BBB:** Ligand A (84.529) and Ligand B (95.696) both have high BBB penetration. Since ADRB2 is not a CNS target, this is less important, but Ligand B is slightly better.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.646 and -4.557), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand A (-2.486) has better solubility than Ligand B (-4.885). This is a positive for Ligand A.
11. **hERG:** Both ligands have low hERG inhibition liability (0.769 and 0.861), which is excellent. No significant difference.
12. **Cl_mic:** Ligand B (86.453) has a significantly higher microsomal clearance than Ligand A (31.456), meaning faster metabolism and potentially lower exposure. Ligand A is strongly favored.
13. **t1/2:** Ligand A (-0.624) has a negative half-life, which is problematic. Ligand B (17.471) has a much more reasonable half-life. Ligand B is strongly favored.
14. **Pgp:** Both ligands have similar Pgp efflux liability (0.299 and 0.81).
15. **Binding Affinity:** Ligand B (-7.7 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.9 kcal/mol). This is a substantial advantage, potentially outweighing some ADME concerns.
**Overall Assessment:**
Ligand B has a significantly better binding affinity and a more reasonable in vitro half-life, despite having a higher logP and lower solubility. The lower TPSA of Ligand B is also a plus. While the Caco-2 values are concerning for both, the stronger binding of Ligand B makes it more likely to achieve efficacy even with reduced absorption. The faster clearance of Ligand B is a drawback, but could be addressed through formulation strategies. The negative half-life of Ligand A is a major red flag.
Output:
0
2025-04-17 19:00:13,620 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Ligand A (364.511 Da) and Ligand B (339.439 Da) both fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (81.42) is slightly higher than Ligand B (64.41). Both are below the 140 threshold for oral absorption, but Ligand B is preferable due to being closer to the 90 threshold for GPCRs.
3. **logP:** Ligand A (3.794) is at the upper end of the optimal range (1-3), while Ligand B (2.828) is well within it. Ligand B is slightly favored here.
4. **HBD:** Ligand A (2) and Ligand B (0) both meet the <=5 criteria. Ligand B is slightly favored as fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (5) and Ligand B (3) both meet the <=10 criteria. Ligand B is favored.
6. **QED:** Both ligands have good QED scores (Ligand A: 0.721, Ligand B: 0.775). Ligand B is slightly better.
7. **DILI:** Ligand A (42.536) and Ligand B (34.626) both have low DILI risk (<40). Ligand B is slightly favored.
8. **BBB:** Ligand A (84.141) and Ligand B (79.062) both have good BBB penetration. Ligand A is slightly favored.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-4.999) is worse than Ligand B (-4.594). Ligand B is favored.
10. **Solubility:** Both are negative, indicating poor solubility. Ligand A (-2.576) is worse than Ligand B (-3.691). Ligand B is favored.
11. **hERG:** Both have low hERG inhibition risk (Ligand A: 0.6, Ligand B: 0.821). Ligand B is slightly favored.
12. **Cl_mic:** Ligand A (57.707) and Ligand B (59.004) are similar. No clear advantage.
13. **t1/2:** Ligand A (61.948) has a longer half-life than Ligand B (-4.674). Ligand A is favored.
14. **Pgp:** Ligand A (0.221) has lower Pgp efflux than Ligand B (0.467). Ligand A is favored.
15. **Affinity:** Ligand B (-6.6 kcal/mol) has a stronger binding affinity than Ligand A (-5.7 kcal/mol). This is a significant advantage (>1.5 kcal/mol difference).
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP, TPSA, and affinity. Ligand A is better in Pgp and half-life, but the affinity difference for Ligand B is substantial enough to outweigh these.
**Overall Assessment:**
Ligand B demonstrates a better balance of properties, particularly with its superior affinity, lower TPSA, and favorable ADME properties (logP, solubility, DILI, hERG). While Ligand A has a better half-life and Pgp profile, the stronger binding affinity of Ligand B is a critical advantage for a GPCR target.
Output:
0
2025-04-17 19:00:13,620 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (366.571) is slightly higher than Ligand B (349.406), but both are acceptable.
2. **TPSA:** Ligand A (58.2) is significantly better than Ligand B (104.45). For a GPCR, lower TPSA is generally preferred for better permeability. Ligand B is above the 90 threshold, which is a concern.
3. **logP:** Both ligands have good logP values (A: 3.503, B: 2.105), falling within the optimal 1-3 range. Ligand A is slightly higher, which could potentially lead to off-target effects, but is still acceptable.
4. **HBD:** Ligand A (2) is preferable to Ligand B (4). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (4). Similar to HBD, fewer HBAs are generally better.
6. **QED:** Ligand A (0.459) is better than Ligand B (0.25), indicating a more drug-like profile.
7. **DILI:** Ligand A (20.008) has a much lower DILI risk than Ligand B (42.264). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (55.719) has better BBB penetration than Ligand B (39.046), although neither are exceptionally high. For a cardiovascular target, BBB isn't a primary concern, but it's still a positive for A.
9. **Caco-2:** Both have negative values, indicating poor permeability. Ligand A (-4.905) is slightly better than Ligand B (-5.394).
10. **Solubility:** Ligand A (-4.204) is slightly better than Ligand B (-2.815), indicating better solubility.
11. **hERG:** Ligand A (0.391) is significantly better than Ligand B (0.639), indicating a lower risk of cardiotoxicity. This is crucial for a cardiovascular target.
12. **Cl_mic:** Ligand A (47.518) has higher metabolic clearance than Ligand B (19.236), meaning it's less metabolically stable. This is a drawback for Ligand A.
13. **t1/2:** Ligand B (-31.095) has a significantly longer in vitro half-life than Ligand A (33.13). This is a major advantage for Ligand B.
14. **Pgp:** Ligand A (0.28) has lower P-gp efflux than Ligand B (0.051), indicating better bioavailability.
15. **Binding Affinity:** Ligand B (-6.2) has a slightly better binding affinity than Ligand A (-5.7). While a 1.5 kcal/mol advantage is usually significant, the other factors are more important here.
**Overall Assessment:**
Ligand A has a significantly better safety profile (lower DILI, lower hERG) and better ADME properties (TPSA, QED, solubility, Pgp). While Ligand B has a longer half-life and slightly better affinity, the superior ADME and safety profile of Ligand A outweigh these advantages. The lower TPSA and H-bond counts of Ligand A are especially favorable for a GPCR target.
Output:
1
2025-04-17 19:00:13,621 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (363.429 Da and 374.75 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (38.33) is significantly better than Ligand B (69.04). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold. Ligand B is approaching the upper limit.
3. **logP:** Ligand A (4.863) is higher than Ligand B (2.971). While both are within the 1-3 range, Ligand A is pushing the upper boundary. This *could* lead to solubility issues, but it's not a dealbreaker.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 3 HBA, Ligand B has 5. Both are acceptable, but Ligand A is slightly preferred.
6. **QED:** Both ligands have good QED scores (0.714 and 0.839), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand B (78.402) has a higher DILI risk than Ligand A (63.746), making Ligand A preferable.
8. **BBB:** Ligand A (84.141) has better BBB penetration than Ligand B (74.176). While not a primary concern for a cardiovascular target, it's a slight advantage.
9. **Caco-2:** Both are negative, indicating poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-5.795) has worse solubility than Ligand B (-4.082). This is a significant drawback for Ligand A.
11. **hERG:** Ligand A (0.577) has a slightly higher hERG risk than Ligand B (0.207). Ligand B is much better here.
12. **Cl_mic:** Ligand B (45.061) has a significantly lower microsomal clearance than Ligand A (89.412), indicating better metabolic stability. This is a major advantage for Ligand B.
13. **t1/2:** Ligand A (13.109) has a longer in vitro half-life than Ligand B (-1.932). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.236) has lower P-gp efflux than Ligand B (0.107). This is a slight advantage for Ligand A.
15. **Binding Affinity:** Ligand A (-7.5 kcal/mol) has a stronger binding affinity than Ligand B (-6.4 kcal/mol). This is a substantial advantage, exceeding the 1.5 kcal/mol threshold.
**Overall Assessment:**
Ligand A has a significantly better binding affinity and a longer half-life, which are crucial for efficacy. It also has a lower DILI risk and slightly better BBB penetration. However, it suffers from poor solubility, higher hERG risk, and higher metabolic clearance. Ligand B has better solubility, lower hERG risk, and much better metabolic stability, but its binding affinity is weaker.
Given the importance of potency for GPCRs, and the substantial difference in binding affinity (-7.5 vs -6.4 kcal/mol), I believe Ligand A is the more promising candidate *despite* its drawbacks. The solubility issue could potentially be addressed through formulation strategies. The higher hERG risk is a concern, but may be mitigated with further optimization. The metabolic instability is also a concern, but the strong binding affinity provides a good starting point for optimization.
Output:
1
2025-04-17 19:00:13,621 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (339.399) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are good, below the 140 threshold for oral absorption (A: 87.05, B: 81.75).
3. **logP:** Ligand A (3.16) is optimal, while Ligand B (0.156) is quite low. This is a significant drawback for B, potentially hindering membrane permeability and bioavailability.
4. **HBD:** Both have 2 HBD, which is acceptable.
5. **HBA:** Both are within the acceptable range (A: 4, B: 5).
6. **QED:** Both are good, above 0.5 (A: 0.747, B: 0.722).
7. **DILI:** Ligand A (57.929) has a moderate risk, while Ligand B (15.626) has a very low risk. This favors Ligand B.
8. **BBB:** Ligand A (76.231) has better BBB penetration than Ligand B (55.642), but BBB isn't a primary concern for ADRB2 (a cardiovascular target).
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. However, the scale is not clear, and negative values may not be directly comparable.
10. **Solubility:** Both have negative solubility values, indicating poor solubility. Again, the scale is unclear.
11. **hERG:** Ligand A (0.34) has a slightly higher hERG risk than Ligand B (0.048), favoring B.
12. **Cl_mic:** Ligand B (0.978) has significantly lower microsomal clearance than Ligand A (36.008), suggesting better metabolic stability. This is a strong advantage for B.
13. **t1/2:** Ligand A (15.075) has a longer half-life than Ligand B (-0.783). This favors A.
14. **Pgp:** Ligand A (0.082) has lower P-gp efflux than Ligand B (0.009), which is favorable.
15. **Affinity:** Ligand B (-3.1 kcal/mol) has a significantly stronger binding affinity than Ligand A (-0.5 kcal/mol). This is a major advantage for B, potentially outweighing some of its ADME drawbacks.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand B excels in affinity and has a better Pgp profile. While its logP is low, the substantial affinity advantage is likely to compensate. Ligand A has a better logP and BBB, but the significantly weaker binding affinity is a major concern.
**Overall Assessment:**
Despite Ligand B's low logP and solubility, its superior binding affinity and metabolic stability (lower Cl_mic) are crucial for a GPCR target. The lower DILI and hERG risks are also beneficial. Ligand A's better logP and half-life are not enough to overcome its weak binding.
Output:
0
2025-04-17 19:00:13,621 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (359.25 & 362.499 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (69.39) is slightly higher than Ligand B (64.16). Both are below the 140 A^2 threshold for good absorption, and reasonably well-positioned for a GPCR.
3. **logP:** Both ligands have good logP values (3.536 & 3.237), falling within the 1-3 range. Ligand A is slightly higher, which could be a minor concern for off-target effects, but not a dealbreaker.
4. **HBD:** Ligand A has 1 HBD, while Ligand B has 0. Both are acceptable.
5. **HBA:** Ligand A has 3 HBA, Ligand B has 6. Ligand B is higher, potentially impacting permeability.
6. **QED:** Both ligands have good QED scores (0.673 & 0.721), indicating good drug-like properties.
7. **DILI:** Ligand A (83.017) has a significantly higher DILI risk than Ligand B (43.66). This is a major concern for Ligand A.
8. **BBB:** Both ligands have good BBB penetration (77.007 & 78.558). This is less critical for ADRB2 (cardiovascular target) but still positive.
9. **Caco-2:** Ligand A (-4.417) is worse than Ligand B (-5.096), indicating poorer intestinal absorption for Ligand A.
10. **Solubility:** Ligand A (-5.468) is worse than Ligand B (-2.826), indicating poorer solubility for Ligand A.
11. **hERG:** Ligand A (0.621) is slightly higher than Ligand B (0.215), indicating a slightly higher risk of hERG inhibition.
12. **Cl_mic:** Ligand B (89.818) has a significantly higher microsomal clearance than Ligand A (58.572), suggesting faster metabolism and potentially lower exposure for Ligand B.
13. **t1/2:** Ligand A (23.784) has a longer in vitro half-life than Ligand B (-1.159). This is a significant advantage for Ligand A.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.277 & 0.273).
15. **Binding Affinity:** Ligand A (-7.2) has a slightly better binding affinity than Ligand B (-6.0). This is a 1.2 kcal/mol difference, which is substantial.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Both ligands perform well on logP and Pgp. TPSA is acceptable for both. The affinity difference is significant, favoring Ligand A. However, the DILI risk for Ligand A is very high, and its solubility and Caco-2 permeability are worse than Ligand B. The faster clearance of Ligand B is a concern, but the lower DILI risk and better solubility/absorption are more important.
**Conclusion:**
Despite the slightly better affinity of Ligand A, the significantly higher DILI risk, lower solubility, and lower Caco-2 permeability make it a less desirable candidate. Ligand B, while having a slightly weaker affinity and faster clearance, presents a much more favorable safety and ADME profile.
Output:
0
2025-04-17 19:00:13,621 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (375.441 and 345.487 Da) are within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (75.44) is slightly higher than Ligand B (61.44). Both are below the 140 threshold for oral absorption, but B is better.
3. **logP:** Both ligands (2.369 and 2.004) are within the optimal 1-3 range. No significant difference.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2) as lower HBD generally improves permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (3), as lower HBA generally improves permeability.
6. **QED:** Both ligands have similar QED values (0.671 and 0.694), indicating good drug-likeness.
7. **DILI:** Ligand B (10.275) has a significantly lower DILI risk than Ligand A (40.946). This is a major advantage for Ligand B.
8. **BBB:** Ligand A (85.731) has a better BBB penetration percentile than Ligand B (71.307). While ADRB2 is not exclusively a CNS target, some CNS exposure might be acceptable or even desirable depending on the specific therapeutic indication.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.197 and -4.979) which is unusual and suggests poor permeability.
10. **Solubility:** Both ligands have negative solubility values (-3.121 and -2.061) which is also unusual and suggests poor solubility.
11. **hERG:** Ligand A (0.548) has a slightly higher hERG inhibition liability than Ligand B (0.264). Lower is better, so Ligand B is preferable.
12. **Cl_mic:** Ligand B (18.181) has a lower microsomal clearance than Ligand A (30.857), indicating better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand B (10.435) has a much longer in vitro half-life than Ligand A (-1.677). This is a major advantage.
14. **Pgp:** Ligand A (0.106) has a lower P-gp efflux liability than Ligand B (0.033), which is preferable.
15. **Binding Affinity:** Ligand A (-7.8 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.3 kcal/mol). This is a substantial advantage, potentially outweighing some ADME drawbacks.
**Overall Assessment:**
While Ligand A has a superior binding affinity, Ligand B demonstrates a much more favorable ADME profile, particularly regarding DILI risk, metabolic stability (lower Cl_mic), and longer half-life. The negative Caco-2 and solubility values are concerning for both, but the difference in DILI and metabolic stability is substantial. For a GPCR target like ADRB2, a balance between potency and ADME properties is crucial. The improved safety profile and pharmacokinetic properties of Ligand B are more compelling, even with the slightly lower binding affinity.
Output:
0
2025-04-17 19:00:13,621 - INFO - Batch 78 complete. Total preferences: 1248
2025-04-17 19:00:13,621 - INFO - Processing batch 79/512...
2025-04-17 19:01:03,742 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (a cardiovascular GPCR) drug candidates.
**Ligand A:** [351.403, 99.18, -0.87, 2, 5, 0.671, 23.575, 48.119, -5.464, -2.028, 0.075, -15.391, -10.579, 0.006, -5.4]
**Ligand B:** [352.475, 75.71, 1.627, 1, 4, 0.606, 21.753, 75.805, -4.387, -1.953, 0.123, 56.49, -1.864, 0.075, -4.6]
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). A is 351.4, B is 352.5. Very similar.
2. **TPSA:** Ligand A (99.18) is slightly higher than Ligand B (75.71). Both are acceptable for oral absorption (<140), but B is better.
3. **logP:** Ligand A (-0.87) is a bit low, potentially hindering permeability. Ligand B (1.627) is within the optimal range (1-3). This is a significant advantage for B.
4. **HBD:** Ligand A (2) and B (1) are both good, within the acceptable limit of 5. B is slightly better.
5. **HBA:** Ligand A (5) and B (4) are both good, within the acceptable limit of 10. B is slightly better.
6. **QED:** Both ligands have similar QED values (A: 0.671, B: 0.606), indicating good drug-like properties.
7. **DILI:** Both ligands have low DILI risk (A: 23.575, B: 21.753), which is excellent.
8. **BBB:** Ligand B (75.805) has a significantly higher BBB penetration score than Ligand A (48.119). While ADRB2 is cardiovascular, some CNS off-target effects are possible with GPCRs, and higher BBB penetration could be a concern, but it's not a primary negative here.
9. **Caco-2:** Ligand A (-5.464) and B (-4.387) both have negative Caco-2 values, which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Both ligands have very poor aqueous solubility (A: -2.028, B: -1.953). This is a major drawback for both.
11. **hERG:** Both ligands show very low hERG inhibition risk (A: 0.075, B: 0.123). This is excellent.
12. **Cl_mic:** Ligand A (-15.391) has a much lower (better) microsomal clearance than Ligand B (56.49). This indicates better metabolic stability for A.
13. **t1/2:** Ligand B (-1.864) has a slightly better in vitro half-life than Ligand A (-10.579).
14. **Pgp:** Both ligands have very low P-gp efflux liability (A: 0.006, B: 0.075). This is good.
15. **Affinity:** Both ligands have similar binding affinities (A: -5.4, B: -4.6 kcal/mol). A is slightly better.
**GPCR-Specific Priorities:**
For a cardiovascular GPCR like ADRB2, logP, TPSA, and affinity are important. While BBB isn't *essential*, it's a consideration.
**Conclusion:**
Ligand B has a better logP and TPSA, and significantly better BBB penetration. Ligand A has better metabolic stability (lower Cl_mic) and slightly better affinity. However, the poor solubility and Caco-2 permeability are major concerns for both. The better logP and TPSA of Ligand B, coupled with its higher BBB score, outweigh the slightly better metabolic stability of Ligand A, especially considering the similar affinities.
Therefore, I prefer Ligand B.
0
2025-04-17 19:01:03,743 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [349.475, 71.0, 2.475, 1.0, 4.0, 0.829, 16.092, 70.26, -4.779, -3.333, 0.129, 44.549, -12.862, 0.086, -8.6]
**Ligand B:** [346.515, 40.62, 3.312, 0.0, 2.0, 0.692, 9.965, 82.086, -4.445, -2.871, 0.536, 42.686, -3.49, 0.119, -5.6]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (346.515) is slightly lower, which is generally favorable.
2. **TPSA:** Ligand A (71) is higher than Ligand B (40.62). Ligand B is significantly better, being well below the 140 threshold for oral absorption and closer to the ideal for GPCRs.
3. **logP:** Both are within the optimal range (1-3). Ligand B (3.312) is slightly higher, which *could* be a minor concern, but not a dealbreaker.
4. **HBD:** Ligand A (1) is acceptable. Ligand B (0) is even better, minimizing potential issues with hydrogen bonding and metabolic liabilities.
5. **HBA:** Ligand A (4) is acceptable. Ligand B (2) is better.
6. **QED:** Ligand A (0.829) is better than Ligand B (0.692), indicating a more drug-like profile.
7. **DILI:** Ligand A (16.092) is better than Ligand B (9.965), indicating a lower risk of drug-induced liver injury.
8. **BBB:** Ligand B (82.086) is significantly better than Ligand A (70.26), which is a key consideration for a GPCR target, even a cardiovascular one. Better CNS penetration can sometimes translate to improved target engagement and distribution.
9. **Caco-2:** Ligand A (-4.779) is slightly better than Ligand B (-4.445). Both are negative, suggesting poor permeability.
10. **Solubility:** Ligand A (-3.333) is slightly worse than Ligand B (-2.871). Both are poor.
11. **hERG:** Ligand A (0.129) is better than Ligand B (0.536), indicating a lower risk of cardiotoxicity.
12. **Cl_mic:** Ligand A (44.549) is slightly higher than Ligand B (42.686), suggesting slightly lower metabolic stability.
13. **t1/2:** Ligand A (-12.862) is much worse than Ligand B (-3.49), indicating a much shorter half-life.
14. **Pgp:** Ligand A (0.086) is better than Ligand B (0.119), indicating lower P-gp efflux.
15. **Affinity:** Ligand A (-8.6) is significantly better than Ligand B (-5.6), a difference of 3 kcal/mol. This is a substantial advantage.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, BBB, and affinity. Ligand B excels in TPSA and BBB, while Ligand A has a much stronger binding affinity. The affinity difference is substantial enough to outweigh the slightly less favorable TPSA and BBB of Ligand A.
**Conclusion:**
Despite Ligand B's better BBB penetration and TPSA, the significantly stronger binding affinity of Ligand A (-8.6 vs -5.6 kcal/mol) is a decisive factor. A 3 kcal/mol difference in binding is substantial and can often overcome minor ADME deficiencies. The lower DILI risk and Pgp efflux of Ligand A are also favorable.
Output:
1
2025-04-17 19:01:03,743 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.475 and 345.443 Da) fall comfortably within the ideal range of 200-500 Da. No significant difference here.
2. **TPSA:** Ligand A (78.51) is slightly higher than Ligand B (74.57), but both are well below the 140 threshold for good oral absorption, and acceptable for a cardiovascular GPCR.
3. **logP:** Both ligands have good logP values (1.611 and 1.29), falling within the optimal 1-3 range. Ligand B is slightly lower, which *could* indicate slightly better solubility, but the difference is small.
4. **HBD:** Both have 2 H-bond donors, which is good.
5. **HBA:** Ligand A has 3 H-bond acceptors, while Ligand B has 4. Both are acceptable, but fewer is generally preferred.
6. **QED:** Both ligands have good QED scores (0.715 and 0.79), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (21.52) has a significantly lower DILI risk than Ligand B (36.797). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (74.952) has a much higher BBB penetration percentile than Ligand B (36.332). While ADRB2 isn't a CNS target, higher BBB is generally a positive indicator of permeability.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.017 and -5.229), which is unusual and suggests very poor permeability. This is a significant concern for both.
10. **Solubility:** Both have very poor aqueous solubility (-2.388 and -2.425). This is a major drawback for both compounds.
11. **hERG:** Both ligands have low hERG inhibition liability (0.216 and 0.178). This is good.
12. **Cl_mic:** Ligand A (26.876) has a lower microsomal clearance than Ligand B (42.316), suggesting better metabolic stability.
13. **t1/2:** Ligand B (22.333) has a substantially longer in vitro half-life than Ligand A (-0.547). This is a significant advantage for Ligand B.
14. **Pgp:** Both have very low Pgp efflux liability (0.027 and 0.132). This is good.
15. **Binding Affinity:** Ligand B (-5.5) has a slightly better binding affinity than Ligand A (-6.0). However, the difference is less than 1.5 kcal/mol, so it's not a decisive factor.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Both ligands perform similarly on logP and Pgp. TPSA is acceptable for both. Ligand B has slightly better affinity, but the difference isn't huge. The biggest differences are in DILI, BBB, and metabolic stability (Cl_mic).
**Overall Assessment:**
Despite Ligand B's slightly better affinity and half-life, Ligand A is the more promising candidate. The significantly lower DILI risk and higher BBB penetration are major advantages. The poor Caco-2 and solubility are concerning for both, but these can potentially be addressed with formulation strategies. The better metabolic stability of Ligand A is also a positive.
Output:
1
2025-04-17 19:01:03,743 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (357.479 and 363.439 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (46.84) is well below the 140 threshold and excellent for oral absorption. Ligand B (87.74) is higher, but still acceptable, though less optimal.
3. **logP:** Ligand A (3.829) is at the higher end of the optimal range (1-3), while Ligand B (1.135) is at the lower end. For a GPCR, a slightly higher logP is generally preferred for membrane permeability.
4. **HBD:** Ligand A (0) is ideal. Ligand B (2) is acceptable, but more donors can sometimes lead to issues with metabolic stability.
5. **HBA:** Both ligands have 5 HBA, which is within the acceptable range.
6. **QED:** Both ligands have similar QED values (0.697 and 0.711), indicating good drug-likeness.
7. **DILI:** Ligand A (48.817) has a lower DILI risk than Ligand B (70.764), which is a significant advantage.
8. **BBB:** Ligand A (65.452) has a better BBB penetration percentile than Ligand B (43.311). While ADRB2 isn't exclusively a CNS target, some CNS exposure may be relevant, and a higher BBB score is generally favorable.
9. **Caco-2:** Ligand A (-4.444) has a more negative Caco-2 value, indicating *better* permeability than Ligand B (-5.033).
10. **Solubility:** Ligand A (-3.656) has a better solubility score than Ligand B (-2.558).
11. **hERG:** Both ligands have very low hERG inhibition liability (0.721 and 0.195), which is excellent.
12. **Cl_mic:** Ligand B (-5.724) has a *lower* (better) microsomal clearance than Ligand A (87.333). This suggests better metabolic stability for Ligand B.
13. **t1/2:** Ligand B (-11.524) has a longer in vitro half-life than Ligand A (10.338). This is a significant advantage.
14. **Pgp:** Both ligands have similar Pgp efflux liability (0.771 and 0.053).
15. **Binding Affinity:** Both ligands have the same binding affinity (-6 kcal/mol).
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A has a better logP and TPSA, while Ligand B has better metabolic stability (Cl_mic and t1/2). The DILI and BBB scores also favor Ligand A. The affinity is the same. Considering the balance, the slightly better ADME profile of Ligand A, particularly the lower DILI risk and better solubility, outweighs the better metabolic stability of Ligand B.
**Final Decision:**
I prefer Ligand A.
1
2025-04-17 19:01:03,744 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (357.39 Da and 362.861 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (57.61) is significantly better than Ligand B (75.19). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand A is well below the 90 A^2 threshold, while Ligand B is approaching it.
**3. logP:** Both ligands have acceptable logP values (3.328 and 2.323, respectively), falling within the 1-3 range. Ligand A is slightly higher, which could be a minor concern for solubility, but not a dealbreaker.
**4. H-Bond Donors:** Both have 1 HBD, which is good.
**5. H-Bond Acceptors:** Ligand A has 3 HBA, and Ligand B has 4. Both are within the acceptable limit of 10.
**6. QED:** Both ligands have high QED scores (0.858 and 0.872), indicating good drug-like properties.
**7. DILI Risk:** Both ligands have similar DILI risk (56.262 and 55.719), and both are below the concerning threshold of 60.
**8. BBB Penetration:** Ligand B (75.805) has a substantially higher BBB penetration percentile than Ligand A (61.225). While ADRB2 is a cardiovascular target and CNS penetration isn't *essential*, some level of BBB penetration can be useful for off-target effects assessment and potential future applications.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and likely indicates a problem with the data or the model. However, the values are similar (-4.54 and -4.978).
**10. Aqueous Solubility:** Both ligands have very poor aqueous solubility (-3.354 and -3.077). This is a significant concern for both, and would require formulation strategies.
**11. hERG Inhibition:** Ligand A (0.785) has a slightly higher hERG inhibition risk than Ligand B (0.147). This is a critical factor, as hERG inhibition can lead to cardiotoxicity. Ligand B is much better here.
**12. Microsomal Clearance:** Ligand B (29.675) has significantly lower microsomal clearance than Ligand A (42.123), indicating better metabolic stability.
**13. In Vitro Half-Life:** Ligand A (92.466) has a much longer in vitro half-life than Ligand B (13.674). This is a significant advantage for dosing convenience.
**14. P-gp Efflux:** Ligand A (0.772) has higher P-gp efflux than Ligand B (0.056). Lower P-gp efflux is preferred for better bioavailability. Ligand B is much better here.
**15. Binding Affinity:** Both ligands have excellent binding affinity (-5.4 kcal/mol and -5.1 kcal/mol). The difference of 0.3 kcal/mol is not substantial enough to override other factors.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), and the overall balance of properties, **Ligand B is the more promising candidate**. While Ligand A has a better half-life, Ligand B's significantly lower hERG risk, P-gp efflux, and microsomal clearance are crucial advantages. The better BBB penetration is a bonus. The solubility issues are a concern for both, but can be addressed with formulation. The lower TPSA of Ligand B is also beneficial.
Output:
0
2025-04-17 19:01:03,744 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (355.435 and 345.399 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (91.76) is significantly better than Ligand A (121.96). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (0.784) is within the optimal range (1-3), while Ligand A (-0.466) is slightly below, potentially hindering permeation. Ligand B is favored.
4. **HBD:** Ligand A (3) and Ligand B (2) are both acceptable, below the threshold of 5.
5. **HBA:** Both ligands (5) are within the acceptable range of 10.
6. **QED:** Ligand B (0.713) is slightly better than Ligand A (0.516), indicating a more drug-like profile.
7. **DILI:** Ligand A (16.44) has a much lower DILI risk than Ligand B (30.942). This is a significant advantage for Ligand A.
8. **BBB:** Ligand B (57.968) is higher than Ligand A (40.403), but this is less crucial for a cardiovascular target like ADRB2.
9. **Caco-2:** Both ligands have similar, poor Caco-2 permeability (-5.4 and -5.01).
10. **Solubility:** Ligand A (-0.823) is slightly better than Ligand B (-2.081), but both are quite poor.
11. **hERG:** Both ligands have very low hERG risk (0.037 and 0.085).
12. **Cl_mic:** Ligand A (9.656) has significantly lower microsomal clearance than Ligand B (34.579), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-24.221) has a very negative in vitro half-life, indicating rapid metabolism. Ligand A (1.41) is much better, although still not ideal.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.006 and 0.017).
15. **Binding Affinity:** Ligand B (-7.5 kcal/mol) has a 1.1 kcal/mol stronger binding affinity than Ligand A (-6.4 kcal/mol). This is a substantial difference and a major factor.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP and affinity, while Ligand A has better DILI and Cl_mic. The affinity difference is significant enough to outweigh the slightly higher DILI risk and poorer metabolic stability of Ligand B. The TPSA difference also favors Ligand B.
**Conclusion:**
Despite Ligand A's advantages in DILI and metabolic stability, the significantly stronger binding affinity of Ligand B (-7.5 vs -6.4 kcal/mol) is the deciding factor. The improved logP and TPSA of Ligand B also contribute to its overall better profile for a GPCR target.
Output:
0
2025-04-17 19:01:03,744 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (340.39 & 348.35 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (88.22) is better than Ligand B (97.11). Both are under 140, but A is closer to the preferred value for good absorption.
3. **logP:** Both ligands have good logP values (2.48 & 1.77), falling within the 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Ligand A (2) is preferable to Ligand B (3). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (6) is preferable to Ligand B (4). Similar to HBD, lower HBA is generally better.
6. **QED:** Both ligands have similar QED values (0.762 & 0.741), indicating good drug-likeness.
7. **DILI:** Ligand B (73.05) has a significantly lower DILI risk than Ligand A (83.13). This is a substantial advantage for Ligand B.
8. **BBB:** Ligand A (74.72) has a slightly better BBB penetration than Ligand B (66.89). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration isn't necessarily detrimental and could allow for off-target effects.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.98 & -5.09), which is unusual and suggests very poor permeability. This is a major concern for both.
10. **Solubility:** Both ligands have negative solubility values (-3.25 & -4.01), indicating poor aqueous solubility. This is another significant drawback for both.
11. **hERG:** Ligand A (0.30) has a slightly better hERG profile than Ligand B (0.49), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand B (33.71) has a lower microsomal clearance than Ligand A (39.39), suggesting better metabolic stability.
13. **t1/2:** Ligand B (7.93) has a much longer in vitro half-life than Ligand A (48.01). This is a significant advantage for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.09) has a lower P-gp efflux liability than Ligand B (0.036), suggesting better oral bioavailability.
15. **Binding Affinity:** Ligand B (-8.0 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.7 kcal/mol). This is a crucial advantage, potentially outweighing some of the ADME drawbacks.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, affinity, logP, Pgp, TPSA, and metabolic stability are key. Ligand B excels in affinity and metabolic stability (lower Cl_mic, longer t1/2). While Ligand A has slightly better TPSA and Pgp, the substantial affinity difference of Ligand B is the most important factor. The DILI risk is also lower for Ligand B. The poor Caco-2 and solubility are concerning for both, but can potentially be addressed with formulation strategies.
**Conclusion:**
Despite the poor permeability and solubility profiles of both compounds, the significantly stronger binding affinity and improved metabolic stability of Ligand B make it the more promising candidate. The lower DILI risk is also a significant benefit.
Output:
0
2025-04-17 19:01:03,744 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [366.403, 112.74 , -0.323, 0. , 8. , 0.723, 87.864, 65.839, -4.719, -2.922, 0.203, 35.26 , -18.978, 0.014, -7.3 ]
**Ligand B:** [349.479, 81.93 , 2.493, 1. , 7. , 0.654, 35.828, 74.254, -4.785, -3.311, 0.164, 76.646, -19.578, 0.229, -5.8 ]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity, and BBB):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (349.479) is slightly lower, which is generally favorable.
2. **TPSA:** Ligand A (112.74) is a bit higher than Ligand B (81.93). Both are below 140, but B is better for permeability.
3. **logP:** Ligand A (-0.323) is quite low, potentially hindering membrane permeability. Ligand B (2.493) is within the optimal 1-3 range. This is a significant advantage for B.
4. **HBD/HBA:** Ligand A (0 HBD, 8 HBA) is better than Ligand B (1 HBD, 7 HBA) in terms of balancing solubility and permeability.
5. **QED:** Both are acceptable (A: 0.723, B: 0.654), indicating reasonable drug-likeness.
6. **DILI:** Ligand A (87.864) has a higher DILI risk than Ligand B (35.828). This is a major concern for A.
7. **BBB:** Ligand B (74.254) shows better BBB penetration potential than Ligand A (65.839), which is important for a GPCR target.
8. **Caco-2:** Both are similar and very poor (-4.719 and -4.785).
9. **Solubility:** Both are very poor (-2.922 and -3.311).
10. **hERG:** Both have low hERG risk (0.203 and 0.164).
11. **Cl_mic:** Ligand A (35.26) has lower microsomal clearance than Ligand B (76.646), suggesting better metabolic stability.
12. **t1/2:** Both have negative in vitro half-lives (-18.978 and -19.578), which is not ideal.
13. **Pgp:** Both have very low Pgp efflux liability (0.014 and 0.229).
14. **Affinity:** Ligand A (-7.3) has a significantly stronger binding affinity than Ligand B (-5.8). This is a substantial advantage.
**Overall Assessment:**
Ligand A has a much better binding affinity, which is a critical factor for GPCRs. However, its low logP, high DILI risk, and lower BBB penetration are significant drawbacks. Ligand B has a more favorable logP, lower DILI, and better BBB penetration, making it more likely to be a viable drug candidate despite its weaker binding affinity. The difference in affinity (-1.5 kcal/mol) is substantial, but the ADME/Tox profile of Ligand A is concerning.
Given the balance of properties and prioritizing a reasonable ADME/Tox profile for a GPCR target, I would choose Ligand B.
0
2025-04-17 19:01:03,744 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (368.459 Da and 371.459 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (102.84 and 101.74) are reasonably low, suggesting good potential for absorption, though slightly above the optimal <90 for CNS targets (less relevant for ADRB2, a cardiovascular target).
3. **logP:** Ligand A (-0.451) is a bit low, potentially hindering membrane permeability. Ligand B (0.964) is better, falling within the optimal 1-3 range. This is a point in favor of Ligand B.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable, being less than 5. Ligand B is slightly better.
5. **HBA:** Both ligands (6) are within the acceptable limit of 10.
6. **QED:** Both ligands (0.701 and 0.683) have good drug-likeness scores, exceeding the 0.5 threshold.
7. **DILI:** Ligand A (45.25) has a significantly lower DILI risk than Ligand B (73.245). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (11.128) has very low BBB penetration, while Ligand B (55.099) is moderate. While ADRB2 isn't a CNS target, some peripheral exposure can be detrimental.
9. **Caco-2:** Both ligands have similar negative Caco-2 values (-5.17 and -4.856), suggesting poor permeability.
10. **Solubility:** Both ligands have negative solubility values (-1.139 and -2.665), indicating poor aqueous solubility. Ligand B is slightly worse.
11. **hERG:** Both ligands have low hERG inhibition risk (0.041 and 0.183). No significant difference.
12. **Cl_mic:** Ligand A (15.823) has a much lower microsomal clearance than Ligand B (68.182), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (-27.459) has a more negative in vitro half-life, suggesting faster metabolism. Ligand B (-32.435) is even worse.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.026 and 0.106). No significant difference.
15. **Binding Affinity:** Ligand A (-7.4) has a slightly better binding affinity than Ligand B (-5.8). This is a substantial advantage for Ligand A.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, and affinity are key. Ligand B has a better logP. However, Ligand A has a significantly better binding affinity, lower DILI risk, and better metabolic stability (lower Cl_mic). The affinity difference is substantial enough to outweigh the slightly lower logP of Ligand A.
**Conclusion:**
Considering the balance of properties, particularly the superior binding affinity, lower DILI risk, and better metabolic stability of Ligand A, it is the more promising drug candidate.
Output:
1
2025-04-17 19:01:03,745 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's analyze each ligand against the provided criteria, keeping in mind ADRB2 is a GPCR and thus we prioritize logP, Pgp, TPSA, and affinity.
* **Molecular Weight:** Both ligands (347.463 and 341.375 Da) fall comfortably within the ideal 200-500 Da range.
* **TPSA:** Ligand A (77.57) is significantly better than Ligand B (107.18). A TPSA under 140 is good for oral absorption, but lower is generally preferred for GPCRs. Ligand A is much closer to the ideal range.
* **logP:** Both ligands have excellent logP values (1.042 and 0.967) within the optimal 1-3 range.
* **H-Bond Donors/Acceptors:** Ligand A (2 HBD, 5 HBA) is slightly better than Ligand B (1 HBD, 8 HBA). Both are within acceptable limits, but fewer H-bonds generally improve permeability.
* **QED:** Both ligands have good QED scores (0.735 and 0.839), indicating good drug-like properties.
* **DILI:** Ligand A (38.193) has a considerably lower DILI risk than Ligand B (66.615). This is a significant advantage.
* **BBB:** Ligand A (66.886) has a better BBB penetration percentile than Ligand B (57.929). While ADRB2 isn't necessarily a CNS target, some peripheral ADRB2 activity can be modulated by CNS effects, and better BBB penetration isn't a negative.
* **Caco-2:** Both ligands have negative Caco-2 values (-5.119 and -5.067), which is unusual and suggests poor permeability. This is a concern for both.
* **Aqueous Solubility:** Ligand A (-0.671) is slightly better than Ligand B (-2.303), indicating better solubility.
* **hERG:** Ligand A (0.48) has a much lower hERG risk than Ligand B (0.036). This is a critical safety parameter.
* **Cl_mic:** Ligand B (12.599) has a lower microsomal clearance than Ligand A (-11.85). Lower clearance suggests better metabolic stability, which is a positive.
* **t1/2:** Ligand A (14.588) has a longer in vitro half-life than Ligand B (-13.049). This is desirable for less frequent dosing.
* **Pgp:** Ligand A (0.007) has a significantly lower P-gp efflux liability than Ligand B (0.028). Lower P-gp efflux is crucial for better oral bioavailability and potentially better CNS exposure.
* **Binding Affinity:** Ligand A (-7.6 kcal/mol) has a slightly better binding affinity than Ligand B (-6.5 kcal/mol). This 1.1 kcal/mol difference is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical parameters, especially safety (DILI, hERG) and ADME properties (TPSA, Pgp, solubility, t1/2). While Ligand B has slightly better metabolic stability (Cl_mic), the advantages of Ligand A are more compelling, particularly the significantly improved safety profile and slightly better binding affinity. The negative Caco-2 values are a concern for both, but the other benefits of Ligand A make it the more promising candidate.
**Output:**
1
2025-04-17 19:01:03,745 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (368.5 & 347.4 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both are slightly above the optimal <140 for good oral absorption, but still reasonable (95.42 & 97.94). For a cardiovascular target, CNS penetration isn't a primary concern, so this isn't a major drawback.
3. **logP:** Ligand A (2.071) is better than Ligand B (0.791). ADRB2 is a GPCR, and a logP between 1-3 is preferred for good membrane permeability and binding. Ligand B is a bit low, potentially hindering permeation.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable.
5. **HBA:** Ligand A (6) and Ligand B (7) are both acceptable.
6. **QED:** Both ligands have good QED scores (0.656 & 0.833), indicating good drug-like properties.
7. **DILI:** Ligand A (52.036) has a slightly better DILI risk profile than Ligand B (57.387), though both are within an acceptable range (<60 is good).
8. **BBB:** Ligand B (54.091) has a higher BBB penetration score than Ligand A (30.438). However, as ADRB2 is primarily a cardiovascular target, BBB penetration is not a high priority.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-5.522) is slightly better than Ligand B (-4.96).
10. **Solubility:** Ligand A (-3.013) has better aqueous solubility than Ligand B (-1.383). Solubility is important for formulation and bioavailability.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.141 & 0.108). This is excellent.
12. **Cl_mic:** Ligand B (35.551) has lower microsomal clearance than Ligand A (43.168), suggesting better metabolic stability.
13. **t1/2:** Ligand B (18.758) has a significantly longer in vitro half-life than Ligand A (-8.629). This is a major advantage, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.042 & 0.026).
15. **Binding Affinity:** Ligand B (-7.2 kcal/mol) has a slightly better binding affinity than Ligand A (-6.7 kcal/mol). This 0.5 kcal/mol difference is significant and can outweigh some minor ADME drawbacks.
**Overall Assessment:**
While Ligand B has a longer half-life and slightly better affinity, Ligand A has better solubility and a slightly better DILI score. The biggest drawback of Ligand B is its lower logP, which could impact its ability to reach the receptor. However, the affinity difference is significant, and the longer half-life is a major benefit. Considering the GPCR-specific priorities (logP, affinity), and the relatively minor impact of the slightly lower logP, Ligand B is the more promising candidate.
Output:
0
2025-04-17 19:01:03,745 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (351.447) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (70.16) is significantly better than Ligand B (87.3). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (2.155) is within the optimal range (1-3), while Ligand A (0.342) is quite low. Low logP can hinder membrane permeability. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (0) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (5) is better than Ligand B (3). Lower HBA is generally better for permeability.
6. **QED:** Both ligands have good QED scores (A: 0.542, B: 0.608), indicating good drug-like properties.
7. **DILI:** Ligand A (9.383) has a much lower DILI risk than Ligand B (24.234). This is a crucial advantage for Ligand A.
8. **BBB:** Both have acceptable BBB penetration, but Ligand A (68.592) is slightly higher than Ligand B (64.87). Not a major factor for a cardiovascular target.
9. **Caco-2:** Ligand A (-4.643) is better than Ligand B (-5.606), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-0.774) is better than Ligand B (-2.59). Better solubility is generally preferred.
11. **hERG:** Ligand A (0.45) has a lower hERG risk than Ligand B (0.22), which is a positive.
12. **Cl_mic:** Ligand B (3.82) has significantly lower microsomal clearance than Ligand A (10.086), indicating better metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand B (26.194) has a much longer in vitro half-life than Ligand A (-5.346). This is a major advantage for Ligand B.
14. **Pgp:** Both ligands have very low Pgp efflux liability, which is good.
15. **Binding Affinity:** Ligand B (-7.4) has a significantly stronger binding affinity than Ligand A (-6.5). A 0.9 kcal/mol difference is substantial and can often outweigh other factors.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP and affinity. Ligand A is better in TPSA, but the difference isn't dramatic, and the strong affinity of Ligand B is a major driver. Pgp is similar for both.
**Overall Assessment:**
While Ligand A has advantages in DILI, solubility, and Caco-2 permeability, Ligand B's superior binding affinity (-7.4 vs -6.5 kcal/mol) and significantly improved metabolic stability (lower Cl_mic, longer t1/2) are more critical for a successful drug candidate, especially for a GPCR target. The slightly lower logP of Ligand A is a concern for permeability.
Output:
0
2025-04-17 19:01:03,745 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (354.372 and 348.491 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (38.5) is significantly better than Ligand B (88.32). For a GPCR, lower TPSA is generally preferred for better permeability, and Ligand A is well below the 140 threshold. Ligand B is higher, potentially impacting absorption.
**3. logP:** Ligand A (4.513) is slightly higher than Ligand B (2.765). While both are within the 1-3 range, Ligand A is approaching the upper limit. This could potentially lead to solubility issues, but is not a major concern at this level.
**4. H-Bond Donors:** Ligand A (0) is preferable to Ligand B (2). Fewer H-bond donors generally improve membrane permeability.
**5. H-Bond Acceptors:** Both ligands have 4 H-bond acceptors, so no difference here.
**6. QED:** Both ligands have similar QED values (0.81 and 0.793), indicating good drug-likeness.
**7. DILI Risk:** Both ligands have similar DILI risk (46.258 and 47.15), and are both below the concerning 60 threshold.
**8. BBB Penetration:** Ligand A (85.731) has significantly better BBB penetration potential than Ligand B (76.735). While ADRB2 is a cardiovascular target, some CNS effects are possible with adrenergic ligands, and better BBB penetration could be beneficial or detrimental depending on the desired profile.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.47 and -4.817). These values are unusual and suggest poor permeability. However, the scale is not specified so it is difficult to interpret.
**10. Aqueous Solubility:** Ligand A (-4.721) is slightly better than Ligand B (-3.205), indicating better solubility.
**11. hERG Inhibition:** Ligand A (0.875) has a slightly lower hERG risk than Ligand B (0.652), which is preferable.
**12. Microsomal Clearance:** Ligand A (46.006) has lower microsomal clearance than Ligand B (64.305), suggesting better metabolic stability.
**13. In vitro Half-Life:** Ligand A (-33.607) has a significantly longer in vitro half-life than Ligand B (34.18). This is a major advantage.
**14. P-gp Efflux:** Ligand A (0.37) has lower P-gp efflux than Ligand B (0.157), which is preferable.
**15. Binding Affinity:** Ligand A (-7.2 kcal/mol) has a stronger binding affinity than Ligand B (-6.4 kcal/mol). This is a substantial difference (0.8 kcal/mol), and is a key driver in the decision.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical ADME properties (TPSA, HBD, BBB, Solubility, hERG, Cl_mic, t1/2, Pgp) and crucially, has a significantly stronger binding affinity. While Ligand A's logP is slightly higher, the benefits in other areas, particularly the superior affinity and metabolic stability, outweigh this minor concern.
Output:
1
2025-04-17 19:01:03,745 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (354.5 and 349.4 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (58.64) is significantly better than Ligand B (104.46). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (3.373) is optimal, while Ligand B (1.646) is on the lower side. This could impact membrane permeability for Ligand B.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (5) for similar reasons as HBD.
6. **QED:** Both ligands have similar, acceptable QED values (0.612 and 0.694).
7. **DILI:** Ligand A (16.25) is *much* better than Ligand B (35.48). This is a significant advantage for Ligand A, as liver toxicity is a major concern.
8. **BBB:** Ligand A (74.64) is better than Ligand B (37.65), but neither is exceptionally high. Since ADRB2 is not a CNS target, this is a lower priority.
9. **Caco-2:** Ligand A (-4.501) is better than Ligand B (-4.931), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-3.116) is better than Ligand B (-2.272).
11. **hERG:** Ligand A (0.797) is better than Ligand B (0.166). Lower hERG inhibition is crucial for avoiding cardiotoxicity, especially for a cardiovascular target.
12. **Cl_mic:** Ligand A (74.255) is better than Ligand B (-0.583). Higher values indicate faster clearance, meaning Ligand B has better metabolic stability.
13. **t1/2:** Ligand A (-8.803) is better than Ligand B (23.11). Longer half-life is preferable, and Ligand A has a much longer in vitro half-life.
14. **Pgp:** Ligand A (0.568) is better than Ligand B (0.092). Lower P-gp efflux is desirable for better bioavailability.
15. **Affinity:** Both ligands have excellent binding affinities (-6.4 and -8.0 kcal/mol). Ligand B is slightly better, but the difference is likely not enough to overcome its ADME liabilities.
**GPCR-specific priorities:** logP, TPSA, Pgp, and affinity are key for GPCRs. Ligand A performs better across these parameters, especially considering the importance of minimizing off-target effects and toxicity.
**Overall Assessment:**
Ligand A demonstrates a superior balance of properties, particularly regarding safety (DILI, hERG) and ADME characteristics (TPSA, logP, solubility, Pgp, Cl_mic, t1/2). While Ligand B has a slightly better binding affinity, the significant advantages of Ligand A in other critical areas make it the more promising drug candidate.
Output:
1
2025-04-17 19:01:03,745 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [340.463, 46.53, 4.503, 1, 3, 0.596, 24.195, 66.266, -4.505, -5.591, 0.822, 101.222, 1.823, 0.848, -6.9]
**Ligand B:** [359.423, 106.2, -1.236, 2, 6, 0.506, 19.426, 49.826, -5.261, -1.235, 0.072, 10.286, -3.9, 0.002, -6.6]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal 200-500 Da range. A (340.463) is slightly preferred.
2. **TPSA:** A (46.53) is excellent, well below 140, and good for permeability. B (106.2) is higher, potentially hindering absorption. This is a significant advantage for A.
3. **logP:** A (4.503) is a bit high, potentially causing solubility issues or off-target effects, but still within a reasonable range. B (-1.236) is too low, likely leading to poor membrane permeability. A is better here.
4. **HBD:** A (1) is good. B (2) is acceptable.
5. **HBA:** A (3) is good. B (6) is higher, potentially impacting permeability. A is slightly favored.
6. **QED:** Both are reasonably good (A: 0.596, B: 0.506), indicating drug-like properties. A is slightly better.
7. **DILI:** Both have low DILI risk (A: 24.195, B: 19.426). B is marginally better.
8. **BBB:** A (66.266) is decent, but B (49.826) is lower. While not a primary concern for a cardiovascular target, higher BBB is generally preferable. A is better.
9. **Caco-2:** A (-4.505) and B (-5.261) are both negative values, which is unusual. Assuming these represent permeability ratios or similar, lower (more negative) values may indicate lower permeability. B is slightly better in this case.
10. **Solubility:** A (-5.591) and B (-1.235) are both negative values. Assuming these are solubility scores, B is better.
11. **hERG:** A (0.822) is better than B (0.072), indicating lower cardiotoxicity risk. This is critical for a cardiovascular drug.
12. **Cl_mic:** A (101.222) is higher than B (10.286), meaning faster metabolic clearance and potentially lower exposure. B is significantly better here.
13. **t1/2:** A (1.823) is much shorter than B (-3.9). B is far better, indicating better *in vitro* stability.
14. **Pgp:** A (0.848) is better than B (0.002), meaning lower efflux and potentially better bioavailability.
15. **Affinity:** A (-6.9) is slightly better than B (-6.6), although the difference is relatively small.
**Overall Assessment:**
Ligand A has a superior TPSA, logP, hERG, and Pgp profile. While its metabolic clearance is higher, its better affinity and more favorable ADME properties (TPSA, logP, Pgp, hERG) outweigh this drawback, particularly for a GPCR target where permeability and minimizing off-target effects are crucial. Ligand B has better metabolic stability and solubility, but its poor logP and higher TPSA are significant concerns.
Therefore, I prefer Ligand A.
1
2025-04-17 19:01:03,746 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (354.397 and 351.437 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (58.64) is higher than Ligand B (40.54). For a cardiovascular GPCR, TPSA is not a major concern, but lower is generally preferable for permeability. Ligand B has an advantage here.
3. **logP:** Ligand A (2.246) is within the optimal 1-3 range. Ligand B (4.434) is higher, potentially leading to solubility issues and off-target interactions. Ligand A has a clear advantage.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 3 HBA, Ligand B has 2. Both are acceptable.
6. **QED:** Both ligands have similar QED values (0.825 and 0.852), indicating good drug-likeness.
7. **DILI:** Ligand A (36.293) has a higher DILI risk than Ligand B (16.402). This is a significant advantage for Ligand B.
8. **BBB:** Both ligands have high BBB penetration (89.104 and 87.127). Since ADRB2 is not a CNS target, this is less critical, but higher is still slightly better.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual. Assuming these are permeability coefficients, lower (more negative) values suggest *lower* permeability. Ligand B (-4.557) is slightly worse than Ligand A (-4.351).
10. **Solubility:** Ligand A (-2.135) has better solubility than Ligand B (-5.178). This is important for bioavailability.
11. **hERG:** Ligand A (0.473) has a lower hERG risk than Ligand B (0.829), which is a significant safety advantage.
12. **Cl_mic:** Ligand A (27.406) has lower microsomal clearance than Ligand B (100.126), indicating better metabolic stability. This is a key advantage.
13. **t1/2:** Ligand A (32.588) has a longer in vitro half-life than Ligand B (-12.094). This is a substantial advantage.
14. **Pgp:** Ligand A (0.089) has lower P-gp efflux than Ligand B (0.308), which is favorable for bioavailability.
15. **Affinity:** Both ligands have very similar binding affinities (-7.0 and -6.9 kcal/mol). The difference is negligible.
**Overall Assessment:**
Ligand A is superior. While Ligand B has a lower DILI risk and slightly lower TPSA, Ligand A excels in crucial ADME properties: solubility, metabolic stability (lower Cl_mic, longer t1/2), lower P-gp efflux, and lower hERG risk. The binding affinities are essentially the same. For a cardiovascular GPCR target, these ADME properties are more important than minimizing BBB penetration or having a slightly lower TPSA. The higher logP of Ligand B is also a concern.
Output:
1
2025-04-17 19:01:03,746 - INFO - Batch 79 complete. Total preferences: 1264
2025-04-17 19:01:03,746 - INFO - Processing batch 80/512...
2025-04-17 19:01:57,938 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.479 and 365.499 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (72.96 and 73.74) are below the 140 A^2 threshold for good oral absorption, which is good.
3. **logP:** Ligand B (1.71) is better than Ligand A (0.302). A logP between 1-3 is optimal, and Ligand A is quite low, potentially causing permeability issues.
4. **HBD:** Both have 1 HBD, which is acceptable.
5. **HBA:** Ligand B (5) is slightly higher than Ligand A (4), but both are within the acceptable range of <=10.
6. **QED:** Both ligands have similar QED values (0.746 and 0.712), indicating good drug-likeness.
7. **DILI:** Ligand A (7.445%) has a significantly lower DILI risk than Ligand B (16.208%). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (65.839%) has a slightly higher BBB penetration than Ligand A (54.634%). While ADRB2 isn't strictly a CNS target, some CNS exposure can be relevant for off-target effects or potential therapeutic strategies.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.276 and -5.032), which is unusual and suggests very poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand A (-0.207) has slightly better solubility than Ligand B (-1.502).
11. **hERG:** Both ligands have low hERG inhibition liability (0.209 and 0.345), which is good.
12. **Cl_mic:** Ligand A (-4.342) has significantly lower microsomal clearance than Ligand B (20.552), indicating better metabolic stability. This is a substantial advantage for Ligand A.
13. **t1/2:** Ligand A (-6.965) has a more negative in vitro half-life, suggesting a longer half-life than Ligand B (-2.903). This is a positive for Ligand A.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.003 and 0.122).
15. **Binding Affinity:** Both ligands have similar binding affinities (-5.7 and -5.5 kcal/mol), which are both good. The difference is not large enough to be decisive.
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Ligand B has a better logP and slightly better BBB penetration, but Ligand A has a significantly better safety profile (DILI), metabolic stability (Cl_mic), and half-life. The Caco-2 permeability is poor for both, which is a major drawback.
**Overall Assessment:**
While Ligand B has a slightly better logP and BBB, the significantly lower DILI risk, better metabolic stability, and longer half-life of Ligand A make it the more promising candidate. The poor Caco-2 values are a concern for both, but can be addressed with formulation strategies. The safety and PK advantages of Ligand A outweigh the slight improvement in logP and BBB seen in Ligand B.
Output:
1
2025-04-17 19:01:57,938 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (402.64 Da) is within the ideal range. Ligand B (349.431 Da) is also within the ideal range, but slightly lower. No strong preference here.
2. **TPSA:** Ligand A (62.3) is good, below the 140 threshold. Ligand B (78.95) is also acceptable, but higher. A favors here.
3. **logP:** Ligand A (4.148) is a bit high, potentially leading to solubility issues and off-target effects. Ligand B (1.198) is excellent, within the optimal range. B favors here.
4. **HBD:** Both ligands have 1 HBD, which is good. No preference.
5. **HBA:** Ligand A has 3 HBAs, Ligand B has 4. Both are acceptable, below the 10 threshold. No strong preference.
6. **QED:** Ligand A (0.477) is borderline, while Ligand B (0.783) is good. B favors here.
7. **DILI:** Ligand A (89.686) has a high DILI risk. Ligand B (41.334) has a low DILI risk. B strongly favors here.
8. **BBB:** Ligand A (83.831) has good BBB penetration, while Ligand B (25.087) is poor. A favors here, as BBB penetration can be important for GPCRs.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Ligand A (-5.65) has very poor solubility. Ligand B (-1.204) has better solubility, though still not ideal. B favors here.
11. **hERG:** Ligand A (0.209) has a low hERG risk. Ligand B (0.064) has a very low hERG risk. No strong preference.
12. **Cl_mic:** Ligand A (42.182) has moderate clearance. Ligand B (47.938) has slightly higher clearance. A favors here.
13. **t1/2:** Ligand A (20.028) has a reasonable half-life. Ligand B (-28.076) has a negative half-life, which is impossible and likely an error. A strongly favors here.
14. **Pgp:** Ligand A (0.105) has low Pgp efflux. Ligand B (0.022) has very low Pgp efflux. No strong preference.
15. **Affinity:** Ligand A (21.8 kcal/mol) has significantly weaker binding affinity than Ligand B (-4.8 kcal/mol). B strongly favors here.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand B excels in logP, Pgp, and significantly in affinity. Ligand A has better TPSA and BBB penetration, but the affinity difference is substantial. The DILI risk for Ligand A is also concerning.
**Overall Assessment:**
Despite Ligand A's better BBB penetration, the significantly stronger binding affinity of Ligand B (-4.8 kcal/mol vs 21.8 kcal/mol), lower DILI risk, and better solubility outweigh the drawbacks. The negative half-life for Ligand B is a data error, and should be ignored. The substantial affinity difference is a major advantage that can compensate for minor ADME issues.
Output:
0
2025-04-17 19:01:57,938 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [345.443, 71.53, 1.782, 1, 4, 0.883, 44.048, 70.609, -4.644, -1.497, 0.249, 21.832, -13.856, 0.043, -8.3]
**Ligand B:** [352.45, 69.64, 1.925, 2, 3, 0.815, 19.038, 72.082, -5.007, -3.066, 0.358, 1.657, -3.483, 0.079, -7.4]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (345.443) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are good, below 140 (Ligand A: 71.53, Ligand B: 69.64). This suggests good oral absorption potential.
3. **logP:** Both are within the optimal range (1-3). Ligand A (1.782) and Ligand B (1.925) are both acceptable.
4. **HBD:** Ligand A (1) is better than Ligand B (2). Lower is preferred.
5. **HBA:** Ligand A (4) is better than Ligand B (3). Lower is preferred.
6. **QED:** Both are good (>0.5), Ligand A (0.883) is slightly better than Ligand B (0.815).
7. **DILI:** Ligand B (19.038) is significantly better than Ligand A (44.048). This is a major advantage for Ligand B.
8. **BBB:** Both have good BBB penetration (>70). Ligand B (72.082) is slightly better than Ligand A (70.609), but the difference is small.
9. **Caco-2:** Ligand B (-5.007) is better than Ligand A (-4.644). Higher values indicate better absorption.
10. **Solubility:** Ligand B (-3.066) is better than Ligand A (-1.497). Higher values indicate better solubility.
11. **hERG:** Both are low risk (Ligand A: 0.249, Ligand B: 0.358).
12. **Cl_mic:** Ligand B (1.657) is significantly better than Ligand A (21.832). Lower clearance indicates better metabolic stability.
13. **t1/2:** Ligand B (-3.483) is better than Ligand A (-13.856). Longer half-life is desirable.
14. **Pgp:** Both are low, indicating minimal efflux. Ligand B (0.079) is slightly better than Ligand A (0.043).
15. **Affinity:** Ligand A (-8.3) is better than Ligand B (-7.4). This is a 0.9 kcal/mol difference, which is significant.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, we prioritize logP, Pgp, TPSA, and affinity. Both ligands perform well on logP, Pgp and TPSA. The affinity difference is the most important factor here. However, the ADME profile of Ligand B is substantially better than Ligand A, particularly regarding DILI, Cl_mic, and t1/2. While Ligand A has a better binding affinity, the superior ADME properties of Ligand B, especially the significantly lower DILI risk, are crucial for a viable drug candidate. The 0.9 kcal/mol difference in affinity can potentially be overcome with further optimization of Ligand B.
**Conclusion:**
Considering the balance of properties and the GPCR-specific priorities, Ligand B is the more promising candidate due to its significantly improved ADME profile, particularly its lower DILI risk and better metabolic stability.
Output:
0
2025-04-17 19:01:57,939 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.415 and 344.327 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (114.43) is better than Ligand B (118.58), both are under the 140 threshold for good absorption.
3. **logP:** Both ligands (1.648 and 1.992) are within the optimal 1-3 range. Ligand B is slightly higher, which could be a minor advantage.
4. **HBD:** Ligand A (3) is higher than Ligand B (1). Lower HBD is generally preferred for better permeability, giving Ligand B a slight edge.
5. **HBA:** Ligand A (4) is lower than Ligand B (6). Lower HBA is generally preferred for better permeability, giving Ligand A a slight edge.
6. **QED:** Ligand B (0.669) is better than Ligand A (0.49), indicating a more drug-like profile. This is a notable advantage for Ligand B.
7. **DILI:** Ligand A (35.905) has a significantly lower DILI risk than Ligand B (71.307). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (52.579) is lower than Ligand B (61.691). While ADRB2 isn't exclusively a CNS target, some CNS penetration might be beneficial, giving Ligand B a slight advantage.
9. **Caco-2:** Ligand A (-5.336) is worse than Ligand B (-4.734). Higher Caco-2 values indicate better absorption, giving Ligand B a slight advantage.
10. **Solubility:** Ligand A (-2.703) is better than Ligand B (-4.215). Better solubility is always a plus, giving Ligand A an advantage.
11. **hERG:** Both ligands (0.197 and 0.231) have very low hERG inhibition risk, which is excellent. No significant difference.
12. **Cl_mic:** Ligand A (33.089) has a significantly lower microsomal clearance than Ligand B (10.785). Lower clearance indicates better metabolic stability, which is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (1.197) is lower than Ligand B (2.505). Longer half-life is generally preferred, giving Ligand B an advantage.
14. **Pgp:** Both ligands (0.045 and 0.029) have low P-gp efflux, which is good. No significant difference.
15. **Binding Affinity:** Ligand B (-7.1 kcal/mol) has a stronger binding affinity than Ligand A (-6.6 kcal/mol). This is a 0.5 kcal/mol difference, which is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand B has a clear advantage in binding affinity and QED, and also shows better Caco-2 permeability and in vitro half-life. However, Ligand A exhibits significantly lower DILI risk and microsomal clearance, and better solubility. Considering ADRB2 is a cardiovascular target, minimizing off-target effects (DILI) and maximizing metabolic stability (low Cl_mic) are crucial. The 0.5 kcal/mol difference in affinity, while significant, can potentially be optimized in later stages of drug development. The lower DILI risk of Ligand A is a major safety benefit.
Therefore, I favor Ligand A.
Output:
1
2025-04-17 19:01:57,939 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [357.841, 62.3, 3.678, 1, 3, 0.83, 62.117, 71.966, -4.819, -4.146, 0.329, 29.743, 32.524, 0.14, -6.8]
**Ligand B:** [351.451, 120, 0.923, 4, 5, 0.607, 56.146, 36.371, -5.396, -2.667, 0.06, 16.629, -15.387, 0.037, -6.9]
Here's a breakdown, prioritizing GPCR properties (logP, Pgp, TPSA, BBB, and affinity):
1. **Molecular Weight:** Both are within the ideal 200-500 Da range. A is 357.8, B is 351.5. A slight edge to B being a bit lower.
2. **TPSA:** Ligand A (62.3) is excellent, well below 140, and good for oral absorption. Ligand B (120) is still acceptable, but less ideal. A is better.
3. **logP:** Ligand A (3.678) is optimal. Ligand B (0.923) is a bit low, potentially hindering membrane permeability. A is significantly better.
4. **H-Bond Donors:** A (1) is good. B (4) is higher, potentially impacting permeability. A is better.
5. **H-Bond Acceptors:** A (3) is good. B (5) is higher. A is better.
6. **QED:** A (0.83) is excellent, indicating high drug-likeness. B (0.607) is still acceptable, but lower. A is better.
7. **DILI:** A (62.117) is moderately risky. B (56.146) is slightly better, but both are within an acceptable range. B is slightly better.
8. **BBB:** A (71.966) is very good, suggesting decent CNS penetration. B (36.371) is low, indicating poor BBB penetration. A is *much* better, even though ADRB2 isn't necessarily a CNS target, better BBB penetration is generally favorable.
9. **Caco-2:** Both are negative, indicating poor permeability. B (-5.396) is slightly worse than A (-4.819). A is slightly better.
10. **Solubility:** Both are negative, indicating poor solubility. B (-2.667) is slightly better than A (-4.146). B is slightly better.
11. **hERG:** A (0.329) is very low risk. B (0.06) is extremely low risk. B is better.
12. **Cl_mic:** A (29.743) is better (lower clearance) than B (16.629). A is better.
13. **t1/2:** A (32.524) is positive, indicating a longer half-life. B (-15.387) is negative, indicating a very short half-life. A is *much* better.
14. **Pgp:** A (0.14) is very low efflux, which is good. B (0.037) is even lower, excellent. B is better.
15. **Binding Affinity:** Both are -6.8 kcal/mol, so affinity is equal.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B in most critical ADME properties (TPSA, logP, H-bonds, QED, BBB, Cl_mic, t1/2) and has equal binding affinity. While Ligand B has slightly better DILI and hERG, and Pgp efflux, the superior overall profile of A, especially its better BBB penetration and metabolic stability (Cl_mic, t1/2), makes it the more promising candidate. The lower logP and higher TPSA of Ligand B are significant drawbacks for a GPCR target.
Output:
1
2025-04-17 19:01:57,939 - INFO - Here's my reasoning and the final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, key priorities are logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB.
Let's compare the ligands property by property:
1. **MW:** Both ligands (341.455 and 346.427 Da) are within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (73.99) is slightly higher than Ligand B (67.87), but both are well below the 140 A^2 threshold for good oral absorption.
3. **logP:** Ligand A (2.389) is optimal, while Ligand B (0.725) is a bit low, potentially impacting permeability.
4. **HBD/HBA:** Ligand A has 3 HBD and 2 HBA, while Ligand B has 1 HBD and 4 HBA. Both are within acceptable limits.
5. **QED:** Both ligands have similar QED values (0.695 and 0.602), indicating good drug-likeness.
6. **DILI:** Ligand A (29.081) has a significantly lower DILI risk than Ligand B (55.138). This is a major advantage.
7. **BBB:** Both have low BBB penetration, which is not a major concern for a cardiovascular target. Ligand B (57.968) is slightly better than Ligand A (50.407).
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability.
9. **Solubility:** Both have negative solubility values, which is also unusual and suggests poor solubility.
10. **hERG:** Both ligands have very low hERG inhibition risk (0.364 and 0.274).
11. **Cl_mic:** Ligand A (16.348) has lower microsomal clearance than Ligand B (23.851), indicating better metabolic stability.
12. **t1/2:** Ligand B (-5.084) has a negative in vitro half-life, which is not realistic. Ligand A (1.867) is a more reasonable value.
13. **Pgp:** Ligand A (0.111) has lower P-gp efflux liability than Ligand B (0.087), which is favorable.
14. **Binding Affinity:** Both ligands have very similar and strong binding affinities (-6.3 and -6.1 kcal/mol). The difference is negligible.
**Overall Assessment:**
Ligand A is the better candidate. While both have similar affinities, Ligand A has a significantly lower DILI risk, better metabolic stability (lower Cl_mic), a more realistic half-life, and a more optimal logP. The slightly lower Pgp efflux of Ligand A is also a benefit. The unusual Caco-2 and solubility values are concerning for both, but the other advantages of Ligand A outweigh these concerns.
**Output:**
1
2025-04-17 19:01:57,939 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (350.419 Da and 348.487 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (98.9) is higher than Ligand B (49.85). For a GPCR, lower TPSA is generally preferred for better permeability. Ligand B is significantly better here.
**3. logP:** Ligand A (-0.383) is quite low, potentially hindering membrane permeability. Ligand B (2.629) is within the optimal 1-3 range. This is a significant advantage for Ligand B.
**4. H-Bond Donors:** Ligand A (2) is acceptable, while Ligand B (0) is even better, potentially improving permeability.
**5. H-Bond Acceptors:** Ligand A (6) is acceptable, and Ligand B (3) is also good.
**6. QED:** Both ligands have reasonable QED scores (0.774 and 0.665), indicating good drug-like properties.
**7. DILI:** Both ligands have low DILI risk (29.159 and 34.781), which is positive.
**8. BBB:** Ligand B (79.721) has a much higher BBB penetration score than Ligand A (46.375). While ADRB2 isn't strictly a CNS target, some CNS exposure can be relevant for off-target effects, and higher BBB is generally a plus.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual. However, the magnitude is similar, so this isn't a major differentiator.
**10. Aqueous Solubility:** Ligand A (-0.806) has slightly better solubility than Ligand B (-2.809), but both are poor. Solubility could be a formulation challenge for both.
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (0.22 and 0.513).
**12. Microsomal Clearance:** Ligand A (-0.418) has a negative clearance, which is excellent, indicating high metabolic stability. Ligand B (86.241) has very high clearance, which is a significant drawback.
**13. In vitro Half-Life:** Ligand A (-4.471) has a negative half-life, which is excellent, indicating high stability. Ligand B (16.065) has a reasonable half-life, but not as good as Ligand A.
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (0.028 and 0.285), which is favorable.
**15. Binding Affinity:** Both ligands have very similar binding affinities (-6.5 and -6.3 kcal/mol). The difference is not substantial enough to outweigh other factors.
**Overall Assessment:**
Ligand B has advantages in TPSA and logP, which are crucial for GPCR targets. However, Ligand A excels in metabolic stability (Cl_mic and t1/2), which is a very important factor for *in vivo* efficacy. Considering the balance, the poor metabolic properties of Ligand B are a significant concern. While Ligand A has a slightly lower logP, this can be addressed with further optimization. The superior metabolic stability of Ligand A makes it the more promising candidate.
Output:
1
2025-04-17 19:01:57,939 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [354.447, 85.89, 0.928, 2, 5, 0.664, 34.742, 71.345, -4.988, -1.515, 0.095, 24.104, 3.979, 0.017, -6.2]
**Ligand B:** [383.861, 96.67, 0.838, 1, 6, 0.789, 84.102, 65.452, -5.291, -4.486, 0.424, 46.144, -28.941, 0.057, 0.1]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (354.447) is slightly preferred due to being a bit lower.
2. **TPSA:** Ligand A (85.89) is better than Ligand B (96.67), both are acceptable for a non-CNS GPCR target like ADRB2, but lower is generally better for permeability.
3. **logP:** Both are good (around 0.8-0.9), falling within the optimal 1-3 range. Ligand A is slightly higher, potentially offering a small advantage in membrane permeability.
4. **HBD:** Ligand A (2) is preferable to Ligand B (1). While both are low, fewer HBDs generally correlate with better permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (6). Similar to HBD, lower HBA is generally better for permeability.
6. **QED:** Both have good QED scores (A: 0.664, B: 0.789), indicating drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (34.742) has a significantly lower DILI risk than Ligand B (84.102). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (71.345) has a better BBB penetration score than Ligand B (65.452), but this is less critical for a cardiovascular target like ADRB2.
9. **Caco-2:** Ligand A (-4.988) is better than Ligand B (-5.291), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-1.515) is better than Ligand B (-4.486). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.095) has a much lower hERG risk than Ligand B (0.424). This is a significant safety advantage for Ligand A.
12. **Cl_mic:** Ligand A (24.104) has a lower microsomal clearance than Ligand B (46.144), suggesting better metabolic stability.
13. **t1/2:** Ligand A (3.979) has a better in vitro half-life than Ligand B (-28.941).
14. **Pgp:** Ligand A (0.017) has a much lower P-gp efflux liability than Ligand B (0.057). This is a positive for bioavailability.
15. **Affinity:** Ligand A (-6.2) has a significantly better binding affinity than Ligand B (0.1). This is the most important factor.
**Overall Assessment:**
Ligand A clearly outperforms Ligand B across most crucial parameters. The significantly better binding affinity, lower DILI risk, lower hERG risk, better solubility, lower Pgp efflux, and better metabolic stability make it a much more promising drug candidate. While Ligand B has a slightly better QED score, the other advantages of Ligand A outweigh this. Given the GPCR target class, the balance of logP, TPSA, Pgp, and affinity all favor Ligand A.
Output:
1
2025-04-17 19:01:57,940 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A:** [357.411, 121.02 , -1.657, 2. , 8. , 0.514, 34.781, 29.12 , -5.324, -0.37 , 0.036, 15.08 , 0.897, 0.006, -7.3 ]
**Ligand B:** [341.411, 75.44 , 2.04 , 1. , 4. , 0.835, 60.566, 74.254, -4.746, -3.627, 0.241, 19.499, -3.363, 0.37 , -7. ]
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand B (341.411) is slightly lower, which could be advantageous for permeability, but the difference isn't substantial.
**2. TPSA:** Ligand A (121.02) is slightly above the preferred <140 for good oral absorption, but still acceptable. Ligand B (75.44) is excellent, well below 100, suggesting better permeability. *This favors Ligand B.*
**3. logP:** Ligand A (-1.657) is a bit low, potentially hindering permeation. Ligand B (2.04) is within the optimal range (1-3). *This strongly favors Ligand B.*
**4. H-Bond Donors:** Ligand A (2) and Ligand B (1) are both within the acceptable limit of <=5. Ligand B is slightly better.
**5. H-Bond Acceptors:** Ligand A (8) and Ligand B (4) are both within the acceptable limit of <=10. Ligand B is better.
**6. QED:** Both ligands have good QED scores (A: 0.514, B: 0.835), indicating drug-like properties. Ligand B is significantly better. *This favors Ligand B.*
**7. DILI Risk:** Ligand A (34.781) has a low DILI risk, well below the 40% threshold. Ligand B (60.566) is approaching the higher risk threshold, but still not critically high. *This favors Ligand A.*
**8. BBB Penetration:** Ligand A (29.12) has poor BBB penetration, while Ligand B (74.254) is good. Since ADRB2 is a GPCR, BBB penetration is a consideration, but not paramount unless targeting CNS indications. *This favors Ligand B.*
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests issues with the experimental setup or data quality. However, the magnitude of the negative value for Ligand A (-5.324) is more negative than Ligand B (-4.746), suggesting potentially worse permeability.
**10. Aqueous Solubility:** Both ligands have negative solubility values, which is also unusual. Ligand A (-0.37) is slightly better than Ligand B (-3.627), suggesting marginally better solubility.
**11. hERG Inhibition:** Both ligands have very low hERG risk (A: 0.036, B: 0.241). *This is neutral.*
**12. Microsomal Clearance:** Ligand A (15.08) has lower clearance than Ligand B (19.499), indicating better metabolic stability. *This favors Ligand A.*
**13. In vitro Half-Life:** Ligand A (0.897) has a very short half-life, while Ligand B (-3.363) is also poor. *This is neutral.*
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (A: 0.006, B: 0.37). *This is neutral.*
**15. Binding Affinity:** Both ligands have excellent binding affinity (-7.3 and -7.0 kcal/mol). The difference is small (0.3 kcal/mol) and unlikely to be decisive.
**Overall Assessment:**
Ligand B clearly outperforms Ligand A in several key areas: logP, TPSA, QED, and BBB penetration. While Ligand A has a slightly lower DILI risk and better metabolic stability, the benefits of Ligand B's superior physicochemical properties and drug-like characteristics outweigh these advantages, especially considering the relatively small difference in binding affinity. The negative Caco-2 and solubility values are concerning for both, but the values are less unfavorable for Ligand B.
Output:
0
2025-04-17 19:01:57,940 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [350.459, 76.66, 1.692, 2, 4, 0.685, 51.183, 66.382, -4.961, -2.394, 0.178, 32.173, 2.15, 0.13, -6.9]**
**Ligand B: [359.499, 63.91, 3.15, 0, 6, 0.762, 40.171, 74.137, -4.91, -3.538, 0.363, 62.67, 6.363, 0.322, -5.6]**
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). A is 350.459, B is 359.499. No significant difference.
2. **TPSA:** A (76.66) is slightly higher than B (63.91). Both are below 140, acceptable for oral absorption, but B is better.
3. **logP:** A (1.692) is optimal, while B (3.15) is towards the higher end of optimal. A is preferred here.
4. **H-Bond Donors:** A (2) is good, B (0) is also good. No clear preference.
5. **H-Bond Acceptors:** A (4) is good, B (6) is acceptable but slightly higher. A is preferred.
6. **QED:** Both are above 0.5 (A: 0.685, B: 0.762), indicating good drug-likeness. B is slightly better.
7. **DILI:** A (51.183) is better than B (40.171), indicating a lower risk of liver injury. A is preferred.
8. **BBB:** B (74.137) is better than A (66.382). This is a key consideration for GPCRs, even if not CNS-focused, as it can influence off-target effects.
9. **Caco-2:** Both are negative, indicating poor permeability. This is a concern for both.
10. **Solubility:** Both are negative, indicating poor solubility. This is a concern for both.
11. **hERG:** A (0.178) is significantly better than B (0.363), indicating lower cardiotoxicity risk. A is strongly preferred.
12. **Cl_mic:** A (32.173) is much lower than B (62.67), suggesting better metabolic stability. A is strongly preferred.
13. **t1/2:** B (6.363) is significantly better than A (2.15), indicating a longer half-life. B is strongly preferred.
14. **Pgp:** A (0.13) is much lower than B (0.322), indicating lower P-gp efflux. A is strongly preferred.
15. **Binding Affinity:** A (-6.9) is better than B (-5.6) by a significant margin (1.3 kcal/mol). This is a major advantage that can outweigh some ADME concerns.
**Overall Assessment:**
For an ADRB2 GPCR target, balancing affinity, metabolic stability, and safety is crucial. Ligand A has a substantially better binding affinity (-6.9 vs -5.6 kcal/mol) and significantly better metabolic stability (lower Cl_mic) and lower hERG risk. While Ligand B has a better BBB penetration and half-life, the superior affinity and safety profile of Ligand A are more important. The poor Caco-2 and solubility are concerns for both, but can be addressed with formulation strategies.
Output:
1
2025-04-17 19:01:57,940 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [357.479, 53.51, 2.879, 0, 4, 0.845, 37.728, 72.586, -4.92, -2.625, 0.567, 40.285, 16.426, 0.215, -7.3]**
**Ligand B: [359.447, 62.91, 4.072, 1, 5, 0.72, 53.509, 48.662, -5.095, -4.87, 0.845, 96.839, 78.548, 0.638, -7.3]**
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). A is 357.479, B is 359.447. No significant difference.
2. **TPSA:** Ligand A (53.51) is better than Ligand B (62.91). ADRB2 is a cardiovascular target, so CNS penetration isn't *essential*, but lower TPSA generally aids absorption.
3. **logP:** Ligand A (2.879) is optimal. Ligand B (4.072) is pushing the upper limit, potentially leading to solubility issues and off-target interactions.
4. **H-Bond Donors:** Ligand A (0) is preferable to Ligand B (1). Fewer HBDs generally improve permeability.
5. **H-Bond Acceptors:** Ligand A (4) is better than Ligand B (5). Lower is better for permeability.
6. **QED:** Ligand A (0.845) is better than Ligand B (0.72). Higher QED indicates better drug-like properties.
7. **DILI:** Ligand A (37.728) is significantly better than Ligand B (53.509). Lower DILI risk is crucial.
8. **BBB:** Ligand A (72.586) is better than Ligand B (48.662). While not a CNS target, some level of BBB penetration can sometimes correlate with better overall distribution.
9. **Caco-2:** Ligand A (-4.92) is better than Ligand B (-5.095). Higher Caco-2 values indicate better absorption.
10. **Solubility:** Ligand A (-2.625) is better than Ligand B (-4.87). Better solubility is important for bioavailability.
11. **hERG:** Both ligands have similar hERG inhibition liability (0.567 and 0.845). This is acceptable, but monitoring would be needed.
12. **Cl_mic:** Ligand A (40.285) is significantly better than Ligand B (96.839). Lower clearance means better metabolic stability.
13. **t1/2:** Ligand A (16.426) is better than Ligand B (78.548). A longer half-life is generally desirable.
14. **Pgp:** Ligand A (0.215) is better than Ligand B (0.638). Lower P-gp efflux improves bioavailability.
15. **Binding Affinity:** Both ligands have the same binding affinity (-7.3 kcal/mol). This removes affinity as a differentiating factor.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most crucial ADME-Tox properties (DILI, Cl_mic, Solubility, TPSA, logP, QED, Pgp). While both have good affinity, the superior ADME profile of Ligand A makes it the more promising drug candidate for the ADRB2 receptor.
Output:
1
2025-04-17 19:01:57,940 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A Analysis:**
* **MW:** 421.36 Da - Within the ideal range (200-500).
* **TPSA:** 49.41 - Good, below the 140 threshold for oral absorption.
* **logP:** 4.442 - Slightly high, potentially leading to solubility issues or off-target interactions, but not drastically so.
* **HBD:** 1 - Good.
* **HBA:** 3 - Good.
* **QED:** 0.745 - Excellent, highly drug-like.
* **DILI:** 53.858 - Acceptable, below the concerning 60 threshold.
* **BBB:** 73.711 - Good, indicating reasonable potential for CNS penetration if desired (though ADRB2 is primarily cardiovascular, some CNS effects are possible).
* **Caco-2:** -4.852 - Negative value is unusual and suggests very poor permeability. This is a significant concern.
* **Solubility:** -5.044 - Very poor solubility, a major drawback.
* **hERG:** 0.537 - Low risk of hERG inhibition.
* **Cl_mic:** 50.302 - Moderate clearance, not ideal but not terrible.
* **t1/2:** 21.184 - Good in vitro half-life.
* **Pgp:** 0.51 - Moderate P-gp efflux, could limit bioavailability.
* **Affinity:** -7.3 kcal/mol - Excellent binding affinity.
**Ligand B Analysis:**
* **MW:** 349.387 Da - Within the ideal range.
* **TPSA:** 100.88 - Acceptable, but approaching the upper limit for good oral absorption.
* **logP:** 0.296 - Low, potentially hindering membrane permeability.
* **HBD:** 2 - Good.
* **HBA:** 5 - Good.
* **QED:** 0.769 - Excellent, highly drug-like.
* **DILI:** 48.623 - Very good, low risk of liver injury.
* **BBB:** 35.595 - Low, limited CNS penetration.
* **Caco-2:** -5.283 - Negative value is unusual and suggests very poor permeability. This is a significant concern.
* **Solubility:** -2.088 - Poor solubility, though not as bad as Ligand A.
* **hERG:** 0.099 - Very low risk of hERG inhibition.
* **Cl_mic:** -15.692 - Negative value is unusual and suggests very slow clearance, potentially leading to accumulation.
* **t1/2:** 32.408 - Excellent in vitro half-life.
* **Pgp:** 0.012 - Very low P-gp efflux, favorable for bioavailability.
* **Affinity:** -7.8 kcal/mol - Excellent, and slightly better than Ligand A.
**Comparison & Decision:**
Both ligands have significant permeability and solubility issues (indicated by the negative Caco-2 and solubility values). However, Ligand B has a better overall profile. Its affinity is slightly higher, DILI risk is lower, P-gp efflux is minimal, and it has a very long half-life. While its logP is low, the extremely poor permeability and solubility of Ligand A are more concerning. The negative clearance value for Ligand B is unusual and warrants further investigation, but is less immediately problematic than the poor absorption predicted for Ligand A. Given the GPCR target class, the slightly better affinity and ADME properties of Ligand B make it the more promising candidate, despite the unusual clearance value.
Output:
0
2025-04-17 19:01:57,940 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [357.841, 62.3, 3.678, 1, 3, 0.83, 62.117, 71.966, -4.819, -4.146, 0.329, 29.743, 32.524, 0.14, -6.8]
**Ligand B:** [387.502, 73.74, 1.832, 1, 6, 0.754, 61.264, 58.24, -4.574, -1.995, 0.294, 23.029, -0.365, 0.243, -6.6]
Here's a step-by-step comparison, keeping GPCR priorities (logP, Pgp, TPSA, and affinity) in mind:
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (357.841) is slightly preferred due to being lower.
2. **TPSA:** Ligand A (62.3) is better than Ligand B (73.74). Both are below 140, but lower is better for absorption.
3. **logP:** Ligand A (3.678) is better than Ligand B (1.832). Ligand A is within the optimal range (1-3), while Ligand B is at the lower end, potentially impacting permeability.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A (3) is better than Ligand B (6). Lower HBA is generally preferred.
6. **QED:** Ligand A (0.83) is slightly better than Ligand B (0.754), indicating a more drug-like profile.
7. **DILI:** Both are relatively similar and acceptable (62.117 and 61.264).
8. **BBB:** Ligand A (71.966) is significantly better than Ligand B (58.24). This is a key advantage for a GPCR target, even if not a CNS target, as it suggests better distribution.
9. **Caco-2:** Ligand A (-4.819) is better than Ligand B (-4.574). Higher (less negative) values indicate better absorption.
10. **Solubility:** Ligand A (-4.146) is better than Ligand B (-1.995). Better solubility is always desired.
11. **hERG:** Both are low (0.329 and 0.294), which is excellent.
12. **Cl_mic:** Ligand B (23.029) has lower clearance, indicating better metabolic stability than Ligand A (29.743).
13. **t1/2:** Ligand A (32.524) has a longer half-life than Ligand B (-0.365). This is a significant advantage.
14. **Pgp:** Ligand A (0.14) is better than Ligand B (0.243). Lower P-gp efflux is desirable.
15. **Affinity:** Ligand A (-6.8) is slightly better than Ligand B (-6.6). While the difference is small, it's still a positive.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical parameters, especially logP, TPSA, BBB, solubility, Caco-2, and Pgp. While Ligand B has slightly better metabolic stability (lower Cl_mic), the other advantages of Ligand A, particularly its superior predicted permeability and distribution (BBB), outweigh this benefit. The slightly better binding affinity of Ligand A further supports its selection.
Output:
1
2025-04-17 19:01:57,940 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [354.426, 105.48 , 1.501, 4. , 5. , 0.418, 52.152, 68.321, -5.165, -2.92 , 0.74 , 44.845, 0.745, 0.063, -6.6 ]**
**Ligand B: [355.429, 52.65 , 1.34 , 1. , 3. , 0.635, 20.589, 88.445, -4.466, -1.675, 0.462, -6.673, -1.07 , 0.025, -5.6 ]**
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). No significant difference.
2. **TPSA:** Ligand A (105.48) is higher than Ligand B (52.65). For a cardiovascular GPCR, TPSA isn't *as* critical as for CNS targets, but lower is generally preferred for better permeability. Ligand B is significantly better here.
3. **logP:** Both ligands have good logP values (1.501 and 1.34, respectively), falling within the optimal 1-3 range. Ligand B is slightly better.
4. **H-Bond Donors:** Ligand A (4) is higher than Ligand B (1). Lower is generally better for permeability, giving an edge to Ligand B.
5. **H-Bond Acceptors:** Ligand A (5) is higher than Ligand B (3). Again, lower is better for permeability, favoring Ligand B.
6. **QED:** Ligand B (0.635) has a better QED score than Ligand A (0.418), indicating a more drug-like profile.
7. **DILI:** Ligand A (52.152) has a higher DILI risk than Ligand B (20.589). This is a significant advantage for Ligand B.
8. **BBB:** Ligand B (88.445) has a much higher BBB penetration percentile than Ligand A (68.321). While ADRB2 isn't exclusively a CNS target, some CNS exposure can occur, and higher BBB is generally favorable.
9. **Caco-2:** Ligand A (-5.165) and Ligand B (-4.466) are both negative, indicating poor permeability. However, Ligand B is slightly better.
10. **Aqueous Solubility:** Ligand A (-2.92) has worse solubility than Ligand B (-1.675). Solubility is important for formulation and bioavailability, favoring Ligand B.
11. **hERG:** Ligand A (0.74) has a slightly higher hERG risk than Ligand B (0.462), but both are reasonably low.
12. **Cl_mic:** Ligand B (-6.673) has a significantly lower (better) microsomal clearance than Ligand A (44.845), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-1.07) has a worse in vitro half-life than Ligand A (0.745).
14. **Pgp:** Ligand B (0.025) has a much lower P-gp efflux liability than Ligand A (0.063), indicating better absorption and potentially better CNS exposure.
15. **Binding Affinity:** Ligand A (-6.6) has a slightly better binding affinity than Ligand B (-5.6). However, the difference is less than 1.5 kcal/mol.
**Overall Assessment:**
Ligand B consistently outperforms Ligand A in most crucial ADME properties (TPSA, HBD, HBA, DILI, BBB, solubility, Cl_mic, Pgp). While Ligand A has slightly better affinity and in vitro half-life, the ADME advantages of Ligand B are substantial, particularly the lower DILI risk and better metabolic stability. Given the GPCR target class, the balance of properties makes Ligand B the more promising candidate.
Output:
0
2025-04-17 19:01:57,941 - INFO - Here's my reasoning and output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (357.401) is slightly higher than Ligand B (345.535), but both are acceptable.
2. **TPSA:** Ligand A (61.88) is better than Ligand B (55.63), both are below the 140 threshold for good absorption.
3. **logP:** Ligand A (0.329) is suboptimal, being below 1. Ligand B (4.12) is high, potentially causing solubility and off-target issues.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A (4) is better than Ligand B (5), both are acceptable.
6. **QED:** Both ligands have good QED scores (A: 0.667, B: 0.77), indicating good drug-like properties.
7. **DILI:** Both ligands have low DILI risk (A: 34.781, B: 32.105), which is excellent.
8. **BBB:** Both ligands have good BBB penetration (A: 78.868, B: 81.621).
9. **Caco-2:** Ligand A (-4.443) is significantly worse than Ligand B (-5.307).
10. **Solubility:** Ligand A (-1.631) is better than Ligand B (-4.289).
11. **hERG:** Both ligands have low hERG inhibition risk (A: 0.341, B: 0.406).
12. **Cl_mic:** Ligand A (-7.949) has much better metabolic stability (lower clearance) than Ligand B (42.743).
13. **t1/2:** Ligand A (-10.281) has a much longer in vitro half-life than Ligand B (4.79).
14. **Pgp:** Ligand A (0.032) has much lower P-gp efflux liability than Ligand B (0.605).
15. **Affinity:** Ligand A (-7.0) has slightly better binding affinity than Ligand B (-6.2).
**GPCR-Specific Priorities:**
For an ADRB2 GPCR, we prioritize logP, Pgp, TPSA, and affinity. Ligand A has a suboptimal logP, but excels in Pgp efflux, has a better TPSA, and has a slightly better affinity. Ligand B has a high logP which is a concern. The superior metabolic stability (Cl_mic and t1/2) and Pgp properties of Ligand A are very important for a GPCR target. The Caco-2 permeability is a drawback for Ligand A, but the other advantages outweigh this.
**Conclusion:**
Considering the balance of properties and the priorities for a GPCR target, Ligand A is the more promising drug candidate.
Output:
1
2025-04-17 19:01:57,941 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (374.48 and 351.45 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (55.63) is significantly better than Ligand A (92.34). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption. Ligand B is well below the 140 threshold.
3. **logP:** Ligand B (3.084) is slightly higher than Ligand A (1.786), but both are within the optimal 1-3 range.
4. **HBD:** Ligand B (1) has fewer HBD than Ligand A (2), which is preferable for permeability.
5. **HBA:** Ligand B (5) and Ligand A (4) are both acceptable, below the 10 threshold.
6. **QED:** Ligand B (0.8) has a higher QED score than Ligand A (0.5), indicating a more drug-like profile.
7. **DILI:** Ligand B (44.44) has a lower DILI risk than Ligand A (57.35), which is a significant advantage.
8. **BBB:** Ligand B (91.59) has higher BBB penetration than Ligand A (75.81). While not critical for a cardiovascular target, it doesn't hurt.
9. **Caco-2:** Both ligands have very poor Caco-2 permeability (-4.703 and -4.879). This is a significant concern for both.
10. **Solubility:** Ligand B (-3.759) has slightly better solubility than Ligand A (-2.54), though both are quite poor.
11. **hERG:** Ligand B (0.443) has a lower hERG risk than Ligand A (0.215), which is a positive.
12. **Cl_mic:** Ligand B (13.81) has significantly lower microsomal clearance than Ligand A (30.96), indicating better metabolic stability.
13. **t1/2:** Ligand B (16.12) has a longer in vitro half-life than Ligand A (25.44), which is desirable.
14. **Pgp:** Ligand B (0.545) has higher P-gp efflux than Ligand A (0.151). This is a negative for Ligand B.
15. **Binding Affinity:** Ligand A (-5.2) has a slightly better binding affinity than Ligand B (-4.4). This is a 0.8 kcal/mol difference, which is noticeable but not overwhelming.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B has better logP, significantly better TPSA, and lower Pgp efflux, and a lower DILI score. While Ligand A has a slightly better affinity, the other ADME properties of Ligand B are far more favorable. The poor Caco-2 permeability is a concern for both, but the other improvements in Ligand B outweigh this.
**Conclusion:**
Considering the balance of properties, particularly the improved ADME profile (lower DILI, better metabolic stability, solubility, and TPSA) of Ligand B, it is the more promising drug candidate despite the slightly weaker binding affinity.
Output:
0
2025-04-17 19:01:57,941 - INFO - Batch 80 complete. Total preferences: 1280
2025-04-17 19:01:57,941 - INFO - Processing batch 81/512...
2025-04-17 19:02:48,971 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [353.463, 89.95, 0.227, 2, 4, 0.669, 18.185, 38.465, -5.154, -0.953, 0.152, 4.092, -4.348, 0.022, -5.6]
**Ligand B:** [357.449, 56.07, 2.854, 0, 6, 0.603, 14.308, 98.333, -4.547, -3.74, 0.516, 42.107, -5.862, 0.213, -5.7]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity, and BBB):
1. **MW:** Both ligands are within the ideal range (200-500 Da).
2. **TPSA:** Ligand A (89.95) is better than Ligand B (56.07). Lower TPSA is generally preferred for GPCRs, aiding permeability.
3. **logP:** Ligand B (2.854) is better. It falls within the optimal range (1-3), while Ligand A (0.227) is quite low, potentially hindering membrane permeability.
4. **HBD/HBA:** Ligand B has 0 HBD and 6 HBA, while Ligand A has 2 HBD and 4 HBA. Both are acceptable, but Ligand B's lower HBD count is slightly preferable.
5. **QED:** Both are similar (0.669 vs 0.603), indicating good drug-likeness.
6. **DILI:** Ligand B (14.308) is significantly better than Ligand A (18.185), indicating a lower risk of liver injury. This is a crucial advantage.
7. **BBB:** Ligand B (98.333) is *much* better than Ligand A (38.465). For a GPCR, even if not a CNS target, some BBB penetration can be beneficial for distribution. Ligand B's high score is a major positive.
8. **Caco-2:** Ligand A (-5.154) is better than Ligand B (-4.547), indicating better intestinal absorption.
9. **Solubility:** Ligand A (-0.953) is better than Ligand B (-3.74), indicating better aqueous solubility.
10. **hERG:** Both are low risk (0.152 and 0.516), which is good.
11. **Cl_mic:** Ligand A (4.092) is better than Ligand B (42.107), indicating better metabolic stability.
12. **t1/2:** Ligand B (-5.862) is better than Ligand A (-4.348), indicating a longer half-life.
13. **Pgp:** Ligand A (0.022) is better than Ligand B (0.213), indicating lower P-gp efflux.
14. **Affinity:** Both have very similar affinity (-5.6 and -5.7 kcal/mol). The difference is negligible.
**Overall Assessment:**
While Ligand A has advantages in Caco-2 permeability, solubility, metabolic stability and Pgp efflux, Ligand B shines in critical areas for a GPCR drug: significantly better BBB penetration, lower DILI risk, and a longer half-life. The logP value of Ligand B is also more favorable. The affinity is almost identical. Given the GPCR-specific priorities, the benefits of Ligand B outweigh the slight drawbacks.
Output:
0
2025-04-17 19:02:48,971 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (345.487 and 366.487 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (43.86) is significantly better than Ligand B (100.19). For a GPCR, lower TPSA is generally preferred for better permeability, and Ligand A is well below the 140 A^2 threshold. Ligand B is approaching a value that could hinder absorption.
**3. logP:** Both ligands have acceptable logP values (1.886 and 1.392), falling within the optimal 1-3 range. Ligand B is slightly lower, which could be marginally less favorable for membrane permeability.
**4. H-Bond Donors:** Ligand A (0) is preferable to Ligand B (3). Fewer H-bond donors generally improve permeability.
**5. H-Bond Acceptors:** Ligand A (3) is preferable to Ligand B (5), for similar reasons as HBD.
**6. QED:** Ligand A (0.731) has a better QED score than Ligand B (0.575), indicating a more drug-like profile.
**7. DILI:** Ligand B (44.552) has a higher DILI risk than Ligand A (11.671). This is a significant advantage for Ligand A.
**8. BBB:** Ligand A (78.17) has a much higher BBB penetration percentile than Ligand B (44.513). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be beneficial for distribution and off-target effects assessment.
**9. Caco-2:** Ligand A (-4.66) is better than Ligand B (-5.438), indicating better intestinal absorption.
**10. Solubility:** Both ligands have similar, very poor aqueous solubility (-1.561 and -1.427). This is a potential formulation challenge for both.
**11. hERG:** Both ligands have very low hERG inhibition risk (0.296 and 0.111), which is excellent.
**12. Cl_mic:** Ligand B (34.646) has lower microsomal clearance than Ligand A (40.118), suggesting better metabolic stability. This is a slight advantage for Ligand B.
**13. t1/2:** Ligand B (16.215) has a significantly longer in vitro half-life than Ligand A (2.694). This is a substantial advantage for Ligand B, potentially allowing for less frequent dosing.
**14. Pgp:** Both ligands have very low P-gp efflux liability (0.094 and 0.044).
**15. Binding Affinity:** Ligand A (-7.1) has a slightly better binding affinity than Ligand B (-6.6). This 0.5 kcal/mol difference is significant enough to outweigh some of the ADME drawbacks of Ligand A.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand A is the more promising candidate. Its significantly lower TPSA, better QED, lower DILI risk, and higher BBB penetration, combined with a slightly stronger binding affinity, outweigh the longer half-life and slightly better metabolic stability of Ligand B. The solubility is a concern for both, but can be addressed with formulation strategies.
Output:
1
2025-04-17 19:02:48,971 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (374.39 and 359.50 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (76.35 and 70.15) are below the 140 A^2 threshold for good oral absorption. They are also reasonably low, which is beneficial for GPCR ligands. Ligand B is slightly better.
3. **logP:** Both ligands (3.17 and 2.48) are within the optimal 1-3 range. Ligand B is slightly lower, which could be advantageous for solubility, but both are acceptable.
4. **HBD:** Ligand A has 1 HBD, while Ligand B has 2. Both are within the acceptable limit of 5.
5. **HBA:** Ligand A has 5 HBA, and Ligand B has 6. Both are below the 10 limit.
6. **QED:** Both ligands have very similar QED values (0.873 and 0.855), indicating good drug-likeness.
7. **DILI:** Ligand A (69.64%) has a higher DILI risk than Ligand B (54.75%). This is a significant advantage for Ligand B.
8. **BBB:** Both ligands have good BBB penetration (72.66% and 68.44%). This is important for a GPCR target, but less critical for ADRB2 specifically as it isn't a CNS target.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual. This suggests poor permeability. Ligand A (-4.895) is slightly better than Ligand B (-5.135), but both are concerning.
10. **Solubility:** Both ligands have very poor solubility (-3.9 and -3.422). This is a major drawback for both.
11. **hERG:** Both ligands have low hERG inhibition risk (0.562 and 0.8). No significant difference.
12. **Cl_mic:** Ligand A (19.88 mL/min/kg) has a significantly lower microsomal clearance than Ligand B (48.05 mL/min/kg), indicating better metabolic stability.
13. **t1/2:** Ligand A (58.52 hours) has a much longer in vitro half-life than Ligand B (32.24 hours). This is a significant advantage for Ligand A.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.304 and 0.177). Ligand B is slightly better.
15. **Binding Affinity:** Ligand B (-8.1 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.8 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME drawbacks.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand B excels in affinity and has good values for the other parameters. While both have poor solubility and Caco-2 permeability, the superior binding affinity of Ligand B is a major factor. The lower DILI risk of Ligand B is also a significant benefit. The longer half-life and lower clearance of Ligand A are attractive, but the difference in binding affinity is more impactful.
**Conclusion:**
Despite the drawbacks in solubility and permeability, the significantly stronger binding affinity of Ligand B, coupled with its lower DILI risk, makes it the more promising drug candidate for ADRB2.
Output:
0
2025-04-17 19:02:48,972 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (352.385 and 349.475 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (58.44) is significantly better than Ligand B (91.32). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold. Ligand B is approaching it, which is less ideal.
3. **logP:** Both ligands have acceptable logP values (2.08 and 2.793), falling within the 1-3 range. Ligand B is slightly higher, which could potentially lead to some off-target interactions, but isn't a major concern.
4. **HBD:** Ligand A has 0 HBD, while Ligand B has 3. Lower is generally preferred for permeability, giving a slight edge to Ligand A.
5. **HBA:** Both ligands have 4 HBA, which is acceptable (<=10).
6. **QED:** Ligand A (0.837) has a better QED score than Ligand B (0.706), indicating a more drug-like profile.
7. **DILI:** Both ligands have similar DILI risk (47.421 and 49.477 percentile), and both are reasonably low risk (<60).
8. **BBB:** Ligand A (93.757) has a much higher BBB penetration percentile than Ligand B (38.813). While ADRB2 isn't a CNS target, higher BBB is generally a positive indicator of permeability.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.574 and -4.904). This is unusual and suggests poor permeability *in vitro*. However, these values are close enough that the difference isn't decisive.
10. **Solubility:** Ligand A (-2.72) has better solubility than Ligand B (-4.116). Better solubility is preferred for bioavailability.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.293 and 0.326). This is excellent.
12. **Cl_mic:** Ligand A (17.386) has a significantly lower microsomal clearance than Ligand B (80.35). Lower clearance means greater metabolic stability, a significant advantage.
13. **t1/2:** Ligand A (-10.737) has a much longer *in vitro* half-life than Ligand B (-23.595). This is a substantial benefit, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.096 and 0.065).
15. **Binding Affinity:** Ligand A (-8.0) has a slightly better binding affinity than Ligand B (-5.8). This is a significant difference (>1.5 kcal/mol), and outweighs many of the minor ADME drawbacks of Ligand B.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A excels in TPSA, has comparable logP and Pgp, and significantly better affinity.
**Conclusion:**
Ligand A consistently outperforms Ligand B across several critical parameters, including TPSA, QED, solubility, metabolic stability (Cl_mic), half-life, and, most importantly, binding affinity. While both have acceptable DILI and hERG profiles, the superior ADME properties and binding affinity of Ligand A make it the more promising drug candidate.
Output:
1
2025-04-17 19:02:48,972 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
The target is ADRB2, a GPCR. Therefore, I will prioritize logP, TPSA, Pgp efflux, BBB penetration, and binding affinity, followed by ADME properties like solubility, metabolic stability, and safety (DILI, hERG).
Let's compare the ligands property by property:
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (351.353) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (74.69) is significantly better than Ligand B (96.44). Lower TPSA is crucial for GPCR ligands to ensure good brain penetration and overall absorption.
3. **logP:** Ligand A (3.054) is better than Ligand B (1.012). While both are within the acceptable range, Ligand A's logP is closer to the optimal 1-3 range, suggesting better membrane permeability and reduced off-target interactions. Ligand B is on the lower side, potentially hindering permeation.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1), but both are acceptable.
5. **HBA:** Ligand A (4) is slightly higher than Ligand B (5), but both are acceptable.
6. **QED:** Ligand A (0.839) is better than Ligand B (0.697), indicating a more drug-like profile.
7. **DILI:** Both are reasonably good, with Ligand A (60.527) being slightly higher than Ligand B (58.976). Both are below the concerning threshold of 60.
8. **BBB:** Both have good BBB penetration (Ligand A: 76.154, Ligand B: 77.821), which is positive.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Ligand A (-3.538) is better than Ligand B (-2.03), indicating better aqueous solubility.
11. **hERG:** Both are very low (Ligand A: 0.494, Ligand B: 0.288), suggesting low cardiotoxicity risk.
12. **Cl_mic:** Ligand B (33.101) has lower microsomal clearance than Ligand A (43.951), indicating better metabolic stability.
13. **t1/2:** Ligand B (9.978) has a longer in vitro half-life than Ligand A (5.663), which is desirable.
14. **Pgp:** Both have very low Pgp efflux (Ligand A: 0.076, Ligand B: 0.077), which is excellent.
15. **Affinity:** Ligand A (-6.5 kcal/mol) has slightly better binding affinity than Ligand B (-6.2 kcal/mol). While the difference is small, it's still a factor.
**Overall Assessment:**
Ligand A is superior due to its better TPSA, logP, QED, and solubility. The slightly better binding affinity also contributes. While Ligand B has better metabolic stability and half-life, the improvements in key GPCR-relevant properties with Ligand A outweigh these benefits. The negative Caco-2 values are a concern for both, but the other factors strongly favor Ligand A.
**Output:**
1
2025-04-17 19:02:48,972 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (336.41 Da) is better than Ligand B (362.495 Da), falling comfortably within the 200-500 Da range. Both are acceptable.
2. **TPSA:** Ligand A (34.03) is significantly better than Ligand B (58.64). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand B's TPSA is getting higher and could be problematic.
3. **logP:** Both ligands have good logP values (A: 4.036, B: 3.37), falling within the 1-3 range. Ligand A is slightly higher, potentially leading to distribution issues, but still acceptable.
4. **HBD:** Both ligands have 1 HBD, which is ideal.
5. **HBA:** Ligand A (2) is better than Ligand B (4). Lower HBA is generally preferred for permeability.
6. **QED:** Both ligands have good QED scores (A: 0.724, B: 0.893), indicating good drug-likeness. Ligand B is slightly better.
7. **DILI:** Both ligands have acceptable DILI risk (A: 53.432, B: 51.687), below the 60 threshold.
8. **BBB:** Ligand B (86.545) has a better BBB penetration score than Ligand A (69.794). However, since ADRB2 is primarily a cardiovascular target, high BBB penetration isn't a critical requirement.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.932 and -4.935), which is unusual. This suggests poor permeability.
10. **Solubility:** Both ligands have poor aqueous solubility (-4.477 and -3.836). This is a significant concern for both.
11. **hERG:** Ligand A (0.876) has a slightly higher hERG risk than Ligand B (0.47). Lower is better, so B is preferred here.
12. **Cl_mic:** Ligand B (18.2) has significantly lower microsomal clearance than Ligand A (74.847), indicating better metabolic stability. This is a major advantage for Ligand B.
13. **t1/2:** Ligand A (25.012) has a longer in vitro half-life than Ligand B (8.404). This is a positive for Ligand A.
14. **Pgp:** Ligand A (0.574) has lower P-gp efflux than Ligand B (0.204), which is favorable.
15. **Binding Affinity:** Ligand B (-7.0 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.1 kcal/mol). This is a substantial advantage that can potentially offset some of its other weaknesses.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in affinity and has better Pgp efflux. Ligand A has better TPSA and logP, but the affinity difference is substantial. Metabolic stability (Cl_mic) is also important, and Ligand B is significantly better in this regard.
**Overall Assessment:**
Despite the solubility and Caco-2 issues shared by both, Ligand B's superior binding affinity and metabolic stability are critical advantages. The stronger binding is likely to translate to greater efficacy, and the lower clearance will result in a longer duration of action. While Ligand A has a slightly better half-life, the affinity difference is more impactful.
Output:
0
2025-04-17 19:02:48,972 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (350.47 and 352.56 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (107.95) is better than Ligand B (32.78). While both are below 140, the lower TPSA of Ligand B is particularly favorable for GPCRs, potentially aiding in membrane permeability.
3. **logP:** Ligand A (1.282) is within the optimal 1-3 range. Ligand B (3.82) is at the higher end, which could lead to solubility issues or off-target interactions, but is still acceptable.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (0). Both are within the acceptable limit of 5.
5. **HBA:** Ligand A (7) is higher than Ligand B (3). Both are below the limit of 10.
6. **QED:** Ligand A (0.767) is better than Ligand B (0.623), indicating a more drug-like profile.
7. **DILI:** Ligand A (29.934) has a significantly lower DILI risk than Ligand B (5.118). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (87.01) has a better BBB penetration percentile than Ligand A (72.005). For a cardiovascular GPCR, BBB penetration is less critical, but still a consideration.
9. **Caco-2:** Ligand A (-5.362) is worse than Ligand B (-4.359), indicating lower intestinal absorption.
10. **Solubility:** Ligand A (-1.983) is worse than Ligand B (-2.494), indicating lower aqueous solubility.
11. **hERG:** Ligand A (0.069) has a lower hERG inhibition liability than Ligand B (0.891). This is a significant safety advantage for Ligand A.
12. **Cl_mic:** Ligand B (19.649) has a slightly lower microsomal clearance than Ligand A (21.718), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-1.654) has a worse in vitro half-life than Ligand B (1.033).
14. **Pgp:** Ligand A (0.029) has a lower P-gp efflux liability than Ligand B (0.34), which is favorable.
15. **Affinity:** Ligand B (-6.3) has a slightly better binding affinity than Ligand A (-6.0). While the difference is small, it's a positive for Ligand B.
**Overall Assessment:**
Considering the priorities for a GPCR target (logP, TPSA, Pgp, and affinity), Ligand B initially appears better due to its lower TPSA and slightly better affinity. However, Ligand A demonstrates a much more favorable safety profile with significantly lower DILI and hERG risk. The slightly lower solubility and Caco-2 permeability of Ligand A are concerns, but can potentially be addressed through formulation strategies. The better QED score also favors Ligand A. Given the importance of minimizing potential toxicity in drug development, especially cardiotoxicity (hERG) and liver injury (DILI), I prioritize Ligand A.
Output:
1
2025-04-17 19:02:48,972 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (363.531 Da) and Ligand B (340.475 Da) both fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (56.07) is better than Ligand B (67.66). Both are below the 140 threshold for oral absorption, but lower TPSA is generally preferred for GPCRs.
3. **logP:** Ligand A (2.238) is within the optimal 1-3 range. Ligand B (3.837) is pushing the upper limit, potentially leading to solubility issues.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (7) is better than Ligand B (6). Both are below the 10 threshold, but lower is better.
6. **QED:** Ligand B (0.75) is better than Ligand A (0.495). A higher QED suggests better overall drug-likeness.
7. **DILI:** Ligand A (15.51) is significantly better than Ligand B (61.264). This is a major advantage for Ligand A, as lower DILI risk is critical.
8. **BBB:** Both Ligand A (83.831) and Ligand B (80.419) have good BBB penetration, but Ligand A is slightly better. While ADRB2 isn't exclusively a CNS target, some CNS exposure can occur, and higher BBB is generally favorable.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-5.135) is slightly better than Ligand B (-4.931).
10. **Solubility:** Ligand A (-3.143) is better than Ligand B (-4.331).
11. **hERG:** Ligand A (0.511) is much better than Ligand B (0.848). Lower hERG inhibition is crucial to avoid cardiotoxicity, a significant concern for cardiovascular targets like ADRB2.
12. **Cl_mic:** Ligand A (31.272) is better than Ligand B (75.333). Lower clearance indicates better metabolic stability.
13. **t1/2:** Ligand B (37.234) is significantly better than Ligand A (-10.675). A longer half-life is generally desirable.
14. **Pgp:** Ligand A (0.292) is better than Ligand B (0.657). Lower P-gp efflux is good for bioavailability.
15. **Affinity:** Ligand B (-7.4) is significantly better than Ligand A (-1.7). This is a substantial difference in binding potency.
**Overall Assessment:**
Ligand B has a much stronger binding affinity (-7.4 kcal/mol vs -1.7 kcal/mol), which is a major advantage. It also has a better QED and *in vitro* half-life. However, Ligand A excels in safety parameters (DILI and hERG) and has better metabolic stability (Cl_mic). The high DILI and hERG risk associated with Ligand B are concerning, especially for a cardiovascular target. While the affinity difference is significant, the safety profile of Ligand A is more compelling. The slightly better TPSA, solubility, and Pgp profile of Ligand A also contribute to its favorability.
Given the GPCR-specific priorities (logP, Pgp, TPSA, and affinity) and the critical importance of safety for a cardiovascular drug, I lean towards Ligand A despite its weaker binding affinity. The safety profile is paramount, and the affinity difference, while large, might be addressable through further optimization.
Output:
1
2025-04-17 19:02:48,972 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (338.46 & 354.54 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (68.52) is slightly higher than Ligand B (58.64). Both are well below the 140 threshold for oral absorption, and acceptable for a cardiovascular target (not necessarily CNS). Ligand B is preferable.
3. **logP:** Both ligands (2.87 & 3.23) are within the optimal 1-3 range. Ligand B is slightly higher, which could be a minor advantage for membrane permeability.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 6 HBA, while Ligand B has 3. Lower HBA generally improves permeability, so Ligand B is preferable.
6. **QED:** Both ligands have similar QED scores (0.786 & 0.763), indicating good drug-likeness.
7. **DILI:** Ligand A (46.65) has a higher DILI risk than Ligand B (16.48). This is a significant advantage for Ligand B.
8. **BBB:** Both ligands show good BBB penetration (77.32 & 70.61). Since ADRB2 is primarily a cardiovascular target, BBB penetration isn't a primary concern, but it doesn't hurt.
9. **Caco-2:** Ligand A (-5.271) has a worse Caco-2 permeability than Ligand B (-4.474). This suggests Ligand B will have better intestinal absorption.
10. **Solubility:** Ligand A (-2.797) has slightly better aqueous solubility than Ligand B (-3.314). Solubility is important, but not a deciding factor here.
11. **hERG:** Ligand A (0.182) has a lower hERG inhibition liability than Ligand B (0.513). This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand A (33.024) has a lower microsomal clearance than Ligand B (88.919). Lower clearance means better metabolic stability, favoring Ligand A.
13. **t1/2:** Ligand A (-22.493) has a much longer in vitro half-life than Ligand B (5.13). This is a major advantage for Ligand A, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.29) has lower P-gp efflux liability than Ligand B (0.074). Lower Pgp efflux is preferable for oral bioavailability.
15. **Affinity:** Ligand A (-6.9 kcal/mol) has a slightly better binding affinity than Ligand B (-6.2 kcal/mol). While both are good, the 0.7 kcal/mol difference is notable.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B has a slightly better logP and TPSA, and significantly lower Pgp efflux. However, Ligand A has a better affinity, lower DILI risk, lower Cl_mic, and a much longer half-life. The affinity and metabolic stability advantages of Ligand A outweigh the slightly better permeability profile of Ligand B. The hERG risk is also lower for Ligand A.
**Conclusion:**
Considering the balance of properties, particularly the superior affinity, metabolic stability, and lower DILI risk of Ligand A, it is the more promising drug candidate for targeting the ADRB2 receptor.
Output:
1
2025-04-17 19:02:48,973 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (374.522) is slightly higher than Ligand B (339.399), but both are acceptable.
2. **TPSA:** Ligand A (49.85) is significantly better than Ligand B (80.12). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have acceptable logP values (Ligand A: 2.2, Ligand B: 0.943), falling within the 1-3 range. Ligand A is slightly better.
4. **HBD:** Ligand A (0) is preferable to Ligand B (1). Fewer HBDs generally improve membrane permeability.
5. **HBA:** Ligand A (4) is better than Ligand B (5). Lower HBA is generally preferred.
6. **QED:** Both ligands have good QED scores (Ligand A: 0.686, Ligand B: 0.879). Ligand B is slightly better here.
7. **DILI:** Ligand A (31.563) has a significantly lower DILI risk than Ligand B (58.511). This is a major advantage for Ligand A.
8. **BBB:** This is less critical for a cardiovascular target. Ligand A (90.306) has a higher BBB score than Ligand B (48.313), but this isn't a deciding factor.
9. **Caco-2:** Ligand A (-4.586) and Ligand B (-5.24) both have negative values, which is unusual. Lower values indicate poorer permeability. Ligand A is slightly better.
10. **Solubility:** Ligand A (-2.93) and Ligand B (-2.079) both have negative values, indicating poor solubility. Ligand B is slightly better.
11. **hERG:** Ligand A (0.701) is much better than Ligand B (0.191). Lower hERG inhibition is crucial for avoiding cardiotoxicity, especially for a cardiovascular target.
12. **Cl_mic:** Ligand A (40.104) has a higher microsomal clearance than Ligand B (15.366), indicating faster metabolism. Ligand B is preferable here.
13. **t1/2:** Ligand B (-5.254) has a longer in vitro half-life than Ligand A (-2.317), which is desirable.
14. **Pgp:** Ligand A (0.144) is better than Ligand B (0.013). Lower P-gp efflux is generally preferred.
15. **Binding Affinity:** Both ligands have very similar binding affinities (Ligand A: -6.7 kcal/mol, Ligand B: -6.5 kcal/mol). The difference is not substantial enough to outweigh other factors.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A is better in terms of logP, TPSA, and Pgp. The affinity difference is minimal.
**Overall Assessment:**
Ligand A demonstrates a better overall profile, particularly regarding safety (DILI, hERG) and permeability (TPSA, HBD, HBA). While Ligand B has a slightly better QED and in vitro half-life, the lower DILI and hERG risks associated with Ligand A are critical for a cardiovascular drug candidate. The slightly better permeability profile of Ligand A is also beneficial.
Output:
1
2025-04-17 19:02:48,973 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (360.523 and 352.45 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (49.41) is better than Ligand B (58.64). Both are below the 140 threshold for oral absorption, but lower is preferable.
3. **logP:** Both ligands have good logP values (2.715 and 1.903, respectively) falling within the 1-3 optimal range. Ligand A is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Both ligands have 1 HBD, which is within the acceptable limit of <=5.
5. **HBA:** Both ligands have 3 HBA, also within the acceptable limit of <=10.
6. **QED:** Both ligands have good QED scores (0.784 and 0.841), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Both ligands have low DILI risk (21.908 and 23.187), well below the concerning threshold of 60. No significant difference.
8. **BBB:** Ligand B (90.074) has a significantly higher BBB penetration percentile than Ligand A (57.154). While ADRB2 isn't *exclusively* a CNS target, some CNS exposure can be relevant for off-target effects or potential therapeutic benefits.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.012 and -4.586). These values are unusual and suggest poor permeability. However, these values are on a scale where negative values are possible.
10. **Solubility:** Ligand A (-4.469) has slightly better solubility than Ligand B (-2.834).
11. **hERG:** Both ligands have very low hERG inhibition risk (0.183 and 0.487), which is excellent.
12. **Cl_mic:** Ligand B (8.743) has a much lower microsomal clearance than Ligand A (28.274). This suggests better metabolic stability for Ligand B.
13. **t1/2:** Ligand A (11.425) has a longer in vitro half-life than Ligand B (-1.545). This is a significant advantage for dosing convenience.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.088 and 0.1). No significant difference.
15. **Binding Affinity:** Ligand A (-7.3) has a significantly stronger binding affinity than Ligand B (-6.8). This is a 0.5 kcal/mol difference, which is substantial and can outweigh some ADME drawbacks.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A has a slightly better logP and significantly better affinity. Ligand B has a much better BBB penetration and lower Cl_mic. The affinity difference is the most important factor here. A strong binding affinity is critical for efficacy, and a 0.5 kcal/mol advantage is substantial. While metabolic stability (Cl_mic) is important, it can often be improved through structural modifications.
**Conclusion:**
Despite Ligand B's better BBB penetration and metabolic stability, the significantly stronger binding affinity of Ligand A makes it the more promising drug candidate. The affinity advantage outweighs the slight drawbacks in those other parameters.
Output:
1
2025-04-17 19:02:48,973 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [348.443, 67.87, 2.288, 1, 4, 0.549, 35.595, 74.254, -5.176, -2.205, 0.669, 32.428, -15.413, 0.189, -7.6]
**Ligand B:** [337.335, 104.46, 1.196, 3, 5, 0.727, 64.521, 24.855, -5.126, -3.958, 0.144, -28.535, 28.545, 0.024, -7.5]
Here's a breakdown, comparing each parameter and considering GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (348.443) is slightly higher than Ligand B (337.335), but both are acceptable.
2. **TPSA:** Ligand A (67.87) is significantly better than Ligand B (104.46). Below 140 is good for oral absorption, and lower is better for GPCRs. Ligand A is much closer to the ideal range.
3. **logP:** Ligand A (2.288) is optimal (1-3). Ligand B (1.196) is on the lower side, potentially hindering permeation.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is preferable to Ligand B (5). Fewer HBAs generally improve permeability.
6. **QED:** Ligand B (0.727) is slightly better than Ligand A (0.549), indicating a more drug-like profile. However, this is a relatively small difference.
7. **DILI:** Ligand A (35.595) is significantly better than Ligand B (64.521). Lower DILI risk is crucial.
8. **BBB:** Ligand A (74.254) is much better than Ligand B (24.855). While ADRB2 isn't strictly a CNS target, some CNS penetration can be beneficial for understanding off-target effects.
9. **Caco-2:** Both are negative, indicating poor permeability. This is a concern for both, but the negative values are close enough that it doesn't heavily sway the decision.
10. **Solubility:** Both have negative solubility values, indicating poor solubility. Ligand B (-3.958) is worse than Ligand A (-2.205). Solubility is a concern for both, but Ligand A is slightly better.
11. **hERG:** Ligand A (0.669) is better than Ligand B (0.144), indicating a lower risk of cardiotoxicity.
12. **Cl_mic:** Ligand B (-28.535) has a lower (better) microsomal clearance than Ligand A (32.428), indicating better metabolic stability.
13. **t1/2:** Ligand B (28.545) has a much longer half-life than Ligand A (-15.413). This is a significant advantage for dosing convenience.
14. **Pgp:** Ligand A (0.189) is better than Ligand B (0.024), indicating lower P-gp efflux. Lower efflux is desirable for bioavailability.
15. **Affinity:** Ligand A (-7.6) is slightly better than Ligand B (-7.5). While the difference is small, it's still a factor.
**Overall Assessment:**
Ligand A is superior despite Ligand B having a better QED and half-life. Ligand A excels in critical areas for a GPCR target: TPSA, logP, DILI risk, BBB penetration, hERG risk, and Pgp efflux. The slightly better affinity of Ligand A is a bonus. While Ligand B has better metabolic stability, the other advantages of Ligand A outweigh this benefit. The poor Caco-2 and solubility for both are concerning and would require further optimization, but the overall profile of Ligand A is more promising.
Output:
1
2025-04-17 19:02:48,973 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.475 and 358.467 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (86.71) is better than Ligand B (67.23). Both are below the 140 A^2 threshold for good oral absorption, but lower TPSA is generally preferred for GPCRs, potentially aiding in brain penetration if desired.
3. **logP:** Both ligands have good logP values (1.365 and 1.838), falling within the optimal 1-3 range. Ligand B is slightly higher, which could be a minor advantage for membrane permeability.
4. **HBD:** Ligand A has 2 HBD, and Ligand B has 1. Both are within the acceptable limit of <=5.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 5. Both are within the acceptable limit of <=10.
6. **QED:** Ligand B (0.83) has a better QED score than Ligand A (0.656), indicating a more drug-like profile.
7. **DILI:** Ligand A (9.655) has a significantly lower DILI risk than Ligand B (64.056). This is a major advantage for Ligand A.
8. **BBB:** Both ligands have reasonable BBB penetration (53.16 and 57.891). Since ADRB2 is a cardiovascular target, high BBB penetration isn't critical, but it's not detrimental.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.942 and -5.168). This is unusual and suggests poor permeability. However, these values are on a scale where negative values are possible, and the absolute values are similar.
10. **Solubility:** Ligand A (-0.991) has slightly better solubility than Ligand B (-2.636).
11. **hERG:** Both ligands have very low hERG inhibition risk (0.181 and 0.239). This is excellent.
12. **Cl_mic:** Ligand A (10.231) has a much lower microsomal clearance than Ligand B (44.449), indicating better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand B (27.217) has a significantly longer in vitro half-life than Ligand A (-10.89). This is a substantial advantage for Ligand B.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.025 and 0.249).
15. **Binding Affinity:** Ligand B (-5.4 kcal/mol) has a significantly stronger binding affinity than Ligand A (-1.5 kcal/mol). This is a very large advantage, potentially outweighing some of the ADME drawbacks.
**Overall Assessment:**
Ligand B has a much stronger binding affinity and a longer half-life, which are crucial for efficacy and dosing frequency. However, it has a significantly higher DILI risk and higher microsomal clearance. Ligand A has a much better safety profile (lower DILI, lower Cl_mic) and slightly better solubility, but its binding affinity is substantially weaker.
Considering the balance, the significantly stronger binding affinity of Ligand B is a major driver. While the DILI risk is concerning, it's a parameter that can be addressed through further medicinal chemistry optimization. The weaker affinity of Ligand A is harder to overcome.
Output:
0
2025-04-17 19:02:48,973 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (374.522 and 348.447 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (60.85) is significantly better than Ligand B (96.25). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold, while B is approaching it.
3. **logP:** Both ligands have acceptable logP values (2.222 and 1.078), falling within the 1-3 range. Ligand A is slightly better, being closer to the optimal range.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Fewer hydrogen bond donors generally improve permeability.
5. **HBA:** Ligand A (4) is preferable to Ligand B (5). Similar to HBD, fewer acceptors are generally better for permeability.
6. **QED:** Both ligands have similar QED values (0.662 and 0.622), both above the 0.5 threshold, indicating good drug-likeness.
7. **DILI:** Ligand A (12.33) has a much lower DILI risk than Ligand B (23.924). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (85.072) has better BBB penetration than Ligand B (44.009), but this isn't a major priority for a cardiovascular target.
9. **Caco-2:** Ligand A (-4.779) is better than Ligand B (-5.414), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-1.859) is better than Ligand B (-1.182), indicating better aqueous solubility.
11. **hERG:** Ligand A (0.688) has a lower hERG inhibition liability than Ligand B (0.16). This is a crucial advantage, as hERG inhibition can lead to cardiotoxicity.
12. **Cl_mic:** Ligand A (38.558) has a higher (worse) microsomal clearance than Ligand B (2.367). This suggests Ligand B is more metabolically stable.
13. **t1/2:** Ligand B (13.257) has a significantly longer in vitro half-life than Ligand A (-1.616). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.266) has lower P-gp efflux liability than Ligand B (0.013), which is preferable.
15. **Binding Affinity:** Ligand A (-6.8 kcal/mol) has a slightly better binding affinity than Ligand B (-5.9 kcal/mol). While the difference is not huge, it's still a positive for Ligand A.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A performs better on logP, TPSA, and Pgp. The affinity difference is small, but favors A.
**Overall Assessment:**
Ligand A has a more favorable profile overall, despite Ligand B's better metabolic stability and half-life. The lower DILI risk and hERG inhibition liability of Ligand A are critical advantages, especially for a cardiovascular target. The better TPSA, logP, and Pgp values also contribute to its improved drug-like properties. While Ligand B has a longer half-life, the safety concerns associated with its higher DILI and hERG risk outweigh this benefit.
Output:
1
2025-04-17 19:02:48,973 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (335.323 and 347.415 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand B (91.76) is significantly better than Ligand A (124.07). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (2.379) is slightly better than Ligand B (1.265), falling more squarely within the optimal 1-3 range. Ligand B is a bit low, potentially impacting permeability.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (2), but both are acceptable (<=5).
5. **HBA:** Ligand A (7) is higher than Ligand B (5), but both are within the acceptable range (<=10).
6. **QED:** Both ligands have good QED scores (0.625 and 0.783), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand B (41.915) has a much lower DILI risk than Ligand A (97.596). This is a significant advantage for Ligand B.
8. **BBB:** Ligand B (38.232) has a higher BBB penetration than Ligand A (20.318). While not critical for a cardiovascular target, it's a slight positive.
9. **Caco-2:** Both ligands have similar, very poor Caco-2 permeability (-4.92 and -4.708). This is a concern for both.
10. **Solubility:** Ligand A (-5.15) is slightly worse than Ligand B (-2.462), but both are poor.
11. **hERG:** Ligand A (0.505) is slightly better than Ligand B (0.165), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand B (38.922) has a slightly higher microsomal clearance than Ligand A (34.599), meaning faster metabolism and potentially lower exposure.
13. **t1/2:** Ligand B (-23.577) has a significantly longer in vitro half-life than Ligand A (-2.571), which is a major advantage.
14. **Pgp:** Ligand A (0.069) has lower P-gp efflux than Ligand B (0.026), indicating better bioavailability.
15. **Binding Affinity:** Ligand A (-7.5) has a slightly better binding affinity than Ligand B (-5.3). This is a 2.2 kcal/mol difference, which is substantial.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), affinity, logP, TPSA, and Pgp are key. Ligand A has a better affinity and Pgp profile, but Ligand B has a much better TPSA, DILI, and half-life. The affinity difference is significant, but the DILI risk for Ligand A is very high. The longer half-life of Ligand B is also a strong advantage. The slightly lower logP of Ligand B is a minor concern.
**Overall Assessment:**
While Ligand A has a better binding affinity, the significantly higher DILI risk and shorter half-life are major drawbacks. Ligand B, despite a slightly weaker affinity, presents a much more favorable safety profile (lower DILI) and better pharmacokinetic properties (longer half-life). The better TPSA is also a plus. The affinity difference, while notable, can potentially be addressed with further optimization, but mitigating a high DILI risk is much more challenging.
Output:
0
2025-04-17 19:02:48,974 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (357.8 & 346.4 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (82.79) is better than Ligand B (87.32). Both are below 140, but lower TPSA generally favors absorption.
3. **logP:** Ligand B (1.887) is slightly lower than Ligand A (2.744), but both are within the optimal 1-3 range.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (7) is higher than Ligand B (4). While both are acceptable, lower HBA is generally preferred.
6. **QED:** Ligand B (0.738) is better than Ligand A (0.515), indicating a more drug-like profile.
7. **DILI:** Ligand B (46.064) has a significantly lower DILI risk than Ligand A (80.109). This is a major advantage for Ligand B.
8. **BBB:** Ligand A (50.756) and Ligand B (57.774) are both relatively low. Since ADRB2 is a cardiovascular target, BBB penetration is not a primary concern.
9. **Caco-2:** Ligand A (-5.01) is slightly better than Ligand B (-4.482), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-3.91) is slightly better than Ligand B (-3.283).
11. **hERG:** Both ligands have very low hERG inhibition liability (0.214 and 0.242 respectively), which is excellent.
12. **Cl_mic:** Ligand B (64.248) has lower microsomal clearance than Ligand A (82.626), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-44.409) has a significantly longer in vitro half-life than Ligand A (-5.728), which is a substantial advantage.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.168 and 0.09 respectively), which is good.
15. **Binding Affinity:** Both ligands have excellent binding affinity (-7.0 and -5.9 kcal/mol respectively). Ligand A is slightly better, but the difference is not huge.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has a slight edge in affinity and Caco-2 permeability, but Ligand B excels in DILI risk, metabolic stability (Cl_mic, t1/2), and QED. The significantly lower DILI risk and improved metabolic stability of Ligand B are crucial for a cardiovascular drug.
**Conclusion:**
Considering the balance of properties and the priorities for a GPCR target, Ligand B is the more promising drug candidate. The lower DILI risk and improved metabolic stability outweigh the slightly better affinity and Caco-2 permeability of Ligand A.
Output:
0
2025-04-17 19:02:48,974 - INFO - Batch 81 complete. Total preferences: 1296
2025-04-17 19:02:48,974 - INFO - Processing batch 82/512...
2025-04-17 19:03:38,655 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (352.435 Da and 359.861 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (104.97) is higher than Ligand B (75.87). For a cardiovascular GPCR, TPSA is moderately important, and lower is generally better for permeability. Ligand B has a clear advantage.
**3. logP:** Ligand A (0.063) is significantly lower than Ligand B (4.731). While a logP between 1-3 is optimal, Ligand B is quite high. This could lead to solubility issues and off-target interactions. Ligand A is much better here.
**4. H-Bond Donors:** Both have 2 HBD, which is within the acceptable limit of <=5. No difference.
**5. H-Bond Acceptors:** Ligand A has 5 HBA, and Ligand B has 6. Both are within the acceptable limit of <=10. No significant difference.
**6. QED:** Ligand A (0.601) is slightly better than Ligand B (0.566), indicating a more drug-like profile.
**7. DILI:** Ligand B (73.401) has a higher DILI risk than Ligand A (7.057). This is a significant concern, as we want to minimize liver toxicity. Ligand A is much preferred.
**8. BBB:** Ligand A (93.292) has significantly better BBB penetration potential than Ligand B (60.915). While not a primary concern for a cardiovascular target, better BBB penetration can sometimes reduce off-target effects.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-5.356 and -5.368), which is unusual and suggests poor permeability. This is a red flag for both.
**10. Aqueous Solubility:** Ligand A (-1.777) has better solubility than Ligand B (-4.477). Solubility is important for bioavailability. Ligand A is better.
**11. hERG Inhibition:** Ligand A (0.388) has a lower hERG inhibition liability than Ligand B (0.815). This is crucial for avoiding cardiotoxicity, especially for a cardiovascular target. Ligand A is much preferred.
**12. Microsomal Clearance:** Ligand B (83.42) has a much higher microsomal clearance than Ligand A (1.06). This means Ligand B is metabolized much faster, leading to a shorter half-life and potentially requiring higher doses. Ligand A is significantly better.
**13. In vitro Half-Life:** Ligand A (-25.447) has a much longer in vitro half-life than Ligand B (200.222). This is a major advantage for Ligand A, as it suggests less frequent dosing.
**14. P-gp Efflux:** Ligand A (0.003) has much lower P-gp efflux than Ligand B (0.511). Lower P-gp efflux is desirable for better bioavailability. Ligand A is better.
**15. Binding Affinity:** Ligand B (-6.5 kcal/mol) has slightly better binding affinity than Ligand A (-5.9 kcal/mol). While affinity is important, the difference of 0.6 kcal/mol is not substantial enough to outweigh the significant ADME advantages of Ligand A.
**Overall Assessment:**
Ligand A is clearly the superior candidate. While Ligand B has slightly better binding affinity, Ligand A excels in almost all ADME properties: lower DILI risk, better BBB penetration, improved solubility, lower hERG inhibition, significantly lower microsomal clearance, longer half-life, and lower P-gp efflux. The logP of Ligand A is also much more favorable. The poor Caco-2 permeability is a concern for both, but the other advantages of Ligand A make it the more promising starting point for optimization.
Output:
1
2025-04-17 19:03:38,655 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (358.429 and 349.479 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (67.43) is better than Ligand B (70.47). Both are reasonably good for oral absorption, but A is closer to the preferred <90 for GPCRs.
3. **logP:** Ligand A (3.236) is optimal, while Ligand B (0.514) is quite low. This is a significant difference. Low logP can lead to poor membrane permeability and bioavailability.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1), but both are within the acceptable limit of 5.
5. **HBA:** Ligand A (3) is lower than Ligand B (5), which is preferable. Higher HBA can sometimes hinder permeability.
6. **QED:** Ligand B (0.743) is slightly better than Ligand A (0.542), indicating a more drug-like profile.
7. **DILI:** Ligand B (13.222) has a much lower DILI risk than Ligand A (42.071). This is a major advantage for Ligand B.
8. **BBB:** Ligand A (89.492) has a significantly higher BBB penetration potential than Ligand B (61.691). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant for off-target effects or potential therapeutic benefits, and is generally a positive attribute.
9. **Caco-2:** Ligand A (-4.106) has a higher Caco-2 permeability than Ligand B (-5.108). Higher is better, suggesting better intestinal absorption.
10. **Solubility:** Ligand A (-3.785) has better aqueous solubility than Ligand B (-0.63). Solubility is important for formulation and bioavailability.
11. **hERG:** Ligand A (0.724) has a slightly better hERG profile than Ligand B (0.18), meaning lower risk of cardiotoxicity.
12. **Cl_mic:** Ligand B (12.438) has a lower microsomal clearance than Ligand A (62.115), indicating better metabolic stability.
13. **t1/2:** Ligand B (3.949) has a longer in vitro half-life than Ligand A (-11.834). A longer half-life is generally desirable.
14. **Pgp:** Ligand B (0.007) has significantly lower P-gp efflux liability than Ligand A (0.203). Lower P-gp efflux is beneficial for bioavailability.
15. **Binding Affinity:** Ligand B (-6.0) has a slightly better binding affinity than Ligand A (-5.9). While the difference is small, it's still a positive for Ligand B.
**Overall Assessment & GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp efflux, and binding affinity are key. Ligand A has a better TPSA and Caco-2 permeability, and a slightly better BBB penetration. However, Ligand B excels in logP, DILI, Cl_mic, t1/2, and Pgp efflux. The significantly lower DILI risk and improved metabolic stability (lower Cl_mic, longer t1/2) of Ligand B are compelling. The better logP of Ligand B is also a critical advantage for permeability and bioavailability. The slight affinity difference is not enough to overcome the other benefits of Ligand B.
Output:
0
2025-04-17 19:03:38,656 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [345.443, 73.74, 1.755, 1, 4, 0.797, 17.72, 68.67, -4.498, -1.507, 0.134, 8.372, 2.642, 0.041, -6.9]
**Ligand B:** [349.475, 92.5, 1.599, 2, 3, 0.619, 10.237, 68.127, -5.253, -2.407, 0.167, 35.006, -18.569, 0.019, -7.4]
Here's a breakdown of the comparison, considering the provided guidelines and GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both ligands are within the ideal range (200-500 Da). A is 345.443, B is 349.475 - very similar.
2. **TPSA:** Ligand A (73.74) is better than Ligand B (92.5). We want <140 for oral absorption, both are fine, but A is preferable.
3. **logP:** Both are good (1.755 and 1.599, respectively), falling within the 1-3 range. B is slightly lower, which *could* be a minor drawback, but both are acceptable.
4. **HBD:** Ligand A (1) is better than Ligand B (2). Lower is generally preferred.
5. **HBA:** Ligand A (4) is better than Ligand B (3). Lower is generally preferred.
6. **QED:** Ligand A (0.797) is better than Ligand B (0.619). Higher QED indicates better drug-likeness.
7. **DILI:** Ligand A (17.72) is significantly better than Ligand B (10.237). Lower DILI risk is crucial.
8. **BBB:** Both are similar (68.67 and 68.127). This is less critical for a cardiovascular target, but still a consideration.
9. **Caco-2:** Ligand A (-4.498) is better than Ligand B (-5.253). Higher is better, indicating better absorption.
10. **Solubility:** Ligand A (-1.507) is better than Ligand B (-2.407). Higher solubility is preferred.
11. **hERG:** Both are very low (0.134 and 0.167), indicating very low cardiotoxicity risk.
12. **Cl_mic:** Ligand A (8.372) is *much* better than Ligand B (35.006). Lower clearance means greater metabolic stability. This is a significant advantage for A.
13. **t1/2:** Ligand A (2.642) is better than Ligand B (-18.569). A positive half-life is preferred, and A has a reasonable value. B's negative value is concerning.
14. **Pgp:** Both are very low (0.041 and 0.019), indicating minimal P-gp efflux.
15. **Affinity:** Ligand B (-7.4) is slightly better than Ligand A (-6.9). This is a 0.5 kcal/mol difference, which is a reasonable advantage, but not overwhelming.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical ADME-Tox properties. The significantly lower DILI risk, much better metabolic stability (Cl_mic), and positive in vitro half-life are major advantages. While Ligand B has a slightly better binding affinity, the ADME profile of Ligand A is far more favorable for development as a drug candidate. The small affinity difference is outweighed by the substantial improvements in safety and pharmacokinetic properties.
Output:
1
2025-04-17 19:03:38,656 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for the ADRB2 receptor, a GPCR involved in cardiovascular function. Therefore, the priorities are logP, Pgp, TPSA, affinity, and, to a lesser extent, BBB.
Let's break down the comparison:
1. **MW:** Both ligands are within the acceptable range (200-500 Da). Ligand A (358.785) is slightly preferred due to being lower.
2. **TPSA:** Ligand B (61.02) is significantly better than Ligand A (90.06). Lower TPSA generally improves permeability, which is crucial for GPCR ligands.
3. **logP:** Both ligands have good logP values (around 3.4-3.8), falling within the optimal 1-3 range. Ligand B is slightly higher, which could be a minor drawback.
4. **HBD/HBA:** Ligand A (1 HBD, 6 HBA) is slightly better than Ligand B (2 HBD, 3 HBA) in terms of hydrogen bonding potential, potentially improving solubility without significantly hindering permeability.
5. **QED:** Ligand B (0.735) has a better QED score than Ligand A (0.414), indicating a more drug-like profile.
6. **DILI:** Ligand B (65.335) has a lower DILI risk than Ligand A (84.335), which is a significant advantage.
7. **BBB:** Both ligands have reasonable BBB penetration (around 70%), but Ligand B is slightly better.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and difficult to interpret without knowing the scale. However, we can assume they both have poor permeability.
9. **Solubility:** Both have negative solubility values, which is also unusual.
10. **hERG:** Ligand A (0.658) has a lower hERG risk than Ligand B (0.834), which is a positive.
11. **Cl_mic:** Ligand A (47.958) has a lower microsomal clearance than Ligand B (66.881), indicating better metabolic stability.
12. **t1/2:** Ligand A (78.846) has a significantly longer in vitro half-life than Ligand B (26.123), which is a major advantage.
13. **Pgp:** Ligand A (0.625) has lower P-gp efflux liability than Ligand B (0.57), which is a positive.
14. **Affinity:** Ligand A (-8.0 kcal/mol) has a significantly stronger binding affinity than Ligand B (-2.2 kcal/mol). This is a substantial difference and a major driver in the decision.
**Overall Assessment:**
While Ligand B has better TPSA, QED, DILI, and slightly better BBB, Ligand A's significantly superior binding affinity (-8.0 vs -2.2 kcal/mol) and longer half-life are critical advantages, especially for a GPCR target. The lower hERG risk and Pgp efflux liability of Ligand A also contribute to its favorability. The unusual negative Caco-2 and solubility values are concerning for both, but the potency advantage of Ligand A is likely to outweigh these concerns, as optimization can address permeability and solubility issues.
**Output:**
1
2025-04-17 19:03:38,656 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (343.431 and 331.368 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (71.33) is well below the 140 threshold and favorable for oral absorption. Ligand B (91.18) is still acceptable, but less optimal.
3. **logP:** Ligand A (1.153) is within the optimal 1-3 range. Ligand B (2.081) is also within range, but slightly higher.
4. **HBD:** Ligand A (0) is excellent, minimizing potential issues with permeability. Ligand B (4) is acceptable, but higher.
5. **HBA:** Ligand A (5) is good. Ligand B (6) is also acceptable.
6. **QED:** Ligand A (0.772) is better than Ligand B (0.606), indicating a more drug-like profile.
7. **DILI:** Ligand A (42.458) has a lower DILI risk than Ligand B (21.404), which is a significant advantage.
8. **BBB:** Ligand A (91.392) shows good potential for BBB penetration, while Ligand B (24.777) is quite low. Since ADRB2 is a GPCR, BBB penetration isn't *critical* unless targeting CNS effects, but it's a positive attribute.
9. **Caco-2:** Ligand A (-4.767) and Ligand B (-5.914) both have negative values, which is unusual and suggests very poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand A (-1.772) and Ligand B (-2.034) both have poor solubility. This is a major drawback for both.
11. **hERG:** Ligand A (0.374) has a lower hERG risk than Ligand B (0.734), which is a positive.
12. **Cl_mic:** Ligand A (43.275) has a higher microsomal clearance than Ligand B (-1.702), suggesting lower metabolic stability. This is a disadvantage for Ligand A.
13. **t1/2:** Ligand B (-9.531) has a longer in vitro half-life than Ligand A (-8.113).
14. **Pgp:** Ligand A (0.124) has lower P-gp efflux liability than Ligand B (0.153), which is favorable.
15. **Affinity:** Both ligands have very similar binding affinities (-6.7 and -6.9 kcal/mol). The difference is negligible.
**Overall Assessment:**
Ligand A is preferable despite the slightly higher Cl_mic. It has better QED, significantly lower DILI risk, better BBB penetration, lower hERG risk, and lower P-gp efflux. While both have poor solubility and Caco-2 permeability, the other advantages of Ligand A outweigh these drawbacks. The slightly better ADME profile of Ligand A makes it a more promising starting point for optimization.
Output:
1
2025-04-17 19:03:38,656 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (389.279) is slightly higher than Ligand B (340.391), but both are acceptable.
2. **TPSA:** Ligand A (71.78) is significantly better than Ligand B (103.41). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is pushing the upper limit for good oral absorption.
3. **logP:** Ligand A (2.444) is optimal. Ligand B (0.524) is quite low, potentially leading to poor membrane permeability and bioavailability.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A (4) is better than Ligand B (8). Higher HBA can sometimes hinder permeability.
6. **QED:** Both ligands have similar QED values (0.728 and 0.702), indicating good drug-likeness.
7. **DILI:** Ligand A (38.581) has a much lower DILI risk than Ligand B (69.988). This is a significant advantage.
8. **BBB:** Ligand A (74.913) has better BBB penetration than Ligand B (36.487). While ADRB2 isn't strictly a CNS target, some CNS exposure can occur, and higher BBB is generally favorable.
9. **Caco-2:** Ligand A (-4.993) is better than Ligand B (-5.469), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-3.725) is better than Ligand B (-1.683).
11. **hERG:** Both ligands have low hERG risk (0.423 and 0.118).
12. **Cl_mic:** Ligand A (31.561) has higher metabolic clearance than Ligand B (16.729), meaning Ligand B is more metabolically stable.
13. **t1/2:** Ligand A (24.012) has a longer half-life than Ligand B (10.244).
14. **Pgp:** Ligand A (0.106) has lower P-gp efflux than Ligand B (0.021), indicating better bioavailability.
15. **Affinity:** Ligand B (-6.8) has a slightly better binding affinity than Ligand A (-6.0). However, the difference is less than 1.5 kcal/mol, so it doesn't automatically outweigh other factors.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A excels in logP and TPSA, and has acceptable Pgp. While Ligand B has slightly better affinity, its poor logP and higher TPSA are significant drawbacks. The lower DILI risk and better BBB penetration of Ligand A are also major advantages.
**Conclusion:**
Considering the balance of properties, particularly the favorable ADME profile of Ligand A (better logP, TPSA, solubility, lower DILI, better BBB, and Pgp) despite a slightly lower binding affinity, I believe Ligand A is the more promising drug candidate.
Output:
1
2025-04-17 19:03:38,656 - INFO - Here's my reasoning and the final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, the priorities are affinity, logP, TPSA, Pgp efflux, and BBB penetration.
Let's compare the ligands property by property:
1. **MW:** Both ligands (340.383 and 348.487 Da) are within the ideal range (200-500 Da).
2. **TPSA:** Ligand A (82.18) is higher than Ligand B (58.64). Ligand B is significantly better, being closer to the optimal <140 for absorption.
3. **logP:** Both ligands (2.446 and 2.799) are within the optimal 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 6 HBA, while Ligand B has 3. Ligand B is better here, minimizing potential issues with solubility and permeability.
6. **QED:** Both are reasonably good (0.714 and 0.686), indicating good drug-like properties.
7. **DILI:** Ligand A (74.835) has a significantly higher DILI risk than Ligand B (15.471). This is a major concern for Ligand A.
8. **BBB:** Ligand B (81.815) has better BBB penetration than Ligand A (60.993). While ADRB2 isn't a CNS target, better BBB penetration can sometimes correlate with improved overall distribution.
9. **Caco-2:** Both have negative Caco-2 values (-4.871 and -4.747), which is unusual and suggests poor permeability. This is a drawback for both.
10. **Solubility:** Both have negative solubility values (-3.211 and -3.083), indicating poor aqueous solubility. This is a significant issue for both.
11. **hERG:** Both have low hERG risk (0.448 and 0.444).
12. **Cl_mic:** Ligand A (78.051) has a higher microsomal clearance than Ligand B (61.723), suggesting lower metabolic stability.
13. **t1/2:** Ligand B (11.445) has a much longer in vitro half-life than Ligand A (-26.138). This is a significant advantage for Ligand B.
14. **Pgp:** Both have low Pgp efflux liability (0.48 and 0.141). Ligand B is better here.
15. **Affinity:** Ligand B (-7.5 kcal/mol) has a significantly better binding affinity than Ligand A (-6.7 kcal/mol). This is a crucial advantage, exceeding the 1.5 kcal/mol threshold.
**Conclusion:**
Ligand B is clearly the superior candidate. It has a better safety profile (lower DILI), better metabolic stability (lower Cl_mic, longer t1/2), better permeability characteristics (lower TPSA), and, most importantly, significantly higher binding affinity. While both have issues with solubility and Caco-2 permeability, the other advantages of Ligand B outweigh these drawbacks.
**Output:**
0
2025-04-17 19:03:38,656 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (351.491 and 347.507 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (101.29) is higher than Ligand B (54.26). For a cardiovascular GPCR like ADRB2, TPSA is not a primary concern unless targeting the CNS, but lower is generally preferred for better absorption. Ligand B is significantly better.
3. **logP:** Both ligands have acceptable logP values (1.58 and 2.682, respectively), falling within the 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Ligand A has 3 HBD, while Ligand B has 0. Lower HBD can improve membrane permeability, making Ligand B slightly preferable.
5. **HBA:** Ligand A has 3 HBA, Ligand B has 5. Ligand A is slightly better here.
6. **QED:** Both ligands have good QED scores (0.588 and 0.645), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (19.542) has a significantly lower DILI risk than Ligand B (33.307). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (70.648) has a higher BBB penetration percentile than Ligand A (63.901). While ADRB2 isn't primarily a CNS target, some CNS exposure can occur, and higher BBB is generally favorable.
9. **Caco-2:** Ligand A (-5.265) and Ligand B (-4.829) both have negative Caco-2 values, indicating poor permeability. This is a concern for both, but the values are similar.
10. **Solubility:** Ligand A (-2.834) has slightly better solubility than Ligand B (-1.584).
11. **hERG:** Ligand A (0.109) has a much lower hERG inhibition liability than Ligand B (0.56). This is a critical advantage for Ligand A, minimizing cardiotoxicity risk.
12. **Cl_mic:** Ligand B (61.544) has a higher microsomal clearance than Ligand A (28.595), indicating lower metabolic stability. This is a significant drawback for Ligand B.
13. **t1/2:** Ligand A (-14.357) has a longer in vitro half-life than Ligand B (-0.221). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.029) has a much lower P-gp efflux liability than Ligand B (0.152). This is a positive for Ligand A, improving bioavailability.
15. **Binding Affinity:** Ligand A (-7.4) has a slightly stronger binding affinity than Ligand B (-6.1). While both are good, the 1.3 kcal/mol difference is substantial enough to be a key factor.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity) and general drug-like properties, Ligand A is the more promising candidate. While Ligand B has slightly better logP and BBB penetration, Ligand A excels in critical areas like DILI risk, hERG inhibition, metabolic stability (lower Cl_mic, longer t1/2), P-gp efflux, and binding affinity. The lower DILI and hERG risks are particularly important for a cardiovascular target. The affinity difference is also significant. The Caco-2 permeability is a concern for both, but the other advantages of Ligand A outweigh this drawback.
Output:
1
2025-04-17 19:03:38,657 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (377.853 and 363.483 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (78.6) is better than Ligand B (88.16). Both are below 140, but lower TPSA generally favors absorption.
3. **logP:** Ligand A (3.898) is slightly higher than Ligand B (2.067). Both are within the 1-3 range, but Ligand A is closer to the upper limit.
4. **HBD:** Both ligands have 2 HBD, which is acceptable.
5. **HBA:** Ligand A has 6 HBA, while Ligand B has 4. Both are below the 10 threshold.
6. **QED:** Both ligands have good QED scores (0.681 and 0.776), indicating good drug-like properties.
7. **DILI:** Ligand B (59.519) has a significantly lower DILI risk than Ligand A (79.992). This is a major advantage for Ligand B.
8. **BBB:** Ligand A (29.12) has a very low BBB penetration, while Ligand B (59.364) is better, but still not high. Since ADRB2 is a cardiovascular target, BBB penetration is not a primary concern, but it's a slight advantage for B.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual. Assuming these are logP-scale values, they suggest poor permeability. Ligand A (-5.063) is worse than Ligand B (-4.97).
10. **Solubility:** Ligand A (-4.252) has slightly better solubility than Ligand B (-3.131).
11. **hERG:** Ligand A (0.589) has a slightly better hERG profile than Ligand B (0.154). Lower is better, so A is preferable.
12. **Cl_mic:** Ligand B (45.235) has a lower microsomal clearance than Ligand A (35.393), indicating better metabolic stability.
13. **t1/2:** Ligand A (100.757) has a significantly longer in vitro half-life than Ligand B (-48.83). This is a substantial advantage for Ligand A.
14. **Pgp:** Ligand A (0.545) has lower P-gp efflux than Ligand B (0.071), which is better.
15. **Affinity:** Ligand A (-7.2 kcal/mol) has a stronger binding affinity than Ligand B (-5.7 kcal/mol). This is a significant advantage, exceeding the 1.5 kcal/mol threshold.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, affinity, and metabolic stability are key. Ligand A has a better logP, TPSA, affinity, and Pgp efflux. Ligand B has better DILI risk and Cl_mic. The difference in binding affinity is substantial. The longer half-life of Ligand A is also a significant benefit. While the DILI risk for Ligand A is higher, the superior binding affinity and half-life outweigh this concern, especially for a cardiovascular target where CNS penetration is not critical.
**Final Decision:**
Given the substantial binding affinity advantage of Ligand A, coupled with its better TPSA, logP, Pgp efflux, and half-life, I believe it is the more promising drug candidate despite the higher DILI risk.
1
2025-04-17 19:03:38,657 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.362 and 349.391 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (88.33) is better than Ligand B (121.23). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (1.86 and 1.641), falling within the 1-3 range. Ligand B is slightly lower, which could be marginally better for solubility.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Both ligands have the same number of HBA (5), which is acceptable.
6. **QED:** Ligand A (0.916) has a significantly better QED score than Ligand B (0.459), indicating a more drug-like profile. This is a substantial advantage.
7. **DILI:** Ligand B (63.94) has a lower DILI risk than Ligand A (74.021), which is a positive.
8. **BBB:** Ligand A (83.56) has a higher BBB penetration percentile than Ligand B (71.268). While not a primary concern for a cardiovascular target, it's not a negative.
9. **Caco-2:** Ligand A (-4.652) has a better Caco-2 permeability than Ligand B (-5.017).
10. **Solubility:** Ligand A (-2.856) has better solubility than Ligand B (-3.423).
11. **hERG:** Both ligands have very low hERG inhibition liability (0.296 and 0.27), which is excellent.
12. **Cl_mic:** Ligand B (8.305) has a lower microsomal clearance than Ligand A (17.719), suggesting better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand B (-25.044) has a much longer in vitro half-life than Ligand A (8.205). This is a major positive for dosing convenience.
14. **Pgp:** Both ligands have similar Pgp efflux liability (0.033 and 0.118).
15. **Binding Affinity:** Ligand A (-6.9) has a slightly better binding affinity than Ligand B (-6.4). While the difference is less than the 1.5 kcal/mol threshold, it's still a positive.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A is better on TPSA, logP, and affinity, while Ligand B is better on Pgp and Cl_mic. However, the substantial advantage of Ligand A in QED, solubility, and Caco-2 permeability, combined with a slightly better affinity, outweighs the metabolic stability and DILI advantages of Ligand B. The longer half-life of Ligand B is attractive, but the overall drug-like properties of Ligand A are more compelling.
**Final Decision:**
I prefer Ligand A.
1
2025-04-17 19:03:38,657 - INFO - Here's my reasoning and the final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, the priorities are logP, Pgp, TPSA, affinity, and to a lesser extent, BBB.
Let's compare the ligands property by property:
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (380.476) is slightly higher, but acceptable.
2. **TPSA:** Ligand A (40.62) is significantly better than Ligand B (91.65). Lower TPSA generally favors oral absorption and GPCR binding.
3. **logP:** Ligand A (3.371) is optimal, while Ligand B (1.473) is a bit low, potentially hindering membrane permeability.
4. **HBD/HBA:** Ligand A (0 HBD, 3 HBA) is preferable to Ligand B (2 HBD, 4 HBA). Fewer hydrogen bonds can improve permeability.
5. **QED:** Both are reasonably good (A: 0.68, B: 0.576), indicating acceptable drug-likeness.
6. **DILI:** Ligand B (40.713) has a better DILI profile than Ligand A (15.471), which is a positive.
7. **BBB:** Ligand A (97.131) has a much higher BBB penetration potential than Ligand B (55.487). While ADRB2 is cardiovascular, some CNS exposure can be relevant for off-target effects, and higher BBB is generally a plus.
8. **Caco-2:** Ligand A (-4.426) is better than Ligand B (-5.151), indicating better intestinal absorption.
9. **Solubility:** Ligand B (-1.793) has better aqueous solubility than Ligand A (-4.386).
10. **hERG:** Ligand A (0.68) has a better hERG profile than Ligand B (0.35).
11. **Cl_mic:** Ligand B (9.932) has significantly better metabolic stability (lower clearance) than Ligand A (51.469). This is a major advantage.
12. **t1/2:** Ligand B (14.924) has a longer half-life than Ligand A (-11.5). This is also a significant advantage.
13. **Pgp:** Ligand A (0.175) has lower P-gp efflux than Ligand B (0.109), which is favorable for bioavailability.
14. **Affinity:** Ligand A (-7.2 kcal/mol) has a stronger binding affinity than Ligand B (-5.9 kcal/mol). This is a substantial difference and a key driver in the decision.
**Overall Assessment:**
Ligand A excels in binding affinity, TPSA, logP, BBB, Caco-2, hERG, and Pgp efflux. Ligand B has advantages in DILI, metabolic stability (Cl_mic), and half-life, and solubility. However, the significantly stronger binding affinity of Ligand A (-7.2 vs -5.9 kcal/mol) outweighs the ADME advantages of Ligand B, especially considering the acceptable ADME profile of Ligand A. The better TPSA and logP of Ligand A also support its potential for good GPCR engagement and permeability.
**Output:**
1
2025-04-17 19:03:38,657 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [350.375, 122.13 , -0.671, 2. , 7. , 0.722, 45.25 , 70.027, -5.095, -0.752, 0.235, -4.324, -12.858, 0.004, -7.7 ]
**Ligand B:** [351.447, 96.53 , 0.649, 3. , 4. , 0.56 , 21.171, 61.923, -5.168, -1.48 , 0.048, 26.804, -2.711, 0.006, -5.8 ]
Here's a breakdown of each parameter and how the ligands compare, keeping GPCR priorities (logP, Pgp, TPSA, affinity) in mind:
1. **MW:** Both ligands are within the ideal range (350-351 Da). No significant difference.
2. **TPSA:** Ligand B (96.53) is significantly better than Ligand A (122.13). Lower TPSA generally favors better cell permeability, crucial for GPCR targeting.
3. **logP:** Ligand B (0.649) is within the optimal range, while Ligand A (-0.671) is slightly below. A slightly negative logP can sometimes be problematic for permeability, though not a dealbreaker.
4. **HBD:** Ligand B (3) has one more HBD than Ligand A (2). This is a minor difference.
5. **HBA:** Ligand B (4) has fewer HBA than Ligand A (7). Fewer HBA is generally preferred for permeability.
6. **QED:** Ligand A (0.722) has a better QED score than Ligand B (0.56), indicating better overall drug-likeness.
7. **DILI:** Ligand B (21.171) has a much lower DILI risk than Ligand A (45.25). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (70.027) has a higher BBB penetration percentile than Ligand B (61.923). While ADRB2 isn't a CNS target, some off-target CNS effects are possible with GPCRs, so higher BBB is slightly favorable.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-5.095) is slightly worse than Ligand B (-5.168).
10. **Solubility:** Both have poor solubility, but Ligand A (-0.752) is slightly better than Ligand B (-1.48).
11. **hERG:** Both have very low hERG inhibition risk (0.235 and 0.048 respectively).
12. **Cl_mic:** Ligand A (-4.324) has a much lower (better) microsomal clearance than Ligand B (26.804). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (-12.858) has a longer in vitro half-life than Ligand B (-2.711). This is a significant advantage for Ligand A.
14. **Pgp:** Both have very low P-gp efflux liability (0.004 and 0.006 respectively).
15. **Affinity:** Ligand A (-7.7) has a significantly stronger binding affinity than Ligand B (-5.8). This is a substantial advantage.
**Overall Assessment:**
Ligand A has a much stronger binding affinity and better metabolic stability (lower Cl_mic, longer t1/2). Ligand B has a lower DILI risk and a better TPSA. The affinity difference is substantial (over 1.5 kcal/mol), and for a GPCR, potency is paramount. While Ligand B's lower DILI is attractive, the superior binding affinity of Ligand A outweighs the slightly higher DILI risk, especially considering the other ADME properties are reasonably balanced. The TPSA difference is also significant, favoring Ligand B, but not enough to overcome the affinity gap.
Therefore, I would choose Ligand A.
1
2025-04-17 19:03:38,658 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Step-by-step comparison:**
1. **MW:** Ligand A (437.312 Da) is within the ideal range, while Ligand B (349.431 Da) is towards the lower end, but still acceptable.
2. **TPSA:** Ligand A (103.82) is slightly higher than the preferred <140, but acceptable. Ligand B (87.74) is excellent.
3. **logP:** Both ligands (A: 1.347, B: 1.36) are within the optimal 1-3 range.
4. **HBD:** Ligand A (1) is good. Ligand B (2) is also acceptable.
5. **HBA:** Ligand A (7) is good. Ligand B (4) is excellent.
6. **QED:** Both ligands (A: 0.643, B: 0.68) are above the 0.5 threshold, indicating good drug-likeness.
7. **DILI:** Ligand A (79.915) is higher risk than Ligand B (35.944). This is a significant concern.
8. **BBB:** Both ligands have good BBB penetration (A: 46.336, B: 79.217), but Ligand B is significantly better.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual. Assuming these are logP values, both are reasonable.
10. **Solubility:** Ligand A (-3.702) has worse solubility than Ligand B (-1.8).
11. **hERG:** Both ligands have very low hERG risk (A: 0.146, B: 0.084).
12. **Cl_mic:** Ligand A (57.196) has higher metabolic clearance than Ligand B (44.533), suggesting lower metabolic stability.
13. **t1/2:** Ligand B (-22.576) has a much longer in vitro half-life than Ligand A (-4.859), which is a major advantage.
14. **Pgp:** Both ligands have very low Pgp efflux (A: 0.059, B: 0.036).
15. **Affinity:** Ligand B (-6.5 kcal/mol) has slightly stronger binding affinity than Ligand A (-6.2 kcal/mol).
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Both ligands perform well on logP and Pgp. Ligand B has a better TPSA. The affinity difference is small, but favors Ligand B. However, the biggest differentiator is the DILI risk and the in vitro half-life. Ligand B has a much lower DILI risk and a significantly longer half-life.
**Conclusion:**
Ligand B is the better candidate due to its significantly lower DILI risk, longer half-life, better TPSA, and slightly improved binding affinity. While Ligand A is within acceptable ranges for most parameters, the higher DILI risk is a major drawback.
Output:
0
2025-04-17 19:03:38,658 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for the ADRB2, a cardiovascular GPCR. Therefore, the priorities are logP, TPSA, Pgp, affinity, and to a lesser extent, BBB.
Let's compare the ligands property by property:
1. **MW:** Both ligands (361.389 and 354.451 Da) fall within the ideal 200-500 Da range.
2. **TPSA:** Ligand B (90.98) is significantly better than Ligand A (112.73). Lower TPSA is preferred for GPCRs, aiding permeability.
3. **logP:** Ligand B (0.733) is slightly better than Ligand A (0.177). Both are a bit low, potentially hindering membrane permeability, but Ligand B is closer to the optimal 1-3 range.
4. **HBD:** Ligand B (2) is better than Ligand A (3). Lower HBD is generally preferred.
5. **HBA:** Both ligands have the same HBA count (4), which is acceptable.
6. **QED:** Both ligands have similar QED scores (0.535 and 0.521), indicating good drug-likeness.
7. **DILI:** Ligand B (41.411) has a slightly better DILI risk profile than Ligand A (34.82), but both are good.
8. **BBB:** Both ligands have similar BBB penetration (57.076 and 55.254). This isn't a primary concern for a cardiovascular target, but it's not detrimental.
9. **Caco-2:** Both ligands have very poor Caco-2 permeability (-5.228 and -5.032). This is a significant drawback for both.
10. **Solubility:** Both ligands have poor aqueous solubility (-2.163 and -1.759).
11. **hERG:** Both ligands have similar hERG inhibition liability (0.31 and 0.311), which is good.
12. **Cl_mic:** Ligand B (-5.427) has a much better (lower, more stable) microsomal clearance than Ligand A (17.033). This is a substantial advantage.
13. **t1/2:** Ligand B (9.787) has a significantly better in vitro half-life than Ligand A (-17.592). This is a major advantage.
14. **Pgp:** Both ligands have similar Pgp efflux liability (0.042 and 0.023), which is good.
15. **Affinity:** Ligand A (-8.3 kcal/mol) has a significantly better binding affinity than Ligand B (-6.8 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME concerns.
**Overall Assessment:**
Ligand A has a much stronger binding affinity, which is paramount for GPCR targets. However, Ligand B has significantly better metabolic stability (Cl_mic and t1/2) and a better TPSA. The poor Caco-2 and solubility for both are concerning, but the affinity difference is large enough to favor Ligand A. The slightly better logP of Ligand B is a minor benefit.
**Output:**
1
2025-04-17 19:03:38,658 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (341.451 Da) is slightly lower, which is generally favorable for permeability.
**2. TPSA:** Ligand A (47.56) is significantly better than Ligand B (60.25). For a GPCR, keeping TPSA low is beneficial for permeability, and A is well under the 140 A^2 threshold.
**3. logP:** Both ligands have acceptable logP values (A: 4.013, B: 3.436), falling within the 1-3 range. Ligand B is slightly better here, being closer to the optimal range.
**4. H-Bond Donors:** Ligand A has 1 HBD, while Ligand B has 0. Both are within the acceptable limit of <=5.
**5. H-Bond Acceptors:** Ligand A has 3 HBA, Ligand B has 6. Ligand A is better, being closer to the ideal of <=10.
**6. QED:** Ligand A (0.823) has a higher QED score than Ligand B (0.664), indicating a more drug-like profile.
**7. DILI:** Ligand B (55.448) has a lower DILI risk than Ligand A (37.728), which is a significant advantage. Lower DILI is always preferred.
**8. BBB:** Ligand A (81.039) has a higher BBB penetration percentile than Ligand B (73.362). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant, and higher BBB is generally better.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.855 and -4.87). This is unusual and suggests poor permeability *in vitro*. However, these values are close, so it doesn't strongly differentiate the two.
**10. Aqueous Solubility:** Ligand A (-4.632) has slightly better solubility than Ligand B (-3.395).
**11. hERG Inhibition:** Ligand A (0.702) has a slightly lower hERG inhibition liability than Ligand B (0.43). Lower is better.
**12. Microsomal Clearance:** Ligand B (74.576) has lower microsomal clearance than Ligand A (83.041), indicating better metabolic stability.
**13. In vitro Half-Life:** Ligand B (60.669 hours) has a significantly longer in vitro half-life than Ligand A (10.803 hours). This is a major advantage, potentially allowing for less frequent dosing.
**14. P-gp Efflux:** Both ligands have similar P-gp efflux liabilities (A: 0.729, B: 0.747).
**15. Binding Affinity:** Ligand B (-7.0 kcal/mol) has a slightly better binding affinity than Ligand A (-6.6 kcal/mol). This 0.4 kcal/mol difference is meaningful and can outweigh some ADME drawbacks.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand B emerges as the more promising candidate. While Ligand A has better TPSA and QED, Ligand B has a significantly longer half-life, lower DILI risk, and a slightly better binding affinity. The longer half-life and reduced toxicity risk are particularly important for a cardiovascular target where chronic administration is often required. The slightly lower TPSA of A is less critical than the other advantages of B.
Output:
0
2025-04-17 19:03:38,658 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Ligand A (383.809 Da) is within the ideal range (200-500 Da). Ligand B (350.503 Da) is also within range. No clear advantage here.
2. **TPSA:** Ligand A (109.77) is slightly higher than the preferred <140, but acceptable. Ligand B (58.64) is excellent, well below 140. This favors Ligand B.
3. **logP:** Both ligands (A: 2.555, B: 2.925) are within the optimal 1-3 range. No significant difference.
4. **HBD:** Ligand A (2) and Ligand B (1) are both good, below the 5 threshold. Ligand B is slightly better.
5. **HBA:** Ligand A (5) and Ligand B (3) are both good, below the 10 threshold. Ligand B is better.
6. **QED:** Ligand A (0.742) is better than Ligand B (0.487). This indicates a more drug-like profile for Ligand A.
7. **DILI:** Ligand A (98.953) has a very high DILI risk, which is a major concern. Ligand B (12.02) has a very low DILI risk, a significant advantage.
8. **BBB:** Ligand A (15.083) has poor BBB penetration. Ligand B (69.407) has good BBB penetration. Considering ADRB2 is a GPCR, BBB penetration is important, favoring Ligand B.
9. **Caco-2:** Ligand A (-5.248) and Ligand B (-4.355) are both negative, which is unusual and suggests very poor permeability. This is a concern for both, but the difference is small.
10. **Solubility:** Ligand A (-3.954) and Ligand B (-2.541) are both poor. This is a significant drawback for both.
11. **hERG:** Ligand A (0.037) is very low risk, while Ligand B (0.637) is slightly higher. This favors Ligand A.
12. **Cl_mic:** Ligand A (2.734) has a lower (better) microsomal clearance than Ligand B (82.779). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (28.114) has a longer half-life than Ligand B (-4.759). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.057) has lower P-gp efflux than Ligand B (0.205). This is a slight advantage for Ligand A.
15. **Binding Affinity:** Ligand B (-6.9 kcal/mol) has a slightly better binding affinity than Ligand A (-6.0 kcal/mol). While the difference is not huge, it's a factor.
**Overall Assessment:**
Ligand A has advantages in QED, Cl_mic, t1/2, hERG, and Pgp. However, its extremely high DILI risk and poor BBB penetration are major red flags, especially for a GPCR target. Ligand B has a much better safety profile (DILI), good BBB penetration, and a slightly better binding affinity. While its QED is lower and solubility is also poor, the safety and BBB properties are more critical for a viable drug candidate. The poor solubility of both compounds would need to be addressed through formulation strategies.
**Output:**
0
2025-04-17 19:03:38,658 - INFO - Batch 82 complete. Total preferences: 1312
2025-04-17 19:03:38,658 - INFO - Processing batch 83/512...
2025-04-17 19:04:27,709 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (384.234 Da) is within the ideal range (200-500 Da). Ligand B (350.503 Da) is also within the ideal range. No clear advantage here.
2. **TPSA:** Ligand A (47.56) is good, well below the 140 threshold. Ligand B (58.64) is still acceptable, but slightly higher. Ligand A is preferred.
3. **logP:** Ligand A (4.785) is a bit high, potentially leading to solubility issues or off-target effects. Ligand B (2.594) is within the optimal range (1-3). Ligand B is preferred.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Both ligands have 3 HBA, which is good.
6. **QED:** Ligand A (0.825) has a better QED score than Ligand B (0.695), indicating better overall drug-likeness. Ligand A is preferred.
7. **DILI:** Ligand A (80.535) has a significantly higher DILI risk than Ligand B (5.894). This is a major concern for Ligand A. Ligand B is strongly preferred.
8. **BBB:** Both ligands have good BBB penetration (Ligand A: 75.107, Ligand B: 78.79). No clear advantage.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. This is a concern for both, but the values are similar.
10. **Solubility:** Ligand A (-5.798) has very poor aqueous solubility, likely due to its high logP. Ligand B (-2.519) is better, though still not ideal. Ligand B is preferred.
11. **hERG:** Both ligands have low hERG inhibition risk (Ligand A: 0.624, Ligand B: 0.53). No clear advantage.
12. **Cl_mic:** Ligand A (54.846) has lower microsomal clearance than Ligand B (76.154), suggesting better metabolic stability. Ligand A is preferred.
13. **t1/2:** Ligand A (66.34) has a much longer in vitro half-life than Ligand B (-11.771). This is a significant advantage for Ligand A.
14. **Pgp:** Both ligands have low P-gp efflux liability (Ligand A: 0.612, Ligand B: 0.082). Ligand B is slightly better.
15. **Binding Affinity:** Both ligands have very similar binding affinities (Ligand A: -5.2 kcal/mol, Ligand B: -4.8 kcal/mol). The difference is not substantial enough to outweigh other factors.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. While Ligand A has slightly better affinity and TPSA, its high logP and very high DILI risk are significant drawbacks. Ligand B has a much better safety profile (DILI), better logP and solubility.
**Overall Assessment:**
Despite Ligand A having a slightly better QED and longer half-life, the significantly higher DILI risk and poor solubility are major concerns. Ligand B presents a much more balanced profile with a lower risk of liver injury and better solubility, making it the more promising candidate for further development.
Output:
0
2025-04-17 19:04:27,709 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [351.422, 60.93, 0.985, 0, 3, 0.694, 40.132, 86.08, -4.179, -1.221, 0.352, 9.399, -23.039, 0.129, -6.1]
**Ligand B:** [375.559, 29.54, 4.655, 0, 4, 0.705, 42.924, 74.176, -5.081, -5.231, 0.791, 123.431, 1.227, 0.825, -6.2]
Here's a breakdown, prioritizing GPCR properties (logP, Pgp, TPSA, BBB, and affinity):
1. **Molecular Weight:** Both are within the ideal range (200-500 Da). A is 351.422, B is 375.559. No strong preference here.
2. **TPSA:** A (60.93) is better than B (29.54). Lower TPSA generally favors permeability, which is crucial for GPCR ligands.
3. **logP:** A (0.985) is slightly better than B (4.655). B is pushing the upper limit and could lead to solubility issues and off-target interactions.
4. **H-Bond Donors/Acceptors:** Both have low HBD (0) and acceptable HBA (3 for A, 4 for B).
5. **QED:** Both are good (A: 0.694, B: 0.705), indicating reasonable drug-likeness.
6. **DILI:** Both are acceptable (A: 40.132, B: 42.924), below the concerning threshold of 60.
7. **BBB:** A (86.08) is significantly better than B (74.176). While not a CNS target, some peripheral GPCRs benefit from limited BBB penetration. This is a notable advantage for A.
8. **Caco-2:** A (-4.179) is better than B (-5.081). Higher values indicate better absorption.
9. **Solubility:** A (-1.221) is better than B (-5.231). Solubility is important for bioavailability.
10. **hERG:** Both are low (A: 0.352, B: 0.791), indicating low cardiotoxicity risk.
11. **Cl_mic:** A (9.399) is significantly better than B (123.431). A has much lower microsomal clearance, suggesting better metabolic stability.
12. **t1/2:** A (-23.039) is better than B (1.227). A has a longer in vitro half-life.
13. **Pgp:** A (0.129) is much better than B (0.825). Lower P-gp efflux is desirable for better bioavailability and potentially better CNS exposure.
14. **Binding Affinity:** Both are very similar (A: -6.1, B: -6.2). The difference is negligible.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across several key ADME properties (logP, TPSA, BBB, solubility, Cl_mic, t1/2, Pgp) and has comparable binding affinity. Ligand B's higher logP and significantly higher microsomal clearance are concerning. While both have acceptable DILI and hERG scores, the superior ADME profile of Ligand A makes it the more promising drug candidate for ADRB2.
Output:
1
2025-04-17 19:04:27,709 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for their potential as drug candidates targeting the ADRB2, a cardiovascular GPCR. Therefore, logP, TPSA, Pgp efflux, BBB penetration, and binding affinity are key considerations.
Let's break down the comparison:
1. **Molecular Weight:** Both ligands (353.419 and 344.499 Da) fall within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (93.9) is slightly higher than Ligand B (49.41). Ligand B is significantly better, being well below the 140 A^2 threshold for oral absorption and more favorable for GPCRs.
3. **logP:** Ligand A (1.005) is within the optimal range, while Ligand B (3.256) is at the higher end, but still acceptable.
4. **H-Bond Donors/Acceptors:** Both have similar, acceptable numbers of HBD (1) and HBA (Ligand A: 6, Ligand B: 2).
5. **QED:** Both ligands have good QED scores (A: 0.666, B: 0.778), indicating good drug-like properties.
6. **DILI:** Ligand B (36.293) has a slightly higher DILI risk than Ligand A (25.165), but both are below the concerning threshold of 60.
7. **BBB:** Ligand A (83.133) shows better BBB penetration than Ligand B (70.027), which is a positive for a GPCR, though not strictly essential for a cardiovascular target.
8. **Caco-2 Permeability:** Both have negative Caco-2 values, which is unusual and indicates poor permeability. Ligand A (-4.786) is slightly better than Ligand B (-4.535).
9. **Aqueous Solubility:** Ligand A (-1.262) has better aqueous solubility than Ligand B (-3.987).
10. **hERG:** Both ligands show low hERG inhibition risk (A: 0.467, B: 0.559).
11. **Microsomal Clearance:** Ligand A (1.425) has significantly lower microsomal clearance than Ligand B (54.587), indicating better metabolic stability.
12. **In vitro Half-Life:** Ligand A (1.992) has a better in vitro half-life than Ligand B (-14.076).
13. **P-gp Efflux:** Ligand A (0.082) has lower P-gp efflux than Ligand B (0.284), which is favorable.
14. **Binding Affinity:** Ligand B (-7.2 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.1 kcal/mol). This is a substantial advantage.
**Overall Assessment:**
The most significant difference is the binding affinity. Ligand B binds almost 2 kcal/mol stronger, which is a large difference and can often outweigh other deficiencies. While Ligand A has better metabolic stability (lower Cl_mic and better half-life) and slightly better BBB penetration, Ligand B's superior TPSA and significantly improved binding affinity make it the more promising candidate. The lower solubility of Ligand B is a concern, but formulation strategies could potentially address this.
Output:
0
2025-04-17 19:04:27,709 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.451 and 352.494 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (94.22) is higher than Ligand B (49.41). For a cardiovascular GPCR like ADRB2, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B has a substantial advantage.
3. **logP:** Ligand A (0.599) is quite low, potentially hindering membrane permeability. Ligand B (3.614) is within the optimal 1-3 range. This is a major advantage for Ligand B.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable.
5. **HBA:** Ligand A (5) and Ligand B (2) are both acceptable.
6. **QED:** Ligand A (0.813) is better than Ligand B (0.611), indicating a more drug-like profile.
7. **DILI:** Ligand A (29.081) has a significantly lower DILI risk than Ligand B (12.214). This is a crucial advantage for Ligand A.
8. **BBB:** Ligand B (85.964) has a much higher BBB penetration percentile than Ligand A (55.797). While ADRB2 isn't a CNS target, some distribution to the CNS can be a concern for off-target effects, and a lower value is preferable.
9. **Caco-2:** Ligand A (-5.208) and Ligand B (-4.759) are both negative, indicating poor permeability. This is a concern for both, but the difference isn't substantial.
10. **Solubility:** Ligand A (-1.898) and Ligand B (-3.218) are both poor. Ligand B is slightly worse.
11. **hERG:** Ligand A (0.128) has a lower hERG inhibition liability than Ligand B (0.593). This is a significant safety advantage for Ligand A.
12. **Cl_mic:** Ligand A (-18.025) has a much lower (better) microsomal clearance than Ligand B (36.792), indicating greater metabolic stability.
13. **t1/2:** Ligand A (1.229) has a shorter half-life than Ligand B (3.242). Ligand B is preferable here.
14. **Pgp:** Ligand A (0.016) has a much lower P-gp efflux liability than Ligand B (0.181), suggesting better bioavailability.
15. **Binding Affinity:** Ligand A (-6.0) and Ligand B (-5.3) are both good, but Ligand A is slightly better.
**GPCR-Specific Priorities & Overall Assessment:**
For ADRB2 (a cardiovascular GPCR), logP, TPSA, and affinity are key. Ligand B excels in logP and TPSA, while Ligand A has a slight edge in affinity. However, the significant advantages of Ligand A in DILI risk, hERG inhibition, and metabolic stability (Cl_mic) are critical for a cardiovascular drug. The slightly better half-life of Ligand B is outweighed by these safety and PK concerns. The lower Pgp efflux for Ligand A is also beneficial.
**Output:**
1
2025-04-17 19:04:27,709 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [368.905, 50.8, 4.34, 1, 4, 0.811, 44.048, 85.072, -4.637, -3.984, 0.905, 45.231, 29.046, 0.492, -5.3]**
**Ligand B: [344.459, 67.23, 2.194, 1, 4, 0.833, 34.587, 67.701, -4.764, -2.983, 0.113, 24.823, 13.664, 0.049, -6.8]**
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand B (344.459) is slightly lower, which could be beneficial for permeability, but both are acceptable.
2. **TPSA:** Ligand A (50.8) is better than Ligand B (67.23). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (4.34) is a bit high, but still within a reasonable range. Ligand B (2.194) is excellent. This favors Ligand B.
4. **H-Bond Donors:** Both have 1 HBD, which is good.
5. **H-Bond Acceptors:** Both have 4 HBA, which is good.
6. **QED:** Both ligands have similar QED values (0.811 and 0.833), indicating good drug-likeness.
7. **DILI Risk:** Ligand A (44.048) has a slightly higher DILI risk than Ligand B (34.587), but both are below the concerning threshold of 60. This favors Ligand B.
8. **BBB Penetration:** Ligand A (85.072) has significantly better BBB penetration than Ligand B (67.701). While not a primary concern for a cardiovascular target, it's a slight positive for Ligand A.
9. **Caco-2 Permeability:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.637) is slightly worse than Ligand B (-4.764).
10. **Aqueous Solubility:** Ligand A (-3.984) is slightly worse than Ligand B (-2.983).
11. **hERG Inhibition:** Ligand A (0.905) has a higher hERG risk than Ligand B (0.113). This is a significant advantage for Ligand B.
12. **Microsomal Clearance:** Ligand B (24.823) has significantly lower microsomal clearance than Ligand A (45.231), indicating better metabolic stability. This is a strong advantage for Ligand B.
13. **In vitro Half-Life:** Ligand A (29.046) has a longer half-life than Ligand B (13.664). This is a positive for Ligand A.
14. **P-gp Efflux:** Ligand A (0.492) has lower P-gp efflux than Ligand B (0.049), which is favorable.
15. **Binding Affinity:** Ligand B (-6.8 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.3 kcal/mol). This is a major advantage for Ligand B, easily outweighing minor ADME drawbacks.
**Overall Assessment:**
Ligand B clearly emerges as the better candidate. Its superior binding affinity, lower DILI risk, better logP, significantly lower microsomal clearance, and lower hERG risk are compelling advantages. While Ligand A has better BBB penetration and in vitro half-life, these are less critical for a cardiovascular target and are outweighed by the benefits of Ligand B. The Caco-2 permeability is poor for both, but the other factors make Ligand B the more promising starting point for optimization.
Output:
0
2025-04-17 19:04:27,709 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A: [342.439, 58.64, 2.208, 1, 3, 0.854, 35.401, 78.596, -4.468, -3.292, 0.183, 38.342, -13.205, 0.156, -5.8]**
**Ligand B: [351.378, 91.76, 1.528, 2, 5, 0.811, 40.287, 72.974, -4.822, -2.828, 0.205, 6.465, -33.405, 0.035, -7.5]**
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, BBB, and affinity are key):
1. **MW:** Both are within the ideal 200-500 Da range. A (342.439) is slightly better.
2. **TPSA:** A (58.64) is excellent, well below the 140 threshold. B (91.76) is still reasonable, but less optimal.
3. **logP:** Both are good (1.528 and 2.208), falling within the 1-3 range. A is slightly better.
4. **HBD/HBA:** A (1 HBD, 3 HBA) is preferable to B (2 HBD, 5 HBA). Lower counts are generally better for permeability.
5. **QED:** Both are good (>0.5), indicating drug-likeness. A (0.854) is slightly better than B (0.811).
6. **DILI:** Both are acceptable, below 40, with A (35.401) being slightly lower risk than B (40.287).
7. **BBB:** A (78.596) is better than B (72.974), though neither are exceptionally high. For a cardiovascular target, BBB isn't *critical*, but a higher value is still preferable.
8. **Caco-2:** Both are negative, indicating poor permeability. This is a significant concern for both.
9. **Solubility:** Both are negative, indicating poor solubility. This is a significant concern for both.
10. **hERG:** Both are very low risk (0.183 and 0.205).
11. **Cl_mic:** A (38.342) is better than B (6.465), indicating better metabolic stability.
12. **t1/2:** A (-13.205) is better than B (-33.405), indicating a longer half-life.
13. **Pgp:** Both are low (0.156 and 0.035), suggesting minimal efflux.
14. **Binding Affinity:** B (-7.5) has a substantially stronger binding affinity than A (-5.8) - a difference of 1.7 kcal/mol. This is a significant advantage.
**Overall Assessment:**
Ligand B has a significantly better binding affinity, which is a crucial factor for GPCRs. However, Ligand A demonstrates superior ADME properties across several parameters (TPSA, logP, DILI, Cl_mic, t1/2). The Caco-2 and solubility are poor for both, and will need to be addressed. The difference in binding affinity is substantial enough to outweigh the slightly less optimal ADME profile of Ligand B.
Therefore, I would choose Ligand B.
Output:
0
2025-04-17 19:04:27,709 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [371.463, 136.18 , -0.319, 3. , 6. , 0.382, 60.644, 39.667, -5.941, -1.533, 0.067, 16.583, -12.893, 0.021, -6.2 ]
**Ligand B:** [349.45 , 71.09 , 3.119, 2. , 3. , 0.757, 35.673, 73.245, -4.74 , -2.715, 0.288, 19.981, 20.671, 0.082, -7.1 ]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, Affinity, and BBB):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (349.45) is slightly smaller, which is generally favorable.
2. **TPSA:** Ligand A (136.18) is pushing the upper limit for good oral absorption (<=140), while Ligand B (71.09) is excellent. This favors Ligand B.
3. **logP:** Ligand A (-0.319) is a bit low, potentially hindering membrane permeability. Ligand B (3.119) is nearly ideal. This strongly favors Ligand B.
4. **HBD/HBA:** Ligand A (3/6) and Ligand B (2/3) are both reasonable.
5. **QED:** Ligand B (0.757) has a better QED score than Ligand A (0.382), indicating a more drug-like profile.
6. **DILI:** Ligand B (35.673) has a significantly lower DILI risk than Ligand A (60.644). This is a major advantage for Ligand B.
7. **BBB:** Ligand B (73.245) has a much higher BBB penetration potential than Ligand A (39.667). While ADRB2 isn't *necessarily* a CNS target, better BBB penetration can sometimes translate to improved distribution and reduced off-target effects.
8. **Caco-2:** Ligand A (-5.941) is poor, while Ligand B (-4.74) is slightly better, but still not great.
9. **Solubility:** Ligand A (-1.533) is poor, while Ligand B (-2.715) is also poor.
10. **hERG:** Both are low risk.
11. **Cl_mic:** Ligand B (19.981) has a slightly lower (better) microsomal clearance than Ligand A (16.583).
12. **t1/2:** Ligand B (20.671) has a significantly longer in vitro half-life than Ligand A (-12.893). This is a substantial advantage.
13. **Pgp:** Ligand A (0.021) has lower P-gp efflux than Ligand B (0.082), which is favorable.
14. **Affinity:** Ligand B (-7.1) has a 0.9 kcal/mol stronger binding affinity than Ligand A (-6.2). This is a significant difference and a major driver in the decision.
**Overall Assessment:**
Ligand B is clearly the superior candidate. It has better logP, TPSA, QED, DILI risk, BBB penetration, metabolic stability (Cl_mic and t1/2), and significantly stronger binding affinity. While both have poor solubility and Caco-2 permeability, the other advantages of Ligand B outweigh this. The stronger binding affinity combined with the improved ADME properties make it a much more promising starting point for drug development.
Output:
0
2025-04-17 19:04:27,709 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (351.491 and 342.439 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (101.29) is higher than Ligand B (71.34). While both are under 140, Ligand B is preferable for better absorption, aligning with GPCR expectations.
3. **logP:** Ligand B (3.492) is slightly higher than Ligand A (1.868). Both are within the 1-3 range, but Ligand B is closer to the upper limit, which could potentially cause issues. However, for a GPCR, a slightly higher logP isn't a major concern.
4. **HBD:** Ligand A (3) and Ligand B (2) are both acceptable, under the threshold of 5.
5. **HBA:** Both ligands have 3 HBA, which is well within the acceptable range of 10.
6. **QED:** Ligand B (0.874) has a better QED score than Ligand A (0.622), indicating a more drug-like profile.
7. **DILI:** Ligand A (26.095) has a significantly lower DILI risk than Ligand B (49.787). This is a substantial advantage for Ligand A.
8. **BBB:** Both ligands have reasonable BBB penetration (Ligand A: 65.723, Ligand B: 61.225). While not exceptionally high, they are not disqualifying.
9. **Caco-2:** Ligand A (-5.241) and Ligand B (-4.73) are both negative, indicating poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-3.552) and Ligand B (-4.072) both have poor solubility. This is a significant drawback for both.
11. **hERG:** Ligand A (0.138) has a lower hERG risk than Ligand B (0.373), which is preferable.
12. **Cl_mic:** Ligand B (29.376) has a significantly lower microsomal clearance than Ligand A (58.284), indicating better metabolic stability.
13. **t1/2:** Ligand B (82.956) has a much longer in vitro half-life than Ligand A (-17.542). This is a major advantage for Ligand B.
14. **Pgp:** Ligand A (0.06) has a lower P-gp efflux liability than Ligand B (0.109), which is preferable.
15. **Binding Affinity:** Ligand B (-7.6 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.5 kcal/mol). This 1.1 kcal/mol difference is substantial and can outweigh many ADME drawbacks.
**Overall Assessment:**
Ligand B has a significantly better binding affinity and a longer half-life, which are critical for a GPCR target. It also has a better QED score and lower Cl_mic. Ligand A has a lower DILI risk and hERG inhibition liability, but the superior potency and metabolic stability of Ligand B are more important in this case. The solubility and Caco-2 permeability are poor for both, but can be addressed with formulation strategies.
Output:
0
2025-04-17 19:04:27,709 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (352.341 and 339.443 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (87.32) is slightly higher than Ligand B (71.84). Both are below the 140 threshold for good oral absorption, but B is preferable given the GPCR target class.
3. **logP:** Ligand A (1.283) is within the optimal range (1-3), while Ligand B (3.074) is at the higher end but still acceptable.
4. **HBD:** Both ligands have 2 H-bond donors, which is good.
5. **HBA:** Ligand A has 5 H-bond acceptors, Ligand B has 4. Both are within the acceptable range of <=10.
6. **QED:** Both ligands have similar QED values (0.85 and 0.826), indicating good drug-likeness.
7. **DILI:** Ligand A (97.325) has a significantly higher DILI risk than Ligand B (66.731). This is a major concern for Ligand A.
8. **BBB:** Ligand B (76.037) has a better BBB penetration percentile than Ligand A (64.831). While ADRB2 isn't exclusively a CNS target, some CNS exposure might be relevant, and lower efflux is generally desirable.
9. **Caco-2:** Ligand A (-4.621) and Ligand B (-5.273) both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale isn't specified, so it's difficult to interpret.
10. **Solubility:** Ligand A (-4.353) and Ligand B (-3.628) both have negative solubility values, indicating poor solubility. Again, the scale is unclear.
11. **hERG:** Ligand A (0.741) has a slightly higher hERG inhibition liability than Ligand B (0.205). Lower is better here.
12. **Cl_mic:** Ligand A (19.485) has a higher microsomal clearance than Ligand B (14.881), meaning it's metabolized faster.
13. **t1/2:** Ligand B (55.008) has a much longer in vitro half-life than Ligand A (-5.1). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.077) has a lower P-gp efflux liability than Ligand B (0.38), which is favorable.
15. **Binding Affinity:** Ligand B (-7.2) has a significantly better binding affinity than Ligand A (-6.3). This 0.9 kcal/mol difference is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand B is the stronger candidate. While both have issues with Caco-2 and solubility (scale unknown), Ligand B demonstrates a superior binding affinity, significantly lower DILI risk, longer half-life, and better BBB penetration. The slightly higher P-gp efflux is a minor drawback compared to the benefits. Ligand A's high DILI risk and faster clearance are major concerns.
Output:
0
2025-04-17 19:04:27,709 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.431 and 344.499 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (91.65) is higher than Ligand B (40.62). For a cardiovascular GPCR, TPSA isn't a *major* concern unless extremely high, but lower is generally preferable for permeability. Ligand B is significantly better.
3. **logP:** Ligand A (1.154) is within the optimal 1-3 range. Ligand B (3.537) is at the higher end but still acceptable.
4. **HBD:** Ligand A (2) and Ligand B (0) are both reasonable.
5. **HBA:** Ligand A (4) and Ligand B (2) are both reasonable.
6. **QED:** Both ligands (0.772 and 0.735) have good drug-likeness scores, exceeding the 0.5 threshold.
7. **DILI:** Ligand A (22.334) has a lower DILI risk than Ligand B (12.175), which is favorable.
8. **BBB:** Ligand A (48.352) has a low BBB penetration, while Ligand B (93.253) has a high BBB penetration. For a cardiovascular target, BBB penetration is not a priority, so Ligand B's high value does not give it an advantage.
9. **Caco-2:** Ligand A (-5.269) has a poor Caco-2 permeability, while Ligand B (-4.587) is better, but still poor.
10. **Solubility:** Ligand A (-1.34) has a slightly better solubility than Ligand B (-3.572).
11. **hERG:** Ligand A (0.172) has a lower hERG risk than Ligand B (0.333), which is favorable.
12. **Cl_mic:** Ligand A (2.263) has a significantly lower microsomal clearance than Ligand B (53.647), indicating better metabolic stability. This is a strong advantage for Ligand A.
13. **t1/2:** Ligand A (17.025) has a longer in vitro half-life than Ligand B (-11.218), which is a significant advantage.
14. **Pgp:** Ligand A (0.034) has a lower Pgp efflux liability than Ligand B (0.238), which is favorable.
15. **Binding Affinity:** Ligand B (-7.3) has a slightly better binding affinity than Ligand A (-6.0). This is a 1.3 kcal/mol difference, which is significant.
**Overall Assessment:**
Ligand B has a better binding affinity and lower TPSA, but Ligand A has superior ADME properties: lower DILI, better solubility, significantly lower Cl_mic, longer t1/2, and lower Pgp efflux. The difference in binding affinity (1.3 kcal/mol) is important, but the ADME advantages of Ligand A are more compelling for overall drug development potential, especially considering the cardiovascular target. The poor Caco-2 permeability of both is a concern, but can be addressed through formulation strategies. The metabolic stability and longer half-life of Ligand A are particularly valuable.
Output:
1
2025-04-17 19:04:27,710 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (340.471 and 349.475 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (58.95) is significantly better than Ligand B (64.09). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand A is well below the 90 A^2 threshold, while Ligand B is approaching it.
**3. logP:** Ligand A (3.076) is optimal, while Ligand B (0.552) is quite low. A logP below 1 can hinder membrane permeability. This is a significant advantage for Ligand A.
**4. H-Bond Donors:** Ligand A (2) and Ligand B (1) are both acceptable.
**5. H-Bond Acceptors:** Ligand A (3) and Ligand B (4) are both acceptable.
**6. QED:** Both ligands have good QED scores (0.627 and 0.712), indicating good drug-like properties.
**7. DILI:** Ligand A (32.377) has a slightly higher DILI risk than Ligand B (13.532), but both are well below the concerning threshold of 60.
**8. BBB:** Ligand A (82.396) has a much better BBB penetration score than Ligand B (42.109). While ADRB2 isn't exclusively a CNS target, some CNS exposure may be acceptable or even desirable depending on the specific therapeutic application.
**9. Caco-2 Permeability:** Ligand A (-4.977) is better than Ligand B (-4.643), indicating better intestinal absorption.
**10. Aqueous Solubility:** Ligand A (-2.496) is better than Ligand B (-0.864).
**11. hERG Inhibition:** Ligand A (0.937) has a slightly higher hERG risk than Ligand B (0.37), but both are relatively low.
**12. Microsomal Clearance:** Ligand B (10.665) has a significantly lower microsomal clearance than Ligand A (27.775), suggesting better metabolic stability.
**13. In vitro Half-Life:** Ligand B (-10.691) has a much longer in vitro half-life than Ligand A (16.436). This is a substantial advantage for Ligand B.
**14. P-gp Efflux:** Ligand A (0.665) has a lower P-gp efflux liability than Ligand B (0.094), which is preferable.
**15. Binding Affinity:** Ligand A (-7.2) has a stronger binding affinity than Ligand B (-6.5). This is a 0.7 kcal/mol difference, which is significant and can outweigh some ADME drawbacks.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand A is the stronger candidate. The significantly better logP and TPSA values are crucial for permeability and absorption. The stronger binding affinity is also a major advantage. While Ligand B has better metabolic stability and half-life, the differences in logP and TPSA are more critical for a GPCR target. The slightly higher DILI and hERG risk for Ligand A are not concerning given the other favorable properties.
Output:
1
2025-04-17 19:04:27,710 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (362.861) is slightly higher than Ligand B (334.383), but both are acceptable.
2. **TPSA:** Both are reasonably low, under the 140 A^2 threshold for good absorption. Ligand A (94.88) is slightly higher than Ligand B (89.51), but both are good.
3. **logP:** Both ligands have optimal logP values (around 3), suggesting good permeability and avoiding solubility issues. Ligand A (3.208) is slightly higher than Ligand B (3.082).
4. **HBD:** Ligand A (2) is preferable to Ligand B (0) as having some HBD can improve solubility.
5. **HBA:** Ligand A (4) is preferable to Ligand B (7). Lower HBA generally improves permeability.
6. **QED:** Both ligands have very similar and good QED scores (0.728 and 0.731), indicating good drug-likeness.
7. **DILI:** Ligand A (38.658) has a significantly lower DILI risk than Ligand B (81.815). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (74.176) has a better BBB penetration score than Ligand B (28.15). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant for off-target effects and overall safety.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, these values are on a different scale and hard to interpret without knowing the scale.
10. **Solubility:** Ligand A (-3.987) is slightly better than Ligand B (-5.306).
11. **hERG:** Both ligands have very low hERG inhibition risk (0.466 and 0.323).
12. **Cl_mic:** Ligand A (35.856) has a lower microsomal clearance than Ligand B (67.238), indicating better metabolic stability.
13. **t1/2:** Ligand A (27.131) has a longer in vitro half-life than Ligand B (-27.033). This is a significant advantage for Ligand A.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.032 and 0.182).
15. **Binding Affinity:** Ligand B (-7.1) has a slightly better binding affinity than Ligand A (-5.5). This is a 1.6 kcal/mol difference, which is significant.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Both ligands perform well on logP and Pgp. Ligand B has a slightly better affinity, but Ligand A has better TPSA, DILI, BBB, Cl_mic, and t1/2. The substantial differences in DILI, metabolic stability (Cl_mic and t1/2), and BBB penetration outweigh the affinity difference.
**Conclusion:**
Ligand A is the more promising candidate due to its significantly improved safety profile (lower DILI), better metabolic stability (lower Cl_mic, longer t1/2), and reasonable BBB penetration, despite a slightly lower binding affinity. The difference in affinity is not large enough to overcome the substantial ADME/Tox advantages of Ligand A.
Output:
1
2025-04-17 19:04:27,710 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (364.471) is slightly higher than Ligand B (345.403), but both are acceptable.
2. **TPSA:** Ligand A (87.32) is better than Ligand B (102.05). Both are below 140, but closer to 90 is preferred for GPCRs, and A is closer.
3. **logP:** Both ligands have good logP values (A: 2.078, B: 1.028), falling within the optimal 1-3 range. Ligand A is slightly better.
4. **HBD:** Both have 2 HBD, which is within the acceptable limit of 5.
5. **HBA:** Ligand A has 5 HBA, while Ligand B has 6. Both are acceptable (<=10), but A is slightly preferred.
6. **QED:** Both have reasonable QED scores (A: 0.751, B: 0.661), indicating good drug-like properties. A is slightly better.
7. **DILI:** Both have similar DILI risk (A: 57.387, B: 57.619), both are acceptable.
8. **BBB:** Ligand A (41.218) is lower than Ligand B (51.725). While ADRB2 isn't strictly a CNS target, some CNS penetration can be beneficial, so B is slightly better here.
9. **Caco-2:** Both have negative Caco-2 values (-5.375 and -5.634), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand A (-2.746) is better than Ligand B (-1.423), indicating better aqueous solubility.
11. **hERG:** Both have very low hERG inhibition risk (A: 0.388, B: 0.088). B is slightly better.
12. **Cl_mic:** Ligand B (38.739) has a lower microsomal clearance than Ligand A (55.475), suggesting better metabolic stability. This is a significant advantage for B.
13. **t1/2:** Ligand B (-5.845) has a longer in vitro half-life than Ligand A (-31.36), which is a significant advantage.
14. **Pgp:** Both have very low P-gp efflux liability (A: 0.099, B: 0.029). B is slightly better.
15. **Binding Affinity:** Ligand B (-8.1 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.7 kcal/mol). This >1.5 kcal/mol difference is a major advantage for B, potentially outweighing some of the ADME drawbacks.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in affinity and has good logP and Pgp values. While TPSA is slightly higher than ideal, the strong affinity and improved metabolic stability (lower Cl_mic and longer t1/2) make it a more promising candidate. The Caco-2 permeability is a concern for both, but the superior binding affinity of B is a strong driver.
Output:
0
2025-04-17 19:04:27,710 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (356.39 and 366.50 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (55.56) is higher than Ligand B (46.34). Both are below the 140 threshold for oral absorption, but lower is better for GPCRs, giving a slight edge to B.
3. **logP:** Ligand A (3.04) is within the optimal range (1-3). Ligand B (4.88) is higher, potentially leading to solubility issues and off-target effects. A favors here.
4. **HBD:** Ligand A (1) is preferable to Ligand B (0) as a single HBD can aid solubility without significantly impacting permeability.
5. **HBA:** Ligand A (3) and Ligand B (4) are both acceptable, but A is slightly better.
6. **QED:** Ligand A (0.91) is significantly better than Ligand B (0.56), indicating a more drug-like profile. A is strongly favored.
7. **DILI:** Ligand A (18.42) has a much lower DILI risk than Ligand B (27.38). This is a significant advantage for A.
8. **BBB:** Both ligands have high BBB penetration (A: 95.19, B: 91.31). This is good, but not a major differentiator.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests a potential issue with permeability prediction. This is a flag for both.
10. **Solubility:** Ligand A (-2.45) is better than Ligand B (-4.06). Solubility is important, and A has a clear advantage.
11. **hERG:** Both ligands have low hERG inhibition risk (A: 0.78, B: 0.86). No clear advantage.
12. **Cl_mic:** Ligand A (-3.52) has a much lower (better) microsomal clearance than Ligand B (97.97). This indicates better metabolic stability for A.
13. **t1/2:** Ligand A (-18.47) has a negative in vitro half-life, which is concerning. Ligand B (54.03) is much better. B is favored here.
14. **Pgp:** Both ligands have low Pgp efflux liability (A: 0.26, B: 0.82). No clear advantage.
15. **Binding Affinity:** Ligand B (-7.3) has a significantly stronger binding affinity than Ligand A (-6.1). This is a substantial advantage for B, potentially outweighing some of the ADME drawbacks.
**Overall Assessment:**
Ligand B has a significantly better binding affinity, which is crucial for GPCR targets. However, it suffers from higher logP, a higher DILI risk, and significantly worse metabolic stability (Cl_mic). Ligand A, while having a weaker binding affinity, presents a much more balanced profile with better solubility, lower DILI risk, better metabolic stability, and a higher QED score. Given the importance of ADME properties for *in vivo* efficacy and safety, and the relatively modest affinity difference, I believe Ligand A is the more promising candidate.
Output:
1
2025-04-17 19:04:27,710 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (339.37 and 343.45 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (62.3) is slightly higher than Ligand B (55.63). Both are below the 140 threshold for oral absorption, but closer to the 90 threshold for CNS targets.
3. **logP:** Ligand A (2.497) is within the optimal 1-3 range. Ligand B (4.219) is a bit high, potentially leading to solubility issues or off-target interactions.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 3 HBA, and Ligand B has 5. Both are acceptable, but Ligand A is slightly preferred.
6. **QED:** Both ligands have good QED scores (0.823 and 0.903), indicating good drug-like properties.
7. **DILI:** Ligand A (61.225) has a slightly higher DILI risk than Ligand B (49.283), but both are reasonably acceptable.
8. **BBB:** Ligand B (88.174) has a significantly higher BBB penetration percentile than Ligand A (63.668). While ADRB2 isn't strictly a CNS target, some CNS exposure can be beneficial or at least not detrimental for cardiovascular drugs.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. Ligand B (-4.907) is slightly worse than Ligand A (-4.464).
10. **Solubility:** Both ligands have negative solubility values, indicating poor solubility. Ligand B (-4.618) is slightly worse than Ligand A (-3.868).
11. **hERG:** Both ligands have very low hERG inhibition liability (0.693 and 0.491), which is excellent.
12. **Cl_mic:** Ligand A (52.607) has a slightly lower microsomal clearance than Ligand B (46.825), suggesting better metabolic stability.
13. **t1/2:** Ligand B (34.267) has a significantly longer in vitro half-life than Ligand A (9.428). This is a major advantage.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.214 and 0.604).
15. **Binding Affinity:** Ligand B (-6.8 kcal/mol) has a slightly better binding affinity than Ligand A (-6.4 kcal/mol). This difference is significant enough to potentially outweigh some ADME drawbacks.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand B excels in affinity and has a better BBB score, while Ligand A has a slightly better logP. However, the longer half-life of Ligand B is a significant advantage.
**Overall Assessment:**
While Ligand A has slightly better logP and metabolic stability, Ligand B's superior binding affinity, longer half-life, and better BBB penetration make it the more promising candidate. The slightly higher logP of Ligand B is a manageable concern.
Output:
0
2025-04-17 19:04:27,710 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
The ADRB2 receptor is a GPCR, so the priorities are logP, Pgp, TPSA, affinity, and BBB. Let's compare the ligands:
1. **Molecular Weight:** Both ligands are within the acceptable range (200-500 Da). Ligand A (341.411) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (73.1) is significantly better than Ligand B (108.21). A TPSA under 140 is good for oral absorption, and lower is better for GPCRs. Ligand B is pushing the upper limit.
3. **logP:** Ligand A (2.397) is within the optimal range (1-3). Ligand B (-1.265) is quite low, potentially leading to poor membrane permeability and bioavailability.
4. **H-Bond Donors/Acceptors:** Ligand A (HBD=1, HBA=5) is better than Ligand B (HBD=2, HBA=6). Lower counts are generally preferred.
5. **QED:** Ligand A (0.928) is excellent, indicating high drug-likeness. Ligand B (0.576) is acceptable but less favorable.
6. **DILI:** Ligand B (21.753) has a much lower DILI risk than Ligand A (64.754), which is a significant advantage.
7. **BBB:** Ligand A (75.572) has better BBB penetration than Ligand B (62.97), but both are not exceptionally high. Since ADRB2 is not necessarily a CNS target, this is less critical.
8. **Caco-2 Permeability:** Ligand A (-4.509) is better than Ligand B (-5.449), indicating better intestinal absorption.
9. **Aqueous Solubility:** Ligand A (-3.369) is better than Ligand B (-1.211).
10. **hERG Inhibition:** Ligand A (0.443) has a lower hERG risk than Ligand B (0.077), which is a significant advantage.
11. **Microsomal Clearance:** Ligand B (-6.383) has a lower (better) microsomal clearance than Ligand A (10.426), suggesting greater metabolic stability.
12. **In vitro Half-Life:** Ligand A (11.631) has a longer half-life than Ligand B (-0.228).
13. **P-gp Efflux:** Ligand A (0.193) has lower P-gp efflux than Ligand B (0.002), which is favorable.
14. **Binding Affinity:** Both ligands have very similar and strong binding affinities (-6.7 kcal/mol and -6.1 kcal/mol respectively). The difference is less than 1.5 kcal/mol, so it doesn't heavily sway the decision.
**Overall Assessment:**
Ligand A has a much better profile in terms of drug-like properties (QED, TPSA, logP, solubility, Caco-2, P-gp efflux) and safety (hERG). While Ligand B has a lower DILI risk and better metabolic stability, the significant drawbacks in permeability and solubility are concerning. The slightly better BBB penetration of Ligand A is a bonus. Considering the GPCR-specific priorities, Ligand A is the more promising candidate.
**Output:**
1
2025-04-17 19:04:27,711 - INFO - Batch 83 complete. Total preferences: 1328
2025-04-17 19:04:27,711 - INFO - Processing batch 84/512...
2025-04-17 19:05:16,830 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (357.455 and 346.519 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (61.28) is significantly better than Ligand A (105.22). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (-2.309) is quite low, potentially hindering membrane permeability. Ligand B (3.909) is within the optimal 1-3 range. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (3) and Ligand B (2) are both acceptable, below the 5 threshold.
5. **HBA:** Ligand A (6) and Ligand B (5) are both acceptable, below the 10 threshold.
6. **QED:** Ligand B (0.846) has a substantially higher QED score than Ligand A (0.401), indicating a more drug-like profile.
7. **DILI:** Ligand A (5.777) has a much lower DILI risk than Ligand B (39.434). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (83.288) has a high BBB penetration, while Ligand A (3.218) has a very low value. While not critical for a cardiovascular target, it's not a negative for Ligand B.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.86 and -5.043), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (0.601) has slightly better solubility than Ligand B (-3.323).
11. **hERG:** Ligand A (0.037) has a very low hERG risk, while Ligand B (0.886) is higher. This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand A (-28.17) has a much lower (better) microsomal clearance than Ligand B (43.583), suggesting greater metabolic stability.
13. **t1/2:** Ligand B (47.812) has a much longer in vitro half-life than Ligand A (-11.598). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.001) has very low P-gp efflux, while Ligand B (0.751) is higher. This is an advantage for Ligand A.
15. **Binding Affinity:** Ligand B (-7.0) has a slightly better binding affinity than Ligand A (-6.7). While the difference is less than 1.5 kcal/mol, it's still a positive for Ligand B.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand B initially appears stronger due to its optimal logP, better TPSA, and slightly better affinity. However, Ligand A has significantly better safety profiles (DILI, hERG) and metabolic stability (Cl_mic), and lower P-gp efflux. The negative Caco-2 values for both are concerning, but the superior ADME properties of Ligand A, particularly the lower DILI and hERG risk, outweigh the slightly better affinity of Ligand B. For a cardiovascular target, minimizing off-target effects and ensuring safety are crucial.
Output:
1
2025-04-17 19:05:16,830 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (353.365 Da and 365.499 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (66.84) is significantly better than Ligand B (95.66). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is bordering on being too high, potentially hindering absorption.
**3. logP:** Both ligands have acceptable logP values (2.866 and 1.549, respectively), falling within the 1-3 range. Ligand A is slightly better, but both are reasonable.
**4. H-Bond Donors:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
**5. H-Bond Acceptors:** Ligand A (4) is preferable to Ligand B (5). Fewer HBAs generally improve permeability.
**6. QED:** Both ligands have reasonable QED scores (0.849 and 0.738), indicating good drug-like properties. Ligand A is better.
**7. DILI:** Ligand A (31.408) has a much lower DILI risk than Ligand B (23.187). This is a significant advantage for Ligand A.
**8. BBB:** Ligand A (92.012) shows significantly better BBB penetration potential than Ligand B (62.699). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be useful for understanding off-target effects and overall distribution.
**9. Caco-2 Permeability:** Ligand A (-4.323) is better than Ligand B (-5.789). Higher values indicate better intestinal absorption.
**10. Aqueous Solubility:** Ligand A (-3.417) is better than Ligand B (-2.938). Higher values indicate better solubility.
**11. hERG Inhibition:** Ligand A (0.587) has a lower hERG inhibition liability than Ligand B (0.241), which is a crucial safety factor.
**12. Microsomal Clearance:** Ligand A (63.031) has a lower microsomal clearance than Ligand B (8.338), indicating better metabolic stability.
**13. In vitro Half-Life:** Ligand A (-8.161) has a longer in vitro half-life than Ligand B (4.563), which is desirable for less frequent dosing.
**14. P-gp Efflux:** Ligand A (0.126) has lower P-gp efflux liability than Ligand B (0.071), which is a positive.
**15. Binding Affinity:** Ligand B (-6.3 kcal/mol) has a slightly better binding affinity than Ligand A (-7.4 kcal/mol). However, the difference is not substantial enough to outweigh the numerous advantages of Ligand A.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical ADME-Tox properties. It has better TPSA, logP, H-bond characteristics, QED, DILI risk, BBB penetration, Caco-2 permeability, solubility, hERG inhibition, microsomal clearance, and in vitro half-life. While Ligand B has slightly better binding affinity, the overall profile of Ligand A is far more favorable for development as a drug candidate.
Output:
1
2025-04-17 19:05:16,830 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (362.539 Da) is slightly higher than Ligand B (346.427 Da), but both are acceptable.
2. **TPSA:** Ligand A (40.62) is significantly better than Ligand B (78.87). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption. Ligand B's TPSA is quite high.
3. **logP:** Both ligands have good logP values (A: 2.912, B: 1.958) within the optimal 1-3 range.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (4). Fewer HBAs generally improve permeability.
6. **QED:** Both have good QED values (A: 0.758, B: 0.825), indicating good drug-likeness.
7. **DILI:** Ligand A (32.105) is better than Ligand B (47.654), indicating a lower risk of drug-induced liver injury.
8. **BBB:** Ligand A (71.501) is better than Ligand B (61.729). While not a primary concern for a cardiovascular target, higher BBB is generally favorable.
9. **Caco-2:** Ligand A (-5.044) is better than Ligand B (-4.675), suggesting better intestinal absorption.
10. **Solubility:** Ligand A (-3.31) is better than Ligand B (-2.803), suggesting better aqueous solubility.
11. **hERG:** Ligand A (0.295) is significantly better than Ligand B (0.446), indicating a lower risk of hERG inhibition and cardiotoxicity. This is *critical* for a cardiovascular target.
12. **Cl_mic:** Ligand A (49.318) is worse than Ligand B (20.881). This suggests Ligand B is more metabolically stable.
13. **t1/2:** Ligand A (3.701) is worse than Ligand B (12.403). Ligand B has a significantly longer in vitro half-life.
14. **Pgp:** Ligand A (0.25) is better than Ligand B (0.188), indicating lower P-gp efflux.
15. **Binding Affinity:** Ligand A (-7.9) is *significantly* better than Ligand B (-4.0). This is a 3.9 kcal/mol difference, which is a substantial advantage and can often outweigh minor ADME concerns.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A excels in affinity, has better TPSA and Pgp values, and comparable logP. While Ligand B has better metabolic stability (Cl_mic and t1/2), the significantly stronger binding affinity of Ligand A, coupled with its better safety profile (DILI, hERG), makes it the more promising candidate. The difference in affinity is large enough to potentially compensate for the slightly higher clearance.
**Output:**
1
2025-04-17 19:05:16,831 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (432.384 Da) is within the ideal range, while Ligand B (350.503 Da) is a bit lower but still acceptable.
2. **TPSA:** Ligand A (63.69) is slightly higher than ideal for a non-CNS GPCR, but still reasonable. Ligand B (49.85) is excellent.
3. **logP:** Both ligands have good logP values (A: 3.862, B: 2.974), falling within the 1-3 range.
4. **HBD:** Ligand A (1) and Ligand B (0) are both good, below the threshold of 5.
5. **HBA:** Ligand A (5) and Ligand B (3) are both good, below the threshold of 10.
6. **QED:** Both ligands have acceptable QED values (A: 0.771, B: 0.676), indicating good drug-likeness.
7. **DILI:** Ligand A (68.98) has a higher DILI risk than Ligand B (35.673). This is a significant negative for Ligand A.
8. **BBB:** Both ligands have high BBB penetration (A: 80.031, B: 86.468), which isn't critical for ADRB2 (a cardiovascular target) but isn't detrimental.
9. **Caco-2:** Both ligands have negative Caco-2 values, suggesting poor permeability. This is a concern for both.
10. **Solubility:** Both ligands have negative solubility values, suggesting poor solubility. This is a concern for both.
11. **hERG:** Both ligands have low hERG inhibition risk (A: 0.458, B: 0.46), which is good.
12. **Cl_mic:** Ligand A (81.423) has a higher microsomal clearance than Ligand B (75.457), suggesting lower metabolic stability.
13. **t1/2:** Ligand B (-9.289) has a negative in vitro half-life, which is concerning. Ligand A (28.297) has a reasonable half-life.
14. **Pgp:** Both ligands have low P-gp efflux liability (A: 0.522, B: 0.429), which is good.
15. **Affinity:** Ligand A (-8.5 kcal/mol) has significantly better binding affinity than Ligand B (-5.4 kcal/mol). This is a substantial advantage.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand A has a slightly higher logP and TPSA, but the *much* stronger binding affinity (-8.5 vs -5.4 kcal/mol) is the dominant factor. The lower DILI risk of Ligand B is attractive, but the affinity difference is substantial enough to outweigh this concern, especially considering the cardiovascular target. While both have poor Caco-2 and solubility, these can be addressed with formulation strategies.
**Conclusion:**
Despite the higher DILI risk and slightly less favorable metabolic stability, Ligand A's significantly superior binding affinity makes it the more promising drug candidate. The potency advantage is likely to be more impactful than the other drawbacks, particularly for a GPCR target.
Output:
1
2025-04-17 19:05:16,831 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (341.411) is slightly better, being closer to the middle of the range.
2. **TPSA:** Ligand A (77.25) is significantly better than Ligand B (111.55). ADRB2 is a cardiovascular target, so CNS penetration isn't critical, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (3.497) is optimal, while Ligand B (0.174) is quite low. Low logP can hinder membrane permeability. This is a significant advantage for Ligand A.
4. **HBD:** Ligand A (1) is preferable to Ligand B (4). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (6) is better than Ligand B (5). Lower HBA is generally preferred.
6. **QED:** Ligand A (0.858) is significantly better than Ligand B (0.529), indicating a more drug-like profile.
7. **DILI:** Ligand B (31.834) has a much lower DILI risk than Ligand A (63.513). This is a strong point in favor of Ligand B.
8. **BBB:** Ligand A (83.753) has better BBB penetration than Ligand B (56.495), but this is less crucial for a cardiovascular target.
9. **Caco-2:** Ligand A (-4.579) is better than Ligand B (-5.167), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-4.253) is better than Ligand B (-2.088).
11. **hERG:** Ligand A (0.454) has a lower hERG risk than Ligand B (0.169). This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand B (35.554) has a lower microsomal clearance than Ligand A (58.171), suggesting better metabolic stability.
13. **t1/2:** Ligand A (14.022) has a longer half-life than Ligand B (-7.445). This is a positive for Ligand A.
14. **Pgp:** Ligand A (0.341) has lower P-gp efflux than Ligand B (0.018). This is a positive for Ligand A.
15. **Affinity:** Ligand A (-6.6 kcal/mol) has a slightly better binding affinity than Ligand B (-5.9 kcal/mol). While the difference is not huge, it's still a positive for Ligand A.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A excels in logP, TPSA, and Pgp, and has slightly better affinity. Ligand B's main advantage is its lower DILI risk. However, the overall profile of Ligand A is more favorable, balancing key ADME properties with good potency. The DILI risk of Ligand A, while higher than Ligand B, is still within an acceptable range.
**Conclusion:**
Considering the balance of properties, especially the crucial GPCR-relevant parameters, Ligand A is the more promising drug candidate.
Output:
1
2025-04-17 19:05:16,831 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
Both ligands have identical binding affinities (-7.7 kcal/mol), which is excellent and removes that as a differentiating factor. Given that ADRB2 is a GPCR, the key properties to prioritize are logP, TPSA, Pgp efflux, BBB penetration, and affinity (which is already equal).
Let's break down the comparison:
1. **Molecular Weight:** Both are within the ideal range (200-500 Da). Ligand A (346.471) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are reasonably low (A: 66.48, B: 67.23), suggesting good potential for oral absorption.
3. **logP:** Both are within the optimal range (1-3), with A (2.006) being slightly higher than B (1.603). A slightly higher logP can be beneficial for membrane permeability, but not excessively so.
4. **H-Bond Donors/Acceptors:** Both have acceptable numbers of HBD (1) and HBA (A: 3, B: 5).
5. **QED:** Both have good QED scores (A: 0.775, B: 0.833), indicating drug-like properties.
6. **DILI Risk:** Ligand A (12.098) has a significantly lower DILI risk than Ligand B (28.228). This is a major advantage for Ligand A.
7. **BBB Penetration:** Ligand A (74.292) has considerably better BBB penetration than Ligand B (51.493). While ADRB2 isn't exclusively a CNS target, some cardiovascular effects are mediated by central pathways, and better BBB penetration could be beneficial or at least not detrimental.
8. **Caco-2 Permeability:** Ligand A (-4.603) shows better Caco-2 permeability than Ligand B (-5.416).
9. **Aqueous Solubility:** Both have poor aqueous solubility (-2.558 and -2.087). This is a potential concern for both, but not a deciding factor.
10. **hERG Inhibition:** Both have very low hERG inhibition risk (0.136 and 0.112).
11. **Microsomal Clearance:** Ligand A (13.939) has a significantly lower microsomal clearance than Ligand B (28.094), indicating better metabolic stability.
12. **In vitro Half-Life:** Ligand A (-13.06) has a much longer in vitro half-life than Ligand B (1.48). This is a significant advantage.
13. **P-gp Efflux:** Both have low P-gp efflux liability (0.032 and 0.057).
**Overall Assessment:**
Ligand A consistently outperforms Ligand B in several crucial ADME properties (DILI, BBB, Caco-2, metabolic stability, half-life) while maintaining comparable potency and drug-likeness. The lower DILI risk and improved pharmacokinetic profile of Ligand A make it the more promising candidate, despite the similar binding affinity.
**Output:**
1
2025-04-17 19:05:16,831 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (a cardiovascular GPCR) drug candidates.
**Ligand A:** [337.427, 70.15, 2.506, 2, 5, 0.9, 60.76, 77.2, -4.78, -3.96, 0.718, 58.412, 7.405, 0.122, -7.8]
**Ligand B:** [345.399, 76.71, 1.663, 1, 5, 0.808, 55.758, 78.674, -4.16, -2.624, 0.192, 44.868, 4.574, 0.114, -5.5]
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal 200-500 Da range. A (337.427) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are reasonably good, below the 140 threshold for oral absorption. A (70.15) is better than B (76.71).
3. **logP:** Both are within the optimal 1-3 range. A (2.506) is slightly higher than B (1.663).
4. **HBD:** A (2) is better than B (1). Lower HBD generally improves permeability.
5. **HBA:** Both have 5 HBA, which is acceptable.
6. **QED:** Both are high, indicating good drug-like properties (A: 0.9, B: 0.808).
7. **DILI:** A (60.76) is a bit higher than B (55.758), indicating a slightly elevated liver injury risk. B is preferable here.
8. **BBB:** Both have good BBB penetration (A: 77.2, B: 78.674). This is good, but less critical for a cardiovascular target.
9. **Caco-2:** Both are negative, indicating good permeability. A (-4.78) is slightly better than B (-4.16).
10. **Solubility:** Both are negative, indicating good solubility. A (-3.96) is slightly better than B (-2.624).
11. **hERG:** A (0.718) is higher than B (0.192), indicating a higher risk of hERG inhibition and cardiotoxicity. B is significantly better here.
12. **Cl_mic:** B (44.868) has significantly lower microsomal clearance than A (58.412), suggesting better metabolic stability. This is a major advantage for B.
13. **t1/2:** A (7.405) has a longer half-life than B (4.574). This is a positive for A, potentially allowing for less frequent dosing.
14. **Pgp:** Both have very low Pgp efflux liability (A: 0.122, B: 0.114).
15. **Binding Affinity:** A (-7.8) has a significantly stronger binding affinity than B (-5.5). This is a substantial advantage for A, potentially outweighing some of its ADME drawbacks.
**GPCR-Specific Priorities:** For ADRB2 (a cardiovascular GPCR), we prioritize logP, Pgp, TPSA, and affinity. Affinity is the most important.
**Decision:**
While Ligand A has a superior binding affinity (-7.8 vs -5.5), the hERG risk is concerning (0.718 vs 0.192). The slightly higher DILI risk is also a negative. Ligand B has better metabolic stability (lower Cl_mic) and a much lower hERG risk, which is crucial for a cardiovascular drug. The difference in affinity, while significant, might be overcome with further optimization of Ligand B. Considering the safety profile and metabolic stability, Ligand B is the more promising candidate.
**Output:**
0
2025-04-17 19:05:16,831 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, the key priorities are logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB.
Let's break down the comparison:
1. **MW:** Both ligands are within the acceptable range (200-500 Da). Ligand A (343.427) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (44.1) has a significantly lower TPSA than Ligand A (66.65). This is a major advantage for Ligand B, as lower TPSA generally correlates with better membrane permeability and oral absorption.
3. **logP:** Both ligands have logP values within the optimal range (1-3), but Ligand B (4.811) is pushing the upper limit. Ligand A (2.406) is better positioned.
4. **HBD/HBA:** Both have low HBDs (0) and acceptable HBAs (4 and 3 respectively).
5. **QED:** Ligand A (0.588) has a better QED score than Ligand B (0.438), indicating a more drug-like profile.
6. **DILI:** Ligand B (10.857) has a much lower DILI risk than Ligand A (28.499). This is a significant advantage for Ligand B.
7. **BBB:** Both ligands have good BBB penetration (Ligand A: 80.962, Ligand B: 83.249), but Ligand B is slightly higher.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the magnitude of the negative value is similar.
9. **Solubility:** Both have negative solubility values, indicating poor aqueous solubility. Ligand A (-2.403) is slightly better than Ligand B (-4.957).
10. **hERG:** Ligand A (0.211) has a lower hERG risk than Ligand B (0.842).
11. **Cl_mic:** Ligand A (48.05) has a lower microsomal clearance than Ligand B (119.85), indicating better metabolic stability.
12. **t1/2:** Ligand A (-37.639) has a much longer in vitro half-life than Ligand B (-12.708). This is a significant advantage for Ligand A.
13. **Pgp:** Ligand A (0.118) has a lower P-gp efflux liability than Ligand B (0.599), which is favorable for bioavailability.
14. **Binding Affinity:** Ligand A (-7.6 kcal/mol) has a slightly better binding affinity than Ligand B (-6.9 kcal/mol). While the difference is not huge, it's enough to consider.
**Overall Assessment:**
Ligand A has a better binding affinity, QED, metabolic stability (lower Cl_mic, longer t1/2), Pgp efflux, and hERG risk. However, Ligand B excels in TPSA and DILI risk. Given the GPCR target, the lower TPSA of Ligand B is a significant advantage, potentially outweighing the slightly weaker binding affinity. The lower DILI risk is also a major plus. While both have solubility and Caco-2 issues, the overall profile of Ligand B is more promising.
**Output:**
0
2025-04-17 19:05:16,832 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [351.332, 75.6, 2.987, 2, 4, 0.742, 84.645, 62.97, -5.353, -3.867, 0.612, 3.713, 24.969, 0.262, -7.8]
**Ligand B:** [341.415, 91.02, 1.411, 1, 5, 0.876, 36.06, 54.052, -5.137, -1.895, 0.259, -14.625, 3.769, 0.025, -7.2]
Here's a breakdown, considering the GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (341.415) is slightly lower, which isn't a major concern.
2. **TPSA:** Ligand A (75.6) is better than Ligand B (91.02). We want <140 for oral absorption, both are fine, but A is preferable.
3. **logP:** Ligand A (2.987) is optimal (1-3). Ligand B (1.411) is on the lower side, potentially impacting permeability. This is a significant advantage for A.
4. **HBD:** Both are acceptable (A: 2, B: 1).
5. **HBA:** Both are acceptable (A: 4, B: 5).
6. **QED:** Both are good (A: 0.742, B: 0.876). B is slightly better here.
7. **DILI:** Ligand A (84.645) is considerably higher risk than Ligand B (36.06). This is a major drawback for A.
8. **BBB:** Ligand A (62.97) is better than Ligand B (54.052), but BBB isn't a huge priority for a cardiovascular target.
9. **Caco-2:** Both are negative, indicating poor permeability. A (-5.353) is worse than B (-5.137).
10. **Solubility:** Both are negative, indicating poor solubility. A (-3.867) is worse than B (-1.895).
11. **hERG:** Both are low risk (A: 0.612, B: 0.259). B is slightly better.
12. **Cl_mic:** Ligand A (3.713) has a much lower clearance than Ligand B (-14.625). This suggests better metabolic stability for A.
13. **t1/2:** Ligand A (24.969) has a longer half-life than Ligand B (3.769). This is a significant advantage for A.
14. **Pgp:** Both are very low (A: 0.262, B: 0.025). B is slightly better.
15. **Affinity:** Ligand A (-7.8) has a stronger binding affinity than Ligand B (-7.2). This is a 0.6 kcal/mol difference, which is significant.
**Overall Assessment:**
Ligand A has a superior binding affinity and metabolic stability (lower Cl_mic, longer t1/2) and a better logP. However, it has a significantly higher DILI risk and worse Caco-2 and solubility. Ligand B has a better safety profile (lower DILI, hERG) and slightly better QED, Pgp, and Caco-2 permeability, but its binding affinity is weaker and metabolic stability is poor.
Considering the balance, the stronger affinity of Ligand A is a substantial advantage for a GPCR target, and the metabolic stability is also a plus. While the DILI risk is concerning, it might be mitigated through structural modifications during lead optimization. The poor solubility and permeability of A are also concerning, but could also be addressed during optimization. Ligand B's weaker affinity is harder to overcome.
Therefore, I would prioritize Ligand A for further development.
Output:
1
2025-04-17 19:05:16,832 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Reasoning:**
Let's systematically compare Ligand A and Ligand B against the provided guidelines, keeping in mind the GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key).
1. **MW:** Both ligands (349.362 and 362.499 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (83.98) is significantly better than Ligand A (99.5). Lower TPSA generally favors better cell permeability, crucial for GPCR ligands.
3. **logP:** Ligand B (2.442) is optimal (1-3), while Ligand A (0.092) is quite low. This is a major concern for Ligand A, potentially hindering membrane permeability and bioavailability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2), but both are acceptable.
5. **HBA:** Both ligands have the same number of HBA (5), which is within the acceptable range.
6. **QED:** Both ligands have good QED scores (0.758 and 0.814), indicating generally drug-like properties.
7. **DILI:** Both ligands have acceptable DILI risk (41.062 and 47.421), below the 60% threshold.
8. **BBB:** Ligand A (83.637) has a significantly higher BBB percentile than Ligand B (59.364). While not a primary concern for ADRB2 (a cardiovascular target), higher BBB is generally favorable.
9. **Caco-2:** Ligand B (-5.104) is better than Ligand A (-4.885).
10. **Solubility:** Ligand B (-3.614) is better than Ligand A (-3.235).
11. **hERG:** Both ligands have very low hERG inhibition risk (0.172 and 0.216).
12. **Cl_mic:** Ligand A (6.853) has a much lower microsomal clearance than Ligand B (38.78), suggesting better metabolic stability.
13. **t1/2:** Ligand B (11.727) has a much longer in vitro half-life than Ligand A (-6.446).
14. **Pgp:** Ligand A (0.068) has a significantly lower P-gp efflux liability than Ligand B (0.268), which is highly desirable for oral bioavailability.
15. **Affinity:** Ligand B (-8.5 kcal/mol) has a substantially stronger binding affinity than Ligand A (-5.0 kcal/mol). This is a >1.5 kcal/mol difference, which is a significant advantage, potentially outweighing some ADME drawbacks.
**Overall Assessment:**
Ligand B excels in binding affinity and has acceptable ADME properties, despite a higher Pgp efflux and lower BBB. Ligand A has a very poor logP, which is a major concern for oral bioavailability and target engagement. While Ligand A has better metabolic stability and lower Pgp efflux, the significantly weaker binding affinity and poor logP make it a less promising candidate. The strong affinity of Ligand B is a critical advantage for a GPCR ligand.
**Output:**
0
2025-04-17 19:05:16,832 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, the key priorities are logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB.
Let's compare the ligands property by property:
1. **MW:** Both ligands (343.3 and 351.4 Da) are within the ideal range (200-500 Da).
2. **TPSA:** Ligand B (70.16) is significantly better than Ligand A (112.93). Lower TPSA generally favors oral absorption and GPCR binding.
3. **logP:** Ligand A (2.338) is optimal, while Ligand B (0.339) is quite low, potentially hindering membrane permeability.
4. **HBD/HBA:** Ligand A has 3 HBD and 4 HBA, while Ligand B has 0 HBD and 5 HBA. Both are acceptable, but Ligand A's HBD count might improve solubility.
5. **QED:** Both are similar (0.711 and 0.683), indicating good drug-likeness.
6. **DILI:** Ligand B (25.436) has a much lower DILI risk than Ligand A (89.88), a significant advantage.
7. **BBB:** Ligand B (55.099) has a higher BBB penetration than Ligand A (29.275), though neither is exceptionally high. This is less critical for a cardiovascular target.
8. **Caco-2:** Ligand A (-5.351) has better Caco-2 permeability than Ligand B (-4.516).
9. **Solubility:** Ligand A (-3.128) has better solubility than Ligand B (-1.164).
10. **hERG:** Both ligands have very low hERG inhibition risk (0.056 and 0.125).
11. **Cl_mic:** Ligand A (-0.875) has a lower (better) microsomal clearance than Ligand B (18.222), indicating better metabolic stability.
12. **t1/2:** Ligand A (-15.95) has a longer in vitro half-life than Ligand B (-2.377).
13. **Pgp:** Both ligands have very low Pgp efflux liability (0.026 and 0.023).
14. **Binding Affinity:** Ligand A (-6.5 kcal/mol) has a slightly better binding affinity than Ligand B (-6.1 kcal/mol), but the difference is not substantial.
**Overall Assessment:**
Ligand B excels in DILI risk and TPSA, which are important. However, its low logP is a significant concern for permeability and potentially bioavailability. Ligand A has a more balanced profile, with a good logP, better metabolic stability (Cl_mic, t1/2), and slightly better binding affinity. While Ligand B's lower DILI is attractive, the permeability issues associated with its low logP are more concerning for a GPCR target.
**Output:**
1
2025-04-17 19:05:16,832 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (345.414) is slightly higher than Ligand B (337.379), but both are acceptable.
2. **TPSA:** Ligand A (58.56) is significantly better than Ligand B (99.58). ADRB2 is a cardiovascular target, not a CNS target, but lower TPSA generally improves absorption. Ligand B's TPSA is approaching a level that could hinder oral bioavailability.
3. **logP:** Ligand A (3.721) is optimal, while Ligand B (1.454) is on the lower side. For a GPCR, a higher logP is generally preferred for membrane permeability and receptor engagement.
4. **HBD:** Both ligands have 2 HBD, which is within the acceptable limit of <=5.
5. **HBA:** Ligand A has 3 HBA, while Ligand B has 5. Both are acceptable, but Ligand A is slightly better.
6. **QED:** Both ligands have good QED scores (A: 0.681, B: 0.86), indicating good drug-like properties.
7. **DILI:** Ligand A (55.991) has a higher DILI risk than Ligand B (41.024), which is a negative for Ligand A.
8. **BBB:** This isn't a primary concern for a cardiovascular target like ADRB2, but Ligand A (41.218) is better than Ligand B (24.661).
9. **Caco-2:** Both have negative values, indicating permeability issues. Ligand A (-4.48) is slightly better than Ligand B (-4.808).
10. **Solubility:** Ligand A (-4.323) is better than Ligand B (-2.682). Solubility is important for formulation and bioavailability.
11. **hERG:** Both ligands have low hERG risk (A: 0.846, B: 0.773).
12. **Cl_mic:** Ligand B (-35.893) has *much* better metabolic stability (lower clearance) than Ligand A (66.561). This is a significant advantage for Ligand B.
13. **t1/2:** Ligand B (28.891) has a slightly longer in vitro half-life than Ligand A (26.161).
14. **Pgp:** Both ligands have low Pgp efflux liability (A: 0.874, B: 0.144). Ligand B is significantly better.
15. **Binding Affinity:** Ligand B (-7.8 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.4 kcal/mol). This is a crucial advantage, as a 2.4 kcal/mol difference is substantial.
**Overall Assessment:**
Ligand B clearly wins due to its superior binding affinity and significantly improved metabolic stability (Cl_mic). While Ligand A has better solubility and a slightly lower DILI risk, the substantial difference in affinity and Cl_mic outweighs these benefits. The lower logP of Ligand B is a minor drawback, but the strong binding should compensate. The Pgp efflux is also much better for Ligand B.
Output:
0
2025-04-17 19:05:16,832 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (336.439 Da) is better than Ligand B (373.9 Da), falling comfortably within the 200-500 Da range. Both are acceptable.
2. **TPSA:** Ligand B (47.36) is significantly better than Ligand A (61.92). Lower TPSA generally favors better absorption, important for oral bioavailability.
3. **logP:** Both ligands have similar and good logP values (A: 3.875, B: 3.744), falling within the optimal 1-3 range.
4. **HBD:** Both have 0 HBD, which is acceptable.
5. **HBA:** Both have 4 HBA, which is acceptable.
6. **QED:** Ligand A (0.851) has a slightly better QED score than Ligand B (0.763), indicating a more drug-like profile.
7. **DILI:** Ligand B (22.993) is *much* better than Ligand A (47.732). Lower DILI risk is crucial. This is a significant advantage for Ligand B.
8. **BBB:** Ligand B (95.076) is better than Ligand A (87.515), although both are high. For a cardiovascular target, BBB penetration isn't *essential*, but a higher value isn't detrimental.
9. **Caco-2:** Both are very poor (-4.264 and -4.27), indicating poor intestinal absorption. This is a shared weakness.
10. **Solubility:** Ligand B (-3.562) is better than Ligand A (-5.849), although both are poor.
11. **hERG:** Ligand A (0.72) is slightly better than Ligand B (0.611), indicating a lower risk of cardiotoxicity.
12. **Cl_mic:** Ligand B (43.527) is better than Ligand A (68.294), suggesting better metabolic stability.
13. **t1/2:** Ligand A (38.749) is significantly better than Ligand B (6.174). A longer half-life is generally preferred.
14. **Pgp:** Ligand B (0.179) is better than Ligand A (0.471), indicating lower P-gp efflux.
15. **Binding Affinity:** Ligand B (-7.3 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.1 kcal/mol). This is a substantial advantage, potentially outweighing some ADME concerns.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand B excels in TPSA, Pgp, and *especially* affinity. While both have good logP values, the superior affinity of Ligand B is a major driver. The lower DILI risk is also a very important factor.
**Overall Assessment:**
Ligand B has a significantly stronger binding affinity and a much lower DILI risk, and better metabolic stability, and Pgp efflux. While Ligand A has a slightly better QED and half-life, the benefits of Ligand B's affinity and safety profile are more important for a GPCR target. The poor Caco-2 and solubility are a concern for both, but can be addressed with formulation strategies.
Output:
0
2025-04-17 19:05:16,832 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
Let's systematically compare Ligand A and Ligand B based on the provided parameters and the guidelines, keeping in mind ADRB2 is a GPCR. Therefore, logP, TPSA, Pgp, BBB, and affinity are key.
1. **Molecular Weight:** Both ligands (349.475 and 349.431 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (84.64) is better than Ligand B (87.74). Both are below the 140 A^2 threshold for good oral absorption, but lower is preferable.
3. **logP:** Ligand A (1.784) is slightly higher than Ligand B (1.052), placing it closer to the optimal 1-3 range. Ligand B is a bit low, potentially hindering permeation.
4. **H-Bond Donors:** Ligand A (1) is better than Ligand B (2). Fewer HBDs generally improve permeability.
5. **H-Bond Acceptors:** Both ligands have 4 HBA, which is acceptable (<=10).
6. **QED:** Ligand A (0.792) is slightly better than Ligand B (0.726), indicating a more drug-like profile.
7. **DILI:** Ligand A (12.369%) is significantly better than Ligand B (27.414%). This is a crucial advantage, as lower DILI risk is highly desirable.
8. **BBB:** Ligand B (79.217%) has a better BBB penetration score than Ligand A (66.925%). While ADRB2 isn't exclusively a CNS target, some degree of BBB penetration can be beneficial, and this is a notable advantage for Ligand B.
9. **Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand B (-4.709) is slightly worse than Ligand A (-4.52).
10. **Aqueous Solubility:** Ligand A (-1.779) is better than Ligand B (-2.559). Higher solubility is generally preferred.
11. **hERG Inhibition:** Ligand A (0.381) is significantly better than Ligand B (0.121). Lower hERG inhibition is critical to avoid cardiotoxicity.
12. **Microsomal Clearance:** Ligand A (11.012) has a lower clearance than Ligand B (35.51), indicating better metabolic stability.
13. **In vitro Half-Life:** Ligand A (-0.868) has a better half-life than Ligand B (-13.649).
14. **P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.032 and 0.016 respectively), which is good.
15. **Binding Affinity:** Ligand B (-7.8 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.7 kcal/mol). This is a substantial advantage (1.1 kcal/mol difference), potentially outweighing some of the ADME drawbacks.
**Overall Assessment:**
Ligand B has a much stronger binding affinity, and a better BBB score. However, it has significantly higher DILI risk, worse hERG inhibition, and higher microsomal clearance. Ligand A is better across most ADME properties, particularly DILI and hERG, and has a reasonable affinity. The difference in affinity is substantial, but the safety profile of Ligand A is far superior. For a cardiovascular target, minimizing cardiotoxicity (hERG) and liver toxicity (DILI) is paramount.
**Output:**
1
2025-04-17 19:05:16,833 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (353.423 and 350.459 Da) are within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand B (67.87) is significantly better than Ligand A (116.56). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (1.335) is within the optimal range (1-3), while Ligand A (-1.013) is below 1, potentially hindering permeability. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (1), but both are acceptable (<=5).
5. **HBA:** Ligand A (6) is higher than Ligand B (4), but both are within the acceptable range (<=10).
6. **QED:** Ligand B (0.812) is considerably better than Ligand A (0.466), indicating a more drug-like profile.
7. **DILI:** Both ligands have similar DILI risk (17.255 vs 18.728), and both are relatively low risk (<40).
8. **BBB:** Ligand B (77.2) has a much higher BBB penetration percentile than Ligand A (24.389). While not a primary concern for a cardiovascular target, it's a slight positive for Ligand B.
9. **Caco-2:** Ligand A (-5.651) and Ligand B (-4.771) are both negative, which is unusual. This suggests poor permeability in this assay. However, the values are close, so this isn't a major differentiator.
10. **Solubility:** Ligand A (-0.71) is better than Ligand B (-1.831), which is a positive for Ligand A.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.058 and 0.228).
12. **Cl_mic:** Ligand A (15.373) has a lower microsomal clearance than Ligand B (21.597), indicating better metabolic stability. This is a positive for Ligand A.
13. **t1/2:** Ligand B (19.874) has a longer in vitro half-life than Ligand A (13.518), which is preferable.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.006 and 0.029).
15. **Binding Affinity:** Ligand A (-7.8) has a significantly better binding affinity than Ligand B (-6.9). This is a substantial advantage for Ligand A, potentially outweighing some of the ADME drawbacks.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP and TPSA, while Ligand A has a much stronger binding affinity. The difference in affinity (-7.8 vs -6.9) is a 0.9 kcal/mol difference, which is significant.
**Overall Assessment:**
While Ligand B has better physicochemical properties (logP, TPSA, QED) and a longer half-life, the significantly stronger binding affinity of Ligand A (-7.8 kcal/mol) is a major advantage. The improved affinity is likely to translate to greater efficacy and potentially allow for a lower dose, mitigating some of the ADME concerns.
Output:
1
2025-04-17 19:05:16,833 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.365 and 351.447 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (63.25) is significantly better than Ligand B (95.67). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold. Ligand B is approaching it, but is less favorable.
3. **logP:** Ligand A (3.032) is optimal, while Ligand B (1.225) is on the lower side. For a GPCR, a logP between 1-3 is preferred, and A is better positioned.
4. **HBD:** Both ligands have 2 HBD, which is within the acceptable limit of 5.
5. **HBA:** Ligand A has 3 HBA, and Ligand B has 5. Both are acceptable (<=10), but A is slightly better.
6. **QED:** Ligand A (0.874) has a better QED score than Ligand B (0.734), indicating a more drug-like profile.
7. **DILI:** Ligand B (32.377) has a much lower DILI risk than Ligand A (61.07). This is a significant advantage for Ligand B.
8. **BBB:** Not a high priority for a cardiovascular target. Ligand A (86.817) has a higher BBB penetration score than Ligand B (32.532), but this is less important in this case.
9. **Caco-2:** Ligand A (-4.25) is better than Ligand B (-5.098). Higher values indicate better intestinal absorption.
10. **Solubility:** Ligand A (-3.926) is better than Ligand B (-1.657). Higher values indicate better solubility.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.274 and 0.202, respectively). No significant difference.
12. **Cl_mic:** Ligand B (17.553) has a significantly lower microsomal clearance than Ligand A (56.877), suggesting better metabolic stability.
13. **t1/2:** Ligand B (9.525) has a longer in vitro half-life than Ligand A (-25.522). This is a substantial advantage for Ligand B.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.099 and 0.093, respectively). No significant difference.
15. **Binding Affinity:** Ligand B (-7.7 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.6 kcal/mol). This is a crucial advantage, exceeding the 1.5 kcal/mol threshold.
**Overall Assessment:**
Ligand B demonstrates a superior binding affinity and better metabolic stability (lower Cl_mic, longer t1/2) and a much lower DILI risk. While Ligand A has better TPSA, logP, solubility and Caco-2 permeability, the substantial advantage in binding affinity and the lower toxicity profile of Ligand B outweigh these factors. For a GPCR, strong binding is paramount, and the improved ADME properties of Ligand B make it a more promising candidate.
Output:
0
2025-04-17 19:05:16,833 - INFO - Batch 84 complete. Total preferences: 1344
2025-04-17 19:05:16,833 - INFO - Processing batch 85/512...
2025-04-17 19:06:06,011 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [355.385, 75.44, 2.517, 1, 4, 0.815, 33.773, 89.763, -4.338, -2.851, 0.378, 48.914, -23.382, 0.063, -7.7]
**Ligand B:** [349.391, 107.84, 0.693, 0, 5, 0.423, 35.595, 70.997, -4.911, -1.506, 0.15, 5.037, 14.116, 0.012, -7.3]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (355.385) is slightly higher, but not significantly.
2. **TPSA:** Ligand A (75.44) is excellent, well below the 140 threshold and good for GPCRs. Ligand B (107.84) is higher, but still acceptable.
3. **logP:** Ligand A (2.517) is optimal. Ligand B (0.693) is a bit low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (1) is good. Ligand B (0) is also acceptable.
5. **HBA:** Ligand A (4) is good. Ligand B (5) is also acceptable.
6. **QED:** Ligand A (0.815) is very good, indicating high drug-likeness. Ligand B (0.423) is lower, suggesting a less favorable overall profile.
7. **DILI:** Both are low (Ligand A: 33.773, Ligand B: 35.595), indicating low liver injury risk.
8. **BBB:** Ligand A (89.763) is excellent, suggesting good potential for CNS penetration if desired (though ADRB2 isn't strictly a CNS target, some peripheral effects might benefit). Ligand B (70.997) is decent, but lower.
9. **Caco-2:** Both are negative, indicating good permeability. Ligand A (-4.338) is slightly better.
10. **Solubility:** Both are negative, indicating good solubility. Ligand A (-2.851) is slightly better.
11. **hERG:** Both are very low (Ligand A: 0.378, Ligand B: 0.15), indicating minimal cardiotoxicity risk.
12. **Cl_mic:** Ligand A (48.914) is better (lower clearance) than Ligand B (5.037), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-23.382) is significantly better (longer half-life) than Ligand B (14.116).
14. **Pgp:** Both are very low (Ligand A: 0.063, Ligand B: 0.012), indicating minimal P-gp efflux.
15. **Affinity:** Ligand A (-7.7) is slightly better than Ligand B (-7.3), although the difference is relatively small.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A excels in logP and has a slightly better affinity. While both have good TPSA and Pgp profiles, Ligand A's superior QED, metabolic stability (Cl_mic, t1/2), and BBB penetration give it an edge.
**Conclusion:**
Ligand A presents a more balanced and favorable profile overall, particularly regarding drug-likeness, metabolic stability, and potential for desirable pharmacokinetic properties. The slightly better affinity further supports its selection.
Output:
1
2025-04-17 19:06:06,011 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
The target is ADRB2, a GPCR. Therefore, I will prioritize logP, TPSA, Pgp efflux, BBB penetration, and binding affinity.
* **Molecular Weight:** Both ligands are within the acceptable range (356.39 and 353.47 Da).
* **TPSA:** Ligand A (32.78) is significantly better than Ligand B (101.56). A TPSA under 140 is good for oral absorption, but for a GPCR, lower is generally preferred to facilitate brain penetration if desired. Ligand B's TPSA is quite high.
* **logP:** Ligand A (3.465) is within the optimal range (1-3), while Ligand B (0.252) is quite low, potentially hindering membrane permeability.
* **H-Bond Donors/Acceptors:** Ligand A has 0 HBD and 3 HBA, a favorable profile. Ligand B has 3 HBD and 5 HBA, which is acceptable but less ideal.
* **QED:** Ligand A (0.831) has a much better QED score than Ligand B (0.56), indicating a more drug-like profile.
* **DILI:** Ligand A (19.93) has a slightly higher DILI risk than Ligand B (13.532), but both are reasonably low.
* **BBB:** Ligand A (97.053) shows excellent BBB penetration potential, while Ligand B (19.038) is poor. This is a significant advantage for Ligand A, even if CNS effects aren't the primary goal, as it suggests good distribution.
* **Caco-2:** Ligand A (-4.397) and Ligand B (-5.486) both have negative Caco-2 values, which is unusual and suggests poor permeability. However, these values are on a log scale and are difficult to interpret without knowing the units.
* **Solubility:** Ligand A (-3.096) and Ligand B (-0.144) both have negative solubility values, suggesting poor solubility.
* **hERG:** Ligand A (0.956) has a slightly higher hERG risk than Ligand B (0.354), but both are relatively low.
* **Cl_mic:** Ligand A (13.969) has a higher microsomal clearance than Ligand B (-2.606), indicating faster metabolism and potentially lower bioavailability. This is a negative for Ligand A.
* **t1/2:** Ligand A (-10.995) has a negative in vitro half-life, which is unusual. Ligand B (-9.586) is also negative.
* **Pgp:** Ligand A (0.413) has lower P-gp efflux than Ligand B (0.03), which is favorable for bioavailability and potential CNS exposure.
* **Binding Affinity:** Both ligands have very similar binding affinities (-7.2 and -7.3 kcal/mol). The difference is negligible.
**Overall Assessment:**
Ligand A is clearly the better candidate. While it has a slightly higher DILI risk and faster metabolic clearance, its superior TPSA, logP, QED, and particularly its excellent BBB penetration potential, outweigh these drawbacks. Ligand B's high TPSA and low logP are significant liabilities. The similar binding affinities make the ADME properties the deciding factor.
**Output:**
1
2025-04-17 19:06:06,011 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
Let's analyze each ligand against the provided guidelines, keeping in mind ADRB2 is a GPCR and thus we prioritize logP, TPSA, Pgp, BBB, and affinity.
* **Molecular Weight:** Both ligands (370.5 and 345.5 Da) fall within the ideal 200-500 Da range.
* **TPSA:** Ligand A (78.7) is better than Ligand B (104.5). A TPSA under 140 is good for oral absorption, and both are within this range, but A is closer to the optimal for GPCRs.
* **logP:** Both ligands have good logP values (1.61 and 1.44), falling within the 1-3 range.
* **H-Bond Donors/Acceptors:** Ligand A (1 HBD, 6 HBA) is preferable to Ligand B (3 HBD, 7 HBA). Lower counts generally improve permeability.
* **QED:** Both have acceptable QED values (0.5 and 0.70), indicating good drug-like properties.
* **DILI:** Both have low DILI risk (27.1 and 32.9), which is good.
* **BBB:** Ligand A (43.6) is significantly better than Ligand B (30.4) in terms of BBB penetration. While ADRB2 isn't exclusively a CNS target, some CNS exposure or lack of efflux is often desirable for broader effects and avoiding off-target issues.
* **Caco-2 Permeability:** Both have negative Caco-2 values, which is unusual and indicates poor permeability. However, the scale is not specified, so it's hard to interpret.
* **Aqueous Solubility:** Both have negative solubility values, again indicating poor solubility.
* **hERG:** Ligand A (0.55) is better than Ligand B (0.17), posing a lower risk of cardiotoxicity.
* **Microsomal Clearance:** Ligand B (-31.6) has significantly *lower* (better) microsomal clearance than Ligand A (44.4), suggesting better metabolic stability. This is a significant advantage.
* **In vitro Half-Life:** Ligand B (1.44) has a very short half-life, while Ligand A (30.6) has a much longer one.
* **P-gp Efflux:** Ligand A (0.46) is better than Ligand B (0.12), meaning it is less likely to be pumped out by P-glycoprotein, leading to better bioavailability.
* **Binding Affinity:** Ligand B (-7.3 kcal/mol) has a 1 kcal/mol stronger binding affinity than Ligand A (-6.3 kcal/mol). This is a substantial difference and a major factor.
**Overall Assessment:**
Ligand B has a significantly stronger binding affinity and better metabolic stability (lower Cl_mic). However, Ligand A has better BBB penetration, P-gp efflux, and a longer half-life. The affinity difference is the most significant factor. While the permeability and solubility are poor for both, the stronger binding of Ligand B makes it more likely to be effective at lower doses, potentially mitigating those issues. The improved metabolic stability also contributes to a more favorable profile.
**Output:**
0
2025-04-17 19:06:06,012 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (334.419 Da) is well within the ideal range (200-500 Da). Ligand B (352.395 Da) is also acceptable. No clear advantage here.
2. **TPSA:** Ligand A (43.6) is excellent, well below the 140 threshold and favorable for absorption. Ligand B (118.45) is higher, but still potentially acceptable, though less optimal. Ligand A is better.
3. **logP:** Ligand A (4.125) is slightly high, potentially leading to solubility issues or off-target interactions. Ligand B (-1.127) is too low, which could hinder membrane permeability. Ligand A is preferred, despite being slightly high, as extremely low logP is more problematic.
4. **HBD:** Ligand A (0) is ideal. Ligand B (2) is acceptable but less desirable. Ligand A is better.
5. **HBA:** Ligand A (4) is good. Ligand B (7) is higher, potentially impacting permeability. Ligand A is better.
6. **QED:** Ligand A (0.677) is good, indicating drug-likeness. Ligand B (0.474) is lower, suggesting a less favorable drug-like profile. Ligand A is better.
7. **DILI:** Ligand A (41.411) is good, with low liver injury risk. Ligand B (51.648) is also acceptable, but slightly higher risk. Ligand A is better.
8. **BBB:** Ligand A (73.711) is good, indicating reasonable potential for CNS penetration (though ADRB2 isn't primarily a CNS target, some penetration isn't necessarily detrimental). Ligand B (40.791) is lower. Ligand A is better.
9. **Caco-2:** Ligand A (-4.752) is a negative value, which is unusual and potentially indicates poor permeability. Ligand B (-5.497) is also negative and similarly poor. This is a concern for both, but the values are close.
10. **Solubility:** Ligand A (-4.468) is poor. Ligand B (-0.871) is slightly better, but still poor. Ligand B is slightly better.
11. **hERG:** Ligand A (0.839) is very low risk. Ligand B (0.028) is extremely low risk. Ligand B is better.
12. **Cl_mic:** Ligand A (74.988) is relatively high, suggesting faster metabolism. Ligand B (-6.852) is excellent, indicating high metabolic stability. Ligand B is better.
13. **t1/2:** Ligand A (-6.502) is poor, suggesting a short half-life. Ligand B (7.09) is good. Ligand B is better.
14. **Pgp:** Ligand A (0.641) is moderate. Ligand B (0.009) is very low, indicating minimal P-gp efflux. Ligand B is better.
15. **Affinity:** Ligand A (-6.7 kcal/mol) is good. Ligand B (-6.3 kcal/mol) is also good, but slightly weaker. Ligand A is better.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A has a better logP (though still slightly high), significantly better TPSA, better affinity, and a moderate Pgp efflux. Ligand B excels in metabolic stability and hERG, but suffers from poor logP and TPSA.
**Overall Assessment:**
While Ligand B has excellent metabolic stability and a very low hERG risk, its poor logP and TPSA are significant drawbacks for a GPCR target. Ligand A, despite having a slightly high logP and poor solubility, presents a more balanced profile with better TPSA, affinity, and drug-likeness. The slightly higher metabolic clearance of Ligand A could be addressed with structural modifications.
Output:
1
2025-04-17 19:06:06,012 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (380.897 and 344.499 Da) fall within the ideal 200-500 Da range. Ligand B is slightly smaller, which could be beneficial for permeability.
2. **TPSA:** Ligand A (49.85) is slightly higher than Ligand B (41.57), but both are well below the 140 threshold for good oral absorption.
3. **logP:** Both ligands have good logP values (2.786 and 3.317), falling within the optimal 1-3 range. Ligand B is slightly higher, potentially increasing membrane permeability.
4. **HBD:** Ligand A has 0 HBD, while Ligand B has 1. Both are acceptable.
5. **HBA:** Ligand A has 4 HBA, Ligand B has 3. Both are below the 10 threshold.
6. **QED:** Both ligands have good QED scores (0.807 and 0.736), indicating good drug-like properties.
7. **DILI:** Ligand A (49.283) has a higher DILI risk than Ligand B (6.786). This is a significant advantage for Ligand B.
8. **BBB:** Both ligands exhibit high BBB penetration (91.198 and 96.355). This is less critical for ADRB2 (a cardiovascular target) but not detrimental.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the values are very close (-4.413 vs -4.798).
10. **Solubility:** Both ligands have negative solubility values, indicating poor aqueous solubility. Ligand B is slightly better (-3.074 vs -4.083).
11. **hERG:** Both ligands have low hERG inhibition liability (0.444 and 0.944).
12. **Cl_mic:** Ligand A has a lower microsomal clearance (37.926) than Ligand B (71.079), indicating better metabolic stability.
13. **t1/2:** Ligand B has a longer in vitro half-life (13.318 hours) compared to Ligand A (7.661 hours).
14. **Pgp:** Both ligands have low P-gp efflux liability (0.58 and 0.594).
15. **Binding Affinity:** Ligand B (-8.2 kcal/mol) has a significantly stronger binding affinity than Ligand A (-7.4 kcal/mol). This >1.5 kcal/mol difference is a major advantage.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Both ligands perform well on logP and Pgp. TPSA is acceptable for both. However, Ligand B has a significantly better binding affinity and a much lower DILI risk. While metabolic stability (Cl_mic) is important, the substantial affinity advantage of Ligand B outweighs the slightly higher clearance.
**Conclusion:**
Ligand B is the more promising candidate due to its significantly stronger binding affinity, lower DILI risk, and longer half-life. While Ligand A has better metabolic stability, the other advantages of Ligand B are more critical for a successful drug candidate targeting ADRB2.
Output:
0
2025-04-17 19:06:06,012 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [360.458, 68.49, 3.735, 1, 5, 0.882, 63.862, 66.77, -4.667, -4.731, 0.939, 32.554, 85.146, 0.505, -6.6]
**Ligand B:** [346.289, 102.41, 2.562, 1, 6, 0.674, 89.957, 58.976, -4.311, -5.683, 0.718, 67.794, 34.787, 0.184, -7.3]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (346.289) is slightly lower, which is generally favorable for permeability, but both are acceptable.
2. **TPSA:** Ligand A (68.49) is significantly better than Ligand B (102.41). For a GPCR, keeping TPSA under 140 is good, but lower is better for permeability. Ligand A is much closer to the ideal range for good oral absorption.
3. **logP:** Ligand A (3.735) is slightly higher than Ligand B (2.562), both are within the optimal range of 1-3.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A (5) is better than Ligand B (6). Lower HBA is generally preferred for permeability.
6. **QED:** Ligand A (0.882) has a much better QED score than Ligand B (0.674), indicating a more drug-like profile.
7. **DILI:** Ligand A (63.862) has a lower DILI risk than Ligand B (89.957). This is a significant advantage.
8. **BBB:** Ligand A (66.77) has a better BBB penetration percentile than Ligand B (58.976). While ADRB2 isn't necessarily a CNS target, some peripheral distribution can be impacted by BBB permeability.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Both have negative solubility values, which is also unusual and suggests poor solubility. This is a concern for both.
11. **hERG:** Ligand A (0.939) has a slightly better hERG profile than Ligand B (0.718), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand A (32.554) has significantly lower microsomal clearance than Ligand B (67.794), suggesting better metabolic stability.
13. **t1/2:** Ligand A (85.146) has a much longer in vitro half-life than Ligand B (34.787). This is a major advantage.
14. **Pgp:** Ligand A (0.505) has lower P-gp efflux liability than Ligand B (0.184), which is favorable for bioavailability.
15. **Affinity:** Ligand B (-7.3) has a significantly stronger binding affinity than Ligand A (-6.6). This is a 0.7 kcal/mol difference, which is substantial.
**Overall Assessment:**
Ligand B has a better binding affinity, which is a crucial factor. However, Ligand A demonstrates a significantly better ADME profile across multiple parameters: better QED, lower DILI risk, better BBB penetration, lower clearance, longer half-life, and lower P-gp efflux. The TPSA is also much more favorable for Ligand A. While both have issues with Caco-2 and solubility, the overall balance of properties favors Ligand A. The improved ADME properties of Ligand A are likely to translate to better *in vivo* performance despite the slightly weaker binding. For a GPCR, metabolic stability and bioavailability are critical, and Ligand A excels in these areas.
Output:
1
2025-04-17 19:06:06,012 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (342.443 and 354.357 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (66.71) is better than Ligand B (84.42). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally favors absorption.
3. **logP:** Ligand A (2.347) is optimal, while Ligand B (0.645) is a bit low. A logP between 1-3 is preferred for good permeability and avoiding off-target effects. Ligand B's lower logP could hinder membrane permeability.
4. **HBD:** Both ligands have 1 HBD, which is within the acceptable limit of 5.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 5. Both are acceptable (<=10).
6. **QED:** Both ligands have good QED scores (0.907 and 0.811, respectively), indicating good drug-like properties.
7. **DILI:** Both ligands have similar, acceptable DILI risk (38.891 and 38.038 percentile).
8. **BBB:** Ligand B (87.864) has a significantly higher BBB penetration score than Ligand A (61.962). However, as ADRB2 is a cardiovascular target, BBB penetration is not a priority.
9. **Caco-2:** Both ligands have similar, poor Caco-2 permeability (-4.7 and -4.636). This is a concern for oral absorption for both.
10. **Solubility:** Both ligands have poor aqueous solubility (-2.206 and -2.09). This could pose formulation challenges.
11. **hERG:** Ligand A (0.664) has a slightly better hERG profile than Ligand B (0.192), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand A (39.874) has a higher microsomal clearance than Ligand B (7.866), meaning it is metabolized faster. This is a disadvantage for Ligand A.
13. **t1/2:** Ligand B (-7.321) has a longer in vitro half-life than Ligand A (-8.356), which is more desirable.
14. **Pgp:** Ligand A (0.065) has lower P-gp efflux than Ligand B (0.004), which is favorable.
15. **Binding Affinity:** Ligand B (-7.2 kcal/mol) has slightly better binding affinity than Ligand A (-6.9 kcal/mol). While the difference is not huge, it is still a factor.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, and affinity are important. Ligand A has a better logP and TPSA, while Ligand B has better affinity and metabolic stability (lower Cl_mic, longer t1/2). The affinity difference is not large enough to overcome the potential permeability issues with Ligand B's lower logP.
**Conclusion:**
Considering the balance of properties, Ligand A is the more promising candidate. Its better logP and TPSA are more important for a cardiovascular GPCR target than the slightly better affinity and metabolic stability of Ligand B. The slightly better hERG profile of Ligand A is also a bonus.
Output:
1
2025-04-17 19:06:06,012 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (349.362 Da and 358.41 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (93.46) is slightly higher than Ligand B (84.94). Both are below the 140 A^2 threshold for good oral absorption, but for a cardiovascular target, CNS penetration isn't a primary concern, so this isn't a major differentiating factor.
**3. logP:** Ligand A (2.377) is within the optimal 1-3 range, while Ligand B (0.81) is slightly below. While lower logP can sometimes indicate permeability issues, it's not a severe concern here.
**4. H-Bond Donors:** Ligand A (2) and Ligand B (1) are both acceptable, being less than 5. Ligand B is slightly better.
**5. H-Bond Acceptors:** Both ligands have 5 H-bond acceptors, which is acceptable.
**6. QED:** Ligand A (0.781) has a significantly better QED score than Ligand B (0.513), indicating a more drug-like profile.
**7. DILI Risk:** Ligand B (38.852) has a substantially lower DILI risk than Ligand A (52.346), which is a significant advantage.
**8. BBB Penetration:** Ligand B (80.031) has higher BBB penetration than Ligand A (64.211), but this is less crucial for a cardiovascular target.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the values are similar (-4.336 and -4.41).
**10. Aqueous Solubility:** Both ligands have negative solubility values, indicating poor solubility. Ligand B (-2.174) is slightly better than Ligand A (-3.344).
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (0.271 and 0.368).
**12. Microsomal Clearance:** Ligand A (84.31) has higher microsomal clearance than Ligand B (55.994), suggesting lower metabolic stability. This is a disadvantage for Ligand A.
**13. In vitro Half-Life:** Ligand B (-25.662) has a significantly longer in vitro half-life than Ligand A (52.615), which is a major advantage.
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (0.031 and 0.076).
**15. Binding Affinity:** Both ligands have very similar binding affinities (-5.1 and -5.2 kcal/mol). The difference is negligible.
**GPCR-Specific Priorities:** For a cardiovascular GPCR like ADRB2, logP, Pgp, TPSA, and affinity are important. Ligand B has a better logP, and slightly better TPSA. The affinities are almost identical. The major advantages of Ligand B are its significantly lower DILI risk, better metabolic stability (lower Cl_mic), and longer half-life. These factors outweigh the slightly better QED of Ligand A.
**Conclusion:**
Considering the balance of properties and the specific priorities for a cardiovascular GPCR target, Ligand B is the more promising drug candidate.
0
2025-04-17 19:06:06,013 - INFO - Reasoning:
Let's analyze Ligand A and Ligand B for their potential as ADRB2 ligands, keeping in mind GPCR priorities (logP, Pgp, TPSA, affinity).
**Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (339.4) is slightly lower, which is generally favorable for permeability.
**TPSA:** Ligand A (84.98) is better than Ligand B (65.12), both are below the 140 threshold for oral absorption.
**logP:** Ligand A (1.462) is within the optimal range (1-3). Ligand B (-0.765) is slightly below 1, which could potentially hinder permeation.
**H-Bond Donors/Acceptors:** Ligand A (2 HBD, 6 HBA) and Ligand B (1 HBD, 5 HBA) are both within acceptable limits.
**QED:** Ligand A (0.735) has a better QED score than Ligand B (0.521), indicating a more drug-like profile.
**DILI:** Ligand B (8.841) has a significantly lower DILI risk than Ligand A (53.587), which is a major advantage.
**BBB:** Ligand A (76.037) has a better BBB penetration score than Ligand B (53.936), but BBB isn't a huge priority for ADRB2 as it's a cardiovascular target.
**Caco-2 Permeability:** Ligand A (-5.698) is worse than Ligand B (-4.833), indicating lower intestinal absorption for Ligand A.
**Aqueous Solubility:** Ligand A (-1.767) is worse than Ligand B (-0.795), indicating lower solubility for Ligand A.
**hERG Inhibition:** Both ligands have low hERG inhibition risk (0.411 and 0.317 respectively).
**Microsomal Clearance:** Ligand B (-13.983) has significantly lower microsomal clearance than Ligand A (7.797), indicating better metabolic stability.
**In vitro Half-Life:** Ligand B (-15.834) has a much longer half-life than Ligand A (50.76), which is highly desirable.
**P-gp Efflux:** Both ligands have low P-gp efflux liability (0.116 and 0.012 respectively).
**Binding Affinity:** Ligand A (-7.5 kcal/mol) has a slightly better binding affinity than Ligand B (-5.5 kcal/mol). This 2 kcal/mol difference is significant.
**Overall Assessment:**
Ligand A has a better binding affinity and slightly better BBB penetration, but Ligand B excels in ADME properties. Specifically, Ligand B has a much lower DILI risk, better metabolic stability (lower Cl_mic, longer t1/2), and better solubility. While Ligand A's affinity is better, the ADME profile of Ligand B is substantially more favorable, especially the lower DILI and improved metabolic stability. For a cardiovascular target, metabolic stability and minimizing off-target effects (like liver toxicity) are crucial. The affinity difference, while present, can potentially be optimized in later stages of drug development.
Output:
0
2025-04-17 19:06:06,013 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (345.49 & 368.47 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (58.36) is better than Ligand B (66.48). Both are below 140, but lower TPSA generally favors absorption.
3. **logP:** Ligand A (3.46) is slightly higher than Ligand B (1.98). Both are within the optimal 1-3 range, but Ligand A is closer to the upper bound.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 3. Both are acceptable, below the 10 threshold.
6. **QED:** Ligand A (0.912) is significantly better than Ligand B (0.763), indicating a more drug-like profile.
7. **DILI:** Ligand A (21.44) is better than Ligand B (26.95), both are below 40, indicating low liver injury risk.
8. **BBB:** Ligand B (89.49) is better than Ligand A (73.87). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be useful for peripheral effects and distribution.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.641 and -4.823). This is unusual and suggests poor permeability.
10. **Solubility:** Both ligands have negative solubility values (-2.851 and -3.213). This is also concerning, indicating very poor aqueous solubility.
11. **hERG:** Both ligands have similar hERG risk (0.493 and 0.682). These values are relatively low, suggesting minimal cardiotoxicity risk.
12. **Cl_mic:** Ligand A (21.97) has a much lower microsomal clearance than Ligand B (30.29), indicating better metabolic stability.
13. **t1/2:** Ligand B (-32.26) has a significantly longer in vitro half-life than Ligand A (5.98). This is a major advantage.
14. **Pgp:** Both ligands have low Pgp efflux (0.557 and 0.149). Ligand B is slightly better.
15. **Binding Affinity:** Both ligands have the same binding affinity (-5.7 kcal/mol), which is excellent.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A has a better logP and TPSA, while Ligand B has better BBB and Pgp. The affinity is the same, so that doesn't differentiate them.
**Overall Assessment:**
The biggest drawbacks for both ligands are the negative Caco-2 and solubility values. However, Ligand A has a significantly better QED and lower Cl_mic, suggesting a more favorable overall drug-like profile and better metabolic stability. Ligand B's advantage is its longer half-life and slightly better BBB penetration, but the poor solubility and permeability are significant concerns. Considering the balance, I favor Ligand A due to its better QED, lower clearance, and more favorable TPSA.
Output:
1
2025-04-17 19:06:06,013 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [352.381, 53.35, 3.781, 0, 5, 0.536, 64.599, 74.137, -4.476, -5.101, 0.681, 104.472, -14.877, 0.568, -4.8]
**Ligand B:** [338.411, 66.71, 2.165, 1, 4, 0.869, 64.831, 60.838, -5.025, -3.418, 0.323, 55.044, -5.922, 0.084, -6.4]
Here's a breakdown, prioritizing GPCR properties (logP, Pgp, TPSA, affinity, and BBB):
1. **Molecular Weight:** Both are within the ideal 200-500 Da range. Ligand B (338.411) is slightly lower, which isn't a major concern.
2. **TPSA:** Ligand A (53.35) is better than Ligand B (66.71). Both are acceptable, but lower TPSA generally favors better absorption.
3. **logP:** Ligand A (3.781) is optimal, while Ligand B (2.165) is a bit low. A logP between 1-3 is preferred, and A is closer to the upper end of that range.
4. **H-Bond Donors/Acceptors:** Ligand A (0 HBD, 5 HBA) is slightly better than Ligand B (1 HBD, 4 HBA) in terms of balancing solubility and permeability.
5. **QED:** Ligand B (0.869) has a better QED score than Ligand A (0.536), indicating a more drug-like profile.
6. **DILI:** Both have similar DILI risk (around 64-65%), which is moderately high, but not disqualifying.
7. **BBB:** Ligand A (74.137) has significantly better BBB penetration potential than Ligand B (60.838). While ADRB2 is cardiovascular, some CNS off-target effects are always a consideration, and higher BBB is generally preferred.
8. **Caco-2:** Ligand A (-4.476) and Ligand B (-5.025) both have negative Caco-2 values, which is unusual. This suggests very poor permeability.
9. **Solubility:** Ligand B (-3.418) has slightly better solubility than Ligand A (-5.101).
10. **hERG:** Both have low hERG inhibition risk (0.681 and 0.323 respectively).
11. **Cl_mic:** Ligand B (55.044) has significantly lower microsomal clearance than Ligand A (104.472), suggesting better metabolic stability.
12. **t1/2:** Ligand B (-5.922) has a longer in vitro half-life than Ligand A (-14.877).
13. **Pgp:** Ligand A (0.568) has lower P-gp efflux than Ligand B (0.084), which is favorable for bioavailability.
14. **Binding Affinity:** Ligand B (-6.4 kcal/mol) has a significantly stronger binding affinity than Ligand A (-4.8 kcal/mol). This is a substantial difference and a major advantage.
**Overall Assessment:**
The biggest differentiator is the binding affinity. Ligand B's -6.4 kcal/mol is considerably better than Ligand A's -4.8 kcal/mol. This difference in potency is significant enough to outweigh some of Ligand A's advantages (slightly better TPSA, BBB, and Pgp). Ligand B also has better metabolic stability (lower Cl_mic) and a longer half-life. While Ligand A has a slightly better logP, the difference isn't substantial enough to overcome the affinity advantage of Ligand B. The Caco-2 values are concerning for both, but the binding affinity is the most important factor here.
Therefore, I would choose Ligand B.
Output:
0
2025-04-17 19:06:06,013 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (353.463 and 346.431 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (113.66) is slightly higher than Ligand B (97.55). Both are below the 140 threshold for good oral absorption, but B is better.
3. **logP:** Ligand A (0.803) is a bit low, potentially hindering permeation. Ligand B (1.209) is better, falling within the optimal 1-3 range.
4. **HBD:** Ligand A (3) is acceptable, while Ligand B (2) is even better, minimizing potential issues with solubility and permeability.
5. **HBA:** Both ligands have 5 HBA, which is acceptable.
6. **QED:** Both ligands have good QED scores (0.597 and 0.723), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (11.361) has a much lower DILI risk than Ligand B (45.832). This is a significant advantage for Ligand A.
8. **BBB:** Ligand B (72.664) has a considerably higher BBB penetration potential than Ligand A (38.813). While ADRB2 isn't strictly a CNS target, some CNS exposure can be relevant for off-target effects or potential therapeutic benefits.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, these values are on a log scale, so the difference is substantial. Ligand A (-5.18) is worse than Ligand B (-5.412).
10. **Solubility:** Both ligands have very poor predicted solubility (-1.758 and -1.519). This is a major concern for both.
11. **hERG:** Both ligands have low hERG risk (0.268 and 0.204), which is good.
12. **Cl_mic:** Ligand A (-6.501) has a lower (better) microsomal clearance than Ligand B (7.497), indicating better metabolic stability.
13. **t1/2:** Ligand B (9.581) has a longer in vitro half-life than Ligand A (6.999), which is desirable.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.007 and 0.009).
15. **Binding Affinity:** Ligand B (-6.1) has a slightly better binding affinity than Ligand A (-5.8). This is a 0.3 kcal/mol difference, which is not huge, but still relevant.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B performs better on logP and TPSA, and has slightly better affinity. However, the DILI risk for Ligand B is significantly higher, which is a major concern. The improved BBB penetration of Ligand B is less critical for a non-CNS primary target.
**Overall Assessment:**
While Ligand B has a slight edge in binding affinity and better permeability characteristics, the significantly higher DILI risk associated with Ligand B is a major drawback. The lower DILI risk of Ligand A, combined with acceptable (though not ideal) ADME properties, makes it the more promising candidate. The solubility issues are a concern for both, but can be addressed through formulation strategies.
Output:
1
2025-04-17 19:06:06,013 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [345.447, 88.91, 1.467, 2, 5, 0.817, 32.067, 50.097, -5.396, -2.012, 0.078, 11.63, 12.312, 0.011, -6.6]
**Ligand B:** [344.415, 88.32, 1.397, 1, 6, 0.892, 47.421, 47.15, -5.004, -1.783, 0.02, -0.383, 6.973, 0.031, -6.0]
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (345.45 Da and 344.42 Da).
2. **TPSA:** Both are good (88.91 and 88.32), well below the 140 threshold for oral absorption.
3. **logP:** Both are optimal (1.467 and 1.397), falling within the 1-3 range.
4. **HBD:** Ligand A (2) is slightly better than Ligand B (1), but both are acceptable.
5. **HBA:** Ligand A (5) is better than Ligand B (6).
6. **QED:** Both are good (0.817 and 0.892), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (32.07%) is significantly better than Ligand B (47.42%). This is a crucial advantage.
8. **BBB:** Both are moderate (50.10% and 47.15%). Not a primary concern for a cardiovascular target, but higher is generally preferable.
9. **Caco-2:** Both are very poor (-5.396 and -5.004). This is a significant drawback for both, indicating poor intestinal absorption.
10. **Solubility:** Both are very poor (-2.012 and -1.783). This is a major concern for both, potentially hindering bioavailability.
11. **hERG:** Both are very low risk (0.078 and 0.02). Excellent.
12. **Cl_mic:** Ligand A (11.63) is worse than Ligand B (-0.383), indicating lower metabolic stability.
13. **t1/2:** Ligand A (12.312) is better than Ligand B (6.973), indicating a longer half-life.
14. **Pgp:** Both are very low (0.011 and 0.031), suggesting minimal efflux.
15. **Affinity:** Ligand A (-6.6) is slightly better than Ligand B (-6.0), a 0.6 kcal/mol advantage.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Both ligands perform similarly on logP, TPSA, and Pgp. Ligand A has a slight edge in affinity. However, the biggest differentiator is the DILI risk. A significantly lower DILI risk is a major advantage for Ligand A. While both have poor Caco-2 and solubility, the lower DILI risk outweighs the slightly better metabolic stability of Ligand B.
**Conclusion:**
Considering the balance of properties, and prioritizing the crucial DILI risk, Ligand A is the more promising candidate.
Output:
1
2025-04-17 19:06:06,013 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (342.443 and 334.394 Da) fall comfortably within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (89.27) is better than Ligand B (26.71). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B is exceptionally low, which *could* indicate poor interactions.
3. **logP:** Ligand A (2.56) is within the optimal 1-3 range. Ligand B (4.69) is higher, potentially leading to solubility issues and off-target interactions. This is a significant negative for Ligand B.
4. **HBD:** Ligand A (3) is acceptable. Ligand B (1) is also good.
5. **HBA:** Ligand A (5) is acceptable. Ligand B (3) is also good.
6. **QED:** Both ligands have good QED scores (0.61 and 0.753), indicating generally drug-like properties.
7. **DILI:** Ligand A (42.846) has a lower DILI risk than Ligand B (68.088). This is a significant advantage for Ligand A.
8. **BBB:** Both are moderate, but Ligand B (66.344) is higher than Ligand A (50.679). For a cardiovascular target, BBB penetration isn't a primary concern, so this difference is less impactful.
9. **Caco-2:** Both are negative, indicating poor permeability. This is a concern for both, but the negative values make direct comparison difficult.
10. **Solubility:** Ligand A (-2.424) is better than Ligand B (-5.186). Solubility is important for bioavailability, and Ligand A has a clear advantage.
11. **hERG:** Both ligands have low hERG inhibition risk (0.791 and 0.959).
12. **Cl_mic:** Ligand A (12.156) has a lower microsomal clearance than Ligand B (92.685), suggesting better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (13.621) has a longer in vitro half-life than Ligand B (-28.383). This is a major advantage for Ligand A, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.18) has lower P-gp efflux liability than Ligand B (0.767), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand B (-8.9) has a significantly stronger binding affinity than Ligand A (-5.3). This is a substantial advantage for Ligand B, potentially outweighing some of its ADME drawbacks. However, the difference is not so large that it completely overshadows the other factors.
**Overall Assessment:**
While Ligand B boasts a superior binding affinity, Ligand A demonstrates a much more balanced profile with better predicted ADME properties. Specifically, Ligand A has lower DILI risk, better solubility, significantly better metabolic stability (lower Cl_mic and longer t1/2), and lower P-gp efflux. The higher logP of Ligand B is a concern, and its poor solubility could hinder its development. For a cardiovascular GPCR, metabolic stability and safety (DILI) are crucial, and Ligand A excels in these areas. The affinity difference, while significant, isn't large enough to overcome the ADME advantages of Ligand A.
Output:
1
2025-04-17 19:06:06,013 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (360.376 & 344.39 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (67.43) is significantly better than Ligand B (82.16). For a GPCR, lower TPSA is generally preferred for better permeability.
3. **logP:** Ligand B (3.29) is slightly higher than Ligand A (1.621). While both are within the optimal 1-3 range, Ligand B is approaching the upper limit.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1). Both are acceptable.
5. **HBA:** Ligand A (3) is lower than Ligand B (5). Lower HBA is generally preferred for permeability.
6. **QED:** Both ligands have good QED scores (0.783 and 0.833), indicating good drug-like properties.
7. **DILI:** Ligand A (35.091) has a much lower DILI risk than Ligand B (60.372). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (83.366) has a better BBB penetration score than Ligand B (70.88). While ADRB2 isn't necessarily a CNS target, some peripheral ADRB2 subtypes can be relevant to CNS effects, and higher BBB is rarely a detriment.
9. **Caco-2:** Ligand A (-5) is better than Ligand B (-4.725).
10. **Solubility:** Ligand A (-3.118) is better than Ligand B (-4.391).
11. **hERG:** Ligand A (0.247) has a lower hERG inhibition liability than Ligand B (0.557). This is a significant safety advantage.
12. **Cl_mic:** Ligand A (15.749) has a much lower microsomal clearance than Ligand B (72.489), indicating better metabolic stability.
13. **t1/2:** Ligand B (49.793) has a significantly longer in vitro half-life than Ligand A (7.3). This is a major advantage for Ligand B.
14. **Pgp:** Ligand A (0.058) has a much lower P-gp efflux liability than Ligand B (0.199). This is a significant advantage for Ligand A.
15. **Binding Affinity:** Ligand A (-6.7) is slightly better than Ligand B (-6.4). While the difference is small, it's still a positive for Ligand A.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical ADME-Tox parameters (DILI, hERG, Cl_mic, Pgp, Solubility, TPSA). While Ligand B has a longer half-life, the superior safety profile and permeability characteristics of Ligand A are more important for initial drug candidate selection. The slight advantage in binding affinity further supports choosing Ligand A.
Output:
1
2025-04-17 19:06:06,014 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (367.421 and 349.337 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (54.46) is significantly better than Ligand B (82.53). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (3.474 and 2.555) within the optimal 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (4). Similar to HBD, lower HBA is generally better.
6. **QED:** Both ligands have very similar and good QED values (0.879 and 0.869), indicating good drug-likeness.
7. **DILI:** Ligand A (67.197) has a slightly higher DILI risk than Ligand B (73.09), but both are acceptable.
8. **BBB:** Ligand A (88.445) has a much higher BBB penetration percentile than Ligand B (52.191). While not a primary concern for a cardiovascular target, higher BBB is generally not detrimental.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.585 and -4.507), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand A (-3.874) has slightly better solubility than Ligand B (-3.531), but both are quite poor.
11. **hERG:** Ligand A (0.811) has a slightly higher hERG risk than Ligand B (0.194). This is a concern, but the difference isn't huge.
12. **Cl_mic:** Ligand A (26.501) has significantly lower microsomal clearance than Ligand B (45.927), indicating better metabolic stability.
13. **t1/2:** Ligand A (5.969) has a longer in vitro half-life than Ligand B (1.389). This is a major advantage.
14. **Pgp:** Ligand A (0.571) has a higher Pgp efflux liability than Ligand B (0.04). This is a negative for Ligand A.
15. **Binding Affinity:** Ligand A (-7.4) has a significantly stronger binding affinity than Ligand B (-0.0). This is a very substantial advantage.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A is better in terms of logP, TPSA, and *significantly* better in affinity. While Pgp is worse for Ligand A, the superior affinity is likely to outweigh this.
**Overall Assessment:**
Despite the poor Caco-2 and solubility for both, Ligand A's dramatically superior binding affinity (-7.4 vs -0.0) and better metabolic stability (lower Cl_mic, longer t1/2) make it the more promising candidate. The slightly higher DILI and Pgp efflux are less concerning given the large affinity difference.
Output:
1
2025-04-17 19:06:06,014 - INFO - Batch 85 complete. Total preferences: 1360
2025-04-17 19:06:06,014 - INFO - Processing batch 86/512...
2025-04-17 19:06:53,618 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (354.403 and 363.483 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (78.51) is significantly better than Ligand A (99.89). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (1.923 and 2.327), falling within the optimal 1-3 range. Ligand B is slightly better.
4. **HBD:** Ligand A has 1 HBD, while Ligand B has 2. Both are acceptable (<=5).
5. **HBA:** Ligand A has 7 HBA, and Ligand B has 4. Ligand B is preferable, being closer to the ideal of <=10.
6. **QED:** Both ligands have good QED scores (0.712 and 0.862), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand B (39.667) has a significantly lower DILI risk than Ligand A (62.272). This is a major advantage for Ligand B.
8. **BBB:** Both have reasonable BBB penetration (73.401 and 68.399), but this isn't a primary concern for a cardiovascular target.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand B (-5.195) is slightly better than Ligand A (-4.762), but both are concerning.
10. **Solubility:** Ligand A (-1.586) has better solubility than Ligand B (-3.029). Solubility is important for bioavailability.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.106 and 0.256), which is excellent.
12. **Cl_mic:** Ligand B (1.393) has significantly lower microsomal clearance than Ligand A (66.273), indicating better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand B (9.757) has a much longer in vitro half-life than Ligand A (-7.477). This is a major advantage, potentially leading to less frequent dosing.
14. **Pgp:** Both have very low Pgp efflux (0.02 and 0.067), which is good.
15. **Binding Affinity:** Ligand B (-8.2 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.2 kcal/mol). This is a substantial advantage, potentially outweighing some minor ADME drawbacks.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP, TPSA, Pgp, and *especially* affinity. While solubility is important, the significantly better affinity and metabolic stability of Ligand B are more critical. The lower DILI risk is also a major benefit.
Output:
0
2025-04-17 19:06:53,618 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (369.447 and 369.487 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (103.87) is slightly higher than Ligand B (100.55). Both are below the 140 threshold for good oral absorption, but closer to the upper end.
3. **logP:** Ligand B (1.316) is significantly better than Ligand A (0.029). A logP between 1-3 is optimal, and Ligand A is quite low, potentially hindering permeability.
4. **HBD:** Ligand A (2) is preferable to Ligand B (3). Lower HBD generally improves permeability.
5. **HBA:** Both ligands have the same HBA count (6), which is acceptable (<=10).
6. **QED:** Ligand A (0.706) has a slightly better QED score than Ligand B (0.642), suggesting a more drug-like profile.
7. **DILI:** Ligand B (57.619) has a lower DILI risk than Ligand A (65.103), which is a clear advantage.
8. **BBB:** Ligand A (52.191) has a better BBB penetration percentile than Ligand B (34.122). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant, and higher BBB is generally favorable.
9. **Caco-2:** Both ligands have very negative Caco-2 values (-5.142 and -5.237), indicating poor permeability. This is a significant concern for both.
10. **Solubility:** Both ligands have very negative solubility values (-1.983 and -1.732). This is a major drawback for both compounds.
11. **hERG:** Ligand A (0.05) has a much lower hERG inhibition liability than Ligand B (0.267), which is a critical safety advantage.
12. **Cl_mic:** Both ligands have similar microsomal clearance values (29.569 and 29.939 mL/min/kg), suggesting comparable metabolic stability.
13. **t1/2:** Ligand B (14.826) has a significantly longer in vitro half-life than Ligand A (-2.355), which is a major advantage.
14. **Pgp:** Ligand A (0.008) has a much lower P-gp efflux liability than Ligand B (0.213), which is a positive for bioavailability.
15. **Binding Affinity:** Ligand B (-5.8 kcal/mol) has a slightly better binding affinity than Ligand A (-6.2 kcal/mol). While the difference is small, it's still a factor.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand B excels in logP and affinity, while Ligand A is better in Pgp and has a slightly better TPSA. The poor Caco-2 and solubility for both are concerning, but can be addressed with formulation strategies. The hERG risk for Ligand A is a significant advantage.
**Overall Assessment:**
Despite Ligand B's slightly better affinity and half-life, the significantly lower hERG risk for Ligand A is a crucial factor. Cardiotoxicity is a major concern for ADRB2 agonists, and minimizing hERG liability is paramount. The better Pgp value of Ligand A also contributes to better bioavailability. While both have permeability and solubility issues, these are formulation challenges, whereas hERG risk is a fundamental safety concern.
Output:
1
2025-04-17 19:06:53,618 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (351.47) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are good, below the 140 A^2 threshold for oral absorption. Ligand B (74.33) is slightly better than Ligand A (84.14).
3. **logP:** Both are within the optimal range (1-3). Ligand B (2.296) is slightly lower than Ligand A (3.303), potentially offering a better balance between permeability and solubility.
4. **HBD:** Both have 2 HBD, which is acceptable.
5. **HBA:** Ligand A has 4 HBA, Ligand B has 5. Both are acceptable, below the 10 threshold.
6. **QED:** Both have good QED scores (>0.5), suggesting good drug-like properties. Ligand B (0.789) is slightly better than Ligand A (0.738).
7. **DILI:** Both have acceptable DILI risk (<40 is good). Ligand A (39.318) is slightly better than Ligand B (46.336).
8. **BBB:** Ligand A (97.014) has significantly better BBB penetration than Ligand B (65.568). While ADRB2 isn't exclusively a CNS target, some cardiovascular effects are mediated by central pathways, and better BBB penetration can be advantageous.
9. **Caco-2:** Ligand B (-5.399) has a better Caco-2 permeability than Ligand A (-4.732).
10. **Solubility:** Both have poor aqueous solubility (-3.x scale). This is a concern for both, but not a deciding factor.
11. **hERG:** Both have low hERG inhibition liability (0.622 and 0.705), which is good.
12. **Cl_mic:** Ligand B (4.564) has a much lower microsomal clearance than Ligand A (45.468), indicating better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand A (-7.516) has a better in vitro half-life than Ligand B (49.452).
14. **Pgp:** Ligand A (0.293) has lower P-gp efflux liability than Ligand B (0.209), which is favorable for bioavailability.
15. **Affinity:** Ligand A (-6.8 kcal/mol) has a better binding affinity than Ligand B (-9.4 kcal/mol). This is a substantial difference.
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A excels in affinity and Pgp efflux, and has a reasonable logP and TPSA. Ligand B has a better TPSA and lower Cl_mic, but significantly weaker binding affinity. The affinity difference is substantial (>1.5 kcal/mol).
**Overall Assessment:**
While Ligand B has better metabolic stability (lower Cl_mic) and Caco-2 permeability, the significantly stronger binding affinity of Ligand A (-6.8 vs -9.4 kcal/mol) is the most critical factor. The better BBB penetration of Ligand A is also a plus. The solubility issues are a concern for both, but can be addressed through formulation strategies. The improved affinity and Pgp profile of Ligand A outweigh the benefits of Ligand B's metabolic stability.
Output:
1
2025-04-17 19:06:53,618 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's break down the comparison of Ligand A and Ligand B based on the provided parameters and the guidelines, keeping in mind ADRB2 is a GPCR and thus we prioritize logP, Pgp, TPSA, and affinity.
1. **Molecular Weight:** Both ligands (349.475 and 380.861 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (61.88) is significantly better than Ligand B (93.01). A TPSA under 140 is good for oral absorption, but lower is preferred for GPCRs, and A is much closer to the ideal range.
3. **logP:** Both ligands have similar logP values (1.169 and 1.199), falling within the optimal 1-3 range.
4. **H-Bond Donors:** Both have 1 HBD, which is good.
5. **H-Bond Acceptors:** Ligand A has 4 HBA, while Ligand B has 7. Ligand A is preferable here, as lower HBA generally improves permeability.
6. **QED:** Both ligands have very similar QED scores (0.809 and 0.812), indicating good drug-likeness.
7. **DILI:** Ligand A (23.575) has a much lower DILI risk than Ligand B (80.729). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (65.839) has a better BBB penetration score than Ligand B (51.066), although neither is exceptionally high. For a cardiovascular target, BBB isn't *critical*, but a higher value is still preferable.
9. **Caco-2:** Ligand A (-4.642) has a better Caco-2 permeability than Ligand B (-5.555).
10. **Solubility:** Ligand A (-1.483) has better aqueous solubility than Ligand B (-2.38).
11. **hERG:** Both have very low hERG inhibition liability (0.252 and 0.138), which is excellent.
12. **Cl_mic:** Ligand B (-3.071) has a *much* lower microsomal clearance than Ligand A (7.298), indicating better metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand B (-0.981) has a slightly better in vitro half-life than Ligand A (15.755).
14. **Pgp:** Both have very low Pgp efflux liability (0.064 and 0.059), which is good.
15. **Binding Affinity:** Ligand B (-7.3) has a slightly better binding affinity than Ligand A (-8.0). While A is better, the difference is not substantial enough to outweigh other factors.
**Overall Assessment:**
Ligand A has several advantages: better TPSA, lower HBA, significantly lower DILI risk, better Caco-2 permeability, and better solubility. Ligand B's primary advantage is its significantly improved metabolic stability (lower Cl_mic) and slightly better half-life. However, the DILI risk associated with Ligand B is concerning. Given the balance of properties, and prioritizing a lower risk profile, Ligand A is the more promising candidate. The slight difference in binding affinity is not enough to overcome the substantial DILI risk of Ligand B.
**Output:**
1
2025-04-17 19:06:53,619 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [370.559, 67.43, 2.593, 2, 4, 0.781, 22.8, 57.619, -5.165, -3.674, 0.358, 65.216, 21.176, 0.041, -4.7]
**Ligand B:** [358.511, 66.91, 3.523, 2, 5, 0.718, 60.721, 64.637, -5.389, -4.076, 0.658, 102.615, 66.195, 0.239, -7]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, Affinity, and BBB):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (358.511) is slightly lower, which is generally favorable.
2. **TPSA:** Both are reasonably good (67.43 and 66.91), suggesting decent permeability. Both are well below the 90 A^2 threshold for CNS targets, though ADRB2 isn't necessarily a CNS target.
3. **logP:** Ligand A (2.593) is better than Ligand B (3.523). Ligand B is pushing the upper limit of the optimal range, potentially leading to solubility issues.
4. **HBD/HBA:** Both have 2 HBD and a reasonable number of HBA (4 and 5 respectively). This is acceptable.
5. **QED:** Both are good (0.781 and 0.718), indicating drug-like properties.
6. **DILI:** Ligand A (22.8) has a significantly lower DILI risk than Ligand B (60.721). This is a major advantage for Ligand A.
7. **BBB:** Ligand B (64.637) has a slightly better BBB penetration than Ligand A (57.619), but both are moderate.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
9. **Solubility:** Both have negative solubility values, which is also unusual. Again, the scale is not specified.
10. **hERG:** Ligand A (0.358) has a lower hERG risk than Ligand B (0.658), which is preferable.
11. **Cl_mic:** Ligand A (65.216) has a lower microsomal clearance than Ligand B (102.615), indicating better metabolic stability.
12. **t1/2:** Ligand B (66.195) has a longer half-life than Ligand A (21.176), which is a positive.
13. **Pgp:** Ligand A (0.041) has significantly lower P-gp efflux than Ligand B (0.239), which is a major advantage for bioavailability.
14. **Affinity:** Ligand B (-7 kcal/mol) has a substantially stronger binding affinity than Ligand A (-4.7 kcal/mol). This is a significant advantage, potentially outweighing some ADME concerns.
**Overall Assessment:**
Ligand B has a significantly better binding affinity, which is critical for a GPCR target. However, it has concerningly higher DILI risk, Pgp efflux, and microsomal clearance. Ligand A has a much better safety profile (lower DILI, hERG, Pgp) and metabolic stability, but its affinity is weaker.
Given the balance, the stronger affinity of Ligand B is a significant advantage for a GPCR. While the ADME properties of Ligand B are less ideal, optimization efforts could potentially address those issues. The weaker affinity of Ligand A makes it less likely to be a successful starting point, even with its better ADME profile.
Output:
0
2025-04-17 19:06:53,619 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [350.463, 107.11 , 1.599, 4. , 4. , 0.507, 13.61 , 29.12 , -5.426, -0.968, 0.237, -18.144, -22.326, 0.03 , -8. ]
**Ligand B:** [358.467, 75.19 , 2.659, 1. , 6. , 0.823, 73.129, 79.139, -5.272, -3.126, 0.532, 60.545, 2.698, 0.122, -5.2 ]
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). A (350.463) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (75.19) is significantly better than Ligand A (107.11). For a GPCR, lower TPSA is preferred for better brain penetration, even if it's not a CNS target.
3. **logP:** Ligand B (2.659) is slightly higher than Ligand A (1.599), and both are within the optimal range (1-3).
4. **HBD:** Ligand B (1) has fewer HBD than Ligand A (4), which is generally preferred for better permeability.
5. **HBA:** Ligand B (6) has more HBA than Ligand A (4). This is less concerning than the HBD difference.
6. **QED:** Ligand B (0.823) has a higher QED score than Ligand A (0.507), indicating a more drug-like profile.
7. **DILI:** Ligand A (13.61) has a much lower DILI risk than Ligand B (73.129). This is a significant advantage for Ligand A.
8. **BBB:** Ligand B (79.139) has a much higher BBB penetration potential than Ligand A (29.12). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be beneficial for distribution.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-5.426) is slightly worse than Ligand B (-5.272).
10. **Solubility:** Ligand A (-0.968) has better solubility than Ligand B (-3.126).
11. **hERG:** Ligand A (0.237) has a lower hERG risk than Ligand B (0.532). This is a significant safety advantage.
12. **Cl_mic:** Ligand A (-18.144) has much lower microsomal clearance than Ligand B (60.545), indicating better metabolic stability.
13. **t1/2:** Ligand A (-22.326) has a longer in vitro half-life than Ligand B (2.698).
14. **Pgp:** Ligand B (0.122) has lower P-gp efflux than Ligand A (0.03), which is favorable.
15. **Affinity:** Both ligands have similar binding affinity (-8 kcal/mol and -5.2 kcal/mol). Ligand A has a significantly better affinity.
**Overall Assessment:**
Ligand A has a much better safety profile (lower DILI, lower hERG) and significantly better metabolic stability (lower Cl_mic, longer t1/2). It also has a better binding affinity. While Ligand B has better TPSA, QED, and Pgp properties, the safety and metabolic stability advantages of Ligand A are more critical for a viable drug candidate. The Caco-2 permeability is poor for both, but can be addressed with formulation strategies.
Therefore, I prefer Ligand A.
Output:
1
2025-04-17 19:06:53,619 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for the ADRB2, a cardiovascular GPCR. Therefore, the key priorities are logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB.
Let's compare the ligands property by property:
1. **MW:** Both ligands (355.454 and 357.445 Da) fall within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (87.3) is higher than Ligand B (58.36). Ligand B is significantly better, being closer to the <90 target for good absorption.
3. **logP:** Ligand A (1.583) is within the optimal range, while Ligand B (2.837) is approaching the upper limit. Both are acceptable, but A is slightly preferred.
4. **HBD/HBA:** Ligand A has 3 HBD and 3 HBA, while Ligand B has 1 HBD and 4 HBA. Both are within acceptable limits.
5. **QED:** Ligand B (0.816) has a better QED score than Ligand A (0.587), indicating a more drug-like profile.
6. **DILI:** Ligand B (25.204) has a much lower DILI risk than Ligand A (38.116), which is a significant advantage.
7. **BBB:** Ligand B (92.284) has a much higher BBB penetration score than Ligand A (70.027). While not critical for a cardiovascular target, it's a bonus.
8. **Caco-2:** Ligand A (-5.099) and Ligand B (-4.243) are both negative, indicating poor permeability.
9. **Solubility:** Both ligands have poor solubility (-2.681 and -2.559 respectively).
10. **hERG:** Ligand A (0.264) has a slightly lower hERG risk than Ligand B (0.568), which is preferable.
11. **Cl_mic:** Ligand A (6.954) has a lower microsomal clearance than Ligand B (50.846), indicating better metabolic stability. This is a significant advantage.
12. **t1/2:** Ligand B (-37.582) has a much longer in vitro half-life than Ligand A (-2.652). This is a major advantage.
13. **Pgp:** Ligand A (0.081) has lower P-gp efflux liability than Ligand B (0.132), which is favorable.
14. **Binding Affinity:** Ligand B (-7.8 kcal/mol) has a significantly stronger binding affinity than Ligand A (-4.9 kcal/mol). This is a substantial advantage that can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand B clearly wins on binding affinity and has a significantly better half-life. It also has a much lower DILI risk and better BBB penetration. While Ligand A has better metabolic stability and Pgp efflux, the substantial advantage in binding affinity and half-life of Ligand B, coupled with the lower DILI risk, makes it the more promising candidate. The TPSA of Ligand B is also significantly better.
**Output:**
0
2025-04-17 19:06:53,619 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.443 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (87.66) is slightly higher than Ligand B (67.87). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is generally preferred for absorption. Ligand B is better here.
3. **logP:** Ligand A (2.314) and Ligand B (1.745) are both within the optimal 1-3 range. Ligand A is slightly more lipophilic, which could aid membrane permeability but also increase off-target interactions.
4. **HBD:** Ligand A (3) is higher than Ligand B (1). Lower HBD is generally preferred for permeability. Ligand B is better.
5. **HBA:** Both ligands have 4 HBA, which is acceptable. No significant difference.
6. **QED:** Ligand B (0.844) has a slightly higher QED score than Ligand A (0.736), indicating a more drug-like profile.
7. **DILI:** Both ligands have acceptable DILI risk, with Ligand B (32.261) being slightly lower than Ligand A (33.773).
8. **BBB:** Both ligands have good BBB penetration (Ligand A: 77.821, Ligand B: 74.758). This isn't a primary concern for a cardiovascular target, but it doesn't hurt.
9. **Caco-2:** Ligand A (-4.276) and Ligand B (-4.78) are both negative, indicating poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-3.097) and Ligand B (-2.238) are both negative, indicating poor solubility. This is a concern for both.
11. **hERG:** Both ligands have very low hERG inhibition risk (Ligand A: 0.236, Ligand B: 0.155). This is excellent.
12. **Cl_mic:** Ligand B (14.79) has significantly lower microsomal clearance than Ligand A (47.131), indicating better metabolic stability. This is a major advantage.
13. **t1/2:** Ligand B (1.832) has a slightly longer in vitro half-life than Ligand A (-32.653). This is a positive.
14. **Pgp:** Both ligands have low P-gp efflux liability (Ligand A: 0.04, Ligand B: 0.048). No significant difference.
15. **Binding Affinity:** Ligand A (-6.8 kcal/mol) has a slightly better binding affinity than Ligand B (-6.2 kcal/mol). This is a 0.6 kcal/mol difference, which is noticeable but not overwhelming.
**Overall Assessment:**
While Ligand A has slightly better binding affinity, Ligand B demonstrates a significantly better ADME profile. Specifically, the lower microsomal clearance and slightly longer half-life of Ligand B are crucial advantages for a drug candidate. The lower TPSA and HBD also contribute to a potentially more favorable absorption profile. The differences in solubility and Caco-2 permeability are concerning for both, but the improved metabolic stability of Ligand B is a key differentiator. Given the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), the balance of properties favors Ligand B.
Output:
0
2025-04-17 19:06:53,619 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**1. Molecular Weight:** Both ligands (355.479 Da and 346.387 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (89.95) is better than Ligand B (101.47). For a GPCR, keeping TPSA low is beneficial for permeability, and A is comfortably below 90.
**3. logP:** Ligand B (1.952) is better than Ligand A (0.758). Both are within the 1-3 range, but B is closer to the optimal range. A is a bit low, potentially impacting permeability.
**4. H-Bond Donors:** Ligand A (2) is slightly better than Ligand B (1). Both are acceptable.
**5. H-Bond Acceptors:** Ligand B (6) is slightly better than Ligand A (4). Both are acceptable.
**6. QED:** Ligand B (0.908) is significantly better than Ligand A (0.736), indicating a more drug-like profile.
**7. DILI:** Ligand A (32.299) is better than Ligand B (41.218). Both are below the 40 threshold, indicating low risk.
**8. BBB:** Ligand B (81.039) is much better than Ligand A (26.367). While ADRB2 isn't exclusively a CNS target, some cardiovascular effects are mediated through CNS pathways, and better BBB penetration could be advantageous.
**9. Caco-2 Permeability:** Both ligands have very negative Caco-2 values (-4.797 and -4.863). This is unusual and suggests a potential issue with the experimental setup or a very poor permeability prediction. It's a red flag for both, but doesn't necessarily disqualify either.
**10. Aqueous Solubility:** Ligand A (-1.642) is better than Ligand B (-3.212). Higher solubility is generally preferred.
**11. hERG Inhibition:** Ligand A (0.258) is better than Ligand B (0.479). Lower hERG inhibition is crucial for avoiding cardiotoxicity, a major concern with cardiovascular drugs.
**12. Microsomal Clearance:** Ligand B (21.648) is better than Ligand A (38.885). Lower clearance indicates better metabolic stability.
**13. In vitro Half-Life:** Ligand B (15.897) is better than Ligand A (-12.062). A positive half-life is preferred over a negative one.
**14. P-gp Efflux:** Ligand A (0.025) is significantly better than Ligand B (0.196). Lower P-gp efflux is desirable for improved bioavailability.
**15. Binding Affinity:** Ligand B (-7.8) is significantly better than Ligand A (-6.1). This is a substantial difference (1.7 kcal/mol), and affinity is a primary driver of potency.
**Overall Assessment:**
Ligand B has a significantly better binding affinity, a better QED score, better metabolic stability (lower Cl_mic, higher t1/2), and superior BBB penetration. While Ligand A has advantages in DILI, hERG, solubility, and P-gp efflux, the substantial affinity advantage of Ligand B outweighs these benefits, especially considering the GPCR target class. The negative Caco-2 values are concerning for both, but the stronger binding of Ligand B suggests it might overcome this permeability issue.
Output:
0
2025-04-17 19:06:53,620 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (345.403 and 342.399 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (102.05) is slightly higher than Ligand B (97.12). Both are below the 140 threshold for good oral absorption, but closer to the 90 threshold for CNS targets, which is less relevant for ADRB2 (cardiovascular).
3. **logP:** Ligand B (1.688) is better than Ligand A (0.594). ADRB2 is a GPCR, and a logP between 1-3 is preferred. Ligand A is a bit low, potentially hindering membrane permeability.
4. **HBD:** Both ligands have 2 HBD, which is within the acceptable limit of 5.
5. **HBA:** Ligand A has 6 HBA, and Ligand B has 5. Both are below the acceptable limit of 10.
6. **QED:** Both ligands have similar QED values (0.693 and 0.712), indicating good drug-likeness.
7. **DILI:** Ligand A (47.15) has a lower DILI risk than Ligand B (54.75). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (49.011) has better BBB penetration than Ligand B (32.726). While not a primary concern for a cardiovascular target, it's a slight positive for Ligand A.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.371 and -5.427), which is unusual and suggests poor permeability. This is a significant drawback for both.
10. **Solubility:** Both ligands have similar, very poor aqueous solubility (-2.09 and -1.947). This is a major concern for both compounds.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.025 and 0.048). This is excellent for both.
12. **Cl_mic:** Ligand A (22.764) has significantly lower microsomal clearance than Ligand B (52.538), indicating better metabolic stability.
13. **t1/2:** Ligand A (16.736) has a positive in vitro half-life, while Ligand B (-30.295) has a negative half-life. This is a major advantage for Ligand A.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.033).
15. **Binding Affinity:** Ligand A (-7.0) has a slightly better binding affinity than Ligand B (-6.9). While the difference is small, it's still a positive for Ligand A.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are important. Ligand B has a better logP, but Ligand A has better affinity, DILI, Cl_mic, and t1/2. The poor Caco-2 and solubility are concerning for both, but the superior metabolic stability and lower DILI risk of Ligand A are more critical for overall drug development success.
**Conclusion:**
Despite the similar Caco-2 and solubility issues, Ligand A demonstrates a more favorable overall profile due to its better binding affinity, lower DILI risk, improved metabolic stability, and longer half-life.
Output:
1
2025-04-17 19:06:53,620 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (408.292) is slightly higher than Ligand B (374.897), but both are acceptable.
2. **TPSA:** Both ligands are below the 140 A^2 threshold for good oral absorption. Ligand A (70) and Ligand B (61.92) are both good, with B being slightly better.
3. **logP:** Both ligands have logP values within the optimal range (1-3). Ligand A (2.733) is slightly better than Ligand B (3.545), as higher logP can sometimes lead to off-target effects.
4. **HBD:** Ligand A (2) and Ligand B (0) are both acceptable, with B being slightly better.
5. **HBA:** Both ligands have 5 HBA, which is acceptable.
6. **QED:** Both ligands have good QED scores (A: 0.658, B: 0.776), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (13.843) has a significantly lower DILI risk than Ligand B (47.421). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (80.884) has a much higher BBB penetration percentile than Ligand A (23.536). While ADRB2 isn't necessarily a CNS target, some cardiovascular effects can be mediated through CNS pathways, so a degree of BBB penetration can be beneficial.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-5.353) is slightly better than Ligand B (-4.951).
10. **Solubility:** Both ligands have negative solubility values, which is also unusual and suggests poor solubility. Ligand A (-3.176) is slightly better than Ligand B (-5.376).
11. **hERG:** Both ligands have low hERG inhibition liability (A: 0.835, B: 0.537), which is good.
12. **Cl_mic:** Ligand A (51.684) has a lower microsomal clearance than Ligand B (71.877), indicating better metabolic stability.
13. **t1/2:** Ligand A (32.271) has a significantly longer in vitro half-life than Ligand B (10.896). This is a major advantage for Ligand A.
14. **Pgp:** Both ligands have low Pgp efflux liability (A: 0.539, B: 0.545), which is good.
15. **Binding Affinity:** Ligand B (-6.8 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.7 kcal/mol). This is a substantial advantage for Ligand B.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand B excels in affinity and has good TPSA and Pgp values. Ligand A has a more favorable logP. However, the DILI and metabolic stability (Cl_mic, t1/2) are also crucial. Ligand A is significantly better in these aspects.
**Overall Assessment:**
While Ligand B has a stronger binding affinity, Ligand A presents a much more favorable safety profile (DILI) and pharmacokinetic profile (Cl_mic, t1/2). The difference in binding affinity (1.1 kcal/mol) is substantial, but not insurmountable, and can potentially be optimized in subsequent iterations. The lower DILI risk and improved metabolic stability of Ligand A are critical for a successful drug candidate. The poor Caco-2 and solubility values are concerning for both, but could be addressed through formulation strategies.
Output:
1
2025-04-17 19:06:53,620 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (348.49 and 365.54 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (58.64) is slightly higher than Ligand B (52.65). Both are below the 140 A^2 threshold for oral absorption, which is good.
**3. logP:** Both ligands have excellent logP values (2.51 and 2.30) falling within the optimal 1-3 range.
**4. H-Bond Donors:** Both have 1 HBD, which is within the acceptable limit of 5.
**5. H-Bond Acceptors:** Ligand A has 3 HBAs, and Ligand B has 4. Both are below the 10 limit.
**6. QED:** Ligand A (0.751) has a slightly better QED score than Ligand B (0.683), indicating better overall drug-likeness.
**7. DILI:** Ligand A (24.74) has a significantly lower DILI risk than Ligand B (10.86). This is a major advantage for Ligand A.
**8. BBB:** Ligand A (76.08) has a higher BBB penetration percentile than Ligand B (63.09). While ADRB2 is a cardiovascular target, some CNS exposure can be relevant for off-target effects and safety assessment.
**9. Caco-2 Permeability:** Ligand A (-4.667) has a worse Caco-2 permeability than Ligand B (-5.249). Lower values indicate lower permeability.
**10. Aqueous Solubility:** Ligand A (-3.159) has worse aqueous solubility than Ligand B (-1.059).
**11. hERG Inhibition:** Ligand A (0.216) has a slightly lower hERG inhibition risk than Ligand B (0.701).
**12. Microsomal Clearance:** Ligand B (24.56) has a lower microsomal clearance than Ligand A (53.37), suggesting better metabolic stability.
**13. In vitro Half-Life:** Ligand B (8.77) has a longer in vitro half-life than Ligand A (4.57).
**14. P-gp Efflux:** Ligand A (0.078) has a much lower P-gp efflux liability than Ligand B (0.212), which is beneficial for bioavailability.
**15. Binding Affinity:** Ligand B (-7.1 kcal/mol) has a slightly better binding affinity than Ligand A (-6.4 kcal/mol). This is a 1.5 kcal/mol difference, which is significant.
**GPCR-Specific Considerations:** For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Both ligands perform well on logP and TPSA. Ligand B has a slightly better affinity, but Ligand A has significantly better P-gp efflux and a much better safety profile (DILI, hERG).
**Overall Assessment:**
While Ligand B has a slightly better affinity and metabolic stability, Ligand A is the more promising candidate. The significantly lower DILI risk, better P-gp efflux, and higher BBB penetration outweigh the minor affinity difference. The solubility and permeability are less ideal for Ligand A, but these can be addressed through formulation strategies. The safety profile is paramount, and Ligand A's lower toxicity liabilities make it the preferred choice.
Output:
1
2025-04-17 19:06:53,620 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
The ADRB2 receptor is a GPCR, so the priorities are logP, Pgp, TPSA, BBB, and affinity. Let's break down the comparison:
1. **Molecular Weight:** Both ligands are within the acceptable range (200-500 Da). Ligand A (354.445 Da) is slightly preferred.
2. **TPSA:** Ligand B (19.37) is significantly better than Ligand A (58.95). Lower TPSA generally correlates with better cell permeability, which is crucial for GPCR ligands.
3. **logP:** Both ligands have logP values around 4.2-4.9, which is slightly high. Ligand B (4.913) is a bit higher, potentially increasing off-target effects and decreasing solubility, but not drastically.
4. **H-Bond Donors:** Ligand A has 2 HBD, while Ligand B has 0. Lower HBD is generally preferred for better membrane permeability. Ligand B is better here.
5. **H-Bond Acceptors:** Both ligands have 3 HBA, which is acceptable.
6. **QED:** Ligand A (0.854) has a slightly better QED score than Ligand B (0.703), indicating a more drug-like profile.
7. **DILI:** Both ligands have acceptable DILI risk (Ligand A: 38.581, Ligand B: 33.695). Ligand B is slightly better.
8. **BBB:** Ligand B (98.333) has a much higher BBB penetration percentile than Ligand A (90.772). While ADRB2 isn't exclusively a CNS target, some peripheral effects are mediated by CNS pathways, and higher BBB penetration can be beneficial.
9. **Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.347) is slightly better than Ligand B (-4.784), but both are concerning.
10. **Aqueous Solubility:** Both ligands have negative solubility values, indicating very poor aqueous solubility. This is a significant drawback for both. Ligand A (-4.988) is slightly better than Ligand B (-4.568).
11. **hERG Inhibition:** Both ligands have low hERG inhibition liability (Ligand A: 0.583, Ligand B: 0.963). Ligand B is better.
12. **Microsomal Clearance:** Both ligands have similar microsomal clearance values (Ligand A: 40.334, Ligand B: 39.123).
13. **In vitro Half-Life:** Ligand A (39.834) has a slightly longer in vitro half-life than Ligand B (28.418), which is desirable.
14. **P-gp Efflux:** Both ligands have very low P-gp efflux liability (Ligand A: 0.108, Ligand B: 0.76). Ligand A is better.
15. **Binding Affinity:** Both ligands have the same binding affinity (-7.6 kcal/mol), so this doesn't differentiate them.
**Overall Assessment:**
Ligand B has a significantly lower TPSA and higher BBB penetration, which are crucial for GPCR ligands. It also has a slightly better DILI and hERG profile. However, Ligand A has a better QED, slightly better solubility, longer half-life, and lower P-gp efflux. The poor Caco-2 and solubility for both are major concerns. Given the importance of TPSA and BBB for GPCRs, and the slightly better overall ADME profile (excluding solubility/permeability), I lean towards Ligand B. The solubility issues would need to be addressed through formulation strategies.
**Output:**
0
2025-04-17 19:06:53,620 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
The target is ADRB2, a GPCR. Therefore, I will prioritize logP, Pgp, TPSA, and affinity, alongside general drug-like properties.
**Ligand A:**
* **MW:** 355.454 Da - Good, within the ideal range.
* **TPSA:** 61.88 - Good, below the 140 threshold for oral absorption.
* **logP:** 0.664 - Slightly low, potentially impacting permeability.
* **HBD:** 1 - Acceptable.
* **HBA:** 4 - Acceptable.
* **QED:** 0.761 - Excellent, highly drug-like.
* **DILI:** 10.237 - Very good, low risk of liver injury.
* **BBB:** 81.776 - Excellent, good potential for CNS penetration (though not crucial for ADRB2, it's a bonus).
* **Caco-2:** -4.754 - Poor, suggests poor intestinal absorption.
* **Solubility:** -0.866 - Poor, could pose formulation challenges.
* **hERG:** 0.444 - Very good, low cardiotoxicity risk.
* **Cl_mic:** -6.333 - Excellent, very metabolically stable.
* **t1/2:** 16.196 - Good, reasonable half-life.
* **Pgp:** 0.016 - Excellent, low efflux, good bioavailability.
* **Affinity:** -5.0 kcal/mol - Good binding affinity.
**Ligand B:**
* **MW:** 367.471 Da - Good, within the ideal range.
* **TPSA:** 97.39 - Higher, approaching the upper limit for good absorption.
* **logP:** 0.773 - Slightly low, similar to Ligand A.
* **HBD:** 2 - Acceptable.
* **HBA:** 5 - Acceptable.
* **QED:** 0.596 - Acceptable, but lower than Ligand A.
* **DILI:** 56.146 - Moderate, higher risk than Ligand A.
* **BBB:** 35.052 - Poor, limited CNS penetration.
* **Caco-2:** -4.886 - Poor, similar to Ligand A.
* **Solubility:** -2.834 - Very poor, significant formulation concerns.
* **hERG:** 0.291 - Very good, low cardiotoxicity risk.
* **Cl_mic:** 10.488 - Moderate, less metabolically stable than Ligand A.
* **t1/2:** -28.944 - Very poor, extremely short half-life.
* **Pgp:** 0.049 - Good, low efflux.
* **Affinity:** -4.7 kcal/mol - Good binding affinity, but weaker than Ligand A.
**Comparison and Decision:**
Both ligands have similar logP values and poor Caco-2 permeability and solubility. However, Ligand A significantly outperforms Ligand B in several critical areas: QED, DILI risk, BBB penetration, metabolic stability (Cl_mic), and in vitro half-life. Most importantly, Ligand A has a better binding affinity (-5.0 vs -4.7 kcal/mol). While the affinity difference isn't huge, combined with the superior ADME properties, it tips the balance in favor of Ligand A. The better metabolic stability and half-life of Ligand A are particularly important for a GPCR target, where sustained signaling can be beneficial.
**Output:**
1
2025-04-17 19:06:53,621 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (345.443 & 370.471 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (80.32) is better than Ligand B (92.78). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally favors absorption.
3. **logP:** Ligand A (1.98) is better than Ligand B (0.43). Both are within the acceptable range, but Ligand A is closer to the optimal 1-3 range. Ligand B is quite low and might have permeability issues.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1), but both are well within the acceptable limit of 5.
5. **HBA:** Ligand A (4) is lower than Ligand B (5), which is preferable.
6. **QED:** Ligand A (0.826) is better than Ligand B (0.685), indicating a more drug-like profile.
7. **DILI:** Both ligands have similar, acceptable DILI risk (around 40%).
8. **BBB:** Both ligands have similar BBB penetration (65.568 and 69.135). Since ADRB2 is a cardiovascular target, BBB penetration is not a high priority.
9. **Caco-2:** Ligand A (-5.058) is slightly better than Ligand B (-5.19), indicating potentially better intestinal absorption.
10. **Solubility:** Ligand A (-2.519) is better than Ligand B (-1.875), indicating better aqueous solubility.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.126 and 0.071).
12. **Cl_mic:** Ligand A (21.506) is considerably higher than Ligand B (0.804). This means Ligand B has significantly better metabolic stability.
13. **t1/2:** Ligand A (15.989) is much better than Ligand B (3.594). A longer half-life is generally desirable.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.053 and 0.055).
15. **Binding Affinity:** Ligand A (-7.7 kcal/mol) is significantly better than Ligand B (-6.3 kcal/mol). This 1.4 kcal/mol difference is substantial and can outweigh some ADME drawbacks.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A performs better on logP, TPSA, and *significantly* better on binding affinity. While Ligand B has better metabolic stability (Cl_mic), the substantial affinity advantage of Ligand A is more critical.
**Conclusion:**
Ligand A presents a more favorable overall profile, particularly due to its superior binding affinity and better physicochemical properties (logP, TPSA, solubility, QED). The improved half-life also contributes to its preference.
Output:
1
2025-04-17 19:06:53,621 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.39 and 351.535 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (86.71) is better than Ligand B (44.81). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower TPSA generally correlates with better permeability. Ligand B is significantly lower.
3. **logP:** Both ligands have good logP values (2.209 and 1.97), falling within the optimal 1-3 range. Ligand B is slightly lower, which could slightly improve solubility.
4. **HBD:** Ligand A has 2 HBD, Ligand B has 1. Both are acceptable, well below the 5 limit.
5. **HBA:** Ligand A has 3 HBA, Ligand B has 4. Both are within the acceptable limit of 10.
6. **QED:** Ligand A (0.872) has a higher QED score than Ligand B (0.726), indicating a more drug-like profile. This is a positive for Ligand A.
7. **DILI:** Ligand A (61.807) has a higher DILI risk than Ligand B (3.994). This is a major concern for Ligand A. Ligand B is excellent here.
8. **BBB:** Ligand A (36.836) has a lower BBB penetration than Ligand B (86.894). While ADRB2 isn't a primary CNS target, some off-target CNS effects are possible, and higher BBB penetration is generally undesirable for peripheral targets. Ligand B is much better.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.815 and -4.864). This is unusual and suggests poor permeability.
10. **Solubility:** Ligand A (-2.234) has worse solubility than Ligand B (-1.141). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.063) has a slightly lower hERG inhibition risk than Ligand B (0.714). This is a minor advantage for Ligand A.
12. **Cl_mic:** Ligand A (-7.487) has significantly lower microsomal clearance than Ligand B (15.928), indicating better metabolic stability. This is a strong positive for Ligand A.
13. **t1/2:** Ligand A (-3.032) has a shorter in vitro half-life than Ligand B (2.014). This is a negative for Ligand A.
14. **Pgp:** Ligand A (0.01) has much lower P-gp efflux liability than Ligand B (0.04). This is a positive for Ligand A.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.9 and -6.7 kcal/mol). The difference is not substantial enough to be a deciding factor.
**Overall Assessment:**
Ligand B is the stronger candidate. While Ligand A has better metabolic stability (Cl_mic) and Pgp efflux, the significantly higher DILI risk and lower BBB penetration are major drawbacks. Ligand B excels in safety (DILI) and has better solubility, and a more favorable BBB profile. The slight difference in half-life and Caco-2 permeability are less concerning than the DILI risk associated with Ligand A. Given the GPCR-specific priorities, the safety profile and permeability are more important than the slight metabolic advantage of Ligand A.
Output:
0
2025-04-17 19:06:53,621 - INFO - Batch 86 complete. Total preferences: 1376
2025-04-17 19:06:53,621 - INFO - Processing batch 87/512...
2025-04-17 19:07:44,560 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (344.375 and 346.471 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (120.08) is higher than Ligand B (69.64). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferable for absorption. Ligand B is significantly better.
3. **logP:** Ligand A (0.368) is quite low, potentially hindering membrane permeability. Ligand B (2.003) is within the optimal 1-3 range. This is a substantial advantage for Ligand B.
4. **HBD:** Ligand A (3) and Ligand B (2) are both acceptable, below the threshold of 5.
5. **HBA:** Ligand A (5) and Ligand B (3) are both acceptable, below the threshold of 10.
6. **QED:** Both ligands have similar QED values (0.74 and 0.723), indicating good drug-likeness.
7. **DILI:** Ligand A (70.841) has a higher DILI risk than Ligand B (6.979). This is a significant concern for Ligand A.
8. **BBB:** Ligand A (42.109) and Ligand B (63.629) are both low, which is fine for a cardiovascular target.
9. **Caco-2:** Ligand A (-5.266) and Ligand B (-4.895) are both negative, indicating poor permeability.
10. **Solubility:** Ligand A (-3.559) and Ligand B (-2.366) are both poor, but Ligand B is slightly better.
11. **hERG:** Ligand A (0.129) and Ligand B (0.278) are both low, indicating low cardiotoxicity risk.
12. **Cl_mic:** Ligand A (-4.863) has a significantly *lower* (better) microsomal clearance than Ligand B (22.334), suggesting greater metabolic stability.
13. **t1/2:** Ligand A (2.066) has a shorter half-life than Ligand B (8.794). This is a disadvantage for Ligand A.
14. **Pgp:** Ligand A (0.015) has a much lower P-gp efflux liability than Ligand B (0.056), which is favorable.
15. **Binding Affinity:** Ligand B (-6.8) has slightly better binding affinity than Ligand A (-6.4), but the difference is relatively small (0.4 kcal/mol).
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand B is the stronger candidate. While Ligand A has better metabolic stability (lower Cl_mic) and lower Pgp efflux, the significantly lower logP and higher DILI risk of Ligand A are major drawbacks. Ligand B's better logP, lower DILI, and slightly better affinity outweigh the slightly shorter half-life and higher Pgp efflux. The TPSA difference is also a significant advantage for Ligand B.
Output:
0
2025-04-17 19:07:44,561 - INFO - Reasoning:
Let's analyze Ligand A and Ligand B for their potential as ADRB2 ligands, keeping in mind GPCR priorities (logP, Pgp, TPSA, affinity).
**Molecular Weight:** Both ligands (364.408 and 365.312 Da) are within the ideal 200-500 Da range.
**TPSA:** Ligand A (69.64) is significantly better than Ligand B (139.34). A TPSA under 140 is good for oral absorption, but lower is preferred for GPCRs, and A is much closer to the ideal.
**logP:** Ligand A (1.884) is within the optimal 1-3 range. Ligand B (-1.119) is below 1, which could hinder permeation.
**H-Bond Donors/Acceptors:** Ligand A (2 HBD, 3 HBA) is preferable to Ligand B (4 HBD, 6 HBA). Lower counts generally improve permeability.
**QED:** Ligand A (0.756) has a better QED score than Ligand B (0.485), indicating a more drug-like profile.
**DILI:** Ligand B (42.691) has a lower DILI risk than Ligand A (14.618), which is a positive.
**BBB:** Ligand A (62.233) has a better BBB penetration score than Ligand B (37.96). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be beneficial or at least not detrimental.
**Caco-2 Permeability:** Ligand A (-4.872) is better than Ligand B (-5.834). Higher values indicate better absorption.
**Aqueous Solubility:** Ligand A (-1.887) is better than Ligand B (-1.356).
**hERG:** Both ligands have very low hERG inhibition liability (0.45 and 0.058), which is excellent.
**Microsomal Clearance:** Ligand B (1.481) has significantly lower microsomal clearance than Ligand A (4.398), suggesting better metabolic stability.
**In vitro Half-Life:** Ligand B (-8.867) has a much longer in vitro half-life than Ligand A (-3.347), which is a significant advantage.
**P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.069 and 0.01).
**Binding Affinity:** Both ligands have very similar binding affinities (-5.9 and -5.3 kcal/mol). The difference is less than 0.6 kcal/mol, so it's not a deciding factor.
**Overall:** Ligand A excels in TPSA, logP, QED, Caco-2 permeability, solubility, and BBB. Ligand B has a better DILI score, lower Cl_mic, and longer half-life. Given the GPCR focus, the superior TPSA and logP of Ligand A are critical. The slightly better metabolic stability and half-life of Ligand B are valuable but can potentially be addressed through further optimization. The affinity difference is negligible.
Output:
1
2025-04-17 19:07:44,561 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.419 and 345.399 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand B (71.97) is significantly better than Ligand A (104.97). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally improves absorption.
3. **logP:** Ligand B (0.942) is closer to the optimal 1-3 range than Ligand A (-0.467), which is slightly below 1. This favors Ligand B for permeability.
4. **HBD:** Ligand A (2) is preferable to Ligand B (0). While both are acceptable, a small number of HBDs can aid solubility.
5. **HBA:** Ligand B (5) is better than Ligand A (4). Both are within the acceptable range.
6. **QED:** Ligand B (0.815) is slightly better than Ligand A (0.654), indicating a more drug-like profile.
7. **DILI:** Ligand A (25.087) is *much* better than Ligand B (65.064). This is a critical advantage for Ligand A.
8. **BBB:** Ligand B (73.129) is better than Ligand A (55.176), but BBB is not a high priority for a cardiovascular target.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand B (-4.32) is slightly better than Ligand A (-4.997).
10. **Solubility:** Both ligands have very poor solubility (-1.111 and -1.997). This is a significant concern for both.
11. **hERG:** Ligand A (0.09) is better than Ligand B (0.268), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand A (-33.537) has a much lower (better) clearance than Ligand B (54.536), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-32.588) has a slightly better half-life than Ligand A (-15.955).
14. **Pgp:** Ligand A (0.003) is significantly better than Ligand B (0.068), indicating lower efflux.
15. **Affinity:** Ligand A (-6.2) has a better binding affinity than Ligand B (-3.6). This is a substantial advantage.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B has a better logP and TPSA, but Ligand A has significantly better affinity and Pgp.
**Overall Assessment:**
Despite Ligand B's slightly better QED and half-life, Ligand A is the stronger candidate. The dramatically lower DILI risk, superior binding affinity, better Pgp profile, and improved metabolic stability (lower Cl_mic) outweigh the slightly less favorable TPSA and logP. The solubility is a concern for both, but can be addressed with formulation strategies. The affinity difference is substantial enough to overcome the other minor drawbacks.
Output:
1
2025-04-17 19:07:44,561 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (357.445 and 335.407 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Both ligands (61.44 and 63.13) are below the 140 A^2 threshold for good oral absorption, and acceptable for a cardiovascular target (not requiring significant BBB penetration). Similar.
3. **logP:** Both ligands have good logP values (2.085 and 1.818), falling within the optimal 1-3 range. Again, very similar.
4. **HBD:** Both have 2 HBD, which is within the acceptable limit of <=5.
5. **HBA:** Both have 3 HBA, which is within the acceptable limit of <=10.
6. **QED:** Ligand B (0.837) has a slightly better QED score than Ligand A (0.621), indicating a more drug-like profile.
7. **DILI:** Ligand A (13.61) has a significantly lower DILI risk than Ligand B (63.823). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (84.684) has better BBB penetration than Ligand B (66.576). While ADRB2 is a cardiovascular target, some CNS effects are possible with beta-blockers, and higher BBB penetration could be a concern. However, it's not a primary driver for this target.
9. **Caco-2:** Both have negative Caco-2 values (-4.948 and -4.824). These values are unusual and suggest poor permeability.
10. **Solubility:** Ligand A (-2.226) has slightly better solubility than Ligand B (-3.475).
11. **hERG:** Ligand A (0.576) has a lower hERG risk than Ligand B (0.247), which is a significant advantage.
12. **Cl_mic:** Ligand A (3.09) has a much lower microsomal clearance than Ligand B (17.058), indicating better metabolic stability. This is a crucial factor.
13. **t1/2:** Ligand A (-12.29) has a much longer in vitro half-life than Ligand B (25.253). This is a significant advantage.
14. **Pgp:** Ligand A (0.019) has a much lower Pgp efflux liability than Ligand B (0.171), which is a positive.
15. **Binding Affinity:** Ligand B (-6.6 kcal/mol) has a slightly better binding affinity than Ligand A (-5.2 kcal/mol). This is a 1.4 kcal/mol difference, which is substantial, but needs to be weighed against the ADME properties.
**Overall Assessment:**
Ligand B has a slightly better binding affinity and QED, but Ligand A shines in ADME properties. Specifically, the significantly lower DILI risk, much better metabolic stability (lower Cl_mic and longer t1/2), and lower Pgp efflux make Ligand A a far more promising drug candidate. The hERG risk is also lower for Ligand A. While the Caco-2 values are concerning for both, the superior ADME profile of Ligand A outweighs the slightly better affinity of Ligand B. For a cardiovascular target, metabolic stability and safety (DILI, hERG) are paramount.
**Output:**
1
2025-04-17 19:07:44,562 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [369.487, 86.79, -0.128, 1, 4, 0.751, 16.402, 58.55, -4.96, -2.234, 0.076, 10.004, -5.058, 0.009, -5.7]
**Ligand B:** [366.487, 84.42, 2.166, 1, 7, 0.777, 47.344, 71.927, -4.732, -3.044, 0.329, 87.031, -2.314, 0.102, -7.6]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (369.487) is slightly higher than Ligand B (366.487), but the difference is negligible.
2. **TPSA:** Both are good, under 140 A2. Ligand A (86.79) is slightly higher than Ligand B (84.42), but still acceptable for a GPCR.
3. **logP:** Ligand A (-0.128) is quite low, potentially hindering membrane permeability. Ligand B (2.166) is within the optimal range (1-3). This is a significant advantage for Ligand B.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A (4) is preferable to Ligand B (7). Higher HBA can sometimes reduce permeability.
6. **QED:** Both are good (>0.5), indicating drug-like properties. Ligand B (0.777) is slightly better.
7. **DILI:** Ligand A (16.402) has a much lower DILI risk than Ligand B (47.344). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (71.927) has a better BBB penetration potential than Ligand A (58.55). While ADRB2 isn't necessarily a CNS target, some peripheral distribution is still desired and BBB can correlate with overall permeability.
9. **Caco-2:** Both have negative values, which is unusual. Assuming these are log scale values, both are quite poor.
10. **Solubility:** Both have negative values, indicating poor solubility. Ligand A (-2.234) is slightly better than Ligand B (-3.044).
11. **hERG:** Ligand A (0.076) has a lower hERG risk than Ligand B (0.329). This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand A (10.004) has a lower microsomal clearance, suggesting better metabolic stability, than Ligand B (87.031). This is a major advantage for Ligand A.
13. **t1/2:** Ligand A (-5.058) has a longer in vitro half-life than Ligand B (-2.314). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.009) has lower P-gp efflux liability than Ligand B (0.102). This is a slight advantage for Ligand A.
15. **Affinity:** Ligand B (-7.6) has a significantly stronger binding affinity than Ligand A (-5.7). This is a substantial advantage for Ligand B (a 1.9 kcal/mol difference).
**GPCR-specific priorities:** For ADRB2 (a GPCR), we prioritize logP, Pgp, TPSA, and affinity. Ligand B excels in affinity and has a better logP. Ligand A has better TPSA and Pgp.
**Overall Assessment:**
While Ligand B has a much better binding affinity, the significant drawbacks in DILI risk, metabolic stability (high Cl_mic), and hERG risk are concerning. Ligand A, despite its weaker affinity, presents a much more favorable ADME-Tox profile. The lower logP of Ligand A is a concern, but the other advantages, particularly the lower DILI, hERG, and Cl_mic, outweigh this. Given the importance of safety and metabolic stability in drug development, I would prioritize Ligand A for further optimization.
Output:
1
2025-04-17 19:07:44,562 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for the ADRB2, a cardiovascular GPCR. Therefore, the key priorities are logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB.
Let's compare the ligands property by property:
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (346.471) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (78.43) is significantly better than Ligand B (95.42). Lower TPSA generally correlates with better oral absorption, a crucial factor for a cardiovascular drug.
3. **logP:** Ligand A (2.183) is optimal, while Ligand B (0.822) is a bit low, potentially hindering membrane permeability.
4. **HBD/HBA:** Ligand A has 3 HBD and 3 HBA, while Ligand B has 2 HBD and 6 HBA. Both are acceptable, but Ligand A's balance is slightly better.
5. **QED:** Both ligands have good QED scores (A: 0.675, B: 0.833), indicating good drug-like properties.
6. **DILI:** Ligand B (74.098) has a significantly higher DILI risk than Ligand A (15.394). This is a major concern.
7. **BBB:** Ligand A (57.464) has a better BBB score than Ligand B (43.854), but neither are particularly high. For a cardiovascular target, BBB isn't a primary concern, but it's still a slight advantage for A.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
9. **Solubility:** Both have negative solubility values, which is also unusual and suggests poor solubility.
10. **hERG:** Both ligands have very low hERG inhibition risk (A: 0.278, B: 0.285).
11. **Cl_mic:** Ligand B (-15.681) has a *much* lower (better) microsomal clearance than Ligand A (32.173), indicating greater metabolic stability. This is a significant advantage for Ligand B.
12. **t1/2:** Ligand B (14.148) has a significantly longer in vitro half-life than Ligand A (-0.909), which is highly desirable.
13. **Pgp:** Both have low Pgp efflux liability (A: 0.058, B: 0.169).
14. **Binding Affinity:** Both have very similar, excellent binding affinities (A: -7.2, B: -7.1). The difference is negligible.
**Overall Assessment:**
Ligand A has advantages in TPSA, logP, and DILI risk. However, Ligand B has a substantial advantage in metabolic stability (Cl_mic) and half-life. Given the importance of metabolic stability for *in vivo* efficacy, and the concerningly high DILI risk for Ligand A, I favor Ligand B. While the lower logP of Ligand B is a minor drawback, the improved metabolic profile and reduced toxicity risk outweigh this concern.
**Output:**
0
2025-04-17 19:07:44,562 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Ligand A (405.227 Da) is within the ideal range, while Ligand B (342.439 Da) is also good, leaning towards the lower end. Both are acceptable.
2. **TPSA:** Ligand A (70.47) is slightly higher than ideal for optimal oral absorption (<=140), but still reasonable. Ligand B (58.64) is excellent.
3. **logP:** Both ligands have good logP values (A: 2.902, B: 2.691), falling within the 1-3 range.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 4 HBA, while Ligand B has 3. Both are acceptable.
6. **QED:** Both ligands have high QED scores (A: 0.713, B: 0.856), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (89.027) has a significantly higher DILI risk than Ligand B (40.83). This is a major concern for Ligand A.
8. **BBB:** Ligand A (77.239) has better BBB penetration than Ligand B (64.948). While ADRB2 isn't strictly a CNS target, some CNS exposure can be relevant for off-target effects or peripheral ADRB2 receptors.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not defined, so it's hard to interpret.
10. **Solubility:** Both have negative solubility values, which is also unusual and suggests poor solubility. Again, the scale is not defined.
11. **hERG:** Ligand A (0.714) has a slightly higher hERG risk than Ligand B (0.443), but both are relatively low.
12. **Cl_mic:** Ligand A (26.136) has a much lower microsomal clearance than Ligand B (52.7), indicating better metabolic stability.
13. **t1/2:** Ligand A (2.045) has a shorter half-life than Ligand B (-18.841). The negative value for Ligand B is concerning and likely an error.
14. **Pgp:** Ligand A (0.482) has lower P-gp efflux than Ligand B (0.274), which is favorable.
15. **Binding Affinity:** Both ligands have very similar and strong binding affinities (A: -8.0 kcal/mol, B: -6.9 kcal/mol). Ligand A has a 1.1 kcal/mol advantage, which is significant.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Both ligands perform well on logP and Pgp. Ligand A has a better affinity and lower Pgp efflux. However, the significantly higher DILI risk for Ligand A is a major red flag.
**Overall Assessment:**
Despite the slightly better affinity and metabolic stability of Ligand A, the substantially higher DILI risk makes it a less attractive candidate. The DILI risk outweighs the benefits. Ligand B, while having a slightly lower affinity, presents a much safer profile with a significantly lower DILI risk.
Output:
0
2025-04-17 19:07:44,562 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (376.791 and 350.419 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (95.42) is better than Ligand B (116.49). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (1.028 and 0.892), falling within the optimal 1-3 range. Ligand A is slightly better.
4. **HBD:** Ligand A (2) is preferable to Ligand B (4). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (6). Fewer HBAs generally improve permeability.
6. **QED:** Ligand A (0.723) is better than Ligand B (0.605), indicating a more drug-like profile.
7. **DILI:** Ligand A (40.054) is significantly better than Ligand B (57.038). Lower DILI risk is crucial.
8. **BBB:** This is less critical for a cardiovascular target. Ligand A (65.801) is better than Ligand B (38.891), but this isn't a major deciding factor.
9. **Caco-2:** Ligand A (-4.893) is better than Ligand B (-5.178). Higher Caco-2 permeability is desired.
10. **Solubility:** Ligand A (-2.664) is better than Ligand B (-2.091). Higher solubility is generally preferred.
11. **hERG:** Both ligands have low hERG inhibition risk (0.217 and 0.305). No significant difference.
12. **Cl_mic:** Ligand A (1.47) is significantly better than Ligand B (7.65). Lower microsomal clearance indicates better metabolic stability.
13. **t1/2:** Ligand A (-12.733) is significantly better than Ligand B (3.08). A longer half-life is generally desirable.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.012 and 0.018). No significant difference.
15. **Binding Affinity:** Ligand A (-7.3) is better than Ligand B (-5.9). The 1.4 kcal/mol difference in binding affinity is substantial and can outweigh some ADME drawbacks.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A performs better on all of these. Additionally, the significantly better DILI, Cl_mic, and t1/2 profiles of Ligand A make it a much safer and more viable candidate.
**Conclusion:**
Ligand A is superior to Ligand B across most critical parameters, including binding affinity, DILI risk, metabolic stability, and drug-likeness.
Output:
1
2025-04-17 19:07:44,562 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (364.402 and 356.451 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (88.37) is slightly higher than Ligand B (66.4). Both are below the 140 threshold for good oral absorption, but Ligand B is preferable due to its lower TPSA.
3. **logP:** Both ligands (2.723 and 2.218) are within the optimal 1-3 range. Ligand B is slightly lower, which could slightly improve solubility, but both are acceptable.
4. **HBD:** Ligand A has 1 HBD, while Ligand B has 0. Both are within the acceptable limit of <=5.
5. **HBA:** Both ligands have 6 HBAs, which is within the acceptable limit of <=10.
6. **QED:** Ligand B (0.783) has a slightly better QED score than Ligand A (0.651), indicating a more drug-like profile.
7. **DILI:** Both ligands have similar DILI risk (70.686 and 72.043 percentile). Both are acceptable, but not ideal.
8. **BBB:** Ligand B (76.154) has a slightly higher BBB penetration percentile than Ligand A (71.811). As ADRB2 is a GPCR, BBB penetration is a consideration, making Ligand B slightly more favorable.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.965 and -4.82). This is unusual and suggests poor permeability. However, the values are very close, so it doesn't significantly differentiate them.
10. **Solubility:** Ligand B (-2.203) has a better solubility score than Ligand A (-4.303). This is a positive for Ligand B.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.591 and 0.441). This is excellent for both.
12. **Cl_mic:** Ligand B (31.517) has a lower microsomal clearance than Ligand A (41.398), indicating better metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand A (26.007) has a longer in vitro half-life than Ligand B (-3.326). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.339) has lower P-gp efflux liability than Ligand B (0.505), which is favorable.
15. **Binding Affinity:** Ligand B (-9.2 kcal/mol) has a significantly stronger binding affinity than Ligand A (-7.1 kcal/mol). This is a substantial advantage, likely outweighing some of the minor ADME drawbacks of Ligand B.
**Overall Assessment:**
Ligand B demonstrates a superior profile overall. While Ligand A has a better half-life and Pgp profile, Ligand B's significantly stronger binding affinity (-9.2 vs -7.1 kcal/mol), better QED, lower TPSA, better solubility, and lower Cl_mic are more critical for a GPCR target like ADRB2. The slightly better BBB penetration also contributes to its favorability. The negative Caco-2 values are concerning for both, but the substantial affinity difference makes Ligand B the better candidate.
Output:
0
2025-04-17 19:07:44,562 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [348.355, 114.84 , 2.451, 2. , 6. , 0.612, 68.437, 36.526, -4.517, -3.84 , 0.534, 42.232, 25.642, 0.427, -6.9 ]
**Ligand B:** [353.507, 72.88 , 1.256, 2. , 4. , 0.644, 5.235, 33.036, -4.887, -0.367, 0.189, 12.261, 3.284, 0.015, -5.1 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (348.355) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (114.84) is higher than Ligand B (72.88). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is still preferred. Ligand B is significantly better here.
3. **logP:** Ligand A (2.451) is within the optimal range, while Ligand B (1.256) is slightly below. Ligand A is better.
4. **HBD:** Both have 2 HBD, which is good.
5. **HBA:** Ligand A has 6 HBA, Ligand B has 4. Both are acceptable.
6. **QED:** Both have similar QED values (0.612 and 0.644), indicating good drug-likeness.
7. **DILI:** Ligand A (68.437) has a significantly higher DILI risk than Ligand B (5.235). This is a major concern for Ligand A.
8. **BBB:** Both have relatively low BBB penetration, which is acceptable for a cardiovascular target. Ligand B (33.036) is slightly better.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. Ligand A (-4.517) is slightly worse than Ligand B (-4.887).
10. **Solubility:** Ligand A (-3.84) has worse solubility than Ligand B (-0.367).
11. **hERG:** Ligand A (0.534) has a higher hERG risk than Ligand B (0.189).
12. **Cl_mic:** Ligand A (42.232) has higher microsomal clearance than Ligand B (12.261), indicating lower metabolic stability.
13. **t1/2:** Ligand A (25.642) has a longer half-life than Ligand B (3.284).
14. **Pgp:** Ligand A (0.427) has lower P-gp efflux than Ligand B (0.015), which is favorable.
15. **Affinity:** Ligand A (-6.9 kcal/mol) has a better binding affinity than Ligand B (-5.1 kcal/mol). This is a substantial difference.
**GPCR-Specific Considerations:**
For ADRB2 (a cardiovascular GPCR), affinity, logP, TPSA, Pgp, and metabolic stability are key. Ligand A has a significantly better affinity, and a better logP and Pgp profile. However, its DILI risk, hERG risk, and clearance are concerning. Ligand B has a much better safety profile (DILI, hERG) and metabolic stability, but weaker affinity and a lower logP.
**Decision:**
The affinity difference (-6.9 vs -5.1 kcal/mol) is substantial. While Ligand A has concerning ADME/Tox properties, the improved binding could potentially be optimized through further medicinal chemistry efforts. The DILI and hERG risks are significant, but might be mitigated with structural modifications. Ligand B, while safer, may not have sufficient potency to be a viable candidate.
Therefore, I will choose Ligand A.
Output:
1
2025-04-17 19:07:44,563 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [361.427, 98.14, 1.051, 2, 8, 0.79, 81.427, 69.833, -4.932, -2.7, 0.475, 28.825, 37.351, 0.216, -6.1]
**Ligand B:** [344.415, 107.69, -0.45, 4, 5, 0.427, 51.221, 14.541, -5.135, -1.926, 0.278, -30.359, -14.526, 0.008, -7.3]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, Affinity, and BBB):
1. **MW:** Both are within the acceptable 200-500 Da range. Ligand B (344.415) is slightly lower, which is generally favorable.
2. **TPSA:** Ligand A (98.14) is better than Ligand B (107.69), both are acceptable for a peripheral GPCR like ADRB2 but lower is generally preferred.
3. **logP:** Ligand A (1.051) is within the optimal 1-3 range. Ligand B (-0.45) is below 1, which is a concern for permeability.
4. **HBD/HBA:** Ligand A (2 HBD, 8 HBA) is better balanced than Ligand B (4 HBD, 5 HBA).
5. **QED:** Ligand A (0.79) is significantly better than Ligand B (0.427), indicating a more drug-like profile.
6. **DILI:** Ligand A (81.427) has a higher DILI risk than Ligand B (51.221), which is a negative.
7. **BBB:** Ligand A (69.833) has a better BBB penetration potential than Ligand B (14.541), but BBB is less critical for ADRB2.
8. **Caco-2:** Ligand A (-4.932) is better than Ligand B (-5.135), indicating better intestinal absorption.
9. **Solubility:** Ligand A (-2.7) is better than Ligand B (-1.926).
10. **hERG:** Ligand A (0.475) is better than Ligand B (0.278), indicating lower cardiotoxicity risk.
11. **Cl_mic:** Ligand A (28.825) has a better metabolic stability than Ligand B (-30.359).
12. **t1/2:** Ligand A (37.351) has a better in vitro half-life than Ligand B (-14.526).
13. **Pgp:** Ligand A (0.216) has a lower P-gp efflux liability than Ligand B (0.008), which is favorable.
14. **Affinity:** Ligand B (-7.3) has a slightly better binding affinity than Ligand A (-6.1), but the difference is not substantial enough to outweigh other factors.
**Overall Assessment:**
Ligand A is generally superior. While Ligand B has slightly better affinity, Ligand A demonstrates a significantly better overall profile with respect to drug-likeness (QED), solubility, metabolic stability (Cl_mic, t1/2), permeability (Caco-2), and P-gp efflux. The lower logP of Ligand B is a significant concern for oral bioavailability. The higher DILI risk of Ligand A is a drawback, but can potentially be addressed with further optimization.
Therefore, I would choose Ligand A.
Output:
1
2025-04-17 19:07:44,563 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.415 and 355.463 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (97.37) is higher than Ligand B (71.09). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is generally preferred for absorption. Ligand B is better.
3. **logP:** Both ligands (2.949 and 3.087) are within the optimal 1-3 range. No significant difference.
4. **HBD:** Both ligands have 2 HBD, which is within the acceptable limit of <=5. No significant difference.
5. **HBA:** Ligand A has 5 HBA, and Ligand B has 4. Both are within the acceptable limit of <=10. No significant difference.
6. **QED:** Ligand B (0.885) has a higher QED score than Ligand A (0.765), indicating a more drug-like profile. Ligand B is better.
7. **DILI:** Ligand A (53.354) has a lower DILI risk than Ligand B (63.862), which is preferable. Ligand A is better.
8. **BBB:** Ligand B (70.958) has a higher BBB penetration percentile than Ligand A (54.634). While ADRB2 isn't a primary CNS target, some brain exposure can occur, and higher BBB is generally favorable. Ligand B is better.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. Ligand B (-5.026) is slightly better than Ligand A (-4.938), but both are concerning.
10. **Solubility:** Both ligands have negative solubility values, indicating poor solubility. Ligand B (-3.603) is slightly better than Ligand A (-3.177), but both are concerning.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.314 and 0.339), which is excellent. No significant difference.
12. **Cl_mic:** Ligand B (28.353) has a significantly lower microsomal clearance than Ligand A (69.339), suggesting better metabolic stability. Ligand B is significantly better.
13. **t1/2:** Ligand B (36.716 hours) has a longer in vitro half-life than Ligand A (17.224 hours), which is desirable. Ligand B is better.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.105 and 0.142). No significant difference.
15. **Binding Affinity:** Ligand B (-7.4 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.1 kcal/mol). This is a substantial advantage, potentially outweighing some ADME drawbacks. Ligand B is significantly better.
**Overall Assessment:**
Ligand B demonstrates a clear advantage in several key areas: QED, metabolic stability (Cl_mic), half-life, BBB penetration, and, most importantly, binding affinity. While Ligand A has a slightly lower DILI risk, the superior binding affinity and ADME properties of Ligand B make it the more promising candidate. The poor Caco-2 and solubility values are concerning for both, but can be addressed with formulation strategies. The stronger binding of Ligand B is a significant driver for selection.
Output:
0
2025-04-17 19:07:44,563 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [358.479, 99.1, 0.821, 3, 5, 0.567, 8.841, 42.962, -4.954, -0.914, 0.158, 16.571, -7.856, 0.024, -6.3]
**Ligand B:** [372.531, 78.87, 1.269, 2, 5, 0.637, 18.224, 60.838, -4.96, -2.116, 0.238, 29.941, -2.351, 0.04, -6.5]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (358.479) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (99.1) is higher than Ligand B (78.87). Both are acceptable for a non-CNS GPCR target like ADRB2, but B is better.
3. **logP:** Ligand A (0.821) is a bit low, potentially hindering membrane permeability. Ligand B (1.269) is better, falling within the optimal 1-3 range.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (2), but both are within the acceptable limit of 5.
5. **HBA:** Both ligands have 5 HBA, which is good.
6. **QED:** Both have good QED scores (A: 0.567, B: 0.637), indicating drug-like properties. B is slightly better.
7. **DILI:** Ligand A (8.841) has a significantly lower DILI risk than Ligand B (18.224). This is a major advantage for A.
8. **BBB:** ADRB2 is primarily a cardiovascular target, so BBB penetration is not a high priority. Ligand B (60.838) has higher BBB penetration than Ligand A (42.962), but this is less important here.
9. **Caco-2:** Both have negative Caco-2 values (-4.954 and -4.96), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-0.914) has slightly better solubility than Ligand B (-2.116).
11. **hERG:** Both have low hERG inhibition risk (A: 0.158, B: 0.238).
12. **Cl_mic:** Ligand A (16.571) has a lower microsomal clearance than Ligand B (29.941), indicating better metabolic stability. This is a significant advantage for A.
13. **t1/2:** Ligand A (-7.856) has a longer in vitro half-life than Ligand B (-2.351). This is a clear advantage for A.
14. **Pgp:** Both have very low Pgp efflux liability (A: 0.024, B: 0.04).
15. **Affinity:** Ligand B (-6.5 kcal/mol) has a slightly better binding affinity than Ligand A (-6.3 kcal/mol). While a difference of 0.2 kcal/mol isn't huge, it's a factor.
**Overall Assessment:**
Ligand A has several advantages: lower DILI risk, better metabolic stability (lower Cl_mic), longer half-life, and slightly better solubility. Ligand B has a slightly better logP and binding affinity, but the differences are not substantial enough to outweigh the ADME benefits of Ligand A. The negative Caco-2 values for both are concerning and would require further investigation, but the overall profile of Ligand A is more promising for development as a drug candidate targeting ADRB2.
Output:
1
2025-04-17 19:07:44,563 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's systematically compare Ligand A and Ligand B against the provided guidelines, keeping in mind the GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key).
1. **MW:** Both ligands (369.45 & 343.34 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Both are above the optimal <140, but Ligand A (104.61) is slightly better than Ligand B (109.75). This is a minor advantage for A, as it suggests slightly better permeability.
3. **logP:** Ligand A (-0.827) is a bit low, potentially hindering membrane permeability. Ligand B (2.515) is much closer to the optimal 1-3 range. This is a significant advantage for Ligand B.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 7 HBA, and Ligand B has 6. Both are acceptable.
6. **QED:** Both are similar (0.702 and 0.66), indicating good drug-likeness.
7. **DILI:** Ligand A (56.844) and Ligand B (52.191) are both reasonably low risk, below the 60% threshold. Ligand B is slightly better.
8. **BBB:** Both have decent BBB penetration (64.99% and 69.68%). Since ADRB2 isn't necessarily a CNS target, this isn't a major deciding factor, but B is slightly better.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Both have negative solubility values, which is concerning. Again, the scale is not specified.
11. **hERG:** Ligand A (0.083) has a very low hERG risk, which is excellent. Ligand B (0.837) is higher, representing a potential cardiotoxicity concern. This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand A (-22.47) has a negative clearance, which is not physically possible. This is a red flag. Ligand B (22.768) is a reasonable value.
13. **t1/2:** Ligand A (22.12) has a better in vitro half-life than Ligand B (-16.242). However, the negative value for B is concerning.
14. **Pgp:** Ligand A (0.009) has very low P-gp efflux, which is desirable. Ligand B (0.455) is higher, suggesting more efflux. This is an advantage for Ligand A.
15. **Affinity:** Both have very similar binding affinities (-6.7 and -6.3 kcal/mol). The difference is not substantial enough to be a primary deciding factor.
**Overall Assessment:**
Ligand A has a superior hERG profile and Pgp efflux. However, it has a problematic negative microsomal clearance and a low logP. Ligand B has a better logP and a more reasonable Cl_mic, but a higher hERG risk. Given the importance of minimizing cardiotoxicity for a cardiovascular target like ADRB2, and the significant issues with Ligand A's Cl_mic, I favor Ligand B despite its slightly higher hERG risk. The logP of Ligand B is much more favorable for permeability.
Output:
0
2025-04-17 19:07:44,563 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
The ADRB2 receptor is a GPCR, so the priorities are logP, Pgp, TPSA, BBB, and affinity. Let's compare the ligands across all parameters:
1. **MW:** Both ligands (342.443 and 352.519 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (80.2) is slightly higher than Ligand B (58.64). Ligand B is preferable here, as lower TPSA generally correlates with better cell permeability.
3. **logP:** Both ligands have good logP values (2.184 and 2.983), falling within the optimal 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability, but isn't a huge difference.
4. **HBD/HBA:** Both ligands have 1 HBD and 3 HBA, which are acceptable values. No significant difference.
5. **QED:** Ligand A (0.894) has a slightly better QED score than Ligand B (0.799), suggesting a more drug-like profile.
6. **DILI:** Ligand B (16.092) has a significantly lower DILI risk than Ligand A (31.214). This is a major advantage for Ligand B.
7. **BBB:** Ligand B (79.139) has a substantially higher BBB penetration percentile than Ligand A (60.644). This is a strong positive for Ligand B, as it suggests better potential for reaching the target receptor if it's expressed in the CNS or if CNS side effects are a concern.
8. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual. Assuming these are logP-like scales where lower is worse, they are similar.
9. **Solubility:** Both ligands have negative solubility values, which is also unusual. Again, assuming a logS-like scale, they are similar.
10. **hERG:** Both ligands have low hERG inhibition liability (0.645 and 0.415), which is good. Ligand B is slightly better.
11. **Cl_mic:** Ligand A (7.373) has a lower microsomal clearance than Ligand B (67.809), indicating better metabolic stability. This is a significant advantage for Ligand A.
12. **t1/2:** Ligand B (-22.572) has a much longer in vitro half-life than Ligand A (-6.729). This is a major benefit for Ligand B, potentially allowing for less frequent dosing.
13. **Pgp:** Ligand A (0.066) has lower P-gp efflux liability than Ligand B (0.157), which is favorable.
14. **Affinity:** Ligand A (-7.3 kcal/mol) has a stronger binding affinity than Ligand B (-5.5 kcal/mol). This is a substantial advantage for Ligand A, potentially outweighing some of the ADME drawbacks.
**Overall Assessment:**
Ligand A has a significantly better binding affinity and lower Pgp efflux, while Ligand B excels in DILI risk, BBB penetration, and in vitro half-life. The stronger affinity of Ligand A is a substantial advantage for a GPCR target, and the lower Pgp efflux is also beneficial. While Ligand B has a better safety profile (DILI) and potentially better CNS exposure (BBB), the potency advantage of Ligand A is likely to be more critical for efficacy. The metabolic stability of Ligand A is also a consideration, but the longer half-life of Ligand B partially mitigates this.
Considering the balance of these factors, and prioritizing affinity for a GPCR target, I believe Ligand A is the more promising candidate.
**Output:**
1
2025-04-17 19:07:44,564 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.459 and 368.905 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (42.43) is better than Ligand B (50.8). Both are below 140, but lower is preferred for absorption.
3. **logP:** Both ligands (4.399 and 4.796) are slightly above the optimal 1-3 range, potentially leading to solubility issues, but are not drastically high. Ligand B is a bit higher.
4. **HBD:** Ligand A (0) is better than Ligand B (1). Fewer HBDs generally improve permeability.
5. **HBA:** Both ligands have 4 HBA, which is acceptable.
6. **QED:** Both ligands have good QED scores (0.683 and 0.829), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (80.69) has a higher DILI risk than Ligand B (46.297). This is a significant concern for Ligand A.
8. **BBB:** Ligand B (72.664) has a better BBB penetration score than Ligand A (57.891). While ADRB2 isn't exclusively a CNS target, some CNS exposure could be relevant depending on the specific indication, and lower efflux is generally desirable.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.834 and -4.441). These values are difficult to interpret without knowing the scale, but negative values generally indicate poor permeability.
10. **Solubility:** Ligand A (-4.713) has slightly better solubility than Ligand B (-5.345), but both are poor.
11. **hERG:** Both ligands have low hERG inhibition risk (0.623 and 0.705).
12. **Cl_mic:** Ligand B (57.027) has lower microsomal clearance than Ligand A (83.753), indicating better metabolic stability.
13. **t1/2:** Ligand B (15.369) has a significantly longer in vitro half-life than Ligand A (-10.07). This is a major advantage for Ligand B.
14. **Pgp:** Ligand A (0.638) has lower P-gp efflux than Ligand B (0.308), which is favorable.
15. **Affinity:** Ligand B (-2.2 kcal/mol) has a better binding affinity than Ligand A (-4.8 kcal/mol). This is a substantial difference.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand B excels in affinity and has better Pgp and TPSA values. While both have high logP, Ligand B's superior affinity and metabolic stability outweigh this concern. The lower DILI risk for Ligand B is also a crucial factor.
**Conclusion:**
Considering the balance of properties, particularly the significantly better affinity, metabolic stability (t1/2 and Cl_mic), lower DILI risk, and improved BBB penetration of Ligand B, it is the more promising drug candidate.
Output:
0
2025-04-17 19:07:44,564 - INFO - Batch 87 complete. Total preferences: 1392
2025-04-17 19:07:44,564 - INFO - Processing batch 88/512...
2025-04-17 19:08:34,020 - INFO - Reasoning:
Let's analyze both ligands based on the provided guidelines, keeping in mind this is for an ADRB2 GPCR (cardiovascular target, so BBB is less critical).
**Ligand A:**
* **MW:** 354.366 Da - Good, within the ideal range.
* **TPSA:** 86.88 - Excellent, well below the 140 threshold.
* **logP:** 2.992 - Excellent, within the optimal range.
* **HBD:** 3 - Good, within the acceptable limit.
* **HBA:** 4 - Good, within the acceptable limit.
* **QED:** 0.484 - Marginal, slightly below the preferred 0.5, but not a dealbreaker.
* **DILI:** 99.341 - Very high risk. This is a significant concern.
* **BBB:** 56.068 - Not particularly relevant for a cardiovascular target.
* **Caco-2:** -5.122 - Very poor permeability. A major drawback.
* **Solubility:** -4.459 - Very poor solubility. A major drawback.
* **hERG:** 0.512 - Low risk, good.
* **Cl_mic:** 2.539 - Low clearance, good metabolic stability.
* **t1/2:** 52.569 - Good in vitro half-life.
* **Pgp:** 0.348 - Low efflux, good.
* **Affinity:** -8.5 kcal/mol - Excellent binding affinity.
**Ligand B:**
* **MW:** 383.861 Da - Good, within the ideal range.
* **TPSA:** 96.67 - Acceptable, but approaching the upper limit for good absorption.
* **logP:** 0.838 - Low, potentially hindering permeation.
* **HBD:** 1 - Good, within the acceptable limit.
* **HBA:** 6 - Good, within the acceptable limit.
* **QED:** 0.789 - Good, above the preferred 0.5.
* **DILI:** 84.102 - Moderate risk, better than Ligand A, but still not ideal.
* **BBB:** 65.452 - Not particularly relevant for a cardiovascular target.
* **Caco-2:** -5.291 - Very poor permeability, similar to Ligand A.
* **Solubility:** -4.486 - Very poor solubility, similar to Ligand A.
* **hERG:** 0.424 - Low risk, good.
* **Cl_mic:** 46.144 - Higher clearance than Ligand A, less metabolic stability.
* **t1/2:** -28.941 - Very short half-life. A major drawback.
* **Pgp:** 0.057 - Low efflux, good.
* **Affinity:** -0.1 kcal/mol - Very weak binding affinity.
**Comparison & Decision:**
Both ligands suffer from extremely poor Caco-2 permeability and solubility. However, Ligand A has a significantly stronger binding affinity (-8.5 kcal/mol vs -0.1 kcal/mol). While Ligand A's DILI risk is very high, the binding affinity is so much better that it could potentially be mitigated through structural modifications. Ligand B's affinity is simply too weak to be a viable starting point, even with better DILI. The short half-life of Ligand B is also a significant negative.
Given the GPCR-specific priorities (affinity is paramount), and the possibility of addressing the DILI risk through medicinal chemistry, I would choose Ligand A.
Output:
1
2025-04-17 19:08:34,020 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
The target is ADRB2, a GPCR. Therefore, I will prioritize logP, TPSA, Pgp efflux, BBB penetration, and binding affinity, alongside general drug-like properties.
* **Molecular Weight:** Both ligands are within the ideal range (359.323 and 364.515 Da).
* **TPSA:** Ligand A (71.09) is better than Ligand B (76.44). Both are below the 140 A^2 threshold for good oral absorption.
* **logP:** Ligand A (2.299) is slightly better than Ligand B (1.25), falling comfortably within the 1-3 range. Ligand B is at the lower end, potentially impacting permeability.
* **H-Bond Donors/Acceptors:** Ligand A (2 HBD, 3 HBA) is slightly preferable to Ligand B (1 HBD, 5 HBA) as it has fewer hydrogen bond acceptors.
* **QED:** Both ligands have similar QED scores (0.734 and 0.718), indicating good drug-likeness.
* **DILI:** Ligand A (49.283) has a significantly higher DILI risk than Ligand B (16.712). This is a major concern.
* **BBB:** Ligand A (83.482) has much better BBB penetration than Ligand B (57.154). While ADRB2 isn't necessarily a CNS target, better BBB penetration can sometimes correlate with improved distribution and reduced off-target effects.
* **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.884) is slightly better than Ligand B (-5.227).
* **Solubility:** Both ligands have negative solubility values, indicating poor solubility. Ligand A (-2.991) is slightly better than Ligand B (-2.247).
* **hERG:** Both ligands have low hERG inhibition liability (0.343 and 0.486), which is good.
* **Cl_mic:** Ligand A (2.281) has significantly lower microsomal clearance than Ligand B (34.975), indicating better metabolic stability.
* **t1/2:** Ligand A (-5.879) has a more negative in vitro half-life, which suggests a longer half-life. Ligand B (-1.448) is less stable.
* **Pgp:** Both ligands have very low Pgp efflux liability (0.049 and 0.011), which is favorable.
* **Binding Affinity:** Ligand A (-6.5 kcal/mol) has a slightly better binding affinity than Ligand B (-6.3 kcal/mol), although the difference is small.
**Overall Assessment:**
Ligand A is generally better across most key parameters, *except* for the significantly higher DILI risk. Ligand B has a much lower DILI risk, which is a critical safety concern. However, the superior metabolic stability (lower Cl_mic, longer t1/2), better BBB penetration, slightly better affinity, and slightly better TPSA/logP of Ligand A are compelling. The difference in binding affinity is not large enough to outweigh the DILI risk.
**Output:**
0
2025-04-17 19:08:34,020 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (366.49 and 344.42 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (65.98) is better than Ligand B (85.05). ADRB2 is not a CNS target, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (1.066 and 0.917), falling within the optimal 1-3 range. Very similar.
4. **HBD:** Ligand A (0) is preferable to Ligand B (1). Fewer HBDs generally improve membrane permeability.
5. **HBA:** Both ligands have 6 HBA, which is acceptable.
6. **QED:** Both ligands have high QED scores (0.78 and 0.874), indicating good drug-like properties.
7. **DILI:** Ligand A (34.39) has a significantly lower DILI risk than Ligand B (58.24). This is a major advantage for Ligand A.
8. **BBB:** Not a primary concern for ADRB2 (cardiovascular target). Ligand A (67.04) is slightly better than Ligand B (59.09).
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.846 and -4.988), which is unusual and suggests poor permeability. However, these values are on the same scale, so it doesn't differentiate the two.
10. **Solubility:** Ligand A (-1.183) is better than Ligand B (-2.545). Better solubility is generally desirable.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.165 and 0.175).
12. **Cl_mic:** Ligand A (3.356) has significantly lower microsomal clearance than Ligand B (22.31). This indicates better metabolic stability for Ligand A.
13. **t1/2:** Ligand B (15.479) has a longer in vitro half-life than Ligand A (3.963). This is a positive for Ligand B, but the difference might be offset by its higher clearance.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.11 and 0.081).
15. **Binding Affinity:** Ligand B (-6.3 kcal/mol) has a slightly better binding affinity than Ligand A (-5.6 kcal/mol). This is a 0.7 kcal/mol difference, which is noticeable but not overwhelming.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity) and the general guidelines, Ligand A is the more promising candidate. While Ligand B has slightly better affinity and in vitro half-life, Ligand A excels in crucial ADME properties like DILI risk, metabolic stability (Cl_mic), and solubility. The lower DILI risk and better metabolic stability are particularly important for a cardiovascular drug, where long-term safety and consistent exposure are critical. The TPSA is also better for Ligand A. The affinity difference is not large enough to overcome the ADME advantages of Ligand A.
Output:
1
2025-04-17 19:08:34,020 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (352.45 and 358.463 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (61.8) is better than Ligand B (69.64). Both are below the 140 threshold for oral absorption, but lower TPSA is generally preferred for GPCR ligands, potentially aiding in brain penetration and receptor binding.
**3. logP:** Both ligands have very similar logP values (3.049 and 2.807), both within the optimal 1-3 range.
**4. H-Bond Donors:** Both ligands have 2 HBD, which is acceptable.
**5. H-Bond Acceptors:** Both ligands have 4 HBA, which is acceptable.
**6. QED:** Both ligands have high QED scores (0.826 and 0.883), indicating good drug-like properties. Ligand B is slightly better.
**7. DILI:** Ligand A (13.843) has a significantly lower DILI risk than Ligand B (47.15). This is a major advantage for Ligand A.
**8. BBB:** Ligand A (68.282) has a better BBB percentile than Ligand B (41.683). While ADRB2 isn't exclusively a CNS target, some brain penetration could be beneficial, and lower Pgp efflux (see below) would support this.
**9. Caco-2 Permeability:** Ligand A (-4.678) has a worse Caco-2 permeability than Ligand B (-5.45).
**10. Aqueous Solubility:** Ligand A (-2.731) has a better aqueous solubility than Ligand B (-3.816).
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (0.807 and 0.518).
**12. Microsomal Clearance:** Ligand B (21.106) has lower microsomal clearance than Ligand A (32.21), suggesting better metabolic stability.
**13. In vitro Half-Life:** Ligand A (22.616) has a better in vitro half-life than Ligand B (-11.891).
**14. P-gp Efflux:** Ligand A (0.142) has lower P-gp efflux than Ligand B (0.188). Lower P-gp efflux is desirable for both oral bioavailability and potential CNS penetration.
**15. Binding Affinity:** Both ligands have very similar binding affinities (-6.3 and -6.1 kcal/mol). The difference is not substantial enough to override other factors.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity) and general drug-like properties, Ligand A is the more promising candidate. The significantly lower DILI risk and better BBB penetration are major advantages. While Ligand B has slightly better metabolic stability and Caco-2 permeability, the risk/benefit profile favors Ligand A.
Output:
1
2025-04-17 19:08:34,021 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (345.4 and 372.4 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (84.66) is slightly higher than Ligand B (66.92). Both are below the 140 threshold for oral absorption, but B is better positioned for potential CNS penetration if desired (though not a primary goal for ADRB2).
3. **logP:** Both ligands (2.287 and 2.469) are within the optimal 1-3 range. Similar.
4. **HBD:** Ligand A has 1 HBD, while Ligand B has 0. Both are acceptable.
5. **HBA:** Ligand A has 5 HBA, Ligand B has 4. Both are below the 10 threshold.
6. **QED:** Ligand A (0.754) has a better QED score than Ligand B (0.614), indicating a more drug-like profile.
7. **DILI:** Ligand B (16.402) has a significantly lower DILI risk than Ligand A (76.425). This is a major advantage for Ligand B.
8. **BBB:** Ligand B (79.682) has a higher BBB penetration percentile than Ligand A (40.675). While ADRB2 isn't primarily a CNS target, higher BBB is generally favorable.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.942 and -4.506), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-2.407) has slightly better solubility than Ligand B (-1.698), but both are quite poor.
11. **hERG:** Ligand A (0.032) has a slightly lower hERG risk than Ligand B (0.313), which is preferable.
12. **Cl_mic:** Ligand A (29.294) has a lower microsomal clearance than Ligand B (51.896), indicating better metabolic stability.
13. **t1/2:** Ligand A (-21.963) has a significantly longer *in vitro* half-life than Ligand B (2.657). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.059) has lower P-gp efflux liability than Ligand B (0.084).
15. **Binding Affinity:** Ligand B (-7.5 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.2 kcal/mol) - a 1.3 kcal/mol difference. This is a substantial advantage.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, affinity is paramount. The 1.3 kcal/mol difference in binding affinity between Ligand B and Ligand A is substantial enough to outweigh several of the drawbacks of Ligand B. While Ligand A has better metabolic stability and half-life, the stronger binding of Ligand B suggests it will be more potent and potentially require a lower dose. The lower DILI risk of Ligand B is also a major positive. The poor Caco-2 values are concerning for both, but can be addressed through formulation strategies.
**Conclusion:**
Despite Ligand A's better metabolic stability and half-life, the significantly stronger binding affinity and lower DILI risk of Ligand B make it the more promising drug candidate for the ADRB2 receptor.
Output:
0
2025-04-17 19:08:34,021 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (338.411 and 347.459 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Both ligands have TPSA values (75.19 and 71.41) below the 140 A^2 threshold for good oral absorption. These are acceptable, but not ideal for potential CNS penetration, which isn't a primary concern for a cardiovascular target.
**3. logP:** Ligand A (1.087) is slightly lower than Ligand B (1.724). Both are within the optimal 1-3 range, but Ligand B is closer to the upper end, potentially leading to some solubility concerns.
**4. H-Bond Donors:** Both have 1 HBD, which is good.
**5. H-Bond Acceptors:** Both have 4 HBA, which is also good.
**6. QED:** Ligand A (0.755) has a significantly better QED score than Ligand B (0.575), suggesting a more drug-like profile overall.
**7. DILI Risk:** Ligand B (30.787 percentile) has a considerably lower DILI risk than Ligand A (41.411 percentile). This is a significant advantage for Ligand B.
**8. BBB Penetration:** Ligand A (63.009) has slightly better BBB penetration than Ligand B (57.736), but since this is a cardiovascular target, BBB penetration is not a high priority.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.594 and -4.81). This is unusual and suggests poor permeability. However, these values are on a log scale, and the negative values might not be directly comparable without knowing the base of the log.
**10. Aqueous Solubility:** Ligand A (-2.478) has slightly better aqueous solubility than Ligand B (-1.202).
**11. hERG Inhibition:** Ligand B (0.355) has a slightly higher hERG inhibition risk than Ligand A (0.12). This is a negative for Ligand B.
**12. Microsomal Clearance:** Ligand B (50.559) has significantly higher microsomal clearance than Ligand A (16.002), indicating faster metabolism and potentially lower bioavailability.
**13. In vitro Half-Life:** Ligand A (-8.216) has a much longer in vitro half-life than Ligand B (-0.154), which is a significant advantage.
**14. P-gp Efflux:** Ligand A (0.021) has much lower P-gp efflux liability than Ligand B (0.205), suggesting better oral bioavailability and potentially better tissue distribution.
**15. Binding Affinity:** Ligand A (-7.4 kcal/mol) has a slightly better binding affinity than Ligand B (-6.5 kcal/mol). This 1.9 kcal/mol difference is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand A is the better candidate. While Ligand B has a lower DILI risk, the significantly better QED, lower P-gp efflux, longer half-life, and stronger binding affinity of Ligand A outweigh this benefit. The slightly better solubility of Ligand A is also a plus. The Caco-2 permeability values are concerning for both, but the other advantages of Ligand A make it the more promising starting point for optimization.
Output:
1
2025-04-17 19:08:34,021 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (337.339 and 345.403 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Both ligands (99 and 96.33) are reasonably low, suggesting good potential for absorption, though slightly above the optimal <90 for CNS targets (less relevant for ADRB2 which is primarily cardiovascular).
3. **logP:** Ligand A (1.916) is within the optimal 1-3 range. Ligand B (-0.181) is slightly below 1, which *could* indicate potential permeability issues. This is a slight advantage for A.
4. **HBD:** Ligand A (1) and Ligand B (2) are both acceptable, below the threshold of 5.
5. **HBA:** Ligand A (7) and Ligand B (5) are both acceptable, below the threshold of 10.
6. **QED:** Both ligands (0.73 and 0.774) have good drug-likeness scores, exceeding 0.5.
7. **DILI:** Ligand A (94.959) has a significantly higher DILI risk than Ligand B (31.563). This is a major concern for Ligand A.
8. **BBB:** Both ligands have relatively low BBB penetration (40.791 and 42.071). This isn't a primary concern for a cardiovascular target like ADRB2.
9. **Caco-2:** Ligand A (-4.685) and Ligand B (-5.583) both have negative values, suggesting poor permeability.
10. **Solubility:** Ligand A (-3.382) and Ligand B (-1.001) both have negative values, suggesting poor solubility.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.217 and 0.063).
12. **Cl_mic:** Ligand A (53.141) has a higher microsomal clearance than Ligand B (-22.941). This suggests Ligand B is more metabolically stable.
13. **t1/2:** Ligand A (8.71) has a longer half-life than Ligand B (2.365).
14. **Pgp:** Both ligands have low P-gp efflux liability (0.086 and 0.006).
15. **Binding Affinity:** Ligand B (-7.8 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.4 kcal/mol). This is a substantial advantage, exceeding the 1.5 kcal/mol threshold.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand A has a better logP, but Ligand B has a *much* better binding affinity and comparable TPSA and Pgp. The DILI risk for Ligand A is a significant red flag.
**Overall Assessment:**
Despite Ligand A's slightly better logP and half-life, the significantly higher DILI risk and weaker binding affinity are major drawbacks. Ligand B's superior binding affinity and much lower DILI risk outweigh the slightly less favorable logP. The negative Caco-2 and solubility values are concerning for both, but can be addressed with formulation strategies.
Output:
0
2025-04-17 19:08:34,021 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (370.852) is slightly higher than Ligand B (353.463), but both are acceptable.
2. **TPSA:** Ligand A (60.85) is significantly better than Ligand B (101.73). For a GPCR, lower TPSA is generally preferred for better permeability. Ligand B is pushing the upper limit for good oral absorption.
3. **logP:** Both ligands have acceptable logP values (Ligand A: 1.977, Ligand B: 0.954), falling within the 1-3 range. Ligand A is slightly more lipophilic, which could be beneficial for membrane permeability, but Ligand B is still reasonable.
4. **HBD:** Ligand A (1) has fewer H-bond donors than Ligand B (2). Lower is generally preferred.
5. **HBA:** Ligand A (3) has fewer H-bond acceptors than Ligand B (4). Lower is generally preferred.
6. **QED:** Ligand A (0.808) has a better QED score than Ligand B (0.603), indicating a more drug-like profile.
7. **DILI:** Ligand A (30.71) has a significantly lower DILI risk than Ligand B (12.718), which is a major advantage.
8. **BBB:** Ligand A (77.898) has a better BBB penetration percentile than Ligand B (58.24). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant, and better BBB penetration is generally favorable.
9. **Caco-2:** Ligand A (-4.658) has a worse Caco-2 permeability than Ligand B (-5.393). Lower values indicate poorer permeability.
10. **Solubility:** Ligand A (-2.941) has better solubility than Ligand B (-1.609).
11. **hERG:** Both ligands have very low hERG inhibition risk (Ligand A: 0.374, Ligand B: 0.226). This is excellent.
12. **Cl_mic:** Ligand A (29.515) has a higher microsomal clearance than Ligand B (-4.416). This means Ligand B is likely more metabolically stable, which is a positive.
13. **t1/2:** Ligand A (-7.197) has a longer in vitro half-life than Ligand B (-12.754). This is a significant advantage for dosing frequency.
14. **Pgp:** Both ligands have very low P-gp efflux liability (Ligand A: 0.032, Ligand B: 0.022).
15. **Binding Affinity:** Ligand B (-7.1) has a slightly better binding affinity than Ligand A (-6.5). However, the difference is only 0.6 kcal/mol, which is not substantial enough to outweigh other significant differences.
**Overall Assessment:**
Ligand A is the stronger candidate. While Ligand B has slightly better binding affinity and metabolic stability, Ligand A excels in crucial areas like TPSA, DILI risk, BBB penetration, QED, solubility, and in vitro half-life. The lower TPSA and DILI risk are particularly important, and the better QED score suggests a more generally drug-like molecule. The slightly worse Caco-2 permeability is a minor drawback compared to the benefits. Given the GPCR target class, the balance of properties favors Ligand A.
Output:
1
2025-04-17 19:08:34,021 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (353.5) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are reasonably low, but Ligand A (61.88) is better than Ligand B (67.43), increasing the chance of good oral absorption.
3. **logP:** Both are in the optimal range (1-3). Ligand A (3.75) is slightly higher, potentially leading to some off-target effects, but not drastically. Ligand B (3.215) is more conservative.
4. **HBD:** Ligand A (1) is better than Ligand B (2). Lower HBD is generally preferred for better permeability.
5. **HBA:** Ligand A (3) is better than Ligand B (4). Similar to HBD, lower HBA is favored.
6. **QED:** Ligand A (0.819) is significantly better than Ligand B (0.665), indicating a more drug-like profile.
7. **DILI:** Ligand A (21.52) is *much* better than Ligand B (47.732), indicating a significantly lower risk of drug-induced liver injury. This is a crucial factor.
8. **BBB:** Ligand A (93.253) is better than Ligand B (73.672). While ADRB2 isn't strictly a CNS target, some CNS penetration can be beneficial, and higher BBB is generally desirable.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-4.304) is slightly better than Ligand B (-4.525).
10. **Solubility:** Both are negative, indicating poor solubility. Ligand A (-3.269) is slightly better than Ligand B (-4.627).
11. **hERG:** Both are very low, indicating a low risk of hERG inhibition and cardiotoxicity. Ligand A (0.483) is slightly better than Ligand B (0.438).
12. **Cl_mic:** Ligand A (52.85) is significantly better than Ligand B (72.491), suggesting better metabolic stability.
13. **t1/2:** Ligand A (3.191) is better than Ligand B (-18.138). A positive half-life is much more desirable.
14. **Pgp:** Both are very low, indicating low P-gp efflux. Ligand A (0.076) is better than Ligand B (0.157).
15. **Affinity:** Ligand A (-7.1) is *significantly* better than Ligand B (-4.5). This is a 2.6 kcal/mol difference, which is substantial and can outweigh many ADME drawbacks.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are particularly important. Ligand A excels in all these areas, especially affinity. The significantly lower DILI risk and better metabolic stability (Cl_mic) of Ligand A are also major advantages.
**Conclusion:**
Ligand A is clearly the superior candidate. Its significantly better binding affinity, lower DILI risk, better metabolic stability, and more favorable drug-like properties (QED, BBB) outweigh the slightly higher logP. While both have poor Caco-2 and solubility, the other advantages of Ligand A make it a much more promising starting point for drug development.
Output:
1
2025-04-17 19:08:34,022 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [338.371, 89.07, 1.393, 1, 7, 0.773, 79.604, 46.219, -5.335, -1.96, 0.052, 35.493, -19.607, 0.051, -6.9]
**Ligand B:** [358.454, 87.66, 1.027, 3, 4, 0.574, 12.214, 72.819, -4.83, -3.064, 0.318, 47.415, -16.102, 0.015, -6]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (338.371) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are good, below 140 (Ligand A: 89.07, Ligand B: 87.66). This suggests reasonable oral absorption potential.
3. **logP:** Both are within the optimal range (1-3), with Ligand A (1.393) being slightly higher than Ligand B (1.027).
4. **HBD:** Ligand A (1) is better than Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (7) is better than Ligand B (4). Fewer HBAs generally improve permeability.
6. **QED:** Ligand A (0.773) is significantly better than Ligand B (0.574), indicating a more drug-like profile.
7. **DILI:** Ligand A (79.604) has a much higher DILI risk than Ligand B (12.214). This is a major concern for Ligand A.
8. **BBB:** Ligand B (72.819) has a better BBB penetration potential than Ligand A (46.219). While not a primary concern for ADRB2 (a cardiovascular target), it's a positive attribute.
9. **Caco-2:** Ligand A (-5.335) is worse than Ligand B (-4.83). Higher values are better, indicating better intestinal absorption.
10. **Solubility:** Ligand B (-3.064) has better aqueous solubility than Ligand A (-1.96).
11. **hERG:** Ligand A (0.052) has a slightly higher hERG risk than Ligand B (0.318), but both are relatively low.
12. **Cl_mic:** Ligand B (47.415) has a higher microsomal clearance than Ligand A (35.493), meaning Ligand A is more metabolically stable.
13. **t1/2:** Ligand A (-19.607) has a longer in vitro half-life than Ligand B (-16.102).
14. **Pgp:** Ligand A (0.051) is better than Ligand B (0.015), indicating lower P-gp efflux.
15. **Affinity:** Both have very similar binding affinities (-6.9 and -6 kcal/mol). The difference is negligible.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Both ligands perform reasonably well on these parameters. However, the significant difference in DILI risk and QED heavily favors Ligand B. While Ligand A has slightly better metabolic stability and Pgp properties, the high DILI risk is a major red flag.
**Conclusion:**
Despite Ligand A having some favorable ADME properties, the significantly higher DILI risk and lower QED make it a less desirable candidate. Ligand B, with its lower DILI risk, better solubility, and acceptable overall profile, is the more promising drug candidate.
Output:
0
2025-04-17 19:08:34,022 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.415 and 348.422 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (98.74) is higher than Ligand B (67.23). For a cardiovascular GPCR like ADRB2, TPSA is less critical than for CNS targets, but lower is generally preferred for permeability. Ligand B is better.
3. **logP:** Ligand A (-0.604) is quite low, potentially hindering membrane permeability. Ligand B (1.568) is within the optimal 1-3 range. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (1). Both are acceptable, but lower is generally preferable. Ligand B is better.
5. **HBA:** Both ligands have 4 HBA, which is within the acceptable range. No significant difference.
6. **QED:** Ligand B (0.822) has a substantially higher QED score than Ligand A (0.441), indicating a more drug-like profile. This is a strong advantage for Ligand B.
7. **DILI:** Ligand A (18.573) has a much lower DILI risk than Ligand B (51.648). This is a significant advantage for Ligand A.
8. **BBB:** Ligand B (82.435) has a higher BBB penetration percentile than Ligand A (28.538). While ADRB2 isn't a primary CNS target, some brain exposure can be relevant for off-target effects or peripheral ADRB2 receptors in the brain.
9. **Caco-2:** Both ligands have similar, very negative Caco-2 values (-4.843 and -4.761), suggesting poor intestinal absorption. This is a concern for both, but doesn't differentiate them.
10. **Solubility:** Ligand A (-1.701) has slightly better solubility than Ligand B (-2.581), but both are poor.
11. **hERG:** Ligand A (0.116) has a lower hERG risk than Ligand B (0.41). This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand A (-4.789) has a much lower microsomal clearance than Ligand B (22.258), indicating better metabolic stability. This is a strong advantage for Ligand A.
13. **t1/2:** Ligand A (-9.538) has a more negative in vitro half-life than Ligand B (-7.667), suggesting faster metabolism. Ligand B is better.
14. **Pgp:** Ligand A (0.006) has a much lower P-gp efflux liability than Ligand B (0.128), suggesting better bioavailability. This is a strong advantage for Ligand A.
15. **Binding Affinity:** Both ligands have comparable binding affinities (-5.8 and -6.3 kcal/mol). The difference is not substantial enough to outweigh other factors.
**Overall Assessment:**
Ligand B has advantages in QED, BBB, and t1/2, and logP. However, Ligand A has significantly better DILI, hERG, Cl_mic, and Pgp profiles. Given the cardiovascular target, minimizing off-target effects (DILI, hERG) and maximizing metabolic stability (Cl_mic) are crucial. The poor logP of Ligand A is a concern, but can potentially be addressed through further medicinal chemistry optimization. The poor Caco-2 values for both compounds are also a concern, but are less critical than safety and metabolism.
Therefore, I favor Ligand A due to its superior safety and pharmacokinetic properties.
Output:
1
2025-04-17 19:08:34,022 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (343.43 and 357.44 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (75.43) is significantly better than Ligand B (92.59). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (1.947 and 1.113), falling within the optimal 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Both ligands have 1 HBD, which is within the acceptable limit of 5.
5. **HBA:** Ligand A has 5 HBA, while Ligand B has 7. Both are acceptable (<=10), but Ligand A is preferable.
6. **QED:** Ligand A (0.921) has a much better QED score than Ligand B (0.71), indicating a more drug-like profile.
7. **DILI:** Ligand B (79.60) has a higher DILI risk than Ligand A (58.40), though both are above the ideal <40. Ligand A is clearly better here.
8. **BBB:** Ligand A (79.68) has a higher BBB penetration percentile than Ligand B (47.15). While not a primary concern for a cardiovascular target, higher BBB is generally a positive attribute.
9. **Caco-2:** Ligand A (-4.44) has a much better Caco-2 permeability than Ligand B (-5.93). This suggests better intestinal absorption for Ligand A.
10. **Solubility:** Ligand A (-3.073) has better aqueous solubility than Ligand B (-1.97).
11. **hERG:** Ligand A (0.726) has a lower hERG inhibition liability than Ligand B (0.139), indicating a lower risk of cardiotoxicity. This is *very* important for a cardiovascular target.
12. **Cl_mic:** Ligand B (45.41) has a lower microsomal clearance than Ligand A (57.66), suggesting better metabolic stability. This is a point in favor of Ligand B.
13. **t1/2:** Ligand B (-9.611) has a longer in vitro half-life than Ligand A (13.981). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.593) has lower P-gp efflux liability than Ligand B (0.112), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand B (-7.5 kcal/mol) has a slightly better binding affinity than Ligand A (-6.2 kcal/mol). This is a 1.3 kcal/mol difference, which is substantial.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B has a slightly better affinity and metabolic stability (lower Cl_mic, longer t1/2), but Ligand A excels in almost all other crucial ADME properties (TPSA, QED, DILI, BBB, Caco-2, solubility, hERG, Pgp). The hERG risk is particularly important for a cardiovascular target, and Ligand A is significantly better in this regard. The affinity difference, while noticeable, is likely surmountable with further optimization, whereas fixing a high hERG risk is much more challenging.
**Conclusion:**
Despite the slightly better affinity of Ligand B, the superior overall ADME profile of Ligand A, particularly its lower hERG risk and better predicted absorption, makes it the more promising drug candidate for ADRB2.
Output:
1
2025-04-17 19:08:34,022 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [367.471, 101.3 , 1.858, 2. , 5. , 0.485, 52.423, 55.642, -5.26 , -2.814, 0.153, 69.366, -39.347, 0.078, -5.9 ]
**Ligand B:** [377.901, 82.7 , 4.374, 3. , 5. , 0.595, 84.839, 40.403, -5.316, -4.423, 0.623, 38.435, 138.501, 0.409, -6.5 ]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity):
1. **MW:** Both are within the ideal range (200-500 Da). A is 367.471, B is 377.901 - very similar.
2. **TPSA:** Ligand A (101.3) is slightly higher than Ligand B (82.7). Both are acceptable for a non-CNS GPCR like ADRB2, but B is better.
3. **logP:** Ligand A (1.858) is optimal. Ligand B (4.374) is pushing the upper limit and could lead to solubility issues.
4. **HBD/HBA:** Both have reasonable HBD (2/3) and HBA (5/5) counts.
5. **QED:** Both are acceptable, but Ligand B (0.595) is better than Ligand A (0.485).
6. **DILI:** Ligand A (52.423) has a much lower DILI risk than Ligand B (84.839). This is a significant advantage for A.
7. **BBB:** Not a primary concern for ADRB2, but Ligand A (55.642) has better BBB penetration than Ligand B (40.403).
8. **Caco-2:** Both are negative, indicating poor permeability.
9. **Solubility:** Ligand A (-2.814) has better solubility than Ligand B (-4.423). This is important given B's higher logP.
10. **hERG:** Ligand A (0.153) has a lower hERG risk than Ligand B (0.623). Another significant advantage for A.
11. **Cl_mic:** Ligand B (38.435) has lower microsomal clearance, suggesting better metabolic stability than Ligand A (69.366).
12. **t1/2:** Ligand B (138.501) has a significantly longer in vitro half-life than Ligand A (-39.347). This is a major advantage for B.
13. **Pgp:** Ligand A (0.078) has lower P-gp efflux, which is good for bioavailability. Ligand B (0.409) is higher.
14. **Affinity:** Ligand B (-6.5 kcal/mol) has a stronger binding affinity than Ligand A (-5.9 kcal/mol). This is a 0.6 kcal/mol difference, which is substantial.
**Overall Assessment:**
Ligand B has a superior binding affinity and a much longer half-life, which are critical for efficacy and dosing. However, it has a higher logP, DILI risk, hERG risk, and Pgp efflux. Ligand A has better solubility, lower toxicity risks (DILI, hERG), and better Pgp properties.
The affinity difference is significant, and for a GPCR, potency is often a key driver. The longer half-life of B is also very attractive. While the ADME properties of B are less ideal, they are not catastrophic, and could potentially be mitigated through formulation or further optimization. The improved safety profile of A is appealing, but the weaker binding may require higher doses, potentially negating some of the safety benefits.
Considering the balance, the stronger binding affinity and longer half-life of Ligand B outweigh its slightly less favorable ADME profile.
Output:
0
2025-04-17 19:08:34,022 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.385 and 364.555 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (67.23) is higher than Ligand B (49.41). For a cardiovascular GPCR, TPSA is moderately important, and Ligand B is preferable due to its lower value, suggesting better permeability.
3. **logP:** Ligand B (3.392) is slightly higher than Ligand A (1.984). Both are within the optimal 1-3 range, but Ligand B is closer to the upper limit. This could potentially lead to solubility issues, but isn't a major concern at this level.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 4 HBA, while Ligand B has 3. Both are acceptable, under the 10 threshold.
6. **QED:** Ligand A (0.816) has a better QED score than Ligand B (0.705), indicating a more drug-like profile overall.
7. **DILI:** Ligand A (37.844) has a slightly higher DILI risk than Ligand B (33.307), but both are below the 40% threshold and considered low risk.
8. **BBB:** Ligand A (88.057) has a significantly higher BBB penetration percentile than Ligand B (58.24). While ADRB2 isn't a CNS target, some peripheral distribution is still desirable, and higher BBB penetration can sometimes correlate with better overall distribution.
9. **Caco-2:** Ligand A (-4.788) has a more negative Caco-2 value than Ligand B (-4.98), indicating lower permeability.
10. **Solubility:** Ligand A (-2.795) has a more negative solubility value than Ligand B (-4.112), indicating lower solubility.
11. **hERG:** Both ligands have low hERG inhibition liability (0.418 and 0.32 respectively). No significant difference.
12. **Cl_mic:** Ligand A (-8.608) has a much lower (better) microsomal clearance than Ligand B (75.586). This suggests greater metabolic stability for Ligand A.
13. **t1/2:** Ligand A (-8.15) has a more negative in vitro half-life, which indicates a longer half-life. Ligand B (6.893) is positive, indicating a shorter half-life.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.036 and 0.278 respectively). No significant difference.
15. **Binding Affinity:** Ligand A (-7.3) has a slightly better binding affinity than Ligand B (-6.0). This is a substantial difference (1.3 kcal/mol), and affinity is a primary driver for GPCR drug candidates.
**Overall Assessment:**
Ligand A has a superior binding affinity and better metabolic stability (lower Cl_mic, longer t1/2), and a better QED score. While Ligand B has a slightly better TPSA and logP, the differences are not substantial enough to outweigh the advantages of Ligand A, especially considering the significant affinity difference. The lower solubility and permeability of Ligand A are concerns, but potentially addressable through formulation strategies.
Output:
1
2025-04-17 19:08:34,022 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [351.451, 98.14, 0.723, 2, 6, 0.605, 23.846, 63.707, -5.377, -0.667, 0.126, 17.976, -2.036, 0.013, -7.6]
**Ligand B:** [346.391, 122.03, -0.262, 3, 7, 0.662, 60.682, 28.344, -5.359, -1.831, 0.214, 28.922, 3.224, 0.012, -6.6]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal 200-500 Da range. A (351.451) and B (346.391) are very close.
2. **TPSA:** A (98.14) is better than B (122.03). Below 140 is good for oral absorption, both are, but A is closer to the ideal <90 for CNS penetration (though ADRB2 isn't strictly a CNS target, lower TPSA is generally favorable).
3. **logP:** A (0.723) is acceptable, but on the lower side. B (-0.262) is quite low, potentially causing permeability issues. This is a significant drawback for B.
4. **HBD/HBA:** A (2 HBD, 6 HBA) is preferable to B (3 HBD, 7 HBA). Fewer H-bonds generally improve permeability.
5. **QED:** Both are good (A: 0.605, B: 0.662), indicating reasonable drug-likeness.
6. **DILI:** A (23.846) is significantly better than B (60.682). Lower DILI risk is crucial.
7. **BBB:** A (63.707) is better than B (28.344). While not a primary concern for ADRB2, higher BBB is still a positive.
8. **Caco-2:** Both are negative (-5.377 and -5.359), which is unusual and suggests poor permeability. This is a concern for both.
9. **Solubility:** Both are negative (-0.667 and -1.831), indicating poor solubility. This is a concern for both.
10. **hERG:** A (0.126) is better than B (0.214), indicating lower cardiotoxicity risk.
11. **Cl_mic:** A (17.976) is much better than B (28.922), suggesting better metabolic stability.
12. **t1/2:** A (-2.036) is better than B (3.224) - a negative value is better here, indicating a longer half-life.
13. **Pgp:** Both are very low (0.013 and 0.012), suggesting minimal P-gp efflux.
14. **Affinity:** A (-7.6) is significantly better than B (-6.6), a difference of 1.0 kcal/mol. This is a substantial advantage.
**Conclusion:**
Ligand A is clearly the superior candidate. While both have issues with Caco-2 and solubility, Ligand A demonstrates better logP, TPSA, DILI risk, metabolic stability, half-life, and, most importantly, significantly stronger binding affinity. The 1.0 kcal/mol difference in binding affinity is a major advantage that outweighs the minor ADME drawbacks.
Output:
1
2025-04-17 19:08:34,023 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [344.43 , 50.36 , 4.21 , 2. , 2. , 0.79 , 40.054, 70.997, -4.514, -4.393, 0.876, 48.776, 49.3 , 0.21 , -6.4 ]
**Ligand B:** [368.419, 119.31 , -0.454, 1. , 9. , 0.665, 70.376, 46.413, -5.578, -1.092, 0.052, 2.785, 3.543, 0.016, -6.1 ]
Here's a breakdown of the comparison, considering GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the acceptable range (200-500 Da). Ligand A (344.43) is slightly preferred.
2. **TPSA:** Ligand A (50.36) is significantly better than Ligand B (119.31). Below 140 is good for oral absorption, but lower is better for GPCRs, and A is much closer to ideal.
3. **logP:** Ligand A (4.21) is good, while Ligand B (-0.454) is quite low. This is a major strike against B, as it may struggle with membrane permeability.
4. **HBD/HBA:** Ligand A (2 HBD, 2 HBA) is better than Ligand B (1 HBD, 9 HBA). Ligand B has a high number of HBA, which could impact permeability.
5. **QED:** Both are reasonable (A: 0.79, B: 0.665), indicating acceptable drug-likeness.
6. **DILI:** Both are acceptable (A: 40.054, B: 70.376), but A is better.
7. **BBB:** Ligand A (70.997) is significantly better than Ligand B (46.413). While ADRB2 isn't necessarily a CNS target, some CNS penetration can be beneficial, and this difference is notable.
8. **Caco-2:** Ligand A (-4.514) is better than Ligand B (-5.578), indicating better intestinal absorption.
9. **Solubility:** Ligand A (-4.393) is better than Ligand B (-1.092).
10. **hERG:** Ligand A (0.876) is better than Ligand B (0.052).
11. **Cl_mic:** Ligand A (48.776) is worse than Ligand B (2.785), indicating lower metabolic stability. This is a drawback for A.
12. **t1/2:** Ligand A (49.3) is better than Ligand B (3.543).
13. **Pgp:** Ligand A (0.21) is much better than Ligand B (0.016). Lower P-gp efflux is highly desirable.
14. **Affinity:** Both have good affinity (-6.4 and -6.1 kcal/mol). The difference is small, but A is slightly better.
**Overall Assessment:**
Ligand A clearly outperforms Ligand B across most critical parameters, especially logP, TPSA, BBB, Caco-2, solubility, hERG, and Pgp. While Ligand A has a higher Cl_mic, the other advantages, particularly the favorable logP and TPSA, are more critical for a GPCR target like ADRB2. The better predicted permeability and reduced off-target effects of Ligand A make it the more promising candidate.
Output:
1
2025-04-17 19:08:34,023 - INFO - Batch 88 complete. Total preferences: 1408
2025-04-17 19:08:34,023 - INFO - Processing batch 89/512...
2025-04-17 19:09:22,524 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (388.559 Da) is slightly higher than Ligand B (342.443 Da), but both are acceptable.
**2. TPSA:** Both ligands have TPSA values below the 140 A^2 threshold for good oral absorption. Ligand A (82.61) is slightly higher than Ligand B (78.09), but both are good.
**3. logP:** Both ligands have logP values within the optimal range (1-3). Ligand A (1.517) and Ligand B (2.099) are both acceptable.
**4. H-Bond Donors:** Ligand A (1) and Ligand B (2) both meet the criteria of being less than or equal to 5.
**5. H-Bond Acceptors:** Ligand A (6) and Ligand B (3) both meet the criteria of being less than or equal to 10.
**6. QED:** Both ligands have QED values above 0.5, indicating good drug-likeness. Ligand B (0.879) is slightly better than Ligand A (0.766).
**7. DILI:** Ligand B (38.62) has a significantly lower DILI risk than Ligand A (69.639). This is a major advantage for Ligand B.
**8. BBB:** Ligand A (67.352) has a slightly higher BBB penetration percentile than Ligand B (54.13). While ADRB2 isn't strictly a CNS target, some distribution into the CNS can occur, and higher BBB is generally favorable.
**9. Caco-2 Permeability:** Ligand A (-4.832) has a more negative Caco-2 value than Ligand B (-5.329), indicating better intestinal absorption.
**10. Aqueous Solubility:** Ligand A (-3.243) has slightly better aqueous solubility than Ligand B (-3.66).
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (Ligand A: 0.461, Ligand B: 0.342).
**12. Microsomal Clearance:** Ligand B (5.242) has significantly lower microsomal clearance than Ligand A (69.967), indicating better metabolic stability.
**13. In vitro Half-Life:** Ligand B (-12.027) has a significantly longer in vitro half-life than Ligand A (-34.064).
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (Ligand A: 0.21, Ligand B: 0.046). Ligand B is slightly better.
**15. Binding Affinity:** Ligand B (-7.8 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.4 kcal/mol). This is a substantial advantage.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand B is the stronger candidate. The significantly improved binding affinity (-7.8 vs -6.4 kcal/mol) and lower DILI risk are major advantages. The better metabolic stability (lower Cl_mic and longer half-life) also contribute to its favorability. While Ligand A has slightly better BBB penetration and Caco-2 permeability, the differences aren't large enough to outweigh the benefits of Ligand B.
Output:
0
2025-04-17 19:09:22,524 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (339.439 and 349.435 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (54.46) is significantly better than Ligand B (89.35). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold, while B is approaching it.
3. **logP:** Both ligands have good logP values (2.761 and 1.673), falling within the 1-3 optimal range. Ligand A is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Both have 1 HBD, which is acceptable.
5. **HBA:** Ligand A has 4 HBAs, and Ligand B has 6. Both are within the acceptable limit of 10, but A is preferable.
6. **QED:** Ligand A (0.879) has a higher QED score than Ligand B (0.685), indicating a more drug-like profile.
7. **DILI:** Ligand A (14.928) has a *much* lower DILI risk than Ligand B (66.693). This is a major advantage for Ligand A.
8. **BBB:** Both ligands have reasonable BBB penetration (77.705 and 79.488). Since ADRB2 is a cardiovascular target, this isn't a primary concern, but higher is generally better.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Both have negative solubility values, which is also unusual. Again, the scale is not specified, making interpretation difficult.
11. **hERG:** Ligand A (0.774) has a slightly higher hERG risk than Ligand B (0.325), but both are relatively low.
12. **Cl_mic:** Ligand A (32.652) has a lower microsomal clearance than Ligand B (40.526), suggesting better metabolic stability.
13. **t1/2:** Ligand B (2.455) has a longer in vitro half-life than Ligand A (0.698). This is a positive for Ligand B.
14. **Pgp:** Ligand A (0.13) has a lower P-gp efflux liability than Ligand B (0.093), suggesting better oral bioavailability.
15. **Binding Affinity:** Ligand B (-6.2 kcal/mol) has a slightly better binding affinity than Ligand A (-6.8 kcal/mol). However, the difference is relatively small (0.6 kcal/mol) and may not be enough to outweigh other factors.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A is better on logP, TPSA, and Pgp. The affinity difference is small. The *significant* advantage of Ligand A is its much lower DILI risk.
**Conclusion:**
Considering all factors, especially the significantly lower DILI risk and better overall drug-like properties (QED, TPSA, Pgp, Cl_mic), Ligand A is the more promising drug candidate. The slightly better affinity of Ligand B is not enough to overcome the higher DILI risk and less favorable ADME profile.
Output:
1
2025-04-17 19:09:22,524 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (356.394 and 349.406 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (91.32) is significantly better than Ligand A (118.89). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (1.511) is within the optimal range (1-3), while Ligand A (0.679) is slightly below, potentially impacting permeability. Ligand B has a clear advantage.
4. **HBD:** Ligand A (5) is at the upper limit, while Ligand B (3) is preferable.
5. **HBA:** Ligand A (5) and Ligand B (4) are both acceptable.
6. **QED:** Both ligands have similar, relatively low QED values (0.422 and 0.377). This isn't a strong discriminator, but suggests room for improvement in either structure.
7. **DILI:** Ligand A (24.351) has a much lower DILI risk than Ligand B (35.595). This is a significant advantage for Ligand A.
8. **BBB:** Ligand B (70.531) shows better BBB penetration than Ligand A (18.069). While not a primary concern for ADRB2, it's a slight positive for Ligand B.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. Ligand B (-4.881) is slightly better than Ligand A (-5.681), but both are concerning.
10. **Solubility:** Ligand A (-1.27) has slightly better solubility than Ligand B (-2.016).
11. **hERG:** Ligand A (0.366) has a lower hERG risk than Ligand B (0.195), which is a positive.
12. **Cl_mic:** Ligand A (-9.189) has a much lower (better) microsomal clearance than Ligand B (28.754). This indicates greater metabolic stability for Ligand A.
13. **t1/2:** Ligand A (8.782) has a longer in vitro half-life than Ligand B (-7.037).
14. **Pgp:** Ligand A (0.04) has lower P-gp efflux than Ligand B (0.036), a slight advantage.
15. **Binding Affinity:** Ligand A (-7.0) has a slightly better binding affinity than Ligand B (-6.2). While the difference is less than 1.5 kcal/mol, it contributes to the overall assessment.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, affinity), Ligand B initially looks better due to its superior logP and TPSA. However, Ligand A demonstrates significantly better ADME properties, particularly concerning DILI risk, metabolic stability (Cl_mic and t1/2), and hERG inhibition. The slightly better affinity of Ligand A further strengthens its profile. While both have poor Caco-2 permeability, the other advantages of Ligand A outweigh the slight benefit of Ligand B in that area.
**Output:**
1
2025-04-17 19:09:22,525 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, the priorities are logP, Pgp, TPSA, and affinity, with a secondary consideration for ADME properties like solubility, metabolic stability, and safety (DILI, hERG).
Let's compare the ligands property by property:
1. **MW:** Both ligands (347.375 and 342.483 Da) are within the ideal 200-500 Da range.
2. **TPSA:** Ligand B (49.41) is significantly better than Ligand A (111.15). Lower TPSA generally favors oral absorption and is particularly important for GPCRs.
3. **logP:** Ligand B (3.49) is better than Ligand A (-0.318). Ligand A's logP is quite low, potentially hindering membrane permeability. Ligand B is within the optimal 1-3 range.
4. **HBD/HBA:** Ligand A has 2 HBD and 7 HBA, while Ligand B has 1 HBD and 2 HBA. Both are acceptable, but Ligand B is slightly more favorable.
5. **QED:** Both ligands have good QED scores (0.77 and 0.852), indicating good drug-like properties.
6. **DILI:** Ligand B (40.054) has a lower DILI risk than Ligand A (63.823), making it safer.
7. **BBB:** Ligand B (72.586) has a better BBB penetration score than Ligand A (34.548). While not a primary concern for a cardiovascular target, it's a bonus.
8. **Caco-2:** Ligand B (-4.547) is better than Ligand A (-5.76), indicating better intestinal absorption.
9. **Solubility:** Ligand A (-1.632) is better than Ligand B (-4.276). Solubility is a concern for both, but Ligand A is slightly better.
10. **hERG:** Ligand A (0.02) has a lower hERG risk than Ligand B (0.653).
11. **Cl_mic:** Ligand A (-20.177) has a much lower (better) microsomal clearance than Ligand B (70.085), suggesting better metabolic stability.
12. **t1/2:** Ligand A (28.365) has a better in vitro half-life than Ligand B (-5.398).
13. **Pgp:** Ligand A (0.009) has a much lower Pgp efflux liability than Ligand B (0.377), suggesting better bioavailability.
14. **Affinity:** Ligand A (-7.8) has slightly better binding affinity than Ligand B (-7.4). However, the difference is less than 1.5 kcal/mol.
**Overall Assessment:**
Ligand B excels in key GPCR properties (TPSA, logP, BBB, Caco-2) and has a better safety profile (lower DILI). While Ligand A has better metabolic stability (Cl_mic, t1/2), Pgp efflux, and a slightly better affinity, the improvements in ADME properties and safety for Ligand B outweigh these advantages. The lower TPSA and improved logP of Ligand B are particularly important for a GPCR target.
**Output:**
0
2025-04-17 19:09:22,525 - INFO - Reasoning:
Let's analyze Ligand A and Ligand B for their potential as ADRB2 ligands, keeping in mind the GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key).
**Molecular Weight:** Both ligands (338.411 and 354.328 Da) fall within the ideal 200-500 Da range.
**TPSA:** Ligand A (74.33) is higher than Ligand B (51.66). While both are reasonably good, Ligand B is better, being closer to the <90 threshold for potential CNS penetration (though not a primary concern for a cardiovascular target).
**logP:** Ligand A (2.046) is within the optimal 1-3 range. Ligand B (3.402) is slightly higher, potentially edging towards solubility issues, but still acceptable.
**H-Bond Donors/Acceptors:** Ligand A has 2 HBD and 4 HBA, while Ligand B has 0 HBD and 4 HBA. Both are within acceptable limits.
**QED:** Ligand A (0.845) has a better QED score than Ligand B (0.746), indicating a more drug-like profile.
**DILI:** Ligand B (63.086) has a slightly higher DILI risk than Ligand A (55.642), but both are moderately risky.
**BBB:** Ligand B (83.249) has significantly better BBB penetration than Ligand A (62.233). While not critical for a cardiovascular target, it's a slight advantage.
**Caco-2 Permeability:** Ligand A (-5.042) shows poorer permeability than Ligand B (-4.424).
**Aqueous Solubility:** Both ligands have very poor aqueous solubility (-3.202 and -3.653 respectively). This is a significant concern for both.
**hERG Inhibition:** Ligand A (0.464) has a lower hERG inhibition liability than Ligand B (0.783), which is a positive.
**Microsomal Clearance:** Ligand A (16.914) has lower microsomal clearance than Ligand B (54.093), suggesting better metabolic stability.
**In vitro Half-Life:** Ligand B (5.781) has a longer half-life than Ligand A (1.323), which is desirable.
**P-gp Efflux:** Ligand A (0.032) has significantly lower P-gp efflux than Ligand B (0.408), which is a major advantage for bioavailability.
**Binding Affinity:** Ligand A (-6.5 kcal/mol) has slightly weaker binding affinity than Ligand B (-6.3 kcal/mol). The difference is relatively small.
**Overall Assessment:**
Ligand A has a better QED score, lower DILI risk, lower hERG, better metabolic stability (lower Cl_mic), and significantly lower P-gp efflux. These factors are crucial for good drug properties. While Ligand B has better BBB penetration and a longer half-life, the solubility issues and higher P-gp efflux are substantial drawbacks. The slight difference in binding affinity is not enough to overcome the ADME advantages of Ligand A.
Output:
1
2025-04-17 19:09:22,525 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (459.078 Da) is within the ideal range, while Ligand B (352.475 Da) is towards the lower end, but still acceptable.
2. **TPSA:** Ligand A (81.07) is acceptable, though approaching the upper limit for good oral absorption. Ligand B (59.08) is excellent.
3. **logP:** Ligand A (3.485) is optimal. Ligand B (1.82) is a bit low, potentially impacting membrane permeability.
4. **HBD:** Ligand A (2) is good. Ligand B (0) is also good, potentially improving permeability.
5. **HBA:** Ligand A (5) is good. Ligand B (4) is also good.
6. **QED:** Both Ligand A (0.694) and Ligand B (0.701) are very good, indicating drug-like properties.
7. **DILI:** Ligand A (74.835) is moderately high risk, while Ligand B (12.524) is very low risk. This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (78.286) is good, while Ligand B (83.831) is excellent. This is important for a GPCR target.
9. **Caco-2:** Both are negative values, indicating permeability.
10. **Solubility:** Ligand A (-4.394) is poor, while Ligand B (-1.089) is better, though still not ideal.
11. **hERG:** Both are very low risk (0.236 and 0.195 respectively).
12. **Cl_mic:** Ligand A (31.415) is better than Ligand B (39.353), suggesting better metabolic stability.
13. **t1/2:** Ligand A (34.076) is significantly better than Ligand B (14.851).
14. **Pgp:** Both are low efflux (0.332 and 0.033 respectively), which is favorable. Ligand B is slightly better.
15. **Affinity:** Ligand B (-7.0) has a significantly better binding affinity than Ligand A (-5.3). This is a substantial advantage, potentially outweighing some ADME concerns.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are crucial. Ligand B excels in affinity and has a good TPSA. While its logP is a bit low, the strong binding affinity could compensate. The significantly lower DILI risk and better BBB penetration of Ligand B are also highly desirable. Although Ligand A has better metabolic stability (Cl_mic and t1/2), the superior binding affinity of Ligand B is a major factor.
**Conclusion:**
Despite Ligand A's better metabolic stability, Ligand B's significantly stronger binding affinity, lower DILI risk, and better BBB penetration make it the more promising drug candidate for ADRB2.
Output:
0
2025-04-17 19:09:22,525 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 drug candidates. ADRB2 is a GPCR, so we'll prioritize logP, Pgp, TPSA, BBB, and affinity.
**Ligand A:**
* **MW:** 354.447 Da - Good, within the ideal range.
* **TPSA:** 77.1 A2 - Good, well below the 140 A2 threshold.
* **logP:** 0.919 - Slightly low, but acceptable. Could potentially impact permeability.
* **HBD:** 1 - Good.
* **HBA:** 5 - Good.
* **QED:** 0.656 - Good, above the 0.5 threshold.
* **DILI:** 11.4 - Excellent, very low risk.
* **BBB:** 73.129 - Good, though not exceptionally high, it's acceptable for a non-CNS focused ADRB2 target.
* **Caco-2:** -4.727 - Very poor permeability. A major concern.
* **Solubility:** -1.658 - Poor solubility.
* **hERG:** 0.158 - Excellent, very low risk.
* **Cl_mic:** 34.512 mL/min/kg - Moderate clearance, could lead to faster metabolism.
* **t1/2:** 15.007 hours - Good.
* **Pgp:** 0.012 - Excellent, low efflux.
* **Affinity:** -6.7 kcal/mol - Very good binding affinity.
**Ligand B:**
* **MW:** 362.417 Da - Good, within the ideal range.
* **TPSA:** 67.87 A2 - Excellent, well below the 140 A2 threshold.
* **logP:** 1.296 - Acceptable, slightly better than Ligand A.
* **HBD:** 1 - Good.
* **HBA:** 4 - Good.
* **QED:** 0.595 - Good, above the 0.5 threshold.
* **DILI:** 20.047 - Good, low risk, but higher than Ligand A.
* **BBB:** 94.455 - Excellent, very high BBB penetration.
* **Caco-2:** -4.712 - Very poor permeability, similar to Ligand A.
* **Solubility:** -1.271 - Poor solubility, similar to Ligand A.
* **hERG:** 0.435 - Good, low risk, but higher than Ligand A.
* **Cl_mic:** 16.449 mL/min/kg - Lower clearance, better metabolic stability than Ligand A.
* **t1/2:** 14.892 hours - Good, comparable to Ligand A.
* **Pgp:** 0.036 - Excellent, low efflux, slightly higher than Ligand A.
* **Affinity:** -6.5 kcal/mol - Good binding affinity, slightly weaker than Ligand A.
**Comparison and Decision:**
Both ligands suffer from poor Caco-2 permeability and solubility, which are significant drawbacks. However, Ligand A has a slightly better binding affinity (-6.7 vs -6.5 kcal/mol) and a much lower DILI risk (11.4 vs 20.047). While Ligand B has a better BBB score, this is less critical for a non-CNS target like ADRB2. The slightly better metabolic stability of Ligand B is outweighed by the superior affinity and safety profile of Ligand A. The affinity difference, while not huge, is enough to tip the scales, especially considering the poor permeability of both compounds will likely require formulation strategies to overcome.
Therefore, I prefer Ligand A.
Output:
1
2025-04-17 19:09:22,525 - INFO - Here's my reasoning and the final output:
**Reasoning:**
We are looking for a ligand targeting ADRB2, a GPCR. Therefore, priorities are affinity, logP, Pgp, TPSA, and BBB. Let's compare Ligand A and Ligand B across all parameters:
1. **MW:** Both ligands (346.431 and 352.519 Da) fall within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (87.46) is slightly higher than Ligand B (78.43), but both are below the 140 threshold for oral absorption, and acceptable for a peripheral GPCR like ADRB2.
3. **logP:** Ligand B (2.48) is better than Ligand A (0.858). A logP between 1-3 is optimal, and Ligand A is a bit low, potentially hindering membrane permeability.
4. **HBD/HBA:** Ligand A (2 HBD, 5 HBA) is slightly better than Ligand B (3 HBD, 3 HBA) in terms of maintaining a balance for permeability and solubility.
5. **QED:** Ligand A (0.748) is better than Ligand B (0.616), indicating a more drug-like profile.
6. **DILI:** Both ligands have low DILI risk (29.624 and 30.748 percentile), which is good.
7. **BBB:** Ligand A (56.727) has a significantly better BBB penetration score than Ligand B (27.801). While ADRB2 isn't a CNS target, some degree of BBB penetration can be helpful for distribution.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
9. **Solubility:** Ligand A (-1.497) has better solubility than Ligand B (-3.559).
10. **hERG:** Ligand A (0.169) has a much lower hERG inhibition liability than Ligand B (0.478), which is a significant advantage for cardiovascular safety.
11. **Cl_mic:** Ligand A (14.387) has a lower microsomal clearance than Ligand B (51.848), indicating better metabolic stability.
12. **t1/2:** Ligand B (3.734) has a longer in vitro half-life than Ligand A (-2.757).
13. **Pgp:** Ligand A (0.023) has much lower P-gp efflux liability than Ligand B (0.176), which is favorable for bioavailability.
14. **Affinity:** Ligand A (-6.8 kcal/mol) has a slightly better binding affinity than Ligand B (-6.3 kcal/mol). While the difference is not huge, it's still a positive factor.
**Overall Assessment:**
Ligand A is clearly the better candidate. It has a better QED score, significantly lower hERG risk, lower P-gp efflux, better solubility, better metabolic stability, and a slightly better binding affinity. While Ligand B has a slightly better logP and half-life, the advantages of Ligand A in safety and pharmacokinetic properties outweigh these minor differences.
**Output:**
1
2025-04-17 19:09:22,525 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (344.46 & 346.48 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (78.43) is better than Ligand B (86.88). Both are below 140, but lower TPSA generally favors absorption.
3. **logP:** Both ligands have excellent logP values (3.04 & 2.94), falling within the optimal 1-3 range. No clear advantage.
4. **HBD:** Both ligands have 3 H-bond donors, which is within the acceptable limit of 5.
5. **HBA:** Both ligands have 3 H-bond acceptors, which is within the acceptable limit of 10.
6. **QED:** Both ligands have good QED scores (0.603 & 0.663), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (24.54) has a significantly lower DILI risk than Ligand B (48.82). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (48.39) has a lower BBB penetration than Ligand B (56.88). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be beneficial or at least not detrimental.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.05 & -4.99), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Both ligands have negative solubility values (-3.46 & -3.74), indicating very poor aqueous solubility. This is a major drawback for both.
11. **hERG:** Both ligands show low hERG inhibition liability (0.62 & 0.36), which is good. Ligand B is slightly better.
12. **Cl_mic:** Ligand B (33.81) has significantly lower microsomal clearance than Ligand A (74.46), indicating better metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand B (-5.73) has a slightly longer in vitro half-life than Ligand A (-15.14), though both are negative and suggest rapid metabolism.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.15 & 0.20). No significant difference.
15. **Affinity:** Both ligands have very similar and excellent binding affinities (-5.7 & -5.8 kcal/mol). The difference is negligible.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Both ligands perform well on logP and Pgp. Affinity is essentially identical. TPSA is better for Ligand A. The biggest differences lie in DILI and Cl_mic. Ligand A has a much lower DILI risk, while Ligand B has better metabolic stability. Given the potential severity of liver toxicity, a lower DILI risk is generally prioritized, *especially* early in development. The poor Caco-2 and solubility for both are concerning, but can be addressed with formulation strategies.
**Conclusion:**
Despite Ligand B's better metabolic stability, the significantly lower DILI risk associated with Ligand A makes it the more promising candidate. The similar affinities and acceptable (though not ideal) other parameters support this decision.
Output:
1
2025-04-17 19:09:22,525 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (364.511 and 366.403 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (58.64) is significantly better than Ligand B (136.06). For a GPCR, lower TPSA is generally preferred for better permeability. Ligand B is above the 140 threshold for good oral absorption, which is a concern.
3. **logP:** Ligand A (3.545) is within the optimal 1-3 range. Ligand B (-0.091) is *below* 1, which is a significant drawback. Low logP can severely hinder membrane permeability and bioavailability.
4. **HBD:** Ligand A (1) is good. Ligand B (2) is acceptable but slightly less favorable.
5. **HBA:** Ligand A (4) is good. Ligand B (9) is getting towards the upper limit and could potentially impact permeability.
6. **QED:** Both ligands (0.645 and 0.644) are very similar and above the 0.5 threshold, indicating good drug-likeness.
7. **DILI:** Ligand A (42.536) is better than Ligand B (86.002). Lower DILI risk is always preferred.
8. **BBB:** Ligand A (89.996) is much better than Ligand B (56.534). While ADRB2 isn't exclusively a CNS target, some CNS exposure can occur, and higher BBB penetration is generally a positive attribute.
9. **Caco-2:** Ligand A (-4.754) is better than Ligand B (-5.363), both are negative values, so this is not a major deciding factor.
10. **Solubility:** Ligand A (-3.708) is better than Ligand B (-2.665). Both are negative, indicating poor solubility.
11. **hERG:** Ligand A (0.86) is much better than Ligand B (0.155). Lower hERG inhibition is crucial to avoid cardiotoxicity, a major concern for cardiovascular targets.
12. **Cl_mic:** Ligand A (108.082) is higher than Ligand B (4.993), indicating faster metabolic clearance and lower metabolic stability. This is a negative for Ligand A.
13. **t1/2:** Ligand A (42.949) is better than Ligand B (-2.395). Longer half-life is generally preferred.
14. **Pgp:** Ligand A (0.66) is better than Ligand B (0.016). Lower P-gp efflux is desirable for better bioavailability.
15. **Binding Affinity:** Ligand A (-6.4) is significantly better than Ligand B (3.0). A difference of over 3 kcal/mol is substantial and can often outweigh minor ADME liabilities.
**Overall Assessment:**
Ligand A has a much more favorable profile overall, particularly regarding TPSA, logP, BBB, hERG, and binding affinity. While its metabolic clearance is higher, the significantly stronger binding affinity and better ADME properties (especially logP and hERG) make it a much more promising candidate. Ligand B's very low logP is a major red flag, likely leading to poor absorption.
Output:
1
2025-04-17 19:09:22,525 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [363.439, 100.55 , 2.472, 3. , 6. , 0.685, 84.102, 49.903, -4.821, -3.567, 0.298, 77.238, 24.208, 0.415, -7.1 ]
**Ligand B:** [345.443, 54.78 , 1.774, 0. , 4. , 0.817, 37.185, 74.758, -4.308, -1.686, 0.49 , 33.15 , 11.233, 0.273, -6.6 ]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, Affinity, and BBB):
1. **MW:** Both are within the acceptable 200-500 Da range. Ligand B (345.443) is slightly preferred due to being lower.
2. **TPSA:** Ligand A (100.55) is higher than Ligand B (54.78). Ligand B is significantly better here, falling well below the 140 A^2 threshold for oral absorption and being more favorable for potential CNS penetration.
3. **logP:** Both are within the optimal 1-3 range. Ligand A (2.472) is slightly higher, which isn't a major concern, but Ligand B (1.774) is closer to the ideal.
4. **HBD/HBA:** Ligand A has 3 HBD and 6 HBA, while Ligand B has 0 HBD and 4 HBA. Ligand B is better as it has fewer HBDs, which can improve permeability.
5. **QED:** Both have good QED scores (A: 0.685, B: 0.817), indicating drug-likeness. Ligand B is slightly better.
6. **DILI:** Ligand A (84.102) has a considerably higher DILI risk than Ligand B (37.185). This is a significant negative for Ligand A.
7. **BBB:** Ligand B (74.758) has a better BBB percentile than Ligand A (49.903). While ADRB2 isn't necessarily a CNS target, better BBB penetration can sometimes correlate with improved distribution.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale isn't specified, so it's hard to interpret.
9. **Solubility:** Both have negative solubility values, which is also unusual. Again, the scale isn't specified.
10. **hERG:** Both have low hERG inhibition liability, which is good.
11. **Cl_mic:** Ligand B (33.15) has lower microsomal clearance than Ligand A (77.238), suggesting better metabolic stability.
12. **t1/2:** Ligand A (24.208) has a longer in vitro half-life than Ligand B (11.233), which is a positive.
13. **Pgp:** Ligand B (0.273) has lower P-gp efflux liability than Ligand A (0.415), which is favorable for bioavailability and potential CNS exposure.
14. **Affinity:** Ligand A (-7.1 kcal/mol) has a slightly better binding affinity than Ligand B (-6.6 kcal/mol). This is a 0.5 kcal/mol difference, which is significant but not overwhelming.
**Overall Assessment:**
Ligand B is the stronger candidate. While Ligand A has slightly better affinity and half-life, Ligand B excels in crucial ADME properties: significantly lower DILI risk, better TPSA, lower Pgp efflux, and lower microsomal clearance. These factors are particularly important for a GPCR target, where good bioavailability and reduced off-target effects are critical. The better BBB penetration is also a plus. The slight difference in binding affinity is outweighed by the superior ADME profile of Ligand B.
Output:
0
2025-04-17 19:09:22,525 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.463 and 364.339 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (83.36) is slightly higher than Ligand B (78.43), but both are well below the 140 threshold for good oral absorption.
3. **logP:** Both ligands have good logP values (2.427 and 1.687), falling within the optimal 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Ligand A (1) has fewer H-bond donors than Ligand B (3). Lower is generally preferred for permeability, giving a slight edge to A.
5. **HBA:** Ligand A (5) has more H-bond acceptors than Ligand B (3). While both are within acceptable limits, B is preferable.
6. **QED:** Ligand A (0.716) has a better QED score than Ligand B (0.615), indicating a more drug-like profile.
7. **DILI:** Ligand A (35.556) has a significantly lower DILI risk than Ligand B (41.45), which is a substantial advantage.
8. **BBB:** Ligand A (64.831) has a better BBB penetration score than Ligand B (56.301). While ADRB2 is a cardiovascular target, some CNS penetration can occur, and higher BBB is generally favorable.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.023 and -4.984), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Both ligands have negative solubility values (-1.804 and -2.46), indicating very poor aqueous solubility. This is a major drawback for both.
11. **hERG:** Ligand A (0.187) has a much lower hERG inhibition liability than Ligand B (0.682), which is a critical safety advantage.
12. **Cl_mic:** Ligand A (24.188) has a lower microsomal clearance than Ligand B (48.686), indicating better metabolic stability.
13. **t1/2:** Ligand A (14.903) has a longer in vitro half-life than Ligand B (-48.36), which is a significant advantage.
14. **Pgp:** Ligand A (0.036) has much lower P-gp efflux liability than Ligand B (0.103), suggesting better bioavailability.
15. **Binding Affinity:** Ligand B (-8.5) has a significantly stronger binding affinity than Ligand A (-6.9). This is a substantial advantage that could potentially outweigh some of the ADME drawbacks.
**Overall Assessment:**
Ligand B has a much better binding affinity, which is a major positive. However, it suffers from significantly worse DILI risk, hERG inhibition, Pgp efflux, and metabolic stability. Both ligands have poor Caco-2 and solubility. Ligand A demonstrates a more balanced profile with better safety (DILI, hERG), ADME properties (Cl_mic, t1/2, Pgp), and a good QED score. While the affinity is lower, the overall risk/benefit profile of Ligand A is more favorable. The poor permeability and solubility are concerns for both, but can be addressed with formulation strategies.
Therefore, I would choose Ligand A.
Output:
1
2025-04-17 19:09:22,525 - INFO - Here's my reasoning and final output for the ligand preference:
**Reasoning:**
We are looking for a ligand for ADRB2, a cardiovascular GPCR. Therefore, the key properties to prioritize are logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB (though less critical for a cardiovascular target than a CNS one).
Let's compare Ligand A and Ligand B across these and other relevant parameters:
1. **Molecular Weight:** Both ligands (346.446 and 346.471 Da) fall comfortably within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (24.94) is significantly better than Ligand B (53.76). Lower TPSA generally favors better cell permeability and oral absorption, crucial for a cardiovascular drug. Ligand A is well below the 140 threshold, while B is approaching it.
3. **logP:** Ligand A (2.25) is within the optimal 1-3 range. Ligand B (3.868) is higher, potentially leading to solubility issues and off-target interactions.
4. **H-Bond Donors/Acceptors:** Both ligands have acceptable HBD/HBA counts (A: 0/4, B: 0/3) within the recommended limits.
5. **QED:** Both are similar (A: 0.583, B: 0.556) and above the 0.5 threshold, indicating good drug-likeness.
6. **DILI:** Ligand A (12.253) has a much lower DILI risk than Ligand B (49.981). This is a significant advantage for A.
7. **BBB:** Ligand A (90.772) has a higher BBB penetration potential than Ligand B (65.374), but this is less critical for a cardiovascular target.
8. **Caco-2 Permeability:** Both have negative values (-4.308 and -4.654), which is unusual and difficult to interpret without context. However, the magnitude is similar.
9. **Aqueous Solubility:** Both have negative values (-1.78 and -2.992), suggesting poor solubility. Ligand B is worse.
10. **hERG Inhibition:** Ligand A (0.987) has a slightly higher hERG risk than Ligand B (0.608), but both are reasonably low.
11. **Microsomal Clearance:** Ligand A (25.461) has a lower clearance than Ligand B (74.754), indicating better metabolic stability.
12. **In vitro Half-Life:** Ligand A (-31.087) has a significantly longer half-life than Ligand B (20.815).
13. **P-gp Efflux:** Ligand A (0.57) has a lower P-gp efflux liability than Ligand B (0.726), which is favorable.
14. **Binding Affinity:** Ligand A (-7.5 kcal/mol) has a stronger binding affinity than Ligand B (-6.2 kcal/mol). This is a substantial difference (1.3 kcal/mol), and outweighs many of the minor ADME drawbacks of Ligand A.
**Conclusion:**
Ligand A is the superior candidate. It has a significantly better TPSA, DILI risk, metabolic stability, half-life, P-gp efflux, and binding affinity. While Ligand B has a slightly lower hERG risk and a more favorable logP, the advantages of Ligand A are more substantial, especially the strong binding affinity and reduced toxicity risk.
**Output:**
1
2025-04-17 19:09:22,526 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 drug candidates. ADRB2 is a GPCR, so we'll prioritize logP, Pgp, TPSA, and affinity, alongside general drug-like properties.
**Ligand A:**
* **MW:** 357.357 Da - Acceptable.
* **TPSA:** 110.52 - Acceptable, but pushing the limit for good oral absorption.
* **logP:** 2.192 - Good, within the optimal range.
* **HBD:** 3 - Acceptable.
* **HBA:** 4 - Acceptable.
* **QED:** 0.75 - Excellent, highly drug-like.
* **DILI:** 63.086 - Moderate risk, a concern.
* **BBB:** 68.399 - Moderate, not ideal for potential CNS effects, but not a primary concern for a cardiovascular target.
* **Caco-2:** -4.982 - Poor permeability.
* **Solubility:** -3.742 - Poor solubility.
* **hERG:** 0.533 - Low risk, good.
* **Cl_mic:** 49.301 - Moderate clearance, could be better.
* **t1/2:** -23.627 - Very long half-life, potentially good.
* **Pgp:** 0.045 - Low efflux, favorable.
* **Affinity:** -7.2 kcal/mol - Excellent binding affinity.
**Ligand B:**
* **MW:** 352.479 Da - Acceptable.
* **TPSA:** 81.75 - Good, well within the acceptable range.
* **logP:** 0.064 - Low, potentially causing permeability issues.
* **HBD:** 2 - Acceptable.
* **HBA:** 4 - Acceptable.
* **QED:** 0.615 - Good, drug-like.
* **DILI:** 5.002 - Very low risk, excellent.
* **BBB:** 57.852 - Low, not relevant for cardiovascular target.
* **Caco-2:** -5.376 - Very poor permeability.
* **Solubility:** -0.753 - Poor solubility.
* **hERG:** 0.189 - Very low risk, excellent.
* **Cl_mic:** -17.205 - Very low clearance, excellent metabolic stability.
* **t1/2:** -12.115 - Long half-life, potentially good.
* **Pgp:** 0.002 - Very low efflux, highly favorable.
* **Affinity:** -5.3 kcal/mol - Good binding affinity, but significantly weaker than Ligand A.
**Comparison and Decision:**
Ligand A has a substantially better binding affinity (-7.2 vs -5.3 kcal/mol). This is a significant advantage for a GPCR target. While Ligand A has a higher DILI risk and slightly worse BBB penetration, the strong affinity is a major driver. Both ligands have poor Caco-2 and solubility, which would need to be addressed in further optimization, but these are formulation challenges rather than fundamental flaws. Ligand B has excellent safety profiles (DILI and hERG) and metabolic stability, but the weaker binding affinity is a critical drawback. Given the GPCR-specific priority on affinity, and the fact that this is an early-stage ranking, I would prioritize the stronger binder.
Output:
1
2025-04-17 19:09:22,526 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [352.519, 69.64, 2.717, 2, 3, 0.772, 14.618, 69.833, -4.564, -2.798, 0.33, 47.074, 3.473, 0.099, -5.9]
**Ligand B:** [345.487, 73.2, 3.172, 1, 3, 0.752, 13.416, 70.686, -4.714, -3.197, 0.518, 42.027, -18.894, 0.095, -6.5]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (345.487) is slightly lower, which could be marginally better for permeability.
2. **TPSA:** Both are reasonably low (A: 69.64, B: 73.2), well under the 140 threshold for oral absorption.
3. **logP:** Both are in the optimal range (A: 2.717, B: 3.172). Ligand B is a bit higher, potentially leading to slightly better membrane permeability, but also a slightly increased risk of off-target interactions.
4. **HBD:** A has 2, B has 1. Both are good.
5. **HBA:** Both have 3, which is good.
6. **QED:** Both are good (A: 0.772, B: 0.752), indicating drug-like properties.
7. **DILI:** Both are relatively low (A: 14.618, B: 13.416), suggesting a low risk of liver injury. B is slightly better.
8. **BBB:** Both are good (A: 69.833, B: 70.686), but not exceptionally high. Since this is a cardiovascular target, BBB penetration isn't *critical*, but it's still a positive. B is slightly better.
9. **Caco-2:** Both are negative, indicating poor permeability. A (-4.564) is slightly better than B (-4.714).
10. **Solubility:** Both are negative, indicating poor solubility. B (-3.197) is slightly better than A (-2.798).
11. **hERG:** Both are very low (A: 0.33, B: 0.518), indicating minimal cardiotoxicity risk. B is slightly higher.
12. **Cl_mic:** A (47.074) has a higher clearance than B (42.027), suggesting lower metabolic stability. This is a significant drawback for A.
13. **t1/2:** B (-18.894) has a much longer half-life than A (3.473). This is a major advantage for B, potentially allowing for less frequent dosing.
14. **Pgp:** Both are very low (A: 0.099, B: 0.095), indicating minimal P-gp efflux.
15. **Affinity:** B (-6.5 kcal/mol) has a slightly better binding affinity than A (-5.9 kcal/mol). While the difference is less than 1.5 kcal/mol, it's still a positive.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Both ligands perform reasonably well on logP and Pgp. TPSA is acceptable for both. The affinity difference is small, but favors B. The biggest difference is in metabolic stability (Cl_mic) and half-life, where Ligand B is significantly better.
**Conclusion:**
Ligand B demonstrates a superior balance of properties, particularly its improved metabolic stability (lower Cl_mic) and significantly longer half-life. While Ligand A has slightly better Caco-2 permeability, the metabolic and PK advantages of B outweigh this.
0
2025-04-17 19:09:22,526 - INFO - Here's my reasoning and the final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, the key priorities are logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB.
Let's compare the ligands property by property:
1. **MW:** Both ligands are within the ideal range (347-357 Da).
2. **TPSA:** Ligand A (80.32) is better than Ligand B (93.9), falling comfortably under the 140 threshold for oral absorption.
3. **logP:** Both ligands have good logP values (1.932 and 1.008), within the optimal 1-3 range. Ligand A is slightly better.
4. **HBD:** Both are acceptable (2 and 1 respectively), below the threshold of 5.
5. **HBA:** Ligand B (6) is slightly higher than Ligand A (4), but both are below the 10 threshold.
6. **QED:** Both have good QED scores (0.662 and 0.799), indicating good drug-like properties.
7. **DILI:** Ligand A (38.387) has a significantly lower DILI risk than Ligand B (58.705), which is a major advantage.
8. **BBB:** Ligand A (73.672) has a better BBB penetration score than Ligand B (60.527), although this is less critical for a cardiovascular target.
9. **Caco-2:** Both have negative values, which is unusual. Assuming these are log scale values, they are similar and suggest poor permeability.
10. **Solubility:** Both have negative values, indicating poor solubility.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.355 and 0.093), which is excellent.
12. **Cl_mic:** Ligand B (39.118) has slightly lower microsomal clearance than Ligand A (43.908), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-28.743) has a significantly longer in vitro half-life than Ligand A (37.166). This is a substantial advantage.
14. **Pgp:** Both have very low Pgp efflux liability (0.106 and 0.084), which is good.
15. **Binding Affinity:** Both ligands have the same binding affinity (-5.6 kcal/mol), so this parameter doesn't differentiate them.
**Overall Assessment:**
Ligand A has advantages in TPSA, logP, DILI risk, and BBB penetration. Ligand B has a significant advantage in in vitro half-life and slightly better metabolic stability. However, the lower DILI risk of Ligand A is a crucial factor, especially for a cardiovascular target where liver toxicity is a concern. The slightly better TPSA and logP of Ligand A also contribute to its potential for better absorption. While the longer half-life of Ligand B is attractive, the DILI risk is a significant drawback.
**Output:**
1
2025-04-17 19:09:22,526 - INFO - Batch 89 complete. Total preferences: 1424
2025-04-17 19:09:22,526 - INFO - Processing batch 90/512...
2025-04-17 19:10:10,582 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A Analysis:**
* **MW:** 381.416 Da - Within the ideal range (200-500).
* **TPSA:** 72.47 - Good, below the 140 threshold for oral absorption.
* **logP:** 3.306 - Optimal, within the 1-3 range.
* **HBD:** 1 - Acceptable, well below the 5 limit.
* **HBA:** 4 - Acceptable, well below the 10 limit.
* **QED:** 0.787 - Excellent, indicating good drug-likeness.
* **DILI:** 55.913 - Acceptable, below the concerning 60 threshold.
* **BBB:** 79.217 - Good, suggesting reasonable potential for CNS penetration, though ADRB2 is primarily cardiovascular, some CNS off-target effects are possible.
* **Caco-2:** -4.732 - Poor permeability. This is a significant drawback.
* **Solubility:** -4.21 - Poor solubility. Another significant drawback.
* **hERG:** 0.669 - Low risk, favorable.
* **Cl_mic:** 39.585 - Moderate clearance. Not ideal, but not terrible.
* **t1/2:** 21.614 - Good in vitro half-life.
* **Pgp:** 0.214 - Low efflux, favorable.
* **Affinity:** -5.7 kcal/mol - Very good binding affinity.
**Ligand B Analysis:**
* **MW:** 375.491 Da - Within the ideal range (200-500).
* **TPSA:** 96.97 - Borderline. Could potentially hinder absorption.
* **logP:** -0.549 - Suboptimal. Likely to have poor membrane permeability.
* **HBD:** 2 - Acceptable.
* **HBA:** 6 - Acceptable.
* **QED:** 0.647 - Good drug-likeness, but slightly lower than Ligand A.
* **DILI:** 48.895 - Very good, low DILI risk.
* **BBB:** 44.552 - Low, not a major concern for a cardiovascular target.
* **Caco-2:** -5.527 - Very poor permeability. A major drawback.
* **Solubility:** -1.06 - Poor solubility, but slightly better than Ligand A.
* **hERG:** 0.133 - Very low risk, excellent.
* **Cl_mic:** -4.259 - Excellent metabolic stability.
* **t1/2:** -8.128 - Excellent in vitro half-life.
* **Pgp:** 0.01 - Very low efflux, favorable.
* **Affinity:** -6.6 kcal/mol - Excellent binding affinity, 0.9 kcal/mol better than Ligand A.
**Comparison and Decision:**
Both ligands have significant drawbacks in terms of permeability (Caco-2) and solubility. However, Ligand B has a substantially better binding affinity (-6.6 vs -5.7 kcal/mol), excellent metabolic stability (Cl_mic), and a very low hERG risk. While its logP is suboptimal, the superior affinity and safety profile are compelling. Ligand A has better TPSA and BBB, but the poor Caco-2 and solubility are major concerns. For a cardiovascular target like ADRB2, the permeability issues of both compounds are critical. However, the significantly improved affinity and metabolic stability of Ligand B, coupled with its lower hERG risk, outweigh the slightly higher TPSA and lower logP.
Therefore, I prefer Ligand B.
Output:
0
2025-04-17 19:10:10,582 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Reasoning:**
Let's systematically compare Ligand A and Ligand B based on the provided parameters and the guidelines, keeping in mind the GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key).
1. **Molecular Weight:** Both ligands (372.372 and 390.893 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (83.12) is significantly better than Ligand B (106). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (1.909) is within the optimal 1-3 range. Ligand B (-0.199) is *below* 1, which is a concern for permeability. This is a substantial negative for Ligand B.
4. **H-Bond Donors:** Both have 3 HBD, which is acceptable.
5. **H-Bond Acceptors:** Ligand A has 5, and Ligand B has 7. Both are within the acceptable limit of 10, but Ligand A is better.
6. **QED:** Ligand A (0.677) is slightly better than Ligand B (0.595), suggesting a more drug-like profile.
7. **DILI:** Ligand B (41.218) has a much lower DILI risk than Ligand A (86.157). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (73.75) has a higher BBB percentile than Ligand B (9.732). While not critical for a cardiovascular target, it's still a slight positive for Ligand A.
9. **Caco-2:** Ligand A (-4.627) has a better Caco-2 permeability than Ligand B (-5.393).
10. **Solubility:** Ligand A (-3.483) has better solubility than Ligand B (-0.805).
11. **hERG:** Ligand A (0.375) has a lower hERG risk than Ligand B (0.118). This is a positive for Ligand A.
12. **Cl_mic:** Ligand B (-28.36) has a *much* lower microsomal clearance than Ligand A (35.614), indicating better metabolic stability. This is a major advantage for Ligand B.
13. **t1/2:** Ligand A (69.445) has a significantly longer in vitro half-life than Ligand B (16.02). This is a strong positive for Ligand A.
14. **Pgp:** Ligand A (0.088) has lower P-gp efflux than Ligand B (0.05).
15. **Binding Affinity:** Ligand A (-6.2 kcal/mol) has a slightly better binding affinity than Ligand B (-5.1 kcal/mol). This 1.1 kcal/mol difference is meaningful.
**Overall Assessment:**
Ligand A has a better binding affinity, solubility, Caco-2 permeability, hERG profile, and half-life. However, Ligand B excels in DILI risk and, crucially, metabolic stability (Cl_mic). Ligand B's logP is a significant concern. The affinity difference between A and B is not large enough to overcome the poor logP of B. The better metabolic stability of B is important, but the poor logP will likely result in poor absorption.
Considering the balance of properties, and prioritizing affinity and ADME properties for a GPCR target, Ligand A is the more promising candidate.
**Output:**
1
2025-04-17 19:10:10,582 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [363.439, 98.25, 1.737, 1, 6, 0.567, 79.372, 60.915, -5.199, -3.037, 0.146, 99.973, -28.449, 0.174, -6.2]
**Ligand B:** [346.471, 58.64, 2.265, 1, 3, 0.777, 14.308, 62.854, -4.761, -2.601, 0.145, 38.899, 9.298, 0.031, -7.8]
Here's a breakdown of the comparison, considering the provided guidelines and GPCR-specific priorities:
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (346.471) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (98.25) is higher than Ligand B (58.64). For a cardiovascular GPCR, TPSA isn't *as* critical as for a CNS target, but lower is still preferred for better absorption. Ligand B is significantly better here.
3. **logP:** Both are within the optimal range (1-3). Ligand B (2.265) is slightly higher, which might offer a slight advantage in membrane permeability.
4. **HBD/HBA:** Both have 1 HBD, which is good. Ligand A has 6 HBA, while Ligand B has 3. Ligand B is preferable here.
5. **QED:** Ligand B (0.777) has a better QED score than Ligand A (0.567), indicating a more drug-like profile.
6. **DILI:** Ligand A (79.372) has a significantly higher DILI risk than Ligand B (14.308). This is a major concern for Ligand A.
7. **BBB:** Both have reasonable BBB penetration, but Ligand B (62.854) is slightly better. Since this is a cardiovascular target, BBB isn't a primary concern, but it's still a positive.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
9. **Solubility:** Both have negative solubility values, which is also unusual and suggests poor solubility. The scale is not specified, so it's difficult to interpret.
10. **hERG:** Both have very low hERG inhibition risk (0.146 and 0.145), which is excellent.
11. **Cl_mic:** Ligand A (99.973) has extremely high microsomal clearance, indicating rapid metabolism. Ligand B (38.899) has much lower clearance, suggesting better metabolic stability. This is a significant advantage for Ligand B.
12. **t1/2:** Ligand A (-28.449) has a very short *in vitro* half-life, consistent with the high clearance. Ligand B (9.298) has a better half-life, though still not ideal.
13. **Pgp:** Both have very low P-gp efflux liability (0.174 and 0.031).
14. **Affinity:** Ligand B (-7.8 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.2 kcal/mol). This is a substantial advantage, potentially outweighing some minor ADME concerns.
**Overall Assessment:**
Ligand B is clearly the more promising candidate. While both have some concerning permeability/solubility values (difficult to interpret without knowing the scale), Ligand B excels in critical areas: significantly lower DILI risk, much better metabolic stability (lower Cl_mic, longer t1/2), a higher QED score, and, most importantly, a substantially stronger binding affinity. The slightly better TPSA and logP values also contribute to its favorability.
0
2025-04-17 19:10:10,583 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (330.431 and 349.45 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (41.99) is significantly better than Ligand B (62.3). ADRB2 is a cardiovascular target, so CNS penetration isn't essential, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (4.357) is slightly higher than Ligand B (2.902). While both are within the acceptable range (1-3), Ligand A is pushing the upper limit.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 2 HBA, Ligand B has 3. Both are acceptable, below the threshold of 10.
6. **QED:** Both ligands have similar QED values (0.73 and 0.746), indicating good drug-likeness.
7. **DILI:** Ligand A (65.917) has a considerably higher DILI risk than Ligand B (18.069). This is a major concern for Ligand A.
8. **BBB:** Ligand B (91.663) has a much higher BBB penetration score than Ligand A (67.933). While not crucial for a cardiovascular target, it doesn't hurt.
9. **Caco-2:** Both have negative Caco-2 values (-4.824 and -4.434). These values are unusual and suggest poor permeability. However, the values are very close.
10. **Solubility:** Ligand B (-2.733) has better solubility than Ligand A (-5.09). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.754) has a slightly higher hERG risk than Ligand B (0.453), but both are reasonably low.
12. **Cl_mic:** Ligand B (62.338) has a lower microsomal clearance than Ligand A (49.786), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-1.4) has a longer in vitro half-life than Ligand A (-4.414).
14. **Pgp:** Ligand A (0.362) has lower P-gp efflux than Ligand B (0.083), which is favorable.
15. **Binding Affinity:** Ligand A (-7.6) has a significantly stronger binding affinity than Ligand B (-6.9). This is a 0.7 kcal/mol difference, which is substantial.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has a better logP and Pgp, and a *much* better affinity. However, the high DILI risk for Ligand A is a major drawback. The better metabolic stability and solubility of Ligand B are also significant advantages.
**Overall Assessment:**
The significantly stronger binding affinity of Ligand A is very attractive. However, the substantially higher DILI risk is a serious concern that outweighs the benefits of slightly better logP and Pgp. Ligand B, while having a weaker affinity, presents a much safer profile with a significantly lower DILI risk, better solubility, and improved metabolic stability. Given the cardiovascular context, minimizing toxicity is paramount.
Output:
0
2025-04-17 19:10:10,583 - INFO - Here's my reasoning and final decision:
**Reasoning:**
We are evaluating two ligands for the ADRB2 receptor, a cardiovascular GPCR. Therefore, key priorities are logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB (though less critical for a cardiovascular target).
Let's compare the ligands property by property:
1. **MW:** Both are within the ideal range (200-500 Da). A (349.435) is slightly preferred.
2. **TPSA:** A (102.48) is better than B (111.63). Both are acceptable, but lower TPSA generally favors permeability.
3. **logP:** A (0.759) is good, while B (-0.061) is a bit low. A higher logP is generally preferred for GPCR ligands to facilitate membrane interactions.
4. **HBD:** A (2) is preferable to B (3). Lower HBDs can improve permeability.
5. **HBA:** A (6) is preferable to B (7). Similar reasoning as HBD.
6. **QED:** A (0.781) is better than B (0.573), indicating a more drug-like profile.
7. **DILI:** A (24.816) is significantly better than B (37.844). Lower DILI risk is crucial.
8. **BBB:** A (83.366) is much better than B (27.801). While not a primary concern for a cardiovascular target, higher BBB is still a positive attribute.
9. **Caco-2:** A (-4.898) is better than B (-5.857), indicating better absorption.
10. **Solubility:** A (-2.258) is better than B (-1.207), suggesting better aqueous solubility.
11. **hERG:** Both are low (A: 0.408, B: 0.232), indicating low cardiotoxicity risk. B is slightly better.
12. **Cl_mic:** A (-8.425) is much better than B (-12.279), meaning A has better metabolic stability.
13. **t1/2:** A (12.464) is better than B (-3.019). A longer half-life is generally desirable.
14. **Pgp:** Both are very low (A: 0.028, B: 0.038), indicating minimal P-gp efflux.
15. **Binding Affinity:** A (-6.1 kcal/mol) is slightly weaker than B (-6.6 kcal/mol). However, the difference is not large enough to outweigh the significant ADME advantages of ligand A.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical ADME properties (TPSA, logP, DILI, BBB, solubility, metabolic stability, half-life, QED). While Ligand B has a slightly better binding affinity, the superior ADME profile of Ligand A makes it a more promising drug candidate, especially considering the need for good bioavailability and reduced toxicity for a cardiovascular drug.
**Output:**
1
2025-04-17 19:10:10,583 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (349.383 Da) is slightly lower, which is generally favorable for permeability.
**2. TPSA:** Ligand A (82.14) is better than Ligand B (41.13). Lower TPSA generally correlates with better membrane permeability, crucial for GPCR ligands.
**3. logP:** Ligand A (2.78) is optimal, while Ligand B (4.736) is pushing the upper limit and could lead to solubility issues or off-target interactions.
**4. H-Bond Donors:** Ligand A (0) is preferable to Ligand B (2). Fewer H-bond donors generally improve membrane permeability.
**5. H-Bond Acceptors:** Ligand A (6) is better than Ligand B (1).
**6. QED:** Both ligands have good QED scores (A: 0.6, B: 0.742), indicating generally drug-like properties.
**7. DILI:** Ligand A (69.756) has a higher DILI risk than Ligand B (38.852), which is a concern. However, the difference isn't drastic.
**8. BBB:** Both ligands have good BBB penetration (A: 80.69, B: 89.066). While ADRB2 isn't a CNS target, some peripheral exposure is still desirable.
**9. Caco-2 Permeability:** Ligand A (-3.741) is better than Ligand B (-4.696).
**10. Aqueous Solubility:** Ligand A (-3.373) is better than Ligand B (-5.511).
**11. hERG Inhibition:** Ligand A (0.203) has a much lower hERG inhibition risk than Ligand B (0.875), a critical safety parameter.
**12. Microsomal Clearance:** Ligand B (79.622) has lower clearance than Ligand A (88.001), suggesting better metabolic stability.
**13. In vitro Half-Life:** Ligand B (71.101) has a much longer half-life than Ligand A (-31.856).
**14. P-gp Efflux:** Ligand A (0.075) has lower P-gp efflux than Ligand B (0.493), which is favorable for bioavailability.
**15. Binding Affinity:** Ligand B (-7.7) has a slightly better binding affinity than Ligand A (-7.0), but the difference is less than 1.5 kcal/mol.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity) and general drug-like properties, Ligand A is the more promising candidate. While Ligand B has slightly better affinity and metabolic stability, Ligand A excels in crucial areas like TPSA, logP, hERG risk, solubility, and P-gp efflux. The lower hERG risk for Ligand A is particularly important, as cardiotoxicity is a significant concern for cardiovascular drugs. The DILI risk for Ligand A is higher, but manageable.
Output:
1
2025-04-17 19:10:10,583 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (365.5) is slightly higher than Ligand B (348.5), but both are acceptable.
2. **TPSA:** Ligand A (87.3) is better than Ligand B (59.1). For a GPCR, lower TPSA is generally preferred for better permeability, but 87.3 is still reasonable.
3. **logP:** Ligand A (1.986) is within the optimal range, while Ligand B (4.192) is pushing the upper limit. High logP can lead to solubility issues and off-target effects. This favors Ligand A.
4. **HBD:** Ligand A (3) and Ligand B (2) are both acceptable.
5. **HBA:** Ligand A (4) and Ligand B (5) are both acceptable.
6. **QED:** Both ligands have good QED scores (A: 0.69, B: 0.774), indicating good drug-like properties.
7. **DILI:** Both ligands have similar, acceptable DILI risk (A: 37.9, B: 38.9).
8. **BBB:** Ligand B (92.2) has significantly better BBB penetration than Ligand A (52.0). While ADRB2 isn't strictly a CNS target, some CNS exposure can be beneficial or at least not detrimental, and minimizing off-target effects is always good.
9. **Caco-2:** Ligand A (-5.165) and Ligand B (-4.772) are both negative, which is unusual. Lower values suggest poor permeability. However, the difference isn't huge.
10. **Solubility:** Ligand A (-2.48) has better solubility than Ligand B (-5.205). Solubility is crucial for bioavailability.
11. **hERG:** Ligand A (0.192) has a much lower hERG risk than Ligand B (0.848). This is a significant advantage for Ligand A, as hERG inhibition can lead to cardiotoxicity.
12. **Cl_mic:** Ligand B (71.591) has a higher microsomal clearance than Ligand A (34.24), indicating faster metabolism and potentially lower *in vivo* exposure. This favors Ligand A.
13. **t1/2:** Ligand B (47.624) has a longer half-life than Ligand A (18.831). Longer half-life is generally desirable.
14. **Pgp:** Ligand A (0.06) has lower P-gp efflux than Ligand B (0.425). Lower P-gp efflux is preferable for better bioavailability.
15. **Affinity:** Ligand A (-6.0) has a slightly better binding affinity than Ligand B (-4.2). A difference of 1.8 kcal/mol is substantial and can outweigh some ADME drawbacks.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has a better logP, lower Pgp efflux, and significantly better affinity. While Ligand B has better BBB penetration, the superior affinity and safety profile (lower hERG, better solubility, lower Cl_mic) of Ligand A are more important.
**Conclusion:**
Considering the balance of properties, particularly the strong affinity, favorable safety profile (hERG), and better metabolic stability of Ligand A, it is the more promising drug candidate.
Output:
1
2025-04-17 19:10:10,583 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, priorities are logP, TPSA, Pgp, affinity, and to a lesser extent, BBB.
* **Molecular Weight:** Both ligands (350.48 and 376.44 Da) fall within the ideal 200-500 Da range.
* **TPSA:** Ligand A (49.41) is significantly better than Ligand B (133.91). A TPSA under 140 is good for oral absorption, but under 90 is preferable for GPCRs, and A is closer.
* **logP:** Ligand A (3.199) is optimal (1-3). Ligand B (-1.755) is too low, potentially hindering membrane permeability.
* **H-Bond Donors/Acceptors:** Ligand A (1 HBD, 2 HBA) is better than Ligand B (3 HBD, 6 HBA). Lower counts generally improve permeability.
* **QED:** Ligand A (0.828) is excellent, indicating high drug-likeness. Ligand B (0.482) is below the 0.5 threshold, raising concerns.
* **DILI:** Ligand B (47.654) has a higher DILI risk than Ligand A (17.449), but both are reasonably acceptable.
* **BBB:** Ligand A (89.104) has a better BBB score than Ligand B (51.454). While not a CNS target, some BBB penetration can be beneficial for distribution.
* **Caco-2:** Ligand A (-4.834) and Ligand B (-5.441) both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
* **Solubility:** Ligand A (-4.44) and Ligand B (-1.664) both have negative solubility values, also difficult to interpret without knowing the scale.
* **hERG:** Ligand A (0.72) is better than Ligand B (0.106), indicating lower cardiotoxicity risk.
* **Cl_mic:** Ligand B (-5.051) has a negative clearance, which is unusual and likely indicates very high metabolic stability. Ligand A (21.563) is moderate.
* **t1/2:** Ligand B (-42.038) has a very long half-life, which is positive. Ligand A (6.323) is moderate.
* **Pgp:** Ligand A (0.158) has lower P-gp efflux liability than Ligand B (0.004), which is preferable.
* **Binding Affinity:** Ligand A (-8.1 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.0 kcal/mol). This is a substantial advantage, exceeding the 1.5 kcal/mol threshold.
**Conclusion:**
Ligand A is clearly superior. It has better logP, TPSA, QED, hERG, and, most importantly, a much stronger binding affinity. While Ligand B has a potentially advantageous (but unusual) negative clearance and very long half-life, the significant drawbacks in logP, TPSA, and affinity outweigh these benefits. The stronger affinity of Ligand A is likely to be crucial for efficacy.
**Output:**
1
2025-04-17 19:10:10,584 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (355.36 and 359.42 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (46.61) is significantly better than Ligand B (79.26). For a GPCR, lower TPSA is generally preferred for better permeability. Ligand B is quite high, potentially hindering absorption.
**3. logP:** Ligand A (2.838) is within the optimal 1-3 range. Ligand B (0.767) is a bit low, potentially leading to poor membrane permeability.
**4. H-Bond Donors:** Ligand A (0) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
**5. H-Bond Acceptors:** Ligand A (3) is better than Ligand B (5). Similar to HBDs, lower HBA counts are generally favorable.
**6. QED:** Both ligands have similar QED values (0.603 vs 0.647), indicating good drug-likeness.
**7. DILI:** Both ligands have acceptable DILI risk (32.49 vs 35.98).
**8. BBB:** Ligand A (97.64) shows significantly better BBB penetration than Ligand B (65.41). While ADRB2 is a cardiovascular target, some CNS exposure can be relevant for off-target effects or potential central modulation.
**9. Caco-2 Permeability:** Both are poor (-4).
**10. Aqueous Solubility:** Ligand A (-2.961) is better than Ligand B (-1.542), although both are quite poor.
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (0.6 and 0.253).
**12. Microsomal Clearance:** Ligand A (81.84) has higher clearance than Ligand B (28.00). This suggests Ligand B is more metabolically stable, a positive attribute.
**13. In vitro Half-Life:** Ligand B (19.86) has a significantly longer half-life than Ligand A (-15.74). This is a major advantage for dosing convenience.
**14. P-gp Efflux:** Both ligands have low P-gp efflux (0.226 and 0.021), which is good.
**15. Binding Affinity:** Ligand B (-7.2) has a slightly better binding affinity than Ligand A (-6.3). This is a 0.9 kcal/mol difference, which is significant, but needs to be weighed against other factors.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand A is better in terms of TPSA, logP, and BBB penetration. Ligand B has a better affinity and half-life, but its high TPSA and low logP are concerning. The slightly better affinity of Ligand B is not enough to overcome the permeability issues.
Output:
1
2025-04-17 19:10:10,584 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.475 and 350.503 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (70.08 and 69.64) are below the 140 A^2 threshold for good oral absorption, and acceptable for a cardiovascular GPCR. Again, no major difference.
3. **logP:** Ligand A (1.273) is slightly better than Ligand B (2.637). While both are within the optimal 1-3 range, Ligand A is closer to the lower end, potentially reducing off-target effects. Ligand B is getting a bit higher, which could lead to solubility issues.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (4) is preferable to Ligand B (3). Similar to HBD, lower HBA is generally favorable.
6. **QED:** Both ligands have good QED scores (0.635 and 0.766), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (18.651) has a significantly lower DILI risk than Ligand B (24.855). This is a crucial advantage, as minimizing liver toxicity is paramount.
8. **BBB:** Ligand B (68.98) has a higher BBB penetration percentile than Ligand A (48.003). However, since ADRB2 is primarily a cardiovascular target, high BBB penetration is *not* a priority.
9. **Caco-2:** Ligand A (-4.179) and Ligand B (-4.496) are both negative, which is unusual. A higher value is better, but the values are so low that it is hard to discern a meaningful difference.
10. **Solubility:** Ligand A (-1.836) is better than Ligand B (-2.894). Higher solubility is important for bioavailability.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.464 and 0.285). This is excellent.
12. **Cl_mic:** Both ligands have similar microsomal clearance (28.327 and 28.959 mL/min/kg).
13. **t1/2:** Ligand B (-4.39) has a longer in vitro half-life than Ligand A (-1.486). This is a positive attribute.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.164 and 0.095).
15. **Binding Affinity:** Ligand B (-9.0) has a significantly stronger binding affinity than Ligand A (-5.5). This is a substantial advantage, potentially outweighing some of the ADME drawbacks of Ligand B.
**Overall Assessment:**
While Ligand B has a better binding affinity and half-life, Ligand A demonstrates a superior safety profile with a much lower DILI risk and better solubility. Considering the target is a cardiovascular GPCR (ADRB2), BBB penetration is not a major concern. The stronger binding of Ligand B is attractive, but the lower DILI risk of Ligand A is a critical advantage. The slight improvements in logP, HBD, and HBA for Ligand A also contribute to a more balanced profile.
Output:
1
2025-04-17 19:10:10,584 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.475 and 361.389 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (78.51) is significantly better than Ligand B (96.53). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (1.445 and 1.033), falling within the optimal 1-3 range. Ligand B is slightly lower, potentially impacting permeability a bit more, but both are acceptable.
4. **HBD:** Ligand A (2) is preferable to Ligand B (3). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (4). Similar rationale as HBD.
6. **QED:** Ligand A (0.762) is much better than Ligand B (0.4). A higher QED suggests a more drug-like profile.
7. **DILI:** Ligand A (17.759) has a significantly lower DILI risk than Ligand B (31.563). This is a crucial advantage, as liver toxicity is a major concern.
8. **BBB:** Ligand B (80.458) has a higher BBB penetration than Ligand A (62.97). While ADRB2 is not a CNS target, some peripheral distribution can be aided by moderate BBB penetration. However, this is a lower priority.
9. **Caco-2:** Ligand A (-4.994) is better than Ligand B (-5.524). This suggests better intestinal absorption for Ligand A.
10. **Solubility:** Ligand A (-2.616) is better than Ligand B (-2.367). Better solubility aids formulation and bioavailability.
11. **hERG:** Both ligands have low hERG inhibition liability (0.125 and 0.246), indicating a low risk of cardiotoxicity. No clear advantage.
12. **Cl_mic:** Ligand B (-8.408) has significantly lower microsomal clearance than Ligand A (40.771). This suggests better metabolic stability for Ligand B.
13. **t1/2:** Ligand A (-13.66) has a much longer in vitro half-life than Ligand B (1.279). This is a significant advantage, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.025 and 0.022). No clear advantage.
15. **Binding Affinity:** Ligand B (-7.1) has a slightly better binding affinity than Ligand A (-6.0). This is a 1.1 kcal/mol difference, which is significant, but needs to be weighed against other factors.
**Overall Assessment:**
Ligand B has a better binding affinity and metabolic stability, but Ligand A excels in nearly all ADME properties, particularly DILI risk, QED, solubility, and half-life. The difference in binding affinity (1.1 kcal/mol) is not substantial enough to outweigh the significant advantages of Ligand A in terms of safety (DILI) and drug-likeness (QED). The longer half-life of Ligand A is also a major benefit. For a cardiovascular target, metabolic stability is less critical than avoiding liver toxicity and ensuring good bioavailability.
Output:
1
2025-04-17 19:10:10,584 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (391.896 and 402.969 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (82.53) is slightly higher than Ligand B (78.43), but both are well below the 140 A^2 threshold for good oral absorption.
3. **logP:** Ligand B (3.495) is a bit higher than Ligand A (1.957). While both are within the optimal 1-3 range, Ligand B is approaching the upper limit.
4. **HBD:** Ligand A (2) has fewer HBD than Ligand B (3). Fewer HBD generally favors permeability.
5. **HBA:** Both ligands have the same number of HBA (5), which is acceptable.
6. **QED:** Both ligands have similar QED scores (0.596 and 0.568), indicating good drug-likeness.
7. **DILI:** Ligand A (53.276) has a significantly lower DILI risk than Ligand B (71.772). This is a substantial advantage for Ligand A.
8. **BBB:** Ligand A (55.797) has a better BBB penetration score than Ligand B (33.85). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be beneficial for distribution and off-target effects.
9. **Caco-2:** Ligand A (-4.714) has a more negative Caco-2 value, indicating better intestinal absorption than Ligand B (-5.357).
10. **Solubility:** Ligand A (-2.778) has better aqueous solubility than Ligand B (-3.988).
11. **hERG:** Ligand A (0.376) has a lower hERG inhibition liability than Ligand B (0.678), indicating a lower risk of cardiotoxicity. This is critical for a cardiovascular target.
12. **Cl_mic:** Both ligands have similar microsomal clearance values (61.315 and 62.39 mL/min/kg).
13. **t1/2:** Ligand B (82.609) has a significantly longer in vitro half-life than Ligand A (36.866). This is a potential advantage for Ligand B, suggesting less frequent dosing.
14. **Pgp:** Ligand A (0.165) has lower P-gp efflux liability than Ligand B (0.443), which is favorable for bioavailability.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.3 and -5.3 kcal/mol). Ligand A is slightly better, but the difference is not substantial enough to outweigh other factors.
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. While Ligand B has a slightly better logP and half-life, Ligand A excels in several critical areas: lower DILI risk, better BBB penetration, superior Caco-2 permeability, improved solubility, and lower hERG inhibition. The lower hERG and DILI are particularly important for a cardiovascular target.
**Conclusion:**
Considering the balance of properties and the specific priorities for a GPCR target, Ligand A is the more promising drug candidate. Its superior safety profile (lower DILI and hERG) and better ADME properties outweigh the slightly longer half-life of Ligand B.
Output:
1
2025-04-17 19:10:10,584 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.5 and 340.4 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (49.4) is significantly better than Ligand B (67.2). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand A is well below the 140 threshold, while B is approaching it.
3. **logP:** Ligand A (3.67) is slightly higher than Ligand B (2.06), both are within the optimal 1-3 range, but A is closer to the upper limit.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 2 HBA, while Ligand B has 4. Lower is generally preferred for permeability, giving a slight edge to A.
6. **QED:** Both ligands have good QED scores (0.715 and 0.806), indicating good drug-like properties. No clear advantage.
7. **DILI:** Ligand A (19.4) has a much lower DILI risk than Ligand B (32.0). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (88.9) has a much higher BBB penetration score than Ligand B (55.1). While ADRB2 isn't strictly a CNS target, some CNS exposure can occur, and higher BBB is generally favorable.
9. **Caco-2:** Ligand A (-4.83) and Ligand B (-5.05) are both very negative, indicating poor Caco-2 permeability. This is a concern for both, but similar.
10. **Solubility:** Ligand A (-3.58) and Ligand B (-2.43) are both negative, indicating poor solubility. B is slightly better, but both are problematic.
11. **hERG:** Ligand A (0.56) has a lower hERG risk than Ligand B (0.24). Lower is better, giving an advantage to A.
12. **Cl_mic:** Ligand A (64.9) has a higher microsomal clearance than Ligand B (14.0). This means Ligand B is more metabolically stable, a significant advantage.
13. **t1/2:** Ligand A (-17.9) has a negative half-life, indicating very rapid clearance, while Ligand B (-12.4) is also negative but less so. This is a major disadvantage for Ligand A.
14. **Pgp:** Ligand A (0.39) has a lower P-gp efflux liability than Ligand B (0.04). Lower is better, giving an advantage to A.
15. **Binding Affinity:** Ligand B (-6.5 kcal/mol) has a significantly better binding affinity than Ligand A (-5.0 kcal/mol). This is a substantial advantage for Ligand B, potentially outweighing some of the ADME concerns.
**Overall Assessment:**
Ligand B has a significantly better binding affinity and metabolic stability (lower Cl_mic, better t1/2). These are critical factors for a viable drug candidate. While Ligand A has advantages in DILI, BBB, hERG, and Pgp, the superior affinity of Ligand B is likely to be more impactful. The solubility and Caco-2 permeability are poor for both, requiring formulation work, but the potency advantage of B is more easily addressed than a poor binding profile.
Output:
0
2025-04-17 19:10:10,585 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.547 and 350.463 Da) fall comfortably within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (49.41) is significantly better than Ligand B (78.67). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold, while Ligand B is approaching it.
3. **logP:** Ligand A (3.704) is good, but slightly higher than ideal. Ligand B (1.274) is on the lower side, potentially hindering permeability. For a GPCR, we want a balance, and Ligand A is closer to the optimal range.
4. **HBD:** Both ligands have 1 HBD, which is acceptable.
5. **HBA:** Ligand A has 2 HBA, while Ligand B has 5. Ligand A is preferable here, as fewer HBA generally improves permeability.
6. **QED:** Both ligands have good QED scores (0.725 and 0.766), indicating good drug-like properties.
7. **DILI:** Ligand A (17.72) has a considerably lower DILI risk than Ligand B (24.234). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (79.449) shows better BBB penetration than Ligand B (50.911), though this isn't a high priority for a cardiovascular target.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the magnitude of the negative value is less important than the trend.
10. **Solubility:** Ligand A (-4.31) has slightly better solubility than Ligand B (-0.749).
11. **hERG:** Ligand A (0.619) has a slightly better hERG profile than Ligand B (0.226), meaning lower risk of cardiotoxicity.
12. **Cl_mic:** Ligand B (25.754) has a significantly lower microsomal clearance than Ligand A (88.083), indicating better metabolic stability. This is a strong point for Ligand B.
13. **t1/2:** Ligand A (16.49) has a longer in vitro half-life than Ligand B (8.619). This is a positive for Ligand A.
14. **Pgp:** Ligand A (0.31) has lower P-gp efflux than Ligand B (0.073), which is preferable.
15. **Binding Affinity:** Ligand A (-6.5 kcal/mol) has slightly better binding affinity than Ligand B (-6.1 kcal/mol). Although the difference is small, it's enough to consider, especially given the other favorable properties of Ligand A.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand A emerges as the more promising candidate. While Ligand B has better metabolic stability (lower Cl_mic), Ligand A excels in TPSA, DILI risk, hERG, Pgp efflux, solubility, and has slightly better affinity. The combination of these factors, particularly the lower DILI and better TPSA/Pgp, outweighs the metabolic stability advantage of Ligand B for a cardiovascular target.
Output:
1
2025-04-17 19:10:10,585 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.5 and 351.4 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (69.64) is significantly better than Ligand B (105.68). For a GPCR, lower TPSA is generally preferred for better permeability, and Ligand A is well below the 140 threshold. Ligand B is approaching a less desirable range.
3. **logP:** Ligand A (2.719) is optimal, while Ligand B (0.041) is very low. This is a major drawback for Ligand B, as low logP can severely hinder membrane permeability and bioavailability.
4. **HBD:** Both ligands have 2 HBD, which is within the acceptable limit of 5.
5. **HBA:** Ligand A has 3 HBA, and Ligand B has 7. Ligand B is higher, potentially impacting permeability.
6. **QED:** Ligand A (0.706) is better than Ligand B (0.453), indicating a more drug-like profile.
7. **DILI:** Ligand B (40.675) is slightly higher than Ligand A (6.747), but both are within the acceptable range (<60).
8. **BBB:** Ligand B (78.984) has a slightly better BBB penetration percentile than Ligand A (70.492), but this is less critical for ADRB2 which isn't necessarily a CNS target.
9. **Caco-2:** Ligand A (-4.671) and Ligand B (-5.141) are both negative, indicating poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Ligand A (-2.295) is slightly better than Ligand B (-1.791), but both are negative, suggesting poor solubility.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.408 and 0.316). This is excellent.
12. **Cl_mic:** Ligand A (39.764) has a significantly lower microsomal clearance than Ligand B (16.333), suggesting better metabolic stability.
13. **t1/2:** Ligand A (10.627) has a positive in vitro half-life, while Ligand B (-25.05) has a negative value. This is a significant advantage for Ligand A.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.044 and 0.004). This is good.
15. **Binding Affinity:** Ligand B (-6.6) has a slightly better binding affinity than Ligand A (-6.4), but the difference is small (0.2 kcal/mol).
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand A excels in logP and TPSA, while the affinity difference is minimal. The better metabolic stability (lower Cl_mic and positive t1/2) and QED of Ligand A further strengthen its profile.
**Conclusion:**
Despite the slightly better binding affinity of Ligand B, Ligand A is the superior candidate due to its significantly better logP, TPSA, QED, metabolic stability, and overall more favorable ADME profile. The small affinity difference is easily outweighed by these factors.
Output:
1
2025-04-17 19:10:10,585 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (357.494 and 360.571 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (20.31) is significantly better than Ligand B (33.95). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have similar logP values (4.813 and 4.968), which are slightly above the optimal range of 1-3, but not drastically so. This might suggest potential off-target interactions, but isn't a dealbreaker.
4. **HBD:** Both have 0 HBD, which is good.
5. **HBA:** Ligand A has 2 HBA, while Ligand B has 5. Ligand A is preferable here, as fewer HBA generally leads to better membrane permeability.
6. **QED:** Both ligands have similar QED values (0.696 and 0.666), indicating reasonable drug-likeness.
7. **DILI:** Ligand A (29.973) has a much lower DILI risk than Ligand B (15.626). This is a significant advantage for Ligand A.
8. **BBB:** Both ligands have good BBB penetration (89.531 and 79.062), but Ligand A is better. While not a primary concern for a cardiovascular target, it's still a positive.
9. **Caco-2:** Ligand A (-4.861) is better than Ligand B (-5.148). Higher (less negative) Caco-2 values indicate better absorption.
10. **Solubility:** Ligand A (-4.841) is better than Ligand B (-3.656). Better solubility is always preferred.
11. **hERG:** Both ligands have similar hERG inhibition liability (0.808 and 0.854), indicating a moderate risk.
12. **Cl_mic:** Ligand B (46.406) has significantly lower microsomal clearance than Ligand A (81.186), suggesting better metabolic stability. This is a strong point for Ligand B.
13. **t1/2:** Ligand B (3.785) has a slightly longer in vitro half-life than Ligand A (3.332), which is beneficial.
14. **Pgp:** Both ligands have similar Pgp efflux liability (0.822 and 0.621).
15. **Binding Affinity:** Ligand B (-6.1 kcal/mol) has slightly better binding affinity than Ligand A (-6.6 kcal/mol). While the difference is not huge, it is a factor.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has better TPSA, and comparable logP and Pgp. Ligand B has slightly better affinity and metabolic stability. However, the significantly lower DILI risk of Ligand A, coupled with its better TPSA, solubility, and Caco-2 permeability, outweigh the slight affinity advantage of Ligand B. The lower DILI risk is particularly important for a cardiovascular drug.
**Conclusion:**
Considering the balance of properties, Ligand A is the more promising drug candidate.
Output:
1
2025-04-17 19:10:10,585 - INFO - Batch 90 complete. Total preferences: 1440
2025-04-17 19:10:10,585 - INFO - Processing batch 91/512...
2025-04-17 19:11:02,094 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (337.47 & 350.46 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (37.27) is significantly better than Ligand B (81.08). ADRB2 is a cardiovascular target, not CNS, but lower TPSA generally improves absorption. Ligand A is well below the 140 threshold, while B is approaching it.
3. **logP:** Ligand A (3.78) is optimal, while Ligand B (0.759) is a bit low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs generally correlate with better permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (4). Similar reasoning as HBD.
6. **QED:** Ligand A (0.925) is significantly better than Ligand B (0.71), indicating a more drug-like profile.
7. **DILI:** Ligand A (43.12) is better than Ligand B (8.80), indicating a lower risk of drug-induced liver injury.
8. **BBB:** Not a primary concern for a cardiovascular target. Ligand A (83.06) is better than Ligand B (65.30), but this is less important.
9. **Caco-2:** Ligand A (-5.065) and Ligand B (-4.822) are both negative, which is unusual and suggests poor permeability in this assay. However, the values are similar.
10. **Solubility:** Ligand A (-3.304) is slightly better than Ligand B (-2.13), indicating better aqueous solubility.
11. **hERG:** Ligand A (0.789) is better than Ligand B (0.432), indicating a lower risk of hERG inhibition and cardiotoxicity.
12. **Cl_mic:** Ligand A (32.68) is much better than Ligand B (12.89), suggesting significantly better metabolic stability.
13. **t1/2:** Ligand A (38.49) is better than Ligand B (15.15), indicating a longer in vitro half-life.
14. **Pgp:** Ligand A (0.702) is better than Ligand B (0.021), suggesting lower P-gp efflux and improved bioavailability.
15. **Affinity:** Ligand A (-7.1) is slightly better than Ligand B (-6.9), although the difference is relatively small (0.2 kcal/mol).
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most crucial ADME-Tox properties (QED, DILI, Cl_mic, t1/2, Pgp, hERG, Solubility) and has a slightly better binding affinity. While both ligands have acceptable molecular weights, Ligand A's superior TPSA, logP, and overall drug-likeness profile make it the more promising candidate. The small advantage in binding affinity further supports this conclusion.
Output:
1
2025-04-17 19:11:02,094 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [342.443, 66.71, 2.347, 1, 4, 0.876, 39.201, 70.997, -4.971, -2.558, 0.783, 40.964, -10.568, 0.122, -5.4]
**Ligand B:** [369.437, 55.32, 3.582, 0, 5, 0.714, 51.842, 88.251, -4.353, -4.109, 0.672, 74.865, 18.325, 0.737, -6.2]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal 200-500 Da range. Ligand A (342.443) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (66.71) is slightly higher than Ligand B (55.32), but both are well below the 140 threshold for oral absorption.
3. **logP:** Both have good logP values (A: 2.347, B: 3.582), falling within the 1-3 optimal range. Ligand B is a bit higher, which could potentially lead to some off-target interactions, but isn't a major concern.
4. **HBD:** Ligand A has 1 HBD, and Ligand B has 0. Both are acceptable.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 5. Both are within the acceptable limit of 10.
6. **QED:** Ligand A (0.876) has a better QED score than Ligand B (0.714), indicating a more drug-like profile.
7. **DILI:** Ligand A (39.201) has a lower DILI risk than Ligand B (51.842), which is a significant advantage.
8. **BBB:** Ligand B (88.251) has a significantly higher BBB penetration percentile than Ligand A (70.997). While ADRB2 is a cardiovascular target, some CNS effects are possible with beta-blockers, and higher BBB penetration could be relevant.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. Ligand A (-4.971) is slightly worse than Ligand B (-4.353).
10. **Solubility:** Both have negative solubility values, indicating poor solubility. Ligand B (-4.109) is slightly worse than Ligand A (-2.558).
11. **hERG:** Both have low hERG inhibition liability (A: 0.783, B: 0.672), which is good.
12. **Cl_mic:** Ligand B (74.865) has a higher microsomal clearance than Ligand A (40.964), suggesting lower metabolic stability.
13. **t1/2:** Ligand B (18.325) has a significantly longer in vitro half-life than Ligand A (-10.568). This is a major advantage.
14. **Pgp:** Ligand A (0.122) has lower P-gp efflux than Ligand B (0.737), which is favorable.
15. **Affinity:** Ligand B (-6.2 kcal/mol) has a stronger binding affinity than Ligand A (-5.4 kcal/mol). This is a 0.8 kcal/mol difference, which is substantial and can outweigh some ADME concerns.
**GPCR-Specific Priorities:** For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B excels in affinity and has a good logP and better BBB penetration. Ligand A has better QED, DILI, and Pgp efflux, but significantly worse half-life and affinity. The poor Caco-2 and solubility for both are concerning, but can be addressed with formulation strategies.
**Conclusion:**
Despite the slightly higher DILI risk and Pgp efflux, the significantly stronger binding affinity and longer half-life of Ligand B make it the more promising candidate. The difference in affinity (0.8 kcal/mol) is a significant driver, and the longer half-life is also a major benefit.
Output:
0
2025-04-17 19:11:02,094 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [341.411, 78.34, 2.617, 2, 3, 0.897, 39.899, 48.003, -5.093, -3.317, 0.378, 20.364, 15.972, 0.037, -2.8]
**Ligand B:** [347.459, 85.43, 1.985, 3, 3, 0.629, 25.591, 51.997, -5.102, -2.952, 0.627, 28.854, -29.137, 0.347, -6.3]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). A (341.411) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are reasonably low (A: 78.34, B: 85.43), suggesting good potential for absorption. A is better here.
3. **logP:** Both are within the optimal range (1-3). A (2.617) is slightly higher than B (1.985), potentially offering better membrane permeability.
4. **HBD:** A (2) is preferable to B (3). Lower HBD generally improves permeability.
5. **HBA:** Both have 3 HBA, which is acceptable.
6. **QED:** A (0.897) is significantly better than B (0.629), indicating a more drug-like profile.
7. **DILI:** A (39.899) is better than B (25.591), indicating a lower risk of drug-induced liver injury.
8. **BBB:** B (51.997) is slightly better than A (48.003), but both are not particularly high. Since ADRB2 is a cardiovascular target, BBB penetration is not a primary concern, but it's still a plus.
9. **Caco-2:** Both are negative, indicating poor permeability. This is a significant concern for both.
10. **Solubility:** Both are negative, indicating poor solubility. This is also a significant concern for both.
11. **hERG:** A (0.378) is significantly better than B (0.627), indicating a lower risk of cardiotoxicity. This is *very* important for a cardiovascular target.
12. **Cl_mic:** A (20.364) is better than B (28.854), suggesting better metabolic stability.
13. **t1/2:** A (15.972) is better than B (-29.137), suggesting a longer half-life.
14. **Pgp:** A (0.037) is much better than B (0.347), indicating lower P-glycoprotein efflux.
15. **Affinity:** B (-6.3) is significantly better than A (-2.8). This is a substantial difference in binding potency.
**GPCR-specific priorities:** For ADRB2 (a GPCR), we prioritize logP, Pgp, TPSA, and affinity.
**Overall Assessment:**
Ligand B has a much stronger binding affinity (-6.3 kcal/mol vs -2.8 kcal/mol). This is a huge advantage, and a difference of 3.5 kcal/mol is very significant. While Ligand A has better ADME properties across the board (QED, DILI, hERG, Cl_mic, t1/2, Pgp), the substantial difference in binding affinity outweighs these concerns. The poor Caco-2 and solubility for both ligands are problematic, but can be addressed with formulation strategies. The hERG risk is also a concern for Ligand B, but not as critical as the binding affinity advantage.
Therefore, I would prioritize Ligand B due to its superior binding affinity.
0
2025-04-17 19:11:02,094 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (346.427 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (73.99) is higher than Ligand B (46.61). For a cardiovascular GPCR like ADRB2, TPSA is less critical than for CNS targets, but lower is still preferred. Ligand B is significantly better here.
3. **logP:** Ligand A (1.799) is within the optimal range, while Ligand B (3.817) is approaching the upper limit. This could potentially lead to solubility issues for Ligand B.
4. **HBD/HBA:** Ligand A has 1 HBD and 4 HBA, while Ligand B has 0 HBD and 3 HBA. Both are acceptable, though Ligand A's slightly higher HBA count might improve solubility.
5. **QED:** Ligand A (0.829) has a better QED score than Ligand B (0.579), indicating a more drug-like profile.
6. **DILI:** Both ligands have acceptable DILI risk (Ligand A: 48.895, Ligand B: 52.772), with Ligand A being marginally better.
7. **BBB:** Ligand B (73.943) has a higher BBB penetration score than Ligand A (58.511). While ADRB2 isn't a CNS target, some peripheral exposure is still possible, and higher BBB can sometimes correlate with better overall distribution.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
9. **Solubility:** Ligand A (-2.089) has better aqueous solubility than Ligand B (-4.794). This is a significant advantage, especially given Ligand B's higher logP.
10. **hERG:** Both ligands have low hERG inhibition risk (Ligand A: 0.309, Ligand B: 0.681), with Ligand A being slightly better.
11. **Cl_mic:** Ligand A (47.328) has a much lower microsomal clearance than Ligand B (109.863), indicating better metabolic stability. This is a crucial factor for drug duration.
12. **t1/2:** Ligand A (16.12) has a slightly longer in vitro half-life than Ligand B (13.658).
13. **Pgp:** Both ligands have low P-gp efflux liability (Ligand A: 0.252, Ligand B: 0.253), which is good.
14. **Binding Affinity:** Ligand A (-7.3 kcal/mol) has a significantly stronger binding affinity than Ligand B (-5.9 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME drawbacks of Ligand B.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), affinity, logP, TPSA, and Pgp are key. Ligand A excels in affinity and has a reasonable logP. Ligand B has a lower TPSA, but suffers from a significantly weaker binding affinity and poorer solubility. The higher metabolic clearance of Ligand B is also a concern.
**Conclusion:**
Despite Ligand B's lower TPSA and higher BBB, the significantly stronger binding affinity of Ligand A, combined with its better QED, solubility, metabolic stability, and slightly lower DILI/hERG risk, makes it the more promising drug candidate. The difference in binding affinity (-1.4 kcal/mol) is substantial and likely to be the dominant factor in *in vivo* efficacy.
Output:
1
2025-04-17 19:11:02,094 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.494 and 348.487 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (49.41) is significantly better than Ligand B (78.43). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold. Ligand B is approaching the upper limit.
3. **logP:** Both ligands have good logP values (3.757 and 2.439), falling within the 1-3 optimal range. Ligand A is slightly higher, which *could* be a minor concern for solubility, but not a dealbreaker.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (2) is preferable to Ligand B (3) for similar reasons as HBD.
6. **QED:** Both ligands have similar QED scores (0.74 and 0.69), indicating good drug-likeness.
7. **DILI:** Ligand A (37.301) has a significantly lower DILI risk than Ligand B (20.9). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (95.657) has much higher BBB penetration than Ligand B (44.979). While not critical for a cardiovascular target, it doesn't hurt, and suggests good overall permeability.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.562 and -4.717). This is unusual and suggests poor permeability *in vitro*. However, these values are very close, so it's not a major differentiator.
10. **Solubility:** Ligand A (-3.891) has slightly better solubility than Ligand B (-3.182), although both are poor. This is a potential concern for both.
11. **hERG:** Ligand A (0.646) has a slightly better hERG profile than Ligand B (0.174), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand B (50.25) has a higher microsomal clearance than Ligand A (36.322), suggesting faster metabolism and potentially lower *in vivo* exposure.
13. **t1/2:** Ligand A (-13.221) has a longer *in vitro* half-life than Ligand B (-9.025). This is a positive for Ligand A.
14. **Pgp:** Ligand A (0.441) has lower P-gp efflux than Ligand B (0.143), which is favorable for bioavailability.
15. **Binding Affinity:** Both ligands have excellent binding affinity (-7.0 and -8.0 kcal/mol). Ligand B is slightly better, but the difference is likely not enough to overcome the other ADME/Tox advantages of Ligand A.
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A performs better on TPSA, Pgp, and has a comparable logP and affinity. The significantly better DILI and BBB scores also contribute to its favorability.
**Conclusion:**
Despite the slightly better binding affinity of Ligand B, Ligand A presents a much more favorable overall profile with lower toxicity risk (DILI), better metabolic stability (Cl_mic, t1/2), better permeability characteristics (TPSA, Pgp), and a slightly better hERG profile. These factors outweigh the minor affinity difference.
Output:
1
2025-04-17 19:11:02,094 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (342.483 & 353.369 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (40.62) is significantly better than Ligand B (75.44). ADRB2 is a cardiovascular target, not CNS, but lower TPSA generally aids absorption. Ligand A is well below the 140 threshold, while Ligand B is approaching it.
3. **logP:** Ligand A (3.26) is within the optimal range (1-3), while Ligand B (1.821) is at the lower end. For a GPCR, a slightly higher logP is often preferred for membrane permeability.
4. **HBD:** Ligand A (0) is preferable to Ligand B (1). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (4). Fewer HBAs generally improve permeability.
6. **QED:** Both ligands have good QED scores (0.825 and 0.896), indicating good drug-like properties.
7. **DILI:** Ligand A (8.414) has a much lower DILI risk than Ligand B (43.04). This is a significant advantage for Ligand A.
8. **BBB:** Both have reasonable BBB penetration, but Ligand A (82.862) is slightly better than Ligand B (78.79). Not a primary concern for a cardiovascular target.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. This is a concern for both.
10. **Solubility:** Both have negative solubility values, indicating poor solubility. This is a concern for both.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.806 and 0.133), which is excellent.
12. **Cl_mic:** Ligand A (14.502) has a lower microsomal clearance than Ligand B (17.994), suggesting better metabolic stability.
13. **t1/2:** Both have very negative in vitro half-lives (-25.211 and -24.538). This is a major concern for both.
14. **Pgp:** Ligand A (0.371) has lower P-gp efflux liability than Ligand B (0.053), which is favorable.
15. **Affinity:** Ligand B (-8.2) has a significantly stronger binding affinity than Ligand A (-5.6). This is a >1.5 kcal/mol difference, which is a substantial advantage.
**Overall Assessment:**
Ligand B has a much stronger binding affinity, which is the most important factor. However, Ligand A has significantly better DILI risk, lower TPSA, fewer HBD/HBA, and better Pgp efflux. Both have poor solubility and permeability, and poor in vitro half-life. The affinity difference is large enough to overcome the other drawbacks of Ligand B, particularly given the acceptable (though not ideal) DILI risk.
Output:
0
2025-04-17 19:11:02,095 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (371.453 Da and 353.413 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Both ligands have TPSA values (62.3 and 61.44) below the 140 A^2 threshold for good oral absorption. This is good for both.
**3. logP:** Both ligands have logP values (2.127 and 2.096) within the optimal 1-3 range. Again, no major distinction.
**4. H-Bond Donors:** Ligand A (1 HBD) is slightly better than Ligand B (2 HBDs) in terms of permeability.
**5. H-Bond Acceptors:** Ligand A (4 HBA) is slightly better than Ligand B (3 HBA) in terms of permeability.
**6. QED:** Ligand A (0.863) has a significantly higher QED score than Ligand B (0.669), indicating a more drug-like profile.
**7. DILI:** Both ligands have low DILI risk (35.014 and 36.06 percentile), which is favorable.
**8. BBB:** Both ligands demonstrate good BBB penetration (78.79 and 70.027 percentile). While not a CNS target, some level of BBB penetration can be acceptable and doesn't disqualify either.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.961 and -4.772). This is unusual and suggests poor permeability. However, these values are on a log scale and are likely representing very low permeability.
**10. Aqueous Solubility:** Both ligands have negative solubility values (-2.662 and -1.397). This is also unusual and indicates very poor aqueous solubility.
**11. hERG Inhibition:** Both ligands have low hERG inhibition liability (0.375 and 0.463 percentile), which is excellent.
**12. Microsomal Clearance:** Ligand A (-1.83 mL/min/kg) has a much lower (better) microsomal clearance than Ligand B (21.366 mL/min/kg), suggesting greater metabolic stability.
**13. In vitro Half-Life:** Ligand A (-3.561 hours) has a negative half-life, which is not possible. This is likely an error in the data. Ligand B (4.605 hours) has a reasonable half-life.
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (0.132 and 0.055 percentile), which is good.
**15. Binding Affinity:** Ligand A (-7.6 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.5 kcal/mol). This is a 1.1 kcal/mol difference, which is substantial and can outweigh some ADME drawbacks.
**GPCR-Specific Considerations:** For a GPCR like ADRB2, affinity, logP, Pgp, TPSA, and metabolic stability are key. Ligand A excels in affinity and metabolic stability. While both have similar logP and Pgp profiles, the significantly better affinity and QED of Ligand A make it more promising. The negative half-life for Ligand A is a major concern, but the substantial affinity advantage is compelling.
**Conclusion:**
Despite the questionable half-life value for Ligand A, its superior binding affinity, QED, and metabolic stability outweigh the concerns.
1
2025-04-17 19:11:02,095 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (370.877 Da and 357.405 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (67.87) is better than Ligand B (80.12). For a cardiovascular GPCR, TPSA should be kept relatively low to ensure good permeability. Ligand A is closer to the <140 threshold, and significantly better than B.
**3. logP:** Both ligands have good logP values (1.964 and 1.871), falling within the optimal 1-3 range. No clear advantage.
**4. H-Bond Donors:** Both have 1 HBD, which is acceptable.
**5. H-Bond Acceptors:** Ligand A has 4 HBAs, and Ligand B has 5. Both are within the acceptable limit of <=10.
**6. QED:** Both ligands have similar QED values (0.744 and 0.77), indicating good drug-likeness.
**7. DILI:** Both ligands have similar, acceptable DILI risk (37.65 and 38.891 percentile).
**8. BBB:** Ligand B (87.398) has a significantly higher BBB penetration percentile than Ligand A (69.135). While ADRB2 is a cardiovascular target, some CNS exposure can be relevant for off-target effects or potential central modulation.
**9. Caco-2 Permeability:** Ligand A (-5.033) shows better Caco-2 permeability than Ligand B (-4.362). This indicates better intestinal absorption.
**10. Aqueous Solubility:** Ligand A (-2.136) has better aqueous solubility than Ligand B (-3.303). Solubility is important for formulation and bioavailability.
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.247 and 0.182). This is excellent.
**12. Microsomal Clearance:** Ligand A (28.167) has a lower microsomal clearance than Ligand B (50.647), suggesting better metabolic stability.
**13. In vitro Half-Life:** Ligand A (30.642 hours) has a much longer in vitro half-life than Ligand B (-32.69 hours). This is a significant advantage, potentially allowing for less frequent dosing.
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (0.086 and 0.026).
**15. Binding Affinity:** Ligand A (-7.9 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.1 kcal/mol). This is a substantial difference (1.8 kcal/mol), and is the most important factor.
**Overall Assessment:**
Ligand A clearly outperforms Ligand B in several crucial areas: binding affinity, metabolic stability (lower Cl_mic, longer t1/2), Caco-2 permeability, and aqueous solubility. While Ligand B has a better BBB score, this is less critical for a primarily cardiovascular target. The significantly stronger binding affinity of Ligand A outweighs the slight advantage of Ligand B in BBB penetration.
Output:
1
2025-04-17 19:11:02,095 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.459 Da and 352.563 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (75.44) is higher than Ligand B (32.78). For a cardiovascular GPCR, TPSA isn't a *major* concern unless extremely high, but lower is generally preferred for better absorption. Ligand B is significantly better here.
3. **logP:** Ligand A (2.483) is within the optimal 1-3 range. Ligand B (3.82) is slightly higher, approaching the upper limit. While still acceptable, Ligand A is preferable.
4. **HBD:** Ligand A (1) is better than Ligand B (0). Having at least one HBD can improve solubility.
5. **HBA:** Ligand A (4) is slightly higher than Ligand B (3). Both are within the acceptable range of <=10.
6. **QED:** Ligand A (0.769) is better than Ligand B (0.623), indicating a more drug-like profile.
7. **DILI:** Ligand A (13.339) has a higher DILI risk than Ligand B (5.118). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (74.486) and Ligand B (87.01) are both reasonably high, suggesting decent potential for CNS penetration, though ADRB2 is primarily a cardiovascular target. Ligand B is slightly better.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-4.931) is slightly worse than Ligand B (-4.359).
10. **Solubility:** Both are negative, indicating poor solubility. Ligand A (-2.36) is slightly better than Ligand B (-2.494).
11. **hERG:** Ligand A (0.289) has a lower hERG risk than Ligand B (0.891). This is a crucial advantage for Ligand A, minimizing cardiotoxicity concerns.
12. **Cl_mic:** Ligand A (25.362) has a higher microsomal clearance than Ligand B (19.649), indicating lower metabolic stability. Ligand B is preferable.
13. **t1/2:** Ligand A (-2.449) has a shorter in vitro half-life than Ligand B (1.033). Ligand B is preferable.
14. **Pgp:** Ligand A (0.084) has lower P-gp efflux than Ligand B (0.34). This is a benefit for Ligand A.
15. **Binding Affinity:** Ligand B (-6.3) has a slightly better binding affinity than Ligand A (-5.9). This is a 1.5 kcal/mol advantage, which is significant.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, and affinity. Ligand B excels in TPSA and affinity, while Ligand A is better in logP and Pgp. However, the DILI risk for Ligand A is concerning. The hERG risk is also lower for Ligand A, which is important.
**Overall Assessment:**
While Ligand A has some advantages (logP, Pgp, hERG), the significantly lower DILI risk and better metabolic stability (lower Cl_mic, longer t1/2) of Ligand B, coupled with its superior binding affinity, make it the more promising candidate. The slightly higher logP of Ligand B is manageable, and the benefits outweigh the drawbacks.
Output:
0
2025-04-17 19:11:02,095 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (353.419 and 351.491 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (96.97) is higher than Ligand B (61.88). For a cardiovascular GPCR, TPSA is not a primary concern unless CNS penetration is desired, but lower is generally preferred for oral absorption. Ligand B is better.
3. **logP:** Ligand A (0.529) is quite low, potentially hindering membrane permeability. Ligand B (1.252) is within the optimal 1-3 range. Ligand B is significantly better.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable, below the threshold of 5. Ligand B is slightly better.
5. **HBA:** Ligand A (5) and Ligand B (4) are both acceptable, below the threshold of 10. Ligand B is slightly better.
6. **QED:** Ligand B (0.81) has a higher QED score than Ligand A (0.59), indicating a more drug-like profile. Ligand B is better.
7. **DILI:** Ligand A (37.146) has a slightly higher DILI risk than Ligand B (3.063), but both are below the concerning threshold of 60. Ligand B is better.
8. **BBB:** Ligand A (54.44) has a lower BBB penetration percentile than Ligand B (76.541). While ADRB2 is primarily a cardiovascular target, some CNS effects can be relevant, making higher BBB penetration potentially beneficial. Ligand B is better.
9. **Caco-2:** Ligand A (-5.625) has a worse Caco-2 permeability than Ligand B (-4.818). Both are negative, which is not ideal, but B is better.
10. **Solubility:** Ligand A (-1.72) has a worse solubility than Ligand B (-1.265). Both are negative, which is not ideal, but B is better.
11. **hERG:** Ligand A (0.152) has a lower hERG inhibition liability than Ligand B (0.501). This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand A (-6.323) has a lower (better) microsomal clearance than Ligand B (10.596), suggesting greater metabolic stability. Ligand A is better.
13. **t1/2:** Ligand A (-3.766) has a worse in vitro half-life than Ligand B (-3.089). Ligand B is better.
14. **Pgp:** Ligand A (0.023) has a lower P-gp efflux liability than Ligand B (0.025). This is a slight advantage for Ligand A.
15. **Binding Affinity:** Ligand B (-6.9 kcal/mol) has a slightly better binding affinity than Ligand A (-6.3 kcal/mol). This is a 1.5 kcal/mol advantage, which is significant.
**Overall Assessment:**
Ligand B consistently outperforms Ligand A across most key ADME properties (logP, TPSA, QED, DILI, BBB, Caco-2, Solubility, t1/2). While Ligand A has advantages in hERG and Cl_mic, the superior binding affinity and overall ADME profile of Ligand B outweigh these benefits. The slightly better affinity of Ligand B, combined with its better predicted pharmacokinetic properties, makes it the more promising drug candidate for the ADRB2 receptor.
Output:
0
2025-04-17 19:11:02,095 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (337.335 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are reasonably low (A: 95.52, B: 99.5), below the 140 threshold for oral absorption, but not optimized for CNS penetration (though not a primary concern for ADRB2).
3. **logP:** Both ligands have good logP values (A: 2.165, B: 1.036), falling within the optimal 1-3 range. Ligand A is slightly higher, potentially offering better membrane permeability.
4. **HBD/HBA:** Ligand A (2 HBD, 4 HBA) is slightly better than Ligand B (1 HBD, 5 HBA) in terms of balancing solubility and permeability.
5. **QED:** Both ligands have good QED scores (A: 0.761, B: 0.812), indicating a generally drug-like profile.
6. **DILI:** Ligand A (96.859) has a significantly higher DILI risk than Ligand B (68.166). This is a major concern.
7. **BBB:** Both have low BBB penetration, which isn't critical for a cardiovascular target like ADRB2. Ligand B (48.895) is higher than A (20.357), but both are low.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-5.186) is slightly better than Ligand B (-4.745).
9. **Solubility:** Both have negative solubility values, which is also unusual and suggests poor aqueous solubility. Ligand A (-3.921) is slightly better than Ligand B (-3.415).
10. **hERG:** Ligand A (0.115) has a much lower hERG inhibition liability than Ligand B (0.578), which is a significant advantage for cardiovascular safety.
11. **Cl_mic:** Ligand A (-7.64) has significantly lower microsomal clearance than Ligand B (36.938), indicating better metabolic stability.
12. **t1/2:** Ligand B (-7.991) has a slightly longer in vitro half-life than Ligand A (-0.515).
13. **Pgp:** Ligand A (0.022) has much lower P-gp efflux liability than Ligand B (0.07), which is favorable for bioavailability.
14. **Binding Affinity:** Ligand A (-7.8 kcal/mol) has a slightly better binding affinity than Ligand B (-7.1 kcal/mol). While the difference is less than the 1.5 kcal/mol threshold, it's still a positive factor.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand A appears better. It has a slightly better logP, significantly lower Pgp efflux, and a better binding affinity. More importantly, Ligand A has a significantly lower hERG risk and much better metabolic stability (lower Cl_mic) which are crucial for a cardiovascular drug. The major drawback for Ligand A is the higher DILI risk, but the significant advantages in safety and PK outweigh this concern, especially since DILI risk can be further mitigated through structural modifications. Both ligands have poor Caco-2 and solubility, which would need to be addressed in later stages of optimization.
Output:
1
2025-04-17 19:11:02,095 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (362.451 and 367.515 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (75.71) is slightly higher than Ligand B (69.72). Both are below the 140 A^2 threshold for good oral absorption, but closer to the 90 A^2 threshold for CNS targets.
3. **logP:** Both ligands have good logP values (1.449 and 1.245), falling within the optimal 1-3 range. Ligand B is slightly lower, which could be marginally better for solubility.
4. **HBD:** Both have 1 HBD, which is acceptable.
5. **HBA:** Ligand A has 5 HBA, and Ligand B has 4. Both are within the acceptable limit of 10.
6. **QED:** Ligand B (0.743) has a significantly better QED score than Ligand A (0.487), indicating a more drug-like profile. This is a notable advantage for Ligand B.
7. **DILI:** Ligand B (55.448) has a lower DILI risk than Ligand A (60.915), both are acceptable, but lower is better.
8. **BBB:** Ligand B (52.811) has a significantly higher BBB penetration percentile than Ligand A (28.848). Given that ADRB2 is a GPCR, and while not necessarily a CNS target, some degree of BBB penetration can be beneficial for off-target profiling and potential peripheral effects.
9. **Caco-2:** Both ligands have very poor Caco-2 permeability (-4.969 and -4.833). This is a significant concern for oral bioavailability for both.
10. **Solubility:** Both ligands have poor aqueous solubility (-2.745 and -2.877). This is a concern, but can be addressed with formulation strategies.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.05 and 0.148), which is excellent.
12. **Cl_mic:** Ligand A (17.927) has a significantly lower microsomal clearance than Ligand B (48.712), indicating better metabolic stability. This is a strong advantage for Ligand A.
13. **t1/2:** Ligand B (-20.441) has a longer in vitro half-life than Ligand A (-15.571), which is desirable.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.088 and 0.056), which is good.
15. **Binding Affinity:** Ligand A (-5.9 kcal/mol) has a slightly better binding affinity than Ligand B (-5.5 kcal/mol). The difference is 0.4 kcal/mol, which is not a huge advantage, but is still relevant.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are important. Both ligands perform similarly on logP and Pgp. TPSA is acceptable for both. Ligand A has a slightly better affinity, while Ligand B has a better QED and BBB. The biggest difference is metabolic stability (Cl_mic), where Ligand A is significantly better.
**Overall Assessment:**
While Ligand B has better QED, BBB, and half-life, the significantly improved metabolic stability (lower Cl_mic) of Ligand A is a critical advantage. Poor metabolic stability can lead to rapid drug clearance and necessitate higher doses, potentially increasing side effects. The slightly better affinity of Ligand A further supports its selection. The poor Caco-2 and solubility are concerns for both, but can be addressed during formulation.
Output:
1
2025-04-17 19:11:02,095 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (351.491 and 350.459 Da) fall comfortably within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (70.67) is slightly higher than Ligand B (67.87), but both are well below the 140 threshold for good oral absorption.
3. **logP:** Both ligands have excellent logP values (1.297 and 1.335), falling within the optimal 1-3 range.
4. **HBD:** Ligand A has 2 HBD, and Ligand B has 1. Both are acceptable, below the 5 threshold.
5. **HBA:** Both ligands have 4 HBA, well within the acceptable limit of 10.
6. **QED:** Ligand B (0.812) has a higher QED score than Ligand A (0.691), indicating a more drug-like profile. This is a slight advantage for Ligand B.
7. **DILI:** Ligand A (9.383) has a significantly lower DILI risk than Ligand B (18.728). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (77.2) has a much higher BBB penetration percentile than Ligand A (42.303). While ADRB2 isn't strictly a CNS target, some CNS exposure can be beneficial or at least not detrimental for cardiovascular drugs, and higher BBB is generally favorable.
9. **Caco-2:** Ligand A (-5.132) and Ligand B (-4.771) both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale isn't specified, so it's hard to interpret the absolute impact.
10. **Solubility:** Both ligands have very poor aqueous solubility (-1.52 and -1.831). This is a significant concern for both.
11. **hERG:** Both ligands have low hERG inhibition risk (0.182 and 0.228).
12. **Cl_mic:** Ligand B (21.597) has a higher microsomal clearance than Ligand A (12.992), indicating faster metabolism and potentially lower *in vivo* exposure. This favors Ligand A.
13. **t1/2:** Ligand B (19.874) has a significantly longer *in vitro* half-life than Ligand A (8.693). This is a substantial advantage for Ligand B.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.03 and 0.029).
15. **Binding Affinity:** Ligand B (-6.9 kcal/mol) has a 1.2 kcal/mol stronger binding affinity than Ligand A (-5.7 kcal/mol). This is a very significant advantage, potentially outweighing some ADME concerns.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Both ligands perform well on logP and Pgp. TPSA is acceptable for both. The substantial difference in binding affinity heavily favors Ligand B. While BBB isn't a primary concern for ADRB2, Ligand B's higher value is a bonus. The lower DILI risk of Ligand A is attractive, but the significantly better affinity of Ligand B is likely to be more impactful, especially given the potential for optimization to address the solubility and clearance issues.
**Conclusion:**
Despite the lower DILI score for Ligand A, the significantly stronger binding affinity (-6.9 vs -5.7 kcal/mol) and longer half-life of Ligand B are more critical for a successful GPCR drug candidate. The solubility and clearance issues can be addressed through further medicinal chemistry optimization.
Output:
0
2025-04-17 19:11:02,095 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (365.37 and 366.49 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand B (74.77) is significantly better than Ligand A (128.5). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (1.662) and Ligand B (0.832) are both within the optimal 1-3 range, but Ligand A is slightly preferred.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 8 HBA, and Ligand B has 6. Both are acceptable, under the limit of 10.
6. **QED:** Ligand B (0.807) is significantly better than Ligand A (0.446), indicating a more drug-like profile.
7. **DILI:** Ligand B (24.622) has a *much* lower DILI risk than Ligand A (96.549). This is a critical advantage.
8. **BBB:** While not a primary concern for a cardiovascular target, Ligand A (66.58) has a slightly better BBB percentile than Ligand B (54.29).
9. **Caco-2:** Both are negative, indicating poor permeability. However, the scale is not specified, so it's difficult to interpret.
10. **Solubility:** Ligand B (-1.469) is better than Ligand A (-4.578), indicating better aqueous solubility.
11. **hERG:** Ligand A (0.276) has a slightly lower hERG risk than Ligand B (0.443), which is favorable.
12. **Cl_mic:** Ligand B (-14.083) has *much* lower microsomal clearance than Ligand A (75.644), indicating better metabolic stability.
13. **t1/2:** Ligand B (14.137 hours) has a significantly longer half-life than Ligand A (38.191 hours). This is a significant advantage for dosing convenience.
14. **Pgp:** Ligand A (0.224) has slightly lower P-gp efflux than Ligand B (0.027), which is favorable.
15. **Affinity:** Ligand A (-7.6 kcal/mol) has a slightly better binding affinity than Ligand B (-6.9 kcal/mol). This is a 0.7 kcal/mol difference, which is moderately significant.
**Overall Assessment:**
Ligand B is significantly better overall. While Ligand A has a slightly better binding affinity and Pgp efflux, Ligand B excels in crucial ADMET properties: lower DILI risk, better QED, improved solubility, significantly lower microsomal clearance (better metabolic stability), and a longer half-life. The lower TPSA is also a plus. The difference in binding affinity (0.7 kcal/mol) is not enough to overcome the substantial advantages of Ligand B in terms of safety and pharmacokinetic properties. For a cardiovascular target, metabolic stability and safety (DILI, hERG) are paramount.
Output:
0
2025-04-17 19:11:02,096 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (367.833 and 357.841 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (84.67) is higher than Ligand B (53.51). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is generally preferred for absorption. Ligand B has a clear advantage.
3. **logP:** Both ligands (2.006 and 2.211) are within the optimal 1-3 range. Similar.
4. **HBD:** Ligand A (1) is slightly better than Ligand B (0). Lower is generally preferred for permeability.
5. **HBA:** Ligand A (5) is higher than Ligand B (3). Lower is generally preferred for permeability. Ligand B has an advantage.
6. **QED:** Ligand A (0.86) is better than Ligand B (0.762), indicating a more drug-like profile. This is a positive for Ligand A.
7. **DILI:** Ligand B (68.244) has a higher DILI risk than Ligand A (52.113), which is undesirable. Ligand A is preferred.
8. **BBB:** Both ligands have good BBB penetration (78.868 and 72.664). Not a major differentiating factor for a cardiovascular target.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.913 and -4.683). This is unusual and suggests poor permeability. However, the values are very close.
10. **Solubility:** Both ligands have negative solubility values (-2.937 and -3.455). This is also unusual and suggests poor solubility. The values are close.
11. **hERG:** Ligand A (0.244) has a lower hERG risk than Ligand B (0.35). This is a significant advantage for Ligand A, as hERG inhibition can lead to cardiotoxicity.
12. **Cl_mic:** Ligand B (50.163) has a lower microsomal clearance than Ligand A (22.035), suggesting better metabolic stability. This is a positive for Ligand B.
13. **t1/2:** Ligand B (-46.135) has a much longer in vitro half-life than Ligand A (15.44). This is a substantial advantage for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.099) has lower P-gp efflux than Ligand B (0.282). This is a slight advantage for Ligand A.
15. **Binding Affinity:** Ligand B (-7.3) has a significantly stronger binding affinity than Ligand A (-4.0). This is a major advantage, potentially outweighing some of the ADME drawbacks. A 3.3 kcal/mol difference is substantial.
**Overall Assessment:**
Ligand B has a significantly better binding affinity and a much longer half-life, which are critical for a GPCR drug candidate. While Ligand A has better QED, lower DILI risk, and lower hERG risk, the affinity difference is substantial enough to outweigh these benefits. The TPSA and HBA values of Ligand B are also favorable. The negative Caco-2 and solubility values are concerning for both, but the superior potency and half-life of Ligand B make it the more promising candidate.
Output:
0
2025-04-17 19:11:02,096 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (353.409 Da and 351.451 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (46.61) is significantly better than Ligand B (90.7). For a GPCR, keeping TPSA low is beneficial for permeability, and Ligand A is well below the 140 threshold, while Ligand B is approaching it.
**3. logP:** Ligand A (3.89) is within the optimal 1-3 range. Ligand B (0.347) is quite low, potentially hindering membrane permeability and absorption. This is a significant drawback for a GPCR ligand.
**4. H-Bond Donors:** Ligand A (0) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
**5. H-Bond Acceptors:** Ligand A (3) is preferable to Ligand B (5). Fewer HBAs generally improve permeability.
**6. QED:** Both ligands have good QED scores (0.755 and 0.774), indicating generally drug-like properties.
**7. DILI:** Ligand A (35.014) has a slightly higher DILI risk than Ligand B (18.108), but both are well below the concerning threshold of 60.
**8. BBB:** Ligand A (92.323) shows much better potential for BBB penetration than Ligand B (46.762). While ADRB2 isn't strictly a CNS target, some peripheral ADRB2 activity can be modulated by CNS effects, and better BBB penetration isn't necessarily a negative.
**9. Caco-2 Permeability:** Ligand A (-4.372) is better than Ligand B (-4.842), indicating better intestinal absorption.
**10. Aqueous Solubility:** Ligand A (-4.068) is better than Ligand B (-0.434), indicating better solubility.
**11. hERG Inhibition:** Ligand A (0.681) has a lower hERG risk than Ligand B (0.26). This is a crucial safety parameter, and Ligand A is preferable.
**12. Microsomal Clearance:** Ligand B (5.76) has lower clearance than Ligand A (69.01), suggesting better metabolic stability. This is a positive for Ligand B.
**13. In vitro Half-Life:** Ligand A (-25.726) has a much longer half-life than Ligand B (-2.158). This is a significant advantage for Ligand A, potentially allowing for less frequent dosing.
**14. P-gp Efflux:** Ligand A (0.387) has lower P-gp efflux than Ligand B (0.007), indicating better bioavailability and potentially better CNS exposure.
**15. Binding Affinity:** Ligand A (-7.8) has a slightly stronger binding affinity than Ligand B (-7.3). While the difference is not huge, it's enough to be considered.
**Overall Assessment:**
Ligand A is clearly the more promising candidate. While Ligand B has better metabolic stability and lower DILI risk, Ligand A excels in critical areas for a GPCR ligand: TPSA, logP, BBB penetration, solubility, hERG risk, and half-life. The slightly stronger binding affinity of Ligand A further supports this conclusion. The low logP of Ligand B is a major concern, likely hindering its ability to reach the target effectively.
Output:
1
2025-04-17 19:11:02,096 - INFO - Batch 91 complete. Total preferences: 1456
2025-04-17 19:11:02,096 - INFO - Processing batch 92/512...
2025-04-17 19:11:50,118 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [349.387, 99.18, 0.35, 2, 5, 0.74, 31.291, 24.389, -5.513, -1.651, 0.101, -12.805, -8.954, 0.016, -6.8]
**Ligand B:** [345.399, 95.41, 1.128, 2, 4, 0.803, 72.586, 60.14, -4.667, -3.488, 0.14, 23.904, -59.051, 0.095, -5]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity) and general drug-like properties:
1. **MW:** Both are within the ideal 200-500 Da range. Ligand B (345.399) is slightly lower, which is generally favorable.
2. **TPSA:** Both are reasonably good, below 140. Ligand B (95.41) is better than Ligand A (99.18), closer to the optimal range for good absorption.
3. **logP:** Ligand A (0.35) is quite low, potentially hindering membrane permeability. Ligand B (1.128) is better, falling within the preferred 1-3 range. This is a significant advantage for Ligand B.
4. **HBD/HBA:** Both have acceptable HBD (2) and HBA (5/4) counts.
5. **QED:** Both have good QED scores (0.74 and 0.803), indicating good drug-like properties.
6. **DILI:** Ligand A (31.291) has a much lower DILI risk than Ligand B (72.586). This is a substantial advantage for Ligand A.
7. **BBB:** Both have low BBB penetration, which is acceptable for a cardiovascular target (not CNS). Ligand B (60.14) is slightly higher than Ligand A (24.389).
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-5.513) is slightly better than Ligand B (-4.667).
9. **Solubility:** Both have negative solubility values, which is also unusual and suggests poor solubility. Ligand A (-1.651) is slightly better than Ligand B (-3.488).
10. **hERG:** Both have very low hERG risk (0.101 and 0.14).
11. **Cl_mic:** Ligand A (-12.805) has a much lower (better) microsomal clearance than Ligand B (23.904), indicating better metabolic stability.
12. **t1/2:** Ligand B (-59.051) has a much longer in vitro half-life than Ligand A (-8.954). This is a significant advantage for Ligand B.
13. **Pgp:** Both have very low Pgp efflux liability (0.016 and 0.095).
14. **Affinity:** Ligand A (-6.8) has a slightly better binding affinity than Ligand B (-5). While the difference isn't huge, it's still a positive for Ligand A.
**Overall Assessment:**
Ligand B has advantages in logP, t1/2, and slightly better TPSA. However, Ligand A has a significantly lower DILI risk, better metabolic stability (Cl_mic), and slightly better binding affinity. The low logP of Ligand A is a concern, but the better affinity and significantly lower DILI risk are compelling. Considering the cardiovascular target, metabolic stability and safety (DILI) are particularly important.
Therefore, I would choose Ligand A.
1
2025-04-17 19:11:50,118 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.406 and 348.487 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (75.19 and 75.27) are below the 140 A^2 threshold for good oral absorption, and acceptable for a cardiovascular GPCR. Very similar.
3. **logP:** Ligand A (1.78) is slightly better than Ligand B (2.581). While both are within the optimal 1-3 range, Ligand A is closer to the lower end, potentially minimizing off-target effects.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is preferable to Ligand B (3). Fewer HBAs generally improve permeability.
6. **QED:** Ligand A (0.852) has a significantly better QED score than Ligand B (0.708), indicating a more drug-like profile.
7. **DILI:** Ligand B (24.544) has a much lower DILI risk than Ligand A (35.479). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (82.513) has a better BBB penetration score than Ligand B (61.923). While ADRB2 is not a CNS target, some degree of BBB penetration can be useful for understanding off-target effects.
9. **Caco-2:** Both ligands have negative Caco-2 permeability values (-4.872 and -4.932), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Both ligands have very poor aqueous solubility (-2.061 and -2.736). This is a major drawback for both.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.11 and 0.119), which is excellent.
12. **Cl_mic:** Ligand B (9.564) has significantly lower microsomal clearance than Ligand A (25.871), indicating better metabolic stability.
13. **t1/2:** Ligand A (3.138) has a longer in vitro half-life than Ligand B (-7.097). This is a positive for Ligand A. However, the negative value for Ligand B is concerning and likely indicates a very short half-life.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.014 and 0.186).
15. **Binding Affinity:** Ligand A (-8.4 kcal/mol) has a stronger binding affinity than Ligand B (-6.6 kcal/mol). This is a substantial difference (1.8 kcal/mol) and is a major advantage for Ligand A.
**GPCR-Specific Considerations:**
For ADRB2 (a cardiovascular GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A is better on logP, TPSA, and significantly better on affinity. While BBB isn't a primary concern, Ligand A is better. Ligand B's advantage in DILI and Cl_mic is valuable, but the superior affinity of Ligand A is likely to outweigh these benefits, particularly given the poor solubility and permeability of both compounds.
**Overall Assessment:**
Despite the poor solubility and permeability of both compounds, Ligand A's significantly stronger binding affinity and better QED score make it the more promising candidate. The lower DILI risk of Ligand B is attractive, but the potency advantage of Ligand A is critical for a GPCR target.
Output:
1
2025-04-17 19:11:50,118 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (350.463 and 360.443 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (85.25) is better than Ligand B (101.8). For a cardiovascular GPCR, we don't *require* extremely low TPSA for BBB penetration, but lower TPSA generally correlates with better permeability.
**3. logP:** Both ligands have good logP values (1.697 and 1.144), falling within the optimal 1-3 range. Ligand B is slightly lower, which could potentially affect permeability, but it's not a major concern.
**4. H-Bond Donors:** Both ligands have 2 HBD, which is within the acceptable limit of <=5.
**5. H-Bond Acceptors:** Ligand A has 5 HBA, while Ligand B has 7. Both are within the acceptable limit of <=10, but Ligand A is preferable.
**6. QED:** Ligand A (0.818) has a higher QED than Ligand B (0.721), indicating a more drug-like profile. This is a positive for Ligand A.
**7. DILI Risk:** Ligand A (25.359) has a significantly lower DILI risk than Ligand B (59.519). This is a crucial advantage for Ligand A, as minimizing liver toxicity is paramount.
**8. BBB Penetration:** Both ligands have relatively low BBB penetration (40.093 and 47.15). As ADRB2 is a cardiovascular target, BBB penetration isn't a primary concern.
**9. Caco-2 Permeability:** Ligand A (-4.77) has better Caco-2 permeability than Ligand B (-5.567).
**10. Aqueous Solubility:** Ligand A (-1.424) has better aqueous solubility than Ligand B (-2.119).
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (0.124 and 0.207).
**12. Microsomal Clearance:** Ligand A (7.374) has significantly lower microsomal clearance than Ligand B (13.481), indicating better metabolic stability.
**13. In vitro Half-Life:** Ligand B (13.736) has a significantly longer half-life than Ligand A (0.5). This is a positive for Ligand B.
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (0.014 and 0.12).
**15. Binding Affinity:** Both ligands have very similar binding affinities (-6.5 and -6.4 kcal/mol). The difference is negligible.
**Overall Assessment:**
Ligand A is the stronger candidate. While Ligand B has a longer in vitro half-life, Ligand A excels in several critical areas: lower DILI risk, better QED, better solubility, better Caco-2 permeability, and lower microsomal clearance. These factors, combined with comparable binding affinity, make Ligand A a more promising starting point for drug development targeting ADRB2.
Output:
1
2025-04-17 19:11:50,118 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (352.41) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (78.67) is significantly better than Ligand B (45.67). Lower TPSA is preferred for GPCRs, aiding in brain penetration and overall absorption.
3. **logP:** Ligand B (2.512) is better positioned within the optimal range (1-3) compared to Ligand A (0.685), which is a bit low and could hinder membrane permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (0). Having at least one HBD can improve solubility.
5. **HBA:** Both ligands have 5 HBA, which is acceptable.
6. **QED:** Ligand A (0.845) has a higher QED score than Ligand B (0.71), indicating better overall drug-likeness.
7. **DILI:** Ligand B (16.014) has a much lower DILI risk than Ligand A (32.299), which is a significant advantage.
8. **BBB:** Ligand A (81.698) shows better BBB penetration potential than Ligand B (77.627), which is important for GPCR targets.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual. I will assume these represent percentile scores, and therefore higher is better. Ligand A (-4.689) is better than Ligand B (-4.905).
10. **Solubility:** Ligand A (-1.362) is better than Ligand B (-2.112).
11. **hERG:** Ligand A (0.224) has a much lower hERG inhibition liability than Ligand B (0.725), which is crucial for avoiding cardiotoxicity.
12. **Cl_mic:** Ligand A (-5.943) has a much lower (better) microsomal clearance than Ligand B (70.581), indicating greater metabolic stability.
13. **t1/2:** Ligand B (3.4) has a longer in vitro half-life than Ligand A (-1.684), which is desirable.
14. **Pgp:** Ligand A (0.031) has lower P-gp efflux liability than Ligand B (0.203), which is favorable for bioavailability.
15. **Affinity:** Ligand A (-6.7 kcal/mol) has a better binding affinity than Ligand B (-4.4 kcal/mol). The difference of 2.3 kcal/mol is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand A is clearly superior in terms of binding affinity, TPSA, QED, DILI, hERG, Cl_mic, and Pgp efflux. While Ligand B has a better logP and in vitro half-life, the significant advantages of Ligand A in potency, safety (hERG, DILI), and metabolic stability are more important for a GPCR target like ADRB2. The slightly lower logP of Ligand A is a manageable concern, and can potentially be addressed through further optimization.
Output:
1
2025-04-17 19:11:50,119 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Step-by-step comparison:**
1. **MW:** Both ligands (346.39 & 351.36 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (117.35) is slightly higher than Ligand B (110.11). Both are acceptable for a non-CNS GPCR target like ADRB2, being under 140.
3. **logP:** Ligand A (0.444) is a bit low, potentially impacting permeability. Ligand B (0.111) is even lower, raising more concern. Both are below the optimal 1-3 range.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (2), but both are within the acceptable limit of 5.
5. **HBA:** Both ligands have 6 HBA, which is within the acceptable limit of 10.
6. **QED:** Ligand B (0.779) has a better QED score than Ligand A (0.67), indicating a more drug-like profile.
7. **DILI:** Ligand B (57.93%) has a slightly lower DILI risk than Ligand A (60.14%), which is favorable. Both are reasonably low.
8. **BBB:** Ligand B (50.68%) has a higher BBB penetration than Ligand A (30.98%). While ADRB2 isn't primarily a CNS target, some degree of BBB penetration isn't necessarily detrimental and could offer some off-target benefits or liabilities.
9. **Caco-2:** Ligand A (-5.462) and Ligand B (-4.87) both have negative Caco-2 values, which is unusual and suggests very poor permeability. This is a major concern for both.
10. **Solubility:** Ligand A (-2.012) and Ligand B (-2.308) both have very poor solubility. This is a significant drawback.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.127 and 0.128 respectively).
12. **Cl_mic:** Ligand B (-40.24) has significantly lower microsomal clearance than Ligand A (27.63), indicating better metabolic stability. This is a substantial advantage.
13. **t1/2:** Ligand B (8.194) has a much longer in vitro half-life than Ligand A (-4.541), further supporting its better metabolic stability.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.058 and 0.009).
15. **Binding Affinity:** Ligand B (-7.1 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.8 kcal/mol). This is a crucial advantage, exceeding the 1.5 kcal/mol threshold.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. While both ligands struggle with logP, Ligand B's superior affinity and metabolic stability (Cl_mic and t1/2) outweigh the slight disadvantages in logP and TPSA. The better QED and lower DILI risk also contribute to its favorability. The poor Caco-2 and solubility are concerning for both, but the strong affinity of Ligand B suggests it might still achieve sufficient target engagement *in vivo*.
**Conclusion:**
Ligand B is the more promising candidate due to its significantly stronger binding affinity, improved metabolic stability, better QED score, and slightly lower DILI risk. The poor permeability and solubility are drawbacks for both, but the potency advantage of Ligand B is likely to be more impactful in driving efficacy.
Output:
0
2025-04-17 19:11:50,119 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 drug candidates. ADRB2 is a GPCR, so we'll prioritize logP, Pgp, TPSA, and affinity, alongside general drug-like properties.
**Ligand A:** [346.366, 97.98, 0.916, 2, 4, 0.787, 70.958, 45.754, -5.038, -2.019, 0.322, -17.587, -18.103, 0.021, -5.6]
**Ligand B:** [352.391, 116.92, -0.872, 3, 7, 0.613, 60.566, 12.408, -5.166, -1.632, 0.168, 6.055, -3.182, 0.016, -5.4]
1. **MW:** Both are within the ideal range (200-500 Da). A (346.366) is slightly preferred.
2. **TPSA:** A (97.98) is better than B (116.92). Both are acceptable for a peripheral GPCR target like ADRB2, but lower is generally better for overall drug-like properties.
3. **logP:** A (0.916) is good, within the optimal range. B (-0.872) is a bit low, potentially impacting permeability. This favors A.
4. **HBD:** A (2) is good. B (3) is acceptable, but slightly less desirable.
5. **HBA:** A (4) is good. B (7) is higher, potentially impacting permeability and increasing the risk of off-target interactions. This favors A.
6. **QED:** A (0.787) is better than B (0.613), indicating a more drug-like profile.
7. **DILI:** A (70.958) is higher than B (60.566), indicating a slightly higher risk of liver injury. B is preferred here.
8. **BBB:** A (45.754) is much better than B (12.408). While ADRB2 isn't a CNS target, some degree of BBB penetration can sometimes indicate favorable partitioning properties.
9. **Caco-2:** Both are negative, indicating poor permeability. A (-5.038) is slightly worse than B (-5.166).
10. **Solubility:** A (-2.019) is slightly worse than B (-1.632), but both are poor.
11. **hERG:** Both are very low (0.322 and 0.168), indicating a low risk of cardiotoxicity.
12. **Cl_mic:** A (-17.587) is *much* better than B (6.055), indicating significantly better metabolic stability. This is a major advantage for A.
13. **t1/2:** A (-18.103) is *much* better than B (-3.182), indicating a significantly longer half-life. This is a major advantage for A.
14. **Pgp:** Both are very low (0.021 and 0.016), indicating minimal P-gp efflux.
15. **Affinity:** Both are very similar (-5.6 and -5.4 kcal/mol). The difference is not substantial enough to be a deciding factor.
**Overall Assessment:**
Ligand A is significantly better due to its superior metabolic stability (Cl_mic and t1/2), better QED, and more favorable logP and TPSA. While Ligand B has a slightly lower DILI risk, the ADME advantages of Ligand A are more critical for overall drug development potential, especially considering the importance of metabolic stability for a GPCR target. The similar affinities make the ADME profile the deciding factor.
Output:
1
2025-04-17 19:11:50,119 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (351.447 and 357.47 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (78.95) is slightly higher than Ligand B (61.88). Both are below the 140 threshold for oral absorption, but B is better positioned, especially considering it's a GPCR.
3. **logP:** Ligand B (1.058) is better than Ligand A (0.385). A logP between 1-3 is optimal, and A is quite low, potentially hindering membrane permeability.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Both ligands have 4 HBA, which is good.
6. **QED:** Both ligands have similar QED values (0.794 and 0.772) indicating good drug-likeness.
7. **DILI:** Ligand B (5.894) has a significantly lower DILI risk than Ligand A (30.787). This is a major advantage for B.
8. **BBB:** Ligand B (83.831) shows significantly better BBB penetration potential than Ligand A (65.18). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant, and a higher BBB percentile is generally favorable.
9. **Caco-2:** Both have negative values, which is unusual. Assuming these are logP values, they are both poor.
10. **Solubility:** Both ligands have very poor solubility (-1.302 and -1.12). This is a concern for both.
11. **hERG:** Ligand A (0.088) is slightly better than Ligand B (0.479) regarding hERG inhibition liability. Lower is better, but both are reasonably low risk.
12. **Cl_mic:** Ligand B (-10.467) has a much lower (better) microsomal clearance than Ligand A (20.555), indicating greater metabolic stability.
13. **t1/2:** Ligand B (-5.844) has a longer in vitro half-life than Ligand A (15.152). This is a significant advantage for B.
14. **Pgp:** Ligand A (0.024) has lower P-gp efflux liability than Ligand B (0.004). Lower is better, and A is slightly better here.
15. **Binding Affinity:** Ligand A (-6.8 kcal/mol) has a slightly better binding affinity than Ligand B (-5.2 kcal/mol). This is a 1.6 kcal/mol difference, which is substantial.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity, Ligand B demonstrates a superior ADME profile. Specifically, the significantly lower DILI risk, better BBB penetration, improved metabolic stability (lower Cl_mic and longer t1/2), and better logP make it a more promising candidate. The solubility is poor for both, but can be addressed with formulation strategies. The affinity difference, while noticeable, can potentially be optimized in later stages of drug development. Given the GPCR target class, the balance of properties in Ligand B is more favorable.
Output:
0
2025-04-17 19:11:50,119 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [360.426, 110.1 , -0.277, 4. , 5. , 0.499, 28.228, 48.468, -5.351, -1.783, 0.273, 1.385, -8.037, 0.05 , -6.6 ]
**Ligand B:** [370.431, 94.09 , -0.357, 0. , 8. , 0.577, 53.509, 61.38 , -4.933, -1.251, 0.167, 10.382, 10.345, 0.038, -5.9 ]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, Affinity, and to a lesser extent BBB):
1. **MW:** Both are within the ideal 200-500 Da range. A (360.426) is slightly preferred.
2. **TPSA:** A (110.1) is a bit higher than B (94.09). B is better here, closer to the <140 threshold for oral absorption and more favorable for GPCRs.
3. **logP:** Both are reasonably good (-0.277 and -0.357), falling within the 1-3 range. They are slightly on the lower side, but not critically so.
4. **HBD:** A (4) is preferable to B (0). Some H-bond donors can be beneficial for solubility.
5. **HBA:** B (8) is better than A (5). Lower HBA is generally preferred for permeability.
6. **QED:** Both are acceptable (A: 0.499, B: 0.577), but B is slightly better.
7. **DILI:** A (28.228) is significantly better than B (53.509). This is a major advantage for A.
8. **BBB:** B (61.38) is better than A (48.468), but neither are particularly high. For a non-CNS target like cardiovascular ADRB2, this is less critical.
9. **Caco-2:** A (-5.351) is better than B (-4.933), indicating better absorption.
10. **Solubility:** A (-1.783) is better than B (-1.251).
11. **hERG:** Both are very low (A: 0.273, B: 0.167), indicating low cardiotoxicity risk. B is slightly better.
12. **Cl_mic:** A (1.385) is *much* better than B (10.382). Lower clearance is highly desirable for metabolic stability.
13. **t1/2:** A (-8.037) is better than B (10.345).
14. **Pgp:** A (0.05) is better than B (0.038), indicating less efflux.
15. **Affinity:** A (-6.6) is better than B (-5.9), a significant 0.7 kcal/mol difference. This is a substantial advantage.
**Overall Assessment:**
Ligand A has a clear advantage in several critical areas: DILI risk, metabolic stability (Cl_mic and t1/2), Pgp efflux, and binding affinity. While Ligand B has slightly better TPSA and QED, the superior safety profile and potency of Ligand A outweigh these minor differences. The slightly lower BBB penetration of A is not a major concern for a cardiovascular target.
Output:
1
2025-04-17 19:11:50,119 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [409.284, 102.3 , 1.878, 2. , 4. , 0.725, 64.676, 51.066, -4.81 , -3.934, 0.511, 42.751, 57.175, 0.088, -6.4 ]
**Ligand B:** [339.414, 39.08 , 4.39 , 1. , 4. , 0.694, 64.133, 50.679, -4.943, -4.562, 0.749, 91.591, 21.682, 0.786, -3.7 ]
**Step-by-step comparison:**
1. **MW:** Ligand A (409.284 Da) is within the ideal range, while Ligand B (339.414 Da) is towards the lower end but still acceptable.
2. **TPSA:** Ligand A (102.3) is slightly above the preferred <140 for good absorption, but not alarming. Ligand B (39.08) is excellent, well below 140.
3. **logP:** Ligand A (1.878) is optimal. Ligand B (4.39) is a bit high, potentially leading to solubility issues or off-target interactions.
4. **HBD:** Both ligands have acceptable HBD counts (2 and 1, respectively).
5. **HBA:** Both ligands have the same HBA count (4), which is acceptable.
6. **QED:** Both ligands have similar QED values (0.725 and 0.694), indicating good drug-likeness.
7. **DILI:** Both ligands have similar DILI risk (64.676 and 64.133), indicating moderate risk.
8. **BBB:** Both ligands have similar BBB penetration (51.066 and 50.679), which is not a high priority for a cardiovascular target, but could be relevant if off-target CNS effects are a concern.
9. **Caco-2:** Both ligands have poor Caco-2 permeability (-4.81 and -4.943).
10. **Solubility:** Both ligands have poor aqueous solubility (-3.934 and -4.562).
11. **hERG:** Ligand A (0.511) has a lower hERG risk than Ligand B (0.749), which is a significant advantage.
12. **Cl_mic:** Ligand A (42.751) has a lower microsomal clearance, indicating better metabolic stability than Ligand B (91.591).
13. **t1/2:** Ligand A (57.175) has a longer in vitro half-life than Ligand B (21.682), which is desirable.
14. **Pgp:** Ligand A (0.088) has lower P-gp efflux liability than Ligand B (0.786), which is beneficial for bioavailability.
15. **Affinity:** Ligand A (-6.4 kcal/mol) has a significantly stronger binding affinity than Ligand B (-3.7 kcal/mol). This is a substantial advantage.
**GPCR-specific priorities:** For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A has a better logP, lower Pgp efflux, and *much* stronger affinity. While Ligand B has a better TPSA, the affinity difference is too large to ignore. The improved metabolic stability and lower hERG risk of Ligand A are also important positives. Both have poor Caco-2 and solubility, which would need to be addressed in formulation.
**Conclusion:**
Ligand A is the more promising candidate due to its significantly higher binding affinity, better metabolic stability, lower hERG risk, and lower P-gp efflux. The slightly higher TPSA is a minor drawback compared to these advantages.
**Output:**
1
2025-04-17 19:11:50,119 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.482 and 363.845 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (38.82) is significantly better than Ligand B (78.45). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold. Ligand B is approaching the upper limit.
3. **logP:** Both ligands (2.446 and 2.767) are within the optimal 1-3 range. No significant difference.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (4). Fewer HBAs generally improve permeability.
6. **QED:** Both ligands (0.704 and 0.756) have good drug-likeness scores, exceeding the 0.5 threshold. No clear advantage.
7. **DILI:** Ligand A (13.106) has a much lower DILI risk than Ligand B (44.126). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (90.035) has better BBB penetration than Ligand B (37.65). While not a primary concern for a cardiovascular target, it's still a positive attribute.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.694 and -4.771). These values are unusual and suggest poor permeability. However, the values are very similar.
10. **Solubility:** Ligand A (-2.19) has slightly better solubility than Ligand B (-3.928).
11. **hERG:** Ligand A (0.957) has a slightly better hERG profile than Ligand B (0.58). Lower is better, indicating reduced cardiotoxicity risk.
12. **Cl_mic:** Ligand A (23.967) has a lower microsomal clearance than Ligand B (33.786), suggesting better metabolic stability.
13. **t1/2:** Ligand B (38.792) has a significantly longer in vitro half-life than Ligand A (5.583). This is a major advantage for Ligand B.
14. **Pgp:** Ligand A (0.089) has a much lower P-gp efflux liability than Ligand B (0.285), indicating better absorption and bioavailability.
15. **Binding Affinity:** Ligand A (-7.5) has a slightly better binding affinity than Ligand B (-6.9). While both are good, the 0.6 kcal/mol difference is noticeable.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity) and the general guidelines, Ligand A is the more promising candidate. It excels in TPSA, DILI risk, Pgp efflux, and has a slightly better binding affinity and solubility. While Ligand B has a longer half-life, the superior ADME profile and safety (DILI) of Ligand A outweigh this benefit. The Caco-2 values are concerning for both, but the other parameters favor A.
Output:
1
2025-04-17 19:11:50,119 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.471 and 353.507 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (67.43) is better than Ligand B (70.67). Both are below the 140 threshold for oral absorption, but lower is generally preferred.
3. **logP:** Ligand A (3.521) is good, within the optimal 1-3 range. Ligand B (1.256) is on the lower end, potentially indicating permeability issues. This is a notable advantage for A.
4. **HBD:** Both have 2 HBD, which is within the acceptable limit of 5.
5. **HBA:** Ligand A has 3 HBA, while Ligand B has 4. Both are within the acceptable limit of 10.
6. **QED:** Ligand A (0.757) is better than Ligand B (0.58), indicating a more drug-like profile.
7. **DILI:** Ligand A (28.383) has a significantly lower DILI risk than Ligand B (19.698). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (76.968) has a much higher BBB penetration percentile than Ligand B (29.003). Given ADRB2's relevance in cardiovascular function, CNS penetration isn't *critical*, but a higher value is still preferable.
9. **Caco-2:** Both have negative values, indicating poor permeability. Ligand A (-4.254) is slightly better than Ligand B (-4.751).
10. **Solubility:** Ligand A (-4.087) is slightly better than Ligand B (-2.346).
11. **hERG:** Ligand A (0.578) has a lower hERG inhibition liability than Ligand B (0.208), indicating a lower risk of cardiotoxicity.
12. **Cl_mic:** Ligand B (35.925) has a much lower microsomal clearance than Ligand A (85.576), suggesting better metabolic stability. This is a significant advantage for B.
13. **t1/2:** Ligand B (-5.864) has a longer in vitro half-life than Ligand A (4.283). This is a significant advantage for B.
14. **Pgp:** Ligand A (0.128) has lower P-gp efflux than Ligand B (0.033).
15. **Binding Affinity:** Ligand A (-7.5) has a slightly better binding affinity than Ligand B (-7.1). While the difference is relatively small (0.4 kcal/mol), it's still a positive for A.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand A is the stronger candidate. While Ligand B has better metabolic stability (lower Cl_mic, longer t1/2), Ligand A excels in logP, DILI risk, BBB penetration, hERG liability, and slightly better affinity. The lower DILI risk and better logP are particularly important for a cardiovascular target. The small advantage in binding affinity further supports choosing Ligand A.
Output:
1
2025-04-17 19:11:50,119 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (354.43 Da and 355.45 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (105.48) is higher than Ligand B (55.84). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is generally preferred for better absorption. Ligand B is significantly better.
**3. logP:** Ligand A (1.501) is within the optimal range (1-3), while Ligand B (4.015) is pushing the upper limit. Higher logP can lead to off-target effects and solubility issues. Ligand A is preferred.
**4. H-Bond Donors:** Ligand A has 4 HBD, and Ligand B has 0. While both are acceptable (<=5), the lack of HBDs in Ligand B might hinder aqueous solubility.
**5. H-Bond Acceptors:** Both ligands have 4 HBA, which is well within the acceptable range (<=10).
**6. QED:** Both ligands have similar QED values (0.418 and 0.41), indicating comparable drug-likeness.
**7. DILI Risk:** Ligand A (52.152) has a higher DILI risk than Ligand B (28.655). Lower DILI is crucial, making Ligand B more favorable.
**8. BBB Penetration:** Ligand A (68.321) has moderate BBB penetration, while Ligand B (94.184) has high penetration. While ADRB2 is primarily a cardiovascular target, some CNS off-target effects are possible, and higher BBB penetration could contribute to that. However, this is less crucial than other factors.
**9. Caco-2 Permeability:** Ligand A (-5.165) has poor Caco-2 permeability, while Ligand B (-4.422) is slightly better, but still poor. Both are problematic.
**10. Aqueous Solubility:** Ligand A (-2.92) has very poor solubility, whereas Ligand B (-4.924) is even worse. Both are significantly below desirable levels.
**11. hERG Inhibition:** Ligand A (0.74) has a slightly higher hERG risk than Ligand B (0.697). Lower hERG is better, so Ligand B is slightly favored.
**12. Microsomal Clearance:** Ligand B (99.737) has significantly higher microsomal clearance than Ligand A (44.845), indicating faster metabolism and potentially lower *in vivo* exposure. Ligand A is preferred.
**13. In vitro Half-Life:** Ligand A (0.745) has a very short half-life, while Ligand B (-3.102) has a longer half-life. Ligand B is significantly better.
**14. P-gp Efflux:** Ligand A (0.063) has lower P-gp efflux than Ligand B (0.278), which is preferable for bioavailability. Ligand A is favored.
**15. Binding Affinity:** Ligand A (-6.6 kcal/mol) has a better binding affinity than Ligand B (-3.9 kcal/mol). This is a substantial difference (2.7 kcal/mol), and affinity is a primary driver for GPCR drug candidates.
**Overall Assessment:**
Ligand A has a significantly better binding affinity and lower P-gp efflux, and better metabolic stability. However, it has poor solubility and permeability. Ligand B has better DILI risk, BBB penetration, and in vitro half-life, but significantly weaker binding affinity and higher metabolic clearance.
Given the importance of potency for GPCRs, the 2.7 kcal/mol difference in binding affinity is a major advantage for Ligand A. While the solubility and permeability issues are concerning, these can potentially be addressed through formulation strategies. The weaker affinity of Ligand B is a more difficult hurdle to overcome.
Output:
1
2025-04-17 19:11:50,119 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's analyze each ligand against the provided guidelines, with emphasis on GPCR-relevant properties (logP, TPSA, Pgp, BBB, and affinity).
* **Molecular Weight:** Both ligands (352.41 and 349.479 Da) fall comfortably within the ideal 200-500 Da range.
* **TPSA:** Ligand A (96.25) is slightly higher than Ligand B (74.49). Both are below the 140 threshold for good oral absorption, but Ligand B is significantly better, which is favorable.
* **logP:** Both ligands have acceptable logP values (0.637 and 0.783, respectively), falling within the 1-3 range.
* **H-Bond Donors/Acceptors:** Ligand A has 3 HBD and 5 HBA, while Ligand B has 1 HBD and 6 HBA. Both are within acceptable limits.
* **QED:** Both ligands have good QED scores (0.671 and 0.751), indicating good drug-like properties.
* **DILI:** Ligand B (8.569) has a much lower DILI risk than Ligand A (52.695), a significant advantage.
* **BBB:** Both ligands have moderate BBB penetration (63.94 and 53.238). While ADRB2 isn't necessarily a CNS target, some level of BBB penetration can be beneficial for distribution.
* **Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests a potential issue with permeability prediction. However, the values are similar.
* **Aqueous Solubility:** Both ligands have negative solubility values, which is also unusual and suggests potential formulation challenges. Again, the values are comparable.
* **hERG Inhibition:** Both ligands show very low hERG inhibition risk (0.125 and 0.141), which is excellent.
* **Microsomal Clearance:** Ligand B (5.321) has a significantly lower microsomal clearance than Ligand A (10.9), indicating better metabolic stability.
* **In vitro Half-Life:** Ligand B (17.33) has a much longer in vitro half-life than Ligand A (4.074), which is a major advantage.
* **P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.044 and 0.037), which is favorable.
* **Binding Affinity:** Ligand A (-7.2 kcal/mol) has a slightly better binding affinity than Ligand B (-7.1 kcal/mol), but the difference is small (0.1 kcal/mol).
**Overall Assessment:**
While Ligand A has a marginally better binding affinity, Ligand B is superior in almost every other crucial ADME-Tox parameter. Specifically, the significantly lower DILI risk, lower microsomal clearance, and longer half-life of Ligand B make it a much more promising drug candidate. The lower TPSA is also a plus. The small difference in binding affinity is unlikely to outweigh these substantial advantages.
**Output:**
0
2025-04-17 19:11:50,119 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.48 & 354.50 Da) fall comfortably within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (40.62) is significantly better than Ligand B (56.33). ADRB2 is not a CNS target, but lower TPSA generally aids absorption.
3. **logP:** Ligand A (3.34) is optimal, while Ligand B (-0.036) is quite low. This is a major concern for Ligand B, as it may struggle with membrane permeability.
4. **HBD:** Both have 0 HBD, which is acceptable.
5. **HBA:** Ligand A (2) is preferable to Ligand B (5). Higher HBA can sometimes hinder permeability.
6. **QED:** Both ligands have similar QED values (0.661 vs 0.642), indicating good drug-likeness.
7. **DILI:** Ligand A (19.27) has a much lower DILI risk than Ligand B (5.47). This is a significant advantage for Ligand A.
8. **BBB:** This is less critical for ADRB2, but Ligand A (96.94) is better than Ligand B (66.93).
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Ligand A (-3.415) is better than Ligand B (0.469). Better solubility is generally preferred.
11. **hERG:** Both ligands show low hERG inhibition risk (0.783 and 0.354), which is good.
12. **Cl_mic:** Ligand A (47.74) has a higher microsomal clearance than Ligand B (29.96), indicating faster metabolism. This is a slight disadvantage for Ligand A.
13. **t1/2:** Ligand B (-28.49) has a much longer in vitro half-life than Ligand A (-6.05). This is a substantial advantage for Ligand B.
14. **Pgp:** Ligand A (0.374) has lower P-gp efflux than Ligand B (0.003), which is preferable.
15. **Binding Affinity:** Ligand B (-6.6) has a slightly better binding affinity than Ligand A (-5.5). However, the difference is less than 1.5 kcal/mol, and other factors are more important.
**Overall Assessment:**
Ligand A is the stronger candidate. While Ligand B has a better binding affinity and longer half-life, Ligand B's very low logP is a major red flag, suggesting poor permeability and bioavailability. Ligand A has a much better logP, lower DILI risk, better solubility, and lower P-gp efflux. The slightly higher clearance of Ligand A is a manageable concern. Considering the GPCR-specific priorities (logP, Pgp, TPSA), Ligand A is the more promising candidate.
Output:
1
2025-04-17 19:11:50,120 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (336.479 Da) is slightly lower, which is generally favorable for permeability.
**2. TPSA:** Ligand A (32.34) is significantly better than Ligand B (90.73). For a GPCR, keeping TPSA low is beneficial for permeability and receptor engagement. Ligand B is quite high and could hinder oral absorption.
**3. logP:** Ligand A (4.914) is higher than Ligand B (1.657). While Ligand A is approaching the upper limit, it's still within an acceptable range. Ligand B is a bit low and might suffer from poor membrane permeability.
**4. H-Bond Donors:** Ligand A (1) is preferable to Ligand B (0). While both are low, a single donor can contribute to solubility without significantly impacting permeability.
**5. H-Bond Acceptors:** Ligand B (7) is higher than Ligand A (2). Lower is generally better for permeability.
**6. QED:** Ligand A (0.779) has a substantially better QED score than Ligand B (0.546), indicating a more drug-like profile.
**7. DILI:** Ligand B (71.811) has a higher DILI risk than Ligand A (43.971). Lower DILI is always preferred.
**8. BBB:** Ligand A (81.078) has a much higher BBB penetration percentile than Ligand B (29.12). While ADRB2 isn't exclusively a CNS target, some CNS exposure can occur, and higher BBB penetration is generally a positive attribute for a GPCR ligand.
**9. Caco-2 Permeability:** Ligand A (-4.675) is better than Ligand B (-4.821), indicating better intestinal absorption.
**10. Aqueous Solubility:** Ligand A (-4.665) is better than Ligand B (-2.757).
**11. hERG Inhibition:** Ligand A (0.929) has a slightly higher hERG risk than Ligand B (0.394), but both are relatively low.
**12. Microsomal Clearance:** Ligand B (57.535) has a lower microsomal clearance than Ligand A (48.926), suggesting better metabolic stability.
**13. In vitro Half-Life:** Ligand B (-27.877) has a much longer in vitro half-life than Ligand A (59.693). This is a significant advantage.
**14. P-gp Efflux:** Ligand A (0.711) has a lower P-gp efflux liability than Ligand B (0.14), which is preferable.
**15. Binding Affinity:** Ligand A (-6.3 kcal/mol) has a slightly better binding affinity than Ligand B (-5.1 kcal/mol). This difference of 1.2 kcal/mol is significant and can outweigh some of the ADME drawbacks of Ligand A.
**Overall Assessment:**
Ligand A is the stronger candidate. It excels in critical GPCR properties like TPSA, BBB penetration, QED, and binding affinity. While Ligand B has a better half-life and lower clearance, the superior permeability, drug-likeness, and potency of Ligand A make it the more promising starting point for drug development. The slightly higher hERG risk of Ligand A is manageable, and the difference in half-life can potentially be addressed through structural modifications.
Output:
1
2025-04-17 19:11:50,120 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [342.403, 101.36 , -0.53 , 2. , 6. , 0.551, 47.693, 58.007, -5.095, -2.367, 0.532, -8.439, 4.341, 0.01 , -5.3 ]
**Ligand B:** [350.463, 80.48 , 1.57 , 1. , 6. , 0.807, 38.813, 64.211, -4.848, -1.891, 0.128, 27.521, -9.55 , 0.154, -5.8 ]
Here's a breakdown of the comparison, considering the provided guidelines and GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (342.4) is slightly lower, which is generally favorable for permeability, but both are acceptable.
2. **TPSA:** Ligand A (101.36) is a bit higher than Ligand B (80.48). Both are below 140, but B is better positioned for oral absorption.
3. **logP:** Ligand A (-0.53) is quite low, potentially hindering membrane permeability. Ligand B (1.57) is much better, falling within the optimal 1-3 range. This is a significant advantage for B.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable.
5. **HBA:** Both ligands have 6 HBA, which is within the acceptable limit.
6. **QED:** Ligand B (0.807) has a higher QED score than Ligand A (0.551), indicating a more drug-like profile.
7. **DILI:** Both have relatively low DILI risk, but Ligand B (38.813) is slightly better than Ligand A (47.693).
8. **BBB:** Ligand B (64.211) has a higher BBB penetration percentile than Ligand A (58.007). While not a primary concern for a cardiovascular target, it's a slight advantage.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Both have negative solubility values, also unusual. This suggests poor solubility.
11. **hERG:** Both have low hERG inhibition risk, which is good.
12. **Cl_mic:** Ligand A (-8.439) has a much lower (better) microsomal clearance than Ligand B (27.521), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-9.55) has a longer in vitro half-life than Ligand A (4.341), which is favorable.
14. **Pgp:** Ligand A (0.01) has a much lower P-gp efflux liability than Ligand B (0.154), indicating better oral bioavailability and potentially better CNS exposure.
15. **Affinity:** Both have strong binding affinities (-5.3 and -5.8 kcal/mol), with Ligand A being slightly better (-5.3). However, the difference is not substantial enough to outweigh other factors.
**Overall Assessment:**
Ligand B clearly has a more favorable profile overall. Its logP is within the optimal range, its QED is higher, it has better BBB penetration, and a longer half-life. While Ligand A has slightly better affinity and metabolic stability, the poor logP of Ligand A is a significant drawback for a GPCR target, potentially hindering its ability to reach the receptor. The slightly better Pgp score of Ligand A is not enough to compensate for the logP issue.
Therefore, I prefer Ligand B.
Output:
0
2025-04-17 19:11:50,120 - INFO - Batch 92 complete. Total preferences: 1472
2025-04-17 19:11:50,120 - INFO - Processing batch 93/512...
2025-04-17 19:12:39,314 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
Let's systematically compare Ligand A and Ligand B based on the provided parameters and the guidelines, keeping in mind that ADRB2 is a GPCR. Therefore, logP, Pgp, TPSA, and affinity are particularly important.
1. **Molecular Weight:** Both ligands (340.427 Da and 402.51 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (67.23) is significantly better than Ligand B (109.85). A TPSA under 140 is good for oral absorption, and Ligand A is comfortably within this range, while Ligand B is approaching the upper limit.
3. **logP:** Ligand A (2.763) is optimal (1-3). Ligand B (-0.436) is below 1, which could hinder permeation. This is a significant advantage for Ligand A.
4. **H-Bond Donors:** Both ligands have 1 HBD, which is acceptable.
5. **H-Bond Acceptors:** Ligand A has 4 HBA, and Ligand B has 6. Both are within the acceptable limit of 10, but Ligand A is slightly better.
6. **QED:** Ligand A (0.91) is excellent, indicating high drug-likeness. Ligand B (0.496) is below the desirable threshold of 0.5. This is a strong point in favor of Ligand A.
7. **DILI:** Both ligands have relatively low DILI risk (47.344 and 43.66, respectively). No significant difference.
8. **BBB:** Both ligands show good BBB penetration (75.107 and 77.821, respectively). Similar values.
9. **Caco-2 Permeability:** Ligand A (-4.345) and Ligand B (-5.266) both have negative values, which is unusual. Lower (more negative) values suggest *lower* permeability. Ligand A is slightly better.
10. **Aqueous Solubility:** Ligand A (-3.105) and Ligand B (-2.436) both have negative solubility values, indicating poor solubility. Ligand B is slightly better.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.213 and 0.536, respectively). No significant difference.
12. **Microsomal Clearance:** Ligand A (46.15) has higher clearance than Ligand B (27.238). This suggests Ligand B is more metabolically stable, which is good.
13. **In vitro Half-Life:** Ligand A (34.532) has a longer half-life than Ligand B (-27.578). This is a significant advantage for Ligand A.
14. **P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.018 and 0.029, respectively). No significant difference.
15. **Binding Affinity:** Ligand A (-7.0) has a slightly better binding affinity than Ligand B (-6.4). While the difference is not huge, it's still a factor.
**Overall Assessment:**
Ligand A clearly outperforms Ligand B in several critical areas. Its superior logP, TPSA, QED, and in vitro half-life, combined with comparable binding affinity and safety profiles, make it a more promising drug candidate. While Ligand B has slightly better metabolic stability and solubility, the issues with its logP and QED are significant drawbacks, especially for a GPCR target where good permeability and drug-likeness are crucial.
Output:
1
2025-04-17 19:12:39,315 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (345.491 and 354.466 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (61.36) is slightly higher than Ligand B (55.57). Both are below the 140 A^2 threshold for good oral absorption, but closer to the ideal for GPCRs. Ligand B is slightly favored.
**3. logP:** Ligand A (2.692) is within the optimal 1-3 range. Ligand B (3.872) is a bit higher, potentially increasing off-target effects and decreasing solubility, but still acceptable. Ligand A is slightly favored.
**4. H-Bond Donors:** Ligand A has 1 HBD, Ligand B has 0. Both are within the acceptable limit of <=5. No significant difference.
**5. H-Bond Acceptors:** Ligand A has 5 HBA, Ligand B has 4. Both are within the acceptable limit of <=10. No significant difference.
**6. QED:** Ligand A (0.889) has a better QED score than Ligand B (0.675), indicating a more drug-like profile. Ligand A is favored.
**7. DILI Risk:** Ligand B (18.534 percentile) has a significantly lower DILI risk than Ligand A (50.33 percentile). This is a major advantage for Ligand B.
**8. BBB Penetration:** Ligand B (96.355 percentile) shows excellent BBB penetration, while Ligand A (89.027 percentile) is good, but not as high. For a cardiovascular GPCR, some CNS penetration isn't necessarily detrimental, but the higher value for B is a plus. Ligand B is favored.
**9. Caco-2 Permeability:** Ligand A (-4.848) shows poor Caco-2 permeability, while Ligand B (-3.965) is better, though still not great. Ligand B is favored.
**10. Aqueous Solubility:** Ligand A (-2.587) has slightly better aqueous solubility than Ligand B (-3.964). Ligand A is favored.
**11. hERG Inhibition:** Ligand A (0.639) has a slightly lower hERG inhibition liability than Ligand B (0.878), which is preferable. Ligand A is favored.
**12. Microsomal Clearance:** Ligand B (96.226) has a significantly higher microsomal clearance than Ligand A (71.977), meaning it's metabolized more quickly. This is a disadvantage for Ligand B. Ligand A is favored.
**13. In vitro Half-Life:** Ligand A (-1.038 hours) has a very short half-life, while Ligand B (-12.299 hours) has a much longer half-life. This is a significant advantage for Ligand B.
**14. P-gp Efflux:** Ligand A (0.294) has lower P-gp efflux than Ligand B (0.768), which is preferable. Ligand A is favored.
**15. Binding Affinity:** Ligand A (-6.5 kcal/mol) has a slightly better binding affinity than Ligand B (-4.6 kcal/mol). This is a substantial advantage for Ligand A, potentially outweighing some ADME concerns.
**Overall Assessment:**
While Ligand B excels in BBB penetration, DILI risk, and *in vitro* half-life, Ligand A has a superior binding affinity, better QED, lower hERG risk, and lower P-gp efflux. The significantly better binding affinity of Ligand A is a critical factor for a GPCR target. The longer half-life of Ligand B is attractive, but can potentially be addressed through prodrug strategies or formulation. The lower DILI risk of Ligand B is good, but not enough to overcome the potency advantage of Ligand A. The poor Caco-2 permeability of Ligand B is also a concern.
Considering the balance of these factors, and prioritizing binding affinity for a GPCR target, I favor Ligand A.
Output:
1
2025-04-17 19:12:39,315 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (376.425 and 368.503 Da) fall comfortably within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Both ligands (98.66 and 94.56) are below the 140 A^2 threshold for good oral absorption, but higher than the 90 A^2 threshold for CNS targets. Since ADRB2 is a cardiovascular target, CNS penetration isn't a primary concern.
3. **logP:** Both ligands have good logP values (1.273 and 1.003), falling within the optimal 1-3 range. Again, no significant difference.
4. **HBD:** Ligand A has 4 HBD, and Ligand B has 3. Both are acceptable (<=5).
5. **HBA:** Ligand A has 5 HBA, and Ligand B has 6. Both are acceptable (<=10).
6. **QED:** Both ligands have good QED scores (0.576 and 0.636), indicating good drug-like properties. Ligand B is slightly better here.
7. **DILI:** Ligand A (38.852) has a slightly higher DILI risk than Ligand B (33.23), but both are below the concerning 60 percentile.
8. **BBB:** Ligand A (58.007) has a higher BBB penetration percentile than Ligand B (33.579). While not a primary concern for a cardiovascular target, higher BBB is generally favorable.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.201 and -5.55). This is unusual and suggests poor permeability. However, these values are on a log scale, so the difference isn't massive.
10. **Solubility:** Ligand A (-2.048) has slightly better solubility than Ligand B (-1.003), but both are poor.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.305 and 0.174). This is excellent.
12. **Cl_mic:** Ligand A (-5.105) has a lower (better) microsomal clearance than Ligand B (-29.142). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (9.297) has a shorter in vitro half-life than Ligand B (24.156). This is a significant advantage for Ligand B.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.032 and 0.039). This is favorable.
15. **Binding Affinity:** Ligand B (-6.7 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.8 kcal/mol). This is a 0.9 kcal/mol difference, which is substantial.
**GPCR-Specific Priorities & Overall Assessment:**
For a GPCR like ADRB2, affinity is paramount. Ligand B's significantly better binding affinity (-6.7 vs -5.8 kcal/mol) is a major advantage that outweighs the slightly worse solubility and DILI risk. The longer half-life of Ligand B is also a positive. While Ligand A has better metabolic stability (lower Cl_mic), the affinity difference is more critical for initial optimization. The Caco-2 values for both are poor, but this can be addressed with formulation strategies.
**Output:**
0
2025-04-17 19:12:39,315 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (373.45 and 353.419 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (88.18) is significantly better than Ligand A (118.36). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (0.775) is slightly lower than Ligand B (-0.071), but both are within the acceptable range of 1-3. Ligand B is a little closer to the lower end, which could be a minor concern for permeability.
4. **HBD:** Ligand B (1) has fewer H-bond donors than Ligand A (3), which is generally favorable for permeability.
5. **HBA:** Ligand B (5) has a similar number of H-bond acceptors to Ligand A (4).
6. **QED:** Ligand B (0.747) has a slightly better QED score than Ligand A (0.592), suggesting a more drug-like profile.
7. **DILI:** Ligand B (26.871) has a much lower DILI risk than Ligand A (50.989). This is a significant advantage.
8. **BBB:** Both ligands have similar BBB penetration (Ligand A: 59.054, Ligand B: 54.091). Not a major factor for a cardiovascular target.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. Ligand A (-5.57) is slightly better than Ligand B (-4.968), but both are concerning.
10. **Solubility:** Both ligands have negative solubility values, indicating poor solubility. Ligand A (-2.073) is slightly better than Ligand B (-1.033), but both are concerning.
11. **hERG:** Both ligands have very low hERG inhibition risk (Ligand A: 0.31, Ligand B: 0.12).
12. **Cl_mic:** Ligand B (-0.844) has a significantly lower microsomal clearance than Ligand A (3.691), indicating better metabolic stability.
13. **t1/2:** Ligand B (0.032) has a very short in vitro half-life, while Ligand A (-20.503) has a negative value, which is not interpretable.
14. **Pgp:** Both ligands have very low P-gp efflux liability (Ligand A: 0.091, Ligand B: 0.009).
15. **Binding Affinity:** Ligand B (-6.2) has a slightly better binding affinity than Ligand A (-5.9). While the difference is small, it's still a positive.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand B performs better on TPSA, Pgp, and has slightly better affinity. The improved metabolic stability (Cl_mic) and significantly lower DILI risk of Ligand B are also major advantages. While both have poor Caco-2 and solubility, the other benefits of Ligand B outweigh this drawback.
**Conclusion:**
Ligand B is the more promising candidate due to its superior DILI profile, metabolic stability, TPSA, and slightly better binding affinity.
Output:
0
2025-04-17 19:12:39,315 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (375.376 and 344.459 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (83.28) is slightly higher than Ligand B (70.25). Both are below 140, suitable for oral absorption, but Ligand B is preferable due to the lower TPSA.
3. **logP:** Ligand A (2.327) is within the optimal 1-3 range. Ligand B (3.552) is at the higher end, potentially increasing off-target effects and decreasing solubility, but still acceptable. Ligand A is slightly better.
4. **HBD:** Both ligands have 2 H-bond donors, which is good.
5. **HBA:** Ligand A has 6 H-bond acceptors, while Ligand B has 3. Lower HBA is generally preferred for better permeability, giving Ligand B an edge.
6. **QED:** Ligand A (0.863) has a higher QED score than Ligand B (0.787), indicating a more drug-like profile. This favors Ligand A.
7. **DILI:** Ligand A (63.746) has a higher DILI risk than Ligand B (43.66). This is a significant advantage for Ligand B.
8. **BBB:** Ligand B (77.007) has a higher BBB penetration percentile than Ligand A (64.211). Since ADRB2 is a GPCR, BBB penetration is a relevant consideration, favoring Ligand B.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.881 and -4.849), which is unusual and suggests poor permeability. This is a concern for both, but not a differentiating factor.
10. **Solubility:** Ligand A (-2.757) has slightly better solubility than Ligand B (-3.78), but both are quite poor.
11. **hERG:** Ligand A (0.26) has a lower hERG inhibition liability than Ligand B (0.841), which is a positive for Ligand A.
12. **Cl_mic:** Ligand A (-2.284) has a lower (better) microsomal clearance than Ligand B (42.689), indicating greater metabolic stability. This strongly favors Ligand A.
13. **t1/2:** Ligand A (13.373) has a longer in vitro half-life than Ligand B (-14.904). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.143) has lower P-gp efflux liability than Ligand B (0.272), which is preferable.
15. **Binding Affinity:** Ligand A (-7.7 kcal/mol) has a better binding affinity than Ligand B (-5.9 kcal/mol). This is a substantial difference and a major factor in favor of Ligand A.
**Overall Assessment:**
Ligand A has a significantly better binding affinity, QED, metabolic stability (Cl_mic), half-life, Pgp efflux, and hERG liability. While Ligand B has advantages in DILI risk and BBB penetration, the substantial difference in binding affinity and the other favorable ADME properties of Ligand A outweigh these benefits. The poor Caco-2 values for both are a concern that would need to be addressed in further optimization, but the potency advantage of Ligand A is too significant to ignore.
Output:
1
2025-04-17 19:12:39,316 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [337.335, 104.46 , 1.196, 3. , 5. , 0.727, 64.521, 24.855, -5.126, -3.958, 0.144, -28.535, 28.545, 0.024, -7.5 ]
**Ligand B:** [373.45 , 83.72 , 1.635, 0. , 5. , 0.692, 51.26 , 94.223, -4.636, -2.346, 0.597, 46.333, -55.172, 0.141, -6.9 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (337.335) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (104.46) is higher than Ligand B (83.72). For a cardiovascular GPCR, TPSA is not a primary concern unless CNS penetration is desired, but lower is generally better.
3. **logP:** Both are within the optimal range (1-3). Ligand B (1.635) is slightly higher, which could potentially lead to off-target interactions, but isn't a major concern.
4. **HBD:** Ligand A (3) is higher than Ligand B (0). Lower HBD is generally preferred for better membrane permeability.
5. **HBA:** Both have 5 HBA, which is acceptable.
6. **QED:** Both are above 0.5, indicating good drug-like properties, with Ligand A (0.727) being slightly better.
7. **DILI:** Ligand B (51.26) has a significantly lower DILI risk than Ligand A (64.521). This is a crucial advantage.
8. **BBB:** Ligand B (94.223) shows much better potential for BBB penetration than Ligand A (24.855). While this isn't critical for a cardiovascular target, it's a bonus.
9. **Caco-2:** Ligand A (-5.126) shows better Caco-2 permeability than Ligand B (-4.636).
10. **Solubility:** Ligand A (-3.958) has slightly worse solubility than Ligand B (-2.346).
11. **hERG:** Ligand A (0.144) has a slightly lower hERG risk than Ligand B (0.597).
12. **Cl_mic:** Ligand A (-28.535) has a much lower microsomal clearance, suggesting better metabolic stability than Ligand B (46.333). This is a significant advantage.
13. **t1/2:** Ligand A (28.545) has a much longer in vitro half-life than Ligand B (-55.172). This is a significant advantage.
14. **Pgp:** Ligand A (0.024) has lower P-gp efflux liability than Ligand B (0.141), which is favorable for bioavailability.
15. **Affinity:** Ligand A (-7.5) has a slightly better binding affinity than Ligand B (-6.9).
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand B has better logP, Pgp, and BBB penetration. However, Ligand A has a better affinity, metabolic stability, and half-life. The affinity difference is substantial (0.6 kcal/mol). The metabolic stability and half-life are also very important.
**Overall Assessment:**
While Ligand B has a lower DILI risk and better BBB penetration, the significantly better affinity, metabolic stability (Cl_mic), and half-life of Ligand A outweigh these advantages. The slightly higher DILI risk of Ligand A can be investigated further during optimization. The improved binding affinity is a crucial factor for a GPCR target.
Output:
1
2025-04-17 19:12:39,316 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (354.451 and 357.38 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (99.77) is higher than Ligand B (61.36). While both are under 140, the lower TPSA of Ligand B is more favorable for permeability, a key consideration for GPCRs.
3. **logP:** Both ligands have good logP values (1.906 and 1.317), falling within the 1-3 range. Ligand B is slightly better.
4. **HBD:** Ligand A has 3 HBD, while Ligand B has 1. Lower HBD is generally preferred for better permeability, making Ligand B slightly better.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 5. Both are acceptable, but lower is preferable.
6. **QED:** Ligand B (0.832) has a higher QED score than Ligand A (0.657), indicating a more drug-like profile.
7. **DILI:** Ligand B (34.238) has a significantly lower DILI risk than Ligand A (47.421). This is a major advantage for Ligand B.
8. **BBB:** Ligand B (88.135) has a higher BBB penetration percentile than Ligand A (70.997). Given that ADRB2 is a GPCR, BBB penetration is a relevant consideration, even if not the primary focus for this specific receptor.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.449 and -4.943). These values are difficult to interpret without knowing the scale, but negative values generally indicate poor permeability.
10. **Solubility:** Ligand B (-1.604) has a slightly better solubility score than Ligand A (-3.347).
11. **hERG:** Ligand A (0.198) has a lower hERG inhibition liability than Ligand B (0.419). This is a positive for Ligand A, as it suggests a lower risk of cardiotoxicity.
12. **Cl_mic:** Ligand B (-17.488) has a *much* lower microsomal clearance than Ligand A (40.431), indicating significantly better metabolic stability. This is a substantial advantage.
13. **t1/2:** Ligand B (-3.476) has a slightly longer in vitro half-life than Ligand A (4.393).
14. **Pgp:** Ligand A (0.021) has a lower P-gp efflux liability than Ligand B (0.012). Lower P-gp efflux is generally preferred.
15. **Binding Affinity:** Ligand B (-6.9 kcal/mol) has a slightly better binding affinity than Ligand A (-5.6 kcal/mol). This difference of 1.3 kcal/mol is significant and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand B consistently outperforms Ligand A in most critical ADME properties (DILI, BBB, Cl_mic, solubility, t1/2, QED) and has a slightly better binding affinity. While Ligand A has a lower hERG risk, the overall profile of Ligand B is much more favorable for development as a drug candidate. The improved metabolic stability (Cl_mic) and reduced toxicity (DILI) are particularly important. The slightly better affinity further strengthens the case for Ligand B.
Output:
0
2025-04-17 19:12:39,316 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
Let's break down the comparison, prioritizing GPCR-relevant properties (logP, TPSA, Pgp, BBB, and affinity) alongside general drug-like characteristics.
1. **Molecular Weight:** Both ligands (406.284 Da and 402.51 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (73.14) is significantly better than Ligand B (109.85). A TPSA under 140 is good for oral absorption, and lower is generally preferred for GPCRs. Ligand B is pushing the upper limit.
3. **logP:** Ligand A (2.268) is within the optimal 1-3 range. Ligand B (-0.436) is below 1, which could indicate poor membrane permeability. This is a substantial negative for Ligand B.
4. **H-Bond Donors:** Ligand A (0) is preferable to Ligand B (1). Fewer HBDs generally improve permeability.
5. **H-Bond Acceptors:** Both have 6 HBA, which is acceptable.
6. **QED:** Ligand A (0.762) is better than Ligand B (0.496), indicating a more drug-like profile.
7. **DILI:** Ligand A (51.338) has a slightly higher DILI risk than Ligand B (43.66), but both are below the concerning threshold of 60.
8. **BBB:** Ligand B (77.821) has a slightly better BBB penetration percentile than Ligand A (70.997), but both are reasonably good.
9. **Caco-2:** Ligand A (-4.624) is better than Ligand B (-5.266). Higher values indicate better absorption.
10. **Solubility:** Ligand A (-2.975) is better than Ligand B (-2.436). Higher values indicate better solubility.
11. **hERG:** Ligand A (0.28) is significantly better than Ligand B (0.536). Lower hERG inhibition is crucial for avoiding cardiotoxicity, especially important for a cardiovascular target like ADRB2.
12. **Cl_mic:** Ligand B (27.238) has lower microsomal clearance than Ligand A (58.099), suggesting better metabolic stability. This is a positive for Ligand B.
13. **t1/2:** Ligand A (-26.91) and Ligand B (-27.578) are comparable. Both are negative, indicating a short half-life.
14. **Pgp:** Ligand A (0.134) is better than Ligand B (0.029). Lower P-gp efflux is desirable for better bioavailability and potential CNS exposure.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.6 kcal/mol and -6.4 kcal/mol). The difference is not substantial enough to override other significant ADME differences.
**Overall Assessment:**
Ligand A is the stronger candidate. While Ligand B has slightly better metabolic stability and BBB penetration, Ligand A excels in crucial areas like logP, TPSA, QED, hERG inhibition, and Caco-2 permeability. The significantly better logP and TPSA of Ligand A are particularly important for a GPCR target, suggesting better membrane permeability and absorption. The lower hERG risk is also a critical advantage for a cardiovascular drug.
Output:
1
2025-04-17 19:12:39,316 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.825 and 338.459 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (58.12 and 60.04) are below the 140 A^2 threshold for good oral absorption, and are reasonably low. No major difference.
3. **logP:** Both ligands (3.394 and 3.732) are within the optimal 1-3 range, suggesting good permeability and avoiding solubility issues. Ligand B is slightly higher, which *could* be a minor drawback.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 6. Both are acceptable (<=10), but A is slightly better.
6. **QED:** Both ligands have similar QED values (0.782 and 0.77), indicating good drug-likeness.
7. **DILI:** Ligand A (83.986) has a higher DILI risk than Ligand B (57.852). This is a significant negative for Ligand A.
8. **BBB:** Both have high BBB penetration (84.684 and 82.047). This isn't a primary concern for ADRB2 (a cardiovascular target), but it doesn't hurt.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Both have negative solubility values, indicating poor solubility. This is a concern for both.
11. **hERG:** Both ligands have low hERG inhibition risk (0.824 and 0.841). This is good.
12. **Cl_mic:** Ligand A (83.752) has a higher microsomal clearance than Ligand B (56.079), indicating lower metabolic stability. This is a negative for Ligand A.
13. **t1/2:** Ligand A (65.651) has a longer in vitro half-life than Ligand B (25.007). This is a positive for Ligand A.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.623 and 0.684). This is good.
15. **Binding Affinity:** Ligand A (-7.8 kcal/mol) has a slightly better binding affinity than Ligand B (-7.0 kcal/mol). This is a significant advantage for Ligand A.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Both ligands perform similarly on logP, Pgp, and TPSA. The affinity difference is notable (0.8 kcal/mol), but the significantly higher DILI risk and higher Cl_mic for Ligand A are major drawbacks. While the longer half-life of Ligand A is positive, the other ADME properties of Ligand B are more favorable.
**Conclusion:**
Despite the slightly better affinity of Ligand A, the significantly lower DILI risk and better metabolic stability (lower Cl_mic) of Ligand B make it the more promising candidate. The poor Caco-2 and solubility are concerns for both, but can be addressed with formulation strategies.
Output:
0
2025-04-17 19:12:39,316 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.419 and 358.467 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand B (75.19) is significantly better than Ligand A (96.41). ADRB2 is a cardiovascular target, and while not a CNS target, lower TPSA generally improves permeability.
3. **logP:** Both ligands have acceptable logP values (0.946 and 2.031, respectively), falling within the 1-3 range. Ligand B is slightly better.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1), but both are within the acceptable limit of 5.
5. **HBA:** Ligand A (7) is higher than Ligand B (5), but both are within the acceptable limit of 10.
6. **QED:** Both ligands have similar QED values (0.862 and 0.8, respectively), indicating good drug-likeness.
7. **DILI:** Ligand A (52.772) has a significantly lower DILI risk than Ligand B (66.615). This is a major advantage for Ligand A.
8. **BBB:** Not a primary concern for a cardiovascular target, but Ligand B (55.642) has a higher BBB percentile than Ligand A (24.351).
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.974 and -4.827), which is unusual and suggests poor permeability. However, the values are very similar.
10. **Solubility:** Ligand A (-1.647) has better solubility than Ligand B (-3.746).
11. **hERG:** Ligand A (0.096) has a much lower hERG inhibition liability than Ligand B (0.421). This is a critical safety parameter.
12. **Cl_mic:** Ligand B (71.277) has a significantly higher microsomal clearance than Ligand A (6.185), indicating lower metabolic stability.
13. **t1/2:** Ligand A (17.763) has a longer in vitro half-life than Ligand B (-26.058). A negative half-life is concerning for Ligand B.
14. **Pgp:** Ligand A (0.062) has lower P-gp efflux liability than Ligand B (0.114).
15. **Affinity:** Ligand A (-7.0) has slightly better binding affinity than Ligand B (-5.9). While both are good, the difference is significant.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand B has a better logP and TPSA. However, Ligand A excels in DILI risk, hERG inhibition, metabolic stability (Cl_mic and t1/2), Pgp efflux, and has slightly better affinity. The safety profile (DILI and hERG) and metabolic stability are crucial for a cardiovascular drug.
**Conclusion:**
Considering the balance of properties, particularly the significantly lower DILI and hERG risk, better metabolic stability, and slightly improved affinity of Ligand A, it is the more promising drug candidate.
Output:
1
2025-04-17 19:12:39,317 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (351.491 and 346.427 Da) fall comfortably within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (87.3) is slightly higher than Ligand B (62.99). Both are below the 140 threshold for good oral absorption, but B is better, especially considering ADRB2 is a cardiovascular target and CNS penetration isn't a primary goal.
3. **logP:** Both ligands have similar logP values (1.598 and 1.698) which are within the optimal 1-3 range. No significant difference.
4. **HBD:** Ligand A has 3 HBD, while Ligand B has 0. Both are acceptable (<=5), but lower HBD can sometimes improve permeability. Ligand B is slightly favored.
5. **HBA:** Ligand A has 3 HBA, and Ligand B has 4. Both are below the 10 threshold. No major difference.
6. **QED:** Ligand B (0.836) has a significantly higher QED score than Ligand A (0.559), indicating a more drug-like profile. This is a substantial advantage.
7. **DILI:** Ligand B (14.618) has a much lower DILI risk than Ligand A (21.287). This is a critical advantage, as minimizing liver toxicity is paramount.
8. **BBB:** Ligand A (73.866) has a higher BBB penetration than Ligand B (53.044). However, as ADRB2 is a cardiovascular target, BBB penetration is not a primary concern.
9. **Caco-2:** Ligand A (-5.144) has a more negative Caco-2 value, suggesting poorer permeability compared to Ligand B (-4.464). This is a slight advantage for B.
10. **Solubility:** Ligand A (-2) has slightly better solubility than Ligand B (-1.62). Solubility is important, but not a deciding factor here.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.163 and 0.173), which is excellent. No difference.
12. **Cl_mic:** Ligand B (30.388) has a lower microsomal clearance than Ligand A (35.397), suggesting better metabolic stability. This is a positive for Ligand B.
13. **t1/2:** Ligand B (28.482 hours) has a significantly longer in vitro half-life than Ligand A (3.794 hours). This is a major advantage, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.014 and 0.018). No difference.
15. **Binding Affinity:** Ligand B (-6.8 kcal/mol) has a slightly better binding affinity than Ligand A (-6.3 kcal/mol). While the difference is less than 1.5 kcal/mol, it contributes to the overall preference for B.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Ligand B performs better on TPSA, has comparable logP and Pgp, and slightly better affinity. The significant advantages in QED, DILI risk, metabolic stability (Cl_mic), and half-life outweigh the slightly higher BBB penetration of Ligand A.
**Conclusion:**
Ligand B is the more promising drug candidate due to its superior drug-like properties (QED), lower toxicity risk (DILI), better metabolic stability (Cl_mic, t1/2), and slightly improved binding affinity.
Output:
0
2025-04-17 19:12:39,317 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
We are targeting ADRB2, a GPCR. Therefore, priorities are logP, Pgp, TPSA, affinity, and BBB. Let's break down each ligand based on the provided parameters:
* **Molecular Weight:** Both ligands are within the ideal range (348-366 Da).
* **TPSA:** Both are acceptable, below 140 A^2, but relatively high.
* **logP:** Both are within the optimal range (1.46-1.96). Ligand B is slightly better.
* **H-Bond Donors/Acceptors:** Both have acceptable HBD (1) and HBA (3-4).
* **QED:** Both have good QED scores (>0.8), indicating good drug-likeness.
* **DILI:** Both have acceptable DILI risk, below 40%. Ligand A is slightly better.
* **BBB:** Both have good BBB penetration, but Ligand B is better (81.7% vs 76.2%). This is a key consideration for a GPCR.
* **Caco-2:** Both have negative Caco-2 values, which is unusual. I will assume these are percentile scores and interpret them as low permeability.
* **Solubility:** Both have negative solubility values, which is also unusual. I will assume these are percentile scores and interpret them as low solubility.
* **hERG:** Both have low hERG inhibition risk.
* **Cl_mic:** Ligand B has slightly lower microsomal clearance (20.36 vs 24.82), suggesting better metabolic stability.
* **t1/2:** Both have negative in vitro half-life values, which is unusual. I will assume these are percentile scores and interpret them as low half-life.
* **Pgp:** Both have low P-gp efflux liability (0.066-0.107).
* **Binding Affinity:** Ligand A has a slightly better binding affinity (-6.3 kcal/mol) compared to Ligand B (-5.5 kcal/mol). This is a 0.8 kcal/mol difference, which is significant.
**Overall Assessment:**
Ligand A has a better binding affinity, and slightly better DILI. However, Ligand B has better BBB penetration and slightly better metabolic stability. Given that ADRB2 is a GPCR and BBB penetration is a key consideration, and the affinity difference is not huge, Ligand B is slightly more favorable. The better BBB penetration of Ligand B will likely translate to better *in vivo* exposure.
**Output:**
0
2025-04-17 19:12:39,317 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (429.742 Da) is within the ideal range, while Ligand B (369.571 Da) is also acceptable. No clear advantage here.
2. **TPSA:** Both ligands (A: 49.85, B: 49.77) are well below the 140 threshold for oral absorption, and suitable for a GPCR target.
3. **logP:** Both ligands have a logP around 3.48, which is optimal.
4. **HBD:** Ligand A has 0 HBD, while Ligand B has 1. Both are acceptable.
5. **HBA:** Ligand A has 3 HBA, Ligand B has 4. Both are acceptable.
6. **QED:** Both ligands have good QED scores (A: 0.736, B: 0.698), indicating good drug-like properties.
7. **DILI:** Ligand A (58.976) has a higher DILI risk than Ligand B (9.849). This is a significant advantage for Ligand B.
8. **BBB:** Both ligands have good BBB penetration (A: 73.168, B: 74.292).
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the values are comparable (-4.833 for A, -4.421 for B).
10. **Solubility:** Both ligands have negative solubility values, suggesting poor solubility. Again, values are comparable (-4.317 for A, -3.922 for B).
11. **hERG:** Both ligands have low hERG inhibition risk (A: 0.562, B: 0.705).
12. **Cl_mic:** Ligand A (41.638) has a lower microsomal clearance than Ligand B (68.538), indicating better metabolic stability.
13. **t1/2:** Ligand A (13.622) has a longer in vitro half-life than Ligand B (-3.499). This is a significant advantage for Ligand A.
14. **Pgp:** Both ligands have low Pgp efflux liability (A: 0.688, B: 0.574).
15. **Binding Affinity:** Ligand A (-8.0 kcal/mol) has a slightly better binding affinity than Ligand B (-6.8 kcal/mol). This is a 1.2 kcal/mol difference, which is substantial.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Both ligands perform well on logP, Pgp, and TPSA. However, Ligand A has a significantly better binding affinity. The DILI risk is also a major consideration, and Ligand B is significantly better in this regard. The metabolic stability (Cl_mic and t1/2) are also important, and Ligand A is better on both metrics.
**Overall Assessment:**
While Ligand B has a much better DILI profile, the significantly stronger binding affinity of Ligand A, coupled with its better metabolic stability (lower Cl_mic and longer t1/2), outweigh the DILI risk. The affinity difference is large enough to potentially overcome the higher DILI risk with careful clinical monitoring.
Output:
1
2025-04-17 19:12:39,317 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (361.394 Da) is slightly higher than Ligand B (344.459 Da), but both are acceptable.
2. **TPSA:** Both ligands have TPSA values below 140, which is good for oral absorption (Ligand A: 68.54, Ligand B: 67.35). They are also well below the 90 threshold for CNS targets, though this is less critical for ADRB2 which is primarily cardiovascular.
3. **logP:** Ligand A (3.998) is at the upper end of the optimal range (1-3), while Ligand B (2.015) is closer to the middle. Ligand A's higher logP *could* lead to solubility issues, but is not immediately disqualifying.
4. **HBD:** Both ligands have 1 H-bond donor, which is good.
5. **HBA:** Ligand A has 4 H-bond acceptors, while Ligand B has 5. Both are within the acceptable limit of 10.
6. **QED:** Both ligands have good QED scores (Ligand A: 0.721, Ligand B: 0.908). Ligand B is significantly better here, indicating a more drug-like profile.
7. **DILI:** Ligand A has a DILI risk of 85.149, which is concerning (high risk, >60). Ligand B has a much lower DILI risk of 26.173, which is excellent. This is a major advantage for Ligand B.
8. **BBB:** Ligand A (64.637) and Ligand B (77.627) both have moderate BBB penetration. Since ADRB2 is primarily a cardiovascular target, BBB penetration isn't a high priority, but Ligand B is slightly better.
9. **Caco-2:** Both ligands have negative Caco-2 permeability values, which is unusual and suggests poor permeability. However, these values are on a log scale and can be misleading.
10. **Solubility:** Ligand A (-5.071) has very poor predicted solubility, while Ligand B (-1.33) is better, but still poor. This is a concern for both, but more so for Ligand A.
11. **hERG:** Ligand A (0.865) has a moderate hERG risk, while Ligand B (0.326) has a very low risk. This is a significant advantage for Ligand B.
12. **Cl_mic:** Ligand A (49.192) has a moderate microsomal clearance, while Ligand B (11.141) has a low clearance, indicating better metabolic stability. This favors Ligand B.
13. **t1/2:** Ligand A (21.451 hours) has a reasonable in vitro half-life, while Ligand B (4.195 hours) has a short half-life. This is a point in favor of Ligand A.
14. **Pgp:** Ligand A (0.454) has moderate P-gp efflux, while Ligand B (0.053) has very low efflux. Lower P-gp efflux is generally preferred, favoring Ligand B.
15. **Binding Affinity:** Ligand A (-7.8 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.4 kcal/mol). This is a substantial advantage for Ligand A, and could potentially outweigh some of its ADME drawbacks.
**Overall Assessment:**
While Ligand A boasts a significantly better binding affinity, its poor solubility, high DILI risk, and moderate hERG risk are major concerns. Ligand B, despite its weaker affinity, has a much more favorable ADME profile, particularly regarding safety (DILI, hERG) and metabolic stability (Cl_mic). For a GPCR target like ADRB2, a balance of potency and good ADME properties is crucial. The difference in affinity (1.4 kcal/mol) is substantial, but the safety and pharmacokinetic advantages of Ligand B are compelling. Given the cardiovascular context, minimizing off-target effects and ensuring reasonable metabolic stability are paramount.
Output:
0
2025-04-17 19:12:39,317 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (349.439 Da and 347.434 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (115.9) is higher than Ligand B (62.3). For a GPCR, lower TPSA is generally preferred for better permeability, so Ligand B has an advantage.
**3. logP:** Ligand A (-0.374) is lower than the optimal 1-3 range, potentially hindering permeability. Ligand B (2.71) is within the optimal range. This is a significant advantage for Ligand B.
**4. H-Bond Donors:** Ligand A (3) is higher than Ligand B (1), but both are within the acceptable limit of 5.
**5. H-Bond Acceptors:** Ligand A (6) is higher than Ligand B (3), but both are within the acceptable limit of 10.
**6. QED:** Ligand B (0.833) has a higher QED score than Ligand A (0.531), indicating a more drug-like profile. This favors Ligand B.
**7. DILI:** Both ligands have acceptable DILI risk (Ligand A: 34.587, Ligand B: 42.071), below the 60% threshold. No major difference.
**8. BBB:** Ligand B (83.831) has a significantly higher BBB penetration percentile than Ligand A (45.522). While ADRB2 isn't exclusively a CNS target, better BBB penetration is generally favorable, reducing potential off-target effects. This is a strong advantage for Ligand B.
**9. Caco-2 Permeability:** Both have negative values, indicating poor permeability. Ligand A (-5.788) is slightly better than Ligand B (-4.542), but both are concerning.
**10. Aqueous Solubility:** Ligand A (-1.423) is better than Ligand B (-3.051). Solubility is important for formulation and bioavailability, favoring Ligand A.
**11. hERG Inhibition:** Ligand A (0.033) has a lower hERG inhibition risk than Ligand B (0.477). This is a significant safety advantage for Ligand A.
**12. Microsomal Clearance:** Ligand A (-4.906) has a lower (better) microsomal clearance than Ligand B (55.853), suggesting better metabolic stability. This is a substantial advantage for Ligand A.
**13. In vitro Half-Life:** Ligand A (3.133) has a shorter half-life than Ligand B (-19.934). A negative half-life is not possible, so the value for Ligand B is likely an error or outlier. This strongly favors Ligand A.
**14. P-gp Efflux:** Ligand A (0.007) has a much lower P-gp efflux liability than Ligand B (0.12). Lower efflux is desirable for better bioavailability, favoring Ligand A.
**15. Binding Affinity:** Ligand B (-6.8 kcal/mol) has a slightly better binding affinity than Ligand A (-5.8 kcal/mol). While a 1 kcal/mol difference is notable, it's not overwhelming, especially considering the other factors.
**Overall Assessment:**
Ligand B has advantages in logP, QED, and BBB penetration. However, Ligand A has significant advantages in hERG inhibition, microsomal clearance, P-gp efflux, and in vitro half-life. The solubility of Ligand A is also better. Given the importance of metabolic stability, safety (hERG), and bioavailability (P-gp), Ligand A appears to be the more promising candidate, despite the slightly weaker binding affinity. The negative half-life for Ligand B is a major red flag.
Output:
1
2025-04-17 19:12:39,318 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Ligand A (421.646 Da) is within the ideal range, while Ligand B (353.463 Da) is also acceptable, being on the lower side. No clear advantage here.
2. **TPSA:** Ligand A (113.41) is slightly above the preferred <140 for oral absorption, but still reasonable. Ligand B (78.95) is excellent, well below the threshold. Advantage: B.
3. **logP:** Ligand A (2.412) is optimal. Ligand B (0.921) is a bit low, potentially impacting membrane permeability. Advantage: A.
4. **HBD:** Ligand A (3) is good. Ligand B (1) is also good. No clear advantage.
5. **HBA:** Ligand A (7) is good. Ligand B (4) is also good. No clear advantage.
6. **QED:** Both Ligand A (0.438) and Ligand B (0.704) are acceptable, but B is significantly better, indicating a more drug-like profile. Advantage: B.
7. **DILI:** Ligand A (99.341) has a very high DILI risk, a major concern. Ligand B (8.686) has a very low DILI risk, a significant advantage. Advantage: B.
8. **BBB:** Ligand A (40.791) has low BBB penetration. Ligand B (85.964) has good BBB penetration. Advantage: B.
9. **Caco-2:** Ligand A (-5.581) is poor. Ligand B (-4.88) is also poor, but slightly better. Advantage: B.
10. **Solubility:** Ligand A (-4.629) is poor. Ligand B (-1.353) is also poor. No clear advantage.
11. **hERG:** Ligand A (0.396) has a low hERG risk. Ligand B (0.176) has an even lower hERG risk. Advantage: B.
12. **Cl_mic:** Ligand A (2.602) has a low microsomal clearance, suggesting good metabolic stability. Ligand B (18.097) has a high microsomal clearance, suggesting poor metabolic stability. Advantage: A.
13. **t1/2:** Ligand A (108.187) has a long half-life. Ligand B (-7.985) has a very short half-life. Advantage: A.
14. **Pgp:** Ligand A (0.222) has low P-gp efflux. Ligand B (0.014) has very low P-gp efflux. Advantage: B.
15. **Affinity:** Ligand A (-6.5 kcal/mol) has a better binding affinity than Ligand B (-1.8 kcal/mol). This is a substantial difference. Advantage: A.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity) and general drug-like properties, Ligand B is the stronger candidate despite the weaker affinity. The extremely high DILI risk associated with Ligand A is a deal-breaker. Ligand B has better TPSA, QED, DILI, BBB, hERG, and Pgp properties. While Ligand A has better metabolic stability (Cl_mic and t1/2) and binding affinity, the safety concerns with A outweigh these benefits. The affinity difference, while significant, might be overcome with further optimization of Ligand B, whereas mitigating the DILI risk of Ligand A would be far more challenging.
Output:
0
2025-04-17 19:12:39,318 - INFO - Batch 93 complete. Total preferences: 1488
2025-04-17 19:12:39,318 - INFO - Processing batch 94/512...
2025-04-17 19:13:31,489 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Step-by-step comparison:**
1. **MW:** Both ligands (352.347 and 353.463 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand B (98.74) is significantly better than Ligand A (127.88). For a GPCR, lower TPSA is generally preferred for better permeability.
3. **logP:** Ligand A (-0.63) is slightly outside the optimal 1-3 range, being a bit too hydrophilic. Ligand B (0.274) is also on the lower side, but closer to the range.
4. **HBD:** Both ligands have 3 HBD, which is acceptable.
5. **HBA:** Ligand A has 7 HBA, while Ligand B has 4. Ligand B is better here, as fewer HBA generally improves permeability.
6. **QED:** Ligand B (0.612) has a better QED score than Ligand A (0.475), indicating a more drug-like profile.
7. **DILI:** Ligand B (7.251) has a much lower DILI risk than Ligand A (88.29). This is a major advantage for Ligand B.
8. **BBB:** Ligand B (66.809) has a better BBB penetration score than Ligand A (48.003). While ADRB2 isn't strictly a CNS target, some peripheral ADRB2 activity can be modulated by CNS effects, and better BBB penetration is rarely a detriment.
9. **Caco-2:** Both ligands have similar, poor Caco-2 permeability (-5.381 and -5.154).
10. **Solubility:** Both ligands have poor aqueous solubility (-2.267 and -1.12).
11. **hERG:** Both ligands have very low hERG inhibition risk (0.111 and 0.109).
12. **Cl_mic:** Ligand A (-24.411) has a significantly lower (better) microsomal clearance than Ligand B (-6.627). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand B (-32.351) has a much longer in vitro half-life than Ligand A (3.341). This is a significant advantage for Ligand B.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.007 and 0.006).
15. **Binding Affinity:** Both ligands have similar, strong binding affinities (-5.9 and -6.0 kcal/mol). The difference is negligible.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B is better in terms of TPSA and Pgp, and has a better logP. The binding affinity is comparable. The significantly lower DILI risk and longer half-life of Ligand B are also very important. While Ligand A has better metabolic stability (lower Cl_mic), the other advantages of Ligand B outweigh this.
**Output:**
0
2025-04-17 19:13:31,489 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.4 & 348.5 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (66.4) is better than Ligand B (70.51). Both are below the 140 threshold for oral absorption, but lower is generally preferred for GPCRs.
3. **logP:** Ligand B (2.835) is slightly higher than Ligand A (1.679), placing it closer to the optimal 1-3 range. Ligand A is still acceptable, but B is better.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is better than Ligand B (6). Lower HBA is preferable for permeability.
6. **QED:** Ligand A (0.835) is significantly better than Ligand B (0.715), indicating a more drug-like profile.
7. **DILI:** Ligand A (35.5) is better than Ligand B (16.1), indicating a lower risk of drug-induced liver injury. Both are good, but A is better.
8. **BBB:** Ligand A (96.7) is significantly better than Ligand B (83.2). This is a key factor for GPCRs, even cardiovascular ones, as off-target CNS effects are a concern.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand B (-4.974) is slightly worse than Ligand A (-4.59).
10. **Solubility:** Both are negative, indicating poor solubility. Ligand A (-2.428) is slightly better than Ligand B (-2.154).
11. **hERG:** Ligand A (0.553) is better than Ligand B (0.848), indicating a lower risk of hERG inhibition and cardiotoxicity.
12. **Cl_mic:** Both are similar (25.2 and 24.8), suggesting comparable metabolic clearance.
13. **t1/2:** Ligand B (48.5) has a significantly longer half-life than Ligand A (-11.6). This is a substantial advantage.
14. **Pgp:** Ligand A (0.031) is much better than Ligand B (0.088), indicating lower P-gp efflux and better bioavailability.
15. **Binding Affinity:** Ligand B (-2.0) is significantly better than Ligand A (-6.4). This is a large difference in potency.
**Overall Assessment:**
Ligand B has a significantly better binding affinity and a longer half-life, which are crucial for a viable drug candidate. However, Ligand A excels in many ADME properties, including TPSA, QED, DILI, BBB, hERG, and Pgp efflux. The superior BBB penetration of Ligand A is a significant advantage, potentially minimizing off-target effects. The substantial difference in binding affinity (-2.0 vs -6.4) is a major factor. While Ligand A has better ADME properties, the potency advantage of Ligand B is likely to outweigh these benefits, especially given that the ADME properties of Ligand B are still within acceptable ranges.
Output:
0
2025-04-17 19:13:31,490 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (338.371 Da) is better, falling comfortably within the 200-500 Da range. Ligand B (398.26 Da) is still acceptable, but closer to the upper limit.
2. **TPSA:** Ligand B (66.32) is significantly better than Ligand A (111.9). Lower TPSA generally improves permeability, a crucial factor for GPCR ligands.
3. **logP:** Ligand A (3.177) is slightly better than Ligand B (4.144). Both are within the optimal 1-3 range, but Ligand B is approaching a level where solubility issues could arise.
4. **HBD:** Ligand A (2) is slightly better than Ligand B (1). Both are well within the acceptable limit of 5.
5. **HBA:** Ligand A (7) is higher than Ligand B (4). Both are below the 10 limit, but Ligand B is preferable.
6. **QED:** Both ligands have good QED scores (A: 0.546, B: 0.676), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Both ligands have similar DILI risk (A: 78.402, B: 77.007), and are within an acceptable range.
8. **BBB:** Ligand A (65.452) is significantly better than Ligand B (31.912). While ADRB2 isn't exclusively a CNS target, some CNS penetration can be beneficial, and minimizing it isn't a priority.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. This is a significant concern for both.
10. **Solubility:** Both ligands have very poor aqueous solubility (-4.172 and -4.067 respectively). This is a major drawback for both.
11. **hERG:** Ligand A (0.672) is better than Ligand B (0.187), indicating a lower risk of cardiotoxicity. This is a critical consideration for a cardiovascular target.
12. **Cl_mic:** Ligand A (25.375) has a lower microsomal clearance than Ligand B (29.662), suggesting better metabolic stability.
13. **t1/2:** Ligand B (12.321) has a much longer in vitro half-life than Ligand A (-2.43). This is a significant advantage for dosing frequency.
14. **Pgp:** Ligand A (0.186) has lower P-gp efflux liability than Ligand B (0.064), indicating better bioavailability.
15. **Affinity:** Ligand A (-7.1 kcal/mol) has a significantly stronger binding affinity than Ligand B (-3.6 kcal/mol). This is a substantial advantage, potentially outweighing some ADME drawbacks.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B has a better TPSA and Pgp, but Ligand A has a much better logP and *significantly* better affinity. The affinity difference is substantial.
**Overall Assessment:**
Despite the poor solubility and Caco-2 permeability for both compounds, Ligand A's superior binding affinity (-7.1 kcal/mol vs -3.6 kcal/mol) and better hERG profile are decisive. The stronger binding is likely to translate to greater efficacy, and the lower hERG risk is crucial for a cardiovascular drug. The longer half-life of Ligand B is attractive, but can potentially be optimized through structural modifications. The solubility and permeability issues will need to be addressed regardless of which ligand is chosen.
Output:
1
2025-04-17 19:13:31,490 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [363.853, 110.75 , 1.575, 3. , 7. , 0.695, 69.678, 64.482, -5.709, -2.625, 0.216, 44.288, 26.35 , 0.05 , -3.3 ]
**Ligand B:** [353.463, 78.95 , 0.633, 1. , 4. , 0.786, 31.563, 52.268, -4.561, -1.263, 0.142, 18.916, 9.668, 0.013, -5.8 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (353.463) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (110.75) is higher than Ligand B (78.95). For a cardiovascular GPCR, TPSA isn't *as* critical as for CNS targets, but lower is still preferred for better absorption. Ligand B is significantly better here.
3. **logP:** Both are within the optimal range (1-3). Ligand A (1.575) is slightly higher, which could be beneficial for membrane permeability, but Ligand B (0.633) is still reasonable.
4. **HBD:** Ligand A (3) is higher than Ligand B (1). Lower is generally better, so Ligand B is favored.
5. **HBA:** Ligand A (7) is higher than Ligand B (4). Again, lower is better, favoring Ligand B.
6. **QED:** Both are good (>0.5), with Ligand B (0.786) being slightly better than Ligand A (0.695).
7. **DILI:** Ligand A (69.678) has a significantly higher DILI risk than Ligand B (31.563). This is a major concern for Ligand A.
8. **BBB:** Both are reasonably low, as expected for a cardiovascular target. Ligand A (64.482) is slightly higher than Ligand B (52.268), but this isn't a primary concern.
9. **Caco-2:** Ligand A (-5.709) is worse than Ligand B (-4.561), indicating lower intestinal absorption.
10. **Solubility:** Ligand A (-2.625) is worse than Ligand B (-1.263). Solubility is important for bioavailability.
11. **hERG:** Both are very low, indicating low cardiotoxicity risk.
12. **Cl_mic:** Ligand A (44.288) has higher microsomal clearance than Ligand B (18.916), meaning faster metabolism and potentially lower exposure.
13. **t1/2:** Ligand A (26.35) has a longer half-life than Ligand B (9.668), which is generally desirable.
14. **Pgp:** Both are very low, indicating minimal P-gp efflux.
15. **Affinity:** Ligand B (-5.8 kcal/mol) has a significantly stronger binding affinity than Ligand A (-3.3 kcal/mol). This is a substantial advantage.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are particularly important. Ligand B excels in TPSA, and has a substantially better binding affinity. The significantly lower DILI risk and better ADME properties (Caco-2, solubility, Cl_mic) of Ligand B are also crucial. While Ligand A has a longer half-life, the other drawbacks outweigh this benefit. The affinity difference is large enough to overcome the half-life difference.
**Conclusion:**
Ligand B is the more promising drug candidate due to its superior ADME properties, lower toxicity risk, and significantly stronger binding affinity.
0
2025-04-17 19:13:31,490 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (384.464 and 371.547 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (58.64) is better than Ligand B (60.93), both are below the 140 threshold for oral absorption.
3. **logP:** Ligand A (2.654) is optimal (1-3). Ligand B (0.936) is slightly low, potentially impacting permeability.
4. **HBD:** Ligand A (1) is better than Ligand B (0). Lower is generally preferred.
5. **HBA:** Both ligands have 4 HBA, which is within the acceptable range.
6. **QED:** Ligand A (0.733) is slightly better than Ligand B (0.668), indicating a more drug-like profile.
7. **DILI:** Ligand A (22.024) is significantly better than Ligand B (11.516), indicating a much lower risk of drug-induced liver injury. This is a crucial advantage.
8. **BBB:** Ligand A (86.623) is better than Ligand B (71.966). While ADRB2 isn't strictly a CNS target, some peripheral effects can be modulated by CNS penetration.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-4.415) is slightly better than Ligand B (-4.731).
10. **Solubility:** Ligand A (-3.812) is better than Ligand B (-1.055). Solubility is important for bioavailability.
11. **hERG:** Both ligands have low hERG inhibition liability (0.398 and 0.456).
12. **Cl_mic:** Ligand B (10.861) has lower microsomal clearance than Ligand A (73.148), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-29.089) has a longer in vitro half-life than Ligand B (-5.685).
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.033 and 0.058).
15. **Binding Affinity:** Ligand A (-5.6 kcal/mol) is slightly better than Ligand B (-4.8 kcal/mol).
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A has a better logP, TPSA, and affinity. While Ligand B has better metabolic stability, the significantly lower DILI risk and better solubility of Ligand A are more important. The slight advantage in binding affinity further supports Ligand A.
**Conclusion:**
Ligand A demonstrates a more favorable balance of properties, particularly regarding safety (DILI) and key ADME parameters for a GPCR target.
Output:
1
2025-04-17 19:13:31,490 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [433.611, 58.2, 4.584, 2, 2, 0.538, 88.91, 75.843, -4.586, -5.566, 0.543, 39.656, 103.897, 0.551, -7.5]
**Ligand B:** [351.403, 111.89, -0.411, 2, 6, 0.673, 28.306, 29.391, -4.867, -1.781, 0.179, -7.121, 22.357, 0.007, -6.5]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, Affinity, and BBB):
1. **MW:** Ligand A (433.611 Da) is within the ideal range. Ligand B (351.403 Da) is also good, but slightly lower.
2. **TPSA:** Ligand A (58.2) is excellent, well below the 140 threshold. Ligand B (111.89) is higher, but still potentially acceptable.
3. **logP:** Ligand A (4.584) is a bit high, potentially leading to off-target effects and solubility issues. Ligand B (-0.411) is *too* low, likely hindering membrane permeability.
4. **HBD/HBA:** Both have 2 HBDs, which is good. Ligand B has 6 HBAs, which is higher than ideal, but not a major concern. Ligand A has 2 HBAs, which is ideal.
5. **QED:** Both ligands have acceptable QED scores (A: 0.538, B: 0.673).
6. **DILI:** Ligand A (88.91) has a concerningly high DILI risk. Ligand B (28.306) has a very low DILI risk, which is a significant advantage.
7. **BBB:** Ligand A (75.843) has a good BBB percentile. Ligand B (29.391) has a very low BBB percentile. While ADRB2 isn't necessarily a CNS target, some peripheral distribution is still desired, and a higher BBB often correlates with better overall drug-like properties.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual. Assuming these are logP-scale values, they suggest poor permeability.
9. **Solubility:** Ligand A (-5.566) has very poor solubility. Ligand B (-1.781) is also poor, but better than A.
10. **hERG:** Ligand A (0.543) has a low hERG risk. Ligand B (0.179) has a very low hERG risk.
11. **Cl_mic:** Ligand A (39.656) has moderate clearance. Ligand B (-7.121) has negative clearance, which is impossible and likely an error in the data.
12. **t1/2:** Ligand A (103.897) has a good in vitro half-life. Ligand B (22.357) has a shorter half-life.
13. **Pgp:** Ligand A (0.551) has moderate Pgp efflux. Ligand B (0.007) has very low Pgp efflux, which is favorable.
14. **Affinity:** Ligand A (-7.5) has a slightly better binding affinity than Ligand B (-6.5). However, the difference is not huge.
**Overall Assessment:**
Ligand A has better affinity and BBB penetration, but suffers from high DILI risk, poor solubility, and a high logP. Ligand B has a much lower DILI risk and Pgp efflux, but its logP is too low, and its in vitro half-life is shorter. The negative clearance value for Ligand B is a red flag, indicating a data error.
Despite the slightly better affinity of Ligand A, the significantly lower DILI risk and Pgp efflux of Ligand B are more compelling, especially for a GPCR target where bioavailability and minimizing off-target effects are crucial. The low logP of Ligand B is a concern, but might be addressed through structural modifications. The negative clearance is a major issue.
Given these considerations, and assuming the negative clearance for Ligand B is an error, I would lean towards Ligand B as the more promising starting point for optimization.
Output:
0
2025-04-17 19:13:31,490 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (346.383 and 349.431 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (87.15) is better than Ligand B (110.69). For a GPCR, keeping TPSA under 140 is good for oral absorption, and lower is generally preferred. Ligand B is pushing the upper limit.
**3. logP:** Ligand A (1.514) is better than Ligand B (0.486). The optimal range is 1-3, and Ligand B is a bit low, potentially hindering membrane permeability.
**4. H-Bond Donors:** Ligand A (1) is better than Ligand B (5). Lower HBD is preferred for better permeability.
**5. H-Bond Acceptors:** Both ligands have 4-5 HBA, which is acceptable.
**6. QED:** Ligand A (0.873) is significantly better than Ligand B (0.492). A higher QED suggests a more drug-like profile.
**7. DILI:** Ligand A (50.523) is slightly higher than Ligand B (34.781), but both are within an acceptable range (<60 is good).
**8. BBB:** Ligand A (76.037) is considerably better than Ligand B (43.311). While ADRB2 isn't necessarily a CNS target, some degree of BBB penetration can be useful for understanding off-target effects and overall distribution.
**9. Caco-2 Permeability:** Ligand A (-4.472) is better than Ligand B (-5.123). Higher Caco-2 permeability is desired, and Ligand A is closer to 0.
**10. Aqueous Solubility:** Both ligands have very poor aqueous solubility (-2.241 and -2.326). This is a concern for both.
**11. hERG Inhibition:** Ligand A (0.02) is much better than Ligand B (0.213). Lower hERG inhibition is crucial to avoid cardiotoxicity, especially for a cardiovascular target.
**12. Microsomal Clearance:** Ligand A (22.417) is higher than Ligand B (6.743). Lower clearance is preferred for metabolic stability, so Ligand B is better here.
**13. In vitro Half-Life:** Ligand A (-18.46) is much worse than Ligand B (4.75). Longer half-life is desirable, so Ligand B is better.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.006 and 0.009).
**15. Binding Affinity:** Ligand B (-7.7) is significantly better than Ligand A (-6.6). A 1.1 kcal/mol difference is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand B has a substantially better binding affinity, which is paramount for GPCR targets. It also has better metabolic stability (lower Cl_mic) and a longer in vitro half-life. However, Ligand A has superior properties in terms of TPSA, logP, QED, BBB penetration, and importantly, a much lower risk of hERG inhibition. The poor solubility of both is a concern, but can be addressed with formulation strategies.
Given the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), and the crucial need to minimize cardiotoxicity for a cardiovascular target, the superior affinity of Ligand B, combined with acceptable ADME properties, makes it the more promising candidate despite the slightly higher DILI risk. The hERG risk of Ligand A is a significant concern.
Output:
0
2025-04-17 19:13:31,491 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (351.416 and 352.406 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (21.06) is significantly better than Ligand B (59.08). For a GPCR, lower TPSA is generally preferred for better permeability. Ligand B's TPSA is quite high, potentially hindering absorption.
3. **logP:** Ligand A (4.565) is higher than Ligand B (1.492). While both are within the acceptable range, Ligand A is approaching the upper limit, which could lead to solubility issues. Ligand B is on the lower end, potentially impacting permeability.
4. **HBD:** Both ligands have 0 HBD, which is good.
5. **HBA:** Ligand A (3) is slightly lower than Ligand B (4). Both are acceptable, but lower is generally better for permeability.
6. **QED:** Both ligands have similar QED values (0.736 and 0.746), indicating good drug-likeness.
7. **DILI:** Ligand A (21.753) has a much lower DILI risk than Ligand B (46.026). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (97.053) has a substantially higher BBB penetration score than Ligand B (89.531). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant, and higher BBB is generally favorable.
9. **Caco-2:** Both ligands have similar, poor Caco-2 permeability (-4.205 and -4.27). This suggests potential absorption issues for both.
10. **Solubility:** Ligand A (-5.283) has slightly worse solubility than Ligand B (-1.464), but both are poor.
11. **hERG:** Ligand A (0.854) has a slightly higher hERG risk than Ligand B (0.354). This is a minor concern for Ligand A.
12. **Cl_mic:** Ligand A (62.229) has a higher microsomal clearance than Ligand B (12.571), indicating lower metabolic stability. This is a disadvantage for Ligand A.
13. **t1/2:** Ligand A (6.494) has a longer half-life than Ligand B (4.629), which is desirable.
14. **Pgp:** Ligand A (0.563) has lower P-gp efflux than Ligand B (0.047), which is favorable.
15. **Binding Affinity:** Ligand A (-7.2 kcal/mol) has a significantly stronger binding affinity than Ligand B (-5.3 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME drawbacks.
**Overall Assessment:**
Ligand A has a significantly better binding affinity and lower DILI risk, and higher BBB penetration. While it has some drawbacks in terms of metabolic stability (higher Cl_mic) and solubility, the strong binding affinity and favorable safety profile are compelling. Ligand B has better metabolic stability and solubility, but its significantly weaker binding affinity and higher DILI risk are major concerns. Considering the GPCR-specific priorities (affinity, logP, TPSA, Pgp), Ligand A is the more promising candidate.
Output:
1
2025-04-17 19:13:31,491 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (361.793 and 358.479 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (108.06) is slightly higher than Ligand B (99.1). Both are below the 140 threshold for good oral absorption, but closer to the 90 threshold for CNS targets, which isn't a primary concern for ADRB2 (cardiovascular).
3. **logP:** Ligand A (2.725) is within the optimal 1-3 range. Ligand B (0.537) is quite low, potentially hindering membrane permeability. This is a significant negative for Ligand B.
4. **HBD:** Both ligands have 3 H-bond donors, which is acceptable.
5. **HBA:** Ligand A has 6 H-bond acceptors, and Ligand B has 5. Both are within the acceptable range of <=10.
6. **QED:** Ligand A (0.659) has a better QED score than Ligand B (0.495), indicating a more drug-like profile.
7. **DILI:** Ligand B (5.428) has a *much* lower DILI risk than Ligand A (98.953). This is a major advantage for Ligand B.
8. **BBB:** Ligand A (51.725) has a slightly higher BBB penetration percentile than Ligand B (46.491), but this isn't a critical factor for a cardiovascular target.
9. **Caco-2:** Ligand A (-5.006) and Ligand B (-4.793) both have negative values, which is unusual and suggests poor permeability.
10. **Solubility:** Ligand A (-5.073) and Ligand B (-0.348) both have negative solubility values, which is concerning. Ligand B is better in this regard.
11. **hERG:** Ligand A (0.472) has a slightly better hERG profile than Ligand B (0.252), but both are relatively low risk.
12. **Cl_mic:** Ligand A (48.258) has a significantly lower microsomal clearance than Ligand B (14.877), suggesting better metabolic stability. This is a key advantage for Ligand A.
13. **t1/2:** Ligand A (49.414) has a much longer in vitro half-life than Ligand B (0.924). This is a substantial benefit for Ligand A.
14. **Pgp:** Ligand A (0.056) has a lower P-gp efflux liability than Ligand B (0.014), indicating better bioavailability.
15. **Binding Affinity:** Ligand A (-6.2 kcal/mol) has a slightly better binding affinity than Ligand B (-5.6 kcal/mol). While the difference is less than 1.5 kcal/mol, it contributes to the overall preference.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are important. Ligand A has a better logP and Pgp profile. Affinity is slightly better for Ligand A.
**Overall Assessment:**
Ligand A demonstrates better overall drug-like properties, particularly in terms of metabolic stability (Cl_mic, t1/2), logP, and Pgp efflux. While Ligand B has a significantly lower DILI risk, the poor logP and short half-life are major drawbacks. The slightly better affinity of Ligand A further supports its selection. The solubility issues are concerning for both, but can be addressed with formulation strategies.
Output:
1
2025-04-17 19:13:31,491 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (339.443 Da) is slightly lower than Ligand B (355.467 Da), which is generally favorable for permeability.
**2. TPSA:** Both ligands have TPSA values around 63-64 A2, which is acceptable for oral absorption, though not optimal for CNS penetration.
**3. logP:** Both ligands have logP values around 3.6-3.7, which is within the optimal range of 1-3.
**4. H-Bond Donors:** Ligand A has 1 HBD, and Ligand B has 0. Both are acceptable.
**5. H-Bond Acceptors:** Ligand A has 4 HBA, and Ligand B has 6. Both are within the acceptable limit of 10.
**6. QED:** Ligand A (0.871) has a significantly better QED score than Ligand B (0.7), indicating a more drug-like profile.
**7. DILI:** Ligand A (38.62) has a much lower DILI risk than Ligand B (76.464), which is a significant advantage.
**8. BBB:** Ligand A (80.962) has a better BBB penetration percentile than Ligand B (73.711), although both are not exceptionally high. Considering ADRB2 is a cardiovascular target, BBB penetration is not a primary concern, but a higher value is still preferable.
**9. Caco-2 Permeability:** Ligand A (-4.741) has a slightly better Caco-2 permeability value than Ligand B (-5.105).
**10. Aqueous Solubility:** Ligand A (-4.056) has a slightly better aqueous solubility than Ligand B (-3.47).
**11. hERG Inhibition:** Ligand A (0.676) has a slightly lower hERG inhibition liability than Ligand B (0.397), which is favorable.
**12. Microsomal Clearance:** Ligand B (62.597) has a slightly lower microsomal clearance than Ligand A (59.673), indicating better metabolic stability.
**13. In vitro Half-Life:** Ligand B (34.516) has a longer in vitro half-life than Ligand A (21.728), which is desirable.
**14. P-gp Efflux:** Ligand A (0.158) has a lower P-gp efflux liability than Ligand B (0.545), which is favorable for bioavailability.
**15. Binding Affinity:** Ligand B (-7.6 kcal/mol) has a slightly better binding affinity than Ligand A (-8.4 kcal/mol). While this is a positive, the difference is not substantial enough to outweigh other factors.
**Overall Assessment:**
Ligand A demonstrates a superior overall profile. It has a better QED score, significantly lower DILI risk, better Caco-2 permeability, solubility, and P-gp efflux liability. While Ligand B has a slightly better half-life and binding affinity, the advantages of Ligand A in ADME-Tox properties are more critical for a successful drug candidate, especially considering the cardiovascular target. The lower DILI risk is a particularly strong point in favor of Ligand A.
Output:
1
2025-04-17 19:13:31,491 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Ligand A (410.36 Da) is within the ideal range, while Ligand B (371.834 Da) is also good. No clear advantage here.
2. **TPSA:** Ligand A (77.04) is acceptable, but higher than ideal for a GPCR. Ligand B (21.06) is excellent, well below the 90 threshold, suggesting better permeability. This favors B.
3. **logP:** Ligand A (2.748) is optimal. Ligand B (4.739) is slightly high, potentially leading to solubility issues and off-target interactions. This favors A.
4. **HBD:** Ligand A (1) is good. Ligand B (0) is also good. No significant difference.
5. **HBA:** Ligand A (5) is good. Ligand B (3) is also good. No significant difference.
6. **QED:** Both ligands (A: 0.814, B: 0.774) have good drug-likeness scores. No clear advantage.
7. **DILI:** Ligand A (42.264) has a slightly higher DILI risk than Ligand B (25.165), which is preferable. This favors B.
8. **BBB:** Ligand A (53.121) is not great for a GPCR, even though it's not a CNS target. Ligand B (90.151) is excellent, indicating good potential for distribution. This strongly favors B.
9. **Caco-2:** Ligand A (-5.536) is very poor. Ligand B (-4.838) is also poor, but slightly better. This favors B.
10. **Solubility:** Ligand A (-2.368) is poor. Ligand B (-4.936) is very poor. Both are problematic, but the higher logP of B contributes to this.
11. **hERG:** Ligand A (0.316) has a lower hERG risk than Ligand B (0.914). This favors A.
12. **Cl_mic:** Ligand A (3.464) has a lower microsomal clearance, indicating better metabolic stability. Ligand B (35.94) is much higher, suggesting rapid metabolism. This strongly favors A.
13. **t1/2:** Ligand A (1.213) is short, but Ligand B (-6.769) is extremely short (likely negative value indicates very rapid degradation). This favors A.
14. **Pgp:** Ligand A (0.145) has lower P-gp efflux, which is good. Ligand B (0.81) has higher efflux. This favors A.
15. **Affinity:** Ligand A (-7.1 kcal/mol) has a slightly better binding affinity than Ligand B (-6.3 kcal/mol), although both are good. This favors A.
**Overall Assessment:**
While Ligand B has excellent TPSA and BBB penetration, its high logP, poor solubility, high Pgp efflux, and very high microsomal clearance are significant drawbacks. Ligand A, despite having a less optimal TPSA and BBB, has a much better ADME profile (lower DILI, better metabolic stability, longer half-life, lower Pgp efflux) and slightly better binding affinity. For a cardiovascular target like ADRB2, metabolic stability and minimizing off-target effects (DILI, hERG) are crucial. The slightly better affinity of A combined with its superior ADME properties make it the more promising candidate.
Output:
1
2025-04-17 19:13:31,491 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (362.417 and 354.397 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (78.87) is higher than Ligand B (62.55). While both are below 140, the lower TPSA of Ligand B is preferable for oral absorption, a key consideration for GPCR targets.
3. **logP:** Ligand A (1.315) is within the optimal range, while Ligand B (2.992) is approaching the upper limit. Both are acceptable, but A is slightly favored.
4. **HBD:** Ligand A (2) and Ligand B (1) are both within the acceptable limit of 5. Ligand B is slightly better.
5. **HBA:** Ligand A (4) and Ligand B (3) are both within the acceptable limit of 10. Ligand B is slightly better.
6. **QED:** Both ligands have good QED scores (0.747 and 0.799, respectively), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (14.696) has a much lower DILI risk than Ligand B (28.344). This is a significant advantage for Ligand A.
8. **BBB:** Ligand B (92.788) has a considerably higher BBB penetration score than Ligand A (63.978). While ADRB2 isn't strictly a CNS target, some CNS exposure can be relevant, and this is a benefit for Ligand B.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.93 and -4.608). This is unusual and suggests poor permeability. However, the values are very close, so this isn't a major differentiator.
10. **Solubility:** Ligand A (-1.162) has better solubility than Ligand B (-3.183). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.453) has a lower hERG risk than Ligand B (0.753). This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand A (-12.524) has a much lower microsomal clearance, indicating better metabolic stability, than Ligand B (19.433). This is a major advantage for Ligand A.
13. **t1/2:** Ligand B (16.582) has a longer in vitro half-life than Ligand A (-6.489). This is a benefit for Ligand B.
14. **Pgp:** Ligand A (0.047) has lower P-gp efflux liability than Ligand B (0.29). This is a benefit for Ligand A.
15. **Binding Affinity:** Both ligands have similar binding affinities (-6.2 and -6.5 kcal/mol). The difference is minor.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), and the general drug-like properties, Ligand A emerges as the more promising candidate. While Ligand B has better BBB penetration and in vitro half-life, Ligand A demonstrates significantly better safety profiles (lower DILI and hERG risk), better metabolic stability (lower Cl_mic), and better solubility. The slightly lower TPSA and Pgp efflux of Ligand A are also beneficial. The small difference in binding affinity is not enough to outweigh the advantages of Ligand A.
Output:
1
2025-04-17 19:13:31,492 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (334.335 and 363.483 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (107.87) is higher than Ligand B (72.48). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is generally preferred for absorption. Ligand B is better here.
3. **logP:** Ligand A (2.151) and Ligand B (3.465) are both within the optimal 1-3 range, but Ligand B is pushing the upper limit. Still acceptable, but A is slightly better.
4. **HBD:** Both ligands have 2 H-bond donors, which is within the acceptable limit of <=5. No difference.
5. **HBA:** Both ligands have 5 H-bond acceptors, also within the acceptable limit of <=10. No difference.
6. **QED:** Ligand B (0.859) has a higher QED score than Ligand A (0.711), indicating a more drug-like profile. This favors Ligand B.
7. **DILI:** Ligand A (95.153) has a significantly higher DILI risk than Ligand B (54.478). This is a major concern for Ligand A. Ligand B is much better.
8. **BBB:** Ligand A (32.765) has very low BBB penetration, while Ligand B (89.027) has high BBB penetration. While ADRB2 isn't primarily a CNS target, some off-target CNS effects are possible with GPCRs, and higher BBB penetration could contribute to this. However, for a cardiovascular target, this isn't a primary concern.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.948 and -4.905), which is unusual and suggests poor permeability. This is a red flag for both.
10. **Solubility:** Ligand A (-5.377) has slightly worse solubility than Ligand B (-4.08), but both are poor. Solubility is a concern for both.
11. **hERG:** Ligand A (0.534) has a slightly higher hERG risk than Ligand B (0.399), but both are relatively low.
12. **Cl_mic:** Ligand B (40.012) has lower microsomal clearance than Ligand A (55.958), indicating better metabolic stability. This favors Ligand B.
13. **t1/2:** Ligand B (47.904) has a longer in vitro half-life than Ligand A (24.679), which is desirable. This favors Ligand B.
14. **Pgp:** Ligand A (0.074) has lower P-gp efflux than Ligand B (0.147), which is preferable. This favors Ligand A.
15. **Binding Affinity:** Ligand B (-6.8 kcal/mol) has a slightly stronger binding affinity than Ligand A (-6.5 kcal/mol). This is a small but potentially significant advantage.
**Overall Assessment:**
Ligand B is the stronger candidate. While both have issues with Caco-2 permeability and solubility, Ligand B demonstrates significantly better safety (lower DILI risk), metabolic stability (lower Cl_mic, longer t1/2), and a slightly better binding affinity. The higher QED score also supports its drug-likeness. Ligand A's high DILI risk is a major drawback. The Pgp advantage of Ligand A is outweighed by the other factors.
Output:
0
2025-04-17 19:13:31,492 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (351.451 Da) is within the ideal range (200-500 Da). Ligand B (389.945 Da) is also acceptable, but slightly higher.
2. **TPSA:** Ligand A (118.4) is better than Ligand B (59). While both are reasonably low, lower TPSA generally correlates with better permeability, and 59 is quite good.
3. **logP:** Ligand A (1.98) is optimal. Ligand B (3.331) is at the higher end of the optimal range, potentially leading to solubility issues.
4. **HBD:** Ligand A (2) is good. Ligand B (1) is also good.
5. **HBA:** Ligand A (4) is good. Ligand B (5) is also acceptable.
6. **QED:** Ligand B (0.777) is significantly better than Ligand A (0.414), indicating a more drug-like profile.
7. **DILI:** Ligand A (20.279) has a much lower DILI risk than Ligand B (44.591). This is a significant advantage for Ligand A.
8. **BBB:** Ligand B (57.425) has a better BBB penetration score than Ligand A (36.758). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be beneficial for distribution.
9. **Caco-2:** Ligand A (-5.057) and Ligand B (-4.734) are similar, and both are negative, indicating low permeability.
10. **Solubility:** Ligand A (-1.833) is better than Ligand B (-3.471), suggesting better aqueous solubility.
11. **hERG:** Ligand A (0.243) has a lower hERG risk than Ligand B (0.537). This is a critical safety parameter.
12. **Cl_mic:** Ligand A (-7.512) has a much lower (better) microsomal clearance than Ligand B (43.49). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand B (55.021) has a significantly longer in vitro half-life than Ligand A (-4.747). This is a major advantage for Ligand B.
14. **Pgp:** Ligand A (0.024) has a much lower Pgp efflux liability than Ligand B (0.636). This is a significant advantage for Ligand A.
15. **Affinity:** Ligand A (-6.6 kcal/mol) is slightly better than Ligand B (-5.2 kcal/mol), although the difference is not huge.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B has a better logP and Pgp, while Ligand A has better TPSA and affinity.
**Overall Assessment:**
Ligand A demonstrates a superior safety profile (lower DILI, hERG) and better metabolic stability (lower Cl_mic). It also has a slightly better binding affinity and lower Pgp efflux. While Ligand B has a better QED and longer half-life, the risks associated with its higher DILI, hERG, and Pgp efflux outweigh these benefits. The solubility of ligand A is also preferable.
Output:
1
2025-04-17 19:13:31,492 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (351.403 and 345.487 Da) are within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (52.65) is significantly better than Ligand A (101.73). ADRB2 is not a CNS target, but lower TPSA generally improves absorption. This favors Ligand B.
3. **logP:** Ligand B (1.648) is within the optimal 1-3 range, while Ligand A (0.348) is quite low. Low logP can hinder membrane permeability. This strongly favors Ligand B.
4. **HBD:** Both ligands have 1 HBD, which is acceptable.
5. **HBA:** Ligand A has 7 HBA, while Ligand B has 3. Both are within the acceptable range of <=10, but Ligand B is preferable.
6. **QED:** Both ligands have similar QED values (0.785 and 0.745), indicating good drug-likeness.
7. **DILI:** Ligand B (4.033) has a much lower DILI risk than Ligand A (41.722). This is a significant advantage for Ligand B.
8. **BBB:** BBB is not a primary concern for ADRB2, but Ligand B (72.082) has a higher percentile than Ligand A (36.836).
9. **Caco-2:** Ligand B (-5.071) has a more negative Caco-2 value, suggesting better permeability than Ligand A (-4.415).
10. **Solubility:** Ligand B (-1.463) has a slightly better solubility score than Ligand A (-2.113).
11. **hERG:** Ligand B (0.457) has a lower hERG risk than Ligand A (0.177), which is preferable.
12. **Cl_mic:** Ligand B (-14.568) has a significantly lower (better) microsomal clearance than Ligand A (44.129), indicating better metabolic stability.
13. **t1/2:** Ligand B (-6.109) has a more negative in vitro half-life, suggesting a longer half-life than Ligand A (-19.623).
14. **Pgp:** Ligand B (0.011) has a lower Pgp efflux liability than Ligand A (0.049), which is preferable.
15. **Binding Affinity:** Ligand A (-6.2 kcal/mol) has a slightly better binding affinity than Ligand B (-5.5 kcal/mol). While affinity is important, the difference of 0.7 kcal/mol is not substantial enough to outweigh the numerous ADME advantages of Ligand B.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, and Pgp are important. Ligand B excels in all these areas. While affinity is a priority, the difference isn't large enough to overcome the substantial ADME benefits of Ligand B.
**Conclusion:**
Ligand B demonstrates a significantly more favorable ADME profile and a lower toxicity risk compared to Ligand A. While Ligand A has slightly better binding affinity, the overall balance of properties strongly favors Ligand B as a more viable drug candidate.
Output:
0
2025-04-17 19:13:31,492 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
The target is ADRB2, a GPCR. Therefore, the priorities are logP, Pgp, TPSA, affinity, and, to a lesser extent, BBB.
Let's analyze each ligand:
* **Molecular Weight:** Both ligands (346.391 and 349.431 Da) are within the ideal 200-500 Da range.
* **TPSA:** Ligand A (127) is slightly higher than Ligand B (121.52), but both are acceptable for oral absorption (<140).
* **logP:** Ligand A (0.5) is lower than optimal (1-3), potentially hindering permeation. Ligand B (-0.164) is even lower, raising concerns about absorption. This is a critical weakness for both.
* **H-Bond Donors/Acceptors:** Both have 4 HBD and 5 HBA, which are within acceptable limits.
* **QED:** Ligand A (0.627) has a better QED score than Ligand B (0.477), indicating a more drug-like profile.
* **DILI:** Ligand B (16.712) has a significantly lower DILI risk than Ligand A (62.001). This is a substantial advantage for Ligand B.
* **BBB:** Ligand B (44.668) has a higher BBB penetration percentile than Ligand A (24.506). While ADRB2 isn't necessarily a CNS target, some peripheral ADRB2 receptors can be affected by CNS penetration.
* **Caco-2 Permeability:** Both have negative Caco-2 values, suggesting poor permeability.
* **Aqueous Solubility:** Both have negative solubility values, suggesting poor solubility.
* **hERG:** Both have very low hERG inhibition liability (0.096 and 0.082), which is excellent.
* **Microsomal Clearance:** Ligand A (-17.568) has much lower (better) microsomal clearance than Ligand B (5.678), indicating greater metabolic stability.
* **In vitro Half-Life:** Ligand A (-21.16) has a longer half-life than Ligand B (23.124).
* **P-gp Efflux:** Both have very low P-gp efflux liability (0.013 and 0.024).
* **Binding Affinity:** Ligand B (-7.7 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.9 kcal/mol). This 0.8 kcal/mol difference is substantial and can outweigh some ADME concerns.
**Overall Assessment:**
Ligand B has a significantly better binding affinity and a much lower DILI risk. While its logP is also low, the substantial affinity advantage is likely to be more impactful. Ligand A has better metabolic stability and half-life, but the difference in binding affinity is more critical for a GPCR target. The poor permeability and solubility are concerns for both, but can be addressed with formulation strategies.
**Output:**
0
2025-04-17 19:13:31,492 - INFO - Batch 94 complete. Total preferences: 1504
2025-04-17 19:13:31,492 - INFO - Processing batch 95/512...
2025-04-17 19:14:20,648 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [368.39 , 112.49 , 1.361, 2. , 6. , 0.763, 71.384, 38.891, -4.918, -3.505, 0.143, 30.584, -31.056, 0.1 , -5.1 ]
**Ligand B:** [351.422, 82.53 , 2.422, 2. , 4. , 0.753, 44.397, 69.794, -4.819, -2.594, 0.371, 4.538, 16.378, 0.142, -6.3 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (351.422) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (112.49) is higher than Ligand B (82.53). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is still preferred for better absorption. Ligand B is significantly better here.
3. **logP:** Both are within the optimal range (1-3). Ligand B (2.422) is slightly higher, which *could* indicate a slightly better ability to cross membranes, but it's a small difference.
4. **HBD:** Both have 2 HBD, which is good.
5. **HBA:** Ligand A has 6 HBA, while Ligand B has 4. Lower is preferred, giving a slight edge to Ligand B.
6. **QED:** Both are very similar (0.763 and 0.753), indicating good drug-like properties.
7. **DILI:** Ligand A (71.384) has a higher DILI risk than Ligand B (44.397). This is a significant concern, as we want to minimize liver toxicity. Ligand B is much better here.
8. **BBB:** Ligand B (69.794) has a better BBB penetration percentile than Ligand A (38.891). While ADRB2 isn't a primary CNS target, some off-target CNS effects are possible, and better BBB penetration can sometimes correlate with better overall distribution.
9. **Caco-2:** Both have negative values, indicating permeability. The values are very similar (-4.918 vs -4.819).
10. **Solubility:** Ligand A (-3.505) has slightly worse solubility than Ligand B (-2.594). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.143) has a slightly lower hERG risk than Ligand B (0.371), which is good.
12. **Cl_mic:** Ligand B (4.538) has significantly lower microsomal clearance than Ligand A (30.584), indicating better metabolic stability. This is a major advantage.
13. **t1/2:** Ligand A (-31.056) has a negative half-life, which is concerning. Ligand B (16.378) has a positive half-life, suggesting better in vitro stability.
14. **Pgp:** Both have low Pgp efflux liability (0.1 and 0.142).
15. **Binding Affinity:** Ligand B (-6.3) has a stronger binding affinity than Ligand A (-5.1). This is a substantial difference (1.2 kcal/mol), and is a key driver in the decision.
**Overall Assessment:**
Ligand B is significantly better across multiple critical parameters. It has a lower DILI risk, better metabolic stability (lower Cl_mic, positive t1/2), better TPSA, and a substantially stronger binding affinity. While Ligand A has a slightly lower hERG risk, the other advantages of Ligand B outweigh this minor benefit. The stronger binding affinity of Ligand B is particularly compelling for a GPCR target.
Output:
0
2025-04-17 19:14:20,648 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [342.439, 58.64, 1.465, 1, 3, 0.773, 29.624, 60.644, -4.642, -3.672, 0.344, 17.499, 10.474, 0.055, -5.1]
**Ligand B:** [362.455, 96.6, 0.81, 1, 5, 0.802, 47.964, 62.699, -5.22, -2.12, 0.132, -8.199, -10.237, 0.061, -5.9]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (342.439) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (58.64) is significantly better than Ligand B (96.6). For a GPCR, keeping TPSA low is good, and Ligand A is well below the 140 threshold. Ligand B is approaching a level that could hinder absorption.
3. **logP:** Both are within the optimal range (1-3), but Ligand A (1.465) is slightly higher than Ligand B (0.81).
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A (3) is better than Ligand B (5). Lower HBA is generally preferred for permeability.
6. **QED:** Both have good QED scores (>0.5), indicating drug-likeness. Ligand B (0.802) is slightly better.
7. **DILI:** Ligand A (29.624) has a much lower DILI risk than Ligand B (47.964). This is a significant advantage for Ligand A.
8. **BBB:** Both have similar BBB penetration (around 60-62%), which isn't exceptionally high, but acceptable for a non-CNS target like ADRB2.
9. **Caco-2:** Ligand A (-4.642) is better than Ligand B (-5.22). Higher values indicate better absorption.
10. **Solubility:** Ligand A (-3.672) is better than Ligand B (-2.12).
11. **hERG:** Both have very low hERG risk (0.344 and 0.132), which is excellent.
12. **Cl_mic:** Ligand B (-8.199) has a significantly *lower* (better) microsomal clearance than Ligand A (17.499), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-10.237) has a longer in vitro half-life than Ligand A (10.474). This is a positive attribute.
14. **Pgp:** Both have low Pgp efflux liability (0.055 and 0.061), which is good.
15. **Affinity:** Ligand B (-5.9) has a slightly better binding affinity than Ligand A (-5.1), a difference of 0.8 kcal/mol.
**GPCR-specific priorities:** For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, and affinity. Ligand A has better logP and TPSA, while Ligand B has slightly better affinity and metabolic stability. The difference in affinity is not large enough to outweigh the significant advantages Ligand A has in TPSA and DILI risk.
**Conclusion:**
Considering the balance of properties, particularly the lower TPSA and DILI risk of Ligand A, I believe it is the more promising drug candidate. The slightly better affinity of Ligand B doesn't compensate for its higher TPSA and potential liver toxicity.
**Output:**
1
2025-04-17 19:14:20,648 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [345.443, 80.32, 1.904, 2, 4, 0.501, 27.181, 44.979, -4.652, -2.408, 0.329, 27.669, 5.136, 0.051, -5.9]
**Ligand B:** [359.535, 29.54, 4.284, 0, 3, 0.681, 26.638, 83.831, -5.172, -4.863, 0.767, 125.288, 4.025, 0.736, -6.3]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal range (200-500 Da). A is 345.443, B is 359.535. No strong preference here.
2. **TPSA:** A is 80.32, B is 29.54. B is significantly better, well under the 90 threshold for CNS penetration, and even better for general absorption.
3. **logP:** A is 1.904, B is 4.284. A is optimal (1-3), while B is pushing the upper limit. Higher logP can lead to off-target effects and solubility issues, but is less of a concern for a peripheral GPCR like ADRB2.
4. **HBD:** A is 2, B is 0. Both are good, but B is slightly better as fewer HBDs generally improve permeability.
5. **HBA:** A is 4, B is 3. Both are good, under the 10 threshold.
6. **QED:** A is 0.501, B is 0.681. B has a better drug-likeness score.
7. **DILI:** A is 27.181, B is 26.638. Both are excellent, indicating very low liver injury risk.
8. **BBB:** A is 44.979, B is 83.831. B is significantly better, although BBB isn't *critical* for ADRB2 (cardiovascular target).
9. **Caco-2:** A is -4.652, B is -5.172. Both are negative, indicating poor permeability. B is slightly worse.
10. **Solubility:** A is -2.408, B is -4.863. A is better, indicating better aqueous solubility.
11. **hERG:** A is 0.329, B is 0.767. A is much better, indicating lower hERG inhibition risk. This is important for cardiovascular drugs.
12. **Cl_mic:** A is 27.669, B is 125.288. A is *much* better, indicating significantly higher metabolic stability.
13. **t1/2:** A is 5.136, B is 4.025. A has a slightly longer in vitro half-life.
14. **Pgp:** A is 0.051, B is 0.736. A is *much* better, indicating lower P-gp efflux.
15. **Affinity:** A is -5.9 kcal/mol, B is -6.3 kcal/mol. B has a slightly better binding affinity (0.4 kcal/mol difference).
**Overall Assessment:**
While Ligand B has a slightly better binding affinity and a superior TPSA, the advantages of Ligand A in terms of metabolic stability (Cl_mic), P-gp efflux, hERG inhibition, solubility, and overall drug-likeness (QED) are more compelling for a cardiovascular drug candidate. The higher logP of Ligand B is a slight concern, and the poor Caco-2 values for both are a drawback that would need to be addressed in further optimization. However, the combination of favorable ADME properties in Ligand A outweighs the minor affinity advantage of Ligand B.
Output:
1
2025-04-17 19:14:20,649 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [349.406, 76.64, 1.522, 2, 3, 0.85, 40.209, 59.093, -4.798, -2.158, 0.537, 2.647, -2.351, 0.039, -6.4]
**Ligand B:** [342.443, 86.88, 2.308, 3, 3, 0.704, 29.236, 60.876, -5.278, -2.656, 0.398, 38.144, -16.325, 0.074, -8.2]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (342.443) is slightly lower, which is generally favorable.
2. **TPSA:** Ligand A (76.64) is better than Ligand B (86.88), being closer to the <140 threshold for good absorption.
3. **logP:** Ligand A (1.522) is optimal, while Ligand B (2.308) is still acceptable but edging towards the higher end.
4. **HBD:** Both have reasonable HBD counts (2 and 3 respectively), within the acceptable limit of 5.
5. **HBA:** Both have reasonable HBA counts (3), within the acceptable limit of 10.
6. **QED:** Ligand A (0.85) has a better QED score than Ligand B (0.704), indicating a more drug-like profile.
7. **DILI:** Ligand A (40.209) is slightly higher than Ligand B (29.236), but both are below the concerning threshold of 60. Ligand B is clearly preferable here.
8. **BBB:** Both are around 60, which isn't ideal for a CNS target, but acceptable for a cardiovascular target like ADRB2. Ligand B (60.876) is slightly better.
9. **Caco-2:** Ligand B (-5.278) has a more negative Caco-2 value, suggesting *better* permeability than Ligand A (-4.798).
10. **Solubility:** Both have negative solubility values, indicating poor solubility. Ligand B (-2.656) is worse than Ligand A (-2.158).
11. **hERG:** Both have low hERG inhibition liability, which is good. Ligand B (0.398) is slightly better.
12. **Cl_mic:** Ligand A (2.647) has a much lower microsomal clearance than Ligand B (38.144), indicating better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand A (-2.351) has a more positive (longer) in vitro half-life than Ligand B (-16.325). This is a substantial advantage.
14. **Pgp:** Both have low Pgp efflux liability. Ligand A (0.039) is slightly better.
15. **Affinity:** Ligand B (-8.2) has a significantly stronger binding affinity than Ligand A (-6.4) - a difference of 1.8 kcal/mol. This is a major factor.
**GPCR-specific priorities:** For ADRB2 (a GPCR), we prioritize logP, Pgp, TPSA, and affinity. Ligand B excels in affinity. Ligand A has better TPSA and metabolic stability.
**Overall Assessment:**
While Ligand A has advantages in QED, metabolic stability (Cl_mic), and half-life, the *substantial* difference in binding affinity (-8.2 vs -6.4 kcal/mol) in favor of Ligand B is a critical factor. A 1.8 kcal/mol difference is often enough to overcome minor ADME drawbacks. The slightly better Caco-2 and DILI scores of Ligand B are also beneficial. The solubility is a concern for both, but can be addressed with formulation strategies.
Therefore, I would prioritize Ligand B.
0
2025-04-17 19:14:20,649 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (341.411 and 354.535 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (80.32 and 78.43) are below the 140 A^2 threshold for good oral absorption, and acceptable for a cardiovascular target (not requiring significant BBB penetration). Very similar.
3. **logP:** Ligand A (1.575) is optimal, while Ligand B (3.157) is approaching the upper limit. This favors A slightly.
4. **HBD:** Ligand A (2) and Ligand B (3) are both acceptable, being less than 5.
5. **HBA:** Ligand A (4) and Ligand B (3) are both acceptable, being less than 10.
6. **QED:** Ligand A (0.726) has a better QED score than Ligand B (0.527), indicating a more drug-like profile. This is a positive for A.
7. **DILI:** Ligand A (49.399) has a significantly higher DILI risk than Ligand B (15.898). This is a major drawback for A.
8. **BBB:** Ligand B (65.374) has a higher BBB penetration percentile than Ligand A (57.154), but BBB isn't a high priority for a cardiovascular target.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.963 and -4.552), which is unusual and suggests poor permeability. However, the values are very close.
10. **Solubility:** Both ligands have negative solubility values (-2.665 and -2.926) suggesting poor aqueous solubility. Again, values are similar.
11. **hERG:** Both ligands have low hERG inhibition liability (0.48 and 0.475), which is good.
12. **Cl_mic:** Ligand A (32.017) has a much lower microsomal clearance than Ligand B (69.62), suggesting better metabolic stability. This is a significant advantage for A.
13. **t1/2:** Ligand A (11.21) has a longer in vitro half-life than Ligand B (1.631). This is a strong positive for A.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.066 and 0.159).
15. **Binding Affinity:** Ligand A (-7.1) has a slightly better binding affinity than Ligand B (-7.0). While the difference is small, it's still a positive for A.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are important. Ligand A has a better logP and slightly better affinity. Both have acceptable TPSA and Pgp. However, the significantly lower DILI risk of Ligand B is a crucial factor.
**Overall Assessment:**
While Ligand A has advantages in metabolic stability (Cl_mic, t1/2), QED, and slightly better affinity, the substantially higher DILI risk is a major concern. The DILI risk outweighs the benefits of the other parameters. Ligand B, despite slightly less favorable ADME properties, presents a much safer profile regarding liver toxicity.
Output:
0
2025-04-17 19:14:20,649 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step Comparison:**
1. **MW:** Ligand A (345.4) is well within the ideal range (200-500). Ligand B (372.5) is also acceptable. No clear advantage here.
2. **TPSA:** Ligand A (111.55) is slightly above the preferred <140 for good oral absorption, but still reasonable. Ligand B (92.34) is excellent, well below 140 and favorable for permeability. **Advantage: B**
3. **logP:** Ligand A (0.881) is a bit low, potentially impacting permeability. Ligand B (1.648) is better, falling within the optimal 1-3 range. **Advantage: B**
4. **HBD:** Ligand A (4) is acceptable. Ligand B (2) is even better, reducing potential for off-target interactions and improving permeability. **Advantage: B**
5. **HBA:** Both ligands have 5 HBA, which is acceptable. No clear advantage.
6. **QED:** Both ligands have similar QED scores (0.605 and 0.61), indicating good drug-likeness. No clear advantage.
7. **DILI:** Ligand A (50.99) is better than Ligand B (34.63), indicating a lower risk of drug-induced liver injury. **Advantage: A**
8. **BBB:** Ligand B (63.28) has a significantly higher BBB penetration percentile than Ligand A (25.32). While ADRB2 isn't strictly a CNS target, some CNS exposure can occur, and better BBB penetration can be beneficial. **Advantage: B**
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Both ligands have very poor aqueous solubility (-2.64 and -2.21). This is a major drawback for both compounds.
11. **hERG:** Ligand A (0.042) has a very low hERG risk, which is excellent. Ligand B (0.319) is also relatively low, but higher than A. **Advantage: A**
12. **Cl_mic:** Ligand A (-8.961) has a much lower (better) microsomal clearance than Ligand B (37.39), indicating greater metabolic stability. **Advantage: A**
13. **t1/2:** Ligand A (-29.604) has a much longer in vitro half-life than Ligand B (5.234), which is highly desirable. **Advantage: A**
14. **Pgp:** Ligand A (0.02) has a much lower P-gp efflux liability than Ligand B (0.147), suggesting better oral bioavailability. **Advantage: A**
15. **Binding Affinity:** Ligand A (-8.2) has a slightly better binding affinity than Ligand B (-6.3). This is a substantial difference (1.9 kcal/mol), and outweighs many of the ADME concerns. **Advantage: A**
**Overall Assessment:**
While Ligand B has advantages in TPSA, logP, and BBB penetration, Ligand A significantly outperforms it in crucial ADME properties (DILI, Cl_mic, t1/2, Pgp) and, most importantly, binding affinity. The poor solubility and Caco-2 values are concerning for both, but the superior potency and ADME profile of Ligand A make it the more promising candidate. The stronger binding affinity is a significant driver, and the better metabolic stability and lower efflux will likely translate to better *in vivo* exposure.
Output:
1
2025-04-17 19:14:20,649 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (429.742 Da) is within the ideal range, while Ligand B (387.933 Da) is also good. No clear advantage here.
2. **TPSA:** Ligand A (49.85) is excellent, well below the 140 threshold, and suitable for oral absorption. Ligand B (91.32) is higher, but still potentially acceptable, though less ideal.
3. **logP:** Both ligands have good logP values (A: 3.483, B: 2.752), falling within the 1-3 range.
4. **HBD:** Ligand A (0) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (3) is better than Ligand B (5). Lower HBA is preferable.
6. **QED:** Both ligands have similar QED values (A: 0.736, B: 0.654), indicating good drug-likeness.
7. **DILI:** Both ligands have similar DILI risk (A: 58.976, B: 60.644), both are acceptable.
8. **BBB:** Ligand A (73.168) has a significantly better BBB penetration percentile than Ligand B (55.293). This is a key advantage for a GPCR target, even if it's not a CNS target, as it suggests better distribution.
9. **Caco-2:** Ligand A (-4.833) and Ligand B (-5.007) are both very poor. This is a significant drawback for both.
10. **Solubility:** Ligand A (-4.317) is slightly better than Ligand B (-3.703), but both are poor.
11. **hERG:** Ligand A (0.562) is significantly better than Ligand B (0.28), indicating a lower risk of cardiotoxicity. This is crucial for a cardiovascular target.
12. **Cl_mic:** Ligand A (41.638) has a lower microsomal clearance than Ligand B (35.475), suggesting better metabolic stability.
13. **t1/2:** Ligand A (13.622) has a longer in vitro half-life than Ligand B (30.204).
14. **Pgp:** Ligand A (0.688) has a lower P-gp efflux liability than Ligand B (0.36), which is favorable for bioavailability.
15. **Affinity:** Ligand A (-8.0) has a significantly stronger binding affinity than Ligand B (-6.4). This is a substantial advantage, potentially outweighing some of the ADME concerns.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are particularly important. Ligand A excels in these areas, especially affinity and BBB penetration. While both have poor Caco-2 and solubility, the superior affinity and better ADME profile of Ligand A make it the more promising candidate.
**Conclusion:**
Ligand A demonstrates a better balance of properties, particularly with its superior binding affinity, BBB penetration, lower hERG risk, and better metabolic stability.
Output:
1
2025-04-17 19:14:20,649 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (366.36 and 363.48 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand B (71.53) is significantly better than Ligand A (103.7), being well below the 140 threshold for oral absorption and more favorable for GPCRs.
3. **logP:** Ligand B (1.694) is within the optimal 1-3 range, while Ligand A (-0.054) is slightly below 1, potentially hindering permeation. This is a notable advantage for Ligand B.
4. **HBD:** Both ligands have 1 HBD, which is acceptable.
5. **HBA:** Ligand A has 6 HBAs, and Ligand B has 5. Both are within the acceptable range of <=10.
6. **QED:** Both ligands have good QED scores (0.752 and 0.808), indicating drug-likeness.
7. **DILI:** Both ligands have acceptable DILI risk (52.42 and 47.93 percentile), below the 60 threshold.
8. **BBB:** Ligand B (55.33) has a better BBB penetration score than Ligand A (31.83), although neither is exceptionally high. For a cardiovascular target, BBB isn't a primary concern, but it's a slight advantage for B.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and problematic. This suggests poor permeability. However, the values are similar (-5.248 and -5.005).
10. **Solubility:** Ligand A (-0.513) has slightly better solubility than Ligand B (-1.713).
11. **hERG:** Both ligands have low hERG inhibition liability (0.05 and 0.121), which is excellent.
12. **Cl_mic:** Ligand A (5.24) has a much lower microsomal clearance than Ligand B (32.663), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand B (18.548) has a considerably longer in vitro half-life than Ligand A (0.966). This is a major advantage for Ligand B.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.012 and 0.055).
15. **Binding Affinity:** Ligand B (-7.5 kcal/mol) has a slightly better binding affinity than Ligand A (-8.4 kcal/mol). While A is better, the difference is not substantial enough to outweigh other factors.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, and affinity are key. Ligand B excels in logP and TPSA, which are crucial for membrane permeability and receptor engagement. While Ligand A has a slightly better affinity, the difference isn't large enough to compensate for its poorer logP and TPSA. Ligand B's significantly improved half-life is also a major benefit.
**Conclusion:**
Considering the balance of properties, particularly the favorable logP, TPSA, and half-life of Ligand B, it is the more promising drug candidate.
Output:
0
2025-04-17 19:14:20,649 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [344.455, 71.34, 3.349, 2, 3, 0.778, 35.944, 65.878, -4.613, -4.057, 0.215, 64.251, 40.109, 0.306, -6.5]
**Ligand B:** [340.379, 73.99, 2.373, 1, 4, 0.871, 66.731, 44.668, -4.985, -2.813, 0.402, 24.563, -2.385, 0.188, -5.9]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). A is 344.455, B is 340.379. Very similar.
2. **TPSA:** Both are reasonably good (A: 71.34, B: 73.99), below the 140 threshold for oral absorption.
3. **logP:** Both are within the optimal range (1-3), A is 3.349 and B is 2.373. A is slightly higher, which could be a minor concern for off-target effects, but still acceptable.
4. **HBD:** A has 2, B has 1. Both are good.
5. **HBA:** A has 3, B has 4. Both are good.
6. **QED:** Both are good (A: 0.778, B: 0.871). B is slightly better here.
7. **DILI:** A (35.944) is significantly better than B (66.731). This is a major advantage for A.
8. **BBB:** A (65.878) is better than B (44.668). While ADRB2 isn't necessarily a CNS target, some peripheral effects can be modulated by CNS penetration, and a higher BBB score is generally favorable.
9. **Caco-2:** Both are negative, indicating poor permeability. A (-4.613) is slightly worse than B (-4.985).
10. **Solubility:** Both are negative, indicating poor solubility. B (-2.813) is slightly better than A (-4.057).
11. **hERG:** Both are very low, indicating minimal hERG inhibition risk. A (0.215) is slightly better than B (0.402).
12. **Cl_mic:** A (64.251) is significantly higher than B (24.563), meaning B has better metabolic stability. This is a significant advantage for B.
13. **t1/2:** A (40.109) is better than B (-2.385).
14. **Pgp:** A (0.306) is better than B (0.188), meaning A is less likely to be a P-gp substrate.
15. **Binding Affinity:** A (-6.5) is 0.6 kcal/mol stronger than B (-5.9). This is a substantial difference in potency.
**GPCR-specific priorities:** For ADRB2 (a GPCR), we prioritize logP, Pgp, TPSA, and affinity. A has a slightly higher logP, better Pgp, similar TPSA, and significantly better affinity. The DILI score and BBB are also much better for A. While B has better metabolic stability, the stronger binding affinity and lower toxicity risk of A are more critical for a GPCR target. The Caco-2 and solubility are both poor for both, which would need to be addressed in further optimization.
**Conclusion:**
Considering the balance of properties and the priorities for a GPCR target, **Ligand A** is the more promising candidate. The stronger binding affinity, lower DILI risk, and better BBB penetration outweigh the slightly worse metabolic stability.
1
2025-04-17 19:14:20,649 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, the key priorities are logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB.
Let's compare the ligands property by property:
1. **MW:** Both ligands (359.369 and 362.543 Da) fall within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (68.23) is slightly higher than Ligand B (61.02), but both are well below the 140 A^2 threshold for good oral absorption.
3. **logP:** Ligand A (1.759) is optimal (1-3). Ligand B (4.433) is higher, potentially leading to solubility issues and off-target effects. This is a significant drawback for Ligand B.
4. **HBD/HBA:** Ligand A (1 HBD, 5 HBA) is preferable to Ligand B (2 HBD, 3 HBA) as it has fewer hydrogen bond donors.
5. **QED:** Both ligands have acceptable QED values (0.804 and 0.73), indicating good drug-likeness.
6. **DILI:** Ligand A (39.434) has a lower DILI risk than Ligand B (51.725), which is desirable.
7. **BBB:** Ligand A (83.172) has a better BBB percentile than Ligand B (70.958), although BBB isn't a primary concern for a cardiovascular target.
8. **Caco-2:** Ligand A (-4.316) shows better permeability than Ligand B (-5.079).
9. **Solubility:** Ligand A (-1.918) has better solubility than Ligand B (-4.183). This is important given Ligand B's higher logP.
10. **hERG:** Both ligands have low hERG inhibition risk (0.455 and 0.9), which is good.
11. **Cl_mic:** Ligand A (6.469) has a lower microsomal clearance, suggesting better metabolic stability than Ligand B (80.682).
12. **t1/2:** Ligand B (69.005) has a much longer in vitro half-life than Ligand A (-11.86). This is a positive for Ligand B.
13. **Pgp:** Ligand A (0.173) has lower P-gp efflux liability than Ligand B (0.366), which is favorable for bioavailability.
14. **Binding Affinity:** Both ligands have similar binding affinities (-6.1 and -6.2 kcal/mol).
**Overall Assessment:**
Ligand A is clearly the better candidate. While Ligand B has a longer half-life, its significantly higher logP, higher DILI risk, lower solubility, and higher Pgp efflux outweigh this benefit. Ligand A balances the key properties better, particularly regarding permeability, solubility, and metabolic stability, all crucial for a successful GPCR drug candidate.
**Output:**
1
2025-04-17 19:14:20,649 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (359.348 and 345.443 Da) fall comfortably within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Both are below the 140 A^2 threshold for good oral absorption (71.53 and 73.74 A^2). Again, no significant difference.
3. **logP:** Ligand A (3.298) is slightly higher than Ligand B (1.755). For a GPCR, a logP between 1-3 is preferred, so both are acceptable, but Ligand B is closer to the lower end.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Both have 4 HBA, also good.
6. **QED:** Ligand A (0.841) has a slightly better QED score than Ligand B (0.797), indicating a more drug-like profile.
7. **DILI:** Ligand B (17.72%) has a *much* lower DILI risk than Ligand A (44.32%). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (90.306%) shows significantly better BBB penetration than Ligand B (68.67%). While ADRB2 isn't necessarily a CNS target, some peripheral ADRB2 receptors can influence CNS function, and better BBB penetration could be beneficial.
9. **Caco-2:** Both have negative Caco-2 values (-4.483 and -4.498), which is unusual and suggests very poor permeability. This is a major concern for both.
10. **Solubility:** Ligand A (-3.721) has slightly better solubility than Ligand B (-1.507), but both are quite poor.
11. **hERG:** Ligand A (0.519) has a slightly higher hERG risk than Ligand B (0.134). Lower is better, so Ligand B is preferable.
12. **Cl_mic:** Ligand B (8.372) has significantly lower microsomal clearance than Ligand A (37.461), indicating better metabolic stability. This is a strong advantage for Ligand B.
13. **t1/2:** Ligand B (2.642) has a longer in vitro half-life than Ligand A (-2.916). This is a positive for Ligand B.
14. **Pgp:** Both have very low Pgp efflux liability (0.045 and 0.041). No significant difference.
15. **Binding Affinity:** Ligand B (-6.9 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.5 kcal/mol). This is a substantial advantage, potentially outweighing some ADME concerns.
**Overall Assessment:**
Ligand B is the stronger candidate. While Ligand A has better BBB penetration and a slightly higher QED, Ligand B excels in crucial areas: significantly lower DILI risk, much better metabolic stability (lower Cl_mic, longer t1/2), lower hERG risk, and, most importantly, a substantially higher binding affinity. The poor Caco-2 permeability is a concern for both, but the superior potency and safety profile of Ligand B make it the more promising starting point for optimization.
Output:
0
2025-04-17 19:14:20,649 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (436.404 Da) is slightly higher than Ligand B (364.511 Da), but both are acceptable.
**2. TPSA:** Ligand A (45.15) is well below the 140 threshold for oral absorption and is quite favorable. Ligand B (53.76) is also acceptable, but slightly higher.
**3. logP:** Both ligands have logP values within the optimal range (1-3), with Ligand A (4.055) being slightly higher than Ligand B (3.501). While 4.055 is approaching the upper limit, it isn't a major concern.
**4. H-Bond Donors:** Both ligands have 0 HBD, which is good for permeability.
**5. H-Bond Acceptors:** Ligand A has 7 HBA, and Ligand B has 4. Both are within the acceptable limit of 10.
**6. QED:** Both ligands have good QED scores (A: 0.618, B: 0.751), indicating drug-likeness. Ligand B is slightly better here.
**7. DILI Risk:** Ligand A (85.227) has a significantly higher DILI risk than Ligand B (48.623). This is a major concern for Ligand A.
**8. BBB Penetration:** Both ligands show good BBB penetration (A: 83.637, B: 77.045). This is important for GPCRs, but less critical for a cardiovascular target like ADRB2.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values which is unusual and suggests poor permeability.
**10. Aqueous Solubility:** Both ligands have negative solubility values which is also unusual and suggests poor solubility.
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (A: 0.78, B: 0.578).
**12. Microsomal Clearance:** Ligand A (59.069) has lower microsomal clearance than Ligand B (75.97), suggesting better metabolic stability.
**13. In vitro Half-Life:** Ligand B (12.783) has a significantly longer in vitro half-life than Ligand A (-12.712). This is a major advantage for Ligand B.
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (A: 0.798, B: 0.644).
**15. Binding Affinity:** Ligand A (-7.2 kcal/mol) has a slightly better binding affinity than Ligand B (-5.9 kcal/mol). This is a 1.3 kcal/mol difference, which is significant.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity and metabolic stability, the significantly higher DILI risk is a major drawback. Ligand B has a better QED score, a much lower DILI risk, and a significantly longer half-life. Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity) and the overall balance of properties, Ligand B is the more promising candidate. The slightly weaker affinity of Ligand B can potentially be optimized in subsequent iterations, but mitigating a high DILI risk is far more challenging.
Output:
0
2025-04-17 19:14:20,650 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.503 and 348.487 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (49.85) is better than Ligand B (54.71). Both are below the 140 threshold for oral absorption, but lower is preferred.
3. **logP:** Both ligands have good logP values (2.974 and 3.517), falling within the optimal 1-3 range. Ligand B is slightly higher, which could potentially lead to some off-target effects, but not drastically.
4. **HBD:** Ligand A (0) is preferable to Ligand B (1). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (4). Lower HBA is generally better for permeability.
6. **QED:** Both ligands have good QED values (0.676 and 0.781), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (35.673) is significantly better than Ligand B (8.375). A lower DILI percentile is crucial for safety. This is a major advantage for Ligand A.
8. **BBB:** Ligand A (86.468) is better than Ligand B (78.79). While ADRB2 isn't strictly a CNS target, some CNS penetration can be acceptable and even beneficial for certain cardiovascular effects.
9. **Caco-2:** Ligand A (-4.39) is better than Ligand B (-4.844). Higher Caco-2 permeability suggests better absorption.
10. **Solubility:** Ligand A (-3.121) is better than Ligand B (-2.516). Higher solubility is important for formulation and bioavailability.
11. **hERG:** Both ligands have similar hERG inhibition liability (0.46 and 0.505), posing a low risk of cardiotoxicity.
12. **Cl_mic:** Ligand B (50.548) is better than Ligand A (75.457). Lower microsomal clearance indicates better metabolic stability.
13. **t1/2:** Ligand B (59.319) is significantly better than Ligand A (-9.289). A longer half-life is generally desirable.
14. **Pgp:** Both ligands have similar Pgp efflux liability (0.429 and 0.098).
15. **Binding Affinity:** Ligand B (-6.5) is slightly better than Ligand A (-5.4). This is a 1.1 kcal/mol difference, which is significant.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B has a slightly better logP and significantly better affinity. However, the DILI risk for Ligand A is much lower, which is a critical safety factor. Metabolic stability (Cl_mic and t1/2) are also important, and Ligand B is better in these aspects.
**Overall Assessment:**
While Ligand B has a better binding affinity and metabolic profile, the significantly lower DILI risk of Ligand A is a major advantage. Given the cardiovascular context, minimizing liver toxicity is paramount. The affinity difference, while notable, isn't so large that it outweighs the safety concerns associated with Ligand B. The slightly better absorption characteristics of Ligand A also contribute to its favorability.
Output:
1
2025-04-17 19:14:20,650 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [352.519, 67.43, 3.193, 2, 3, 0.659, 19.426, 75.378, -4.486, -3.709, 0.192, 68.48, 4.851, 0.056, -7.0]**
**Ligand B: [370.425, 66.71, 1.209, 1, 5, 0.859, 50.989, 78.558, -5.004, -1.751, 0.602, 16.155, -1.827, 0.039, -8.1]**
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (352.519) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are reasonably low (67.43 and 66.71), suggesting good potential for oral absorption.
3. **logP:** Ligand A (3.193) is optimal, while Ligand B (1.209) is on the lower side. Lower logP can hinder membrane permeability.
4. **H-Bond Donors:** Both have acceptable numbers (2 and 1, respectively).
5. **H-Bond Acceptors:** Both are acceptable (3 and 5, respectively).
6. **QED:** Both have reasonable QED scores (0.659 and 0.859), indicating drug-like properties. Ligand B is better here.
7. **DILI:** Ligand A (19.426) has a significantly lower DILI risk than Ligand B (50.989). This is a major advantage for Ligand A.
8. **BBB:** Both have good BBB penetration (75.378 and 78.558).
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand B (-5.004) is worse than Ligand A (-4.486).
10. **Solubility:** Ligand A (-3.709) has better solubility than Ligand B (-1.751).
11. **hERG:** Ligand A (0.192) has a much lower hERG risk than Ligand B (0.602). This is a significant safety advantage.
12. **Cl_mic:** Ligand B (16.155) has a much lower microsomal clearance, indicating better metabolic stability than Ligand A (68.48).
13. **t1/2:** Ligand A (4.851) has a longer in vitro half-life than Ligand B (-1.827).
14. **Pgp:** Both have very low Pgp efflux liability (0.056 and 0.039).
15. **Binding Affinity:** Ligand B (-8.1) has a significantly stronger binding affinity than Ligand A (-7.0). This is a 1.1 kcal/mol difference, which is substantial.
**GPCR-Specific Priorities:** For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand B excels in affinity, but falls short on logP. Ligand A has a better logP, acceptable affinity, and crucially, much better safety profiles (DILI and hERG). The improved metabolic stability of Ligand B is a plus, but the safety concerns and lower logP are significant drawbacks. The difference in binding affinity, while substantial, can potentially be addressed through further optimization. The safety profile is harder to fix later in development.
**Conclusion:**
Considering the balance of properties, particularly the significantly lower DILI and hERG risk for Ligand A, and the importance of safety in drug development, I favor Ligand A.
```
1
```
2025-04-17 19:14:20,650 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's break down the comparison of Ligand A and Ligand B across the 15 parameters, keeping in mind the GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key).
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (361.419) is slightly higher than Ligand B (349.339), but this difference isn't critical.
2. **TPSA:** Ligand A (92.7) is better than Ligand B (108). Both are acceptable for oral absorption, but lower is generally preferred.
3. **logP:** Ligand A (3.079) is optimal, while Ligand B (0.166) is quite low. This is a significant advantage for Ligand A, as good lipophilicity is crucial for GPCR binding and membrane permeability.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1), but both are within the acceptable limit of 5.
5. **HBA:** Ligand A (6) is slightly higher than Ligand B (7), but both are within the acceptable limit of 10.
6. **QED:** Both ligands have similar QED values (0.449 vs. 0.424), indicating moderate drug-likeness.
7. **DILI:** Ligand A (72.043) has a slightly higher DILI risk than Ligand B (62.815), but both are below the concerning threshold of 60.
8. **BBB:** Ligand B (75.805) has better BBB penetration than Ligand A (39.511). However, for ADRB2, which is primarily a cardiovascular target, BBB penetration isn't a primary concern.
9. **Caco-2:** Ligand A (-5.265) has a more negative Caco-2 value, suggesting better permeability. Ligand B (-4.683) is also good, but A is better.
10. **Solubility:** Ligand A (-4.246) has slightly better solubility than Ligand B (-3.025).
11. **hERG:** Both ligands have very low hERG inhibition liability (0.177 and 0.09, respectively), which is excellent.
12. **Cl_mic:** Ligand B (48.462) has significantly lower microsomal clearance than Ligand A (83.017), indicating better metabolic stability.
13. **t1/2:** Ligand B (-8.956) has a longer in vitro half-life than Ligand A (-5.013), which is desirable.
14. **Pgp:** Ligand A (0.373) has slightly lower P-gp efflux liability than Ligand B (0.088), which is preferable.
15. **Affinity:** Ligand A (-5.9 kcal/mol) has a significantly stronger binding affinity than Ligand B (-2.0 kcal/mol). This is a decisive advantage, as a difference of >1.5 kcal/mol can often outweigh other ADME drawbacks.
**Overall Assessment:**
Ligand A is the stronger candidate. While Ligand B has better metabolic stability (lower Cl_mic and longer t1/2) and BBB penetration, Ligand A's superior logP, Caco-2 permeability, Pgp efflux, and *much* stronger binding affinity are more critical for a GPCR target like ADRB2. The slight increase in DILI risk for Ligand A is acceptable given its significantly improved potency. The low logP of Ligand B is a major concern for its ability to effectively engage the receptor.
**Output:**
1
2025-04-17 19:14:20,650 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.459 Da and 387.311 Da) are within the ideal range (200-500 Da). No significant difference here.
2. **TPSA:** Ligand A (87.66) is better than Ligand B (58.44). Both are below 140, but B is closer to the optimal for GPCRs.
3. **logP:** Ligand A (0.974) is slightly lower than Ligand B (2.26), but both are within the optimal 1-3 range. Ligand B is preferable here.
4. **HBD:** Ligand A (3) is higher than Ligand B (0). Lower HBD is generally preferred for permeability, making Ligand B better.
5. **HBA:** Both ligands have 4 HBA, which is acceptable.
6. **QED:** Both ligands have good QED scores (0.666 and 0.729), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (23.575) has a significantly lower DILI risk than Ligand B (30.71). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (77.821) has a much higher BBB penetration percentile than Ligand A (51.764). Given ADRB2's cardiovascular involvement, BBB penetration is less critical than for CNS targets, but still a consideration.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-5.136) is slightly better (less negative) than Ligand B (-4.922).
10. **Solubility:** Both ligands have negative solubility values, indicating poor aqueous solubility. Ligand A (-2.144) is slightly better than Ligand B (-2.366).
11. **hERG:** Both ligands have very low hERG inhibition risk (0.183 and 0.313). No significant difference.
12. **Cl_mic:** Ligand A (16.989) has lower microsomal clearance than Ligand B (20.789), suggesting better metabolic stability.
13. **t1/2:** Ligand A (21.592) has a longer in vitro half-life than Ligand B (-0.925). This is a significant advantage for Ligand A.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.029 and 0.087). No significant difference.
15. **Binding Affinity:** Ligand A (-7.6) has a slightly stronger binding affinity than Ligand B (-7.3). While the difference is small, it's still a positive for Ligand A.
**Overall Assessment:**
Ligand A demonstrates a better safety profile (lower DILI) and superior pharmacokinetic properties (lower Cl_mic, longer t1/2). While Ligand B has better BBB penetration and logP, the cardiovascular target context makes these less critical. The slightly better binding affinity of Ligand A further strengthens its position. The negative Caco-2 and solubility values are concerning for both, but Ligand A is marginally better in these areas.
Output:
1
2025-04-17 19:14:20,650 - INFO - Batch 95 complete. Total preferences: 1520
2025-04-17 19:14:20,650 - INFO - Processing batch 96/512...
2025-04-17 19:15:09,013 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [371.467, 117.66 , -1.217, 1. , 7. , 0.709, 49.632, 48.662, -5.509, -1.093, 0.111, -17.653, 16.266, 0.009, -6.8 ]
**Ligand B:** [383.579, 49.77 , 3.25 , 1. , 5. , 0.7 , 36.216, 85.459, -5.223, -3.515, 0.788, 94.124, 21.527, 0.836, -6.2 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (371.467) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (117.66) is better than Ligand B (49.77), being closer to the <140 threshold for oral absorption.
3. **logP:** Ligand B (3.25) is optimal (1-3), while Ligand A (-1.217) is too low, potentially hindering membrane permeability. This is a significant drawback for Ligand A.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A (7) is slightly higher than Ligand B (5), but both are acceptable.
6. **QED:** Both are good (>=0.5), indicating drug-like properties.
7. **DILI:** Ligand B (36.216) has a lower DILI risk than Ligand A (49.632), which is preferable.
8. **BBB:** Ligand B (85.459) has significantly better BBB penetration potential than Ligand A (48.662). For a GPCR, even if not specifically a CNS target, some BBB penetration can be useful for distribution.
9. **Caco-2:** Both have negative values, which is unusual. Assuming these are logP-scaled Caco-2 values, they are similar and suggest moderate permeability.
10. **Solubility:** Ligand A (-1.093) has better solubility than Ligand B (-3.515).
11. **hERG:** Ligand A (0.111) has a lower hERG risk than Ligand B (0.788), which is a positive.
12. **Cl_mic:** Ligand A (-17.653) has a much lower (better) microsomal clearance than Ligand B (94.124), indicating better metabolic stability.
13. **t1/2:** Ligand B (21.527) has a longer in vitro half-life than Ligand A (16.266), which is generally desirable.
14. **Pgp:** Ligand B (0.836) has higher P-gp efflux than Ligand A (0.009). Lower P-gp is preferred.
15. **Affinity:** Both have similar binding affinities (-6.8 and -6.2 kcal/mol). The difference isn't substantial enough to be a deciding factor on its own.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are crucial. Ligand B excels in logP and BBB penetration, while Ligand A has better TPSA, Pgp, hERG, and Cl_mic. The logP of Ligand A is a major concern, as it could severely limit its ability to cross cell membranes. Although Ligand A has better metabolic stability, the poor logP is a critical issue.
**Conclusion:**
Despite Ligand A's advantages in metabolic stability and hERG risk, Ligand B's superior logP, BBB penetration, and lower P-gp efflux make it the more promising candidate overall for a GPCR target like ADRB2. The slightly weaker affinity is outweighed by the improved pharmacokinetic properties.
0
2025-04-17 19:15:09,013 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (356.482 and 348.399 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (58.64) is significantly better than Ligand B (93.73). ADRB2 is a cardiovascular target, not CNS, but lower TPSA generally aids absorption. Ligand A is well below the 140 threshold, while B is approaching it.
3. **logP:** Both ligands have good logP values (2.544 and 1.135), falling within the 1-3 range. Ligand A is slightly better, but both are acceptable.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (5). Lower HBA generally improves permeability.
6. **QED:** Ligand A (0.646) is better than Ligand B (0.531), indicating a more drug-like profile.
7. **DILI:** Ligand B (41.334) is better than Ligand A (10.469), indicating a lower risk of drug-induced liver injury. This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (89.88) is significantly better than Ligand B (69.523). While ADRB2 is not a CNS target, higher BBB penetration can sometimes correlate with better overall distribution.
9. **Caco-2:** Ligand A (-4.54) is better than Ligand B (-5.132). Higher Caco-2 permeability indicates better intestinal absorption.
10. **Solubility:** Ligand A (-2.733) is better than Ligand B (-2.657). Solubility is important for formulation and bioavailability.
11. **hERG:** Ligand A (0.772) is better than Ligand B (0.153). Lower hERG inhibition is crucial for avoiding cardiotoxicity, a major concern for cardiovascular drugs.
12. **Cl_mic:** Ligand B (22.498) is significantly better than Ligand A (45.339). Lower microsomal clearance indicates greater metabolic stability, a major advantage for Ligand B.
13. **t1/2:** Ligand B (-10.269) is significantly better than Ligand A (-2.259). A longer in vitro half-life is desirable.
14. **Pgp:** Ligand A (0.185) is better than Ligand B (0.025). Lower P-gp efflux is beneficial for bioavailability.
15. **Affinity:** Both ligands have very similar binding affinities (-6.9 and -6.7 kcal/mol). The difference is negligible.
**Overall Assessment:**
Ligand A has advantages in TPSA, logP, HBD, HBA, QED, Caco-2, Solubility, hERG, and Pgp. However, Ligand B has a significant advantage in DILI risk, microsomal clearance, and in vitro half-life. Considering ADRB2 is a cardiovascular target, minimizing cardiotoxicity (hERG) and maximizing metabolic stability (Cl_mic, t1/2) are critical. The lower DILI risk is also a major plus. While Ligand A has slightly better absorption characteristics, the improved safety and pharmacokinetic profile of Ligand B outweigh those benefits.
Output:
0
2025-04-17 19:15:09,013 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.391 and 371.547 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand B (64.09) is significantly better than Ligand A (121.89). ADRB2 is not a CNS target, but lower TPSA generally improves absorption. This is a strong advantage for Ligand B.
3. **logP:** Both ligands have similar logP values (0.922 and 0.892), falling within the optimal 1-3 range. No clear advantage.
4. **HBD:** Ligand B (1) has fewer HBDs than Ligand A (3). Fewer HBDs are generally preferred for better permeability. Advantage: Ligand B.
5. **HBA:** Ligand B (5) has fewer HBAs than Ligand A (6). Similar to HBD, fewer HBAs are preferred. Advantage: Ligand B.
6. **QED:** Both ligands have good QED scores (0.653 and 0.778), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand B (5.894) has a *much* lower DILI risk than Ligand A (63.94). This is a major advantage for Ligand B. A DILI percentile above 60 is concerning.
8. **BBB:** Both ligands have similar BBB penetration (47.15 and 62.233). Since ADRB2 is not a CNS target, this is less critical, but Ligand B is slightly better.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.163 and -4.9). These values are difficult to interpret without knowing the scale, but negative values suggest poor permeability. No clear advantage.
10. **Solubility:** Ligand B (-1.028) is slightly better than Ligand A (-2.564), indicating better aqueous solubility.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.199 and 0.187). No significant difference.
12. **Cl_mic:** Ligand B (10.415) has lower microsomal clearance than Ligand A (12.974), suggesting better metabolic stability. Advantage: Ligand B.
13. **t1/2:** Ligand B (-11.501) has a longer in vitro half-life than Ligand A (-23.32). Advantage: Ligand B.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.004 and 0.006). No significant difference.
15. **Binding Affinity:** Both ligands have identical binding affinities (-4.9 kcal/mol).
**Overall Assessment:**
Ligand B consistently outperforms Ligand A across most ADME properties. The most significant advantage is the dramatically lower DILI risk. It also has better TPSA, HBD, HBA, QED, solubility, metabolic stability (lower Cl_mic), and a longer half-life. While both have similar binding affinity, the improved ADME profile of Ligand B makes it a much more promising drug candidate.
Output:
0
2025-04-17 19:15:09,014 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (366.49 & 387.89 Da) are within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (84.42) is slightly higher than Ligand B (78.95). Both are below the 140 threshold for oral absorption, and acceptable for a peripheral GPCR like ADRB2. Ligand B is slightly preferred.
3. **logP:** Both ligands (1.83 & 1.15) fall within the optimal 1-3 range. Ligand A is slightly higher, potentially offering better membrane permeability, but both are good.
4. **HBD:** Both have 1 HBD, which is within the acceptable limit of 5.
5. **HBA:** Ligand A has 6 HBA, and Ligand B has 5. Both are below the 10 limit.
6. **QED:** Both ligands have good QED scores (0.796 & 0.821), indicating good drug-like properties.
7. **DILI:** Ligand B (61.81%) has a slightly higher DILI risk than Ligand A (55.76%), but both are still reasonably acceptable.
8. **BBB:** Both have low BBB penetration (59.09% & 61.03%). This is not a major concern for ADRB2, a cardiovascular target.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.87 & -4.68), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Both ligands have very poor aqueous solubility (-2.70 & -2.22). This is a major drawback for both compounds.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.19 & 0.16). This is excellent.
12. **Cl_mic:** Ligand B (29.30) has significantly lower microsomal clearance than Ligand A (77.53), indicating better metabolic stability. This is a substantial advantage.
13. **t1/2:** Ligand B (11.86) has a longer in vitro half-life than Ligand A (9.11), further supporting its better metabolic stability.
14. **Pgp:** Both have very low Pgp efflux liability (0.12 & 0.06).
15. **Binding Affinity:** Ligand B (-6.4 kcal/mol) has a slightly stronger binding affinity than Ligand A (-6.8 kcal/mol). While A is slightly better, the difference is not huge.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are important. Both ligands perform similarly on logP and Pgp. TPSA is comparable. Ligand B has a slightly better affinity. However, the biggest differentiator is the significantly improved metabolic stability of Ligand B (lower Cl_mic and longer t1/2). The poor Caco-2 and solubility are concerning for both, but metabolic stability is crucial for *in vivo* efficacy.
**Conclusion:**
Considering the balance of properties, especially the improved metabolic stability of Ligand B, I would choose Ligand B as the more promising drug candidate.
Output:
0
2025-04-17 19:15:09,014 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.431 and 373.429 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (67.67) is significantly better than Ligand B (92.42). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands (1.283 and 1.5) are within the optimal 1-3 range. Ligand B is slightly higher, which *could* be a minor advantage for membrane permeability, but not a major factor.
4. **HBD:** Ligand A (0) is preferable to Ligand B (1). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (6). Lower HBA is generally better for permeability.
6. **QED:** Both ligands are good (0.806 and 0.863), indicating good drug-like properties. No clear winner.
7. **DILI:** Ligand A (34.82) has a much lower DILI risk than Ligand B (63.668). This is a significant advantage for Ligand A.
8. **BBB:** Both ligands have high BBB penetration (90.074 and 86.817). Not a primary concern for a cardiovascular target.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.661 and -4.85). These values are unusual and suggest poor permeability. However, the values are very similar.
10. **Solubility:** Ligand A (-1.61) is better than Ligand B (-3.362). Better solubility is always preferred.
11. **hERG:** Both ligands have low hERG inhibition liability (0.568 and 0.28). No significant difference.
12. **Cl_mic:** Ligand A (46.962) has a significantly lower microsomal clearance than Ligand B (15.558), indicating better metabolic stability. This is a key advantage for Ligand A.
13. **t1/2:** Ligand A (-10.366) has a longer in vitro half-life than Ligand B (0.602). This is a significant advantage.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.178 and 0.047). No significant difference.
15. **Binding Affinity:** Both ligands have the same binding affinity (-6.1 kcal/mol).
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A is better on TPSA, and has a better balance of properties overall.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B in several critical ADME properties (DILI, Cl_mic, t1/2, solubility, TPSA, HBD, HBA) while maintaining comparable binding affinity and acceptable logP. The lower DILI risk and improved metabolic stability of Ligand A make it a more promising drug candidate. The negative Caco-2 values are concerning for both, but the other advantages of A outweigh this.
Output:
1
2025-04-17 19:15:09,014 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [359.348, 63.69, 1.842, 1, 4, 0.895, 50.756, 88.29, -4.573, -2.019, 0.341, 0.98, 2.936, 0.036, -6.1]
**Ligand B:** [360.483, 65.54, 1.095, 1, 5, 0.799, 30.012, 50.058, -5.064, -1.782, 0.257, -4.071, -2.249, 0.031, -4.4]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). A is 359.348, B is 360.483 - very similar.
2. **TPSA:** Both are reasonably low (A: 63.69, B: 65.54), suggesting good potential for absorption.
3. **logP:** Both are within the optimal range (1-3), A (1.842) is slightly better than B (1.095).
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** A has 4, B has 5. Both are acceptable, but A is slightly preferable.
6. **QED:** A (0.895) is significantly better than B (0.799), indicating a more drug-like profile.
7. **DILI:** A (50.756) is higher than B (30.012), meaning B has a lower risk of liver injury. This is a significant advantage for B.
8. **BBB:** A (88.29) is much better than B (50.058). For a GPCR, even if not specifically a CNS target, some BBB penetration can be beneficial for distribution.
9. **Caco-2:** A (-4.573) is better than B (-5.064), indicating better intestinal absorption.
10. **Solubility:** A (-2.019) is better than B (-1.782), though both are poor.
11. **hERG:** A (0.341) is better than B (0.257), indicating lower cardiotoxicity risk.
12. **Cl_mic:** A (0.98) is much better than B (-4.071), suggesting better metabolic stability.
13. **t1/2:** A (2.936) is better than B (-2.249).
14. **Pgp:** A (0.036) is better than B (0.031), indicating less P-gp efflux.
15. **Affinity:** A (-6.1) is better than B (-4.4), a significant 1.7 kcal/mol difference.
**GPCR-specific priorities:** LogP, Pgp, TPSA, and affinity are key. A performs better on all of these. While B has a better DILI score, the substantial advantage in binding affinity (-6.1 vs -4.4 kcal/mol) for A, coupled with better metabolic stability (Cl_mic) and BBB penetration, outweighs the DILI concern, especially considering the relatively moderate DILI risk of A (50.756). The improved QED score also favors A.
**Conclusion:**
Ligand A is the more promising candidate.
1
2025-04-17 19:15:09,014 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (339.4 and 358.5 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (80.1 and 76.7 A^2) are below the 140 A^2 threshold for good oral absorption, and are reasonable for a peripherally acting GPCR target like ADRB2. Ligand B is slightly better.
3. **logP:** Both ligands (0.94 and 1.72) are within the optimal 1-3 range. Ligand B is slightly better, leaning towards the more desirable end of the range.
4. **HBD:** Ligand A (1 HBD) is preferable to Ligand B (2 HBDs). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (5 HBA) is preferable to Ligand B (4 HBA). Fewer HBA's generally improve permeability.
6. **QED:** Ligand A (0.879) has a significantly better QED score than Ligand B (0.727), indicating a more drug-like profile.
7. **DILI:** Ligand B (38.1%) has a much lower DILI risk than Ligand A (58.5%). This is a significant advantage for Ligand B.
8. **BBB:** Ligand B (75.9%) has a higher BBB penetration percentile than Ligand A (48.3%). While ADRB2 isn't a CNS target, some degree of BBB penetration can sometimes indicate favorable permeability characteristics.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-5.24) is slightly better than Ligand B (-4.873).
10. **Solubility:** Both ligands have negative solubility values, indicating very poor aqueous solubility. This is a major concern. Ligand A (-2.079) is slightly better than Ligand B (-2.089).
11. **hERG:** Both ligands have very low hERG inhibition liability (0.191 and 0.407), which is excellent.
12. **Cl_mic:** Ligand A (15.37 mL/min/kg) has a lower microsomal clearance than Ligand B (18.14 mL/min/kg), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-5.254 hours) has a more negative in vitro half-life than Ligand B (4.303 hours). This indicates a shorter half-life for Ligand A, which is undesirable.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.013 and 0.035).
15. **Binding Affinity:** Ligand A (-6.5 kcal/mol) has a better binding affinity than Ligand B (-4.7 kcal/mol). This is a substantial difference (1.8 kcal/mol), and is a key driver in the decision.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are important. Ligand B has a slightly better logP and TPSA, while Ligand A has significantly better affinity. The DILI risk is also a major consideration, and Ligand B is significantly better in this regard.
**Overall Assessment:**
While Ligand B has a better safety profile (lower DILI) and slightly better permeability indicators (logP, TPSA, BBB), the substantial difference in binding affinity (-6.5 vs -4.7 kcal/mol) for Ligand A is a major advantage. The affinity difference is likely to outweigh the slightly higher DILI risk and poorer solubility. The shorter half-life of Ligand A is a concern, but can potentially be addressed through formulation or structural modifications.
Output:
1
2025-04-17 19:15:09,014 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
The target is ADRB2, a GPCR. Therefore, I will prioritize logP, Pgp, TPSA, and binding affinity, alongside general drug-like properties.
* **Molecular Weight:** Both ligands are within the ideal range (349-353 Da).
* **TPSA:** Both are acceptable, below 140, but Ligand A (92.71) is slightly better than Ligand B (96.45).
* **logP:** Ligand A (2.154) is optimal, while Ligand B (0.308) is quite low, potentially hindering permeability. This is a significant negative for Ligand B.
* **H-Bond Donors/Acceptors:** Both have reasonable HBD (3/2) and HBA (6/6) counts.
* **QED:** Both are above 0.5, indicating good drug-likeness. Ligand B (0.666) is marginally better.
* **DILI:** Ligand B (38.736) has a considerably lower DILI risk than Ligand A (11.594), which is a positive for Ligand B.
* **BBB:** Ligand B (62.97) has a better BBB penetration percentile than Ligand A (43.583). While ADRB2 isn't necessarily a CNS target, some peripheral ADRB2 receptors can be relevant in CNS pathways, so this is a slight benefit for B.
* **Caco-2 Permeability:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.705) is slightly better than Ligand B (-4.629).
* **Aqueous Solubility:** Both have negative solubility values, which is also unusual and suggests poor solubility. Ligand A (-2.139) is slightly better than Ligand B (-1.627).
* **hERG:** Both have low hERG inhibition liability, which is good. Ligand A (0.609) is slightly higher.
* **Microsomal Clearance:** Ligand B (19.696) has significantly lower microsomal clearance than Ligand A (46.985), indicating better metabolic stability.
* **In vitro Half-Life:** Ligand B (-28.555) has a much longer in vitro half-life than Ligand A (-14.541).
* **P-gp Efflux:** Both have very low P-gp efflux liability, which is good. Ligand A (0.067) is slightly higher.
* **Binding Affinity:** Ligand B (-7.3 kcal/mol) has a substantially stronger binding affinity than Ligand A (-5.7 kcal/mol). This is a significant advantage for Ligand B, potentially outweighing some of its ADME drawbacks.
**Overall Assessment:**
While Ligand B has better DILI, BBB, metabolic stability, and half-life, and *significantly* better binding affinity, its low logP is a major concern. However, the substantial improvement in binding affinity (-7.3 vs -5.7 kcal/mol) is a significant advantage that could potentially overcome the permeability issues. Ligand A has a more favorable logP, but its weaker binding affinity and higher clearance are substantial drawbacks. Given the GPCR target class, binding affinity is paramount.
**Output:**
0
2025-04-17 19:15:09,014 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A: [348.443, 84.5, 1.534, 2, 4, 0.376, 22.8, 54.905, -4.66, -2.723, 0.091, 55.404, -21.16, 0.024, -5.9]**
**Ligand B: [346.387, 129.43, 1.041, 2, 5, 0.795, 39.473, 59.325, -5.278, -3.294, 0.419, -18.754, 20.599, 0.039, -7.3]**
Here's a breakdown, considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal range (200-500 Da). A is 348.443, B is 346.387. Very similar.
2. **TPSA:** A (84.5) is excellent, well below 140 and good for oral absorption. B (129.43) is still acceptable, but less optimal.
3. **logP:** A (1.534) is ideal. B (1.041) is slightly low, potentially impacting permeability.
4. **HBD:** Both have 2, which is good.
5. **HBA:** A has 4, B has 5. Both are acceptable.
6. **QED:** A (0.376) is below the 0.5 threshold, indicating a less drug-like profile. B (0.795) is above the threshold, which is a significant advantage.
7. **DILI:** A (22.8) is very good, low risk. B (39.473) is also acceptable, but higher.
8. **BBB:** A (54.905) is moderate. B (59.325) is slightly better, but neither are exceptionally high. For a cardiovascular target, BBB isn't *critical*, but some penetration can be beneficial.
9. **Caco-2:** A (-4.66) is very poor, suggesting very low intestinal absorption. B (-5.278) is also poor, but slightly better.
10. **Solubility:** A (-2.723) is poor. B (-3.294) is also poor. Both will likely require formulation strategies.
11. **hERG:** A (0.091) is very low risk. B (0.419) is slightly higher, but still acceptable.
12. **Cl_mic:** A (55.404) is relatively high, suggesting faster metabolism. B (-18.754) is *much* lower, indicating better metabolic stability. This is a significant advantage.
13. **t1/2:** A (-21.16) is very short. B (20.599) is significantly longer, which is desirable.
14. **Pgp:** A (0.024) is very low efflux, excellent. B (0.039) is also low, but slightly higher.
15. **Affinity:** A (-5.9) is good. B (-7.3) is *significantly* better, a 1.4 kcal/mol advantage. This is a substantial difference.
**Overall Assessment:**
Ligand B has a substantial advantage in binding affinity, significantly better metabolic stability (lower Cl_mic, longer t1/2), and a better QED score. While both have poor Caco-2 and solubility, the improved affinity and metabolic profile of B outweigh these drawbacks. The slightly higher logP of A is less important than the other factors. The lower DILI score of A is good, but not enough to overcome the other advantages of B.
Output:
0
2025-04-17 19:15:09,014 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (347.459 Da) is slightly lower, which is generally favorable for permeability.
**2. TPSA:** Ligand A (80.32) is better than Ligand B (59.07). While both are below 140, lower TPSA is generally preferred for GPCRs to facilitate receptor binding and permeability.
**3. logP:** Ligand A (1.983) is within the optimal range (1-3), while Ligand B (3.825) is approaching the upper limit. Higher logP can lead to off-target effects and solubility issues.
**4. H-Bond Donors:** Both have 2 HBD, which is acceptable.
**5. H-Bond Acceptors:** Ligand A has 4 HBA, while Ligand B has 7. Ligand A is preferable.
**6. QED:** Ligand A (0.753) has a better QED score than Ligand B (0.639), indicating a more drug-like profile.
**7. DILI:** Ligand A (27.879) has a significantly lower DILI risk than Ligand B (85.537). This is a crucial advantage.
**8. BBB:** Ligand B (89.492) has a higher BBB penetration percentile than Ligand A (51.725). However, since ADRB2 is primarily a cardiovascular target, high BBB penetration is not a primary concern.
**9. Caco-2 Permeability:** Both ligands have similar, and poor, Caco-2 permeability scores.
**10. Aqueous Solubility:** Ligand A (-2.065) has a better solubility score than Ligand B (-4.182).
**11. hERG Inhibition:** Ligand A (0.123) has a lower hERG inhibition liability than Ligand B (0.933), which is a significant safety advantage.
**12. Microsomal Clearance:** Ligand A (9.008) has a lower microsomal clearance than Ligand B (106.814), indicating better metabolic stability.
**13. In vitro Half-Life:** Ligand B (63.904) has a longer in vitro half-life than Ligand A (27.755). This is a positive attribute, but can be offset by higher clearance.
**14. P-gp Efflux:** Ligand A (0.019) has significantly lower P-gp efflux liability than Ligand B (0.581). This is favorable for bioavailability.
**15. Binding Affinity:** Ligand B (-6.9 kcal/mol) has a slightly better binding affinity than Ligand A (-6.3 kcal/mol). While affinity is important, the difference of 0.6 kcal/mol is not substantial enough to outweigh the numerous ADME/Tox advantages of Ligand A.
**Overall Assessment:**
Ligand A demonstrates a significantly better overall profile, particularly regarding safety (DILI, hERG), metabolic stability (Cl_mic), and bioavailability (P-gp efflux, solubility). While Ligand B has a slightly better binding affinity and BBB penetration, these are less critical for a cardiovascular target. The combination of favorable ADME properties and lower toxicity risk makes Ligand A the more promising drug candidate.
Output:
1
2025-04-17 19:15:09,014 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (356.363 and 350.39 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (136.89) is slightly higher than Ligand B (87.66). Ligand B is preferable as it is closer to the <140 threshold for good oral absorption.
3. **logP:** Both ligands (2.011 and 1.99) are within the optimal 1-3 range. No significant difference.
4. **HBD:** Ligand A (1) is better than Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (6) is better than Ligand B (4). Fewer HBAs generally improve permeability.
6. **QED:** Both ligands have good QED scores (0.621 and 0.685), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (89.376) has a higher DILI risk than Ligand B (47.926). This is a significant advantage for Ligand B.
8. **BBB:** Ligand B (71.501) has a higher BBB penetration score than Ligand A (38.465). While ADRB2 isn't strictly a CNS target, some peripheral ADRB2 receptors can be affected by CNS penetration, and higher BBB is generally favorable.
9. **Caco-2:** Ligand A (-4.888) and Ligand B (-5.39) both have negative values, which is unusual. Lower (more negative) values indicate poorer permeability. No clear winner here, but both are concerning.
10. **Solubility:** Ligand A (-4.514) is slightly better than Ligand B (-3.343). Higher values are better.
11. **hERG:** Ligand A (0.629) has a slightly higher hERG inhibition liability than Ligand B (0.419). Ligand B is preferable.
12. **Cl_mic:** Ligand B (-6.053) has a lower (better) microsomal clearance than Ligand A (34.456). This suggests better metabolic stability for Ligand B.
13. **t1/2:** Ligand A (-9.321) has a shorter in vitro half-life than Ligand B (-1.997). Ligand B is preferable.
14. **Pgp:** Ligand A (0.161) has a lower Pgp efflux liability than Ligand B (0.081). Lower Pgp is better, so Ligand A is preferable.
15. **Binding Affinity:** Ligand B (-6.4) has a slightly better binding affinity than Ligand A (-7.0). While A is better, the difference is not substantial enough to outweigh other factors.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity) and the general guidelines, Ligand B is the more promising candidate. It demonstrates a significantly lower DILI risk, better metabolic stability (lower Cl_mic, longer t1/2), and higher BBB penetration. While Ligand A has a slightly better binding affinity and Pgp profile, the advantages of Ligand B in safety (DILI) and pharmacokinetics (Cl_mic, t1/2) are more critical for overall drug development success. The TPSA is also significantly better for Ligand B.
Output:
0
2025-04-17 19:15:09,014 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (423.292 Da) is within the ideal range, while Ligand B (361.873 Da) is also acceptable, being slightly lower. No clear advantage here.
2. **TPSA:** Ligand A (77.75) is slightly higher than Ligand B (62.3). Both are below the 140 threshold for oral absorption, but B is better.
3. **logP:** Both ligands have good logP values (A: 3.483, B: 2.778), falling within the optimal 1-3 range.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 7 HBAs, while Ligand B has 3. Ligand B is preferable here.
6. **QED:** Ligand B (0.896) has a significantly better QED score than Ligand A (0.634), indicating better overall drug-likeness.
7. **DILI:** Ligand A (98.139) has a very high DILI risk, which is a major concern. Ligand B (31.989) has a low DILI risk, a significant advantage.
8. **BBB:** Ligand B (77.976) shows better BBB penetration than Ligand A (55.021). While ADRB2 isn't strictly a CNS target, some peripheral ADRB2 receptors can be affected by CNS penetration.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.767) is slightly better than Ligand B (-5.047).
10. **Solubility:** Ligand A (-4.874) and Ligand B (-3.918) both have poor solubility.
11. **hERG:** Ligand A (0.571) has a slightly higher hERG risk than Ligand B (0.259), though both are relatively low.
12. **Cl_mic:** Ligand B (49.543) has lower microsomal clearance than Ligand A (75.158), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-2.436) has a negative in vitro half-life, which is concerning. Ligand A (45.413) has a reasonable half-life.
14. **Pgp:** Ligand B (0.048) has much lower P-gp efflux liability than Ligand A (0.639), which is a significant advantage for bioavailability.
15. **Binding Affinity:** Ligand B (-6.9 kcal/mol) has a slightly better binding affinity than Ligand A (-6.6 kcal/mol), but the difference is not substantial enough to outweigh other factors.
**GPCR-specific priorities:** logP, Pgp, TPSA, and affinity are important for GPCRs. Ligand B excels in logP, Pgp, and TPSA. Affinity is similar. The biggest issue with Ligand A is its extremely high DILI risk.
**Overall Assessment:**
Ligand B is the clear preference. While its in vitro half-life is concerning, the significantly lower DILI risk, better QED, lower P-gp efflux, and better TPSA outweigh the slight disadvantage in half-life and Caco-2 permeability. The improved metabolic stability (lower Cl_mic) is also a positive. The slightly better binding affinity of Ligand B is a bonus. The high DILI risk of Ligand A is a deal-breaker.
Output:
0
2025-04-17 19:15:09,014 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
Let's break down the comparison based on the provided guidelines and GPCR priorities (logP, Pgp, TPSA, and affinity being key).
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (340.471) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (51.02) is significantly better than Ligand B (79.8). ADRB2 is not a CNS target, but lower TPSA generally improves absorption. Ligand B's TPSA is relatively high.
3. **logP:** Both ligands have good logP values (A: 3.718, B: 3.324) falling within the optimal 1-3 range.
4. **H-Bond Donors/Acceptors:** Ligand A (0 HBD, 4 HBA) is more favorable than Ligand B (2 HBD, 7 HBA). Fewer hydrogen bonds generally improve membrane permeability.
5. **QED:** Both ligands have acceptable QED values (A: 0.805, B: 0.693), indicating reasonable drug-likeness.
6. **DILI Risk:** Ligand A (33.656) has a much lower DILI risk than Ligand B (79.333). This is a significant advantage for Ligand A.
7. **BBB:** While not a primary concern for ADRB2, Ligand A (82.823) has a better BBB penetration score than Ligand B (74.913).
8. **Caco-2 Permeability:** Ligand A (-4.791) has a better Caco-2 permeability score than Ligand B (-5.224).
9. **Aqueous Solubility:** Both ligands have poor aqueous solubility (-3.55 and -3.96 respectively).
10. **hERG Inhibition:** Both ligands have low hERG inhibition liability (A: 0.634, B: 0.728).
11. **Microsomal Clearance:** Ligand B (52.314) has a significantly lower microsomal clearance than Ligand A (83.161), suggesting better metabolic stability.
12. **In vitro Half-Life:** Ligand B (62.186) has a much longer in vitro half-life than Ligand A (-26.976). This is a major advantage for Ligand B.
13. **P-gp Efflux:** Ligand A (0.429) has a lower P-gp efflux liability than Ligand B (0.246), which is favorable for bioavailability.
14. **Binding Affinity:** Both ligands have very similar binding affinities (A: -6.7 kcal/mol, B: -6.5 kcal/mol). The difference is not substantial enough to outweigh other factors.
**Overall Assessment:**
Ligand A demonstrates a better balance of properties, particularly regarding safety (DILI risk) and permeability (TPSA, Caco-2, P-gp). Ligand B has a better metabolic stability (lower Cl_mic) and longer half-life, but the higher TPSA and DILI risk are concerning. The slight advantage in half-life doesn't outweigh the other benefits of Ligand A.
**Output:**
1
2025-04-17 19:15:09,015 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (a cardiovascular GPCR) drug candidates.
**Ligand A:** [350.415, 83.22, 1.26, 1, 5, 0.864, 35.13, 50.019, -4.416, -1.755, 0.331, 19.009, 23.785, 0.345, -6.4]
**Ligand B:** [352.435, 90.98, -0.209, 2, 5, 0.69, 14.23, 46.879, -5.208, -0.796, 0.185, -38.777, -7.719, 0.001, -5.4]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). A: 350.4, B: 352.4 - very similar.
2. **TPSA:** A: 83.22, B: 90.98. Both are acceptable for a cardiovascular target, being under 140. A is slightly better.
3. **logP:** A: 1.26, B: -0.209. A is optimal (1-3). B is slightly below 1, which *could* indicate permeability issues.
4. **HBD:** A: 1, B: 2. Both are good, under the 5 threshold.
5. **HBA:** Both are 5, acceptable.
6. **QED:** A: 0.864, B: 0.69. A is significantly better, indicating a more drug-like profile.
7. **DILI:** A: 35.13, B: 14.23. B is *much* better, indicating a lower risk of liver injury. This is a significant advantage for B.
8. **BBB:** A: 50.019, B: 46.879. Not a huge difference, and not critical for a cardiovascular target (unlike a CNS target).
9. **Caco-2:** A: -4.416, B: -5.208. Both are negative, indicating poor permeability. B is slightly worse.
10. **Solubility:** A: -1.755, B: -0.796. B is better, indicating slightly better solubility.
11. **hERG:** A: 0.331, B: 0.185. B is better, lower hERG inhibition risk.
12. **Cl_mic:** A: 19.009, B: -38.777. B is *much* better, indicating significantly higher metabolic stability. This is a major advantage for B.
13. **t1/2:** A: 23.785, B: -7.719. A is better, indicating a longer in vitro half-life.
14. **Pgp:** A: 0.345, B: 0.001. B is *much* better, indicating lower P-gp efflux.
15. **Affinity:** A: -6.4, B: -5.4. A has a 1.0 kcal/mol advantage in binding affinity. This is a substantial difference.
**GPCR-specific priorities:** For ADRB2 (a cardiovascular GPCR), logP, Pgp, TPSA, and affinity are key.
**Overall Assessment:**
Ligand A has a better binding affinity and half-life, and a better QED score. However, Ligand B significantly outperforms A in DILI risk, metabolic stability (Cl_mic), P-gp efflux, and hERG inhibition. The lower logP of B is a minor concern, but the substantial improvements in safety and pharmacokinetic parameters outweigh this. The affinity difference, while notable, isn't so large that it completely overshadows the ADME/Tox advantages of B.
Therefore, considering the balance of properties and the importance of safety and metabolic stability for a cardiovascular drug, I would select Ligand B.
0
2025-04-17 19:15:09,015 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, the priorities are logP, Pgp, TPSA, and affinity, with metabolic stability (Cl_mic, t1/2) also being important.
Let's compare the ligands property by property:
1. **MW:** Both are around 350 Da, well within the ideal range.
2. **TPSA:** Ligand A (58.64) is significantly better than Ligand B (75.93). Lower TPSA is preferred for GPCRs to facilitate membrane permeability.
3. **logP:** Ligand A (2.737) is optimal, while Ligand B (0.956) is slightly low, potentially hindering permeability.
4. **HBD/HBA:** Both have acceptable HBD (1) and HBA (3/5).
5. **QED:** Both are good (>0.7).
6. **DILI:** Ligand A (4.459) is slightly better than Ligand B (37.185), indicating a lower risk of liver injury.
7. **BBB:** Ligand A (81.698) is better than Ligand B (70.648), though neither is exceptionally high. This is less critical for a cardiovascular target.
8. **Caco-2:** Both are negative, indicating poor permeability.
9. **Solubility:** Both are negative, indicating poor solubility.
10. **hERG:** Both are low, which is good.
11. **Cl_mic:** Ligand A (31.811) has a significantly better (lower) microsomal clearance than Ligand B (7.172), suggesting better metabolic stability.
12. **t1/2:** Ligand A (-6.807) is better than Ligand B (-2.719).
13. **Pgp:** Ligand A (0.067) is much better than Ligand B (0.098), indicating lower P-gp efflux and potentially better bioavailability.
14. **Affinity:** Both have similar binding affinities (-3.4 and -3.6 kcal/mol). The difference is negligible.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across several key ADME properties (TPSA, logP, DILI, Cl_mic, t1/2, Pgp) while maintaining comparable binding affinity. The lower TPSA and better logP of Ligand A are particularly advantageous for a GPCR target. While both have poor Caco-2 and solubility, the superior ADME profile of Ligand A makes it the more promising candidate.
**Output:**
1
2025-04-17 19:15:09,015 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (349.435 Da) is slightly lower, which could be beneficial for permeability.
2. **TPSA:** Both are good, below the 140 A^2 threshold for oral absorption. Ligand B (86.63) is better than Ligand A (100.25), which is preferable for GPCRs.
3. **logP:** Both are within the optimal range (1-3). Ligand A (1.074) is slightly lower, while Ligand B (1.3) is a bit better.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 6 HBA, and Ligand B has 7. Both are acceptable, below the 10 threshold.
6. **QED:** Both are above 0.5, indicating good drug-likeness. Ligand A (0.719) is slightly better.
7. **DILI:** Both have acceptable DILI risk (Ligand A: 44.591, Ligand B: 47.034).
8. **BBB:** Both have relatively low BBB penetration, which isn't a major concern for ADRB2 (a cardiovascular target). Ligand A (58.821) is slightly better.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand B (-5.437) is slightly better than Ligand A (-4.703).
10. **Solubility:** Both are negative, indicating poor solubility. Ligand B (-1.515) is slightly better than Ligand A (-2.316).
11. **hERG:** Both have very low hERG inhibition risk (Ligand A: 0.351, Ligand B: 0.147). Ligand B is better.
12. **Cl_mic:** Ligand B (28.614) has significantly lower microsomal clearance than Ligand A (48.029), suggesting better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand B (-3.062) has a negative half-life, which is concerning, while Ligand A (30.754) has a reasonable half-life.
14. **Pgp:** Both have low Pgp efflux liability (Ligand A: 0.141, Ligand B: 0.176).
15. **Binding Affinity:** Both have excellent binding affinity (-5.8 kcal/mol and -5.0 kcal/mol respectively). Ligand A has a 0.8 kcal/mol advantage.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, TPSA, logP, and metabolic stability are important. Ligand B has a lower TPSA and better metabolic stability (lower Cl_mic). While Ligand A has a slightly better QED and binding affinity, the improved metabolic stability of Ligand B is more crucial for *in vivo* efficacy. The negative half-life for Ligand B is a significant concern, however.
**Overall Assessment:**
Despite the negative half-life, Ligand B's better TPSA, lower Cl_mic, and lower hERG risk make it the more promising candidate. The binding affinity difference is not substantial enough to outweigh these ADME advantages. The negative half-life would need to be addressed in further optimization.
Output:
0
2025-04-17 19:15:09,015 - INFO - Batch 96 complete. Total preferences: 1536
2025-04-17 19:15:09,015 - INFO - Processing batch 97/512...
2025-04-17 19:15:53,564 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, the key priorities are logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB.
Let's break down the comparison:
1. **MW:** Both ligands are within the acceptable range (200-500 Da). Ligand B (356.457 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (67.35) is higher than Ligand B (49.41). Both are below 140, but Ligand B is better positioned for oral absorption.
3. **logP:** Both ligands have good logP values (2.936 and 3.521), falling within the optimal 1-3 range. Ligand B is slightly higher, which *could* be a minor concern for solubility, but not a dealbreaker.
4. **HBD/HBA:** Both have acceptable HBD (1) and HBA (Ligand A: 5, Ligand B: 2) counts.
5. **QED:** Both ligands have good QED scores (0.654 and 0.74), indicating good drug-likeness.
6. **DILI:** Ligand A (46.956) has a higher DILI risk than Ligand B (24.777). This is a significant advantage for Ligand B.
7. **BBB:** Ligand A (94.416) has better BBB penetration than Ligand B (88.988), but this is less critical for a cardiovascular target.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. This is a concern for both.
9. **Solubility:** Both have negative solubility values, indicating very poor aqueous solubility. This is a significant drawback for both compounds.
10. **hERG:** Both have low hERG inhibition liability (0.796 and 0.565), which is good.
11. **Cl_mic:** Ligand A (28.746) has a slightly higher microsomal clearance than Ligand B (26.296), suggesting lower metabolic stability.
12. **t1/2:** Ligand B (-13.81) has a negative in vitro half-life, which is concerning. Ligand A (27.996) is much better.
13. **Pgp:** Both have very low Pgp efflux liability (0.17 and 0.103), which is favorable.
14. **Binding Affinity:** Ligand A (-7.2 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.2 kcal/mol). This 1 kcal/mol difference is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand A has a much stronger binding affinity, which is paramount for GPCR targets. While Ligand B has better DILI and TPSA, the difference in affinity is substantial. The negative Caco-2 and solubility values are concerning for both, but can potentially be addressed through formulation strategies. The better half-life for Ligand A is also a plus.
**Output:**
1
2025-04-17 19:15:53,564 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (356.463 Da) is within the ideal range, while Ligand B (239.315 Da) is at the lower end, potentially impacting potency.
2. **TPSA:** Ligand A (99.1) is acceptable, though approaching the upper limit for good absorption. Ligand B (72.72) is excellent.
3. **logP:** Ligand A (0.432) is quite low, potentially hindering membrane permeability. Ligand B (1.306) is better, falling within the optimal range.
4. **HBD:** Ligand A (3) is good. Ligand B (4) is also acceptable.
5. **HBA:** Ligand A (5) is good. Ligand B (4) is good.
6. **QED:** Both ligands (A: 0.614, B: 0.639) have good drug-likeness scores.
7. **DILI:** Ligand A (9.267) has a slightly elevated DILI risk, but still relatively low. Ligand B (0.775) has a very low DILI risk, a significant advantage.
8. **BBB:** Ligand A (51.415) has moderate BBB penetration. Ligand B (9.655) has very low BBB penetration. Since ADRB2 is a cardiovascular target, high BBB penetration is not a priority.
9. **Caco-2:** Ligand A (-4.922) and Ligand B (-5.234) both have poor Caco-2 permeability.
10. **Solubility:** Ligand A (-0.614) has poor solubility. Ligand B (-1.218) has even worse solubility.
11. **hERG:** Both ligands (A: 0.102, B: 0.097) have very low hERG inhibition risk, which is excellent.
12. **Cl_mic:** Ligand A (-10.992) has a lower (better) microsomal clearance than Ligand B (-9.218).
13. **t1/2:** Ligand A (1.343) has a very short half-life. Ligand B (-7.021) has a very long half-life, a significant advantage.
14. **Pgp:** Both ligands (A: 0.01, B: 0.006) have very low P-gp efflux, which is good.
15. **Affinity:** Ligand B (-7.1 kcal/mol) has a significantly stronger binding affinity than Ligand A (-3.9 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME concerns.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand B excels in logP and significantly outperforms Ligand A in binding affinity. While TPSA is good for both, the affinity difference is substantial. The poor solubility and Caco-2 permeability are concerns for both, but can potentially be addressed through formulation strategies. The lower DILI risk and longer half-life of Ligand B are also beneficial.
**Conclusion:**
Despite the solubility and permeability issues shared by both compounds, Ligand B's superior binding affinity and favorable DILI/half-life profile make it the more promising candidate. The stronger binding is likely to translate to greater efficacy, and the improved ADME properties are valuable.
Output:
0
2025-04-17 19:15:53,564 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (366.389) is slightly higher than Ligand B (344.459), but both are acceptable.
2. **TPSA:** Both ligands have TPSA values below 140, suggesting good oral absorption potential. Ligand A (68.29) is slightly higher than Ligand B (66.4), but the difference is minor.
3. **logP:** Both ligands have logP values within the optimal range (1-3). Ligand A (3.318) is at the upper end, while Ligand B (2.347) is closer to the middle. This is a slight advantage for B, as higher logP can sometimes lead to off-target effects.
4. **HBD:** Ligand A has 1 HBD, while Ligand B has 0. Both are within the acceptable limit of 5.
5. **HBA:** Ligand A has 5 HBA, while Ligand B has 4. Both are below the limit of 10.
6. **QED:** Both ligands have good QED scores (A: 0.629, B: 0.794). Ligand B has a notably higher QED, indicating a more drug-like profile.
7. **DILI:** Ligand A has a DILI risk of 87.01%, which is high. Ligand B has a much lower DILI risk of 31.485%, which is excellent. This is a significant advantage for Ligand B.
8. **BBB:** Both ligands have good BBB penetration (A: 76.154%, B: 86.817%). Ligand B is slightly better, but both are acceptable for a peripherally acting GPCR like ADRB2.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, negative values are sometimes artifacts of the prediction method.
10. **Solubility:** Both ligands have negative solubility values, which is also unusual and suggests poor solubility. Again, this may be an artifact of the prediction method.
11. **hERG:** Both ligands have low hERG inhibition risk (A: 0.223, B: 0.371).
12. **Cl_mic:** Ligand A has a higher microsomal clearance (110.09) than Ligand B (39.044), indicating faster metabolism and potentially lower bioavailability. This favors Ligand B.
13. **t1/2:** Ligand B has a significantly longer in vitro half-life (-12.669 hours) than Ligand A (0.018 hours). This is a major advantage for Ligand B.
14. **Pgp:** Both ligands have low P-gp efflux liability (A: 0.251, B: 0.329).
15. **Binding Affinity:** Both ligands have very similar and strong binding affinities (A: -5.9 kcal/mol, B: -4.9 kcal/mol). The difference of 1 kcal/mol is not substantial enough to outweigh other factors.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Both ligands perform similarly on these metrics. However, metabolic stability (Cl_mic and t1/2) and safety (DILI) are also crucial. Ligand B is significantly better in both of these areas.
**Conclusion:**
Ligand B demonstrates a superior overall profile, particularly regarding DILI risk, metabolic stability (lower Cl_mic, longer t1/2), and QED. While both ligands have similar affinities, the improved ADMET properties of Ligand B make it the more promising drug candidate.
Output:
0
2025-04-17 19:15:53,565 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's analyze each ligand against the provided guidelines, keeping in mind ADRB2 is a GPCR, so logP, TPSA, Pgp, and affinity are key.
* **Molecular Weight:** Both ligands (361.423 and 352.435 Da) are within the ideal 200-500 Da range.
* **TPSA:** Ligand A (97.39) is slightly higher than Ligand B (87.9). Both are acceptable for oral absorption, but B is better.
* **logP:** Ligand A (2.001) is optimal. Ligand B (-0.191) is quite low, potentially hindering membrane permeability. This is a significant drawback.
* **H-Bond Donors:** Both have acceptable HBD counts (2 and 1, respectively).
* **H-Bond Acceptors:** Both have similar HBA counts (6).
* **QED:** Both have good QED scores (0.627 and 0.767), indicating drug-likeness.
* **DILI:** Ligand A (81.039) has a higher DILI risk than Ligand B (34.277). This is a concern for A.
* **BBB:** Ligand A (69.794) has better BBB penetration than Ligand B (50.523). While not a primary concern for peripheral GPCRs like ADRB2, it's a slight positive for A.
* **Caco-2:** Both have very poor Caco-2 permeability (-4.559 and -4.859). This is a significant issue for both.
* **Solubility:** Ligand B (0.081) has slightly better solubility than Ligand A (-3.592), but both are very poor.
* **hERG:** Both have very low hERG inhibition liability (0.223 and 0.186), which is excellent.
* **Cl_mic:** Ligand B (4.595) has significantly lower microsomal clearance than Ligand A (61.365), suggesting better metabolic stability. This is a major advantage for B.
* **t1/2:** Ligand B (5.688) has a slightly longer in vitro half-life than Ligand A (14.987).
* **Pgp:** Both have low P-gp efflux liability (0.16 and 0.068).
* **Binding Affinity:** Ligand B (-5.3 kcal/mol) has a slightly better binding affinity than Ligand A (-6.5 kcal/mol). While A is better, the difference is not substantial enough to overcome other issues.
**Overall Assessment:**
Ligand B is the more promising candidate despite its lower logP. The significantly lower DILI risk and much better metabolic stability (lower Cl_mic and longer t1/2) are crucial advantages. While the logP is a concern, it might be addressable through further medicinal chemistry optimization. The Caco-2 permeability is a problem for both, but can be addressed with formulation strategies. Ligand A's higher DILI risk is a more difficult issue to resolve. The slightly better affinity of A is not enough to overcome the other drawbacks.
Output:
0
2025-04-17 19:15:53,565 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (423.738 Da) is within the ideal range, while Ligand B (343.387 Da) is towards the lower end but still acceptable.
2. **TPSA:** Ligand A (41.57) is excellent, well below the 140 threshold. Ligand B (110.01) is higher, but still reasonable for a peripherally acting GPCR target.
3. **logP:** Ligand A (4.496) is slightly high, potentially leading to solubility issues or off-target interactions. Ligand B (2.388) is optimal.
4. **HBD:** Both ligands have acceptable HBD counts (1 and 2 respectively).
5. **HBA:** Both ligands have acceptable HBA counts (3 and 6 respectively).
6. **QED:** Both ligands have similar and good QED values (0.787 and 0.779).
7. **DILI:** Ligand B (72.47) has a higher DILI risk than Ligand A (57.038), but both are within a tolerable range.
8. **BBB:** Ligand A (81.621) has significantly better BBB penetration potential than Ligand B (52.811). While ADRB2 isn't exclusively a CNS target, some CNS exposure could be beneficial or at least needs to be considered.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.753) is slightly better than Ligand B (-5.086).
10. **Solubility:** Ligand A (-5.209) has worse solubility than Ligand B (-2.683). This is a concern given Ligand A's higher logP.
11. **hERG:** Ligand A (0.92) has a slightly higher hERG risk than Ligand B (0.131). This is a significant advantage for Ligand B.
12. **Cl_mic:** Ligand B (65.742) has lower microsomal clearance, suggesting better metabolic stability than Ligand A (81.452).
13. **t1/2:** Ligand B (-22.29) has a significantly longer in vitro half-life than Ligand A (51.433). This is a major advantage.
14. **Pgp:** Ligand A (0.758) has higher P-gp efflux liability than Ligand B (0.03). This is a significant advantage for Ligand B.
15. **Affinity:** Ligand B (-7.6 kcal/mol) has a substantially stronger binding affinity than Ligand A (-4.2 kcal/mol). This is a decisive factor.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand B excels in logP, Pgp, and significantly in affinity. While Ligand A has better BBB penetration, the substantial affinity advantage of Ligand B outweighs this. The better metabolic stability (lower Cl_mic and longer t1/2) and lower hERG risk of Ligand B are also significant benefits.
**Conclusion:**
Ligand B is the superior candidate due to its significantly stronger binding affinity, better ADME properties (lower Cl_mic, longer t1/2, lower Pgp efflux, lower hERG risk), and optimal logP. While Ligand A has slightly better BBB penetration, the other advantages of Ligand B are more critical for overall drug development success.
Output:
0
2025-04-17 19:15:53,565 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.475 and 343.471 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (67.23) is slightly higher than Ligand B (53.51). Both are below the 140 threshold for oral absorption, but Ligand B is preferable due to being closer to the <90 target for GPCRs.
3. **logP:** Ligand A (1.754) is within the optimal 1-3 range. Ligand B (3.116) is at the higher end of the optimal range.
4. **HBD:** Ligand A (1) is preferable to Ligand B (0). While both are acceptable, a single HBD can aid solubility.
5. **HBA:** Ligand A (4) is preferable to Ligand B (3). Both are within the acceptable range.
6. **QED:** Both ligands have similar QED values (0.818 and 0.789), indicating good drug-likeness.
7. **DILI:** Ligand A (13.61) has a significantly lower DILI risk than Ligand B (47.732). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (80.264) has a better BBB penetration score than Ligand B (71.384). This is important for GPCR targets.
9. **Caco-2:** Ligand A (-5.116) is worse than Ligand B (-4.591), indicating lower intestinal absorption.
10. **Solubility:** Ligand A (-1.4) is better than Ligand B (-2.319).
11. **hERG:** Ligand A (0.263) has a much lower hERG inhibition liability than Ligand B (0.581). This is a critical safety parameter.
12. **Cl_mic:** Ligand A (15.395) has a lower microsomal clearance than Ligand B (74.345), indicating better metabolic stability.
13. **t1/2:** Ligand A (-8.119) has a much longer in vitro half-life than Ligand B (-23.937). This is a significant advantage.
14. **Pgp:** Ligand A (0.083) has a lower P-gp efflux liability than Ligand B (0.325).
15. **Affinity:** Ligand A (-7.7) has a slightly better binding affinity than Ligand B (-5.6).
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical ADMET properties, especially DILI, hERG, Cl_mic, and t1/2. While Ligand B has a slightly better Caco-2 permeability, the superior safety profile and metabolic stability of Ligand A are far more important for a viable drug candidate. The slightly better binding affinity of Ligand A further solidifies its preference. Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand A is the better choice.
Output:
1
2025-04-17 19:15:53,565 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (374.75 and 358.43 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (69.04) is significantly better than Ligand B (84.22). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (2.971) is optimal, while Ligand B (0.802) is a bit low. A logP below 1 can sometimes hinder permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (0). While both are acceptable, having one HBD can aid solubility.
5. **HBA:** Ligand A (5) is better than Ligand B (7). Lower HBA is generally preferred for permeability.
6. **QED:** Both ligands have similar QED values (0.839 and 0.758), indicating good drug-likeness.
7. **DILI:** Ligand A (78.402) is slightly higher than Ligand B (72.043), but both are within an acceptable range (<80 is generally considered good).
8. **BBB:** Both ligands have similar BBB penetration (74.176 and 74.098). This isn't a critical factor for a cardiovascular target.
9. **Caco-2:** Ligand A (-4.675) is better than Ligand B (-5.16). Higher (less negative) Caco-2 values indicate better absorption.
10. **Solubility:** Ligand A (-4.082) is better than Ligand B (-2.353). Better solubility is always a plus.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.207 and 0.144), which is excellent.
12. **Cl_mic:** Ligand B (39.367) has a lower microsomal clearance than Ligand A (45.061), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-11.757) has a much longer in vitro half-life than Ligand A (-1.932). This is a significant advantage.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.107 and 0.2), which is good.
15. **Affinity:** Ligand B (-6.8 kcal/mol) has a slightly better binding affinity than Ligand A (-6.4 kcal/mol). While the difference is not huge, it's enough to consider.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A has a better logP and TPSA. Ligand B has a better affinity and metabolic stability (lower Cl_mic and longer t1/2). The affinity difference is small, but the longer half-life of Ligand B is a significant advantage, potentially allowing for less frequent dosing.
**Overall Assessment:**
While Ligand A has some advantages in terms of TPSA and solubility, the superior metabolic stability (longer half-life) and slightly better binding affinity of Ligand B outweigh these benefits. The slightly lower logP of Ligand B is not a major concern.
Output:
0
2025-04-17 19:15:53,565 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (369.49 & 384.52 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both are good (92.51 & 89.87), being under 140. This suggests reasonable oral absorption potential.
3. **logP:** Both ligands have acceptable logP values (1.12 & 0.93), falling within the 1-3 range.
4. **HBD:** Ligand A (1) is better than Ligand B (3). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (5) is better than Ligand B (6). Lower HBA generally improves permeability.
6. **QED:** Ligand A (0.704) is significantly better than Ligand B (0.551), indicating a more drug-like profile.
7. **DILI:** Ligand A (25.51) has a much lower DILI risk than Ligand B (39.51), which is a significant advantage.
8. **BBB:** Ligand A (60.88) is slightly better than Ligand B (57.74), although both are not high enough to be considered CNS-optimized. However, for a cardiovascular target, BBB penetration is less critical.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-5.23) is slightly better than Ligand B (-5.55).
10. **Solubility:** Ligand A (-0.95) is better than Ligand B (-2.54), indicating better aqueous solubility.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.16 & 0.47).
12. **Cl_mic:** Ligand A (26.20) has lower microsomal clearance than Ligand B (32.43), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-13.80) has a much more negative in vitro half-life than Ligand B (2.13), suggesting a shorter half-life. This is a drawback for Ligand A.
14. **Pgp:** Both have low P-gp efflux liability (0.055 & 0.075).
15. **Affinity:** Ligand B (-7.2 kcal/mol) has a slightly better binding affinity than Ligand A (-7.0 kcal/mol). While the difference is small, it's still a factor.
**GPCR-specific priorities:** For ADRB2 (a GPCR), we prioritize logP, Pgp, TPSA, and affinity. Both ligands perform well on logP and Pgp. TPSA is acceptable for both. Ligand B has a slightly better affinity. However, Ligand A has significantly better QED, DILI, solubility, and metabolic stability. The shorter half-life of Ligand A is a concern, but the other advantages outweigh this.
**Conclusion:** Considering the balance of properties, especially the lower DILI risk and better overall drug-likeness (QED, solubility, metabolic stability) of Ligand A, it is the more promising candidate despite the slightly weaker affinity and shorter half-life.
Output:
1
2025-04-17 19:15:53,565 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step Comparison:**
1. **MW:** Both ligands (358.435 and 371.459 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (85.38) is better than Ligand B (88.18). Both are below the 140 threshold for oral absorption, but closer to the 90 threshold for CNS targets (though ADRB2 isn't necessarily a CNS target, lower TPSA is generally favorable).
3. **logP:** Both ligands have good logP values (1.075 and 0.749), falling within the optimal 1-3 range. Ligand A is slightly higher, which could be marginally better for permeability.
4. **HBD:** Ligand A has 0 HBD, while Ligand B has 1. Lower is generally preferred for permeability, so Ligand A is slightly better.
5. **HBA:** Ligand A has 7 HBA, while Ligand B has 5. Both are under the 10 threshold.
6. **QED:** Both ligands have similar QED values (0.657 and 0.681), indicating good drug-likeness.
7. **DILI:** Ligand A (41.024) has a lower DILI risk than Ligand B (47.654), both are acceptable.
8. **BBB:** Ligand A (79.992) has a better BBB penetration percentile than Ligand B (70.027). While ADRB2 isn't exclusively a CNS target, higher BBB is still a plus.
9. **Caco-2:** Ligand A (-3.951) has a worse Caco-2 permeability than Ligand B (-4.552). Lower values indicate poorer permeability. Ligand B is better.
10. **Solubility:** Both ligands have very poor aqueous solubility (-1.811 and -1.868). This is a significant concern for both.
11. **hERG:** Ligand A (0.319) has a lower hERG inhibition liability than Ligand B (0.526), which is a critical advantage for cardiovascular targets.
12. **Cl_mic:** Ligand A (84.934) has a higher microsomal clearance than Ligand B (28.24). This means Ligand B is more metabolically stable.
13. **t1/2:** Ligand A (-32.778) has a much shorter in vitro half-life than Ligand B (-60.24). This is a significant drawback for Ligand A.
14. **Pgp:** Ligand A (0.117) has lower P-gp efflux liability than Ligand B (0.048). Lower Pgp is better.
15. **Binding Affinity:** Ligand A (-7.5) has a slightly better binding affinity than Ligand B (-6.9). This 0.6 kcal/mol difference is substantial enough to consider.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A has a slightly better logP, TPSA, and Pgp profile, and a significantly better binding affinity. However, Ligand B has better Caco-2 permeability and a much better metabolic stability profile (lower Cl_mic and longer t1/2). The hERG risk is also lower for Ligand A, which is crucial for a cardiovascular target.
**Overall Assessment:**
The biggest concerns are the poor solubility of both compounds. However, the slightly better binding affinity, lower hERG risk, and slightly better BBB penetration of Ligand A, combined with its lower DILI risk, outweigh the metabolic stability advantage of Ligand B. The affinity difference is significant enough to overcome the metabolic concerns, especially considering optimization could address the half-life issue.
Output:
1
2025-04-17 19:15:53,565 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (362.821 and 380.945 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (97.98) is higher than Ligand B (59.81). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B is better.
3. **logP:** Ligand A (1.398) is within the optimal range (1-3). Ligand B (3.669) is at the higher end, potentially increasing off-target effects and decreasing solubility. Ligand A is better.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable, below the threshold of 5. No significant difference.
5. **HBA:** Ligand A (4) and Ligand B (5) are both acceptable, below the threshold of 10. No significant difference.
6. **QED:** Ligand A (0.862) has a significantly better QED score than Ligand B (0.674), indicating a more drug-like profile. Ligand A is better.
7. **DILI:** Ligand A (66.072) has a higher DILI risk than Ligand B (48.313). Ligand B is better.
8. **BBB:** Both are low, which is fine for a cardiovascular target. Ligand B (51.066) is slightly better than Ligand A (31.291), but this isn't a major factor here.
9. **Caco-2:** Both are negative, indicating poor permeability. This is a concern for both, but the scale is not specified, so it's difficult to interpret the magnitude of the negative values.
10. **Solubility:** Both are negative, indicating poor solubility. Similar to Caco-2, the scale is not specified.
11. **hERG:** Both ligands have low hERG inhibition risk (0.226 and 0.39, respectively). No significant difference.
12. **Cl_mic:** Ligand A (9.66) has a much lower microsomal clearance than Ligand B (82.748), suggesting better metabolic stability. Ligand A is significantly better.
13. **t1/2:** Ligand B (51.454) has a much longer in vitro half-life than Ligand A (-1.997). This is a significant advantage for Ligand B.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.069 and 0.406, respectively). No significant difference.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.9 and -6.8 kcal/mol). The difference is negligible.
**Overall Assessment:**
For a cardiovascular GPCR like ADRB2, the key priorities are potency (affinity), metabolic stability, and a reasonable balance of physicochemical properties. While Ligand B has a better half-life and lower DILI risk, Ligand A has a significantly better QED score, lower microsomal clearance (better metabolic stability), and a slightly better logP. The difference in binding affinity is minimal. The poor Caco-2 and solubility for both are concerning, but can be addressed with formulation strategies. The improved drug-likeness and metabolic stability of Ligand A outweigh the slight advantages of Ligand B.
Output:
1
2025-04-17 19:15:53,565 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Step-by-step comparison:**
1. **MW:** Both ligands (351.407 and 353.398 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (114.47) is slightly higher than Ligand B (98.4). Both are below the 140 threshold for good oral absorption, but Ligand B is closer to the preferred <90 for GPCRs.
3. **logP:** Ligand A (1.483) is within the optimal 1-3 range. Ligand B (0.121) is quite low, potentially hindering membrane permeability. This is a significant drawback for a GPCR ligand.
4. **HBD:** Ligand A (3) and Ligand B (2) are both acceptable, below the 5 limit.
5. **HBA:** Ligand A (7) and Ligand B (4) are both acceptable, below the 10 limit.
6. **QED:** Ligand B (0.727) has a better QED score than Ligand A (0.544), indicating a more drug-like profile.
7. **DILI:** Ligand B (43.66) has a significantly lower DILI risk than Ligand A (78.054). This is a substantial advantage for Ligand B.
8. **BBB:** Ligand A (66.188) has a better BBB penetration score than Ligand B (47.499). While ADRB2 isn't exclusively a CNS target, some CNS exposure could be relevant depending on the specific therapeutic application.
9. **Caco-2:** Ligand A (-4.833) and Ligand B (-5.036) are both very poor. This suggests poor intestinal absorption for both.
10. **Solubility:** Ligand A (-3.119) is slightly better than Ligand B (-1.962), but both are quite poor.
11. **hERG:** Both ligands have low hERG inhibition risk (0.108 and 0.246 respectively).
12. **Cl_mic:** Ligand B (12.699) has a much lower microsomal clearance than Ligand A (42.129), indicating better metabolic stability. This is a major advantage.
13. **t1/2:** Ligand B (-28.801) has a significantly longer in vitro half-life than Ligand A (16.728). This is a substantial advantage.
14. **Pgp:** Both ligands show low P-gp efflux liability (0.018 and 0.02 respectively).
15. **Binding Affinity:** Ligand A (-7.1) has a stronger binding affinity than Ligand B (-5.5). This is a 1.6 kcal/mol difference, which is significant and can outweigh some ADME drawbacks.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has a better logP and significantly better affinity. Ligand B has better TPSA, DILI, Cl_mic, and t1/2. The low logP of Ligand B is a major concern, as it will likely limit its ability to cross cell membranes and reach the receptor. The substantial affinity advantage of Ligand A, combined with acceptable (though not ideal) ADME properties, outweighs the benefits of Ligand B's improved metabolic stability and reduced toxicity.
**Conclusion:**
Despite the better QED, DILI, and metabolic stability of Ligand B, the significantly stronger binding affinity and more favorable logP of Ligand A make it the more promising drug candidate for ADRB2.
Output:
1
2025-04-17 19:15:53,565 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (342.399 and 361.515 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (88.33) is slightly higher than Ligand B (66.81). Both are below the 140 A^2 threshold for good oral absorption, but Ligand B is preferable due to being closer to the 90 A^2 target for GPCRs.
3. **logP:** Both ligands (2.111 and 2.556) are within the optimal 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Both ligands have 1 HBD, which is within the acceptable limit of <=5.
5. **HBA:** Both ligands have 5 HBA, which is within the acceptable limit of <=10.
6. **QED:** Both ligands have similar QED values (0.779 and 0.745), indicating good drug-likeness.
7. **DILI:** Ligand A (51.609) has a significantly higher DILI risk than Ligand B (15.743). This is a major concern, as lower DILI is highly desirable.
8. **BBB:** Ligand A (73.866) has a better BBB penetration percentile than Ligand B (54.556). While ADRB2 isn't exclusively a CNS target, some CNS exposure may be acceptable or even desirable depending on the specific therapeutic goal.
9. **Caco-2:** Ligand A (-4.831) and Ligand B (-5.601) both have negative Caco-2 permeability values, which is unusual and indicates poor permeability. Ligand B is slightly worse.
10. **Solubility:** Ligand A (-2.735) has slightly better solubility than Ligand B (-1.834), but both are poor.
11. **hERG:** Ligand A (0.28) has a lower hERG inhibition liability than Ligand B (0.479), which is preferable.
12. **Cl_mic:** Ligand B (38.858) has a lower microsomal clearance than Ligand A (52.845), indicating better metabolic stability.
13. **t1/2:** Ligand B (-11.799) has a significantly longer in vitro half-life than Ligand A (18.189). This is a major advantage.
14. **Pgp:** Ligand A (0.114) has lower P-gp efflux liability than Ligand B (0.056), which is preferable.
15. **Binding Affinity:** Ligand B (-5.2) has a slightly better binding affinity than Ligand A (-8.0). This is a significant advantage, as a 1.5 kcal/mol difference can outweigh minor ADME drawbacks.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B is better in terms of TPSA, Cl_mic, t1/2, and affinity. The lower DILI risk for Ligand B is also a crucial factor. While Ligand A has slightly better BBB penetration and Pgp efflux, the significantly lower DILI risk and improved metabolic stability of Ligand B outweigh these benefits.
**Output:**
0
2025-04-17 19:15:53,565 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (339.395) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (81.01) is significantly better than Ligand B (93.53). ADRB2 is a cardiovascular target, not CNS, but lower TPSA is still desirable for absorption.
3. **logP:** Ligand A (3.607) is optimal, while Ligand B (-0.271) is quite low. This is a major concern for Ligand B, as it may struggle with membrane permeability.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A (5) is better than Ligand B (7).
6. **QED:** Both are similar and acceptable (A: 0.768, B: 0.712).
7. **DILI:** Ligand A (78.17) is higher than Ligand B (60.644), but both are within an acceptable range.
8. **BBB:** Not a primary concern for a cardiovascular target, but Ligand B (50.407) is higher than Ligand A (30.71).
9. **Caco-2:** Ligand A (-4.741) is better than Ligand B (-5.359).
10. **Solubility:** Ligand A (-5.556) is better than Ligand B (-1.064).
11. **hERG:** Ligand A (0.656) is better than Ligand B (0.04).
12. **Cl_mic:** Ligand B (23.227) has lower clearance, suggesting better metabolic stability, which is good. Ligand A (37.905) is higher.
13. **t1/2:** Ligand B (-27.652) has a longer half-life, which is favorable. Ligand A (-20.265) is shorter.
14. **Pgp:** Ligand A (0.441) is better than Ligand B (0.011). Lower P-gp efflux is preferred.
15. **Affinity:** Ligand B (-5.2 kcal/mol) has significantly better binding affinity than Ligand A (-1.9 kcal/mol). This is a substantial advantage.
**Overall Assessment:**
The biggest advantage of Ligand B is its significantly stronger binding affinity. However, its very low logP is a major drawback, potentially leading to poor absorption and bioavailability. Ligand A has a much more balanced profile, with good logP, TPSA, solubility, and Pgp efflux properties. While its affinity is weaker, the ADME properties are more favorable. Considering the importance of good ADME properties for *in vivo* efficacy, and the fact that a 3.3 kcal/mol difference in binding can be overcome with optimization, I believe Ligand A is the more promising starting point.
Output:
1
2025-04-17 19:15:53,566 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [350.409, 32.78, 2.392, 0, 3, 0.839, 8.763, 91.508, -4.264, -1.602, 0.675, 12.539, -4.906, 0.049, -6.2]
**Ligand B:** [357.483, 64.34, 3.876, 1, 7, 0.751, 84.335, 69.252, -4.928, -3.806, 0.759, 48.176, 20.024, 0.701, -7.4]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity, and BBB):
1. **MW:** Both are within the ideal range (200-500 Da). A is slightly lower, which is generally favorable.
2. **TPSA:** Ligand A (32.78) is excellent, well below the 140 threshold and suggesting good oral absorption. Ligand B (64.34) is higher, but still acceptable.
3. **logP:** Both are good (between 1-3), but Ligand A (2.392) is closer to the optimal range than Ligand B (3.876). Higher logP can sometimes lead to off-target effects.
4. **HBD/HBA:** Ligand A (0 HBD, 3 HBA) is better than Ligand B (1 HBD, 7 HBA). Fewer H-bonds generally improve permeability.
5. **QED:** Ligand A (0.839) is better than Ligand B (0.751), indicating a more drug-like profile.
6. **DILI:** Both are reasonably low, but Ligand A (8.763) is significantly better than Ligand B (84.335), indicating a lower risk of liver injury.
7. **BBB:** Ligand A (91.508) has excellent BBB penetration, which is a plus for a GPCR, even a cardiovascular one, as it suggests potential for off-target effects in the CNS might be manageable. Ligand B (69.252) is lower.
8. **Caco-2:** Both are negative, indicating poor permeability. This is a concern for both.
9. **Solubility:** Both are negative, indicating poor solubility. This is a concern for both.
10. **hERG:** Both are low, indicating low cardiotoxicity risk.
11. **Cl_mic:** Ligand A (12.539) has a lower clearance, suggesting better metabolic stability than Ligand B (48.176).
12. **t1/2:** Ligand A (-4.906) has a longer half-life than Ligand B (20.024).
13. **Pgp:** Both are very low, suggesting minimal P-gp efflux.
14. **Affinity:** Ligand B (-7.4) has a significantly stronger binding affinity than Ligand A (-6.2) - a difference of 1.2 kcal/mol. This is a substantial advantage.
**Overall Assessment:**
Ligand B's significantly stronger binding affinity (-7.4 kcal/mol vs -6.2 kcal/mol) is a major advantage. While Ligand A has better ADME properties (lower DILI, better BBB, better metabolic stability, better QED), the difference in affinity is substantial enough to outweigh these concerns, especially considering the cardiovascular target. The poor Caco-2 and solubility for both ligands are concerning and would need to be addressed in further optimization, but the potency advantage of B is compelling.
Output:
0
2025-04-17 19:15:53,566 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (381.738) is slightly higher than Ligand B (348.403), but both are acceptable.
2. **TPSA:** Both are reasonably good, below the 140 A^2 threshold for oral absorption. Ligand A (109.7) is slightly higher than Ligand B (104.65), but still acceptable for a non-CNS target.
3. **logP:** Ligand A (2.474) is optimal, while Ligand B (-0.098) is quite low, potentially leading to poor membrane permeability. This is a significant drawback for Ligand B.
4. **HBD:** Both have 2 H-bond donors, which is within the acceptable limit of 5.
5. **HBA:** Ligand A has 5 H-bond acceptors, and Ligand B has 6. Both are within the acceptable limit of 10.
6. **QED:** Both ligands have good QED scores (A: 0.615, B: 0.744), indicating generally drug-like properties. Ligand B is slightly better here.
7. **DILI:** Ligand A (50.989) has a higher DILI risk than Ligand B (37.922), but both are below the concerning threshold of 60.
8. **BBB:** This is less critical for ADRB2 (a cardiovascular target), but Ligand A (81.582) has better BBB penetration than Ligand B (64.056).
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
10. **Solubility:** Both have negative solubility values, which is also unusual and suggests poor solubility. Again, the scale is not specified.
11. **hERG:** Both have low hERG inhibition liability (A: 0.679, B: 0.181), which is good. Ligand B is better here.
12. **Cl_mic:** Ligand B (-3.086) has a *negative* microsomal clearance, which is highly unusual and suggests very high metabolic stability. Ligand A (7.606) is more typical.
13. **t1/2:** Ligand B (8.057) has a longer in vitro half-life than Ligand A (4.461), which is desirable.
14. **Pgp:** Ligand A (0.464) has lower P-gp efflux liability than Ligand B (0.006), which is preferable for oral bioavailability.
15. **Binding Affinity:** Ligand B (-6.6 kcal/mol) has a slightly better binding affinity than Ligand A (-5.7 kcal/mol). This is a 0.9 kcal/mol difference, which is significant but not overwhelming.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, and affinity are key. Ligand A has a much better logP value, which is crucial for membrane permeability and receptor engagement. While Ligand B has a slightly better affinity and half-life, the very low logP is a major concern. The negative clearance for Ligand B is also highly suspect and warrants further investigation.
**Conclusion:**
Despite the slightly better affinity and half-life of Ligand B, the significantly better logP of Ligand A, combined with acceptable DILI and Pgp values, makes it the more promising drug candidate. The unusual negative clearance for Ligand B raises red flags.
Output:
1
2025-04-17 19:15:53,566 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (401.264 Da) is slightly higher than Ligand B (385.335 Da), but both are acceptable.
**2. TPSA:** Ligand B (53.43) is significantly better than Ligand A (79.9). Lower TPSA generally favors better cell permeability, which is crucial for GPCR ligands.
**3. logP:** Both ligands have good logP values (Ligand A: 4.015, Ligand B: 3.501), falling within the optimal 1-3 range. Ligand B is slightly preferred.
**4. H-Bond Donors:** Ligand A (2) and Ligand B (1) are both within the acceptable limit of 5. Ligand B is slightly better.
**5. H-Bond Acceptors:** Ligand A (4) and Ligand B (3) are both within the acceptable limit of 10. Ligand B is slightly better.
**6. QED:** Both ligands have similar and acceptable QED values (Ligand A: 0.677, Ligand B: 0.697).
**7. DILI:** Ligand B (11.283) has a *much* lower DILI risk than Ligand A (84.994). This is a significant advantage for Ligand B.
**8. BBB:** Ligand B (79.062) has a better BBB penetration score than Ligand A (50.872). While ADRB2 isn't exclusively a CNS target, some peripheral ADRB2 activity can be modulated by CNS effects, and better BBB penetration isn't detrimental.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual. However, the magnitude is similar (-5.318 for A, -4.805 for B), so this isn't a major differentiator.
**10. Aqueous Solubility:** Both ligands have negative solubility values, which is also unusual. Again, the values are similar (-4.889 for A, -3.495 for B), so this isn't a major differentiator.
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (Ligand A: 0.796, Ligand B: 0.61). Both are acceptable.
**12. Microsomal Clearance:** Ligand B (44.853) has lower microsomal clearance than Ligand A (61.599), indicating better metabolic stability.
**13. In vitro Half-Life:** Ligand B (46.898) has a significantly longer in vitro half-life than Ligand A (23.02). This is a major advantage for Ligand B, potentially allowing for less frequent dosing.
**14. P-gp Efflux:** Both ligands have similar low P-gp efflux liability (Ligand A: 0.427, Ligand B: 0.49).
**15. Binding Affinity:** Both ligands have very similar and strong binding affinities (Ligand A: -5.7 kcal/mol, Ligand B: -5.8 kcal/mol). The difference is negligible.
**Overall Assessment:**
Ligand B consistently outperforms Ligand A in several critical ADME properties (DILI, BBB, microsomal clearance, half-life) and has a slightly better TPSA and logP. While the binding affinities are nearly identical, the superior ADME profile of Ligand B makes it the more promising drug candidate for the ADRB2 target.
Output:
0
2025-04-17 19:15:53,566 - INFO - Batch 97 complete. Total preferences: 1552
2025-04-17 19:15:53,566 - INFO - Processing batch 98/512...
2025-04-17 19:16:42,840 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.375 and 347.415 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (92.84) is slightly higher than Ligand B (89.95). Both are below the 140 threshold for good oral absorption, but closer to the 90 threshold for CNS targets (though ADRB2 isn't strictly a CNS target, lower TPSA is generally favorable for GPCRs). Ligand B is slightly preferred.
3. **logP:** Ligand A (1.986) is within the optimal 1-3 range. Ligand B (-0.94) is below 1, which could indicate potential permeability issues. This is a significant advantage for Ligand A.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (6) is preferable to Ligand B (4). Lower HBA generally improves permeability.
6. **QED:** Ligand A (0.916) has a much better QED score than Ligand B (0.607), indicating a more drug-like profile.
7. **DILI:** Ligand B (11.09) has a significantly lower DILI risk than Ligand A (80.962). This is a major advantage for Ligand B.
8. **BBB:** Ligand A (74.719) has a better BBB penetration percentile than Ligand B (44.32). While ADRB2 isn't a primary CNS target, some degree of BBB penetration can be useful for understanding off-target effects.
9. **Caco-2:** Ligand A (-4.638) is better than Ligand B (-5.117). Higher Caco-2 permeability is better.
10. **Solubility:** Ligand A (-2.727) is better than Ligand B (-1.355). Higher solubility is better.
11. **hERG:** Ligand A (0.323) has a lower hERG inhibition liability than Ligand B (0.092). This is a significant advantage for Ligand A, reducing cardiotoxicity risk.
12. **Cl_mic:** Ligand B (-29.134) has a much lower microsomal clearance than Ligand A (23.806), indicating greater metabolic stability. This is a major advantage for Ligand B.
13. **t1/2:** Ligand A (18.058) has a longer in vitro half-life than Ligand B (0.295). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.055) has lower P-gp efflux than Ligand B (0.003). Lower Pgp efflux is better.
15. **Binding Affinity:** Ligand A (-7.2) has a slightly better binding affinity than Ligand B (-6.2). While both are good, the 1 kcal/mol difference is notable.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A excels in logP, affinity, and Pgp. Ligand B has a better TPSA and significantly better DILI and Cl_mic.
**Overall Assessment:**
Ligand A has a superior drug-like profile (QED), better binding affinity, and better permeability characteristics (logP, Caco-2, solubility). However, Ligand B has a much lower DILI risk and significantly better metabolic stability (lower Cl_mic). The binding affinity difference is not large enough to completely outweigh the ADME advantages of Ligand B. The lower DILI risk is particularly important for a cardiovascular target.
Output:
0
2025-04-17 19:16:42,840 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (349.439) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are reasonably good, but Ligand B (100.19) is better than Ligand A (115.9), falling comfortably under the 140 threshold for oral absorption.
3. **logP:** Ligand B (0.779) is better than Ligand A (-0.374). A logP between 1-3 is optimal, and Ligand B is within this range, while A is slightly negative, potentially hindering permeation.
4. **HBD:** Both have 3 HBD, which is acceptable.
5. **HBA:** Ligand B (5) is slightly better than Ligand A (6). Lower HBA generally improves permeability.
6. **QED:** Both ligands have good QED scores (A: 0.531, B: 0.564), indicating good drug-like properties.
7. **DILI:** Both have acceptable DILI risk (A: 34.587, B: 43.234), both under the 40 threshold.
8. **BBB:** Both have relatively low BBB penetration (A: 45.522, B: 41.334). Since ADRB2 is a cardiovascular target, BBB penetration is not a primary concern.
9. **Caco-2:** Both have negative Caco-2 values (-5.788 and -5.852), which is unusual and could indicate poor permeability. This is a concern for both.
10. **Solubility:** Both have negative solubility values (-1.423 and -0.724), which is also concerning. Poor solubility can hinder bioavailability.
11. **hERG:** Both have very low hERG inhibition risk (A: 0.033, B: 0.113), which is excellent.
12. **Cl_mic:** Ligand A (-4.906) has a more negative value, suggesting lower clearance and better metabolic stability than Ligand B (3.245).
13. **t1/2:** Ligand B (19.582) has a significantly longer half-life than Ligand A (3.133), which is a major advantage.
14. **Pgp:** Both have very low Pgp efflux liability (A: 0.007, B: 0.075).
15. **Binding Affinity:** Ligand B (-7.1) has a significantly stronger binding affinity than Ligand A (-5.8). This is a substantial advantage, potentially outweighing some of the ADME drawbacks.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand B excels in logP and significantly in affinity. While both have issues with Caco-2 and solubility, the stronger binding of Ligand B is a critical factor. The longer half-life of Ligand B is also a significant benefit.
**Conclusion:**
Despite the shared issues with Caco-2 and solubility, Ligand B's superior binding affinity, better logP, and longer half-life make it the more promising candidate. The difference in binding affinity (-7.1 vs -5.8) is substantial and likely to be decisive.
Output:
0
2025-04-17 19:16:42,840 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for the ADRB2, a cardiovascular GPCR. Therefore, prioritizing logP, TPSA, Pgp efflux, and binding affinity is crucial. Metabolic stability (Cl_mic, t1/2) and safety (DILI, hERG) are also important.
Let's compare the ligands property by property:
1. **MW:** Both ligands (364.5 and 360.4) are within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (69.6) is slightly higher than Ligand B (58.6). Both are below the 140 threshold for oral absorption, but B is better.
3. **logP:** Both ligands (2.349 and 2.446) are within the optimal 1-3 range. Very similar.
4. **HBD:** Ligand A has 2 HBDs, and Ligand B has 1. Lower is generally preferred for permeability, giving a slight edge to B.
5. **HBA:** Ligand A has 4 HBAs, and Ligand B has 3. Again, B is slightly better.
6. **QED:** Ligand A (0.862) has a slightly better QED score than Ligand B (0.792), suggesting a more drug-like profile.
7. **DILI:** Ligand A (39.0) has a slightly higher DILI risk than Ligand B (35.8), but both are well below the concerning threshold of 60.
8. **BBB:** Ligand B (90.1) shows significantly better BBB penetration potential than Ligand A (48.4). While ADRB2 is cardiovascular, some CNS off-target effects are possible, and lower BBB penetration is generally preferred for peripheral targets.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
10. **Solubility:** Both have negative solubility values, also unusual. Again, the scale is unknown.
11. **hERG:** Ligand A (0.458) has a lower hERG risk than Ligand B (0.608), which is a significant advantage.
12. **Cl_mic:** Ligand A (17.3) has a much lower microsomal clearance than Ligand B (37.3), indicating better metabolic stability.
13. **t1/2:** Ligand A (31.1) has a significantly longer in vitro half-life than Ligand B (-23.0). The negative value for B is concerning and likely an error.
14. **Pgp:** Ligand A (0.207) has a lower Pgp efflux liability than Ligand B (0.108), suggesting better oral bioavailability and potentially better tissue distribution.
15. **Affinity:** Ligand B (-5.3) has a stronger binding affinity than Ligand A (-4.2) by 1.1 kcal/mol. This is a substantial difference and a major factor.
**Overall Assessment:**
While Ligand A has better QED, lower DILI, better metabolic stability, longer half-life, and lower Pgp efflux, the significantly stronger binding affinity of Ligand B (-5.3 vs -4.2 kcal/mol) is the most critical factor for a GPCR target. The improved BBB penetration of Ligand B is less desirable for a cardiovascular target, but the affinity difference outweighs this concern. The negative values for Caco-2 and solubility are concerning for both, but the affinity difference is the deciding factor.
Output:
0
2025-04-17 19:16:42,840 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.435 and 352.431 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (104.7) is higher than Ligand B (77.1). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is generally preferred for absorption. Ligand B is better here.
3. **logP:** Ligand A (0.888) is slightly higher than Ligand B (0.493), both are a bit low, but still acceptable. A logP between 1-3 is optimal. Ligand A is slightly favored.
4. **HBD:** Ligand A (3) is higher than Ligand B (1). Lower is generally better for permeability, so Ligand B is favored.
5. **HBA:** Both ligands have 5 HBA, which is within the acceptable range. No significant difference.
6. **QED:** Ligand B (0.746) has a slightly better QED score than Ligand A (0.594), indicating a more drug-like profile. Ligand B is favored.
7. **DILI:** Ligand A (38.193) has a lower DILI risk than Ligand B (43.66). Lower is better, so Ligand A is favored.
8. **BBB:** Ligand B (63.94) has a higher BBB penetration percentile than Ligand A (32.493). While ADRB2 isn't a primary CNS target, some brain exposure can be relevant for off-target effects. Ligand B is favored.
9. **Caco-2:** Ligand A (-5.775) has a worse Caco-2 permeability than Ligand B (-4.719). Higher is better, so Ligand B is favored.
10. **Solubility:** Both ligands have very poor solubility (-1.583 and -1.612). This is a significant concern for both, but similar for both.
11. **hERG:** Ligand A (0.547) has a slightly higher hERG inhibition liability than Ligand B (0.162). Lower is better, so Ligand B is favored.
12. **Cl_mic:** Ligand B (12.795) has a lower microsomal clearance than Ligand A (15.189), suggesting better metabolic stability. Ligand B is favored.
13. **t1/2:** Ligand B (-7.33) has a negative in vitro half-life, which is concerning. Ligand A (2.131) has a positive, albeit short, half-life. Ligand A is favored.
14. **Pgp:** Ligand A (0.01) has a much lower P-gp efflux liability than Ligand B (0.031). Lower is better, so Ligand A is favored.
15. **Binding Affinity:** Ligand B (-8.7 kcal/mol) has a significantly stronger binding affinity than Ligand A (-7.1 kcal/mol). This is a substantial advantage (1.6 kcal/mol difference) that can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand B has a significantly better binding affinity, better Caco-2 permeability, lower hERG risk, and better metabolic stability. While its solubility is poor, it is similar to Ligand A. Ligand A has a better DILI score and Pgp efflux, but the affinity difference is substantial. For a GPCR, binding affinity is paramount, and the other advantages of Ligand B outweigh its drawbacks.
Output:
0
2025-04-17 19:16:42,840 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (347.459 Da and 350.507 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (71.0) is higher than Ligand B (47.1). For a cardiovascular GPCR, TPSA is moderately important, and lower is generally better for permeability. Ligand B has a clear advantage.
**3. logP:** Ligand A (1.941) is within the optimal 1-3 range. Ligand B (0.872) is slightly below this, potentially indicating some permeability issues, but not drastically so. Ligand A is preferable here.
**4. H-Bond Donors:** Ligand A (1) is good. Ligand B (0) is also good, potentially improving membrane permeability. No strong preference.
**5. H-Bond Acceptors:** Both ligands have 4 H-bond acceptors, which is acceptable.
**6. QED:** Ligand A (0.826) is slightly better than Ligand B (0.713), indicating a more drug-like profile.
**7. DILI:** Ligand B (5.584) has a significantly lower DILI risk than Ligand A (33.773). This is a crucial advantage, as liver toxicity is a major concern in drug development.
**8. BBB:** Both ligands have similar BBB penetration (Ligand A: 63.784, Ligand B: 61.535). Since ADRB2 is a cardiovascular target, BBB penetration isn't a primary concern, but it's good they aren't exceptionally low.
**9. Caco-2 Permeability:** Both have negative values, indicating low permeability. Ligand A (-4.723) is slightly worse than Ligand B (-4.808), but the difference is minimal.
**10. Aqueous Solubility:** Ligand A (-3.166) is slightly better than Ligand B (-0.13). Solubility is important for formulation, but not a major differentiating factor here.
**11. hERG Inhibition:** Ligand A (0.188) has a slightly lower hERG risk than Ligand B (0.421), which is favorable.
**12. Microsomal Clearance:** Ligand B (-5.448) has a significantly *lower* (better) microsomal clearance than Ligand A (19.494). This suggests greater metabolic stability for Ligand B.
**13. In vitro Half-Life:** Ligand B (3.028) has a longer half-life than Ligand A (0.126). This is a significant advantage, potentially allowing for less frequent dosing.
**14. P-gp Efflux:** Ligand A (0.158) has lower P-gp efflux than Ligand B (0.017), which is preferable.
**15. Binding Affinity:** Ligand B (-7.1 kcal/mol) has a slightly better binding affinity than Ligand A (-6.8 kcal/mol). While the difference is not huge, it's enough to be considered.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity) and general drug-like properties, Ligand B emerges as the stronger candidate. The significantly lower DILI risk and improved metabolic stability (lower Cl_mic, longer t1/2) are major advantages. The slightly better affinity of Ligand B further supports this choice. While Ligand A has a slightly better logP and P-gp efflux, the safety and pharmacokinetic benefits of Ligand B outweigh these minor differences.
Output:
0
2025-04-17 19:16:42,840 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
We are targeting ADRB2, a GPCR. Therefore, key properties to prioritize are binding affinity, logP, TPSA, Pgp efflux, and BBB penetration.
Let's compare the ligands property by property:
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (342.483 Da) is slightly lower than Ligand B (390.571 Da), which is generally favorable for permeability.
2. **TPSA:** Ligand A (49.41) is significantly better than Ligand B (92.34). A TPSA under 140 is good for oral absorption, but lower is better for GPCRs, and Ligand A is much closer to the ideal range for CNS penetration as well.
3. **logP:** Ligand A (3.173) is within the optimal range (1-3), while Ligand B (1.356) is at the lower end. While not terrible, lower logP can sometimes indicate poor membrane permeability.
4. **HBD/HBA:** Ligand A has 1 HBD and 2 HBA, while Ligand B has 2 HBD and 5 HBA. Both are acceptable, but Ligand A is slightly more favorable.
5. **QED:** Ligand A (0.798) has a better QED score than Ligand B (0.587), indicating better overall drug-likeness.
6. **DILI:** Ligand B (35.014) has a significantly lower DILI risk than Ligand A (19.465), which is a major advantage.
7. **BBB:** Ligand A (73.943) shows better BBB penetration than Ligand B (65.413). While neither is exceptionally high, the difference is noticeable and important for a GPCR.
8. **Caco-2:** Ligand A (-4.945) shows better Caco-2 permeability than Ligand B (-5.619).
9. **Solubility:** Ligand A (-4.47) shows better solubility than Ligand B (-2.651).
10. **hERG:** Both ligands have very low hERG risk (0.293 and 0.205 respectively).
11. **Cl_mic:** Both have similar microsomal clearance (47.904 and 48.817 respectively).
12. **t1/2:** Ligand B (21.005) has a longer in vitro half-life than Ligand A (12.177), which is a positive.
13. **Pgp:** Ligand A (0.18) has lower Pgp efflux than Ligand B (0.094), which is favorable for bioavailability.
14. **Binding Affinity:** Ligand B (-7.0 kcal/mol) has a significantly stronger binding affinity than Ligand A (-1.2 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME drawbacks.
**Overall Assessment:**
The biggest difference is the binding affinity. Ligand B binds almost 6 kcal/mol stronger. This is a huge advantage. While Ligand A has better TPSA, solubility, and BBB, the potency of Ligand B is significantly higher. The DILI score is also better for Ligand B. The longer half-life of Ligand B is also a plus. Considering these factors, the superior binding affinity of Ligand B makes it the more promising candidate, despite some slightly less ideal ADME properties.
**Output:**
0
2025-04-17 19:16:42,841 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [377.794, 61.44, 3.712, 2, 2, 0.825, 53.432, 83.715, -4.731, -4.495, 0.487, 12.475, -22.427, 0.076, -5.8]
**Ligand B:** [355.454, 61.88, 1.67, 1, 4, 0.531, 28.189, 86.545, -4.94, -1.892, 0.485, 4.931, -2.922, 0.078, -6.7]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (355.454) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are around 61-62, which is acceptable, though ideally below 90 for GPCRs. No significant difference.
3. **logP:** Ligand A (3.712) is better than Ligand B (1.67). A logP between 1-3 is optimal, and Ligand A is closer to the upper end of that range, suggesting better membrane permeability. Ligand B is a bit low, potentially hindering permeation.
4. **HBD:** Ligand A (2) is slightly better than Ligand B (1). Both are within the acceptable limit of 5.
5. **HBA:** Ligand A (2) is better than Ligand B (4). Both are within the acceptable limit of 10.
6. **QED:** Ligand A (0.825) is significantly better than Ligand B (0.531), indicating a more drug-like profile.
7. **DILI:** Ligand B (28.189) is *much* better than Ligand A (53.432). Lower DILI is crucial. This is a significant advantage for Ligand B.
8. **BBB:** Both have good BBB penetration (Ligand A: 83.715, Ligand B: 86.545). Ligand B is slightly better.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand B (-4.94) is slightly worse than Ligand A (-4.731).
10. **Solubility:** Both are negative, indicating poor solubility. Ligand B (-1.892) is slightly better than Ligand A (-4.495).
11. **hERG:** Both are low (0.487 and 0.485), indicating low cardiotoxicity risk. No significant difference.
12. **Cl_mic:** Ligand B (4.931) has significantly lower microsomal clearance than Ligand A (12.475), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-22.427) has a much longer in vitro half-life than Ligand B (-2.922). This is a significant advantage for Ligand A.
14. **Pgp:** Both are very low (0.076 and 0.078), indicating minimal P-gp efflux. No significant difference.
15. **Affinity:** Ligand B (-6.7 kcal/mol) has a slightly better binding affinity than Ligand A (-5.8 kcal/mol). This is a 0.9 kcal/mol difference, which is a good advantage.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, we prioritize logP, Pgp, TPSA, and affinity. Ligand A has a better logP, while Ligand B has better affinity. Both have good Pgp and similar TPSA. However, the *significant* advantage of Ligand B in terms of DILI risk and metabolic stability (Cl_mic) outweighs the slightly better logP and half-life of Ligand A. The affinity difference, while present, isn't large enough to overcome the ADME concerns with Ligand A.
**Conclusion:**
Considering the balance of properties and the priorities for a GPCR target, Ligand B is the more promising drug candidate.
0
2025-04-17 19:16:42,841 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (352.519 Da and 341.415 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (58.64) is significantly better than Ligand B (80.12). For a GPCR, lower TPSA is generally preferred for better permeability. Ligand A is well below the 140 threshold, while Ligand B is approaching it.
**3. logP:** Ligand A (3.127) is within the optimal 1-3 range. Ligand B (1.01) is at the lower end, potentially impacting permeability.
**4. H-Bond Donors:** Both ligands have 1 HBD, which is acceptable.
**5. H-Bond Acceptors:** Ligand A has 3 HBAs, while Ligand B has 5. Both are within the acceptable limit of 10, but fewer is generally better for permeability.
**6. QED:** Ligand A (0.649) has a slightly better QED score than Ligand B (0.593), indicating a more drug-like profile.
**7. DILI:** Ligand B (48.623) has a significantly lower DILI risk than Ligand A (9.306), which is a major advantage.
**8. BBB:** Ligand A (77.394) has a better BBB penetration score than Ligand B (58.821). While ADRB2 is cardiovascular, some CNS off-target effects are always a concern, and higher BBB penetration could contribute to this.
**9. Caco-2:** Both ligands have negative Caco-2 values, which is unusual. It's difficult to interpret these values without knowing the scale. However, assuming lower values indicate poorer permeability, both are concerning.
**10. Solubility:** Both ligands have negative solubility values, which is also unusual. Again, assuming lower values indicate poorer solubility, both are concerning.
**11. hERG:** Ligand A (0.685) has a slightly higher hERG risk than Ligand B (0.113), which is a significant advantage for Ligand B.
**12. Cl_mic:** Ligand B (26.031) has a much lower microsomal clearance than Ligand A (63.446), indicating better metabolic stability.
**13. t1/2:** Ligand B (-17.128) has a longer in vitro half-life than Ligand A (-14.414), which is favorable.
**14. Pgp:** Ligand A (0.421) has a lower P-gp efflux liability than Ligand B (0.067), which is a slight advantage.
**15. Binding Affinity:** Both ligands have very similar binding affinities (-6.1 and -6.2 kcal/mol). The difference is negligible.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand A initially looks better due to its TPSA and Pgp values. However, the significantly lower DILI risk, better metabolic stability (lower Cl_mic and longer t1/2), and lower hERG risk of Ligand B are crucial for a viable drug candidate. While Ligand A has a slightly better BBB score, the safety profile of Ligand B is far more compelling, especially given the cardiovascular target. The slightly lower logP of Ligand B is a concern, but can be addressed with further optimization.
Output:
0
2025-04-17 19:16:42,841 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (352.385 and 350.503 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (67.23) is higher than Ligand B (49.85). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B has a clear advantage.
3. **logP:** Ligand B (2.975) is closer to the optimal 1-3 range than Ligand A (1.198). ADRB2 is not a CNS target, so moderate lipophilicity is good for membrane permeability. Ligand B is better.
4. **HBD:** Ligand A (1) is slightly higher than Ligand B (0). Both are acceptable.
5. **HBA:** Ligand A (4) is slightly higher than Ligand B (3). Both are acceptable.
6. **QED:** Ligand A (0.81) is slightly better than Ligand B (0.709), indicating a marginally more drug-like profile.
7. **DILI:** Ligand B (32.377) has a significantly lower DILI risk than Ligand A (52.346). This is a major advantage for Ligand B.
8. **BBB:** Both have high BBB penetration, but Ligand B (90.074) is slightly higher than Ligand A (83.986). Not a major concern for a cardiovascular target.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand B (-4.247) is slightly better than Ligand A (-4.829).
10. **Solubility:** Both are negative, indicating poor solubility. Ligand B (-2.836) is slightly better than Ligand A (-2.045).
11. **hERG:** Ligand A (0.209) has a slightly lower hERG risk than Ligand B (0.633). This is a small advantage for Ligand A.
12. **Cl_mic:** Ligand A (17.902) has a significantly lower microsomal clearance than Ligand B (83.985), indicating better metabolic stability. This is a substantial advantage for Ligand A.
13. **t1/2:** Ligand A (-24.442) has a much longer in vitro half-life than Ligand B (2.381). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.034) has a much lower P-gp efflux liability than Ligand B (0.256). This is a substantial advantage for Ligand A.
15. **Binding Affinity:** Ligand B (-6.8) has a slightly better binding affinity than Ligand A (-6.4). While a 1.5 kcal/mol difference is significant, the other factors are more important here.
**Overall Assessment:**
While Ligand B has slightly better logP and affinity, Ligand A demonstrates a superior ADME profile. Specifically, its significantly lower DILI risk, better metabolic stability (lower Cl_mic and longer t1/2), and lower P-gp efflux are crucial advantages. The slightly lower hERG risk is also beneficial. The solubility and Caco-2 values are poor for both, but Ligand A's other advantages outweigh this. For a cardiovascular GPCR, metabolic stability and minimizing off-target effects (DILI) are paramount.
Output:
1
2025-04-17 19:16:42,841 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (376.36 and 354.535 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (103.35) is higher than Ligand B (67.43). For a cardiovascular GPCR, TPSA is moderately important, and lower is generally better for permeability. Ligand B is significantly better.
**3. logP:** Both ligands have good logP values (2.69 and 3.417), falling within the optimal 1-3 range. Ligand B is slightly higher, which could be a minor advantage.
**4. H-Bond Donors:** Ligand A has 4 HBD, and Ligand B has 2. Both are acceptable (<=5).
**5. H-Bond Acceptors:** Ligand A has 5 HBA, and Ligand B has 3. Both are acceptable (<=10).
**6. QED:** Both ligands have similar QED values (0.644 and 0.667), indicating good drug-likeness.
**7. DILI Risk:** Ligand A (87.049) has a considerably higher DILI risk than Ligand B (18.728). This is a major concern, as minimizing liver toxicity is crucial.
**8. BBB Penetration:** Ligand B (76.541) has better BBB penetration than Ligand A (58.86). While ADRB2 is primarily a cardiovascular target, some CNS effects are possible with beta-blockers, and higher BBB penetration isn't necessarily detrimental.
**9. Caco-2 Permeability:** Ligand A (-5.164) has worse Caco-2 permeability than Ligand B (-4.271). Lower values indicate poorer absorption.
**10. Aqueous Solubility:** Both ligands have similar, poor aqueous solubility (-3.506 and -3.656). This could pose formulation challenges.
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (0.478 and 0.441). This is good.
**12. Microsomal Clearance:** Ligand B (69.284) has a higher microsomal clearance than Ligand A (27.398), meaning it's metabolized faster. This is a disadvantage.
**13. In vitro Half-Life:** Ligand A (70.26) has a significantly longer in vitro half-life than Ligand B (17.455). This is a strong advantage, potentially leading to less frequent dosing.
**14. P-gp Efflux:** Both ligands have similar, low P-gp efflux liability (0.131 and 0.073).
**15. Binding Affinity:** Ligand A (-5.9 kcal/mol) has a slightly better binding affinity than Ligand B (-5.2 kcal/mol). This 0.7 kcal/mol difference is significant, and can outweigh some ADME drawbacks.
**Overall Assessment:**
While Ligand A has a better binding affinity and longer half-life, the significantly higher DILI risk (87.049 vs 18.728) is a major red flag. The lower TPSA and better Caco-2 permeability of Ligand B are also favorable. Considering the cardiovascular context, minimizing toxicity is paramount. The slightly weaker binding of Ligand B is a manageable drawback compared to the potential for liver damage with Ligand A.
Output:
0
2025-04-17 19:16:42,841 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
The ADRB2 receptor is a GPCR, so the priorities are logP, TPSA, Pgp efflux, BBB penetration, and binding affinity. Metabolic stability and solubility are also important, but slightly lower priority.
Let's compare the ligands:
1. **MW:** Both ligands (370.5 and 356.5 Da) fall within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (81.08) is slightly higher than Ligand B (77.1). Both are well below the 140 threshold for oral absorption, and acceptable for a non-CNS GPCR target.
3. **logP:** Ligand B (0.962) is slightly better than Ligand A (0.712), falling more squarely in the optimal 1-3 range. Ligand A is a little low, potentially impacting permeability.
4. **HBD/HBA:** Ligand A has 2 HBD and 5 HBA, while Ligand B has 1 HBD and 5 HBA. Both are within acceptable limits.
5. **QED:** Both ligands have similar QED values (0.615 and 0.666), indicating good drug-likeness.
6. **DILI:** Ligand B (15.86) has a significantly lower DILI risk than Ligand A (20.59), which is a major advantage.
7. **BBB:** Ligand B (73.13) has better BBB penetration than Ligand A (63.13), though this is less critical for a non-CNS target like ADRB2.
8. **Caco-2:** Ligand A (-5.219) has slightly better Caco-2 permeability than Ligand B (-4.462).
9. **Solubility:** Ligand B (-0.634) has better aqueous solubility than Ligand A (-1.93).
10. **hERG:** Both ligands have low hERG inhibition liability (0.482 and 0.204), which is good.
11. **Cl_mic:** Ligand B (27.84) has significantly lower microsomal clearance than Ligand A (47.44), indicating better metabolic stability.
12. **t1/2:** Ligand B (-7.666) has a longer in vitro half-life than Ligand A (-3.723), which is desirable.
13. **Pgp:** Both ligands have very low Pgp efflux liability (0.182 and 0.01).
14. **Binding Affinity:** Ligand A (-6.5) has slightly better binding affinity than Ligand B (-6.2), but the difference is small (0.3 kcal/mol).
**Overall Assessment:**
While Ligand A has a slightly better binding affinity, Ligand B is superior in almost every other crucial ADME-Tox parameter. Specifically, the significantly lower DILI risk, better metabolic stability (lower Cl_mic, longer t1/2), and improved solubility of Ligand B outweigh the small difference in binding affinity. The slightly better logP of Ligand B also contributes to its overall better profile. Given the GPCR target class, the balance of properties in Ligand B makes it the more promising drug candidate.
**Output:**
0
2025-04-17 19:16:42,841 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
We are targeting ADRB2, a GPCR, so the priorities are logP, Pgp, TPSA, affinity, and BBB. Let's break down each ligand based on the provided parameters:
**Ligand A:**
* **MW:** 350.459 Da (Good - within range)
* **TPSA:** 98.66 (Acceptable, but approaching the upper limit for good absorption)
* **logP:** 0.999 (Low - could hinder permeation)
* **HBD:** 4 (Good)
* **HBA:** 4 (Good)
* **QED:** 0.537 (Good - drug-like)
* **DILI:** 24.351 (Excellent - very low risk)
* **BBB:** 17.138 (Low - poor CNS penetration)
* **Caco-2:** -5.01 (Very poor - significant absorption issues)
* **Solubility:** -2.209 (Poor - formulation challenges)
* **hERG:** 0.099 (Excellent - very low risk)
* **Cl_mic:** -15.045 (Excellent - very stable)
* **t1/2:** 2.019 (Short - frequent dosing may be needed)
* **Pgp:** 0.043 (Excellent - low efflux)
* **Affinity:** -5.7 kcal/mol (Good)
**Ligand B:**
* **MW:** 360.885 Da (Good - within range)
* **TPSA:** 64.33 (Excellent - favorable for absorption)
* **logP:** 3.854 (High - potential solubility/off-target issues, but acceptable for a GPCR)
* **HBD:** 1 (Good)
* **HBA:** 3 (Good)
* **QED:** 0.783 (Excellent - highly drug-like)
* **DILI:** 27.142 (Excellent - very low risk)
* **BBB:** 55.099 (Moderate - some CNS penetration possible)
* **Caco-2:** -4.427 (Poor - absorption issues, but better than A)
* **Solubility:** -4.501 (Poor - formulation challenges)
* **hERG:** 0.776 (Acceptable - moderate risk)
* **Cl_mic:** 69.69 (High - less metabolically stable)
* **t1/2:** 20.382 (Long - less frequent dosing)
* **Pgp:** 0.453 (Moderate - some efflux)
* **Affinity:** -8.3 kcal/mol (Excellent - significantly stronger binding)
**Comparison & Decision:**
The most striking difference is the binding affinity: Ligand B is significantly more potent (-8.3 kcal/mol vs. -5.7 kcal/mol). This >1.5 kcal/mol advantage is a major factor favoring Ligand B, even considering its drawbacks.
Ligand A has better DILI and Pgp scores, but these are less critical than affinity for a non-CNS target. Ligand A's extremely poor Caco-2 permeability and solubility are major red flags. While Ligand B also has poor solubility and Caco-2 permeability, its superior affinity and longer half-life make it a more promising starting point for optimization. The higher logP of Ligand B is a concern, but manageable through structural modifications. Ligand B's BBB score is also better than Ligand A, which is a plus.
Considering the GPCR-specific priorities and the overall balance of properties, Ligand B is the better candidate.
**Output:**
0
2025-04-17 19:16:42,841 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (344.499 Da and 367.515 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (49.41) is significantly better than Ligand B (78.51). For a GPCR, lower TPSA is generally preferred for better permeability, and Ligand A is well below the 140 A^2 threshold. Ligand B is approaching a less desirable range.
**3. logP:** Ligand A (3.575) is within the optimal 1-3 range. Ligand B (1.006) is at the lower end, potentially indicating permeability issues. This favors Ligand A.
**4. H-Bond Donors:** Both have acceptable HBD counts (1 and 2 respectively), well below the 5 threshold.
**5. H-Bond Acceptors:** Both have acceptable HBA counts (2 and 4 respectively), well below the 10 threshold.
**6. QED:** Both ligands have good QED scores (0.612 and 0.711), indicating good drug-like properties.
**7. DILI:** Both ligands have similar and acceptable DILI risk (31.601 and 31.02).
**8. BBB:** Ligand B (62.233) has a slightly better BBB penetration score than Ligand A (54.75). However, since ADRB2 is primarily a cardiovascular target, high BBB penetration isn't a critical priority.
**9. Caco-2 Permeability:** Ligand A (-4.89) has a more negative Caco-2 value, which is better, indicating higher permeability. Ligand B (-5.245) is also good, but slightly less favorable.
**10. Aqueous Solubility:** Ligand A (-2.727) has slightly better solubility than Ligand B (-3.371).
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (0.432 and 0.182). Ligand B is slightly better here.
**12. Microsomal Clearance:** Ligand A (23.566) has a lower microsomal clearance, suggesting better metabolic stability, which is preferable. Ligand B (31.064) has higher clearance.
**13. In vitro Half-Life:** Ligand A (-6.214) has a much better in vitro half-life than Ligand B (6.156).
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.283 and 0.016). Ligand B is slightly better.
**15. Binding Affinity:** Ligand B (-7.6) has a slightly better binding affinity than Ligand A (-7.4). This is a 0.2 kcal/mol difference, which is a reasonable advantage.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand A is the more promising candidate. While Ligand B has a slightly better binding affinity and P-gp efflux, Ligand A excels in TPSA, logP, Caco-2 permeability, and crucially, metabolic stability (lower Cl_mic and better half-life). The slightly lower affinity of Ligand A can likely be optimized in further iterations, whereas improving the permeability and metabolic stability of Ligand B would be more challenging. The cardiovascular target also reduces the importance of BBB penetration.
Output:
1
2025-04-17 19:16:42,841 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (344.46 and 351.42 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (57.58) is better than Ligand B (62.74). Both are below 140, but lower TPSA generally favors absorption.
3. **logP:** Both ligands (1.23 and 1.45) are within the optimal 1-3 range. Ligand B is slightly higher, which could be marginally better for membrane permeability, but the difference is small.
4. **HBD:** Ligand A (1) is better than Ligand B (0). While both are low, having one HBD can sometimes improve solubility without significantly impacting permeability.
5. **HBA:** Both ligands (4) are within the acceptable limit of 10. No significant difference.
6. **QED:** Ligand A (0.874) is significantly better than Ligand B (0.64), indicating a more drug-like profile.
7. **DILI:** Ligand A (13.07%) is *much* better than Ligand B (23.23%). This is a crucial factor, as lower DILI risk is highly desirable. Ligand B is approaching a concerning percentile.
8. **BBB:** Ligand B (87.94%) is significantly better than Ligand A (67.35%). For a GPCR, particularly one outside the CNS, BBB isn't the highest priority, but it's still a positive attribute.
9. **Caco-2:** Ligand A (-5.015) is better than Ligand B (-4.659). Higher Caco-2 permeability indicates better intestinal absorption.
10. **Solubility:** Ligand A (-0.976) is better than Ligand B (-0.469). Higher solubility is generally preferred.
11. **hERG:** Both ligands (0.32 and 0.479) have low hERG inhibition liability, which is excellent. No significant difference.
12. **Cl_mic:** Ligand A (-6.271) is *much* better than Ligand B (22.46). Lower clearance indicates better metabolic stability, a critical factor for drug duration and efficacy.
13. **t1/2:** Ligand A (11.729) is better than Ligand B (6.336). A longer half-life is generally desirable.
14. **Pgp:** Both ligands (0.021 and 0.069) have low P-gp efflux, which is good. No significant difference.
15. **Binding Affinity:** Ligand B (-6.7) is slightly better than Ligand A (-5.3). This is a 1.4 kcal/mol difference, which is substantial and could potentially outweigh some ADME drawbacks.
**Overall Assessment & GPCR-Specific Priorities:**
For an ADRB2 GPCR, affinity, logP, TPSA, Pgp, and metabolic stability are key. While Ligand B has a better affinity, the significant advantages of Ligand A in terms of DILI risk, QED, metabolic stability (Cl_mic), solubility, and half-life are too important to ignore. The slightly lower BBB penetration of Ligand A is not a major concern for a cardiovascular target. The superior ADME profile of Ligand A makes it the more promising drug candidate.
Output:
1
2025-04-17 19:16:42,842 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (363.483 and 347.463 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (78.51) is higher than Ligand B (63.49). Both are below the 140 threshold for oral absorption, but B is better.
3. **logP:** Both ligands (1.666 and 1.312) are within the optimal 1-3 range. Ligand B is slightly lower, which could be a minor drawback.
4. **HBD:** Ligand A has 2 HBD, and Ligand B has 0. Both are acceptable (<=5).
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 6. Both are acceptable (<=10), but A is better.
6. **QED:** Ligand A (0.755) has a better QED score than Ligand B (0.63), indicating a more drug-like profile.
7. **DILI:** Ligand A (36.681) has a higher DILI risk than Ligand B (23.846). This is a significant advantage for Ligand B.
8. **BBB:** Ligand B (69.407) has a better BBB penetration percentile than Ligand A (56.689). While ADRB2 isn't strictly a CNS target, some peripheral ADRB2 receptors can be affected by CNS penetration.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-5.393) is slightly worse than Ligand B (-4.933).
10. **Solubility:** Ligand A (-1.85) has slightly worse solubility than Ligand B (-0.542).
11. **hERG:** Both ligands have very low hERG inhibition risk (0.196 and 0.224). No significant difference.
12. **Cl_mic:** Ligand B (35.121) has a lower microsomal clearance than Ligand A (52.858), indicating better metabolic stability.
13. **t1/2:** Ligand A (14.953) has a longer in vitro half-life than Ligand B (10.543). This is a positive for Ligand A.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.066 and 0.06). No significant difference.
15. **Binding Affinity:** Ligand A (-6.4 kcal/mol) has a slightly better binding affinity than Ligand B (-4.9 kcal/mol). This is a 1.5 kcal/mol difference, which is significant.
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Ligand A has a better affinity and QED, but Ligand B has better TPSA, DILI, BBB, and Cl_mic. The affinity difference is substantial, and the slightly better metabolic stability of B is helpful. However, the lower DILI risk of Ligand B is a major advantage.
**Overall Assessment:**
While Ligand A has a better binding affinity and half-life, Ligand B's significantly lower DILI risk, better TPSA, and improved metabolic stability make it the more promising candidate. The 1.5 kcal/mol affinity difference can potentially be optimized in later stages of drug development. The lower DILI risk is a crucial factor for clinical success.
Output:
0
2025-04-17 19:16:42,842 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [355.337, 65.07, 2.119, 0., 5., 0.761, 68.592, 83.133, -3.848, -2.926, 0.319, 67.076, 5.595, 0.052, -6.1]
**Ligand B:** [340.467, 50.36, 4.405, 2., 2., 0.847, 47.383, 89.066, -4.692, -4.368, 0.88, 36.339, 47.782, 0.474, -6.3]
Here's a breakdown, considering the GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (340.467) is slightly lower, which is generally favorable.
2. **TPSA:** Ligand A (65.07) is higher than Ligand B (50.36). Both are acceptable, but Ligand B is better for permeability.
3. **logP:** Ligand A (2.119) is optimal. Ligand B (4.405) is pushing the upper limit and could lead to solubility issues or off-target effects.
4. **HBD/HBA:** Ligand A (0 HBD, 5 HBA) is better than Ligand B (2 HBD, 2 HBA) in terms of balancing solubility and permeability.
5. **QED:** Both are good (A: 0.761, B: 0.847), indicating drug-like properties. Ligand B is slightly better.
6. **DILI:** Ligand A (68.592) has a higher DILI risk than Ligand B (47.383). This is a significant advantage for Ligand B.
7. **BBB:** Both have good BBB penetration (A: 83.133, B: 89.066). Ligand B is slightly better.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual. This suggests poor permeability. Ligand B (-4.692) is worse than Ligand A (-3.848).
9. **Solubility:** Both have negative solubility values, which is also unusual and suggests very poor solubility. Ligand B (-4.368) is worse than Ligand A (-2.926).
10. **hERG:** Ligand A (0.319) has a lower hERG risk than Ligand B (0.88).
11. **Cl_mic:** Ligand B (36.339) has significantly lower microsomal clearance than Ligand A (67.076), suggesting better metabolic stability.
12. **t1/2:** Ligand B (47.782) has a longer half-life than Ligand A (5.595).
13. **Pgp:** Ligand A (0.052) has lower P-gp efflux liability than Ligand B (0.474), which is favorable.
14. **Affinity:** Ligand B (-6.3) has a slightly better binding affinity than Ligand A (-6.1). While the difference is small, it's still a positive for Ligand B.
**Overall Assessment:**
Despite the unusual Caco-2 and solubility values, Ligand B appears to be the better candidate. Its lower DILI risk, better metabolic stability (lower Cl_mic, longer t1/2), and slightly improved affinity outweigh the slightly higher logP and Pgp efflux. The better BBB penetration is also a plus for a GPCR target. Ligand A's lower hERG risk is a benefit, but the higher DILI risk is a significant concern.
Output:
0
2025-04-17 19:16:42,842 - INFO - Batch 98 complete. Total preferences: 1568
2025-04-17 19:16:42,842 - INFO - Processing batch 99/512...
2025-04-17 19:17:30,116 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Overall Strategy:** Given ADRB2 is a GPCR, I'll prioritize logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB. Metabolic stability (Cl_mic, t1/2) and safety (DILI, hERG) are also important.
**Ligand A Analysis:**
* **MW:** 365.43 Da - Acceptable.
* **TPSA:** 71.53 - Acceptable, but approaching the upper limit for good absorption.
* **logP:** 2.304 - Excellent. Within the optimal range.
* **HBD:** 1 - Good.
* **HBA:** 5 - Good.
* **QED:** 0.62 - Very good, indicating good drug-likeness.
* **DILI:** 68.321 - Moderate risk, but not alarming.
* **BBB:** 77.627 - Good, suggesting some brain penetration, though not a primary concern for ADRB2 (cardiovascular target).
* **Caco-2:** -4.43 - Poor permeability. This is a significant drawback.
* **Solubility:** -3.642 - Poor solubility. Another significant drawback.
* **hERG:** 0.318 - Low risk, excellent.
* **Cl_mic:** 73.281 - Moderate clearance, not ideal.
* **t1/2:** -23.16 - Very short half-life, a major concern.
* **Pgp:** 0.245 - Low efflux, favorable.
* **Affinity:** -7.6 kcal/mol - Excellent binding affinity.
**Ligand B Analysis:**
* **MW:** 352.479 Da - Acceptable.
* **TPSA:** 69.48 - Acceptable, similar to Ligand A.
* **logP:** 2.548 - Excellent, slightly higher than Ligand A.
* **HBD:** 0 - Good.
* **HBA:** 6 - Good.
* **QED:** 0.647 - Very good, slightly better than Ligand A.
* **DILI:** 42.691 - Lower risk than Ligand A, favorable.
* **BBB:** 80.496 - Good, similar to Ligand A.
* **Caco-2:** -4.287 - Poor permeability, similar to Ligand A.
* **Solubility:** -3.514 - Poor solubility, similar to Ligand A.
* **hERG:** 0.359 - Low risk, excellent.
* **Cl_mic:** 85.921 - Higher clearance than Ligand A, less favorable.
* **t1/2:** -17.913 - Longer half-life than Ligand A, but still short.
* **Pgp:** 0.4 - Slightly higher efflux than Ligand A, less favorable.
* **Affinity:** -6.7 kcal/mol - Good binding affinity, but 0.9 kcal/mol weaker than Ligand A.
**Comparison and Decision:**
Both ligands suffer from poor Caco-2 permeability and aqueous solubility. However, Ligand A has a significantly better binding affinity (-7.6 vs -6.7 kcal/mol). While Ligand B has a slightly better DILI score and a marginally longer half-life, the substantial difference in binding affinity outweighs these advantages, especially for a GPCR target where potency is crucial. The poor permeability and solubility of both compounds are serious issues that would need to be addressed in subsequent optimization, but a strong starting point with high affinity is preferable.
Therefore, I choose Ligand A.
Output:
1
2025-04-17 19:17:30,116 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (342.483 and 351.451 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (49.41) is significantly better than Ligand B (122.27). ADRB2 is not a CNS target, but lower TPSA generally improves absorption. Ligand A is well below the 140 threshold, while B is approaching it.
3. **logP:** Ligand A (3.571) is optimal, while Ligand B (0.57) is quite low. Low logP can hinder membrane permeability. This is a significant advantage for Ligand A.
4. **HBD:** Ligand A (1) is preferable to Ligand B (4). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (2) is preferable to Ligand B (6). Similar reasoning as HBD.
6. **QED:** Ligand A (0.734) is better than Ligand B (0.491), indicating a more drug-like profile.
7. **DILI:** Ligand B (29.159) has a lower DILI risk than Ligand A (33.501), which is good. However, both are below the concerning threshold of 60.
8. **BBB:** Ligand A (72.237) has a higher BBB penetration percentile than Ligand B (57.736). While ADRB2 isn't a primary CNS target, some peripheral exposure is still desirable.
9. **Caco-2:** Ligand A (-4.36) is better than Ligand B (-5.568). Higher values indicate better intestinal absorption.
10. **Solubility:** Ligand A (-4.22) is better than Ligand B (-2.042). Higher values indicate better solubility.
11. **hERG:** Ligand A (0.457) has a lower hERG inhibition liability than Ligand B (0.431). Both are very low risk.
12. **Cl_mic:** Ligand B (1.298) has significantly lower microsomal clearance than Ligand A (64.066), suggesting better metabolic stability. This is a strong advantage for Ligand B.
13. **t1/2:** Ligand B (12.548) has a longer in vitro half-life than Ligand A (6.64). This is also a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.25) has lower P-gp efflux liability than Ligand B (0.019). Lower efflux is generally preferred.
15. **Binding Affinity:** Ligand A (-6.1) has a slightly better binding affinity than Ligand B (-5.1). A 1 kcal/mol difference is significant and can outweigh some ADME drawbacks.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, and affinity are crucial. Ligand A excels in logP, TPSA, and has a better affinity. Ligand B has a better metabolic profile (Cl_mic and t1/2). However, the poor logP and higher TPSA of Ligand B are significant drawbacks that could hinder its absorption and bioavailability. The slightly better affinity of Ligand A, combined with its superior physicochemical properties, makes it the more promising candidate.
**Final Decision:**
1
2025-04-17 19:17:30,117 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for the ADRB2, a cardiovascular GPCR. Therefore, the key priorities are logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB.
Let's break down the comparison:
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand B (344.455 Da) is slightly smaller, which could be advantageous for permeability.
2. **TPSA:** Ligand A (89.54) is better than Ligand B (49.85). Lower TPSA generally improves oral absorption, and both are acceptable, but A is preferable.
3. **logP:** Both ligands have good logP values (A: 3.345, B: 2.303) within the optimal 1-3 range.
4. **HBD/HBA:** Ligand A has 1 HBD and 6 HBA, while Ligand B has 0 HBD and 3 HBA. Both are within acceptable limits.
5. **QED:** Ligand A (0.79) has a significantly better QED score than Ligand B (0.437), indicating a more drug-like profile.
6. **DILI:** Ligand A (88.251) has a higher DILI risk than Ligand B (44.591). This is a significant drawback for Ligand A.
7. **BBB:** Ligand B (82.202) has better BBB penetration than Ligand A (38.426). While not a primary concern for a cardiovascular target, it's a slight advantage.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and difficult to interpret without knowing the scale.
9. **Solubility:** Both have negative solubility values, which is also unusual and difficult to interpret.
10. **hERG:** Both ligands have very low hERG inhibition risk (A: 0.27, B: 0.168).
11. **Cl_mic:** Ligand A (44.974) has lower microsomal clearance than Ligand B (65.258), suggesting better metabolic stability.
12. **t1/2:** Ligand A (48.904) has a much longer in vitro half-life than Ligand B (-11.803). This is a significant advantage.
13. **Pgp:** Ligand A (0.25) has lower P-gp efflux than Ligand B (0.138), which is favorable for bioavailability.
14. **Binding Affinity:** Ligand A (-8.0 kcal/mol) has a slightly better binding affinity than Ligand B (-7.0 kcal/mol). This 1 kcal/mol difference is substantial and can outweigh some ADME concerns.
**Overall Assessment:**
Ligand A has a superior binding affinity, better QED, lower Pgp efflux, and longer half-life. However, it has a significantly higher DILI risk. Ligand B has a lower DILI risk and better BBB penetration, but weaker binding affinity, lower QED, and faster clearance.
Given the importance of potency for GPCRs, and the 1 kcal/mol advantage of Ligand A, I believe the stronger binding is the most critical factor. The DILI risk is a concern, but can potentially be mitigated through structural modifications in later stages of optimization. The longer half-life and lower Pgp efflux also contribute to better overall drug-like properties.
Output:
1
2025-04-17 19:17:30,117 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (379.819 Da) is within the ideal range. Ligand B (357.439 Da) is also good. No clear advantage.
2. **TPSA:** Ligand A (54.88) is excellent, well below the 140 threshold. Ligand B (96.87) is still reasonable, but higher. This favors Ligand A.
3. **logP:** Ligand A (4.621) is a bit high, potentially leading to solubility issues and off-target effects. Ligand B (1.194) is quite low, potentially hindering permeability. This is a trade-off, but the higher logP of A is less concerning for a peripherally acting GPCR like ADRB2.
4. **HBD:** Ligand A (1) is good. Ligand B (2) is acceptable.
5. **HBA:** Ligand A (4) is good. Ligand B (6) is acceptable.
6. **QED:** Both ligands (A: 0.719, B: 0.519) are above the 0.5 threshold, indicating good drug-likeness, but A is better.
7. **DILI:** Ligand A (86.002) has a higher DILI risk than Ligand B (63.125), which is a significant drawback.
8. **BBB:** Ligand A (71.229) has good BBB penetration, while Ligand B (34.044) is low. While ADRB2 isn't primarily a CNS target, some CNS penetration can be acceptable and even beneficial for off-target effects.
9. **Caco-2:** Ligand A (-4.671) is poor, indicating poor intestinal absorption. Ligand B (-5.493) is also poor, but slightly worse.
10. **Solubility:** Ligand A (-5.603) is very poor. Ligand B (-2.457) is better, though still not ideal.
11. **hERG:** Ligand A (0.512) is low risk. Ligand B (0.155) is very low risk, a significant advantage.
12. **Cl_mic:** Ligand A (49.927) is moderate. Ligand B (2.982) is very low, indicating excellent metabolic stability. This is a strong advantage for Ligand B.
13. **t1/2:** Ligand A (76.768) is good. Ligand B (6.979) is poor.
14. **Pgp:** Ligand A (0.629) is relatively low. Ligand B (0.06) is very low, indicating minimal efflux. This is a strong advantage for Ligand B.
15. **Affinity:** Ligand A (-7.0) is slightly better than Ligand B (-5.8), a 1.2 kcal/mol difference. This is a substantial advantage that can outweigh some ADME concerns.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand A has a higher logP (potentially problematic but manageable), better TPSA, and significantly better affinity. Ligand B has better Pgp and lower hERG.
**Overall Assessment:**
Ligand A's superior binding affinity is a major driver. While its solubility and DILI risk are concerns, the strong binding could potentially allow for a lower dose, mitigating some of the DILI risk. The slightly higher logP is less concerning for a peripheral target. Ligand B has better ADME properties overall, but the significantly weaker binding affinity is a major drawback. The difference in affinity is large enough to outweigh the ADME advantages of Ligand B.
Output:
1
2025-04-17 19:17:30,117 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 drug candidates. ADRB2 is a GPCR, so we'll prioritize logP, Pgp, TPSA, and affinity, alongside general drug-like properties.
**Ligand A:**
* **MW:** 346.515 Da - Good, within the ideal range.
* **TPSA:** 40.62 - Excellent, well below the 140 threshold.
* **logP:** 3.312 - Excellent, within the optimal 1-3 range.
* **HBD:** 0 - Good, low number of H-bond donors.
* **HBA:** 2 - Good, low number of H-bond acceptors.
* **QED:** 0.692 - Excellent, highly drug-like.
* **DILI:** 9.965 - Excellent, very low risk.
* **BBB:** 82.086 - Good, reasonably high BBB penetration.
* **Caco-2:** -4.445 - Concerning, suggests poor permeability.
* **Solubility:** -2.871 - Concerning, suggests poor solubility.
* **hERG:** 0.536 - Good, low risk of hERG inhibition.
* **Cl_mic:** 42.686 - Moderate, could be better for metabolic stability.
* **t1/2:** -3.49 - Moderate, could be better.
* **Pgp:** 0.119 - Excellent, low P-gp efflux.
* **Affinity:** -5.6 kcal/mol - Very good binding affinity.
**Ligand B:**
* **MW:** 352.391 Da - Good, within the ideal range.
* **TPSA:** 116.92 - Concerning, above the 140 threshold, potentially impacting absorption.
* **logP:** -0.872 - Poor, below the optimal range, potentially hindering permeation.
* **HBD:** 3 - Acceptable, within the limit.
* **HBA:** 7 - Acceptable, within the limit.
* **QED:** 0.613 - Good, drug-like.
* **DILI:** 60.566 - Moderate, higher DILI risk than Ligand A.
* **BBB:** 12.408 - Poor, very low BBB penetration.
* **Caco-2:** -5.166 - Concerning, suggests poor permeability.
* **Solubility:** -1.632 - Concerning, suggests poor solubility.
* **hERG:** 0.168 - Good, low risk of hERG inhibition.
* **Cl_mic:** 6.055 - Excellent, very low clearance, good metabolic stability.
* **t1/2:** -3.182 - Moderate, could be better.
* **Pgp:** 0.016 - Excellent, low P-gp efflux.
* **Affinity:** -5.4 kcal/mol - Good binding affinity, slightly weaker than Ligand A.
**Comparison & Decision:**
Both ligands have good affinity and low P-gp efflux, which are positives. However, Ligand A significantly outperforms Ligand B in several critical areas for a GPCR target. Ligand A has a much better logP, TPSA, and a significantly lower DILI risk. While both have concerning Caco-2 and solubility values, Ligand A's superior logP and TPSA suggest it *might* be more amenable to formulation strategies to overcome these issues. Ligand B's poor logP and high TPSA are more fundamental barriers to oral absorption. The higher BBB value for Ligand A is also a plus, even though ADRB2 isn't primarily a CNS target, some off-target CNS effects are possible with beta-agonists. Ligand B's improved metabolic stability (lower Cl_mic) is a benefit, but the difference in affinity (-5.6 vs -5.4) and the other ADME properties are more impactful.
Therefore, I would select Ligand A as the more promising drug candidate.
Output:
1
2025-04-17 19:17:30,117 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [403.251, 44.12, 4.482, 0, 4, 0.59, 80.807, 73.827, -4.629, -6.26, 0.469, 125.866, -2.034, 0.403, -5.5]
**Ligand B:** [372.506, 62.66, 3.417, 1, 5, 0.684, 31.834, 85.615, -4.187, -3.451, 0.685, 65.826, -20.561, 0.501, -5.6]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (372.5) is slightly lower, which can be favorable for permeability.
2. **TPSA:** Ligand A (44.12) is better than Ligand B (62.66). Both are acceptable, but lower TPSA is generally preferred for better absorption.
3. **logP:** Ligand A (4.482) is a bit high, potentially leading to solubility issues and off-target effects. Ligand B (3.417) is closer to the optimal range (1-3).
4. **HBD:** Ligand A (0) is better than Ligand B (1). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is better than Ligand B (5). Lower HBA is generally preferred for permeability.
6. **QED:** Both are good (A: 0.59, B: 0.684), indicating drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (80.807) has a significantly higher DILI risk than Ligand B (31.834). This is a major concern.
8. **BBB:** Ligand B (85.615) has better BBB penetration than Ligand A (73.827). This is important for GPCRs, though not strictly required for ADRB2.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-4.629) is slightly worse than Ligand B (-4.187).
10. **Solubility:** Ligand B (-3.451) has better solubility than Ligand A (-6.26).
11. **hERG:** Both are low (A: 0.469, B: 0.685), indicating low cardiotoxicity risk.
12. **Cl_mic:** Ligand B (65.826) has significantly lower microsomal clearance than Ligand A (125.866), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-20.561) has a much longer in vitro half-life than Ligand A (-2.034). This is a significant advantage.
14. **Pgp:** Both are similar (A: 0.403, B: 0.501).
15. **Affinity:** Both have similar binding affinity (-5.5 and -5.6 kcal/mol).
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, and affinity. While BBB is less critical for peripheral targets like ADRB2, it's still a consideration.
**Overall Assessment:**
Ligand A has a concerningly high DILI risk and poorer metabolic stability (higher Cl_mic) and shorter half-life. Its logP is also higher. Ligand B, while having a slightly higher TPSA, excels in DILI risk, metabolic stability, half-life, solubility, and BBB penetration. The similar binding affinities make the ADME properties the deciding factor.
Therefore, I prefer Ligand B.
Output:
0
2025-04-17 19:17:30,117 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (344.46 and 348.49 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (78.09) is slightly higher than Ligand B (70.51). Both are below the 140 threshold for good oral absorption, and acceptable for a cardiovascular GPCR. Ligand B is preferable.
3. **logP:** Both ligands (2.358 and 2.835) are within the optimal 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability, but not dramatically so.
4. **HBD:** Both ligands have 2 HBD, which is within the acceptable limit of <=5. No difference.
5. **HBA:** Ligand A has 3 HBA, while Ligand B has 6. Ligand A is preferable here, as fewer HBA generally correlate with better permeability.
6. **QED:** Ligand A (0.823) has a better QED score than Ligand B (0.715), indicating a more drug-like profile. This is a significant advantage for Ligand A.
7. **DILI:** Ligand A (33.23%) has a considerably higher DILI risk than Ligand B (16.053%). This is a major drawback for Ligand A.
8. **BBB:** Ligand B (83.249%) has a significantly higher BBB penetration score than Ligand A (68.282%). While ADRB2 is a cardiovascular target and CNS penetration isn't *essential*, some level of BBB penetration can be beneficial for off-target effects assessment and potential future therapeutic applications.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual. It suggests poor permeability. However, the values are similar (-5.098 vs -4.974).
10. **Solubility:** Both ligands have negative solubility values, which is also unusual and indicates poor aqueous solubility. Again, values are similar (-2.739 vs -2.154).
11. **hERG:** Ligand A (0.526) has a slightly lower hERG inhibition liability than Ligand B (0.848), which is preferable.
12. **Cl_mic:** Ligand A (6.672) has a significantly lower microsomal clearance than Ligand B (24.814), suggesting better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand B (48.486) has a much longer in vitro half-life than Ligand A (-28.865). This is a major advantage for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.144) has a lower P-gp efflux liability than Ligand B (0.088), which is preferable.
15. **Binding Affinity:** Ligand B (-2.0 kcal/mol) has a slightly better binding affinity than Ligand A (-4.5 kcal/mol). This is a substantial advantage for Ligand B.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B performs better on logP, TPSA, and significantly better on affinity. While BBB isn't critical for a cardiovascular target, Ligand B's higher score is a plus.
**Overall Assessment:**
Ligand B has a superior profile overall. While Ligand A has advantages in QED, Cl_mic, and Pgp, Ligand B's significantly better binding affinity, longer half-life, lower DILI risk, and better BBB penetration outweigh these advantages. The similar Caco-2 and solubility values are concerning for both, but can be addressed through formulation strategies. The DILI risk associated with Ligand A is a major concern.
Output:
0
2025-04-17 19:17:30,118 - INFO - Here's my reasoning and the final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, the key priorities are logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB.
Let's break down the comparison:
1. **MW:** Both are within the acceptable range (200-500 Da). Ligand B (348.403) is slightly lower, which can be advantageous for permeability.
2. **TPSA:** Ligand A (45.98) is significantly better than Ligand B (128.25). A TPSA under 140 is good for oral absorption, but Ligand B is pushing the limit.
3. **logP:** Ligand A (4.422) is higher than ideal (1-3). Ligand B (0.772) is quite low, potentially hindering membrane permeability.
4. **HBD/HBA:** Ligand A (1 HBD, 6 HBA) is preferable to Ligand B (3 HBD, 6 HBA). Lower HBD is generally better for permeability.
5. **QED:** Ligand A (0.851) is better than Ligand B (0.605), indicating a more drug-like profile.
6. **DILI:** Both are reasonably good, with Ligand A (53.974) slightly higher than Ligand B (47.732), but both below the concerning threshold of 60.
7. **BBB:** Ligand A (83.908) has a much better BBB penetration score than Ligand B (35.712). While ADRB2 isn't a CNS target, some distribution to the CNS can occur, and higher BBB is generally favorable.
8. **Caco-2:** Both are negative, which is unusual and suggests poor permeability. However, the scale is not specified, so it is difficult to interpret.
9. **Solubility:** Both are negative, suggesting poor solubility. The scale is not specified, so it is difficult to interpret.
10. **hERG:** Ligand A (0.767) is slightly higher than Ligand B (0.168), indicating a slightly higher risk of hERG inhibition, but both are relatively low.
11. **Cl_mic:** Ligand A (52.497) has a higher clearance than Ligand B (19.532), meaning it's less metabolically stable.
12. **t1/2:** Ligand B (-26.756) has a much longer half-life than Ligand A (66.275). This is a significant advantage.
13. **Pgp:** Ligand A (0.702) has a lower Pgp efflux liability than Ligand B (0.027), which is desirable for better bioavailability.
14. **Binding Affinity:** Ligand B (-7.6 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.6 kcal/mol). This is a >1 kcal/mol difference, which is a major advantage.
**Overall Assessment:**
Ligand B's significantly stronger binding affinity (-7.6 vs -6.6 kcal/mol) is a major driver. The longer half-life is also a significant advantage. While Ligand B has a lower logP and higher TPSA, the substantial affinity difference outweighs these drawbacks, especially considering the context of a cardiovascular target where CNS penetration is not critical. Ligand A has better BBB, Pgp and QED, but the affinity difference is too large to ignore.
Output:
0
2025-04-17 19:17:30,118 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (354.47 & 351.40 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (58.64) is significantly better than Ligand B (82.89). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (2.296) is optimal, while Ligand B (0.914) is slightly low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (0). Having at least one HBD can improve solubility.
5. **HBA:** Ligand B (7) is better than Ligand A (3). While both are acceptable, fewer HBA can be beneficial for permeability.
6. **QED:** Both ligands (0.728 & 0.734) have excellent drug-likeness scores. No significant difference.
7. **DILI:** Ligand A (17.80) has a much lower DILI risk than Ligand B (40.71). This is a crucial advantage.
8. **BBB:** Ligand A (96.94) has a very high BBB penetration, while Ligand B (66.42) is lower. While ADRB2 isn't a CNS target, higher BBB can sometimes correlate with better overall distribution.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
10. **Solubility:** Ligand A (-3.022) is better than Ligand B (-1.169). Higher solubility is always preferred.
11. **hERG:** Ligand A (0.655) is better than Ligand B (0.131), indicating lower cardiotoxicity risk. This is particularly important for a cardiovascular target.
12. **Cl_mic:** Ligand B (-9.68) has a *negative* microsomal clearance, which is highly unusual and suggests very high metabolic stability. Ligand A (49.91) is more typical.
13. **t1/2:** Ligand B (11.72) has a longer half-life than Ligand A (-14.06). This is a significant advantage.
14. **Pgp:** Ligand A (0.179) is better than Ligand B (0.032), indicating lower P-gp efflux.
15. **Binding Affinity:** Ligand B (-7.9) has a significantly better binding affinity than Ligand A (-5.4). This is a 2.5 kcal/mol difference, which is substantial.
**Overall Assessment and GPCR-Specific Priorities:**
For a GPCR like ADRB2, affinity, logP, and metabolic stability are key. Ligand B excels in affinity and has a remarkably high metabolic stability (negative Cl_mic). While Ligand A has better TPSA, solubility, and a much lower DILI risk, the substantial affinity advantage of Ligand B outweighs these benefits. The slightly lower logP of Ligand B is a minor concern, and can potentially be addressed through further optimization. The longer half-life of Ligand B is also a significant positive.
Output:
0
2025-04-17 19:17:30,118 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (349.479) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (59) is significantly better than Ligand A (98.17). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have excellent logP values (3.423 and 3.331) falling within the optimal 1-3 range.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand B (5) has more HBA than Ligand A (3), but both are acceptable.
6. **QED:** Ligand B (0.777) has a substantially better QED score than Ligand A (0.283), indicating a more drug-like profile.
7. **DILI:** Ligand A (32.183) has a lower DILI risk than Ligand B (44.591), which is a significant advantage.
8. **BBB:** Both are moderate, but Ligand A (62.97) is slightly better. This isn't a major factor for a cardiovascular target.
9. **Caco-2:** Both are negative, indicating poor permeability.
10. **Solubility:** Both are negative, indicating poor solubility.
11. **hERG:** Ligand A (0.38) has a much lower hERG risk than Ligand B (0.537), which is critical for cardiovascular drugs.
12. **Cl_mic:** Ligand B (43.49) has lower microsomal clearance than Ligand A (62.211), suggesting better metabolic stability.
13. **t1/2:** Ligand B (55.021) has a much longer in vitro half-life than Ligand A (12.37), which is a major advantage.
14. **Pgp:** Ligand A (0.044) has significantly lower P-gp efflux liability than Ligand B (0.636), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand A (-6.9 kcal/mol) has a slightly better binding affinity than Ligand B (-5.2 kcal/mol), a difference of 1.7 kcal/mol.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A excels in affinity and Pgp, while Ligand B is better in TPSA and metabolic stability (Cl_mic, t1/2). The difference in affinity (1.7 kcal/mol) is substantial enough to outweigh the other benefits of Ligand B, especially considering the lower hERG risk of Ligand A. The QED score of Ligand B is good, but the DILI risk is concerning.
**Conclusion:**
Considering the balance of properties, particularly the superior affinity and lower hERG risk of Ligand A, I believe it is the more promising drug candidate for ADRB2.
Output:
1
2025-04-17 19:17:30,118 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (344.415 and 350.423 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (70.84) is significantly better than Ligand B (118.01). ADRB2 is a cardiovascular target, not necessarily CNS, but lower TPSA generally aids absorption. Ligand B is pushing the upper limit for good oral absorption.
3. **logP:** Ligand A (1.832) is optimal. Ligand B (-0.396) is a bit low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (6). Fewer HBAs generally improve permeability.
6. **QED:** Ligand A (0.916) is excellent, indicating high drug-likeness. Ligand B (0.56) is acceptable but less optimal.
7. **DILI:** Ligand A (37.999) has a lower DILI risk than Ligand B (42.962), both are good.
8. **BBB:** Ligand A (94.998) has much higher BBB penetration than Ligand B (49.942). While ADRB2 isn't a primary CNS target, higher BBB penetration can sometimes indicate better overall distribution characteristics.
9. **Caco-2:** Ligand A (-4.729) is better than Ligand B (-5.263). Higher Caco-2 values indicate better intestinal absorption.
10. **Solubility:** Ligand A (-1.54) is slightly better than Ligand B (-1.665). Both are similar.
11. **hERG:** Ligand A (0.473) is significantly better than Ligand B (0.164). Lower hERG inhibition is crucial to avoid cardiotoxicity, especially for a cardiovascular target.
12. **Cl_mic:** Ligand A (30.658) has lower microsomal clearance than Ligand B (14.928), suggesting better metabolic stability.
13. **t1/2:** Ligand A (14.362) has a longer half-life than Ligand B (6.288). This is desirable for less frequent dosing.
14. **Pgp:** Ligand A (0.037) has lower P-gp efflux than Ligand B (0.01). Lower P-gp efflux improves bioavailability.
15. **Binding Affinity:** Ligand A (-7.5) has a slightly better binding affinity than Ligand B (-5.3). While the difference is 2.2 kcal/mol, it's a substantial advantage.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A excels in all these areas. The significantly better TPSA, logP, hERG, Cl_mic, t1/2, Pgp, and affinity of Ligand A outweigh any minor advantages Ligand B might have.
Output:
1
2025-04-17 19:17:30,118 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Step-by-step comparison:**
1. **MW:** Both ligands (346.5 and 348.4 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (40.62) is significantly better than Ligand B (76.46). ADRB2 is not a CNS target, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (3.476) is optimal, while Ligand B (1.278) is a bit low, potentially hindering membrane permeability.
4. **HBD:** Both have acceptable HBD counts (0 for A, 1 for B).
5. **HBA:** Ligand A (2) is better than Ligand B (5). Lower HBA is generally preferred for permeability.
6. **QED:** Both ligands have good QED scores (0.715 and 0.753), indicating good drug-likeness.
7. **DILI:** Ligand A (12.4) has a much lower DILI risk than Ligand B (43.1). This is a significant advantage.
8. **BBB:** Not a primary concern for ADRB2, but Ligand A (85.1) is better than Ligand B (56.2).
9. **Caco-2:** Ligand A (-4.451) and Ligand B (-5.017) are both negative, indicating poor permeability.
10. **Solubility:** Ligand A (-3.415) is better than Ligand B (-1.357), though both are poor.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.53 and 0.096).
12. **Cl_mic:** Ligand A (78.994) has a higher clearance than Ligand B (20.023), indicating lower metabolic stability. This favors Ligand B.
13. **t1/2:** Ligand A (-4.507) and Ligand B (-4.051) are similar.
14. **Pgp:** Ligand A (0.384) is better than Ligand B (0.04), indicating less P-gp efflux.
15. **Affinity:** Ligand B (-6.6) has a slightly better binding affinity than Ligand A (-6.0), but the difference is not substantial enough to outweigh other factors.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Ligand A is better in logP, TPSA, and Pgp. The affinity difference is small.
**Overall Assessment:**
Ligand A has a significantly better safety profile (lower DILI), better permeability characteristics (lower TPSA, better logP, better Pgp), and acceptable affinity. While Ligand B has better metabolic stability (lower Cl_mic), the other advantages of Ligand A are more crucial for overall drug development success. The solubility of both is poor, but can be addressed with formulation strategies.
Output:
1
2025-04-17 19:17:30,119 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (421.733 Da) is slightly higher than Ligand B (346.431 Da), but both are acceptable.
**2. TPSA:** Ligand A (75.27) is better than Ligand B (85.25). For a cardiovascular GPCR, TPSA should be <140, and both are well within this limit. Lower TPSA generally favors better membrane permeability.
**3. logP:** Ligand A (4.587) is higher than Ligand B (0.548). While the optimal range is 1-3, Ligand A is pushing the upper limit. Ligand B is quite low, potentially indicating poor membrane permeability.
**4. H-Bond Donors:** Both ligands have 2 HBD, which is within the acceptable limit of <=5.
**5. H-Bond Acceptors:** Ligand A has 3 HBA, while Ligand B has 5. Both are within the acceptable limit of <=10.
**6. QED:** Both ligands have similar QED values (0.716 and 0.673), indicating good drug-like properties.
**7. DILI Risk:** Ligand A (90.539) has a significantly higher DILI risk than Ligand B (48.197). This is a major concern for Ligand A.
**8. BBB Penetration:** Ligand A (43.815) has lower BBB penetration than Ligand B (54.595). While not a primary concern for a cardiovascular target, some CNS exposure can sometimes lead to off-target effects.
**9. Caco-2 Permeability:** Ligand A (-4.684) shows poor Caco-2 permeability, while Ligand B (-5.002) is also poor. Both are unfavorable.
**10. Aqueous Solubility:** Ligand A (-5.011) has slightly better solubility than Ligand B (-1.223), but both are quite poor.
**11. hERG Inhibition:** Ligand A (0.623) has a slightly higher hERG inhibition risk than Ligand B (0.322), but both are relatively low.
**12. Microsomal Clearance:** Ligand A (12.643) has higher microsomal clearance than Ligand B (4.431), indicating lower metabolic stability.
**13. In vitro Half-Life:** Ligand A (139.182) has a much longer half-life than Ligand B (-1.24). This is a significant advantage for Ligand A.
**14. P-gp Efflux:** Ligand A (0.489) has lower P-gp efflux than Ligand B (0.047), which is favorable.
**15. Binding Affinity:** Ligand B (-6.0) has a slightly better binding affinity than Ligand A (-5.7). However, the difference is not substantial enough to outweigh other factors.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand B appears more promising despite its lower affinity. Ligand A's high DILI risk and poor Caco-2 permeability are major drawbacks. Although Ligand A has a longer half-life and lower P-gp efflux, the safety concerns and absorption issues outweigh these benefits. Ligand B, while having lower logP, is better balanced overall, with a significantly lower DILI risk.
Output:
0
2025-04-17 19:17:30,119 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [364.511, 69.64, 2.349, 2, 4, 0.862, 39.046, 48.391, -4.907, -2.721, 0.458, 17.274, 31.142, 0.207, -4.2]
**Ligand B:** [342.399, 107.11, 0.816, 4, 4, 0.597, 51.725, 41.218, -5.461, -3.165, 0.268, -10.452, -2.386, 0.028, -5.8]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (342.399) is slightly lower, which could be advantageous for permeability, but both are acceptable.
2. **TPSA:** Ligand A (69.64) is significantly better than Ligand B (107.11). For a GPCR, keeping TPSA low is good, and A is well under the 140 threshold. B is getting closer to a concerning level.
3. **logP:** Ligand A (2.349) is optimal. Ligand B (0.816) is a bit low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (2) is preferable to Ligand B (4). Fewer HBDs generally improve permeability.
5. **HBA:** Both have 4 HBA, which is acceptable.
6. **QED:** Ligand A (0.862) is better than Ligand B (0.597), indicating a more drug-like profile.
7. **DILI:** Ligand A (39.046) has a lower DILI risk than Ligand B (51.725). Both are acceptable, but A is preferable.
8. **BBB:** Ligand A (48.391) is better than Ligand B (41.218), though neither is particularly high. Since this is a cardiovascular target, BBB penetration isn't *critical*, but it's still a positive.
9. **Caco-2:** Ligand A (-4.907) is better than Ligand B (-5.461), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-2.721) is better than Ligand B (-3.165).
11. **hERG:** Both are very low, indicating low cardiotoxicity risk. Ligand A (0.458) is slightly better than Ligand B (0.268).
12. **Cl_mic:** Ligand A (17.274) has a better (lower) microsomal clearance than Ligand B (-10.452), suggesting better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand A (31.142) has a longer in vitro half-life than Ligand B (-2.386). This is a significant advantage.
14. **Pgp:** Ligand A (0.207) has lower P-gp efflux than Ligand B (0.028), indicating better bioavailability.
15. **Affinity:** Ligand B (-5.8) has a slightly better binding affinity than Ligand A (-4.2). This is a 1.6 kcal/mol difference, which is significant.
**Overall Assessment:**
While Ligand B has a slightly better binding affinity, Ligand A consistently outperforms it across almost all ADME-Tox properties. The differences in TPSA, logP, QED, DILI, Cl_mic, t1/2, and Pgp are all substantial and favor Ligand A. For a GPCR, a balance of potency *and* good drug-like properties is crucial. The improved ADME profile of Ligand A outweighs the slightly weaker binding affinity.
**Output:**
1
2025-04-17 19:17:30,119 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (407.312 Da) is slightly higher than Ligand B (356.388 Da), but both are acceptable.
**2. TPSA:** Ligand A (79.9) is higher than Ligand B (61.36). For a GPCR, lower TPSA is generally preferred for better permeability, giving a slight edge to Ligand B.
**3. logP:** Both ligands have similar and optimal logP values (Ligand A: 3.346, Ligand B: 3.476), falling within the 1-3 range.
**4. H-Bond Donors:** Ligand A (2) is better than Ligand B (3). Fewer HBDs are generally preferred for permeability.
**5. H-Bond Acceptors:** Ligand A (4) is better than Ligand B (2).
**6. QED:** Both ligands have similar QED values (Ligand A: 0.77, Ligand B: 0.708), indicating good drug-likeness.
**7. DILI Risk:** Ligand B (15.083) has a significantly lower DILI risk than Ligand A (53.432). This is a major advantage for Ligand B.
**8. BBB Penetration:** Ligand A (74.952) has better BBB penetration than Ligand B (55.797). While ADRB2 is not strictly a CNS target, some CNS exposure could be beneficial or at least not detrimental, so this is a slight positive for Ligand A.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and requires further investigation. However, the values are similar (-4.936 for A, -4.725 for B).
**10. Aqueous Solubility:** Both ligands have negative solubility values, which is also unusual and requires further investigation. The values are similar (-5.187 for A, -4.183 for B).
**11. hERG Inhibition:** Ligand A (0.541) has a slightly lower hERG risk than Ligand B (0.656), which is preferable.
**12. Microsomal Clearance:** Ligand B (8.213) has significantly lower microsomal clearance than Ligand A (61.149), indicating better metabolic stability. This is a significant advantage for Ligand B.
**13. In vitro Half-Life:** Ligand B (6.189) has a slightly longer half-life than Ligand A (22.184).
**14. P-gp Efflux:** Ligand A (0.559) has lower P-gp efflux than Ligand B (0.148), which is preferable.
**15. Binding Affinity:** Ligand B (-6.5 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.0 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME drawbacks of Ligand A.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand B is the stronger candidate. While Ligand A has better BBB penetration and P-gp efflux, Ligand B's significantly better binding affinity, lower DILI risk, and lower microsomal clearance are more critical for a viable drug candidate. The similar logP values and acceptable TPSA for both compounds further support this conclusion. The unusual Caco-2 and solubility values would need to be investigated, but the overall profile of Ligand B is more promising.
Output:
0
2025-04-17 19:17:30,119 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, the priorities are logP, Pgp, TPSA, affinity, and, to a lesser extent, BBB.
Let's break down the comparison:
1. **MW:** Both ligands (361.471 and 357.47 Da) are within the ideal 200-500 Da range.
2. **TPSA:** Both ligands (72.28 and 72.88) are below the 140 A^2 threshold for good oral absorption, which is good.
3. **logP:** Ligand A (2.08) is optimal, while Ligand B (0.933) is slightly below the preferred range of 1-3, potentially impacting permeability.
4. **HBD/HBA:** Ligand A has 1 HBD and 7 HBA, while Ligand B has 2 HBD and 4 HBA. Both are within acceptable limits.
5. **QED:** Ligand A (0.883) has a better QED score than Ligand B (0.742), indicating better overall drug-likeness.
6. **DILI:** Ligand B (7.445) has a significantly lower DILI risk than Ligand A (66.072), which is a major advantage.
7. **BBB:** Ligand A (75.145) has a slightly better BBB penetration than Ligand B (63.513), but BBB is less crucial for a cardiovascular target.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
9. **Solubility:** Both ligands have negative solubility values, which is also unusual and suggests poor solubility.
10. **hERG:** Both ligands have low hERG inhibition risk (0.489 and 0.424).
11. **Cl_mic:** Ligand B (-17.728) has a *much* lower (and therefore better) microsomal clearance than Ligand A (25.879), indicating greater metabolic stability.
12. **t1/2:** Ligand A (28.921) has a longer in vitro half-life than Ligand B (-4.189).
13. **Pgp:** Ligand A (0.153) has lower P-gp efflux than Ligand B (0.026), which is favorable.
14. **Affinity:** Ligand A (-6.7 kcal/mol) has a slightly better binding affinity than Ligand B (-5.4 kcal/mol). The difference is 1.3 kcal/mol, which is significant.
**Overall Assessment:**
Ligand A has a better binding affinity and Pgp profile, and a longer half-life. However, Ligand B has a significantly lower DILI risk and *much* better metabolic stability (lower Cl_mic). The lower logP of Ligand B is a concern, but the substantial improvement in metabolic stability and DILI risk outweighs this drawback, especially for a cardiovascular target where CNS penetration is not paramount. The affinity difference, while present, isn't large enough to overcome the ADME advantages of Ligand B.
**Output:**
0
2025-04-17 19:17:30,119 - INFO - Batch 99 complete. Total preferences: 1584
2025-04-17 19:17:30,119 - INFO - Processing batch 100/512...
2025-04-17 19:18:22,605 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [402.519, 109.41 , 2.014, 2. , 6. , 0.768, 96.045, 39.046, -5.613, -2.833, 0.229, -4.102, 89.177, 0.207, -6.2 ]
**Ligand B:** [359.495, 66.32 , 3.958, 1. , 5. , 0.877, 24.118, 58.472, -4.722, -4.334, 0.4 , 61.255, -11.665, 0.026, -9.7 ]
**Step-by-step comparison:**
1. **MW:** Ligand A (402.519) is within the ideal range (200-500 Da). Ligand B (359.495) is also good. No clear advantage here.
2. **TPSA:** Ligand A (109.41) is slightly above the preferred <140 for oral absorption, but acceptable. Ligand B (66.32) is excellent, well below 140. Advantage: B.
3. **logP:** Ligand A (2.014) is optimal (1-3). Ligand B (3.958) is getting towards the upper limit, but still acceptable. Slight advantage: A.
4. **HBD:** Ligand A (2) and Ligand B (1) are both good, under the limit of 5. Advantage: B (slightly lower is often preferred).
5. **HBA:** Ligand A (6) and Ligand B (5) are both good, under the limit of 10. Advantage: B (slightly lower is often preferred).
6. **QED:** Both ligands have good QED scores (A: 0.768, B: 0.877). Advantage: B.
7. **DILI:** Ligand A (96.045) has a very high DILI risk. This is a major concern. Ligand B (24.118) has a low DILI risk. Significant advantage: B.
8. **BBB:** Ligand A (39.046) has poor BBB penetration. Ligand B (58.472) has moderate penetration. Advantage: B.
9. **Caco-2:** Ligand A (-5.613) has poor Caco-2 permeability. Ligand B (-4.722) is slightly better, but still poor. No clear advantage.
10. **Solubility:** Ligand A (-2.833) has poor solubility. Ligand B (-4.334) has even worse solubility. No clear advantage.
11. **hERG:** Ligand A (0.229) has low hERG risk. Ligand B (0.4) has slightly higher hERG risk, but still acceptable. Advantage: A.
12. **Cl_mic:** Ligand A (-4.102) has good metabolic stability (negative value). Ligand B (61.255) has relatively high metabolic clearance. Significant advantage: A.
13. **t1/2:** Ligand A (89.177) has a long in vitro half-life. Ligand B (-11.665) has a very short half-life. Significant advantage: A.
14. **Pgp:** Ligand A (0.207) has low P-gp efflux. Ligand B (0.026) has very low P-gp efflux. Advantage: B.
15. **Affinity:** Ligand B (-9.7) has a significantly stronger binding affinity than Ligand A (-6.2). This is a substantial advantage.
**GPCR-Specific Priorities:** For GPCRs, logP, TPSA, Pgp, and affinity are key. Ligand B excels in TPSA, Pgp, and *especially* affinity. Ligand A has a better logP and Cl_mic, but the DILI risk and poor BBB penetration are major drawbacks.
**Overall Assessment:**
Despite Ligand A's better metabolic stability and hERG profile, the extremely high DILI risk and poor BBB penetration are deal-breakers. Ligand B's superior affinity, lower DILI risk, better TPSA, and Pgp efflux profile outweigh its slightly higher logP and shorter half-life. The strong binding affinity is a significant advantage that can compensate for some ADME liabilities.
Output:
0
2025-04-17 19:18:22,606 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (359.8 and 376.4 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (80.55) is significantly better than Ligand B (98.66). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (3.064) is optimal, while Ligand B (1.273) is on the lower side. This could impact membrane permeability for Ligand B.
4. **HBD:** Ligand A (2) is preferable to Ligand B (4). Fewer HBDs generally improve permeability.
5. **HBA:** Both ligands have 5 HBA, which is acceptable.
6. **QED:** Ligand A (0.733) has a better QED score than Ligand B (0.576), indicating a more drug-like profile.
7. **DILI:** Ligand B (38.852) has a much lower DILI risk than Ligand A (89.802). This is a significant advantage for Ligand B.
8. **BBB:** Not a major priority for a cardiovascular target. Ligand A (61.962) is slightly better than Ligand B (58.007).
9. **Caco-2:** Ligand A (-4.844) is better than Ligand B (-5.201), suggesting better intestinal absorption.
10. **Solubility:** Ligand A (-4.495) is better than Ligand B (-2.048), indicating better aqueous solubility.
11. **hERG:** Ligand A (0.603) is better than Ligand B (0.305), indicating lower hERG inhibition liability.
12. **Cl_mic:** Ligand B (-5.105) has a *much* lower (better) microsomal clearance than Ligand A (83.803), suggesting greater metabolic stability.
13. **t1/2:** Ligand B (9.297) has a longer in vitro half-life than Ligand A (32.142). This is a significant advantage.
14. **Pgp:** Ligand A (0.485) is better than Ligand B (0.032), indicating lower P-gp efflux.
15. **Affinity:** Ligand A (-7.7 kcal/mol) has a stronger binding affinity than Ligand B (-5.8 kcal/mol). This is a substantial advantage.
**GPCR-Specific Priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A excels in logP, TPSA, and affinity. Ligand B excels in metabolic stability (Cl_mic and t1/2) and has a significantly better DILI profile.
**Overall Assessment:**
The affinity difference (-7.7 vs -5.8) is substantial. While Ligand B has better metabolic stability and lower DILI, the potency advantage of Ligand A is likely to outweigh these benefits, especially considering the cardiovascular target. The better solubility and permeability predictions for Ligand A also contribute to its favorability. The DILI risk for Ligand A is concerning, but not prohibitive given the strong binding.
Output:
1
2025-04-17 19:18:22,606 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (349.43 & 344.42 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (90.23) is better than Ligand B (108.02). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (2.118) is better than Ligand A (0.786). A logP between 1-3 is optimal, and Ligand B falls comfortably within this range, while Ligand A is slightly below.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (2), but both are acceptable (<=5).
5. **HBA:** Both ligands have 5 HBA, which is acceptable (<=10).
6. **QED:** Both ligands have similar QED values (0.731 and 0.751), indicating good drug-likeness.
7. **DILI:** Ligand B (27.69%) has a lower DILI risk than Ligand A (30.44%), which is preferable.
8. **BBB:** Ligand B (70.03%) has better BBB penetration than Ligand A (60.64%). While not a primary concern for a cardiovascular target, it's a slight advantage.
9. **Caco-2:** Ligand A (-5.014) and Ligand B (-4.759) are similar, suggesting comparable intestinal absorption.
10. **Solubility:** Ligand A (-1.84) is better than Ligand B (-3.101). Better solubility is generally preferred.
11. **hERG:** Ligand A (0.47) has a lower hERG risk than Ligand B (0.333), which is a significant advantage.
12. **Cl_mic:** Ligand A (15.54) has a lower microsomal clearance than Ligand B (32.576), indicating better metabolic stability. This is a key advantage.
13. **t1/2:** Ligand A (40.627) has a much longer in vitro half-life than Ligand B (-20.282). This is a substantial benefit, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.26) has lower P-gp efflux than Ligand B (0.016), which is preferable.
15. **Affinity:** Ligand A (-6.8 kcal/mol) has a slightly better binding affinity than Ligand B (-6.0 kcal/mol). This 1.5 kcal/mol difference is significant and can outweigh some ADME drawbacks.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand B has a better logP and BBB penetration, but Ligand A has better TPSA, Pgp, metabolic stability (Cl_mic, t1/2), and a superior binding affinity. The binding affinity difference is the most important factor, and the improved metabolic stability and half-life of Ligand A are also crucial.
**Conclusion:**
Considering the balance of properties, especially the significantly better binding affinity, metabolic stability, and half-life, Ligand A is the more promising drug candidate.
Output:
1
2025-04-17 19:18:22,606 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (a GPCR) drug candidates.
**Ligand A:** [345.403, 100.21 , 0.009, 2. , 5. , 0.783, 41.256, 59.364, -5.582, -1.885, 0.086, -6.86 , 0.589, 0.005, -6.1 ]
**Ligand B:** [347.463, 77.57 , 0.943, 2. , 5. , 0.65 , 13.959, 66.227, -5.237, -0.876, 0.469, -12.319, 11.134, 0.01 , -7.1 ]
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). A: 345.4, B: 347.5 - very similar.
2. **TPSA:** Ligand A (100.21) is slightly higher than Ligand B (77.57). Both are acceptable for a non-CNS GPCR target like ADRB2, but B is better.
3. **logP:** Ligand A (0.009) is very low, potentially hindering membrane permeability. Ligand B (0.943) is much better, falling within the optimal range. This is a significant advantage for B.
4. **HBD:** Both have 2 HBD, which is good.
5. **HBA:** Both have 5 HBA, which is good.
6. **QED:** Ligand A (0.783) has a slightly better QED score than Ligand B (0.65), indicating a more drug-like profile.
7. **DILI:** Ligand A (41.26%) has a better DILI score than Ligand B (13.96%), indicating lower potential for liver injury.
8. **BBB:** Both are relatively low, which is fine for a cardiovascular target. Ligand B (66.23%) is slightly higher than A (59.36%).
9. **Caco-2:** Both are negative, indicating poor permeability.
10. **Solubility:** Both are negative, indicating poor solubility.
11. **hERG:** Ligand A (0.086) has a lower hERG risk than Ligand B (0.469), which is preferable.
12. **Cl_mic:** Ligand A (-6.86) has a lower (better) microsomal clearance than Ligand B (-12.319), suggesting greater metabolic stability.
13. **t1/2:** Ligand B (11.134) has a significantly longer in vitro half-life than Ligand A (0.589), which is a major advantage.
14. **Pgp:** Both are very low, indicating minimal P-gp efflux.
15. **Affinity:** Ligand B (-7.1 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.1 kcal/mol). This is a substantial advantage, potentially outweighing some ADME concerns.
**GPCR-Specific Priorities:** For ADRB2 (a GPCR), we prioritize logP, TPSA, affinity, and metabolic stability.
**Overall Assessment:**
Ligand B has a much better logP, significantly stronger binding affinity, and a longer half-life. While Ligand A has a slightly better QED, lower DILI risk, and lower hERG risk, the substantial advantage in affinity and logP for Ligand B outweighs these factors. The improved logP is crucial for membrane permeability and overall bioavailability. The longer half-life is also a major benefit.
Output:
0
2025-04-17 19:18:22,607 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's break down the comparison based on the provided guidelines and GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key).
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (381.57) is slightly higher than Ligand B (358.36), but this isn't a major concern.
2. **TPSA:** Ligand A (57.36) is significantly better than Ligand B (69.64). ADRB2 is not a CNS target, but lower TPSA generally correlates with better permeability.
3. **logP:** Ligand A (3.851) is at the upper end of the optimal range, while Ligand B (1.946) is at the lower end. While both are acceptable, a logP closer to 3 is generally preferred for good balance of solubility and permeability. Ligand A is better here.
4. **H-Bond Donors/Acceptors:** Both have 2 HBD and similar HBA counts (4 vs 3). This is acceptable for both.
5. **QED:** Ligand B (0.763) has a better QED score than Ligand A (0.459), indicating a more drug-like profile.
6. **DILI Risk:** Ligand B (40.985) has a lower DILI risk than Ligand A (58.395), which is a significant advantage.
7. **BBB:** Not a primary concern for ADRB2 (cardiovascular target), but Ligand B (59.325) has a higher BBB penetration than Ligand A (18.961).
8. **Caco-2 Permeability:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not defined, so it's hard to interpret.
9. **Aqueous Solubility:** Both have negative solubility values, which is also unusual. Again, the scale is undefined.
10. **hERG Inhibition:** Ligand A (0.522) has a slightly higher hERG risk than Ligand B (0.075). This is a significant advantage for Ligand B.
11. **Microsomal Clearance:** Ligand B (-4.467) has a *much* lower (better) microsomal clearance than Ligand A (117.997), indicating better metabolic stability.
12. **In vitro Half-Life:** Ligand B (-11.355) has a much longer in vitro half-life than Ligand A (35.224), which is highly desirable.
13. **P-gp Efflux:** Ligand A (0.303) has lower P-gp efflux than Ligand B (0.008), which is better.
14. **Binding Affinity:** Ligand B (-6.1 kcal/mol) has a slightly better binding affinity than Ligand A (-5.6 kcal/mol). While the difference is not huge, it's enough to be considered.
**Overall Assessment:**
While Ligand A has a slightly better logP and P-gp efflux, Ligand B overwhelmingly wins on critical ADME-Tox properties. Specifically, the significantly lower DILI risk, much better metabolic stability (lower Cl_mic and longer t1/2), and lower hERG risk are crucial advantages. The slightly better binding affinity of Ligand B further solidifies its position as the more promising candidate. The unusual negative values for Caco-2 and solubility are a concern for both, but the differences in other parameters are more impactful.
**Output:**
0
2025-04-17 19:18:22,607 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (351.422 Da and 354.401 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (91.32) is slightly higher than Ligand B (76.02). For a cardiovascular GPCR, TPSA is moderately important, and Ligand B's lower TPSA is preferable for potentially better absorption.
**3. logP:** Both ligands have good logP values (1.844 and 2.33), falling within the optimal 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability.
**4. H-Bond Donors:** Ligand A has 3 HBD, while Ligand B has 2. Both are acceptable, being within the guideline of <=5.
**5. H-Bond Acceptors:** Both ligands have 4 HBA, well within the acceptable limit of <=10.
**6. QED:** Both ligands have similar QED values (0.755 and 0.738), indicating good drug-likeness.
**7. DILI Risk:** Ligand A (44.862) has a lower DILI risk than Ligand B (52.423). This is a significant advantage for Ligand A.
**8. BBB Penetration:** Ligand B (73.943) has a considerably higher BBB penetration percentile than Ligand A (60.45). While ADRB2 is a cardiovascular target, some CNS off-target effects are always a consideration, and higher BBB penetration could be a drawback. However, for a GPCR, this isn't a dealbreaker.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.72 and -4.961). These values are unusual and likely indicate poor permeability *in vitro*. However, these values can be misleading, and *in vivo* permeability may differ.
**10. Aqueous Solubility:** Both ligands have negative solubility values (-1.898 and -2.933). This is concerning. Poor solubility can hinder bioavailability. Ligand B is slightly worse.
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.189 and 0.183). This is excellent.
**12. Microsomal Clearance:** Ligand A (2.851) has significantly lower microsomal clearance than Ligand B (15.806). Lower clearance means greater metabolic stability, a crucial factor for drug duration and dosing frequency.
**13. In vitro Half-Life:** Ligand A (1.431 hours) has a shorter half-life than Ligand B (-12.755 hours). This is a major drawback for Ligand A.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.031 and 0.063). This is favorable.
**15. Binding Affinity:** Ligand A (-7.2 kcal/mol) has a slightly better binding affinity than Ligand B (-6.8 kcal/mol). This 0.4 kcal/mol difference is meaningful, especially for a GPCR.
**Overall Assessment:**
Ligand A has a better safety profile (lower DILI), better metabolic stability (lower Cl_mic), and slightly better binding affinity. However, Ligand B has better BBB penetration and a significantly longer *in vitro* half-life. Both have poor solubility and permeability.
Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity) and the importance of metabolic stability for cardiovascular drugs, the slightly better affinity and lower clearance of Ligand A are more compelling than the longer half-life of Ligand B. The DILI risk is also a significant factor. The solubility and permeability issues would need to be addressed through formulation strategies regardless of which ligand is chosen.
Output:
1
2025-04-17 19:18:22,607 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [356.463, 85.89, 1.069, 2, 5, 0.604, 27.453, 72.237, -4.855, -1.865, 0.214, 36.318, -3.24, 0.023, -7.1]
**Ligand B:** [352.406, 75.71, 1.038, 1, 4, 0.767, 33.579, 83.715, -4.701, -2.296, 0.318, 21.48, -3.197, 0.064, -7.6]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). A (356.463) is slightly higher than B (352.406), but the difference is negligible.
2. **TPSA:** Both are good, below the 140 A^2 threshold for oral absorption. Ligand B (75.71) is better than A (85.89), closer to the 90 A^2 target for CNS penetration, although ADRB2 isn't necessarily a CNS target.
3. **logP:** Both are optimal (around 1.0), suggesting good permeability and avoiding solubility issues. A (1.069) is slightly higher than B (1.038), but again, a minor difference.
4. **HBD:** Both are acceptable (A: 2, B: 1). Lower is generally preferred, so B is slightly better.
5. **HBA:** Both are acceptable (A: 5, B: 4). Lower is generally preferred, so B is slightly better.
6. **QED:** Both are good, above 0.5, indicating drug-like properties. B (0.767) is better than A (0.604).
7. **DILI:** Both are low risk (A: 27.453, B: 33.579), well below the 40% threshold. B is slightly higher, but still very acceptable.
8. **BBB:** Ligand B (83.715) is significantly better than A (72.237) in terms of predicted BBB penetration. While ADRB2 isn't exclusively a CNS target, higher BBB penetration can be beneficial for overall distribution and potentially accessing peripheral sites.
9. **Caco-2:** Both are negative, indicating poor permeability. However, the scale is not specified, so it's difficult to interpret.
10. **Solubility:** Both are negative, indicating poor solubility. Again, the scale is not specified, so it's difficult to interpret.
11. **hERG:** Both are very low risk (A: 0.214, B: 0.318).
12. **Cl_mic:** Ligand B (21.48) has significantly lower microsomal clearance than A (36.318), indicating better metabolic stability. This is a significant advantage.
13. **t1/2:** Both have negative in vitro half-lives, which is not ideal. A (-3.24) is slightly better than B (-3.197).
14. **Pgp:** Both are very low (A: 0.023, B: 0.064), indicating minimal P-gp efflux.
15. **Affinity:** Ligand B (-7.6 kcal/mol) has a slightly better binding affinity than A (-7.1 kcal/mol). This is a 0.5 kcal/mol difference, which is a meaningful improvement.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Both ligands perform well on logP and Pgp. Ligand B is better on TPSA and significantly better on metabolic stability (Cl_mic). The affinity difference is also in favor of B.
**Conclusion:**
Considering the overall profile, Ligand B is the more promising candidate. Its superior metabolic stability, slightly better affinity, better TPSA, and higher predicted BBB penetration outweigh the minor disadvantages in DILI and half-life.
```
0
```
2025-04-17 19:18:22,607 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step Comparison:**
1. **MW:** Both ligands (353.47 & 347.46 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand B (70.59) is significantly better than Ligand A (98.14). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (2.389) is within the optimal range (1-3), while Ligand B (0.92) is at the lower end. While not terrible, lower logP can sometimes indicate permeability issues.
4. **HBD:** Both have acceptable HBD counts (2 and 1, respectively), well below the threshold of 5.
5. **HBA:** Both ligands have 6 HBA, which is acceptable.
6. **QED:** Ligand B (0.825) has a slightly better QED score than Ligand A (0.629), indicating a more drug-like profile.
7. **DILI:** Ligand B (19.04) has a *much* lower DILI risk than Ligand A (63.40). This is a significant advantage.
8. **BBB:** Both have good BBB penetration (71.77 & 81.58), but Ligand B is better.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.849) is slightly better than Ligand B (-5.146).
10. **Solubility:** Ligand B (-0.7) is better than Ligand A (-3.269).
11. **hERG:** Ligand A (0.136) has a slightly lower hERG risk than Ligand B (0.436), but both are low enough to not be a major concern.
12. **Cl_mic:** Ligand B (-7.222) has a *much* lower (better) microsomal clearance than Ligand A (89.70). This suggests better metabolic stability.
13. **t1/2:** Ligand B (11.173 hours) has a significantly longer in vitro half-life than Ligand A (-15.861 hours). This is a major advantage.
14. **Pgp:** Ligand A (0.103) has lower P-gp efflux than Ligand B (0.014), which is preferable.
15. **Binding Affinity:** Both ligands have very similar, excellent binding affinities (-5.9 and -6.9 kcal/mol). The difference of 1 kcal/mol is not enough to outweigh other factors.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, and metabolic stability (Cl_mic, t1/2) are important. Ligand B excels in TPSA, DILI, Cl_mic, and t1/2, while Ligand A has a slightly better logP and Pgp. The superior ADME properties of Ligand B, particularly the significantly lower DILI risk and better metabolic stability, are more important than the minor logP advantage of Ligand A.
**Conclusion:**
Ligand B is the more promising drug candidate due to its superior ADME profile, particularly its lower DILI risk, better metabolic stability, and longer half-life.
Output:
0
2025-04-17 19:18:22,607 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (446.252 Da) is higher, but still acceptable. Ligand B (352.475 Da) is slightly preferred here.
**2. TPSA:** Ligand A (77.11) is better than Ligand B (81.08). Both are reasonably good for oral absorption, being under 140, but lower is generally better.
**3. logP:** Ligand A (3.264) is within the optimal range (1-3), while Ligand B (1.004) is at the lower end. For a GPCR, a slightly higher logP is often beneficial for membrane permeability and receptor engagement. Ligand A is preferred.
**4. H-Bond Donors:** Ligand A (1) is better than Ligand B (2). Fewer HBDs generally improve permeability.
**5. H-Bond Acceptors:** Ligand A (6) is better than Ligand B (4). Similar to HBDs, fewer HBAs are generally preferred.
**6. QED:** Ligand B (0.791) is better than Ligand A (0.491). A higher QED suggests a more drug-like profile.
**7. DILI Risk:** Ligand B (10.12) is *significantly* better than Ligand A (93.602). This is a major advantage for Ligand B. High DILI risk is a serious concern.
**8. BBB Penetration:** Both ligands have similar BBB penetration (Ligand A: 62.699, Ligand B: 65.839). While not a primary concern for a cardiovascular target, it's good that neither is severely limited.
**9. Caco-2 Permeability:** Ligand A (-5.192) is worse than Ligand B (-4.612). Higher Caco-2 permeability is desirable.
**10. Aqueous Solubility:** Ligand A (-3.955) is worse than Ligand B (-2.477). Better solubility is generally preferred.
**11. hERG Inhibition:** Ligand A (0.802) is better than Ligand B (0.24). Lower hERG inhibition is crucial to avoid cardiotoxicity.
**12. Microsomal Clearance:** Ligand B (31.604) is much better than Ligand A (67.099). Lower clearance indicates greater metabolic stability.
**13. In vitro Half-Life:** Ligand A (109.451) is better than Ligand B (-4.958). A longer half-life is generally desirable.
**14. P-gp Efflux:** Ligand A (0.722) is better than Ligand B (0.016). Lower P-gp efflux is preferred.
**15. Binding Affinity:** Ligand B (-5.7) has a slightly better binding affinity than Ligand A (-6.0). While Ligand A is better, the difference is not substantial enough to outweigh other factors.
**Overall Assessment:**
Ligand B is significantly better due to its dramatically lower DILI risk (10.12 vs. 93.602). This is a critical factor. While Ligand A has some advantages in terms of half-life, P-gp efflux, and hERG, the DILI risk associated with Ligand A is unacceptable. Ligand B also has better QED, Caco-2 permeability, solubility, and metabolic stability. The slight difference in binding affinity is not enough to overcome the substantial safety concerns with Ligand A.
Output:
0
2025-04-17 19:18:22,608 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (364.431 and 361.446 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (134.9) is slightly higher than Ligand B (82.7). Ligand B is significantly better, being well below the 140 threshold for good oral absorption and closer to the ideal for GPCRs.
3. **logP:** Ligand A (-0.236) is quite low, potentially hindering permeability. Ligand B (3.559) is within the optimal 1-3 range. This is a substantial advantage for Ligand B.
4. **HBD:** Both ligands have acceptable HBD counts (4 and 3 respectively), below the threshold of 5.
5. **HBA:** Both ligands have acceptable HBA counts (7 and 5 respectively), below the threshold of 10.
6. **QED:** Both ligands have similar and good QED scores (0.538 and 0.536), indicating good drug-like properties.
7. **DILI:** Ligand A (54.323) has a lower DILI risk than Ligand B (86.002). This is a positive for Ligand A, but not overwhelmingly so.
8. **BBB:** Ligand B (70.415) has a better BBB penetration percentile than Ligand A (53.625). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be beneficial or at least not detrimental, and higher BBB is generally preferred.
9. **Caco-2:** Both ligands have similar negative Caco-2 values (-5.88 and -5.633), which is not ideal. However, this is less critical than other parameters.
10. **Solubility:** Ligand A (-2.58) has slightly better solubility than Ligand B (-4.083), but both are poor.
11. **hERG:** Ligand A (0.216) has a lower hERG risk than Ligand B (0.896). This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand A (-15.042) has a much lower (better) microsomal clearance than Ligand B (76.601). This indicates better metabolic stability for Ligand A.
13. **t1/2:** Ligand B (82.127) has a significantly longer in vitro half-life than Ligand A (-8.016). This is a major advantage for Ligand B.
14. **Pgp:** Ligand A (0.037) has a lower P-gp efflux liability than Ligand B (0.483), which is favorable.
15. **Binding Affinity:** Ligand A (-7.1) has a slightly better binding affinity than Ligand B (-6.3). While a 0.8 kcal/mol difference is noticeable, it's not a massive advantage, especially considering the other factors.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand B is more promising. Its superior logP and TPSA values suggest better permeability and absorption. The longer half-life is also a major plus. While Ligand A has advantages in DILI, hERG, Cl_mic and Pgp, the improvements in ADME properties with Ligand B outweigh these benefits. The slightly weaker affinity of Ligand B can potentially be optimized in later stages of drug development.
Output:
0
2025-04-17 19:18:22,608 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (339.355) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (112.91) is better than Ligand B (48.99), falling below the 140 threshold for good oral absorption. Ligand B is quite low, which is good, but potentially at the cost of solubility.
3. **logP:** Ligand A (1.414) is within the optimal range (1-3). Ligand B (4.641) is higher, potentially leading to solubility issues and off-target interactions, though not excessively high.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (1), but both are acceptable (<=5).
5. **HBA:** Ligand A (5) is higher than Ligand B (3), but both are acceptable (<=10).
6. **QED:** Both ligands have good QED values (A: 0.65, B: 0.813). Ligand B is slightly better.
7. **DILI:** Ligand A (81.621) has a significantly higher DILI risk than Ligand B (36.642). This is a major concern for Ligand A.
8. **BBB:** Ligand B (89.027) has a much higher BBB penetration score than Ligand A (45.909). While ADRB2 isn't strictly a CNS target, some CNS exposure can be relevant for off-target effects and overall safety.
9. **Caco-2:** Ligand A (-5.582) and Ligand B (-4.77) both have negative Caco-2 values, indicating poor permeability. This is a significant drawback for both.
10. **Solubility:** Ligand A (-3.284) has slightly better solubility than Ligand B (-4.642), but both are poor.
11. **hERG:** Ligand A (0.403) has a lower hERG risk than Ligand B (0.75), which is favorable.
12. **Cl_mic:** Ligand A (18.743) has a much lower microsomal clearance than Ligand B (70.174), indicating better metabolic stability.
13. **t1/2:** Ligand A (-7.151) has a significantly longer in vitro half-life than Ligand B (11.101).
14. **Pgp:** Ligand A (0.177) has a lower P-gp efflux liability than Ligand B (0.751), which is favorable.
15. **Affinity:** Ligand A (-6.8) has a slightly better binding affinity than Ligand B (-6.2), but the difference is small (0.6 kcal/mol).
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Ligand B has a better logP and Pgp profile, but a worse TPSA. The affinity difference is small. The biggest differentiator is the DILI risk and metabolic stability. Ligand A has a much higher DILI risk, and while Ligand B has a higher Cl_mic, Ligand A's significantly longer half-life is a strong positive.
**Overall Assessment:**
Despite the slightly better affinity of Ligand A, the significantly higher DILI risk and poorer BBB penetration are major drawbacks. Ligand B, while having a higher logP and lower TPSA, presents a much more favorable safety profile and better metabolic properties. The small difference in binding affinity doesn't outweigh these ADME/Tox concerns.
Output:
0
2025-04-17 19:18:22,608 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
We are targeting ADRB2, a GPCR, so the priorities are logP, TPSA, Pgp, BBB, and affinity. Let's break down each ligand across all parameters:
* **Molecular Weight:** Both ligands (348.49 and 347.46 Da) are within the ideal 200-500 Da range.
* **TPSA:** Ligand A (69.64) is better than Ligand B (82.43). Lower TPSA generally favors better absorption, crucial for oral bioavailability.
* **logP:** Both ligands have excellent logP values (2.08 and 1.99), falling within the optimal 1-3 range.
* **H-Bond Donors/Acceptors:** Ligand A has 2 HBD and 3 HBA, while Ligand B has 1 HBD and 4 HBA. Both are acceptable, but Ligand A's profile is slightly more favorable.
* **QED:** Both ligands have good QED scores (0.722 and 0.843), indicating good drug-like properties.
* **DILI:** Ligand A (13.07%) has a significantly lower DILI risk than Ligand B (24.16%). This is a major advantage.
* **BBB:** Ligand B (61.92%) has a better BBB penetration score than Ligand A (47.15%). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be beneficial, and minimizing off-target effects is valuable.
* **Caco-2 Permeability:** Both have negative Caco-2 values, which is unusual and requires further investigation. However, the values are similar (-4.623 vs -4.844).
* **Aqueous Solubility:** Both ligands have negative solubility values, which is also unusual and requires further investigation. The values are similar (-2.829 vs -1.906).
* **hERG:** Both ligands have very low hERG inhibition liability (0.141 and 0.156), which is excellent.
* **Microsomal Clearance:** Ligand B (6.65) has significantly lower microsomal clearance than Ligand A (22.69). Lower clearance indicates better metabolic stability.
* **In vitro Half-Life:** Ligand B (30.42) has a much longer in vitro half-life than Ligand A (-11.59). This is a significant advantage, potentially allowing for less frequent dosing.
* **P-gp Efflux:** Both ligands have low P-gp efflux liability (0.032 and 0.028), which is good.
* **Binding Affinity:** Ligand B (-7.7 kcal/mol) has a stronger binding affinity than Ligand A (-6.7 kcal/mol). This is a 1.0 kcal/mol difference, which is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand B has a significantly better binding affinity and metabolic stability (lower Cl_mic, longer t1/2). However, Ligand A has a much lower DILI risk and a slightly better TPSA. The stronger binding affinity of Ligand B is a critical advantage for a GPCR target. The longer half-life is also highly desirable. While the DILI risk for Ligand A is lower, it's still within an acceptable range, and the benefits of Ligand B's potency and PK profile outweigh this concern.
**Output:**
0
2025-04-17 19:18:22,608 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [338.451, 43.78, 1.861, 1, 3, 0.911, 17.642, 76.231, -4.753, -1.791, 0.809, 26.386, -12.703, 0.429, -7.3]
**Ligand B:** [350.419, 85.69, 0.777, 1, 6, 0.819, 54.634, 73.905, -4.856, -1.75, 0.156, 14.062, 22.553, 0.038, -6.2]
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (338.451) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (43.78) is significantly better than Ligand B (85.69). For a GPCR, keeping TPSA low is good, but not as critical as for CNS targets. Ligand B is quite high, potentially hindering absorption.
3. **logP:** Ligand A (1.861) is within the optimal range, while Ligand B (0.777) is a bit low. Lower logP can lead to poor membrane permeability.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A (3) is better than Ligand B (6). Higher HBA can sometimes reduce permeability.
6. **QED:** Both are good (A: 0.911, B: 0.819), indicating drug-like properties.
7. **DILI:** Ligand A (17.642) has a much lower DILI risk than Ligand B (54.634). This is a significant advantage.
8. **BBB:** Both have reasonable BBB penetration (A: 76.231, B: 73.905), but A is slightly better. For a cardiovascular target, BBB penetration isn't *essential* but can be beneficial for off-target effects.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
10. **Solubility:** Both have negative solubility values, which is also unusual. Again, the scale is unknown.
11. **hERG:** Ligand A (0.809) has a lower hERG risk than Ligand B (0.156). This is a critical safety parameter.
12. **Cl_mic:** Ligand A (26.386) has a higher (worse) microsomal clearance than Ligand B (14.062), suggesting faster metabolism.
13. **t1/2:** Ligand A (-12.703) has a negative in vitro half-life, which is concerning. Ligand B (22.553) has a positive, and more reasonable half-life.
14. **Pgp:** Ligand A (0.429) has lower P-gp efflux than Ligand B (0.038), which is favorable for bioavailability.
15. **Affinity:** Ligand A (-7.3) has a significantly stronger binding affinity than Ligand B (-6.2). This is a 1.1 kcal/mol difference, which is substantial.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, and affinity. Ligand A excels in affinity and Pgp, and has a better logP and TPSA. While Ligand B has a better half-life, the significantly better affinity of Ligand A, coupled with the lower DILI and hERG risks, outweighs the metabolic stability concern. The negative values for Caco-2 and solubility are concerning for both, but the superior binding affinity of Ligand A makes it more likely to be optimized.
**Conclusion:**
Ligand A is the more promising candidate due to its superior binding affinity, lower DILI and hERG risk, and better logP and TPSA. The faster metabolism is a drawback, but potentially addressable through structural modifications.
**Output:**
1
2025-04-17 19:18:22,608 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (352.479 Da) is within the ideal range (200-500 Da). Ligand B (383.901 Da) is also acceptable. No clear advantage here.
2. **TPSA:** Ligand A (64.17) is excellent, well below the 140 threshold for oral absorption. Ligand B (83.36) is still reasonable, but higher. A favors here.
3. **logP:** Ligand A (0.112) is quite low, potentially hindering permeability. Ligand B (3.145) is within the optimal range (1-3). B is significantly better.
4. **HBD:** Ligand A (0) is good. Ligand B (3) is acceptable, but higher. A is slightly favored.
5. **HBA:** Ligand A (4) is good. Ligand B (5) is acceptable. A is slightly favored.
6. **QED:** Ligand A (0.659) is good, above the 0.5 threshold. Ligand B (0.52) is acceptable, but lower. A is favored.
7. **DILI:** Ligand A (7.716) has a very low DILI risk. Ligand B (56.572) is higher, indicating a moderate risk. A is strongly favored.
8. **BBB:** Ligand A (79.411) shows good BBB penetration. Ligand B (48.662) is lower. Given that ADRB2 is a GPCR, BBB penetration is a consideration, favoring A.
9. **Caco-2:** Ligand A (-4.586) is very poor. Ligand B (-5.081) is also poor. Both are unfavorable, but similar.
10. **Solubility:** Ligand A (-0.318) is poor. Ligand B (-4.296) is even worse. Both are unfavorable, but B is worse.
11. **hERG:** Ligand A (0.221) has very low hERG inhibition risk. Ligand B (0.196) is also very low. Similar.
12. **Cl_mic:** Ligand A (0.036) has very low clearance, indicating good metabolic stability. Ligand B (43.814) has high clearance, indicating poor metabolic stability. A is strongly favored.
13. **t1/2:** Ligand A (-28.879) is very long, suggesting a long half-life. Ligand B (4.494) is short. A is strongly favored.
14. **Pgp:** Ligand A (0.007) has very low P-gp efflux. Ligand B (0.132) is slightly higher, but still low. A is slightly favored.
15. **Affinity:** Ligand B (-6.8 kcal/mol) has a slightly better binding affinity than Ligand A (-6.3 kcal/mol). This is a 0.5 kcal/mol difference, which is not a huge advantage.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B in most crucial ADME-Tox properties (DILI, Cl_mic, t1/2, BBB, QED, TPSA). While Ligand B has a slightly better binding affinity, the significant advantages of Ligand A in safety (DILI, hERG) and pharmacokinetic properties (Cl_mic, t1/2, BBB) outweigh this small difference in potency. The poor Caco-2 and solubility of both are concerns, but can be addressed with formulation strategies. Given the GPCR target class, the improved BBB penetration of A is also a significant advantage.
Output:
1
2025-04-17 19:18:22,609 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's break down the comparison of Ligand A and Ligand B, considering the provided guidelines and the GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key).
1. **Molecular Weight:** Both ligands (371.384 Da and 346.475 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (56.15) is significantly better than Ligand B (76.02). ADRB2 is not a CNS target, but lower TPSA generally correlates with better permeability.
3. **logP:** Both ligands have good logP values (2.919 and 2.354, respectively), falling within the optimal 1-3 range. Ligand A is slightly higher, which might be beneficial for membrane permeability.
4. **H-Bond Donors:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **H-Bond Acceptors:** Ligand A (5) is preferable to Ligand B (4). Fewer HBAs generally improve permeability.
6. **QED:** Both ligands have similar QED values (0.821 and 0.796), indicating good drug-likeness.
7. **DILI:** Ligand B (29.895) has a *much* lower DILI risk than Ligand A (55.332). This is a major advantage for Ligand B.
8. **BBB:** This isn't a primary concern for ADRB2, but Ligand A (84.878) has a higher BBB penetration percentile than Ligand B (64.172).
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.964 and -4.873). These values are unusual and suggest poor permeability.
10. **Solubility:** Both ligands have negative solubility values (-3.82 and -2.817). These values are also unusual and suggest poor solubility.
11. **hERG:** Both ligands have low hERG inhibition liability (0.342 and 0.488). This is good, indicating a low risk of cardiotoxicity.
12. **Cl_mic:** Both ligands have similar microsomal clearance values (44.271 and 41.066).
13. **t1/2:** Ligand B (-9.902) has a significantly longer in vitro half-life than Ligand A (11.701). This is a substantial advantage for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.497) has a slightly lower Pgp efflux liability than Ligand B (0.169), which is favorable.
15. **Binding Affinity:** Ligand B (-6.3) has a slightly better binding affinity than Ligand A (-5.6). While the difference is less than the 1.5 kcal/mol threshold, it's still a positive for Ligand B.
**Overall Assessment:**
While Ligand A has slightly better TPSA, logP, Pgp and BBB, Ligand B has a significantly lower DILI risk and a much longer half-life. The lower DILI risk is a critical advantage, as liver toxicity is a major concern in drug development. The longer half-life is also a significant benefit. The slight affinity advantage of Ligand B further supports its selection. The negative Caco-2 and solubility values are concerning for both, but the other advantages of Ligand B outweigh these issues.
**Output:**
0
2025-04-17 19:18:22,609 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**1. Molecular Weight:** Both ligands (367.49 Da and 348.407 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (55.81) is significantly better than Ligand B (107.35). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is above the preferred threshold of 90.
**3. logP:** Ligand A (2.039) is within the optimal 1-3 range, while Ligand B (0.782) is slightly below 1. This could potentially hinder membrane permeability for Ligand B.
**4. H-Bond Donors:** Both ligands have 2 HBD, which is acceptable.
**5. H-Bond Acceptors:** Ligand A has 4 HBA, and Ligand B has 6. Both are within the acceptable limit of 10, but Ligand A is slightly preferred.
**6. QED:** Both ligands have similar QED values (0.836 and 0.769), indicating good drug-likeness.
**7. DILI:** Ligand A (20.822) has a much lower DILI risk than Ligand B (48.662). This is a significant advantage for Ligand A.
**8. BBB:** Ligand A (43.854) has a better BBB penetration percentile than Ligand B (20.085). While ADRB2 isn't exclusively a CNS target, some distribution into the CNS is possible, and higher BBB penetration is generally favorable.
**9. Caco-2:** Both ligands have negative Caco-2 values (-5.074 and -5.039), suggesting poor permeability. This is a concern for both.
**10. Solubility:** Both ligands have negative solubility values (-2.415 and -1.491), indicating poor aqueous solubility. This is a significant drawback for both, potentially impacting bioavailability.
**11. hERG:** Both ligands have very low hERG inhibition risk (0.784 and 0.228). This is excellent for both.
**12. Cl_mic:** Ligand A (3.049) has a much lower microsomal clearance than Ligand B (14.616), indicating better metabolic stability. This is a crucial advantage for Ligand A.
**13. t1/2:** Ligand A (30.937) has a significantly longer in vitro half-life than Ligand B (-16.365). This is a major advantage, suggesting less frequent dosing potential.
**14. Pgp:** Ligand A (0.158) has lower P-gp efflux liability than Ligand B (0.034). Lower Pgp is preferred.
**15. Binding Affinity:** Ligand B (-7.1) has a slightly better binding affinity than Ligand A (-5.3). However, the difference is less than 1.5 kcal/mol, and the other ADME properties of Ligand A are far superior.
**Overall Assessment:**
Ligand A clearly outperforms Ligand B across most critical ADME properties. While Ligand B has a slightly better binding affinity, the superior metabolic stability (lower Cl_mic, longer t1/2), lower DILI risk, better BBB penetration, and more favorable TPSA and logP values of Ligand A make it a much more promising drug candidate for the ADRB2 receptor. The poor Caco-2 and solubility for both are concerns that would need to be addressed through formulation strategies, but these are less critical than the metabolic and toxicity liabilities of Ligand B.
Output:
1
2025-04-17 19:18:22,609 - INFO - Batch 100 complete. Total preferences: 1600
2025-04-17 19:18:22,609 - INFO - Processing batch 101/512...
2025-04-17 19:19:11,456 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.459 and 344.459 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (93.43) is slightly higher than Ligand B (76.02). Both are below the 140 A^2 threshold for good oral absorption, but Ligand B is preferable due to being closer to the 90 A^2 threshold for potential CNS penetration (though ADRB2 isn't necessarily a CNS target).
3. **logP:** Both ligands have good logP values (1.893 and 2.429), falling within the optimal 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Both ligands have 2 H-bond donors, which is within the acceptable limit of 5. No difference.
5. **HBA:** Both ligands have 4 H-bond acceptors, also within the acceptable limit of 10. No difference.
6. **QED:** Ligand A (0.688) has a better QED score than Ligand B (0.505), indicating a more drug-like profile. This is a positive for Ligand A.
7. **DILI:** Ligand B (33.191) has a significantly lower DILI risk than Ligand A (8.375), which is a major advantage. Lower DILI is crucial for drug development.
8. **BBB:** Ligand A (70.143) has a higher BBB penetration percentile than Ligand B (57.619). While ADRB2 isn't a primary CNS target, some peripheral ADRB2 activity can influence CNS processes, so this is a slight advantage for A.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.914 and -4.957), indicating poor permeability. This is a concern for both.
10. **Solubility:** Both ligands have negative solubility values (-2.225 and -2.87), indicating poor aqueous solubility. This is a significant drawback for both and could hinder bioavailability.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.284 and 0.283). This is excellent.
12. **Cl_mic:** Ligand A (-10.182) has a much lower microsomal clearance than Ligand B (32.362), indicating better metabolic stability. This is a strong advantage for Ligand A.
13. **t1/2:** Ligand A (-14.6) has a more negative in vitro half-life, which is not ideal. Ligand B (11.545) has a better half life.
14. **Pgp:** Both ligands have similar Pgp efflux liability (0.02 and 0.088), indicating low efflux. No significant difference.
15. **Binding Affinity:** Ligand B (-5.8 kcal/mol) has a slightly better binding affinity than Ligand A (-4.7 kcal/mol). This 1.1 kcal/mol difference is substantial and could outweigh some of the ADME drawbacks.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B performs better on logP, TPSA, and significantly better on binding affinity. However, the DILI risk for Ligand A is much lower. Metabolic stability (Cl_mic) is also important, and Ligand A is superior in this regard.
**Overall Assessment:**
While Ligand A has a better QED and metabolic stability, the significantly lower DILI risk and superior binding affinity of Ligand B are more critical factors. The poor Caco-2 and solubility for both ligands are concerning, but these can potentially be addressed through formulation strategies. The stronger binding of Ligand B is likely to translate to greater efficacy, and the lower DILI risk is crucial for safety.
Output:
0
2025-04-17 19:19:11,456 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (367.515 and 346.475 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (78.51) is better than Ligand B (86.88). Both are below 140, but lower TPSA generally favors absorption.
3. **logP:** Ligand B (2.877) is closer to the optimal 1-3 range than Ligand A (1.152). While A isn't *bad*, B's logP suggests better membrane permeability.
4. **HBD:** Ligand A (2) is preferable to Ligand B (3). Lower HBDs are generally favored for permeability.
5. **HBA:** Ligand A (4) is preferable to Ligand B (3). Lower HBA is generally favored for permeability.
6. **QED:** Ligand A (0.784) has a significantly better QED score than Ligand B (0.569), indicating a more drug-like profile overall.
7. **DILI:** Ligand B (54.711) has a lower DILI risk than Ligand A (16.867), which is a significant advantage. Lower DILI is crucial.
8. **BBB:** Ligand A (57.774) and Ligand B (60.644) are similar, and both are not high enough to be considered CNS-penetrant. However, since ADRB2 is primarily a cardiovascular target, BBB penetration is not a primary concern.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.116 and -5.066), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Both ligands have negative solubility values (-3.131 and -3.871), indicating very poor aqueous solubility. This is a major drawback for both.
11. **hERG:** Ligand A (0.089) has a much lower hERG risk than Ligand B (0.329). This is a substantial advantage for Ligand A.
12. **Cl_mic:** Ligand A (36.44) has a lower microsomal clearance than Ligand B (74.143), indicating better metabolic stability.
13. **t1/2:** Ligand A (-14.517) has a more negative in vitro half-life than Ligand B (-11.932), which is not ideal.
14. **Pgp:** Ligand A (0.033) has a much lower P-gp efflux liability than Ligand B (0.188), suggesting better oral bioavailability and potentially better tissue distribution.
15. **Binding Affinity:** Ligand B (-6.0) has a slightly better binding affinity than Ligand A (-5.9), but the difference is small (0.1 kcal/mol).
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, and affinity are important. Ligand B has a better logP. However, Ligand A has better TPSA, QED, hERG, Cl_mic, and Pgp. The DILI risk is much lower for Ligand B. The affinity difference is minimal.
**Overall Assessment:**
Despite Ligand B's slightly better affinity and lower DILI, Ligand A is the more promising candidate. The significantly better QED, hERG profile, metabolic stability (lower Cl_mic), and lower P-gp efflux outweigh the minor affinity advantage of Ligand B. The poor solubility and Caco-2 values are concerns for both, but can potentially be addressed through formulation strategies. The lower DILI risk of Ligand B is attractive, but the other ADME properties of Ligand A are more favorable for overall drug development success.
Output:
1
2025-04-17 19:19:11,456 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands (366.355 and 349.475 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Both ligands (58.64 and 57.0) are well below the 140 A^2 threshold for good oral absorption, and suitable for a non-CNS GPCR target like ADRB2. No clear advantage.
3. **logP:** Both ligands (1.808 and 2.112) are within the optimal 1-3 range. No significant difference.
4. **HBD:** Ligand A (1) is slightly better than Ligand B (0) as it has one hydrogen bond donor. This can help with solubility.
5. **HBA:** Ligand B (4) has one more HBA than Ligand A (3). This isn't a major concern, but slightly favors A.
6. **QED:** Ligand A (0.755) has a slightly better QED score than Ligand B (0.641), indicating a more drug-like profile.
7. **DILI:** Ligand B (21.908) has a significantly lower DILI risk than Ligand A (32.997). This is a substantial advantage for Ligand B.
8. **BBB:** While not a primary concern for ADRB2 (a cardiovascular target), Ligand A (90.694) has a higher BBB penetration percentile than Ligand B (67.468).
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.651 and -4.768), which is unusual and suggests poor permeability. This is a significant drawback for both.
10. **Solubility:** Ligand B (-0.675) has better aqueous solubility than Ligand A (-2.381). This is a positive for Ligand B.
11. **hERG:** Both ligands have low hERG inhibition risk (0.419 and 0.554). No clear advantage.
12. **Cl_mic:** Ligand A (11.611) has a significantly lower microsomal clearance than Ligand B (60.492), indicating better metabolic stability. This is a major advantage for Ligand A.
13. **t1/2:** Ligand B (51.172) has a much longer in vitro half-life than Ligand A (-12.91). This is a substantial advantage for Ligand B.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.047 and 0.164). No clear advantage.
15. **Binding Affinity:** Both ligands have similar binding affinities (-6.6 and -6.1 kcal/mol). The difference is less than the 1.5 kcal/mol threshold.
**GPCR-specific priorities:** For ADRB2, logP, Pgp, TPSA, and affinity are key. Both ligands perform similarly on logP, Pgp, and TPSA. Affinity is also comparable. However, metabolic stability (Cl_mic) and DILI risk are important considerations. Ligand A has better metabolic stability, while Ligand B has a much lower DILI risk and longer half-life. The longer half-life of Ligand B is a significant advantage, potentially allowing for less frequent dosing. The lower DILI risk is also very important.
**Conclusion:**
Considering the balance of properties, particularly the lower DILI risk and longer half-life of Ligand B, I believe it is the more promising drug candidate despite the slightly higher metabolic clearance.
Output:
0
2025-04-17 19:19:11,456 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.5 & 359.3 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (49.85) is significantly better than Ligand B (91.32). ADRB2 is not a CNS target, but lower TPSA generally correlates with better permeability. Ligand A is well below the 140 threshold. Ligand B is approaching the upper limit.
3. **logP:** Both ligands have good logP values (2.711 and 2.144), falling within the optimal 1-3 range. Ligand A is slightly more lipophilic, which could be beneficial for membrane permeability.
4. **HBD:** Ligand A (0) is preferable to Ligand B (3). Fewer hydrogen bond donors generally improve permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (4). Fewer hydrogen bond acceptors generally improve permeability.
6. **QED:** Both ligands have acceptable QED values (0.692 and 0.751), indicating good drug-like properties. No clear advantage.
7. **DILI:** Ligand A (13.959) has a much lower DILI risk than Ligand B (41.489). This is a significant advantage for Ligand A.
8. **BBB:** Both ligands have similar BBB penetration (75.96 and 71.656). Not a primary concern for ADRB2, but higher is generally better.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
10. **Solubility:** Both ligands have negative solubility values, which is also unusual. Again, the scale is not specified.
11. **hERG:** Both ligands have low hERG inhibition risk (0.52 and 0.233), which is good. Ligand B is slightly better.
12. **Cl_mic:** Ligand A (70.401) has a higher microsomal clearance than Ligand B (10.128), suggesting lower metabolic stability. This is a significant drawback for Ligand A.
13. **t1/2:** Ligand B (-29.123) has a much longer in vitro half-life than Ligand A (3.15). This is a major advantage for Ligand B.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.068 and 0.031). No significant difference.
15. **Binding Affinity:** Ligand A (-7.0) has a slightly better binding affinity than Ligand B (-5.6). This is a 1.4 kcal/mol difference, which is substantial and can outweigh some ADME drawbacks.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A excels in logP, TPSA, and affinity. Ligand B excels in metabolic stability (Cl_mic, t1/2) and has a slightly better hERG profile. The DILI risk is also much lower for Ligand A.
**Overall Assessment:**
While Ligand A has a better binding affinity and lower DILI risk, the significantly better metabolic stability (lower Cl_mic and longer t1/2) of Ligand B is a crucial factor. A longer half-life translates to less frequent dosing and potentially better patient compliance. The slightly lower affinity of Ligand B can potentially be optimized in later stages of drug development. The lower DILI risk of Ligand A is attractive, but the metabolic liabilities of Ligand A are concerning.
Output:
0
2025-04-17 19:19:11,456 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (356.419 and 348.487 Da) are within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand B (58.64) is significantly better than Ligand A (102.96). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have acceptable logP values (1.355 and 2.511, respectively), falling within the 1-3 range. Ligand B is slightly better.
4. **HBD:** Ligand A (2) and Ligand B (1) are both good, below the threshold of 5. Ligand B is slightly better.
5. **HBA:** Ligand A (6) and Ligand B (3) are both acceptable, below the threshold of 10. Ligand B is better.
6. **QED:** Ligand B (0.751) is better than Ligand A (0.452), indicating a more drug-like profile.
7. **DILI:** Ligand B (24.738) is *much* better than Ligand A (59.403). This is a significant advantage for Ligand B.
8. **BBB:** Ligand B (76.076) is better than Ligand A (49.515), but neither is particularly high. This isn't a major factor for a cardiovascular target.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-5.222) is worse than Ligand B (-4.667).
10. **Solubility:** Both are negative, indicating poor solubility. Ligand A (-1.826) is worse than Ligand B (-3.159).
11. **hERG:** Both ligands have very low hERG inhibition risk (0.212 and 0.216). No significant difference.
12. **Cl_mic:** Ligand B (53.368) is slightly better than Ligand A (56.375), indicating slightly better metabolic stability.
13. **t1/2:** Ligand B (4.565) is better than Ligand A (-8.747).
14. **Pgp:** Both ligands have low Pgp efflux liability (0.129 and 0.078). Ligand B is slightly better.
15. **Binding Affinity:** Ligand A (-7.3) is better than Ligand B (-6.4). This is a 0.9 kcal/mol difference, which is substantial.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B has better logP, TPSA, and Pgp. However, Ligand A has a significantly better binding affinity. The affinity difference is large enough to outweigh the ADME advantages of Ligand B. The DILI risk for Ligand A is concerning, but the binding affinity is a strong driver.
**Overall Assessment:**
While Ligand B has a superior ADME profile, the significantly stronger binding affinity of Ligand A makes it the more promising candidate. The DILI risk is a concern that would need to be addressed in further optimization, but the potency advantage is substantial.
Output:
1
2025-04-17 19:19:11,456 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (351.412 and 344.455 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (21.26) is significantly better than Ligand B (58.64). ADRB2 is not a CNS target, but lower TPSA generally improves absorption. Ligand A is well below the 140 threshold. Ligand B is higher, potentially hindering absorption.
3. **logP:** Ligand A (4.869) is at the upper end of the optimal range (1-3), while Ligand B (2.163) is well within. Ligand A's higher logP *could* lead to solubility issues or off-target interactions, but is still acceptable.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 2 HBA, Ligand B has 3. Both are acceptable, below the 10 threshold.
6. **QED:** Both ligands have good QED scores (0.651 and 0.751), indicating good drug-like properties.
7. **DILI:** Both ligands have low DILI risk (19.116 and 21.791), both well below the 40 threshold.
8. **BBB:** Both ligands show reasonable BBB penetration (77.705 and 80.264). This isn't a primary concern for ADRB2, but it's not detrimental.
9. **Caco-2:** Both have negative Caco-2 values (-4.732 and -4.812). This is unusual and suggests poor permeability. However, these values are close and likely indicate a similar issue.
10. **Solubility:** Ligand A (-3.888) is slightly worse than Ligand B (-2.779). This is consistent with Ligand A's higher logP.
11. **hERG:** Both ligands have very low hERG risk (0.993 and 0.263).
12. **Cl_mic:** Ligand A (29.123) has significantly lower microsomal clearance than Ligand B (54.698), indicating better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand A (-10.146) has a more negative in vitro half-life, which is not ideal. Ligand B (17.249) has a positive half-life, which is much better.
14. **Pgp:** Ligand A (0.929) has lower P-gp efflux than Ligand B (0.084). Lower Pgp is generally better for bioavailability.
15. **Binding Affinity:** Ligand B (-6.8 kcal/mol) has a 1.1 kcal/mol stronger binding affinity than Ligand A (-5.7 kcal/mol). This is a substantial difference and a major advantage.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A has a better TPSA and Pgp, but Ligand B has a more favorable logP and significantly better binding affinity. The binding affinity difference is substantial enough to outweigh the slightly less favorable TPSA and logP of Ligand B.
**Overall Assessment:**
While Ligand A has better metabolic stability (Cl_mic) and Pgp properties, the significantly stronger binding affinity of Ligand B (-6.8 vs -5.7 kcal/mol) is the most critical factor. The difference in half-life is concerning for Ligand A. The slightly higher TPSA of Ligand B is not a dealbreaker.
Output:
0
2025-04-17 19:19:11,456 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (345.359) is slightly lower, which could be beneficial for permeability, but both are acceptable.
2. **TPSA:** Ligand B (78.68) is significantly better than Ligand A (106.51). ADRB2 is a cardiovascular target, not a CNS target, but lower TPSA generally improves absorption.
3. **logP:** Both ligands have acceptable logP values (A: 0.938, B: 2.046), falling within the 1-3 range. Ligand B is slightly better positioned.
4. **HBD:** Ligand A (3) is higher than Ligand B (1). While both are within the acceptable limit of 5, lower HBD is generally preferred for better permeability.
5. **HBA:** Ligand A (7) is higher than Ligand B (5). Again, both are within the acceptable limit of 10, but lower is preferable.
6. **QED:** Both ligands have good QED scores (A: 0.719, B: 0.799), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand B (54.556) has a significantly lower DILI risk than Ligand A (76.89). This is a major advantage for Ligand B.
8. **BBB:** Both ligands have high BBB penetration (A: 80.69, B: 78.48), but this is less critical for a cardiovascular target like ADRB2.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests a potential issue with the data or modeling. However, we can assume they both have low permeability.
10. **Solubility:** Both ligands have negative solubility values, which is also unusual. This suggests both compounds might have solubility issues.
11. **hERG:** Both ligands have low hERG inhibition liability (A: 0.266, B: 0.096). Ligand B is slightly better.
12. **Cl_mic:** Ligand A (12.514) has a significantly lower microsomal clearance than Ligand B (57.138), indicating better metabolic stability. This is a strong advantage for Ligand A.
13. **t1/2:** Ligand A (26.468) has a longer in vitro half-life than Ligand B (10.626). This is another significant advantage for Ligand A.
14. **Pgp:** Both ligands have very low P-gp efflux liability (A: 0.02, B: 0.064).
15. **Binding Affinity:** Ligand A (-7.8 kcal/mol) has a stronger binding affinity than Ligand B (-6.8 kcal/mol). This is a substantial advantage for Ligand A, potentially outweighing some ADME drawbacks.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand B has a better logP and TPSA, while Ligand A has significantly better affinity.
**Overall Assessment:**
Ligand A has a stronger binding affinity and better metabolic stability (lower Cl_mic, longer t1/2). The difference in affinity (-7.8 vs -6.8 kcal/mol) is substantial. While Ligand B has a lower DILI risk and better TPSA, the improved potency and metabolic stability of Ligand A are more critical for a successful drug candidate, especially given the relatively low priority of BBB for a cardiovascular target. The solubility and Caco-2 values are concerning for both, but the potency advantage of A is likely to be more impactful in early optimization.
Output:
1
2025-04-17 19:19:11,457 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (344.371 and 346.475 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (126.55) is slightly higher than Ligand B (83.98). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is generally preferred for absorption. Ligand B has a clear advantage.
3. **logP:** Ligand A (-0.725) is quite low, potentially hindering membrane permeability. Ligand B (2.544) is within the optimal 1-3 range. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (3) and Ligand B (2) are both acceptable, below the threshold of 5.
5. **HBA:** Ligand A (6) and Ligand B (4) are both acceptable, below the threshold of 10.
6. **QED:** Both ligands have good QED scores (0.647 and 0.795), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Both ligands have acceptable DILI risk (34.277 and 39.977), below the 40% threshold. No major difference.
8. **BBB:** Ligand A (21.171) has very low BBB penetration, while Ligand B (76.231) is moderately good. While ADRB2 isn't strictly a CNS target, some brain exposure can be relevant for off-target effects, and higher BBB is generally preferred. Ligand B is better.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.346 and -4.708), which is unusual and suggests poor permeability. This is a concern for both, but the values are similar.
10. **Solubility:** Both ligands have very poor solubility (-2.339 and -4.046). This is a significant drawback for both, and would require formulation strategies. Ligand B is slightly worse.
11. **hERG:** Both ligands have low hERG inhibition risk (0.157 and 0.196). No significant difference.
12. **Cl_mic:** Ligand A (-34.326) has a much lower (better) microsomal clearance than Ligand B (51.162), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (17.223 hours) has a much longer half-life than Ligand B (1 hour). This is a substantial advantage for Ligand A, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have very low Pgp efflux (0.003 and 0.044). No significant difference.
15. **Binding Affinity:** Ligand B (-6.5 kcal/mol) has a significantly stronger binding affinity than Ligand A (-1.3 kcal/mol). This is a *major* advantage for Ligand B, potentially outweighing some of the ADME concerns.
**Overall Assessment:**
Ligand B has a superior binding affinity and better logP and TPSA values. However, Ligand A exhibits much better metabolic stability (lower Cl_mic) and a significantly longer half-life. The poor solubility and Caco-2 values are concerning for both. Given the importance of potency for GPCRs, and the substantial difference in binding affinity (-6.5 vs -1.3 kcal/mol), I believe Ligand B is the more promising candidate, despite its metabolic liabilities. Formulation strategies could be explored to address the solubility issues.
Output:
0
2025-04-17 19:19:11,457 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (382.77 and 358.429 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (58.64) is significantly better than Ligand A (76.46). Lower TPSA generally improves permeability, crucial for GPCRs.
3. **logP:** Both ligands have good logP values (1.924 and 2.344), falling within the optimal 1-3 range. Ligand B is slightly better.
4. **HBD:** Both have 1 HBD, which is within the acceptable limit of 5.
5. **HBA:** Ligand A has 5 HBA, and Ligand B has 3. Both are below the 10 threshold.
6. **QED:** Both ligands have good QED scores (0.731 and 0.793), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand B (26.095) has a much lower DILI risk than Ligand A (65.258). This is a significant advantage for Ligand B.
8. **BBB:** Both ligands have high BBB penetration (87.398 and 90.617). This is good, but less critical for ADRB2, which is not a CNS target.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.754 and -4.545), which is unusual and indicates poor permeability. This is a major concern for both.
10. **Solubility:** Both ligands have negative solubility values (-3.213 and -2.298), indicating very poor aqueous solubility. This is a significant drawback for both.
11. **hERG:** Both ligands have low hERG inhibition liability (0.214 and 0.49). This is good.
12. **Cl_mic:** Ligand B (5.46) has significantly lower microsomal clearance than Ligand A (17.525). Lower clearance suggests better metabolic stability.
13. **t1/2:** Ligand B (7.37) has a longer in vitro half-life than Ligand A (-11.237). This is a major advantage for Ligand B.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.113 and 0.052). This is good.
15. **Binding Affinity:** Both ligands have the same binding affinity (-6 kcal/mol).
**Overall Assessment:**
Given the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand B is the better candidate. While both have issues with Caco-2 and solubility, Ligand B demonstrates superior ADME properties: significantly lower DILI risk, lower microsomal clearance, and a longer half-life. The slightly better TPSA and QED scores also contribute to its favorability. The equal binding affinity removes that as a differentiating factor.
Output:
0
2025-04-17 19:19:11,457 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (354.353 and 352.41 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (76.66) is well below the 140 threshold and favorable for oral absorption. Ligand B (107.11) is still acceptable but higher, potentially impacting absorption.
3. **logP:** Both ligands have good logP values (2.161 and 1.109), falling within the 1-3 range. Ligand A's is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Ligand A (2) and Ligand B (4) are both within the acceptable limit of 5. Ligand A is preferable.
5. **HBA:** Both ligands have 4 HBA, which is acceptable (<=10).
6. **QED:** Both ligands have reasonable QED scores (0.405 and 0.534), suggesting decent drug-likeness. Ligand B is slightly better.
7. **DILI:** Ligand A (58.046) has a higher DILI risk than Ligand B (33.385). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (82.513) shows better BBB penetration potential than Ligand B (55.138). Given ADRB2's cardiovascular role, BBB penetration isn't a *primary* concern, but it's a positive attribute.
9. **Caco-2:** Ligand A (-4.719) and Ligand B (-5.156) have negative values, which is unusual and suggests very poor permeability. This is a major concern for both.
10. **Solubility:** Ligand A (-3.886) and Ligand B (-1.731) have negative solubility values, which is a significant issue. Ligand B is slightly better.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.56 and 0.221), which is excellent.
12. **Cl_mic:** Ligand A (67.29) has a higher microsomal clearance than Ligand B (4.473), indicating lower metabolic stability. Ligand B is significantly better here.
13. **t1/2:** Ligand B (-15.248) has a much longer in vitro half-life than Ligand A (-9.806). This is a substantial advantage for Ligand B.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.25 and 0.023), which is good.
15. **Binding Affinity:** Ligand B (-7.5 kcal/mol) has a slightly better binding affinity than Ligand A (-6.7 kcal/mol). This 0.8 kcal/mol difference is significant, potentially outweighing some ADME drawbacks.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), and balancing the general drug-like properties, Ligand B emerges as the more promising candidate. While Ligand A has better BBB penetration, Ligand B's significantly lower DILI risk, much better metabolic stability (lower Cl_mic and longer t1/2), and slightly improved binding affinity are more critical for a viable drug candidate, even with its slightly higher TPSA. The poor Caco-2 and solubility values are concerning for both, but can be addressed through formulation strategies.
Output:
0
2025-04-17 19:19:11,457 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (372.451 and 366.531 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (136.83) is slightly higher than Ligand B (76.02). For a cardiovascular GPCR, TPSA isn't *as* critical as for CNS targets, but lower is generally preferred for absorption. Ligand B has a substantial advantage.
3. **logP:** Both ligands have good logP values (1.645 and 2.521), falling within the 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Ligand A (1) and Ligand B (2) are both acceptable, below the threshold of 5.
5. **HBA:** Ligand A (6) and Ligand B (5) are both acceptable, below the threshold of 10.
6. **QED:** Ligand B (0.704) has a significantly better QED score than Ligand A (0.445), indicating a more drug-like profile.
7. **DILI:** Ligand A (36.72) has a lower DILI risk than Ligand B (43.66), which is preferable.
8. **BBB:** Ligand A (75.107) has a better BBB percentile than Ligand B (51.764). While ADRB2 isn't necessarily a CNS target, some degree of BBB penetration can be useful for understanding off-target effects.
9. **Caco-2:** Ligand A (-4.709) and Ligand B (-5.48) are both negative, indicating poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-1.985) and Ligand B (-2.367) are both poor. Solubility is a concern for both.
11. **hERG:** Both ligands have low hERG inhibition liability (0.23 and 0.355), which is good.
12. **Cl_mic:** Ligand A (-23.113) has a much lower (better) microsomal clearance than Ligand B (41.055), suggesting better metabolic stability.
13. **t1/2:** Ligand A (14.701) and Ligand B (15.692) are similar in vitro half-life.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.012 and 0.049), which is good.
15. **Binding Affinity:** Ligand A (-8.2 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.9 kcal/mol). This is a substantial advantage.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand B has a slightly better logP and significantly better TPSA. However, Ligand A's *much* stronger binding affinity (-8.2 vs -6.9 kcal/mol) is a decisive factor. A 1.3 kcal/mol difference in binding is substantial and can often outweigh minor ADME drawbacks. The better metabolic stability (lower Cl_mic) of Ligand A further strengthens its profile.
**Conclusion:**
Despite Ligand B's better QED and TPSA, the significantly improved binding affinity and metabolic stability of Ligand A make it the more promising drug candidate.
Output:
1
2025-04-17 19:19:11,457 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (355.479) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (79.9) is better than Ligand B (25.36). ADRB2 is not a CNS target, but lower TPSA generally improves absorption.
3. **logP:** Ligand B (4.827) is higher than Ligand A (0.248). This is a significant difference. While logP >4 can be problematic, for a GPCR, a higher logP can be beneficial for membrane interactions and receptor binding, *provided* solubility isn't severely compromised.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (0). Both are acceptable.
5. **HBA:** Ligand A (5) is higher than Ligand B (4). Both are acceptable.
6. **QED:** Both ligands have similar, good QED values (A: 0.62, B: 0.673).
7. **DILI:** Ligand A (11.206) has a much lower DILI risk than Ligand B (30.826). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (95.231) has a much higher BBB penetration than Ligand A (62.854). While ADRB2 isn't a primary CNS target, some peripheral ADRB2 receptors can influence CNS function, and higher BBB penetration isn't necessarily detrimental.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. Ligand A (-4.867) is slightly better than Ligand B (-4.503).
10. **Solubility:** Ligand A (-1.889) has better solubility than Ligand B (-5.635). This is important, especially given Ligand B's higher logP.
11. **hERG:** Ligand A (0.352) has a lower hERG risk than Ligand B (0.886). This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand B (105.886) has a much higher microsomal clearance than Ligand A (37.578), indicating lower metabolic stability. This is a significant drawback for Ligand B.
13. **t1/2:** Ligand A (-6.98) has a longer in vitro half-life than Ligand B (3.753). This is a major advantage for Ligand A.
14. **Pgp:** Ligand A (0.003) has much lower P-gp efflux than Ligand B (0.869). This is a significant advantage for Ligand A.
15. **Binding Affinity:** Ligand B (-5.8 kcal/mol) has slightly better binding affinity than Ligand A (-6.5 kcal/mol). While this is a positive for Ligand B, the difference is not substantial enough to outweigh the other significant drawbacks.
**Overall Assessment:**
Ligand A demonstrates a much more favorable ADMET profile. It has lower DILI risk, lower hERG risk, better solubility, better metabolic stability (lower Cl_mic, longer t1/2), and lower P-gp efflux. While Ligand B has a slightly better binding affinity and higher BBB penetration, the significant liabilities in DILI, metabolic stability, and solubility make it a less desirable candidate. The higher logP of Ligand B is concerning given the solubility issues. For a cardiovascular target like ADRB2, a balanced profile with good safety and reasonable PK is crucial.
Output:
1
2025-04-17 19:19:11,457 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [421.259, 71.06, 3.502, 0, 6, 0.473, 55.68, 74.99, -4.138, -4.582, 0.664, 117.577, 14.163, 0.309, -4.5]**
**Ligand B: [369.466, 95.04, 1.555, 1, 7, 0.699, 35.789, 65.839, -5.137, -2.003, 0.392, 8.022, -2.376, 0.175, -5.5]**
1. **Molecular Weight:** Ligand A (421.259 Da) is within the ideal range, while Ligand B (369.466 Da) is also acceptable, leaning towards the lower end. No strong preference here.
2. **TPSA:** Ligand A (71.06) is excellent, well below 140 and suitable for oral absorption. Ligand B (95.04) is still reasonable but less optimal. A favors here.
3. **logP:** Ligand A (3.502) is within the optimal range. Ligand B (1.555) is a bit low, potentially hindering permeation. A is favored.
4. **H-Bond Donors:** Ligand A (0) is excellent. Ligand B (1) is acceptable. A is slightly favored.
5. **H-Bond Acceptors:** Ligand A (6) is good. Ligand B (7) is also acceptable. No strong preference.
6. **QED:** Both ligands have acceptable QED values (A: 0.473, B: 0.699). Ligand B is slightly better.
7. **DILI:** Ligand A (55.68) is better than Ligand B (35.789), indicating lower liver injury risk. A is favored.
8. **BBB:** Ligand A (74.99) is good, suggesting reasonable brain penetration. Ligand B (65.839) is lower. A is favored, although ADRB2 is not necessarily a CNS target, some peripheral distribution is still important.
9. **Caco-2:** Both have negative values, indicating permeability. Ligand A (-4.138) is slightly better than Ligand B (-5.137).
10. **Solubility:** Both have negative values, indicating solubility. Ligand A (-4.582) is slightly better than Ligand B (-2.003).
11. **hERG:** Both have low hERG inhibition risk (A: 0.664, B: 0.392). B is slightly favored.
12. **Cl_mic:** Ligand A (117.577) has higher clearance, indicating lower metabolic stability. Ligand B (8.022) is much better. B is strongly favored.
13. **t1/2:** Ligand A (14.163) has a longer half-life than Ligand B (-2.376). A is favored.
14. **Pgp:** Ligand A (0.309) has lower P-gp efflux, which is good. Ligand B (0.175) is even better. B is favored.
15. **Binding Affinity:** Ligand B (-5.5 kcal/mol) has a stronger binding affinity than Ligand A (-4.5 kcal/mol). This is a significant advantage. B is strongly favored.
**Overall Assessment:**
Ligand B has a significantly better binding affinity (-5.5 vs -4.5 kcal/mol) and superior metabolic stability (lower Cl_mic). While Ligand A has advantages in TPSA, BBB, and half-life, the potency and metabolic stability of Ligand B are more critical for a GPCR target like ADRB2. The slightly lower logP of Ligand B is a minor concern that could be addressed with further optimization.
Output:
0
2025-04-17 19:19:11,457 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Ligand A: [352.45 , 61.8 , 2.327, 2. , 4. , 0.705, 4.769, 81. , -5.081, -2.065, 0.836, 14.161, -1.75 , 0.151, -5.5 ]**
**Ligand B: [350.503, 78.43 , 2.661, 3. , 3. , 0.667, 30.361, 30.748, -5.034, -3.312, 0.328, 13.091, 8.764, 0.392, -6.6 ]**
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). A is 352.45, B is 350.503 - very similar.
**2. TPSA:** Ligand A (61.8) is well below the 140 threshold and favorable for oral absorption. Ligand B (78.43) is still acceptable, but less optimal.
**3. logP:** Both ligands have good logP values (A: 2.327, B: 2.661) falling within the 1-3 range.
**4. H-Bond Donors:** Ligand A (2) is preferable to Ligand B (3). Lower HBD generally improves permeability.
**5. H-Bond Acceptors:** Ligand A (4) is preferable to Ligand B (3). Lower HBA generally improves permeability.
**6. QED:** Both ligands have acceptable QED values (A: 0.705, B: 0.667), indicating good drug-like properties.
**7. DILI:** Ligand A (4.769) has a significantly lower DILI risk than Ligand B (30.361). This is a major advantage for A.
**8. BBB:** Ligand A (81) has a much higher BBB penetration percentile than Ligand B (30.748). This is *very* important for a GPCR target like ADRB2, even if it's not strictly a CNS target, as off-target CNS effects are a concern.
**9. Caco-2:** Both have negative Caco-2 values, which is unusual. Assuming these are logP values, both are very poor.
**10. Solubility:** Both have negative solubility values, which is unusual. Assuming these are logS values, both are very poor.
**11. hERG:** Ligand A (0.836) has a lower hERG inhibition liability than Ligand B (0.328), indicating a lower risk of cardiotoxicity.
**12. Cl_mic:** Both have similar microsomal clearance values (A: 14.161, B: 13.091).
**13. t1/2:** Ligand A (-1.75) has a shorter in vitro half-life than Ligand B (8.764). This is a drawback for A.
**14. Pgp:** Ligand A (0.151) has a lower P-gp efflux liability than Ligand B (0.392). This is favorable for A.
**15. Binding Affinity:** Ligand B (-6.6) has a slightly better binding affinity than Ligand A (-5.5). This is a 1.1 kcal/mol difference, which is significant, but needs to be weighed against other factors.
**Overall Assessment:**
Ligand A is significantly better overall. While Ligand B has a slightly better binding affinity, Ligand A excels in crucial ADME-Tox properties: lower DILI risk, much higher BBB penetration, lower hERG inhibition, and lower P-gp efflux. The longer half-life of Ligand B is a plus, but the other advantages of Ligand A are more critical for a balanced drug profile, especially for a GPCR. The poor Caco-2 and solubility values are concerning for both, but can be addressed through formulation strategies.
Output:
1
2025-04-17 19:19:11,457 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.5 & 366.5 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (67.43 & 66.48) are below the 140 A^2 threshold for good oral absorption, and acceptable for a cardiovascular target (not requiring significant CNS penetration). Very similar.
3. **logP:** Both ligands (2.664 & 1.916) are within the optimal 1-3 range. Ligand A is slightly higher, which *could* be beneficial for membrane permeability, but both are good.
4. **HBD:** Ligand A has 2 HBD, and Ligand B has 1. Lower is generally preferable, and Ligand B is slightly better here.
5. **HBA:** Both ligands have 3 HBA, which is well within the acceptable limit of 10.
6. **QED:** Both ligands have good QED scores (0.724 & 0.81), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (14.89%) has a significantly lower DILI risk than Ligand B (55.18%). This is a *major* advantage for Ligand A. DILI is a critical safety concern.
8. **BBB:** Both ligands have similar BBB penetration (80.69% & 79.22%). Since ADRB2 is primarily a cardiovascular target, high BBB penetration isn't essential, but it doesn't hurt.
9. **Caco-2:** Both have negative values, indicating poor permeability. This is concerning for both.
10. **Solubility:** Both ligands have poor solubility (-3.448 & -3.645). This is a significant drawback for both, potentially impacting bioavailability.
11. **hERG:** Both ligands show low hERG inhibition risk (0.34 & 0.65). This is good, minimizing cardiotoxicity concerns.
12. **Cl_mic:** Ligand A (79.82 mL/min/kg) has a higher microsomal clearance than Ligand B (65.38 mL/min/kg), suggesting faster metabolism and potentially lower *in vivo* exposure. Ligand B is preferable here.
13. **t1/2:** Ligand B (-37.622 hours) has a much longer *in vitro* half-life than Ligand A (-4.858 hours). This is a substantial advantage for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.016 & 0.255). This is good, suggesting good oral bioavailability.
15. **Binding Affinity:** Ligand B (-6.5 kcal/mol) has a significantly stronger binding affinity than Ligand A (-3.5 kcal/mol). This is a *major* advantage for Ligand B, potentially outweighing some of the ADME drawbacks. A 3 kcal/mol difference is substantial.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Both ligands perform well on logP and Pgp. TPSA is acceptable for both. However, Ligand B has a much stronger binding affinity, which is the most important factor for GPCRs.
**Overall Assessment:**
While Ligand A has a significantly better DILI profile, the substantial difference in binding affinity (3 kcal/mol) and the longer half-life of Ligand B are more critical for a GPCR target. The poor solubility and Caco-2 permeability are concerns for both, but can potentially be addressed through formulation strategies. The lower DILI risk of A is attractive, but the potency and PK of B are more compelling.
Output:
0
2025-04-17 19:19:11,457 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (346.431 and 347.419 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (98.32) is slightly higher than Ligand B (90.56). Both are below the 140 A^2 threshold for good oral absorption, but Ligand B is closer to the preferred <90 A^2 for GPCRs.
**3. logP:** Ligand A (1.073) is within the optimal 1-3 range. Ligand B (-0.23) is slightly below 1, which *could* indicate potential permeability issues. This is a point in favor of Ligand A.
**4. H-Bond Donors:** Ligand A (3) and Ligand B (2) are both acceptable, below the 5 threshold.
**5. H-Bond Acceptors:** Ligand A (4) and Ligand B (5) are both below the 10 threshold.
**6. QED:** Both ligands have good QED scores (0.71 and 0.788), indicating good drug-like properties.
**7. DILI:** Ligand B (35.285) has a significantly lower DILI risk than Ligand A (43.66). This is a substantial advantage for Ligand B.
**8. BBB:** Ligand B (45.444) has a better BBB penetration score than Ligand A (32.144). While ADRB2 isn't a CNS target, some peripheral exposure can be reduced by good BBB penetration.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-5.191 and -5.132). This is unusual and suggests poor permeability. However, the values are very similar.
**10. Aqueous Solubility:** Both ligands have negative solubility values (-2.271 and -1.939). This is also concerning, suggesting poor solubility. Again, the values are similar.
**11. hERG Inhibition:** Ligand A (0.118) has a slightly lower hERG inhibition risk than Ligand B (0.273). This is a small advantage for Ligand A.
**12. Microsomal Clearance:** Ligand A (-5.666) has significantly lower (better) microsomal clearance than Ligand B (-12.688), indicating greater metabolic stability. This is a significant advantage for Ligand A.
**13. In vitro Half-Life:** Ligand A (-17.805) has a longer in vitro half-life than Ligand B (-12.198). This is a positive for Ligand A.
**14. P-gp Efflux:** Ligand A (0.023) has a lower P-gp efflux liability than Ligand B (0.012). This is a small advantage for Ligand A.
**15. Binding Affinity:** Ligand B (-8.2) has a significantly stronger binding affinity than Ligand A (-5.9). This is a substantial advantage for Ligand B, potentially outweighing some of the ADME drawbacks.
**Overall Assessment:**
The most critical factor for GPCRs is binding affinity. Ligand B's significantly stronger affinity (-8.2 vs -5.9) is a major advantage. While Ligand B has a slightly lower logP and higher hERG risk, the superior affinity, lower DILI risk, and better BBB penetration make it the more promising candidate. Ligand A has better metabolic stability and half-life, but the affinity difference is too large to ignore.
Output:
0
2025-04-17 19:19:11,458 - INFO - Batch 101 complete. Total preferences: 1616
2025-04-17 19:19:11,458 - INFO - Processing batch 102/512...
2025-04-17 19:19:57,934 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.48 & 357.49 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (40.62) is significantly better than Ligand B (90.55). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold, while Ligand B is approaching it.
3. **logP:** Both ligands have good logP values (3.01 & 2.68), falling within the optimal 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Ligand A (0) is preferable to Ligand B (4). Fewer hydrogen bond donors generally improve permeability.
5. **HBA:** Ligand A (2) is preferable to Ligand B (7). Fewer hydrogen bond acceptors also generally improve permeability.
6. **QED:** Ligand A (0.739) is better than Ligand B (0.561), indicating a more drug-like profile.
7. **DILI:** Ligand A (7.33) is *much* better than Ligand B (77.39). This is a critical difference. A DILI percentile of 77 is concerning and would likely halt development.
8. **BBB:** Ligand A (94.26) is better than Ligand B (54.91), but BBB isn't a high priority for a cardiovascular target.
9. **Caco-2:** Ligand A (-4.569) is better than Ligand B (-5.828). Higher Caco-2 permeability is preferred.
10. **Solubility:** Ligand A (-2.966) is better than Ligand B (-2.67). Higher solubility is preferable.
11. **hERG:** Both ligands have similar hERG inhibition liability (0.68 & 0.789), which is acceptable.
12. **Cl_mic:** Ligand A (45.45) is worse than Ligand B (14.84). Lower clearance is preferred for metabolic stability. This is a point in favor of Ligand B.
13. **t1/2:** Ligand A (-16.55) is worse than Ligand B (-2.66). Longer half-life is preferred. This is another point in favor of Ligand B.
14. **Pgp:** Both ligands have similar Pgp efflux liability (0.16 & 0.049).
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.3 & -6.5 kcal/mol). The difference is negligible.
**Overall Assessment:**
Ligand A is significantly better across several key ADME properties (TPSA, HBD, HBA, QED, and *especially* DILI). While Ligand B has better metabolic stability (Cl_mic) and half-life, the high DILI risk associated with Ligand B is a major red flag. The slight advantage in metabolic stability doesn't outweigh the potential for liver toxicity. For a cardiovascular target, the slightly lower BBB penetration of Ligand A is not a significant drawback.
Therefore, I prefer Ligand A.
Output:
1
2025-04-17 19:19:57,935 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (349.479 and 354.357 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (69.64) is significantly better than Ligand B (84.42). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand A is well below the 140 threshold, while Ligand B is approaching it.
**3. logP:** Ligand A (1.437) is slightly higher than Ligand B (0.645), both are within the optimal 1-3 range. Ligand A is preferable.
**4. H-Bond Donors:** Ligand A (0) is better than Ligand B (1). Fewer HBDs generally improve permeability.
**5. H-Bond Acceptors:** Both ligands have 5 HBA, which is acceptable.
**6. QED:** Ligand B (0.811) has a better QED score than Ligand A (0.639), indicating a more drug-like profile. This is a point in favor of Ligand B.
**7. DILI:** Ligand A (23.963) has a significantly lower DILI risk than Ligand B (38.038). This is a crucial advantage for Ligand A.
**8. BBB:** Ligand B (87.864) shows better BBB penetration than Ligand A (72.354). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be acceptable or even desirable for certain cardiovascular indications.
**9. Caco-2 Permeability:** Ligand A (-4.926) is slightly better than Ligand B (-4.636), indicating better intestinal absorption.
**10. Aqueous Solubility:** Ligand A (-0.375) is better than Ligand B (-2.09). Solubility is important for formulation and bioavailability.
**11. hERG Inhibition:** Ligand A (0.534) has a lower hERG inhibition liability than Ligand B (0.192). This is a significant safety advantage for Ligand A.
**12. Microsomal Clearance:** Ligand B (7.866) has a lower microsomal clearance than Ligand A (35.296), indicating better metabolic stability. This is a point in favor of Ligand B.
**13. In vitro Half-Life:** Ligand B (-7.321) has a much longer in vitro half-life than Ligand A (2.255). This is a significant advantage for Ligand B, potentially allowing for less frequent dosing.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.035 and 0.004 respectively).
**15. Binding Affinity:** Ligand A (-6.4) has slightly weaker binding affinity than Ligand B (-7.2). However, the difference is not substantial enough to outweigh the other advantages of Ligand A.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), and the general drug-like properties, Ligand A appears to be the better candidate. While Ligand B has a better QED, longer half-life, and slightly better affinity, Ligand A excels in crucial areas like DILI risk, hERG inhibition, solubility, and TPSA. The lower TPSA and DILI risk are particularly important for a cardiovascular drug candidate. The slightly weaker affinity of Ligand A can be potentially addressed through further optimization.
Output:
1
2025-04-17 19:19:57,935 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (345.443 and 351.447 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (87.3) is better than Ligand B (98.74). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (1.004) is within the optimal range (1-3), while Ligand B (0.027) is quite low. A logP this low can hinder membrane permeability and potentially reduce binding affinity. This is a significant strike against Ligand B.
4. **HBD:** Both ligands have 3 HBD, which is acceptable.
5. **HBA:** Ligand A has 3 HBA, while Ligand B has 4. Both are within the acceptable range of <=10.
6. **QED:** Ligand B (0.602) has a slightly better QED score than Ligand A (0.475), indicating a more drug-like profile. However, this is somewhat offset by other issues with Ligand B.
7. **DILI:** Ligand A (21.985) has a much lower DILI risk than Ligand B (31.563). This is a substantial advantage for Ligand A.
8. **BBB:** Not a primary concern for a cardiovascular target, but Ligand A (40.52) is slightly better than Ligand B (33.734).
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.109 and -5.19), which is unusual and suggests poor permeability. However, these values are very close, so this isn't a major differentiator.
10. **Solubility:** Ligand A (-3.287) has slightly better solubility than Ligand B (-1.909).
11. **hERG:** Ligand A (0.073) has a lower hERG risk than Ligand B (0.104), which is preferable.
12. **Cl_mic:** Both ligands have similar microsomal clearance (14.148 and 14.218 mL/min/kg), suggesting comparable metabolic stability.
13. **t1/2:** Ligand A (-1.126) has a slightly worse in vitro half-life than Ligand B (13.818). This is a minor drawback for Ligand A.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.039 and 0.037), which is good.
15. **Binding Affinity:** Ligand A (-7.2 kcal/mol) has a significantly better binding affinity than Ligand B (-5.6 kcal/mol). A 1.6 kcal/mol difference is substantial and can often outweigh minor ADME concerns.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, and affinity are key. Ligand A excels in logP and significantly outperforms Ligand B in binding affinity. While Ligand B has a slightly better QED, the poor logP and weaker affinity are major drawbacks. The lower DILI risk for Ligand A is also a significant benefit.
**Conclusion:**
Ligand A is the more promising drug candidate due to its superior binding affinity, better logP, lower DILI risk, and acceptable overall profile. The slightly worse half-life is a minor concern compared to the significant advantages in other areas.
Output:
1
2025-04-17 19:19:57,935 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (337.423) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (71.09) is better than Ligand B (29.02). Lower TPSA generally improves oral absorption, and is particularly important for GPCRs.
3. **logP:** Ligand A (1.494) is within the optimal range, while Ligand B (4.847) is high. High logP can lead to solubility issues and off-target effects.
4. **HBD:** Ligand A (2) is reasonable. Ligand B (0) is also acceptable.
5. **HBA:** Ligand A (3) is good. Ligand B (4) is also acceptable.
6. **QED:** Ligand A (0.818) is excellent, indicating high drug-likeness. Ligand B (0.67) is still acceptable, but less ideal.
7. **DILI:** Both ligands have low DILI risk (Ligand A: 30.748, Ligand B: 25.087), which is good.
8. **BBB:** Ligand B (92.323) has significantly better BBB penetration than Ligand A (46.646). While ADRB2 isn't exclusively a CNS target, some cardiovascular effects are mediated through CNS pathways, and better BBB penetration could be beneficial.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and potentially problematic. However, the values are similar (-4.662 vs -4.569).
10. **Solubility:** Ligand A (-2.955) has better solubility than Ligand B (-4.974). Solubility is crucial for bioavailability.
11. **hERG:** Both ligands have very low hERG inhibition risk (Ligand A: 0.091, Ligand B: 0.815).
12. **Cl_mic:** Ligand A (0.913) has much lower microsomal clearance than Ligand B (48.178), indicating better metabolic stability.
13. **t1/2:** Ligand A (-5.321) has a longer in vitro half-life than Ligand B (12.267).
14. **Pgp:** Ligand A (0.015) has significantly lower P-gp efflux liability than Ligand B (0.369). Lower P-gp efflux improves bioavailability.
15. **Affinity:** Ligand A (-6.7 kcal/mol) has slightly better binding affinity than Ligand B (-6.2 kcal/mol).
**GPCR-specific priorities:** For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, and affinity. Ligand A excels in TPSA, Pgp, and has a slightly better affinity. Ligand B has a significantly better BBB, but its high logP is a concern. The better metabolic stability (lower Cl_mic and longer t1/2) and solubility of Ligand A are also strong advantages. The small difference in binding affinity is outweighed by the other factors.
**Conclusion:**
Considering the balance of properties and the priorities for a GPCR target, Ligand A is the more promising drug candidate.
Output:
1
2025-04-17 19:19:57,935 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (353.4 and 356.4 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (89.35) is better than Ligand B (49.5). For a cardiovascular GPCR, TPSA is moderately important. Lower TPSA generally means better permeability, and both are acceptable, but A is slightly preferred.
**3. logP:** Ligand B (3.997) is better than Ligand A (0.129). The optimal range is 1-3, and B is within this range, while A is significantly below. This is a major drawback for A, as low logP can hinder membrane permeability.
**4. H-Bond Donors:** Both ligands have 1 HBD, which is within the acceptable limit of <=5.
**5. H-Bond Acceptors:** Ligand A has 6 HBAs, while Ligand B has 4. Both are within the acceptable limit of <=10.
**6. QED:** Both ligands have similar QED values (0.831 and 0.815), indicating good drug-like properties.
**7. DILI Risk:** Ligand B (13.843) is significantly better than Ligand A (49.515). Lower DILI risk is crucial, and B is much safer in this regard.
**8. BBB Penetration:** Both ligands have good BBB penetration (71.811 and 79.411), which is less critical for a cardiovascular target but still a positive. B is slightly better.
**9. Caco-2 Permeability:** Ligand A (-5) is better than Ligand B (-4.71). While both are negative, indicating poor permeability, A is slightly better.
**10. Aqueous Solubility:** Ligand A (-1.471) is better than Ligand B (-3.875). Higher solubility is generally desirable, and A has a better score.
**11. hERG Inhibition:** Ligand A (0.073) is better than Ligand B (0.945). Lower hERG inhibition is crucial to avoid cardiotoxicity, and A is significantly safer.
**12. Microsomal Clearance:** Ligand A (1.472) is significantly better than Ligand B (45.179). Lower clearance indicates better metabolic stability, a major advantage for A.
**13. In vitro Half-Life:** Ligand B (41.155) is much better than Ligand A (-9.213). A longer half-life is generally desirable, and B is far superior.
**14. P-gp Efflux:** Ligand A (0.014) is much better than Ligand B (0.513). Lower P-gp efflux is desirable for better bioavailability.
**15. Binding Affinity:** Both ligands have the same binding affinity (-7.3 kcal/mol), so this parameter doesn't differentiate them.
**Overall Assessment:**
While Ligand A has better Caco-2 permeability, solubility, hERG inhibition, and metabolic stability, its significantly low logP is a major concern. Ligand B has a much better logP, lower DILI risk, and a significantly longer half-life. Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), and the importance of minimizing toxicity (DILI, hERG), Ligand B is the more promising candidate despite its higher P-gp efflux and clearance. The improved logP and safety profile outweigh the drawbacks.
Output:
0
2025-04-17 19:19:57,935 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (368.474 and 355.414 Da) are within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (67.43) is significantly better than Ligand B (89.35). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (3.215) is optimal, while Ligand B (0.23) is quite low. This is a significant drawback for Ligand B, potentially hindering membrane permeability and bioavailability.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable.
5. **HBA:** Ligand A (4) and Ligand B (6) are both acceptable, but Ligand A is slightly better.
6. **QED:** Both ligands have good QED scores (0.665 and 0.721), indicating generally drug-like properties.
7. **DILI:** Ligand A (47.732) is slightly higher than Ligand B (36.758), but both are below the concerning threshold of 60.
8. **BBB:** Both ligands have good BBB penetration (73.672 and 78.79). This isn't a primary concern for a cardiovascular target, but it doesn't hurt.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.525 and -4.733). This is unusual and suggests poor permeability.
10. **Solubility:** Ligand A (-4.627) is slightly better than Ligand B (-1.273), indicating better aqueous solubility.
11. **hERG:** Both ligands have low hERG inhibition risk (0.438 and 0.129).
12. **Cl_mic:** Ligand A (72.491) has a higher clearance than Ligand B (7.499), suggesting lower metabolic stability. This is a negative for Ligand A.
13. **t1/2:** Ligand B (3.418) has a slightly longer half-life than Ligand A (-18.138). The negative half-life for Ligand A is a major concern.
14. **Pgp:** Both ligands have very low Pgp efflux (0.157 and 0.025).
15. **Affinity:** Ligand B (-6.9 kcal/mol) has a significantly stronger binding affinity than Ligand A (-4.5 kcal/mol). This is a substantial advantage, exceeding the 1.5 kcal/mol threshold.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand A excels in TPSA and has an acceptable logP. However, Ligand B's superior affinity and acceptable TPSA, despite the lower logP, are more compelling. The significantly better binding affinity of Ligand B outweighs the concerns about its lower logP, especially considering the other parameters are relatively comparable. The negative half-life of Ligand A is a major red flag.
Output:
0
2025-04-17 19:19:57,935 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
The ADRB2 receptor is a GPCR, so the priorities are logP, Pgp, TPSA, affinity, and BBB. Let's analyze each ligand against these and other key parameters.
* **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (426.742) is slightly higher than Ligand B (349.431), but both are acceptable.
* **TPSA:** Ligand A (72.36) is significantly better than Ligand B (105.64). A TPSA under 140 is good for oral absorption, and lower is generally preferred for GPCRs. Ligand B is pushing the upper limit.
* **logP:** Ligand A (3.614) is optimal, while Ligand B (1.392) is on the lower side. While not terrible, lower logP can sometimes indicate permeability issues.
* **H-Bond Donors/Acceptors:** Both are reasonable. Ligand A has 1 HBD and 4 HBA, while Ligand B has 2 HBD and 4 HBA.
* **QED:** Both ligands have similar QED scores (0.792 and 0.776), indicating good drug-likeness.
* **DILI:** Ligand A (33.773) has a much lower DILI risk than Ligand B (16.557). This is a significant advantage for Ligand A.
* **BBB:** Ligand A (80.884) has a substantially higher BBB penetration score than Ligand B (47.15). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be beneficial, and avoiding it isn't a priority.
* **Caco-2 Permeability:** Both have negative Caco-2 values, indicating poor permeability.
* **Aqueous Solubility:** Both have negative solubility values, indicating poor solubility.
* **hERG:** Ligand A (0.807) has a slightly higher hERG risk than Ligand B (0.112), but both are low and acceptable.
* **Microsomal Clearance:** Ligand B (-0.391) has a negative clearance, which is very good. Ligand A (14.06) is higher, indicating faster metabolism.
* **In vitro Half-Life:** Ligand A (18.449) has a longer half-life than Ligand B (13.79).
* **P-gp Efflux:** Ligand A (0.638) has a lower P-gp efflux liability than Ligand B (0.007), which is favorable.
* **Binding Affinity:** Both ligands have excellent binding affinity (-7.0 and -5.2 kcal/mol respectively). Ligand A is significantly more potent. The 1.8 kcal/mol difference is substantial enough to outweigh some of the ADME concerns with Ligand A.
**Overall Assessment:**
Ligand A is the stronger candidate. Its superior binding affinity, lower DILI risk, higher BBB penetration, and lower P-gp efflux liability are significant advantages. While Ligand B has better microsomal clearance, the difference isn't enough to offset the other benefits of Ligand A. The permeability and solubility issues are similar for both, and can be addressed with formulation strategies. The potency difference is the key driver here.
**Output:**
1
2025-04-17 19:19:57,936 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (343.335 and 365.459 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (98.76 and 92.63) are below the 140 A^2 threshold for good oral absorption. Ligand B is slightly better.
3. **logP:** Both ligands (2.696 and 1.627) are within the optimal 1-3 range. Ligand A is slightly higher, potentially offering better membrane permeability, but both are acceptable.
4. **HBD:** Ligand A (0) has fewer H-bond donors than Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (7) has fewer H-bond acceptors than Ligand B (9). Similar to HBD, this favors Ligand A for permeability.
6. **QED:** Both ligands have similar QED values (0.713 and 0.765), indicating good drug-likeness.
7. **DILI:** Both ligands have acceptable DILI risk (78.17 and 75.184 percentile), below the concerning threshold of 60. Ligand B is slightly better.
8. **BBB:** Ligand B (44.552) has a slightly better BBB penetration percentile than Ligand A (39.822). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be beneficial for distribution.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.163 and -4.911). This is unusual and suggests poor permeability.
10. **Solubility:** Both ligands have negative solubility values (-4.852 and -3.377). This is also concerning, indicating very poor aqueous solubility.
11. **hERG:** Ligand A (0.44) has a significantly lower hERG inhibition liability than Ligand B (0.754), which is a crucial safety advantage.
12. **Cl_mic:** Ligand B (59.248) has a lower microsomal clearance than Ligand A (88.341), suggesting better metabolic stability.
13. **t1/2:** Ligand A (27.091) has a much longer in vitro half-life than Ligand B (6.347), which is a significant advantage for dosing frequency.
14. **Pgp:** Ligand A (0.204) has lower P-gp efflux liability than Ligand B (0.059), which is favorable for bioavailability.
15. **Affinity:** Ligand A (-6.6 kcal/mol) has a slightly better binding affinity than Ligand B (-4.8 kcal/mol). This is a substantial difference and a major driver in the decision.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A has a slightly better logP, lower Pgp efflux, and significantly better affinity. The longer half-life is also a major plus. While Ligand B has slightly better DILI and BBB, the hERG risk and lower affinity of Ligand B are significant drawbacks. The poor Caco-2 and solubility of both are concerning, but can be addressed with formulation strategies.
**Conclusion:**
Despite the poor permeability and solubility predictions for both, Ligand A's superior binding affinity, longer half-life, lower hERG risk, and lower Pgp efflux outweigh the slight advantages of Ligand B.
Output:
1
2025-04-17 19:19:57,936 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (364.511 and 356.463 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (58.64) is significantly better than Ligand B (99.1). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold, while Ligand B is approaching it.
3. **logP:** Ligand A (3.545) is optimal, while Ligand B (0.146) is quite low. This is a major concern for Ligand B, as low logP can severely hinder membrane permeability and bioavailability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is preferable to Ligand B (5). Fewer HBAs generally improve permeability.
6. **QED:** Both ligands are similar (0.645 and 0.629), both above the 0.5 threshold, indicating good drug-like properties.
7. **DILI:** Ligand A (42.536) is better than Ligand B (15.898), indicating a lower risk of drug-induced liver injury.
8. **BBB:** This is less critical for a cardiovascular target. Ligand A (89.996) is higher than Ligand B (23.536), but this isn't a deciding factor.
9. **Caco-2:** Ligand A (-4.754) is better than Ligand B (-5.003), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-3.708) is better than Ligand B (-1.54). Solubility is important for formulation.
11. **hERG:** Ligand A (0.86) is better than Ligand B (0.128), indicating a lower risk of cardiotoxicity.
12. **Cl_mic:** Ligand A (108.082) is higher than Ligand B (18.111), indicating faster metabolic clearance and lower metabolic stability. This is a negative for Ligand A.
13. **t1/2:** Ligand A (42.949) is much better than Ligand B (9.418), indicating a longer in vitro half-life.
14. **Pgp:** Ligand A (0.66) is better than Ligand B (0.028), indicating lower P-gp efflux.
15. **Binding Affinity:** Ligand B (-7.4 kcal/mol) has a 1 kcal/mol advantage in binding affinity over Ligand A (-6.4 kcal/mol). This is a significant advantage.
**Overall Assessment:**
Ligand B has a substantially better binding affinity, which is a key factor for GPCR targets. However, its extremely low logP is a major concern, likely leading to poor absorption and bioavailability. Ligand A has a more balanced profile, with good TPSA, logP, solubility, and lower DILI and hERG risks. While its metabolic clearance is higher, the overall ADME properties are much more favorable. The affinity difference, while significant, might be overcome with further optimization of Ligand A. Given the importance of bioavailability for a cardiovascular drug, I favor Ligand A.
Output:
1
2025-04-17 19:19:57,936 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (378.885 Da and 363.351 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (83.98) is higher than Ligand B (55.4). For a peripheral GPCR like ADRB2, TPSA is less critical than for a CNS target, but lower is generally preferred for better absorption. Ligand B has a clear advantage.
**3. logP:** Ligand A (2.537) and Ligand B (3.699) are both within the optimal 1-3 range, but Ligand B is pushing the upper limit. While acceptable, it could potentially lead to solubility issues or off-target interactions. Ligand A is slightly favored.
**4. H-Bond Donors:** Ligand A (2) and Ligand B (1) are both acceptable.
**5. H-Bond Acceptors:** Ligand A (5) and Ligand B (3) are both acceptable.
**6. QED:** Both ligands have similar QED values (0.474 and 0.414), indicating reasonable drug-likeness, but are below the ideal 0.5.
**7. DILI Risk:** Ligand A (75.107) has a significantly higher DILI risk than Ligand B (39.511). This is a major concern, as liver toxicity is a common reason for drug failure. Ligand B is strongly favored.
**8. BBB Penetration:** This is less critical for ADRB2 (a cardiovascular target) but Ligand B (87.088) has higher BBB penetration than Ligand A (52.191).
**9. Caco-2 Permeability:** Ligand A (-5.41) and Ligand B (-4.356) both have negative values, indicating poor permeability. Ligand B is slightly better.
**10. Aqueous Solubility:** Ligand A (-3.614) and Ligand B (-4.261) both have poor solubility.
**11. hERG Inhibition:** Ligand A (0.096) has a lower hERG inhibition risk than Ligand B (0.891). This is a significant advantage for Ligand A, as hERG inhibition can cause cardiotoxicity.
**12. Microsomal Clearance:** Ligand A (46.049) has lower microsomal clearance than Ligand B (60.666), indicating better metabolic stability. This is a positive for Ligand A.
**13. In vitro Half-Life:** Ligand B (27.368) has a longer half-life than Ligand A (15.262), which is generally desirable.
**14. P-gp Efflux:** Ligand A (0.114) has lower P-gp efflux than Ligand B (0.251), which is favorable for bioavailability.
**15. Binding Affinity:** Ligand B (-5.7) has a slightly better binding affinity than Ligand A (-7.0). However, the difference is not substantial enough to outweigh other factors.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity) and general drug-like properties, Ligand B is the more promising candidate. While Ligand A has better hERG inhibition and metabolic stability, the significantly lower DILI risk of Ligand B is a critical advantage. The slightly better affinity of Ligand B is also a positive. The lower TPSA of Ligand B is also favorable. The solubility and permeability are poor for both, but this can be addressed with formulation strategies.
Output:
0
2025-04-17 19:19:57,936 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (372.531 and 366.849 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (83.55) is better than Ligand B (95.42). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (1.745 and 1.426), falling within the optimal 1-3 range. Ligand B is slightly lower, which could marginally improve solubility.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves membrane permeability.
5. **HBA:** Ligand A (4) is preferable to Ligand B (5). Similar to HBD, lower HBA is generally favorable.
6. **QED:** Both ligands have similar and acceptable QED values (0.703 and 0.712).
7. **DILI:** Ligand A (37.379) has a significantly lower DILI risk than Ligand B (50.95). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (68.631) has a better BBB percentile than Ligand B (35.983), but this is less critical for a cardiovascular target.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.037 and -4.919), which is unusual and suggests poor permeability. However, the values are very similar.
10. **Solubility:** Both ligands have negative solubility values (-2.458 and -2.042), indicating poor aqueous solubility. This is a concern for both.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.285 and 0.243). This is excellent.
12. **Cl_mic:** Ligand A (21.772) has a lower microsomal clearance than Ligand B (33.24), indicating better metabolic stability.
13. **t1/2:** Ligand A (1.714) has a slightly longer in vitro half-life than Ligand B (1.842).
14. **Pgp:** Both ligands have low P-gp efflux liability (0.227 and 0.043). Ligand B is slightly better.
15. **Binding Affinity:** Ligand B (-7.3 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.5 kcal/mol). This is a substantial advantage (1.8 kcal/mol difference).
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. While both ligands have acceptable logP and Pgp values, Ligand B has a much stronger binding affinity. The TPSA difference favors Ligand A, but the affinity difference is more impactful.
**Overall Assessment:**
Ligand B's significantly stronger binding affinity outweighs its slightly higher TPSA and DILI risk. The similar Caco-2 and solubility values are concerning for both, but can be addressed with formulation strategies. The better metabolic stability of Ligand A is a plus, but the potency advantage of Ligand B is more crucial for a GPCR target.
Output:
0
2025-04-17 19:19:57,936 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [349.475, 71.53, 2.195, 1, 4, 0.742, 21.985, 73.401, -4.5, -1.625, 0.568, 57.771, 12.567, 0.074, -5.8]
**Ligand B:** [347.459, 95.66, 1.625, 3, 4, 0.705, 23.769, 67.468, -5.063, -1.709, 0.672, -2.874, -15.862, 0.035, -7.3]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). A is 349.475, B is 347.459 - very similar.
2. **TPSA:** Ligand A (71.53) is better than Ligand B (95.66). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally aids absorption.
3. **logP:** Both are good (1.625 and 2.195), falling within the optimal 1-3 range. Ligand A is slightly better.
4. **HBD:** Ligand A (1) is better than Ligand B (3). Fewer HBDs are generally preferred for better permeability.
5. **HBA:** Both have 4 HBA, which is acceptable.
6. **QED:** Both are good (0.742 and 0.705), indicating drug-like properties.
7. **DILI:** Ligand A (21.985) has a significantly lower DILI risk than Ligand B (23.769). This is a substantial advantage.
8. **BBB:** Ligand A (73.401) has better BBB penetration than Ligand B (67.468). While not critical for a cardiovascular target, it's a bonus.
9. **Caco-2:** Ligand A (-4.5) is better than Ligand B (-5.063), indicating slightly better intestinal absorption.
10. **Solubility:** Ligand A (-1.625) is better than Ligand B (-1.709).
11. **hERG:** Both are low (0.568 and 0.672), indicating low cardiotoxicity risk.
12. **Cl_mic:** Ligand B (-2.874) has *much* lower microsomal clearance than Ligand A (57.771). This suggests significantly better metabolic stability for Ligand B.
13. **t1/2:** Ligand B (-15.862) has a longer in vitro half-life than Ligand A (12.567). This is a major advantage.
14. **Pgp:** Both are very low (0.074 and 0.035), indicating minimal P-gp efflux.
15. **Affinity:** Ligand B (-7.3) has a significantly stronger binding affinity than Ligand A (-5.8). This is a 1.5 kcal/mol advantage, which is substantial.
**GPCR-Specific Priorities:** For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, and affinity. Ligand B has a slightly lower logP and TPSA, very low Pgp, and a much better affinity. The significantly improved metabolic stability (Cl_mic and t1/2) of Ligand B is also a major plus. While Ligand A has better DILI and BBB, the affinity difference and metabolic stability are more important for this target.
**Conclusion:**
Despite Ligand A's slightly better DILI and BBB, the significantly stronger binding affinity and improved metabolic stability of Ligand B make it the more promising drug candidate.
0
2025-04-17 19:19:57,936 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (344.375 Da and 380.392 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Both ligands have TPSA values (95.14 and 93.09) that are acceptable for oral absorption (<=140), but not optimized for CNS penetration (<=90). Since ADRB2 is a cardiovascular target, CNS penetration is not a high priority.
**3. logP:** Ligand A (0.783) is slightly lower than Ligand B (1.032). Both are within the optimal 1-3 range, but Ligand A is closer to the lower bound.
**4. H-Bond Donors/Acceptors:** Ligand A (0 HBD, 8 HBA) has a more favorable profile than Ligand B (2 HBD, 5 HBA) regarding hydrogen bonding potential. Fewer H-bonds generally improve membrane permeability.
**5. QED:** Ligand A (0.744) has a slightly better QED score than Ligand B (0.626), indicating a more drug-like profile.
**6. DILI Risk:** Ligand B (59.984) has a lower DILI risk than Ligand A (73.517), which is a significant advantage. Lower DILI risk is always preferred.
**7. BBB Penetration:** Both ligands have relatively low BBB penetration (67.197 and 58.55). As ADRB2 is a cardiovascular target, this isn't a major concern.
**8. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.625 and -4.981), which is unusual and suggests poor permeability. This is a potential red flag for both.
**9. Aqueous Solubility:** Both ligands have negative solubility values (-2.299 and -3.38), indicating very poor aqueous solubility. This is a significant drawback for both compounds and could hinder bioavailability.
**10. hERG Inhibition:** Ligand A (0.052) has a much lower hERG inhibition risk than Ligand B (0.142). This is a critical advantage, as hERG inhibition can lead to cardiotoxicity.
**11. Microsomal Clearance:** Ligand A (40.018) has a higher microsomal clearance than Ligand B (23.96), indicating faster metabolism and potentially lower *in vivo* exposure.
**12. In vitro Half-Life:** Ligand B (-37.128) has a significantly longer in vitro half-life than Ligand A (-7.467). This is a major advantage, suggesting less frequent dosing may be possible.
**13. P-gp Efflux:** Both ligands have low P-gp efflux liability (0.041 and 0.068).
**14. Binding Affinity:** Ligand A (-7.0) has a slightly better binding affinity than Ligand B (-6.7). While both are good, the difference is not substantial enough to outweigh other factors.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity) and the general drug-like properties, Ligand A appears slightly more promising despite its higher DILI risk and faster clearance. The significantly lower hERG inhibition risk is a crucial factor, given the cardiovascular target. The slightly better affinity also contributes. The poor solubility and permeability are concerns for both, but can potentially be addressed with formulation strategies.
Output:
1
2025-04-17 19:19:57,936 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (351.4 and 346.4 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (52.65) is slightly higher than Ligand B (49.41). Both are below the 140 threshold for oral absorption, which is good.
**3. logP:** Ligand A (1.636) is within the optimal 1-3 range. Ligand B (3.24) is at the higher end of the optimal range, potentially increasing off-target effects and decreasing solubility.
**4. H-Bond Donors:** Both ligands have 1 HBD, which is acceptable.
**5. H-Bond Acceptors:** Ligand A has 3 HBAs, and Ligand B has 2. Both are within the acceptable range of <=10.
**6. QED:** Ligand A (0.897) has a higher QED score than Ligand B (0.771), indicating better overall drug-likeness.
**7. DILI:** Ligand A (31.291) has a slightly higher DILI risk than Ligand B (28.887), but both are well below the concerning threshold of 60.
**8. BBB:** Ligand B (86.817) has significantly better BBB penetration than Ligand A (70.027). While ADRB2 is a cardiovascular target, some CNS effects are possible with certain ligands, and higher BBB penetration could be beneficial or detrimental depending on the desired profile.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.777 and -4.659) which is unusual and suggests poor permeability. This is a significant concern for both.
**10. Aqueous Solubility:** Ligand A (-1.866) has better aqueous solubility than Ligand B (-3.518). Solubility is important for formulation and bioavailability.
**11. hERG Inhibition:** Ligand A (0.7) has a slightly lower hERG inhibition risk than Ligand B (0.807), which is preferable.
**12. Microsomal Clearance:** Ligand A (-19.834) has a much lower (better) microsomal clearance than Ligand B (62.309), indicating greater metabolic stability.
**13. In vitro Half-Life:** Ligand A (15.357 hours) has a substantially longer half-life than Ligand B (7.416 hours), which is a significant advantage for dosing convenience.
**14. P-gp Efflux:** Ligand A (0.053) has lower P-gp efflux than Ligand B (0.227), which is favorable for bioavailability.
**15. Binding Affinity:** Ligand B (-6.0 kcal/mol) has a stronger binding affinity than Ligand A (-3.2 kcal/mol). This is a substantial difference (2.8 kcal/mol), and generally outweighs minor ADME concerns.
**GPCR Specific Considerations:** For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are particularly important. Ligand B excels in affinity, and has acceptable logP and Pgp values. While Ligand A has better ADME properties overall, the significant affinity advantage of Ligand B is crucial. The poor Caco-2 permeability is a concern for both, but can potentially be addressed through formulation strategies.
**Conclusion:**
Despite Ligand A's better overall ADME profile, the significantly stronger binding affinity of Ligand B (-6.0 vs -3.2 kcal/mol) is a decisive factor for a GPCR target. The affinity difference is large enough to potentially overcome the slightly less favorable ADME properties of Ligand B.
0
2025-04-17 19:19:57,937 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (343.427 Da) is well within the ideal range (200-500 Da). Ligand B (423.336 Da) is also acceptable, but closer to the upper limit.
2. **TPSA:** Ligand A (61.88) is good, well below the 140 threshold. Ligand B (89.18) is still reasonable, but higher, potentially impacting absorption.
3. **logP:** Both ligands have good logP values (A: 1.405, B: 2.197), falling within the optimal 1-3 range.
4. **HBD:** Both have 1 HBD, which is acceptable.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 6. Both are within the acceptable limit of 10.
6. **QED:** Ligand A (0.901) is excellent, indicating high drug-likeness. Ligand B (0.759) is still good, but lower.
7. **DILI:** Ligand A (53.936) has a slightly better DILI risk profile than Ligand B (64.676), both are acceptable.
8. **BBB:** Ligand A (73.517) has good BBB penetration, while Ligand B (86.894) is even better. This is a positive for both, but more important for CNS targets. Since ADRB2 is a cardiovascular target, BBB is less critical, but still a benefit.
9. **Caco-2:** Ligand A (-4.627) and Ligand B (-5.051) both have negative Caco-2 values, which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Both ligands have very poor aqueous solubility (-3.047 and -3.783 respectively). This is a major drawback for both.
11. **hERG:** Both ligands have low hERG inhibition risk (A: 0.389, B: 0.601).
12. **Cl_mic:** Ligand A (-20.942) has significantly lower (better) microsomal clearance than Ligand B (51.926), indicating better metabolic stability.
13. **t1/2:** Ligand A (7.876) has a shorter half-life than Ligand B (-11.129).
14. **Pgp:** Both ligands have very low Pgp efflux liability (A: 0.018, B: 0.502).
15. **Affinity:** Both ligands have very similar binding affinities (-6.7 and -6.9 kcal/mol). The difference is negligible.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Both ligands perform reasonably well on logP and Pgp. TPSA is acceptable for both. Affinity is nearly identical. The major differentiating factors are QED, solubility, and metabolic stability.
**Overall Assessment:**
Ligand A has a significantly better QED score and, crucially, much better metabolic stability (lower Cl_mic). While both have poor solubility and Caco-2 permeability, the improved drug-likeness and metabolic profile of Ligand A outweigh the slightly better BBB penetration of Ligand B. The poor solubility and permeability are serious issues that would need to be addressed in either case through formulation strategies.
Output:
1
2025-04-17 19:19:57,937 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A Analysis:**
* **MW:** 383.279 Da - Within the ideal range (200-500).
* **TPSA:** 69.04 A2 - Excellent, well below the 140 A2 threshold for oral absorption, and suitable for a GPCR.
* **logP:** 3.429 - Optimal, within the 1-3 range.
* **HBD:** 1 - Good, below the 5 threshold.
* **HBA:** 5 - Good, below the 10 threshold.
* **QED:** 0.796 - Excellent, indicating good drug-likeness.
* **DILI:** 60.14 - Moderate risk, slightly above the preferred <40, but not alarming.
* **BBB:** 81.97 - Very good, suggesting reasonable potential for CNS penetration, though not strictly necessary for ADRB2 (cardiovascular target).
* **Caco-2:** -4.455 - Poor permeability. This is a significant concern.
* **Solubility:** -4.646 - Very poor solubility. This is a major drawback.
* **hERG:** 0.599 - Low risk, good.
* **Cl_mic:** 56.985 mL/min/kg - Moderate clearance, could be better.
* **t1/2:** 10.35 hours - Reasonable half-life.
* **Pgp:** 0.181 - Low efflux, good.
* **Affinity:** -6.4 kcal/mol - Good binding affinity.
**Ligand B Analysis:**
* **MW:** 359.423 Da - Within the ideal range (200-500).
* **TPSA:** 117.2 A2 - Acceptable, but approaching the upper limit for good oral absorption.
* **logP:** -1.358 - Suboptimal, potentially hindering permeation.
* **HBD:** 3 - Good, below the 5 threshold.
* **HBA:** 7 - Good, below the 10 threshold.
* **QED:** 0.38 - Below ideal, indicating a less drug-like profile.
* **DILI:** 24.467 - Excellent, very low risk.
* **BBB:** 17.449 - Poor, not a priority for this target, but still a negative.
* **Caco-2:** -5.277 - Very poor permeability.
* **Solubility:** -0.221 - Poor solubility, but slightly better than Ligand A.
* **hERG:** 0.092 - Very low risk, excellent.
* **Cl_mic:** 19.409 mL/min/kg - Low clearance, suggesting good metabolic stability.
* **t1/2:** -33.519 hours - Very long half-life, potentially advantageous.
* **Pgp:** 0.004 - Very low efflux, excellent.
* **Affinity:** -7.7 kcal/mol - Excellent, significantly stronger binding affinity than Ligand A.
**Comparison & Decision:**
Both ligands have significant issues with permeability (Caco-2) and solubility. However, Ligand B possesses a substantially better binding affinity (-7.7 vs -6.4 kcal/mol), a much lower DILI risk, and better metabolic stability (lower Cl_mic, longer t1/2). While its logP is suboptimal, the strong affinity could potentially overcome this. Ligand A has a better BBB score, but this is less crucial for a cardiovascular target like ADRB2. The poor solubility and permeability of Ligand A are more concerning than the slightly lower logP of Ligand B. The superior affinity and safety profile of Ligand B outweigh its drawbacks.
Output:
0
2025-04-17 19:19:57,937 - INFO - Batch 102 complete. Total preferences: 1632
2025-04-17 19:19:57,937 - INFO - Processing batch 103/512...
2025-04-17 19:20:46,964 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands (372.847 and 357.479 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Both ligands (51.97 and 53.51) are reasonably low, suggesting good potential for absorption.
3. **logP:** Ligand A (3.536) is slightly higher than Ligand B (2.101). For a GPCR, a logP in the 1-3 range is preferred, so both are acceptable, but A is closer to the upper limit.
4. **HBD/HBA:** Ligand A has 1 HBD and 5 HBA, while Ligand B has 0 HBD and 4 HBA. Both are within acceptable limits.
5. **QED:** Both ligands have good QED scores (0.648 and 0.779), indicating generally drug-like properties. Ligand B is slightly better.
6. **DILI:** Ligand B (26.328) has a significantly lower DILI risk than Ligand A (43.622). This is a major advantage for Ligand B.
7. **BBB:** Ligand B (87.088) shows better BBB penetration potential than Ligand A (70.531). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant for off-target effects and overall safety assessment.
8. **Caco-2:** Both ligands have negative Caco-2 values (-4.583 and -4.891), which is unusual and suggests poor permeability. This is a significant concern for both.
9. **Solubility:** Both ligands have negative solubility values (-3.241 and -2.934), indicating very poor aqueous solubility. This is a major drawback for both.
10. **hERG:** Ligand A (0.868) has a slightly higher hERG risk than Ligand B (0.207). Lower is better, so Ligand B is preferable.
11. **Cl_mic:** Ligand A (29.68) has a lower (better) microsomal clearance than Ligand B (61.37). This suggests better metabolic stability for Ligand A.
12. **t1/2:** Ligand A (73.121) has a much longer in vitro half-life than Ligand B (-4.109). This is a significant advantage for Ligand A.
13. **Pgp:** Ligand A (0.739) has a higher Pgp efflux liability than Ligand B (0.196). Lower is better, so Ligand B is preferable.
14. **Binding Affinity:** Ligand A (-7.2 kcal/mol) has a slightly better binding affinity than Ligand B (-6.4 kcal/mol). This is a crucial factor, and the 0.8 kcal/mol difference is significant.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, Pgp, TPSA, and affinity. Ligand A has a slightly better logP and significantly better affinity. Ligand B has better Pgp, lower DILI, and better BBB. The poor Caco-2 and solubility for both are concerning. However, the affinity difference is substantial.
**Overall Assessment:**
While Ligand B has advantages in safety (DILI, hERG) and potentially bioavailability (Pgp, BBB), the significantly stronger binding affinity of Ligand A (-7.2 vs -6.4 kcal/mol) is a decisive factor. A strong binding affinity can often compensate for minor ADME deficiencies, especially if optimization efforts can improve solubility and permeability. The longer half-life of Ligand A is also a plus.
Output:
1
2025-04-17 19:20:46,965 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (376.551 and 367.446 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (58.12) is significantly better than Ligand B (82.53). ADRB2 is a cardiovascular target, not CNS, but lower TPSA is generally favorable for absorption. Ligand A is well below the 140 threshold. Ligand B is approaching the upper limit.
3. **logP:** Ligand A (3.168) is optimal, while Ligand B (1.388) is on the lower side. For a GPCR, a logP between 1-3 is preferred, and Ligand A is better positioned.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (6) is preferable to Ligand B (5). Lower HBA generally improves permeability.
6. **QED:** Ligand B (0.745) has a slightly better QED score than Ligand A (0.477), indicating a more drug-like profile. This is a minor advantage for Ligand B.
7. **DILI:** Ligand B (43.234) has a much lower DILI risk than Ligand A (63.901). This is a significant advantage for Ligand B.
8. **BBB:** Both ligands have reasonably good BBB penetration (Ligand A: 79.566, Ligand B: 68.554), but Ligand A is better. This isn't a primary concern for a cardiovascular target, but it's a slight positive for A.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.436 and -4.831). This is unusual and suggests poor permeability. However, the values are similar, so it doesn't differentiate them significantly.
10. **Solubility:** Both ligands have very poor aqueous solubility (-2.446 and -2.49). This is a significant drawback for both.
11. **hERG:** Ligand A (0.62) has a slightly higher hERG risk than Ligand B (0.291). This favors Ligand B.
12. **Cl_mic:** Ligand B (0.477) has significantly lower microsomal clearance than Ligand A (73.656), indicating better metabolic stability. This is a major advantage for Ligand B.
13. **t1/2:** Ligand A (61.904) has a much longer in vitro half-life than Ligand B (-1.925). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.524) has lower P-gp efflux than Ligand B (0.133). This is a slight advantage for Ligand A.
15. **Binding Affinity:** Ligand A (-7.7 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.0 kcal/mol). This is a substantial advantage for Ligand A, potentially outweighing some of its ADME drawbacks.
**Overall Assessment:**
Ligand A has a much better binding affinity and a longer half-life. However, Ligand B has a significantly lower DILI risk and better metabolic stability (lower Cl_mic). Both have poor solubility and Caco-2 permeability. Considering the GPCR-specific priorities (logP, TPSA, affinity), Ligand A's superior affinity and logP, combined with acceptable TPSA, are more compelling than Ligand B's advantages in safety and metabolism. The strong binding affinity of Ligand A is likely to be crucial for efficacy. While the solubility and permeability are concerning, these can be addressed through formulation strategies.
Output:
1
2025-04-17 19:20:46,965 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [353.348, 77.04, 2.009, 1, 5, 0.916, 56.572, 87.088, -4.888, -2.695, 0.638, -33.474, 2.713, 0.093, -5.9]
**Ligand B:** [350.423, 128.01, 0.355, 5, 4, 0.455, 39.473, 39.899, -5.801, -1.469, 0.068, -12.607, -3.006, 0.006, -8.4]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). A is 353.348, B is 350.423 - very similar.
2. **TPSA:** A (77.04) is excellent, well below 140, and good for GPCRs. B (128.01) is still acceptable but higher, potentially impacting permeability.
3. **logP:** A (2.009) is optimal. B (0.355) is quite low, which could hinder membrane permeability and bioavailability.
4. **HBD:** A (1) is good. B (5) is at the upper limit, potentially affecting permeability.
5. **HBA:** A (5) is good. B (4) is good.
6. **QED:** A (0.916) is excellent, indicating high drug-likeness. B (0.455) is below the desirable threshold of 0.5, raising concerns.
7. **DILI:** A (56.572) is acceptable. B (39.473) is better, indicating lower liver injury risk.
8. **BBB:** A (87.088) is very good, suggesting good potential for CNS penetration if desired (though less critical for ADRB2 which is primarily cardiovascular). B (39.899) is low.
9. **Caco-2:** A (-4.888) is very good, indicating excellent absorption. B (-5.801) is also good, but slightly less favorable.
10. **Solubility:** A (-2.695) is good. B (-1.469) is good.
11. **hERG:** A (0.638) is low risk. B (0.068) is very low risk - excellent.
12. **Cl_mic:** A (-33.474) is excellent, indicating high metabolic stability. B (-12.607) is good, but less stable than A.
13. **t1/2:** A (2.713) is okay, but could be better. B (-3.006) is poor.
14. **Pgp:** A (0.093) is low efflux, good. B (0.006) is very low efflux, excellent.
15. **Affinity:** A (-5.9) is very good. B (-8.4) is excellent, a significant 2.5 kcal/mol advantage.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B has a significantly better binding affinity (-8.4 vs -5.9 kcal/mol). This is a substantial difference that can often outweigh other drawbacks. However, Ligand B's low logP and QED are concerning. Ligand A has a much better overall profile in terms of drug-likeness and permeability, despite the slightly weaker binding.
**Decision:**
While Ligand B has a superior binding affinity, the combination of its poor logP, low QED, and shorter half-life make it a less attractive candidate. Ligand A, with its better balance of properties, especially its favorable TPSA, logP, QED, and metabolic stability, is more likely to be a viable drug candidate.
Output:
1
2025-04-17 19:20:46,965 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (373.494 and 344.499 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (87.3) is higher than Ligand B (49.41). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is still preferred for better absorption. Ligand B is significantly better.
3. **logP:** Both ligands have good logP values (2.942 and 3.132), falling within the optimal 1-3 range. Similar.
4. **HBD:** Ligand A (3) is higher than Ligand B (1). Lower HBD is generally preferred for permeability, giving a slight edge to Ligand B.
5. **HBA:** Ligand A (4) is higher than Ligand B (2). Similar to HBD, Ligand B is slightly better.
6. **QED:** Ligand B (0.855) has a better QED score than Ligand A (0.621), indicating a more drug-like profile. This is a significant advantage for Ligand B.
7. **DILI:** Ligand A (60.876) has a higher DILI risk than Ligand B (25.785). This is a major concern for Ligand A. Ligand B is much safer.
8. **BBB:** Ligand A (59.248) has lower BBB penetration than Ligand B (84.606). While ADRB2 isn't a primary CNS target, some off-target CNS effects are possible, and higher BBB is generally preferable to avoid these. Ligand B is better.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.904 and -4.776), which is unusual and suggests poor permeability. This is a concern for both, but the values are similar.
10. **Solubility:** Both ligands have negative solubility values (-3.461 and -4.179), indicating poor aqueous solubility. This is a significant drawback for both, potentially impacting bioavailability.
11. **hERG:** Ligand A (0.646) has a slightly higher hERG risk than Ligand B (0.48). Lower is better, favoring Ligand B.
12. **Cl_mic:** Ligand A (37.333) has a lower microsomal clearance than Ligand B (72.056), suggesting better metabolic stability. This is a positive for Ligand A.
13. **t1/2:** Ligand A (46.642) has a longer in vitro half-life than Ligand B (-4.436). This is a significant advantage for Ligand A, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.183) has lower P-gp efflux than Ligand B (0.22), suggesting better absorption and bioavailability. This is a slight advantage for Ligand A.
15. **Binding Affinity:** Ligand A (-6.3 kcal/mol) has a slightly better binding affinity than Ligand B (-5.2 kcal/mol). This is a positive for Ligand A, but the difference is not overwhelming.
**Overall Assessment:**
Ligand B is the stronger candidate. While Ligand A has a slightly better binding affinity and metabolic stability, Ligand B excels in critical ADME properties: significantly lower DILI risk, better QED, higher BBB penetration, and lower hERG risk. The poor Caco-2 and solubility for both are concerning, but the safety profile and drug-likeness of Ligand B outweigh the modest affinity advantage of Ligand A. For a cardiovascular target, minimizing off-target effects and ensuring a favorable safety profile are paramount.
Output:
0
2025-04-17 19:20:46,965 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [339.395, 75.44, 1.999, 1, 4, 0.846, 44.048, 45.832, -5.079, -2.534, 0.082, 42.371, 1.743, 0.057, -7.4]
**Ligand B:** [352.475, 78.87, 1.629, 2, 4, 0.651, 8.453, 65.607, -4.724, -1.639, 0.286, 11.369, -4.318, 0.056, -6]
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (339.395) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are acceptable (below 140), but Ligand A (75.44) is better than Ligand B (78.87) for oral absorption.
3. **logP:** Both are within the optimal range (1-3). Ligand B (1.629) is slightly lower, which could potentially affect permeability.
4. **HBD:** Ligand A (1) is better than Ligand B (2). Lower HBD is generally preferred for better permeability.
5. **HBA:** Both have 4 HBA, which is acceptable.
6. **QED:** Ligand A (0.846) has a significantly better QED score than Ligand B (0.651), indicating a more drug-like profile.
7. **DILI:** Ligand A (44.048) has a much lower DILI risk than Ligand B (8.453), a crucial advantage for safety.
8. **BBB:** Ligand B (65.607) has a better BBB penetration than Ligand A (45.832). While ADRB2 is not a CNS target, some degree of BBB penetration can be helpful for distribution.
9. **Caco-2:** Ligand A (-5.079) has a more negative Caco-2 value, which is counterintuitive. Caco-2 values are typically positive, indicating permeability. Ligand B (-4.724) is also negative, but less so. This is concerning for both, but more so for A.
10. **Solubility:** Ligand B (-1.639) is better than Ligand A (-2.534).
11. **hERG:** Ligand A (0.082) has a lower hERG risk than Ligand B (0.286).
12. **Cl_mic:** Ligand A (42.371) has a lower microsomal clearance, suggesting better metabolic stability than Ligand B (11.369).
13. **t1/2:** Ligand A (1.743) has a better in vitro half-life than Ligand B (-4.318).
14. **Pgp:** Both have very low Pgp efflux liability (0.057 and 0.056).
15. **Affinity:** Ligand A (-7.4) has a slightly better binding affinity than Ligand B (-6).
**GPCR-Specific Priorities:**
For a cardiovascular GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. While BBB isn't a primary concern, it's a bonus.
**Overall Assessment:**
Ligand A is significantly better across several critical parameters: QED, DILI, metabolic stability (Cl_mic and t1/2), hERG risk, and binding affinity. The Caco-2 values are concerning for both, but the other advantages of Ligand A outweigh this drawback. Ligand B's better solubility and BBB penetration are not enough to compensate for its higher DILI risk and lower drug-likeness.
**Output:**
1
2025-04-17 19:20:46,965 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (342.399) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (85.37) is significantly better than Ligand B (101.9). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (3.207) is optimal, while Ligand B (-0.14) is quite low. This is a major drawback for Ligand B, potentially hindering membrane permeability and bioavailability.
4. **HBD:** Ligand A (2) is preferable to Ligand B (4). Fewer HBDs generally improve permeability.
5. **HBA:** Both ligands have the same number of HBA (5), which is acceptable.
6. **QED:** Ligand A (0.769) has a better QED score than Ligand B (0.509), indicating a more drug-like profile.
7. **DILI:** Ligand B (6.359) has a much lower DILI risk than Ligand A (53.974), which is a significant advantage.
8. **BBB:** Ligand A (74.486) has better BBB penetration than Ligand B (25.126), but this isn't a critical factor for a cardiovascular target.
9. **Caco-2:** Ligand A (-4.529) is better than Ligand B (-5.582), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-3.764) is better than Ligand B (-0.994).
11. **hERG:** Both ligands have very low hERG risk (0.47 and 0.098 respectively).
12. **Cl_mic:** Ligand B (-21.673) has a much lower (better) microsomal clearance than Ligand A (26.581), suggesting greater metabolic stability.
13. **t1/2:** Ligand A (8.651) has a better in vitro half-life than Ligand B (-1.16).
14. **Pgp:** Ligand A (0.017) has a lower Pgp efflux liability than Ligand B (0.003), which is favorable.
15. **Binding Affinity:** Ligand A (-6.4) has a slightly better binding affinity than Ligand B (-3.7). This difference in affinity is substantial.
**GPCR-specific considerations:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A excels in logP, TPSA, and affinity, while Ligand B has a better DILI score and Cl_mic. However, the significantly poor logP of Ligand B is a major concern, likely impacting its ability to reach the target. The superior binding affinity of Ligand A, coupled with its more favorable physicochemical properties, outweighs the higher DILI risk.
**Conclusion:**
Ligand A is the more promising candidate due to its superior logP, TPSA, binding affinity, and overall drug-like properties. While Ligand B has a lower DILI risk and better metabolic stability, its poor logP is a critical drawback for a GPCR ligand.
Output:
1
2025-04-17 19:20:46,966 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (364.423) is slightly higher than Ligand B (355.435), but both are acceptable.
2. **TPSA:** Ligand A (93.73) is better than Ligand B (116.76). For a GPCR, keeping TPSA lower is preferable for permeability. Ligand A is comfortably under the 140 threshold.
3. **logP:** Ligand A (2.22) is within the optimal range (1-3). Ligand B (-0.546) is *below* 1, which is a concern for permeability and could lead to poor absorption. This is a significant drawback for Ligand B.
4. **HBD:** Ligand A (2) is good. Ligand B (4) is higher, potentially impacting permeability.
5. **HBA:** Both ligands have 5 HBA, which is acceptable.
6. **QED:** Ligand A (0.701) is significantly better than Ligand B (0.414), indicating a more drug-like profile.
7. **DILI:** Ligand B (17.449) has a much lower DILI risk than Ligand A (83.598), which is a strong positive for Ligand B.
8. **BBB:** Ligand A (65.607) has better BBB penetration than Ligand B (53.548). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration isn't necessarily detrimental, and could allow for some off-target effects.
9. **Caco-2:** Ligand A (-4.963) is better than Ligand B (-5.482). Higher (less negative) values indicate better absorption.
10. **Solubility:** Ligand A (-4.049) is better than Ligand B (-1.253).
11. **hERG:** Ligand A (0.556) has a lower hERG risk than Ligand B (0.056). This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand B (13.467) has a much lower microsomal clearance than Ligand A (37.616), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-12.319) has a longer half-life than Ligand B (2.138).
14. **Pgp:** Ligand A (0.229) has lower P-gp efflux than Ligand B (0.003).
15. **Affinity:** Ligand A (-7.5 kcal/mol) has a slightly better binding affinity than Ligand B (-5.9 kcal/mol). The difference is 1.6 kcal/mol, which is significant enough to potentially outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand A is stronger in most key areas. While Ligand B has a much better DILI score and metabolic stability, Ligand B's low logP is a major concern for oral bioavailability. Ligand A's superior TPSA, QED, solubility, hERG profile, Caco-2 permeability, and binding affinity make it the more promising candidate, despite the higher DILI risk. The affinity difference is also substantial. For a cardiovascular target, the slightly higher DILI risk is acceptable given the other favorable properties.
Output:
1
2025-04-17 19:20:46,966 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [352.406, 59.08, 1.492, 0, 4, 0.746, 46.026, 89.531, -4.27, -1.464, 0.354, 12.571, 4.629, 0.047, -5.3]
**Ligand B:** [369.487, 80.76, 1.86, 1, 6, 0.853, 56.766, 75.649, -4.753, -3.617, 0.574, 39.548, -2.708, 0.062, -6.3]
Here's a breakdown, considering the provided guidelines and GPCR-specific priorities (logP, Pgp, TPSA, affinity, and BBB):
1. **MW:** Both are within the ideal range (200-500 Da). A is 352.4, B is 369.5. Slight edge to A for being a bit lower.
2. **TPSA:** A (59.08) is excellent, well below 140 and favorable for absorption. B (80.76) is still acceptable, but less ideal.
3. **logP:** Both are good (1.492 and 1.86, respectively), falling within the 1-3 range. B is slightly higher, which could be a minor concern for off-target effects, but not a major issue.
4. **HBD:** A (0) is ideal. B (1) is acceptable.
5. **HBA:** A (4) is good. B (6) is acceptable, but higher.
6. **QED:** Both are good (0.746 and 0.853), indicating drug-like properties. B is slightly better.
7. **DILI:** Both have acceptable DILI risk (A: 46.03, B: 56.77), below the 60% threshold. A is slightly better.
8. **BBB:** A (89.53) is very good, suggesting decent potential for CNS penetration if desired (though less crucial for a cardiovascular target). B (75.65) is still reasonable, but significantly lower.
9. **Caco-2:** Both are negative, indicating poor permeability. A (-4.27) is slightly better than B (-4.753).
10. **Solubility:** Both are negative, indicating poor solubility. A (-1.464) is slightly better than B (-3.617).
11. **hERG:** Both are low risk (A: 0.354, B: 0.574). A is better.
12. **Cl_mic:** A (12.57) is much better (lower = more stable) than B (39.55). This is a significant advantage for A.
13. **t1/2:** A (4.63) is better than B (-2.71).
14. **Pgp:** Both are very low (A: 0.047, B: 0.062), suggesting minimal efflux.
15. **Affinity:** B (-6.3) is 1 kcal/mol stronger than A (-5.3). This is a substantial difference in binding.
**Overall Assessment:**
Ligand B has a clear advantage in binding affinity (-6.3 vs -5.3 kcal/mol). However, Ligand A demonstrates superior ADME properties, particularly in terms of metabolic stability (Cl_mic), half-life, and lower TPSA. The better BBB score for A is a bonus. While the affinity difference is significant, the improved ADME profile of A, especially the lower clearance, makes it a more promising starting point for optimization. A lower clearance translates to potentially lower doses and less frequent administration. The slightly better solubility and hERG profile also contribute to its favorability.
Given the balance of properties, and the importance of metabolic stability for a cardiovascular drug, I favor Ligand A.
1
2025-04-17 19:20:46,966 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [354.407, 117.79 , 1.847, 2. , 7. , 0.847, 52.772, 77.821, -4.647, -3.072, 0.113, 29.498, -25.232, 0.019, -6.5 ]
**Ligand B:** [355.459, 48.42 , 4.464, 0. , 5. , 0.587, 63.086, 60.605, -4.559, -5.947, 0.338, 87.673, -34.141, 0.47 , -1.8 ]
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (354-355 Da). No significant difference.
2. **TPSA:** Ligand A (117.79) is higher than Ligand B (48.42). For a cardiovascular GPCR, lower TPSA is generally preferred for better permeability, giving a slight edge to Ligand B.
3. **logP:** Ligand A (1.847) is optimal, while Ligand B (4.464) is pushing the upper limit and could potentially lead to solubility issues and off-target interactions. Ligand A is favored.
4. **HBD:** Ligand A (2) is reasonable, and Ligand B (0) is also acceptable. No strong preference.
5. **HBA:** Ligand A (7) is reasonable, and Ligand B (5) is also acceptable. No strong preference.
6. **QED:** Ligand A (0.847) is excellent, indicating good drug-like properties. Ligand B (0.587) is acceptable, but less optimal. Ligand A is favored.
7. **DILI:** Ligand A (52.772) has a lower DILI risk than Ligand B (63.086). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (77.821) has better BBB penetration than Ligand B (60.605). While not a primary concern for a cardiovascular target, it's a positive attribute.
9. **Caco-2:** Both are negative, which is unusual. However, the absolute value is closer to zero for Ligand A (-4.647 vs -4.559), suggesting slightly better permeability.
10. **Solubility:** Ligand A (-3.072) has better aqueous solubility than Ligand B (-5.947). This is important for bioavailability.
11. **hERG:** Ligand A (0.113) has a much lower hERG inhibition liability than Ligand B (0.338). This is a crucial safety parameter, strongly favoring Ligand A.
12. **Cl_mic:** Ligand A (29.498) has lower microsomal clearance than Ligand B (87.673), indicating better metabolic stability.
13. **t1/2:** Ligand A (-25.232) has a longer in vitro half-life than Ligand B (-34.141).
14. **Pgp:** Ligand A (0.019) has much lower P-gp efflux liability than Ligand B (0.47). This is beneficial for bioavailability.
15. **Affinity:** Ligand A (-6.5 kcal/mol) has significantly better binding affinity than Ligand B (-1.8 kcal/mol). This is the most important factor, and the difference is substantial.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical parameters. It has a superior binding affinity, better ADME properties (solubility, metabolic stability, permeability, P-gp efflux), and a significantly lower risk of DILI and hERG inhibition. While Ligand B has a lower TPSA, the benefits of Ligand A far outweigh this single advantage. The substantial difference in binding affinity (-6.5 vs -1.8 kcal/mol) is a decisive factor.
Output:
1
2025-04-17 19:20:46,966 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (387.571 and 363.487 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (87.3) is slightly higher than Ligand B (76.3). Both are below the 140 threshold for good oral absorption, and acceptable for a cardiovascular target (not requiring significant BBB penetration). Ligand B is slightly favored.
3. **logP:** Both ligands have good logP values (1.642 and 1.338), falling within the optimal 1-3 range. No significant difference.
4. **HBD:** Ligand A (3) is higher than Ligand B (1). While both are acceptable (<=5), lower HBD is generally preferred for permeability, slightly favoring Ligand B.
5. **HBA:** Ligand A (5) is lower than Ligand B (8). Ligand A is favored here.
6. **QED:** Ligand B (0.758) has a better QED score than Ligand A (0.589), indicating a more drug-like profile. Ligand B is favored.
7. **DILI:** Ligand A (39.201) has a lower DILI risk than Ligand B (45.715), which is a significant advantage. Ligand A is favored.
8. **BBB:** Ligand B (53.703) has a higher BBB penetration percentile than Ligand A (45.25). However, as ADRB2 is a cardiovascular target, BBB penetration is not a primary concern.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.513 and -5.374), which is unusual and suggests poor permeability. This is a concern for both, but the values are very similar.
10. **Solubility:** Both ligands have negative solubility values (-2.143 and -2.469), indicating very poor aqueous solubility. This is a significant drawback for both.
11. **hERG:** Ligand A (0.042) has a much lower hERG inhibition liability than Ligand B (0.215). This is a major advantage for Ligand A, as hERG inhibition can lead to cardiotoxicity.
12. **Cl_mic:** Ligand A (16.428) has significantly lower microsomal clearance than Ligand B (28.688), suggesting better metabolic stability. Ligand A is favored.
13. **t1/2:** Both ligands have similar in vitro half-lives (15.422 and 15.784 hours). No significant difference.
14. **Pgp:** Ligand A (0.015) has much lower P-gp efflux liability than Ligand B (0.194), which is favorable for oral bioavailability. Ligand A is favored.
15. **Binding Affinity:** Ligand B (-7.0 kcal/mol) has a slightly better binding affinity than Ligand A (-6.1 kcal/mol). This is a 0.9 kcal/mol difference, which is substantial and could outweigh some of the ADME drawbacks.
**Overall Assessment:**
While Ligand B has a slightly better binding affinity and QED, Ligand A demonstrates a significantly better safety profile (lower DILI and hERG) and improved ADME properties (lower Cl_mic and Pgp efflux). The poor solubility and Caco-2 permeability are concerns for both, but the superior safety and metabolic stability of Ligand A are crucial for a cardiovascular drug candidate. Given the GPCR-specific priorities, and the fact that BBB is not a major concern for this target, the benefits of Ligand A outweigh the slightly better affinity of Ligand B.
Output:
1
2025-04-17 19:20:46,966 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [367.427, 101.78 , 1.28 , 1. , 6. , 0.551, 46.956, 67.584, -5.191, -2.777, 0.148, 13.416, -0.124, 0.063, -6.5 ]
**Ligand B:** [346.431, 84.3 , 1.103, 1. , 5. , 0.809, 39.162, 70.182, -4.905, -1.784, 0.145, 14.148, -8.357, 0.046, -6.9 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (346.431) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (101.78) is a bit higher than Ligand B (84.3). Both are acceptable for a non-CNS GPCR target like ADRB2, but B is better.
3. **logP:** Both are excellent (around 1.1-1.3), falling within the optimal 1-3 range.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 6 HBA, Ligand B has 5. Both are within the acceptable limit of 10.
6. **QED:** Ligand B (0.809) has a significantly better QED score than Ligand A (0.551), indicating a more drug-like profile.
7. **DILI:** Ligand B (39.162) has a lower DILI risk than Ligand A (46.956), which is a significant advantage.
8. **BBB:** Both have reasonable BBB penetration, but Ligand B (70.182) is slightly better than Ligand A (67.584). While ADRB2 isn't a primary CNS target, some peripheral exposure is still possible.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. It's difficult to interpret these values without knowing the scale.
10. **Solubility:** Both have negative solubility values, which is also unusual and suggests poor solubility.
11. **hERG:** Both have very low hERG inhibition risk (0.148 and 0.145), which is excellent.
12. **Cl_mic:** Ligand A (13.416) has slightly lower microsomal clearance than Ligand B (14.148), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-8.357) has a significantly longer in vitro half-life than Ligand A (-0.124), which is a major advantage.
14. **Pgp:** Both have very low P-gp efflux liability (0.063 and 0.046), which is favorable.
15. **Affinity:** Ligand B (-6.9 kcal/mol) has slightly better binding affinity than Ligand A (-6.5 kcal/mol), though the difference is relatively small.
**GPCR-specific priorities:** For ADRB2, logP, TPSA, Pgp, and affinity are important. Both ligands perform well on logP and Pgp. Ligand B has a better TPSA. The affinity difference is small. However, the significant advantages of Ligand B in QED, DILI risk, and especially *in vitro* half-life, outweigh the slight advantage of Ligand A in metabolic clearance.
**Conclusion:**
Ligand B is the more promising candidate due to its superior drug-like properties (QED), lower toxicity risk (DILI), longer half-life, and slightly better TPSA and BBB penetration.
0
2025-04-17 19:20:46,967 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.431 Da and 349.475 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (108.29) is higher than Ligand B (61.88). For a cardiovascular GPCR, TPSA isn't a *critical* factor like it would be for a CNS target, but lower is generally preferred for better absorption. Ligand B has a substantial advantage.
3. **logP:** Both ligands (1.435 and 1.559) are within the optimal 1-3 range. Very similar.
4. **HBD:** Ligand A (3) is higher than Ligand B (1). Lower is generally better for permeability, giving a slight edge to Ligand B.
5. **HBA:** Ligand A (3) is lower than Ligand B (4). Similar to HBD, lower is preferable, favoring Ligand A slightly.
6. **QED:** Both ligands (0.678 and 0.676) are very similar and above the 0.5 threshold, indicating good drug-likeness.
7. **DILI:** Ligand A (38.116) has a significantly lower DILI risk than Ligand B (7.057). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (64.87) has a higher BBB penetration percentile than Ligand A (41.644). While ADRB2 isn't a CNS target, some peripheral exposure can be mitigated by lower BBB penetration.
9. **Caco-2:** Ligand A (-5.363) and Ligand B (-5.207) are similar.
10. **Solubility:** Ligand A (-3.487) is better than Ligand B (-1.606). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.136) has a lower hERG risk than Ligand B (0.27). Lower is better, making Ligand A safer from a cardiotoxicity perspective.
12. **Cl_mic:** Ligand A (-9.76) has a lower (better) microsomal clearance than Ligand B (-14.63). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (-18.182) has a longer in vitro half-life than Ligand B (10.821). This is a significant advantage for Ligand A, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.023) has a lower P-gp efflux liability than Ligand B (0.008). Lower P-gp efflux is generally desirable for improved oral bioavailability.
15. **Binding Affinity:** Ligand B (-7.3) has a stronger binding affinity than Ligand A (-5.7). This is a 1.6 kcal/mol difference, which is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand B has a clear advantage in binding affinity. However, Ligand A demonstrates a much more favorable safety profile (lower DILI, lower hERG) and better metabolic stability (lower Cl_mic, longer t1/2). The lower TPSA and improved solubility of Ligand A are also beneficial. While Ligand B's higher BBB penetration isn't a major concern for a cardiovascular target, the other ADMET properties of Ligand A are more compelling. The substantial difference in DILI risk is a key deciding factor.
Output:
1
2025-04-17 19:20:46,967 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (382.917 and 369.864 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (58.44) is slightly higher than Ligand B (49.77). Both are well below the 140 threshold for oral absorption, and acceptable for a cardiovascular GPCR. Ligand B is slightly preferred.
3. **logP:** Ligand A (2.034) is within the optimal 1-3 range. Ligand B (3.939) is approaching the upper limit but still acceptable. Ligand A is slightly preferred.
4. **HBD:** Ligand A (0) is better than Ligand B (1) as fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (5) is better than Ligand B (3) as fewer HBAs generally improve permeability.
6. **QED:** Both ligands have good QED scores (0.785 and 0.826), indicating good drug-like properties. No significant difference.
7. **DILI:** Ligand A (49.011) has a higher DILI risk than Ligand B (19.426). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (72.392) and Ligand B (86.351) both have acceptable BBB penetration, but Ligand B is better. This is important for GPCRs, even cardiovascular ones, as off-target effects are always a concern.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual. This suggests poor permeability. However, the values are similar (-5.045 and -4.906), so no clear advantage.
10. **Solubility:** Both ligands have negative solubility values, which is also unusual and suggests poor solubility. The values are similar (-3.503 and -4.358), so no clear advantage.
11. **hERG:** Ligand A (0.36) has a lower hERG risk than Ligand B (0.836). This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand A (57.801) has a lower microsomal clearance than Ligand B (70.894), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (-9.723) has a negative half-life, which is not realistic. Ligand B (8.633) has a positive half-life. This is a huge advantage for Ligand B.
14. **Pgp:** Ligand A (0.431) has lower P-gp efflux than Ligand B (0.515), which is preferred.
15. **Binding Affinity:** Ligand B (-7.9) has a slightly better binding affinity than Ligand A (-7.2). While the difference is not huge (0.7 kcal/mol), it is still a factor.
**Overall Assessment:**
Ligand B has a significantly better safety profile (lower DILI) and a more realistic half-life. It also has better BBB penetration and slightly better binding affinity. Ligand A has advantages in hERG inhibition and metabolic stability, but the negative half-life is a major concern. Given the GPCR target class, the improved safety profile and BBB penetration of Ligand B outweigh the slight advantages of Ligand A.
Output:
0
2025-04-17 19:20:46,967 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.475 and 382.873 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (84.5) is significantly better than Ligand B (97.12). ADRB2 is a cardiovascular target, not CNS, but lower TPSA generally aids absorption.
3. **logP:** Both ligands (2.189 and 2.846) are within the optimal 1-3 range. Ligand B is slightly higher, which *could* be a minor concern for solubility, but not a major issue.
4. **HBD:** Both have 2 HBD, which is good.
5. **HBA:** Ligand A has 4 HBA, while Ligand B has 6. Ligand A is preferable here, staying further below the 10 threshold.
6. **QED:** Ligand B (0.8) is substantially better than Ligand A (0.492), indicating a more drug-like profile overall. This is a significant positive for Ligand B.
7. **DILI:** Ligand A (33.5) has a much lower DILI risk than Ligand B (77.2). This is a major advantage for Ligand A.
8. **BBB:** Not a primary concern for a cardiovascular target. Ligand A (60.3) is better than Ligand B (50.6), but this isn't decisive.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-4.672) is slightly better than Ligand B (-5.081), but both are concerning.
10. **Solubility:** Both are negative, indicating poor solubility. Ligand A (-3.221) is slightly better than Ligand B (-3.453), but both are concerning.
11. **hERG:** Both are very low (0.118 and 0.191), indicating minimal hERG inhibition risk. No significant difference.
12. **Cl_mic:** Ligand B (30.3) has a significantly lower microsomal clearance than Ligand A (85.44), suggesting better metabolic stability. This is a key advantage for Ligand B.
13. **t1/2:** Ligand B (2.784) has a longer in vitro half-life than Ligand A (-16.694). This is a substantial advantage for Ligand B.
14. **Pgp:** Both are very low (0.077 and 0.248), indicating minimal P-gp efflux. No significant difference.
15. **Binding Affinity:** Ligand B (-6.8 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.6 kcal/mol). This is a crucial advantage, exceeding the 1.5 kcal/mol threshold.
**Overall Assessment:**
Ligand B has a substantially better binding affinity and metabolic stability (lower Cl_mic, longer t1/2), and a better QED score. These are significant advantages. While Ligand A has a lower DILI risk, the difference in binding affinity is large enough to outweigh this concern, especially considering the cardiovascular target. The Caco-2 and solubility issues are present in both, and would need to be addressed through formulation or further structural modifications.
Output:
0
2025-04-17 19:20:46,967 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands are within the acceptable range (200-500 Da). Ligand A (354.403 Da) is slightly lower, which is generally favorable for permeability.
**2. TPSA:** Ligand B (67.87) is significantly lower than Ligand A (105.17). For a GPCR, lower TPSA is generally preferred as it aids membrane permeability.
**3. logP:** Ligand B (2.34) is within the optimal range (1-3), while Ligand A (-0.556) is below 1, potentially hindering permeability. This is a significant advantage for Ligand B.
**4. H-Bond Donors:** Ligand A (2) is slightly higher than Ligand B (1), but both are acceptable.
**5. H-Bond Acceptors:** Both ligands have a reasonable number of H-bond acceptors (Ligand A: 6, Ligand B: 5).
**6. QED:** Both ligands have good QED values (Ligand A: 0.62, Ligand B: 0.762), indicating good drug-like properties. Ligand B is slightly better.
**7. DILI Risk:** Ligand A (29.314) has a much lower DILI risk than Ligand B (68.205). This is a crucial advantage for Ligand A.
**8. BBB Penetration:** Ligand B (59.984) has better BBB penetration than Ligand A (49.244), but neither are particularly high. Since ADRB2 isn't exclusively a CNS target, this isn't a deciding factor.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-5.002) is slightly better than Ligand B (-4.784).
**10. Aqueous Solubility:** Ligand A (-0.38) is slightly better than Ligand B (-2.973), but both are poor.
**11. hERG Inhibition:** Ligand A (0.093) has a lower hERG inhibition risk than Ligand B (0.31).
**12. Microsomal Clearance:** Ligand A (-0.889) has significantly lower microsomal clearance, indicating better metabolic stability, than Ligand B (20.432).
**13. In vitro Half-Life:** Ligand A (11.603) has a shorter half-life than Ligand B (16.874).
**14. P-gp Efflux:** Ligand A (0.015) has much lower P-gp efflux liability than Ligand B (0.137), which is favorable for bioavailability.
**15. Binding Affinity:** Ligand B (-7.0 kcal/mol) has a significantly stronger binding affinity than Ligand A (-4.5 kcal/mol). This is a substantial advantage for Ligand B, potentially outweighing some ADME concerns.
**Overall Assessment:**
While Ligand A has advantages in DILI risk, metabolic stability, P-gp efflux, and hERG inhibition, Ligand B's superior binding affinity and logP are critical for a GPCR target. The lower TPSA of Ligand B is also beneficial. The binding affinity difference is large enough to compensate for the slightly higher DILI risk and lower solubility.
Output:
0
2025-04-17 19:20:46,968 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (345.443 and 349.519 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (75.44) is higher than Ligand B (52.65). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is generally preferred for absorption. Ligand B has a clear advantage.
3. **logP:** Both ligands have good logP values (2.133 and 2.572), falling within the optimal 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Both ligands have 1 HBD, which is within the acceptable limit of <=5.
5. **HBA:** Ligand A has 4 HBAs, while Ligand B has 3. Both are within the acceptable limit of <=10.
6. **QED:** Ligand A (0.802) has a significantly better QED score than Ligand B (0.685), indicating a more drug-like profile.
7. **DILI:** Ligand A (25.514) has a much lower DILI risk than Ligand B (4.459). This is a substantial advantage for Ligand A.
8. **BBB:** Ligand B (86.08) has a much higher BBB penetration percentile than Ligand A (57.852). While ADRB2 isn't a primary CNS target, some brain exposure can be relevant for off-target effects or peripheral effects mediated by receptors in the brainstem.
9. **Caco-2:** Ligand A (-4.579) and Ligand B (-4.868) both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale isn't specified, so it's difficult to interpret.
10. **Solubility:** Ligand A (-2.091) and Ligand B (-1.255) both have negative solubility values, which is also unusual and suggests poor solubility.
11. **hERG:** Ligand A (0.04) has a slightly lower hERG risk than Ligand B (0.503), which is preferable.
12. **Cl_mic:** Ligand B (8.416) has a slightly higher microsomal clearance than Ligand A (8.045), indicating slightly lower metabolic stability.
13. **t1/2:** Ligand A (21.596) has a significantly longer in vitro half-life than Ligand B (-14.033). This is a major advantage for Ligand A, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.046) has a lower P-gp efflux liability than Ligand B (0.027), indicating better bioavailability.
15. **Binding Affinity:** Ligand A (-7.1) has a stronger binding affinity than Ligand B (-5.8). This is a substantial advantage, as a >1.5 kcal/mol difference can outweigh other drawbacks.
**Overall Assessment:**
Ligand A demonstrates a superior profile overall. While Ligand B has better BBB penetration and a slightly higher logP, Ligand A excels in critical areas: significantly better QED, much lower DILI risk, a longer half-life, stronger binding affinity, and lower P-gp efflux. The negative Caco-2 and solubility values are concerning for both, but the other advantages of Ligand A outweigh these concerns, especially given the strong binding affinity. The lower DILI risk is particularly important.
Output:
1
2025-04-17 19:20:46,968 - INFO - Batch 103 complete. Total preferences: 1648
2025-04-17 19:20:46,968 - INFO - Processing batch 104/512...
2025-04-17 19:21:34,043 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (467.117 Da) is within the ideal range, while Ligand B (381.479 Da) is slightly below, but still acceptable.
2. **TPSA:** Ligand A (68.34) is good, well below the 140 threshold. Ligand B (89.55) is also acceptable, but higher.
3. **logP:** Ligand A (3.559) is optimal. Ligand B (1.807) is on the lower side, potentially impacting permeability.
4. **HBD:** Ligand A (0) is excellent. Ligand B (2) is acceptable.
5. **HBA:** Ligand A (5) is good. Ligand B (7) is acceptable, but higher.
6. **QED:** Both Ligand A (0.549) and Ligand B (0.728) are good, exceeding the 0.5 threshold. Ligand B is slightly better here.
7. **DILI:** Ligand A (88.717) is concerningly high, indicating a significant risk of liver injury. Ligand B (69.407) is still elevated, but considerably lower and more acceptable.
8. **BBB:** Ligand A (72.664) is good. Ligand B (54.866) is lower, suggesting less CNS penetration. Since ADRB2 is a cardiovascular target, BBB isn't a primary concern, but it's still a factor.
9. **Caco-2:** Both have negative values which is unusual. I will assume these are logP values and interpret them as such. Ligand A (-4.94) is very poor, indicating extremely low permeability. Ligand B (-5.384) is also poor, but slightly better.
10. **Solubility:** Ligand A (-4.391) is very poor. Ligand B (-2.797) is also poor.
11. **hERG:** Ligand A (0.507) is good, low risk. Ligand B (0.243) is very good, even lower risk.
12. **Cl_mic:** Ligand A (57.138) is reasonable. Ligand B (31.541) is better, indicating higher metabolic stability.
13. **t1/2:** Ligand A (83.074) is good. Ligand B (16.905) is poor, suggesting rapid clearance.
14. **Pgp:** Ligand A (0.843) is acceptable. Ligand B (0.082) is very good, indicating low efflux.
15. **Affinity:** Ligand A (-7.6 kcal/mol) is significantly better than Ligand B (-5.3 kcal/mol). This is a substantial difference in binding strength.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand A has a better logP and significantly better affinity. Ligand B has better Pgp.
**Overall Assessment:**
Despite Ligand A's superior binding affinity, its extremely high DILI risk and poor Caco-2/Solubility make it a highly problematic candidate. The poor solubility and permeability would likely lead to very poor bioavailability. Ligand B, while having a weaker affinity, presents a much more favorable ADME-Tox profile, particularly the significantly lower DILI risk and better metabolic stability. The lower affinity *could* be addressed through further optimization, but the DILI risk of Ligand A is a more difficult problem to solve.
Therefore, I would prioritize Ligand B.
Output:
0
2025-04-17 19:21:34,043 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [349.475, 101.29 , 1.478, 3. , 3. , 0.7 , 30.826, 48.74 , -5.305, -2.92 , 0.091, 27.557, 2.071, 0.032, -6.5 ]
**Ligand B:** [342.443, 78.09 , 1.268, 2. , 3. , 0.846, 27.22 , 49.128, -5.198, -2.008, 0.071, -4.857, -2.039, 0.047, -7.1 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (342.443) is slightly lower, which is generally favorable.
2. **TPSA:** Ligand A (101.29) is a bit higher than Ligand B (78.09). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is still preferred for permeability. Ligand B is better here.
3. **logP:** Both are excellent (1.478 and 1.268, respectively), falling within the optimal 1-3 range. Ligand B is slightly lower, which could be a minor advantage for solubility.
4. **HBD:** Ligand A has 3, Ligand B has 2. Both are acceptable (<=5). Ligand B is slightly better.
5. **HBA:** Both have 3, which is good (<=10).
6. **QED:** Both are good (0.7 and 0.846), indicating drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (30.826) is slightly higher than Ligand B (27.22), but both are well below the concerning threshold of 60. Ligand B is better.
8. **BBB:** Both are similar (48.74 and 49.128). Since this is a cardiovascular target, BBB penetration isn't a primary concern, but it's not detrimental to have some level of it.
9. **Caco-2:** Both are negative, indicating poor permeability. This is a significant drawback for both.
10. **Solubility:** Both are negative, indicating poor solubility. This is a significant drawback for both.
11. **hERG:** Both are very low (0.091 and 0.071), indicating very low cardiotoxicity risk. Excellent for both.
12. **Cl_mic:** Ligand B (-4.857) has a *much* lower (better) microsomal clearance than Ligand A (27.557). This suggests significantly improved metabolic stability for Ligand B.
13. **t1/2:** Ligand B (-2.039) has a longer in vitro half-life than Ligand A (2.071). This is a clear advantage for Ligand B.
14. **Pgp:** Both are very low (0.032 and 0.047), indicating minimal P-gp efflux. Excellent for both.
15. **Affinity:** Ligand B (-7.1) has a significantly stronger binding affinity than Ligand A (-6.5) - a difference of 0.6 kcal/mol. This is a substantial advantage, potentially outweighing some of the ADME drawbacks.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, affinity, logP, and metabolic stability are key. Ligand B excels in affinity and has a much better metabolic profile (lower Cl_mic, longer t1/2). While both have poor Caco-2 and solubility, the superior binding and metabolic properties of Ligand B make it the more promising candidate.
**Conclusion:**
Ligand B is the better candidate.
0
2025-04-17 19:21:34,044 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
The target is ADRB2, a GPCR. Therefore, key priorities are logP, TPSA, Pgp efflux, BBB penetration, and binding affinity. Metabolic stability and solubility are also important, but slightly less so than the first set.
Let's compare the ligands property by property:
1. **MW:** Both are within the ideal range (200-500 Da).
2. **TPSA:** Ligand A (49.41) is significantly better than Ligand B (99.06). A TPSA under 140 is good for oral absorption, and Ligand A is well within that range, while Ligand B is approaching the upper limit.
3. **logP:** Both are within the optimal range (1-3), but Ligand A (2.44) is slightly higher than Ligand B (1.644). Higher logP can be beneficial for membrane permeability.
4. **HBD/HBA:** Ligand A has 1 HBD and 2 HBA, while Ligand B has 2 HBD and 4 HBA. Both are acceptable, but Ligand A is slightly more favorable.
5. **QED:** Ligand A (0.793) is better than Ligand B (0.647), indicating a more drug-like profile.
6. **DILI:** Ligand A (27.491) has a significantly lower DILI risk than Ligand B (35.634).
7. **BBB:** Ligand A (87.01) has much better predicted BBB penetration than Ligand B (57.425). While ADRB2 isn't exclusively a CNS target, some peripheral ADRB2 activity can be modulated by CNS effects, and better BBB penetration is generally a plus.
8. **Caco-2:** Ligand A (-4.615) is better than Ligand B (-5.077), indicating better intestinal absorption.
9. **Solubility:** Ligand A (-3.676) is better than Ligand B (-3.322).
10. **hERG:** Both have similar hERG inhibition liability (0.45 and 0.6).
11. **Cl_mic:** Ligand A (19.383) has a significantly lower microsomal clearance than Ligand B (40.691), suggesting better metabolic stability.
12. **t1/2:** Ligand A (11.549) has a positive in vitro half-life, while Ligand B (-19.58) has a negative half-life.
13. **Pgp:** Both have very low Pgp efflux liability (0.172 and 0.071).
14. **Binding Affinity:** Both have very similar binding affinities (-6.0 and -5.7 kcal/mol). The difference is minimal.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical ADME properties (TPSA, BBB, DILI, Cl_mic, solubility, Caco-2, and QED). While the binding affinities are comparable, the superior ADME profile of Ligand A makes it a more promising drug candidate. The lower TPSA, better BBB penetration, lower DILI risk, and improved metabolic stability are particularly important for a GPCR target like ADRB2.
**Output:**
1
2025-04-17 19:21:34,044 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (409.328 Da) is within the ideal range, while Ligand B (365.583 Da) is also acceptable. No clear advantage here.
2. **TPSA:** Ligand A (67.35) is better than Ligand B (29.54). Both are well below the 140 threshold for oral absorption, but the lower TPSA of Ligand B might suggest better permeability.
3. **logP:** Ligand A (2.697) is optimal, while Ligand B (4.376) is slightly high. This could lead to solubility issues and off-target interactions for Ligand B.
4. **HBD:** Ligand A (1) is good, Ligand B (0) is also good.
5. **HBA:** Ligand A (5) is good, Ligand B (3) is also good.
6. **QED:** Ligand A (0.702) is significantly better than Ligand B (0.449), indicating a more drug-like profile.
7. **DILI:** Ligand A (47.344) is better than Ligand B (16.363), indicating a lower risk of drug-induced liver injury.
8. **BBB:** Ligand A (82.125) is good, while Ligand B (92.129) is even better. Since ADRB2 is a GPCR, BBB penetration is a consideration, though not paramount unless targeting CNS effects.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-5.12) is slightly better than Ligand B (-4.692).
10. **Solubility:** Ligand A (-3.135) is better than Ligand B (-4.953), indicating better aqueous solubility.
11. **hERG:** Ligand A (0.53) is better than Ligand B (0.869), indicating a lower risk of hERG inhibition and cardiotoxicity.
12. **Cl_mic:** Ligand A (73.179) is significantly better than Ligand B (120.242), suggesting better metabolic stability.
13. **t1/2:** Ligand A (8.917) is better than Ligand B (36.178), indicating a longer in vitro half-life.
14. **Pgp:** Ligand A (0.222) is better than Ligand B (0.841), indicating lower P-gp efflux.
15. **Affinity:** Ligand A (-4.8) is slightly weaker than Ligand B (-5.2). However, the difference is not substantial enough to outweigh the other advantages.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A has a better logP and Pgp profile, and a more favorable overall ADME profile. While Ligand B has slightly better affinity and BBB penetration, the higher logP, worse QED, higher DILI risk, and significantly higher Cl_mic are concerning.
**Overall Assessment:**
Ligand A presents a better balance of properties, with a more favorable ADME profile and a lower risk of toxicity. The slight difference in binding affinity is outweighed by the other advantages.
Output:
1
2025-04-17 19:21:34,044 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (385.247 and 345.447 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (80.68 and 80.12) are below 140, good for oral absorption, but not optimized for CNS penetration (target is cardiovascular, so CNS penetration is not a priority). No significant difference.
3. **logP:** Ligand A (3.907) is optimal, while Ligand B (1.621) is on the lower side, potentially hindering permeability. This favors Ligand A.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable, below the threshold of 5. No significant difference.
5. **HBA:** Both ligands (5) are below the threshold of 10. No significant difference.
6. **QED:** Both ligands (0.756 and 0.795) are > 0.5, indicating good drug-likeness. No significant difference.
7. **DILI:** Ligand A (77.627) has a higher DILI risk than Ligand B (36.565). This strongly favors Ligand B.
8. **BBB:** Not a primary concern for a cardiovascular target. Ligand B (66.654) is higher, but this isn't a deciding factor.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.68 and -4.874), which is unusual and suggests poor permeability. This is a concern for both, but doesn't differentiate them.
10. **Solubility:** Ligand A (-4.984) has worse solubility than Ligand B (-2.665). This favors Ligand B.
11. **hERG:** Both ligands (0.471 and 0.122) have low hERG inhibition risk, which is good. Ligand B is slightly better.
12. **Cl_mic:** Ligand B (36.573) has lower microsomal clearance than Ligand A (51.987), suggesting better metabolic stability. This favors Ligand B.
13. **t1/2:** Ligand B (-1.063) has a negative in vitro half-life, which is concerning and suggests rapid degradation. Ligand A (44.646) is much better. This favors Ligand A.
14. **Pgp:** Both ligands (0.332 and 0.068) have relatively low P-gp efflux, which is good. Ligand B is slightly better.
15. **Binding Affinity:** Ligand B (-6.5 kcal/mol) has a slightly better binding affinity than Ligand A (-5.8 kcal/mol). This favors Ligand B, but the difference is not huge.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity), Ligand A initially looks better due to its optimal logP. However, the significantly lower DILI risk, better solubility, and lower Cl_mic of Ligand B are crucial advantages. While Ligand A has a better in vitro half-life, the other ADME properties of Ligand B are more favorable, and the binding affinity difference is not substantial enough to overcome these advantages. The negative Caco-2 values are concerning for both, but can be addressed through formulation strategies.
Output:
0
2025-04-17 19:21:34,044 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.431 and 348.418 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (78.67) is higher than Ligand B (67.43). Both are below the 140 threshold for oral absorption, but closer to the 90 threshold for CNS targets (less relevant for ADRB2, a cardiovascular target). Ligand B is slightly preferred.
3. **logP:** Ligand A (0.668) is a bit low, potentially hindering permeability. Ligand B (2.19) is within the optimal 1-3 range. Ligand B is significantly preferred.
4. **HBD:** Ligand A (1) and Ligand B (2) are both acceptable, below the 5 threshold. No major difference.
5. **HBA:** Ligand A (5) and Ligand B (3) are both acceptable, below the 10 threshold. Ligand B is slightly preferred.
6. **QED:** Both ligands have high QED scores (0.813 and 0.828), indicating good drug-like properties. No significant difference.
7. **DILI:** Ligand A (34.277) has a lower DILI risk than Ligand B (56.262). This is a significant advantage for Ligand A.
8. **BBB:** Both are relatively low, but Ligand B (78.907) is higher than Ligand A (66.188). This isn't a primary concern for an ADRB2 cardiovascular target, but still slightly favors Ligand B.
9. **Caco-2:** Both have negative values (-4.77 and -4.861), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Both have negative values (-1.604 and -2.882), which is also unusual and suggests poor solubility. This is a concern for both.
11. **hERG:** Both ligands have low hERG inhibition risk (0.383 and 0.408). No significant difference.
12. **Cl_mic:** Ligand A (22.604) has lower microsomal clearance than Ligand B (24.199), indicating better metabolic stability. This favors Ligand A.
13. **t1/2:** Ligand A (-10.722) has a negative half-life, which is unusual. Ligand B (17.343) has a positive half-life. This is a strong advantage for Ligand B.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.176 and 0.171). No significant difference.
15. **Binding Affinity:** Ligand B (-7.2 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.6 kcal/mol). This is a substantial advantage for Ligand B, potentially outweighing some ADME concerns.
**Overall Assessment & GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, and binding affinity are key. Ligand B excels in logP and affinity. While Ligand A has a better DILI score and Cl_mic, the significantly stronger binding affinity of Ligand B is crucial. The slightly better solubility and permeability of ligand B are also beneficial. The unusual negative values for Caco-2 and Solubility are concerning for both, but the potency advantage of Ligand B is likely to be more impactful in early development.
Output:
0
2025-04-17 19:21:34,044 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Step-by-step comparison:**
1. **MW:** Both ligands (370.39 and 354.88 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (69.64) is higher than Ligand B (36.26). For a cardiovascular GPCR, TPSA isn't *as* critical as for CNS targets, but lower is generally preferred for permeability. Ligand B is significantly better here.
3. **logP:** Ligand A (2.18) is within the optimal 1-3 range. Ligand B (4.941) is high, potentially leading to solubility issues and off-target interactions. Ligand A is better.
4. **HBD:** Ligand A (2) and Ligand B (0) are both acceptable, below the threshold of 5.
5. **HBA:** Both ligands (3) are below the threshold of 10.
6. **QED:** Both ligands (0.675 and 0.706) are good, above 0.5, indicating drug-like properties. No significant difference.
7. **DILI:** Ligand A (36.25) has a slightly higher DILI risk than Ligand B (12.21), but both are below the concerning threshold of 60. Ligand B is better.
8. **BBB:** Both ligands have good BBB penetration (70.11 and 72.08), which isn't a primary concern for a cardiovascular target, but isn't detrimental.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand A (-2.455) has better solubility than Ligand B (-5.826). This is important for bioavailability. Ligand A is better.
11. **hERG:** Both ligands have low hERG inhibition risk (0.626 and 0.955). No significant difference.
12. **Cl_mic:** Ligand A (23.96) has significantly lower microsomal clearance than Ligand B (75.11), indicating better metabolic stability. Ligand A is better.
13. **t1/2:** Ligand A (-21.244) has a negative half-life, which is problematic. Ligand B (35.30) has a positive half-life. Ligand B is better.
14. **Pgp:** Both ligands have low Pgp efflux (0.163 and 0.696). No significant difference.
15. **Binding Affinity:** Ligand A (-6.7) has slightly better binding affinity than Ligand B (-5.8). While the difference is less than the 1.5 kcal/mol threshold, it is still a factor.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has a better logP and affinity, while Ligand B has a significantly lower TPSA. Metabolic stability (Cl_mic) is also important, favoring Ligand A. Solubility is also a factor, favoring Ligand A. The half-life is a major concern for Ligand A.
**Overall Assessment:**
While Ligand B has a lower TPSA and better half-life, the higher logP and potential solubility issues are concerning. Ligand A, despite the negative half-life, has a more balanced profile with better solubility, metabolic stability, and affinity. The negative half-life is a significant drawback, but could potentially be addressed through structural modifications.
Output:
1
2025-04-17 19:21:34,044 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 drug candidates. ADRB2 is a GPCR, so we'll prioritize logP, Pgp, TPSA, and affinity, alongside general drug-like properties.
**Ligand A:**
* **MW:** 343.471 Da - Good, within the ideal range.
* **TPSA:** 61.44 - Good, well below the 140 threshold.
* **logP:** 2.317 - Excellent, within the optimal 1-3 range.
* **HBD:** 2 - Good, below the threshold of 5.
* **HBA:** 3 - Good, below the threshold of 10.
* **QED:** 0.799 - Excellent, highly drug-like.
* **DILI:** 19.426 - Excellent, very low risk.
* **BBB:** 70.919 - Good, above the 70% threshold, suggesting reasonable CNS penetration if desired.
* **Caco-2:** -4.718 - Poor, indicating low intestinal absorption.
* **Solubility:** -2.364 - Poor, indicating low aqueous solubility.
* **hERG:** 0.434 - Good, low risk of hERG inhibition.
* **Cl_mic:** 38.373 - Moderate, indicating moderate metabolic clearance.
* **t1/2:** -3.728 - Poor, suggesting a short half-life.
* **Pgp:** 0.049 - Excellent, low P-gp efflux.
* **Affinity:** -5.7 kcal/mol - Good, a solid binding affinity.
**Ligand B:**
* **MW:** 347.371 Da - Good, within the ideal range.
* **TPSA:** 117.51 - Moderate, above the ideal <140 but still potentially acceptable.
* **logP:** 0.385 - Poor, below the optimal range, potentially hindering permeation.
* **HBD:** 3 - Good, below the threshold of 5.
* **HBA:** 5 - Good, below the threshold of 10.
* **QED:** 0.666 - Good, reasonably drug-like.
* **DILI:** 63.978 - Moderate, higher DILI risk than Ligand A.
* **BBB:** 41.218 - Poor, low BBB penetration.
* **Caco-2:** -5.413 - Poor, indicating low intestinal absorption.
* **Solubility:** -2.602 - Poor, indicating low aqueous solubility.
* **hERG:** 0.035 - Excellent, very low risk of hERG inhibition.
* **Cl_mic:** -2.684 - Excellent, very low metabolic clearance.
* **t1/2:** 5.849 - Good, suggesting a longer half-life.
* **Pgp:** 0.025 - Excellent, low P-gp efflux.
* **Affinity:** -7.5 kcal/mol - Excellent, significantly stronger binding affinity than Ligand A.
**Comparison and Decision:**
Ligand B has a significantly better binding affinity (-7.5 vs -5.7 kcal/mol), which is a major advantage for a GPCR target. It also has excellent metabolic stability (very low Cl_mic) and a longer half-life. However, its logP is quite low, potentially causing permeability issues. Ligand A has a better logP and lower DILI risk, but suffers from poor Caco-2 permeability, solubility, and a shorter half-life.
Despite the low logP, the substantial affinity difference of Ligand B is a critical factor. For a GPCR, achieving high target engagement is paramount. The lower logP could potentially be addressed with formulation strategies or further chemical modifications, but a strong initial binding affinity is harder to achieve. The better metabolic stability and half-life also contribute to its potential.
Therefore, I would prioritize Ligand B.
0
2025-04-17 19:21:34,044 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (354.397 and 355.435 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (50.8) is significantly better than Ligand B (130.75). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is quite high, potentially hindering absorption.
3. **logP:** Ligand A (3.04) is optimal, while Ligand B (-0.392) is quite low. Low logP can lead to poor membrane permeability and bioavailability. This is a significant advantage for Ligand A.
4. **HBD:** Ligand A (1) is preferable to Ligand B (4). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (5) for similar reasons as HBD.
6. **QED:** Ligand A (0.908) is excellent, indicating high drug-likeness. Ligand B (0.418) is below the desirable threshold of 0.5.
7. **DILI:** Ligand A (56.727) is higher than Ligand B (14.889), indicating a higher risk of drug-induced liver injury. This is a drawback for Ligand A.
8. **BBB:** Ligand A (85.072) is much better than Ligand B (38.232). While ADRB2 isn't exclusively a CNS target, some CNS penetration can be beneficial, and a lower BBB score can indicate more P-gp efflux.
9. **Caco-2:** Ligand A (-4.15) is better than Ligand B (-5.86), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-2.972) is better than Ligand B (-1.886), indicating better aqueous solubility.
11. **hERG:** Both ligands (0.397 and 0.055) have low hERG inhibition risk, which is good. Ligand B is slightly better.
12. **Cl_mic:** Ligand A (42.48) is better than Ligand B (27.014), indicating better metabolic stability.
13. **t1/2:** Ligand A (-8.007) is better than Ligand B (-7.24), indicating a longer half-life.
14. **Pgp:** Both ligands (0.152 and 0.005) have low P-gp efflux liability, which is good. Ligand B is slightly better.
15. **Binding Affinity:** Both ligands (-6.5 kcal/mol) have the same binding affinity.
**Overall Assessment:**
Ligand A has a significantly better profile regarding key ADME properties (TPSA, logP, QED, solubility, Caco-2, Cl_mic, t1/2) and BBB penetration, which are important for GPCRs. While Ligand A has a higher DILI risk, the substantial advantages in other areas outweigh this concern, especially given that DILI risk can be further mitigated during lead optimization. Ligand B suffers from a high TPSA and a very low logP, which are major drawbacks for oral bioavailability and permeability.
Output:
1
2025-04-17 19:21:34,044 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (340.39) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (76.02) has a significantly lower TPSA than Ligand A (95.08). This is a major advantage for oral absorption and potentially better BBB penetration, aligning with GPCR priorities.
3. **logP:** Ligand B (1.91) is closer to the optimal range (1-3) than Ligand A (0.676), which is a bit low and could indicate permeability issues.
4. **HBD/HBA:** Ligand A (1 HBD, 5 HBA) has fewer hydrogen bond donors and acceptors than Ligand B (2 HBD, 4 HBA). This is generally favorable for permeability.
5. **QED:** Ligand A (0.886) has a higher QED score than Ligand B (0.752), indicating a more drug-like profile.
6. **DILI:** Ligand B (28.54) has a much lower DILI risk than Ligand A (63.13). This is a critical advantage, as liver toxicity is a major concern in drug development.
7. **BBB:** Ligand B (75.38) has a significantly higher BBB penetration percentile than Ligand A (23.54). This is highly desirable for a GPCR target, even if not directly in the CNS, as it can influence off-target effects.
8. **Caco-2:** Both ligands have similar, very negative Caco-2 permeability values. This is concerning for both, indicating poor intestinal absorption.
9. **Solubility:** Both ligands have similar, very negative solubility values. This is a significant drawback for both.
10. **hERG:** Ligand A (0.134) has a slightly lower hERG inhibition liability than Ligand B (0.393), which is a slight advantage.
11. **Cl_mic:** Ligand A (-10.264) has a much lower (better) microsomal clearance than Ligand B (11.48). This suggests better metabolic stability.
12. **t1/2:** Ligand A (-9.881) has a much longer in vitro half-life than Ligand B (1.548). This is a significant advantage.
13. **Pgp:** Ligand A (0.013) has a much lower P-gp efflux liability than Ligand B (0.157), which is a positive.
14. **Binding Affinity:** Ligand A (-7.4 kcal/mol) has a slightly better binding affinity than Ligand B (-5.5 kcal/mol). This is a notable advantage.
**Overall Assessment:**
While Ligand A has a better binding affinity, longer half-life, lower Pgp efflux, and lower Cl_mic, Ligand B excels in key areas crucial for a GPCR drug candidate: lower TPSA, better logP, significantly lower DILI risk, and substantially higher BBB penetration. The poor Caco-2 and solubility for both are concerning, but can potentially be addressed with formulation strategies. The lower DILI and better BBB penetration of Ligand B are particularly compelling, outweighing the slightly weaker affinity. The affinity difference (1.9 kcal/mol) is not substantial enough to overcome the ADME advantages of Ligand B.
**Output:**
0
2025-04-17 19:21:34,044 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (346.435 Da) is slightly lower, which is generally favorable for permeability.
**2. TPSA:** Ligand B (75.71) is significantly better than Ligand A (107.83). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally correlates with better absorption.
**3. logP:** Both ligands have good logP values (A: 1.794, B: 1.342) falling within the optimal 1-3 range.
**4. H-Bond Donors:** Ligand B (1) is better than Ligand A (2). Fewer HBDs generally improve permeability.
**5. H-Bond Acceptors:** Ligand B (4) is better than Ligand A (6). Fewer HBAs generally improve permeability.
**6. QED:** Ligand A (0.71) is slightly better than Ligand B (0.582), indicating a more drug-like profile.
**7. DILI Risk:** Ligand B (29.934) has a much lower DILI risk than Ligand A (52.346). This is a significant advantage.
**8. BBB Penetration:** Both ligands have similar BBB penetration (A: 68.554, B: 67.546). This isn't a critical factor for a cardiovascular target.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, indicating poor permeability. However, Ligand B (-4.985) is slightly better than Ligand A (-5.195).
**10. Aqueous Solubility:** Both ligands have very poor solubility (-2.34 and -2.978). This is a major concern for both.
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (A: 0.06, B: 0.268). This is excellent.
**12. Microsomal Clearance:** Ligand B (17.762) has lower microsomal clearance than Ligand A (21.329), suggesting better metabolic stability.
**13. In vitro Half-Life:** Ligand B (-7.433) has a significantly longer in vitro half-life than Ligand A (-1.237). This is a major advantage.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux (A: 0.214, B: 0.053), which is good.
**15. Binding Affinity:** Ligand B (-5.6 kcal/mol) has a slightly better binding affinity than Ligand A (-3.6 kcal/mol). This 2 kcal/mol difference is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
While Ligand A has a slightly better QED score, Ligand B is superior in almost every other critical parameter. The lower DILI risk, better metabolic stability (lower Cl_mic, longer t1/2), and significantly improved binding affinity of Ligand B make it the more promising candidate. The solubility is a concern for both, but the other advantages of Ligand B are more impactful for a GPCR target like ADRB2.
Output:
0
2025-04-17 19:21:34,045 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (345-350 Da). No significant difference.
2. **TPSA:** Both are reasonably low (96.77 and 91.76), suggesting good potential for absorption. Ligand B is slightly better.
3. **logP:** Both are within the optimal range (1.644 and 0.933). Ligand B is slightly lower, which could be a minor drawback, but still acceptable.
4. **HBD:** Both have 2 HBD, which is good.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 5. Both are acceptable, but lower is generally preferred.
6. **QED:** Both have high QED scores (0.876 and 0.85), indicating good drug-likeness.
7. **DILI:** Ligand A (54.634) has a higher DILI risk than Ligand B (41.877). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (82.047) has better BBB penetration than Ligand B (54.634). While ADRB2 isn't strictly a CNS target, some CNS exposure can occur, and higher BBB is generally favorable.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. Ligand B (-4.875) is slightly worse than Ligand A (-4.585).
10. **Solubility:** Both have negative solubility values, indicating poor solubility. Ligand B (-2.579) is slightly worse than Ligand A (-3.13).
11. **hERG:** Both have low hERG inhibition risk (0.603 and 0.131). Ligand B is significantly better here.
12. **Cl_mic:** Ligand A has a negative clearance (-1.434), which is excellent (indicates very slow clearance/high stability). Ligand B has a positive clearance (7.476), indicating faster metabolism. This is a major advantage for Ligand A.
13. **t1/2:** Ligand A has a significantly longer half-life (-9.211) than Ligand B (-14.252). This is a substantial advantage for Ligand A.
14. **Pgp:** Both have very low Pgp efflux liability (0.238 and 0.019). Ligand B is negligibly better.
15. **Binding Affinity:** Ligand A (-6.1 kcal/mol) has slightly better binding affinity than Ligand B (-5.7 kcal/mol), but the difference is not huge.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Both ligands perform reasonably well on logP and TPSA. Pgp is low for both. Affinity is slightly better for Ligand A. However, ADME properties are crucial. Ligand A has significantly better metabolic stability (Cl_mic and t1/2) and a lower DILI risk, which are critical for a viable drug candidate. While Ligand A has slightly worse BBB penetration, the benefits in ADME and safety outweigh this. The poor Caco-2 and solubility for both are concerning, but could be addressed with formulation strategies.
**Conclusion:**
Considering the balance of properties, especially the superior metabolic stability, lower DILI risk, and slightly better affinity of Ligand A, it is the more promising drug candidate.
Output:
1
2025-04-17 19:21:34,045 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (379.5 and 362.5 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand B (49.41) is significantly better than Ligand A (91.32). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (1.873 and 2.673), falling within the 1-3 range. Ligand B is slightly better.
4. **HBD:** Ligand A has 3 HBD, while Ligand B has 1. Both are acceptable (<=5). Ligand B is slightly preferred.
5. **HBA:** Ligand A has 6 HBA, Ligand B has 3. Both are within the acceptable range (<=10). Ligand B is preferred.
6. **QED:** Ligand B (0.836) has a better QED score than Ligand A (0.653), indicating a more drug-like profile.
7. **DILI:** Ligand B (17.216) has a much lower DILI risk than Ligand A (65.568). This is a significant advantage for Ligand B.
8. **BBB:** Ligand B (75.843) has a higher BBB penetration percentile than Ligand A (43.505). While not critical for a cardiovascular target, it's a bonus.
9. **Caco-2:** Both have negative Caco-2 values (-5.281 and -5.106), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Both have negative solubility values (-2.861 and -3.709), indicating poor aqueous solubility. This is a significant drawback for both.
11. **hERG:** Ligand A (0.273) has a slightly lower hERG risk than Ligand B (0.458), which is a slight advantage.
12. **Cl_mic:** Ligand A (28.858) has a lower microsomal clearance than Ligand B (67.236), indicating better metabolic stability. This is a positive for Ligand A.
13. **t1/2:** Ligand A (31.743) has a significantly longer in vitro half-life than Ligand B (3.977). This is a major advantage for Ligand A.
14. **Pgp:** Ligand A (0.204) has lower P-gp efflux liability than Ligand B (0.083). Lower is better, so Ligand A is preferred.
15. **Affinity:** Ligand A (-7.6 kcal/mol) has a stronger binding affinity than Ligand B (-6.5 kcal/mol). This is a 1.1 kcal/mol difference, which is substantial and can outweigh some ADME concerns.
**Overall Assessment:**
Ligand A has a significantly better binding affinity and metabolic stability (lower Cl_mic, longer t1/2), and lower Pgp efflux. Ligand B excels in DILI risk, QED, TPSA, and BBB penetration. The poor Caco-2 and solubility are concerning for both. However, the strong affinity of Ligand A is a critical factor for GPCR targets, and the 1.1 kcal/mol advantage is substantial. The better metabolic stability and Pgp profile of Ligand A also contribute to its potential for improved *in vivo* performance.
Output:
1
2025-04-17 19:21:34,045 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (396.171) is slightly higher than Ligand B (345.443), but both are acceptable.
2. **TPSA:** Ligand A (45.23) is well below the 140 threshold and is good. Ligand B (80.32) is still under 140, but higher, potentially impacting permeability.
3. **logP:** Ligand A (4.621) is a bit high, potentially leading to solubility issues or off-target interactions. Ligand B (1.76) is optimal.
4. **HBD:** Both ligands have acceptable HBD counts (Ligand A: 1, Ligand B: 2).
5. **HBA:** Both ligands have acceptable HBA counts (Ligand A: 3, Ligand B: 4).
6. **QED:** Both ligands have similar and acceptable QED values (Ligand A: 0.606, Ligand B: 0.528).
7. **DILI:** Ligand A (79.333) has a higher DILI risk than Ligand B (35.324). This is a significant negative for Ligand A.
8. **BBB:** Ligand A (75.649) has better BBB penetration than Ligand B (63.164). While ADRB2 isn't strictly a CNS target, some CNS exposure can occur, and better BBB is generally favorable.
9. **Caco-2:** Ligand A (-4.613) and Ligand B (-5.256) both have negative Caco-2 values, which is unusual and suggests poor permeability.
10. **Solubility:** Ligand A (-5.406) has worse solubility than Ligand B (-1.966). This is concerning, especially given Ligand A's higher logP.
11. **hERG:** Ligand A (0.575) has a slightly higher hERG risk than Ligand B (0.171).
12. **Cl_mic:** Ligand A (60.522) has a higher microsomal clearance than Ligand B (29.301), indicating lower metabolic stability.
13. **t1/2:** Ligand A (77.539) has a significantly longer in vitro half-life than Ligand B (5.285). This is a strong positive for Ligand A.
14. **Pgp:** Ligand A (0.412) has lower P-gp efflux than Ligand B (0.074).
15. **Affinity:** Ligand B (-6.3 kcal/mol) has a stronger binding affinity than Ligand A (-5.9 kcal/mol). This is a 0.4 kcal/mol difference, which is meaningful.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP and has a better affinity. While Ligand A has better BBB and Pgp, its high logP, poor solubility, and higher DILI risk are major drawbacks. The longer half-life of Ligand A is attractive, but can be addressed through structural modifications.
**Overall Assessment:**
Ligand B is the more promising candidate. Its superior binding affinity, lower DILI risk, better solubility, and optimal logP outweigh the slightly lower BBB penetration and shorter half-life. The half-life can be improved through medicinal chemistry efforts.
Output:
0
2025-04-17 19:21:34,045 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.359 and 341.415 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (105.02) is slightly higher than Ligand B (90.12). Both are below the 140 threshold for good oral absorption, but Ligand B is closer to the preferred <90 for GPCRs.
3. **logP:** Ligand B (3.161) is optimal (1-3), while Ligand A (0.466) is quite low, potentially hindering membrane permeability. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (7) is preferable to Ligand B (3). Fewer HBAs generally improve permeability.
6. **QED:** Ligand B (0.798) has a better QED score than Ligand A (0.468), indicating a more drug-like profile.
7. **DILI:** Ligand A (61.148) has a lower DILI risk than Ligand B (79.449), which is better.
8. **BBB:** Both ligands have similar BBB penetration (Ligand A: 53.897, Ligand B: 54.634). Not a major differentiating factor for a cardiovascular target like ADRB2.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-2.679) has better solubility than Ligand B (-4.388).
11. **hERG:** Both ligands have low hERG inhibition risk (Ligand A: 0.432, Ligand B: 0.474).
12. **Cl_mic:** Ligand B (-6.53) has significantly lower microsomal clearance than Ligand A (12.395), indicating better metabolic stability. This is a substantial advantage.
13. **t1/2:** Ligand B (27.652) has a much longer in vitro half-life than Ligand A (-8.761). This is a major advantage, potentially leading to less frequent dosing.
14. **Pgp:** Both ligands have very low Pgp efflux liability (Ligand A: 0.035, Ligand B: 0.042).
15. **Binding Affinity:** Both ligands have similar binding affinities (Ligand A: -6.7, Ligand B: -6.6). The difference is negligible.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand B is the stronger candidate. While Ligand A has better solubility and lower DILI risk, Ligand B's optimal logP, lower TPSA, significantly improved metabolic stability (Cl_mic and t1/2), and comparable binding affinity outweigh these advantages. The low logP of Ligand A is a major concern for permeability, and the poor Caco-2 values for both are a red flag that would require further investigation.
Output:
0
2025-04-17 19:21:34,045 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (360.401 and 357.487 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (75.71) is significantly better than Ligand B (92.31). For a GPCR, keeping TPSA under 140 is good for absorption, and lower is generally preferred.
**3. logP:** Both ligands have acceptable logP values (1.727 and 2.78), falling within the 1-3 range. Ligand B is slightly higher, which could potentially lead to some solubility issues, but is still within an acceptable range.
**4. H-Bond Donors:** Both have 1 HBD, which is excellent.
**5. H-Bond Acceptors:** Ligand A has 4 HBA, while Ligand B has 8. This is a significant difference. Higher HBA can sometimes hinder permeability.
**6. QED:** Ligand B (0.884) has a substantially better QED score than Ligand A (0.578), indicating a more drug-like profile overall.
**7. DILI:** Ligand A (47.421) has a slightly better DILI score than Ligand B (54.866), indicating a lower risk of drug-induced liver injury. Both are still reasonably good.
**8. BBB:** Ligand A (80.613) has a significantly better BBB penetration score than Ligand B (65.801). While ADRB2 isn't exclusively a CNS target, some CNS penetration can be beneficial, and minimizing it isn't a priority.
**9. Caco-2 Permeability:** Ligand A (-4.512) has a better Caco-2 permeability score than Ligand B (-5.511), suggesting better intestinal absorption.
**10. Aqueous Solubility:** Ligand A (-2.314) has a better aqueous solubility score than Ligand B (-3.295).
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.332 and 0.156), which is excellent.
**12. Microsomal Clearance:** Ligand A (37.558) has a better (lower) microsomal clearance than Ligand B (7.075), suggesting better metabolic stability.
**13. In vitro Half-Life:** Ligand A (-16.563) has a much better (longer) in vitro half-life than Ligand B (0.927).
**14. P-gp Efflux:** Ligand A (0.043) has a much lower P-gp efflux liability than Ligand B (0.184). Lower P-gp efflux is desirable for better bioavailability.
**15. Binding Affinity:** Ligand B (-4.6) has a slightly better binding affinity than Ligand A (-6.0). However, the difference is not substantial enough to outweigh the other ADME properties.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand A emerges as the more promising candidate. While Ligand B has a better QED and slightly better affinity, Ligand A excels in critical ADME properties like TPSA, BBB penetration, Caco-2 permeability, solubility, metabolic stability (Cl_mic and t1/2), and P-gp efflux. These factors are crucial for ensuring adequate bioavailability and minimizing potential off-target effects. The difference in affinity is not large enough to overcome the significant ADME advantages of Ligand A.
Output:
1
2025-04-17 19:21:34,045 - INFO - Batch 104 complete. Total preferences: 1664
2025-04-17 19:21:34,045 - INFO - Processing batch 105/512...
2025-04-17 19:22:22,529 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's break down the comparison of Ligand A and Ligand B, focusing on the guidelines and GPCR-specific priorities (logP, Pgp, TPSA, and affinity).
1. **Molecular Weight:** Both ligands (350.463 and 348.443 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (96.25) is higher than Ligand B (71.78). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B has a clear advantage.
3. **logP:** Ligand A (1.081) is within the optimal range, while Ligand B (2.053) is also acceptable but trending higher. Both are good, but A is slightly better.
4. **H-Bond Donors/Acceptors:** Ligand A has 3 HBD and 5 HBA, while Ligand B has 1 HBD and 4 HBA. Both are within acceptable limits, and B is slightly better.
5. **QED:** Both ligands have good QED scores (0.621 and 0.78), indicating good drug-like properties. Ligand B is slightly better.
6. **DILI:** Ligand A (29.236) has a slightly higher DILI risk than Ligand B (21.52), but both are well below the concerning threshold of 60.
7. **BBB:** Ligand A (51.377) has a lower BBB penetration percentile than Ligand B (69.523). Since ADRB2 is not a CNS target, this is less important, but B is still preferable.
8. **Caco-2 Permeability:** Ligand A (-5.092) has worse Caco-2 permeability than Ligand B (-4.683).
9. **Aqueous Solubility:** Ligand A (-1.916) has worse aqueous solubility than Ligand B (-1.571).
10. **hERG Inhibition:** Ligand A (0.052) has a slightly lower hERG inhibition risk than Ligand B (0.212), which is a positive.
11. **Microsomal Clearance:** Ligand A (23.094) has higher microsomal clearance than Ligand B (17.036), indicating faster metabolism and potentially lower *in vivo* exposure. Ligand B is preferable.
12. **In vitro Half-Life:** Ligand A (-0.463) has a shorter half-life than Ligand B (35.043). This is a significant advantage for Ligand B.
13. **P-gp Efflux:** Ligand A (0.016) has lower P-gp efflux than Ligand B (0.063), which is preferable.
14. **Binding Affinity:** Ligand A (-7.7 kcal/mol) has a slightly stronger binding affinity than Ligand B (-6.2 kcal/mol). This is a substantial advantage for Ligand A, and can outweigh some of the ADME drawbacks.
**Overall Assessment:**
While Ligand B excels in several ADME properties (TPSA, logP, solubility, permeability, clearance, half-life), Ligand A boasts a significantly stronger binding affinity (-7.7 vs -6.2 kcal/mol). For a GPCR, potency is paramount. The difference of 1.5 kcal/mol is substantial enough to overcome the slightly less favorable ADME profile of Ligand A, especially considering both ligands are within acceptable ranges for most parameters. The lower hERG risk for Ligand A is also a bonus.
**Output:**
1
2025-04-17 19:22:22,530 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (366.296 and 348.447 Da) are within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (87.46) is significantly better than Ligand A (137.36). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have acceptable logP values (0.861 and 1.031, respectively), falling within the 1-3 range. Ligand B is slightly better.
4. **HBD:** Ligand A has 4 HBD, while Ligand B has 2. Ligand B is preferable as it is closer to the ideal of <=5.
5. **HBA:** Both ligands have 5 HBA, which is acceptable.
6. **QED:** Ligand B (0.804) has a much better QED score than Ligand A (0.399), indicating a more drug-like profile. This is a significant advantage.
7. **DILI:** Ligand B (40.403) has a lower DILI risk than Ligand A (67.003). Lower is better, and Ligand B is comfortably below the 60% threshold.
8. **BBB:** Ligand B (44.591) has a slightly higher BBB penetration than Ligand A (35.828). While not critical for a cardiovascular target, it's a minor positive.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-5.429) is slightly better.
10. **Solubility:** Both ligands have negative solubility values, indicating poor aqueous solubility. Ligand A (-2.682) is slightly better.
11. **hERG:** Both ligands have low hERG inhibition liability (0.466 and 0.23, respectively), which is good. Ligand B is better.
12. **Cl_mic:** Ligand B (17.701) has a much higher microsomal clearance than Ligand A (0.26). This is a significant negative for Ligand B, suggesting faster metabolism.
13. **t1/2:** Ligand B (15.877) has a much longer in vitro half-life than Ligand A (-16.769). This is a significant positive for Ligand B.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.053 and 0.066, respectively). No clear advantage.
15. **Binding Affinity:** Ligand A (-5.0 kcal/mol) has a significantly better binding affinity than Ligand B (-6.5 kcal/mol). This is a substantial advantage, potentially outweighing some ADME concerns.
**Overall Assessment:**
Ligand A has a much better binding affinity, which is the most important factor for GPCRs. However, Ligand B has superior drug-like properties (QED, DILI, TPSA, HBD, hERG) and a longer half-life. The biggest drawback for Ligand B is its higher microsomal clearance. The difference in binding affinity is substantial (1.5 kcal/mol), and given the importance of potency for GPCRs, this outweighs the ADME concerns for Ligand B.
Output:
1
2025-04-17 19:22:22,530 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (349.39 Da) is slightly larger than Ligand B (334.42 Da), but this difference isn't significant.
**2. TPSA:** Ligand A (123.66) is higher than Ligand B (59.81). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for permeability. Ligand B has a much more favorable TPSA.
**3. logP:** Ligand B (3.637) is better than Ligand A (0.386). The optimal range is 1-3, and Ligand A is below this, potentially hindering membrane permeability. Ligand B is at the upper end, but still acceptable.
**4. H-Bond Donors:** Ligand A (3) is higher than Ligand B (1). Lower is generally better for permeability.
**5. H-Bond Acceptors:** Ligand A (5) is higher than Ligand B (4). Again, lower is generally better for permeability.
**6. QED:** Both ligands have good QED scores (A: 0.685, B: 0.749), indicating good drug-like properties.
**7. DILI Risk:** Ligand A (42.46%) has a significantly lower DILI risk than Ligand B (77.78%). This is a major advantage for Ligand A.
**8. BBB Penetration:** This is less critical for a cardiovascular target, but Ligand A (59.79%) is better than Ligand B (49.86%).
**9. Caco-2 Permeability:** Ligand A (-5.75) is better than Ligand B (-4.998). Higher Caco-2 values indicate better absorption.
**10. Aqueous Solubility:** Ligand A (-2.554) is better than Ligand B (-5.059).
**11. hERG Inhibition:** Ligand A (0.022) has a much lower hERG risk than Ligand B (0.465). This is a critical safety parameter.
**12. Microsomal Clearance:** Ligand A (-0.033) has a lower (better) microsomal clearance than Ligand B (65.629). This suggests better metabolic stability.
**13. In vitro Half-Life:** Ligand B (14.624) has a longer half-life than Ligand A (17.359).
**14. P-gp Efflux:** Ligand A (0.005) has a much lower P-gp efflux liability than Ligand B (0.645). This is important for bioavailability.
**15. Binding Affinity:** Ligand B (-6.9) has a slightly better binding affinity than Ligand A (-6.6). However, the difference is relatively small (0.3 kcal/mol).
**Overall Assessment:**
While Ligand B has slightly better binding affinity and in vitro half-life, Ligand A is significantly superior in terms of safety (DILI, hERG), ADME properties (logP, TPSA, solubility, permeability, clearance, P-gp efflux), and has acceptable binding affinity. The lower DILI and hERG risk are particularly important for a cardiovascular drug. The better ADME profile of Ligand A suggests it will have better bioavailability and metabolic stability.
Output:
1
2025-04-17 19:22:22,530 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [352.391, 94.92, 0.284, 1, 7, 0.41, 65.103, 55.874, -5.044, -1.183, 0.167, -2.097, -25.044, 0.022, -7.5]
**Ligand B:** [366.845, 71.78, 2.779, 1, 4, 0.813, 51.842, 45.638, -4.872, -3.435, 0.204, 7.436, 44.787, 0.097, -5.3]
Here's a breakdown, considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal 200-500 Da range. Ligand A (352.391) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (94.92) is higher than Ligand B (71.78). Both are acceptable, but Ligand B is better for oral absorption.
3. **logP:** Ligand B (2.779) is optimal (1-3). Ligand A (0.284) is quite low, potentially hindering membrane permeability and bioavailability. This is a significant drawback.
4. **HBD/HBA:** Both have 1 HBD, which is good. Ligand A has 7 HBA, while Ligand B has 4. Both are within acceptable limits, but Ligand B is slightly better.
5. **QED:** Ligand B (0.813) has a much better QED score than Ligand A (0.41), indicating a more drug-like profile.
6. **DILI:** Ligand B (51.842) has a lower DILI risk than Ligand A (65.103), which is desirable.
7. **BBB:** Both are moderate, but Ligand A (55.874) is slightly higher. This is less critical for a cardiovascular target like ADRB2, but still a consideration.
8. **Caco-2:** Both are negative, indicating poor permeability.
9. **Solubility:** Both are negative, indicating poor solubility.
10. **hERG:** Both are very low, indicating minimal hERG inhibition risk.
11. **Cl_mic:** Ligand A (-2.097) has a *negative* clearance, which is impossible. This is a red flag and suggests a data error or a very unusual metabolic profile. Ligand B (7.436) is reasonable.
12. **t1/2:** Ligand B (44.787) has a significantly longer in vitro half-life than Ligand A (-25.044), which is a major advantage.
13. **Pgp:** Both are very low, indicating minimal P-gp efflux.
14. **Affinity:** Ligand A (-7.5) has a slightly better binding affinity than Ligand B (-5.3). However, the difference is not huge, and other factors are more important.
**Overall Assessment:**
Ligand A's low logP is a major concern, potentially leading to poor absorption. The negative microsomal clearance is a data quality issue and highly problematic. While it has slightly better affinity, the other ADME properties of Ligand B are far superior, making it a much more promising candidate. Ligand B has a better QED score, lower DILI risk, and a much more reasonable half-life.
Therefore, I prefer Ligand B.
0
2025-04-17 19:22:22,530 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (383.86 & 364.48 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (84.67) is better than Ligand B (101.8), being closer to the <140 threshold for good absorption.
3. **logP:** Both ligands have good logP values (2.359 & 1.852), falling within the 1-3 range. Ligand B is slightly lower, which *could* indicate slightly better solubility, but is not a major concern.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (6) is preferable to Ligand B (7). Lower HBA generally improves permeability.
6. **QED:** Ligand A (0.856) has a slightly better QED score than Ligand B (0.777), indicating a more drug-like profile.
7. **DILI:** Ligand B (65.374) has a lower DILI risk than Ligand A (78.131), which is a significant advantage.
8. **BBB:** Both ligands have similar BBB penetration (60.644 & 65.413). Not a major differentiating factor for a cardiovascular target like ADRB2.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.877 & -5.265), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Both ligands have negative solubility values (-3.134 & -3.423), indicating very poor aqueous solubility. This is a major drawback for both.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.257 & 0.186), which is excellent.
12. **Cl_mic:** Ligand B (30.034) has lower microsomal clearance than Ligand A (20.975), suggesting better metabolic stability.
13. **t1/2:** Ligand A (35.888) has a longer in vitro half-life than Ligand B (-4.919). This is a significant advantage.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.185 & 0.116), which is good.
15. **Binding Affinity:** Ligand A (-6.7 kcal/mol) has a significantly better binding affinity than Ligand B (-4.6 kcal/mol). This is a 2.1 kcal/mol difference, which is substantial and can outweigh some ADME drawbacks.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A excels in affinity and has better TPSA and H-bonding characteristics. While Ligand B has a better DILI score and Cl_mic, the significantly stronger binding affinity of Ligand A is likely to be more important for achieving efficacy. The poor solubility and Caco-2 values are concerning for both, but can potentially be addressed through formulation strategies.
**Conclusion:**
Despite the better DILI and Cl_mic of Ligand B, the substantially stronger binding affinity of Ligand A makes it the more promising candidate. The affinity difference is large enough to potentially overcome the solubility and permeability concerns.
Output:
1
2025-04-17 19:22:22,530 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (343.431 and 349.431 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (81.93) is better than Ligand B (91.76). Both are below 140, but closer to 90 is preferable for GPCRs, and A is closer.
3. **logP:** Ligand A (1.795) is better than Ligand B (0.756). Both are within the optimal 1-3 range, but A is closer to the middle of that range.
4. **HBD:** Ligand A (1) is better than Ligand B (2). Lower is generally preferred.
5. **HBA:** Ligand A (6) is better than Ligand B (5). Both are acceptable, but A is slightly better.
6. **QED:** Both ligands have similar QED values (0.751 and 0.791), indicating good drug-likeness.
7. **DILI:** Ligand B (32.299) is significantly better than Ligand A (44.591). Lower DILI risk is a major advantage.
8. **BBB:** Ligand A (76.309) is significantly better than Ligand B (50.679). While ADRB2 isn't necessarily a CNS target, higher BBB penetration can sometimes translate to better overall distribution.
9. **Caco-2:** Both ligands have very similar, and poor, Caco-2 permeability (-4.791 and -4.688). This is a concern for oral bioavailability for both.
10. **Solubility:** Ligand A (-2.276) is better than Ligand B (-1.702). Higher solubility is generally preferred.
11. **hERG:** Ligand A (0.073) is significantly better than Ligand B (0.234). Lower hERG risk is crucial for cardiovascular targets.
12. **Cl_mic:** Ligand B (-2.692) is significantly better than Ligand A (54.923). Lower clearance indicates better metabolic stability, a significant advantage.
13. **t1/2:** Ligand B (10.707) is significantly better than Ligand A (-9.48). Longer half-life is desirable.
14. **Pgp:** Ligand A (0.059) is better than Ligand B (0.099). Lower P-gp efflux is preferred.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.0 and -5.4 kcal/mol). The difference of 0.6 kcal/mol is not substantial enough to override other factors.
**Overall Assessment:**
Ligand B has a clear advantage in terms of safety (DILI, hERG) and pharmacokinetics (Cl_mic, t1/2). While Ligand A has some advantages in TPSA, logP, solubility, and BBB, the superior safety and PK profile of Ligand B are more important for a cardiovascular target. The Caco-2 permeability is a concern for both, but can be addressed with formulation strategies. The slight difference in binding affinity is not enough to overcome the other benefits of Ligand B.
Output:
0
2025-04-17 19:22:22,530 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (348.491 and 344.463 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (88.32) is slightly higher than Ligand B (77.63). Both are below the 140 A^2 threshold for good oral absorption, but closer to the 90 A^2 threshold for CNS targets.
3. **logP:** Both ligands (2.765 and 2.33) are within the optimal 1-3 range. Ligand B is slightly lower, potentially indicating slightly better solubility, but both are acceptable.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1). Both are within the acceptable limit of <=5.
5. **HBA:** Ligand A (4) is lower than Ligand B (6). Both are within the acceptable limit of <=10.
6. **QED:** Ligand A (0.793) has a significantly better QED score than Ligand B (0.53), suggesting a more drug-like profile.
7. **DILI:** Ligand B (31.718) has a much lower DILI risk than Ligand A (47.15), making it safer from a liver toxicity perspective. This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (76.735) has a higher BBB penetration percentile than Ligand B (45.211). While ADRB2 isn't *strictly* a CNS target, some CNS exposure can be relevant for off-target effects, and higher BBB is generally better.
9. **Caco-2:** Ligand A (-4.817) and Ligand B (-5.385) both have negative values, which is unusual. Lower (more negative) values indicate poorer permeability. Ligand B is slightly worse here.
10. **Solubility:** Ligand A (-3.205) has slightly better solubility than Ligand B (-1.37).
11. **hERG:** Both ligands (0.652 and 0.297) have low hERG inhibition liability, indicating a low risk of cardiotoxicity. Ligand B is slightly better.
12. **Cl_mic:** Ligand B (33.118) has a lower microsomal clearance than Ligand A (64.305), suggesting better metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand A (34.18) has a significantly longer in vitro half-life than Ligand B (-2.915). This is a major advantage for Ligand A, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands (0.157 and 0.106) have low P-gp efflux liability. Ligand B is slightly better.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.4 and -6.3 kcal/mol). The difference is negligible.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Both ligands perform reasonably well on these metrics. However, metabolic stability (Cl_mic, t1/2) and safety (DILI, hERG) are also crucial. Ligand B excels in DILI and Cl_mic, while Ligand A has a much better t1/2.
**Overall Assessment:**
While Ligand A has a better QED and longer half-life, Ligand B's significantly lower DILI risk and improved metabolic stability are more compelling. The slight advantage in BBB for Ligand A is less critical for a non-CNS primary target. The similar affinities mean that the ADME/Tox profile becomes the deciding factor.
Output:
0
2025-04-17 19:22:22,530 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's systematically compare Ligand A and Ligand B based on the provided parameters and the guidelines, keeping in mind ADRB2 is a GPCR.
1. **Molecular Weight:** Both ligands (366.53 & 370.56 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (58.64) is better than Ligand B (67.43). Both are below the 140 threshold for oral absorption, but lower TPSA is generally preferred for GPCRs to aid in permeability.
3. **logP:** Both ligands have good logP values (3.22 and 2.73) within the optimal 1-3 range. Ligand A is slightly higher, which could be advantageous for membrane permeability.
4. **H-Bond Donors:** Ligand A (1) is better than Ligand B (2). Lower HBD generally improves permeability.
5. **H-Bond Acceptors:** Both ligands have the same number of HBA (4), which is within the acceptable limit of 10.
6. **QED:** Both ligands have similar QED values (0.719 and 0.723), indicating good drug-likeness.
7. **DILI:** Ligand B (21.17%) is significantly better than Ligand A (31.06%). Lower DILI is crucial.
8. **BBB:** Ligand B (70.84%) is slightly better than Ligand A (66.34%). While not a primary concern for ADRB2 (a cardiovascular target), higher BBB is still a positive.
9. **Caco-2 Permeability:** Ligand A (-4.614) is better than Ligand B (-5.139). Higher Caco-2 permeability indicates better absorption.
10. **Aqueous Solubility:** Ligand A (-3.45) is slightly better than Ligand B (-3.148). Both are poor, but A is less poor.
11. **hERG Inhibition:** Ligand A (0.329) is better than Ligand B (0.259). Lower hERG inhibition is critical for avoiding cardiotoxicity, especially important for a cardiovascular target.
12. **Microsomal Clearance:** Ligand B (48.05) is better than Ligand A (100.65). Lower clearance suggests better metabolic stability.
13. **In vitro Half-Life:** Ligand A (53.40) is much better than Ligand B (4.22). A longer half-life is desirable for less frequent dosing.
14. **P-gp Efflux:** Ligand A (0.139) is better than Ligand B (0.03). Lower P-gp efflux is favorable for bioavailability.
15. **Binding Affinity:** Ligand A (-6.9 kcal/mol) is slightly better than Ligand B (-6.5 kcal/mol). This difference is significant enough to consider, as it exceeds the 1.5 kcal/mol advantage threshold.
**Overall Assessment:**
Ligand A has a better binding affinity, better TPSA, better HBD, better Caco-2 permeability, better solubility, and better hERG inhibition. Ligand B has a significantly better DILI score and slightly better BBB penetration and microsomal clearance. The affinity difference and the hERG profile of Ligand A are compelling, especially given the cardiovascular target. While DILI is important, a percentile of 31 is still acceptable, and can be further optimized. The longer half-life of Ligand A is also a significant advantage.
Output:
1
2025-04-17 19:22:22,530 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (354.4 and 355.4 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (66.29) is better than Ligand B (39.72). Lower TPSA generally favors better absorption, and for a peripheral GPCR like ADRB2, CNS penetration isn't a primary concern, so lower TPSA is beneficial.
3. **logP:** Ligand A (1.06) is optimal, while Ligand B (4.597) is high. High logP can lead to poor solubility and off-target effects. This is a significant negative for Ligand B.
4. **HBD:** Both ligands have 1 HBD, which is within the acceptable limit.
5. **HBA:** Ligand A has 6 HBA, while Ligand B has 4. Both are within the acceptable limit.
6. **QED:** Ligand A (0.879) is better than Ligand B (0.776), indicating a more drug-like profile.
7. **DILI:** Ligand A (25.281) has a much lower DILI risk than Ligand B (46.685). This is a crucial factor favoring Ligand A.
8. **BBB:** Both have high BBB penetration (85.421 and 88.29), but this is less critical for ADRB2 as it's not a CNS target.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual, but the values are similar.
10. **Solubility:** Ligand A (-1.321) is better than Ligand B (-4.799). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.491) has lower hERG inhibition risk than Ligand B (0.779). This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand A (-37.855) has much lower microsomal clearance than Ligand B (54.505), indicating better metabolic stability.
13. **t1/2:** Ligand A (9.054) has a shorter half-life than Ligand B (17.834). While longer is generally preferred, the difference isn't drastic and can be addressed through formulation.
14. **Pgp:** Ligand A (0.056) has lower P-gp efflux than Ligand B (0.442), which is favorable for absorption.
15. **Affinity:** Ligand A (-8.6 kcal/mol) has a slightly better binding affinity than Ligand B (-6.5 kcal/mol). This difference of 2.1 kcal/mol is substantial and can outweigh some of the ADME drawbacks of a less optimal molecule.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A excels in logP, TPSA, and Pgp, and has a significantly better affinity. While BBB isn't critical, both ligands perform well.
**Overall Assessment:**
Ligand A is clearly the superior candidate. It has a better safety profile (lower DILI, hERG), better ADME properties (logP, solubility, Cl_mic, Pgp), a higher QED score, and a significantly stronger binding affinity. Ligand B's high logP and DILI risk are major concerns.
Output:
1
2025-04-17 19:22:22,531 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [347.507, 83.6, 3.438, 1, 5, 0.657, 41.877, 45.56, -4.877, -4.142, 0.617, 81.964, 16.529, 0.519, -7.8]
**Ligand B:** [341.371, 88.01, 2.389, 0, 7, 0.464, 77.2, 63.474, -4.995, -2.992, 0.473, 51.147, -27.634, 0.538, -7.9]
Here's a breakdown, considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (341.371) is slightly lower, which is generally favorable.
2. **TPSA:** Both are reasonably good (83.6 and 88.01), being under 140, suggesting decent absorption.
3. **logP:** Ligand A (3.438) is slightly better than Ligand B (2.389), falling more squarely within the optimal 1-3 range. Ligand B is a bit low, potentially impacting permeability.
4. **HBD/HBA:** Ligand A (1 HBD, 5 HBA) is slightly better than Ligand B (0 HBD, 7 HBA). Lower HBD/HBA is generally preferred.
5. **QED:** Ligand A (0.657) has a better QED score than Ligand B (0.464), indicating a more drug-like profile.
6. **DILI:** Ligand A (41.877) has a significantly lower DILI risk than Ligand B (77.2). This is a major advantage for Ligand A.
7. **BBB:** Ligand B (63.474) has a higher BBB penetration percentile than Ligand A (45.56). While not a primary concern for a cardiovascular target, it's a slight positive for Ligand B.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not defined, so it's hard to interpret.
9. **Solubility:** Both have negative solubility values, which is also unusual.
10. **hERG:** Both have low hERG inhibition liability (0.617 and 0.473), which is good.
11. **Cl_mic:** Ligand B (51.147) has a significantly lower microsomal clearance than Ligand A (81.964), indicating better metabolic stability. This is a significant advantage for Ligand B.
12. **t1/2:** Ligand B (-27.634) has a much longer in vitro half-life than Ligand A (16.529). This is a substantial advantage for Ligand B.
13. **Pgp:** Both have similar Pgp efflux liability (0.519 and 0.538).
14. **Affinity:** Ligand B (-7.9) has a slightly better binding affinity than Ligand A (-7.8), but the difference is small.
**Overall Assessment:**
Ligand A has a better QED, lower DILI risk, and a more optimal logP. However, Ligand B has significantly better metabolic stability (lower Cl_mic) and a longer half-life, and slightly better binding affinity. The lower DILI risk of Ligand A is a strong point, but the improved PK profile of Ligand B (Cl_mic and t1/2) is also very important. Considering the balance, and the fact that metabolic stability is crucial for *in vivo* efficacy, I lean towards Ligand B.
Output:
0
2025-04-17 19:22:22,531 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (343.39 and 344.43 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (100.21) is higher than Ligand B (50.16). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B is significantly better.
3. **logP:** Ligand A (0.259) is quite low, potentially hindering membrane permeability. Ligand B (3.056) is within the optimal 1-3 range. This is a major advantage for Ligand B.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable, below the threshold of 5.
5. **HBA:** Ligand A (5) and Ligand B (3) are both acceptable, below the threshold of 10.
6. **QED:** Both ligands have high QED scores (0.811 and 0.906), indicating good drug-like properties.
7. **DILI:** Ligand A (65.37) has a higher DILI risk than Ligand B (49.40), though both are reasonably acceptable.
8. **BBB:** Ligand A (47.50) has a lower BBB penetration percentile than Ligand B (83.25). While ADRB2 isn't a CNS target, some degree of BBB penetration can be beneficial for off-target effects assessment. Ligand B is better.
9. **Caco-2:** Ligand A (-5.362) has a very poor Caco-2 permeability, indicating poor absorption. Ligand B (-4.749) is also poor, but slightly better than A.
10. **Solubility:** Ligand A (-2.181) has poor aqueous solubility, while Ligand B (-3.096) is also poor. This is a concern for both, but slightly worse for B.
11. **hERG:** Ligand A (0.02) has a very low hERG inhibition risk, which is excellent. Ligand B (0.765) is higher, but still relatively low.
12. **Cl_mic:** Ligand A (-16.6) has a very low (good) microsomal clearance, indicating high metabolic stability. Ligand B (39.861) has a significantly higher clearance, suggesting faster metabolism. This is a substantial advantage for Ligand A.
13. **t1/2:** Ligand A (4.432) has a shorter in vitro half-life than Ligand B (17.975). Longer half-life is generally preferred.
14. **Pgp:** Ligand A (0.029) has very low P-gp efflux, which is excellent. Ligand B (0.268) is higher, but still relatively low.
15. **Binding Affinity:** Ligand B (-8.0) has a stronger binding affinity than Ligand A (-6.9). This is a 1.1 kcal/mol difference, which is significant and can outweigh some ADME drawbacks.
**Overall Assessment & GPCR Priorities:**
For a cardiovascular GPCR like ADRB2, potency (binding affinity) and permeability are key. Ligand B has a significantly better binding affinity (-8.0 vs -6.9 kcal/mol). While its solubility and Caco-2 permeability are poor, the strong binding and good logP (3.056) are substantial advantages. Ligand A's low logP is a major concern, likely leading to poor absorption despite its good metabolic stability and low P-gp efflux. The better TPSA and lower DILI of B are also beneficial.
**Output:**
0
2025-04-17 19:22:22,531 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (367.5 and 348.5 Da) fall comfortably within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (78.43) is slightly higher than Ligand B (67.43). Both are below the 140 threshold for oral absorption, but closer to the 90 threshold for CNS targets (though ADRB2 isn't necessarily a CNS target). Ligand B is slightly preferred.
3. **logP:** Ligand A (1.627) is within the optimal 1-3 range. Ligand B (2.908) is also within range, but approaching the upper limit. Ligand A is slightly preferred.
4. **HBD:** Ligand A (1) is better than Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (6) is higher than Ligand B (3). Lower HBA is generally preferred for permeability. Ligand B is preferred.
6. **QED:** Ligand A (0.792) is significantly better than Ligand B (0.597), indicating a more drug-like profile. This is a substantial advantage for Ligand A.
7. **DILI:** Both ligands have low DILI risk (25.4 and 26.4 percentile), which is good. No significant difference.
8. **BBB:** Both ligands have reasonably good BBB penetration (68.3 and 69.7 percentile). Since ADRB2 isn't a primary CNS target, this isn't a major deciding factor, but slightly favors Ligand B.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Both ligands have negative solubility values, which is also unusual and suggests poor solubility. This is a concern for both.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.477 and 0.408 percentile), which is excellent. No significant difference.
12. **Cl_mic:** Ligand A (18.444) has a much lower microsomal clearance than Ligand B (71.886), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (28.233) has a positive in vitro half-life, while Ligand B (-24.091) has a negative value, which is concerning. Ligand A is strongly preferred.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.05 and 0.533 percentile), which is good. Ligand A is slightly preferred.
15. **Binding Affinity:** Ligand B (-7.1 kcal/mol) has a slightly better binding affinity than Ligand A (-6.0 kcal/mol). This is a 1.1 kcal/mol difference, which is noticeable but not overwhelmingly decisive.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), and the general drug-like properties, Ligand A is the stronger candidate. While Ligand B has slightly better affinity and BBB penetration, Ligand A excels in QED, metabolic stability (Cl_mic), and in vitro half-life. The negative Caco-2 and solubility values are concerning for both, but the superior ADME profile of Ligand A, particularly its metabolic stability and drug-likeness, outweighs the small affinity advantage of Ligand B.
Output:
1
2025-04-17 19:22:22,531 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (351.797 and 353.507 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (68.77) is better than Ligand B (72.88), both are under the 140 threshold for oral absorption.
3. **logP:** Ligand A (3.777) is optimal, while Ligand B (1.377) is on the lower end, potentially causing permeability issues. This is a significant advantage for Ligand A.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2).
5. **HBA:** Ligand A (6) is preferable to Ligand B (4).
6. **QED:** Both ligands have good QED scores (0.608 and 0.757), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand B (6.282) has a much lower DILI risk than Ligand A (96.433). This is a major advantage for Ligand B.
8. **BBB:** Ligand A (67.352) is better than Ligand B (44.436). While ADRB2 isn't necessarily a CNS target, some peripheral effects might be desired, and better BBB penetration could contribute to broader distribution.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.79 and -4.917), which is unusual and suggests poor permeability.
10. **Solubility:** Ligand B (-1.695) is better than Ligand A (-5.334).
11. **hERG:** Ligand A (0.778) has a lower hERG risk than Ligand B (0.386).
12. **Cl_mic:** Ligand B (13.379) has much lower microsomal clearance, indicating better metabolic stability, than Ligand A (68.006).
13. **t1/2:** Ligand B (-6.373) has a longer in vitro half-life than Ligand A (0.995).
14. **Pgp:** Ligand B (0.012) has much lower P-gp efflux liability than Ligand A (0.577).
15. **Binding Affinity:** Ligand A (-7.6) has a slightly better binding affinity than Ligand B (-6.1). However, the difference is not substantial enough to outweigh other factors.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand A excels in logP and has slightly better affinity. Ligand B is superior in Pgp efflux and has a much better DILI score and metabolic stability.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity and logP, Ligand B demonstrates a significantly more favorable safety profile (DILI) and ADME properties (Cl_mic, t1/2, Pgp). The lower DILI risk and improved metabolic stability are crucial for a viable drug candidate. The slightly lower affinity of Ligand B can potentially be optimized in later stages of drug development. The poor Caco-2 values for both are concerning, but can be addressed with formulation strategies.
Output:
0
2025-04-17 19:22:22,531 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
The target is ADRB2, a GPCR. Therefore, I will prioritize logP, Pgp, TPSA, and binding affinity, alongside general drug-like properties.
* **Molecular Weight:** Both ligands are within the ideal range (200-500 Da).
* **TPSA:** Ligand B (77.04) is significantly better than Ligand A (101.73). Lower TPSA generally improves oral absorption, a key consideration for a peripherally acting GPCR like ADRB2.
* **logP:** Ligand A (0.954) is slightly lower than ideal (1-3), but acceptable. Ligand B (3.225) is at the higher end of the optimal range.
* **H-Bond Donors/Acceptors:** Ligand A has 2 HBD and 4 HBA, while Ligand B has 1 HBD and 5 HBA. Both are within acceptable limits.
* **QED:** Both ligands have good QED scores (A: 0.603, B: 0.854), indicating good overall drug-likeness. Ligand B is better.
* **DILI:** Ligand A (12.718) has a much lower DILI risk than Ligand B (29.236). This is a significant advantage for Ligand A.
* **BBB:** Ligand B (77.2) has a higher BBB penetration score than Ligand A (58.24). While ADRB2 is primarily a peripheral target, some CNS exposure is possible, and higher BBB is generally favorable.
* **Caco-2 Permeability:** Ligand A (-5.393) has a worse Caco-2 permeability than Ligand B (-4.981).
* **Aqueous Solubility:** Ligand A (-1.609) has better aqueous solubility than Ligand B (-2.88).
* **hERG:** Ligand A (0.226) has a much lower hERG inhibition liability than Ligand B (0.784). This is a critical safety parameter, and Ligand A is significantly better.
* **Microsomal Clearance:** Ligand A (-4.416) has a much lower (better) microsomal clearance than Ligand B (49.364), implying better metabolic stability.
* **In vitro Half-Life:** Ligand A (-12.754) has a worse in vitro half-life than Ligand B (22.789).
* **P-gp Efflux:** Ligand A (0.022) has a much lower P-gp efflux liability than Ligand B (0.09). Lower efflux is generally preferred.
* **Binding Affinity:** Ligand A (-7.1) has a slightly better binding affinity than Ligand B (-5.6). While both are good, the 1.5 kcal/mol difference is substantial.
**Overall Assessment:**
Ligand A demonstrates a superior safety profile (lower DILI, lower hERG) and better predicted pharmacokinetic properties (lower Cl_mic, lower P-gp efflux). While Ligand B has a slightly better TPSA and BBB, the safety and PK advantages of Ligand A, coupled with its slightly better binding affinity, outweigh these factors for a peripherally acting GPCR target like ADRB2.
**Output:**
1
2025-04-17 19:22:22,531 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (362.817 Da and 350.467 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (90.54) is slightly higher than Ligand B (85.17), but both are below the 140 threshold for good oral absorption and are reasonable for a cardiovascular target (not requiring significant BBB penetration).
3. **logP:** Both ligands have good logP values (1.059 and 1.294), falling within the optimal 1-3 range. Again, no major difference.
4. **HBD:** Ligand A (3) is higher than Ligand B (1). While both are acceptable (<=5), lower HBD is generally preferred for better permeability.
5. **HBA:** Ligand A (3) is lower than Ligand B (7). This is a significant difference. Higher HBA can sometimes hinder permeability.
6. **QED:** Both ligands have similar QED values (0.699 and 0.684), indicating good drug-likeness.
7. **DILI:** Ligand A (50.795) has a slightly higher DILI risk than Ligand B (44.63), but both are below the concerning 60 threshold.
8. **BBB:** Ligand B (79.217) has a significantly higher BBB penetration percentile than Ligand A (61.38). While ADRB2 isn't primarily a CNS target, some level of BBB penetration isn't necessarily detrimental and could offer potential for off-target effects.
9. **Caco-2:** Ligand A (-4.872) has a lower Caco-2 value than Ligand B (-5.457). Lower values indicate poorer intestinal absorption.
10. **Solubility:** Ligand B (-1.286) has better aqueous solubility than Ligand A (-3.323). Solubility is important for bioavailability.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.151 and 0.088), which is excellent.
12. **Cl_mic:** Ligand A (-29.248) has a much lower (better) microsomal clearance than Ligand B (34.358). This suggests greater metabolic stability for Ligand A.
13. **t1/2:** Ligand B (19.457) has a significantly longer in vitro half-life than Ligand A (-3.907). This is a major advantage for dosing convenience.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.009 and 0.069).
15. **Binding Affinity:** Ligand B (-7.0) has a slightly better binding affinity than Ligand A (-6.1). This 0.9 kcal/mol difference is substantial and can outweigh some ADME drawbacks.
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B excels in affinity and has favorable values for the other parameters. While Ligand A has better metabolic stability (Cl_mic), the superior binding affinity and longer half-life of Ligand B are more critical for a GPCR target. The slightly better solubility of Ligand B is also a plus.
**Conclusion:**
Considering the balance of properties, especially the significantly stronger binding affinity and longer half-life of Ligand B, it is the more promising drug candidate for the ADRB2 receptor.
Output:
0
2025-04-17 19:22:22,531 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [348.443, 66.92, 1.601, 0, 4, 0.572, 25.514, 83.443, -4.316, -2.011, 0.216, 69.689, -13.598, 0.102, -3.3]**
**Ligand B: [358.473, 49.41, 3.747, 1, 2, 0.638, 11.09, 93.292, -4.509, -3.102, 0.799, 54.434, -11.009, 0.208, -4.9]**
**1. Molecular Weight (MW):** Both ligands are within the ideal range (200-500 Da). A (348.443) is slightly preferred.
**2. TPSA:** Ligand A (66.92) is higher than Ligand B (49.41). For a GPCR, lower TPSA is generally preferred for better permeability. B is better here.
**3. logP:** Ligand A (1.601) is within the optimal range, while Ligand B (3.747) is approaching the upper limit. A is better.
**4. H-Bond Donors:** Ligand A (0) is excellent, while Ligand B (1) is acceptable. A is better.
**5. H-Bond Acceptors:** Ligand A (4) is good, while Ligand B (2) is also good. A is slightly better.
**6. QED:** Ligand B (0.638) is slightly better than Ligand A (0.572), indicating a marginally more drug-like profile.
**7. DILI:** Ligand A (25.514) has a significantly lower DILI risk than Ligand B (11.09). This is a major advantage for A.
**8. BBB:** Ligand B (93.292) has a higher BBB penetration percentile than Ligand A (83.443). While ADRB2 isn't strictly a CNS target, some CNS exposure can be acceptable or even beneficial depending on the specific therapeutic goal. B is better.
**9. Caco-2:** Both ligands have negative Caco-2 values, which is unusual and indicates poor permeability. Ligand B (-4.509) is slightly worse than Ligand A (-4.316). A is slightly better.
**10. Solubility:** Ligand B (-3.102) has better solubility than Ligand A (-2.011). B is better.
**11. hERG:** Ligand A (0.216) has a lower hERG inhibition liability than Ligand B (0.799). A is better.
**12. Cl_mic:** Ligand B (54.434) has lower microsomal clearance than Ligand A (69.689), indicating better metabolic stability. B is better.
**13. t1/2:** Ligand B (-11.009) has a longer in vitro half-life than Ligand A (-13.598). B is better.
**14. Pgp:** Ligand A (0.102) has lower P-gp efflux liability than Ligand B (0.208). A is better.
**15. Binding Affinity:** Ligand B (-4.9) has a significantly stronger binding affinity than Ligand A (-3.3). This is a substantial advantage for B.
**Overall Assessment:**
Ligand B has a significantly better binding affinity and better metabolic stability (lower Cl_mic, longer t1/2). It also has better solubility and BBB penetration. Ligand A excels in DILI risk and hERG inhibition, and has a slightly better logP. However, the substantial affinity advantage of Ligand B, combined with its better metabolic profile, outweighs the benefits of Ligand A. The Caco-2 values for both are concerning, but the stronger binding of B suggests it might overcome this issue with further optimization.
Output:
0
2025-04-17 19:22:22,531 - INFO - Batch 105 complete. Total preferences: 1680
2025-04-17 19:22:22,531 - INFO - Processing batch 106/512...
2025-04-17 19:23:11,056 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal 200-500 Da range (A: 342.443, B: 374.794). No significant difference here.
2. **TPSA:** Ligand A (75.19) is higher than Ligand B (59.07). For a cardiovascular GPCR, TPSA is moderately important, and B is better here, being closer to the <90 threshold.
3. **logP:** Ligand A (2.045) is within the optimal 1-3 range. Ligand B (4.64) is higher, potentially leading to solubility issues and off-target interactions. This favors A.
4. **HBD:** Both ligands have 2 HBD, which is acceptable.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 5. Both are acceptable, but A is slightly better.
6. **QED:** Both ligands have similar QED values (A: 0.734, B: 0.739), indicating good drug-likeness.
7. **DILI:** Ligand A (26.057) has a significantly lower DILI risk than Ligand B (69.833). This is a major advantage for A.
8. **BBB:** Ligand A (70.686) has a better BBB penetration score than Ligand B (63.125). While ADRB2 isn't strictly a CNS target, some CNS exposure is possible, and this favors A.
9. **Caco-2:** Both have negative values, indicating poor permeability. However, A (-5.119) is slightly better than B (-4.9).
10. **Solubility:** Ligand A (-1.465) has better aqueous solubility than Ligand B (-5.155). This is important for bioavailability and favors A.
11. **hERG:** Ligand A (0.151) has a much lower hERG inhibition liability than Ligand B (0.689). This is a critical safety parameter, strongly favoring A.
12. **Cl_mic:** Ligand A (24.792) has lower microsomal clearance than Ligand B (56.329), indicating better metabolic stability. This is a significant advantage for A.
13. **t1/2:** Ligand B (22.627) has a longer in vitro half-life than Ligand A (-2.061). This is a positive for B, but the negative value for A is concerning.
14. **Pgp:** Ligand A (0.012) has lower P-gp efflux liability than Ligand B (0.172). This is favorable for absorption and bioavailability, favoring A.
15. **Binding Affinity:** Ligand A (-6.2 kcal/mol) has a slightly better binding affinity than Ligand B (-3.4 kcal/mol). This is a substantial difference, and the affinity difference outweighs many of B's minor advantages.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical parameters, especially safety (DILI, hERG) and ADME properties (solubility, Cl_mic, Pgp). While Ligand B has a longer half-life, the negative value for A is concerning, but the substantial advantages of A in other areas, particularly the significantly better binding affinity and safety profile, make it the more promising candidate. The higher logP of B is also a concern.
Output:
1
2025-04-17 19:23:11,057 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.425 & 347.415 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (58.2) is significantly better than Ligand B (100.45). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold. Ligand B is approaching the upper limit.
3. **logP:** Ligand A (3.227) is optimal, while Ligand B (1.073) is a bit low, potentially hindering membrane permeability.
4. **HBD:** Both have 2 HBD, which is within the acceptable range.
5. **HBA:** Ligand A (2) is better than Ligand B (5). Lower HBA is generally preferred for permeability.
6. **QED:** Both ligands have similar QED values (0.792 and 0.696), indicating good drug-likeness.
7. **DILI:** Ligand A (37.728) has a slightly better DILI score than Ligand B (42.264), indicating a lower risk of liver injury. Both are acceptable.
8. **BBB:** Ligand A (89.066) has a much higher BBB penetration percentile than Ligand B (44.824). While not a primary concern for a cardiovascular target, higher BBB is rarely detrimental.
9. **Caco-2:** Ligand A (-4.483) and Ligand B (-4.889) are both poor, suggesting limited intestinal absorption.
10. **Solubility:** Ligand A (-3.939) is better than Ligand B (-2.366), indicating better aqueous solubility.
11. **hERG:** Both ligands have similar hERG inhibition liability (0.615 and 0.622), suggesting similar cardiac risk.
12. **Cl_mic:** Ligand B (35.953) has a lower microsomal clearance than Ligand A (42.534), suggesting better metabolic stability.
13. **t1/2:** Ligand B (35.656) has a significantly longer in vitro half-life than Ligand A (3.555). This is a major advantage.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.137 and 0.052).
15. **Binding Affinity:** Ligand B (-6.1 kcal/mol) has a significantly stronger binding affinity than Ligand A (-3.2 kcal/mol). This is a substantial advantage, potentially outweighing some ADME drawbacks.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B has a better affinity, and while its logP is lower, the significantly stronger binding is a major benefit. Ligand A has better TPSA, but the affinity difference is more important.
**Overall Assessment:**
Ligand B's superior binding affinity (-6.1 vs -3.2 kcal/mol) and longer half-life are compelling advantages. While its TPSA and logP are less ideal than Ligand A, the substantial improvement in potency and metabolic stability is likely to translate to better *in vivo* efficacy. The slightly higher DILI risk is acceptable given the other benefits.
Output:
0
2025-04-17 19:23:11,057 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (338.407) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (62.55) is significantly better than Ligand B (101.56). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (3.182) is optimal, while Ligand B (0.252) is quite low. Low logP can hinder membrane permeability and bioavailability. This is a significant drawback for Ligand B.
4. **HBD/HBA:** Ligand A (HBD=1, HBA=3) is better than Ligand B (HBD=3, HBA=5). Both are acceptable, but fewer H-bonds are generally preferred for better permeability.
5. **QED:** Both ligands have reasonable QED scores (A: 0.935, B: 0.56), indicating good drug-like properties. Ligand A is superior.
6. **DILI:** Ligand A (59.907) is higher than Ligand B (13.532), indicating a higher risk of drug-induced liver injury. This is a concern for Ligand A.
7. **BBB:** Not a primary concern for a cardiovascular target, but Ligand A (61.923) is better than Ligand B (19.038).
8. **Caco-2:** Ligand A (-4.751) and Ligand B (-5.486) are both negative, which is unusual. It's difficult to interpret without knowing the scale, but lower values are generally worse.
9. **Solubility:** Ligand A (-3.789) is better than Ligand B (-0.144). Solubility is important for bioavailability.
10. **hERG:** Ligand A (0.547) is better than Ligand B (0.354), indicating lower cardiotoxicity risk.
11. **Cl_mic:** Ligand A (54.01) is higher than Ligand B (-2.606), indicating faster metabolism and lower stability. This is a negative for Ligand A.
12. **t1/2:** Ligand A (74.797) is significantly better than Ligand B (-9.586), suggesting a much longer half-life.
13. **Pgp:** Ligand A (0.259) is better than Ligand B (0.03), indicating lower P-gp efflux.
14. **Affinity:** Ligand A (-7.7 kcal/mol) has a slightly better binding affinity than Ligand B (-7.3 kcal/mol). While the difference is not huge, it is still a factor.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are crucial. Ligand A excels in logP, TPSA, and Pgp, and has slightly better affinity. Ligand B has a much better DILI score. However, the poor logP of Ligand B is a major concern, potentially leading to poor absorption and bioavailability. The slightly higher DILI risk for Ligand A can potentially be mitigated through structural modifications, but a poor logP is harder to fix. The better half-life for Ligand A is also a significant advantage.
**Conclusion:**
Considering the balance of properties and the GPCR-specific priorities, Ligand A is the more promising candidate despite the slightly higher DILI risk. The superior logP, TPSA, Pgp, and half-life outweigh the DILI concern, which can be addressed in further optimization.
Output:
1
2025-04-17 19:23:11,057 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [367.427, 99.93, 0.399, 1, 5, 0.763, 66.111, 54.44, -5.205, -2.411, 0.238, 67.283, 33.342, 0.047, -5.8]
**Ligand B:** [353.419, 105.76, -0.647, 3, 5, 0.478, 26.173, 60.644, -5.368, -1.297, 0.06, 20.886, 1.426, 0.003, -6.4]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (353.419) is slightly lower, which is generally favorable.
2. **TPSA:** Ligand A (99.93) is better than Ligand B (105.76), both are acceptable for a non-CNS GPCR target like ADRB2.
3. **logP:** Ligand A (0.399) is a bit low, potentially hindering permeability. Ligand B (-0.647) is even lower, raising concerns about absorption. Both are suboptimal.
4. **HBD:** Ligand A (1) is better than Ligand B (3). Lower HBD is generally preferred for permeability.
5. **HBA:** Both have 5 HBA, which is acceptable.
6. **QED:** Ligand A (0.763) has a significantly better QED score than Ligand B (0.478), indicating better overall drug-likeness.
7. **DILI:** Ligand A (66.111) has a higher DILI risk than Ligand B (26.173). This is a significant drawback for Ligand A.
8. **BBB:** Not a primary concern for ADRB2 (cardiovascular target), but Ligand B (60.644) is slightly better than Ligand A (54.44).
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-5.205) is slightly better than Ligand B (-5.368).
10. **Solubility:** Both have negative solubility values, suggesting poor aqueous solubility. Ligand B (-1.297) is slightly better than Ligand A (-2.411).
11. **hERG:** Ligand A (0.238) has a lower hERG risk than Ligand B (0.06), which is a significant advantage.
12. **Cl_mic:** Ligand B (20.886) has a much lower microsomal clearance than Ligand A (67.283), indicating better metabolic stability.
13. **t1/2:** Ligand A (33.342) has a significantly longer in vitro half-life than Ligand B (1.426), which is a major advantage.
14. **Pgp:** Ligand A (0.047) has lower P-gp efflux than Ligand B (0.003), which is favorable.
15. **Affinity:** Ligand B (-6.4 kcal/mol) has a stronger binding affinity than Ligand A (-5.8 kcal/mol). This is a 1.5 kcal/mol difference, which is substantial.
**GPCR-specific priorities:** For ADRB2, we prioritize logP, Pgp, TPSA, and affinity. While both ligands have issues with logP, Ligand B has a better affinity. The lower DILI risk of Ligand B is also a significant advantage. The improved metabolic stability (lower Cl_mic) and Pgp efflux also favor Ligand B. Although Ligand A has a better half-life, the superior binding affinity and safety profile of Ligand B outweigh this benefit.
**Conclusion:**
Considering the balance of properties, especially the significantly stronger binding affinity and lower DILI risk of Ligand B, it appears to be a more promising drug candidate for ADRB2.
0
2025-04-17 19:23:11,057 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (366.49 & 348.49 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (59.31 & 58.64) are below the 140 A^2 threshold for good oral absorption and are also favorable for a peripheral GPCR like ADRB2. No major distinction.
3. **logP:** Ligand A (0.845) is slightly lower than Ligand B (2.514). While both are within the 1-3 range, Ligand B is closer to the optimal value. This is a slight advantage for B, as GPCRs generally benefit from moderate lipophilicity.
4. **HBD:** Ligand A (0) has no H-bond donors, while Ligand B (1) has one. Both are within the acceptable limit of 5.
5. **HBA:** Ligand A (8) and Ligand B (3) differ significantly. Ligand B's lower HBA count is favorable for permeability.
6. **QED:** Ligand A (0.646) has a better QED score than Ligand B (0.375), indicating a more drug-like profile. This is a significant advantage for A.
7. **DILI:** Ligand A (39.55) has a slightly higher DILI risk than Ligand B (19.504), but both are below the concerning threshold of 60. B is preferable here.
8. **BBB:** Ligand A (78.402) has a higher BBB penetration percentile than Ligand B (68.05). While ADRB2 is not a CNS target, some degree of BBB penetration isn't necessarily detrimental, and a higher value is generally better.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.733 and -4.264). This is unusual and suggests poor permeability. However, the values are similar.
10. **Solubility:** Ligand A (-1.014) has better solubility than Ligand B (-2.343). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.881) has a lower hERG risk than Ligand B (0.27). This is a significant advantage for A, as hERG inhibition can lead to cardiotoxicity.
12. **Cl_mic:** Ligand A (39.072) has lower microsomal clearance than Ligand B (61.98), meaning it's likely more metabolically stable. This is a substantial advantage for A.
13. **t1/2:** Ligand A (13.335) has a longer in vitro half-life than Ligand B (-2.602). This is a clear advantage for A.
14. **Pgp:** Ligand A (0.124) has lower P-gp efflux liability than Ligand B (0.152). Lower P-gp efflux is generally desirable.
15. **Binding Affinity:** Ligand A (-7.6 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.4 kcal/mol). This 1.2 kcal/mol difference is substantial and can outweigh minor ADME drawbacks.
**Overall Assessment:**
Ligand A demonstrates superior binding affinity, metabolic stability (lower Cl_mic, longer t1/2), better QED, and lower hERG risk. While Ligand B has a slightly better logP and DILI profile, the advantages of Ligand A are more critical for a successful drug candidate, particularly the strong binding affinity and favorable ADME properties. The negative Caco-2 values for both are concerning and would require further investigation, but the overall profile of A is more promising.
Output:
1
2025-04-17 19:23:11,058 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.443 and 362.417 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (76.66) is better than Ligand B (89.87). Both are under 140, but A is closer to the preferred <90 for potential CNS penetration, even though ADRB2 isn't necessarily a CNS target.
3. **logP:** Both ligands have good logP values (1.324 and 1.052), falling within the optimal 1-3 range. Ligand B is slightly lower, which could potentially impact permeability, but the difference is small.
4. **HBD:** Ligand A (2) is preferable to Ligand B (3). Lower HBD generally improves permeability.
5. **HBA:** Both ligands have the same number of HBA (4), which is acceptable (<=10).
6. **QED:** Ligand A (0.681) is slightly better than Ligand B (0.602), indicating a more drug-like profile.
7. **DILI:** Ligand A (37.263) has a slightly higher DILI risk than Ligand B (25.165), but both are well below the concerning threshold of 60. Ligand B is preferable here.
8. **BBB:** Ligand B (70.182) has a slightly better BBB penetration percentile than Ligand A (68.205). While ADRB2 isn't a primary CNS target, some peripheral ADRB2 activity can influence CNS pathways, so slightly better BBB is a small positive.
9. **Caco-2:** Both ligands have very poor Caco-2 permeability (-4.874 and -4.826). This is a significant concern for oral bioavailability for both.
10. **Solubility:** Ligand A (-2.187) has slightly better solubility than Ligand B (-1.876), but both are poor.
11. **hERG:** Ligand A (0.1) has a significantly lower hERG inhibition liability than Ligand B (0.451). This is a critical advantage, as hERG inhibition can lead to cardiotoxicity.
12. **Cl_mic:** Ligand B (-10.196) has significantly lower microsomal clearance than Ligand A (26.941), indicating better metabolic stability. This is a major advantage.
13. **t1/2:** Ligand B (5.724) has a slightly longer in vitro half-life than Ligand A (6.549).
14. **Pgp:** Ligand A (0.07) has lower P-gp efflux liability than Ligand B (0.037), which is preferable.
15. **Binding Affinity:** Both ligands have excellent binding affinity (-6.8 and -6.9 kcal/mol), with Ligand B being slightly better. This is a very small difference, and other factors become more important.
**GPCR-Specific Priorities & Overall Assessment:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Both ligands perform well on logP and affinity. Ligand A has a better TPSA and Pgp profile. However, the *significant* advantage of Ligand B in terms of metabolic stability (Cl_mic) and lower DILI risk outweighs the slight advantages of Ligand A. The hERG risk for Ligand A is also concerning. While both have poor Caco-2 permeability, this is a formulation challenge that can be addressed. The improved metabolic stability of Ligand B is crucial for maintaining therapeutic concentrations *in vivo*.
Output:
0
2025-04-17 19:23:11,058 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (351.403 and 345.443 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (100.99) is slightly higher than Ligand B (71.53). Ligand B is better, being closer to the <140 threshold for good oral absorption, and more favorable for a GPCR.
3. **logP:** Ligand B (1.995) is within the optimal 1-3 range, while Ligand A (0.417) is a bit low, potentially hindering membrane permeability. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable, below the threshold of 5.
5. **HBA:** Ligand A (6) and Ligand B (4) are both acceptable, below the threshold of 10.
6. **QED:** Ligand B (0.886) has a higher QED score than Ligand A (0.658), indicating a more drug-like profile.
7. **DILI:** Ligand B (26.018) has a significantly lower DILI risk than Ligand A (41.024). This is a major advantage for Ligand B.
8. **BBB:** Ligand B (84.684) has a much higher BBB penetration percentile than Ligand A (46.064). While ADRB2 isn't strictly a CNS target, some distribution to the CNS is possible, and higher BBB is generally preferred.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.835 and -4.599), which is unusual and indicates poor permeability. This is a concern for both, but not a differentiating factor.
10. **Solubility:** Ligand A (-1.635) has slightly better solubility than Ligand B (-2.425), but both are poor.
11. **hERG:** Ligand A (0.151) has a lower hERG risk than Ligand B (0.435). This is a slight advantage for Ligand A.
12. **Cl_mic:** Ligand A (-0.962) has a lower (better) microsomal clearance than Ligand B (25.133), suggesting better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand B (-6.274) has a longer in vitro half-life than Ligand A (-18.902). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.015) has lower P-gp efflux liability than Ligand B (0.025), which is preferable.
15. **Binding Affinity:** Ligand B (-6.0) has a better binding affinity than Ligand A (-0.7). This is a very significant advantage for Ligand B.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand B is clearly superior. The better logP, significantly lower DILI risk, higher BBB penetration, and substantially improved binding affinity outweigh the slightly better hERG and Cl_mic values of Ligand A. The improved QED and t1/2 also favor Ligand B. The poor Caco-2 values are a concern for both, but the other advantages of Ligand B are more impactful for overall drug potential.
Output:
0
2025-04-17 19:23:11,058 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (359.312 Da) is slightly higher than Ligand B (338.451 Da), but both are acceptable.
2. **TPSA:** Ligand A (106.85) is higher than Ligand B (49.41). For a cardiovascular GPCR like ADRB2, TPSA is less critical than for CNS targets, but lower is generally preferred for better permeability. Ligand B is significantly better here.
3. **logP:** Both ligands have good logP values (Ligand A: 1.3, Ligand B: 2.294), falling within the optimal range of 1-3. Ligand B is slightly more lipophilic, which could be beneficial for membrane permeability.
4. **HBD:** Ligand A (2) and Ligand B (1) are both within the acceptable limit of <=5. Ligand B is slightly better.
5. **HBA:** Ligand A (7) and Ligand B (2) are both within the acceptable limit of <=10. Ligand B is significantly better.
6. **QED:** Both ligands have good QED scores (Ligand A: 0.722, Ligand B: 0.855), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (72.043) has a higher DILI risk than Ligand B (18.883). This is a significant advantage for Ligand B.
8. **BBB:** Both ligands have similar BBB penetration (Ligand A: 83.715, Ligand B: 83.288). Since ADRB2 is not a CNS target, this is less important.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the values are similar (-5.183 for A, -4.906 for B).
10. **Solubility:** Both ligands have poor solubility (-2.19 for A, -3.667 for B). This is a concern for both, but Ligand B is slightly worse.
11. **hERG:** Both ligands have very low hERG inhibition risk (Ligand A: 0.115, Ligand B: 0.176). This is excellent for both.
12. **Cl_mic:** Ligand A (26.632) has lower microsomal clearance than Ligand B (35.683), indicating better metabolic stability.
13. **t1/2:** Ligand A (-10.423) has a slightly longer in vitro half-life than Ligand B (-9.575).
14. **Pgp:** Both ligands have low P-gp efflux liability (Ligand A: 0.124, Ligand B: 0.171).
15. **Binding Affinity:** Ligand B (-7.9 kcal/mol) has a slightly better binding affinity than Ligand A (-7.0 kcal/mol). This difference of 0.9 kcal/mol is significant.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in TPSA, has a slightly better logP, comparable Pgp, and a significantly better binding affinity. The lower DILI risk of Ligand B is also a major advantage. While Ligand A has better metabolic stability (lower Cl_mic) and half-life, the benefits of Ligand B in terms of ADME and potency outweigh these factors.
**Conclusion:**
Ligand B is the more promising candidate due to its superior DILI profile, lower TPSA and HBA, better binding affinity, and acceptable logP.
Output:
0
2025-04-17 19:23:11,058 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (368.455 and 352.435 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (103.01 and 103.53) are slightly above the optimal <140 for oral absorption, but acceptable. Given ADRB2 is a cardiovascular target, CNS penetration isn't a primary concern, so this isn't a major drawback.
3. **logP:** Ligand A (0.677) is better than Ligand B (0.308). While both are a bit low, Ligand A is closer to the optimal 1-3 range. Low logP can hinder membrane permeability.
4. **HBD:** Both ligands have 3 HBD, which is within the acceptable limit of <=5.
5. **HBA:** Ligand A has 6 HBA, while Ligand B has 4. Both are within the acceptable limit of <=10.
6. **QED:** Ligand A (0.654) has a significantly better QED score than Ligand B (0.416), indicating a more drug-like profile.
7. **DILI:** Ligand A (39.511) has a slightly better DILI percentile than Ligand B (41.024), indicating a lower risk of liver injury. Both are acceptable, but lower is better.
8. **BBB:** Ligand B (42.264) has a higher BBB percentile than Ligand A (26.599). However, as ADRB2 is a cardiovascular target, BBB penetration is not a priority.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.719 and -5.234), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand A (-2.27) has slightly better solubility than Ligand B (-1.543), although both are poor.
11. **hERG:** Ligand A (0.042) has a much lower hERG inhibition liability than Ligand B (0.257), which is a crucial advantage for cardiovascular drugs.
12. **Cl_mic:** Ligand A (-3.554) has a significantly lower (better) microsomal clearance than Ligand B (20.519), indicating greater metabolic stability.
13. **t1/2:** Ligand A (31.291) has a much longer in vitro half-life than Ligand B (1.814), which is desirable for less frequent dosing.
14. **Pgp:** Ligand A (0.008) has a much lower P-gp efflux liability than Ligand B (0.062), suggesting better oral bioavailability.
15. **Binding Affinity:** Ligand B (-8.6 kcal/mol) has a significantly stronger binding affinity than Ligand A (-4.3 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME drawbacks. However, the difference is large enough that it's worth considering.
**Overall Assessment:**
While Ligand B has a much better binding affinity, Ligand A demonstrates a significantly superior ADME profile. It has a better QED, lower DILI risk, substantially lower hERG inhibition, better metabolic stability (lower Cl_mic and longer t1/2), and lower P-gp efflux. The Caco-2 values are poor for both, but the other factors strongly favor Ligand A. For a cardiovascular target, minimizing off-target effects (like hERG inhibition) and ensuring reasonable metabolic stability are critical. The superior binding affinity of Ligand B is attractive, but the ADME liabilities are too significant.
Output:
1
2025-04-17 19:23:11,058 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [345.407, 97.94, 0.086, 1, 7, 0.828, 54.556, 57.193, -5.172, -1.147, 0.082, 25.96, 28.12, 0.051, -6.8]
**Ligand B:** [382.873, 96.25, 1.364, 3, 6, 0.63, 67.584, 29.042, -5.335, -2.612, 0.217, 27.631, 25.213, 0.116, -5.3]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity):
1. **MW:** Both are within the acceptable 200-500 Da range. Ligand A (345.4) is slightly preferred.
2. **TPSA:** Both are good, under 140. Ligand B (96.25) is slightly better.
3. **logP:** Ligand A (0.086) is very low, potentially causing permeability issues. Ligand B (1.364) is much better, falling within the optimal 1-3 range. This is a significant advantage for Ligand B.
4. **HBD/HBA:** Ligand A (1 HBD, 7 HBA) is better than Ligand B (3 HBD, 6 HBA).
5. **QED:** Ligand A (0.828) is significantly better than Ligand B (0.63), indicating a more drug-like profile.
6. **DILI:** Ligand A (54.556) has a lower DILI risk than Ligand B (67.584).
7. **BBB:** Ligand A (57.193) has better BBB penetration than Ligand B (29.042).
8. **Caco-2:** Both are negative, indicating poor permeability.
9. **Solubility:** Both are negative, indicating poor solubility.
10. **hERG:** Both are very low, indicating low hERG inhibition risk.
11. **Cl_mic:** Similar values for both.
12. **t1/2:** Ligand A (28.12) has a slightly longer half-life than Ligand B (25.213).
13. **Pgp:** Ligand A (0.051) has significantly lower P-gp efflux liability than Ligand B (0.116).
14. **Affinity:** Ligand A (-6.8 kcal/mol) has a better binding affinity than Ligand B (-5.3 kcal/mol). This is a 1.5 kcal/mol difference, which is substantial.
**Overall Assessment:**
Ligand A has a better binding affinity, better P-gp efflux, better QED, lower DILI, and better BBB penetration. However, its logP is very low, which is a major concern for permeability. Ligand B has a much better logP, but suffers from lower QED, higher DILI, poorer BBB penetration, and weaker binding affinity.
Given the GPCR target and the importance of permeability (addressed by logP) and affinity, the stronger affinity of Ligand A, combined with its better drug-like properties (QED, DILI, Pgp, BBB) outweighs the concern of its low logP. While the low logP is a drawback, it might be addressable through formulation strategies. The affinity difference is significant enough to prioritize Ligand A.
Output:
1
2025-04-17 19:23:11,058 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (338.451 and 345.403 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (53.43) is significantly better than Ligand B (103). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (3.564) is within the optimal 1-3 range. Ligand B (-0.819) is *below* 1, which is concerning for permeability. This is a significant negative for Ligand B.
4. **HBD:** Both ligands have acceptable HBD counts (1 and 2, respectively), well below the threshold of 5.
5. **HBA:** Ligand A (3) is better than Ligand B (6), keeping within the desirable range of <=10.
6. **QED:** Both ligands have good QED scores (0.911 and 0.742), indicating good drug-like properties. Ligand A is slightly better.
7. **DILI:** Ligand A (25.281) has a much lower DILI risk than Ligand B (54.323). This is a substantial advantage for Ligand A.
8. **BBB:** Ligand A (84.529) has better BBB penetration than Ligand B (48.972), but this isn't a high priority for a cardiovascular target.
9. **Caco-2:** Ligand A (-4.542) and Ligand B (-5.12) are both negative, indicating poor permeability.
10. **Solubility:** Ligand A (-2.606) is better than Ligand B (-0.847), but both are poor.
11. **hERG:** Ligand A (0.823) has a lower hERG risk than Ligand B (0.23). This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand A (32.909) has better metabolic stability (lower clearance) than Ligand B (-13.154, indicating rapid clearance).
13. **t1/2:** Ligand A (24.616) has a much longer in vitro half-life than Ligand B (-0.437).
14. **Pgp:** Ligand A (0.482) has lower P-gp efflux than Ligand B (0.013).
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.7 and -6.4 kcal/mol). The difference is not substantial enough to outweigh other factors.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A excels in logP, TPSA, and Pgp, while the affinities are comparable.
**Overall Assessment:**
Ligand A is significantly superior to Ligand B. It has better predicted ADME properties (lower DILI, better metabolic stability, longer half-life, lower P-gp efflux, better solubility, and better hERG profile) and a more favorable logP value. While both have poor Caco-2 permeability, the other advantages of Ligand A make it the more promising candidate.
Output:
1
2025-04-17 19:23:11,059 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (346.475 Da and 361.433 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (62.47) is significantly better than Ligand B (79.46). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand A is well below the 90 A^2 threshold, while Ligand B is approaching it.
**3. logP:** Both ligands have good logP values (3.364 and 3.168), falling within the optimal 1-3 range. No clear advantage.
**4. H-Bond Donors:** Ligand A (0) is preferable to Ligand B (3). Fewer H-bond donors generally improve permeability.
**5. H-Bond Acceptors:** Ligand A (4) is slightly better than Ligand B (3), but both are within acceptable limits.
**6. QED:** Ligand A (0.842) has a higher QED score than Ligand B (0.704), indicating a more drug-like profile.
**7. DILI:** Ligand A (26.057) has a significantly lower DILI risk than Ligand B (32.726). This is a crucial advantage.
**8. BBB:** Ligand A (97.053) shows excellent BBB penetration potential, while Ligand B (81.233) is good, but not as high. Given that ADRB2 is a GPCR, and modulating CNS effects can be relevant, this is a significant advantage for Ligand A.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests a potential issue with the data or the model. However, Ligand A (-4.663) is slightly less negative than Ligand B (-4.44).
**10. Aqueous Solubility:** Both ligands have negative solubility values, which is also unusual. Ligand B (-3.668) is slightly worse than Ligand A (-3.199).
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (0.64 and 0.468). No significant difference.
**12. Microsomal Clearance:** Ligand A (74.674) has higher microsomal clearance than Ligand B (64.371), indicating lower metabolic stability. This is a drawback for Ligand A.
**13. In vitro Half-Life:** Ligand B (-18.822) has a much longer in vitro half-life than Ligand A (-2.195). This is a significant advantage for Ligand B.
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (0.501 and 0.058). Ligand B is slightly better.
**15. Binding Affinity:** Ligand B (-7.5) has a significantly stronger binding affinity than Ligand A (-5.7). This is a substantial advantage, potentially outweighing some of the ADME drawbacks.
**Overall Assessment:**
While Ligand B has a superior binding affinity and better metabolic stability (longer half-life), Ligand A demonstrates a significantly better safety profile (lower DILI) and better predicted BBB penetration. Considering the GPCR target class, the balance of properties leans towards Ligand A. The strong BBB penetration and lower DILI risk are particularly valuable for a GPCR target, and the slightly better TPSA and QED contribute to its overall drug-likeness. The affinity difference is significant, but not insurmountable, and could potentially be optimized in further iterations.
Output:
1
2025-04-17 19:23:11,059 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (372.418 and 348.422 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (88.1) is slightly higher than Ligand B (75.19). Both are below the 140 threshold for good oral absorption, and reasonably close to the 90 threshold for CNS targets (though ADRB2 isn't strictly a CNS target, lower TPSA is still beneficial for permeability). Ligand B is preferable here.
3. **logP:** Ligand B (1.976) is within the optimal 1-3 range, while Ligand A (0.453) is a bit low, potentially hindering permeation. Ligand B is significantly better.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable, being less than 5. Ligand B is slightly better.
5. **HBA:** Ligand A (5) and Ligand B (4) are both acceptable, being less than 10. Ligand B is slightly better.
6. **QED:** Both ligands have very similar QED scores (0.784 and 0.798), indicating good drug-likeness. No significant difference.
7. **DILI:** Ligand B (39.511) has a lower DILI risk than Ligand A (45.25), both are below the 40 threshold. Ligand B is preferable.
8. **BBB:** Ligand B (81.776) has a higher BBB penetration percentile than Ligand A (70.919). While ADRB2 isn't a primary CNS target, higher BBB is generally favorable, indicating better distribution. Ligand B is preferable.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.679 and -4.748). These values are unusual and suggest poor permeability. It's difficult to interpret without knowing the scale, but they both indicate a potential issue.
10. **Solubility:** Both ligands have negative solubility values (-1.553 and -2.511). Similar to Caco-2, these values are unusual and suggest poor solubility. This is a significant concern for bioavailability.
11. **hERG:** Ligand A (0.225) has a lower hERG inhibition liability than Ligand B (0.47), indicating a lower risk of cardiotoxicity. Ligand A is preferable.
12. **Cl_mic:** Ligand A (-8.052) has a much lower microsomal clearance than Ligand B (54.618), suggesting better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (28.788) has a longer in vitro half-life than Ligand B (-5.731). This is a major advantage for Ligand A, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.072) has a lower P-gp efflux liability than Ligand B (0.091), suggesting better oral bioavailability and potentially better CNS exposure. Ligand A is preferable.
15. **Binding Affinity:** Ligand B (-11.3 kcal/mol) has a significantly stronger binding affinity than Ligand A (-7.1 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME drawbacks.
**Overall Assessment:**
Ligand B has a better logP, TPSA, DILI, BBB, and, most importantly, *much* stronger binding affinity. However, Ligand A has superior metabolic stability (Cl_mic, t1/2), lower Pgp efflux, and lower hERG risk. The negative Caco-2 and Solubility values are concerning for both.
Given the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), and the substantial affinity advantage of Ligand B, I believe Ligand B is the more promising candidate *despite* the metabolic concerns. The strong binding is likely to be more impactful than the slightly less favorable ADME profile, and metabolic stability can be addressed through further optimization.
Output:
0
2025-04-17 19:23:11,059 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [348.451, 83.36, 0.325, 1, 6, 0.829, 21.908, 34.122, -5.405, -0.2, 0.048, -17.44, 17.307, 0.01, -7.2]
**Ligand B:** [359.415, 108.92, 1.069, 2, 8, 0.717, 88.057, 36.836, -5.393, -3.189, 0.727, 10.463, -6.756, 0.045, -6.2]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). A (348.451) is slightly preferred.
2. **TPSA:** A (83.36) is better than B (108.92). Both are reasonably good for oral absorption, but A is closer to the ideal <90 for potential CNS penetration, even though this is a cardiovascular target.
3. **logP:** A (0.325) is a bit low, potentially hindering permeability. B (1.069) is better, falling within the optimal 1-3 range.
4. **HBD:** A (1) is good. B (2) is acceptable.
5. **HBA:** A (6) is good. B (8) is acceptable.
6. **QED:** A (0.829) is significantly better than B (0.717), indicating a more drug-like profile.
7. **DILI:** A (21.908) is *much* better than B (88.057). This is a major advantage for A.
8. **BBB:** Both are similar (A: 34.122, B: 36.836) and relatively low, which is fine for a cardiovascular target.
9. **Caco-2:** Both are very poor (-5.405 and -5.393). This is a concern for both, suggesting limited intestinal absorption.
10. **Solubility:** A (-0.2) is slightly better than B (-3.189), but both are quite poor.
11. **hERG:** A (0.048) is much better than B (0.727), indicating a lower risk of cardiotoxicity. This is critical for a cardiovascular drug.
12. **Cl_mic:** A (-17.44) is much better than B (10.463), indicating significantly better metabolic stability.
13. **t1/2:** A (17.307) is better than B (-6.756), suggesting a longer half-life.
14. **Pgp:** Both are very low (A: 0.01, B: 0.045), suggesting minimal P-gp efflux.
15. **Affinity:** A (-7.2) is slightly better than B (-6.2), although the difference is not huge.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, and affinity. A has a lower TPSA and better affinity, and lower DILI and hERG. B has a better logP, but the significantly worse DILI, hERG, metabolic stability, and solubility are major drawbacks.
**Conclusion:**
Ligand A is significantly more promising. While its logP is a bit low, its superior drug-likeness (QED), dramatically lower DILI and hERG risk, better metabolic stability, and slightly better affinity outweigh the logP concern. The poor Caco-2 values are a concern for both, but can be addressed with formulation strategies.
**Output:**
1
2025-04-17 19:23:11,059 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (355.479 and 350.478 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (82.11) is higher than Ligand B (49.41). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for permeability. Ligand B is better.
3. **logP:** Ligand A (0.223) is quite low, potentially hindering membrane permeability. Ligand B (3.572) is within the optimal 1-3 range. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable, below the threshold of 5. Ligand B is slightly better.
5. **HBA:** Ligand A (5) and Ligand B (2) are both acceptable, below the threshold of 10. Ligand B is better.
6. **QED:** Both ligands have good QED scores (0.683 and 0.727), indicating good drug-like properties. No clear winner.
7. **DILI:** Ligand A (7.445%) has a much lower DILI risk than Ligand B (17.449%). This is a substantial advantage for Ligand A.
8. **BBB:** Ligand A (29.508%) has a low BBB penetration, while Ligand B (89.027%) has a high BBB penetration. Since ADRB2 is a cardiovascular target, high BBB penetration is not a priority and is even undesirable. Ligand A is better.
9. **Caco-2:** Ligand A (-5.117) and Ligand B (-4.388) both have negative Caco-2 values, indicating poor permeability. This is a concern for both, but Ligand B is slightly better.
10. **Solubility:** Ligand A (-0.094) and Ligand B (-3.879) both have negative solubility values. Ligand A is better.
11. **hERG:** Both ligands have low hERG inhibition risk (0.231 and 0.316). No significant difference.
12. **Cl_mic:** Ligand A (-2.141) has a lower (better) microsomal clearance than Ligand B (65.527). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (9.658) has a shorter half-life than Ligand B (16.706). Ligand B is better.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.019 and 0.178). No significant difference.
15. **Binding Affinity:** Ligand B (-6.2) has a slightly better binding affinity than Ligand A (-5.6). This is a 0.6 kcal/mol difference, which is significant, but not overwhelming.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand B initially appears stronger due to its better logP and affinity. However, Ligand A has a much better safety profile (DILI) and metabolic stability (Cl_mic). The low logP of Ligand A is a concern, but the significantly lower DILI risk and better metabolic stability are crucial for a cardiovascular drug candidate. The BBB penetration is also much lower for Ligand A, which is desirable for a peripheral target. While Ligand B has better affinity, the difference isn't large enough to outweigh the safety and metabolic advantages of Ligand A.
Output:
1
2025-04-17 19:23:11,059 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (363.845 and 363.82 Da) are within the ideal range (200-500 Da). No significant difference.
2. **TPSA:** Ligand A (56.07) is better than Ligand B (58.22). Both are below 140, but lower is preferred for absorption.
3. **logP:** Ligand A (2.674) is better than Ligand B (3.5). Ligand B is pushing the upper limit of the optimal range (1-3).
4. **HBD:** Ligand A (0) is better than Ligand B (1). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (5) is better than Ligand B (3). Both are acceptable, but lower is generally preferred.
6. **QED:** Both ligands have similar QED values (0.841 and 0.827), indicating good drug-likeness.
7. **DILI:** Ligand B (51.648) is significantly better than Ligand A (64.599). Lower DILI risk is a major advantage.
8. **BBB:** Both ligands have good BBB penetration (Ligand A: 70.648, Ligand B: 74.758), which is a positive for a GPCR target. Ligand B is slightly better.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand B (-4.813) is slightly worse than Ligand A (-4.697).
10. **Solubility:** Ligand A (-2.075) is better than Ligand B (-4.359). Higher solubility is preferred.
11. **hERG:** Ligand A (0.451) is better than Ligand B (0.876). Lower hERG inhibition is crucial for avoiding cardiotoxicity.
12. **Cl_mic:** Ligand A (32.952) is better than Ligand B (65.578). Lower microsomal clearance indicates better metabolic stability.
13. **t1/2:** Ligand A (57.084) is significantly better than Ligand B (0.486). A longer half-life is desirable.
14. **Pgp:** Ligand A (0.227) is better than Ligand B (0.743). Lower P-gp efflux is preferred.
15. **Binding Affinity:** Ligand A (-7.5) is better than Ligand B (-6.0). This is a substantial difference in potency.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, Pgp, TPSA, and affinity. Ligand A performs better on logP, Pgp, and significantly better on affinity. While both have acceptable TPSA and BBB, Ligand A still has the edge. The substantial difference in binding affinity (-7.5 vs -6.0) is a major factor. The improved metabolic stability (Cl_mic and t1/2) and reduced hERG risk of Ligand A are also significant advantages. Although Ligand B has a lower DILI risk, the other factors strongly favor Ligand A.
**Conclusion:**
Ligand A is the more promising drug candidate due to its superior binding affinity, better ADME properties (Cl_mic, t1/2, Pgp, solubility), and lower hERG risk.
Output:
1
2025-04-17 19:23:11,060 - INFO - Batch 106 complete. Total preferences: 1696
2025-04-17 19:23:11,060 - INFO - Processing batch 107/512...
2025-04-17 19:23:57,006 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (365.5 & 360.5 Da) fall comfortably within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (91.32) is higher than Ligand B (62.55). For a cardiovascular GPCR, TPSA is moderately important, and Ligand B is significantly better, being well below the 140 threshold.
3. **logP:** Ligand A (1.822) and Ligand B (3.318) are both within the optimal 1-3 range, but Ligand B is closer to the upper limit. This could potentially lead to solubility issues, but is still acceptable.
4. **HBD:** Ligand A (3) is higher than Ligand B (1). Lower HBD is generally preferred for permeability, giving a slight edge to Ligand B.
5. **HBA:** Ligand A (5) is higher than Ligand B (4). Similar to HBD, lower HBA is preferred, favoring Ligand B.
6. **QED:** Ligand B (0.824) has a substantially better QED score than Ligand A (0.582), indicating a more drug-like profile.
7. **DILI:** Ligand A (43.1) has a lower DILI risk than Ligand B (54.2). This is a significant advantage for Ligand A.
8. **BBB:** Ligand B (70.65) shows significantly better BBB penetration than Ligand A (40.68). While ADRB2 isn't a CNS target, some peripheral exposure can sometimes be reduced by BBB efflux, so this is a slight positive for Ligand B.
9. **Caco-2:** Both ligands have similar, very negative Caco-2 values (-5.132 and -5.115). This suggests poor permeability for both, which is concerning.
10. **Solubility:** Ligand A (-2.123) has better solubility than Ligand B (-3.663). This is a positive for Ligand A.
11. **hERG:** Ligand A (0.19) has a much lower hERG risk than Ligand B (0.739). This is a critical advantage for Ligand A, given the cardiovascular target.
12. **Cl_mic:** Ligand B (53.77) has a lower microsomal clearance than Ligand A (34.17), indicating better metabolic stability. This is a positive for Ligand B.
13. **t1/2:** Ligand B (24.003) has a significantly longer in vitro half-life than Ligand A (6.404). This is a substantial advantage for Ligand B.
14. **Pgp:** Ligand A (0.126) has lower P-gp efflux than Ligand B (0.537), which is favorable.
15. **Binding Affinity:** Ligand B (-7.2 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.9 kcal/mol). This is a major advantage that can outweigh some ADME concerns.
**Overall Assessment:**
Ligand B has a superior binding affinity and a longer half-life. It also has a better QED score and lower TPSA. However, Ligand A has a significantly lower DILI risk and hERG inhibition liability, which are crucial for a cardiovascular drug. The poor Caco-2 permeability is a concern for both.
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), and the importance of safety (DILI, hERG) for a cardiovascular target, the stronger binding affinity of Ligand B is a compelling factor. While the slightly higher DILI and hERG risks are concerning, they are not prohibitive given the substantial potency advantage. The longer half-life is also very beneficial.
Output:
0
2025-04-17 19:23:57,006 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [342.399, 98.06, 0.678, 3, 4, 0.699, 57.736, 41.218, -5.115, -3.479, 0.429, -43.725, 4.782, 0.036, -8.4]
**Ligand B:** [375.441, 84.23, 2.067, 2, 5, 0.727, 70.841, 70.919, -5.185, -2.883, 0.168, 50.265, -33.698, 0.135, -7.3]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (342.399) is slightly preferred due to being a bit lower.
2. **TPSA:** Both are acceptable for oral absorption (under 140). Ligand B (84.23) is better than Ligand A (98.06).
3. **logP:** Ligand A (0.678) is a bit low, potentially hindering permeation. Ligand B (2.067) is much better, falling within the optimal 1-3 range.
4. **HBD:** Both are within the acceptable limit of 5. Ligand B (2) is slightly better.
5. **HBA:** Both are within the acceptable limit of 10. Ligand B (5) is slightly better.
6. **QED:** Both are good (>0.5), with Ligand B (0.727) being slightly better.
7. **DILI:** Ligand A (57.736) is preferable as it has a lower DILI risk than Ligand B (70.841).
8. **BBB:** Ligand B (70.919) is significantly better than Ligand A (41.218). This is important for a GPCR, even if not a CNS target, as it can influence distribution.
9. **Caco-2:** Both are negative, indicating poor permeability. This is a significant concern for both.
10. **Solubility:** Both are negative, indicating poor solubility. This is also a significant concern for both.
11. **hERG:** Both have low hERG risk. Ligand A (0.429) is slightly better.
12. **Cl_mic:** Ligand A (-43.725) has a much lower (better) microsomal clearance than Ligand B (50.265), indicating greater metabolic stability.
13. **t1/2:** Ligand B (-33.698) has a much longer in vitro half-life than Ligand A (4.782).
14. **Pgp:** Ligand A (0.036) has a lower Pgp efflux liability than Ligand B (0.135).
15. **Binding Affinity:** Ligand A (-8.4) has a stronger binding affinity than Ligand B (-7.3). This is a substantial difference.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, and affinity. Ligand B has a better logP and TPSA, and a better BBB score. However, Ligand A has a significantly better binding affinity and lower Pgp efflux. The strong affinity of Ligand A is a major advantage, and the lower clearance is also beneficial. While the Caco-2 and solubility are poor for both, the affinity difference is substantial enough to outweigh these concerns, especially considering optimization potential.
**Conclusion:**
Despite the slightly better BBB penetration of Ligand B, the significantly stronger binding affinity and better metabolic stability of Ligand A make it the more promising drug candidate.
Output:
1
2025-04-17 19:23:57,006 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for the ADRB2, a cardiovascular GPCR. Therefore, key priorities are logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB.
Let's compare the ligands property by property:
1. **MW:** Both ligands (354.353 and 345.487 Da) are within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (81.47) is slightly higher than Ligand B (75.43). Both are below the 140 threshold for good oral absorption, and acceptable for a non-CNS GPCR.
3. **logP:** Both ligands have good logP values (3.008 and 3.146), falling within the optimal 1-3 range.
4. **HBD/HBA:** Ligand A has 1 HBD and 4 HBA, while Ligand B has 2 HBD and 3 HBA. Both are within acceptable limits.
5. **QED:** Both ligands have reasonable QED scores (0.651 and 0.561), indicating good drug-like properties.
6. **DILI:** Ligand B (30.826) has a significantly lower DILI risk than Ligand A (54.517). This is a substantial advantage.
7. **BBB:** Ligand A (85.576) has better BBB penetration than Ligand B (71.772), but BBB is less critical for a cardiovascular target.
8. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. Ligand B (-4.988) is slightly worse than Ligand A (-4.527).
9. **Solubility:** Both ligands have negative solubility values, indicating poor solubility. Ligand B (-3.625) is slightly worse than Ligand A (-4.185).
10. **hERG:** Both ligands have low hERG inhibition risk (0.569 and 0.771).
11. **Cl_mic:** Ligand A (12.036) has a lower microsomal clearance than Ligand B (53.532), suggesting better metabolic stability. This is a significant advantage.
12. **t1/2:** Ligand A (40.909) has a longer in vitro half-life than Ligand B (10.05). This is a significant advantage.
13. **Pgp:** Both ligands have low Pgp efflux liability (0.185 and 0.107).
14. **Binding Affinity:** Ligand A (-6.5 kcal/mol) has a slightly better binding affinity than Ligand B (-5.9 kcal/mol), a difference of 0.6 kcal/mol.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity and metabolic stability, Ligand B demonstrates a substantially lower DILI risk. Given the cardiovascular target, minimizing toxicity is paramount. The difference in binding affinity (0.6 kcal/mol) is not large enough to outweigh the significant reduction in potential liver toxicity offered by Ligand B. The poor Caco-2 and solubility are concerns for both, but can be addressed with formulation strategies.
**Output:**
0
2025-04-17 19:23:57,007 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.451 and 351.447 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (110.2) is higher than Ligand B (79.9). For a cardiovascular GPCR, TPSA is not a primary concern, but lower is generally preferred for better absorption. Ligand B is better.
3. **logP:** Ligand A (1.428) is within the optimal range (1-3), while Ligand B (0.453) is slightly below, potentially impacting permeability. Ligand A is better.
4. **HBD:** Both ligands have 2 H-bond donors, which is acceptable.
5. **HBA:** Ligand A has 4 H-bond acceptors, and Ligand B has 5. Both are within the acceptable limit of 10.
6. **QED:** Both ligands have similar QED values (0.412 and 0.49), indicating moderate drug-likeness.
7. **DILI:** Ligand A (15.355) has a significantly lower DILI risk than Ligand B (20.628). This is a crucial advantage.
8. **BBB:** Ligand A (59.131) has a higher BBB penetration percentile than Ligand B (39.473). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be useful for understanding off-target effects and overall distribution.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.51 and -5.29), which is unusual and suggests poor permeability. This is a significant drawback for both.
10. **Solubility:** Both ligands have negative solubility values (-1.617 and -1.303), indicating poor aqueous solubility. This is a major concern for both.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.259 and 0.141), which is excellent.
12. **Cl_mic:** Ligand A (5.852) has a lower microsomal clearance than Ligand B (-32.95). This indicates better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (16.134) has a longer in vitro half-life than Ligand B (14.754). This is a positive for Ligand A.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.008 and 0.006).
15. **Binding Affinity:** Ligand B (-7.0 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.0 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME concerns.
**Overall Assessment & GPCR-Specific Priorities:**
For a cardiovascular GPCR like ADRB2, binding affinity is paramount. Ligand B's -7.0 kcal/mol is a strong advantage. However, the poor Caco-2 and solubility for both are concerning. Ligand A has better ADME properties (lower DILI, higher BBB, better Cl_mic, longer t1/2) but weaker affinity. The difference in affinity is significant (1 kcal/mol), and for a GPCR, this is often a deciding factor. The lower DILI risk for Ligand A is also a strong consideration. Given the balance, the stronger affinity of Ligand B is the most important factor, but the ADME profile of Ligand A is more favorable.
Considering the overall profile, and the importance of affinity for GPCRs, I lean towards Ligand B despite its ADME drawbacks. Further optimization could address the solubility and permeability issues.
Output:
0
2025-04-17 19:23:57,007 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (359.813 and 368.371 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (49.85) is significantly better than Ligand A (71.53). ADRB2 is not a CNS target, but lower TPSA generally improves absorption.
3. **logP:** Ligand A (3.651) is slightly higher than Ligand B (2.153), but both are within the optimal 1-3 range. Ligand A is closer to the upper limit, which could present solubility issues.
4. **HBD:** Ligand A (1) is better than Ligand B (0). Having at least one HBD can be beneficial for solubility.
5. **HBA:** Ligand A (4) is slightly higher than Ligand B (3). Both are acceptable.
6. **QED:** Ligand A (0.849) is significantly better than Ligand B (0.715), indicating a more drug-like profile.
7. **DILI:** Ligand B (25.553) is *much* better than Ligand A (80.729). This is a major advantage for Ligand B. A DILI percentile over 60 is concerning.
8. **BBB:** Both ligands have high BBB penetration (Ligand A: 82.706, Ligand B: 87.864). This isn't a primary concern for ADRB2, but higher is generally better.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.659 and -4.252). This is unusual and suggests poor permeability.
10. **Solubility:** Ligand B (-2.248) is better than Ligand A (-5.045). Better solubility is always desirable.
11. **hERG:** Both ligands have low hERG inhibition risk (Ligand A: 0.471, Ligand B: 0.625).
12. **Cl_mic:** Ligand B (25.93) has significantly lower microsomal clearance than Ligand A (74.533), indicating better metabolic stability.
13. **t1/2:** Ligand A (18.192) has a longer in vitro half-life than Ligand B (-15.162). This is a positive for Ligand A, but the negative value for B is concerning.
14. **Pgp:** Both ligands have very low Pgp efflux (Ligand A: 0.549, Ligand B: 0.027). Ligand B is slightly better.
15. **Binding Affinity:** Ligand A (-6.0) is slightly better than Ligand B (-5.3). However, the difference is less than 1.5 kcal/mol.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand B has better TPSA, Pgp, and solubility. Ligand A has a slightly better affinity and half-life, but the DILI risk is a major concern.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity and half-life, the significantly higher DILI risk and poorer solubility are major drawbacks. Ligand B, despite a slightly lower affinity, presents a much more favorable safety profile (DILI) and better ADME properties (lower Cl_mic, better solubility, better TPSA). The negative Caco-2 values for both are concerning and would require further investigation, but the overall balance of properties favors Ligand B.
Output:
0
2025-04-17 19:23:57,007 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (351.403 and 350.503 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (111.87) is higher than Ligand B (55.57). For a GPCR, lower TPSA is generally preferred for better BBB penetration, giving a slight edge to Ligand B.
3. **logP:** Ligand A (-0.399) is quite low, potentially hindering membrane permeability. Ligand B (4.578) is high, potentially causing solubility issues and off-target effects. This is a significant drawback for Ligand B.
4. **HBD:** Ligand A (3) is acceptable, while Ligand B (0) is very low. A small number of HBDs can be beneficial for solubility, so Ligand A is slightly favored.
5. **HBA:** Ligand A (6) and Ligand B (4) are both within the acceptable range (<=10). No major difference.
6. **QED:** Both ligands have similar QED values (0.642 and 0.58), indicating reasonable drug-likeness.
7. **DILI:** Ligand A (45.87) has a better DILI percentile than Ligand B (8.53), indicating a lower risk of liver injury. This is a significant advantage for Ligand A.
8. **BBB:** Ligand B (83.908) has a much higher BBB percentile than Ligand A (40.403). This is a major advantage for Ligand B, especially for a GPCR target.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.786 and -4.37), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-1.764) has better solubility than Ligand B (-4.818). Solubility is important for bioavailability, favoring Ligand A.
11. **hERG:** Ligand A (0.177) shows a lower hERG inhibition liability than Ligand B (0.661), which is crucial for avoiding cardiotoxicity. This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand A (-18.152) has a lower (better) microsomal clearance than Ligand B (92.047), indicating greater metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand B (39.152) has a longer in vitro half-life than Ligand A (14.315). This is a positive for Ligand B.
14. **Pgp:** Ligand A (0.024) has lower P-gp efflux liability than Ligand B (0.246), which is favorable for bioavailability and CNS exposure. This is a slight advantage for Ligand A.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.5 and -6.0 kcal/mol). The difference is not significant enough to outweigh other factors.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand B initially appears attractive due to its higher BBB penetration and longer half-life. However, its high logP, poor solubility, and higher DILI risk are significant drawbacks. Ligand A, while having lower BBB penetration, presents a more balanced profile with better solubility, lower DILI risk, lower hERG inhibition, and better metabolic stability. The slightly lower logP is also less concerning.
Given the cardiovascular implications of targeting ADRB2, minimizing cardiotoxicity (hERG) and liver injury (DILI) are paramount. Ligand A's superior performance in these areas, coupled with its better metabolic stability, makes it the more promising candidate despite the lower BBB penetration.
Output:
1
2025-04-17 19:23:57,007 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (357.401 Da) is slightly lower, which is generally favorable for permeability.
**2. TPSA:** Ligand A (61.88) is better than Ligand B (73.66). Both are below 140, but lower TPSA is preferred for GPCRs to aid in brain penetration and overall absorption.
**3. logP:** Ligand A (0.329) is quite low, potentially hindering membrane permeability. Ligand B (3.802) is within the optimal range (1-3). This is a significant advantage for Ligand B.
**4. H-Bond Donors:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
**5. H-Bond Acceptors:** Ligand A (4) is better than Ligand B (6). Lower HBA counts are generally preferred.
**6. QED:** Both ligands have good QED scores (A: 0.667, B: 0.774), indicating good drug-like properties. Ligand B is slightly better.
**7. DILI:** Ligand A (34.781) has a significantly lower DILI risk than Ligand B (51.028). This is a major advantage for Ligand A.
**8. BBB:** Ligand A (78.868) has a better BBB penetration score than Ligand B (54.478). While ADRB2 is a cardiovascular target, some CNS effects are possible with beta-blockers, and better BBB penetration could be relevant.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, indicating poor permeability. Ligand A (-4.443) is slightly better than Ligand B (-4.832), but both are concerning.
**10. Aqueous Solubility:** Ligand A (-1.631) is slightly better than Ligand B (-4.335). Both are poor, but solubility can often be improved with formulation strategies.
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (A: 0.341, B: 0.411).
**12. Microsomal Clearance:** Ligand A (-7.949) has much lower (better) microsomal clearance than Ligand B (45.084), indicating better metabolic stability.
**13. In vitro Half-Life:** Ligand A (-10.281) has a much longer in vitro half-life than Ligand B (26.632). This is a significant advantage for Ligand A.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (A: 0.032, B: 0.559). Ligand A is slightly better.
**15. Binding Affinity:** Ligand B (-7.4) has slightly better binding affinity than Ligand A (-7.0). While a 0.4 kcal/mol difference is not huge, it's a positive for Ligand B.
**Overall Assessment:**
Ligand A has several key advantages: significantly lower DILI risk, better BBB penetration, much better metabolic stability (lower Cl_mic, longer t1/2), and slightly better permeability and P-gp efflux. Ligand B's main advantage is its logP and slightly better binding affinity. However, the poor logP of Ligand A is a significant concern, but can be addressed with prodrug strategies. The DILI risk and metabolic stability of Ligand A are more critical factors for a successful drug candidate.
Therefore, I prefer Ligand A.
Output:
1
2025-04-17 19:23:57,007 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.415 and 357.445 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (78.95) is higher than Ligand B (58.36). For a cardiovascular GPCR, TPSA is not a primary concern, but lower is generally preferred for better absorption. Ligand B has an advantage.
3. **logP:** Ligand A (0.761) is a bit low, potentially hindering permeability. Ligand B (2.837) is within the optimal 1-3 range. Ligand B is clearly better here.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Both have 4 HBA, which is good.
6. **QED:** Both are above 0.5 (0.745 and 0.816), indicating good drug-likeness. Ligand B is slightly better.
7. **DILI:** Ligand A (40.054) is slightly higher than Ligand B (25.204), but both are below the 60% threshold, indicating acceptable liver injury risk. Ligand B is preferred.
8. **BBB:** Ligand A (61.923) is lower than Ligand B (92.284). While ADRB2 isn't necessarily a CNS target, higher BBB penetration can sometimes indicate better overall distribution and reduced off-target effects. Ligand B has a significant advantage.
9. **Caco-2:** Both are negative, indicating poor permeability. This is a concern for both.
10. **Solubility:** Both are negative, indicating poor solubility. This is a concern for both.
11. **hERG:** Ligand A (0.233) is lower than Ligand B (0.568), suggesting a lower risk of cardiotoxicity. This is a crucial advantage for a cardiovascular target.
12. **Cl_mic:** Ligand A (24.14) has a lower microsomal clearance than Ligand B (50.846), indicating better metabolic stability. This is a significant advantage.
13. **t1/2:** Both have negative in vitro half-lives (-38.901 and -37.582). This is a major concern for both compounds.
14. **Pgp:** Ligand A (0.025) has much lower P-gp efflux liability than Ligand B (0.132), suggesting better oral bioavailability and potentially better tissue distribution. This is a significant advantage.
15. **Binding Affinity:** Ligand B (-7.8 kcal/mol) has a stronger binding affinity than Ligand A (-6.2 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME drawbacks.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand B excels in logP, BBB, and affinity. Ligand A has a better hERG profile and Pgp efflux. However, the significantly stronger binding affinity of Ligand B (-7.8 vs -6.2) is a major driver, and the better logP and BBB are also beneficial. The slightly better DILI risk for Ligand B is also a plus.
**Overall Assessment:**
While Ligand A has advantages in hERG and Pgp, the superior binding affinity, logP, and BBB penetration of Ligand B, combined with acceptable DILI risk, make it the more promising candidate. The poor Caco-2 and solubility are concerns for both, but can be addressed with formulation strategies.
Output:
0
2025-04-17 19:23:57,008 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (405.3) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (69.64) is significantly lower than Ligand A (96.25). This is a major advantage for Ligand B, as lower TPSA generally correlates with better oral absorption and potentially better BBB penetration.
3. **logP:** Both ligands have logP values within the optimal range (1-3). Ligand B (2.83) is slightly lower than Ligand A (4.439), which is preferable as it reduces the risk of off-target effects and solubility issues.
4. **HBD:** Both ligands have acceptable HBD counts (Ligand A: 4, Ligand B: 2).
5. **HBA:** Both ligands have acceptable HBA counts (Ligand A: 2, Ligand B: 5).
6. **QED:** Both ligands have good QED scores (Ligand A: 0.605, Ligand B: 0.724), indicating drug-like properties. Ligand B is slightly better.
7. **DILI:** Both ligands have similar DILI risk (Ligand A: 69.76, Ligand B: 66.69), and are within an acceptable range (<80).
8. **BBB:** Ligand A (59.21) has a better BBB percentile than Ligand B (39.82). While ADRB2 isn't necessarily a CNS target, some peripheral ADRB2 activity can influence CNS pathways, and better BBB penetration isn't detrimental.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and likely indicates poor permeability in this assay. This is a concern for both.
10. **Solubility:** Both ligands have negative solubility values, which is also unusual and suggests poor aqueous solubility. This is a significant drawback for both.
11. **hERG:** Both ligands have low hERG inhibition liability (Ligand A: 0.539, Ligand B: 0.767), which is good.
12. **Cl_mic:** Ligand A (35.99) has significantly lower microsomal clearance than Ligand B (64.98). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (84.39) has a much longer in vitro half-life than Ligand B (9.36). This is a significant advantage for Ligand A.
14. **Pgp:** Both ligands have low P-gp efflux liability (Ligand A: 0.194, Ligand B: 0.389).
15. **Binding Affinity:** Ligand A (-7.8 kcal/mol) has a slightly better binding affinity than Ligand B (-7.4 kcal/mol). While the difference is relatively small, it's still a positive factor.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, and affinity are crucial. Ligand B excels in logP and TPSA, while Ligand A has a slight edge in affinity. Metabolic stability (Cl_mic and t1/2) are also important, and Ligand A is significantly better in these aspects. BBB is less critical for a peripheral target like ADRB2, but Ligand A is better.
**Overall Assessment:**
Ligand A has a better balance of properties, particularly regarding metabolic stability (lower Cl_mic, longer t1/2) and slightly better binding affinity. While Ligand B has a lower TPSA and logP, the significantly worse metabolic properties of Ligand B outweigh these advantages. The poor Caco-2 and solubility values for both are concerning and would require further investigation/optimization, but are not decisive at this stage.
Output:
1
2025-04-17 19:23:57,008 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (413.356 Da) is within the ideal range, while Ligand B (360.414 Da) is also acceptable. No clear advantage here.
2. **TPSA:** Ligand A (59.59) is better than Ligand B (83.98). Lower TPSA generally favors better absorption, and is particularly important for GPCRs.
3. **logP:** Ligand A (4.543) is slightly higher than Ligand B (2.384). While both are within the acceptable range, Ligand A is approaching the upper limit, potentially raising solubility concerns.
4. **HBD:** Both ligands have 2 HBD, which is good.
5. **HBA:** Ligand A (4) is better than Ligand B (5). Lower HBA is generally favorable.
6. **QED:** Ligand B (0.648) has a better QED score than Ligand A (0.461), indicating a more drug-like profile.
7. **DILI:** Ligand A (31.059) has a significantly lower DILI risk than Ligand B (78.286). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (61.458) has a better BBB penetration than Ligand B (46.336). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be beneficial or at least needs to be considered.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the absolute value for Ligand A (-4.989) is less negative than Ligand B (-4.833), suggesting slightly better permeability.
10. **Solubility:** Both ligands have negative solubility values, which is also unusual and suggests poor solubility. The values are similar, so no clear advantage.
11. **hERG:** Ligand A (0.833) has a lower hERG risk than Ligand B (0.468). This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand B (35.906) has a lower microsomal clearance than Ligand A (80.813), indicating better metabolic stability. This is a key advantage for Ligand B.
13. **t1/2:** Ligand A (56.034) has a much longer in vitro half-life than Ligand B (8.14). This is a substantial advantage for Ligand A.
14. **Pgp:** Ligand A (0.338) has a lower P-gp efflux liability than Ligand B (0.099), suggesting better bioavailability.
15. **Binding Affinity:** Ligand B (-6.5) has a slightly better binding affinity than Ligand A (-6.4), but the difference is marginal.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand A appears to be the better candidate. While Ligand B has a slightly better affinity and metabolic stability, Ligand A excels in critical safety parameters (DILI, hERG), has a more favorable TPSA, better BBB penetration, and a significantly longer half-life. The slightly higher logP of Ligand A is a minor concern that could be addressed through further optimization. The poor Caco-2 and solubility values are concerning for both, but the other advantages of Ligand A outweigh this drawback.
Output:
1
2025-04-17 19:23:57,008 - INFO - Here's my reasoning and final output for the ligand preference:
**Reasoning:**
We are targeting ADRB2, a GPCR, so the priorities are logP, Pgp, TPSA, affinity, and BBB. Let's break down the comparison:
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da).
2. **TPSA:** Ligand B (49.85) is significantly better than Ligand A (95.5), falling well below the 140 threshold for oral absorption and closer to the ideal for GPCRs.
3. **logP:** Both are good (around 2), within the optimal 1-3 range. Ligand B is slightly higher at 2.302, which could be beneficial for membrane permeability.
4. **H-Bond Donors/Acceptors:** Ligand A has 3 HBD and 3 HBA, while Ligand B has 0 HBD and 3 HBA. This is a slight advantage for Ligand B, as fewer donors can sometimes improve permeability.
5. **QED:** Both are similar (0.637 vs 0.633), indicating good drug-likeness.
6. **DILI:** Ligand B (6.669) is *much* better than Ligand A (41.14), indicating a significantly lower risk of drug-induced liver injury. This is a major advantage.
7. **BBB:** Ligand B (90.849) is excellent, suggesting good potential for CNS penetration if desired (though not explicitly stated as a goal). Ligand A (37.301) is much lower.
8. **Caco-2 Permeability:** Ligand A (-5.95) is better than Ligand B (-4.325), suggesting better intestinal absorption.
9. **Aqueous Solubility:** Ligand A (-1.177) is slightly better than Ligand B (-2.253), but both are poor.
10. **hERG:** Ligand A (0.03) is slightly better than Ligand B (0.51), indicating lower cardiotoxicity risk.
11. **Cl_mic:** Ligand A (-7.896) is *much* better than Ligand B (52.924), indicating significantly better metabolic stability. This is a major advantage.
12. **t1/2:** Ligand A (15.782) has a longer half-life than Ligand B (7.579).
13. **Pgp:** Ligand A (0.012) is much better than Ligand B (0.059), indicating lower P-glycoprotein efflux.
14. **Binding Affinity:** Ligand A (-6.3) is better than Ligand B (-5.1), a difference of 1.2 kcal/mol, which is substantial.
**Overall Assessment:**
While Ligand A has a better binding affinity and metabolic stability, Ligand B has a much better safety profile (DILI), BBB penetration, and TPSA. The lower TPSA and DILI risk of Ligand B are particularly compelling for a GPCR target, outweighing the affinity advantage of Ligand A. The better BBB penetration is also a plus. The slightly worse solubility and permeability of Ligand B are less concerning than the potential for liver toxicity with Ligand A.
**Output:**
0
2025-04-17 19:23:57,008 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [366.483, 67.87, 2.186, 1, 5, 0.751, 56.883, 69.407, -4.974, -2.014, 0.225, 48.578, 37.236, 0.158, -6.5]
**Ligand B:** [388.515, 121.18, 1.655, 2, 7, 0.629, 58.395, 38.038, -5.447, -2.594, 0.284, 41.793, 12.488, 0.105, -6.5]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (366.483) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (67.87) is significantly better than Ligand B (121.18). For a GPCR, keeping TPSA low is beneficial for permeability and potentially BBB penetration.
3. **logP:** Both are within the optimal range (1-3). Ligand A (2.186) is slightly higher, which could be a minor advantage.
4. **HBD:** Ligand A (1) is better than Ligand B (2). Lower HBD is generally preferred for better membrane permeability.
5. **HBA:** Ligand A (5) is better than Ligand B (7). Similar to HBD, lower HBA is generally preferred.
6. **QED:** Ligand A (0.751) is better than Ligand B (0.629), indicating a more drug-like profile.
7. **DILI:** Both are acceptable, with Ligand A (56.883) being slightly better than Ligand B (58.395). Both are below the 60% threshold.
8. **BBB:** Ligand A (69.407) is significantly better than Ligand B (38.038). This is a crucial parameter for GPCRs, even if not a CNS target, as it indicates better distribution characteristics.
9. **Caco-2:** Ligand A (-4.974) is better than Ligand B (-5.447). Higher Caco-2 permeability suggests better absorption.
10. **Solubility:** Ligand A (-2.014) is better than Ligand B (-2.594), although both are quite poor.
11. **hERG:** Both are very low (0.225 and 0.284), indicating minimal hERG inhibition risk.
12. **Cl_mic:** Ligand A (48.578) is better than Ligand B (41.793). Lower clearance is favorable for metabolic stability.
13. **t1/2:** Ligand A (37.236) is significantly better than Ligand B (12.488). A longer half-life is generally preferred.
14. **Pgp:** Both are very low (0.158 and 0.105), suggesting minimal P-gp efflux.
15. **Affinity:** Both have the same binding affinity (-6.5 kcal/mol).
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most key ADME properties, particularly TPSA, BBB, QED, Caco-2 permeability, and *t1/2*. While both ligands have acceptable DILI and hERG profiles and identical binding affinity, the superior ADME profile of Ligand A makes it the more promising drug candidate for the ADRB2 target. The lower TPSA and higher BBB penetration are especially important for a GPCR.
Output:
1
2025-04-17 19:23:57,008 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (341.382 Da) is slightly lower, which is generally favorable for permeability.
**2. TPSA:** Ligand A (38.77) is significantly better than Ligand B (62.66). For a cardiovascular GPCR, TPSA is important for balancing permeability and solubility. Lower TPSA is preferred.
**3. logP:** Both ligands have good logP values (A: 3.671, B: 3.822), falling within the optimal 1-3 range.
**4. H-Bond Donors:** Ligand A (0) is better than Ligand B (1). Fewer HBDs generally improve membrane permeability.
**5. H-Bond Acceptors:** Ligand A (3) is better than Ligand B (5). Fewer HBAs also contribute to better permeability.
**6. QED:** Both ligands have good QED scores (A: 0.837, B: 0.878), indicating good drug-like properties.
**7. DILI Risk:** Ligand B (56.844) has a lower DILI risk than Ligand A (66.615), which is a positive.
**8. BBB Penetration:** Ligand A (87.088) has significantly better BBB penetration than Ligand B (77.705). While ADRB2 is a cardiovascular target, some CNS effects are possible with certain ligands, and better BBB penetration could be advantageous or a concern depending on the desired selectivity.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests a potential issue with the assay or data. However, the values are similar (-4.146 for A, -4.503 for B).
**10. Aqueous Solubility:** Both ligands have negative solubility values, which is also unusual. Again, the values are similar (-4.383 for A, -5.023 for B).
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (A: 0.856, B: 0.758).
**12. Microsomal Clearance:** Ligand B (27.221) has much lower microsomal clearance than Ligand A (86.796), indicating better metabolic stability. This is a significant advantage.
**13. In vitro Half-Life:** Ligand B (14.852 hours) has a longer in vitro half-life than Ligand A (32.365 hours). This is a positive.
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (A: 0.8, B: 0.65).
**15. Binding Affinity:** Ligand B (-5.9 kcal/mol) has a slightly better binding affinity than Ligand A (-5.5 kcal/mol), which is a crucial factor.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand B is the more promising candidate. While Ligand A has better BBB penetration, the significantly improved metabolic stability (lower Cl_mic, longer t1/2), lower DILI risk, and slightly better binding affinity of Ligand B outweigh this advantage. The TPSA is also much better for Ligand B. The similar Caco-2 and solubility values are concerning, but don't strongly sway the decision given the other advantages of Ligand B.
Output:
0
2025-04-17 19:23:57,009 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (337.47 & 349.43 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (36.44) is significantly better than Ligand B (85.87). ADRB2 is not a CNS target, but lower TPSA generally improves absorption. Ligand A is well below the 140 threshold, while Ligand B is approaching it.
3. **logP:** Ligand A (3.438) is within the optimal 1-3 range. Ligand B (0.928) is a bit low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (4). Fewer HBAs generally improve permeability.
6. **QED:** Both ligands have similar QED scores (0.838 and 0.828), indicating good drug-likeness.
7. **DILI:** Ligand A (31.214) has a much lower DILI risk than Ligand B (40.83). This is a significant advantage for Ligand A.
8. **BBB:** This is less critical for ADRB2 (a cardiovascular target), but Ligand A (82.823) is better than Ligand B (29.74).
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the absolute value is smaller for Ligand A (-4.613 vs -4.847), suggesting slightly better permeability.
10. **Solubility:** Ligand A (-2.93) is slightly better than Ligand B (-1.562), though both are quite poor.
11. **hERG:** Ligand A (0.838) is significantly better than Ligand B (0.269), indicating a lower risk of cardiotoxicity. This is *very* important for a cardiovascular target.
12. **Cl_mic:** Ligand A (80.683) has a higher microsomal clearance than Ligand B (-2.941), indicating lower metabolic stability. This is a drawback for Ligand A.
13. **t1/2:** Ligand A (30.775) has a much longer in vitro half-life than Ligand B (-12.941). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.567) has lower P-gp efflux liability than Ligand B (0.036), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand B (-8.1 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.7 kcal/mol). This is a substantial advantage for Ligand B, potentially outweighing some of its ADME drawbacks.
**Overall Assessment:**
Ligand B has a much stronger binding affinity, which is crucial. However, it suffers from poor logP, higher DILI risk, and a significantly higher risk of hERG inhibition. Ligand A has better ADME properties overall (lower DILI, better hERG, better Pgp efflux, longer half-life), but its binding affinity is weaker.
Considering the ADRB2 target and the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), the affinity difference is substantial enough to favor Ligand B, *despite* its ADME liabilities. The hERG risk with Ligand B is concerning, but could potentially be mitigated with structural modifications. The poor logP could also be addressed. The better ADME profile of Ligand A is less valuable without comparable potency.
Output:
0
2025-04-17 19:23:57,009 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.475 and 346.515 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (76.66) is higher than Ligand B (58.2). Both are below the 140 threshold for oral absorption, but B is better positioned for potential CNS penetration if that were a goal.
3. **logP:** Ligand A (1.795) is within the optimal 1-3 range. Ligand B (3.402) is slightly higher, nearing the upper limit. While still acceptable, it raises a slight concern for potential off-target interactions and solubility issues.
4. **HBD:** Both ligands have 2 H-bond donors, which is good.
5. **HBA:** Ligand A has 4 H-bond acceptors, while Ligand B has 2. Lower HBA is generally favorable for permeability. Ligand B is better here.
6. **QED:** Ligand B (0.819) has a significantly better QED score than Ligand A (0.62), indicating a more drug-like profile.
7. **DILI:** Ligand A (25.669) has a much lower DILI risk than Ligand B (33.23). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (73.866) has a slightly higher BBB penetration percentile than Ligand A (66.266). While ADRB2 isn't strictly a CNS target, some peripheral ADRB2 receptors can be relevant in CNS-related conditions, and higher BBB is rarely a negative.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-4.494) is slightly better than Ligand B (-4.68).
10. **Solubility:** Ligand A (-2.832) has better solubility than Ligand B (-4.326). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.151) has a lower hERG inhibition liability than Ligand B (0.415), which is a significant safety advantage.
12. **Cl_mic:** Ligand B (24.097) has a significantly lower microsomal clearance than Ligand A (75.178), indicating better metabolic stability.
13. **t1/2:** Ligand B (38.02) has a much longer in vitro half-life than Ligand A (-11.706). This is a major advantage for Ligand B.
14. **Pgp:** Both are low, with Ligand A (0.127) being slightly lower.
15. **Binding Affinity:** Ligand B (-8.1 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.1 kcal/mol). This is a substantial advantage, potentially outweighing some ADME concerns.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, affinity, logP, TPSA, and Pgp are key. Ligand B excels in affinity and has a reasonable logP and Pgp. While TPSA is slightly higher than ideal, the strong binding affinity is a major driver. The improved metabolic stability (lower Cl_mic and longer t1/2) is also very beneficial.
**Overall Assessment:**
Ligand B has a superior binding affinity and better metabolic stability. While Ligand A has a lower DILI risk and better solubility, the difference in affinity is substantial, and the longer half-life of Ligand B is a significant advantage. The slightly higher logP of Ligand B is a minor concern that can potentially be addressed through further optimization.
Output:
0
2025-04-17 19:23:57,009 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (360.38 and 348.378 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (70.39) is significantly better than Ligand B (103.09). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (2.919) is optimal, while Ligand B (0.303) is quite low. This is a significant drawback for Ligand B, potentially hindering membrane permeability.
4. **HBD:** Ligand A (2) is preferable to Ligand B (4). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is slightly better than Ligand B (3), but both are acceptable.
6. **QED:** Both ligands have reasonable QED scores (0.809 and 0.629), indicating good drug-like properties. Ligand A is slightly better.
7. **DILI:** Ligand A (30.671) has a much lower DILI risk than Ligand B (60.644). This is a critical advantage, as liver toxicity is a major concern.
8. **BBB:** Ligand A (92.71) has a higher BBB penetration score than Ligand B (51.221). While not a primary concern for a cardiovascular target, it isn't detrimental.
9. **Caco-2:** Ligand A (-4.826) is better than Ligand B (-5.44). Higher is better, indicating better intestinal absorption.
10. **Solubility:** Both ligands have similar, very poor aqueous solubility (-2.923 and -2.921). This is a potential formulation challenge for both.
11. **hERG:** Both ligands have low hERG risk (0.637 and 0.235).
12. **Cl_mic:** Ligand A (19.095) has a lower (better) microsomal clearance than Ligand B (-19.358). This suggests better metabolic stability.
13. **t1/2:** Ligand B (21.338) has a longer in vitro half-life than Ligand A (-15.308). This is a positive attribute.
14. **Pgp:** Ligand A (0.364) has lower P-gp efflux liability than Ligand B (0.007). Lower is better, improving bioavailability.
15. **Affinity:** Ligand B (-7.3) has a significantly better binding affinity than Ligand A (-4.9). This is a substantial advantage (2.4 kcal/mol difference).
**Overall Assessment:**
Ligand B has a significantly stronger binding affinity, which is a major plus. However, it suffers from a low logP, higher DILI risk, and lower Pgp efflux. Ligand A, while having weaker affinity, presents a much more balanced profile with better predicted ADME properties, particularly regarding safety (DILI) and permeability (logP, TPSA, Pgp). Given the GPCR-specific priorities, and the fact that the affinity difference, while substantial, isn't insurmountable in optimization, the better overall profile of Ligand A makes it the more promising starting point.
Output:
1
2025-04-17 19:23:57,009 - INFO - Batch 107 complete. Total preferences: 1712
2025-04-17 19:23:57,009 - INFO - Processing batch 108/512...
2025-04-17 19:24:45,549 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.459 Da and 345.403 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (75.71) is better than Ligand B (100.21). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is generally preferred for absorption.
3. **logP:** Both ligands have good logP values (1.729 and 1.15) within the optimal 1-3 range. Ligand B is slightly lower, which *could* be a minor drawback, but not a major concern.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is preferable to Ligand B (5). Similar to HBD, lower HBA is generally better.
6. **QED:** Both ligands have good QED scores (0.74 and 0.784), indicating good drug-like properties. No significant difference.
7. **DILI:** Ligand A (36.332) has a significantly lower DILI risk than Ligand B (53.276). This is a crucial advantage, as minimizing liver toxicity is paramount.
8. **BBB:** Ligand A (53.238) has a better BBB percentile than Ligand B (27.763). While ADRB2 isn't primarily a CNS target, some peripheral exposure is expected, and higher BBB penetration can sometimes correlate with better overall distribution.
9. **Caco-2:** Ligand A (-4.795) has a better Caco-2 permeability than Ligand B (-5.138). Higher values indicate better intestinal absorption.
10. **Solubility:** Both ligands have similar, poor aqueous solubility (-2.105 and -2.143). This is a potential formulation challenge for both.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.161 and 0.166), which is excellent.
12. **Cl_mic:** Ligand A (30.234) has a higher microsomal clearance than Ligand B (12.592), indicating faster metabolism and potentially lower *in vivo* exposure. This is a disadvantage for Ligand A.
13. **t1/2:** Ligand B (10.838) has a significantly longer *in vitro* half-life than Ligand A (-14.776). This is a major advantage for Ligand B, as it suggests less frequent dosing could be possible.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.172 and 0.02). No significant difference.
15. **Binding Affinity:** Ligand B (-6.8 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.5 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME drawbacks of Ligand B.
**Overall Assessment:**
Ligand B has a significantly better binding affinity and a much longer half-life, which are very important for a GPCR target. While Ligand A has a lower DILI risk and better TPSA, the stronger binding and improved metabolic stability of Ligand B are more critical for efficacy and dosing. The solubility is a concern for both, but can be addressed with formulation strategies.
Output:
0
2025-04-17 19:24:45,549 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (358.463) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (68.29) is significantly better than Ligand B (101.29). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (4.23) is higher than Ligand B (1.271). While both are within acceptable ranges, Ligand A is pushing the upper limit and could potentially have solubility issues. Ligand B's logP is quite low, which could hinder membrane permeability.
4. **HBD/HBA:** Ligand A (1 HBD, 5 HBA) is preferable to Ligand B (3 HBD, 4 HBA). Fewer H-bonds are generally better for permeability.
5. **QED:** Ligand A (0.834) has a better QED score than Ligand B (0.693), indicating a more drug-like profile.
6. **DILI:** Ligand B (41.877) has a much lower DILI risk than Ligand A (81.427). This is a significant advantage for Ligand B.
7. **BBB:** Ligand A (70.919) has a better BBB score than Ligand B (61.38). However, since ADRB2 is primarily a cardiovascular target, BBB penetration is not a major priority.
8. **Caco-2:** Ligand A (-4.544) has a worse Caco-2 permeability than Ligand B (-5.433). Both are negative, indicating poor permeability.
9. **Solubility:** Ligand B (-2.882) has better solubility than Ligand A (-5.859). This is important, especially given Ligand A's higher logP.
10. **hERG:** Ligand A (0.295) has a lower hERG risk than Ligand B (0.455), which is a positive.
11. **Cl_mic:** Ligand B (3.783) has much lower microsomal clearance than Ligand A (111.24). Lower clearance indicates better metabolic stability, a crucial factor.
12. **t1/2:** Ligand B (-27.696) has a longer in vitro half-life than Ligand A (29.664). This is a significant advantage for Ligand B.
13. **Pgp:** Ligand A (0.36) has lower P-gp efflux than Ligand B (0.047).
14. **Binding Affinity:** Ligand B (-6.8 kcal/mol) has a slightly better binding affinity than Ligand A (-6.4 kcal/mol). While the difference is not huge, it's still a positive for Ligand B.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Ligand A has a higher logP, but also a lower TPSA and Pgp efflux. Ligand B has a lower logP, but better solubility, metabolic stability (Cl_mic, t1/2), and DILI risk. The slightly better affinity of Ligand B is also a plus.
**Overall Assessment:**
While Ligand A has some favorable properties (lower TPSA, Pgp), Ligand B's significantly better DILI profile, metabolic stability (lower Cl_mic and longer t1/2), and solubility outweigh the advantages of Ligand A. The slightly better affinity of Ligand B further supports its selection. Therefore, Ligand B is the more promising drug candidate.
Output:
0
2025-04-17 19:24:45,549 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [365.539, 63.24, 3.811, 1, 3, 0.686, 37.456, 78.092, -4.849, -3.948, 0.607, 62.147, 18.627, 0.526, -6.3]
**Ligand B:** [340.427, 80.2, 2.14, 1, 3, 0.912, 25.165, 71.811, -4.828, -3.661, 0.661, 15.002, -3.471, 0.027, -7.4]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (340.427) is slightly lower, which could be marginally better for permeability, but the difference isn't substantial.
2. **TPSA:** Ligand A (63.24) is better than Ligand B (80.2), falling comfortably under the 140 threshold for oral absorption and closer to the 90 threshold for CNS penetration (though ADRB2 isn't necessarily a CNS target).
3. **logP:** Ligand A (3.811) is slightly higher than Ligand B (2.14), both are within the optimal range of 1-3, but A is closer to the upper limit.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Both have 3 HBA, which is good.
6. **QED:** Ligand B (0.912) has a significantly better QED score than Ligand A (0.686), indicating a more drug-like profile.
7. **DILI:** Ligand A (37.456) has a higher DILI risk than Ligand B (25.165), which is preferable.
8. **BBB:** Ligand A (78.092) has a slightly better BBB penetration score than Ligand B (71.811).
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. This is a significant concern for both.
10. **Solubility:** Both have negative solubility values, indicating poor solubility. This is also a concern for both.
11. **hERG:** Both have low hERG inhibition liability, which is good.
12. **Cl_mic:** Ligand B (15.002) has a significantly lower microsomal clearance than Ligand A (62.147), suggesting better metabolic stability.
13. **t1/2:** Ligand A (18.627) has a longer in vitro half-life than Ligand B (-3.471), which is desirable.
14. **Pgp:** Ligand A (0.526) has lower P-gp efflux liability than Ligand B (0.027), which is preferable.
15. **Binding Affinity:** Ligand B (-7.4) has a significantly stronger binding affinity than Ligand A (-6.3), a difference of 1.1 kcal/mol. This is a substantial advantage.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp efflux, and binding affinity are key. Ligand B excels in binding affinity. While Ligand A has a slightly better TPSA and BBB, the large difference in binding affinity and the better metabolic stability (lower Cl_mic) of Ligand B outweigh these factors. The QED score of Ligand B is also much more favorable. The poor Caco-2 and solubility are concerning for both, but can be addressed with formulation strategies.
**Conclusion:**
Despite the concerns with Caco-2 and solubility, the significantly stronger binding affinity of Ligand B, coupled with its better QED and metabolic stability, makes it the more promising drug candidate.
0
2025-04-17 19:24:45,549 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (388.917 Da) is slightly higher than Ligand B (365.539 Da), but this difference isn't significant.
**2. TPSA:** Ligand B (38.77) is significantly better than Ligand A (75.71). Lower TPSA generally correlates with better cell permeability, crucial for GPCR ligands.
**3. logP:** Ligand A (2.666) is within the optimal range (1-3). Ligand B (4.078) is slightly above, potentially increasing the risk of off-target effects and solubility issues, but still within a manageable range.
**4. H-Bond Donors:** Ligand A has 1 HBD, and Ligand B has 0. Both are acceptable.
**5. H-Bond Acceptors:** Both ligands have 4 HBAs, which is within the acceptable range.
**6. QED:** Both ligands have similar QED values (0.779 and 0.73), indicating good drug-likeness.
**7. DILI Risk:** Ligand B (36.06) has a significantly lower DILI risk than Ligand A (56.185). This is a major advantage for Ligand B.
**8. BBB Penetration:** Ligand B (75.921) shows better BBB penetration than Ligand A (53.083). While ADRB2 isn't strictly a CNS target, some CNS exposure might be acceptable or even desirable for certain cardiovascular effects, and better BBB penetration is generally favorable.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.975 and -4.809), which is unusual and suggests poor permeability. This is a concern for both.
**10. Aqueous Solubility:** Both ligands have negative solubility values (-4.106 and -4.26), indicating very poor aqueous solubility. This is a significant drawback for both.
**11. hERG Inhibition:** Ligand A (0.499) has a lower hERG inhibition risk than Ligand B (0.914), which is favorable.
**12. Microsomal Clearance:** Ligand A (46.429) has significantly lower microsomal clearance than Ligand B (125.903), indicating better metabolic stability.
**13. In vitro Half-Life:** Ligand B (43.641) has a longer in vitro half-life than Ligand A (-6.3). This is a positive for Ligand B.
**14. P-gp Efflux:** Ligand A (0.269) has lower P-gp efflux than Ligand B (0.682), which is favorable.
**15. Binding Affinity:** Ligand A (-7.5 kcal/mol) has a slightly better binding affinity than Ligand B (-6.7 kcal/mol). This is a notable advantage for Ligand A, but the difference isn't huge.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand B appears to be the more promising candidate. While Ligand A has better affinity and lower P-gp efflux, Ligand B excels in crucial ADME properties: significantly lower DILI risk, better BBB penetration, and a longer half-life. The lower TPSA of Ligand B is also a significant advantage. The solubility and permeability issues are concerning for both, but can potentially be addressed through formulation strategies. The lower DILI risk of Ligand B is a major factor in its favor, as it reduces the likelihood of drug-induced liver injury.
Output:
0
2025-04-17 19:24:45,550 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Step-by-step comparison:**
1. **MW:** Ligand A (361.423 Da) and Ligand B (343.402 Da) are both within the ideal range (200-500 Da). No significant difference here.
2. **TPSA:** Ligand A (110.52) is higher than Ligand B (62.3). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B is significantly better.
3. **logP:** Ligand A (1.808) and Ligand B (2.37) are both within the optimal range (1-3). Ligand B is slightly better.
4. **HBD:** Ligand A (3) and Ligand B (1) are both acceptable. Ligand B is better, as fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (5) and Ligand B (3) are both acceptable. Ligand B is better, for similar reasons as HBD.
6. **QED:** Ligand B (0.835) has a significantly higher QED score than Ligand A (0.537), indicating a more drug-like profile.
7. **DILI:** Ligand A (93.37) has a much higher DILI risk than Ligand B (44.824). This is a major concern for Ligand A.
8. **BBB:** Ligand A (51.221) and Ligand B (94.416). While ADRB2 isn't a CNS target, higher BBB penetration can sometimes correlate with better overall distribution and reduced off-target effects. Ligand B is better.
9. **Caco-2:** Ligand A (-5.36) and Ligand B (-4.546). Both are negative, indicating poor permeability. This is a concern for both, but Ligand B is slightly better.
10. **Solubility:** Ligand A (-3.59) and Ligand B (-3.289). Both are poor, but Ligand B is slightly better.
11. **hERG:** Ligand A (0.317) and Ligand B (0.444). Both are relatively low risk, but Ligand B is slightly higher.
12. **Cl_mic:** Ligand A (20.165) has a lower microsomal clearance than Ligand B (36.391), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-9.884) has a much longer in vitro half-life than Ligand B (-24.872). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.201) has lower P-gp efflux than Ligand B (0.185). Both are low, suggesting minimal efflux issues.
15. **Binding Affinity:** Ligand A (-6.8 kcal/mol) has a slightly better binding affinity than Ligand B (-6.1 kcal/mol). This is a positive for Ligand A, but the difference isn't huge.
**GPCR-Specific Priorities & Overall Assessment:**
For ADRB2 (a cardiovascular GPCR), logP, TPSA, and affinity are key. Ligand B excels in TPSA and logP, and has a good QED score. Ligand A has slightly better affinity and metabolic stability (lower Cl_mic, longer t1/2), but suffers from a significantly higher DILI risk and a lower QED. The DILI risk is a major red flag. While the affinity difference isn't massive, the overall ADME profile of Ligand B is far more promising.
**Output:**
0
2025-04-17 19:24:45,550 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [352.366, 117.13 , 1.853, 3. , 4. , 0.394, 61.303, 74.874, -5.091, -3.295, 0.472, 10.326, 11.729, 0.111, -7.3 ]
**Ligand B:** [368.413, 85.94 , 1.508, 3. , 6. , 0.67 , 82.435, 75.533, -5.559, -3.884, 0.854, 29.482, 8.403, 0.05 , -7. ]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, Affinity, and BBB):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (352.366) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (117.13) is better than Ligand B (85.94). Both are below the 140 threshold for oral absorption. Ligand B is closer to the 90 threshold for CNS targets, but this isn't a primary concern for a cardiovascular target.
3. **logP:** Both have good logP values (A: 1.853, B: 1.508) within the optimal 1-3 range.
4. **HBD/HBA:** Both have acceptable HBD (3) and Ligand A has fewer HBA (4 vs 6), which is slightly favorable.
5. **QED:** Ligand B (0.67) has a better QED score than Ligand A (0.394), indicating a more drug-like profile.
6. **DILI:** Ligand A (61.303) has a lower DILI risk than Ligand B (82.435), which is a significant advantage.
7. **BBB:** Both have reasonably good BBB penetration (A: 74.874, B: 75.533). Not a major factor here.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. This is a concern for both, but the magnitude is similar.
9. **Solubility:** Both have negative solubility values, which is also unusual and suggests poor solubility. This is a concern for both, but the magnitude is similar.
10. **hERG:** Both have very low hERG inhibition risk (A: 0.472, B: 0.854), which is excellent.
11. **Cl_mic:** Ligand A (10.326) has significantly lower microsomal clearance than Ligand B (29.482), indicating better metabolic stability.
12. **t1/2:** Ligand A (11.729) has a longer in vitro half-life than Ligand B (8.403).
13. **Pgp:** Ligand A (0.111) has lower P-gp efflux liability than Ligand B (0.05), which is favorable for bioavailability.
14. **Affinity:** Ligand A (-7.3) has slightly better binding affinity than Ligand B (-7.0). While the difference is small, it's within the range where it can outweigh other factors.
**Overall Assessment:**
Ligand A is preferable. While Ligand B has a better QED score, Ligand A demonstrates a superior safety profile (lower DILI), better metabolic stability (lower Cl_mic, longer t1/2), lower P-gp efflux, and slightly better binding affinity. The similar Caco-2 and solubility values are concerning for both, but the other advantages of Ligand A make it the more promising candidate. The slightly better affinity, combined with the improved ADME properties, outweighs the QED difference.
Output:
1
2025-04-17 19:24:45,550 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (382.77 and 343.471 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Both ligands (76.46 and 71.09) are below the 140 A^2 threshold for good oral absorption, which is good.
3. **logP:** Ligand A (1.924) is optimal, while Ligand B (3.139) is slightly higher but still within the acceptable range. Ligand A is slightly preferred here.
4. **HBD:** Ligand A (1) and Ligand B (2) are both acceptable, below the 5 threshold.
5. **HBA:** Ligand A (5) and Ligand B (3) are both acceptable, below the 10 threshold.
6. **QED:** Ligand A (0.731) has a better QED score than Ligand B (0.506), indicating a more drug-like profile.
7. **DILI:** Ligand A (65.258) has a higher DILI risk than Ligand B (32.028). This is a significant negative for Ligand A.
8. **BBB:** Ligand A (87.398) has better BBB penetration than Ligand B (76.192). While ADRB2 isn't *necessarily* a CNS target, some peripheral ADRB2 activity can influence CNS function, and better BBB penetration isn't a major negative.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Both ligands have negative solubility values, which is also unusual and suggests poor solubility. This is a concern for both.
11. **hERG:** Both ligands have low hERG inhibition liability (0.214 and 0.49), which is good.
12. **Cl_mic:** Ligand A (17.525) has a lower microsomal clearance than Ligand B (68.002), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-11.237) has a negative in vitro half-life, which is concerning. Ligand B (-4.145) is also negative, but less so.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.113 and 0.264), which is good.
15. **Binding Affinity:** Ligand A (-6.0) has a slightly better binding affinity than Ligand B (-4.9). This is a significant advantage.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand A has a better logP, Pgp, and affinity. Ligand B has a much better DILI score. The negative Caco-2 and solubility values are concerning for both.
**Overall Assessment:**
Ligand A is stronger in terms of key GPCR properties (affinity, logP, Pgp) and has better metabolic stability (lower Cl_mic). However, its significantly higher DILI risk is a major concern. Ligand B has a much better safety profile regarding liver toxicity, but its affinity is weaker and its metabolic stability is lower.
Despite the DILI risk, the stronger binding affinity of Ligand A, coupled with its better logP and Pgp properties, makes it a slightly more promising starting point for optimization. The DILI risk can potentially be addressed through structural modifications. The lower affinity of Ligand B might require more substantial changes to achieve sufficient potency.
Output:
1
2025-04-17 19:24:45,550 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (343.471 and 346.387 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (65.2) is significantly better than Ligand B (102.58). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally aids absorption. Ligand B is pushing the upper limit for good oral absorption.
3. **logP:** Ligand A (3.179) is optimal, while Ligand B (-0.395) is quite low. This is a major concern for Ligand B, as it may struggle with membrane permeability.
4. **HBD:** Both ligands have 2 HBD, which is within the acceptable range.
5. **HBA:** Ligand A has 2 HBA, while Ligand B has 4. Both are acceptable, but Ligand A is slightly preferred.
6. **QED:** Both ligands have reasonable QED scores (0.833 and 0.701), indicating good drug-like properties.
7. **DILI:** Ligand A (53.587) has a higher DILI risk than Ligand B (24.312). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (65.452) has slightly better BBB penetration than Ligand B (59.403), but neither is particularly high. This isn't a major factor for a cardiovascular target.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale isn't specified, so it's hard to interpret.
10. **Solubility:** Ligand A (-3.967) has slightly better solubility than Ligand B (-1.769).
11. **hERG:** Ligand A (0.67) has a slightly higher hERG risk than Ligand B (0.039). This is a significant advantage for Ligand B.
12. **Cl_mic:** Ligand A (56.601) has a much better (lower) microsomal clearance than Ligand B (-18.151). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (14.142) has a longer in vitro half-life than Ligand B (-13.395). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.455) has lower P-gp efflux than Ligand B (0.009), which is favorable.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.9 and -6.7 kcal/mol). The difference is not substantial enough to outweigh other factors.
**Overall Assessment:**
Ligand B has advantages in DILI risk and hERG inhibition, which are important safety parameters. However, its significantly lower logP is a major concern, suggesting poor permeability and potentially poor bioavailability. Ligand A, while having slightly higher DILI and hERG, has a much better logP, metabolic stability (lower Cl_mic, longer t1/2), and P-gp efflux profile. Considering the GPCR-specific priorities (logP, TPSA), and the overall balance of properties, Ligand A appears to be the more promising candidate.
Output:
1
2025-04-17 19:24:45,550 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [340.467, 62.22, 3.388, 2, 3, 0.877, 42.458, 64.017, -4.752, -4.198, 0.698, 73.82, 26.517, 0.674, -6]
**Ligand B:** [352.519, 49.85, 3.076, 0, 3, 0.641, 13.532, 86.623, -4.084, -2.795, 0.483, 73.163, 5.65, 0.141, -7]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity, and BBB):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (340.467) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (62.22) is higher than Ligand B (49.85). Both are acceptable, but Ligand B is better for oral absorption.
3. **logP:** Both are in the optimal range (1-3). Ligand A (3.388) is slightly higher, potentially increasing off-target effects, but not dramatically. Ligand B (3.076) is slightly better.
4. **HBD:** Ligand A (2) is better than Ligand B (0). Having some HBD can improve solubility.
5. **HBA:** Both have 3 HBA, which is good.
6. **QED:** Ligand A (0.877) is significantly better than Ligand B (0.641), indicating a more drug-like profile.
7. **DILI:** Ligand A (42.458) is higher than Ligand B (13.532). This is a significant advantage for Ligand B, as it has a much lower risk of liver injury.
8. **BBB:** Ligand B (86.623) is substantially better than Ligand A (64.017) in terms of BBB penetration. This is a key consideration for a GPCR, even a cardiovascular one, as some CNS off-target effects are possible.
9. **Caco-2:** Both have negative values, which is unusual. Assuming these are log values, both have poor permeability.
10. **Solubility:** Ligand B (-2.795) is better than Ligand A (-4.198), indicating better aqueous solubility.
11. **hERG:** Ligand A (0.698) is higher than Ligand B (0.483), suggesting a slightly higher risk of hERG inhibition.
12. **Cl_mic:** Both are similar (around 73 mL/min/kg), indicating comparable metabolic stability.
13. **t1/2:** Ligand A (26.517) has a much longer in vitro half-life than Ligand B (5.65). This is a significant advantage for dosing convenience.
14. **Pgp:** Ligand A (0.674) is higher than Ligand B (0.141), meaning Ligand B is less likely to be a P-gp substrate and will have better bioavailability.
15. **Affinity:** Ligand B (-7 kcal/mol) has a slightly better binding affinity than Ligand A (-6 kcal/mol). While the difference isn't huge, it's enough to be noticeable.
**Overall Assessment:**
Ligand B is the better candidate. While Ligand A has a better QED and half-life, Ligand B excels in the critical GPCR-relevant parameters: lower DILI risk, significantly better BBB penetration, lower P-gp efflux, and slightly better affinity. The improved solubility is also a plus. The slightly lower half-life of Ligand B can potentially be addressed through structural modifications. The superior safety profile (DILI) and potential for better CNS exposure (BBB, Pgp) outweigh the benefits of Ligand A's longer half-life and slightly higher QED.
Output:
0
2025-04-17 19:24:45,550 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (356.463 and 360.443 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (85.89) is better than Ligand B (104.7). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (1.99 and 1.11), falling within the optimal 1-3 range. Ligand A is slightly more lipophilic, which could be beneficial for membrane permeability.
4. **HBD:** Ligand A (2) is preferable to Ligand B (3). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (6). Similar reasoning as HBD.
6. **QED:** Ligand A (0.76) is better than Ligand B (0.642), indicating a more drug-like profile.
7. **DILI:** Ligand A (33.773) has a significantly lower DILI risk than Ligand B (72.47). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (78.79) has a better BBB penetration score than Ligand B (26.599). While not a primary concern for a cardiovascular target, it's still a positive attribute.
9. **Caco-2:** Ligand A (-4.509) is better than Ligand B (-5.97). Higher Caco-2 permeability suggests better intestinal absorption.
10. **Solubility:** Ligand A (-2.421) is better than Ligand B (-2.68). Better solubility is generally desirable.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.219 and 0.248), which is excellent. No significant difference.
12. **Cl_mic:** Ligand A (44.427) has a lower microsomal clearance than Ligand B (-10.769). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (-1.3) is better than Ligand B (-15.236). Longer half-life is generally preferred.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.021 and 0.032). No significant difference.
15. **Binding Affinity:** Both ligands have similar binding affinities (-6.4 and -6.2 kcal/mol). The difference is negligible.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A is better across most of these parameters (TPSA, logP, Pgp, and has a better QED score). The significantly lower DILI risk and improved metabolic stability (lower Cl_mic and better half-life) of Ligand A are also crucial advantages.
**Conclusion:**
Ligand A consistently outperforms Ligand B across multiple key ADME-Tox properties, and has a significantly better safety profile (lower DILI). While both have comparable affinity, the overall balance of properties makes Ligand A the more promising drug candidate.
Output:
1
2025-04-17 19:24:45,550 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (390.893 and 352.391 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Both ligands (106.0 and 108.05) are slightly above the optimal <140 for oral absorption, but acceptable. Given ADRB2 is a cardiovascular target, CNS penetration isn't a primary concern, so this isn't a major drawback.
3. **logP:** Ligand A (-0.199) is borderline low, potentially hindering permeability. Ligand B (-0.93) is also on the lower side, but slightly better. This is a slight advantage for Ligand B.
4. **HBD:** Ligand A (3) and Ligand B (2) are both within the acceptable limit of <=5. Ligand B is slightly better.
5. **HBA:** Ligand A (7) and Ligand B (5) are both within the acceptable limit of <=10. Ligand B is better.
6. **QED:** Both ligands have good QED scores (0.595 and 0.668), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (41.218) has a lower DILI risk than Ligand B (54.517). This is a significant advantage for Ligand A.
8. **BBB:** Both are low, not a major concern for a cardiovascular target. Ligand B (49.787) is higher than Ligand A (9.732), but this is not a priority.
9. **Caco-2:** Both have negative Caco-2 values (-5.393 and -5.093), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Both have negative solubility values (-0.805 and -1.419), which is also unusual and suggests poor solubility. This is a concern for both.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.118 and 0.067), which is excellent. No significant difference.
12. **Cl_mic:** Ligand A (-28.36) has a lower (better) microsomal clearance than Ligand B (-20.443), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand B (21.656) has a longer in vitro half-life than Ligand A (16.02). This is a slight advantage for Ligand B.
14. **Pgp:** Both have very low Pgp efflux liability (0.05 and 0.002), which is excellent. Ligand B is slightly better.
15. **Binding Affinity:** Ligand B (-5.9 kcal/mol) has a slightly better binding affinity than Ligand A (-5.1 kcal/mol). This is a significant advantage for Ligand B, as a 0.8 kcal/mol difference is substantial.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand B performs better on logP, Pgp, and affinity. However, the DILI and Cl_mic values for Ligand A are significantly better.
**Overall Assessment:**
While Ligand B has a better binding affinity and slightly better Pgp and logP, Ligand A's significantly lower DILI risk and improved metabolic stability (lower Cl_mic) are crucial for a viable drug candidate. The solubility and permeability issues are concerning for both, but can be addressed through formulation strategies. The lower DILI risk is a major safety advantage.
Output:
1
2025-04-17 19:24:45,550 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (346.446) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (49.41) is significantly better than Ligand B (85.89). ADRB2 is a cardiovascular target, not a CNS target, but lower TPSA is still desirable for absorption. Ligand B is pushing the upper limit for good oral absorption.
3. **logP:** Ligand A (2.286) is optimal. Ligand B (0.761) is a bit low, potentially hindering membrane permeability.
4. **HBD:** Both have acceptable HBD counts (Ligand A: 1, Ligand B: 2).
5. **HBA:** Ligand A (2) is better than Ligand B (5). Lower HBA is generally preferred for permeability.
6. **QED:** Both ligands have good QED scores (Ligand A: 0.541, Ligand B: 0.597), indicating generally drug-like properties.
7. **DILI:** Ligand A (12.136) has a much lower DILI risk than Ligand B (19.659). This is a significant advantage.
8. **BBB:** Not a primary concern for a cardiovascular target, but Ligand A (87.864) has better BBB penetration than Ligand B (50.679).
9. **Caco-2:** Ligand A (-4.578) is better than Ligand B (-5.287), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-2.955) is better than Ligand B (-1.235), which is important for bioavailability.
11. **hERG:** Ligand A (0.652) has a lower hERG risk than Ligand B (0.254). This is a significant safety advantage.
12. **Cl_mic:** Ligand A (16.284) has higher metabolic clearance than Ligand B (6.402), meaning Ligand B is more metabolically stable.
13. **t1/2:** Ligand B (8.826) has a significantly longer in vitro half-life than Ligand A (1.036). This is a major advantage.
14. **Pgp:** Ligand A (0.115) has lower P-gp efflux than Ligand B (0.025), which is favorable for bioavailability.
15. **Affinity:** Ligand B (-6.3 kcal/mol) has a slightly better binding affinity than Ligand A (-5.9 kcal/mol). This is a 1.5kcal/mol advantage, which is significant.
**Overall Assessment:**
Ligand B has a superior binding affinity and a much longer half-life. However, Ligand A has a significantly better safety profile (lower DILI and hERG risk), better solubility, better permeability (TPSA, logP, Caco-2), and lower P-gp efflux. While the longer half-life of Ligand B is attractive, the safety concerns and potential bioavailability issues associated with Ligand B are substantial. For a cardiovascular target, metabolic stability is important, but not at the expense of safety and absorption. The affinity difference is not large enough to overcome the other advantages of Ligand A.
**Output:**
1
2025-04-17 19:24:45,551 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [364.511, 49.85, 2.067, 0, 4, 0.704, 44.436, 79.837, -5.103, -3.032, 0.362, 57.174, -5.527, 0.314, -3.9]
**Ligand B:** [352.469, 36.36, 4.851, 1, 3, 0.762, 19.426, 91.857, -4.547, -4.085, 0.897, 57.113, -16.289, 0.539, -8.0]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (352.469) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (49.85) is better than Ligand B (36.36), both are below the 140 threshold for oral absorption.
3. **logP:** Ligand A (2.067) is optimal (1-3). Ligand B (4.851) is pushing the upper limit and could potentially lead to solubility issues or off-target interactions.
4. **HBD:** Ligand A (0) is better than Ligand B (1). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is better than Ligand B (3). Fewer HBAs generally improve permeability.
6. **QED:** Both are good (>=0.5), with Ligand B (0.762) being slightly better.
7. **DILI:** Ligand B (19.426) is significantly better than Ligand A (44.436), indicating a much lower risk of liver injury. This is a crucial advantage.
8. **BBB:** Ligand B (91.857) is significantly better than Ligand A (79.837). For a GPCR, even if not specifically a CNS target, some BBB penetration can be beneficial for distribution.
9. **Caco-2:** Ligand A (-5.103) is better than Ligand B (-4.547), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-3.032) is better than Ligand B (-4.085).
11. **hERG:** Ligand A (0.362) is better than Ligand B (0.897), indicating a lower risk of cardiotoxicity.
12. **Cl_mic:** Both are similar (around 57 mL/min/kg), suggesting comparable metabolic stability.
13. **t1/2:** Ligand B (-16.289) is significantly better than Ligand A (-5.527), indicating a much longer half-life.
14. **Pgp:** Ligand A (0.314) is better than Ligand B (0.539), indicating lower P-gp efflux.
15. **Affinity:** Ligand B (-8.0) is *significantly* better than Ligand A (-3.9). This is a 4.1 kcal/mol difference, which is a substantial advantage and can outweigh many ADME concerns.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, Pgp, TPSA, and affinity. Ligand B excels in affinity and BBB penetration, while Ligand A has slightly better logP and Pgp. However, the massive difference in binding affinity is the most critical factor. The DILI and half-life are also significantly better for Ligand B. While Ligand A has better solubility and hERG, these are less critical than the binding affinity and safety profile.
**Conclusion:**
Despite some slightly better ADME properties in Ligand A, the overwhelmingly superior binding affinity, significantly improved DILI risk, and longer half-life of Ligand B make it the far more promising drug candidate.
0
2025-04-17 19:24:45,551 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.475 and 345.443 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (73.64) is better than Ligand B (81.67). Both are under the 140 A^2 threshold for oral absorption, but lower is preferable.
3. **logP:** Both ligands have good logP values (2.05 and 1.316), falling within the 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Ligand A (0) is better than Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Both ligands have 4 HBA, which is acceptable.
6. **QED:** Both ligands have similar QED values (0.629 and 0.651), indicating good drug-likeness.
7. **DILI:** Ligand A (8.53) is *significantly* better than Ligand B (46.219). This is a major advantage for Ligand A, as DILI risk is a critical factor.
8. **BBB:** Ligand A (85.576) is much better than Ligand B (54.75). While ADRB2 isn't strictly a CNS target, some CNS exposure can occur, and higher BBB penetration is generally favorable for GPCRs.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.295 and -4.922), which is unusual and suggests very poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand A (-1.439) is slightly better than Ligand B (-2.061). Both are quite poor, suggesting formulation challenges.
11. **hERG:** Both ligands have similar, low hERG inhibition liability (0.699 and 0.5). This is good.
12. **Cl_mic:** Ligand A (47.059) is better than Ligand B (2.456). Lower clearance is preferred for metabolic stability.
13. **t1/2:** Ligand A (-10.733) is much better than Ligand B (18.538). A negative value indicates a very long half-life, which is highly desirable.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.106 and 0.064). This is good.
15. **Binding Affinity:** Both ligands have identical binding affinities (-6.2 kcal/mol).
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Ligand A is better in terms of logP, TPSA, and significantly better in terms of DILI and metabolic stability (Cl_mic and t1/2). While both have the same affinity, the superior ADME properties of Ligand A make it the more promising candidate. The poor Caco-2 values are a concern for both, but can potentially be addressed through formulation strategies.
**Conclusion:**
Ligand A clearly outperforms Ligand B due to its significantly lower DILI risk, better metabolic stability, longer half-life, and slightly improved TPSA and solubility.
Output:
1
2025-04-17 19:24:45,551 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's break down the comparison of Ligand A and Ligand B based on the provided parameters and the guidelines, keeping in mind ADRB2 is a GPCR.
1. **Molecular Weight:** Both ligands (358.345 Da and 385.917 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (93.53) is slightly higher than Ligand B (69.72). For a GPCR, lower TPSA is generally preferred for better BBB penetration, giving a slight edge to Ligand B.
3. **logP:** Ligand B (2.085) is within the optimal 1-3 range, while Ligand A (0.115) is quite low. This is a significant drawback for Ligand A, as low logP can hinder membrane permeability. Ligand B is clearly better here.
4. **H-Bond Donors:** Both have 1 HBD, which is acceptable.
5. **H-Bond Acceptors:** Ligand A has 6 HBA, and Ligand B has 4. Both are within the acceptable range of <=10.
6. **QED:** Both ligands have good QED scores (0.755 and 0.78), indicating good drug-like properties.
7. **DILI:** Both have similar DILI risk (49.205 and 50.33), both falling within the acceptable range (<60).
8. **BBB:** Ligand A has a significantly higher BBB percentile (86.817) than Ligand B (71.074). While ADRB2 isn't necessarily a CNS target, better BBB penetration is generally favorable, reducing potential off-target effects.
9. **Caco-2:** Both have negative Caco-2 values (-4.554 and -4.788). These values are unusual and likely indicate poor permeability. However, the values are very similar.
10. **Solubility:** Ligand A (-1.5) is better than Ligand B (-3.02). Solubility is important for bioavailability.
11. **hERG:** Both ligands have low hERG inhibition liability (0.312 and 0.242), which is excellent.
12. **Cl_mic:** Ligand A (21.723) has a lower microsomal clearance than Ligand B (31.95), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-20.154) has a much longer in vitro half-life than Ligand B (19.471). This is a significant advantage.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.058 and 0.091).
15. **Binding Affinity:** Ligand A (-6.9 kcal/mol) has a slightly better binding affinity than Ligand B (-5.9 kcal/mol). This 1 kcal/mol difference is significant, and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand A has a better binding affinity and longer half-life, and better BBB penetration. However, its biggest drawback is the very low logP, which is a major concern for permeability and oral bioavailability. Ligand B has a more favorable logP, but suffers from a shorter half-life and lower binding affinity. Considering the importance of logP for GPCRs and the relatively small difference in binding affinity, I believe Ligand B is the more promising candidate. While the Caco-2 values are concerning for both, the better logP of Ligand B suggests it might be more amenable to optimization to improve permeability.
**Output:**
0
2025-04-17 19:24:45,551 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**1. Molecular Weight:** Both ligands (377.897 and 393.443 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (59.23) is significantly lower than Ligand B (128.08). This is a major advantage for Ligand A, as lower TPSA generally correlates with better cell permeability, crucial for GPCR targeting. Ligand B is above the preferred 90 A^2 for CNS targets and even the 140 A^2 for good oral absorption.
**3. logP:** Ligand A (3.912) is within the optimal range (1-3), while Ligand B (0.063) is quite low. Low logP can hinder membrane permeability. This favors Ligand A.
**4. H-Bond Donors:** Both ligands have 1 HBD, which is acceptable.
**5. H-Bond Acceptors:** Ligand A has 5 HBAs, and Ligand B has 8. Both are within the acceptable range, but Ligand A is preferable.
**6. QED:** Ligand A (0.824) has a substantially higher QED score than Ligand B (0.512), indicating a more drug-like profile.
**7. DILI Risk:** Ligand B (84.645) has a considerably higher DILI risk than Ligand A (66.615). This is a significant concern, as liver toxicity is a major cause of drug attrition.
**8. BBB Penetration:** Both ligands have similar BBB penetration (74.176 and 75.998). This isn't a primary concern for ADRB2, which isn't a CNS target, but it's not a differentiating factor.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, indicating poor permeability. However, Ligand A (-4.969) is slightly better than Ligand B (-5.034).
**10. Aqueous Solubility:** Ligand A (-4.352) has slightly better solubility than Ligand B (-2.967).
**11. hERG Inhibition:** Ligand A (0.265) has a much lower hERG inhibition liability than Ligand B (0.547), reducing the risk of cardiotoxicity.
**12. Microsomal Clearance:** Ligand B (19.889) has a lower microsomal clearance than Ligand A (34.741), suggesting better metabolic stability. This is a point in favor of Ligand B.
**13. In vitro Half-Life:** Ligand B (-24.233) has a negative half-life, which is concerning. Ligand A (15.876) has a reasonable half-life.
**14. P-gp Efflux:** Ligand A (0.637) has lower P-gp efflux than Ligand B (0.087), which is favorable for bioavailability.
**15. Binding Affinity:** Both ligands have excellent binding affinities (-8.0 and -5.2 kcal/mol). Ligand A is significantly more potent.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand A is clearly superior. Its lower TPSA, better logP, higher QED, lower DILI risk, lower hERG inhibition, and significantly stronger binding affinity outweigh the slightly higher microsomal clearance. Ligand B's low logP and high DILI risk are major drawbacks. The negative half-life for Ligand B is also a serious concern.
Output:
1
2025-04-17 19:24:45,551 - INFO - Batch 108 complete. Total preferences: 1728
2025-04-17 19:24:45,551 - INFO - Processing batch 109/512...
2025-04-17 19:25:33,301 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. The key priorities for GPCRs, as outlined, are logP, Pgp efflux, TPSA, and binding affinity, with BBB being less critical for a cardiovascular target.
Let's compare the ligands property by property:
1. **MW:** Both ligands (350.5 and 349.4 Da) are within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (64.68) is significantly better than Ligand B (75.88). Lower TPSA generally favors oral absorption, and is important for GPCRs.
3. **logP:** Ligand B (1.544) is better than Ligand A (0.824). Both are within the optimal 1-3 range, but Ligand B is closer to the sweet spot.
4. **HBD/HBA:** Ligand A has 2 HBD and 4 HBA, while Ligand B has 0 HBD and 5 HBA. Both are acceptable, but A's HBD count might slightly improve solubility.
5. **QED:** Both ligands have good QED scores (0.646 and 0.779), indicating good drug-like properties.
6. **DILI:** Ligand A (2.133) has a much lower DILI risk than Ligand B (42.807). This is a significant advantage for Ligand A.
7. **BBB:** Ligand B (84.257) has a higher BBB penetration than Ligand A (63.862). However, BBB is less critical for a cardiovascular target.
8. **Caco-2:** Ligand A (-5.374) has a worse Caco-2 permeability than Ligand B (-4.463).
9. **Solubility:** Ligand A (-0.924) has slightly better solubility than Ligand B (-0.774).
10. **hERG:** Ligand A (0.472) has a lower hERG risk than Ligand B (0.159). This is a significant advantage for Ligand A.
11. **Cl_mic:** Ligand A (-1.678) has much better metabolic stability (lower clearance) than Ligand B (47.248). This is a major advantage for Ligand A.
12. **t1/2:** Ligand A (-2.525) has a longer in vitro half-life than Ligand B (-14.564). This is a significant advantage for Ligand A.
13. **Pgp:** Ligand A (0.002) has a much lower P-gp efflux liability than Ligand B (0.077). This is a significant advantage for Ligand A.
14. **Binding Affinity:** Ligand A (-6.9 kcal/mol) has a slightly better binding affinity than Ligand B (-6.4 kcal/mol), though the difference is relatively small.
**Overall Assessment:**
Ligand A is clearly the superior candidate. While Ligand B has a slightly better logP and Caco-2 permeability, Ligand A excels in critical areas like DILI risk, hERG inhibition, metabolic stability (Cl_mic and t1/2), P-gp efflux, and has a slightly better binding affinity. The lower TPSA of Ligand A is also beneficial. The differences in these parameters outweigh the slight advantage of Ligand B in logP and Caco-2.
Output:
1
2025-04-17 19:25:33,301 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
Let's break down the comparison of Ligand A and Ligand B, considering the provided guidelines and GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key).
1. **Molecular Weight:** Both ligands (346.431 Da and 339.443 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (69.89) is slightly higher than Ligand B (63.05), but both are well below the 140 threshold for good oral absorption.
3. **logP:** Ligand B (2.463) is within the optimal 1-3 range, while Ligand A (0.761) is slightly below, potentially impacting permeability. This favors Ligand B.
4. **H-Bond Donors:** Ligand A has 0 HBDs, while Ligand B has 1. Both are acceptable.
5. **H-Bond Acceptors:** Both ligands have 5 HBAs, which is within the acceptable limit of 10.
6. **QED:** Ligand B (0.909) has a significantly higher QED score than Ligand A (0.805), indicating a more drug-like profile. This favors Ligand B.
7. **DILI:** Ligand A (15.471%) has a much lower DILI risk than Ligand B (24.816%). This is a significant advantage for Ligand A.
8. **BBB:** Ligand B (90.151%) shows much better predicted BBB penetration than Ligand A (65.529%). While ADRB2 isn't exclusively a CNS target, some cardiovascular effects are mediated by central pathways, and better BBB penetration could be beneficial. This favors Ligand B.
9. **Caco-2 Permeability:** Both have negative Caco-2 values, indicating poor permeability. Ligand A (-4.891) is slightly better than Ligand B (-4.933), but both are concerning.
10. **Aqueous Solubility:** Ligand A (-0.725) has better aqueous solubility than Ligand B (-2.843). This is a positive for Ligand A.
11. **hERG Inhibition:** Ligand A (0.186) has a lower hERG inhibition risk than Ligand B (0.47). This is a significant advantage for Ligand A.
12. **Microsomal Clearance:** Ligand B (32.139) has a much higher microsomal clearance than Ligand A (2.247), suggesting lower metabolic stability. This strongly favors Ligand A.
13. **In vitro Half-Life:** Ligand A (14.246 hours) has a considerably longer in vitro half-life than Ligand B (11.524 hours). This favors Ligand A.
14. **P-gp Efflux:** Ligand A (0.044) has lower P-gp efflux liability than Ligand B (0.08). This favors Ligand A.
15. **Binding Affinity:** Ligand A (-7.6 kcal/mol) has a slightly better binding affinity than Ligand B (-6.9 kcal/mol). While the difference is not huge, it's enough to consider.
**Overall Assessment:**
Ligand A excels in safety parameters (DILI, hERG), metabolic stability (Cl_mic, t1/2), P-gp efflux, and has a slightly better binding affinity. Ligand B has a better QED score, logP, and BBB penetration. The poor Caco-2 permeability for both is a concern, but the superior ADME profile of Ligand A, particularly its lower DILI and hERG risk, combined with its better metabolic stability and binding affinity, makes it the more promising candidate.
Output:
1
2025-04-17 19:25:33,301 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (348.531 and 350.354 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (49.41) is significantly better than Ligand B (133.15). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally correlates with better absorption. Ligand B's TPSA is quite high, potentially hindering oral bioavailability.
3. **logP:** Ligand A (3.602) is optimal. Ligand B (0.981) is a bit low, potentially leading to poor membrane permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (4). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (2) is preferable to Ligand B (8). Similar reasoning as with HBD.
6. **QED:** Ligand A (0.764) is better than Ligand B (0.581), indicating a more drug-like profile.
7. **DILI:** Ligand A (23.769) has a much lower DILI risk than Ligand B (77.394). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (82.086) has better BBB penetration than Ligand B (47.15). While not critical for a cardiovascular target, it's a bonus.
9. **Caco-2:** Ligand A (-4.804) is better than Ligand B (-5.448). Both are negative, indicating poor permeability, but A is slightly better.
10. **Solubility:** Ligand A (-4.15) is better than Ligand B (-3.1). Both are poor, but A is less poor.
11. **hERG:** Ligand A (0.604) is better than Ligand B (0.372). Lower hERG inhibition is crucial for avoiding cardiotoxicity.
12. **Cl_mic:** Ligand B (31.381) has a lower microsomal clearance than Ligand A (64.467), suggesting better metabolic stability. This is a point in favor of Ligand B.
13. **t1/2:** Ligand B (-15.588) has a longer in vitro half-life than Ligand A (-10.607). This is another point in favor of Ligand B.
14. **Pgp:** Ligand A (0.482) has lower P-gp efflux liability than Ligand B (0.031). Lower P-gp is better for bioavailability.
15. **Binding Affinity:** Ligand B (-6.7 kcal/mol) has a significantly stronger binding affinity than Ligand A (-1.4 kcal/mol). This is a *major* advantage for Ligand B, potentially outweighing some of its ADME drawbacks.
**Overall Assessment:**
Ligand B has a substantially better binding affinity, which is paramount for a drug candidate. While it suffers from higher TPSA, HBD/HBA counts, and DILI risk, the strong binding could potentially be optimized through further medicinal chemistry efforts. Ligand A has a more favorable ADME profile overall, but its weak binding affinity is a significant drawback. Given the GPCR-specific priorities (affinity is key), I favor Ligand B.
Output:
0
2025-04-17 19:25:33,302 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (350.459 Da and 340.379 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (67.87) is better than Ligand B (75.69). For a GPCR, keeping TPSA under 140 is good for oral absorption, and both are well below this.
**3. logP:** Ligand A (1.335) is within the optimal 1-3 range, while Ligand B (2.749) is approaching the upper limit. While 2.749 isn't *bad*, the lower logP of A is slightly preferable for balancing permeability and avoiding off-target interactions.
**4. H-Bond Donors:** Both ligands have 1 HBD, which is acceptable.
**5. H-Bond Acceptors:** Both ligands have 4 HBA, which is acceptable.
**6. QED:** Ligand A (0.812) has a significantly better QED score than Ligand B (0.671), indicating a more drug-like profile.
**7. DILI:** Ligand B (64.521) has a higher DILI risk than Ligand A (20.9). This is a significant advantage for Ligand A.
**8. BBB:** Ligand A (63.164) has a better BBB penetration percentile than Ligand B (45.715). While ADRB2 is a cardiovascular target, some CNS penetration can occur, and minimizing it isn't a high priority, a higher BBB score isn't necessarily detrimental.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.846 and -4.955). This is unusual and suggests poor permeability *in vitro*. However, the values are very similar.
**10. Aqueous Solubility:** Ligand A (-1.469) is better than Ligand B (-3.221). Solubility is important for formulation and bioavailability.
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (0.189 and 0.236).
**12. Microsomal Clearance:** Ligand A (9.74) has a significantly lower microsomal clearance than Ligand B (42.281), suggesting better metabolic stability.
**13. In vitro Half-Life:** Ligand A (8.589) has a better in vitro half-life than Ligand B (27.368).
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (0.041 and 0.131).
**15. Binding Affinity:** Ligand A (-7.3 kcal/mol) has a significantly better binding affinity than Ligand B (-6.3 kcal/mol). This 1.0 kcal/mol difference is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across multiple critical parameters, including DILI risk, QED, solubility, metabolic stability (Cl_mic and t1/2), and, most importantly, binding affinity. While both have issues with Caco-2 permeability, the superior profile of Ligand A makes it the more promising drug candidate. The stronger binding affinity of Ligand A is a major advantage for a GPCR target.
Output:
1
2025-04-17 19:25:33,302 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A: [348.349, 67.43, 2.641, 2, 3, 0.623, 70.686, 69.446, -4.58, -3.337, 0.747, 37.945, 15.852, 0.284, -6.4]**
**Ligand B: [408.3, 65.18, 2.708, 0, 6, 0.784, 63.048, 75.107, -5.069, -2.387, 0.306, 33.542, 23.525, 0.54, -5.3]**
Here's a breakdown, comparing each parameter and considering GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Ligand A (348.349 Da) is better, falling nicely within the 200-500 Da range. Ligand B (408.3 Da) is still acceptable but pushing the upper limit.
2. **TPSA:** Both are good (67.43 and 65.18 respectively), well below the 140 threshold for oral absorption.
3. **logP:** Both are excellent (2.641 and 2.708), within the optimal 1-3 range.
4. **HBD:** Ligand A (2) is preferable to Ligand B (0). While low HBD can sometimes indicate poor aqueous solubility, it can also improve membrane permeability.
5. **HBA:** Ligand B (6) is slightly higher than Ligand A (3). Both are within the acceptable range, but lower is generally preferred.
6. **QED:** Both are good (0.623 and 0.784), indicating drug-like properties. Ligand B is slightly better.
7. **DILI:** Both have acceptable DILI risk (70.686 and 63.048). Ligand B is slightly better.
8. **BBB:** Ligand B (75.107) is better than Ligand A (69.446). While not a primary concern for a cardiovascular target, higher BBB penetration isn't detrimental.
9. **Caco-2:** Ligand B (-5.069) is better than Ligand A (-4.58). Higher (less negative) values indicate better absorption.
10. **Solubility:** Ligand B (-2.387) is better than Ligand A (-3.337).
11. **hERG:** Ligand A (0.747) is better than Ligand B (0.306). Lower hERG inhibition is crucial for avoiding cardiotoxicity, especially for a cardiovascular target.
12. **Cl_mic:** Ligand B (33.542) has lower clearance than Ligand A (37.945), suggesting better metabolic stability.
13. **t1/2:** Ligand B (23.525) has a longer half-life than Ligand A (15.852), which is desirable.
14. **Pgp:** Ligand A (0.284) is better than Ligand B (0.54). Lower P-gp efflux is better.
15. **Affinity:** Ligand A (-6.4 kcal/mol) has a slightly better binding affinity than Ligand B (-5.3 kcal/mol). This is a significant advantage.
**Overall Assessment:**
While Ligand B has some advantages in terms of Caco-2 permeability, solubility, metabolic stability, and BBB penetration, Ligand A is preferable due to its better hERG profile and significantly stronger binding affinity. The affinity difference of 1.1 kcal/mol is substantial and can often outweigh minor ADME drawbacks. The lower Pgp efflux for Ligand A is also a positive. Given that this is a cardiovascular target, minimizing cardiotoxicity (hERG) is paramount.
Therefore, I choose Ligand A.
1
2025-04-17 19:25:33,302 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (342.42 & 351.40 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (62.46) is significantly better than Ligand B (99.18). ADRB2 is a cardiovascular target, not CNS, but lower TPSA generally aids absorption. Ligand A is well below the 140 threshold, while Ligand B is approaching it.
3. **logP:** Ligand A (1.482) is within the optimal 1-3 range. Ligand B (-0.968) is slightly below 1, which *could* indicate potential permeability issues.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Both ligands have 5 HBA, which is acceptable.
6. **QED:** Ligand A (0.806) has a better QED score than Ligand B (0.621), indicating a more drug-like profile.
7. **DILI:** Ligand A (44.242) has a slightly higher DILI risk than Ligand B (18.728), but both are below the concerning 60 threshold. Ligand B is significantly better here.
8. **BBB:** This is less critical for a cardiovascular target. Ligand A (84.374) is higher than Ligand B (28.073), but this isn't a major deciding factor.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.006 and -5.048), which is unusual and suggests poor permeability *in vitro*. This is a red flag for both.
10. **Solubility:** Ligand A (-2.358) has slightly better solubility than Ligand B (-0.91), but both are poor.
11. **hERG:** Ligand A (0.93) has a slightly higher hERG risk than Ligand B (0.047). Ligand B is significantly better here, which is crucial for cardiovascular drugs.
12. **Cl_mic:** Ligand A (38.188) has a higher microsomal clearance than Ligand B (2.747), indicating lower metabolic stability. Ligand B is significantly better here.
13. **t1/2:** Ligand B (-7.182) has a much longer *in vitro* half-life than Ligand A (-34.951). This is a significant advantage.
14. **Pgp:** Ligand A (0.53) has lower P-gp efflux than Ligand B (0.008), which is preferable.
15. **Binding Affinity:** Ligand B (-7.5 kcal/mol) has a slightly better binding affinity than Ligand A (-6.4 kcal/mol). This 1.1 kcal/mol difference is substantial and can outweigh some of the ADME drawbacks.
**Overall Assessment:**
While Ligand A has better TPSA, QED, and Pgp properties, Ligand B excels in crucial areas for a cardiovascular drug: significantly lower DILI risk, much better metabolic stability (lower Cl_mic, longer t1/2), and a lower hERG risk. The slightly better binding affinity of Ligand B further strengthens its position. The poor Caco-2 values are concerning for both, but the ADME profile of Ligand B is overall more favorable, particularly considering the cardiovascular target.
Output:
0
2025-04-17 19:25:33,302 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (347.434 Da) is better than Ligand B (381.567 Da). Both are within the ideal range, but A is closer to the lower, preferred end.
2. **TPSA:** Ligand A (52.65) is significantly better than Ligand B (71.09). ADRB2 is not a CNS target, but lower TPSA generally aids absorption.
3. **logP:** Both ligands have acceptable logP values (A: 1.941, B: 3.036). Ligand B is slightly higher, which could be a minor concern for off-target effects, but still within the optimal range.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs generally improve membrane permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (5). Similar reasoning as HBD.
6. **QED:** Both ligands are similar (A: 0.82, B: 0.726) and above the 0.5 threshold, indicating good drug-likeness.
7. **DILI:** Ligand A (29.236) is significantly better than Ligand B (48.468). Lower DILI risk is crucial.
8. **BBB:** Ligand A (81.815) is better than Ligand B (58.278). While ADRB2 isn't a primary CNS target, higher BBB penetration can sometimes indicate better overall distribution and reduced off-target effects.
9. **Caco-2:** Ligand A (-4.719) is better than Ligand B (-5.35). Higher Caco-2 permeability suggests better absorption.
10. **Solubility:** Ligand A (-1.715) is better than Ligand B (-3.985), indicating better aqueous solubility.
11. **hERG:** Both ligands have low hERG inhibition risk (A: 0.769, B: 0.478), which is good.
12. **Cl_mic:** Ligand A (33.456) is significantly better than Ligand B (63.751). Lower clearance indicates better metabolic stability.
13. **t1/2:** Ligand B (18.789) is better than Ligand A (9.051). A longer half-life is generally desirable.
14. **Pgp:** Ligand A (0.067) is significantly better than Ligand B (0.247). Lower P-gp efflux is favorable for bioavailability.
15. **Affinity:** Both ligands have very similar binding affinities (A: -5.5 kcal/mol, B: -4.8 kcal/mol). Ligand A has a slight advantage.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical ADME properties (TPSA, DILI, Cl_mic, Pgp, Solubility, Caco-2) and has a slightly better binding affinity. While Ligand B has a longer half-life, the superior ADME profile and lower toxicity risk of Ligand A make it the more promising drug candidate. The differences in half-life can potentially be addressed through formulation or structural modifications.
Output:
1
2025-04-17 19:25:33,302 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (355.479) is slightly higher than Ligand B (344.415), but both are acceptable.
2. **TPSA:** Ligand A (71.11) is significantly better than Ligand B (93.21). For a GPCR, lower TPSA is generally preferred for better permeability. Ligand B is pushing the upper limit for good oral absorption.
3. **logP:** Ligand B (1.322) is better than Ligand A (0.344). A logP between 1-3 is optimal, and Ligand B falls within this range, while Ligand A is quite low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (1) is better than Ligand B (2). Lower HBD is generally preferred.
5. **HBA:** Both ligands have the same number of HBA (5), which is acceptable.
6. **QED:** Both ligands have good QED scores (A: 0.68, B: 0.759), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (7.445) is significantly better than Ligand B (63.048). Lower DILI is crucial, and Ligand B's score is concerningly high.
8. **BBB:** Ligand B (68.282) is better than Ligand A (56.146), but neither is exceptionally high. For ADRB2, which is not necessarily a CNS target, this isn't a primary driver, but a slight advantage for B.
9. **Caco-2:** Both have negative values, indicating permeability issues. Ligand A (-4.741) is slightly better than Ligand B (-4.645), but both are poor.
10. **Solubility:** Ligand A (-0.282) is better than Ligand B (-3.28). Higher solubility is preferred.
11. **hERG:** Both ligands have very low hERG inhibition risk (A: 0.309, B: 0.125). This is excellent.
12. **Cl_mic:** Ligand A (-2.961) is significantly better than Ligand B (53.498). Lower clearance indicates better metabolic stability, a crucial factor.
13. **t1/2:** Ligand A (-17.449) is better than Ligand B (-20.316), indicating a longer half-life.
14. **Pgp:** Both ligands have very low Pgp efflux liability (A: 0.005, B: 0.057). This is excellent.
15. **Binding Affinity:** Both ligands have very similar binding affinities (A: -6.5 kcal/mol, B: -6.3 kcal/mol). The difference is not substantial enough to outweigh other factors.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are important. Ligand B has a better logP and slightly better BBB penetration. However, Ligand A has a significantly better TPSA, DILI, Cl_mic, and t1/2. The DILI and metabolic stability (Cl_mic) are major concerns for Ligand B.
**Overall Assessment:**
Despite Ligand B having a slightly better logP and BBB, the significantly lower DILI risk, better metabolic stability (Cl_mic), and better solubility of Ligand A make it the more promising candidate. The small difference in binding affinity is not enough to overcome the substantial ADME/Tox advantages of Ligand A.
Output:
1
2025-04-17 19:25:33,303 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (345.49 & 353.42 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (73.2) is significantly better than Ligand B (127.63). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold. Ligand B is approaching the upper limit.
3. **logP:** Ligand A (3.29) is optimal, while Ligand B (1.114) is a bit low. A logP between 1-3 is preferred, and Ligand A is closer to the upper end of that range, which is generally favorable for GPCRs.
4. **HBD:** Ligand A (1) is better than Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (3) is better than Ligand B (5). Similar reasoning as HBD.
6. **QED:** Ligand A (0.751) is significantly better than Ligand B (0.385). A higher QED suggests a more drug-like profile.
7. **DILI:** Ligand A (15.083) is significantly better than Ligand B (24.04). Lower DILI risk is crucial. Ligand A is well below the 40% threshold, while Ligand B is approaching it.
8. **BBB:** Ligand A (65.064) is better than Ligand B (47.421), but neither is particularly high. Since ADRB2 isn't a CNS target, this isn't a major deciding factor.
9. **Caco-2:** Ligand A (-4.987) is better than Ligand B (-5.297). Both are negative, indicating poor permeability, but A is slightly better.
10. **Solubility:** Ligand A (-3.328) is better than Ligand B (-0.353). Higher solubility is preferred.
11. **hERG:** Ligand A (0.648) is better than Ligand B (0.13). Lower hERG inhibition is critical for avoiding cardiotoxicity.
12. **Cl_mic:** Ligand A (34.2) is worse than Ligand B (-1.995). Lower clearance is preferred for metabolic stability. Ligand B is significantly better.
13. **t1/2:** Ligand A (-6.627) is much better than Ligand B (14.413). Longer half-life is generally desirable.
14. **Pgp:** Ligand A (0.259) is better than Ligand B (0.011). Lower P-gp efflux is preferred.
15. **Binding Affinity:** Ligand A (-8.5) is significantly better than Ligand B (-6.1). A difference of 2.4 kcal/mol is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand A clearly outperforms Ligand B across most critical parameters. While Ligand B has better metabolic stability (Cl_mic), the significant advantages of Ligand A in binding affinity, DILI risk, QED, TPSA, solubility, and hERG inhibition outweigh this single benefit. The stronger binding affinity of Ligand A is particularly important for a GPCR target like ADRB2. The lower DILI and hERG risks are also crucial for cardiovascular drug development.
Output:
1
2025-04-17 19:25:33,303 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [360.523, 49.41, 2.715, 1, 3, 0.784, 21.908, 57.154, -5.012, -4.469, 0.183, 28.274, 11.425, 0.088, -7.3]
**Ligand B:** [357.426, 78.95, 1.03, 1, 4, 0.72, 33.773, 89.608, -4.842, -1.984, 0.19, -8.87, -12.013, 0.011, -6.1]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, Affinity, and BBB):
1. **MW:** Both are within the ideal range (200-500 Da). A is 360.523, B is 357.426. No significant difference.
2. **TPSA:** A (49.41) is excellent, well below 140 and good for oral absorption. B (78.95) is higher, but still acceptable, though less ideal.
3. **logP:** A (2.715) is optimal. B (1.03) is a bit low, potentially hindering membrane permeability.
4. **HBD/HBA:** Both have 1 HBD, which is good. A has 3 HBA, B has 4. Both are within acceptable limits.
5. **QED:** Both are good (A: 0.784, B: 0.72), indicating drug-like properties.
6. **DILI:** A (21.908) is significantly better (lower risk) than B (33.773).
7. **BBB:** A (57.154) is moderate. B (89.608) is very good, suggesting better potential for CNS penetration if desired (though ADRB2 is primarily cardiovascular).
8. **Caco-2:** Both are negative, indicating poor permeability. A (-5.012) is slightly better than B (-4.842).
9. **Solubility:** Both are negative, indicating poor solubility. A (-4.469) is slightly better than B (-1.984).
10. **hERG:** Both are very low risk (A: 0.183, B: 0.19).
11. **Cl_mic:** A (28.274) is better (lower clearance, more stable) than B (-8.87, indicating very rapid clearance).
12. **t1/2:** A (11.425) is better (longer half-life) than B (-12.013, indicating very short half-life).
13. **Pgp:** Both are very low efflux (A: 0.088, B: 0.011). B is slightly better.
14. **Affinity:** A (-7.3) is significantly better than B (-6.1). This is a 1.2 kcal/mol difference, which is substantial.
**Overall Assessment:**
Ligand A is clearly superior. The most important factor is the significantly better binding affinity (-7.3 vs -6.1 kcal/mol). While Ligand B has a better BBB score, the ADRB2 target is primarily cardiovascular, making CNS penetration less critical. Ligand A also demonstrates better metabolic stability (Cl_mic, t1/2) and a lower DILI risk. The slightly lower logP of Ligand B is a concern, and its poor metabolic stability is a major drawback. Although both have poor Caco-2 and solubility, A is slightly better in these parameters.
Output:
1
2025-04-17 19:25:33,303 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, the most important parameters are binding affinity, logP, TPSA, Pgp efflux, and to a lesser extent, BBB.
Let's compare the ligands property by property:
1. **MW:** Both ligands (350.5 and 342.4) fall within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (78.43) is better than Ligand B (87.75). Lower TPSA generally favors oral absorption, important for a cardiovascular target.
3. **logP:** Both ligands (2.231 and 2.875) are within the optimal 1-3 range. Ligand B is slightly higher, which could be a minor concern for solubility, but not a dealbreaker.
4. **HBD/HBA:** Both have 3 HBD and acceptable HBA counts (3 and 6 respectively).
5. **QED:** Both have good QED scores (0.628 and 0.748), indicating drug-likeness.
6. **DILI:** Ligand A (12.524) has a significantly lower DILI risk than Ligand B (49.942). This is a major advantage for Ligand A.
7. **BBB:** Ligand B (72.276) has a higher BBB penetration than Ligand A (56.65). However, BBB is less critical for a cardiovascular target.
8. **Caco-2:** Ligand A (-4.814) has a better Caco-2 permeability than Ligand B (-5.253).
9. **Solubility:** Ligand A (-3.23) has better solubility than Ligand B (-3.537).
10. **hERG:** Ligand A (0.292) has a lower hERG inhibition liability than Ligand B (0.796). This is a significant safety advantage.
11. **Cl_mic:** Ligand A (29.118) has a lower microsomal clearance than Ligand B (46.089), indicating better metabolic stability.
12. **t1/2:** Both have similar in vitro half-lives (1.293 and 1.182 hours).
13. **Pgp:** Ligand A (0.162) has a lower P-gp efflux liability than Ligand B (0.066). Lower efflux is generally desirable.
14. **Binding Affinity:** Ligand A (-7.3) has a stronger binding affinity than Ligand B (-6.4). This is a 0.9 kcal/mol difference, which is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand A is the superior candidate. It has a significantly better safety profile (lower DILI and hERG), better metabolic stability (lower Cl_mic), better solubility, better Caco-2 permeability, and a substantially stronger binding affinity. While Ligand B has slightly better BBB penetration, this is less important for a cardiovascular target. The combination of improved safety, ADME properties, and potency makes Ligand A the more promising drug candidate.
**Output:**
1
2025-04-17 19:25:33,303 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (368.949 and 348.539 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (33.73) is significantly better than Ligand B (88.75). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally correlates with better absorption. Ligand B's TPSA is quite high, potentially hindering oral bioavailability.
3. **logP:** Both ligands have similar logP values (4.492 and 4.32), both slightly above the optimal range but not excessively so.
4. **HBD/HBA:** Ligand A (1 HBD, 4 HBA) is preferable to Ligand B (3 HBD, 6 HBA). Lower counts are generally better for permeability.
5. **QED:** Both ligands have acceptable QED values (0.617 and 0.583), indicating reasonable drug-likeness.
6. **DILI:** Ligand A (9.112) has a much lower DILI risk than Ligand B (36.448). This is a major advantage for Ligand A.
7. **BBB:** Ligand B (92.168) has a higher BBB penetration than Ligand A (80.031). However, since ADRB2 is primarily a cardiovascular target, high BBB penetration is not a priority.
8. **Caco-2:** Both ligands have negative Caco-2 values (-4.777 and -4.935), which is unusual and suggests poor permeability. This is a concern for both.
9. **Solubility:** Ligand A (-2.727) has slightly better solubility than Ligand B (-5.669), although both are poor.
10. **hERG:** Both ligands have low hERG inhibition liability (0.945 and 0.781), which is good.
11. **Cl_mic:** Ligand B (80.34) has a higher microsomal clearance than Ligand A (51.263), indicating faster metabolism and potentially lower *in vivo* exposure.
12. **t1/2:** Ligand A (41.16) has a longer half-life than Ligand B (34.98), which is desirable.
13. **Pgp:** Ligand A (0.433) has lower P-gp efflux liability than Ligand B (0.139), which is beneficial for bioavailability.
14. **Binding Affinity:** Both ligands have very similar and strong binding affinities (-5.6 and -5.8 kcal/mol). The difference is negligible.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A performs better on TPSA and Pgp, while logP and affinity are comparable. The significantly lower DILI risk and better metabolic stability (lower Cl_mic, longer t1/2) of Ligand A are also crucial advantages.
**Conclusion:**
Considering the balance of properties, Ligand A is the more promising drug candidate. Its lower DILI risk, better metabolic stability, lower Pgp efflux, and more favorable TPSA outweigh the slightly lower BBB penetration (which isn't critical for a cardiovascular target).
Output:
1
2025-04-17 19:25:33,303 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (374.453) is slightly higher than Ligand B (345.411), but both are acceptable.
2. **TPSA:** Ligand A (75.27) is significantly better than Ligand B (126.88). For a GPCR, lower TPSA is generally preferred for better permeability. Ligand B is pushing the upper limit for good oral absorption.
3. **logP:** Ligand A (3.958) is optimal, while Ligand B (-0.373) is quite low. Low logP can lead to poor membrane permeability and bioavailability. This is a significant advantage for Ligand A.
4. **HBD:** Both have acceptable HBD counts (Ligand A: 2, Ligand B: 3).
5. **HBA:** Ligand A (3) is better than Ligand B (10). Higher HBA can sometimes hinder permeability.
6. **QED:** Both are reasonably good (Ligand A: 0.784, Ligand B: 0.615), indicating drug-like properties.
7. **DILI:** Both have similar DILI risk (Ligand A: 61.07, Ligand B: 62.66), and are in the acceptable range.
8. **BBB:** Ligand A (86.157) is significantly better than Ligand B (51.842). While ADRB2 isn't exclusively a CNS target, some CNS penetration can be beneficial, and lower efflux is always desirable.
9. **Caco-2:** Ligand A (-4.332) is better than Ligand B (-5.682), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-4.779) is better than Ligand B (-2.338), indicating better aqueous solubility.
11. **hERG:** Both have similar hERG risk (Ligand A: 0.508, Ligand B: 0.577), which is acceptable.
12. **Cl_mic:** Ligand A (21.368) is higher than Ligand B (5.686), meaning Ligand B has better metabolic stability.
13. **t1/2:** Ligand A (44.519) is better than Ligand B (-6.088), indicating a longer in vitro half-life.
14. **Pgp:** Ligand A (0.246) is better than Ligand B (0.004), suggesting lower P-gp efflux and better bioavailability.
15. **Binding Affinity:** Ligand B (-6.4) is slightly better than Ligand A (-5.5). However, the difference is less than 1.5 kcal/mol, and can be overcome by other favorable properties.
**Overall Assessment:**
Ligand A is significantly better overall. While Ligand B has slightly better binding affinity, Ligand A excels in critical ADME properties like logP, TPSA, BBB penetration, solubility, Caco-2 permeability, and P-gp efflux. These properties are particularly important for a GPCR target like ADRB2, where good bioavailability and distribution are crucial. The improved metabolic stability of Ligand B is a benefit, but the other advantages of Ligand A outweigh this.
Output:
1
2025-04-17 19:25:33,304 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (361.515 Da) is within the ideal range (200-500 Da). Ligand B (397.591 Da) is also acceptable. No clear advantage here.
2. **TPSA:** Ligand A (70.15) and Ligand B (66.32) are both well below the 140 A^2 threshold for oral absorption, and suitable for a GPCR target. Ligand B is slightly better.
3. **logP:** Ligand A (1.989) is within the optimal range (1-3). Ligand B (3.576) is at the higher end, but still acceptable. Ligand A is slightly preferred.
4. **HBD:** Ligand A (2) and Ligand B (1) are both good, below the threshold of 5. Ligand B is slightly better.
5. **HBA:** Ligand A (6) and Ligand B (7) are both acceptable, below the threshold of 10. Ligand A is slightly preferred.
6. **QED:** Ligand A (0.617) and Ligand B (0.807) are both good, above 0.5. Ligand B is better.
7. **DILI:** Ligand A (34.277) has a much lower DILI risk than Ligand B (65.917). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (62.04) and Ligand B (45.328) are both relatively low, but not a major concern for a cardiovascular target like ADRB2.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.488 and -5.36), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-2.108) and Ligand B (-3.752) both have negative solubility values, indicating very poor aqueous solubility. This is a significant drawback for both.
11. **hERG:** Ligand A (0.279) has a much lower hERG risk than Ligand B (0.511). This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand A (16.064) has a lower microsomal clearance than Ligand B (51.465), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (4.766) has a shorter half-life than Ligand B (14.028). Ligand B is preferred.
14. **Pgp:** Ligand A (0.017) has a much lower P-gp efflux liability than Ligand B (0.553). This is a significant advantage for Ligand A.
15. **Binding Affinity:** Ligand B (-7.0 kcal/mol) has a slightly better binding affinity than Ligand A (-6.2 kcal/mol). This is a good advantage for Ligand B.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), and the general drug-like properties, Ligand A is the more promising candidate. While Ligand B has a slightly better affinity and half-life, Ligand A demonstrates significantly better safety profiles (DILI, hERG) and better metabolic stability (Cl_mic), and Pgp efflux. The poor Caco-2 and solubility are concerns for both, but can be addressed with formulation strategies. The lower DILI and hERG risks are critical for a cardiovascular target.
Output:
1
2025-04-17 19:25:33,304 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (347.459 Da and 353.348 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (83.22) is higher than Ligand B (61.36). For a cardiovascular GPCR, TPSA is moderately important. Lower is generally better for permeability, and Ligand B has a clear advantage.
**3. logP:** Ligand A (2.237) and Ligand B (1.447) are both within the optimal 1-3 range. Ligand A is slightly more lipophilic.
**4. H-Bond Donors:** Ligand A (3) is higher than Ligand B (1). Lower is generally preferred for better permeability, giving Ligand B an advantage.
**5. H-Bond Acceptors:** Ligand A (3) and Ligand B (5) are both acceptable, but Ligand B is higher.
**6. QED:** Ligand B (0.902) has a significantly higher QED score than Ligand A (0.568), indicating a more drug-like profile overall. This is a substantial positive for Ligand B.
**7. DILI Risk:** Ligand A (39.783) has a much lower DILI risk than Ligand B (88.639). This is a critical advantage for Ligand A. A DILI percentile >60 is concerning.
**8. BBB Penetration:** Both ligands show good BBB penetration (Ligand A: 70.143, Ligand B: 83.521). While ADRB2 is primarily a cardiovascular target, some CNS off-target effects are possible, and higher BBB penetration isn't necessarily detrimental. Ligand B is slightly better.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and requires further investigation. However, the values are similar (-4.711 and -4.568) and don't differentiate the two.
**10. Aqueous Solubility:** Both ligands have similar, very poor aqueous solubility (-3.906 and -3.646). This is a potential formulation challenge for both.
**11. hERG Inhibition:** Ligand A (0.322) has a lower hERG inhibition liability than Ligand B (0.719), which is a significant safety advantage.
**12. Microsomal Clearance:** Both ligands have similar microsomal clearance rates (Ligand A: 50.167, Ligand B: 52.536).
**13. In vitro Half-Life:** Ligand A (-19.129) has a significantly *shorter* half-life than Ligand B (20.377). This is a negative for Ligand A.
**14. P-gp Efflux:** Ligand A (0.215) has lower P-gp efflux than Ligand B (0.101), which is a slight advantage.
**15. Binding Affinity:** Ligand A (-7.9 kcal/mol) has a stronger binding affinity than Ligand B (-5.7 kcal/mol). This is a substantial advantage for Ligand A, exceeding the 1.5 kcal/mol threshold.
**Overall Assessment:**
While Ligand B has a better QED score and slightly better BBB penetration, the significantly higher DILI risk and shorter half-life are major concerns. Ligand A's superior binding affinity and lower DILI/hERG risk outweigh its slightly lower QED and shorter half-life, especially given the cardiovascular target. The binding affinity difference is substantial. The solubility issues are similar for both and would require formulation work regardless.
Output:
1
2025-04-17 19:25:33,304 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [374.853, 88.99, 2.636, 2, 4, 0.862, 69.833, 54.517, -5.173, -4.791, 0.638, -7.575, -14.393, 0.128, -7.3]
**Ligand B:** [367.515, 80.32, 2.676, 2, 5, 0.74, 52.966, 49.244, -4.851, -2.761, 0.173, 30.656, 20.222, 0.124, -7.1]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (367.515) is slightly lower, which is generally favorable.
2. **TPSA:** Both are good, below the 140 A^2 threshold for oral absorption. Ligand B (80.32) is better than Ligand A (88.99).
3. **logP:** Both are within the optimal range (1-3). Very similar values, so no clear advantage.
4. **HBD:** Both have 2 HBD, which is good.
5. **HBA:** Ligand A has 4 HBA, Ligand B has 5. Both are acceptable, but Ligand A is slightly better.
6. **QED:** Ligand A (0.862) is significantly better than Ligand B (0.74), indicating a more drug-like profile.
7. **DILI:** Ligand A (69.833) has a higher DILI risk than Ligand B (52.966). This is a significant drawback for Ligand A.
8. **BBB:** Both have moderate BBB penetration. Ligand A (54.517) is slightly better than Ligand B (49.244), but neither is exceptionally high.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-5.173) is slightly better (less negative) than Ligand B (-4.851).
10. **Solubility:** Ligand B (-2.761) has better aqueous solubility than Ligand A (-4.791).
11. **hERG:** Ligand A (0.638) has a lower hERG risk than Ligand B (0.173). This is a positive for Ligand A.
12. **Cl_mic:** Ligand A (-7.575) has significantly lower (better) microsomal clearance than Ligand B (30.656), indicating better metabolic stability.
13. **t1/2:** Ligand B (20.222) has a longer in vitro half-life than Ligand A (-14.393). This is a positive for Ligand B.
14. **Pgp:** Both have very low Pgp efflux liability. Similar values.
15. **Binding Affinity:** Ligand A (-7.3) has a slightly better binding affinity than Ligand B (-7.1).
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Both ligands are comparable in logP and Pgp. Ligand A has slightly better affinity and TPSA, while Ligand B has better solubility and half-life. The DILI risk for Ligand A is concerning, and the metabolic stability (Cl_mic) is a major advantage for Ligand A.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity and metabolic stability, the significantly higher DILI risk is a major concern. Ligand B, despite a slightly lower affinity, presents a much more favorable safety profile (lower DILI) and better solubility, which are crucial for oral bioavailability and reducing potential adverse effects. The longer half-life of Ligand B is also beneficial.
Therefore, I would choose Ligand B.
0
2025-04-17 19:25:33,304 - INFO - Batch 109 complete. Total preferences: 1744
2025-04-17 19:25:33,304 - INFO - Processing batch 110/512...
2025-04-17 19:26:20,292 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [354.495, 95.74, 0.585, 2, 4, 0.633, 10.392, 64.56, -5.359, -1.217, 0.161, 17.956, -19.749, 0.001, -6.4]
**Ligand B:** [367.515, 82.43, 1.802, 1, 5, 0.596, 27.724, 64.793, -5.017, -2.422, 0.588, 29.66, 2.541, 0.137, -6.1]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (354.495) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (95.74) is slightly higher than Ligand B (82.43). Both are acceptable for a non-CNS GPCR target like ADRB2, but Ligand B is better.
3. **logP:** Ligand A (0.585) is quite low, potentially hindering membrane permeability. Ligand B (1.802) is much better, falling within the optimal 1-3 range. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable.
5. **HBA:** Ligand A (4) and Ligand B (5) are both acceptable.
6. **QED:** Both are similar (0.633 and 0.596) and above the 0.5 threshold, indicating good drug-like properties.
7. **DILI:** Ligand A (10.392) has a much lower DILI risk than Ligand B (27.724). This is a substantial advantage for Ligand A.
8. **BBB:** Both have similar BBB penetration (64.56 and 64.793). Since ADRB2 is not a primary CNS target, this is less critical.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not defined, so it's hard to interpret.
10. **Solubility:** Both have negative solubility values, which is also unusual.
11. **hERG:** Both have low hERG inhibition liability (0.161 and 0.588), which is good.
12. **Cl_mic:** Ligand A (17.956) has a lower microsomal clearance than Ligand B (29.66), indicating better metabolic stability.
13. **t1/2:** Ligand A (-19.749) has a much longer in vitro half-life than Ligand B (2.541). This is a significant advantage for Ligand A.
14. **Pgp:** Both have very low Pgp efflux liability (0.001 and 0.137).
15. **Affinity:** Ligand A (-6.4) has a slightly better binding affinity than Ligand B (-6.1), but the difference is small.
**GPCR-Specific Priorities:** For ADRB2 (a GPCR), logP, TPSA, and affinity are important. Ligand B excels in logP and has a slightly better TPSA. Ligand A has a slightly better affinity, but the difference is small. However, Ligand A has a significantly better safety profile (lower DILI) and better metabolic stability (lower Cl_mic and longer t1/2).
**Conclusion:**
While Ligand B has a more favorable logP, the significantly lower DILI risk, better metabolic stability, and longer half-life of Ligand A outweigh this benefit. The slightly better affinity of Ligand A also contributes. Therefore, I prefer Ligand A.
Output:
1
2025-04-17 19:26:20,293 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (363.845 Da and 353.438 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Both ligands have a TPSA of 75.44, which is above the optimal <90 for CNS targets, but acceptable for a peripheral GPCR like ADRB2. No significant difference.
**3. logP:** Ligand A (3.364) is slightly higher than Ligand B (2.157). Both are within the optimal 1-3 range, but Ligand A is closer to the upper limit.
**4. H-Bond Donors:** Both have 1 HBD, which is good.
**5. H-Bond Acceptors:** Both have 4 HBA, which is good.
**6. QED:** Both ligands have high QED scores (0.853 and 0.815), indicating good drug-like properties.
**7. DILI:** Ligand B (41.954) has a significantly lower DILI risk than Ligand A (54.556). This is a substantial advantage for Ligand B.
**8. BBB:** Ligand B (82.319) has a higher BBB penetration percentile than Ligand A (51.997). While ADRB2 is a cardiovascular target, some CNS exposure can occur, and higher BBB is generally favorable.
**9. Caco-2 Permeability:** Ligand A (-4.927) has slightly better Caco-2 permeability than Ligand B (-4.568), suggesting potentially better absorption.
**10. Aqueous Solubility:** Ligand A (-3.201) has slightly better aqueous solubility than Ligand B (-2.777).
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (0.324 and 0.429).
**12. Microsomal Clearance:** Ligand B (39.656) has significantly lower microsomal clearance than Ligand A (73.988), indicating better metabolic stability.
**13. In vitro Half-Life:** Ligand B (-5.127) has a significantly longer in vitro half-life than Ligand A (18.153). This is a major advantage for Ligand B.
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (0.207 and 0.161).
**15. Binding Affinity:** Ligand A (-7.7 kcal/mol) has a slightly better binding affinity than Ligand B (-7.3 kcal/mol). This is a 0.4 kcal/mol difference, which is not a huge advantage, but is noticeable.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), and the general guidelines, Ligand B emerges as the more promising candidate. While Ligand A has a slightly better binding affinity and Caco-2 permeability, Ligand B demonstrates significantly better ADME properties: lower DILI risk, higher BBB penetration, lower microsomal clearance, and a longer in vitro half-life. The difference in binding affinity is not large enough to outweigh these substantial advantages in ADME. The improved metabolic stability and reduced toxicity risk of Ligand B are particularly important for a cardiovascular drug.
Output:
0
2025-04-17 19:26:20,293 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (342.439 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (60.45) is significantly better than Ligand B (90.9). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally aids absorption.
3. **logP:** Ligand A (3.63) is within the optimal range (1-3), while Ligand B (-0.121) is quite low, potentially hindering membrane permeability. This is a significant drawback for Ligand B.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is preferable to Ligand B (5). Fewer HBAs generally improve permeability.
6. **QED:** Ligand A (0.835) is significantly better than Ligand B (0.566), indicating a more drug-like profile.
7. **DILI:** Ligand B (6.747) has a much lower DILI risk than Ligand A (58.705). This is a substantial advantage for Ligand B.
8. **BBB:** Ligand A (51.415) is better than Ligand B (39.55), but BBB isn't a high priority for a cardiovascular target.
9. **Caco-2:** Ligand A (-4.584) and Ligand B (-5.133) have similar Caco-2 permeability, both indicating reasonable absorption.
10. **Solubility:** Ligand A (-4.733) and Ligand B (-0.647) have similar solubility, both indicating reasonable solubility.
11. **hERG:** Ligand A (0.496) is better than Ligand B (0.103), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand B (7.417) has significantly lower microsomal clearance than Ligand A (100.086), suggesting better metabolic stability.
13. **t1/2:** Ligand B (19.352) has a much longer in vitro half-life than Ligand A (6.501), which is a significant advantage.
14. **Pgp:** Ligand A (0.154) is better than Ligand B (0.004), indicating lower P-gp efflux.
15. **Affinity:** Both ligands have similar binding affinity (-5.8 kcal/mol).
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, and affinity are important. Ligand A excels in TPSA and has a better logP. However, the significantly better DILI, Cl_mic, and t1/2 of Ligand B are very attractive. The similar affinity balances this out. While the low logP of Ligand B is a concern, the improved metabolic stability and reduced toxicity are likely to be more impactful for overall drug development success.
**Conclusion:**
Considering the balance of properties, and prioritizing metabolic stability and reduced toxicity, Ligand B appears to be the more promising candidate.
Output:
0
2025-04-17 19:26:20,293 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.394 and 346.431 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (67.67) is significantly better than Ligand B (98.32). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold. Ligand B is approaching it, but less favorably.
3. **logP:** Ligand B (1.239) is better than Ligand A (0.317). A logP between 1-3 is optimal. Ligand A is a bit low, potentially hindering permeability.
4. **HBD:** Ligand A (0) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (4). Both are within acceptable limits (<=10).
6. **QED:** Both ligands are very similar (0.734 and 0.714), indicating good drug-likeness.
7. **DILI:** Ligand A (32.028) is significantly better than Ligand B (42.807). Lower DILI risk is always preferred. Both are below the concerning threshold of 60.
8. **BBB:** Ligand A (84.684) is much better than Ligand B (43.893). While not a CNS target, higher BBB penetration can sometimes correlate with better overall distribution.
9. **Caco-2:** Ligand A (-4.47) is better than Ligand B (-5.315). Higher Caco-2 permeability is better, and both are negative, indicating good permeability.
10. **Solubility:** Ligand A (-1.143) is better than Ligand B (-1.874). Higher solubility is generally preferred.
11. **hERG:** Ligand A (0.263) is better than Ligand B (0.468). Lower hERG inhibition is crucial for avoiding cardiotoxicity, especially for a cardiovascular target.
12. **Cl_mic:** Ligand B (-18.543) is better than Ligand A (18.993). Lower clearance indicates better metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand B (-27.17) is better than Ligand A (-28.795). Both are negative, indicating long half-lives.
14. **Pgp:** Ligand A (0.03) is better than Ligand B (0.074). Lower P-gp efflux is preferred.
15. **Affinity:** Ligand A (-7.6) is significantly better than Ligand B (-6.2). A difference of 1.4 kcal/mol is substantial and can often outweigh minor ADME drawbacks.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A excels in affinity and has better TPSA and Pgp. Ligand B has better logP and Cl_mic. However, the substantial affinity advantage of Ligand A, coupled with its better safety profile (DILI, hERG) and reasonable ADME properties, makes it the more promising candidate. The slightly lower logP of Ligand A is a manageable concern given its superior binding.
**Output:**
1
2025-04-17 19:26:20,293 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (362.459 Da and 348.487 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (103.91) is higher than Ligand B (67.43). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is generally preferred for absorption. Ligand B is significantly better here.
**3. logP:** Ligand B (3.455) is better than Ligand A (0.488). A logP between 1-3 is optimal, and Ligand A is quite low, potentially hindering permeability. Ligand B is within the ideal range.
**4. H-Bond Donors:** Ligand A (1) is better than Ligand B (2). Lower HBDs are generally preferred for permeability.
**5. H-Bond Acceptors:** Ligand A (7) is higher than Ligand B (3). Lower HBA is preferred for permeability. Ligand B is significantly better here.
**6. QED:** Both ligands have similar QED values (0.739 and 0.707), indicating good drug-likeness.
**7. DILI:** Ligand B (32.183) has a much lower DILI risk than Ligand A (51.028). This is a significant advantage for Ligand B.
**8. BBB:** Both ligands have similar BBB penetration (49.787 and 51.105). Since ADRB2 is not a CNS target, this is a lower priority.
**9. Caco-2 Permeability:** Ligand A (-5.43) has better Caco-2 permeability than Ligand B (-4.492), but both are negative, and the scale is unclear.
**10. Aqueous Solubility:** Ligand A (-2.753) has better aqueous solubility than Ligand B (-3.544), but both are negative, and the scale is unclear.
**11. hERG Inhibition:** Ligand A (0.099) has a slightly lower hERG inhibition risk than Ligand B (0.737), which is preferable.
**12. Microsomal Clearance:** Ligand A (10.983) has significantly lower microsomal clearance than Ligand B (64.125), indicating better metabolic stability.
**13. In vitro Half-Life:** Ligand A (7.164) has a better in vitro half-life than Ligand B (-11.32).
**14. P-gp Efflux:** Ligand A (0.068) has lower P-gp efflux than Ligand B (0.267), which is preferable.
**15. Binding Affinity:** Ligand A (-7.5) has a slightly better binding affinity than Ligand B (-6.7). However, the difference is not substantial enough to outweigh the ADME advantages of Ligand B.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand B is the stronger candidate. While Ligand A has slightly better affinity and metabolic stability, Ligand B excels in logP, TPSA, and significantly reduces the risk of DILI. The lower TPSA and better logP of Ligand B are crucial for good absorption and distribution, which are important for a cardiovascular target. The lower DILI risk is also a major advantage.
Output:
0
2025-04-17 19:26:20,294 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (365.459) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (82.53) is significantly better than Ligand A (107.19). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally improves absorption.
3. **logP:** Ligand B (2.417) is optimal, while Ligand A (0.455) is quite low. Low logP can hinder membrane permeability. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (3) and Ligand B (2) are both acceptable.
5. **HBA:** Ligand A (5) and Ligand B (6) are both acceptable.
6. **QED:** Both ligands have good QED scores (A: 0.58, B: 0.699), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Both ligands have similar DILI risk (A: 56.844, B: 59.752), and are within an acceptable range.
8. **BBB:** Not a primary concern for a cardiovascular target. Ligand A (66.615) has slightly better BBB penetration than Ligand B (47.189), but this is less important.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it is hard to interpret.
10. **Solubility:** Both ligands have negative solubility values, which is also unusual. This suggests poor solubility.
11. **hERG:** Ligand A (0.339) has a lower hERG risk than Ligand B (0.669), which is a significant advantage.
12. **Cl_mic:** Ligand A (21.424) has a much lower microsomal clearance than Ligand B (65.42), indicating better metabolic stability. This is a strong point for Ligand A.
13. **t1/2:** Ligand A (-17.122) has a negative half-life, which is not possible. Ligand B (-0.649) also has a negative half-life, which is not possible.
14. **Pgp:** Ligand A (0.026) has much lower P-gp efflux than Ligand B (0.161), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand B (-7.8) has a significantly stronger binding affinity than Ligand A (-6.2). This is a substantial advantage, potentially outweighing some ADME concerns.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP and affinity, while Ligand A has better TPSA and Pgp.
**Overall Assessment:**
Ligand B's significantly stronger binding affinity (-7.8 kcal/mol vs -6.2 kcal/mol) is a major advantage. While Ligand A has better metabolic stability (lower Cl_mic) and Pgp efflux, the difference in affinity is substantial enough to likely overcome those drawbacks, especially considering the cardiovascular target. The lower logP of Ligand A is a concern. The negative values for Caco-2 and solubility are concerning for both, but the affinity of Ligand B is a strong driver.
Output:
0
2025-04-17 19:26:20,294 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (347.39 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are below the 140 A^2 threshold for good oral absorption (A: 73.48, B: 71.09). They are also both well below the 90 A^2 threshold for CNS targets, though that's less critical here.
3. **logP:** Ligand A (1.108) is within the optimal range (1-3), while Ligand B (3.711) is approaching the upper limit. Higher logP can lead to solubility issues and off-target interactions.
4. **HBD/HBA:** Ligand A (HBD=1, HBA=3) has fewer hydrogen bond donors and acceptors than Ligand B (HBD=2, HBA=5). This is generally favorable for permeability.
5. **QED:** Both have acceptable QED values (A: 0.811, B: 0.782), indicating good drug-like properties.
6. **DILI:** Ligand A (42.536) has a significantly lower DILI risk than Ligand B (69.678). This is a major advantage.
7. **BBB:** Ligand A (65.529) has better BBB penetration than Ligand B (57.968). While ADRB2 isn't exclusively a CNS target, some CNS exposure could be relevant, and higher BBB is generally preferred.
8. **Caco-2:** Ligand A (-4.51) and Ligand B (-5.104) both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it is difficult to interpret.
9. **Solubility:** Ligand A (-2.394) has better solubility than Ligand B (-4.541). This is important for bioavailability.
10. **hERG:** Both have low hERG inhibition risk (A: 0.37, B: 0.425).
11. **Cl_mic:** Ligand A (-6.76) has a much lower (better) microsomal clearance than Ligand B (39.064), indicating greater metabolic stability.
12. **t1/2:** Ligand A (-31.261) has a longer in vitro half-life than Ligand B (35.185).
13. **Pgp:** Both have low P-gp efflux liability (A: 0.061, B: 0.228), which is good.
14. **Binding Affinity:** Ligand B (-6.1) has a slightly better binding affinity than Ligand A (-5.8). However, the difference is only 0.3 kcal/mol, which is not substantial enough to outweigh the other significant advantages of Ligand A.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Ligand A is better on logP, TPSA, Pgp, and has a good affinity. Ligand B has a slightly better affinity, but the other ADME properties are less favorable.
**Conclusion:**
Ligand A demonstrates a significantly better overall profile, particularly regarding DILI risk, metabolic stability (Cl_mic, t1/2), solubility, and BBB penetration. The slightly weaker binding affinity of Ligand A is not a major concern given its superior ADME properties.
Output:
1
2025-04-17 19:26:20,294 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (370.877 and 388.53 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (84.5) is slightly higher than Ligand B (66.48). Both are below the 140 threshold for oral absorption, but B is preferable given the GPCR target class.
3. **logP:** Ligand A (1.542) is within the optimal 1-3 range. Ligand B (3.131) is at the higher end of the optimal range. Both are acceptable, but A is slightly favored.
4. **HBD:** Ligand A (2) and Ligand B (1) are both good, being less than 5. B is slightly better.
5. **HBA:** Both ligands have 4 HBA, which is acceptable.
6. **QED:** Ligand B (0.814) has a higher QED score than Ligand A (0.603), indicating a more drug-like profile. This is a significant advantage for B.
7. **DILI:** Ligand B (63.242) has a higher DILI risk than Ligand A (29.43). A is significantly better here.
8. **BBB:** Ligand B (87.01) has a much higher BBB penetration percentile than Ligand A (60.644). This is a key advantage for B, given that ADRB2 is a GPCR.
9. **Caco-2:** Both ligands have similar, very negative Caco-2 values (-5.083 and -5.064). This suggests poor permeability.
10. **Solubility:** Ligand A (-2.335) has better solubility than Ligand B (-4.339).
11. **hERG:** Both ligands have very low hERG inhibition risk (0.095 and 0.811). No significant difference.
12. **Cl_mic:** Ligand A (8.042) has a lower microsomal clearance than Ligand B (36.303), suggesting better metabolic stability. This is a significant advantage for A.
13. **t1/2:** Ligand B (-6.625) has a longer in vitro half-life than Ligand A (5.11). This is a positive for B.
14. **Pgp:** Ligand A (0.095) has lower P-gp efflux liability than Ligand B (0.372). This is a slight advantage for A.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-5.6 and -5.7 kcal/mol). The difference is negligible.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand B is more promising. While Ligand A has advantages in DILI risk and metabolic stability, Ligand B's superior BBB penetration and QED score are more critical for a GPCR target. The slightly higher logP of B is acceptable, and its longer half-life is also beneficial. The poor Caco-2 values for both ligands are concerning, but can be addressed in later optimization stages.
Output:
0
2025-04-17 19:26:20,294 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.475 and 343.295 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (84.5) is significantly better than Ligand B (135.55). ADRB2 is a cardiovascular target, not CNS, but lower TPSA generally improves absorption. Ligand A is well below the 140 threshold, while B is approaching it.
3. **logP:** Both ligands have acceptable logP values (2.165 and 1.173), falling within the 1-3 range. Ligand A is slightly more lipophilic, which could aid membrane permeability, but Ligand B is still reasonable.
4. **HBD:** Both have 2 HBD, which is within the acceptable limit of 5.
5. **HBA:** Ligand A has 4 HBA, while Ligand B has 7. Ligand A is preferable here, as lower HBA generally improves permeability.
6. **QED:** Both ligands have similar QED values (0.656 and 0.589), both above the 0.5 threshold, indicating good drug-likeness.
7. **DILI:** Ligand A (30.748) has a much lower DILI risk than Ligand B (99.263). This is a significant advantage for Ligand A.
8. **BBB:** This is less critical for a cardiovascular target. Ligand A (64.599) is better than Ligand B (31.756), but it's not a deciding factor.
9. **Caco-2:** Ligand A (-4.552) and Ligand B (-5.257) are both negative, indicating poor permeability. However, the scale isn't specified, so it's hard to interpret.
10. **Solubility:** Ligand A (-2.807) and Ligand B (-3.292) are both negative, indicating poor solubility. Again, the scale is unknown.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.154 and 0.018), which is excellent.
12. **Cl_mic:** Ligand B (26.508) has significantly lower microsomal clearance than Ligand A (65.821), suggesting better metabolic stability. This is a positive for Ligand B.
13. **t1/2:** Ligand B (-16.699) has a longer in vitro half-life than Ligand A (-11.17), which is also a positive for Ligand B.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.036 and 0.015), which is favorable.
15. **Binding Affinity:** Ligand A (-7.4) has a slightly better binding affinity than Ligand B (-6.1), a difference of 1.3 kcal/mol. This is a substantial difference and a major advantage for Ligand A.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand A is the better candidate. While Ligand B has advantages in metabolic stability (Cl_mic, t1/2), the significantly lower DILI risk and better binding affinity of Ligand A outweigh these benefits. The lower TPSA and HBA of Ligand A also contribute to its improved drug-like properties. The affinity difference is large enough to overcome the metabolic concerns.
Output:
1
2025-04-17 19:26:20,294 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (347.327 Da and 346.471 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (97.41) is higher than Ligand B (67.43). For a cardiovascular GPCR, TPSA is moderately important. Ligand B's lower TPSA is preferable for better permeability.
**3. logP:** Ligand A (0.325) is quite low, potentially hindering membrane permeability. Ligand B (2.462) is within the optimal 1-3 range. This is a significant advantage for Ligand B.
**4. H-Bond Donors:** Ligand A (1) is good. Ligand B (2) is acceptable, but slightly less desirable.
**5. H-Bond Acceptors:** Ligand A (6) is good. Ligand B (3) is also good.
**6. QED:** Ligand A (0.735) is better than Ligand B (0.524), indicating a more drug-like profile overall.
**7. DILI:** Ligand A (80.225) has a significantly higher DILI risk than Ligand B (25.979). This is a major concern for Ligand A.
**8. BBB:** Both ligands have relatively low BBB penetration (Ligand A: 57.231, Ligand B: 65.297). Since this is a cardiovascular target, BBB penetration isn't a primary concern, but Ligand B is slightly better.
**9. Caco-2 Permeability:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.478) is slightly better than Ligand B (-4.858), but both are problematic.
**10. Aqueous Solubility:** Both have negative solubility values, indicating poor solubility. Ligand A (-3.023) is slightly better than Ligand B (-2.471).
**11. hERG Inhibition:** Both ligands show very low hERG inhibition risk (Ligand A: 0.185, Ligand B: 0.3). This is excellent for both.
**12. Microsomal Clearance:** Ligand A (3.7) has much lower microsomal clearance than Ligand B (30.858), suggesting better metabolic stability. This is a significant advantage for Ligand A.
**13. In vitro Half-Life:** Ligand A (-12.02) has a negative half-life, which is not realistic. Ligand B (-3.267) is also negative, but less so. Both are problematic.
**14. P-gp Efflux:** Both ligands show very low P-gp efflux liability (Ligand A: 0.03, Ligand B: 0.122). This is excellent for both.
**15. Binding Affinity:** Both ligands have comparable binding affinities (Ligand A: -6.1 kcal/mol, Ligand B: -6.3 kcal/mol). The difference is minimal.
**Overall Assessment:**
Ligand B has a significantly better logP and a much lower DILI risk, which are crucial for a viable drug candidate. While Ligand A has better QED and lower Cl_mic, the high DILI risk is a major red flag. The negative Caco-2 and half-life values for both are concerning and would require further investigation, but the DILI risk for Ligand A is a more immediate concern. Given the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand B is the more promising candidate.
Output:
0
2025-04-17 19:26:20,294 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (367.4 & 370.5 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand B (94.48) is better than Ligand A (113.48). Lower TPSA generally favors oral absorption, and is particularly important for GPCRs.
3. **logP:** Both ligands have very low logP values (0.066 and 0.117). While not ideal (optimal is 1-3), they are relatively close. This could indicate potential permeability issues, but is not a dealbreaker at this stage.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (2), but both are within the acceptable limit of 5.
5. **HBA:** Ligand B (8) is slightly lower than Ligand A (7), but both are within the acceptable limit of 10.
6. **QED:** Ligand A (0.707) is slightly better than Ligand B (0.633), indicating a more drug-like profile.
7. **DILI:** Ligand B (50.291) has a significantly lower DILI risk than Ligand A (68.941). This is a crucial advantage, as minimizing liver toxicity is paramount.
8. **BBB:** Both ligands have similar BBB penetration (55.642 and 52.617). Neither is particularly high, but for a cardiovascular target like ADRB2, BBB penetration isn't a primary concern.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.377 and -5.178), which is unusual and suggests very poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand B (-1.606) is better than Ligand A (-2.431), indicating slightly better aqueous solubility.
11. **hERG:** Ligand A (0.409) has a lower hERG inhibition liability than Ligand B (0.758), which is a positive.
12. **Cl_mic:** Ligand A (-16.766) has a much lower (better) microsomal clearance than Ligand B (33.73). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (12.125 hours) has a significantly longer in vitro half-life than Ligand B (5.183 hours). This is a major advantage, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand B (0.083) has a slightly lower P-gp efflux liability than Ligand A (0.058), which is a minor benefit.
15. **Binding Affinity:** Ligand A (-7.0 kcal/mol) has a slightly better binding affinity than Ligand B (-6.7 kcal/mol). While the difference is not huge, it is still a positive for Ligand A.
**Overall Assessment:**
Ligand A has a better binding affinity, metabolic stability (lower Cl_mic), and longer half-life. However, Ligand B has a significantly lower DILI risk and slightly better solubility and TPSA. Both have poor Caco-2 permeability and low logP values. Considering the GPCR-specific priorities (logP, TPSA, affinity) and the overall drug-like properties, the lower DILI risk of Ligand B is a very important factor. While the binding affinity of Ligand A is slightly better, the potential for liver toxicity with Ligand A is a significant concern.
Output:
0
2025-04-17 19:26:20,295 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (405.311 Da) is within the ideal range, while Ligand B (350.507 Da) is towards the lower end but still acceptable.
2. **TPSA:** Ligand A (41.13) is excellent, well below the 140 threshold. Ligand B (68.3) is still reasonable, but higher.
3. **logP:** Both ligands have good logP values (A: 4.736, B: 3.485), within the optimal 1-3 range. Ligand A is slightly higher, which could be a minor concern for solubility.
4. **HBD:** Both have 2 HBD, which is good.
5. **HBA:** Ligand A has 1 HBA, while Ligand B has 6. Ligand B is higher, potentially impacting permeability.
6. **QED:** Both ligands have similar QED values (A: 0.742, B: 0.711), indicating good drug-likeness.
7. **DILI:** Both have low DILI risk (A: 38.852, B: 35.905), which is positive.
8. **BBB:** Both have good BBB penetration (A: 89.066, B: 76.774). Ligand A is better.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability.
10. **Solubility:** Both have negative solubility values, indicating poor solubility.
11. **hERG:** Both have low hERG risk (A: 0.875, B: 0.854).
12. **Cl_mic:** Ligand B has lower microsomal clearance (59.453) than Ligand A (79.622), suggesting better metabolic stability.
13. **t1/2:** Ligand A has a longer in vitro half-life (71.101 hours) than Ligand B (49.569 hours).
14. **Pgp:** Both have low Pgp efflux liability (A: 0.493, B: 0.275). Ligand B is better.
15. **Binding Affinity:** Ligand A has a significantly stronger binding affinity (-7.7 kcal/mol) compared to Ligand B (-5.7 kcal/mol). This is a substantial difference.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, affinity, logP, TPSA, Pgp, and BBB are key. Ligand A excels in affinity and BBB penetration. While Ligand B has better metabolic stability (lower Cl_mic) and Pgp efflux, the significantly stronger binding affinity of Ligand A outweighs these advantages. The slightly higher logP of Ligand A is a minor concern, but the strong binding is likely to compensate. Both have poor Caco-2 and solubility, which would need to be addressed in further optimization.
**Conclusion:**
The superior binding affinity of Ligand A makes it the more promising candidate despite some minor drawbacks.
Output:
1
2025-04-17 19:26:20,295 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [348.399, 103.01 , 0.572, 3. , 5. , 0.722, 27.142, 38.852, -5.145, -1.553, 0.267, -23.636, 46.368, 0.013, -9.5 ]
**Ligand B:** [379.507, 75.44 , 2.422, 1. , 6. , 0.863, 66.615, 63.474, -5.373, -3.362, 0.116, 75.777, 8.292, 0.24 , -7.5 ]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity, and to a lesser extent BBB):
1. **MW:** Both are within the ideal range (200-500 Da). A is slightly better at 348 vs 379.
2. **TPSA:** A (103) is higher than B (75). B is significantly better, being well under the 140 threshold for good absorption.
3. **logP:** A (0.572) is quite low, potentially hindering permeability. B (2.422) is much better, falling within the optimal 1-3 range.
4. **HBD/HBA:** A has 3 HBD and 5 HBA, while B has 1 HBD and 6 HBA. Both are acceptable, but B is slightly more favorable.
5. **QED:** Both have good QED values (A: 0.722, B: 0.863), indicating drug-likeness. B is better.
6. **DILI:** A (27.142) has a much lower DILI risk than B (66.615). This is a significant advantage for A.
7. **BBB:** A (38.852) has a lower BBB penetration than B (63.474). While not a primary concern for a cardiovascular target, higher BBB is generally preferable.
8. **Caco-2:** Both are negative, indicating poor permeability.
9. **Solubility:** Both are negative, indicating poor solubility.
10. **hERG:** A (0.267) has a much lower hERG risk than B (0.116). This is a significant advantage for A.
11. **Cl_mic:** A (-23.636) has a much lower (better) microsomal clearance than B (75.777), suggesting better metabolic stability.
12. **t1/2:** A (46.368) has a longer in vitro half-life than B (8.292). This is a significant advantage for A.
13. **Pgp:** A (0.013) has a much lower P-gp efflux liability than B (0.24). This is a significant advantage for A.
14. **Affinity:** B (-7.5) has a significantly stronger binding affinity than A (-9.5). This is a major advantage for B, and could potentially outweigh some ADME concerns.
**Overall Assessment:**
Ligand B has a substantially better binding affinity (-7.5 vs -9.5 kcal/mol). This is a critical factor for GPCRs. However, it suffers from higher DILI risk, higher P-gp efflux, higher microsomal clearance, and a shorter half-life. Ligand A has a much better safety profile (lower DILI, hERG, Pgp) and better metabolic stability (lower Cl_mic, longer t1/2). The logP for A is concerning, but the strong affinity of B might compensate for some permeability issues.
Considering the balance, the significantly stronger binding affinity of Ligand B is a compelling factor, especially for a GPCR target. While the ADME properties of B are less ideal, the potency advantage is substantial.
Output:
0
2025-04-17 19:26:20,295 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (358.316 and 350.459 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (88.42) is slightly higher than Ligand B (67.87). Both are below the 140 threshold for oral absorption, but Ligand B is better positioned, especially considering ADRB2 is a cardiovascular target and CNS penetration isn't a primary goal.
3. **logP:** Ligand A (3.137) and Ligand B (2.158) are both within the optimal 1-3 range. Ligand A is slightly higher, which *could* present a minor solubility challenge, but isn't a major concern.
4. **HBD:** Both ligands have 1 H-bond donor, which is good.
5. **HBA:** Ligand A has 5 H-bond acceptors, and Ligand B has 4. Both are acceptable (<=10).
6. **QED:** Both ligands have good QED scores (0.541 and 0.564), indicating good drug-like properties.
7. **DILI:** Ligand A (60.915) is slightly higher DILI risk than Ligand B (52.772). Both are acceptable, but lower is always preferred.
8. **BBB:** Both ligands have reasonable BBB penetration, but Ligand A (74.564) is higher than Ligand B (69.911). This isn't a critical factor for a cardiovascular target like ADRB2.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the values are very close (-4.551 vs -4.715).
10. **Solubility:** Ligand B (-2.373) has better aqueous solubility than Ligand A (-4.244). This is a positive for bioavailability.
11. **hERG:** Ligand A (0.652) has a slightly higher hERG risk than Ligand B (0.21). This is a significant advantage for Ligand B, as hERG inhibition can lead to cardiotoxicity, a critical concern for a cardiovascular target.
12. **Cl_mic:** Ligand B (50.381) has lower microsomal clearance than Ligand A (55.595), indicating better metabolic stability.
13. **t1/2:** Ligand B (4.913) has a longer in vitro half-life than Ligand A (2.693). This is desirable for less frequent dosing.
14. **Pgp:** Ligand A (0.08) has lower P-gp efflux than Ligand B (0.112), which could lead to better absorption.
15. **Binding Affinity:** Ligand A (-7.1 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.5 kcal/mol). This is a 0.6 kcal/mol difference, which is substantial and can often outweigh minor ADME drawbacks.
**Overall Assessment & GPCR-Specific Priorities:**
For a GPCR like ADRB2, affinity is paramount. Ligand A's significantly stronger binding affinity (-7.1 vs -6.5 kcal/mol) is a major advantage. While Ligand B has better solubility, lower hERG risk, and better metabolic stability, the difference in affinity is substantial enough to overcome these drawbacks. The slight increase in DILI risk for Ligand A is also acceptable given the potency advantage.
Output:
1
2025-04-17 19:26:20,295 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A: [347.419, 102.05 , 1.856, 2. , 6. , 0.759, 48.468, 55.254, -5.264, -2.934, 0.505, 19.577, 29.215, 0.17 , -5.5 ]**
**Ligand B: [365.459, 108.09 , 0.487, 1. , 6. , 0.817, 51.609, 66.925, -5.067, -3.281, 0.454, 28.044, -28.733, 0.044, -6.6 ]**
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal range (200-500 Da). A (347.419) is slightly preferred.
2. **TPSA:** Both are reasonably good (A: 102.05, B: 108.09), under the 140 threshold for oral absorption.
3. **logP:** A (1.856) is better than B (0.487). B is quite low, potentially hindering membrane permeability.
4. **HBD:** Both are acceptable (A: 2, B: 1).
5. **HBA:** Both are acceptable (A: 6, B: 6).
6. **QED:** Both are good (A: 0.759, B: 0.817), indicating drug-like properties. B is slightly better.
7. **DILI:** Both are good (A: 48.468, B: 51.609), below the 60% threshold.
8. **BBB:** B (66.925) is better than A (55.254), but BBB is less critical for a cardiovascular target.
9. **Caco-2:** Both are negative, indicating poor permeability. A (-5.264) is slightly better than B (-5.067).
10. **Solubility:** Both are negative, indicating poor solubility. A (-2.934) is slightly better than B (-3.281).
11. **hERG:** Both are very low (A: 0.505, B: 0.454), indicating low cardiotoxicity risk.
12. **Cl_mic:** A (19.577) is better than B (28.044), suggesting better metabolic stability.
13. **t1/2:** A (29.215) is significantly better than B (-28.733). A positive half-life is highly desirable.
14. **Pgp:** Both are very low (A: 0.17, B: 0.044), indicating low efflux. B is slightly better.
15. **Affinity:** B (-6.6) is 1.1 kcal/mol better than A (-5.5). This is a substantial difference in binding.
**Overall Assessment:**
While Ligand B has a better binding affinity and slightly better Pgp and QED scores, Ligand A has significantly better metabolic stability (Cl_mic and t1/2) and a more favorable logP. The poor Caco-2 and solubility for both are concerning, but the substantial difference in affinity for Ligand B is a strong driver. The improved metabolic stability of Ligand A is valuable, but the affinity difference is likely to outweigh this.
Therefore, I favor Ligand B.
Output:
0
2025-04-17 19:26:20,295 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (351.378 and 343.387 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (87.74) is better than Ligand B (110.01). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (-0.269) is slightly below the optimal 1-3 range, while Ligand B (1.59) is within the optimal range. Ligand B has a clear advantage here.
4. **HBD:** Both ligands have 2 HBD, which is within the acceptable limit of <=5. No difference.
5. **HBA:** Ligand A has 4 HBA, while Ligand B has 6. Both are within the acceptable limit of <=10, but Ligand A is slightly preferable.
6. **QED:** Both ligands have good QED scores (0.539 and 0.704), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Both ligands have acceptable DILI risk (71.19 and 68.166), below the 60 threshold. No significant difference.
8. **BBB:** Both ligands have similar BBB penetration (71.268 and 70.88). Since ADRB2 is a cardiovascular target, BBB penetration is not a major priority.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.652 and -5.125), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Both ligands have negative solubility values (-1.626 and -2.81). This is a major red flag for both compounds.
11. **hERG:** Both ligands have low hERG inhibition liability (0.26 and 0.241), which is good. No difference.
12. **Cl_mic:** Ligand A (13.935) has significantly lower microsomal clearance than Ligand B (31.213), suggesting better metabolic stability. This is a substantial advantage for Ligand A.
13. **t1/2:** Ligand A (-10.61) has a negative in vitro half-life, which is concerning. Ligand B (6.758) has a positive half-life. Ligand B is better.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.106 and 0.058). No significant difference.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.3 and -6.5 kcal/mol). The difference is negligible.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, and affinity are key. While affinity is similar, Ligand B has a better logP and a slightly better QED. However, Ligand A has a significantly better Cl_mic, which is important for maintaining therapeutic concentrations. The solubility and Caco-2 values are poor for both.
**Overall Assessment:**
Despite Ligand B's slightly better logP and QED, Ligand A's significantly lower microsomal clearance is a major advantage. Metabolic stability is crucial for *in vivo* efficacy. The poor solubility and Caco-2 values are concerning for both, but can potentially be addressed with formulation strategies. The negative half-life for Ligand A is a significant drawback.
Considering the balance of properties and prioritizing metabolic stability, I believe Ligand A is the more promising candidate.
Output:
1
2025-04-17 19:26:20,296 - INFO - Batch 110 complete. Total preferences: 1760
2025-04-17 19:26:20,296 - INFO - Processing batch 111/512...
2025-04-17 19:27:13,363 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [345.399, 92.55, 0.974, 1, 4, 0.356, 17.449, 56.65, -5.054, -2.413, 0.069, -18.347, -13.171, 0.026, -6.8]
**Ligand B:** [343.427, 74.59, 1.814, 1, 5, 0.779, 33.618, 46.064, -4.74, -1.971, 0.448, 53.815, 32.132, 0.047, -6.4]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal range (200-500 Da). A is 345.4, B is 343.4. Very similar.
2. **TPSA:** A is 92.55, B is 74.59. B is significantly better, falling comfortably under the 90 A^2 threshold for potential CNS penetration (though not a CNS target here, lower TPSA generally aids absorption).
3. **logP:** A is 0.974, B is 1.814. B is better, closer to the optimal 1-3 range. A is a bit low, potentially impacting permeability.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** A has 4, B has 5. Both are acceptable, under the 10 threshold.
6. **QED:** A is 0.356, B is 0.779. B is *much* better, indicating a significantly more drug-like profile.
7. **DILI:** A is 17.45, B is 33.62. A is substantially better, indicating a lower risk of drug-induced liver injury.
8. **BBB:** A is 56.65, B is 46.06. Not a primary concern for a cardiovascular target, but A is slightly better.
9. **Caco-2:** A is -5.054, B is -4.74. Both are negative, which is unusual and suggests poor permeability. B is slightly better.
10. **Solubility:** A is -2.413, B is -1.971. Both are poor, but B is slightly better.
11. **hERG:** A is 0.069, B is 0.448. A is significantly better, indicating lower risk of hERG inhibition and cardiotoxicity.
12. **Cl_mic:** A is -18.347, B is 53.815. A is *much* better (lower is better), suggesting significantly higher metabolic stability.
13. **t1/2:** A is -13.171, B is 32.132. B is far better, suggesting a much longer in vitro half-life.
14. **Pgp:** A is 0.026, B is 0.047. A is slightly better, indicating lower P-glycoprotein efflux.
15. **Affinity:** A is -6.8 kcal/mol, B is -6.4 kcal/mol. A has a slightly better binding affinity.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity and lower DILI risk, Ligand B overwhelmingly wins on ADME properties. The significantly better QED, metabolic stability (Cl_mic), in vitro half-life, and TPSA make it a far more promising starting point for drug development. The slightly lower affinity can likely be optimized during lead optimization. The poor Caco-2 and solubility are concerns for both, but are addressable. The lower hERG risk for A is good, but not enough to overcome the ADME deficiencies.
Therefore, I recommend prioritizing Ligand B.
0
2025-04-17 19:27:13,363 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (373.837 and 343.362 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (93.9) is slightly higher than Ligand B (80.12). Both are below the 140 threshold for oral absorption, but closer to the 90 threshold for CNS targets, which isn't a primary concern for ADRB2 (cardiovascular). Ligand B is preferable.
3. **logP:** Both ligands have good logP values (1.489 and 0.899), falling within the optimal 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 6 HBA, and Ligand B has 5. Both are acceptable, below the 10 threshold.
6. **QED:** Both ligands have similar QED scores (0.811 and 0.837), indicating good drug-likeness.
7. **DILI:** Ligand A (62.233) has a slightly higher DILI risk than Ligand B (54.517), but both are reasonably acceptable (below 60).
8. **BBB:** Both have similar BBB penetration (58.085 and 57.968). This isn't a high priority for a cardiovascular target.
9. **Caco-2:** Both have negative Caco-2 values (-4.653 and -4.893), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand A (-2.789) has slightly better solubility than Ligand B (-1.74), which is preferable.
11. **hERG:** Both have very low hERG inhibition risk (0.142 and 0.209).
12. **Cl_mic:** Ligand A (17.351) has lower microsomal clearance than Ligand B (19.291), indicating better metabolic stability. This is a positive for Ligand A.
13. **t1/2:** Ligand B has a negative in vitro half-life (-19.095), which is highly unusual and suggests very rapid degradation. Ligand A (16.482) is much better.
14. **Pgp:** Both have low Pgp efflux liability (0.083 and 0.033).
15. **Binding Affinity:** Ligand A (-7.1) has a slightly better binding affinity than Ligand B (-7.0). While the difference is small, it's within the range where it could outweigh minor ADME drawbacks.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Both ligands perform reasonably well on logP and Pgp. Ligand B has a slightly better TPSA. However, Ligand A has a more favorable metabolic profile (lower Cl_mic, positive t1/2) and a slightly better binding affinity. The significantly better half-life of Ligand A is a major advantage. The negative Caco-2 values for both are concerning, but the superior overall profile of Ligand A makes it more promising.
**Conclusion:**
Considering the balance of properties, particularly the improved metabolic stability and slightly better binding affinity of Ligand A, I believe it is the more viable drug candidate.
Output:
1
2025-04-17 19:27:13,363 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (369.422 Da) is within the ideal range, while Ligand B (339.487 Da) is also acceptable. No clear advantage here.
2. **TPSA:** Ligand A (100.35) is slightly higher than ideal for oral absorption, but still reasonable. Ligand B (53.94) is excellent, well below the 140 threshold. Advantage: B
3. **logP:** Ligand A (0.173) is quite low, potentially hindering permeability. Ligand B (4.288) is high, potentially causing solubility issues and off-target effects, but is more favorable for GPCRs. Advantage: B
4. **HBD:** Ligand A (2) is good. Ligand B (1) is also good. No clear advantage.
5. **HBA:** Ligand A (7) is acceptable. Ligand B (5) is also acceptable. No clear advantage.
6. **QED:** Both ligands have good QED scores (A: 0.753, B: 0.9), indicating good drug-like properties. No clear advantage.
7. **DILI:** Ligand A (65.491) has a higher DILI risk than Ligand B (51.377), though both are within an acceptable range. Advantage: B
8. **BBB:** Ligand A (36.758) has poor BBB penetration, while Ligand B (72.896) is good. Advantage: B. This is important for GPCRs.
9. **Caco-2:** Ligand A (-5.471) has poor Caco-2 permeability, while Ligand B (-4.995) is slightly better, but still poor. No clear advantage.
10. **Solubility:** Ligand A (-2.72) has poor solubility, while Ligand B (-4.137) is also poor. No clear advantage.
11. **hERG:** Ligand A (0.506) has a lower hERG risk than Ligand B (0.86). Advantage: A
12. **Cl_mic:** Ligand A (26.902) has a lower microsomal clearance, indicating better metabolic stability, than Ligand B (87.414). Advantage: A
13. **t1/2:** Ligand A (-21.703) has a shorter in vitro half-life than Ligand B (21.322). Advantage: B
14. **Pgp:** Ligand A (0.087) has lower P-gp efflux, which is favorable for bioavailability and CNS exposure. Ligand B (0.351) is higher. Advantage: A
15. **Affinity:** Ligand A (-7.5) has a slightly better binding affinity than Ligand B (-6.5). Advantage: A. A 1 kcal/mol difference is significant.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand B initially appears more promising due to its better TPSA, BBB penetration and logP. However, Ligand A has a significant advantage in binding affinity, better metabolic stability (lower Cl_mic), and lower P-gp efflux. The low logP and solubility of Ligand A are concerns, but the superior affinity and metabolic properties, combined with lower P-gp efflux, are likely to outweigh these drawbacks, especially given the potential for optimization of solubility. The hERG risk is also lower for Ligand A.
Therefore, I believe Ligand A is the more viable drug candidate.
Output:
1
2025-04-17 19:27:13,364 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (348.397 and 347.459 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (58.12) is significantly better than Ligand B (82.53). ADRB2 is a cardiovascular target, not CNS, but lower TPSA generally improves absorption. Ligand A is well below the 140 threshold. Ligand B is approaching the upper limit.
3. **logP:** Ligand A (4.106) is higher than Ligand B (1.386). While 4.106 is at the upper end of the ideal range, it's not excessively high. Ligand B is quite low, potentially hindering permeation.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (4). Similar to HBD, lower HBA is generally better.
6. **QED:** Ligand A (0.905) is significantly better than Ligand B (0.707), indicating a more drug-like profile.
7. **DILI:** Ligand B (5.7) is *much* better than Ligand A (70.105). This is a major concern for Ligand A.
8. **BBB:** Ligand A (82.009) is better than Ligand B (51.725), but BBB isn't a primary concern for a cardiovascular target.
9. **Caco-2:** Ligand A (-4.326) and Ligand B (-4.78) are both negative, indicating poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Ligand A (-5.608) is better than Ligand B (-1.115), indicating better aqueous solubility.
11. **hERG:** Both ligands (0.537 and 0.2) have low hERG inhibition liability, which is good.
12. **Cl_mic:** Ligand B (18.63) has significantly lower microsomal clearance than Ligand A (87.932), suggesting better metabolic stability.
13. **t1/2:** Ligand A (22.837) has a longer in vitro half-life than Ligand B (0.759). This is a positive for Ligand A.
14. **Pgp:** Ligand A (0.226) is preferable to Ligand B (0.008), indicating lower P-gp efflux.
15. **Binding Affinity:** Both ligands have the same binding affinity (-5.8 kcal/mol).
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, and affinity are important. Ligand A performs better on logP and TPSA. Affinity is identical. However, the *extremely* high DILI risk for Ligand A is a deal-breaker. While metabolic stability (Cl_mic) is important, the DILI risk outweighs the benefit of a longer half-life.
**Conclusion:**
Despite Ligand A having some favorable ADME properties (TPSA, logP, solubility, Pgp, t1/2), the significantly higher DILI risk associated with Ligand A makes it a less viable candidate. Ligand B, while having a lower QED and higher TPSA, presents a much lower risk of liver injury and better metabolic stability.
Output:
0
2025-04-17 19:27:13,364 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (375.51 Da) is slightly higher than Ligand B (341.503 Da), but both are acceptable.
**2. TPSA:** Ligand A (87.3) is better than Ligand B (55.63). For a GPCR, lower TPSA is generally preferred for better permeability, and Ligand B is quite good here.
**3. logP:** Ligand A (1.393) is within the optimal range (1-3), while Ligand B (4.071) is slightly high. This is a point in favor of Ligand A, as high logP can lead to solubility issues and off-target interactions.
**4. H-Bond Donors:** Ligand A (3) is reasonable, while Ligand B (1) is even better. Lower HBDs are generally preferred for permeability.
**5. H-Bond Acceptors:** Ligand A (4) and Ligand B (5) are both acceptable, falling within the guideline of <=10.
**6. QED:** Both ligands have good QED values (Ligand A: 0.539, Ligand B: 0.662), indicating good drug-like properties. Ligand B is slightly better.
**7. DILI Risk:** Ligand A (25.553) has a significantly lower DILI risk than Ligand B (46.297). This is a major advantage for Ligand A.
**8. BBB Penetration:** Ligand A (72.16) has better BBB penetration than Ligand B (66.344). While ADRB2 isn't exclusively a CNS target, some CNS exposure could be beneficial or at least avoid unexpected side effects.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual. This suggests poor permeability. Ligand A (-5.4) is slightly better than Ligand B (-5.374).
**10. Aqueous Solubility:** Both ligands have negative solubility values, which is also unusual and concerning. Ligand A (-3.027) is slightly better than Ligand B (-4.012).
**11. hERG Inhibition:** Ligand A (0.188) has a much lower hERG inhibition risk than Ligand B (0.412). This is a critical advantage for Ligand A, as hERG inhibition can cause cardiotoxicity.
**12. Microsomal Clearance:** Ligand A (36.028) has lower microsomal clearance than Ligand B (60.475), indicating better metabolic stability.
**13. In vitro Half-Life:** Ligand B (9.82) has a significantly longer in vitro half-life than Ligand A (4.376). This is a positive for Ligand B.
**14. P-gp Efflux:** Ligand A (0.03) has much lower P-gp efflux than Ligand B (0.652). Lower P-gp efflux is preferred for better bioavailability.
**15. Binding Affinity:** Ligand B (-7.3) has a significantly stronger binding affinity than Ligand A (-5.4). This is a substantial advantage for Ligand B, potentially outweighing some of its ADME drawbacks.
**Overall Assessment:**
While Ligand B has a superior binding affinity, Ligand A demonstrates a significantly better safety profile (lower DILI, lower hERG) and better metabolic stability (lower Cl_mic). The slightly better BBB penetration and P-gp efflux of Ligand A are also beneficial. The negative Caco-2 and solubility values are concerning for both, but Ligand A is slightly better. Considering the GPCR target class, a balance between potency and safety/ADME properties is crucial. The substantial affinity difference is tempting, but the safety concerns with Ligand B are significant.
Therefore, I would prioritize Ligand A.
1
2025-04-17 19:27:13,364 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (344.39) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (67.23) is significantly better than Ligand B (115.9). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (1.636) is within the optimal range, while Ligand B (0.248) is a bit low. Low logP can hinder membrane permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is better than Ligand B (6). Similar reasoning as HBD.
6. **QED:** Ligand A (0.897) has a much better QED score than Ligand B (0.675), indicating a more drug-like profile.
7. **DILI:** Both are acceptable, but Ligand A (31.795) is better than Ligand B (39.201).
8. **BBB:** Ligand A (76.231) is better than Ligand B (25.785), though BBB isn't a primary concern for a cardiovascular target.
9. **Caco-2:** Ligand A (-4.979) is better than Ligand B (-5.107). Both are poor.
10. **Solubility:** Ligand A (-2.066) is better than Ligand B (-0.798).
11. **hERG:** Both are low (0.259 and 0.254), indicating low cardiotoxicity risk.
12. **Cl_mic:** Ligand A (10.66) is better than Ligand B (13.315), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-19.818) is better than Ligand B (-20.617).
14. **Pgp:** Both are very low (0.071 and 0.089), suggesting minimal efflux.
15. **Binding Affinity:** Ligand A (-7.8) is significantly better than Ligand B (-6.1). A 1.7 kcal/mol difference in binding is substantial and can often outweigh minor ADME deficiencies.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A excels in these areas. While BBB isn't critical here, the lower TPSA and better logP of Ligand A still contribute to better overall drug-like properties. The significantly improved binding affinity of Ligand A is the most important factor.
**Conclusion:**
Ligand A is clearly superior to Ligand B based on a comprehensive evaluation of its properties, particularly its significantly stronger binding affinity and more favorable ADME profile.
Output:
1
2025-04-17 19:27:13,364 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (335.451 and 348.403 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (41.19) is significantly better than Ligand B (113.33). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand B's TPSA is quite high, potentially hindering oral bioavailability.
3. **logP:** Ligand A (3.866) is within the optimal 1-3 range. Ligand B (0.522) is *below* 1, which is concerning for membrane permeability. This is a major drawback for Ligand B.
4. **HBD:** Ligand A (0) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is better than Ligand B (5). Lower HBA is generally preferred.
6. **QED:** Both ligands have similar QED values (0.797 and 0.734), indicating good drug-likeness.
7. **DILI:** Ligand A (17.449) has a much lower DILI risk than Ligand B (56.572). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (96.316) has a higher BBB penetration percentile than Ligand B (37.456). While ADRB2 isn't a CNS target, higher BBB isn't necessarily detrimental and could indicate better overall permeability.
9. **Caco-2:** Ligand A (-4.788) and Ligand B (-5.416) are both negative, which is unusual and suggests poor permeability in this assay. However, the scale is not specified, so it's difficult to interpret.
10. **Solubility:** Ligand A (-3.036) and Ligand B (-2.335) are both negative, suggesting poor solubility. This is a concern for both, but the scale is not specified.
11. **hERG:** Ligand A (0.981) is better than Ligand B (0.051), indicating a lower risk of hERG inhibition and cardiotoxicity.
12. **Cl_mic:** Ligand A (53.211) has a higher microsomal clearance than Ligand B (-1.761). This suggests Ligand B is more metabolically stable, which is a positive.
13. **t1/2:** Ligand A (22.826) has a longer in vitro half-life than Ligand B (15.458), which is desirable.
14. **Pgp:** Ligand A (0.717) has a lower P-gp efflux liability than Ligand B (0.02). Lower Pgp is preferred.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.7 and -6.5 kcal/mol). The difference is negligible.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, and Pgp are important. Ligand A significantly outperforms Ligand B in logP and TPSA. Pgp is also better for Ligand A. While metabolic stability is important, the difference in Cl_mic isn't large enough to outweigh the other advantages of Ligand A.
**Conclusion:**
Ligand A is clearly the superior candidate. It has better predicted permeability (logP, TPSA, Pgp), lower DILI risk, lower hERG risk, and a longer half-life. The slight advantage in metabolic stability for Ligand B is not enough to compensate for its significant drawbacks.
Output:
1
2025-04-17 19:27:13,364 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (351.491) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are reasonably low, but Ligand A (64.09) is better than Ligand B (69.81), falling well below the 140 threshold for oral absorption.
3. **logP:** Ligand A (1.083) is closer to the optimal range (1-3) than Ligand B (2.64). While 2.64 isn't terrible, 1.083 suggests better solubility.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A (4) is better than Ligand B (5), keeping the number of H-bonds lower.
6. **QED:** Both are very similar (0.805 vs 0.793) and above the 0.5 threshold, indicating good drug-likeness.
7. **DILI:** Ligand A (3.218) has a significantly lower DILI risk than Ligand B (10.585). This is a major advantage.
8. **BBB:** Ligand B (91.392) has a higher BBB penetration percentile than Ligand A (80.574). While ADRB2 isn't necessarily a CNS target, some cardiovascular effects can be mediated centrally, so this is a slight advantage for B.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. Ligand A (-4.665) is slightly better than Ligand B (-4.825).
10. **Solubility:** Ligand A (-1.16) has better solubility than Ligand B (-2.313).
11. **hERG:** Ligand A (0.551) has a lower hERG risk than Ligand B (0.719). This is a significant advantage, as hERG inhibition can cause cardiotoxicity.
12. **Cl_mic:** Ligand A (17.293) has a lower microsomal clearance than Ligand B (6.677), suggesting better metabolic stability.
13. **t1/2:** Ligand B (9.271) has a longer in vitro half-life than Ligand A (-7.665). This is a positive for B.
14. **Pgp:** Ligand A (0.019) has a much lower P-gp efflux liability than Ligand B (0.38). Lower P-gp efflux is generally desirable for improved bioavailability.
15. **Binding Affinity:** Ligand A (-6.9 kcal/mol) has a slightly better binding affinity than Ligand B (-4.8 kcal/mol). This is a substantial difference, and a >2 kcal/mol advantage can often outweigh minor ADME drawbacks.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A excels in logP, TPSA, Pgp, and significantly in affinity. Ligand B has a better BBB score and half-life, but the DILI and hERG risks are concerning.
**Overall Assessment:**
Ligand A is the stronger candidate. The significantly lower DILI and hERG risks, combined with better solubility, metabolic stability, and a much stronger binding affinity, outweigh the slightly lower BBB penetration and shorter half-life. The Caco-2 permeability is poor for both, but can be addressed with formulation strategies.
Output:
1
2025-04-17 19:27:13,364 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (363.405 Da and 354.407 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (79.9) is significantly better than Ligand B (120). For a GPCR, keeping TPSA under 140 is good for oral absorption, and A is comfortably within this range while B is approaching the upper limit.
**3. logP:** Ligand B (-1.578) is lower than Ligand A (0.142). While both are somewhat low, A is closer to the optimal 1-3 range. A logP below 1 can hinder permeability.
**4. H-Bond Donors:** Ligand A (2) is preferable to Ligand B (4). Lower HBD generally improves permeability.
**5. H-Bond Acceptors:** Ligand A (5) is preferable to Ligand B (6). Lower HBA generally improves permeability.
**6. QED:** Ligand A (0.702) is significantly better than Ligand B (0.391). A higher QED indicates a more drug-like profile.
**7. DILI:** Both ligands have acceptable DILI risk (A: 30.477, B: 36.254), both below the 40 threshold.
**8. BBB:** Ligand A (71.307) is substantially better than Ligand B (21.753). While ADRB2 is a cardiovascular target, some CNS penetration can be relevant for off-target effects and overall safety assessment.
**9. Caco-2 Permeability:** Ligand A (-4.971) is better than Ligand B (-5.354), indicating slightly better intestinal absorption.
**10. Aqueous Solubility:** Ligand A (-1.001) is better than Ligand B (-0.588).
**11. hERG Inhibition:** Both ligands have very low hERG risk (A: 0.194, B: 0.044).
**12. Microsomal Clearance:** Ligand A (-22.408) is significantly better than Ligand B (-6.846). Lower clearance indicates greater metabolic stability, a crucial factor for drug duration.
**13. In vitro Half-Life:** Ligand B (-23.125) is better than Ligand A (-2.92). Longer half-life is generally desirable.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (A: 0.015, B: 0.003).
**15. Binding Affinity:** Both ligands have similar binding affinity (A: -6.8 kcal/mol, B: -5.9 kcal/mol), with A being slightly better. The 0.9 kcal/mol difference is significant, but not overwhelming given the other ADME considerations.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most key ADME properties, including TPSA, logP, QED, BBB, microsomal clearance, and solubility. While Ligand B has a slightly longer in vitro half-life, the superior overall profile of Ligand A, particularly its better predicted permeability, metabolic stability, and drug-likeness, makes it the more promising drug candidate. The slight advantage in binding affinity further supports this conclusion.
Output:
1
2025-04-17 19:27:13,365 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [376.873, 88.49, 2.787, 2, 6, 0.646, 78.247, 30.05, -5.504, -3.433, 0.265, 42.872, -6.957, 0.268, -7.1]
**Ligand B:** [384.527, 82.61, 1.312, 1, 6, 0.717, 57.154, 43.699, -4.976, -2.123, 0.154, 20.223, 10.332, 0.044, -6.9]
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). A (376.873) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are reasonably good, below the 140 A^2 threshold for oral absorption. Ligand B (82.61) is better than Ligand A (88.49).
3. **logP:** Both are within the optimal range (1-3). Ligand B (1.312) is slightly lower, which could potentially affect permeability, but is still acceptable. Ligand A (2.787) is better.
4. **HBD:** Both are acceptable (<=5). Ligand A (2) is slightly better than Ligand B (1).
5. **HBA:** Both are acceptable (<=10), both at 6.
6. **QED:** Both are above 0.5, indicating good drug-likeness. Ligand B (0.717) is slightly better than Ligand A (0.646).
7. **DILI:** Ligand A (78.247) has a significantly higher DILI risk than Ligand B (57.154). This is a major concern.
8. **BBB:** Ligand B (43.699) has a better BBB penetration score than Ligand A (30.05). While not a primary concern for a cardiovascular target, it's a positive attribute.
9. **Caco-2:** Both have negative values, indicating poor permeability. Ligand A (-5.504) is worse than Ligand B (-4.976).
10. **Solubility:** Both have negative values, indicating poor solubility. Ligand B (-2.123) is better than Ligand A (-3.433).
11. **hERG:** Both have very low hERG inhibition liability, which is excellent. Ligand B (0.154) is slightly better than Ligand A (0.265).
12. **Cl_mic:** Ligand B (20.223) has significantly lower microsomal clearance, suggesting better metabolic stability, than Ligand A (42.872).
13. **t1/2:** Ligand B (10.332) has a longer in vitro half-life than Ligand A (-6.957). This is a significant advantage.
14. **Pgp:** Both have low P-gp efflux liability. Ligand B (0.044) is slightly better than Ligand A (0.268).
15. **Affinity:** Both have very similar and excellent binding affinities (-7.1 and -6.9 kcal/mol). The difference is not substantial enough to be decisive.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Both ligands perform reasonably well on these. However, the significantly higher DILI risk associated with Ligand A is a major red flag. Metabolic stability (Cl_mic and t1/2) are also important, and Ligand B is superior in these aspects.
**Conclusion:**
Despite the slightly better logP of Ligand A, the significantly lower DILI risk, better metabolic stability, and longer half-life of Ligand B make it the more promising drug candidate.
0
2025-04-17 19:27:13,365 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate targeting the ADRB2 receptor:
**Reasoning:**
The ADRB2 receptor is a GPCR involved in cardiovascular function. Therefore, the priorities are logP, TPSA, Pgp efflux, binding affinity, and, to a lesser extent, BBB penetration.
Let's analyze each ligand against these criteria and the general guidelines:
* **Molecular Weight:** Both ligands (352.479 Da and 365.543 Da) fall within the ideal 200-500 Da range.
* **TPSA:** Ligand A (99.33) is higher than Ligand B (43.86). Ligand B is significantly better, being well below the 140 A^2 threshold for good absorption, and closer to the ideal for GPCRs.
* **logP:** Both ligands have acceptable logP values (1.287 and 1.672, respectively), falling within the 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability.
* **H-Bond Donors/Acceptors:** Ligand A has 4 HBD and 3 HBA, while Ligand B has 0 HBD and 4 HBA. Both are within acceptable limits.
* **QED:** Ligand B (0.743) has a better QED score than Ligand A (0.446), indicating a more drug-like profile.
* **DILI:** Ligand B (13.339) has a much lower DILI risk than Ligand A (18.108), which is a significant advantage.
* **BBB:** Ligand B (84.839) has a higher BBB penetration percentile than Ligand A (74.37), although BBB is less critical for a cardiovascular target.
* **Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.921 and -4.875), which is unusual and suggests poor permeability. This is a concern for both.
* **Aqueous Solubility:** Both ligands have negative solubility values (-2.1 and -1.923), indicating very poor aqueous solubility. This is a major drawback for both.
* **hERG Inhibition:** Both ligands have low hERG inhibition liability (0.406 and 0.46, respectively).
* **Microsomal Clearance:** Ligand B (49.757) has a higher microsomal clearance than Ligand A (22.979), meaning it's metabolized faster. This is a disadvantage for Ligand B.
* **In vitro Half-Life:** Ligand A (6.621) has a longer in vitro half-life than Ligand B (-0.55), which is a significant advantage.
* **P-gp Efflux:** Both ligands have low P-gp efflux liability (0.019 and 0.115, respectively).
* **Binding Affinity:** Ligand B (-5.6 kcal/mol) has a significantly better binding affinity than Ligand A (-3.9 kcal/mol). This is a crucial factor, as the >1.5 kcal/mol difference can outweigh other drawbacks.
**Overall Assessment:**
Ligand B demonstrates a substantially stronger binding affinity and a significantly lower DILI risk. While its metabolic clearance is higher and solubility is poor (like Ligand A), the improved affinity and safety profile are compelling. The lower TPSA of Ligand B is also a positive. The Caco-2 and solubility issues would need to be addressed through formulation strategies, but the core pharmacodynamic and safety properties of Ligand B are superior.
Output:
0
2025-04-17 19:27:13,365 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (340.379 and 345.487 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (79.73) is higher than Ligand B (52.65). While both are below 140, the lower TPSA of Ligand B is preferable for better absorption, a key consideration for GPCRs.
3. **logP:** Ligand A (2.713) and Ligand B (1.648) are both within the optimal 1-3 range, but Ligand B is closer to the lower bound. Ligand A's logP is better.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 4 HBAs, and Ligand B has 3. Both are acceptable (<=10).
6. **QED:** Ligand A (0.929) has a significantly better QED score than Ligand B (0.788), indicating a more drug-like profile.
7. **DILI:** Ligand A (82.939) has a higher DILI risk than Ligand B (9.461). This is a major concern for Ligand A.
8. **BBB:** Ligand B (89.066) shows significantly better BBB penetration potential than Ligand A (52.617). While ADRB2 isn't exclusively a CNS target, some CNS exposure is not necessarily detrimental, and higher BBB is generally a plus.
9. **Caco-2:** Both ligands have negative Caco-2 values, suggesting poor permeability. Ligand A (-4.624) is slightly better than Ligand B (-4.986), but both are concerning.
10. **Solubility:** Ligand A (-3.394) has slightly better solubility than Ligand B (-2.053).
11. **hERG:** Ligand A (0.061) has a lower hERG risk than Ligand B (0.477). This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand A (8.428) has a much lower microsomal clearance than Ligand B (18.911), indicating better metabolic stability.
13. **t1/2:** Ligand A (10.092) has a longer in vitro half-life than Ligand B (-1.926). This is a positive for Ligand A.
14. **Pgp:** Ligand A (0.017) has a much lower Pgp efflux liability than Ligand B (0.098). This is beneficial for bioavailability.
15. **Binding Affinity:** Ligand B (-8.2 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.9 kcal/mol). This is a substantial advantage for Ligand B, potentially outweighing some ADME drawbacks.
**Overall Assessment:**
Ligand B has a much better binding affinity, which is paramount for GPCR targets. It also has a much lower DILI risk and better BBB penetration. Although its logP is slightly lower and Caco-2 permeability is concerning, the strong affinity and improved safety profile are more important. Ligand A has better QED, solubility, metabolic stability, and lower Pgp efflux, but the high DILI risk is a major red flag. The difference in binding affinity is also substantial.
Output:
0
2025-04-17 19:27:13,365 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (347.46 and 348.45 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (78.51) is significantly better than Ligand B (100.27). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have acceptable logP values (1.22 and 0.82), falling within the 1-3 range. Ligand A is slightly higher, potentially offering a small advantage in membrane permeability.
4. **HBD:** Ligand A (2) is preferable to Ligand B (3). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (6). Similar to HBD, lower HBA is generally better for permeability.
6. **QED:** Ligand A (0.751) has a better QED score than Ligand B (0.574), indicating a more drug-like profile.
7. **DILI:** Ligand A (15.2%) has a significantly lower DILI risk than Ligand B (17.2%). This is a crucial advantage, as liver toxicity is a major concern in drug development.
8. **BBB:** Ligand A (63.01%) has a better BBB penetration score than Ligand B (40.52%). While ADRB2 is not a CNS target, some peripheral exposure can be advantageous.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.064 and -5.191), which is unusual and suggests poor permeability. This is a significant drawback for both, but the values are similar.
10. **Solubility:** Ligand A (-2.188) has slightly better solubility than Ligand B (-1.401).
11. **hERG:** Both ligands show very low hERG inhibition risk (0.15 and 0.033), which is excellent.
12. **Cl_mic:** Ligand A (-3.626) has a much lower (better) microsomal clearance than Ligand B (15.978). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (-3.962) has a better in vitro half-life than Ligand B (10.435).
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.022 and 0.047).
15. **Binding Affinity:** Ligand A (-6.3 kcal/mol) has a slightly better binding affinity than Ligand B (-5.8 kcal/mol). While the difference is not huge, it's a positive factor.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Ligand A performs better in all of these categories, except for Pgp where they are similar.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical ADME-Tox parameters, including DILI risk, metabolic stability (Cl_mic and t1/2), QED, and TPSA. The slightly better binding affinity further strengthens its position. While both ligands have poor Caco-2 permeability, the other advantages of Ligand A make it the more promising candidate.
Output:
1
2025-04-17 19:27:13,365 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (354.47 & 363.89 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (69.64) is significantly better than Ligand B (81.99). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both are good (2.17 & 3.15), falling within the 1-3 optimal range. Ligand B is slightly higher, which *could* be a minor concern for solubility, but not a dealbreaker.
4. **HBD:** Both have 2 HBD, which is within the acceptable limit of 5.
5. **HBA:** Both have 3 HBA, also within the acceptable limit of 10.
6. **QED:** Both are similar (0.795 vs 0.76), indicating good drug-likeness.
7. **DILI:** Ligand A (18.57) has a *much* lower DILI risk than Ligand B (32.30). This is a significant advantage.
8. **BBB:** Ligand A (83.17) has better BBB penetration than Ligand B (60.76). While not a primary concern for a cardiovascular target, it isn't detrimental.
9. **Caco-2:** Both have negative values (-4.77 and -4.80), which are unusual. The magnitude is similar, so this isn't a differentiating factor.
10. **Solubility:** Ligand A (-1.84) has better aqueous solubility than Ligand B (-4.43). This is a positive.
11. **hERG:** Both are low (0.51 & 0.45), indicating low cardiotoxicity risk.
12. **Cl_mic:** Ligand A (-17.39) has *much* lower microsomal clearance than Ligand B (57.82). This suggests significantly better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (-0.98) has a negative half-life, which is unusual. Ligand B (13.98) has a reasonable half-life. This is a significant negative for Ligand A.
14. **Pgp:** Both are low (0.13), indicating low P-gp efflux.
15. **Binding Affinity:** Both are very similar (-6.2 and -5.8 kcal/mol). The difference of 0.4 kcal/mol is not substantial enough to override other factors.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Both ligands perform reasonably well on logP and Pgp. Ligand A is better on TPSA. The affinity difference is minimal.
**Overall Assessment:**
Ligand A has several key advantages: lower DILI risk, better solubility, and significantly better metabolic stability (lower Cl_mic). While its half-life is unusual, the other benefits outweigh this concern. Ligand B has a more reasonable half-life, but the higher DILI risk and poorer metabolic stability are significant drawbacks.
Output:
1
2025-04-17 19:27:13,366 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [351.407, 114.47 , 1.483, 3. , 7. , 0.544, 78.054, 66.188, -4.833, -3.119, 0.108, 42.129, 16.728, 0.018, -7.1 ]
**Ligand B:** [344.499, 49.41 , 3.136, 1. , 2. , 0.615, 22.489, 67.701, -4.695, -3.144, 0.392, 40.341, -13.123, 0.185, -4.4 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (344.499) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (114.47) is higher than Ligand B (49.41). For a cardiovascular GPCR, TPSA isn't *as* critical as for CNS targets, but lower is still preferred for better absorption. Ligand B is significantly better here.
3. **logP:** Both are within the optimal range (1-3). Ligand B (3.136) is at the higher end, potentially raising solubility concerns, but not dramatically. Ligand A (1.483) is a bit low, potentially impacting membrane permeability.
4. **HBD:** Ligand A (3) is higher than Ligand B (1). Lower is generally better, so Ligand B is preferable.
5. **HBA:** Ligand A (7) is higher than Ligand B (2). Again, lower is better, favoring Ligand B.
6. **QED:** Both have good QED scores (A: 0.544, B: 0.615), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (78.054) has a significantly higher DILI risk than Ligand B (22.489). This is a major concern for Ligand A.
8. **BBB:** Both have reasonable BBB penetration (A: 66.188, B: 67.701), but it's not a primary concern for a cardiovascular target.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Both have negative solubility values, which is also unusual. Again, the scale is not specified.
11. **hERG:** Ligand A (0.108) has a lower hERG risk than Ligand B (0.392), which is a positive.
12. **Cl_mic:** Both have similar microsomal clearance values (A: 42.129, B: 40.341).
13. **t1/2:** Ligand A (16.728) has a longer half-life than Ligand B (-13.123). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.018) shows much lower P-gp efflux than Ligand B (0.185). This is a positive for Ligand A.
15. **Affinity:** Ligand A (-7.1 kcal/mol) has a significantly stronger binding affinity than Ligand B (-4.4 kcal/mol). This is a substantial advantage.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, and affinity. Ligand B excels in TPSA and has a reasonable logP. Ligand A has a better logP, significantly lower Pgp efflux, and *much* stronger affinity. However, the high DILI risk for Ligand A is a major drawback.
**Overall Assessment:**
The significantly stronger binding affinity of Ligand A is very attractive. The lower Pgp efflux is also a plus. However, the substantially higher DILI risk is a major concern. Ligand B has a much better safety profile (lower DILI) and acceptable ADME properties, despite its weaker binding affinity. The difference in affinity (2.7 kcal/mol) is substantial, but the DILI risk for Ligand A is too high to ignore.
Considering the balance of properties, and the importance of safety in drug development, I believe **Ligand B** is the more viable drug candidate.
Output:
0
2025-04-17 19:27:13,366 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (353.4 and 348.4 Da) fall comfortably within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (89.35) is better than Ligand B (102.3). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (0.84 and 0.95), falling within the 1-3 optimal range. Ligand B is slightly higher, which could be marginally better for membrane permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (6) is preferable to Ligand B (4). Lower HBA is generally better for permeability.
6. **QED:** Ligand A (0.81) has a significantly better QED score than Ligand B (0.669), indicating a more drug-like profile overall.
7. **DILI:** Ligand A (55.9) has a higher DILI risk than Ligand B (16.2). This is a significant drawback for Ligand A.
8. **BBB:** Ligand A (84.1) has better BBB penetration than Ligand B (53.9). While not critical for a cardiovascular target, it's a slight positive for A.
9. **Caco-2:** Ligand A (-4.869) is better than Ligand B (-5.221). Higher Caco-2 permeability suggests better intestinal absorption.
10. **Solubility:** Ligand A (-1.511) is better than Ligand B (-1.585). Better solubility is always a plus.
11. **hERG:** Ligand A (0.096) has a lower hERG risk than Ligand B (0.406). This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand B (-19.562) has significantly better metabolic stability (lower clearance) than Ligand A (35.394). This is a major advantage for B.
13. **t1/2:** Ligand A (5.138) has a longer half-life than Ligand B (-1.939). This is a positive for A.
14. **Pgp:** Ligand A (0.103) has lower P-gp efflux than Ligand B (0.021). Lower P-gp efflux is generally favorable.
15. **Binding Affinity:** Ligand A (-7.3) has a slightly better binding affinity than Ligand B (-7.1). While the difference is small (0.2 kcal/mol), it's still a positive for A.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A performs better on logP, TPSA, Pgp, and affinity. However, the significantly lower DILI risk of Ligand B and its superior metabolic stability (Cl_mic) are very important considerations. The difference in binding affinity is small enough that it doesn't outweigh the ADME benefits of Ligand B.
**Overall Assessment:**
Ligand A has a slightly better binding affinity, QED, solubility, and half-life, but suffers from a higher DILI risk and poorer metabolic stability. Ligand B has a much lower DILI risk, better metabolic stability, and acceptable properties across the board. Given the importance of avoiding liver toxicity and ensuring reasonable drug exposure (through metabolic stability), Ligand B is the more promising candidate.
Output:
0
2025-04-17 19:27:13,366 - INFO - Batch 111 complete. Total preferences: 1776
2025-04-17 19:27:13,366 - INFO - Processing batch 112/512...
2025-04-17 19:28:01,543 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [367.427, 99.93, 0.399, 1, 5, 0.763, 66.111, 54.44, -5.205, -2.411, 0.238, 67.283, 33.342, 0.047, -5.8]
**Ligand B:** [363.527, 70.23, 3.756, 3, 3, 0.659, 38.309, 76.347, -4.8, -4.513, 0.562, 69.414, 38.605, 0.106, -5.4]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, BBB, affinity):
1. **MW:** Both are within the ideal 200-500 Da range. A (367.4) and B (363.5) are very similar.
2. **TPSA:** A (99.93) is higher than the preferred <140, but still acceptable. B (70.23) is excellent, well below 140. This favors B.
3. **logP:** A (0.399) is quite low, potentially hindering permeability. B (3.756) is excellent, falling right within the optimal 1-3 range. This strongly favors B.
4. **HBD/HBA:** A (1 HBD, 5 HBA) is good. B (3 HBD, 3 HBA) is also good. No clear advantage.
5. **QED:** A (0.763) is better than B (0.659), indicating a slightly more drug-like profile. This favors A.
6. **DILI:** A (66.111) is higher risk than B (38.309). This strongly favors B.
7. **BBB:** A (54.44) is lower than B (76.347). While ADRB2 isn't a CNS target, some distribution to the CNS is possible, and higher BBB is generally preferable. This favors B.
8. **Caco-2:** Both are negative, indicating poor permeability. A (-5.205) is worse than B (-4.8). This favors B.
9. **Solubility:** Both are negative, indicating poor solubility. A (-2.411) is worse than B (-4.513). This favors B.
10. **hERG:** A (0.238) is better than B (0.562), indicating lower cardiotoxicity risk. This favors A.
11. **Cl_mic:** A (67.283) is slightly lower than B (69.414), suggesting slightly better metabolic stability. This favors A.
12. **t1/2:** B (38.605) has a longer half-life than A (33.342). This favors B.
13. **Pgp:** A (0.047) is much lower than B (0.106), suggesting less P-gp efflux and better bioavailability. This strongly favors A.
14. **Affinity:** A (-5.8) is slightly better than B (-5.4), a 0.4 kcal/mol difference. This favors A.
**Overall Assessment:**
Ligand B consistently outperforms Ligand A in critical ADME properties (logP, TPSA, DILI, BBB, Caco-2, Solubility) and has a longer half-life. While Ligand A has a slightly better affinity and Pgp efflux profile, the ADME liabilities of Ligand A, particularly the low logP and higher DILI risk, are significant concerns for a cardiovascular drug. The 0.4 kcal/mol difference in binding affinity is unlikely to overcome these substantial ADME drawbacks.
Therefore, I would choose Ligand B.
0
2025-04-17 19:28:01,544 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.39 and 356.42 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (104.81) is better than Ligand B (117.12). ADRB2 is a cardiovascular target, so CNS penetration isn't critical, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands (-0.67 and -0.899) are a bit low. Ideally, we want 1-3. This could be a potential issue for permeability, but not a dealbreaker if other properties are favorable. Ligand B is slightly worse.
4. **HBD:** Ligand A (2) is preferable to Ligand B (4). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (6). Similar reasoning as HBD.
6. **QED:** Both ligands (0.389 and 0.419) are below the ideal 0.5, suggesting room for improvement in drug-likeness. Ligand B is slightly better.
7. **DILI:** Ligand A (42.92) is slightly higher than Ligand B (31.64), indicating a slightly higher risk of liver injury. Ligand B is preferable.
8. **BBB:** Ligand A (20.51) is much lower than Ligand B (44.94). While not a primary concern for a cardiovascular target, higher BBB is generally a positive attribute. Ligand B is preferable.
9. **Caco-2:** Both ligands (-5.124 and -5.445) have very poor Caco-2 permeability. This is a significant concern for oral bioavailability.
10. **Solubility:** Ligand A (-2.293) is better than Ligand B (-0.879). Solubility is important for formulation and absorption.
11. **hERG:** Both ligands (0.022 and 0.08) have very low hERG inhibition risk, which is excellent.
12. **Cl_mic:** Ligand A (-8.94) has a much lower (better) microsomal clearance than Ligand B (-0.982), indicating greater metabolic stability.
13. **t1/2:** Ligand A (-15.997) has a much longer (better) in vitro half-life than Ligand B (8.501).
14. **Pgp:** Both ligands (0.024 and 0.02) have very low P-gp efflux liability, which is good.
15. **Binding Affinity:** Ligand A (-5.8) is slightly better than Ligand B (-6.0). The difference is not substantial enough to outweigh other factors.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has better TPSA, Pgp, and metabolic stability. Ligand B has better BBB and DILI. The low logP for both is a concern.
**Overall Assessment:**
Ligand A is the better candidate. While both have poor Caco-2 permeability and suboptimal logP, Ligand A's superior metabolic stability (Cl_mic, t1/2), lower TPSA, and slightly better affinity outweigh the slightly higher DILI risk and lower BBB. The metabolic stability is particularly important for a GPCR target, as it influences duration of action.
Output:
1
2025-04-17 19:28:01,544 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (346.471 and 359.539 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (70.59) is better than Ligand B (35.58) as it is closer to the 140 cutoff, and still reasonable for a non-CNS target.
3. **logP:** Ligand A (2.545) is optimal, while Ligand B (4.478) is pushing the upper limit. Higher logP can lead to off-target effects and solubility issues.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (1), but both are within the acceptable limit of 5.
5. **HBA:** Both ligands have 3 HBA, which is well within the acceptable range.
6. **QED:** Both ligands have good QED scores (0.71 and 0.858), indicating good drug-like properties.
7. **DILI:** Ligand A (17.759) has a significantly lower DILI risk than Ligand B (39.201). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (90.733) has a higher BBB penetration than Ligand A (76.541). However, since ADRB2 is primarily a cardiovascular target, high BBB penetration is not a priority and can even be undesirable.
9. **Caco-2:** Both ligands have negative Caco-2 values, suggesting poor permeability. This is a concern for both.
10. **Solubility:** Both ligands have negative solubility values, indicating poor solubility. This is a concern for both.
11. **hERG:** Ligand A (0.773) has a lower hERG inhibition liability than Ligand B (0.925), which is preferable.
12. **Cl_mic:** Ligand A (32.513) has a lower microsomal clearance than Ligand B (40.292), suggesting better metabolic stability.
13. **t1/2:** Ligand B (65.999) has a longer in vitro half-life than Ligand A (31.986). This is a positive for Ligand B.
14. **Pgp:** Ligand A (0.285) has lower P-gp efflux liability than Ligand B (0.406), which is preferable.
15. **Binding Affinity:** Ligand B (-6.0) has a slightly better binding affinity than Ligand A (-5.9), but the difference is small (0.1 kcal/mol).
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A excels in logP, Pgp, and has a reasonable TPSA. While Ligand B has slightly better affinity, the higher logP, Pgp efflux, and significantly higher DILI risk outweigh this benefit.
**Overall Assessment:**
Ligand A presents a better overall profile, particularly regarding safety (DILI) and ADME properties (Cl_mic, Pgp). The small difference in binding affinity is not enough to overcome the advantages of Ligand A. Both compounds have issues with permeability and solubility that would need to be addressed in further optimization.
Output:
1
2025-04-17 19:28:01,544 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's break down the comparison of Ligand A and Ligand B based on the provided parameters and the guidelines, keeping in mind ADRB2 is a GPCR.
1. **Molecular Weight:** Both ligands (389.807 Da and 358.41 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (72.47) is better than Ligand B (84.94). Both are acceptable, but lower TPSA generally favors better absorption.
3. **logP:** Ligand A (3.42) is within the optimal range (1-3), while Ligand B (0.81) is a bit low, potentially hindering membrane permeability. This is a significant advantage for Ligand A.
4. **H-Bond Donors:** Both have 1 HBD, which is good.
5. **H-Bond Acceptors:** Both have 5 HBA, which is good.
6. **QED:** Ligand A (0.793) has a significantly better QED score than Ligand B (0.513), indicating a more drug-like profile.
7. **DILI:** Ligand B (38.852) has a much lower DILI risk than Ligand A (93.292). This is a major advantage for Ligand B.
8. **BBB:** Ligand B (80.031) has better BBB penetration than Ligand A (68.282), though neither are exceptionally high. For a cardiovascular target, BBB penetration isn't *critical* but can be helpful for off-target effects.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-5.377) has better solubility than Ligand B (-2.174).
11. **hERG:** Ligand A (0.503) has a slightly better hERG profile than Ligand B (0.368), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand B (55.994) has lower microsomal clearance than Ligand A (64.521), suggesting better metabolic stability.
13. **t1/2:** Ligand A (110.724) has a significantly longer in vitro half-life than Ligand B (-25.662). This is a substantial advantage for Ligand A.
14. **Pgp:** Ligand A (0.513) has lower P-gp efflux than Ligand B (0.076), which is preferable.
15. **Binding Affinity:** Ligand A (-6.2 kcal/mol) has a slightly better binding affinity than Ligand B (-5.2 kcal/mol). While the difference is not huge, it's still a positive for Ligand A.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Ligand A performs better in logP, Pgp, and affinity. Ligand B has a better DILI score. The longer half-life of Ligand A is also a significant advantage.
**Overall Assessment:**
While Ligand B has a much better DILI profile, Ligand A has several advantages that outweigh this concern. The better logP, QED, binding affinity, longer half-life, and lower Pgp efflux make it a more promising candidate. The DILI risk of Ligand A is still within a manageable range, and further optimization could potentially reduce it. The poor Caco-2 values are a concern for both, but can be addressed through formulation strategies.
Output:
1
2025-04-17 19:28:01,544 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's break down the comparison of Ligand A and Ligand B based on the provided parameters, keeping in mind the GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key).
1. **Molecular Weight:** Both ligands (359.495 and 349.475 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (66.06) is significantly better than Ligand B (78.51). A lower TPSA generally favors better cell permeability, which is crucial for GPCR targeting. Ligand A is well below the 140 threshold, while B is approaching it.
3. **logP:** Both ligands have good logP values (2.506 and 1.59), falling within the optimal 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability, but not dramatically so.
4. **H-Bond Donors:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **H-Bond Acceptors:** Ligand A (4) is preferable to Ligand B (3). Fewer HBAs also contribute to better permeability.
6. **QED:** Ligand A (0.911) has a substantially higher QED score than Ligand B (0.621), indicating a more drug-like profile overall.
7. **DILI:** Ligand A (41.024) has a slightly higher DILI risk than Ligand B (15.355), but both are within acceptable limits (<60).
8. **BBB:** Ligand A (76.231) shows better BBB penetration potential than Ligand B (69.407), although neither is exceptionally high. This is a moderate consideration for ADRB2, which isn't necessarily a CNS target, but some peripheral ADRB2 activity can be influenced by CNS effects.
9. **Caco-2:** Both have negative Caco-2 values which is unusual. Assuming these are log values, both are poor.
10. **Solubility:** Both ligands have very poor solubility (-2.781 and -2.182). This is a significant drawback for both, and would require formulation strategies.
11. **hERG:** Ligand A (0.792) has a slightly higher hERG risk than Ligand B (0.269), which is a concern.
12. **Cl_mic:** Ligand A (16.353) has a significantly lower microsomal clearance than Ligand B (29.803), suggesting better metabolic stability. This is a major advantage.
13. **t1/2:** Ligand A (-23.425) has a much longer in vitro half-life than Ligand B (-15.962), indicating slower metabolism and potentially less frequent dosing.
14. **Pgp:** Ligand A (0.386) has a lower Pgp efflux liability than Ligand B (0.045), meaning it's less likely to be pumped out of cells, improving bioavailability.
15. **Binding Affinity:** Ligand B (-6.0) has a slightly better binding affinity than Ligand A (-5.1), a difference of 0.9 kcal/mol. While affinity is critical, the other ADME properties are more concerning for Ligand B.
**Overall Assessment:**
Despite the slightly better binding affinity of Ligand B, Ligand A is the more promising candidate. Its superior QED, lower Pgp efflux, better metabolic stability (lower Cl_mic and longer t1/2), and lower TPSA outweigh the slightly higher DILI and hERG risk. The solubility issues are a concern for both, but can be addressed through formulation. The combination of favorable ADME properties makes Ligand A a more likely candidate to translate into a viable drug.
**Output:**
1
2025-04-17 19:28:01,544 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (408.929 Da) is slightly higher than Ligand B (378.46 Da), but both are acceptable.
**2. TPSA:** Ligand A (109.41) is higher than Ligand B (49.41). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower TPSA generally favors better absorption. Ligand B is significantly better here.
**3. logP:** Both ligands have good logP values (A: 2.221, B: 2.644), falling within the optimal range of 1-3. Ligand B is slightly higher, potentially improving membrane permeability.
**4. H-Bond Donors:** Ligand A (2) and Ligand B (1) are both within the acceptable limit of <=5. Ligand B is slightly better.
**5. H-Bond Acceptors:** Ligand A (5) and Ligand B (3) are both within the acceptable limit of <=10. Ligand B is better.
**6. QED:** Ligand A (0.793) has a better QED score than Ligand B (0.595), indicating a more drug-like profile.
**7. DILI Risk:** Ligand A (76.192) has a significantly higher DILI risk than Ligand B (25.165). This is a major concern for Ligand A.
**8. BBB Penetration:** This is less critical for a cardiovascular target, but Ligand B (90.112) has better BBB penetration than Ligand A (65.607).
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.878 and -4.809). This is unusual and suggests poor permeability *in vitro*. However, the values are similar, so this doesn't strongly differentiate them.
**10. Aqueous Solubility:** Both ligands have negative solubility values (-3.6 and -3.232), indicating poor aqueous solubility. This is a concern for both, but again, similar.
**11. hERG Inhibition:** Both ligands show low hERG inhibition risk (A: 0.172, B: 0.431).
**12. Microsomal Clearance:** Ligand A (-9.91) has a much lower (better) microsomal clearance than Ligand B (37.196), suggesting better metabolic stability.
**13. In vitro Half-Life:** Ligand A (116.083) has a significantly longer in vitro half-life than Ligand B (-12.277), which is very desirable.
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (A: 0.17, B: 0.049). Ligand B is slightly better.
**15. Binding Affinity:** Both ligands have similar binding affinities (-6.3 and -6.4 kcal/mol). The difference is negligible.
**Overall Assessment:**
While Ligand A has a better QED, longer half-life, and better metabolic stability, the significantly higher DILI risk is a major red flag. Ligand B, despite a lower QED and shorter half-life, has a much lower DILI risk and a better TPSA. For a cardiovascular GPCR, minimizing toxicity (DILI) is paramount. The slightly better permeability profile of Ligand B (lower TPSA, slightly higher logP) also contributes to its favorability.
Therefore, I prefer Ligand B.
0
2025-04-17 19:28:01,544 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (356.463 and 347.423 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (90.31) is significantly better than Ligand B (120.24). ADRB2 is not a CNS target, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (0.386) is slightly lower than Ligand B (-0.384). Both are a bit low, potentially hindering membrane permeability, but Ligand A is marginally better.
4. **HBD:** Ligand A (2) is better than Ligand B (3). Lower HBD is generally preferred for permeability.
5. **HBA:** Both ligands have the same number of HBA (6), which is acceptable.
6. **QED:** Ligand A (0.693) has a better QED score than Ligand B (0.476), indicating a more drug-like profile.
7. **DILI:** Ligand B (38.193) has a slightly better DILI risk profile than Ligand A (10.392), but both are reasonably low risk.
8. **BBB:** This is less critical for ADRB2, but Ligand B (54.634) has a higher BBB percentile than Ligand A (46.84).
9. **Caco-2:** Ligand A (-4.607) has a much better Caco-2 permeability than Ligand B (-5.823).
10. **Solubility:** Ligand A (-1.267) has a better solubility than Ligand B (-1.884).
11. **hERG:** Ligand A (0.372) has a lower hERG inhibition liability than Ligand B (0.588). This is a significant advantage as it reduces cardiotoxicity risk.
12. **Cl_mic:** Ligand B (-11.655) has a lower (better) microsomal clearance than Ligand A (38.17). This suggests better metabolic stability for Ligand B.
13. **t1/2:** Ligand B (-20.937) has a longer in vitro half-life than Ligand A (-11.73), which is desirable.
14. **Pgp:** Ligand A (0.015) has a much lower Pgp efflux liability than Ligand B (0.003). Lower Pgp is better for bioavailability.
15. **Binding Affinity:** Ligand B (-7.3) has a slightly better binding affinity than Ligand A (-6.2). This is a 1.1 kcal/mol difference, which is substantial.
**Overall Assessment:**
Ligand B has a better binding affinity and metabolic stability (lower Cl_mic, longer t1/2). However, Ligand A excels in several key ADME properties: TPSA, QED, Caco-2 permeability, solubility, and crucially, hERG inhibition. The better hERG profile of Ligand A is a significant advantage for a cardiovascular target like ADRB2, mitigating potential cardiotoxicity. While the affinity difference is notable, the combined improvements in ADME properties, particularly the reduced hERG risk, make Ligand A the more promising candidate.
**Output:**
1
2025-04-17 19:28:01,544 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
Let's systematically compare Ligand A and Ligand B against the provided guidelines, keeping in mind that ADRB2 is a GPCR, so logP, TPSA, Pgp, BBB, and affinity are particularly important.
1. **MW:** Both ligands (370.559 Da and 355.475 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (49.85) is better than Ligand B (57.23). Both are below 140, but lower is preferred for absorption.
3. **logP:** Both ligands have good logP values (2.642 and 2.207), falling within the optimal 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Both have 0 HBD, which is good.
5. **HBA:** Ligand A (4) is slightly better than Ligand B (5). Lower is preferred.
6. **QED:** Both ligands have good QED scores (0.616 and 0.731), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (20.744) has a significantly lower DILI risk than Ligand B (29.857). This is a crucial advantage.
8. **BBB:** Both ligands have good BBB penetration (83.831 and 76.347). Ligand A is slightly better.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale isn't specified, so it's hard to interpret.
10. **Solubility:** Both ligands have negative solubility values, which is also unusual. Again, the scale is unclear.
11. **hERG:** Both ligands have low hERG inhibition liability (0.837 and 0.457), which is excellent. Ligand B is slightly better.
12. **Cl_mic:** Ligand A (75.499) has a higher microsomal clearance than Ligand B (50.037), meaning it's metabolized faster. This is a disadvantage for Ligand A.
13. **t1/2:** Ligand B (37.686) has a significantly longer in vitro half-life than Ligand A (-3.495). This is a major advantage for Ligand B.
14. **Pgp:** Ligand A (0.257) has lower P-gp efflux liability than Ligand B (0.15). Lower is better, so Ligand A is slightly better.
15. **Affinity:** Both ligands have very similar and excellent binding affinities (-6.4 and -6.5 kcal/mol). The difference is negligible.
**Overall Assessment:**
Ligand B has a clear advantage in terms of metabolic stability (lower Cl_mic and significantly longer t1/2). It also has a slightly better QED and hERG profile. While Ligand A has slightly better TPSA and Pgp efflux, the DILI risk is a significant concern. For a GPCR target like ADRB2, metabolic stability is crucial for maintaining therapeutic concentrations. The longer half-life of Ligand B will likely translate to less frequent dosing and better patient compliance.
**Output:**
0
2025-04-17 19:28:01,544 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [342.395, 71.03, 2.15, 2, 5, 0.842, 42.885, 55.176, -4.9, -3.106, 0.841, 51.329, 5.292, 0.388, -7.4]
**Ligand B:** [352.385, 78.09, 1.412, 2, 3, 0.813, 39.201, 71.772, -5.096, -2.525, 0.421, -10.904, -7.804, 0.035, -6.2]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, Affinity, and BBB):
1. **MW:** Both are within the ideal range (200-500 Da). A is 342.4, B is 352.4. No significant difference.
2. **TPSA:** A is 71.03, B is 78.09. Both are acceptable for oral absorption (<140), but A is slightly better.
3. **logP:** A is 2.15, B is 1.412. Both are within the optimal range (1-3), but A is slightly higher and potentially better for membrane permeability.
4. **HBD:** Both have 2 HBD, which is good.
5. **HBA:** A has 5, B has 3. Both are acceptable (<10), B is slightly better.
6. **QED:** Both are good (>=0.5), A is 0.842, B is 0.813. No significant difference.
7. **DILI:** A is 42.885, B is 39.201. Both are good (<40 is ideal, <60 is acceptable). B is slightly better.
8. **BBB:** A is 55.176, B is 71.772. B is significantly better, indicating greater potential for CNS penetration, though this isn't a primary concern for ADRB2 unless targeting CNS effects.
9. **Caco-2:** A is -4.9, B is -5.096. Both are poor, indicating poor intestinal absorption. B is slightly worse.
10. **Solubility:** A is -3.106, B is -2.525. B is slightly better, indicating better aqueous solubility.
11. **hERG:** A is 0.841, B is 0.421. B is significantly better, indicating lower risk of cardiotoxicity, a crucial consideration for a cardiovascular target.
12. **Cl_mic:** A is 51.329, B is -10.904. B is *much* better, indicating significantly improved metabolic stability. This is a major advantage.
13. **t1/2:** A is 5.292, B is -7.804. B is *much* better, indicating a significantly longer half-life.
14. **Pgp:** A is 0.388, B is 0.035. B is significantly better, indicating lower P-gp efflux.
15. **Affinity:** A is -7.4 kcal/mol, B is -6.2 kcal/mol. A has a substantially better binding affinity. This is a significant advantage.
**Overall Assessment:**
Ligand A has a better binding affinity, which is paramount. However, Ligand B demonstrates significantly better ADME properties, particularly in metabolic stability (Cl_mic and t1/2), hERG risk, and P-gp efflux. The improved metabolic stability and reduced hERG risk are very important for a cardiovascular drug. While A's affinity is better, the ADME profile of B is substantially improved, and the affinity difference, while notable, might be surmountable with further optimization. Considering the importance of ADME properties for a viable drug candidate, especially for a cardiovascular target where safety is critical, I believe Ligand B is the more promising candidate.
Output:
0
2025-04-17 19:28:01,545 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (355.463) is slightly lower, which is generally favorable for permeability.
**2. TPSA:** Both ligands have TPSA values around 74, which is acceptable but bordering on the higher side for optimal oral absorption.
**3. logP:** Ligand A (3.532) has a more optimal logP value compared to Ligand B (1.404). A logP between 1-3 is preferred, and Ligand B is a bit low, potentially hindering membrane permeability.
**4. H-Bond Donors & Acceptors:** Ligand A has 3 HBD and 3 HBA, while Ligand B has 0 HBD and 5 HBA. Both are within acceptable limits, but the balance in Ligand A is slightly better.
**5. QED:** Both ligands have similar QED values (0.655 and 0.657), indicating good drug-like properties.
**6. DILI:** Ligand A has a DILI risk of 71.656, which is moderately high. Ligand B has a significantly lower DILI risk (38.736), which is a major advantage.
**7. BBB:** Ligand A has a BBB penetration of 72.974, while Ligand B is at 62.466. Although ADRB2 isn't exclusively a CNS target, some CNS penetration can be beneficial.
**8. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-5.485 and -5.129). This is unusual and suggests poor permeability.
**9. Aqueous Solubility:** Both ligands have negative solubility values (-3.6 and -2.3). This is also concerning and indicates poor aqueous solubility.
**10. hERG Inhibition:** Ligand A (0.583) has a slightly higher hERG inhibition liability than Ligand B (0.185). Lower is better here, so Ligand B is preferable.
**11. Microsomal Clearance:** Ligand A has a higher microsomal clearance (56.996) than Ligand B (15.711), indicating lower metabolic stability. Ligand B is significantly better in this regard.
**12. In vitro Half-Life:** Ligand A has a longer half-life (46.18 hours) than Ligand B (4.376 hours). This is a significant advantage for Ligand A.
**13. P-gp Efflux:** Ligand A (0.441) has lower P-gp efflux liability than Ligand B (0.133), which is favorable.
**14. Binding Affinity:** Ligand A (-6.4 kcal/mol) has a slightly better binding affinity than Ligand B (-5.2 kcal/mol). This is a crucial factor, and the 1.2 kcal/mol difference is substantial.
**GPCR-Specific Priorities:** For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand A has a better logP and Pgp profile, and a significantly better binding affinity. However, Ligand B has a much lower DILI risk and better metabolic stability. The poor solubility and permeability of both are concerning.
**Overall Assessment:**
While Ligand A boasts superior binding affinity and a better logP, the significantly lower DILI risk and improved metabolic stability of Ligand B are compelling. The poor solubility and permeability of both are problematic, but these can be addressed with formulation strategies. Given the importance of minimizing toxicity and maximizing duration of action, the improved safety profile and metabolic stability of Ligand B outweigh the slightly better affinity of Ligand A.
Output:
0
2025-04-17 19:28:01,545 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (332.363) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both ligands are below the 140 A^2 threshold for good oral absorption (A: 90.94, B: 88.49). This is good.
3. **logP:** Ligand A (3.319) is optimal, while Ligand B (0.596) is quite low. Low logP can hinder membrane permeability. This is a significant advantage for A.
4. **HBD:** Both have 2 HBD, which is within the acceptable limit of 5.
5. **HBA:** Ligand A has 5 HBA, and Ligand B has 6. Both are within the acceptable limit of 10.
6. **QED:** Both ligands have similar QED values (A: 0.77, B: 0.68), indicating good drug-likeness.
7. **DILI:** Ligand A (90.268) has a higher DILI risk than Ligand B (34.432). This is a concern for Ligand A.
8. **BBB:** Ligand B (63.086) has a significantly higher BBB penetration percentile than Ligand A (20.512). While ADRB2 isn't strictly a CNS target, some CNS exposure can occur, and higher BBB is generally preferred.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual. However, the magnitude is similar (-5.164 for A, -5.061 for B).
10. **Solubility:** Ligand A (-5.66) has worse solubility than Ligand B (-1.294). Solubility is important for bioavailability.
11. **hERG:** Both ligands have low hERG inhibition risk (A: 0.606, B: 0.224). Ligand B is slightly better here.
12. **Cl_mic:** Ligand A (67.503) has a higher microsomal clearance than Ligand B (17.175), indicating lower metabolic stability. This is a significant drawback for A.
13. **t1/2:** Ligand B (14.433) has a much longer in vitro half-life than Ligand A (-4.847). This is a major advantage for B.
14. **Pgp:** Ligand A (0.278) has lower P-gp efflux than Ligand B (0.017). Lower P-gp efflux is generally preferred.
15. **Binding Affinity:** Ligand B (-6.3 kcal/mol) has a stronger binding affinity than Ligand A (-5.3 kcal/mol). This is a substantial advantage for B, exceeding the 1.5 kcal/mol threshold.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are crucial. Ligand A has a better logP and Pgp, but Ligand B significantly outperforms in affinity and has acceptable TPSA. The lower metabolic stability and solubility of A, coupled with the higher DILI risk, are substantial concerns.
**Overall Assessment:**
Despite the higher DILI risk for Ligand A, the significantly better binding affinity, longer half-life, and lower clearance of Ligand B outweigh the drawbacks. The low logP of Ligand B is a concern, but the superior binding affinity is likely to compensate for this.
Output:
0
2025-04-17 19:28:01,545 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands (345.403 and 349.435 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (89.35) is better than Ligand B (115.98). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have low logP values (0.368 and 0.27). While both are below the optimal 1-3 range, they aren't drastically low.
4. **HBD:** Ligand A (1) is better than Ligand B (4). Lower HBD is generally preferred for better permeability.
5. **HBA:** Ligand A (6) is better than Ligand B (4). Lower HBA is generally preferred for better permeability.
6. **QED:** Both ligands have similar QED values (0.438 and 0.485), indicating moderate drug-likeness.
7. **DILI:** Ligand A (49.903) has a significantly higher DILI risk than Ligand B (16.596). This is a major concern for Ligand A.
8. **BBB:** Ligand A (65.529) has a higher BBB penetration percentile than Ligand B (45.522). While not a primary concern for a cardiovascular target, it's a slight advantage.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.39 and -5.683), which is unusual and suggests very poor permeability.
10. **Solubility:** Both ligands have negative solubility values (-1.75 and -1.501), indicating very poor aqueous solubility.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.19 and 0.112), which is excellent.
12. **Cl_mic:** Ligand A (-10.166) has a much lower (better) microsomal clearance than Ligand B (-1.052), indicating better metabolic stability.
13. **t1/2:** Ligand B (-30.512) has a much longer in vitro half-life than Ligand A (1.99). This is a significant advantage for Ligand B.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.022 and 0.005).
15. **Binding Affinity:** Ligand A (-6.8) has a slightly better binding affinity than Ligand B (-6.4), but the difference is less than 1.5 kcal/mol.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A has better TPSA and slightly better affinity, but Ligand B has a much better half-life and significantly lower DILI risk. The poor Caco-2 and solubility for both are concerning, but the DILI risk for Ligand A is a major red flag.
**Conclusion:**
Despite the slightly better affinity of Ligand A, the significantly lower DILI risk and longer half-life of Ligand B make it the more promising candidate. The poor permeability and solubility are shared issues that would need to be addressed in either case, but the safety profile is paramount.
Output:
0
2025-04-17 19:28:01,545 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (350.459 Da and 352.356 Da) are within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (87.66) is higher than Ligand B (58.2). For a cardiovascular GPCR, TPSA is moderately important, and lower is generally preferred for better permeability. Ligand B has a clear advantage here.
**3. logP:** Ligand A (0.979) is slightly lower than the optimal 1-3 range, while Ligand B (2.298) is well within it. LogP is crucial for GPCRs, and Ligand B is better positioned for good membrane permeability and receptor engagement.
**4. H-Bond Donors:** Ligand A (3) and Ligand B (2) are both acceptable, being less than 5.
**5. H-Bond Acceptors:** Ligand A (4) and Ligand B (2) are both acceptable, being less than 10.
**6. QED:** Ligand B (0.772) has a higher QED score than Ligand A (0.597), indicating a more drug-like profile.
**7. DILI Risk:** Ligand A (35.285) has a lower DILI risk than Ligand B (47.77), which is a significant advantage.
**8. BBB Penetration:** Ligand B (89.957) has significantly better BBB penetration than Ligand A (36.371). While this isn't *essential* for a cardiovascular target, it could be beneficial for off-target effects or potential CNS side effects.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.816 and -4.62). This is unusual and suggests poor permeability *in vitro*. However, the values are very close, so this isn't a major differentiator.
**10. Aqueous Solubility:** Ligand A (-1.905) has better aqueous solubility than Ligand B (-4.006). This is a positive for formulation and bioavailability.
**11. hERG Inhibition:** Ligand A (0.22) has a lower hERG inhibition risk than Ligand B (0.584). This is a critical safety parameter, and Ligand A is preferable.
**12. Microsomal Clearance:** Ligand A (18.944) has higher microsomal clearance than Ligand B (13.114), indicating faster metabolism and potentially a shorter half-life. Ligand B is better here.
**13. In vitro Half-Life:** Ligand B (6.466) has a longer in vitro half-life than Ligand A (-8.172). This is a significant advantage for dosing frequency.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.042 and 0.086).
**15. Binding Affinity:** Ligand B (-6.9 kcal/mol) has a slightly better binding affinity than Ligand A (-5.9 kcal/mol). This 1 kcal/mol difference is substantial and can outweigh some ADME concerns.
**Overall Assessment:**
Ligand B is the better candidate. While Ligand A has advantages in DILI risk and hERG inhibition, Ligand B excels in key GPCR properties like logP, TPSA, QED, and binding affinity. The longer half-life of Ligand B is also a significant benefit. The slightly higher DILI and hERG risks of Ligand B are acceptable given its superior potency and drug-like characteristics.
Output:
0
2025-04-17 19:28:01,545 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
We are targeting ADRB2, a GPCR. Therefore, the key priorities are logP, TPSA, Pgp efflux, BBB penetration, and binding affinity. Let's analyze each ligand against these and other relevant parameters.
* **Molecular Weight:** Both ligands (352.425 and 345.403 Da) fall within the ideal 200-500 Da range.
* **TPSA:** Ligand A (50.36) is significantly better than Ligand B (102.05). A TPSA under 140 is good for oral absorption, but lower is generally preferred for GPCRs, and A is much closer to the ideal range.
* **logP:** Ligand A (4.205) is higher than Ligand B (1.374). While 4.205 is approaching the upper limit of optimal, it's still acceptable, and higher logP can be beneficial for membrane permeability. Ligand B's 1.374 is rather low and might hinder permeation.
* **H-Bond Donors/Acceptors:** Both have 2 HBDs, which is good. Ligand B has 6 HBAs, which is higher than A's 2. Higher HBA can sometimes reduce permeability.
* **QED:** Both are reasonably good (0.834 and 0.789), indicating drug-like properties.
* **DILI:** Ligand A (35.246) has a much lower DILI risk than Ligand B (56.262). This is a significant advantage.
* **BBB:** Ligand A (77.239) has better BBB penetration than Ligand B (55.099). While not exceptionally high, it's a positive attribute for a GPCR target.
* **Caco-2:** Both have negative Caco-2 values which is unusual. It is likely these are logP values.
* **Solubility:** Both have negative solubility values which is unusual. It is likely these are logS values.
* **hERG:** Ligand A (0.494) has a lower hERG risk than Ligand B (0.073). This is a critical safety parameter.
* **Cl_mic:** Ligand A (37.739) has a higher microsomal clearance than Ligand B (17.16). Lower is better for metabolic stability, so Ligand B is preferable here.
* **t1/2:** Ligand A (39.455) has a longer in vitro half-life than Ligand B (7.659). This is a major advantage.
* **Pgp:** Ligand A (0.236) has lower P-gp efflux than Ligand B (0.03). Lower Pgp is better for bioavailability.
* **Binding Affinity:** Ligand B (-7.2 kcal/mol) has a slightly better binding affinity than Ligand A (-7.0 kcal/mol). While a 0.2 kcal/mol difference is not huge, it's a factor.
**Overall Assessment:**
Ligand A demonstrates a better balance of properties, particularly regarding safety (DILI, hERG), permeability (TPSA, logP, Pgp), and metabolic stability (t1/2). While Ligand B has slightly better binding affinity and lower Cl_mic, the advantages of Ligand A in other crucial areas outweigh this difference. The lower DILI and hERG risks are particularly important for a cardiovascular target.
**Output:**
1
2025-04-17 19:28:01,545 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (351.407 and 344.499 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (58.2) is significantly better than Ligand A (114.47). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary goal, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have acceptable logP values (1.483 and 3.2), falling within the 1-3 range. Ligand B is slightly higher, potentially aiding membrane permeability.
4. **HBD:** Ligand A (3) and Ligand B (2) are both acceptable.
5. **HBA:** Ligand A (7) and Ligand B (2) are both acceptable. Ligand B is better here.
6. **QED:** Both ligands have similar, good QED values (0.544 and 0.55).
7. **DILI:** Ligand B (37.069) has a much lower DILI risk than Ligand A (78.054). This is a significant advantage for Ligand B.
8. **BBB:** Both ligands have similar BBB penetration (66.188 and 66.615). Not a major factor for a cardiovascular target.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.833 and -4.927), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Both ligands have negative solubility values (-3.119 and -4.333), indicating very poor aqueous solubility. This is a major drawback for both.
11. **hERG:** Both ligands have low hERG inhibition liability (0.108 and 0.191).
12. **Cl_mic:** Ligand A (42.129) has a lower microsomal clearance than Ligand B (58.109), suggesting better metabolic stability.
13. **t1/2:** Ligand A (16.728) has a longer in vitro half-life than Ligand B (3.03). This is a significant advantage for Ligand A.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.018 and 0.306).
15. **Binding Affinity:** Ligand A (-7.1 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.1 kcal/mol). This is a substantial advantage, potentially outweighing some ADME concerns.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B has better logP and TPSA. Ligand A has a much better binding affinity. The DILI risk is also a critical factor, and Ligand B is significantly better in this regard.
**Overall Assessment:**
While both ligands have concerning solubility and Caco-2 permeability values, the significantly stronger binding affinity of Ligand A (-7.1 vs -6.1) is a major advantage. The longer half-life of Ligand A is also beneficial. The lower DILI risk of Ligand B is attractive, but the potency difference is substantial. Given the importance of affinity for GPCRs, and the fact that formulation strategies can sometimes address solubility issues, I believe Ligand A is the more promising candidate.
Output:
1
2025-04-17 19:28:01,545 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (368.459 Da and 373.519 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (83.05) is slightly higher than Ligand B (70.16). Both are below the 140 A^2 threshold for oral absorption, but Ligand B is preferable due to the lower TPSA.
**3. logP:** Ligand A (-0.152) is slightly below the optimal 1-3 range, potentially hindering permeability. Ligand B (0.083) is closer to the ideal range. Ligand B is favored here.
**4. H-Bond Donors:** Both ligands have 0 HBD, which is good.
**5. H-Bond Acceptors:** Ligand A has 6 HBA, and Ligand B has 5. Both are acceptable, below the 10 threshold.
**6. QED:** Both ligands have acceptable QED values (0.722 and 0.617, respectively), indicating good drug-likeness.
**7. DILI:** Ligand A (55.758) has a higher DILI risk than Ligand B (19.271). This is a significant advantage for Ligand B.
**8. BBB:** Ligand B (70.88) has a better BBB penetration percentile than Ligand A (55.642). While ADRB2 is primarily a cardiovascular target, some CNS off-target effects are possible with GPCRs, and better BBB penetration is generally desirable.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.912 and -4.892), which is unusual and suggests poor permeability. This is a concern for both.
**10. Aqueous Solubility:** Both ligands have negative solubility values (-0.977 and -0.75), indicating very poor aqueous solubility. This is a major drawback for both.
**11. hERG Inhibition:** Ligand A (0.064) has a slightly lower hERG inhibition risk than Ligand B (0.666), which is preferable.
**12. Microsomal Clearance:** Ligand A (20.013) has lower microsomal clearance than Ligand B (27.582), suggesting better metabolic stability.
**13. In vitro Half-Life:** Ligand A (-21.578) has a more negative (and thus worse) in vitro half-life compared to Ligand B (-24.303).
**14. P-gp Efflux:** Ligand A (0.031) has lower P-gp efflux liability than Ligand B (0.025), which is preferable.
**15. Binding Affinity:** Ligand B (-6.8 kcal/mol) has a stronger binding affinity than Ligand A (-5.5 kcal/mol). This is a 1.3 kcal/mol difference, which is substantial and can outweigh some of the ADME drawbacks.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand B is the stronger candidate. It has a better logP, lower TPSA, significantly lower DILI risk, better BBB penetration, and most importantly, a substantially higher binding affinity. While both ligands have poor solubility and Caco-2 permeability, the superior binding affinity and safety profile of Ligand B make it the more promising starting point for further optimization. The improved affinity could potentially allow for a lower dose, mitigating some solubility concerns.
Output:
0
2025-04-17 19:28:01,545 - INFO - Batch 112 complete. Total preferences: 1792
2025-04-17 19:28:01,545 - INFO - Processing batch 113/512...
2025-04-17 19:28:48,794 - INFO - Here's my reasoning and final output:
**Reasoning:**
Both ligands are reasonably drug-like, with QED values above 0.7. The target is ADRB2, a GPCR, so I will prioritize logP, TPSA, Pgp, BBB, and binding affinity.
* **Molecular Weight:** Both are within the ideal range (200-500 Da).
* **TPSA:** Both are below the 140 A^2 threshold for good absorption.
* **logP:** Ligand A (3.483) is better than Ligand B (1.447). While 1.447 isn't terrible, 3.483 is closer to the optimal 1-3 range and will likely have better membrane permeability.
* **H-Bond Donors/Acceptors:** Both have acceptable numbers of HBD and HBA.
* **DILI:** Ligand B (11.516) has a significantly lower DILI risk than Ligand A (33.307), which is a major advantage.
* **BBB:** Both have similar BBB penetration (around 50%), which isn't exceptionally high, but acceptable for a peripherally acting GPCR like ADRB2.
* **Caco-2:** Both have negative Caco-2 values, which is unusual. I will assume these represent low permeability.
* **Solubility:** Ligand B (-0.183) is slightly better than Ligand A (-1.834), but both are poor.
* **hERG:** Both have low hERG inhibition risk.
* **Microsomal Clearance:** Ligand A (9.457) has significantly lower microsomal clearance than Ligand B (18.459), suggesting better metabolic stability.
* **In vitro Half-Life:** Ligand A (54.01) has a much longer half-life than Ligand B (0.818), which is a significant advantage.
* **P-gp Efflux:** Ligand A (0.082) has lower P-gp efflux than Ligand B (0.036), which is favorable.
* **Binding Affinity:** Ligand B (-5.6 kcal/mol) has a slightly better binding affinity than Ligand A (-5.4 kcal/mol), but the difference is small.
**Overall Assessment:**
Ligand A has a better logP, lower Cl_mic, longer half-life, and lower P-gp efflux. Ligand B has a significantly lower DILI risk. Considering the importance of metabolic stability and half-life for *in vivo* efficacy, and the relatively small difference in binding affinity, Ligand A appears to be the more promising candidate despite the higher DILI risk. The DILI risk, while not ideal, is still below the 60% threshold considered high risk. The improved pharmacokinetic properties of Ligand A are likely to translate to better *in vivo* exposure and efficacy.
**Output:**
1
2025-04-17 19:28:48,795 - INFO - Here's my reasoning and the final output:
**Reasoning:**
We are evaluating two ligands for the ADRB2, a cardiovascular GPCR. Therefore, the key properties to prioritize are binding affinity, logP, TPSA, Pgp efflux, and to a lesser extent, BBB.
Let's break down each ligand:
**Ligand A:**
* **MW:** 371.815 Da - Good, within the ideal range.
* **TPSA:** 51.39 - Good, well below the 140 threshold.
* **logP:** 3.679 - Excellent, within the optimal range.
* **HBD:** 0 - Acceptable, low.
* **HBA:** 5 - Acceptable, within the limit.
* **QED:** 0.775 - Excellent, highly drug-like.
* **DILI:** 57.968 - Moderate, but acceptable.
* **BBB:** 97.906 - Excellent, very high BBB penetration.
* **Caco-2:** -4.581 - Poor, suggests poor absorption.
* **Solubility:** -3.931 - Poor, suggests poor solubility.
* **hERG:** 0.929 - Low risk, good.
* **Cl_mic:** 24.251 - Moderate, could be better.
* **t1/2:** -16.794 - Very poor, extremely short half-life.
* **Pgp:** 0.627 - Low efflux, good.
* **Affinity:** -6.2 kcal/mol - Good binding affinity.
**Ligand B:**
* **MW:** 357.426 Da - Good, within the ideal range.
* **TPSA:** 98.74 - High, above the preferred 140 threshold.
* **logP:** 0.261 - Poor, below the optimal range, may hinder permeation.
* **HBD:** 3 - Acceptable, moderate.
* **HBA:** 4 - Acceptable, within the limit.
* **QED:** 0.58 - Acceptable, moderately drug-like.
* **DILI:** 18.302 - Excellent, very low DILI risk.
* **BBB:** 65.413 - Moderate, not ideal for a GPCR.
* **Caco-2:** -5.24 - Poor, suggests poor absorption.
* **Solubility:** -1.105 - Poor, suggests poor solubility.
* **hERG:** 0.058 - Very low risk, excellent.
* **Cl_mic:** -15.58 - Excellent, very low clearance.
* **t1/2:** 0.574 - Very poor, extremely short half-life.
* **Pgp:** 0.012 - Very low efflux, excellent.
* **Affinity:** -6.6 kcal/mol - Excellent, slightly better binding affinity than Ligand A.
**Comparison and Decision:**
Both ligands have significant drawbacks in terms of solubility, Caco-2 permeability, and in vitro half-life. However, Ligand B has a slightly better binding affinity (-6.6 vs -6.2 kcal/mol). While Ligand A has better BBB penetration, the ADRB2 is a cardiovascular target, so high BBB penetration is less crucial. Ligand B also has a significantly lower DILI risk and lower Pgp efflux. The slightly better affinity and significantly improved safety profile of Ligand B outweigh the moderate BBB score.
Therefore, I prefer Ligand B.
**Output:**
0
2025-04-17 19:28:48,795 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (355.435 and 348.418 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand B (67.43) is significantly better than Ligand A (116.76). ADRB2 is not a CNS target, but lower TPSA generally improves absorption.
3. **logP:** Ligand B (2.48) is within the optimal 1-3 range, while Ligand A (-0.545) is below 1, potentially hindering permeation. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (4) is acceptable, and Ligand B (2) is even better, both being <=5.
5. **HBA:** Ligand A (5) is acceptable, and Ligand B (3) is even better, both being <=10.
6. **QED:** Ligand B (0.795) is better than Ligand A (0.443), indicating a more drug-like profile.
7. **DILI:** Ligand B (40.83) is slightly higher than Ligand A (15.626), but both are below the concerning threshold of 60. Ligand A is preferable here.
8. **BBB:** Not a primary concern for ADRB2, but Ligand B (89.841) is higher than Ligand A (39.162).
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand B (-4.523) is slightly less negative than Ligand A (-5.623), suggesting marginally better absorption.
10. **Solubility:** Ligand A (-0.313) is slightly better than Ligand B (-3.925), but both are very poor.
11. **hERG:** Ligand A (0.115) is preferable to Ligand B (0.538) as it has a lower hERG inhibition liability.
12. **Cl_mic:** Ligand A (-11.834) has a much lower (better) microsomal clearance than Ligand B (17.358), indicating better metabolic stability.
13. **t1/2:** Ligand B (22.38) has a significantly longer in vitro half-life than Ligand A (13.081), which is a desirable trait.
14. **Pgp:** Ligand A (0.004) has a much lower Pgp efflux liability than Ligand B (0.178), which is preferable.
15. **Binding Affinity:** Ligand B (-7.2) has a significantly stronger binding affinity than Ligand A (-5.8). This is a substantial advantage, potentially outweighing some ADME concerns.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP and affinity, while Ligand A is better in Pgp and has a slight edge in DILI and hERG. Ligand B's superior affinity is a major driver, and its better TPSA is also beneficial. The longer half-life is also a positive. While the solubility and Caco-2 values are poor for both, the strong binding and favorable logP of Ligand B are more critical for initial optimization.
**Conclusion:**
Despite some drawbacks in solubility and Caco-2 permeability, Ligand B's significantly stronger binding affinity, better logP, QED, and half-life make it the more promising candidate for further development as an ADRB2 ligand.
Output:
0
2025-04-17 19:28:48,795 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (359.344 and 343.431 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (66.84) is significantly better than Ligand B (80.12). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary goal, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (2.967 and 1.13), falling within the 1-3 optimal range. Ligand A is slightly higher, which *could* be beneficial for membrane permeability, but isn't a major concern.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 3 HBA, while Ligand B has 5. Ligand A is preferable here, staying within the desired range.
6. **QED:** Both ligands have acceptable QED values (0.898 and 0.785), indicating good drug-likeness. Ligand A is slightly better.
7. **DILI:** Ligand A (39.085) has a significantly lower DILI risk than Ligand B (51.493). This is a crucial factor, as liver toxicity is a major concern in drug development.
8. **BBB:** While not a primary concern for a cardiovascular target, Ligand A (83.56) has better BBB penetration than Ligand B (70.57).
9. **Caco-2:** Ligand A (-4.664) is better than Ligand B (-5.33), indicating better intestinal absorption.
10. **Solubility:** Both ligands have poor solubility (-2.349 and -2.448). This is a potential issue for both, but not a deciding factor.
11. **hERG:** Both ligands have low hERG inhibition liability (0.338 and 0.106), which is good.
12. **Cl_mic:** Ligand A (-1.473) has a *much* lower (better) microsomal clearance than Ligand B (33.363). This indicates significantly better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (-20.505) has a longer half-life than Ligand B (-1.647). This is a significant advantage, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have low P-gp efflux (0.091 and 0.071), which is good.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.6 and -6.8 kcal/mol). The difference is negligible.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, and affinity are important. Ligand A performs better on TPSA and has a slightly better logP. The difference in affinity is minimal. However, the significant advantages of Ligand A in DILI risk and metabolic stability (Cl_mic and t1/2) are critical.
**Conclusion:**
Ligand A is the superior candidate due to its lower DILI risk, significantly improved metabolic stability, longer half-life, better TPSA, and comparable binding affinity. While both have solubility issues, the other advantages of Ligand A outweigh this concern.
Output:
1
2025-04-17 19:28:48,795 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A:**
* **MW:** 369.443 Da - Acceptable.
* **TPSA:** 97.83 - Acceptable, but approaching the upper limit for good absorption.
* **logP:** 0.369 - Low. Could lead to poor membrane permeability.
* **HBD:** 1 - Good.
* **HBA:** 7 - Good.
* **QED:** 0.665 - Good, drug-like.
* **DILI:** 72.082 - Moderate risk.
* **BBB:** 23.187 - Low. Not a concern for a cardiovascular target, but limits CNS potential.
* **Caco-2:** -5.061 - Very poor permeability.
* **Solubility:** -1.232 - Poor solubility.
* **hERG:** 0.024 - Very low risk.
* **Cl_mic:** 9.186 - Low, good metabolic stability.
* **t1/2:** 4.911 - Moderate half-life.
* **Pgp:** 0.021 - Low efflux, good.
* **Affinity:** -5.6 kcal/mol - Good binding affinity.
**Ligand B:**
* **MW:** 381.929 Da - Acceptable.
* **TPSA:** 62.3 - Excellent, promotes good absorption.
* **logP:** 2.882 - Optimal.
* **HBD:** 1 - Good.
* **HBA:** 4 - Good.
* **QED:** 0.853 - Excellent, very drug-like.
* **DILI:** 31.02 - Low risk.
* **BBB:** 76.658 - Good, potentially useful if CNS effects are desired.
* **Caco-2:** -5.088 - Very poor permeability.
* **Solubility:** -3.12 - Very poor solubility.
* **hERG:** 0.255 - Low risk.
* **Cl_mic:** 32.82 - Moderate clearance, less ideal than Ligand A.
* **t1/2:** -1.469 - Very short half-life.
* **Pgp:** 0.279 - Low efflux, good.
* **Affinity:** -7.1 kcal/mol - Excellent binding affinity, 1.5 kcal/mol stronger than Ligand A.
**Comparison & Decision:**
Both ligands have significant solubility and permeability issues (negative Caco-2 and solubility values). However, Ligand B has a substantially better binding affinity (-7.1 vs -5.6 kcal/mol). This 1.5 kcal/mol difference is significant, and can often outweigh moderate ADME deficiencies, especially if formulation strategies can be employed to address solubility. Ligand B also has a better QED score, lower DILI risk, and a more optimal logP. While Ligand A has better metabolic stability (lower Cl_mic), the stronger binding of Ligand B is a more critical factor for a GPCR target like ADRB2. The half-life of Ligand B is a concern, but can be addressed in later optimization stages.
Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity), Ligand B is the better candidate.
**Output:**
0
2025-04-17 19:28:48,795 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (343.358 Da) is slightly lower, which is generally favorable for permeability.
**2. TPSA:** Both ligands are below the 140 A^2 threshold for good oral absorption. Ligand B (67.34 A^2) is better than Ligand A (75.48 A^2), which is good for GPCRs.
**3. logP:** Both ligands have logP values within the optimal range (1-3). Ligand B (2.98) is slightly lower than Ligand A (3.217), which is slightly better.
**4. H-Bond Donors:** Ligand A has 1 HBD, while Ligand B has 0. Both are acceptable.
**5. H-Bond Acceptors:** Both ligands have 4 HBAs, which is within the acceptable range.
**6. QED:** Both ligands have QED values above 0.5, indicating good drug-likeness. Ligand B (0.744) is slightly better than Ligand A (0.686).
**7. DILI Risk:** Ligand A has a DILI risk of 80.729%, which is high. Ligand B has a DILI risk of 31.718%, which is much lower and a significant advantage.
**8. BBB Penetration:** Both ligands have good BBB penetration, but Ligand B (87.67%) is better than Ligand A (77.898%). While ADRB2 is a cardiovascular target, some CNS off-target effects are possible with GPCRs, so some BBB penetration is not necessarily a negative.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability.
**10. Aqueous Solubility:** Both ligands have negative solubility values, which is also unusual and suggests poor solubility.
**11. hERG Inhibition:** Ligand A (0.805) has a slightly higher hERG inhibition risk than Ligand B (0.476), which is a concern.
**12. Microsomal Clearance:** Ligand A (47.249 mL/min/kg) has lower clearance than Ligand B (63.122 mL/min/kg), suggesting better metabolic stability.
**13. In vitro Half-Life:** Ligand B (-2.383 hours) has a negative half-life, which is not possible. Ligand A (43.594 hours) has a good half-life.
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability. Ligand A (0.42) is slightly lower than Ligand B (0.533).
**15. Binding Affinity:** Ligand A (-9.4 kcal/mol) has a significantly stronger binding affinity than Ligand B (-5.1 kcal/mol). This is a substantial advantage, potentially outweighing some ADME drawbacks.
**Overall Assessment:**
Ligand A has a much stronger binding affinity, a better half-life, and lower P-gp efflux. However, it has a significantly higher DILI risk and slightly higher hERG inhibition. Ligand B has a much better safety profile (lower DILI, lower hERG), better TPSA, and better BBB penetration, but its binding affinity is considerably weaker.
Given the cardiovascular target and the importance of minimizing off-target effects and toxicity, the lower DILI risk of Ligand B is a critical factor. While the affinity difference is substantial, it's not insurmountable in a lead optimization campaign. The poor solubility and permeability of both compounds would need to be addressed, but the safety profile of Ligand B makes it a more promising starting point.
Output:
0
2025-04-17 19:28:48,795 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.35 Da and 360.445 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (109.42) is higher than Ligand B (49.85). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B is significantly better here.
3. **logP:** Ligand A (-0.894) is lower than the optimal 1-3 range, potentially hindering permeability. Ligand B (2.196) is within the optimal range. Ligand B is clearly superior.
4. **HBD:** Ligand A (3) is within the acceptable limit of 5. Ligand B (0) is excellent.
5. **HBA:** Ligand A (5) is within the acceptable limit of 10. Ligand B (3) is also good.
6. **QED:** Both ligands have reasonable QED scores (0.32 and 0.624), but Ligand B is better.
7. **DILI:** Ligand A (44.126) has a moderate DILI risk, while Ligand B (21.287) has a much lower risk. This is a significant advantage for Ligand B.
8. **BBB:** Both have good BBB penetration, but Ligand B (93.68) is higher than Ligand A (83.87). While ADRB2 isn't a CNS target, higher BBB penetration can sometimes correlate with better overall distribution.
9. **Caco-2:** Ligand A (-5.473) is very poor, indicating poor intestinal absorption. Ligand B (-4.347) is also poor, but slightly better.
10. **Solubility:** Both ligands have poor aqueous solubility (-2.058 and -1.705). This is a concern for both, but not a deciding factor.
11. **hERG:** Ligand A (0.198) has a slightly better hERG profile than Ligand B (0.722), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand A (-1.077) has a lower (better) microsomal clearance than Ligand B (42.145), suggesting better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (-8.999) has a very short half-life, which is a major drawback. Ligand B (9.985) has a better half-life.
14. **Pgp:** Ligand A (0.006) has very low P-gp efflux, which is good. Ligand B (0.294) is also low, but higher than A.
15. **Binding Affinity:** Ligand A (-7.6) has a slightly better binding affinity than Ligand B (-6.2). This is a 1.4 kcal/mol difference, which is significant.
**Overall Assessment:**
Ligand A has the advantage in binding affinity and metabolic stability (Cl_mic and Pgp) but suffers from very poor Caco-2 permeability and a short half-life. Ligand B has better physicochemical properties (logP, TPSA, solubility) and a lower DILI risk, but its binding affinity is weaker.
Given that ADRB2 is a cardiovascular target, metabolic stability and potency are important, but absorption is also crucial. The poor Caco-2 and short half-life of Ligand A are major concerns that would likely hinder its development. While the affinity difference is notable, the ADME profile of Ligand B is more promising, particularly the lower DILI risk and better logP.
Therefore, I would choose Ligand B.
Output:
0
2025-04-17 19:28:48,795 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (364.433 and 359.455 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (87.66) is slightly higher than Ligand B (77.05). Both are below the 140 threshold for good oral absorption, but closer to the 90 threshold for CNS targets (less relevant for ADRB2, a cardiovascular target). Ligand B is preferable here.
3. **logP:** Ligand A (1.466) is within the optimal range (1-3), while Ligand B (2.986) is towards the higher end. Both are acceptable, but A is slightly better balanced.
4. **HBD:** Ligand A (3) is higher than Ligand B (0). While both are acceptable (<=5), lower HBD is generally preferred for better permeability, making B slightly better.
5. **HBA:** Ligand A (4) is lower than Ligand B (7). Again, lower is generally better for permeability. A is preferable.
6. **QED:** Both ligands have similar QED values (0.609 and 0.648), indicating good drug-likeness. No significant difference.
7. **DILI:** Ligand A (28.926) has a significantly lower DILI risk than Ligand B (59.17). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (66.072) has a higher BBB penetration than Ligand B (57.154). While not a primary concern for a cardiovascular target, higher BBB is generally favorable.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.049 and -5.222), which is unusual and suggests poor permeability. This is a significant drawback for both.
10. **Solubility:** Both ligands have similar, very poor aqueous solubility (-1.944 and -1.921). This is a major concern for both.
11. **hERG:** Both ligands have similar, low hERG inhibition risk (0.545 and 0.585). No significant difference.
12. **Cl_mic:** Ligand A (26.621) has a lower microsomal clearance than Ligand B (73.457), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (-1.322) has a negative in vitro half-life, which is highly unfavorable. Ligand B (-34.266) is even worse. Both are extremely poor.
14. **Pgp:** Both ligands have similar, low P-gp efflux liability (0.03 and 0.258). No significant difference.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.3 and -6.1 kcal/mol). The difference is negligible.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are important. While both ligands have acceptable logP and similar affinity, Ligand B has a lower TPSA. However, the significantly lower DILI risk and better metabolic stability (lower Cl_mic) of Ligand A, combined with slightly better BBB penetration, outweigh the TPSA advantage of Ligand B. The extremely poor half-lives of both are a major concern, but this is something that can be addressed in later optimization stages.
**Conclusion:**
Despite the poor Caco-2 and solubility, Ligand A's superior safety profile (DILI) and metabolic stability make it the more promising candidate.
Output:
1
2025-04-17 19:28:48,795 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (378.332 and 380.457 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (116.31) is slightly higher than Ligand B (86.71). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is generally preferred for absorption. Ligand B has a clear advantage.
3. **logP:** Both ligands (0.738 and 0.658) are reasonably within the optimal 1-3 range, but on the lower side. This might suggest potential permeability issues, but is not a major concern.
4. **HBD:** Both ligands have 2 HBD, which is within the acceptable limit of <=5.
5. **HBA:** Ligand A has 6 HBA, while Ligand B has 4. Both are within the acceptable limit of <=10.
6. **QED:** Ligand A (0.769) has a better QED score than Ligand B (0.615), indicating a more drug-like profile.
7. **DILI:** Ligand B (24.544) has a significantly lower DILI risk than Ligand A (90.733). This is a major advantage for Ligand B.
8. **BBB:** Ligand B (76.231) has a higher BBB penetration percentile than Ligand A (65.413). While ADRB2 isn't a primary CNS target, some brain exposure is possible, and higher BBB is generally favorable.
9. **Caco-2:** Ligand A (-5.133) and Ligand B (-4.924) both have negative Caco-2 values, which is unusual and suggests poor permeability.
10. **Solubility:** Ligand A (-3.268) has slightly better solubility than Ligand B (-1.839), but both are poor.
11. **hERG:** Ligand A (0.153) has a lower hERG risk than Ligand B (0.402). This is a positive for Ligand A.
12. **Cl_mic:** Ligand B (17.598) has a significantly higher microsomal clearance than Ligand A (2.69). This indicates lower metabolic stability for Ligand B.
13. **t1/2:** Ligand A (4.377) has a better in vitro half-life than Ligand B (-20.137). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.093) has lower P-gp efflux liability than Ligand B (0.107).
15. **Binding Affinity:** Ligand B (-7.6) has a significantly stronger binding affinity than Ligand A (-5.2). This is a substantial advantage, potentially outweighing some ADME concerns.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), affinity, logP, TPSA, and Pgp are key. Ligand B excels in affinity, has a better TPSA, and comparable logP. The higher DILI risk and poorer metabolic stability are concerning for Ligand B, but the substantial binding affinity advantage is likely to be critical.
**Overall Assessment:**
Ligand B's significantly stronger binding affinity (-7.6 vs -5.2 kcal/mol) is the most important factor. While Ligand A has better QED, DILI, metabolic stability, and half-life, the potency difference is large enough to potentially overcome these issues through further optimization. The slightly better TPSA and BBB of Ligand B are also beneficial.
Output:
0
2025-04-17 19:28:48,796 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.397 and 341.455 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (59.81) is better than Ligand B (62.3). Both are below the 140 A^2 threshold for good oral absorption, but closer to the ideal for GPCRs.
3. **logP:** Ligand A (3.16) is slightly higher than Ligand B (2.479), both are within the optimal 1-3 range.
4. **HBD:** Both ligands have 1 HBD, which is excellent.
5. **HBA:** Ligand A has 4 HBA, while Ligand B has 3. Both are within the acceptable range of <=10.
6. **QED:** Ligand A (0.927) has a significantly higher QED score than Ligand B (0.829), indicating better overall drug-likeness.
7. **DILI:** Ligand A (63.086) has a higher DILI risk than Ligand B (21.714). This is a significant negative for Ligand A.
8. **BBB:** Ligand A (93.563) has a much higher BBB penetration percentile than Ligand B (71.888). While ADRB2 isn't *necessarily* a CNS target, higher BBB penetration can sometimes correlate with better distribution and reduced off-target effects.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.582) is slightly better than Ligand B (-4.845).
10. **Solubility:** Ligand A (-4.24) has a slightly better solubility score than Ligand B (-2.069), though both are poor.
11. **hERG:** Ligand A (0.677) has a lower hERG inhibition liability than Ligand B (0.433), which is favorable.
12. **Cl_mic:** Ligand B (56.703) has a lower microsomal clearance than Ligand A (35.407), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-21.805) has a much longer in vitro half-life than Ligand A (19.274). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.234) has lower P-gp efflux liability than Ligand B (0.168), which is favorable.
15. **Binding Affinity:** Ligand B (-6.4 kcal/mol) has a slightly better binding affinity than Ligand A (-5.4 kcal/mol). This is a 1.0 kcal/mol difference, which is substantial.
**Overall Assessment and GPCR-Specific Priorities:**
For a GPCR like ADRB2, affinity, logP, TPSA, and metabolic stability are key. Ligand B excels in binding affinity and has better metabolic stability (lower Cl_mic, longer t1/2). While Ligand A has a better QED and BBB, the significantly lower DILI risk of Ligand B and its superior binding affinity outweigh these advantages. The poor Caco-2 and solubility are concerning for both, but can be addressed through formulation strategies. The improved affinity of Ligand B is likely to translate to a lower required dose, potentially mitigating some of the permeability issues.
Output:
0
2025-04-17 19:28:48,796 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (366.571 and 368.499 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (58.2) is significantly better than Ligand B (87.66). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (3.81) is optimal, while Ligand B (0.991) is a bit low. A logP below 1 can hinder membrane permeability.
4. **HBD:** Both ligands have acceptable HBD counts (2 and 3 respectively), well within the limit of 5.
5. **HBA:** Ligand A (3) is better than Ligand B (5), keeping within the preferable range of <=10.
6. **QED:** Both ligands have similar and acceptable QED values (0.642 and 0.689, respectively).
7. **DILI:** Ligand A (19.271) has a much lower DILI risk than Ligand B (48.313). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (70.415) has better BBB penetration than Ligand B (28.189), but since this is a cardiovascular target, this isn't a major deciding factor.
9. **Caco-2:** Ligand A (-4.988) and Ligand B (-5.505) are similar, indicating comparable intestinal absorption.
10. **Solubility:** Ligand A (-4.118) is better than Ligand B (-2.175). Better solubility is generally preferred.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.379 and 0.118 respectively).
12. **Cl_mic:** Ligand A (82.533) has a higher microsomal clearance than Ligand B (11.127), meaning it's metabolized faster. This is a disadvantage for Ligand A.
13. **t1/2:** Ligand B (19.044) has a longer in vitro half-life than Ligand A (10.375), which is preferable.
14. **Pgp:** Ligand A (0.146) has lower P-gp efflux than Ligand B (0.049), which is favorable.
15. **Binding Affinity:** Ligand B (-7.2 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.0 kcal/mol). This is a substantial advantage that can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand B has a significantly better binding affinity, a longer half-life, and lower microsomal clearance. While Ligand A has better TPSA, solubility, and lower DILI risk, the stronger binding of Ligand B is a crucial advantage for a GPCR target. The difference in binding affinity (-1.2 kcal/mol) is substantial and likely to translate to greater efficacy. The slightly lower logP of Ligand B is a minor concern, but can potentially be addressed through further optimization. The DILI risk of Ligand B is acceptable.
Therefore, I favor Ligand B.
Output:
0
2025-04-17 19:28:48,796 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [358.427, 94.82, 1.837, 1, 8, 0.618, 89.259, 58.007, -5.419, -2.723, 0.262, 48.016, -17.189, 0.358, -7.4]
**Ligand B:** [364.467, 95.5, 0.807, 3, 5, 0.634, 41.411, 20.512, -5.608, -2.486, 0.053, 37.631, 1.751, 0.168, -6.7]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (358.427) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are reasonably good (94.82 and 95.5), being under 140, but not ideal for CNS penetration if that were a goal.
3. **logP:** Ligand A (1.837) is better than Ligand B (0.807). ADRB2 is a cardiovascular target, so strong CNS penetration isn't essential, but a logP in the 1-3 range is preferred for good absorption and distribution. Ligand B is a bit low.
4. **HBD/HBA:** Ligand A (1 HBD, 8 HBA) is better than Ligand B (3 HBD, 5 HBA). Lower numbers are generally preferred for better permeability.
5. **QED:** Both are similar and acceptable (0.618 and 0.634), indicating good drug-like properties.
6. **DILI:** Ligand A (89.259) has a significantly higher DILI risk than Ligand B (41.411). This is a major concern.
7. **BBB:** Ligand A (58.007) has a higher BBB penetration potential than Ligand B (20.512), but as this is a cardiovascular target, this isn't a primary driver.
8. **Caco-2:** Both are negative, indicating poor permeability.
9. **Solubility:** Both are negative, indicating poor solubility.
10. **hERG:** Ligand A (0.262) has a slightly higher hERG risk than Ligand B (0.053), but both are relatively low.
11. **Cl_mic:** Ligand B (37.631) has lower microsomal clearance than Ligand A (48.016), suggesting better metabolic stability.
12. **t1/2:** Ligand A (-17.189) has a negative half-life, which is concerning. Ligand B (1.751) has a short, but positive half-life.
13. **Pgp:** Ligand A (0.358) has lower P-gp efflux than Ligand B (0.168), which is favorable.
14. **Affinity:** Ligand A (-7.4 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.7 kcal/mol). This is a 0.7 kcal/mol difference, which is substantial.
**GPCR-specific priorities:** For ADRB2 (a cardiovascular GPCR), we prioritize logP, Pgp, TPSA, and affinity. Affinity is the most important.
**Conclusion:**
Despite the stronger affinity of Ligand A, the significantly higher DILI risk and negative half-life are major red flags. Ligand B, while having a weaker affinity, has a much better safety profile (lower DILI) and a positive half-life, and acceptable logP. The difference in affinity, while significant, can potentially be addressed through further optimization. The safety concerns with Ligand A are harder to fix.
Therefore, I would choose Ligand B.
0
2025-04-17 19:28:48,796 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (358.316 and 365.499 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (68.73) is significantly better than Ligand B (102.22). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (2.358) is optimal, while Ligand B (1.101) is on the lower side. A logP between 1-3 is preferred, and Ligand A is closer to this.
4. **HBD:** Ligand A (0) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Both ligands have 5 HBA, which is acceptable.
6. **QED:** Ligand A (0.756) is better than Ligand B (0.64), indicating a more drug-like profile.
7. **DILI:** Ligand A (68.592) has a higher DILI risk than Ligand B (23.846). This is a significant drawback for Ligand A.
8. **BBB:** Ligand A (90.772) has a higher BBB penetration than Ligand B (27.646). While not critical for a cardiovascular target, it doesn't hurt.
9. **Caco-2:** Ligand A (-4.122) is better than Ligand B (-5.621), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-3.429) is better than Ligand B (-1.899), which is important for bioavailability.
11. **hERG:** Ligand A (0.434) has a lower hERG risk than Ligand B (0.729), which is a significant advantage.
12. **Cl_mic:** Ligand A (85.244) has a higher microsomal clearance than Ligand B (-3.899). Ligand B has a negative value, indicating *lower* clearance and thus better metabolic stability.
13. **t1/2:** Ligand A (-44.817) has a much shorter in vitro half-life than Ligand B (-24.771). This is a major disadvantage for Ligand A.
14. **Pgp:** Ligand A (0.223) has lower P-gp efflux than Ligand B (0.075), which is a slight advantage.
15. **Affinity:** Ligand B (-7.1) has a slightly better binding affinity than Ligand A (-6.9). While the difference is small, it's still a factor.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A is better on logP, TPSA, and Pgp. Ligand B has a slightly better affinity. However, the significantly better DILI and metabolic stability (lower Cl_mic, longer t1/2) of Ligand B outweigh the small affinity advantage of Ligand B.
**Conclusion:**
Despite Ligand A having some favorable properties (logP, TPSA, Pgp, hERG), the significant concerns with its DILI risk and poor metabolic stability (high Cl_mic, short t1/2) make it a less desirable candidate. Ligand B, while not perfect, presents a better overall profile, particularly regarding safety (DILI) and pharmacokinetics (Cl_mic, t1/2).
Output:
0
2025-04-17 19:28:48,796 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [354.422, 75.71, 1.573, 1, 4, 0.601, 28.228, 84.451, -4.638, -2.686, 0.306, 45.813, -4.182, 0.074, -4.9]
**Ligand B:** [365.821, 87.54, 0.025, 1, 5, 0.818, 56.146, 68.903, -5.078, -2.708, 0.119, -0.85, 15.604, 0.035, -7.7]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity, and BBB):
1. **MW:** Both are within the ideal range (200-500 Da). A is 354.4, B is 365.8. No significant difference.
2. **TPSA:** A (75.71) is better than B (87.54). Lower TPSA generally favors better absorption, crucial for oral bioavailability.
3. **logP:** A (1.573) is optimal. B (0.025) is very low, potentially hindering membrane permeability and absorption. This is a significant drawback for B.
4. **HBD/HBA:** Both have 1 HBD. A has 4 HBA, B has 5. Both are acceptable.
5. **QED:** B (0.818) is better than A (0.601), indicating a more drug-like profile overall.
6. **DILI:** A (28.228) is significantly better than B (56.146). Lower DILI is critical.
7. **BBB:** A (84.451) is much better than B (68.903). While ADRB2 isn't necessarily a CNS target, some peripheral distribution is still desired, and higher BBB penetration can indicate better overall permeability.
8. **Caco-2:** A (-4.638) is better than B (-5.078). Both are negative, indicating good permeability.
9. **Solubility:** Both are similarly poor (-2.686 and -2.708). This could pose formulation challenges, but isn't a deciding factor here.
10. **hERG:** Both are very low (0.306 and 0.119), indicating low cardiotoxicity risk.
11. **Cl_mic:** A (45.813) is higher than B (-0.85). B has a negative clearance, which is unusual and suggests very high metabolic stability (potentially too stable, which could hinder metabolite clearance).
12. **t1/2:** A (-4.182) is better than B (15.604). A negative half-life is unusual, but in this context, it likely means it's very short, and B has a very long half-life.
13. **Pgp:** A (0.074) is much better than B (0.035). Lower P-gp efflux is desirable for better bioavailability.
14. **Affinity:** B (-7.7) is significantly better than A (-4.9). This is a substantial difference in binding strength (2.8 kcal/mol).
**Overall Assessment:**
Ligand B has a superior binding affinity, which is a major advantage. However, its extremely low logP, higher DILI risk, and lower BBB penetration are significant concerns. Ligand A, while having a weaker binding affinity, presents a much more balanced profile with better logP, DILI, BBB, and Pgp properties. The difference in affinity, while substantial, may be overcome with further optimization of Ligand A, whereas fixing the logP of Ligand B would require more extensive structural changes. Given the GPCR-specific priorities and the need for a balanced profile, I believe Ligand A is the more promising starting point.
Output:
1
2025-04-17 19:28:48,796 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (346.343) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (64.16) is significantly better than Ligand A (126.32). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (3.37) is within the optimal range (1-3), while Ligand A (0.128) is quite low. This is a major drawback for Ligand A, potentially hindering membrane permeability and bioavailability.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (0), but both are acceptable.
5. **HBA:** Ligand A (6) is slightly higher than Ligand B (5), but both are acceptable.
6. **QED:** Both ligands have good QED scores (A: 0.706, B: 0.651), indicating good drug-like properties.
7. **DILI:** Ligand B (30.399) has a much lower DILI risk than Ligand A (85.653). This is a significant advantage for Ligand B.
8. **BBB:** Ligand B (95.657) has a much higher BBB penetration than Ligand A (27.801). While not critical for a cardiovascular target, it doesn't hurt.
9. **Caco-2:** Ligand A (-5.734) is significantly better than Ligand B (-4.679).
10. **Solubility:** Ligand A (-2.978) is slightly better than Ligand B (-3.02), but both are poor.
11. **hERG:** Ligand A (0.052) has a slightly lower hERG risk than Ligand B (0.882), which is favorable.
12. **Cl_mic:** Ligand A (-21.523) has a much lower (better) microsomal clearance than Ligand B (52.996), indicating better metabolic stability.
13. **t1/2:** Both ligands have similar in vitro half-lives (A: 29.641, B: 29.334).
14. **Pgp:** Ligand A (0.019) has a much lower P-gp efflux liability than Ligand B (0.823), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand B (-6.6) has a slightly better binding affinity than Ligand A (-8.0). While A is better, the difference is not substantial enough to outweigh the other significant drawbacks.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand B excels in logP and has acceptable TPSA. Ligand A's very low logP is a major concern. While Ligand A has a better binding affinity, the other ADME properties of Ligand B are far more favorable.
**Conclusion:**
Despite Ligand A's slightly better binding affinity and Caco-2 permeability, Ligand B is the more promising candidate due to its significantly better logP, lower DILI risk, and lower P-gp efflux. The combination of these factors suggests a higher probability of successful *in vivo* performance and a more favorable safety profile.
Output:
0
2025-04-17 19:28:48,796 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (351.491 and 363.483 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (53.09) is significantly better than Ligand B (71.53). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have acceptable logP values (1.226 and 1.976), falling within the 1-3 range. Ligand B is slightly higher, which could be a minor concern for solubility.
4. **HBD:** Ligand A (0) is preferable to Ligand B (1). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is preferable to Ligand B (5). Similar to HBD, lower HBA is generally better for permeability.
6. **QED:** Both ligands have good QED scores (0.586 and 0.752), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (12.796) has a much lower DILI risk than Ligand B (56.262). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (70.57) has a higher BBB penetration score than Ligand B (44.203). While not critical for a cardiovascular target, it's a positive attribute.
9. **Caco-2:** Ligand A (-4.22) is better than Ligand B (-5.055). Higher Caco-2 permeability suggests better intestinal absorption.
10. **Solubility:** Ligand A (-0.877) is better than Ligand B (-2.134). Better solubility is generally desirable.
11. **hERG:** Ligand A (0.301) has a lower hERG inhibition liability than Ligand B (0.156). Lower is better, indicating a reduced risk of cardiotoxicity.
12. **Cl_mic:** Ligand B (31.758) has lower microsomal clearance than Ligand A (46.957), suggesting better metabolic stability. This is a positive for Ligand B.
13. **t1/2:** Ligand B (17.342) has a significantly longer in vitro half-life than Ligand A (5.454). This is a substantial advantage for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.022) has lower P-gp efflux liability than Ligand B (0.118). Lower Pgp efflux is generally preferred.
15. **Affinity:** Ligand A (-6.4) has slightly better binding affinity than Ligand B (-5.6). While the difference is not huge, it's still a positive for Ligand A.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A performs better in most of these areas. While Ligand B has a better half-life and lower clearance, the superior ADME profile (lower DILI, better solubility, lower Pgp, better TPSA, and slightly better affinity) of Ligand A outweighs these benefits.
**Conclusion:**
Ligand A presents a more balanced and favorable profile overall, particularly regarding safety (DILI, hERG) and absorption/permeability (TPSA, Caco-2, solubility). The slightly better affinity further supports its selection.
Output:
1
2025-04-17 19:28:48,797 - INFO - Batch 113 complete. Total preferences: 1808
2025-04-17 19:28:48,797 - INFO - Processing batch 114/512...
2025-04-17 19:29:37,714 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (353.491 and 353.419 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (36.44) is excellent, well below the 140 threshold and very favorable for oral absorption. Ligand B (88.18) is higher, but still acceptable, though less optimal. This favors A.
3. **logP:** Ligand A (3.539) is within the optimal range (1-3). Ligand B (0.873) is a bit low, potentially hindering membrane permeability. This favors A.
4. **HBD:** Both ligands have acceptable HBD counts (0 for A, 1 for B), well below the 5 threshold.
5. **HBA:** Both ligands have acceptable HBA counts (4 for A, 5 for B), well below the 10 threshold.
6. **QED:** Both ligands have good QED scores (0.775 and 0.813), indicating good drug-like properties. No significant difference.
7. **DILI:** Ligand A (61.07) has a slightly higher DILI risk than Ligand B (47.305), but both are still within a reasonably acceptable range (<60 is good).
8. **BBB:** Ligand A (85.847) has significantly better BBB penetration potential than Ligand B (51.415). Given ADRB2's role in cardiovascular function, CNS penetration isn't *essential*, but can be beneficial for potential off-target effects or exploring central effects. This favors A.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.92 and -4.51), which is unusual and suggests poor permeability. This is a concern for both, but the values are similar.
10. **Solubility:** Ligand A (-3.044) has worse solubility than Ligand B (-1.006). Solubility is important, so this favors B.
11. **hERG:** Ligand A (0.793) has a slightly higher hERG risk than Ligand B (0.205). Lower hERG is preferred, so this favors B.
12. **Cl_mic:** Ligand A (59.762) has a higher microsomal clearance than Ligand B (42.397), suggesting lower metabolic stability. This favors B.
13. **t1/2:** Ligand B (-28.674) has a significantly longer in vitro half-life than Ligand A (-8.355). This is a major advantage for B, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.603) has slightly higher Pgp efflux than Ligand B (0.026). Lower Pgp is preferred, so this favors B.
15. **Binding Affinity:** Ligand A (-7.5) has a slightly better binding affinity than Ligand B (-6.0). This is a significant advantage, potentially outweighing some of the ADME drawbacks.
**Overall Assessment & GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, and affinity are key. Ligand A excels in logP, TPSA, and affinity. Ligand B has better solubility, hERG, metabolic stability (Cl_mic, t1/2), and Pgp efflux. While solubility and safety (hERG) are important, the superior affinity and TPSA of Ligand A, combined with acceptable BBB penetration, make it a more promising starting point. The slightly higher DILI risk of A is manageable. The affinity difference is substantial enough to outweigh the ADME concerns, especially considering optimization can address those later.
Output:
1
2025-04-17 19:29:37,715 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (346.475 and 354.51 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (67.23) is higher than Ligand B (49.41). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is generally preferred for absorption. Ligand B has a clear advantage.
3. **logP:** Ligand B (3.86) is slightly higher than Ligand A (2.582). Both are within the optimal 1-3 range, but Ligand B is approaching the upper limit. This could potentially lead to solubility issues, but it's not a major concern at this level.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 4 HBAs, while Ligand B has 2. Lower HBA is generally favorable for permeability. Ligand B has an advantage.
6. **QED:** Ligand A (0.772) has a better QED score than Ligand B (0.639), indicating a more drug-like profile. This is a positive for Ligand A.
7. **DILI:** Ligand A (30.787) has a significantly lower DILI risk than Ligand B (12.136). This is a major advantage for Ligand A, as minimizing liver toxicity is crucial.
8. **BBB:** Both ligands have good BBB penetration (Ligand A: 74.719, Ligand B: 85.576). Since ADRB2 is not a CNS target, this is less of a deciding factor, but Ligand B is slightly better.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.447 and -4.388). These values are unusual and suggest poor permeability. However, the values are very similar.
10. **Solubility:** Both ligands have negative solubility values (-2.758 and -3.712). These values are also unusual and suggest poor solubility. Ligand B is slightly better.
11. **hERG:** Ligand A (0.122) has a much lower hERG inhibition liability than Ligand B (0.651). This is a significant advantage for Ligand A, as hERG inhibition can cause cardiotoxicity.
12. **Cl_mic:** Ligand B (58.704) has a lower microsomal clearance than Ligand A (69.969), suggesting better metabolic stability. This is a positive for Ligand B.
13. **t1/2:** Ligand A (8.319) has a longer in vitro half-life than Ligand B (-5.292). This is a positive for Ligand A, suggesting less frequent dosing potential.
14. **Pgp:** Ligand A (0.078) has lower P-gp efflux liability than Ligand B (0.266). This is a positive for Ligand A, potentially improving bioavailability.
15. **Binding Affinity:** Both ligands have the same binding affinity (-5.9 kcal/mol). This eliminates affinity as a differentiating factor.
**GPCR-specific priorities:** For ADRB2 (a cardiovascular GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B has a slightly better logP and BBB, but Ligand A excels in DILI risk, hERG inhibition, Pgp efflux, and in vitro half-life. The lower DILI and hERG risks for Ligand A are particularly important for a cardiovascular drug.
**Conclusion:**
Considering the balance of properties, particularly the significantly lower DILI and hERG risks, and the longer half-life, Ligand A is the more promising drug candidate.
Output:
1
2025-04-17 19:29:37,715 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
Let's break down the comparison of Ligand A and Ligand B, considering the provided guidelines and the GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key).
1. **Molecular Weight:** Both ligands (386.88 and 366.85 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both are around 75-76 A^2, slightly above the optimal <140 A^2 for oral absorption, but acceptable. Not a major differentiator.
3. **logP:** Ligand A (2.23) is better than Ligand B (1.08). The optimal range is 1-3, and Ligand B is at the lower end, potentially impacting permeability.
4. **H-Bond Donors:** Ligand A (2) is slightly higher than Ligand B (1), but both are within the acceptable limit of <=5.
5. **H-Bond Acceptors:** Ligand B (5) is higher than Ligand A (3). Both are within the acceptable limit of <=10.
6. **QED:** Both ligands have good QED scores (0.557 and 0.578), indicating good drug-like properties.
7. **DILI:** Ligand B (43.66%) has a significantly lower DILI risk than Ligand A (52.73%). This is a substantial advantage for Ligand B.
8. **BBB:** Ligand A (81.74%) has a much higher BBB penetration potential than Ligand B (58.24%). While ADRB2 isn't strictly a CNS target, some CNS exposure can be relevant for off-target effects and broader safety profiling.
9. **Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.996 and -4.967), which is unusual and suggests poor permeability. This is a concern for both.
10. **Aqueous Solubility:** Ligand A (-3.668) has slightly worse solubility than Ligand B (-2.436).
11. **hERG Inhibition:** Both ligands have low hERG inhibition risk (0.65 and 0.34), which is good.
12. **Microsomal Clearance:** Ligand A (48.33 mL/min/kg) has significantly better metabolic stability (lower clearance) than Ligand B (6.45 mL/min/kg). This is a major advantage for Ligand A.
13. **In vitro Half-Life:** Ligand A (9.39 hours) has a longer half-life than Ligand B (4.79 hours), which is desirable.
14. **P-gp Efflux:** Both ligands have low P-gp efflux liability (0.359 and 0.245).
15. **Binding Affinity:** Ligand A (-7.3 kcal/mol) has a significantly stronger binding affinity than Ligand B (-5.0 kcal/mol). This is a substantial advantage, and a difference of >1.5 kcal/mol can often outweigh other drawbacks.
**Overall Assessment:**
Ligand A has a much stronger binding affinity and better metabolic stability (lower Cl_mic, longer t1/2). The higher BBB penetration is also a plus. Ligand B has a lower DILI risk, which is important, but the substantial difference in affinity and metabolic stability outweighs this benefit. The poor Caco-2 permeability is a concern for both, but the superior potency of Ligand A makes it more likely to be optimized to overcome this issue.
Output:
1
2025-04-17 19:29:37,715 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [352.341, 100.19 , 0.121, 3. , 4. , 0.701, 61.807, 69.717, -5.138, -2.247, 0.147, -18.957, 15.356, 0.006, -7.1 ]
**Ligand B:** [355.463, 51.27 , 4.319, 0. , 5. , 0.634, 47.926, 68.786, -5.041, -3.844, 0.741, 83.851, 32.348, 0.529, -6.4 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). A (352.341) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** A (100.19) is higher than B (51.27). For a cardiovascular GPCR, TPSA isn't *as* critical as for a CNS target, but lower is still preferred for better absorption. B is significantly better here.
3. **logP:** A (0.121) is very low, potentially causing permeability issues. B (4.319) is high, bordering on problematic, but still within an acceptable range. B is much better.
4. **HBD:** A (3) is reasonable. B (0) is excellent, minimizing potential off-target interactions and improving membrane permeability.
5. **HBA:** A (4) is good. B (5) is also acceptable.
6. **QED:** Both are good (A: 0.701, B: 0.634), indicating drug-like properties. A is slightly better.
7. **DILI:** A (61.807) is higher than B (47.926). B is preferable here, indicating lower liver injury risk.
8. **BBB:** Both are reasonably good (A: 69.717, B: 68.786), but not exceptionally high. Since ADRB2 isn't a primary CNS target, this isn't a major deciding factor.
9. **Caco-2:** Both are negative, indicating poor permeability. This is a significant concern for both.
10. **Solubility:** Both are negative, indicating poor solubility. This is a significant concern for both.
11. **hERG:** A (0.147) is much lower than B (0.741), indicating a lower risk of cardiotoxicity. This is a crucial advantage for a cardiovascular target.
12. **Cl_mic:** A (-18.957) is *much* lower than B (83.851), suggesting significantly better metabolic stability. This is a major advantage for A.
13. **t1/2:** A (15.356) is shorter than B (32.348), but still acceptable. B is preferable.
14. **Pgp:** A (0.006) is much lower than B (0.529), indicating less P-gp efflux and potentially better bioavailability. This is a significant advantage for A.
15. **Affinity:** A (-7.1) is slightly better than B (-6.4), though the difference isn't huge.
**Overall Assessment:**
Ligand A has a major advantage in metabolic stability (Cl_mic), P-gp efflux, and hERG inhibition. While its logP is concerningly low, its superior metabolic profile and reduced cardiotoxicity risk are highly valuable for a cardiovascular drug candidate. Ligand B has better TPSA and a slightly longer half-life, but its higher DILI risk, P-gp efflux, and poorer metabolic stability are significant drawbacks. The slightly better affinity of A also tips the balance.
Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity) and the overall profile, Ligand A appears to be the more promising candidate.
Output:
1
2025-04-17 19:29:37,715 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (340.383 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are acceptable, but Ligand B (86.71) is better than Ligand A (92.35) as it is closer to the <140 threshold.
3. **logP:** Both ligands have good logP values (A: 2.49, B: 1.919) falling within the optimal 1-3 range.
4. **HBD:** Ligand A (3) has slightly more HBD than Ligand B (2). This isn't a major concern for either.
5. **HBA:** Both ligands have the same number of HBA (5), which is within the acceptable limit of 10.
6. **QED:** Ligand B (0.75) has a higher QED score than Ligand A (0.587), indicating a more drug-like profile.
7. **DILI:** Ligand B (59.984) has a lower DILI risk than Ligand A (77.394), which is a significant advantage.
8. **BBB:** Ligand A (66.421) has a better BBB penetration than Ligand B (51.299). While ADRB2 isn't strictly a CNS target, some peripheral ADRB2 receptors can influence CNS function, and better BBB penetration isn't necessarily a negative.
9. **Caco-2:** Ligand B (-5.303) has a more negative Caco-2 value, indicating better intestinal absorption than Ligand A (-4.87).
10. **Solubility:** Ligand B (-3.295) has better aqueous solubility than Ligand A (-4.048).
11. **hERG:** Both ligands have similar hERG inhibition liability (A: 0.319, B: 0.389), and are at low risk.
12. **Cl_mic:** Ligand B (41.212) has a lower microsomal clearance than Ligand A (55.478), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-45.683) has a significantly longer in vitro half-life than Ligand A (26.721), which is highly desirable.
14. **Pgp:** Both ligands have similar Pgp efflux liability (A: 0.087, B: 0.2).
15. **Binding Affinity:** Ligand B (-7.0 kcal/mol) has a slightly better binding affinity than Ligand A (-6.9 kcal/mol), but the difference is minimal.
**GPCR-specific priorities:** For GPCRs, logP, TPSA, Pgp, and affinity are key. Both ligands perform well on logP. Ligand B has a better TPSA and slightly better affinity. The biggest differences are in ADME properties: Ligand B has a significantly better QED, lower DILI risk, better solubility, lower clearance, and a longer half-life.
**Conclusion:**
While Ligand A has slightly better BBB penetration, the overall profile of Ligand B is superior. The lower DILI risk, better metabolic stability (lower Cl_mic and longer t1/2), improved solubility, and higher QED outweigh the minor difference in BBB penetration. The binding affinity difference is negligible. Therefore, Ligand B is the more promising drug candidate.
Output:
0
2025-04-17 19:29:37,716 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (361.467) is slightly higher than Ligand B (343.427), but both are acceptable.
2. **TPSA:** Ligand A (63.57) is better than Ligand B (76.64). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (Ligand A: 2.253, Ligand B: 1.25), falling within the optimal 1-3 range. Ligand A is slightly more lipophilic.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (3). Lower HBA also aids permeability.
6. **QED:** Both ligands have similar QED values (Ligand A: 0.821, Ligand B: 0.79), both indicating good drug-like properties.
7. **DILI:** Ligand A (69.833) has a significantly higher DILI risk than Ligand B (18.573). This is a major concern.
8. **BBB:** This is less critical for a cardiovascular target. Ligand A (71.888) is slightly better than Ligand B (54.789).
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. Ligand A (-4.855) is slightly better than Ligand B (-5.107).
10. **Solubility:** Ligand A (-3.546) is slightly better than Ligand B (-1.564), but both are poor.
11. **hERG:** Both ligands have low hERG inhibition risk (Ligand A: 0.404, Ligand B: 0.226). Ligand B is slightly better.
12. **Cl_mic:** Ligand B (-3.96) has a significantly *lower* (better) microsomal clearance than Ligand A (43.138). This suggests better metabolic stability for Ligand B.
13. **t1/2:** Ligand B (-34.402) has a significantly *longer* (better) in vitro half-life than Ligand A (40.642).
14. **Pgp:** Both ligands have very low Pgp efflux liability (Ligand A: 0.133, Ligand B: 0.054). Ligand B is slightly better.
15. **Binding Affinity:** Ligand B (-6.4) has a slightly better binding affinity than Ligand A (-6.1). While the difference is small, it's still a factor.
**Overall Assessment:**
While Ligand A has slightly better TPSA and logP, the significantly higher DILI risk and poorer metabolic stability (higher Cl_mic, shorter t1/2) are major drawbacks. Ligand B demonstrates a much more favorable safety profile (lower DILI) and improved pharmacokinetic properties (lower Cl_mic, longer t1/2, lower Pgp). The slightly better binding affinity of Ligand B further supports its selection. Given the GPCR-specific priorities, and the importance of balancing ADME properties, Ligand B is the more promising candidate.
Output:
0
2025-04-17 19:29:37,716 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for the ADRB2 receptor, a GPCR involved in cardiovascular function. Therefore, priorities are logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB.
Let's compare the ligands property by property:
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (377.535) is slightly higher than Ligand B (347.39), but both are acceptable.
2. **TPSA:** Ligand A (54.46) is significantly better than Ligand B (74.59). Lower TPSA generally favors oral absorption, crucial for a cardiovascular drug.
3. **logP:** Both ligands have good logP values (A: 3.419, B: 3.295), falling within the optimal 1-3 range.
4. **HBD/HBA:** Both have acceptable HBD (1) and HBA (A: 6, B: 4) counts.
5. **QED:** Both have good QED scores (A: 0.75, B: 0.801), indicating drug-likeness.
6. **DILI:** Ligand A (69.872) has a higher DILI risk than Ligand B (58.589), which is unfavorable.
7. **BBB:** Ligand B (82.164) has a better BBB penetration score than Ligand A (62.699), but BBB isn't a primary concern for a cardiovascular target.
8. **Caco-2:** Ligand A (-5.105) has a worse Caco-2 permeability than Ligand B (-4.276).
9. **Solubility:** Ligand A (-3.75) has a worse solubility than Ligand B (-4.239).
10. **hERG:** Ligand A (0.491) has a lower hERG risk than Ligand B (0.703), which is favorable.
11. **Cl_mic:** Ligand B (26.325) has significantly lower microsomal clearance than Ligand A (53.22), indicating better metabolic stability.
12. **t1/2:** Ligand B (27.568) has a much longer in vitro half-life than Ligand A (7.073), which is a significant advantage.
13. **Pgp:** Ligand A (0.469) has lower P-gp efflux than Ligand B (0.204), which is favorable.
14. **Binding Affinity:** Ligand A (-7.3) has a significantly stronger binding affinity than Ligand B (-6.4). This is a substantial advantage, potentially outweighing some ADME concerns.
**Overall Assessment:**
Ligand A has a significantly better binding affinity. However, Ligand B exhibits superior ADME properties, particularly in terms of metabolic stability (lower Cl_mic) and half-life, as well as better solubility and Caco-2 permeability. While Ligand A has a lower Pgp efflux and hERG risk, the substantial difference in binding affinity of Ligand A is the most important factor. The slightly higher DILI risk of Ligand A is a concern, but potentially manageable with further optimization.
**Output:**
1
2025-04-17 19:29:37,716 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (353.413 and 362.455 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (52.65) is significantly better than Ligand B (76.46). ADRB2 is not a CNS target, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (2.677 and 1.164), falling within the optimal 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Both have 1 HBD, which is within the acceptable limit of 5.
5. **HBA:** Ligand A (2) is better than Ligand B (6). Higher HBA can sometimes hinder permeability.
6. **QED:** Both ligands have good QED scores (0.905 and 0.837), indicating good drug-like properties.
7. **DILI:** Ligand A (47.305) has a slightly better DILI score than Ligand B (54.944), indicating a lower risk of liver injury. Both are acceptable (<60).
8. **BBB:** This is less critical for ADRB2 (a cardiovascular target), but Ligand A (86.157) has a higher BBB percentile than Ligand B (64.715).
9. **Caco-2:** Ligand B (-5.126) has a slightly better Caco-2 permeability than Ligand A (-4.385), suggesting better intestinal absorption.
10. **Solubility:** Ligand B (-1.627) has slightly better solubility than Ligand A (-2.88), which is a positive.
11. **hERG:** Both ligands have low hERG inhibition liability (0.738 and 0.399), which is good.
12. **Cl_mic:** Ligand A (8.701) has a much lower microsomal clearance than Ligand B (32.086), indicating better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand B (-7.152) has a significantly longer in vitro half-life than Ligand A (1.235). This is a major advantage for dosing convenience.
14. **Pgp:** Ligand A (0.127) has lower P-gp efflux liability than Ligand B (0.07), which is a slight advantage.
15. **Binding Affinity:** Both ligands have the same binding affinity (-6.3 kcal/mol).
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand A appears to be the better candidate. While Ligand B has a longer half-life and slightly better solubility and Caco-2 permeability, Ligand A excels in TPSA, DILI, and crucially, *metabolic stability* (Cl_mic). The lower clearance of Ligand A is a significant benefit, potentially leading to higher plasma concentrations and a more predictable pharmacokinetic profile. The similar binding affinity makes the ADME properties the deciding factor.
Output:
1
2025-04-17 19:29:37,716 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (334.379 and 347.503 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (60.25) is slightly higher than Ligand B (52.65). Both are below the 140 threshold for oral absorption, but closer to the 90 threshold for CNS targets. Ligand B is preferable.
3. **logP:** Ligand A (2.203) and Ligand B (1.899) are both within the optimal 1-3 range. No significant difference.
4. **HBD:** Ligand A (0) is better than Ligand B (1). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (5) is better than Ligand B (3). Fewer HBAs generally improve permeability.
6. **QED:** Ligand A (0.684) is better than Ligand B (0.512), indicating a more drug-like profile.
7. **DILI:** Ligand B (4.188) is *significantly* better than Ligand A (74.021). This is a major advantage for Ligand B.
8. **BBB:** Both ligands have good BBB penetration (Ligand A: 68.166, Ligand B: 67.197). No significant difference.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual. This suggests poor permeability. No clear advantage.
10. **Solubility:** Ligand A (-2.269) is better than Ligand B (-1.498). Higher solubility is preferable.
11. **hERG:** Both ligands have low hERG inhibition risk (Ligand A: 0.425, Ligand B: 0.501). No significant difference.
12. **Cl_mic:** Ligand B (2.597) has *much* lower microsomal clearance than Ligand A (48.064), indicating better metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand B (-8.081) has a longer in vitro half-life than Ligand A (30.509). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.145) is better than Ligand B (0.018). Lower P-gp efflux is preferable.
15. **Affinity:** Ligand A (-8.2) has a slightly better binding affinity than Ligand B (-7.5). The difference is 0.7 kcal/mol, which is not a huge advantage.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand B has a slightly lower logP and better TPSA. Ligand A has better Pgp and affinity, but the affinity difference is small. The *major* advantage of Ligand B is its significantly lower DILI risk and better metabolic stability (lower Cl_mic and longer t1/2). These factors are crucial for overall drug development success.
**Conclusion:**
While Ligand A has slightly better affinity and Pgp properties, Ligand B's significantly improved safety profile (DILI), metabolic stability (Cl_mic, t1/2), and acceptable TPSA and logP make it the more promising drug candidate. The small difference in binding affinity is outweighed by the substantial improvements in ADME-Tox properties.
Output:
0
2025-04-17 19:29:37,716 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (365.539 Da and 363.889 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (55.4) is significantly better than Ligand B (71.09). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (4.157) is slightly higher than Ligand A (3.668). While both are above the optimal 1-3 range, Ligand B is edging towards a potentially problematic value.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Both ligands have 3 HBA, which is within the acceptable range.
6. **QED:** Ligand A (0.802) has a slightly better QED score than Ligand B (0.764), indicating a more drug-like profile.
7. **DILI:** Ligand A (36.06) has a considerably lower DILI risk than Ligand B (49.632). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (81) has a higher BBB penetration percentile than Ligand B (69.794). While not a primary concern for a cardiovascular target, higher BBB is generally favorable.
9. **Caco-2:** Both ligands have very similar, and poor, Caco-2 permeability values (-4.969 and -4.906). This suggests potential absorption issues for both.
10. **Solubility:** Ligand A (-4.463) has slightly better solubility than Ligand B (-3.961).
11. **hERG:** Ligand A (0.779) has a lower hERG inhibition liability than Ligand B (0.38). Lower is better, making Ligand A safer from a cardiotoxicity perspective.
12. **Cl_mic:** Ligand B (64.708) has a slightly lower microsomal clearance than Ligand A (67.794), indicating potentially better metabolic stability.
13. **t1/2:** Ligand B (81.186) has a significantly longer in vitro half-life than Ligand A (-31.296). This is a major advantage for Ligand B.
14. **Pgp:** Ligand A (0.516) has a lower P-gp efflux liability than Ligand B (0.277), which is favorable for bioavailability.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-5.6 and -5.8 kcal/mol). The difference is negligible.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B in most crucial ADME properties (DILI, hERG, TPSA, Solubility, Pgp efflux) and has a slightly better QED score. While Ligand B has a longer half-life and slightly better metabolic stability, the safety profile and absorption characteristics of Ligand A are more appealing. Given the cardiovascular target, minimizing off-target effects (DILI, hERG) and optimizing absorption are critical. The slightly longer half-life of Ligand B isn't enough to overcome the other advantages of Ligand A.
Output:
1
2025-04-17 19:29:37,716 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.463 and 349.475 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (79.26) is better than Ligand B (83.22) as it is closer to the <140 threshold for good oral absorption.
3. **logP:** Ligand B (2.687) is better than Ligand A (0.727). A logP between 1-3 is optimal, and Ligand B is within this range, while Ligand A is slightly low, potentially impacting permeability.
4. **HBD:** Ligand A (2) is preferable to Ligand B (3). Lower HBDs generally improve permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (3). Lower HBAs generally improve permeability.
6. **QED:** Ligand A (0.762) is slightly better than Ligand B (0.662), indicating a more drug-like profile.
7. **DILI:** Ligand A (18.379) is significantly better than Ligand B (41.76). Lower DILI risk is crucial, and Ligand A is well below the concerning threshold of 60.
8. **BBB:** Both ligands have similar BBB penetration (67.352 and 67.468). While not exceptionally high, it's acceptable for a non-CNS target like ADRB2.
9. **Caco-2:** Ligand A (-5.243) is better than Ligand B (-4.695). Higher Caco-2 permeability suggests better absorption.
10. **Solubility:** Ligand A (-1.918) is better than Ligand B (-3.794). Higher aqueous solubility is generally desirable.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.493 and 0.338). This is excellent.
12. **Cl_mic:** Ligand A (16.254) is significantly better than Ligand B (69.497). Lower microsomal clearance indicates greater metabolic stability.
13. **t1/2:** Ligand A (18.05) is significantly better than Ligand B (-14.852). A longer in vitro half-life is preferable.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.02 and 0.19).
15. **Binding Affinity:** Ligand B (-6.8) has a slightly better binding affinity than Ligand A (-6.6). However, the difference is only 0.2 kcal/mol, which is not substantial enough to outweigh the significant ADME advantages of Ligand A.
**GPCR-specific priorities:** For GPCRs, logP, TPSA, Pgp, and affinity are important. While Ligand B has a better logP and slightly better affinity, Ligand A excels in TPSA, Pgp, and has a much more favorable ADME profile overall (DILI, Cl_mic, t1/2, solubility, Caco-2). The small affinity difference is not enough to overcome the superior ADME properties of Ligand A.
**Conclusion:**
Ligand A presents a much more balanced and favorable profile for drug development, particularly considering its significantly better metabolic stability (lower Cl_mic), longer half-life, lower DILI risk, and better solubility. The slightly lower logP is a minor drawback compared to the substantial benefits in other key parameters.
Output:
1
2025-04-17 19:29:37,717 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [348.311, 117.07 , 1.248, 1. , 9. , 0.582, 96.704, 46.336, -4.531, -2.988, 0.076, 72.669, -26.263, 0.154, -5.2 ]
**Ligand B:** [347.346, 95.67 , 2.108, 2. , 5. , 0.829, 65.762, 49.748, -4.894, -4.176, 0.389, 33.387, -32.239, 0.049, -6.4 ]
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). A: 348.311, B: 347.346 - very similar.
2. **TPSA:** Ligand A (117.07) is slightly higher than Ligand B (95.67). Both are acceptable for a non-CNS GPCR, but B is preferable.
3. **logP:** Ligand A (1.248) is within the optimal range, while Ligand B (2.108) is also good. A is slightly better.
4. **HBD:** Ligand A (1) is better than Ligand B (2). Lower is generally preferred.
5. **HBA:** Ligand A (9) is better than Ligand B (5). Lower is generally preferred.
6. **QED:** Ligand B (0.829) is significantly better than Ligand A (0.582), indicating a more drug-like profile.
7. **DILI:** Ligand A (96.704) has a significantly higher DILI risk than Ligand B (65.762). This is a major concern for A.
8. **BBB:** Both are relatively low, which is fine for a cardiovascular target. Ligand B (49.748) is slightly better than Ligand A (46.336).
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand B (-4.894) is slightly worse than Ligand A (-4.531).
10. **Solubility:** Both are negative, indicating poor solubility. Ligand B (-4.176) is slightly worse than Ligand A (-2.988).
11. **hERG:** Ligand A (0.076) is much better than Ligand B (0.389), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand B (33.387) has a significantly lower clearance than Ligand A (72.669), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-32.239) has a longer half-life than Ligand A (-26.263).
14. **Pgp:** Ligand A (0.154) has lower P-gp efflux than Ligand B (0.049).
15. **Affinity:** Ligand B (-6.4) has a stronger binding affinity than Ligand A (-5.2) by 1.2 kcal/mol. This is a substantial difference.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), we prioritize logP, Pgp, TPSA, and affinity. Ligand B has a better logP, better TPSA, and significantly better affinity. While Ligand A has slightly better Pgp and hERG, the DILI risk and lower affinity of Ligand A are major drawbacks. The improved metabolic stability (lower Cl_mic and longer t1/2) of Ligand B are also highly desirable.
**Conclusion:**
Despite the slightly worse Caco-2 and solubility, the superior binding affinity, lower DILI risk, and better metabolic stability of Ligand B outweigh the advantages of Ligand A.
Output:
0
2025-04-17 19:29:37,717 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (353.419 Da) is slightly higher than Ligand B (339.443 Da), but both are acceptable.
2. **TPSA:** Ligand A (96.97) is higher than Ligand B (63.05). For a cardiovascular GPCR, TPSA is not a major concern unless targeting the CNS, but lower is generally preferred for better absorption. Ligand B is significantly better here.
3. **logP:** Both ligands have good logP values (Ligand A: 1.102, Ligand B: 2.463), falling within the optimal 1-3 range. Ligand B is slightly better, leaning towards the more desirable end of the range.
4. **HBD:** Ligand A has 2 HBD, and Ligand B has 1. Both are acceptable (<=5).
5. **HBA:** Both ligands have 5 HBA, which is acceptable (<=10).
6. **QED:** Ligand B (0.909) has a much higher QED score than Ligand A (0.668), indicating a more drug-like profile. This is a significant advantage for Ligand B.
7. **DILI:** Ligand B (24.816) has a much lower DILI risk than Ligand A (49.709). This is a major advantage for Ligand B, as minimizing liver toxicity is crucial.
8. **BBB:** Ligand B (90.151) has a significantly higher BBB penetration score than Ligand A (55.138). While ADRB2 isn't exclusively a CNS target, some CNS exposure can occur, and higher BBB is generally favorable.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.22 and -4.933), which is unusual and suggests poor permeability. This is a significant drawback for both.
10. **Solubility:** Both ligands have negative solubility values (-2.505 and -2.843), which is also unusual and suggests poor aqueous solubility. This is a significant drawback for both.
11. **hERG:** Ligand A (0.134) has a slightly lower hERG inhibition liability than Ligand B (0.47), which is preferable.
12. **Cl_mic:** Ligand A (-17.298) has a much lower (better) microsomal clearance than Ligand B (32.139), indicating greater metabolic stability.
13. **t1/2:** Ligand B (11.524) has a significantly longer in vitro half-life than Ligand A (-8.83). This is a significant advantage for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.025) has a much lower P-gp efflux liability than Ligand B (0.08), which is preferable.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.8 and -6.9 kcal/mol). The difference is negligible.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP, TPSA, and BBB. While Ligand A has better Pgp and hERG, the superior DILI, QED, and t1/2 of Ligand B outweigh these factors. The Caco-2 and solubility issues are concerning for both, but can potentially be addressed with formulation strategies.
**Conclusion:**
Despite the permeability and solubility concerns shared by both, Ligand B presents a more favorable overall profile due to its significantly better DILI risk, QED, BBB penetration, and in vitro half-life. These factors are crucial for developing a safe and effective drug.
Output:
0
2025-04-17 19:29:37,717 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [355.479, 82.11, 0.386, 2, 5, 0.585, 21.791, 24.002, -4.951, -0.405, 0.07, 17.003, -4.177, 0.012, -6.1]
**Ligand B:** [361.511, 62.3, 3.246, 1, 4, 0.758, 42.148, 68.282, -4.785, -3.801, 0.379, 75.421, -5.444, 0.272, -5.6]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (355.479) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (82.11) is higher than Ligand B (62.3). Both are acceptable for a non-CNS GPCR, but Ligand B is better.
3. **logP:** Ligand B (3.246) is optimal, while Ligand A (0.386) is very low, potentially hindering membrane permeability and absorption. This is a significant drawback for Ligand A.
4. **HBD:** Ligand A (2) and Ligand B (1) are both within the acceptable limit of 5. Ligand B is slightly better.
5. **HBA:** Ligand A (5) and Ligand B (4) are both within the acceptable limit of 10. Ligand B is slightly better.
6. **QED:** Ligand B (0.758) is better than Ligand A (0.585), indicating a more drug-like profile.
7. **DILI:** Ligand A (21.791) has a much lower DILI risk than Ligand B (42.148). This is a significant advantage for Ligand A.
8. **BBB:** BBB is less critical for a cardiovascular target. Ligand B (68.282) is higher, but it's not a major deciding factor here.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-4.951) is slightly worse than Ligand B (-4.785).
10. **Solubility:** Ligand A (-0.405) is better than Ligand B (-3.801).
11. **hERG:** Ligand A (0.07) has a much lower hERG risk than Ligand B (0.379). This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand A (17.003) has lower clearance, suggesting better metabolic stability than Ligand B (75.421).
13. **t1/2:** Ligand B (-5.444) has a slightly longer half-life than Ligand A (-4.177).
14. **Pgp:** Ligand A (0.012) has lower P-gp efflux, which is favorable for bioavailability. Ligand B (0.272) is higher.
15. **Affinity:** Both have excellent binding affinity (-6.1 and -5.6 kcal/mol). Ligand A is slightly better.
**GPCR-Specific Priorities:** For ADRB2 (a cardiovascular GPCR), logP, TPSA, and affinity are key. While Ligand A has better DILI, hERG, Cl_mic, Pgp, and a slightly better affinity, its extremely low logP is a major concern. This will likely translate to very poor absorption and bioavailability. Ligand B, while having a higher DILI and hERG risk, has a much more favorable logP, which is crucial for oral absorption and target engagement.
**Conclusion:**
Despite the slightly better safety profile of Ligand A, the significantly better logP and overall drug-like properties (QED) of Ligand B make it the more promising candidate. The low logP of Ligand A is a substantial hurdle that is unlikely to be overcome.
Output:
0
2025-04-17 19:29:37,717 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (335.363) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (72.39) is significantly better than Ligand B (87.46). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (2.689) is optimal, while Ligand B (0.643) is a bit low. A logP below 1 can hinder membrane permeability.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Both ligands have 5 HBA, which is acceptable.
6. **QED:** Both ligands have similar QED scores (0.686 and 0.674), indicating good drug-likeness.
7. **DILI:** Ligand A (78.17) has a higher DILI risk than Ligand B (18.224). This is a significant drawback for Ligand A.
8. **BBB:** This is less critical for a cardiovascular target, but Ligand A (72.237) is better than Ligand B (49.826).
9. **Caco-2:** Ligand A (-4.415) is better than Ligand B (-5.02), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-3.175) is better than Ligand B (-0.978), which is important for bioavailability.
11. **hERG:** Both ligands have very low hERG risk (0.267 and 0.167).
12. **Cl_mic:** Ligand A (111.461) has a higher microsomal clearance than Ligand B (21.582), indicating lower metabolic stability.
13. **t1/2:** Ligand B (5.169) has a significantly longer in vitro half-life than Ligand A (-5.61). This is a major advantage for Ligand B.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.134 and 0.029).
15. **Binding Affinity:** Ligand A (-7.5) has a slightly better binding affinity than Ligand B (-5.8). The difference is 1.7 kcal/mol, which is substantial.
**Overall Assessment & GPCR-Specific Priorities:**
For a GPCR like ADRB2, affinity, logP, and metabolic stability are key. While Ligand A has a better affinity, its significantly higher DILI risk and higher Cl_mic (lower metabolic stability) are major concerns. Ligand B, despite a slightly weaker affinity, has a much better safety profile (DILI) and improved metabolic stability (t1/2 and Cl_mic). The logP for Ligand B is lower, but still within an acceptable range. The better solubility of Ligand A is a plus, but is outweighed by the safety and stability concerns.
Given these considerations, I prioritize the safety and metabolic stability offered by Ligand B.
Output:
0
2025-04-17 19:29:37,717 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's analyze each ligand against the provided guidelines, keeping in mind ADRB2 is a GPCR and therefore we prioritize logP, Pgp, TPSA, and affinity.
* **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand B (350.503 Da) is slightly lower, which could be a minor advantage for permeability.
* **TPSA:** Both are reasonably low (59.59 and 58.64), well below the 140 threshold for oral absorption.
* **logP:** Ligand A (4.89) is higher than Ligand B (2.737). While 4.89 is approaching the upper limit, it's not drastically high and could be acceptable given strong affinity. Ligand B is well within the optimal range.
* **H-Bond Donors/Acceptors:** Both have acceptable numbers of HBDs (2 and 1) and HBAs (3).
* **QED:** Both have similar, acceptable QED scores (0.658 and 0.616).
* **DILI:** Ligand B (15.122) has a significantly lower DILI risk than Ligand A (56.844). This is a major advantage for Ligand B.
* **BBB:** Ligand A (83.637) shows better BBB penetration than Ligand B (62.311). While ADRB2 isn't necessarily a CNS target, some peripheral ADRB2 activity can impact CNS function, so moderate BBB penetration isn't necessarily a negative.
* **Caco-2 Permeability:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. This is a concern for both.
* **Aqueous Solubility:** Both have negative solubility values, which is also concerning.
* **hERG:** Ligand A (0.749) has a slightly higher hERG risk than Ligand B (0.256), favoring Ligand B.
* **Microsomal Clearance:** Ligand B (57.486) has lower microsomal clearance than Ligand A (104.787), indicating better metabolic stability.
* **In vitro Half-Life:** Ligand A (29.03) has a longer half-life than Ligand B (9.759). This is a positive for Ligand A.
* **P-gp Efflux:** Ligand A (0.544) has lower P-gp efflux than Ligand B (0.078), which is favorable.
* **Binding Affinity:** Ligand A (-6.7 kcal/mol) has a slightly better binding affinity than Ligand B (-6.1 kcal/mol). This 1.5 kcal/mol difference is significant.
**Overall Assessment:**
Ligand A has a better binding affinity and half-life, and lower P-gp efflux. However, its significantly higher DILI risk and slightly higher hERG risk are major drawbacks. Ligand B has a much better safety profile (DILI, hERG) and metabolic stability. The affinity difference, while notable, is not large enough to overcome the safety concerns with Ligand A. Considering the balance of properties, especially the crucial safety parameters, Ligand B is the more promising candidate.
**Output:**
0
2025-04-17 19:29:37,717 - INFO - Batch 114 complete. Total preferences: 1824
2025-04-17 19:29:37,718 - INFO - Processing batch 115/512...
2025-04-17 19:30:29,257 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (346.39 and 350.46 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (102.32) is higher than Ligand B (67.67). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is generally preferred for absorption. Ligand B is better here.
3. **logP:** Ligand B (1.314) is within the optimal range (1-3), while Ligand A (0.543) is slightly below. This could potentially hinder membrane permeability for Ligand A. Ligand B is better.
4. **HBD:** Ligand A (2) is reasonable, while Ligand B (0) is even better. Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (6) and Ligand B (5) are both acceptable, below the threshold of 10.
6. **QED:** Ligand B (0.744) has a significantly better QED score than Ligand A (0.528), suggesting a more drug-like profile.
7. **DILI:** Ligand B (7.794) has a much lower DILI risk than Ligand A (66.15). This is a major advantage for Ligand B.
8. **BBB:** Ligand B (75.107) has a higher BBB penetration percentile than Ligand A (44.591). While ADRB2 isn't a primary CNS target, some brain exposure can occur, and higher BBB is generally favorable.
9. **Caco-2:** Both ligands have similar, poor Caco-2 permeability (-4.762 and -4.694). This is a concern for both, indicating potential absorption issues.
10. **Solubility:** Ligand B (-0.225) has slightly better solubility than Ligand A (-2.627).
11. **hERG:** Ligand A (0.026) has a slightly lower hERG risk than Ligand B (0.34), but both are very low and not a major concern.
12. **Cl_mic:** Ligand B (4.994) has significantly lower microsomal clearance than Ligand A (45.404), indicating better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand B (-3.308) has a longer in vitro half-life than Ligand A (-2.219), which is desirable.
14. **Pgp:** Ligand A (0.011) has a much lower P-gp efflux liability than Ligand B (0.034), which is a slight advantage.
15. **Binding Affinity:** Both ligands have the same binding affinity (-6.9 kcal/mol). This eliminates affinity as a differentiating factor.
**Overall Assessment:**
Ligand B consistently outperforms Ligand A across most critical ADME properties (DILI, BBB, Cl_mic, t1/2, QED, logP, TPSA, Solubility). While Ligand A has a slightly better P-gp profile, the substantial advantages of Ligand B in safety (DILI), metabolic stability (Cl_mic), and drug-likeness (QED) outweigh this minor difference. The similar Caco-2 values are a concern for both, but can be addressed with formulation strategies. Given the GPCR target class, the balance of properties in Ligand B is more favorable.
Output:
0
2025-04-17 19:30:29,257 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**1. Molecular Weight:** Both ligands (363.849 Da and 354.447 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (74.5) is better than Ligand B (77.1), both are under the 140 threshold for oral absorption.
**3. logP:** Ligand A (3.014) is optimal, while Ligand B (0.57) is quite low. For a GPCR, a logP between 1-3 is preferred, making Ligand A significantly better. Low logP can hinder membrane permeability.
**4. H-Bond Donors:** Both ligands have 1 HBD, which is good.
**5. H-Bond Acceptors:** Both ligands have 5 HBA, which is good.
**6. QED:** Ligand A (0.907) has a higher QED score than Ligand B (0.799), indicating better overall drug-likeness.
**7. DILI:** Ligand B (45.173) has a much lower DILI risk than Ligand A (71.617). This is a significant advantage for Ligand B.
**8. BBB:** Ligand A (83.249) has better BBB penetration than Ligand B (65.607). While ADRB2 isn't strictly a CNS target, some CNS exposure can be relevant for off-target effects, and higher BBB is generally preferable.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.985) is slightly better than Ligand B (-4.657).
**10. Aqueous Solubility:** Ligand A (-3.763) has better solubility than Ligand B (-1.38).
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.269 and 0.171 respectively).
**12. Microsomal Clearance:** Ligand B (4.235) has significantly lower microsomal clearance than Ligand A (65.275), indicating better metabolic stability.
**13. In vitro Half-Life:** Ligand B (-7.441) has a much longer in vitro half-life than Ligand A (18.19).
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (0.133 and 0.037 respectively).
**15. Binding Affinity:** Ligand B (-7.3 kcal/mol) has slightly better binding affinity than Ligand A (-6.5 kcal/mol). This 0.8 kcal/mol difference is substantial and can outweigh some ADME concerns.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand B is the stronger candidate. While Ligand A has better BBB penetration and solubility, Ligand B's superior binding affinity, significantly lower DILI risk, and improved metabolic stability (lower Cl_mic, longer t1/2) are more crucial for a viable drug candidate. The low logP of Ligand A is a major drawback. The Caco-2 permeability issues are concerning for both, but the other benefits of Ligand B outweigh this.
Output:
0
2025-04-17 19:30:29,257 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (346.391 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both ligands are reasonably low (A: 116.32, B: 118.56), below the 140 threshold for good oral absorption.
3. **logP:** Ligand A (-0.599) is a bit low, potentially hindering permeation. Ligand B (0.263) is better, falling within the optimal 1-3 range.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (1), but both are acceptable.
5. **HBA:** Ligand A (5) is lower than Ligand B (8), which is preferable.
6. **QED:** Both ligands have similar, good QED values (A: 0.636, B: 0.633).
7. **DILI:** Ligand A (47.15) has a significantly lower DILI risk than Ligand B (75.688). This is a major advantage for Ligand A.
8. **BBB:** Both ligands have similar BBB penetration (A: 63.901, B: 62.97). While not CNS-focused for ADRB2, higher is better.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.453 and -5.272), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Both ligands have negative solubility values (-1.654 and -2.824), indicating poor aqueous solubility. This is a significant drawback for both.
11. **hERG:** Ligand A (0.011) has a much lower hERG risk than Ligand B (0.2). This is a critical advantage for Ligand A, given the cardiovascular target.
12. **Cl_mic:** Ligand A (-7.281) has a significantly lower (better) microsomal clearance than Ligand B (52.735), indicating better metabolic stability.
13. **t1/2:** Ligand A (13.622) has a positive in vitro half-life, while Ligand B (-26.42) has a negative value, which is highly unusual and suggests very rapid degradation.
14. **Pgp:** Both ligands have very low Pgp efflux liability (A: 0.001, B: 0.044).
15. **Binding Affinity:** Both ligands have good binding affinity (A: -6.6, B: -6.8 kcal/mol), with Ligand B being slightly better. However, the difference is small.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand B has a slightly better logP and affinity, but Ligand A excels in crucial ADME-Tox properties like DILI, hERG, and Cl_mic. The poor Caco-2 and solubility for both are concerning, but can be addressed with formulation strategies.
**Overall Assessment:**
Despite the slightly better affinity of Ligand B, Ligand A is the more promising candidate. Its significantly lower DILI and hERG risk, combined with better metabolic stability (lower Cl_mic) and a more reasonable half-life, outweigh the minor advantage in binding affinity of Ligand B. The cardiovascular nature of the target makes minimizing cardiotoxicity (hERG) and liver toxicity (DILI) paramount.
Output:
1
2025-04-17 19:30:29,257 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [379.833, 106.73 , 0.909, 2. , 8. , 0.515, 98.604, 53.47 , -5.467, -3.135, 0.058, 44.483, 31.486, 0.124, -7.6 ]
**Ligand B:** [365.43 , 75.44 , 2.348, 1. , 5. , 0.883, 41.915, 80.419, -4.926, -2.777, 0.424, 14.533, 10.739, 0.087, -6.2 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (365.43) is slightly lower, which is generally favorable.
2. **TPSA:** Ligand A (106.73) is higher than Ligand B (75.44). Ligand B is better, being well under the 140 A^2 threshold for oral absorption.
3. **logP:** Ligand A (0.909) is a bit low, potentially hindering permeation. Ligand B (2.348) is within the optimal 1-3 range. Ligand B is better.
4. **HBD:** Both are acceptable (Ligand A: 2, Ligand B: 1). Ligand B is slightly better.
5. **HBA:** Both are acceptable (Ligand A: 8, Ligand B: 5). Ligand B is better.
6. **QED:** Ligand B (0.883) is significantly better than Ligand A (0.515), indicating a more drug-like profile.
7. **DILI:** Ligand A (98.604) has a very high DILI risk, a major concern. Ligand B (41.915) is much lower and acceptable. Ligand B is *significantly* better.
8. **BBB:** Ligand B (80.419) has better BBB penetration than Ligand A (53.47). While not a primary concern for a cardiovascular target, it's a bonus.
9. **Caco-2:** Ligand A (-5.467) is very poor. Ligand B (-4.926) is also poor, but slightly better.
10. **Solubility:** Ligand A (-3.135) is poor. Ligand B (-2.777) is also poor, but slightly better.
11. **hERG:** Ligand A (0.058) is very low risk. Ligand B (0.424) is slightly higher, but still acceptable. Ligand A is better.
12. **Cl_mic:** Ligand B (14.533) has significantly lower microsomal clearance than Ligand A (44.483), indicating better metabolic stability. Ligand B is better.
13. **t1/2:** Ligand A (31.486) has a longer half-life than Ligand B (10.739). Ligand A is better.
14. **Pgp:** Ligand A (0.124) has lower P-gp efflux than Ligand B (0.087), suggesting better bioavailability. Ligand A is better.
15. **Affinity:** Ligand A (-7.6) has a stronger binding affinity than Ligand B (-6.2). This is a substantial difference (1.4 kcal/mol), and is a major advantage for Ligand A.
**GPCR-specific priorities:** For ADRB2 (a GPCR), we prioritize logP, Pgp, TPSA, and affinity. Ligand B excels in TPSA and logP, and has better metabolic stability. However, Ligand A has a significantly better binding affinity and better Pgp efflux. The DILI risk for Ligand A is a huge red flag.
**Overall Assessment:**
Despite the superior binding affinity of Ligand A, the extremely high DILI risk is a deal-breaker. While a 1.4 kcal/mol difference in affinity is substantial, the safety concerns associated with Ligand A outweigh this benefit. Ligand B, while having a weaker affinity, presents a much more favorable ADMET profile, particularly regarding liver toxicity.
Output:
0
2025-04-17 19:30:29,257 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (344.46 and 363.58 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (78.09) is higher than Ligand B (56.41). For a cardiovascular GPCR, TPSA is moderately important, and lower is generally better for permeability. Ligand B has a clear advantage.
**3. logP:** Both ligands have good logP values (2.70 and 3.21), falling within the optimal 1-3 range. Ligand B is slightly higher, which *could* be a minor drawback if it leads to off-target effects, but is not a major concern.
**4. H-Bond Donors & Acceptors:** Ligand A has 2 HBD and 3 HBA, while Ligand B has 1 HBD and 2 HBA. Both are within acceptable limits (<=5 HBD, <=10 HBA). Ligand B is slightly more favorable.
**5. QED:** Both have good QED scores (0.779 and 0.817), indicating good drug-like properties. No significant difference.
**6. DILI Risk:** Ligand A (40.40) has a slightly higher DILI risk than Ligand B (25.48), but both are below the 40% threshold considered good. Ligand B is preferred.
**7. BBB Penetration:** Both ligands show similar BBB penetration (67.12% and 67.47%). Since this is a cardiovascular target, BBB penetration is not a primary concern, but it's good to see reasonable values.
**8. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.979 and -4.665). This is unusual and suggests poor permeability *in vitro*. This is a significant concern for both.
**9. Aqueous Solubility:** Both ligands have very poor aqueous solubility (-3.9 and -4.116). This is a major drawback for both compounds, potentially hindering bioavailability.
**10. hERG Inhibition:** Ligand A (0.168) has a lower hERG inhibition risk than Ligand B (0.744). This is a significant advantage for Ligand A.
**11. Microsomal Clearance:** Ligand A (59.79) has lower microsomal clearance than Ligand B (65.65), suggesting better metabolic stability. This is a positive for Ligand A.
**12. In vitro Half-Life:** Ligand A (-28.73) has a significantly longer *in vitro* half-life than Ligand B (1.90). This is a substantial advantage for Ligand A, potentially allowing for less frequent dosing.
**13. P-gp Efflux:** Ligand A (0.103) has lower P-gp efflux than Ligand B (0.261), which is favorable for bioavailability.
**14. Binding Affinity:** Ligand B (-6.7 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.5 kcal/mol). This is a >1.5 kcal/mol difference, a substantial advantage that can outweigh some ADME drawbacks.
**Overall Assessment:**
While both compounds have significant issues with solubility and Caco-2 permeability, the stronger binding affinity of Ligand B is a major advantage for a GPCR target. The slightly better DILI and TPSA values of Ligand B also contribute. Ligand A has advantages in hERG, metabolic stability, and half-life, but the potency difference is too significant to ignore. The poor solubility of both compounds would need to be addressed through formulation strategies.
Output:
0
2025-04-17 19:30:29,257 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.406 and 351.441 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (78.87) is higher than Ligand B (38.13). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is generally preferred for permeability. Ligand B is significantly better.
3. **logP:** Ligand A (1.334) is within the optimal range (1-3), while Ligand B (3.919) is approaching the upper limit. While still acceptable, Ligand A's logP is more balanced.
4. **HBD:** Ligand A (2) and Ligand B (0) are both acceptable.
5. **HBA:** Ligand A (4) and Ligand B (3) are both acceptable.
6. **QED:** Both ligands (0.776 and 0.729) have good drug-likeness scores (>0.5). No major difference.
7. **DILI:** Ligand A (30.438) and Ligand B (35.285) both have low DILI risk (<40), indicating good safety profiles. No significant difference.
8. **BBB:** Ligand B (95.192) has a much higher BBB penetration percentile than Ligand A (76.309). While ADRB2 isn't a CNS target, some degree of BBB penetration can be beneficial for off-target effects and distribution.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.319 and -4.38). This is unusual and suggests poor permeability. However, the values are very similar.
10. **Solubility:** Ligand A (-1.76) is better than Ligand B (-4.072). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.452) has a lower hERG inhibition liability than Ligand B (0.796), which is preferable for cardiac safety.
12. **Cl_mic:** Ligand A (27.207) has a lower microsomal clearance than Ligand B (71.018), suggesting better metabolic stability.
13. **t1/2:** Ligand A (5.145) has a longer in vitro half-life than Ligand B (2.502), which is desirable.
14. **Pgp:** Ligand A (0.087) has much lower P-gp efflux liability than Ligand B (0.687), suggesting better oral bioavailability and potentially better tissue distribution.
15. **Binding Affinity:** Ligand B (-6.0) has a slightly better binding affinity than Ligand A (-5.7). However, the difference is only 0.3 kcal/mol, which is not substantial enough to overcome the other ADME deficiencies of Ligand B.
**Overall Assessment:**
Ligand A demonstrates a superior balance of properties. While Ligand B has slightly better binding affinity and BBB penetration, Ligand A excels in crucial ADME properties like solubility, metabolic stability (lower Cl_mic and longer t1/2), lower P-gp efflux, and lower hERG risk. The lower TPSA of Ligand B is a benefit, but the negative Caco-2 values for both are concerning. Given the cardiovascular target, the improved ADME profile of Ligand A, particularly the lower hERG risk and better metabolic stability, makes it the more promising candidate.
Output:
1
2025-04-17 19:30:29,257 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (364.423 Da and 348.368 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (94.99) is higher than Ligand B (32.34). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for permeability. Ligand B is significantly better.
**3. logP:** Ligand A (1.529) is within the optimal range (1-3). Ligand B (4.498) is slightly high, potentially leading to solubility issues and off-target interactions. Ligand A is better.
**4. H-Bond Donors:** Both have 1 HBD, which is acceptable.
**5. H-Bond Acceptors:** Ligand A has 4 HBAs, and Ligand B has 2. Both are within the acceptable limit of 10.
**6. QED:** Both ligands have similar QED values (0.878 and 0.834), indicating good drug-likeness.
**7. DILI Risk:** Ligand A (72.664) has a higher DILI risk than Ligand B (56.689). This is a concern for Ligand A.
**8. BBB Penetration:** Ligand A (59.946) has lower BBB penetration than Ligand B (90.617). While ADRB2 is a cardiovascular target, some CNS exposure is possible and not necessarily detrimental, and higher BBB is generally favorable. Ligand B is better.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-5.033 and -4.849). This is unusual and suggests poor permeability. However, the values are similar, so it doesn't strongly favor either.
**10. Aqueous Solubility:** Both ligands have very poor aqueous solubility (-2.6 and -4.813). This is a significant drawback for both, but worse for Ligand B.
**11. hERG Inhibition:** Ligand A (0.032) has a very low hERG risk, which is excellent. Ligand B (0.946) has a moderate hERG risk, which is a concern. Ligand A is significantly better.
**12. Microsomal Clearance:** Ligand B (35.856) has a higher microsomal clearance than Ligand A (26.043), indicating faster metabolism and potentially lower *in vivo* exposure. Ligand A is better.
**13. In vitro Half-Life:** Ligand A (-12.943) has a negative half-life, which is not possible. This is a data error. Ligand B (1.662) has a short half-life, but it is at least a plausible value.
**14. P-gp Efflux:** Ligand A (0.021) has very low P-gp efflux, which is favorable. Ligand B (0.554) has moderate P-gp efflux. Ligand A is better.
**15. Binding Affinity:** Ligand B (-8.4 kcal/mol) has a significantly stronger binding affinity than Ligand A (-7.0 kcal/mol). This is a substantial advantage for Ligand B.
**Overall Assessment:**
Despite the strong affinity of Ligand B, several factors weigh against it. Its high logP, moderate hERG risk, faster clearance, and poor solubility are significant concerns. Ligand A, while having a slightly weaker affinity, has a much better safety profile (low hERG, low P-gp efflux, lower DILI risk) and better metabolic stability. The negative half-life for Ligand A is a data error and cannot be considered. The lower TPSA of Ligand B is a plus, but the other issues are more critical for overall drug development potential.
Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity), and balancing the ADME-Tox properties, Ligand A appears to be the more viable candidate.
Output:
1
2025-04-17 19:30:29,258 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Step-by-step comparison:**
1. **MW:** Both ligands (344.39 & 350.46 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (51.66) is significantly better than Ligand B (82.03). ADRB2 is not a CNS target, but lower TPSA generally improves absorption.
3. **logP:** Both are good (3.29 and 2.14), falling within the 1-3 range. Ligand A is slightly higher, which *could* be beneficial for membrane permeability, but isn't a major concern.
4. **HBD:** Ligand A (0) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Both have 4 HBA, which is acceptable.
6. **QED:** Both are similar (0.773 and 0.734), indicating good drug-likeness.
7. **DILI:** Ligand B (27.72) has a much lower DILI risk than Ligand A (42.92). This is a significant advantage for Ligand B.
8. **BBB:** Not a primary concern for ADRB2, but Ligand A (92.05) has a higher BBB penetration than Ligand B (40.52).
9. **Caco-2:** Ligand A (-3.96) is better than Ligand B (-4.623), indicating better intestinal absorption.
10. **Solubility:** Ligand B (-1.503) has better aqueous solubility than Ligand A (-4.395). This is a positive for formulation.
11. **hERG:** Both are relatively low (0.76 and 0.437), indicating low cardiotoxicity risk.
12. **Cl_mic:** Ligand B (-0.561) has a *much* lower microsomal clearance than Ligand A (86.206), suggesting better metabolic stability. This is a major advantage.
13. **t1/2:** Ligand B (12.367 hours) has a significantly longer in vitro half-life than Ligand A (-24.762 hours). This is a substantial benefit, potentially allowing for less frequent dosing.
14. **Pgp:** Both are low (0.386 and 0.122), indicating minimal P-gp efflux.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.3 and -5.5 kcal/mol). The difference is not substantial enough to outweigh other factors.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, and affinity are important. Ligand A has a slight edge in logP and Caco-2, but Ligand B excels in DILI, Cl_mic, and t1/2.
**Overall Assessment:**
Ligand B is the stronger candidate. While Ligand A has slightly better Caco-2 permeability, Ligand B's significantly lower DILI risk, better metabolic stability (lower Cl_mic), and longer half-life are crucial advantages. These factors contribute to a safer and more practical drug profile. The affinity difference is minimal.
Output:
0
2025-04-17 19:30:29,258 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (351.491 Da) fall comfortably within the ideal 200-500 Da range. No difference here.
2. **TPSA:** Both ligands (81.67) are below the 140 A^2 threshold for good oral absorption, and acceptable for a non-CNS GPCR target like ADRB2. No difference.
3. **logP:** Both ligands have logP values within the optimal 1-3 range (1.036 and 1.201 respectively). Ligand B is slightly higher, which *could* be beneficial for membrane permeability, but the difference is small.
4. **HBD:** Both ligands have 3 H-bond donors, which is within the acceptable limit of <=5. No difference.
5. **HBA:** Both ligands have 4 H-bond acceptors, also within the acceptable limit of <=10. No difference.
6. **QED:** Ligand A (0.61) has a better QED score than Ligand B (0.408), indicating a more drug-like profile. This is a moderate advantage for A.
7. **DILI:** Ligand A (4.382%) has a significantly lower DILI risk than Ligand B (5.467%). This is a substantial advantage for A, as liver toxicity is a major concern.
8. **BBB:** Ligand A (68.127%) has a much higher BBB penetration percentile than Ligand B (36.06%). While ADRB2 isn't a primary CNS target, some degree of BBB penetration can sometimes influence off-target effects or distribution.
9. **Caco-2:** Ligand A (-5.205) has a slightly better Caco-2 permeability than Ligand B (-5.051), suggesting better intestinal absorption.
10. **Solubility:** Ligand A (-1.923) has slightly better aqueous solubility than Ligand B (-1.198).
11. **hERG:** Ligand A (0.34) has a lower hERG inhibition liability than Ligand B (0.173), making it safer from a cardiotoxicity perspective. This is a significant advantage for A.
12. **Cl_mic:** Ligand A (-3.238 mL/min/kg) has a substantially *lower* (better) microsomal clearance than Ligand B (24.821 mL/min/kg). This indicates much greater metabolic stability for Ligand A.
13. **t1/2:** Ligand A (-15.342 hours) has a longer in vitro half-life than Ligand B (-0.188 hours). This is a major advantage for A, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.008) has a lower P-gp efflux liability than Ligand B (0.04), which is favorable for bioavailability.
15. **Binding Affinity:** Both ligands have comparable binding affinity (-7.0 kcal/mol and -5.3 kcal/mol, respectively). However, Ligand A has a significantly better affinity.
**GPCR-specific priorities:** For ADRB2, logP, TPSA, and affinity are important. Both ligands perform similarly on logP and TPSA. Ligand A has a superior binding affinity.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical ADME-Tox properties (DILI, hERG, Cl_mic, t1/2, Pgp) and has a better QED score. While the binding affinity is similar, the superior ADME profile of Ligand A makes it a far more promising drug candidate. The significant differences in metabolic stability (Cl_mic and t1/2) and safety (DILI and hERG) are decisive.
Output:
1
2025-04-17 19:30:29,258 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (348.378) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are reasonably low, but Ligand B (87.3) is better than Ligand A (95.42), being closer to the <90 threshold for potential CNS penetration (though not a primary concern for ADRB2 unless CNS effects are desired).
3. **logP:** Ligand B (1.836) is better positioned within the optimal 1-3 range than Ligand A (0.449), which is quite low and could hinder membrane permeability.
4. **HBD:** Ligand A (2) is preferable to Ligand B (3). Lower HBD generally improves permeability.
5. **HBA:** Ligand B (3) is preferable to Ligand A (5). Lower HBA generally improves permeability.
6. **QED:** Ligand A (0.824) has a significantly better QED score than Ligand B (0.61), indicating a more drug-like profile.
7. **DILI:** Ligand B (21.946) has a much lower DILI risk than Ligand A (56.689), a critical advantage.
8. **BBB:** Ligand A (77.588) has a better BBB penetration score than Ligand B (59.093), but this isn't a high priority for a cardiovascular target.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability in both cases. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Both have negative solubility values, which is also unusual. Again, the scale is not specified.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.158 and 0.1 respectively), which is excellent.
12. **Cl_mic:** Ligand A (-28.588) has a much lower (better) microsomal clearance than Ligand B (47.774), suggesting greater metabolic stability.
13. **t1/2:** Ligand B (17.609) has a significantly longer in vitro half-life than Ligand A (6.328), which is desirable.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.035 and 0.017 respectively), which is good.
15. **Binding Affinity:** Ligand A (-7.3 kcal/mol) has a stronger binding affinity than Ligand B (-6.1 kcal/mol). This is a substantial difference and a major advantage.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has a better affinity, but Ligand B has a better logP and TPSA. The DILI risk for Ligand B is also significantly lower, which is a major safety concern.
**Overall Assessment:**
While Ligand A has a superior binding affinity and QED, the significantly lower DILI risk and better logP of Ligand B are compelling. The longer half-life of Ligand B is also a significant advantage. The affinity difference, while substantial, might be overcome with further optimization of Ligand B. The negative solubility and Caco-2 values are concerning for both, but could be addressed during formulation. Given the importance of safety (DILI) and permeability (logP) for a cardiovascular drug, I favor Ligand B.
Output:
0
2025-04-17 19:30:29,258 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (338.371 and 339.443 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (93.96) is slightly higher than Ligand B (81.1). Both are below the 140 threshold for oral absorption, but closer to the 90 threshold for CNS targets (less relevant here, but still a positive). Ligand B is preferable here.
3. **logP:** Ligand A (1.721) is within the optimal 1-3 range. Ligand B (4.386) is higher, potentially leading to solubility issues and off-target effects. Ligand A is significantly better.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable, below the 5 threshold. No strong preference.
5. **HBA:** Ligand A (6) and Ligand B (3) are both acceptable, below the 10 threshold. Ligand B is preferable.
6. **QED:** Ligand A (0.755) is much better than Ligand B (0.374), indicating a stronger drug-like profile. This is a significant advantage for Ligand A.
7. **DILI:** Ligand A (82.668) has a higher DILI risk than Ligand B (50.291). Ligand B is preferable.
8. **BBB:** Both ligands have good BBB penetration (Ligand A: 73.013, Ligand B: 75.107). Not a major differentiating factor for ADRB2, but slightly better for Ligand B.
9. **Caco-2:** Both have negative values, indicating poor permeability. Ligand A (-5.421) is worse than Ligand B (-4.748). Ligand B is preferable.
10. **Solubility:** Ligand A (-2.59) is better than Ligand B (-4.271). Ligand A is preferable.
11. **hERG:** Ligand A (0.106) has a much lower hERG risk than Ligand B (0.605). This is a crucial advantage for Ligand A, minimizing cardiotoxicity concerns.
12. **Cl_mic:** Ligand A (2.412) has a lower microsomal clearance than Ligand B (51.275), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand B (84.768) has a longer in vitro half-life than Ligand A (56.379). Ligand B is preferable.
14. **Pgp:** Ligand A (0.04) has lower P-gp efflux than Ligand B (0.521). Ligand A is preferable.
15. **Binding Affinity:** Ligand A (-7.2 kcal/mol) has a slightly better binding affinity than Ligand B (-6.4 kcal/mol). This difference (0.8 kcal/mol) is significant enough to outweigh some of the ADME drawbacks of Ligand A.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand A emerges as the more promising candidate. While Ligand B has better DILI and t1/2, Ligand A's superior logP, QED, hERG safety, metabolic stability (Cl_mic), Pgp profile, and slightly better binding affinity are more critical for a GPCR target like ADRB2. The higher DILI risk of Ligand A could be investigated further, but the other advantages make it the preferred choice.
Output:
1
2025-04-17 19:30:29,258 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [354.451, 110.77 , -0.18 , 4. , 4. , 0.508, 20.279, 40.132, -5.309, -0.905, 0.089, -4.937, 12.201, 0.003, -5.1 ]
**Ligand B:** [352.435, 96.69 , 1.068, 2. , 6. , 0.747, 39.434, 50.097, -5.155, -1.45 , 0.512, 25.609, -4.269, 0.083, -7. ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). A (354.451) and B (352.435) are very close, no significant difference.
2. **TPSA:** A (110.77) is slightly higher than B (96.69). B is better, closer to the <140 threshold for good absorption.
3. **logP:** A (-0.18) is quite low, potentially hindering permeability. B (1.068) is much better, falling within the optimal 1-3 range. This is a significant advantage for B.
4. **HBD:** A (4) is acceptable. B (2) is better, reducing potential for off-target interactions and improving permeability.
5. **HBA:** A (4) is acceptable. B (6) is also acceptable, but slightly higher.
6. **QED:** Both are good (A: 0.508, B: 0.747), but B is better, indicating a more drug-like profile.
7. **DILI:** Both are good (A: 20.279, B: 39.434), below the 40% threshold. A is slightly better.
8. **BBB:** B (50.097) is better than A (40.132), although neither are particularly high. For a cardiovascular target, BBB isn't *critical*, but higher is still preferred.
9. **Caco-2:** Both are negative, indicating poor permeability. A (-5.309) is slightly worse than B (-5.155).
10. **Solubility:** Both are negative, indicating poor solubility. A (-0.905) is slightly better than B (-1.45).
11. **hERG:** Both are very low (A: 0.089, B: 0.512), indicating very low risk of cardiotoxicity. A is slightly better.
12. **Cl_mic:** A (-4.937) is much better (lower is better) than B (25.609), suggesting significantly better metabolic stability.
13. **t1/2:** A (12.201) is better than B (-4.269), indicating a longer half-life.
14. **Pgp:** A (0.003) is much better (lower is better) than B (0.083), indicating less efflux and better bioavailability.
15. **Affinity:** B (-7.0) is significantly better than A (-5.1), representing a substantial advantage in binding.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. B excels in logP and affinity. A has better Pgp, but B's superior affinity likely outweighs this. TPSA is better for B.
**Overall Assessment:**
While Ligand A has some advantages in DILI, hERG, Cl_mic, t1/2 and Pgp, Ligand B's significantly stronger binding affinity (-7.0 vs -5.1 kcal/mol) and better logP, TPSA, and QED are more critical for a GPCR target. The improved affinity is likely to overcome the slightly higher Pgp and lower metabolic stability. The poor Caco-2 and solubility for both compounds would need to be addressed in further optimization, but the binding affinity is the most important factor at this stage.
Output:
0
2025-04-17 19:30:29,258 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (363.447 and 364.471 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (137.08) is slightly higher than Ligand B (114.18). Both are below the 140 A^2 threshold for good oral absorption, but Ligand B is preferable due to being closer to the 90 A^2 target for GPCRs.
3. **logP:** Both ligands have good logP values (1.699 and 1.368), falling within the optimal 1-3 range. Ligand B is slightly lower, which could be beneficial for solubility.
4. **HBD:** Ligand A has 2 HBD, and Ligand B has 3. Both are acceptable, being less than 5.
5. **HBA:** Ligand A has 6 HBA, and Ligand B has 5. Both are acceptable, being less than 10.
6. **QED:** Ligand B (0.644) has a better QED score than Ligand A (0.467), indicating a more drug-like profile.
7. **DILI:** Ligand B (48.817) has a significantly lower DILI risk than Ligand A (68.437). This is a major advantage for Ligand B.
8. **BBB:** Both ligands have reasonable BBB penetration (67.623 and 65.607). While not exceptionally high, they are acceptable for a non-CNS target like ADRB2.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.343 and -5.431). This is unusual and suggests poor permeability. However, the values are very similar.
10. **Solubility:** Both ligands have very poor aqueous solubility (-3.424 and -3.442). This is a significant drawback for both.
11. **hERG:** Both ligands have low hERG inhibition risk (0.394 and 0.247). Ligand B is slightly better here.
12. **Cl_mic:** Ligand A (9.975) has a lower microsomal clearance than Ligand B (8.751), suggesting better metabolic stability.
13. **t1/2:** Ligand B (18.761) has a significantly longer in vitro half-life than Ligand A (-8.257). This is a strong advantage for Ligand B.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.054 and 0.042).
15. **Binding Affinity:** Ligand B (-7.9 kcal/mol) has a slightly better binding affinity than Ligand A (-7.2 kcal/mol). This 0.7 kcal/mol difference is significant and can outweigh some ADME drawbacks.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are crucial. Ligand B excels in TPSA, DILI, hERG, half-life, and affinity. While both have poor solubility and Caco-2 permeability, the superior affinity and safety profile of Ligand B make it the better candidate. The slightly better metabolic stability of Ligand A is not enough to offset these advantages.
**Output:**
0
2025-04-17 19:30:29,258 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [336.435, 40.62, 3.002, 0, 2, 0.626, 25.785, 92.012, -4.352, -3.338, 0.457, 25.502, -17.26, 0.256, -5.8]**
**Ligand B: [356.438, 67.87, 1.28, 1, 4, 0.806, 26.095, 84.141, -4.843, -3.066, 0.343, 40.21, 10.614, 0.046, -6.8]**
1. **Molecular Weight:** Both are within the ideal range (200-500 Da). Ligand A (336.435 Da) is slightly preferred due to being a bit lower.
2. **TPSA:** Ligand A (40.62) is significantly better than Ligand B (67.87). ADRB2 is not a CNS target, but lower TPSA generally improves absorption.
3. **logP:** Ligand A (3.002) is optimal, while Ligand B (1.28) is on the lower side. This favors Ligand A for permeability.
4. **H-Bond Donors:** Ligand A (0) is better than Ligand B (1). Fewer HBDs generally improve permeability.
5. **H-Bond Acceptors:** Ligand A (2) is better than Ligand B (4). Fewer HBAs generally improve permeability.
6. **QED:** Ligand B (0.806) is better than Ligand A (0.626), indicating a more drug-like profile.
7. **DILI:** Both are good, with Ligand A (25.785) and Ligand B (26.095) being very similar and low risk.
8. **BBB:** Ligand A (92.012) is significantly better than Ligand B (84.141), although BBB isn't a primary concern for ADRB2.
9. **Caco-2 Permeability:** Ligand A (-4.352) is better than Ligand B (-4.843). Higher (less negative) values indicate better permeability.
10. **Aqueous Solubility:** Ligand A (-3.338) is better than Ligand B (-3.066). Higher (less negative) values indicate better solubility.
11. **hERG Inhibition:** Both are very low (Ligand A: 0.457, Ligand B: 0.343), indicating minimal cardiotoxicity risk.
12. **Microsomal Clearance:** Ligand A (25.502) is significantly better than Ligand B (40.21). Lower clearance is preferred for metabolic stability.
13. **In vitro Half-Life:** Ligand A (-17.26) is significantly better than Ligand B (10.614). Longer half-life is preferred.
14. **P-gp Efflux:** Ligand A (0.256) is significantly better than Ligand B (0.046). Lower P-gp efflux is preferred for better bioavailability.
15. **Binding Affinity:** Ligand B (-6.8) is 0.9 kcal/mol better than Ligand A (-5.8). This is a substantial difference in potency.
**Overall Assessment:**
Ligand B has a significantly better binding affinity, which is a crucial factor for GPCRs. However, Ligand A demonstrates superior ADME properties across multiple parameters (TPSA, logP, H-bonds, clearance, half-life, P-gp efflux, solubility, and Caco-2 permeability). The difference in affinity is substantial, and while ADME is important, a strong binding affinity is paramount for a GPCR ligand. The QED score is also better for Ligand B.
Therefore, despite the ADME advantages of Ligand A, the superior binding affinity of Ligand B makes it the more promising drug candidate.
Output:
0
2025-04-17 19:30:29,258 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (345.403 and 352.429 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand B (66.91) is significantly better than Ligand A (102.16). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (3.641) is higher than Ligand A (1.673). While both are within the acceptable range, Ligand B is approaching the upper limit. This could potentially lead to off-target effects, but is not a major concern.
4. **HBD:** Both ligands have 2 HBD, which is good.
5. **HBA:** Ligand A has 7 HBA, while Ligand B has 4. Lower HBA is generally preferred for better permeability. Ligand B is better here.
6. **QED:** Ligand A (0.826) has a slightly better QED score than Ligand B (0.767), indicating a more drug-like profile.
7. **DILI:** Ligand B (47.848) has a significantly lower DILI risk than Ligand A (70.26). This is a substantial advantage for Ligand B.
8. **BBB:** Ligand B (82.047) has better BBB penetration than Ligand A (62.699). While not a primary concern for a cardiovascular target, it's a bonus.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.726) is slightly better than Ligand B (-4.898), but both are problematic.
10. **Solubility:** Ligand A (-3.316) has slightly better solubility than Ligand B (-3.853), but both are poor.
11. **hERG:** Ligand A (0.237) has a lower hERG risk than Ligand B (0.652). This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand B (44.464) has a lower microsomal clearance than Ligand A (26.409), indicating better metabolic stability. This is a major advantage for Ligand B.
13. **t1/2:** Ligand B (33.179) has a longer in vitro half-life than Ligand A (-28.563). This is a substantial advantage for Ligand B.
14. **Pgp:** Ligand A (0.176) has lower P-gp efflux than Ligand B (0.208), which is preferable.
15. **Binding Affinity:** Ligand A (-6.4 kcal/mol) has a slightly better binding affinity than Ligand B (-4.9 kcal/mol). This is a 1.5 kcal/mol difference, which is significant and could outweigh some ADME drawbacks.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B is better on logP, TPSA, and Pgp. Ligand A has a slightly better affinity, but the difference might not be enough to overcome the other ADME advantages of Ligand B.
**Overall Assessment:**
Ligand B has a significantly better safety profile (lower DILI), better metabolic stability (lower Cl_mic, longer t1/2), and better TPSA. While Ligand A has a slightly better affinity and hERG, the ADME advantages of Ligand B are more compelling for overall drug development potential. The poor Caco-2 values for both are concerning, but can be addressed with formulation strategies.
Output:
0
2025-04-17 19:30:29,259 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (366.622 and 346.431 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (49.41) is significantly better than Ligand B (76.46). ADRB2 is a cardiovascular target, not a CNS target, but lower TPSA generally improves absorption.
3. **logP:** Ligand A (3.894) is optimal, while Ligand B (0.581) is quite low. This is a significant drawback for Ligand B, potentially hindering membrane permeability.
4. **HBD:** Both ligands have 1 HBD, which is within the acceptable limit.
5. **HBA:** Ligand A (2) is better than Ligand B (5). Lower HBA is generally preferred for better permeability.
6. **QED:** Both ligands have good QED scores (0.75 and 0.792), indicating drug-like properties.
7. **DILI:** Ligand A (26.755) has a much lower DILI risk than Ligand B (49.321). This is a major advantage for Ligand A.
8. **BBB:** This is less critical for a cardiovascular target. Ligand A (81.815) is higher than Ligand B (60.76), but the difference isn't decisive.
9. **Caco-2:** Ligand A (-4.783) is better than Ligand B (-5.012), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-4.493) is better than Ligand B (-1.342). Better solubility is always a plus.
11. **hERG:** Both ligands have low hERG inhibition risk (0.458 and 0.166), which is good.
12. **Cl_mic:** Ligand A (66.166) has a higher clearance than Ligand B (10.98). Ligand B is more metabolically stable.
13. **t1/2:** Ligand B (18.918) has a significantly longer half-life than Ligand A (-11.352). This is a substantial advantage for Ligand B.
14. **Pgp:** Ligand A (0.228) has lower P-gp efflux than Ligand B (0.047). Lower P-gp efflux is preferable.
15. **Binding Affinity:** Ligand B (-7.1) has a slightly better binding affinity than Ligand A (-6.9). However, the difference is less than 1.5 kcal/mol, and can be overcome by other properties.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand A is the stronger candidate. While Ligand B has a slightly better affinity and half-life, Ligand A excels in crucial properties like logP, TPSA, DILI risk, solubility, and Pgp efflux. The low logP of Ligand B is a significant concern for permeability and overall bioavailability. The lower DILI risk of Ligand A is also a major advantage. The slightly longer half-life of Ligand B is beneficial, but not enough to outweigh the other drawbacks.
Output:
1
2025-04-17 19:30:29,259 - INFO - Batch 115 complete. Total preferences: 1840
2025-04-17 19:30:29,259 - INFO - Processing batch 116/512...
2025-04-17 19:31:14,823 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (367.373 and 374.522 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (72.47) is slightly higher than Ligand B (58.64). Both are below the 140 threshold for oral absorption, but B is closer to the preferred <90 for GPCRs.
3. **logP:** Both ligands have excellent logP values (2.449 and 2.39), falling within the optimal 1-3 range.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Both have 4 HBA, which is good.
6. **QED:** Ligand A (0.824) has a better QED score than Ligand B (0.709), indicating a more drug-like profile.
7. **DILI:** Ligand B (26.095) is *significantly* better than Ligand A (82.784) regarding DILI risk. This is a major advantage for Ligand B.
8. **BBB:** Ligand B (93.68) has a much higher BBB penetration percentile than Ligand A (57.193). While ADRB2 isn't exclusively a CNS target, improved BBB penetration can still be beneficial for distribution and reducing off-target effects.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual. I'll assume these are percentile scores and interpret them as low permeability. Ligand A (-4.65) is slightly worse than Ligand B (-4.814).
10. **Solubility:** Ligand B (-2.969) has better solubility than Ligand A (-4.445).
11. **hERG:** Ligand A (0.317) has a slightly better hERG profile than Ligand B (0.642), but both are reasonably low risk.
12. **Cl_mic:** Ligand B (41.811) has a lower microsomal clearance than Ligand A (59.443), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-7.43) has a longer in vitro half-life than Ligand A (6.896).
14. **Pgp:** Ligand A (0.466) has lower P-gp efflux liability than Ligand B (0.291), which is favorable.
15. **Binding Affinity:** Ligand B (-5.0) has a slightly better binding affinity than Ligand A (-6.2). While A is stronger, the difference is not substantial enough to outweigh the ADME advantages of B.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Both ligands perform well on logP. Ligand B is better on TPSA and Pgp, and has a good binding affinity. Ligand B's superior DILI score and BBB penetration are also significant advantages.
**Overall Assessment:**
While Ligand A has a slightly better QED and binding affinity, Ligand B demonstrates a significantly more favorable ADME profile, particularly regarding DILI risk, metabolic stability (Cl_mic, t1/2), solubility, and BBB penetration. These factors are crucial for developing a safe and effective drug. The small difference in binding affinity is outweighed by the substantial improvements in other critical parameters.
Output:
0
2025-04-17 19:31:14,824 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [368.543, 67.43, 3.456, 2, 3, 0.808, 28.499, 75.107, -4.397, -3.166, 0.625, 58.854, 22.009, 0.09, -6.5]
**Ligand B:** [365.411, 115.9, 0.406, 3, 7, 0.707, 70.686, 9.539, -5.399, -2.088, 0.105, -12.489, 32.876, 0.153, -6.6]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, BBB, affinity):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B is slightly lower, which isn't a major concern.
2. **TPSA:** Ligand A (67.43) is significantly better than Ligand B (115.9). Below 140 is good for oral absorption, but lower is generally preferred for GPCRs, and A is much closer to the ideal for CNS penetration if needed.
3. **logP:** Ligand A (3.456) is optimal (1-3). Ligand B (0.406) is quite low, potentially leading to poor membrane permeability and bioavailability. This is a significant drawback.
4. **HBD/HBA:** Ligand A (2/3) is better than Ligand B (3/7). Fewer H-bonds are generally preferred for permeability.
5. **QED:** Both are decent (A: 0.808, B: 0.707), indicating good drug-like properties.
6. **DILI:** Ligand A (28.499) is much better than Ligand B (70.686). A lower DILI risk is crucial.
7. **BBB:** Ligand A (75.107) is good, while Ligand B (9.539) is very poor. This is a key factor for a GPCR, even if not targeting the CNS directly, as it suggests better distribution characteristics.
8. **Caco-2:** Ligand A (-4.397) is better than Ligand B (-5.399), indicating better absorption.
9. **Solubility:** Ligand A (-3.166) is better than Ligand B (-2.088).
10. **hERG:** Both are very low (A: 0.625, B: 0.105), indicating low cardiotoxicity risk.
11. **Cl_mic:** Ligand B (-12.489) has a much lower (better) microsomal clearance than Ligand A (58.854), suggesting greater metabolic stability.
12. **t1/2:** Ligand B (32.876) has a longer half-life than Ligand A (22.009).
13. **Pgp:** Ligand A (0.09) is better than Ligand B (0.153), indicating less P-gp efflux.
14. **Affinity:** Both have very similar and excellent binding affinities (-6.5 and -6.6 kcal/mol). The difference is negligible.
**Conclusion:**
While Ligand B has better metabolic stability (Cl_mic, t1/2), the significant drawbacks of its low logP, high DILI risk, poor BBB penetration, and higher HBA count outweigh this benefit. Ligand A excels in crucial GPCR-relevant properties like logP, TPSA, BBB, and DILI risk, making it a much more promising drug candidate. The similar binding affinities further solidify this preference.
Output:
1
2025-04-17 19:31:14,824 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (385.222 and 363.38 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (67.43) is significantly better than Ligand B (84.23). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (3.919 and 2.696, respectively), falling within the 1-3 range. Ligand A is slightly higher, which *could* be a minor concern for solubility, but is likely acceptable.
4. **HBD:** Both have 2 HBD, which is within the acceptable limit of <=5.
5. **HBA:** Ligand A has 3 HBA, while Ligand B has 4. Both are within the acceptable limit of <=10.
6. **QED:** Both ligands have similar QED values (0.767 and 0.744), indicating good drug-likeness.
7. **DILI:** Ligand A (75.378) has a higher DILI risk than Ligand B (58.511). This is a significant negative for Ligand A. Lower DILI is highly desirable.
8. **BBB:** Both ligands have good BBB penetration (70.027 and 74.06), but this isn't a high priority for a cardiovascular target.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual. Assuming these are percentile scores, both have poor permeability.
10. **Solubility:** Ligand B (-3.047) has better solubility than Ligand A (-5.547). Better solubility is always preferred.
11. **hERG:** Ligand A (0.61) has a slightly higher hERG risk than Ligand B (0.452), but both are relatively low.
12. **Cl_mic:** Ligand B (52.705) has significantly lower microsomal clearance than Ligand A (85.787), suggesting better metabolic stability. This is a substantial advantage for Ligand B.
13. **t1/2:** Ligand B (-9.508) has a negative half-life, which is unusual. Ligand A (47.034) has a more reasonable half-life.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.162 and 0.157).
15. **Binding Affinity:** Ligand A (-6.9 kcal/mol) has a slightly better binding affinity than Ligand B (-6.6 kcal/mol). This 0.3 kcal/mol difference is not substantial enough to outweigh other factors.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity) and general drug-like properties, Ligand B is the more promising candidate. While Ligand A has slightly better affinity, Ligand B has significantly better DILI risk, solubility, and metabolic stability (lower Cl_mic). The TPSA is also more favorable for Ligand B. The unusual negative half-life for Ligand B is concerning, but the other advantages are more compelling.
Output:
0
2025-04-17 19:31:14,824 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Ligand A (346.471 Da) is well within the ideal range (200-500 Da). Ligand B (411.34 Da) is also acceptable, but closer to the upper limit.
2. **TPSA:** Ligand A (49.85) is excellent, well below the 140 threshold for oral absorption. Ligand B (67.43) is still reasonable, but higher.
3. **logP:** Both ligands (A: 2.841, B: 3.801) are within the optimal 1-3 range. Ligand B is slightly higher, potentially increasing off-target interactions, but not drastically.
4. **HBD:** Ligand A (0) is ideal. Ligand B (2) is acceptable.
5. **HBA:** Ligand A (4) is good. Ligand B (3) is also good.
6. **QED:** Ligand A (0.713) is better than Ligand B (0.53), indicating a more drug-like profile.
7. **DILI:** Ligand A (13.339) has a significantly lower DILI risk than Ligand B (33.424). This is a major advantage.
8. **BBB:** Ligand A (86.274) has better BBB penetration than Ligand B (77.239), which is important for GPCRs.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-4.041) is slightly better than Ligand B (-4.765).
10. **Solubility:** Both have negative solubility values, indicating poor aqueous solubility. Ligand A (-2.491) is better than Ligand B (-4.704).
11. **hERG:** Both have low hERG inhibition liability (A: 0.571, B: 0.745).
12. **Cl_mic:** Ligand A (98.882) has higher metabolic clearance than Ligand B (76.043), meaning it's less metabolically stable.
13. **t1/2:** Ligand B (33.132) has a much longer in vitro half-life than Ligand A (1.191). This is a significant advantage.
14. **Pgp:** Ligand A (0.056) has lower P-gp efflux than Ligand B (0.377), which is good.
15. **Affinity:** Ligand B (-7.5 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.8 kcal/mol). This is a substantial advantage, potentially outweighing some ADME concerns.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, Pgp, TPSA, BBB, and affinity. Ligand B excels in affinity and has acceptable values for the other parameters. Ligand A has better DILI and Pgp, but the affinity difference is substantial. The longer half-life of Ligand B is also a significant benefit.
**Overall Assessment:**
While Ligand A has a better safety profile (lower DILI) and slightly better permeability/solubility, the significantly stronger binding affinity (-7.5 vs -5.8 kcal/mol) of Ligand B, coupled with its longer half-life, makes it the more promising candidate. The affinity difference is large enough to potentially overcome the slightly higher DILI risk and lower BBB penetration.
Output:
0
2025-04-17 19:31:14,824 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (345.389 and 344.459 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (29.54) is significantly better than Ligand B (74.33). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold, while Ligand B is approaching it.
3. **logP:** Ligand A (4.492) is a bit high, potentially leading to solubility issues or off-target interactions. Ligand B (2.759) is much better, falling squarely within the optimal 1-3 range.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (2) is preferable to Ligand B (3). Fewer HBAs generally improve permeability.
6. **QED:** Both ligands have good QED scores (0.747 and 0.866), indicating good overall drug-likeness.
7. **DILI:** Ligand B (39.201) has a significantly lower DILI risk than Ligand A (59.984). This is a major advantage for Ligand B.
8. **BBB:** Both ligands have reasonably high BBB penetration (85.964 and 82.358). This isn't a critical factor for a cardiovascular target, but it doesn't hurt.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.455 and -4.682). This is unusual and suggests poor permeability.
10. **Solubility:** Ligand A (-5.013) has slightly better solubility than Ligand B (-3.455), but both are very poor.
11. **hERG:** Ligand A (0.91) has a slightly higher hERG risk than Ligand B (0.489). Lower is better.
12. **Cl_mic:** Ligand B (38.573) has significantly better metabolic stability (lower clearance) than Ligand A (115.044).
13. **t1/2:** Ligand A (15.917) has a slightly longer half-life than Ligand B (12.005).
14. **Pgp:** Ligand A (0.934) has slightly higher P-gp efflux than Ligand B (0.088). Lower is better.
15. **Binding Affinity:** Ligand B (-7.6 kcal/mol) has a *much* stronger binding affinity than Ligand A (-5.6 kcal/mol). This is a 2 kcal/mol difference, which is substantial and can often outweigh minor ADME drawbacks.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand B excels in logP, Pgp, and *especially* affinity. While Ligand A has a lower TPSA, the superior binding affinity and better ADME profile of Ligand B (lower DILI, better metabolic stability, lower Pgp efflux) are more important.
**Conclusion:**
Despite the poor Caco-2 and solubility values for both, Ligand B's significantly stronger binding affinity, lower DILI risk, and improved metabolic stability make it the more promising drug candidate. The higher logP is a concern, but the substantial affinity advantage is likely to outweigh that drawback.
Output:
0
2025-04-17 19:31:14,824 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (358.429 and 374.503 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (49.85) is significantly better than Ligand B (93.73). ADRB2 is a cardiovascular target, not CNS, but lower TPSA generally favors absorption. Ligand A is well below the 140 threshold. Ligand B is approaching a concerning level.
3. **logP:** Ligand A (2.296) is optimal, while Ligand B (0.795) is a bit low, potentially impacting permeability.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (3) is better than Ligand B (5). Lower HBA is generally preferred for permeability.
6. **QED:** Both are reasonably good (0.778 and 0.655), above the 0.5 threshold.
7. **DILI:** Both have acceptable DILI risk (32.687 and 42.148), both below the 40% threshold.
8. **BBB:** Not a primary concern for a cardiovascular target, but Ligand A (86.661) is better than Ligand B (57.464).
9. **Caco-2:** Ligand A (-4.242) is better than Ligand B (-5.403). Higher values indicate better absorption.
10. **Solubility:** Ligand A (-2.818) is better than Ligand B (-1.943). Higher solubility is generally preferred.
11. **hERG:** Both are very low (0.469 and 0.29), indicating minimal risk of cardiotoxicity.
12. **Cl_mic:** Ligand B (17.674) has significantly lower clearance than Ligand A (40.862), suggesting better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand B (-7.411) has a longer half-life than Ligand A (-15.38), which is a clear advantage.
14. **Pgp:** Both are very low (0.104 and 0.032), indicating minimal P-gp efflux.
15. **Binding Affinity:** Both have identical binding affinity (-5.5 kcal/mol).
**Overall Assessment:**
Ligand A has advantages in TPSA, logP, HBD, HBA, Caco-2 and solubility. However, Ligand B has a substantial advantage in metabolic stability (lower Cl_mic) and half-life. For a cardiovascular target, metabolic stability and duration of action (half-life) are critical. While Ligand A has better absorption characteristics, the improved PK profile of Ligand B outweighs these benefits. The binding affinity is the same for both.
**Output:**
0
2025-04-17 19:31:14,824 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**1. Molecular Weight:** Both ligands (378.46 and 361.471 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (49.41) is significantly better than Ligand B (71.33). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is quite high, potentially hindering absorption.
**3. logP:** Both ligands have acceptable logP values (3.483 and 2.045, respectively), falling within the 1-3 range. Ligand A is slightly higher, which could be a minor concern for solubility, but not a dealbreaker.
**4. H-Bond Donors:** Ligand A has 1 HBD, while Ligand B has 0. Both are within the acceptable limit of 5.
**5. H-Bond Acceptors:** Ligand A has 3 HBA, and Ligand B has 6. Both are within the acceptable limit of 10, but Ligand A is preferable.
**6. QED:** Both ligands have good QED scores (0.72 and 0.817), indicating good drug-like properties.
**7. DILI Risk:** Ligand A (34.471) has a lower DILI risk than Ligand B (58.511). This is a significant advantage for Ligand A.
**8. BBB Penetration:** Ligand A (90.074) has significantly better BBB penetration potential than Ligand B (71.307). While ADRB2 isn't exclusively a CNS target, some cardiovascular effects are mediated by central pathways, and better BBB penetration could be advantageous.
**9. Caco-2 Permeability:** Both are negative, indicating poor permeability. However, the scale is different, and -4.871 (Ligand A) is preferable to -4.836 (Ligand B).
**10. Aqueous Solubility:** Both ligands have negative solubility values (-4.184 and -2.291). Ligand B is slightly better, but both are poor.
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (0.526 and 0.238). Ligand B is slightly better.
**12. Microsomal Clearance:** Ligand A (39.846) has a lower microsomal clearance than Ligand B (42.61), suggesting better metabolic stability.
**13. In vitro Half-Life:** Ligand A has a much longer in vitro half-life (-32.492) than Ligand B (23.242), which is a significant advantage.
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (0.199 and 0.195). No significant difference.
**15. Binding Affinity:** Ligand B (-6.0 kcal/mol) has a slightly better binding affinity than Ligand A (-5.6 kcal/mol). While a difference of 0.4 kcal/mol is noticeable, it's not overwhelmingly large, especially considering the other factors.
**Overall Assessment:**
Ligand A is the stronger candidate. It has a significantly lower DILI risk, better BBB penetration, better metabolic stability (lower Cl_mic, longer t1/2), and a more favorable TPSA. While Ligand B has slightly better binding affinity and solubility, the advantages of Ligand A in ADME-Tox properties outweigh this difference, particularly for a GPCR target where permeability and metabolic stability are crucial.
Output:
1
2025-04-17 19:31:14,824 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
Let's break down the comparison of Ligand A and Ligand B, considering the provided guidelines and GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key).
1. **Molecular Weight:** Both ligands (347.463 and 342.403 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (79.26) is significantly better than Ligand B (122.89). A TPSA under 140 is good for oral absorption, but lower is preferred for GPCRs. Ligand A is much closer to the optimal range for GPCRs.
3. **logP:** Both ligands have acceptable logP values (0.727 and 1.172, respectively), falling within the 1-3 range. Ligand B is slightly better, but both are good.
4. **H-Bond Donors:** Ligand A (2) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **H-Bond Acceptors:** Ligand A (5) is preferable to Ligand B (6). Fewer HBAs generally improve permeability.
6. **QED:** Ligand A (0.762) is better than Ligand B (0.649), indicating a more drug-like profile.
7. **DILI:** Ligand A (18.379) has a much lower DILI risk than Ligand B (66.964). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (67.352) shows better BBB penetration than Ligand B (50.523). While ADRB2 isn't exclusively a CNS target, some CNS exposure is not necessarily detrimental and could offer additional therapeutic avenues.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.243 and -5.603). This is unusual and suggests poor permeability. However, the values are similar.
10. **Solubility:** Ligand A (-1.918) has slightly better solubility than Ligand B (-3.038).
11. **hERG:** Both ligands have very low hERG inhibition risk (0.493 and 0.645). This is excellent.
12. **Cl_mic:** Ligand A (16.254) has a higher microsomal clearance than Ligand B (1.159). This suggests Ligand B is more metabolically stable.
13. **t1/2:** Ligand A (18.05) has a longer in vitro half-life than Ligand B (9.947). This is a significant advantage for Ligand A.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.02 and 0.026). This is excellent.
15. **Binding Affinity:** Ligand B (-7.1 kcal/mol) has a slightly better binding affinity than Ligand A (-6.6 kcal/mol). This is a 0.5 kcal/mol difference, which is a notable advantage, but not overwhelming given the other factors.
**Overall Assessment:**
Ligand A demonstrates a superior balance of properties. It has a lower DILI risk, better TPSA, better QED, better BBB penetration, better solubility, and a longer half-life. While Ligand B has slightly better binding affinity and metabolic stability, the other advantages of Ligand A, particularly the significantly lower DILI risk and better TPSA, outweigh this difference. The Caco-2 permeability is concerning for both, but the other properties suggest Ligand A has a higher chance of being optimized.
**Output:**
1
2025-04-17 19:31:14,825 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Ligand A (349.5) is well within the ideal range (200-500). Ligand B (452.8) is at the higher end but still acceptable.
2. **TPSA:** Ligand A (92.5) is good, under the 140 threshold. Ligand B (69.7) is excellent, further improving chances of good absorption.
3. **logP:** Both ligands (A: 1.286, B: 2.324) are within the optimal 1-3 range. Ligand B is slightly better.
4. **HBD:** Ligand A (2) and Ligand B (1) are both good, below the 5 threshold.
5. **HBA:** Ligand A (3) and Ligand B (5) are both acceptable, below the 10 threshold.
6. **QED:** Both ligands (A: 0.757, B: 0.687) are above 0.5, indicating good drug-likeness. Ligand A is slightly better.
7. **DILI:** Ligand A (19.4) has a significantly lower DILI risk than Ligand B (53.0). This is a major advantage for Ligand A.
8. **BBB:** Both ligands (A: 65.4, B: 66.2) have similar BBB penetration, which is acceptable but not outstanding for a non-CNS target like ADRB2.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Both ligands have negative solubility values, which is also unusual and suggests poor solubility. This is a concern for both.
11. **hERG:** Ligand A (0.102) has a much lower hERG risk than Ligand B (0.635). This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand A (29.3) has a higher (worse) microsomal clearance than Ligand B (-8.8). Ligand B shows a negative clearance, which is extremely favorable, indicating high metabolic stability.
13. **t1/2:** Ligand A (0.445) has a very short in vitro half-life, while Ligand B (46.4) has a long half-life. This is a substantial advantage for Ligand B.
14. **Pgp:** Ligand A (0.019) has very low P-gp efflux, while Ligand B (0.065) is slightly higher. Both are good.
15. **Affinity:** Ligand A (-6.8) has a slightly better binding affinity than Ligand B (-6.0).
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, and affinity are important. Ligand B has a slightly better logP and TPSA. Ligand A has a slightly better affinity. However, the significant advantages of Ligand A in terms of DILI and hERG risk, combined with its acceptable affinity, outweigh the benefits of Ligand B's metabolic stability and half-life. The negative Caco-2 and solubility values are concerning for both, but can be addressed through formulation strategies.
**Conclusion:**
Despite Ligand B's superior metabolic stability and half-life, the lower DILI and hERG risk of Ligand A make it the more promising drug candidate.
Output:
1
2025-04-17 19:31:14,825 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (373.4) is slightly higher than Ligand B (349.347), but both are acceptable.
2. **TPSA:** Ligand A (61.44) is significantly better than Ligand B (126.13). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is above the preferred threshold of 140, which is a concern.
3. **logP:** Ligand A (2.72) is within the optimal range (1-3). Ligand B (-1.173) is below this range, potentially hindering membrane permeability.
4. **HBD:** Both ligands have 2 H-bond donors, which is within the acceptable limit of 5.
5. **HBA:** Ligand A (3) is better than Ligand B (7). Lower HBA is generally preferred for better permeability.
6. **QED:** Ligand A (0.801) has a higher QED score than Ligand B (0.69), indicating a more drug-like profile.
7. **DILI:** Ligand A (32.377) has a significantly lower DILI risk than Ligand B (60.915). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (73.866) has a better BBB penetration score than Ligand B (45.909). While ADRB2 isn't exclusively a CNS target, some CNS exposure can occur, and better BBB penetration is generally favorable.
9. **Caco-2:** Ligand A (-5.021) and Ligand B (-5.502) are both negative, which is unusual. It's difficult to interpret without knowing the scale, but it suggests poor permeability.
10. **Solubility:** Ligand A (-3.562) is better than Ligand B (-1.628). Better solubility is generally desirable.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.045 and 0.041 respectively). This is excellent.
12. **Cl_mic:** Ligand B (-12.06) has lower microsomal clearance than Ligand A (5.011), indicating better metabolic stability.
13. **t1/2:** Ligand B (33.161) has a much longer in vitro half-life than Ligand A (-13.637). This is a significant advantage for Ligand B.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.033 and 0.017 respectively). This is excellent.
15. **Binding Affinity:** Both ligands have the same binding affinity (-6.1 kcal/mol).
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, and Pgp are particularly important. Ligand A excels in logP and TPSA, while both are similar in Pgp. Metabolic stability (Cl_mic and t1/2) is also important. Ligand B has a better half-life, but Ligand A has better metabolic clearance.
**Overall Assessment:**
Ligand A has a more balanced profile overall. It has better TPSA, logP, QED, solubility, and a significantly lower DILI risk. While Ligand B has a longer half-life, the superior ADME properties and lower toxicity risk of Ligand A make it the more promising candidate.
Output:
1
2025-04-17 19:31:14,825 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (352.431 Da) is within the ideal range. Ligand B (405.384 Da) is also acceptable, though approaching the upper limit.
2. **TPSA:** Ligand A (107.89) is good for oral absorption, but higher than ideal for a GPCR. Ligand B (33.95) is excellent, well below the 90 threshold and very favorable for permeability.
3. **logP:** Ligand A (1.502) is optimal. Ligand B (4.764) is slightly high, potentially leading to solubility issues and off-target interactions.
4. **HBD:** Ligand A (4) is acceptable. Ligand B (0) is also good, potentially improving membrane permeability.
5. **HBA:** Both Ligand A (5) and Ligand B (4) are within the acceptable range.
6. **QED:** Both ligands have good QED scores (A: 0.567, B: 0.603), indicating drug-likeness.
7. **DILI:** Ligand A (28.306) has a slightly higher DILI risk than Ligand B (16.092), but both are below the concerning threshold of 60.
8. **BBB:** Ligand A (32.416) has poor BBB penetration. Ligand B (87.825) has excellent BBB penetration, a significant advantage for a GPCR.
9. **Caco-2:** Ligand A (-4.922) has poor Caco-2 permeability. Ligand B (-5.061) also has poor Caco-2 permeability.
10. **Solubility:** Ligand A (-1.9) has slightly better solubility than Ligand B (-3.624).
11. **hERG:** Ligand A (0.218) has a lower hERG risk than Ligand B (0.901), which is a positive.
12. **Cl_mic:** Ligand A (38.13) has better metabolic stability (lower clearance) than Ligand B (66.914).
13. **t1/2:** Ligand B (54.1) has a much longer half-life than Ligand A (-20.691), which is a significant advantage.
14. **Pgp:** Ligand A (0.037) has lower P-gp efflux, which is favorable. Ligand B (0.764) has moderate P-gp efflux.
15. **Affinity:** Ligand B (-7.6 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.5 kcal/mol) - a difference of 1.1 kcal/mol.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, BBB, and affinity are crucial. Ligand B excels in TPSA and BBB penetration. The affinity difference is substantial. While Ligand B's logP is a bit high, the strong affinity and excellent BBB penetration outweigh this concern. Ligand A has a better hERG profile and lower DILI risk, but the significantly weaker binding and poor BBB penetration are major drawbacks.
**Conclusion:**
Considering the GPCR-specific priorities and the overall balance of properties, Ligand B is the more promising drug candidate. The superior binding affinity and BBB penetration are critical advantages.
Output:
0
2025-04-17 19:31:14,825 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (411.246 and 405.684 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (52.57) is slightly higher than Ligand B (42.31). Both are below the 140 A^2 threshold for oral absorption, but B is preferable.
**3. logP:** Ligand A (3.809) is within the optimal 1-3 range, while Ligand B (4.345) is slightly above. This is a minor concern for B, but still acceptable.
**4. H-Bond Donors:** Ligand A has 2 HBD, and Ligand B has 0. Both are within the acceptable limit of <=5.
**5. H-Bond Acceptors:** Ligand A has 3 HBA, and Ligand B has 4. Both are within the acceptable limit of <=10.
**6. QED:** Ligand A (0.805) has a better QED score than Ligand B (0.549), indicating a more drug-like profile.
**7. DILI:** Both ligands have relatively high DILI risk (A: 69.794, B: 62.001), but B is slightly better. This is a concern for both, and further investigation would be needed.
**8. BBB:** Ligand B (92.71) shows significantly better BBB penetration than Ligand A (69.717). This is a crucial advantage for a GPCR target, even if it's not strictly CNS-focused, as it can influence distribution and off-target effects.
**9. Caco-2 Permeability:** Ligand A (-4.884) has better Caco-2 permeability than Ligand B (-4.284).
**10. Aqueous Solubility:** Ligand A (-4.445) has better aqueous solubility than Ligand B (-4.794).
**11. hERG Inhibition:** Ligand A (0.887) has slightly higher hERG inhibition risk than Ligand B (0.695), making B preferable.
**12. Microsomal Clearance:** Ligand B (89.063) has a significantly higher microsomal clearance than Ligand A (25.223), indicating lower metabolic stability. This is a significant drawback for B.
**13. In vitro Half-Life:** Ligand B (62.13) has a much longer in vitro half-life than Ligand A (4.563). This is a major advantage for B.
**14. P-gp Efflux:** Ligand A (0.583) has lower P-gp efflux than Ligand B (0.775), which is preferable.
**15. Binding Affinity:** Ligand B (-8.6 kcal/mol) has a substantially stronger binding affinity than Ligand A (-7.1 kcal/mol). This is a >1.5 kcal/mol advantage, which can outweigh some ADME concerns.
**Overall Assessment:**
While Ligand A has better QED, solubility, Caco-2 permeability, and P-gp efflux, Ligand B excels in binding affinity and BBB penetration, and has a longer half-life. The significantly stronger binding affinity of Ligand B is a major advantage for a GPCR target. The better BBB penetration is also a plus. The higher clearance is a concern, but the superior affinity and half-life are likely to be more impactful. The DILI risk is similar for both, requiring further investigation.
Therefore, I favor Ligand B.
0
2025-04-17 19:31:14,825 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (368.459 Da and 371.503 Da) fall comfortably within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (82.97) is significantly better than Ligand A (113.44). For a GPCR, lower TPSA is generally preferred for good permeability.
3. **logP:** Ligand B (2.338) is optimal, while Ligand A (0.12) is quite low, potentially hindering membrane permeability. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (1), but both are within the acceptable limit of 5.
5. **HBA:** Ligand A (7) is higher than Ligand B (6), but both are within the acceptable limit of 10.
6. **QED:** Both ligands have good QED scores (0.63 and 0.709), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand B (38.348) has a lower DILI risk than Ligand A (50.33). Lower is better, so Ligand B is preferable.
8. **BBB:** Ligand B (71.656) has a significantly higher BBB penetration score than Ligand A (51.881). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant, and higher BBB is generally favorable.
9. **Caco-2:** Ligand A (-5.398) and Ligand B (-4.622) have negative values, which is unusual. It's hard to interpret these without knowing the scale, but generally, higher values are better.
10. **Solubility:** Ligand A (-1.781) and Ligand B (-1.905) have negative solubility values, which is also unusual. Again, without knowing the scale, it's hard to interpret.
11. **hERG:** Ligand A (0.056) has a lower hERG risk than Ligand B (0.642). Lower is better, so Ligand A is preferable.
12. **Cl_mic:** Ligand A (30.346) has a lower microsomal clearance than Ligand B (69.014), suggesting better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (34.56) has a longer in vitro half-life than Ligand B (-20.298). This is a substantial advantage for Ligand A.
14. **Pgp:** Ligand A (0.152) has lower P-gp efflux liability than Ligand B (0.3). Lower is better, so Ligand A is preferable.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.4 kcal/mol and -6.3 kcal/mol). The difference is negligible.
**Overall Assessment:**
Ligand B excels in TPSA, logP, DILI, and BBB penetration, which are important for GPCR targets. However, Ligand A demonstrates superior metabolic stability (lower Cl_mic, longer t1/2), lower Pgp efflux, and lower hERG risk. The low logP of Ligand A is a concern, but the substantial advantages in metabolic stability and safety profile outweigh this drawback. The similar binding affinities make these factors the deciding ones.
Considering the balance of properties, I believe Ligand A is the more promising drug candidate.
Output:
1
2025-04-17 19:31:14,826 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (342.439 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (70.59) is better than Ligand B (88.32). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA is still generally preferred for absorption.
3. **logP:** Ligand B (1.911) is better. It falls squarely within the optimal 1-3 range. Ligand A (4.905) is too high, potentially leading to solubility issues and off-target interactions.
4. **HBD:** Ligand B (2) is slightly better than Ligand A (3). Lower is generally preferred.
5. **HBA:** Ligand B (5) is better than Ligand A (3). Lower is generally preferred.
6. **QED:** Both ligands have good QED scores (A: 0.692, B: 0.848), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Both have acceptable DILI risk (A: 68.437, B: 70.531), though ideally, we'd want them lower. The difference is minimal.
8. **BBB:** Ligand B (65.839) is better than Ligand A (43.815), but neither is particularly high. This isn't a critical factor for a cardiovascular target.
9. **Caco-2:** Ligand A (-4.836) is better than Ligand B (-5.062). Higher values indicate better absorption.
10. **Solubility:** Ligand B (-3.629) is better than Ligand A (-5.786). Higher values indicate better solubility.
11. **hERG:** Ligand A (0.776) is better than Ligand B (0.402). Lower is better to avoid cardiotoxicity.
12. **Cl_mic:** Ligand B (36.377) is significantly better than Ligand A (106.89). Lower clearance indicates better metabolic stability.
13. **t1/2:** Ligand A (20.311) is better than Ligand B (3.472). Longer half-life is generally preferred.
14. **Pgp:** Ligand A (0.423) is better than Ligand B (0.047). Lower efflux improves bioavailability.
15. **Affinity:** Ligand A (-7.9 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.6 kcal/mol). This is a >1.3 kcal/mol advantage, which is substantial.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B has a better logP and TPSA, and Pgp. However, Ligand A has a *much* stronger binding affinity. The affinity difference is the most important factor here. While the higher logP of Ligand A is a concern, the substantial binding affinity advantage likely outweighs this drawback, especially considering the other parameters are reasonably balanced.
**Conclusion:**
Despite Ligand B having better logP and metabolic stability, the significantly stronger binding affinity of Ligand A makes it the more promising drug candidate.
Output:
1
2025-04-17 19:31:14,826 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (354.447) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are good, below the 140 A^2 threshold for oral absorption. Ligand B (75.44) is slightly better than Ligand A (84.94).
3. **logP:** Both ligands have acceptable logP values (1.252 and 1.735 respectively), falling within the optimal 1-3 range. Ligand B is slightly higher, potentially improving membrane permeability.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Both have 5 HBA, which is good.
6. **QED:** Both have good QED scores (0.63 and 0.749), indicating drug-likeness. Ligand B is better.
7. **DILI:** Ligand A (17.449) has a significantly lower DILI risk than Ligand B (37.65). This is a major advantage for Ligand A.
8. **BBB:** Both have reasonable BBB penetration, but Ligand B (73.711) is better than Ligand A (66.576). Given that ADRB2 is a GPCR, BBB penetration is a consideration, although not paramount for cardiovascular targets.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual. Assuming these are permeability coefficients, lower (more negative) values indicate *lower* permeability. Ligand B (-5.042) is worse than Ligand A (-4.755).
10. **Solubility:** Both have negative solubility values, which is also unusual. Assuming these are logS values, lower values indicate *lower* solubility. Ligand B (-2.115) is worse than Ligand A (-1.237).
11. **hERG:** Both have very low hERG inhibition risk (0.204 and 0.253).
12. **Cl_mic:** Ligand B (33.902) has a significantly lower microsomal clearance than Ligand A (56.669), indicating better metabolic stability.
13. **t1/2:** Ligand B (-42.967) has a much longer in vitro half-life than Ligand A (-14.145). This is a significant advantage for Ligand B.
14. **Pgp:** Both have low P-gp efflux liability (0.02 and 0.144).
15. **Affinity:** Ligand B (-7.0 kcal/mol) has a slightly better binding affinity than Ligand A (-6.5 kcal/mol). This is a meaningful difference.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand B is better in logP, TPSA, and affinity. However, DILI risk is a critical factor, and Ligand A has a much lower risk. Metabolic stability (Cl_mic and t1/2) are also important, and Ligand B is better in these aspects.
**Overall Assessment:**
Ligand B has a slight edge in binding affinity and metabolic stability (longer half-life, lower clearance), and better BBB penetration. However, the significantly lower DILI risk associated with Ligand A is a major advantage. While the solubility and Caco-2 values are unusual and concerning for both, the DILI risk outweighs the other benefits of Ligand B. A lower DILI risk is crucial for clinical success.
Output:
1
2025-04-17 19:31:14,826 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.431 and 360.462 Da) are within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand B (78.52) is significantly better than Ligand A (104.46). For a GPCR, lower TPSA is generally preferred for better permeability.
3. **logP:** Ligand B (3.682) is higher than Ligand A (1.646). While both are within the 1-3 range, Ligand B is approaching the upper limit. This could potentially lead to solubility issues, but for a GPCR, a slightly higher logP can be acceptable.
4. **HBD:** Both ligands have 3 HBD, which is within the acceptable limit of 5. No clear advantage.
5. **HBA:** Ligand B (6) has one more HBA than Ligand A (5), both are within the acceptable limit of 10. No clear advantage.
6. **QED:** Ligand A (0.694) has a slightly better QED score than Ligand B (0.599), indicating slightly better overall drug-likeness.
7. **DILI:** Ligand A (35.479) has a much lower DILI risk than Ligand B (79.953). This is a significant advantage for Ligand A.
8. **BBB:** Ligand B (72.896) has a better BBB penetration score than Ligand A (37.65). While ADRB2 isn't strictly a CNS target, some CNS exposure can be beneficial or at least needs to be considered for off-target effects.
9. **Caco-2:** Ligand A (-4.931) has a better Caco-2 permeability than Ligand B (-5.19), but both are negative values, which is difficult to interpret without knowing the scale.
10. **Solubility:** Ligand A (-2.272) has better solubility than Ligand B (-4.188).
11. **hERG:** Ligand A (0.166) has a lower hERG risk than Ligand B (0.828). This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand A (-0.583) has a lower (better) microsomal clearance than Ligand B (49.784). This indicates better metabolic stability for Ligand A.
13. **t1/2:** Ligand B (48.582) has a significantly longer in vitro half-life than Ligand A (23.11). This is a major advantage for Ligand B.
14. **Pgp:** Ligand A (0.092) has lower P-gp efflux than Ligand B (0.415). This is a slight advantage for Ligand A.
15. **Binding Affinity:** Ligand B (-6.5) has a better binding affinity than Ligand A (-8.0). This is a significant advantage for Ligand B.
**Overall Assessment:**
Ligand B has a significantly better binding affinity and a longer half-life, which are both highly desirable. However, it suffers from a much higher DILI risk, higher hERG risk, and worse metabolic stability. Ligand A has a better safety profile (lower DILI and hERG), better metabolic stability, and better solubility. The TPSA of Ligand B is also more favorable.
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), and balancing potency with safety and ADME properties, I lean towards **Ligand B** because the affinity difference is substantial (-6.5 vs -8.0 kcal/mol), and the longer half-life could offset some of the metabolic concerns. While the DILI and hERG risks are higher, these can potentially be mitigated through further structural modifications.
Output:
0
2025-04-17 19:31:14,826 - INFO - Batch 116 complete. Total preferences: 1856
2025-04-17 19:31:14,826 - INFO - Processing batch 117/512...
2025-04-17 19:31:59,558 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
The ADRB2 receptor is a GPCR, so prioritizing logP, TPSA, Pgp efflux, BBB penetration, and binding affinity is crucial.
Let's compare the ligands property by property:
1. **MW:** Both ligands (346.471 and 351.422 Da) are within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (42.01) is significantly better than Ligand B (82.53). A TPSA under 140 is good for oral absorption, but lower is preferred for GPCRs, and A is much closer to optimal.
3. **logP:** Both ligands have good logP values (3.099 and 2.422), falling within the 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer hydrogen bond donors generally improve permeability.
5. **HBA:** Both ligands have the same number of HBA (4).
6. **QED:** Both are reasonably good (0.822 and 0.753), indicating good drug-like properties.
7. **DILI:** Ligand A (10.702) has a much lower DILI risk than Ligand B (44.397). This is a significant advantage.
8. **BBB:** Ligand A (77.588) has better BBB penetration than Ligand B (69.794), which is a positive for a GPCR target.
9. **Caco-2:** Both have negative values, indicating poor permeability, but Ligand A (-4.61) is slightly better than Ligand B (-4.819).
10. **Solubility:** Ligand A (-1.215) has slightly better solubility than Ligand B (-2.594).
11. **hERG:** Both ligands have similar hERG inhibition liability (0.779 and 0.371).
12. **Cl_mic:** Ligand A (6.517) has a lower microsomal clearance than Ligand B (4.538), suggesting better metabolic stability.
13. **t1/2:** Ligand B (16.378) has a significantly longer in vitro half-life than Ligand A (-6.306). This is a major advantage for Ligand B.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.14 and 0.142).
15. **Binding Affinity:** Both ligands have the same binding affinity (-6.3 kcal/mol).
**Overall Assessment:**
Ligand A excels in several key areas: TPSA, DILI risk, BBB penetration, and metabolic stability. While Ligand B has a longer half-life, the superior ADME profile and lower toxicity risk of Ligand A are more critical for a GPCR drug candidate. The half-life can be improved through structural modifications, but fixing a high DILI risk or poor permeability is much more challenging.
**Output:**
1
2025-04-17 19:31:59,559 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (418.316 and 391.921 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (62.3) is significantly better than Ligand B (81.5). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (3.698) is optimal, while Ligand B (1.65) is on the lower side. A logP between 1-3 is preferred, and Ligand A is closer to this ideal. Lower logP can hinder membrane permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (0). While both are low, having one HBD can improve solubility without significantly impacting permeability.
5. **HBA:** Ligand A (4) is better than Ligand B (6). Lower HBA is generally preferred for permeability.
6. **QED:** Both ligands have similar, good QED values (0.688 and 0.736, respectively).
7. **DILI:** Ligand B (53.742) has a significantly lower DILI risk than Ligand A (70.105). This is a substantial advantage for Ligand B.
8. **BBB:** Both ligands have acceptable BBB penetration (75.882 and 70.415). Since ADRB2 is a cardiovascular target, this isn't a primary concern.
9. **Caco-2:** Both ligands have similar, poor Caco-2 permeability (-4.98 and -4.942). This is a concern for both, suggesting potential absorption issues.
10. **Solubility:** Ligand B (-1.999) is better than Ligand A (-3.523). Better solubility is always a plus.
11. **hERG:** Ligand A (0.71) has a slightly higher hERG risk than Ligand B (0.295). Lower hERG is crucial for avoiding cardiotoxicity.
12. **Cl_mic:** Ligand B (13.941) has a much lower microsomal clearance than Ligand A (69.7). This indicates better metabolic stability for Ligand B, a significant advantage.
13. **t1/2:** Ligand A (91.813) has a much longer in vitro half-life than Ligand B (6.072). This is a major benefit for Ligand A, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.542) has lower P-gp efflux than Ligand B (0.2). This is a slight advantage for Ligand A, potentially improving bioavailability.
15. **Binding Affinity:** Ligand B (-5.2 kcal/mol) has a slightly better binding affinity than Ligand A (-6.5 kcal/mol). While Ligand A has better affinity, the difference is not substantial enough to outweigh other factors.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A excels in logP and Pgp, and has slightly better affinity. Ligand B has a better TPSA and significantly better DILI and Cl_mic.
**Overall Assessment:**
While Ligand A has a longer half-life and slightly better affinity, Ligand B demonstrates a superior safety profile (lower DILI, hERG) and better metabolic stability (lower Cl_mic). The lower logP and higher TPSA of Ligand B are less ideal, but the improved safety and metabolic properties are more critical for a cardiovascular drug candidate. The Caco-2 permeability is poor for both, which would need to be addressed in further optimization, but the other advantages of Ligand B make it the more promising starting point.
Output:
0
2025-04-17 19:31:59,559 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (370.463 and 351.447 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (89.35) is better than Ligand B (95.67), both being below the 140 threshold for oral absorption, and closer to the 90 threshold for CNS targets.
3. **logP:** Both ligands have good logP values (2.869 and 1.756), falling within the optimal 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2), as lower HBD generally improves permeability.
5. **HBA:** Ligand A (8) is preferable to Ligand B (5), as lower HBA generally improves permeability.
6. **QED:** Ligand B (0.661) has a slightly better QED score than Ligand A (0.439), indicating a more drug-like profile.
7. **DILI:** Ligand B (27.918) has a *much* lower DILI risk than Ligand A (96.549). This is a significant advantage for Ligand B.
8. **BBB:** Both ligands have reasonable BBB penetration (47.499 and 51.493). While not exceptional, they are acceptable for a peripherally acting target like ADRB2.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.555 and -4.804). These values are not interpretable and likely indicate an error or unusual experimental result. Without further information, this parameter cannot be used for comparison.
10. **Solubility:** Ligand B (-1.611) has a slightly better (less negative) solubility score than Ligand A (-3.879), suggesting it might be easier to formulate.
11. **hERG:** Both ligands show low hERG inhibition liability (0.288 and 0.351), which is excellent.
12. **Cl_mic:** Ligand B (31.035) has a lower microsomal clearance than Ligand A (44.043), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-5.569) has a longer in vitro half-life than Ligand B (5.594). This is a positive for Ligand A.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.462 and 0.228).
15. **Binding Affinity:** Ligand A (-6.9 kcal/mol) has a slightly better binding affinity than Ligand B (-5.8 kcal/mol). This is a 1.1 kcal/mol difference, which is significant, and can often outweigh minor ADME drawbacks.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A has a slightly better logP, TPSA, and significantly better affinity. However, the *extremely* high DILI risk associated with Ligand A is a major concern. While ADRB2 isn't a CNS target, minimizing toxicity is always paramount.
**Overall Assessment:**
While Ligand A has a better binding affinity and half-life, the drastically higher DILI risk of Ligand A makes it a less desirable candidate. Ligand B has a better safety profile (lower DILI), better metabolic stability, and acceptable ADME properties. The slightly lower affinity is a reasonable trade-off for a significantly reduced toxicity risk.
Output:
0
2025-04-17 19:31:59,559 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.36 and 343.39 Da) fall comfortably within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (99) is significantly better than Ligand A (134.59). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (1.85) is within the optimal 1-3 range. Ligand A (-0.71) is slightly below 1, which *could* indicate permeability issues. This is a significant point in favor of Ligand B.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (1), but both are acceptable (<=5).
5. **HBA:** Ligand A (5) is lower than Ligand B (7), both are within the acceptable range (<=10).
6. **QED:** Both ligands have good QED scores (0.604 and 0.674), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (50.91) has a much lower DILI risk than Ligand B (83.79). This is a major advantage for Ligand A.
8. **BBB:** Both have moderate BBB penetration (56.65 and 67.70), but this isn't a critical factor for a cardiovascular target.
9. **Caco-2:** Both have negative Caco-2 values which is unusual and indicates poor permeability.
10. **Solubility:** Both ligands have negative solubility values, which is also unusual and indicates poor solubility.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.055 and 0.034).
12. **Cl_mic:** Ligand A (-24.77) has a much lower (better) microsomal clearance than Ligand B (42.61). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (-26.14) has a much longer in vitro half-life than Ligand B (2.55). This is a significant advantage for Ligand A.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.005 and 0.193).
15. **Binding Affinity:** Ligand A (-7.7) has a significantly stronger binding affinity than Ligand B (-3.8). This is a substantial advantage, potentially outweighing some ADME concerns.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, and affinity are key. Ligand B has a better logP and TPSA. However, Ligand A's *much* stronger binding affinity (-7.7 vs -3.8) is a decisive factor. The improved metabolic stability (lower Cl_mic, longer t1/2) and lower DILI risk further solidify its position. The negative Caco-2 and solubility values are concerning for both, but the potency advantage of ligand A is significant.
**Conclusion:**
Despite some ADME drawbacks shared by both, Ligand A's superior binding affinity, metabolic stability, lower DILI risk, and longer half-life make it the more promising drug candidate.
Output:
1
2025-04-17 19:31:59,559 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (366.53 and 365.55 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (58.64) is better than Ligand B (63.05). Both are below the 140 threshold for oral absorption, but lower TPSA is generally preferred for GPCRs.
3. **logP:** Both ligands (2.05 and 2.48) are within the optimal 1-3 range. Ligand B is slightly higher, which *could* be a minor concern for solubility, but not a dealbreaker.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 4 HBA, while Ligand B has 6. Ligand A is preferable here, as lower HBA generally improves permeability.
6. **QED:** Ligand A (0.782) has a better QED score than Ligand B (0.69), indicating a more drug-like profile.
7. **DILI:** Ligand A (35.09) has a slightly higher DILI risk than Ligand B (29.78), but both are well below the concerning 60 percentile. Ligand B is preferable here.
8. **BBB:** Ligand A (71.89) has a significantly better BBB penetration score than Ligand B (61.34). This is a key consideration for a GPCR target, even a cardiovascular one, as some CNS off-target effects are possible.
9. **Caco-2:** Ligand A (-4.95) has a worse Caco-2 permeability than Ligand B (-5.63). Both are very poor, indicating potential absorption issues.
10. **Solubility:** Ligand A (-3.596) has slightly worse solubility than Ligand B (-1.98). Solubility is a concern for both, but Ligand B is better.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.46 and 0.30 respectively). No significant difference.
12. **Cl_mic:** Ligand A (41.70) has a lower microsomal clearance than Ligand B (45.05), suggesting better metabolic stability. This is a positive for Ligand A.
13. **t1/2:** Ligand A (14.53) has a shorter in vitro half-life than Ligand B (24.65). This is a negative for Ligand A.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.19 and 0.17 respectively). No significant difference.
15. **Binding Affinity:** Ligand B (-7.8 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.7 kcal/mol). This is a substantial advantage for Ligand B, and can often outweigh minor ADME drawbacks.
**Overall Assessment:**
Ligand B has a significantly stronger binding affinity, which is paramount for GPCR targets. It also has better solubility, Caco-2 permeability, and in vitro half-life. While Ligand A has better TPSA, QED, and Cl_mic, the difference in binding affinity is substantial enough to outweigh these advantages. The BBB score for Ligand A is better, but not enough to overcome the potency difference.
Output:
0
2025-04-17 19:31:59,559 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (369.447 and 373.337 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (120.5) is higher than the preferred <140 for oral absorption, but still acceptable. Ligand B (29.54) is excellent, well below 90, suggesting good permeability. This favors B.
3. **logP:** Ligand A (0.609) is a bit low, potentially hindering permeation. Ligand B (3.576) is within the optimal 1-3 range. This favors B.
4. **HBD:** Ligand A (3) is acceptable. Ligand B (0) is also good, potentially improving membrane permeability. No strong preference.
5. **HBA:** Ligand A (5) is acceptable. Ligand B (2) is also good. No strong preference.
6. **QED:** Both ligands have similar QED values (0.672 and 0.693), indicating good drug-likeness. No significant difference.
7. **DILI:** Ligand A (77.782) has a higher DILI risk than Ligand B (41.218). This strongly favors B.
8. **BBB:** Ligand A (64.017) is moderate, while Ligand B (98.139) is very high. Given ADRB2's role in cardiovascular function, CNS penetration isn't a primary goal, but higher BBB is generally a positive attribute. This favors B.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.816 and -4.499), which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Both ligands have negative solubility values (-3.77 and -3.655), which is also unusual. Again, the scale is not specified.
11. **hERG:** Ligand A (0.037) has a slightly lower hERG risk than Ligand B (0.687). This favors A, but the difference isn't huge.
12. **Cl_mic:** Ligand A (7.735) has significantly lower microsomal clearance than Ligand B (30.079), indicating better metabolic stability. This strongly favors A.
13. **t1/2:** Ligand A (-13.75) has a negative half-life, which is not possible. Ligand B (14.055) has a reasonable half-life. This strongly favors B.
14. **Pgp:** Ligand A (0.029) has lower P-gp efflux liability than Ligand B (0.206), which is beneficial for bioavailability. This favors A.
15. **Binding Affinity:** Ligand A (-6.4) has a slightly better binding affinity than Ligand B (-5.1). This favors A, but the difference is less than 1.5 kcal/mol.
**Overall Assessment:**
Ligand B has several advantages: significantly lower DILI risk, much higher BBB penetration, a better logP, and a reasonable half-life. Ligand A has better metabolic stability (lower Cl_mic) and slightly better binding affinity, but the negative half-life is a major concern. The unusual negative values for Caco-2 and Solubility are concerning for both, but the other properties of Ligand B are more favorable overall for a starting point in drug development.
Output:
0
2025-04-17 19:31:59,559 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (355.459 and 354.407 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (46.61) is significantly better than Ligand B (121.73). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold, while B is approaching the upper limit.
3. **logP:** Ligand A (3.295) is within the optimal 1-3 range. Ligand B (0.835) is a bit low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is better than Ligand B (7). Lower HBA also favors permeability.
6. **QED:** Ligand A (0.794) is better than Ligand B (0.5), indicating a more drug-like profile.
7. **DILI:** Ligand B (44.901) has a lower DILI risk than Ligand A (56.844), which is a positive.
8. **BBB:** Ligand A (77.511) has slightly better BBB penetration than Ligand B (68.515), but this is less critical for a cardiovascular target.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.733 and -4.819), which is unusual and suggests poor permeability *in vitro*. This is a concern for both.
10. **Solubility:** Ligand A (-4.087) has slightly better solubility than Ligand B (-2.087), but both are quite poor.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.457 and 0.279). This is excellent.
12. **Cl_mic:** Ligand B (8.096) has significantly lower microsomal clearance than Ligand A (121.046), indicating better metabolic stability. This is a major advantage.
13. **t1/2:** Ligand B (-25.824) has a negative in vitro half-life, which is concerning and likely indicates rapid degradation. Ligand A (12.645) has a reasonable half-life.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.644 and 0.109).
15. **Binding Affinity:** Both ligands have the same binding affinity (-7.0 kcal/mol), so this parameter doesn't differentiate them.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, and metabolic stability (Cl_mic, t1/2) are key. Ligand A has better TPSA and logP, but Ligand B has *much* better metabolic stability. The negative half-life for Ligand B is a significant red flag.
**Overall Assessment:**
While Ligand B has a lower DILI risk and better metabolic stability, the extremely poor in vitro half-life is a major concern. Ligand A's slightly worse metabolic stability is more manageable, especially given its better TPSA, logP, QED, and solubility. The Caco-2 values for both are problematic, but can be addressed with formulation strategies.
Therefore, I favor Ligand A.
Output:
1
2025-04-17 19:31:59,560 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.418 and 347.459 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (69.64) is better than Ligand B (75.44). Both are under the 140 A^2 threshold for good absorption, but lower is preferred for GPCRs.
3. **logP:** Both ligands have acceptable logP values (1.873 and 2.541), falling within the 1-3 range. Ligand B is slightly higher, which could be a minor concern for solubility.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1). Both are well within the acceptable limit of 5.
5. **HBA:** Ligand A (3) is slightly higher than Ligand B (4). Both are within the acceptable limit of 10.
6. **QED:** Ligand A (0.873) has a better QED score than Ligand B (0.784), suggesting a more drug-like profile.
7. **DILI:** Ligand A (33.656) has a significantly lower DILI risk than Ligand B (18.418). This is a major advantage for Ligand A.
8. **BBB:** Both ligands have good BBB penetration (69.213 and 74.176). Both are reasonably high, but not exceptional.
9. **Caco-2:** Ligand A (-4.585) has a better Caco-2 value than Ligand B (-5.244), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-1.932) has better aqueous solubility than Ligand B (-1.585).
11. **hERG:** Both ligands have low hERG inhibition liability (0.666 and 0.321), which is good.
12. **Cl_mic:** Ligand A (20.834) has a significantly lower microsomal clearance than Ligand B (51.819), indicating better metabolic stability.
13. **t1/2:** Ligand A (-11.35) has a longer in vitro half-life than Ligand B (-21.278).
14. **Pgp:** Ligand A (0.356) has lower P-gp efflux liability than Ligand B (0.092).
15. **Affinity:** Ligand A (-7.8 kcal/mol) has a significantly better binding affinity than Ligand B (-6.2 kcal/mol). This is a substantial advantage.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are particularly important. Both ligands are acceptable in terms of logP and BBB. Ligand A is better in terms of TPSA and Pgp. However, the most significant difference is the binding affinity, where Ligand A is 1.6 kcal/mol stronger. This difference in affinity is large enough to outweigh any minor drawbacks. Additionally, Ligand A has a much better safety profile (lower DILI) and better ADME properties (lower Cl_mic, longer t1/2, better solubility and Caco-2).
**Conclusion:**
Ligand A is the superior candidate due to its significantly better binding affinity, improved ADME properties, and lower DILI risk.
Output:
1
2025-04-17 19:31:59,560 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (378.523) is slightly higher than Ligand B (350.415), but both are acceptable.
2. **TPSA:** Ligand A (68.09) is better than Ligand B (83.22). For a GPCR, lower TPSA is generally preferred for better permeability, although both are reasonably low.
3. **logP:** Ligand A (2.268) is within the optimal range (1-3), while Ligand B (1.26) is at the lower end. ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but a slightly higher logP is still beneficial for membrane permeability.
4. **HBD:** Ligand A (0) is preferable to Ligand B (1). Fewer hydrogen bond donors generally improve permeability.
5. **HBA:** Ligand A (7) is better than Ligand B (5). Both are within the acceptable range, but lower is generally better.
6. **QED:** Both ligands have good QED scores (Ligand A: 0.747, Ligand B: 0.864). Ligand B is slightly better here, indicating a more drug-like profile.
7. **DILI:** Ligand B (35.13) has a significantly lower DILI risk than Ligand A (75.766). This is a major advantage for Ligand B.
8. **BBB:** Ligand A (64.017) is better than Ligand B (50.019), but BBB penetration isn't a high priority for a cardiovascular target.
9. **Caco-2:** Ligand A (-5.125) and Ligand B (-4.416) are both negative, which is unusual and suggests poor permeability. However, the scale isn't specified, so it's hard to interpret.
10. **Solubility:** Ligand A (-3.035) is better than Ligand B (-1.755) indicating better solubility.
11. **hERG:** Both ligands have very low hERG risk (Ligand A: 0.324, Ligand B: 0.331).
12. **Cl_mic:** Ligand B (19.009) has significantly lower microsomal clearance than Ligand A (81.592), suggesting better metabolic stability.
13. **t1/2:** Ligand B (23.785) has a much longer in vitro half-life than Ligand A (2.365). This is a significant advantage.
14. **Pgp:** Both ligands have low P-gp efflux liability (Ligand A: 0.425, Ligand B: 0.345).
15. **Binding Affinity:** Ligand B (-6.4) has slightly better binding affinity than Ligand A (-6.2). While the difference is small, it's still a positive for Ligand B.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity) and the general guidelines, Ligand B is the more promising candidate. While Ligand A has slightly better TPSA and solubility, Ligand B excels in crucial areas like DILI risk, metabolic stability (Cl_mic and t1/2), and binding affinity. The lower DILI risk and improved metabolic stability are particularly important for a cardiovascular drug. The slightly better binding affinity further strengthens its position.
Output:
0
2025-04-17 19:31:59,560 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (338.39 & 343.47 Da) fall comfortably within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (47.09) is significantly better than Ligand B (71.09). ADRB2 is a cardiovascular target, not a CNS target, but lower TPSA generally improves permeability. Ligand A is well below the 140 threshold. Ligand B is approaching the upper limit.
3. **logP:** Both ligands have good logP values (3.50 & 3.14), falling within the optimal 1-3 range. Ligand A is slightly higher, which *could* be a minor concern for solubility, but isn't a dealbreaker.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer HBDs generally correlate with better permeability.
5. **HBA:** Ligand A (5) is better than Ligand B (3). Lower HBA is generally preferred.
6. **QED:** Ligand A (0.73) is substantially better than Ligand B (0.506), indicating a more drug-like profile.
7. **DILI:** Ligand B (32.03%) is significantly better than Ligand A (56.96%). This is a major advantage for Ligand B. DILI risk is a critical factor.
8. **BBB:** Both ligands have reasonable BBB penetration (86.08% and 76.19%), but this isn't a primary concern for a cardiovascular target.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.947 and -4.981), which is unusual and suggests poor permeability. This is a concern for both, but similar for both.
10. **Solubility:** Both ligands have negative solubility values (-2.696 and -2.845), indicating poor aqueous solubility. This is a significant issue for both.
11. **hERG:** Ligand A (0.921) is slightly better than Ligand B (0.49), indicating a lower risk of hERG inhibition.
12. **Cl_mic:** Ligand B (68.002) has lower microsomal clearance than Ligand A (76.42), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-49.268) has a much more negative in vitro half-life than Ligand B (-4.145). This is a significant negative for Ligand A, indicating very rapid metabolism.
14. **Pgp:** Ligand A (0.758) is slightly better than Ligand B (0.264), indicating lower P-gp efflux.
15. **Binding Affinity:** Ligand A (-6.7 kcal/mol) has a significantly stronger binding affinity than Ligand B (-4.9 kcal/mol). This is a substantial advantage for Ligand A, exceeding the 1.5 kcal/mol threshold.
**Overall Assessment:**
Ligand A has a significantly better binding affinity and a more favorable QED score. However, it suffers from a higher DILI risk and a very poor in vitro half-life. Ligand B has a much better safety profile (lower DILI) and better metabolic stability (lower Cl_mic, better t1/2), but its binding affinity is weaker.
Given that ADRB2 is a cardiovascular target, safety (DILI) and metabolic stability are crucial. While the affinity difference is substantial, a weaker but safer and more stable compound is preferable. The poor solubility and Caco-2 values are concerning for both, but can potentially be addressed with formulation strategies. The strong affinity of Ligand A doesn't outweigh its significant liabilities.
Output:
0
2025-04-17 19:31:59,560 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (388.823 and 390.305 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (81.42) is slightly higher than Ligand B (75.27). Both are below the 140 threshold for good oral absorption, and acceptable for a cardiovascular GPCR.
3. **logP:** Ligand A (3.442) is slightly higher than Ligand B (2.052). Both are within the optimal 1-3 range, but Ligand B is closer to the lower bound.
4. **HBD:** Both ligands have 2 H-bond donors, which is within the acceptable limit of <=5.
5. **HBA:** Ligand A has 4 H-bond acceptors, and Ligand B has 3. Both are within the acceptable limit of <=10.
6. **QED:** Ligand A (0.795) has a better QED score than Ligand B (0.597), indicating a more drug-like profile.
7. **DILI:** Both ligands have similar DILI risk (64.676 and 64.754 percentile), which is acceptable (below 60 is preferred, but these are not high risk).
8. **BBB:** Both ligands have good BBB penetration (76.658 and 77.821 percentile). This is less critical for a cardiovascular target, but not detrimental.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.858 and -4.834), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand A (-5.255) has slightly worse solubility than Ligand B (-3.113). Solubility is important, but can be addressed with formulation.
11. **hERG:** Both ligands have low hERG inhibition risk (0.49 and 0.582 percentile), which is excellent.
12. **Cl_mic:** Ligand A (50.554) has a higher microsomal clearance than Ligand B (11.037). This indicates Ligand B is more metabolically stable, which is desirable.
13. **t1/2:** Ligand B (-24.643) has a significantly longer in vitro half-life than Ligand A (20.041). This is a major advantage for Ligand B.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.171 and 0.08).
15. **Binding Affinity:** Ligand A (-6.9 kcal/mol) has a slightly better binding affinity than Ligand B (-6.2 kcal/mol). This is a 0.7 kcal/mol difference, which is a reasonable advantage.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Both ligands perform reasonably well on logP and Pgp. TPSA is acceptable for both. The affinity difference is relatively small. However, the significantly improved metabolic stability (lower Cl_mic) and longer half-life of Ligand B are compelling advantages. The Caco-2 values are concerning for both, but a longer half-life can partially compensate for lower absorption.
**Conclusion:**
While Ligand A has slightly better affinity and QED, Ligand B's superior metabolic stability and half-life, combined with acceptable properties across the board, make it the more promising drug candidate.
Output:
0
2025-04-17 19:31:59,560 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (351.491 and 346.515 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (70.67) is higher than Ligand B (58.2). Both are below the 140 threshold for oral absorption, but B is closer to the preferred <90 for GPCRs.
3. **logP:** Ligand B (3.262) is higher than Ligand A (1.297). While both are within the optimal 1-3 range, B is approaching the upper limit. A is preferable here.
4. **HBD:** Both ligands have 2 H-bond donors, meeting the <5 guideline.
5. **HBA:** Ligand A has 4 H-bond acceptors, while Ligand B has 2. Both are below the 10 guideline.
6. **QED:** Both ligands have similar QED values (0.691 and 0.695), indicating good drug-likeness.
7. **DILI:** Ligand B (28.189) has a *much* lower DILI risk than Ligand A (9.383). This is a significant advantage for B.
8. **BBB:** Ligand B (51.415) has a better BBB penetration percentile than Ligand A (42.303). While neither are exceptionally high, this is a positive for B, given ADRB2's relevance to cardiovascular function where CNS side effects are a concern.
9. **Caco-2:** Ligand A (-5.132) has a worse Caco-2 permeability than Ligand B (-4.556), indicating lower intestinal absorption.
10. **Solubility:** Ligand A (-1.52) has better aqueous solubility than Ligand B (-4.419).
11. **hERG:** Both ligands have very low hERG inhibition risk (0.182 and 0.188).
12. **Cl_mic:** Ligand A (12.992) has a significantly lower microsomal clearance than Ligand B (39.063), suggesting better metabolic stability. This is a substantial advantage for A.
13. **t1/2:** Ligand B (11.857) has a longer in vitro half-life than Ligand A (8.693).
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.03 and 0.176).
15. **Binding Affinity:** Both ligands have very similar binding affinities (-5.7 and -5.6 kcal/mol). The difference is negligible.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), and the general guidelines, Ligand A and B present a trade-off. Ligand B has better TPSA, DILI, BBB, Caco-2 permeability, and half-life. Ligand A has better logP, solubility, and significantly better metabolic stability (Cl_mic). The DILI risk for Ligand B is a major advantage. The slightly better metabolic stability of Ligand A is helpful, but the lower DILI risk of B is more impactful for overall drug safety. The binding affinities are essentially the same, so that doesn't differentiate them.
Given the balance of these factors, and prioritizing a lower DILI risk and better permeability, I favor Ligand B.
Output:
0
2025-04-17 19:31:59,560 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (351.359 Da and 346.475 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (121.71) is slightly higher than Ligand B (65.54). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B is significantly better.
3. **logP:** Ligand A (0.03) is quite low, potentially hindering membrane permeability. Ligand B (1.617) is within the optimal 1-3 range. Ligand B is significantly better.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable, below the threshold of 5.
5. **HBA:** Ligand A (6) and Ligand B (4) are both acceptable, below the threshold of 10.
6. **QED:** Both ligands have good QED scores (0.738 and 0.88), indicating good drug-like properties.
7. **DILI:** Ligand A (58.511) has a higher DILI risk than Ligand B (11.361). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (37.495) has lower BBB penetration than Ligand B (64.482). While ADRB2 isn't a CNS target, some distribution to the CNS can sometimes lead to off-target effects, so moderate penetration is acceptable. Ligand B is better.
9. **Caco-2:** Ligand A (-5.007) has a very poor Caco-2 permeability, suggesting poor absorption. Ligand B (-4.66) is still not great, but better than Ligand A.
10. **Solubility:** Ligand A (-1.796) has poor solubility. Ligand B (-0.732) is slightly better, but still not ideal.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.085 and 0.226).
12. **Cl_mic:** Ligand A (1.606) has lower microsomal clearance than Ligand B (2.621), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-25.339) has a very short in vitro half-life, which is a major concern. Ligand B (5.075) has a much more reasonable half-life.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.01 and 0.016).
15. **Binding Affinity:** Ligand A (-6.7 kcal/mol) has a slightly better binding affinity than Ligand B (-5.6 kcal/mol). This is a 1.1 kcal/mol difference, which is significant, but must be weighed against the other ADME properties.
**Overall Assessment:**
Ligand A has a slightly better binding affinity, but suffers from very poor Caco-2 permeability, poor solubility, and a very short half-life. The DILI risk is also higher. Ligand B, while having a slightly weaker affinity, has significantly better ADME properties: a much lower DILI risk, better Caco-2 permeability, better solubility, and a much longer half-life. Given the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), and the overall balance of properties, Ligand B is the more promising drug candidate. The affinity difference can likely be overcome with further optimization, while fixing the severe ADME issues of Ligand A would be much more challenging.
Output:
0
2025-04-17 19:31:59,560 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (351.495 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (70.47) is significantly better than Ligand B (101.74). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have acceptable logP values (A: 1.275, B: 1.69), falling within the optimal 1-3 range.
4. **HBD/HBA:** Both ligands have 1 HBD, which is good. Ligand A has 5 HBA, while Ligand B has 7. Both are acceptable, but A is slightly better.
5. **QED:** Both ligands have good QED scores (A: 0.689, B: 0.749), indicating drug-likeness. B is slightly better here.
6. **DILI:** Ligand A (22.257) has a much lower DILI risk than Ligand B (82.862). This is a significant advantage for A.
7. **BBB:** BBB is less critical for a cardiovascular target. Ligand A (51.725) is lower than Ligand B (38.813), but this isn't a major deciding factor.
8. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the absolute value for A (-5.068) is less negative than B (-4.761), suggesting slightly better permeability.
9. **Solubility:** Both have negative solubility values, which is also unusual. A (-1.007) is slightly better than B (-2.556).
10. **hERG:** Both ligands have very low hERG inhibition risk (A: 0.218, B: 0.093). B is slightly better here.
11. **Cl_mic:** Ligand A (50.57) has lower microsomal clearance than Ligand B (56.18), indicating better metabolic stability.
12. **t1/2:** Ligand B (42.693) has a longer in vitro half-life than Ligand A (21.229). This is a positive for B.
13. **Pgp:** Both ligands have very low Pgp efflux liability (A: 0.011, B: 0.12). A is slightly better.
14. **Binding Affinity:** Both ligands have very similar binding affinities (A: -6.7 kcal/mol, B: -6.6 kcal/mol). The difference is negligible.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, and affinity. Both ligands are good on logP and affinity. Ligand A is significantly better on TPSA and Pgp. The DILI risk for Ligand A is also much lower, which is a critical safety consideration. While Ligand B has a slightly longer half-life, the other advantages of Ligand A outweigh this.
**Conclusion:**
Ligand A presents a more favorable overall profile, particularly regarding safety (DILI) and absorption/permeability (TPSA, Caco-2, Solubility). The binding affinity is comparable, and the slight advantage in metabolic stability is valuable.
**Output:**
1
2025-04-17 19:31:59,560 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (369.487 Da) and Ligand B (346.471 Da) both fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (91.76) is slightly higher than Ligand B (58.64). For a cardiovascular GPCR, TPSA is not a primary concern, but lower is generally better for permeability. Ligand B has a clear advantage.
3. **logP:** Ligand A (0.826) is a bit low, potentially hindering membrane permeability. Ligand B (1.977) is better, falling within the optimal 1-3 range. Ligand B is preferable.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable.
5. **HBA:** Ligand A (6) and Ligand B (3) are both acceptable.
6. **QED:** Both ligands have good QED scores (A: 0.708, B: 0.775), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (37.03) has a higher DILI risk than Ligand B (17.449). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (31.912) has a low BBB penetration, while Ligand B (64.482) is significantly better. Since ADRB2 is a GPCR, and while this is cardiovascular, some CNS penetration is not necessarily detrimental, and higher BBB is generally preferred. Ligand B is preferable.
9. **Caco-2:** Ligand A (-5.007) and Ligand B (-4.696) are both negative, indicating poor permeability. This is concerning for both, but the difference is minimal.
10. **Solubility:** Ligand A (-1.297) and Ligand B (-2.873) both have poor solubility. This is a drawback for both, but Ligand B is slightly worse.
11. **hERG:** Ligand A (0.096) has a very low hERG risk, which is excellent. Ligand B (0.217) is slightly higher, but still relatively low. Ligand A is preferable.
12. **Cl_mic:** Ligand A (3.031) has much lower microsomal clearance than Ligand B (25.476), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (8.158) has a longer in vitro half-life than Ligand B (5.521). This is a positive for Ligand A.
14. **Pgp:** Ligand A (0.043) has lower P-gp efflux than Ligand B (0.078), suggesting better bioavailability. This is a slight advantage for Ligand A.
15. **Binding Affinity:** Ligand A (-6.6 kcal/mol) has a slightly better binding affinity than Ligand B (-4.6 kcal/mol). This 1.5 kcal/mol difference is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand A has a better binding affinity, lower DILI risk, better metabolic stability (lower Cl_mic, longer t1/2), and lower P-gp efflux. Ligand B has better TPSA, logP, and BBB penetration. The significantly better binding affinity and lower DILI risk of Ligand A, coupled with its improved metabolic stability, are more critical for a viable drug candidate, especially considering the cardiovascular target. While both have solubility and Caco-2 permeability issues, the potency and safety profile of Ligand A are more favorable.
Output:
1
2025-04-17 19:31:59,560 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.547 and 352.479 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (49.41) is significantly better than Ligand B (72.96). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is pushing the upper limit for good oral absorption.
3. **logP:** Ligand A (3.704) is optimal, while Ligand B (0.302) is quite low. Low logP can hinder membrane permeability and reduce binding affinity. This is a major strike against Ligand B.
4. **HBD:** Both ligands have 1 HBD, which is acceptable.
5. **HBA:** Ligand A has 2 HBA, while Ligand B has 4. Both are within the acceptable range of <=10, but Ligand A is preferable.
6. **QED:** Both ligands have similar QED values (0.725 and 0.773), indicating good drug-likeness.
7. **DILI:** Ligand A (17.72) has a much lower DILI risk than Ligand B (13.3). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (79.449) has a better BBB penetration percentile than Ligand B (55.797). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be useful for understanding off-target effects and overall distribution.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual, but the magnitude is similar.
10. **Solubility:** Ligand A (-4.31) has better solubility than Ligand B (-1.013).
11. **hERG:** Ligand A (0.619) has a lower hERG inhibition liability than Ligand B (0.15). This is a crucial safety parameter, and Ligand A is significantly better.
12. **Cl_mic:** Ligand A (88.083) has a higher microsomal clearance than Ligand B (9.18). This means Ligand B is more metabolically stable, which is a positive.
13. **t1/2:** Ligand A (16.49) has a longer in vitro half-life than Ligand B (-0.671). This is favorable.
14. **Pgp:** Ligand A (0.31) has lower P-gp efflux liability than Ligand B (0.01). Lower P-gp efflux is generally preferred for better bioavailability.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.5 and -6.6 kcal/mol). The difference is negligible.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical ADME-Tox properties. The most significant advantages for Ligand A are its better logP, lower DILI risk, better hERG profile, and better solubility. While Ligand B has better metabolic stability (lower Cl_mic), the other advantages of Ligand A outweigh this benefit, especially considering the similar binding affinities. Given the GPCR target class, optimizing for permeability (TPSA, logP) and minimizing off-target effects (DILI, hERG) are crucial.
Output:
1
2025-04-17 19:31:59,561 - INFO - Batch 117 complete. Total preferences: 1872
2025-04-17 19:31:59,561 - INFO - Processing batch 118/512...
2025-04-17 19:32:47,880 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (342.41 and 358.551 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (43.37) is higher than Ligand B (32.34). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B has a slight advantage.
3. **logP:** Both ligands (4.607 and 4.73) are slightly above the optimal 1-3 range, potentially raising concerns about solubility and off-target effects. However, for a GPCR, a slightly higher logP can be acceptable if it contributes to binding. No clear advantage.
4. **HBD:** Ligand A (0) has fewer H-bond donors than Ligand B (1). Fewer HBDs generally improve permeability. Ligand A has a slight advantage.
5. **HBA:** Both ligands have 3 H-bond acceptors. No clear advantage.
6. **QED:** Ligand B (0.789) has a better QED score than Ligand A (0.569), indicating a more drug-like profile. Ligand B has a clear advantage.
7. **DILI:** Ligand A (65.413) has a significantly higher DILI risk than Ligand B (31.291). This is a major concern for Ligand A. Ligand B has a substantial advantage.
8. **BBB:** Ligand A (71.229) and Ligand B (92.361) both have reasonable BBB penetration, but Ligand B is significantly higher. While ADRB2 isn't primarily a CNS target, some degree of BBB penetration can be useful for understanding off-target effects. Ligand B has an advantage.
9. **Caco-2:** Ligand A (-4.237) has a worse Caco-2 permeability than Ligand B (-5.412). Lower values indicate poorer permeability. Ligand B has a slight advantage.
10. **Solubility:** Ligand A (-5.898) has a worse solubility than Ligand B (-4.71). Lower values indicate poorer solubility. Ligand B has a slight advantage.
11. **hERG:** Ligand A (0.409) has a lower hERG inhibition liability than Ligand B (0.752). Lower is better. Ligand A has a slight advantage.
12. **Cl_mic:** Ligand B (66.539) has a lower microsomal clearance than Ligand A (123.748), indicating better metabolic stability. Ligand B has a clear advantage.
13. **t1/2:** Ligand B (33.097) has a longer in vitro half-life than Ligand A (25.382). This is desirable. Ligand B has a slight advantage.
14. **Pgp:** Ligand A (0.647) has slightly lower P-gp efflux than Ligand B (0.642). Lower is better. Ligand A has a slight advantage.
15. **Binding Affinity:** Ligand B (-7.4) has a significantly stronger binding affinity than Ligand A (-5.4). This is a crucial advantage, potentially outweighing some of the minor ADME drawbacks.
**Overall Assessment:**
Ligand B consistently outperforms Ligand A across most critical ADME properties (DILI, Cl_mic, solubility, Caco-2, t1/2, BBB) and, most importantly, has a *much* stronger binding affinity. While Ligand A has a slight advantage in hERG and Pgp, the significant DILI risk and weaker binding make it a less attractive candidate. The slightly higher logP of both compounds is a minor concern that could be addressed with further optimization.
Output:
0
2025-04-17 19:32:47,881 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [367.471, 78.95, 1.799, 1, 5, 0.829, 47.499, 88.096, -4.718, -1.864, 0.281, -9.154, 15.149, 0.033, -4.6]
**Ligand B:** [350.394, 67.67, 0.317, 0, 5, 0.734, 32.028, 84.684, -4.47, -1.143, 0.263, 18.993, -28.795, 0.03, -7.6]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, BBB, and affinity are key):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (350.394) is slightly lower, which is generally favorable.
2. **TPSA:** Ligand A (78.95) is a bit higher than Ligand B (67.67). Both are acceptable for a non-CNS GPCR target like ADRB2, but lower is generally better for permeability.
3. **logP:** Ligand A (1.799) is optimal. Ligand B (0.317) is a bit low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (0). Fewer HBDs generally improve permeability.
5. **HBA:** Both have 5 HBA, which is acceptable.
6. **QED:** Ligand A (0.829) is better than Ligand B (0.734), indicating a more drug-like profile.
7. **DILI:** Ligand A (47.499) has a slightly higher DILI risk than Ligand B (32.028), but both are below the concerning threshold of 60.
8. **BBB:** Both have good BBB penetration (Ligand A: 88.096, Ligand B: 84.684). This isn't a primary concern for ADRB2, but it doesn't hurt.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. This is a red flag for both, but the scale is not specified, so it's hard to interpret.
10. **Solubility:** Both have negative solubility values, which is also unusual. This is a concern for both.
11. **hERG:** Both have very low hERG inhibition risk (Ligand A: 0.281, Ligand B: 0.263).
12. **Cl_mic:** Ligand A (-9.154) has significantly *lower* (better) microsomal clearance than Ligand B (18.993), indicating greater metabolic stability.
13. **t1/2:** Ligand A (15.149) has a longer in vitro half-life than Ligand B (-28.795). This is a significant advantage.
14. **Pgp:** Both show very low P-gp efflux (0.033 and 0.03).
15. **Affinity:** Ligand B (-7.6) has a significantly stronger binding affinity than Ligand A (-4.6) - a difference of 3 kcal/mol. This is a substantial advantage.
**Overall Assessment:**
Ligand B has a significantly better binding affinity, which is the most important factor. While Ligand A has better metabolic stability (Cl_mic, t1/2) and a slightly better QED score, the 3 kcal/mol difference in binding affinity is likely to outweigh these benefits, especially for a GPCR target. The low logP of Ligand B is a concern, but the strong binding could compensate. The negative Caco-2 and solubility values are concerning for both, and would need further investigation.
Therefore, I would choose Ligand B.
0
2025-04-17 19:32:47,881 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (366.893 and 346.439 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (97.11) is better than Ligand B (109.65). Both are below 140, but closer to 90 is preferred for GPCRs, and A is closer.
3. **logP:** Ligand A (2.79) is better than Ligand B (1.335). Both are within the 1-3 range, but Ligand B is on the lower side, potentially impacting permeability.
4. **HBD:** Both ligands have 3 HBD, which is acceptable.
5. **HBA:** Ligand A (4) is better than Ligand B (8). Lower HBA is generally preferred for better permeability.
6. **QED:** Both ligands have similar QED scores (0.616 and 0.628), indicating good drug-likeness.
7. **DILI:** Both ligands have similar DILI risk (54.634 and 53.742), both are good (below 60).
8. **BBB:** Ligand A (61.38) is better than Ligand B (36.797). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant, and higher BBB is preferable.
9. **Caco-2:** Ligand A (-5.234) is better than Ligand B (-5.419). Both are negative, meaning low permeability, but A is slightly better.
10. **Solubility:** Ligand A (-3.269) is better than Ligand B (-2.094). Both are poor, but A is slightly better.
11. **hERG:** Ligand A (0.559) is better than Ligand B (0.094). Lower hERG inhibition is crucial for avoiding cardiotoxicity, and A has a much lower risk.
12. **Cl_mic:** Ligand A (40.314) is better than Ligand B (42.658). Lower clearance is preferred for metabolic stability.
13. **t1/2:** Ligand A (44.288) is better than Ligand B (21.334). A longer half-life is desirable.
14. **Pgp:** Ligand A (0.093) is better than Ligand B (0.011). Lower P-gp efflux is preferred for better bioavailability.
15. **Affinity:** Ligand A (-7.3 kcal/mol) is significantly better than Ligand B (-6.2 kcal/mol). This is a 1.1 kcal/mol difference, which is substantial and can outweigh minor ADME drawbacks.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most parameters, particularly in crucial areas like binding affinity, hERG inhibition, BBB, and metabolic stability. While both ligands have some weaknesses (poor solubility and Caco-2 permeability), Ligand A's superior affinity and safety profile make it the more promising candidate. The GPCR-specific priorities (logP, TPSA, Pgp, and affinity) all favor Ligand A.
Output:
1
2025-04-17 19:32:47,881 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (356.765 and 351.353 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (88.41) is slightly higher than Ligand B (73.48). Both are below the 140 threshold for good oral absorption, but B is better positioned.
3. **logP:** Ligand A (3.058) is optimal, while Ligand B (1.146) is a bit low, potentially impacting permeability. This favors A.
4. **HBD:** Ligand A (2) and Ligand B (1) are both within the acceptable limit of 5. B is slightly better.
5. **HBA:** Ligand A (4) and Ligand B (3) are both within the acceptable limit of 10. B is slightly better.
6. **QED:** Both ligands have good QED scores (A: 0.755, B: 0.809), indicating good drug-like properties. B is slightly better.
7. **DILI:** Ligand A (98.565) has a very high DILI risk, which is a major concern. Ligand B (39.667) has a much lower, acceptable DILI risk. This heavily favors B.
8. **BBB:** Ligand A (50.019) has a low BBB penetration, while Ligand B (90.151) has high BBB penetration. While ADRB2 isn't *strictly* a CNS target, some CNS exposure can be relevant for off-target effects and understanding the overall safety profile. This favors B.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.664 and -4.723), which is unusual and suggests poor permeability. This is a concern for both, but doesn't differentiate them.
10. **Solubility:** Ligand A (-5.416) has worse solubility than Ligand B (-2.326). This favors B.
11. **hERG:** Both ligands have low hERG inhibition liability (A: 0.432, B: 0.249). B is slightly better.
12. **Cl_mic:** Ligand A (22.394) has a moderate clearance, while Ligand B (-12.574) has a negative clearance, indicating very high metabolic stability. This strongly favors B.
13. **t1/2:** Ligand A (114.336) has a good in vitro half-life, while Ligand B (-37.445) has a negative half-life, which is problematic. This favors A.
14. **Pgp:** Ligand A (0.236) has lower P-gp efflux than Ligand B (0.029). This favors A.
15. **Binding Affinity:** Ligand A (-6.7) has a slightly better binding affinity than Ligand B (-6.1). While a 0.6 kcal/mol difference is noticeable, it's not a huge advantage given the other factors.
**Overall Assessment:**
Ligand B is significantly better overall. The major deciding factor is the drastically lower DILI risk. The better metabolic stability (negative Cl_mic), higher BBB penetration, and better solubility also contribute to its superior profile. While Ligand A has slightly better affinity and Pgp efflux, these are outweighed by the serious DILI concern and the other advantages of Ligand B. The negative Caco-2 values are concerning for both, but can be addressed in later optimization stages.
Output:
0
2025-04-17 19:32:47,881 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (363.439 Da) and Ligand B (345.443 Da) both fall within the ideal 200-500 Da range. No strong preference here.
2. **TPSA:** Ligand A (86.88) is better than Ligand B (66.65). Both are below 140, indicating good potential for oral absorption. Given ADRB2 is a cardiovascular target, CNS penetration isn't a primary concern, but lower TPSA is generally favorable.
3. **logP:** Ligand A (2.414) and Ligand B (2.827) are both within the optimal 1-3 range. No significant difference.
4. **HBD:** Ligand A (1) is preferable to Ligand B (0). While both are low, a single HBD can aid solubility without significantly impacting permeability.
5. **HBA:** Ligand A (6) is slightly higher than Ligand B (4). Both are acceptable (<10).
6. **QED:** Ligand A (0.848) is better than Ligand B (0.77), suggesting a more drug-like profile.
7. **DILI:** Ligand A (52.385) and Ligand B (56.301) are both acceptable, below the 60 threshold. No strong preference.
8. **BBB:** Ligand B (85.537) is significantly better than Ligand A (66.615). However, as ADRB2 is a cardiovascular target, BBB penetration is not a high priority.
9. **Caco-2:** Ligand A (-5.253) and Ligand B (-4.68) are both negative, which is unusual and suggests very poor permeability. This is a significant concern for both compounds.
10. **Solubility:** Ligand A (-1.788) is better than Ligand B (-3.316), although both are poor. Solubility is a concern for both, but Ligand A is slightly better.
11. **hERG:** Ligand A (0.081) is much better than Ligand B (0.303), indicating a lower risk of cardiotoxicity. This is *very* important for a cardiovascular target.
12. **Cl_mic:** Ligand A (-14.177) is much better than Ligand B (70.331), indicating significantly better metabolic stability. This is a major advantage for Ligand A.
13. **t1/2:** Ligand A (-2.617) is better than Ligand B (-25.206), indicating a longer in vitro half-life.
14. **Pgp:** Ligand A (0.025) is much better than Ligand B (0.457), indicating lower P-gp efflux.
15. **Affinity:** Ligand B (-5.1) is significantly better than Ligand A (-1.0). This is a substantial difference in potency.
**Overall Assessment:**
While Ligand B has a significantly better binding affinity, Ligand A has a much more favorable ADME-Tox profile. Specifically, the lower hERG inhibition, significantly better metabolic stability (Cl_mic and t1/2), and lower P-gp efflux of Ligand A are critical advantages, especially for a cardiovascular target where cardiotoxicity and bioavailability are key concerns. The poor Caco-2 values are a concern for both, but the superior ADME properties of Ligand A outweigh the affinity difference. The affinity of Ligand A is still reasonable, and optimization could potentially improve it.
Output:
1
2025-04-17 19:32:47,882 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (354.491 Da) is slightly higher than Ligand B (341.327 Da), but this difference isn't significant.
**2. TPSA:** Ligand A (81.86) is well below the 140 threshold for oral absorption and is favorable. Ligand B (102.49) is still acceptable but less optimal.
**3. logP:** Ligand A (2.102) is within the optimal range (1-3). Ligand B (0.636) is a bit low, potentially hindering membrane permeability.
**4. H-Bond Donors:** Both ligands have 1 HBD, which is good.
**5. H-Bond Acceptors:** Ligand A has 5 HBA, and Ligand B has 7. Both are within the acceptable limit of 10.
**6. QED:** Both ligands have good QED scores (A: 0.675, B: 0.75), indicating good drug-like properties.
**7. DILI:** Ligand A (6.282) has a very low DILI risk, significantly better than Ligand B (99.341), which is a major concern.
**8. BBB:** Ligand A (89.957) shows good BBB penetration, while Ligand B (40.093) is quite low. While ADRB2 isn't exclusively a CNS target, some peripheral effects may be desirable, and better BBB penetration can sometimes correlate with better overall distribution.
**9. Caco-2 Permeability:** Both have negative Caco-2 values, which is unusual. I will interpret these as very low permeability.
**10. Aqueous Solubility:** Both have negative solubility values, which is also unusual. I will interpret these as very low solubility.
**11. hERG Inhibition:** Ligand A (0.651) has a lower hERG risk than Ligand B (0.175).
**12. Microsomal Clearance:** Ligand A (58.027) has a higher (worse) microsomal clearance than Ligand B (10.225), indicating faster metabolism.
**13. In vitro Half-Life:** Ligand A (-12.786) has a negative half-life, which is impossible. Ligand B (36.125) has a reasonable half-life.
**14. P-gp Efflux:** Ligand A (0.138) has lower P-gp efflux than Ligand B (0.023), which is favorable.
**15. Binding Affinity:** Ligand B (-7.9 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.1 kcal/mol) - a difference of 1.8 kcal/mol. This is a substantial advantage.
**GPCR-Specific Considerations:** For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are crucial. Ligand B excels in affinity, and has acceptable TPSA. Ligand A has better logP and Pgp. However, the extremely high DILI risk for Ligand B and the impossible half-life for Ligand A are major red flags.
**Overall Assessment:**
Despite the superior binding affinity of Ligand B, the extremely high DILI risk and the unusual solubility/permeability values are concerning. Ligand A has a much better safety profile (DILI) and more reasonable ADME properties, even with a lower affinity. The negative values for solubility and Caco-2 are concerning for both, but the DILI risk for B is a deal breaker.
Output:
1
2025-04-17 19:32:47,882 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (350.463 and 367.515 Da) fall comfortably within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (96.11) is slightly higher than Ligand B (82.53). Both are below the 140 threshold for good oral absorption, but B is closer to the <90 ideal for CNS penetration (though this is less critical for a cardiovascular target).
3. **logP:** Both ligands (1.971 and 2.321) are within the optimal 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Ligand A (3) and Ligand B (2) are both acceptable, below the 5 threshold. Ligand B is slightly better.
5. **HBA:** Ligand A (4) and Ligand B (5) are both acceptable, below the 10 threshold.
6. **QED:** Both ligands have good QED scores (0.731 and 0.835), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Both ligands have acceptable DILI risk (50.795 and 47.77), well below the concerning 60 threshold. Ligand B is slightly better.
8. **BBB:** Both ligands have good BBB penetration (73.672 and 76.464). This isn't a primary concern for a cardiovascular target, but higher is generally preferred. Ligand B is slightly better.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.651 and -4.987). This is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Both ligands have negative solubility values (-3.841 and -3.788). Again, the scale is unspecified, making interpretation difficult.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.266 and 0.845). This is excellent.
12. **Cl_mic:** Ligand B (45.854) has a lower microsomal clearance than Ligand A (56.139), suggesting better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand B (-14.072) has a much longer in vitro half-life than Ligand A (-49.717). This is a major advantage, potentially leading to less frequent dosing.
14. **Pgp:** Ligand A (0.057) has lower P-gp efflux than Ligand B (0.212), which is preferable.
15. **Binding Affinity:** Ligand B (-8.0) has a significantly stronger binding affinity than Ligand A (-5.9). This is a substantial advantage, potentially outweighing minor ADME drawbacks.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand B has a slightly better logP, lower Pgp efflux, lower TPSA, and *significantly* better affinity. The improved metabolic stability (lower Cl_mic) and longer half-life are also very important.
**Conclusion:**
While Ligand A has a slight advantage in P-gp efflux, the substantial improvements in binding affinity, metabolic stability, and half-life exhibited by Ligand B make it the more promising drug candidate.
Output:
0
2025-04-17 19:32:47,882 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
The ADRB2 receptor is a GPCR, so the priorities are logP, TPSA, Pgp efflux, BBB penetration, and binding affinity. Let's analyze each ligand against these and other key properties.
* **Molecular Weight:** Both ligands (345.363 and 350.463 Da) fall within the ideal 200-500 Da range.
* **TPSA:** Ligand B (87.46) is significantly better than Ligand A (130.04). A TPSA under 140 is good for oral absorption, and under 90 is preferable for CNS targets (though less critical for peripheral GPCRs like ADRB2, lower is still better).
* **logP:** Ligand B (1.097) is within the optimal 1-3 range, while Ligand A (-0.136) is below 1, potentially hindering permeation. This is a significant advantage for Ligand B.
* **H-Bond Donors/Acceptors:** Ligand B (2 HBD, 5 HBA) is slightly better than Ligand A (4 HBD, 6 HBA) in terms of balancing solubility and permeability.
* **QED:** Ligand B (0.771) has a substantially better QED score than Ligand A (0.453), indicating a more drug-like profile.
* **DILI Risk:** Ligand B (31.175) has a much lower DILI risk than Ligand A (94.649). This is a critical advantage.
* **BBB:** Ligand A (40.791) and Ligand B (29.236) both have low BBB penetration, which is not a major concern for ADRB2, as it's not primarily a CNS target.
* **Caco-2 Permeability:** Both ligands have similar, very poor Caco-2 permeability (-5.483 and -5.264).
* **Aqueous Solubility:** Both ligands have poor aqueous solubility (-3.703 and -1.474).
* **hERG Inhibition:** Ligand B (0.215) has a slightly better hERG profile than Ligand A (0.098), but both are relatively low risk.
* **Microsomal Clearance:** Ligand B (8.786) has lower clearance than Ligand A (10.662), suggesting better metabolic stability.
* **In vitro Half-Life:** Ligand B (13.247 hours) has a significantly longer half-life than Ligand A (48.581 hours).
* **P-gp Efflux:** Ligand A (0.014) has slightly lower P-gp efflux than Ligand B (0.059), but the difference is small.
* **Binding Affinity:** Ligand A (-7.9 kcal/mol) has a stronger binding affinity than Ligand B (-6.4 kcal/mol). This is a 1.5 kcal/mol difference, which is substantial.
**Overall Assessment:**
While Ligand A has a better binding affinity, the significant advantages of Ligand B in terms of DILI risk, logP, QED, metabolic stability, and half-life outweigh this difference. The poor Caco-2 and solubility are concerns for both, but can be addressed with formulation strategies. The lower logP of Ligand A is a major drawback, potentially limiting its absorption. The very high DILI risk associated with Ligand A is a deal-breaker.
Therefore, I prefer Ligand B.
**Output:**
0
2025-04-17 19:32:47,882 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (367.435 Da and 345.443 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (124.18) is slightly higher than Ligand B (75.44). For a cardiovascular GPCR, TPSA is moderately important. Ligand B is significantly better, being well below the 140 A^2 threshold, suggesting better permeability.
**3. logP:** Ligand A (-1.057) is lower than the optimal 1-3 range, potentially hindering membrane permeability. Ligand B (2.595) is within the optimal range. This is a significant advantage for Ligand B.
**4. H-Bond Donors:** Ligand A (2) and Ligand B (1) are both acceptable.
**5. H-Bond Acceptors:** Ligand A (7) and Ligand B (4) are both acceptable.
**6. QED:** Both ligands have good QED scores (0.636 and 0.86), indicating drug-likeness. Ligand B is slightly better.
**7. DILI:** Ligand A (71.694) has a higher DILI risk than Ligand B (23.342). This is a substantial advantage for Ligand B.
**8. BBB:** Ligand A (34.548) has poor BBB penetration, while Ligand B (79.294) is better, though not exceptionally high. Since ADRB2 is a cardiovascular target, BBB penetration is less critical, but still a consideration.
**9. Caco-2 Permeability:** Ligand A (-6.105) has very poor Caco-2 permeability, indicating poor absorption. Ligand B (-4.994) is better, but still not great.
**10. Aqueous Solubility:** Both ligands have poor aqueous solubility (-2.117 and -2.581). This could pose formulation challenges, but is not a deciding factor.
**11. hERG Inhibition:** Ligand A (0.014) has very low hERG inhibition risk, which is excellent. Ligand B (0.105) is slightly higher, but still relatively low.
**12. Microsomal Clearance:** Ligand A (-7.4) has a lower (better) microsomal clearance than Ligand B (31.126), indicating better metabolic stability.
**13. In vitro Half-Life:** Ligand A (-1.184) has a shorter half-life than Ligand B (-8.546).
**14. P-gp Efflux:** Ligand A (0.028) has lower P-gp efflux than Ligand B (0.09), which is favorable for bioavailability.
**15. Binding Affinity:** Both ligands have strong binding affinities (-6.6 kcal/mol and -5.9 kcal/mol). Ligand A has a 0.7 kcal/mol advantage, which is significant.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand A's superior affinity is a strong point. However, Ligand A's poor Caco-2 permeability and higher DILI risk are major drawbacks. Ligand B has a more balanced profile with better logP, TPSA, DILI, and P-gp efflux, even though its affinity is slightly lower. The better ADME properties of Ligand B outweigh the slightly lower affinity, making it a more promising starting point for drug development.
Output:
0
2025-04-17 19:32:47,882 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (348.487) is slightly lower than Ligand B (362.539), which is generally favorable for permeability.
2. **TPSA:** Ligand B (40.62) is significantly better than Ligand A (61.8). ADRB2 is not a CNS target, but lower TPSA generally improves absorption.
3. **logP:** Both ligands have good logP values (A: 2.575, B: 2.914), falling within the optimal 1-3 range. Ligand B is slightly higher, which could potentially lead to some off-target interactions, but is still acceptable.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (0). Both are acceptable, but lower is generally preferred.
5. **HBA:** Ligand A (4) is slightly higher than Ligand B (3). Both are within the acceptable limit of 10.
6. **QED:** Both ligands have good QED scores (A: 0.674, B: 0.722), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (2.365) has a much lower DILI risk than Ligand B (26.095). This is a significant advantage for Ligand A.
8. **BBB:** This is less critical for ADRB2, but Ligand B (83.637) has a higher BBB penetration than Ligand A (68.941).
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.667 and -4.885). This is unusual and suggests poor permeability. However, the values are similar.
10. **Solubility:** Ligand A (-1.639) has better solubility than Ligand B (-3.194).
11. **hERG:** Both ligands have low hERG inhibition liability (A: 0.935, B: 0.443), which is good. Ligand B is slightly better.
12. **Cl_mic:** Ligand A (17.969) has significantly lower microsomal clearance than Ligand B (56.657), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-14.091) has a shorter in vitro half-life than Ligand B (-16.142). This is a drawback for Ligand A.
14. **Pgp:** Both ligands have low Pgp efflux liability (A: 0.495, B: 0.338). Ligand B is slightly better.
15. **Binding Affinity:** Both ligands have similar binding affinities (A: -5.9 kcal/mol, B: -5.4 kcal/mol). Ligand A has a slightly better affinity.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand B has better TPSA, Pgp, and BBB, while Ligand A has slightly better logP and affinity. However, the significantly lower DILI risk and better metabolic stability of Ligand A are crucial factors. The Caco-2 values are concerning for both, but the other advantages of Ligand A outweigh this.
**Conclusion:**
Considering the balance of properties, especially the lower DILI risk and better metabolic stability of Ligand A, I believe it is the more promising drug candidate.
Output:
1
2025-04-17 19:32:47,882 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [348.403, 112.58 , -0.012, 4. , 5. , 0.572, 60.062, 51.57 ,
-5.045, -1.862, 0.08 , -14.271, 26.269, 0.003, -8.1 ]
**Ligand B:** [343.471, 75.43 , 2.37 , 2. , 3. , 0.885, 38.93 , 85.343,
-4.987, -3.1 , 0.471, 42.756, 1.45 , 0.066, -8.7 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (343.471) is slightly lower, which is generally favorable.
2. **TPSA:** Ligand A (112.58) is higher than Ligand B (75.43). Ligand B is better, being closer to the <140 threshold for good absorption.
3. **logP:** Ligand A (-0.012) is quite low, potentially hindering permeation. Ligand B (2.37) is within the optimal 1-3 range. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (4) is acceptable, Ligand B (2) is even better.
5. **HBA:** Ligand A (5) is acceptable, Ligand B (3) is even better.
6. **QED:** Both are good (A: 0.572, B: 0.885), but Ligand B is significantly better, indicating a more drug-like profile.
7. **DILI:** Ligand A (60.062) is borderline high risk, while Ligand B (38.93) is good. This is a substantial advantage for Ligand B.
8. **BBB:** Ligand B (85.343) is much better than Ligand A (51.57). While ADRB2 isn't exclusively a CNS target, some CNS penetration can be beneficial and reduces the risk of off-target effects.
9. **Caco-2:** Both are similar and negative, indicating poor permeability.
10. **Solubility:** Both are negative, indicating poor solubility.
11. **hERG:** Both are low, indicating low risk of cardiotoxicity.
12. **Cl_mic:** Ligand A (-14.271) is much lower (better) than Ligand B (42.756), indicating greater metabolic stability.
13. **t1/2:** Ligand A (26.269) is much better than Ligand B (1.45).
14. **Pgp:** Ligand A (0.003) is much lower (better) than Ligand B (0.066), indicating less efflux.
15. **Affinity:** Ligand B (-8.7) is slightly better than Ligand A (-8.1), but the difference is not substantial enough to outweigh other factors.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are crucial. Ligand B excels in logP, TPSA, and Pgp. While the affinity difference isn't huge, Ligand B is still slightly better. Ligand A has better metabolic stability and half-life, but the DILI risk and poor logP are major concerns.
**Conclusion:**
Despite Ligand A's better metabolic stability and half-life, the superior ADME profile of Ligand B (better logP, TPSA, lower DILI risk, better BBB penetration, lower Pgp efflux) makes it the more promising drug candidate. The slightly better affinity of Ligand B further reinforces this decision.
Output:
0
2025-04-17 19:32:47,883 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.371 and 350.503 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (93.9) is slightly higher than Ligand B (69.64). Both are below the 140 threshold for oral absorption, but B is better positioned for potential CNS penetration, though this isn't a primary goal for ADRB2.
3. **logP:** Ligand B (2.469) is closer to the optimal 1-3 range than Ligand A (1.008). A's logP is a bit low, potentially impacting permeability.
4. **HBD:** Ligand A (1) has fewer HBDs than Ligand B (2). Both are within the acceptable limit of 5.
5. **HBA:** Ligand A (6) has more HBAs than Ligand B (3). Both are below the acceptable limit of 10.
6. **QED:** Both ligands have similar QED values (0.799 and 0.741), indicating good drug-likeness.
7. **DILI:** Ligand B (12.369) has a significantly lower DILI risk than Ligand A (58.705). This is a major advantage for Ligand B.
8. **BBB:** Both have similar BBB penetration (60.527 and 61.497). Not a high priority for ADRB2.
9. **Caco-2:** Both have negative Caco-2 values (-4.685 and -4.582). These values are difficult to interpret without knowing the scale, but the similarity suggests similar absorption potential.
10. **Solubility:** Both have negative solubility values (-2.145 and -2.694). Similar to Caco-2, the scale is unknown, but similar values suggest similar solubility.
11. **hERG:** Ligand A (0.093) has a slightly lower hERG risk than Ligand B (0.231), which is favorable.
12. **Cl_mic:** Ligand B (36.77) has a slightly lower microsomal clearance than Ligand A (39.118), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-28.743) has a much more negative in vitro half-life than Ligand B (-1.553). This suggests a significantly shorter half-life for Ligand A, which is undesirable.
14. **Pgp:** Ligand A (0.084) has lower P-gp efflux than Ligand B (0.116), which is favorable.
15. **Binding Affinity:** Ligand B (1.7 kcal/mol) has a significantly *worse* binding affinity than Ligand A (-5.6 kcal/mol). This is a substantial difference.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, and affinity are key. Ligand B has a better logP and TPSA. However, the affinity difference is substantial. The DILI risk for Ligand B is also significantly lower, which is a critical safety consideration. The shorter half-life of Ligand A is a major drawback.
**Overall Assessment:**
While Ligand A has a much stronger binding affinity, the significantly higher DILI risk and shorter half-life are concerning. Ligand B, despite the weaker binding, presents a much more favorable safety profile and better metabolic stability. The affinity difference, while significant, might be overcome with further optimization, whereas mitigating high DILI risk is often much more challenging.
Output:
0
2025-04-17 19:32:47,883 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (360.384 and 343.427 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (86.8) is slightly higher than Ligand B (72.48). Both are below the 140 threshold for good oral absorption, and reasonably close to the 90 threshold for CNS targets (though ADRB2 isn't necessarily a CNS target). Ligand B is preferable here.
3. **logP:** Both ligands have good logP values (2.043 and 2.832), falling within the optimal 1-3 range. Ligand B is slightly higher, which *could* be a minor benefit for membrane permeability, but isn't a major concern for either.
4. **HBD:** Both have 2 HBD, which is within the acceptable limit of <=5.
5. **HBA:** Ligand A has 5 HBA and Ligand B has 6. Both are acceptable, but Ligand A is slightly better.
6. **QED:** Ligand A (0.861) has a better QED score than Ligand B (0.786), indicating a more drug-like profile. This is a positive for Ligand A.
7. **DILI:** Both ligands have very similar DILI risk (50.33 and 50.291 percentile), and are both considered low risk (<60).
8. **BBB:** Ligand A (88.445) has a slightly higher BBB penetration percentile than Ligand B (83.094). While ADRB2 isn't strictly a CNS target, some peripheral distribution is still desired, and higher BBB penetration often correlates with better overall distribution.
9. **Caco-2:** Ligand A (-5.124) has a worse Caco-2 permeability than Ligand B (-4.785). Lower (more negative) values indicate lower permeability. Ligand B is preferable.
10. **Solubility:** Ligand A (-3.556) has slightly worse solubility than Ligand B (-3.037). Higher values are better. Ligand B is preferable.
11. **hERG:** Ligand A (0.279) has a significantly lower hERG inhibition liability than Ligand B (0.893). This is a *major* advantage for Ligand A, as hERG inhibition can lead to cardiotoxicity, a critical concern for cardiovascular targets like ADRB2.
12. **Cl_mic:** Ligand A (8.911) has a significantly lower microsomal clearance than Ligand B (36.894). Lower clearance indicates better metabolic stability, which is highly desirable. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (-24.407) has a much longer in vitro half-life than Ligand B (15.893). This is a major advantage for Ligand A, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.039) has a much lower P-gp efflux liability than Ligand B (0.154). Lower efflux is better for bioavailability. This is a significant advantage for Ligand A.
15. **Affinity:** Ligand A (-7.6) has a slightly better binding affinity than Ligand B (-5.8). This is a substantial advantage for Ligand A.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A excels in affinity, Pgp, and has a reasonable logP and TPSA. While Ligand B has a slightly better logP and Caco-2, Ligand A's superior affinity, metabolic stability (Cl_mic, t1/2), lower hERG risk, and lower Pgp efflux are far more important.
**Conclusion:**
Ligand A is the stronger candidate. Its superior binding affinity, metabolic stability, reduced toxicity (hERG), and better pharmacokinetic properties (Pgp, t1/2) outweigh the slightly better Caco-2 and solubility of Ligand B.
Output:
1
2025-04-17 19:32:47,883 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [362.832, 41.57, 3.169, 1, 3, 0.888, 52.423, 87.515, -4.743, -3.965, 0.799, 43.597, 11.428, 0.229, -5.9]
**Ligand B:** [381.523, 62.74, 1.781, 0, 6, 0.728, 59.519, 57.968, -5.189, -2.056, 0.152, 45.312, 1.312, 0.137, -6.4]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal 200-500 Da range. Ligand A (362.832) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (41.57) is significantly better than Ligand B (62.74), falling well below the 140 threshold for oral absorption and closer to the 90 threshold for CNS penetration.
3. **logP:** Ligand A (3.169) is optimal, while Ligand B (1.781) is a bit low, potentially hindering permeation.
4. **HBD:** Ligand A (1) is preferable to Ligand B (0). Having at least one HBD can aid solubility.
5. **HBA:** Ligand B (6) is better than Ligand A (3).
6. **QED:** Both are reasonably good (A: 0.888, B: 0.728), indicating drug-like properties. Ligand A is better.
7. **DILI:** Both have acceptable DILI risk (A: 52.423, B: 59.519), below the 60 threshold.
8. **BBB:** Ligand A (87.515) is significantly better than Ligand B (57.968). While ADRB2 is not strictly a CNS target, some brain penetration can be beneficial for understanding off-target effects and potential side effects.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-4.743) is slightly worse than Ligand B (-5.189).
10. **Solubility:** Ligand B (-2.056) is better than Ligand A (-3.965), which is a positive.
11. **hERG:** Ligand A (0.799) is better than Ligand B (0.152), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Both are similar (A: 43.597, B: 45.312), suggesting comparable metabolic stability.
13. **t1/2:** Ligand A (11.428) has a longer half-life than Ligand B (1.312), which is desirable.
14. **Pgp:** Ligand A (0.229) is better than Ligand B (0.137), suggesting less P-gp efflux.
15. **Affinity:** Ligand B (-6.4) has a slightly better binding affinity than Ligand A (-5.9), a 0.5 kcal/mol difference.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A excels in logP, TPSA, and Pgp, while Ligand B has a slightly better affinity. The difference in affinity (0.5 kcal/mol) is not substantial enough to outweigh the significant advantages of Ligand A in terms of TPSA, logP, BBB, and half-life. The better TPSA and logP of Ligand A suggest it will have better absorption and distribution properties.
**Conclusion:**
Considering the balance of properties and the priorities for a GPCR target, Ligand A is the more promising drug candidate.
**Output:**
1
2025-04-17 19:32:47,883 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's systematically compare Ligand A and Ligand B based on the provided parameters and the guidelines, keeping in mind this is a GPCR target (ADRB2, cardiovascular). Therefore, logP, TPSA, Pgp, BBB, and affinity are prioritized.
1. **MW:** Both ligands (350.5 & 354.4 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (32.8) is significantly better than Ligand B (61.0). A TPSA under 140 is good for oral absorption, but lower is preferred for GPCRs. Ligand A is much closer to the ideal range.
3. **logP:** Ligand A (3.55) is good, within the 1-3 range. Ligand B (1.85) is at the lower end, potentially impacting permeability.
4. **HBD/HBA:** Both have 0 HBD, which is good. Ligand A has 3 HBA, and Ligand B has 7. While both are under the 10 limit, Ligand A is preferable.
5. **QED:** Both are similar (0.604 vs 0.652), indicating good drug-likeness.
6. **DILI:** Ligand B (33.8) has a significantly lower DILI risk than Ligand A (4.4). This is a strong advantage for Ligand B.
7. **BBB:** Both have excellent BBB penetration (92.8% vs 91.5%). This isn't a primary concern for a cardiovascular target, but it's good to see.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests a potential issue with the experimental setup or data quality. However, the values are similar.
9. **Solubility:** Both have negative solubility values, again suggesting data quality issues. The values are similar.
10. **hERG:** Ligand A (0.86) is slightly higher than Ligand B (0.57), indicating a potentially higher risk of hERG inhibition.
11. **Cl_mic:** Ligand B (13.6) has significantly lower microsomal clearance than Ligand A (103.5), suggesting better metabolic stability.
12. **t1/2:** Ligand A (25.3) has a longer in vitro half-life than Ligand B (9.7).
13. **Pgp:** Ligand A (0.25) has lower P-gp efflux than Ligand B (0.15), which is favorable for bioavailability.
14. **Affinity:** Ligand A (-6.5 kcal/mol) has a slightly better binding affinity than Ligand B (-5.5 kcal/mol). This is a 1 kcal/mol difference, which is significant.
**Overall Assessment:**
Ligand A has a better profile regarding key GPCR properties like TPSA, logP, Pgp efflux, and binding affinity. The 1 kcal/mol difference in binding affinity is a substantial advantage. However, Ligand B has a much lower DILI risk and better metabolic stability (lower Cl_mic). The negative solubility and Caco-2 values are concerning for both, but similar. Considering the importance of potency for GPCRs and the relatively small difference in DILI risk, the stronger binding affinity and better physicochemical properties of Ligand A make it the more promising candidate.
**Output:**
1
2025-04-17 19:32:47,883 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step Comparison:**
1. **MW:** Both ligands (343.431 and 342.483 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (95.06) is higher than Ligand B (58.2). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferable for absorption. Ligand B is significantly better here.
3. **logP:** Ligand A (1.318) is within the optimal range, while Ligand B (3.082) is at the higher end. Both are acceptable, but Ligand A is slightly preferred for potentially fewer off-target interactions.
4. **HBD:** Both ligands have 2 HBD, which is good.
5. **HBA:** Ligand A has 6 HBA, while Ligand B has 2. Lower HBA is generally favorable for permeability, giving Ligand B an advantage.
6. **QED:** Ligand A (0.79) has a better QED score than Ligand B (0.576), indicating a more drug-like profile.
7. **DILI:** Ligand A (62.195) has a higher DILI risk than Ligand B (31.64). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (64.25) has a slightly better BBB penetration than Ligand B (49.67). However, BBB is not a primary concern for a cardiovascular target.
9. **Caco-2:** Ligand A (-5.356) has a worse Caco-2 permeability than Ligand B (-4.703). Better Caco-2 permeability suggests better absorption.
10. **Solubility:** Ligand A (-2.633) has a worse solubility than Ligand B (-4.78). Solubility is important for bioavailability, favoring Ligand B.
11. **hERG:** Ligand A (0.38) has a slightly higher hERG inhibition liability than Ligand B (0.156). Lower hERG risk is crucial for cardiovascular drugs, favoring Ligand B.
12. **Cl_mic:** Ligand A (10.485) has a lower microsomal clearance than Ligand B (45.148), suggesting better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (18.046) has a longer in vitro half-life than Ligand B (-4.11). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.213) has a lower P-gp efflux liability than Ligand B (0.185). Lower P-gp efflux is generally desirable, giving Ligand A a slight edge.
15. **Affinity:** Ligand B (-7.3) has a slightly better binding affinity than Ligand A (-6.9). While both are good, the 1.5kcal/mol difference is noteworthy.
**Overall Assessment:**
Ligand B has a clear advantage in ADME properties: lower DILI risk, better solubility, lower hERG inhibition, and better Caco-2 permeability. While Ligand A has better metabolic stability (lower Cl_mic) and half-life, the ADME profile of Ligand B is more favorable, especially considering the cardiovascular target. The slightly better affinity of Ligand B is also a plus. The lower TPSA and HBA of Ligand B also contribute to better permeability.
Output:
0
2025-04-17 19:32:47,884 - INFO - Batch 118 complete. Total preferences: 1888
2025-04-17 19:32:47,884 - INFO - Processing batch 119/512...
2025-04-17 19:33:31,973 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (398.26 and 372.471 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (71.09 and 72.2) are below the 140 A^2 threshold for good oral absorption, and acceptable for a cardiovascular GPCR. Again, no major difference.
3. **logP:** Both ligands have a logP around 3.88, which is optimal.
4. **HBD:** Ligand A has 2 HBD, and Ligand B has 1. Both are within the acceptable limit of <=5.
5. **HBA:** Ligand A has 3 HBA, and Ligand B has 5. Both are within the acceptable limit of <=10.
6. **QED:** Ligand A (0.701) has a better QED score than Ligand B (0.577), suggesting a more drug-like profile.
7. **DILI:** Both ligands have high DILI risk (85.653 and 89.415 percentile). This is a concern for both, but not a deciding factor *between* them.
8. **BBB:** Ligand A (78.558%) has a better BBB penetration score than Ligand B (62.854%). While ADRB2 is a cardiovascular target, some CNS exposure is not necessarily detrimental and can be a bonus.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.069 and -5.495). This is unusual and suggests poor permeability.
10. **Solubility:** Both ligands have negative solubility values (-4.694 and -3.988). This is also concerning and indicates poor aqueous solubility.
11. **hERG:** Both ligands have low hERG inhibition liability (0.641 and 0.626), which is good.
12. **Cl_mic:** Ligand A (65.989) has a lower microsomal clearance than Ligand B (90.751), indicating better metabolic stability.
13. **t1/2:** Ligand A (86.255) has a significantly longer in vitro half-life than Ligand B (7.309). This is a major advantage.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.43 and 0.72).
15. **Binding Affinity:** Ligand A (-8.4 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.3 kcal/mol). This is a substantial advantage, exceeding the 1.5 kcal/mol threshold.
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Both ligands are good on logP and Pgp. TPSA is acceptable for both. However, Ligand A *significantly* outperforms Ligand B in binding affinity and has better metabolic stability (Cl_mic and t1/2). The better BBB penetration of Ligand A is a bonus. While both have poor Caco-2 and solubility, the strong affinity of Ligand A makes it more likely that formulation strategies could overcome these issues.
**Conclusion:**
Ligand A is the superior candidate due to its significantly stronger binding affinity, better metabolic stability, longer half-life, and slightly better BBB penetration. The poor Caco-2 and solubility are drawbacks for both, but the potency advantage of Ligand A is substantial enough to outweigh these concerns.
Output:
1
2025-04-17 19:33:31,974 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (366-376 Da). No significant difference.
2. **TPSA:** Ligand B (78.27) is significantly better than Ligand A (110.8), falling well below the 140 threshold for good oral absorption. This is a strong positive for B.
3. **logP:** Ligand B (1.231) is within the optimal range, while Ligand A (-0.372) is slightly below, potentially impacting permeability. This favors B.
4. **HBD:** Both ligands have acceptable HBD counts (1 and 2 respectively). No clear advantage.
5. **HBA:** Both ligands have acceptable HBA counts (7 and 6 respectively). No clear advantage.
6. **QED:** Ligand B (0.782) has a slightly better QED score than Ligand A (0.538), indicating a more drug-like profile. This favors B.
7. **DILI:** Ligand B (48.313) has a lower DILI risk than Ligand A (37.301), which is preferable. This favors B.
8. **BBB:** Ligand A (67.197) has a better BBB penetration score than Ligand B (57.193). While ADRB2 isn't necessarily a CNS target, some peripheral ADRB2 receptors can be involved in CNS effects, so this is a slight positive for A.
9. **Caco-2:** Both ligands have very similar, and poor, Caco-2 permeability values (-5.508 and -5.552). This is a concern for both.
10. **Solubility:** Ligand A (-1.259) has slightly better solubility than Ligand B (-2.504). This is a minor positive for A.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.107 and 0.084). No significant difference.
12. **Cl_mic:** Ligand A (3.015) has significantly lower microsomal clearance than Ligand B (22.672), indicating better metabolic stability. This is a strong positive for A.
13. **t1/2:** Both ligands have similar in vitro half-lives (10.272 and 10.307). No significant difference.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.022 and 0.063). No significant difference.
15. **Binding Affinity:** Ligand A (-7.0) has a slightly better binding affinity than Ligand B (-5.2). This is a significant advantage for A, potentially outweighing some ADME drawbacks.
**GPCR-Specific Considerations:**
For GPCRs, logP, TPSA, Pgp, and affinity are key. Ligand B excels in TPSA and logP, while Ligand A has a superior binding affinity and better metabolic stability (Cl_mic). The affinity difference is substantial (1.8 kcal/mol). While the Caco-2 permeability is poor for both, the stronger binding of Ligand A makes it more likely to achieve efficacy *in vivo* despite potential absorption challenges.
**Overall Assessment:**
Despite Ligand B's advantages in TPSA, logP, and DILI, the significantly stronger binding affinity of Ligand A, combined with its better metabolic stability, makes it the more promising candidate. The affinity difference is large enough to potentially overcome the slightly less favorable logP and the poor Caco-2 permeability.
Output:
1
2025-04-17 19:33:31,974 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (367.4 & 358.5 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand B (58.2) is significantly better than Ligand A (84.7). Lower TPSA generally favors better absorption, crucial for GPCRs.
3. **logP:** Ligand A (1.95) is optimal, while Ligand B (3.65) is approaching the upper limit. While still acceptable, higher logP can lead to off-target effects.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs can improve membrane permeability.
5. **HBA:** Ligand A (6) is better than Ligand B (2). Lower HBA also aids permeability.
6. **QED:** Ligand A (0.893) is significantly better than Ligand B (0.73), indicating a more drug-like profile.
7. **DILI:** Ligand B (20.7) is *much* better than Ligand A (79.5). This is a major advantage for Ligand B. DILI risk is a critical factor.
8. **BBB:** Ligand B (88.3) is significantly better than Ligand A (67.4). While ADRB2 isn't strictly a CNS target, some CNS penetration can be beneficial, and avoiding high CNS exposure is generally preferred.
9. **Caco-2:** Both are very negative (-4.55 and -4.56), indicating poor permeability. This is a significant drawback for both.
10. **Solubility:** Ligand B (-4.12) is slightly better than Ligand A (-3.07), but both are poor. Solubility is a concern for both.
11. **hERG:** Ligand A (0.38) is better than Ligand B (0.56), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand A (34.4) is significantly better than Ligand B (43.5), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-15.9) is better than Ligand B (-18.4), indicating a longer half-life.
14. **Pgp:** Ligand A (0.16) is better than Ligand B (0.10), suggesting lower P-gp efflux.
15. **Affinity:** Ligand A (-7.3) is slightly better than Ligand B (-6.8), but the difference is relatively small.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, and affinity are important. Ligand A has a better logP and slightly better affinity. However, Ligand B has a *much* lower TPSA and a dramatically lower DILI risk. The DILI risk for Ligand A is concerningly high. While Caco-2 permeability is poor for both, the lower DILI risk of Ligand B, coupled with its better TPSA and BBB, outweighs the slightly better affinity and logP of Ligand A.
**Conclusion:**
Despite the slightly weaker binding affinity, Ligand B's superior safety profile (DILI) and better physicochemical properties (TPSA, BBB) make it the more promising drug candidate.
Output:
0
2025-04-17 19:33:31,974 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
Let's analyze each ligand against the provided guidelines, with a focus on GPCR-relevant properties (logP, TPSA, Pgp, BBB, and affinity).
* **Molecular Weight:** Both ligands are within the acceptable 200-500 Da range. Ligand A (342.355 Da) is slightly better.
* **TPSA:** Ligand B (61.36) is significantly better than Ligand A (98.39). Lower TPSA generally favors oral absorption and potentially BBB penetration.
* **logP:** Ligand A (2.758) is optimal, while Ligand B (4.268) is pushing the upper limit. High logP can lead to solubility issues and off-target interactions.
* **H-Bond Donors/Acceptors:** Ligand A (2 HBD, 6 HBA) is slightly better balanced than Ligand B (3 HBD, 2 HBA).
* **QED:** Both ligands have similar QED values (0.695 vs 0.683), indicating good drug-likeness.
* **DILI:** Ligand A (93.292) has a considerably higher DILI risk than Ligand B (35.789). This is a significant negative for Ligand A.
* **BBB:** Ligand B (81.853) shows better BBB penetration potential than Ligand A (59.674). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant, and minimizing efflux is always beneficial.
* **Caco-2 Permeability:** Both have negative values, indicating low permeability. Ligand A (-4.921) is slightly better than Ligand B (-4.44).
* **Aqueous Solubility:** Both have negative values, indicating low solubility. Ligand B (-5.141) is slightly worse than Ligand A (-4.222).
* **hERG:** Ligand A (0.346) has a lower hERG risk than Ligand B (0.724), which is a positive.
* **Microsomal Clearance:** Ligand B (51.769) has lower microsomal clearance than Ligand A (78.593), suggesting better metabolic stability.
* **In vitro Half-Life:** Ligand A (112.215) has a longer half-life than Ligand B (44.889), which is a positive.
* **P-gp Efflux:** Ligand A (0.126) has lower P-gp efflux than Ligand B (0.452), indicating better bioavailability and potential for CNS exposure.
* **Binding Affinity:** Ligand B (-6.7 kcal/mol) has a slightly better binding affinity than Ligand A (-6.3 kcal/mol), but the difference is relatively small.
**Overall Assessment:**
Ligand B has a significantly better safety profile (lower DILI) and better BBB penetration, which are important for a GPCR target. While Ligand A has a slightly better half-life and P-gp efflux, the higher DILI risk and worse BBB penetration of Ligand A are major drawbacks. The slightly better affinity of Ligand B is also a plus. Considering the balance of properties, Ligand B is the more promising candidate.
**Output:**
0
2025-04-17 19:33:31,974 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (356.813 and 358.433 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (64.16) is significantly better than Ligand B (86.88). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand A is well below the 140 threshold, while Ligand B is approaching it.
3. **logP:** Ligand A (3.474) is slightly higher than Ligand B (2.924), both within the optimal 1-3 range. Ligand A is closer to the upper limit, but still acceptable.
4. **HBD:** Ligand A (0) is preferable to Ligand B (3). Fewer hydrogen bond donors generally improve permeability.
5. **HBA:** Ligand A (5) is better than Ligand B (3). Lower HBA is generally preferred for permeability.
6. **QED:** Ligand A (0.72) is slightly better than Ligand B (0.634), indicating a more drug-like profile.
7. **DILI:** Ligand B (40.869) is *much* better than Ligand A (79.411). This is a significant advantage for Ligand B. A DILI percentile under 40 is highly desirable.
8. **BBB:** Ligand A (76.037) is better than Ligand B (59.131). While ADRB2 isn't exclusively a CNS target, some CNS penetration can be useful, and a higher BBB percentile is generally favorable.
9. **Caco-2:** Ligand A (-4.87) is better than Ligand B (-5.232). Higher Caco-2 permeability is better, but both are negative values, indicating poor permeability.
10. **Solubility:** Ligand A (-4.355) is better than Ligand B (-2.827). Higher solubility is better.
11. **hERG:** Ligand A (0.574) is better than Ligand B (0.48). Lower hERG inhibition is preferred.
12. **Cl_mic:** Ligand B (16.109) is *much* better than Ligand A (67.373). Lower microsomal clearance indicates greater metabolic stability, a crucial factor for drug duration.
13. **t1/2:** Ligand B (-22.205) is better than Ligand A (58.86). A negative value indicates a longer half-life.
14. **Pgp:** Ligand A (0.673) is better than Ligand B (0.097). Lower P-gp efflux is preferred.
15. **Binding Affinity:** Ligand A (-6.7) is better than Ligand B (-4.8). This is a substantial difference in binding affinity (1.9 kcal/mol), which can often outweigh other ADME concerns.
**Overall Assessment:**
Ligand A has a significantly stronger binding affinity, better TPSA, HBD, HBA, QED, BBB, solubility, hERG, and Pgp. However, Ligand B has a *much* lower DILI risk and significantly better metabolic stability (Cl_mic and t1/2).
Given the GPCR target class, I prioritize affinity and permeability (reflected in TPSA, logP, and H-bonding). The substantial affinity advantage of Ligand A, coupled with its better TPSA and permeability-related properties, outweighs the DILI and metabolic stability concerns. While DILI and metabolic stability are important, they can be addressed through further optimization. A strong starting point with high affinity is crucial.
Output:
1
2025-04-17 19:33:31,975 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (351.435 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (71.87) is better than Ligand B (83.98). Both are below 140, but lower TPSA generally improves oral absorption, a key consideration for a cardiovascular drug.
3. **logP:** Both ligands have good logP values (A: 3.048, B: 2.214), falling within the 1-3 range. Ligand A is slightly higher, which could potentially lead to off-target effects, but not drastically.
4. **HBD:** Ligand A (0) is preferable to Ligand B (3). Fewer HBDs generally improve membrane permeability.
5. **HBA:** Ligand A (6) is preferable to Ligand B (5). Lower HBA is generally better for permeability.
6. **QED:** Both ligands have similar QED values (A: 0.682, B: 0.641), indicating good drug-likeness.
7. **DILI:** Ligand B (70.958) has a slightly higher DILI risk than Ligand A (68.166), but both are reasonably acceptable.
8. **BBB:** Both ligands have good BBB penetration (A: 70.143, B: 72.354). This is less critical for a cardiovascular target, but still a positive attribute.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual. It suggests poor permeability. Ligand A (-5.036) is slightly better than Ligand B (-4.873), but both are concerning.
10. **Solubility:** Both ligands have negative solubility values, which is also unusual and concerning. Ligand A (-3.201) is slightly better than Ligand B (-3.676).
11. **hERG:** Both ligands have very low hERG inhibition risk (A: 0.338, B: 0.279). This is excellent.
12. **Cl_mic:** Ligand B (18.262) has significantly lower microsomal clearance than Ligand A (40.857), indicating better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand B (7.383) has a longer in vitro half-life than Ligand A (3.548), further supporting its better metabolic stability.
14. **Pgp:** Both ligands have very low P-gp efflux liability (A: 0.121, B: 0.049). This is favorable.
15. **Binding Affinity:** Ligand A (-7.8 kcal/mol) has a stronger binding affinity than Ligand B (-5.7 kcal/mol). This is a substantial difference (2.1 kcal/mol) and a major advantage.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A performs better on TPSA, logP, and significantly better on affinity. Ligand B excels in metabolic stability (Cl_mic and t1/2). The strong affinity of Ligand A is a significant advantage that outweighs the slightly less favorable metabolic properties. The negative Caco-2 and solubility values are concerning for both, but the higher affinity of A suggests it might overcome these issues.
**Conclusion:**
Despite the metabolic stability advantage of Ligand B, the significantly stronger binding affinity of Ligand A makes it the more promising drug candidate for ADRB2.
Output:
1
2025-04-17 19:33:31,975 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (401.22 Da) is within the ideal range, while Ligand B (354.407 Da) is also acceptable. No clear advantage here.
2. **TPSA:** Ligand A (86.23) is excellent, well below the 140 threshold for oral absorption. Ligand B (111.21) is still reasonable, but less optimal.
3. **logP:** Ligand A (3.687) is within the optimal range. Ligand B (-1.629) is significantly lower, potentially hindering membrane permeability and absorption. This is a substantial negative for Ligand B.
4. **HBD:** Ligand A (1) and Ligand B (3) are both acceptable, but Ligand A is preferable.
5. **HBA:** Ligand A (6) and Ligand B (5) are both acceptable.
6. **QED:** Both ligands (A: 0.702, B: 0.561) have good drug-likeness scores, but Ligand A is slightly better.
7. **DILI:** Ligand A (96.627) has a high DILI risk, which is concerning. Ligand B (21.83) has a very low DILI risk, a significant advantage.
8. **BBB:** Ligand A (67.08) is moderate, while Ligand B (46.336) is lower. While ADRB2 isn't strictly a CNS target, some CNS penetration can be beneficial for understanding off-target effects.
9. **Caco-2:** Ligand A (-4.914) is poor, indicating very low intestinal absorption. Ligand B (-5.041) is also poor, but similar to Ligand A.
10. **Solubility:** Ligand A (-4.816) is poor, while Ligand B (-0.446) is slightly better, but still not great.
11. **hERG:** Ligand A (0.596) has a low hERG risk, which is good. Ligand B (0.107) is even lower, an advantage.
12. **Cl_mic:** Ligand A (75.668) has moderate clearance. Ligand B (-23.024) has negative clearance, which is highly unusual and suggests very high metabolic stability. This is a major positive for Ligand B.
13. **t1/2:** Ligand A (-17.11) is very short, indicating rapid metabolism. Ligand B (1.054) is also short, but better than Ligand A.
14. **Pgp:** Ligand A (0.259) has low P-gp efflux, which is good. Ligand B (0.001) has extremely low P-gp efflux, a significant advantage.
15. **Affinity:** Ligand A (-3.8 kcal/mol) and Ligand B (-6.9 kcal/mol) show a substantial difference in binding affinity, with Ligand B being significantly more potent. This is a major advantage for Ligand B.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand B excels in Pgp, has a better affinity, and a more favorable TPSA. While Ligand A has a better DILI score, the significantly better binding affinity and metabolic stability of Ligand B outweigh this concern, especially given the low DILI risk of Ligand B. The poor Caco-2 and solubility of both are drawbacks, but can be addressed with formulation strategies.
**Conclusion:**
Despite the higher DILI risk of Ligand A, the superior binding affinity, metabolic stability, and P-gp properties of Ligand B make it the more promising drug candidate.
Output:
0
2025-04-17 19:33:31,975 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's systematically compare Ligand A and Ligand B across the provided parameters, keeping in mind the GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key).
1. **MW:** Both ligands (349.475 and 340.431 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (70.67) is better than Ligand B (85.94). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (1.792 and 1.908), falling within the optimal 1-3 range. A slight edge to Ligand B.
4. **HBD:** Ligand A (2) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is preferable to Ligand B (5) for the same reason as HBD.
6. **QED:** Both ligands have good QED scores (0.656 and 0.724), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (14.23) is significantly better than Ligand B (65.374). This is a major advantage for Ligand A. DILI risk is a critical factor.
8. **BBB:** Ligand B (73.672) is better than Ligand A (57.619), but this isn't a high priority for a cardiovascular target.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.469 and -5.346), which is unusual and suggests poor permeability. This is a concern for both, but the values are similar.
10. **Solubility:** Ligand A (-1.694) is better than Ligand B (-3.068). Better solubility is generally preferred.
11. **hERG:** Ligand A (0.124) is much better than Ligand B (0.771). Lower hERG inhibition is crucial for avoiding cardiotoxicity, especially for a cardiovascular target.
12. **Cl_mic:** Ligand A (-8.264) is significantly better than Ligand B (40.076). Lower microsomal clearance indicates greater metabolic stability.
13. **t1/2:** Ligand B (8.353) is better than Ligand A (2.235). A longer half-life is generally desirable.
14. **Pgp:** Ligand A (0.013) is much better than Ligand B (0.071). Lower P-gp efflux is beneficial for bioavailability.
15. **Affinity:** Ligand A (-6.6 kcal/mol) is slightly better than Ligand B (-5.3 kcal/mol). A difference of 1.3 kcal/mol is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand A demonstrates a superior balance of properties. While Ligand B has slightly better QED and half-life, Ligand A excels in critical areas like DILI risk, hERG inhibition, metabolic stability (Cl_mic), P-gp efflux, and binding affinity. The significantly lower DILI and hERG risk are particularly important for a cardiovascular drug. The better affinity also contributes to its overall viability. The Caco-2 values are concerning for both, but the other advantages of Ligand A outweigh this drawback.
Output:
1
2025-04-17 19:33:31,975 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Ligand A (362.495 Da) is within the ideal range (200-500 Da). Ligand B (403.368 Da) is also acceptable, but closer to the upper limit.
2. **TPSA:** Ligand A (62.55) is excellent, well below the 140 threshold for oral absorption. Ligand B (49.84) is even better.
3. **logP:** Ligand A (2.523) is optimal (1-3). Ligand B (4.887) is a bit high, potentially leading to solubility issues and off-target interactions.
4. **HBD:** Ligand A (1) is good. Ligand B (2) is acceptable, but slightly higher.
5. **HBA:** Both Ligand A (4) and Ligand B (4) are within the acceptable range (<=10).
6. **QED:** Ligand A (0.845) is very good, indicating high drug-likeness. Ligand B (0.438) is significantly lower, raising concerns about its overall drug-like properties.
7. **DILI:** Ligand A (23.226) has a very low DILI risk. Ligand B (37.224) is higher, but still within an acceptable range.
8. **BBB:** Ligand A (64.482) is moderate. Ligand B (83.288) is significantly better, indicating higher potential for CNS penetration, although ADRB2 is primarily a cardiovascular target, some CNS exposure can be a concern for off-target effects.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.307 and -5.354), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand A (-2.875) is better than Ligand B (-4.756), indicating better aqueous solubility.
11. **hERG:** Ligand A (0.254) has a very low hERG risk. Ligand B (0.948) is higher, posing a potential cardiotoxicity concern.
12. **Cl_mic:** Ligand A (32.204) has lower microsomal clearance, suggesting better metabolic stability. Ligand B (99.272) has very high clearance, indicating rapid metabolism.
13. **t1/2:** Ligand B (72.21) has a much longer in vitro half-life than Ligand A (31.308).
14. **Pgp:** Ligand A (0.149) has lower P-gp efflux, which is favorable. Ligand B (0.823) has higher efflux.
15. **Affinity:** Ligand B (-6.8 kcal/mol) has a stronger binding affinity than Ligand A (-5.9 kcal/mol). This is a substantial difference.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in affinity and BBB penetration, but suffers from a high logP and Pgp efflux. Ligand A has a better balance of properties, with a good logP, lower Pgp efflux, and excellent QED and DILI scores. The poor Caco-2 values are concerning for both, but the superior metabolic stability and safety profile of Ligand A are more desirable. The affinity difference is significant, but can potentially be overcome with further optimization of Ligand A.
**Conclusion:**
Despite the stronger binding affinity of Ligand B, the significantly better overall drug-like properties, lower risk profile (DILI, hERG), and better metabolic stability of Ligand A make it the more promising candidate.
Output:
1
2025-04-17 19:33:31,975 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (356.463 and 348.403 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (85.89) is better than Ligand B (115.65). ADRB2 is a cardiovascular target, not CNS, but lower TPSA generally improves absorption.
3. **logP:** Ligand A (1.418) is within the optimal 1-3 range. Ligand B (-0.359) is slightly below 1, which *could* indicate permeability issues. This is a slight negative for Ligand B.
4. **HBD:** Ligand A (2) and Ligand B (3) are both acceptable, below the threshold of 5.
5. **HBA:** Ligand A (5) and Ligand B (6) are both acceptable, below the threshold of 10.
6. **QED:** Both ligands have good QED scores (0.578 and 0.669), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (26.095) has a significantly lower DILI risk than Ligand B (40.752). This is a major advantage for Ligand A.
8. **BBB:** Not a primary concern for a cardiovascular target like ADRB2, but Ligand A (68.748) is better than Ligand B (39.007).
9. **Caco-2:** Both are negative, indicating poor permeability. No clear winner.
10. **Solubility:** Both are negative, indicating poor solubility. No clear winner.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.267 and 0.082). No significant difference.
12. **Cl_mic:** Ligand A (1.813) has a lower (better) microsomal clearance than Ligand B (-2.497). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (7.824) has a longer in vitro half-life than Ligand B (4.497). This is a positive for Ligand A.
14. **Pgp:** Both are very low (0.015 and 0.005), indicating minimal P-gp efflux. No significant difference.
15. **Binding Affinity:** Both ligands have the same binding affinity (-6.0 kcal/mol).
**Overall Assessment:**
Ligand A is the stronger candidate. While both have comparable binding affinity, Ligand A demonstrates superior ADME properties: lower DILI risk, better metabolic stability (lower Cl_mic, longer t1/2), and a slightly better logP and TPSA. Ligand B's slightly higher QED is outweighed by its higher DILI risk and poorer metabolic profile. For a cardiovascular target, metabolic stability and minimizing off-target effects (like liver toxicity) are crucial.
Output:
1
2025-04-17 19:33:31,976 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.479 and 353.507 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (70.47 and 70.67) are below the 140 A^2 threshold for good oral absorption, and acceptable for a cardiovascular target (not CNS). No significant difference.
3. **logP:** Ligand A (0.514) is lower than Ligand B (1.687). While both are within the 1-3 range, Ligand B is closer to the optimal range. Lower logP can sometimes indicate poor membrane permeability, which is a concern for GPCRs.
4. **HBD:** Ligand A (1) has fewer HBD than Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (5) has more HBA than Ligand B (4). Fewer HBA generally improve permeability.
6. **QED:** Both ligands have similar QED values (0.743 and 0.697), indicating good drug-likeness.
7. **DILI:** Ligand A (13.222) has a significantly higher DILI risk than Ligand B (6.398). This is a major concern, as liver toxicity is a frequent cause of drug failure.
8. **BBB:** Both ligands have similar BBB penetration (61.691 and 62.582). Since ADRB2 is primarily a cardiovascular target, BBB penetration is not a high priority.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.108 and -5.254). This is unusual and suggests poor permeability.
10. **Solubility:** Both ligands have negative solubility values (-0.63 and -0.949). This is also unusual and suggests poor solubility.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.18 and 0.31). This is excellent.
12. **Cl_mic:** Ligand A (12.438) has a slightly higher microsomal clearance than Ligand B (11.513). Lower clearance is preferred for metabolic stability.
13. **t1/2:** Ligand B (4.748) has a slightly longer in vitro half-life than Ligand A (3.949). Longer half-life is generally desirable.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.007 and 0.011). This is good.
15. **Binding Affinity:** Ligand B (-6.1 kcal/mol) has a slightly better binding affinity than Ligand A (-6.0 kcal/mol). While the difference is small, it's still a factor.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand B has a more favorable logP and slightly better affinity. The most significant difference is the DILI risk, where Ligand B is substantially better.
**Overall Assessment:**
Despite the unusual negative Caco-2 and solubility values for both, Ligand B is the more promising candidate. The lower DILI risk and slightly better affinity outweigh the minor differences in other parameters. The negative solubility and permeability values would require further investigation and potentially prodrug strategies, but the reduced toxicity profile of Ligand B makes it the better starting point.
Output:
0
2025-04-17 19:33:31,976 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (355.438 and 350.419 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (58.64) is significantly better than Ligand B (94.48). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold, while Ligand B is approaching it.
3. **logP:** Ligand A (4.295) is slightly higher than Ligand B (2.665). While both are within the 1-3 range, Ligand A is pushing the upper limit. This could potentially lead to solubility issues, but is not a dealbreaker.
4. **HBD:** Ligand A (1) is better than Ligand B (2). Lower HBD is generally preferred for permeability.
5. **HBA:** Ligand A (4) is better than Ligand B (6). Similar reasoning as HBD.
6. **QED:** Ligand B (0.874) is better than Ligand A (0.612). A higher QED is desirable, indicating better overall drug-likeness.
7. **DILI:** Both ligands have acceptable DILI risk (71.152 and 68.786 percentile). No major difference.
8. **BBB:** Ligand B (76.154) is slightly better than Ligand A (69.523). While not a CNS target, some BBB penetration can be beneficial for distribution.
9. **Caco-2:** Ligand A (-5.297) is significantly better than Ligand B (-4.53). Higher Caco-2 permeability indicates better intestinal absorption.
10. **Solubility:** Ligand A (-4.798) is slightly better than Ligand B (-4.28). Better solubility is always preferred.
11. **hERG:** Ligand A (0.624) is better than Ligand B (0.166). Lower hERG inhibition is crucial for avoiding cardiotoxicity, a major concern for cardiovascular drugs.
12. **Cl_mic:** Ligand B (45.123) is significantly better than Ligand A (80.834). Lower microsomal clearance indicates better metabolic stability.
13. **t1/2:** Ligand B (14.341) is significantly better than Ligand A (0.995). A longer half-life is generally desirable.
14. **Pgp:** Ligand A (0.885) is better than Ligand B (0.047). Lower P-gp efflux is preferred for better bioavailability.
15. **Binding Affinity:** Ligand B (-7.5 kcal/mol) is significantly better than Ligand A (-6.7 kcal/mol). This is a substantial difference in potency. A 0.8 kcal/mol advantage is significant enough to potentially outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand B has a significantly better binding affinity and metabolic stability (lower Cl_mic, longer t1/2). While Ligand A has better TPSA, Caco-2, solubility, and hERG, the substantial affinity advantage of Ligand B is critical for a GPCR target. The slightly higher TPSA of Ligand B is not a major concern for a cardiovascular target. The better QED score of Ligand B is also a plus. The improved Pgp efflux liability of Ligand A is a minor benefit, but doesn't outweigh the affinity difference.
Therefore, I favor Ligand B.
Output:
0
2025-04-17 19:33:31,976 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 drug candidates. ADRB2 is a GPCR, so we'll prioritize logP, Pgp, TPSA, and affinity, alongside general drug-like properties.
**Ligand A:**
* **MW:** 359.354 Da - Good, within the ideal range.
* **TPSA:** 106.2 A2 - Acceptable, but pushing the upper limit for good oral absorption.
* **logP:** -0.492 - Low. This is a significant concern for permeability.
* **HBD:** 2 - Good.
* **HBA:** 6 - Good.
* **QED:** 0.62 - Good, drug-like.
* **DILI:** 59.829 - Moderate risk, but acceptable.
* **BBB:** 59.364 - Low, not ideal for a GPCR, but not a primary concern for ADRB2 (cardiovascular target).
* **Caco-2:** -5.228 - Very poor permeability. Consistent with the low logP.
* **Solubility:** -2.099 - Poor solubility.
* **hERG:** 0.104 - Low risk, good.
* **Cl_mic:** -31.781 - Excellent metabolic stability (negative value indicates low clearance).
* **t1/2:** 4.168 - Moderate half-life.
* **Pgp:** 0.021 - Low efflux, good.
* **Affinity:** -7.6 kcal/mol - Excellent binding affinity.
**Ligand B:**
* **MW:** 378.872 Da - Good, within the ideal range.
* **TPSA:** 78.87 A2 - Excellent, well within the optimal range.
* **logP:** 1.382 - Good, within the optimal range.
* **HBD:** 2 - Good.
* **HBA:** 4 - Good.
* **QED:** 0.684 - Good, drug-like.
* **DILI:** 20.706 - Very low risk, excellent.
* **BBB:** 72.896 - Good, though not essential for ADRB2.
* **Caco-2:** -4.81 - Moderate permeability.
* **Solubility:** -1.648 - Moderate solubility.
* **hERG:** 0.376 - Low risk, good.
* **Cl_mic:** -6.623 - Good metabolic stability.
* **t1/2:** 10.633 - Good half-life.
* **Pgp:** 0.077 - Low efflux, good.
* **Affinity:** -7.4 kcal/mol - Very good binding affinity, slightly weaker than Ligand A.
**Comparison and Decision:**
Ligand A has a slightly better binding affinity (-7.6 vs -7.4 kcal/mol). However, its extremely low logP and poor Caco-2 permeability are major drawbacks. These properties will likely lead to very poor oral bioavailability, regardless of its affinity. The poor solubility also doesn't help.
Ligand B, while having slightly weaker affinity, has a much more favorable logP, TPSA, and Caco-2 permeability profile. Its DILI score is also significantly lower, indicating a better safety profile. While its solubility is not ideal, it's better than Ligand A. The longer half-life is also a plus.
For a cardiovascular target like ADRB2, oral bioavailability is crucial. Therefore, I prioritize Ligand B due to its superior ADME properties, despite the slightly lower binding affinity. The 0.2 kcal/mol difference in affinity is unlikely to overcome the significant bioavailability issues of Ligand A.
Output:
0
2025-04-17 19:33:31,976 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **Molecular Weight:** Both ligands (353.813 and 349.391 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (62.53) is well below the 140 threshold and favorable for oral absorption. Ligand B (129.88) is still within acceptable limits, but less optimal.
3. **logP:** Ligand A (3.704) is within the optimal 1-3 range. Ligand B (0.002) is *very* low, potentially causing permeability issues. This is a significant drawback for a GPCR ligand.
4. **H-Bond Donors:** Ligand A (1) is good. Ligand B (3) is acceptable, but higher.
5. **H-Bond Acceptors:** Ligand A (4) is good. Ligand B (5) is acceptable, but higher.
6. **QED:** Both ligands have reasonable QED scores (0.764 and 0.639), indicating good drug-like properties.
7. **DILI:** Ligand A (90.733) has a high DILI risk, which is concerning. Ligand B (36.293) has a much lower and acceptable DILI risk.
8. **BBB:** Ligand A (84.064) has good BBB penetration. Ligand B (57.193) is lower, but not a critical concern for a non-CNS target like ADRB2.
9. **Caco-2:** Ligand A (-4.862) is poor. Ligand B (-5.702) is also poor.
10. **Solubility:** Ligand A (-5.6) is poor. Ligand B (-2.379) is also poor.
11. **hERG:** Ligand A (0.474) has a low hERG risk, which is favorable. Ligand B (0.138) also has a low hERG risk.
12. **Cl_mic:** Ligand A (91.16) has high metabolic clearance, which is undesirable. Ligand B (10.483) has low metabolic clearance, which is favorable.
13. **t1/2:** Ligand A (31.241) has a reasonable half-life. Ligand B (-6.483) has a very short half-life, which is a significant drawback.
14. **Pgp:** Ligand A (0.498) has low P-gp efflux, which is favorable. Ligand B (0.037) has very low P-gp efflux, which is even more favorable.
15. **Binding Affinity:** Ligand A (-7.7) has a slightly better binding affinity than Ligand B (-7.2), but the difference is relatively small.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp efflux, and binding affinity are particularly important. Ligand A has a better logP and slightly better affinity, but Ligand B has significantly better metabolic stability (lower Cl_mic) and a much lower DILI risk. The poor Caco-2 and solubility of both are concerning, but can be addressed with formulation strategies.
**Overall Assessment:**
While Ligand A has slightly better affinity, the combination of Ligand B's significantly lower DILI risk, better metabolic stability, and favorable Pgp efflux outweighs the small affinity difference. The very low logP of Ligand B is a significant concern, but potentially addressable through prodrug strategies or formulation. The high DILI risk of Ligand A is a major red flag.
Output:
0
2025-04-17 19:33:31,976 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (417.3 Da) is within the ideal range, while Ligand B (388.892 Da) is also good. No clear advantage here.
2. **TPSA:** Ligand A (86.75) is acceptable, but higher than Ligand B (75.27). Lower TPSA is generally better for permeability, giving a slight edge to Ligand B.
3. **logP:** Both ligands have good logP values (A: 3.589, B: 2.445), falling within the optimal 1-3 range. Ligand B is slightly more hydrophilic, which could be beneficial for solubility.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (6) is preferable to Ligand B (3). Fewer HBAs generally improve permeability.
6. **QED:** Both ligands have good QED scores (A: 0.683, B: 0.704), indicating good drug-likeness. No significant difference.
7. **DILI:** Ligand B (41.838) has a significantly lower DILI risk than Ligand A (60.682). This is a major advantage for Ligand B.
8. **BBB:** Both ligands have good BBB penetration (A: 70.609, B: 71.772). No significant difference.
9. **Caco-2:** Ligand B (-5.024) has a better Caco-2 permeability than Ligand A (-4.508). This suggests better intestinal absorption for Ligand B.
10. **Solubility:** Both ligands have similar poor aqueous solubility (-4.4 and -4.184).
11. **hERG:** Ligand B (0.545) has a slightly higher hERG risk than Ligand A (0.331), but both are relatively low.
12. **Cl_mic:** Ligand B (40.323) has a significantly lower microsomal clearance than Ligand A (111.495), indicating better metabolic stability. This is a substantial advantage for Ligand B.
13. **t1/2:** Ligand B (-17.67) has a much longer in vitro half-life than Ligand A (-3.982). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand B (0.101) has a lower P-gp efflux liability than Ligand A (0.059), which is favorable.
15. **Affinity:** Ligand B (-7.3 kcal/mol) has a stronger binding affinity than Ligand A (-6.6 kcal/mol). This is a significant advantage, as affinity is a primary driver for GPCR drug candidates.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, affinity, logP, Pgp, TPSA, and metabolic stability are key. Ligand B excels in affinity, Pgp, and metabolic stability (Cl_mic and t1/2). While Ligand A has slightly better TPSA, the other advantages of Ligand B outweigh this. The lower DILI risk for Ligand B is also a significant benefit.
**Conclusion:**
Ligand B demonstrates a superior balance of properties, particularly in terms of affinity, metabolic stability, DILI risk, and permeability. While both ligands are within acceptable ranges for many parameters, Ligand B's advantages are more compelling for a GPCR drug candidate.
Output:
0
2025-04-17 19:33:31,976 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (351.491 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (81.67) is significantly better than Ligand A (101.29). ADRB2 is not a CNS target, but lower TPSA generally improves absorption.
3. **logP:** Both ligands have good logP values (A: 1.868, B: 1.123) within the optimal range of 1-3. Ligand B is slightly lower, which could be a minor concern for permeability but is not a major issue.
4. **HBD:** Both ligands have 3 HBD, which is within the acceptable limit of 5.
5. **HBA:** Ligand A has 3 HBA, while Ligand B has 4. Both are within the acceptable limit of 10.
6. **QED:** Ligand A (0.622) has a better QED score than Ligand B (0.462), indicating a more drug-like profile.
7. **DILI:** Ligand A (26.095) has a significantly lower DILI risk than Ligand B (48.468), which is a crucial advantage.
8. **BBB:** BBB is less critical for ADRB2 (a cardiovascular target). Ligand A (65.723) is better than Ligand B (50.523), but this isn't a primary driver.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.241 and -5.264), which is unusual and suggests poor permeability. This is a significant drawback for both.
10. **Solubility:** Both ligands have negative solubility values (-3.552 and -2.196), indicating poor aqueous solubility. This is a major concern for bioavailability.
11. **hERG:** Both ligands have very low hERG inhibition risk (A: 0.138, B: 0.413). This is excellent.
12. **Cl_mic:** Ligand B (5.289) has a significantly lower microsomal clearance than Ligand A (58.284), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-13.428) has a longer in vitro half-life than Ligand A (-17.542), which is favorable.
14. **Pgp:** Both ligands have very low Pgp efflux liability (A: 0.06, B: 0.016). This is excellent.
15. **Affinity:** Both ligands have very similar binding affinities (-6.5 kcal/mol and -6.3 kcal/mol). The difference is not substantial enough to be a deciding factor.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are important. Ligand B has a slightly better logP and significantly better TPSA. However, the poor Caco-2 and solubility for both are concerning. The lower DILI risk for Ligand A is a major advantage, and the slightly better QED score also favors it. Metabolic stability (Cl_mic and t1/2) is also important, and Ligand B is superior in these aspects.
**Overall Assessment:**
Despite the better TPSA and metabolic stability of Ligand B, the significantly lower DILI risk and better QED score of Ligand A are more compelling. The poor Caco-2 and solubility are shared drawbacks that would need to be addressed regardless of which ligand is chosen. Given the cardiovascular target, the DILI risk is a critical factor.
Output:
1
2025-04-17 19:33:31,977 - INFO - Batch 119 complete. Total preferences: 1904
2025-04-17 19:33:31,977 - INFO - Processing batch 120/512...
2025-04-17 19:34:21,612 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [340.427, 68.44, 1.449, 2, 3, 0.889, 36.448, 63.784, -5.08, -2.767, 0.612, -18.611, -0.239, 0.068, -5.6]**
**Ligand B: [345.418, 66.64, 2.271, 1, 3, 0.836, 45.25, 86.584, -4.743, -3.156, 0.759, 29.845, -4.494, 0.149, -3]**
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). A (340.427) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are reasonably low (A: 68.44, B: 66.64), suggesting good potential for oral absorption.
3. **logP:** Both are within the optimal range (1-3), but Ligand B (2.271) is slightly higher. This could be a minor advantage for membrane permeability, but needs to be balanced against solubility.
4. **H-Bond Donors:** Ligand A (2) has one more HBD than Ligand B (1). Lower is generally preferred, making B slightly better here.
5. **H-Bond Acceptors:** Both have the same number of HBAs (3).
6. **QED:** Both have good QED scores (A: 0.889, B: 0.836), indicating good drug-like properties.
7. **DILI:** Ligand A (36.448) has a significantly lower DILI risk than Ligand B (45.25). This is a major advantage for A.
8. **BBB:** Ligand B (86.584) has a much higher BBB penetration potential than Ligand A (63.784). Given ADRB2 is a GPCR, and while not necessarily a CNS target, increased BBB penetration is still a positive attribute.
9. **Caco-2 Permeability:** Ligand A (-5.08) has lower Caco-2 permeability than Ligand B (-4.743). This suggests B might be absorbed better.
10. **Aqueous Solubility:** Ligand B (-3.156) has better aqueous solubility than Ligand A (-2.767). This is a positive for formulation and bioavailability.
11. **hERG Inhibition:** Both have relatively low hERG inhibition risk (A: 0.612, B: 0.759), but A is slightly better.
12. **Microsomal Clearance:** Ligand A (-18.611) has significantly lower microsomal clearance than Ligand B (29.845), indicating better metabolic stability. This is a major advantage for A.
13. **In vitro Half-Life:** Ligand B (-4.494) has a longer in vitro half-life than Ligand A (-0.239). This is a positive for B.
14. **P-gp Efflux:** Ligand A (0.068) has lower P-gp efflux than Ligand B (0.149), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand A (-5.6) has a stronger binding affinity than Ligand B (-3). This is a substantial advantage for A, potentially outweighing some ADME concerns.
**Overall Assessment:**
Ligand A has a significantly better binding affinity, lower DILI risk, and better metabolic stability (lower Cl_mic). While Ligand B has better BBB penetration, Caco-2 permeability, solubility, and half-life, the superior affinity and safety profile of Ligand A are more critical for a GPCR target like ADRB2. The 1.6 kcal/mol difference in binding is substantial. The slightly lower permeability of A is less concerning than the higher DILI risk and faster metabolism of B.
Output:
1
2025-04-17 19:34:21,613 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (357.523 and 358.467 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (59.22) is significantly better than Ligand B (88.32). For a GPCR, lower TPSA is generally preferred for better permeability. Ligand B is approaching a level that could hinder oral absorption.
**3. logP:** Ligand A (4.647) is higher than Ligand B (2.042). While both are within the acceptable range (1-3 is optimal), Ligand A is pushing the upper limit. Ligand B is closer to the ideal range.
**4. H-Bond Donors:** Ligand A (1) is better than Ligand B (2). Fewer HBDs generally improve permeability.
**5. H-Bond Acceptors:** Both ligands have the same number of HBA (4).
**6. QED:** Both ligands have similar QED values (0.819 and 0.828), indicating good drug-likeness.
**7. DILI Risk:** Ligand A (31.989) has a considerably lower DILI risk than Ligand B (58.666). This is a significant advantage for Ligand A.
**8. BBB Penetration:** Ligand A (85.072) shows better BBB penetration than Ligand B (78.247). While ADRB2 is primarily a cardiovascular target, some CNS effects are possible with adrenergic agonists, and a degree of BBB penetration isn't necessarily detrimental.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.964 and -4.873), which is unusual and suggests poor permeability. However, the values are very similar.
**10. Aqueous Solubility:** Ligand A (-4.222) is slightly better than Ligand B (-2.571), indicating better solubility.
**11. hERG Inhibition:** Ligand A (0.846) has a slightly higher hERG risk than Ligand B (0.266). This is a concern for Ligand A.
**12. Microsomal Clearance:** Ligand A (66.224) has higher microsomal clearance than Ligand B (26.933), suggesting lower metabolic stability. This is a disadvantage for Ligand A.
**13. In vitro Half-Life:** Ligand B (-21.197) has a significantly longer in vitro half-life than Ligand A (26.368). This is a major advantage for Ligand B.
**14. P-gp Efflux:** Ligand A (0.544) has lower P-gp efflux than Ligand B (0.14), which is preferable.
**15. Binding Affinity:** Ligand A (-6.9 kcal/mol) has a slightly better binding affinity than Ligand B (-6.3 kcal/mol). This 0.6 kcal/mol difference is notable, but not overwhelmingly large.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity) and the general drug-like properties, **Ligand B** is the more promising candidate. While Ligand A has slightly better affinity and P-gp properties, Ligand B excels in crucial areas like DILI risk, metabolic stability (half-life), and TPSA. The lower hERG risk for Ligand B is also a significant safety advantage. The better solubility of Ligand B is also a plus. The relatively small advantage in binding affinity of Ligand A doesn't outweigh the significant ADME/Tox benefits of Ligand B.
Output:
0
2025-04-17 19:34:21,613 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
The target is ADRB2, a GPCR. Therefore, the key properties to prioritize are binding affinity, logP, TPSA, Pgp efflux, and BBB penetration. While BBB isn't *essential* for ADRB2 (it's primarily cardiovascular), it's still a beneficial property to consider.
Let's break down the comparison:
1. **Molecular Weight:** Both ligands (360.483 and 348.491 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (94.88) is higher than Ligand B (55.89). Ligand B is significantly better, being well below the 140 A^2 threshold for good oral absorption.
3. **logP:** Ligand A (2.463) is within the optimal 1-3 range. Ligand B (0.552) is a bit low, potentially hindering membrane permeability.
4. **H-Bond Donors:** Ligand A (2) and Ligand B (1) are both acceptable.
5. **H-Bond Acceptors:** Ligand A (5) and Ligand B (4) are both acceptable.
6. **QED:** Both ligands (0.843 and 0.73) have good drug-likeness scores.
7. **DILI:** Ligand A (42.924) has a slightly higher DILI risk than Ligand B (4.769), but both are reasonably low.
8. **BBB:** Ligand B (80.419) has significantly better BBB penetration than Ligand A (48.468). This is a positive for potential off-target effects, but also could be a benefit.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-5.032) is slightly worse than Ligand B (-4.87).
10. **Solubility:** Both ligands have poor solubility (-3.428 and -0.863 respectively).
11. **hERG:** Both ligands have low hERG inhibition risk (0.127 and 0.39 respectively).
12. **Cl_mic:** Ligand B (1.61) has a much lower microsomal clearance than Ligand A (19.294), indicating better metabolic stability.
13. **t1/2:** Ligand A (-6.02) has a slightly longer in vitro half-life than Ligand B (-0.551).
14. **Pgp:** Ligand A (0.035) has lower P-gp efflux liability than Ligand B (0.009), which is favorable.
15. **Binding Affinity:** Ligand A (-7.3 kcal/mol) has a slightly better binding affinity than Ligand B (-6.8 kcal/mol). This 0.5 kcal/mol difference is significant.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity and lower Pgp efflux, Ligand B has a much better TPSA, significantly better BBB penetration, and dramatically improved metabolic stability (lower Cl_mic). The lower logP of Ligand B is a concern, but the superior TPSA and metabolic stability are more critical for a GPCR target like ADRB2. The difference in binding affinity is not large enough to overcome the ADME advantages of Ligand B.
**Output:**
0
2025-04-17 19:34:21,613 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (364.43 & 370.56 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand B (58.64) is significantly better than Ligand A (102.58). ADRB2 is a GPCR, and lower TPSA generally favors better permeability.
3. **logP:** Ligand B (2.544) is within the optimal 1-3 range, while Ligand A (0.42) is quite low, potentially hindering membrane permeability. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1), but both are acceptable.
5. **HBA:** Both ligands have 4 HBA, which is within the acceptable range.
6. **QED:** Ligand A (0.821) has a slightly better QED score than Ligand B (0.678), indicating slightly better overall drug-likeness.
7. **DILI:** Ligand B (21.714) has a much lower DILI risk than Ligand A (70.841). This is a crucial advantage for Ligand B, as liver toxicity is a major concern.
8. **BBB:** Ligand B (75.998) has a higher BBB penetration percentile than Ligand A (52.811). While ADRB2 isn't necessarily a CNS target, some peripheral ADRB2 activity can be modulated by CNS effects, and higher BBB penetration isn't necessarily detrimental.
9. **Caco-2:** Both ligands have similar, poor Caco-2 permeability (-4.89 and -4.9).
10. **Solubility:** Ligand A (-3.657) has slightly better solubility than Ligand B (-2.851), but both are quite poor.
11. **hERG:** Ligand A (0.389) has a slightly lower hERG risk than Ligand B (0.496), but both are acceptable.
12. **Cl_mic:** Ligand B (60.465) has a significantly higher microsomal clearance than Ligand A (1.369), indicating faster metabolism and potentially lower *in vivo* exposure. This is a disadvantage for Ligand B.
13. **t1/2:** Ligand B (8.227) has a much longer *in vitro* half-life than Ligand A (-7.155). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.017) has a much lower P-gp efflux liability than Ligand B (0.161). This is a significant advantage for Ligand A.
15. **Affinity:** Ligand B (-7.6 kcal/mol) has a slightly better binding affinity than Ligand A (-6.2 kcal/mol). This is a significant advantage for Ligand B.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand B is the more promising candidate. While Ligand A has a slightly better QED and Pgp profile, Ligand B excels in crucial areas like logP, DILI risk, BBB penetration, and binding affinity. The significantly lower DILI risk and better affinity of Ligand B outweigh the slightly poorer Pgp and QED scores. The longer half-life also contributes to its favorability. The poor Caco-2 values for both are a concern, but can be addressed with formulation strategies.
Output:
0
2025-04-17 19:34:21,613 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (361.47 & 366.53 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (80.2) is slightly higher than Ligand B (66.48). Both are below the 140 threshold for oral absorption, but B is better positioned for potential CNS penetration if desired (though ADRB2 is primarily cardiovascular).
3. **logP:** Both ligands have good logP values (2.878 & 2.385), falling within the optimal 1-3 range. Ligand B is slightly lower, which could marginally improve solubility.
4. **HBD:** Ligand A has 2 HBD, and Ligand B has 1. Both are acceptable (<=5).
5. **HBA:** Both ligands have 4 HBA, well within the acceptable range (<=10).
6. **QED:** Ligand A (0.83) has a slightly better QED score than Ligand B (0.759), indicating a more drug-like profile.
7. **DILI:** Ligand B (41.411) has a significantly lower DILI risk than Ligand A (68.282). This is a major advantage for Ligand B.
8. **BBB:** Ligand B (63.358) has a slightly higher BBB penetration percentile than Ligand A (54.091). While not a primary concern for a cardiovascular target, it's a small benefit.
9. **Caco-2:** Ligand A (-4.839) and Ligand B (-5.193) both have negative Caco-2 values, which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand B (-3.044) has slightly better aqueous solubility than Ligand A (-3.704).
11. **hERG:** Both ligands have very low hERG inhibition liability (0.314 & 0.141), which is excellent.
12. **Cl_mic:** Ligand A (15.454) has a much lower microsomal clearance than Ligand B (44.799), suggesting better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (70.761) has a substantially longer in vitro half-life than Ligand B (-13.802). This is a major advantage for Ligand A.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.17 & 0.154), which is good.
15. **Binding Affinity:** Ligand B (-7.0) has a slightly better binding affinity than Ligand A (-6.1). This difference of 0.9 kcal/mol is substantial and could outweigh some ADME drawbacks.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Both ligands are good on logP and Pgp. Ligand B has a better TPSA and a significantly better binding affinity. However, the metabolic stability and half-life of Ligand A are far superior, and the DILI risk is lower. The Caco-2 values are concerning for both.
**Overall Assessment:**
While Ligand B has a better binding affinity and slightly better solubility and TPSA, the significantly improved metabolic stability (lower Cl_mic, longer t1/2) and lower DILI risk of Ligand A are more crucial for overall drug development success. The affinity difference, while notable, isn't so large that it completely overshadows the ADME benefits of Ligand A. The poor Caco-2 values are a concern for both, and would require further investigation (formulation strategies, prodrug approaches).
Output:
1
2025-04-17 19:34:21,613 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (351.447 and 345.447 Da) fall comfortably within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (87.74) is slightly higher than Ligand B (70.47). Both are below the 140 threshold for good oral absorption, but B is better.
3. **logP:** Ligand A (1.418) is better than Ligand B (0.354). Both are within the optimal 1-3 range, but B is a bit low, potentially hindering permeability.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1). Both are within the acceptable limit of 5.
5. **HBA:** Ligand A (4) is lower than Ligand B (5). Both are within the acceptable limit of 10.
6. **QED:** Both ligands have good QED scores (0.726 and 0.782, respectively), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (17.449) has a significantly lower DILI risk than Ligand B (14.773). This is a substantial advantage for Ligand A.
8. **BBB:** Ligand A (75.843) has a better BBB penetration score than Ligand B (46.84). While ADRB2 isn't exclusively a CNS target, some CNS exposure could be relevant, and this favors A.
9. **Caco-2:** Ligand A (-4.589) is worse than Ligand B (-5.309). Lower values are less desirable.
10. **Solubility:** Ligand A (-2.179) is worse than Ligand B (-1.142). Lower values are less desirable.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.261 and 0.146, respectively). No significant difference.
12. **Cl_mic:** Ligand B (-23.031) has much lower microsomal clearance than Ligand A (25.258), suggesting better metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand B (2.687) has a slightly longer in vitro half-life than Ligand A (-16.815). This is a positive for Ligand B.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.012 and 0.009, respectively). No significant difference.
15. **Binding Affinity:** Ligand A (-7.6) has a slightly better binding affinity than Ligand B (-5.5). This is a substantial advantage for Ligand A.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A has a better logP and significantly better affinity. Ligand B has a better TPSA and Cl_mic. The affinity difference is substantial (2.1 kcal/mol), and this outweighs the slightly better TPSA and Cl_mic of Ligand B. The lower DILI risk of Ligand A is also a significant positive.
**Conclusion:**
Considering the balance of properties, particularly the superior binding affinity and lower DILI risk of Ligand A, it is the more promising drug candidate.
Output:
1
2025-04-17 19:34:21,614 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (384.483 Da) is within the ideal range (200-500 Da). Ligand B (346.515 Da) is also within the ideal range. No clear advantage here.
2. **TPSA:** Ligand A (103.6) is slightly above the preferred <140 for oral absorption, but acceptable. Ligand B (49.41) is excellent, well below 140, suggesting good absorption. Advantage: B.
3. **logP:** Ligand A (1.003) is within the optimal range (1-3). Ligand B (3.358) is at the higher end of optimal, potentially edging towards solubility issues, but still acceptable. No strong advantage.
4. **HBD:** Ligand A (0) is good. Ligand B (1) is also acceptable. No significant difference.
5. **HBA:** Ligand A (7) is good, within the preferred limit. Ligand B (2) is excellent. Advantage: B.
6. **QED:** Both Ligand A (0.713) and Ligand B (0.83) are above 0.5, indicating good drug-likeness. Ligand B is slightly better. Advantage: B.
7. **DILI:** Ligand A (74.176) is moderate risk. Ligand B (9.655) is very low risk. Significant advantage: B.
8. **BBB:** Ligand A (46.375) is low, indicating poor brain penetration. Ligand B (88.29) is high, suggesting good brain penetration. Since ADRB2 is a GPCR, BBB is a consideration, though not paramount for cardiovascular targets. Advantage: B.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.522 and -4.802). This is unusual and suggests poor permeability. It's difficult to interpret without further information, but it's a negative for both.
10. **Solubility:** Both ligands have negative solubility values (-4.547 and -4.195), also unusual and suggesting poor aqueous solubility. This is a concern for both.
11. **hERG:** Ligand A (0.413) is better than Ligand B (0.656), indicating lower cardiotoxicity risk. Advantage: A.
12. **Cl_mic:** Ligand A (81.662) has a higher clearance than Ligand B (60.302), meaning it's less metabolically stable. Advantage: B.
13. **t1/2:** Ligand A (-0.228) has a very short half-life. Ligand B (-5.829) is also short, but less so than A. Advantage: B.
14. **Pgp:** Ligand A (0.084) has low P-gp efflux, which is good. Ligand B (0.113) is slightly higher, but still relatively low. No strong advantage.
15. **Binding Affinity:** Both ligands have very good binding affinity (-6.0 and -5.9 kcal/mol). The difference is minimal.
**Overall Assessment:**
While Ligand A has a slightly better hERG profile, Ligand B consistently outperforms it in crucial ADME properties: TPSA, HBA, QED, DILI, BBB, Cl_mic, and t1/2. The lower DILI risk and better metabolic stability (lower Cl_mic, longer t1/2) of Ligand B are particularly important. The negative Caco-2 and solubility values are concerning for both, but the other advantages of B outweigh this. Given that this is a cardiovascular target, BBB is less critical, but still a positive for B. For a GPCR, a balance of properties is key, and Ligand B strikes a better balance overall.
Output:
0
2025-04-17 19:34:21,614 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
Let's analyze each ligand against the provided guidelines, keeping in mind the GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key).
* **Molecular Weight:** Both ligands (339.351 and 347.459 Da) fall comfortably within the ideal 200-500 Da range.
* **TPSA:** Ligand A (94.32) is slightly higher than Ligand B (84.23). Both are below the 140 A^2 threshold for good oral absorption, but B is better.
* **logP:** Both ligands have good logP values (2.809 and 2.99), falling within the optimal 1-3 range.
* **H-Bond Donors/Acceptors:** Ligand A (HBD=1, HBA=6) is preferable to Ligand B (HBD=2, HBA=4) as it has fewer H-bond donors.
* **QED:** Both ligands have similar and acceptable QED values (0.735 and 0.743).
* **DILI:** Ligand B (41.877) has a significantly lower DILI risk than Ligand A (91.004). This is a major advantage for Ligand B.
* **BBB:** Ligand B (71.074) has a better BBB penetration percentile than Ligand A (53.432). While ADRB2 isn't exclusively a CNS target, some cardiovascular effects are mediated through CNS pathways, so moderate BBB penetration can be beneficial.
* **Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.735 and -4.665), which is unusual and suggests poor permeability. This is a concern for both.
* **Aqueous Solubility:** Both ligands have negative solubility values (-4.01 and -3.557), indicating poor aqueous solubility. This is a significant drawback for both.
* **hERG Inhibition:** Both ligands have low hERG inhibition liability (0.209 and 0.133), which is good.
* **Microsomal Clearance:** Ligand A (99.25) has a higher microsomal clearance than Ligand B (68.328), meaning it's likely to be metabolized more quickly. This favors Ligand B.
* **In vitro Half-Life:** Ligand B (-15.859) has a longer in vitro half-life than Ligand A (-12.131). This is a positive for Ligand B.
* **P-gp Efflux:** Both ligands have low P-gp efflux liability (0.129 and 0.123), which is favorable.
* **Binding Affinity:** Ligand A (-6.3 kcal/mol) has a slightly better binding affinity than Ligand B (-5.6 kcal/mol). The difference is 0.7 kcal/mol, which is not substantial enough to outweigh the ADME advantages of Ligand B.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity, Ligand B demonstrates a significantly better safety profile (lower DILI), improved BBB penetration, better metabolic stability (lower Cl_mic, longer t1/2), and is comparable in other key parameters. The poor Caco-2 and solubility for both are concerning, but the ADME profile of Ligand B is more favorable overall for a GPCR target.
**Output:**
0
2025-04-17 19:34:21,614 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (339.439 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (65.46) is better than Ligand B (70.08), both are acceptable but lower is better for oral absorption.
3. **logP:** Ligand A (3.093) is optimal, while Ligand B (0.881) is a bit low, potentially hindering membrane permeability.
4. **HBD:** Both ligands have acceptable HBD counts (Ligand A: 2, Ligand B: 1).
5. **HBA:** Both ligands have acceptable HBA counts (Ligand A: 3, Ligand B: 4).
6. **QED:** Both ligands have good QED scores (Ligand A: 0.899, Ligand B: 0.772), indicating good drug-like properties.
7. **DILI:** Ligand A (21.985) has a significantly lower DILI risk than Ligand B (11.361), which is a major advantage.
8. **BBB:** Ligand A (72.005) has a better BBB penetration score than Ligand B (61.535). While ADRB2 isn't strictly a CNS target, some CNS exposure can be relevant for off-target effects.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Ligand A (-2.522) has better solubility than Ligand B (-0.643).
11. **hERG:** Ligand A (0.502) has a lower hERG risk than Ligand B (0.215), which is a significant safety advantage.
12. **Cl_mic:** Ligand A (-7.245) has much better metabolic stability (lower clearance) than Ligand B (4.442).
13. **t1/2:** Ligand A (22.788 hours) has a much longer half-life than Ligand B (2.997 hours), which is highly desirable for dosing convenience.
14. **Pgp:** Ligand A (0.086) has lower P-gp efflux than Ligand B (0.072).
15. **Binding Affinity:** Ligand B (-9.1 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.7 kcal/mol). This is a substantial advantage.
**Overall Assessment:**
Ligand B has a significantly better binding affinity, which is crucial for GPCRs. However, Ligand A consistently outperforms in ADME-Tox properties: lower DILI risk, better BBB penetration, better solubility, significantly better metabolic stability (lower Cl_mic and longer t1/2), and lower hERG risk. The difference in binding affinity (-2.4 kcal/mol) is substantial, but the ADME profile of Ligand B is concerning. The improved ADME properties of Ligand A are likely to translate to better *in vivo* efficacy and a safer profile, outweighing the potency difference.
**Output:**
1
2025-04-17 19:34:21,614 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands (367.471 and 348.378 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Both ligands (102.76 and 104.53) are reasonably close to the 140 A^2 threshold for oral absorption, but higher than ideal for CNS penetration.
3. **logP:** Ligand B (0.771) is slightly better than Ligand A (0.315). Ligand A is a bit low, potentially hindering permeation.
4. **HBD:** Both have 3 HBD, which is acceptable.
5. **HBA:** Ligand A has 6 HBA, while Ligand B has 3. Ligand B is preferable here, as fewer HBA generally improves permeability.
6. **QED:** Both are very similar (0.695 and 0.685), indicating good drug-likeness.
7. **DILI:** Ligand A (43.234) has a lower DILI risk than Ligand B (49.864), which is a significant advantage.
8. **BBB:** Ligand B (75.533) has a substantially higher BBB penetration percentile than Ligand A (12.99). This is a major factor for a GPCR, even a cardiovascular one, as some CNS off-target effects are possible.
9. **Caco-2:** Ligand A (-5.469) and Ligand B (-5.234) are both poor.
10. **Solubility:** Ligand A (-0.938) is better than Ligand B (-2.428). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.078) has a lower hERG risk than Ligand B (0.127), which is a positive.
12. **Cl_mic:** Ligand B (-14.878) has a significantly lower (better) microsomal clearance than Ligand A (-11.276), indicating better metabolic stability.
13. **t1/2:** Ligand B (3.147) has a longer in vitro half-life than Ligand A (-9.289), which is desirable.
14. **Pgp:** Ligand A (0.061) has a lower Pgp efflux liability than Ligand B (0.013), which is preferable.
15. **Binding Affinity:** Ligand A (-8.6 kcal/mol) has a slightly better binding affinity than Ligand B (-7.0 kcal/mol). This is a 1.6 kcal/mol difference, which is substantial.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), we prioritize logP, Pgp, TPSA, and affinity. Ligand B has better logP, Pgp, and Cl_mic/t1/2. Ligand A has better affinity, DILI, and hERG. The affinity difference is significant, but the metabolic stability and BBB penetration of Ligand B are also important.
**Overall Assessment:**
While Ligand A has a better binding affinity and lower DILI/hERG risk, Ligand B's superior metabolic stability (Cl_mic, t1/2) and significantly higher BBB penetration are more critical for a GPCR target. The slightly lower affinity of Ligand B can potentially be optimized in later stages of drug development. The better logP and Pgp profile of Ligand B also contribute to its potential for better overall PK.
Output:
0
2025-04-17 19:34:21,614 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (363.439 and 353.463 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand B (89.95) is significantly better than Ligand A (116.13). Lower TPSA generally favors better absorption, which is important for a GPCR target.
3. **logP:** Both ligands have good logP values (1.368 and 1.549), falling within the optimal 1-3 range. Ligand B is slightly better.
4. **HBD:** Both ligands have 2 H-bond donors, which is within the acceptable limit of <=5.
5. **HBA:** Ligand B (4) is slightly better than Ligand A (5), both are acceptable.
6. **QED:** Ligand A (0.792) has a better QED score than Ligand B (0.512), indicating a more drug-like profile.
7. **DILI:** Ligand B (25.94) has a much lower DILI risk than Ligand A (66.421). This is a significant advantage for Ligand B.
8. **BBB:** Ligand B (67.041) has a better BBB penetration score than Ligand A (41.373). While ADRB2 isn't strictly a CNS target, some CNS exposure can be beneficial or at least less detrimental, and minimizing it isn't a high priority.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.032 and -5.055), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand B (-1.713) has better solubility than Ligand A (-3.16).
11. **hERG:** Ligand B (0.206) has a much lower hERG inhibition liability than Ligand A (0.086). This is a crucial safety parameter, and Ligand B is significantly better.
12. **Cl_mic:** Ligand A (7.592) has a lower microsomal clearance, suggesting better metabolic stability, than Ligand B (18.445).
13. **t1/2:** Ligand A (30.629) has a longer in vitro half-life than Ligand B (-3.712). This is a positive for Ligand A.
14. **Pgp:** Ligand B (0.02) has a much lower P-gp efflux liability than Ligand A (0.088). This is favorable for bioavailability.
15. **Binding Affinity:** Ligand A (-7.7 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.3 kcal/mol). This is a substantial advantage for Ligand A.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP, TPSA, and Pgp, while Ligand A has a much stronger binding affinity. Safety parameters (DILI, hERG) are also critical. Ligand B is significantly better in both of these areas.
**Overall Assessment:**
The affinity difference is substantial (~1.4 kcal/mol). However, Ligand B presents a much more favorable safety profile (DILI, hERG) and better ADME properties (TPSA, Pgp, solubility). While the Caco-2 values are concerning for both, the overall balance of properties, particularly the safety profile and ADME characteristics, makes Ligand B the more promising candidate. The stronger binding of Ligand A is tempting, but the higher risk profile is a significant drawback.
Output:
0
2025-04-17 19:34:21,614 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.431 and 342.439 Da) fall comfortably within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (68.62) is higher than Ligand B (49.85). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B has a slight advantage.
3. **logP:** Both ligands have good logP values (2.396 and 1.132), falling within the 1-3 optimal range. Ligand A is slightly higher, which *could* be beneficial for membrane permeability, but isn't a major concern.
4. **HBD:** Ligand A has 1 HBD, while Ligand B has 0. This is a minor difference, both are within the acceptable limit of 5.
5. **HBA:** Ligand A has 5 HBA, and Ligand B has 3. Both are under the acceptable limit of 10.
6. **QED:** Ligand A (0.872) has a higher QED than Ligand B (0.723), indicating a more drug-like profile. This is a significant advantage for Ligand A.
7. **DILI:** Ligand B (31.989) has a significantly lower DILI risk than Ligand A (52.966). This is a major advantage for Ligand B, as minimizing liver toxicity is crucial.
8. **BBB:** Both ligands have good BBB penetration (73.905 and 78.868). Since ADRB2 is not a CNS target, this is less important, but higher is still preferable. Ligand B is slightly better.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.437 and -4.41). These values are difficult to interpret without knowing the scale, but the similarity suggests similar absorption potential.
10. **Solubility:** Both ligands have negative solubility values (-2.311 and -2.821). Again, the scale is unknown, but the similarity suggests similar solubility.
11. **hERG:** Both ligands have low hERG inhibition risk (0.448 and 0.398), which is good. No significant difference.
12. **Cl_mic:** Ligand B (32.737) has significantly lower microsomal clearance than Ligand A (69.68), indicating better metabolic stability. This is a substantial advantage for Ligand B.
13. **t1/2:** Ligand B (-2.448) has a longer in vitro half-life than Ligand A (-6.473). This is a significant advantage for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.04 and 0.089). No significant difference.
15. **Binding Affinity:** Both ligands have the same binding affinity (-6.4 kcal/mol). This eliminates affinity as a differentiating factor.
**Overall Assessment:**
While Ligand A has a better QED score, Ligand B demonstrates a superior safety profile (lower DILI) and better pharmacokinetic properties (lower Cl_mic, longer t1/2). Given the importance of minimizing toxicity and optimizing drug exposure, the advantages of Ligand B outweigh the slightly better QED of Ligand A. For a cardiovascular GPCR, metabolic stability and reduced toxicity are paramount.
Output:
0
2025-04-17 19:34:21,615 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (360.8 and 350.4 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (97.55) is better than Ligand B (115.39). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally aids absorption.
3. **logP:** Ligand A (2.317) is optimal, while Ligand B (0.432) is a bit low. A logP below 1 can hinder permeation. This favors Ligand A.
4. **HBD:** Ligand A (2) and Ligand B (3) are both acceptable, being less than 5.
5. **HBA:** Both ligands have 5 HBA, which is acceptable (<=10).
6. **QED:** Ligand A (0.872) is better than Ligand B (0.728), indicating a more drug-like profile.
7. **DILI:** Ligand A (85.653) has a higher DILI risk than Ligand B (62.156). This favors Ligand B.
8. **BBB:** Ligand A (62.389) is better than Ligand B (15.161). While not critical for a cardiovascular target, higher BBB is generally a positive attribute.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. Ligand A (-5.017) is slightly better than Ligand B (-5.322).
10. **Solubility:** Ligand A (-3.888) is slightly better than Ligand B (-2.566), indicating better solubility.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.298 and 0.101). No significant difference.
12. **Cl_mic:** Ligand A (-3.207) has slightly better metabolic stability (lower clearance) than Ligand B (-3.851).
13. **t1/2:** Ligand A (-2.887) has a slightly longer in vitro half-life than Ligand B (-4.856).
14. **Pgp:** Both ligands show very low P-gp efflux (0.056 and 0.044). No significant difference.
15. **Binding Affinity:** Ligand A (-7.7 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.9 kcal/mol). This is a 0.8 kcal/mol difference, which is substantial and can outweigh some ADME drawbacks.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, and affinity are key. Ligand A excels in logP and significantly outperforms Ligand B in binding affinity. While Ligand B has a better DILI score, the substantial affinity advantage of Ligand A, combined with acceptable (though not ideal) ADME properties, makes it the more promising candidate. The slightly better solubility and metabolic stability of Ligand A also contribute to its favorability.
**Output:**
1
2025-04-17 19:34:21,615 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [370.471, 101.57 , 1.143, 2. , 5. , 0.679, 53.354, 54.905, -5.277, -1.504, 0.373, 17.521, -2.248, 0.097, -6.4 ]
**Ligand B:** [352.395, 111.47 , -1.168, 1. , 8. , 0.627, 57.154, 61.535, -5.394, -1.251, 0.023, -1.951, 22.964, 0.024, -7. ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (352.395) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are reasonably good, but Ligand A (101.57) is better than Ligand B (111.47), being closer to the <140 threshold for oral absorption.
3. **logP:** Ligand A (1.143) is within the optimal range (1-3), while Ligand B (-1.168) is slightly below 1, potentially hindering permeation. This is a significant negative for Ligand B.
4. **HBD:** Both have acceptable HBD counts (2 and 1 respectively), well below the 5 threshold.
5. **HBA:** Ligand A (5) is better than Ligand B (8), as lower HBA generally improves permeability.
6. **QED:** Both have similar QED values (0.679 and 0.627), indicating good drug-likeness.
7. **DILI:** Both have acceptable DILI risk (53.354 and 57.154), below the concerning 60 threshold.
8. **BBB:** Ligand B (61.535) has a slightly better BBB penetration score than Ligand A (54.905), but neither is particularly high. Since ADRB2 is a cardiovascular target, BBB penetration is not a primary concern, but it's still a positive.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Both have negative solubility values, which is also unusual. Again, the scale is not specified.
11. **hERG:** Ligand A (0.373) has a much lower hERG risk than Ligand B (0.023), which is a significant advantage.
12. **Cl_mic:** Ligand B (-1.951) has a lower (better) microsomal clearance than Ligand A (17.521), indicating better metabolic stability.
13. **t1/2:** Ligand B (22.964) has a significantly longer in vitro half-life than Ligand A (-2.248), which is a major advantage.
14. **Pgp:** Ligand A (0.097) has lower P-gp efflux liability than Ligand B (0.024), which is favorable for oral bioavailability.
15. **Affinity:** Ligand B (-7.0) has a slightly better binding affinity than Ligand A (-6.4), a 0.6 kcal/mol difference.
**GPCR-specific priorities:** For ADRB2 (a GPCR), we prioritize logP, Pgp, TPSA, and affinity. Ligand A has a better logP and Pgp, and a better TPSA. Ligand B has a slightly better affinity, but the difference is not substantial enough to outweigh the other drawbacks.
**Overall Assessment:**
Ligand A is the better candidate. While Ligand B has a slightly better affinity and half-life, its significantly lower logP and higher hERG risk are major concerns. The better logP, TPSA and Pgp profile of Ligand A make it more likely to have acceptable permeability and bioavailability. The hERG risk is also much lower for Ligand A.
**Output:**
1
2025-04-17 19:34:21,615 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (347.459 Da) is well within the ideal range (200-500 Da). Ligand B (402.3 Da) is also acceptable, but closer to the upper limit.
2. **TPSA:** Ligand A (72.88) is excellent, well below the 140 threshold for good absorption. Ligand B (94.69) is still reasonable, but less optimal.
3. **logP:** Ligand A (1.228) is within the optimal range (1-3). Ligand B (4.054) is at the higher end, potentially causing solubility issues and off-target effects.
4. **HBD:** Both ligands have 2 HBD, which is good.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 6 HBA, both are acceptable, but Ligand A is slightly better.
6. **QED:** Ligand A (0.84) has a very good drug-likeness score. Ligand B (0.459) is significantly lower, indicating a less desirable overall drug-like profile.
7. **DILI:** Ligand A (17.914) has a much lower DILI risk than Ligand B (76.464), a significant advantage.
8. **BBB:** Ligand A (69.523) has a better BBB penetration score than Ligand B (47.421). While ADRB2 isn't strictly a CNS target, some peripheral distribution is still desired, and higher BBB penetration often correlates with better overall permeability.
9. **Caco-2:** Ligand A (-4.815) and Ligand B (-5.414) are both negative, indicating poor permeability.
10. **Solubility:** Ligand A (-1.401) is better than Ligand B (-4.637).
11. **hERG:** Ligand A (0.622) has a lower hERG risk than Ligand B (0.913).
12. **Cl_mic:** Ligand A (0.777) has significantly lower microsomal clearance, suggesting better metabolic stability. Ligand B (43.332) is quite high.
13. **t1/2:** Ligand A (10.118) has a better in vitro half-life than Ligand B (72.022).
14. **Pgp:** Ligand A (0.086) has lower P-gp efflux, which is favorable. Ligand B (0.898) has higher efflux.
15. **Affinity:** Ligand A (-6.5 kcal/mol) and Ligand B (-5.7 kcal/mol) both have good binding affinity, but Ligand A is slightly better.
**GPCR-specific priorities:** For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A is better in all of these parameters.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical ADME-Tox properties, including DILI, BBB, solubility, metabolic stability, and P-gp efflux. While both ligands have acceptable binding affinity, Ligand A's superior ADME profile and slightly better affinity make it the more promising drug candidate. Ligand B's high logP and DILI risk are significant concerns.
Output:
1
2025-04-17 19:34:21,615 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands (355.429 and 347.419 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (37.83) is significantly better than Ligand B (93.26). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B's TPSA is quite high, potentially hindering absorption.
3. **logP:** Both ligands have good logP values (2.536 and 1.448), falling within the 1-3 range. Ligand A is slightly more lipophilic, which could be advantageous for membrane permeability.
4. **HBD:** Ligand A (0) is preferable to Ligand B (1). Fewer hydrogen bond donors generally improve permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (6). Lower HBA is generally better for permeability.
6. **QED:** Both ligands have similar, acceptable QED values (0.759 and 0.78).
7. **DILI:** Ligand A (5.545) is significantly better than Ligand B (52.346). Lower DILI risk is crucial. Ligand B's DILI percentile is concerning.
8. **BBB:** Ligand A (97.208) is *much* better than Ligand B (61.535). While ADRB2 isn't exclusively a CNS target, some CNS exposure can occur, and a higher BBB percentile is generally favorable.
9. **Caco-2:** Ligand A (-4.414) is better than Ligand B (-4.878), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-1.301) is better than Ligand B (-0.967). Better solubility is generally preferred.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.877 and 0.151), which is excellent.
12. **Cl_mic:** Ligand A (-9.637) is *much* better than Ligand B (51.236). Lower microsomal clearance indicates greater metabolic stability, a critical factor for drug duration.
13. **t1/2:** Ligand A (-3.392) is better than Ligand B (-5.112). Longer in vitro half-life is desirable.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.059 and 0.024).
15. **Binding Affinity:** Ligand B (-6.7) is slightly better than Ligand A (-6.5), but the difference is small (0.2 kcal/mol). This difference is unlikely to outweigh the substantial ADME advantages of Ligand A.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A excels in TPSA, logP, and Pgp. While Ligand B has slightly better affinity, the significant improvements in ADME properties (DILI, BBB, Cl_mic, t1/2, solubility) for Ligand A are far more important for overall drug development success.
**Conclusion:**
Ligand A is the superior candidate due to its significantly better ADME profile, particularly its lower DILI risk, higher BBB penetration, and improved metabolic stability. The slightly lower binding affinity is a minor drawback compared to the substantial benefits in other critical parameters.
Output:
1
2025-04-17 19:34:21,616 - INFO - Batch 120 complete. Total preferences: 1920
2025-04-17 19:34:21,616 - INFO - Processing batch 121/512...
2025-04-17 19:35:08,915 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (366.443 and 351.447 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand B (87.74) is significantly better than Ligand A (127.31). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (0.433) is slightly better than Ligand A (-0.205), both are within the acceptable range, but closer to the lower end.
4. **HBD:** Ligand B (2) has fewer HBDs than Ligand A (3), which is preferable for permeability.
5. **HBA:** Ligand B (4) has fewer HBAs than Ligand A (7), again favoring permeability.
6. **QED:** Ligand B (0.752) has a higher QED score than Ligand A (0.593), indicating a more drug-like profile.
7. **DILI:** Ligand B (19.349) has a *much* lower DILI risk than Ligand A (57.154). This is a major advantage for Ligand B.
8. **BBB:** Ligand B (52.695) has a higher BBB penetration than Ligand A (24.855), but this is less critical for a cardiovascular target.
9. **Caco-2:** Both ligands have similar, poor Caco-2 permeability (-5.919 and -5.162).
10. **Solubility:** Both ligands have similar, poor solubility (-1.317 and -2.08).
11. **hERG:** Both ligands have low hERG inhibition liability (0.12 and 0.164).
12. **Cl_mic:** Ligand B (-10.628) has a lower (better) microsomal clearance than Ligand A (-12.647), suggesting better metabolic stability.
13. **t1/2:** Ligand B (7.134) has a slightly longer in vitro half-life than Ligand A (53.761).
14. **Pgp:** Both ligands have low Pgp efflux liability (0.074 and 0.013).
15. **Binding Affinity:** Ligand A (-8.5) has a significantly better binding affinity than Ligand B (-6.2). This is a 2.3 kcal/mol difference, which is substantial and can often outweigh other ADME concerns.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. While Ligand B has better TPSA, logP, and Pgp, the significant advantage in binding affinity for Ligand A is the deciding factor. The lower DILI risk of Ligand B is also very attractive, but the potency difference is substantial enough to prioritize.
**Conclusion:**
Despite some ADME drawbacks in both compounds, the significantly stronger binding affinity of Ligand A makes it the more promising drug candidate.
Output:
1
2025-04-17 19:35:08,915 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**1. Molecular Weight:** Both ligands (342.399 Da and 346.427 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (84.42) is slightly higher than Ligand B (70.83). Both are below the 140 A^2 threshold for good oral absorption, and acceptable for a peripherally acting GPCR like ADRB2. Ligand B is preferable here.
**3. logP:** Ligand A (1.064) is within the optimal range (1-3), while Ligand B (2.266) is closer to the upper limit. Both are acceptable, but Ligand A is slightly preferred.
**4. H-Bond Donors:** Ligand A has 1 HBD, and Ligand B has 0. Both are well within the acceptable limit of <=5. No strong preference.
**5. H-Bond Acceptors:** Ligand A has 5 HBA, and Ligand B has 4. Both are below the acceptable limit of <=10. No strong preference.
**6. QED:** Both ligands have similar QED values (0.885 and 0.842), indicating good drug-likeness. No significant difference.
**7. DILI Risk:** Ligand A (52.036) has a slightly higher DILI risk than Ligand B (34.432). Ligand B is preferable.
**8. BBB Penetration:** Both ligands have good BBB penetration (79.488 and 70.57). Since ADRB2 is not a primary CNS target, this isn't a major deciding factor, but Ligand A is slightly better.
**9. Caco-2 Permeability:** Ligand A (-4.803) has better Caco-2 permeability than Ligand B (-4.461). This suggests better intestinal absorption for Ligand A.
**10. Aqueous Solubility:** Both ligands have very poor aqueous solubility (-1.606 and -1.974). This is a concern for both, and formulation strategies would be needed. No strong preference.
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.12 and 0.086). This is excellent for both. No strong preference.
**12. Microsomal Clearance:** Ligand A (23.191) has significantly lower microsomal clearance than Ligand B (40.314), indicating better metabolic stability. This is a significant advantage for Ligand A.
**13. In vitro Half-Life:** Ligand A (1.369) has a shorter in vitro half-life than Ligand B (20.65). This is a significant advantage for Ligand B.
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (0.032 and 0.157). No strong preference.
**15. Binding Affinity:** Ligand A (-7.5) has a slightly stronger binding affinity than Ligand B (-6.9). This is a 0.6 kcal/mol difference, which is significant and can outweigh some ADME drawbacks.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), and the general guidelines, Ligand A emerges as the more promising candidate. While Ligand B has a lower DILI risk and better half-life, Ligand A's superior binding affinity, better Caco-2 permeability, and significantly improved metabolic stability (lower Cl_mic) are more critical for a successful drug candidate. The slightly higher DILI risk of Ligand A can be investigated further during development.
Output:
1
2025-04-17 19:35:08,915 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
The ADRB2 receptor is a GPCR, so the priorities are logP, TPSA, Pgp efflux, BBB penetration, and binding affinity. Metabolic stability and solubility are also important, but slightly less so.
Let's compare the ligands property by property:
1. **MW:** Both are within the ideal range (200-500 Da).
2. **TPSA:** Ligand A (58.95) is significantly better than Ligand B (121.8), falling well below the 140 threshold for good absorption. Ligand B is pushing the upper limit.
3. **logP:** Ligand A (4.126) is a bit high, potentially causing solubility issues, but still within a reasonable range. Ligand B (1.329) is on the lower side, which could hinder permeation.
4. **HBD/HBA:** Ligand B has more HBDs and HBAs (3/6) than Ligand A (2/3). This could slightly reduce permeability.
5. **QED:** Ligand A (0.733) has a much better QED score than Ligand B (0.357), indicating a more drug-like profile.
6. **DILI:** Ligand B (52.152) has a significantly lower DILI risk than Ligand A (96.859). This is a major advantage for Ligand B.
7. **BBB:** Ligand A (66.305) has better BBB penetration than Ligand B (57.154), but neither are exceptionally high.
8. **Caco-2:** Ligand A (-4.472) has a better Caco-2 permeability than Ligand B (-5.372).
9. **Solubility:** Ligand B (-2.841) has better aqueous solubility than Ligand A (-5.844).
10. **hERG:** Both ligands have low hERG inhibition risk (0.424 and 0.489).
11. **Cl_mic:** Ligand A (44.482) has lower microsomal clearance, suggesting better metabolic stability, than Ligand B (68.285).
12. **t1/2:** Ligand A (78.026) has a much longer in vitro half-life than Ligand B (-16.327). This is a significant advantage for Ligand A.
13. **Pgp:** Both ligands have low Pgp efflux liability (0.197 and 0.114).
14. **Binding Affinity:** Ligand A (-7.6) has a significantly stronger binding affinity than Ligand B (-6.4). This is a substantial advantage.
**Overall Assessment:**
Ligand A excels in binding affinity, metabolic stability (lower Cl_mic, longer t1/2), Caco-2 permeability, TPSA, and QED. However, it has a higher DILI risk and lower solubility. Ligand B has a lower DILI risk and better solubility, but suffers from weaker binding affinity, poorer metabolic stability, and a higher TPSA.
Given the GPCR target, strong binding affinity is paramount. The 1.2 kcal/mol difference in binding affinity is substantial and likely outweighs the drawbacks of Ligand A's higher DILI risk and lower solubility, which can be addressed through formulation strategies or further chemical modification. The better TPSA and QED of Ligand A also contribute to its overall potential.
**Output:**
1
2025-04-17 19:35:08,915 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (380.206) is slightly higher than Ligand B (348.531), but both are acceptable.
2. **TPSA:** Ligand B (41.57) is significantly better than Ligand A (68.02). Lower TPSA is favorable for permeability, especially for a GPCR target.
3. **logP:** Both ligands have good logP values (A: 4.125, B: 3.351), falling within the optimal range of 1-3. Ligand B is slightly better.
4. **HBD:** Both ligands have 1 HBD, which is within the acceptable limit of <=5.
5. **HBA:** Ligand B (3) is better than Ligand A (4), as lower HBA is generally preferred for permeability.
6. **QED:** Both ligands have good QED scores (A: 0.676, B: 0.847), indicating good drug-like properties. Ligand B is better.
7. **DILI:** Ligand B (6.049) is *much* better than Ligand A (90.384). This is a critical advantage for Ligand B, as DILI risk is a major concern.
8. **BBB:** Ligand B (94.184) is significantly better than Ligand A (77.627). While ADRB2 isn't exclusively a CNS target, some CNS penetration can be beneficial, and higher BBB is generally desirable.
9. **Caco-2:** Both ligands have similar, and very poor, Caco-2 permeability values (-4.777 and -4.653). This is a concern for both.
10. **Solubility:** Both ligands have poor solubility (-5.346 and -4.134). This is a drawback for both.
11. **hERG:** Ligand B (0.705) is better than Ligand A (0.447). Lower hERG inhibition is crucial for avoiding cardiotoxicity, which is particularly important for a cardiovascular target like ADRB2.
12. **Cl_mic:** Ligand B (41.74) has a lower microsomal clearance than Ligand A (59.647), indicating better metabolic stability.
13. **t1/2:** Ligand B (7.31) has a longer in vitro half-life than Ligand A (5.094), which is desirable.
14. **Pgp:** Ligand B (0.055) is significantly better than Ligand A (0.3), indicating lower P-gp efflux and potentially better bioavailability.
15. **Binding Affinity:** Ligand A (-8.6) has a significantly stronger binding affinity than Ligand B (-5.9). This is a substantial advantage for Ligand A. A difference of >1.5 kcal/mol can often outweigh other drawbacks.
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A has a better logP and *much* better affinity. However, Ligand B excels in TPSA, Pgp, and crucially, DILI and hERG risk.
**Overall Assessment:**
While Ligand A's binding affinity is very strong, the significant DILI risk (90.384) and relatively poor hERG profile (0.447) are major red flags. The improved ADME properties of Ligand B (lower DILI, better hERG, lower Cl_mic, longer t1/2, better Pgp, and lower TPSA) outweigh the affinity difference. The poor Caco-2 and solubility are concerns for both, but can be addressed with formulation strategies. The safety profile of Ligand B is far superior.
Output:
0
2025-04-17 19:35:08,915 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (355.825 Da) is slightly lower, which is generally favorable for permeability.
**2. TPSA:** Ligand A (61.44) is significantly better than Ligand B (83.48). For a GPCR, keeping TPSA low is beneficial for permeability and receptor engagement. Ligand B is pushing the upper limit for good oral absorption.
**3. logP:** Both ligands have acceptable logP values (A: 4.647, B: 3.265), falling within the 1-3 range, though Ligand A is a bit high.
**4. H-Bond Donors & Acceptors:** Ligand A (HBD=2, HBA=2) is preferable to Ligand B (HBD=3, HBA=4) as it has fewer hydrogen bond forming groups, which can improve membrane permeability.
**5. QED:** Both ligands have similar QED values (A: 0.787, B: 0.704), indicating good drug-like properties.
**6. DILI:** Both ligands have similar, and relatively high, DILI risk (A: 84.917, B: 83.133). This is a concern for both, and further investigation would be needed.
**7. BBB:** Ligand A (73.672) has a significantly better BBB penetration prediction than Ligand B (36.371). While ADRB2 is a cardiovascular target, some CNS effects are possible with adrenergic ligands, and better BBB penetration could lead to off-target effects. However, for a cardiovascular target, this is less critical than for a CNS target.
**8. Caco-2 Permeability:** Both ligands show poor Caco-2 permeability (A: -4.925, B: -4.781), indicating potential absorption issues.
**9. Aqueous Solubility:** Ligand A (-6.149) has slightly better predicted solubility than Ligand B (-4.096), though both are poor.
**10. hERG Inhibition:** Ligand A (0.683) has a lower hERG inhibition liability than Ligand B (0.279), which is a significant advantage for cardiovascular safety.
**11. Microsomal Clearance:** Ligand B (39.065) has a slightly higher microsomal clearance than Ligand A (32.802), suggesting faster metabolism and potentially lower exposure.
**12. In vitro Half-Life:** Ligand A (67.792) has a longer in vitro half-life than Ligand B (56.736), which is desirable.
**13. P-gp Efflux:** Ligand A (0.329) has a lower P-gp efflux liability than Ligand B (0.095), which is favorable for bioavailability.
**14. Binding Affinity:** Ligand B (-8.0) has a significantly stronger binding affinity than Ligand A (-2.5). This is a major advantage, potentially outweighing some of the ADME drawbacks. A difference of >1.5 kcal/mol is substantial.
**Overall Assessment:**
While Ligand A has better ADME properties across the board (TPSA, H-bonds, BBB, solubility, hERG, clearance, half-life, P-gp efflux), the significantly stronger binding affinity of Ligand B (-8.0 kcal/mol vs -2.5 kcal/mol) is a critical factor, especially for a GPCR target. The improved potency could allow for a lower dose, potentially mitigating some of the ADME concerns. The DILI risk is high for both, but the potency advantage of Ligand B is compelling.
Output:
0
2025-04-17 19:35:08,915 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (345.399 and 358.479 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (91.76) is better than Ligand B (96.89). Both are acceptable for a non-CNS GPCR, being under 140, but lower is generally preferred.
3. **logP:** Ligand A (1.475) is slightly better than Ligand B (0.99), both fall within the optimal 1-3 range.
4. **HBD:** Ligand A (2) is preferable to Ligand B (3). Lower HBD generally improves permeability.
5. **HBA:** Both ligands have 5 HBA, which is acceptable.
6. **QED:** Ligand A (0.807) has a significantly better QED score than Ligand B (0.601), indicating a more drug-like profile.
7. **DILI:** Ligand A (48.158) has a much lower DILI risk than Ligand B (11.4). This is a major advantage for Ligand A.
8. **BBB:** This is less critical for a cardiovascular target like ADRB2. Ligand A (59.597) is better than Ligand B (38.813), but not a deciding factor.
9. **Caco-2:** Ligand A (-4.927) is better than Ligand B (-5.138), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-2.842) is better than Ligand B (-1.231), which is important for bioavailability.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.229 and 0.177 respectively).
12. **Cl_mic:** Ligand B (19.509) has a lower microsomal clearance than Ligand A (27.095), suggesting better metabolic stability.
13. **t1/2:** Ligand B (17.203) has a much longer in vitro half-life than Ligand A (-4.176), which is a significant advantage.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.02 and 0.017 respectively).
15. **Binding Affinity:** Ligand B (-6.8 kcal/mol) has a stronger binding affinity than Ligand A (-5.6 kcal/mol), a difference of 1.2 kcal/mol. This is a substantial advantage.
**Overall Assessment:**
Ligand B has a significantly stronger binding affinity and a longer half-life, which are very important. However, Ligand A has a much better safety profile (lower DILI) and better predicted absorption/solubility. Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity), the affinity difference is substantial enough to outweigh the slightly less favorable ADME properties of Ligand B. The lower DILI risk of Ligand A is also a significant benefit.
Output:
0
2025-04-17 19:35:08,915 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (345.443 and 349.475 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (86.34) is slightly higher than Ligand B (67.6). Both are below the 140 threshold for oral absorption, but Ligand B is better positioned for potential CNS penetration if desired (though not a primary goal for ADRB2).
3. **logP:** Both ligands (2.885 and 2.974) are within the optimal 1-3 range. Again, a minor difference.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 4 HBA, Ligand B has 5. Both are acceptable, but Ligand A is slightly better.
6. **QED:** Both ligands have high QED scores (0.859 and 0.885), indicating good drug-like properties.
7. **DILI:** Ligand A (41.411) has a slightly higher DILI risk than Ligand B (23.963), but both are below the concerning 60 percentile. Ligand B is preferable here.
8. **BBB:** Ligand B (78.79) has a significantly higher BBB penetration percentile than Ligand A (65.025). While ADRB2 isn't necessarily a CNS target, higher BBB penetration can sometimes correlate with better overall distribution.
9. **Caco-2:** Ligand A (-4.611) and Ligand B (-4.911) have similar, and quite poor, Caco-2 permeability values. This is a concern for both.
10. **Solubility:** Ligand A (-3.191) has slightly better solubility than Ligand B (-2.489), which is a positive.
11. **hERG:** Both ligands have low hERG inhibition risk (0.659 and 0.358), which is excellent. Ligand B is slightly better.
12. **Cl_mic:** Ligand A (28.775) has significantly lower microsomal clearance than Ligand B (61.704), indicating better metabolic stability. This is a major advantage for Ligand A.
13. **t1/2:** Ligand A (19.249 hours) has a much longer in vitro half-life than Ligand B (-11.615 hours). This is a substantial benefit for Ligand A, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.326 and 0.229), which is good. Ligand B is slightly better.
15. **Binding Affinity:** Ligand B (-7.6 kcal/mol) has a slightly stronger binding affinity than Ligand A (-7.1 kcal/mol). This 0.5 kcal/mol difference is significant and could outweigh some of the ADME drawbacks of Ligand B.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Both ligands perform well on logP and Pgp. Ligand B has a better TPSA and affinity, while Ligand A has better metabolic stability (Cl_mic) and half-life. The affinity difference is the most substantial single difference.
**Overall Assessment:**
The improved binding affinity of Ligand B (-7.6 kcal/mol vs -7.1 kcal/mol) is a significant advantage, especially for a GPCR target. While Ligand A has better metabolic stability and half-life, the potency gain with Ligand B is likely to be more impactful in driving efficacy. The slightly better DILI and hERG profiles of Ligand B are also favorable. The Caco-2 permeability is a concern for both, but can be addressed during formulation.
Output:
0
2025-04-17 19:35:08,916 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (382.255 Da) is slightly higher than Ligand B (355.385 Da), but both are acceptable.
2. **TPSA:** Ligand A (107.71) is higher than Ligand B (62.74). For a cardiovascular GPCR like ADRB2, TPSA is not a *major* concern unless it's excessively high, which it isn't for either. Ligand B is significantly better here, suggesting better permeability.
3. **logP:** Ligand A (4.425) is higher than Ligand B (1.731). Ligand A is pushing the upper limit of acceptable logP, potentially leading to solubility issues and off-target interactions. Ligand B is within the optimal range.
4. **H-Bond Donors:** Ligand A (2) is reasonable, and Ligand B (0) is also good.
5. **H-Bond Acceptors:** Both ligands have 4 H-bond acceptors, which is acceptable.
6. **QED:** Both ligands have good QED scores (A: 0.42, B: 0.713), but Ligand B is significantly better, indicating a more drug-like profile.
7. **DILI Risk:** Ligand A (72.043) has a higher DILI risk than Ligand B (34.936). This is a significant advantage for Ligand B.
8. **BBB Penetration:** Ligand A (61.923) and Ligand B (96.355). While ADRB2 isn't a primary CNS target, some peripheral ADRB2 modulation can have CNS side effects, and better BBB penetration *could* translate to unwanted effects. However, for a cardiovascular target, this is a lower priority. Ligand B is better here.
9. **Caco-2 Permeability:** Both have negative values (-4.824 and -4.123), which is unusual and suggests poor permeability. However, these values are on a scale where negative values are common and don't necessarily mean *zero* permeability.
10. **Aqueous Solubility:** Ligand A (-4.952) is worse than Ligand B (-1.541), consistent with its higher logP. Solubility is a concern for Ligand A.
11. **hERG Inhibition:** Both ligands have low hERG inhibition risk (A: 0.652, B: 0.253), which is good. Ligand B is slightly better.
12. **Microsomal Clearance:** Ligand A (56.634) has higher clearance than Ligand B (20.737), indicating lower metabolic stability. Ligand B is significantly better here.
13. **In vitro Half-Life:** Ligand A (93.457) has a much longer half-life than Ligand B (-5.64). This is a major advantage for Ligand A, potentially allowing for less frequent dosing.
14. **P-gp Efflux:** Ligand A (0.242) has lower P-gp efflux than Ligand B (0.039), which is favorable for bioavailability.
15. **Binding Affinity:** Both ligands have comparable binding affinity (-6.3 kcal/mol and -6.4 kcal/mol). The difference is negligible.
**GPCR-Specific Priorities & Overall Assessment:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP, TPSA, DILI, and metabolic stability (Cl_mic). Ligand A has a significantly longer half-life and slightly better P-gp efflux. However, the higher logP, DILI risk, and lower solubility of Ligand A are concerning. The longer half-life is attractive, but can be addressed through formulation or prodrug strategies. The overall balance of properties favors Ligand B.
**Output:**
0
2025-04-17 19:35:08,916 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (375.441 and 382.501 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (71) is slightly higher than Ligand B (41.99). Both are below the 140 threshold for oral absorption, but Ligand B is significantly better, especially considering ADRB2 is a GPCR and lower TPSA is generally favored.
3. **logP:** Ligand A (1.504) is within the optimal 1-3 range. Ligand B (4.873) is higher, potentially leading to solubility issues and off-target interactions. This is a significant negative for Ligand B.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 5 HBA, Ligand B has 4. Both are acceptable.
6. **QED:** Both ligands have similar QED values (0.732 and 0.75), indicating good drug-likeness.
7. **DILI:** Ligand A (32.842) has a much lower DILI risk than Ligand B (59.442). This is a crucial advantage for Ligand A.
8. **BBB:** Ligand B (89.415) has a higher BBB penetration percentile than Ligand A (75.107). While ADRB2 isn't strictly a CNS target, some peripheral ADRB2 receptors can be affected by CNS penetration and a higher value is generally preferred.
9. **Caco-2:** Ligand A (-5.068) has a worse Caco-2 permeability than Ligand B (-4.662).
10. **Solubility:** Ligand A (-2.149) has better aqueous solubility than Ligand B (-5.22). This is important, especially given Ligand B's higher logP.
11. **hERG:** Ligand A (0.23) has a much lower hERG inhibition liability than Ligand B (0.555). This is a major advantage for Ligand A, as hERG inhibition can cause cardiotoxicity.
12. **Cl_mic:** Ligand A (-3.21) has a lower (better) microsomal clearance than Ligand B (55.979). This indicates better metabolic stability for Ligand A.
13. **t1/2:** Ligand B (38.61) has a significantly longer in vitro half-life than Ligand A (-7.668). This is a positive for Ligand B.
14. **Pgp:** Ligand A (0.042) has lower P-gp efflux liability than Ligand B (0.585). This is a positive for Ligand A.
15. **Affinity:** Ligand B (-6.7) has a slightly better binding affinity than Ligand A (-6.2). While a 0.5 kcal/mol difference is noticeable, it's not substantial enough to outweigh the other significant advantages of Ligand A.
**Overall Assessment:**
Ligand A demonstrates a superior balance of properties. It has a lower DILI risk, lower hERG inhibition, better solubility, lower microsomal clearance, and lower P-gp efflux. While Ligand B has a slightly better affinity and BBB penetration, the risks associated with its higher logP, DILI, hERG, and clearance are too significant. The slightly better affinity of Ligand B doesn't compensate for these liabilities.
Output:
1
2025-04-17 19:35:08,916 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (351.451 and 364.515 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (84.99) is better than Ligand B (65.54). Both are below 140, suggesting good oral absorption potential, but Ligand B is closer to the optimal range for GPCRs.
3. **logP:** Ligand B (1.624) is better than Ligand A (0.302). Ligand A is quite low, potentially hindering membrane permeability. Ligand B is within the optimal 1-3 range.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1), but both are acceptable (<=5).
5. **HBA:** Ligand B (5) is higher than Ligand A (3). Both are acceptable (<=10).
6. **QED:** Both ligands have good QED scores (0.75 and 0.862), indicating good drug-like properties.
7. **DILI:** Ligand A (32.571) is significantly better than Ligand B (47.499) in terms of DILI risk. Lower is better, and Ligand A is comfortably below the 40% threshold.
8. **BBB:** Ligand B (75.107) is better than Ligand A (60.527). For a GPCR, higher BBB penetration is desirable, although not strictly essential for ADRB2 which is not primarily a CNS target.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.713 and -4.937), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand A (-1.629) is better than Ligand B (-2.162), indicating better aqueous solubility.
11. **hERG:** Both ligands have low hERG inhibition risk (0.325 and 0.474).
12. **Cl_mic:** Ligand A (-14.638) is much better than Ligand B (63.717). Lower clearance indicates better metabolic stability, a crucial factor.
13. **t1/2:** Ligand A (-14.299) is much better than Ligand B (-1.659). A longer in vitro half-life is desirable.
14. **Pgp:** Ligand A (0.009) is much better than Ligand B (0.313). Lower P-gp efflux is preferred for better bioavailability.
15. **Binding Affinity:** Ligand A (-8.1) is significantly better than Ligand B (-6.8). A 1.3 kcal/mol difference is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand A has a significantly better binding affinity, much better metabolic stability (Cl_mic and t1/2), lower DILI risk, and lower P-gp efflux. While Ligand B has a slightly better logP and BBB penetration, the substantial advantages of Ligand A in potency, metabolic stability, and safety outweigh these. The negative Caco-2 values are concerning for both, but the superior binding affinity of Ligand A suggests it might overcome this limitation with further optimization.
Output:
1
2025-04-17 19:35:08,916 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (345.418 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (53.51) is better than Ligand B (40.62), both are below 140, but Ligand A is closer to the ideal for oral absorption.
3. **logP:** Ligand A (1.822) is optimal (1-3), while Ligand B (4.184) is pushing the upper limit and could present solubility issues. This is a significant advantage for Ligand A.
4. **HBD:** Both have 0 HBD, which is good.
5. **HBA:** Both have 3 HBA, which is good.
6. **QED:** Ligand A (0.818) is superior to Ligand B (0.631), indicating a more drug-like profile.
7. **DILI:** Ligand A (20.861) has a much lower DILI risk than Ligand B (26.444). This is a crucial advantage.
8. **BBB:** Ligand A (91.508) has a significantly higher BBB penetration percentile than Ligand B (74.758). While ADRB2 isn't *necessarily* a CNS target, higher BBB is rarely detrimental and can open up possibilities.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand B (-4.885) is slightly worse than Ligand A (-4.629).
10. **Solubility:** Ligand A (-1.842) is better than Ligand B (-3.81), although both are poor. The lower logP of Ligand A contributes to this.
11. **hERG:** Ligand A (0.248) has a much lower hERG inhibition liability than Ligand B (0.759), which is a critical safety advantage.
12. **Cl_mic:** Ligand B (94.642) has a much higher microsomal clearance than Ligand A (20.151), indicating poorer metabolic stability. This is a major drawback for Ligand B.
13. **t1/2:** Ligand A (-3.776) has a negative half-life, which is concerning. Ligand B (4.726) has a positive half-life, which is favorable.
14. **Pgp:** Ligand A (0.034) has lower P-gp efflux liability than Ligand B (0.657), which is beneficial for bioavailability.
15. **Binding Affinity:** Ligand B (-6.3) is slightly better than Ligand A (-6.6), but the difference is small (0.3 kcal/mol) and likely not enough to overcome the significant ADME/Tox advantages of Ligand A.
**GPCR-specific considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A excels in logP, TPSA, and Pgp, while the affinity difference is minimal. The significantly better safety profile (DILI, hERG) and metabolic stability (Cl_mic) of Ligand A are also highly important.
**Conclusion:**
Despite Ligand B having a slightly better binding affinity, Ligand A is the superior candidate due to its significantly better ADME/Tox profile, particularly its lower DILI and hERG risk, improved metabolic stability, and better solubility. The small affinity difference is easily outweighed by these factors.
Output:
1
2025-04-17 19:35:08,916 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [346.427, 75.71, 1.535, 1, 4, 0.725, 30.826, 70.027, -4.182, -2.045, 0.129, 77.21, -16.325, 0.048, -7.3]
**Ligand B:** [351.407, 106.42, 0.268, 1, 7, 0.737, 56.727, 64.87, -4.945, -1.761, 0.095, 23.337, -6.287, 0.038, -6.5]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, Affinity, and BBB):
1. **MW:** Both are within the ideal 200-500 Da range. A (346.427) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** A (75.71) is better than B (106.42). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA is still preferred for good absorption.
3. **logP:** A (1.535) is optimal. B (0.268) is quite low, potentially leading to poor membrane permeability and bioavailability. This is a significant drawback.
4. **HBD/HBA:** Both have 1 HBD, which is good. A has 4 HBA, B has 7. Both are acceptable, but A is slightly better.
5. **QED:** Both are good (0.725 and 0.737), indicating drug-like properties.
6. **DILI:** A (30.826) is significantly better than B (56.727), indicating a lower risk of liver injury.
7. **BBB:** A (70.027) is better than B (64.87). While not critical for a cardiovascular target, higher BBB is generally a positive.
8. **Caco-2:** Both are negative, indicating poor permeability. A (-4.182) is slightly better than B (-4.945).
9. **Solubility:** Both are negative, indicating poor solubility. A (-2.045) is slightly better than B (-1.761).
10. **hERG:** Both are very low (0.129 and 0.095), which is excellent and minimizes cardiotoxicity risk.
11. **Cl_mic:** A (77.21) is higher than B (23.337), meaning faster clearance and potentially lower exposure. This is a negative for A.
12. **t1/2:** A (-16.325) is much worse than B (-6.287), indicating a very short half-life and potentially requiring frequent dosing. This is a major negative for A.
13. **Pgp:** Both are very low (0.048 and 0.038), indicating minimal P-gp efflux.
14. **Affinity:** A (-7.3) is slightly better than B (-6.5), a difference of 0.8 kcal/mol. While a difference of 1.5 kcal/mol is usually considered significant, 0.8 kcal/mol is less decisive.
**Overall Assessment:**
Ligand A has advantages in TPSA, logP, DILI, and BBB, and a slightly better binding affinity. However, Ligand B has a much better metabolic stability profile (lower Cl_mic, longer t1/2). The low logP of Ligand B is a major concern, but the significantly improved metabolic stability is a strong counterpoint, especially for a GPCR where maintaining therapeutic concentrations is important. The poor half-life of Ligand A is a significant drawback. Considering the balance, the improved metabolic stability of Ligand B outweighs its lower logP.
Output:
0
2025-04-17 19:35:08,916 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [367.467, 81.7, 1.883, 1, 5, 0.71, 49.244, 67.546, -4.885, -3.35, 0.393, 70.712, -35.551, 0.092, -7.1]
**Ligand B:** [382.595, 58.2, 3.676, 2, 4, 0.721, 49.283, 56.766, -5.61, -3.813, 0.395, 69.414, 17.243, 0.458, -5.2]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal 200-500 Da range. A (367.47) is slightly preferred.
2. **TPSA:** A (81.7) is higher than B (58.2). B is significantly better here, falling well below the 140 threshold for oral absorption and closer to the range desirable for GPCRs.
3. **logP:** A (1.883) is optimal. B (3.676) is pushing the upper limit, potentially leading to solubility issues. A is better.
4. **HBD:** A (1) is preferred over B (2). Fewer HBDs generally improve permeability.
5. **HBA:** A (5) is preferred over B (4).
6. **QED:** Both are good (A: 0.71, B: 0.721), indicating drug-likeness. Similar.
7. **DILI:** Both are very similar and acceptable (around 49%). Similar.
8. **BBB:** A (67.55) is better than B (56.77), although neither is exceptionally high. For a cardiovascular target, BBB isn't *critical*, but a higher value is still a slight advantage.
9. **Caco-2:** A (-4.885) is better than B (-5.61), indicating better absorption.
10. **Solubility:** A (-3.35) is better than B (-3.813).
11. **hERG:** Both are low (A: 0.393, B: 0.395), indicating low cardiotoxicity risk. Similar.
12. **Cl_mic:** A (70.712) is better than B (69.414), indicating better metabolic stability.
13. **t1/2:** A (-35.551) is *much* better than B (17.243). This is a significant advantage for dosing frequency.
14. **Pgp:** A (0.092) is better than B (0.458), indicating lower efflux and potentially better bioavailability.
15. **Affinity:** A (-7.1) is significantly better than B (-5.2). A 1.9 kcal/mol difference is substantial and can outweigh minor ADME drawbacks.
**Overall Assessment:**
Ligand A is clearly superior. While Ligand B has a better TPSA, Ligand A excels in almost every other critical parameter, most notably its significantly stronger binding affinity and much improved *in vitro* half-life. The better logP, solubility, Pgp, and metabolic stability of Ligand A further solidify its position as the more promising drug candidate. The affinity difference is large enough to compensate for the slightly higher TPSA.
Output:
1
2025-04-17 19:35:08,916 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (358.463 Da and 354.447 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (69.64) is significantly better than Ligand B (104.73). For a GPCR, keeping TPSA under 140 is good for oral absorption, and lower is generally preferred. Ligand B is pushing the upper limit and could have absorption issues.
**3. logP:** Ligand A (2.513) is within the optimal 1-3 range. Ligand B (0.89) is slightly below 1, which could hinder membrane permeability.
**4. H-Bond Donors:** Ligand A (2) is good. Ligand B (3) is acceptable, but slightly less desirable.
**5. H-Bond Acceptors:** Ligand A (4) is good. Ligand B (5) is acceptable.
**6. QED:** Ligand A (0.834) is excellent, indicating a highly drug-like profile. Ligand B (0.533) is acceptable, but lower.
**7. DILI Risk:** Ligand B (37.495) has a much lower DILI risk than Ligand A (54.556). This is a significant advantage for Ligand B.
**8. BBB Penetration:** Ligand A (64.793) has better BBB penetration than Ligand B (31.834). While ADRB2 isn't exclusively a CNS target, some CNS exposure might be beneficial or at least not detrimental, and is a GPCR priority.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-5.083 and -5.21). This is unusual and suggests poor permeability *in vitro*. However, the values are very close.
**10. Aqueous Solubility:** Ligand A (-3.277) is better than Ligand B (-1.952), indicating better solubility.
**11. hERG Inhibition:** Ligand A (0.579) has a slightly higher hERG risk than Ligand B (0.076). Lower is better here, so Ligand B is preferred.
**12. Microsomal Clearance:** Ligand B (-0.617) has *much* lower (better) microsomal clearance than Ligand A (43.617). This suggests significantly improved metabolic stability for Ligand B.
**13. In vitro Half-Life:** Ligand B (-12.316) has a much longer in vitro half-life than Ligand A (34.829). This is a major advantage for Ligand B.
**14. P-gp Efflux:** Ligand A (0.54) has a slightly lower P-gp efflux liability than Ligand B (0.092). Lower is better.
**15. Binding Affinity:** Both ligands have very similar and strong binding affinities (-5.9 kcal/mol and -4.8 kcal/mol). The 1.1 kcal/mol difference is not enough to overcome other significant ADME differences.
**Overall Assessment:**
Ligand B is the stronger candidate. While Ligand A has better BBB penetration and solubility, Ligand B excels in critical ADME properties: significantly lower DILI risk, dramatically improved metabolic stability (lower Cl_mic and longer t1/2), and lower hERG risk. The slightly lower logP of Ligand B is a minor concern compared to the substantial benefits in safety and pharmacokinetics. The TPSA is a concern for Ligand B, but the other benefits outweigh this.
Output:
0
2025-04-17 19:35:08,916 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
The target is ADRB2, a GPCR. Therefore, the most important parameters are binding affinity, logP, TPSA, Pgp efflux, and BBB penetration. Metabolic stability (Cl_mic and t1/2) and safety (DILI, hERG) are also crucial.
Let's compare the ligands:
1. **Molecular Weight:** Both ligands (352.475 and 362.474 Da) fall within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (84.5) is slightly higher than Ligand B (59.07). Both are below 140, but B is significantly better for permeability.
3. **logP:** Ligand A (2.189) is within the optimal range (1-3), while Ligand B (3.478) is at the higher end. While still acceptable, B's higher logP *could* lead to solubility issues.
4. **H-Bond Donors:** Both have 2 HBDs, which is good.
5. **H-Bond Acceptors:** Ligand A has 4, and Ligand B has 6. Both are acceptable, but A is slightly preferable.
6. **QED:** Ligand B (0.82) has a substantially better QED score than Ligand A (0.492), indicating better overall drug-likeness.
7. **DILI:** Ligand A (33.501) has a much lower DILI risk than Ligand B (82.202). This is a significant advantage for A.
8. **BBB:** Ligand B (94.339) has excellent BBB penetration, while Ligand A (60.295) is moderate. While ADRB2 isn't necessarily a CNS target, better BBB penetration can sometimes improve overall distribution.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. This is a concern for both, but the values are similar.
10. **Solubility:** Ligand A (-3.221) has better solubility than Ligand B (-5.122).
11. **hERG:** Ligand A (0.118) has a lower hERG risk than Ligand B (0.89). This is a significant safety advantage for A.
12. **Cl_mic:** Ligand B (77.686) has slightly lower microsomal clearance than Ligand A (85.44), suggesting better metabolic stability.
13. **t1/2:** Ligand B (73.958) has a significantly longer in vitro half-life than Ligand A (-16.694). This is a major advantage for B.
14. **Pgp:** Ligand A (0.077) has lower P-gp efflux than Ligand B (0.297), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand B (-6.7 kcal/mol) has a stronger binding affinity than Ligand A (-5.6 kcal/mol). This is a 1.1 kcal/mol difference, which is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand B has a significantly better binding affinity and half-life, and excellent BBB penetration. However, it has a much higher DILI risk, higher hERG risk, and worse solubility. Ligand A has a much better safety profile (DILI and hERG), better solubility, and lower Pgp efflux. The difference in binding affinity is significant, but the safety concerns with Ligand B are substantial. Given the cardiovascular context, minimizing hERG and DILI risks is paramount.
Therefore, I prioritize the safety profile and solubility of Ligand A despite the slightly weaker binding affinity.
**Output:**
1
2025-04-17 19:35:08,916 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [347.419, 111.26 , 0.911, 2. , 6. , 0.642, 24.855, 56.534, -5.329, -1.37 , 0.451, -4.346, -9.334, 0.008, -6.7 ]
**Ligand B:** [345.447, 72.28 , 0.744, 1. , 6. , 0.797, 24.855, 70.997, -4.964, -1.572, 0.137, 1.537, 4.126, 0.027, -6.2 ]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, Affinity, and BBB):
1. **MW:** Both are within the ideal range (200-500 Da). A is 347.4, B is 345.4 - very similar.
2. **TPSA:** A is 111.26, B is 72.28. B is significantly better, falling well below the 140 threshold for oral absorption and closer to the <90 threshold desirable for CNS penetration (though ADRB2 isn't necessarily a CNS target).
3. **logP:** A is 0.911, B is 0.744. Both are acceptable, but slightly on the lower side. A is a bit better.
4. **HBD:** A is 2, B is 1. B is preferable - fewer HBDs generally improve permeability.
5. **HBA:** Both are 6, which is acceptable.
6. **QED:** A is 0.642, B is 0.797. B is better, indicating a more drug-like profile.
7. **DILI:** Both are 24.855, so identical and low risk.
8. **BBB:** A is 56.534, B is 70.997. B is significantly better, suggesting better potential for CNS penetration if needed (although ADRB2 is primarily cardiovascular).
9. **Caco-2:** A is -5.329, B is -4.964. Both are negative, which is unusual and suggests very poor permeability. B is slightly better.
10. **Solubility:** A is -1.37, B is -1.572. Both are poor. B is slightly worse.
11. **hERG:** A is 0.451, B is 0.137. B is *much* better, indicating lower cardiotoxicity risk. This is crucial for a cardiovascular target.
12. **Cl_mic:** A is -4.346, B is 1.537. A is significantly better, indicating higher metabolic stability.
13. **t1/2:** A is -9.334, B is 4.126. B is *much* better, suggesting a longer half-life.
14. **Pgp:** A is 0.008, B is 0.027. A is slightly better, indicating less P-gp efflux.
15. **Affinity:** A is -6.7 kcal/mol, B is -6.2 kcal/mol. A has a slightly better binding affinity.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity and metabolic stability, Ligand B overwhelmingly wins on critical ADME properties, particularly hERG inhibition, BBB penetration, and *in vitro* half-life. The lower TPSA of Ligand B is also a significant advantage. The slightly better affinity of A is unlikely to overcome the substantial ADME advantages of B, especially given that both ligands have reasonable affinity. For a cardiovascular GPCR target, minimizing cardiotoxicity (hERG) and achieving reasonable exposure (BBB, t1/2) are paramount.
Therefore, I prefer Ligand B.
0
2025-04-17 19:35:08,917 - INFO - Batch 121 complete. Total preferences: 1936
2025-04-17 19:35:08,917 - INFO - Processing batch 122/512...
2025-04-17 19:35:57,655 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
The ADRB2 receptor is a GPCR, so the priorities are logP, TPSA, Pgp, BBB, and affinity. Let's break down the comparison:
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (347.394) is slightly lower than Ligand B (367.515), which is a minor advantage.
2. **TPSA:** Ligand B (80.32) is significantly better than Ligand A (98.17). A lower TPSA generally indicates better cell permeability, crucial for GPCR targeting.
3. **logP:** Both ligands have good logP values (A: 2.823, B: 2.385), falling within the optimal 1-3 range. Ligand B is slightly lower, which could be beneficial for solubility.
4. **H-Bond Donors/Acceptors:** Ligand A (HBD=1, HBA=3) has a more favorable profile than Ligand B (HBD=2, HBA=5). Fewer hydrogen bonds can improve permeability.
5. **QED:** Ligand B (0.775) has a significantly better QED score than Ligand A (0.466), suggesting it's more drug-like overall.
6. **DILI Risk:** Ligand A (35.828) has a much lower DILI risk than Ligand B (50.795). This is a significant advantage for Ligand A.
7. **BBB Penetration:** Ligand A (71.539) shows better BBB penetration than Ligand B (46.84). While ADRB2 isn't exclusively a CNS target, some peripheral effects are mediated by CNS pathways, and better BBB penetration is generally favorable.
8. **Caco-2 Permeability:** Ligand A (-4.777) has a better Caco-2 permeability than Ligand B (-4.995).
9. **Aqueous Solubility:** Ligand A (-3.247) has better aqueous solubility than Ligand B (-2.766).
10. **hERG Inhibition:** Both ligands have low hERG inhibition risk (A: 0.549, B: 0.333), which is good.
11. **Microsomal Clearance:** Ligand A (7.974) has significantly lower microsomal clearance than Ligand B (41.653), indicating better metabolic stability.
12. **In vitro Half-Life:** Ligand B (9.695) has a significantly longer in vitro half-life than Ligand A (-0.908). This is a major advantage for Ligand B.
13. **P-gp Efflux:** Both ligands have low P-gp efflux (A: 0.021, B: 0.14), which is good.
14. **Binding Affinity:** Ligand B (-6.6 kcal/mol) has a slightly better binding affinity than Ligand A (-6.2 kcal/mol). This is a 0.4 kcal/mol difference, which is not huge, but still a positive for Ligand B.
**Overall Assessment:**
Ligand B has a better QED score, longer half-life, and slightly better affinity. However, Ligand A has a significantly lower DILI risk, better BBB penetration, better solubility, and better metabolic stability. Considering the balance, the lower DILI risk and metabolic stability of Ligand A are more critical for a viable drug candidate, especially given the relatively small affinity difference. The better TPSA of Ligand B is a plus, but the other advantages of Ligand A outweigh this.
**Output:**
1
2025-04-17 19:35:57,656 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (337.427 and 367.427 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (64.74) is significantly better than Ligand B (121.53). ADRB2 is a cardiovascular target, not CNS, but lower TPSA generally improves absorption.
3. **logP:** Ligand A (3.354) is optimal, while Ligand B (1.077) is on the lower side, potentially hindering permeability. This favors Ligand A.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (6). Fewer HBAs generally improve permeability.
6. **QED:** Ligand A (0.776) is better than Ligand B (0.642), indicating a more drug-like profile.
7. **DILI:** Ligand A (55.68) is significantly better than Ligand B (86.002). Lower DILI risk is crucial.
8. **BBB:** Not a primary concern for a cardiovascular target. Ligand A (58.782) is better than Ligand B (28.887), but this is less important.
9. **Caco-2:** Ligand A (-4.937) and Ligand B (-5.463) are similar, indicating comparable intestinal absorption.
10. **Solubility:** Ligand A (-2.837) is better than Ligand B (-2.449). Higher solubility is generally desirable.
11. **hERG:** Ligand A (0.745) is better than Ligand B (0.152). Lower hERG inhibition is critical for avoiding cardiotoxicity.
12. **Cl_mic:** Ligand B (24.757) has lower microsomal clearance than Ligand A (37.713), suggesting better metabolic stability. This is a point in favor of Ligand B.
13. **t1/2:** Ligand B (38.603) has a longer half-life than Ligand A (19.3), which is desirable. This is another point in favor of Ligand B.
14. **Pgp:** Ligand A (0.378) is better than Ligand B (0.177). Lower P-gp efflux is favorable.
15. **Affinity:** Both ligands have very similar binding affinities (-6.5 and -5.6 kcal/mol). The 1.5 kcal/mol difference is not enough to outweigh the other significant differences.
**Overall Assessment:**
Ligand A demonstrates a significantly better profile across most critical ADME properties (TPSA, logP, HBD, HBA, QED, DILI, hERG, Solubility, Pgp) and has comparable affinity. While Ligand B has better metabolic stability (Cl_mic) and half-life, the higher DILI risk and poorer permeability-related properties make it less attractive. For a cardiovascular GPCR target, balancing permeability, safety, and drug-likeness is paramount, and Ligand A excels in these areas.
Output:
1
2025-04-17 19:35:57,656 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (346.471 Da) is well within the ideal range (200-500 Da). Ligand B (372.828 Da) is also acceptable. No clear advantage here.
2. **TPSA:** Ligand A (58.64) is excellent, well below the 140 threshold for good absorption. Ligand B (108.55) is still reasonable, but higher. Ligand A is preferred.
3. **logP:** Ligand A (3.384) is optimal. Ligand B (1.006) is a bit low, potentially hindering permeability. Ligand A is preferred.
4. **HBD:** Ligand A (1) is good. Ligand B (3) is acceptable but less ideal. Ligand A is preferred.
5. **HBA:** Ligand A (3) is good. Ligand B (5) is acceptable, but higher. Ligand A is preferred.
6. **QED:** Both ligands (A: 0.734, B: 0.646) are above the 0.5 threshold, indicating good drug-likeness. Ligand A is slightly better.
7. **DILI:** Ligand A (31.02) has a lower DILI risk than Ligand B (35.983), both are acceptable. Ligand A is preferred.
8. **BBB:** Ligand A (87.67) shows good BBB penetration, while Ligand B (54.75) is considerably lower. Given ADRB2's role in cardiovascular function, CNS penetration isn't a primary goal, but it's still a positive attribute. Ligand A is preferred.
9. **Caco-2:** Ligand A (-4.613) and Ligand B (-5.102) are both negative, indicating poor permeability. This is a concern for both, but the difference is small.
10. **Solubility:** Ligand A (-3.455) and Ligand B (-2.236) are both negative, indicating poor solubility. This is a concern for both, but Ligand B is slightly better.
11. **hERG:** Ligand A (0.769) has a lower hERG risk than Ligand B (0.341). Ligand A is preferred.
12. **Cl_mic:** Ligand A (49.023) has a higher clearance than Ligand B (-9.799), meaning Ligand B is more metabolically stable. Ligand B is preferred.
13. **t1/2:** Ligand A (19.969) has a longer half-life than Ligand B (-13.643). Ligand A is preferred.
14. **Pgp:** Ligand A (0.482) has lower P-gp efflux than Ligand B (0.011). Ligand A is preferred.
15. **Binding Affinity:** Ligand A (-7.0) and Ligand B (-5.7) both have good binding affinity, but Ligand A is significantly stronger. This is a major advantage.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical parameters, especially TPSA, logP, BBB, hERG, Pgp, and importantly, binding affinity. While Ligand B has better metabolic stability (lower Cl_mic), the stronger binding affinity of Ligand A, coupled with its more favorable ADME properties, makes it a more promising drug candidate for the ADRB2 receptor. The difference in binding affinity is substantial enough to outweigh the metabolic stability advantage of Ligand B.
Output:
1
2025-04-17 19:35:57,656 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.362 and 346.431 Da) are within the ideal range (200-500 Da). No significant difference here.
2. **TPSA:** Ligand A (88.33) is slightly higher than Ligand B (67.67). Both are below the 140 threshold for oral absorption, but Ligand B is better positioned for potential CNS penetration, although that's less critical for ADRB2.
3. **logP:** Ligand A (1.86) is better than Ligand B (0.787), falling squarely within the optimal 1-3 range. Ligand B is at the lower end, potentially impacting permeability.
4. **HBD:** Ligand A (1) is slightly better than Ligand B (0). Lower is generally preferred for permeability.
5. **HBA:** Both ligands have 5 HBA, which is acceptable.
6. **QED:** Ligand A (0.916) has a significantly higher QED score than Ligand B (0.764), indicating a more drug-like profile.
7. **DILI:** Ligand B (34.471) has a much lower DILI risk than Ligand A (74.021). This is a major advantage for Ligand B.
8. **BBB:** Ligand A (83.56) has slightly better BBB penetration than Ligand B (70.105). However, BBB isn't a primary concern for a cardiovascular target like ADRB2.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.652) is slightly worse than Ligand B (-4.573).
10. **Solubility:** Ligand A (-2.856) has better solubility than Ligand B (0.031).
11. **hERG:** Both ligands have low hERG inhibition risk (0.296 and 0.275).
12. **Cl_mic:** Ligand A (17.719) has significantly lower microsomal clearance than Ligand B (24.008), indicating better metabolic stability.
13. **t1/2:** Ligand A (8.205) has a longer in vitro half-life than Ligand B (3.447).
14. **Pgp:** Both ligands have low Pgp efflux liability (0.033 and 0.065).
15. **Affinity:** Ligand A (-6.9 kcal/mol) has a slightly better binding affinity than Ligand B (-6.7 kcal/mol), though the difference is small.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has a better logP and slightly better affinity. Ligand B has a lower TPSA and significantly lower DILI risk. The Caco-2 values are concerning for both, but the difference isn't substantial.
**Overall Assessment:**
While Ligand B has a much better safety profile (DILI) and a slightly lower TPSA, Ligand A's superior QED, logP, metabolic stability (lower Cl_mic, longer t1/2), and slightly better affinity are more compelling for a cardiovascular GPCR target. The DILI risk for Ligand A is still within an acceptable range. The slightly better solubility of Ligand A is also a plus.
Output:
1
2025-04-17 19:35:57,656 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (344.434 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (50.16) is better than Ligand B (61.92), being closer to the <140 threshold for good oral absorption and more favorable for GPCRs.
3. **logP:** Both ligands have good logP values (around 3), falling within the optimal 1-3 range. Ligand B (3.139) is slightly higher, which could potentially lead to off-target effects, but is not a major concern.
4. **HBD:** Ligand A (1) is preferable to Ligand B (0) as having at least one HBD can improve solubility.
5. **HBA:** Ligand A (3) is preferable to Ligand B (5). Lower HBA is generally better for permeability.
6. **QED:** Ligand A (0.906) has a significantly better QED score than Ligand B (0.714), indicating a more drug-like profile.
7. **DILI:** Ligand B (17.216) has a much lower DILI risk than Ligand A (49.399), which is a significant advantage.
8. **BBB:** Ligand A (83.249) has a slightly better BBB penetration percentile than Ligand B (79.139), but both are acceptable.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. This is a concern for both.
10. **Solubility:** Both ligands have negative solubility values, indicating poor solubility. This is a concern for both.
11. **hERG:** Both ligands have low hERG inhibition liability, which is good. Ligand A (0.765) is slightly higher than Ligand B (0.641), but both are acceptable.
12. **Cl_mic:** Ligand A (39.861) has a lower microsomal clearance than Ligand B (76.566), suggesting better metabolic stability.
13. **t1/2:** Ligand A (17.975) has a longer in vitro half-life than Ligand B (-14.874), which is a significant advantage.
14. **Pgp:** Ligand A (0.268) has lower P-gp efflux liability than Ligand B (0.432), which is favorable for bioavailability.
15. **Affinity:** Ligand A (-8.0) has a slightly better binding affinity than Ligand B (-6.5).
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are particularly important. Both ligands have acceptable logP values. Ligand A has a better TPSA and Pgp profile. The affinity difference is 1.5 kcal/mol, which is a substantial advantage for Ligand A.
**Overall Assessment:**
Ligand A has a better overall profile. It has a better QED score, lower TPSA, lower Pgp efflux, better metabolic stability (lower Cl_mic, longer t1/2), and a significantly better binding affinity. While Ligand B has a lower DILI risk, the advantages of Ligand A in terms of drug-like properties and target engagement outweigh this concern. The poor Caco-2 and solubility for both are concerning, but can be addressed through formulation strategies.
Output:
1
2025-04-17 19:35:57,656 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands (367.921 and 350.463 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (44.81) is significantly better than Ligand B (85.25). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (3.086 and 2.332), falling within the 1-3 optimal range. Ligand A is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD is generally better for permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (5). Lower HBA is generally better for permeability.
6. **QED:** Both are reasonable (0.729 and 0.678), indicating good drug-like properties. No significant difference.
7. **DILI:** Ligand A (11.594) is significantly better than Ligand B (42.148). Lower DILI risk is crucial.
8. **BBB:** Ligand A (91.857) is better than Ligand B (79.333). While not a primary concern for a cardiovascular target, higher BBB is generally favorable.
9. **Caco-2:** Both are negative, suggesting poor permeability. Ligand A (-4.214) is slightly better than Ligand B (-4.528), but both are concerning.
10. **Solubility:** Ligand A (-2.413) is better than Ligand B (-3.75). Better solubility is always preferred.
11. **hERG:** Ligand A (0.802) is better than Ligand B (0.266). Lower hERG inhibition is critical for avoiding cardiotoxicity.
12. **Cl_mic:** Ligand A (42.81) is better than Ligand B (58.916). Lower clearance indicates better metabolic stability.
13. **t1/2:** Ligand A (46.846) is much better than Ligand B (12.295). A longer half-life is desirable.
14. **Pgp:** Ligand A (0.084) is better than Ligand B (0.069). Lower Pgp efflux is better.
15. **Affinity:** Ligand B (-6.6 kcal/mol) is slightly better than Ligand A (-5.9 kcal/mol). This is a 0.7 kcal/mol difference, which is not substantial enough to outweigh the significant ADME advantages of Ligand A.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A has a slightly better logP and Pgp, significantly better TPSA, and a comparable affinity. The ADME profile of Ligand A is substantially superior.
**Conclusion:**
Considering the overall balance of properties, particularly the significantly better ADME profile (DILI, Cl_mic, t1/2, solubility, hERG) and acceptable affinity, Ligand A is the more promising drug candidate. The slight affinity advantage of Ligand B is not enough to overcome the substantial ADME liabilities.
Output:
1
2025-04-17 19:35:57,657 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (369.462 Da and 350.463 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (80.32 and 76.58) are below the 140 A^2 threshold for good oral absorption, and acceptable for a cardiovascular target (not CNS). Ligand B is slightly better.
3. **logP:** Both ligands (1.983 and 1.802) are within the optimal 1-3 range. Again, a small advantage to Ligand B.
4. **HBD:** Ligand A has 2 HBD, and Ligand B has 1. Both are acceptable (<=5). Ligand B is slightly preferred.
5. **HBA:** Ligand A has 5 HBA, and Ligand B has 6. Both are within the acceptable range (<=10).
6. **QED:** Both ligands have high QED scores (0.832 and 0.808), indicating good drug-like properties.
7. **DILI:** Ligand A has a DILI risk of 65.762, while Ligand B is 48.623. Ligand B is significantly better, falling well below the 60% threshold for high risk. This is a crucial advantage.
8. **BBB:** Ligand A has 70.027 and Ligand B has 83.831. While ADRB2 isn't necessarily a CNS target, higher BBB penetration is generally favorable, and Ligand B is better.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.987 and -4.65). This is unusual and suggests poor permeability. However, the values are very close, so this isn't a major differentiator.
10. **Solubility:** Both ligands have negative solubility values (-2.906 and -1.814). This is concerning, as poor solubility can hinder bioavailability. Ligand B is slightly better.
11. **hERG:** Both ligands have low hERG inhibition liability (0.32 and 0.323). This is good, minimizing cardiotoxicity risk.
12. **Cl_mic:** Ligand A has a lower microsomal clearance (10.659) than Ligand B (63.147), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand B has a longer in vitro half-life (17.319 hours) than Ligand A (13.607 hours). This is a positive for Ligand B.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.244 and 0.041). Ligand B is slightly better.
15. **Binding Affinity:** Ligand B has a significantly stronger binding affinity (-7.2 kcal/mol) compared to Ligand A (-6.3 kcal/mol). This >1.5 kcal/mol difference is a major advantage, potentially outweighing some ADME drawbacks.
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand B excels in logP, Pgp, and *especially* affinity. While Ligand A has better metabolic stability (Cl_mic), the substantial binding affinity advantage of Ligand B is more critical. The lower DILI risk for Ligand B is also a significant benefit.
**Conclusion:**
Despite Ligand A's better metabolic stability, Ligand B's superior binding affinity, lower DILI risk, and slightly better overall ADME profile (logP, Pgp, BBB, solubility) make it the more promising drug candidate for the ADRB2 receptor.
Output:
0
2025-04-17 19:35:57,657 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A Analysis:**
* **MW:** 350.365 Da - Good, within the ideal range.
* **TPSA:** 51.66 A^2 - Excellent, well below the 140 A^2 threshold for oral absorption.
* **logP:** 2.7 - Optimal, within the 1-3 range.
* **HBD:** 0 - Acceptable, low number of hydrogen bond donors.
* **HBA:** 5 - Acceptable, within the limit of 10.
* **QED:** 0.685 - Good, above the 0.5 threshold.
* **DILI:** 52.695 - Good, below the 60% risk threshold.
* **BBB:** 82.241 - Very good, indicating reasonable potential for CNS penetration (though not critical for ADRB2, it's not detrimental).
* **Caco-2:** -3.994 - Poor, indicates poor permeability.
* **Solubility:** -2.965 - Poor, indicates low solubility.
* **hERG:** 0.719 - Acceptable, relatively low risk.
* **Cl_mic:** 80.343 - Moderate, could be better for metabolic stability.
* **t1/2:** 3.835 - Moderate, could be improved.
* **Pgp:** 0.404 - Acceptable, relatively low efflux.
* **Affinity:** -5.9 kcal/mol - Good binding affinity.
**Ligand B Analysis:**
* **MW:** 354.407 Da - Good, within the ideal range.
* **TPSA:** 116.84 A^2 - Moderate, higher than ideal but still potentially acceptable.
* **logP:** -0.47 - Suboptimal, potentially hindering permeability.
* **HBD:** 3 - Acceptable, within the limit of 5.
* **HBA:** 5 - Acceptable, within the limit of 10.
* **QED:** 0.362 - Moderate, below the 0.5 threshold.
* **DILI:** 42.807 - Good, below the 60% risk threshold.
* **BBB:** 78.79 - Moderate, indicating limited CNS penetration.
* **Caco-2:** -5.308 - Very poor, indicates very poor permeability.
* **Solubility:** -1.595 - Moderate, indicates low solubility.
* **hERG:** 0.054 - Excellent, very low risk.
* **Cl_mic:** 16.009 - Excellent, very low clearance, indicating high metabolic stability.
* **t1/2:** 2.063 - Poor, short half-life.
* **Pgp:** 0.006 - Excellent, very low efflux.
* **Affinity:** -6.3 kcal/mol - Excellent, stronger binding affinity than Ligand A.
**Comparison and Decision:**
Given that the target is a GPCR (ADRB2), the key priorities are logP, TPSA, Pgp, and affinity. Ligand B has a significantly better binding affinity (-6.3 vs -5.9 kcal/mol), which is a substantial advantage. While Ligand B's logP is lower than ideal, its Pgp efflux is extremely low, which could compensate for some permeability issues. Ligand A has better TPSA, but its Caco-2 and solubility are very poor. Ligand B also has superior metabolic stability (lower Cl_mic). Although Ligand B has a lower QED and shorter half-life, the stronger binding affinity and improved metabolic stability are more critical for a GPCR target. The poor permeability of both compounds is a concern, but the stronger binding of Ligand B gives it a better starting point for optimization.
Output:
0
2025-04-17 19:35:57,657 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (385.848 Da) is within the ideal range, while Ligand B (349.431 Da) is slightly below, but still acceptable.
2. **TPSA:** Ligand A (79.37) is good, below the 140 threshold. Ligand B (91.5) is also acceptable, but closer to the limit.
3. **logP:** Both ligands have good logP values (A: 2.939, B: 1.158), falling within the 1-3 range. Ligand A is slightly preferred here.
4. **HBD:** Ligand A (1) and Ligand B (2) are both acceptable.
5. **HBA:** Both ligands have 4 HBA, which is good.
6. **QED:** Both ligands have reasonable QED scores (A: 0.802, B: 0.7), indicating good drug-likeness. Ligand A is slightly better.
7. **DILI:** Ligand A (85.576) has a significantly higher DILI risk than Ligand B (18.302). This is a major concern for Ligand A.
8. **BBB:** Both ligands have moderate BBB penetration (A: 53.47, B: 61.923). Since ADRB2 is a cardiovascular target, BBB penetration isn't a primary concern, but higher is generally better.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. This is a red flag for both.
10. **Solubility:** Both ligands have negative solubility values, which is also unusual and suggests poor solubility. This is a red flag for both.
11. **hERG:** Both ligands have low hERG inhibition risk (A: 0.422, B: 0.2).
12. **Cl_mic:** Ligand A (61.444) has a higher microsomal clearance than Ligand B (30.176), indicating lower metabolic stability.
13. **t1/2:** Ligand B (-23.25) has a negative in vitro half-life, which is not possible. Ligand A (45.075) has a reasonable half-life.
14. **Pgp:** Both ligands have low Pgp efflux liability (A: 0.251, B: 0.017). Ligand B is slightly better.
15. **Affinity:** Ligand A (-7.3 kcal/mol) has a significantly stronger binding affinity than Ligand B (-5.9 kcal/mol). This is a substantial advantage.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are important. Ligand A is better in terms of logP and significantly better in terms of affinity. While TPSA is acceptable for both, the DILI risk for Ligand A is a major drawback. The negative Caco-2 and solubility values are concerning for both, but the strong affinity of Ligand A might overcome these issues with formulation strategies. The negative half-life for Ligand B is a fatal flaw.
**Conclusion:**
Despite the higher DILI risk and unusual solubility/permeability values, Ligand A's substantially stronger binding affinity outweighs the drawbacks, especially considering the potential for formulation optimization. Ligand B's negative half-life is a non-starter.
Output:
1
2025-04-17 19:35:57,657 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (a cardiovascular GPCR) drug candidates.
**Ligand A:** [348.531, 58.2, 3.506, 2, 2, 0.74, 18.379, 76.619, -4.691, -4.832, 0.459, 85.973, 12.079, 0.133, -5.8]
**Ligand B:** [356.354, 117.57, 1.571, 2, 5, 0.613, 62.35, 72.276, -5.079, -2.902, 0.425, -14.23, -12.841, 0.018, -6.5]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, Affinity, and to a lesser extent BBB):
1. **MW:** Both are within the ideal range (200-500 Da). A is 348.5, B is 356.4. No significant difference.
2. **TPSA:** A (58.2) is excellent, well below 140 and very favorable for oral absorption. B (117.57) is higher, but still acceptable.
3. **logP:** A (3.506) is optimal. B (1.571) is on the lower side, potentially hindering permeability.
4. **HBD/HBA:** Both have 2 HBD, which is good. A has 2 HBA, B has 5. B's higher HBA count could slightly impact permeability.
5. **QED:** Both are reasonably good (A: 0.74, B: 0.613), indicating drug-like properties.
6. **DILI:** A (18.379) is significantly better than B (62.35), indicating a much lower risk of liver injury. This is a major advantage for A.
7. **BBB:** A (76.619) is good, while B (72.276) is also acceptable. Not a primary concern for a cardiovascular target, but A is slightly better.
8. **Caco-2:** Both are negative, indicating poor permeability. A (-4.691) is slightly better than B (-5.079).
9. **Solubility:** Both are negative, indicating poor solubility. A (-4.832) is slightly better than B (-2.902).
10. **hERG:** Both are low (A: 0.459, B: 0.425), indicating low cardiotoxicity risk.
11. **Cl_mic:** A (85.973) is higher, meaning faster clearance and lower metabolic stability. B (-14.23) is *much* better, indicating high metabolic stability. This is a significant advantage for B.
12. **t1/2:** A (12.079) is reasonable. B (-12.841) is very poor.
13. **Pgp:** A (0.133) is much lower, indicating less P-gp efflux and better bioavailability. B (0.018) is very high efflux.
14. **Affinity:** A (-5.8) is slightly better than B (-6.5), although both are excellent.
**Overall Assessment:**
Ligand A has a better balance of properties. While Ligand B has superior metabolic stability (Cl_mic), Ligand A excels in DILI risk, P-gp efflux, logP, and has a slightly better binding affinity. The lower DILI risk and P-gp efflux are particularly important for a cardiovascular drug, as they can improve safety and bioavailability. The slightly better logP of A is also beneficial for membrane permeability. The difference in affinity is small enough that it is outweighed by the other factors.
Therefore, I would choose Ligand A.
Output:
1
2025-04-17 19:35:57,657 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [358.511, 57.26, 2.969, 2, 5, 0.882, 71.152, 66.576, -5.011, -3.385, 0.79, 30.221, 36.654, 0.498, -7]
**Ligand B:** [352.475, 67.87, 1.583, 1, 4, 0.788, 12.641, 83.831, -4.399, -2.181, 0.272, 47.125, -0.706, 0.021, -5.4]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (352.475) is slightly lower, which is generally favorable.
2. **TPSA:** Ligand A (57.26) is better than Ligand B (67.87). Both are acceptable, but lower TPSA generally improves permeability.
3. **logP:** Ligand A (2.969) is optimal, while Ligand B (1.583) is on the lower side. This could impact membrane permeability for Ligand B.
4. **HBD:** Ligand A (2) and Ligand B (1) are both good.
5. **HBA:** Ligand A (5) and Ligand B (4) are both good.
6. **QED:** Both are similar (0.882 and 0.788) and above the 0.5 threshold, indicating good drug-likeness.
7. **DILI:** Ligand A (71.152) has a significantly higher DILI risk than Ligand B (12.641). This is a major concern for Ligand A.
8. **BBB:** Ligand B (83.831) has a better BBB penetration potential than Ligand A (66.576). While not a primary concern for a cardiovascular target, it's a slight advantage.
9. **Caco-2:** Ligand A (-5.011) and Ligand B (-4.399) are both negative, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Ligand A (-3.385) and Ligand B (-2.181) are both negative, indicating poor solubility.
11. **hERG:** Ligand A (0.79) is higher than Ligand B (0.272), suggesting a greater risk of hERG inhibition and potential cardiotoxicity.
12. **Cl_mic:** Ligand A (30.221) has a lower clearance than Ligand B (47.125), indicating better metabolic stability.
13. **t1/2:** Ligand A (36.654) has a longer half-life than Ligand B (-0.706). This is a significant advantage for dosing convenience.
14. **Pgp:** Ligand A (0.498) has lower P-gp efflux than Ligand B (0.021), which is favorable for bioavailability.
15. **Affinity:** Ligand A (-7) has a slightly better binding affinity than Ligand B (-5.4).
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are crucial. Ligand A has a better logP and Pgp, and slightly better affinity. However, the significantly higher DILI risk and hERG inhibition liability of Ligand A are major drawbacks. The longer half-life is a plus, but can't outweigh the toxicity concerns. Ligand B, despite having a slightly lower affinity and logP, presents a much safer profile with a significantly lower DILI and hERG risk.
**Conclusion:**
Considering the balance of properties and the critical need for a safe profile in a cardiovascular drug, Ligand B is the more promising candidate. The lower DILI and hERG risks outweigh the slightly lower affinity and logP.
Output:
0
2025-04-17 19:35:57,658 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (343.43 & 350.46 Da) fall comfortably within the 200-500 Da ideal range. No significant difference here.
2. **TPSA:** Both ligands (78.19 & 78.68) are below 140, suggesting good oral absorption potential.
3. **logP:** Ligand A (3.659) is optimal, while Ligand B (1.445) is on the lower side. For a GPCR, a slightly higher logP is generally preferred for membrane permeability, giving an edge to Ligand A.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable.
5. **HBA:** Ligand A (3) and Ligand B (5) are both acceptable, but Ligand B is slightly higher.
6. **QED:** Both ligands (0.829 & 0.729) have good drug-likeness scores, exceeding the 0.5 threshold.
7. **DILI:** Ligand A (62.35) has a moderate DILI risk, while Ligand B (12.641) has a very low risk. This is a significant advantage for Ligand B.
8. **BBB:** Both ligands (54.866 & 61.38) have moderate BBB penetration. Since ADRB2 is a cardiovascular target, BBB penetration is not a primary concern, but a higher value is still slightly favorable.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Both ligands have negative solubility values, which is also unusual. Again, the scale is not specified, making interpretation difficult.
11. **hERG:** Ligand A (0.591) has a slightly higher hERG risk than Ligand B (0.217), making Ligand B safer from a cardiotoxicity perspective.
12. **Cl_mic:** Ligand A (37.809) has a higher microsomal clearance than Ligand B (12.421), indicating lower metabolic stability. Ligand B is preferable here.
13. **t1/2:** Ligand B (17.897) has a longer in vitro half-life than Ligand A (13.349), which is beneficial for dosing frequency.
14. **Pgp:** Ligand A (0.263) has lower P-gp efflux than Ligand B (0.018), which is preferable.
15. **Binding Affinity:** Ligand B (-7.0 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.5 kcal/mol). This 1.5 kcal/mol difference is substantial and can outweigh minor ADME drawbacks.
**Overall Assessment:**
Ligand B demonstrates a superior profile overall. While Ligand A has a slightly better logP and Pgp efflux, Ligand B excels in crucial areas: significantly stronger binding affinity, lower DILI risk, lower hERG risk, and improved metabolic stability (lower Cl_mic and longer t1/2). The lower DILI and hERG risks are particularly important for a cardiovascular target. The substantial binding affinity difference is the most decisive factor.
Output:
0
2025-04-17 19:35:57,658 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (349.431 and 344.415 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (78.95) is better than Ligand B (80.37). Both are below the 140 A^2 threshold for oral absorption, but closer to the ideal for GPCRs.
**3. logP:** Ligand A (0.98) is slightly lower than Ligand B (1.992), but both are within the optimal 1-3 range. Ligand B is better here.
**4. H-Bond Donors:** Both ligands have 1 HBD, which is good.
**5. H-Bond Acceptors:** Ligand A has 4 HBAs, and Ligand B has 5. Both are acceptable, below the 10 threshold.
**6. QED:** Ligand B (0.92) has a higher QED score than Ligand A (0.771), indicating a more drug-like profile. This is a significant advantage.
**7. DILI:** Ligand A (30.399) has a lower DILI risk than Ligand B (45.25), which is a major advantage. Lower DILI is crucial.
**8. BBB:** Ligand A (80.419) has a significantly higher BBB penetration percentile than Ligand B (68.631). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant for off-target effects and a higher BBB score is generally favorable.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual. It suggests poor permeability. Ligand A (-4.587) is slightly better than Ligand B (-4.897).
**10. Aqueous Solubility:** Both ligands have negative solubility values, indicating poor solubility. Ligand A (-1.71) is slightly better than Ligand B (-2.428).
**11. hERG Inhibition:** Ligand A (0.242) has a much lower hERG inhibition risk than Ligand B (0.317). This is a critical safety parameter.
**12. Microsomal Clearance:** Ligand A (45.502) has a higher microsomal clearance than Ligand B (30.164), meaning faster metabolism and potentially lower exposure. Ligand B is better here.
**13. In vitro Half-Life:** Ligand B (-21.275) has a much longer in vitro half-life than Ligand A (-4.7). This is a significant advantage for dosing frequency.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.025 and 0.185 respectively). No significant difference.
**15. Binding Affinity:** Ligand A (-7.9 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.6 kcal/mol). This is a substantial advantage, potentially outweighing some ADME drawbacks.
**Overall Assessment:**
While Ligand B has a better QED and half-life, Ligand A wins out due to its significantly better binding affinity, lower DILI risk, and lower hERG risk. The higher BBB penetration is also a bonus. The slightly poorer metabolic stability of Ligand A can be addressed through structural modifications if needed, but the strong affinity is a key starting point. The solubility and permeability issues are concerning for both, but can be addressed through formulation strategies.
Output:
1
2025-04-17 19:35:57,658 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
We are targeting ADRB2, a GPCR, so the priorities are logP, Pgp, TPSA, BBB, and affinity. Let's break down the comparison:
1. **Molecular Weight:** Both ligands (350.415 and 348.447 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand B (83.56) is significantly better than Ligand A (103.01). Lower TPSA is preferred for better cell permeability, and crucial for GPCRs.
3. **logP:** Ligand B (1.681) is within the optimal 1-3 range, while Ligand A (0.31) is quite low. This is a major drawback for Ligand A, as it may struggle with membrane permeability.
4. **H-Bond Donors:** Ligand A (3) is slightly higher than Ligand B (2), but both are acceptable.
5. **H-Bond Acceptors:** Both ligands have 5 HBA, which is acceptable.
6. **QED:** Both ligands have similar QED values (0.657 and 0.629), indicating good drug-likeness.
7. **DILI:** Ligand A (11.283) has a much lower DILI risk than Ligand B (49.283), which is a significant advantage.
8. **BBB:** Ligand B (62.117) has a better BBB penetration percentile than Ligand A (44.397), which is good for a GPCR, but not crucial for ADRB2 specifically.
9. **Caco-2:** Ligand A (-5.196) and Ligand B (-4.826) are both poor, suggesting limited intestinal absorption.
10. **Solubility:** Ligand A (-0.796) is better than Ligand B (-2.137).
11. **hERG:** Ligand A (0.158) has a lower hERG inhibition liability than Ligand B (0.505), which is a positive.
12. **Cl_mic:** Ligand A (-20.835) has a much lower (better) microsomal clearance than Ligand B (36.867), indicating better metabolic stability.
13. **t1/2:** Ligand B (40.775) has a longer in vitro half-life than Ligand A (15.677), which is desirable.
14. **Pgp:** Ligand A (0.014) has much lower P-gp efflux liability than Ligand B (0.049), which is favorable for bioavailability.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.5 and -6.6 kcal/mol). The difference is negligible.
**Overall Assessment:**
Ligand B has advantages in BBB penetration and in vitro half-life. However, Ligand A is superior in several critical areas: logP (much better for permeability), DILI risk (significantly lower), Cl_mic (better metabolic stability), and Pgp efflux (lower). The low logP of Ligand A is a major concern, but the other advantages, particularly the lower DILI and better metabolic stability, outweigh this drawback, especially considering the similar binding affinities. The TPSA of Ligand B is also a significant advantage.
**Output:**
0
2025-04-17 19:35:57,658 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (349.406) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (82.53) is significantly better than Ligand B (113.44). For a GPCR, a lower TPSA is preferred for better permeability.
3. **logP:** Ligand A (3.069) is optimal, while Ligand B (0.542) is quite low. A logP below 1 can hinder permeation. This is a significant advantage for Ligand A.
4. **HBD:** Both are acceptable (Ligand A: 2, Ligand B: 3).
5. **HBA:** Both are acceptable (Ligand A: 4, Ligand B: 7).
6. **QED:** Both are reasonably good (Ligand A: 0.819, Ligand B: 0.675), indicating drug-like properties. Ligand A is better.
7. **DILI:** Both have acceptable DILI risk (Ligand A: 52.617, Ligand B: 47.926). Ligand B is slightly better here, but the difference is small.
8. **BBB:** Ligand A (78.79) is considerably better than Ligand B (43.893). While ADRB2 isn't necessarily a CNS target, some degree of BBB penetration can be useful for peripheral distribution and avoiding off-target effects.
9. **Caco-2:** Ligand A (-4.57) is better than Ligand B (-5.531), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-3.416) is better than Ligand B (-1.337).
11. **hERG:** Both have low hERG inhibition liability (Ligand A: 0.364, Ligand B: 0.075). Ligand B is slightly better.
12. **Cl_mic:** Ligand B (-13.812) has significantly lower microsomal clearance than Ligand A (25.304), suggesting better metabolic stability. This is a strong point for Ligand B.
13. **t1/2:** Ligand B (21.786) has a longer in vitro half-life than Ligand A (-33.19), which is a significant advantage.
14. **Pgp:** Both have low P-gp efflux liability (Ligand A: 0.095, Ligand B: 0.018). Ligand B is slightly better.
15. **Binding Affinity:** Ligand A (-7.2) has a slightly better binding affinity than Ligand B (-5.3). While both are good, the 1.9 kcal/mol difference is substantial and can outweigh other minor drawbacks.
**Overall Assessment:**
Ligand A excels in key areas for a GPCR target: TPSA, logP, solubility, Caco-2 permeability, BBB penetration, and, crucially, binding affinity. Ligand B has better metabolic stability (Cl_mic and t1/2) and slightly better Pgp and hERG profiles. However, the significantly lower logP of Ligand B is a major concern, potentially hindering its ability to cross cell membranes and reach the target. The superior binding affinity of Ligand A, combined with its more favorable physicochemical properties, makes it the more promising candidate despite the slightly higher Cl_mic.
Output:
1
2025-04-17 19:35:57,658 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (336.391) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (67.43) is significantly better than Ligand B (96.53). For a GPCR, keeping TPSA low is beneficial for permeability and receptor engagement. Ligand B is pushing the upper limit for good oral absorption.
3. **logP:** Ligand A (3.396) is optimal, while Ligand B (1.443) is a bit low. A logP between 1-3 is preferred, and Ligand B might have issues with membrane permeability.
4. **HBD:** Ligand A (2) is preferable to Ligand B (3). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (4). Similar reasoning as HBD.
6. **QED:** Ligand A (0.823) is better than Ligand B (0.663), indicating a more drug-like profile.
7. **DILI:** Ligand B (39.201) has a much lower DILI risk than Ligand A (78.488). This is a significant advantage for Ligand B.
8. **BBB:** Both ligands have good BBB penetration (Ligand A: 71.888, Ligand B: 70.648). Since ADRB2 isn't exclusively a CNS target, this isn't a deciding factor, but it's positive for both.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale isn't specified, so it's hard to interpret.
10. **Solubility:** Ligand A (-5.446) has better solubility than Ligand B (-3.174). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.538) has a lower hERG risk than Ligand B (0.13). This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand B (40.393) has slightly better metabolic stability (lower clearance) than Ligand A (34.289).
13. **t1/2:** Ligand A (6.51) has a much longer half-life than Ligand B (-19.967). This is a major advantage for Ligand A, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.228) has lower P-gp efflux than Ligand B (0.025), which is favorable for bioavailability.
15. **Affinity:** Both ligands have very similar binding affinities (-8 kcal/mol and -7 kcal/mol respectively). The difference is negligible.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A excels in logP and TPSA, and has better Pgp efflux. While Ligand B has a lower DILI risk, the superior ADME properties of Ligand A, particularly its TPSA, logP, and half-life, outweigh this concern. The similar binding affinities make the ADME profile the deciding factor.
**Conclusion:**
Ligand A presents a more balanced and favorable profile for development as a drug candidate targeting ADRB2.
Output:
1
2025-04-17 19:35:57,659 - INFO - Batch 122 complete. Total preferences: 1952
2025-04-17 19:35:57,659 - INFO - Processing batch 123/512...
2025-04-17 19:36:47,365 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (368.5 and 390.5 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Both ligands (93.01 and 92.78) are below the 140 A^2 threshold for good oral absorption, and acceptable for a non-CNS GPCR target like ADRB2. They are very similar.
3. **logP:** Ligand A (0.843) is slightly higher than Ligand B (0.603), placing it closer to the optimal 1-3 range. Ligand B is a bit low, potentially impacting permeability.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 7 HBA, while Ligand B has 6. Both are within the acceptable range of <=10.
6. **QED:** Both ligands have similar QED values (0.694 and 0.61), indicating reasonable drug-likeness.
7. **DILI:** Ligand A (37.73%) has a slightly higher DILI risk than Ligand B (33.50%), but both are below the concerning 60% threshold.
8. **BBB:** Ligand A (71.89%) has a significantly higher BBB penetration percentile than Ligand B (59.64%). While ADRB2 isn't a primary CNS target, some degree of BBB penetration isn't necessarily detrimental and could offer some off-target safety information.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.119 and -5.051). These values are unusual and suggest very poor permeability. This is a significant concern for both.
10. **Solubility:** Both ligands have very poor aqueous solubility (-1.934 and -2.81). This is a major drawback for both.
11. **hERG:** Ligand A (0.026) has a much lower hERG inhibition liability than Ligand B (0.212), which is a significant safety advantage.
12. **Cl_mic:** Ligand A (72.654) has a higher microsomal clearance than Ligand B (63.004), suggesting lower metabolic stability.
13. **t1/2:** Ligand B (-56.416) has a significantly longer in vitro half-life than Ligand A (-30.098). This is a major advantage for Ligand B.
14. **Pgp:** Ligand A (0.048) has lower P-gp efflux liability than Ligand B (0.017). Lower Pgp is generally preferred.
15. **Binding Affinity:** Ligand B (-7.2 kcal/mol) has a stronger binding affinity than Ligand A (-6.4 kcal/mol). This is a substantial advantage (1.8 kcal/mol difference), and can often outweigh other drawbacks.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand B has a better affinity, lower Pgp efflux, and a reasonable TPSA. While its logP is a little low, the affinity difference is substantial. The poor Caco-2 and solubility are concerning for both, but the stronger binding of Ligand B is a significant advantage. The longer half-life of Ligand B is also a positive.
**Conclusion:**
Despite the poor permeability and solubility of both compounds, Ligand B's significantly stronger binding affinity and longer half-life outweigh the slightly higher DILI risk and lower BBB penetration compared to Ligand A. The hERG risk is also lower for Ligand A, but the affinity difference is more critical for a GPCR target.
Output:
0
2025-04-17 19:36:47,366 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.463 and 346.431 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (76.46) is better than Ligand B (91.4). ADRB2 is a cardiovascular target, so CNS penetration isn't critical, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (2.502) is better than Ligand B (1.095). Both are within the optimal 1-3 range, but Ligand A is closer to the sweet spot.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (4). Fewer HBAs generally improve permeability.
6. **QED:** Ligand A (0.905) is significantly better than Ligand B (0.807), indicating a more drug-like profile.
7. **DILI:** Ligand A (44.281) is slightly higher than Ligand B (39.822), but both are well below the concerning threshold of 60. Ligand B is slightly better here.
8. **BBB:** Ligand A (76.347) is much better than Ligand B (40.791). While not a CNS target, higher BBB penetration can sometimes correlate with better overall distribution.
9. **Caco-2:** Ligand A (-4.432) is better than Ligand B (-4.948). Higher values indicate better absorption.
10. **Solubility:** Ligand A (-2.285) is better than Ligand B (-1.866). Higher solubility is generally desirable.
11. **hERG:** Both ligands (0.287 and 0.055) have very low hERG inhibition risk, which is excellent.
12. **Cl_mic:** Ligand B (-7.278) has a *much* lower (better) microsomal clearance than Ligand A (39.334). This suggests significantly improved metabolic stability for Ligand B.
13. **t1/2:** Ligand B (12.696) has a significantly longer in vitro half-life than Ligand A (1.58). This is a major advantage.
14. **Pgp:** Both ligands (0.054 and 0.007) have very low P-gp efflux liability, which is excellent.
15. **Binding Affinity:** Ligand A (-7.3) has a slightly better binding affinity than Ligand B (-6.3). This is a 1.0 kcal/mol difference, which is significant.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand A excels in logP and affinity, and is better in TPSA. However, Ligand B has a *much* better metabolic profile (Cl_mic and t1/2). While affinity is important, metabolic stability is crucial for *in vivo* efficacy. A slightly lower affinity can be overcome with a longer half-life and reduced clearance.
**Overall Assessment:**
Ligand A has a slight edge in binding affinity and drug-likeness (QED), but Ligand B's superior metabolic stability (lower Cl_mic, longer t1/2) is a more critical advantage for a cardiovascular drug. The better solubility and DILI profile of Ligand B also contribute to its overall favorability.
Output:
0
2025-04-17 19:36:47,366 - INFO - Here's a step-by-step reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [344.499, 49.41, 3.136, 1, 2, 0.615, 22.489, 67.701, -4.695, -3.144, 0.392, 40.341, -13.123, 0.185, -4.4]**
**Ligand B: [377.539, 82.96, 3.753, 3, 8, 0.527, 79.333, 46.724, -5.506, -3.498, 0.821, 75.451, 85.226, 0.498, -5.7]**
1. **Molecular Weight:** Both are within the ideal range (200-500 Da). Ligand A (344.499) is slightly preferred as it's closer to the lower end, potentially aiding permeability.
2. **TPSA:** Ligand A (49.41) is excellent, well below 140 and suitable for good oral absorption. Ligand B (82.96) is higher, but still acceptable.
3. **logP:** Both ligands have good logP values (A: 3.136, B: 3.753) falling within the optimal 1-3 range.
4. **H-Bond Donors:** Ligand A (1) is better than Ligand B (3). Fewer HBDs generally improve permeability.
5. **H-Bond Acceptors:** Ligand A (2) is significantly better than Ligand B (8). Lower HBA is preferred for permeability.
6. **QED:** Both are reasonable, but Ligand A (0.615) is better than Ligand B (0.527), indicating a more drug-like profile.
7. **DILI:** Ligand A (22.489) has a much lower DILI risk than Ligand B (79.333). This is a significant advantage.
8. **BBB:** Ligand A (67.701) has a better BBB percentile than Ligand B (46.724), though neither are exceptionally high. As ADRB2 is a GPCR, some CNS penetration could be beneficial, but is not critical.
9. **Caco-2:** Ligand A (-4.695) is better than Ligand B (-5.506). Higher Caco-2 permeability is preferred.
10. **Solubility:** Both have poor aqueous solubility (-3.144 and -3.498 respectively). This is a concern for both, but not a deciding factor.
11. **hERG:** Ligand A (0.392) has a lower hERG risk than Ligand B (0.821). This is a significant safety advantage.
12. **Cl_mic:** Ligand A (40.341) has a lower microsomal clearance than Ligand B (75.451), suggesting better metabolic stability.
13. **t1/2:** Ligand B (85.226) has a significantly longer in vitro half-life than Ligand A (-13.123). This is a strong advantage for Ligand B.
14. **Pgp:** Ligand A (0.185) has lower P-gp efflux than Ligand B (0.498), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand B (-5.7) has a slightly better binding affinity than Ligand A (-4.4). This is a 1.3 kcal/mol difference, which is significant, but needs to be weighed against other factors.
**Overall Assessment:**
Ligand A has a significantly better safety profile (lower DILI, lower hERG), better ADME properties (lower Cl_mic, better Pgp efflux, better Caco-2), and a more drug-like QED score. While Ligand B has a slightly better binding affinity and longer half-life, the advantages of Ligand A in terms of safety and ADME are more critical, particularly for a cardiovascular target where off-target effects and metabolic stability are paramount. The difference in binding affinity, while present, is not large enough to overcome the substantial advantages of Ligand A.
Output:
1
2025-04-17 19:36:47,366 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (340.379 and 349.439 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (77.52) is well below the 140 threshold and good for oral absorption, and is preferable to Ligand B (96.25).
3. **logP:** Ligand A (1.975) is within the optimal 1-3 range. Ligand B (-0.571) is slightly below 1, which *could* indicate permeability issues, though not drastically.
4. **HBD:** Both ligands have 1 HBD, which is acceptable.
5. **HBA:** Ligand A (5) is good. Ligand B (7) is slightly higher, but still within the acceptable range of <=10.
6. **QED:** Both ligands have reasonable QED scores (0.842 and 0.782), indicating good drug-likeness.
7. **DILI:** Ligand A (85.459) has a significantly higher DILI risk than Ligand B (30.942). This is a major concern for Ligand A.
8. **BBB:** Both ligands have moderate BBB penetration (56.805 and 50.795). Since ADRB2 is a cardiovascular target, BBB penetration is not a high priority, but lower is preferable.
9. **Caco-2:** Ligand A (-4.712) and Ligand B (-5.376) both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
10. **Solubility:** Ligand A (-3.229) and Ligand B (-0.016) both have negative solubility values, which is also unusual and suggests poor solubility.
11. **hERG:** Ligand A (0.243) has a slightly higher hERG risk than Ligand B (0.05).
12. **Cl_mic:** Ligand B (-3.857) has a lower (better) microsomal clearance than Ligand A (50.888), indicating better metabolic stability.
13. **t1/2:** Ligand B (13.329) has a significantly longer in vitro half-life than Ligand A (-9.263). This is a major advantage for Ligand B.
14. **Pgp:** Ligand A (0.13) has lower P-gp efflux than Ligand B (0.011), which is slightly better.
15. **Affinity:** Ligand B (-7.0) has a slightly better binding affinity than Ligand A (-6.8), although the difference is small.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A has a better logP and Pgp, but Ligand B has a better TPSA and slightly better affinity. The significant advantage of Ligand B is its much lower DILI risk and longer half-life, which are crucial for a viable drug candidate.
**Conclusion:**
Despite Ligand A's slightly better logP and Pgp, the significantly lower DILI risk, better metabolic stability (lower Cl_mic), and longer half-life of Ligand B make it the more promising drug candidate. The negative Caco-2 and solubility values are concerning for both, but the other advantages of Ligand B outweigh these concerns.
Output:
0
2025-04-17 19:36:47,366 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (370.471 and 350.459 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Both ligands have TPSA values (88.1 and 84.5) below the 140 A^2 threshold for good oral absorption. They are also reasonably low, which is good for GPCRs. Ligand B is slightly better.
**3. logP:** Ligand A (0.593) is quite low, potentially hindering membrane permeability. Ligand B (1.941) is much better, falling within the optimal 1-3 range. This is a significant advantage for Ligand B.
**4. H-Bond Donors:** Both have 2 HBD, which is acceptable.
**5. H-Bond Acceptors:** Ligand A has 6 HBA, while Ligand B has 4. Both are within the acceptable range of <=10.
**6. QED:** Both have reasonable QED values (0.762 and 0.566), indicating good drug-like properties. Ligand A is slightly better.
**7. DILI Risk:** Ligand A (17.449%) has a much lower DILI risk than Ligand B (33.773%). This is a substantial advantage for Ligand A.
**8. BBB Penetration:** Ligand A (73.943%) shows better BBB penetration than Ligand B (46.84%). While ADRB2 is a cardiovascular target, some CNS effects are possible with beta-blockers, and higher BBB penetration could be relevant for off-target effects.
**9. Caco-2 Permeability:** Ligand A (-5.444) has a worse Caco-2 permeability than Ligand B (-4.712).
**10. Aqueous Solubility:** Ligand A (-1.349) and Ligand B (-2.351) are both poor in aqueous solubility.
**11. hERG Inhibition:** Ligand A (0.701) has a lower hERG inhibition liability than Ligand B (0.096). This is a significant advantage for Ligand A, reducing the risk of cardiotoxicity.
**12. Microsomal Clearance:** Ligand A (-8.204) has a much lower microsomal clearance, indicating better metabolic stability, than Ligand B (52.021). This is a major advantage for Ligand A.
**13. In vitro Half-Life:** Ligand A (-2.72) has a better in vitro half-life than Ligand B (-10.957).
**14. P-gp Efflux:** Ligand A (0.068) has lower P-gp efflux than Ligand B (0.037).
**15. Binding Affinity:** Ligand A (-6.7 kcal/mol) has a slightly better binding affinity than Ligand B (-3.8 kcal/mol). The difference is substantial (2.9 kcal/mol), and this is a critical factor.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand A is the better candidate. While Ligand B has a better logP, Ligand A's significantly superior binding affinity, lower DILI risk, better BBB penetration, lower hERG inhibition, and improved metabolic stability outweigh this advantage. The lower clearance and longer half-life of Ligand A are also highly desirable. The solubility is poor for both, but can be addressed with formulation strategies.
Output:
1
2025-04-17 19:36:47,366 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (364.379 and 355.454 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (70.67) is significantly better than Ligand A (116.92). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have acceptable logP values (2.132 and 1.0), falling within the 1-3 range. Ligand B is slightly lower, which could be a minor drawback.
4. **HBD:** Both have 2 HBD, which is good.
5. **HBA:** Ligand A has 5 HBA, and Ligand B has 4. Both are acceptable, below the 10 threshold.
6. **QED:** Ligand A (0.862) has a better QED score than Ligand B (0.746), indicating a more drug-like profile.
7. **DILI:** Ligand A (95.89) has a very high DILI risk, which is a significant concern. Ligand B (16.014) has a very low DILI risk, a major advantage.
8. **BBB:** Ligand B (74.447) has a higher BBB penetration than Ligand A (17.138). While not critical for a cardiovascular target, higher BBB is generally a positive.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
10. **Solubility:** Both have negative solubility values, which is also unusual and suggests poor solubility.
11. **hERG:** Ligand A (0.043) has a slightly better hERG profile than Ligand B (0.22), but both are very low risk.
12. **Cl_mic:** Ligand B (-16.469) has a much lower (better) microsomal clearance than Ligand A (8.307), indicating greater metabolic stability.
13. **t1/2:** Ligand B (14.732) has a longer in vitro half-life than Ligand A (63.501).
14. **Pgp:** Ligand A (0.031) has a lower Pgp efflux liability than Ligand B (0.013), which is slightly favorable.
15. **Binding Affinity:** Ligand A (-6.8 kcal/mol) has a slightly better binding affinity than Ligand B (-5.8 kcal/mol). This is a 1.0 kcal/mol difference, which is significant but not overwhelming.
**GPCR-Specific Priorities & Overall Assessment:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Ligand A has slightly better affinity and Pgp, but Ligand B excels in TPSA, DILI risk, Cl_mic, and t1/2. The extremely high DILI risk associated with Ligand A is a deal-breaker. Even with slightly better affinity, the safety concerns outweigh the benefit. Ligand B's improved metabolic stability and lower toxicity profile are more desirable.
**Output:**
0
2025-04-17 19:36:47,367 - INFO - Here's my reasoning and output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
Let's break down the comparison, prioritizing GPCR-relevant parameters (logP, TPSA, Pgp, BBB, and affinity).
1. **Molecular Weight:** Both ligands are within the acceptable range (200-500 Da). Ligand B (345.418 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (35.58) is significantly better than Ligand B (53.51). A TPSA under 140 is good for oral absorption, and both are, but lower is better, especially for potential CNS effects (though ADRB2 isn't strictly a CNS target).
3. **logP:** Ligand A (4.478) is higher than the optimal range (1-3), potentially causing solubility issues and off-target interactions. Ligand B (1.822) is within the ideal range. This is a significant advantage for Ligand B.
4. **H-Bond Donors/Acceptors:** Both have reasonable HBD/HBA counts. Ligand A has 1 HBD and 3 HBA, while Ligand B has 0 HBD and 3 HBA. This difference isn't a major deciding factor.
5. **QED:** Both ligands have similar QED scores (0.858 and 0.818), indicating good drug-likeness.
6. **DILI:** Ligand B (20.861) has a much lower DILI risk than Ligand A (39.201). This is a crucial advantage, as liver toxicity is a major concern in drug development.
7. **BBB:** Both ligands show high BBB penetration (90.733 and 91.508). This isn't a primary concern for ADRB2, but it doesn't hurt.
8. **Caco-2 Permeability:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. This is a potential issue for both.
9. **Aqueous Solubility:** Both have negative solubility values, suggesting poor solubility. This is a concern, but can be addressed with formulation strategies.
10. **hERG Inhibition:** Ligand B (0.248) has a significantly lower hERG inhibition risk than Ligand A (0.925). This is a critical advantage, as hERG inhibition can lead to cardiotoxicity.
11. **Microsomal Clearance:** Ligand B (20.151) has much lower microsomal clearance than Ligand A (40.292), indicating better metabolic stability.
12. **In vitro Half-Life:** Ligand A (65.999) has a longer half-life than Ligand B (-3.776). This is a positive for Ligand A, potentially allowing for less frequent dosing. However, the negative value for Ligand B is concerning and may indicate instability in the assay.
13. **P-gp Efflux:** Both ligands have similar P-gp efflux liability (0.406 and 0.034).
14. **Binding Affinity:** Ligand B (-6.6 kcal/mol) has a slightly better binding affinity than Ligand A (-6.0 kcal/mol). While the difference is less than the 1.5kcal/mol threshold, it's still a positive.
**Overall Assessment:**
Ligand B is the stronger candidate. While Ligand A has a longer half-life, Ligand B excels in crucial areas like DILI risk, hERG inhibition, logP, and metabolic stability. The lower logP and DILI risk are particularly important. The negative Caco-2 and solubility values are concerns for both, but formulation strategies can potentially mitigate these. The slightly better affinity of Ligand B further supports its selection.
Output:
0
2025-04-17 19:36:47,367 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (368-385 Da). No significant difference.
2. **TPSA:** Ligand A (52.57) is slightly higher than Ligand B (42.43). Both are below the 140 threshold for oral absorption, but B is better.
3. **logP:** Both are good (around 4.0-4.36). No major difference.
4. **HBD:** Ligand A (2) is better than Ligand B (0). A small number of HBDs is generally preferred for balance.
5. **HBA:** Ligand A (2) is better than Ligand B (4). Lower is better.
6. **QED:** Both are reasonable (0.791 and 0.695), indicating good drug-likeness.
7. **DILI:** Both have similar, acceptable DILI risk (around 18-19%).
8. **BBB:** Both have high BBB penetration (90.384 and 93.563). This is good, but less critical for ADRB2 as it's not a CNS target.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Both have negative solubility values, which is also unusual and suggests poor solubility. This is a significant concern for both.
11. **hERG:** Both have low hERG inhibition risk (0.844 and 0.703).
12. **Cl_mic:** Ligand A (12.5) has significantly lower microsomal clearance than Ligand B (110.828), indicating better metabolic stability. This is a major advantage.
13. **t1/2:** Ligand A (57.274) has a much longer in vitro half-life than Ligand B (-10.897). This is a substantial advantage.
14. **Pgp:** Both have low Pgp efflux liability (0.549 and 0.353).
15. **Binding Affinity:** Ligand B (-7.3) has slightly better binding affinity than Ligand A (-7.2). However, the difference is small (0.1 kcal/mol).
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Both ligands perform similarly on logP and Pgp. Ligand B has slightly better affinity, but Ligand A has better TPSA, and *significantly* better metabolic stability (Cl_mic) and half-life. The poor Caco-2 and solubility are concerning for both, but the improved PK profile of A is more valuable.
**Conclusion:**
Despite the slightly better affinity of Ligand B, the significantly improved metabolic stability and half-life of Ligand A make it the more promising drug candidate. The poor Caco-2 and solubility will need to be addressed in either case, but a better PK profile provides a stronger foundation for optimization.
Output:
1
2025-04-17 19:36:47,367 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [349.387, 93.37, 0.667, 1, 6, 0.602, 46.801, 65.297, -4.817, -1.027, 0.226, 9.806, 15.025, 0.051, -6.5]
**Ligand B:** [353.348, 61.36, 1.447, 1, 5, 0.902, 88.639, 83.521, -4.568, -3.646, 0.719, 52.536, 20.377, 0.101, -5.7]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity, and to a lesser extent BBB):
1. **MW:** Both are within the ideal range (200-500 Da). A is 349.39, B is 353.35 - very similar.
2. **TPSA:** A (93.37) is slightly higher than B (61.36). B is significantly better, being well below the 140 threshold for oral absorption and closer to the ideal for GPCRs.
3. **logP:** A (0.667) is a bit low, potentially hindering permeability. B (1.447) is better, falling within the optimal 1-3 range.
4. **HBD/HBA:** Both have 1 HBD, which is good. A has 6 HBA, B has 5. Both are acceptable.
5. **QED:** B (0.902) is significantly better than A (0.602), indicating a more drug-like profile.
6. **DILI:** A (46.801) is much better than B (88.639). This is a significant advantage for A.
7. **BBB:** A (65.297) is lower than B (83.521). While not a primary concern for a cardiovascular target, higher BBB is generally favorable.
8. **Caco-2:** Both are negative, indicating poor permeability. A (-4.817) is worse than B (-4.568).
9. **Solubility:** A (-1.027) is worse than B (-3.646). Solubility is a concern for both, but B is better.
10. **hERG:** A (0.226) is much better than B (0.719), indicating lower cardiotoxicity risk.
11. **Cl_mic:** A (9.806) is much lower than B (52.536), suggesting better metabolic stability.
12. **t1/2:** B (20.377) has a longer half-life than A (15.025).
13. **Pgp:** A (0.051) is much lower than B (0.101), indicating less P-gp efflux and potentially better bioavailability.
14. **Affinity:** A (-6.5) is slightly better than B (-5.7), but the difference is less than 1.5 kcal/mol.
**Overall Assessment:**
Ligand B has a better TPSA, logP, QED, BBB, and half-life. However, it suffers from significantly higher DILI risk, higher hERG inhibition, and higher P-gp efflux. Ligand A has a better DILI profile, lower hERG, lower P-gp, and better metabolic stability. The affinity difference is small.
Given the cardiovascular target and the importance of minimizing off-target effects (especially cardiotoxicity), the lower DILI and hERG risk of Ligand A are crucial. The slightly better affinity isn't enough to overcome the ADME/Tox liabilities of Ligand B.
Output:
1
2025-04-17 19:36:47,367 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for their potential as drug candidates targeting the ADRB2, a cardiovascular GPCR. Therefore, the GPCR-specific priorities (logP, Pgp, TPSA, and affinity) are crucial.
Let's compare the ligands property by property:
1. **MW:** Both ligands (348.45 & 377.91 Da) fall within the ideal range of 200-500 Da.
2. **TPSA:** Both are acceptable (96.25 & 90.55), being below the 140 threshold for oral absorption.
3. **logP:** Ligand A (1.392) is optimal, while Ligand B (3.797) is pushing the upper limit but still acceptable.
4. **HBD/HBA:** Ligand A (3 HBD, 5 HBA) is slightly better than Ligand B (4 HBD, 7 HBA) in terms of balancing solubility and permeability.
5. **QED:** Ligand A (0.724) has a significantly better QED score than Ligand B (0.5), indicating better overall drug-likeness.
6. **DILI:** Ligand A (47.964) has a much lower DILI risk than Ligand B (76.464), a significant advantage.
7. **BBB:** Both have moderate BBB penetration (40.56 & 49.01), which isn't a primary concern for a cardiovascular target.
8. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. This is a concern for both.
9. **Solubility:** Both have negative solubility values, indicating poor solubility. This is a concern for both.
10. **hERG:** Ligand A (0.055) has a much lower hERG risk than Ligand B (0.695), a crucial safety parameter.
11. **Cl_mic:** Ligand A (27.96) has a significantly lower microsomal clearance than Ligand B (70.71), suggesting better metabolic stability.
12. **t1/2:** Ligand B (50.98) has a longer in vitro half-life than Ligand A (2.88), which is a positive.
13. **Pgp:** Ligand A (0.039) shows lower P-gp efflux liability than Ligand B (0.193), which is favorable.
14. **Affinity:** Ligand B (-7.2 kcal/mol) has a slightly better binding affinity than Ligand A (-6.9 kcal/mol). While a 1.5 kcal/mol difference is usually significant, the other factors weigh heavily against Ligand B.
**Overall Assessment:**
Ligand A is the stronger candidate. Despite slightly weaker binding affinity, it demonstrates a significantly better safety profile (lower DILI, hERG), better drug-likeness (higher QED), and improved ADME properties (lower Cl_mic, Pgp efflux). The lower metabolic clearance and Pgp efflux suggest better bioavailability. While both have poor Caco-2 and solubility, the other advantages of Ligand A make it the more promising starting point for optimization.
**Output:**
1
2025-04-17 19:36:47,367 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (368.865 Da) is slightly higher than Ligand B (348.403 Da), but both are acceptable.
2. **TPSA:** Ligand A (78.53) is significantly better than Ligand B (104.54). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is pushing the upper limit for good oral absorption.
3. **logP:** Ligand A (1.941) is optimal, while Ligand B (0.619) is a bit low, potentially hindering membrane permeability.
4. **HBD:** Both ligands have acceptable HBD counts (Ligand A: 1, Ligand B: 2).
5. **HBA:** Both ligands have acceptable HBA counts (Ligand A: 4, Ligand B: 5).
6. **QED:** Both ligands have similar and good QED values (Ligand A: 0.88, Ligand B: 0.833).
7. **DILI:** Both ligands have similar and acceptable DILI risk (Ligand A: 53.587, Ligand B: 51.028).
8. **BBB:** Ligand A (66.964) is better than Ligand B (49.748), although neither is exceptionally high. For a cardiovascular target like ADRB2, BBB penetration isn't *critical* but can be useful for off-target effects.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual. Assuming these are logP-scale values, this suggests poor permeability. However, the values are similar.
10. **Solubility:** Ligand A (-3.286) is better than Ligand B (-2.32), indicating better aqueous solubility.
11. **hERG:** Ligand A (0.463) is better than Ligand B (0.089), indicating lower hERG inhibition liability. This is a crucial safety parameter.
12. **Cl_mic:** Ligand A (11.718) is significantly better than Ligand B (-20.863). A positive value for B suggests rapid clearance, a major drawback.
13. **t1/2:** Ligand A (-7.409) is better than Ligand B (5.884). A more negative value indicates a longer half-life.
14. **Pgp:** Ligand A (0.25) is better than Ligand B (0.012), suggesting lower P-gp efflux.
15. **Binding Affinity:** Ligand B (-7.8) has a slightly better binding affinity than Ligand A (-6.9). This is a 0.9 kcal/mol difference, which is significant.
**Overall Assessment:**
While Ligand B has a slightly better binding affinity, Ligand A is significantly better across multiple crucial ADME properties. Specifically, the much improved metabolic stability (Cl_mic and t1/2), lower hERG risk, better solubility, and lower P-gp efflux make Ligand A a far more promising drug candidate. The TPSA is also much more favorable for Ligand A. The small affinity difference is outweighed by the substantial improvements in drug-like properties.
Output:
1
2025-04-17 19:36:47,368 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [416.316, 94.92, 2.32, 3, 5, 0.685, 39.046, 60.101, -4.836, -2.652, 0.248, 31.316, -8.233, 0.024, -5.2]
**Ligand B:** [339.395, 75.44, 1.999, 1, 4, 0.846, 44.048, 45.832, -5.079, -2.534, 0.082, 42.371, 1.743, 0.057, -7.4]
**Step-by-step comparison:**
1. **MW:** Ligand A (416.316 Da) is within the ideal range, while Ligand B (339.395 Da) is towards the lower end, but still acceptable.
2. **TPSA:** Ligand A (94.92) is slightly higher, but still within a reasonable range for oral absorption. Ligand B (75.44) is excellent.
3. **logP:** Both ligands (A: 2.32, B: 1.999) are within the optimal 1-3 range.
4. **HBD:** Ligand A (3) is acceptable, Ligand B (1) is even better.
5. **HBA:** Ligand A (5) is acceptable, Ligand B (4) is also good.
6. **QED:** Ligand B (0.846) has a significantly better QED score than Ligand A (0.685), indicating better overall drug-likeness.
7. **DILI:** Both have acceptable DILI risk (A: 39.046, B: 44.048), below the 60% threshold.
8. **BBB:** Ligand A (60.101) is moderate, while Ligand B (45.832) is lower. Since ADRB2 isn't necessarily a CNS target, this isn't a major deciding factor, but higher is generally preferable.
9. **Caco-2:** Both have negative values, which is unusual. Assuming these are log values, both are poor.
10. **Solubility:** Both have negative values, which is unusual. Assuming these are log values, both are poor.
11. **hERG:** Both have very low hERG risk (A: 0.248, B: 0.082).
12. **Cl_mic:** Ligand A (31.316) has a lower (better) microsomal clearance than Ligand B (42.371), suggesting better metabolic stability.
13. **t1/2:** Ligand B (1.743) has a slightly better in vitro half-life than Ligand A (-8.233).
14. **Pgp:** Both have very low Pgp efflux liability (A: 0.024, B: 0.057).
15. **Affinity:** Ligand B (-7.4 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.2 kcal/mol) - a difference of 2.2 kcal/mol. This is a substantial advantage.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP, TPSA, and *especially* affinity. While BBB isn't critical here, the difference isn't large enough to outweigh the other benefits of Ligand B. The better QED score and slightly improved half-life of Ligand B further support its selection. The lower clearance of Ligand A is a positive, but the large affinity difference is more important.
**Conclusion:**
Ligand B is the more promising candidate due to its significantly stronger binding affinity, better QED, and favorable logP and TPSA values.
```
0
```
2025-04-17 19:36:47,368 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 receptor (a GPCR):
**1. Molecular Weight:** Both ligands (344.415 and 348.443 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (92.26) is higher than Ligand B (59.08). For a GPCR, lower TPSA is generally preferred for better permeability, and Ligand B is significantly better in this regard.
**3. logP:** Both ligands have good logP values (1.986 and 1.207), falling within the optimal 1-3 range. Ligand B is slightly lower, which could be beneficial for solubility, but both are acceptable.
**4. H-Bond Donors:** Ligand A has 1 HBD, and Ligand B has 0. Both are within the acceptable limit of <=5.
**5. H-Bond Acceptors:** Ligand A has 7 HBA, and Ligand B has 4. Both are within the acceptable limit of <=10.
**6. QED:** Both ligands have similar QED values (0.736 and 0.649), indicating good drug-like properties.
**7. DILI Risk:** Ligand B (22.722 percentile) has a much lower DILI risk than Ligand A (49.128 percentile). This is a significant advantage for Ligand B.
**8. BBB Penetration:** Ligand B (77.976 percentile) shows significantly better BBB penetration than Ligand A (63.746 percentile). As ADRB2 is a GPCR, and while not exclusively a CNS target, some degree of CNS exposure is not necessarily detrimental and could even be beneficial in certain therapeutic contexts.
**9. Caco-2 Permeability:** Both have negative values, indicating permeability data is on a different scale. However, Ligand B (-4.692) is slightly better than Ligand A (-5.287).
**10. Aqueous Solubility:** Both ligands have poor aqueous solubility (-1.821 and -1.658). This is a potential issue for both, but not a deciding factor.
**11. hERG Inhibition:** Both ligands show low hERG inhibition risk (0.186 and 0.336 percentile), which is excellent.
**12. Microsomal Clearance:** Ligand A (17.058 mL/min/kg) has lower microsomal clearance than Ligand B (43.3 mL/min/kg), suggesting better metabolic stability. This is a positive for Ligand A.
**13. In vitro Half-Life:** Ligand A (-8.587 hours) has a significantly longer in vitro half-life than Ligand B (1.92 hours). This is a substantial advantage for Ligand A.
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (0.354 and 0.079 percentile).
**15. Binding Affinity:** Both ligands have the same binding affinity (-6.0 kcal/mol).
**Overall Assessment:**
Ligand B clearly wins on several key GPCR-relevant parameters: lower TPSA, significantly lower DILI risk, and better BBB penetration. While Ligand A has better metabolic stability (lower Cl_mic) and a longer half-life, the improvements in ADME properties and safety with Ligand B outweigh these benefits. The similar binding affinity makes the ADME/Tox profile the deciding factor.
Output:
0
2025-04-17 19:36:47,368 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (366.483 Da) is slightly higher than Ligand B (344.419 Da), but both are acceptable.
2. **TPSA:** Ligand A (67.87) is better than Ligand B (100.94). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (Ligand A: 2.04, Ligand B: 1.035), falling within the optimal 1-3 range. Ligand A is slightly more lipophilic, which could be beneficial for membrane permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Fewer hydrogen bond donors generally improve permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (6). Similar reasoning as with HBD.
6. **QED:** Ligand A (0.802) is significantly better than Ligand B (0.631), indicating a more drug-like profile.
7. **DILI:** Ligand B (59.907) has a higher DILI risk than Ligand A (48.623), though both are reasonably acceptable.
8. **BBB:** Ligand A (65.297) has better BBB penetration than Ligand B (36.642), but since ADRB2 is not a CNS target, this is less important.
9. **Caco-2:** Ligand A (-4.847) shows better Caco-2 permeability than Ligand B (-5.676).
10. **Solubility:** Ligand B (-1.842) has slightly better aqueous solubility than Ligand A (-2.825). Solubility is important, but can often be addressed through formulation.
11. **hERG:** Both ligands have very low hERG inhibition risk (Ligand A: 0.399, Ligand B: 0.345).
12. **Cl_mic:** Ligand B (12.387) has a significantly lower microsomal clearance than Ligand A (32.972), suggesting better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand B (49.922) has a much longer in vitro half-life than Ligand A (14.869), further supporting its better metabolic stability.
14. **Pgp:** Both ligands have low P-gp efflux liability (Ligand A: 0.144, Ligand B: 0.019). Ligand B is slightly better.
15. **Binding Affinity:** Ligand A (-7.1 kcal/mol) has a slightly better binding affinity than Ligand B (-6.2 kcal/mol). This 0.9 kcal/mol difference is substantial and can often outweigh minor ADME drawbacks.
**Overall Assessment:**
Ligand A has a better QED, TPSA, logP, HBD, HBA, Caco-2 permeability, and crucially, a significantly stronger binding affinity. Ligand B excels in metabolic stability (lower Cl_mic, longer t1/2) and has slightly better solubility and Pgp efflux. However, the affinity difference is substantial. For a GPCR target like ADRB2, potency is paramount, and the improved ADME properties of Ligand B don't fully compensate for the affinity difference.
Output:
1
2025-04-17 19:36:47,368 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (357.4 and 353.5 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (78.51) is slightly higher than Ligand B (72.88), but both are well below the 140 threshold for good oral absorption and acceptable for a cardiovascular GPCR target (no strong CNS requirement).
3. **logP:** Both ligands have good logP values (1.196 and 1.378), falling within the optimal 1-3 range. Ligand B is slightly higher, potentially offering a small advantage in membrane permeability.
4. **HBD:** Both ligands have 2 H-bond donors, which is within the acceptable limit of 5.
5. **HBA:** Ligand A has 3 H-bond acceptors, while Ligand B has 4. Both are below the 10 limit.
6. **QED:** Ligand A (0.75) has a slightly better QED score than Ligand B (0.691), suggesting a more drug-like profile.
7. **DILI:** Ligand A (27.608) has a significantly lower DILI risk than Ligand B (8.996). This is a major advantage for Ligand A. A DILI percentile under 40 is very favorable.
8. **BBB:** Ligand A (83.366) has a much higher BBB penetration percentile than Ligand B (42.226). While ADRB2 isn't a primary CNS target, some degree of BBB penetration can be beneficial for overall distribution and potentially off-target effects.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.863 and -4.953), which is unusual and suggests poor permeability. This is a significant concern for both compounds.
10. **Solubility:** Both ligands have negative solubility values (-2.23 and -1.662), indicating very poor aqueous solubility. This is a major drawback for both.
11. **hERG:** Ligand A (0.154) has a significantly lower hERG inhibition liability than Ligand B (0.508). This is a crucial advantage, as hERG inhibition can lead to cardiotoxicity.
12. **Cl_mic:** Ligand A (1.054) has a much lower microsomal clearance than Ligand B (18.633), indicating better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand A (-1.634) has a slightly longer in vitro half-life than Ligand B (-1.161).
14. **Pgp:** Ligand A (0.01) has a much lower P-gp efflux liability than Ligand B (0.088), which is beneficial for oral bioavailability.
15. **Binding Affinity:** Ligand A (-7.3 kcal/mol) has a slightly better binding affinity than Ligand B (-5.1 kcal/mol). This 1.5 kcal/mol difference is substantial and can outweigh some of the ADME drawbacks.
**Overall Assessment:**
Ligand A is the stronger candidate. While both compounds suffer from poor Caco-2 permeability and solubility, Ligand A demonstrates significantly better ADME properties: lower DILI risk, higher BBB penetration, lower hERG inhibition, lower microsomal clearance, and lower P-gp efflux. The slightly better binding affinity further solidifies its position. The poor solubility and permeability are concerning, but could potentially be addressed with formulation strategies.
Output:
1
2025-04-17 19:36:47,368 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (351.403 and 344.419 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand B (85.05) is significantly better than Ligand A (104.9). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (0.903) is lower than Ligand A (0.521). Both are a bit low, potentially hindering permeability, but Ligand B is slightly better.
4. **HBD:** Ligand B (1) has fewer HBD than Ligand A (2). Fewer HBDs are generally preferred for better permeability.
5. **HBA:** Both ligands have the same number of HBA (6), which is acceptable.
6. **QED:** Ligand B (0.873) has a better QED score than Ligand A (0.662), indicating a more drug-like profile.
7. **DILI:** Ligand A (48.275) has a lower DILI risk than Ligand B (56.805), which is a positive.
8. **BBB:** Ligand B (66.77) has a higher BBB penetration percentile than Ligand A (49.554). While ADRB2 isn't a CNS target, some degree of BBB penetration can sometimes indicate favorable partitioning.
9. **Caco-2:** Ligand A (-4.833) has a much better Caco-2 permeability than Ligand B (-5.111). This suggests better intestinal absorption for Ligand A.
10. **Solubility:** Ligand A (-1.863) has better solubility than Ligand B (-2.001).
11. **hERG:** Both ligands have very low hERG inhibition risk (0.112 and 0.246, respectively).
12. **Cl_mic:** Ligand A (16.975) has a significantly lower microsomal clearance than Ligand B (38.62), suggesting better metabolic stability.
13. **t1/2:** Ligand A (25.863) has a longer in vitro half-life than Ligand B (19.706).
14. **Pgp:** Both ligands have low P-gp efflux liability (0.06 and 0.073, respectively).
15. **Binding Affinity:** Ligand B (-6.6 kcal/mol) has a stronger binding affinity than Ligand A (-5.6 kcal/mol). This is a 1.0 kcal/mol difference, which is a substantial advantage.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B excels in affinity and has a lower TPSA, but suffers from a slightly lower logP and higher DILI. Ligand A has better ADME properties (Cl_mic, t1/2, solubility, Caco-2) and lower DILI, but its affinity is weaker. The 1.0 kcal/mol difference in affinity is significant enough to outweigh the slightly less favorable ADME profile of Ligand B.
**Conclusion:**
Despite Ligand A's better ADME properties, the significantly stronger binding affinity of Ligand B makes it the more promising candidate for further development.
Output:
0
2025-04-17 19:36:47,369 - INFO - Batch 123 complete. Total preferences: 1968
2025-04-17 19:36:47,369 - INFO - Processing batch 124/512...
2025-04-17 19:37:34,742 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (358.394 and 370.446 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (72.24) is slightly higher than Ligand B (67.87). Both are below the 140 A^2 threshold for good oral absorption, and acceptable for a peripherally acting GPCR like ADRB2.
3. **logP:** Ligand A (4.495) is higher than Ligand B (1.852). While Ligand A is at the upper end of the optimal range, it's still acceptable. Ligand B is well within the optimal range. This favors Ligand B slightly, as excessively high logP can lead to off-target effects.
4. **HBD:** Both ligands have 1 HBD, which is within the acceptable limit of <=5.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 5. Both are within the acceptable limit of <=10.
6. **QED:** Ligand B (0.744) has a better QED score than Ligand A (0.551), indicating a more drug-like profile. This favors Ligand B.
7. **DILI:** Ligand B (47.421) has a significantly lower DILI risk than Ligand A (89.841). This is a major advantage for Ligand B.
8. **BBB:** Ligand A (76.89) and Ligand B (91.043). While BBB isn't a primary concern for ADRB2 (a cardiovascular target), higher BBB penetration is generally favorable. Ligand B is better here.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.68 and -4.715), which is unusual and suggests poor permeability. However, the values are very similar, so this doesn't differentiate them significantly.
10. **Solubility:** Ligand B (-2.757) has better solubility than Ligand A (-5.517). Better solubility is generally preferred.
11. **hERG:** Both ligands have low hERG inhibition risk (0.611 and 0.61). No significant difference.
12. **Cl_mic:** Ligand B (20.675) has significantly lower microsomal clearance than Ligand A (79.279), indicating better metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand B (-8.811) has a longer in vitro half-life than Ligand A (84.204). This is a significant advantage for Ligand B.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.557 and 0.122). Ligand B is better here.
15. **Binding Affinity:** Ligand A (-7.0) has slightly better binding affinity than Ligand B (-5.6). However, the difference is 1.4 kcal/mol, which is not substantial enough to outweigh the significant ADME advantages of Ligand B.
**GPCR-specific priorities:** For ADRB2, logP, Pgp, TPSA, and affinity are important. Ligand B is better in logP, Pgp, and TPSA. While Ligand A has slightly better affinity, the ADME profile of Ligand B is far superior.
**Conclusion:**
Ligand B demonstrates a significantly more favorable ADME profile, with lower DILI risk, better solubility, lower clearance, longer half-life, and better BBB penetration, despite slightly lower binding affinity. These factors collectively make Ligand B a more promising drug candidate for ADRB2.
Output:
0
2025-04-17 19:37:34,742 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 GPCR, followed by the final output.
**Ligand A: [403.255, 61.88, 3.69, 1, 3, 0.664, 70.492, 71.85, -5.07, -3.693, 0.852, 48.239, 22.983, 0.62, -5.6]**
**Ligand B: [357.495, 90.9, 0.515, 3, 5, 0.589, 9.926, 24.002, -5.248, -0.724, 0.216, 24.74, 12.048, 0.01, -6.8]**
1. **Molecular Weight:** Ligand A (403.255 Da) is within the ideal range (200-500 Da). Ligand B (357.495 Da) is also within range. No clear advantage here.
2. **TPSA:** Ligand A (61.88) is excellent, well below the 140 threshold. Ligand B (90.9) is still reasonable, but higher. A favors better absorption.
3. **logP:** Ligand A (3.69) is optimal. Ligand B (0.515) is quite low, potentially hindering membrane permeability. A is significantly better.
4. **H-Bond Donors:** Both ligands have acceptable HBD counts (A: 1, B: 3).
5. **H-Bond Acceptors:** Both ligands have acceptable HBA counts (A: 3, B: 5).
6. **QED:** Ligand A (0.664) is better than Ligand B (0.589), indicating a more drug-like profile.
7. **DILI:** Ligand A (70.492) is higher than Ligand B (9.926), indicating a greater risk of liver injury. B is much better here.
8. **BBB:** Ligand A (71.85) is good, while Ligand B (24.002) is low. This is important for GPCRs, and A is favored.
9. **Caco-2:** Both have negative values, indicating poor permeability. A (-5.07) is slightly better than B (-5.248).
10. **Solubility:** Ligand A (-3.693) is worse than Ligand B (-0.724). B is better.
11. **hERG:** Ligand A (0.852) is better than Ligand B (0.216), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand A (48.239) has a lower clearance than Ligand B (24.74), suggesting better metabolic stability. A is better.
13. **t1/2:** Ligand A (22.983) has a longer half-life than Ligand B (12.048). A is better.
14. **Pgp:** Ligand A (0.62) is better than Ligand B (0.01), indicating lower P-gp efflux.
15. **Binding Affinity:** Ligand B (-6.8 kcal/mol) has a 1.2 kcal/mol advantage in binding affinity over Ligand A (-5.6 kcal/mol). This is a substantial difference.
**Overall Assessment:**
Ligand B has a significantly better binding affinity and lower DILI risk, which are important factors. However, its low logP is a major concern for permeability and bioavailability. Ligand A has a much better logP, TPSA, QED, BBB penetration, metabolic stability, and P-gp efflux profile. While its DILI risk is higher, the overall balance of properties, particularly for a GPCR target like ADRB2, favors Ligand A. The affinity difference, while notable, can potentially be optimized in subsequent iterations of drug design, whereas correcting a poor logP is often more challenging.
Output:
1
2025-04-17 19:37:34,743 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
The ADRB2 receptor is a GPCR involved in cardiovascular function. Therefore, prioritizing logP, TPSA, Pgp efflux, and binding affinity is crucial. While BBB isn't a primary concern for a cardiovascular target, it's still a factor to consider.
Let's compare the ligands property by property:
1. **MW:** Both ligands are within the acceptable range (200-500 Da). Ligand A (363.527) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (63.13) is significantly better than Ligand B (83.9). Lower TPSA generally improves oral absorption, which is important.
3. **logP:** Both ligands have similar logP values (A: 2.634, B: 2.698), falling within the optimal range of 1-3.
4. **HBD:** Ligand A (2) has slightly more HBD than Ligand B (1), but both are acceptable.
5. **HBA:** Ligand B (6) has more HBA than Ligand A (4). While both are under the 10 threshold, the lower number for A is slightly preferred.
6. **QED:** Ligand A (0.817) has a higher QED score than Ligand B (0.68), indicating a more drug-like profile.
7. **DILI:** Both ligands have acceptable DILI risk (A: 47.887, B: 57.774), though A is slightly better.
8. **BBB:** Ligand B (83.715) has a higher BBB percentile than Ligand A (55.021). However, as this is a cardiovascular target, BBB penetration isn't a major priority.
9. **Caco-2:** Both ligands have negative Caco-2 values, suggesting poor permeability. This is a concern for both.
10. **Solubility:** Both ligands have negative solubility values, suggesting poor solubility. This is a concern for both.
11. **hERG:** Ligand A (0.239) has a much lower hERG inhibition liability than Ligand B (0.565), which is a significant advantage.
12. **Cl_mic:** Ligand A (37.589) has a lower microsomal clearance than Ligand B (66.402), indicating better metabolic stability.
13. **t1/2:** Ligand B (32.451) has a longer in vitro half-life than Ligand A (12.611), which is a positive.
14. **Pgp:** Ligand A (0.171) has lower P-gp efflux liability than Ligand B (0.105), which is preferable.
15. **Binding Affinity:** Ligand B (-6.9 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.5 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME drawbacks.
**Overall Assessment:**
Ligand B has a significantly better binding affinity, which is a critical factor for GPCR targets. However, Ligand A has a better safety profile (lower hERG, DILI), better drug-likeness (QED), and better metabolic stability (lower Cl_mic). The poor Caco-2 and solubility for both are concerning, but can be addressed during lead optimization. Given the importance of potency at a GPCR, the stronger binding affinity of Ligand B is the deciding factor.
Output:
0
2025-04-17 19:37:34,743 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (344.455 Da) is slightly lower, which is generally favorable for permeability.
**2. TPSA:** Ligand A (60.85) is significantly better than Ligand B (96.44). For a cardiovascular GPCR, TPSA under 140 is acceptable, but lower is preferred. Ligand A is much closer to the ideal range for good oral absorption.
**3. logP:** Both ligands have good logP values (A: 1.682, B: 1.012) falling within the 1-3 range.
**4. H-Bond Donors:** Both have 1 HBD, which is good.
**5. H-Bond Acceptors:** Ligand A has 3 HBA, while Ligand B has 5. Both are acceptable (under 10), but A is slightly better.
**6. QED:** Ligand A (0.829) has a substantially better QED score than Ligand B (0.697), indicating a more drug-like profile.
**7. DILI Risk:** Ligand B (58.976) has a higher DILI risk than Ligand A (17.41). This is a significant advantage for Ligand A.
**8. BBB Penetration:** Ligand B (77.821) has better BBB penetration than Ligand A (62.466). While ADRB2 is a cardiovascular target, some CNS effects are possible with beta-blockers, so some BBB penetration isn't necessarily detrimental, but it's not a primary driver.
**9. Caco-2 Permeability:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
**10. Aqueous Solubility:** Both have negative solubility values, which is also unusual. Again, the scale is unknown, making interpretation difficult.
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (A: 0.214, B: 0.288), which is good.
**12. Microsomal Clearance:** Ligand A (8.437) has significantly lower microsomal clearance than Ligand B (33.101), suggesting better metabolic stability.
**13. In vitro Half-Life:** Ligand A (26.61) has a longer in vitro half-life than Ligand B (9.978), which is desirable.
**14. P-gp Efflux:** Both have low P-gp efflux liability (A: 0.092, B: 0.077).
**15. Binding Affinity:** Ligand A (-8.4 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.2 kcal/mol). This is a substantial advantage, exceeding the 1.5 kcal/mol threshold.
**Overall Assessment:**
Ligand A clearly outperforms Ligand B across most critical parameters. The significantly better binding affinity, lower DILI risk, better QED, and improved metabolic stability (lower Cl_mic and longer t1/2) outweigh the slightly better BBB penetration of Ligand B. The TPSA value of Ligand A is also much more favorable. While the Caco-2 and solubility values are concerning for both, the overall profile of Ligand A is far superior for development as a cardiovascular drug targeting ADRB2.
Output:
1
2025-04-17 19:37:34,743 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (359.407) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (92.71) is better than Ligand B (128.03). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA is still generally preferred for absorption.
3. **logP:** Ligand A (3.341) is optimal, while Ligand B (-0.293) is significantly lower. This is a major drawback for Ligand B, potentially hindering membrane permeability and bioavailability.
4. **HBD:** Both have acceptable HBD counts (3 and 2, respectively).
5. **HBA:** Both have acceptable HBA counts (6).
6. **QED:** Both have reasonable QED scores (0.65 and 0.53), indicating good drug-like properties.
7. **DILI:** Ligand B (35.789) has a much lower DILI risk than Ligand A (87.515), which is a significant advantage.
8. **BBB:** Ligand B (73.284) has a higher BBB penetration than Ligand A (41.528), but since this is a cardiovascular target, this is less critical.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
10. **Solubility:** Ligand B (-1.627) has slightly better solubility than Ligand A (-3.854).
11. **hERG:** Ligand A (0.559) has a slightly higher hERG risk than Ligand B (0.098), but both are relatively low.
12. **Cl_mic:** Ligand B (16.5) has significantly lower microsomal clearance than Ligand A (54.333), indicating better metabolic stability.
13. **t1/2:** Ligand B (14.046) has a longer in vitro half-life than Ligand A (-13.34), which is a significant advantage.
14. **Pgp:** Ligand B (0.011) has much lower P-gp efflux liability than Ligand A (0.278), which is beneficial for bioavailability.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.2 and -5.7 kcal/mol). The difference is not substantial enough to override the other ADME considerations.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has a better TPSA, but Ligand B excels in logP, Pgp efflux, and metabolic stability (Cl_mic and t1/2). The DILI risk is also much lower for Ligand B. While affinity is similar, the ADME properties of Ligand B are significantly more favorable.
**Conclusion:**
Considering the balance of properties, especially the critical importance of logP and metabolic stability for a cardiovascular drug, Ligand B is the more promising candidate. The lower DILI risk and Pgp efflux are also significant advantages.
Output:
0
2025-04-17 19:37:34,743 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
The ADRB2 receptor is a GPCR, so the priorities are logP, Pgp, TPSA, affinity, and, to a lesser extent, BBB. Let's break down each ligand against these criteria and the other important ADME/Tox properties.
* **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand B (341.415 Da) is slightly smaller than Ligand A (377.491 Da), which is generally favorable for permeability.
* **TPSA:** Ligand A (72.36) is better than Ligand B (90.12). ADRB2 is not a CNS target, so we don't need to be *extremely* strict on TPSA, but lower is still preferred for oral absorption.
* **logP:** Both ligands have good logP values (A: 3.976, B: 3.161), falling within the optimal 1-3 range. Ligand A is a bit higher, which *could* lead to some off-target interactions, but it's not a major concern.
* **H-Bond Donors/Acceptors:** Ligand A (HBD=2, HBA=6) is slightly better than Ligand B (HBD=3, HBA=3) in terms of balancing solubility and permeability.
* **QED:** Ligand B (0.798) has a better QED score than Ligand A (0.59), indicating a more drug-like profile.
* **DILI:** Both ligands have acceptable DILI risk (A: 83.249, B: 79.449), but both are relatively high.
* **BBB:** Ligand A (76.541) has a better BBB penetration score than Ligand B (54.634), but this isn't a critical factor for ADRB2.
* **Caco-2 Permeability:** Ligand A (-4.454) has better Caco-2 permeability than Ligand B (-5.086).
* **Aqueous Solubility:** Ligand A (-5.833) has better aqueous solubility than Ligand B (-4.388).
* **hERG Inhibition:** Both ligands have low hERG inhibition risk (A: 0.266, B: 0.474).
* **Microsomal Clearance:** Ligand A (97.091) has a higher microsomal clearance than Ligand B (-6.53). This means Ligand B is likely to have better metabolic stability.
* **In vitro Half-Life:** Ligand B (27.652) has a longer in vitro half-life than Ligand A (33.653).
* **P-gp Efflux:** Ligand A (0.231) has lower P-gp efflux than Ligand B (0.042). This is a significant advantage for Ligand A, potentially leading to better oral bioavailability.
* **Binding Affinity:** Ligand A (-7.3 kcal/mol) has a slightly better binding affinity than Ligand B (-6.6 kcal/mol). This 0.7 kcal/mol difference is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand A has a better binding affinity, better Caco-2 permeability, better solubility, and lower P-gp efflux. While Ligand B has a better QED and metabolic stability, the stronger binding affinity of Ligand A is a crucial advantage for a GPCR target. The slightly higher logP of Ligand A is manageable, and the other ADME properties are reasonable.
**Output:**
1
2025-04-17 19:37:34,744 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (350.415 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are reasonably good, but Ligand A (91.26) is better than Ligand B (99.6), being closer to the <140 threshold for oral absorption.
3. **logP:** Both ligands have acceptable logP values (A: 1.594, B: 0.819), falling within the 1-3 range. Ligand A is slightly better.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (2), but both are within the acceptable limit of 5.
5. **HBA:** Ligand A (5) is slightly higher than Ligand B (6), but both are within the acceptable limit of 10.
6. **QED:** Both ligands have similar and good QED values (A: 0.767, B: 0.782), indicating good drug-likeness.
7. **DILI:** Ligand A (38.348) has a significantly lower DILI risk than Ligand B (55.913). This is a substantial advantage.
8. **BBB:** Ligand A (65.801) has better BBB penetration than Ligand B (47.344), although neither is exceptionally high. For a cardiovascular target, BBB isn't *critical*, but some penetration can be beneficial for understanding off-target effects.
9. **Caco-2:** Ligand A (-4.555) has a better Caco-2 permeability than Ligand B (-5.349).
10. **Solubility:** Ligand A (-1.731) has better aqueous solubility than Ligand B (-3.15).
11. **hERG:** Both ligands have very low hERG inhibition risk (A: 0.273, B: 0.295).
12. **Cl_mic:** Ligand B (-9.442) has a *much* lower microsomal clearance than Ligand A (0.545), indicating better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand B (4.13) has a better in vitro half-life than Ligand A (-12.876).
14. **Pgp:** Both ligands have similar Pgp efflux liability (A: 0.029, B: 0.158).
15. **Binding Affinity:** Ligand A (-8.9 kcal/mol) has a slightly better binding affinity than Ligand B (-7.4 kcal/mol). This ~1.5 kcal/mol difference is substantial and can outweigh some ADME drawbacks.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A performs better on logP, TPSA, and significantly better on affinity. Ligand B has a clear advantage in metabolic stability (Cl_mic and t1/2). The DILI risk is also lower for Ligand A.
**Overall Assessment:**
While Ligand B has superior metabolic stability, the combination of better affinity, lower DILI risk, better solubility, and acceptable BBB penetration makes Ligand A the more promising candidate. The 1.5 kcal/mol difference in binding affinity is a significant factor, and the lower DILI risk is crucial.
Output:
1
2025-04-17 19:37:34,744 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for the ADRB2, a cardiovascular GPCR. Therefore, the key priorities are logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB.
Let's compare the ligands property by property:
1. **MW:** Both ligands (360.361 and 347.459 Da) are within the ideal 200-500 Da range.
2. **TPSA:** Ligand B (75.44) is significantly better than Ligand A (96.69). Lower TPSA generally favors oral absorption, which is important for a cardiovascular drug.
3. **logP:** Both ligands have acceptable logP values (1.387 and 2.625), falling within the 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability.
4. **HBD/HBA:** Ligand B has fewer HBDs (1 vs 2) and HBAs (4 vs 6), which is generally favorable for permeability.
5. **QED:** Both ligands have similar QED values (0.791 and 0.769), indicating good drug-likeness.
6. **DILI:** Ligand B (21.985) has a much lower DILI risk than Ligand A (53.858). This is a significant advantage.
7. **BBB:** Ligand A (85.925) has a better BBB penetration score than Ligand B (71.501). However, since ADRB2 is primarily a cardiovascular target, high BBB penetration is not a critical requirement.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability.
9. **Solubility:** Both have negative solubility values, suggesting poor solubility.
10. **hERG:** Both ligands show very low hERG inhibition liability (0.498 and 0.059), which is excellent.
11. **Cl_mic:** Ligand A (24.498) has a lower microsomal clearance than Ligand B (57.997), indicating better metabolic stability.
12. **t1/2:** Ligand B has a significantly longer in vitro half-life (-12.091) than Ligand A (-2.819). This is a major advantage.
13. **Pgp:** Ligand A (0.066) has lower P-gp efflux liability than Ligand B (0.092), which is favorable.
14. **Binding Affinity:** Ligand A (-6.8 kcal/mol) has a slightly better binding affinity than Ligand B (-4.4 kcal/mol). This is a 2.4 kcal/mol difference, which is substantial.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity and lower Pgp efflux, Ligand B is superior overall. The significantly lower DILI risk, longer half-life, and lower TPSA of Ligand B outweigh the minor advantage in binding affinity and Pgp for a cardiovascular target. The poor Caco-2 and solubility values are concerning for both, but can be addressed with formulation strategies.
**Output:**
0
2025-04-17 19:37:34,745 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (349.391) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (62.3) is significantly better than Ligand A (124.26). ADRB2 is a cardiovascular target, not CNS, but lower TPSA is still generally preferred for absorption.
3. **logP:** Ligand B (3.266) is optimal, while Ligand A (-0.593) is quite low, potentially hindering membrane permeability. This is a significant drawback for Ligand A.
4. **HBD:** Ligand A (3) is higher than Ligand B (1), but both are acceptable.
5. **HBA:** Ligand A (5) is higher than Ligand B (4), but both are acceptable.
6. **QED:** Both ligands have good QED scores (A: 0.567, B: 0.687), indicating generally drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand B (42.264) has a lower DILI risk than Ligand A (70.26). This is a clear advantage for Ligand B.
8. **BBB:** Not a primary concern for a cardiovascular target. Ligand B (76.037) is higher, but this isn't a deciding factor.
9. **Caco-2:** Both have negative values, indicating poor permeability. Ligand A (-5.412) is worse than Ligand B (-4.617).
10. **Solubility:** Both ligands have negative solubility values, indicating poor solubility. Ligand A (-2.774) is slightly better than Ligand B (-3.291).
11. **hERG:** Ligand A (0.258) has a lower hERG risk than Ligand B (0.555), which is a positive.
12. **Cl_mic:** Ligand A (13.804) has a significantly lower microsomal clearance than Ligand B (82.687), suggesting better metabolic stability. This is a strong advantage for Ligand A.
13. **t1/2:** Ligand B (10.403) has a longer in vitro half-life than Ligand A (-20.434). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.029) has lower P-gp efflux liability than Ligand B (0.502), which is favorable.
15. **Affinity:** Ligand A (-7.2) has a slightly better binding affinity than Ligand B (-6.2). However, the difference is less than 1.5 kcal/mol, so it doesn't overwhelmingly outweigh other factors.
**Overall Assessment:**
Ligand B has a better overall profile, despite the slightly weaker affinity. The significant advantages in logP, DILI risk, and in vitro half-life outweigh the drawbacks. Ligand A's low logP is a major concern for permeability, and while it has better metabolic stability, the overall ADME profile is less favorable. The slightly better affinity of Ligand A is not enough to compensate for these issues.
Output:
0
2025-04-17 19:37:34,745 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (383.455) is slightly higher than Ligand B (348.447), but both are acceptable.
2. **TPSA:** Ligand B (87.32) is significantly better than Ligand A (117.54). For a GPCR, lower TPSA is generally preferred for better permeability.
3. **logP:** Ligand B (1.263) is within the optimal range, while Ligand A (0.042) is quite low. This is a significant drawback for Ligand A, potentially hindering membrane permeability and bioavailability.
4. **HBD:** Both ligands have 2 HBD, which is acceptable.
5. **HBA:** Ligand B (4) has fewer HBA than Ligand A (9). Lower HBA is generally favorable for permeability.
6. **QED:** Both ligands have good QED scores (A: 0.693, B: 0.777), indicating good drug-like properties.
7. **DILI:** Ligand B (26.367) has a much lower DILI risk than Ligand A (72.005). This is a crucial advantage for Ligand B.
8. **BBB:** Ligand B (52.036) has a better BBB penetration score than Ligand A (21.598), although neither is particularly high. For ADRB2, which isn't necessarily a CNS target, this isn't a primary driver, but it's still a positive for B.
9. **Caco-2:** Both have negative values, which is unusual. Assuming these are logP-scaled values, they are similar and don't strongly differentiate the two.
10. **Solubility:** Both have similar, very poor solubility scores (-1.6 and -1.695). This is a concern for both, but can be addressed through formulation.
11. **hERG:** Both have low hERG risk (0.101 and 0.119), which is good.
12. **Cl_mic:** Ligand A (-9.321) has a much lower (better) microsomal clearance than Ligand B (0.709), indicating greater metabolic stability.
13. **t1/2:** Ligand A (-8.642) has a longer in vitro half-life than Ligand B (1.62). This is a significant advantage for Ligand A.
14. **Pgp:** Both have very low Pgp efflux liability (0.03 and 0.016), which is favorable.
15. **Affinity:** Ligand A (-6.9 kcal/mol) has slightly better binding affinity than Ligand B (-6.4 kcal/mol), but the difference is not substantial.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand B is the stronger candidate. While Ligand A has better metabolic stability (Cl_mic and t1/2) and slightly better affinity, Ligand B's significantly better logP, TPSA, and DILI profile outweigh these advantages. The poor logP of Ligand A is a major concern, potentially leading to poor absorption. The lower DILI risk of Ligand B is also a critical factor. Both have similar solubility and hERG, and Pgp efflux is low for both.
Output:
0
2025-04-17 19:37:34,745 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 drug candidates. ADRB2 is a GPCR, so we'll prioritize logP, Pgp, TPSA, and affinity, alongside general drug-like properties.
**Ligand A:** [350.507, 55.89, 0.776, 1, 4, 0.769, 1.473, 83.87, -5.16, -0.836, 0.55, 1.396, -5.754, 0.008, -6.3]
**Ligand B:** [348.403, 103.53, -0.403, 3, 4, 0.609, 55.525, 55.138, -5.345, -2.219, 0.171, 9.345, -15.756, 0.028, -6.7]
1. **MW:** Both are within the ideal range (200-500 Da). A is 350.5, B is 348.4 - very similar.
2. **TPSA:** A (55.89) is excellent, well below the 140 threshold. B (103.53) is higher, but still acceptable, although less optimal for permeability.
3. **logP:** A (0.776) is good, within the 1-3 range. B (-0.403) is slightly below 1, which could pose permeability challenges.
4. **HBD:** A (1) is good. B (3) is higher, potentially impacting permeability.
5. **HBA:** Both A (4) and B (4) are acceptable.
6. **QED:** A (0.769) is better than B (0.609), indicating a more drug-like profile.
7. **DILI:** A (1.473) is *much* better than B (55.525). This is a significant advantage for A.
8. **BBB:** A (83.87) is good, indicating reasonable potential for CNS penetration (though not critical for ADRB2, it's a bonus). B (55.138) is lower.
9. **Caco-2:** Both are negative, indicating poor permeability. A (-5.16) is slightly better than B (-5.345).
10. **Solubility:** A (-0.836) is better than B (-2.219).
11. **hERG:** A (0.55) is much better than B (0.171), indicating lower cardiotoxicity risk.
12. **Cl_mic:** A (1.396) is significantly lower than B (9.345), suggesting better metabolic stability.
13. **t1/2:** A (-5.754) is better than B (-15.756), indicating a longer half-life.
14. **Pgp:** A (0.008) is much lower than B (0.028), indicating less P-gp efflux.
15. **Affinity:** A (-6.3) is slightly better than B (-6.7), although the difference is relatively small.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical ADME-Tox properties. The most significant differences are in DILI risk, metabolic stability (Cl_mic and t1/2), P-gp efflux, and hERG inhibition, all of which are crucial for a safe and effective drug. While both have poor Caco-2 permeability, A's other advantages outweigh this drawback. The slightly better affinity of A is a bonus.
Therefore, I recommend Ligand A.
Output:
1
2025-04-17 19:37:34,745 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (341.455 and 352.381 Da) are within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (62.3) is slightly higher than Ligand B (58.64). Both are well below the 140 threshold for oral absorption, and acceptable for a GPCR. Slight advantage to B.
3. **logP:** Ligand A (2.113) is within the optimal 1-3 range. Ligand B (3.146) is at the higher end, but still acceptable. No major concern for either.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Both ligands have 3 HBA, which is good.
6. **QED:** Ligand B (0.856) has a significantly higher QED score than Ligand A (0.553), indicating better overall drug-likeness. This is a substantial advantage for B.
7. **DILI:** Ligand A (13.183) has a much lower DILI risk than Ligand B (64.599). This is a major advantage for A.
8. **BBB:** Ligand B (81.698) has a much higher BBB penetration percentile than Ligand A (52.811). While ADRB2 isn't strictly a CNS target, some CNS exposure can be beneficial or at least less detrimental than complete lack of penetration. Advantage B.
9. **Caco-2:** Both have negative values, indicating permeability is predicted to be poor. However, Ligand B (-4.481) is slightly better than Ligand A (-4.673). Slight advantage to B.
10. **Solubility:** Both ligands have very poor predicted aqueous solubility (-2.6 and -3.856). This is a significant concern for both, and may require formulation strategies. No clear advantage.
11. **hERG:** Ligand A (0.273) has a much lower hERG inhibition liability than Ligand B (0.784). This is a critical advantage for A, as hERG inhibition can lead to cardiotoxicity, particularly relevant for a cardiovascular target.
12. **Cl_mic:** Ligand A (59.716) has lower microsomal clearance than Ligand B (68.315), suggesting better metabolic stability. Advantage A.
13. **t1/2:** Ligand B (-33.248) has a much longer in vitro half-life than Ligand A (-4.808). This is a significant advantage for B, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.058) has much lower P-gp efflux liability than Ligand B (0.294). This is a significant advantage for A, improving bioavailability.
15. **Binding Affinity:** Ligand B (-7.3) has a stronger binding affinity than Ligand A (-6.6). This is a 1.5 kcal/mol difference, which is substantial and can outweigh some ADME drawbacks. Advantage B.
**Overall Assessment:**
Ligand B has a better binding affinity, QED, BBB, Caco-2 permeability, and in vitro half-life. However, it suffers from significantly higher DILI risk, hERG inhibition, and P-gp efflux. Ligand A has a much better safety profile (lower DILI and hERG) and better metabolic stability (lower Cl_mic, lower Pgp efflux), but weaker binding affinity and a lower QED.
Considering ADRB2 is a cardiovascular target, minimizing cardiotoxicity (hERG) and liver toxicity (DILI) are paramount. The stronger binding affinity of Ligand B is attractive, but the higher hERG risk is a major concern. The improved metabolic stability and reduced efflux of Ligand A, combined with its lower toxicity profile, make it the more promising candidate, despite the slightly weaker affinity.
Output:
1
2025-04-17 19:37:34,745 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
We are targeting ADRB2, a GPCR. Therefore, the priorities are logP, Pgp, TPSA, affinity, and BBB. Let's analyze each ligand against these and other relevant parameters.
* **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand B (345.487 Da) is slightly lower, which is generally favorable for permeability.
* **TPSA:** Ligand B (73.2) is significantly better than Ligand A (86.31). Lower TPSA generally improves oral absorption, a key consideration for GPCR ligands.
* **logP:** Ligand A (4.457) is higher than Ligand B (3.006). While both are within the acceptable range (1-3 is optimal, up to 4 is tolerable), Ligand A is pushing the upper limit and could lead to solubility issues or off-target interactions. Ligand B is closer to optimal.
* **H-Bond Donors/Acceptors:** Both have similar and acceptable numbers of HBD (1) and HBA (Ligand A: 6, Ligand B: 3).
* **QED:** Both ligands have good QED scores (A: 0.579, B: 0.721), indicating good drug-like properties. Ligand B is slightly better.
* **DILI:** Ligand A has a very high DILI risk (99.341%), which is a major red flag. Ligand B has a very low DILI risk (14.385%), making it much safer.
* **BBB:** Ligand B (58.123%) has a better BBB penetration score than Ligand A (30.71%). While not a primary concern for all GPCRs, it's a positive attribute.
* **Caco-2 Permeability:** Both have negative Caco-2 values, which is unusual and suggests potential issues with permeability prediction. However, the scale is not specified, so it's hard to interpret.
* **Aqueous Solubility:** Ligand B (-2.598) is better than Ligand A (-5.942). Higher solubility is generally preferred.
* **hERG Inhibition:** Ligand A (0.696) has a slightly higher hERG risk than Ligand B (0.478), but both are relatively low.
* **Microsomal Clearance:** Ligand B (14.021) has a significantly lower (better) microsomal clearance than Ligand A (32.716), indicating better metabolic stability.
* **In vitro Half-Life:** Ligand B (-4.684) has a much longer in vitro half-life than Ligand A (79.331).
* **P-gp Efflux:** Ligand A (0.688) has a slightly higher P-gp efflux liability than Ligand B (0.042). Lower efflux is preferred.
* **Binding Affinity:** Ligand B (-7.0 kcal/mol) has a slightly better binding affinity than Ligand A (-6.7 kcal/mol). While the difference is not huge, it is still favorable.
**Overall Assessment:**
Ligand B is significantly better than Ligand A. The primary driver is the drastically lower DILI risk for Ligand B. Additionally, Ligand B has better TPSA, logP, solubility, metabolic stability, half-life, P-gp efflux, and slightly better binding affinity. While Ligand A has a slightly better QED, the safety concerns and other ADME drawbacks outweigh this benefit.
**Output:**
0
2025-04-17 19:37:34,746 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (364.5 and 358.5 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Both ligands (75.2 and 78.1) are below the 140 A^2 threshold for good oral absorption, but also not optimized for CNS penetration (below 90). No clear advantage.
3. **logP:** Both ligands (2.55 and 2.09) are within the optimal 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Ligand A has 1 HBD, Ligand B has 2. Both are acceptable (<=5).
5. **HBA:** Ligand A has 5 HBA, Ligand B has 4. Both are acceptable (<=10).
6. **QED:** Both ligands have good QED scores (0.787 and 0.878), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (47.7) has a lower DILI risk than Ligand B (58.4). This is a significant advantage.
8. **BBB:** Ligand A (61.8) has better BBB penetration potential than Ligand B (50.5). While ADRB2 isn't exclusively a CNS target, some distribution to the CNS is possible and not necessarily detrimental.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.162 and -5.306), which is unusual and suggests poor permeability. This is a major concern for both.
10. **Solubility:** Both ligands have very poor aqueous solubility (-2.675 and -3.228). This is a significant drawback.
11. **hERG:** Both ligands have low hERG inhibition risk (0.126 and 0.322). No clear advantage.
12. **Cl_mic:** Ligand A (50.08) has a higher microsomal clearance than Ligand B (14.15). This suggests Ligand B is more metabolically stable. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand A (-1.99) has a negative in vitro half-life, which is not possible. Ligand B (-19.87) is also very low. Both are extremely unfavorable.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.283 and 0.102). No clear advantage.
15. **Affinity:** Ligand A (-6.9 kcal/mol) has a significantly better binding affinity than Ligand B (-3.3 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME concerns.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A has a slightly better logP, comparable TPSA and Pgp, and *much* better affinity. The improved DILI and BBB are also positives. The biggest drawback for both is the poor Caco-2 and solubility, and the very poor half-life. However, the large difference in binding affinity is a major factor.
**Conclusion:**
Despite the poor solubility and permeability predictions, the significantly stronger binding affinity of Ligand A (-6.9 kcal/mol vs -3.3 kcal/mol) is a decisive advantage. The better DILI and BBB profiles also contribute to its favorability. While Ligand B has better metabolic stability, the potency difference is too large to ignore.
Output:
1
2025-04-17 19:37:34,746 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Step-by-step comparison:**
1. **MW:** Both ligands (346.39 & 350.44 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand B (58.2) is significantly better than Ligand A (117.35). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (4.55) is higher than Ligand A (0.44). While 4.55 is approaching the upper limit, it's still acceptable. Ligand A's 0.44 is quite low and could indicate poor membrane permeability.
4. **HBD:** Ligand A (3) and Ligand B (2) are both within the acceptable range of <=5.
5. **HBA:** Ligand A (6) and Ligand B (3) are both within the acceptable range of <=10.
6. **QED:** Ligand B (0.85) has a higher QED score than Ligand A (0.67), indicating a more drug-like profile.
7. **DILI:** Ligand A (60.14) is better than Ligand B (77.2), indicating a lower risk of drug-induced liver injury. This is a significant advantage for Ligand A.
8. **BBB:** Ligand B (69.1) is better than Ligand A (30.98), but BBB isn't a high priority for a cardiovascular target.
9. **Caco-2:** Ligand A (-5.46) is better than Ligand B (-4.88).
10. **Solubility:** Ligand A (-2.01) is better than Ligand B (-5.55).
11. **hERG:** Ligand A (0.13) is better than Ligand B (0.60), indicating a lower risk of cardiotoxicity. This is a crucial advantage for a cardiovascular drug.
12. **Cl_mic:** Ligand A (27.63) has a lower microsomal clearance than Ligand B (50.999), suggesting better metabolic stability.
13. **t1/2:** Ligand B (34.07) has a longer in vitro half-life than Ligand A (-4.54).
14. **Pgp:** Ligand A (0.058) has lower P-gp efflux than Ligand B (0.541), which is advantageous for bioavailability.
15. **Binding Affinity:** Ligand B (-6.7 kcal/mol) has a significantly better binding affinity than Ligand A (-5.8 kcal/mol). This is a 0.9 kcal/mol difference, which is substantial enough to potentially outweigh some ADME concerns.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP and affinity. Ligand A is better in TPSA and Pgp.
**Overall Assessment:**
While Ligand A has advantages in DILI, hERG, solubility, and metabolic stability, the significantly stronger binding affinity of Ligand B (-6.7 vs -5.8 kcal/mol) is a major deciding factor. The higher logP of Ligand B, while approaching the upper limit, is also more favorable for receptor engagement. The differences in other ADME properties are not as critical, and can potentially be optimized in later stages of drug development. The better half-life of Ligand B is also a plus.
Output:
0
2025-04-17 19:37:34,746 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
Let's systematically compare Ligand A and Ligand B based on the provided parameters, keeping in mind the GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key).
1. **Molecular Weight:** Both ligands (350.5 & 343.5 Da) fall comfortably within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (78.43) is slightly higher than Ligand B (71.09). Both are below the 140 threshold for oral absorption, but closer to the upper end.
3. **logP:** Both ligands have good logP values (2.52 & 2.795), falling within the optimal 1-3 range. Ligand B is slightly higher, potentially offering better membrane permeability.
4. **H-Bond Donors:** Ligand A has 3 HBDs, while Ligand B has 2. Both are acceptable (<=5).
5. **H-Bond Acceptors:** Both ligands have 3 HBAs, well within the acceptable range (<=10).
6. **QED:** Ligand A (0.629) has a slightly better QED score than Ligand B (0.507), indicating a more drug-like profile.
7. **DILI Risk:** Ligand B (34.393) has a significantly lower DILI risk than Ligand A (14.036). This is a major advantage for Ligand B.
8. **BBB Penetration:** Both ligands have similar BBB penetration (54.983 vs 55.293). For a cardiovascular target like ADRB2, BBB penetration isn't a primary concern, but it's not detrimental.
9. **Caco-2 Permeability:** Both ligands exhibit poor Caco-2 permeability (-4.767 and -4.983). This suggests potential absorption issues, but is not a deciding factor.
10. **Aqueous Solubility:** Both ligands have poor aqueous solubility (-3.104 and -2.365). Solubility is a concern, but can be addressed with formulation strategies.
11. **hERG Inhibition:** Both ligands have low hERG inhibition risk (0.354 and 0.489). This is good, minimizing cardiotoxicity concerns.
12. **Microsomal Clearance:** Ligand A (50.647) has lower microsomal clearance than Ligand B (53.208), suggesting better metabolic stability.
13. **In vitro Half-Life:** Ligand B (14.072) has a significantly longer in vitro half-life than Ligand A (-7.804). This is a substantial advantage, potentially leading to less frequent dosing.
14. **P-gp Efflux:** Both ligands have low P-gp efflux liability (0.154 and 0.104), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand B (-6.8 kcal/mol) has a slightly better binding affinity than Ligand A (-6.1 kcal/mol). While the difference is less than the 1.5 kcal/mol threshold, it's still a positive factor.
**Overall Assessment:**
Ligand B is the better candidate. While Ligand A has a slightly better QED and lower Cl_mic, Ligand B's significantly lower DILI risk and longer half-life are more critical advantages. The slightly better binding affinity of Ligand B further supports this conclusion. The poor Caco-2 and solubility are drawbacks for both, but formulation strategies can potentially mitigate these issues. The lower DILI risk is a major safety consideration, and the longer half-life is a significant benefit for dosing convenience.
Output:
0
2025-04-17 19:37:34,746 - INFO - Batch 124 complete. Total preferences: 1984
2025-04-17 19:37:34,746 - INFO - Processing batch 125/512...
2025-04-17 19:38:20,953 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [342.487, 38.82, 2.129, 1, 3, 0.911, 7.057, 71.462, -4.838, -1.451, 0.847, -9.99, 7.878, 0.021, -7.1]
**Ligand B:** [340.387, 113.24, 0.443, 3, 5, 0.684, 56.146, 78.558, -5.514, -2.637, 0.271, 32.814, -17.418, 0.006, -5.3]
Here's a breakdown, considering the GPCR priorities (logP, Pgp, TPSA, BBB, and affinity):
1. **MW:** Both are within the ideal range (200-500 Da). A is 342.487, B is 340.387 - very similar.
2. **TPSA:** Ligand A (38.82) is excellent, well below the 140 threshold and very favorable for permeability. Ligand B (113.24) is higher, but still acceptable, though less optimal.
3. **logP:** Ligand A (2.129) is optimal. Ligand B (0.443) is low, potentially hindering membrane permeability and absorption.
4. **HBD/HBA:** A (1/3) is better than B (3/5). Fewer H-bonds generally improve permeability.
5. **QED:** Ligand A (0.911) is excellent, indicating high drug-likeness. Ligand B (0.684) is still reasonable, but less desirable.
6. **DILI:** Ligand A (7.057) has a very low DILI risk. Ligand B (56.146) is higher, indicating a moderate risk.
7. **BBB:** Both have good BBB penetration (A: 71.462, B: 78.558). B is slightly better, but both are acceptable.
8. **Caco-2:** Ligand A (-4.838) is better than Ligand B (-5.514), indicating better intestinal absorption.
9. **Solubility:** Ligand A (-1.451) is better than Ligand B (-2.637).
10. **hERG:** Ligand A (0.847) is much better than Ligand B (0.271), indicating a lower risk of cardiotoxicity.
11. **Cl_mic:** Ligand A (-9.99) is significantly better (lower clearance, more stable) than Ligand B (32.814).
12. **t1/2:** Ligand A (7.878) is much better than Ligand B (-17.418).
13. **Pgp:** Ligand A (0.021) is much better than Ligand B (0.006) indicating lower efflux and better bioavailability.
14. **Affinity:** Ligand A (-7.1) is better than Ligand B (-5.3) by 1.8 kcal/mol, a substantial difference.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical parameters, especially those prioritized for GPCRs. The superior logP, lower DILI risk, better metabolic stability (Cl_mic and t1/2), lower Pgp efflux, and significantly stronger binding affinity make Ligand A the far more promising candidate. While Ligand B has acceptable BBB penetration, its poor logP, higher DILI, and weaker binding affinity are significant drawbacks.
Output:
1
2025-04-17 19:38:20,954 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (372.49 & 366.40 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (76.15) is significantly better than Ligand B (87.66). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (2.669) is within the optimal 1-3 range, while Ligand A (0.359) is quite low. This is a substantial negative for Ligand A, potentially hindering membrane permeability.
4. **HBD:** Ligand A (0) is preferable to Ligand B (1). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (6). Similar to HBD, lower HBA is generally better for permeability.
6. **QED:** Both ligands have good QED scores (0.696 and 0.725), indicating generally drug-like properties.
7. **DILI:** Ligand A (20.36) has a much lower DILI risk than Ligand B (82.44). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (74.29) is better than Ligand B (64.48), but this isn't a critical factor for a cardiovascular target.
9. **Caco-2:** Ligand A (-4.701) is better than Ligand B (-5.109). Higher Caco-2 values indicate better intestinal absorption.
10. **Solubility:** Ligand A (-1.496) is better than Ligand B (-3.754). Better solubility is always a plus.
11. **hERG:** Ligand A (0.214) has a significantly lower hERG risk than Ligand B (0.475). This is a crucial safety parameter.
12. **Cl_mic:** Ligand A (14.26) has a much lower microsomal clearance than Ligand B (42.73). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand B (11.14) has a longer in vitro half-life than Ligand A (6.10). This is a slight advantage for Ligand B.
14. **Pgp:** Ligand A (0.019) has a much lower P-gp efflux liability than Ligand B (0.256). This suggests better oral bioavailability for Ligand A.
15. **Binding Affinity:** Ligand A (-7.0) has a slightly better binding affinity than Ligand B (-6.2). While the difference is not huge, it's still a positive for Ligand A.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Ligand A is superior in TPSA, Pgp, and has comparable affinity. Ligand B has a better logP, but Ligand A's logP is still acceptable.
**Overall Assessment:**
Ligand A demonstrates a significantly more favorable profile across critical ADME-Tox parameters (DILI, hERG, Cl_mic, Pgp) and has a slightly better binding affinity. While Ligand B has a better logP and half-life, the safety and metabolic advantages of Ligand A are more compelling, especially considering the cardiovascular context where minimizing off-target effects is paramount.
Output:
1
2025-04-17 19:38:20,954 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Ligand A (415.255 Da) is within the ideal range, while Ligand B (369.849 Da) is also acceptable. No clear advantage here.
2. **TPSA:** Ligand A (64.99) is good, well below the 140 threshold. Ligand B (74.87) is also acceptable.
3. **logP:** Ligand A (3.658) is at the higher end of the optimal range, but still acceptable. Ligand B (1.537) is lower, potentially impacting permeability. This favors Ligand A.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 5 HBA, and Ligand B has 4. Both are within the acceptable range.
6. **QED:** Ligand B (0.873) has a significantly better QED score than Ligand A (0.527), indicating a more drug-like profile. This favors Ligand B.
7. **DILI:** Ligand A (60.682) is approaching a concerning DILI risk, while Ligand B (70.919) is higher. This favors Ligand A.
8. **BBB:** Ligand A (79.062) has better BBB penetration than Ligand B (58.511). Given ADRB2 involvement in cardiovascular function, CNS penetration isn't a primary concern, but it's a slight advantage for A.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
10. **Solubility:** Both ligands have negative solubility values, which is also unusual. Again, the scale is not specified.
11. **hERG:** Ligand A (0.821) has a slightly higher hERG risk than Ligand B (0.219). This favors Ligand B.
12. **Cl_mic:** Ligand A (100.061) has a much higher microsomal clearance than Ligand B (1.568), indicating lower metabolic stability. This strongly favors Ligand B.
13. **t1/2:** Ligand A (93.673) has a significantly longer in vitro half-life than Ligand B (16.429). This favors Ligand A.
14. **Pgp:** Ligand A (0.783) has a higher P-gp efflux liability than Ligand B (0.102). This favors Ligand B.
15. **Binding Affinity:** Ligand B (-7.0 kcal/mol) has a significantly better binding affinity than Ligand A (-6.5 kcal/mol). This is a substantial advantage for Ligand B.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand B excels in affinity and Pgp efflux, and has a reasonable logP. While Ligand A has better BBB penetration, this is less critical for a cardiovascular target. The improved metabolic stability of Ligand B (lower Cl_mic) is also a significant advantage. The higher QED score of Ligand B is also a positive factor.
**Overall Assessment:**
Despite the longer half-life of Ligand A, the superior binding affinity, lower Pgp efflux, better QED, and improved metabolic stability of Ligand B outweigh the benefits of Ligand A. The DILI risk of Ligand B is a concern, but can be addressed in further optimization.
Output:
0
2025-04-17 19:38:20,954 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Ligand A (422.055 Da) is within the ideal range, while Ligand B (365.543 Da) is also good, slightly lower but still acceptable.
2. **TPSA:** Ligand A (93.21) is acceptable, though approaching the upper limit for good oral absorption. Ligand B (62.3) is excellent, well below the 140 threshold.
3. **logP:** Both ligands (A: 3.567, B: 3.385) are within the optimal 1-3 range.
4. **HBD:** Ligand A (2) and Ligand B (1) are both good, well under the 5 limit.
5. **HBA:** Ligand A (6) and Ligand B (4) are both good, under the 10 limit.
6. **QED:** Both ligands have good QED scores (A: 0.736, B: 0.768), indicating drug-likeness.
7. **DILI:** Ligand A (99.457) has a very high DILI risk, which is a major concern. Ligand B (41.179) has a low DILI risk, a significant advantage.
8. **BBB:** Ligand A (53.703) has moderate BBB penetration, while Ligand B (62.854) is also moderate. BBB is less critical for ADRB2 (cardiovascular target) than for CNS targets, but still a consideration.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.766 and -4.967), which is unusual and suggests poor permeability. This is concerning for both.
10. **Solubility:** Ligand A (-5.538) and Ligand B (-3.24) both have poor aqueous solubility.
11. **hERG:** Ligand A (0.241) has a slightly higher hERG risk than Ligand B (0.345), but both are relatively low.
12. **Cl_mic:** Ligand A (14.323) has a lower (better) microsomal clearance than Ligand B (70.354), indicating better metabolic stability.
13. **t1/2:** Ligand A (19.861) has a longer half-life than Ligand B (9.339), which is desirable.
14. **Pgp:** Ligand A (0.479) has lower P-gp efflux than Ligand B (0.262), which is favorable.
15. **Affinity:** Ligand B (-6.8 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.4 kcal/mol), a difference of 1.4 kcal/mol. This is a substantial advantage.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in TPSA and affinity. The biggest drawback for Ligand A is its extremely high DILI risk. While both have poor solubility and Caco-2 permeability, the DILI risk for Ligand A is a dealbreaker. The significantly better affinity of Ligand B, combined with its much lower DILI risk, outweighs its slightly higher Cl_mic and lower half-life.
**Output:**
0
2025-04-17 19:38:20,954 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.403 and 347.463 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (95.22) is higher than Ligand B (77.37). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is generally preferred for absorption. Ligand B has a clear advantage here.
3. **logP:** Ligand A (0.085) is quite low, potentially hindering membrane permeability. Ligand B (1.562) is within the optimal 1-3 range. Ligand B is significantly better.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 7 HBA, while Ligand B has 5. Both are acceptable, but Ligand B is slightly better.
6. **QED:** Both ligands have similar QED scores (0.778 and 0.784), indicating good drug-likeness.
7. **DILI:** Ligand A (56.805) has a higher DILI risk than Ligand B (20.047). This is a significant advantage for Ligand B.
8. **BBB:** Both ligands have reasonable BBB penetration (63.086 and 68.282). Since ADRB2 is not primarily a CNS target, this is less critical, but Ligand B is slightly better.
9. **Caco-2:** Both ligands have similar, poor Caco-2 permeability (-4.909 and -4.986). This is a concern for both, but not a deciding factor.
10. **Solubility:** Both ligands have very poor aqueous solubility (-1.892 and -1.768). This is a significant drawback for both, and may require formulation strategies.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.095 and 0.104). This is excellent for both.
12. **Cl_mic:** Ligand A (45.237) has a higher microsomal clearance than Ligand B (-2.172). Ligand B indicates better metabolic stability, which is desirable.
13. **t1/2:** Ligand B (2.52) has a longer in vitro half-life than Ligand A (0.878). This is a significant advantage for Ligand B.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.113 and 0.008). Ligand B is slightly better.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.2 and -6.3 kcal/mol). The difference is negligible.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand B is clearly superior. It has a much better logP, lower TPSA, significantly lower DILI risk, better metabolic stability (lower Cl_mic), and a longer half-life. While both have poor solubility and Caco-2 permeability, these are formulation challenges that can be addressed. The slight advantage in BBB penetration and Pgp efflux also favor Ligand B. The binding affinity is essentially the same.
Output:
0
2025-04-17 19:38:20,954 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (361.364 and 345.443 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (91.32) is slightly higher than Ligand B (82.53). Both are below the 140 threshold for good oral absorption, but closer to the 90 threshold for CNS targets (less relevant for ADRB2, a cardiovascular target). Ligand B is preferable.
3. **logP:** Both ligands have similar logP values (1.787 and 1.746), falling within the optimal 1-3 range. No significant difference.
4. **HBD:** Ligand A has 3 HBD, while Ligand B has 2. Both are within the acceptable limit of <=5. Ligand B is slightly preferred.
5. **HBA:** Both ligands have 4 HBA, well within the acceptable limit of <=10. No significant difference.
6. **QED:** Both ligands have good QED scores (0.72 and 0.77), indicating good drug-like properties. No significant difference.
7. **DILI:** Ligand A (39.434) has a slightly higher DILI risk than Ligand B (31.718), but both are below the concerning threshold of 60. Ligand B is preferable.
8. **BBB:** Ligand A (54.285) has a higher BBB penetration percentile than Ligand B (29.508). While ADRB2 is not a CNS target, some degree of BBB penetration isn't necessarily detrimental, and could allow for off-target effects.
9. **Caco-2:** Ligand A (-5.028) has a worse Caco-2 permeability than Ligand B (-4.826). Ligand B is preferable.
10. **Solubility:** Ligand A (-2.949) has worse aqueous solubility than Ligand B (-1.738). Ligand B is preferable.
11. **hERG:** Ligand A (0.456) has a slightly higher hERG inhibition liability than Ligand B (0.188). Ligand B is preferable.
12. **Cl_mic:** Ligand A (6.56) has a significantly lower microsomal clearance than Ligand B (17.652), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (-5.181) has a significantly longer in vitro half-life than Ligand B (-12.62). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.056) has lower P-gp efflux liability than Ligand B (0.096). Ligand A is preferable.
15. **Binding Affinity:** Ligand B (-6.0) has a stronger binding affinity than Ligand A (-5.1). This is a substantial advantage for Ligand B.
**Overall Assessment:**
Ligand B has a clear advantage in binding affinity (-6.0 vs -5.1 kcal/mol). This is a crucial factor for GPCRs. While Ligand A excels in metabolic stability (Cl_mic and t1/2) and Pgp efflux, the difference in affinity is substantial enough to outweigh these benefits. Ligand B also shows better scores for TPSA, DILI, Caco-2, solubility and hERG.
Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity), and the importance of potency for this target class, Ligand B is the more promising candidate.
Output:
0
2025-04-17 19:38:20,955 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (363.418 Da and 374.819 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (83.29) is slightly higher than Ligand B (78.09). Both are below the 140 threshold for good oral absorption, and acceptable for a peripheral GPCR like ADRB2.
3. **logP:** Ligand A (1.115) is within the optimal range (1-3), while Ligand B (2.55) is leaning towards the higher end but still acceptable.
4. **HBD:** Both ligands have 2 H-bond donors, which is good.
5. **HBA:** Ligand A has 5 H-bond acceptors, while Ligand B has 3. Both are within the acceptable limit of 10.
6. **QED:** Both ligands have good QED scores (0.713 and 0.795), indicating good drug-like properties.
7. **DILI:** Ligand A (73.245) has a higher DILI risk than Ligand B (53.858). This is a significant negative for Ligand A.
8. **BBB:** Both ligands have moderate BBB penetration, but Ligand A (74.719) is slightly higher than Ligand B (64.25). While ADRB2 is not a CNS target, some degree of BBB penetration isn't necessarily detrimental.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the values are close enough that this isn't a major differentiator.
10. **Solubility:** Both ligands have negative solubility values, indicating poor solubility. This is a concern for both.
11. **hERG:** Ligand A (0.604) has a slightly higher hERG risk than Ligand B (0.398), but both are relatively low.
12. **Cl_mic:** Ligand A (34.334) has a significantly lower microsomal clearance than Ligand B (7.842). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (12.711) has a longer in vitro half-life than Ligand B (-25.565). The negative value for ligand B is concerning and suggests very rapid metabolism.
14. **Pgp:** Ligand A (0.232) has a lower P-gp efflux liability than Ligand B (0.065), which is favorable.
15. **Binding Affinity:** Ligand B (-7.5) has a slightly better binding affinity than Ligand A (-7.0). While a 0.5 kcal/mol difference isn't huge, it's noticeable.
**Overall Assessment & GPCR-Specific Priorities:**
For a GPCR like ADRB2, potency (affinity) is crucial. Ligand B has a slightly better affinity. However, the significantly higher DILI risk for Ligand A and the extremely short half-life and low Pgp for Ligand B are major drawbacks. The better metabolic stability (lower Cl_mic and longer t1/2) and lower Pgp efflux of Ligand A are very attractive. The slightly higher DILI risk is concerning, but the improved ADME profile outweighs this risk, especially given the similar affinities.
Output:
1
2025-04-17 19:38:20,955 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (359.348 and 349.431 Da) fall within the ideal range of 200-500 Da. No significant difference here.
2. **TPSA:** Ligand A (63.69) is significantly better than Ligand B (84.67). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally aids absorption.
3. **logP:** Both ligands have good logP values (3.026 and 2.146), falling within the optimal 1-3 range. Ligand A is slightly higher, which *could* be a minor advantage for membrane permeability, but it's not a large difference.
4. **HBD:** Both ligands have 1 HBD, which is within the acceptable limit of <=5.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 5. Both are acceptable (<=10).
6. **QED:** Ligand A (0.882) has a considerably higher QED score than Ligand B (0.691), indicating a more drug-like profile.
7. **DILI:** Ligand A (43.66) has a slightly higher DILI risk than Ligand B (39.201), but both are below the 40 threshold and considered good.
8. **BBB:** Ligand A (96.937) has much higher BBB penetration than Ligand B (79.682). While not the highest priority for a cardiovascular target, higher BBB is generally favorable and may indicate better overall distribution.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.643 and -4.524), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand A (-3.733) has slightly better solubility than Ligand B (-2.526), though both are poor.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.583 and 0.387). This is excellent.
12. **Cl_mic:** Ligand A (13.469) has significantly lower microsomal clearance than Ligand B (69.391), indicating better metabolic stability. This is a major advantage.
13. **t1/2:** Ligand A (-2.011) has a negative half-life, which is unusual, while Ligand B (4.914) has a positive half-life. This suggests Ligand B is more stable *in vitro*.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.248 and 0.156).
15. **Binding Affinity:** Ligand B (-6.9 kcal/mol) has a slightly better binding affinity than Ligand A (-6.2 kcal/mol). This is a 0.7 kcal/mol difference, which is significant, but not overwhelming.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Both ligands are reasonable in logP and Pgp. Ligand A has a better TPSA. The affinity difference is present but not huge. The biggest differentiator is the metabolic stability (Cl_mic) and QED, both favoring Ligand A.
**Overall Assessment:**
Despite the slightly better affinity of Ligand B, Ligand A is the more promising candidate. Its superior QED score, significantly lower microsomal clearance (better metabolic stability), and better TPSA outweigh the small affinity difference. The poor Caco-2 values for both are a concern that would need to be addressed in further optimization, but Ligand A's other properties give it a better starting point.
Output:
1
2025-04-17 19:38:20,955 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands (362.539 Da and 360.376 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (49.41) is better than Ligand B (67.43). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (2.839 and 1.621), falling within the 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Both ligands have the same HBA count (3), which is acceptable (<=10).
6. **QED:** Both ligands have similar QED values (0.765 and 0.783), indicating good drug-likeness.
7. **DILI:** Ligand A (16.014%) has a significantly lower DILI risk than Ligand B (35.091%). This is a major advantage for Ligand A.
8. **BBB:** Both ligands have good BBB penetration (80.264% and 83.366%). Since ADRB2 is primarily cardiovascular, this isn't a critical factor, but higher is not detrimental.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.168 and -5.0). This is unusual and suggests poor permeability. However, the values are similar.
10. **Solubility:** Both ligands have negative solubility values (-3.564 and -3.118). This is also concerning, indicating poor aqueous solubility. Again, the values are similar.
11. **hERG:** Both ligands have low hERG inhibition liability (0.494 and 0.247), which is good.
12. **Cl_mic:** Ligand B (15.749) has significantly lower microsomal clearance than Ligand A (51.866), indicating better metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand B (7.3) has a longer in vitro half-life than Ligand A (-7.596). This is a strong advantage for Ligand B.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.145 and 0.058), which is good.
15. **Binding Affinity:** Ligand B (-6.7 kcal/mol) has a slightly better binding affinity than Ligand A (-5.6 kcal/mol). This 1.1 kcal/mol difference is substantial and could outweigh some ADME drawbacks.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has a slightly better logP and TPSA, while Ligand B has better affinity and Pgp efflux. The biggest differentiator is the DILI risk, where Ligand A is significantly better. Metabolic stability (Cl_mic and t1/2) are also important, and Ligand B is superior in these aspects.
**Overall Assessment:**
While Ligand B has a better binding affinity and improved metabolic stability, the significantly lower DILI risk associated with Ligand A is a critical advantage. DILI is a major cause of drug attrition, and minimizing this risk is paramount. The slight advantage in affinity for Ligand B is unlikely to overcome the substantial DILI risk. The solubility and Caco-2 values are poor for both, but can be addressed with formulation strategies.
Output:
1
2025-04-17 19:38:20,955 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (350.419 and 348.353 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (96.69) is higher than Ligand B (67.23). While both are under 140, the lower TPSA of Ligand B is preferable for oral absorption, a general benefit.
3. **logP:** Ligand A (-0.362) is quite low, potentially hindering membrane permeability. Ligand B (1.462) is within the optimal 1-3 range. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable, below the threshold of 5.
5. **HBA:** Ligand A (6) and Ligand B (4) are both acceptable, below the threshold of 10.
6. **QED:** Both ligands have good QED scores (0.756 and 0.91), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Both ligands have acceptable DILI risk (37.611 and 41.024), below the 40% threshold. No major difference.
8. **BBB:** Ligand A (25.746) has very poor BBB penetration, while Ligand B (81.698) has good BBB penetration. While ADRB2 isn't exclusively a CNS target, some CNS exposure can occur, and better BBB penetration is generally favorable.
9. **Caco-2:** Ligand A (-5.227) and Ligand B (-4.532) both have negative values, which is unusual and suggests poor permeability. However, the value for Ligand B is slightly less negative.
10. **Solubility:** Ligand A (-0.944) and Ligand B (-2.581) both have negative solubility values, indicating poor solubility. Ligand A is slightly better.
11. **hERG:** Both ligands have low hERG inhibition liability (0.084 and 0.449), which is excellent. No significant difference.
12. **Cl_mic:** Ligand A (-9.341) has a much lower (better) microsomal clearance than Ligand B (20.359). This suggests greater metabolic stability for Ligand A.
13. **t1/2:** Ligand A (22.038) has a longer in vitro half-life than Ligand B (-21.853). This is a significant advantage for Ligand A.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.013 and 0.066). No significant difference.
15. **Binding Affinity:** Both ligands have similar binding affinities (-5.4 and -5.5 kcal/mol).
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, and affinity are key. Ligand B excels in logP and has a lower TPSA. While affinity is similar, the better logP and TPSA of Ligand B, combined with its better BBB penetration, outweigh the advantages of Ligand A's metabolic stability and half-life.
**Conclusion:**
Ligand B demonstrates a better balance of properties for a viable drug candidate targeting ADRB2, particularly concerning permeability and absorption.
Output:
0
2025-04-17 19:38:20,956 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [363.439, 116.13 , 1.368, 2. , 5. , 0.792, 66.421, 41.373, -5.032, -3.16 , 0.086, 7.592, 30.629, 0.088, -7.7 ]
**Ligand B:** [366.487, 111.09 , 0.703, 3. , 5. , 0.548, 18.728, 63.28 , -5.668, -2.585, 0.214, 3.176, -10.897, 0.025, -6.8 ]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, Affinity, BBB):
1. **MW:** Both are within the ideal range (200-500 Da).
2. **TPSA:** Ligand A (116.13) is slightly higher than Ligand B (111.09), but both are acceptable for a non-CNS GPCR target like ADRB2.
3. **logP:** Ligand A (1.368) is better than Ligand B (0.703). Ligand B is a bit low, potentially impacting permeability.
4. **HBD/HBA:** Ligand A (2 HBD, 5 HBA) is slightly more favorable than Ligand B (3 HBD, 5 HBA).
5. **QED:** Ligand A (0.792) is significantly better than Ligand B (0.548), indicating a more drug-like profile.
6. **DILI:** Ligand B (18.728) has a much lower DILI risk than Ligand A (66.421). This is a significant advantage for Ligand B.
7. **BBB:** Ligand B (63.28) has a better BBB penetration than Ligand A (41.373), but this is less critical for ADRB2 which is not a primary CNS target.
8. **Caco-2:** Both are negative, which is unusual and suggests poor permeability. Ligand A (-5.032) is worse than Ligand B (-5.668).
9. **Solubility:** Both have very poor solubility (-3.16 and -2.585). This is a major concern for both compounds.
10. **hERG:** Ligand A (0.086) has a slightly lower hERG risk than Ligand B (0.214).
11. **Cl_mic:** Ligand B (3.176) has a much lower microsomal clearance than Ligand A (7.592), suggesting better metabolic stability.
12. **t1/2:** Ligand A (30.629) has a better in vitro half-life than Ligand B (-10.897).
13. **Pgp:** Ligand A (0.088) has a lower P-gp efflux liability than Ligand B (0.025), which is favorable for bioavailability.
14. **Affinity:** Ligand A (-7.7 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.8 kcal/mol). This is a substantial advantage.
**Overall Assessment:**
The biggest differentiator is the binding affinity. Ligand A has a 0.9 kcal/mol advantage, which is a significant difference. While Ligand B has better metabolic stability (lower Cl_mic) and a lower DILI risk, the strong binding of Ligand A, combined with its better QED and Pgp profile, outweighs these benefits. Both compounds have poor solubility and Caco-2 permeability, which would need to be addressed in further optimization, but the potency advantage of Ligand A is crucial for a GPCR target.
Output:
1
2025-04-17 19:38:20,956 - INFO - Reasoning:
Let's analyze Ligand A and Ligand B for their potential as ADRB2 ligands, keeping in mind the GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key).
**Molecular Weight:** Both ligands (355.479 and 351.466 Da) fall comfortably within the ideal 200-500 Da range.
**TPSA:** Ligand A (89.95) is slightly higher than Ligand B (56.67). Both are below the 140 threshold for oral absorption, but Ligand B is significantly better, potentially indicating better cell permeability.
**logP:** Ligand A (0.756) is a bit low, potentially hindering membrane permeability. Ligand B (2.169) is within the optimal 1-3 range. This is a clear advantage for Ligand B.
**H-Bond Donors/Acceptors:** Ligand A has 2 HBD and 4 HBA, while Ligand B has 1 HBD and 4 HBA. Both are within acceptable limits.
**QED:** Both ligands have good QED scores (0.705 and 0.818), suggesting good drug-like properties.
**DILI:** Ligand A (12.524) has a higher DILI risk than Ligand B (4.459). This is a significant advantage for Ligand B.
**BBB:** Ligand A (18.457) has very low BBB penetration, while Ligand B (92.749) has excellent BBB penetration. Since ADRB2 is a GPCR, and while not exclusively a CNS target, improved CNS exposure can be beneficial and is not detrimental in this case.
**Caco-2 Permeability:** Ligand A (-5.144) has poor Caco-2 permeability, while Ligand B (-4.658) is slightly better, but still poor.
**Aqueous Solubility:** Both ligands have very poor aqueous solubility (-0.811 and -0.997). This could pose formulation challenges.
**hERG Inhibition:** Ligand A (0.114) has a slightly lower hERG risk than Ligand B (0.841), but both are relatively low.
**Microsomal Clearance:** Ligand A (12.406) has higher microsomal clearance than Ligand B (10.669), suggesting lower metabolic stability.
**In vitro Half-Life:** Ligand B (-22.834) has a significantly longer in vitro half-life than Ligand A (-9.162), indicating better stability.
**P-gp Efflux:** Ligand A (0.021) has very low P-gp efflux, while Ligand B (0.265) has slightly higher efflux. This is a minor advantage for Ligand A.
**Binding Affinity:** Ligand A (-5.9 kcal/mol) has a significantly stronger binding affinity than Ligand B (-0.3 kcal/mol). This is a substantial advantage for Ligand A.
**Overall Assessment:**
Despite the significantly stronger binding affinity of Ligand A, the ADME properties of Ligand B are far superior. Ligand B has better logP, significantly lower DILI risk, excellent BBB penetration, and a much longer half-life. The poor solubility of both is a concern, but can potentially be addressed with formulation strategies. The strong affinity of Ligand A is tempting, but the poor ADME profile, particularly the low logP and higher DILI risk, make it less likely to succeed as a drug candidate. The significant difference in binding affinity *could* outweigh the ADME concerns, but the combination of improvements in Ligand B's profile is compelling.
Output:
0
2025-04-17 19:38:20,956 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
Let's break down the comparison of Ligand A and Ligand B based on the provided parameters, keeping in mind the GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key).
1. **Molecular Weight:** Both ligands are within the acceptable range (200-500 Da). Ligand B (361.511 Da) is slightly smaller, which can be advantageous for permeability.
2. **TPSA:** Both are reasonably low (A: 69.81, B: 71.09), suggesting good potential for absorption.
3. **logP:** Both have good logP values (A: 4.904, B: 3.112), falling within the optimal 1-3 range. Ligand B is preferable here as A is slightly high, potentially leading to off-target effects.
4. **H-Bond Donors/Acceptors:** Ligand A has 3 HBD and 3 HBA, while Ligand B has 2 HBD and 4 HBA. Both are acceptable.
5. **QED:** Both have reasonable QED scores (A: 0.444, B: 0.524), indicating moderate drug-likeness. Ligand B is slightly better.
6. **DILI Risk:** Ligand A (89.841) has a significantly higher DILI risk than Ligand B (34.238). This is a major concern for Ligand A.
7. **BBB Penetration:** Ligand A (78.519) shows better BBB penetration than Ligand B (62.078). While ADRB2 isn't exclusively a CNS target, some cardiovascular effects might benefit from some CNS exposure.
8. **Caco-2 Permeability:** Both have negative Caco-2 values, which is unusual and indicates poor permeability. However, the scale is not specified, so it is difficult to interpret.
9. **Aqueous Solubility:** Both have negative solubility values, indicating poor solubility. Again, the scale is not specified.
10. **hERG Inhibition:** Ligand A (0.818) has a slightly higher hERG risk than Ligand B (0.413), but both are relatively low.
11. **Microsomal Clearance:** Ligand A (58.209) has higher clearance than Ligand B (29.349), suggesting lower metabolic stability.
12. **In vitro Half-Life:** Ligand A (82.514) has a longer half-life than Ligand B (14.093). This is a positive for Ligand A.
13. **P-gp Efflux:** Ligand A (0.634) has higher P-gp efflux than Ligand B (0.275), which is undesirable.
14. **Binding Affinity:** Ligand A (-8.3 kcal/mol) has a significantly stronger binding affinity than Ligand B (-4.3 kcal/mol). This is a substantial advantage for Ligand A.
**Overall Assessment:**
The biggest differentiating factor is the binding affinity. Ligand A's affinity is *much* stronger. However, this comes with significant drawbacks: higher DILI risk, higher P-gp efflux, and higher microsomal clearance. Ligand B is more balanced, with lower DILI risk, better P-gp efflux, and better metabolic stability. While its affinity is weaker, it is still in a reasonable range. Given the importance of avoiding toxicity (DILI) and maintaining reasonable ADME properties for a cardiovascular drug, I believe the more balanced profile of Ligand B outweighs the affinity advantage of Ligand A.
Output:
0
2025-04-17 19:38:20,956 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [392.937, 66.91, 4.05, 2, 6, 0.594, 84.296, 81.233, -5.477, -4.667, 0.811, 96.819, 88.992, 0.824, -6.2]
**Ligand B:** [346.471, 49.85, 2.075, 0, 3, 0.692, 14.889, 83.133, -4.384, -2.416, 0.189, 60.753, 6.391, 0.127, -7.3]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, Affinity, and BBB):
1. **MW:** Both are within the acceptable range (200-500 Da). Ligand B (346.471) is slightly preferred due to being lower.
2. **TPSA:** Ligand A (66.91) is higher than Ligand B (49.85). Ligand B is better here, being closer to the ideal <140 for oral absorption.
3. **logP:** Ligand A (4.05) is at the upper end of the optimal range, while Ligand B (2.075) is well within the ideal 1-3 range. Ligand B is preferred.
4. **HBD/HBA:** Ligand A has 2 HBD and 6 HBA, while Ligand B has 0 HBD and 3 HBA. Both are reasonable, but Ligand B is slightly better with fewer H-bond donors.
5. **QED:** Both have acceptable QED values (A: 0.594, B: 0.692). Ligand B is slightly better.
6. **DILI:** Ligand A (84.296) has a significantly higher DILI risk than Ligand B (14.889). This is a major concern for Ligand A.
7. **BBB:** Both have good BBB penetration (A: 81.233, B: 83.133). Similar.
8. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability.
9. **Solubility:** Both have negative solubility values, indicating poor solubility.
10. **hERG:** Ligand A (0.811) has a slightly higher hERG risk than Ligand B (0.189). Ligand B is preferred.
11. **Cl_mic:** Ligand A (96.819) has a higher microsomal clearance, indicating faster metabolism, compared to Ligand B (60.753). Ligand B is preferred.
12. **t1/2:** Ligand A (88.992) has a significantly longer in vitro half-life than Ligand B (6.391). This is a strong point for Ligand A.
13. **Pgp:** Ligand A (0.824) has higher P-gp efflux liability than Ligand B (0.127). Ligand B is preferred.
14. **Affinity:** Ligand B (-7.3 kcal/mol) has a stronger binding affinity than Ligand A (-6.2 kcal/mol). This is a substantial advantage for Ligand B (a >1.1 kcal/mol difference).
**Overall Assessment:**
While Ligand A has a longer half-life, the significant concerns regarding its DILI risk, higher logP, higher hERG, and higher P-gp efflux, coupled with the superior binding affinity of Ligand B, make **Ligand B the more promising candidate**. The stronger binding affinity of Ligand B can potentially offset its shorter half-life through optimized dosing. The lower DILI risk is also a critical advantage.
Output:
0
2025-04-17 19:38:20,956 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (374.5 and 376.9 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (78.9) is higher than Ligand B (64.2). While both are reasonably good, Ligand B is better positioned for permeability, being closer to the <90 target for GPCRs.
3. **logP:** Ligand A (1.66) is within the optimal 1-3 range. Ligand B (3.92) is at the higher end, potentially leading to solubility issues and off-target interactions.
4. **HBD:** Ligand A (2) is preferable to Ligand B (0). A small number of HBDs can aid solubility without significantly hindering permeability.
5. **HBA:** Ligand A (5) and Ligand B (6) are both acceptable, below the 10 threshold.
6. **QED:** Ligand A (0.642) is slightly better than Ligand B (0.586), indicating a more drug-like profile.
7. **DILI:** Ligand A (19.8) has a significantly lower DILI risk than Ligand B (68.9). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (68.3) shows better BBB penetration than Ligand A (36.3). While ADRB2 isn't strictly a CNS target, some CNS exposure can be relevant for side effect profiles.
9. **Caco-2:** Both ligands show poor Caco-2 permeability (-4.98 and -5.12). This is a concern for oral bioavailability for both.
10. **Solubility:** Ligand A (-2.32) is better than Ligand B (-4.09). Solubility is a concern for Ligand B due to its higher logP.
11. **hERG:** Both ligands have low hERG inhibition risk (0.45 and 0.3), which is good.
12. **Cl_mic:** Ligand A (29.4) has a significantly lower microsomal clearance than Ligand B (85.4), suggesting better metabolic stability.
13. **t1/2:** Ligand B (12.1) has a longer in vitro half-life than Ligand A (6.5). This is a positive for Ligand B.
14. **Pgp:** Ligand A (0.14) shows lower P-gp efflux than Ligand B (0.61), which is favorable for bioavailability.
15. **Affinity:** Ligand A (-7.1) has a stronger binding affinity than Ligand B (-6.2). This is a substantial advantage for Ligand A, potentially outweighing some of its ADME drawbacks.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A has a better logP and Pgp profile. Ligand B has better TPSA and BBB penetration. However, the significantly better affinity of Ligand A (-7.1 vs -6.2) and its much lower DILI risk are critical advantages. The longer half-life of Ligand B is a plus, but the metabolic stability of Ligand A is also reasonable.
**Conclusion:**
Despite the slightly better BBB penetration and half-life of Ligand B, Ligand A is the more promising candidate due to its superior binding affinity, lower DILI risk, better logP, and lower P-gp efflux. The poor Caco-2 permeability is a concern for both, but can be addressed through formulation strategies.
Output:
1
2025-04-17 19:38:20,956 - INFO - Here's my reasoning and final output for the ligand preference:
**Reasoning:**
We are targeting ADRB2, a GPCR. Therefore, the priorities are logP, Pgp, TPSA, affinity, and BBB. Let's break down the comparison:
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da).
2. **TPSA:** Ligand B (55.89) is significantly better than Ligand A (100.74). Lower TPSA generally correlates with better blood-brain barrier penetration and oral absorption, which is crucial for GPCRs.
3. **logP:** Both ligands have similar, optimal logP values (around 1.6).
4. **H-Bond Donors/Acceptors:** Ligand B has fewer HBDs and HBAs (1/3) compared to Ligand A (2/6), which is generally favorable for permeability.
5. **QED:** Both ligands have good QED scores (around 0.79).
6. **DILI:** Ligand B has a much lower DILI risk (7.871) compared to Ligand A (47.266). This is a significant advantage.
7. **BBB:** Ligand B has a higher BBB percentile (81.155) than Ligand A (65.18), which is important for GPCR targeting, even if not strictly CNS-focused.
8. **Caco-2:** Ligand A (-5.091) shows better Caco-2 permeability than Ligand B (-4.719), but the difference is small.
9. **Solubility:** Ligand A (-2.111) has slightly better solubility than Ligand B (-1.316).
10. **hERG:** Ligand B (0.615) has a slightly higher hERG risk than Ligand A (0.322), but both are relatively low.
11. **Cl_mic:** Ligand B (-7.889) has significantly better metabolic stability (lower clearance) than Ligand A (27.004).
12. **t1/2:** Ligand B (2.586) has a slightly better in vitro half-life than Ligand A (-12.117).
13. **Pgp:** Ligand A (0.051) has a slightly lower P-gp efflux liability than Ligand B (0.026), which is a small advantage.
14. **Binding Affinity:** Ligand A (-7.4) has a slightly better binding affinity than Ligand B (-6.7), but the difference is only 0.7 kcal/mol. While affinity is important, the other ADME properties of Ligand B are much more favorable.
**Overall Assessment:**
Ligand B demonstrates a superior balance of properties, particularly regarding safety (DILI), metabolic stability (Cl_mic), and BBB penetration. While Ligand A has slightly better affinity and Caco-2 permeability, the advantages of Ligand B in key ADME/Tox parameters outweigh these minor differences, especially considering the GPCR target class.
**Output:**
0
2025-04-17 19:38:20,957 - INFO - Batch 125 complete. Total preferences: 2000
2025-04-17 19:38:20,957 - INFO - Processing batch 126/512...
2025-04-17 19:39:11,292 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (348.359) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are good, below the 140 A^2 threshold. Ligand B (96.52) is better, being closer to the 90 A^2 threshold, which is beneficial for GPCRs.
3. **logP:** Ligand B (2.585) is optimal (1-3), while Ligand A (0.383) is quite low, potentially hindering membrane permeability. This is a significant drawback for Ligand A.
4. **HBD:** Both have 2 HBD, which is within the acceptable limit of 5.
5. **HBA:** Ligand A has 7 HBA, while Ligand B has 5. Both are under the 10 limit.
6. **QED:** Both ligands have very similar QED scores (0.774 and 0.77), indicating good drug-likeness.
7. **DILI:** Ligand B (47.46) has a lower DILI risk than Ligand A (68.825), which is preferable.
8. **BBB:** Ligand B (65.529) shows better BBB penetration than Ligand A (50.64), although neither is exceptionally high. For a cardiovascular target, BBB isn't paramount, but it's a plus.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. This is concerning for both.
10. **Solubility:** Both have negative solubility values, indicating poor solubility. This is concerning for both.
11. **hERG:** Both have low hERG inhibition liability (0.128 and 0.438), which is good.
12. **Cl_mic:** Ligand A (12.382) has significantly lower microsomal clearance than Ligand B (35.16), suggesting better metabolic stability.
13. **t1/2:** Both have similar in vitro half-lives (21.556 and 20.572).
14. **Pgp:** Ligand B (0.136) has lower P-gp efflux liability than Ligand A (0.024), which is favorable for bioavailability.
15. **Binding Affinity:** Both have very similar binding affinities (-6.3 and -6.2 kcal/mol). The difference is negligible.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, and Pgp are important. Ligand B excels in logP and TPSA, and has better Pgp efflux. While both have poor Caco-2 and solubility, the superior logP and lower Pgp efflux of Ligand B are more critical for a GPCR target. The lower DILI risk also favors Ligand B. The slightly better metabolic stability of Ligand A is outweighed by its poor logP.
**Conclusion:**
Considering the balance of properties and the priorities for a GPCR target, Ligand B is the more promising drug candidate.
Output:
0
2025-04-17 19:39:11,293 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (336.479 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (32.34) is significantly better than Ligand B (96.87). ADRB2 is a cardiovascular target, not a CNS target, but lower TPSA generally improves absorption. Ligand B's TPSA is quite high.
3. **logP:** Ligand A (3.945) is at the upper end of the optimal range, while Ligand B (1.909) is at the lower end. Both are acceptable, but Ligand A's higher logP might lead to some off-target interactions or solubility issues.
4. **HBD/HBA:** Ligand A has 1 HBD and 2 HBA, while Ligand B has 2 HBD and 6 HBA. Both are within acceptable limits, but Ligand B has a higher number of HBA, potentially impacting permeability.
5. **QED:** Both ligands have similar QED values (0.897 vs 0.85), indicating good drug-likeness.
6. **DILI:** Ligand A (19.504) has a much lower DILI risk than Ligand B (76.076). This is a significant advantage for Ligand A.
7. **BBB:** This is less critical for a cardiovascular target. Ligand A (87.67) has a higher BBB penetration than Ligand B (45.909).
8. **Caco-2:** Ligand A (-4.915) and Ligand B (-5.149) have similar Caco-2 permeability.
9. **Solubility:** Ligand A (-3.37) and Ligand B (-3.145) have similar solubility.
10. **hERG:** Ligand A (0.977) has a slightly higher hERG risk than Ligand B (0.069). This is a concern for Ligand A.
11. **Cl_mic:** Ligand A (3.5) has a much lower microsomal clearance than Ligand B (24.909), indicating better metabolic stability.
12. **t1/2:** Ligand A (15.957) has a longer in vitro half-life than Ligand B (11.16), which is desirable.
13. **Pgp:** Ligand A (0.649) has a lower P-gp efflux liability than Ligand B (0.033), suggesting better bioavailability.
14. **Binding Affinity:** Ligand B (-7.3) has a significantly stronger binding affinity than Ligand A (-3.0). This is a substantial advantage for Ligand B.
**Overall Assessment:**
Ligand B has a much stronger binding affinity, which is paramount for GPCR targets. However, it suffers from a high TPSA, elevated DILI risk, and higher metabolic clearance. Ligand A has a better safety profile (lower DILI), better metabolic stability (lower Cl_mic, longer t1/2), and better permeability characteristics (lower TPSA, lower Pgp efflux). The affinity difference is significant (4.3 kcal/mol), but the combination of ADME/Tox advantages for Ligand A is compelling. Considering the cardiovascular target, a slightly lower affinity can be tolerated if it translates to a safer and more bioavailable drug.
Given the balance of properties, and prioritizing a favorable ADME/Tox profile for a cardiovascular drug, I lean towards Ligand A.
Output:
1
2025-04-17 19:39:11,293 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (348.447 and 345.487 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (87.32) is slightly higher than Ligand B (64.41). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is generally preferred for permeability. Ligand B has a clear advantage.
**3. logP:** Ligand A (1.263) is within the optimal range, while Ligand B (2.817) is approaching the upper limit. Both are acceptable, but Ligand A is slightly better positioned.
**4. H-Bond Donors:** Ligand A (2) is reasonable, and Ligand B (0) is also good. No strong preference.
**5. H-Bond Acceptors:** Ligand A (4) and Ligand B (3) are both within the acceptable limit of 10. No strong preference.
**6. QED:** Ligand A (0.81) has a significantly better QED score than Ligand B (0.635), indicating a more drug-like profile. This is a substantial advantage for Ligand A.
**7. DILI Risk:** Ligand B (11.361) has a much lower DILI risk than Ligand A (36.487). This is a critical advantage for Ligand B, as minimizing liver toxicity is paramount.
**8. BBB Penetration:** Ligand B (72.237) shows better BBB penetration than Ligand A (45.211). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant, and higher BBB is generally favorable.
**9. Caco-2 Permeability:** Ligand A (-5.139) has a worse Caco-2 permeability than Ligand B (-4.498). Both are negative, indicating poor permeability, but Ligand B is slightly better.
**10. Aqueous Solubility:** Both ligands have very poor aqueous solubility (-2.581 and -2.636 respectively). This is a significant drawback for both, and formulation strategies would be required.
**11. hERG Inhibition:** Ligand A (0.15) has a lower hERG inhibition risk than Ligand B (0.697). This is a significant advantage for Ligand A, as hERG inhibition can lead to cardiotoxicity.
**12. Microsomal Clearance:** Ligand B (31.973) has a significantly lower microsomal clearance than Ligand A (7.058), suggesting better metabolic stability. This is a substantial advantage for Ligand B.
**13. In vitro Half-Life:** Ligand A (-13.663) has a worse in vitro half-life than Ligand B (-7.335). This is a clear advantage for Ligand B.
**14. P-gp Efflux:** Ligand A (0.018) has a much lower P-gp efflux liability than Ligand B (0.135). This is a significant advantage for Ligand A, improving bioavailability.
**15. Binding Affinity:** Ligand A (-7.7 kcal/mol) has a slightly better binding affinity than Ligand B (-5.6 kcal/mol). This is a significant advantage for Ligand A.
**Overall Assessment:**
Ligand A has advantages in QED, hERG inhibition, P-gp efflux, and binding affinity. However, Ligand B excels in DILI risk, BBB penetration, microsomal clearance, and in vitro half-life. The lower DILI risk and better metabolic stability of Ligand B are particularly important. While the binding affinity of Ligand A is better, the difference isn't substantial enough to overcome the safety and PK advantages of Ligand B. Given the cardiovascular target, minimizing liver toxicity and maximizing metabolic stability are crucial.
Output:
0
2025-04-17 19:39:11,293 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
The target is ADRB2, a GPCR. Therefore, the priorities are logP, Pgp, TPSA, affinity, and BBB. Let's analyze each ligand against these and other important parameters.
* **Molecular Weight:** Both ligands (364.555 and 359.539 Da) fall within the ideal 200-500 Da range.
* **TPSA:** Ligand B (29.77) is significantly better than Ligand A (58.2). Lower TPSA generally improves cell permeability, crucial for GPCR ligands.
* **logP:** Both ligands have good logP values (3.42 and 3.623), falling within the optimal 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability.
* **H-Bond Donors/Acceptors:** Ligand A has 2 HBD and 3 HBA, while Ligand B has 0 HBD and 5 HBA. Both are acceptable, but lower HBDs are generally preferred.
* **QED:** Ligand B (0.788) has a better QED score than Ligand A (0.512), indicating a more drug-like profile.
* **DILI:** Ligand B (30.826) has a significantly lower DILI risk than Ligand A (19.775). This is a major advantage.
* **BBB:** Ligand B (83.676) has a much higher BBB penetration percentile than Ligand A (56.301). While ADRB2 isn't strictly a CNS target, some peripheral distribution is still desired, and higher BBB penetration often correlates with better overall distribution.
* **Caco-2 Permeability:** Both are negative, indicating poor permeability. Ligand A (-5.153) is slightly worse than Ligand B (-5.293).
* **Aqueous Solubility:** Both have negative solubility values, indicating poor solubility. Ligand A (-3.924) is slightly better than Ligand B (-2.953).
* **hERG Inhibition:** Ligand B (0.957) has a slightly higher hERG inhibition risk than Ligand A (0.455), which is less desirable.
* **Microsomal Clearance:** Ligand B (72.926) has a slightly higher microsomal clearance than Ligand A (66.096), indicating faster metabolism.
* **In vitro Half-Life:** Ligand B (27.873) has a significantly longer in vitro half-life than Ligand A (7.345). This is a major advantage.
* **P-gp Efflux:** Ligand A (0.3) has a lower P-gp efflux liability than Ligand B (0.764), which is preferable.
* **Binding Affinity:** Ligand B (-6.6 kcal/mol) has a stronger binding affinity than Ligand A (-5.5 kcal/mol). This 1.1 kcal/mol difference is substantial and outweighs many of the minor ADME drawbacks of Ligand B.
**Overall Assessment:**
Ligand B is the stronger candidate. Its superior binding affinity, lower DILI risk, higher BBB penetration, and longer half-life are significant advantages. While its P-gp efflux is slightly higher and Caco-2 permeability is slightly lower, the benefits outweigh these drawbacks. The lower TPSA is also a major plus for a GPCR ligand.
**Output:**
0
2025-04-17 19:39:11,293 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (328.415 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (41.99) is significantly better than Ligand B (61.44). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (2.842) is closer to the optimal range (1-3) than Ligand A (4.742), which is a bit high. High logP can lead to poor solubility and off-target effects.
4. **HBD/HBA:** Ligand A has 1 HBD and 2 HBA, while Ligand B has 2 HBD and 3 HBA. Both are acceptable.
5. **QED:** Both ligands have similar QED values (0.703 and 0.707), indicating good drug-likeness.
6. **DILI:** Ligand A (72.043) has a higher DILI risk than Ligand B (9.151). This is a significant drawback for Ligand A.
7. **BBB:** Not a primary concern for a cardiovascular target, but Ligand A (78.247) has better BBB penetration than Ligand B (61.38).
8. **Caco-2:** Ligand A (-4.683) has a slightly better Caco-2 permeability than Ligand B (-4.881), but both are negative values which is not ideal.
9. **Solubility:** Ligand B (-1.833) has significantly better aqueous solubility than Ligand A (-5.164). This is a major advantage for Ligand B.
10. **hERG:** Ligand A (0.812) has a slightly higher hERG risk than Ligand B (0.521), but both are reasonably low.
11. **Cl_mic:** Ligand B (24.815) has much better metabolic stability (lower clearance) than Ligand A (92.293). This is a substantial advantage.
12. **t1/2:** Ligand B (17.211) has a significantly longer in vitro half-life than Ligand A (8.951). This is another important advantage.
13. **Pgp:** Ligand A (0.68) has slightly lower P-gp efflux than Ligand B (0.118), which is good.
14. **Binding Affinity:** Ligand A (-6.6 kcal/mol) has a slightly better binding affinity than Ligand B (-6.4 kcal/mol). However, the difference is small (0.2 kcal/mol) and may not be enough to overcome the other significant drawbacks of Ligand A.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B performs better on logP and TPSA, and has acceptable Pgp and affinity. Ligand A's higher logP and DILI risk are concerning.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity, Ligand B is a much more balanced candidate. It exhibits significantly better solubility, metabolic stability, lower DILI risk, and a longer half-life. These factors are crucial for developing a viable drug candidate, and outweigh the small advantage in binding affinity offered by Ligand A.
Output:
0
2025-04-17 19:39:11,293 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (348.447 Da) is better than Ligand B (372.412 Da), falling comfortably within the 200-500 Da range.
2. **TPSA:** Ligand B (58.2) is significantly better than Ligand A (94.56). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (2.946) is optimal, while Ligand A (0.681) is a bit low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (3) and Ligand B (2) are both acceptable.
5. **HBA:** Ligand A (5) and Ligand B (3) are both acceptable.
6. **QED:** Ligand B (0.854) is better than Ligand A (0.642), indicating a more drug-like profile.
7. **DILI:** Ligand A (19.232) is *much* better than Ligand B (55.176). This is a significant advantage for Ligand A.
8. **BBB:** Ligand B (87.553) is better than Ligand A (48.895). However, as ADRB2 is a cardiovascular target, BBB penetration is not a high priority.
9. **Caco-2:** Ligand A (-5.141) and Ligand B (-4.924) are both negative, suggesting poor permeability. This is a concern for both, but the values are similar.
10. **Solubility:** Ligand A (-1.117) is better than Ligand B (-4.083).
11. **hERG:** Ligand A (0.079) is much better than Ligand B (0.468), indicating a lower risk of cardiotoxicity. This is crucial for a cardiovascular target.
12. **Cl_mic:** Ligand A (2.523) is better than Ligand B (7.327), suggesting better metabolic stability.
13. **t1/2:** Ligand B (23.621) is significantly better than Ligand A (1.328), indicating a much longer half-life.
14. **Pgp:** Ligand A (0.006) is much better than Ligand B (0.26), suggesting lower efflux.
15. **Affinity:** Ligand B (-8.1 kcal/mol) is significantly better than Ligand A (-6.2 kcal/mol). This is a substantial difference in binding potency.
**GPCR-specific priorities:** For ADRB2 (a GPCR), we prioritize logP, Pgp, TPSA, and affinity. Ligand B excels in logP and affinity, and is better in TPSA and Pgp.
**Overall Assessment:**
Ligand B has a significantly better binding affinity and a longer half-life, which are major advantages. While Ligand A has better DILI and hERG scores, the potency difference of 1.9 kcal/mol is substantial enough to outweigh these concerns, especially given that the hERG risk for Ligand B is not excessively high. The improved logP of Ligand B also supports better membrane permeability. Although Ligand A has better solubility, the poor Caco-2 values for both are concerning and would require further investigation. The DILI risk for Ligand B is higher, but not prohibitively so, and could potentially be mitigated through structural modifications.
Therefore, I favor Ligand B.
Output:
0
2025-04-17 19:39:11,293 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (345.443 and 346.431 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (71.41) is better than Ligand B (76.46). Both are below the 140 A^2 threshold for oral absorption, but lower TPSA is generally preferred for GPCRs.
3. **logP:** Ligand A (1.851) is slightly higher than Ligand B (0.949), and both are within the optimal 1-3 range. Ligand A is preferable here.
4. **HBD:** Both ligands have 1 HBD, which is within the acceptable limit of <=5.
5. **HBA:** Ligand A has 4 HBA, while Ligand B has 5. Both are below the 10 limit, but Ligand A is slightly better.
6. **QED:** Both ligands have similar QED values (0.8 and 0.861), indicating good drug-likeness.
7. **DILI:** Both ligands have low DILI risk (36.448 and 35.983 percentile), which is excellent. No significant difference.
8. **BBB:** Ligand A (65.839) has a better BBB penetration percentile than Ligand B (56.495). While ADRB2 isn't strictly a CNS target, some CNS exposure can be beneficial or at least not detrimental, and higher BBB is generally favorable.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.892 and -4.907). This is unusual and suggests poor permeability. However, the values are very similar.
10. **Solubility:** Ligand A (-2.701) has slightly better solubility than Ligand B (-1.218), though both are quite poor.
11. **hERG:** Ligand A (0.191) has a much lower hERG inhibition liability than Ligand B (0.347), which is a significant advantage for cardiovascular safety.
12. **Cl_mic:** Ligand A (4.61) has a slightly lower microsomal clearance than Ligand B (3.942), indicating better metabolic stability.
13. **t1/2:** Ligand B (8.503) has a significantly longer in vitro half-life than Ligand A (-3.258). This is a substantial advantage.
14. **Pgp:** Ligand A (0.127) has a lower P-gp efflux liability than Ligand B (0.016), which is preferable for bioavailability.
15. **Binding Affinity:** Ligand B (-8.3 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.1 kcal/mol). This is a major advantage, potentially outweighing some of the ADME drawbacks. A 3.2 kcal/mol difference is substantial.
**Overall Assessment:**
Ligand B's significantly superior binding affinity (-8.3 vs -5.1 kcal/mol) is the most important factor. While Ligand A has some advantages in terms of TPSA, logP, hERG, and Pgp, the potency difference is substantial enough to overcome the slightly poorer ADME profile of Ligand B. The longer half-life of Ligand B is also a significant benefit. The poor Caco-2 values for both are concerning, but can be addressed with formulation strategies.
Output:
0
2025-04-17 19:39:11,293 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [363.439, 98.25, 1.737, 1, 6, 0.567, 79.372, 60.915, -5.199, -3.037, 0.146, 99.973, -28.449, 0.174, -6.2]
**Ligand B:** [366.527, 58.64, 3.148, 1, 4, 0.806, 22.257, 77.782, -4.845, -3.061, 0.714, 26.639, 40.368, 0.364, -6.5]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). A (363.439) and B (366.527) are very close, so this isn't a major differentiator.
2. **TPSA:** A (98.25) is higher than B (58.64). For a GPCR, lower TPSA is generally preferred for better brain penetration, even though ADRB2 isn't exclusively a CNS target. B is significantly better here.
3. **logP:** A (1.737) is good, within the optimal range. B (3.148) is slightly higher, still acceptable but edging towards potential solubility issues.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** A has 6, B has 4. Both are acceptable, but B is slightly better.
6. **QED:** B (0.806) is better than A (0.567), indicating a more drug-like profile.
7. **DILI:** A (79.372) has a significantly higher DILI risk than B (22.257). This is a major concern for A.
8. **BBB:** B (77.782) has a better BBB penetration potential than A (60.915). While ADRB2 isn't solely a CNS target, some CNS exposure can be beneficial or at least avoid off-target effects.
9. **Caco-2:** Both are negative, indicating poor permeability. A (-5.199) is worse than B (-4.845).
10. **Solubility:** Both are very poor (-3.037 and -3.061). This is a significant drawback for both, but not a deciding factor between the two.
11. **hERG:** A (0.146) has a lower hERG risk than B (0.714), which is a positive.
12. **Cl_mic:** A (99.973) has a much higher microsomal clearance than B (26.639), meaning it's metabolized much faster. This is a significant negative for A.
13. **t1/2:** B (40.368) has a much longer in vitro half-life than A (-28.449). This is a major advantage for B.
14. **Pgp:** A (0.174) has lower P-gp efflux than B (0.364), which is slightly better.
15. **Affinity:** B (-6.5) has a slightly better binding affinity than A (-6.2), but the difference is small.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, and affinity. B excels in TPSA, QED, DILI, BBB, Cl_mic, and t1/2. A has a slight edge in hERG and Pgp, but the DILI and metabolic stability issues are too significant to ignore. The slightly better affinity of B is a bonus.
**Conclusion:**
Considering the balance of properties, particularly the significantly lower DILI risk, better metabolic stability (lower Cl_mic, longer t1/2), and improved TPSA and QED of Ligand B, it is the more promising drug candidate.
0
2025-04-17 19:39:11,294 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (358.423 and 348.403 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (91.23) is better than Ligand B (115.65). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (1.492) is within the optimal 1-3 range. Ligand B (-0.359) is slightly below 1, which *could* indicate permeability issues. This is a point in favor of A.
4. **HBD:** Ligand A (2) and Ligand B (3) are both acceptable, below the 5 threshold.
5. **HBA:** Ligand A (5) and Ligand B (6) are both acceptable, below the 10 threshold.
6. **QED:** Both ligands have similar QED values (0.764 and 0.669), indicating good drug-likeness.
7. **DILI:** Ligand A (71.19) has a higher DILI risk than Ligand B (40.752). This is a significant advantage for Ligand B.
8. **BBB:** Both are low, which is expected for a cardiovascular target. Ligand B (39.007) is slightly higher than Ligand A (28.461), but this is not a major factor.
9. **Caco-2:** Both ligands have very negative Caco-2 values (-5.218 and -5.153). This suggests poor permeability, and is a concern for both.
10. **Solubility:** Ligand A (-4.483) has slightly better solubility than Ligand B (-1.71), but both are poor.
11. **hERG:** Ligand A (0.303) has a lower hERG risk than Ligand B (0.082), which is a positive.
12. **Cl_mic:** Ligand A (-0.565) has a lower (better) microsomal clearance than Ligand B (-2.497), suggesting greater metabolic stability.
13. **t1/2:** Ligand A (13.129) has a significantly longer in vitro half-life than Ligand B (4.497). This is a major advantage for Ligand A.
14. **Pgp:** Ligand A (0.128) has lower P-gp efflux liability than Ligand B (0.005), which is a positive.
15. **Affinity:** Ligand A (-8.0) has a slightly better binding affinity than Ligand B (-6.0). While both are good, the 2 kcal/mol difference is significant.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A performs better on logP, TPSA, Pgp, and significantly better on affinity. While Ligand B has a better DILI score, the superior binding affinity and metabolic stability of Ligand A outweigh this concern. The poor Caco-2 values are concerning for both, but can be addressed with formulation strategies.
**Conclusion:**
Ligand A is the more promising candidate due to its superior binding affinity, metabolic stability, lower P-gp efflux, and better logP and TPSA values, despite a slightly higher DILI risk.
Output:
1
2025-04-17 19:39:11,294 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (368.356 and 350.434 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (69.64) is significantly better than Ligand A (99.77). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (1.871) is within the optimal range (1-3), while Ligand A (0.544) is a bit low, potentially hindering membrane permeability. Ligand B has a clear advantage.
4. **HBD:** Both ligands have acceptable HBD counts (3 for A, 2 for B), well below the threshold of 5.
5. **HBA:** Both ligands have acceptable HBA counts (5 for A, 3 for B), well below the threshold of 10.
6. **QED:** Both ligands have good QED scores (0.57 for A, 0.744 for B), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand B (16.092) has a much lower DILI risk than Ligand A (28.112). This is a significant advantage for Ligand B.
8. **BBB:** Both ligands have high BBB penetration (85.537 and 81.698), but this is less critical for a cardiovascular target like ADRB2.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual. Assuming these are logP-scale values, lower values indicate poorer permeability. Ligand A (-5.486) is worse than Ligand B (-4.868).
10. **Solubility:** Both ligands have negative solubility values, which is also unusual. Assuming these are logS values, lower values indicate poorer solubility. Ligand A (-2.282) is worse than Ligand B (-2.125).
11. **hERG:** Both ligands have low hERG inhibition liability (0.221 and 0.31), which is good.
12. **Cl_mic:** Ligand A (-43.217) has much lower (better) microsomal clearance than Ligand B (0.615), suggesting greater metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand B (-16.898) has a slightly longer in vitro half-life than Ligand A (-15.542), which is a minor advantage.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.002 and 0.08).
15. **Binding Affinity:** Ligand B (-6.0) has a significantly stronger binding affinity than Ligand A (-2.7). This is a substantial advantage, potentially outweighing some ADME concerns.
**Overall Assessment:**
Ligand B has a better balance of properties. It has a more favorable logP, lower DILI risk, better QED, and significantly stronger binding affinity. While Ligand A has better metabolic stability (lower Cl_mic), the affinity difference is substantial. For a GPCR target like ADRB2, binding affinity is paramount. The slightly lower metabolic stability of Ligand B can potentially be addressed through structural modifications during lead optimization. The lower TPSA and better logP of Ligand B also suggest better absorption.
Output:
0
2025-04-17 19:39:11,294 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [346.431, 95.74, 1.055, 2, 4, 0.833, 23.769, 79.992, -5.337, -2.421, 0.352, -36.291, -7.031, 0.011, -5.4]
**Ligand B:** [339.439, 47.36, 3.291, 0, 4, 0.862, 53.742, 83.443, -4.667, -2.919, 0.273, 45.693, 10.122, 0.514, -9.7]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (346.431) is slightly higher than Ligand B (339.439), but both are acceptable.
2. **TPSA:** Ligand A (95.74) is higher than Ligand B (47.36). For a cardiovascular GPCR, TPSA isn't *as* critical as for a CNS target, but lower is generally better for permeability. Ligand B is significantly better here.
3. **logP:** Ligand A (1.055) is within the optimal range, while Ligand B (3.291) is towards the higher end. Both are acceptable, but Ligand A is slightly preferred.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (0). Both are within the acceptable limit of 5.
5. **HBA:** Both ligands have 4 HBA, which is good.
6. **QED:** Both ligands have good QED scores (A: 0.833, B: 0.862), indicating good drug-like properties.
7. **DILI:** Ligand A (23.769) has a much lower DILI risk than Ligand B (53.742). This is a significant advantage for Ligand A.
8. **BBB:** Ligand B (83.443) has a slightly higher BBB penetration than Ligand A (79.992), but for a cardiovascular target, this isn't a primary concern.
9. **Caco-2:** Ligand A (-5.337) is worse than Ligand B (-4.667), indicating lower intestinal absorption.
10. **Solubility:** Ligand A (-2.421) is slightly better than Ligand B (-2.919).
11. **hERG:** Both ligands have very low hERG risk (A: 0.352, B: 0.273).
12. **Cl_mic:** Ligand A (-36.291) has a much lower (better) microsomal clearance than Ligand B (45.693), suggesting better metabolic stability.
13. **t1/2:** Ligand B (10.122) has a longer in vitro half-life than Ligand A (-7.031). This is a positive for Ligand B.
14. **Pgp:** Ligand A (0.011) has a much lower Pgp efflux liability than Ligand B (0.514), suggesting better bioavailability.
15. **Affinity:** Ligand B (-9.7) has a significantly stronger binding affinity than Ligand A (-5.4). This is a substantial advantage for Ligand B.
**GPCR-Specific Priorities:**
For ADRB2 (a cardiovascular GPCR), we prioritize logP, TPSA, Pgp, and affinity. Ligand B excels in affinity and has a better TPSA. Ligand A has a better logP and Pgp. However, the significant difference in affinity (-9.7 vs -5.4) is a major factor. The lower DILI and better metabolic stability of Ligand A are also very attractive.
**Overall Assessment:**
While Ligand A has advantages in DILI, metabolic stability, and Pgp efflux, the substantially stronger binding affinity of Ligand B (-9.7 kcal/mol vs -5.4 kcal/mol) is a critical advantage for a GPCR target. The difference in affinity is large enough to outweigh the other drawbacks of Ligand B.
Output:
0
2025-04-17 19:39:11,294 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (345.49 and 367.52 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (52.65) is significantly better than Ligand B (82.53). ADRB2 is a cardiovascular target, not CNS, but lower TPSA generally improves absorption.
3. **logP:** Both ligands have acceptable logP values (1.48 and 2.32), within the 1-3 range. Ligand B is slightly higher, potentially improving membrane permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (5). Lower HBA generally improves permeability.
6. **QED:** Both ligands have good QED scores (0.768 and 0.835), indicating good drug-likeness. No clear advantage.
7. **DILI:** Ligand A (6.94) is *much* better than Ligand B (47.77). This is a significant advantage for Ligand A, as lower DILI risk is crucial.
8. **BBB:** Both ligands have reasonable BBB penetration (69.79 and 76.46). Since ADRB2 is not a CNS target, this is less critical, but higher is still slightly preferred. Ligand B is better here.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.76 and -4.99), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-1.47) is better than Ligand B (-3.79). Higher solubility is generally preferred, though both are quite poor.
11. **hERG:** Ligand A (0.24) is significantly better than Ligand B (0.85). Lower hERG inhibition is crucial to avoid cardiotoxicity, a major concern for cardiovascular drugs.
12. **Cl_mic:** Ligand A (0.57) is *much* better than Ligand B (45.85). Lower microsomal clearance indicates better metabolic stability, a significant advantage.
13. **t1/2:** Ligand A (-0.46) is better than Ligand B (-14.07). A longer half-life is generally preferred.
14. **Pgp:** Ligand A (0.04) is much better than Ligand B (0.21). Lower P-gp efflux is preferred for better bioavailability.
15. **Binding Affinity:** Ligand B (-8.0) is significantly better than Ligand A (-6.2). A 1.8 kcal/mol difference in binding affinity is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
While Ligand B has a significantly better binding affinity, Ligand A has a much more favorable ADMET profile. Specifically, the DILI risk, hERG inhibition, and microsomal clearance of Ligand A are far superior. For a cardiovascular target, minimizing cardiotoxicity (hERG) and liver toxicity (DILI) are paramount. The improved metabolic stability (Cl_mic) and Pgp efflux profile of Ligand A are also very important. The slightly better solubility of Ligand A is also a plus. The Caco-2 permeability is poor for both, but the other advantages of Ligand A outweigh the affinity difference.
Output:
1
2025-04-17 19:39:11,294 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (341.371 and 345.487 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (111.21) is higher than Ligand B (54.34). For a GPCR, lower TPSA is generally preferred for better brain penetration, even though ADRB2 isn't strictly a CNS target. Ligand B is significantly better here.
3. **logP:** Ligand A (0.052) is quite low, potentially hindering membrane permeability. Ligand B (2.501) is within the optimal 1-3 range. Ligand B is significantly better.
4. **HBD:** Ligand A (3) is higher than Ligand B (1). While both are acceptable, lower HBD can improve permeability. Ligand B is slightly better.
5. **HBA:** Ligand A (5) is higher than Ligand B (3). Similar to HBD, lower HBA is generally preferred. Ligand B is better.
6. **QED:** Both ligands have good QED scores (0.728 and 0.825), indicating good drug-like properties. No significant difference.
7. **DILI:** Ligand A (64.87) has a higher DILI risk than Ligand B (12.524). This is a substantial difference, and lower DILI is highly desirable. Ligand B is much better.
8. **BBB:** Ligand A (16.247) has very low BBB penetration, while Ligand B (82.745) is quite high. While ADRB2 isn't a primary CNS target, higher BBB is still a positive attribute. Ligand B is significantly better.
9. **Caco-2:** Ligand A (-5.738) is worse than Ligand B (-4.897), indicating lower intestinal absorption. Ligand B is slightly better.
10. **Solubility:** Ligand A (-1.909) is slightly better than Ligand B (-2.293), but both are quite poor. Solubility is a concern for both, but not a deciding factor.
11. **hERG:** Both ligands have low hERG inhibition liability (0.118 and 0.452), which is good. No significant difference.
12. **Cl_mic:** Ligand A (-31.609) has a much lower (better) microsomal clearance than Ligand B (47.631), indicating greater metabolic stability. Ligand A is significantly better.
13. **t1/2:** Ligand A (-20.561) has a more negative (better) in vitro half-life than Ligand B (-4.82). Ligand A is significantly better.
14. **Pgp:** Ligand A (0.006) has much lower P-gp efflux liability than Ligand B (0.378), suggesting better oral bioavailability and potentially better CNS exposure. Ligand A is significantly better.
15. **Binding Affinity:** Ligand B (-6.6) has a slightly better binding affinity than Ligand A (-6.3). This is a small difference, but it's a positive for Ligand B.
**Overall Assessment:**
Ligand B excels in key GPCR-relevant properties like logP, TPSA, and BBB penetration. It also has a significantly lower DILI risk. However, Ligand A demonstrates superior metabolic stability (Cl_mic and t1/2) and P-gp efflux properties. The binding affinity difference is minimal.
Considering the balance, the lower DILI risk and better ADME properties (logP, TPSA, BBB) of Ligand B outweigh the slightly better metabolic stability of Ligand A. The slightly better binding affinity of Ligand B also tips the scales.
Output:
0
2025-04-17 19:39:11,295 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (354.495 and 351.451 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Both ligands (104.53 and 109.0) are below the 140 A^2 threshold for good oral absorption, but are not optimized for CNS penetration (above 90 A^2). No major difference.
3. **logP:** Both ligands (1.613 and 1.054) are within the optimal 1-3 range. Ligand A is slightly more lipophilic, which can be beneficial for membrane permeability.
4. **HBD:** Both have 3 H-bond donors, which is acceptable.
5. **HBA:** Ligand A has 3 H-bond acceptors, while Ligand B has 5. Lower HBA is generally preferred.
6. **QED:** Both ligands have similar QED values (0.647 and 0.616), indicating good drug-likeness.
7. **DILI:** Ligand B has a higher DILI risk (38.62%) than Ligand A (16.208%). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A has a substantially higher BBB penetration percentile (74.564%) compared to Ligand B (58.085%). While ADRB2 isn't necessarily a CNS target, higher BBB is generally favorable.
9. **Caco-2:** Both have negative Caco-2 values (-5.032 and -5.047), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Both ligands have very poor aqueous solubility (-2.349 and -2.218). This is a major drawback for both.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.184 and 0.175). This is good.
12. **Cl_mic:** Ligand A has a higher microsomal clearance (40.634) than Ligand B (18.967). Lower clearance is preferred for metabolic stability, favoring Ligand B.
13. **t1/2:** Ligand B has a significantly longer in vitro half-life (4.688 hours) compared to Ligand A (1.483 hours). This is a substantial advantage for Ligand B.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.005 and 0.055). This is good.
15. **Binding Affinity:** Ligand A has a slightly better binding affinity (-7.3 kcal/mol) than Ligand B (-7.0 kcal/mol). This difference is not huge, but is still a positive for Ligand A.
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Ligand A has a slightly better logP and affinity. However, the significantly lower DILI risk and longer half-life of Ligand B are very important factors. The Caco-2 and solubility issues are concerning for both, but can potentially be addressed with formulation strategies.
**Overall Assessment:**
While Ligand A has a slight edge in binding affinity and BBB penetration, Ligand B's significantly lower DILI risk and better metabolic stability (longer half-life) are more critical for overall drug development success. The solubility and permeability issues are shared by both, and would require further optimization.
Output:
0
2025-04-17 19:39:11,295 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step Comparison:**
1. **MW:** Ligand A (369.799 Da) is within the ideal range, while Ligand B (343.479 Da) is also good. No strong preference here.
2. **TPSA:** Ligand A (64.11) is excellent, well below the 140 threshold. Ligand B (72.97) is still acceptable, but less optimal.
3. **logP:** Ligand A (4.59) is a bit high, potentially leading to solubility issues and off-target effects. Ligand B (2.165) is within the optimal range. This favors Ligand B.
4. **HBD:** Ligand A (1) is good. Ligand B (2) is also acceptable.
5. **HBA:** Ligand A (4) is good. Ligand B (6) is acceptable, but higher.
6. **QED:** Ligand A (0.856) is excellent, indicating high drug-likeness. Ligand B (0.751) is still good, but slightly lower.
7. **DILI:** Ligand A (85.576) has a significantly higher DILI risk than Ligand B (25.087). This is a major concern for Ligand A.
8. **BBB:** Both ligands have similar BBB penetration (Ligand A: 68.631, Ligand B: 69.756). Not a deciding factor.
9. **Caco-2:** Ligand A (-4.626) and Ligand B (-5.453) both show poor Caco-2 permeability.
10. **Solubility:** Ligand A (-5.81) has very poor solubility, consistent with its high logP. Ligand B (-1.798) is better, but still not ideal.
11. **hERG:** Ligand A (0.369) has a lower hERG risk than Ligand B (0.934), which is favorable.
12. **Cl_mic:** Ligand A (72.936) has a higher microsomal clearance than Ligand B (26.577), suggesting lower metabolic stability. This favors Ligand B.
13. **t1/2:** Ligand A (7.52) has a longer half-life than Ligand B (0.988). This is a positive for Ligand A.
14. **Pgp:** Ligand A (0.182) has lower P-gp efflux, which is good. Ligand B (0.067) is even better. This favors Ligand B.
15. **Affinity:** Ligand A (-6.9 kcal/mol) has a slightly better binding affinity than Ligand B (-6.5 kcal/mol). While a 0.4 kcal/mol difference is noticeable, it's not a huge advantage, and is outweighed by other factors.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp efflux, and affinity are particularly important. Ligand B excels in logP and Pgp, and has acceptable TPSA. While Ligand A has slightly better affinity, its high logP, poor solubility, and significantly higher DILI risk are major drawbacks.
**Overall Assessment:**
Ligand B presents a much more balanced profile, with better predicted ADME properties (lower DILI, better solubility, lower Cl_mic, better Pgp) despite slightly lower affinity. The higher DILI risk associated with Ligand A is a significant concern that would likely halt its development.
Output:
0
2025-04-17 19:39:11,295 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [369.531, 74.69, 2.974, 2, 6, 0.773, 37.922, 43.079, -4.697, -2.459, 0.48, 34.643, 14.894, 0.255, -6.8]**
**Ligand B: [364.515, 76.02, 2.113, 2, 5, 0.727, 37.224, 39.822, -5.734, -2.082, 0.324, 44.104, 6.962, 0.083, -7.0]**
**1. Molecular Weight (MW):** Both ligands are within the ideal range (200-500 Da). Ligand B (364.515) is slightly lower, which is generally favorable for permeability, but the difference isn't substantial.
**2. TPSA:** Both are reasonably good (74.69 and 76.02). Both are below 140, suggesting reasonable oral absorption potential.
**3. logP:** Both ligands have logP values within the optimal range (1-3). Ligand A (2.974) is slightly higher than Ligand B (2.113). This could be a minor advantage for membrane permeability, but needs to be considered alongside solubility.
**4. H-Bond Donors (HBD):** Both have 2 HBD, which is good.
**5. H-Bond Acceptors (HBA):** Ligand A has 6 HBA, Ligand B has 5. Both are acceptable.
**6. QED:** Both have good QED scores (>0.5), indicating good drug-like properties. Ligand A (0.773) is slightly better than Ligand B (0.727).
**7. DILI:** Both have similar, low DILI risk (37.922 and 37.224 percentile). This is excellent.
**8. BBB:** Ligand A (43.079) has a slightly higher BBB penetration potential than Ligand B (39.822), but both are relatively low. Since ADRB2 is a cardiovascular target, BBB penetration is not a high priority.
**9. Caco-2 Permeability:** Ligand B (-5.734) has a much higher Caco-2 permeability than Ligand A (-4.697). This suggests better intestinal absorption for Ligand B.
**10. Aqueous Solubility:** Ligand B (-2.082) has better aqueous solubility than Ligand A (-2.459). This is a positive attribute.
**11. hERG Inhibition:** Both have low hERG inhibition risk (0.48 and 0.324). This is good.
**12. Microsomal Clearance:** Ligand A (34.643) has lower microsomal clearance than Ligand B (44.104), indicating better metabolic stability.
**13. In vitro Half-Life:** Ligand A (14.894) has a longer in vitro half-life than Ligand B (6.962). This is a significant advantage.
**14. P-gp Efflux:** Ligand A (0.255) has lower P-gp efflux than Ligand B (0.083), suggesting better bioavailability.
**15. Binding Affinity:** Ligand B (-7.0 kcal/mol) has a slightly stronger binding affinity than Ligand A (-6.8 kcal/mol). This is a key advantage, as a 0.2 kcal/mol difference can be significant.
**Overall Assessment:**
Given that this is a cardiovascular target (ADRB2), BBB penetration is not a primary concern. Ligand B has a significant advantage in binding affinity (-7.0 vs -6.8 kcal/mol) and Caco-2 permeability. It also has better solubility. While Ligand A has better metabolic stability and half-life, the stronger binding of Ligand B is more critical for a GPCR target. The difference in half-life is not substantial enough to outweigh the affinity advantage.
Output:
0
2025-04-17 19:39:11,295 - INFO - Batch 126 complete. Total preferences: 2016
2025-04-17 19:39:11,295 - INFO - Processing batch 127/512...
2025-04-17 19:39:57,345 - INFO - Reasoning:
Let's analyze Ligand A and Ligand B for their potential as ADRB2 ligands, keeping in mind the GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key).
**Molecular Weight:** Both ligands (350.46 and 346.47 Da) fall comfortably within the ideal 200-500 Da range.
**TPSA:** Ligand A (78.87) is higher than Ligand B (53.76). While both are reasonably good, Ligand B is better, being closer to the <90 target for potential CNS penetration (though not a primary concern for ADRB2 which is cardiovascular).
**logP:** Ligand A (1.095) is within the optimal range (1-3), while Ligand B (3.099) is at the upper end. Both are acceptable, but Ligand A's lower logP might suggest better solubility.
**H-Bond Donors/Acceptors:** Ligand A has 2 HBD and 4 HBA, while Ligand B has 0 HBD and 3 HBA. Both are within acceptable limits.
**QED:** Both ligands have good QED scores (0.703 and 0.842), indicating good drug-like properties.
**DILI:** Ligand A (14.62) has a significantly lower DILI risk than Ligand B (17.91). This is a substantial advantage for Ligand A.
**BBB:** Both have good BBB penetration (72.82 and 70.69), but this is less critical for a cardiovascular target.
**Caco-2 Permeability:** Both have negative Caco-2 values, which is unusual and potentially problematic. However, the values are similar (-4.525 vs -4.593).
**Aqueous Solubility:** Ligand A (-1.909) is better than Ligand B (-3.158).
**hERG Inhibition:** Ligand A (0.253) has a lower hERG risk than Ligand B (0.55). This is a significant advantage.
**Microsomal Clearance:** Ligand A (34.44) has a lower (better) microsomal clearance than Ligand B (68.13). This suggests better metabolic stability.
**In vitro Half-Life:** Ligand B (23.39) has a significantly longer half-life than Ligand A (1.315). This is a major advantage for Ligand B.
**P-gp Efflux:** Ligand A (0.04) has lower P-gp efflux than Ligand B (0.254). This is a positive for Ligand A.
**Binding Affinity:** Ligand B (-6.7) has a slightly better binding affinity than Ligand A (-6.3). This 1.5 kcal/mol difference is notable.
**Overall Assessment:**
Ligand B has a slightly better binding affinity and a significantly longer half-life. However, Ligand A excels in safety parameters (lower DILI, lower hERG) and has better solubility and P-gp efflux. The lower metabolic clearance of Ligand A is also favorable. Given the cardiovascular target, metabolic stability and safety are paramount. While the affinity difference is noticeable, the other advantages of Ligand A, particularly the lower DILI and hERG risks, make it a more promising candidate.
Output:
1
2025-04-17 19:39:57,345 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands (344.455 and 338.451 Da) are within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (67.43) is slightly higher than Ligand B (58.2). Both are below 140, but B is preferable for GPCRs.
3. **logP:** Ligand B (3.498) is higher than Ligand A (2.215). While both are within the optimal 1-3 range, B is closer to the upper limit. For a GPCR, a slightly higher logP can be acceptable, potentially aiding membrane permeability.
4. **HBD:** Both ligands have 2 H-bond donors, which is good.
5. **HBA:** Ligand A has 3 H-bond acceptors, while Ligand B has 2. Lower is generally better for permeability, giving a slight edge to B.
6. **QED:** Both ligands have similar QED values (0.831 and 0.807), indicating good drug-likeness.
7. **DILI:** Ligand A (29.159) has a significantly lower DILI risk than Ligand B (41.993). This is a substantial advantage for A.
8. **BBB:** Ligand A (71.656) has a higher BBB penetration percentile than Ligand B (55.874). This is important for GPCRs, though not strictly required for ADRB2 as it's primarily cardiovascular.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.843 and -4.746), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-2.809) has slightly better solubility than Ligand B (-4.148).
11. **hERG:** Ligand A (0.465) has a lower hERG inhibition liability than Ligand B (0.183), indicating a lower risk of cardiotoxicity. This is a significant advantage for A, given the cardiovascular target.
12. **Cl_mic:** Ligand B (31.166) has a lower microsomal clearance than Ligand A (60.267), suggesting better metabolic stability. This is a positive for B.
13. **t1/2:** Ligand B (-5.403) has a negative in vitro half-life, which is concerning. Ligand A (1.047) has a short but positive half-life.
14. **Pgp:** Ligand A (0.109) has lower P-gp efflux liability than Ligand B (0.2). This is a slight advantage for A.
15. **Binding Affinity:** Ligand A (-7.4 kcal/mol) has a stronger binding affinity than Ligand B (-5.7 kcal/mol). This is a substantial advantage for A, potentially outweighing some ADME drawbacks.
**Overall Assessment:**
Ligand A demonstrates a superior profile overall, particularly concerning safety (DILI, hERG) and potency (binding affinity). While Ligand B has better metabolic stability (Cl_mic) and a slightly more favorable logP, the stronger binding affinity of Ligand A, combined with its lower toxicity liabilities, makes it the more promising candidate. The negative Caco-2 values are concerning for both, but the potency advantage of A is likely to be more impactful in driving forward development.
Output:
1
2025-04-17 19:39:57,346 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (341.36 & 347.42 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (42.24) is significantly better than Ligand B (93.26). ADRB2 is a cardiovascular target, so CNS penetration isn't critical, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold, while Ligand B is approaching it.
3. **logP:** Ligand A (4.99) is higher than Ligand B (1.45). While both are within the acceptable range (1-3 is optimal), Ligand A is pushing the upper limit. This could lead to solubility issues or off-target interactions. Ligand B is well within the optimal range.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 2 HBA, while Ligand B has 6. Ligand B is higher, potentially impacting permeability.
6. **QED:** Both ligands have similar QED values (0.71 and 0.78), indicating good drug-likeness.
7. **DILI:** Ligand B (52.35) has a significantly lower DILI risk than Ligand A (79.33). This is a major advantage for Ligand B.
8. **BBB:** Both have moderate BBB penetration (65.45 and 61.54), which isn't a primary concern for a cardiovascular target.
9. **Caco-2:** Both have negative Caco-2 values (-4.715 and -4.878). This is unusual and suggests poor permeability. However, the values are similar.
10. **Solubility:** Ligand A (-5.16) has slightly better solubility than Ligand B (-0.967), but both are poor.
11. **hERG:** Ligand A (0.843) has a higher hERG risk than Ligand B (0.151). This is a significant advantage for Ligand B, as it reduces the risk of cardiotoxicity.
12. **Cl_mic:** Ligand B (51.24) has slightly lower microsomal clearance than Ligand A (59.33), suggesting better metabolic stability.
13. **t1/2:** Ligand A (48.31) has a longer in vitro half-life than Ligand B (-5.11). This is a positive for Ligand A.
14. **Pgp:** Ligand A (0.5) has lower P-gp efflux than Ligand B (0.024), which is favorable.
15. **Affinity:** Ligand A (-7.1 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.7 kcal/mol). This is a substantial advantage for Ligand A, potentially outweighing some of its ADME drawbacks.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, and affinity are key. Ligand A has a higher logP (potentially problematic), lower TPSA (good), and significantly better affinity. However, Ligand B has a much better safety profile (lower DILI, lower hERG).
**Overall Assessment:**
While Ligand A boasts a superior binding affinity, the significantly higher DILI and hERG risk associated with it are concerning. The slightly longer half-life and lower P-gp efflux are positives, but the safety liabilities are substantial. Ligand B, despite the weaker affinity, presents a much more favorable ADMET profile, particularly regarding safety. The difference in affinity (0.4 kcal/mol) is not large enough to overcome the safety concerns with Ligand A.
Output:
0
2025-04-17 19:39:57,346 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (354.401 and 350.459 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (78.09) is significantly better than Ligand B (95.5). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is approaching the upper limit for good oral absorption.
3. **logP:** Both ligands have good logP values (1.862 and 1.475), falling within the optimal 1-3 range. Ligand B is slightly lower, which could potentially affect permeability, but it's not a major concern.
4. **HBD:** Ligand A (2) is preferable to Ligand B (3). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (4). Similar reasoning as HBD.
6. **QED:** Ligand A (0.766) is significantly better than Ligand B (0.433). A higher QED indicates a more drug-like profile.
7. **DILI:** Ligand A (49.011) has a much lower DILI risk than Ligand B (21.83). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (73.517) has a better BBB penetration percentile than Ligand B (63.862). While ADRB2 isn't exclusively a CNS target, some peripheral effects are mediated by CNS pathways, and better BBB penetration isn't a detriment.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.063 and -4.995), which is unusual and suggests poor permeability. However, the values are very similar, so this isn't a deciding factor.
10. **Solubility:** Both ligands have negative solubility values (-3.069 and -2.233), which is also unusual and suggests poor solubility. Again, the values are similar.
11. **hERG:** Ligand A (0.473) has a lower hERG inhibition liability than Ligand B (0.077), indicating a lower risk of cardiotoxicity.
12. **Cl_mic:** Ligand A (1.665) has significantly lower microsomal clearance than Ligand B (25.464). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (-22.488) has a much longer in vitro half-life than Ligand B (-32.316). This is a major advantage for Ligand A, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.064) has lower P-gp efflux liability than Ligand B (0.014), suggesting better bioavailability.
15. **Binding Affinity:** Ligand A (-7.2) has a slightly better binding affinity than Ligand B (-6.0). While the difference isn't huge, it's enough to be considered, especially given the other advantages of Ligand A.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical ADME-Tox properties (DILI, Cl_mic, t1/2, Pgp, QED, HBD, HBA, BBB, hERG). While both have issues with Caco-2 and solubility, these are less critical than the metabolic stability and safety profiles. The slightly better binding affinity of Ligand A further solidifies its position as the more promising candidate.
Output:
1
2025-04-17 19:39:57,346 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
The target is ADRB2, a GPCR. Therefore, I will prioritize logP, TPSA, Pgp efflux, BBB penetration, and binding affinity, while also considering the general drug-likeness parameters.
* **Molecular Weight:** Both ligands (352.439 and 362.499 Da) fall within the ideal 200-500 Da range.
* **TPSA:** Ligand B (71.25) is significantly better than Ligand A (126.37). A lower TPSA generally indicates better cell permeability, and is particularly important for GPCRs.
* **logP:** Ligand B (2.857) is within the optimal 1-3 range, while Ligand A (-0.234) is quite low, potentially hindering membrane permeability. This is a significant advantage for Ligand B.
* **H-Bond Donors/Acceptors:** Ligand A has 3 HBD and 7 HBA, while Ligand B has 1 HBD and 6 HBA. Both are acceptable, though Ligand B is slightly more favorable.
* **QED:** Both ligands have good QED scores (0.555 and 0.784), indicating good drug-like properties. Ligand B is better.
* **DILI:** Both ligands have low DILI risk (32.067 and 34.471), which is good.
* **BBB:** Ligand B (58.938) has a slightly better BBB penetration score than Ligand A (52.074), though both are not exceptionally high.
* **Caco-2 Permeability:** Ligand A (-5.59) and Ligand B (-4.864) are both negative, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
* **Aqueous Solubility:** Ligand A (-1.141) has better solubility than Ligand B (-3.248).
* **hERG:** Ligand A (0.192) has a lower hERG risk than Ligand B (0.479), which is a positive.
* **Microsomal Clearance:** Ligand B (49.035) has significantly higher microsomal clearance than Ligand A (0.009), indicating lower metabolic stability. This is a major drawback for Ligand B.
* **In vitro Half-Life:** Ligand B (29.698) has a much longer half-life than Ligand A (-13.768), which is a significant advantage.
* **P-gp Efflux:** Ligand A (0.016) has a lower P-gp efflux liability than Ligand B (0.267), which is favorable.
* **Binding Affinity:** Both ligands have comparable binding affinities (-6.9 and -6.0 kcal/mol). The difference of 0.9 kcal/mol is not large enough to outweigh other significant differences.
**Overall Assessment:**
Ligand B has advantages in TPSA, logP, QED, and half-life. However, it suffers from significantly higher microsomal clearance and P-gp efflux, and lower solubility. Ligand A has better solubility, lower hERG risk, and lower P-gp efflux. The low logP of Ligand A is a concern. Considering the importance of logP and TPSA for GPCR targets, and the significant metabolic instability of Ligand B, I believe Ligand A is the more promising candidate despite its lower logP. The better solubility and lower hERG risk also contribute to its favorability.
**Output:**
1
2025-04-17 19:39:57,346 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [357.426, 73.32, -0.372, 1, 5, 0.73, 20.9, 43.583, -4.613, -0.376, 0.234, -15.948, -17.706, 0.033, -5.7]
**Ligand B:** [350.434, 67.43, 1.852, 2, 3, 0.519, 16.557, 83.443, -4.652, -2.816, 0.325, 15.093, 14.946, 0.057, -4.8]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity):
1. **MW:** Both are within the ideal range (200-500 Da). A is 357.4, B is 350.4 - very similar.
2. **TPSA:** A (73.32) is slightly higher than B (67.43). Both are acceptable for a non-CNS GPCR target like ADRB2, being under 140.
3. **logP:** A (-0.372) is a bit low, potentially hindering permeability. B (1.852) is much better, falling within the optimal 1-3 range. This is a significant advantage for B.
4. **HBD/HBA:** A has 1 HBD and 5 HBA, B has 2 HBD and 3 HBA. Both are reasonable.
5. **QED:** A (0.73) is better than B (0.519), indicating a more drug-like profile.
6. **DILI:** A (20.9) has a much lower DILI risk than B (16.557), a substantial advantage.
7. **BBB:** A (43.583) is lower than B (83.443). While ADRB2 isn't a primary CNS target, some CNS penetration can sometimes be beneficial or at least avoided as an off-target effect. B is better here.
8. **Caco-2:** Both are very poor (-4.613 and -4.652). This is a concern for oral bioavailability for both.
9. **Solubility:** A (-0.376) is slightly better than B (-2.816), but both are poor.
10. **hERG:** A (0.234) is better than B (0.325), indicating lower cardiotoxicity risk.
11. **Cl_mic:** A (-15.948) is *much* better than B (15.093). Lower clearance means greater metabolic stability, a huge plus for A.
12. **t1/2:** A (-17.706) is better than B (14.946), indicating a longer half-life.
13. **Pgp:** A (0.033) is much lower than B (0.057), suggesting less P-gp efflux and better bioavailability.
14. **Affinity:** Both are very similar (-5.7 and -4.8 kcal/mol). The difference of 0.9 kcal/mol is not large enough to overcome other significant differences.
**Overall Assessment:**
Ligand A has a significantly better safety profile (lower DILI), better metabolic stability (lower Cl_mic, longer t1/2), and lower P-gp efflux. While its logP is suboptimal, the other advantages, especially the metabolic stability and safety, outweigh this. Ligand B has a better logP and BBB, but suffers from higher DILI risk, poorer metabolic stability, and higher P-gp efflux. The affinity difference is not substantial enough to favor B.
Therefore, I prefer Ligand A.
Output:
1
2025-04-17 19:39:57,346 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.523 and 348.443 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (55.89) is significantly better than Ligand B (71.63). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary goal, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (1.025) is optimal, while Ligand B (3.608) is approaching the higher end of the preferred range. Higher logP can sometimes lead to off-target effects and solubility issues.
4. **HBD:** Both ligands have 1 HBD, which is acceptable.
5. **HBA:** Both ligands have 4 HBA, which is acceptable.
6. **QED:** Ligand A (0.743) is slightly better than Ligand B (0.666), indicating a more drug-like profile.
7. **DILI:** Ligand A (6.049%) has a much lower DILI risk than Ligand B (37.728%). This is a crucial factor, as liver toxicity is a major concern in drug development.
8. **BBB:** Both are acceptable, but Ligand B (77.084%) is higher than Ligand A (67.468%). This isn't a major priority for a cardiovascular target.
9. **Caco-2:** Both have negative values, indicating poor permeability. Ligand A (-4.809) is slightly better than Ligand B (-4.536).
10. **Solubility:** Ligand A (-0.79) is better than Ligand B (-4.039). Solubility is important for bioavailability.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.495 and 0.618), which is excellent.
12. **Cl_mic:** Ligand A (12.106 mL/min/kg) has significantly lower microsomal clearance than Ligand B (66.964 mL/min/kg), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-12.336 hours) has a negative half-life, which is concerning. Ligand B (-25.31 hours) is also negative, but more so. Both are poor.
14. **Pgp:** Both ligands have very low Pgp efflux (0.006 and 0.156), which is good.
15. **Binding Affinity:** Both ligands have the same binding affinity (-6.2 kcal/mol).
**GPCR-Specific Priorities:** For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand A has a better logP and TPSA. While affinity is the same, the superior ADME properties of Ligand A (lower DILI, better solubility, lower Cl_mic) make it a more promising candidate. The negative half-life is a concern for both, but the other advantages of Ligand A outweigh this.
**Conclusion:**
Ligand A is the better candidate due to its superior predicted ADME properties, particularly its lower DILI risk, better solubility, and improved metabolic stability, despite both having negative in vitro half-lives.
Output:
1
2025-04-17 19:39:57,347 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (335.403 Da) is slightly lower, which is generally favorable for permeability.
**2. TPSA:** Ligand B (36.36) is significantly better than Ligand A (59.32). For a GPCR, keeping TPSA low is beneficial for permeability and receptor engagement.
**3. logP:** Both have good logP values (A: 4.146, B: 4.727), falling within the optimal 1-3 range, although slightly above. Ligand B is a bit higher, which *could* lead to solubility issues, but isn't a major concern at this level.
**4. H-Bond Donors:** Ligand A has 0 HBD, and Ligand B has 1. Both are acceptable.
**5. H-Bond Acceptors:** Both ligands have 4 HBA, which is well within the acceptable range.
**6. QED:** Ligand B (0.777) has a higher QED score than Ligand A (0.537), indicating a more drug-like profile.
**7. DILI Risk:** Ligand A has a significantly higher DILI risk (60.101%) compared to Ligand B (9.965%). This is a major red flag for Ligand A.
**8. BBB Penetration:** Ligand B (78.519%) shows better BBB penetration than Ligand A (55.254%). While ADRB2 isn't exclusively a CNS target, some cardiovascular effects are mediated by central pathways, and better BBB penetration isn't detrimental.
**9. Caco-2 Permeability:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
**10. Aqueous Solubility:** Both have negative solubility values, indicating poor solubility. This is a concern.
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (A: 0.851, B: 0.827).
**12. Microsomal Clearance:** Ligand B (44.528) has significantly lower microsomal clearance than Ligand A (115.544), suggesting better metabolic stability.
**13. In vitro Half-Life:** Ligand A (-17.357) has a negative half-life, which is not possible. This is a significant issue. Ligand B (-6.574) is also negative, but less so.
**14. P-gp Efflux:** Both have similar P-gp efflux liability (A: 0.609, B: 0.567).
**15. Binding Affinity:** Both ligands have very similar binding affinities (A: -6.5 kcal/mol, B: -6.2 kcal/mol). The difference is not substantial enough to outweigh other factors.
**Overall Assessment:**
Ligand B is clearly the superior candidate. While both have solubility and permeability concerns (indicated by negative Caco-2 and solubility values), Ligand B excels in critical areas: significantly lower DILI risk, better BBB penetration, and much better metabolic stability (lower Cl_mic). The negative half-life for Ligand A is a critical flaw. The slightly higher QED score for Ligand B further supports its selection.
Output:
0
2025-04-17 19:39:57,347 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [356.369, 60.03, 2.619, 1, 4, 0.851, 35.673, 89.027, -4.421, -3.209, 0.627, 31.957, -20.684, 0.072, -5.1]
**Ligand B:** [349.519, 52.65, 2.119, 1, 3, 0.799, 4.963, 90.19, -4.689, -1.872, 0.542, 41.814, 3.455, 0.064, -6.1]
Here's a breakdown, considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (349.519) is slightly lower, which is generally favorable.
2. **TPSA:** Both are good, below the 140 A^2 threshold for oral absorption. Ligand B (52.65) is better than Ligand A (60.03).
3. **logP:** Both are within the optimal 1-3 range. Ligand B (2.119) is slightly lower, which is acceptable.
4. **HBD/HBA:** Both have 1 HBD, which is good. Ligand B has 3 HBA, slightly better than Ligand A's 4.
5. **QED:** Both are above 0.5, indicating good drug-likeness, but Ligand A (0.851) is better than Ligand B (0.799).
6. **DILI:** Ligand B (4.963) has a significantly lower DILI risk than Ligand A (35.673). This is a major advantage.
7. **BBB:** Both have high BBB penetration, but Ligand B (90.19) is slightly higher than Ligand A (89.027). While not critical for a cardiovascular target, it's a positive.
8. **Caco-2:** Both have negative values, indicating poor permeability. Ligand A (-4.421) is slightly worse than Ligand B (-4.689).
9. **Solubility:** Both have negative solubility values, indicating poor solubility. Ligand B (-1.872) is better than Ligand A (-3.209).
10. **hERG:** Both have low hERG inhibition risk, which is good. Ligand B (0.542) is slightly better than Ligand A (0.627).
11. **Cl_mic:** Ligand A (31.957) has lower microsomal clearance, suggesting better metabolic stability than Ligand B (41.814).
12. **t1/2:** Ligand A (-20.684) has a longer in vitro half-life than Ligand B (3.455). This is a significant advantage.
13. **Pgp:** Both have low P-gp efflux, which is good. Ligand A (0.072) is slightly better than Ligand B (0.064).
14. **Affinity:** Ligand B (-6.1 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.1 kcal/mol). This is a crucial advantage, exceeding the 1.5 kcal/mol threshold.
**Overall Assessment:**
Ligand B demonstrates a superior balance of properties. While Ligand A has better QED, t1/2, and Pgp, Ligand B's significantly lower DILI risk and substantially stronger binding affinity outweigh these advantages. The better solubility and TPSA of Ligand B are also beneficial. The affinity difference is particularly important for a GPCR target.
Output:
0
2025-04-17 19:39:57,347 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [371.478, 88.16, 1.721, 2, 4, 0.692, 41.838, 74.292, -5.283, -2.132, 0.225, 8.631, -18.905, 0.085, -5.9]
**Ligand B:** [353.495, 62.73, 4.751, 2, 6, 0.693, 83.637, 67.158, -5.047, -5.015, 0.644, 83.609, 55.217, 0.312, -5.2]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (353.495) is slightly lower, which could be a minor advantage for permeability.
2. **TPSA:** Ligand A (88.16) is better than Ligand B (62.73), being closer to the ideal threshold of <140 for oral absorption.
3. **logP:** Ligand A (1.721) is optimal (1-3). Ligand B (4.751) is pushing the upper limit and could potentially lead to solubility issues or off-target interactions.
4. **HBD:** Both have 2 HBD, which is good.
5. **HBA:** Ligand A (4) is better than Ligand B (6).
6. **QED:** Both are similar (0.692 and 0.693), indicating good drug-likeness.
7. **DILI:** Ligand A (41.838) has a significantly lower DILI risk than Ligand B (83.637). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (74.292) has better BBB penetration than Ligand B (67.158). While ADRB2 isn't exclusively a CNS target, some peripheral effects are mediated by CNS pathways, and better BBB penetration isn't detrimental.
9. **Caco-2:** Both are negative, indicating poor permeability.
10. **Solubility:** Ligand A (-2.132) is better than Ligand B (-5.015).
11. **hERG:** Ligand A (0.225) has a much lower hERG inhibition liability than Ligand B (0.644), reducing the risk of cardiotoxicity.
12. **Cl_mic:** Ligand A (8.631) has lower microsomal clearance, suggesting better metabolic stability.
13. **t1/2:** Ligand A (-18.905) has a much longer in vitro half-life than Ligand B (55.217).
14. **Pgp:** Ligand A (0.085) has lower P-gp efflux liability than Ligand B (0.312).
15. **Affinity:** Both have similar binding affinities (-5.9 and -5.2 kcal/mol). The difference is not substantial enough to outweigh other factors.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A is better in most of these categories.
**Conclusion:**
Ligand A clearly outperforms Ligand B in several critical ADME-Tox properties (DILI, hERG, Cl_mic, t1/2, Pgp, solubility) and has a more favorable logP. While both have similar binding affinities, the superior ADME profile of Ligand A makes it a more promising drug candidate.
Output:
1
2025-04-17 19:39:57,347 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Ligand A (479.231 Da) is within the ideal range, while Ligand B (357.395 Da) is towards the lower end, but still acceptable.
2. **TPSA:** Ligand A (35.58) is excellent, well below the 140 threshold and favorable for absorption. Ligand B (110.01) is higher, but still within a reasonable range for a non-CNS target.
3. **logP:** Both ligands have good logP values (A: 3.247, B: 2.325), falling within the 1-3 optimal range.
4. **HBD:** Both ligands have acceptable HBD counts (A: 1, B: 2).
5. **HBA:** Ligand A (2) is better than Ligand B (7) in terms of HBA. Higher HBA can sometimes hinder permeability.
6. **QED:** Ligand B (0.725) has a significantly better QED score than Ligand A (0.371), indicating a more drug-like profile.
7. **DILI:** Ligand A (39.434) has a much lower DILI risk than Ligand B (91.857). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (82.668) has a better BBB penetration score than Ligand B (53.781). While ADRB2 isn't exclusively a CNS target, some peripheral ADRB2 receptors can be relevant in CNS-related conditions, and better BBB penetration isn't necessarily a detriment.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual. Assuming these are logP values, they are both very poor.
10. **Solubility:** Both have negative solubility values, which is also unusual.
11. **hERG:** Ligand A (0.918) has a slightly higher hERG risk than Ligand B (0.272), but both are relatively low.
12. **Cl_mic:** Ligand A (34.61) has a lower microsomal clearance than Ligand B (54.184), suggesting better metabolic stability.
13. **t1/2:** Ligand B (45.861) has a slightly longer in vitro half-life than Ligand A (40.819).
14. **Pgp:** Ligand A (0.316) has a lower P-gp efflux liability than Ligand B (0.125), which is favorable for oral bioavailability.
15. **Affinity:** Ligand B (-8.4 kcal/mol) has a significantly stronger binding affinity than Ligand A (-7.8 kcal/mol). This is a substantial advantage.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, affinity, logP, TPSA, and Pgp are key. Ligand B excels in affinity, and has acceptable values for the other parameters. Ligand A has a better safety profile (DILI) and metabolic stability (Cl_mic), but the affinity difference is substantial.
**Overall Assessment:**
The significantly stronger binding affinity of Ligand B (-8.4 kcal/mol vs -7.8 kcal/mol) is a major driver. While Ligand A has advantages in DILI risk and metabolic stability, the potency advantage of Ligand B is likely to outweigh these concerns, especially in early-stage drug discovery. The QED score of Ligand B is also a positive. The unusual Caco-2 and Solubility values are concerning for both, and would need to be investigated further.
Output:
0
2025-04-17 19:39:57,348 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (351.45 & 363.44 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (85.61) is significantly better than Ligand B (128.32). ADRB2 is a cardiovascular target, not CNS, but lower TPSA generally improves absorption.
3. **logP:** Both ligands have acceptable logP values (1.32 & 0.79), falling within the 1-3 range. Ligand A is slightly better.
4. **HBD:** Ligand A (2) is preferable to Ligand B (3). Lower HBD is generally better for permeability.
5. **HBA:** Ligand A (6) is preferable to Ligand B (5). Lower HBA is generally better for permeability.
6. **QED:** Ligand A (0.807) is significantly better than Ligand B (0.619), indicating a more drug-like profile.
7. **DILI:** Ligand A (33.35) has a much lower DILI risk than Ligand B (47.03). This is a significant advantage.
8. **BBB:** Not a primary concern for a cardiovascular target. Ligand B (67.08) is higher, but this isn't a deciding factor.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-5.232) is slightly less negative than Ligand B (-5.475), suggesting marginally better permeability.
10. **Solubility:** Both ligands have negative solubility values, indicating poor solubility. Ligand A (-0.768) is better than Ligand B (-2.532).
11. **hERG:** Both ligands have low hERG inhibition risk (0.309 & 0.502). No clear advantage.
12. **Cl_mic:** Ligand A (4.485) has a much lower microsomal clearance than Ligand B (-19.719), indicating better metabolic stability.
13. **t1/2:** Ligand A (27.19) has a significantly longer in vitro half-life than Ligand B (9.04). This is a major advantage.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.097 & 0.028). No clear advantage.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.1 & -6.2 kcal/mol). The difference is negligible.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical ADME properties. It has a better QED score, lower DILI risk, better solubility, significantly better metabolic stability (lower Cl_mic, longer t1/2), and slightly better permeability and logP. While both have similar binding affinities, the superior ADME profile of Ligand A makes it a much more promising drug candidate.
Output:
1
2025-04-17 19:39:57,348 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for the ADRB2, a cardiovascular GPCR. Therefore, key properties to prioritize are logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB.
Let's compare the ligands property by property:
1. **MW:** Both ligands (350.48 and 361.56 Da) fall within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (49.41) is better than Ligand B (55.63), being closer to the desirable <140 threshold for oral absorption.
3. **logP:** Both ligands have good logP values (2.91 and 3.39), falling within the optimal 1-3 range. Ligand B is slightly higher, which could be a minor concern for solubility.
4. **HBD/HBA:** Both have acceptable HBD (1) and Ligand A has 2 HBA while Ligand B has 6. Ligand A is preferable.
5. **QED:** Both have similar QED values (0.847 and 0.815), indicating good drug-likeness.
6. **DILI:** Ligand A (17.45) has a significantly lower DILI risk than Ligand B (36.18), a crucial advantage.
7. **BBB:** Ligand A (93.25) has a much higher BBB penetration percentile than Ligand B (70.99). While ADRB2 is cardiovascular, some CNS exposure can occur, and higher BBB is generally favorable.
8. **Caco-2:** Ligand A (-4.915) is better than Ligand B (-5.398), indicating better intestinal absorption.
9. **Solubility:** Both have similar, very poor solubility (-4.042 and -4.171). This is a concern for both, but not a deciding factor.
10. **hERG:** Ligand A (0.655) has a slightly better hERG profile than Ligand B (0.21), indicating lower cardiotoxicity risk.
11. **Cl_mic:** Ligand B (18.53) has a lower microsomal clearance than Ligand A (25.1), suggesting better metabolic stability. This is a point in favor of Ligand B.
12. **t1/2:** Ligand B (-7.441) has a better in vitro half-life than Ligand A (8.432). This is a point in favor of Ligand B.
13. **Pgp:** Ligand A (0.098) has a lower Pgp efflux liability than Ligand B (0.131), which is preferable for bioavailability.
14. **Binding Affinity:** Both ligands have excellent binding affinities (-4.4 and -5.4 kcal/mol). Ligand B is 1 kcal/mol better.
**Overall Assessment:**
Ligand B has a slightly better binding affinity and metabolic stability (lower Cl_mic, better t1/2). However, Ligand A significantly outperforms Ligand B in crucial areas like DILI risk, BBB penetration, Caco-2 permeability, and Pgp efflux. The lower DILI risk and better predicted absorption (Caco-2, Pgp) are particularly important. The slightly better affinity of Ligand B is unlikely to outweigh these significant ADME advantages.
**Output:**
1
2025-04-17 19:39:57,348 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (349.475 Da) is slightly lower, which is generally favorable for permeability.
**2. TPSA:** Both ligands have TPSA values below the 140 A^2 threshold for good oral absorption. Ligand B (79.37 A^2) is slightly lower than Ligand A (84.64 A^2), which is a minor advantage.
**3. logP:** Both ligands have logP values within the optimal range (1-3). Ligand A (2.071) and Ligand B (1.79) are both good.
**4. H-Bond Donors:** Both ligands have 1 HBD, which is within the acceptable limit of 5.
**5. H-Bond Acceptors:** Ligand A has 4 HBA, and Ligand B has 5. Both are within the acceptable limit of 10.
**6. QED:** Both ligands have QED values above 0.5, indicating good drug-like properties. Ligand A (0.823) is slightly better than Ligand B (0.75).
**7. DILI Risk:** Ligand A (20.202 percentile) has a significantly lower DILI risk than Ligand B (60.527 percentile). This is a major advantage for Ligand A.
**8. BBB Penetration:** Ligand B (83.443 percentile) has better BBB penetration than Ligand A (57.27 percentile). While ADRB2 is a cardiovascular target, some CNS effects are possible with beta-blockers, and some degree of BBB penetration could be beneficial.
**9. Caco-2 Permeability:** Ligand A (-4.578) shows better Caco-2 permeability than Ligand B (-5.095).
**10. Aqueous Solubility:** Ligand A (-1.794) has better aqueous solubility than Ligand B (-3.584). This is important for formulation and bioavailability.
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (0.586 and 0.387 respectively).
**12. Microsomal Clearance:** Ligand A (14.321 mL/min/kg) has significantly lower microsomal clearance than Ligand B (39.559 mL/min/kg), indicating better metabolic stability.
**13. In vitro Half-Life:** Ligand A (-3.141 hours) has a longer in vitro half-life than Ligand B (-22.42 hours).
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (0.15 and 0.195 respectively).
**15. Binding Affinity:** Ligand B (-7.4 kcal/mol) has a stronger binding affinity than Ligand A (-5.9 kcal/mol). This is a substantial difference (1.5 kcal/mol), and is a significant advantage.
**Overall Assessment:**
While Ligand B has a better binding affinity, the significant advantages of Ligand A in terms of DILI risk, metabolic stability (lower Cl_mic, longer t1/2), solubility, and Caco-2 permeability outweigh the affinity difference. The lower DILI risk is particularly important. For a cardiovascular target, high BBB penetration is less critical. Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity) and the overall balance of properties, Ligand A presents a more favorable profile for drug development.
Output:
1
2025-04-17 19:39:57,348 - INFO - Here's my reasoning and final output for the ligand preference:
**Reasoning:**
We are looking for a ligand for ADRB2, a cardiovascular GPCR. Therefore, the priorities are affinity, logP, TPSA, Pgp, and to a lesser extent, BBB.
Let's compare Ligand A and Ligand B across the 15 parameters:
1. **MW:** Both are within the ideal range (352.41 vs 363.483 Da).
2. **TPSA:** Ligand B (71.53) is significantly better than Ligand A (95.16), falling well below the 140 threshold for oral absorption.
3. **logP:** Both are good (1.838 and 1.976), within the optimal 1-3 range.
4. **HBD:** Ligand B (1) is preferable to Ligand A (2) as lower HBD generally improves permeability.
5. **HBA:** Ligand B (5) is slightly better than Ligand A (4), but both are acceptable.
6. **QED:** Both are good (0.698 and 0.752), indicating good drug-like properties.
7. **DILI:** Both are acceptable, with Ligand B (56.262) being slightly better than Ligand A (60.489), both being below the 60 threshold.
8. **BBB:** Ligand A (54.13) is slightly better than Ligand B (44.203), but BBB is not a high priority for a cardiovascular target.
9. **Caco-2:** Both are very poor (-5.009 and -5.055). This is a significant drawback for both.
10. **Solubility:** Both are very poor (-1.949 and -2.134). This is also a significant drawback for both.
11. **hERG:** Both are very low risk (0.075 and 0.156).
12. **Cl_mic:** Both are similar (32.464 and 31.758), indicating similar metabolic clearance.
13. **t1/2:** Ligand B (17.342) has a significantly longer half-life than Ligand A (-6.193), which is a major advantage.
14. **Pgp:** Both are very low (0.046 and 0.118), indicating low efflux.
15. **Affinity:** Ligand A (-7.5) has a slightly better binding affinity than Ligand B (-5.6), a difference of 1.9 kcal/mol.
**Conclusion:**
While Ligand A has a slightly better binding affinity, Ligand B has a significantly better TPSA, HBD, and *much* better in vitro half-life. The poor Caco-2 and solubility are concerning for both, but the improved ADME profile of Ligand B, particularly the longer half-life, outweighs the small difference in binding affinity for a cardiovascular GPCR target.
**Output:**
0
2025-04-17 19:39:57,348 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (336.351 and 351.451 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (103.35) is higher than Ligand B (79.7). While both are reasonably good, Ligand B is better, being closer to the <140 threshold for oral absorption and more favorable for a GPCR.
3. **logP:** Both ligands have good logP values (2.085 and 1.642) within the optimal 1-3 range. Ligand B is slightly lower, which could be beneficial for solubility.
4. **HBD:** Ligand A has 4 HBDs, while Ligand B has 1. Lower HBD is generally preferred for better permeability, giving an edge to Ligand B.
5. **HBA:** Ligand A has 4 HBAs, and Ligand B has 5. Both are acceptable, being under the 10 threshold.
6. **QED:** Ligand B (0.81) has a significantly better QED score than Ligand A (0.55), indicating a more drug-like profile.
7. **DILI:** Ligand A (84.994) has a considerably higher DILI risk than Ligand B (23.187). This is a major concern, as lower DILI is crucial.
8. **BBB:** Ligand B (85.459) shows better BBB penetration than Ligand A (44.591). While ADRB2 isn't exclusively a CNS target, some CNS exposure can occur, and higher BBB is generally desirable.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual. However, the absolute value is smaller for Ligand B (-4.477 vs -5.092), suggesting slightly better permeability.
10. **Solubility:** Ligand B (-1.417) has better aqueous solubility than Ligand A (-3.819).
11. **hERG:** Ligand A (0.234) has a slightly lower hERG risk than Ligand B (0.525), but both are relatively low.
12. **Cl_mic:** Ligand B (12.116) has significantly lower microsomal clearance than Ligand A (42.109), indicating better metabolic stability.
13. **t1/2:** Ligand B (5.412) has a longer in vitro half-life than Ligand A (-6.114). This is a positive attribute.
14. **Pgp:** Ligand A (0.046) has lower P-gp efflux liability than Ligand B (0.016). Lower Pgp is better.
15. **Binding Affinity:** Ligand B (-6.6 kcal/mol) has a slightly better binding affinity than Ligand A (-6.2 kcal/mol). While the difference is not huge, it's enough to be considered.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in TPSA, Pgp, and has comparable logP and slightly better affinity. The significant improvements in ADME properties (DILI, BBB, solubility, Cl_mic, t1/2, QED) of Ligand B outweigh the slightly higher Pgp efflux and slightly lower affinity.
**Conclusion:**
Ligand B demonstrates a superior balance of properties, particularly regarding safety (DILI), ADME characteristics, and drug-likeness. The slightly better affinity is a bonus.
Output:
0
2025-04-17 19:39:57,348 - INFO - Batch 127 complete. Total preferences: 2032
2025-04-17 19:39:57,349 - INFO - Processing batch 128/512...
2025-04-17 19:40:48,416 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (361.433 and 368.587 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (70.67) is higher than Ligand B (32.78). For a cardiovascular GPCR, TPSA is not a primary concern unless CNS penetration is desired, but lower is generally better for absorption. Ligand B is significantly better.
3. **logP:** Ligand A (0.806) is slightly lower than the optimal 1-3 range, potentially impacting permeability. Ligand B (3.258) is within the optimal range. Ligand B is better.
4. **HBD:** Ligand A (2) is reasonable, while Ligand B (0) is even better, minimizing potential for off-target interactions and improving permeability.
5. **HBA:** Both ligands (A: 4, B: 4) are within the acceptable limit of 10. No significant difference.
6. **QED:** Both ligands have good QED scores (A: 0.671, B: 0.746), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (11.632) has a higher DILI risk than Ligand B (5.312). This is a significant advantage for Ligand B.
8. **BBB:** Both ligands have high BBB penetration (A: 81.466, B: 81.698). Since ADRB2 is primarily a cardiovascular target, high BBB penetration isn't critical, but it doesn't hurt.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.022 and -4.926). This is unusual and suggests poor permeability. However, the values are very similar.
10. **Solubility:** Both ligands have poor solubility (-1.466 and -2.245). This is a concern, but can be addressed through formulation.
11. **hERG:** Both ligands have very low hERG inhibition risk (A: 0.271, B: 0.791). This is excellent.
12. **Cl_mic:** Ligand A (1.883) has significantly lower microsomal clearance than Ligand B (31.754), indicating better metabolic stability. This is a major advantage for Ligand A.
13. **t1/2:** Ligand A (-2.562) has a negative in vitro half-life, which is unusual and concerning. Ligand B (4.312) has a reasonable half-life. This is a significant advantage for Ligand B.
14. **Pgp:** Both ligands have very low Pgp efflux liability (A: 0.008, B: 0.266). This is excellent.
15. **Binding Affinity:** Both ligands have the same binding affinity (-5.8 kcal/mol).
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are important. Ligand B excels in logP and TPSA. Affinity is equal. However, metabolic stability (Cl_mic) and DILI risk are also crucial. Ligand A has better metabolic stability, but Ligand B has a significantly lower DILI risk. The negative half-life of Ligand A is a major red flag.
**Overall Assessment:**
While Ligand A has better metabolic stability, the significantly lower DILI risk and more favorable half-life of Ligand B outweigh this advantage. The lower TPSA and optimal logP of Ligand B also contribute to its potential for better absorption. The negative half-life for Ligand A is a dealbreaker.
Output:
0
2025-04-17 19:40:48,417 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (341.411 and 346.391 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (73.1) is significantly better than Ligand B (106.15). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is pushing the upper limit for good oral absorption.
**3. logP:** Ligand A (2.397) is optimal, while Ligand B (0.133) is quite low. Low logP can lead to poor membrane permeability and bioavailability. This is a substantial advantage for Ligand A.
**4. H-Bond Donors:** Both have 1 HBD, which is acceptable.
**5. H-Bond Acceptors:** Ligand A has 5 HBA, while Ligand B has 7. Both are within the acceptable range, but Ligand A is slightly better.
**6. QED:** Ligand A (0.928) has a much better QED score than Ligand B (0.797), indicating a more drug-like profile.
**7. DILI:** Ligand B (58.976) has a slightly lower DILI risk than Ligand A (64.754), but both are reasonably acceptable.
**8. BBB:** Ligand A (75.572) has a significantly higher BBB penetration percentile than Ligand B (38.348). While ADRB2 is a cardiovascular target, some CNS penetration can be acceptable or even beneficial depending on the specific therapeutic goal and potential off-target effects.
**9. Caco-2 Permeability:** Ligand A (-4.509) has better Caco-2 permeability than Ligand B (-5.436).
**10. Aqueous Solubility:** Ligand A (-3.369) has better aqueous solubility than Ligand B (-1.506).
**11. hERG Inhibition:** Ligand A (0.443) has a lower hERG inhibition liability than Ligand B (0.04), which is a significant safety advantage.
**12. Microsomal Clearance:** Ligand B (16.076) has a higher microsomal clearance than Ligand A (10.426), suggesting faster metabolism and potentially lower exposure.
**13. In vitro Half-Life:** Ligand A (11.631) has a longer in vitro half-life than Ligand B (-6.622), which is a positive attribute.
**14. P-gp Efflux:** Ligand A (0.193) has lower P-gp efflux than Ligand B (0.01), which is favorable for bioavailability.
**15. Binding Affinity:** Both ligands have very similar binding affinities (-6.7 and -6.5 kcal/mol). The difference is negligible.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most crucial ADME properties (logP, TPSA, QED, solubility, hERG, permeability, clearance, half-life, P-gp efflux) while maintaining comparable binding affinity. Ligand B's only advantage is a slightly lower DILI risk, which is outweighed by the numerous benefits of Ligand A. Given the GPCR target class, prioritizing properties like TPSA, logP, and P-gp efflux is crucial, and Ligand A excels in these areas.
Output:
1
2025-04-17 19:40:48,417 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (366.571 Da) is within the ideal range (200-500 Da). Ligand B (345.411 Da) is also within the ideal range. No clear advantage here.
2. **TPSA:** Ligand A (49.41) is excellent, well below the 140 threshold for oral absorption and suitable for a GPCR. Ligand B (126.88) is still acceptable, but higher, potentially impacting absorption.
3. **logP:** Ligand A (3.453) is optimal (1-3). Ligand B (-0.373) is significantly lower, which is a major concern for membrane permeability and bioavailability.
4. **HBD:** Both Ligand A (1) and Ligand B (3) are within the acceptable limit of 5.
5. **HBA:** Ligand A (3) is good. Ligand B (10) is at the upper limit, potentially affecting permeability.
6. **QED:** Ligand A (0.811) is excellent, indicating high drug-likeness. Ligand B (0.615) is still acceptable, but lower.
7. **DILI:** Ligand A (23.032) has a very low DILI risk. Ligand B (62.66) is higher, indicating a moderate risk of liver injury.
8. **BBB:** Ligand A (79.488) shows good potential for BBB penetration, which is beneficial for GPCR targets. Ligand B (51.842) is lower, suggesting limited CNS exposure.
9. **Caco-2:** Ligand A (-4.972) and Ligand B (-5.682) are both negative values, which is unusual. Assuming these are logPapp values, lower (more negative) values indicate *lower* permeability. However, the difference isn't massive.
10. **Solubility:** Ligand A (-3.924) and Ligand B (-2.338) are both negative values, indicating poor solubility. Ligand B is slightly better.
11. **hERG:** Both Ligand A (0.551) and Ligand B (0.577) have similar, relatively low hERG inhibition risk.
12. **Cl_mic:** Ligand A (72.381) has a moderate clearance. Ligand B (5.686) has very low clearance, indicating better metabolic stability.
13. **t1/2:** Ligand A (-4.057) has a negative half-life, which is unusual and likely an error or a very short half-life. Ligand B (-6.088) also has a negative half-life, but is even more negative.
14. **Pgp:** Both Ligand A (0.3) and Ligand B (0.004) have low P-gp efflux, which is good. Ligand B is slightly better.
15. **Affinity:** Ligand B (-6.4) has a slightly better binding affinity than Ligand A (-6.0). While the difference is not huge, it is greater than 1.5 kcal/mol, which is a significant advantage.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A excels in TPSA and BBB penetration. Ligand B has a slight edge in affinity and Pgp efflux, and significantly better metabolic stability. However, the very low logP of Ligand B is a major red flag.
**Overall Assessment:**
Despite Ligand B's slightly better affinity and metabolic stability, the significantly lower logP is a critical drawback. Poor logP will likely result in poor absorption and bioavailability. Ligand A, while not perfect, has a much more favorable balance of properties, particularly its logP, TPSA, and DILI risk. The negative half-life values are concerning for both, but the other properties of Ligand A are more promising.
Output:
1
2025-04-17 19:40:48,417 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [347.371, 97.83, 1.115, 1, 6, 0.82, 74.021, 61.38, -4.664, -2.738, 0.066, -21.343, -13.14, 0.026, -7.7]
**Ligand B:** [347.419, 96.33, 0.296, 2, 5, 0.766, 49.554, 82.202, -4.742, -2.495, 0.145, 32.975, 19.981, 0.011, -7.1]
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (around 347 Da). No significant difference.
2. **TPSA:** Both are acceptable for oral absorption (<140), but Ligand B (96.33) is slightly better than Ligand A (97.83).
3. **logP:** Ligand A (1.115) is better than Ligand B (0.296). A logP between 1-3 is optimal, and Ligand B is a bit low, potentially impacting permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (6) is preferable to Ligand B (5). Fewer HBAs generally improve permeability.
6. **QED:** Ligand A (0.82) is slightly better than Ligand B (0.766), indicating a more drug-like profile.
7. **DILI:** Ligand B (49.554) is significantly better than Ligand A (74.021). Lower DILI risk is crucial.
8. **BBB:** Ligand B (82.202) is significantly better than Ligand A (61.38). For a GPCR, even if not specifically a CNS target, some BBB penetration can be beneficial for distribution and potentially off-target effects.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-4.664) is slightly worse than Ligand B (-4.742).
10. **Solubility:** Both are negative, indicating poor solubility. Ligand A (-2.738) is slightly worse than Ligand B (-2.495).
11. **hERG:** Both are very low risk (0.066 and 0.145). No significant difference.
12. **Cl_mic:** Ligand A (-21.343) is much better than Ligand B (32.975). Lower clearance indicates better metabolic stability.
13. **t1/2:** Ligand B (19.981) is significantly better than Ligand A (-13.14). Longer half-life is desirable.
14. **Pgp:** Both are very low efflux (0.026 and 0.011). No significant difference.
15. **Affinity:** Ligand B (-7.1) is slightly better than Ligand A (-7.7). While the difference is small, it's still a positive.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, Pgp, TPSA, and affinity. Ligand A has a better logP, but Ligand B has better TPSA, Pgp, and affinity. The significantly better BBB penetration and lower DILI risk of Ligand B are also very important. The longer half-life of Ligand B is also a significant advantage. While Ligand A has better metabolic stability (Cl_mic), the other advantages of Ligand B outweigh this.
**Conclusion:**
Considering the balance of properties and the priorities for a GPCR target, Ligand B is the more promising candidate. The improved DILI, BBB, half-life, and slightly better affinity outweigh the slightly lower logP and worse metabolic stability.
Output:
0
2025-04-17 19:40:48,417 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (381.929 Da) is slightly higher than Ligand B (356.491 Da), but both are acceptable.
2. **TPSA:** Ligand A (62.3) is slightly higher than Ligand B (51.22). Both are below the 140 A^2 threshold for good oral absorption, and reasonably good for a GPCR.
3. **logP:** Both ligands have good logP values (A: 3.488, B: 4.031), falling within the optimal 1-3 range. Ligand B is slightly higher, which could potentially lead to solubility issues, but is still acceptable.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Both have 4 HBA, which is good.
6. **QED:** Ligand A (0.868) has a better QED score than Ligand B (0.69), indicating a more drug-like profile.
7. **DILI:** Both have acceptable DILI risk (A: 53.044, B: 58.123), both below the 60 threshold.
8. **BBB:** Ligand A (73.75) has a significantly better BBB penetration percentile than Ligand B (52.268). While ADRB2 isn't strictly a CNS target, some CNS exposure can be relevant for off-target effects and overall safety assessment.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. Ligand A (-5.071) is slightly better than Ligand B (-4.803), but both are concerning.
10. **Solubility:** Both have negative solubility values, indicating poor aqueous solubility. Ligand A (-4.193) is slightly better than Ligand B (-4.878).
11. **hERG:** Both have low hERG inhibition liability (A: 0.405, B: 0.565), which is favorable.
12. **Cl_mic:** Ligand A (37.175) has a lower microsomal clearance than Ligand B (75.266), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-5.333) has a much longer in vitro half-life than Ligand B (18.349). This is a significant advantage.
14. **Pgp:** Both have low Pgp efflux liability (A: 0.529, B: 0.487).
15. **Binding Affinity:** Ligand B (-6.4 kcal/mol) has a significantly stronger binding affinity than Ligand A (-3.5 kcal/mol). This is a substantial advantage, exceeding the 1.5 kcal/mol threshold.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are crucial. While both ligands have acceptable logP and Pgp, Ligand B's significantly higher binding affinity is the most important factor. The lower Caco-2 and solubility are drawbacks, but the strong affinity could potentially be optimized through structural modifications. The better metabolic stability and half-life of Ligand A are also valuable, but the affinity difference is too large to ignore.
**Conclusion:**
Despite the drawbacks in solubility and permeability, Ligand B's significantly stronger binding affinity makes it the more promising candidate. The affinity advantage is likely to outweigh the ADME concerns, which can be addressed through further optimization.
Output:
0
2025-04-17 19:40:48,417 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (360.489 and 364.519 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (40.62) is significantly better than Ligand B (86.89). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand B's TPSA is quite high, potentially hindering oral bioavailability.
3. **logP:** Both ligands have good logP values (3.945 and 3.71), falling within the optimal 1-3 range. Ligand A is slightly higher, which *could* be a minor advantage for membrane permeability.
4. **HBD:** Both have 0 HBD, which is acceptable.
5. **HBA:** Ligand A (2) is better than Ligand B (5). Lower HBA is generally preferred for better permeability.
6. **QED:** Ligand A (0.554) is significantly better than Ligand B (0.274). A higher QED indicates a more drug-like profile.
7. **DILI:** Ligand A (21.869) has a much lower DILI risk than Ligand B (29.43). This is a crucial advantage.
8. **BBB:** Ligand A (97.674) has higher BBB penetration than Ligand B (70.376). While not a primary concern for a cardiovascular target, it isn't a detriment.
9. **Caco-2:** Ligand A (-4.224) is better than Ligand B (-5.035). Higher (less negative) Caco-2 values indicate better intestinal absorption.
10. **Solubility:** Ligand A (-3.887) is better than Ligand B (-2.697). Better solubility is generally preferred.
11. **hERG:** Both ligands have low hERG inhibition liability (0.91 and 0.519), which is good.
12. **Cl_mic:** Ligand B (72.29) has slightly lower microsomal clearance than Ligand A (74.9), suggesting better metabolic stability. This is a small advantage.
13. **t1/2:** Ligand B (17.055) has a significantly longer in vitro half-life than Ligand A (3.676). This is a substantial advantage, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.445) has lower P-gp efflux liability than Ligand B (0.239), which is preferable.
15. **Binding Affinity:** Ligand B (-6.1) has a slightly better binding affinity than Ligand A (-6.6). While a difference of 0.5 kcal/mol is noticeable, it's not a massive difference, and can be overcome by superior ADME properties.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Both ligands are good on logP. Ligand A is significantly better on TPSA and Pgp. Ligand B has a slightly better affinity and half-life, but Ligand A has a much better safety profile (DILI) and overall drug-likeness (QED).
**Overall Assessment:**
Ligand A demonstrates a significantly more balanced profile. While Ligand B has a slightly better binding affinity and half-life, Ligand A excels in crucial ADME properties like TPSA, solubility, DILI risk, and QED. The lower DILI risk is particularly important. The better overall drug-likeness and absorption potential of Ligand A outweigh the small advantage in binding affinity of Ligand B.
Output:
1
2025-04-17 19:40:48,418 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [355.479, 101.9 , 0.004, 4. , 5. , 0.491, 12.02 , 22.606, -5.448, -0.928, 0.142, -14.247, 6.976, 0.021, -6.8 ]
**Ligand B:** [362.539, 58.2 , 4.347, 2. , 3. , 0.642, 34.277, 69.523, -4.983, -3.747, 0.411, 65.091, 24.93 , 0.303, -4.9 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (355.479) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (101.9) is higher than Ligand B (58.2). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is still preferred. Ligand B is significantly better here.
3. **logP:** Ligand A (0.004) is very low, potentially causing permeability issues. Ligand B (4.347) is high, potentially leading to solubility and off-target issues, but is within the acceptable range. This is a significant advantage for B.
4. **HBD:** Ligand A (4) is higher than Ligand B (2). Lower is generally better, so B is slightly favored.
5. **HBA:** Ligand A (5) is higher than Ligand B (3). Again, lower is better, favoring B.
6. **QED:** Ligand B (0.642) has a better QED score than Ligand A (0.491), indicating a more drug-like profile.
7. **DILI:** Ligand A (12.02) has a much lower DILI risk than Ligand B (34.277). This is a major advantage for A.
8. **BBB:** Ligand B (69.523) has a higher BBB penetration percentile than Ligand A (22.606). While ADRB2 isn't a CNS target, some distribution to the CNS is possible and can contribute to side effects.
9. **Caco-2:** Ligand A (-5.448) has a worse Caco-2 permeability than Ligand B (-4.983).
10. **Solubility:** Ligand A (-0.928) has a worse solubility than Ligand B (-3.747).
11. **hERG:** Ligand A (0.142) shows lower hERG inhibition liability than Ligand B (0.411), which is a critical safety parameter.
12. **Cl_mic:** Ligand A (-14.247) has a much lower (better) microsomal clearance than Ligand B (65.091), indicating better metabolic stability.
13. **t1/2:** Ligand B (24.93) has a longer in vitro half-life than Ligand A (6.976). This is favorable.
14. **Pgp:** Ligand A (0.021) has a lower P-gp efflux liability than Ligand B (0.303). This is favorable.
15. **Affinity:** Ligand A (-6.8) has a slightly better binding affinity than Ligand B (-4.9).
**GPCR-Specific Considerations:**
For ADRB2 (a cardiovascular GPCR), logP, TPSA, and affinity are key. Ligand B excels in logP and TPSA, while Ligand A has a slightly better affinity. However, the significant advantages of Ligand A in DILI risk, hERG inhibition, and metabolic stability (Cl_mic) outweigh the slightly better affinity of Ligand A. The poor logP of Ligand A is a concern, but can be addressed with further optimization.
**Conclusion:**
Considering all factors, particularly the safety profile (DILI, hERG) and metabolic stability, Ligand A appears to be the more promising candidate.
Output:
1
2025-04-17 19:40:48,418 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A: [338.367, 100.02 , 2.792, 3. , 4. , 0.666, 79.643, 49.515, -5.329, -4.267, 0.526, 16.775, 35.097, 0.094, -6.2 ]**
**Ligand B: [343.431, 88.91 , 2.254, 2. , 5. , 0.807, 68.399, 52.579, -5.065, -3.582, 0.304, 38.067, 45.113, 0.04 , -8. ]**
Here's a breakdown, prioritizing GPCR-relevant parameters:
1. **Molecular Weight:** Both are within the ideal 200-500 Da range. A (338.37) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are reasonably low (A: 100.02, B: 88.91), below the 140 threshold for oral absorption. B is better here, closer to the 90 threshold for potential CNS penetration, though this isn't a primary goal for a cardiovascular target.
3. **logP:** Both are within the optimal 1-3 range (A: 2.792, B: 2.254). A is slightly higher, which could be a minor advantage for membrane permeability.
4. **H-Bond Donors/Acceptors:** A has 3 HBD and 4 HBA, B has 2 HBD and 5 HBA. Both are acceptable, within the guidelines.
5. **QED:** Both are good (A: 0.666, B: 0.807), indicating drug-like properties. B is better here.
6. **DILI Risk:** A is significantly higher (79.643) than B (68.399). This is a substantial negative for A.
7. **BBB Penetration:** Both are relatively low (A: 49.515, B: 52.579), which is expected for a cardiovascular target. Not a major differentiating factor.
8. **Caco-2 Permeability:** Both are negative, indicating poor permeability. A (-5.329) is worse than B (-5.065).
9. **Aqueous Solubility:** Both are negative, indicating poor solubility. A (-4.267) is worse than B (-3.582).
10. **hERG Inhibition:** Both are very low (A: 0.526, B: 0.304), indicating low cardiotoxicity risk. B is slightly better.
11. **Microsomal Clearance:** A (16.775) is significantly lower than B (38.067), suggesting better metabolic stability. This is a significant advantage for A.
12. **In vitro Half-Life:** A (35.097) is lower than B (45.113), meaning B has a longer half-life.
13. **P-gp Efflux:** Both are very low (A: 0.094, B: 0.04), suggesting minimal efflux liability. B is slightly better.
14. **Binding Affinity:** B (-8.0) has a significantly stronger binding affinity than A (-6.2). This is a substantial advantage for B, potentially outweighing some ADME concerns.
**Overall Assessment:**
While Ligand A has better metabolic stability (lower Cl_mic) and a slightly better logP, the significantly higher DILI risk and weaker binding affinity are major drawbacks. Ligand B has a superior binding affinity, lower DILI risk, better QED, and slightly better scores on several other key parameters (hERG, P-gp, half-life). The Caco-2 and Solubility are poor for both, but the stronger binding and safety profile of B are more critical for a GPCR target.
Therefore, I prefer Ligand B.
0
2025-04-17 19:40:48,418 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [339.359, 108.28 , 0.211, 2. , 7. , 0.706, 80.341, 57.193, -5.464, -3.666, 0.668, -3.81 , 6.581, 0.131, -6.9 ]
**Ligand B:** [344.375, 111.03 , 1.688, 2. , 7. , 0.584, 82.862, 79.333, -4.849, -3.193, 0.046, 40.273, -3.263, 0.102, -5.8 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal 200-500 Da range. Ligand A (339.359) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are above the optimal <140, but not excessively so. Ligand B (111.03) is slightly higher than Ligand A (108.28).
3. **logP:** Ligand A (0.211) is quite low, potentially hindering membrane permeability. Ligand B (1.688) is better, falling within the 1-3 range. This is a significant advantage for Ligand B.
4. **HBD/HBA:** Both have 2 HBD and 7 HBA, which are acceptable.
5. **QED:** Ligand A (0.706) has a better QED score than Ligand B (0.584), indicating better overall drug-likeness.
6. **DILI:** Both have relatively high DILI risk (Ligand A: 80.341, Ligand B: 82.862). This is a concern for both, but not a deciding factor between them.
7. **BBB:** Ligand B (79.333) has a significantly better BBB penetration score than Ligand A (57.193). For a GPCR, even a non-CNS target, some BBB penetration can be beneficial for distribution.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-5.464) is worse than Ligand B (-4.849).
9. **Solubility:** Both have negative solubility values, indicating very poor aqueous solubility. Ligand B (-3.193) is slightly better than Ligand A (-3.666).
10. **hERG:** Ligand A (0.668) has a slightly higher hERG risk than Ligand B (0.046). This is a positive for Ligand B.
11. **Cl_mic:** Ligand A (-3.81) has a much lower (better) microsomal clearance than Ligand B (40.273), suggesting greater metabolic stability.
12. **t1/2:** Ligand A (6.581) has a longer in vitro half-life than Ligand B (-3.263).
13. **Pgp:** Ligand A (0.131) has lower P-gp efflux than Ligand B (0.102), which is favorable.
14. **Affinity:** Ligand A (-6.9 kcal/mol) has a stronger binding affinity than Ligand B (-5.8 kcal/mol). This is a substantial advantage for Ligand A.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B has a much better logP and BBB penetration. Ligand A has a significantly better affinity and metabolic stability (lower Cl_mic and longer t1/2). The affinity difference is substantial (>1.0 kcal/mol). While Ligand A's logP is poor, the strong binding could potentially compensate. The poor solubility and permeability (Caco-2) are concerning for both.
**Conclusion:**
Despite the poor logP of Ligand A, the significantly stronger binding affinity (-6.9 vs -5.8 kcal/mol) and better metabolic stability are the deciding factors. The affinity advantage is likely to outweigh the permeability concerns, especially given that formulation strategies can sometimes address solubility issues.
Output:
1
2025-04-17 19:40:48,418 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (363.571 and 363.527 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (44.37) is better than Ligand B (53.51). Both are below 140, but lower TPSA generally favors absorption.
3. **logP:** Ligand B (3.061) is closer to the optimal 1-3 range than Ligand A (4.156). Ligand A's logP is a bit high, potentially leading to solubility issues or off-target interactions.
4. **HBD:** Ligand A (2) is preferable to Ligand B (0). While both are acceptable, a small number of HBDs can aid solubility.
5. **HBA:** Ligand B (4) is slightly better than Ligand A (3). Both are within the acceptable range.
6. **QED:** Ligand B (0.826) has a significantly better QED score than Ligand A (0.564), indicating a more drug-like profile.
7. **DILI:** Ligand A (23.071) has a much lower DILI risk than Ligand B (61.691). This is a substantial advantage for Ligand A.
8. **BBB:** Ligand A (90.5) has better BBB penetration than Ligand B (78.247). While ADRB2 isn't strictly a CNS target, some CNS exposure can occur, and higher BBB is generally favorable.
9. **Caco-2:** Ligand A (-5.048) is better than Ligand B (-4.712), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-3.407) is better than Ligand B (-3.365).
11. **hERG:** Ligand A (0.894) is better than Ligand B (0.462), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand B (85.862) has lower microsomal clearance than Ligand A (78.348), suggesting better metabolic stability.
13. **t1/2:** Ligand A (48.381) has a much longer in vitro half-life than Ligand B (-12.399). This is a significant advantage.
14. **Pgp:** Ligand A (0.718) is better than Ligand B (0.369), indicating lower P-gp efflux.
15. **Binding Affinity:** Ligand A (-7.5) has a stronger binding affinity than Ligand B (-6.3). This is a 1.2 kcal/mol difference, which is substantial and can outweigh some ADME drawbacks.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A has a slightly higher logP, but its superior affinity, lower Pgp efflux, and better TPSA are more important. The significantly better DILI and hERG profiles of Ligand A are also crucial for cardiovascular safety. While Ligand B has a better QED and Cl_mic, the overall balance favors Ligand A.
**Conclusion:**
Ligand A demonstrates a more favorable balance of properties, particularly regarding safety (DILI, hERG), potency (affinity), and absorption/efflux (Caco-2, Pgp). The stronger binding affinity is a significant advantage.
Output:
1
2025-04-17 19:40:48,419 - INFO - Here's my reasoning and final output:
**Reasoning:**
Let's analyze both ligands against the provided guidelines, keeping in mind this is for an ADRB2 GPCR (cardiovascular target, so BBB is less critical than for CNS targets).
**Ligand A:**
* **MW:** 355.312 Da - Good, within the ideal range.
* **TPSA:** 63.68 - Good, well below the 140 threshold.
* **logP:** 2.225 - Excellent, within the optimal range.
* **HBD:** 0 - Acceptable, low.
* **HBA:** 4 - Acceptable, within the limit.
* **QED:** 0.763 - Excellent, highly drug-like.
* **DILI:** 63.358 - Moderate risk, slightly elevated but not alarming.
* **BBB:** 98.41 - Very high, but less important for a cardiovascular target.
* **Caco-2:** -4.115 - Very poor, significant absorption issue.
* **Solubility:** -3.412 - Very poor, formulation challenges.
* **hERG:** 0.586 - Low risk, good.
* **Cl_mic:** 35.543 - Moderate, could be better.
* **t1/2:** -1.7 - Very short, problematic.
* **Pgp:** 0.339 - Low efflux, good.
* **Affinity:** -4.5 kcal/mol - Good binding affinity.
**Ligand B:**
* **MW:** 363.487 Da - Good, within the ideal range.
* **TPSA:** 79.38 - Acceptable, still below 140, but getting closer.
* **logP:** 1.877 - Good, within the optimal range.
* **HBD:** 2 - Acceptable, low.
* **HBA:** 7 - Acceptable, within the limit.
* **QED:** 0.845 - Excellent, highly drug-like.
* **DILI:** 69.794 - Moderate risk, slightly higher than Ligand A.
* **BBB:** 76.658 - Moderate, less important for a cardiovascular target.
* **Caco-2:** -5.133 - Very poor, similar to Ligand A.
* **Solubility:** -3.481 - Very poor, similar to Ligand A.
* **hERG:** 0.378 - Low risk, good.
* **Cl_mic:** 57.085 - Higher than Ligand A, less favorable.
* **t1/2:** 44.209 - Excellent, long half-life.
* **Pgp:** 0.044 - Very low efflux, excellent.
* **Affinity:** -6.3 kcal/mol - Significantly better binding affinity than Ligand A.
**Comparison & Decision:**
Both ligands suffer from very poor Caco-2 permeability and solubility, which are major drawbacks. However, Ligand B has a substantially better binding affinity (-6.3 vs -4.5 kcal/mol), a significantly longer half-life (44.2 vs -1.7 hours), and lower P-gp efflux. The improved affinity and PK properties outweigh the slightly higher DILI risk and TPSA. While both have poor absorption characteristics, a longer half-life and better affinity give Ligand B a better chance of achieving therapeutic concentrations *if* formulation challenges can be overcome. For a GPCR, affinity is paramount.
Therefore, I prefer Ligand B.
**Output:**
0
2025-04-17 19:40:48,419 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (360.885 and 361.467 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (51.22) is significantly better than Ligand B (75.55). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold. Ligand B is approaching the upper limit.
3. **logP:** Ligand A (4.625) is a bit high, but still within a reasonable range. Ligand B (2.501) is excellent. For a GPCR, logP is important for membrane permeability.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 3 HBA, while Ligand B has 6. Ligand A is preferable here.
6. **QED:** Ligand A (0.817) is better than Ligand B (0.52), indicating a more drug-like profile.
7. **DILI:** Ligand B (44.397) has a significantly lower DILI risk than Ligand A (65.374). This is a substantial advantage for Ligand B.
8. **BBB:** Both are around 50-60%, so not particularly high or low. Not a major differentiating factor for a cardiovascular target.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.841) is slightly better than Ligand B (-5.1).
10. **Solubility:** Ligand A (-5.763) is better than Ligand B (-1.734), indicating better aqueous solubility.
11. **hERG:** Both are very low (0.428 and 0.386), indicating low cardiotoxicity risk. No significant difference.
12. **Cl_mic:** Ligand B (60.385) has a lower microsomal clearance than Ligand A (104.891), suggesting better metabolic stability.
13. **t1/2:** Ligand A (22.832) has a slightly longer half-life than Ligand B (20.524).
14. **Pgp:** Both are low (0.362 and 0.341), indicating low P-gp efflux. No significant difference.
15. **Binding Affinity:** Ligand A (-8.6 kcal/mol) has a significantly stronger binding affinity than Ligand B (-7.5 kcal/mol). This is a 1.1 kcal/mol difference, which is substantial enough to potentially outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand A has a significantly better binding affinity and better solubility, QED, and HBA count. However, Ligand B has a much lower DILI risk and better metabolic stability (lower Cl_mic). The higher logP of Ligand A is a slight concern, but not a dealbreaker. The TPSA of Ligand B is higher, which is less desirable. The substantial difference in binding affinity (-8.6 vs -7.5) is the most important factor, especially for a GPCR where potency is crucial. While DILI risk is important, it can often be mitigated with further structural modifications.
Therefore, I favor Ligand A.
Output:
1
2025-04-17 19:40:48,419 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (345.4 & 346.4 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (108.8 & 105.9) are reasonably low, suggesting good potential for absorption. Ligand B is slightly better.
3. **logP:** Ligand A (0.656) is a bit low, potentially hindering permeability. Ligand B (0.974) is better, falling within the optimal 1-3 range, but still on the lower side.
4. **HBD:** Ligand A (2) is preferable to Ligand B (4). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (6) is preferable to Ligand B (4). Fewer HBAs generally improve permeability.
6. **QED:** Ligand A (0.846) has a significantly better QED score than Ligand B (0.571), indicating a more drug-like profile.
7. **DILI:** Ligand B (39.55) has a much lower DILI risk than Ligand A (67.003). This is a substantial advantage for Ligand B.
8. **BBB:** Ligand A (26.483) has a lower BBB penetration percentile than Ligand B (18.34). While ADRB2 isn't strictly a CNS target, some level of BBB penetration is not detrimental and could open up possibilities for exploring CNS effects.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not defined, so it's hard to interpret.
10. **Solubility:** Both ligands have negative solubility values, which is also unusual. Again, the scale is not defined, making interpretation difficult.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.106 & 0.269), which is excellent.
12. **Cl_mic:** Ligand A (-3.996) has a much lower (better) microsomal clearance than Ligand B (-13.393), suggesting greater metabolic stability.
13. **t1/2:** Ligand B (8.827) has a significantly longer in vitro half-life than Ligand A (-7.37). This is a major advantage for Ligand B.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.007 & 0.01).
15. **Binding Affinity:** Ligand A (-6.7 kcal/mol) has a slightly better binding affinity than Ligand B (-5.1 kcal/mol). This is a 1.6 kcal/mol difference, which is significant.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B has a slightly better logP and Pgp profile. Ligand A has a better affinity. However, the DILI risk for Ligand A is concerning, and the longer half-life of Ligand B is a significant benefit.
**Overall Assessment:**
While Ligand A has a better binding affinity and QED, the significantly higher DILI risk and shorter half-life are major drawbacks. Ligand B, despite a slightly weaker affinity, presents a much more favorable safety profile (lower DILI) and improved pharmacokinetic properties (longer half-life). The affinity difference, while notable, can potentially be optimized in further iterations.
Output:
0
2025-04-17 19:40:48,419 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (a cardiovascular GPCR) drug candidates.
**Ligand A:** [347.415, 83.76, 1.315, 0, 4, 0.438, 34.161, 71.384, -4.813, -2.861, 0.18, 57.36, -14.453, 0.171, -5.6]
**Ligand B:** [380.476, 49.41, 3.382, 1, 3, 0.493, 18.108, 85.111, -5.008, -4.184, 0.696, 53.736, -3.78, 0.269, -7.1]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity) and general drug-like properties:
1. **MW:** Both are within the acceptable range (200-500 Da). Ligand A (347.415) is slightly preferred due to being lower.
2. **TPSA:** Ligand B (49.41) is significantly better than Ligand A (83.76). Lower TPSA generally improves permeability, which is crucial for GPCR ligands.
3. **logP:** Ligand A (1.315) is good, within the optimal range. Ligand B (3.382) is at the higher end, but still acceptable.
4. **HBD/HBA:** Ligand A (0 HBD, 4 HBA) is slightly better than Ligand B (1 HBD, 3 HBA) in terms of balancing solubility and permeability.
5. **QED:** Both are reasonably good (A: 0.438, B: 0.493), indicating acceptable drug-likeness. Ligand B is slightly better.
6. **DILI:** Ligand B (18.108) has a much lower DILI risk than Ligand A (34.161). This is a significant advantage.
7. **BBB:** Ligand B (85.111) has a much higher BBB penetration potential than Ligand A (71.384). While not a primary concern for a cardiovascular target, it's a positive attribute.
8. **Caco-2:** Both have negative values, which is unusual. Assuming these are logP-scale values, lower values indicate poorer permeability. Ligand A (-4.813) is slightly better than Ligand B (-5.008).
9. **Solubility:** Both have negative values, which is also unusual. Assuming these are logS values, lower values indicate poorer solubility. Ligand B (-4.184) is slightly better than Ligand A (-2.861).
10. **hERG:** Both have low hERG inhibition risk (A: 0.18, B: 0.696), which is good.
11. **Cl_mic:** Ligand B (53.736) has slightly lower microsomal clearance than Ligand A (57.36), suggesting better metabolic stability.
12. **t1/2:** Ligand A (-14.453) has a longer in vitro half-life than Ligand B (-3.78), which is a positive.
13. **Pgp:** Ligand A (0.171) has lower P-gp efflux liability than Ligand B (0.269), which is favorable for bioavailability.
14. **Affinity:** Ligand B (-7.1) has a significantly stronger binding affinity than Ligand A (-5.6). This is a crucial advantage, especially for GPCRs.
**Overall Assessment:**
While Ligand A has some advantages (lower MW, slightly better Pgp, longer half-life), Ligand B is the stronger candidate. The significantly better affinity (-7.1 vs -5.6 kcal/mol) outweighs the minor drawbacks. The lower DILI risk and higher BBB penetration are also significant positives. The lower TPSA of Ligand B is also a key advantage for a GPCR ligand.
Output:
0
2025-04-17 19:40:48,419 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (366.334 Da) is within the ideal range, while Ligand B (380.495 Da) is also acceptable. No clear advantage.
2. **TPSA:** Ligand A (39.68) is excellent for oral absorption and GPCR targeting. Ligand B (106.32) is significantly higher, potentially hindering absorption. This is a substantial negative for Ligand B.
3. **logP:** Ligand A (2.928) is optimal. Ligand B (0.738) is a bit low, potentially impacting membrane permeability.
4. **HBD:** Ligand A (0) is good. Ligand B (2) is acceptable.
5. **HBA:** Ligand A (3) is good. Ligand B (7) is higher, potentially impacting permeability.
6. **QED:** Both ligands have similar QED values (0.773 vs 0.641), indicating good drug-likeness.
7. **DILI:** Ligand A (38.93) has a lower DILI risk than Ligand B (50.136), which is preferable.
8. **BBB:** Ligand A (88.445) has a good BBB penetration potential, while Ligand B (18.147) is very low. Since ADRB2 is a GPCR, BBB penetration isn't a primary concern unless targeting CNS effects, but it's a positive for Ligand A.
9. **Caco-2:** Ligand A (-4.499) is better than Ligand B (-5.571), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-2.879) is better than Ligand B (-2.452), indicating better solubility.
11. **hERG:** Both ligands have low hERG risk (0.485 and 0.185, respectively).
12. **Cl_mic:** Ligand A (29.915) has a higher microsomal clearance than Ligand B (12.632), suggesting faster metabolism and potentially lower *in vivo* exposure. This favors Ligand B.
13. **t1/2:** Ligand A (11.297) has a longer half-life than Ligand B (-1.928), which is preferable.
14. **Pgp:** Ligand A (0.064) has lower P-gp efflux than Ligand B (0.034), which is preferable.
15. **Affinity:** Ligand B (-7.2 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.9 kcal/mol). This is a substantial advantage for Ligand B.
**Overall Assessment:**
Ligand B has a significantly better binding affinity, which is the most important factor. While Ligand B has a lower logP and higher TPSA, the affinity difference is substantial enough to outweigh these drawbacks. The lower metabolic clearance of Ligand B is also a positive. Ligand A has better TPSA, BBB, solubility, and half-life, but the affinity difference is too large to ignore.
Output:
0
2025-04-17 19:40:48,420 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 drug candidates. ADRB2 is a GPCR, so we'll prioritize logP, Pgp, TPSA, and affinity, alongside general drug-like properties.
**Ligand A:** [346.402, 58.64, 2.766, 1, 3, 0.806, 44.048, 73.129, -4.406, -3.239, 0.601, 35.557, -15.902, 0.207, -6.5]
**Ligand B:** [344.455, 58.64, 2.481, 1, 3, 0.737, 34.432, 65.607, -4.396, -3.29, 0.412, 73.376, -5.498, 0.138, -6.2]
1. **MW:** Both are within the ideal range (344-346 Da). No significant difference.
2. **TPSA:** Both are at 58.64, which is good for oral absorption.
3. **logP:** Ligand A (2.766) is slightly higher than Ligand B (2.481), both are within the optimal 1-3 range.
4. **HBD/HBA:** Both have 1 HBD and 3 HBA, which is acceptable.
5. **QED:** Ligand A (0.806) has a better QED score than Ligand B (0.737), indicating better overall drug-likeness.
6. **DILI:** Ligand A (44.048) has a slightly higher DILI risk than Ligand B (34.432), but both are below the concerning threshold of 60.
7. **BBB:** Ligand A (73.129) has a significantly higher BBB penetration percentile than Ligand B (65.607). This is a positive for a GPCR, even if not strictly CNS-targeted, as it suggests better distribution.
8. **Caco-2:** Both have similar, very poor Caco-2 permeability (-4.406 and -4.396). This is a concern for oral bioavailability.
9. **Solubility:** Both have similar, very poor solubility (-3.239 and -3.29). This is a significant drawback.
10. **hERG:** Ligand A (0.601) has a slightly higher hERG risk than Ligand B (0.412), but both are relatively low.
11. **Cl_mic:** Ligand B (73.376) has a higher microsomal clearance than Ligand A (35.557), meaning Ligand A is more metabolically stable.
12. **t1/2:** Ligand A (-15.902) has a longer in vitro half-life than Ligand B (-5.498). This is a positive.
13. **Pgp:** Ligand A (0.207) has lower P-gp efflux than Ligand B (0.138), suggesting better absorption and distribution.
14. **Affinity:** Ligand A (-6.5 kcal/mol) has a slightly better binding affinity than Ligand B (-6.2 kcal/mol). While the difference is small, it's still a factor.
**Overall Assessment:**
Ligand A appears to be the better candidate. It has a better QED score, significantly better BBB penetration, lower P-gp efflux, better metabolic stability (lower Cl_mic, longer t1/2), and slightly better binding affinity. While both have poor Caco-2 and solubility, the other advantages of Ligand A outweigh the small difference in affinity and the slightly higher DILI risk. The improved BBB and metabolic stability are particularly valuable for a GPCR target.
Output:
1
2025-04-17 19:40:48,420 - INFO - Batch 128 complete. Total preferences: 2048
2025-04-17 19:40:48,420 - INFO - Processing batch 129/512...
2025-04-17 19:41:35,596 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (359.344 and 356.457 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (59.0) is slightly higher than Ligand B (49.41). Both are well below the 140 threshold for oral absorption, and suitable for a GPCR target. Ligand B is slightly favored.
3. **logP:** Ligand A (1.876) is within the optimal 1-3 range. Ligand B (3.521) is at the higher end, potentially raising concerns about solubility and off-target effects, but still acceptable. Ligand A is slightly favored.
4. **HBD:** Both ligands have 1 HBD, which is ideal. No difference.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 2. Both are within the acceptable range of <=10. Ligand B is slightly favored.
6. **QED:** Ligand A (0.895) has a better QED score than Ligand B (0.74), indicating a more drug-like profile. Ligand A is favored.
7. **DILI:** Ligand A (38.077) has a significantly lower DILI risk than Ligand B (24.777). This is a major advantage for Ligand A.
8. **BBB:** Both ligands have good BBB penetration (Ligand A: 81.698, Ligand B: 88.988). Ligand B is slightly favored.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.504 and -4.58). This is unusual and suggests poor permeability. However, the values are very similar.
10. **Solubility:** Ligand A (-2.697) has better solubility than Ligand B (-3.465). Ligand A is favored.
11. **hERG:** Ligand A (0.766) has a slightly higher hERG risk than Ligand B (0.565), but both are relatively low. Ligand B is slightly favored.
12. **Cl_mic:** Ligand A (14.661) has significantly lower microsomal clearance than Ligand B (26.296), indicating better metabolic stability. Ligand A is strongly favored.
13. **t1/2:** Ligand A (-7.455) has a much longer in vitro half-life than Ligand B (-13.81). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.325) has lower P-gp efflux liability than Ligand B (0.103). Ligand A is favored.
15. **Binding Affinity:** Ligand A (-7.2 kcal/mol) has a slightly better binding affinity than Ligand B (-6.2 kcal/mol). This difference of 1 kcal/mol is substantial and favors Ligand A.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A has a better balance of these properties, with a more favorable logP, better Pgp efflux, and significantly better binding affinity. While Ligand B has slightly better BBB penetration, the other advantages of Ligand A outweigh this.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across several critical parameters, including DILI risk, metabolic stability (Cl_mic, t1/2), solubility, Pgp efflux, and binding affinity. The slightly higher TPSA and hERG risk are minor concerns compared to the substantial benefits of Ligand A.
Output:
1
2025-04-17 19:41:35,596 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (356.348 and 346.427 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (69.04) is significantly better than Ligand B (91.57). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand A is well below the 140 threshold, while B is approaching it.
3. **logP:** Both ligands have acceptable logP values (2.882 and 1.481), falling within the 1-3 range. Ligand A is slightly better, but both are reasonable.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (4). Lower HBA generally improves permeability.
6. **QED:** Ligand A (0.864) is significantly better than Ligand B (0.652), indicating a more drug-like profile.
7. **DILI:** Ligand B (27.336) has a much lower DILI risk than Ligand A (55.758). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (81.698) has a substantially higher BBB penetration potential than Ligand B (40.558). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant, and higher BBB is generally favorable.
9. **Caco-2:** Both ligands have very poor Caco-2 permeability (-4.76 and -4.749). This is a significant concern for both.
10. **Solubility:** Ligand A (-3.502) is slightly better than Ligand B (-2.12), but both are very poor.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.126 and 0.127). This is good.
12. **Cl_mic:** Ligand B (15.74) has lower microsomal clearance than Ligand A (27.54), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-9.651) has a significantly longer in vitro half-life than Ligand A (4.842). This is a major advantage for Ligand B.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.204 and 0.044). This is good.
15. **Binding Affinity:** Ligand A (-6.0) has a slightly better binding affinity than Ligand B (-5.3). However, the difference is not substantial enough to outweigh other factors.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A excels in logP and has slightly better affinity. However, Ligand B has a much better DILI score, significantly better metabolic stability (lower Cl_mic and longer t1/2), and a more drug-like QED score. The TPSA of Ligand A is also significantly better. While BBB is a consideration, it's less critical for ADRB2 than for a CNS-focused GPCR. The poor Caco-2 permeability is a concern for both, but the superior ADME properties of Ligand A (lower Cl_mic, longer t1/2, better QED) and its better TPSA make it the more promising candidate.
**Final Decision:**
1
2025-04-17 19:41:35,596 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 drug candidates. ADRB2 is a GPCR, so we'll prioritize logP, Pgp, TPSA, and affinity, alongside general drug-like properties.
**Ligand A:**
* **MW:** 354.51 Da - Good, within the ideal range.
* **TPSA:** 58.2 - Good, well below the 140 threshold.
* **logP:** 3.741 - Excellent, within the optimal range.
* **HBD:** 2 - Good, within the acceptable limit.
* **HBA:** 2 - Good, within the acceptable limit.
* **QED:** 0.732 - Excellent, highly drug-like.
* **DILI:** 38.891 - Very good, low risk of liver injury.
* **BBB:** 83.249 - Excellent, high potential for CNS penetration (though not crucial for ADRB2, it's a bonus).
* **Caco-2:** -4.558 - Poor, suggests limited intestinal absorption.
* **Solubility:** -4.543 - Poor, suggests low aqueous solubility.
* **hERG:** 0.58 - Good, low risk of hERG inhibition.
* **Cl_mic:** 50.603 - Moderate, clearance is not ideal.
* **t1/2:** 23.084 - Moderate, half-life is acceptable.
* **Pgp:** 0.342 - Excellent, low P-gp efflux.
* **Affinity:** -7.9 kcal/mol - Excellent, very strong binding.
**Ligand B:**
* **MW:** 402.651 Da - Good, within the ideal range.
* **TPSA:** 50.27 - Good, well below the 140 threshold.
* **logP:** 3.646 - Excellent, within the optimal range.
* **HBD:** 0 - Good, within the acceptable limit.
* **HBA:** 6 - Good, within the acceptable limit.
* **QED:** 0.631 - Good, drug-like.
* **DILI:** 50.136 - Acceptable, moderate risk of liver injury.
* **BBB:** 71.966 - Moderate, lower BBB penetration than Ligand A.
* **Caco-2:** -5.489 - Poor, suggests limited intestinal absorption.
* **Solubility:** -3.785 - Poor, suggests low aqueous solubility.
* **hERG:** 0.66 - Good, low risk of hERG inhibition.
* **Cl_mic:** 35.322 - Good, lower clearance than Ligand A, indicating better metabolic stability.
* **t1/2:** 7.254 - Poor, short half-life.
* **Pgp:** 0.399 - Excellent, low P-gp efflux.
* **Affinity:** -6.1 kcal/mol - Good, strong binding, but significantly weaker than Ligand A.
**Comparison and Decision:**
Both ligands have issues with Caco-2 permeability and solubility, which would require formulation strategies to address. However, Ligand A stands out due to its significantly stronger binding affinity (-7.9 vs -6.1 kcal/mol). This difference in affinity is substantial and could outweigh the slightly higher DILI risk and moderate clearance. Ligand A also has a better BBB score. While Ligand B has a better metabolic stability (lower Cl_mic), the difference isn't large enough to compensate for the substantial affinity difference.
Given the GPCR target class and the importance of binding affinity, I would prioritize Ligand A.
Output:
1
2025-04-17 19:41:35,597 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [343.391, 106.73 , 0.12 , 2. , 7. , 0.725, 63.086, 38.193, -5.494, -2.277, 0.045, 11.527, 15.404, 0.059, -7. ]
**Ligand B:** [352.395, 109.35 , 0.321, 1. , 10. , 0.646, 57.076, 68.67 , -5.461, -0.65 , 0.075, 5.142, 27.217, 0.03 , -6.3 ]
Here's a step-by-step comparison, keeping GPCR priorities (logP, Pgp, TPSA, affinity, and BBB) in mind:
1. **MW:** Both are within the ideal range (200-500 Da). A is 343.391, B is 352.395. No significant difference.
2. **TPSA:** Both are reasonably good, at 106.73 and 109.35, respectively. Both are below the 140 threshold for oral absorption.
3. **logP:** Ligand A (0.12) is quite low, potentially hindering membrane permeability. Ligand B (0.321) is also low, but slightly better. This is a concern for both, but more so for A.
4. **HBD:** A has 2, B has 1. Both are acceptable.
5. **HBA:** A has 7, B has 10. Both are acceptable, but B is closer to the upper limit.
6. **QED:** Both are good (A: 0.725, B: 0.646), indicating drug-like properties.
7. **DILI:** A (63.086) is higher than B (57.076). B is preferable here.
8. **BBB:** Ligand B (68.67) has a significantly better BBB percentile than A (38.193). This is a crucial advantage for a GPCR target.
9. **Caco-2:** Both are negative (-5.494 and -5.461), which is unusual and suggests poor permeability. This is a major flag for both.
10. **Solubility:** A (-2.277) is worse than B (-0.65). B is preferable.
11. **hERG:** Both are very low (A: 0.045, B: 0.075), indicating low cardiotoxicity risk.
12. **Cl_mic:** Ligand B (5.142) has significantly lower microsomal clearance than A (11.527), suggesting better metabolic stability.
13. **t1/2:** B (27.217) has a much longer in vitro half-life than A (15.404). This is a significant advantage.
14. **Pgp:** Both are very low (A: 0.059, B: 0.03), indicating low P-gp efflux.
15. **Affinity:** A (-7.0) has a slightly better binding affinity than B (-6.3). This is a 0.7 kcal/mol difference.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity, the other ADME properties of Ligand B are substantially better, especially regarding BBB penetration, metabolic stability (Cl_mic and t1/2), and DILI risk. The low logP values for both are concerning, but the other advantages of B outweigh this. The Caco-2 values are concerning for both, but the other parameters suggest B is more likely to be optimized. Given the GPCR nature of the target, BBB penetration is particularly important.
Therefore, I prefer Ligand B.
0
2025-04-17 19:41:35,597 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [377.438, 98.23, -1.644, 1, 5, 0.633, 30.942, 54.362, -4.727, -0.271, 0.115, -0.151, -30.56, 0.014, -5.4]**
**Ligand B: [343.427, 71.41, 1.154, 1, 4, 0.788, 23.497, 75.107, -4.79, -2.121, 0.388, 40.467, -9.133, 0.082, -6]**
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand B (343.427) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (98.23) is higher than Ligand B (71.41). Both are acceptable for a non-CNS GPCR target like ADRB2, but Ligand B is better.
3. **logP:** Ligand A (-1.644) is lower than the optimal range (1-3), potentially hindering permeability. Ligand B (1.154) is within the optimal range. This is a significant advantage for Ligand B.
4. **H-Bond Donors:** Both have 1 HBD, which is good.
5. **H-Bond Acceptors:** Ligand A has 5, Ligand B has 4. Both are acceptable.
6. **QED:** Both ligands have good QED scores (A: 0.633, B: 0.788), indicating drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (30.942) has a slightly higher DILI risk than Ligand B (23.497), but both are reasonably low.
8. **BBB:** BBB penetration is less critical for ADRB2 (a cardiovascular target). Ligand B (75.107) is higher, but this isn't a major deciding factor.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability.
10. **Aqueous Solubility:** Both have negative solubility values, which is also unusual and suggests poor solubility.
11. **hERG:** Ligand A (0.115) has a slightly lower hERG risk than Ligand B (0.388), which is preferable.
12. **Microsomal Clearance:** Ligand A (-0.151) has a lower (better) microsomal clearance than Ligand B (40.467), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **In vitro Half-Life:** Ligand A (-30.56) has a longer half-life than Ligand B (-9.133), which is desirable.
14. **P-gp Efflux:** Ligand A (0.014) has lower P-gp efflux than Ligand B (0.082), which is favorable for bioavailability.
15. **Binding Affinity:** Both have strong binding affinities (A: -5.4, B: -6). Ligand B is slightly better, but the difference is not substantial enough to outweigh other factors.
**Overall Assessment:**
Ligand B has advantages in logP, TPSA, QED, and binding affinity. However, Ligand A has a significantly better metabolic profile (lower Cl_mic, longer half-life) and lower P-gp efflux. The negative Caco-2 and solubility values are concerning for both, but the metabolic stability and P-gp efflux of Ligand A are more critical for a successful drug candidate, especially considering the cardiovascular target. The slightly better hERG profile of Ligand A is also a plus.
Therefore, I favor Ligand A.
Output:
1
2025-04-17 19:41:35,597 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step Comparison:**
1. **MW:** Both ligands (347.419 & 357.495 Da) are within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (93.26) is better than Ligand B (96.53), both are under the 140 threshold for oral absorption, but closer to the limit for GPCRs.
3. **logP:** Ligand A (1.068) is optimal, while Ligand B (2.206) is still within the acceptable range but edging towards potentially causing solubility issues.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (6) is better than Ligand B (4), both are within the acceptable range.
6. **QED:** Ligand A (0.732) is significantly better than Ligand B (0.522), indicating a more drug-like profile.
7. **DILI:** Ligand A (38.736) is slightly higher than Ligand B (21.52), but both are well below the concerning 60 percentile threshold. Ligand B is preferable here.
8. **BBB:** Ligand B (77.2) is significantly better than Ligand A (57.193). While ADRB2 isn't necessarily a CNS target, better BBB penetration can sometimes translate to improved distribution and reduced off-target effects.
9. **Caco-2:** Ligand A (-5.282) is slightly better than Ligand B (-4.794), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-0.995) is better than Ligand B (-2.57), indicating better aqueous solubility.
11. **hERG:** Both ligands (0.093 & 0.613) have very low hERG inhibition risk, which is excellent. No clear advantage.
12. **Cl_mic:** Ligand A (32.172) has a significantly lower microsomal clearance than Ligand B (59.321), suggesting better metabolic stability.
13. **t1/2:** Ligand A (42.746) has a longer in vitro half-life than Ligand B (-23.98), which is a significant advantage.
14. **Pgp:** Both ligands (0.024 & 0.037) have very low P-gp efflux liability. No clear advantage.
15. **Binding Affinity:** Ligand B (-7.4) has a slightly better binding affinity than Ligand A (-7.0), but the difference is small.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A has a better logP and TPSA, while Ligand B has better BBB penetration and slightly better affinity. However, the metabolic stability (Cl_mic and t1/2) and QED of Ligand A are substantially better. The small affinity difference is outweighed by the more favorable ADME properties of Ligand A.
**Conclusion:**
Considering the balance of properties, particularly the superior QED, metabolic stability, solubility, and permeability indicators of Ligand A, it is the more promising drug candidate.
Output:
1
2025-04-17 19:41:35,597 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (349.5 and 340.5 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (52.65) is slightly higher than Ligand B (41.05). Ligand B is better, being closer to the <140 threshold for good absorption, and more favorable for a GPCR.
3. **logP:** Ligand A (2.26) is within the optimal 1-3 range. Ligand B (4.36) is a bit high, potentially leading to solubility issues and off-target interactions. Ligand A is preferred.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 3 HBA, Ligand B has 4. Both are acceptable, but Ligand A is slightly better.
6. **QED:** Ligand A (0.8) is significantly better than Ligand B (0.617), indicating a more drug-like profile.
7. **DILI:** Ligand B (39.473) has a much lower DILI risk than Ligand A (7.871), which is a significant advantage.
8. **BBB:** Ligand B (94.3) has excellent BBB penetration, while Ligand A (83.094) is good but lower. For a GPCR, especially if CNS effects are possible, higher BBB is desirable.
9. **Caco-2:** Ligand A (-4.792) and Ligand B (-5.027) are both poor, indicating low intestinal absorption.
10. **Solubility:** Ligand A (-1.807) is better than Ligand B (-4.461). Solubility is a concern for Ligand B due to its higher logP.
11. **hERG:** Ligand A (0.475) has a lower hERG risk than Ligand B (0.918), which is a crucial safety factor.
12. **Cl_mic:** Ligand B (93.396) has a much higher microsomal clearance than Ligand A (23.975), meaning it will be metabolized more quickly and have lower systemic exposure. Ligand A is strongly preferred.
13. **t1/2:** Ligand B (34.186) has a significantly longer in vitro half-life than Ligand A (-2.757). This is a positive for Ligand B.
14. **Pgp:** Ligand A (0.05) has lower P-gp efflux liability than Ligand B (0.726), which is favorable for bioavailability.
15. **Affinity:** Both ligands have very similar and excellent binding affinities (-7.2 and -7.0 kcal/mol). The difference is negligible.
**Overall Assessment:**
While Ligand B has better BBB penetration and *t1/2*, its significantly higher DILI risk, higher logP, higher Pgp efflux, and much higher microsomal clearance are major drawbacks. Ligand A, despite having a slightly lower BBB score, presents a much more balanced profile with better solubility, lower toxicity risk, lower clearance, and better Pgp properties. The similar binding affinities make the ADME/Tox profile the deciding factor. Given the GPCR target class, balancing logP, TPSA, Pgp, and metabolic stability is crucial, and Ligand A does this better.
Output:
1
2025-04-17 19:41:35,597 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (348.49 & 338.41 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (60.85) is better than Ligand B (76.02). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (2.20 & 1.03), falling within the 1-3 range. Ligand A is slightly better, being closer to the optimal range.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (4). Similar to HBD, lower HBA is generally better.
6. **QED:** Both ligands have similar and acceptable QED values (0.513 & 0.549).
7. **DILI:** Ligand A (5.31) has a significantly lower DILI risk than Ligand B (49.48). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (65.61) has a better BBB penetration than Ligand B (45.10). While not a primary concern for a cardiovascular target, it's a slight positive.
9. **Caco-2:** Ligand A (-4.679) has a better Caco-2 permeability than Ligand B (-5.092).
10. **Solubility:** Ligand B (-2.301) has a better solubility than Ligand A (-1.14). Solubility is important, but can often be addressed with formulation.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.451 & 0.176). This is excellent for both.
12. **Cl_mic:** Ligand A (35.88) has a higher microsomal clearance than Ligand B (18.57). This indicates Ligand B has better metabolic stability.
13. **t1/2:** Ligand B (9.689) has a significantly longer in vitro half-life than Ligand A (-1.402). This is a significant advantage for Ligand B.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.127 & 0.065). This is excellent for both.
15. **Binding Affinity:** Both ligands have the same binding affinity (-5.1 kcal/mol).
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Both ligands perform similarly on logP, Pgp, and affinity. Ligand A has a better TPSA. The biggest differentiator is DILI risk, where Ligand A is far superior. While Ligand B has a better half-life and metabolic stability, the lower DILI risk of Ligand A is a critical advantage, especially in early-stage drug development.
**Conclusion:**
Considering the balance of properties, particularly the significantly lower DILI risk, Ligand A is the more promising drug candidate.
Output:
1
2025-04-17 19:41:35,597 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands (368.459 and 359.491 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (116.4) is higher than Ligand B (66.4). For a GPCR, lower TPSA is generally preferred for better permeability, giving a slight edge to Ligand B.
3. **logP:** Ligand B (3.746) is higher than Ligand A (0.916). While both are within the acceptable range, Ligand B is approaching the upper limit. Ligand A is quite low, potentially hindering membrane permeability. This favors Ligand B.
4. **HBD:** Ligand A (4) and Ligand B (2) are both acceptable, but fewer HBDs are generally better for permeability. Ligand B is slightly favored.
5. **HBA:** Ligand A (4) and Ligand B (3) are both acceptable. No strong preference.
6. **QED:** Ligand B (0.754) has a higher QED score than Ligand A (0.546), indicating a more drug-like profile. This favors Ligand B.
7. **DILI:** Ligand B (60.682) has a slightly higher DILI risk than Ligand A (49.632), but both are within an acceptable range.
8. **BBB:** Ligand A (65.452) has a significantly higher BBB penetration percentile than Ligand B (42.032). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be beneficial for distribution. This favors Ligand A.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.349 and -5.26), which is unusual and suggests very poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand A (-2.752) has a slightly better solubility score than Ligand B (-3.24), but both are poor.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.242 and 0.09). No significant difference.
12. **Cl_mic:** Both ligands have similar microsomal clearance (30.971 and 31.16). No significant difference.
13. **t1/2:** Ligand A (-16.329) has a much more negative in vitro half-life than Ligand B (-1.333), indicating a much shorter half-life and faster metabolism. This is a major drawback for Ligand A.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.01 and 0.103). No significant difference.
15. **Binding Affinity:** Ligand B (-6.7 kcal/mol) has a slightly better binding affinity than Ligand A (-6.5 kcal/mol). While the difference is small, it's still a positive for Ligand B.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B performs better on logP and TPSA, while affinity is only slightly better. Ligand A has a better BBB score, but the poor half-life and solubility are major drawbacks. The Caco-2 permeability is poor for both, but this is a property that can be addressed with formulation.
**Conclusion:**
Considering the balance of properties, Ligand B is the more promising candidate. Its better logP, TPSA, QED, and slightly improved affinity outweigh the slightly higher DILI risk and lower BBB penetration. The significantly shorter half-life of Ligand A is a critical disadvantage.
Output:
0
2025-04-17 19:41:35,597 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (342.439 and 357.47 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (53.76) is well below the 140 threshold, and even better, below 90, making it favorable for potential CNS penetration, even though ADRB2 isn't necessarily a CNS target. Ligand B (72.88) is still under 140, but less optimal.
3. **logP:** Ligand A (2.473) is within the optimal 1-3 range. Ligand B (0.792) is slightly below 1, which could potentially hinder permeability. This is a point against Ligand B.
4. **HBD:** Ligand A (0) is excellent, minimizing potential issues with hydrogen bonding and maximizing permeability. Ligand B (2) is acceptable, but not as good.
5. **HBA:** Ligand A (3) is good. Ligand B (4) is also acceptable.
6. **QED:** Both ligands have reasonable QED scores (0.848 and 0.707), indicating good drug-like properties. Ligand A is slightly better.
7. **DILI:** Ligand A (31.059) has a much lower DILI risk than Ligand B (5.584), a significant advantage.
8. **BBB:** Both ligands have good BBB penetration (74.835 and 71.966). This isn't a primary concern for ADRB2, but it's a neutral point.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.806 and -4.955). This is unusual and suggests poor permeability.
10. **Solubility:** Both ligands have negative solubility values (-2.462 and -0.957). This is also unusual and suggests poor solubility.
11. **hERG:** Both ligands have low hERG inhibition risk (0.59 and 0.419).
12. **Cl_mic:** Ligand A (28.907) has a higher microsomal clearance than Ligand B (-10.63). This suggests Ligand B is more metabolically stable.
13. **t1/2:** Ligand A (39.951) has a longer in vitro half-life than Ligand B (-2.698). This is a positive for Ligand A.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.29 and 0.013).
15. **Binding Affinity:** Ligand A (-7.2 kcal/mol) has a slightly better binding affinity than Ligand B (-5.3 kcal/mol). This 1.9 kcal/mol difference is substantial and can outweigh some ADME drawbacks.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A excels in TPSA, logP, and affinity. While both have good Pgp profiles, Ligand A's superior affinity and better logP/TPSA balance are crucial. The lower DILI risk for Ligand A is also a significant benefit.
**Overall Assessment:**
Despite the unusual negative values for Caco-2 and solubility, Ligand A is the stronger candidate. Its superior binding affinity, favorable logP and TPSA, lower DILI risk, and longer half-life outweigh the metabolic stability advantage of Ligand B.
Output:
1
2025-04-17 19:41:35,598 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
We are targeting ADRB2, a GPCR, so the priorities are logP, TPSA, Pgp, BBB, and affinity. Let's break down the comparison:
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (344.386) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (67.43) is significantly better than Ligand B (95.5). A TPSA under 140 is good for oral absorption, but lower is better for GPCRs, and A is much closer to the ideal range for CNS penetration if needed.
3. **logP:** Both ligands have acceptable logP values (A: 3.285, B: 2.514), falling within the 1-3 range. Ligand A is slightly higher, which could be a minor concern for solubility, but not a deal-breaker.
4. **H-Bond Donors/Acceptors:** Ligand A (HBD=2, HBA=3) is preferable to Ligand B (HBD=3, HBA=4). Lower values generally improve permeability.
5. **QED:** Ligand A (0.845) has a substantially better QED score than Ligand B (0.671), indicating a more drug-like profile.
6. **DILI:** Ligand B (35.479) has a much lower DILI risk than Ligand A (75.378). This is a significant advantage for Ligand B.
7. **BBB:** Both ligands have reasonable BBB penetration (A: 61.225, B: 63.746), but neither is exceptionally high. This isn't a primary concern for a non-CNS target like ADRB2, but it's still good to have some level of penetration.
8. **Caco-2:** Ligand A (-4.612) shows better Caco-2 permeability than Ligand B (-5.075), suggesting better intestinal absorption.
9. **Solubility:** Ligand A (-4.463) has slightly better aqueous solubility than Ligand B (-3.706).
10. **hERG:** Ligand A (0.712) has a slightly better hERG profile than Ligand B (0.14). Lower is better, and A is significantly lower.
11. **Cl_mic:** Ligand B (35.056) has significantly lower microsomal clearance than Ligand A (65.841), indicating better metabolic stability.
12. **t1/2:** Ligand A (14.14) has a longer in vitro half-life than Ligand B (-12.303). This is a positive for dosing convenience.
13. **Pgp:** Ligand A (0.392) has lower P-gp efflux liability than Ligand B (0.026), which is favorable for bioavailability.
14. **Binding Affinity:** Ligand B (-7.1) has a slightly stronger binding affinity than Ligand A (-6.5). This is a 0.6 kcal/mol difference, which is significant but not overwhelming.
**Overall Assessment:**
Ligand A has a better overall profile, particularly regarding drug-likeness (QED), TPSA, permeability (Caco-2), hERG, and half-life. While Ligand B has a lower DILI risk and slightly better affinity, the advantages of Ligand A in key ADME properties and its superior drug-like characteristics outweigh these benefits. The slightly better affinity of B is not enough to overcome A's advantages in overall balance.
**Output:**
1
2025-04-17 19:41:35,598 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (332.363) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both ligands are well below the 140 A^2 threshold for good oral absorption (A: 84.06, B: 84.5).
3. **logP:** Both ligands have acceptable logP values (A: 3.417, B: 2.165), falling within the 1-3 range. Ligand A is slightly higher, which *could* present a minor solubility issue, but is still within an acceptable range.
4. **HBD:** Both have 2 HBD, which is good.
5. **HBA:** Ligand A has 6 HBA, Ligand B has 4. Both are below the 10 threshold.
6. **QED:** Both have good QED scores (A: 0.587, B: 0.718), indicating drug-likeness. Ligand B is slightly better here.
7. **DILI:** Ligand A has a significantly higher DILI risk (94.649) than Ligand B (40.364). This is a major concern for Ligand A.
8. **BBB:** Ligand B has a much higher BBB penetration score (68.554) than Ligand A (29.818). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant for off-target effects or potential therapeutic benefits, and lower CNS penetration is generally preferred to minimize side effects.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. This is concerning for both.
10. **Solubility:** Both have negative solubility values, indicating poor solubility. This is concerning for both.
11. **hERG:** Both have very low hERG inhibition liability (A: 0.444, B: 0.112), which is excellent.
12. **Cl_mic:** Ligand B has lower microsomal clearance (25.033) than Ligand A (33.309), indicating better metabolic stability.
13. **t1/2:** Ligand B has a more negative in vitro half-life (-4.872) than Ligand A (-1.683), suggesting a longer half-life and potentially less frequent dosing.
14. **Pgp:** Both have low Pgp efflux liability (A: 0.491, B: 0.042). Ligand B is better here.
15. **Binding Affinity:** Ligand B has a significantly better binding affinity (-6.9 kcal/mol) than Ligand A (-5.0 kcal/mol). This is a substantial difference, exceeding the 1.5 kcal/mol advantage threshold.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand B excels in affinity and Pgp efflux. While both have acceptable logP and TPSA, Ligand B's better metabolic stability and BBB penetration are also beneficial. The most significant drawback of Ligand A is its high DILI risk, which is a major red flag.
**Conclusion:**
Despite both ligands having some shortcomings in permeability and solubility, Ligand B is the far superior candidate due to its significantly better binding affinity, lower DILI risk, improved metabolic stability, and better BBB penetration. The strong binding affinity outweighs the permeability/solubility concerns, and the DILI risk for Ligand A is unacceptable.
Output:
0
2025-04-17 19:41:35,598 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (381.445) is slightly higher than Ligand B (342.403), but both are acceptable.
2. **TPSA:** Ligand A (95.58) is better than Ligand B (104.7), being closer to the <140 threshold for good absorption.
3. **logP:** Ligand B (0.94) is slightly better than Ligand A (-0.576), being closer to the optimal 1-3 range. Ligand A is a bit low, potentially hindering permeation.
4. **HBD:** Ligand A (2) is preferable to Ligand B (3). Lower HBD generally improves permeability.
5. **HBA:** Both ligands have the same number of HBA (5), which is acceptable.
6. **QED:** Both ligands have good QED scores (A: 0.616, B: 0.726), indicating good drug-likeness. Ligand B is slightly better.
7. **DILI:** Ligand A (32.842) has a significantly lower DILI risk than Ligand B (59.907). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (64.831) has better BBB penetration than Ligand B (39.667). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant and this is a positive for Ligand A.
9. **Caco-2:** Both ligands have similar, poor Caco-2 permeability (-5.456 and -5.551).
10. **Solubility:** Both ligands have poor aqueous solubility (-1.557 and -2.763).
11. **hERG:** Both ligands have very low hERG risk (0.113 and 0.103).
12. **Cl_mic:** Ligand A (-12.298) has a significantly lower (better) microsomal clearance than Ligand B (-4.81). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Both ligands have similar in vitro half-lives (7.012 and 6.873).
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.008 and 0.022).
15. **Affinity:** Ligand B (-6.6 kcal/mol) has a slightly better binding affinity than Ligand A (-5.5 kcal/mol). This is a 1.1 kcal/mol difference, which is considerable.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B has a better logP and affinity. However, the significantly lower DILI risk and better BBB penetration of Ligand A, coupled with its better metabolic stability (lower Cl_mic), are crucial advantages. The affinity difference, while notable, isn't large enough to overcome these other factors. The poor Caco-2 and solubility are concerns for both, but can be addressed with formulation strategies.
**Conclusion:**
Considering the balance of properties, especially the lower DILI risk, better metabolic stability, and acceptable BBB penetration, Ligand A is the more promising drug candidate.
Output:
1
2025-04-17 19:41:35,598 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (351.422 and 353.379 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (82.53) is significantly better than Ligand B (128.61). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally improves absorption. Ligand A is well below the 140 threshold, while B is approaching it.
3. **logP:** Ligand A (1.649) is within the optimal 1-3 range. Ligand B (-0.749) is slightly below 1, potentially hindering permeation. This is a notable drawback for Ligand B.
4. **HBD:** Both ligands have 2 HBD, which is acceptable.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 6. Both are within the acceptable limit of 10, but Ligand A is preferable.
6. **QED:** Ligand A (0.663) has a better QED score than Ligand B (0.444), indicating a more drug-like profile.
7. **DILI:** Ligand A (34.432) has a much lower DILI risk than Ligand B (55.487). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (58.821) has a higher BBB penetration percentile than Ligand B (30.748). While not crucial for a cardiovascular target, it's a slight positive for A.
9. **Caco-2:** Ligand A (-4.78) is better than Ligand B (-5.533). Higher values are better, indicating better intestinal absorption.
10. **Solubility:** Ligand A (-1.21) is better than Ligand B (-0.578). Higher values are better.
11. **hERG:** Ligand A (0.512) has a lower hERG inhibition liability than Ligand B (0.008). This is a major advantage for Ligand A, reducing cardiotoxicity risk.
12. **Cl_mic:** Ligand A (29.591) has a lower microsomal clearance than Ligand B (12.429), suggesting better metabolic stability.
13. **t1/2:** Ligand A (25.254) has a longer in vitro half-life than Ligand B (-10.534). A longer half-life is generally desirable.
14. **Pgp:** Ligand A (0.119) has lower P-gp efflux liability than Ligand B (0.008). Lower efflux is better.
15. **Binding Affinity:** Ligand B (-8.9 kcal/mol) has a significantly stronger binding affinity than Ligand A (-7.1 kcal/mol). This is a substantial advantage for Ligand B. The difference is >1.5kcal/mol, which is a significant advantage.
**Overall Assessment:**
Ligand B has a much stronger binding affinity, which is a critical factor. However, it suffers from a lower logP, higher TPSA, higher DILI risk, lower solubility, and a significantly shorter half-life. Ligand A excels in almost all ADME-Tox properties, and while its affinity is lower, the overall balance is more favorable for a viable drug candidate. The improved safety profile (lower DILI, lower hERG) and better pharmacokinetic properties of Ligand A outweigh the affinity difference, especially for a cardiovascular target where extremely high potency isn't always essential.
**Output:**
1
2025-04-17 19:41:35,598 - INFO - Reasoning:
Let's analyze Ligand A and Ligand B for their potential as ADRB2 ligands, keeping in mind the GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key).
**Molecular Weight:** Both ligands (358.479 and 359.495 Da) fall comfortably within the ideal 200-500 Da range.
**TPSA:** Ligand A (88.1) is slightly higher than Ligand B (62.3). Both are below the 140 threshold for oral absorption, but Ligand B is significantly better, suggesting potentially improved cell permeability.
**logP:** Ligand A (0.942) is a bit low, potentially hindering membrane permeability. Ligand B (3.25) is within the optimal 1-3 range. This is a significant advantage for Ligand B.
**H-Bond Donors/Acceptors:** Ligand A has 2 HBD and 5 HBA, while Ligand B has 1 HBD and 4 HBA. Both are within acceptable limits.
**QED:** Both ligands have good QED scores (0.64 and 0.825), indicating good drug-like properties.
**DILI:** Ligand A (16.324) has a much lower DILI risk than Ligand B (44.436). This is a substantial advantage for Ligand A.
**BBB:** Ligand A (45.677) has a lower BBB penetration percentile than Ligand B (54.866). While ADRB2 isn't a primary CNS target, some peripheral distribution is still desired, and higher BBB penetration can sometimes correlate with better overall distribution.
**Caco-2 Permeability:** Ligand A (-4.789) and Ligand B (-5.035) both have negative values, indicating poor permeability.
**Aqueous Solubility:** Ligand A (-0.716) and Ligand B (-3.41) both have negative values, indicating poor solubility.
**hERG Inhibition:** Ligand A (0.242) has a lower hERG inhibition liability than Ligand B (0.601), which is preferable.
**Microsomal Clearance:** Ligand A (21.371) has a lower microsomal clearance than Ligand B (84.97), indicating better metabolic stability.
**In vitro Half-Life:** Both ligands have similar in vitro half-lives (13.015 and 12.92 hours).
**P-gp Efflux:** Ligand A (0.038) has much lower P-gp efflux liability than Ligand B (0.287). This is a significant advantage for Ligand A, improving bioavailability.
**Binding Affinity:** Ligand B (-6.1 kcal/mol) has a slightly better binding affinity than Ligand A (-5.6 kcal/mol). This is a 0.5 kcal/mol difference, which is notable but not overwhelming.
**Overall Assessment:**
Ligand A excels in safety (DILI, hERG, P-gp efflux) and metabolic stability (Cl_mic). Ligand B has a better logP and slightly better affinity. Considering the GPCR-specific priorities, logP is crucial for membrane permeability and target engagement. However, the significantly lower DILI and P-gp efflux of Ligand A, coupled with its better hERG profile and metabolic stability, outweigh the slight affinity advantage of Ligand B. The poor Caco-2 and solubility for both are concerning, but can be addressed with formulation strategies.
Output:
1
2025-04-17 19:41:35,598 - INFO - Here's my reasoning and the final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, the key priorities are logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB.
Let's break down the comparison:
1. **MW:** Both ligands are within the acceptable range (200-500 Da). Ligand A (343.343) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (59.22) is significantly better than Ligand A (116.02). Lower TPSA is preferred for GPCRs to facilitate membrane permeability.
3. **logP:** Ligand A (1.848) is within the optimal range (1-3). Ligand B (3.765) is at the higher end, potentially causing solubility issues, but still acceptable.
4. **HBD/HBA:** Both have 1 HBD, which is good. Ligand A has 8 HBA, while Ligand B has 4. Both are acceptable, but lower HBA is generally preferred.
5. **QED:** Ligand B (0.858) has a better QED score than Ligand A (0.646), indicating better overall drug-likeness.
6. **DILI:** Ligand A (88.639) has a considerably higher DILI risk than Ligand B (38.348). This is a significant drawback for Ligand A.
7. **BBB:** Ligand B (92.555) shows much better BBB penetration than Ligand A (52.268). While not essential for a cardiovascular target, it's a bonus.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
9. **Solubility:** Both have similar, very poor aqueous solubility scores (-3.859 and -3.884). This is a concern for both.
10. **hERG:** Ligand A (0.22) has a slightly lower hERG risk than Ligand B (0.871), which is favorable.
11. **Cl_mic:** Ligand A (53.224) has a lower microsomal clearance than Ligand B (76.594), suggesting better metabolic stability.
12. **t1/2:** Ligand A (-29.783) has a negative half-life, which is not possible. Ligand B (0.524) has a very short half-life. Both are concerning, but the negative value for A is a clear error.
13. **Pgp:** Ligand A (0.184) has a lower Pgp efflux liability than Ligand B (0.706), which is beneficial.
14. **Binding Affinity:** Ligand B (-8.4 kcal/mol) has a significantly stronger binding affinity than Ligand A (-4.6 kcal/mol). This is a major advantage, potentially outweighing some of the ADME drawbacks.
**Overall Assessment:**
Ligand B is the stronger candidate. The significantly improved binding affinity (-8.4 vs -4.6 kcal/mol) is a crucial advantage for a GPCR target. While its logP is higher and solubility is poor, the lower DILI risk, better BBB penetration, and better QED score make it more promising. The negative half-life for Ligand A is a red flag and likely indicates an issue with the data. Ligand A's lower Pgp efflux is a plus, but not enough to overcome the affinity and safety concerns.
Output:
0
2025-04-17 19:41:35,598 - INFO - Batch 129 complete. Total preferences: 2064
2025-04-17 19:41:35,598 - INFO - Processing batch 130/512...
2025-04-17 19:42:22,730 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (361.467 and 358.429 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (73.22) is higher than Ligand B (58.64). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B has a slight advantage.
3. **logP:** Both ligands (2.649 and 2.344) are within the optimal 1-3 range. Again, a small advantage to Ligand B being slightly lower.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 6 HBA, while Ligand B has 3. Lower HBA is generally preferred for permeability, giving Ligand B an advantage.
6. **QED:** Ligand B (0.793) has a better QED score than Ligand A (0.606), indicating a more drug-like profile.
7. **DILI:** Ligand A (63.862) has a significantly higher DILI risk than Ligand B (24.428). This is a major concern, as liver toxicity is a common reason for drug failure.
8. **BBB:** Ligand A (59.093) has a lower BBB penetration than Ligand B (92.943). While ADRB2 isn't a CNS target, some off-target CNS effects are possible, and higher BBB is generally better.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.96 and -4.637). This is unusual and suggests poor permeability. However, the values are similar.
10. **Solubility:** Ligand A (-3.583) has slightly worse solubility than Ligand B (-2.132).
11. **hERG:** Both ligands have very low hERG inhibition risk (0.36 and 0.323).
12. **Cl_mic:** Ligand A (133.729) has a much higher microsomal clearance than Ligand B (25.3), indicating lower metabolic stability.
13. **t1/2:** Ligand B (7.616) has a significantly longer in vitro half-life than Ligand A (-27.471). This is a substantial advantage.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.363 and 0.062).
15. **Binding Affinity:** Both ligands have identical binding affinities (-6.2 kcal/mol).
**Overall Assessment:**
Ligand B is clearly the superior candidate. While both have similar binding affinity and some permeability issues (indicated by negative Caco-2 values), Ligand B excels in crucial ADME properties. It has a significantly lower DILI risk, better QED, higher BBB penetration, lower microsomal clearance, and a much longer half-life. These factors collectively make Ligand B a far more promising starting point for drug development targeting ADRB2. The lower TPSA and HBA also contribute to its improved profile.
Output:
0
2025-04-17 19:42:22,730 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.415 and 345.403 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (77.96) is significantly better than Ligand B (102.16). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is pushing the upper limit for good oral absorption.
3. **logP:** Both ligands have good logP values (1.429 and 1.272), falling within the optimal 1-3 range. Very similar.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer HBDs generally improve membrane permeability.
5. **HBA:** Ligand A (6) is better than Ligand B (8). Similar to HBD, lower HBA is generally preferred.
6. **QED:** Both ligands have good QED scores (0.722 and 0.787), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Both ligands have acceptable DILI risk (50.679 and 56.572 percentile). Ligand B is slightly higher, but both are below the concerning 60% threshold.
8. **BBB:** Ligand A (72.586) is significantly better than Ligand B (48.352). While ADRB2 isn't strictly a CNS target, some CNS penetration can be beneficial, and avoiding high CNS exposure is generally desirable.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.28 and -4.894), which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Ligand A (-1.134) is better than Ligand B (-2.094). Higher solubility is generally preferred.
11. **hERG:** Both ligands have very low hERG risk (0.137 and 0.092). Excellent.
12. **Cl_mic:** Ligand B (6.877) is *much* better than Ligand A (53.818). Lower clearance is critical for metabolic stability and longer duration of action.
13. **t1/2:** Ligand B (-1.589) is significantly better than Ligand A (-25.288). Longer half-life is desirable.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.049 and 0.019). Excellent.
15. **Affinity:** Ligand B (-6.9 kcal/mol) is slightly better than Ligand A (-6.1 kcal/mol). While the difference isn't huge, it's enough to consider, especially given the other ADME properties.
**Overall Assessment:**
Ligand B has a clear advantage in metabolic stability (Cl_mic and t1/2) and a slightly better binding affinity. These are crucial factors for a viable drug candidate. While Ligand A has better TPSA and solubility, the improvements in metabolic stability with Ligand B outweigh these benefits. The slightly better QED of Ligand B is also a positive.
Output:
0
2025-04-17 19:42:22,731 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (334.463 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (32.34) is significantly better than Ligand B (61.44). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (3.827) is optimal, while Ligand B (1.693) is on the lower side. A logP between 1-3 is preferred, and Ligand A is closer to this ideal.
4. **HBD:** Both ligands have acceptable HBD counts (1 and 2, respectively), well below the threshold of 5.
5. **HBA:** Both ligands have acceptable HBA counts (2 and 3, respectively), well below the threshold of 10.
6. **QED:** Ligand A (0.922) has a much better QED score than Ligand B (0.713), indicating a more drug-like profile.
7. **DILI:** Ligand B (26.522) has a significantly lower DILI risk than Ligand A (33.695), which is a major advantage.
8. **BBB:** Both have reasonable BBB penetration, but Ligand A is better (87.088 vs 72.78). However, as ADRB2 is a cardiovascular target, BBB penetration is not a high priority.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability.
10. **Solubility:** Both have negative solubility values, which is also unusual and suggests poor solubility.
11. **hERG:** Ligand A (0.857) has a slightly higher hERG risk than Ligand B (0.512), but both are relatively low.
12. **Cl_mic:** Ligand B (-13.579) has significantly lower (better) microsomal clearance than Ligand A (50.748), indicating better metabolic stability.
13. **t1/2:** Ligand B (-1.503) has a negative half-life, which is unusual. Ligand A (5.498) is more reasonable.
14. **Pgp:** Ligand A (0.65) has better Pgp efflux liability than Ligand B (0.025), meaning it is less likely to be pumped out of cells.
15. **Binding Affinity:** Ligand B (-6.6 kcal/mol) has a slightly better binding affinity than Ligand A (-6.0 kcal/mol), but the difference is not substantial.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A excels in logP and Pgp, while Ligand B has a slightly better affinity. Ligand A has a much better TPSA. The biggest advantage for Ligand B is the significantly lower DILI risk and better metabolic stability (Cl_mic).
**Overall Assessment:**
While Ligand A has better QED, logP, and Pgp properties, the significantly lower DILI risk and improved metabolic stability of Ligand B are crucial for a viable drug candidate. The slightly better affinity of Ligand B is a bonus. The negative values for Caco-2 and solubility are concerning for both, but can be addressed with formulation strategies. Given the importance of minimizing liver toxicity and maximizing metabolic stability, Ligand B is the preferred candidate.
Output:
0
2025-04-17 19:42:22,731 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (357.435 and 351.451 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (79.37) is better than Ligand B (100.35). For a GPCR, keeping TPSA lower is beneficial for permeability, although both are acceptable.
**3. logP:** Ligand A (3.21) is optimal. Ligand B (0.574) is quite low, potentially hindering membrane permeability and absorption. This is a significant negative for Ligand B.
**4. H-Bond Donors:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
**5. H-Bond Acceptors:** Ligand A (5) is preferable to Ligand B (6). Lower HBA generally improves permeability.
**6. QED:** Both ligands have reasonable QED values (0.856 and 0.713), indicating good drug-like properties.
**7. DILI:** Ligand A (86.196) has a higher DILI risk than Ligand B (33.889). This is a concern for Ligand A, but not a deal-breaker at this stage.
**8. BBB:** Ligand A (80.264) has better BBB penetration than Ligand B (30.942). While ADRB2 isn't strictly a CNS target, some CNS exposure can occur, and higher BBB is generally a positive.
**9. Caco-2 Permeability:** Ligand A (-4.504) is better than Ligand B (-5.275). Higher Caco-2 values indicate better absorption.
**10. Aqueous Solubility:** Ligand A (-6.098) is better than Ligand B (-1.195). Solubility is important for formulation and bioavailability.
**11. hERG Inhibition:** Ligand A (0.628) has a slightly higher hERG risk than Ligand B (0.07). This is a positive for Ligand B.
**12. Microsomal Clearance:** Ligand A (43.863) has better metabolic stability (lower clearance) than Ligand B (-14.684). This is a significant advantage for Ligand A.
**13. In vitro Half-Life:** Ligand A (75.342) has a significantly longer half-life than Ligand B (5.383). This is a major advantage for Ligand A, potentially allowing for less frequent dosing.
**14. P-gp Efflux:** Ligand A (0.418) has lower P-gp efflux than Ligand B (0.017). Lower efflux is better for bioavailability.
**15. Binding Affinity:** Ligand A (-7.8 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.5 kcal/mol). This 1.3 kcal/mol difference is substantial and can outweigh some of the ADME drawbacks of Ligand A.
**Overall Assessment:**
Ligand A is the stronger candidate. While it has a higher DILI risk, its superior logP, metabolic stability (lower Cl_mic, longer t1/2), P-gp efflux, solubility, Caco-2 permeability, and *significantly* better binding affinity outweigh the DILI concern. The low logP of Ligand B is a major drawback, likely to severely impact its oral bioavailability. For a GPCR, the strong affinity of Ligand A is particularly important.
Output:
1
2025-04-17 19:42:22,731 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (432.265 Da) is within the ideal range, while Ligand B (352.435 Da) is also acceptable, leaning towards the lower end. No strong preference here.
2. **TPSA:** Ligand A (57.78) is excellent, well below the 140 threshold. Ligand B (104.39) is still reasonable, but higher. This favors Ligand A.
3. **logP:** Ligand A (4.687) is slightly high, potentially leading to solubility issues. Ligand B (1.557) is quite low, which could hinder permeability. ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but good permeability is still important. This favors Ligand A slightly.
4. **HBD:** Both ligands have 2 HBD, which is within the ideal range. No preference.
5. **HBA:** Ligand A has 3 HBA, and Ligand B has 5. Both are acceptable, but Ligand A is slightly better.
6. **QED:** Ligand A (0.629) is good, indicating drug-likeness. Ligand B (0.491) is lower, suggesting a less favorable drug-like profile. This favors Ligand A.
7. **DILI:** Ligand A (85.537) has a higher DILI risk than Ligand B (27.142). This is a significant drawback for Ligand A.
8. **BBB:** Ligand A (77.2) is reasonable, while Ligand B (36.526) is low. Since ADRB2 is cardiovascular, BBB penetration isn't critical, so this doesn't strongly favor either.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. This is a concern for both, but the magnitude of the negative value is similar.
10. **Solubility:** Ligand A (-5.395) has very poor solubility, likely due to the high logP. Ligand B (-0.505) is better, but still not ideal. This favors Ligand B.
11. **hERG:** Ligand A (0.779) has a slightly higher hERG risk than Ligand B (0.333). This favors Ligand B.
12. **Cl_mic:** Ligand A (33.553) has lower microsomal clearance than Ligand B (37.186), indicating better metabolic stability. This favors Ligand A.
13. **t1/2:** Ligand A (50.13) has a much longer half-life than Ligand B (-36.45). This is a major advantage for Ligand A, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.633) has lower P-gp efflux than Ligand B (0.028), which is better for bioavailability. This favors Ligand A.
15. **Binding Affinity:** Ligand A (-7.1) has significantly stronger binding affinity than Ligand B (-6.0). This is a substantial advantage, and can often outweigh minor ADME concerns.
**Overall Assessment:**
Ligand A has a significantly better binding affinity and a longer half-life, which are crucial for efficacy. It also has better TPSA, QED, and Pgp properties. However, it suffers from higher DILI risk and very poor solubility. Ligand B has a lower DILI risk and better solubility, but its binding affinity is considerably weaker, and its half-life is very short.
Considering the GPCR-specific priorities (affinity being paramount), and the fact that we're targeting a cardiovascular receptor (less emphasis on BBB), the stronger binding affinity of Ligand A is the deciding factor. The poor solubility and DILI risk of Ligand A would need to be addressed through further optimization, but the initial potency is a strong starting point.
Output:
1
2025-04-17 19:42:22,731 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for the ADRB2, a cardiovascular GPCR. Therefore, the priorities are logP, TPSA, Pgp, affinity, and to a lesser extent, BBB.
Let's break down the comparison:
1. **MW:** Both ligands are within the ideal range (351-352 Da).
2. **TPSA:** Ligand B (81.08) is significantly better than Ligand A (121.71). Lower TPSA is preferred for GPCRs, aiding permeability.
3. **logP:** Ligand B (1.314) is better than Ligand A (0.03). Ligand A's logP is very low, potentially leading to poor membrane permeability.
4. **HBD/HBA:** Both have acceptable HBD (2) and HBA counts (6 for A, 4 for B).
5. **QED:** Both are good (0.738 and 0.707).
6. **DILI:** Ligand B (19.698) is *much* better than Ligand A (58.511), indicating a significantly lower risk of liver injury. This is a major advantage for Ligand B.
7. **BBB:** Ligand B (65.839) is better than Ligand A (37.495), though neither is exceptionally high. For a cardiovascular target, BBB isn't critical, but it's a bonus.
8. **Caco-2:** Ligand B (-4.639) is slightly better than Ligand A (-5.007).
9. **Solubility:** Ligand B (-1.464) is slightly better than Ligand A (-1.796).
10. **hERG:** Ligand B (0.322) is better than Ligand A (0.085), indicating a lower risk of cardiotoxicity.
11. **Cl_mic:** Ligand A (1.606) is *much* better than Ligand B (8.009), suggesting significantly higher metabolic stability.
12. **t1/2:** Ligand B (4.843) is better than Ligand A (-25.339), indicating a longer half-life.
13. **Pgp:** Ligand B (0.131) is better than Ligand A (0.01), suggesting lower efflux.
14. **Affinity:** Ligand A (-6.7 kcal/mol) is slightly better than Ligand B (-5.4 kcal/mol), but the difference is not substantial enough to overcome the other significant advantages of Ligand B.
**Overall Assessment:**
Ligand B has a superior profile regarding crucial ADME properties (DILI, logP, TPSA, Pgp, hERG) and a reasonable binding affinity. While Ligand A has slightly better affinity and metabolic stability, the significantly lower DILI risk, improved logP and TPSA, and better Pgp profile of Ligand B make it the more promising drug candidate. The low logP of Ligand A is a significant concern.
**Output:**
0
2025-04-17 19:42:22,731 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.45 & 359.54 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (76.46) is higher than Ligand B (44.29). For a cardiovascular GPCR, TPSA isn't a *major* concern unless it's excessively high, but lower is generally preferred for better permeability. Ligand B is significantly better.
3. **logP:** Ligand A (1.056) is within the optimal 1-3 range. Ligand B (3.545) is at the upper end of optimal, potentially raising concerns about solubility and off-target effects, but still acceptable.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 5 HBA, and Ligand B has 6 HBA. Both are within the acceptable limit of 10.
6. **QED:** Both ligands have high QED scores (0.834 and 0.854), indicating good drug-like properties.
7. **DILI:** Ligand A (29.78%) has a much lower DILI risk than Ligand B (57.58%). This is a significant advantage for Ligand A.
8. **BBB:** Ligand B (83.64%) has better BBB penetration than Ligand A (73.36%). While ADRB2 isn't a CNS target, some peripheral ADRB2 receptors can be influenced by CNS activity, and higher BBB penetration isn't necessarily detrimental.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.038 and -5.085). This is unusual and suggests poor permeability.
10. **Solubility:** Ligand A (-1.104) has better solubility than Ligand B (-3.535). This is important for bioavailability.
11. **hERG:** Ligand A (0.102) has a much lower hERG inhibition liability than Ligand B (0.955). This is a crucial advantage for Ligand A, as hERG inhibition can cause cardiotoxicity.
12. **Cl_mic:** Ligand A (7.747) has lower microsomal clearance than Ligand B (78.369), indicating better metabolic stability.
13. **t1/2:** Ligand A (7.017) has a longer in vitro half-life than Ligand B (-5.647). This is a positive for Ligand A.
14. **Pgp:** Ligand A (0.034) has significantly lower P-gp efflux liability than Ligand B (0.515). Lower P-gp efflux is favorable for oral bioavailability.
15. **Binding Affinity:** Ligand B (-6.6 kcal/mol) has a slightly better binding affinity than Ligand A (-5.9 kcal/mol). This is a 0.7 kcal/mol difference, which is a moderate advantage.
**Overall Assessment & GPCR Priorities:**
For a cardiovascular GPCR like ADRB2, balancing potency (affinity) with ADME properties is critical. Ligand B has a slightly better affinity, but Ligand A excels in almost all other crucial parameters: DILI risk, hERG inhibition, metabolic stability (Cl_mic & t1/2), P-gp efflux, and solubility. The lower TPSA of Ligand B is a plus, but the substantial improvements in safety (DILI, hERG) and ADME properties with Ligand A outweigh the small affinity difference. The negative Caco-2 values for both are concerning, but can be addressed in further optimization.
Output:
1
2025-04-17 19:42:22,731 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (367.5 and 348.4 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (73.22) is better than Ligand B (81.01). While both are below 140, lower TPSA generally favors oral absorption, a key consideration.
**3. logP:** Both ligands have good logP values (2.386 and 1.282), falling within the 1-3 optimal range. Ligand A is slightly higher, which *could* be beneficial for membrane permeability, but not drastically.
**4. H-Bond Donors:** Both have 1 HBD, which is ideal.
**5. H-Bond Acceptors:** Both have 5 HBA, also ideal.
**6. QED:** Both ligands have the same QED score (0.867), indicating good drug-likeness.
**7. DILI:** Ligand A (37.22) has a significantly lower DILI risk than Ligand B (43.27). This is a major advantage for Ligand A. Lower DILI is always preferred.
**8. BBB:** Ligand A (71.77) has a much higher BBB penetration percentile than Ligand B (49.75). While ADRB2 is a cardiovascular target, some CNS penetration can be acceptable or even desirable for off-target effects, and higher BBB is generally a positive attribute.
**9. Caco-2 Permeability:** Ligand A (-5.096) has a slightly better Caco-2 permeability than Ligand B (-4.589).
**10. Aqueous Solubility:** Ligand A (-3.174) has a slightly better aqueous solubility than Ligand B (-1.937).
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (0.6 and 0.239 respectively), which is excellent.
**12. Microsomal Clearance:** Ligand B (23.902) has a significantly lower microsomal clearance than Ligand A (52.811). This suggests better metabolic stability for Ligand B.
**13. In vitro Half-Life:** Ligand B (30.024) has a longer in vitro half-life than Ligand A (-27.828). This is a significant advantage for Ligand B, potentially leading to less frequent dosing.
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (0.187 and 0.035 respectively).
**15. Binding Affinity:** Ligand B (-6.3) has a slightly better binding affinity than Ligand A (-5.8). A 0.5 kcal/mol difference is meaningful, but not overwhelming.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity) and the general guidelines, Ligand A emerges as the more favorable candidate. While Ligand B has better metabolic stability and half-life, Ligand A has a substantially lower DILI risk, better BBB penetration, and slightly better permeability and solubility. The difference in binding affinity is not large enough to outweigh the advantages of Ligand A's safety and pharmacokinetic profile.
Output:
1
2025-04-17 19:42:22,731 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands (346.475 and 346.515 Da) fall comfortably within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (80.48) is higher than Ligand B (40.62). For a GPCR, lower TPSA is generally preferred for better permeability, giving a slight edge to Ligand B.
3. **logP:** Ligand B (3.308) is higher than Ligand A (1.204). While both are within the acceptable range (1-3), Ligand B is approaching the upper limit. Ligand A is better here.
4. **HBD:** Ligand A (2) is higher than Ligand B (0). Both are acceptable, but lower HBD can sometimes improve permeability. Ligand B is slightly favored.
5. **HBA:** Ligand A (5) is higher than Ligand B (2). Similar to HBD, lower HBA is generally preferred for permeability. Ligand B is favored.
6. **QED:** Both ligands have similar QED values (0.775 and 0.783), indicating good drug-like properties. No significant difference.
7. **DILI:** Ligand B (15.781) has a *much* lower DILI risk than Ligand A (6.514). This is a significant advantage for Ligand B.
8. **BBB:** Ligand B (79.721) has a significantly higher BBB penetration percentile than Ligand A (55.176). This is a major advantage for Ligand B, given that ADRB2 is a GPCR and CNS penetration could be beneficial depending on the therapeutic target.
9. **Caco-2:** Ligand A (-5.273) and Ligand B (-4.682) are both negative, indicating poor permeability. Ligand B is slightly better.
10. **Solubility:** Ligand A (-0.58) is better than Ligand B (-3.947). Solubility is important, and Ligand A has a better score.
11. **hERG:** Both ligands have low hERG inhibition liability (0.601 and 0.549), which is good. No significant difference.
12. **Cl_mic:** Ligand A (-50.095) has a *much* lower microsomal clearance than Ligand B (64.388), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (22.962) has a longer in vitro half-life than Ligand B (-5.258). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.03) has a lower Pgp efflux liability than Ligand B (0.44). This is a slight advantage for Ligand A.
15. **Binding Affinity:** Ligand A (-8.0) has a slightly better binding affinity than Ligand B (-6.1). This is a 1.9 kcal/mol difference, which is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand A has a better binding affinity, metabolic stability (Cl_mic), half-life, and Pgp efflux. However, Ligand B excels in DILI risk, BBB penetration, and has a lower TPSA. Considering ADRB2 is a GPCR, BBB penetration is a valuable property. The significantly lower DILI risk of Ligand B is also a major positive. The affinity difference is important, but the combined advantages of Ligand B in safety and permeability (lower TPSA) are compelling.
Output:
0
2025-04-17 19:42:22,731 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (348.399) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (84.94) is significantly better than Ligand B (116.13). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (2.587) is optimal, while Ligand B (0.372) is quite low. A logP below 1 can hinder membrane permeability. This is a significant drawback for Ligand B.
4. **HBD:** Both ligands have acceptable HBD counts (1 and 2, respectively), well within the limit of 5.
5. **HBA:** Both ligands have acceptable HBA counts (5), well within the limit of 10.
6. **QED:** Both ligands have good QED scores (0.849 and 0.728), indicating good drug-like properties.
7. **DILI:** Ligand A (63.513) has a higher DILI risk than Ligand B (39.395). This is a negative for Ligand A, but not a dealbreaker.
8. **BBB:** Ligand A (79.411) has better BBB penetration than Ligand B (33.579), but this is less critical for a cardiovascular target.
9. **Caco-2:** Ligand A (-4.45) and Ligand B (-5.626) both have negative Caco-2 values, indicating poor permeability. This is concerning for both.
10. **Solubility:** Ligand A (-3.694) has slightly better solubility than Ligand B (-2.397), but both are poor.
11. **hERG:** Ligand A (0.386) has a lower hERG risk than Ligand B (0.144), which is a positive.
12. **Cl_mic:** Ligand B (-15.316) has significantly lower microsomal clearance than Ligand A (50.08), indicating better metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand B (33.323) has a longer in vitro half-life than Ligand A (-11.76), which is a positive.
14. **Pgp:** Ligand A (0.076) has lower P-gp efflux than Ligand B (0.02), which is favorable.
15. **Affinity:** Ligand B (-7.1) has a significantly stronger binding affinity than Ligand A (-4.7). This is a substantial advantage, potentially outweighing some of the ADME drawbacks.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has better logP and Pgp, but Ligand B has a much better affinity and acceptable TPSA. The difference in affinity is substantial (2.4 kcal/mol). While Ligand B has poorer solubility and Caco-2 permeability, the strong binding affinity and improved metabolic stability are likely to be more critical for *in vivo* efficacy.
**Conclusion:**
Despite some ADME liabilities, Ligand B's significantly stronger binding affinity and better metabolic stability make it the more promising candidate. The affinity difference is large enough to potentially overcome the solubility and permeability issues through formulation strategies.
Output:
0
2025-04-17 19:42:22,732 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (432.34 Da) is within the ideal range, while Ligand B (345.403 Da) is at the lower end, but still acceptable.
2. **TPSA:** Ligand A (95.58) is good, below 140, and Ligand B (103.25) is also acceptable.
3. **logP:** Ligand A (1.626) is optimal. Ligand B (0.556) is a bit low, potentially hindering permeability.
4. **HBD:** Ligand A (2) and Ligand B (3) are both acceptable.
5. **HBA:** Ligand A (4) and Ligand B (5) are both acceptable.
6. **QED:** Both Ligand A (0.707) and Ligand B (0.682) have good drug-likeness scores.
7. **DILI:** Ligand A (59.48) has a slightly higher DILI risk than Ligand B (40.287), but both are reasonably low.
8. **BBB:** Ligand A (74.176) has significantly better BBB penetration than Ligand B (17.371). While ADRB2 isn't *necessarily* a CNS target, some cardiovascular effects can be mediated centrally, and better BBB penetration can be a plus.
9. **Caco-2:** Ligand A (-4.979) and Ligand B (-5.517) both have negative values, indicating poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-3.689) and Ligand B (-1.997) both have poor solubility.
11. **hERG:** Ligand A (0.468) has a lower hERG risk than Ligand B (0.223), which is preferable.
12. **Cl_mic:** Ligand A (24.221) has a higher microsomal clearance than Ligand B (-10.084). This suggests Ligand B is more metabolically stable.
13. **t1/2:** Ligand A (-44.66) has a very negative in vitro half-life, indicating rapid metabolism. Ligand B (-12.706) is also negative, but less so.
14. **Pgp:** Ligand A (0.077) has lower P-gp efflux than Ligand B (0.007), which is favorable.
15. **Affinity:** Ligand A (-5.6 kcal/mol) has a slightly better binding affinity than Ligand B (-6.9 kcal/mol). This 1.3 kcal/mol difference is significant.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand A has a better logP and Pgp profile, and a better binding affinity. While both have issues with Caco-2 and solubility, the affinity and logP advantages of Ligand A are more important. The better BBB penetration of Ligand A is also a slight advantage. The metabolic stability of Ligand B is good, but the affinity difference outweighs this.
**Conclusion:**
Considering the balance of properties and the GPCR-specific priorities, Ligand A is the more promising drug candidate.
Output:
1
2025-04-17 19:42:22,732 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Step-by-step comparison:**
1. **MW:** Both ligands (344.375 and 354.332 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand B (92.08) is significantly better than Ligand A (122.03). For a GPCR, lower TPSA is generally preferred for better permeability.
3. **logP:** Ligand B (2.028) is within the optimal 1-3 range, while Ligand A (0.24) is quite low, potentially hindering membrane permeability. This is a substantial advantage for Ligand B.
4. **HBD:** Ligand A (3) and Ligand B (2) are both acceptable, below the threshold of 5.
5. **HBA:** Ligand A (7) and Ligand B (3) are both acceptable, below the threshold of 10. Ligand B is better here.
6. **QED:** Ligand B (0.823) has a higher QED score than Ligand A (0.69), indicating a more drug-like profile.
7. **DILI:** Ligand B (39.473) has a much lower DILI risk than Ligand A (68.825). This is a significant advantage for Ligand B.
8. **BBB:** Ligand B (91.392) has a much higher BBB penetration score than Ligand A (35.052). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be beneficial or at least avoid unexpected side effects.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
10. **Solubility:** Both ligands have negative solubility values, which is also unusual. Again, the scale is unknown, making interpretation difficult.
11. **hERG:** Ligand A (0.059) has a lower hERG inhibition liability than Ligand B (0.676), which is better.
12. **Cl_mic:** Ligand A (9.455) has a significantly lower microsomal clearance than Ligand B (26.252), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-13.029) has a much longer in vitro half-life than Ligand A (-3.268). This is a major advantage for Ligand B.
14. **Pgp:** Ligand A (0.005) has a lower P-gp efflux liability than Ligand B (0.061), which is better.
15. **Affinity:** Ligand A (-6.7 kcal/mol) has a slightly better binding affinity than Ligand B (-3.2 kcal/mol). This is a significant difference, but can be overcome by other factors.
**Overall Assessment:**
Ligand B is the stronger candidate. While Ligand A has a slightly better binding affinity and lower Pgp efflux, Ligand B excels in almost all other critical ADME properties. Specifically, its superior logP, TPSA, QED, DILI risk, BBB penetration, and *especially* its significantly longer half-life are compelling advantages. The lower hERG risk of Ligand A is a consideration, but the other benefits of Ligand B outweigh this concern, particularly given the substantial difference in half-life and DILI.
**Output:**
0
2025-04-17 19:42:22,732 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (386.46 & 347.42 Da) fall within the ideal 200-500 Da range.
2. **TPSA:** Ligand B (97.94) is significantly better than Ligand A (133.38). ADRB2 is not a CNS target, but lower TPSA generally improves absorption.
3. **logP:** Both are good (0.754 & 0.791), falling within the 1-3 range.
4. **HBD:** Ligand B (1) is preferable to Ligand A (2) as lower HBD generally improves permeability.
5. **HBA:** Both have 7 HBA, which is acceptable.
6. **QED:** Both are good (0.753 & 0.833), indicating good drug-like properties.
7. **DILI:** Ligand B (57.39) is *much* better than Ligand A (97.87). This is a major advantage for Ligand B.
8. **BBB:** Not a primary concern for ADRB2, but Ligand B (54.09) is better than Ligand A (39.47).
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand B (-4.96) is slightly better than Ligand A (-5.16).
10. **Solubility:** Both are negative, indicating poor solubility. Ligand B (-1.383) is slightly better than Ligand A (-2.414).
11. **hERG:** Both are very low (0.054 & 0.108), indicating minimal hERG inhibition risk.
12. **Cl_mic:** Ligand A (1.039) is significantly better than Ligand B (35.551), indicating better metabolic stability.
13. **t1/2:** Ligand B (18.76) has a longer half-life than Ligand A (25.88).
14. **Pgp:** Both are very low (0.105 & 0.026), indicating minimal P-gp efflux.
15. **Affinity:** Ligand B (-7.2 kcal/mol) has a significantly stronger binding affinity than Ligand A (-4.4 kcal/mol) - a difference of 2.8 kcal/mol, which is substantial.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B is superior in TPSA, Pgp, and *significantly* in affinity. The DILI score for Ligand B is also a major advantage. While Ligand A has better metabolic stability (Cl_mic), the substantial affinity difference and lower toxicity risk of Ligand B outweigh this benefit. The slightly better half-life of Ligand B is also a positive.
**Conclusion:**
Ligand B is the more promising drug candidate due to its superior binding affinity, significantly lower DILI risk, better TPSA, and comparable ADME properties.
Output:
0
2025-04-17 19:42:22,732 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (363.483 and 371.459 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (73.22) is significantly better than Ligand B (110.53). For a GPCR, keeping TPSA below 140 is good for oral absorption, and lower is generally preferred. Ligand B is pushing the upper limit.
**3. logP:** Ligand A (2.387) is optimal (1-3). Ligand B (0.604) is a bit low, potentially hindering membrane permeability.
**4. H-Bond Donors:** Ligand A (1) is good. Ligand B (2) is acceptable, but slightly less favorable.
**5. H-Bond Acceptors:** Ligand A (5) is good. Ligand B (6) is acceptable.
**6. QED:** Ligand A (0.855) is excellent, indicating high drug-likeness. Ligand B (0.692) is still acceptable, but lower.
**7. DILI:** Both ligands have acceptable DILI risk (61.497 and 51.221 percentile). Ligand B is slightly better.
**8. BBB:** Both ligands have similar BBB penetration (59.325 and 59.442 percentile). While not exceptionally high, it's not a primary concern for ADRB2, which isn't necessarily a CNS target.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-5.224 and -5.135), which is unusual and suggests poor permeability *in vitro*. This is a concern for both.
**10. Aqueous Solubility:** Both ligands have negative solubility values (-3.163 and -1.762). This is also concerning, indicating poor aqueous solubility. Ligand B is slightly better.
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.339 and 0.11 percentile). This is excellent for both.
**12. Microsomal Clearance:** Ligand A (46.245 mL/min/kg) is higher than Ligand B (19.001 mL/min/kg), meaning Ligand B has better metabolic stability.
**13. In vitro Half-Life:** Ligand A (-14.976 hours) is very poor, while Ligand B (1.389 hours) is also not great, but better than A.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.146 and 0.044 percentile). This is excellent for both.
**15. Binding Affinity:** Both ligands have the same binding affinity (-6.5 kcal/mol), which is good.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand A is superior. Its better logP and significantly lower TPSA are key advantages for permeability and absorption. While both have issues with Caco-2 and solubility, Ligand A's better drug-likeness (QED) and slightly better H-bond donor count make it more promising. Ligand B has better metabolic stability and solubility, but the TPSA and logP are significant drawbacks. The similar binding affinity means those ADME properties are the deciding factors.
Output:
1
2025-04-17 19:42:22,732 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [363.37 , 20.31 , 4.778, 0. , 1. , 0.69 , 17.449, 97.247, -4.585, -4.711, 0.952, 37.337, -16.784, 0.592, -7. ]
**Ligand B:** [350.463, 87.46 , 1.097, 2. , 5. , 0.771, 31.175, 29.236, -5.264, -1.474, 0.215, 8.786, 13.247, 0.059, -6.4 ]
Here's a breakdown, considering the GPCR priorities (logP, Pgp, TPSA, affinity, and BBB):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (350.463) is slightly lower, which is generally favorable.
2. **TPSA:** Ligand A (20.31) is *much* better than Ligand B (87.46). A TPSA under 140 is good for oral absorption, but lower is better for GPCRs, and A is significantly lower.
3. **logP:** Ligand A (4.778) is a bit high, but still within a tolerable range. Ligand B (1.097) is quite low, potentially leading to permeability issues.
4. **HBD/HBA:** Ligand A (0/1) is preferable to Ligand B (2/5). Fewer H-bonds are generally better for membrane permeability.
5. **QED:** Both are decent (A: 0.69, B: 0.771), indicating reasonable drug-likeness.
6. **DILI:** Ligand A (17.449) has a significantly lower DILI risk than Ligand B (31.175). This is a major advantage.
7. **BBB:** Ligand A (97.247) has excellent BBB penetration, while Ligand B (29.236) is poor. This is *very* important for a GPCR target, even if not strictly CNS-focused, as it suggests better distribution.
8. **Caco-2:** Ligand A (-4.585) and Ligand B (-5.264) are both negative, which is unusual. This suggests poor permeability. However, the negative values are close, so this isn't a major differentiator.
9. **Solubility:** Ligand A (-4.711) is worse than Ligand B (-1.474). Solubility is a concern for A.
10. **hERG:** Ligand A (0.952) is better than Ligand B (0.215), indicating lower cardiotoxicity risk.
11. **Cl_mic:** Ligand B (8.786) has significantly lower microsomal clearance than Ligand A (37.337), suggesting better metabolic stability.
12. **t1/2:** Ligand B (13.247) has a longer in vitro half-life than Ligand A (-16.784).
13. **Pgp:** Ligand A (0.592) has lower P-gp efflux than Ligand B (0.059), which is favorable.
14. **Affinity:** Both have good binding affinity (-7.0 and -6.4 kcal/mol respectively), with Ligand A being slightly better. The difference is not substantial enough to override other factors.
**Overall Assessment:**
Ligand A has a superior profile for a GPCR target. Its low TPSA, excellent BBB penetration, low DILI risk, and slightly better affinity outweigh its slightly higher logP and lower solubility. Ligand B's lower logP and better metabolic stability are positives, but the high TPSA and poor BBB penetration are significant drawbacks for a GPCR.
Output:
1
2025-04-17 19:42:22,732 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [360.357, 93.73, 0.231, 2, 5, 0.685, 54.168, 78.868, -5.084, -1.922, 0.204, 9.358, -9.564, 0.026, -5.7]
**Ligand B:** [361.515, 66.81, 2.556, 1, 5, 0.745, 15.743, 54.556, -5.601, -1.834, 0.479, 38.858, -11.799, 0.056, -5.2]
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (360-362 Da). No significant difference.
2. **TPSA:** Ligand A (93.73) is higher than Ligand B (66.81). For a GPCR, lower TPSA is generally preferred for better brain penetration, even though ADRB2 isn't strictly a CNS target. Ligand B is better here.
3. **logP:** Ligand A (0.231) is quite low, potentially hindering membrane permeability. Ligand B (2.556) is within the optimal range (1-3). Ligand B is significantly better.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable. Ligand B is slightly better.
5. **HBA:** Both ligands have 5 HBA, which is acceptable. No significant difference.
6. **QED:** Both ligands have good QED scores (A: 0.685, B: 0.745), indicating drug-likeness. Ligand B is slightly better.
7. **DILI:** Ligand A (54.168) has a higher DILI risk than Ligand B (15.743). Ligand B is much better.
8. **BBB:** Ligand A (78.868) has a better BBB penetration score than Ligand B (54.556). This is a positive for Ligand A.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual. Assuming these are logP-like scales, lower values indicate poorer permeability. No clear advantage.
10. **Solubility:** Both ligands have very poor solubility scores (-1.922 and -1.834). This is a significant concern for both.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.204 and 0.479). No significant difference.
12. **Cl_mic:** Ligand A (9.358) has a lower microsomal clearance than Ligand B (38.858), suggesting better metabolic stability. Ligand A is better.
13. **t1/2:** Ligand A (-9.564) has a longer in vitro half-life than Ligand B (-11.799). Ligand A is better.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.026 and 0.056). No significant difference.
15. **Affinity:** Ligand A (-5.7) has a slightly better binding affinity than Ligand B (-5.2).
**Overall Assessment:**
While Ligand A has a better binding affinity, longer half-life, and lower clearance, Ligand B has superior properties in several critical areas for a GPCR drug candidate: significantly lower DILI risk, a much better logP value, and a lower TPSA. The poor solubility of both compounds is a major concern, but the other advantages of Ligand B outweigh the slight affinity difference. The better logP and lower DILI risk are particularly important.
Output:
0
2025-04-17 19:42:22,732 - INFO - Batch 130 complete. Total preferences: 2080
2025-04-17 19:42:22,732 - INFO - Processing batch 131/512...
2025-04-17 19:43:15,076 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (337.383 and 346.427 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (71.76) is slightly higher than Ligand B (66.92). Both are below the 140 A^2 threshold for good oral absorption, and acceptable for a cardiovascular GPCR.
3. **logP:** Ligand A (1.525) is slightly higher than Ligand B (0.984), both are within the optimal 1-3 range.
4. **HBD:** Ligand A has 1 HBD, while Ligand B has 0. Both are within the acceptable limit of <=5.
5. **HBA:** Ligand A has 6 HBA, Ligand B has 4. Both are below the acceptable limit of <=10.
6. **QED:** Both ligands have similar QED values (0.785 and 0.764), indicating good drug-likeness.
7. **DILI:** Ligand A (69.794) has a higher DILI risk than Ligand B (28.306). This is a significant negative for Ligand A.
8. **BBB:** Ligand B (83.249) has a much higher BBB penetration percentile than Ligand A (62.737). While ADRB2 isn't a CNS target, some off-target CNS effects are always a consideration, and higher BBB is generally preferable.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.653 and -4.372). This is unusual and suggests poor permeability.
10. **Solubility:** Both ligands have negative solubility values (-2.143 and -2.289). This is also unusual and suggests poor aqueous solubility.
11. **hERG:** Ligand A (0.719) has a slightly higher hERG inhibition liability than Ligand B (0.135). This is a negative for Ligand A, as lower hERG is preferred.
12. **Cl_mic:** Ligand B (47.369) has a higher microsomal clearance than Ligand A (33.999), meaning Ligand A is more metabolically stable.
13. **t1/2:** Ligand B (4.508) has a longer in vitro half-life than Ligand A (-3.836). This is a positive for Ligand B.
14. **Pgp:** Ligand A (0.062) has lower P-gp efflux liability than Ligand B (0.041). This is a slight positive for Ligand A.
15. **Binding Affinity:** Ligand A (-8.3 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.9 kcal/mol). This is a substantial advantage for Ligand A.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, affinity, logP, and metabolic stability are key. Ligand A has a significantly better binding affinity, and better metabolic stability (lower Cl_mic). However, the DILI risk is a major concern. Ligand B has a much better safety profile (lower DILI, lower hERG) and better BBB penetration, but weaker binding affinity.
**Overall Assessment:**
The difference in binding affinity is substantial (1.4 kcal/mol). While the DILI risk for Ligand A is concerning, the strong binding affinity could potentially allow for a lower dose, mitigating some of the DILI risk. The better metabolic stability of Ligand A is also a plus. The negative Caco-2 and solubility values are concerning for both, but may be addressable through formulation strategies.
Considering the balance of properties, the superior binding affinity of Ligand A outweighs its drawbacks, especially given the potential to optimize formulation.
Output:
1
2025-04-17 19:43:15,077 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (366.527 and 364.27 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (57.69) is better than Ligand B (61.19). Both are below the 140 threshold for oral absorption, but lower TPSA is generally preferred for GPCRs, potentially aiding in receptor penetration.
3. **logP:** Both ligands have good logP values (2.817 and 3.068), falling within the optimal 1-3 range. Ligand B is slightly higher, which could be a minor concern for solubility.
4. **HBD:** Both have 0 HBD, which is acceptable.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 5. Both are below the 10 threshold.
6. **QED:** Ligand A (0.777) has a significantly better QED score than Ligand B (0.465), indicating a more drug-like profile.
7. **DILI:** Ligand A (35.789) has a much lower DILI risk than Ligand B (68.205). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (96.2) has a significantly higher BBB penetration percentile than Ligand A (76.154). While ADRB2 isn't strictly a CNS target, some CNS exposure could be acceptable or even beneficial depending on the desired therapeutic profile.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.684) is slightly better than Ligand B (-4.452), but both are concerning.
10. **Solubility:** Ligand A (-2.191) has better solubility than Ligand B (-4.147).
11. **hERG:** Both ligands have low hERG inhibition liability (0.615 and 0.706), which is good.
12. **Cl_mic:** Ligand A (0.809) has much lower microsomal clearance than Ligand B (86.382), indicating better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand A (49.579) has a much longer in vitro half-life than Ligand B (7.255). This is a substantial benefit.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.399 and 0.554).
15. **Binding Affinity:** Ligand B (-6.1) has a slightly better binding affinity than Ligand A (-6.0). However, the difference is small (0.1 kcal/mol) and likely not enough to overcome the significant ADME advantages of Ligand A.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Ligand B has a slightly better logP and affinity, and a much better BBB. However, Ligand A excels in TPSA, Pgp, and crucially, ADME properties like DILI, Cl_mic, and t1/2. The significantly better metabolic stability and lower toxicity risk of Ligand A are more important than the slight affinity advantage of Ligand B. The Caco-2 permeability is a concern for both, but can be addressed with formulation strategies.
**Conclusion:**
Considering the balance of properties, particularly the superior ADME profile and lower toxicity risk, Ligand A is the more promising drug candidate.
Output:
1
2025-04-17 19:43:15,077 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (a cardiovascular GPCR) drug candidates.
**Ligand A:** [349.435, 96.45, 0.308, 2, 6, 0.666, 38.736, 62.97, -4.629, -1.627, 0.075, 19.696, -28.555, 0.004, -7.3]
**Ligand B:** [363.82, 58.22, 3.5, 1, 3, 0.827, 51.648, 74.758, -4.813, -4.359, 0.876, 65.578, 0.486, 0.743, -6]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal 200-500 Da range. Ligand A (349.435 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (96.45) is higher than Ligand B (58.22). For a cardiovascular GPCR, TPSA isn't *as* critical as for a CNS target, but lower is still preferred for better absorption. Ligand B is significantly better here.
3. **logP:** Ligand A (0.308) is quite low, potentially hindering membrane permeability. Ligand B (3.5) is within the optimal 1-3 range. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable.
5. **HBA:** Ligand A (6) and Ligand B (3) are both acceptable.
6. **QED:** Both have good QED values, Ligand B (0.827) being slightly better than Ligand A (0.666).
7. **DILI:** Ligand A (38.736) has a lower DILI risk than Ligand B (51.648), which is a positive.
8. **BBB:** Ligand B (74.758) has a better BBB penetration percentile than Ligand A (62.97). While not a CNS target, some distribution into the CNS is possible, and higher BBB is generally a good sign of permeability.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.629) is slightly worse than Ligand B (-4.813).
10. **Solubility:** Both have negative solubility values, which is also unusual and suggests poor solubility. Ligand B (-4.359) is slightly better than Ligand A (-1.627).
11. **hERG:** Ligand A (0.075) has a much lower hERG risk than Ligand B (0.876). This is a critical advantage for Ligand A, as hERG inhibition can lead to cardiotoxicity.
12. **Cl_mic:** Ligand A (19.696) has a lower microsomal clearance, indicating better metabolic stability, than Ligand B (65.578).
13. **t1/2:** Ligand A (-28.555) has a negative in vitro half-life, which is concerning. Ligand B (0.486) is also very low.
14. **Pgp:** Ligand A (0.004) has a much lower P-gp efflux liability than Ligand B (0.743). This is favorable for bioavailability.
15. **Affinity:** Ligand A (-7.3) has a slightly better binding affinity than Ligand B (-6). However, the difference is relatively small.
**GPCR-specific priorities:** For ADRB2 (a cardiovascular GPCR), logP, TPSA, Pgp, and affinity are important. Ligand B excels in logP and TPSA. Ligand A has a slight edge in affinity and a significant advantage in hERG and Pgp.
**Overall Assessment:**
Ligand B has better physicochemical properties (logP, TPSA) which are important for GPCRs. However, the significantly higher hERG risk and Pgp efflux liability of Ligand B are major concerns. Ligand A, despite its lower logP and poor Caco-2/solubility, has a much more favorable safety profile (hERG) and better metabolic stability (Cl_mic). The slightly better affinity of Ligand A also contributes. Given the cardiovascular context, minimizing cardiotoxicity (hERG) is paramount.
Therefore, I would choose Ligand A.
Output:
1
2025-04-17 19:43:15,077 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, key priorities are logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB.
Let's compare the ligands property by property:
1. **MW:** Both ligands (344.371 and 348.443 Da) are within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (99.51) is slightly higher than Ligand B (89.87). Both are acceptable, but B is preferable as it's closer to the <140 threshold for good absorption.
3. **logP:** Ligand B (2.293) is much better than Ligand A (0.507). A logP of 0.507 is quite low and could lead to poor membrane permeability. Ligand B falls nicely within the 1-3 optimal range.
4. **HBD/HBA:** Ligand A has 1 HBD and 5 HBA, while Ligand B has 3 HBD and 4 HBA. Both are acceptable within the guidelines.
5. **QED:** Ligand A (0.874) has a better QED score than Ligand B (0.705), indicating better overall drug-likeness.
6. **DILI:** Ligand B (11.128) has a significantly lower DILI risk than Ligand A (63.164). This is a major advantage for Ligand B.
7. **BBB:** Both have similar BBB penetration (Ligand A: 51.415, Ligand B: 50.872). BBB isn't a huge priority for a cardiovascular target.
8. **Caco-2:** Both have negative Caco-2 values (-5.043 and -5.013), which is unusual and suggests poor permeability based on this metric.
9. **Solubility:** Ligand A (-1.552) has better aqueous solubility than Ligand B (-3.285).
10. **hERG:** Ligand A (0.152) has a lower hERG risk than Ligand B (0.397).
11. **Cl_mic:** Ligand A (5.585) has significantly lower microsomal clearance than Ligand B (48.637), indicating better metabolic stability.
12. **t1/2:** Ligand B (-14.982) has a much longer in vitro half-life than Ligand A (-5.813). This is a significant advantage.
13. **Pgp:** Ligand A (0.031) has lower P-gp efflux liability than Ligand B (0.014), which is favorable.
14. **Binding Affinity:** Ligand A (-6.7 kcal/mol) has a slightly better binding affinity than Ligand B (-6.4 kcal/mol), but the difference is small (0.3 kcal/mol).
**Overall Assessment:**
While Ligand A has a slightly better binding affinity and QED, Ligand B has a much better logP, significantly lower DILI risk, and a substantially longer half-life. The poor logP of Ligand A is a major concern for permeability and oral bioavailability. The lower DILI risk of Ligand B is also a critical advantage. The improved half-life of Ligand B is also a strong positive. Considering the GPCR-specific priorities and the overall balance of properties, Ligand B is the more promising candidate.
**Output:**
0
2025-04-17 19:43:15,077 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (352.479) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (75.71) is significantly better than Ligand A (99.33). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (A: 1.287, B: 1.556), falling within the optimal 1-3 range.
4. **HBD:** Ligand B (1) is better than Ligand A (4). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand B (5) is better than Ligand A (3). Fewer HBAs generally improve permeability.
6. **QED:** Ligand B (0.81) is significantly better than Ligand A (0.446), indicating a more drug-like profile.
7. **DILI:** Ligand A (18.108) has a much lower DILI risk than Ligand B (49.632), a critical advantage.
8. **BBB:** Both are reasonable, but Ligand A (74.37) is slightly better than Ligand B (69.911). While not a primary concern for a cardiovascular target, it's a slight positive.
9. **Caco-2:** Both are negative, indicating poor permeability. This is a concern for both.
10. **Solubility:** Both are negative, indicating poor solubility. This is a concern for both.
11. **hERG:** Ligand A (0.406) has a lower hERG risk than Ligand B (0.237), which is a significant advantage.
12. **Cl_mic:** Ligand A (22.979) has a much lower microsomal clearance than Ligand B (58.637), suggesting better metabolic stability.
13. **t1/2:** Ligand A (6.621) has a longer in vitro half-life than Ligand B (1.176), which is desirable.
14. **Pgp:** Ligand A (0.019) has a much lower P-gp efflux liability than Ligand B (0.158), which is favorable for oral bioavailability.
15. **Affinity:** Ligand B (-4.6) has slightly better binding affinity than Ligand A (-3.9), a difference of 0.7 kcal/mol.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand B has slightly better logP and affinity, and lower TPSA. However, Ligand A excels in crucial ADME properties: DILI, hERG, Cl_mic, t1/2, and Pgp. The difference in affinity (0.7 kcal/mol) is not substantial enough to outweigh the significant advantages of Ligand A in terms of safety (DILI, hERG) and pharmacokinetic properties (Cl_mic, t1/2, Pgp).
**Conclusion:**
Considering the balance of potency, safety, and ADME properties, Ligand A is the more promising drug candidate.
Output:
1
2025-04-17 19:43:15,078 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [349.391, 129.88 , 0.002, 3. , 5. , 0.639, 36.293, 57.193, -5.702, -2.379, 0.138, 10.483, -6.483, 0.037, -7.2 ]
**Ligand B:** [339.443, 64.86 , 3.244, 1. , 6. , 0.926, 48.313, 82.513, -4.851, -4.233, 0.361, 52.256, -7.68 , 0.397, -7.7 ]
Here's a breakdown, prioritizing GPCR-relevant parameters:
1. **Molecular Weight:** Both are within the ideal 200-500 Da range. Ligand B (339.443) is slightly lower, which is generally favorable.
2. **TPSA:** Ligand A (129.88) is borderline, but acceptable for a non-CNS GPCR target. Ligand B (64.86) is excellent, well below the 140 threshold and suggesting good permeability.
3. **logP:** Ligand A (0.002) is *very* low, a significant concern. It suggests poor membrane permeability and potential bioavailability issues. Ligand B (3.244) is optimal.
4. **H-Bond Donors/Acceptors:** Ligand A (3/5) and Ligand B (1/6) are both reasonable.
5. **QED:** Ligand B (0.926) is significantly better than Ligand A (0.639), indicating a more drug-like profile.
6. **DILI:** Ligand A (36.293) has a lower DILI risk than Ligand B (48.313), which is positive.
7. **BBB:** Both are relatively low, which is fine for a cardiovascular target. Ligand B (82.513) is better than Ligand A (57.193) but not a major factor here.
8. **Caco-2:** Ligand A (-5.702) is very poor, consistent with its low logP. Ligand B (-4.851) is better, but still not great.
9. **Solubility:** Ligand A (-2.379) is poor. Ligand B (-4.233) is also poor.
10. **hERG:** Ligand A (0.138) is very low risk, excellent. Ligand B (0.361) is also low risk.
11. **Microsomal Clearance:** Ligand A (10.483) is lower (better) than Ligand B (52.256), suggesting better metabolic stability.
12. **In vitro Half-Life:** Ligand B (-7.68) has a longer half-life than Ligand A (-6.483).
13. **P-gp Efflux:** Ligand A (0.037) is very low, indicating minimal efflux. Ligand B (0.397) is higher, but still acceptable.
14. **Binding Affinity:** Ligand B (-7.7) is slightly better than Ligand A (-7.2), but the difference is not huge.
**Overall Assessment:**
Ligand A suffers from a critically low logP, which will severely impact its permeability and bioavailability. While it has a lower DILI risk and better metabolic stability, these advantages are outweighed by the permeability issue. Ligand B, while not perfect, has a much more favorable logP, better QED, and a slightly better binding affinity. The solubility is poor for both, but can be addressed with formulation strategies.
Therefore, I recommend **Ligand B**.
0
2025-04-17 19:43:15,078 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (360.401 and 374.453 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (81.08) is slightly higher than Ligand B (78.43), but both are well below the 140 threshold for good oral absorption, and acceptable for a cardiovascular GPCR.
3. **logP:** Ligand B (2.598) is within the optimal 1-3 range, while Ligand A (0.265) is quite low. This is a significant negative for Ligand A, as it may struggle with membrane permeability.
4. **HBD:** Ligand A (2) and Ligand B (3) are both acceptable, below the 5 threshold.
5. **HBA:** Both ligands have 4 HBA, well within the acceptable limit of 10.
6. **QED:** Ligand A (0.757) has a better QED score than Ligand B (0.621), indicating a more drug-like profile.
7. **DILI:** Ligand A (20.202) has a much lower DILI risk than Ligand B (36.06). This is a crucial advantage for Ligand A.
8. **BBB:** Both ligands have relatively low BBB penetration (44.746 and 48.003 respectively). Since ADRB2 is a cardiovascular target, BBB penetration isn't a primary concern, but it's not a positive for either.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.001 and -5.681), which is unusual and suggests poor permeability. However, the values are similar.
10. **Solubility:** Ligand A (-1.041) has better solubility than Ligand B (-3.35). This is a positive for Ligand A.
11. **hERG:** Ligand A (0.263) has a much lower hERG risk than Ligand B (0.464). This is a significant advantage for Ligand A, as it reduces the risk of cardiotoxicity.
12. **Cl_mic:** Ligand A (-8.695) has a much lower (better) microsomal clearance than Ligand B (89.06). This indicates better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (-1.194) has a slightly better (less negative) in vitro half-life than Ligand B (-13.638).
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.049 and 0.083).
15. **Binding Affinity:** Ligand B (-7.1) has a slightly better binding affinity than Ligand A (-6.7), a 0.4 kcal/mol difference. While affinity is important, the other factors are more concerning.
**GPCR-Specific Priorities:**
For a cardiovascular GPCR like ADRB2, logP, TPSA, and affinity are key. Ligand B has a better logP and slightly better affinity. However, Ligand A excels in safety parameters (DILI, hERG) and metabolic stability (Cl_mic), and has better solubility. The low logP of Ligand A is a significant concern, but the substantial improvements in safety and metabolic stability outweigh the modest affinity difference, especially given the similar Caco-2 values.
**Conclusion:**
Considering the balance of properties, particularly the significantly better safety profile and metabolic stability of Ligand A, I believe it is the more promising drug candidate.
Output:
1
2025-04-17 19:43:15,078 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (379.5) is slightly higher than Ligand B (338.5), but both are acceptable.
**2. TPSA:** Ligand A (88.2) is better than Ligand B (49.4). While both are below the 140 threshold for oral absorption, lower TPSA is generally preferred for GPCR ligands as it can aid membrane permeability.
**3. logP:** Both ligands have good logP values (A: 2.36, B: 3.61), falling within the optimal 1-3 range. Ligand B is slightly higher, which *could* indicate potential off-target interactions, but isn't a major concern at this level.
**4. H-Bond Donors:** Ligand A (2) and Ligand B (1) are both within the acceptable limit of 5.
**5. H-Bond Acceptors:** Ligand A (5) and Ligand B (2) are both within the acceptable limit of 10.
**6. QED:** Both ligands have similar, good QED values (A: 0.835, B: 0.834), indicating good drug-like properties.
**7. DILI:** Ligand A (82.4) has a significantly higher DILI risk than Ligand B (32.8). This is a major concern, as a lower DILI risk is crucial for drug development.
**8. BBB:** Ligand B (87.9) has a much higher BBB penetration percentile than Ligand A (64.8). While ADRB2 is a cardiovascular target and CNS penetration isn't *essential*, some level of BBB penetration can be beneficial for understanding off-target effects and potential systemic interactions.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the values are similar (-4.924 for A, -4.504 for B).
**10. Aqueous Solubility:** Both ligands have negative solubility values, which is also unusual and suggests poor solubility. Again, the values are similar (-3.721 for A, -3.913 for B).
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (A: 0.323, B: 0.405).
**12. Microsomal Clearance:** Ligand B (50.1) has slightly higher microsomal clearance than Ligand A (45.6), indicating potentially lower metabolic stability.
**13. In vitro Half-Life:** Ligand A (28.96) has a significantly longer in vitro half-life than Ligand B (-5.15). This is a substantial advantage, as it suggests less frequent dosing may be possible.
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (A: 0.48, B: 0.201).
**15. Binding Affinity:** Ligand A (-7.5) has a stronger binding affinity than Ligand B (-6.7). This is a 0.8 kcal/mol difference, which is significant and can outweigh some ADME drawbacks.
**Overall Assessment:**
The key differentiating factors are DILI risk, BBB penetration, and in vitro half-life. Ligand B has a much lower DILI risk, which is a critical safety parameter. Ligand B also exhibits better BBB penetration. However, Ligand A has a significantly longer half-life and stronger binding affinity. Considering the GPCR-specific priorities (logP, TPSA, affinity) and the importance of minimizing toxicity, the lower DILI risk of Ligand B is a decisive factor. While the affinity difference is notable, the safety profile is paramount.
Output:
0
2025-04-17 19:43:15,078 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (352.469 Da and 348.462 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (24.5) is significantly better than Ligand B (49.41). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary goal, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (4.172) is slightly higher than Ligand B (2.978). Both are within the acceptable range (1-3), but Ligand A is pushing the upper limit.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 3 HBA, while Ligand B has 2. Both are acceptable.
6. **QED:** Both ligands have very similar QED scores (0.797 and 0.794), indicating good drug-likeness.
7. **DILI:** Ligand A (8.181) has a much lower DILI risk than Ligand B (30.71). This is a significant advantage for Ligand A.
8. **BBB:** Both have high BBB penetration (88.833 and 88.019), but this is less critical for a cardiovascular target.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-2.548) has slightly better solubility than Ligand B (-4.035), though both are poor.
11. **hERG:** Ligand A (0.94) has a slightly higher hERG risk than Ligand B (0.506), but both are relatively low.
12. **Cl_mic:** Ligand B (56.58) has a significantly higher microsomal clearance than Ligand A (2.501). This means Ligand A is much more metabolically stable.
13. **t1/2:** Ligand B (-6.96) has a longer in vitro half-life than Ligand A (1.286). This is a positive for Ligand B, but the difference may not be substantial enough to outweigh other factors.
14. **Pgp:** Ligand A (0.183) has lower P-gp efflux than Ligand B (0.307). This is favorable for absorption.
15. **Binding Affinity:** Ligand B (-7.5) has a stronger binding affinity than Ligand A (-5.7). This is a 1.8 kcal/mol difference, which is substantial and a major advantage for Ligand B.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand B has better affinity and a more optimal logP. However, Ligand A has significantly better DILI, Cl_mic, and Pgp properties, and a much lower TPSA. The poor Caco-2 values for both are concerning, but the superior metabolic stability and safety profile of Ligand A, combined with its lower TPSA, make it a more promising starting point for optimization. The affinity difference, while significant, can potentially be addressed through medicinal chemistry efforts.
**Output:**
1
2025-04-17 19:43:15,078 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (353.329 Da and 351.422 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (81.39) is higher than Ligand B (65.64). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is generally preferred for absorption. Ligand B has a slight advantage.
3. **logP:** Ligand A (1.416) and Ligand B (2.033) are both within the optimal 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Both ligands have 1 HBD, which is within the acceptable limit of 5.
5. **HBA:** Ligand A has 6 HBAs, while Ligand B has 3. Ligand B has a clear advantage here, as fewer HBAs generally correlate with better permeability.
6. **QED:** Both ligands have good QED scores (0.885 and 0.906), indicating good drug-like properties. No significant difference.
7. **DILI:** Ligand A (90.733) has a significantly higher DILI risk than Ligand B (42.458). This is a major concern for Ligand A.
8. **BBB:** Ligand A (68.205) and Ligand B (78.48) are both reasonably good, but Ligand B is better. While ADRB2 isn't a CNS target, some off-target CNS effects are possible, and higher BBB is generally preferable.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.528 and -4.514). These values are unusual and suggest poor permeability. However, the values are very close, so this isn't a deciding factor.
10. **Solubility:** Both ligands have negative solubility values (-3.084 and -2.34). These values are also unusual and suggest poor solubility. Ligand B is slightly better.
11. **hERG:** Ligand A (0.141) has a lower hERG risk than Ligand B (0.537). This is a positive for Ligand A.
12. **Cl_mic:** Ligand A (-7.211) has much lower microsomal clearance than Ligand B (17.879), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (-2.726) and Ligand B (-2.381) have negative half-life values, which is unusual. This likely indicates rapid metabolism. Ligand B is slightly better.
14. **Pgp:** Ligand A (0.032) has much lower P-gp efflux liability than Ligand B (0.122), which is a positive for Ligand A.
15. **Binding Affinity:** Ligand B (-6.6) has a slightly better binding affinity than Ligand A (-6.3). While the difference is small (0.3 kcal/mol), it's still a factor.
**Overall Assessment:**
Ligand A has advantages in metabolic stability (Cl_mic), P-gp efflux, and hERG risk. However, its significantly higher DILI risk is a major red flag. Ligand B, while having slightly weaker affinity, has a much better safety profile (lower DILI) and better permeability characteristics (lower TPSA, fewer HBAs). The slight improvement in binding affinity of Ligand B is likely outweighed by the substantial safety concerns with Ligand A. Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand B is the more promising candidate.
Output:
0
2025-04-17 19:43:15,079 - INFO - Here's a step-by-step comparison of Ligand A and Ligand B, followed by my final decision:
**1. Molecular Weight (MW):**
* Ligand A: 412.219 Da - Within the ideal range (200-500 Da).
* Ligand B: 351.407 Da - Also within the ideal range.
* *Comment:* Both are good.
**2. Topological Polar Surface Area (TPSA):**
* Ligand A: 106.1 - Acceptable for oral absorption (<140).
* Ligand B: 107.77 - Acceptable for oral absorption (<140).
* *Comment:* Both are good.
**3. Lipophilicity (logP):**
* Ligand A: 1.949 - Optimal (1-3).
* Ligand B: -1.576 - Below optimal (<1). May have permeability issues.
* *Comment:* Ligand A is significantly better here.
**4. H-Bond Donors (HBD):**
* Ligand A: 2 - Good (<=5).
* Ligand B: 2 - Good (<=5).
* *Comment:* Both are good.
**5. H-Bond Acceptors (HBA):**
* Ligand A: 6 - Good (<=10).
* Ligand B: 7 - Good (<=10).
* *Comment:* Both are good.
**6. QED:**
* Ligand A: 0.555 - Good (>=0.5).
* Ligand B: 0.614 - Good (>=0.5).
* *Comment:* Both are good, B slightly better.
**7. DILI:**
* Ligand A: 81.776 - High risk (>60).
* Ligand B: 30.361 - Low risk (<40).
* *Comment:* Ligand B is significantly better.
**8. BBB:**
* Ligand A: 69.678 - Moderate.
* Ligand B: 21.287 - Low.
* *Comment:* ADRB2 is a cardiovascular target, so BBB penetration is not a high priority. Ligand A is better, but neither is particularly strong.
**9. Caco-2 Permeability:**
* Ligand A: -4.944 - Poor permeability.
* Ligand B: -5.347 - Poor permeability.
* *Comment:* Both are poor, but similar.
**10. Aqueous Solubility:**
* Ligand A: -3.059 - Poor solubility.
* Ligand B: 0.048 - Poor solubility.
* *Comment:* Both are poor, but B is slightly better.
**11. hERG Inhibition:**
* Ligand A: 0.095 - Low risk.
* Ligand B: 0.073 - Low risk.
* *Comment:* Both are good.
**12. Microsomal Clearance:**
* Ligand A: 82.006 - High clearance (poor metabolic stability).
* Ligand B: -27.38 - Low clearance (good metabolic stability).
* *Comment:* Ligand B is significantly better.
**13. In vitro Half-Life:**
* Ligand A: 26.51 - Moderate.
* Ligand B: 6.182 - Low.
* *Comment:* Ligand A is better.
**14. P-gp Efflux:**
* Ligand A: 0.022 - Low efflux.
* Ligand B: 0.005 - Low efflux.
* *Comment:* Both are good.
**15. Binding Affinity:**
* Ligand A: -6.3 kcal/mol
* Ligand B: -6.5 kcal/mol
* *Comment:* Ligand B is slightly better, but the difference is small.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity) and the general guidelines, Ligand B is the more promising candidate. While Ligand A has a slightly better half-life and BBB, Ligand B excels in crucial areas: significantly lower DILI risk, better metabolic stability (lower Cl_mic), and a slightly better binding affinity. The poor logP of Ligand A is a major concern, potentially leading to poor absorption. The DILI risk of Ligand A is also a significant drawback.
Output:
0
2025-04-17 19:43:15,079 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (354.45 & 348.49 Da) fall comfortably within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (85.89) is higher than Ligand B (58.64). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is generally preferred for absorption. Ligand B is better here.
3. **logP:** Ligand B (2.511) is closer to the optimal 1-3 range than Ligand A (0.905). Ligand A is a bit low, potentially hindering membrane permeability. Ligand B is better.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable, below the threshold of 5. Ligand B is slightly better.
5. **HBA:** Ligand A (5) and Ligand B (3) are both acceptable, below the threshold of 10. Ligand B is better.
6. **QED:** Both ligands have good QED scores (0.677 and 0.777 respectively), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand B (11.13) has a significantly lower DILI risk than Ligand A (22.84). This is a major advantage for Ligand B.
8. **BBB:** Ligand B (79.53) has a much higher BBB penetration score than Ligand A (49.44). While ADRB2 isn't strictly a CNS target, some CNS exposure can occur, and higher BBB is generally favorable. Ligand B is better.
9. **Caco-2:** Ligand A (-5.204) and Ligand B (-4.553) both have negative values, which is unusual and suggests poor permeability. However, the scale isn't specified, so it's hard to interpret.
10. **Solubility:** Ligand A (-1.442) and Ligand B (-2.448) both have negative solubility values, indicating poor solubility. This is a concern for both.
11. **hERG:** Both ligands have low hERG inhibition liability (0.129 and 0.282), which is good. No clear advantage.
12. **Cl_mic:** Ligand A (20.46) has a lower microsomal clearance than Ligand B (33.95), suggesting better metabolic stability. Ligand A is better.
13. **t1/2:** Ligand A (26.54) has a longer in vitro half-life than Ligand B (-3.28). This is a significant advantage for Ligand A.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.036 and 0.062). No clear advantage.
15. **Binding Affinity:** Ligand A (-7.7) has a slightly better binding affinity than Ligand B (-6.8). This is a 0.9 kcal/mol difference, which is substantial.
**Overall Assessment:**
Ligand A has a better binding affinity and metabolic stability (lower Cl_mic, longer t1/2). However, Ligand B excels in several critical ADME properties: lower DILI risk, better logP, lower TPSA, higher BBB penetration, and a better QED score. The binding affinity difference, while notable, can potentially be optimized further in later stages of drug development. The superior ADME profile of Ligand B, particularly the lower DILI risk, makes it a more promising starting point for a drug candidate targeting ADRB2.
Output:
0
2025-04-17 19:43:15,079 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [353.423, 119.64 , -1.063, 4. , 4. , 0.466, 22.761, 65.839, -5.442, -0.981, 0.03 , -23.696, 2.928, 0.001, -6.5 ]
**Ligand B:** [346.479, 80.79 , 1.898, 2. , 7. , 0.725, 20.861, 53.625, -5.427, -1.605, 0.169, 11.737, 19.425, 0.071, -7.1 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (346.479) is slightly smaller, which could be a minor advantage for permeability.
2. **TPSA:** Ligand A (119.64) is better than Ligand B (80.79), being closer to the 140 cutoff. This is a positive for oral absorption.
3. **logP:** Ligand B (1.898) is within the optimal range (1-3), while Ligand A (-1.063) is below 1, which could hinder permeation. This is a significant negative for Ligand A.
4. **HBD:** Both are acceptable (Ligand A: 4, Ligand B: 2), within the limit of 5.
5. **HBA:** Ligand B (7) is better than Ligand A (4), being closer to the limit of 10.
6. **QED:** Ligand B (0.725) has a better QED score than Ligand A (0.466), indicating a more drug-like profile.
7. **DILI:** Both have low DILI risk (Ligand A: 22.761, Ligand B: 20.861), both well below the 40 threshold.
8. **BBB:** Ligand A (65.839) has a better BBB penetration percentile than Ligand B (53.625). While ADRB2 isn't strictly a CNS target, some CNS exposure can be beneficial or at least not detrimental depending on the desired therapeutic profile.
9. **Caco-2:** Both have poor Caco-2 permeability (-5.442 and -5.427).
10. **Solubility:** Both have poor solubility (-0.981 and -1.605).
11. **hERG:** Both have very low hERG risk (0.03 and 0.169).
12. **Cl_mic:** Ligand A (-23.696) has significantly lower (better) microsomal clearance than Ligand B (11.737), indicating better metabolic stability.
13. **t1/2:** Ligand B (19.425) has a much longer in vitro half-life than Ligand A (2.928), which is a significant advantage.
14. **Pgp:** Both have very low Pgp efflux (0.001 and 0.071).
15. **Affinity:** Ligand B (-7.1) has a stronger binding affinity than Ligand A (-6.5) by 0.6 kcal/mol. This is a substantial difference and a major factor.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP and affinity, while Ligand A has a better TPSA and BBB. However, the strong affinity of Ligand B and its better logP outweigh the advantages of Ligand A. The longer half-life of Ligand B is also a significant benefit.
**Conclusion:**
Despite Ligand A's slightly better TPSA and BBB, Ligand B is the more promising candidate due to its superior logP, QED, binding affinity, and in vitro half-life. The affinity difference is particularly important.
0
2025-04-17 19:43:15,079 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
We are targeting ADRB2, a GPCR. Therefore, the key properties to prioritize are logP, TPSA, Pgp efflux, BBB penetration, and binding affinity. Metabolic stability (Cl_mic, t1/2) and safety (DILI, hERG) are also important, but slightly less so than the first set.
Let's compare the ligands property by property:
1. **MW:** Both ligands (347.415 and 358.341 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (91.5) is better than Ligand B (103.01). Lower TPSA generally favors better absorption.
3. **logP:** Ligand A (0.995) is slightly better than Ligand B (0.225). Both are on the lower side of the optimal 1-3 range, but Ligand A is closer.
4. **HBD:** Ligand A (2) is better than Ligand B (3). Fewer HBDs are generally preferred for permeability.
5. **HBA:** Ligand A (4) is better than Ligand B (5). Fewer HBAs are generally preferred for permeability.
6. **QED:** Ligand A (0.751) is better than Ligand B (0.654). Higher QED indicates better drug-likeness.
7. **DILI:** Ligand B (56.883) is slightly better than Ligand A (54.75), but both are acceptable.
8. **BBB:** Ligand A (38.852) is better than Ligand B (31.834). While ADRB2 isn't necessarily a CNS target, some peripheral distribution is needed, and higher BBB penetration can indicate better overall permeability.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-4.873) is better than Ligand B (-4.975) but both are poor.
10. **Solubility:** Ligand A (-2.082) is better than Ligand B (-1.481). Higher solubility is generally preferred.
11. **hERG:** Ligand A (0.124) is significantly better than Ligand B (0.334). Lower hERG risk is crucial for cardiovascular targets.
12. **Cl_mic:** Ligand A (-11.934) is significantly better than Ligand B (5.916). Lower clearance indicates better metabolic stability.
13. **t1/2:** Ligand A (-21.404) is better than Ligand B (-11.589). Longer half-life is generally preferred.
14. **Pgp:** Ligand A (0.029) is significantly better than Ligand B (0.051). Lower Pgp efflux is desirable.
15. **Affinity:** Ligand B (-6.7) is slightly better than Ligand A (-6.2). This is a 0.5 kcal/mol difference, which is significant, but needs to be weighed against the other properties.
**Overall Assessment:**
While Ligand B has a slightly better binding affinity, Ligand A demonstrates superior ADME properties across the board, particularly in crucial areas like metabolic stability (Cl_mic, t1/2), hERG risk, Pgp efflux, and solubility. The difference in binding affinity (0.5 kcal/mol) is not substantial enough to outweigh the significant advantages Ligand A has in ADME and safety. The lower TPSA, HBD, and HBA of Ligand A also contribute to better predicted permeability.
**Output:**
1
2025-04-17 19:43:15,080 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (352.419 and 370.515 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (75.19) is slightly higher than Ligand B (67.87). Both are below the 140 A^2 threshold for good oral absorption, but closer to the 90 A^2 threshold for CNS targets. Ligand B is preferable.
3. **logP:** Ligand A (2.915) is within the optimal 1-3 range. Ligand B (1.288) is at the lower end, potentially hindering permeation. Ligand A is preferable.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Both ligands have 5 HBA, which is good.
6. **QED:** Both ligands have similar QED values (0.733 and 0.714), indicating good drug-likeness.
7. **DILI:** Ligand A (98.022) has a significantly higher DILI risk than Ligand B (30.438). This is a major concern for Ligand A. Ligand B is strongly preferable.
8. **BBB:** Ligand A (79.256) has better BBB penetration than Ligand B (67.623). While ADRB2 isn't strictly a CNS target, some CNS exposure can occur, and this is a slight advantage for Ligand A.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.932 and -4.977). This indicates very poor permeability. This is a significant issue for both.
10. **Solubility:** Ligand B (-2.707) has better solubility than Ligand A (-5.182). Solubility is important for bioavailability. Ligand B is preferable.
11. **hERG:** Ligand A (0.286) has a slightly lower hERG risk than Ligand B (0.419), which is good.
12. **Cl_mic:** Ligand A (50.366) has a higher microsomal clearance than Ligand B (40.279), meaning it's less metabolically stable. Ligand B is preferable.
13. **t1/2:** Ligand B (6.855) has a much longer in vitro half-life than Ligand A (58.444). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.231) has lower P-gp efflux than Ligand B (0.065), which is preferable.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.7 and -6.8 kcal/mol). The difference is negligible.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), and the general drug-like properties, Ligand B is the more promising candidate. While Ligand A has slightly better BBB penetration and Pgp efflux, the significantly lower DILI risk, better solubility, and longer half-life of Ligand B outweigh these minor advantages. The poor Caco-2 values for both are concerning, but the other ADME properties of Ligand B are more favorable. The DILI risk associated with Ligand A is a major red flag.
Output:
0
2025-04-17 19:43:15,080 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (340.43 and 386.95 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (60.25) is better than Ligand B (69.64). Both are below 140, but lower TPSA generally favors absorption.
3. **logP:** Both ligands have similar logP values (2.575 and 2.668), falling within the optimal 1-3 range.
4. **HBD:** Ligand A (0) is better than Ligand B (2). Fewer HBDs are generally preferred for better permeability.
5. **HBA:** Ligand A (6) is slightly higher than Ligand B (4), but both are within the acceptable limit of 10.
6. **QED:** Ligand A (0.783) is better than Ligand B (0.606), indicating a more drug-like profile.
7. **DILI:** Ligand A (44.591) is slightly higher than Ligand B (30.71), but both are well below the concerning threshold of 60. Ligand B is preferable here.
8. **BBB:** Ligand A (59.636) is significantly better than Ligand B (34.742). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be useful for understanding off-target effects and distribution.
9. **Caco-2:** Both ligands have very similar and poor Caco-2 permeability (-4.978 and -4.944). This is a concern for oral absorption for both.
10. **Solubility:** Ligand A (-2.288) is better than Ligand B (-3.279), indicating better aqueous solubility.
11. **hERG:** Both ligands have similar and low hERG inhibition risk (0.711 and 0.708).
12. **Cl_mic:** Ligand A (26.499) has a significantly lower microsomal clearance than Ligand B (60.305), suggesting better metabolic stability.
13. **t1/2:** Ligand B (20.979) has a much longer in vitro half-life than Ligand A (2.392). This is a significant advantage.
14. **Pgp:** Both ligands have similar and low P-gp efflux liability (0.268 and 0.212).
15. **Binding Affinity:** Ligand A (-6.9 kcal/mol) has a slightly better binding affinity than Ligand B (-5.9 kcal/mol). This difference is >1.5 kcal/mol, making it a significant factor.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Both ligands are good on logP and Pgp. Ligand A has a lower TPSA and better affinity, which are both favorable. The longer half-life of Ligand B is attractive, but the better affinity of Ligand A is a stronger driver, especially given the similar Caco-2 permeability.
**Overall Assessment:**
Ligand A demonstrates a better balance of properties, particularly with its superior affinity, lower TPSA, better QED, and lower microsomal clearance. While Ligand B has a longer half-life, the affinity difference is substantial enough to outweigh this benefit.
Output:
1
2025-04-17 19:43:15,080 - INFO - Batch 131 complete. Total preferences: 2096
2025-04-17 19:43:15,080 - INFO - Processing batch 132/512...
2025-04-17 19:44:02,396 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
We are targeting ADRB2, a GPCR, so the priorities are logP, Pgp, TPSA, affinity, and BBB. Let's break down each ligand's properties:
**Ligand A:**
* **MW:** 354.519 Da - Acceptable.
* **TPSA:** 32.34 - Excellent, well below the 140 threshold.
* **logP:** 4.747 - Slightly high, could potentially cause solubility issues or off-target effects.
* **HBD:** 1 - Good.
* **HBA:** 3 - Good.
* **QED:** 0.76 - Excellent, very drug-like.
* **DILI:** 44.63 - Good, low risk.
* **BBB:** 93.602 - Excellent, high penetration potential.
* **Caco-2:** -4.999 - Very poor permeability. A major concern.
* **Solubility:** -4.577 - Very poor solubility. A major concern.
* **hERG:** 0.964 - Low risk.
* **Cl_mic:** 103.529 - Moderate clearance, not ideal but not terrible.
* **t1/2:** 50.768 - Good half-life.
* **Pgp:** 0.77 - Moderate efflux, could limit bioavailability.
* **Affinity:** -6.2 kcal/mol - Very good.
**Ligand B:**
* **MW:** 348.487 Da - Acceptable.
* **TPSA:** 49.85 - Good, still under the 140 threshold.
* **logP:** 2.629 - Optimal.
* **HBD:** 0 - Good.
* **HBA:** 3 - Good.
* **QED:** 0.665 - Good, drug-like.
* **DILI:** 34.781 - Excellent, very low risk.
* **BBB:** 79.721 - Good, reasonable penetration.
* **Caco-2:** -4.103 - Poor permeability, but better than Ligand A.
* **Solubility:** -2.809 - Poor solubility, but better than Ligand A.
* **hERG:** 0.513 - Low risk.
* **Cl_mic:** 86.241 - Lower clearance, better metabolic stability.
* **t1/2:** 16.065 - Shorter half-life, less desirable.
* **Pgp:** 0.285 - Low efflux, better bioavailability.
* **Affinity:** -6.3 kcal/mol - Slightly better affinity than Ligand A.
**Comparison & Decision:**
Both ligands have issues with solubility and permeability. However, Ligand B has a significantly better logP, lower DILI risk, lower Pgp efflux, and slightly better affinity. While Ligand A has a better BBB score, the extremely poor Caco-2 and solubility of Ligand A are major drawbacks that are difficult to overcome. The slightly better affinity of Ligand B, combined with its superior ADME profile (particularly the lower Pgp efflux and better logP) outweighs the slightly lower BBB score.
Therefore, I prefer Ligand B.
**Output:**
0
2025-04-17 19:44:02,396 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, priorities are logP, TPSA, Pgp, affinity, and to a lesser extent, BBB.
* **Molecular Weight:** Both ligands (344.4 and 346.4 Da) are within the ideal 200-500 Da range.
* **TPSA:** Ligand A (114.85) is higher than Ligand B (78.87). Ligand B is significantly better, being well below the 140 threshold for oral absorption and more favorable for GPCRs.
* **logP:** Both ligands have good logP values (1.62 and 0.90), falling within the 1-3 range. Ligand B is slightly lower, which could be beneficial for solubility.
* **H-Bond Donors/Acceptors:** Both have acceptable HBD/HBA counts (A: 3/4, B: 2/4), well within the guidelines.
* **QED:** Both have good QED scores (A: 0.62, B: 0.79), indicating good drug-like properties. Ligand B is better.
* **DILI:** Both have acceptable DILI risk (A: 39.7, B: 47.3), below the 60 threshold.
* **BBB:** Ligand B (71.8) has a better BBB percentile than Ligand A (51.7), although BBB isn't a primary concern for a cardiovascular target.
* **Caco-2:** Ligand A (-5.24) is worse than Ligand B (-4.59).
* **Solubility:** Both have negative solubility values, indicating poor aqueous solubility. Ligand A is slightly worse (-3.07 vs -3.39).
* **hERG:** Both have low hERG risk (A: 0.46, B: 0.39).
* **Cl_mic:** Ligand A (-4.26) has a much lower (better) microsomal clearance than Ligand B (15.66). This suggests better metabolic stability for Ligand A.
* **t1/2:** Ligand A (-9.65) has a much longer in vitro half-life than Ligand B (-23.47).
* **Pgp:** Both have low Pgp efflux liability (A: 0.06, B: 0.07).
* **Binding Affinity:** Ligand A (-7.5 kcal/mol) has a slightly better binding affinity than Ligand B (-6.1 kcal/mol). This is a 1.4 kcal/mol difference, which is significant.
**Overall Assessment:**
Ligand A has a stronger binding affinity and better metabolic stability (lower Cl_mic, longer t1/2). However, Ligand B excels in TPSA and BBB penetration, and has a slightly better QED score. The difference in binding affinity (1.4 kcal/mol) is substantial enough to outweigh the slightly less favorable TPSA and BBB of Ligand A, especially considering this is a cardiovascular target where CNS penetration isn't critical. The improved metabolic stability of Ligand A is also a significant advantage.
**Output:**
1
2025-04-17 19:44:02,396 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (363.439 and 348.338 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (86.79) is significantly better than Ligand B (132.03). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold. Ligand B is approaching the upper limit.
3. **logP:** Both ligands have similar logP values (0.346 and 0.259), which are a bit low. Ideally, we want 1-3. This could potentially impact permeability, but isn't a dealbreaker.
4. **HBD:** Ligand A (1) is preferable to Ligand B (5). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is preferable to Ligand B (5). Fewer HBAs generally improve permeability.
6. **QED:** Ligand A (0.782) has a better QED score than Ligand B (0.541), indicating a more drug-like profile.
7. **DILI:** Ligand B (78.945) has a higher DILI risk than Ligand A (47.964). This is a significant concern, as we want to minimize liver toxicity.
8. **BBB:** Not a primary concern for a cardiovascular target, but Ligand A (82.474) has a higher BBB percentile than Ligand B (60.993).
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.014 and -5.224). These values are unusual and suggest poor permeability.
10. **Solubility:** Both ligands have negative solubility values (-3.332 and -3.687). These values are also unusual and suggest poor solubility.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.251 and 0.243). This is excellent.
12. **Cl_mic:** Ligand A (15.987) has a lower microsomal clearance than Ligand B (-5.518). Lower clearance indicates better metabolic stability, which is desirable.
13. **t1/2:** Ligand A (-8.239) has a more negative in vitro half-life than Ligand B (43.576). This is unusual, and suggests a shorter half-life.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.024 and 0.055). This is good.
15. **Binding Affinity:** Ligand B (-7.4 kcal/mol) has a slightly better binding affinity than Ligand A (-6.9 kcal/mol). This is a 0.5 kcal/mol difference, which is significant, but not overwhelming.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand A is the better candidate. While Ligand B has a slightly better binding affinity, Ligand A excels in several crucial ADME properties: TPSA, HBD, HBA, QED, DILI risk, and metabolic stability (Cl_mic). The negative Caco-2 and solubility values are concerning for both, but the superior overall profile of Ligand A makes it the more promising starting point for optimization. The lower DILI risk for Ligand A is a major advantage.
Output:
1
2025-04-17 19:44:02,397 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (348.422 and 350.383 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (58.44) is significantly better than Ligand B (139.85). For a GPCR, lower TPSA is generally preferred for better permeability. Ligand B is approaching the upper limit for good oral absorption (<=140), while A is well below.
**3. logP:** Ligand A (1.283) is within the optimal 1-3 range. Ligand B (-1.734) is below 1, which could indicate poor membrane permeability. This is a significant drawback for a GPCR ligand.
**4. H-Bond Donors:** Ligand A (0) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
**5. H-Bond Acceptors:** Ligand A (4) is better than Ligand B (9). Lower HBA counts are generally preferred for permeability.
**6. QED:** Ligand A (0.824) has a much better QED score than Ligand B (0.488), indicating a more drug-like profile.
**7. DILI:** Ligand A (23.187) has a significantly lower DILI risk than Ligand B (64.521). This is a crucial safety parameter.
**8. BBB:** Ligand A (85.459) has a much higher BBB penetration percentile than Ligand B (19.93). While ADRB2 isn't strictly a CNS target, some CNS exposure can occur, and higher BBB is rarely detrimental.
**9. Caco-2 Permeability:** Ligand A (-4.719) is better than Ligand B (-5.924). Both are negative, which is unusual and suggests poor permeability, but A is less negative.
**10. Aqueous Solubility:** Ligand A (-1.764) is better than Ligand B (-0.97). Both are negative, indicating poor solubility, but A is less negative.
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.283 and 0.031, respectively). No significant difference.
**12. Microsomal Clearance:** Ligand A (12.318) is higher than Ligand B (3.694), meaning it has faster clearance and lower metabolic stability. This is a negative for Ligand A.
**13. In vitro Half-Life:** Ligand B (17.636) has a much longer in vitro half-life than Ligand A (-9.797). This is a significant advantage for Ligand B.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.033 and 0.021, respectively). No significant difference.
**15. Binding Affinity:** Ligand B (-1.0 kcal/mol) has a slightly better binding affinity than Ligand A (-6.7 kcal/mol). However, the difference is not substantial enough to outweigh the many ADME advantages of Ligand A.
**Overall Assessment:**
Ligand A clearly outperforms Ligand B across most critical ADME properties (TPSA, logP, HBD, HBA, QED, DILI, BBB, solubility). While Ligand B has better metabolic stability and half-life, the poor logP and high TPSA are major concerns for a GPCR target. The superior drug-likeness and safety profile of Ligand A make it the more promising candidate despite the slightly lower metabolic stability.
Output:
1
2025-04-17 19:44:02,397 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (351.47 & 350.50 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (43.86) is significantly better than Ligand B (58.64). ADRB2 is a cardiovascular target, not CNS, but lower TPSA generally improves permeability.
3. **logP:** Ligand B (3.045) is slightly higher than Ligand A (1.526). While both are within the optimal 1-3 range, Ligand B is closer to the upper limit.
4. **HBD:** Ligand A (0) is preferable to Ligand B (1). Fewer HBDs generally improve permeability.
5. **HBA:** Both ligands have 3 HBA, which is acceptable.
6. **QED:** Both ligands have similar QED scores (0.729 and 0.732), indicating good drug-likeness.
7. **DILI:** Ligand A (13.57) has a much lower DILI risk than Ligand B (18.92). This is a significant advantage for Ligand A.
8. **BBB:** Not a primary concern for a cardiovascular target, but Ligand A (87.48) has a higher BBB percentile than Ligand B (78.52).
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.631 and -4.508). These values are unusual and suggest poor permeability. However, the difference is minimal.
10. **Solubility:** Ligand A (-1.574) is better than Ligand B (-2.308). Better solubility is generally desirable.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.538 and 0.246), which is excellent.
12. **Cl_mic:** Ligand A (15.46) has significantly lower microsomal clearance than Ligand B (66.41). This indicates better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (-0.55) has a slightly longer in vitro half-life than Ligand B (0.532).
14. **Pgp:** Both ligands have low Pgp efflux liability (0.107 and 0.166).
15. **Binding Affinity:** Both ligands have the same binding affinity (-6.1 kcal/mol).
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Ligand A has a better TPSA and logP, and similar Pgp and affinity. The significant advantages of Ligand A in DILI risk and metabolic stability (Cl_mic) further solidify its preference.
**Conclusion:**
Ligand A demonstrates a more favorable balance of properties, particularly regarding safety (DILI) and metabolic stability (Cl_mic), while maintaining comparable binding affinity.
Output:
1
2025-04-17 19:44:02,397 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
The target is ADRB2, a GPCR. Therefore, I will prioritize logP, TPSA, Pgp efflux, BBB penetration, and binding affinity. Metabolic stability (Cl_mic, t1/2) and safety (DILI, hERG) are also important.
**Ligand A:**
* **MW:** 348.491 Da - Good. Within the ideal range.
* **TPSA:** 47.1 - Excellent. Well below the 140 threshold for absorption.
* **logP:** 0.484 - Low. Below the optimal 1-3 range, potentially hindering permeation.
* **HBD:** 0 - Good. Low, which is favorable for permeability.
* **HBA:** 4 - Good. Within the acceptable range.
* **QED:** 0.628 - Good. Above the 0.5 threshold.
* **DILI:** 12.02 - Excellent. Very low risk.
* **BBB:** 62.699 - Moderate. Not ideal for a CNS target, but acceptable for a peripherally acting GPCR like ADRB2.
* **Caco-2:** -4.659 - Very poor. Indicates very low intestinal absorption.
* **Solubility:** -0.994 - Poor. Could pose formulation challenges.
* **hERG:** 0.515 - Low risk.
* **Cl_mic:** 31.387 - Moderate. Not ideal, but not excessively high.
* **t1/2:** 3.498 - Short. May require frequent dosing.
* **Pgp:** 0.014 - Very low efflux. Favorable.
* **Affinity:** -6.4 kcal/mol - Good.
**Ligand B:**
* **MW:** 366.487 Da - Good. Within the ideal range.
* **TPSA:** 91.4 - Moderate. Approaching the upper limit for good absorption, but still acceptable.
* **logP:** 1.583 - Good. Within the optimal range.
* **HBD:** 2 - Good.
* **HBA:** 5 - Good.
* **QED:** 0.764 - Good.
* **DILI:** 37.456 - Good. Low risk.
* **BBB:** 66.576 - Moderate. Similar to Ligand A, acceptable for a peripheral target.
* **Caco-2:** -5.176 - Very poor. Similar to Ligand A, indicates very low intestinal absorption.
* **Solubility:** -3.392 - Very poor. Significant formulation challenges.
* **hERG:** 0.348 - Low risk.
* **Cl_mic:** 35.017 - Moderate. Similar to Ligand A.
* **t1/2:** -11.985 - Very short. Highly unfavorable.
* **Pgp:** 0.028 - Very low efflux. Favorable.
* **Affinity:** -5.9 kcal/mol - Good.
**Comparison and Decision:**
Both ligands have poor Caco-2 permeability and solubility, which are significant drawbacks. However, Ligand A has a slightly better affinity (-6.4 vs -5.9 kcal/mol) and a much lower DILI risk (12.02 vs 37.456). Ligand B has a better logP, but the difference isn't substantial enough to overcome the other issues. The shorter half-life of Ligand B is also a concern.
Given the GPCR target class, the slightly better affinity and significantly lower DILI risk of Ligand A make it the more promising candidate, despite its lower logP and solubility issues. Solubility and permeability can be addressed with formulation strategies, but a higher DILI risk is harder to mitigate.
**Output:**
1
2025-04-17 19:44:02,397 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [352.475, 86.71, 1.529, 2, 4, 0.512, 34.548, 44.397, -4.681, -2.078, 0.174, 21.748, -46.339, 0.096, -6.9]
**Ligand B:** [343.329, 59.32, 3.834, 0, 4, 0.792, 65.529, 84.374, -3.846, -5.293, 0.71, 83.581, 12.758, 0.321, -7.4]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal 200-500 Da range. A (352.475) and B (343.329) are comparable.
2. **TPSA:** A (86.71) is slightly higher than B (59.32). B is better here, being closer to the <90 target for potential CNS penetration, though ADRB2 isn't necessarily a CNS target.
3. **logP:** A (1.529) is optimal. B (3.834) is approaching the upper limit, potentially hinting at solubility issues or off-target interactions.
4. **HBD:** A (2) is good. B (0) is also acceptable, but sometimes a donor can aid solubility.
5. **HBA:** Both A (4) and B (4) are within the acceptable range.
6. **QED:** B (0.792) is better than A (0.512), indicating a more drug-like profile.
7. **DILI:** A (34.548) is significantly better than B (65.529). This is a major advantage for A.
8. **BBB:** B (84.374) is much better than A (44.397). While not critical for ADRB2, it's a positive for B.
9. **Caco-2:** A (-4.681) is worse than B (-3.846), suggesting lower intestinal absorption for A.
10. **Solubility:** A (-2.078) is better than B (-5.293), which is important.
11. **hERG:** A (0.174) is much better than B (0.71), indicating lower cardiotoxicity risk.
12. **Cl_mic:** A (21.748) is much better than B (83.581), suggesting better metabolic stability for A.
13. **t1/2:** A (-46.339) is much better than B (12.758), indicating a longer half-life for A.
14. **Pgp:** A (0.096) is much better than B (0.321), meaning less efflux and better bioavailability for A.
15. **Affinity:** B (-7.4) is 0.5 kcal/mol better than A (-6.9). This is a significant difference, and a strong driver.
**Overall Assessment:**
Ligand B has a better QED, BBB penetration, and a notably stronger binding affinity. However, it suffers from a higher DILI risk, poorer metabolic stability (high Cl_mic), shorter half-life, and higher P-gp efflux. Ligand A has a much better safety profile (DILI, hERG), better metabolic stability, longer half-life, and lower P-gp efflux. The affinity difference is significant, but the ADME/Tox profile of Ligand A is far more favorable for a drug candidate. The improved ADME/Tox properties of Ligand A, particularly the DILI and metabolic stability, outweigh the affinity difference.
Therefore, I prefer Ligand A.
1
2025-04-17 19:44:02,397 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (367.511 Da) is slightly higher than Ligand B (341.371 Da), but both are acceptable.
2. **TPSA:** Ligand A (75.63) is better than Ligand B (120.91). ADRB2 is a cardiovascular target, so BBB isn't a primary concern, but lower TPSA generally correlates with better absorption. Ligand B is pushing the upper limit for good oral absorption.
3. **logP:** Both ligands have good logP values (A: 2.794, B: 1.419), falling within the optimal 1-3 range. Ligand A is slightly more lipophilic, which could be beneficial for membrane permeability.
4. **HBD:** Both have 2 HBD, which is within the acceptable limit of 5.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 6. Both are within the acceptable limit of 10, but Ligand A is preferable.
6. **QED:** Both ligands have good QED scores (A: 0.777, B: 0.819), indicating good drug-like properties.
7. **DILI:** Ligand A (44.591) has a significantly lower DILI risk than Ligand B (72.974). This is a major advantage for Ligand A.
8. **BBB:** Not a primary concern for a cardiovascular target. Ligand A (57.852) is slightly higher than Ligand B (47.964).
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.68) is slightly better than Ligand B (-5.05).
10. **Solubility:** Both have negative solubility values, which is also unusual and suggests poor solubility. Ligand A (-4.531) is slightly better than Ligand B (-3.683).
11. **hERG:** Ligand A (0.667) has a slightly higher hERG risk than Ligand B (0.112). This favors Ligand B.
12. **Cl_mic:** Ligand B (49.23) has a significantly lower microsomal clearance than Ligand A (104.238), indicating better metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand A (-28.25) has a negative in vitro half-life, which is concerning. Ligand B (0.648) is very short but positive.
14. **Pgp:** Ligand A (0.795) has a higher Pgp efflux liability than Ligand B (0.058). This favors Ligand B.
15. **Binding Affinity:** Ligand A (-6.9 kcal/mol) has a slightly better binding affinity than Ligand B (-5.2 kcal/mol). This is a 1.7 kcal/mol difference, which is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand A has a significantly better binding affinity and lower DILI risk, which are critical factors. While Ligand B has better metabolic stability and lower Pgp efflux, the affinity difference and DILI risk of Ligand A are more important for a GPCR target like ADRB2. The negative Caco-2 and solubility values are concerning for both, but the superior binding and safety profile of Ligand A make it the more promising candidate.
Output:
1
2025-04-17 19:44:02,397 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for the ADRB2, a cardiovascular GPCR. Therefore, key properties to prioritize are logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB (though less critical for a cardiovascular target).
Let's break down the comparison:
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (349.435) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (100.35) is better than Ligand B (127.59), falling comfortably under the 140 A^2 threshold for good absorption.
3. **logP:** Both are very low (A: 0.014, B: 0.047). This is a significant drawback for both, potentially hindering membrane permeability. However, the slight advantage to B is negligible.
4. **HBD/HBA:** Ligand A (2 HBD, 6 HBA) is slightly better than Ligand B (3 HBD, 5 HBA). Both are acceptable, but lower counts are generally preferred.
5. **QED:** Ligand A (0.754) has a significantly better QED score than Ligand B (0.465), indicating a more drug-like profile.
6. **DILI:** Both are good, with low DILI risk (A: 41.334, B: 40.287).
7. **BBB:** Both have relatively low BBB penetration (A: 43.001, B: 46.375), which isn't a major concern for a cardiovascular target.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability.
9. **Solubility:** Both have negative solubility values, which is also unusual and suggests poor solubility.
10. **hERG:** Both have very low hERG inhibition risk (A: 0.024, B: 0.068).
11. **Cl_mic:** Ligand A (3.986) has significantly lower microsomal clearance than Ligand B (33.472), suggesting better metabolic stability.
12. **t1/2:** Ligand A (8.491) has a positive in vitro half-life, while Ligand B (-32.654) has a negative value, which is concerning.
13. **Pgp:** Both have low Pgp efflux liability (A: 0.013, B: 0.027).
14. **Binding Affinity:** Ligand B (-6.3 kcal/mol) has a slightly better binding affinity than Ligand A (-6.1 kcal/mol), but the difference is small.
**Overall Assessment:**
Despite the similar binding affinities, Ligand A is the more promising candidate. Its superior QED score, lower microsomal clearance, positive in vitro half-life, and lower TPSA outweigh the slightly better affinity of Ligand B. The low logP values are a concern for both, but the other ADME properties of Ligand A are more favorable. The negative Caco-2 and solubility values are concerning for both, and would need to be addressed in further optimization.
**Output:**
1
2025-04-17 19:44:02,398 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Ligand A:**
* **MW:** 372.877 Da - Good, within the ideal range.
* **TPSA:** 50.27 - Good, below the 140 threshold for absorption.
* **logP:** 3.944 - Slightly high, approaching the upper limit, but acceptable.
* **HBD:** 0 - Low, good for permeability.
* **HBA:** 3 - Good, within the acceptable range.
* **QED:** 0.64 - Good, indicates a drug-like profile.
* **DILI:** 78.054 - Concerningly high, indicating a significant risk of liver injury.
* **BBB:** 65.568 - Moderate, not ideal for a CNS target, but ADRB2 is primarily cardiovascular so less critical.
* **Caco-2:** -5 - Very poor permeability.
* **Solubility:** -5.787 - Very poor solubility.
* **hERG:** 0.629 - Low risk, good.
* **Cl_mic:** 86.587 - High, indicating rapid metabolism and low stability.
* **t1/2:** 7.431 - Moderate half-life.
* **Pgp:** 0.421 - Low efflux, good.
* **Affinity:** -6.9 kcal/mol - Very good binding affinity.
**Ligand B:**
* **MW:** 385.511 Da - Good, within the ideal range.
* **TPSA:** 99.6 - Higher, but still potentially acceptable, though approaching the upper limit for good absorption.
* **logP:** 0.819 - Low, potentially hindering permeation.
* **HBD:** 2 - Good, within the acceptable range.
* **HBA:** 6 - Good, within the acceptable range.
* **QED:** 0.782 - Good, indicates a drug-like profile.
* **DILI:** 55.913 - Moderate, acceptable risk.
* **BBB:** 47.344 - Low, not relevant for a cardiovascular target.
* **Caco-2:** -5.349 - Very poor permeability.
* **Solubility:** -3.15 - Poor solubility.
* **hERG:** 0.295 - Very low risk, excellent.
* **Cl_mic:** -9.442 - Very low, indicating excellent metabolic stability.
* **t1/2:** 4.13 - Short half-life.
* **Pgp:** 0.158 - Low efflux, good.
* **Affinity:** -7.4 kcal/mol - Excellent binding affinity, 0.5 kcal/mol better than Ligand A.
**Comparison & Decision:**
Both ligands have significant issues with Caco-2 permeability and aqueous solubility. However, Ligand B has a substantially better binding affinity (-7.4 vs -6.9 kcal/mol), significantly lower DILI risk (55.9 vs 78.1), and much better metabolic stability (Cl_mic of -9.442 vs 86.587). While Ligand B's logP is lower, and TPSA is higher, the superior affinity and safety profile outweigh these drawbacks, especially for a cardiovascular target where BBB penetration is not a primary concern. The improved metabolic stability is a major advantage.
Therefore, I prefer Ligand B.
Output:
0
2025-04-17 19:44:02,398 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [359.392, 61.44, 1.231, 2, 3, 0.702, 31.136, 74.254, -4.753, -2.455, 0.152, 5.765, -15.834, 0.005, -5.7]**
**Ligand B: [340.475, 65.97, 3.549, 2, 6, 0.868, 63.513, 77.937, -4.903, -4.69, 0.81, 81.865, 33.362, 0.238, -6.1]**
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand B (340.475) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are reasonably good (61.44 and 65.97). Both are below 140, suggesting reasonable oral absorption.
3. **logP:** Ligand A (1.231) is better than Ligand B (3.549). Ligand B is approaching the upper limit where solubility issues could arise.
4. **H-Bond Donors:** Both have 2 HBD, which is good.
5. **H-Bond Acceptors:** Ligand A has 3 HBA, while Ligand B has 6. Ligand A is preferable here, as fewer HBA generally improves permeability.
6. **QED:** Both have acceptable QED values (0.702 and 0.868), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (31.136) has a significantly lower DILI risk than Ligand B (63.513). This is a major advantage for Ligand A.
8. **BBB:** Both have good BBB penetration (74.254 and 77.937). This is important for GPCRs, but less critical for ADRB2 specifically as it's primarily a cardiovascular target.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual. Assuming these are logP-scaled permeability values, lower (more negative) values indicate *lower* permeability. Ligand A (-4.753) is slightly better than Ligand B (-4.903).
10. **Aqueous Solubility:** Ligand A (-2.455) is better than Ligand B (-4.69).
11. **hERG:** Both have very low hERG inhibition risk (0.152 and 0.81).
12. **Cl_mic:** Ligand A (5.765) has a much lower microsomal clearance than Ligand B (81.865), indicating better metabolic stability.
13. **t1/2:** Ligand B (33.362) has a significantly longer in vitro half-life than Ligand A (-15.834). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.005) has much lower P-gp efflux than Ligand B (0.238).
15. **Binding Affinity:** Ligand B (-6.1) has a slightly better binding affinity than Ligand A (-5.7). However, the difference is less than 1.5 kcal/mol.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity) and the general guidelines, Ligand A is the stronger candidate. While Ligand B has a slightly better affinity and half-life, Ligand A excels in critical areas like DILI risk, metabolic stability (Cl_mic), solubility, and P-gp efflux. The lower DILI risk and better metabolic stability are particularly important for a cardiovascular drug. The slightly better logP and fewer HBA also contribute to better predicted permeability.
Output:
1
2025-04-17 19:44:02,398 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (356.438 and 349.406 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (78.87) is better than Ligand B (80.32). Both are below 140, but closer to 90 is preferred for GPCRs, and A is closer.
3. **logP:** Both ligands (1.187 and 1.518) are within the optimal 1-3 range. Ligand B is slightly higher, which could be a minor advantage for membrane permeability, but not substantial.
4. **HBD:** Both ligands have 2 HBD, which is within the acceptable limit of <=5.
5. **HBA:** Both ligands have 4 HBA, also within the acceptable limit of <=10.
6. **QED:** Ligand B (0.816) has a significantly better QED score than Ligand A (0.64), indicating a more drug-like profile. This is a notable advantage for B.
7. **DILI:** Ligand A (13.3) has a much lower DILI risk than Ligand B (44.397). This is a significant advantage for A, as lower DILI is crucial.
8. **BBB:** Ligand B (87.553) has a substantially higher BBB penetration score than Ligand A (72.354). Given ADRB2's cardiovascular involvement, CNS penetration isn't a *primary* concern, but it's still a positive attribute.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.694 and -4.779), which is unusual and suggests poor permeability. This is a significant drawback for both.
10. **Solubility:** Ligand A (-1.796) has slightly better solubility than Ligand B (-2.113), though both are poor.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.279 and 0.341), which is excellent.
12. **Cl_mic:** Ligand B (16.96) has a lower microsomal clearance than Ligand A (23.301), indicating better metabolic stability. This is a positive for B.
13. **t1/2:** Ligand A (-11.294) has a much longer in vitro half-life than Ligand B (-1.93). This is a significant advantage for A.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.047 and 0.044).
15. **Binding Affinity:** Ligand A (-7.3) has a slightly better binding affinity than Ligand B (-6.7). While both are good, the 0.6 kcal/mol difference is meaningful.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), and the general drug-like properties, the decision is complex. Ligand B has a better QED, BBB, and Cl_mic. However, Ligand A has a significantly lower DILI risk, a longer half-life, and slightly better binding affinity. The poor Caco-2 permeability is a major concern for both, but can potentially be addressed through formulation strategies.
The lower DILI risk of Ligand A is a critical factor, especially for a cardiovascular target where liver toxicity is a major concern. The slightly better affinity and longer half-life further tip the balance in its favor.
Output:
1
2025-04-17 19:44:02,398 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's systematically compare Ligand A and Ligand B based on the provided parameters and the guidelines, keeping in mind ADRB2 is a GPCR.
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (362.367 Da) is slightly preferred due to being lower.
2. **TPSA:** Ligand B (96.45) is better than Ligand A (125.88). TPSA < 140 is good for oral absorption, both are within this range, but lower is better.
3. **logP:** Ligand A (0.742) is significantly better than Ligand B (3.822). Ligand B is pushing the upper limit and could have solubility issues.
4. **H-Bond Donors:** Ligand A (1) is preferred over Ligand B (2). Fewer HBDs generally improve permeability.
5. **H-Bond Acceptors:** Ligand A (8) is slightly better than Ligand B (5). Both are within acceptable limits.
6. **QED:** Both ligands have similar QED values (0.663 vs 0.641), indicating comparable drug-likeness.
7. **DILI:** Ligand B (87.127) is better than Ligand A (98.759). Lower DILI risk is crucial.
8. **BBB:** Ligand A (47.615) is better than Ligand B (23.924). While ADRB2 isn't necessarily a CNS target, some peripheral ADRB2 activity can influence CNS pathways, and higher BBB penetration isn't a major negative.
9. **Caco-2:** Both ligands have poor Caco-2 permeability (-5.019 and -5.24). This is a concern for oral bioavailability.
10. **Solubility:** Ligand A (-3.226) is better than Ligand B (-4.54). Solubility is important for formulation and absorption.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.128 and 0.287). This is excellent.
12. **Cl_mic:** Ligand A (57.007) is better than Ligand B (17.544). Lower clearance suggests better metabolic stability.
13. **t1/2:** Ligand B (14.927) is much better than Ligand A (-2.929). A longer half-life is desirable.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.17 and 0.131).
15. **Binding Affinity:** Ligand B (-7.3) is significantly better than Ligand A (-6.2). A 1.1 kcal/mol difference in binding is substantial and can often outweigh other ADME concerns.
**Overall Assessment:**
Ligand B has a significantly better binding affinity, and a much better half-life. While Ligand A has better logP and TPSA, the affinity difference is substantial. The DILI risk is also lower for Ligand B. The poor Caco-2 permeability is a concern for both, but can be addressed with formulation strategies. The higher logP of Ligand B is a concern, but the strong binding affinity makes it more likely to be effective at lower doses, potentially mitigating solubility issues.
**Output:**
0
2025-04-17 19:44:02,398 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (353.467 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (58.64) is significantly better than Ligand A (98.14). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have acceptable logP values (A: 2.389, B: 3.216), falling within the 1-3 range. Ligand B is slightly higher, which could potentially lead to some off-target interactions, but isn't a major concern.
4. **HBD/HBA:** Ligand A has 2 HBD and 6 HBA, while Ligand B has 1 HBD and 4 HBA. Both are within acceptable limits, but Ligand B is slightly more favorable.
5. **QED:** Both ligands have good QED scores (A: 0.629, B: 0.819), indicating good drug-like properties. Ligand B is better.
6. **DILI:** Ligand B (30.516) has a much lower DILI risk than Ligand A (63.397). This is a significant advantage for Ligand B.
7. **BBB:** Both have reasonable BBB penetration (A: 71.772, B: 75.572), but this is less critical for a cardiovascular target.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the values are similar (-4.849 for A, -5.076 for B).
9. **Solubility:** Both have negative solubility values, which is also unusual and suggests poor solubility. Again, values are similar (-3.269 for A, -3.165 for B).
10. **hERG:** Both have low hERG inhibition risk (A: 0.136, B: 0.443), which is good.
11. **Cl_mic:** Ligand B (28.371) has significantly lower microsomal clearance than Ligand A (89.697), indicating better metabolic stability.
12. **t1/2:** Ligand B (32.549) has a much longer in vitro half-life than Ligand A (-15.861). This is a major advantage.
13. **Pgp:** Both have low Pgp efflux liability (A: 0.103, B: 0.216).
14. **Binding Affinity:** Both ligands have very similar binding affinities (A: -5.9 kcal/mol, B: -5.7 kcal/mol). The difference is negligible.
**Overall Assessment:**
Ligand B is clearly superior. While both ligands have similar binding affinities, Ligand B demonstrates significantly better ADME properties: lower DILI risk, lower microsomal clearance, and a longer half-life. The lower TPSA is also a plus. The slightly higher logP is not a major concern. The unusual negative Caco-2 and solubility values are a concern for both, but are similar enough to not be a deciding factor. Given the GPCR-specific priorities, metabolic stability and safety (DILI) are crucial, and Ligand B excels in these areas.
Output:
0
2025-04-17 19:44:02,399 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (355.435 and 341.455 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (71.09) is significantly better than Ligand A (121.96). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (3.018) is optimal, while Ligand A (-0.321) is quite low, potentially hindering membrane permeability. This is a significant negative for Ligand A.
4. **HBD:** Ligand A (3) and Ligand B (2) are both acceptable.
5. **HBA:** Ligand A (5) and Ligand B (3) are both acceptable.
6. **QED:** Both ligands (0.551 and 0.564) are good, indicating drug-like properties.
7. **DILI:** Ligand B (44.824) has a better DILI score than Ligand A (16.053), indicating lower potential for liver injury.
8. **BBB:** Ligand B (62.117) has a higher BBB penetration score than Ligand A (42.226), but this isn't a critical factor for a cardiovascular target.
9. **Caco-2:** Ligand B (-4.979) is slightly better than Ligand A (-5.732), suggesting better intestinal absorption.
10. **Solubility:** Ligand A (-1.369) is better than Ligand B (-2.97), which is good.
11. **hERG:** Both ligands (0.104 and 0.254) have low hERG inhibition liability, which is positive.
12. **Cl_mic:** Ligand A (-13.702) has significantly better metabolic stability (lower clearance) than Ligand B (68.6). This is a major advantage for Ligand A.
13. **t1/2:** Ligand B (19.866) has a longer half-life than Ligand A (14.456), which is generally desirable.
14. **Pgp:** Ligand A (0.013) has much lower P-gp efflux liability than Ligand B (0.121), which is a significant advantage.
15. **Affinity:** Ligand A (-7.5) has a slightly better binding affinity than Ligand B (-5.7). While the difference is less than the 1.5 kcal/mol threshold, it's still a positive for Ligand A.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp efflux, and affinity are key. Ligand B excels in TPSA and has a good logP. However, Ligand A's superior Pgp profile, slightly better affinity, and significantly better metabolic stability (Cl_mic) are crucial. The low logP of Ligand A is a concern, but the other benefits outweigh this drawback.
**Conclusion:**
Considering the balance of properties, particularly the favorable metabolic stability and Pgp efflux profile of Ligand A, along with its slightly better affinity, I believe Ligand A is the more promising drug candidate.
Output:
1
2025-04-17 19:44:02,399 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (379.869 Da) is slightly higher than Ligand B (351.455 Da), but both are acceptable.
2. **TPSA:** Both are reasonably good, below the 140 A^2 threshold for oral absorption. Ligand A (92.18) is slightly better than Ligand B (95.39).
3. **logP:** Ligand A (2.81) is optimal. Ligand B (-0.567) is significantly lower, potentially hindering membrane permeability and absorption. This is a major drawback for a GPCR target.
4. **HBD:** Both ligands have 2 HBD, which is within the acceptable range.
5. **HBA:** Ligand A (5) is better than Ligand B (7), as lower HBA generally improves permeability.
6. **QED:** Both ligands have good QED scores (A: 0.514, B: 0.651), indicating good drug-like properties. Ligand B is slightly better here.
7. **DILI:** Ligand A (71.539) has a higher DILI risk than Ligand B (23.226). This is a significant concern for Ligand A.
8. **BBB:** Ligand B (47.266) has a better BBB penetration score than Ligand A (32.765), but neither are particularly high. This is less critical for ADRB2 (a cardiovascular target) than for a CNS target, but still a consideration.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. This is a concern for both.
10. **Solubility:** Both have negative solubility values, indicating poor solubility. This is a concern for both.
11. **hERG:** Both ligands have very low hERG inhibition risk (A: 0.074, B: 0.049), which is excellent.
12. **Cl_mic:** Ligand A (16.139) has a lower (better) microsomal clearance than Ligand B (-27.555). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (-1.961) has a slightly better (less negative) in vitro half-life than Ligand B (-2.418).
14. **Pgp:** Both ligands have very low Pgp efflux liability (A: 0.054, B: 0.002).
15. **Binding Affinity:** Ligand A (-7.4) has a slightly better binding affinity than Ligand B (-7.0). While the difference is not huge, it is still a positive for Ligand A.
**Overall Assessment & GPCR Prioritization:**
For a GPCR like ADRB2, logP is a crucial parameter. Ligand B's significantly negative logP is a major red flag, suggesting poor membrane permeability and likely poor oral bioavailability. While Ligand A has a higher DILI risk, this can potentially be mitigated through structural modifications. The better affinity and metabolic stability of Ligand A, combined with its more favorable logP, outweigh the DILI concern. The Caco-2 and solubility issues are present in both and would need to be addressed in subsequent optimization.
**Output:**
1
2025-04-17 19:44:02,399 - INFO - Batch 132 complete. Total preferences: 2112
2025-04-17 19:44:02,399 - INFO - Processing batch 133/512...
2025-04-17 19:44:47,831 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (378.47) is slightly higher than Ligand B (343.343), but both are acceptable.
2. **TPSA:** Both ligands are below the 140 A^2 threshold for good oral absorption. Ligand B (101.66) is slightly better than Ligand A (112.81).
3. **logP:** Ligand A (-0.795) is a bit low, potentially hindering permeation. Ligand B (0.359) is closer to the optimal range of 1-3. This favors Ligand B.
4. **HBD:** Ligand A has 2 HBD, which is good. Ligand B has 0, also good.
5. **HBA:** Ligand A has 5 HBA, within the acceptable limit. Ligand B has 7, still reasonable.
6. **QED:** Both ligands have good QED scores (A: 0.651, B: 0.79), indicating drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (44.668) has a lower DILI risk than Ligand B (73.09). This favors Ligand A.
8. **BBB:** Both ligands have acceptable BBB penetration (A: 66.033, B: 61.807), but neither is exceptionally high. For a cardiovascular target, BBB isn't a primary concern, so this isn't a major differentiator.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-5.477) is slightly better than Ligand B (-4.751), but both are problematic.
10. **Solubility:** Both ligands have negative solubility values, which is also unusual and suggests poor solubility. Ligand A (-1.564) is slightly better than Ligand B (-1.701).
11. **hERG:** Both ligands have very low hERG inhibition risk (A: 0.283, B: 0.151). This is excellent for both.
12. **Cl_mic:** Ligand A (-3.031) has a lower (better) microsomal clearance than Ligand B (9.684), indicating better metabolic stability. This favors Ligand A.
13. **t1/2:** Ligand A (-26.171) has a more negative (better) in vitro half-life than Ligand B (-5.228). This favors Ligand A.
14. **Pgp:** Both ligands have very low Pgp efflux liability (A: 0.041, B: 0.028). This is excellent for both.
15. **Binding Affinity:** Both ligands have excellent binding affinity (A: -8.3 kcal/mol, B: -8.0 kcal/mol). Ligand A is slightly better.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are particularly important. Ligand B has a better logP and TPSA, while Ligand A has a slightly better affinity. However, the differences in logP and TPSA are not substantial enough to outweigh the superior metabolic stability (Cl_mic and t1/2) and lower DILI risk of Ligand A. The slightly better affinity of Ligand A is also a plus.
**Conclusion:**
Considering the balance of properties, particularly the better metabolic stability, lower DILI risk, and slightly better affinity of Ligand A, I believe it is the more promising drug candidate.
Output:
1
2025-04-17 19:44:47,831 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [341.367, 121.52 , 1.53 , 4. , 4. , 0.58 , 56.844, 59.829, -5.867, -2.612, 0.113, -8.428, -5.775, 0.018, -6.1 ]
**Ligand B:** [361.364, 91.32 , 1.787, 3. , 4. , 0.72 , 39.434, 54.285, -5.028, -2.949, 0.456, 6.56 , -5.181, 0.056, -5.1 ]
Here's a breakdown, considering the GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal range (200-500 Da). A is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (91.32) is significantly better than Ligand A (121.52). Lower TPSA is preferred for GPCRs, aiding in brain penetration and overall absorption.
3. **logP:** Both are good (around 1.5-1.8), falling within the optimal 1-3 range. Ligand B is slightly higher, which could be a minor advantage.
4. **HBD/HBA:** Both have acceptable numbers of H-bond donors and acceptors. Ligand B has fewer HBDs (3 vs 4), which can be slightly beneficial for permeability.
5. **QED:** Both have reasonable QED values (0.58 and 0.72), indicating drug-likeness. Ligand B is better here.
6. **DILI:** Ligand B (39.434) has a significantly lower DILI risk than Ligand A (56.844). This is a major advantage.
7. **BBB:** Both have moderate BBB penetration (around 55-60%). This isn't a primary concern for a cardiovascular target, but slightly higher is always better.
8. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. This is a significant drawback for both.
9. **Solubility:** Both have negative solubility values, indicating poor solubility. This is a significant drawback for both.
10. **hERG:** Ligand A (0.113) has a slightly lower hERG risk than Ligand B (0.456), which is good.
11. **Cl_mic:** Ligand A (-8.428) has a much lower (better) microsomal clearance than Ligand B (6.56). This suggests better metabolic stability.
12. **t1/2:** Both have negative in vitro half-lives, indicating very short half-lives. This is a significant drawback for both.
13. **Pgp:** Both have very low Pgp efflux liability (close to 0). This is good.
14. **Binding Affinity:** Ligand A (-6.1) has a slightly better binding affinity than Ligand B (-5.1). This is a 1 kcal/mol difference, which is notable.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity and metabolic stability, Ligand B has a significantly lower DILI risk, better TPSA, and a slightly better QED. The lower DILI risk is a crucial factor, as liver toxicity is a major concern in drug development. The TPSA difference also favors Ligand B. The poor Caco-2 and solubility for both ligands are concerning and would require addressing through formulation or structural modifications, but the other advantages of Ligand B outweigh the slightly better affinity of Ligand A.
Therefore, I prefer Ligand B.
Output:
0
2025-04-17 19:44:47,831 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (346.471 and 342.483 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (58.64) is slightly higher than Ligand B (49.41). Both are below the 140 A^2 threshold for good oral absorption, but Ligand B is better positioned, particularly for potential CNS penetration (though less critical for a cardiovascular target).
**3. logP:** Ligand A (1.96) is within the optimal range (1-3), while Ligand B (3.03) is at the higher end. While still acceptable, higher logP can sometimes lead to off-target effects.
**4. H-Bond Donors:** Both ligands have 1 HBD, which is good.
**5. H-Bond Acceptors:** Ligand A has 3 HBAs, and Ligand B has 2. Both are within the acceptable limit of 10.
**6. QED:** Both ligands have good QED scores (0.748 and 0.806), indicating good drug-like properties.
**7. DILI Risk:** Both ligands have low DILI risk (30.787 and 28.228 percentile), which is excellent.
**8. BBB Penetration:** Ligand B (75.107) shows better BBB penetration than Ligand A (71.229). While ADRB2 is a cardiovascular target, some degree of CNS penetration can be relevant for off-target effects assessment.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.5 and -4.797), which is unusual and suggests poor permeability. This is a significant concern for both.
**10. Aqueous Solubility:** Both ligands have very poor aqueous solubility (-3.179 and -3.756), which is a major drawback.
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.373 and 0.39), which is positive.
**12. Microsomal Clearance:** Ligand B (56.859) has a higher microsomal clearance than Ligand A (41.398), indicating faster metabolism and potentially lower *in vivo* exposure.
**13. In vitro Half-Life:** Ligand A (-10.743) has a longer in vitro half-life than Ligand B (-7.362). This is a positive for Ligand A.
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (0.099 and 0.27).
**15. Binding Affinity:** Ligand A (-7.4 kcal/mol) has a slightly better binding affinity than Ligand B (-6.1 kcal/mol). This is a 1.3 kcal/mol difference, which is significant and can outweigh some ADME drawbacks.
**Overall Assessment & GPCR-Specific Priorities:**
Given that this is a GPCR target, logP, TPSA, Pgp, and affinity are important. Ligand A has a more favorable logP and significantly better binding affinity. While both have poor solubility and permeability, the stronger binding of Ligand A is a crucial advantage. The slightly better BBB penetration of Ligand B is less important for a cardiovascular target. The longer half-life of Ligand A is also beneficial. Although Ligand B has slightly better TPSA, the affinity difference is more impactful.
Therefore, I prefer Ligand A.
Output:
1
2025-04-17 19:44:47,832 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (347.415 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (75.71) is better than Ligand A (91.76). Both are below 140, but lower TPSA is preferred for oral absorption, making Ligand B slightly better.
3. **logP:** Both ligands have good logP values (A: 1.181, B: 2.068), falling within the optimal range of 1-3. Ligand B is slightly better.
4. **HBD:** Ligand A (2) is slightly better than Ligand B (1). Both are within the acceptable limit of 5.
5. **HBA:** Ligand A (5) is slightly better than Ligand B (4). Both are within the acceptable limit of 10.
6. **QED:** Ligand A (0.853) is significantly better than Ligand B (0.694), indicating a more drug-like profile.
7. **DILI:** Ligand A (35.983) has a lower DILI risk than Ligand B (40.054), which is favorable. Both are below the concerning threshold of 60.
8. **BBB:** Ligand B (69.794) has a significantly higher BBB penetration percentile than Ligand A (50.523). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant for off-target effects and overall safety.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.93) is slightly better than Ligand B (-4.639), but both are problematic.
10. **Solubility:** Both ligands have negative solubility values, indicating poor aqueous solubility. Ligand A (-2.162) is slightly better than Ligand B (-3.1).
11. **hERG:** Both ligands have very low hERG inhibition risk (A: 0.198, B: 0.307), which is excellent.
12. **Cl_mic:** Ligand A (-10.819) has a much lower (better) microsomal clearance than Ligand B (63.485), indicating better metabolic stability.
13. **t1/2:** Ligand A (-6.21) has a shorter in vitro half-life than Ligand B (-37.666). This is a significant advantage for Ligand B.
14. **Pgp:** Both ligands have very low P-gp efflux liability (A: 0.03, B: 0.046), which is favorable.
15. **Binding Affinity:** Both ligands have the same binding affinity (-6.4 kcal/mol).
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B has a better logP and TPSA, and slightly better BBB penetration. However, Ligand A has a much better QED, lower DILI risk, and significantly better metabolic stability (Cl_mic). The Caco-2 and solubility are poor for both.
**Overall Assessment:**
While Ligand B has some advantages in terms of BBB and TPSA, the superior drug-likeness (QED), lower DILI risk, and significantly improved metabolic stability of Ligand A are more critical for overall drug development success. The similar binding affinity means the ADME properties become the deciding factor. The poor Caco-2 and solubility for both are concerning, but can be addressed with formulation strategies.
Output:
1
2025-04-17 19:44:47,832 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (366.49 and 351.41 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (87.32) is significantly better than Ligand B (124.84). For a GPCR, keeping TPSA low is beneficial for permeability.
3. **logP:** Ligand A (1.35) is within the optimal range (1-3). Ligand B (-1.368) is slightly below, which *could* hinder permeability, though not drastically.
4. **HBD:** Ligand A (2) is preferable to Ligand B (3). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (4). Lower HBA generally improves permeability.
6. **QED:** Ligand A (0.821) is much better than Ligand B (0.403). A higher QED indicates a more drug-like profile.
7. **DILI:** Ligand A (56.77) is better than Ligand B (26.10), indicating a lower risk of drug-induced liver injury.
8. **BBB:** Both ligands have similar BBB penetration (Ligand A: 55.64, Ligand B: 58.51). Since ADRB2 is a cardiovascular target, BBB penetration is not a primary concern.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.202 and -5.116). This suggests poor permeability, but the scale is unclear, and negative values might indicate a different measurement.
10. **Solubility:** Ligand A (-3.345) is better than Ligand B (-1.62). Higher solubility is generally preferred.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.213 and 0.059). This is excellent.
12. **Cl_mic:** Ligand B (-13.475) has significantly lower microsomal clearance than Ligand A (24.909), suggesting better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand B (-20.683) has a longer in vitro half-life than Ligand A (-25.378). This is a positive attribute.
14. **Pgp:** Both ligands have very low P-gp efflux (0.078 and 0.002).
15. **Binding Affinity:** Ligand B (-6.2) has a slightly better binding affinity than Ligand A (-5.9). This is a 0.3 kcal/mol difference, which is not substantial enough to outweigh other factors.
**Overall Assessment:**
Ligand A has superior drug-like properties (QED, DILI, Solubility, TPSA, HBD/HBA) and acceptable binding affinity. Ligand B has better metabolic stability (Cl_mic, t1/2) and slightly better binding affinity, but suffers from a lower QED, higher DILI risk, and higher TPSA.
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand A's lower TPSA and better overall drug-likeness profile make it the more promising candidate. The slight advantage in binding affinity for Ligand B is not enough to offset the other drawbacks.
Output:
1
2025-04-17 19:44:47,832 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (345.483) is slightly lower, which could be beneficial for permeability.
2. **TPSA:** Ligand A (47.56) is significantly better than Ligand B (67.87). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (4.248) is higher than the optimal range (1-3), potentially leading to solubility issues. Ligand B (1.91) is within the optimal range. This is a significant advantage for Ligand B.
4. **HBD:** Both ligands have 1 HBD, which is acceptable.
5. **HBA:** Ligand A has 4 HBAs, and Ligand B has 5. Both are acceptable.
6. **QED:** Both ligands have good QED scores (A: 0.783, B: 0.8), indicating good drug-like properties.
7. **DILI:** Ligand A (20.706) has a much lower DILI risk than Ligand B (34.432). This is a crucial advantage for Ligand A.
8. **BBB:** Ligand B (70.997) has better BBB penetration than Ligand A (50.872). However, since ADRB2 is primarily a cardiovascular target, BBB penetration isn't a high priority.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability.
10. **Solubility:** Ligand B (-2.466) is better than Ligand A (-4.518), which is important given Ligand A's higher logP.
11. **hERG:** Ligand A (0.67) has a slightly higher hERG risk than Ligand B (0.308), but both are relatively low.
12. **Cl_mic:** Ligand B (24.311) has significantly lower microsomal clearance than Ligand A (52.355), indicating better metabolic stability. This is a major advantage for Ligand B.
13. **t1/2:** Ligand B (15.912) has a much longer in vitro half-life than Ligand A (3.044), which is highly desirable.
14. **Pgp:** Ligand A (0.463) has lower P-gp efflux than Ligand B (0.064), which is favorable.
15. **Affinity:** Ligand A (-7.0) has slightly better binding affinity than Ligand B (-4.5). This 2.5 kcal/mol difference is significant.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP and metabolic stability (Cl_mic and t1/2), while Ligand A has a better affinity and Pgp profile. The DILI risk is also a major consideration.
**Overall Assessment:**
Despite Ligand A's slightly better affinity, Ligand B's superior metabolic stability (lower Cl_mic, longer t1/2), lower DILI risk, and acceptable logP make it the more promising candidate. The affinity difference, while notable, can potentially be optimized in later stages of drug development. The lower DILI risk and improved pharmacokinetic properties of Ligand B are more critical for overall drug viability.
Output:
0
2025-04-17 19:44:47,832 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (351.447 and 366.571 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (89.95) is better than Ligand B (58.2). Both are below the 140 threshold for oral absorption, but lower TPSA is generally preferred for GPCRs, potentially aiding BBB penetration.
3. **logP:** Ligand B (3.522) is better than Ligand A (0.123). Ligand A's logP is very low, which is a significant concern for membrane permeability and bioavailability. Ligand B is within the optimal 1-3 range.
4. **HBD:** Both ligands have 2 HBD, which is acceptable.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 3. Both are within the acceptable range of <=10.
6. **QED:** Ligand A (0.756) has a better QED score than Ligand B (0.582), indicating a more drug-like profile overall.
7. **DILI:** Ligand A (18.922) has a significantly lower DILI risk than Ligand B (21.985). Both are good, but A is preferable.
8. **BBB:** Ligand B (67.429) has a slightly better BBB penetration percentile than Ligand A (59.829). While ADRB2 isn't strictly a CNS target, some CNS penetration could be beneficial or at least avoid unexpected side effects.
9. **Caco-2:** Ligand A (-4.763) has a much worse Caco-2 permeability than Ligand B (-5). Both are poor, but B is slightly better.
10. **Solubility:** Ligand A (-1.537) has better solubility than Ligand B (-4.393).
11. **hERG:** Ligand A (0.164) has a much lower hERG inhibition liability than Ligand B (0.406). This is a critical advantage for cardiovascular targets.
12. **Cl_mic:** Ligand B (87.391) has a significantly higher microsomal clearance than Ligand A (-0.87). This means Ligand A is more metabolically stable.
13. **t1/2:** Ligand B (22.809) has a much longer in vitro half-life than Ligand A (7.099). This is a significant advantage.
14. **Pgp:** Ligand A (0.01) has a much lower P-gp efflux liability than Ligand B (0.242). This is beneficial for bioavailability.
15. **Binding Affinity:** Ligand B (-6.0) has a significantly better binding affinity than Ligand A (-3.7). This is a major advantage, potentially outweighing some ADME concerns.
**Overall Assessment:**
Ligand B has a much stronger binding affinity, a longer half-life, and slightly better BBB penetration. However, it suffers from a higher logP, higher DILI risk, higher hERG inhibition, and higher P-gp efflux. Ligand A has a better QED, lower DILI and hERG, better solubility, and better metabolic stability.
Given the cardiovascular target (ADRB2), minimizing hERG inhibition is paramount. The significantly lower hERG risk of Ligand A, combined with its better metabolic stability and lower DILI, makes it the more promising candidate despite its weaker binding affinity and lower logP. The difference in binding affinity is substantial, but optimization could potentially improve Ligand A's potency. The ADME properties of Ligand A are more favorable for developing a safe and effective drug.
Output:
1
2025-04-17 19:44:47,832 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.475 and 352.454 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (78.87) is slightly higher than Ligand B (67.23). Both are below the 140 A^2 threshold for good oral absorption, but Ligand B is preferable due to the lower TPSA.
3. **logP:** Ligand A (1.458) is within the optimal range (1-3), while Ligand B (2.675) is towards the higher end. Both are acceptable, but Ligand A is slightly favored.
4. **HBD:** Ligand A (2) and Ligand B (1) both meet the criteria of <=5. Ligand B is slightly better.
5. **HBA:** Both ligands have 4 HBA, which is well within the acceptable limit of <=10.
6. **QED:** Both ligands have good QED values (0.727 and 0.82), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (8.414%) has a significantly lower DILI risk than Ligand B (19.969%). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (87.088%) has a much higher BBB penetration potential than Ligand A (60.838%). Given ADRB2's cardiovascular involvement, CNS penetration isn't a primary goal, but it's a slight advantage for Ligand B.
9. **Caco-2:** Both ligands have very negative Caco-2 values (-4.65 and -4.647), indicating poor permeability. This is a concern for both.
10. **Solubility:** Both ligands have poor aqueous solubility (-2.089 and -2.368). This is a significant drawback for both, potentially impacting bioavailability.
11. **hERG:** Ligand A (0.24) has a lower hERG inhibition liability than Ligand B (0.751). This is a significant advantage for Ligand A, reducing the risk of cardiotoxicity.
12. **Cl_mic:** Ligand A (7.892) has a lower microsomal clearance than Ligand B (14.331), suggesting better metabolic stability. This is a key advantage for Ligand A.
13. **t1/2:** Ligand A (-1.021) has a negative in vitro half-life, while Ligand B (-16.187) is even worse. Both are very poor.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.078 and 0.075).
15. **Binding Affinity:** Ligand B (-7.4 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.1 kcal/mol). This is a substantial advantage for Ligand B, potentially outweighing some of its ADME drawbacks.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are critical. Ligand B has a better logP, TPSA, and significantly better affinity. However, the DILI and hERG risks associated with Ligand B are concerning. The improved metabolic stability (lower Cl_mic) and lower DILI/hERG risks of Ligand A are very important, even with the slightly lower affinity.
**Overall Assessment:**
While Ligand B boasts a stronger binding affinity, the significantly higher DILI and hERG risks, coupled with worse metabolic stability, make it a less desirable candidate. Ligand A, despite its weaker binding, presents a much more favorable safety profile and better metabolic properties. The affinity difference, while substantial, may be addressable through further optimization, whereas mitigating high DILI/hERG risks is often far more challenging.
Output:
1
2025-04-17 19:44:47,832 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (336.395 Da) is well within the ideal range (200-500 Da). Ligand B (408.256 Da) is also acceptable but approaching the upper limit.
2. **TPSA:** Ligand A (71.11) is excellent, well below the 140 threshold for good absorption. Ligand B (102.48) is still reasonable, but less optimal.
3. **logP:** Ligand A (2.868) is within the optimal 1-3 range. Ligand B (0.758) is a bit low, potentially hindering permeation.
4. **HBD:** Both ligands have acceptable HBD counts (Ligand A: 1, Ligand B: 2), well below the 5 threshold.
5. **HBA:** Both ligands have acceptable HBA counts (Ligand A: 4, Ligand B: 6), below the 10 threshold.
6. **QED:** Both ligands have similar and good QED values (Ligand A: 0.798, Ligand B: 0.731), indicating good drug-like properties.
7. **DILI:** Both ligands have similar DILI risk (Ligand A: 72.043, Ligand B: 75.184), which is acceptable (below 80).
8. **BBB:** Ligand B (70.027) shows better BBB penetration than Ligand A (43.505). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be beneficial or at least needs to be considered.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual. Assuming these are logP-like scales, lower values indicate poorer permeability. Ligand A (-5.018) is slightly worse than Ligand B (-4.871).
10. **Solubility:** Both ligands have negative solubility values, which is also unusual. Assuming these are logS-like scales, lower values indicate poorer solubility. Ligand A (-3.573) is slightly worse than Ligand B (-3.258).
11. **hERG:** Both ligands have low hERG risk (Ligand A: 0.632, Ligand B: 0.423).
12. **Cl_mic:** Ligand A (26.806) has a higher microsomal clearance than Ligand B (-4.158), suggesting lower metabolic stability. This is a significant drawback.
13. **t1/2:** Ligand B (6.602) has a much longer in vitro half-life than Ligand A (-4.849). This is a major advantage.
14. **Pgp:** Ligand A (0.205) has lower P-gp efflux liability than Ligand B (0.054), which is preferable.
15. **Affinity:** Both ligands have excellent binding affinity (Ligand A: -7.0 kcal/mol, Ligand B: -6.8 kcal/mol). Ligand A is slightly better, but the difference is not substantial.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has better TPSA and Pgp, and slightly better affinity. However, Ligand B has a better logP, significantly better metabolic stability (lower Cl_mic, longer t1/2), and better BBB penetration. Considering the balance, the improved metabolic stability and half-life of Ligand B outweigh the slight advantages of Ligand A.
**Output:**
0
2025-04-17 19:44:47,832 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.45 and 359.417 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (49.85) is significantly better than Ligand B (84.66). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold. Ligand B is approaching the upper limit.
3. **logP:** Both ligands have good logP values (1.999 and 1.059), falling within the optimal 1-3 range. Ligand B is slightly lower, which *could* indicate slightly lower permeability, but it's not a major concern.
4. **HBD:** Ligand A has 0 HBD, while Ligand B has 2. Lower is generally preferred for permeability, giving a slight edge to Ligand A.
5. **HBA:** Ligand A has 3 HBA, and Ligand B has 4. Again, Ligand A is slightly better.
6. **QED:** Ligand A (0.778) has a better QED score than Ligand B (0.476), indicating a more drug-like profile. This is a significant advantage for Ligand A.
7. **DILI:** Both ligands have low DILI risk (22.993 and 21.055), both well below the 40 threshold. No significant difference.
8. **BBB:** Both ligands have good BBB penetration (88.135 and 92.943). Since ADRB2 is not a CNS target, this isn't a major deciding factor, but Ligand B is slightly better.
9. **Caco-2:** Ligand A (-4.521) and Ligand B (-5.082) both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand B is slightly worse.
10. **Solubility:** Both ligands have poor aqueous solubility (-2.296 and -2.056). This is a concern for both, but not a deciding factor on its own.
11. **hERG:** Both ligands have low hERG inhibition liability (0.512 and 0.52). No significant difference.
12. **Cl_mic:** Ligand A (26.469) has a higher microsomal clearance than Ligand B (15.312), suggesting faster metabolism and potentially lower *in vivo* exposure. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand A (0.328) has a very short *in vitro* half-life, while Ligand B (-15.024) has a negative value, which is also concerning. Both are poor, but negative values are more unusual.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.157 and 0.036). Ligand B is slightly better.
15. **Binding Affinity:** Ligand B (-4.9 kcal/mol) has a significantly stronger binding affinity than Ligand A (0.0 kcal/mol). This is a *major* advantage for Ligand B, potentially outweighing some of its ADME drawbacks.
**Overall Assessment:**
Ligand B has a much stronger binding affinity, which is the most important factor for a GPCR target. While Ligand A has better TPSA and QED, the substantial difference in affinity, combined with acceptable (though not ideal) ADME properties, makes Ligand B the more promising candidate. The lower clearance and Pgp efflux for Ligand B are also beneficial. The poor solubility and Caco-2 values are concerns for both, but can be addressed through formulation strategies.
Output:
0
2025-04-17 19:44:47,833 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (346.475 Da) is well within the ideal range (200-500 Da). Ligand B (370.484 Da) is also acceptable. No clear advantage here.
2. **TPSA:** Ligand A (67.23) is good, below the 140 threshold for oral absorption. Ligand B (16.13) is *excellent*, significantly lower than 90, suggesting good permeability. Advantage: B
3. **logP:** Ligand A (1.883) is optimal (1-3). Ligand B (4.846) is slightly high, potentially leading to solubility issues and off-target interactions. Advantage: A
4. **HBD:** Ligand A (1) is good. Ligand B (0) is also acceptable. No clear advantage.
5. **HBA:** Ligand A (4) is good. Ligand B (3) is also good. No clear advantage.
6. **QED:** Ligand A (0.909) is excellent, indicating high drug-likeness. Ligand B (0.712) is still respectable, but lower. Advantage: A
7. **DILI:** Ligand A (20.9) has a very low DILI risk. Ligand B (12.485) also has a low DILI risk. No clear advantage.
8. **BBB:** Ligand A (71.539) is good, but Ligand B (96.937) is *excellent*. This is a significant advantage for a GPCR, even a cardiovascular one, as some CNS off-target effects are possible. Advantage: B
9. **Caco-2:** Ligand A (-4.717) is poor. Ligand B (-5.006) is also poor. Both have very low permeability. No clear advantage.
10. **Solubility:** Ligand A (-1.216) is poor. Ligand B (-4.863) is very poor. Both have solubility concerns. No clear advantage.
11. **hERG:** Ligand A (0.228) has a very low hERG risk. Ligand B (0.931) has a slightly higher, but still acceptable, hERG risk. Advantage: A
12. **Cl_mic:** Ligand A (46.94) and Ligand B (47.396) are comparable. No clear advantage.
13. **t1/2:** Ligand A (-3.203) is poor. Ligand B (-15.511) is *very* poor. Advantage: A
14. **Pgp:** Ligand A (0.064) has low P-gp efflux. Ligand B (0.62) has higher P-gp efflux. Advantage: A
15. **Affinity:** Ligand A (-7.3) is slightly better than Ligand B (-6.9), but the difference is not huge. Advantage: A
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand B has a significant advantage in TPSA and BBB penetration, which are crucial for receptor engagement and potential off-target effects. However, Ligand A has better QED, hERG, half-life, and Pgp efflux. The solubility and Caco-2 permeability are poor for both. The slightly better affinity of Ligand A is a plus.
Despite Ligand A's slightly better affinity, the superior BBB penetration of Ligand B, coupled with its lower TPSA, makes it more likely to achieve sufficient target engagement *in vivo* and potentially avoid off-target side effects. The higher logP of Ligand B is a concern, but can potentially be addressed with formulation strategies. The poor solubility and Caco-2 values are shared drawbacks that would need to be addressed in either case.
Output:
0
2025-04-17 19:44:47,833 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (340.423) is slightly lower than Ligand B (370.881), which is generally favorable for permeability.
2. **TPSA:** Both ligands are below the 140 A^2 threshold for good oral absorption. Ligand A (81.42) is slightly higher than Ligand B (78.68), but both are acceptable.
3. **logP:** Both ligands have optimal logP values (between 1 and 3). Ligand A (2.989) is slightly higher than Ligand B (2.169). For a GPCR, a slightly higher logP can be beneficial for membrane permeability.
4. **HBD:** Ligand A (2) and Ligand B (1) are both within the acceptable limit of <=5. Ligand B is slightly better.
5. **HBA:** Ligand A (4) and Ligand B (5) are both within the acceptable limit of <=10.
6. **QED:** Both ligands have good QED scores (0.792 and 0.795), indicating good drug-like properties.
7. **DILI:** Ligand A (58.511) has a higher DILI risk than Ligand B (30.283). This is a significant advantage for Ligand B.
8. **BBB:** Both ligands have good BBB penetration (74.176 and 71.074). This is less critical for ADRB2, which is not a CNS target, but still desirable.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not defined, so it's difficult to interpret.
10. **Solubility:** Both ligands have negative solubility values, which is also unusual. Again, the scale is not defined.
11. **hERG:** Ligand A (0.752) has a slightly higher hERG risk than Ligand B (0.46). Lower is better here, so Ligand B is preferable.
12. **Cl_mic:** Ligand A (72.209) has a higher microsomal clearance than Ligand B (3.705), indicating lower metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand A (-5.187) has a negative in vitro half-life, which is not possible. Ligand B (43.144) has a reasonable half-life. This is a major advantage for Ligand B.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.176 and 0.141).
15. **Binding Affinity:** Ligand A (-6.5 kcal/mol) has a slightly better binding affinity than Ligand B (-6.2 kcal/mol). However, the difference is relatively small (0.3 kcal/mol).
**Overall Assessment:**
While Ligand A has slightly better binding affinity, Ligand B is significantly better in terms of safety (DILI, hERG) and ADME properties (Cl_mic, t1/2). The negative values for Caco-2 and solubility are concerning for both, but the other advantages of Ligand B outweigh the small affinity difference. Given the GPCR target class, the improved ADME profile and safety of Ligand B make it the more promising candidate.
Output:
0
2025-04-17 19:44:47,834 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (363.8) is within the ideal range (200-500), while Ligand B (345.4) is also good. No clear advantage.
2. **TPSA:** Ligand A (107.4) is acceptable, but higher than ideal for optimal absorption. Ligand B (91.76) is better, falling comfortably below the 140 threshold and closer to the 90 threshold which is beneficial for GPCRs.
3. **logP:** Ligand A (2.668) is within the optimal range (1-3). Ligand B (0.352) is a bit low, potentially hindering membrane permeability. This is a significant drawback for a GPCR ligand.
4. **HBD:** Both ligands have acceptable HBD counts (Ligand A: 1, Ligand B: 2).
5. **HBA:** Both ligands have acceptable HBA counts (Ligand A: 4, Ligand B: 5).
6. **QED:** Ligand B (0.726) has a significantly better QED score than Ligand A (0.376), indicating a more drug-like profile.
7. **DILI:** Ligand B (40.132) has a much lower DILI risk than Ligand A (59.131), which is a substantial advantage.
8. **BBB:** Ligand A (77.898) has a better BBB penetration percentile than Ligand B (32.881). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be beneficial for distribution.
9. **Caco-2:** Ligand A (-4.759) and Ligand B (-5.063) both have very poor Caco-2 permeability, indicating poor intestinal absorption.
10. **Solubility:** Ligand A (-3.299) and Ligand B (-1.296) both have poor aqueous solubility.
11. **hERG:** Ligand A (0.353) has a slightly higher hERG risk than Ligand B (0.138), but both are relatively low.
12. **Cl_mic:** Ligand B (-11.23) has a significantly lower (better) microsomal clearance than Ligand A (1.792), suggesting better metabolic stability.
13. **t1/2:** Ligand B (16.061) has a much longer in vitro half-life than Ligand A (7.068), which is a major advantage.
14. **Pgp:** Ligand A (0.1) has lower P-gp efflux liability than Ligand B (0.009), which is a slight advantage.
15. **Binding Affinity:** Ligand A (-8.4) has a significantly stronger binding affinity than Ligand B (-6.1). This is a substantial advantage, potentially outweighing some ADME concerns.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A has a better logP and Pgp profile, but Ligand B excels in TPSA, DILI, Cl_mic, and t1/2. The affinity difference is significant (-8.4 vs -6.1 kcal/mol).
**Overall Assessment:**
While Ligand B has a better overall ADME profile (lower DILI, better metabolic stability, longer half-life, better TPSA), the significantly stronger binding affinity of Ligand A (-8.4 kcal/mol) is a crucial factor. A strong binding affinity can often compensate for minor ADME deficiencies, especially if optimization can improve solubility and permeability. The difference in affinity is greater than the 1.5 kcal/mol advantage mentioned in the guidelines.
Output:
1
2025-04-17 19:44:47,834 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.391 and 352.435 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand B (85.69) is significantly better than Ligand A (102.12). ADRB2 is not a CNS target, but lower TPSA generally improves absorption.
3. **logP:** Both ligands have very low logP values (0.177 and 0.121). This is a concern as it may hinder membrane permeability. However, they are relatively close.
4. **HBD:** Both have 1 HBD, which is acceptable.
5. **HBA:** Ligand A has 7 HBA, while Ligand B has 6. Both are within the acceptable limit of 10.
6. **QED:** Ligand A (0.804) has a better QED score than Ligand B (0.682), indicating a more drug-like profile.
7. **DILI:** Ligand B (22.334) has a much lower DILI risk than Ligand A (67.429). This is a significant advantage for Ligand B.
8. **BBB:** Not a primary concern for ADRB2, but Ligand A (70.919) has a higher BBB penetration than Ligand B (51.997).
9. **Caco-2:** Ligand B (-5.34) has a slightly better Caco-2 permeability than Ligand A (-4.962), suggesting better absorption.
10. **Solubility:** Ligand B (0.326) has better aqueous solubility than Ligand A (-2.096). This is a positive for bioavailability.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.207 and 0.129), which is excellent.
12. **Cl_mic:** Ligand B (-1.539) has a *much* lower microsomal clearance than Ligand A (29.632), indicating significantly better metabolic stability. This is a major advantage.
13. **t1/2:** Ligand A (41.295) has a longer in vitro half-life than Ligand B (20.468).
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.099 and 0.008).
15. **Affinity:** Ligand A (-8.3 kcal/mol) has a better binding affinity than Ligand B (-6.3 kcal/mol). This is a substantial difference (2 kcal/mol) and a significant advantage.
**Overall Assessment:**
While Ligand A has a better binding affinity and QED score, Ligand B demonstrates a superior ADME profile. Specifically, the significantly lower DILI risk and dramatically improved metabolic stability (lower Cl_mic) are crucial advantages. The better solubility and Caco-2 permeability also contribute to a more favorable pharmacokinetic profile. The affinity difference, while notable, can potentially be optimized in later stages of development. For a GPCR, metabolic stability and minimizing off-target effects (like liver toxicity) are paramount.
Therefore, I prefer Ligand B.
Output:
0
2025-04-17 19:44:47,834 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (362.455 and 374.462 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Both are good (87.46 and 84.5), being under 140, suggesting reasonable absorption.
3. **logP:** Both are within the optimal 1-3 range (1.951 and 2.666). Ligand B is slightly higher, potentially aiding membrane permeability.
4. **HBD:** Both have 2 HBD, which is acceptable.
5. **HBA:** Ligand A has 6 HBA, and Ligand B has 4. Both are acceptable, below the threshold of 10.
6. **QED:** Ligand A (0.87) has a significantly better QED score than Ligand B (0.64), indicating a more drug-like profile.
7. **DILI:** Ligand A (61.613) has a higher DILI risk than Ligand B (19.465). This is a significant negative for Ligand A.
8. **BBB:** Ligand B (67.468) has a better BBB penetration percentile than Ligand A (43.273). While ADRB2 isn't necessarily a CNS target, better BBB penetration can sometimes correlate with improved distribution.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. Ligand A (-5.298) is worse than Ligand B (-4.807).
10. **Solubility:** Both have negative solubility values, indicating poor solubility. Ligand A (-3.128) is worse than Ligand B (-2.888).
11. **hERG:** Both have very low hERG risk (0.26 and 0.2).
12. **Cl_mic:** Ligand A (-0.067) has a *negative* microsomal clearance, which is highly unusual and suggests very high metabolic stability. Ligand B (66.171) has a high clearance, indicating rapid metabolism. This is a major advantage for Ligand A.
13. **t1/2:** Ligand A (11.981 hours) has a better in vitro half-life than Ligand B (1.316 hours).
14. **Pgp:** Ligand A (0.1) has lower P-gp efflux than Ligand B (0.025), which is beneficial.
15. **Affinity:** Ligand B (-7.6 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.9 kcal/mol). This is a substantial advantage for Ligand B.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are important. Ligand B excels in affinity and has a good logP. While Ligand A has better Pgp, the significantly better affinity of Ligand B outweighs this. The DILI risk for Ligand A is concerning.
**Overall Assessment:**
Ligand B has a much stronger binding affinity, a lower DILI risk, and better BBB penetration. While it has a higher microsomal clearance and lower half-life, the potency advantage is substantial. Ligand A's negative clearance is a red flag and could indicate an artifact or unusual behavior. The poor Caco-2 and solubility for both are drawbacks, but can potentially be addressed with formulation strategies.
Output:
0
2025-04-17 19:44:47,835 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (359.495 and 368.865 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (71.09) is better than Ligand B (81.75). Both are below 140, but lower TPSA generally favors absorption.
3. **logP:** Ligand A (2.09) is better than Ligand B (0.896). Both are within the optimal range of 1-3, but Ligand B is closer to the lower limit, potentially impacting permeability.
4. **HBD:** Both ligands have 2 HBD, which is acceptable.
5. **HBA:** Ligand A (4) is slightly higher than Ligand B (3), but both are within the acceptable range of <=10.
6. **QED:** Ligand A (0.864) is better than Ligand B (0.756), indicating a more drug-like profile.
7. **DILI:** Ligand B (23.575) is significantly better than Ligand A (57.619). This is a major advantage for Ligand B, as lower DILI risk is crucial.
8. **BBB:** Ligand B (77.549) is better than Ligand A (54.478). While ADRB2 isn't exclusively a CNS target, some CNS exposure might be acceptable or even desirable depending on the specific therapeutic goal.
9. **Caco-2:** Ligand A (-5.521) is better than Ligand B (-4.901). Higher (less negative) Caco-2 values indicate better intestinal absorption.
10. **Solubility:** Ligand A (-2.625) is better than Ligand B (-2.471). Higher solubility is generally preferred.
11. **hERG:** Both ligands have very low hERG risk (0.228 and 0.245). No significant difference.
12. **Cl_mic:** Ligand B (-4.157) is better than Ligand A (11.327). Lower microsomal clearance indicates greater metabolic stability, a significant advantage.
13. **t1/2:** Ligand A (29.31) is better than Ligand B (6.046). Longer half-life is generally preferred.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.101 and 0.011). No significant difference.
15. **Binding Affinity:** Ligand B (-6.4) is significantly better than Ligand A (-4.6). A 1.8 kcal/mol difference in binding affinity is substantial and can outweigh some ADME drawbacks.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are particularly important. Ligand B excels in affinity and has a good BBB score. While Ligand A has better TPSA and Caco-2, the substantial affinity advantage of Ligand B, combined with its significantly improved DILI and Cl_mic profiles, makes it the more promising candidate. The slightly lower logP of Ligand B is a minor concern that could potentially be addressed through further optimization.
**Final Decision:**
Ligand B is the more viable drug candidate.
0
2025-04-17 19:44:47,835 - INFO - Batch 133 complete. Total preferences: 2128
2025-04-17 19:44:47,835 - INFO - Processing batch 134/512...
2025-04-17 19:45:37,322 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A: [443.128, 54.79, 4.697, 0, 4, 0.689, 75.572, 79.566, -4.518, -5.427, 0.581, 42.683, 70.04, 0.643, -4.9]**
**Ligand B: [357.519, 46.17, 4.298, 1, 3, 0.752, 41.062, 68.786, -5.046, -4.213, 0.834, 50.977, 18.594, 0.758, -6.9]**
Here's a breakdown, considering the provided guidelines and GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Ligand A (443.128 Da) is within the ideal range, while Ligand B (357.519 Da) is a bit lower, but still acceptable.
2. **TPSA:** Ligand A (54.79) is slightly higher than ideal for good oral absorption (<140), but still reasonable. Ligand B (46.17) is excellent.
3. **logP:** Both ligands (A: 4.697, B: 4.298) are slightly above the optimal range (1-3), but not drastically so. This could potentially lead to some off-target interactions or solubility issues, but is manageable.
4. **HBD/HBA:** Ligand A (0 HBD, 4 HBA) is better than Ligand B (1 HBD, 3 HBA) in terms of balancing solubility and permeability.
5. **QED:** Both ligands have acceptable QED scores (A: 0.689, B: 0.752), indicating reasonable drug-likeness.
6. **DILI:** Ligand A (75.572) has a higher DILI risk than Ligand B (41.062). This is a significant concern.
7. **BBB:** Ligand A (79.566) has better BBB penetration than Ligand B (68.786), but this isn't a primary concern for a cardiovascular target.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.518) is worse than Ligand B (-5.046).
9. **Solubility:** Both have negative solubility values, which is also unusual and suggests poor solubility. Ligand A (-5.427) is worse than Ligand B (-4.213).
10. **hERG:** Ligand A (0.581) has a lower hERG risk than Ligand B (0.834), which is favorable.
11. **Cl_mic:** Ligand A (42.683) has lower microsomal clearance, indicating better metabolic stability, than Ligand B (50.977).
12. **t1/2:** Ligand A (70.04) has a significantly longer in vitro half-life than Ligand B (18.594), which is a major advantage.
13. **Pgp:** Ligand A (0.643) has lower P-gp efflux, which is beneficial for bioavailability, than Ligand B (0.758).
14. **Affinity:** Ligand B (-6.9 kcal/mol) has a substantially stronger binding affinity than Ligand A (-4.9 kcal/mol). This is a 2 kcal/mol difference, which is a significant advantage.
**Overall Assessment:**
While Ligand A has some advantages in terms of metabolic stability (Cl_mic, t1/2) and P-gp efflux, the significantly higher DILI risk and weaker binding affinity are major drawbacks. Ligand B, despite slightly worse metabolic stability, has a much stronger binding affinity, a lower DILI risk, and better TPSA. The superior affinity of Ligand B is likely to outweigh the minor ADME disadvantages. The negative Caco-2 and solubility values are concerning for both, but can be addressed with formulation strategies.
Therefore, I would choose Ligand B.
Output:
0
2025-04-17 19:45:37,322 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (361.364 and 364.917 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (83.48) is better than Ligand B (42.43). Lower TPSA generally favors better cell permeability, which is crucial for GPCR targeting.
3. **logP:** Ligand A (1.73) is optimal, while Ligand B (4.233) is pushing the upper limit. High logP can lead to poor solubility and off-target effects.
4. **HBD:** Ligand A (3) is acceptable, while Ligand B (0) is also good.
5. **HBA:** Ligand A (4) is acceptable, while Ligand B (3) is also good.
6. **QED:** Both ligands have good QED scores (0.691 and 0.727), indicating generally drug-like properties.
7. **DILI:** Ligand A (14.851) is slightly higher than Ligand B (13.106), but both are well below the concerning threshold of 60, indicating low liver injury risk.
8. **BBB:** Ligand B (89.104) has a significantly higher BBB penetration percentile than Ligand A (77.937). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be beneficial for distribution and off-target effects assessment.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.723) is slightly worse than Ligand B (-4.461).
10. **Solubility:** Ligand A (-2.002) is better than Ligand B (-3.987). Higher solubility is generally preferred.
11. **hERG:** Ligand A (0.337) is significantly better than Ligand B (0.652), indicating a lower risk of cardiotoxicity. This is *very* important for a cardiovascular target.
12. **Cl_mic:** Ligand A (-9.116) has a much lower (better) microsomal clearance than Ligand B (95.933), indicating better metabolic stability.
13. **t1/2:** Ligand B (20.276) has a longer in vitro half-life than Ligand A (16.78), which is generally desirable.
14. **Pgp:** Ligand A (0.028) has a much lower Pgp efflux liability than Ligand B (0.617), which is favorable for bioavailability.
15. **Binding Affinity:** Both ligands have similar binding affinities (-6.3 and -6.4 kcal/mol). The difference is negligible.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A has a better logP and TPSA, and significantly better Pgp efflux liability. While Ligand B has better BBB penetration and half-life, the lower hERG risk and metabolic stability of Ligand A are more critical for a cardiovascular drug. The Caco-2 values are problematic for both, but the other advantages of Ligand A outweigh this concern.
**Conclusion:**
Considering the balance of properties, particularly the lower hERG risk, better metabolic stability, and more favorable logP/TPSA, Ligand A is the more promising drug candidate.
Output:
1
2025-04-17 19:45:37,323 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (347.415 Da and 368.821 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (75.88) is significantly better than Ligand B (115.57). For a GPCR, keeping TPSA under 140 is good for oral absorption, and lower is generally preferred. Ligand B is pushing the upper limit.
**3. logP:** Both ligands have similar logP values (1.264 and 1.22), falling within the optimal 1-3 range.
**4. H-Bond Donors:** Ligand A has 0 HBD, which is excellent. Ligand B has 3, which is acceptable but less ideal.
**5. H-Bond Acceptors:** Ligand A has 5 HBA, while Ligand B has 6. Both are within the acceptable limit of 10.
**6. QED:** Ligand A (0.802) has a better QED score than Ligand B (0.695), indicating a more drug-like profile.
**7. DILI:** Ligand A (29.081) has a much lower DILI risk than Ligand B (74.835). This is a significant advantage for Ligand A.
**8. BBB:** Ligand A (76.89) has a better BBB penetration percentile than Ligand B (49.826). While ADRB2 isn't strictly a CNS target, some CNS exposure is possible, and better BBB penetration is generally favorable.
**9. Caco-2 Permeability:** Ligand A (-4.643) has a better Caco-2 permeability than Ligand B (-5.365).
**10. Aqueous Solubility:** Ligand A (-1.312) has better aqueous solubility than Ligand B (-3.301).
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (0.094 and 0.25), which is good.
**12. Microsomal Clearance:** Ligand B (37.288) has a higher microsomal clearance than Ligand A (19.689), suggesting lower metabolic stability.
**13. In vitro Half-Life:** Ligand A (17.479) has a significantly longer in vitro half-life than Ligand B (9.793).
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (0.036 and 0.048).
**15. Binding Affinity:** Ligand B (-7.7) has a stronger binding affinity than Ligand A (-5.5). This is a 2.2 kcal/mol difference, which is substantial.
**Overall Assessment:**
While Ligand B has a better binding affinity, Ligand A is superior in almost all ADME-Tox properties. The lower DILI risk, better BBB penetration, improved solubility, longer half-life, and better QED score of Ligand A outweigh the affinity difference. For a cardiovascular GPCR, metabolic stability (reflected in lower Cl_mic and longer t1/2) and minimizing off-target effects (DILI) are crucial. The affinity of -5.5 kcal/mol for Ligand A is still considered good.
Output:
1
2025-04-17 19:45:37,323 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Step-by-step comparison:**
1. **MW:** Both ligands (350.365 Da and 348.403 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (51.66) is significantly better than Ligand B (109.42). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is quite high, potentially hindering absorption.
3. **logP:** Ligand A (2.7) is within the optimal range (1-3). Ligand B (0.767) is on the lower side, which could lead to permeability issues.
4. **HBD:** Ligand A (0) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Both ligands have 5 HBA, which is acceptable.
6. **QED:** Both ligands have similar QED values (0.685 and 0.703), indicating good drug-likeness.
7. **DILI:** Ligand A (52.695) has a slightly higher DILI risk than Ligand B (44.591), but both are below the concerning threshold of 60.
8. **BBB:** Ligand A (82.241) has a better BBB penetration score than Ligand B (67.701). While ADRB2 isn't exclusively a CNS target, some CNS exposure can occur, and higher BBB is generally favorable.
9. **Caco-2:** Ligand A (-3.994) is better than Ligand B (-4.91). Higher Caco-2 permeability suggests better intestinal absorption.
10. **Solubility:** Ligand A (-2.965) is better than Ligand B (-1.953). Better solubility is always a plus.
11. **hERG:** Ligand A (0.719) has a slightly higher hERG risk than Ligand B (0.064). This is a significant advantage for Ligand B.
12. **Cl_mic:** Ligand A (80.343) has a higher microsomal clearance than Ligand B (18.909), meaning it's metabolized faster. Ligand B's lower clearance is a major advantage for metabolic stability.
13. **t1/2:** Ligand A (3.835) has a shorter half-life than Ligand B (-11.96). The negative value for Ligand B indicates a very long half-life. This is a substantial benefit for Ligand B.
14. **Pgp:** Ligand A (0.404) is better than Ligand B (0.013). Lower P-gp efflux is preferable.
15. **Binding Affinity:** Ligand A (-5.9 kcal/mol) has a slightly better binding affinity than Ligand B (-4.6 kcal/mol). This is a 1.3 kcal/mol difference, which is significant.
**Overall Assessment:**
Ligand A has a better binding affinity, TPSA, Caco-2, solubility, and Pgp efflux. However, Ligand B shines in metabolic stability (much lower Cl_mic and a very long half-life), hERG risk, and has a reasonable DILI score. The lower logP of Ligand B is a concern, but the significant improvements in metabolic stability and hERG outweigh this drawback, especially considering the moderate affinity. For a GPCR, balancing affinity with good ADME properties is crucial. The longer half-life of Ligand B could translate to less frequent dosing, a significant clinical advantage.
**Output:**
0
2025-04-17 19:45:37,323 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (347.5) is slightly higher than Ligand B (338.5), but both are acceptable.
2. **TPSA:** Ligand A (52.65) is significantly better than Ligand B (88.75). ADRB2 is a cardiovascular target, not CNS, but lower TPSA generally improves absorption. Ligand B's TPSA is approaching a level that could hinder oral bioavailability.
3. **logP:** Both ligands have acceptable logP values (Ligand A: 2.036, Ligand B: 3.323), falling within the 1-3 range. Ligand B is slightly higher, which *could* lead to solubility issues, but isn't a major concern.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Fewer hydrogen bond donors generally improve permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (6). Similar to HBD, fewer hydrogen bond acceptors are generally better for permeability.
6. **QED:** Ligand A (0.748) has a better QED score than Ligand B (0.505), indicating a more drug-like profile.
7. **DILI:** Ligand A (11.83) is significantly better than Ligand B (60.22). This is a crucial advantage, as lower DILI risk is highly desirable.
8. **BBB:** Both ligands have good BBB penetration (Ligand A: 74.49, Ligand B: 71.66), though not critical for a cardiovascular target.
9. **Caco-2:** Ligand A (-4.909) is better than Ligand B (-5.525). Higher Caco-2 permeability suggests better intestinal absorption.
10. **Solubility:** Ligand A (-2.263) is better than Ligand B (-2.957). Although both are negative, a less negative value indicates better solubility.
11. **hERG:** Ligand A (0.369) is significantly better than Ligand B (0.885). Lower hERG inhibition is crucial to avoid cardiotoxicity, especially for a cardiovascular target.
12. **Cl_mic:** Ligand A (37.55) is better than Ligand B (60.68). Lower microsomal clearance indicates better metabolic stability.
13. **t1/2:** Ligand A (17.31) is better than Ligand B (15.05). A longer half-life is generally preferred.
14. **Pgp:** Ligand A (0.031) is significantly better than Ligand B (0.262). Lower P-gp efflux improves bioavailability.
15. **Binding Affinity:** Ligand B (-6.1) has a slightly better binding affinity than Ligand A (-6.5). However, the difference is only 0.4 kcal/mol, and is outweighed by the significant advantages of Ligand A in other critical parameters.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most key ADME-Tox properties, including DILI, hERG, Cl_mic, solubility, and Pgp efflux. While Ligand B has slightly better binding affinity, the difference isn't substantial enough to overcome the significant safety and pharmacokinetic advantages of Ligand A. Given the cardiovascular target, minimizing cardiotoxicity (hERG) and maximizing metabolic stability (Cl_mic) are particularly important.
Output:
1
2025-04-17 19:45:37,323 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Ligand A (344.415 Da) is well within the ideal range (200-500). Ligand B (399.837 Da) is also acceptable, but closer to the upper limit.
2. **TPSA:** Ligand A (84.42) is good for oral absorption, being below 140. Ligand B (29.54) is *excellent* and suggests good permeability.
3. **logP:** Ligand A (1.706) is optimal. Ligand B (4.281) is slightly high, potentially leading to solubility issues and off-target interactions, but not drastically so.
4. **HBD:** Ligand A (1) is good. Ligand B (0) is also good.
5. **HBA:** Ligand A (5) is good. Ligand B (3) is also good.
6. **QED:** Ligand A (0.899) is excellent, indicating high drug-likeness. Ligand B (0.611) is still acceptable, but lower.
7. **DILI:** Ligand A (63.125) is moderately risky. Ligand B (43.583) is better, indicating lower liver injury risk.
8. **BBB:** Ligand A (67.895) is moderate. Ligand B (93.021) is *very* good, suggesting significant brain penetration. While ADRB2 isn't strictly a CNS target, some peripheral ADRB2 activity can influence CNS pathways, and better BBB penetration isn't necessarily detrimental.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
10. **Solubility:** Both ligands have negative solubility values, which is also unusual. This is a concern, especially for Ligand B with its higher logP.
11. **hERG:** Ligand A (0.196) is very low risk. Ligand B (0.67) is slightly higher, but still relatively low.
12. **Cl_mic:** Ligand A (32.254) is moderate. Ligand B (96.686) is high, suggesting rapid metabolism and potentially low bioavailability.
13. **t1/2:** Ligand A (-19.331) is very concerning, indicating extremely rapid elimination. Ligand B (0.07) is also unfavorable, but less so than Ligand A.
14. **Pgp:** Ligand A (0.13) is low, suggesting minimal efflux. Ligand B (0.436) is also relatively low.
15. **Affinity:** Both ligands have similar binding affinities (-6.1 kcal/mol and -6.2 kcal/mol). The difference is negligible.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in TPSA and BBB penetration. Ligand A has a better logP and slightly better Pgp profile. However, the major drawback for Ligand A is its extremely poor *in vitro* half-life. The high microsomal clearance of Ligand B is also a concern, but less severe than the rapid elimination of Ligand A. Solubility is a concern for both, but the negative values make comparison difficult.
**Overall Assessment:**
Despite the slightly higher logP and moderate DILI risk, Ligand B is the more promising candidate. The significantly better BBB penetration, coupled with a less disastrous *in vitro* half-life, outweigh the drawbacks. The similar binding affinities mean that the ADME properties become the deciding factor. The negative Caco-2 and solubility values are concerning for both, but these can be addressed through formulation strategies. The rapid clearance of Ligand A is a much harder problem to solve.
Output:
0
2025-04-17 19:45:37,323 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (388.965 and 385.511 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (57.7) is significantly better than Ligand B (102.76). For a GPCR, lower TPSA is preferred for permeability. Ligand B is quite high and could present absorption challenges.
3. **logP:** Ligand A (3.742) is optimal, while Ligand B (0.96) is on the lower side. A logP below 1 can hinder membrane permeability. Ligand A has a clear advantage.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (6) is preferable to Ligand B (7). Fewer HBAs generally improve permeability.
6. **QED:** Both ligands have similar QED values (0.804 and 0.698), indicating good drug-likeness.
7. **DILI:** Both ligands have acceptable DILI risk (56.572 and 52.772 percentile), below the 60% threshold. No significant difference.
8. **BBB:** Ligand A (80.419) is much better than Ligand B (12.175). While ADRB2 isn't exclusively a CNS target, some CNS penetration can be beneficial, and a low BBB score suggests significant efflux.
9. **Caco-2:** Ligand A (-4.676) is better than Ligand B (-5.651). Lower values here indicate better permeability.
10. **Solubility:** Ligand A (-4.416) is better than Ligand B (-3.131). Higher solubility is generally preferred.
11. **hERG:** Ligand A (0.656) is better than Ligand B (0.066). Lower hERG inhibition is crucial for avoiding cardiotoxicity, a significant concern with cardiovascular targets.
12. **Cl_mic:** Ligand A (70.363) is higher than Ligand B (7.286), meaning it has faster clearance. This is a negative for Ligand A.
13. **t1/2:** Ligand A (63.603) is much better than Ligand B (-1.573). A longer half-life is generally desirable.
14. **Pgp:** Ligand A (0.347) is better than Ligand B (0.053). Lower P-gp efflux is preferred for better bioavailability.
15. **Binding Affinity:** Ligand B (-6.9 kcal/mol) is slightly better than Ligand A (-6.1 kcal/mol). This is a 0.8 kcal/mol difference, which is notable, but not overwhelming given the other factors.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical ADME properties (TPSA, logP, HBD, HBA, BBB, solubility, hERG, Pgp) and has a reasonable half-life. While Ligand B has slightly better binding affinity, the significant drawbacks in permeability (high TPSA, low logP), efflux (low Pgp), and hERG risk make it a less desirable candidate. The faster clearance of Ligand A is a concern, but can potentially be addressed through structural modifications.
**Output:**
1
2025-04-17 19:45:37,323 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (351.422 and 342.399 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (75.44) is better than Ligand B (80.37), being closer to the <140 threshold for good absorption. While neither is problematic, A is slightly preferred.
3. **logP:** Both ligands (2.147 and 2.52) are within the optimal 1-3 range. No clear advantage.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 4 HBA, while Ligand B has 5. Ligand A is slightly preferred.
6. **QED:** Both ligands have high QED scores (0.852 and 0.905), indicating good drug-like properties. Ligand B is marginally better.
7. **DILI:** Ligand A (35.595) has a significantly lower DILI risk than Ligand B (57.658). This is a substantial advantage for Ligand A.
8. **BBB:** Ligand A (87.01) has a much higher BBB penetration percentile than Ligand B (62.699). While ADRB2 isn't strictly a CNS target, some CNS exposure can occur, and higher BBB is generally favorable.
9. **Caco-2:** Both are very negative (-4.871 and -4.853), indicating poor permeability. This is a significant drawback for both.
10. **Solubility:** Ligand A (-2.051) has better solubility than Ligand B (-4.088). This is a positive for Ligand A.
11. **hERG:** Both ligands have low hERG inhibition liability (0.205 and 0.259), which is good.
12. **Cl_mic:** Ligand A (19.974) has significantly lower microsomal clearance than Ligand B (37.089), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-21.574) has a more negative in vitro half-life, which translates to a longer half-life and is preferred.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.085 and 0.04). No significant difference.
15. **Binding Affinity:** Ligand B (-6.1) has a slightly better binding affinity than Ligand A (-6.6). However, the difference is less than 1.5 kcal/mol.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. While Ligand B has slightly better affinity, Ligand A excels in other critical areas like DILI risk, BBB penetration, solubility, and metabolic stability (Cl_mic and t1/2). The lower DILI risk and better metabolic stability are particularly valuable for a chronic cardiovascular condition where long-term treatment is likely. The slightly better solubility of Ligand A is also beneficial.
**Conclusion:**
Considering the balance of properties and the GPCR-specific priorities, Ligand A is the more promising drug candidate. The better safety profile (lower DILI), improved pharmacokinetic properties (Cl_mic, t1/2, solubility, BBB), and acceptable affinity outweigh the slightly weaker binding compared to Ligand B.
Output:
1
2025-04-17 19:45:37,323 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (377.872 Da) is within the ideal range (200-500 Da). Ligand B (352.435 Da) is also excellent. No clear advantage here.
2. **TPSA:** Ligand A (49.25) is very good, well below the 140 threshold. Ligand B (87.91) is still acceptable, but higher. A favors permeability.
3. **logP:** Ligand A (4.086) is at the upper end of the optimal range, potentially leading to solubility issues. Ligand B (1.935) is excellent, right in the sweet spot. B is better here.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 5 HBA, acceptable. Ligand B has 6 HBA, also acceptable.
6. **QED:** Both ligands have good QED scores (0.747 and 0.833), indicating good drug-like properties.
7. **DILI:** Ligand A (68.98) is slightly higher risk than Ligand B (52.423). B is preferred.
8. **BBB:** Both ligands show good BBB penetration (74.06 and 76.464). Not a major differentiating factor for ADRB2, as it's primarily a cardiovascular target, but still positive.
9. **Caco-2:** Ligand A (-5.036) is poor, indicating poor intestinal absorption. Ligand B (-4.445) is also poor, but slightly better.
10. **Solubility:** Ligand A (-4.116) is poor. Ligand B (-2.643) is also poor, but better. B is preferred.
11. **hERG:** Ligand A (0.781) is preferable to Ligand B (0.343) as it has a lower hERG inhibition liability. A is preferred.
12. **Cl_mic:** Ligand A (25.818) has a lower clearance, suggesting better metabolic stability. Ligand B (78.851) is much higher, indicating faster metabolism. A is strongly preferred.
13. **t1/2:** Ligand A (50.294) has a much longer half-life than Ligand B (-12.297). A is strongly preferred.
14. **Pgp:** Ligand A (0.833) has higher Pgp efflux liability than Ligand B (0.036). B is strongly preferred.
15. **Affinity:** Ligand A (-7.2 kcal/mol) has a slightly better binding affinity than Ligand B (-6.4 kcal/mol). This is a significant advantage.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B has a better logP and Pgp profile, while Ligand A has better TPSA and affinity. However, the metabolic stability (Cl_mic and t1/2) and DILI risk are critical. Ligand A is far superior in these aspects. The affinity difference is also substantial.
**Overall Assessment:**
While Ligand B has some advantages in logP and Pgp, Ligand A's significantly better metabolic stability (lower Cl_mic, longer t1/2), lower DILI risk, and stronger binding affinity outweigh these benefits. The poor Caco-2 and solubility of both are concerning, but can be addressed with formulation strategies. The affinity difference is large enough to compensate for the slightly higher logP of Ligand A.
Output:
1
2025-04-17 19:45:37,324 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (366.483 and 367.877 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (75.71 and 74.43) are below the 140 A^2 threshold for good oral absorption, which is good.
3. **logP:** Both ligands (2.585 and 2.616) are within the optimal 1-3 range. Again, no major difference.
4. **HBD:** Ligand A has 1 HBD, while Ligand B has 2. Both are acceptable, well below the 5 limit.
5. **HBA:** Ligand A has 5 HBA, Ligand B has 3. Both are below the 10 limit.
6. **QED:** Ligand A (0.785) has a slightly better QED score than Ligand B (0.727), indicating a more drug-like profile.
7. **DILI:** Both ligands have very similar, acceptable DILI risk (46.917 and 46.297 percentile).
8. **BBB:** Ligand A (82.474) has a significantly better BBB penetration percentile than Ligand B (66.615). As ADRB2 is a GPCR, BBB penetration is a consideration, though not paramount unless targeting CNS effects.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.618 and -4.911). This is unusual and suggests poor permeability. However, these values are on a scale where negative values are possible and don't necessarily disqualify the compounds.
10. **Solubility:** Ligand A (-2.877) has better aqueous solubility than Ligand B (-4.03). Solubility is important for bioavailability.
11. **hERG:** Both ligands have low hERG inhibition liability (0.368 and 0.416). This is excellent, minimizing cardiotoxicity risk.
12. **Cl_mic:** Ligand A (73.848) has a lower microsomal clearance than Ligand B (10.469), suggesting better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand A (12.707) has a longer in vitro half-life than Ligand B (10.461). This is also a positive for dosing considerations.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.14 and 0.164).
15. **Binding Affinity:** Ligand A (-7.2 kcal/mol) has a slightly better binding affinity than Ligand B (-7.0 kcal/mol). While the difference is small, it's still a factor.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B in several key ADME properties (BBB, solubility, metabolic stability, half-life) and has a slightly better binding affinity and QED score. While both have acceptable DILI and hERG profiles, the improvements in Ligand A's ADME properties make it the more promising candidate. The negative Caco-2 values are a concern for both, but the other advantages of Ligand A outweigh this.
Output:
1
2025-04-17 19:45:37,324 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (357.43 & 358.42 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (87.74) is better than Ligand B (93.84). Both are below the 140 threshold for oral absorption, but lower TPSA is generally preferred for GPCRs.
3. **logP:** Ligand B (2.092) is better. It falls within the optimal 1-3 range, while Ligand A (0.385) is quite low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (2) is slightly better than Ligand B (1). Both are acceptable.
5. **HBA:** Ligand B (6) is better than Ligand A (4). Both are within the acceptable range.
6. **QED:** Both ligands have similar QED values (0.69 and 0.683), indicating good drug-likeness.
7. **DILI:** Ligand A (28.62) is *significantly* better than Ligand B (51.38). A lower DILI percentile is crucial for drug safety.
8. **BBB:** Ligand A (79.22) is better than Ligand B (60.10). While ADRB2 isn't necessarily a CNS target, higher BBB penetration can sometimes be beneficial and indicates better overall permeability.
9. **Caco-2:** Ligand A (-4.912) is better than Ligand B (-5.311). Higher values are better, indicating improved intestinal absorption.
10. **Solubility:** Ligand A (-1.456) is better than Ligand B (-2.509). Better solubility is generally desirable.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.197 and 0.16), which is excellent.
12. **Cl_mic:** Ligand A (5.076) is *much* better than Ligand B (37.702). Lower microsomal clearance indicates greater metabolic stability, a key factor for drug duration of action.
13. **t1/2:** Ligand B (-9.099) is better than Ligand A (-4.882). A longer half-life is generally preferred.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.009 and 0.09).
15. **Binding Affinity:** Ligand A (-7.8) is significantly better than Ligand B (-6.1). A 1.7 kcal/mol difference in binding affinity is substantial and can often outweigh minor ADME drawbacks.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are particularly important. While Ligand B has a better logP, Ligand A excels in almost all other critical areas, *especially* binding affinity and DILI risk. The significantly stronger binding affinity of Ligand A (-7.8 vs -6.1) is a major advantage, and the much lower DILI risk is a critical safety factor. The better metabolic stability (lower Cl_mic) and solubility of Ligand A further strengthen its profile.
**Output:**
1
2025-04-17 19:45:37,324 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, the key priorities are logP, Pgp, TPSA, and binding affinity, with metabolic stability and solubility also being important.
Let's break down the comparison:
1. **MW:** Both ligands (351.462 and 347.438 Da) are within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (58.56) is better than Ligand B (64.86), being closer to the <140 threshold for good absorption.
3. **logP:** Both ligands have good logP values (3.669 and 2.722), falling within the optimal 1-3 range. Ligand A is slightly higher, which *could* be a minor drawback, but not significant.
4. **HBD/HBA:** Ligand A (2 HBD, 4 HBA) is slightly more favorable than Ligand B (1 HBD, 6 HBA) in terms of balancing solubility and permeability.
5. **QED:** Both ligands have good QED scores (0.526 and 0.67), indicating good drug-like properties.
6. **DILI:** Ligand B (42.109) has a significantly lower DILI risk than Ligand A (7.057), which is a major advantage.
7. **BBB:** Ligand B (90.772) has a higher BBB penetration percentile than Ligand A (83.715), though this is less critical for a cardiovascular target.
8. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. Ligand A (-4.337) is slightly better than Ligand B (-4.89).
9. **Solubility:** Both have negative solubility values, indicating poor solubility. Ligand A (-2.668) is slightly better than Ligand B (-2.761).
10. **hERG:** Both ligands have low hERG inhibition liability (0.856 and 0.376), which is good.
11. **Cl_mic:** Both have similar microsomal clearance values (48.432 and 49.708), suggesting comparable metabolic stability.
12. **t1/2:** Ligand A (19.509 hours) has a longer in vitro half-life than Ligand B (11.651 hours), which is desirable.
13. **Pgp:** Ligand A (0.47) has lower P-gp efflux liability than Ligand B (0.621), which is favorable for bioavailability.
14. **Binding Affinity:** Ligand B (-5.9 kcal/mol) has a slightly better binding affinity than Ligand A (-5.2 kcal/mol). This is a 0.7 kcal/mol difference, which is significant.
**Overall Assessment:**
While Ligand A has slightly better TPSA, Caco-2, solubility, half-life, and Pgp properties, Ligand B demonstrates a substantially lower DILI risk and a better binding affinity. The lower DILI risk is a critical advantage, as liver toxicity is a major concern in drug development. The improved binding affinity further strengthens Ligand B's profile. The slightly worse Pgp and half-life of Ligand B are less concerning than the higher DILI risk of Ligand A.
Output:
0
2025-04-17 19:45:37,324 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (339.33 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (88.91) is better than Ligand B (105.56), falling comfortably under the 140 threshold for good oral absorption.
3. **logP:** Both ligands have acceptable logP values (A: 2.617, B: 1.361), within the 1-3 range. Ligand A is slightly better.
4. **HBD:** Both have 2 HBD, which is good.
5. **HBA:** Ligand A (5) is better than Ligand B (7).
6. **QED:** Both are good (A: 0.715, B: 0.721), indicating drug-like properties.
7. **DILI:** Both have very high DILI risk (A: 96.045, B: 96.161). This is a significant concern for both.
8. **BBB:** Both have low BBB penetration (A: 44.591, B: 40.016). Since ADRB2 is a cardiovascular target, BBB penetration is not a primary concern, but it's not helpful.
9. **Caco-2:** Ligand A (-4.837) is better than Ligand B (-5.148), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-4.066) is better than Ligand B (-3.446).
11. **hERG:** Both have very low hERG inhibition risk (A: 0.348, B: 0.143), which is excellent.
12. **Cl_mic:** Ligand A (14.56) is higher than Ligand B (6.557), meaning Ligand B has better metabolic stability.
13. **t1/2:** Ligand B (-31.201) is significantly better than Ligand A (38.037), suggesting a much longer half-life.
14. **Pgp:** Both have low Pgp efflux (A: 0.038, B: 0.096).
15. **Binding Affinity:** Ligand B (-9.4) has a substantially stronger binding affinity than Ligand A (-5.8), a difference of 3.6 kcal/mol. This is a very large advantage.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, Pgp, TPSA, and affinity. Ligand B excels in affinity, and is comparable in the other parameters.
**Overall Assessment:**
While both ligands have concerningly high DILI risk, Ligand B's significantly stronger binding affinity (-9.4 kcal/mol vs -5.8 kcal/mol) and substantially longer half-life outweigh the slightly better TPSA and solubility of Ligand A. The difference in affinity is large enough to potentially overcome the DILI risk with further optimization. The improved metabolic stability (lower Cl_mic, longer t1/2) is also a significant advantage.
Output:
0
2025-04-17 19:45:37,324 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (341.455 & 348.443 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (53.51) is better than Ligand B (66.92). Both are below 140, but A is closer to the optimal for oral absorption.
3. **logP:** Both ligands have good logP values (2.038 & 1.542), falling within the 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Both have 0 HBD, which is good.
5. **HBA:** Ligand A has 3 HBA, while Ligand B has 4. Both are acceptable, but A is slightly better.
6. **QED:** Ligand A (0.845) has a significantly better QED score than Ligand B (0.655), indicating a more drug-like profile.
7. **DILI:** Ligand A (10.237) has a much lower DILI risk than Ligand B (16.402). This is a crucial advantage.
8. **BBB:** Ligand A (92.168) has a higher BBB penetration percentile than Ligand B (76.813). While ADRB2 isn't strictly a CNS target, some CNS exposure can occur, and higher BBB is generally favorable.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.713 & -4.699), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand A (-2.183) shows slightly better solubility than Ligand B (-1.062), although both are quite poor.
11. **hERG:** Both ligands show very low hERG inhibition liability (0.315 & 0.119), which is excellent.
12. **Cl_mic:** Ligand A (62.4) has a higher microsomal clearance than Ligand B (28.846), suggesting faster metabolism and potentially lower *in vivo* exposure. This is a drawback for Ligand A.
13. **t1/2:** Ligand B (-4.096) has a slightly better in vitro half-life than Ligand A (-21.386), indicating better stability.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.149 & 0.045), which is good.
15. **Binding Affinity:** Ligand B (-6.6 kcal/mol) has a significantly stronger binding affinity than Ligand A (-3.4 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME drawbacks.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B excels in affinity. While Ligand A has better TPSA and BBB, the substantial difference in binding affinity is the most important factor. The slightly higher DILI risk for Ligand B is concerning but potentially manageable with further optimization. The Caco-2 values are a shared concern.
**Conclusion:**
Despite the better ADME profile of Ligand A, the significantly stronger binding affinity of Ligand B makes it the more promising candidate. The potency advantage is likely to be more impactful than the minor ADME differences, especially considering the potential for optimization to address the DILI risk and permeability issues.
Output:
0
2025-04-17 19:45:37,324 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (350.478 Da and 363.483 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (40.62) is significantly better than Ligand B (64.02). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand A is well below the 140 threshold, while Ligand B is approaching the upper limit.
**3. logP:** Both ligands have good logP values (3.344 and 3.166), falling within the optimal 1-3 range. No major difference.
**4. H-Bond Donors:** Both have 0 HBD, which is good.
**5. H-Bond Acceptors:** Ligand A has 2 HBA, while Ligand B has 6. Lower HBA is generally preferred for better permeability, giving a slight edge to Ligand A.
**6. QED:** Both ligands have similar QED values (0.689 and 0.698), indicating good drug-likeness.
**7. DILI Risk:** Ligand A (19.271) has a substantially lower DILI risk than Ligand B (51.57). This is a crucial advantage, as minimizing liver toxicity is paramount.
**8. BBB Penetration:** Ligand A (86.972) shows better BBB penetration than Ligand B (65.064). While ADRB2 is a cardiovascular target and doesn't *require* high BBB penetration, some level is still desirable for potential off-target effects and overall distribution.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.422 and -4.301). This is unusual and suggests poor permeability *in vitro*. However, the values are very close, so it's not a major differentiator.
**10. Aqueous Solubility:** Both ligands have negative solubility values (-3.548 and -3.977). This is concerning, indicating poor aqueous solubility. This could pose formulation challenges. Again, the values are similar.
**11. hERG Inhibition:** Ligand A (0.587) has a lower hERG inhibition risk than Ligand B (0.249). Lower is better, making Ligand A preferable.
**12. Microsomal Clearance:** Ligand B (63.459) has a higher microsomal clearance than Ligand A (54.813), suggesting faster metabolism and potentially lower *in vivo* exposure. Ligand A is preferable.
**13. In vitro Half-Life:** Ligand A (5.531 hours) has a significantly longer half-life than Ligand B (-11.529 hours). This is a major advantage, potentially allowing for less frequent dosing.
**14. P-gp Efflux:** Ligand A (0.154) has lower P-gp efflux than Ligand B (0.301), which is preferable for better bioavailability.
**15. Binding Affinity:** Ligand B (-6.6 kcal/mol) has a slightly better binding affinity than Ligand A (-5.3 kcal/mol). While affinity is important, the 1.3 kcal/mol difference is not large enough to overcome the significant ADME advantages of Ligand A.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across several critical ADME properties (DILI, BBB, hERG, Cl_mic, t1/2, Pgp) and has a more favorable TPSA and HBA profile. While Ligand B has slightly better binding affinity, the ADME profile of Ligand A is far superior, making it a more promising drug candidate.
Output:
1
2025-04-17 19:45:37,324 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.365 and 358.404 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (63.25) is higher than Ligand B (42.43). For a cardiovascular GPCR, TPSA is not a primary concern, but lower is generally preferred for better absorption. Ligand B is better.
3. **logP:** Both ligands have good logP values (3.032 and 3.656), falling within the optimal 1-3 range. Ligand B is slightly higher, which could potentially lead to some off-target effects, but isn't a major concern.
4. **HBD:** Ligand A has 2 HBD, while Ligand B has 0. Both are acceptable, but fewer HBDs often correlate with better membrane permeability. Ligand B is better.
5. **HBA:** Both ligands have 3 HBA, which is within the acceptable range. No significant difference.
6. **QED:** Ligand A (0.874) has a significantly higher QED score than Ligand B (0.677), indicating a more drug-like profile. This is a strong advantage for Ligand A.
7. **DILI:** Ligand A (61.07) has a higher DILI risk than Ligand B (20.163). This is a significant concern, as lower DILI is highly desirable. Ligand B is much better.
8. **BBB:** Ligand A (86.817) has a good BBB percentile, while Ligand B (96.161) is even better. For a cardiovascular target, BBB penetration isn't critical, but higher is not detrimental. Ligand B is better.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.25 and -4.106), which is unusual and suggests poor permeability. This is a significant drawback for both.
10. **Solubility:** Both ligands have negative solubility values (-3.926 and -3.775), indicating very poor aqueous solubility. This is a major issue for both compounds and will likely require formulation strategies.
11. **hERG:** Both ligands have low hERG inhibition liability (0.274 and 0.636), which is excellent. No significant difference.
12. **Cl_mic:** Ligand A (56.877) has lower microsomal clearance than Ligand B (67.514), suggesting better metabolic stability. This is a positive for Ligand A.
13. **t1/2:** Ligand A (-25.522) has a negative in vitro half-life, which is concerning. Ligand B (-6.615) is also negative, but less so. Both are problematic.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.099 and 0.215), which is good. No significant difference.
15. **Binding Affinity:** Both ligands have very similar and strong binding affinities (-5.6 and -6.4 kcal/mol). Ligand B has a slightly better affinity, but the difference is small.
**GPCR-Specific Priorities & Overall Assessment:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, and affinity. Ligand B performs better on TPSA, Pgp, and BBB. However, Ligand A has a better QED and lower Cl_mic. The biggest differentiating factor is the DILI risk, where Ligand B is significantly better. The negative Caco-2 and solubility values are concerning for both, but can potentially be addressed with formulation. The negative half-lives are also concerning, but the lower Cl_mic for Ligand A might mitigate this somewhat.
Considering the significant DILI risk associated with Ligand A, and the slightly better overall profile of Ligand B (better TPSA, BBB, DILI, and affinity), I favor Ligand B.
Output:
0
2025-04-17 19:45:37,324 - INFO - Batch 134 complete. Total preferences: 2144
2025-04-17 19:45:37,324 - INFO - Processing batch 135/512...
2025-04-17 19:46:26,428 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.355 and 345.487 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (110.03) is higher than Ligand B (73.2). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is still preferable for absorption. Ligand B is better.
3. **logP:** Ligand B (3.004) is slightly higher than Ligand A (1.8). Both are within the optimal 1-3 range, but Ligand B is closer to the upper end, potentially aiding membrane permeability.
4. **HBD:** Ligand A (3) is higher than Ligand B (1). Lower HBD is generally preferred for better permeability, making Ligand B better.
5. **HBA:** Ligand A (6) is higher than Ligand B (3). Similar to HBD, lower HBA is preferred, favoring Ligand B.
6. **QED:** Both ligands have similar QED values (0.658 and 0.661), indicating good drug-likeness. No significant difference.
7. **DILI:** Ligand B (17.449) has a significantly lower DILI risk than Ligand A (79.139). This is a major advantage for Ligand B.
8. **BBB:** Ligand B (74.68) has a higher BBB penetration percentile than Ligand A (37.069). While ADRB2 isn't strictly a CNS target, some CNS exposure can occur, and higher BBB is generally favorable.
9. **Caco-2:** Ligand A (-4.854) has a more negative Caco-2 value, indicating better permeability than Ligand B (-4.597).
10. **Solubility:** Ligand A (-3.423) has a slightly better solubility than Ligand B (-4.03).
11. **hERG:** Ligand A (0.352) has a lower hERG inhibition liability than Ligand B (0.626). This is a significant advantage for Ligand A, as it suggests a lower risk of cardiotoxicity.
12. **Cl_mic:** Ligand B (80.787) has a higher microsomal clearance than Ligand A (44.168), meaning it's metabolized faster. Ligand A is better in terms of metabolic stability.
13. **t1/2:** Ligand A (22.705) has a longer in vitro half-life than Ligand B (-7.882). This is a significant advantage for Ligand A, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.072) has a lower P-gp efflux liability than Ligand B (0.243). Lower P-gp efflux is generally desirable for improved bioavailability.
15. **Binding Affinity:** Ligand B (-4.9) has a significantly stronger binding affinity than Ligand A (-7.1). This is a substantial advantage for Ligand B, potentially outweighing some of the ADME drawbacks.
**Overall Assessment:**
Ligand B has a substantially better binding affinity and a much lower DILI risk. It also has better TPSA, HBD, and HBA values. While Ligand A has advantages in metabolic stability (Cl_mic, t1/2), hERG, and P-gp efflux, the strong binding affinity and safety profile of Ligand B are more critical for a GPCR target like ADRB2. The difference in binding affinity (-4.9 vs -7.1) is significant.
Output:
0
2025-04-17 19:46:26,428 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
We are targeting ADRB2, a GPCR. Therefore, the priorities are logP, Pgp, TPSA, BBB, and affinity. Let's break down the comparison:
1. **Molecular Weight:** Both ligands (374.522 and 373.965 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (60.85) is better than Ligand B (38.77). Lower TPSA generally favors better cell permeability, which is crucial for GPCR targeting.
3. **logP:** Ligand A (2.222) is within the optimal 1-3 range. Ligand B (4.304) is higher, potentially leading to solubility issues and off-target interactions. This is a significant negative for Ligand B.
4. **H-Bond Donors/Acceptors:** Ligand A (1 HBD, 4 HBA) and Ligand B (0 HBD, 3 HBA) are both reasonable.
5. **QED:** Ligand A (0.662) is better than Ligand B (0.446), indicating a more drug-like profile.
6. **DILI:** Both ligands have low DILI risk (12.33 and 12.059 percentile), which is good.
7. **BBB:** Both ligands have high BBB penetration (85.072 and 89.88 percentile), which is good, but Ligand B is slightly better.
8. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the values are similar.
9. **Solubility:** Ligand A (-1.859) is better than Ligand B (-4.45), indicating better aqueous solubility. This is important given Ligand B's higher logP.
10. **hERG:** Both ligands have low hERG inhibition risk (0.688 and 0.723 percentile).
11. **Cl_mic:** Ligand A (38.558 mL/min/kg) has significantly lower microsomal clearance than Ligand B (103.196 mL/min/kg), suggesting better metabolic stability.
12. **t1/2:** Ligand A (-1.616 hours) has a shorter half-life than Ligand B (18.712 hours). This is a negative for Ligand A, but can be addressed with formulation.
13. **Pgp:** Both ligands have low P-gp efflux (0.266 and 0.659 percentile).
14. **Binding Affinity:** Both ligands have similar binding affinities (-6.8 and -6.7 kcal/mol). The difference is negligible.
**Overall Assessment:**
Ligand A is preferable. While Ligand B has slightly better BBB penetration and in vitro half-life, Ligand A excels in crucial areas: TPSA, logP, QED, solubility, and, importantly, metabolic stability (lower Cl_mic). Ligand B's higher logP is a significant concern, potentially leading to poor solubility and off-target effects. The better TPSA and QED of Ligand A also contribute to its improved drug-like properties. The difference in half-life can be mitigated through formulation strategies.
**Output:**
1
2025-04-17 19:46:26,428 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (350.463) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (78.68) is better than Ligand B (96.12). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA is still preferred for oral absorption.
3. **logP:** Ligand A (1.606) is within the optimal range, while Ligand B (3.162) is approaching the upper limit. Higher logP can sometimes lead to off-target effects and solubility issues.
4. **HBD:** Ligand A (1) is preferable to Ligand B (0) as it provides a balance between solubility and permeability.
5. **HBA:** Both ligands have the same number of HBA (5), which is acceptable.
6. **QED:** Ligand A (0.873) has a significantly better QED score than Ligand B (0.38), indicating a more drug-like profile.
7. **DILI:** Ligand A (18.922) has a much lower DILI risk than Ligand B (37.999), a critical advantage.
8. **BBB:** Both ligands have similar BBB penetration (Ligand A: 72.741, Ligand B: 72.237). This isn't a primary concern for a cardiovascular target.
9. **Caco-2:** Ligand A (-4.847) has a slightly better Caco-2 permeability than Ligand B (-4.571).
10. **Solubility:** Ligand A (-1.683) is better than Ligand B (-3.132). Solubility is important for bioavailability.
11. **hERG:** Both ligands have very low hERG inhibition risk (Ligand A: 0.394, Ligand B: 0.404).
12. **Cl_mic:** Ligand A (3.869) has a much lower microsomal clearance than Ligand B (58.679), indicating better metabolic stability.
13. **t1/2:** Ligand A (9.352) has a shorter half-life than Ligand B (12.01), but the difference is not substantial.
14. **Pgp:** Both ligands have low Pgp efflux liability (Ligand A: 0.036, Ligand B: 0.128).
15. **Binding Affinity:** Ligand A (-7.2) has a slightly better binding affinity than Ligand B (-6.9), although the difference is less than 1.5 kcal/mol.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A performs better on TPSA, logP, and has a slightly better affinity. The significant advantages in QED, DILI, and Cl_mic further solidify its preference.
**Conclusion:**
Ligand A is the superior candidate due to its better overall drug-like properties, lower toxicity risk, and improved metabolic stability. While the affinity difference is small, the combined benefits of Ligand A outweigh the slightly better half-life of Ligand B.
Output:
1
2025-04-17 19:46:26,428 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (a cardiovascular GPCR) drug candidates.
**Ligand A:** [367.852, 55.81, 1.632, 2, 4, 0.852, 39.977, 67.08, -4.949, -2.491, 0.708, 0.681, -0.777, 0.149, -7.5]
**Ligand B:** [353.447, 71.09, 2.97, 2, 4, 0.83, 63.397, 61.729, -4.676, -4.897, 0.26, 20.137, 22.657, 0.157, -7.7]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (353.447) is slightly lower, which could be marginally better for permeability.
2. **TPSA:** Ligand A (55.81) is significantly better than Ligand B (71.09). For a cardiovascular GPCR, we don't *require* extremely low TPSA for CNS penetration, but lower is generally preferable for oral absorption.
3. **logP:** Both are within the optimal range (1-3). Ligand B (2.97) is a bit higher, potentially increasing off-target interactions or decreasing solubility, but not drastically. Ligand A (1.632) is a bit more balanced.
4. **HBD:** Both have 2 HBD, which is good.
5. **HBA:** Both have 4 HBA, which is good.
6. **QED:** Both are similar and above the 0.5 threshold, indicating good drug-likeness.
7. **DILI:** Ligand A (39.977) has a significantly lower DILI risk than Ligand B (63.397). This is a major advantage for Ligand A.
8. **BBB:** Both are reasonably good, but Ligand A (67.08) is slightly better than Ligand B (61.729). While not a primary concern for a cardiovascular target, some peripheral ADRB2 receptors may benefit from some BBB penetration.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-4.949) is slightly worse than Ligand B (-4.676).
10. **Solubility:** Ligand A (-2.491) is better than Ligand B (-4.897). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.708) is better than Ligand B (0.26). Lower hERG inhibition is crucial to avoid cardiotoxicity.
12. **Cl_mic:** Ligand A (0.681) has significantly lower microsomal clearance than Ligand B (20.137). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand B (22.657) has a much longer in vitro half-life than Ligand A (-0.777). This is a significant advantage for Ligand B.
14. **Pgp:** Both have low Pgp efflux liability, with Ligand A (0.149) being slightly lower.
15. **Affinity:** Ligand B (-7.7) has a slightly better binding affinity than Ligand A (-7.5). This is a 1.5 kcal/mol advantage, which is significant.
**Overall Assessment:**
Ligand B has a better binding affinity and a significantly longer half-life. However, Ligand A excels in several crucial ADME-Tox parameters: lower DILI risk, better solubility, lower hERG inhibition, and significantly better metabolic stability (lower Cl_mic). The TPSA is also more favorable for Ligand A.
Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity) and the overall balance, the lower DILI risk, better solubility, and improved metabolic stability of Ligand A outweigh the slightly better affinity and half-life of Ligand B. A slightly longer half-life can often be addressed through formulation or prodrug strategies, but mitigating potential liver toxicity and ensuring adequate metabolic stability are more fundamental.
Output:
1
2025-04-17 19:46:26,429 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (366.49 and 369.45 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (79.74) is higher than Ligand B (64.43). While both are below the 140 threshold for oral absorption, the lower TPSA of Ligand B is slightly preferable for a GPCR, potentially aiding in membrane permeability.
3. **logP:** Ligand A (1.40) is within the optimal 1-3 range. Ligand B (3.06) is at the higher end, but still acceptable.
4. **HBD:** Ligand A has 2 HBD, while Ligand B has 0. Both are within the acceptable limit of 5.
5. **HBA:** Ligand A has 8 HBA, and Ligand B has 5. Both are within the acceptable limit of 10.
6. **QED:** Ligand A (0.81) has a higher QED score than Ligand B (0.595), indicating better overall drug-likeness. This is a significant advantage for Ligand A.
7. **DILI:** Ligand A (60.22) has a higher DILI risk than Ligand B (19.70). This is a major concern for Ligand A. Ligand B is well below the 40% threshold, indicating low liver injury risk.
8. **BBB:** Ligand B (78.05) has a higher BBB penetration percentile than Ligand A (69.68). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be beneficial for understanding off-target effects and overall distribution.
9. **Caco-2:** Ligand A (-5.095) and Ligand B (-4.542) both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Ligand A (-2.719) and Ligand B (-2.025) both have negative solubility values, which is also unusual and suggests poor solubility. Again, the scale is not specified.
11. **hERG:** Ligand A (0.598) has a slightly higher hERG inhibition risk than Ligand B (0.393), but both are relatively low.
12. **Cl_mic:** Ligand B (63.48) has a higher microsomal clearance than Ligand A (47.70), meaning Ligand A is more metabolically stable.
13. **t1/2:** Ligand A (43.01) has a significantly longer in vitro half-life than Ligand B (21.58). This is a substantial advantage for Ligand A, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.045) has a much lower Pgp efflux liability than Ligand B (0.293). Lower Pgp is generally desirable for improved bioavailability.
15. **Binding Affinity:** Both ligands have the same binding affinity (-6.7 kcal/mol). This eliminates affinity as a differentiating factor.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B has a more favorable logP and TPSA. Ligand A has a much lower Pgp efflux liability. However, the DILI risk for Ligand A is significantly higher, which is a major concern.
**Overall Assessment:**
While Ligand A has advantages in QED, metabolic stability (Cl_mic), and half-life, the significantly higher DILI risk and slightly worse BBB penetration are major drawbacks. Ligand B, despite having a slightly higher logP and Pgp efflux, presents a much safer profile with a very low DILI risk. Given the importance of safety in drug development, and the comparable binding affinity, Ligand B is the more promising candidate.
Output:
0
2025-04-17 19:46:26,429 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (341.415 and 348.531 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (80.12) is better than Ligand B (49.41). Both are below 140, but A is closer to the upper limit. For a cardiovascular GPCR, CNS penetration isn't a primary goal, so TPSA isn't *as* critical, but lower is generally preferred.
3. **logP:** Ligand A (1.47) is optimal, while Ligand B (4.055) is pushing the upper limit. High logP can lead to poor solubility and off-target effects. This is a significant advantage for Ligand A.
4. **HBD:** Both have 1 HBD, which is within the ideal range.
5. **HBA:** Ligand A has 5 HBA, while Ligand B has 2. Both are within the ideal range.
6. **QED:** Ligand A (0.913) is excellent, indicating high drug-likeness. Ligand B (0.639) is still acceptable, but lower.
7. **DILI:** Ligand A (47.77) has a slightly higher DILI risk than Ligand B (13.571), but both are well below the concerning threshold of 60.
8. **BBB:** Ligand B (78.868) has a higher BBB penetration percentile than Ligand A (67.119). However, as ADRB2 is a cardiovascular target, BBB penetration is not a major priority.
9. **Caco-2:** Both ligands have very negative Caco-2 values (-4.823 and -4.809). This suggests poor permeability, which is a concern.
10. **Solubility:** Ligand A (-1.322) has better solubility than Ligand B (-4.148). Solubility is important for bioavailability.
11. **hERG:** Both ligands have low hERG inhibition risk (0.253 and 0.484).
12. **Cl_mic:** Ligand A (-2.953) has a more negative value, indicating lower clearance and better metabolic stability than Ligand B (57.072). This is a significant advantage.
13. **t1/2:** Ligand A (-8.5) has a more negative value, indicating a longer half-life than Ligand B (-11.924).
14. **Pgp:** Both have very low Pgp efflux liability (0.03 and 0.449).
15. **Binding Affinity:** Both ligands have the same binding affinity (-5.4 kcal/mol).
**Overall Assessment:**
Ligand A is superior. While Ligand B has a slightly better BBB score (irrelevant for this target) and lower DILI risk, Ligand A excels in crucial areas: logP, QED, solubility, metabolic stability (Cl_mic), and half-life. The poor Caco-2 values are a concern for both, but can be addressed through formulation strategies. The more favorable ADME profile of Ligand A, combined with equal binding affinity, makes it the more promising drug candidate for ADRB2.
Output:
1
2025-04-17 19:46:26,429 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (343.431 Da and 357.841 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (81.93) is higher than Ligand B (53.51). For a cardiovascular GPCR, TPSA is moderately important. Ligand B's lower TPSA is preferable, suggesting better potential for membrane permeability.
**3. logP:** Both ligands have good logP values (1.795 and 2.211, respectively), falling within the optimal 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability.
**4. H-Bond Donors:** Ligand A has 1 HBD, while Ligand B has 0. Both are acceptable, staying within the guideline of <=5.
**5. H-Bond Acceptors:** Ligand A has 6 HBA, and Ligand B has 3. Both are within the acceptable range of <=10. Ligand B is preferable here.
**6. QED:** Both ligands have similar QED values (0.751 and 0.762), indicating good drug-likeness. No significant difference.
**7. DILI Risk:** Ligand A (44.591) has a lower DILI risk than Ligand B (68.244). This is a significant advantage for Ligand A.
**8. BBB Penetration:** Both ligands show reasonable BBB penetration (76.309 and 72.664). Since this is a cardiovascular target, BBB penetration isn't *critical*, but it's a bonus.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.791 and -4.683), which is unusual and suggests poor permeability. This is a concern for both.
**10. Aqueous Solubility:** Both ligands have negative solubility values (-2.276 and -3.455). This is also a concern, indicating poor aqueous solubility.
**11. hERG Inhibition:** Ligand A (0.073) has a much lower hERG inhibition risk than Ligand B (0.35). This is a crucial advantage for Ligand A, as hERG inhibition can lead to cardiotoxicity.
**12. Microsomal Clearance:** Ligand A (54.923) has a higher microsomal clearance than Ligand B (50.163), indicating faster metabolism. Ligand B is preferable here.
**13. In vitro Half-Life:** Ligand B (-46.135) has a significantly longer in vitro half-life than Ligand A (-9.48). This is a major advantage for Ligand B, potentially allowing for less frequent dosing.
**14. P-gp Efflux:** Ligand A (0.059) has lower P-gp efflux than Ligand B (0.282), which is preferable for bioavailability.
**15. Binding Affinity:** Ligand B (-7.3) has a significantly stronger binding affinity than Ligand A (-6.0). This is a substantial advantage, potentially outweighing some of the ADME drawbacks.
**Overall Assessment:**
Ligand B has a significantly better binding affinity and a longer half-life. While Ligand A has a lower DILI risk and hERG inhibition, the stronger binding affinity of Ligand B is a critical factor for GPCR targets. The slightly better logP and TPSA of Ligand B are also beneficial. The poor Caco-2 and solubility values are concerns for both, but can potentially be addressed through formulation strategies. The improved binding affinity of Ligand B is likely to translate to greater efficacy, making it the more promising candidate.
Output:
0
2025-04-17 19:46:26,429 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (363.845 Da and 358.427 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (77.25) is significantly better than Ligand B (104.03). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is approaching a concerning level.
3. **logP:** Ligand A (4.236) is higher than Ligand B (1.077). While both are within the acceptable range, Ligand A is on the higher side. Ligand B is quite low, potentially hindering membrane permeability.
4. **HBD:** Both ligands have 1 HBD, which is ideal.
5. **HBA:** Ligand A has 5 HBA, while Ligand B has 8. Ligand A is preferable here, as lower HBA generally improves permeability.
6. **QED:** Both ligands have similar QED values (0.859 and 0.872), indicating good drug-likeness.
7. **DILI:** Ligand B (81.776) has a higher DILI risk than Ligand A (70.066), though both are reasonably acceptable. Lower is always preferred.
8. **BBB:** Ligand A (82.745) has a significantly higher BBB penetration score than Ligand B (53.083). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be useful for understanding off-target effects and overall distribution.
9. **Caco-2:** Ligand A (-4.331) and Ligand B (-5.221) both have negative Caco-2 values, which is unusual and suggests very poor permeability. However, the scale is not specified, so it is hard to interpret.
10. **Solubility:** Ligand A (-5.344) and Ligand B (-3.318) both have negative solubility values, which is also unusual and suggests very poor solubility. However, the scale is not specified, so it is hard to interpret.
11. **hERG:** Ligand A (0.207) has a lower hERG inhibition liability than Ligand B (0.364), which is preferable.
12. **Cl_mic:** Ligand A (70.377) has a higher microsomal clearance than Ligand B (24.362), suggesting lower metabolic stability. This is a significant drawback for Ligand A.
13. **t1/2:** Ligand B (9.499) has a longer in vitro half-life than Ligand A (11.414). This is a positive for Ligand B.
14. **Pgp:** Ligand A (0.082) has lower P-gp efflux liability than Ligand B (0.121), which is preferable.
15. **Binding Affinity:** Ligand B (-7.0 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.9 kcal/mol). This is a substantial advantage for Ligand B, potentially outweighing some of its ADME drawbacks.
**Overall Assessment:**
Ligand B has a superior binding affinity, better metabolic stability (lower Cl_mic, longer t1/2), and lower Pgp efflux. While its TPSA is higher and logP lower than ideal, the substantial affinity advantage and better metabolic profile are compelling. Ligand A has better TPSA and Pgp, but suffers from higher Cl_mic and a weaker binding affinity. Given the GPCR target class, the strong binding affinity of Ligand B is a key driver.
Output:
0
2025-04-17 19:46:26,429 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (363.439 and 371.459 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (101.15) is slightly higher than Ligand B (96.97). Both are below the 140 threshold for oral absorption, but closer to the 90 threshold for CNS targets. Ligand B is slightly better.
3. **logP:** Both ligands have good logP values (1.787 and 1.1), falling within the 1-3 optimal range. Ligand B is slightly lower, which could potentially impact permeability, but is still acceptable.
4. **HBD:** Both ligands have 2 H-bond donors, which is within the acceptable limit of <=5. No clear advantage.
5. **HBA:** Ligand A has 6 H-bond acceptors, while Ligand B has 5. Both are below the 10 limit. No clear advantage.
6. **QED:** Ligand B (0.748) has a higher QED score than Ligand A (0.55), indicating a more drug-like profile. This is a significant advantage.
7. **DILI:** Ligand B (60.915) has a lower DILI risk than Ligand A (76.774), which is preferable.
8. **BBB:** Ligand B (63.203) has a significantly higher BBB penetration percentile than Ligand A (45.56). While ADRB2 isn't strictly a CNS target, some CNS exposure can occur, and higher BBB is generally favorable.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.49 and -4.995), which is unusual and suggests poor permeability. These values are likely errors, or represent a very low permeability.
10. **Solubility:** Both ligands have negative solubility values (-2.403 and -2.604), which is also unusual and suggests very poor aqueous solubility. These values are likely errors, or represent a very low solubility.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.262 and 0.284). No clear advantage.
12. **Cl_mic:** Ligand B (45.529) has slightly lower microsomal clearance than Ligand A (47.262), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-27.62) has a significantly *longer* in vitro half-life than Ligand A (11.771). This is a major advantage.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.164 and 0.077). Ligand B is slightly better.
15. **Binding Affinity:** Ligand A (-6.9 kcal/mol) has a slightly better binding affinity than Ligand B (-5.9 kcal/mol). This is a 1.0 kcal/mol difference, which is a good advantage.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand A has a slightly better affinity. However, Ligand B excels in several other critical areas: QED, DILI, BBB, metabolic stability (Cl_mic and t1/2), and Pgp efflux. The better overall ADME profile of Ligand B, combined with acceptable affinity, outweighs the slight advantage in binding affinity of Ligand A. The negative Caco-2 and solubility values are concerning for both, but the superior ADME properties of Ligand B make it the more promising candidate.
**Output:**
0
2025-04-17 19:46:26,430 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (344.46 and 349.44 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (67.23) is significantly better than Ligand B (100.35). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally correlates with better absorption. Ligand B is pushing the upper limit for good oral absorption.
3. **logP:** Ligand A (2.419) is optimal, while Ligand B (0.014) is very low. This is a major concern for Ligand B, as it may struggle with membrane permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (4) is better than Ligand B (6). Similar to HBD, fewer HBA is generally preferred.
6. **QED:** Both ligands have similar, acceptable QED values (0.7 and 0.754).
7. **DILI:** Ligand A (28.89) has a significantly lower DILI risk than Ligand B (41.33). This is a crucial advantage.
8. **BBB:** Ligand A (71.89) has better BBB penetration than Ligand B (43.00). While not a primary concern for a cardiovascular target, it's a bonus.
9. **Caco-2:** Ligand A (-4.642) is better than Ligand B (-5.184). Both are negative, which is unusual, but a less negative value is preferred.
10. **Solubility:** Ligand A (-2.444) is better than Ligand B (-1.208). Better solubility is always desirable.
11. **hERG:** Ligand A (0.48) is much better than Ligand B (0.024). Lower hERG inhibition is critical for avoiding cardiotoxicity, especially for a cardiovascular target.
12. **Cl_mic:** Ligand A (43.74) has higher metabolic clearance than Ligand B (3.99). Lower clearance is preferred for longer duration of action.
13. **t1/2:** Ligand B (8.49) has a significantly longer in vitro half-life than Ligand A (-13.65). This is a substantial advantage for Ligand B.
14. **Pgp:** Ligand A (0.104) has lower P-gp efflux than Ligand B (0.013). Lower Pgp is generally better for bioavailability.
15. **Binding Affinity:** Ligand A (-7.1) has a slightly better binding affinity than Ligand B (-6.1). While the difference is 1 kcal/mol, it's enough to consider, especially given the other favorable properties of Ligand A.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A excels in logP, TPSA, and Pgp, and has a slightly better affinity. Ligand B's only major advantage is its longer half-life, but the poor logP, higher TPSA, and higher DILI/hERG risks are significant drawbacks.
**Conclusion:**
Despite Ligand B's longer half-life, Ligand A is the more promising candidate due to its superior ADME properties (logP, TPSA, solubility, DILI, hERG) and comparable binding affinity. The combination of these factors makes Ligand A a more likely successful drug candidate.
Output:
1
2025-04-17 19:46:26,430 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, priorities are logP, TPSA, Pgp efflux, affinity, and to a lesser extent, BBB.
Let's break down the comparison:
1. **MW:** Both ligands (358.36 and 350.423 Da) fall comfortably within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (69.64) is significantly better than Ligand B (128.69). A TPSA under 140 is good for oral absorption, but lower is better for GPCRs, and A is much closer to optimal.
3. **logP:** Ligand A (1.946) is within the optimal 1-3 range. Ligand B (0.689) is a bit low, potentially hindering permeability.
4. **HBD/HBA:** Ligand A (2 HBD, 3 HBA) is preferable to Ligand B (4 HBD, 6 HBA). Lower counts are generally better for permeability.
5. **QED:** Ligand A (0.763) is better than Ligand B (0.469), indicating a more drug-like profile.
6. **DILI:** Ligand B (54.556) is slightly better than Ligand A (40.985), but both are acceptable (<60).
7. **BBB:** Ligand A (59.325) is better than Ligand B (9.616). While not a primary concern for a cardiovascular target, higher BBB is generally favorable.
8. **Caco-2:** Both are negative, indicating poor permeability. However, the scale is not provided, so it's difficult to interpret the absolute values.
9. **Solubility:** Both are negative, indicating poor solubility. Again, the scale is not provided.
10. **hERG:** Ligand A (0.075) is significantly better than Ligand B (0.337), indicating a lower risk of cardiotoxicity. This is crucial for a cardiovascular target.
11. **Cl_mic:** Ligand B (-10.681) is better (lower clearance) than Ligand A (-4.467), suggesting better metabolic stability.
12. **t1/2:** Ligand B (-7.274) is better (longer half-life) than Ligand A (-11.355).
13. **Pgp:** Ligand A (0.008) is *much* better than Ligand B (0.131), indicating lower P-gp efflux and potentially better bioavailability.
14. **Affinity:** Ligand B (-7.8 kcal/mol) has a slightly better affinity than Ligand A (-6.1 kcal/mol). This is a 1.7 kcal/mol difference, which is significant and could outweigh some ADME drawbacks.
**Overall Assessment:**
While Ligand B has better affinity and metabolic stability, Ligand A has superior TPSA, logP, QED, BBB, hERG, and Pgp properties. The combination of better TPSA, logP, Pgp, and a much lower hERG risk makes Ligand A a more promising candidate, especially considering it's a GPCR target. The affinity difference, while notable, isn't large enough to overcome the ADME advantages of Ligand A.
**Output:**
1
2025-04-17 19:46:26,430 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.38 and 341.41 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand B (85.43) is significantly better than Ligand A (103.09). ADRB2 is not a CNS target, but lower TPSA generally correlates with better absorption, making B preferable.
3. **logP:** Ligand B (1.517) is within the optimal 1-3 range, while Ligand A (0.303) is quite low. This is a significant advantage for B, as low logP can hinder membrane permeability.
4. **HBD:** Both have 3-4 HBD, which is acceptable.
5. **HBA:** Both have 3 HBA, which is acceptable.
6. **QED:** Both ligands have good QED scores (0.629 and 0.788), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand B (45.522) has a much lower DILI risk than Ligand A (60.644). This is a crucial advantage, as minimizing liver toxicity is paramount.
8. **BBB:** BBB is not a high priority for ADRB2. Both are relatively low, which is fine.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. This is a concern for both, but the lower TPSA and better logP of Ligand B suggest it *might* overcome this better.
10. **Solubility:** Both have negative solubility values, indicating poor solubility. This is a concern for both.
11. **hERG:** Ligand B (0.404) has a slightly better hERG profile than Ligand A (0.235), though both are relatively low risk.
12. **Cl_mic:** Ligand A (-19.358) has significantly lower (better) microsomal clearance than Ligand B (10.532). This suggests greater metabolic stability for A.
13. **t1/2:** Ligand A (21.338 hours) has a much longer in vitro half-life than Ligand B (-10.259 hours). This is a significant advantage for A, potentially allowing for less frequent dosing.
14. **Pgp:** Both have very low Pgp efflux liability, which is good.
15. **Binding Affinity:** Ligand A (-7.3 kcal/mol) has a slightly better binding affinity than Ligand B (-6.1 kcal/mol). This is a 1.2 kcal/mol difference, which is a meaningful advantage.
**Overall Assessment:**
While Ligand A has better binding affinity and metabolic stability (lower Cl_mic, longer t1/2), Ligand B has a significantly better logP, lower DILI risk, and a slightly better QED and hERG profile. Given that ADRB2 is not a CNS target, the BBB parameter is less important. The combination of improved ADME properties (especially logP and DILI) outweighs the modest difference in binding affinity. The poor Caco-2 and solubility are concerns for both, but the better physicochemical properties of B suggest it might be optimized more effectively.
Output:
0
2025-04-17 19:46:26,430 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (384.267 Da) is slightly higher than Ligand B (343.427 Da), but both are acceptable.
2. **TPSA:** Ligand A (72.28) is better than Ligand B (80.32). Both are below 140, but lower is preferred for permeability.
3. **logP:** Both ligands have good logP values (A: 2.888, B: 1.656) falling within the optimal 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability, but not excessively high.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (4). Lower HBA generally improves permeability.
6. **QED:** Ligand A (0.88) is significantly better than Ligand B (0.608), indicating a more drug-like profile.
7. **DILI:** Ligand B (55.68) has a lower DILI risk than Ligand A (76.192), which is a significant advantage.
8. **BBB:** Ligand A (65.607) has a better BBB penetration potential than Ligand B (53.238). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be useful for understanding off-target effects and distribution.
9. **Caco-2:** Both ligands have very negative Caco-2 values (-4.829 and -4.843). This is unusual and suggests poor permeability *in vitro*. This is a significant concern for both.
10. **Solubility:** Ligand A (-3.182) has slightly better solubility than Ligand B (-2.329), though both are quite poor.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.225 and 0.216), which is excellent.
12. **Cl_mic:** Ligand B (15.256) has significantly lower microsomal clearance than Ligand A (25.024), indicating better metabolic stability.
13. **t1/2:** Ligand B (-6.423) has a longer in vitro half-life than Ligand A (26.129). This is a significant advantage.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.054 and 0.07), which is good.
15. **Binding Affinity:** Ligand A (-6.0) has a significantly better binding affinity than Ligand B (-0.7). This is a crucial factor, as a >1.5 kcal/mol difference can outweigh other drawbacks.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A excels in logP and *especially* affinity. Ligand B has better metabolic stability (Cl_mic and t1/2) and lower DILI risk. The negative Caco-2 values for both are concerning, but the substantial affinity difference of Ligand A is a major driver.
**Overall Assessment:**
Despite the poor Caco-2 values and slightly higher DILI risk, Ligand A's significantly stronger binding affinity (-6.0 kcal/mol vs -0.7 kcal/mol) is a decisive advantage. The potency is so much higher that it outweighs the other drawbacks, especially considering the low hERG risk for both. Optimization efforts could then focus on improving permeability and reducing DILI risk.
Output:
1
2025-04-17 19:46:26,430 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.43 & 350.42 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (66.92) is significantly better than Ligand B (87.91). ADRB2 is a cardiovascular target, not CNS, but lower TPSA generally aids absorption. Ligand A is well below the 140 threshold. Ligand B is approaching the upper limit.
3. **logP:** Both ligands have acceptable logP values (0.984 & 0.66), falling within the 1-3 range. Ligand A is slightly better.
4. **HBD:** Ligand A (0) is preferable to Ligand B (1). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is better than Ligand B (6). Lower HBA contributes to better permeability.
6. **QED:** Both ligands have similar and good QED scores (0.764 & 0.727), indicating good drug-like properties.
7. **DILI:** Ligand A (28.31%) has a lower DILI risk than Ligand B (36.10%). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (83.25%) has a much higher BBB penetration score than Ligand B (64.99%). While ADRB2 isn't a CNS target, higher BBB penetration *can* sometimes correlate with better overall distribution.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.372 & -4.894). This is unusual and suggests poor permeability *in vitro*. However, the values are similar.
10. **Solubility:** Ligand A (-2.289) is slightly better than Ligand B (-0.804), indicating better aqueous solubility.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.135 & 0.153), which is excellent.
12. **Cl_mic:** Ligand A (47.37) has a higher microsomal clearance than Ligand B (14.80). This suggests Ligand B is more metabolically stable, a positive attribute.
13. **t1/2:** Ligand A (4.51) has a longer in vitro half-life than Ligand B (1.62). This is a significant advantage for Ligand A.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.041 & 0.009).
15. **Binding Affinity:** Ligand A (-6.9 kcal/mol) has a slightly better binding affinity than Ligand B (-6.7 kcal/mol). While the difference is small, it's still a positive for Ligand A.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A excels in TPSA, logP, and has slightly better affinity. While BBB isn't critical here, it's not detrimental to have a higher value. Metabolic stability (Cl_mic) is important, and Ligand B has an advantage there. However, the other benefits of Ligand A, particularly the lower DILI risk, longer half-life, and better TPSA/logP, outweigh the metabolic stability advantage of Ligand B.
**Conclusion:**
Ligand A presents a more balanced profile with better predicted absorption, lower toxicity risk, and slightly better binding.
Output:
1
2025-04-17 19:46:26,431 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (380.897) is slightly higher than Ligand B (351.447), but both are acceptable.
2. **TPSA:** Ligand A (60.85) is better than Ligand B (75.88). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally aids absorption.
3. **logP:** Both ligands have good logP values (A: 2.24, B: 2.109), falling within the optimal 1-3 range.
4. **HBD:** Ligand A (1) is preferable to Ligand B (0). A single H-bond donor can contribute to solubility without significantly hindering permeability.
5. **HBA:** Ligand A (4) is preferable to Ligand B (5). Lower HBA is generally better for permeability.
6. **QED:** Both ligands have similar QED values (A: 0.8, B: 0.752), indicating good drug-likeness.
7. **DILI:** Ligand A (25.785) has a significantly lower DILI risk than Ligand B (34.626). This is a crucial advantage.
8. **BBB:** Ligand B (83.404) has a higher BBB penetration percentile than Ligand A (56.301). However, as ADRB2 is primarily a cardiovascular target, high BBB penetration is not a major priority.
9. **Caco-2:** Ligand A (-4.718) and Ligand B (-4.472) have similar Caco-2 permeability values.
10. **Solubility:** Ligand B (-0.731) has better aqueous solubility than Ligand A (-3.133). Solubility is important, but can often be addressed with formulation strategies.
11. **hERG:** Ligand A (0.51) has a lower hERG inhibition liability than Ligand B (0.313). This is a significant safety advantage.
12. **Cl_mic:** Ligand A (0.9) has significantly lower microsomal clearance than Ligand B (52.265), indicating better metabolic stability.
13. **t1/2:** Ligand A (-6.169) has a much longer in vitro half-life than Ligand B (-12.516). This is a major advantage, potentially leading to less frequent dosing.
14. **Pgp:** Ligand A (0.266) has lower P-gp efflux liability than Ligand B (0.125). Lower P-gp efflux is generally desirable.
15. **Binding Affinity:** Ligand B (16.2) has a significantly stronger binding affinity than Ligand A (-7.6). This is a substantial advantage, potentially outweighing some of the ADME drawbacks of Ligand B. However, the difference is not *that* large, and Ligand A has a much more favorable ADME profile.
**Overall Assessment:**
While Ligand B boasts a stronger binding affinity, Ligand A presents a far superior ADME profile. Specifically, the lower DILI risk, lower microsomal clearance, longer half-life, and lower hERG inhibition are critical advantages for a drug candidate. The slightly lower affinity of Ligand A is a reasonable trade-off for these improved safety and pharmacokinetic properties. Given the GPCR-specific priorities (logP, Pgp, TPSA, affinity), and the fact that this is a cardiovascular target (less emphasis on BBB), Ligand A is the more promising candidate.
Output:
1
2025-04-17 19:46:26,431 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [361.467, 83.96, 1.729, 2, 5, 0.75, 52.656, 58.24, -5.451, -3.569, 0.49, 36.033, 5.062, 0.133, -6.7]
**Ligand B:** [339.37, 62.3, 2.497, 1, 3, 0.823, 61.225, 63.668, -4.464, -3.868, 0.693, 52.607, 9.428, 0.214, -6.4]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity) and general drug-like properties:
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (339.37) is slightly smaller, which *could* be advantageous for permeability, but the difference isn't huge.
2. **TPSA:** Ligand A (83.96) is a bit higher than Ligand B (62.3). Both are below the 140 threshold for oral absorption, but Ligand B is significantly better, suggesting potentially improved absorption.
3. **logP:** Both are in the optimal range (1-3). Ligand B (2.497) is slightly higher, which might offer a small advantage in membrane permeability.
4. **HBD/HBA:** Ligand A has 2 HBD and 5 HBA, while Ligand B has 1 HBD and 3 HBA. Both are within acceptable limits, and Ligand B is slightly more favorable.
5. **QED:** Both have good QED scores (A: 0.75, B: 0.823), indicating good overall drug-likeness. Ligand B is slightly better.
6. **DILI:** Ligand A (52.656) has a lower DILI risk than Ligand B (61.225), which is a significant advantage.
7. **BBB:** Both have relatively low BBB penetration (A: 58.24, B: 63.668). Since this is a cardiovascular target, BBB penetration isn't a primary concern, so this isn't a major differentiator.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-5.451) is worse than Ligand B (-4.464).
9. **Solubility:** Both have negative solubility values, indicating poor aqueous solubility. Ligand A (-3.569) is slightly worse than Ligand B (-3.868).
10. **hERG:** Both have low hERG risk (A: 0.49, B: 0.693).
11. **Cl_mic:** Ligand A (36.033) has a lower microsomal clearance than Ligand B (52.607), indicating better metabolic stability.
12. **t1/2:** Ligand B (9.428) has a longer in vitro half-life than Ligand A (5.062), which is desirable.
13. **Pgp:** Both have low P-gp efflux liability (A: 0.133, B: 0.214).
14. **Affinity:** Ligand A (-6.7 kcal/mol) has a slightly better binding affinity than Ligand B (-6.4 kcal/mol). The difference is 0.3 kcal/mol, which is not a huge advantage, but still noteworthy.
**Overall Assessment:**
Ligand A has a better binding affinity and lower DILI risk, and better metabolic stability. However, Ligand B has better TPSA, QED, half-life, and slightly better logP. Both have poor predicted permeability and solubility. The slightly better affinity of Ligand A, combined with the lower DILI risk and better metabolic stability, outweigh the advantages of Ligand B.
Therefore, I would choose Ligand A.
1
2025-04-17 19:46:26,431 - INFO - Batch 135 complete. Total preferences: 2160
2025-04-17 19:46:26,431 - INFO - Processing batch 136/512...
2025-04-17 19:47:11,915 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, priorities are affinity, logP, TPSA, Pgp efflux, and BBB penetration.
Let's compare the ligands property by property:
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (349.45) is slightly higher than Ligand B (341.455), but both are acceptable.
2. **TPSA:** Ligand A (43.86) is significantly better than Ligand B (73.2). Lower TPSA generally favors oral absorption and is important for GPCRs.
3. **logP:** Both ligands have acceptable logP values (A: 1.302, B: 2.503), falling within the 1-3 range. Ligand B is slightly higher, which could potentially lead to off-target effects, but isn't a major concern.
4. **HBD:** Both have low HBD counts (A: 0, B: 1), which is favorable.
5. **HBA:** Both have similar HBA counts (A: 3, B: 3), within the acceptable range.
6. **QED:** Both have good QED scores (A: 0.703, B: 0.894), indicating drug-likeness. Ligand B is slightly better.
7. **DILI:** Ligand A (15.316) has a significantly lower DILI risk than Ligand B (27.104), which is a major advantage.
8. **BBB:** Ligand A (94.067) has substantially better BBB penetration than Ligand B (68.941). While not a CNS target, some peripheral GPCRs benefit from limited BBB penetration to minimize off-target effects.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. This is a concern for both.
10. **Solubility:** Both have negative solubility values, indicating poor solubility. This is a concern for both.
11. **hERG:** Both have low hERG inhibition liability (A: 0.619, B: 0.639), which is good.
12. **Cl_mic:** Similar microsomal clearance (A: 38.034, B: 39.565).
13. **t1/2:** Ligand B (1.975) has a slightly longer in vitro half-life than Ligand A (-4.778), which is a positive.
14. **Pgp:** Both have very low Pgp efflux liability (A: 0.115, B: 0.279), which is favorable.
15. **Affinity:** Ligand B (-6.6 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.7 kcal/mol). This is a substantial advantage.
**Overall Assessment:**
Ligand B has a significantly better binding affinity (-6.6 vs -5.7 kcal/mol). However, Ligand A has a much better safety profile (lower DILI, better BBB) and better TPSA. The difference in affinity is substantial (1.5 kcal/mol), which can often outweigh ADME concerns. Considering the GPCR target class, the improved affinity of Ligand B is a critical factor. While the lower TPSA and better safety profile of Ligand A are attractive, the stronger binding of Ligand B is more likely to translate to efficacy.
Output:
0
2025-04-17 19:47:11,915 - INFO - Here's my reasoning and final output for the ligand preference:
**Reasoning:**
We are targeting ADRB2, a GPCR, so the priorities are logP, TPSA, Pgp, BBB, and affinity. Let's break down the comparison:
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da).
2. **TPSA:** Ligand A (81.08) is significantly better than Ligand B (130.9). Lower TPSA generally favors oral absorption, crucial for a cardiovascular drug.
3. **logP:** Both are good (around 1.2), falling within the optimal 1-3 range.
4. **H-Bond Donors/Acceptors:** Ligand A (2/4) is slightly better than Ligand B (4/5) in terms of balancing solubility and permeability.
5. **QED:** Ligand A (0.755) is better than Ligand B (0.563), indicating a more drug-like profile.
6. **DILI:** Ligand A (13.067) has a much lower DILI risk than Ligand B (60.217). This is a significant advantage.
7. **BBB:** Ligand A (66.499) has a better BBB percentile than Ligand B (11.439), although not exceptionally high, it's still preferable.
8. **Caco-2:** Ligand A (-4.69) is better than Ligand B (-5.822), indicating better intestinal absorption.
9. **Solubility:** Ligand A (-2.067) is better than Ligand B (-3.361).
10. **hERG:** Ligand A (0.3) has a lower hERG risk than Ligand B (0.718).
11. **Cl_mic:** Ligand A (34.733) has higher clearance than Ligand B (5.776), indicating lower metabolic stability. This is a drawback for Ligand A.
12. **t1/2:** Ligand B (-29.1) has a much longer in vitro half-life than Ligand A (-7.658). This is a significant advantage for Ligand B.
13. **Pgp:** Ligand A (0.052) has much lower P-gp efflux than Ligand B (0.093).
14. **Binding Affinity:** Ligand B (-6.6 kcal/mol) has a slightly better binding affinity than Ligand A (-5.5 kcal/mol). While a 1.1 kcal/mol difference is noticeable, it's not overwhelming, especially considering the other factors.
**Overall Assessment:**
Ligand A has a much better safety profile (DILI, hERG) and better ADME properties (TPSA, QED, solubility, Caco-2, Pgp). While Ligand B has a longer half-life and slightly better affinity, the superior ADME and safety profile of Ligand A outweigh these advantages, especially given the target is a cardiovascular GPCR where systemic exposure and minimizing off-target effects are critical. The higher clearance of Ligand A is a concern, but can potentially be addressed with structural modifications.
**Output:**
1
2025-04-17 19:47:11,916 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
We're targeting ADRB2, a GPCR. Therefore, key properties to prioritize are logP, TPSA, Pgp efflux, BBB penetration (though less critical for a cardiovascular target), and binding affinity.
Let's compare the ligands property by property:
1. **MW:** Both ligands (349.337 and 349.391 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (71.53) is significantly better than Ligand B (130.67). ADRB2 is not a CNS target, but lower TPSA generally improves permeability. Ligand A is well below the 140 threshold. Ligand B is approaching the upper limit.
3. **logP:** Ligand A (2.24) is optimal (1-3). Ligand B (-0.68) is below 1, which could hinder permeability. This is a substantial negative for Ligand B.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is better than Ligand B (7). Lower HBA also favors permeability.
6. **QED:** Ligand A (0.863) is significantly better than Ligand B (0.556), indicating a more drug-like profile.
7. **DILI:** Ligand A (73.905) is higher than Ligand B (58.55), but both are acceptable.
8. **BBB:** Ligand A (90.655) is better than Ligand B (65.335), but BBB is not a primary concern for a cardiovascular target.
9. **Caco-2:** Ligand A (-4.49) is better than Ligand B (-5.486), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-3.671) is better than Ligand B (-1.564).
11. **hERG:** Ligand A (0.541) is better than Ligand B (0.278), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand B (-3.835) has a *negative* clearance, which is unusual and suggests very high metabolic stability. Ligand A (29.584) is moderate.
13. **t1/2:** Ligand B (-6.945) has a negative half-life which is not possible. Ligand A (2.188) is reasonable.
14. **Pgp:** Ligand A (0.113) is better than Ligand B (0.005), indicating lower P-gp efflux.
15. **Affinity:** Ligand A (-6.9 kcal/mol) is slightly better than Ligand B (-6.4 kcal/mol), but the difference is relatively small.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across the majority of key ADME properties (TPSA, logP, HBD, HBA, QED, Solubility, hERG, Pgp) and has a reasonable binding affinity. Ligand B has a concerningly low logP, higher TPSA, and a negative half-life which is not possible. While Ligand B has a potentially advantageous (but unusual) negative clearance, the other significant drawbacks outweigh this benefit.
**Output:**
1
2025-04-17 19:47:11,916 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.49 & 349.48 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (53.01) is better than Ligand B (69.72). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (2.388 & 1.564), falling within the 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Both have 1 HBD, which is acceptable.
5. **HBA:** Ligand A has 4 HBA, Ligand B has 3. Both are within the acceptable range of <=10.
6. **QED:** Ligand A (0.858) has a significantly better QED score than Ligand B (0.621), indicating a more drug-like profile.
7. **DILI:** Ligand A (11.32) has a much lower DILI risk than Ligand B (27.14). This is a critical advantage.
8. **BBB:** Ligand B (74.49) has a higher BBB penetration than Ligand A (63.78). However, as ADRB2 is a cardiovascular target, BBB penetration is not a high priority.
9. **Caco-2:** Both have negative Caco-2 values (-4.256 & -4.447), which is unusual and suggests poor permeability. This is a concern for both, but not a deciding factor.
10. **Solubility:** Both have negative solubility values (-1.458 & -1.977), indicating poor aqueous solubility. This is a significant drawback for both compounds.
11. **hERG:** Ligand A (0.838) has a slightly higher hERG risk than Ligand B (0.087). This is a concern for Ligand A, but the difference isn't huge.
12. **Cl_mic:** Ligand A (39.42) has a higher microsomal clearance than Ligand B (29.25), suggesting faster metabolism and potentially lower in vivo exposure.
13. **t1/2:** Ligand B (-14.39) has a negative in vitro half-life, which is highly problematic. Ligand A (16.22) has a reasonable half-life.
14. **Pgp:** Ligand A (0.27) has lower P-gp efflux than Ligand B (0.014), indicating better bioavailability.
15. **Binding Affinity:** Ligand B (-1.7 kcal/mol) has a significantly weaker binding affinity than Ligand A (-6.4 kcal/mol). This is a major difference. A 4.7 kcal/mol difference is substantial and likely outweighs many of the ADME concerns.
**GPCR-specific priorities:**
For a GPCR like ADRB2, affinity is paramount. While logP, TPSA, and Pgp are important, a strong binding affinity can often compensate for minor ADME issues. In this case, the significantly better affinity of Ligand A is the deciding factor. The lower DILI risk and better QED score further strengthen the case for Ligand A. The poor solubility and Caco-2 values are concerns for both, but can potentially be addressed through formulation strategies.
Output:
1
2025-04-17 19:47:11,916 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (364.28 Da) is within the ideal range, while Ligand B (397.89 Da) is approaching the upper limit but still acceptable.
2. **TPSA:** Ligand A (116.84) is borderline for good oral absorption, but acceptable for a peripherally acting GPCR. Ligand B (40.54) is excellent, suggesting good permeability.
3. **logP:** Ligand A (-1.51) is a bit low, potentially hindering membrane permeability. Ligand B (4.166) is high, potentially causing solubility issues and off-target effects.
4. **HBD:** Ligand A (3) is good. Ligand B (1) is also good.
5. **HBA:** Ligand A (5) is good. Ligand B (3) is excellent.
6. **QED:** Both ligands have good QED scores (A: 0.515, B: 0.75), indicating drug-like properties. Ligand B is better.
7. **DILI:** Ligand A (58.86) is moderate risk, while Ligand B (33.695) is low risk. Ligand B is significantly better.
8. **BBB:** Ligand A (62.854) is moderate, while Ligand B (70.415) is good. Since ADRB2 is not primarily a CNS target, this is a minor advantage for B.
9. **Caco-2:** Ligand A (-5.289) is poor, suggesting poor absorption. Ligand B (-4.629) is also poor, but slightly better.
10. **Solubility:** Ligand A (-2.014) is poor, while Ligand B (-4.482) is very poor. Both are concerning.
11. **hERG:** Ligand A (0.089) is very low risk, while Ligand B (0.828) is moderate. Ligand A is significantly better.
12. **Cl_mic:** Ligand A (-23.995) is excellent (low clearance, high metabolic stability). Ligand B (80.519) is poor (high clearance). This is a major advantage for Ligand A.
13. **t1/2:** Ligand A (-0.162) is poor. Ligand B (6.081) is good.
14. **Pgp:** Ligand A (0.002) is very low efflux, while Ligand B (0.564) is moderate. Ligand A is better.
15. **Affinity:** Ligand A (-7.2) is excellent, while Ligand B (-3.3) is moderate. This is a substantial advantage for Ligand A.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand B has better TPSA and Pgp, but Ligand A has a much stronger binding affinity and a more favorable logP (although still suboptimal). The significantly better metabolic stability (Cl_mic) and lower hERG risk of Ligand A are also crucial. The DILI risk is also lower for Ligand B.
**Overall Assessment:**
While Ligand B has some advantages in TPSA, Pgp, and DILI, Ligand A's superior binding affinity, metabolic stability, and significantly lower hERG risk outweigh these benefits. The poor solubility and Caco-2 values of both are concerning, but can be addressed with formulation strategies. The higher affinity of Ligand A is a critical factor for a GPCR target.
Output:
1
2025-04-17 19:47:11,916 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands (352.494 and 365.449 Da) are within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (49.41) is better than Ligand B (54.02), both being under the 140 threshold for oral absorption, and reasonably low for a GPCR.
3. **logP:** Ligand A (3.162) is optimal, while Ligand B (4.659) is pushing the upper limit and could lead to solubility issues.
4. **HBD:** Ligand A (1) is better than Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (2) is better than Ligand B (4). Lower HBA is also generally favorable for permeability.
6. **QED:** Both are similar (0.765 and 0.715), both indicating good drug-likeness.
7. **DILI:** Ligand A (15.083) is significantly better than Ligand B (64.482). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (91.508) is better than Ligand B (83.288), though both are good. While ADRB2 isn't strictly a CNS target, some CNS penetration can be beneficial for off-target effects assessment.
9. **Caco-2:** Both are very poor (-4.703 and -4.714). This is a concern for both, indicating poor intestinal absorption.
10. **Solubility:** Ligand A (-3.036) is better than Ligand B (-5.15). Solubility is a concern for both, but less so for A.
11. **hERG:** Ligand A (0.66) is better than Ligand B (0.483), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand A (26.392) is significantly better than Ligand B (61.688), indicating better metabolic stability.
13. **t1/2:** Ligand B (35.48) is much better than Ligand A (-15.89). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.282) is better than Ligand B (0.38), indicating lower P-gp efflux.
15. **Affinity:** Ligand B (-7.5) is significantly better than Ligand A (-6.1). This is a substantial advantage for Ligand B.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B has a higher logP, but also a much better affinity. Ligand A has better TPSA and Pgp.
**Overall Assessment:**
Ligand B's significantly stronger binding affinity (-7.5 vs -6.1 kcal/mol) is a major advantage that can outweigh some of its ADME drawbacks. While Ligand B has higher DILI risk and lower metabolic stability, the potency difference is substantial. The poor Caco-2 values are a concern for both, but can be addressed with formulation strategies. Ligand A has a better safety profile (DILI, hERG) and metabolic stability, but the weaker binding makes it less likely to be effective.
Therefore, I favor Ligand B.
Output:
0
2025-04-17 19:47:11,916 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (410.268 Da) is within the ideal range, while Ligand B (368.811 Da) is also acceptable, leaning towards the lower end. No strong preference here.
2. **TPSA:** Ligand A (100.45) is slightly higher than ideal for optimal oral absorption (<=140), but still reasonable. Ligand B (45.48) is excellent, well below the threshold. This favors Ligand B.
3. **logP:** Ligand A (2.799) is within the optimal range. Ligand B (4.978) is a bit high, potentially leading to solubility issues and off-target interactions. This favors Ligand A.
4. **HBD:** Both ligands have acceptable HBD counts (Ligand A: 2, Ligand B: 1). No strong preference.
5. **HBA:** Both ligands have acceptable HBA counts (Ligand A: 5, Ligand B: 2). No strong preference.
6. **QED:** Both ligands have good QED scores (Ligand A: 0.798, Ligand B: 0.812), indicating good drug-like properties. No strong preference.
7. **DILI:** Ligand A (74.99) has a higher DILI risk than Ligand B (49.399). This favors Ligand B.
8. **BBB:** Ligand A (57.193) has moderate BBB penetration, while Ligand B (94.61) has very high BBB penetration. For a cardiovascular target like ADRB2, BBB penetration isn't *critical*, but higher is generally better for potential off-target effects and broader distribution. This favors Ligand B.
9. **Caco-2:** Both ligands have negative Caco-2 values which is unusual. Assuming these are logP values, both ligands have poor permeability.
10. **Solubility:** Ligand A (-4.514) has slightly better solubility than Ligand B (-5.44). This favors Ligand A.
11. **hERG:** Ligand A (0.563) has a lower hERG risk than Ligand B (0.76). This is a significant advantage for Ligand A, as hERG inhibition can cause cardiotoxicity.
12. **Cl_mic:** Ligand A (50.135) has a higher microsomal clearance than Ligand B (8.144), meaning it's metabolized faster. This favors Ligand B.
13. **t1/2:** Ligand B (72.045) has a significantly longer in vitro half-life than Ligand A (14.494). This is a major advantage for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.096) has lower P-gp efflux than Ligand B (0.204). This favors Ligand A.
15. **Binding Affinity:** Ligand B (-6.8 kcal/mol) has a stronger binding affinity than Ligand A (-5.7 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME drawbacks of Ligand B.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B excels in affinity and TPSA, and has good BBB penetration. Ligand A has a better logP and Pgp profile, but its affinity is weaker and its metabolic stability is lower. The stronger affinity of Ligand B is a significant advantage.
**Overall Assessment:**
While Ligand A has some favorable ADME properties (logP, solubility, hERG, Pgp), Ligand B's significantly stronger binding affinity (-6.8 vs -5.7 kcal/mol) and longer half-life are compelling. The higher TPSA of Ligand B is also beneficial. The slightly higher logP and DILI risk of Ligand B are manageable, especially given the potency advantage.
Output:
0
2025-04-17 19:47:11,916 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (342.355 and 350.459 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (95.43) is higher than Ligand B (59.08). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B is significantly better here.
3. **logP:** Both ligands (1.653 and 1.455) are within the optimal 1-3 range. No significant difference.
4. **HBD:** Ligand A (1) is slightly higher than Ligand B (0). Both are acceptable.
5. **HBA:** Ligand A (8) is higher than Ligand B (4). Lower HBA is generally preferred for permeability. Ligand B is better.
6. **QED:** Both ligands (0.753 and 0.773) have good drug-likeness scores, exceeding the 0.5 threshold. No significant difference.
7. **DILI:** Ligand A (80.186) has a significantly higher DILI risk than Ligand B (19.698). This is a major concern for Ligand A.
8. **BBB:** Ligand A (43.699) has a lower BBB penetration percentile than Ligand B (73.827). While ADRB2 isn't a CNS target, some distribution into the CNS can lead to off-target effects. Ligand B is better.
9. **Caco-2:** Ligand A (-4.909) and Ligand B (-4.326) both have negative Caco-2 values which is unusual and suggests poor permeability.
10. **Solubility:** Ligand A (-2.878) and Ligand B (-1.357) both have negative solubility values which is unusual and suggests poor solubility.
11. **hERG:** Both ligands (0.504 and 0.352) have low hERG inhibition liability, which is good. Ligand B is slightly better.
12. **Cl_mic:** Ligand A (35.347) has a higher microsomal clearance than Ligand B (24.384), indicating lower metabolic stability. Ligand B is better.
13. **t1/2:** Ligand A (7.605) has a shorter in vitro half-life than Ligand B (-5.026). The negative value for Ligand B is unusual and suggests very high stability. Ligand B is better.
14. **Pgp:** Ligand A (0.203) has a lower P-gp efflux liability than Ligand B (0.056). This is slightly better for Ligand A.
15. **Binding Affinity:** Both ligands (-5.5 kcal/mol) have the same binding affinity.
**Overall Assessment:**
Ligand B is significantly better overall. The primary driver is the much lower DILI risk. It also has better TPSA, HBA, BBB, Cl_mic, and t1/2 values. While Ligand A has slightly lower Pgp efflux, the DILI risk and other ADME properties of Ligand B make it a much more promising candidate. The unusual Caco-2 and solubility values for both ligands are a concern that would require further investigation, but the other factors strongly favor Ligand B.
Output:
0
2025-04-17 19:47:11,917 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (362.46 & 380.46 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand B (86.8) is better than Ligand A (94.31). Both are below 140, but closer to 90 is preferable for GPCRs, and B is closer.
3. **logP:** Ligand B (2.83) is optimal (1-3), while Ligand A (0.39) is quite low, potentially hindering membrane permeability. This is a significant advantage for B.
4. **HBD:** Ligand A (4) is slightly higher than Ligand B (2), but both are acceptable (<=5).
5. **HBA:** Ligand B (7) is better than Ligand A (5), both are acceptable (<=10).
6. **QED:** Ligand B (0.71) is significantly better than Ligand A (0.35), indicating a more drug-like profile.
7. **DILI:** Ligand B (70.88) is higher than Ligand A (66.27), but both are acceptable (below 60 is good, these are both moderately risky).
8. **BBB:** Ligand B (42.26) is better than Ligand A (35.01), though neither is particularly high. For a cardiovascular target like ADRB2, BBB penetration isn't a primary concern, but it's a slight advantage for B.
9. **Caco-2:** Both ligands have very poor Caco-2 permeability (-5.67 and -5.46). This is a significant drawback for both.
10. **Solubility:** Both ligands have poor aqueous solubility (-2.55 and -3.24). This is a concern for both.
11. **hERG:** Both ligands have low hERG inhibition risk (0.74 and 0.64).
12. **Cl_mic:** Ligand A (-30.59) has a much lower (better) microsomal clearance than Ligand B (57.45), indicating greater metabolic stability. This is a significant advantage for A.
13. **t1/2:** Ligand B (24.21) has a longer half-life than Ligand A (10.73), which is generally desirable.
14. **Pgp:** Ligand B (0.18) has a lower Pgp efflux liability than Ligand A (0.06), suggesting better absorption and bioavailability.
15. **Binding Affinity:** Ligand A (-3.1) is weaker than Ligand B (-2.1). A difference of 1.0 kcal/mol is substantial and favors A.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP and Pgp, and has a better TPSA. Ligand A has a significantly better binding affinity and metabolic stability (Cl_mic). The affinity difference is the most important factor here.
**Overall Assessment:**
While Ligand B has better drug-like properties (QED) and a longer half-life, the significantly stronger binding affinity of Ligand A (-3.1 vs -2.1 kcal/mol) is a crucial advantage for a GPCR target. The lower metabolic clearance of Ligand A is also a positive. The poor Caco-2 and solubility are concerns for both, but can be addressed with formulation strategies. The affinity difference outweighs the other drawbacks.
Output:
1
2025-04-17 19:47:11,917 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, priorities are logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB.
**Molecular Weight:** Both ligands (352.431 and 356.442 Da) fall comfortably within the ideal 200-500 Da range.
**TPSA:** Ligand A (84.94) is better than Ligand B (96.25). Both are below 140, but A is closer to the desirable threshold for good absorption.
**logP:** Ligand B (1.335) is slightly better than Ligand A (0.68), falling more squarely in the optimal 1-3 range. Ligand A is a bit low, potentially hindering permeability.
**H-Bond Donors/Acceptors:** Ligand A has 1 HBD and 5 HBA, while Ligand B has 3 HBD and 5 HBA. Both are within acceptable limits.
**QED:** Ligand B (0.655) has a better QED score than Ligand A (0.487), indicating better overall drug-likeness.
**DILI:** Both ligands have acceptable DILI risk (34.277 and 38.348, respectively), both well below the 60 threshold.
**BBB:** Ligand A (56.611) and Ligand B (64.831) are both relatively low, which is fine for a cardiovascular target. BBB isn't a high priority here.
**Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.852 and -4.976), which is unusual and suggests poor permeability. This is a significant concern for both.
**Aqueous Solubility:** Both ligands have negative solubility values (-1.027 and -1.93), indicating very poor aqueous solubility. This is a major drawback for both.
**hERG Inhibition:** Ligand A (0.061) has a significantly lower hERG risk than Ligand B (0.324), which is a crucial advantage.
**Microsomal Clearance:** Ligand B (33.686) has slightly lower microsomal clearance than Ligand A (21.138), suggesting better metabolic stability.
**In vitro Half-Life:** Ligand B (-1.174) has a slightly better in vitro half-life than Ligand A (-4.309).
**P-gp Efflux:** Ligand A (0.016) has a much lower P-gp efflux liability than Ligand B (0.046), which is a positive.
**Binding Affinity:** Both ligands have the same binding affinity (-6.9 kcal/mol), so this parameter doesn't differentiate them.
**Overall Assessment:**
Despite Ligand B's slightly better QED and metabolic stability, Ligand A is preferable due to its significantly lower hERG risk and P-gp efflux liability, and better TPSA. The poor solubility and Caco-2 permeability are concerning for both, but the hERG risk is a critical factor for cardiovascular drugs. The slightly lower logP of Ligand A is a minor drawback compared to the hERG advantage.
**Output:**
1
2025-04-17 19:47:11,917 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
We are targeting ADRB2, a GPCR. Therefore, the priorities are logP, Pgp, TPSA, affinity, and BBB. Let's compare the ligands property by property:
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (358.429) is slightly lower than Ligand B (375.466), which is marginally preferable.
2. **TPSA:** Ligand A (67.43) is significantly better than Ligand B (100.78). Lower TPSA generally favors better absorption, which is crucial for oral bioavailability.
3. **logP:** Ligand A (3.236) is optimal, while Ligand B (0.91) is a bit low, potentially hindering membrane permeability.
4. **HBD/HBA:** Ligand A (2 HBD, 3 HBA) and Ligand B (1 HBD, 4 HBA) are both acceptable, falling within the desired ranges.
5. **QED:** Both ligands have good QED scores (A: 0.542, B: 0.697), indicating good drug-like properties. Ligand B is slightly better.
6. **DILI:** Both have acceptable DILI risk (A: 42.071, B: 45.056), with Ligand B being slightly higher, but still within a reasonable range.
7. **BBB:** Ligand A (89.492) has a substantially better BBB percentile than Ligand B (79.217). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be beneficial and is not necessarily detrimental in this case.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the values are close (-4.106 for A vs -4.896 for B) and don't significantly differentiate the two.
9. **Solubility:** Ligand A (-3.785) has slightly better solubility than Ligand B (-2.148).
10. **hERG:** Both ligands exhibit low hERG inhibition risk (A: 0.724, B: 0.258), which is excellent. Ligand B is slightly better.
11. **Cl_mic:** Ligand B (-2.024) has a significantly *lower* (better) microsomal clearance than Ligand A (62.115), indicating greater metabolic stability. This is a significant advantage.
12. **t1/2:** Ligand B (-19.53) has a much longer in vitro half-life than Ligand A (-11.834), which is highly desirable.
13. **Pgp:** Ligand A (0.203) has lower P-gp efflux liability than Ligand B (0.096), which is preferable for bioavailability.
14. **Affinity:** Both ligands have excellent binding affinities (A: -5.9 kcal/mol, B: -6.3 kcal/mol), but Ligand B is slightly stronger.
**Overall Assessment:**
Ligand B has a clear advantage in metabolic stability (Cl_mic and t1/2) and slightly better binding affinity. While Ligand A has better TPSA and BBB penetration, the improvements in metabolic stability and binding affinity of Ligand B are more critical for a GPCR target like ADRB2. The slightly lower logP of Ligand B is a minor concern, but the other benefits outweigh this.
**Output:**
0
2025-04-17 19:47:11,917 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (351.407 Da and 375.441 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (106.42) is higher than Ligand B (75.44). For a cardiovascular GPCR, lower TPSA is preferable for better permeability, giving a slight edge to Ligand B.
**3. logP:** Ligand B (1.735) is within the optimal 1-3 range, while Ligand A (0.268) is quite low. Low logP can hinder membrane permeability. This is a significant advantage for Ligand B.
**4. H-Bond Donors:** Both ligands have 1 HBD, which is within the acceptable limit of 5.
**5. H-Bond Acceptors:** Ligand A has 7 HBAs, and Ligand B has 5. Both are below the 10 threshold, but Ligand B is slightly better.
**6. QED:** Both ligands have similar QED values (0.737 and 0.749), indicating good drug-likeness.
**7. DILI Risk:** Ligand B (37.65) has a considerably lower DILI risk than Ligand A (56.727). This is a crucial advantage for Ligand B.
**8. BBB Penetration:** Both ligands show reasonable BBB penetration (64.87% and 73.711%). While higher is generally better, this isn't a primary concern for a cardiovascular target. Ligand B is slightly better.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and indicates poor permeability. However, the absolute value is more important. Ligand A (-4.945) is better than Ligand B (-5.042).
**10. Aqueous Solubility:** Both ligands have negative solubility values, which is also unusual. Ligand A (-1.761) is slightly better than Ligand B (-2.115).
**11. hERG Inhibition:** Ligand A (0.095) has a lower hERG inhibition risk than Ligand B (0.253), which is a positive.
**12. Microsomal Clearance:** Ligand B (33.902) has lower microsomal clearance than Ligand A (23.337), suggesting better metabolic stability.
**13. In vitro Half-Life:** Ligand B (-42.967) has a significantly longer in vitro half-life than Ligand A (-6.287). This is a major advantage for Ligand B.
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (0.038 and 0.144).
**15. Binding Affinity:** Ligand B (-7.0 kcal/mol) has a slightly better binding affinity than Ligand A (-6.5 kcal/mol). This 0.5 kcal/mol difference is significant and can outweigh some ADME drawbacks.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand B is the stronger candidate. It has a more favorable logP, lower DILI risk, better metabolic stability (lower Cl_mic and longer t1/2), and slightly better binding affinity. While Ligand A has a slightly better hERG profile and Caco-2/Solubility, the advantages of Ligand B in terms of ADME and potency are more critical for a successful drug candidate.
Output:
0
2025-04-17 19:47:11,917 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (344.455 Da) is slightly lower, which could be beneficial for permeability.
2. **TPSA:** Ligand A (62.55) is better than Ligand B (37.38). Lower TPSA generally favors oral absorption, important for a cardiovascular target.
3. **logP:** Ligand B (4.812) is higher than Ligand A (3.395). While both are above the optimal range of 1-3, Ligand B is pushing the upper limit and could present solubility issues.
4. **HBD:** Ligand A (1) is preferable to Ligand B (0). Having at least one HBD can improve solubility.
5. **HBA:** Both ligands have 3 HBA, which is within the acceptable range.
6. **QED:** Both ligands have similar QED values (0.609 and 0.625), indicating good drug-likeness.
7. **DILI:** Ligand B (35.673) has a lower DILI risk than Ligand A (45.328), which is a significant advantage.
8. **BBB:** Both ligands have good BBB penetration (Ligand A: 64.482, Ligand B: 73.401). While ADRB2 isn't exclusively a CNS target, some CNS exposure is possible, and higher BBB is generally favorable. Ligand B is better here.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. This is a concern for both.
10. **Solubility:** Ligand B (-4.514) is slightly better than Ligand A (-3.486), but both are very poor.
11. **hERG:** Both ligands have low hERG risk (Ligand A: 0.681, Ligand B: 0.666).
12. **Cl_mic:** Ligand B (76.77) has slightly higher clearance than Ligand A (79.926), suggesting better metabolic stability.
13. **t1/2:** Ligand B (60.908) has a substantially longer half-life than Ligand A (40.012), a major advantage for dosing convenience.
14. **Pgp:** Both ligands have low Pgp efflux liability (Ligand A: 0.764, Ligand B: 0.811).
15. **Binding Affinity:** Ligand B (-7.3 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.7 kcal/mol). This is a crucial difference, as a 1.6 kcal/mol advantage can often outweigh minor ADME drawbacks.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand B excels in affinity and has a better BBB score. While its logP is higher, the significantly improved binding affinity and longer half-life are compelling. The lower DILI risk is also a major positive. The poor Caco-2 and solubility are concerns for both, but can be addressed with formulation strategies.
**Conclusion:**
Despite the slightly higher logP, Ligand B's superior binding affinity, longer half-life, and lower DILI risk make it the more promising drug candidate for the ADRB2 receptor.
Output:
0
2025-04-17 19:47:11,918 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (375.445 and 370.881 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (80.21) is better than Ligand B (87.47). Both are below 140, suitable for oral absorption, but lower is generally preferred.
3. **logP:** Both ligands have acceptable logP values (1.765 and 2.217), falling within the 1-3 range. Ligand B is slightly higher, which *could* be beneficial for membrane permeability, but not dramatically so.
4. **HBD:** Ligand A has 3 HBD, while Ligand B has 2. Both are within the acceptable limit of 5.
5. **HBA:** Both ligands have 5 HBA, which is within the acceptable limit of 10.
6. **QED:** Ligand B (0.695) has a slightly better QED score than Ligand A (0.519), indicating a more drug-like profile.
7. **DILI:** Ligand A (72.276) has a significantly higher DILI risk than Ligand B (38.038). This is a major concern for Ligand A.
8. **BBB:** Both ligands have good BBB penetration (66.576 and 70.609). Ligand B is slightly better, but both are acceptable.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.051 and -5.033). This is unusual and suggests poor permeability. However, the values are very similar.
10. **Solubility:** Ligand A (-3.708) has slightly worse solubility than Ligand B (-2.782). Solubility is important for bioavailability.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.402 and 0.246). This is excellent.
12. **Cl_mic:** Ligand A (4.818) has a lower microsomal clearance than Ligand B (43.519), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand B (77.441) has a significantly longer in vitro half-life than Ligand A (30.446). This is a major advantage for Ligand B.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.161 and 0.081). Ligand B is slightly better.
15. **Binding Affinity:** Ligand B (-6.2 kcal/mol) has a stronger binding affinity than Ligand A (-5.3 kcal/mol). This is a substantial difference (0.9 kcal/mol), which is a significant advantage for Ligand B.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, Pgp, TPSA, and affinity. Ligand B is slightly better on logP and Pgp, has a better affinity, and comparable TPSA. The biggest concern for Ligand A is its significantly higher DILI risk, which outweighs its better metabolic stability. The superior binding affinity and longer half-life of Ligand B are also compelling.
**Conclusion:**
Despite Ligand A's better metabolic stability, the significantly lower DILI risk, stronger binding affinity, and longer half-life of Ligand B make it the more promising drug candidate.
Output:
0
2025-04-17 19:47:11,918 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
We are targeting ADRB2, a GPCR, so the priorities are logP, TPSA, Pgp efflux, BBB penetration, and binding affinity.
Let's analyze each ligand against the guidelines:
* **Molecular Weight:** Both ligands (356.419 and 374.463 Da) fall within the ideal 200-500 Da range.
* **TPSA:** Ligand A (116.17) is better than Ligand B (133.04), being closer to the <140 threshold for good oral absorption.
* **logP:** Ligand B (-1.61) is lower than Ligand A (-0.575). Both are within the 1-3 range, but Ligand A is closer to the optimal range.
* **H-Bond Donors/Acceptors:** Both have 3 HBD and similar HBA counts (6 vs 5). This is acceptable.
* **QED:** Both ligands have similar QED values (0.526 and 0.532), indicating good drug-likeness.
* **DILI:** Ligand B (30.826) has a slightly lower DILI risk than Ligand A (37.767), which is favorable.
* **BBB:** Both ligands have similar BBB penetration (45.134 and 41.218). Neither is particularly high, but this isn't a major concern for a non-CNS target like ADRB2.
* **Caco-2 Permeability:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-5.073) is slightly better than Ligand B (-5.644).
* **Aqueous Solubility:** Both have negative solubility values, indicating poor solubility. Ligand A (-1.086) is slightly better than Ligand B (-1.422).
* **hERG:** Both ligands have very low hERG inhibition risk (0.087 and 0.106).
* **Microsomal Clearance:** Ligand B (-16.389) has significantly lower microsomal clearance than Ligand A (13.967), suggesting better metabolic stability. This is a significant advantage.
* **In vitro Half-Life:** Ligand B (6.543) has a longer half-life than Ligand A (-9.156). This is also a significant advantage.
* **P-gp Efflux:** Both have very low P-gp efflux liability (0.015 and 0.003).
* **Binding Affinity:** Ligand A (-8.0) has a slightly better binding affinity than Ligand B (-6.6). This is a 1.4 kcal/mol difference, which is substantial.
**Overall Assessment:**
Ligand A has a better binding affinity and slightly better TPSA, Caco-2, and solubility. However, Ligand B has significantly better metabolic stability (lower Cl_mic) and a longer half-life, and a slightly lower DILI risk. Considering the importance of metabolic stability and half-life for *in vivo* efficacy, and the substantial difference in these parameters, Ligand B is the more promising candidate. The slightly better affinity of Ligand A can potentially be optimized later, but improving metabolic stability is often more challenging.
**Output:**
0
2025-04-17 19:47:11,918 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, key properties are binding affinity, logP, TPSA, Pgp efflux, and BBB penetration.
Let's compare the ligands property by property:
1. **MW:** Both ligands (341.411 and 363.498 Da) are within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (77.25) is better than Ligand B (29.54). Lower TPSA generally favors better absorption and permeability, which is crucial for GPCR ligands.
3. **logP:** Ligand B (4.272) is slightly higher than Ligand A (3.497). While both are above the optimal 1-3 range, Ligand B is approaching a level where solubility issues might arise.
4. **HBD/HBA:** Ligand A has 1 HBD and 6 HBA, while Ligand B has 0 HBD and 3 HBA. Ligand B is slightly better here, as fewer H-bonds can improve membrane permeability.
5. **QED:** Ligand A (0.858) has a significantly better QED score than Ligand B (0.678), indicating a more drug-like profile.
6. **DILI:** Ligand B (32.067) has a much lower DILI risk than Ligand A (63.513), a significant advantage.
7. **BBB:** Both ligands have good BBB penetration (Ligand A: 83.753, Ligand B: 88.445), but Ligand B is slightly better.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability.
9. **Solubility:** Both have negative solubility values, which is also unusual and suggests poor solubility.
10. **hERG:** Ligand A (0.454) and Ligand B (0.859) both have relatively low hERG inhibition liability.
11. **Cl_mic:** Ligand A (58.171) has a lower microsomal clearance than Ligand B (107.941), indicating better metabolic stability.
12. **t1/2:** Ligand B (-8.2) has a negative in vitro half-life, which is not possible. Ligand A (14.022) has a reasonable half-life.
13. **Pgp:** Ligand A (0.341) has lower P-gp efflux liability than Ligand B (0.691), which is favorable for bioavailability.
14. **Binding Affinity:** Both ligands have comparable binding affinities (-6.6 and -6.2 kcal/mol). The difference is not substantial enough to be a deciding factor.
**Overall Assessment:**
Ligand B has a lower DILI risk and slightly better BBB penetration. However, Ligand A has a significantly better QED score, lower microsomal clearance (better metabolic stability), lower P-gp efflux, and a reasonable in vitro half-life. The negative Caco-2 and solubility values are concerning for both, but the other advantages of Ligand A, particularly its better drug-like properties and metabolic stability, make it the more promising candidate.
**Output:**
1
2025-04-17 19:47:11,918 - INFO - Batch 136 complete. Total preferences: 2176
2025-04-17 19:47:11,918 - INFO - Processing batch 137/512...
2025-04-17 19:48:00,164 - INFO - Here's my reasoning and final decision:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, key priorities are logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB.
Let's break down the comparison:
1. **MW:** Both ligands (344.46 and 358.45 Da) fall within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (67.23) is slightly higher than Ligand B (59.08). Both are acceptable for oral absorption, but B is preferable.
3. **logP:** Both ligands have good logP values (1.84 and 1.49), within the 1-3 range. Ligand B is slightly better here.
4. **HBD/HBA:** Ligand A has 1 HBD and 4 HBA, while Ligand B has 0 HBD and 4 HBA. Both are within acceptable limits.
5. **QED:** Ligand A (0.829) has a significantly better QED score than Ligand B (0.692), indicating better overall drug-likeness.
6. **DILI:** Ligand B (17.64) has a much lower DILI risk than Ligand A (36.29), a significant advantage.
7. **BBB:** Ligand B (91.66) has a much higher BBB penetration score than Ligand A (71.66). While not a primary concern for a cardiovascular target, higher BBB is generally favorable.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand B (-4.22) is slightly better than Ligand A (-4.98).
9. **Solubility:** Both have negative solubility values, indicating poor aqueous solubility. Ligand B (-1.01) is slightly better than Ligand A (-1.73).
10. **hERG:** Ligand A (0.17) has a slightly lower hERG risk than Ligand B (0.55), which is preferable.
11. **Cl_mic:** Ligand B (21.27) has a slightly lower microsomal clearance than Ligand A (23.66), suggesting better metabolic stability.
12. **t1/2:** Ligand B (10.90) has a longer in vitro half-life than Ligand A (-9.65), a significant advantage.
13. **Pgp:** Ligand A (0.094) has a lower Pgp efflux liability than Ligand B (0.058), which is preferable.
14. **Binding Affinity:** Ligand A (-7.4 kcal/mol) has a slightly better binding affinity than Ligand B (-6.2 kcal/mol). This is a crucial factor. The difference of 1.2 kcal/mol is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand A has a better binding affinity and Pgp efflux liability, while Ligand B excels in DILI risk, BBB penetration, and in vitro half-life. The binding affinity difference is significant. While the solubility and Caco-2 values are poor for both, the stronger binding of Ligand A is likely to be more impactful for *in vivo* efficacy. The lower DILI risk of Ligand B is attractive, but the affinity difference is a stronger driver for a GPCR target.
**Output:**
1
2025-04-17 19:48:00,164 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (347.463) is slightly lower, which could be advantageous for permeability.
2. **TPSA:** Ligand A (88.91) is better than Ligand B (42.43). For a GPCR, lower TPSA is generally preferred for better brain penetration, even though ADRB2 isn't strictly a CNS target.
3. **logP:** Ligand A (1.758) is optimal, while Ligand B (4.296) is pushing the upper limit. High logP can lead to poor solubility and off-target effects.
4. **HBD:** Ligand A (2) is reasonable, and Ligand B (0) is also acceptable.
5. **HBA:** Ligand A (5) is good, and Ligand B (4) is also good.
6. **QED:** Both ligands have acceptable QED scores (A: 0.75, B: 0.623), indicating reasonable drug-likeness.
7. **DILI:** Both ligands have low DILI risk (A: 47.421, B: 40.985), which is positive.
8. **BBB:** Ligand B (82.706) has significantly better BBB penetration than Ligand A (54.478). While ADRB2 isn't a primary CNS target, some peripheral ADRB2 activity can influence CNS pathways, so some BBB penetration isn't necessarily detrimental.
9. **Caco-2:** Ligand A (-5.236) and Ligand B (-4.582) both have negative Caco-2 values, which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand A (-2.12) and Ligand B (-3.693) both have poor aqueous solubility. This is a major drawback for both compounds.
11. **hERG:** Ligand A (0.124) has a much lower hERG risk than Ligand B (0.895). This is a critical advantage for Ligand A.
12. **Cl_mic:** Ligand A (37.665) has lower microsomal clearance than Ligand B (80.298), indicating better metabolic stability.
13. **t1/2:** Ligand B (43.814) has a significantly longer in vitro half-life than Ligand A (6.847). This is a substantial advantage for Ligand B.
14. **Pgp:** Ligand A (0.046) has lower P-gp efflux than Ligand B (0.858), which is favorable for bioavailability.
15. **Affinity:** Ligand B (-7.2) has a stronger binding affinity than Ligand A (-6.7). This is a 0.5 kcal/mol difference, which is significant and can outweigh some ADME drawbacks.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, and affinity. Ligand B excels in affinity and BBB penetration, while Ligand A has better logP, TPSA, Pgp, and hERG. The poor Caco-2 and solubility for both are concerning. However, the affinity difference of 0.5 kcal/mol is substantial. The longer half-life of Ligand B is also a significant advantage.
**Overall Assessment:**
Despite the slightly higher logP and Pgp efflux, Ligand B's superior binding affinity and significantly longer half-life are compelling. The better BBB penetration is also a plus. While both compounds have solubility and permeability issues, the potency advantage of Ligand B is likely to be more impactful in driving forward development, provided solubility/permeability can be addressed through formulation or further chemical modification.
Output:
0
2025-04-17 19:48:00,165 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (366.53 & 352.41 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (58.64) is significantly better than Ligand B (78.87). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (2.71 & 1.92), falling within the optimal 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Both ligands have the same number of HBA (4), which is acceptable.
6. **QED:** Ligand A (0.731) has a slightly better QED score than Ligand B (0.666), indicating a more drug-like profile.
7. **DILI:** Ligand A (13.53) has a much lower DILI risk than Ligand B (36.25). This is a significant advantage for Ligand A.
8. **BBB:** Both ligands have reasonably high BBB penetration, but Ligand A (82.20) is better than Ligand B (75.03). While not a primary concern for a cardiovascular target, it's still a positive attribute.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the values are close (-4.93 vs -4.71).
10. **Solubility:** Both ligands have negative solubility values, which is also unusual. Again, the values are close (-2.07 vs -2.31).
11. **hERG:** Ligand A (0.558) has a slightly better hERG profile than Ligand B (0.322), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand A (25.68) has a higher microsomal clearance than Ligand B (13.29), suggesting faster metabolism and potentially lower *in vivo* exposure. This is a negative for Ligand A.
13. **t1/2:** Ligand B (-15.32) has a much longer *in vitro* half-life than Ligand A (9.27), which is a significant advantage.
14. **Pgp:** Ligand A (0.139) has a lower Pgp efflux liability than Ligand B (0.052), which is favorable.
15. **Affinity:** Both ligands have very similar binding affinities (-6.3 and -6.0 kcal/mol). The difference is not substantial enough to outweigh other factors.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A performs better on logP, TPSA, and Pgp. The affinities are similar.
**Overall Assessment:**
Ligand A has several advantages: lower DILI risk, better TPSA, better Pgp efflux, and a slightly better QED and hERG profile. The biggest drawback for Ligand A is the higher microsomal clearance and shorter half-life. However, the lower DILI risk and better ADME properties (TPSA, Pgp) are more critical for initial candidate selection. The slightly longer half-life of Ligand B is a benefit, but can be addressed in later optimization stages.
Output:
1
2025-04-17 19:48:00,165 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [345.403, 102.05 , 1.203, 2. , 6. , 0.785, 64.133, 43.699, -5.283, -2.151, 0.092, 13.782, 28.825, 0.008, -4.1 ]
**Ligand B:** [364.917, 42.43 , 4.233, 0. , 3. , 0.727, 13.106, 89.104, -4.461, -3.987, 0.652, 95.933, 20.276, 0.617, -6.4 ]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, Affinity, and BBB):
1. **MW:** Both are within the acceptable 200-500 Da range. Ligand A (345.4) is slightly preferred.
2. **TPSA:** Ligand B (42.43) is significantly better than Ligand A (102.05). Lower TPSA is crucial for GPCRs, aiding in brain penetration and overall absorption.
3. **logP:** Ligand A (1.203) is optimal (1-3). Ligand B (4.233) is pushing the upper limit and could lead to solubility issues and off-target interactions.
4. **HBD/HBA:** Ligand A (2 HBD, 6 HBA) is slightly higher in both counts but still acceptable. Ligand B (0 HBD, 3 HBA) is better.
5. **QED:** Both are good (above 0.5), with Ligand A slightly higher (0.785 vs 0.727).
6. **DILI:** Ligand B (13.106) is *much* better than Ligand A (64.133). This is a significant advantage for Ligand B.
7. **BBB:** Ligand B (89.104) is substantially better than Ligand A (43.699). This is a critical factor for GPCRs, even if not specifically CNS-targeted, as it indicates better distribution.
8. **Caco-2:** Ligand A (-5.283) is better than Ligand B (-4.461), indicating better intestinal absorption.
9. **Solubility:** Ligand A (-2.151) is better than Ligand B (-3.987).
10. **hERG:** Ligand A (0.092) is better than Ligand B (0.652).
11. **Cl_mic:** Ligand A (13.782) is better than Ligand B (95.933). Lower is better.
12. **t1/2:** Ligand A (28.825) is better than Ligand B (20.276).
13. **Pgp:** Ligand A (0.008) is *much* better than Ligand B (0.617). Lower Pgp efflux is highly desirable.
14. **Affinity:** Ligand B (-6.4) is significantly stronger than Ligand A (-4.1). A 2.3 kcal/mol difference is substantial.
**Overall Assessment:**
Ligand B has a much stronger binding affinity and significantly better BBB penetration and DILI risk. However, it suffers from a higher logP and Pgp efflux. Ligand A has better ADME properties (solubility, permeability, metabolic stability, Pgp efflux), but its affinity is weaker.
Given the GPCR target class, the strong affinity of Ligand B is a major advantage. While the higher logP and Pgp efflux are concerns, they might be addressable through further optimization. The lower DILI risk is also a significant benefit. The improved BBB penetration is also a plus. The difference in affinity is large enough to outweigh the ADME concerns, especially considering optimization potential.
Therefore, I favor Ligand B.
0
2025-04-17 19:48:00,165 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (352.291 and 368.499 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (59.93) is significantly better than Ligand B (82.78). For a GPCR, lower TPSA is generally preferred for better permeability. Ligand A is well below the 140 threshold, while Ligand B is approaching it.
3. **logP:** Ligand A (3.674) is slightly higher than Ligand B (2.059), both within the optimal 1-3 range. Ligand B is on the lower end, which *could* indicate permeability issues.
4. **HBD:** Ligand A (1) is better than Ligand B (2). Fewer HBDs are generally preferred for permeability.
5. **HBA:** Both ligands have 5 HBA, which is acceptable.
6. **QED:** Ligand B (0.77) has a slightly better QED score than Ligand A (0.561), suggesting a more drug-like profile overall.
7. **DILI:** Ligand B (61.07) has a higher DILI risk than Ligand A (91.935). This is a significant advantage for Ligand A. Lower DILI is crucial.
8. **BBB:** Ligand A (73.827) has a substantially better BBB penetration percentile than Ligand B (34.548). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant for off-target effects and overall safety.
9. **Caco-2:** Ligand A (-4.713) and Ligand B (-5.149) both have negative Caco-2 values, which is unusual and suggests very poor permeability. However, the scale is not specified, and negative values may indicate a different scale.
10. **Solubility:** Ligand A (-4.58) and Ligand B (-3.148) both have negative solubility values, which is also unusual.
11. **hERG:** Ligand A (0.892) has a slightly better hERG profile than Ligand B (0.315), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand B (55.44) has a lower microsomal clearance than Ligand A (70.089), suggesting better metabolic stability.
13. **t1/2:** Ligand B (52.235) has a significantly longer in vitro half-life than Ligand A (-15.842). This is a major advantage for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.286) has a lower P-gp efflux liability than Ligand B (0.314), which is favorable for bioavailability.
15. **Affinity:** Both ligands have very similar binding affinities (-6.2 and -5.6 kcal/mol). The difference is less than 1.5 kcal/mol, so it's not a deciding factor.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, TPSA, logP, Pgp, and affinity are key. Ligand A excels in TPSA, Pgp, and has a reasonable logP. Ligand B has a better half-life and QED, but suffers from a higher TPSA, higher DILI risk, and lower BBB penetration. The slightly better metabolic stability of Ligand B is offset by the other significant drawbacks.
**Conclusion:**
Despite the better half-life and QED of Ligand B, the combination of lower TPSA, lower DILI risk, better BBB penetration, and slightly better hERG profile makes **Ligand A** the more promising drug candidate. The negative Caco-2 and solubility values are concerning for both, but the other advantages of Ligand A outweigh the benefits of Ligand B's longer half-life.
Output:
1
2025-04-17 19:48:00,165 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (355.781 and 361.383 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (96.03) is better than Ligand B (124.09). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (3.468 and 3.342), falling within the optimal 1-3 range. Very similar.
4. **HBD:** Both have 1 HBD, which is acceptable.
5. **HBA:** Ligand A has 4 HBA, while Ligand B has 8. Ligand A is preferable here, as higher HBA can sometimes hinder permeability.
6. **QED:** Both ligands have similar QED scores (0.656 and 0.635), indicating good drug-likeness.
7. **DILI:** Ligand A (74.021) has a significantly lower DILI risk than Ligand B (96.433). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (73.478) has better BBB penetration than Ligand B (53.276), but this is less critical for a cardiovascular target.
9. **Caco-2:** Ligand A (-4.517) is better than Ligand B (-5.315), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-5.722) is slightly better than Ligand B (-4.812).
11. **hERG:** Both ligands have low hERG inhibition risk (0.498 and 0.438).
12. **Cl_mic:** Ligand A (48.285) has a higher (worse) microsomal clearance than Ligand B (27.023), suggesting faster metabolism. This favors Ligand B.
13. **t1/2:** Ligand B (-1.421) has a better in vitro half-life than Ligand A (-4.707). This favors Ligand B.
14. **Pgp:** Ligand A (0.142) has better Pgp efflux liability than Ligand B (0.067), meaning it's less likely to be pumped out of cells.
15. **Affinity:** Ligand B (-8.2 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.5 kcal/mol). This is a substantial advantage, potentially outweighing some ADME concerns.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), affinity, logP, TPSA, and Pgp are key. Ligand B excels in affinity, while Ligand A is better in TPSA and Pgp. Ligand B's superior affinity is a significant driver.
**Overall Assessment:**
While Ligand A has better safety (DILI) and absorption (Caco-2) profiles, Ligand B's substantially stronger binding affinity (-8.2 vs -5.5 kcal/mol) is the most critical factor for a GPCR target. The slightly worse metabolic stability (higher Cl_mic) and half-life of Ligand B can potentially be addressed through structural modifications in later optimization stages. The lower DILI risk of Ligand A is good, but a strong starting affinity is paramount.
Output:
0
2025-04-17 19:48:00,165 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (344.411 and 347.375 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (88.41) is better than Ligand B (104.08). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally favors absorption.
3. **logP:** Ligand A (1.897) is within the optimal 1-3 range. Ligand B (-0.138) is slightly below 1, which *could* indicate permeability issues. This is a point in favor of A.
4. **HBD:** Both ligands have acceptable HBD counts (2 and 1, respectively), well below the threshold of 5.
5. **HBA:** Ligand A (4) is better than Ligand B (6), keeping it closer to the preferred maximum of 10.
6. **QED:** Both ligands have reasonable QED scores (0.825 and 0.747), indicating good drug-like properties.
7. **DILI:** Ligand A (46.956) has a significantly lower DILI risk than Ligand B (61.38). This is a substantial advantage for Ligand A.
8. **BBB:** Not a high priority for a cardiovascular target, but Ligand A (69.484) is better than Ligand B (38.426).
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.839 and -4.928), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-3.032) is better than Ligand B (-1.818). Higher solubility is generally preferred.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.169 and 0.108), which is excellent.
12. **Cl_mic:** Ligand A (23.661) has a higher microsomal clearance than Ligand B (-2.545). This suggests Ligand B is more metabolically stable, which is a positive.
13. **t1/2:** Ligand A (27.141) has a longer in vitro half-life than Ligand B (-0.0). This is a significant advantage for Ligand A.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.187 and 0.018).
15. **Binding Affinity:** Ligand A (-7.3 kcal/mol) has a slightly better binding affinity than Ligand B (-6.7 kcal/mol). While the difference is not huge, it's enough to consider.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A is better on logP and TPSA. Affinity is slightly better for A. Pgp is similar for both.
**Overall Assessment:**
Ligand A demonstrates a more favorable balance of properties. It has better logP, TPSA, solubility, DILI risk, and in vitro half-life, and a slightly better binding affinity. While both have poor Caco-2 permeability, the other advantages of Ligand A outweigh this concern. The negative Caco-2 values for both ligands suggest a potential issue that would need to be addressed through further structural modifications. However, given the current data, Ligand A appears to be the more promising candidate.
Output:
1
2025-04-17 19:48:00,165 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
The ADRB2 receptor is a GPCR, so the priorities are logP, Pgp, TPSA, BBB, and affinity. Let's break down the comparison:
1. **Molecular Weight:** Both ligands are within the ideal 200-500 Da range. Ligand A (372.447) is slightly higher than Ligand B (343.423), but both are acceptable.
2. **TPSA:** Ligand B (64.63) is significantly better than Ligand A (121.61). A TPSA under 90 is preferred, and Ligand B is well within this range, suggesting better permeability. Ligand A is borderline.
3. **logP:** Ligand B (3.275) is at the upper end of the optimal range (1-3), while Ligand A (-0.441) is below 1, which is a concern for permeability. This is a significant advantage for Ligand B.
4. **H-Bond Donors/Acceptors:** Ligand A has 2 HBD and 6 HBA, while Ligand B has 1 HBD and 4 HBA. Both are within acceptable limits.
5. **QED:** Both ligands have good QED scores (A: 0.626, B: 0.673), indicating drug-like properties.
6. **DILI:** Ligand A (63.086) has a higher DILI risk than Ligand B (46.297), though both are reasonably low.
7. **BBB:** Ligand B (78.558) has a significantly better BBB percentile than Ligand A (52.579). Although ADRB2 isn't exclusively a CNS target, some CNS penetration can be beneficial, and lower efflux is always good.
8. **Caco-2 Permeability:** Ligand A (-5.316) has a worse Caco-2 permeability than Ligand B (-4.049).
9. **Aqueous Solubility:** Ligand A (-2.001) has better solubility than Ligand B (-4.493).
10. **hERG:** Ligand A (0.138) has a lower hERG risk than Ligand B (0.414). This is a positive for Ligand A.
11. **Microsomal Clearance:** Ligand B (89.029) has a much higher microsomal clearance than Ligand A (44.608), indicating faster metabolism and potentially lower *in vivo* exposure.
12. **In vitro Half-Life:** Ligand A (-13.668) has a longer half-life than Ligand B (-7.028).
13. **P-gp Efflux:** Ligand A (0.015) has a much lower P-gp efflux liability than Ligand B (0.174). This is a significant advantage for Ligand A.
14. **Binding Affinity:** Ligand A (-7.2) has a slightly better binding affinity than Ligand B (-6.3). While both are good, the 0.9 kcal/mol difference is notable.
**Overall Assessment:**
Ligand B excels in TPSA and BBB penetration, and has a reasonable logP. However, its higher P-gp efflux and clearance are significant drawbacks. Ligand A has a better logP, lower P-gp efflux, better metabolic stability, and a slightly better binding affinity, despite its higher TPSA. The combination of these factors, particularly the improved permeability and reduced efflux, makes Ligand A the more promising candidate, even with the slightly higher TPSA. The better affinity also tips the balance.
**Output:**
1
2025-04-17 19:48:00,165 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [365.415, 133.31 , 1.741, 4. , 6. , 0.597, 82.435, 32.028, -5.555, -3.395, 0.15 , 34.765, -13.851, 0.014, -5.6 ]
**Ligand B:** [358.391, 125.4 , -0.891, 3. , 7. , 0.43 , 42.536, 25.475, -5.344, -0.725, 0.065, -8.686, 2.363, 0.012, -7.9 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (358.391) is slightly lower, which is generally favorable.
2. **TPSA:** Both are good, under 140. Ligand B (125.4) is better than Ligand A (133.31), closer to the optimal for GPCRs.
3. **logP:** Ligand A (1.741) is within the optimal range (1-3). Ligand B (-0.891) is below 1, which is a concern for permeability.
4. **HBD:** Both have acceptable HBD counts (4 and 3 respectively), below the threshold of 5.
5. **HBA:** Both have acceptable HBA counts (6 and 7 respectively), below the threshold of 10.
6. **QED:** Ligand A (0.597) is better than Ligand B (0.43), indicating a more drug-like profile.
7. **DILI:** Ligand A (82.435) has a higher DILI risk than Ligand B (42.536). This is a significant drawback for Ligand A.
8. **BBB:** Ligand A (32.028) has a low BBB penetration, while Ligand B (25.475) is also low. BBB is less critical for peripheral GPCRs like ADRB2, but still a consideration.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability.
10. **Solubility:** Both have negative solubility values, which is also unusual and suggests poor solubility.
11. **hERG:** Both have very low hERG inhibition risk, which is good.
12. **Cl_mic:** Ligand B (-8.686) has a significantly lower (better) microsomal clearance than Ligand A (34.765), indicating better metabolic stability.
13. **t1/2:** Ligand B (2.363) has a slightly better in vitro half-life than Ligand A (-13.851).
14. **Pgp:** Both have very low Pgp efflux liability, which is good.
15. **Affinity:** Ligand B (-7.9) has a stronger binding affinity than Ligand A (-5.6), by a substantial margin (2.3 kcal/mol). This is a major advantage.
**GPCR-Specific Considerations:**
For ADRB2, a GPCR, logP, TPSA, Pgp, and affinity are key. Ligand B has a better TPSA and significantly better affinity. While its logP is suboptimal, the strong affinity could compensate. Ligand A's high DILI risk is a major concern.
**Conclusion:**
Despite the lower logP, Ligand B's superior binding affinity, lower DILI risk, and better metabolic stability outweigh the drawbacks. The 2.3 kcal/mol difference in binding affinity is substantial and likely to translate to better *in vivo* efficacy.
Output:
0
2025-04-17 19:48:00,165 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (347.419 and 347.438 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (112.04) is higher than Ligand B (64.86). For a cardiovascular GPCR, TPSA isn't *as* critical as for CNS targets, but lower TPSA generally favors better permeability. Ligand B is significantly better.
**3. logP:** Ligand A (0.735) is lower than Ligand B (2.722). While both are within the 1-3 range, Ligand B is closer to the optimal range, suggesting better membrane permeability.
**4. H-Bond Donors:** Ligand A (4) is higher than Ligand B (1). Lower HBD is generally preferred for permeability. Ligand B is better.
**5. H-Bond Acceptors:** Ligand A (5) is equal to Ligand B (6). No significant difference.
**6. QED:** Both ligands have good QED scores (0.564 and 0.67), indicating good drug-like properties. Ligand B is slightly better.
**7. DILI:** Ligand A (50.33) and Ligand B (42.109) are both within acceptable ranges (<60). Ligand B has a slightly lower risk.
**8. BBB:** Ligand A (15.82) is significantly lower than Ligand B (90.772). While ADRB2 isn't a CNS target, higher BBB penetration can sometimes correlate with better overall distribution and reduced off-target effects. However, this is a lower priority.
**9. Caco-2:** Ligand A (-5.573) is worse than Ligand B (-4.89). Higher Caco-2 values indicate better absorption. Ligand B is better.
**10. Solubility:** Ligand A (-2.388) is slightly better than Ligand B (-2.761). Solubility is important, but not a major differentiating factor here.
**11. hERG:** Both ligands have low hERG inhibition risk (0.315 and 0.376). No significant difference.
**12. Cl_mic:** Ligand A (-3.118) is better than Ligand B (49.708). Lower clearance indicates better metabolic stability, a crucial factor for drug duration.
**13. t1/2:** Ligand A (35.982) is much better than Ligand B (11.651). A longer half-life is generally desirable.
**14. Pgp:** Both ligands have low P-gp efflux liability (0.061 and 0.621). Ligand A is better.
**15. Binding Affinity:** Ligand B (-5.9) is better than Ligand A (-4.8). A 1.1 kcal/mol difference in binding affinity is substantial and can often outweigh minor ADME drawbacks.
**Overall Assessment:**
Ligand B has a significantly better profile regarding key GPCR properties (logP, TPSA, Caco-2, and most importantly, binding affinity). While Ligand A has advantages in metabolic stability (Cl_mic, t1/2) and Pgp efflux, the substantial binding affinity advantage of Ligand B, coupled with its better permeability characteristics, makes it the more promising candidate. The slightly better DILI score for Ligand B is also a positive.
Output:
0
2025-04-17 19:48:00,165 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (346.45 and 343.427 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Both ligands have TPSA values (56.73 and 55.73) below the 140 A^2 threshold for good oral absorption. They are also reasonably low, which is good for GPCRs. No strong preference.
**3. logP:** Both ligands have logP values around 2.56, which is optimal (1-3). No significant difference.
**4. H-Bond Donors:** Ligand A (2) has slightly fewer HBD than Ligand B (1). This is a minor advantage for Ligand A, potentially improving permeability.
**5. H-Bond Acceptors:** Ligand B (6) has more HBA than Ligand A (4). This could slightly hinder permeability compared to Ligand A.
**6. QED:** Both ligands have good QED scores (0.881 and 0.846), indicating good drug-like properties.
**7. DILI:** Ligand A (15.2) has a significantly lower DILI risk than Ligand B (68.592). This is a *major* advantage for Ligand A. DILI is a critical safety concern.
**8. BBB:** Both ligands have good BBB penetration (77.821 and 71.035). This is important for GPCRs, but less critical for ADRB2 which is not a CNS target.
**9. Caco-2 Permeability:** Ligand A (-5.294) has slightly better Caco-2 permeability than Ligand B (-4.529).
**10. Aqueous Solubility:** Ligand A (-2.169) has better aqueous solubility than Ligand B (-3.264). This is a slight advantage for Ligand A.
**11. hERG Inhibition:** Ligand A (0.911) has a slightly higher hERG inhibition risk than Ligand B (0.592). This is a minor concern, but Ligand B is preferable here.
**12. Microsomal Clearance:** Ligand A (-13.827) has *much* lower microsomal clearance than Ligand B (67.673). This indicates significantly better metabolic stability for Ligand A.
**13. In vitro Half-Life:** Ligand A (6.285) has a shorter half-life than Ligand B (13.536). This is a disadvantage for Ligand A, but can be mitigated with formulation strategies.
**14. P-gp Efflux:** Ligand A (0.275) has lower P-gp efflux than Ligand B (0.197). Lower P-gp efflux is preferable.
**15. Binding Affinity:** Ligand A (-7.3) has a slightly better binding affinity than Ligand B (-6.2). While the difference is not huge, it's enough to be considered.
**Overall Assessment:**
Ligand A is the stronger candidate. The significantly lower DILI risk and much improved metabolic stability (lower Cl_mic) are critical advantages that outweigh the slightly shorter half-life. The better solubility, permeability, and binding affinity also contribute to its preference. While Ligand B has a slightly better hERG profile and half-life, the safety and metabolic stability concerns with Ligand B are too significant to ignore.
Output:
1
2025-04-17 19:48:00,166 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (349.431 and 357.479 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (84.67) is better than Ligand B (65.2). Both are below the 140 A^2 threshold for good oral absorption, but for a GPCR, lower TPSA is generally preferred to facilitate receptor binding.
**3. logP:** Ligand B (3.161) is slightly higher than Ligand A (2.229), pushing it towards the upper end of the optimal 1-3 range. While still acceptable, a lower logP is often preferred for reducing off-target effects.
**4. H-Bond Donors:** Ligand A has 1 HBD, and Ligand B has 2. Both are within the acceptable limit of 5.
**5. H-Bond Acceptors:** Ligand A has 5 HBA, and Ligand B has 3. Both are within the acceptable limit of 10.
**6. QED:** Both ligands have very similar QED values (0.816 and 0.807), indicating good drug-likeness.
**7. DILI Risk:** Ligand B (61.07) has a slightly higher DILI risk than Ligand A (44.126), but both are still within a reasonable range (<60 is good).
**8. BBB Penetration:** Ligand B (73.517) shows significantly better BBB penetration than Ligand A (52.268). While ADRB2 is primarily a cardiovascular target, some CNS off-target effects are possible with GPCR ligands, and better BBB penetration could contribute to those. However, for a cardiovascular target, this isn't a primary driver.
**9. Caco-2 Permeability:** Ligand A (-4.904) has better Caco-2 permeability than Ligand B (-5.344). This suggests better intestinal absorption for Ligand A.
**10. Aqueous Solubility:** Ligand A (-1.408) has better aqueous solubility than Ligand B (-4.3). Solubility is crucial for formulation and bioavailability.
**11. hERG Inhibition:** Ligand A (0.24) has a much lower hERG inhibition liability than Ligand B (0.549). This is a significant advantage, as hERG inhibition can lead to cardiotoxicity.
**12. Microsomal Clearance:** Ligand B (25.794) has significantly lower microsomal clearance than Ligand A (60.574), indicating better metabolic stability. This is a key advantage for longer duration of action.
**13. In vitro Half-Life:** Ligand B (-16.03) has a much longer in vitro half-life than Ligand A (7.877). This reinforces the better metabolic stability of Ligand B.
**14. P-gp Efflux:** Both ligands have similar P-gp efflux liability (0.1 and 0.13).
**15. Binding Affinity:** Ligand A (-7.1) has a significantly stronger binding affinity than Ligand B (-5.7). A 1.4 kcal/mol difference is substantial and can often outweigh minor ADME drawbacks.
**Overall Assessment:**
While Ligand B has better metabolic stability (lower Cl_mic, longer t1/2) and BBB penetration, the significantly stronger binding affinity of Ligand A (-7.1 vs -5.7 kcal/mol) and its much lower hERG risk are decisive. The improved solubility and Caco-2 permeability of Ligand A are also beneficial. For a GPCR, strong binding is paramount, and the hERG risk associated with Ligand B is a major concern.
Therefore, I prefer Ligand A.
Output:
1
2025-04-17 19:48:00,166 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (356.419 and 349.406 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand B (71.53) is significantly better than Ligand A (116.17). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (1.807) is within the optimal 1-3 range, while Ligand A (-0.575) is below 1, potentially hindering permeation. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (1), but both are acceptable (<=5).
5. **HBA:** Ligand A (6) is higher than Ligand B (4), but both are within the acceptable range (<=10).
6. **QED:** Ligand B (0.85) is better than Ligand A (0.526), indicating a more drug-like profile.
7. **DILI:** Both ligands have similar, acceptable DILI risk (37.767 and 38.387 percentile).
8. **BBB:** Ligand B (88.561) is much higher than Ligand A (45.134). While not a primary concern for a cardiovascular target, higher BBB is generally a positive attribute.
9. **Caco-2:** Ligand A (-5.073) and Ligand B (-4.366) are both negative, indicating poor permeability. However, Ligand B is slightly better.
10. **Solubility:** Ligand A (-1.086) is slightly better than Ligand B (-2.814), but both are very poor. This is a concern for both compounds.
11. **hERG:** Ligand A (0.087) is better than Ligand B (0.544), indicating lower cardiotoxicity risk. This is a crucial factor for a cardiovascular target.
12. **Cl_mic:** Ligand A (13.967) has significantly lower microsomal clearance than Ligand B (24.619), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-39.122) has a much longer in vitro half-life than Ligand A (-9.156). This is a significant advantage.
14. **Pgp:** Ligand A (0.015) has much lower P-gp efflux than Ligand B (0.05). This is a positive for bioavailability.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-8.0 and -6.9 kcal/mol). Ligand A is slightly better, but the difference is not substantial enough to overcome other issues.
**Overall Assessment:**
Ligand B has several advantages: better logP, QED, BBB, and a significantly longer half-life. Ligand A has better hERG inhibition and lower P-gp efflux, and slightly better affinity, and lower Cl_mic. However, the poor solubility of both compounds is a major concern. Considering the GPCR-specific priorities (logP, TPSA, Pgp, affinity), Ligand B's superior logP, QED, and half-life outweigh the slightly better hERG and P-gp profile of Ligand A. The slightly better affinity of Ligand A is not enough to compensate for the other shortcomings.
Output:
0
2025-04-17 19:48:00,166 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands (351.426 & 363.443 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (84.46) is better than Ligand B (94.64). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (1.203) is better than Ligand B (0.28). Both are within the acceptable range (1-3), but Ligand A is closer to the optimal range, suggesting better membrane permeability. Ligand B is quite low and may have absorption issues.
4. **HBD:** Ligand A (1) is better than Ligand B (2). Fewer HBDs are generally preferred for better permeability.
5. **HBA:** Ligand A (5) is better than Ligand B (6). Similar to HBD, lower HBA is favorable.
6. **QED:** Both ligands are very similar (0.835 vs 0.804), and both are excellent, indicating good drug-like properties.
7. **DILI:** Ligand A (45.638) is significantly better than Ligand B (65.917). Lower DILI risk is crucial.
8. **BBB:** Ligand A (88.057) is better than Ligand B (54.517). While not a CNS target, some level of BBB penetration can sometimes indicate better overall distribution.
9. **Caco-2:** Ligand A (-4.949) is better than Ligand B (-5.018). Both are very negative, indicating poor Caco-2 permeability.
10. **Solubility:** Ligand A (-2.58) is better than Ligand B (-3.158). Both are poor, but A is slightly better.
11. **hERG:** Ligand A (0.549) is better than Ligand B (0.145). Lower hERG inhibition is critical for avoiding cardiotoxicity, a major concern for a cardiovascular target.
12. **Cl_mic:** Ligand A (20.568) is worse than Ligand B (5.593). Lower clearance is preferred for metabolic stability, so B is better here.
13. **t1/2:** Ligand A (-14.901) is worse than Ligand B (-1.436). Longer half-life is preferred, so B is better here.
14. **Pgp:** Ligand A (0.092) is better than Ligand B (0.031). Lower P-gp efflux is favorable for bioavailability.
15. **Affinity:** Ligand A (-6.4) is better than Ligand B (-5.5). This is a 0.9 kcal/mol difference, which is significant and can outweigh some ADME drawbacks.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A excels in logP, TPSA, and Pgp, and has a substantially better binding affinity. While Ligand B has better metabolic stability (Cl_mic and t1/2), the superior affinity and more favorable ADME profile (particularly logP, DILI, and hERG) of Ligand A are more important for this target.
**Conclusion:**
Ligand A is the more promising candidate due to its superior binding affinity, better predicted permeability (logP, TPSA), lower DILI and hERG risk, and acceptable QED. The slight metabolic liabilities can be addressed through further optimization.
Output:
1
2025-04-17 19:48:00,166 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (344.375 Da) is within the ideal range (200-500), while Ligand B (375.881 Da) is also acceptable. No clear advantage here.
2. **TPSA:** Ligand A (122.03) is borderline, but acceptable for a non-CNS target. Ligand B (57.01) is excellent, well below the 140 threshold, and suggests good permeability. Advantage: B.
3. **logP:** Ligand A (0.043) is quite low, potentially hindering membrane permeability. Ligand B (4.771) is high, potentially causing solubility issues and off-target interactions, but is within the acceptable range. Advantage: A (slightly, due to B being at the high end).
4. **HBD:** Ligand A (3) is good. Ligand B (0) is also good, minimizing potential for unwanted interactions. No clear advantage.
5. **HBA:** Ligand A (7) is good. Ligand B (6) is also good. No clear advantage.
6. **QED:** Both ligands (A: 0.581, B: 0.602) have good drug-likeness scores. No clear advantage.
7. **DILI:** Ligand A (52.772) has a lower DILI risk than Ligand B (81.117). Advantage: A.
8. **BBB:** ADRB2 is a cardiovascular target, so BBB penetration is not a primary concern. Ligand A (25.242) and Ligand B (68.864) are both low, which is fine. Advantage: B (slightly).
9. **Caco-2:** Ligand A (-5.525) is very poor, indicating poor intestinal absorption. Ligand B (-4.795) is also poor, but slightly better than A. Advantage: B.
10. **Solubility:** Ligand A (-2.144) is poor. Ligand B (-5.442) is very poor. Both are concerning, but the higher logP of B contributes to this. No clear advantage.
11. **hERG:** Ligand A (0.028) has a very low hERG risk. Ligand B (0.376) is also low, but slightly higher. Advantage: A.
12. **Cl_mic:** Ligand A (5.483) has a lower microsomal clearance, suggesting better metabolic stability. Ligand B (108.08) has high clearance. Advantage: A.
13. **t1/2:** Ligand A (-8.822) has a negative half-life, which is unusual and suggests very rapid clearance. Ligand B (-2.006) is also short, but better than A. Advantage: B.
14. **Pgp:** Ligand A (0.013) has very low P-gp efflux liability. Ligand B (0.429) has moderate P-gp efflux. Advantage: A.
15. **Affinity:** Ligand A (-7.1) has a slightly better binding affinity than Ligand B (-5.2). Advantage: A.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand A emerges as the more promising candidate. While Ligand B has a better TPSA, the significantly lower logP of Ligand A, lower DILI risk, better metabolic stability (lower Cl_mic), lower Pgp efflux, and slightly better affinity outweigh this advantage. The poor solubility of both is a concern, but can be addressed with formulation strategies. The negative half-life of A is a significant drawback, but the other factors are more important for initial selection.
Output:
1
2025-04-17 19:48:00,166 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [343.427, 82.53, 2.112, 2, 4, 0.708, 25.165, 56.844, -4.806, -3.17, 0.327, 53.641, -18.121, 0.112, -7.2]
**Ligand B:** [346.435, 86.86, 1.561, 1, 7, 0.822, 48.313, 67.352, -4.511, -2.886, 0.19, 32.023, 11.221, 0.048, -6.4]
Here's a breakdown, considering the GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal range (200-500 Da). A is 343.43, B is 346.44 - very similar.
2. **TPSA:** Both are good, below 140. A is 82.53, B is 86.86. A is slightly better.
3. **logP:** Both are within the optimal range (1-3). A is 2.11, B is 1.56. A is better, closer to the ideal range.
4. **HBD:** A has 2, B has 1. Lower is generally better for permeability, so B is slightly favored.
5. **HBA:** A has 4, B has 7. A is better.
6. **QED:** Both are good (>0.5). B (0.822) is slightly better than A (0.708).
7. **DILI:** A (25.17) is significantly better than B (48.31). This is a major advantage for A.
8. **BBB:** B (67.35) is better than A (56.84). While not a primary concern for a cardiovascular target, it's a slight advantage for B.
9. **Caco-2:** Both are negative, indicating good permeability. A (-4.81) is slightly better.
10. **Solubility:** Both are negative, indicating good solubility. A (-3.17) is slightly better.
11. **hERG:** Both are very low, indicating minimal risk. A (0.33) is slightly better.
12. **Cl_mic:** B (32.02) is significantly better than A (53.64). Lower clearance is preferred.
13. **t1/2:** A (-18.12) is better than B (11.22). Negative values indicate longer half-life.
14. **Pgp:** Both are very low, indicating minimal efflux. A (0.11) is slightly better.
15. **Affinity:** A (-7.2) is significantly better than B (-6.4). A 0.8 kcal/mol difference is substantial.
**Overall Assessment:**
Ligand A has a significantly better binding affinity and a much lower DILI risk. It also has slightly better TPSA, logP, Caco-2, solubility, hERG, and Pgp values. While Ligand B has a slightly better QED and BBB penetration, and a lower Cl_mic, the substantial advantage in affinity and the critical improvement in DILI risk for Ligand A outweigh these benefits. The affinity difference is large enough to overcome the slightly higher clearance of Ligand A.
Therefore, I prefer Ligand A.
Output:
1
2025-04-17 19:48:00,166 - INFO - Batch 137 complete. Total preferences: 2192
2025-04-17 19:48:00,166 - INFO - Processing batch 138/512...
2025-04-17 19:48:49,933 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (358.433 and 350.503 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (86.88) is slightly higher than Ligand B (60.85). Both are below the 140 threshold for oral absorption, but Ligand B is better positioned, especially considering ADRB2 is a cardiovascular target and CNS penetration isn't a primary goal.
3. **logP:** Both ligands (2.924 and 2.567) are within the optimal 1-3 range. Ligand B is slightly lower, which could be beneficial for solubility.
4. **HBD:** Ligand A (3) is higher than Ligand B (1). Lower HBD is generally preferred for better permeability, giving a slight edge to Ligand B.
5. **HBA:** Both ligands have 3 HBA, which is within the acceptable range.
6. **QED:** Ligand B (0.801) has a significantly higher QED score than Ligand A (0.634), indicating a more drug-like profile. This is a substantial advantage.
7. **DILI:** Ligand B (21.714) has a much lower DILI risk than Ligand A (40.869). This is a critical advantage, as minimizing liver toxicity is paramount.
8. **BBB:** Both ligands have moderate BBB penetration (59.131 and 63.746). Since ADRB2 is primarily a cardiovascular target, high BBB penetration isn't crucial.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and indicates poor permeability. Ligand A (-5.232) is slightly worse than Ligand B (-4.692).
10. **Solubility:** Both ligands have negative solubility values, indicating poor aqueous solubility. Ligand A (-2.827) is slightly worse than Ligand B (-2.474).
11. **hERG:** Both ligands have low hERG inhibition risk (0.48 and 0.552). No significant difference.
12. **Cl_mic:** Ligand B (52.564) has a significantly lower microsomal clearance than Ligand A (16.109), suggesting better metabolic stability. This is a major advantage.
13. **t1/2:** Ligand A (-22.205) has a negative half-life, which is concerning. Ligand B (3.099) has a positive, albeit short, half-life.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.097 and 0.539). No significant difference.
15. **Binding Affinity:** Ligand B (-5.3) has a slightly better binding affinity than Ligand A (-4.8). While the difference is not huge (0.5 kcal/mol), it's a positive factor.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand B performs better on TPSA, logP, and affinity. The significant advantages in DILI risk and metabolic stability (Cl_mic) further solidify its position.
**Conclusion:**
Ligand B consistently outperforms Ligand A across several crucial ADME-Tox properties (DILI, Cl_mic, QED) and has a slightly better binding affinity. While both have issues with Caco-2 and solubility, the overall profile of Ligand B is more favorable for development as a drug candidate.
Output:
0
2025-04-17 19:48:49,933 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
Both ligands are fairly similar in molecular weight (around 346 Da) and TPSA (around 71.3-71.5), falling within acceptable ranges for oral absorption. Given that ADRB2 is a cardiovascular target (not CNS), BBB is less critical, but still considered. Let's break down the comparison parameter by parameter:
1. **MW:** Both are good (348 vs 345 Da).
2. **TPSA:** Both are good (71.3 vs 71.5).
3. **logP:** Both are good (2.92 vs 1.99). Ligand A is slightly better, being closer to the optimal 1-3 range.
4. **HBD:** Ligand A (2) is slightly better than Ligand B (1) - both are acceptable.
5. **HBA:** Ligand B (4) is slightly better than Ligand A (3) - both are acceptable.
6. **QED:** Both are good (0.83 vs 0.89). Ligand B is slightly better.
7. **DILI:** Ligand B (26.0) is significantly better than Ligand A (37.8), indicating a lower risk of liver injury. This is a significant advantage.
8. **BBB:** Ligand B (84.7) is better than Ligand A (76.5), but less important for a cardiovascular target.
9. **Caco-2:** Both are poor (-4.65 vs -4.60), indicating poor intestinal absorption.
10. **Solubility:** Ligand B (-2.43) is better than Ligand A (-3.59).
11. **hERG:** Ligand B (0.44) is better than Ligand A (0.32), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand A (14.8) is better than Ligand B (25.1), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-6.27) is better than Ligand A (31.66), suggesting a longer half-life.
14. **Pgp:** Ligand B (0.025) is significantly better than Ligand A (0.123), indicating lower P-glycoprotein efflux.
15. **Affinity:** Ligand A (-6.5) is slightly better than Ligand B (-6.0).
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are important. Ligand A has a slightly better logP and affinity. However, Ligand B excels in Pgp efflux (much lower) and has a better DILI and hERG profile. The improved metabolic stability of Ligand A is also a plus.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity and metabolic stability, Ligand B's significantly better safety profile (DILI, hERG) and improved Pgp efflux outweigh these advantages. The poor Caco-2 values for both are concerning and would need to be addressed in further optimization, but the safety profile is paramount at this stage.
**Output:**
0
2025-04-17 19:48:49,933 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (344.46 and 344.54 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (59.39) is higher than Ligand B (32.34). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is generally preferred for absorption. Ligand B is better here.
3. **logP:** Ligand A (3.768) is within the optimal range (1-3), while Ligand B (4.282) is slightly above. This could potentially lead to solubility issues for Ligand B, but isn't a major concern.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 2. Both are acceptable, but lower is generally better for permeability. Ligand B is better.
6. **QED:** Ligand A (0.898) has a significantly higher QED score than Ligand B (0.729), indicating better overall drug-likeness. This is a substantial advantage for Ligand A.
7. **DILI:** Ligand A (48.042) has a higher DILI risk than Ligand B (8.569). This is a significant negative for Ligand A.
8. **BBB:** Ligand A (78.79) has a lower BBB penetration percentile than Ligand B (87.127). While ADRB2 isn't a primary CNS target, some degree of BBB penetration can be relevant for off-target effects. Ligand B is better.
9. **Caco-2:** Ligand A (-4.399) and Ligand B (-4.959) both have negative Caco-2 values, which is unusual and suggests very poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Ligand A (-2.894) has better solubility than Ligand B (-4.272).
11. **hERG:** Both ligands have low hERG inhibition risk (0.621 and 0.71, respectively). No significant difference.
12. **Cl_mic:** Ligand A (36.437) has lower microsomal clearance than Ligand B (53.214), suggesting better metabolic stability. This is a positive for Ligand A.
13. **t1/2:** Ligand A (40.916) has a longer in vitro half-life than Ligand B (-4.81). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.098) has lower P-gp efflux liability than Ligand B (0.26). This is a positive for Ligand A.
15. **Binding Affinity:** Ligand B (-7.1 kcal/mol) has a significantly stronger binding affinity than Ligand A (-4.3 kcal/mol). This is a crucial advantage for Ligand B, potentially outweighing some of the ADME drawbacks.
**Overall Assessment:**
Ligand B has a significantly better binding affinity, lower DILI risk, better BBB penetration, and lower HBA/TPSA. While Ligand A has better QED, solubility, metabolic stability (Cl_mic), half-life, and lower Pgp efflux, the substantial binding affinity advantage of Ligand B is the most important factor for a GPCR target like ADRB2. The slightly higher logP of Ligand B is manageable. The poor Caco-2 values are concerning for both, but the binding affinity difference is decisive.
Output:
0
2025-04-17 19:48:49,933 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (349.475 and 350.415 Da). No significant difference here.
2. **TPSA:** Ligand A (70.67) is better than Ligand B (79.31). ADRB2 is a cardiovascular target, so CNS penetration isn't critical, but lower TPSA generally favors absorption.
3. **logP:** Ligand A (2.05) is within the optimal range, while Ligand B (-0.212) is below 1, which could hinder permeation. This is a significant advantage for Ligand A.
4. **HBD:** Both ligands have acceptable HBD counts (2 and 1, respectively).
5. **HBA:** Both ligands have acceptable HBA counts (4 and 5, respectively).
6. **QED:** Both ligands have similar, good QED values (0.716 and 0.71).
7. **DILI:** Ligand A (19.387) has a much lower DILI risk than Ligand B (30.826). This is a crucial advantage for Ligand A.
8. **BBB:** Not a primary concern for a cardiovascular target, but Ligand B (50.679) is slightly higher than Ligand A (40.481).
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the values are very close (-4.856 vs -4.757).
10. **Solubility:** Both have negative solubility values, indicating poor aqueous solubility. Again, values are very close (-1.056 vs -1.171).
11. **hERG:** Both have very low hERG inhibition risk (0.381 and 0.127).
12. **Cl_mic:** Ligand A (12.984) has a significantly lower microsomal clearance than Ligand B (21.122), indicating better metabolic stability.
13. **t1/2:** Ligand B (18.359) has a longer in vitro half-life than Ligand A (-9.726). This is a positive for Ligand B, but the negative value for A is concerning.
14. **Pgp:** Both have very low Pgp efflux liability (0.023 and 0.028).
15. **Binding Affinity:** Ligand B (-7.0) has a significantly stronger binding affinity than Ligand A (0.0). This is a major advantage for Ligand B.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand A has a better logP and TPSA, but Ligand B has a substantially better binding affinity. The DILI risk is also a major consideration, and Ligand A is significantly better in this regard. Metabolic stability (Cl_mic) is also important, favoring Ligand A.
**Overall Assessment:**
While Ligand B has a superior binding affinity, the combination of Ligand A's better logP, lower DILI risk, and lower Cl_mic makes it the more promising candidate. The poor solubility and Caco-2 values are concerns for both, but can be addressed through formulation strategies. The significantly better affinity of Ligand B is tempting, but the higher DILI risk and faster clearance are substantial drawbacks.
Output:
1
2025-04-17 19:48:49,934 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [359.853, 57.61, 4.694, 1, 2, 0.779, 69.794, 21.675, -4.546, -3.641, 0.158, 38.441, 39.193, 0.112, -6.2]
**Ligand B:** [357.495, 82.11, 1.018, 2, 5, 0.634, 23.769, 30.593, -5.039, -1.577, 0.265, 14.197, -1.481, 0.021, -7.6]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). A: 359.853, B: 357.495 - very similar.
2. **TPSA:** A (57.61) is excellent, well below 140 and good for oral absorption. B (82.11) is higher, but still acceptable, though less ideal.
3. **logP:** A (4.694) is pushing the upper limit, potentially causing solubility issues. B (1.018) is quite low, which could hinder membrane permeability.
4. **HBD:** Both have acceptable HBD counts (A: 1, B: 2).
5. **HBA:** Both are acceptable (A: 2, B: 5).
6. **QED:** Both are reasonable (A: 0.779, B: 0.634), indicating drug-like properties. A is slightly better.
7. **DILI:** A (69.794) is concerning, indicating a higher risk of liver injury. B (23.769) is excellent, very low risk.
8. **BBB:** A (21.675) is low, suggesting poor brain penetration. B (30.593) is also low, but slightly better. For a cardiovascular target, BBB isn't *critical*, but some distribution to the CNS can have off-target effects.
9. **Caco-2:** Both are negative, indicating poor permeability. A (-4.546) is worse than B (-5.039).
10. **Solubility:** A (-3.641) is very poor. B (-1.577) is also poor, but better than A.
11. **hERG:** Both are low risk (A: 0.158, B: 0.265).
12. **Cl_mic:** A (38.441) is moderate. B (14.197) is significantly lower, indicating better metabolic stability.
13. **t1/2:** A (39.193) is good. B (-1.481) is very poor, suggesting rapid metabolism.
14. **Pgp:** Both have low Pgp efflux liability (A: 0.112, B: 0.021). B is slightly better.
15. **Affinity:** B (-7.6) has a significantly stronger binding affinity than A (-6.2) - a difference of 1.4 kcal/mol.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, and affinity. While BBB isn't paramount for a cardiovascular target, it's still a consideration.
**Decision:**
Ligand A has a better TPSA and QED, but suffers from a high DILI risk, poor solubility, and a weaker binding affinity. Ligand B has a significantly stronger binding affinity, lower DILI risk, and better metabolic stability, despite a higher TPSA and lower logP. The 1.4 kcal/mol advantage in binding affinity for Ligand B is substantial and outweighs the drawbacks of its slightly higher TPSA and lower logP. The DILI risk for Ligand A is a major concern. The poor solubility of both is a formulation challenge, but can be addressed. The poor Caco-2 values are concerning for both, but the higher affinity of B may allow for lower dosing to compensate.
Therefore, I prefer **Ligand B**.
Output:
0
2025-04-17 19:48:49,934 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (341.43 and 351.447 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (45.23) is significantly better than Ligand B (101.73). For a GPCR, lower TPSA is generally preferred for better permeability, and Ligand A is well below the 140 threshold. Ligand B is pushing the limit.
3. **logP:** Ligand A (4.134) is higher than Ligand B (1.259). While both are within the acceptable range, Ligand A is at the upper end. This could potentially lead to solubility issues, but it might also improve membrane permeability. Ligand B's logP is quite low, which could hinder permeability.
4. **HBD:** Ligand A (1) is better than Ligand B (2). Lower is generally preferred.
5. **HBA:** Ligand A (3) is better than Ligand B (4). Lower is generally preferred.
6. **QED:** Ligand A (0.889) is superior to Ligand B (0.674), indicating a more drug-like profile.
7. **DILI:** Ligand B (32.61) has a much lower DILI risk than Ligand A (54.672). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (78.519) has a better BBB penetration score than Ligand B (58.356). While ADRB2 isn't exclusively a CNS target, some peripheral ADRB2 activity can be modulated by CNS effects, and better BBB penetration isn't necessarily a detriment.
9. **Caco-2:** Ligand A (-4.759) is better than Ligand B (-5.558). Higher values indicate better intestinal absorption.
10. **Solubility:** Ligand A (-4.308) is better than Ligand B (-2.767). Higher values indicate better solubility.
11. **hERG:** Ligand A (0.823) is better than Ligand B (0.211). Lower hERG inhibition is crucial for avoiding cardiotoxicity, a major concern with cardiovascular targets.
12. **Cl_mic:** Ligand B (10.182) has significantly lower microsomal clearance than Ligand A (39.944), indicating better metabolic stability.
13. **t1/2:** Ligand A (12.356) has a longer in vitro half-life than Ligand B (-0.697). This is a positive for Ligand A.
14. **Pgp:** Ligand A (0.559) is better than Ligand B (0.037). Lower P-gp efflux is preferred.
15. **Binding Affinity:** Ligand B (-8.0) has a significantly stronger binding affinity than Ligand A (-6.0). This is a substantial advantage for Ligand B, potentially outweighing some of its ADME drawbacks.
**Overall Assessment:**
Ligand B has a significantly better binding affinity and lower DILI risk, and better metabolic stability. Ligand A has better TPSA, solubility, and BBB penetration, but its higher DILI risk and lower affinity are concerning. The strong affinity of Ligand B is a key advantage for a GPCR target. While Ligand B's logP is lower, the overall profile is more favorable, especially considering the importance of potency for GPCRs.
Output:
0
2025-04-17 19:48:49,934 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (349.435 Da and 343.387 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (96.33) is better than Ligand B (104.6). Both are below 140, but closer to 90 is preferable for GPCRs. Ligand A is slightly better positioned for permeability.
**3. logP:** Ligand A (0.447) is slightly better than Ligand B (0.238). Both are a bit low, potentially impacting membrane permeability, but not drastically.
**4. H-Bond Donors:** Ligand A (2) is better than Ligand B (3). Lower is generally preferred for permeability.
**5. H-Bond Acceptors:** Both ligands have 5 H-bond acceptors, which is acceptable.
**6. QED:** Ligand B (0.699) has a notably higher QED score than Ligand A (0.552), indicating a more favorable drug-like profile overall.
**7. DILI Risk:** Ligand A (38.852) has a significantly lower DILI risk than Ligand B (67.507). This is a crucial advantage as liver toxicity is a major concern.
**8. BBB Penetration:** Both ligands have similar BBB penetration (41.14% and 41.605%). Since ADRB2 is a cardiovascular target, BBB penetration isn't a primary concern, but it's not detrimental to have some.
**9. Caco-2 Permeability:** Both ligands have very poor Caco-2 permeability (-5.508 and -5.561). This is a significant drawback for both.
**10. Aqueous Solubility:** Both ligands have poor aqueous solubility (-1.135 and -2.431). This could pose formulation challenges.
**11. hERG Inhibition:** Ligand A (0.087) has a much lower hERG inhibition risk than Ligand B (0.168). This is a critical safety parameter, and Ligand A is clearly superior.
**12. Microsomal Clearance:** Ligand A (17.396) has higher microsomal clearance than Ligand B (0.932), meaning it is less metabolically stable. This is a disadvantage for Ligand A.
**13. In vitro Half-Life:** Ligand B (21.971) has a longer in vitro half-life than Ligand A (20.606). This is a slight advantage for Ligand B.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.015 and 0.008). This is good.
**15. Binding Affinity:** Ligand B (-7.6 kcal/mol) has a stronger binding affinity than Ligand A (-8.2 kcal/mol). This is a significant advantage for Ligand B.
**Overall Assessment:**
While Ligand B has a better binding affinity and QED score, the significantly lower DILI risk and hERG inhibition liability of Ligand A are critical advantages. The poor Caco-2 and solubility are concerning for both, but can potentially be addressed with formulation strategies. The slightly higher metabolic clearance of Ligand A is a drawback, but the safety profile is paramount. Given the GPCR target class, balancing affinity with safety and permeability is key. The lower DILI and hERG risks of Ligand A outweigh the slightly better affinity of Ligand B.
Output:
1
2025-04-17 19:48:49,934 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.399 and 368.499 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (93.73) is slightly higher than Ligand B (67.87). For a cardiovascular GPCR, TPSA isn't a *major* concern unless it's excessively high, but Ligand B is better positioned for potential CNS penetration if needed.
3. **logP:** Ligand B (1.249) is better than Ligand A (0.491). ADRB2 is a GPCR, and a logP between 1-3 is preferred. Ligand A is a bit low, potentially impacting permeability.
4. **HBD:** Ligand A (2) has more HBD than Ligand B (1). This isn't a huge difference, but fewer HBDs generally correlate with better permeability.
5. **HBA:** Both ligands have the same number of HBA (5).
6. **QED:** Ligand B (0.685) has a better QED score than Ligand A (0.527), indicating a more drug-like profile.
7. **DILI:** Ligand B (29.159) has a significantly lower DILI risk than Ligand A (49.632). This is a substantial advantage.
8. **BBB:** Ligand B (56.146) has a higher BBB penetration score than Ligand A (29.779). While not a primary concern for a cardiovascular target, it's a positive attribute.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Ligand A (-1.579) has slightly better solubility than Ligand B (-3.152). Solubility isn't a major concern given the other factors.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.137 and 0.193).
12. **Cl_mic:** Both have similar microsomal clearance values (17.94 and 16.982).
13. **t1/2:** Ligand B (15.179) has a significantly longer in vitro half-life than Ligand A (-4.298). This is a major advantage, suggesting less frequent dosing.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.037 and 0.04).
15. **Binding Affinity:** Ligand B (-6.4) has a slightly better binding affinity than Ligand A (-5.8). While the difference is less than 1.5 kcal/mol, it contributes to the overall preference.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand B excels in logP, has a better TPSA, and a slightly better affinity. The DILI and half-life improvements are also significant.
**Conclusion:**
Ligand B demonstrates a superior balance of properties, particularly regarding safety (DILI), metabolic stability (t1/2), and drug-likeness (QED). While Ligand A has slightly better solubility, the other advantages of Ligand B outweigh this minor difference.
Output:
0
2025-04-17 19:48:49,934 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [340.431, 75.08, 2.264, 2, 5, 0.811, 37.728, 68.67, -5.15, -2.641, 0.238, 12.391, 40.177, 0.026, -7.6]
**Ligand B:** [371.459, 85.11, 0.662, 0, 7, 0.621, 61.109, 74.874, -4.826, -1.506, 0.198, 56.063, -35.233, 0.074, -4.3]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (340.431) is slightly preferred.
2. **TPSA:** Ligand A (75.08) is better than Ligand B (85.11). Both are acceptable for a non-CNS GPCR target like ADRB2, but lower is generally better for permeability.
3. **logP:** Ligand A (2.264) is optimal, while Ligand B (0.662) is a bit low, potentially hindering membrane permeability. This is a significant advantage for A.
4. **HBD/HBA:** Ligand A (2 HBD, 5 HBA) is slightly better than Ligand B (0 HBD, 7 HBA). Both are within acceptable limits.
5. **QED:** Ligand A (0.811) is significantly better than Ligand B (0.621), indicating a more drug-like profile.
6. **DILI:** Ligand A (37.728) has a much lower DILI risk than Ligand B (61.109). This is a crucial advantage for A.
7. **BBB:** Ligand B (74.874) has a slightly higher BBB penetration, but this isn't a primary concern for a cardiovascular target.
8. **Caco-2:** Ligand A (-5.15) is better than Ligand B (-4.826), indicating better intestinal absorption.
9. **Solubility:** Ligand A (-2.641) is better than Ligand B (-1.506).
10. **hERG:** Both are very low, indicating minimal cardiotoxicity risk.
11. **Cl_mic:** Ligand A (12.391) has a lower microsomal clearance, suggesting better metabolic stability than Ligand B (56.063).
12. **t1/2:** Ligand A (40.177) has a longer in vitro half-life than Ligand B (-35.233). This is a significant advantage for A.
13. **Pgp:** Both are very low, indicating minimal P-gp efflux.
14. **Affinity:** Ligand A (-7.6 kcal/mol) has a significantly stronger binding affinity than Ligand B (-4.3 kcal/mol). This is a major advantage for A.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical parameters. It has a better logP, QED, lower DILI risk, better metabolic stability (lower Cl_mic, longer t1/2), and, most importantly, a much stronger binding affinity. While Ligand B has slightly better BBB penetration, this is less important for a cardiovascular target. The superior affinity of Ligand A is likely to outweigh any minor drawbacks.
Output:
1
2025-04-17 19:48:49,934 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (373.475 and 361.515 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (96.02) is slightly higher than Ligand B (70.15). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is generally preferred for absorption. Ligand B has a clear advantage.
3. **logP:** Ligand A (-0.588) is quite low, potentially hindering membrane permeability. Ligand B (1.989) is within the optimal 1-3 range. This is a significant advantage for Ligand B.
4. **HBD:** Both ligands have acceptable HBD counts (1 and 2, respectively).
5. **HBA:** Both ligands have acceptable HBA counts (5 and 6, respectively).
6. **QED:** Both ligands have similar, good QED values (0.671 and 0.617).
7. **DILI:** Both ligands have low DILI risk (35.014 and 34.277 percentile), indicating a similar safety profile regarding liver toxicity.
8. **BBB:** Both have moderate BBB penetration (65.839 and 62.04 percentile). Since ADRB2 is not a CNS target, this is not a major differentiating factor.
9. **Caco-2:** Both ligands show poor Caco-2 permeability (-4.978 and -5.488). This is a concern for oral absorption for both, but slightly worse for Ligand B.
10. **Solubility:** Both ligands exhibit poor aqueous solubility (-1.608 and -2.108). This is a significant drawback for both.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.119 and 0.279 percentile). This is excellent.
12. **Cl_mic:** Ligand A (12.908 mL/min/kg) has a lower microsomal clearance than Ligand B (16.064 mL/min/kg), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-12.525 hours) has a negative in vitro half-life, which is not possible. This is a red flag. Ligand B (4.766 hours) is reasonable.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.025 and 0.017).
15. **Binding Affinity:** Both ligands have similar, strong binding affinities (-6.1 and -6.2 kcal/mol). The difference is negligible.
**GPCR-Specific Priorities & Overall Assessment:**
For ADRB2 (a cardiovascular GPCR), logP, TPSA, and affinity are key. Ligand B significantly outperforms Ligand A in logP and TPSA. While both have poor solubility and Caco-2 permeability, the more favorable logP of Ligand B suggests it might have a better chance of overcoming these issues. The negative half-life for Ligand A is a critical flaw.
**Output:**
0
2025-04-17 19:48:49,935 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (346.475 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (86.88) is slightly higher than Ligand B (76.02). Both are below the 140 A^2 threshold for oral absorption, but B is closer to the preferred <90 A^2 for GPCRs, giving it a slight edge.
**3. logP:** Both ligands have good logP values (A: 2.915, B: 2.006), falling within the optimal 1-3 range. B is a bit lower, which could slightly improve solubility, but both are acceptable.
**4. H-Bond Donors:** Ligand A (3) is slightly higher than Ligand B (2). Both are within the acceptable limit of <=5.
**5. H-Bond Acceptors:** Ligand A (3) and Ligand B (4) are both within the acceptable limit of <=10.
**6. QED:** Both ligands have good QED scores (A: 0.766, B: 0.793), indicating good drug-like properties. B is marginally better.
**7. DILI Risk:** Ligand B (18.651) has a significantly lower DILI risk than Ligand A (53.432). This is a major advantage for Ligand B.
**8. BBB Penetration:** Both ligands have reasonable BBB penetration (A: 61.38, B: 68.825). While not exceptionally high, B is slightly better. For a cardiovascular target, BBB penetration isn't *critical*, but it's a bonus.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-5.003 and -4.937). This is unusual and suggests poor permeability. However, the values are very similar.
**10. Aqueous Solubility:** Ligand B (-2.243) has better solubility than Ligand A (-4.419). This is a positive attribute.
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (A: 0.262, B: 0.178). B is slightly better.
**12. Microsomal Clearance:** Ligand B (29.57) has lower microsomal clearance than Ligand A (40.368), indicating better metabolic stability. This is a significant advantage.
**13. In vitro Half-Life:** Ligand B (16.034) has a longer in vitro half-life than Ligand A (-13.454). This is a major advantage, potentially leading to less frequent dosing.
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (A: 0.125, B: 0.03). B is significantly better, which is important for bioavailability.
**15. Binding Affinity:** Ligand B (-6.6 kcal/mol) has slightly better binding affinity than Ligand A (-6.1 kcal/mol). While the difference is not huge, it's enough to be considered.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity) and the general drug-like properties, Ligand B is the superior candidate. Its lower DILI risk, better metabolic stability (lower Cl_mic, longer t1/2), improved solubility, lower P-gp efflux, and slightly better affinity outweigh the small differences in TPSA and BBB penetration. The negative Caco-2 values are concerning for both, but the other advantages of B make it the more promising option.
Output:
0
2025-04-17 19:48:49,935 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (377.491 Da and 354.495 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (72.36) is slightly higher than Ligand B (65.12). Both are below the 140 A^2 threshold for good oral absorption, but closer to the 90 A^2 threshold for CNS targets (less relevant for a cardiovascular target, but still favorable). Ligand B is slightly preferred.
**3. logP:** Ligand A (3.976) is within the optimal 1-3 range, while Ligand B (0.158) is quite low. Low logP can hinder membrane permeability. Ligand A is significantly preferred here.
**4. H-Bond Donors:** Ligand A (2) and Ligand B (1) are both within the acceptable limit of <=5. No significant difference.
**5. H-Bond Acceptors:** Ligand A (6) and Ligand B (5) are both within the acceptable limit of <=10. No significant difference.
**6. QED:** Both ligands have very similar QED values (0.59 and 0.598), indicating good drug-likeness.
**7. DILI Risk:** Ligand A (83.249) has a considerably higher DILI risk than Ligand B (3.8). This is a major concern for Ligand A. Ligand B is strongly preferred.
**8. BBB Penetration:** Ligand A (76.541) has better BBB penetration than Ligand B (53.354). While not a primary concern for a cardiovascular target, it's a slight advantage for Ligand A.
**9. Caco-2 Permeability:** Ligand A (-4.454) has worse Caco-2 permeability than Ligand B (-5.029). Lower values indicate lower permeability. Ligand B is slightly preferred.
**10. Aqueous Solubility:** Ligand A (-5.833) has worse aqueous solubility than Ligand B (-0.007). Solubility is important for bioavailability. Ligand B is preferred.
**11. hERG Inhibition:** Ligand A (0.266) has a lower hERG inhibition risk than Ligand B (0.596). This is a significant advantage for Ligand A.
**12. Microsomal Clearance:** Ligand A (97.091) has higher microsomal clearance than Ligand B (-7.021), meaning it's less metabolically stable. Ligand B is strongly preferred.
**13. In vitro Half-Life:** Ligand A (33.653) has a shorter half-life than Ligand B (-20.566). Ligand B is preferred.
**14. P-gp Efflux:** Ligand A (0.231) has lower P-gp efflux than Ligand B (0.006). Lower efflux is generally preferred. Ligand A is preferred.
**15. Binding Affinity:** Ligand A (-7.3) has a slightly better binding affinity than Ligand B (-6.7). This is a 0.6 kcal/mol difference, which is significant but not overwhelming.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity) and the general drug-like properties, Ligand B is the more promising candidate. While Ligand A has slightly better affinity and P-gp efflux, its significantly higher DILI risk, poor logP, and higher clearance are major drawbacks. Ligand B has a much more favorable safety profile (low DILI) and better ADME properties (logP, clearance, half-life, solubility, Caco-2 permeability) despite slightly lower affinity. The affinity difference is not large enough to overcome the ADME/Tox concerns with Ligand A.
Output:
0
2025-04-17 19:48:49,935 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (338.37) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (90.45) is better than Ligand B (115.97). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally aids absorption.
3. **logP:** Ligand A (2.068) is within the optimal range (1-3). Ligand B (-0.731) is below 1, which could hinder membrane permeability. This is a significant drawback for Ligand B.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (6) is better than Ligand B (4). Both are acceptable, but lower is generally preferred.
6. **QED:** Ligand A (0.736) is better than Ligand B (0.567), indicating a more drug-like profile.
7. **DILI:** Ligand A (89.104) has a higher DILI risk than Ligand B (18.883). This is a significant concern for Ligand A.
8. **BBB:** Not a primary concern for a cardiovascular target, but Ligand A (77.976) is better than Ligand B (43.001).
9. **Caco-2:** Ligand A (-4.604) is better than Ligand B (-5.287), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-3.36) is better than Ligand B (-1.076), which is important for bioavailability.
11. **hERG:** Ligand A (0.323) is much better than Ligand B (0.138), indicating a lower risk of cardiotoxicity. This is crucial for a cardiovascular target.
12. **Cl_mic:** Ligand B (-47.926) has a much lower (better) microsomal clearance than Ligand A (81.054), suggesting greater metabolic stability.
13. **t1/2:** Ligand A (21) has a significantly longer half-life than Ligand B (2.979). This is a major advantage for dosing convenience.
14. **Pgp:** Ligand A (0.094) is better than Ligand B (0.003), indicating lower P-gp efflux.
15. **Affinity:** Ligand A (-7.2 kcal/mol) has a slightly better binding affinity than Ligand B (-6.5 kcal/mol). While the difference isn't huge, it's still a positive.
**Overall Assessment:**
Ligand A has several advantages: better logP, TPSA, QED, Caco-2 permeability, solubility, hERG risk, Pgp efflux, and binding affinity. It also has a much longer half-life. However, its DILI risk is substantially higher. Ligand B has a much better DILI profile and metabolic stability, but suffers from poor logP, lower QED, and a shorter half-life.
Considering the target (ADRB2, cardiovascular), cardiotoxicity (hERG) and liver toxicity (DILI) are critical concerns. While Ligand B has a significantly lower DILI risk, Ligand A's superior hERG profile and overall better ADME properties (especially logP and permeability) are more critical. The slightly better affinity of Ligand A also contributes. The DILI risk of Ligand A can potentially be mitigated through structural modifications during lead optimization.
Therefore, I believe Ligand A is the more promising candidate.
Output:
1
2025-04-17 19:48:49,935 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (364.486 and 350.507 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (49.41 and 47.1) are well below the 140 A^2 threshold for good oral absorption, and suitable for a peripherally acting GPCR like ADRB2.
3. **logP:** Ligand A (3.844) is optimal, while Ligand B (0.872) is a bit low, potentially hindering membrane permeability. This is a point in favor of A.
4. **HBD:** Ligand A (1) and Ligand B (0) are both acceptable, being less than 5.
5. **HBA:** Ligand A (3) and Ligand B (4) are both acceptable, being less than 10.
6. **QED:** Both ligands (0.882 and 0.713) have good drug-likeness scores, above the 0.5 threshold.
7. **DILI:** Ligand A (43.622) has a slightly higher DILI risk than Ligand B (5.584), but both are below the concerning 60 percentile.
8. **BBB:** Ligand A (95.735) shows high BBB penetration, while Ligand B (61.535) is lower. While ADRB2 isn't primarily a CNS target, some level of BBB penetration isn't necessarily detrimental and could allow for off-target effects.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.927 and -4.808), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand A (-4.392) and Ligand B (-0.13) both have negative solubility values, which is also concerning. Ligand B is slightly better here.
11. **hERG:** Ligand A (0.739) and Ligand B (0.421) both have low hERG inhibition liability, which is good.
12. **Cl_mic:** Ligand A (40.922) has a higher microsomal clearance than Ligand B (-5.448). This suggests Ligand B is more metabolically stable, a positive attribute.
13. **t1/2:** Ligand A (14.888) has a longer in vitro half-life than Ligand B (3.028), which is desirable.
14. **Pgp:** Ligand A (0.43) has lower P-gp efflux than Ligand B (0.017), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand B (-7.1 kcal/mol) has a significantly stronger binding affinity than Ligand A (-2.7 kcal/mol). This is a substantial advantage, potentially outweighing some ADME concerns.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand A has a better logP and Pgp profile, while Ligand B has a much better binding affinity. The TPSA is comparable for both. The significant difference in binding affinity is the most important factor.
**Overall Assessment:**
Despite the concerning negative Caco-2 and solubility values for both compounds, the dramatically superior binding affinity of Ligand B (-7.1 kcal/mol vs -2.7 kcal/mol) is a decisive advantage. While Ligand A has better metabolic stability and Pgp properties, the potency difference is likely to be more impactful in driving efficacy. The slightly better DILI profile of Ligand B is also a plus. The poor permeability and solubility would need to be addressed through formulation strategies, but a strong starting point with high affinity is crucial.
Output:
0
2025-04-17 19:48:49,935 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Ligand A (342.399 Da) is within the ideal range (200-500 Da). Ligand B (378.447 Da) is also acceptable, but slightly higher.
2. **TPSA:** Ligand A (85.37) is excellent, well below the 140 threshold for oral absorption and good for a GPCR. Ligand B (133.24) is higher, approaching the upper limit for good absorption.
3. **logP:** Ligand A (3.207) is optimal. Ligand B (-1.408) is significantly lower, which could hinder membrane permeability and bioavailability. This is a major concern for a GPCR target.
4. **HBD:** Both ligands are acceptable (Ligand A: 2, Ligand B: 3).
5. **HBA:** Both ligands are acceptable (Ligand A: 5, Ligand B: 7).
6. **QED:** Both ligands have reasonable QED values (A: 0.769, B: 0.535), suggesting drug-like properties.
7. **DILI:** Ligand A (53.974) has a slightly higher DILI risk than Ligand B (41.062), but both are below the concerning 60 threshold.
8. **BBB:** Ligand A (74.486) has better BBB penetration potential than Ligand B (33.967). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be beneficial or at least needs to be considered.
9. **Caco-2:** Ligand A (-4.529) and Ligand B (-5.973) both have negative values, indicating poor permeability.
10. **Solubility:** Ligand A (-3.764) and Ligand B (-1.23) both have negative values, indicating poor solubility.
11. **hERG:** Both ligands show very low hERG inhibition risk (A: 0.47, B: 0.111).
12. **Cl_mic:** Ligand B (-21.918) has a significantly lower (better) microsomal clearance than Ligand A (26.581), indicating greater metabolic stability.
13. **t1/2:** Ligand B (23.703) has a longer in vitro half-life than Ligand A (8.651), which is desirable.
14. **Pgp:** Both ligands have very low P-gp efflux liability (A: 0.017, B: 0.018).
15. **Binding Affinity:** Both ligands have comparable binding affinities (-6.4 kcal/mol and -6.3 kcal/mol). The difference is negligible.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, and Pgp are particularly important. Ligand A excels in logP and TPSA, while both are similar in Pgp. Ligand B has better metabolic stability (Cl_mic) and half-life, but its significantly lower logP is a major drawback.
**Overall Assessment:**
Despite Ligand B's better metabolic stability and half-life, the significantly lower logP is a critical issue. Poor logP often translates to poor permeability and bioavailability, which are crucial for GPCR ligands to reach their target. Ligand A, with its optimal logP and acceptable TPSA, is more likely to be a viable drug candidate.
Output:
1
2025-04-17 19:48:49,936 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.415 and 355.429 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (99.5) is higher than Ligand B (58.22). For a GPCR, lower TPSA is generally preferred for better brain penetration, even though ADRB2 isn't strictly a CNS target. Ligand B is significantly better here.
3. **logP:** Ligand A (0.843) is a bit low, potentially hindering membrane permeability. Ligand B (3.161) is within the optimal 1-3 range. Ligand B is better.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 5 HBA, and Ligand B has 3. Both are acceptable, but lower is often better for permeability. Ligand B is slightly better.
6. **QED:** Both ligands have good QED scores (0.76 and 0.853), indicating good drug-like properties. No significant difference.
7. **DILI:** Both ligands have relatively low DILI risk (35.052 and 37.03), below the 40 threshold. No significant difference.
8. **BBB:** Ligand B (87.088) has a much higher BBB percentile than Ligand A (56.65). While ADRB2 isn't a primary CNS target, some degree of BBB penetration can be beneficial for distribution and off-target effects. Ligand B is better.
9. **Caco-2:** Ligand A (-4.535) and Ligand B (-4.707) are both negative, which is not ideal. It's difficult to interpret negative Caco-2 values, but they generally indicate poor permeability. No clear winner.
10. **Solubility:** Ligand A (-2.182) and Ligand B (-3.02) are both poor. Solubility is a concern for both, but Ligand B is slightly worse.
11. **hERG:** Ligand A (0.213) has a lower hERG risk than Ligand B (0.63). This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand B (33.514) has a lower microsomal clearance than Ligand A (26.229), suggesting better metabolic stability. Ligand B is better.
13. **t1/2:** Ligand B (-7.928) has a significantly longer in vitro half-life than Ligand A (-3.625). This is a major advantage for Ligand B.
14. **Pgp:** Ligand A (0.016) has a much lower P-gp efflux liability than Ligand B (0.158). This is a significant advantage for Ligand A.
15. **Binding Affinity:** Ligand B (-6.1 kcal/mol) has a slightly better binding affinity than Ligand A (-8.1 kcal/mol). This is a significant advantage for Ligand B.
**Overall Assessment:**
Ligand B has several advantages: better logP, lower TPSA, better metabolic stability (lower Cl_mic), and a longer half-life. The significantly better binding affinity also contributes to its favorability. While Ligand A has a lower hERG risk and Pgp efflux, the benefits of Ligand B's ADME profile and affinity outweigh these concerns. The solubility is a concern for both, but can be addressed with formulation strategies.
Output:
0
2025-04-17 19:48:49,936 - INFO - Batch 138 complete. Total preferences: 2208
2025-04-17 19:48:49,936 - INFO - Processing batch 139/512...
2025-04-17 19:49:39,495 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.5 & 379.6 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (60.85) is better than Ligand B (47.36), being under the 140 threshold. GPCRs benefit from lower TPSA for permeability.
3. **logP:** Both ligands (2.425 & 3.512) are within the optimal 1-3 range. Ligand B is slightly higher, potentially increasing off-target interactions, but still acceptable.
4. **HBD:** Ligand A (1) is preferable to Ligand B (0) as it allows for some hydrogen bonding potential.
5. **HBA:** Ligand A (3) is preferable to Ligand B (6), as lower HBA is generally better for permeability.
6. **QED:** Ligand A (0.847) has a significantly better QED score than Ligand B (0.691), indicating a more drug-like profile.
7. **DILI:** Ligand A (8.104) has a much lower DILI risk than Ligand B (54.556). This is a significant advantage, as liver toxicity is a major concern.
8. **BBB:** Both ligands have good BBB penetration (71.733 & 77.627), but Ligand B is slightly better. This is relevant for a GPCR, but less critical for ADRB2 specifically as it's primarily cardiovascular.
9. **Caco-2:** Ligand A (-4.499) is better than Ligand B (-5.324), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-1.699) is better than Ligand B (-3.562), indicating better aqueous solubility.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.492 & 0.499). No significant difference here.
12. **Cl_mic:** Ligand A (48.407) has a significantly lower microsomal clearance than Ligand B (84.517), indicating better metabolic stability.
13. **t1/2:** Ligand A (-8.522) has a much longer in vitro half-life than Ligand B (16.729). This is a significant advantage.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.053 & 0.51). Ligand A is slightly better.
15. **Binding Affinity:** Both ligands have similar and strong binding affinities (-5.5 & -4.9 kcal/mol). The difference of 0.6 kcal/mol is not substantial enough to outweigh other factors.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across multiple critical ADME-Tox properties. Specifically, its superior QED, significantly lower DILI risk, better solubility, lower clearance, and longer half-life make it a much more promising drug candidate. While Ligand B has slightly better BBB penetration and logP, these are less critical for a cardiovascular target like ADRB2 and are outweighed by the substantial advantages of Ligand A.
Output:
1
2025-04-17 19:49:39,495 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (408.34 Da) is within the ideal range. Ligand B (383.543 Da) is also good. No clear advantage.
2. **TPSA:** Ligand A (58.22) is excellent, well below the 140 threshold and favorable for absorption. Ligand B (92.93) is higher, but still acceptable, though less optimal. A favors here.
3. **logP:** Ligand A (4.125) is slightly high, potentially leading to solubility issues or off-target interactions. Ligand B (1.785) is within the optimal range. B favors here.
4. **HBD:** Ligand A (1) is good. Ligand B (2) is also acceptable. No significant difference.
5. **HBA:** Ligand A (4) is good. Ligand B (8) is higher, potentially impacting permeability. A favors here.
6. **QED:** Ligand A (0.777) is excellent. Ligand B (0.608) is still reasonable, but less desirable. A favors here.
7. **DILI:** Ligand A (26.018) has a very low DILI risk, excellent. Ligand B (65.491) is higher, indicating a moderate risk. A strongly favors here.
8. **BBB:** Ligand A (74.292) shows good BBB penetration. Ligand B (16.014) has very poor BBB penetration. Given ADRB2 is a GPCR, BBB penetration is a consideration, and A favors here.
9. **Caco-2:** Ligand A (-4.973) and Ligand B (-5.733) are both negative, indicating poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-4.04) is poor. Ligand B (-2.093) is also poor, but slightly better. B favors here.
11. **hERG:** Ligand A (0.894) has a low hERG risk. Ligand B (0.154) has a very low hERG risk. No significant difference.
12. **Cl_mic:** Ligand A (67.49) is moderate. Ligand B (31.946) is lower, indicating better metabolic stability. B favors here.
13. **t1/2:** Ligand A (-5.127) is poor. Ligand B (-0.845) is also poor, but slightly better. B favors here.
14. **Pgp:** Ligand A (0.373) has low P-gp efflux, which is good. Ligand B (0.067) has very low P-gp efflux, which is even better. B favors here.
15. **Affinity:** Ligand A (-7.0) is slightly better than Ligand B (-6.7). This is a 1.5kcal/mol advantage, which is significant. A favors here.
**Overall Assessment:**
Ligand A has a better QED, DILI profile, and BBB penetration, and a slightly better binding affinity. These are important factors for a GPCR target. However, Ligand B has better metabolic stability (lower Cl_mic), slightly better solubility, and lower P-gp efflux. While Ligand A's logP is a concern, its superior binding affinity and safety profile (DILI) outweigh this. The poor Caco-2 values for both are concerning and would need to be addressed in further optimization, but the binding affinity difference is significant.
**Output:**
1
2025-04-17 19:49:39,495 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (364.4 and 350.4 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (58.64) is significantly better than Ligand B (77.1). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (3.013) is optimal, while Ligand B (0.758) is a bit low. A logP below 1 can hinder membrane permeability. This is a notable advantage for Ligand A.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 3 HBA, Ligand B has 5. Both are acceptable, but Ligand A is slightly preferred.
6. **QED:** Ligand A (0.755) is better than Ligand B (0.542), indicating a more drug-like profile.
7. **DILI:** Both ligands have low DILI risk (39.7% and 37.0%), which is excellent.
8. **BBB:** Ligand A (74.3%) is better than Ligand B (43.6%). While not a primary concern for a cardiovascular target, higher BBB is generally favorable.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.566 and -4.911). This is unusual and suggests poor permeability *in vitro*. However, the values are similar.
10. **Solubility:** Ligand A (-2.685) is better than Ligand B (-1.968), indicating better aqueous solubility.
11. **hERG:** Both ligands have low hERG risk (0.603 and 0.147), which is excellent.
12. **Cl_mic:** Ligand A (60.59) has a higher microsomal clearance than Ligand B (19.645), suggesting faster metabolism and potentially lower *in vivo* exposure. This is a significant drawback for Ligand A.
13. **t1/2:** Ligand B (-13.377) has a longer *in vitro* half-life than Ligand A (-11.089), which is preferable.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.147 and 0.028), which is good.
15. **Binding Affinity:** Ligand B (-8.6 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.6 kcal/mol). This 3 kcal/mol difference is substantial and can often outweigh minor ADME drawbacks.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has better logP and TPSA, but Ligand B has a *much* stronger binding affinity. The difference in affinity is the most important factor here. While Ligand A has better metabolic stability (lower Cl_mic) and solubility, the superior binding of Ligand B is likely to translate to greater efficacy *in vivo*, even with slightly faster metabolism.
**Conclusion:**
Despite Ligand A's advantages in some ADME properties, the significantly stronger binding affinity of Ligand B makes it the more promising drug candidate for ADRB2.
0
2025-04-17 19:49:39,495 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (354.45 & 368.46 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (79.31) is significantly better than Ligand B (127.32). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (0.57) is slightly lower than Ligand B (0.286), but both are a bit low. A logP between 1-3 is optimal. Ligand B is closer to the lower boundary, potentially causing permeability issues.
4. **HBD:** Ligand A (1) is better than Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (5) is better than Ligand B (6). Fewer HBAs generally improve permeability.
6. **QED:** Ligand B (0.605) is slightly better than Ligand A (0.509), indicating a marginally more drug-like profile.
7. **DILI:** Ligand A (14.85) has a significantly lower DILI risk than Ligand B (43.62). This is a major advantage for Ligand A.
8. **BBB:** Both ligands have relatively low BBB penetration (A: 50.68, B: 55.45). This isn't critical for a cardiovascular target like ADRB2.
9. **Caco-2:** Ligand A (-4.644) is better than Ligand B (-5.893), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-0.215) is better than Ligand B (-2.752), which is a significant advantage. Poor solubility can hinder bioavailability.
11. **hERG:** Both ligands have very low hERG inhibition risk (A: 0.209, B: 0.029). No significant difference.
12. **Cl_mic:** Ligand B (21.06) has slightly lower microsomal clearance than Ligand A (24.66), suggesting better metabolic stability.
13. **t1/2:** Ligand B (17.76) has a significantly longer in vitro half-life than Ligand A (6.68). This is a substantial advantage.
14. **Pgp:** Both ligands have very low P-gp efflux (A: 0.029, B: 0.015). No significant difference.
15. **Affinity:** Ligand A (-6.4) has a slightly better binding affinity than Ligand B (-5.6). While the difference is less than the 1.5 kcal/mol threshold, it still contributes to the overall preference.
**Overall Assessment:**
Ligand A has a more favorable profile overall, particularly regarding DILI risk, solubility, and Caco-2 permeability. While Ligand B has a longer half-life, the lower DILI and better absorption characteristics of Ligand A are more critical for a successful drug candidate. The slightly better affinity of Ligand A further supports this decision. Considering ADRB2 is a cardiovascular target, the emphasis on properties like solubility and permeability is higher than BBB penetration.
Output:
1
2025-04-17 19:49:39,495 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (370.881 and 346.475 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (76.58) is slightly higher than Ligand B (68.44). Both are below the 140 A^2 threshold for good oral absorption, but closer to the 90 A^2 threshold for CNS targets. Given ADRB2 is cardiovascular, TPSA is less critical.
**3. logP:** Ligand A (3.265) is within the optimal 1-3 range. Ligand B (1.537) is on the lower end, potentially impacting permeability. This favors Ligand A.
**4. H-Bond Donors:** Ligand A (1) is better than Ligand B (2). Fewer HBDs generally improve permeability.
**5. H-Bond Acceptors:** Ligand A (6) is higher than Ligand B (3). Both are acceptable, but lower is generally better.
**6. QED:** Both ligands have similar QED values (0.823 and 0.787), indicating good drug-likeness.
**7. DILI:** Ligand B (7.949) has a significantly lower DILI risk than Ligand A (59.519). This is a major advantage for Ligand B.
**8. BBB:** Ligand A (70.609) has a better BBB penetration percentile than Ligand B (49.244). However, since ADRB2 is a cardiovascular target, BBB penetration is not a primary concern.
**9. Caco-2 Permeability:** Ligand A (-4.514) has a worse Caco-2 permeability than Ligand B (-5.281).
**10. Aqueous Solubility:** Ligand A (-3.763) has a worse aqueous solubility than Ligand B (-1.181).
**11. hERG Inhibition:** Ligand A (0.214) has a slightly lower hERG inhibition risk than Ligand B (0.439).
**12. Microsomal Clearance:** Ligand B (1.168) has a much lower microsomal clearance than Ligand A (61.489), indicating better metabolic stability. This is a significant advantage for Ligand B.
**13. In vitro Half-Life:** Ligand B (-5.459) has a much longer in vitro half-life than Ligand A (2.689).
**14. P-gp Efflux:** Ligand A (0.05) has a lower P-gp efflux liability than Ligand B (0.027).
**15. Binding Affinity:** Ligand B (-7.2 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.6 kcal/mol). This 1.6 kcal/mol difference is substantial and outweighs many of the minor ADME drawbacks of Ligand B.
**GPCR-Specific Priorities:** For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand B excels in affinity and has acceptable logP and TPSA. The lower P-gp efflux is also beneficial. While Ligand A has better BBB penetration, it's not a priority for a cardiovascular target.
**Conclusion:**
Despite Ligand A's slightly better BBB and P-gp efflux, Ligand B is the superior candidate due to its significantly stronger binding affinity, lower DILI risk, and improved metabolic stability (lower Cl_mic and longer half-life). The affinity difference is substantial enough to overcome the slightly lower logP and solubility.
0
2025-04-17 19:49:39,495 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (368.499 Da and 385.877 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (77.92) is better than Ligand B (89.35). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (0.73) is slightly lower than Ligand B (2.3). Both are within the optimal 1-3 range, but Ligand B is closer to the upper end.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 5 HBA, while Ligand B has 8. Ligand A is preferable here.
6. **QED:** Both ligands have similar QED values (0.768 and 0.735), indicating good drug-likeness.
7. **DILI:** Ligand A (9.926) has a *much* lower DILI risk than Ligand B (74.952). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (57.154) has a better BBB percentile than Ligand B (40.52), but neither is particularly high. Since ADRB2 is a cardiovascular target, BBB penetration is not a high priority.
9. **Caco-2:** Ligand A (-5.089) and Ligand B (-4.675) have similar Caco-2 permeability values.
10. **Solubility:** Ligand A (-0.956) has slightly better solubility than Ligand B (-2.405).
11. **hERG:** Both ligands have very low hERG inhibition risk (0.354 and 0.353).
12. **Cl_mic:** Ligand A (-17.241) has a significantly *lower* (better) microsomal clearance than Ligand B (76.406). This suggests greater metabolic stability for Ligand A.
13. **t1/2:** Ligand B (27.839) has a longer in vitro half-life than Ligand A (13.67). This is a positive for Ligand B, but not enough to overcome other issues.
14. **Pgp:** Both ligands have similar Pgp efflux liability (0.048 and 0.122).
15. **Binding Affinity:** Ligand B (-6.7 kcal/mol) has a slightly better binding affinity than Ligand A (-5.8 kcal/mol). This is a 0.9 kcal/mol difference, which is a noticeable but not overwhelming advantage.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand B has a slightly better logP and affinity, but Ligand A has better TPSA. The *major* deciding factor is the drastically lower DILI risk and better metabolic stability (lower Cl_mic) of Ligand A. The affinity difference isn't large enough to offset these significant ADME advantages.
**Conclusion:**
Ligand A is the more promising drug candidate due to its superior safety profile (DILI) and metabolic stability, despite a slightly lower binding affinity.
Output:
1
2025-04-17 19:49:39,495 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (364.511 and 352.475 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (58.64) is significantly better than Ligand B (78.87). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (2.46 and 1.485), falling within the 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Both ligands have the same number of HBA (4), which is acceptable.
6. **QED:** Ligand A (0.771) has a higher QED score than Ligand B (0.616), indicating a more drug-like profile.
7. **DILI:** Ligand A (13.843) has a much lower DILI risk than Ligand B (5.312). This is a significant advantage, as liver toxicity is a major concern in drug development.
8. **BBB:** Ligand A (74.952) has a slightly higher BBB penetration than Ligand B (68.864), but this is less critical for a cardiovascular target.
9. **Caco-2:** Ligand A (-5.129) and Ligand B (-4.746) are both negative, indicating poor permeability. However, Ligand A is slightly better.
10. **Solubility:** Ligand A (-2.48) is slightly better than Ligand B (-1.402).
11. **hERG:** Both ligands have low hERG inhibition liability (0.448 and 0.356), which is good.
12. **Cl_mic:** Ligand B (10.362) has a lower microsomal clearance than Ligand A (30.369), suggesting better metabolic stability. This is a positive for Ligand B.
13. **t1/2:** Ligand B (-12.318) has a negative in vitro half-life, which is concerning, while Ligand A (10.011) is positive.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.06 and 0.083).
15. **Binding Affinity:** Ligand B (-6.8 kcal/mol) has a slightly better binding affinity than Ligand A (-5.2 kcal/mol). This is a 1.6 kcal/mol difference, which is significant.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. While Ligand B has better affinity and Cl_mic, Ligand A excels in TPSA, DILI risk, QED, and has a more reasonable half-life. The DILI risk is a major concern, and the affinity difference, while notable, might be overcome with further optimization.
**Conclusion:**
Considering the balance of properties, especially the significantly lower DILI risk and better overall drug-likeness (QED) of Ligand A, I believe it is the more promising drug candidate despite the slightly weaker binding affinity. The affinity can be improved during lead optimization, but mitigating potential liver toxicity early on is crucial.
Output:
1
2025-04-17 19:49:39,496 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (391.559) is slightly higher than Ligand B (349.406), but both are acceptable.
2. **TPSA:** Both are below the 140 A^2 threshold for good oral absorption. Ligand B (87.3) is better than Ligand A (99.56), favoring oral bioavailability.
3. **logP:** Both ligands have optimal logP values (between 1 and 3). Ligand B (1.884) is slightly higher than Ligand A (1.072), which could be beneficial for membrane permeability.
4. **HBD:** Both are within the acceptable limit of <=5. Ligand A has 2 HBDs, and Ligand B has 3.
5. **HBA:** Both are within the acceptable limit of <=10. Ligand A has 6 HBAs, and Ligand B has 3.
6. **QED:** Both ligands have good QED scores (>=0.5). Ligand B (0.657) is slightly better than Ligand A (0.603).
7. **DILI:** Ligand A (36.254) has a significantly lower DILI risk than Ligand B (51.648), which is a major advantage.
8. **BBB:** Both have acceptable BBB penetration (around 65-67%). This isn't a high priority for ADRB2, which isn't a CNS target, but it's not a detriment.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. This is concerning for both.
10. **Solubility:** Both have negative solubility values, indicating poor solubility. This is concerning for both.
11. **hERG:** Both have low hERG inhibition liability, which is good. Ligand B (0.344) is slightly better than Ligand A (0.304).
12. **Cl_mic:** Ligand B (4.126) has a significantly lower microsomal clearance than Ligand A (10.575), indicating better metabolic stability.
13. **t1/2:** Ligand B (22.121) has a longer in vitro half-life than Ligand A (27.8), which is preferable.
14. **Pgp:** Both have low P-gp efflux liability, which is good. Ligand A (0.064) is slightly better than Ligand B (0.118).
15. **Binding Affinity:** Ligand B (-8.9 kcal/mol) has a significantly stronger binding affinity than Ligand A (-7.8 kcal/mol). This is a substantial advantage, potentially outweighing some ADME drawbacks.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B is slightly better in logP and TPSA. Both have good Pgp. However, the significantly stronger binding affinity of Ligand B is the most important factor. While both have concerning Caco-2 and solubility values, the potency advantage of Ligand B is likely to be more easily addressed through formulation strategies. The lower DILI risk of Ligand A is attractive, but the affinity difference is larger.
**Conclusion:**
Considering the balance of properties, particularly the significantly improved binding affinity of Ligand B, I believe it is the more promising drug candidate despite the slightly higher DILI risk and lower metabolic stability.
Output:
0
2025-04-17 19:49:39,496 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [340.339, 109.3 , -0.123, 3. , 5. , 0.677, 93.951, 43.893, -5.121, -3.158, 0.023, -19.799, 7.499, 0.026, -7.1 ]
**Ligand B:** [381.889, 106.96 , 3.366, 2. , 4. , 0.296, 47.964, 43.273, -5.023, -3.383, 0.496, 25.449, 25.266, 0.1 , -5.8 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (340.339) is slightly preferred due to being lower.
2. **TPSA:** Both are reasonably good (109.3 and 106.96), being under 140.
3. **logP:** Ligand A (-0.123) is quite low, potentially hindering membrane permeability. Ligand B (3.366) is much better, falling within the optimal 1-3 range. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (3) and Ligand B (2) are both acceptable.
5. **HBA:** Ligand A (5) and Ligand B (4) are both acceptable.
6. **QED:** Ligand A (0.677) is good, indicating drug-likeness. Ligand B (0.296) is poor, suggesting potential issues.
7. **DILI:** Ligand A (93.951) has a high DILI risk. Ligand B (47.964) is much better, indicating a lower risk of liver injury. This is a major advantage for Ligand B.
8. **BBB:** Both have similar, relatively low BBB penetration (43.893 and 43.273). Since ADRB2 isn't a CNS target, this isn't a major deciding factor.
9. **Caco-2:** Both are very poor (-5.121 and -5.023).
10. **Solubility:** Both are very poor (-3.158 and -3.383).
11. **hERG:** Ligand A (0.023) is very low risk. Ligand B (0.496) is slightly higher, but still relatively low.
12. **Cl_mic:** Ligand A (-19.799) has a very low (good) microsomal clearance, indicating high metabolic stability. Ligand B (25.449) has a moderate clearance, which is less desirable.
13. **t1/2:** Ligand A (7.499) has a moderate half-life. Ligand B (25.266) has a significantly longer half-life, which is a positive.
14. **Pgp:** Ligand A (0.026) has low P-gp efflux, which is good. Ligand B (0.1) is also low, but slightly higher.
15. **Affinity:** Ligand A (-7.1) has a slightly better binding affinity than Ligand B (-5.8). This is a 1.3 kcal/mol difference, which is significant.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand B excels in logP and has acceptable Pgp and TPSA values. While Ligand A has a slightly better affinity, its poor logP and high DILI risk are major concerns. The longer half-life of Ligand B is also a benefit.
**Conclusion:**
Despite the slightly better affinity of Ligand A, the significantly better logP, lower DILI risk, and longer half-life of Ligand B make it the more promising drug candidate. The poor solubility and Caco-2 values of both are concerning, but can be addressed with formulation strategies. The DILI risk associated with Ligand A is a significant hurdle.
0
2025-04-17 19:49:39,496 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [348.447, 87.32, 1.122, 2, 4, 0.62, 26.134, 25.126, -5.006, -1.109, 0.11, -3.294, -9.209, 0.018, -3.5]
**Ligand B:** [352.45, 58.64, 2.216, 1, 3, 0.484, 10.237, 88.406, -4.741, -2.12, 0.578, 50.179, -13.811, 0.207, -7.4]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). A (348.447) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** A (87.32) is higher than B (58.64). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is still preferred. B is significantly better here.
3. **logP:** Both are within the optimal range (1-3). A (1.122) is slightly lower, while B (2.216) is better positioned.
4. **HBD:** A (2) and B (1) are both acceptable, with B being slightly better.
5. **HBA:** A (4) and B (3) are both acceptable, with B being slightly better.
6. **QED:** A (0.62) is better than B (0.484), indicating a more drug-like profile.
7. **DILI:** A (26.134) is *much* better than B (10.237). This is a significant advantage for A.
8. **BBB:** B (88.406) is significantly better than A (25.126). While not a primary concern for a cardiovascular target, higher BBB is generally a positive.
9. **Caco-2:** A (-5.006) is worse than B (-4.741), indicating lower intestinal absorption.
10. **Solubility:** A (-1.109) is worse than B (-2.12), indicating lower aqueous solubility.
11. **hERG:** A (0.11) is better than B (0.578), indicating lower hERG inhibition risk.
12. **Cl_mic:** A (-3.294) is better than B (50.179), indicating better metabolic stability.
13. **t1/2:** A (-9.209) is better than B (-13.811), indicating a longer in vitro half-life.
14. **Pgp:** A (0.018) is *much* better than B (0.207), indicating lower P-gp efflux.
15. **Affinity:** B (-7.4) is significantly better than A (-3.5). This is a substantial difference in binding potency.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, and affinity. B excels in logP and affinity, while A has a better Pgp profile. B has a much lower TPSA. The large affinity difference is a major factor.
**Overall Assessment:**
While Ligand A has advantages in DILI, metabolic stability, and Pgp efflux, the significantly stronger binding affinity of Ligand B (-7.4 vs -3.5 kcal/mol) is a decisive factor. A 3.9 kcal/mol difference is substantial and likely to outweigh the drawbacks of B in terms of DILI and metabolic stability, especially in early-stage drug discovery. The lower TPSA of B is also a plus.
Output:
0
2025-04-17 19:49:39,496 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (368.411 Da) is slightly higher than Ligand B (342.418 Da), but both are acceptable.
2. **TPSA:** Ligand A (103.82) is higher than Ligand B (39.68). For a cardiovascular GPCR like ADRB2, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B is significantly better here.
3. **logP:** Both ligands have good logP values (A: 1.424, B: 2.172), falling within the optimal 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Ligand A has 1 HBD, and Ligand B has 0. Both are within the acceptable limit of <=5.
5. **HBA:** Ligand A has 7 HBA, and Ligand B has 4. Both are within the acceptable limit of <=10.
6. **QED:** Both have good QED scores (A: 0.703, B: 0.799), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A has a DILI risk of 89.957, which is concerningly high. Ligand B has a much lower DILI risk of 49.593, which is a significant advantage.
8. **BBB:** Both have reasonable BBB penetration (A: 74.913, B: 83.986). While ADRB2 isn't a CNS target, some peripheral exposure can be undesirable. Ligand B is slightly better.
9. **Caco-2:** Both have negative Caco-2 values (-4.881 and -4.614). These values are difficult to interpret without knowing the scale, but negative values suggest poor permeability.
10. **Solubility:** Both have negative solubility values (-3.409 and -2.241). Similar to Caco-2, these values are difficult to interpret, but suggest poor solubility.
11. **hERG:** Ligand A (0.389) has a lower hERG risk than Ligand B (0.702), which is a positive.
12. **Cl_mic:** Ligand A (70.576) has a higher microsomal clearance than Ligand B (47.989), indicating lower metabolic stability. Ligand B is preferred.
13. **t1/2:** Ligand A (23.642) has a longer half-life than Ligand B (-17.509). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.09) has lower P-gp efflux liability than Ligand B (0.159), which is favorable.
15. **Binding Affinity:** Ligand B (-7.9 kcal/mol) has a slightly better binding affinity than Ligand A (-7.4 kcal/mol). While the difference is not huge, it's enough to consider.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are important. Ligand B excels in logP and TPSA. The affinity difference is small, but favors Ligand B. The biggest difference is the DILI risk, where Ligand B is significantly better. The longer half-life of Ligand A is appealing, but the high DILI risk is a major concern.
**Conclusion:**
Despite the longer half-life of Ligand A, the significantly lower DILI risk and better overall ADME profile of Ligand B make it the more promising drug candidate for ADRB2.
Output:
0
2025-04-17 19:49:39,496 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (359.344 and 359.451 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (59.0) is significantly better than Ligand B (102.22). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is pushing the upper limit for good oral absorption.
3. **logP:** Both ligands have acceptable logP values (1.876 and 1.557), falling within the 1-3 range. Ligand B is slightly lower, but still reasonable.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is preferable to Ligand B (5). Similar to HBD, lower HBA is generally better for permeability.
6. **QED:** Ligand A (0.895) has a better QED score than Ligand B (0.742), indicating a more drug-like profile.
7. **DILI:** Ligand A (38.077) has a much lower DILI risk than Ligand B (53.509). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (81.698) has a substantially higher BBB penetration percentile than Ligand B (27.84). While ADRB2 isn't exclusively a CNS target, some CNS exposure can occur, and higher BBB is generally a plus, especially given the good overall profile of A.
9. **Caco-2:** Ligand A (-4.504) and Ligand B (-5.185) both have negative Caco-2 values, indicating poor permeability. This is concerning for both, but the difference isn't substantial.
10. **Solubility:** Ligand A (-2.697) has better aqueous solubility than Ligand B (-3.456).
11. **hERG:** Both ligands have low hERG inhibition risk (0.766 and 0.416), which is good.
12. **Cl_mic:** Ligand A (14.661) has a significantly lower microsomal clearance than Ligand B (1.647), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-7.455) has a much longer in vitro half-life than Ligand B (16.838). This is a major advantage for Ligand A.
14. **Pgp:** Ligand A (0.325) has lower P-gp efflux liability than Ligand B (0.064). Lower Pgp is generally preferred.
15. **Binding Affinity:** Ligand B (-6.6 kcal/mol) has a slightly better binding affinity than Ligand A (-7.2 kcal/mol). While a difference of 0.6 kcal/mol is noticeable, the other advantages of Ligand A are more compelling.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical ADME-Tox properties (DILI, BBB, Cl_mic, t1/2, Pgp, solubility, TPSA, QED). While Ligand B has slightly better binding affinity, the significantly improved drug-like properties and safety profile of Ligand A make it the more promising candidate. The lower TPSA and H-bonding capabilities of Ligand A are also favorable for GPCR targeting.
Output:
1
2025-04-17 19:49:39,496 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's systematically compare Ligand A and Ligand B based on the provided parameters and the guidelines, keeping in mind ADRB2 is a GPCR and thus we prioritize logP, Pgp, TPSA, and affinity.
1. **MW:** Both ligands (348.422 and 352.475 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (75.19) is slightly higher than Ligand B (70.08). Both are below the 140 threshold for oral absorption, but closer to the ideal for GPCRs. Ligand B is slightly preferred.
3. **logP:** Ligand A (2.117) and Ligand B (1.578) are both within the optimal 1-3 range. Ligand A is slightly better.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Both ligands have 4 HBA, which is good.
6. **QED:** Ligand A (0.904) has a significantly higher QED score than Ligand B (0.532), indicating a more drug-like profile. This is a substantial advantage for Ligand A.
7. **DILI:** Ligand B (14.23) has a much lower DILI risk than Ligand A (41.218). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (83.908) has a higher BBB penetration percentile than Ligand B (64.482). While ADRB2 isn't necessarily a CNS target, some peripheral ADRB2 activity can be influenced by CNS effects, so this is a slight advantage for Ligand A.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual. It's hard to interpret without knowing the scale.
10. **Solubility:** Ligand B (-1.358) has a better solubility score than Ligand A (-3.274). Better solubility is always a plus.
11. **hERG:** Both ligands have very low hERG risk (0.402 and 0.467). No significant difference.
12. **Cl_mic:** Both ligands have similar microsomal clearance (37.154 and 36.705).
13. **t1/2:** Ligand A (-6.949) has a significantly longer in vitro half-life than Ligand B (0.295). This is a major advantage for Ligand A.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.12 and 0.184). No significant difference.
15. **Affinity:** Ligand A (-6.6 kcal/mol) has a slightly better binding affinity than Ligand B (-6.0 kcal/mol). While the difference is less than the 1.5 kcal/mol threshold, it contributes to the overall preference.
**Overall Assessment:**
Ligand A excels in QED, BBB, and in vitro half-life, and has a slightly better affinity. Ligand B shines with a much lower DILI risk and better solubility. The longer half-life and better drug-likeness of Ligand A are very attractive, and the affinity difference, while small, is still a plus. The DILI risk of Ligand A is a concern, but the other benefits outweigh this risk, particularly given the relatively low absolute value.
Output:
1
2025-04-17 19:49:39,496 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
The ADRB2 receptor is a GPCR, so the priorities are logP, TPSA, Pgp, BBB, and binding affinity. Metabolic stability and solubility are also important.
Let's compare the ligands property by property:
1. **MW:** Both ligands (357.8 & 355.5 Da) are within the ideal 200-500 Da range.
2. **TPSA:** Ligand B (61.44) is significantly better than Ligand A (73.95). Lower TPSA generally favors oral absorption and BBB penetration.
3. **logP:** Both ligands have good logP values (2.955 & 2.256), falling within the 1-3 range. Ligand B is slightly lower, which could be beneficial for solubility.
4. **HBD/HBA:** Ligand A has 1 HBD and 4 HBA, while Ligand B has 2 HBD and 3 HBA. Both are acceptable.
5. **QED:** Ligand A (0.917) has a much better QED score than Ligand B (0.736), indicating better overall drug-likeness.
6. **DILI:** Ligand B (7.135) has a significantly lower DILI risk than Ligand A (63.668). This is a major advantage for Ligand B.
7. **BBB:** Ligand B (87.67) has a much higher BBB penetration percentile than Ligand A (64.986). This is crucial for GPCR targets, even if it's not a CNS target, as it can influence distribution.
8. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-4.636) is slightly worse than Ligand B (-4.919).
9. **Solubility:** Ligand B (-1.701) has better solubility than Ligand A (-5.014).
10. **hERG:** Both ligands have low hERG inhibition risk (0.389 & 0.528).
11. **Cl_mic:** Ligand B (-7.624) has a significantly *lower* (better) microsomal clearance than Ligand A (46.845), suggesting better metabolic stability.
12. **t1/2:** Ligand B (3.678) has a slightly longer in vitro half-life than Ligand A (24.117).
13. **Pgp:** Ligand B (0.032) has a much lower P-gp efflux liability than Ligand A (0.145), which is favorable for bioavailability and potential CNS exposure.
14. **Binding Affinity:** Ligand A (-7.7 kcal/mol) has a slightly better binding affinity than Ligand B (-7.3 kcal/mol). However, the difference is only 0.4 kcal/mol, which is not substantial enough to outweigh the significant ADME advantages of Ligand B.
**Conclusion:**
While Ligand A has slightly better binding affinity and QED, Ligand B overwhelmingly wins on ADME properties critical for a GPCR target. Specifically, its superior BBB penetration, lower DILI risk, better metabolic stability (lower Cl_mic, longer t1/2), lower P-gp efflux, and improved solubility make it a far more promising drug candidate. The 0.4 kcal/mol difference in binding affinity is unlikely to be a deciding factor given the substantial improvements in other parameters.
**Output:**
0
2025-04-17 19:49:39,496 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (349.347 Da) is slightly lower, which is generally favorable for permeability.
**2. TPSA:** Ligand B (91.4) is significantly better than Ligand A (136.65). For a GPCR, keeping TPSA low is desirable for good permeability and potentially better brain penetration, even though this isn't a CNS target.
**3. logP:** Ligand B (0.946) is closer to the optimal range (1-3) than Ligand A (-1.21). A negative logP can indicate poor membrane permeability.
**4. H-Bond Donors:** Ligand A (4) is slightly higher than Ligand B (2), but both are acceptable.
**5. H-Bond Acceptors:** Ligand A (6) is slightly higher than Ligand B (5), but both are acceptable.
**6. QED:** Ligand B (0.761) has a better QED score than Ligand A (0.381), indicating a more drug-like profile.
**7. DILI Risk:** Ligand B (49.011) has a significantly lower DILI risk than Ligand A (68.941). This is a crucial advantage.
**8. BBB Penetration:** While not a CNS target, Ligand B (41.722) shows better BBB penetration potential than Ligand A (18.961).
**9. Caco-2 Permeability:** Both ligands have similar, very negative Caco-2 values, suggesting poor permeability. This is a concern for both.
**10. Aqueous Solubility:** Both ligands have very poor aqueous solubility (-2.128 and -2.88). This is a significant drawback for both.
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.107 and 0.296).
**12. Microsomal Clearance:** Ligand A (-12.191) has a much lower (better) microsomal clearance than Ligand B (13.485), indicating greater metabolic stability.
**13. In vitro Half-Life:** Ligand B (18.067) has a slightly longer half-life than Ligand A (21.836), but the difference is not substantial.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.011 and 0.051).
**15. Binding Affinity:** Both ligands have identical binding affinities (-6.1 kcal/mol).
**Overall Assessment:**
Ligand B is the better candidate. While both have poor solubility and Caco-2 permeability, Ligand B excels in several critical areas: lower DILI risk, better logP, better TPSA, and a higher QED score. The improved metabolic stability of Ligand A is a plus, but the other advantages of Ligand B outweigh this benefit, especially considering the importance of minimizing toxicity (DILI) and optimizing ADME properties for a GPCR target.
Output:
0
2025-04-17 19:49:39,496 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (361.463 and 347.419 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (68.54) is well below the 140 threshold and closer to the desirable <90 for CNS targets (though ADRB2 isn't strictly a CNS target, lower TPSA is generally favorable for permeability). Ligand B (80.56) is still under 140, but less optimal. Advantage: A.
3. **logP:** Ligand A (4.967) is at the upper end of the optimal range (1-3) and could potentially cause solubility issues. Ligand B (0.223) is *far* below the optimal range, suggesting poor membrane permeability. Significant advantage: A.
4. **HBD:** Ligand A (1) is good. Ligand B (0) is also acceptable, but having one HBD can aid solubility. Slight advantage: A.
5. **HBA:** Both ligands (A: 5, B: 6) are within the acceptable limit of 10. No clear difference.
6. **QED:** Both ligands have good QED scores (A: 0.506, B: 0.765). Ligand B is slightly better here, indicating a more drug-like profile. Advantage: B.
7. **DILI:** Ligand A (68.941) is moderately risky, but still within an acceptable range. Ligand B (40.752) has a much lower DILI risk, which is a significant advantage. Advantage: B.
8. **BBB:** Ligand A (83.327) has good BBB penetration, while Ligand B (62.195) is lower. Given ADRB2's cardiovascular role, BBB penetration isn't *critical*, but it's a bonus. Advantage: A.
9. **Caco-2:** Both ligands have very poor Caco-2 permeability (-4.686 and -4.687). This is concerning for oral bioavailability. No clear difference.
10. **Solubility:** Ligand A (-5.938) has very poor solubility. Ligand B (-1.415) is better, but still not great. Advantage: B.
11. **hERG:** Ligand A (0.648) has a low hERG risk, which is excellent. Ligand B (0.205) is even lower, a slight advantage. Advantage: B.
12. **Cl_mic:** Ligand A (120.349) has a higher microsomal clearance, indicating faster metabolism. Ligand B (30.954) has much lower clearance, suggesting better metabolic stability. Significant advantage: B.
13. **t1/2:** Ligand A (64.099) has a reasonable in vitro half-life. Ligand B (4.129) has a very short half-life, which is a major drawback. Advantage: A.
14. **Pgp:** Ligand A (0.799) has moderate Pgp efflux. Ligand B (0.012) has very low Pgp efflux, which is highly desirable. Advantage: B.
15. **Affinity:** Ligand A (-6.9 kcal/mol) has significantly stronger binding affinity than Ligand B (-1.8 kcal/mol). This is a *substantial* advantage, potentially outweighing some of the ADME concerns. Advantage: A.
**Overall Assessment:**
Ligand A has a much stronger binding affinity, which is paramount for a GPCR ligand. It also has better BBB penetration and a longer half-life. However, it suffers from poor solubility, higher DILI risk, and faster metabolism. Ligand B has better ADME properties (lower DILI, better metabolic stability, lower Pgp efflux, better solubility), but its binding affinity is very weak.
Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity), and the fact that a strong affinity can often compensate for some ADME liabilities, **Ligand A is the more promising candidate**. While its ADME profile isn't ideal, the significantly stronger binding is likely to be crucial for efficacy. Optimization efforts could then focus on improving its solubility and metabolic stability.
Output:
1
2025-04-17 19:49:39,496 - INFO - Batch 139 complete. Total preferences: 2224
2025-04-17 19:49:39,496 - INFO - Processing batch 140/512...
2025-04-17 19:50:27,077 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (363.571) is slightly higher than Ligand B (350.415), but both are acceptable.
2. **TPSA:** Ligand A (44.37) is significantly better than Ligand B (103.01). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption. Ligand B's TPSA is quite high, potentially hindering oral bioavailability.
3. **logP:** Ligand A (4.156) is higher than Ligand B (0.829). While 4.156 is approaching the upper limit of the optimal range, it's still acceptable. Ligand B's logP is quite low, potentially leading to poor membrane permeability.
4. **HBD:** Ligand A (2) is better than Ligand B (3). Lower HBD is generally preferable for permeability.
5. **HBA:** Ligand A (3) is better than Ligand B (5). Lower HBA is generally preferable for permeability.
6. **QED:** Both ligands have good QED scores (A: 0.564, B: 0.73), indicating good drug-like properties. Ligand B is slightly better here.
7. **DILI:** Both ligands have low DILI risk (A: 23.071, B: 21.171), which is positive. They are very close in this parameter.
8. **BBB:** Ligand A (90.5) has a much higher BBB penetration percentile than Ligand B (26.561). While not a primary concern for a cardiovascular target, higher BBB is generally not detrimental.
9. **Caco-2:** Ligand A (-5.048) and Ligand B (-5.313) are similar, and both are negative, indicating poor permeability.
10. **Solubility:** Ligand A (-3.407) is better than Ligand B (-1.131), indicating better aqueous solubility.
11. **hERG:** Ligand A (0.894) is better than Ligand B (0.08). Lower hERG inhibition is crucial to avoid cardiotoxicity, making Ligand A more favorable.
12. **Cl_mic:** Ligand A (78.348) is higher than Ligand B (-24.608). A negative value for Ligand B suggests very *low* clearance, which is good. However, a very low clearance can sometimes indicate issues with metabolism or formulation.
13. **t1/2:** Ligand A (48.381) is better than Ligand B (23.715). A longer half-life is generally preferred.
14. **Pgp:** Ligand A (0.718) is better than Ligand B (0.015). Lower P-gp efflux is desirable for improved bioavailability.
15. **Affinity:** Ligand A (-7.5) has a slightly better binding affinity than Ligand B (-7.3). While the difference is small, it's enough to consider, especially given the other favorable properties of Ligand A.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A is superior in logP, TPSA, and Pgp. The affinity difference is small, but favors A.
**Overall Assessment:**
Ligand A presents a better overall profile. It has a more favorable balance of properties, particularly regarding TPSA, logP, hERG, and solubility. While Ligand B has a slightly better QED and exceptionally low clearance, the potential issues with its high TPSA and low logP outweigh these benefits. The slightly better affinity of Ligand A further strengthens its position.
Output:
1
2025-04-17 19:50:27,077 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.39 and 346.47 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (106.35) is higher than Ligand B (67.43). For a cardiovascular GPCR, TPSA is moderately important. Ligand B is significantly better here, suggesting potentially improved permeability.
3. **logP:** Both ligands (2.02 and 2.29) are within the optimal 1-3 range. No major difference.
4. **HBD:** Both ligands have 2 H-bond donors, satisfying the <=5 guideline.
5. **HBA:** Ligand A has 6 H-bond acceptors, while Ligand B has 3. Both are within the acceptable range of <=10. Ligand B is preferable.
6. **QED:** Ligand A (0.743) has a slightly better QED score than Ligand B (0.695), indicating a more drug-like profile.
7. **DILI:** Ligand A (78.13) has a considerably higher DILI risk than Ligand B (20.59). This is a major concern for Ligand A.
8. **BBB:** Ligand A (81.66) has a better BBB penetration score than Ligand B (53.59). While ADRB2 isn't necessarily a CNS target, some degree of BBB penetration can be beneficial for off-target effects and overall distribution.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.925 and -4.629). These values are unusual and suggest poor permeability.
10. **Solubility:** Both ligands have similar, very poor aqueous solubility (-3.147 and -3.175). This is a significant drawback for both.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.162 and 0.12).
12. **Cl_mic:** Ligand A (78.58) has a much higher microsomal clearance than Ligand B (22.93), indicating lower metabolic stability.
13. **t1/2:** Ligand B (4.979) has a longer in vitro half-life than Ligand A (-2.354).
14. **Pgp:** Both ligands have low P-gp efflux liability (0.082 and 0.069).
15. **Binding Affinity:** Ligand A (-6.4 kcal/mol) has a slightly better binding affinity than Ligand B (-5.8 kcal/mol). This is a 0.6 kcal/mol difference, which is noticeable but not overwhelming.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Ligand B excels in TPSA and Pgp, and has a good logP. While Ligand A has a slightly better affinity, the significantly higher DILI risk and poorer metabolic stability (higher Cl_mic) are major drawbacks. The longer half-life of Ligand B is also a plus.
**Conclusion:**
Despite the slightly better affinity of Ligand A, the substantial advantages of Ligand B in terms of DILI risk, metabolic stability, and TPSA make it the more promising drug candidate. The poor solubility and Caco-2 values are concerning for both, but can potentially be addressed through formulation strategies.
Output:
0
2025-04-17 19:50:27,078 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.419 and 343.431 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (114.11) is slightly higher than Ligand B (101.21). Both are below the 140 A^2 threshold for good oral absorption, but closer to the 90 A^2 threshold for CNS targets.
3. **logP:** Ligand B (1.214) is slightly higher than Ligand A (0.828), both within the optimal 1-3 range.
4. **HBD:** Ligand A has 4 HBD, while Ligand B has 2. Both are acceptable (<=5).
5. **HBA:** Ligand A has 4 HBA, while Ligand B has 5. Both are acceptable (<=10).
6. **QED:** Ligand B (0.837) has a significantly better QED score than Ligand A (0.566), indicating a more drug-like profile.
7. **DILI:** Ligand B (47.964) has a slightly lower DILI risk than Ligand A (51.687), both are good (<60).
8. **BBB:** Ligand B (73.866) has a substantially higher BBB penetration percentile than Ligand A (10.741). This is a *major* advantage for a GPCR target, even if not specifically a CNS target, as it suggests better distribution.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.674 and -5.009). These values are unusual and suggest very poor permeability. This is a significant concern for both.
10. **Solubility:** Both ligands have negative solubility values (-1.901 and -2.964). These values are also unusual and suggest very poor solubility. This is a significant concern for both.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.219 and 0.223), which is excellent.
12. **Cl_mic:** Ligand A (-0.052) has a much lower (better) microsomal clearance than Ligand B (27.112). This suggests greater metabolic stability for Ligand A.
13. **t1/2:** Ligand A (3.287 hours) has a significantly longer in vitro half-life than Ligand B (-10.268 hours). This is a major advantage for Ligand A.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.01 and 0.006).
15. **Binding Affinity:** Ligand B (-8.3 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.2 kcal/mol). This is a substantial advantage, potentially outweighing some ADME concerns.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand B excels in affinity and has a better logP and TPSA. The significantly higher BBB penetration is also a major plus. While Ligand A has better metabolic stability and half-life, the difference in binding affinity is substantial (3.1 kcal/mol). This difference is large enough to potentially overcome the ADME drawbacks. The poor Caco-2 and solubility are concerning for both, but can be addressed through formulation strategies.
**Conclusion:**
Despite the concerns around Caco-2 and solubility, the superior binding affinity and BBB penetration of Ligand B make it the more promising candidate. The difference in affinity is large enough to outweigh the slightly worse metabolic stability.
Output:
0
2025-04-17 19:50:27,078 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's break down the comparison of Ligand A and Ligand B based on the provided parameters and the guidelines, keeping in mind ADRB2 is a GPCR.
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (362.47) is slightly higher than Ligand B (339.439), but this isn't a major concern.
2. **TPSA:** Ligand A (52.57) is better than Ligand B (65.2). A lower TPSA generally favors better absorption.
3. **logP:** Both ligands have good logP values (A: 3.727, B: 3.079), falling within the optimal range of 1-3. Ligand A is slightly higher, which could potentially lead to some off-target effects, but is still acceptable.
4. **H-Bond Donors:** Both have 2 HBD, which is good.
5. **H-Bond Acceptors:** Ligand A has 3 HBA, and Ligand B has 2. Both are within the acceptable range of <=10.
6. **QED:** Both ligands have high QED values (A: 0.871, B: 0.899), indicating good drug-like properties. Ligand B is marginally better.
7. **DILI Risk:** Ligand A (30.322) has a significantly lower DILI risk than Ligand B (47.421). This is a crucial advantage.
8. **BBB Penetration:** Ligand A (83.249) has better BBB penetration than Ligand B (78.945). While ADRB2 isn't exclusively a CNS target, some CNS exposure might be acceptable or even desirable depending on the specific therapeutic goal.
9. **Caco-2 Permeability:** Ligand A (-4.758) has better Caco-2 permeability than Ligand B (-5.016).
10. **Aqueous Solubility:** Ligand A (-3.654) has better aqueous solubility than Ligand B (-4.421).
11. **hERG Inhibition:** Both ligands have low hERG inhibition risk (A: 0.784, B: 0.737).
12. **Microsomal Clearance:** Ligand A (22.178) has lower microsomal clearance than Ligand B (44.578), indicating better metabolic stability.
13. **In vitro Half-Life:** Ligand B (-2.784) has a longer in vitro half-life than Ligand A (5.008). This is a positive for Ligand B.
14. **P-gp Efflux:** Both ligands have similar P-gp efflux liability (A: 0.358, B: 0.138), with Ligand B being slightly better.
15. **Binding Affinity:** Ligand B (-6.3) has a slightly better binding affinity than Ligand A (-5.6). This is a 0.7 kcal/mol difference, which is significant but not overwhelming.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp efflux, and affinity are key. Both ligands perform reasonably well on logP. Ligand A has a better TPSA. Ligand B has a slightly better Pgp efflux and affinity. However, the significantly lower DILI risk and better metabolic stability (lower Cl_mic) of Ligand A are very important factors. The better solubility and BBB penetration of Ligand A are also beneficial.
**Conclusion:**
While Ligand B has a slightly better binding affinity and half-life, the superior safety profile (DILI), metabolic stability, solubility, and permeability of Ligand A outweigh these advantages. Therefore, I believe Ligand A is the more promising drug candidate.
**Output:**
1
2025-04-17 19:50:27,078 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (367.471 and 358.511 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (89.55) is better than Ligand B (66.91), both are below the 140 threshold for oral absorption, and Ligand B is closer to the 90 threshold for CNS targets.
3. **logP:** Ligand A (1.677) is optimal, while Ligand B (3.523) is approaching the upper limit of the optimal range. Ligand A is preferable.
4. **HBD:** Both ligands have 2 HBD, which is within the acceptable limit of <=5.
5. **HBA:** Ligand A has 6 HBA, and Ligand B has 5. Both are within the acceptable limit of <=10.
6. **QED:** Both ligands have good QED scores (0.614 and 0.718), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Both ligands have DILI risk around 60, which is moderately high. Ligand B (60.721) is slightly higher than Ligand A (58.55).
8. **BBB:** Both ligands have acceptable BBB penetration (61.846 and 64.637). Since ADRB2 isn't a primary CNS target, this isn't a major deciding factor.
9. **Caco-2:** Ligand A (-4.638) has a worse Caco-2 permeability than Ligand B (-5.389). This suggests Ligand B may have better intestinal absorption.
10. **Solubility:** Ligand A (-2.715) has better solubility than Ligand B (-4.076). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.16) has a much lower hERG inhibition liability than Ligand B (0.658), which is a significant advantage for cardiovascular safety.
12. **Cl_mic:** Ligand A (54.015) has a lower microsomal clearance, suggesting better metabolic stability than Ligand B (102.615).
13. **t1/2:** Ligand A (-33.224) has a negative in vitro half-life, which is concerning. Ligand B (66.195) has a positive half-life.
14. **Pgp:** Ligand A (0.191) has lower P-gp efflux liability than Ligand B (0.239). Lower efflux is generally preferred.
15. **Binding Affinity:** Ligand B (-7.0) has a significantly stronger binding affinity than Ligand A (-5.7). This is a substantial advantage, potentially outweighing some ADME concerns.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B has a better logP, slightly better TPSA, and a *much* better binding affinity. While Ligand A has a better hERG profile and lower Cl_mic, the substantial affinity difference of Ligand B is a major factor. The negative half-life of Ligand A is also a significant concern.
**Overall Assessment:**
Despite some ADME drawbacks (higher Cl_mic, slightly higher DILI, and worse solubility), Ligand B's significantly stronger binding affinity (-7.0 vs -5.7 kcal/mol) is a decisive advantage for a GPCR target. The improved Caco-2 permeability is also a positive. The hERG risk is higher, but potentially manageable with further optimization.
Output:
0
2025-04-17 19:50:27,078 - INFO - Reasoning:
Let's analyze both ligands based on the provided parameters and guidelines, prioritizing those relevant to GPCRs (logP, Pgp, TPSA, and affinity).
**Ligand A:**
* **MW:** 341.455 Da - Good, within the ideal range.
* **TPSA:** 48.31 - Excellent, well below the 140 threshold, suggesting good absorption.
* **logP:** 2.517 - Optimal, within the 1-3 range.
* **HBD:** 1 - Good.
* **HBA:** 5 - Good.
* **QED:** 0.908 - Excellent, highly drug-like.
* **DILI:** 27.142 - Very good, low risk.
* **BBB:** 82.823 - Good, suggesting reasonable potential for CNS penetration if desired, but not critical for a cardiovascular target.
* **Caco-2:** -5.307 - Poor, indicating low intestinal absorption. This is a significant drawback.
* **Solubility:** -2.115 - Poor, indicating low aqueous solubility.
* **hERG:** 0.88 - Acceptable, relatively low risk.
* **Cl_mic:** 8.524 - Moderate, could be better for metabolic stability.
* **t1/2:** 24.974 - Good, reasonable half-life.
* **Pgp:** 0.479 - Low efflux, favorable for bioavailability.
* **Affinity:** -6.6 kcal/mol - Good binding affinity.
**Ligand B:**
* **MW:** 348.531 Da - Good, within the ideal range.
* **TPSA:** 40.62 - Excellent, very good for absorption.
* **logP:** 3.556 - Slightly above optimal, but still acceptable.
* **HBD:** 0 - Good.
* **HBA:** 2 - Good.
* **QED:** 0.779 - Good, drug-like.
* **DILI:** 12.175 - Excellent, very low risk.
* **BBB:** 88.445 - Good, suggesting reasonable potential for CNS penetration.
* **Caco-2:** -4.483 - Poor, indicating low intestinal absorption.
* **Solubility:** -3.707 - Poor, indicating low aqueous solubility.
* **hERG:** 0.608 - Acceptable, relatively low risk.
* **Cl_mic:** 87.607 - High, indicating poor metabolic stability.
* **t1/2:** -8.015 - Very poor, extremely short half-life.
* **Pgp:** 0.168 - Low efflux, favorable for bioavailability.
* **Affinity:** -6.6 kcal/mol - Good binding affinity, same as Ligand A.
**Comparison and Decision:**
Both ligands have similar binding affinities. The biggest issues for both are poor Caco-2 permeability and solubility. However, Ligand A has a better QED score, lower DILI risk, and a significantly better in vitro half-life. Ligand B has a higher logP and BBB, but its extremely short half-life and high microsomal clearance are major drawbacks. For a cardiovascular target, a longer half-life is generally preferred to reduce dosing frequency, and the slightly higher logP of Ligand B doesn't offer a substantial advantage. The better metabolic stability of Ligand A is a key advantage.
Therefore, I prefer Ligand A.
Output:
1
2025-04-17 19:50:27,079 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [389.876, 63.68, 3.117, 0, 4, 0.742, 54.789, 89.066, -4.417, -5.154, 0.675, 79.023, -3.622, 0.283, -7.6]
**Ligand B:** [351.447, 87.74, 1.418, 2, 4, 0.726, 17.449, 75.843, -4.589, -2.179, 0.261, 25.258, -16.815, 0.012, -7.6]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (351.447) is slightly lower, which *could* be beneficial for permeability, but both are acceptable.
2. **TPSA:** Ligand A (63.68) is better than Ligand B (87.74). ADRB2 is not a CNS target, but lower TPSA generally favors absorption.
3. **logP:** Ligand A (3.117) is optimal, while Ligand B (1.418) is on the lower side. This is a significant advantage for A, as it will likely have better membrane permeability.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Both have 4 HBA, which is acceptable.
6. **QED:** Both are similar (A: 0.742, B: 0.726) and above the 0.5 threshold, indicating good drug-likeness.
7. **DILI:** Ligand B (17.449) is *much* better than Ligand A (54.789). This is a major concern for Ligand A.
8. **BBB:** Not a primary concern for a cardiovascular target, but Ligand A (89.066) is higher than Ligand B (75.843).
9. **Caco-2:** Both are negative, indicating poor permeability. This is a drawback for both.
10. **Solubility:** Ligand B (-2.179) is better than Ligand A (-5.154).
11. **hERG:** Ligand A (0.675) is better than Ligand B (0.261). Lower hERG is preferred.
12. **Cl_mic:** Ligand B (25.258) is significantly better than Ligand A (79.023). Lower clearance means greater metabolic stability.
13. **t1/2:** Ligand B (-16.815) is much better than Ligand A (-3.622). A longer half-life is generally desirable.
14. **Pgp:** Ligand A (0.283) is better than Ligand B (0.012). Lower P-gp efflux is preferred.
15. **Affinity:** Both have the same binding affinity (-7.6 kcal/mol), so this doesn't differentiate them.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, and affinity. Ligand A has a better logP and Pgp, but Ligand B has a much better DILI score and metabolic stability (Cl_mic, t1/2). The DILI risk for Ligand A is concerning.
**Conclusion:**
Despite Ligand A having slightly better logP and Pgp properties, the significantly higher DILI risk and poorer metabolic stability (higher Cl_mic, shorter t1/2) outweigh these advantages. Ligand B, while having a lower logP, presents a much safer profile with a substantially lower DILI risk and better metabolic properties. Therefore, Ligand B is the more viable drug candidate.
0
2025-04-17 19:50:27,079 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (342.286 Da and 346.299 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (111.16) is better than Ligand B (127.01). For a GPCR, keeping TPSA under 140 is good for oral absorption, and A is closer to the lower end, suggesting better permeability.
**3. logP:** Ligand A (2.6) is optimal, while Ligand B (0.109) is quite low. A logP below 1 can hinder membrane permeation. This is a significant advantage for Ligand A.
**4. H-Bond Donors:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
**5. H-Bond Acceptors:** Ligand B (8) is higher than Ligand A (6). While both are within the acceptable range of 10, lower is generally better for permeability.
**6. QED:** Ligand B (0.784) has a better QED score than Ligand A (0.433), indicating a more drug-like profile overall. This is a positive for B, but not decisive.
**7. DILI:** Ligand A (99.147) has a very high DILI risk, while Ligand B (85.77) is still high but considerably lower. This is a major concern for Ligand A.
**8. BBB:** Ligand A (66.576) has a moderate BBB penetration, while Ligand B (20.202) is very low. While ADRB2 is a cardiovascular target, some CNS penetration can be associated with off-target effects, and this difference isn't critical.
**9. Caco-2 Permeability:** Both are negative, indicating poor permeability, but Ligand A (-5.061) is slightly better than Ligand B (-5.406).
**10. Aqueous Solubility:** Ligand A (-4.128) is slightly better than Ligand B (-2.371).
**11. hERG Inhibition:** Ligand A (0.421) shows a lower risk of hERG inhibition than Ligand B (0.013). This is a significant advantage for Ligand A.
**12. Microsomal Clearance:** Ligand A (62.435) has a significantly lower clearance than Ligand B (14.325), suggesting better metabolic stability.
**13. In vitro Half-Life:** Ligand A (69.034) has a much longer half-life than Ligand B (7.475). This is a substantial advantage for Ligand A.
**14. P-gp Efflux:** Ligand A (0.327) has lower P-gp efflux than Ligand B (0.012), suggesting better bioavailability.
**15. Binding Affinity:** Ligand B (-8.1) has a slightly better binding affinity than Ligand A (-7.7). While a 0.4 kcal/mol difference is noticeable, it's not a massive advantage, especially considering the other factors.
**Overall Assessment:**
Ligand A is superior despite the slightly lower affinity. Its significantly better logP, metabolic stability (lower Cl_mic, longer t1/2), lower P-gp efflux, and lower DILI risk outweigh the slightly weaker binding. The high DILI risk associated with Ligand A is a major concern. While Ligand B has a better QED, its extremely low logP and high P-gp efflux are problematic.
Output:
1
2025-04-17 19:50:27,079 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (344.415 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are good, below the 140 A^2 threshold for oral absorption. Ligand B (82.97) is slightly better than Ligand A (89.53).
3. **logP:** Ligand A (0.173) is quite low, potentially hindering membrane permeability. Ligand B (1.09) is better, falling within the optimal 1-3 range. This is a significant advantage for Ligand B, especially for a GPCR.
4. **HBD:** Both have acceptable HBD counts (Ligand A: 2, Ligand B: 1).
5. **HBA:** Both are acceptable, Ligand A (4) is better than Ligand B (6).
6. **QED:** Both are good (>0.5), indicating drug-like properties. Ligand A (0.815) is slightly better.
7. **DILI:** Ligand A (29.236) has a much lower DILI risk than Ligand B (44.009), a substantial advantage.
8. **BBB:** Ligand B (69.988) has a better BBB penetration percentile than Ligand A (38.193). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant, and this favors Ligand B.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. Ligand B (-4.66) is slightly better than Ligand A (-5.277).
10. **Solubility:** Both have negative solubility values, indicating poor solubility. Ligand A (-1.967) is slightly better than Ligand B (-2.638).
11. **hERG:** Both have low hERG inhibition liability. Ligand A (0.156) is better than Ligand B (0.644).
12. **Cl_mic:** Ligand A (3.389) has significantly lower microsomal clearance, indicating better metabolic stability, which is a major plus. Ligand B (29.262) is quite high.
13. **t1/2:** Ligand A (-11.311) has a negative half-life, which is concerning. Ligand B (3.87) is positive, indicating a reasonable half-life.
14. **Pgp:** Both have low Pgp efflux liability. Ligand A (0.011) is much lower than Ligand B (0.081).
15. **Affinity:** Ligand B (-6.5 kcal/mol) has a significantly stronger binding affinity than Ligand A (-3.3 kcal/mol). This is a very large difference, and a key factor.
**Overall Assessment:**
Ligand B has a much stronger binding affinity, which is paramount for GPCR targets. It also has better BBB penetration and a more reasonable in vitro half-life. However, it suffers from higher DILI risk, higher microsomal clearance, and a less optimal logP. Ligand A has a better safety profile (lower DILI, hERG, Pgp) and metabolic stability (lower Cl_mic), but its weak binding affinity and low logP are significant drawbacks.
Given the importance of affinity for GPCRs, and the fact that the difference in binding energy is substantial (3.2 kcal/mol), I believe Ligand B is the more promising starting point, despite its ADME liabilities. These liabilities can be addressed through further optimization, but a weak binder is much harder to improve.
Output:
0
2025-04-17 19:50:27,079 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (340.379 and 373.356 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (85.36 and 80.32) are below the 140 A^2 threshold for good oral absorption, and acceptable for a non-CNS GPCR like ADRB2. Ligand B is slightly better.
3. **logP:** Both ligands (1.788 and 2.648) are within the optimal 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability but needs to be balanced against solubility.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Both ligands have 5 HBA, which is acceptable.
6. **QED:** Both ligands (0.81 and 0.79) are above 0.5, indicating good drug-likeness. No significant difference.
7. **DILI:** Ligand A (71.888) has a lower DILI risk than Ligand B (81.504), which is a significant advantage. Lower DILI is always preferred.
8. **BBB:** Both ligands have similar BBB penetration (66.654 and 67.701). This isn't a primary concern for ADRB2, which isn't a CNS target, but higher is generally better.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. This is a concern for both.
10. **Solubility:** Both ligands have negative solubility values, indicating poor solubility. This is a concern for both.
11. **hERG:** Ligand A (0.047) has a much lower hERG inhibition liability than Ligand B (0.327). This is a crucial advantage, as hERG inhibition can lead to cardiotoxicity.
12. **Cl_mic:** Ligand B (48.25) has a lower microsomal clearance than Ligand A (67.527), suggesting better metabolic stability. This is a positive for Ligand B.
13. **t1/2:** Ligand B (-12.564) has a slightly longer in vitro half-life than Ligand A (-12.415), but both are negative, which is concerning.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.037 and 0.193).
15. **Binding Affinity:** Both ligands have the same binding affinity (-6.3 kcal/mol).
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are important. Both ligands perform similarly in these areas. However, minimizing off-target effects (DILI, hERG) is critical for cardiovascular drugs.
**Overall Assessment:**
Ligand A is preferable due to its significantly lower DILI and hERG risk. While Ligand B has slightly better metabolic stability (lower Cl_mic) and logP, the safety profiles of Ligand A are more favorable, outweighing these minor advantages. The poor Caco-2 and solubility are concerns for both, but can be addressed with formulation strategies.
Output:
1
2025-04-17 19:50:27,080 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [360.361, 94.48, 0.564, 2, 6, 0.707, 61.07, 74.292, -4.96, -2.491, 0.244, 5.243, 17.818, 0.031, -6.5]
**Ligand B:** [374.888, 59.39, 2.337, 1, 5, 0.744, 16.557, 90.074, -4.618, -2.71, 0.662, 16.341, 8.162, 0.087, -6.8]
Here's a breakdown of each parameter and how the ligands compare, keeping GPCR priorities (logP, Pgp, TPSA, affinity) in mind:
1. **MW:** Both are within the ideal range (200-500 Da). A is 360.361, B is 374.888. No significant difference.
2. **TPSA:** A (94.48) is slightly higher than B (59.39). B is better, being closer to the ideal <90 for potential CNS penetration (though less critical for a cardiovascular target).
3. **logP:** A (0.564) is quite low, potentially hindering permeability. B (2.337) is much better, falling within the optimal 1-3 range. This is a significant advantage for B.
4. **HBD:** A (2) and B (1) are both acceptable. B is slightly better.
5. **HBA:** A (6) and B (5) are both acceptable. B is slightly better.
6. **QED:** Both are good (A: 0.707, B: 0.744), indicating drug-like properties. B is marginally better.
7. **DILI:** A (61.07) is higher than B (16.557). B is significantly better, indicating a lower risk of liver injury.
8. **BBB:** A (74.292) is good, but B (90.074) is even better. While not the primary focus for a cardiovascular target, higher BBB is generally favorable.
9. **Caco-2:** Both are negative, indicating poor permeability. A (-4.96) is slightly worse than B (-4.618).
10. **Solubility:** Both are negative, indicating poor solubility. A (-2.491) is slightly worse than B (-2.71).
11. **hERG:** A (0.244) is better than B (0.662), indicating lower cardiotoxicity risk.
12. **Cl_mic:** A (5.243) is lower than B (16.341), suggesting better metabolic stability. This is a significant advantage for A.
13. **t1/2:** A (17.818) is much longer than B (8.162). This is a major advantage for A, potentially allowing for less frequent dosing.
14. **Pgp:** A (0.031) is much lower than B (0.087), indicating less P-glycoprotein efflux and potentially better bioavailability. This is a significant advantage for A.
15. **Affinity:** B (-6.8) is slightly better than A (-6.5), though the difference is relatively small (0.3 kcal/mol).
**Overall Assessment:**
Ligand B has advantages in logP, TPSA, DILI, and BBB. However, Ligand A excels in metabolic stability (Cl_mic, t1/2), Pgp efflux, and has a lower hERG risk. The slightly better affinity of Ligand B is not enough to overcome the significant ADME advantages of Ligand A. Considering the GPCR target class, the balance of properties in Ligand A is more favorable. The longer half-life and reduced efflux are particularly valuable.
Output:
1
2025-04-17 19:50:27,080 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (370.316) is slightly higher than Ligand B (335.455), but both are acceptable.
2. **TPSA:** Ligand A (105.56) is higher than Ligand B (65.63). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B is significantly better here.
3. **logP:** Ligand A (1.361) is within the optimal range, while Ligand B (3.05) is at the higher end. Both are acceptable, but Ligand A is slightly more balanced.
4. **HBD:** Ligand A (2) and Ligand B (3) are both acceptable, falling below the threshold of 5.
5. **HBA:** Ligand A (7) and Ligand B (4) are both below the threshold of 10.
6. **QED:** Ligand A (0.721) has a better QED score than Ligand B (0.526), indicating a more drug-like profile.
7. **DILI:** Ligand B (32.067) has a much lower DILI risk than Ligand A (96.161). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (40.016) and Ligand B (33.23) are both low, which is expected for a cardiovascular target. This parameter isn't a major differentiator here.
9. **Caco-2:** Ligand A (-5.148) and Ligand B (-5.77) are both negative, indicating poor permeability. Ligand B is slightly worse.
10. **Solubility:** Ligand A (-3.446) and Ligand B (-1.961) are both poor, but Ligand B is better.
11. **hERG:** Ligand A (0.143) has a lower hERG risk than Ligand B (0.909), which is a significant advantage.
12. **Cl_mic:** Ligand B (-3.437) has a lower (better) microsomal clearance than Ligand A (6.557), indicating better metabolic stability.
13. **t1/2:** Ligand B (7.186) has a longer in vitro half-life than Ligand A (-31.201). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.096) has a lower Pgp efflux liability than Ligand B (0.296), which is a slight advantage.
15. **Binding Affinity:** Ligand A (-9.4) has a significantly stronger binding affinity than Ligand B (-6.4). This is a substantial advantage for Ligand A.
**GPCR-specific priorities:** For ADRB2 (a cardiovascular GPCR), affinity, logP, TPSA, Pgp, and metabolic stability are key. Ligand A excels in affinity, and has a reasonable logP. Ligand B has better TPSA and metabolic stability (Cl_mic and t1/2), and a much better DILI score. However, the substantial difference in binding affinity (-9.4 vs -6.4 kcal/mol) is a major driver. A 3 kcal/mol difference is often enough to overcome other deficiencies. The hERG risk is also better for Ligand A.
**Conclusion:**
Despite Ligand B's advantages in DILI, metabolic stability, and TPSA, the significantly stronger binding affinity of Ligand A, coupled with its better hERG profile, makes it the more promising drug candidate.
Output:
1
2025-04-17 19:50:27,080 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's systematically compare Ligand A and Ligand B based on the provided parameters, keeping in mind the GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key).
1. **Molecular Weight:** Both ligands (340.423 and 350.467 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (62.55) is significantly better than Ligand B (82.62). A TPSA under 140 is good for oral absorption, and lower is generally better for GPCRs. Ligand B is pushing the upper limit.
3. **logP:** Ligand A (3.965) is at the higher end of the optimal range (1-3), while Ligand B (0.492) is quite low. For a GPCR, a slightly higher logP is often preferred for membrane permeability, but 3.965 is approaching a potential issue. Ligand B's low logP is a more serious concern, potentially hindering absorption.
4. **H-Bond Donors:** Ligand A (1) is better than Ligand B (2). Lower is preferred for permeability.
5. **H-Bond Acceptors:** Ligand A (3) is better than Ligand B (7). Lower is preferred for permeability.
6. **QED:** Both ligands have similar QED values (0.857 and 0.627), both above the 0.5 threshold, indicating good drug-likeness.
7. **DILI:** Ligand A (60.915) is higher than Ligand B (36.487). Ligand B has a significantly lower DILI risk, which is a major advantage.
8. **BBB:** Both ligands have good BBB penetration (77.239 and 71.966). This isn't a primary concern for ADRB2 (a cardiovascular target), but it's not detrimental.
9. **Caco-2:** Ligand A (-4.648) is better than Ligand B (-5.126). Higher values indicate better absorption.
10. **Solubility:** Ligand A (-4.905) is better than Ligand B (-1.003). Higher values indicate better solubility.
11. **hERG:** Both ligands have similar hERG inhibition liability (0.645 and 0.694).
12. **Cl_mic:** Ligand A (50.277) has a higher microsomal clearance than Ligand B (23.895), meaning it's metabolized faster. Lower is better for metabolic stability.
13. **t1/2:** Ligand A (68.208) has a much longer half-life than Ligand B (1.499). This is a significant advantage for dosing convenience.
14. **Pgp:** Ligand A (0.461) has lower P-gp efflux than Ligand B (0.012). Lower Pgp is preferred.
15. **Binding Affinity:** Ligand A (-6.2 kcal/mol) has a slightly better binding affinity than Ligand B (-5.9 kcal/mol). While the difference is not huge, it's still a positive.
**Overall Assessment:**
Ligand A has a better balance of properties. While its logP is a bit high, its superior TPSA, solubility, Caco-2 permeability, half-life, and Pgp profile outweigh this concern. Ligand B's very low logP is a significant drawback, potentially leading to poor absorption. Ligand B's lower DILI risk is attractive, but the other ADME issues are more critical for a GPCR target like ADRB2. The slightly better affinity of Ligand A further supports its selection.
**Output:**
1
2025-04-17 19:50:27,080 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A Analysis:**
* **MW:** 354.519 Da - Within the ideal range (200-500).
* **TPSA:** 41.99 - Good, below the 140 threshold for oral absorption.
* **logP:** 4.842 - Slightly high, potentially leading to solubility issues or off-target effects.
* **HBD:** 1 - Good, low enough to not hinder permeability.
* **HBA:** 3 - Good, within acceptable limits.
* **QED:** 0.835 - Excellent, very drug-like.
* **DILI:** 44.281 - Good, low risk of liver injury.
* **BBB:** 72.547 - Good, suggesting reasonable potential for CNS penetration, though ADRB2 is primarily cardiovascular.
* **Caco-2:** -4.894 - Negative value is concerning and likely indicates poor permeability.
* **Solubility:** -5.218 - Very poor solubility, a major concern.
* **hERG:** 0.517 - Acceptable hERG risk.
* **Cl_mic:** 85.169 - Relatively high, indicating faster metabolism.
* **t1/2:** 25.969 - Moderate half-life.
* **Pgp:** 0.366 - Low P-gp efflux, favorable.
* **Affinity:** -5.9 kcal/mol - Good binding affinity.
**Ligand B Analysis:**
* **MW:** 348.403 Da - Within the ideal range.
* **TPSA:** 127.32 - Higher than ideal, potentially impacting oral absorption.
* **logP:** 0.796 - Low, potentially hindering permeation.
* **HBD:** 3 - Acceptable.
* **HBA:** 5 - Acceptable.
* **QED:** 0.671 - Good, reasonably drug-like.
* **DILI:** 36.952 - Good, low risk of liver injury.
* **BBB:** 58.434 - Lower, less potential for CNS penetration.
* **Caco-2:** -5.587 - Negative value is concerning and likely indicates poor permeability.
* **Solubility:** -2.676 - Poor solubility, but less severe than Ligand A.
* **hERG:** 0.091 - Very low hERG risk, excellent.
* **Cl_mic:** -6.848 - Very low, indicating high metabolic stability.
* **t1/2:** 15.027 - Shorter half-life.
* **Pgp:** 0.027 - Very low P-gp efflux, excellent.
* **Affinity:** -8.6 kcal/mol - Excellent binding affinity, significantly stronger than Ligand A.
**Comparison & Decision:**
Both ligands have issues with Caco-2 permeability and aqueous solubility. However, Ligand B's significantly stronger binding affinity (-8.6 kcal/mol vs -5.9 kcal/mol) is a major advantage, especially for a GPCR target like ADRB2. The improved metabolic stability (lower Cl_mic) and very low hERG and Pgp liabilities of Ligand B are also highly desirable. While Ligand A has a slightly better BBB score, this is less critical for a cardiovascular target. The slightly higher TPSA of Ligand B is a drawback, but the superior affinity and safety profile outweigh this concern.
Therefore, Ligand B is the more promising drug candidate.
Output:
0
2025-04-17 19:50:27,080 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, the priorities are logP, Pgp, TPSA, and affinity, with metabolic stability and safety (DILI, hERG) also being important.
Let's compare the ligands property by property:
1. **MW:** Both are within the acceptable 200-500 Da range. Ligand A (365.411) is slightly higher than Ligand B (344.371), but this isn't a major concern.
2. **TPSA:** Ligand A (104.81) is better than Ligand B (117.13), falling comfortably under the 140 threshold for oral absorption.
3. **logP:** Ligand B (1.628) is better than Ligand A (0.108). A logP of 0.108 is quite low and could indicate poor membrane permeability. Ligand B is within the optimal 1-3 range.
4. **HBD:** Ligand A (2) is preferable to Ligand B (3).
5. **HBA:** Ligand A (5) is preferable to Ligand B (4).
6. **QED:** Ligand A (0.74) is significantly better than Ligand B (0.402), indicating a more drug-like profile.
7. **DILI:** Ligand A (64.831) is better than Ligand B (72.703), indicating lower potential for liver injury. Both are acceptable, but A is preferred.
8. **BBB:** Both ligands have similar BBB penetration (around 57%). This isn't a primary concern for a cardiovascular target.
9. **Caco-2:** Ligand A (-4.865) is better than Ligand B (-5.268) indicating better intestinal absorption.
10. **Solubility:** Ligand A (-2.429) is better than Ligand B (-4.328).
11. **hERG:** Ligand A (0.179) is better than Ligand B (0.618), indicating a lower risk of cardiotoxicity.
12. **Cl_mic:** Ligand A (-0.083) is *much* better than Ligand B (38.435), indicating significantly better metabolic stability.
13. **t1/2:** Ligand A (0.887) is better than Ligand B (-8.622).
14. **Pgp:** Ligand A (0.02) is much better than Ligand B (0.202), indicating lower P-gp efflux.
15. **Affinity:** Ligand A (-6.8 kcal/mol) is significantly better than Ligand B (-3.9 kcal/mol). This is a substantial difference in binding potency.
**Overall Assessment:**
Ligand A is superior to Ligand B. While Ligand B has a better logP, Ligand A excels in almost every other critical parameter, particularly affinity, metabolic stability (Cl_mic and t1/2), Pgp efflux, hERG risk, and QED. The significantly stronger binding affinity of Ligand A (-6.8 vs -3.9 kcal/mol) is a major advantage that outweighs the slightly lower logP. The better ADME properties of Ligand A also contribute to its higher likelihood of success as a drug candidate.
**Output:**
1
2025-04-17 19:50:27,080 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (341.39 and 346.475 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (62.53) is better than Ligand B (68.44). Both are below the 140 A^2 threshold for oral absorption, but lower is generally preferred.
3. **logP:** Both ligands have good logP values (2.168 and 1.537), falling within the optimal 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (3). Lower HBA generally improves permeability.
6. **QED:** Both ligands have similar and good QED values (0.773 and 0.787), indicating good drug-like properties.
7. **DILI:** Ligand A (54.401) has a higher DILI risk than Ligand B (7.949). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (86.002) has a better BBB penetration percentile than Ligand B (49.244). While ADRB2 isn't strictly a CNS target, some CNS exposure can be acceptable or even desirable for off-target effects assessment.
9. **Caco-2:** Ligand A (-4.939) is better than Ligand B (-5.281). Higher Caco-2 permeability is preferred.
10. **Solubility:** Ligand A (-2.447) is better than Ligand B (-1.181). Higher solubility is preferred.
11. **hERG:** Ligand A (0.861) is better than Ligand B (0.439). Lower hERG inhibition is preferred.
12. **Cl_mic:** Ligand A (51.055) has a higher microsomal clearance than Ligand B (1.168). This suggests Ligand B is more metabolically stable, which is a significant advantage.
13. **t1/2:** Ligand A (17.173) has a longer in vitro half-life than Ligand B (-5.459). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.366) is better than Ligand B (0.027). Lower P-gp efflux is preferred.
15. **Affinity:** Ligand B (-7.2) has a slightly better binding affinity than Ligand A (-7.1). While the difference is small (0.1 kcal/mol), it's still a factor.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A has slightly better logP, TPSA, and Pgp. Ligand B has a marginally better affinity. However, the *significant* advantage of Ligand B in terms of DILI risk and metabolic stability (Cl_mic) outweighs the minor affinity difference.
**Overall Assessment:**
Ligand B presents a much more favorable safety profile (DILI) and better metabolic stability. While Ligand A has some advantages in permeability and half-life, the lower DILI risk and improved metabolic stability of Ligand B are more critical for a successful drug candidate.
Output:
0
2025-04-17 19:50:27,081 - INFO - Batch 140 complete. Total preferences: 2240
2025-04-17 19:50:27,081 - INFO - Processing batch 141/512...
2025-04-17 19:51:15,431 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (367.743 and 350.463 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (81.93) is slightly higher than Ligand B (76.46). Both are below the 140 threshold for oral absorption, but closer to the 90 threshold for CNS targets (though ADRB2 isn't necessarily a CNS target). Ligand B is slightly preferred.
3. **logP:** Both ligands have good logP values (3.006 and 2.3), falling within the optimal 1-3 range. Ligand A is slightly higher, which could potentially lead to off-target effects, but it's not a major concern.
4. **HBD:** Both have 1 HBD, which is within the acceptable limit of 5.
5. **HBA:** Ligand A has 6 HBA, and Ligand B has 5. Both are below the acceptable limit of 10.
6. **QED:** Both have good QED scores (0.701 and 0.827), indicating drug-like properties. Ligand B is slightly better.
7. **DILI:** This is a critical parameter. Ligand A has a very high DILI risk (98.41 percentile), which is a major red flag. Ligand B has a much lower DILI risk (27.608 percentile), making it significantly safer.
8. **BBB:** Ligand A (61.38) has a moderate BBB penetration, while Ligand B (88.949) has a high BBB penetration. While ADRB2 isn't a primary CNS target, higher BBB penetration is generally favorable for GPCRs, improving distribution.
9. **Caco-2:** Both have negative Caco-2 values (-4.696 and -4.341), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand B (-1.798) has better solubility than Ligand A (-4.56).
11. **hERG:** Both ligands have low hERG inhibition risk (0.406 and 0.288).
12. **Cl_mic:** Ligand A (48.867) has lower microsomal clearance than Ligand B (59.435), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-1.903) has a negative in vitro half-life, which is concerning. Ligand A (10.466) has a reasonable half-life.
14. **Pgp:** Ligand A (0.299) has lower P-gp efflux than Ligand B (0.063), which is preferable for bioavailability.
15. **Binding Affinity:** Ligand B (-5.5 kcal/mol) has a slightly better binding affinity than Ligand A (-4.0 kcal/mol). This is a 1.5 kcal/mol difference, which is significant.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. While both ligands are reasonable in logP and TPSA, Ligand B excels in Pgp and has a better binding affinity. The *massive* difference in DILI risk is the deciding factor.
**Conclusion:**
Despite Ligand A's better metabolic stability and slightly better Pgp profile, the extremely high DILI risk associated with Ligand A makes it a poor candidate. Ligand B, while having a slightly worse metabolic profile and Pgp efflux, is far safer and has a better binding affinity.
Output:
0
2025-04-17 19:51:15,431 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (380.495 Da) is slightly higher than Ligand B (354.491 Da), but both are acceptable.
2. **TPSA:** Ligand A (109.73) is higher than the preferred <140, but still reasonable. Ligand B (59.08) is excellent, well below 140 and suggesting good absorption. This favors Ligand B.
3. **logP:** Ligand A (0.936) is a bit low, potentially hindering permeation. Ligand B (2.09) is within the optimal 1-3 range. This favors Ligand B.
4. **HBD:** Ligand A (2) is acceptable. Ligand B (0) is also good, potentially improving permeability.
5. **HBA:** Ligand A (6) is acceptable. Ligand B (4) is also good.
6. **QED:** Ligand A (0.767) is better than Ligand B (0.564), indicating a more drug-like profile. This favors Ligand A.
7. **DILI:** Ligand A (72.586) has a higher DILI risk than Ligand B (17.914). This strongly favors Ligand B.
8. **BBB:** Ligand A (63.048) is moderate. Ligand B (89.802) is very good, suggesting better potential for CNS penetration if desired (though ADRB2 is primarily cardiovascular, some CNS effects are possible). This favors Ligand B.
9. **Caco-2:** Ligand A (-5.495) is poor. Ligand B (-4.208) is also poor, but slightly better.
10. **Solubility:** Ligand A (-2.859) is poor. Ligand B (-1.627) is also poor, but slightly better.
11. **hERG:** Ligand A (0.684) is better than Ligand B (0.46), indicating lower cardiotoxicity risk. This favors Ligand A.
12. **Cl_mic:** Ligand A (8.15) is much lower than Ligand B (29.064), suggesting better metabolic stability. This strongly favors Ligand A.
13. **t1/2:** Ligand A (11.12) is significantly longer than Ligand B (3.745), indicating a longer duration of action. This strongly favors Ligand A.
14. **Pgp:** Ligand A (0.068) is much lower than Ligand B (0.241), indicating lower P-gp efflux. This favors Ligand A.
15. **Affinity:** Ligand A (-6.0) is better than Ligand B (-2.3), indicating a stronger binding affinity. This strongly favors Ligand A.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B has better logP and TPSA, and a better BBB score. However, Ligand A has a *much* stronger binding affinity, lower Pgp efflux, and better metabolic stability (Cl_mic and t1/2). The substantial difference in binding affinity (-6.0 vs -2.3 kcal/mol) is a major advantage that can outweigh some of the ADME drawbacks of Ligand A. The DILI risk is a concern for Ligand A, but it is not as critical as potency for initial optimization.
**Conclusion:**
Despite Ligand B's better TPSA, logP, and lower DILI, the significantly stronger binding affinity, improved metabolic stability, and lower P-gp efflux of Ligand A make it the more promising drug candidate.
Output:
1
2025-04-17 19:51:15,432 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (a GPCR) drug candidates.
**Ligand A:** [346.391, 113.25 , 1.158, 2. , 7. , 0.807, 77.162, 56.96 , -4.915, -2.537, 0.144, 62.74 , -16.854, 0.016, -5.1 ]
**Ligand B:** [346.471, 49.85 , 2.358, 0. , 3. , 0.734, 28.306, 82.474, -4.433, -2.459, 0.257, 46.24 , -18.723, 0.217, -6. ]
Here's a step-by-step comparison, keeping GPCR priorities (logP, Pgp, TPSA, and affinity) in mind:
1. **MW:** Both are within the ideal range (around 346 Da). No significant difference.
2. **TPSA:** Ligand A (113.25) is higher than Ligand B (49.85). Ligand B is much better, being well below the 140 threshold for good absorption.
3. **logP:** Ligand A (1.158) is slightly lower than Ligand B (2.358), both are within the optimal range. Ligand B is preferable.
4. **HBD:** Ligand A (2) is higher than Ligand B (0). Lower is generally better for permeability, so Ligand B is preferable.
5. **HBA:** Ligand A (7) is higher than Ligand B (3). Again, Ligand B is preferable.
6. **QED:** Ligand A (0.807) is slightly better than Ligand B (0.734), both are good.
7. **DILI:** Ligand A (77.162) is significantly higher than Ligand B (28.306). This is a major concern. Ligand B is *much* safer.
8. **BBB:** Ligand B (82.474) is significantly higher than Ligand A (56.96). This is a key advantage for a GPCR, even if not a CNS target, as it suggests better distribution.
9. **Caco-2:** Ligand A (-4.915) is lower than Ligand B (-4.433). Higher is better, so Ligand B is preferable.
10. **Solubility:** Both are similarly poor (-2.537 and -2.459). This is a potential issue for both, but not a deciding factor.
11. **hERG:** Ligand A (0.144) is lower than Ligand B (0.257). Lower is better, so Ligand A is preferable.
12. **Cl_mic:** Ligand B (46.24) is lower than Ligand A (62.74). Lower clearance is better, indicating greater metabolic stability, so Ligand B is preferable.
13. **t1/2:** Ligand B (-18.723) is more negative than Ligand A (-16.854). More negative means a longer half-life, so Ligand B is preferable.
14. **Pgp:** Ligand A (0.016) is much lower than Ligand B (0.217). Lower P-gp efflux is better, so Ligand A is preferable.
15. **Affinity:** Ligand B (-6.0) is slightly better than Ligand A (-5.1). While not a huge difference, it's a positive for Ligand B.
**Overall Assessment:**
Ligand B clearly outperforms Ligand A in several critical areas. The most significant advantages are the much lower DILI risk, better BBB penetration, lower microsomal clearance, and longer half-life. While Ligand A has a slight edge in P-gp efflux and hERG, the safety and pharmacokinetic benefits of Ligand B are far more important for a viable drug candidate. The slightly better affinity of Ligand B also contributes to its preference.
Output:
0
2025-04-17 19:51:15,432 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (337.379 and 353.467 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (76.38) is better than Ligand B (92.37). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary goal, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (3.076 and 2.216), falling within the 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Both have 2 HBD, which is acceptable.
5. **HBA:** Both have 5 HBA, which is acceptable.
6. **QED:** Both ligands have similar QED scores (0.75 and 0.747), indicating good drug-likeness.
7. **DILI:** Ligand A (73.982) has a significantly higher DILI risk than Ligand B (39.356). This is a major concern.
8. **BBB:** Ligand B (80.962) has a higher BBB penetration percentile than Ligand A (35.052). While not critical for a cardiovascular target, it isn't a negative.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Ligand A (-3.924) has worse solubility than Ligand B (-1.809). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.565) has a slightly higher hERG risk than Ligand B (0.274), but both are relatively low.
12. **Cl_mic:** Ligand B (-7.699) has a *much* lower (better) microsomal clearance than Ligand A (65.877). This indicates significantly better metabolic stability for Ligand B.
13. **t1/2:** Ligand B (14.234) has a much longer in vitro half-life than Ligand A (-29.39). This is a significant advantage.
14. **Pgp:** Ligand A (0.336) has lower P-gp efflux than Ligand B (0.028), which is favorable.
15. **Binding Affinity:** Ligand A (-7.4) has a slightly better binding affinity than Ligand B (-6.1). This is a 1.3 kcal/mol difference, which is significant.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Ligand A has a slightly better logP and significantly better affinity. However, the significantly higher DILI risk, worse solubility, and much worse metabolic stability (Cl_mic and t1/2) of Ligand A are major drawbacks. The better Pgp value of A is not enough to offset these issues.
**Conclusion:**
Despite the slightly better affinity of Ligand A, the superior ADME profile of Ligand B, particularly the much lower DILI risk and improved metabolic stability, makes it the more promising drug candidate. The 1.3 kcal/mol difference in affinity can likely be optimized in subsequent rounds of medicinal chemistry, while mitigating the significant liabilities of Ligand A would be much more challenging.
Output:
0
2025-04-17 19:51:15,432 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.49 & 354.49 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (49.85) is significantly better than Ligand B (67.87). ADRB2 is not a CNS target, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands (2.30 & 2.69) are within the optimal 1-3 range. Ligand B is slightly higher, which *could* be a minor drawback, but not a major concern.
4. **HBD:** Ligand A (0) is preferable to Ligand B (1). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (4). Similar to HBD, fewer HBAs are generally better for permeability.
6. **QED:** Ligand A (0.633) is significantly better than Ligand B (0.413). A higher QED indicates a more drug-like profile.
7. **DILI:** Ligand A (6.669%) is considerably better than Ligand B (26.406%). This is a crucial factor; lower DILI risk is highly desirable.
8. **BBB:** Both ligands have high BBB penetration (90.85% and 80.07%). While not a primary concern for ADRB2, it doesn't hurt.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.325 and -4.914). These values are difficult to interpret directly, but suggest poor permeability.
10. **Solubility:** Both ligands have negative solubility values (-2.253 and -2.742). These values are difficult to interpret directly, but suggest poor solubility.
11. **hERG:** Both ligands have low hERG inhibition liability (0.51 and 0.587). This is good, indicating a low risk of cardiotoxicity.
12. **Cl_mic:** Ligand A (52.924) has a higher microsomal clearance than Ligand B (23.39). This suggests Ligand B is more metabolically stable.
13. **t1/2:** Ligand A (7.579) has a longer half-life than Ligand B (-1.868). This is a positive attribute.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.059 and 0.063).
15. **Binding Affinity:** Ligand B (-6.2 kcal/mol) has a stronger binding affinity than Ligand A (-5.1 kcal/mol). This is a 1.1 kcal/mol difference, which is significant.
**Overall Assessment:**
While Ligand B has a better binding affinity, Ligand A is significantly better across several crucial ADME-Tox properties, particularly DILI risk and QED. The lower DILI risk is a major advantage. The slightly longer half-life of Ligand A is also beneficial. The difference in binding affinity, while noticeable, is likely outweighed by the superior ADME-Tox profile of Ligand A. For a GPCR target like ADRB2, a balance of potency and favorable drug-like properties is essential, and Ligand A strikes that balance better.
Output:
1
2025-04-17 19:51:15,432 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [353.507, 61.88, 2.767, 1, 4, 0.847, 16.712, 71.384, -4.513, -1.542, 0.492, 34.454, 8.535, 0.086, -7.0]
**Ligand B:** [360.841, 58.64, 3.103, 1, 5, 0.445, 75.649, 64.482, -4.729, -5.898, 0.834, 46.543, 52.412, 0.832, -6.6]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity, and, to a lesser extent, BBB):
1. **MW:** Both are within the ideal range (200-500 Da). A is 353.5, B is 360.8. No significant difference.
2. **TPSA:** Both are good, below the 140 threshold for oral absorption. A is 61.88, B is 58.64. B is slightly better.
3. **logP:** Both are within the optimal 1-3 range. A is 2.767, B is 3.103. B is slightly higher, potentially leading to better membrane permeability.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** A has 4, B has 5. Both are acceptable, but A is slightly better.
6. **QED:** A (0.847) is significantly better than B (0.445), indicating a more drug-like profile.
7. **DILI:** A (16.712%) is much better than B (75.649%), indicating a lower risk of liver injury. This is a major advantage for A.
8. **BBB:** A (71.384%) is better than B (64.482%), although neither is exceptionally high. For a cardiovascular target, BBB isn't *critical*, but it's a bonus.
9. **Caco-2:** Both are negative, indicating poor permeability. A (-4.513) is slightly better than B (-4.729).
10. **Solubility:** A (-1.542) is better than B (-5.898). Solubility is important for bioavailability.
11. **hERG:** A (0.492) is significantly better than B (0.834), indicating lower cardiotoxicity risk. This is crucial for a cardiovascular target.
12. **Cl_mic:** A (34.454) is better than B (46.543), meaning A has better metabolic stability.
13. **t1/2:** B (52.412) is much better than A (8.535), suggesting a longer duration of action.
14. **Pgp:** A (0.086) is much better than B (0.832), meaning A is less susceptible to efflux.
15. **Affinity:** A (-7.0) is slightly better than B (-6.6), although the difference is relatively small.
**Overall Assessment:**
Ligand A clearly wins out. While Ligand B has a slightly better logP and *much* better in vitro half-life, Ligand A excels in critical areas like DILI risk, hERG inhibition, metabolic stability, P-gp efflux, solubility, and QED. The slightly better affinity of A is a bonus. The lower DILI and hERG risks are particularly important for a cardiovascular drug. The better QED score suggests a more generally favorable profile. The longer half-life of B is attractive, but can be addressed through structural modifications.
Output:
1
2025-04-17 19:51:15,432 - INFO - Here's my reasoning and output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
Let's analyze each ligand against the provided guidelines, keeping in mind ADRB2 is a GPCR, so logP, Pgp, TPSA, and affinity are key.
* **Molecular Weight:** Both ligands (360.38 and 350.46 Da) fall comfortably within the 200-500 Da range.
* **TPSA:** Both are below 140, which is good for oral absorption (76.02 and 70.08).
* **logP:** Ligand A (2.116) is optimal, while Ligand B (1.058) is a bit low, potentially hindering permeability.
* **H-Bond Donors:** Both have acceptable HBD counts (2 and 1 respectively).
* **H-Bond Acceptors:** Both have acceptable HBA counts (4).
* **QED:** Both have good QED scores (0.782 and 0.727), indicating drug-likeness.
* **DILI:** Ligand B (15.63) has a significantly lower DILI risk than Ligand A (41.61), a major advantage.
* **BBB:** Ligand A (83.33) has a much better BBB penetration potential than Ligand B (37.77). While ADRB2 isn't necessarily a CNS target, some peripheral ADRB2 activity can influence CNS pathways, and better BBB penetration isn't necessarily a negative.
* **Caco-2:** Both have negative Caco-2 values, which is unusual and difficult to interpret without knowing the scale. We'll assume these represent permeability, and lower values indicate lower permeability.
* **Solubility:** Ligand B (-1.143) has better aqueous solubility than Ligand A (-3.311).
* **hERG:** Both have low hERG inhibition risk (0.452 and 0.172).
* **Cl_mic:** Ligand B (36.19) has slightly higher microsomal clearance than Ligand A (30.24), indicating potentially lower metabolic stability.
* **t1/2:** Ligand A (-28.55) has a much longer in vitro half-life than Ligand B (0.004). This is a significant advantage.
* **Pgp:** Ligand A (0.069) has lower P-gp efflux than Ligand B (0.042), which is beneficial.
* **Binding Affinity:** Ligand A (-7.2 kcal/mol) has a stronger binding affinity than Ligand B (-6.5 kcal/mol). This 0.7 kcal/mol difference is substantial and can outweigh some ADME concerns.
**Overall Assessment:**
Ligand A has a significantly better binding affinity and a longer half-life, which are crucial for efficacy. It also has better Pgp properties. However, Ligand B has a much lower DILI risk and better solubility. The lower logP of Ligand B is a concern, potentially impacting permeability. Considering the strong affinity advantage of Ligand A and the importance of potency for GPCRs, I believe it is the more promising candidate despite the higher DILI risk, which can be further investigated and potentially mitigated through structural modifications.
**Output:**
1
2025-04-17 19:51:15,433 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (350.415 Da) is within the ideal range (200-500 Da). Ligand B (423.292 Da) is also acceptable, but approaching the upper limit.
2. **TPSA:** Both ligands (A: 84.94, B: 81.27) are below 140, suggesting good oral absorption potential. They are also well below the 90 threshold for CNS targets, though ADRB2 is not primarily a CNS target.
3. **logP:** Ligand A (2.0) is optimal. Ligand B (3.467) is slightly higher, but still within the acceptable range (1-3).
4. **HBD:** Ligand A (1) and Ligand B (0) are both good, meeting the <=5 criteria.
5. **HBA:** Ligand A (5) and Ligand B (6) are both acceptable, below the 10 threshold.
6. **QED:** Ligand A (0.544) is better than Ligand B (0.418), indicating a more drug-like profile.
7. **DILI:** Both ligands have acceptable DILI risk (A: 50.291, B: 80.651), but Ligand A is significantly lower, indicating a better safety profile.
8. **BBB:** Ligand A (81.892) shows better BBB penetration than Ligand B (78.558), though this isn't a primary concern for ADRB2.
9. **Caco-2:** Ligand A (-4.475) and Ligand B (-5.123) are both negative, indicating good permeability.
10. **Solubility:** Ligand A (-2.166) is better than Ligand B (-4.187), indicating better aqueous solubility.
11. **hERG:** Both ligands have low hERG inhibition risk (A: 0.627, B: 0.494).
12. **Cl_mic:** Ligand A (86.392) has higher microsomal clearance than Ligand B (57.835), suggesting lower metabolic stability.
13. **t1/2:** Ligand B (-48.07) has a longer in vitro half-life than Ligand A (-41.06), which is desirable.
14. **Pgp:** Ligand A (0.101) has lower P-gp efflux liability than Ligand B (0.722), which is favorable for bioavailability.
15. **Affinity:** Ligand B (-7.3 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.1 kcal/mol) - a difference of 1.2 kcal/mol. This is a substantial advantage.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand B excels in affinity. Ligand A is better in logP, Pgp, solubility and DILI. The affinity difference is substantial enough to outweigh the slightly less favorable ADME properties of Ligand B.
**Conclusion:**
While Ligand A has a better safety profile (lower DILI) and better solubility, the significantly stronger binding affinity of Ligand B (-7.3 kcal/mol vs -6.1 kcal/mol) is a critical advantage for a GPCR target. This difference in potency is likely to outweigh the minor ADME drawbacks of Ligand B.
Output:
0
2025-04-17 19:51:15,433 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [409.284, 102.3 , 1.878, 2. , 4. , 0.725, 64.676, 51.066, -4.81 , -3.934, 0.511, 42.751, 57.175, 0.088, -6.4 ]
**Ligand B:** [345.443, 79.37 , 1.972, 1. , 4. , 0.828, 41.411, 60.14 , -4.646, -2.433, 0.257, 45.683, -35.201, 0.056, -7.1 ]
Here's a step-by-step comparison, keeping GPCR priorities (logP, Pgp, TPSA, affinity) in mind:
1. **MW:** Ligand A (409.284 Da) is within the ideal range, while Ligand B (345.443 Da) is towards the lower end, but still acceptable.
2. **TPSA:** Ligand A (102.3) is slightly above the preferred <140 for oral absorption, but not a major concern. Ligand B (79.37) is excellent.
3. **logP:** Both are good (A: 1.878, B: 1.972), falling within the 1-3 range.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable.
5. **HBA:** Both ligands have 4 HBA, which is good.
6. **QED:** Both ligands have good QED scores (A: 0.725, B: 0.828).
7. **DILI:** Ligand A (64.676) has a higher DILI risk than Ligand B (41.411). This is a significant negative for Ligand A.
8. **BBB:** Ligand B (60.14) has better BBB penetration than Ligand A (51.066), though neither are exceptionally high.
9. **Caco-2:** Ligand A (-4.81) is worse than Ligand B (-4.646).
10. **Solubility:** Ligand A (-3.934) is worse than Ligand B (-2.433).
11. **hERG:** Ligand A (0.511) has a slightly higher hERG risk than Ligand B (0.257).
12. **Cl_mic:** Ligand A (42.751) has a lower clearance than Ligand B (45.683), indicating better metabolic stability.
13. **t1/2:** Ligand B (-35.201) has a much longer in vitro half-life than Ligand A (57.175).
14. **Pgp:** Ligand A (0.088) has lower P-gp efflux than Ligand B (0.056), which is favorable.
15. **Affinity:** Ligand B (-7.1 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.4 kcal/mol) - a difference of 0.7 kcal/mol. This is a substantial advantage.
**Overall Assessment:**
Ligand B is the stronger candidate. While Ligand A has slightly better Pgp efflux and metabolic stability, Ligand B excels in several key areas: significantly better binding affinity, lower DILI risk, better solubility, longer half-life, and a more favorable TPSA. The affinity difference is particularly important for a GPCR target, and the lower DILI risk is crucial for safety. The better BBB penetration is also a plus.
Output:
0
2025-04-17 19:51:15,433 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (350.478 and 349.519 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (40.62) is better than Ligand B (52.65). Both are below 140, but A is closer to the preferred <90 for potential CNS penetration, though this is less critical for a cardiovascular target like ADRB2.
3. **logP:** Both ligands have good logP values (3.156 and 2.592) within the optimal 1-3 range. Ligand A is slightly higher, which *could* be beneficial for membrane permeability, but isn't a major concern for either.
4. **HBD:** Ligand A (0) is preferable to Ligand B (1). Fewer hydrogen bond donors generally improve permeability.
5. **HBA:** Ligand A (2) is better than Ligand B (3). Lower HBA is generally preferred for better permeability.
6. **QED:** Ligand A (0.784) is significantly better than Ligand B (0.617), indicating a more drug-like profile.
7. **DILI:** Ligand A (19.814) has a much lower DILI risk than Ligand B (10.818). This is a crucial advantage, as liver toxicity is a major concern in drug development.
8. **BBB:** Ligand A (85.925) has a higher BBB penetration percentile than Ligand B (52.811). While ADRB2 isn't a CNS target, some off-target CNS effects are always a consideration, and higher BBB can sometimes correlate with better overall distribution.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.557 and -4.766), which is unusual and suggests poor permeability. This is a significant drawback for both.
10. **Solubility:** Ligand A (-3.357) is slightly better than Ligand B (-1.461), but both are very poor, indicating potential formulation challenges.
11. **hERG:** Ligand A (0.761) has a lower hERG inhibition liability than Ligand B (0.22). This is a significant advantage, reducing the risk of cardiotoxicity.
12. **Cl_mic:** Ligand A (55.915) has a higher microsomal clearance than Ligand B (11.033), meaning it's metabolized faster. This is a disadvantage for Ligand A.
13. **t1/2:** Ligand B (15.403) has a much longer in vitro half-life than Ligand A (-6.633). This is a significant advantage for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.227) has a lower P-gp efflux liability than Ligand B (0.033). Lower P-gp efflux is generally preferred for better bioavailability.
15. **Affinity:** Ligand A (-6.8) has a slightly better binding affinity than Ligand B (-6.0). While the difference is not huge, it's still a positive for Ligand A.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A performs better on logP, TPSA, and Pgp, and has a slightly better affinity.
**Overall Assessment:**
Despite Ligand B's superior half-life, Ligand A is the more promising candidate. The significantly lower DILI risk, lower hERG liability, better QED, and slightly better affinity outweigh the faster clearance. The poor Caco-2 and solubility are concerning for both, but can potentially be addressed with formulation strategies. The lower TPSA and HBD/HBA counts in Ligand A also favor better permeability, mitigating some of the Caco-2 concern.
Output:
1
2025-04-17 19:51:15,433 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.462 and 334.394 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (32.78) is slightly higher than Ligand B (26.71). Both are well below the 140 threshold for oral absorption, and acceptable for a GPCR. Ligand B is preferable.
3. **logP:** Ligand A (3.132) is within the optimal 1-3 range. Ligand B (4.69) is a bit high, potentially leading to solubility issues and off-target interactions. Ligand A is preferable.
4. **HBD:** Ligand A (0) is better than Ligand B (1). Fewer HBDs generally improve permeability.
5. **HBA:** Both ligands have 3 HBA, which is acceptable.
6. **QED:** Ligand A (0.838) has a slightly higher QED than Ligand B (0.753), indicating a more drug-like profile. Ligand A is preferable.
7. **DILI:** Ligand A (21.171) has a significantly lower DILI risk than Ligand B (68.088). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (93.912) has a much higher BBB penetration percentile than Ligand B (66.344). While ADRB2 isn't strictly a CNS target, some peripheral ADRB2 receptors can be affected by CNS penetration, and higher BBB is generally favorable. Ligand A is preferable.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. Ligand B (-4.888) is slightly worse than Ligand A (-4.221). Ligand A is preferable.
10. **Solubility:** Ligand A (-2.336) has better solubility than Ligand B (-5.186). This is important for bioavailability. Ligand A is preferable.
11. **hERG:** Both ligands have similar hERG inhibition liability (0.948 and 0.959), indicating low risk.
12. **Cl_mic:** Ligand B (92.685) has a significantly higher microsomal clearance than Ligand A (32.816), suggesting lower metabolic stability. Ligand A is preferable.
13. **t1/2:** Ligand A (4.985) has a shorter half-life than Ligand B (-28.383). However, the negative value for Ligand B is concerning and likely represents an extrapolation or error in the model. Ligand A is preferable.
14. **Pgp:** Both ligands have similar Pgp efflux liability (0.624 and 0.767).
15. **Binding Affinity:** Ligand B (-8.9 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.9 kcal/mol). This is a substantial advantage (3 kcal/mol difference).
**Overall Assessment:**
While Ligand B boasts a superior binding affinity, Ligand A consistently outperforms it in crucial ADME-Tox properties. Specifically, the significantly lower DILI risk, better BBB penetration, improved solubility, and lower microsomal clearance of Ligand A are compelling advantages. The difference in binding affinity, while substantial, can potentially be optimized in later stages of drug development. The ADME-Tox profile of Ligand B is concerning, particularly the high DILI risk and poor metabolic stability. For a GPCR target like ADRB2, a balanced profile is more important than absolute potency, especially in the early stages of development.
Output:
1
2025-04-17 19:51:15,433 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (349.431 and 361.408 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (86.88) is better than Ligand B (47.36). For a cardiovascular GPCR, lower TPSA is generally preferred for better permeability.
**3. logP:** Ligand B (3.296) is slightly higher than Ligand A (1.545). While both are within the acceptable 1-3 range, Ligand B is approaching the upper limit.
**4. H-Bond Donors:** Ligand A has 1 HBD, while Ligand B has 0. Both are acceptable.
**5. H-Bond Acceptors:** Ligand A has 5 HBA, and Ligand B has 4. Both are within the acceptable limit of 10.
**6. QED:** Both ligands have similar QED values (0.72 and 0.781), indicating good drug-likeness.
**7. DILI Risk:** Ligand B (16.983) has a significantly lower DILI risk than Ligand A (44.591). This is a crucial advantage.
**8. BBB Penetration:** Ligand B (91.043) exhibits much better BBB penetration than Ligand A (60.644). While ADRB2 is primarily a cardiovascular target, some CNS effects are possible with certain ligands, and higher BBB penetration could lead to off-target effects. However, for a cardiovascular target, this is less critical than for a CNS target.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.434 and -4.045). This is unusual and suggests poor permeability.
**10. Aqueous Solubility:** Ligand A (-1.404) has slightly better aqueous solubility than Ligand B (-3.26).
**11. hERG Inhibition:** Ligand A (0.135) has a lower hERG inhibition risk than Ligand B (0.723). This is a significant advantage for cardiovascular safety.
**12. Microsomal Clearance:** Ligand B (59.621) has a higher microsomal clearance than Ligand A (38.794), indicating lower metabolic stability.
**13. In vitro Half-Life:** Ligand A (-30.852) has a longer in vitro half-life than Ligand B (-17.711). This is a positive attribute.
**14. P-gp Efflux:** Ligand A (0.194) has lower P-gp efflux than Ligand B (0.091), which is preferable.
**15. Binding Affinity:** Ligand B (-6.1) has a slightly better binding affinity than Ligand A (-6.5). However, the difference is less than 1.5 kcal/mol, so it's not a decisive factor.
**Overall Assessment:**
Ligand B has a significantly lower DILI risk and better BBB penetration. However, it has poorer metabolic stability (higher Cl_mic) and lower hERG safety. Ligand A has better hERG safety, metabolic stability, and P-gp efflux. Considering the cardiovascular target, minimizing DILI risk is paramount. The slightly better affinity of Ligand B is not enough to offset the higher DILI risk. The negative Caco-2 values for both are concerning, but can be addressed with formulation strategies.
Therefore, I favor Ligand A.
Output:
1
2025-04-17 19:51:15,433 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Step-by-step comparison:**
1. **MW:** Both ligands (347.419 and 350.478 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (98.14) is higher than Ligand B (40.62). For a GPCR, lower TPSA is generally preferred for better brain penetration and overall permeability. Ligand B is significantly better.
3. **logP:** Ligand A (0.969) is slightly below the optimal 1-3 range, while Ligand B (3.034) is well within it. Ligand B has a more favorable logP for membrane permeability and binding.
4. **HBD:** Ligand A (2) and Ligand B (0) both are acceptable.
5. **HBA:** Ligand A (6) and Ligand B (2) are both acceptable.
6. **QED:** Ligand B (0.631) has a better QED score than Ligand A (0.394), indicating a more drug-like profile.
7. **DILI:** Ligand A (46.879) has a slightly higher DILI risk than Ligand B (18.108), but both are below the concerning threshold of 60.
8. **BBB:** Ligand B (94.416) has a much higher BBB penetration percentile than Ligand A (52.423). This is a significant advantage for a GPCR target, even if not specifically a CNS target, as it suggests better distribution.
9. **Caco-2:** Both ligands have negative Caco-2 values which is unusual. Assuming these are percentile scores, Ligand A (-5.59) is worse than Ligand B (-4.679).
10. **Solubility:** Ligand A (-2.777) is worse than Ligand B (-3.26).
11. **hERG:** Ligand A (0.108) has a lower hERG inhibition liability than Ligand B (0.783), which is a positive.
12. **Cl_mic:** Ligand B (52.073) has a lower microsomal clearance than Ligand A (16.666), suggesting better metabolic stability.
13. **t1/2:** Ligand A (7.336) has a longer in vitro half-life than Ligand B (1.491). This is a positive for Ligand A.
14. **Pgp:** Ligand A (0.012) has much lower P-gp efflux liability than Ligand B (0.369), which is a significant advantage for bioavailability and potential CNS exposure.
15. **Affinity:** Ligand B (-6.2 kcal/mol) has a significantly better binding affinity than Ligand A (-4.7 kcal/mol). This difference of 1.5 kcal/mol is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand B demonstrates a superior balance of properties, particularly regarding its logP, TPSA, BBB penetration, QED, and, most importantly, its binding affinity. While Ligand A has a better hERG profile and longer half-life, the significantly stronger binding affinity of Ligand B, coupled with its better predicted permeability and drug-likeness, makes it the more promising candidate. The lower Pgp efflux for Ligand A is a benefit, but the affinity difference is substantial.
Output:
0
2025-04-17 19:51:15,434 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (367.5 & 361.5 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (80.32) is slightly higher than Ligand B (67.6). Both are below the 140 threshold for good oral absorption, but Ligand B is better positioned for potential CNS penetration if desired (though not a primary goal for ADRB2).
3. **logP:** Both ligands have excellent logP values (2.38 & 2.478), falling within the optimal 1-3 range.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1), but both are well within the acceptable limit of 5.
5. **HBA:** Ligand A (5) and Ligand B (6) are both reasonable, under the 10 threshold.
6. **QED:** Both ligands have good QED scores (0.7 & 0.817), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (33.773) has a significantly lower DILI risk than Ligand B (52.423). This is a major advantage for Ligand A.
8. **BBB:** Both ligands have moderate BBB penetration (50.6 & 49.9). This isn't a primary concern for a cardiovascular target like ADRB2.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability in this assay. This is a potential concern for both, but the values are similar.
10. **Solubility:** Ligand A (-2.935) has better solubility than Ligand B (-4.151). This is a positive for Ligand A.
11. **hERG:** Ligand A (0.261) has a much lower hERG inhibition liability than Ligand B (0.42). This is a significant safety advantage for Ligand A.
12. **Cl_mic:** Ligand A (58.791) has lower microsomal clearance than Ligand B (61.544), suggesting better metabolic stability.
13. **t1/2:** Ligand A (15.387) has a longer in vitro half-life than Ligand B (9.163). This is a positive for Ligand A.
14. **Pgp:** Ligand A (0.026) has significantly lower P-gp efflux liability than Ligand B (0.192), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand B (-7.7) has a substantially stronger binding affinity than Ligand A (-5.6). This is a 2.1 kcal/mol difference, which is a significant advantage.
**Overall Assessment:**
Ligand B has a stronger binding affinity, which is a key factor for GPCRs. However, Ligand A demonstrates a much more favorable safety profile (lower DILI, lower hERG) and better ADME properties (better solubility, lower clearance, longer half-life, lower Pgp efflux). The affinity difference, while substantial, can potentially be optimized in later stages of drug development. The safety and ADME advantages of Ligand A are more difficult to address later. Given the cardiovascular target, minimizing off-target effects and ensuring good pharmacokinetic properties are crucial.
Output:
1
2025-04-17 19:51:15,434 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (359.373 and 348.443 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (67.87) is significantly better than Ligand A (95.67). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (1.568 and 0.944), falling within the 1-3 range. Ligand B is slightly lower, which could be beneficial for solubility.
4. **HBD:** Ligand B (1) has fewer H-bond donors than Ligand A (2), which is preferable for permeability.
5. **HBA:** Ligand B (4) has fewer H-bond acceptors than Ligand A (5), again favoring permeability.
6. **QED:** Both ligands have good QED scores (0.77 and 0.803), indicating good drug-like properties.
7. **DILI:** Ligand B (22.8) has a much lower DILI risk than Ligand A (43.234), a significant advantage.
8. **BBB:** While not a primary concern for a cardiovascular target, Ligand A (75.572) has a higher BBB percentile than Ligand B (57.736). This is a minor point in this case.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.595 and -4.765). This is unusual and suggests poor permeability *in vitro*. However, the values are similar, so it doesn't differentiate the ligands.
10. **Solubility:** Ligand B (-1.861) has slightly better (less negative) solubility than Ligand A (-2.485).
11. **hERG:** Both ligands have very low hERG inhibition risk (0.261 and 0.222).
12. **Cl_mic:** Ligand B (-1.533) has a *much* lower (better) microsomal clearance than Ligand A (33.281). This suggests significantly improved metabolic stability.
13. **t1/2:** Ligand B (8.672) has a better *in vitro* half-life than Ligand A (-38.058). This is a substantial advantage.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.028 and 0.03).
15. **Binding Affinity:** Ligand A (-6.1 kcal/mol) has a slightly better binding affinity than Ligand B (-5.4 kcal/mol). This is a 0.7 kcal/mol difference, which is not a huge advantage, especially considering the other factors.
**Overall Assessment:**
Ligand B consistently outperforms Ligand A in crucial ADME properties: DILI risk, metabolic stability (Cl_mic), and *in vitro* half-life. It also has better TPSA, HBD/HBA counts, and solubility. While Ligand A has a slightly better binding affinity, the improvements in ADME for Ligand B are more compelling for overall drug development potential. For a GPCR, balancing affinity with good ADME properties is crucial, and Ligand B strikes a better balance.
Output:
0
2025-04-17 19:51:15,434 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (334.379 and 349.431 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (86.88) is significantly better than Ligand B (114.43). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (1.562 and 1.395), falling within the 1-3 optimal range. Similar.
4. **HBD:** Both ligands have 3 H-bond donors, which is acceptable. Similar.
5. **HBA:** Ligand A has 3 H-bond acceptors, while Ligand B has 4. Ligand A is slightly better.
6. **QED:** Both ligands have good QED scores (0.553 and 0.658), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (62.389) has a higher DILI risk than Ligand B (40.403). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (49.67) has lower BBB penetration than Ligand B (65.297). While not crucial for a cardiovascular target, higher BBB is generally a positive attribute.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.017 and -5.216). These values are unusual and suggest poor permeability. However, the values are similar.
10. **Solubility:** Both ligands have poor aqueous solubility (-3.712 and -3.371). Solubility is a concern for both.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.074 and 0.136). Excellent for both.
12. **Cl_mic:** Ligand A (-1.849) has a much lower (better) microsomal clearance than Ligand B (30.491). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (-14.044) has a much longer in vitro half-life than Ligand B (3.405). This is a significant advantage for Ligand A.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.022 and 0.038). Excellent for both.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.4 and -6.2 kcal/mol). The difference is negligible.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, and affinity are important. Both ligands perform similarly on logP and affinity. Ligand A has a significantly better TPSA. Metabolic stability (Cl_mic and t1/2) is also important, and Ligand A is far superior in these aspects. DILI risk is a critical factor, and Ligand B has a lower risk.
**Overall Assessment:**
While Ligand B has a lower DILI risk, Ligand A's superior metabolic stability (lower Cl_mic, longer t1/2) and better TPSA outweigh this advantage. The similar binding affinities make the ADME properties the deciding factors. The poor solubility and Caco-2 values are concerning for both, but can potentially be addressed with formulation strategies.
Output:
1
2025-04-17 19:51:15,434 - INFO - Batch 141 complete. Total preferences: 2256
2025-04-17 19:51:15,434 - INFO - Processing batch 142/512...
2025-04-17 19:52:03,181 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (388.6 and 359.5 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (58.64) is slightly higher than Ligand B (49.77). Both are below the 140 A^2 threshold for good oral absorption, but Ligand B is closer to the preferred <90 A^2 for GPCRs, giving it a slight edge.
**3. logP:** Both ligands have good logP values (2.88 and 3.76), falling within the optimal 1-3 range. Ligand B is a bit higher, which could potentially lead to slight solubility issues, but is still acceptable.
**4. H-Bond Donors:** Both have 1 HBD, which is within the acceptable limit of <=5.
**5. H-Bond Acceptors:** Ligand A has 5 HBAs, and Ligand B has 4. Both are below the limit of <=10.
**6. QED:** Both ligands have very similar QED values (0.693 and 0.694), indicating good drug-likeness.
**7. DILI Risk:** Ligand A (49.17%) has a slightly higher DILI risk than Ligand B (44.44%), but both are below the concerning 60% threshold.
**8. BBB Penetration:** Ligand B (73.13%) shows significantly better BBB penetration than Ligand A (62.47%). While ADRB2 is primarily a cardiovascular target, some CNS effects are possible with beta-blockers, and better BBB penetration could be beneficial or detrimental depending on the desired effect profile. For a cardiovascular target, this isn't a *major* priority, but it's a positive for Ligand B.
**9. Caco-2 Permeability:** Ligand A (-5.074) and Ligand B (-4.697) both have negative Caco-2 values, which is unusual and suggests poor permeability. This is a significant concern for both, but is slightly better for Ligand B.
**10. Aqueous Solubility:** Ligand A (-3.52) and Ligand B (-4.348) both have very poor aqueous solubility. This is a major drawback for both compounds and would require formulation strategies to improve bioavailability. Ligand B is slightly better.
**11. hERG Inhibition:** Ligand A (0.223) has a lower hERG inhibition risk than Ligand B (0.794), which is a crucial advantage. Cardiovascular drugs *must* have low hERG liability.
**12. Microsomal Clearance:** Ligand B (107.153) has a much higher microsomal clearance than Ligand A (87.748), indicating faster metabolism and potentially lower *in vivo* exposure. This is a significant negative for Ligand B.
**13. In Vitro Half-Life:** Ligand B (67.744 hours) has a much longer in vitro half-life than Ligand A (-3.041 hours). This is a strong positive for Ligand B.
**14. P-gp Efflux:** Ligand A (0.209) has lower P-gp efflux than Ligand B (0.832), which is favorable for bioavailability.
**15. Binding Affinity:** Ligand B (-8.0 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.6 kcal/mol). This >1.5 kcal/mol difference in affinity is a major advantage, potentially outweighing some of the ADME drawbacks.
**Overall Assessment:**
Ligand B has a substantially better binding affinity and a longer half-life. While it has some ADME liabilities (higher logP, higher P-gp efflux, higher hERG, and higher clearance), the strong affinity and longer half-life are critical for a GPCR target. Ligand A's lower hERG risk is attractive, but the weaker binding affinity is a major drawback. The solubility issues are concerning for both, but can be addressed with formulation.
Therefore, I favor Ligand B.
0
2025-04-17 19:52:03,181 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.463 and 348.359 Da) fall comfortably within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (87.46) is significantly better than Ligand B (128.53). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have acceptable logP values (0.643 and 0.546), falling within the 1-3 range. Ligand A is slightly better.
4. **HBD:** Ligand A (2) is preferable to Ligand B (3). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (6). Lower HBA generally improves permeability.
6. **QED:** Both ligands have similar QED scores (0.674 and 0.67), indicating good drug-likeness.
7. **DILI:** Ligand B (50.136) has a slightly higher DILI risk than Ligand A (18.224), though both are below the concerning threshold of 60. A lower DILI risk is always preferred.
8. **BBB:** Ligand A (49.826) has a higher BBB penetration score than Ligand B (19.542). While not a primary concern for a cardiovascular target, higher BBB is generally favorable, indicating better distribution.
9. **Caco-2:** Ligand A (-5.02) and Ligand B (-5.503) are both very poor. This is a significant drawback for both.
10. **Solubility:** Ligand A (-0.978) is better than Ligand B (-1.623), indicating better aqueous solubility.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.167 and 0.133), which is excellent.
12. **Cl_mic:** Ligand B (-0.505) has a *much* lower (better) microsomal clearance than Ligand A (21.582). This suggests significantly improved metabolic stability for Ligand B.
13. **t1/2:** Ligand B (-34.157) has a *much* longer in vitro half-life than Ligand A (5.169). This is a major advantage for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.029 and 0.032).
15. **Binding Affinity:** Ligand A (-5.8 kcal/mol) has a better binding affinity than Ligand B (-4.3 kcal/mol). This is a substantial difference (1.5 kcal/mol), and a strong binding affinity is a critical factor.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A performs better on logP, TPSA, and significantly better on affinity. However, Ligand B has a much better metabolic profile (Cl_mic and t1/2).
**Overall Assessment:**
The affinity difference is substantial. While Ligand B has a superior metabolic profile, the strong binding affinity of Ligand A is a significant advantage, especially for a GPCR target. The slightly better solubility and lower DILI risk of Ligand A are also beneficial. The poor Caco-2 values are concerning for both, but can be addressed in formulation. The stronger binding of Ligand A is likely to be more impactful than the improved metabolic stability of Ligand B.
Output:
1
2025-04-17 19:52:03,181 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (342.46 and 360.57 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (33.29) is significantly better than Ligand B (44.1). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand A is well below the 140 threshold, while Ligand B is approaching it.
**3. logP:** Both ligands have similar logP values (4.308 and 4.811), both slightly above the optimal 1-3 range, but not excessively high. Ligand B is a bit higher, potentially increasing off-target interactions.
**4. H-Bond Donors:** Ligand A has 2 HBD, while Ligand B has 0. Both are acceptable, but having some HBD can improve solubility.
**5. H-Bond Acceptors:** Both ligands have 3 HBA, which is within the acceptable range.
**6. QED:** Ligand A (0.702) has a much better QED score than Ligand B (0.438). This indicates Ligand A is more "drug-like" overall.
**7. DILI Risk:** Ligand A (27.1%) has a significantly lower DILI risk than Ligand B (10.9%). This is a crucial advantage, as liver toxicity is a major concern in drug development.
**8. BBB Penetration:** Both ligands have reasonably good BBB penetration (78.5% and 83.2%). Since ADRB2 is a cardiovascular target, BBB penetration is not a primary concern, but it's still a positive attribute.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.758 and -4.798), indicating poor permeability. This is a significant drawback for both.
**10. Aqueous Solubility:** Both ligands have negative solubility values (-3.484 and -4.957), indicating poor solubility. This is a concern for bioavailability.
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (0.979 and 0.842), which is excellent.
**12. Microsomal Clearance:** Ligand A (52.126) has a lower microsomal clearance than Ligand B (119.85), suggesting better metabolic stability.
**13. In vitro Half-Life:** Ligand A (16.665) has a longer half-life than Ligand B (-12.708). This is a significant advantage, potentially allowing for less frequent dosing.
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (0.773 and 0.599), which is good.
**15. Binding Affinity:** Ligand B (-6.9 kcal/mol) has a slightly better binding affinity than Ligand A (-6.6 kcal/mol), but the difference is not substantial enough to outweigh the other factors.
**Overall Assessment:**
Ligand A is the stronger candidate. It has a significantly better QED score, lower DILI risk, better metabolic stability (lower Cl_mic, longer t1/2), and a more favorable TPSA. While both have poor Caco-2 permeability and solubility, Ligand A's other advantages outweigh the slightly better affinity of Ligand B. The lower DILI risk is particularly important.
Output:
1
2025-04-17 19:52:03,181 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (354.382 and 358.467 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (104.65) is higher than Ligand B (78.09). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for better permeability. Ligand B has a clear advantage.
**3. logP:** Ligand A (-0.283) is quite low, potentially hindering membrane permeability. Ligand B (2.088) is within the optimal 1-3 range. This is a significant advantage for Ligand B.
**4. H-Bond Donors:** Both have 2 HBD, which is acceptable.
**5. H-Bond Acceptors:** Ligand A has 6 HBA, while Ligand B has 4. Both are within the acceptable limit of 10, but lower is generally better. Ligand B is slightly favored.
**6. QED:** Both ligands have good QED scores (0.698 and 0.878), indicating good drug-like properties. Ligand B is slightly better.
**7. DILI Risk:** Both ligands have DILI risk around the 50-60 percentile, which is acceptable, but not ideal. No clear advantage.
**8. BBB Penetration:** Ligand A (70.027) shows better BBB penetration than Ligand B (50.523). However, since ADRB2 is primarily a cardiovascular target, BBB penetration is less crucial.
**9. Caco-2 Permeability:** Ligand A (-4.883) has poor Caco-2 permeability, while Ligand B (-5.306) is also poor. Both are unfavorable.
**10. Aqueous Solubility:** Ligand A (-0.881) has slightly better solubility than Ligand B (-3.228). Solubility is important, but can often be addressed through formulation.
**11. hERG Inhibition:** Ligand A (0.157) has a slightly lower hERG risk than Ligand B (0.322). This is a positive for Ligand A, as hERG inhibition can lead to cardiotoxicity.
**12. Microsomal Clearance:** Ligand A (-6.348) has significantly lower (better) microsomal clearance than Ligand B (14.153), indicating greater metabolic stability. This is a major advantage for Ligand A.
**13. In vitro Half-Life:** Ligand A (12.789 hours) has a longer half-life than Ligand B (-19.872 hours). This is a significant advantage for Ligand A, potentially allowing for less frequent dosing.
**14. P-gp Efflux:** Ligand A (0.029) has very low P-gp efflux, while Ligand B (0.102) is slightly higher. Lower efflux is preferred for better bioavailability. Ligand A is favored.
**15. Binding Affinity:** Ligand A (-6.5 kcal/mol) has a slightly better binding affinity than Ligand B (-3.3 kcal/mol). This is a substantial advantage, as a difference of >1.5 kcal/mol can outweigh minor ADME drawbacks.
**Overall Assessment:**
While Ligand A has a slightly lower logP and Caco-2 permeability, its significantly better binding affinity, metabolic stability (lower Cl_mic), longer half-life, lower P-gp efflux, and slightly better hERG profile outweigh these drawbacks. Ligand B has better TPSA and QED, but the affinity difference is too large to ignore. For a cardiovascular GPCR, metabolic stability and potency are key.
Output:
1
2025-04-17 19:52:03,182 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [351.403, 91.34, 0.767, 2, 5, 0.818, 66.731, 54.866, -4.632, -0.705, 0.214, -19.076, -17.49, 0.018, -6.6]
**Ligand B:** [371.503, 62.32, -0.076, 0, 6, 0.417, 22.8, 65.607, -4.794, -0.937, 0.485, 43.493, -18.714, 0.021, -6.3]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (351.4) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (91.34) is higher than Ligand B (62.32). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is still preferred for better absorption. Ligand B is significantly better here.
3. **logP:** Ligand A (0.767) is within the optimal range, but on the lower side. Ligand B (-0.076) is slightly below 1, which could indicate permeability issues.
4. **HBD:** Ligand A (2) is good. Ligand B (0) is also acceptable.
5. **HBA:** Ligand A (5) is good. Ligand B (6) is also acceptable.
6. **QED:** Ligand A (0.818) is excellent, indicating a very drug-like profile. Ligand B (0.417) is below the 0.5 threshold, suggesting potential issues.
7. **DILI:** Ligand A (66.731) is higher than Ligand B (22.8). Ligand B is significantly better in terms of liver toxicity risk.
8. **BBB:** Both are reasonably high (A: 54.866, B: 65.607), but not a primary concern for a cardiovascular target. Ligand B is slightly better.
9. **Caco-2:** Both are negative, indicating poor permeability.
10. **Solubility:** Both are negative, indicating poor solubility.
11. **hERG:** Both are very low (A: 0.214, B: 0.485), indicating a low risk of cardiotoxicity.
12. **Cl_mic:** Ligand A (-19.076) has a much lower (better) microsomal clearance than Ligand B (43.493), suggesting better metabolic stability.
13. **t1/2:** Both are negative, indicating short half-lives. Ligand B (-18.714) is slightly better.
14. **Pgp:** Both are very low (A: 0.018, B: 0.021), indicating minimal P-gp efflux.
15. **Affinity:** Both have similar binding affinities (-6.6 and -6.3 kcal/mol).
**GPCR-Specific Priorities:**
For ADRB2 (a cardiovascular GPCR), we prioritize logP, TPSA, Pgp, and affinity. While BBB isn't crucial, it's still a consideration.
**Overall Assessment:**
Ligand A has a better QED score and significantly better metabolic stability (lower Cl_mic). However, Ligand B has a lower TPSA and DILI risk. The binding affinities are comparable. The poor Caco-2 and solubility for both ligands are concerning, but can be addressed with formulation strategies. Given the importance of metabolic stability for *in vivo* efficacy, and the better overall drug-likeness profile (QED), I lean towards Ligand A.
Output:
1
2025-04-17 19:52:03,182 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (371.5 and 351.5 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand B (64.1) is significantly better than Ligand A (92.5). ADRB2 is a cardiovascular target, so BBB isn't paramount, but lower TPSA generally aids absorption.
3. **logP:** Ligand A (1.775) is preferable to Ligand B (0.795). Both are within the optimal 1-3 range, but Ligand A is closer to the middle, suggesting a better balance of solubility and permeability. Ligand B is a bit low, potentially hindering permeation.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1), but both are acceptable (<=5).
5. **HBA:** Both ligands have 4 HBA, which is well within the acceptable range (<=10).
6. **QED:** Ligand B (0.799) has a better QED score than Ligand A (0.573), indicating a more drug-like profile.
7. **DILI:** Ligand B (4.7) has a much lower DILI risk than Ligand A (12.2). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (65.4) has a slightly better BBB penetration than Ligand B (55.5), but this is less critical for a cardiovascular target.
9. **Caco-2:** Ligand A (-5.486) has a better Caco-2 permeability than Ligand B (-4.755).
10. **Solubility:** Ligand B (-0.193) has a better solubility than Ligand A (-2.645).
11. **hERG:** Both ligands have very similar hERG inhibition liability (0.344 and 0.341). This isn't a differentiating factor.
12. **Cl_mic:** Ligand B (-19.2) has a significantly lower microsomal clearance than Ligand A (30.4). This suggests better metabolic stability for Ligand B.
13. **t1/2:** Ligand B (2.879) has a slightly better in vitro half-life than Ligand A (-18.099).
14. **Pgp:** Both ligands have very similar Pgp efflux liability (0.042 and 0.019).
15. **Binding Affinity:** Both ligands have very similar binding affinities (-5.7 and -4.9 kcal/mol). The difference of 0.8 kcal/mol is not substantial enough to outweigh other factors.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, and affinity are important. Ligand A has a better logP and Caco-2, but Ligand B has a much better TPSA, DILI, Cl_mic, solubility, and QED. The affinity difference is minimal.
**Overall Assessment:**
Ligand B is the more promising candidate. While Ligand A has slightly better Caco-2 permeability and logP, Ligand B's significantly lower DILI risk, improved metabolic stability (lower Cl_mic), better solubility, and higher QED score are more important considerations. The TPSA is also more favorable. The slight difference in binding affinity is not enough to overcome these advantages.
Output:
0
2025-04-17 19:52:03,182 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Step-by-step comparison:**
1. **MW:** Both ligands (350.415 and 367.406 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (103.01) is better than Ligand B (113.48). Both are under the 140 threshold for oral absorption, but lower is preferred for GPCRs.
3. **logP:** Ligand A (0.912) is better than Ligand B (0.066). Ligand B is quite low, potentially causing permeability issues. ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but good permeability is still vital.
4. **HBD:** Both ligands have 3 H-bond donors, which is acceptable.
5. **HBA:** Ligand A (5) is better than Ligand B (7). Lower HBA is generally preferred for better permeability.
6. **QED:** Both ligands have similar QED values (0.732 and 0.707), indicating good drug-likeness.
7. **DILI:** Ligand A (37.03) is significantly better than Ligand B (68.941). Lower DILI risk is crucial.
8. **BBB:** Both are moderate, but Ligand A (47.111) is lower than Ligand B (55.642). Since this is a cardiovascular target, BBB is not a major factor.
9. **Caco-2:** Ligand A (-4.939) is better than Ligand B (-5.377). Higher Caco-2 permeability is desirable.
10. **Solubility:** Ligand A (-1.61) is better than Ligand B (-2.431). Better solubility is always a plus.
11. **hERG:** Ligand A (0.151) is significantly better than Ligand B (0.409). Lower hERG inhibition is critical for avoiding cardiotoxicity, especially for a cardiovascular target.
12. **Cl_mic:** Ligand A (-4.217) is significantly better than Ligand B (-16.766). Lower clearance indicates better metabolic stability.
13. **t1/2:** Ligand B (12.125) is better than Ligand A (0.919). Longer half-life is generally preferred.
14. **Pgp:** Ligand A (0.046) is better than Ligand B (0.058). Lower P-gp efflux is preferred.
15. **Binding Affinity:** Ligand B (-7.0) is slightly better than Ligand A (-6.6). However, the difference is less than 1.5 kcal/mol and can be outweighed by other factors.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B in most crucial ADME-Tox properties, including DILI, hERG, metabolic stability (Cl_mic), solubility, and permeability (Caco-2). While Ligand B has a slightly better binding affinity, the significant advantages of Ligand A in safety and pharmacokinetic parameters make it the more promising drug candidate. The slightly longer half-life of Ligand B is a benefit, but not enough to overcome the other drawbacks.
**Output:**
1
2025-04-17 19:52:03,182 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [403.32 , 41.57 , 4.628, 1. , 3. , 0.792, 58.666, 75.107, -4.762, -4.497, 0.873, 104.797, 78.603, 0.846, -6. ]
**Ligand B:** [345.443, 62.74 , 1.947, 0. , 4. , 0.584, 21.946, 63.784, -3.916, -1.885, 0.192, 74.57 , -15.945, 0.024, -5.2 ]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, Affinity, and BBB):
1. **MW:** Ligand B (345.443 Da) is better, falling nicely within the 200-500 range and closer to the optimal lower end. Ligand A (403.32 Da) is still acceptable, but slightly higher.
2. **TPSA:** Ligand A (41.57) is significantly better than Ligand B (62.74). ADRB2 is not a CNS target, but lower TPSA generally aids absorption.
3. **logP:** Ligand A (4.628) is a bit high, potentially leading to off-target effects and solubility issues. Ligand B (1.947) is almost ideal.
4. **HBD/HBA:** Ligand A (1 HBD, 3 HBA) is preferable to Ligand B (0 HBD, 4 HBA). Both are within acceptable limits.
5. **QED:** Ligand A (0.792) is better than Ligand B (0.584), indicating a more drug-like profile.
6. **DILI:** Ligand B (21.946) has a much lower DILI risk than Ligand A (58.666). This is a significant advantage for Ligand B.
7. **BBB:** Ligand A (75.107) has better BBB penetration, but this isn't critical for a cardiovascular target.
8. **Caco-2:** Ligand A (-4.762) is worse than Ligand B (-3.916), indicating lower intestinal absorption.
9. **Solubility:** Ligand A (-4.497) is worse than Ligand B (-1.885), which is concerning.
10. **hERG:** Ligand A (0.873) is slightly higher than Ligand B (0.192), indicating a slightly higher risk of cardiotoxicity.
11. **Cl_mic:** Ligand B (74.57) has lower microsomal clearance, suggesting better metabolic stability than Ligand A (104.797).
12. **t1/2:** Ligand A (78.603) has a much longer in vitro half-life than Ligand B (-15.945). This is a significant advantage for Ligand A.
13. **Pgp:** Ligand A (0.846) has a slightly lower P-gp efflux liability than Ligand B (0.024), which is good.
14. **Affinity:** Ligand A (-6.0) has a slightly better binding affinity than Ligand B (-5.2).
**Overall Assessment:**
Ligand B has a significantly better safety profile (lower DILI, lower hERG) and better ADME properties (logP, Cl_mic, solubility). While Ligand A has a slightly better affinity and half-life, the ADME and safety concerns with Ligand A are substantial. The difference in affinity (0.8 kcal/mol) is not large enough to overcome the other drawbacks. The slightly longer half-life of A is a benefit, but can be addressed through formulation or prodrug strategies.
Therefore, I would choose Ligand B.
0
2025-04-17 19:52:03,182 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (349.431 and 347.415 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (90.08) is better than Ligand B (111.55). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally improves absorption.
3. **logP:** Both ligands have good logP values (1.715 and 1.443), falling within the optimal 1-3 range. Ligand B is slightly lower, which could be a minor drawback.
4. **HBD:** Ligand A (2) is preferable to Ligand B (4). Fewer HBDs generally correlate with better membrane permeability.
5. **HBA:** Ligand A (6) is preferable to Ligand B (5). Similar to HBD, fewer HBAs are generally favored.
6. **QED:** Ligand A (0.6) is slightly better than Ligand B (0.532), indicating a more drug-like profile.
7. **DILI:** Ligand A (37.728) is significantly better than Ligand B (21.791). Lower DILI risk is *critical*. Ligand B's DILI percentile is concerningly low.
8. **BBB:** Ligand A (61.962) is better than Ligand B (23.808), but this isn't a high priority for a cardiovascular target.
9. **Caco-2:** Ligand A (-4.927) is better than Ligand B (-5.372). Both are negative, which is unusual and requires further investigation, but A is slightly better.
10. **Solubility:** Ligand A (-2.079) is better than Ligand B (-2.277). Both are poor, but A is slightly better.
11. **hERG:** Ligand A (0.838) is better than Ligand B (0.065). Lower hERG inhibition is crucial for avoiding cardiotoxicity, and Ligand B is concerningly low.
12. **Cl_mic:** Ligand B (9.326) is better than Ligand A (8.445). Lower clearance is preferred for metabolic stability.
13. **t1/2:** Ligand A (1.136) is better than Ligand B (-10.92). A positive half-life is much preferred to a negative one.
14. **Pgp:** Ligand A (0.325) is better than Ligand B (0.024). Lower P-gp efflux is desirable for improved bioavailability.
15. **Binding Affinity:** Ligand B (-6.3) is better than Ligand A (-8). A difference of 1.7 kcal/mol is significant.
**Overall Assessment:**
While Ligand B has a slightly better binding affinity, the significant concerns with its DILI risk, hERG inhibition, and negative in vitro half-life outweigh this benefit. Ligand A demonstrates a much more favorable safety profile (DILI, hERG) and better overall ADME properties (TPSA, HBD, HBA, QED, Pgp). The slightly lower binding affinity of Ligand A can likely be optimized in subsequent iterations of drug design. The cardiovascular context makes BBB less critical, and the other ADME properties of Ligand A are more balanced and promising.
Output:
1
2025-04-17 19:52:03,182 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
Let's analyze each ligand against the provided guidelines, keeping in mind ADRB2 is a GPCR, so logP, Pgp, TPSA, and affinity are key.
* **Molecular Weight:** Both ligands (363.483 and 348.447 Da) fall within the ideal 200-500 Da range.
* **TPSA:** Ligand A (72.48) is significantly better than Ligand B (98.32). A TPSA under 140 is good for oral absorption, and lower is generally preferred for GPCRs. Ligand A is much closer to the ideal range.
* **logP:** Ligand A (3.465) is optimal, while Ligand B (1.318) is on the lower side, potentially hindering permeability.
* **H-Bond Donors/Acceptors:** Ligand A (2 HBD, 5 HBA) is slightly better than Ligand B (3 HBD, 4 HBA), both are within acceptable limits.
* **QED:** Both ligands have reasonable QED scores (0.859 and 0.747), indicating good drug-like properties.
* **DILI:** Ligand A (54.478) has a higher DILI risk than Ligand B (33.191), but both are below the concerning threshold of 60.
* **BBB:** Ligand A (89.027) has significantly better BBB penetration potential than Ligand B (52.423). While ADRB2 isn't necessarily a CNS target, higher BBB is generally favorable.
* **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests a potential issue with the data or modeling. However, the values are close enough that this doesn't heavily sway the decision.
* **Solubility:** Ligand A (-4.08) has slightly better solubility than Ligand B (-2.544).
* **hERG:** Both ligands have low hERG inhibition risk (0.399 and 0.502).
* **Cl_mic:** Ligand B (3.329) has much lower microsomal clearance than Ligand A (40.012), indicating better metabolic stability. This is a significant advantage for Ligand B.
* **t1/2:** Ligand B (-38.318) has a significantly longer in vitro half-life than Ligand A (47.904). This is a major advantage for Ligand B.
* **Pgp:** Ligand A (0.147) has much lower P-gp efflux liability than Ligand B (0.036), which is desirable for better bioavailability.
* **Binding Affinity:** Ligand A (-6.8 kcal/mol) has a slightly better binding affinity than Ligand B (-6.4 kcal/mol). While the difference is not huge, it is still a factor.
**Overall Assessment:**
Ligand A excels in TPSA, logP, BBB penetration, and Pgp efflux, and has a slightly better binding affinity. However, Ligand B demonstrates superior metabolic stability (lower Cl_mic) and a significantly longer half-life, which are crucial for *in vivo* efficacy. The lower logP of Ligand B is a concern, but the substantial improvements in metabolic stability and half-life outweigh this drawback, especially for a GPCR target where sustained signaling is often important.
**Output:**
0
2025-04-17 19:52:03,182 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (359.423 and 357.376 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand B (55.32) is significantly better than Ligand A (106.2), falling well below the 140 threshold for good absorption and being more favorable for GPCRs.
3. **logP:** Ligand B (3.206) is within the optimal 1-3 range, while Ligand A (-1.236) is too low, potentially hindering membrane permeability. This is a significant advantage for Ligand B, especially for a GPCR target.
4. **HBD:** Ligand A (2) is preferable to Ligand B (0). While both are acceptable, some HBD can aid solubility.
5. **HBA:** Ligand B (4) is better than Ligand A (6). Fewer HBA generally leads to better permeability.
6. **QED:** Ligand B (0.703) is better than Ligand A (0.506), indicating a more drug-like profile.
7. **DILI:** Ligand B (47.732) has a lower DILI risk than Ligand A (19.426), which is a significant advantage.
8. **BBB:** Ligand B (85.111) is much better than Ligand A (49.826). While ADRB2 isn't strictly a CNS target, higher BBB penetration is rarely detrimental and can provide some off-target safety information.
9. **Caco-2:** Ligand B (-4.201) is better than Ligand A (-5.261), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-1.235) is better than Ligand B (-3.393). Solubility is important, but can be formulated around.
11. **hERG:** Ligand B (0.645) is better than Ligand A (0.072), indicating a lower risk of cardiotoxicity, a critical consideration for a cardiovascular target like ADRB2.
12. **Cl_mic:** Ligand A (10.286) has a lower microsomal clearance than Ligand B (65.447), suggesting better metabolic stability. This is a positive for Ligand A.
13. **t1/2:** Ligand B (-28.159) has a much longer in vitro half-life than Ligand A (-3.9). This is a substantial advantage for Ligand B.
14. **Pgp:** Ligand B (0.28) is better than Ligand A (0.002), indicating lower P-gp efflux.
15. **Affinity:** Ligand A (-6.6) has a slightly better binding affinity than Ligand B (-5.7). However, the difference is less than 1.5 kcal/mol, and can be overcome by other favorable properties.
**Overall Assessment:**
Ligand B demonstrates a significantly more favorable profile overall. It excels in key GPCR-relevant properties (TPSA, logP, BBB, Pgp) and has better ADME characteristics (DILI, t1/2, Caco-2, hERG). While Ligand A has slightly better affinity and metabolic stability, the substantial advantages of Ligand B in other crucial areas outweigh these minor drawbacks. The lower logP and higher TPSA of Ligand A are concerning for permeability.
**Output:**
0
2025-04-17 19:52:03,182 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (367.471 Da) is within the ideal range, while Ligand B (343.45 Da) is also good. No clear advantage here.
2. **TPSA:** Ligand A (121.52) is borderline acceptable for oral absorption, while Ligand B (55.63) is excellent. This favors Ligand B.
3. **logP:** Ligand A (0.406) is quite low, potentially hindering permeability. Ligand B (3.594) is within the optimal range. This strongly favors Ligand B.
4. **HBD:** Ligand A (4) is acceptable, Ligand B (1) is better. Favors Ligand B.
5. **HBA:** Both Ligand A (5) and Ligand B (5) are acceptable.
6. **QED:** Both Ligand A (0.614) and Ligand B (0.67) are good, indicating drug-likeness. No significant difference.
7. **DILI:** Both Ligand A (31.679) and Ligand B (36.448) have low DILI risk, below the 40% threshold. No significant difference.
8. **BBB:** Ligand A (36.603) has very low BBB penetration, while Ligand B (90.617) has excellent BBB penetration. Since ADRB2 is a GPCR, and while not exclusively a CNS target, increased BBB penetration can be beneficial for broader distribution and potentially accessing peripheral ADRB2 receptors. This strongly favors Ligand B.
9. **Caco-2:** Ligand A (-6.207) is poor, while Ligand B (-5.077) is also poor. Both are unfavorable.
10. **Solubility:** Ligand A (-1.126) is poor, while Ligand B (-3.62) is even worse. Both are unfavorable.
11. **hERG:** Ligand A (0.108) has a very low hERG risk, while Ligand B (0.599) is slightly higher but still acceptable. This favors Ligand A, but the difference isn't huge.
12. **Cl_mic:** Ligand A (-38.944) has a very low (good) microsomal clearance, indicating good metabolic stability. Ligand B (56.253) has a higher clearance, suggesting faster metabolism. This strongly favors Ligand A.
13. **t1/2:** Ligand A (7.494) has a reasonable half-life, while Ligand B (3.887) is shorter. This favors Ligand A.
14. **Pgp:** Ligand A (0.011) has very low P-gp efflux, while Ligand B (0.519) has higher efflux. This favors Ligand A.
15. **Affinity:** Ligand B (-6.8 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.8 kcal/mol). This is a substantial advantage.
**Overall Assessment:**
Ligand B has a clear advantage in terms of logP, TPSA, and crucially, binding affinity. The improved BBB penetration is also a plus for a GPCR target. However, Ligand A demonstrates superior metabolic stability (Cl_mic, t1/2) and lower P-gp efflux, and a better hERG profile. The solubility and Caco-2 values are poor for both.
The difference in binding affinity (-6.8 vs -5.8 kcal/mol) is significant (1.0 kcal/mol), and is likely to outweigh the ADME advantages of Ligand A. While Ligand A's metabolic stability is appealing, it can be addressed through structural modifications. The poor solubility of both compounds is a concern that would need to be addressed in formulation.
Therefore, I favor Ligand B.
Output:
0
2025-04-17 19:52:03,182 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (343.36 & 350.46 Da) fall comfortably within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (75.48) is better than Ligand B (84.5). Both are below 140, but lower TPSA generally favors absorption.
3. **logP:** Ligand A (3.217) is slightly higher than Ligand B (1.941), placing it more optimally within the 1-3 range. Ligand B is at the lower end, potentially causing permeability issues.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD is generally better for permeability.
5. **HBA:** Both ligands have 4 HBA, which is acceptable.
6. **QED:** Ligand A (0.686) has a better QED score than Ligand B (0.566), indicating a more drug-like profile.
7. **DILI:** Ligand B (33.773) has a significantly lower DILI risk than Ligand A (80.729). This is a major advantage for Ligand B.
8. **BBB:** Ligand A (77.898) shows better BBB penetration than Ligand B (46.84). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant, and higher BBB is generally favorable.
9. **Caco-2:** Both ligands have very poor Caco-2 permeability (-4.727 and -4.712). This is a significant concern for both.
10. **Solubility:** Ligand A (-4.7) has slightly worse solubility than Ligand B (-2.351), but both are poor.
11. **hERG:** Ligand A (0.805) has a higher hERG risk than Ligand B (0.096). This is a substantial advantage for Ligand B.
12. **Cl_mic:** Ligand B (52.021) has a higher microsomal clearance than Ligand A (47.249), suggesting faster metabolism and lower metabolic stability. Ligand A is preferable here.
13. **t1/2:** Ligand A (43.594) has a significantly longer in vitro half-life than Ligand B (-10.957). This is a major advantage for Ligand A.
14. **Pgp:** Ligand A (0.42) has lower P-gp efflux than Ligand B (0.037), which is preferable.
15. **Binding Affinity:** Ligand A (-9.4 kcal/mol) has a substantially stronger binding affinity than Ligand B (-3.8 kcal/mol). This is a very significant advantage for Ligand A.
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A is better in logP, TPSA, and Pgp. The difference in binding affinity is *massive* (-9.4 vs -3.8 kcal/mol). While Ligand B has a much better safety profile (DILI, hERG), the significantly stronger binding of Ligand A is likely to outweigh these concerns, especially during lead optimization where these safety liabilities can be addressed. The poor Caco-2 values for both are concerning, but can be improved through prodrug strategies or formulation.
**Conclusion:**
Despite the safety advantages of Ligand B, the superior binding affinity and better overall drug-like properties (QED, t1/2, Pgp) of Ligand A make it the more promising candidate for further development.
Output:
1
2025-04-17 19:52:03,182 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A: [413.268, 82.81, 2.049, 1, 7, 0.7, 75.572, 58.86, -5.116, -2.562, 0.45, 49.757, 70.821, 0.375, -6.3]**
**Ligand B: [365.503, 88.91, 1.212, 2, 6, 0.687, 51.803, 54.44, -5.864, -2.236, 0.169, 32.304, 11.434, 0.025, -6.8]**
Here's a breakdown, considering the guidelines and GPCR priorities (logP, Pgp, TPSA, affinity):
1. **MW:** Ligand A (413.268 Da) is within the ideal range, while Ligand B (365.503 Da) is slightly below, but still acceptable.
2. **TPSA:** Both ligands (A: 82.81, B: 88.91) are below the 140 threshold for oral absorption, which is good.
3. **logP:** Ligand A (2.049) is optimal, while Ligand B (1.212) is a bit low, potentially impacting permeability.
4. **HBD/HBA:** Ligand A (1 HBD, 7 HBA) is better than Ligand B (2 HBD, 6 HBA) in terms of balancing solubility and permeability.
5. **QED:** Both are acceptable (A: 0.7, B: 0.687), indicating reasonable drug-likeness.
6. **DILI:** Ligand A (75.572) has a higher DILI risk than Ligand B (51.803), which is a concern.
7. **BBB:** Both have relatively low BBB penetration (A: 58.86, B: 54.44), which isn't critical for a cardiovascular target, but not ideal.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability.
9. **Solubility:** Both have negative solubility values, also unusual.
10. **hERG:** Both have low hERG risk (A: 0.45, B: 0.169), which is good.
11. **Cl_mic:** Ligand B (32.304) has a significantly lower microsomal clearance than Ligand A (49.757), suggesting better metabolic stability.
12. **t1/2:** Ligand A (70.821) has a much longer in vitro half-life than Ligand B (11.434), which is a significant advantage.
13. **Pgp:** Both have low Pgp efflux (A: 0.375, B: 0.025), which is favorable.
14. **Affinity:** Ligand B (-6.8 kcal/mol) has a slightly better binding affinity than Ligand A (-6.3 kcal/mol). This 0.5 kcal/mol difference is significant.
**Overall Assessment:**
Ligand B has a better binding affinity, lower DILI risk, and better metabolic stability. However, Ligand A has a better logP and longer half-life. The slightly better affinity of Ligand B, coupled with the lower DILI risk, outweighs the advantages of Ligand A, especially considering the negative Caco-2 and solubility values for both. While the half-life of A is better, the affinity difference is more critical for initial potency and efficacy.
Output:
0
2025-04-17 19:52:03,183 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (a cardiovascular GPCR) drug candidates.
**Ligand A:** [346.402, 58.64, 2.766, 1, 3, 0.806, 44.048, 73.129, -4.406, -3.239, 0.601, 35.557, -15.902, 0.207, -6.5]
**Ligand B:** [350.463, 87.46, 1.315, 2, 5, 0.74, 32.183, 63.048, -4.878, -2.021, 0.211, 47.027, -6.263, 0.133, -6.9]
Here's a breakdown, prioritizing GPCR-relevant properties:
1. **Molecular Weight:** Both are within the ideal 200-500 Da range. A is 346.4, B is 350.5 - very similar.
2. **TPSA:** Ligand A (58.64) is significantly better than Ligand B (87.46). GPCRs benefit from lower TPSA for permeability.
3. **logP:** Ligand A (2.766) is optimal, while Ligand B (1.315) is a bit low, potentially hindering membrane permeability.
4. **H-Bond Donors/Acceptors:** A (1/3) is preferable to B (2/5). Lower counts generally improve permeability.
5. **QED:** Both are reasonable (A: 0.806, B: 0.74), indicating good drug-like properties. A is slightly better.
6. **DILI:** Both have acceptable DILI risk (A: 44.05, B: 32.18). B is slightly better here.
7. **BBB:** Ligand A (73.13) is significantly better than Ligand B (63.05). While not a CNS target, some distribution into the CNS can sometimes occur, and higher BBB is generally favorable.
8. **Caco-2:** Both are negative, indicating poor permeability. A (-4.406) is slightly better than B (-4.878).
9. **Solubility:** Both are negative, indicating poor solubility. A (-3.239) is slightly better than B (-2.021).
10. **hERG:** Both are very low (A: 0.601, B: 0.211), indicating a low risk of cardiotoxicity, which is crucial for a cardiovascular target. B is slightly better.
11. **Cl_mic:** Ligand A (35.56) has lower clearance than Ligand B (47.03), suggesting better metabolic stability.
12. **t1/2:** Ligand A (-15.90) has a longer half-life than Ligand B (-6.26), which is a positive.
13. **Pgp:** Both are very low (A: 0.207, B: 0.133), indicating minimal P-glycoprotein efflux.
14. **Binding Affinity:** Ligand B (-6.9) has a slightly better binding affinity than Ligand A (-6.5), a 0.4 kcal/mol difference.
**Overall Assessment:**
While Ligand B has a slightly better binding affinity and lower hERG, Ligand A is significantly better in several key areas for a GPCR: TPSA, logP, BBB, metabolic stability (Cl_mic), and half-life. The difference in binding affinity (0.4 kcal/mol) is not substantial enough to outweigh the advantages of Ligand A, especially considering the importance of permeability and metabolic stability for GPCR targets. The slightly better solubility of A is also a benefit.
Therefore, I favor Ligand A.
Output:
1
2025-04-17 19:52:03,183 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (352.431 Da and 346.435 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (88.1) is better than Ligand B (101.8). For a GPCR, keeping TPSA lower is beneficial for permeability. Ligand A is comfortably below the 140 threshold.
**3. logP:** Ligand B (0.821) is slightly better than Ligand A (-0.223). While both are within acceptable ranges, a logP closer to 1-3 is preferred. Ligand A is a little low, potentially hindering membrane permeability.
**4. H-Bond Donors:** Both ligands have 2 HBD, which is good.
**5. H-Bond Acceptors:** Ligand B has 6 HBA, slightly higher than Ligand A's 5. Both are within the acceptable limit of 10.
**6. QED:** Both ligands have good QED values (0.619 and 0.712), indicating good drug-like properties.
**7. DILI:** Ligand A (25.553) has a significantly lower DILI risk than Ligand B (48.119). This is a major advantage for Ligand A.
**8. BBB:** Ligand B (71.268) has a much higher BBB penetration percentile than Ligand A (29.003). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant, and higher BBB is generally desirable.
**9. Caco-2 Permeability:** Ligand A (-4.661) has better Caco-2 permeability than Ligand B (-5.523).
**10. Aqueous Solubility:** Ligand A (-1.698) has slightly better solubility than Ligand B (-2.136).
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.157 and 0.022).
**12. Microsomal Clearance:** Ligand A (-0.067) has significantly lower microsomal clearance than Ligand B (24.077), indicating better metabolic stability.
**13. In vitro Half-Life:** Ligand A (-3.08) has a longer in vitro half-life than Ligand B (1.311).
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.067 and 0.078).
**15. Binding Affinity:** Ligand B (-6.6 kcal/mol) has a slightly better binding affinity than Ligand A (-5.5 kcal/mol). This is a 1.1 kcal/mol difference, which is substantial.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), and the general drug-like properties, Ligand B's superior binding affinity and BBB penetration are attractive. However, Ligand A has a much better safety profile (DILI) and metabolic stability (Cl_mic, t1/2), and better Caco-2 permeability. The difference in binding affinity (1.1 kcal/mol) is significant, but can potentially be optimized in later stages of drug development. The lower DILI risk and improved metabolic stability of Ligand A are more critical for overall drug viability, especially in the context of a cardiovascular target where long-term safety is paramount.
Therefore, I prefer Ligand A.
Output:
1
2025-04-17 19:52:03,183 - INFO - Batch 142 complete. Total preferences: 2272
2025-04-17 19:52:03,183 - INFO - Processing batch 143/512...
2025-04-17 19:52:52,032 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.487 and 366.531 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands have similar TPSA values (58.64 and 58.44), well below the 140 A^2 threshold for good oral absorption. This is favorable for both.
3. **logP:** Both ligands have logP values within the optimal range (2.511 and 2.006). Ligand B is slightly lower, which *could* be marginally better for solubility, but both are acceptable.
4. **HBD:** Ligand A has 1 HBD, and Ligand B has 0. Both are within the acceptable limit of <=5.
5. **HBA:** Ligand A has 3 HBA, and Ligand B has 5. Both are within the acceptable limit of <=10.
6. **QED:** Ligand B (0.741) has a slightly higher QED score than Ligand A (0.542), suggesting a more drug-like profile. This is a small advantage for Ligand B.
7. **DILI:** Both ligands have relatively low DILI risk (10.896 and 11.981 percentile). No major concern for either.
8. **BBB:** Both ligands have identical BBB penetration (72.78 percentile). This is good, but not exceptional.
9. **Caco-2:** Ligand A (-4.591) has a better Caco-2 permeability than Ligand B (-5.02). This suggests better intestinal absorption for Ligand A.
10. **Solubility:** Ligand A (-2.434) has better aqueous solubility than Ligand B (-1.423). This is a positive for Ligand A.
11. **hERG:** Both ligands have low hERG inhibition liability (0.352 and 0.513). No significant cardiotoxicity risk for either.
12. **Cl_mic:** Both ligands have similar microsomal clearance (56.807 and 57.215 mL/min/kg), suggesting similar metabolic stability.
13. **t1/2:** Ligand B (-11.276) has a longer in vitro half-life than Ligand A (-10.498). This is a slight advantage for Ligand B.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.25 and 0.071). Ligand B is slightly better.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.3 and -6.4 kcal/mol). The difference is negligible.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Both ligands perform well on these metrics. Solubility is also important for formulation. Ligand A has a slight edge in solubility and Caco-2 permeability. Ligand B has a slightly better QED and Pgp efflux.
**Overall Assessment:**
The differences between the two ligands are subtle. Ligand A has a slight advantage in solubility and intestinal absorption (Caco-2), which are important for oral bioavailability. Ligand B has a slightly better QED and Pgp efflux, and a marginally longer half-life. Given the very similar binding affinities and acceptable profiles across most parameters, the better solubility and absorption of Ligand A are slightly more compelling for initial development.
Output:
1
2025-04-17 19:52:52,032 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.409 Da and 349.435 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (32.78) is excellent, well below the 140 threshold and very favorable for oral absorption. Ligand B (90.7) is higher, but still potentially acceptable, though less ideal.
3. **logP:** Ligand A (2.392) is optimal (1-3). Ligand B (-0.486) is below 1, which is a concern for permeability.
4. **HBD:** Ligand A (0) is good. Ligand B (2) is acceptable.
5. **HBA:** Ligand A (3) is good. Ligand B (6) is higher, but still within the acceptable range of 10.
6. **QED:** Both ligands have good QED scores (0.839 and 0.766), indicating good drug-like properties.
7. **DILI:** Ligand A (8.763) has a very low DILI risk. Ligand B (27.142) is still relatively low, but higher than A.
8. **BBB:** Ligand A (91.508) has excellent BBB penetration, which is a plus for GPCRs. Ligand B (26.134) is poor.
9. **Caco-2:** Ligand A (-4.264) is negative, indicating good permeability. Ligand B (-5.188) is also negative, indicating good permeability.
10. **Solubility:** Ligand A (-1.602) is negative, indicating good solubility. Ligand B (-0.917) is also negative, indicating good solubility.
11. **hERG:** Both ligands have low hERG risk (0.675 and 0.257).
12. **Cl_mic:** Ligand A (12.539) has a moderate clearance. Ligand B (-1.528) has a negative clearance, which is excellent (indicating high metabolic stability).
13. **t1/2:** Ligand A (-4.906) has a negative half-life, indicating a long half-life. Ligand B (4.527) has a shorter half-life.
14. **Pgp:** Both ligands have low Pgp efflux (0.049 and 0.022).
15. **Binding Affinity:** Ligand A (-6.2) has a slightly better binding affinity than Ligand B (-3.6). This is a significant difference.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are crucial. Ligand A excels in logP, TPSA, and affinity. Ligand B's lower logP is a significant drawback. While Ligand B has better metabolic stability (Cl_mic), the superior affinity and permeability of Ligand A, combined with its excellent BBB penetration, outweigh this benefit.
**Conclusion:**
Ligand A is the more promising candidate due to its better balance of properties, particularly its optimal logP, TPSA, excellent BBB penetration, and superior binding affinity.
Output:
1
2025-04-17 19:52:52,034 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 drug candidates. ADRB2 is a GPCR, so we'll prioritize logP, Pgp, TPSA, and affinity, alongside general drug-like properties.
**Ligand A:**
* **MW:** 342.399 Da - Good, within the ideal range.
* **TPSA:** 78.15 - Good, below the 140 threshold for oral absorption.
* **logP:** 0.941 - Acceptable, but on the lower side. Could potentially impact permeability.
* **HBD:** 1 - Good.
* **HBA:** 6 - Good.
* **QED:** 0.897 - Excellent, very drug-like.
* **DILI:** 62.815 - Moderate risk, but manageable.
* **BBB:** 73.711 - Good, suggesting reasonable potential for some CNS penetration, although ADRB2 is primarily cardiovascular.
* **Caco-2:** -5.253 - Very poor permeability. A major concern.
* **Solubility:** -2.618 - Poor solubility. Another significant issue.
* **hERG:** 0.104 - Very low risk, excellent.
* **Cl_mic:** 40.719 - Moderate clearance.
* **t1/2:** 4.603 - Moderate half-life.
* **Pgp:** 0.303 - Low efflux, good.
* **Affinity:** -6.4 kcal/mol - Good binding affinity.
**Ligand B:**
* **MW:** 344.371 Da - Good, within the ideal range.
* **TPSA:** 127.17 - Acceptable, but approaching the upper limit for good absorption.
* **logP:** 1.141 - Acceptable, similar to Ligand A.
* **HBD:** 3 - Good.
* **HBA:** 5 - Good.
* **QED:** 0.554 - Acceptable, but lower than Ligand A.
* **DILI:** 75.378 - Higher DILI risk than Ligand A.
* **BBB:** 46.219 - Lower BBB penetration than Ligand A.
* **Caco-2:** -5.154 - Very poor permeability, similar to Ligand A.
* **Solubility:** -4.124 - Very poor solubility, worse than Ligand A.
* **hERG:** 0.185 - Low risk, acceptable.
* **Cl_mic:** 42.222 - Moderate clearance, similar to Ligand A.
* **t1/2:** -31.561 - Very short half-life, a significant drawback.
* **Pgp:** 0.045 - Very low efflux, excellent.
* **Affinity:** -6.7 kcal/mol - Slightly better binding affinity than Ligand A.
**Comparison and Decision:**
Both ligands suffer from very poor Caco-2 permeability and solubility. However, Ligand A has a significantly better QED score, lower DILI risk, and a better BBB score. While Ligand B has a slightly better binding affinity (-6.7 vs -6.4 kcal/mol), the difference isn't large enough to overcome the other significant drawbacks. The short half-life of Ligand B is also a major concern.
Given the importance of absorption and the overall better ADME profile of Ligand A, I would choose Ligand A as the more promising candidate, despite its lower logP and permeability issues. These could potentially be addressed through further optimization, but the more favorable starting point of Ligand A makes it the better choice.
Output:
1
2025-04-17 19:52:52,034 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (345.407 and 348.399 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand B (93.73) is significantly better than Ligand A (138.68). For a GPCR, lower TPSA is generally preferred for better permeability, and B is well below the 140 threshold.
**3. logP:** Ligand B (1.619) is better than Ligand A (0.65). Both are within the optimal 1-3 range, but A is on the lower side, potentially impacting permeability.
**4. H-Bond Donors:** Ligand A (4) is slightly higher than Ligand B (2). Both are acceptable, but B is preferable.
**5. H-Bond Acceptors:** Ligand A (6) is slightly higher than Ligand B (5). Both are acceptable, but B is preferable.
**6. QED:** Both ligands have similar QED values (0.581 and 0.577), indicating good drug-likeness.
**7. DILI:** Both ligands have similar DILI risk (63.746 and 62.35), indicating moderate risk. This isn't a major differentiating factor.
**8. BBB:** Ligand B (48.391) is significantly better than Ligand A (35.246). While ADRB2 is a cardiovascular target, some CNS penetration can be acceptable or even beneficial depending on the specific therapeutic goal. Higher BBB is generally favorable.
**9. Caco-2 Permeability:** Ligand A (-5.915) is better than Ligand B (-4.937). Higher values indicate better intestinal absorption.
**10. Aqueous Solubility:** Ligand A (-2.251) is better than Ligand B (-2.682). Higher solubility is generally preferred.
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.198 and 0.193). This is excellent.
**12. Microsomal Clearance:** Ligand B (-5.24) has a lower (better) microsomal clearance than Ligand A (0.479), suggesting greater metabolic stability.
**13. In vitro Half-Life:** Ligand B (7.735) has a significantly longer half-life than Ligand A (-12.944). This is a major advantage, potentially leading to less frequent dosing.
**14. P-gp Efflux:** Both ligands have similar P-gp efflux liability (0.008 and 0.037).
**15. Binding Affinity:** Ligand B (-6.4) has a slightly better binding affinity than Ligand A (-6.1). While the difference is small, it's still a positive.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand B is the stronger candidate. It has a lower TPSA, a better logP, a longer half-life, better metabolic stability (lower Cl_mic), and slightly better binding affinity. While Ligand A has better Caco-2 permeability and solubility, the advantages of Ligand B in terms of permeability, metabolic stability, and half-life outweigh these factors for a GPCR target.
Output:
0
2025-04-17 19:52:52,034 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [353.482, 61.44, 2.383, 2, 3, 0.691, 13.532, 86.041, -4.899, -1.636, 0.607, -8.323, -5.671, 0.085, -6.4]
**Ligand B:** [367.515, 54.9, 2.247, 0, 6, 0.772, 28.693, 84.606, -4.478, -2.138, 0.551, 56.695, -3.645, 0.137, -6.0]
Here's a breakdown, prioritizing GPCR-relevant parameters:
1. **Molecular Weight:** Both are within the ideal 200-500 Da range. A (353.482) is slightly preferred.
2. **TPSA:** Both are reasonably low (A: 61.44, B: 54.9), suggesting good permeability. B is slightly better here.
3. **logP:** Both are excellent (A: 2.383, B: 2.247), falling within the optimal 1-3 range. Very similar.
4. **H-Bond Donors/Acceptors:** A (2/3) is better than B (0/6). Fewer H-bonds generally improve permeability.
5. **QED:** Both are good (A: 0.691, B: 0.772), indicating drug-like properties. B is slightly better.
6. **DILI:** A (13.532) is *significantly* better than B (28.693). This is a major advantage for A.
7. **BBB:** Both are high (A: 86.041, B: 84.606), which is good for a GPCR, but less critical for ADRB2 specifically (cardiovascular target).
8. **Caco-2:** Both are negative, indicating poor permeability. A (-4.899) is slightly better than B (-4.478).
9. **Solubility:** Both are negative, indicating poor solubility. B (-2.138) is slightly worse than A (-1.636).
10. **hERG:** Both are low (A: 0.607, B: 0.551), indicating low cardiotoxicity risk. Very similar.
11. **Cl_mic:** A (-8.323) is *much* better than B (56.695), indicating significantly better metabolic stability.
12. **t1/2:** A (-5.671) is better than B (-3.645), suggesting a longer half-life.
13. **Pgp:** Both are very low (A: 0.085, B: 0.137), indicating minimal efflux. A is slightly better.
14. **Binding Affinity:** A (-6.4) is slightly better than B (-6.0), although the difference is not huge.
**Overall Assessment:**
Ligand A clearly wins out. While Ligand B has a slightly better QED and TPSA, Ligand A has a *much* lower DILI risk, significantly better metabolic stability (Cl_mic), a longer half-life, and slightly better permeability and binding affinity. The lower DILI and improved metabolic properties are critical for drug development, outweighing the minor advantages of Ligand B.
Output:
1
2025-04-17 19:52:52,034 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (a cardiovascular GPCR) drug candidates.
**Ligand A:** [404.312, 83.6, 3.268, 1, 5, 0.685, 57.697, 50.717, -5.283, -3.937, 0.713, 47.949, 43.677, 0.517, -6.1]
**Ligand B:** [368.543, 78.43, 2.083, 3, 4, 0.516, 11.128, 50.756, -5.563, -2.723, 0.423, 40.612, -4.172, 0.065, -6.9]
Here's a breakdown, considering the GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (368.543) is slightly preferred due to being lower.
2. **TPSA:** Both are good, below 140. Ligand B (78.43) is slightly better than A (83.6).
3. **logP:** Both are within the optimal range (1-3). Ligand A (3.268) is slightly higher, which could be a minor concern for off-target effects, but still acceptable. Ligand B (2.083) is better.
4. **HBD/HBA:** Ligand A (1 HBD, 5 HBA) is better than Ligand B (3 HBD, 4 HBA). Fewer H-bonds are generally preferred for permeability.
5. **QED:** Both are reasonable, but Ligand A (0.685) is better than Ligand B (0.516).
6. **DILI:** Ligand B (11.128) is *significantly* better than Ligand A (57.697). This is a major advantage for B.
7. **BBB:** Both have similar BBB penetration (around 50%), which isn't a primary concern for a cardiovascular target, but isn't detrimental.
8. **Caco-2:** Both are negative, indicating poor permeability. This is a significant drawback for both.
9. **Solubility:** Both are negative, indicating poor solubility. This is a significant drawback for both.
10. **hERG:** Both are low, indicating low risk of hERG inhibition.
11. **Cl_mic:** Ligand B (40.612) has lower clearance than Ligand A (47.949), indicating better metabolic stability.
12. **t1/2:** Ligand A (43.677) has a longer half-life than Ligand B (-4.172). This is a positive for A.
13. **Pgp:** Ligand A (0.517) has lower P-gp efflux than Ligand B (0.065), which is better for bioavailability.
14. **Affinity:** Ligand B (-6.9 kcal/mol) has a stronger binding affinity than Ligand A (-6.1 kcal/mol). The difference is 0.8 kcal/mol, which is substantial.
**Overall Assessment:**
While Ligand A has a slightly better QED, longer half-life, and lower P-gp efflux, Ligand B has a *much* lower DILI risk and a significantly better binding affinity. The lower DILI risk is a critical advantage, as liver toxicity is a major cause of drug failure. The stronger binding affinity also outweighs the other minor drawbacks. The poor Caco-2 and solubility are concerns for both, but can be addressed with formulation strategies.
Therefore, I would choose Ligand B.
Output:
0
2025-04-17 19:52:52,034 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (355.316 Da) is well within the ideal range (200-500 Da). Ligand B (403.328 Da) is also acceptable, but slightly higher.
2. **TPSA:** Ligand A (87.3) is good, below the 140 threshold for oral absorption. Ligand B (58.87) is excellent, further enhancing absorption potential.
3. **logP:** Both ligands (A: 2.351, B: 3.283) fall within the optimal 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability but needs to be balanced with solubility.
4. **HBD:** Ligand A (3) is acceptable. Ligand B (1) is even better, potentially improving permeability.
5. **HBA:** Ligand A (4) is good. Ligand B (6) is still within the acceptable limit of 10.
6. **QED:** Both ligands have good QED scores (A: 0.572, B: 0.853), indicating good drug-like properties, with B being superior.
7. **DILI:** Ligand A (70.105) is borderline, indicating moderate risk. Ligand B (47.383) is much better, with a lower DILI risk. This is a significant advantage for Ligand B.
8. **BBB:** Both ligands have high BBB penetration (A: 83.947, B: 83.017), which is good, but not crucial for ADRB2 as it is not a CNS target.
9. **Caco-2:** Both ligands show poor Caco-2 permeability (A: -5.183, B: -5.073). This is a concern for oral bioavailability.
10. **Solubility:** Both ligands have poor aqueous solubility (A: -4.18, B: -2.906). This is a significant drawback for both, potentially hindering formulation and bioavailability.
11. **hERG:** Both ligands have very low hERG risk (A: 0.298, B: 0.64). This is excellent.
12. **Cl_mic:** Ligand A (-9.167) has significantly lower microsomal clearance, suggesting better metabolic stability than Ligand B (27.401). This is a major advantage for Ligand A.
13. **t1/2:** Ligand B (37.767) has a longer in vitro half-life than Ligand A (14.924). This is a positive for Ligand B.
14. **Pgp:** Both ligands have low P-gp efflux (A: 0.064, B: 0.397). This is favorable.
15. **Binding Affinity:** Ligand B (-6.5 kcal/mol) has a slightly better binding affinity than Ligand A (-5.6 kcal/mol). This difference of 0.9 kcal/mol is substantial and could outweigh some of the ADME drawbacks.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, affinity, and metabolic stability are key. While both ligands have acceptable logP and TPSA, Ligand B has a better affinity. Ligand A has better metabolic stability (lower Cl_mic), but Ligand B has a longer half-life. The DILI risk is also significantly lower for Ligand B. The Caco-2 and solubility are poor for both, but the affinity and safety profile of Ligand B are more compelling.
**Conclusion:**
Considering the balance of properties, particularly the superior binding affinity and lower DILI risk of Ligand B, it is the more promising drug candidate despite the slightly higher logP and poorer metabolic stability compared to Ligand A.
Output:
0
2025-04-17 19:52:52,034 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (364.471 and 340.427 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand B (76.02) is significantly better than Ligand A (104.53). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (1.245 and 1.024), falling within the 1-3 range. No significant difference.
4. **HBD:** Ligand B (2) has fewer H-bond donors than Ligand A (3), which is slightly preferable.
5. **HBA:** Both ligands have the same number of H-bond acceptors (4).
6. **QED:** Both ligands have similar QED scores (0.54 and 0.575), indicating good drug-likeness.
7. **DILI:** Ligand B (37.456) has a slightly lower DILI risk than Ligand A (40.287), which is a positive.
8. **BBB:** Both are relatively low, as expected for a cardiovascular target. Ligand A (55.874) is slightly higher than Ligand B (48.313), but this isn't a major factor here.
9. **Caco-2:** Ligand A (-5.359) shows better Caco-2 permeability than Ligand B (-4.933). This suggests better intestinal absorption for Ligand A.
10. **Solubility:** Ligand A (-2.389) and Ligand B (-2.456) have similar solubility, both being relatively poor.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.067 and 0.086).
12. **Cl_mic:** Ligand A (-1.016) has a *much* lower (better) microsomal clearance than Ligand B (6.104). This indicates significantly better metabolic stability for Ligand A.
13. **t1/2:** Ligand B (-7.355) has a much longer in vitro half-life than Ligand A (-3.029). This is a significant advantage for Ligand B.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.028 and 0.039).
15. **Binding Affinity:** Ligand A (-6.8 kcal/mol) has a slightly better binding affinity than Ligand B (-4.8 kcal/mol). This is a substantial difference (2.0 kcal/mol), and affinity is a key driver for GPCRs.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), affinity is paramount. The 2.0 kcal/mol difference in binding affinity between Ligand A and Ligand B is substantial. While Ligand B has a better half-life and slightly lower DILI, the superior affinity of Ligand A is likely to outweigh these benefits. The lower clearance of Ligand A is also a significant advantage.
**Conclusion:**
Ligand A presents a more compelling profile due to its significantly better binding affinity and metabolic stability, despite slightly poorer Caco-2 permeability and half-life.
Output:
1
2025-04-17 19:52:52,034 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [352.825, 50.16, 3.462, 1, 4, 0.782, 84.839, 72.703, -4.821, -4.59, 0.773, 44.702, -1.012, 0.303, -8.3]
**Ligand B:** [365.43, 69.85, 2.959, 1, 6, 0.652, 56.727, 82.784, -4.903, -3.673, 0.958, 37.798, 17.191, 0.774, -7.3]
Here's a breakdown of each parameter, comparing A and B, and considering GPCR priorities:
1. **MW:** Both are within the ideal range (200-500 Da). A (352.825) is slightly preferred.
2. **TPSA:** A (50.16) is better than B (69.85). GPCRs benefit from lower TPSA for permeability.
3. **logP:** Both are good (around 3), but A (3.462) is slightly higher, potentially improving membrane permeability.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** A (4) is better than B (6). Lower HBA is generally preferred for permeability.
6. **QED:** A (0.782) is better than B (0.652), indicating a more drug-like profile.
7. **DILI:** B (56.727) is significantly better than A (84.839). This is a major concern for A.
8. **BBB:** B (82.784) is better than A (72.703). While not a primary concern for a cardiovascular target, higher BBB is generally favorable.
9. **Caco-2:** Both are very poor (-4.821 and -4.903). This is a significant drawback for both, suggesting poor intestinal absorption.
10. **Solubility:** B (-3.673) is better than A (-4.59). Better solubility is always a plus.
11. **hERG:** A (0.773) is better than B (0.958), indicating lower cardiotoxicity risk.
12. **Cl_mic:** B (37.798) is better than A (44.702), suggesting better metabolic stability.
13. **t1/2:** B (17.191) is significantly better than A (-1.012). A longer half-life is highly desirable.
14. **Pgp:** B (0.774) is better than A (0.303). Lower P-gp efflux is preferred.
15. **Affinity:** A (-8.3) is significantly better than B (-7.3). A difference of 1 kcal/mol is substantial and can often outweigh other drawbacks.
**Overall Assessment:**
Ligand A has a significantly better binding affinity, which is paramount for GPCR targets. It also has better TPSA, logP, HBA, QED, and hERG. However, it has a substantially higher DILI risk and a very poor in vitro half-life. Ligand B has a better safety profile (DILI), better metabolic stability (t1/2, Cl_mic), solubility, and Pgp efflux. However, its affinity is weaker, and its TPSA and HBA are higher.
Given the strong affinity advantage of Ligand A, and the fact that the cardiovascular system isn't as reliant on BBB penetration as CNS targets, I believe the higher affinity outweighs the DILI and metabolic stability concerns *at this stage*. Optimization could focus on mitigating the DILI risk while maintaining the potent binding. The poor Caco-2 values are a concern for both, but can be addressed with formulation strategies.
Output:
1
2025-04-17 19:52:52,034 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (351.447 and 362.459 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (89.95) is better than Ligand B (93.01), both are below the 140 threshold for oral absorption, and closer to the 90 threshold for GPCRs.
3. **logP:** Ligand B (1.545) is better than Ligand A (0.267). Ligand A is quite low, potentially hindering membrane permeability. The optimal range is 1-3, and B is within this range.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1), but both are acceptable.
5. **HBA:** Ligand B (7) is higher than Ligand A (4). Both are within the acceptable limit of 10.
6. **QED:** Ligand B (0.871) is significantly better than Ligand A (0.657), indicating a more drug-like profile.
7. **DILI:** Ligand A (10.392) is *much* better than Ligand B (74.603). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (53.47) is better than Ligand B (44.009), though neither is exceptionally high. For a cardiovascular target, BBB penetration isn't critical, but it's still a slight benefit for A.
9. **Caco-2:** Ligand A (-4.989) is better than Ligand B (-5.565). Higher values indicate better absorption.
10. **Solubility:** Ligand A (-0.957) is better than Ligand B (-2.205). Better solubility is generally preferred.
11. **hERG:** Both ligands (0.118 and 0.12) are very low, indicating minimal hERG inhibition risk. No clear advantage.
12. **Cl_mic:** Ligand A (-5.543) is *much* better than Ligand B (26.521). Lower clearance indicates greater metabolic stability.
13. **t1/2:** Ligand A (5.421) is better than Ligand B (25.238). A longer half-life is generally desirable.
14. **Pgp:** Both ligands (0.009 and 0.213) are low, indicating minimal P-gp efflux. Ligand A is slightly better.
15. **Affinity:** Ligand A (-6.3) is slightly better than Ligand B (-5.7), but the difference is not huge.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand B has a better logP, but Ligand A excels in TPSA, Pgp, and has comparable affinity. The significant advantages of Ligand A in DILI risk, metabolic stability (Cl_mic), and half-life outweigh the slightly better logP of Ligand B.
**Conclusion:**
Considering the balance of properties and the priorities for a GPCR target, Ligand A is the more promising drug candidate. Its superior safety profile (DILI), metabolic stability, and half-life are crucial advantages.
Output:
1
2025-04-17 19:52:52,035 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (358.5) is slightly higher than Ligand B (349.4), but both are acceptable.
2. **TPSA:** Ligand A (49.41) is significantly better than Ligand B (125.21). For a GPCR, lower TPSA is generally preferred for better permeability, and Ligand A is well below the 140 threshold. Ligand B is approaching a level that could hinder oral absorption.
3. **logP:** Ligand A (3.442) is optimal, while Ligand B (-0.431) is quite low. This is a major drawback for Ligand B, as low logP can severely limit membrane permeability and bioavailability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (4). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (5) for similar reasons as HBDs.
6. **QED:** Ligand A (0.838) is excellent, indicating high drug-likeness. Ligand B (0.497) is below the desirable threshold of 0.5.
7. **DILI:** Ligand A (38.581) has a much lower DILI risk than Ligand B (66.615). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (74.137) is better than Ligand B (46.685), although neither is exceptionally high. For ADRB2, which isn't necessarily a CNS target, this isn't a primary concern, but higher is still preferred.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Both ligands have negative solubility values, which is also unusual.
11. **hERG:** Ligand A (0.447) has a lower hERG risk than Ligand B (0.189), which is a positive.
12. **Cl_mic:** Ligand A (50.089) has a higher microsomal clearance than Ligand B (26.533), suggesting faster metabolism and potentially lower *in vivo* exposure. This is a negative for Ligand A.
13. **t1/2:** Ligand A (7.732) has a much longer half-life than Ligand B (-26.047). The negative value for Ligand B is concerning.
14. **Pgp:** Ligand A (0.304) has lower P-gp efflux than Ligand B (0.027), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand A (-7.2) has a slightly better binding affinity than Ligand B (-6.6). While the difference is not huge, it's still a positive for Ligand A.
**Overall Assessment:**
Ligand A is significantly better overall. It has superior drug-likeness (QED), lower DILI risk, a more optimal logP, fewer H-bonds, and a slightly better binding affinity. While its metabolic clearance is higher, the substantial advantages in other key ADME properties and safety outweigh this drawback. Ligand B suffers from a very low logP, poor QED, higher DILI risk, and a negative in vitro half-life, making it a less promising candidate.
**Output:**
1
2025-04-17 19:52:52,035 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (366.389 and 356.413 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Both ligands (66.48 and 67.43) are below the 140 A^2 threshold for good oral absorption, and well below the 90 A^2 for CNS targets (though ADRB2 is primarily cardiovascular, some CNS off-target effects are possible). No clear advantage.
3. **logP:** Both ligands (2.816 and 1.863) are within the optimal 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability, but Ligand B is still acceptable.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Both ligands have 3 HBA, which is within the acceptable limit of 10. No clear advantage.
6. **QED:** Ligand A (0.905) has a significantly higher QED score than Ligand B (0.685), indicating a more drug-like profile. This is a substantial advantage.
7. **DILI:** Ligand B (31.059) has a much lower DILI risk than Ligand A (79.139). This is a significant advantage for Ligand B.
8. **BBB:** Ligand B (81.466) has a higher BBB penetration percentile than Ligand A (69.407). While ADRB2 isn't a CNS target, higher BBB is generally favorable, minimizing potential off-target CNS effects.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.644 and -4.657), which is unusual and suggests poor permeability. This is a significant drawback for both.
10. **Solubility:** Ligand A (-3.996) has slightly worse solubility than Ligand B (-2.969). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.702) has a slightly higher hERG risk than Ligand B (0.322). Lower hERG risk is crucial for avoiding cardiotoxicity, a critical concern for cardiovascular targets.
12. **Cl_mic:** Ligand B (3.435) has significantly lower microsomal clearance than Ligand A (23.14). Lower clearance indicates better metabolic stability, a major advantage.
13. **t1/2:** Ligand A (60.245) has a much longer in vitro half-life than Ligand B (1.013). This is a significant advantage for Ligand A, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand B (0.02) has a much lower P-gp efflux liability than Ligand A (0.416). Lower P-gp efflux improves oral bioavailability.
15. **Binding Affinity:** Ligand A (-6.8 kcal/mol) has a slightly better binding affinity than Ligand B (-5.5 kcal/mol). This is a 1.3 kcal/mol difference, which is substantial enough to be a key factor.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are important. Ligand A has a slightly better logP and significantly better affinity. Ligand B has better Pgp and TPSA.
**Overall Assessment:**
While Ligand A has a superior binding affinity and longer half-life, Ligand B demonstrates a much more favorable safety profile (lower DILI, lower hERG, lower Pgp efflux) and better metabolic stability (lower Cl_mic). The difference in binding affinity (1.3 kcal/mol) is significant, but the safety and ADME advantages of Ligand B are compelling, especially for a cardiovascular target where minimizing off-target effects and ensuring metabolic stability are paramount. The poor Caco-2 values for both are a concern that would need to be addressed through formulation or further structural modifications. However, given the balance of properties, I believe Ligand B is the more promising candidate.
Output:
0
2025-04-17 19:52:52,035 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (429.742 Da) is within the ideal range, while Ligand B (364.515 Da) is also acceptable, leaning towards the lower end. No strong preference here.
2. **TPSA:** Ligand A (49.85) is excellent, well below the 140 threshold, and good for permeability. Ligand B (74.33) is still reasonable, but higher. This favors Ligand A.
3. **logP:** Ligand A (3.483) is optimal. Ligand B (1.633) is a bit low, potentially hindering membrane permeability. This favors Ligand A.
4. **HBD:** Ligand A (0) is ideal. Ligand B (2) is acceptable but less optimal. This favors Ligand A.
5. **HBA:** Ligand A (3) is good. Ligand B (5) is acceptable, but higher. This favors Ligand A.
6. **QED:** Both Ligand A (0.736) and Ligand B (0.735) are excellent, indicating strong drug-like properties. No preference.
7. **DILI:** Ligand A (58.976) is moderate risk, but acceptable. Ligand B (22.722) is very good, indicating low liver injury risk. This favors Ligand B.
8. **BBB:** Ligand A (73.168) is good, suggesting reasonable brain penetration if desired. Ligand B (41.644) is lower, indicating less BBB penetration. Given ADRB2's cardiovascular role, BBB penetration isn't a primary concern, but it's a slight edge for Ligand A.
9. **Caco-2:** Ligand A (-4.833) is poor, indicating low intestinal absorption. Ligand B (-5.56) is also poor, but slightly better. No strong preference.
10. **Solubility:** Ligand A (-4.317) is poor, while Ligand B (-0.799) is also poor, but better. This favors Ligand B.
11. **hERG:** Ligand A (0.562) is good, indicating low cardiotoxicity risk. Ligand B (0.207) is excellent, even lower risk. This favors Ligand B.
12. **Cl_mic:** Ligand A (41.638) is moderate, indicating moderate metabolic stability. Ligand B (-17.009) is excellent, suggesting high metabolic stability. This strongly favors Ligand B.
13. **t1/2:** Ligand A (13.622) is good. Ligand B (6.069) is acceptable, but shorter. This favors Ligand A.
14. **Pgp:** Ligand A (0.688) is good, indicating low efflux. Ligand B (0.024) is excellent, suggesting minimal efflux. This favors Ligand B.
15. **Affinity:** Ligand A (-8.0) is significantly stronger than Ligand B (-6.9). This is a substantial advantage, potentially outweighing some ADME drawbacks.
**Overall Assessment:**
Ligand A has a superior binding affinity and better TPSA, logP, and half-life. However, Ligand B excels in safety parameters (DILI, hERG), metabolic stability (Cl_mic), and P-gp efflux. Solubility is also better for Ligand B. Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity), and the fact that the affinity difference is substantial, I believe the stronger binding of Ligand A is the most important factor. While Ligand B has better ADME properties, these can be further optimized. The strong binding affinity of Ligand A provides a better starting point for optimization.
Output:
1
2025-04-17 19:52:52,035 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 (a cardiovascular GPCR):
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (397.649 Da) is slightly higher than Ligand B (364.511 Da), but both are acceptable.
**2. TPSA:** Ligand A (80.91) is slightly higher than Ligand B (67.43). Both are below the 140 A^2 threshold for good oral absorption, which is good.
**3. logP:** Both ligands have good logP values (A: 3.951, B: 3.222), falling within the optimal 1-3 range.
**4. H-Bond Donors:** Ligand A (1) is better than Ligand B (2). Fewer HBDs generally improve permeability.
**5. H-Bond Acceptors:** Ligand A (5) is better than Ligand B (4). Fewer HBAs generally improve permeability.
**6. QED:** Both ligands have similar and acceptable QED values (A: 0.659, B: 0.66).
**7. DILI:** Ligand B (53.47) has a significantly lower DILI risk than Ligand A (84.374). This is a major advantage for Ligand B.
**8. BBB:** Ligand A (62.97) has a slightly better BBB penetration than Ligand B (52.423). While ADRB2 is a cardiovascular target, some CNS effects are possible with beta-blockers, so moderate BBB penetration isn't necessarily a negative.
**9. Caco-2 Permeability:** Ligand A (-4.819) is better than Ligand B (-5.134). Higher values indicate better intestinal absorption.
**10. Aqueous Solubility:** Ligand A (-5.104) is better than Ligand B (-3.946). Higher solubility is generally preferred.
**11. hERG Inhibition:** Ligand A (0.619) is better than Ligand B (0.182). Lower hERG inhibition is crucial for avoiding cardiotoxicity.
**12. Microsomal Clearance:** Ligand B (44.862) has lower microsomal clearance than Ligand A (57.014), suggesting better metabolic stability.
**13. In vitro Half-Life:** Ligand A (21.257) has a longer half-life than Ligand B (-13.734). This is a positive attribute.
**14. P-gp Efflux:** Ligand A (0.265) has lower P-gp efflux than Ligand B (0.042), indicating better bioavailability.
**15. Binding Affinity:** Ligand B (-6.6) has a slightly better binding affinity than Ligand A (-6.2). While the difference is not huge, it's a positive for Ligand B.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity) and general drug-like properties, Ligand B emerges as the more promising candidate. The significantly lower DILI risk is a major advantage, and the slightly better affinity offsets the minor drawbacks in BBB penetration and P-gp efflux. The better metabolic stability (lower Cl_mic) is also a positive. While Ligand A has a longer half-life and better solubility, the safety profile of Ligand B is more favorable.
Output:
0
2025-04-17 19:52:52,035 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [349.475, 63.57, 2.051, 1, 4, 0.658, 31.563, 56.805, -4.568, -1.639, 0.293, 59.623, 14.323, 0.125, -6.8]
**Ligand B:** [349.519, 52.65, 2.141, 1, 3, 0.799, 10.702, 77.627, -4.57, -2.047, 0.635, 37.324, -1.206, 0.126, -1.5]
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (around 350 Da). No significant difference.
2. **TPSA:** Ligand A (63.57) is slightly higher than Ligand B (52.65). Ligand B is better, closer to the <90 target for GPCRs.
3. **logP:** Both are good (around 2.1), falling within the optimal 1-3 range. Ligand B is slightly higher.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 4 HBA, Ligand B has 3. Ligand B is better, closer to the <10 target.
6. **QED:** Ligand B (0.799) is better than Ligand A (0.658), indicating a more drug-like profile.
7. **DILI:** Ligand B (10.702) has a *much* lower DILI risk than Ligand A (31.563). This is a significant advantage.
8. **BBB:** Ligand B (77.627) has a significantly higher BBB penetration potential than Ligand A (56.805). This is crucial for a GPCR target, even a cardiovascular one, as some CNS off-target effects are always a concern.
9. **Caco-2:** Both are negative, indicating poor permeability. This is a concern for both.
10. **Solubility:** Both are negative, indicating poor solubility. This is a concern for both.
11. **hERG:** Ligand B (0.635) has a slightly higher hERG risk than Ligand A (0.293). Ligand A is better here.
12. **Cl_mic:** Ligand B (37.324) has a significantly lower microsomal clearance than Ligand A (59.623), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-1.206) has a negative half-life, which is concerning, while Ligand A (14.323) has a reasonable half-life. Ligand A is better here.
14. **Pgp:** Both have very low Pgp efflux liability (0.125 and 0.126). No significant difference.
15. **Affinity:** Ligand A (-6.8 kcal/mol) has a *much* stronger binding affinity than Ligand B (-1.5 kcal/mol). This is a huge difference.
**Overall Assessment:**
The most critical factor here is the binding affinity. Ligand A's affinity is significantly stronger. However, Ligand B has a much better safety profile (DILI) and better BBB penetration, and metabolic stability. The Caco-2 and solubility are poor for both.
Given the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), the strong affinity of Ligand A is a major advantage. While Ligand B has better ADME properties in several areas, the large difference in binding affinity outweighs these benefits. A strong starting point with high affinity allows for more optimization of ADME properties.
Therefore, I would choose Ligand A.
Output:
1
2025-04-17 19:52:52,035 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [357.431, 79.55, 2.772, 1, 6, 0.735, 47.034, 58.123, -4.478, -4.46, 0.417, 51.424, 16.067, 0.276, -6.5]
**Ligand B:** [340.383, 96.11, 1.811, 3, 4, 0.504, 64.056, 51.842, -5.561, -3.15, 0.194, -8.262, -16.213, 0.025, -4.9]
Here's a breakdown comparing each parameter, keeping GPCR priorities (logP, Pgp, TPSA, affinity) in mind:
1. **MW:** Both are within the ideal 200-500 Da range. Ligand B (340.383) is slightly lower, which could be marginally beneficial for permeability.
2. **TPSA:** Ligand A (79.55) is better than Ligand B (96.11). Both are acceptable, but lower TPSA generally favors better absorption.
3. **logP:** Ligand A (2.772) is optimal, while Ligand B (1.811) is a bit low. ADRB2 is a cardiovascular target, so CNS penetration isn't critical, but a good logP is still important for membrane permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (6) is preferable to Ligand B (4). Fewer HBAs generally improve permeability.
6. **QED:** Ligand A (0.735) is significantly better than Ligand B (0.504), indicating a more drug-like profile.
7. **DILI:** Ligand A (47.034) has a much lower DILI risk than Ligand B (64.056). This is a significant advantage.
8. **BBB:** Both are relatively low, which is fine for a cardiovascular target. Ligand A (58.123) is slightly better than Ligand B (51.842).
9. **Caco-2:** Ligand B (-5.561) is better than Ligand A (-4.478), suggesting better intestinal absorption.
10. **Solubility:** Ligand B (-3.15) is better than Ligand A (-4.46), which is a positive.
11. **hERG:** Ligand A (0.417) is better than Ligand B (0.194), indicating a lower risk of cardiotoxicity.
12. **Cl_mic:** Ligand B (-8.262) has a *much* lower microsomal clearance than Ligand A (51.424), suggesting significantly better metabolic stability. This is a major advantage.
13. **t1/2:** Ligand B (-16.213) has a much longer in vitro half-life than Ligand A (16.067). This is a major advantage.
14. **Pgp:** Ligand A (0.276) is better than Ligand B (0.025), indicating lower P-gp efflux.
15. **Affinity:** Ligand A (-6.5) has a better binding affinity than Ligand B (-4.9). This is a significant advantage.
**Overall Assessment:**
While Ligand B has advantages in Caco-2 permeability, solubility, metabolic stability (Cl_mic and t1/2), and Pgp efflux, Ligand A has a superior drug-like profile (QED), lower DILI risk, better affinity, and a better hERG profile. The affinity difference is substantial, and for a GPCR, potency is paramount. The lower DILI risk is also a critical factor. While metabolic stability is important, the strong binding affinity of Ligand A, combined with its better safety profile, outweighs the metabolic concerns.
Therefore, I prefer Ligand A.
Output:
1
2025-04-17 19:52:52,035 - INFO - Batch 143 complete. Total preferences: 2288
2025-04-17 19:52:52,035 - INFO - Processing batch 144/512...
2025-04-17 19:53:42,492 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
We are targeting ADRB2, a GPCR, so the priorities are logP, TPSA, Pgp, BBB, and affinity. Let's break down the comparison:
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (341.411) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are acceptable, but Ligand B (87.65) is better than Ligand A (94.22), being closer to the <90 threshold for potential CNS penetration (though not a primary concern here).
3. **logP:** Ligand A (2.244) is optimal, while Ligand B (0.954) is a bit low. A logP below 1 can sometimes hinder membrane permeability.
4. **H-Bond Donors:** Ligand A (4) is acceptable, while Ligand B (0) is also good.
5. **H-Bond Acceptors:** Ligand A (3) is good, while Ligand B (6) is acceptable.
6. **QED:** Both are good, above 0.5, indicating good drug-like properties. Ligand B (0.77) is slightly better.
7. **DILI:** Ligand A (39.667) is significantly better than Ligand B (71.229). Lower DILI risk is crucial.
8. **BBB:** Ligand B (70.105) has a better BBB penetration percentile than Ligand A (36.138). While not the highest priority for a cardiovascular target, it's a positive.
9. **Caco-2:** Both have negative values, indicating poor permeability. Ligand A (-5.11) is slightly worse than Ligand B (-4.696).
10. **Solubility:** Ligand A (-4.288) is better than Ligand B (-2.45).
11. **hERG:** Both are very low, indicating minimal hERG inhibition risk.
12. **Cl_mic:** Ligand B (14.382) has a much lower microsomal clearance than Ligand A (43.364), suggesting better metabolic stability.
13. **t1/2:** Ligand B (19.213) has a much longer in vitro half-life than Ligand A (-39.192), which is a significant advantage.
14. **Pgp:** Both have very low Pgp efflux liability.
15. **Binding Affinity:** Ligand B (-5.9 kcal/mol) has a significantly stronger binding affinity than Ligand A (-4.6 kcal/mol). This >1.5 kcal/mol difference is a major factor.
**Overall Assessment:**
While Ligand A has better solubility and logP, Ligand B excels in several critical areas: significantly better binding affinity, lower DILI risk, much better metabolic stability (lower Cl_mic, longer t1/2), and better BBB penetration. The stronger binding affinity of Ligand B is a substantial advantage that outweighs the slightly lower logP and Caco-2 permeability. The lower DILI risk is also a major positive.
Output:
0
2025-04-17 19:53:42,493 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [355.507, 36.44, 3.115, 0., 4., 0.845, 27.608, 74.292, -5.085, -2.52, 0.803, 51.582, -14.904, 0.602, -6.9]
**Ligand B:** [366.487, 95.74, 1.486, 2., 4., 0.826, 34.626, 80.264, -5.115, -1.946, 0.22, -5.751, -0.565, 0.021, -5.5]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). A (355.5) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** A (36.44) is significantly better than B (95.74). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA is still generally beneficial for absorption. B is quite high, potentially hindering oral absorption.
3. **logP:** A (3.115) is optimal, while B (1.486) is on the lower side. Lower logP can lead to poorer membrane permeability.
4. **HBD:** A (0) is preferable to B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Both have 4 HBA, which is acceptable.
6. **QED:** Both are good (A: 0.845, B: 0.826), indicating good drug-like properties.
7. **DILI:** A (27.6) is better than B (34.6), indicating a lower risk of liver injury.
8. **BBB:** B (80.264) is slightly better than A (74.292), but this isn't a primary concern for a cardiovascular target.
9. **Caco-2:** Both are negative, which is unusual and suggests poor permeability. However, the scale isn't specified, so it's hard to interpret.
10. **Solubility:** Both are negative, indicating poor solubility. A (-2.52) is slightly worse than B (-1.946).
11. **hERG:** A (0.803) is better than B (0.22), indicating a lower risk of cardiotoxicity. This is *critical* for a cardiovascular target.
12. **Cl_mic:** A (51.582) is better than B (-5.751). A positive value for B suggests very rapid clearance, which is undesirable.
13. **t1/2:** A (-14.904) is better than B (-0.565). A longer half-life is generally preferred.
14. **Pgp:** A (0.602) is better than B (0.021). Lower P-gp efflux is desirable.
15. **Affinity:** A (-6.9) is slightly better than B (-5.5), a difference of 1.4 kcal/mol, which is significant.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A excels in these areas. While BBB isn't crucial here, the lower TPSA and better logP of A are more important for overall absorption and bioavailability. The significantly better hERG and Cl_mic profiles of A are also major advantages, especially for a cardiovascular drug. The affinity difference, while not huge, adds to A's favor.
**Conclusion:**
Ligand A is the more promising candidate due to its superior ADME properties (TPSA, logP, Cl_mic, Pgp, hERG) and slightly better binding affinity. While both have solubility concerns, A's overall profile is more favorable for development as a cardiovascular drug.
1
2025-04-17 19:53:42,493 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (382.473) is slightly higher than Ligand B (357.439), but both are acceptable.
2. **TPSA:** Ligand A (89.87) is excellent, well below the 140 threshold for oral absorption and good for a GPCR. Ligand B (110) is still reasonable, but less optimal.
3. **logP:** Both ligands have good logP values (A: 0.861, B: 1.458), falling within the 1-3 range. Ligand B is slightly better.
4. **HBD:** Both have 3 HBD, which is within the acceptable limit of 5.
5. **HBA:** Ligand A has 5 HBA, and Ligand B has 6. Both are within the acceptable limit of 10.
6. **QED:** Both ligands have good QED scores (A: 0.522, B: 0.678), indicating good drug-like properties. Ligand B is better.
7. **DILI:** Ligand A (17.72) has a significantly lower DILI risk than Ligand B (74.719). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (55.603) and Ligand B (63.009) are both moderate. While higher is better, neither is exceptionally high, and BBB isn't a primary concern for ADRB2 (a cardiovascular target).
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.025 and -5.901), which is unusual and suggests poor permeability. However, these values are on a scale where negative values are possible, and the absolute magnitude is important. Both are similarly poor.
10. **Solubility:** Ligand A (-1.394) is better than Ligand B (-3.121).
11. **hERG:** Both ligands have low hERG inhibition risk (A: 0.161, B: 0.417), which is good. Ligand A is slightly better.
12. **Cl_mic:** Ligand A (22.303) has a higher microsomal clearance than Ligand B (5.286), indicating lower metabolic stability. This is a disadvantage for Ligand A.
13. **t1/2:** Ligand A (-13.321) has a shorter in vitro half-life than Ligand B (-5.897). This is a disadvantage for Ligand A.
14. **Pgp:** Both ligands have very low Pgp efflux liability (A: 0.034, B: 0.066), which is excellent.
15. **Affinity:** Ligand B (-7.6) has a slightly better binding affinity than Ligand A (-7.3). While the difference is small (0.3 kcal/mol), it's enough to be considered.
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B has a slightly better logP and affinity. Ligand A has a much better DILI score and solubility. The metabolic stability and half-life of Ligand B are significantly better.
**Overall Assessment:**
While Ligand B has a slightly better binding affinity, the significantly lower DILI risk and better solubility of Ligand A are more crucial for overall drug development. The slightly worse metabolic stability of Ligand A can be addressed through structural modifications during optimization. The Caco-2 values for both are concerning, but can be improved.
Output:
1
2025-04-17 19:53:42,493 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (334.379 Da) is better, falling comfortably within the 200-500 Da range. Ligand B (389.543 Da) is still acceptable, but closer to the upper limit.
2. **TPSA:** Ligand A (60.25) is significantly better than Ligand B (97.39). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (A: 2.203, B: 2.078), falling within the optimal 1-3 range. Very similar here.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (5) is better than Ligand B (6). Lower HBA is generally preferred for permeability.
6. **QED:** Both ligands have similar QED values (A: 0.684, B: 0.63), indicating good drug-likeness.
7. **DILI:** Ligand A (74.021) is slightly better than Ligand B (65.723), indicating a lower risk of drug-induced liver injury. Both are acceptable.
8. **BBB:** Ligand A (68.166) is better than Ligand B (59.558). While not a CNS target, some off-target effects in the brain are possible, and lower BBB penetration is generally preferred.
9. **Caco-2:** Both ligands have very poor Caco-2 permeability (-4.735 and -4.763). This is a significant concern for both.
10. **Solubility:** Ligand A (-2.269) is slightly better than Ligand B (-3.071), but both are very poor. This is a major drawback for both compounds.
11. **hERG:** Both ligands have low hERG inhibition liability (A: 0.425, B: 0.381), which is excellent.
12. **Cl_mic:** Ligand A (48.064) has a lower microsomal clearance than Ligand B (61.645), suggesting better metabolic stability.
13. **t1/2:** Ligand A (30.509) has a significantly longer in vitro half-life than Ligand B (-45.79). This is a major advantage for Ligand A.
14. **Pgp:** Both ligands have low P-gp efflux liability (A: 0.145, B: 0.441), which is good. Ligand A is better.
15. **Binding Affinity:** Ligand A (-8.2 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.4 kcal/mol). This is a substantial advantage that can outweigh some of the ADME concerns.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A excels in affinity and has better TPSA, logP, and Pgp values. While both have poor Caco-2 and solubility, the superior affinity and metabolic stability of Ligand A make it the more promising candidate.
**Conclusion:**
Ligand A is the better candidate due to its significantly stronger binding affinity, better TPSA, lower clearance, longer half-life, and slightly better scores on other relevant parameters. The poor Caco-2 and solubility are concerns for both, but the potency advantage of Ligand A is substantial.
Output:
1
2025-04-17 19:53:42,493 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (a GPCR) drug candidates.
**Ligand A: [342.439, 58.64, 1.488, 1, 3, 0.608, 15.626, 52.811, -4.738, -2.544, 0.104, 12.824, 3.509, 0.046, -7.5]**
**Ligand B: [348.487, 58.64, 2.489, 1, 3, 0.83, 12.524, 73.943, -4.76, -2.265, 0.351, 29.637, 6.768, 0.107, -5.3]**
Here's a breakdown, prioritizing GPCR-relevant parameters:
1. **Molecular Weight:** Both ligands are within the ideal 200-500 Da range. A is 342.439, B is 348.487. Very similar.
2. **TPSA:** Both are at 58.64, well below the 140 threshold for oral absorption.
3. **logP:** A (1.488) is good, within the 1-3 range. B (2.489) is also good, leaning towards the higher end of optimal.
4. **H-Bond Donors/Acceptors:** Both have 1 HBD and 3 HBA, which are acceptable.
5. **QED:** A (0.608) is decent, but B (0.83) is significantly better, indicating a more drug-like profile.
6. **DILI:** A (15.626) is better than B (12.524), indicating lower potential for liver injury.
7. **BBB:** This is a key GPCR parameter. B (73.943) is much better than A (52.811). A higher BBB percentile is desirable.
8. **Caco-2:** Both are negative, indicating poor permeability. This is a concern for both.
9. **Solubility:** Both are negative, indicating poor solubility. This is a concern for both.
10. **hERG:** A (0.104) is better than B (0.351), suggesting lower cardiotoxicity risk.
11. **Cl_mic:** A (12.824) is much better than B (29.637), indicating better metabolic stability.
12. **t1/2:** B (6.768) has a longer half-life than A (3.509), which is generally preferred.
13. **Pgp:** Both are very low (0.046 and 0.107), suggesting minimal P-glycoprotein efflux.
14. **Binding Affinity:** A (-7.5 kcal/mol) has a significantly stronger binding affinity than B (-5.3 kcal/mol). This is a substantial difference.
**Overall Assessment:**
Ligand A has a stronger binding affinity and better metabolic stability (lower Cl_mic) and lower DILI risk. Ligand B has a better QED score and significantly better BBB penetration, and a longer half-life.
Given that this is targeting ADRB2, a GPCR, BBB penetration is a crucial factor, especially if any CNS effects are desired or need to be mitigated. The difference in BBB (52.811 vs 73.943) is substantial. The affinity difference is significant (-7.5 vs -5.3), but a good BBB score can sometimes compensate for a slightly lower affinity, especially if the receptor is highly expressed. The longer half-life of B is also a plus. While A has better metabolic stability, the improved BBB and QED of B are more compelling for a GPCR target.
Therefore, I believe Ligand B is the more promising candidate.
Output:
0
2025-04-17 19:53:42,494 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [382.511, 118.2 , 2.145, 3. , 7. , 0.64 , 82.668, 64.211, -5.918, -2.773, 0.131, 17.037, -14.599, 0.033, -5.2 ]
**Ligand B:** [348.403, 102.74 , 0.627, 1. , 5. , 0.785, 32.842, 71.811, -4.749, -1.952, 0.16 , -43.109, -2.376, 0.007, -5.3 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (348.4) is slightly lower, which *could* be beneficial for permeability, but both are acceptable.
2. **TPSA:** Ligand A (118.2) is slightly above the preferred <140 for good oral absorption, while Ligand B (102.74) is well within. This favors Ligand B.
3. **logP:** Ligand A (2.145) is optimal. Ligand B (0.627) is a bit low, potentially hindering membrane permeability. This favors Ligand A.
4. **HBD:** Ligand A (3) is acceptable. Ligand B (1) is also good.
5. **HBA:** Ligand A (7) is acceptable. Ligand B (5) is also good.
6. **QED:** Both have good QED scores (A: 0.64, B: 0.785), indicating drug-likeness. Ligand B is slightly better.
7. **DILI:** Ligand A (82.668) has a concerning DILI risk (high risk >60). Ligand B (32.842) has a much lower, and acceptable, DILI risk. This is a *major* advantage for Ligand B.
8. **BBB:** Ligand B (71.811) has a better BBB penetration score than Ligand A (64.211). While not strictly required for ADRB2 (cardiovascular target), better BBB penetration is generally preferable.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and likely indicates poor permeability in this *in vitro* assay. However, the values are similar, so this isn't a strong differentiator.
10. **Solubility:** Both have negative solubility values, which is also unusual. Again, similar values, so not a key differentiator.
11. **hERG:** Both have very low hERG risk (0.131 and 0.16), which is excellent.
12. **Cl_mic:** Ligand A (17.037) has a lower (better) microsomal clearance than Ligand B (-43.109). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (-14.599) has a negative half-life, which is unusual and suggests rapid elimination. Ligand B (-2.376) is also negative, but less so.
14. **Pgp:** Both have very low P-gp efflux liability (0.033 and 0.007), which is good.
15. **Affinity:** Both have very similar binding affinities (-5.2 and -5.3 kcal/mol). This difference is negligible.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Ligand A has a better logP, but Ligand B has a better TPSA and Pgp profile. The *critical* factor here is the significantly higher DILI risk associated with Ligand A. DILI is a major concern in drug development, and a high percentile score like 82.668 is a red flag.
**Conclusion:**
Despite Ligand A having a slightly better logP and metabolic stability, the significantly higher DILI risk makes it a less desirable candidate. Ligand B, with its lower DILI risk, better TPSA, and acceptable BBB penetration, is the more promising candidate overall.
Output:
0
2025-04-17 19:53:42,494 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [358.41 , 79.31 , 0.311, 1. , 5. , 0.765, 20.396, 85.111, -4.632, -0.839, 0.293, -9.134, 14.262, 0.041, -6.5 ]
**Ligand B:** [356.482, 60.85 , 2.514, 1. , 3. , 0.762, 19.232, 92.904, -4.286, -2.369, 0.552, 29.505, -12.435, 0.164, -5.7 ]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, Affinity, and BBB):
1. **MW:** Both are within the ideal range (356-358 Da). No significant difference.
2. **TPSA:** Ligand B (60.85) is better than Ligand A (79.31). Lower TPSA generally improves permeability.
3. **logP:** Ligand B (2.514) is better than Ligand A (0.311). Ligand A's logP is quite low, potentially hindering membrane permeability.
4. **HBD/HBA:** Both have 1 HBD, which is good. Ligand B has 3 HBA, which is preferable to Ligand A's 5. Fewer H-bonds are generally better for permeability.
5. **QED:** Both are good (0.765 and 0.762).
6. **DILI:** Both are very good, with low risk (20.396 and 19.232).
7. **BBB:** Ligand B (92.904) is better than Ligand A (85.111), though both are good. While not a CNS target, some BBB penetration can be beneficial for distribution.
8. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-4.632) is worse than Ligand B (-4.286).
9. **Solubility:** Ligand A (-0.839) is slightly better than Ligand B (-2.369), but both are poor.
10. **hERG:** Both are low risk (0.293 and 0.552).
11. **Cl_mic:** Ligand A (-9.134) is *much* better than Ligand B (29.505). Lower clearance indicates better metabolic stability.
12. **t1/2:** Ligand A (14.262) is better than Ligand B (-12.435). Longer half-life is generally preferred.
13. **Pgp:** Ligand A (0.041) is much better than Ligand B (0.164). Lower P-gp efflux is desirable.
14. **Affinity:** Ligand A (-6.5) is slightly better than Ligand B (-5.7). A 0.8 kcal/mol difference is significant.
**Overall Assessment:**
Ligand A has a better binding affinity, better metabolic stability (lower Cl_mic, longer t1/2), and lower P-gp efflux. However, Ligand B has a better logP and TPSA, which are crucial for permeability. The low logP of Ligand A is a significant concern, potentially limiting its absorption. While Ligand A has a slightly better affinity, the permeability issues outweigh this advantage. Ligand B, despite the higher Cl_mic, has a more balanced profile and a better chance of achieving adequate bioavailability.
Therefore, I prefer Ligand B.
Output:
0
2025-04-17 19:53:42,494 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
We are targeting ADRB2, a GPCR. Therefore, the key priorities are logP, TPSA, Pgp efflux, BBB penetration, and binding affinity. Metabolic stability and solubility are also important, but slightly less so than the GPCR-specific parameters.
Let's compare the ligands property by property:
1. **MW:** Both ligands (343.471 and 350.503 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (64.41) is better than Ligand B (69.64). Lower TPSA generally favors better absorption, crucial for oral bioavailability.
3. **logP:** Both ligands have similar logP values (2.732 and 2.781), falling within the optimal 1-3 range.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer HBDs generally improve membrane permeability.
5. **HBA:** Both ligands have the same number of HBA (3).
6. **QED:** Ligand A (0.737) is better than Ligand B (0.628), indicating a more drug-like profile.
7. **DILI:** Ligand A (17.41) is significantly better than Ligand B (13.339). Lower DILI risk is highly desirable.
8. **BBB:** Ligand A (81.543) has a much better BBB percentile than Ligand B (68.282). This is a significant advantage for a GPCR target, even if not strictly CNS-focused, as it suggests better distribution.
9. **Caco-2:** Ligand A (-4.542) is better than Ligand B (-4.673). Higher Caco-2 permeability indicates better intestinal absorption.
10. **Solubility:** Ligand A (-3.527) is better than Ligand B (-2.07). Higher solubility is generally preferred.
11. **hERG:** Both ligands have similar hERG inhibition liability (0.406 and 0.281), and are at acceptable levels.
12. **Cl_mic:** Ligand B (35.038) has lower microsomal clearance than Ligand A (49.441), suggesting better metabolic stability. This is a slight advantage for Ligand B.
13. **t1/2:** Ligand B (-9.751) has a longer in vitro half-life than Ligand A (-4.651), which is preferable.
14. **Pgp:** Both ligands have similar Pgp efflux liability (0.09 and 0.092).
15. **Binding Affinity:** Both ligands have the same binding affinity (-5.8 kcal/mol).
**Overall Assessment:**
Ligand A consistently outperforms Ligand B in most key ADME properties (TPSA, HBD, QED, DILI, BBB, Caco-2, Solubility) and has equal binding affinity. While Ligand B has slightly better metabolic stability and half-life, the advantages of Ligand A in terms of absorption, distribution (BBB), and safety (DILI) are more critical for a GPCR target like ADRB2. The better BBB penetration of Ligand A is particularly important.
Output:
1
2025-04-17 19:53:42,494 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, key priorities are logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB (though less critical for a cardiovascular target).
Let's break down the comparison:
1. **MW:** Both ligands (348.49 & 363.46 Da) are within the ideal 200-500 Da range.
2. **TPSA:** Both are reasonably low (67.43 & 69.22), suggesting good potential for absorption, well below the 140 threshold.
3. **logP:** Both ligands have good logP values (3.455 & 3.267), falling within the optimal 1-3 range.
4. **HBD/HBA:** Both have acceptable HBD (2) and HBA (3/4) counts, balancing solubility and permeability.
5. **QED:** Both have good QED scores (0.707 & 0.855), indicating drug-likeness.
6. **DILI:** Ligand A (32.183) has a significantly lower DILI risk than Ligand B (49.981), which is a major advantage.
7. **BBB:** Ligand B (68.205) has a higher BBB penetration than Ligand A (51.105), but BBB is less crucial for a cardiovascular target.
8. **Caco-2:** Ligand B (-5.084) has a better Caco-2 permeability than Ligand A (-4.492).
9. **Solubility:** Ligand B (-4.548) has slightly better solubility than Ligand A (-3.544).
10. **hERG:** Both ligands have low hERG inhibition risk (0.737 & 0.84).
11. **Cl_mic:** Both ligands have similar microsomal clearance (64.125 & 63.586).
12. **t1/2:** Ligand B (-27.642) has a significantly longer *in vitro* half-life than Ligand A (-11.32), which is a positive.
13. **Pgp:** Both ligands have low Pgp efflux liability (0.267 & 0.499).
14. **Binding Affinity:** Ligand A (-6.7 kcal/mol) has a slightly better binding affinity than Ligand B (-6.1 kcal/mol). This 0.6 kcal/mol difference is significant.
**Overall Assessment:**
Ligand A has a substantial advantage in DILI risk and a slightly better binding affinity. While Ligand B has better Caco-2 permeability and half-life, the lower DILI risk of Ligand A is a critical factor for a cardiovascular drug, as liver toxicity is a major concern. The affinity difference is also enough to tip the scales.
**Output:**
1
2025-04-17 19:53:42,494 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (345.49 and 350.50 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (81.99) is higher than Ligand B (58.64). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is generally preferred for absorption. Ligand B has a clear advantage.
3. **logP:** Both ligands (3.07 and 2.93) are within the optimal 1-3 range. Very similar.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable. Ligand B is slightly better.
5. **HBA:** Both ligands (3) are within the acceptable limit of 10. No significant difference.
6. **QED:** Ligand A (0.821) has a higher QED score than Ligand B (0.685), indicating better overall drug-likeness. This is a significant advantage for Ligand A.
7. **DILI:** Ligand A (34.78) has a higher DILI risk than Ligand B (15.01). This is a substantial advantage for Ligand B.
8. **BBB:** Ligand B (72.63) has a higher BBB penetration percentile than Ligand A (63.47). While ADRB2 isn't a primary CNS target, some brain exposure can contribute to side effects, and better control is desirable. Ligand B is better.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-4.64) is slightly worse than Ligand B (-4.37).
10. **Solubility:** Both have negative solubility values, suggesting poor aqueous solubility. Ligand B (-3.22) is slightly better than Ligand A (-4.42).
11. **hERG:** Ligand A (0.34) has a lower hERG inhibition liability than Ligand B (0.57). This is a significant advantage for Ligand A, as it reduces the risk of cardiotoxicity.
12. **Cl_mic:** Both ligands have similar microsomal clearance values (53.37 and 50.83). No major difference.
13. **t1/2:** Ligand B (-13.35) has a longer in vitro half-life than Ligand A (-10.08). This is a positive for Ligand B.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.1 and 0.13). No significant difference.
15. **Binding Affinity:** Ligand B (-7.1 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.6 kcal/mol). This is a substantial advantage for Ligand B, potentially outweighing some of the ADME drawbacks.
**Overall Assessment:**
Ligand B has a superior binding affinity, lower DILI risk, better BBB penetration, and a longer half-life. While Ligand A has a better QED and lower hERG risk, the affinity difference is substantial. For a GPCR target like ADRB2, binding affinity is paramount, and the lower DILI risk of Ligand B is also very important. The slightly lower TPSA of Ligand B is also beneficial. The solubility and Caco-2 values are poor for both, but can be addressed through formulation strategies.
Output:
0
2025-04-17 19:53:42,495 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (348.45 and 350.39 Da). No significant difference here.
2. **TPSA:** Both are good (87.32 and 87.46), below the 140 threshold for oral absorption.
3. **logP:** Ligand A (2.341) is optimal, while Ligand B (0.259) is quite low, potentially hindering membrane permeability. This is a significant negative for Ligand B.
4. **HBD:** Both have 2 HBD, which is acceptable.
5. **HBA:** Ligand A has 4 HBA, Ligand B has 5. Both are acceptable, but Ligand A is slightly better.
6. **QED:** Both are good (0.8 and 0.746), indicating drug-like properties.
7. **DILI:** Ligand A (27.26%) has a much lower DILI risk than Ligand B (41.84%). This is a crucial advantage for Ligand A.
8. **BBB:** Ligand A (77.82%) has better BBB penetration than Ligand B (55.33%). While ADRB2 isn't exclusively a CNS target, some CNS exposure can occur, and better BBB penetration is generally favorable.
9. **Caco-2:** Ligand A (-4.894) is better than Ligand B (-5.151), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-2.046) is better than Ligand B (-1.022).
11. **hERG:** Both are low (0.409 and 0.231), indicating low cardiotoxicity risk.
12. **Cl_mic:** Ligand A (27.79) has a better (lower) microsomal clearance than Ligand B (-15.758). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (-7.774) has a better (longer) half-life than Ligand B (-14.405).
14. **Pgp:** Ligand A (0.057) has lower P-gp efflux than Ligand B (0.026).
15. **Binding Affinity:** Ligand B (-8.9 kcal/mol) has a slightly better binding affinity than Ligand A (-7.4 kcal/mol). This is a 1.5 kcal/mol difference, which is significant.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B has superior affinity, but its very low logP is a major concern. Poor logP often translates to poor permeability and bioavailability. Ligand A has a good logP, better ADME properties (DILI, BBB, Cl_mic, t1/2, solubility), and acceptable affinity. While Ligand B's affinity is better, the ADME liabilities of Ligand B are too significant to ignore. The slightly better affinity of Ligand B is unlikely to overcome the poor permeability and potential for rapid metabolism and efflux.
**Conclusion:**
Considering the balance of properties, especially the critical importance of logP and ADME properties for a GPCR target, Ligand A is the more promising drug candidate.
Output:
1
2025-04-17 19:53:42,495 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [368.503, 81.75, -0.472, 2, 5, 0.566, 23.071, 27.608, -5.341, -1.918, 0.089, 17.425, -5.892, 0.004, -6.7]
**Ligand B:** [353.369, 101.29, 0.97, 3, 3, 0.607, 35.595, 83.986, -5.226, -3.249, 0.33, 13.429, -17.414, 0.017, -6.2]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (353.369) is slightly lower, which is generally favorable.
2. **TPSA:** Ligand A (81.75) is better than Ligand B (101.29). Both are acceptable for a non-CNS GPCR, but lower is preferred.
3. **logP:** Ligand A (-0.472) is a bit low, potentially hindering permeability. Ligand B (0.97) is better, falling within the optimal range.
4. **HBD:** Ligand A (2) is better than Ligand B (3). Lower is generally preferred.
5. **HBA:** Ligand A (5) is better than Ligand B (3). Lower is generally preferred.
6. **QED:** Both are good (A: 0.566, B: 0.607), indicating drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (23.071) has a significantly lower DILI risk than Ligand B (35.595). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (83.986) has much better BBB penetration than Ligand A (27.608). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be beneficial.
9. **Caco-2:** Both are similarly poor (-5.341 and -5.226). This suggests potential absorption issues for both.
10. **Solubility:** Ligand A (-1.918) is better than Ligand B (-3.249).
11. **hERG:** Ligand A (0.089) is better than Ligand B (0.33), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand B (13.429) has a lower microsomal clearance, suggesting better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand A (-5.892) has a better in vitro half-life than Ligand B (-17.414).
14. **Pgp:** Ligand A (0.004) has lower P-gp efflux liability than Ligand B (0.017).
15. **Affinity:** Ligand A (-6.7) has a slightly better binding affinity than Ligand B (-6.2).
**GPCR-specific priorities:** For ADRB2 (a GPCR), we prioritize logP, Pgp, TPSA, and affinity. Ligand B has better logP and Pgp. Ligand A has better TPSA and affinity.
**Overall Assessment:**
Ligand A has a significantly better safety profile (lower DILI, lower hERG) and slightly better affinity and half-life. Ligand B has better metabolic stability (lower Cl_mic) and BBB penetration. The lower DILI risk of Ligand A is a crucial factor, especially in cardiovascular drug development. The slight advantage in binding affinity also tips the scale. While Ligand B's metabolic stability is good, the safety concerns associated with Ligand B are too significant to ignore.
Output:
1
2025-04-17 19:53:42,495 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (349.479) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (70.47) is higher than Ligand B (51.55). Both are below 140, but B is better for oral absorption.
3. **logP:** Ligand A (0.971) is optimal, while Ligand B (4.356) is high. High logP can lead to solubility issues and off-target interactions. This is a significant drawback for Ligand B.
4. **HBD:** Ligand A (1) is good, Ligand B (0) is also acceptable.
5. **HBA:** Both ligands have 5 HBA, which is within the acceptable range.
6. **QED:** Ligand A (0.759) has a better QED score than Ligand B (0.509), indicating a more drug-like profile.
7. **DILI:** Ligand A (13.843) has a much lower DILI risk than Ligand B (87.282). This is a critical advantage for Ligand A.
8. **BBB:** Both ligands have similar BBB penetration (63.474 and 62.699). This isn't a primary concern for ADRB2, as it's a cardiovascular target, but it's not detrimental.
9. **Caco-2:** Ligand A (-5.045) and Ligand B (-4.547) are similar.
10. **Solubility:** Ligand A (-0.196) is better than Ligand B (-5.87). The high logP of Ligand B likely contributes to its poor solubility.
11. **hERG:** Ligand A (0.136) has a lower hERG risk than Ligand B (0.366).
12. **Cl_mic:** Ligand A (11.114) has a lower microsomal clearance than Ligand B (87.578), suggesting better metabolic stability.
13. **t1/2:** Ligand A (12.125) has a longer in vitro half-life than Ligand B (-19.053).
14. **Pgp:** Ligand A (0.012) has a lower Pgp efflux liability than Ligand B (0.487).
15. **Affinity:** Both ligands have very similar binding affinities (-7.5 and -7.0 kcal/mol). The difference is less than the 1.5 kcal/mol threshold.
**GPCR-specific considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. While both ligands have good affinity, Ligand B's high logP is a major concern, leading to poor solubility and potentially increased off-target effects. Ligand A has a more balanced profile across all parameters, especially regarding safety (DILI, hERG) and ADME properties (Cl_mic, t1/2, Pgp, solubility).
**Conclusion:**
Ligand A is the superior candidate due to its better overall ADME-Tox profile, particularly its lower DILI risk, better solubility, metabolic stability, and lower Pgp efflux. Although Ligand B has a slightly lower TPSA, the benefits of Ligand A outweigh this minor difference.
Output:
1
2025-04-17 19:53:42,495 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [359.373, 87.74, 0.21, 2, 4, 0.503, 37.185, 77.898, -5.056, -1.925, 0.22, -19.293, -9.587, 0.016, -7.1]
**Ligand B:** [357.439, 73.14, 2.459, 0, 7, 0.55, 79.953, 64.25, -5.154, -3.114, 0.247, 96.925, -24.739, 0.398, -7.2]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, Affinity, and BBB):
1. **MW:** Both are within the ideal 200-500 Da range. A (359.373) and B (357.439) are very similar.
2. **TPSA:** A (87.74) is slightly higher than B (73.14). Both are acceptable for a non-CNS GPCR like ADRB2, but B is preferable.
3. **logP:** A (0.21) is quite low, potentially hindering membrane permeability. B (2.459) is much better, falling within the optimal 1-3 range. This is a significant advantage for B.
4. **HBD/HBA:** A has 2 HBD and 4 HBA, while B has 0 HBD and 7 HBA. Both are reasonable, but B's lower HBD count is slightly more favorable for permeability.
5. **QED:** Both have good QED scores (A: 0.503, B: 0.55), indicating good drug-like properties.
6. **DILI:** A (37.185) has a lower DILI risk than B (79.953). This is a strong positive for A.
7. **BBB:** A (77.898) has a better BBB penetration score than B (64.25). However, since ADRB2 is primarily a cardiovascular target, BBB penetration is less critical.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. A (-5.056) is slightly better than B (-5.154), but both are concerning.
9. **Solubility:** Both have negative solubility values, which is also unusual and suggests poor solubility. A (-1.925) is slightly better than B (-3.114).
10. **hERG:** Both have very low hERG inhibition liability (A: 0.22, B: 0.247), which is excellent.
11. **Cl_mic:** A (-19.293) has a much lower (better) microsomal clearance than B (96.925), indicating better metabolic stability. This is a significant advantage for A.
12. **t1/2:** A (-9.587) has a shorter in vitro half-life than B (-24.739). B is preferable here.
13. **Pgp:** Both have very low P-gp efflux liability (A: 0.016, B: 0.398), which is good.
14. **Affinity:** Both have very similar binding affinities (A: -7.1, B: -7.2). The difference is negligible.
**Overall Assessment:**
Ligand B has a much more favorable logP, which is crucial for GPCR ligands. While Ligand A has a lower DILI risk and better metabolic stability (Cl_mic), the poor logP is a major drawback. The similar binding affinities mean that the ADME properties become the deciding factor. The negative Caco-2 and solubility values for both are concerning, but the better logP of B makes it more likely to be optimized for absorption.
Therefore, I prefer Ligand B.
0
2025-04-17 19:53:42,495 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (340.335 Da) is well within the ideal range (200-500 Da). Ligand B (417.288 Da) is at the higher end but still acceptable.
2. **TPSA:** Ligand A (94.57) is good, below the 140 threshold for oral absorption. Ligand B (77) is excellent, suggesting good absorption and potentially better BBB penetration.
3. **logP:** Ligand A (2.58) is optimal. Ligand B (4.046) is slightly higher, potentially leading to solubility issues or off-target interactions, but still within a manageable range.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Both ligands have 6 HBA, which is good.
6. **QED:** Both ligands have similar QED values (0.693 and 0.632), indicating good drug-likeness.
7. **DILI:** Both ligands have high DILI risk (85.692 and 88.29), which is concerning. This will be a key factor to address in further optimization, but doesn't immediately disqualify either.
8. **BBB:** Ligand A (66.111) has a moderate BBB penetration score. Ligand B (51.997) is lower, suggesting less CNS penetration. For ADRB2 (cardiovascular target), BBB penetration is not a primary concern, so this difference isn't strongly favoring one ligand.
9. **Caco-2:** Ligand A (-4.702) and Ligand B (-5.107) both have negative Caco-2 values, which is unusual. It's difficult to interpret without knowing the scale. Assuming lower values indicate lower permeability, both are suboptimal.
10. **Solubility:** Ligand A (-4.581) and Ligand B (-4.734) both have negative solubility values, which is also unusual. Assuming lower values indicate lower solubility, both are suboptimal.
11. **hERG:** Both ligands have low hERG inhibition risk (0.275 and 0.477), which is excellent.
12. **Cl_mic:** Ligand A (77.973) has a higher microsomal clearance than Ligand B (60.36), suggesting lower metabolic stability.
13. **t1/2:** Ligand A (26.314) has a longer in vitro half-life than Ligand B (10.751).
14. **Pgp:** Both ligands have low Pgp efflux liability (0.455 and 0.364).
15. **Binding Affinity:** Ligand B (-8.3 kcal/mol) has a significantly stronger binding affinity than Ligand A (-7.4 kcal/mol). This is a >1 kcal/mol difference, which is substantial.
**GPCR-specific considerations:**
For a GPCR like ADRB2, logP, TPSA, and affinity are crucial. Ligand B has a better logP and significantly better affinity. While its TPSA is slightly lower, it's still within an acceptable range. The higher DILI risk for both is a concern, but the substantial affinity advantage of Ligand B outweighs the other minor drawbacks.
**Conclusion:**
Considering the stronger binding affinity of Ligand B and its acceptable ADME properties, it is the more promising drug candidate.
Output:
0
2025-04-17 19:53:42,496 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
The ADRB2 receptor is a GPCR, so the priorities are logP, Pgp, TPSA, BBB, and binding affinity. Let's compare the ligands:
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (376.475) is slightly higher than Ligand B (359.499), but this isn't a major concern.
2. **TPSA:** Ligand B (63.91) is significantly better than Ligand A (121.8). Lower TPSA generally indicates better cell permeability, crucial for GPCR ligands.
3. **logP:** Ligand B (3.15) is optimal, while Ligand A (-0.495) is quite low. A low logP can hinder membrane permeability and reduce oral absorption. This is a significant drawback for Ligand A.
4. **H-Bond Donors:** Ligand A (3) is reasonable, while Ligand B (0) is even better. Fewer H-bond donors generally improve permeability.
5. **H-Bond Acceptors:** Both ligands have 6 HBA, which is acceptable.
6. **QED:** Ligand B (0.762) has a better QED score than Ligand A (0.491), indicating a more drug-like profile.
7. **DILI:** Both ligands have similar DILI risk (around 40%), which is acceptable.
8. **BBB:** Ligand B (74.137) has a much higher BBB penetration percentile than Ligand A (47.926). While ADRB2 isn't exclusively a CNS target, some peripheral effects can be modulated by CNS penetration, and higher BBB is generally favorable.
9. **Caco-2 Permeability:** Both have negative values, which is unusual. However, the magnitude of the negative value is smaller for Ligand B (-4.91) than for Ligand A (-5.522), suggesting slightly better permeability.
10. **Aqueous Solubility:** Both have negative solubility values, which is also unusual. Ligand A (-1.758) is slightly better than Ligand B (-3.538).
11. **hERG:** Ligand A (0.085) has a slightly lower hERG risk than Ligand B (0.363), but both are low enough to not be a major concern.
12. **Microsomal Clearance:** Ligand A (19.919) has a significantly lower microsomal clearance than Ligand B (62.67), indicating better metabolic stability.
13. **In vitro Half-Life:** Ligand A (13.514) has a better in vitro half-life than Ligand B (6.363).
14. **P-gp Efflux:** Ligand A (0.034) has a much lower P-gp efflux liability than Ligand B (0.322), which is a significant advantage for bioavailability and potentially CNS exposure.
15. **Binding Affinity:** Ligand A (-7.0) has a slightly better binding affinity than Ligand B (-5.6). However, the difference is only 1.4 kcal/mol, which, while noticeable, isn't enough to overcome the significant ADME deficiencies of Ligand A.
**Overall Assessment:**
Ligand B clearly outperforms Ligand A in several crucial ADME properties (TPSA, logP, BBB, P-gp efflux). While Ligand A has slightly better binding affinity, metabolic stability and half-life, the poor logP and higher TPSA of Ligand A are major drawbacks for a GPCR ligand, potentially leading to poor absorption and bioavailability. The better predicted permeability and brain penetration of Ligand B make it a more promising candidate.
**Output:**
0
2025-04-17 19:53:42,496 - INFO - Batch 144 complete. Total preferences: 2304
2025-04-17 19:53:42,496 - INFO - Processing batch 145/512...
2025-04-17 19:54:29,028 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
The target is ADRB2, a GPCR. Therefore, I will prioritize logP, Pgp, TPSA, affinity, and BBB.
* **Molecular Weight:** Both ligands (370.343 and 354.447 Da) fall within the ideal 200-500 Da range. No significant difference here.
* **TPSA:** Ligand A (78.87) is better than Ligand B (85.89), being closer to the <140 threshold for good oral absorption.
* **logP:** Ligand B (0.928) is slightly better than Ligand A (0.434), falling closer to the optimal 1-3 range. Ligand A is a bit low and might have permeability issues.
* **H-Bond Donors/Acceptors:** Both have 2 HBD and are within acceptable limits. Ligand B has 5 HBA vs 4 for Ligand A. This isn't a major discriminator.
* **QED:** Both ligands have good QED scores (0.608 and 0.664).
* **DILI:** Ligand A (22.838) has a significantly lower DILI risk than Ligand B (34.742). This is a substantial advantage for Ligand A.
* **BBB:** Ligand A (77.898) has a better BBB penetration percentile than Ligand B (71.345), though both are reasonable.
* **Caco-2 Permeability:** Both are negative, indicating poor permeability. Ligand A (-4.832) is slightly better than Ligand B (-4.988), but both are concerning.
* **Aqueous Solubility:** Both are negative, indicating poor solubility. Ligand A (-1.198) is slightly better than Ligand B (-1.515).
* **hERG Inhibition:** Ligand A (0.384) is much better than Ligand B (0.095), indicating a lower risk of cardiotoxicity. This is a significant advantage.
* **Microsomal Clearance:** Ligand A (-3.302) has a much lower (better) microsomal clearance than Ligand B (24.104), suggesting better metabolic stability.
* **In vitro Half-Life:** Ligand A (-23.554) has a much longer half-life than Ligand B (3.979).
* **P-gp Efflux:** Both are very low (0.035 and 0.017), indicating minimal P-gp efflux.
* **Binding Affinity:** Ligand B (-6.2) has a slightly better binding affinity than Ligand A (-5.9), but the difference is only 0.3 kcal/mol. Given the other advantages of Ligand A, this difference is unlikely to be decisive.
**Overall Assessment:**
Ligand A demonstrates a significantly better safety profile (lower DILI, lower hERG inhibition) and improved pharmacokinetic properties (lower clearance, longer half-life) compared to Ligand B. While Ligand B has a slightly better logP and binding affinity, the advantages of Ligand A in ADME-Tox are more critical for overall drug development success, especially given the cardiovascular implications of targeting ADRB2. The slightly lower affinity of Ligand A can likely be optimized in subsequent iterations.
**Output:**
1
2025-04-17 19:54:29,028 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.5 and 341.4 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (69.64) is significantly better than Ligand B (112.95). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold, while B is approaching it.
3. **logP:** Ligand A (2.495) is optimal, while Ligand B (1.192) is a bit low. A logP between 1-3 is preferred, and Ligand A is closer to the upper end, suggesting better membrane permeability.
4. **HBD:** Both ligands have 2 HBD, which is within the acceptable limit of <=5.
5. **HBA:** Ligand A has 3 HBA, while Ligand B has 6. Ligand A is preferable here, staying well below the 10 HBA threshold.
6. **QED:** Both ligands have good QED scores (0.773 and 0.819), indicating good drug-like properties.
7. **DILI:** Ligand A (10.392) has a much lower DILI risk than Ligand B (61.07). This is a substantial advantage for Ligand A.
8. **BBB:** Ligand A (68.554) has slightly better BBB penetration than Ligand B (53.819), but this is less critical for a cardiovascular target.
9. **Caco-2:** Ligand A (-4.675) and Ligand B (-5.091) are both poor, indicating limited intestinal absorption.
10. **Solubility:** Ligand A (-2.602) is better than Ligand B (-3.627). Higher solubility is generally preferred.
11. **hERG:** Ligand A (0.539) has a slightly better hERG profile than Ligand B (0.101), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand B (3.097) has significantly lower microsomal clearance than Ligand A (28.48). This suggests better metabolic stability for Ligand B.
13. **t1/2:** Ligand B (31.236) has a much longer in vitro half-life than Ligand A (-2.193). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.209) has lower P-gp efflux than Ligand B (0.038), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand B (-7.2) has a significantly stronger binding affinity than Ligand A (-5.4). This is a 1.8 kcal/mol difference, which is a substantial advantage that can outweigh some ADME drawbacks.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in affinity, while Ligand A has better TPSA, logP, and Pgp. However, the large difference in binding affinity is the most important factor. The longer half-life of Ligand B is also a significant benefit. While Ligand A has a better DILI score, the affinity difference is substantial enough to overcome this concern, especially considering the cardiovascular context.
**Conclusion:**
Despite some ADME advantages for Ligand A, the significantly stronger binding affinity of Ligand B (-7.2 kcal/mol vs -5.4 kcal/mol) and its longer half-life make it the more promising drug candidate for the ADRB2 receptor.
Output:
0
2025-04-17 19:54:29,029 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (360.38 and 367.48 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (59.59) is significantly better than Ligand B (95.07). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand B's TPSA is quite high.
3. **logP:** Both ligands have good logP values (3.04 and 2.42), falling within the 1-3 optimal range. Ligand A is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1), but both are within the acceptable limit of 5.
5. **HBA:** Ligand A (3) is lower than Ligand B (9). This is a significant advantage for Ligand A, as fewer HBA generally improves permeability.
6. **QED:** Ligand A (0.735) has a better QED score than Ligand B (0.505), indicating a more drug-like profile.
7. **DILI:** Ligand A (29.04) has a much lower DILI risk than Ligand B (77.59). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (94.03) has a higher BBB penetration percentile than Ligand B (43.82). While not a primary concern for a cardiovascular target, higher BBB is rarely detrimental.
9. **Caco-2:** Ligand A (-4.49) has a better Caco-2 permeability than Ligand B (-5.45).
10. **Solubility:** Ligand A (-2.91) has a better solubility than Ligand B (-3.52).
11. **hERG:** Ligand A (0.794) has a lower hERG inhibition liability than Ligand B (0.044). This is a significant safety advantage for Ligand A.
12. **Cl_mic:** Ligand B (97.36) has a higher microsomal clearance than Ligand A (59.83), indicating faster metabolism and potentially lower *in vivo* exposure.
13. **t1/2:** Ligand B (23.03) has a longer in vitro half-life than Ligand A (2.20). This is a positive for Ligand B, but the difference might be offset by the higher clearance.
14. **Pgp:** Ligand A (0.299) has a lower P-gp efflux liability than Ligand B (0.252).
15. **Binding Affinity:** Ligand B (-6.2 kcal/mol) has a stronger binding affinity than Ligand A (-4.8 kcal/mol). This is a substantial advantage for Ligand B, a difference of 1.4 kcal/mol.
**Overall Assessment:**
Ligand B has a significantly better binding affinity. However, Ligand A demonstrates a much more favorable ADMET profile. Specifically, the lower DILI risk, better solubility, lower hERG inhibition, and better Caco-2 permeability are crucial advantages. While the affinity difference is notable, the improved safety and pharmacokinetic properties of Ligand A are more compelling for a cardiovascular drug candidate. The higher TPSA and HBA of Ligand B raise concerns about absorption and potential off-target effects. The longer half-life of Ligand B is a plus, but the higher clearance reduces its overall benefit.
Output:
1
2025-04-17 19:54:29,029 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (365.5 & 352.5 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand B (78.87) is significantly better than Ligand A (105.21). Lower TPSA generally improves oral absorption and is prioritized for GPCRs.
3. **logP:** Both ligands have good logP values (3.14 & 2.16), falling within the 1-3 range. Ligand A is slightly higher, which *could* be a minor drawback, but both are acceptable.
4. **HBD:** Both have 2 HBD, which is within the ideal range. No difference.
5. **HBA:** Ligand B (4) is slightly better than Ligand A (5), but both are within the acceptable range.
6. **QED:** Both ligands have good QED scores (0.65 & 0.74), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand B (23.5%) is *much* better than Ligand A (63.6%). This is a critical advantage. A lower DILI score is highly desirable.
8. **BBB:** Ligand A (57.6%) is better than Ligand B (40.8%). While ADRB2 isn't exclusively a CNS target, some CNS penetration can be beneficial, and this is a slight edge for A.
9. **Caco-2:** Both ligands have similar, poor Caco-2 permeability (-5.14 & -5.14). This is a concern for both.
10. **Solubility:** Both ligands have poor aqueous solubility (-3.49 & -2.34). This is a concern for both, and may require formulation strategies.
11. **hERG:** Ligand B (0.17) is significantly better than Ligand A (0.65), indicating a lower risk of cardiotoxicity. This is a major advantage, especially for a cardiovascular target.
12. **Cl_mic:** Ligand B (3.24) has *much* lower microsomal clearance than Ligand A (46.8). This suggests better metabolic stability for Ligand B.
13. **t1/2:** Ligand B (-12.19) has a significantly longer in vitro half-life than Ligand A (6.06). This is a significant advantage.
14. **Pgp:** Ligand B (0.09) has much lower P-gp efflux than Ligand A (0.33). This is a significant advantage, improving bioavailability.
15. **Binding Affinity:** Ligand A (-6.8) has a slightly better binding affinity than Ligand B (-5.9), a 0.9 kcal/mol difference. While affinity is important, the other ADME properties are more concerning for Ligand A.
**Overall Assessment:**
Ligand B is clearly the superior candidate. While Ligand A has slightly better binding affinity, Ligand B excels in almost all crucial ADME properties: significantly lower DILI risk, better hERG profile, much lower microsomal clearance, longer half-life, lower P-gp efflux, and lower TPSA. The poor Caco-2 and solubility are concerns for both, but these can be addressed with formulation strategies. The substantial improvements in safety (DILI, hERG) and pharmacokinetic properties (Cl_mic, t1/2, Pgp) outweigh the small difference in binding affinity.
Output:
0
2025-04-17 19:54:29,029 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (359.729 Da and 350.419 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Both ligands have TPSA values around 130 A2, which is acceptable for a non-CNS GPCR target like ADRB2, but not ideal. Lower is generally preferred for better absorption.
**3. logP:** Ligand A (1.559) has a more optimal logP value compared to Ligand B (0.186). A logP between 1-3 is preferred, and Ligand B's value is quite low, potentially hindering membrane permeability.
**4. H-Bond Donors/Acceptors:** Ligand A has 3 HBD and 6 HBA, while Ligand B has 4 HBD and 4 HBA. Both are within acceptable ranges.
**5. QED:** Ligand A (0.648) has a slightly higher QED score than Ligand B (0.522), indicating a more drug-like profile.
**6. DILI Risk:** This is a critical parameter. Ligand A has a very high DILI risk (99.38 percentile), which is a major red flag. Ligand B has a much lower, and acceptable, DILI risk (41.024 percentile).
**7. BBB Penetration:** BBB is less critical for a cardiovascular target. Ligand A (12.253) and Ligand B (87.398) are both not particularly high, but Ligand B is significantly higher.
**8. Caco-2 Permeability:** Both ligands have negative Caco-2 values, indicating poor permeability.
**9. Aqueous Solubility:** Both ligands have negative solubility values, indicating poor solubility.
**10. hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.025 and 0.06 respectively).
**11. Microsomal Clearance:** Ligand A (-22.32 mL/min/kg) has a much lower (better) microsomal clearance than Ligand B (41.189 mL/min/kg), suggesting greater metabolic stability.
**12. In vitro Half-Life:** Ligand A (10.333 hours) has a longer half-life than Ligand B (-5.112 hours), which is desirable.
**13. P-gp Efflux:** Both ligands show very low P-gp efflux liability (0.01 and 0.023 respectively).
**14. Binding Affinity:** Ligand A (-7.6 kcal/mol) has a slightly better binding affinity than Ligand B (-6.4 kcal/mol). However, the difference is not substantial enough to overcome the other significant drawbacks of Ligand A.
**Overall Assessment:**
While Ligand A has slightly better affinity and metabolic stability, the extremely high DILI risk is a deal-breaker. The low logP of Ligand B is a concern, but the significantly lower DILI risk and better BBB penetration make it the more promising candidate. The slightly weaker affinity can potentially be optimized in future iterations.
Output:
0
2025-04-17 19:54:29,029 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.394 and 347.419 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (79.6) is well below the 140 threshold and quite good for oral absorption. Ligand B (115.98) is still under 140, but closer to the upper limit. A is better here.
3. **logP:** Ligand A (1.444) is within the optimal 1-3 range. Ligand B (0.328) is slightly below 1, which *could* indicate permeability issues. A is better.
4. **HBD:** Ligand A (1) is good. Ligand B (4) is higher, potentially impacting permeability. A is better.
5. **HBA:** Ligand A (5) is good. Ligand B (4) is also good. No significant difference.
6. **QED:** Both ligands have reasonable QED scores (0.908 and 0.507), indicating drug-likeness, but A is significantly better.
7. **DILI:** Ligand A (65.917) is higher risk than Ligand B (42.613). B is better here.
8. **BBB:** Ligand A (90.655) has excellent BBB penetration, while Ligand B (43.699) is poor. Given ADRB2's involvement in cardiovascular function, CNS penetration isn't a primary goal, but it's not detrimental. A is better.
9. **Caco-2:** Ligand A (-4.779) and Ligand B (-5.447) both have negative Caco-2 values, which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-3.329) and Ligand B (-2.538) both have negative solubility values, suggesting poor solubility. B is slightly better.
11. **hERG:** Ligand A (0.517) is better than Ligand B (0.135), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand A (14.204) has a lower microsomal clearance than Ligand B (-3.785), suggesting better metabolic stability. A is better.
13. **t1/2:** Ligand A (-3.719) has a longer in vitro half-life than Ligand B (-22.495). A is significantly better.
14. **Pgp:** Ligand A (0.179) has lower P-gp efflux than Ligand B (0.019), indicating better bioavailability. A is better.
15. **Binding Affinity:** Ligand A (-7.4) has a slightly better binding affinity than Ligand B (-6.8). While the difference is not huge, it's enough to consider.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A performs better on logP, TPSA, Pgp, and affinity.
**Overall Assessment:**
Ligand A is the stronger candidate. It has a better balance of properties, particularly regarding predicted permeability (TPSA, logP, Caco-2), metabolic stability (Cl_mic, t1/2), P-gp efflux, and binding affinity. While Ligand B has a lower DILI risk, the other advantages of Ligand A outweigh this concern.
Output:
1
2025-04-17 19:54:29,029 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [350.419, 97.56, 1.072, 1, 6, 0.705, 35.867, 77.2, -4.802, -1.629, 0.1, 59.023, -5.847, 0.049, -7.2]
**Ligand B:** [343.387, 119.9, 0.355, 3, 5, 0.688, 46.219, 40.403, -5.499, -2.641, 0.484, -13.988, 12.281, 0.011, -6.7]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). A (350.419) is slightly higher than B (343.387), but both are acceptable.
2. **TPSA:** A (97.56) is better than B (119.9), falling well under the 140 threshold for oral absorption. B is still acceptable, but A is preferred.
3. **logP:** A (1.072) is optimal, while B (0.355) is a bit low. A higher logP generally aids membrane permeability, which is important for GPCRs.
4. **HBD:** A (1) is better than B (3). Lower HBD generally improves permeability.
5. **HBA:** A (6) is better than B (5).
6. **QED:** Both are good (A: 0.705, B: 0.688), indicating drug-like properties.
7. **DILI:** A (35.867) is significantly better than B (46.219). Lower DILI risk is crucial.
8. **BBB:** A (77.2) is significantly better than B (40.403). For a GPCR, even if not specifically a CNS target, some BBB penetration can be beneficial for distribution and avoiding off-target effects.
9. **Caco-2:** A (-4.802) is better than B (-5.499). Higher Caco-2 values indicate better absorption.
10. **Solubility:** A (-1.629) is better than B (-2.641).
11. **hERG:** Both are very low (A: 0.1, B: 0.484), indicating minimal cardiotoxicity risk.
12. **Cl_mic:** A (59.023) is higher than B (-13.988), meaning B has better metabolic stability. This is a significant advantage for B.
13. **t1/2:** A (-5.847) is better than B (12.281).
14. **Pgp:** A (0.049) is better than B (0.011). Lower P-gp efflux is preferred.
15. **Affinity:** A (-7.2) is slightly better than B (-6.7). While both are good, the 0.5 kcal/mol difference is noticeable.
**GPCR-specific priorities:** logP, Pgp, TPSA, and affinity are key. A excels in logP, TPSA, and Pgp. Affinity is only marginally better for A. B has a substantial advantage in metabolic stability (Cl_mic and t1/2).
**Overall Assessment:**
While Ligand B has a clear advantage in metabolic stability, Ligand A has a more favorable profile across several crucial parameters for a GPCR drug candidate, including logP, TPSA, BBB penetration, and DILI risk. The slightly better affinity of A also contributes. The metabolic stability of B is a concern, and can be addressed in later optimization stages.
Therefore, I would prioritize Ligand A.
1
2025-04-17 19:54:29,030 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (344.302) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (110.93) is better than Ligand B (39.5). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally aids absorption. Ligand B is very low, which could be a concern for binding.
3. **logP:** Both ligands have good logP values (A: 1.621, B: 2.892), falling within the optimal 1-3 range. Ligand B is slightly higher, which could potentially lead to off-target interactions, but isn't a major concern.
4. **HBD:** Both ligands have 0 HBD, which is acceptable.
5. **HBA:** Ligand A (7) is higher than Ligand B (4). While both are within the acceptable range, lower HBA is generally preferred for better permeability.
6. **QED:** Both ligands have good QED scores (A: 0.618, B: 0.702), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (82.396) has a significantly higher DILI risk than Ligand B (15.898). This is a major red flag for Ligand A.
8. **BBB:** Both ligands have reasonable BBB penetration, but Ligand B (93.292) is much higher than Ligand A (78.092). While not critical for a cardiovascular target, higher BBB is generally favorable.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability.
10. **Solubility:** Ligand A (-5.05) has worse solubility than Ligand B (-2.37). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.343) has a lower hERG risk than Ligand B (0.981), which is positive.
12. **Cl_mic:** Ligand A (25.506) has higher microsomal clearance than Ligand B (12.756), indicating lower metabolic stability.
13. **t1/2:** Ligand B (-10.696) has a longer in vitro half-life than Ligand A (-22). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.17) has lower P-gp efflux than Ligand B (0.247), which is favorable.
15. **Binding Affinity:** Ligand B (-7.5) has a slightly better binding affinity than Ligand A (-7.1). While the difference is small, it's enough to consider.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B performs better on logP, TPSA, and affinity. The DILI score for Ligand A is a major concern.
**Overall Assessment:**
Ligand B is the stronger candidate. While Ligand A has a slightly better hERG profile and Pgp efflux, the significantly higher DILI risk, worse solubility, and higher clearance of Ligand A outweigh these benefits. Ligand B has a better binding affinity, better metabolic stability, and a much lower DILI risk, making it the more promising drug candidate.
Output:
0
2025-04-17 19:54:29,030 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (366.5 and 372.5 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (67.43) is significantly better than Ligand B (84.94). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand A is well below the 140 threshold, while Ligand B is approaching it.
**3. logP:** Ligand A (2.878) is optimal, while Ligand B (0.815) is a bit low. A logP between 1-3 is preferred, and Ligand B is closer to the lower limit, potentially impacting membrane permeability.
**4. H-Bond Donors:** Ligand A (2) and Ligand B (1) are both acceptable.
**5. H-Bond Acceptors:** Ligand A (4) and Ligand B (6) are both acceptable, though Ligand A is slightly better.
**6. QED:** Both ligands have good QED scores (0.661 and 0.719), indicating good drug-like properties.
**7. DILI Risk:** Ligand A (21.0) has a much lower DILI risk than Ligand B (46.5). This is a significant advantage for Ligand A.
**8. BBB Penetration:** Ligand A (75.6) shows better BBB penetration than Ligand B (46.5). While ADRB2 is primarily a cardiovascular target, some CNS effects are possible with adrenergic ligands, and better BBB penetration isn't necessarily a negative.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests a potential issue with the assay or the compounds themselves. However, the values are similar (-5.05 and -4.988).
**10. Aqueous Solubility:** Both ligands have negative solubility values, which is also unusual. Again, the values are similar (-2.765 and -2.502).
**11. hERG Inhibition:** Ligand A (0.522) has a slightly higher hERG risk than Ligand B (0.121), but both are relatively low.
**12. Microsomal Clearance:** Ligand A (74.8) has higher microsomal clearance than Ligand B (68.3), indicating faster metabolism and potentially lower *in vivo* exposure.
**13. In vitro Half-Life:** Ligand B (-5.167) has a negative half-life, which is impossible. This is a significant red flag. Ligand A (19.084) has a reasonable half-life.
**14. P-gp Efflux:** Ligand A (0.175) has lower P-gp efflux than Ligand B (0.039), which is favorable for bioavailability.
**15. Binding Affinity:** Ligand B (-7.1) has a slightly better binding affinity than Ligand A (-6.1). However, the difference is 1 kcal/mol, which is not substantial enough to overcome the other significant advantages of Ligand A.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), and the general drug-like properties, Ligand A is the more promising candidate. It has better TPSA, logP, DILI risk, BBB penetration, P-gp efflux, and a reasonable half-life. While Ligand B has slightly better affinity, the negative half-life is a critical flaw. The other advantages of Ligand A outweigh the small difference in binding affinity.
Output:
1
2025-04-17 19:54:29,030 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (341.363 Da) is within the ideal range, while Ligand B (370.515 Da) is slightly higher but still acceptable.
2. **TPSA:** Both ligands are good (A: 86.51, B: 78.87), well below the 140 threshold for oral absorption.
3. **logP:** Ligand A (3.816) is at the upper end of the optimal range, while Ligand B (1.189) is a bit low, potentially impacting permeability.
4. **HBD:** Ligand A (0) is excellent, while Ligand B (2) is still acceptable.
5. **HBA:** Both ligands have 5 HBA, which is good.
6. **QED:** Both ligands have similar QED scores (A: 0.453, B: 0.496), indicating moderate drug-likeness.
7. **DILI:** Ligand A (87.786) has a significantly higher DILI risk than Ligand B (31.059). This is a major concern.
8. **BBB:** Ligand A (60.799) has a moderate BBB penetration, while Ligand B (46.336) is lower. For a cardiovascular target, BBB penetration is less critical, but still a consideration.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not defined, so we can't interpret this directly.
10. **Solubility:** Both ligands have negative solubility values, which is also unusual. Again, the scale is undefined.
11. **hERG:** Both ligands have low hERG inhibition risk (A: 0.415, B: 0.357).
12. **Cl_mic:** Ligand A (100.923) has a higher microsomal clearance than Ligand B (52.054), suggesting lower metabolic stability.
13. **t1/2:** Both ligands have negative in vitro half-life values (-13.875 and -13.108), which is not interpretable without knowing the scale.
14. **Pgp:** Both ligands have low Pgp efflux liability (A: 0.451, B: 0.074). Ligand B is significantly lower, which is favorable.
15. **Affinity:** Ligand A (-7.4 kcal/mol) has a slightly better binding affinity than Ligand B (-7.2 kcal/mol).
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are important. Ligand A has a better logP and affinity, but Ligand B has a much lower Pgp efflux liability and a significantly lower DILI risk.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity, the significantly higher DILI risk and higher microsomal clearance are major drawbacks. Ligand B, despite a slightly lower affinity and logP, presents a much more favorable safety profile (lower DILI) and potentially better metabolic stability. The lower Pgp efflux is also a plus. Given the importance of safety in drug development, especially for a cardiovascular target, I would prioritize Ligand B.
Output:
0
2025-04-17 19:54:29,030 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [421.257, 64.35, 3.941, 2, 3, 0.777, 37.456, 87.553, -5.028, -4.426, 0.754, 13.412, 25.973, 0.291, -8.1]
**Ligand B:** [365.413, 71.76, 2.629, 1, 8, 0.749, 91.47, 59.946, -4.995, -3.892, 0.876, 33.222, 12.334, 0.225, -5.7]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, Affinity, and to a lesser extent BBB):
1. **MW:** Ligand B (365.413) is preferable as it is closer to the ideal range (200-500 Da) and lower than Ligand A (421.257).
2. **TPSA:** Ligand A (64.35) is better than Ligand B (71.76). Both are reasonably good, but lower TPSA generally favors permeability.
3. **logP:** Ligand A (3.941) is slightly better, being closer to the optimal 1-3 range, while Ligand B (2.629) is a little lower.
4. **HBD/HBA:** Ligand B has 1 HBD and 8 HBA, while Ligand A has 2 HBD and 3 HBA. Ligand A is slightly better here, with fewer hydrogen bonding groups.
5. **QED:** Both are very similar (0.777 vs 0.749), indicating good drug-likeness.
6. **DILI:** Ligand A (37.456) is significantly better, indicating a much lower risk of drug-induced liver injury compared to Ligand B (91.47). This is a major advantage.
7. **BBB:** Ligand A (87.553) has a significantly higher BBB penetration percentile than Ligand B (59.946). While ADRB2 isn't a CNS target, some off-target CNS effects are possible with GPCRs, and higher BBB is generally a positive.
8. **Caco-2:** Both are negative, indicating poor permeability. This is a concern for both, but the negative values are similar.
9. **Solubility:** Both are negative, indicating poor solubility. Ligand B is slightly better (-3.892 vs -4.426).
10. **hERG:** Both are low risk (0.754 and 0.876).
11. **Cl_mic:** Ligand A (13.412) has a lower microsomal clearance, suggesting better metabolic stability than Ligand B (33.222).
12. **t1/2:** Ligand A (25.973) has a longer in vitro half-life than Ligand B (12.334).
13. **Pgp:** Ligand A (0.291) has lower P-gp efflux liability than Ligand B (0.225), which is favorable for bioavailability.
14. **Affinity:** Ligand A (-8.1 kcal/mol) has a significantly stronger binding affinity than Ligand B (-5.7 kcal/mol). This is a substantial advantage.
**Overall Assessment:**
Ligand A clearly outperforms Ligand B. The significantly stronger binding affinity (-8.1 vs -5.7 kcal/mol) is a major driver. It also has better DILI risk, BBB penetration, metabolic stability (lower Cl_mic, longer t1/2), and lower P-gp efflux. While both have issues with Caco-2 and solubility, the superior affinity and safety profile of Ligand A outweigh these concerns.
Output:
1
2025-04-17 19:54:29,030 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.415 and 344.459 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (84.94) is slightly higher than Ligand B (78.09), but both are well below the 140 threshold for good oral absorption. Given ADRB2 is a cardiovascular target (not CNS), TPSA is less critical, but lower is still preferred. Ligand B is slightly better.
3. **logP:** Ligand A (0.757) is a bit low, potentially hindering permeation. Ligand B (2.839) is within the optimal 1-3 range. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (3). Fewer HBAs generally improve permeability.
6. **QED:** Ligand A (0.715) is slightly better than Ligand B (0.641), indicating a more drug-like profile.
7. **DILI:** Ligand A (45.522) has a lower DILI risk than Ligand B (54.983), which is a clear advantage.
8. **BBB:** This is less critical for a cardiovascular target. Ligand A (43.505) and Ligand B (58.86) are both relatively low, which is fine in this context.
9. **Caco-2:** Ligand A (-4.804) is better than Ligand B (-5.361), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-2.118) is better than Ligand B (-3.313), indicating better aqueous solubility.
11. **hERG:** Ligand A (0.054) has a much lower hERG inhibition liability than Ligand B (0.242), a crucial safety advantage.
12. **Cl_mic:** Ligand A (-19.726) has a significantly *lower* (better) microsomal clearance than Ligand B (48.488), suggesting greater metabolic stability.
13. **t1/2:** Ligand A (14.06) has a longer in vitro half-life than Ligand B (8.935), which is desirable.
14. **Pgp:** Ligand A (0.039) has a lower P-gp efflux liability than Ligand B (0.177), improving oral bioavailability.
15. **Binding Affinity:** Ligand B (-6.2) has a stronger binding affinity than Ligand A (-3.5). This is a substantial difference (2.7 kcal/mol) and a major factor.
**Overall Assessment:**
While Ligand B has a superior binding affinity, Ligand A demonstrates a significantly better ADMET profile. Specifically, the lower DILI risk, hERG inhibition, and microsomal clearance, coupled with better solubility, Pgp efflux, and half-life, make it a much safer and more likely to succeed as a drug candidate. The logP of Ligand A is a slight concern, but the other advantages outweigh this. The affinity difference, while substantial, can potentially be addressed through further optimization of Ligand A, whereas fixing the ADMET liabilities of Ligand B would be far more challenging.
Output:
1
2025-04-17 19:54:29,031 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (389.321) is slightly higher than Ligand B (356.486), but both are acceptable.
2. **TPSA:** Both are below the 140 A^2 threshold for oral absorption. Ligand A (71.09) is a bit higher than Ligand B (64.68), but both are good.
3. **logP:** Ligand A (3.349) is optimal, while Ligand B (0.773) is a bit low. A logP below 1 can sometimes hinder membrane permeability. This is a slight advantage for Ligand A.
4. **HBD:** Both ligands have 2 HBD, which is within the acceptable limit of 5.
5. **HBA:** Both ligands have 4 HBA, which is within the acceptable limit of 10.
6. **QED:** Both ligands have QED values above 0.5 (Ligand A: 0.776, Ligand B: 0.674), indicating good drug-likeness. Ligand A is slightly better.
7. **DILI:** Ligand A (68.98) has a higher DILI risk than Ligand B (5.7). This is a significant advantage for Ligand B.
8. **BBB:** Both ligands have good BBB penetration (Ligand A: 71.733, Ligand B: 75.145). Ligand B is slightly better.
9. **Caco-2:** Both have negative values, which is unusual. However, the magnitude of the negative value indicates permeability. Ligand A (-4.645) is slightly better than Ligand B (-5.297).
10. **Solubility:** Ligand A (-4.214) is better than Ligand B (-0.886). Solubility is important for bioavailability.
11. **hERG:** Both ligands have low hERG inhibition risk (Ligand A: 0.193, Ligand B: 0.627). Ligand A is better.
12. **Cl_mic:** Ligand B (-38.455) has a lower (better) microsomal clearance than Ligand A (37.554), indicating greater metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand B (-3.352) has a slightly longer in vitro half-life than Ligand A (-26.596).
14. **Pgp:** Both ligands have very low Pgp efflux liability (Ligand A: 0.032, Ligand B: 0.009). Ligand B is slightly better.
15. **Binding Affinity:** Both ligands have very similar binding affinities (Ligand A: -6.7 kcal/mol, Ligand B: -6.4 kcal/mol). The difference is not substantial enough to be a deciding factor.
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand A has a better logP and slightly better Caco-2 permeability, but Ligand B has better BBB penetration, lower DILI risk, and better metabolic stability (Cl_mic). The DILI risk and metabolic stability are particularly important considerations for a cardiovascular target.
**Overall Assessment:**
While Ligand A has some advantages in solubility and logP, Ligand B's significantly lower DILI risk and improved metabolic stability are more critical for a cardiovascular drug candidate. The slight advantage in BBB penetration also helps. The binding affinities are comparable.
Output:
0
2025-04-17 19:54:29,031 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (369.487 and 368.459 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (91.76 and 91.84) are slightly above the optimal <140 for oral absorption, but acceptable for a peripherally acting GPCR like ADRB2. No major difference.
3. **logP:** Ligand A (1.061) is better than Ligand B (0.498). While both are within the acceptable range, Ligand A is closer to the optimal 1-3 range, suggesting better membrane permeability. Ligand B is a bit low and could have absorption issues.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1), but both are well within the acceptable limit of <=5.
5. **HBA:** Both ligands (6) are within the acceptable limit of <=10.
6. **QED:** Ligand B (0.757) has a better QED score than Ligand A (0.578), indicating a more drug-like profile. This is a positive for Ligand B.
7. **DILI:** Ligand A (33.23) has a significantly lower DILI risk than Ligand B (62.001). This is a substantial advantage for Ligand A. DILI is a critical factor in drug development.
8. **BBB:** Both ligands have similar BBB penetration (54.052 and 55.254). Since ADRB2 is not a primary CNS target, this isn't a major deciding factor.
9. **Caco-2:** Ligand B (-5.117) has a slightly better Caco-2 permeability than Ligand A (-4.885), suggesting slightly better intestinal absorption.
10. **Solubility:** Ligand B (-2.285) has a worse solubility than Ligand A (-1.265). Solubility is important for bioavailability.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.22 and 0.153), which is excellent.
12. **Cl_mic:** Ligand A (7.522) has a significantly lower microsomal clearance than Ligand B (26.821). This indicates better metabolic stability for Ligand A, leading to a potentially longer duration of action.
13. **t1/2:** Ligand B (-19.307) has a much longer in vitro half-life than Ligand A (-9.07). This is a strong positive for Ligand B.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.064 and 0.056).
15. **Binding Affinity:** Both ligands have the same binding affinity (-6.2 kcal/mol).
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand A has a slight edge in logP and significantly better metabolic stability (Cl_mic). Ligand B has a better QED and half-life, but the higher DILI risk and lower logP are concerning. The lower DILI risk of Ligand A is a major advantage, and the slightly better logP and metabolic stability outweigh the longer half-life of Ligand B.
Output:
1
2025-04-17 19:54:29,031 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (369.487 Da) is slightly higher than Ligand B (350.503 Da), but this difference isn't significant.
**2. TPSA:** Ligand A (87.74) is better than Ligand B (55.57). For a cardiovascular GPCR, TPSA is important for permeability, and both are acceptable, but Ligand B is better.
**3. logP:** Ligand A (1.351) is within the optimal range (1-3), while Ligand B (4.578) is on the higher side. High logP can lead to solubility issues and off-target effects. Ligand A is preferable here.
**4. H-Bond Donors:** Ligand A (2) is preferable to Ligand B (0). A small number of HBDs is good for permeability.
**5. H-Bond Acceptors:** Both ligands have 4 HBA, which is acceptable.
**6. QED:** Ligand A (0.759) has a higher QED score than Ligand B (0.58), indicating a more drug-like profile.
**7. DILI Risk:** Ligand A (49.632) has a lower DILI risk than Ligand B (8.53), which is a significant advantage.
**8. BBB Penetration:** Ligand B (83.908) has better BBB penetration than Ligand A (75.727). While this is important for CNS targets, ADRB2 is primarily a cardiovascular target, so this is less critical.
**9. Caco-2 Permeability:** Ligand A (-4.934) is better than Ligand B (-4.37).
**10. Aqueous Solubility:** Ligand A (-2.122) is better than Ligand B (-4.818).
**11. hERG Inhibition:** Ligand A (0.39) has a lower hERG inhibition risk than Ligand B (0.661), which is crucial for avoiding cardiotoxicity.
**12. Microsomal Clearance:** Ligand B (92.047) has a higher microsomal clearance than Ligand A (7.378), meaning it's metabolized faster. Lower clearance is preferred for longer duration of action.
**13. In vitro Half-Life:** Ligand A (-38.698) has a longer in vitro half-life than Ligand B (39.152).
**14. P-gp Efflux:** Ligand A (0.056) has lower P-gp efflux than Ligand B (0.246), which is beneficial for bioavailability.
**15. Binding Affinity:** Both ligands have similar binding affinities (-6.1 and -6.0 kcal/mol). The difference is negligible.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity) and general drug-like properties, Ligand A is the better candidate. It has a more favorable logP, lower DILI risk, lower hERG inhibition, better solubility, lower P-gp efflux, and a longer half-life. While Ligand B has slightly better BBB penetration, this is less important for a cardiovascular target. The superior ADME profile of Ligand A outweighs the minor difference in BBB penetration.
Output:
1
2025-04-17 19:54:29,031 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (345.531 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (36.53) is significantly better than Ligand B (79.24). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally improves absorption. Ligand B's TPSA is quite high, potentially hindering oral bioavailability.
3. **logP:** Both ligands have logP values within the optimal range (1-3), but Ligand B (4.493) is pushing the upper limit. This could lead to solubility issues and increased off-target binding. Ligand A (3.597) is more favorable.
4. **HBD/HBA:** Ligand A (HBD=2, HBA=4) and Ligand B (HBD=1, HBA=3) are both acceptable, falling within the recommended limits.
5. **QED:** Ligand A (0.792) has a much better QED score than Ligand B (0.325), indicating a more drug-like profile.
6. **DILI:** Ligand A (27.491) has a significantly lower DILI risk than Ligand B (64.754). This is a critical advantage.
7. **BBB:** Both have moderate BBB penetration, but Ligand A (74.719) is better than Ligand B (64.482). While not a primary concern for a cardiovascular target, higher BBB is generally preferable.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and difficult to interpret without further context. Assuming these represent permeability, a less negative value is better, making Ligand A (-5.18) slightly preferable to Ligand B (-5.026).
9. **Solubility:** Ligand A (-1.443) has better solubility than Ligand B (-5.487). This is important for formulation and bioavailability.
10. **hERG:** Both ligands have low hERG inhibition risk (0.865 and 0.822 respectively), which is good.
11. **Cl_mic:** Ligand A (-28.307) has a much lower (better) microsomal clearance than Ligand B (79.374), indicating greater metabolic stability.
12. **t1/2:** Ligand A (19.883 hours) has a longer in vitro half-life than Ligand B (11.805 hours), which is desirable for less frequent dosing.
13. **Pgp:** Both ligands have low Pgp efflux liability (0.211 and 0.602 respectively), which is good.
14. **Binding Affinity:** Ligand B (-4.8 kcal/mol) has a slightly better binding affinity than Ligand A (-0.6 kcal/mol). However, the difference is substantial enough to potentially outweigh other drawbacks.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B has a better affinity, but Ligand A excels in TPSA, logP, DILI, solubility, metabolic stability (Cl_mic), and half-life. The combination of these factors, particularly the significantly lower DILI risk and better ADME properties, makes Ligand A the more promising candidate. The difference in binding affinity is large, but not insurmountable, and can potentially be optimized in subsequent iterations.
**Output:**
1
2025-04-17 19:54:29,031 - INFO - Batch 145 complete. Total preferences: 2320
2025-04-17 19:54:29,031 - INFO - Processing batch 146/512...
2025-04-17 19:55:19,545 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
Let's systematically compare the two ligands based on the provided parameters and the guidelines, keeping in mind that ADRB2 is a GPCR, so logP, Pgp, TPSA, and affinity are particularly important.
1. **Molecular Weight:** Both ligands (360.8 and 352.5 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands have similar TPSA values (84.4 and 84.5 A^2), which are acceptable for oral absorption, though on the higher side.
3. **logP:** Ligand A (1.668) is slightly lower than Ligand B (2.165), but both are within the optimal 1-3 range.
4. **H-Bond Donors:** Ligand A has 1 HBD, while Ligand B has 2. Both are acceptable.
5. **H-Bond Acceptors:** Ligand A has 6 HBA, and Ligand B has 4. Both are within the acceptable range of <=10.
6. **QED:** Ligand A (0.835) has a significantly better QED score than Ligand B (0.623), suggesting a more drug-like profile.
7. **DILI:** Ligand A (84.5%) has a much higher DILI risk than Ligand B (25.4%). This is a major concern for Ligand A.
8. **BBB:** Ligand A (77.4%) has a better BBB penetration percentile than Ligand B (63.7%). While ADRB2 isn't necessarily a CNS target, some peripheral ADRB2 activity can influence CNS pathways, and better BBB penetration isn't necessarily a negative.
9. **Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.851 and -4.583), which is unusual. It suggests very poor permeability.
10. **Aqueous Solubility:** Both ligands have negative solubility values (-4.142 and -3.167), indicating poor aqueous solubility.
11. **hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.233 and 0.296).
12. **Microsomal Clearance:** Ligand B (86.967) has a higher microsomal clearance than Ligand A (79.076), suggesting faster metabolism and potentially lower *in vivo* exposure.
13. **In vitro Half-Life:** Ligand A (12.929 hours) has a significantly longer half-life than Ligand B (-18.879 hours). The negative value for Ligand B is concerning.
14. **P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.269 and 0.11).
15. **Binding Affinity:** Ligand B (-7.2 kcal/mol) has a significantly stronger binding affinity than Ligand A (-4.0 kcal/mol). This is a substantial difference (3.2 kcal/mol) and is a major advantage for Ligand B.
**Overall Assessment:**
While Ligand A has a better QED and BBB penetration, the significantly higher DILI risk and weaker binding affinity are major drawbacks. Ligand B, despite having a lower QED, exhibits a much stronger binding affinity, lower DILI risk, and acceptable logP. The negative Caco-2 and solubility values are concerning for both, but the affinity difference is substantial enough to outweigh these concerns, especially for a GPCR target where potency is crucial. The negative half-life for Ligand B is a red flag, but could be improved through structural modification.
**Output:**
0
2025-04-17 19:55:19,545 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [346.387, 114.62 , -0.453, 2. , 5. , 0.717, 43.66 , 68.205, -5.12 , -2.356, 0.061, -4.914, 7.316, 0.019, -6.1 ]
**Ligand B:** [361.873, 69.22 , 3.573, 2. , 3. , 0.792, 41.024, 48.972, -4.897, -4.301, 0.506, 48.157, 23.03 , 0.48 , -6.4 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (346.387) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (114.62) is better than Ligand B (69.22), being closer to the 140 threshold, but both are good.
3. **logP:** Ligand B (3.573) is within the optimal range (1-3), while Ligand A (-0.453) is significantly lower. This is a major drawback for Ligand A, potentially hindering membrane permeability.
4. **HBD:** Both have 2 HBD, which is acceptable.
5. **HBA:** Ligand A (5) has more HBA than Ligand B (3). While not a huge difference, lower HBA is generally preferred.
6. **QED:** Both have good QED scores (A: 0.717, B: 0.792), indicating drug-like properties.
7. **DILI:** Both have acceptable DILI risk (A: 43.66, B: 41.024), below the 60 threshold.
8. **BBB:** Ligand A (68.205) has a significantly higher BBB penetration percentile than Ligand B (48.972). However, for ADRB2, which is not necessarily a CNS target, this isn't a primary driver.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-5.12) is slightly worse than Ligand B (-4.897).
10. **Solubility:** Both have negative solubility values, which is also unusual. Ligand B (-4.301) is slightly better than Ligand A (-2.356).
11. **hERG:** Ligand A (0.061) has a slightly lower hERG risk than Ligand B (0.506), which is good.
12. **Cl_mic:** Ligand A (-4.914) has a much lower (better) microsomal clearance than Ligand B (48.157), indicating better metabolic stability.
13. **t1/2:** Ligand B (23.03) has a significantly longer in vitro half-life than Ligand A (7.316).
14. **Pgp:** Ligand A (0.019) has a much lower Pgp efflux liability than Ligand B (0.48), which is favorable for bioavailability.
15. **Affinity:** Ligand B (-6.4) has a slightly better binding affinity than Ligand A (-6.1).
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp efflux, and affinity are key. Ligand B has a much better logP, which is crucial for membrane permeability and receptor engagement. While Ligand A has better BBB penetration and Pgp efflux, the poor logP is a significant concern. The slightly better affinity of Ligand B also tips the balance. The better metabolic stability of Ligand A is a plus, but can be addressed during optimization.
**Conclusion:**
Despite Ligand A's advantages in BBB, Pgp, and Cl_mic, the significantly lower logP and poorer Caco-2/solubility are major drawbacks. Ligand B, with its optimal logP and slightly better affinity, is more likely to be a viable starting point for drug development.
**Output:**
0
2025-04-17 19:55:19,546 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [360.399, 135.76 , 1.057, 3. , 6. , 0.625, 96.51 , 40.791, -5.431, -3.479, 0.227, 17.505, -17.169, 0.04 , -5.4 ]
**Ligand B:** [348.349, 72.05 , 3.252, 1. , 4. , 0.861, 70.919, 85.731, -4.574, -4.857, 0.449, 40.851, -11.771, 0.334, -8. ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (348.349) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (135.76) is borderline for good oral absorption, while Ligand B (72.05) is excellent. This is a significant advantage for B.
3. **logP:** Ligand A (1.057) is at the lower end of optimal, potentially hindering permeation. Ligand B (3.252) is well within the optimal range.
4. **HBD:** Ligand A (3) is acceptable, Ligand B (1) is even better.
5. **HBA:** Ligand A (6) is acceptable, Ligand B (4) is better.
6. **QED:** Both are above 0.5, indicating good drug-likeness, with Ligand B (0.861) being superior.
7. **DILI:** Ligand A (96.51) has a very high DILI risk, which is a major concern. Ligand B (70.919) is still elevated, but significantly lower and more acceptable.
8. **BBB:** Ligand B (85.731) has a much higher BBB penetration potential than Ligand A (40.791). This is important for a GPCR target, even if not strictly CNS-focused.
9. **Caco-2:** Ligand A (-5.431) and Ligand B (-4.574) are both negative, which is unusual. Assuming these are log scale values, lower negative values are better. Ligand B is slightly better.
10. **Solubility:** Ligand A (-3.479) and Ligand B (-4.857) are both negative, indicating poor solubility. Ligand B is slightly better.
11. **hERG:** Ligand A (0.227) has a lower hERG risk than Ligand B (0.449), which is good.
12. **Cl_mic:** Ligand B (40.851) has a lower microsomal clearance than Ligand A (17.505), indicating better metabolic stability.
13. **t1/2:** Ligand A (-17.169) has a negative half-life, which is not possible. This is likely an error in the data. Ligand B (-11.771) is also negative, but less so. Both are problematic, but A is worse.
14. **Pgp:** Ligand A (0.04) has lower P-gp efflux than Ligand B (0.334), which is favorable.
15. **Affinity:** Ligand B (-8.0) has a significantly stronger binding affinity than Ligand A (-5.4). This difference of 2.6 kcal/mol is substantial and can outweigh many other drawbacks.
**Overall Assessment:**
Ligand B is significantly better. While Ligand A has a slightly lower hERG risk and Pgp efflux, the high DILI risk, poor BBB penetration, and significantly weaker binding affinity are major drawbacks. Ligand B excels in key GPCR properties (TPSA, logP, BBB, affinity), has better metabolic stability and drug-likeness, and a lower DILI risk. The negative half-life values are concerning for both, but the overall profile of Ligand B is far more promising.
Output:
0
2025-04-17 19:55:19,546 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands (352.431 and 347.415 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (88.1) is better than Ligand B (102.76). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (0.085) is slightly lower than Ligand B (-0.138), but both are a bit low. Ideally, we want 1-3. This could be a potential issue for both, but less so for A.
4. **HBD:** Ligand A (2) is preferable to Ligand B (3). Lower HBD generally improves permeability.
5. **HBA:** Both ligands have 5 HBA, which is acceptable.
6. **QED:** Both ligands have good QED scores (0.634 and 0.688), indicating good overall drug-likeness.
7. **DILI:** Ligand A (15.743) has a significantly lower DILI risk than Ligand B (37.96). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (68.282) has a higher BBB penetration score than Ligand B (41.722). While not a primary concern for a cardiovascular target, higher BBB is generally not detrimental.
9. **Caco-2:** Ligand A (-4.819) is better than Ligand B (-5.338), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-1.275) is better than Ligand B (-1.632). Better solubility is always preferred.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.213 and 0.074), which is excellent.
12. **Cl_mic:** Ligand B (-13.378) has a significantly lower (better) microsomal clearance than Ligand A (26.154). This suggests better metabolic stability for Ligand B.
13. **t1/2:** Ligand B (4.93) has a longer in vitro half-life than Ligand A (-1.37). This is a clear advantage for Ligand B.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.021 and 0.014).
15. **Binding Affinity:** Ligand B (-7.9) has a slightly better binding affinity than Ligand A (-7.1). This is a 0.8 kcal/mol difference, which is significant and could outweigh some ADME drawbacks.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), we prioritize logP, Pgp, TPSA, and affinity. Ligand B has a slightly better affinity and lower Pgp efflux, but a higher TPSA and lower logP. However, the significantly lower DILI risk and better metabolic stability (Cl_mic and t1/2) of Ligand A are crucial factors. The affinity difference, while notable, isn't large enough to overcome the safety and PK advantages of Ligand A.
**Conclusion:**
Considering the balance of properties, particularly the lower DILI risk, better solubility, and acceptable ADME profile, Ligand A is the more promising drug candidate.
Output:
1
2025-04-17 19:55:19,546 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's break down the comparison of Ligand A and Ligand B across the 15 parameters, keeping in mind the GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key).
1. **MW:** Both ligands (357.495 and 344.459 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (90.9) is slightly higher than Ligand B (70.39). Both are below 140, which is good for oral absorption. Ligand B is preferable here.
3. **logP:** Ligand A (0.515) is quite low, potentially hindering membrane permeability. Ligand B (2.616) is within the optimal 1-3 range. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (2), but both are acceptable (<=5).
5. **HBA:** Both ligands have 5 HBA, which is acceptable.
6. **QED:** Ligand B (0.772) has a better QED score than Ligand A (0.496), indicating a more drug-like profile.
7. **DILI:** Ligand A (4.188) has a slightly better DILI score than Ligand B (22.334), indicating lower liver injury risk. However, both are below the concerning threshold of 60.
8. **BBB:** Ligand A (36.371) has a very low BBB penetration percentile, while Ligand B (27.646) is also low. BBB isn't a primary concern for ADRB2 (cardiovascular target), but higher is generally better.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability.
10. **Solubility:** Ligand A (-0.281) has slightly better solubility than Ligand B (-3.154). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.258) has a lower hERG inhibition liability than Ligand B (0.179), which is preferable.
12. **Cl_mic:** Ligand A (-0.81) has a lower (better) microsomal clearance than Ligand B (75.227), indicating greater metabolic stability.
13. **t1/2:** Ligand A (10.859) has a longer in vitro half-life than Ligand B (13.262).
14. **Pgp:** Ligand A (0.016) has a much lower P-gp efflux liability than Ligand B (0.032), which is favorable for bioavailability.
15. **Affinity:** Ligand A (-7.1 kcal/mol) has a slightly better binding affinity than Ligand B (-5.3 kcal/mol). This is a significant advantage, potentially outweighing some ADME drawbacks.
**Overall Assessment:**
While Ligand A has a slightly better affinity and lower Pgp efflux, Ligand B demonstrates superior characteristics in crucial ADME properties for a GPCR target. Specifically, the significantly better logP value of Ligand B is a major advantage, as it's likely to translate to better membrane permeability and oral bioavailability. The QED score is also considerably higher for Ligand B. The lower metabolic stability of Ligand B is a concern, but the affinity difference isn't large enough to overcome the ADME advantages of Ligand B.
**Output:**
0
2025-04-17 19:55:19,546 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (370.559 Da and 350.467 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (67.43) is significantly better than Ligand B (82.62). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (2.878) is optimal, while Ligand B (0.492) is a bit low. A logP below 1 can hinder membrane permeability. Ligand A is favored.
4. **HBD:** Both ligands have 2 HBD, which is within the acceptable limit of 5.
5. **HBA:** Ligand A has 4 HBA, while Ligand B has 7. Ligand A is better, as lower HBA contributes to better permeability.
6. **QED:** Both ligands have similar QED values (0.62 and 0.627), indicating good drug-likeness.
7. **DILI:** Ligand A (21.908) has a much lower DILI risk than Ligand B (36.487). This is a significant advantage for Ligand A.
8. **BBB:** Both ligands have reasonable BBB penetration (68.36% and 71.966%), but this isn't a primary concern for a cardiovascular target.
9. **Caco-2:** Ligand A (-4.958) and Ligand B (-5.126) are both very poor. This is a concern for both.
10. **Solubility:** Ligand A (-3.28) is better than Ligand B (-1.003), indicating better aqueous solubility.
11. **hERG:** Ligand A (0.434) has a lower hERG inhibition liability than Ligand B (0.694), reducing the risk of cardiotoxicity.
12. **Cl_mic:** Ligand A (68.256) has a higher microsomal clearance than Ligand B (23.895), suggesting faster metabolism. Ligand B is favored here.
13. **t1/2:** Ligand A (9.433) has a longer in vitro half-life than Ligand B (1.499). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.238) has lower P-gp efflux liability than Ligand B (0.012). This is a significant advantage for Ligand A.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-5.8 kcal/mol and -5.9 kcal/mol). The difference is negligible.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, and Pgp are important. Ligand A is superior in logP, TPSA, and Pgp. While metabolic stability is important, the difference in Cl_mic isn't large enough to outweigh the advantages of Ligand A in other crucial parameters. The lower DILI risk and better solubility of Ligand A are also significant benefits.
**Conclusion:**
Ligand A demonstrates a more favorable balance of properties, particularly regarding permeability (TPSA, logP), safety (DILI, hERG), and metabolic properties (t1/2, Pgp).
Output:
1
2025-04-17 19:55:19,546 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.459 Da and 358.408 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (69.72) is slightly higher than Ligand B (61.28), but both are well below the 140 threshold for good oral absorption and acceptable for a cardiovascular GPCR.
3. **logP:** Ligand A (1.174) is optimal, while Ligand B (3.137) is approaching the upper limit of the optimal range. This favors Ligand A slightly.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (5). Lower HBA generally improves permeability.
6. **QED:** Both ligands have good QED scores (0.779 and 0.847), indicating good drug-like properties. No clear advantage.
7. **DILI:** Ligand A (21.442) has a significantly lower DILI risk than Ligand B (48.313). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (77.821) has a higher BBB penetration percentile than Ligand A (63.629). While ADRB2 is a cardiovascular target and CNS penetration isn't *critical*, some level of BBB penetration can be beneficial for off-target effects assessment.
9. **Caco-2:** Both ligands have very similar, and poor, Caco-2 permeability (-4.974 and -4.963). This suggests potential absorption issues for both.
10. **Solubility:** Ligand A (-1.828) has better solubility than Ligand B (-3.95). Better solubility is always preferred.
11. **hERG:** Ligand A (0.1) has a much lower hERG inhibition liability than Ligand B (0.864). This is a significant safety advantage for Ligand A.
12. **Cl_mic:** Ligand B (27.389) has lower microsomal clearance than Ligand A (33.043), indicating better metabolic stability. This favors Ligand B.
13. **t1/2:** Ligand B (11.689) has a longer in vitro half-life than Ligand A (7.678). This is a positive for Ligand B.
14. **Pgp:** Ligand A (0.039) has much lower P-gp efflux liability than Ligand B (0.164). Lower P-gp efflux is beneficial for bioavailability.
15. **Binding Affinity:** Ligand A (-6.9) has a slightly better binding affinity than Ligand B (-6.4). While the difference is not huge, it's enough to be considered.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A performs better in logP, TPSA, and Pgp. The affinity difference is small, but favors Ligand A.
**Overall Assessment:**
Ligand A has a significantly better safety profile (lower DILI and hERG) and better solubility, logP, Pgp efflux, and affinity. While Ligand B has better metabolic stability (lower Cl_mic) and half-life, and slightly better BBB penetration, the safety concerns with Ligand B are substantial. The slightly better metabolic properties of Ligand B do not outweigh the safety issues.
Output:
1
2025-04-17 19:55:19,546 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (435.344 Da) is within the ideal range, while Ligand B (349.431 Da) is towards the lower end but still acceptable.
2. **TPSA:** Ligand A (93.53) is good, under the 140 threshold. Ligand B (121.52) is higher, potentially impacting absorption, but still within a reasonable range.
3. **logP:** Ligand A (1.716) is optimal. Ligand B (-0.164) is slightly low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (1) is good. Ligand B (4) is higher, potentially impacting permeability.
5. **HBA:** Ligand A (6) is good. Ligand B (4) is good.
6. **QED:** Ligand A (0.778) is excellent. Ligand B (0.477) is acceptable but lower.
7. **DILI:** Ligand A (56.727) has a moderate risk, but is still acceptable. Ligand B (16.712) has a very low DILI risk, a significant advantage.
8. **BBB:** Ligand A (70.299) is good. Ligand B (44.668) is lower, potentially limiting CNS exposure if that were desired (though less critical for a peripheral target like ADRB2).
9. **Caco-2:** Ligand A (-4.676) is poor. Ligand B (-5.838) is also poor. Both have very low Caco-2 permeability.
10. **Solubility:** Ligand A (-3.51) is poor. Ligand B (-2.57) is also poor. Both have low solubility.
11. **hERG:** Ligand A (0.377) is very low risk. Ligand B (0.082) is extremely low risk, a significant advantage.
12. **Cl_mic:** Ligand A (43.742) is moderate. Ligand B (5.678) is very low, indicating better metabolic stability.
13. **t1/2:** Ligand A (-37.119) is very short. Ligand B (23.124) is better, but still not ideal.
14. **Pgp:** Ligand A (0.1) is very low efflux, a significant advantage. Ligand B (0.024) is extremely low efflux, an even greater advantage.
15. **Affinity:** Ligand A (-8.1 kcal/mol) is excellent. Ligand B (-7.7 kcal/mol) is very good, but slightly weaker. The difference is 1.5 kcal/mol, which is a substantial advantage for Ligand A.
**GPCR-specific considerations:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand A has a better logP and significantly better affinity. Ligand B has better Pgp and hERG, and a lower DILI risk. Both have poor Caco-2 and solubility.
**Overall Assessment:**
While Ligand B has advantages in safety (DILI, hERG) and metabolic stability (Cl_mic), the significantly stronger binding affinity of Ligand A (-8.1 vs -7.7 kcal/mol) is a major driver. The 1.5 kcal/mol difference is substantial and can often outweigh minor ADME drawbacks, especially given that ADRB2 is not a CNS target where BBB penetration is critical. The slightly better Pgp profile of Ligand B is not enough to offset the affinity difference.
Output:
1
2025-04-17 19:55:19,546 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [366.487, 91.4, 2.732, 2, 4, 0.802, 54.75, 66.615, -4.608, -4.242, 0.24, 56.38, -7.472, 0.089, -7.7]
**Ligand B:** [367.515, 80.32, 2.671, 2, 5, 0.74, 40.287, 65.529, -4.668, -3.426, 0.267, 54.199, 31.143, 0.074, -6.2]
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (366-368 Da). No significant difference.
2. **TPSA:** Ligand A (91.4) is slightly higher than Ligand B (80.32). Both are acceptable for a non-CNS GPCR target like ADRB2, but B is preferable.
3. **logP:** Both ligands have excellent logP values (2.732 and 2.671), falling within the optimal 1-3 range. No significant difference.
4. **HBD:** Both have 2 HBD, which is good. No difference.
5. **HBA:** Ligand A has 4 HBA, while Ligand B has 5. Both are acceptable, but A is slightly better.
6. **QED:** Ligand A (0.802) has a better QED score than Ligand B (0.74), indicating a more drug-like profile. This is a positive for A.
7. **DILI:** Ligand A (54.75%) has a higher DILI risk than Ligand B (40.287%). This is a significant advantage for B.
8. **BBB:** Both have similar BBB penetration (66.615% and 65.529%). Not a major factor for a cardiovascular target.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. This is a concern for both, but the values are similar.
10. **Solubility:** Ligand A (-4.242) has slightly worse solubility than Ligand B (-3.426). B is preferable.
11. **hERG:** Both have low hERG inhibition liability (0.24 and 0.267), which is good. No significant difference.
12. **Cl_mic:** Ligand A (56.38) has a higher microsomal clearance than Ligand B (54.199), suggesting lower metabolic stability. B is preferable.
13. **t1/2:** Ligand A (-7.472) has a much longer in vitro half-life than Ligand B (31.143). This is a major advantage for A.
14. **Pgp:** Both have low Pgp efflux liability (0.089 and 0.074). No significant difference.
15. **Binding Affinity:** Ligand A (-7.7) has a significantly stronger binding affinity than Ligand B (-6.2) (1.5 kcal/mol difference). This is a substantial advantage for A, potentially outweighing some of the ADME drawbacks.
**Overall Assessment:**
Ligand A has a significantly better binding affinity and a longer half-life. While it has a slightly higher TPSA and DILI risk, the substantial affinity advantage and longer half-life are critical for a GPCR target. The slightly lower solubility and higher clearance of A are less concerning than the weaker binding of B. The DILI risk of A is still within an acceptable range.
Therefore, I would choose Ligand A.
Output:
1
2025-04-17 19:55:19,546 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (349.431 and 344.499 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (84.67) is slightly higher than Ligand B (49.41). For a cardiovascular GPCR, TPSA is not a *major* concern unless it exceeds 140, which neither does. Ligand B is better here.
**3. logP:** Both ligands have good logP values (2.511 and 3.276), falling within the optimal 1-3 range. Ligand B is slightly higher, which *could* be a minor drawback if it leads to off-target effects, but it's not a strong negative.
**4. H-Bond Donors:** Both have 1 HBD, which is good.
**5. H-Bond Acceptors:** Ligand A has 5 HBA, while Ligand B has 2. Both are within the acceptable limit of 10. Ligand B is better.
**6. QED:** Ligand A (0.826) has a significantly better QED score than Ligand B (0.687), indicating a more drug-like profile. This is a positive for Ligand A.
**7. DILI:** Ligand A (43.195) has a higher DILI risk than Ligand B (14.889). This is a significant advantage for Ligand B.
**8. BBB:** Both ligands have good BBB penetration (75.107 and 73.401). Since this is a cardiovascular target, BBB penetration isn't a primary concern, but it's good to see reasonable values for both.
**9. Caco-2 Permeability:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the values are similar (-4.766 and -4.825).
**10. Aqueous Solubility:** Both have negative solubility values, which is also unusual and suggests poor solubility. Ligand B is slightly worse (-4.098 vs -2.254).
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (0.365 and 0.46), which is excellent.
**12. Microsomal Clearance:** Both have similar microsomal clearance values (61.968 and 69.006), suggesting comparable metabolic stability.
**13. In vitro Half-Life:** Ligand A (-13.96) has a much more negative half-life than Ligand B (0.883), indicating significantly poorer in vitro stability. This is a major drawback for Ligand A.
**14. P-gp Efflux:** Both have low P-gp efflux liability (0.13 and 0.318), which is good.
**15. Binding Affinity:** Ligand A (-6.6 kcal/mol) has a slightly better binding affinity than Ligand B (-6.3 kcal/mol). This 0.3 kcal/mol difference is not substantial enough to outweigh other significant factors.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity) and the general guidelines, Ligand B is the more promising candidate. While Ligand A has a slightly better QED and affinity, Ligand B has a much lower DILI risk and a significantly better in vitro half-life. The poor solubility and permeability are concerning for both, but the DILI and metabolic stability are more critical factors for initial optimization.
Output:
0
2025-04-17 19:55:19,546 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (353.438) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (61.88) is higher than Ligand B (25.36). For a cardiovascular GPCR like ADRB2, TPSA is less critical than for CNS targets, but lower is still generally preferred. Ligand B is significantly better here.
3. **logP:** Ligand B (4.529) is higher than Ligand A (0.562). This is a significant difference. While logP > 4 can be problematic, it's less concerning for a non-CNS target like ADRB2, and can be beneficial for membrane permeability. Ligand B is better.
4. **HBD:** Ligand A (1) is slightly better than Ligand B (0). Both are acceptable.
5. **HBA:** Both ligands have 4 HBA, which is good.
6. **QED:** Both ligands have similar QED values (0.802 and 0.753), indicating good drug-likeness.
7. **DILI:** Ligand A (16.789) has a much lower DILI risk than Ligand B (23.73). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (73.129) has a moderate BBB penetration, while Ligand B (95.58) has very high BBB penetration. Since ADRB2 is primarily a cardiovascular target, high BBB penetration is *not* desirable and is a negative for Ligand B.
9. **Caco-2:** Both ligands have negative Caco-2 values, suggesting poor permeability. However, the scale is not specified, so the absolute values are hard to interpret.
10. **Solubility:** Ligand A (-1.466) has better solubility than Ligand B (-4.295). Better solubility is favorable.
11. **hERG:** Ligand A (0.398) has a lower hERG risk than Ligand B (0.894). This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand A (-6.278) has a much lower (better) microsomal clearance than Ligand B (55.065). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (9.535) has a longer half-life than Ligand B (2.71). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.024) has a much lower P-gp efflux liability than Ligand B (0.674). This is a significant advantage for Ligand A, improving bioavailability.
15. **Binding Affinity:** Ligand B (-7.8) has a significantly stronger binding affinity than Ligand A (-6.1). This is a substantial advantage for Ligand B, potentially outweighing some of its ADME drawbacks.
**Overall Assessment:**
Ligand B has a significantly better binding affinity. However, it suffers from high logP, high BBB penetration (undesirable for a cardiovascular target), higher DILI risk, higher hERG risk, much higher Cl_mic, shorter half-life, and higher P-gp efflux. Ligand A, while having weaker affinity, has a much more favorable ADME profile, particularly regarding safety (DILI, hERG), metabolic stability (Cl_mic, t1/2), and bioavailability (Pgp).
Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity), and the fact that this is a cardiovascular target (less emphasis on BBB), the superior ADME properties of Ligand A, combined with acceptable affinity, make it the more promising candidate. The affinity difference, while substantial, might be overcome with further optimization of Ligand A. The ADME liabilities of Ligand B are more difficult to address.
Output:
1
2025-04-17 19:55:19,547 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.499 and 347.434 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (38.77) is significantly better than Ligand B (51.39). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary goal, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (4.073 and 3.507), falling within the optimal 1-3 range. Ligand A is slightly higher, which *could* be a minor drawback, but not a major concern.
4. **HBD:** Both ligands have 0 H-bond donors, which is acceptable.
5. **HBA:** Ligand A has 3 HBA, while Ligand B has 5. Both are acceptable, but lower is generally preferred.
6. **QED:** Ligand B (0.828) has a slightly better QED score than Ligand A (0.599), suggesting a more drug-like profile.
7. **DILI:** Ligand A (29.236) has a significantly lower DILI risk than Ligand B (42.652). This is a substantial advantage for Ligand A.
8. **BBB:** Ligand B (96.316) has a much higher BBB penetration percentile than Ligand A (64.095). While ADRB2 is not a CNS target, higher BBB is rarely a negative.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.612 and -4.489), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Both ligands have very poor aqueous solubility (-3.72 and -3.677). This is a major issue for both compounds, requiring formulation strategies.
11. **hERG:** Both ligands have similar hERG inhibition liability (0.769 and 0.958), indicating a moderate risk.
12. **Cl_mic:** Ligand B (37.707) has a significantly lower microsomal clearance than Ligand A (88.923), indicating better metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand B (10.049 hours) has a longer in vitro half-life than Ligand A (7.884 hours), which is desirable.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.852 and 0.562).
15. **Binding Affinity:** Both ligands have the same binding affinity (-5.3 kcal/mol), so this parameter doesn't differentiate them.
**GPCR-Specific Priorities & Overall Assessment:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Both ligands perform reasonably well on logP and affinity. Ligand A has a better TPSA. However, Ligand B has a much better metabolic profile (lower Cl_mic, longer t1/2) and a slightly better QED score. The DILI risk is significantly lower for Ligand A, which is a major benefit. The poor Caco-2 and solubility are concerning for both, but can potentially be addressed with formulation.
Considering the balance, the lower DILI risk of Ligand A is a critical advantage, outweighing the slightly better metabolic stability of Ligand B.
Output:
1
2025-04-17 19:55:19,547 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (370.515 and 382.423 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (78.87) is higher than Ligand B (40.62). For a cardiovascular GPCR, lower TPSA is generally preferred for better permeability, giving a slight edge to Ligand B.
3. **logP:** Both ligands have acceptable logP values (1.189 and 2.79, respectively), falling within the 1-3 range. Ligand B is slightly better positioned within the optimal range.
4. **HBD:** Ligand A has 2 HBD, while Ligand B has 0. Lower HBD can sometimes improve membrane permeability, favoring Ligand B.
5. **HBA:** Ligand A has 5 HBA, and Ligand B has 3. Again, lower HBA is generally preferred for permeability, favoring Ligand B.
6. **QED:** Both ligands have good QED scores (0.496 and 0.524), indicating reasonable drug-likeness. No clear advantage.
7. **DILI:** Ligand A (31.059) has a significantly lower DILI risk than Ligand B (49.632). This is a substantial advantage for Ligand A.
8. **BBB:** Ligand B (92.827) has a much higher BBB penetration percentile than Ligand A (46.336). While ADRB2 isn't a CNS target, some distribution to the CNS can sometimes lead to off-target effects. However, for a cardiovascular target, this isn't a primary concern, and the benefit is minimal.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.093 and -4.614). This is unusual and suggests poor permeability *in vitro*. However, these values are close, so the difference isn't decisive.
10. **Solubility:** Both ligands have very poor aqueous solubility (-3.032 and -3.221). This is a significant concern for both.
11. **hERG:** Ligand A (0.357) has a lower hERG risk than Ligand B (0.569), which is a positive for Ligand A.
12. **Cl_mic:** Ligand B (44.473) has a lower microsomal clearance than Ligand A (52.054), suggesting better metabolic stability, favoring Ligand B.
13. **t1/2:** Ligand A (-13.108) has a negative in vitro half-life, which is concerning. Ligand B (-44.582) is also negative, but more so. Both are very poor, but Ligand A is slightly better.
14. **Pgp:** Ligand A (0.074) has a lower P-gp efflux liability than Ligand B (0.162), which is favorable for bioavailability.
15. **Affinity:** Ligand A (-7.2) has a significantly stronger binding affinity than Ligand B (-6.3). This is a 0.9 kcal/mol difference, which is substantial and outweighs many of the ADME concerns.
**Overall Assessment:**
Ligand A demonstrates a significantly stronger binding affinity, lower DILI risk, and lower hERG risk. While Ligand B has better TPSA, logP, and Cl_mic, the superior affinity of Ligand A is a critical advantage for a GPCR target. The poor solubility and Caco-2 values are concerning for both, but can be addressed with formulation strategies. The negative half-lives are also concerning, but the affinity difference is significant enough to prioritize Ligand A.
Output:
1
2025-04-17 19:55:19,547 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (360.479 and 343.475 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (66.48) is slightly higher than Ligand B (62.19), but both are well below the 140 threshold for good oral absorption, and acceptable for a cardiovascular GPCR.
3. **logP:** Both ligands have good logP values (3.079 and 3.375), falling within the optimal 1-3 range. Ligand B is slightly higher, which *could* be a minor advantage for membrane permeability, but also slightly increases the risk of off-target interactions.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (4). Similar reasoning as HBD.
6. **QED:** Both ligands have acceptable QED values (0.824 and 0.772), indicating good drug-like properties.
7. **DILI:** Ligand B (30.826) has a significantly lower DILI risk than Ligand A (55.913). This is a major advantage for Ligand B.
8. **BBB:** Ligand A (72.237) has a higher BBB penetration percentile than Ligand B (66.925). While ADRB2 isn't a CNS target, some peripheral distribution is still desirable, and higher BBB penetration *can* correlate with better overall tissue distribution.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.762) is slightly better than Ligand B (-5.074), but both are concerning.
10. **Solubility:** Ligand B (-2.28) has better (less negative) aqueous solubility than Ligand A (-4.935). This is a significant advantage, as solubility is crucial for bioavailability.
11. **hERG:** Both ligands have low hERG inhibition liability (0.632 and 0.879), which is good. No significant difference.
12. **Cl_mic:** Ligand B (34.1) has a lower microsomal clearance than Ligand A (50.463), indicating better metabolic stability. This is a positive for Ligand B.
13. **t1/2:** Ligand B (55.224) has a significantly longer in vitro half-life than Ligand A (5.204). This is a major advantage, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.171 and 0.097). No significant difference.
15. **Binding Affinity:** Ligand A (-5.7) has slightly better binding affinity than Ligand B (-4.9). This is a 0.8 kcal/mol difference, which is noticeable but not overwhelming given the other factors.
**GPCR-specific priorities:**
For ADRB2 (a cardiovascular GPCR), logP, TPSA, and affinity are important. Ligand B has slightly better logP and solubility, and a significantly better safety profile (DILI) and metabolic stability (Cl_mic, t1/2). The affinity difference is not large enough to outweigh these advantages.
**Conclusion:**
Considering all parameters, Ligand B is the more promising drug candidate. Its superior DILI profile, solubility, metabolic stability, and half-life outweigh the slightly better affinity of Ligand A. The Caco-2 values are concerning for both, but can be addressed through formulation strategies.
Output:
0
2025-04-17 19:55:19,547 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (349.347) is slightly higher than Ligand B (339.443), but both are acceptable.
2. **TPSA:** Ligand A (124.84) is slightly above the preferred <140 for oral absorption, but still reasonable. Ligand B (77.04) is excellent, well below 140, suggesting better permeability.
3. **logP:** Ligand A (-0.558) is a bit low, potentially hindering membrane permeability. Ligand B (2.65) is within the optimal 1-3 range. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (2) and Ligand B (1) are both within the acceptable limit of <=5.
5. **HBA:** Ligand A (6) and Ligand B (5) are both within the acceptable limit of <=10.
6. **QED:** Both ligands have similar and good QED scores (A: 0.702, B: 0.671), indicating good drug-like properties.
7. **DILI:** Ligand A (63.009) is slightly higher than Ligand B (50.291), indicating a slightly higher risk of liver injury, but both are acceptable.
8. **BBB:** Ligand B (73.556) has a significantly higher BBB penetration percentile than Ligand A (60.372). Given ADRB2's role in cardiovascular function, CNS penetration is less crucial, but still a positive attribute.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.608 and -5.095). This is unusual and suggests poor permeability in this assay. However, the TPSA values suggest Ligand B should have better permeability.
10. **Solubility:** Both ligands have very poor solubility scores (-1.331 and -2.24). This is a significant concern for both.
11. **hERG:** Ligand A (0.01) has a very low hERG risk, which is excellent. Ligand B (0.394) is slightly higher, but still relatively low.
12. **Cl_mic:** Ligand A (-42.229) has a much lower (better) microsomal clearance than Ligand B (22.695), indicating greater metabolic stability.
13. **t1/2:** Ligand B (-23.981) has a longer in vitro half-life than Ligand A (-15.55), which is favorable.
14. **Pgp:** Ligand A (0.001) has a very low P-gp efflux liability, which is excellent. Ligand B (0.257) is slightly higher.
15. **Binding Affinity:** Ligand B (-8.3) has a significantly stronger binding affinity than Ligand A (-4.9). This is a substantial advantage, potentially outweighing some of the ADME drawbacks.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are particularly important. Ligand B excels in logP and affinity, and has a better TPSA and Pgp profile. While solubility is a concern for both, the superior binding affinity of Ligand B is a major factor. The improved BBB is a bonus.
**Conclusion:**
Despite the solubility concerns shared by both, Ligand B's significantly stronger binding affinity, better logP, and favorable BBB penetration make it the more promising candidate. The improved half-life also contributes to its overall potential.
Output:
0
2025-04-17 19:55:19,547 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (478.181 Da) is within the ideal range, while Ligand B (366.443 Da) is also acceptable, though slightly on the lower side.
2. **TPSA:** Ligand A (76.66) is good, below the 140 threshold. Ligand B (104.43) is still reasonable, but less optimal.
3. **logP:** Ligand A (3.022) is excellent. Ligand B (0.21) is quite low, potentially causing permeability issues. This is a significant drawback for a GPCR target.
4. **HBD:** Both ligands have acceptable HBD counts (Ligand A: 2, Ligand B: 1).
5. **HBA:** Both ligands have acceptable HBA counts (Ligand A: 4, Ligand B: 6).
6. **QED:** Both ligands have good QED scores (Ligand A: 0.592, Ligand B: 0.82), indicating drug-likeness. Ligand B is slightly better here.
7. **DILI:** Ligand A (39.201) has a better DILI score than Ligand B (69.639).
8. **BBB:** Ligand A (86.894) has a significantly better BBB score than Ligand B (59.636). While ADRB2 isn't exclusively a CNS target, some CNS penetration can be beneficial for off-target effects assessment and potentially for peripheral ADRB2 subtypes.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and requires further investigation. However, we can still compare their relative values; Ligand A (-4.696) is better than Ligand B (-4.963).
10. **Solubility:** Ligand A (-3.875) is better than Ligand B (-3.29).
11. **hERG:** Both ligands have low hERG risk (Ligand A: 0.606, Ligand B: 0.529).
12. **Cl_mic:** Ligand A (78.59) has a higher clearance than Ligand B (2.04), meaning Ligand B is more metabolically stable.
13. **t1/2:** Ligand A (16.663) has a longer half-life than Ligand B (-2.062).
14. **Pgp:** Both ligands have low Pgp efflux liability (Ligand A: 0.177, Ligand B: 0.033). Ligand B is slightly better here.
15. **Binding Affinity:** Ligand B (-7.3 kcal/mol) has a significantly better binding affinity than Ligand A (-5.6 kcal/mol). This is a substantial advantage.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are crucial. Ligand A excels in logP and has a reasonable TPSA. Ligand B has a very poor logP, which is a major concern. However, the binding affinity of Ligand B is significantly stronger. The difference in affinity (-7.3 vs -5.6 kcal/mol) is substantial and likely outweighs the logP concern, *provided* formulation strategies can be employed to address the solubility and permeability issues. The better metabolic stability of Ligand B is also a plus.
**Conclusion:**
Despite the lower logP, the significantly improved binding affinity of Ligand B makes it the more promising candidate, assuming formulation challenges can be overcome.
Output:
0
2025-04-17 19:55:19,548 - INFO - Batch 146 complete. Total preferences: 2336
2025-04-17 19:55:19,548 - INFO - Processing batch 147/512...
2025-04-17 19:56:10,590 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (353.315 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (38.33) is significantly better than Ligand B (84.23). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA is still beneficial for absorption. Ligand B's TPSA is quite high, potentially hindering oral bioavailability.
3. **logP:** Both ligands have acceptable logP values (A: 3.667, B: 2.925), falling within the 1-3 range.
4. **HBD/HBA:** Ligand A (HBD=1, HBA=2) is preferable to Ligand B (HBD=2, HBA=5) as it has fewer hydrogen bond donors and acceptors, generally leading to better membrane permeability.
5. **QED:** Ligand B (0.755) has a better QED score than Ligand A (0.357), suggesting a more drug-like profile overall. However, QED is a composite score, and individual properties are more informative.
6. **DILI:** Both ligands have acceptable DILI risk (A: 68.244, B: 63.978), below the 60% threshold for high risk.
7. **BBB:** Ligand A (73.517) has a better BBB percentile than Ligand B (42.032). While not a primary concern for a cardiovascular target, some level of CNS penetration can sometimes be beneficial or at least not detrimental.
8. **Caco-2:** Ligand A (-4.377) has a much better Caco-2 permeability than Ligand B (-5.224). This suggests better intestinal absorption for Ligand A.
9. **Solubility:** Ligand A (-4.71) has better aqueous solubility than Ligand B (-2.863).
10. **hERG:** Ligand A (0.736) has a lower hERG inhibition liability than Ligand B (0.291), which is a significant advantage for cardiovascular drugs.
11. **Cl_mic:** Ligand B (67.971) has a slightly lower microsomal clearance than Ligand A (76.441), suggesting better metabolic stability.
12. **t1/2:** Ligand B (37.492) has a longer in vitro half-life than Ligand A (19.234), which is desirable.
13. **Pgp:** Ligand A (0.444) has lower P-gp efflux liability than Ligand B (0.148), which is favorable for bioavailability.
14. **Binding Affinity:** Ligand B (-6.7 kcal/mol) has a slightly better binding affinity than Ligand A (-6.4 kcal/mol). This is a 0.3 kcal/mol difference, which is not substantial enough to outweigh other significant differences.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A excels in logP, TPSA, and Pgp. While Ligand B has slightly better affinity, the differences in TPSA and Caco-2 permeability are substantial and favor Ligand A. The lower hERG risk of Ligand A is also a critical advantage for a cardiovascular drug.
**Conclusion:**
Despite Ligand B's slightly better QED and half-life, Ligand A demonstrates a superior balance of properties, particularly regarding absorption, permeability, and safety (hERG). The slightly better affinity of Ligand B is not enough to overcome the significant advantages of Ligand A.
Output:
1
2025-04-17 19:56:10,590 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 drug candidates. ADRB2 is a GPCR, so we'll prioritize logP, Pgp, TPSA, and affinity, alongside general drug-like properties.
**Ligand A:**
* **MW:** 338.411 Da (Good - within range)
* **TPSA:** 72.94 (Good - below 140)
* **logP:** 3.325 (Good - within optimal range)
* **HBD:** 1 (Good - low)
* **HBA:** 5 (Good - low)
* **QED:** 0.748 (Excellent - highly drug-like)
* **DILI:** 84.374 (Poor - high risk)
* **BBB:** 32.571 (Poor - low penetration)
* **Caco-2:** -5.173 (Very Poor - likely very low absorption)
* **Solubility:** -3.827 (Very Poor - likely very low solubility)
* **hERG:** 0.052 (Excellent - very low risk)
* **Cl_mic:** 23.049 (Moderate - could be better)
* **t1/2:** -27.521 (Excellent - very long half-life)
* **Pgp:** 0.113 (Excellent - low efflux)
* **Affinity:** -7.2 kcal/mol (Excellent - very strong binding)
**Ligand B:**
* **MW:** 346.406 Da (Good - within range)
* **TPSA:** 65.54 (Good - below 140)
* **logP:** 1.74 (Acceptable - on the lower side, but within range)
* **HBD:** 1 (Good - low)
* **HBA:** 4 (Good - low)
* **QED:** 0.844 (Excellent - highly drug-like)
* **DILI:** 60.915 (Moderate - acceptable risk)
* **BBB:** 80.031 (Good - good penetration)
* **Caco-2:** -4.578 (Poor - likely low absorption)
* **Solubility:** -2.835 (Poor - likely low solubility)
* **hERG:** 0.431 (Acceptable - moderate risk)
* **Cl_mic:** 34.223 (Moderate - could be better)
* **t1/2:** 12.196 (Moderate - acceptable half-life)
* **Pgp:** 0.027 (Excellent - low efflux)
* **Affinity:** -6.3 kcal/mol (Good - strong binding)
**Comparison & Decision:**
Ligand A has a significantly better binding affinity (-7.2 vs -6.3 kcal/mol), a very long half-life, and low Pgp efflux. However, its DILI risk is very high, and its Caco-2 permeability and solubility are extremely poor. These ADME properties are major red flags.
Ligand B has a lower, but still good, binding affinity. It has a much better DILI profile, and a significantly better BBB penetration. While its Caco-2 and solubility are also poor, they are not as disastrous as Ligand A. The slightly lower logP is also less concerning.
Given the GPCR target and the need for reasonable ADME properties, I prioritize a lower DILI risk and better permeability/BBB penetration over the slightly higher affinity of Ligand A. The poor ADME profile of Ligand A is likely to lead to insurmountable challenges in development. While Ligand B's properties aren't perfect, they are more balanced and offer a better starting point for optimization.
Output:
0
2025-04-17 19:56:10,590 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [398.26 , 71.09 , 3.886, 2. , 3. , 0.701, 85.653, 78.558, -5.069, -4.694, 0.641, 65.989, 86.255, 0.43 , -8.4 ]
**Ligand B:** [350.478, 53.43 , 3.574, 1. , 3. , 0.741, 6.592, 93.68 , -4.388, -2.84 , 0.832, 56.843, -11.612, 0.603, -8.5 ]
Here's a breakdown of the comparison, considering the guidelines and GPCR-specific priorities:
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (350.478) is slightly lower, which could be beneficial for permeability, but both are acceptable.
2. **TPSA:** Ligand A (71.09) is higher than Ligand B (53.43). Both are below 140, but Ligand B is better positioned for good oral absorption.
3. **logP:** Both are within the optimal range (1-3). Ligand A (3.886) is at the higher end, potentially raising concerns about off-target effects, while Ligand B (3.574) is more optimal.
4. **HBD:** Ligand A (2) and Ligand B (1) are both good, well within the limit of 5.
5. **HBA:** Both have 3 HBA, which is good.
6. **QED:** Both have good QED scores (A: 0.701, B: 0.741), indicating drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (85.653) has a significantly higher DILI risk than Ligand B (6.592). This is a major concern for Ligand A.
8. **BBB:** Ligand B (93.68) has a much higher BBB penetration potential than Ligand A (78.558). While not strictly necessary for a cardiovascular target, higher BBB penetration can sometimes indicate better overall permeability and distribution.
9. **Caco-2:** Ligand A (-5.069) has a negative Caco-2 value, which is concerning. Ligand B (-4.388) is also negative, but less so.
10. **Solubility:** Ligand B (-2.84) has better aqueous solubility than Ligand A (-4.694).
11. **hERG:** Ligand A (0.641) has a slightly higher hERG risk than Ligand B (0.832), but both are acceptable.
12. **Cl_mic:** Ligand B (56.843) has a lower microsomal clearance than Ligand A (65.989), suggesting better metabolic stability.
13. **t1/2:** Ligand A (86.255) has a longer in vitro half-life than Ligand B (-11.612). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.43) has lower P-gp efflux than Ligand B (0.603), which is favorable for bioavailability.
15. **Affinity:** Both ligands have very similar and excellent binding affinities (-8.4 and -8.5 kcal/mol). The difference is negligible.
**Overall Assessment:**
Ligand B is the stronger candidate. While Ligand A has a longer half-life and lower P-gp efflux, the significantly higher DILI risk and poorer solubility/Caco-2 permeability are major drawbacks. Ligand B presents a much more favorable safety profile (DILI) and better ADME properties (solubility, permeability, metabolic stability) while maintaining comparable binding affinity. The slightly lower half-life of Ligand B is less concerning than the potential liver toxicity of Ligand A.
Output:
0
2025-04-17 19:56:10,590 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (360.328 and 346.471 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (72.83) is slightly higher than Ligand B (58.64). Both are below the 140 threshold for oral absorption, but B is better positioned, especially considering ADRB2 isn't necessarily a CNS target.
3. **logP:** Both ligands have good logP values (2.966 and 2.267), falling within the optimal 1-3 range. Ligand B is slightly lower, which could be beneficial for solubility.
4. **HBD:** Both have 1 HBD, which is acceptable.
5. **HBA:** Ligand A has 5 HBA, while Ligand B has 3. Both are within the acceptable limit of 10.
6. **QED:** Both ligands have similar QED values (0.598 and 0.686), indicating good drug-likeness.
7. **DILI:** Ligand A (52.966) has a higher DILI risk than Ligand B (15.898). This is a significant advantage for Ligand B.
8. **BBB:** Both ligands have reasonably high BBB penetration (78.945 and 72.896). This isn't a primary concern for ADRB2, but higher is generally better.
9. **Caco-2:** Both have negative Caco-2 values, suggesting poor permeability. This is a concern for both.
10. **Solubility:** Ligand B (-2.431) has better solubility than Ligand A (-4.001).
11. **hERG:** Ligand A (0.686) has a slightly higher hERG risk than Ligand B (0.263). This favors Ligand B.
12. **Cl_mic:** Ligand B (51.9) has lower microsomal clearance than Ligand A (73.146), indicating better metabolic stability.
13. **t1/2:** Ligand B (-27.981) has a significantly longer in vitro half-life than Ligand A (-8.352). This is a major advantage for Ligand B.
14. **Pgp:** Ligand A (0.567) has slightly lower P-gp efflux than Ligand B (0.114).
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.3 and -6.5 kcal/mol). The difference is negligible.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand B is better on TPSA, solubility, DILI, hERG, Cl_mic and t1/2. While Ligand A has slightly better Pgp, the other advantages of Ligand B outweigh this.
**Conclusion:**
Ligand B demonstrates a superior ADMET profile, particularly with its lower DILI risk, better solubility, improved metabolic stability (lower Cl_mic and longer t1/2), and lower hERG risk. While both ligands have similar binding affinities and acceptable logP/TPSA values, the overall balance of properties favors Ligand B as a more promising drug candidate.
Output:
0
2025-04-17 19:56:10,590 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [346.383, 104.71 , 2.101, 3. , 5. , 0.679, 36.603, 43.699, -5.001, -2.505, 0.232, 13.439, 38.431, 0.049, -7.1 ]
**Ligand B:** [239.315, 72.72 , 1.306, 4. , 4. , 0.639, 0.853, 8.104, -5.233, -1.252, 0.095, -8.038, -6.514, 0.007, -6.7 ]
**Step-by-step comparison:**
1. **MW:** Ligand A (346.383 Da) is within the ideal range. Ligand B (239.315 Da) is at the lower end, but still acceptable.
2. **TPSA:** Ligand A (104.71) is acceptable, though approaching the upper limit for good oral absorption. Ligand B (72.72) is excellent.
3. **logP:** Both are good (A: 2.101, B: 1.306), falling within the optimal 1-3 range.
4. **HBD:** Both are acceptable (A: 3, B: 4).
5. **HBA:** Both are acceptable (A: 5, B: 4).
6. **QED:** Both are similar and good (A: 0.679, B: 0.639).
7. **DILI:** Ligand A (36.603) is moderate, but acceptable. Ligand B (0.853) is *very* good, indicating a low risk of liver injury.
8. **BBB:** Ligand A (43.699) is moderate. Ligand B (8.104) is quite low.
9. **Caco-2:** Both are negative, indicating poor permeability. This is concerning for both.
10. **Solubility:** Both are negative, indicating poor solubility. This is concerning for both.
11. **hERG:** Both are very low risk (A: 0.232, B: 0.095).
12. **Cl_mic:** Ligand A (13.439) is moderate. Ligand B (-8.038) is *excellent* - indicating very high metabolic stability.
13. **t1/2:** Ligand A (38.431) is good. Ligand B (-6.514) is excellent, indicating a very long half-life.
14. **Pgp:** Both are very low efflux (A: 0.049, B: 0.007).
15. **Affinity:** Ligand A (-7.1) is slightly better than Ligand B (-6.7), but the difference is not huge.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), we prioritize logP, Pgp, TPSA, and affinity. Both ligands are good on logP and Pgp. Ligand B has a significantly better TPSA. The affinity difference is small, but favors Ligand A. However, the significantly better metabolic stability (Cl_mic, t1/2) and much lower DILI risk of Ligand B are highly attractive. The poor Caco-2 and solubility are concerning for both, but can potentially be addressed through formulation strategies.
**Conclusion:**
While Ligand A has a slightly better binding affinity, the superior ADME properties of Ligand B (particularly the DILI risk and metabolic stability) make it the more promising drug candidate. The lower TPSA is also beneficial. Therefore, I choose Ligand B.
0
2025-04-17 19:56:10,591 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (358.316 Da and 361.511 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (68.73) is higher than Ligand B (53.51). For a peripheral GPCR like ADRB2, TPSA is less critical than for a CNS target, but lower is generally preferred for absorption. Ligand B has a better TPSA.
**3. logP:** Both ligands have good logP values (2.358 and 3.098, respectively), falling within the optimal 1-3 range. Ligand B is slightly higher, which could be marginally better for membrane permeability.
**4. H-Bond Donors:** Both have 0 HBD, which is excellent.
**5. H-Bond Acceptors:** Ligand A has 5 HBA, and Ligand B has 4. Both are acceptable, under the threshold of 10.
**6. QED:** Ligand A (0.756) has a better QED score than Ligand B (0.598), indicating a more drug-like profile.
**7. DILI Risk:** Ligand B (41.062) has a significantly lower DILI risk than Ligand A (68.592). This is a major advantage for Ligand B.
**8. BBB Penetration:** Both have reasonably high BBB penetration (Ligand A: 90.772, Ligand B: 70.764). However, as ADRB2 is not a primary CNS target, this is less of a deciding factor.
**9. Caco-2 Permeability:** Both have negative Caco-2 values, which is unusual and suggests a potential issue with permeability prediction. However, the values are similar (-4.122 and -4.921).
**10. Aqueous Solubility:** Both have negative solubility values, which is also unusual. Ligand B (-2.88) is slightly better than Ligand A (-3.429).
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (0.434 and 0.632).
**12. Microsomal Clearance:** Ligand B (59.672) has lower microsomal clearance than Ligand A (85.244), indicating better metabolic stability.
**13. In vitro Half-Life:** Ligand A (-44.817) has a much longer in vitro half-life than Ligand B (-3.9). This is a significant advantage for Ligand A.
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (0.223 and 0.626).
**15. Binding Affinity:** Ligand A (-6.9 kcal/mol) has a slightly better binding affinity than Ligand B (-6.4 kcal/mol). While the difference is not huge, it's a positive for Ligand A.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity) and the general drug-like properties, Ligand B appears to be the more promising candidate. The significantly lower DILI risk and better metabolic stability (lower Cl_mic) are crucial advantages. While Ligand A has a slightly better QED, longer half-life, and affinity, the DILI risk is a major concern. The TPSA of Ligand B is also more favorable. The slight affinity difference is unlikely to outweigh the safety and metabolic advantages of Ligand B.
Output:
0
2025-04-17 19:56:10,591 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, the key priorities are logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB.
Let's compare the ligands property by property:
1. **MW:** Both ligands (348.451 and 366.575 Da) fall within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (112.7) is better than Ligand B (52.23). Lower TPSA generally favors better absorption, and is particularly important for GPCRs.
3. **logP:** Ligand B (3.176) is slightly higher than Ligand A (1.387), but both are within the optimal 1-3 range.
4. **HBD/HBA:** Ligand A has 2 HBD and 6 HBA, while Ligand B has 1 HBD and 4 HBA. Both are acceptable.
5. **QED:** Both ligands have similar QED values (0.7 and 0.691), indicating good drug-likeness.
6. **DILI:** Ligand A (36.022) has a higher DILI risk than Ligand B (15.355). This is a significant negative for Ligand A.
7. **BBB:** Ligand B (56.921) has a higher BBB percentile than Ligand A (42.032). While not a primary concern for a cardiovascular target, higher BBB is generally favorable.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual. However, the magnitude of the negative value is similar.
9. **Solubility:** Ligand A (-1.752) has better solubility than Ligand B (-2.308).
10. **hERG:** Ligand A (0.106) has a significantly lower hERG risk than Ligand B (0.836). This is a major advantage for Ligand A.
11. **Cl_mic:** Ligand B (72.755) has a higher microsomal clearance than Ligand A (27.216), indicating lower metabolic stability.
12. **t1/2:** Ligand A (15.446) has a longer in vitro half-life than Ligand B (12.465).
13. **Pgp:** Ligand A (0.012) shows much lower P-gp efflux liability than Ligand B (0.223). This is a significant advantage for Ligand A.
14. **Binding Affinity:** Ligand A (-7.4 kcal/mol) has a stronger binding affinity than Ligand B (-6.1 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME concerns.
**Overall Assessment:**
Ligand A has a significantly better binding affinity, lower Pgp efflux, lower hERG risk, and better metabolic stability (lower Cl_mic, longer t1/2). While Ligand B has a lower DILI risk and slightly better logP, the superior potency and ADME profile of Ligand A, particularly the lower Pgp efflux and hERG risk, make it the more promising candidate for further development. The TPSA is also better for Ligand A.
Output:
1
2025-04-17 19:56:10,591 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (359.86 and 345.42 Da). No significant difference here.
2. **TPSA:** Both are below the 140 A^2 threshold for good oral absorption (67.59 and 64.86 A^2). Ligand B is slightly better.
3. **logP:** Both are within the optimal range (3.20 and 2.34). Ligand A is slightly higher, which could be a minor concern for off-target effects, but still acceptable.
4. **HBD:** Ligand A has 2 HBD, and Ligand B has 1. Both are within the acceptable limit of <=5.
5. **HBA:** Ligand A has 4 HBA, Ligand B has 6. Both are within the acceptable limit of <=10.
6. **QED:** Both have good QED scores (0.879 and 0.901), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A has a DILI risk of 67.47%, while Ligand B has 42.15%. Ligand B is significantly better here, indicating a lower risk of liver injury. This is a crucial factor.
8. **BBB:** Ligand A has a BBB penetration of 66.42%, while Ligand B has 91.51%. ADRB2 is a cardiovascular target, so BBB penetration is not *critical* but can be beneficial for potential off-target effects. Ligand B is substantially better.
9. **Caco-2:** Both have negative Caco-2 values (-4.951 and -5.041), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Both have negative solubility values (-4.115 and -3.061), which is also concerning. Poor solubility can hinder bioavailability. Ligand B is slightly better.
11. **hERG:** Both have very low hERG inhibition risk (0.586 and 0.32). This is excellent for both.
12. **Cl_mic:** Ligand A has a more negative Cl_mic (-5.585), indicating lower clearance and better metabolic stability, which is favorable. Ligand B has 21.901.
13. **t1/2:** Ligand A has a longer in vitro half-life (39.893 hours) compared to Ligand B (8.651 hours). This is a significant advantage for Ligand A.
14. **Pgp:** Both have low Pgp efflux liability (0.184 and 0.405).
15. **Binding Affinity:** Both have the same binding affinity (-5.8 kcal/mol).
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. While both ligands perform similarly in affinity, Ligand B excels in TPSA and Pgp, and has a much better BBB score. However, the significantly better DILI score and longer half-life of Ligand A are important considerations. The poor Caco-2 and solubility for both are concerning and would require further investigation/optimization.
**Overall Assessment:**
Despite the similar binding affinity, Ligand B has a significantly better safety profile (lower DILI) and better predicted permeability/absorption (higher BBB, better TPSA). Ligand A has better metabolic stability and half-life, but the DILI risk is a major concern. Given the balance of properties, and the importance of minimizing toxicity, Ligand B appears to be the more promising candidate.
Output:
0
2025-04-17 19:56:10,591 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [348.418, 75.79, 1.228, 2, 4, 0.858, 13.261, 89.957, -4.675, -1.734, 0.798, -5.226, 3.004, 0.107, -6.3]**
**Ligand B: [346.471, 58.64, 2.265, 1, 3, 0.777, 14.308, 62.854, -4.761, -2.601, 0.145, 38.899, 9.298, 0.031, -7.8]**
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). A is 348.418, B is 346.471. No significant difference.
2. **TPSA:** Ligand A (75.79) is slightly higher than Ligand B (58.64). Both are acceptable for oral absorption (<140), but B is better.
3. **logP:** Ligand A (1.228) is within the optimal range, while Ligand B (2.265) is approaching the upper limit. A is slightly preferred here.
4. **H-Bond Donors:** Ligand A (2) is better than Ligand B (1), as it's still within the acceptable limit of 5.
5. **H-Bond Acceptors:** Ligand A (4) is slightly higher than Ligand B (3), but both are within the acceptable limit of 10.
6. **QED:** Ligand A (0.858) is better than Ligand B (0.777), indicating a more drug-like profile.
7. **DILI:** Ligand A (13.261) is significantly better than Ligand B (14.308), indicating lower liver injury risk.
8. **BBB:** Ligand A (89.957) is much better than Ligand B (62.854). As ADRB2 is a GPCR, BBB penetration is a desirable characteristic, especially if CNS effects are anticipated or if targeting peripheral ADRB2 requires sufficient distribution.
9. **Caco-2 Permeability:** Both are negative, indicating poor permeability. Ligand B (-4.761) is slightly worse than Ligand A (-4.675).
10. **Aqueous Solubility:** Both are negative, indicating poor solubility. Ligand B (-2.601) is worse than Ligand A (-1.734).
11. **hERG Inhibition:** Ligand A (0.798) is better than Ligand B (0.145), indicating lower cardiotoxicity risk.
12. **Microsomal Clearance:** Ligand A (-5.226) is much better than Ligand B (38.899), indicating better metabolic stability.
13. **In vitro Half-Life:** Ligand A (3.004) is significantly better than Ligand B (9.298).
14. **P-gp Efflux:** Ligand A (0.107) is better than Ligand B (0.031), indicating lower efflux.
15. **Binding Affinity:** Ligand B (-7.8) is significantly better than Ligand A (-6.3). This is a 1.5 kcal/mol advantage, which is substantial.
**Overall Assessment:**
Ligand B has a significantly better binding affinity (-7.8 kcal/mol vs -6.3 kcal/mol). However, Ligand A demonstrates superior ADME properties across the board, including better BBB penetration, lower DILI risk, better metabolic stability, and lower hERG inhibition. Given that we are dealing with a GPCR, the balance between potency and ADME is crucial. While the affinity difference is notable, the substantial improvements in ADME properties with Ligand A, particularly the BBB penetration and reduced toxicity risks, make it a more promising drug candidate.
Output:
1
2025-04-17 19:56:10,591 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (339.483 and 351.447 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (37.27) is significantly better than Ligand B (84.67). ADRB2 is not a CNS target, but lower TPSA generally improves absorption. Ligand A is well below the 140 threshold, while B is approaching it.
3. **logP:** Ligand A (4.005) is slightly higher than Ligand B (1.612). While both are within the acceptable range (1-3), A is pushing the upper limit and could potentially have solubility issues. B is closer to the ideal range.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 2 HBA, while Ligand B has 5. Ligand A is preferable here, as higher HBA can sometimes reduce permeability.
6. **QED:** Ligand A (0.901) is slightly better than Ligand B (0.842), indicating a more drug-like profile.
7. **DILI:** Both ligands have acceptable DILI risk (32.842 and 35.169), below the 40 threshold.
8. **BBB:** Ligand A (97.053) has a much higher BBB penetration score than Ligand B (77.162). While not a primary concern for ADRB2 (cardiovascular target), higher BBB is generally a positive attribute.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.559 and -4.577), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand A (-3.896) has slightly worse solubility than Ligand B (-2.443).
11. **hERG:** Ligand A (0.921) has a slightly higher hERG risk than Ligand B (0.255). This is a negative for Ligand A.
12. **Cl_mic:** Ligand B (22.083) has significantly lower microsomal clearance than Ligand A (51.73), indicating better metabolic stability.
13. **t1/2:** Ligand B (-6.953) has a longer in vitro half-life than Ligand A (35.575). This is a significant advantage for B.
14. **Pgp:** Ligand A (0.565) has lower P-gp efflux than Ligand B (0.129), which is favorable.
15. **Affinity:** Ligand B (-7.3) has a slightly better binding affinity than Ligand A (-6.9). While the difference is not huge, it's enough to consider.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A has a better logP and Pgp, but Ligand B has a much better TPSA and comparable affinity. The metabolic stability (Cl_mic and t1/2) of Ligand B is also a significant advantage.
**Overall Assessment:**
Despite the slightly better logP and Pgp of Ligand A, Ligand B's superior TPSA, metabolic stability (lower Cl_mic, longer t1/2), and slightly better affinity outweigh the drawbacks. The negative Caco-2 values are concerning for both, but the other properties of Ligand B make it a more promising starting point for optimization.
Output:
0
2025-04-17 19:56:10,591 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**1. Molecular Weight:** Both ligands (355.479 Da and 349.475 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (89.95) is better than Ligand B (69.72). Both are below the 140 A^2 threshold for good oral absorption, but lower TPSA is generally preferred for GPCRs, and Ligand B is significantly lower.
**3. logP:** Ligand B (1.542) is better than Ligand A (0.756). Both are within the optimal 1-3 range, but Ligand A is a bit low, potentially impacting membrane permeability.
**4. H-Bond Donors:** Ligand A (2) is slightly better than Ligand B (1). Both are acceptable.
**5. H-Bond Acceptors:** Ligand A (4) is slightly better than Ligand B (3). Both are acceptable.
**6. QED:** Both ligands have similar QED values (0.705 and 0.783), indicating good drug-likeness.
**7. DILI:** Ligand A (12.524) is significantly better than Ligand B (24.544). This is a major advantage for Ligand A, as lower DILI risk is crucial.
**8. BBB:** Ligand B (67.158) is better than Ligand A (18.457). While ADRB2 isn't strictly a CNS target, some CNS penetration can be beneficial for understanding off-target effects and potential side effects.
**9. Caco-2 Permeability:** Ligand A (-5.144) is better than Ligand B (-4.742). Higher values indicate better intestinal absorption.
**10. Aqueous Solubility:** Ligand A (-0.811) is better than Ligand B (-1.919). Higher solubility is generally preferred.
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.114 and 0.134), which is excellent.
**12. Microsomal Clearance:** Ligand A (12.406) is significantly better than Ligand B (26.119). Lower clearance indicates better metabolic stability.
**13. In vitro Half-Life:** Ligand A (-9.162) is significantly better than Ligand B (2.245). A longer half-life is desirable.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.021 and 0.043).
**15. Binding Affinity:** Ligand B (-6.9) is better than Ligand A (-5.9). This is a 1.0 kcal/mol difference, which is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
While Ligand B has a better binding affinity and BBB penetration, Ligand A demonstrates a significantly superior safety profile (DILI) and better ADME properties (Cl_mic, t1/2, solubility, Caco-2). The 1.0 kcal/mol difference in binding affinity is important, but the substantial improvements in safety and ADME for Ligand A are more critical for overall drug development success. Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), the balance leans towards Ligand A due to its favorable safety and ADME profile.
Output:
1
2025-04-17 19:56:10,591 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (340.427 and 353.507 Da) are within the ideal range of 200-500 Da. No significant difference here.
2. **TPSA:** Ligand A (88.99) is better than Ligand B (53.09). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally aids absorption.
3. **logP:** Both ligands have good logP values (2.414 and 1.593), falling within the optimal 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Ligand A (2) is reasonable, while Ligand B (0) is also good.
5. **HBA:** Ligand A (3) is reasonable, and Ligand B (4) is also acceptable.
6. **QED:** Ligand A (0.862) is significantly better than Ligand B (0.632), indicating a more drug-like profile.
7. **DILI:** Ligand B (14.657) is *much* better than Ligand A (56.689). This is a major advantage for Ligand B, as liver toxicity is a critical concern.
8. **BBB:** Ligand B (72.819) is better than Ligand A (53.044), but since this is a cardiovascular target, BBB penetration is not a high priority.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.78 and -4.617), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand A (-4.003) is better than Ligand B (0.165), indicating better aqueous solubility.
11. **hERG:** Ligand A (0.331) is better than Ligand B (0.639), suggesting a lower risk of cardiotoxicity.
12. **Cl_mic:** Ligand B (8.222) has a significantly lower microsomal clearance than Ligand A (23.235), indicating better metabolic stability.
13. **t1/2:** Ligand A (6.867) has a longer in vitro half-life than Ligand B (-0.67). This is a positive for Ligand A.
14. **Pgp:** Ligand A (0.063) is better than Ligand B (0.051), indicating lower P-gp efflux.
15. **Binding Affinity:** Both ligands have very similar and excellent binding affinities (-6.1 and -5.9 kcal/mol). The difference is not substantial enough to be a deciding factor.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A has a slightly better logP and Pgp, while Ligand B has a significantly better TPSA and *much* better DILI risk. The affinities are comparable.
**Overall Assessment:**
While Ligand A has some advantages in solubility, half-life, and Pgp efflux, the significantly lower DILI risk for Ligand B is a major factor. The poor Caco-2 permeability is a concern for both, but the potential for liver toxicity with Ligand A is a greater risk. Considering the cardiovascular context, metabolic stability (lower Cl_mic) is also important, and Ligand B excels here.
Output:
0
2025-04-17 19:56:10,591 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [363.845, 78.6, 4.152, 2, 4, 0.855, 72.819, 85.072, -4.659, -4.757, 0.474, 17.134, 46.361, 0.575, -6.5]**
**Ligand B: [344.419, 101.06, 1.355, 3, 7, 0.631, 45.638, 52.036, -5.301, -1.917, 0.236, 31.899, 24.668, 0.006, -5.5]**
1. **Molecular Weight:** Both are within the ideal range (200-500 Da). Ligand B (344.419) is slightly lower, which is generally favorable for permeability, but both are acceptable.
2. **TPSA:** Ligand A (78.6) is better than Ligand B (101.06). ADRB2 is not a CNS target, but lower TPSA generally improves absorption.
3. **logP:** Ligand A (4.152) is higher than Ligand B (1.355). While 4.152 is approaching the upper limit, it's still within a reasonable range. Ligand B's logP is quite low and could hinder membrane permeability.
4. **H-Bond Donors:** Ligand A (2) is better than Ligand B (3). Lower is preferred.
5. **H-Bond Acceptors:** Ligand A (4) is better than Ligand B (7). Lower is preferred.
6. **QED:** Ligand A (0.855) is significantly better than Ligand B (0.631), indicating a more drug-like profile.
7. **DILI:** Ligand A (72.819) is higher than Ligand B (45.638), indicating a higher risk of liver injury. This is a significant drawback for Ligand A.
8. **BBB:** Ligand A (85.072) is much higher than Ligand B (52.036). While ADRB2 isn't a primary CNS target, some off-target CNS effects are possible with GPCRs, and higher BBB penetration *could* contribute to this. However, it's not a critical factor here.
9. **Caco-2:** Ligand A (-4.659) is better than Ligand B (-5.301). Higher values indicate better absorption.
10. **Aqueous Solubility:** Ligand A (-4.757) is better than Ligand B (-1.917). Higher values are preferred.
11. **hERG:** Ligand A (0.474) is better than Ligand B (0.236). Lower is preferred.
12. **Cl_mic:** Ligand A (17.134) is significantly better than Ligand B (31.899). Lower clearance indicates better metabolic stability.
13. **t1/2:** Ligand A (46.361) is better than Ligand B (24.668). Longer half-life is desirable.
14. **Pgp:** Ligand A (0.575) is better than Ligand B (0.006). Lower efflux is preferred.
15. **Binding Affinity:** Ligand A (-6.5) is slightly better than Ligand B (-5.5), a 1 kcal/mol difference. This is a significant advantage.
**Overall Assessment:**
Ligand A has a clear advantage in most key ADME properties (QED, Cl_mic, t1/2, Pgp, solubility, Caco-2) and a slightly better binding affinity. However, its DILI risk is considerably higher. Ligand B has a lower DILI risk, but suffers from a low logP, higher HBD/HBA counts, and poorer ADME properties overall.
Given the importance of metabolic stability and absorption for a successful drug, and the slight but meaningful affinity advantage, I believe Ligand A is the more promising candidate *despite* the higher DILI risk. DILI risk can be further investigated and potentially mitigated through structural modifications. The poor ADME profile of Ligand B is more difficult to address.
Output:
1
2025-04-17 19:56:10,592 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's systematically compare Ligand A and Ligand B against the provided guidelines, keeping in mind that ADRB2 is a GPCR, so logP, Pgp, TPSA, and affinity are particularly important.
1. **MW:** Both ligands (352.479 Da and 391.27 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (113.32) is better than Ligand B (53.76) as it is closer to the threshold for good oral absorption.
3. **logP:** Ligand B (3.48) is slightly higher than Ligand A (1.128). While both are within the 1-3 range, Ligand B is approaching the upper limit where solubility issues could arise.
4. **HBD:** Ligand A (4) is higher than Ligand B (0). While higher HBD can improve solubility, it can also reduce permeability.
5. **HBA:** Both ligands have 3 HBA, which is acceptable.
6. **QED:** Ligand B (0.723) has a better QED score than Ligand A (0.525), indicating a more drug-like profile.
7. **DILI:** Ligand A (18.922) has a significantly lower DILI risk than Ligand B (53.276). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (85.964) has a much higher BBB penetration percentile than Ligand A (64.831). While ADRB2 isn't necessarily a CNS target, higher BBB penetration can sometimes correlate with better overall distribution.
9. **Caco-2:** Ligand A (-5.156) has a better Caco-2 permeability than Ligand B (-4.423).
10. **Solubility:** Ligand A (-2.684) has better solubility than Ligand B (-3.617).
11. **hERG:** Ligand A (0.164) has a lower hERG inhibition liability than Ligand B (0.669), which is crucial for avoiding cardiotoxicity.
12. **Cl_mic:** Ligand A (25.14) has a lower microsomal clearance than Ligand B (56.949), indicating better metabolic stability.
13. **t1/2:** Ligand B (32.616) has a longer in vitro half-life than Ligand A (-4.369). This is a positive for Ligand B.
14. **Pgp:** Ligand A (0.016) has a much lower P-gp efflux liability than Ligand B (0.507). Lower Pgp efflux is favorable for oral bioavailability.
15. **Affinity:** Both ligands have very similar binding affinities (-6.4 kcal/mol and -4.4 kcal/mol). However, Ligand A has a significantly better affinity.
**Overall Assessment:**
Ligand A presents a more favorable balance of properties. While Ligand B has a better QED and half-life, Ligand A excels in critical areas like DILI risk, hERG inhibition, metabolic stability (Cl_mic), P-gp efflux, solubility, and Caco-2 permeability. The significantly better affinity of Ligand A also outweighs the slight advantage of Ligand B in BBB penetration. The lower TPSA of Ligand B is also a plus. However, the superior safety profile and ADME properties of Ligand A make it the more promising candidate.
**Output:**
1
2025-04-17 19:56:10,592 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (347.5 and 342.4 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (43.86) is significantly better than Ligand B (104.62). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is quite high and may suffer from poor absorption.
3. **logP:** Ligand A (2.275) is within the optimal 1-3 range. Ligand B (0.99) is a bit low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer hydrogen bond donors generally improve permeability.
5. **HBA:** Ligand A (3) is better than Ligand B (7). Lower HBA counts also favor permeability.
6. **QED:** Both ligands have similar QED values (0.717 and 0.692), indicating good drug-likeness.
7. **DILI:** Ligand A (5.777) has a much lower DILI risk than Ligand B (58.24). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (81) is much better than Ligand B (28.461). While ADRB2 isn't strictly a CNS target, some CNS penetration can be beneficial for understanding off-target effects and potential side effects.
9. **Caco-2:** Ligand A (-4.59) is better than Ligand B (-5.746), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-1.752) is better than Ligand B (-2.467).
11. **hERG:** Ligand A (0.582) is better than Ligand B (0.272). Lower hERG inhibition is crucial for avoiding cardiotoxicity, a significant concern with cardiovascular targets.
12. **Cl_mic:** Ligand A (23.524) has a better (lower) microsomal clearance than Ligand B (-5.452). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand B (38.84) has a longer in vitro half-life than Ligand A (22.791). This is a positive for Ligand B, but not enough to overcome other issues.
14. **Pgp:** Ligand A (0.052) has lower P-gp efflux than Ligand B (0.026).
15. **Binding Affinity:** Ligand B (-6.3) has a slightly better binding affinity than Ligand A (-4.8). However, the difference is 1.5 kcal/mol, which is not enough to overcome the significant ADME deficiencies of Ligand B.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical ADME properties (TPSA, logP, HBD, HBA, DILI, BBB, solubility, hERG, Cl_mic). While Ligand B has a slightly better binding affinity and half-life, the superior ADME profile of Ligand A makes it a much more promising drug candidate. The lower DILI risk and better TPSA are particularly important.
Output:
1
2025-04-17 19:56:10,592 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [361.427, 127.74 , 1.008, 3. , 5. , 0.605, 85.227, 34.238, -5.613, -3.613, 0.747, 10.359, -23.372, 0.062, -3.5 ]
**Ligand B:** [343.431, 83.28 , 1.817, 2. , 5. , 0.887, 37.922, 78.364, -4.776, -2.065, 0.268, 5.896, 13.257, 0.103, -6.7 ]
Here's a step-by-step comparison, considering GPCR priorities (logP, Pgp, TPSA, Affinity):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (343.431) is slightly lower, which is generally favorable.
2. **TPSA:** Ligand A (127.74) is higher than Ligand B (83.28). Ligand B is better, being closer to the <140 threshold for good oral absorption.
3. **logP:** Ligand A (1.008) is a bit low, potentially hindering permeability. Ligand B (1.817) is better, falling within the optimal 1-3 range.
4. **HBD:** Ligand A (3) and Ligand B (2) are both acceptable.
5. **HBA:** Both ligands have 5 HBA, which is acceptable.
6. **QED:** Ligand B (0.887) has a significantly better QED score than Ligand A (0.605), indicating a more drug-like profile.
7. **DILI:** Ligand A (85.227) has a higher DILI risk than Ligand B (37.922). This is a significant negative for Ligand A.
8. **BBB:** Ligand B (78.364) has a better BBB penetration score than Ligand A (34.238), although for a cardiovascular target, this isn't *critical*, it's still a plus.
9. **Caco-2:** Ligand A (-5.613) is worse than Ligand B (-4.776), indicating lower intestinal absorption.
10. **Solubility:** Ligand A (-3.613) is worse than Ligand B (-2.065).
11. **hERG:** Ligand A (0.747) is slightly higher than Ligand B (0.268), indicating a slightly higher risk of hERG inhibition.
12. **Cl_mic:** Ligand B (5.896) has a lower microsomal clearance than Ligand A (10.359), suggesting better metabolic stability.
13. **t1/2:** Ligand B (13.257) has a longer in vitro half-life than Ligand A (-23.372), which is a significant advantage.
14. **Pgp:** Ligand A (0.062) has a lower P-gp efflux liability than Ligand B (0.103), which is a slight advantage.
15. **Affinity:** Ligand B (-6.7 kcal/mol) has a significantly better binding affinity than Ligand A (-3.5 kcal/mol). This is a substantial advantage, more than offsetting any minor drawbacks.
**Overall Assessment:**
Ligand B is clearly the superior candidate. It has a better QED score, lower DILI risk, better BBB penetration, improved solubility, better Caco-2 permeability, lower microsomal clearance, longer half-life, and *significantly* stronger binding affinity. While Ligand A has slightly lower P-gp efflux, the other advantages of Ligand B far outweigh this. The affinity difference is particularly important for a GPCR target.
Output:
0
2025-04-17 19:56:10,592 - INFO - Batch 147 complete. Total preferences: 2352
2025-04-17 19:56:10,592 - INFO - Processing batch 148/512...
2025-04-17 19:56:59,366 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (370.431 and 349.519 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (61.44) is significantly better than Ligand A (115.89). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (2.476) is within the optimal 1-3 range, while Ligand A (-0.385) is quite low, potentially hindering membrane permeability. This is a significant advantage for Ligand B.
4. **HBD:** Both ligands have 2 HBD, which is acceptable.
5. **HBA:** Ligand B (3) has fewer HBA than Ligand A (5), which is slightly preferable.
6. **QED:** Both ligands have the same QED (0.662), indicating similar drug-likeness.
7. **DILI:** Ligand A (65.491) has a higher DILI risk than Ligand B (7.832). This is a major concern for Ligand A.
8. **BBB:** Ligand B (70.88) shows better BBB penetration than Ligand A (46.762), but this isn't a primary concern for a cardiovascular target.
9. **Caco-2:** Both ligands have similar negative Caco-2 values (-5.314 and -5.048). This suggests poor permeability for both, but the difference isn't substantial.
10. **Solubility:** Both ligands have similar negative solubility values (-2.091 and -2.049), indicating poor aqueous solubility.
11. **hERG:** Ligand A (0.113) has a slightly lower hERG risk than Ligand B (0.457), but both are relatively low.
12. **Cl_mic:** Ligand A (-2.881) has a much lower (better) microsomal clearance than Ligand B (27.006), suggesting better metabolic stability.
13. **t1/2:** Both ligands have similar in vitro half-lives (-6.641 and -6.717).
14. **Pgp:** Ligand A (0.015) has much lower P-gp efflux liability than Ligand B (0.032), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand B (-6.0) has a slightly better binding affinity than Ligand A (-4.8), but the difference is not substantial enough to outweigh other factors.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, and affinity are important. Ligand B excels in logP and has a better TPSA. While Ligand A has better Pgp efflux, the significantly higher DILI risk and poorer logP make it less desirable. The slightly better affinity of Ligand B is a bonus.
**Conclusion:**
Considering the balance of properties, Ligand B is the more promising drug candidate. Its lower DILI risk, better logP, and favorable TPSA outweigh the slightly better metabolic stability and Pgp profile of Ligand A.
Output:
0
2025-04-17 19:56:59,367 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (350.5 & 367.8 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Both ligands (78.43 & 71.53) are below the 140 A^2 threshold for good oral absorption, and acceptable for a non-CNS GPCR target like ADRB2. Ligand B is slightly better.
3. **logP:** Both ligands (2.375 & 2.041) are within the optimal 1-3 range. No strong preference.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (1), but both are acceptable (<=5).
5. **HBA:** Ligand A (3) and Ligand B (4) are both within the acceptable range (<=10).
6. **QED:** Ligand B (0.83) has a better QED score than Ligand A (0.629), indicating a more drug-like profile.
7. **DILI:** Ligand B (50.989) has a higher DILI risk than Ligand A (15.006). This is a significant negative for Ligand B.
8. **BBB:** BBB is less critical for ADRB2 (cardiovascular target). Ligand B (89.57) is higher than Ligand A (53.432), but this isn't a primary driver.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.799) is slightly better than Ligand B (-4.756).
10. **Solubility:** Ligand B (-4.392) is slightly better than Ligand A (-3.07) in terms of solubility, but both are poor.
11. **hERG:** Both ligands have low hERG inhibition liability (0.277 & 0.34), which is good.
12. **Cl_mic:** Ligand B (18.554) has a significantly lower microsomal clearance than Ligand A (50.178), indicating better metabolic stability.
13. **t1/2:** Ligand B (-14.995) has a longer in vitro half-life than Ligand A (-10.609), which is desirable.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.202 & 0.018), which is good.
15. **Binding Affinity:** Ligand B (-7.1 kcal/mol) has a slightly better binding affinity than Ligand A (-6.8 kcal/mol). This is a 0.3 kcal/mol difference, which is not huge but still relevant.
**Overall Assessment:**
Ligand B has a better QED, metabolic stability (Cl_mic), half-life, and binding affinity. However, its DILI risk is significantly higher than Ligand A. The DILI risk is a major concern, especially in cardiovascular drug development. While the affinity difference is favorable for Ligand B, the substantial DILI risk outweighs this benefit. Ligand A, while not perfect, presents a better overall safety profile.
**Output:**
1
2025-04-17 19:56:59,367 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (363.757 Da) and Ligand B (348.443 Da) both fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (124.63) is slightly above the preferred <140 for good oral absorption, but still reasonable. Ligand B (59.08) is excellent, well below 140. This favors Ligand B.
3. **logP:** Ligand A (1.781) is within the optimal 1-3 range. Ligand B (0.919) is a little low, potentially impacting permeability. This favors Ligand A.
4. **HBD:** Ligand A (2) and Ligand B (0) are both acceptable, below the limit of 5.
5. **HBA:** Ligand A (8) is acceptable, below the limit of 10. Ligand B (4) is also good.
6. **QED:** Both Ligand A (0.79) and Ligand B (0.709) are above 0.5, indicating good drug-like properties. Ligand A is slightly better.
7. **DILI:** Ligand A (99.341) has a very high DILI risk, which is a significant concern. Ligand B (23.149) has a very low DILI risk. This *strongly* favors Ligand B.
8. **BBB:** Ligand A (50.756) has moderate BBB penetration. Ligand B (68.166) is better, but still not exceptionally high. Considering ADRB2 is a cardiovascular target, BBB penetration is not a primary concern, but it's a slight advantage for Ligand B.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.754 and -4.636), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-4.825) and Ligand B (-1.425) both have negative solubility values, indicating poor aqueous solubility. Ligand B is better.
11. **hERG:** Ligand A (0.273) has a low hERG risk, which is excellent. Ligand B (0.389) is also low, but slightly higher. This favors Ligand A.
12. **Cl_mic:** Ligand A (64.989) has a moderate microsomal clearance. Ligand B (33.596) has a lower clearance, suggesting better metabolic stability. This favors Ligand B.
13. **t1/2:** Ligand A (-40.413) has a very negative in vitro half-life, which is concerning. Ligand B (5.931) has a positive half-life, indicating better stability. This *strongly* favors Ligand B.
14. **Pgp:** Ligand A (0.202) has low P-gp efflux, which is good. Ligand B (0.098) is even lower, which is better. This favors Ligand B.
15. **Affinity:** Ligand A (-6.3 kcal/mol) has slightly better binding affinity than Ligand B (-5.8 kcal/mol). This is a positive for Ligand A, but the difference is not huge.
**Overall Assessment:**
While Ligand A has slightly better affinity and hERG risk, the extremely high DILI risk and poor in vitro half-life are major red flags. Ligand B, despite having a slightly lower affinity and logP, presents a much more favorable ADMET profile, particularly the significantly lower DILI risk and improved metabolic stability. For a cardiovascular target like ADRB2, metabolic stability and minimizing toxicity are paramount. The slightly lower affinity of Ligand B can potentially be optimized in subsequent iterations.
Output:
0
2025-04-17 19:56:59,367 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (354.535 Da and 342.33 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (69.64) is better than Ligand B (79.13). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (3.107 and 2.323), falling within the 1-3 optimal range. Ligand A is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Ligand A (2) is preferable to Ligand B (0). While both are acceptable, a small number of HBDs can aid solubility without drastically impacting permeability.
5. **HBA:** Ligand B (7) is higher than Ligand A (3). Lower HBA is generally preferred for better permeability.
6. **QED:** Both ligands have similar QED values (0.633 and 0.662), indicating good drug-likeness.
7. **DILI:** Ligand A (11.632) is significantly better than Ligand B (88.872). This is a *major* advantage for Ligand A. DILI is a critical safety concern.
8. **BBB:** Ligand A (74.254) is better than Ligand B (69.135), but this is less important for a cardiovascular target.
9. **Caco-2:** Ligand A (-4.561) is better than Ligand B (-4.148). Higher Caco-2 permeability suggests better intestinal absorption.
10. **Solubility:** Ligand A (-3.033) is better than Ligand B (-4.19). Better solubility is always a plus.
11. **hERG:** Ligand A (0.539) is better than Ligand B (0.218). Lower hERG inhibition is crucial for avoiding cardiotoxicity, especially for a cardiovascular target.
12. **Cl_mic:** Ligand A (72.044) is better than Ligand B (109.36). Lower clearance indicates better metabolic stability.
13. **t1/2:** Ligand A (-8.701) is significantly better than Ligand B (-35.073). A longer half-life is desirable for less frequent dosing.
14. **Pgp:** Ligand A (0.074) is better than Ligand B (0.195). Lower P-gp efflux improves bioavailability.
15. **Binding Affinity:** Ligand B (-7.5) has a slightly better binding affinity than Ligand A (-6.2). However, the difference of 1.3 kcal/mol is not substantial enough to outweigh the numerous advantages of Ligand A.
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Ligand A is competitive in these areas, and *significantly* outperforms Ligand B in crucial ADMET properties (DILI, hERG, Cl_mic, t1/2). The slightly better affinity of Ligand B is not enough to compensate for its poor safety and pharmacokinetic profile.
**Conclusion:**
Ligand A is the far superior candidate due to its significantly better safety profile (DILI, hERG), improved metabolic stability (Cl_mic, t1/2), better solubility, and favorable Caco-2 and Pgp values. The slightly lower binding affinity is a manageable trade-off.
Output:
1
2025-04-17 19:56:59,367 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
The target is ADRB2, a GPCR. Therefore, priorities are logP, Pgp, TPSA, affinity, and BBB. Let's analyze each ligand against these and other important parameters.
* **Molecular Weight:** Both ligands are within the acceptable range (200-500 Da). Ligand A (346.471 Da) is slightly preferred due to being lower.
* **TPSA:** Both are around 51, which is acceptable for oral absorption, but higher than ideal for CNS penetration (though not a primary concern for ADRB2 unless CNS effects are desired).
* **logP:** Ligand A (3.099) is better than Ligand B (4.948). Ligand B is pushing the upper limit of acceptable logP, potentially leading to solubility issues and off-target interactions.
* **H-Bond Donors/Acceptors:** Both have reasonable HBD (1) and HBA (4/5) counts.
* **QED:** Ligand A (0.771) has a significantly better QED score than Ligand B (0.588), indicating better overall drug-likeness.
* **DILI:** Ligand A (21.908) has a much lower DILI risk than Ligand B (85.498). This is a critical advantage.
* **BBB:** Ligand A (73.827) shows better BBB penetration than Ligand B (67.584), although both are not exceptionally high.
* **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
* **Solubility:** Ligand A (-1.852) has better solubility than Ligand B (-5.302).
* **hERG:** Both ligands show low hERG inhibition liability (0.8 and 0.878).
* **Cl_mic:** Ligand B (72.886) has a higher microsomal clearance than Ligand A (30.212), indicating faster metabolism and potentially lower *in vivo* exposure.
* **t1/2:** Ligand B (56.92) has a significantly longer half-life than Ligand A (-6.525). This is a positive for Ligand B, but can be offset by the higher clearance.
* **Pgp:** Both ligands have similar Pgp efflux liability (0.236 and 0.887).
* **Binding Affinity:** Ligand A (-6.6 kcal/mol) has slightly better binding affinity than Ligand B (-5.7 kcal/mol). While the difference isn't huge, it's enough to be considered.
**Overall Assessment:**
Ligand A is the stronger candidate. It has a better balance of properties, with a lower molecular weight, better logP, significantly lower DILI risk, better solubility, and slightly better binding affinity. While Ligand B has a longer half-life, its higher logP, higher DILI risk, and faster metabolism are significant drawbacks. The better QED score for Ligand A also supports its selection.
**Output:**
1
2025-04-17 19:56:59,367 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (337.423) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (61.44) is significantly better than Ligand B (87.66). For a GPCR, keeping TPSA low is good, and Ligand A is well below the 140 threshold.
3. **logP:** Ligand A (4.049) is higher than Ligand B (1.611). While 4.049 is approaching the upper limit, it's still acceptable. Ligand B is quite low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (2) is better than Ligand B (3). Lower is preferred.
5. **HBA:** Ligand A (2) is better than Ligand B (4). Lower is preferred.
6. **QED:** Ligand A (0.827) is much better than Ligand B (0.618), indicating a more drug-like profile.
7. **DILI:** Ligand B (8.026) is *significantly* better than Ligand A (84.025). This is a major concern for Ligand A.
8. **BBB:** Ligand A (71.462) is better than Ligand B (61.535), although both are moderate. For a cardiovascular target, BBB isn't a primary concern, but it's still a bonus.
9. **Caco-2:** Both are negative, indicating poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-5.23) is significantly worse than Ligand B (-1.76). Solubility is a concern for both, but more so for Ligand A.
11. **hERG:** Ligand A (0.724) is better than Ligand B (0.285). Lower is better, and Ligand A has a lower risk of cardiotoxicity.
12. **Cl_mic:** Ligand B (40.814) is better than Ligand A (55.008). Lower clearance indicates better metabolic stability.
13. **t1/2:** Ligand A (35.151) is much better than Ligand B (-0.182). A longer half-life is desirable.
14. **Pgp:** Ligand A (0.23) is better than Ligand B (0.027). Lower efflux is better.
15. **Binding Affinity:** Ligand A (-8.2) is *significantly* better than Ligand B (-6.6). This is a 1.6 kcal/mol difference, which is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand A has a much stronger binding affinity, a better QED score, better BBB penetration, longer half-life, and lower Pgp efflux. However, it has a very high DILI risk and poor solubility. Ligand B has a much better safety profile (DILI) and better metabolic stability, but its binding affinity is significantly weaker, and its QED is lower.
Given the GPCR target class, potency (affinity) is paramount. The 1.6 kcal/mol difference in binding affinity is a substantial advantage for Ligand A. While the DILI risk is concerning, it might be mitigated through structural modifications during lead optimization. The solubility issue is also addressable. The weaker affinity of Ligand B makes it less likely to be successful, even with its better safety profile.
Output:
1
2025-04-17 19:56:59,368 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (a cardiovascular GPCR) drug candidates.
**Ligand A:** [368.752, 117.39 , 2.946, 3. , 5. , 0.554, 85.227, 49.981, -4.949, -4.131, 0.401, 20.347, 92.005, 0.166, -6.9 ]
**Ligand B:** [385.892, 53.51 , 3.165, 0. , 4. , 0.751, 50.33 , 88.523, -4.511, -4.413, 0.354, 34.185, -13.17 , 0.282, -7.5 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (368.752) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (117.39) is higher than Ligand B (53.51). For a cardiovascular GPCR, TPSA isn't *as* critical as for CNS targets, but lower is still preferred for better absorption. Ligand B is significantly better here.
3. **logP:** Both are in the optimal range (1-3). Ligand A (2.946) and Ligand B (3.165) are comparable.
4. **HBD:** Ligand A (3) is higher than Ligand B (0). Lower HBD is generally preferred for better permeability. Ligand B is better.
5. **HBA:** Ligand A (5) is higher than Ligand B (4). Similar to HBD, lower HBA is preferred. Ligand B is better.
6. **QED:** Ligand B (0.751) has a better QED score than Ligand A (0.554), indicating a more drug-like profile.
7. **DILI:** Ligand A (85.227) has a higher DILI risk than Ligand B (50.33). This is a significant concern, as we want to minimize liver toxicity. Ligand B is much better.
8. **BBB:** Both have relatively low BBB penetration, which is expected for a cardiovascular target. Ligand B (88.523) is better than Ligand A (49.981).
9. **Caco-2:** Both have negative Caco-2 values, which is unusual. This suggests poor permeability.
10. **Solubility:** Both have negative solubility values, which is also unusual and suggests poor solubility.
11. **hERG:** Both have low hERG inhibition risk, which is good. Ligand A (0.401) is slightly higher than Ligand B (0.354).
12. **Cl_mic:** Ligand A (20.347) has lower microsomal clearance than Ligand B (34.185), indicating better metabolic stability.
13. **t1/2:** Ligand A (92.005) has a much longer in vitro half-life than Ligand B (-13.17). This is a substantial advantage.
14. **Pgp:** Ligand A (0.166) has lower P-gp efflux than Ligand B (0.282), which is favorable.
15. **Affinity:** Ligand B (-7.5 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.9 kcal/mol). This 1.5 kcal/mol difference is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand B has a significantly better safety profile (lower DILI) and a stronger binding affinity. It also has a better TPSA, HBD, HBA, and QED score. While Ligand A has better metabolic stability and half-life, the superior affinity and safety of Ligand B are more critical for a GPCR target, especially considering the cardiovascular context. The negative Caco-2 and solubility values are concerning for both, but the stronger binding and better overall profile of Ligand B make it the more promising candidate.
Output:
0
2025-04-17 19:56:59,368 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.391 and 342.443 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand B (76.44) is significantly better than Ligand A (94.92). ADRB2 is not a CNS target, but lower TPSA generally improves absorption.
3. **logP:** Ligand B (1.539) is better than Ligand A (0.282). Ligand A is quite low, potentially causing permeability issues. ADRB2 benefits from a logP in the 1-3 range.
4. **HBD:** Both ligands have 1 HBD, which is acceptable.
5. **HBA:** Ligand B (4) is better than Ligand A (7). Lower HBA is generally preferred for permeability.
6. **QED:** Ligand B (0.904) is substantially better than Ligand A (0.41). A higher QED indicates a more drug-like molecule.
7. **DILI:** Ligand B (41.179) is much better than Ligand A (64.172). Lower DILI is crucial.
8. **BBB:** This is less critical for ADRB2 (a cardiovascular target). Ligand A (61.691) and Ligand B (43.815) are both relatively low.
9. **Caco-2:** Both are negative, indicating poor permeability. However, the scale is not provided, so it's hard to interpret the absolute values.
10. **Solubility:** Both are negative, indicating poor solubility. Again, the scale is missing.
11. **hERG:** Ligand B (0.564) is better than Ligand A (0.208). Lower hERG inhibition is preferred.
12. **Cl_mic:** Ligand B (-4.566) is significantly better than Ligand A (9.615). A negative value for Cl_mic suggests very good metabolic stability.
13. **t1/2:** Ligand B (29.583) is much better than Ligand A (-13.27). A longer half-life is desirable.
14. **Pgp:** Ligand B (0.049) is better than Ligand A (0.058). Lower P-gp efflux is preferred.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.9 and -6.7 kcal/mol). The difference is not substantial enough to override the other significant differences.
**Overall Assessment:**
Ligand B is clearly superior. It has better predicted ADME properties across the board (logP, TPSA, HBA, QED, DILI, Cl_mic, t1/2, Pgp) and a comparable binding affinity to Ligand A. The most significant advantages are the much lower DILI risk and improved metabolic stability (Cl_mic and t1/2) of Ligand B. While both have poor Caco-2 and solubility, the other improvements make Ligand B the more promising candidate.
Output:
0
2025-04-17 19:56:59,368 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [354.451, 90.98, 0.037, 2, 5, 0.657, 29.042, 74.292, -4.661, -0.917, 0.376, 31.2, -30.573, 0.016, -6.5]
**Ligand B:** [352.435, 96.55, 0.881, 2, 5, 0.759, 52.695, 45.56, -5.033, -1.554, 0.226, 3.612, -14.673, 0.012, -6]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity, and BBB):
1. **Molecular Weight:** Both ligands are within the ideal range (354.451 and 352.435 Da). No significant difference here.
2. **TPSA:** Ligand A (90.98) is better than Ligand B (96.55). Both are below the 140 threshold for oral absorption, but closer to the 90 threshold is preferable.
3. **logP:** Ligand B (0.881) is slightly better than Ligand A (0.037). Ligand A is very close to 0, which could indicate poor membrane permeability.
4. **H-Bond Donors:** Both have 2 HBD, which is good.
5. **H-Bond Acceptors:** Both have 5 HBA, which is good.
6. **QED:** Ligand B (0.759) is slightly better than Ligand A (0.657), indicating a more drug-like profile.
7. **DILI:** Ligand A (29.042) has a significantly lower DILI risk than Ligand B (52.695). This is a substantial advantage for Ligand A.
8. **BBB:** Ligand A (74.292) has a much higher BBB penetration potential than Ligand B (45.56). While ADRB2 isn't *strictly* a CNS target, some CNS exposure can occur, and higher BBB is generally favorable.
9. **Caco-2:** Ligand A (-4.661) is significantly better than Ligand B (-5.033). Higher values indicate better absorption.
10. **Solubility:** Ligand A (-0.917) is better than Ligand B (-1.554).
11. **hERG:** Both are very low (0.376 and 0.226), indicating minimal hERG inhibition risk.
12. **Cl_mic:** Ligand A (31.2) has a higher clearance than Ligand B (3.612). This means Ligand B is more metabolically stable.
13. **t1/2:** Ligand B (-14.673) has a much longer in vitro half-life than Ligand A (-30.573). This is a significant advantage for Ligand B.
14. **Pgp:** Both are very low (0.016 and 0.012), indicating minimal P-gp efflux.
15. **Binding Affinity:** Both have very similar binding affinities (-6.5 and -6 kcal/mol).
**Overall Assessment:**
Ligand A excels in DILI risk, BBB penetration, Caco-2 permeability, and solubility. Ligand B has better metabolic stability (lower Cl_mic and longer t1/2) and a slightly better QED score. The logP of Ligand A is concerningly low. However, the substantial advantage in DILI and BBB, combined with better permeability and solubility, outweighs the slightly lower metabolic stability and logP for a cardiovascular GPCR target. The affinity is comparable.
Therefore, I prefer Ligand A.
Output:
1
2025-04-17 19:56:59,368 - INFO - Here's my reasoning and the final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, priorities are logP, TPSA, Pgp, affinity, and to a lesser extent, BBB.
Let's compare the ligands property by property:
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (364.471) is slightly higher than Ligand B (348.487), but both are acceptable.
2. **TPSA:** Ligand A (87.46) is slightly higher than Ligand B (78.43), but both are below the 140 threshold for oral absorption, and reasonably good for a GPCR.
3. **logP:** Ligand A (0.991) is a bit low, potentially hindering permeability. Ligand B (2.437) is within the optimal 1-3 range. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (2) is better than Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (6) is better than Ligand B (3). Fewer HBAs generally improve permeability.
6. **QED:** Ligand A (0.832) is better than Ligand B (0.714), indicating a more drug-like profile.
7. **DILI:** Both are good, with Ligand A (39.356) slightly better than Ligand B (31.563).
8. **BBB:** Both have low BBB penetration, which isn't a major concern for a cardiovascular target. Ligand B (42.458) is slightly better than Ligand A (40.558).
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and likely indicates poor permeability. This is a significant drawback for both.
10. **Solubility:** Both have negative solubility values, which is also unusual and indicates poor solubility.
11. **hERG:** Both have very low hERG inhibition risk, which is excellent.
12. **Cl_mic:** Ligand A (31.077) has lower microsomal clearance, suggesting better metabolic stability than Ligand B (33.263).
13. **t1/2:** Ligand A (-18.757) has a more negative half-life, which is not ideal. Ligand B (-8.375) is also not ideal, but better than A.
14. **Pgp:** Both have very low Pgp efflux liability, which is good. Ligand A (0.024) is slightly better than Ligand B (0.336).
15. **Affinity:** Ligand B (-7.7 kcal/mol) has slightly better binding affinity than Ligand A (-7.4 kcal/mol). While the difference is small, it's still a factor.
**Overall Assessment:**
Ligand B has a better logP value, which is crucial for GPCR targets. It also has slightly better affinity. While Ligand A has a better QED and slightly better DILI and Pgp values, the logP advantage of Ligand B outweighs these benefits. The poor Caco-2 and solubility values are concerning for both, but the better logP of Ligand B suggests it might be more amenable to formulation strategies to address these issues.
Output:
0
2025-04-17 19:56:59,368 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (363.571 and 352.475 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (35.58) is significantly better than Ligand B (70.08). For a GPCR, lower TPSA is generally preferred for better permeability, and Ligand A is well below the 140 threshold. Ligand B is higher and could present absorption challenges.
3. **logP:** Ligand A (3.334) is within the optimal range (1-3), while Ligand B (1.412) is at the lower end. For a GPCR, a slightly higher logP is often beneficial for membrane permeability and receptor engagement. Ligand A has an advantage.
4. **HBD:** Both ligands have 1 HBD, which is acceptable.
5. **HBA:** Both ligands have 4 HBA, which is acceptable.
6. **QED:** Ligand A (0.895) has a better QED score than Ligand B (0.785), indicating a more drug-like profile.
7. **DILI:** Both ligands have low DILI risk (24.506 and 20.706, respectively), which is good. No significant difference.
8. **BBB:** Ligand A (81.815) has a considerably higher BBB penetration percentile than Ligand B (62.66). While ADRB2 isn't exclusively a CNS target, some CNS exposure can occur, and higher BBB penetration is generally a positive attribute.
9. **Caco-2:** Ligand A (-5.017) has a worse Caco-2 permeability than Ligand B (-4.508). This is a negative for Ligand A.
10. **Solubility:** Ligand A (-2.395) has slightly worse solubility than Ligand B (-1.991). Solubility is important, but not as critical as permeability for this target.
11. **hERG:** Ligand A (0.858) has a slightly higher hERG risk than Ligand B (0.389). This is a negative for Ligand A, as hERG inhibition can lead to cardiotoxicity.
12. **Cl_mic:** Ligand B (35.72) has a significantly higher microsomal clearance than Ligand A (0.625). Lower clearance is preferred for better metabolic stability, giving a clear advantage to Ligand A.
13. **t1/2:** Ligand A (22.952) has a much longer in vitro half-life than Ligand B (5.497). This is a significant advantage for Ligand A, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.207) has lower P-gp efflux than Ligand B (0.24). Lower Pgp is better.
15. **Binding Affinity:** Ligand A (-7.5 kcal/mol) has a slightly better binding affinity than Ligand B (-6.9 kcal/mol). While the difference is not huge, it's enough to be considered.
**Overall Assessment:**
Ligand A demonstrates a superior profile overall, particularly regarding crucial GPCR properties like TPSA, logP, BBB penetration, metabolic stability (Cl_mic and t1/2), and binding affinity. While Ligand A has slightly lower Caco-2 permeability and higher hERG risk, the advantages in other key areas outweigh these drawbacks. Ligand B's higher TPSA and clearance are significant concerns.
Output:
1
2025-04-17 19:56:59,369 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (367.921 and 370.559 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (44.81) is significantly better than Ligand B (69.64). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (3.086 and 2.448), falling within the optimal 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (4). Similar to HBD, fewer HBA are generally better for permeability.
6. **QED:** Ligand A (0.729) is significantly better than Ligand B (0.458), indicating a more drug-like profile.
7. **DILI:** Ligand A (11.594) has a much lower DILI risk than Ligand B (16.712). This is a crucial advantage.
8. **BBB:** Ligand A (91.857) has a higher BBB penetration percentile than Ligand B (35.324). While not a primary concern for a cardiovascular target, higher BBB is generally not detrimental.
9. **Caco-2:** Ligand A (-4.214) is better than Ligand B (-5.119), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-2.413) is better than Ligand B (-3.065), indicating better aqueous solubility.
11. **hERG:** Both ligands have low hERG inhibition liability (0.802 and 0.485), which is good.
12. **Cl_mic:** Ligand A (42.81) has lower microsomal clearance than Ligand B (57.117), suggesting better metabolic stability.
13. **t1/2:** Ligand A (46.846) has a significantly longer in vitro half-life than Ligand B (4.718). This is a major advantage for dosing convenience.
14. **Pgp:** Ligand A (0.084) has lower P-gp efflux liability than Ligand B (0.205), improving bioavailability.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-5.9 and -5.7 kcal/mol). The difference is negligible.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Ligand A excels in most of these areas, particularly TPSA, Pgp, and metabolic stability (Cl_mic and t1/2). While BBB isn't critical for a cardiovascular target, the higher value for Ligand A isn't a disadvantage. The substantial improvements in DILI risk and QED for Ligand A further solidify its preference.
**Conclusion:**
Ligand A demonstrates a significantly more favorable profile across multiple key ADME-Tox parameters, alongside comparable binding affinity. The lower DILI risk, better QED, improved metabolic stability, and enhanced permeability characteristics make it the superior candidate.
Output:
1
2025-04-17 19:56:59,369 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [355.781, 96.03, 3.468, 1, 4, 0.656, 74.021, 73.478, -4.517, -5.722, 0.498, 48.285, -4.707, 0.142, -5.5]
**Ligand B:** [350.369, 67.35, 1.825, 1, 5, 0.787, 56.844, 71.733, -4.729, -1.431, 0.533, 8.825, 0.452, 0.086, 3.3]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal 200-500 Da range. A (355.781) and B (350.369) are very similar.
2. **TPSA:** A (96.03) is slightly higher than B (67.35). B is better here, closer to the <90 ideal for potential CNS penetration, though it's not a CNS target.
3. **logP:** A (3.468) is optimal, while B (1.825) is on the lower side. This favors A for permeability.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** A has 4, B has 5. Both are acceptable.
6. **QED:** Both are good (A: 0.656, B: 0.787), but B is slightly better.
7. **DILI:** A (74.021) is significantly higher than B (56.844). This is a major concern for A. B is much preferred.
8. **BBB:** Both are high (A: 73.478, B: 71.733), but not critical for ADRB2.
9. **Caco-2:** Both are negative, indicating poor permeability. This is a significant issue for both.
10. **Solubility:** A (-5.722) is much worse than B (-1.431). B is significantly better.
11. **hERG:** A (0.498) is slightly better than B (0.533), but both are acceptable.
12. **Cl_mic:** A (48.285) is much better than B (8.825). A has better metabolic stability.
13. **t1/2:** A (-4.707) is better than B (0.452), indicating a longer half-life.
14. **Pgp:** A (0.142) is much better than B (0.086). A has lower P-gp efflux.
15. **Affinity:** A (-5.5) is *significantly* better than B (-3.3). This is a >2 kcal/mol difference, which is a substantial advantage.
**Overall Assessment:**
Ligand A has a much stronger binding affinity and better metabolic stability (Cl_mic, t1/2) and Pgp efflux. However, it has a significantly higher DILI risk and worse solubility. Ligand B has better solubility, lower DILI risk, and a slightly better QED, but significantly weaker binding affinity.
Given the importance of potency for GPCRs, and the fact that the affinity difference is so large, the stronger binding of Ligand A outweighs its drawbacks, *provided* the DILI risk can be addressed through further optimization. The solubility issue is also concerning, but potentially more tractable than the DILI risk.
Therefore, I would prioritize Ligand A for further development.
Output:
1
2025-04-17 19:56:59,369 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (344.419 and 346.471 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (85.17) is slightly higher than Ligand B (69.64). Both are below the 140 threshold for oral absorption, but B is better positioned, especially considering ADRB2 is a GPCR.
3. **logP:** Both ligands have good logP values (1.797 and 2.145), falling within the optimal 1-3 range. Ligand B is slightly higher, which might be beneficial for membrane permeability.
4. **HBD:** Ligand A has 1 HBD, while Ligand B has 2. Both are acceptable, staying under the 5 limit.
5. **HBA:** Ligand A has 7 HBA, and Ligand B has 3. Both are under the 10 limit. Ligand B is preferable here.
6. **QED:** Ligand A (0.91) has a significantly better QED score than Ligand B (0.75), indicating a more drug-like profile. This is a strong point for Ligand A.
7. **DILI:** Ligand A (60.721) has a higher DILI risk than Ligand B (12.641). This is a significant drawback for Ligand A. Ligand B is much safer in this regard.
8. **BBB:** Both ligands have good BBB penetration (79.256 and 70.143). Since ADRB2 isn't a primary CNS target, this isn't a major deciding factor, but it's good to have.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the values are similar (-5.014 and -4.95), so this doesn't differentiate them.
10. **Solubility:** Both ligands have very poor aqueous solubility (-2.354 and -2.806). This is a concern for both, and would require formulation strategies.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.132 and 0.316). This is excellent for both.
12. **Cl_mic:** Ligand B (24.765) has significantly lower microsomal clearance than Ligand A (53.653), indicating better metabolic stability. This is a key advantage for Ligand B.
13. **t1/2:** Ligand B (19.367) has a longer in vitro half-life than Ligand A (10.891), which is desirable.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.26 and 0.054). This is good for both.
15. **Binding Affinity:** Both ligands have the same binding affinity (-6.5 kcal/mol).
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, and metabolic stability (Cl_mic, t1/2) are important. Ligand B excels in TPSA, Cl_mic, and t1/2. While Ligand A has a better QED, the significantly higher DILI risk and poorer metabolic stability are major concerns.
**Conclusion:**
Despite Ligand A's slightly better QED score, Ligand B is the more promising candidate due to its significantly lower DILI risk, improved metabolic stability (lower Cl_mic, longer t1/2), and better TPSA. The similar binding affinity makes these ADME properties the deciding factors.
Output:
0
2025-04-17 19:56:59,369 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's systematically compare Ligand A and Ligand B against the provided guidelines, keeping in mind that ADRB2 is a GPCR, so logP, TPSA, Pgp, and affinity are particularly important.
1. **MW:** Both ligands (347.3 and 343.5 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand B (68.77) is significantly better than Ligand A (130.02). Lower TPSA generally improves oral absorption and is highly desirable for GPCRs.
3. **logP:** Both ligands have acceptable logP values (2.076 and 3.835), falling within the 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability, but not excessively high.
4. **HBD:** Ligand A has 3 HBD, while Ligand B has 1. Lower HBD is generally preferred for better permeability. Ligand B is better here.
5. **HBA:** Ligand A has 5 HBA, Ligand B has 6. Both are acceptable, under the 10 threshold.
6. **QED:** Both ligands have good QED scores (0.576 and 0.738), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A has a concerningly high DILI risk (97.829%), while Ligand B is much lower (41.024%). This is a major drawback for Ligand A.
8. **BBB:** Ligand B (68.554%) has a better BBB penetration score than Ligand A (56.883%). While not a primary concern for ADRB2 (cardiovascular target), it's a slight advantage.
9. **Caco-2:** Ligand A (-4.861) has a better Caco-2 permeability than Ligand B (-5.33).
10. **Solubility:** Ligand A (-5.263) has better solubility than Ligand B (-4.35).
11. **hERG:** Ligand A (0.598) has a slightly better hERG profile than Ligand B (0.169).
12. **Cl_mic:** Ligand A (22.217) has a significantly lower microsomal clearance than Ligand B (42.749), indicating better metabolic stability.
13. **t1/2:** Ligand A (69.79) has a longer in vitro half-life than Ligand B (22.304). This is a significant advantage.
14. **Pgp:** Ligand A (0.098) has a lower P-gp efflux liability than Ligand B (0.243), which is favorable for bioavailability.
15. **Affinity:** Ligand B (-7.2 kcal/mol) has a stronger binding affinity than Ligand A (-6.9 kcal/mol). This is a crucial advantage, exceeding the 1.5 kcal/mol threshold.
**Overall Assessment:**
While Ligand A has some advantages in terms of metabolic stability (Cl_mic, t1/2), Pgp efflux, solubility and Caco-2 permeability, the extremely high DILI risk is a major red flag. Ligand B excels in key GPCR-relevant properties (low TPSA, good logP, good QED) and, critically, has a significantly better safety profile (lower DILI) and a stronger binding affinity. The affinity difference is substantial enough to outweigh the slightly less favorable metabolic properties of Ligand B.
**Output:**
0
2025-04-17 19:56:59,369 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
The ADRB2 receptor is a GPCR, so the key properties to prioritize are logP, TPSA, Pgp efflux, BBB penetration, and binding affinity. Metabolic stability (Cl_mic, t1/2) and safety (DILI, hERG) are also important.
Let's compare the ligands:
1. **Molecular Weight:** Both ligands (344.415 and 345.487 Da) are within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (65.86) is higher than Ligand B (43.86). Ligand B is significantly better, being closer to the <90 A^2 threshold for good absorption.
3. **logP:** Ligand B (1.437) is within the optimal 1-3 range, while Ligand A (0.381) is slightly low, potentially hindering permeation.
4. **H-Bond Donors/Acceptors:** Both have reasonable HBD (0) and HBA (4/3) counts.
5. **QED:** Both are above 0.5 (0.779 and 0.724), indicating good drug-likeness.
6. **DILI:** Ligand B (12.524) has a much lower DILI risk than Ligand A (42.575), a significant advantage.
7. **BBB:** Ligand B (70.803) shows better BBB penetration than Ligand A (62.195), which is a positive for a GPCR target.
8. **Caco-2:** Both have negative Caco-2 values (-4.517 and -4.596), which is unusual and difficult to interpret without more context. However, the values are very similar.
9. **Solubility:** Both have negative solubility values (-1.25 and -1.966), also unusual. Again, values are similar.
10. **hERG:** Ligand B (0.615) has a slightly higher hERG risk than Ligand A (0.206), but both are relatively low.
11. **Cl_mic:** Ligand A (30.622) has lower microsomal clearance, suggesting better metabolic stability than Ligand B (44.258).
12. **t1/2:** Ligand A (-1.986) has a slightly longer in vitro half-life than Ligand B (-2.154).
13. **Pgp:** Ligand A (0.066) has lower P-gp efflux liability than Ligand B (0.091), which is favorable.
14. **Binding Affinity:** Ligand A (-7.8 kcal/mol) has a significantly stronger binding affinity than Ligand B (-5.9 kcal/mol) - a difference of 1.9 kcal/mol. This is a substantial advantage.
**Overall Assessment:**
While Ligand A has a superior binding affinity and better metabolic stability, Ligand B demonstrates a much more favorable ADME profile, particularly regarding DILI risk, BBB penetration, and TPSA. The stronger binding of Ligand A is attractive, but the ADME advantages of Ligand B, especially the lower DILI and better BBB, are crucial for a viable drug candidate targeting a GPCR. The slightly lower logP of Ligand A is also a concern. The 1.9 kcal/mol difference in binding affinity can potentially be overcome with further optimization of Ligand B.
**Output:**
0
2025-04-17 19:56:59,370 - INFO - Batch 148 complete. Total preferences: 2368
2025-04-17 19:56:59,370 - INFO - Processing batch 149/512...
2025-04-17 19:57:48,687 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 drug candidates. ADRB2 is a GPCR, so we'll prioritize logP, Pgp, TPSA, and affinity, alongside general drug-like properties.
**Ligand A:**
* **MW:** 366.483 Da - Acceptable.
* **TPSA:** 77.52 A2 - Good, well below the 140 A2 threshold.
* **logP:** 2.57 - Optimal.
* **HBD:** 1 - Good.
* **HBA:** 6 - Good.
* **QED:** 0.829 - Excellent.
* **DILI:** 65.452 - Moderate risk, but not alarming.
* **BBB:** 65.064 - Moderate, not ideal for CNS but acceptable for a peripheral GPCR like ADRB2.
* **Caco-2:** -4.869 - Poor permeability. This is a significant drawback.
* **Solubility:** -3.389 - Very poor solubility. A major concern.
* **hERG:** 0.143 - Low risk.
* **Cl_mic:** 88.536 - High metabolic clearance, indicating poor stability.
* **t1/2:** -1.878 - Very short half-life.
* **Pgp:** 0.171 - Low efflux, favorable.
* **Affinity:** -6.8 kcal/mol - Very good binding affinity.
**Ligand B:**
* **MW:** 350.419 Da - Acceptable.
* **TPSA:** 93.19 A2 - Slightly higher, but still within reasonable limits for oral absorption.
* **logP:** -1.585 - Suboptimal. May have permeability issues.
* **HBD:** 2 - Good.
* **HBA:** 5 - Good.
* **QED:** 0.471 - Below ideal, but not terrible.
* **DILI:** 14.773 - Very low risk.
* **BBB:** 8.181 - Very low, not relevant here.
* **Caco-2:** -5.293 - Very poor permeability. Similar to Ligand A.
* **Solubility:** -0.605 - Poor solubility, but slightly better than Ligand A.
* **hERG:** 0.083 - Very low risk.
* **Cl_mic:** -16.73 - Very low clearance, excellent metabolic stability.
* **t1/2:** -3.497 - Long half-life.
* **Pgp:** 0.006 - Very low efflux, favorable.
* **Affinity:** -6.7 kcal/mol - Good binding affinity, very close to Ligand A.
**Comparison and Decision:**
Both ligands suffer from poor Caco-2 permeability and solubility. However, Ligand B has a significantly better metabolic profile (much lower Cl_mic and longer t1/2) and a lower DILI risk. While Ligand A has a slightly better affinity (-6.8 vs -6.7 kcal/mol), the difference is minimal. Given the importance of metabolic stability and safety (DILI) for a cardiovascular drug, and the fact that both have poor permeability, Ligand B is the more promising candidate. The slightly lower logP of Ligand B is a concern, but the superior metabolic properties and safety profile outweigh this drawback.
Output:
0
2025-04-17 19:57:48,687 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**1. Molecular Weight:** Both ligands (359.455 Da and 350.503 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (88.91) is slightly higher than Ligand B (58.64). For a cardiovascular GPCR, TPSA is not a primary concern, but lower is generally preferable for absorption. Ligand B has a substantial advantage here.
**3. logP:** Ligand A (1.033) is within the optimal range (1-3), while Ligand B (3.047) is at the higher end. This could potentially lead to solubility issues for Ligand B, but is still acceptable.
**4. H-Bond Donors:** Ligand A (2) and Ligand B (1) are both within the acceptable limit of 5. Ligand B is slightly better.
**5. H-Bond Acceptors:** Ligand A (6) and Ligand B (3) are both within the acceptable limit of 10. Ligand B is better.
**6. QED:** Ligand A (0.804) has a significantly better QED score than Ligand B (0.616), indicating a more drug-like profile overall.
**7. DILI Risk:** Ligand A (69.678) has a higher DILI risk than Ligand B (11.361). This is a significant concern, as lower DILI risk is crucial. Ligand B is much better.
**8. BBB Penetration:** Ligand A (45.638) has lower BBB penetration than Ligand B (80.574). While ADRB2 isn't a CNS target, some peripheral exposure is still desirable, and higher BBB penetration can correlate with better overall distribution. Ligand B is better.
**9. Caco-2 Permeability:** Ligand A (-5.643) has worse Caco-2 permeability than Ligand B (-4.638). Both are negative, indicating poor permeability, but Ligand B is slightly better.
**10. Aqueous Solubility:** Both ligands have very poor solubility (-2.604 and -2.104). This is a major drawback for both, but slightly better for Ligand B.
**11. hERG Inhibition:** Ligand A (0.139) has a slightly lower hERG inhibition risk than Ligand B (0.361), which is preferable.
**12. Microsomal Clearance:** Ligand A (20.556) has lower microsomal clearance than Ligand B (70.666), suggesting better metabolic stability. This is a significant advantage for Ligand A.
**13. In vitro Half-Life:** Ligand A (9.467) has a shorter half-life than Ligand B (17.409). Longer half-life is generally preferred. Ligand B is better.
**14. P-gp Efflux:** Ligand A (0.017) has significantly lower P-gp efflux than Ligand B (0.036), which is a positive attribute for bioavailability.
**15. Binding Affinity:** Ligand A (-7.2 kcal/mol) has a better binding affinity than Ligand B (-5.5 kcal/mol). This is a substantial advantage, potentially outweighing some ADME drawbacks.
**Overall Assessment:**
While Ligand A has a superior binding affinity and better metabolic stability, its significantly higher DILI risk is a major concern. Ligand B, despite having a weaker binding affinity, demonstrates a much more favorable safety profile (lower DILI) and better permeability characteristics. Considering the cardiovascular context, a safer profile is paramount. The affinity difference, while notable, might be overcome with further optimization.
Output:
0
2025-04-17 19:57:48,687 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (345.29 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (111.54) is higher than Ligand B (64.16). For a cardiovascular GPCR like ADRB2, TPSA isn't *as* critical as for CNS targets, but lower is still preferred for better absorption. Ligand B is significantly better here.
3. **logP:** Ligand A (0.86) is lower than Ligand B (3.355). While 0.86 is on the lower side, it's not drastically outside the optimal range. 3.355 is approaching the upper limit and could potentially cause solubility issues.
4. **HBD:** Ligand A (1) is better than Ligand B (0). Having at least one HBD can improve solubility.
5. **HBA:** Ligand A (7) is higher than Ligand B (5). Lower is preferred, and Ligand B is better.
6. **QED:** Ligand B (0.654) is better than Ligand A (0.419). A higher QED suggests a more drug-like profile.
7. **DILI:** Ligand A (85.77) has a significantly higher DILI risk than Ligand B (38.658). This is a major concern for Ligand A.
8. **BBB:** Both are reasonably high, but Ligand B (83.443) is slightly higher than Ligand A (72.237). For a cardiovascular target, BBB isn't a primary concern, but higher is generally better.
9. **Caco-2:** Both are negative, indicating poor permeability. This is a significant drawback for both compounds.
10. **Solubility:** Ligand A (-2.702) is better than Ligand B (-3.667).
11. **hERG:** Both are very low, indicating minimal hERG inhibition risk.
12. **Cl_mic:** Ligand A (31.671) has a lower microsomal clearance than Ligand B (54.404), suggesting better metabolic stability.
13. **t1/2:** Ligand A (15.721) has a longer half-life than Ligand B (12.816).
14. **Pgp:** Both are low, indicating minimal P-gp efflux.
15. **Binding Affinity:** Ligand B (-5.3 kcal/mol) has a slightly better binding affinity than Ligand A (-4.9 kcal/mol). While the difference is not huge, it is still a factor.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand B excels in TPSA and has a slightly better affinity. While its logP is higher, the significant reduction in DILI risk and the better QED outweigh this concern. The slightly lower metabolic stability and half-life of Ligand B are less concerning than the high DILI risk of Ligand A.
**Conclusion:**
Despite the slightly worse logP and metabolic stability, Ligand B is the more promising candidate due to its significantly lower DILI risk, better TPSA, and slightly better binding affinity. The higher QED also contributes to its overall drug-likeness.
Output:
0
2025-04-17 19:57:48,688 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [345.403, 104.12 , 1.64 , 2. , 5. , 0.708, 63.513, 55.099, -5.501, -2.821, 0.331, 57.245, 2.428, 0.147, -7.2 ]
**Ligand B:** [355.391, 106.2 , -0.889, 2. , 6. , 0.547, 37.999, 75.843, -5.052, -1.385, 0.188, -41.567, -24.928, 0.005, -7.3 ]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, Affinity, and BBB):
1. **MW:** Both are within the ideal range (200-500 Da). A is 345.4, B is 355.4. No significant difference.
2. **TPSA:** Both are acceptable for oral absorption (<140), A (104.12) is slightly better than B (106.2).
3. **logP:** A (1.64) is optimal. B (-0.889) is a bit low, potentially hindering permeability. This is a strike against B.
4. **HBD/HBA:** Both have 2 HBD and reasonable HBA counts (5 & 6 respectively). No major concerns for either.
5. **QED:** A (0.708) is better than B (0.547), indicating a more drug-like profile.
6. **DILI:** B (37.999) is significantly better than A (63.513). This is a strong advantage for B.
7. **BBB:** B (75.843) is considerably better than A (55.099). While not a primary concern for a cardiovascular target, higher BBB is generally favorable.
8. **Caco-2:** Both are negative, indicating poor permeability. A (-5.501) is slightly worse than B (-5.052).
9. **Solubility:** Both are negative, indicating poor solubility. B (-1.385) is slightly better than A (-2.821).
10. **hERG:** Both are low risk (0.331 and 0.188). No significant difference.
11. **Cl_mic:** B (-41.567) has *much* lower (better) microsomal clearance than A (57.245), indicating greater metabolic stability. This is a major advantage for B.
12. **t1/2:** B (-24.928) has a longer half-life than A (2.428). Another significant advantage for B.
13. **Pgp:** A (0.147) is better than B (0.005), suggesting less P-glycoprotein efflux. This is a positive for A.
14. **Affinity:** B (-7.3) has slightly better binding affinity than A (-7.2). While the difference is small, it's still a plus for B.
**Overall Assessment:**
Ligand B has several key advantages: significantly lower DILI risk, much better metabolic stability (lower Cl_mic), longer half-life, and slightly better binding affinity. While Ligand A has better Pgp properties and a slightly better QED, the ADME profile of Ligand B is far superior, and the small affinity difference is outweighed by these factors. The logP of Ligand A is also a concern. For a GPCR, metabolic stability and minimizing off-target effects (DILI) are critical.
Output:
0
2025-04-17 19:57:48,688 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.422 and 354.491 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (73.47) is higher than Ligand B (59.08). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is generally preferred for permeability. Ligand B has an advantage.
3. **logP:** Both ligands (2.824 and 2.066) are within the optimal 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability, but not dramatically so.
4. **HBD:** Ligand A (3) is higher than Ligand B (0). Lower HBD is generally preferred for better permeability. Ligand B has an advantage.
5. **HBA:** Ligand A (3) and Ligand B (4) are both acceptable, below the 10 threshold. No major difference.
6. **QED:** Both ligands (0.736 and 0.758) have excellent drug-likeness scores, well above the 0.5 threshold. No significant difference.
7. **DILI:** Ligand A (72.703) has a higher DILI risk than Ligand B (32.648). This is a significant concern; lower DILI is crucial. Ligand B has a substantial advantage.
8. **BBB:** Both ligands have good BBB penetration (76.851 and 71.501). Since ADRB2 is not a primary CNS target, this is less critical, but higher is still favorable. Ligand A has a slight edge.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. This is a concern for both, but the values are close.
10. **Solubility:** Ligand A (-4.91) has significantly worse solubility than Ligand B (-1.748). Solubility is important for bioavailability. Ligand B has a clear advantage.
11. **hERG:** Both ligands have low hERG inhibition risk (0.328 and 0.448). No significant difference.
12. **Cl_mic:** Ligand A (29.493) has lower microsomal clearance than Ligand B (46.132), indicating better metabolic stability. This is a positive for Ligand A.
13. **t1/2:** Ligand A (50.43) has a much longer in vitro half-life than Ligand B (15.4). This is a significant advantage for Ligand A, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.052 and 0.079). No significant difference.
15. **Binding Affinity:** Ligand A (-7.2) has a stronger binding affinity than Ligand B (-5.5). This is a substantial advantage, potentially outweighing some ADME drawbacks. The difference is >1.5 kcal/mol.
**Overall Assessment:**
Ligand A has a significantly stronger binding affinity and better metabolic stability (lower Cl_mic, longer t1/2). However, Ligand B demonstrates a much better safety profile with a significantly lower DILI risk and better solubility. Considering the GPCR-specific priorities (logP, TPSA, affinity), the strong affinity of Ligand A is a major driver. The DILI risk of Ligand A is concerning, but the substantial binding affinity advantage, combined with acceptable values for other parameters, makes it the more promising candidate.
Output:
1
2025-04-17 19:57:48,688 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [337.423, 73.2, 2.652, 1, 3, 0.777, 39.705, 75.107, -4.578, -4.157, 0.355, 50.238, -3.511, 0.218, -5.7]**
**Ligand B: [370.559, 69.64, 2.568, 2, 4, 0.644, 33.307, 71.074, -5.135, -3.027, 0.588, 50.796, -2.871, 0.397, -6.2]**
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (337.423 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are good, below 140. Ligand A (73.2) is slightly higher than Ligand B (69.64), but both are acceptable for a cardiovascular target.
3. **logP:** Both ligands have optimal logP values (around 2.6), indicating good balance between hydrophobicity and hydrophilicity.
4. **H-Bond Donors:** Ligand A (1) is better than Ligand B (2). Fewer HBDs generally improve membrane permeability.
5. **H-Bond Acceptors:** Ligand A (3) is better than Ligand B (4). Similar to HBDs, fewer HBAs are preferred for permeability.
6. **QED:** Ligand A (0.777) has a better QED score than Ligand B (0.644), indicating a more drug-like profile.
7. **DILI:** Both are acceptable, but Ligand B (33.307) has a significantly lower DILI risk than Ligand A (39.705). This is a substantial advantage for Ligand B.
8. **BBB:** Both have good BBB penetration (Ligand A: 75.107, Ligand B: 71.074). While ADRB2 isn't exclusively a CNS target, some CNS exposure can occur, so this is a positive for both.
9. **Caco-2 Permeability:** Ligand B (-5.135) has better Caco-2 permeability than Ligand A (-4.578), suggesting better intestinal absorption.
10. **Aqueous Solubility:** Ligand B (-3.027) has better aqueous solubility than Ligand A (-4.157).
11. **hERG Inhibition:** Both are low, indicating minimal cardiotoxicity risk. Ligand B (0.588) is slightly higher than Ligand A (0.355), but both are acceptable.
12. **Microsomal Clearance:** Both have similar microsomal clearance rates (around 50 mL/min/kg).
13. **In vitro Half-Life:** Ligand B (-2.871) has a slightly better in vitro half-life than Ligand A (-3.511).
14. **P-gp Efflux:** Ligand B (0.397) has lower P-gp efflux than Ligand A (0.218), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand B (-6.2 kcal/mol) has a slightly better binding affinity than Ligand A (-5.7 kcal/mol). This 0.5 kcal/mol difference is significant.
**Overall Assessment:**
Ligand B consistently outperforms Ligand A in several crucial ADME properties (DILI, Caco-2, Solubility, P-gp efflux, and half-life) and has a slightly better binding affinity. While Ligand A has a slightly better QED and fewer H-bonds, the advantages of Ligand B in safety (DILI) and absorption/bioavailability are more critical for a successful drug candidate. The binding affinity difference is also substantial enough to outweigh the minor drawbacks of Ligand B. Given that this is a GPCR target, the balance of properties in Ligand B is more favorable.
Output:
0
2025-04-17 19:57:48,688 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (351.491 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are acceptable, but Ligand A (83.71) is better than Ligand B (92.5). Lower TPSA generally improves oral absorption, important for a cardiovascular target.
3. **logP:** Both are within the optimal range (1-3). Ligand A (1.774) is slightly higher, which could be beneficial for membrane permeability. Ligand B (1.136) is a bit low, potentially hindering permeation.
4. **HBD:** Ligand A (1) is better than Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (3) is better than Ligand B (5). Fewer HBAs generally improve permeability.
6. **QED:** Both are very similar and good (0.759 and 0.741).
7. **DILI:** Ligand A (7.251) is *significantly* better than Ligand B (36.293). This is a major advantage for Ligand A, as liver toxicity is a critical concern.
8. **BBB:** Ligand A (87.398) is better than Ligand B (74.486). While ADRB2 isn't a CNS target, some off-target CNS effects are possible with GPCR ligands, and higher BBB penetration is usually preferable.
9. **Caco-2:** Ligand A (-5.066) is better than Ligand B (-5.605). Higher Caco-2 permeability indicates better intestinal absorption.
10. **Solubility:** Ligand A (-2.196) is better than Ligand B (-2.242). Though both are poor, A is slightly better.
11. **hERG:** Both are very low (0.341 and 0.189), indicating low cardiotoxicity risk.
12. **Cl_mic:** Ligand B (24.107) has a lower microsomal clearance than Ligand A (32.834), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-19.648) has a longer in vitro half-life than Ligand A (-24.583). This is a positive for Ligand B.
14. **Pgp:** Both are very low (0.021 and 0.097), indicating low P-gp efflux.
15. **Binding Affinity:** Ligand B (-8.1) has a significantly stronger binding affinity than Ligand A (-5.7). This is a substantial advantage for Ligand B. A difference of 2.4 kcal/mol is quite large.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B has better affinity. Ligand A has better logP, TPSA, and Pgp. However, the *massive* difference in DILI risk for Ligand A is a critical factor. The superior affinity of Ligand B is important, but a high DILI risk is a dealbreaker.
**Overall Assessment:**
While Ligand B has a significantly better binding affinity and metabolic stability, the dramatically lower DILI risk associated with Ligand A makes it the more promising candidate. The difference in affinity, while substantial, can potentially be addressed through further optimization. A high DILI risk is much harder to fix.
Output:
1
2025-04-17 19:57:48,688 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 GPCR, followed by the final output.
**Ligand A: [345.443, 75.44, 2.599, 1, 4, 0.86, 31.524, 90.229, -4.844, -3.27, 0.49, 67.915, -26.568, 0.153, -5.7]**
**Ligand B: [350.547, 58.2, 4.04, 2, 2, 0.694, 22.761, 69.407, -4.602, -5.043, 0.509, 96.093, 1.832, 0.317, -5.8]**
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). A (345.443) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (75.44) is higher than Ligand B (58.2). Both are below the 140 A^2 threshold for oral absorption, but B is better.
3. **logP:** Ligand A (2.599) is within the optimal range (1-3). Ligand B (4.04) is slightly above, potentially leading to solubility issues and off-target interactions.
4. **H-Bond Donors:** Ligand A (1) is better than Ligand B (2). Lower HBD is generally preferred for better permeability.
5. **H-Bond Acceptors:** Ligand A (4) is higher than Ligand B (2). Lower HBA is generally preferred for permeability.
6. **QED:** Ligand A (0.86) is significantly better than Ligand B (0.694), indicating a more drug-like profile.
7. **DILI:** Ligand A (31.524) has a slightly higher DILI risk than Ligand B (22.761), but both are below the concerning threshold of 60.
8. **BBB:** Ligand A (90.229) has a significantly higher BBB penetration potential than Ligand B (69.407). This is a key advantage for a GPCR target, even if not a CNS target, as it suggests better distribution.
9. **Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.844) is slightly worse than Ligand B (-4.602).
10. **Aqueous Solubility:** Ligand B (-5.043) has better aqueous solubility than Ligand A (-3.27).
11. **hERG Inhibition:** Both ligands have low hERG inhibition risk (0.49 and 0.509 respectively).
12. **Microsomal Clearance:** Ligand B (96.093) has a much higher microsomal clearance than Ligand A (67.915), indicating lower metabolic stability.
13. **In vitro Half-Life:** Ligand A (-26.568) has a much longer in vitro half-life than Ligand B (1.832), indicating better stability.
14. **P-gp Efflux:** Ligand A (0.153) has lower P-gp efflux liability than Ligand B (0.317), which is desirable.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-5.7 and -5.8 kcal/mol).
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand A is the better candidate. While Ligand B has slightly better solubility, Ligand A excels in crucial areas like BBB penetration, QED, metabolic stability (lower Cl_mic and longer t1/2), and P-gp efflux. The slightly higher DILI risk for Ligand A is less concerning than the poorer metabolic profile of Ligand B. The similar binding affinities mean that the ADME properties are the deciding factors.
Output:
1
2025-04-17 19:57:48,689 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (379.4 and 363.5 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (75.6 and 72.5) are below the 140 A^2 threshold for good oral absorption, and acceptable for a non-CNS GPCR target like ADRB2. Ligand B is slightly better.
3. **logP:** Both ligands (2.13 and 1.77) are within the optimal 1-3 range. Ligand B is slightly lower, which could be beneficial for solubility, but isn't a major concern.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 6 HBA, and Ligand B has 4 HBA. Both are within the acceptable range of <=10.
6. **QED:** Both ligands have high QED scores (0.848 and 0.885), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Both ligands have similar, low DILI risk (43.2 and 42.2 percentile).
8. **BBB:** Ligand A has a higher BBB penetration (88.8%) than Ligand B (71.8%). While ADRB2 is not a CNS target, some peripheral exposure can be undesirable.
9. **Caco-2:** Ligand A (-4.591) and Ligand B (-5.152) both have negative Caco-2 values, indicating poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand A (-3.441) and Ligand B (-2.756) have poor solubility. Ligand B is slightly better.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.146 and 0.46).
12. **Cl_mic:** Ligand B (21.69 mL/min/kg) has lower microsomal clearance than Ligand A (26.96 mL/min/kg), suggesting better metabolic stability.
13. **t1/2:** Ligand B (18.1 hours) has a significantly longer in vitro half-life than Ligand A (8.99 hours). This is a major advantage.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.143 and 0.219).
15. **Binding Affinity:** Ligand B (-6.2 kcal/mol) has a slightly better binding affinity than Ligand A (-6.0 kcal/mol). While the difference is small, it's still a positive.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are important. Both ligands perform similarly on logP and Pgp. TPSA is acceptable for both. Ligand B has a slightly better affinity. The biggest differences are in metabolic stability (Cl_mic and t1/2), where Ligand B is significantly better, and solubility, where Ligand B is also slightly better. The poor Caco-2 permeability is a concern for both, but can be addressed with formulation strategies.
**Conclusion:**
Ligand B demonstrates a better overall profile, primarily due to its improved metabolic stability (longer half-life, lower clearance) and slightly better binding affinity. While both have poor Caco-2 permeability, the other advantages of Ligand B outweigh this drawback.
Output:
0
2025-04-17 19:57:48,689 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (339.403) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (95.94) is better than Ligand A (111.48), being closer to the <140 threshold for good oral absorption.
3. **logP:** Both are good (between 1-3), with Ligand B (1.092) being slightly lower than Ligand A (1.338).
4. **HBD:** Ligand B (2) is preferable to Ligand A (4) as fewer HBDs generally improve permeability.
5. **HBA:** Both have 5 HBA, which is acceptable.
6. **QED:** Ligand A (0.563) has a slightly better QED score than Ligand B (0.476), indicating a more drug-like profile.
7. **DILI:** Ligand B (9.965) is significantly better than Ligand A (63.862) regarding DILI risk, a crucial factor for cardiovascular drugs.
8. **BBB:** Both have reasonable BBB penetration (Ligand A: 57.968, Ligand B: 53.47). While not CNS-focused for ADRB2, some level of BBB penetration can be acceptable.
9. **Caco-2:** Ligand A (-6.015) has a more negative Caco-2 value, suggesting *lower* permeability than Ligand B (-4.802).
10. **Solubility:** Ligand A (-2.369) has a more negative solubility value, suggesting *lower* solubility than Ligand B (-1.324).
11. **hERG:** Both ligands have low hERG inhibition risk (Ligand A: 0.364, Ligand B: 0.297).
12. **Cl_mic:** Ligand A (-7.993) has a significantly lower (better) microsomal clearance than Ligand B (50.473), indicating greater metabolic stability.
13. **t1/2:** Ligand A (73.845) has a much longer in vitro half-life than Ligand B (-25.261). This is a significant advantage.
14. **Pgp:** Both have very low Pgp efflux liability (Ligand A: 0.039, Ligand B: 0.019).
15. **Affinity:** Both ligands have excellent binding affinity (Ligand A: -5.3 kcal/mol, Ligand B: -6.1 kcal/mol). Ligand B is slightly better.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B has a slightly better logP and TPSA. The affinity difference is relatively small (0.8 kcal/mol). However, the significantly lower DILI risk and better Caco-2/Solubility of Ligand B are major advantages. While Ligand A has better metabolic stability and half-life, the DILI risk is a serious concern.
**Overall Assessment:**
Ligand B is the more promising candidate. The lower DILI risk is paramount for a cardiovascular drug. The slightly better TPSA and Caco-2/Solubility, coupled with comparable affinity, outweigh the benefits of Ligand A's improved metabolic stability and half-life.
Output:
0
2025-04-17 19:57:48,689 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (360.439 Da and 347.39 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (93.21) is slightly higher than Ligand B (70.58). For a cardiovascular GPCR, TPSA is not a primary concern, but lower is generally preferred for better absorption. Ligand B is better.
3. **logP:** Both ligands have good logP values (1.935 and 1.509, respectively), falling within the optimal 1-3 range. Ligand B is slightly lower, which could be beneficial for solubility.
4. **HBD:** Ligand A has 2 HBD, while Ligand B has 0. This is a slight advantage for Ligand B, as fewer HBDs generally correlate with better membrane permeability.
5. **HBA:** Ligand A has 6 HBA, and Ligand B has 4. Again, Ligand B is better, aligning with permeability considerations.
6. **QED:** Both ligands have similar QED values (0.85 and 0.813), indicating good drug-likeness.
7. **DILI:** Ligand A has a DILI risk of 88.639, which is concerningly high. Ligand B has a much lower DILI risk (54.478), which is a significant advantage.
8. **BBB:** Ligand A (68.786) and Ligand B (90.849). While ADRB2 isn't strictly a CNS target, some CNS penetration can be acceptable and even desirable for understanding off-target effects. Ligand B is better.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.187 and -4.412). This is unusual and suggests poor permeability. However, these values are on a scale where negative values are possible, and the absolute magnitude isn't directly interpretable without knowing the scale's specifics.
10. **Solubility:** Ligand A (-3.678) has worse solubility than Ligand B (-1.585). Better solubility is always a plus.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.226 and 0.123). This is excellent.
12. **Cl_mic:** Ligand A (26.612) has lower microsomal clearance than Ligand B (31.483), indicating better metabolic stability.
13. **t1/2:** Ligand A (27.931) has a positive in vitro half-life, while Ligand B is negative (-39.19). This is a major concern for Ligand B.
14. **Pgp:** Ligand A (0.135) has lower P-gp efflux than Ligand B (0.064), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand A (-7.4) has slightly better binding affinity than Ligand B (-7.1). This is a 0.3 kcal/mol difference, which is not huge, but still notable.
**Overall Assessment:**
Ligand B excels in several key areas: lower TPSA, fewer HBD/HBA, significantly lower DILI risk, and better BBB penetration. Ligand A has a slight edge in binding affinity and metabolic stability (lower Cl_mic), but the high DILI risk for Ligand A is a major red flag. The negative in vitro half-life for Ligand B is concerning, but the other advantages outweigh this drawback. Given the GPCR target class, the balance of properties in Ligand B is more favorable.
Output:
0
2025-04-17 19:57:48,689 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [363.443, 79.82, 1.587, 1, 7, 0.869, 84.529, 64.211, -4.724, -2.984, 0.473, 46.188, -18.888, 0.031, -3.7]
**Ligand B:** [352.387, 102.96, 0.224, 2, 6, 0.368, 51.338, 60.45, -5.494, -1.878, 0.098, 20.695, -17.196, 0.044, -6.9]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity) are paramount, followed by ADME properties:
1. **MW:** Both are within the ideal range (200-500 Da). A (363.443) is slightly higher than B (352.387), but not significantly.
2. **TPSA:** A (79.82) is excellent, well below 140 and good for oral absorption. B (102.96) is still acceptable, but less ideal.
3. **logP:** A (1.587) is optimal. B (0.224) is quite low, potentially causing permeability issues. This is a significant drawback for a GPCR ligand.
4. **HBD/HBA:** A (1 HBD, 7 HBA) is better balanced. B (2 HBD, 6 HBA) is also reasonable.
5. **QED:** A (0.869) is very good, indicating high drug-likeness. B (0.368) is considerably lower, suggesting potential issues.
6. **DILI:** A (84.529) is concerning, indicating a higher risk of liver injury. B (51.338) is much better.
7. **BBB:** Both are reasonable (A: 64.211, B: 60.45). Not a primary concern for ADRB2, which isn't a CNS target.
8. **Caco-2:** A (-4.724) is poor, suggesting low intestinal absorption. B (-5.494) is similarly poor.
9. **Solubility:** A (-2.984) is poor. B (-1.878) is slightly better, but still not great.
10. **hERG:** Both are low risk (A: 0.473, B: 0.098). B is slightly better.
11. **Cl_mic:** A (46.188) is moderate. B (20.695) is better, indicating higher metabolic stability.
12. **t1/2:** Both are negative and similar (-18.888 for A, -17.196 for B), suggesting short half-lives.
13. **Pgp:** Both are very low (A: 0.031, B: 0.044), which is good, minimizing efflux.
14. **Affinity:** B (-6.9 kcal/mol) is significantly stronger than A (-3.7 kcal/mol). This is a substantial advantage.
**Overall Assessment:**
Ligand B has a much stronger binding affinity, which is the most important factor. While its logP is low and QED is poor, the affinity difference is substantial enough to potentially overcome these issues through further optimization. The lower DILI risk and better metabolic stability of B are also advantages. Ligand A has a better TPSA and QED, but the poor Caco-2 permeability and significantly weaker affinity are major drawbacks. The high DILI risk is also concerning.
Therefore, despite its shortcomings, Ligand B is the more promising starting point for drug development.
0
2025-04-17 19:57:48,689 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (367.431 and 352.387 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (102.96) is better than Ligand A (116.42) as it is closer to the <140 threshold for good oral absorption.
3. **logP:** Both are very low (0.023 and 0.224), which is suboptimal. Ideally, we want 1-3. Ligand B is slightly better. Low logP can lead to poor membrane permeability.
4. **HBD:** Ligand A has 3 HBD, Ligand B has 2. Both are acceptable.
5. **HBA:** Ligand A has 5 HBA, Ligand B has 6. Both are acceptable.
6. **QED:** Ligand A (0.689) is significantly better than Ligand B (0.368), indicating a more drug-like profile.
7. **DILI:** Ligand B (51.338) has a lower DILI risk than Ligand A (75.378), which is a significant advantage.
8. **BBB:** Ligand B (60.45) has a better BBB penetration percentile than Ligand A (52.85). While ADRB2 isn't *strictly* a CNS target, some peripheral ADRB2 receptors can be affected by CNS-related factors, and better BBB penetration isn't necessarily a negative.
9. **Caco-2:** Both are negative (-5.346 and -5.494), which is not ideal. This suggests poor intestinal absorption.
10. **Solubility:** Both are negative (-2.523 and -1.878), indicating poor aqueous solubility. This is a concern for bioavailability.
11. **hERG:** Both are very low (0.139 and 0.098), suggesting minimal hERG inhibition risk, which is excellent.
12. **Cl_mic:** Ligand A (-5.935) has a *much* lower (better) microsomal clearance than Ligand B (20.695). This suggests significantly better metabolic stability.
13. **t1/2:** Ligand A (-49.152) has a longer in vitro half-life than Ligand B (-17.196), which is desirable.
14. **Pgp:** Both are very low (0.004 and 0.044), indicating minimal P-gp efflux liability.
15. **Binding Affinity:** Ligand B (-6.9 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.0 kcal/mol). This is a >1.5 kcal/mol advantage, which is substantial.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. While both ligands have poor logP, Ligand B has better TPSA and significantly better affinity. The improved DILI and BBB are also beneficial. The major drawback of Ligand B is the higher Cl_mic, but the much stronger binding affinity likely outweighs this concern. Ligand A has better metabolic stability and half-life, but its weaker binding affinity is a critical disadvantage.
**Conclusion:**
Despite the metabolic concerns with Ligand B, the significantly stronger binding affinity is the deciding factor. The better DILI profile and TPSA also contribute to its favorability.
Output:
0
2025-04-17 19:57:48,690 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (374.819 Da) is slightly higher than Ligand B (344.415 Da), but both are acceptable.
2. **TPSA:** Both ligands are below the 140 A^2 threshold for good oral absorption. Ligand A (78.67 A^2) is slightly lower than Ligand B (80.49 A^2), which is preferable.
3. **logP:** Both ligands have optimal logP values (between 1 and 3). Ligand A (1.979) is slightly lower than Ligand B (2.834). While both are good, a slightly lower logP is generally preferred to avoid potential off-target effects.
4. **HBD:** Ligand A has 2 HBD, and Ligand B has 1. Both are within the acceptable limit of <=5.
5. **HBA:** Ligand A has 3 HBA, and Ligand B has 6. Ligand A is preferable here, as lower HBA generally improves permeability.
6. **QED:** Both ligands have high QED scores (A: 0.827, B: 0.918), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (39.938%) has a significantly lower DILI risk than Ligand B (65.413%). This is a major advantage for Ligand A.
8. **BBB:** Both ligands have good BBB penetration (A: 85.498%, B: 80.264%). This is important for GPCRs, but less critical for ADRB2 specifically as it's primarily a cardiovascular target.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-5.006) is slightly better than Ligand B (-4.562).
10. **Solubility:** Both ligands have very poor aqueous solubility (A: -2.698, B: -3.577). This is a significant concern for both.
11. **hERG:** Both ligands have low hERG inhibition liability (A: 0.679%, B: 0.513%), which is good.
12. **Cl_mic:** Ligand A has very low microsomal clearance (0.006 mL/min/kg), indicating excellent metabolic stability. Ligand B has significantly higher clearance (30.74 mL/min/kg), which is a major drawback.
13. **t1/2:** Ligand A has a very long in vitro half-life (-14.728 hours), which is excellent. Ligand B has a shorter half-life (-7.233 hours).
14. **Pgp:** Both ligands have low P-gp efflux liability (A: 0.037, B: 0.183).
15. **Binding Affinity:** Ligand B (-7.4 kcal/mol) has a slightly better binding affinity than Ligand A (-6.7 kcal/mol). However, the difference is not substantial enough to outweigh the other significant advantages of Ligand A.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand B has a slightly better logP and affinity, but Ligand A excels in TPSA and Pgp. The crucial difference lies in the ADME properties: Ligand A has a much lower DILI risk, significantly better metabolic stability (lower Cl_mic), and a longer half-life. These factors are critical for overall drug viability.
**Conclusion:**
Despite the slightly better binding affinity of Ligand B, Ligand A is the more promising drug candidate due to its significantly improved safety profile (lower DILI), superior metabolic stability, longer half-life, and acceptable TPSA. The solubility issues are a concern for both, but can be addressed through formulation strategies.
Output:
1
2025-04-17 19:57:48,690 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [338.319, 91.52, 3.21, 0, 7, 0.503, 90.5, 64.637, -4.412, -4.351, 0.088, 124.061, -57.823, 0.275, -7.2]
**Ligand B:** [355.391, 106.2, -0.889, 2, 6, 0.547, 37.999, 75.843, -5.052, -1.385, 0.188, -41.567, -24.928, 0.005, -7.3]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, BBB, and affinity are key):
1. **MW:** Both are within the ideal 200-500 Da range. A (338) is slightly preferred.
2. **TPSA:** A (91.52) is better than B (106.2), falling comfortably under the 140 threshold for oral absorption.
3. **logP:** A (3.21) is optimal. B (-0.889) is significantly lower, potentially causing permeability issues. This is a major drawback for B.
4. **HBD/HBA:** A (0/7) is better than B (2/6). Lower HBD is generally preferred.
5. **QED:** Both are good (A: 0.503, B: 0.547), indicating drug-likeness. B is slightly better.
6. **DILI:** A (90.5) is concerningly high. B (37.999) is much better, indicating lower liver injury risk.
7. **BBB:** A (64.637) is moderate. B (75.843) is better, although not exceptionally high.
8. **Caco-2:** Both are negative, indicating poor permeability. A (-4.412) is slightly better than B (-5.052).
9. **Solubility:** Both are negative, indicating poor solubility. A (-4.351) is slightly better than B (-1.385).
10. **hERG:** A (0.088) is very low risk. B (0.188) is also low risk.
11. **Cl_mic:** A (124.061) is higher than B (-41.567), indicating faster metabolism and lower stability. B is significantly better here.
12. **t1/2:** A (-57.823) is very poor. B (-24.928) is better, but still not ideal.
13. **Pgp:** A (0.275) is better than B (0.005), meaning less efflux.
14. **Affinity:** Both have excellent affinity (-7.2 and -7.3 kcal/mol), with B being slightly better. The difference is small enough that it doesn't outweigh other factors.
**Overall Assessment:**
Ligand B has a much better safety profile (DILI) and metabolic stability (Cl_mic, t1/2). However, its low logP is a significant concern for permeability and oral bioavailability. Ligand A has a better logP and Pgp efflux, but a concerningly high DILI risk and poor metabolic stability.
Considering the GPCR target and the balance of properties, the slightly better affinity of Ligand B and its significantly improved metabolic stability and safety profile are more attractive. While the logP is a concern, it might be addressable through further optimization. The high DILI risk of Ligand A is a more difficult hurdle.
Output:
0
2025-04-17 19:57:48,690 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [346.387, 108.29 , 0.887, 2. , 5. , 0.854, 73.129, 37.301, -5.66 , -2.804, 0.033, -26.341, -21.975, 0.01 , -5.8 ]
**Ligand B:** [346.471, 58.64 , 2.732, 1. , 3. , 0.787, 29.081, 75.727, -4.671, -2.771, 0.714, 70.533, 19.253, 0.206, -5.3 ]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, Affinity, and BBB):
1. **MW:** Both are within the ideal range (346 Da).
2. **TPSA:** Ligand B (58.64) is significantly better than Ligand A (108.29). Lower TPSA generally favors better permeability, crucial for GPCRs.
3. **logP:** Ligand B (2.732) is better positioned within the optimal range (1-3) than Ligand A (0.887), which is a bit low and could hinder membrane permeability.
4. **HBD/HBA:** Ligand B has fewer HBD/HBA (1/3) compared to Ligand A (2/5). This is favorable for permeability.
5. **QED:** Ligand A (0.854) has a slightly better QED score than Ligand B (0.787), indicating a marginally more drug-like profile.
6. **DILI:** Ligand B (29.081) has a much lower DILI risk than Ligand A (73.129). This is a significant advantage.
7. **BBB:** Ligand B (75.727) has a better BBB penetration percentile than Ligand A (37.301). While ADRB2 isn't exclusively a CNS target, some peripheral effects are mediated by CNS pathways, and better BBB penetration is generally desirable.
8. **Caco-2:** Ligand B (-4.671) is better than Ligand A (-5.66), indicating better intestinal absorption.
9. **Solubility:** Both are similarly poor (-2.804 and -2.771). This could pose formulation challenges but isn't a deal-breaker.
10. **hERG:** Ligand B (0.714) has a slightly higher hERG risk than Ligand A (0.033), but both are relatively low.
11. **Cl_mic:** Ligand A (-26.341) has a significantly lower (better) microsomal clearance than Ligand B (70.533), suggesting better metabolic stability.
12. **t1/2:** Ligand B (19.253) has a longer in vitro half-life than Ligand A (-21.975).
13. **Pgp:** Ligand B (0.206) has a lower P-gp efflux liability than Ligand A (0.01). This is a significant advantage for bioavailability.
14. **Affinity:** Both have very similar binding affinities (-5.8 and -5.3 kcal/mol). The difference is not substantial enough to override other factors.
**Overall Assessment:**
Ligand B clearly outperforms Ligand A across several critical parameters for a GPCR drug candidate. Its superior TPSA, logP, lower DILI risk, better BBB penetration, improved Caco-2 permeability, and lower P-gp efflux outweigh Ligand A's slightly better QED and metabolic stability. The similar binding affinities make the ADME properties the deciding factor.
Output:
0
2025-04-17 19:57:48,690 - INFO - Batch 149 complete. Total preferences: 2384
2025-04-17 19:57:48,690 - INFO - Processing batch 150/512...
2025-04-17 19:58:37,324 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (364.423 and 352.381 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (93.73) is higher than Ligand B (58.64). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferable for absorption. Ligand B is better.
3. **logP:** Ligand B (3.146) is slightly higher than Ligand A (2.22), but both are within the optimal 1-3 range. No major concern for either.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable, well below the 5 threshold. Ligand B is slightly better.
5. **HBA:** Ligand A (5) and Ligand B (3) are both acceptable, below the 10 threshold. Ligand B is better.
6. **QED:** Both ligands have good QED scores (0.701 and 0.856), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (83.598) has a higher DILI risk than Ligand B (64.599). Lower is better, so Ligand B is preferred.
8. **BBB:** Ligand A (65.607) has a lower BBB penetration than Ligand B (81.698). While ADRB2 isn't a primary CNS target, some degree of BBB penetration can be beneficial for off-target effects and distribution. Ligand B is better.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.963 and -4.481). This is unusual and suggests poor permeability. However, the values are similar.
10. **Solubility:** Both ligands have negative solubility values (-4.049 and -3.856). This is also unusual and suggests poor solubility. Again, the values are similar.
11. **hERG:** Ligand A (0.556) has a slightly lower hERG risk than Ligand B (0.784). Lower is better, so Ligand A is slightly preferred.
12. **Cl_mic:** Ligand A (37.616) has a lower microsomal clearance than Ligand B (68.315), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (-12.319) has a *negative* in vitro half-life, which is highly problematic. Ligand B (-33.248) also has a negative half-life, but is still slightly better. Both are very poor.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.229 and 0.294). This is good.
15. **Binding Affinity:** Ligand A (-7.5) has a slightly stronger binding affinity than Ligand B (-7.3). While the difference is small, it's still a positive for Ligand A.
**Overall Assessment:**
Ligand B consistently scores better on several key ADME properties (TPSA, HBD, HBA, QED, DILI, BBB) and has a less negative in vitro half-life. Ligand A has a slight edge in binding affinity and metabolic stability (Cl_mic) and hERG risk, but the negative half-life is a major concern. Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity), and the overall balance of properties, Ligand B appears to be the more promising candidate, despite the slightly higher hERG risk. The negative half-life for both is a major issue that would require significant optimization.
Output:
0
2025-04-17 19:58:37,325 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (363.483 and 368.503 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (78.51) is significantly better than Ligand B (96.25). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (2.327) is optimal, while Ligand B (0.825) is slightly low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (2) is preferable to Ligand B (3), keeping H-bonding within a reasonable range.
5. **HBA:** Ligand A (4) is better than Ligand B (6). Lower HBA contributes to better permeability.
6. **QED:** Ligand A (0.862) is significantly better than Ligand B (0.532), indicating a more drug-like profile.
7. **DILI:** Both ligands have acceptable DILI risk (Ligand A: 39.667, Ligand B: 32.765), with Ligand B being slightly better.
8. **BBB:** Ligand A (68.399) is better than Ligand B (36.332), but BBB is not a primary concern for a cardiovascular target.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-5.195) is slightly better than Ligand B (-5.597).
10. **Solubility:** Ligand A (-3.029) is better than Ligand B (-1.392), indicating better aqueous solubility.
11. **hERG:** Both ligands have very low hERG risk (Ligand A: 0.256, Ligand B: 0.211). No significant difference.
12. **Cl_mic:** Ligand A (1.393) has significantly lower microsomal clearance than Ligand B (21.576), suggesting better metabolic stability.
13. **t1/2:** Ligand A (9.757) has a much longer in vitro half-life than Ligand B (-20.439). This is a major advantage.
14. **Pgp:** Both have low Pgp efflux (Ligand A: 0.067, Ligand B: 0.043). No significant difference.
15. **Binding Affinity:** Ligand A (-8.2) has a significantly stronger binding affinity than Ligand B (-6.0). This is a substantial advantage, potentially outweighing minor ADME drawbacks.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A excels in all these areas. While BBB isn't critical, Ligand A is still better. The significantly improved metabolic stability (Cl_mic and t1/2) and binding affinity of Ligand A are decisive.
**Conclusion:**
Ligand A is the superior candidate due to its better drug-like properties (QED, solubility, TPSA, logP, HBD, HBA), significantly improved metabolic stability, longer half-life, and much stronger binding affinity.
Output:
1
2025-04-17 19:58:37,325 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [346.471, 49.85, 2.365, 0., 3., 0.385, 31.059, 69.794, -4.519, -2.195, 0.415, 26.288, 8.515, 0.286, 0.]
**Ligand B:** [347.459, 80.32, 2.388, 2., 4., 0.672, 32.61, 58.938, -4.766, -2.592, 0.406, 68.1, 2.762, 0.051, -5.7]
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). A: 346.471, B: 347.459 - very similar.
2. **TPSA:** Ligand A (49.85) is significantly better than Ligand B (80.32). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally correlates with better absorption.
3. **logP:** Both are good (around 2.3-2.4), falling within the optimal 1-3 range. A: 2.365, B: 2.388 - very similar.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (4). Fewer HBAs generally improve permeability.
6. **QED:** Ligand B (0.672) is better than Ligand A (0.385). Higher QED is desirable.
7. **DILI:** Both are good, with low risk (A: 31.059, B: 32.61).
8. **BBB:** Ligand A (69.794) is better than Ligand B (58.938), though neither is exceptionally high. Not a primary concern for a cardiovascular target.
9. **Caco-2:** Both are negative, indicating poor permeability. A: -4.519, B: -4.766 - B is slightly worse.
10. **Solubility:** Both are negative, indicating poor solubility. A: -2.195, B: -2.592 - B is slightly worse.
11. **hERG:** Both are very low risk (A: 0.415, B: 0.406).
12. **Cl_mic:** Ligand A (26.288) has a significantly lower (better) clearance than Ligand B (68.1). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (8.515) has a longer half-life than Ligand B (2.762).
14. **Pgp:** Both are very low efflux (A: 0.286, B: 0.051). B is slightly better.
15. **Binding Affinity:** Ligand B (-5.7) has a *much* stronger binding affinity than Ligand A (0). This is a significant advantage.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, affinity, logP, TPSA, and Pgp are key. Ligand B wins on affinity by a large margin. Ligand A wins on TPSA and has comparable logP and Pgp. However, the substantial difference in binding affinity is a major factor. While Ligand A has better metabolic stability (Cl_mic and t1/2), the potency advantage of Ligand B is likely to outweigh these ADME benefits, especially in early-stage drug discovery.
**Conclusion:**
Despite some ADME advantages for Ligand A, the significantly stronger binding affinity of Ligand B makes it the more promising candidate.
0
2025-04-17 19:58:37,325 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (359.294 and 349.475 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (29.54) is excellent, well below the 140 threshold and highly favorable for absorption. Ligand B (84.23) is higher, but still acceptable, though less optimal.
**3. logP:** Both ligands have good logP values (3.592 and 3.063), falling within the 1-3 range.
**4. H-Bond Donors:** Ligand A (0) is preferable to Ligand B (2). Fewer H-bond donors generally improve membrane permeability.
**5. H-Bond Acceptors:** Ligand A (2) is preferable to Ligand B (4). Fewer H-bond acceptors generally improve membrane permeability.
**6. QED:** Both ligands have acceptable QED values (0.603 and 0.502), indicating reasonable drug-likeness.
**7. DILI:** Ligand A (60.45) has a higher DILI risk than Ligand B (27.026). This is a significant drawback for Ligand A.
**8. BBB:** Ligand A (81.698) shows better BBB penetration than Ligand B (44.746). While ADRB2 is a cardiovascular target, some CNS exposure can occur, and higher BBB penetration is generally favorable.
**9. Caco-2 Permeability:** Ligand A (-3.961) has better Caco-2 permeability than Ligand B (-5.131).
**10. Aqueous Solubility:** Ligand A (-3.8) has better aqueous solubility than Ligand B (-2.795).
**11. hERG Inhibition:** Ligand A (0.76) has a lower hERG inhibition risk than Ligand B (0.27). This is a significant advantage for Ligand A.
**12. Microsomal Clearance:** Ligand B (57.719) has lower microsomal clearance, suggesting better metabolic stability, than Ligand A (81.439).
**13. In vitro Half-Life:** Ligand B (12.867) has a longer in vitro half-life than Ligand A (8.404).
**14. P-gp Efflux:** Ligand A (0.482) has lower P-gp efflux liability than Ligand B (0.18). Lower efflux is generally preferred.
**15. Binding Affinity:** Ligand A (-7.6) has a significantly stronger binding affinity than Ligand B (-6.6), a difference of 1.0 kcal/mol. This is a substantial advantage that can outweigh some ADME concerns.
**Overall Assessment:**
Ligand A has a significantly better binding affinity and preferable permeability characteristics (TPSA, Caco-2, P-gp). While it has a higher DILI risk, the strong binding affinity and better permeability profile are compelling. Ligand B has better metabolic stability and lower DILI, but its weaker binding affinity is a major drawback. Given the importance of potency for GPCR targets, and the acceptable (though not ideal) DILI risk of Ligand A, I favor Ligand A.
Output:
1
2025-04-17 19:58:37,325 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [346.471, 49.85, 2.075, 0, 3, 0.692, 14.889, 83.133, -4.384, -2.416, 0.189, 60.753, 6.391, 0.127, -7.3]
**Ligand B:** [344.459, 79.53, 1.876, 1, 4, 0.904, 21.753, 94.378, -4.894, -2.55, 0.772, 15.792, -12.694, 0.041, -6.3]
Here's a breakdown, prioritizing GPCR-relevant parameters:
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). A is 346.471, B is 344.459. Very similar.
2. **TPSA:** Ligand A (49.85) is excellent, well below the 140 cutoff and good for oral absorption. Ligand B (79.53) is higher, but still acceptable, though less ideal.
3. **logP:** Both are good (around 2), falling within the 1-3 optimal range. A is 2.075, B is 1.876. Again, very similar.
4. **H-Bond Donors/Acceptors:** Ligand A (0 HBD, 3 HBA) is better than Ligand B (1 HBD, 4 HBA). Fewer H-bonds generally improve permeability.
5. **QED:** Ligand B (0.904) has a better QED score than Ligand A (0.692), indicating a more drug-like profile overall.
6. **DILI Risk:** Ligand A (14.889) has a significantly lower DILI risk than Ligand B (21.753). This is a major advantage for A.
7. **BBB Penetration:** Ligand B (94.378) has much better BBB penetration than Ligand A (83.133). While ADRB2 is primarily cardiovascular, some CNS off-target effects are possible, and better BBB penetration could be a concern, but not a dealbreaker.
8. **Caco-2 Permeability:** Both are negative, indicating poor permeability. A (-4.384) is slightly worse than B (-4.894).
9. **Aqueous Solubility:** Both are negative, indicating poor solubility. A (-2.416) is slightly better than B (-2.55).
10. **hERG Inhibition:** Ligand A (0.189) has a much lower hERG risk than Ligand B (0.772). This is a critical advantage for A, as hERG inhibition can cause cardiotoxicity.
11. **Microsomal Clearance:** Ligand B (15.792) has significantly lower clearance than Ligand A (60.753), suggesting better metabolic stability.
12. **In vitro Half-Life:** Ligand B (-12.694) has a much longer half-life than Ligand A (6.391). This is a significant advantage for B.
13. **P-gp Efflux:** Ligand A (0.127) has lower P-gp efflux than Ligand B (0.041), which is beneficial for bioavailability.
14. **Binding Affinity:** Ligand A (-7.3) has a significantly stronger binding affinity than Ligand B (-6.3). This is a substantial advantage, potentially outweighing some ADME drawbacks.
**Overall Assessment:**
Ligand A has a superior binding affinity and significantly better safety profiles (lower DILI and hERG risk). While Ligand B has better QED, BBB penetration, metabolic stability, and half-life, the strong affinity of Ligand A, coupled with the critical safety advantages, make it the more promising candidate. The slightly poorer permeability and solubility of A can be addressed with formulation strategies. The better affinity is a major driver for a GPCR target.
Output:
1
2025-04-17 19:58:37,326 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (352.519 Da and 351.535 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (67.43) is higher than Ligand B (52.65). For a peripheral GPCR like ADRB2, TPSA is less critical than for a CNS target, but lower is generally preferable for absorption. Ligand B has a slight advantage.
**3. logP:** Both ligands have good logP values (3.195 and 2.818, respectively), falling within the optimal 1-3 range. No clear advantage.
**4. H-Bond Donors:** Ligand A has 2 HBD, while Ligand B has 1. Both are acceptable (<=5), with Ligand B being slightly better.
**5. H-Bond Acceptors:** Both ligands have 3 HBA, which is well within the acceptable limit of <=10.
**6. QED:** Both ligands have good QED scores (0.692 and 0.718), indicating good drug-like properties. No significant difference.
**7. DILI Risk:** Ligand B (6.437) has a significantly lower DILI risk than Ligand A (29.391). This is a major advantage for Ligand B.
**8. BBB Penetration:** Ligand B (79.256) has better BBB penetration than Ligand A (60.876). While ADRB2 is not a primary CNS target, some CNS exposure can contribute to side effects, and better control of this is desirable.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.794 and -4.627). This is unusual and suggests poor permeability *in vitro*. However, these values are close, and the absolute value isn't dramatically different.
**10. Aqueous Solubility:** Ligand B (-1.894) has better aqueous solubility than Ligand A (-3.268). This is a positive for formulation and bioavailability.
**11. hERG Inhibition:** Ligand A (0.362) has a slightly lower hERG inhibition risk than Ligand B (0.614), which is preferable.
**12. Microsomal Clearance:** Ligand B (23.924) has significantly lower microsomal clearance than Ligand A (63.361), indicating better metabolic stability. This is a significant advantage.
**13. In vitro Half-Life:** Ligand B (-10.998) has a negative half-life, which is highly unusual and concerning. Ligand A (15.512) has a reasonable half-life. This is a major drawback for Ligand B.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.08 and 0.034). No significant difference.
**15. Binding Affinity:** Ligand B (-6.5) has a slightly better binding affinity than Ligand A (-5.4). This difference of 1.1 kcal/mol is substantial and can outweigh some ADME concerns.
**Overall Assessment:**
Ligand B has several advantages: lower DILI risk, better BBB penetration, better solubility, and significantly better metabolic stability. It also has a better binding affinity. However, the negative *in vitro* half-life is a major red flag. Ligand A has a reasonable half-life and slightly lower hERG risk. The difference in binding affinity is significant, but the metabolic stability and DILI risk of Ligand B are compelling.
Considering the balance, the significantly improved ADME properties of Ligand B (lower DILI, better metabolic stability, better solubility) and its superior binding affinity outweigh the concern of the negative half-life. The negative half-life suggests a potential issue with the assay or a very rapid metabolism that could be addressed through structural modifications.
Output:
0
2025-04-17 19:58:37,326 - INFO - Here's my reasoning and final output for the ligand preference:
**Reasoning:**
We are looking for a drug candidate for ADRB2, a cardiovascular GPCR. Therefore, the priorities are affinity, logP, TPSA, Pgp efflux, and to a lesser extent, BBB.
Let's compare Ligand A and Ligand B across the 15 parameters:
1. **MW:** Both ligands (352.41 and 348.451 Da) are within the ideal range (200-500 Da).
2. **TPSA:** Ligand A (86.63) is slightly higher than Ligand B (79.54), but both are well below the 140 threshold for good absorption.
3. **logP:** Ligand A (0.822) is a bit lower than Ligand B (1.106), but both are within the optimal 1-3 range.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 5 HBA, while Ligand B has 8. Ligand A is slightly preferred here.
6. **QED:** Both are reasonably good (0.785 and 0.727), indicating drug-likeness.
7. **DILI:** Ligand A (43.117) has a lower DILI risk than Ligand B (58.434), which is a significant advantage.
8. **BBB:** Ligand B (84.141) has a higher BBB penetration than Ligand A (62.854). However, since this is a cardiovascular target, BBB penetration is less critical.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. Ligand A (-4.643) is slightly better than Ligand B (-4.718).
10. **Solubility:** Ligand A (-0.543) has better solubility than Ligand B (-1.691).
11. **hERG:** Ligand A (0.149) has a much lower hERG inhibition risk than Ligand B (0.712). This is a major advantage.
12. **Cl_mic:** Ligand A (8.43) has significantly lower microsomal clearance than Ligand B (46.693), suggesting better metabolic stability.
13. **t1/2:** Ligand B (61.075) has a longer in vitro half-life than Ligand A (14.99), which is a positive.
14. **Pgp:** Ligand A (0.024) has much lower P-gp efflux liability than Ligand B (0.241). This is a significant advantage for bioavailability.
15. **Affinity:** Ligand B (-6.2) has a slightly better binding affinity than Ligand A (-5.8), a 0.4 kcal/mol difference.
**Overall Assessment:**
While Ligand B has a slightly better binding affinity and longer half-life, Ligand A demonstrates a significantly better safety profile (lower DILI and hERG risk), better solubility, lower P-gp efflux, and lower microsomal clearance. The difference in binding affinity (0.4 kcal/mol) is not substantial enough to outweigh the substantial ADME/Tox advantages of Ligand A, especially considering the cardiovascular target where BBB penetration is not a primary concern. The improved metabolic stability and reduced efflux are particularly valuable.
Output:
1
2025-04-17 19:58:37,326 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.49 & 376.55 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (60.85) is higher than Ligand B (42.43). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for permeability. Ligand B has a slight edge.
3. **logP:** Ligand A (2.036) is within the optimal 1-3 range. Ligand B (4.744) is higher, potentially leading to solubility issues and off-target interactions. Ligand A is significantly better here.
4. **HBD:** Ligand A (1) is preferable to Ligand B (0). While both are low, a single HBD can aid solubility without significantly impacting permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (5). Lower HBA is generally better for permeability.
6. **QED:** Both ligands have similar QED values (0.716 and 0.731), indicating good drug-likeness. No significant difference.
7. **DILI:** Ligand A (12.37%) has a much lower DILI risk than Ligand B (40.29%). This is a substantial advantage for Ligand A.
8. **BBB:** Ligand B (83.37%) shows higher BBB penetration than Ligand A (54.44%). While ADRB2 isn't a primary CNS target, some brain exposure can be relevant for peripheral effects. However, this is less important than other factors.
9. **Caco-2:** Both ligands show negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.538) is slightly better than Ligand B (-4.64).
10. **Solubility:** Ligand A (-2.169) has better solubility than Ligand B (-5.647). This is important for bioavailability.
11. **hERG:** Ligand A (0.467) has a lower hERG risk than Ligand B (0.712). This is a significant safety advantage for Ligand A.
12. **Cl_mic:** Ligand A (36.132) has lower microsomal clearance than Ligand B (120.20). This indicates better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (-6.903) has a longer *in vitro* half-life than Ligand B (25.087). This is a crucial advantage for dosing convenience.
14. **Pgp:** Ligand A (0.272) has lower P-gp efflux than Ligand B (0.732), suggesting better bioavailability.
15. **Binding Affinity:** Ligand B (-7.1 kcal/mol) has a slightly better binding affinity than Ligand A (-5.9 kcal/mol). This 1.2 kcal/mol difference is significant, but needs to be weighed against the other ADME properties.
**Overall Assessment:**
Ligand B has a slightly better binding affinity and BBB penetration. However, Ligand A excels in almost all other critical ADME properties: lower DILI risk, better solubility, lower hERG risk, better metabolic stability (lower Cl_mic and longer t1/2), and lower P-gp efflux. The higher logP of Ligand B is a concern, and its significantly higher DILI risk is a major drawback. For a cardiovascular target like ADRB2, metabolic stability, safety (DILI, hERG), and bioavailability are paramount. While affinity is important, the substantial advantages of Ligand A in these areas outweigh the slightly weaker binding.
Output:
1
2025-04-17 19:58:37,326 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (366.487) is slightly higher than Ligand B (346.471), but this isn't a major concern.
2. **TPSA:** Ligand A (85.77) is higher than Ligand B (58.64). While both are reasonably low, Ligand B is significantly better, falling well below the 90 A^2 threshold for good oral absorption and potentially better CNS penetration.
3. **logP:** Ligand A (0.568) is lower than the optimal range (1-3), potentially hindering permeability. Ligand B (2.409) is within the optimal range. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable.
5. **HBA:** Ligand A (6) and Ligand B (3) are both acceptable. Ligand B is preferable.
6. **QED:** Both ligands have good QED scores (A: 0.737, B: 0.85), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (25.708) has a slightly higher DILI risk than Ligand B (18.108), but both are below the concerning threshold of 40.
8. **BBB:** Ligand A (21.675) has a low BBB penetration percentile, while Ligand B (79.217) is very good. For a GPCR, even a peripherally acting one like ADRB2, some degree of BBB penetration can be useful for understanding off-target effects and potential CNS side effects. This is a strong advantage for Ligand B.
9. **Caco-2:** Ligand A (-5.283) and Ligand B (-4.535) are both negative, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Ligand A (-1.048) and Ligand B (-2.908) are both negative, suggesting poor aqueous solubility.
11. **hERG:** Ligand A (0.446) has a slightly lower hERG risk than Ligand B (0.245), which is preferable.
12. **Cl_mic:** Ligand A (-1.259) has a lower (better) microsomal clearance than Ligand B (27.244), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (6.879) has a shorter half-life than Ligand B (14.582). Ligand B is preferable.
14. **Pgp:** Ligand A (0.054) has a lower Pgp efflux liability than Ligand B (0.038), which is preferable.
15. **Binding Affinity:** Ligand B (-8.1) has a significantly stronger binding affinity than Ligand A (-6.5), a difference of 1.6 kcal/mol. This is a substantial advantage that can outweigh some of the ADME drawbacks.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are particularly important. Ligand B excels in logP, TPSA, and especially affinity. While Ligand A has better metabolic stability (Cl_mic), the significantly stronger binding affinity of Ligand B is a major advantage and likely to be more impactful in driving efficacy.
**Conclusion:**
Despite Ligand A's better metabolic stability and slightly lower hERG risk, Ligand B's superior logP, TPSA, BBB penetration, and *significantly* stronger binding affinity make it the more promising drug candidate for ADRB2.
Output:
0
2025-04-17 19:58:37,326 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (345.447) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (90.98) is better than Ligand B (49.22). For a cardiovascular GPCR, TPSA isn't a *major* concern unless CNS penetration is desired, but lower is generally preferred for oral absorption.
3. **logP:** Ligand B (3.865) is higher than Ligand A (1.743). While both are within the optimal range, Ligand B is approaching the upper limit, which could potentially lead to solubility issues.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1), but both are acceptable.
5. **HBA:** Ligand A (4) is slightly higher than Ligand B (5), but both are acceptable.
6. **QED:** Ligand A (0.85) is significantly better than Ligand B (0.692), indicating a more drug-like profile.
7. **DILI:** Ligand A (25.475) has a much lower DILI risk than Ligand B (44.281). This is a significant advantage.
8. **BBB:** Ligand B (76.619) has better BBB penetration than Ligand A (64.095). However, for a cardiovascular target, BBB penetration is not a primary concern.
9. **Caco-2:** Ligand A (-5.193) and Ligand B (-4.988) are similar, and both indicate reasonable permeability.
10. **Solubility:** Ligand A (-2.938) has better solubility than Ligand B (-3.571).
11. **hERG:** Ligand A (0.263) has a much lower hERG risk than Ligand B (0.954), a critical safety parameter.
12. **Cl_mic:** Ligand B (17.778) has a significantly lower microsomal clearance than Ligand A (33.184), suggesting better metabolic stability.
13. **t1/2:** Ligand B (4.817) has a longer in vitro half-life than Ligand A (-18.743). This is a considerable advantage.
14. **Pgp:** Ligand A (0.057) has lower P-gp efflux liability than Ligand B (0.397), which is favorable for bioavailability.
15. **Affinity:** Both ligands have the same binding affinity (-7.2 kcal/mol), so this parameter doesn't differentiate them.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B has a better logP and Pgp profile, and the same affinity. However, Ligand A excels in QED, DILI, hERG, and solubility. The lower DILI and hERG risks for Ligand A are crucial safety advantages that outweigh the slightly less favorable logP and Pgp values. The longer half-life of Ligand B is also attractive, but the safety profile of Ligand A is more compelling.
**Conclusion:**
Considering the balance of properties, especially the significantly lower DILI and hERG risks, and the better QED and solubility, Ligand A is the more promising drug candidate.
Output:
1
2025-04-17 19:58:37,327 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (353.419 and 346.475 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Both ligands (88.18 and 86.88) are below the 140 A^2 threshold for good oral absorption, and acceptable for a cardiovascular GPCR. Again, no strong difference.
3. **logP:** Ligand A (0.363) is a bit low, potentially hindering permeability. Ligand B (2.796) is closer to the optimal 1-3 range. This favors Ligand B.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3), as fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (3), as fewer HBAs generally improve permeability.
6. **QED:** Ligand A (0.771) has a better QED score than Ligand B (0.633), indicating a more drug-like profile. This favors Ligand A.
7. **DILI:** Ligand A (34.161) has a significantly lower DILI risk than Ligand B (50.136). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (59.636) has a higher BBB penetration percentile than Ligand B (46.84). While ADRB2 isn't a CNS target, some degree of BBB penetration can be useful for off-target profiling.
9. **Caco-2:** Ligand A (-4.9) has a better Caco-2 permeability than Ligand B (-5.204).
10. **Solubility:** Ligand A (-1.37) has better solubility than Ligand B (-3.488).
11. **hERG:** Ligand A (0.173) has a much lower hERG inhibition liability than Ligand B (0.6). This is a crucial safety parameter, strongly favoring Ligand A.
12. **Cl_mic:** Ligand A (-35.175) has a significantly lower (better) microsomal clearance than Ligand B (57.161), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (-4.699) has a better in vitro half-life than Ligand B (-11.598).
14. **Pgp:** Ligand A (0.014) has a much lower P-gp efflux liability than Ligand B (0.228), which is favorable for bioavailability.
15. **Affinity:** Both ligands have very similar binding affinities (-7.8 and -7.0 kcal/mol). The difference of 0.8 kcal/mol is not substantial enough to outweigh the significant ADME advantages of Ligand A.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical ADME-Tox parameters (DILI, hERG, Cl_mic, Pgp, solubility). While Ligand B has a slightly better logP, the benefits of Ligand A's superior safety profile and metabolic stability are far more important for a cardiovascular drug candidate. The binding affinity difference is minimal.
Output:
1
2025-04-17 19:58:37,327 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (342.355 Da and 349.431 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (104.65) is higher than Ligand B (75.88). For a cardiovascular GPCR, TPSA is moderately important, and lower is generally better for permeability. Ligand B has a clear advantage.
**3. logP:** Both ligands have good logP values (2.036 and 1.582), falling within the optimal 1-3 range. Ligand B is slightly lower, which could be beneficial for solubility, but not a major factor.
**4. H-Bond Donors:** Ligand A has 2 HBD, and Ligand B has 0. Both are acceptable (<=5).
**5. H-Bond Acceptors:** Ligand A has 6 HBA, and Ligand B has 5. Both are acceptable (<=10).
**6. QED:** Both ligands have similar QED values (0.856 and 0.828), indicating good drug-likeness.
**7. DILI Risk:** Ligand A has a high DILI risk (98.41 percentile), which is a major concern. Ligand B has a much lower DILI risk (42.885 percentile), making it significantly safer from a liver toxicity perspective.
**8. BBB Penetration:** Ligand A has very low BBB penetration (20.318 percentile), while Ligand B has good BBB penetration (75.688 percentile). While ADRB2 is primarily a cardiovascular target, some CNS effects are possible with certain ligands, and better BBB penetration could be advantageous or a concern depending on the desired selectivity.
**9. Caco-2 Permeability:** Ligand A has poor Caco-2 permeability (-5.054), indicating poor intestinal absorption. Ligand B has better Caco-2 permeability (-4.416), though still not ideal.
**10. Aqueous Solubility:** Ligand A has very poor aqueous solubility (-3.701), while Ligand B has slightly better solubility (-1.06). Solubility is important for formulation and bioavailability.
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (0.13 and 0.316), which is good.
**12. Microsomal Clearance:** Ligand A has lower microsomal clearance (6.564 mL/min/kg) than Ligand B (31.845 mL/min/kg), suggesting better metabolic stability.
**13. In vitro Half-Life:** Ligand A has a short in vitro half-life (1.054 hours), while Ligand B has a very long in vitro half-life (-25.059 hours). This is a significant advantage for Ligand B, potentially allowing for less frequent dosing.
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (0.017 and 0.141), which is favorable.
**15. Binding Affinity:** Ligand B has a significantly stronger binding affinity (-6.7 kcal/mol) compared to Ligand A (-3.9 kcal/mol). This difference of 2.8 kcal/mol is substantial and can outweigh minor drawbacks in other properties.
**Overall Assessment:**
Ligand B is the clear winner. While Ligand A has better metabolic stability, its extremely high DILI risk, poor solubility, and poor Caco-2 permeability are major red flags. Ligand B's superior binding affinity, lower DILI risk, better BBB penetration, and significantly longer half-life outweigh its slightly higher microsomal clearance. The stronger binding affinity is particularly important for a GPCR target.
Output:
0
2025-04-17 19:58:37,327 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (369.491 and 352.475 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (103.43) is higher than Ligand B (76.66). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B is better.
3. **logP:** Ligand A (1.014) is at the lower end of the optimal range (1-3), while Ligand B (2.635) is well within it. Ligand B has better lipophilicity, which is important for GPCR binding and membrane permeability.
4. **HBD:** Ligand A (3) and Ligand B (2) both fall within the acceptable limit of <=5. Ligand B is slightly better.
5. **HBA:** Ligand A (5) and Ligand B (4) both fall within the acceptable limit of <=10. Ligand B is slightly better.
6. **QED:** Ligand A (0.636) is significantly better than Ligand B (0.36), indicating a more drug-like profile. This is a substantial advantage for Ligand A.
7. **DILI:** Ligand A (38.465) has a slightly higher DILI risk than Ligand B (28.306), but both are below the concerning threshold of 60. Ligand B is better.
8. **BBB:** Ligand A (51.377) and Ligand B (68.67) are both relatively low, which is expected for a cardiovascular target. Ligand B is better.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.221 and -5.258), which is unusual and suggests poor permeability. This is a significant drawback for both.
10. **Solubility:** Ligand A (-1.229) and Ligand B (-1.983) both have negative solubility values, indicating poor aqueous solubility. Ligand B is slightly worse.
11. **hERG:** Ligand A (0.093) has a lower hERG risk than Ligand B (0.328). This is a significant advantage for Ligand A, as hERG inhibition can lead to cardiotoxicity.
12. **Cl_mic:** Ligand A (25.988) has lower microsomal clearance than Ligand B (30.024), suggesting better metabolic stability. This is a positive for Ligand A.
13. **t1/2:** Ligand A (8.628) has a longer in vitro half-life than Ligand B (-1.299). This is a significant advantage for Ligand A, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.013) has significantly lower P-gp efflux liability than Ligand B (0.047). This is a positive for Ligand A, improving bioavailability.
15. **Binding Affinity:** Ligand B (-7.1 kcal/mol) has a substantially stronger binding affinity than Ligand A (-5.6 kcal/mol). This is a 1.5 kcal/mol difference, which is a significant advantage for Ligand B and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand B has a better logP, TPSA, BBB, and most importantly, a significantly higher binding affinity. However, Ligand A demonstrates superior drug-likeness (QED), metabolic stability (Cl_mic), half-life, lower P-gp efflux, and lower hERG risk. The negative Caco-2 and solubility values are concerning for both.
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), the stronger binding affinity of Ligand B is a major advantage. While Ligand A has better ADME properties overall, the potency difference is substantial enough to favor Ligand B, assuming the permeability issues can be addressed through formulation or structural modifications.
Output:
0
2025-04-17 19:58:37,327 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (353.5) is within the ideal range (200-500). Ligand B (370.5) is also within the ideal range. No clear advantage here.
2. **TPSA:** Ligand A (81.7) is good for oral absorption, being below 140. Ligand B (42.4) is excellent, well below 90, suggesting potentially better permeability. Advantage: B
3. **logP:** Ligand A (1.42) is optimal. Ligand B (4.91) is pushing the upper limit and could present solubility challenges. Advantage: A
4. **HBD:** Ligand A (3) is acceptable. Ligand B (0) is also acceptable. No clear advantage.
5. **HBA:** Ligand A (4) is acceptable. Ligand B (5) is acceptable. No clear advantage.
6. **QED:** Ligand A (0.675) is good. Ligand B (0.594) is acceptable, but slightly lower. Advantage: A
7. **DILI:** Ligand A (5.86) is very good, indicating low liver injury risk. Ligand B (19.47) is still acceptable, but higher than A. Advantage: A
8. **BBB:** Ligand A (55.95) is moderate. Ligand B (94.15) is excellent, suggesting good potential for CNS penetration if desired (though ADRB2 is primarily cardiovascular, some CNS off-target effects are possible). Advantage: B
9. **Caco-2:** Ligand A (-5.06) is poor permeability. Ligand B (-4.85) is also poor permeability. No clear advantage.
10. **Solubility:** Ligand A (-1.51) is poor. Ligand B (-4.93) is very poor. Both are problematic, but B is worse. Advantage: A
11. **hERG:** Ligand A (0.17) is very low risk. Ligand B (0.92) is slightly higher risk. Advantage: A
12. **Cl_mic:** Ligand A (-3.89) suggests good metabolic stability (negative value). Ligand B (86.45) suggests rapid metabolism. Significant advantage: A
13. **t1/2:** Ligand A (-9.29) suggests a very long half-life. Ligand B (19.06) is moderate. Significant advantage: A
14. **Pgp:** Ligand A (0.017) suggests low P-gp efflux. Ligand B (0.578) suggests moderate P-gp efflux. Advantage: A
15. **Affinity:** Ligand A (-6.0) is good. Ligand B (-6.7) is slightly better. Advantage: B
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity), and the general drug-like properties, Ligand A is the stronger candidate. While Ligand B has a slightly better affinity and excellent BBB penetration, its significantly poorer solubility, high metabolic clearance, and moderate P-gp efflux are major drawbacks. Ligand A demonstrates a better balance of properties, particularly regarding safety (DILI, hERG) and pharmacokinetic parameters (Cl_mic, t1/2). The solubility issue with A is concerning, but potentially addressable through formulation strategies. The metabolic instability of B is harder to fix.
Output:
1
2025-04-17 19:58:37,327 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's break down the comparison of Ligand A and Ligand B based on the provided parameters and the GPCR-specific priorities (logP, Pgp, TPSA, and affinity being most important).
1. **Molecular Weight:** Both ligands (340.471 and 362.402 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (83.8) is better than Ligand B (100.21). Lower TPSA generally favors better absorption, and is important for GPCRs.
3. **logP:** Ligand A (3.177) is within the optimal range (1-3), while Ligand B (-1.312) is significantly lower. This is a major drawback for Ligand B, as it may struggle with membrane permeability.
4. **H-Bond Donors/Acceptors:** Ligand A has 3 HBD and 3 HBA, while Ligand B has 2 HBD and 6 HBA. Both are acceptable, but Ligand A is slightly more balanced.
5. **QED:** Ligand A (0.69) is significantly better than Ligand B (0.37), indicating a more drug-like profile.
6. **DILI:** Ligand A (14.734) has a much lower DILI risk than Ligand B (29.081), which is a significant advantage.
7. **BBB:** Ligand B (74.68) has a slightly better BBB penetration than Ligand A (68.282), but this is less critical for ADRB2, which isn't necessarily a CNS target.
8. **Caco-2 Permeability:** Both are negative, indicating poor permeability. Ligand A (-5.494) is slightly better than Ligand B (-5.307).
9. **Aqueous Solubility:** Both are negative, indicating poor solubility. Ligand A (-1.823) is slightly better than Ligand B (-0.447).
10. **hERG Inhibition:** Ligand A (0.723) has a lower hERG risk than Ligand B (0.154), which is a positive.
11. **Microsomal Clearance:** Ligand A (-11.21) has a lower (better) microsomal clearance than Ligand B (-1.087), suggesting better metabolic stability.
12. **In vitro Half-Life:** Ligand A (-7.268) has a much longer in vitro half-life than Ligand B (-40.457), which is a significant advantage.
13. **P-gp Efflux:** Ligand A (0.169) has a lower P-gp efflux liability than Ligand B (0.002), which is better.
14. **Binding Affinity:** Ligand B (-7.3 kcal/mol) has a slightly better binding affinity than Ligand A (-6.4 kcal/mol). While a 1.5 kcal/mol difference is usually significant, the overall ADME profile of Ligand B is substantially worse.
**Overall Assessment:**
Ligand A is the superior candidate. While Ligand B has slightly better binding affinity, Ligand A excels in almost all other critical parameters, especially logP, QED, DILI, metabolic stability (Cl_mic and t1/2), and P-gp efflux. The poor logP of Ligand B is a major concern, likely leading to poor absorption. The significantly better ADME profile of Ligand A outweighs the small difference in binding affinity.
**Output:**
1
2025-04-17 19:58:37,328 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (358.404 and 355.507 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (49.41) is better than Ligand B (41.15). Both are below the 140 threshold for oral absorption, and acceptable for a cardiovascular target.
3. **logP:** Ligand A (2.32) is optimal (1-3). Ligand B (4.992) is pushing the upper limit and could potentially lead to solubility issues or off-target interactions, though not drastically.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A (2) is preferable to Ligand B (4). Lower HBA generally improves permeability.
6. **QED:** Ligand A (0.839) is significantly better than Ligand B (0.411), indicating a much more drug-like profile.
7. **DILI:** Ligand A (15.355) has a much lower DILI risk than Ligand B (52.074). This is a critical advantage.
8. **BBB:** Ligand A (90.074) has better BBB penetration than Ligand B (65.297). While ADRB2 isn't necessarily a CNS target, some distribution into the CNS is possible, and higher BBB is generally favorable.
9. **Caco-2:** Ligand A (-4.916) is better than Ligand B (-5.216), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-3.179) is better than Ligand B (-4.428). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.492) has a lower hERG risk than Ligand B (0.933). This is a significant safety advantage.
12. **Cl_mic:** Ligand A (4.388) has significantly lower microsomal clearance than Ligand B (73.432), indicating better metabolic stability.
13. **t1/2:** Ligand A (1.423) has a shorter half-life than Ligand B (-14.739). This is a negative for Ligand A.
14. **Pgp:** Ligand A (0.069) has lower P-gp efflux than Ligand B (0.788), which is favorable for bioavailability.
15. **Affinity:** Ligand A (-8.4 kcal/mol) has a slightly better binding affinity than Ligand B (-5.5 kcal/mol). This is a substantial difference and a major driver in the decision.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are particularly important. Ligand A excels in all these areas except for the half-life, which is a drawback. However, the significantly better affinity, lower DILI risk, lower hERG risk, better metabolic stability, and better solubility of Ligand A outweigh the shorter half-life.
**Conclusion:**
Ligand A is the superior candidate due to its significantly better ADME-Tox profile (lower DILI, hERG, Cl_mic, Pgp) and substantially stronger binding affinity. The slightly shorter half-life can be addressed through formulation strategies if needed.
Output:
1
2025-04-17 19:58:37,328 - INFO - Batch 150 complete. Total preferences: 2400
2025-04-17 19:58:37,328 - INFO - Processing batch 151/512...
2025-04-17 19:59:27,335 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (405.267 Da) is within the ideal range. Ligand B (351.491 Da) is also within the ideal range, slightly lower. No strong preference here.
2. **TPSA:** Ligand A (49.5) is good, below the 140 threshold. Ligand B (64.09) is still reasonable, but higher. This favors Ligand A slightly.
3. **logP:** Ligand A (4.238) is a bit high, potentially causing solubility issues or off-target effects. Ligand B (1.081) is excellent, within the optimal range. This strongly favors Ligand B.
4. **HBD:** Both ligands have 1 HBD, which is good. No preference.
5. **HBA:** Both ligands have 4 HBA, which is good. No preference.
6. **QED:** Ligand A (0.639) is good. Ligand B (0.823) is even better, indicating a more drug-like profile. This favors Ligand B.
7. **DILI:** Ligand A (52.074) is acceptable, below the 60% threshold. Ligand B (5.739) is excellent, very low risk. This strongly favors Ligand B.
8. **BBB:** Ligand A (78.79) is good, suggesting reasonable brain penetration. Ligand B (52.579) is lower. Since ADRB2 is a GPCR, BBB penetration isn't a primary concern unless targeting CNS effects, but Ligand A is better here.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
10. **Solubility:** Both ligands have negative solubility values, which is also unusual and suggests poor solubility. Again, the scale is not specified.
11. **hERG:** Ligand A (0.967) is low risk. Ligand B (0.293) is even lower, excellent. This strongly favors Ligand B.
12. **Cl_mic:** Ligand A (59.082) is moderate, indicating reasonable metabolic stability. Ligand B (-1.07) is *very* low, suggesting excellent metabolic stability. This strongly favors Ligand B.
13. **t1/2:** Ligand A (75.157) is good. Ligand B (9.55) is relatively short. This favors Ligand A.
14. **Pgp:** Ligand A (0.96) is low efflux, good. Ligand B (0.021) is very low efflux, excellent. This strongly favors Ligand B.
15. **Affinity:** Ligand A (-7.7 kcal/mol) is significantly better than Ligand B (-6.0 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME drawbacks of Ligand A.
**Overall Assessment:**
Ligand B has a superior ADME profile across most parameters (logP, QED, DILI, hERG, Cl_mic, Pgp). While Ligand A has a better half-life and a significantly stronger binding affinity, the ADME profile of Ligand B is more favorable for overall drug development. The high logP of Ligand A is a concern, and the excellent metabolic stability of Ligand B is a significant advantage for a GPCR target. The substantial affinity difference is important, but the other benefits of Ligand B are more crucial for a successful drug candidate.
Output:
0
2025-04-17 19:59:27,335 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [340.387, 98.73, 2.322, 1, 7, 0.782, 72.121, 41.218, -5.087, -3.198, 0.258, 39.898, -5.851, 0.034, -6.6]
**Ligand B:** [333.395, 75.08, 2.882, 2, 4, 0.552, 69.756, 57.154, -5.605, -3.553, 0.917, 52.193, -22.249, 0.533, -7.5]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (333.395) is slightly lower, which is generally favorable.
2. **TPSA:** Ligand A (98.73) is higher than Ligand B (75.08). Both are acceptable for a non-CNS GPCR target like ADRB2, but B is better.
3. **logP:** Both are in the optimal range (1-3). Ligand B (2.882) is slightly higher, which could be a minor advantage for membrane permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower is better for permeability.
5. **HBA:** Ligand A (7) is higher than Ligand B (4). Ligand B is preferable.
6. **QED:** Ligand A (0.782) has a significantly better QED score than Ligand B (0.552), indicating a more drug-like profile.
7. **DILI:** Both are reasonably good, with Ligand A (72.121) slightly higher than Ligand B (69.756). This difference is not substantial.
8. **BBB:** ADRB2 is primarily a cardiovascular target, so BBB penetration isn't a major priority. Ligand B (57.154) is higher than Ligand A (41.218), but this isn't a deciding factor.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand B (-5.605) is slightly better than A (-5.087).
10. **Solubility:** Both have negative solubility values, which is also unusual. Ligand B (-3.553) is slightly better than A (-3.198).
11. **hERG:** Ligand A (0.258) has a much lower hERG risk than Ligand B (0.917). This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand A (39.898) has lower microsomal clearance than Ligand B (52.193), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-22.249) has a much longer in vitro half-life than Ligand A (-5.851). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.034) has much lower P-gp efflux liability than Ligand B (0.533). This is a significant advantage for Ligand A.
15. **Affinity:** Ligand B (-7.5) has a better binding affinity than Ligand A (-6.6) by 0.9 kcal/mol. This is a substantial difference and a major advantage for Ligand B.
**Overall Assessment:**
Ligand B has a better binding affinity and a longer half-life, which are crucial for a GPCR target. However, Ligand A has a better QED score, lower hERG risk, and lower P-gp efflux. The negative Caco-2 and solubility values are concerning for both, but the affinity difference is substantial enough to outweigh the other factors.
Therefore, I prefer Ligand B.
0
2025-04-17 19:59:27,335 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
The ADRB2 receptor is a GPCR involved in cardiovascular function. Therefore, prioritizing logP, TPSA, Pgp efflux, and binding affinity is crucial, alongside general drug-like properties.
Let's break down the comparison:
1. **Molecular Weight:** Both ligands (353.453 and 353.419 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (21.7) is significantly better than Ligand B (105.76). A TPSA under 140 is good for oral absorption, but lower is better for GPCRs, and A is substantially lower.
3. **logP:** Ligand A (4.538) is good, falling within the 1-3 range, though on the higher end. Ligand B (-0.647) is poor, being significantly below 1 and potentially hindering permeation. This is a major disadvantage for B.
4. **H-Bond Donors:** Ligand A (0) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **H-Bond Acceptors:** Ligand A (3) is preferable to Ligand B (5). Fewer HBAs generally improve permeability.
6. **QED:** Ligand A (0.776) is better than Ligand B (0.478), indicating a more drug-like profile.
7. **DILI:** Ligand A (12.02) is significantly better than Ligand B (26.173), indicating a lower risk of drug-induced liver injury.
8. **BBB:** Ligand A (93.874) is excellent, while Ligand B (60.644) is moderate. While ADRB2 isn't strictly a CNS target, good BBB penetration is rarely detrimental and can offer some flexibility.
9. **Caco-2:** Ligand A (-4.409) is better than Ligand B (-5.368), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-3.233) is better than Ligand B (-1.297), suggesting better aqueous solubility.
11. **hERG:** Ligand A (0.956) is better than Ligand B (0.06), indicating a lower risk of hERG inhibition and cardiotoxicity.
12. **Cl_mic:** Ligand A (28.688) is better than Ligand B (20.886), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-10.496) is better than Ligand B (1.426), indicating a longer in vitro half-life.
14. **Pgp:** Ligand A (0.388) is better than Ligand B (0.003), indicating lower P-gp efflux.
15. **Binding Affinity:** Ligand B (-6.4) is slightly better than Ligand A (-6.1), but the difference (0.3 kcal/mol) is not substantial enough to outweigh the numerous advantages of Ligand A.
**Conclusion:**
Ligand A consistently outperforms Ligand B across most critical ADME properties, including TPSA, logP, solubility, DILI risk, BBB penetration, and metabolic stability. While Ligand B has a marginally better binding affinity, the overall profile of Ligand A is far more favorable for development as a drug candidate targeting the ADRB2 receptor.
**Output:**
1
2025-04-17 19:59:27,335 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [347.459, 62.74, 2.132, 0, 4, 0.758, 33.501, 71.501, -4.276, -1.56, 0.304, 54.718, 18.623, 0.079, -6.1]
**Ligand B:** [348.487, 49.85, 2.894, 0, 3, 0.475, 17.798, 90.655, -4.579, -2.044, 0.602, 67.201, -8.732, 0.304, -6.1]
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). A: 347.459, B: 348.487 - very similar.
2. **TPSA:** Ligand A (62.74) is slightly higher than Ligand B (49.85). Both are acceptable, but B is better for permeability.
3. **logP:** Both are within the optimal range (1-3). Ligand B (2.894) is slightly higher than A (2.132), which is generally favorable for GPCR ligands.
4. **HBD:** Both have 0 HBD, which is good.
5. **HBA:** Ligand A (4) has one more HBA than Ligand B (3). Lower is generally better for permeability.
6. **QED:** Ligand A (0.758) has a significantly better QED score than Ligand B (0.475), indicating a more drug-like profile.
7. **DILI:** Ligand B (17.798) has a much lower DILI risk than Ligand A (33.501). This is a significant advantage for B.
8. **BBB:** Ligand B (90.655) has a much higher BBB penetration potential than Ligand A (71.501). Given that ADRB2 is a GPCR, and even though it's cardiovascular, some CNS off-target effects are a consideration, and higher BBB is generally preferred.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. Ligand B (-4.579) is slightly worse than A (-4.276).
10. **Solubility:** Ligand B (-2.044) has slightly worse solubility than A (-1.56).
11. **hERG:** Both have very low hERG risk (0.304 and 0.602).
12. **Cl_mic:** Ligand A (54.718) has a lower microsomal clearance than Ligand B (67.201), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-8.732) has a negative in vitro half-life, which is concerning. Ligand A (18.623) has a reasonable half-life.
14. **Pgp:** Both have low Pgp efflux liability (0.079 and 0.304).
15. **Affinity:** Both have the same binding affinity (-6.1 kcal/mol).
**GPCR-Specific Priorities:** For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP and TPSA, and has a significantly better BBB score. Ligand A has a better QED and metabolic stability (Cl_mic and t1/2). The negative half-life of Ligand B is a major concern.
**Overall Assessment:**
While Ligand A has a better QED and metabolic stability, Ligand B's significantly lower DILI risk, better TPSA, higher logP, and substantially improved BBB penetration are more compelling for a GPCR target. The negative half-life of Ligand B is a serious drawback, but could potentially be addressed with structural modifications. The improved ADME properties of Ligand B outweigh the better QED of Ligand A.
Output:
0
2025-04-17 19:59:27,336 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (365.547 and 365.455 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (51.71) is significantly better than Ligand B (93.97). ADRB2 is a cardiovascular target, not a CNS target, but lower TPSA generally improves absorption. Ligand A is well below the 140 threshold, while B is approaching it.
3. **logP:** Ligand A (1.724) is within the optimal 1-3 range. Ligand B (0.399) is slightly low, potentially hindering permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (6). Lower HBA generally improves permeability.
6. **QED:** Both ligands have similar QED values (0.883 and 0.791), indicating good drug-likeness.
7. **DILI:** Ligand A (13.416) has a much lower DILI risk than Ligand B (46.995). This is a significant advantage for Ligand A.
8. **BBB:** While not a primary concern for a cardiovascular target, Ligand A (76.541) has a higher BBB penetration percentile than Ligand B (31.756).
9. **Caco-2:** Ligand A (-4.801) and Ligand B (-5.073) have similar Caco-2 permeability values.
10. **Solubility:** Ligand A (-0.457) is better than Ligand B (-1.856). Better solubility is always desirable.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.654 and 0.24), which is excellent.
12. **Cl_mic:** Ligand A (-24.064) has a much lower (better) microsomal clearance than Ligand B (5.741), indicating greater metabolic stability.
13. **t1/2:** Ligand A (-4.17) has a more negative (longer) in vitro half-life than Ligand B (3.492).
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.023 and 0.047).
15. **Binding Affinity:** Ligand B (-7.1) has a slightly better binding affinity than Ligand A (-7.6). However, the difference is relatively small (0.5 kcal/mol) and can be overcome by other favorable properties.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most crucial ADME properties (TPSA, logP, DILI, Cl_mic, solubility, t1/2). While Ligand B has a slightly better binding affinity, the improvements in ADME properties with Ligand A are more significant for overall drug development potential. The lower DILI risk and improved metabolic stability of Ligand A are particularly compelling. Given that this is a cardiovascular target, the BBB value is less critical, and the slightly weaker binding affinity of Ligand A is acceptable given its superior ADME profile.
Output:
1
2025-04-17 19:59:27,336 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (353.463 and 343.391 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (96.53) is significantly better than Ligand B (135.78). ADRB2 is not a CNS target, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (1.711) is optimal, while Ligand B (0.372) is slightly low, potentially impacting permeability.
4. **HBD:** Both ligands have 3 HBD, which is acceptable.
5. **HBA:** Ligand A (4) is better than Ligand B (7). Lower HBA generally improves permeability.
6. **QED:** Both ligands have similar QED scores (0.677 and 0.689), indicating good drug-likeness.
7. **DILI:** Ligand A (43.389) has a much lower DILI risk than Ligand B (66.421). This is a significant advantage.
8. **BBB:** Both ligands have similar BBB penetration (55.293 and 57.736), which isn't critical for a non-CNS target like ADRB2.
9. **Caco-2:** Ligand A (-4.986) is better than Ligand B (-5.602), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-2.809) is better than Ligand B (-2.629), though both are poor.
11. **hERG:** Both ligands have very low hERG risk (0.096 and 0.17).
12. **Cl_mic:** Ligand A (18.193) has significantly lower microsomal clearance than Ligand B (26.668), indicating better metabolic stability.
13. **t1/2:** Ligand A (-27.162) has a much longer in vitro half-life than Ligand B (-10.663). This is a substantial advantage.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.031 and 0.003).
15. **Binding Affinity:** Ligand A (-6.9) is slightly better than Ligand B (-6.5), but the difference is relatively small.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, and affinity are important. Ligand A is superior in logP and TPSA. While the affinity difference is small, Ligand A also has better ADME properties (DILI, Cl_mic, t1/2, solubility, Caco-2).
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical ADME properties and has a slightly better binding affinity. The lower DILI risk, improved metabolic stability (lower Cl_mic, longer t1/2), and better absorption (Caco-2) make it a more promising drug candidate.
Output:
1
2025-04-17 19:59:27,336 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (345.403 and 349.337 Da) fall comfortably within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (82.53) is significantly better than Ligand A (102.05). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (2.555) is slightly higher than Ligand A (1.074), placing it more optimally within the 1-3 range. Ligand A is a bit low, potentially hindering permeation.
4. **HBD:** Both ligands have 2 HBD, which is within the acceptable limit of 5.
5. **HBA:** Ligand B (4) is better than Ligand A (6), contributing to better predicted permeability.
6. **QED:** Both ligands have good QED scores (0.782 and 0.869), indicating good drug-like properties.
7. **DILI:** Ligand A (50.291) has a much lower DILI risk than Ligand B (73.09). This is a significant advantage for Ligand A.
8. **BBB:** Ligand B (52.191) has a higher BBB penetration score than Ligand A (37.96). While not a primary concern for a cardiovascular target, it's a slight positive for Ligand B.
9. **Caco-2:** Ligand A (-5.158) shows better Caco-2 permeability than Ligand B (-4.507).
10. **Solubility:** Ligand A (-2.377) has better solubility than Ligand B (-3.531).
11. **hERG:** Ligand A (0.031) has a much lower hERG inhibition liability than Ligand B (0.194), a crucial safety parameter.
12. **Cl_mic:** Ligand A (20.046) has significantly lower microsomal clearance than Ligand B (45.927), indicating better metabolic stability.
13. **t1/2:** Ligand A (4.543) has a longer in vitro half-life than Ligand B (1.389).
14. **Pgp:** Ligand A (0.012) has lower P-gp efflux liability than Ligand B (0.04).
15. **Binding Affinity:** Ligand B (-0.0) has a slightly better binding affinity than Ligand A (-6.4). However, the difference is not substantial enough to overcome the other significant advantages of Ligand A.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand B has a slight edge in logP and affinity, but Ligand A excels in TPSA, Pgp, and crucially, safety parameters (DILI, hERG) and metabolic stability (Cl_mic, t1/2).
**Overall Assessment:**
While Ligand B has a slightly better binding affinity and logP, Ligand A demonstrates a significantly more favorable ADMET profile, particularly regarding safety (DILI, hERG) and metabolic stability. The improved solubility and permeability also contribute to its potential for better bioavailability. Given the importance of minimizing off-target effects and ensuring a reasonable duration of action for a cardiovascular drug, Ligand A is the more promising candidate.
Output:
1
2025-04-17 19:59:27,336 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (362.861 and 348.487 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (67.35) is slightly higher than Ligand B (58.64). Both are below the 140 threshold for oral absorption, but closer to the 90 threshold for CNS targets, which isn't a primary concern for ADRB2 (cardiovascular). Ligand B is preferable.
3. **logP:** Ligand A (3.82) is at the upper end of the optimal range (1-3), while Ligand B (2.368) is well within it. Ligand B is preferable due to the lower risk of off-target effects and solubility issues.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 3. Both are acceptable (<=10).
6. **QED:** Ligand A (0.848) has a better QED score than Ligand B (0.719), indicating a more drug-like profile. This favors Ligand A.
7. **DILI:** Ligand B (13.61) has a significantly lower DILI risk than Ligand A (57.348). This is a major advantage for Ligand B.
8. **BBB:** Ligand B (83.598) has a much higher BBB penetration percentile than Ligand A (43.815). While ADRB2 isn't a CNS target, higher BBB is generally a positive indicator of permeability.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.717 and -4.648), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Both ligands have negative solubility values (-3.676 and -3.343), indicating very poor aqueous solubility. This is a major drawback for both.
11. **hERG:** Ligand A (0.2) has a slightly lower hERG inhibition liability than Ligand B (0.606), which is preferable.
12. **Cl_mic:** Ligand B (66.787) has a slightly higher microsomal clearance than Ligand A (63.904), indicating slightly lower metabolic stability. Ligand A is preferable.
13. **t1/2:** Ligand A (24.048) has a significantly longer in vitro half-life than Ligand B (-11.882). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.039) has a much lower P-gp efflux liability than Ligand B (0.245), which is preferable.
15. **Binding Affinity:** Ligand B (-5.7) has a slightly better binding affinity than Ligand A (-5.2). This is a 0.5 kcal/mol difference, which is significant, but needs to be weighed against other factors.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP and affinity, and has a better TPSA. Ligand A has better Pgp efflux.
**Overall Assessment:**
While Ligand B has a superior binding affinity and lower DILI risk, the significantly longer half-life, lower Pgp efflux, and slightly better hERG profile of Ligand A are compelling. The poor Caco-2 and solubility for both are concerning, but can potentially be addressed through formulation strategies. The longer half-life of Ligand A is particularly valuable for a cardiovascular target where sustained action is often desired.
Output:
1
2025-04-17 19:59:27,336 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [357.303, 48.42, 4.475, 0, 4, 0.598, 62.776, 73.323, -4.289, -5.576, 0.534, 100.051, -6.584, 0.451, -7.4]
**Ligand B:** [353.463, 78.95, 1.762, 1, 4, 0.789, 29.236, 83.908, -4.546, -2.412, 0.416, 43.671, -29.896, 0.069, -6.4]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, Affinity, and BBB):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B is slightly lower, which is generally favorable.
2. **TPSA:** Ligand A (48.42) is significantly better than Ligand B (78.95). A lower TPSA is preferred for better permeability, especially for a GPCR.
3. **logP:** Ligand A (4.475) is a bit high, potentially leading to off-target effects and solubility issues. Ligand B (1.762) is closer to the optimal range (1-3).
4. **HBD/HBA:** Both have acceptable numbers of H-bond donors and acceptors.
5. **QED:** Both have good QED scores (>0.5), indicating drug-likeness. Ligand B is slightly better.
6. **DILI:** Ligand A (62.776) has a higher DILI risk than Ligand B (29.236). This is a significant advantage for Ligand B.
7. **BBB:** Both have good BBB penetration, but Ligand B (83.908) is better than Ligand A (73.323). This is important for GPCRs.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual. This suggests poor permeability, but the scale is not well-defined.
9. **Solubility:** Ligand B (-2.412) is better than Ligand A (-5.576).
10. **hERG:** Both have low hERG inhibition risk.
11. **Cl_mic:** Ligand A (100.051) has a much higher microsomal clearance than Ligand B (43.671), indicating faster metabolism and potentially lower *in vivo* exposure.
12. **t1/2:** Ligand B (-29.896) has a much longer *in vitro* half-life than Ligand A (-6.584). This is a major advantage for Ligand B.
13. **Pgp:** Ligand A (0.451) has lower P-gp efflux than Ligand B (0.069), which is a positive.
14. **Affinity:** Ligand A (-7.4) has a slightly better binding affinity than Ligand B (-6.4), but the difference is less than 1.5 kcal/mol.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity and lower P-gp efflux, Ligand B is clearly superior due to its significantly better ADME profile. Specifically, its lower DILI risk, better BBB penetration, improved solubility, and *much* longer half-life and lower clearance are critical advantages for a GPCR drug candidate. The slightly higher logP of Ligand A is a concern, and the difference in affinity is not substantial enough to overcome the ADME liabilities.
Output:
0
2025-04-17 19:59:27,337 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.419 and 349.391 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (112.04) is slightly higher than Ligand B (98.58). Both are below the 140 threshold for good oral absorption, but B is closer to the preferred <90 for GPCRs.
3. **logP:** Ligand A (0.735) is a bit low, potentially hindering permeability. Ligand B (-0.786) is even lower, raising concerns about absorption. Both are suboptimal, but A is slightly better.
4. **HBD:** Ligand A (4) is higher than Ligand B (1). While both are within the acceptable limit of 5, lower is generally preferred for permeability. B is better here.
5. **HBA:** Ligand A (5) is lower than Ligand B (7). Again, lower is better, so A is favored.
6. **QED:** Both ligands have good QED scores (0.564 and 0.693), indicating good drug-like properties. B is slightly better.
7. **DILI:** Both ligands have acceptable DILI risk (50.33 and 48.662), below the 60 threshold. No significant difference.
8. **BBB:** Ligand A (15.82) has very poor BBB penetration, while Ligand B (38.813) is better, though still not ideal. Since ADRB2 is a GPCR, BBB penetration is a consideration, favoring B.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.573 and -5.07). This is unusual and suggests poor permeability. It's difficult to interpret without knowing the scale, but it's a negative for both.
10. **Solubility:** Ligand A (-2.388) has slightly worse solubility than Ligand B (-1.185). Solubility is important, so B is favored.
11. **hERG:** Both ligands have low hERG inhibition risk (0.315 and 0.053). B is better here, indicating lower cardiotoxicity potential.
12. **Cl_mic:** Ligand B (-5.498) has significantly lower microsomal clearance than Ligand A (-3.118), suggesting better metabolic stability. This is a significant advantage for B.
13. **t1/2:** Ligand A (35.982) has a much longer in vitro half-life than Ligand B (19.699). This is a major advantage for A, potentially leading to less frequent dosing.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.061 and 0.006). No significant difference.
15. **Binding Affinity:** Ligand B (-6.0) has a stronger binding affinity than Ligand A (-4.8). This is a substantial difference (1.2 kcal/mol) and a key factor favoring B.
**Overall Assessment:**
Ligand B has several advantages: better TPSA, lower HBD, better solubility, lower hERG risk, significantly better metabolic stability (lower Cl_mic), and a much stronger binding affinity. While Ligand A has a longer half-life, the affinity difference is substantial enough to outweigh this benefit, especially for a GPCR target where achieving sufficient receptor occupancy is crucial. The slightly better BBB penetration of Ligand B is also a plus. The low logP values for both are concerning, but the overall profile of B is more promising.
Output:
0
2025-04-17 19:59:27,337 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [354.422, 89.87, 0.508, 3, 4, 0.686, 15.238, 52.268, -5.116, -1.84, 0.391, -0.502, 8.699, 0.029, -6.9]**
**Ligand B: [349.381, 58.37, 3.243, 1, 4, 0.87, 39.473, 70.919, -4.959, -2.934, 0.661, 28.19, 5.678, 0.061, -7.5]**
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (354.422) is slightly higher than Ligand B (349.381), but the difference is negligible.
2. **TPSA:** Ligand A (89.87) is better than Ligand B (58.37) as it is closer to the ideal range for GPCRs.
3. **logP:** Ligand B (3.243) is optimal, while Ligand A (0.508) is quite low, potentially hindering membrane permeability. This is a significant drawback for Ligand A.
4. **H-Bond Donors:** Ligand A (3) is acceptable, while Ligand B (1) is even better.
5. **H-Bond Acceptors:** Both ligands have 4 H-bond acceptors, which is within the acceptable range.
6. **QED:** Ligand B (0.87) has a better QED score than Ligand A (0.686), indicating a more drug-like profile.
7. **DILI:** Ligand A (15.238) has a much lower DILI risk than Ligand B (39.473). This is a strong advantage for Ligand A.
8. **BBB:** Ligand B (70.919) has a better BBB penetration score than Ligand A (52.268). While ADRB2 isn't exclusively a CNS target, some peripheral effects are mediated by CNS pathways, so some BBB penetration is beneficial.
9. **Caco-2 Permeability:** Ligand A (-5.116) has worse Caco-2 permeability than Ligand B (-4.959), but both are negative.
10. **Aqueous Solubility:** Ligand B (-2.934) has better aqueous solubility than Ligand A (-1.84).
11. **hERG Inhibition:** Ligand A (0.391) has a lower hERG inhibition risk than Ligand B (0.661). This is a significant advantage for Ligand A.
12. **Microsomal Clearance:** Ligand A (-0.502) has a lower microsomal clearance, indicating better metabolic stability, compared to Ligand B (28.19).
13. **In vitro Half-Life:** Ligand A (8.699) has a longer in vitro half-life than Ligand B (5.678).
14. **P-gp Efflux:** Ligand A (0.029) has lower P-gp efflux than Ligand B (0.061).
15. **Binding Affinity:** Ligand B (-7.5) has a stronger binding affinity than Ligand A (-6.9). The difference is 0.6 kcal/mol, which is substantial.
**Overall Assessment:**
Ligand B has a significantly better binding affinity and a better QED score. It also exhibits better solubility, BBB penetration, and Caco-2 permeability. However, Ligand A has a much lower DILI risk, lower hERG inhibition, better metabolic stability (lower Cl_mic, longer t1/2), and lower P-gp efflux.
Given the GPCR-specific priorities (logP, Pgp, TPSA, affinity), the stronger affinity of Ligand B is a major advantage. While Ligand A has better safety profiles, the potency difference is significant enough to outweigh those benefits. The low logP of Ligand A is a serious concern for permeability.
Therefore, I would choose Ligand B.
Output:
0
2025-04-17 19:59:27,337 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.415 and 342.443 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (84.67 and 83.98) are below the 140 A^2 threshold for good oral absorption and are reasonably well-suited for a peripherally acting GPCR like ADRB2. Again, no major difference.
3. **logP:** Ligand A (1.24) is slightly lower than Ligand B (1.988), but both are within the optimal 1-3 range. Ligand B is preferable here, being closer to the middle of the range.
4. **HBD:** Ligand A (1) has fewer H-bond donors than Ligand B (2). Fewer is generally preferable for permeability, giving a slight edge to Ligand A.
5. **HBA:** Ligand A (5) has slightly more H-bond acceptors than Ligand B (4). This isn't a major concern for either, but slightly favors Ligand B.
6. **QED:** Both ligands have very similar QED values (0.866 and 0.857), indicating good drug-likeness.
7. **DILI:** Ligand A (37.611) has a significantly lower DILI risk than Ligand B (47.77). This is a substantial advantage for Ligand A.
8. **BBB:** Ligand A (78.868) has a higher BBB penetration percentile than Ligand B (54.246). While ADRB2 isn't a CNS target, some degree of BBB penetration can sometimes indicate favorable partitioning characteristics.
9. **Caco-2:** Ligand A (-4.804) shows better Caco-2 permeability than Ligand B (-5.012). Better absorption is always preferred.
10. **Solubility:** Ligand A (-2.183) has better aqueous solubility than Ligand B (-2.975). Solubility is important for formulation and bioavailability.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.243 and 0.178), which is excellent.
12. **Cl_mic:** Ligand A (30.13) has a higher microsomal clearance than Ligand B (16.356). Lower clearance is better for metabolic stability, giving a clear advantage to Ligand B.
13. **t1/2:** Ligand A (6.745) has a longer in vitro half-life than Ligand B (-1.639). This is a significant advantage for Ligand A, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.123 and 0.067).
15. **Binding Affinity:** Ligand B (-8.3 kcal/mol) has a significantly stronger binding affinity than Ligand A (-7.3 kcal/mol). This is a >1 kcal/mol advantage, which is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
The key trade-offs are between binding affinity (Ligand B) and metabolic stability/half-life/DILI (Ligand A). The significantly stronger binding affinity of Ligand B is a major advantage for a GPCR target. While Ligand A has better DILI, solubility, and half-life, the 1 kcal/mol difference in binding is substantial. Given the importance of potency for GPCRs, and the relatively good ADME profile of Ligand B, I favor Ligand B.
Output:
0
2025-04-17 19:59:27,337 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
Let's analyze each ligand against the provided guidelines, with a focus on GPCR-relevant properties (logP, TPSA, Pgp, BBB, and affinity).
* **Molecular Weight:** Both ligands (361.877 and 350.503 Da) fall comfortably within the ideal 200-500 Da range.
* **TPSA:** Ligand A (64.86) is slightly higher than Ligand B (49.85). Both are below the 140 threshold for oral absorption, but B is better.
* **logP:** Ligand A (3.805) is at the upper end of the optimal range (1-3), while Ligand B (2.543) is well within it. This favors B.
* **H-Bond Donors/Acceptors:** Ligand A has 1 HBD and 6 HBA, while Ligand B has 0 HBD and 3 HBA. Both are acceptable.
* **QED:** Ligand A (0.897) has a significantly higher QED score than Ligand B (0.709), indicating better overall drug-likeness. This favors A.
* **DILI:** Ligand B (11.632) has a much lower DILI risk than Ligand A (62.35), which is a significant advantage.
* **BBB:** Both ligands show good BBB penetration (A: 83.986, B: 88.329), but B is slightly better.
* **Caco-2 Permeability:** Ligand A (-5.152) has a negative Caco-2 value, which is concerning. Ligand B (-4.311) is also negative but less so.
* **Aqueous Solubility:** Ligand A (-4.556) has worse solubility than Ligand B (-2.609).
* **hERG:** Both ligands have low hERG inhibition risk (A: 0.261, B: 0.367).
* **Microsomal Clearance:** Ligand B (66.738) has a higher microsomal clearance than Ligand A (45.11), indicating faster metabolism. This favors A.
* **In vitro Half-Life:** Ligand A (7.162) has a much longer half-life than Ligand B (0.062). This is a major advantage for A.
* **P-gp Efflux:** Both ligands have low P-gp efflux liability (A: 0.459, B: 0.113). B is slightly better.
* **Binding Affinity:** Ligand A (-6.8 kcal/mol) has a slightly better binding affinity than Ligand B (-6.5 kcal/mol), but the difference is not substantial.
**Overall Assessment:**
While Ligand A has a better QED, longer half-life, and slightly better affinity, Ligand B presents a significantly better safety profile (lower DILI) and slightly better BBB penetration, Caco-2 permeability, and P-gp efflux. The negative Caco-2 values for both are concerning, but less so for B. The lower metabolic stability of B is a drawback, but the substantial difference in DILI risk is a critical factor. For a cardiovascular target, minimizing potential liver toxicity is paramount.
**Output:**
0
2025-04-17 19:59:27,337 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (356.304) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (85.25) is significantly better than Ligand B (130.67). For a GPCR, keeping TPSA low is beneficial for permeability and receptor engagement. Ligand B is above the preferred 140 threshold for good oral absorption.
3. **logP:** Ligand A (2.507) is within the optimal range (1-3). Ligand B (-0.537) is below 1, which could hinder membrane permeability.
4. **HBD:** Ligand A (2) and Ligand B (3) are both acceptable, below the threshold of 5.
5. **HBA:** Ligand A (5) and Ligand B (6) are both acceptable, below the threshold of 10.
6. **QED:** Both ligands have reasonable QED values (A: 0.651, B: 0.522), indicating good drug-like properties.
7. **DILI:** Ligand A (86.778) has a higher DILI risk than Ligand B (52.734). This is a significant concern for Ligand A.
8. **BBB:** Ligand A (74.758) has a better BBB penetration score than Ligand B (67.158), though both are not exceptionally high. This is less critical for ADRB2, which isn't a CNS target, but still a positive for A.
9. **Caco-2:** Ligand A (-4.443) is better than Ligand B (-5.411). Higher (less negative) values indicate better absorption.
10. **Solubility:** Ligand A (-4.064) is better than Ligand B (-1.515). Higher (less negative) values indicate better solubility.
11. **hERG:** Ligand A (0.273) has a lower hERG risk than Ligand B (0.055). This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand A (69.395) has a higher metabolic clearance than Ligand B (3.808). This is a negative for Ligand A, suggesting faster metabolism.
13. **t1/2:** Ligand A (65.091) has a longer half-life than Ligand B (5.191). This is a positive for Ligand A.
14. **Pgp:** Ligand A (0.153) has lower P-gp efflux than Ligand B (0.027). Lower efflux is favorable.
15. **Binding Affinity:** Ligand A (-8.0) has a significantly stronger binding affinity than Ligand B (-6.0). This is a substantial advantage for Ligand A, potentially outweighing some of its ADME drawbacks.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand A excels in logP, TPSA, and *especially* affinity. While Ligand B has a lower DILI risk, the substantial difference in binding affinity and the better TPSA/logP profile of Ligand A are more critical. The longer half-life of Ligand A is also a benefit. The higher DILI risk of Ligand A is a concern, but could be mitigated with structural modifications in later optimization stages.
**Conclusion:**
Despite the higher DILI risk, Ligand A's superior binding affinity, favorable TPSA and logP, and better permeability properties make it the more promising candidate for further development as an ADRB2 ligand.
Output:
1
2025-04-17 19:59:27,338 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [362.539, 46.34, 4.108, 0, 4, 0.653, 27.453, 85.537, -4.999, -4.417, 0.531, 119.565, 10.26, 0.707, -5.8]
**Ligand B:** [364.412, 52.41, 2.494, 0, 6, 0.639, 27.181, 95.502, -4.543, -2.665, 0.744, 32.872, 8.17, 0.255, -6.7]
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). A: 362.5, B: 364.4 - very similar.
2. **TPSA:** A: 46.34, B: 52.41. Both are below the 140 threshold for oral absorption, and acceptable for a GPCR. B is slightly higher, but still good.
3. **logP:** A: 4.108, B: 2.494. A is a bit high, potentially leading to solubility issues or off-target interactions. B is within the optimal 1-3 range. This is a significant advantage for B.
4. **HBD:** Both are 0, which is good.
5. **HBA:** A: 4, B: 6. Both are within the acceptable limit of 10.
6. **QED:** Both are above 0.5 (A: 0.653, B: 0.639), indicating good drug-like properties.
7. **DILI:** Both are low (A: 27.453, B: 27.181), indicating low liver injury risk.
8. **BBB:** A: 85.537, B: 95.502. B has a significantly higher BBB penetration percentile, which is important for a GPCR target, even if not strictly CNS-focused.
9. **Caco-2:** Both are negative, indicating poor permeability. This is a concern for both.
10. **Solubility:** A: -4.417, B: -2.665. B has better aqueous solubility. A's solubility is quite poor.
11. **hERG:** A: 0.531, B: 0.744. A has a slightly lower hERG risk, which is preferable.
12. **Cl_mic:** A: 119.565, B: 32.872. B has significantly lower microsomal clearance, indicating better metabolic stability. This is a major advantage for B.
13. **t1/2:** A: 10.26, B: 8.17. A has a slightly longer half-life, but the difference isn't huge.
14. **Pgp:** A: 0.707, B: 0.255. B has much lower P-gp efflux, which is beneficial for bioavailability and potentially CNS exposure.
15. **Affinity:** A: -5.8 kcal/mol, B: -6.7 kcal/mol. B has a significantly stronger binding affinity (1.5 kcal/mol advantage). This is a substantial benefit and can often outweigh minor ADME drawbacks.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, Pgp, TPSA, and affinity. B excels in logP, Pgp, and affinity. While A has a slightly better hERG profile, the benefits of B in the other key areas are more significant. The higher BBB penetration for B is also a plus.
**Conclusion:**
Considering the balance of properties and the priorities for a GPCR target, **Ligand B is the more promising drug candidate.** The stronger binding affinity, better logP, lower Pgp efflux, and improved metabolic stability outweigh the slightly higher TPSA and slightly lower half-life.
0
2025-04-17 19:59:27,338 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (372.853) is slightly higher than Ligand B (341.411), but both are acceptable.
2. **TPSA:** Ligand A (98.76) is higher than Ligand B (71.53). For a cardiovascular GPCR, TPSA is not a major concern unless CNS penetration is desired, which isn't explicitly stated. Ligand B is preferable here.
3. **logP:** Both ligands have good logP values (Ligand A: 1.679, Ligand B: 2.524), falling within the optimal 1-3 range. Ligand B is slightly better.
4. **HBD:** Ligand A has 2 HBD, and Ligand B has 1. Both are within the acceptable limit of 5.
5. **HBA:** Ligand A has 5 HBA, and Ligand B has 4. Both are within the acceptable limit of 10.
6. **QED:** Both ligands have similar QED values (Ligand A: 0.822, Ligand B: 0.82), indicating good drug-likeness.
7. **DILI:** Ligand A (70.841) has a slightly higher DILI risk than Ligand B (61.691), but both are still reasonably low. Ligand B is preferable.
8. **BBB:** Ligand B (73.905) has a significantly higher BBB penetration percentile than Ligand A (19.698). While not a primary concern for a cardiovascular target, higher BBB is generally favorable, suggesting less off-target activity.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.786 and -4.473). This is unusual and suggests poor permeability. However, the values are close, so this isn't a major differentiator.
10. **Solubility:** Both ligands have negative solubility values (-2.565 and -3.022). This is also unusual and suggests poor solubility. Again, the values are close.
11. **hERG:** Both ligands have low hERG inhibition liability (Ligand A: 0.287, Ligand B: 0.43). This is excellent.
12. **Cl_mic:** Ligand A (34.001) has a lower microsomal clearance than Ligand B (60.703), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (-17.353) has a negative in vitro half-life, while Ligand B has a positive value (28.95). This is a major red flag for Ligand A.
14. **Pgp:** Both ligands have low P-gp efflux liability (Ligand A: 0.156, Ligand B: 0.134).
15. **Binding Affinity:** Ligand A (-9.0) has a significantly stronger binding affinity than Ligand B (-6.1). This is a substantial advantage (2.9 kcal/mol difference).
**Overall Assessment:**
Ligand A has a much stronger binding affinity and better metabolic stability (lower Cl_mic). However, it has a concerning negative in vitro half-life. Ligand B has better TPSA, logP, DILI risk, and BBB penetration, but its binding affinity is significantly weaker.
Given the importance of potency for GPCRs, the 2.9 kcal/mol advantage of Ligand A is substantial. While the negative half-life is concerning, it's an *in vitro* value and could potentially be improved through structural modifications. The weaker affinity of Ligand B would likely require a higher dose to achieve the same effect, potentially increasing the risk of off-target effects.
Therefore, I favor Ligand A, despite its drawbacks, due to its superior binding affinity.
Output:
1
2025-04-17 19:59:27,338 - INFO - Batch 151 complete. Total preferences: 2416
2025-04-17 19:59:27,338 - INFO - Processing batch 152/512...
2025-04-17 20:00:16,381 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (354.495 and 366.527 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (104.53) is higher than Ligand B (67.43). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for better absorption. Ligand B is better here.
3. **logP:** Both ligands have good logP values (1.757 and 2.241), falling within the optimal 1-3 range. Ligand B is slightly better.
4. **HBD:** Ligand A has 3 HBD, and Ligand B has 2. Both are within the acceptable limit of 5.
5. **HBA:** Ligand A has 3 HBA, and Ligand B has 4. Both are within the acceptable limit of 10.
6. **QED:** Both ligands have good QED scores (0.521 and 0.691), indicating good drug-like properties. Ligand B is better.
7. **DILI:** Ligand A (22.489%) has a significantly lower DILI risk than Ligand B (30.71%). This is a substantial advantage for Ligand A.
8. **BBB:** Ligand A (78.674%) has a higher BBB penetration score than Ligand B (52.966%). While ADRB2 isn't a CNS target, some degree of BBB penetration can be useful for understanding off-target effects.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.131 and -5.067), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Both ligands have negative solubility values (-2.832 and -2.962), indicating poor aqueous solubility. This is a significant drawback for both.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.367 and 0.174), which is excellent.
12. **Cl_mic:** Ligand A (33.501) has a higher microsomal clearance than Ligand B (29.751), indicating faster metabolism and potentially lower *in vivo* exposure. Ligand B is better.
13. **t1/2:** Ligand B (9.588) has a significantly longer *in vitro* half-life than Ligand A (-10.859). This is a major advantage for Ligand B.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.056 and 0.108).
15. **Binding Affinity:** Ligand B (-5.7 kcal/mol) has a stronger binding affinity than Ligand A (-4.7 kcal/mol). This 1.0 kcal/mol difference is substantial and can outweigh some ADME concerns.
**GPCR-Specific Priorities:**
For ADRB2 (a cardiovascular GPCR), affinity, logP, and metabolic stability are key. Ligand B excels in affinity and has better metabolic stability (lower Cl_mic, longer t1/2). While Ligand A has a lower DILI risk, the significantly better binding affinity of Ligand B is a more critical factor for a GPCR target. The poor solubility and permeability are concerning for both, but can be addressed with formulation strategies.
**Conclusion:**
Despite the lower DILI score for Ligand A, the significantly stronger binding affinity and improved metabolic stability of Ligand B make it the more promising drug candidate for ADRB2.
Output:
0
2025-04-17 20:00:16,381 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
We are targeting ADRB2, a GPCR, so the priorities are logP, Pgp, TPSA, affinity, and BBB. Let's compare the ligands step-by-step:
1. **MW:** Both are within the ideal range (352.391 and 350.591 Da).
2. **TPSA:** Ligand A (117.79) is better than Ligand B (23.55). Lower TPSA generally improves permeability, and while <90 is preferred for CNS targets, it's still beneficial for peripheral GPCRs like ADRB2.
3. **logP:** Ligand B (4.954) is significantly higher than Ligand A (-0.575). While a logP of 4.954 is pushing the upper limit, the very negative logP of A is concerning for membrane permeability.
4. **HBD/HBA:** Ligand A (2 HBD, 7 HBA) is slightly higher in both, but still within acceptable limits. Ligand B (0 HBD, 2 HBA) is lower, which is generally favorable.
5. **QED:** Both are reasonably good (0.703 and 0.618), indicating good drug-like properties.
6. **DILI:** Ligand A (49.011) has a higher DILI risk than Ligand B (11.594). This is a significant advantage for Ligand B.
7. **BBB:** Ligand B (90.617) has much better BBB penetration than Ligand A (48.197). While ADRB2 isn't strictly a CNS target, some CNS exposure can occur, and higher BBB is generally a positive.
8. **Caco-2:** Ligand A (-5.15) and Ligand B (-4.688) are both negative, which is unusual. It's hard to interpret these values without knowing the scale.
9. **Solubility:** Ligand A (-1.148) has better solubility than Ligand B (-4.171). Solubility is important for bioavailability.
10. **hERG:** Ligand A (0.102) has a lower hERG risk than Ligand B (0.937). This is a critical advantage for Ligand A.
11. **Cl_mic:** Ligand B (89.346) has a much higher microsomal clearance than Ligand A (7.228), indicating faster metabolism and potentially lower *in vivo* exposure.
12. **t1/2:** Ligand A (-1.078) has a negative half-life, which is impossible. This is a red flag. Ligand B (6.612) has a reasonable half-life.
13. **Pgp:** Ligand A (0.01) has significantly lower P-gp efflux than Ligand B (0.775), which is favorable for bioavailability.
14. **Affinity:** Ligand A (-6.9 kcal/mol) has a slightly better binding affinity than Ligand B (-5.9 kcal/mol). This is a 1 kcal/mol difference, which is notable but not overwhelming.
**Overall Assessment:**
Ligand A has better affinity and Pgp efflux, and lower hERG risk. However, the negative in vitro half-life is a major concern, indicating a potential issue with the data or the molecule's stability. Ligand B has a much better safety profile (lower DILI), better BBB penetration, and a reasonable half-life, despite the higher logP. The high logP is a concern, but the other advantages, particularly the much better metabolic stability and safety profile, outweigh this drawback.
**Output:**
0
2025-04-17 20:00:16,382 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (363.483 and 352.366 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (78.51) is significantly better than Ligand B (104.97). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (0.537) is slightly lower than optimal (1-3), but still reasonable. Ligand B (0.147) is quite low, potentially hindering membrane permeability. This is a significant drawback for a GPCR ligand.
4. **HBD:** Both ligands have 2 HBD, which is within the acceptable limit of 5.
5. **HBA:** Ligand A has 4 HBA, while Ligand B has 5. Both are acceptable (<=10).
6. **QED:** Ligand A (0.715) has a much better QED score than Ligand B (0.448), indicating a more drug-like profile.
7. **DILI:** Ligand A (25.979) has a substantially lower DILI risk than Ligand B (68.98). This is a critical advantage.
8. **BBB:** While not a primary concern for a cardiovascular target, Ligand A (36.409) has a lower BBB percentile than Ligand B (49.787). This isn't a major factor in this case.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual. Assuming these are logP-scale values, they suggest poor permeability. Ligand A (-5.579) is slightly better than Ligand B (-5.044).
10. **Solubility:** Both ligands have very poor aqueous solubility (-2.527 and -2.366). This is a concern for both, but could be addressed with formulation strategies.
11. **hERG:** Ligand A (0.057) has a much lower hERG risk than Ligand B (0.353), a crucial safety parameter.
12. **Cl_mic:** Ligand A (3.294) has a significantly lower microsomal clearance than Ligand B (-5.673), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-7.281) has a much longer in vitro half-life than Ligand B (-28.149). This is a substantial advantage.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.014 and 0.012).
15. **Binding Affinity:** Ligand A (-6.6 kcal/mol) has a slightly better binding affinity than Ligand B (-5.0 kcal/mol). While the difference isn't huge, it's a positive factor.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, and affinity are important. Ligand A is superior in logP and TPSA, and has a slightly better affinity. The substantial advantages in DILI risk, hERG inhibition, metabolic stability (Cl_mic, t1/2), and QED make Ligand A the clear winner.
**Conclusion:**
Ligand A demonstrates a significantly more favorable overall profile, particularly regarding safety (DILI, hERG) and pharmacokinetic properties (Cl_mic, t1/2). While solubility is a concern for both, the other advantages of Ligand A outweigh this drawback.
Output:
1
2025-04-17 20:00:16,382 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [423.16 , 81.59 , 4.34 , 4. , 3. , 0.438, 68.903, 46.375, -5.384, -4.929, 0.747, 41.834, 30.344, 0.289, -8.0 ]
**Ligand B:** [346.515, 49.41 , 3.641, 1. , 2. , 0.845, 26.095, 88.174, -4.985, -4.499, 0.475, 41.577, 5.88 , 0.232, -6.3 ]
**Step-by-step comparison:**
1. **MW:** Ligand A (423.16 Da) is within the ideal range, while Ligand B (346.515 Da) is on the lower side, but still acceptable.
2. **TPSA:** Ligand A (81.59) is higher than optimal (<=140) but not a major concern. Ligand B (49.41) is excellent.
3. **logP:** Ligand A (4.34) is slightly high, potentially leading to solubility issues. Ligand B (3.641) is within the optimal range.
4. **HBD:** Ligand A (4) is acceptable. Ligand B (1) is excellent.
5. **HBA:** Ligand A (3) is acceptable. Ligand B (2) is excellent.
6. **QED:** Ligand A (0.438) is below the desired threshold of 0.5, indicating a less drug-like profile. Ligand B (0.845) is very good.
7. **DILI:** Ligand A (68.903) is moderately high risk. Ligand B (26.095) is very low risk.
8. **BBB:** Ligand A (46.375) is low, while Ligand B (88.174) is very high. This is a significant advantage for Ligand B, given ADRB2's potential relevance to CNS effects.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-5.384) is worse than Ligand B (-4.985).
10. **Solubility:** Both are negative, indicating poor solubility. Ligand A (-4.929) is worse than Ligand B (-4.499).
11. **hERG:** Both are low risk. Ligand A (0.747) is slightly higher than Ligand B (0.475).
12. **Cl_mic:** Both have similar microsomal clearance rates (around 41.5-41.8), suggesting comparable metabolic stability.
13. **t1/2:** Ligand A (30.344) has a much longer half-life than Ligand B (5.88).
14. **Pgp:** Both have low P-gp efflux liability. Ligand A (0.289) is slightly higher than Ligand B (0.232).
15. **Affinity:** Ligand A (-8.0 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.3 kcal/mol). This is a substantial advantage.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, BBB, and affinity are key. Ligand B excels in BBB, TPSA, logP, and has a better QED and DILI profile. However, Ligand A's binding affinity is considerably stronger. The difference in affinity (-8.0 vs -6.3) is a 1.7 kcal/mol difference, which is substantial enough to potentially overcome some of the ADME liabilities of Ligand A. The longer half-life of Ligand A is also a plus.
**Conclusion:**
Despite Ligand A's slightly higher logP and DILI risk, the significantly stronger binding affinity and longer half-life are crucial for a GPCR target. The substantial affinity difference outweighs the moderate ADME concerns.
Output:
1
2025-04-17 20:00:16,382 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (478.225 Da) is within the ideal range, while Ligand B (345.403 Da) is on the lower side, but still acceptable.
2. **TPSA:** Ligand A (42.96) is excellent, well below the 140 threshold. Ligand B (112.91) is higher, but still reasonable for a peripherally acting GPCR.
3. **logP:** Both ligands have good logP values (A: 3.002, B: 1.363), falling within the 1-3 range.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Lower HBD generally improves permeability.
5. **HBA:** Both have the same number of HBA (5), which is acceptable.
6. **QED:** Both ligands have similar and good QED scores (A: 0.554, B: 0.594).
7. **DILI:** Ligand A (23.226) has a significantly lower DILI risk than Ligand B (60.915), a major advantage.
8. **BBB:** Ligand A (77.2) has a better BBB penetration score than Ligand B (39.55). While ADRB2 isn't necessarily a CNS target, some CNS exposure can be beneficial or at least less detrimental than none.
9. **Caco-2:** Ligand A (-5.127) has a worse Caco-2 permeability than Ligand B (-5.85).
10. **Solubility:** Ligand A (-2.767) has a slightly better solubility than Ligand B (-2.576).
11. **hERG:** Ligand A (0.848) has a slightly better hERG profile than Ligand B (0.208).
12. **Cl_mic:** Ligand A (38.037) has a higher microsomal clearance than Ligand B (33.543), meaning it's less metabolically stable.
13. **t1/2:** Ligand A (5.465) has a longer half-life than Ligand B (4.062).
14. **Pgp:** Ligand A (0.459) has better Pgp efflux liability than Ligand B (0.083).
15. **Affinity:** Ligand B (-7.4 kcal/mol) has a significantly stronger binding affinity than Ligand A (-1.7 kcal/mol). This is a substantial difference.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in affinity, and has good logP and TPSA. Ligand A has better Pgp efflux. However, the large difference in binding affinity (-7.4 vs -1.7) is a major factor. The lower DILI risk and better BBB penetration of Ligand A are also attractive, but can be addressed during further optimization. The slightly higher clearance of Ligand A is a concern, but less critical than the potency difference.
**Conclusion:**
Despite some advantages of Ligand A in terms of safety and permeability, the significantly stronger binding affinity of Ligand B makes it the more promising starting point for drug development. The potency advantage outweighs the other drawbacks, which can be addressed through further medicinal chemistry efforts.
Output:
0
2025-04-17 20:00:16,382 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [355.415, 83.47, 2.879, 2, 4, 0.754, 78.131, 40.52, -5.29, -3.909, 0.569, 41.602, 25.902, 0.314, -7.2]
**Ligand B:** [353.463, 92.71, 2.154, 3, 6, 0.589, 11.594, 43.583, -4.705, -2.139, 0.609, 46.985, -14.541, 0.067, -5.7]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). A: 355.415, B: 353.463 - very similar.
2. **TPSA:** A: 83.47, B: 92.71. Both are acceptable for a non-CNS GPCR target like ADRB2 (under 140), but A is preferable.
3. **logP:** A: 2.879, B: 2.154. Both are within the optimal 1-3 range, but A is slightly better.
4. **HBD:** A: 2, B: 3. A is preferable.
5. **HBA:** A: 4, B: 6. A is preferable.
6. **QED:** A: 0.754, B: 0.589. A is significantly better, indicating a more drug-like profile.
7. **DILI:** A: 78.131, B: 11.594. B is *much* better here, indicating a significantly lower risk of liver injury. This is a major advantage for B.
8. **BBB:** Both are relatively low, which is fine for a cardiovascular target. A: 40.52, B: 43.583 - B is slightly better.
9. **Caco-2:** A: -5.29, B: -4.705. Both are negative, indicating poor permeability. B is slightly better.
10. **Solubility:** A: -3.909, B: -2.139. B has better aqueous solubility.
11. **hERG:** A: 0.569, B: 0.609. Both are relatively low, indicating low hERG inhibition risk. B is slightly worse.
12. **Cl_mic:** A: 41.602, B: 46.985. A has lower microsomal clearance, suggesting better metabolic stability.
13. **t1/2:** A: 25.902, B: -14.541. A has a much longer in vitro half-life, which is a significant advantage.
14. **Pgp:** A: 0.314, B: 0.067. B has lower P-gp efflux, which is preferable.
15. **Affinity:** A: -7.2, B: -5.7. A has a *significantly* stronger binding affinity (1.5 kcal/mol difference). This is a substantial advantage.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, Pgp, TPSA, and affinity. A is better in logP, affinity, and TPSA. B is better in Pgp. The large difference in affinity for A is a major factor. The DILI risk for B is also very attractive. However, the substantially better half-life and QED of A are also important.
**Conclusion:**
Despite the lower DILI risk of Ligand B, the significantly stronger binding affinity (-7.2 vs -5.7 kcal/mol) and better overall drug-like properties (QED, t1/2) of Ligand A outweigh the DILI concern. The difference in affinity is large enough to potentially overcome any metabolic liabilities that might arise from the slightly higher DILI risk.
Output:
1
2025-04-17 20:00:16,382 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.403 and 366.487 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (110.26 and 114.18) are reasonably good, being under 140, suggesting acceptable absorption.
3. **logP:** Ligand A (2.382) is better than Ligand B (1.153). A logP between 1-3 is optimal, and Ligand B is on the lower end, potentially impacting permeability.
4. **HBD:** Ligand A (2) is preferable to Ligand B (3). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (6) is slightly better than Ligand B (5). Both are within the acceptable range.
6. **QED:** Ligand A (0.758) has a significantly better QED score than Ligand B (0.569), indicating a more drug-like profile.
7. **DILI:** Ligand B (36.409) has a much lower DILI risk than Ligand A (70.686). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (54.517) has a better BBB penetration score than Ligand B (45.056), but both are not high enough to be considered CNS-optimized. Since ADRB2 is primarily a cardiovascular target, BBB isn't a primary concern.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.049 and -5.651), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Both ligands have negative solubility values (-2.9 and -2.405), which is also unusual and suggests poor solubility.
11. **hERG:** Ligand A (0.203) has a slightly better hERG profile than Ligand B (0.079), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand B (26.584) has a significantly lower microsomal clearance than Ligand A (66.417), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-22.619) has a longer in vitro half-life than Ligand B (-6.662), which is desirable.
14. **Pgp:** Ligand B (0.019) has a much lower P-gp efflux liability than Ligand A (0.14), indicating better bioavailability.
15. **Affinity:** Both ligands have very similar binding affinities (-6.0 and -5.6 kcal/mol). The difference is less than 1.5 kcal/mol, so it's not a deciding factor.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are important. Ligand A has a better logP, while Ligand B has better Pgp efflux and lower DILI. The affinities are comparable.
**Overall Assessment:**
Ligand B is preferable. While Ligand A has a better QED and slightly better hERG, Ligand B's significantly lower DILI risk and P-gp efflux liability are more important. The lower microsomal clearance of Ligand B also contributes to its better metabolic stability. The similar affinities and comparable TPSA/logP values make the ADME advantages of Ligand B more compelling. The negative Caco-2 and solubility values are concerning for both, but can be addressed in later optimization stages.
Output:
0
2025-04-17 20:00:16,383 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.467 and 348.487 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (82.5) is higher than Ligand B (58.64). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is generally preferred for absorption. Ligand B is better.
3. **logP:** Both ligands have acceptable logP values (1.354 and 2.679). Ligand B is slightly higher, which could be beneficial for membrane permeability, but not dramatically so.
4. **HBD:** Ligand A (2) and Ligand B (1) are both good, under the threshold of 5. Ligand B is slightly better.
5. **HBA:** Ligand A (5) and Ligand B (3) are both good, under the threshold of 10. Ligand B is better.
6. **QED:** Ligand A (0.741) has a better QED score than Ligand B (0.542), indicating a more drug-like profile. This is a significant advantage for Ligand A.
7. **DILI:** Ligand A (41.45) has a higher DILI risk than Ligand B (21.52). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (53.703) has a lower BBB penetration than Ligand B (81.233). Since ADRB2 is not a CNS target, this is less important, but higher BBB is still generally favorable. Ligand B is better.
9. **Caco-2:** Ligand A (-5.172) has a worse Caco-2 permeability than Ligand B (-4.393). This suggests Ligand B will have better intestinal absorption. Ligand B is better.
10. **Solubility:** Ligand A (-1.94) has a slightly better solubility than Ligand B (-2.391).
11. **hERG:** Both ligands have very low hERG inhibition risk (0.207 and 0.242). No significant difference.
12. **Cl_mic:** Ligand A (22.612) has a lower microsomal clearance than Ligand B (62.47), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (34.232) has a longer in vitro half-life than Ligand B (-8.074). This is a significant advantage for Ligand A.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.008 and 0.051). No significant difference.
15. **Binding Affinity:** Ligand A (-6.7) has a slightly better binding affinity than Ligand B (-5.7). While not a huge difference, it's still a positive for Ligand A.
**Overall Assessment:**
Ligand A has advantages in QED, metabolic stability (Cl_mic), half-life, and binding affinity. Ligand B excels in DILI risk, BBB, Caco-2 permeability, and TPSA. Considering this is a cardiovascular target (ADRB2), metabolic stability and binding affinity are crucial. While Ligand B has a better safety profile (lower DILI), the superior metabolic stability and slightly better binding affinity of Ligand A, coupled with its good QED score, make it the more promising candidate.
Output:
1
2025-04-17 20:00:16,383 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (350.547 and 346.431 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (58.2) is significantly better than Ligand B (87.32). For a GPCR, lower TPSA is generally preferred for better permeability. Ligand B is approaching a level that could hinder absorption.
**3. logP:** Ligand A (4.183) is higher than Ligand B (1.812). While both are within the acceptable range (1-3), Ligand A is slightly above, which *could* lead to solubility issues, but is still reasonable. Ligand B is on the lower side, potentially impacting permeability.
**4. H-Bond Donors:** Both ligands have 2 HBD, which is within the ideal limit of 5.
**5. H-Bond Acceptors:** Ligand A has 2 HBA, while Ligand B has 4. Both are below the 10 limit, but Ligand A is preferable.
**6. QED:** Both ligands have good QED values (0.655 and 0.763), indicating good drug-like properties.
**7. DILI Risk:** Ligand A (30.05%) has a lower DILI risk than Ligand B (40.403%). This is a significant advantage for Ligand A.
**8. BBB Penetration:** Ligand A (71.927%) has much better BBB penetration than Ligand B (55.021%). This is a crucial factor for GPCR targets, even if not specifically CNS targets, as it can influence distribution and off-target effects.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.675 and -4.969). This is unusual and suggests poor permeability *in vitro*. However, the values are quite similar.
**10. Aqueous Solubility:** Ligand A (-4.535) has slightly better solubility than Ligand B (-2.263), though both are poor.
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (0.523 and 0.581).
**12. Microsomal Clearance:** Ligand A (67.042) has higher microsomal clearance than Ligand B (24.236), indicating faster metabolism and potentially shorter duration of action. This is a drawback for Ligand A.
**13. In vitro Half-Life:** Ligand B (27.57 hours) has a significantly longer in vitro half-life than Ligand A (13.073 hours). This is a significant advantage for Ligand B.
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (0.424 and 0.037). Ligand B is slightly better.
**15. Binding Affinity:** Ligand A (-6.4 kcal/mol) has a slightly better binding affinity than Ligand B (-5.5 kcal/mol). This 0.9 kcal/mol difference is substantial and can outweigh some of the ADME drawbacks.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand A is the stronger candidate. Its superior TPSA, lower DILI risk, and better BBB penetration are significant advantages. While Ligand B has a better half-life and slightly lower P-gp efflux, the affinity difference of 0.9 kcal/mol in favor of Ligand A, combined with the other favorable properties, makes it the more promising drug candidate. The slightly higher logP of Ligand A is a minor concern that could be addressed with further optimization.
Output:
1
2025-04-17 20:00:16,383 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (343.43 & 353.41 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (66.65) is better than Ligand B (71.09). Both are below the 140 threshold for oral absorption, but lower TPSA is generally preferred for GPCRs to aid permeability.
3. **logP:** Ligand A (2.322) is within the optimal 1-3 range. Ligand B (3.224) is slightly higher, still acceptable but edging towards potential solubility issues.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is slightly better than Ligand B (3). Both are within the acceptable limit of 10.
6. **QED:** Both ligands have good QED scores (0.773 and 0.825), indicating good drug-like properties. No significant difference.
7. **DILI:** Ligand A (31.524) has a lower DILI risk than Ligand B (37.999), which is a clear advantage.
8. **BBB:** Ligand A (91.198) shows significantly better BBB penetration potential than Ligand B (84.374). While ADRB2 isn't exclusively a CNS target, some cardiovascular effects can be mediated through CNS pathways, and better BBB penetration can be beneficial.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.759 and -4.597). These values are unusual and suggest poor permeability. However, the magnitude of the negative value is similar for both, so it doesn't differentiate them.
10. **Solubility:** Ligand A (-1.812) has better aqueous solubility than Ligand B (-3.587). This is a positive attribute.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.377 and 0.428), which is excellent.
12. **Cl_mic:** Ligand B (28.956) has lower microsomal clearance than Ligand A (42.148), indicating better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand B (-6.497) has a longer in vitro half-life than Ligand A (-17.484). This is a substantial advantage, potentially leading to less frequent dosing.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.173 and 0.084), which is good.
15. **Binding Affinity:** Ligand B (-8.2 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.1 kcal/mol). This 2.1 kcal/mol difference is a major advantage and can outweigh some of the ADME drawbacks.
**Overall Assessment:**
Ligand B has a significantly stronger binding affinity and better metabolic stability (lower Cl_mic and longer t1/2). While Ligand A has better TPSA, solubility, and DILI risk, the substantial affinity advantage of Ligand B is crucial for a GPCR target like ADRB2. The slightly higher logP of Ligand B is a minor concern compared to its superior potency and pharmacokinetic properties.
Output:
0
2025-04-17 20:00:16,383 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, the most important properties are binding affinity, logP, TPSA, Pgp efflux, and BBB penetration. Metabolic stability (Cl_mic, t1/2) and safety (DILI, hERG) are also important considerations.
Let's compare the ligands property by property:
1. **MW:** Both ligands (348.443 and 344.503 Da) fall within the ideal 200-500 Da range.
2. **TPSA:** Both ligands (60.03 and 61.28) are below the 140 A^2 threshold for good oral absorption, and acceptable for a non-CNS GPCR.
3. **logP:** Both ligands (3.465 and 3.624) are within the optimal 1-3 range. Ligand B is slightly higher, which could be a minor concern for solubility, but not a dealbreaker.
4. **HBD/HBA:** Ligand A has 1 HBD and 4 HBA, while Ligand B has 2 HBD and 5 HBA. Both are within acceptable limits.
5. **QED:** Ligand A (0.905) has a significantly better QED score than Ligand B (0.772), indicating a more drug-like profile.
6. **DILI:** Ligand B (34.354) has a much lower DILI risk than Ligand A (46.142), which is a significant advantage.
7. **BBB:** Both ligands have good BBB penetration (80.651 and 77.511), but Ligand A is slightly better. This is less critical for a cardiovascular target.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability.
9. **Solubility:** Both have negative solubility values, which is also unusual and suggests poor solubility.
10. **hERG:** Both ligands have low hERG inhibition liability (0.655 and 0.885).
11. **Cl_mic:** Ligand A (43.916) has significantly lower microsomal clearance than Ligand B (63.555), suggesting better metabolic stability.
12. **t1/2:** Ligand B (36.375) has a longer in vitro half-life than Ligand A (14.711), which is desirable.
13. **Pgp:** Both ligands have low Pgp efflux liability (0.219 and 0.509).
14. **Binding Affinity:** Ligand B (-6.6 kcal/mol) has a slightly better binding affinity than Ligand A (-6.1 kcal/mol). This 0.5 kcal/mol difference is substantial.
**Overall Assessment:**
Ligand B has a clear advantage in binding affinity and a significantly lower DILI risk, and a longer half-life. While Ligand A has a better QED and slightly better BBB penetration, the improved safety profile and potency of Ligand B outweigh these factors. The negative Caco-2 and solubility values for both are concerning, but can be addressed with formulation strategies.
**Output:**
0
2025-04-17 20:00:16,383 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (348.462) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (32.78) is significantly better than Ligand B (52.65). ADRB2 is a cardiovascular target, not a CNS target, but lower TPSA generally improves absorption.
3. **logP:** Both ligands have acceptable logP values (A: 2.527, B: 1.45), falling within the 1-3 range. Ligand A is slightly more lipophilic, which could aid membrane permeability.
4. **HBD:** Ligand A (0) is preferable to Ligand B (1). Fewer hydrogen bond donors generally improve permeability.
5. **HBA:** Ligand A (4) is preferable to Ligand B (5). Fewer hydrogen bond acceptors generally improve permeability.
6. **QED:** Both ligands have similar QED values (A: 0.74, B: 0.704), indicating good drug-likeness.
7. **DILI:** Ligand A (7.057) has a *much* better DILI score than Ligand B (22.257). This is a critical advantage, as liver toxicity is a major concern.
8. **BBB:** This is less critical for a cardiovascular target. Ligand A (96.937) has a much higher BBB penetration score than Ligand B (50.679).
9. **Caco-2:** Ligand A (-4.549) is better than Ligand B (-5.435), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-2.585) is better than Ligand B (-2.262), indicating better aqueous solubility.
11. **hERG:** Ligand A (0.943) is better than Ligand B (0.37), indicating a lower risk of cardiotoxicity.
12. **Cl_mic:** Ligand A (52.967) has a higher clearance than Ligand B (20.061), meaning it's less metabolically stable. This is a drawback for Ligand A.
13. **t1/2:** Ligand B (7.254) has a longer in vitro half-life than Ligand A (-21.104). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.172) is better than Ligand B (0.061), indicating lower P-gp efflux.
15. **Binding Affinity:** Ligand A (-7.7) has a significantly stronger binding affinity than Ligand B (-4.4). This is a substantial advantage that can outweigh some of the ADME drawbacks.
**Overall Assessment:**
Ligand A has a significantly better binding affinity, a much lower DILI risk, better TPSA, HBD, HBA, Caco-2, solubility, hERG, and Pgp efflux. While Ligand B has a longer half-life and better metabolic stability, the superior potency and safety profile of Ligand A, particularly the drastically lower DILI risk, make it the more promising candidate. The difference in binding affinity is also substantial.
Output:
1
2025-04-17 20:00:16,384 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's break down the comparison of Ligand A and Ligand B based on the provided parameters and the GPCR-specific priorities (logP, Pgp, TPSA, and affinity being most important).
1. **Molecular Weight:** Both ligands (374.775 Da and 359.495 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand B (71.09) is significantly better than Ligand A (88.27). Lower TPSA generally correlates with better cell permeability, a key factor for GPCR ligands.
3. **logP:** Both ligands have acceptable logP values (3.08 and 2.09, respectively), falling within the optimal 1-3 range. Ligand B is slightly better, being closer to the lower end of the range, potentially reducing off-target effects.
4. **H-Bond Donors/Acceptors:** Ligand A has 3 HBD and 4 HBA, while Ligand B has 2 HBD and 4 HBA. Both are within acceptable limits (<=5 HBD and <=10 HBA).
5. **QED:** Ligand B (0.864) has a higher QED score than Ligand A (0.662), indicating a more drug-like profile overall.
6. **DILI Risk:** Ligand B (57.619) has a significantly lower DILI risk than Ligand A (84.917). This is a major advantage for Ligand B.
7. **BBB Penetration:** Ligand A (71.268) has slightly better BBB penetration than Ligand B (54.478). However, for a cardiovascular target like ADRB2, high BBB penetration isn't critical, and is less important than other factors.
8. **Caco-2 Permeability:** Ligand A (-4.958) has better Caco-2 permeability than Ligand B (-5.521). This suggests better intestinal absorption for Ligand A.
9. **Aqueous Solubility:** Ligand A (-4.748) has better aqueous solubility than Ligand B (-2.625). This is a positive for formulation.
10. **hERG Inhibition:** Both ligands have low hERG inhibition risk (0.674 and 0.228 respectively). Ligand B is slightly better.
11. **Microsomal Clearance:** Ligand B (11.327) has significantly lower microsomal clearance than Ligand A (43.249), indicating better metabolic stability.
12. **In vitro Half-Life:** Ligand B (29.31) has a much longer in vitro half-life than Ligand A (-17.348). This is a significant advantage, potentially allowing for less frequent dosing.
13. **P-gp Efflux:** Ligand A (0.369) has lower P-gp efflux than Ligand B (0.101). Lower P-gp efflux is generally preferred for better bioavailability.
14. **Binding Affinity:** Both ligands have excellent binding affinities (-5.9 kcal/mol and -4.6 kcal/mol, respectively). Ligand A has a 1.3 kcal/mol advantage, which is substantial and could outweigh some ADME drawbacks.
**Overall Assessment:**
While Ligand A has a better binding affinity and Caco-2 permeability, Ligand B demonstrates a superior ADME profile. Specifically, the lower DILI risk, significantly better metabolic stability (lower Cl_mic and longer t1/2), and higher QED score are compelling advantages. The slightly lower BBB penetration is not a major concern for a cardiovascular target. The difference in binding affinity, while notable, is likely surmountable with further optimization, whereas fixing poor ADME properties is often more challenging.
**Output:**
0
2025-04-17 20:00:16,384 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Ligand A (468.372 Da) is within the ideal range, while Ligand B (370.475 Da) is also good. No clear advantage here.
2. **TPSA:** Both ligands (A: 106.61, B: 105.48) are reasonably close to the 140 A^2 threshold for oral absorption, but higher than the 90 A^2 ideal for CNS targets (not a primary concern for ADRB2, a cardiovascular target).
3. **logP:** Ligand A (2.643) is optimal, while Ligand B (0.367) is quite low, potentially hindering membrane permeability. This is a significant negative for Ligand B.
4. **HBD:** Ligand A (1) is good, and Ligand B (3) is acceptable, but slightly less desirable.
5. **HBA:** Both ligands (A: 7, B: 7) are within the acceptable range.
6. **QED:** Both ligands have similar QED scores (A: 0.654, B: 0.61), indicating good drug-likeness.
7. **DILI:** Ligand A (98.449) has a very high DILI risk, which is a major concern. Ligand B (57.154) is much better, falling well below the 60% threshold.
8. **BBB:** Both are relatively low, but Ligand A (61.923) is better than Ligand B (33.269). BBB isn't a huge priority for a cardiovascular target, but it's still a slight advantage for A.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability.
10. **Solubility:** Both have negative solubility values, which is also unusual and suggests poor solubility.
11. **hERG:** Ligand A (0.363) has a slightly better hERG profile than Ligand B (0.1).
12. **Cl_mic:** Ligand A (27.231) has a higher clearance than Ligand B (17.065), suggesting lower metabolic stability.
13. **t1/2:** Ligand A (95.428) has a significantly longer half-life than Ligand B (3.332). This is a major advantage for A.
14. **Pgp:** Ligand B (0.014) has much lower P-gp efflux liability than Ligand A (0.531), which is beneficial for bioavailability.
15. **Affinity:** Ligand B (-6.6 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.0 kcal/mol). This is a substantial advantage for B, potentially outweighing some ADME concerns.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand B excels in affinity and Pgp, but suffers from a low logP. Ligand A has a better logP and half-life, but a very high DILI risk.
**Overall Assessment:**
Despite the strong affinity of Ligand B, the very high DILI risk associated with Ligand A is a deal-breaker. While the low logP of Ligand B is concerning, it is potentially addressable through formulation or prodrug strategies. The DILI risk is much harder to mitigate. The longer half-life of Ligand A is attractive, but not enough to overcome the DILI concern.
Output:
0
2025-04-17 20:00:16,384 - INFO - Reasoning:
Let's analyze Ligand A and Ligand B for their potential as ADRB2 ligands, keeping in mind the GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key).
**Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (348.443) is slightly lower, which is generally favorable for permeability.
**TPSA:** Ligand A (59.08) is significantly better than Ligand B (73.14). A lower TPSA generally indicates better cell permeability, crucial for GPCR targeting. Ligand A is well below the 140 A^2 threshold.
**logP:** Both ligands have acceptable logP values (Ligand A: 1.211, Ligand B: 2.507), falling within the optimal 1-3 range. Ligand B is slightly higher, which could potentially lead to some solubility issues, but it's not a major concern.
**H-Bond Donors/Acceptors:** Ligand A (0 HBD, 4 HBA) and Ligand B (0 HBD, 7 HBA) both have reasonable numbers of hydrogen bond donors and acceptors.
**QED:** Both ligands have good QED scores (Ligand A: 0.513, Ligand B: 0.713), indicating good drug-like properties. Ligand B is slightly better here.
**DILI:** Ligand A (29.779) has a significantly lower DILI risk than Ligand B (41.295), which is a major advantage.
**BBB:** Ligand B (93.486) has a much higher BBB penetration percentile than Ligand A (60.876). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be beneficial, and this is a notable difference.
**Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not defined, so it's hard to interpret.
**Aqueous Solubility:** Ligand A (-1.511) has better aqueous solubility than Ligand B (-3.922).
**hERG:** Both ligands have low hERG inhibition liability (Ligand A: 0.316, Ligand B: 0.489), which is good.
**Microsomal Clearance:** Ligand A (18.416) has a lower microsomal clearance than Ligand B (48.668), indicating better metabolic stability.
**In vitro Half-Life:** Ligand A (-7.522) has a significantly longer in vitro half-life than Ligand B (-3.597).
**P-gp Efflux:** Both ligands have low P-gp efflux liability (Ligand A: 0.105, Ligand B: 0.218).
**Binding Affinity:** Ligand B (-6.8 kcal/mol) has a slightly better binding affinity than Ligand A (-6.4 kcal/mol). However, the difference is only 0.4 kcal/mol, which isn't a huge advantage.
**Overall Assessment:**
Ligand A excels in several critical ADME properties (DILI, solubility, metabolic stability, half-life, TPSA) and has a reasonable binding affinity. Ligand B's main advantage is its higher BBB penetration and slightly better affinity, but it suffers from higher DILI risk, poorer solubility, and lower metabolic stability. Given the importance of balancing ADME properties for a viable drug candidate, and the relatively small difference in binding affinity, Ligand A appears to be the more promising candidate.
Output:
1
2025-04-17 20:00:16,384 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (348.38 and 349.52 Da) fall comfortably within the ideal 200-500 Da range.
**2. TPSA:** Ligand A (99.23) is higher than Ligand B (64.86). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for better absorption. Ligand B is significantly better here.
**3. logP:** Ligand A (1.805) is within the optimal range (1-3), while Ligand B (3.163) is at the higher end. While still acceptable, Ligand B's higher logP could potentially lead to off-target interactions or solubility issues.
**4. H-Bond Donors:** Both have 1 HBD, which is good.
**5. H-Bond Acceptors:** Ligand A has 5, and Ligand B has 6. Both are acceptable, below the 10 threshold.
**6. QED:** Ligand A (0.875) has a better QED score than Ligand B (0.73), indicating a more drug-like profile.
**7. DILI:** Ligand A (52.89%) has a higher DILI risk than Ligand B (23.19%). This is a significant advantage for Ligand B.
**8. BBB:** Ligand A (87.09%) shows better BBB penetration than Ligand B (72.01%). While ADRB2 is primarily a cardiovascular target, some CNS effects are possible with beta-blockers, and higher BBB penetration isn't necessarily detrimental.
**9. Caco-2 Permeability:** Ligand A (-4.554) has better Caco-2 permeability than Ligand B (-5.086).
**10. Aqueous Solubility:** Both ligands have very poor aqueous solubility (-3.515 and -3.433 respectively). This is a concern for both, but not a deciding factor between them.
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (0.394 and 0.264 respectively).
**12. Microsomal Clearance:** Ligand A (29.873) has lower microsomal clearance than Ligand B (40.495), suggesting better metabolic stability.
**13. In vitro Half-Life:** Ligand A (-38.491) has a significantly longer in vitro half-life than Ligand B (-4.409). This is a substantial advantage.
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (0.099 and 0.043 respectively).
**15. Binding Affinity:** Ligand B (-7.5 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.7 kcal/mol). This is a 1.8 kcal/mol difference, which is a substantial advantage that can outweigh some ADME concerns.
**Overall Assessment:**
The primary trade-off is between Ligand B's superior binding affinity and Ligand A's better metabolic stability and QED score. Given that ADRB2 is a GPCR, binding affinity is paramount. The 1.8 kcal/mol difference is substantial. Ligand B also has a much lower DILI risk, which is a critical safety parameter. While Ligand A has better metabolic stability, the difference isn't large enough to overcome the affinity and safety advantages of Ligand B. The slightly higher logP of Ligand B is manageable.
Output:
0
2025-04-17 20:00:16,384 - INFO - Batch 152 complete. Total preferences: 2432
2025-04-17 20:00:16,384 - INFO - Processing batch 153/512...
2025-04-17 20:01:03,488 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [408.187, 109.86 , 1.971, 2. , 6. , 0.639, 98.72 , 60.954, -4.909, -4.426, 0.481, 67.506, 20.481, 0.302, -4.4 ]
**Ligand B:** [352.425, 40.62 , 2.534, 0. , 2. , 0.564, 51.028, 87.127, -4.28 , -2.485, 0.834, 42.562, -40.318, 0.478, -5.9 ]
**Step-by-step comparison:**
1. **MW:** A (408.187) is within the ideal range, B (352.425) is also good. No clear advantage.
2. **TPSA:** A (109.86) is borderline for good oral absorption, but acceptable for a non-CNS GPCR. B (40.62) is excellent, suggesting good permeability. Advantage B.
3. **logP:** Both A (1.971) and B (2.534) are within the optimal range. No clear advantage.
4. **HBD:** A (2) is good, B (0) is excellent. Advantage B.
5. **HBA:** A (6) is good, B (2) is excellent. Advantage B.
6. **QED:** A (0.639) is better than B (0.564), indicating a slightly more drug-like profile. Advantage A.
7. **DILI:** A (98.72) is very high risk, a major concern. B (51.028) is acceptable. Significant advantage B.
8. **BBB:** A (60.954) is not particularly high, consistent with a non-CNS focus. B (87.127) is excellent, but less critical for ADRB2 which isn't a primary CNS target.
9. **Caco-2:** Both are negative, indicating poor permeability. A (-4.909) is worse than B (-4.28). Advantage B.
10. **Solubility:** Both are negative, indicating poor solubility. A (-4.426) is worse than B (-2.485). Advantage B.
11. **hERG:** A (0.481) is better than B (0.834), indicating lower cardiotoxicity risk. Advantage A.
12. **Cl_mic:** A (67.506) is higher than B (42.562), suggesting lower metabolic stability. Advantage B.
13. **t1/2:** A (20.481) is better than B (-40.318), indicating a longer half-life. Advantage A.
14. **Pgp:** A (0.302) is better than B (0.478), suggesting lower efflux. Advantage A.
15. **Affinity:** B (-5.9) is significantly better than A (-4.4), a difference of 1.5 kcal/mol. This is a substantial advantage.
**Overall Assessment:**
Ligand B clearly outperforms Ligand A in most critical ADME properties. The most significant factor is the drastically lower DILI risk for Ligand B. While Ligand A has some advantages (QED, t1/2, Pgp, hERG), the high DILI risk is a major red flag. Ligand B also has a much better binding affinity, which is paramount for GPCR targets. The improved TPSA, HBD/HBA, solubility, and metabolic stability further solidify its position as the superior candidate. The higher BBB penetration is a bonus, even though ADRB2 isn't a primary CNS target.
0
2025-04-17 20:01:03,488 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (376.444 Da) is within the ideal range (200-500 Da). Ligand B (420.292 Da) is also acceptable, but approaching the upper limit.
2. **TPSA:** Ligand A (49.41) is excellent, well below the 140 threshold and suggesting good absorption. Ligand B (100.03) is higher, but still potentially acceptable for a peripherally acting GPCR.
3. **logP:** Both ligands (A: 3.091, B: 2.91) are within the optimal 1-3 range.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (3) is better than Ligand B (7). Lower HBA is generally favorable for permeability.
6. **QED:** Ligand A (0.75) is better than Ligand B (0.531), indicating a more drug-like profile.
7. **DILI:** Ligand A (21.598) has a significantly lower DILI risk than Ligand B (88.639). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (92.555) has a much higher BBB penetration potential than Ligand B (32.765). While ADRB2 isn't necessarily a CNS target, some CNS exposure can occur, and higher BBB is generally favorable.
9. **Caco-2:** Ligand A (-4.885) and Ligand B (-5.443) have similar, poor Caco-2 permeability.
10. **Solubility:** Ligand A (-4.626) is slightly better than Ligand B (-3.704), but both are poor.
11. **hERG:** Ligand A (0.499) has a lower hERG risk than Ligand B (0.692).
12. **Cl_mic:** Ligand A (32.169) has lower microsomal clearance, suggesting better metabolic stability, than Ligand B (43.434).
13. **t1/2:** Ligand A (-9.648) has a longer in vitro half-life than Ligand B (-6.247).
14. **Pgp:** Ligand A (0.169) has lower P-gp efflux liability than Ligand B (0.197).
15. **Affinity:** Ligand B (-6.6 kcal/mol) has a significantly stronger binding affinity than Ligand A (-4.3 kcal/mol). This is a substantial difference.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Both ligands have acceptable logP values. Ligand A has a much better TPSA and Pgp profile. The affinity difference is significant, but the superior ADME properties of Ligand A, especially the drastically lower DILI risk, are compelling. The difference in affinity (-6.6 vs -4.3) is 2.3 kcal/mol, which is a substantial difference, but the ADME profile of Ligand A is so much better that it outweighs the affinity difference.
**Conclusion:**
While Ligand B has a stronger binding affinity, Ligand A demonstrates a significantly better overall profile regarding ADME properties, particularly DILI risk, metabolic stability, and BBB penetration. These factors are critical for developing a safe and effective drug.
Output:
1
2025-04-17 20:01:03,488 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [361.423, 111.55 , 1.036, 4. , 6. , 0.614, 47.421, 16.363, -5.691, -2.493, 0.082, -4.258, -25.424, 0.013, -3.8 ]
**Ligand B:** [370.515, 78.87 , 1.189, 2. , 5. , 0.496, 31.059, 46.336, -5.093, -3.032, 0.357, 52.054, -13.108, 0.074, -7.2 ]
Here's a breakdown comparing each parameter:
1. **MW:** Both are within the ideal range (200-500 Da). A (361.423) is slightly preferred.
2. **TPSA:** A (111.55) is above the optimal <140 for oral absorption, but still acceptable. B (78.87) is excellent. B is preferred.
3. **logP:** Both are good (around 1.0-1.2), falling within the optimal 1-3 range. B is slightly better.
4. **HBD:** A (4) is acceptable, B (2) is better. B is preferred.
5. **HBA:** A (6) is acceptable, B (5) is better. B is preferred.
6. **QED:** A (0.614) is good, indicating drug-likeness. B (0.496) is lower, suggesting a less ideal drug-like profile. A is preferred.
7. **DILI:** A (47.421) is better than B (31.059), both are good. A is preferred.
8. **BBB:** B (46.336) is better than A (16.363). B is preferred.
9. **Caco-2:** Both are negative, which is unusual. It suggests poor permeability. A (-5.691) is slightly better than B (-5.093).
10. **Solubility:** Both are negative, indicating poor solubility. A (-2.493) is slightly better than B (-3.032).
11. **hERG:** A (0.082) is very low risk, excellent. B (0.357) is slightly higher, but still acceptable. A is preferred.
12. **Cl_mic:** A (-4.258) is excellent (lower is better). B (52.054) is very high, indicating rapid metabolism. A is *strongly* preferred.
13. **t1/2:** A (-25.424) is excellent (longer is better). B (-13.108) is good, but not as good as A. A is preferred.
14. **Pgp:** Both are very low (0.013 and 0.074), indicating minimal efflux. A is slightly better.
15. **Binding Affinity:** B (-7.2) is significantly better than A (-3.8). This is a substantial advantage.
**Overall Assessment:**
For a GPCR target like ADRB2, affinity is paramount. The 3.4 kcal/mol difference in binding affinity between B and A is *very* significant. While Ligand A has better ADME properties (particularly metabolic stability and lower hERG risk), the superior binding affinity of Ligand B is likely to outweigh these benefits. The slightly lower QED and DILI scores of B are acceptable given the substantial improvement in potency. The TPSA and logP values of B are also more favorable.
Therefore, I would choose Ligand B.
Output:
0
2025-04-17 20:01:03,489 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (335.37 & 347.33 Da) fall comfortably within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (106.91) is slightly higher than Ligand B (97.41). Both are below the 140 threshold for good oral absorption, but closer to the 90 threshold for CNS targets (less relevant for ADRB2, a cardiovascular target). Ligand B is slightly preferred.
3. **logP:** Ligand A (1.869) is within the optimal 1-3 range. Ligand B (0.325) is a bit low, potentially hindering permeation. Ligand A is significantly preferred here.
4. **HBD:** Ligand A (3) is higher than Ligand B (1). Both are within the acceptable limit of 5.
5. **HBA:** Ligand A (4) is lower than Ligand B (6). Both are within the acceptable limit of 10.
6. **QED:** Both ligands have similar QED values (0.796 and 0.735), indicating good drug-like properties.
7. **DILI:** Both ligands have high DILI risk (83.99 & 80.23). This is a concern for both, but doesn't differentiate them.
8. **BBB:** Both have low BBB penetration (55.06 & 57.23). Not a critical factor for ADRB2, a cardiovascular target.
9. **Caco-2:** Ligand A (-5.145) is worse than Ligand B (-4.478), indicating lower intestinal absorption. Ligand B is preferred.
10. **Solubility:** Ligand A (-4.506) is worse than Ligand B (-3.023). Ligand B is preferred.
11. **hERG:** Ligand A (0.444) is better than Ligand B (0.185), indicating lower cardiotoxicity risk. Ligand A is preferred.
12. **Cl_mic:** Ligand A (11.244) is higher than Ligand B (3.7), indicating faster metabolic clearance and lower metabolic stability. Ligand B is strongly preferred.
13. **t1/2:** Ligand A (70.662) is significantly better than Ligand B (-12.02). Ligand A is strongly preferred.
14. **Pgp:** Ligand A (0.064) is much better than Ligand B (0.03), indicating lower P-gp efflux. Ligand A is preferred.
15. **Binding Affinity:** Ligand B (-6.1 kcal/mol) has a significantly stronger binding affinity than Ligand A (-3.9 kcal/mol). This is a substantial advantage.
**GPCR-Specific Priorities & Overall Assessment:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand A has a better logP, Pgp, and TPSA, while Ligand B has a much better binding affinity. The difference in binding affinity (-6.1 vs -3.9 kcal/mol) is substantial and likely outweighs the slight advantages Ligand A has in other parameters. The metabolic stability of Ligand B is also much better. While both have concerning DILI scores, this is a problem for both and doesn't help differentiate.
**Output:**
0
2025-04-17 20:01:03,489 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (355.356 and 351.426 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (55.4) is significantly better than Ligand B (70.47). ADRB2 is a cardiovascular target, not CNS, but lower TPSA generally improves absorption.
3. **logP:** Ligand A (3.767) is good, within the optimal 1-3 range. Ligand B (1.028) is on the lower side, potentially hindering permeability.
4. **HBD:** Both ligands have 1 HBD, which is acceptable.
5. **HBA:** Ligand A has 3 HBA, while Ligand B has 5. Both are within the acceptable limit of 10, but A is preferable.
6. **QED:** Both ligands have good QED scores (0.791 and 0.88), indicating good drug-likeness.
7. **DILI:** Ligand A (54.323) has a higher DILI risk than Ligand B (35.401). This is a significant drawback for Ligand A.
8. **BBB:** This is less critical for a cardiovascular target. Ligand A (95.386) has a higher BBB penetration than Ligand B (82.513).
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.182) is slightly better than Ligand B (-4.965).
10. **Solubility:** Ligand A (-4.958) has worse solubility than Ligand B (-2.284). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.651) has a slightly higher hERG risk than Ligand B (0.436), but both are relatively low.
12. **Cl_mic:** Ligand B (3.582) has significantly lower microsomal clearance than Ligand A (75.321), indicating better metabolic stability. This is a major advantage for Ligand B.
13. **t1/2:** Ligand B (18.644) has a much longer in vitro half-life than Ligand A (-2.906). This is a substantial advantage for Ligand B.
14. **Pgp:** Ligand A (0.174) has lower P-gp efflux than Ligand B (0.019), which is favorable.
15. **Binding Affinity:** Ligand B (-6.1 kcal/mol) has a significantly stronger binding affinity than Ligand A (-4.2 kcal/mol). This is a crucial advantage, as a 1.9 kcal/mol difference is substantial.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, Pgp, TPSA and affinity are important. Ligand B is better in logP, Pgp, and *significantly* better in affinity. Ligand A is better in TPSA, but the affinity difference outweighs this.
**Overall Assessment:**
While Ligand A has some favorable properties (better TPSA, Pgp, and BBB), Ligand B is superior due to its significantly stronger binding affinity, lower DILI risk, better metabolic stability (lower Cl_mic), and longer half-life. The lower logP of Ligand B is a concern, but the strong affinity and improved ADME properties make it the more promising candidate.
Output:
0
2025-04-17 20:01:03,489 - INFO - Here's my reasoning and final output for the ligand preference:
**Reasoning:**
We are targeting ADRB2, a GPCR, so the priorities are logP, Pgp, TPSA, affinity, and BBB. Let's compare Ligand A and Ligand B across all parameters:
1. **MW:** Both are within the ideal range (356 vs 352).
2. **TPSA:** Ligand B (78.43) is significantly better than Ligand A (111.24). Lower TPSA is preferred for GPCRs, aiding permeability.
3. **logP:** Ligand B (1.876) is within the optimal range, while Ligand A (-0.743) is slightly below, potentially hindering permeation.
4. **HBD/HBA:** Ligand A has 1 HBD and 7 HBA, while Ligand B has 3 HBD and 3 HBA. Both are acceptable, but Ligand B is slightly more balanced.
5. **QED:** Ligand B (0.584) is better than Ligand A (0.363), indicating a more drug-like profile.
6. **DILI:** Ligand B (14.424) has a much lower DILI risk than Ligand A (52.191). This is a significant advantage.
7. **BBB:** Ligand B (67.08) is better than Ligand A (43.117), though neither is exceptionally high. Still, for a GPCR, higher BBB is a plus.
8. **Caco-2:** Both are very poor (-5.018 and -4.939). This is a concern for both, but not a deciding factor.
9. **Solubility:** Both are poor (-1.24 and -2.559).
10. **hERG:** Ligand A (0.055) is slightly better than Ligand B (0.26), but both are low risk.
11. **Cl_mic:** Ligand B (18.77) has lower clearance, indicating better metabolic stability than Ligand A (34.827).
12. **t1/2:** Ligand B (-2.802) is better than Ligand A (-20.851).
13. **Pgp:** Both are very low (0.014 and 0.063), suggesting minimal efflux.
14. **Affinity:** Ligand B (-6.4) is slightly better than Ligand A (-6.0), but the difference is not huge.
**Overall Assessment:**
Ligand B is significantly better overall. It has a superior TPSA, logP, QED, DILI score, BBB penetration, metabolic stability, and in vitro half-life. While both ligands have poor Caco-2 and solubility, the other advantages of Ligand B outweigh these drawbacks, especially considering the GPCR target class. The slightly better affinity of Ligand B further solidifies its preference.
**Output:**
0
2025-04-17 20:01:03,489 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands are within the ideal 200-500 Da range (A: 391.852, B: 344.419). No significant difference here.
**2. TPSA:** Ligand A (83.76) is better than Ligand B (121.34). For a GPCR, keeping TPSA lower is generally favorable for permeability. Ligand B is above the preferred 90 A^2 threshold for CNS targets, while A is comfortably below.
**3. logP:** Ligand A (2.448) is within the optimal range (1-3). Ligand B (-0.086) is slightly below 1, which could potentially hinder permeation. This is a significant advantage for A.
**4. H-Bond Donors:** Ligand A (0) is preferable to Ligand B (3). Fewer HBDs generally correlate with better membrane permeability.
**5. H-Bond Acceptors:** Both ligands have 5 HBA, which is acceptable.
**6. QED:** Both ligands have good QED scores (A: 0.568, B: 0.7), indicating good drug-like properties.
**7. DILI Risk:** Ligand A (83.211) has a higher DILI risk than Ligand B (44.707). This is a concern for A, but not a deal-breaker if other properties are strongly favorable.
**8. BBB Penetration:** Ligand A (85.498) has significantly better BBB penetration potential than Ligand B (32.183). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be beneficial or at least not detrimental.
**9. Caco-2 Permeability:** Ligand A (-4.934) has a better Caco-2 permeability than Ligand B (-5.804).
**10. Aqueous Solubility:** Ligand A (-5.126) has a better solubility than Ligand B (-1.154).
**11. hERG Inhibition:** Ligand A (0.788) has a lower hERG inhibition liability than Ligand B (0.593), which is a safety advantage.
**12. Microsomal Clearance:** Ligand B (-23.254) has a lower (better) microsomal clearance than Ligand A (41.365), suggesting better metabolic stability.
**13. In vitro Half-Life:** Ligand B (-2.185) has a longer in vitro half-life than Ligand A (-25.146).
**14. P-gp Efflux:** Ligand A (0.283) has lower P-gp efflux liability than Ligand B (0.006), which is a positive.
**15. Binding Affinity:** Ligand B (-9.0) has a stronger binding affinity than Ligand A (-7.7). This is a substantial difference (1.3 kcal/mol) and a major factor.
**Overall Assessment:**
Ligand A has several advantages: better logP, TPSA, BBB penetration, solubility, hERG, and P-gp efflux. However, Ligand B has a significantly stronger binding affinity and better metabolic stability. Given that we are dealing with a GPCR, the combination of good permeability (reflected in logP and TPSA), and a reasonable safety profile are critical. The substantial difference in binding affinity for Ligand B is a compelling advantage that outweighs the slightly higher DILI risk and lower BBB penetration.
Output:
0
2025-04-17 20:01:03,489 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [352.45 , 71.34 , 3.385, 2. , 3. , 0.753, 38.852, 86.778, -4.44 , -4.187, 0.571, 68.125, 28.947, 0.49 , -5.9 ]
**Ligand B:** [355.471, 82.62 , 3.014, 2. , 7. , 0.749, 84.451, 68.786, -5.389, -3.715, 0.737, 39.303, 0.981, 0.108, -6.1 ]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, BBB, and affinity are key):
1. **MW:** Both are within the ideal 200-500 Da range. A is 352.45, B is 355.471. Very similar.
2. **TPSA:** A (71.34) is better than B (82.62). Lower TPSA generally favors better absorption and BBB penetration.
3. **logP:** A (3.385) is slightly better than B (3.014). Both are within the optimal 1-3 range, but A is closer to the upper end, which could be beneficial for membrane permeability.
4. **HBD:** Both have 2 HBD, which is good.
5. **HBA:** A has 3 HBA, while B has 7. A is preferable here, as fewer HBA generally improves permeability.
6. **QED:** Both are very similar (A: 0.753, B: 0.749), indicating good drug-likeness.
7. **DILI:** A (38.852) is significantly better than B (84.451). This is a major advantage for Ligand A.
8. **BBB:** A (86.778) is significantly better than B (68.786). For a GPCR, even if not a CNS target, some BBB penetration can be useful for distribution.
9. **Caco-2:** A (-4.44) is better than B (-5.389). Higher (less negative) Caco-2 values indicate better permeability.
10. **Solubility:** A (-4.187) is better than B (-3.715). Higher (less negative) solubility values are preferred.
11. **hERG:** A (0.571) is better than B (0.737). Lower hERG inhibition is crucial for avoiding cardiotoxicity.
12. **Cl_mic:** A (68.125) is better than B (39.303). Lower clearance means better metabolic stability.
13. **t1/2:** A (28.947) is much better than B (0.981). A longer half-life is generally desirable.
14. **Pgp:** A (0.49) is better than B (0.108). Lower P-gp efflux is preferred for better bioavailability.
15. **Affinity:** B (-6.1) is slightly better than A (-5.9). While affinity is crucial, the difference of 0.2 kcal/mol is not substantial enough to outweigh the numerous advantages of Ligand A.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical ADME-Tox properties, including DILI risk, BBB penetration, solubility, metabolic stability, and P-gp efflux. While Ligand B has slightly better binding affinity, the difference is small, and the superior ADME profile of Ligand A makes it a much more promising drug candidate. The combination of lower risk (DILI, hERG) and better pharmacokinetic properties (BBB, Cl_mic, t1/2, Pgp) strongly favors Ligand A.
Output:
1
2025-04-17 20:01:03,489 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (337.423 and 349.431 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (67.01) is better than Ligand B (71.44). Both are below the 140 threshold for oral absorption, but lower is preferable for GPCRs.
3. **logP:** Ligand A (3.549) is optimal, while Ligand B (0.887) is a bit low, potentially hindering membrane permeability. This is a significant advantage for Ligand A.
4. **HBD:** Ligand A (2) is reasonable, while Ligand B (0) is also acceptable.
5. **HBA:** Ligand A (3) is good, Ligand B (5) is also acceptable.
6. **QED:** Ligand A (0.748) is better than Ligand B (0.61), indicating a more drug-like profile.
7. **DILI:** Ligand B (35.712) is significantly better than Ligand A (75.029), indicating a much lower risk of drug-induced liver injury. This is a major advantage for Ligand B.
8. **BBB:** Ligand B (73.866) is better than Ligand A (47.344). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be beneficial for distribution.
9. **Caco-2:** Ligand A (-5.045) is better than Ligand B (-4.492), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-5.604) is better than Ligand B (-2.258), indicating better solubility.
11. **hERG:** Ligand A (0.886) is better than Ligand B (0.363), indicating lower risk of hERG inhibition and cardiotoxicity.
12. **Cl_mic:** Ligand B (40.201) is better than Ligand A (67.836), indicating better metabolic stability.
13. **t1/2:** Ligand A (26.117) is better than Ligand B (-4.036), indicating a longer half-life.
14. **Pgp:** Ligand A (0.661) is better than Ligand B (0.163), indicating lower P-gp efflux.
15. **Affinity:** Ligand A (-6.1 kcal/mol) is slightly better than Ligand B (-5.8 kcal/mol). While the difference isn't huge, it's a positive for Ligand A.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A excels in logP, TPSA, and Pgp, and has a slightly better affinity. Ligand B has a significant advantage in DILI and BBB, and better metabolic stability.
**Overall Assessment:**
Ligand A has a more balanced profile overall, with better predicted permeability (logP, Caco-2), solubility, and a slightly better binding affinity. The DILI risk for Ligand A is concerning, but the other favorable properties, particularly the logP and Pgp values, make it a more promising starting point for optimization. The slightly better affinity also contributes. While Ligand B has a much better DILI profile, its lower logP and higher Pgp efflux are significant drawbacks for a GPCR target.
Output:
1
2025-04-17 20:01:03,490 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [335.367, 101.88 , 1.332, 2. , 4. , 0.883, 67.778, 35.983, -5.022, -4.056, 0.315, -6.309, -25.62 , 0.023, -6.2 ]
**Ligand B:** [346.406, 78.09 , 2.423, 2. , 3. , 0.843, 45.095, 82.629, -5.006, -3.658, 0.613, -11.654, 11.15 , 0.046, -6.1 ]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity):
1. **MW:** Both are within the ideal 200-500 Da range. A (335.37) is slightly preferred.
2. **TPSA:** A (101.88) is a bit higher than B (78.09). B is better here, closer to the <90 ideal for GPCRs.
3. **logP:** Both are good (1.332 and 2.423), falling within the 1-3 range. B is slightly better.
4. **HBD:** Both have 2 HBD, which is good.
5. **HBA:** A has 4, B has 3. Both are acceptable.
6. **QED:** Both are high (0.883 and 0.843), indicating good drug-like properties.
7. **DILI:** A (67.78%) has a higher DILI risk than B (45.10%). B is significantly better here.
8. **BBB:** B (82.63%) has much better BBB penetration potential than A (35.98%). This is a significant advantage for a GPCR target.
9. **Caco-2:** Both are negative, indicating poor permeability. A (-5.022) is slightly worse than B (-5.006).
10. **Solubility:** Both are negative, indicating poor solubility. A (-4.056) is slightly worse than B (-3.658).
11. **hERG:** Both are low (0.315 and 0.613), indicating low cardiotoxicity risk.
12. **Cl_mic:** A (-6.309) has a lower (better) clearance than B (-11.654), suggesting better metabolic stability.
13. **t1/2:** B (11.15) has a significantly longer half-life than A (-25.62). This is a major advantage.
14. **Pgp:** Both are very low (0.023 and 0.046), indicating minimal P-gp efflux.
15. **Affinity:** Both have comparable binding affinity (-6.2 kcal/mol and -6.1 kcal/mol).
**Overall Assessment:**
While Ligand A has a slightly better MW and metabolic stability (Cl_mic), Ligand B clearly wins on several critical GPCR-relevant parameters. Its lower TPSA, better BBB penetration, lower DILI risk, and significantly longer half-life outweigh the slight advantage of A in Cl_mic. The comparable binding affinity seals the deal.
Therefore, I prefer Ligand B.
0
2025-04-17 20:01:03,490 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
We are targeting ADRB2, a GPCR. Therefore, the most important parameters are binding affinity, logP, TPSA, Pgp efflux, and BBB penetration. Metabolic stability (Cl_mic and t1/2) and safety (DILI, hERG) are also important.
Let's compare the ligands property by property:
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (334.379) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (86.88) is better than Ligand B (59.22). Lower TPSA generally improves oral absorption and CNS penetration.
3. **logP:** Ligand A (1.562) is within the optimal range, while Ligand B (4.647) is high. High logP can lead to poor solubility and off-target effects.
4. **HBD/HBA:** Ligand A has 3 HBD and 3 HBA, while Ligand B has 1 HBD and 4 HBA. Both are acceptable, but Ligand A is slightly better balanced.
5. **QED:** Ligand B (0.819) has a better QED score than Ligand A (0.553), suggesting a more drug-like profile overall.
6. **DILI:** Ligand B (31.989) has a significantly lower DILI risk than Ligand A (62.389), a major advantage.
7. **BBB:** Ligand B (85.072) has a much higher BBB penetration percentile than Ligand A (49.67). While ADRB2 isn't exclusively a CNS target, some CNS exposure may be acceptable or even desirable depending on the specific therapeutic goal.
8. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-5.017) is slightly better than Ligand B (-4.964).
9. **Solubility:** Both have negative solubility values, indicating poor solubility. Ligand A (-3.712) is slightly better than Ligand B (-4.222).
10. **hERG:** Ligand A (0.074) has a lower hERG risk than Ligand B (0.846), which is preferable.
11. **Cl_mic:** Ligand A (-1.849) has a lower (better) microsomal clearance than Ligand B (66.224), indicating greater metabolic stability.
12. **t1/2:** Ligand A (-14.044) has a longer in vitro half-life than Ligand B (26.368), which is desirable.
13. **Pgp:** Ligand A (0.022) has a lower Pgp efflux liability than Ligand B (0.544), which is favorable for bioavailability.
14. **Binding Affinity:** Ligand B (-6.9 kcal/mol) has a slightly better binding affinity than Ligand A (-6.4 kcal/mol), but the difference is not substantial enough to outweigh other significant drawbacks.
**Overall Assessment:**
Ligand B has a better QED score and binding affinity, and a significantly lower DILI risk and higher BBB penetration. However, it suffers from a high logP, poor metabolic stability (high Cl_mic, low t1/2), and higher Pgp efflux. Ligand A has better ADME properties (lower logP, better metabolic stability, lower Pgp efflux, better solubility) and a lower hERG risk, but its QED and binding affinity are slightly lower.
Considering the GPCR-specific priorities, and the balance of properties, Ligand A is the more promising candidate. The lower logP, better metabolic stability, and lower Pgp efflux are crucial for good oral bioavailability and reduced off-target effects. The slightly weaker binding affinity can potentially be optimized in later stages of drug development. The lower DILI and higher BBB of Ligand B are attractive, but the high logP and poor metabolic stability are significant concerns.
**Output:**
1
2025-04-17 20:01:03,490 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (367.45 & 371.459 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (90.98) is better than Ligand B (104.9). Both are acceptable for a non-CNS GPCR, but lower is generally preferred.
3. **logP:** Ligand A (1.164) is within the optimal range (1-3). Ligand B (0.063) is quite low, potentially causing permeability issues. This is a significant negative for Ligand B.
4. **HBD:** Both ligands have 2 HBD, which is ideal.
5. **HBA:** Ligand A has 5 HBA, which is good. Ligand B has 7, which is higher but still within acceptable limits.
6. **QED:** Both ligands have good QED scores (0.558 and 0.666), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (66.421) has a higher DILI risk than Ligand B (54.285). This favors Ligand B.
8. **BBB:** This is less critical for a cardiovascular target like ADRB2. Ligand A (78.558) is better than Ligand B (22.606), but this isn't a major deciding factor.
9. **Caco-2:** Both have negative values, indicating poor permeability. However, Ligand A (-5.85) is better than Ligand B (-5.43).
10. **Solubility:** Both have negative solubility values. Ligand A (-3.077) is slightly better than Ligand B (-2.04).
11. **hERG:** Both ligands have very low hERG inhibition risk (0.386 and 0.085), which is excellent. Ligand B is slightly better.
12. **Cl_mic:** Ligand A (20.47) has a slightly higher clearance than Ligand B (16.268), suggesting lower metabolic stability. This favors Ligand B.
13. **t1/2:** Ligand A (-26.678) has a much longer in vitro half-life than Ligand B (-0.828). This is a significant advantage for Ligand A.
14. **Pgp:** Both have very low Pgp efflux liability (0.137 and 0.02). Ligand B is slightly better.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.5 and -6.3 kcal/mol). The difference is not substantial enough to be a primary deciding factor.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand A has a much better logP and TPSA. While Ligand B has slightly better DILI and Pgp, the poor logP is a significant drawback. The longer half-life of Ligand A is also a major advantage.
**Conclusion:**
Considering the balance of properties, particularly the crucial logP and TPSA values for GPCR targets, and the significantly longer half-life, Ligand A appears to be the more promising drug candidate.
Output:
1
2025-04-17 20:01:03,490 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (361.873 Da and 353.419 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (65.2) is significantly better than Ligand B (107.97). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is quite high, potentially hindering absorption.
**3. logP:** Ligand A (3.651) is within the optimal range (1-3), while Ligand B (-0.983) is below 1, which could indicate poor membrane permeability. This is a significant advantage for Ligand A.
**4. H-Bond Donors:** Both have acceptable HBD counts (2 and 3 respectively), within the guideline of <=5.
**5. H-Bond Acceptors:** Both have acceptable HBA counts (2 and 5 respectively), within the guideline of <=10.
**6. QED:** Ligand A (0.872) has a higher QED score than Ligand B (0.602), indicating better overall drug-likeness.
**7. DILI Risk:** Ligand A (64.288) has a higher DILI risk than Ligand B (28.616). This is a negative for Ligand A, but not a dealbreaker at this stage.
**8. BBB Penetration:** Ligand A (70.764) has significantly better BBB penetration than Ligand B (20.861). While ADRB2 is a cardiovascular target, some CNS effects are possible with beta-blockers, and better BBB penetration isn't necessarily a negative.
**9. Caco-2 Permeability:** Ligand A (-4.916) is better than Ligand B (-5.305), but both are negative values which is unusual.
**10. Aqueous Solubility:** Ligand A (-4.789) is better than Ligand B (-0.444), but both are negative values which is unusual.
**11. hERG Inhibition:** Ligand A (0.729) has a slightly higher hERG risk than Ligand B (0.087). This is a negative for Ligand A, but still relatively low.
**12. Microsomal Clearance:** Ligand B (-17.759) has much lower (better) microsomal clearance than Ligand A (33.599), indicating greater metabolic stability. This is a significant advantage for Ligand B.
**13. In vitro Half-Life:** Ligand A (32.597) has a longer half-life than Ligand B (13.797), which is desirable.
**14. P-gp Efflux:** Ligand A (0.415) has lower P-gp efflux than Ligand B (0.005), which is preferable.
**15. Binding Affinity:** Ligand B (-8.5 kcal/mol) has a stronger binding affinity than Ligand A (-7.0 kcal/mol). This is a substantial advantage for Ligand B, exceeding the 1.5 kcal/mol threshold.
**Overall Assessment:**
Ligand B has a significantly stronger binding affinity and better metabolic stability (lower Cl_mic). While Ligand A has better TPSA, logP, QED, BBB, and half-life, the superior affinity of Ligand B, combined with its lower DILI risk, outweighs these advantages. The lower logP and higher TPSA of Ligand A are concerning for permeability. The affinity difference is substantial enough to overcome the other drawbacks of Ligand B.
Output:
0
2025-04-17 20:01:03,490 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands are within the acceptable range (200-500 Da). Ligand A (332.363 Da) is slightly lower, which is generally favorable for permeability.
**2. TPSA:** Ligand B (70.08) is significantly better than Ligand A (90.68). For a GPCR, lower TPSA is preferred as it generally correlates with better membrane permeability.
**3. logP:** Ligand A (2.657) is within the optimal range (1-3), while Ligand B (0.978) is slightly below. While not ideal, Ligand B's logP isn't drastically low.
**4. H-Bond Donors:** Both ligands have acceptable HBD counts (Ligand A: 2, Ligand B: 1).
**5. H-Bond Acceptors:** Both ligands have acceptable HBA counts (Ligand A: 4, Ligand B: 5).
**6. QED:** Both ligands have similar and good QED values (Ligand A: 0.769, Ligand B: 0.781), indicating good drug-like properties.
**7. DILI:** Ligand B (23.149) has a *much* lower DILI risk than Ligand A (85.227). This is a significant advantage for Ligand B.
**8. BBB:** Ligand B (40.558) has a slightly better BBB penetration score than Ligand A (35.983), though neither are particularly high. Since ADRB2 is a cardiovascular target, BBB penetration is not a primary concern, but a slight advantage is still beneficial.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-5.1) is slightly better than Ligand B (-4.911).
**10. Aqueous Solubility:** Ligand A (-5.41) has better aqueous solubility than Ligand B (-1.733).
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (Ligand A: 0.67, Ligand B: 0.268), which is excellent.
**12. Microsomal Clearance:** Ligand B (16.764) has a slightly higher microsomal clearance than Ligand A (14.178), indicating potentially lower metabolic stability.
**13. In vitro Half-Life:** Ligand A (33.788) has a significantly longer in vitro half-life than Ligand B (-5.372). This is a substantial advantage for Ligand A.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (Ligand A: 0.263, Ligand B: 0.081).
**15. Binding Affinity:** Ligand A (-7.0) has a slightly better binding affinity than Ligand B (-6.3). While the difference is not huge, it's still a positive for Ligand A.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand B emerges as the more promising candidate. The significantly lower DILI risk is a major factor, as liver toxicity is a common cause of drug failure. While Ligand A has better affinity and half-life, the lower TPSA and substantially reduced DILI risk of Ligand B outweigh these advantages. The slightly lower logP of Ligand B is not a critical concern.
Output:
0
2025-04-17 20:01:03,491 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for the ADRB2, a cardiovascular GPCR. Therefore, we prioritize logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB.
Let's break down the comparison:
1. **MW:** Both ligands (350.434 and 351.422 Da) are within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (58.64) is better than Ligand B (60.93), both are below the 140 threshold for oral absorption, but closer to the ideal for GPCRs.
3. **logP:** Ligand A (1.824) is slightly better than Ligand B (0.985). Both are within the optimal 1-3 range, but B is closer to the lower limit which *could* indicate permeability issues.
4. **HBD/HBA:** Ligand A has 1 HBD and 3 HBA, while Ligand B has 0 HBD and 3 HBA. This isn't a major differentiator.
5. **QED:** Ligand A (0.744) is slightly better than Ligand B (0.694), indicating a more drug-like profile.
6. **DILI:** Ligand A (29.159) has a significantly lower DILI risk than Ligand B (40.132). This is a substantial advantage for Ligand A.
7. **BBB:** Ligand A (93.098) has better BBB penetration than Ligand B (86.08), though both are reasonably good.
8. **Caco-2:** Ligand A (-4.524) is slightly better than Ligand B (-4.179), indicating potentially better absorption.
9. **Solubility:** Ligand A (-2.848) is better than Ligand B (-1.221). Solubility is important for bioavailability.
10. **hERG:** Both ligands have low hERG inhibition risk (0.443 and 0.352 respectively).
11. **Cl_mic:** Ligand B (9.399) has a much lower microsomal clearance than Ligand A (39.571), indicating better metabolic stability. This is a significant advantage for Ligand B.
12. **t1/2:** Ligand B (-23.039) has a longer in vitro half-life than Ligand A (-17.455). This is another advantage for Ligand B.
13. **Pgp:** Ligand A (0.193) has lower P-gp efflux than Ligand B (0.129), which is desirable.
14. **Binding Affinity:** Ligand A (-7.3) has a significantly stronger binding affinity than Ligand B (-6.1). This is a 1.2 kcal/mol difference, which is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand A has a significantly better binding affinity and lower DILI risk, and better solubility. Ligand B has better metabolic stability (lower Cl_mic) and a longer half-life. The binding affinity difference is substantial, and the lower DILI risk of Ligand A is very attractive. While metabolic stability is important, the strong binding of Ligand A, coupled with acceptable metabolic parameters, makes it the more promising candidate.
**Output:**
1
2025-04-17 20:01:03,491 - INFO - Here's my reasoning and final output for the ligand preference:
**Reasoning:**
We are evaluating ligands for ADRB2, a cardiovascular GPCR. Therefore, the key priorities are logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB (though less critical for a cardiovascular target).
Let's compare Ligand A and Ligand B across the 15 parameters:
1. **MW:** Both are within the ideal range (346 & 349 Da).
2. **TPSA:** Ligand A (66.92) is significantly better than Ligand B (128.78). Lower TPSA generally favors oral absorption and GPCR penetration.
3. **logP:** Ligand A (1.494) is better than Ligand B (0.476). Both are within the acceptable range, but Ligand A is closer to the optimal 1-3 range.
4. **HBD/HBA:** Ligand A (0/4) is preferable to Ligand B (3/6). Fewer H-bonds can improve membrane permeability.
5. **QED:** Ligand B (0.736) is slightly better than Ligand A (0.574), indicating a marginally more drug-like profile.
6. **DILI:** Ligand A (27.181) is significantly better than Ligand B (74.99), indicating a lower risk of drug-induced liver injury. This is a crucial factor.
7. **BBB:** Ligand A (84.878) is much better than Ligand B (13.765). While not a primary concern for a cardiovascular target, higher BBB is still a positive.
8. **Caco-2:** Ligand A (-4.554) is better than Ligand B (-5.381), indicating better intestinal absorption.
9. **Solubility:** Ligand A (-3.191) is better than Ligand B (-2.726), though both are quite poor.
10. **hERG:** Both ligands have very low hERG inhibition risk (0.142 and 0.054).
11. **Cl_mic:** Ligand B (-18.321) has a lower (better) microsomal clearance than Ligand A (54.207), suggesting better metabolic stability.
12. **t1/2:** Ligand B (-5.058) has a longer half-life than Ligand A (-15.194), which is desirable.
13. **Pgp:** Ligand A (0.215) is better than Ligand B (0.023), indicating lower P-gp efflux and potentially better bioavailability.
14. **Binding Affinity:** Both ligands have the same binding affinity (-4.6 kcal/mol).
**Overall Assessment:**
Ligand A is clearly superior. While Ligand B has slightly better QED, t1/2 and Cl_mic, Ligand A excels in critical areas for a GPCR drug candidate: TPSA, logP, DILI risk, BBB penetration, Caco-2 permeability, and Pgp efflux. The significantly lower DILI risk and better TPSA/logP profile of Ligand A outweigh the minor advantages of Ligand B.
**Output:**
1
2025-04-17 20:01:03,491 - INFO - Batch 153 complete. Total preferences: 2448
2025-04-17 20:01:03,491 - INFO - Processing batch 154/512...
2025-04-17 20:01:56,367 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (354.451 and 370.494 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (90.98) is slightly higher than Ligand B (67.23). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferable for absorption. Ligand B has a clear advantage.
3. **logP:** Ligand A (0.037) is quite low, potentially hindering membrane permeability. Ligand B (1.815) is within the optimal 1-3 range. Ligand B is significantly better.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable, below the threshold of 5. Ligand B is slightly better.
5. **HBA:** Both ligands (5) are within the acceptable range of <=10. No significant difference.
6. **QED:** Both ligands (0.657 and 0.795) have good drug-likeness scores, exceeding the 0.5 threshold. Ligand B is slightly better.
7. **DILI:** Ligand A (29.042) has a lower DILI risk than Ligand B (39.201), which is preferable. Ligand A is better.
8. **BBB:** Both ligands have good BBB penetration (74.292 and 76.309), but this is less critical for a cardiovascular target. No clear advantage.
9. **Caco-2:** Ligand A (-4.661) and Ligand B (-5.086) are both negative, indicating poor permeability. Ligand A is slightly better.
10. **Solubility:** Ligand A (-0.917) is better than Ligand B (-2.317) in terms of solubility, which is important for bioavailability. Ligand A is better.
11. **hERG:** Both ligands (0.376 and 0.229) have low hERG inhibition risk, which is excellent. Ligand B is slightly better.
12. **Cl_mic:** Ligand A (31.2) has a lower microsomal clearance than Ligand B (34.299), indicating better metabolic stability. Ligand A is better.
13. **t1/2:** Ligand A (-30.573) has a much longer in vitro half-life than Ligand B (-1.154). This is a significant advantage. Ligand A is much better.
14. **Pgp:** Both ligands (0.016 and 0.065) have low P-gp efflux, which is good. Ligand A is slightly better.
15. **Affinity:** Ligand A (-6.5 kcal/mol) and Ligand B (-5.9 kcal/mol) both have good binding affinity, but Ligand A is stronger. This is a significant advantage. Ligand A is better.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand A emerges as the more promising candidate. While Ligand B has a slightly better TPSA and hERG, Ligand A excels in crucial areas like logP, binding affinity, metabolic stability (Cl_mic and t1/2), solubility, and DILI risk. The stronger binding affinity of Ligand A (-6.5 vs -5.9 kcal/mol) is a significant advantage that can outweigh minor ADME drawbacks. The longer half-life is also a major positive.
Output:
1
2025-04-17 20:01:56,367 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (356.853 and 357.451 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (54.28) is significantly better than Ligand B (96.97). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B's TPSA is quite high, potentially hindering absorption.
**3. logP:** Ligand A (4.795) is high, but still within a range that *could* be acceptable. Ligand B (0.061) is very low, which is a major concern for membrane permeability and bioavailability. A logP this low suggests poor absorption.
**4. H-Bond Donors:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
**5. H-Bond Acceptors:** Ligand A (4) is preferable to Ligand B (6). Lower HBA generally improves permeability.
**6. QED:** Both ligands have similar QED values (0.491 and 0.424), indicating moderate drug-likeness. Not a major differentiating factor.
**7. DILI Risk:** Ligand B (37.418) has a significantly lower DILI risk than Ligand A (60.682), which is a positive attribute.
**8. BBB Penetration:** Ligand B (52.385) shows slightly better BBB penetration than Ligand A (45.677), but neither is particularly high. For a cardiovascular target, BBB penetration isn't a primary concern, but it's a slight advantage for B.
**9. Caco-2 Permeability:** Ligand A (-4.829) shows better Caco-2 permeability than Ligand B (-5.102).
**10. Aqueous Solubility:** Ligand A (-5.526) shows better solubility than Ligand B (-1.051).
**11. hERG Inhibition:** Ligand A (0.88) has a slightly higher hERG risk than Ligand B (0.136), which is a negative for A.
**12. Microsomal Clearance:** Ligand B (45.309) has lower microsomal clearance, suggesting better metabolic stability, which is a positive. Ligand A (78.853) has higher clearance.
**13. In vitro Half-Life:** Ligand A (60.473) has a much longer in vitro half-life than Ligand B (-24.808). This is a significant advantage for A.
**14. P-gp Efflux:** Ligand A (0.703) has lower P-gp efflux than Ligand B (0.018), which is a positive.
**15. Binding Affinity:** Ligand B (-6.7) has a slightly better binding affinity than Ligand A (-6.3). While a 0.4 kcal/mol difference is noticeable, it's not overwhelmingly large.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand A is the more promising candidate. While Ligand B has lower DILI risk and slightly better affinity, its extremely low logP and high TPSA are major drawbacks that will likely lead to poor absorption and bioavailability. Ligand A's higher logP, lower TPSA, better solubility, and longer half-life outweigh the slightly higher DILI risk and hERG inhibition. The improved P-gp profile also favors A. The difference in binding affinity is not large enough to overcome the ADME deficiencies of Ligand B.
Output:
1
2025-04-17 20:01:56,368 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B, followed by the final output:
**1. Molecular Weight (MW):**
* Ligand A: 337.383 Da - Excellent, within the ideal range.
* Ligand B: 363.483 Da - Good, still within the ideal range.
* *Advantage: Ligand A (slightly lower)*
**2. Topological Polar Surface Area (TPSA):**
* Ligand A: 86.36 - Very good, well below the 140 threshold for oral absorption and suitable for a GPCR.
* Ligand B: 62.74 - Excellent, even better for permeability.
* *Advantage: Ligand B*
**3. Lipophilicity (logP):**
* Ligand A: 1.509 - Optimal.
* Ligand B: 1.948 - Optimal.
* *Advantage: Neither*
**4. H-Bond Donors (HBD):**
* Ligand A: 3 - Good, within the acceptable limit.
* Ligand B: 0 - Excellent, potentially improving permeability.
* *Advantage: Ligand B*
**5. H-Bond Acceptors (HBA):**
* Ligand A: 4 - Good, within the acceptable limit.
* Ligand B: 5 - Good, within the acceptable limit.
* *Advantage: Neither*
**6. Quantitative Estimate of Drug-likeness (QED):**
* Ligand A: 0.792 - Excellent, strong drug-like properties.
* Ligand B: 0.823 - Excellent, slightly better.
* *Advantage: Ligand B (slightly)*
**7. DILI Risk (DILI):**
* Ligand A: 78.17 - Moderate risk, approaching the higher end of acceptable.
* Ligand B: 62.854 - Lower risk, preferable.
* *Advantage: Ligand B*
**8. Blood-Brain Barrier (BBB):**
* Ligand A: 65.839 - Moderate, not ideal but acceptable for a cardiovascular target.
* Ligand B: 55.138 - Lower, less likely to cross BBB.
* *Advantage: Ligand A*
**9. Caco-2 Permeability:**
* Ligand A: -5.3 - Poor permeability.
* Ligand B: -4.756 - Poor permeability, but slightly better than A.
* *Advantage: Ligand B (slightly)*
**10. Aqueous Solubility:**
* Ligand A: -3.017 - Poor solubility.
* Ligand B: -1.857 - Poor solubility, but slightly better than A.
* *Advantage: Ligand B (slightly)*
**11. hERG Inhibition:**
* Ligand A: 0.431 - Low risk, excellent.
* Ligand B: 0.376 - Low risk, excellent.
* *Advantage: Neither*
**12. Microsomal Clearance (Cl_mic):**
* Ligand A: -19.447 - Very low clearance, excellent metabolic stability.
* Ligand B: 42.724 - High clearance, poor metabolic stability.
* *Advantage: Ligand A*
**13. In vitro Half-Life:**
* Ligand A: 68.354 - Good half-life.
* Ligand B: 17.17 - Short half-life, less desirable.
* *Advantage: Ligand A*
**14. P-gp Efflux:**
* Ligand A: 0.02 - Very low efflux, excellent.
* Ligand B: 0.281 - Low efflux, good.
* *Advantage: Ligand A*
**15. Binding Affinity:**
* Ligand A: 2.1 kcal/mol - Moderate affinity.
* Ligand B: -5.6 kcal/mol - Strong affinity.
* *Advantage: Ligand B (significant)*
**Overall Assessment:**
Ligand B has a significantly better binding affinity (-5.6 kcal/mol vs 2.1 kcal/mol), which is a major advantage for a GPCR target. It also has better DILI risk, QED, TPSA, HBD, Caco-2 permeability and solubility. While Ligand A has better metabolic stability (Cl_mic, t1/2) and P-gp efflux, the substantial affinity difference of Ligand B outweighs these benefits. The cardiovascular target doesn't require high BBB penetration, so Ligand A's slightly better BBB score is not a deciding factor.
Therefore, Ligand B is the more promising drug candidate.
0
2025-04-17 20:01:56,368 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [342.399, 85.37, 3.137, 2, 5, 0.872, 83.598, 75.843, -4.77, -4.509, 0.34, 60.953, 24.342, 0.334, -7.4]
**Ligand B:** [342.359, 104.19, -0.827, 1, 6, 0.784, 61.807, 33.385, -5.31, -2.126, 0.202, -4.604, -4.228, 0.009, -6.2]
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (around 342 Da). No significant difference.
2. **TPSA:** Ligand A (85.37) is better than Ligand B (104.19). ADRB2 is a cardiovascular target, so CNS penetration isn't *essential* but still helpful. Lower TPSA generally improves permeability.
3. **logP:** Ligand A (3.137) is optimal. Ligand B (-0.827) is too low, potentially hindering membrane permeability and bioavailability. This is a significant drawback.
4. **HBD:** Both are acceptable (2 and 1 respectively).
5. **HBA:** Both are acceptable (5 and 6 respectively).
6. **QED:** Both are good (0.872 and 0.784), indicating drug-like properties.
7. **DILI:** Ligand A (83.598) has a higher DILI risk than Ligand B (61.807), but both are reasonably acceptable.
8. **BBB:** Ligand A (75.843) has better BBB penetration potential than Ligand B (33.385). While not critical for a cardiovascular target, it's a bonus.
9. **Caco-2:** Both are poor (-4.77 and -5.31). This is a concern for oral absorption, but can be mitigated with formulation strategies.
10. **Solubility:** Ligand A (-4.509) is better than Ligand B (-2.126). Solubility is important for bioavailability.
11. **hERG:** Both are very low risk (0.34 and 0.202).
12. **Cl_mic:** Ligand B (-4.604) has significantly lower microsomal clearance than Ligand A (60.953), meaning it's more metabolically stable. This is a strong advantage.
13. **t1/2:** Ligand B (-4.228) has a longer in vitro half-life than Ligand A (24.342), further supporting its better metabolic stability.
14. **Pgp:** Ligand A (0.334) has lower P-gp efflux than Ligand B (0.009), which is favorable for bioavailability.
15. **Affinity:** Ligand A (-7.4) has a slightly better binding affinity than Ligand B (-6.2). This is a 1.2 kcal/mol difference, which is significant.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A excels in logP, TPSA, Pgp and affinity. Ligand B has a significantly better metabolic profile (Cl_mic and t1/2).
**Overall Assessment:**
While Ligand B has a superior metabolic profile, the significantly lower logP is a major concern. Poor logP often translates to poor permeability and bioavailability, which are critical for oral drugs. Ligand A, despite slightly higher metabolic clearance, has a much more favorable logP, better solubility, and a slightly better affinity. The difference in affinity (1.2 kcal/mol) is enough to outweigh the metabolic concerns, especially considering formulation strategies can potentially address metabolic instability.
Therefore, I prefer Ligand A.
Output:
1
2025-04-17 20:01:56,368 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (358.433 Da) is within the ideal range (200-500 Da). Ligand B (446.132 Da) is also acceptable, but approaching the upper limit.
2. **TPSA:** Ligand A (86.88) is excellent, well below the 140 threshold for oral absorption. Ligand B (67.18) is also very good.
3. **logP:** Ligand A (2.924) is optimal (1-3). Ligand B (4.678) is slightly higher, potentially leading to solubility issues or off-target interactions, but still within a reasonable range.
4. **HBD:** Ligand A (3) is good. Ligand B (1) is also good.
5. **HBA:** Ligand A (3) is good. Ligand B (5) is acceptable but higher.
6. **QED:** Both Ligand A (0.634) and Ligand B (0.571) are above 0.5, indicating good drug-likeness.
7. **DILI:** Ligand A (40.869) has a better DILI risk profile than Ligand B (63.513), being below the 60 threshold.
8. **BBB:** Ligand A (59.131) shows moderate BBB penetration. Ligand B (43.893) has lower BBB penetration. While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant for side effect profiles.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the values are close enough that this isn't a major differentiator.
10. **Solubility:** Ligand A (-2.827) has better solubility than Ligand B (-5.486).
11. **hERG:** Ligand A (0.48) has a lower hERG risk than Ligand B (0.802).
12. **Cl_mic:** Ligand A (16.109) has a lower microsomal clearance, suggesting better metabolic stability, than Ligand B (59.301).
13. **t1/2:** Ligand B (80.216) has a significantly longer in vitro half-life than Ligand A (-22.205). This is a major advantage.
14. **Pgp:** Ligand A (0.097) has lower P-gp efflux liability than Ligand B (0.295).
15. **Affinity:** Ligand B (-6.7 kcal/mol) has a substantially stronger binding affinity than Ligand A (-4.8 kcal/mol). This is a >1.5 kcal/mol difference, which is significant.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, affinity, logP, TPSA, and Pgp are key. Ligand B excels in affinity. While Ligand A has better logP and Pgp, the difference in affinity is substantial enough to outweigh these factors. The longer half-life of Ligand B is also a significant benefit. The slightly higher DILI risk for Ligand B is a concern, but manageable.
**Conclusion:**
Despite some drawbacks in DILI and logP, the significantly improved binding affinity and half-life of Ligand B make it the more promising drug candidate for ADRB2.
Output:
0
2025-04-17 20:01:56,368 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (368.474 and 385.877 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (67.43) is significantly better than Ligand B (89.35). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (3.215 and 2.3), falling within the 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability, but not dramatically so.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1), but both are well within the acceptable limit of 5.
5. **HBA:** Ligand A (4) is lower than Ligand B (8). This is a notable difference. Higher HBA can sometimes hinder permeability.
6. **QED:** Both ligands have good QED scores (0.665 and 0.735), indicating good drug-like properties. Ligand B is marginally better.
7. **DILI:** Ligand B (74.952) has a higher DILI risk than Ligand A (47.732). This is a significant concern, as minimizing liver toxicity is crucial.
8. **BBB:** Ligand A (73.672) has a much higher BBB penetration potential than Ligand B (40.52). While not a primary concern for a cardiovascular target, it's still a positive attribute.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.525 and -4.675). These values are unusual and suggest poor permeability. However, the scale isn't defined, so it's hard to interpret.
10. **Solubility:** Ligand A (-4.627) has slightly better solubility than Ligand B (-2.405) based on these values, but again, the scale is unclear.
11. **hERG:** Both ligands have low hERG inhibition liability (0.438 and 0.353), which is excellent.
12. **Cl_mic:** Ligand A (72.491) has a lower microsomal clearance than Ligand B (76.406), suggesting better metabolic stability.
13. **t1/2:** Ligand B (27.839) has a significantly longer in vitro half-life than Ligand A (-18.138). This is a major advantage.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.157 and 0.122).
15. **Binding Affinity:** Ligand B (-6.7 kcal/mol) has a substantially stronger binding affinity than Ligand A (-4.5 kcal/mol). This is a >2 kcal/mol difference, which is a significant advantage that can often outweigh other drawbacks.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, and affinity. Ligand B excels in affinity. Ligand A is better in TPSA and has a slightly better logP. The DILI risk for Ligand A is also significantly lower. The longer half-life of Ligand B is also a positive.
**Overall Assessment:**
The significantly stronger binding affinity of Ligand B is the most important factor. While Ligand A has advantages in TPSA, DILI, and metabolic stability, the large difference in binding affinity is likely to be decisive. The longer half-life of Ligand B is also a significant benefit. The slightly higher TPSA and DILI risk of Ligand B are acceptable trade-offs for the much improved potency.
Output:
0
2025-04-17 20:01:56,368 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (354.841 Da and 363.439 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (59.81) is significantly better than Ligand B (92.94). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is pushing the upper limit for good oral absorption (<=140), while A is well below.
**3. logP:** Ligand A (3.261) is within the optimal 1-3 range. Ligand B (0.56) is quite low, potentially hindering membrane permeability and absorption. This is a significant drawback for a GPCR ligand.
**4. H-Bond Donors:** Both have 1 HBD, which is acceptable.
**5. H-Bond Acceptors:** Ligand A has 4, and Ligand B has 5. Both are within the acceptable limit of <=10.
**6. QED:** Ligand A (0.739) has a better QED score than Ligand B (0.59), indicating a more drug-like profile.
**7. DILI:** Ligand B (52.152) has a lower DILI risk than Ligand A (73.09), which is a positive attribute.
**8. BBB:** Ligand B (61.613) has a higher BBB penetration percentile than Ligand A (49.205). While ADRB2 is a cardiovascular target, some CNS exposure can occur, so this is a slight advantage for Ligand B.
**9. Caco-2 Permeability:** Ligand A (-5.138) has a worse Caco-2 permeability score than Ligand B (-4.855).
**10. Aqueous Solubility:** Ligand A (-4.288) has a worse aqueous solubility score than Ligand B (-2.237).
**11. hERG Inhibition:** Ligand A (0.527) has a slightly higher hERG inhibition risk than Ligand B (0.399), but both are relatively low.
**12. Microsomal Clearance:** Ligand B (-1.563) has a significantly *lower* (better) microsomal clearance than Ligand A (68.926), suggesting better metabolic stability.
**13. In vitro Half-Life:** Ligand A (17.791) has a longer in vitro half-life than Ligand B (-6.955).
**14. P-gp Efflux:** Ligand A (0.35) has a lower P-gp efflux liability than Ligand B (0.064), which is favorable.
**15. Binding Affinity:** Both ligands have very similar binding affinities (-7.0 and -5.9 kcal/mol). Ligand A is slightly better, but the difference is not substantial enough to outweigh other factors.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand A is the superior candidate. While Ligand B has better DILI and metabolic stability, its significantly lower logP and higher TPSA are major drawbacks for a GPCR ligand, potentially leading to poor permeability and bioavailability. Ligand A's better logP, TPSA, QED, P-gp efflux, and slightly better affinity outweigh the slightly higher DILI risk and lower metabolic stability.
Output:
1
2025-04-17 20:01:56,369 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (339.439 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (53.51) is significantly better than Ligand B (109.58). For a GPCR, keeping TPSA low is beneficial for permeability and potentially BBB penetration. Ligand B is pushing the upper limit for good oral absorption.
3. **logP:** Ligand A (1.79) is optimal, while Ligand B (-0.256) is quite low. Low logP can lead to poor membrane permeability.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (3) is better than Ligand B (7). Lower HBA also favors permeability.
6. **QED:** Ligand A (0.844) is significantly better than Ligand B (0.635), indicating a more drug-like profile.
7. **DILI:** Ligand A (19.232) has a much lower DILI risk than Ligand B (58.395). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (86.274) has a much higher BBB penetration potential than Ligand B (48.662). While ADRB2 isn't exclusively a CNS target, some peripheral effects are mediated by CNS pathways, and higher BBB penetration isn't necessarily detrimental.
9. **Caco-2:** Ligand A (-4.89) is better than Ligand B (-5.145). Both are negative, which is not ideal, but Ligand A is slightly better.
10. **Solubility:** Ligand A (-1.842) is better than Ligand B (-1.231). Both are poor, but Ligand A is slightly better.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.169 and 0.153 respectively), which is excellent.
12. **Cl_mic:** Ligand A (49.307) has a higher clearance than Ligand B (24.876), indicating lower metabolic stability. This is a drawback for Ligand A.
13. **t1/2:** Ligand B (12.504) has a much longer in vitro half-life than Ligand A (-18.568). This is a significant advantage for Ligand B.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.19 and 0.045 respectively), which is excellent.
15. **Binding Affinity:** Both ligands have similar and strong binding affinities (-6.1 and -6.3 kcal/mol). The difference is negligible.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp) and general drug-like properties, Ligand A is significantly better. Its superior TPSA, logP, QED, DILI risk, and BBB penetration outweigh the slightly higher Cl_mic and shorter half-life. The binding affinity is comparable. The poor solubility of both compounds is a concern, but can potentially be addressed with formulation strategies.
Output:
1
2025-04-17 20:01:56,369 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (371.478 Da) is slightly higher than Ligand B (349.391 Da), but both are acceptable.
**2. TPSA:** Ligand A (95.66) is better than Ligand B (116.56). For a cardiovascular GPCR, TPSA should be relatively low to facilitate good absorption, and Ligand A is closer to the preferred threshold of <140.
**3. logP:** Ligand A (1.716) is within the optimal range (1-3), while Ligand B (-1.279) is below 1, which could hinder permeation. This is a significant advantage for Ligand A.
**4. H-Bond Donors:** Both ligands have 3 HBD, which is acceptable.
**5. H-Bond Acceptors:** Ligand A has 5 HBA, and Ligand B has 6. Both are within the acceptable limit of 10.
**6. QED:** Both ligands have reasonable QED values (0.734 and 0.612, respectively), indicating good drug-like properties.
**7. DILI:** Both ligands have low DILI risk (33.23 and 32.571, respectively), which is positive.
**8. BBB:** Ligand A (74.68) has a much better BBB percentile than Ligand B (13.92). While ADRB2 is a cardiovascular target, some CNS penetration can be acceptable or even desirable for off-target effects assessment.
**9. Caco-2 Permeability:** Ligand A (-5.143) is better than Ligand B (-5.578), indicating better intestinal absorption.
**10. Aqueous Solubility:** Ligand A (-3.115) is better than Ligand B (-1.289).
**11. hERG Inhibition:** Ligand A (0.485) is better than Ligand B (0.016), indicating a lower risk of cardiotoxicity. This is crucial for a cardiovascular target.
**12. Microsomal Clearance:** Ligand B (-1.272) has a much lower (better) microsomal clearance than Ligand A (21.169). This suggests greater metabolic stability for Ligand B.
**13. In vitro Half-Life:** Ligand A (-28.128) has a much longer half-life than Ligand B (-5.281).
**14. P-gp Efflux:** Ligand A (0.046) is better than Ligand B (0.002), indicating lower P-gp efflux.
**15. Binding Affinity:** Ligand B (-7.6) has a slightly better binding affinity than Ligand A (-9.3). However, the difference is not substantial enough to outweigh the other factors.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity) and the general drug-like properties, Ligand A is the more promising candidate. While Ligand B has a slightly better affinity and metabolic stability, Ligand A excels in logP, TPSA, BBB penetration, solubility, and hERG inhibition. The combination of these factors makes Ligand A a more balanced and potentially viable drug candidate for the ADRB2 receptor.
Output:
1
2025-04-17 20:01:56,369 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (349.391 Da) is well within the ideal range. Ligand B (401.579 Da) is also acceptable, though approaching the upper limit.
2. **TPSA:** Ligand A (97.63) is slightly above the preferred <90 for CNS targets, but still reasonable for a peripherally acting GPCR like ADRB2. Ligand B (79.37) is excellent.
3. **logP:** Ligand A (-0.001) is very low, potentially hindering membrane permeability. Ligand B (1.803) is optimal. This is a significant advantage for B.
4. **HBD:** Both ligands have acceptable HBD counts (A: 0, B: 1).
5. **HBA:** Both ligands have acceptable HBA counts (A: 7, B: 6).
6. **QED:** Both ligands have good QED scores (A: 0.53, B: 0.814), indicating good drug-like properties. B is significantly better.
7. **DILI:** Ligand A (54.75) is borderline, while Ligand B (49.515) is better, both are acceptable.
8. **BBB:** Both ligands show reasonable BBB penetration (A: 74.758, B: 70.415). This isn't a primary concern for ADRB2, but higher is generally preferred.
9. **Caco-2:** Ligand A (-4.636) is very poor, indicating very low intestinal absorption. Ligand B (-5.328) is also poor, but slightly better.
10. **Solubility:** Ligand A (-1.084) is poor, while Ligand B (-4.132) is even worse. Both are concerning.
11. **hERG:** Both ligands have low hERG inhibition risk (A: 0.06, B: 0.442), which is excellent.
12. **Cl_mic:** Ligand A (57.122) has a higher microsomal clearance, suggesting lower metabolic stability. Ligand B (26.74) is much better.
13. **t1/2:** Ligand A (4.24) has a short in vitro half-life. Ligand B (-22.124) has a very long in vitro half-life. This is a substantial advantage for B.
14. **Pgp:** Both ligands have low P-gp efflux liability (A: 0.1, B: 0.108).
15. **Affinity:** Ligand B (-7.1) has a significantly stronger binding affinity than Ligand A (-4.9). This difference (>1.5 kcal/mol) is a major deciding factor.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP, has a better TPSA, comparable Pgp, and a *much* stronger affinity. While solubility and Caco-2 are poor for both, the superior affinity and metabolic stability of Ligand B outweigh these concerns. The better QED and lower DILI risk also favor Ligand B.
**Conclusion:**
Ligand B is the far superior candidate due to its significantly improved binding affinity, logP, metabolic stability, and QED score. The poor solubility and Caco-2 values are drawbacks, but can potentially be addressed through formulation strategies.
Output:
0
2025-04-17 20:01:56,369 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [338.451, 58.2, 3.451, 2, 3, 0.76, 39.434, 80.264, -5.479, -2.561, 0.696, -8.936, 44.834, 0.5, -6.5]**
**Ligand B: [368.457, 75.62, 4.047, 2, 7, 0.768, 67.623, 71.268, -4.978, -4.606, 0.541, 39.894, 41.902, 0.087, -7.3]**
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). A (338.451) is slightly preferred due to being lower.
2. **TPSA:** Ligand A (58.2) is significantly better than Ligand B (75.62). ADRB2 is not a CNS target, but lower TPSA generally aids absorption.
3. **logP:** Both ligands have acceptable logP values (A: 3.451, B: 4.047). Ligand A is slightly preferred as it's closer to the optimal 1-3 range. Ligand B is pushing the upper limit.
4. **H-Bond Donors:** Both have 2 HBD, which is good.
5. **H-Bond Acceptors:** Ligand A (3) is better than Ligand B (7). Lower HBA is generally preferred for permeability.
6. **QED:** Both have similar QED values (A: 0.76, B: 0.768), indicating good drug-likeness.
7. **DILI:** Ligand A (39.434) has a significantly lower DILI risk than Ligand B (67.623). This is a major advantage for Ligand A.
8. **BBB:** Not a primary concern for ADRB2, but Ligand A (80.264) is better than Ligand B (71.268).
9. **Caco-2:** Ligand A (-5.479) and Ligand B (-4.978) are both poor, but B is slightly better.
10. **Aqueous Solubility:** Ligand A (-2.561) is better than Ligand B (-4.606).
11. **hERG:** Ligand A (0.696) has a lower hERG risk than Ligand B (0.541), which is favorable.
12. **Microsomal Clearance:** Ligand A (-8.936) has a much lower (better) microsomal clearance than Ligand B (39.894), indicating better metabolic stability.
13. **In vitro Half-Life:** Ligand A (44.834) has a slightly longer half-life than Ligand B (41.902).
14. **P-gp Efflux:** Ligand A (0.5) has lower P-gp efflux than Ligand B (0.087), which is favorable.
15. **Binding Affinity:** Ligand B (-7.3) has a slightly better binding affinity than Ligand A (-6.5), a difference of 0.8 kcal/mol. While affinity is important, the other ADME properties of Ligand A are substantially better.
**Overall Assessment:**
Ligand A demonstrates a significantly superior ADME profile, with lower DILI risk, better metabolic stability (lower Cl_mic), better solubility, lower hERG risk, and lower P-gp efflux. While Ligand B has a slightly better binding affinity, the substantial improvements in ADME properties for Ligand A outweigh this difference. For a GPCR like ADRB2, a balanced profile is crucial, and Ligand A provides that balance more effectively.
Output:
1
2025-04-17 20:01:56,369 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (352.45 Da) is slightly lower, which is generally favorable for permeability.
**2. TPSA:** Ligand A (61.8) is significantly better than Ligand B (92.51). For a cardiovascular GPCR, TPSA < 140 is acceptable, but lower is preferred for good absorption. Ligand B is approaching a level that might hinder oral bioavailability.
**3. logP:** Both ligands have good logP values (A: 2.327, B: 2.081), falling within the optimal 1-3 range.
**4. H-Bond Donors:** Ligand A (2) is slightly higher than Ligand B (1), but both are within the acceptable limit of 5.
**5. H-Bond Acceptors:** Ligand A (4) is lower than Ligand B (5), which is preferable.
**6. QED:** Both ligands have good QED scores (A: 0.705, B: 0.88), indicating good drug-like properties. Ligand B is slightly better.
**7. DILI:** Ligand A (4.769) has a significantly lower DILI risk than Ligand B (37.805). This is a major advantage for Ligand A.
**8. BBB:** Both ligands have high BBB penetration (A: 81, B: 80.264), which isn't a primary concern for a cardiovascular target, but isn't detrimental.
**9. Caco-2 Permeability:** Ligand A (-5.081) shows better Caco-2 permeability than Ligand B (-4.617).
**10. Aqueous Solubility:** Ligand A (-2.065) has better aqueous solubility than Ligand B (-2.65).
**11. hERG Inhibition:** Ligand A (0.836) has a lower hERG inhibition liability than Ligand B (0.129), indicating a lower risk of cardiotoxicity. This is crucial for a cardiovascular drug.
**12. Microsomal Clearance:** Ligand B (16.343) has a higher microsomal clearance than Ligand A (14.161), meaning Ligand A is more metabolically stable.
**13. In vitro Half-Life:** Ligand B (12.158) has a longer in vitro half-life than Ligand A (-1.75).
**14. P-gp Efflux:** Ligand A (0.151) has lower P-gp efflux liability than Ligand B (0.038), which is favorable for bioavailability.
**15. Binding Affinity:** Ligand B (-6.7 kcal/mol) has a slightly better binding affinity than Ligand A (-5.5 kcal/mol). This is a 1.2 kcal/mol difference, which is significant but needs to be weighed against other factors.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand A emerges as the more promising candidate. While Ligand B has a slightly better binding affinity and half-life, Ligand A excels in crucial ADME properties like TPSA, DILI risk, hERG inhibition, solubility, and P-gp efflux. The lower DILI and hERG risk are particularly important for a cardiovascular drug. The better TPSA and solubility also suggest better absorption. The affinity difference, while present, is not large enough to outweigh the significant advantages of Ligand A in terms of safety and ADME.
Output:
1
2025-04-17 20:01:56,370 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (439.316 Da) is slightly higher than Ligand B (385.295 Da), but both are acceptable.
2. **TPSA:** Ligand B (64.16) is significantly better than Ligand A (106.32). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (A: 2.352, B: 3.355), falling within the 1-3 optimal range. Ligand B is slightly higher, which could potentially lead to some solubility issues, but is still acceptable.
4. **HBD:** Ligand A has 2 HBD, while Ligand B has 0. Both are within the acceptable limit of 5.
5. **HBA:** Ligand A has 7 HBA, Ligand B has 5. Both are within the acceptable limit of 10.
6. **QED:** Both ligands have similar QED values (A: 0.712, B: 0.654), indicating good drug-likeness.
7. **DILI:** Ligand B (38.658) has a much lower DILI risk than Ligand A (93.37). This is a significant advantage for Ligand B.
8. **BBB:** Ligand B (83.443) has a higher BBB penetration score than Ligand A (35.401). While not critical for a cardiovascular target, higher BBB is generally favorable.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and requires careful interpretation. It suggests poor permeability. Ligand A (-5.069) is slightly worse than Ligand B (-4.96).
10. **Solubility:** Ligand A (-5.348) has slightly better solubility than Ligand B (-3.667), but both are very poor.
11. **hERG:** Ligand B (0.253) has a significantly lower hERG inhibition liability than Ligand A (0.606). This is a crucial advantage, as hERG inhibition can lead to cardiotoxicity.
12. **Cl_mic:** Ligand B (54.404) has a lower microsomal clearance than Ligand A (39.054), indicating better metabolic stability.
13. **t1/2:** Ligand A (42.517) has a much longer in vitro half-life than Ligand B (12.816). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.398) has lower P-gp efflux than Ligand B (0.284), which is favorable.
15. **Binding Affinity:** Ligand A (-6.2 kcal/mol) has a slightly better binding affinity than Ligand B (-5.3 kcal/mol). This difference of 0.9 kcal/mol is notable, but not overwhelming.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand B excels in TPSA, DILI, hERG, and Cl_mic, while Ligand A has a slight edge in affinity and half-life. The significant improvements in safety (DILI, hERG) and metabolic stability (Cl_mic) offered by Ligand B, combined with its better TPSA, outweigh the slightly better affinity and half-life of Ligand A. The poor Caco-2 values for both are concerning and would require further investigation, but the overall profile of Ligand B is more promising.
**Output:**
0
2025-04-17 20:01:56,370 - INFO - Here's my reasoning and the final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. The key priorities for GPCRs, as outlined, are binding affinity, logP, Pgp efflux, TPSA, and BBB penetration. Let's compare the ligands property by property:
1. **MW:** Both ligands (344.434 and 364.427 Da) fall within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (50.16) is significantly better than Ligand B (101.91). A TPSA under 140 is good for oral absorption, but lower is generally preferred for GPCRs, and Ligand A is much closer to the ideal range for CNS penetration as well.
3. **logP:** Ligand A (3.056) is optimal, while Ligand B (1.228) is a bit low, potentially hindering membrane permeability.
4. **HBD/HBA:** Ligand A (1 HBD, 3 HBA) is better than Ligand B (2 HBD, 7 HBA). Lower counts are generally preferred for better permeability.
5. **QED:** Both are good (0.906 and 0.818), indicating drug-like properties.
6. **DILI:** Ligand B (67.119) has a higher DILI risk than Ligand A (49.399), which is undesirable.
7. **BBB:** Ligand A (83.249) has significantly better BBB penetration potential than Ligand B (45.56). While this isn't *critical* for a cardiovascular target, it's a bonus.
8. **Caco-2:** Both are negative, indicating poor permeability. This is a concern for both, but the lower TPSA of Ligand A may mitigate this somewhat.
9. **Solubility:** Both are negative, indicating poor solubility.
10. **hERG:** Ligand A (0.765) has a slightly higher hERG risk than Ligand B (0.141), but both are relatively low.
11. **Cl_mic:** Ligand B (5.723) has much lower microsomal clearance than Ligand A (39.861), suggesting better metabolic stability. This is a significant advantage for Ligand B.
12. **t1/2:** Ligand B (28.168) has a longer in vitro half-life than Ligand A (17.975), which is desirable.
13. **Pgp:** Ligand A (0.268) has lower P-gp efflux than Ligand B (0.092), which is a positive.
14. **Affinity:** Ligand A (-8.0 kcal/mol) has a slightly better binding affinity than Ligand B (-6.8 kcal/mol). This is a substantial difference, and the most important factor.
**Overall Assessment:**
Ligand A has a significantly better binding affinity and more favorable TPSA, logP, BBB, and Pgp properties. While Ligand B has better metabolic stability (lower Cl_mic) and half-life, the superior binding affinity of Ligand A, combined with its better permeability-related properties (TPSA, logP, Pgp), outweigh these advantages. The slightly higher DILI risk for Ligand A is less concerning than the poor permeability profile of Ligand B. The difference in binding affinity is also substantial enough to overcome the other drawbacks.
**Output:**
1
2025-04-17 20:01:56,370 - INFO - Reasoning:
Let's analyze both ligands based on the provided parameters and guidelines, keeping in mind this is for an ADRB2 GPCR (cardiovascular target).
**Ligand A:**
* **MW:** 348.487 Da - Good, within the ideal range.
* **TPSA:** 78.43 - Good, below the 140 threshold for oral absorption.
* **logP:** 2.293 - Excellent, within the optimal 1-3 range.
* **HBD:** 3 - Good, within the limit of 5.
* **HBA:** 3 - Good, within the limit of 10.
* **QED:** 0.527 - Good, above the 0.5 threshold.
* **DILI:** 22.8 - Excellent, very low risk.
* **BBB:** 27.763 - Moderate. Not a primary concern for a cardiovascular target, but not ideal.
* **Caco-2:** -4.975 - Poor. Indicates poor intestinal absorption.
* **Solubility:** -3.107 - Poor. Could present formulation challenges.
* **hERG:** 0.225 - Excellent, very low risk.
* **Cl_mic:** 3.907 - Moderate. Not ideal, but not extremely high.
* **t1/2:** 19.805 - Good, a reasonable half-life.
* **Pgp:** 0.151 - Low efflux, favorable.
* **Affinity:** -6.2 kcal/mol - Very good binding affinity.
**Ligand B:**
* **MW:** 351.403 Da - Good, within the ideal range.
* **TPSA:** 96.97 - Moderate. Approaching the upper limit for good absorption.
* **logP:** -0.961 - Poor. Below the optimal range, potentially hindering permeation.
* **HBD:** 2 - Good, within the limit of 5.
* **HBA:** 5 - Good, within the limit of 10.
* **QED:** 0.455 - Acceptable, but lower than Ligand A.
* **DILI:** 25.902 - Good, low risk, slightly higher than Ligand A.
* **BBB:** 40.52 - Moderate. Not a primary concern for a cardiovascular target, but not ideal.
* **Caco-2:** -4.971 - Poor. Similar to Ligand A, indicating poor intestinal absorption.
* **Solubility:** -1.375 - Poor. Similar to Ligand A, could present formulation challenges.
* **hERG:** 0.048 - Excellent, very low risk.
* **Cl_mic:** -11.241 - Excellent, very low clearance, indicating high metabolic stability.
* **t1/2:** -5.3 - Poor. Very short half-life.
* **Pgp:** 0.005 - Very low efflux, highly favorable.
* **Affinity:** -6.7 kcal/mol - Excellent, slightly better binding affinity than Ligand A.
**Comparison & Decision:**
Both ligands have poor Caco-2 permeability and solubility, which are significant drawbacks. However, for a cardiovascular target, these are less critical than potency and safety. Ligand B has a slightly better affinity (-6.7 vs -6.2 kcal/mol) and *significantly* better metabolic stability (Cl_mic of -11.241 vs 3.907). While Ligand A has a slightly better QED and lower DILI, the improved metabolic stability of Ligand B is a major advantage, especially for a GPCR where sustained signaling is often desired. The half-life is a major concern for Ligand B, but the metabolic stability suggests that this could be improved with further optimization. Ligand A's Caco-2 and solubility issues are harder to address. Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity), and the importance of metabolic stability for sustained receptor engagement, Ligand B is the more promising candidate.
Output:
0
2025-04-17 20:01:56,370 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (355.429 Da and 361.881 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (71.09 and 71.76) are below the 140 threshold for good oral absorption, which is good.
3. **logP:** Both ligands (2.692 and 2.887) are within the optimal 1-3 range. Again, no major distinction.
4. **HBD:** Ligand A has 2 HBD, and Ligand B has 1. Both are acceptable (<=5).
5. **HBA:** Ligand A has 3 HBA, and Ligand B has 7. Ligand A is preferable here, as higher HBA can sometimes hinder permeability.
6. **QED:** Both ligands have good QED scores (0.715 and 0.882), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (40.016) has a better DILI score than Ligand B (69.872). This is a significant advantage for Ligand A, as lower DILI risk is crucial.
8. **BBB:** Ligand A (65.839) and Ligand B (77.472) both have reasonably good BBB penetration, but Ligand B is better. For a cardiovascular target like ADRB2, BBB penetration is less critical than for CNS targets, but still a consideration.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.917 and -5.184). This is unusual and suggests poor permeability.
10. **Solubility:** Both ligands have negative solubility values (-3.036 and -3.963). This is also unusual and suggests poor solubility.
11. **hERG:** Both ligands have low hERG inhibition liability (0.556 and 0.495), which is good.
12. **Cl_mic:** Ligand A (47.684) has a lower microsomal clearance than Ligand B (86.306), indicating better metabolic stability. This is a positive for Ligand A.
13. **t1/2:** Ligand A (10.291) and Ligand B (11.362) have similar in vitro half-lives.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.081 and 0.126), which is favorable.
15. **Binding Affinity:** Ligand B (-6.6 kcal/mol) has a stronger binding affinity than Ligand A (-5.9 kcal/mol). This is a 0.7 kcal/mol difference, which is significant.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Both ligands perform similarly on logP and Pgp. Ligand B has slightly better BBB penetration. However, the significant advantage of Ligand A in DILI risk and metabolic stability (lower Cl_mic) outweighs the slightly better affinity of Ligand B. The poor Caco-2 and solubility scores are concerning for both, and would require further investigation/optimization.
**Conclusion:**
Despite the slightly better affinity of Ligand B, Ligand A's superior DILI profile and metabolic stability make it the more promising candidate. The lower DILI risk is a critical factor in drug development, and the better metabolic stability suggests a potentially longer duration of action.
Output:
1
2025-04-17 20:01:56,370 - INFO - Batch 154 complete. Total preferences: 2464
2025-04-17 20:01:56,370 - INFO - Processing batch 155/512...
2025-04-17 20:02:46,247 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (363.53 and 349.48 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (53.51) is better than Ligand B (69.72). For a cardiovascular GPCR, TPSA is moderately important, and lower is generally preferred for better absorption. Ligand A is closer to the <140 threshold.
**3. logP:** Ligand A (2.985) is slightly higher than Ligand B (1.563), placing it more optimally within the 1-3 range. Ligand B is a bit low, potentially hindering permeation.
**4. H-Bond Donors:** Both have acceptable numbers (0 for A, 1 for B), well below the 5 threshold.
**5. H-Bond Acceptors:** Both ligands are also acceptable (4 for A, 3 for B), below the 10 threshold.
**6. QED:** Both ligands have similar and good QED values (0.78 and 0.786), indicating good drug-like properties.
**7. DILI Risk:** Ligand A (39.40%) has a slightly higher DILI risk than Ligand B (29.62%), but both are below the concerning 60% threshold.
**8. BBB Penetration:** Both ligands have similar and good BBB penetration (76.74% and 75.11%). While ADRB2 is not a CNS target, some level of BBB penetration isn't detrimental.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and likely indicates a problem with the assay or data. It's difficult to interpret this data without further information.
**10. Aqueous Solubility:** Both ligands have negative solubility values, which is also unusual and likely indicates a problem with the assay or data. It's difficult to interpret this data without further information.
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.483 and 0.168), which is excellent.
**12. Microsomal Clearance:** Ligand A (89.21 mL/min/kg) has significantly higher clearance than Ligand B (38.20 mL/min/kg). This suggests Ligand B is more metabolically stable, a desirable trait.
**13. In vitro Half-Life:** Ligand B (-11.62 hours) has a negative half-life, which is impossible. Ligand A (8.64 hours) is reasonable. This is a major red flag for Ligand B.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.183 and 0.03), which is favorable.
**15. Binding Affinity:** Ligand B (-6.7 kcal/mol) has slightly better binding affinity than Ligand A (-6.5 kcal/mol), but the difference is small.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand A is preferable. While Ligand B has slightly better affinity and lower clearance, the negative half-life is a critical flaw. Ligand A has a better logP, lower TPSA, and a reasonable half-life. The slightly higher DILI risk for Ligand A is less concerning than the impossible half-life of Ligand B. The questionable Caco-2 and solubility values for both ligands would need further investigation, but the half-life issue for B is a dealbreaker.
Output:
1
2025-04-17 20:02:46,247 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [341.415, 111.25 , 1.469, 3. , 4. , 0.77 , 34.626, 70.027, -5.355, -3.169, 0.573, -16.987, 19.987, 0.008, -5.9 ]
**Ligand B:** [344.411, 75.71 , 1.336, 1. , 4. , 0.464, 32.067, 46.026, -4.678, -2.588, 0.074, 33.169, 3.571, 0.017, -4.8 ]
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal 200-500 Da range. (A: 341.415, B: 344.411) - No clear advantage.
2. **TPSA:** Ligand A (111.25) is slightly higher than Ligand B (75.71). For a GPCR, lower TPSA is generally preferred for better BBB penetration, giving a slight edge to B.
3. **logP:** Both are within the optimal 1-3 range. (A: 1.469, B: 1.336) - Very similar.
4. **HBD:** Ligand A has 3 HBD, while Ligand B has 1. Lower HBD is often preferred for permeability, favoring B.
5. **HBA:** Both have 4 HBA. - No clear advantage.
6. **QED:** Ligand A (0.77) has a better QED score than Ligand B (0.464), indicating a more drug-like profile. This is a significant advantage for A.
7. **DILI:** Both have acceptable DILI risk (A: 34.626, B: 32.067), below the 40% threshold. B is slightly better.
8. **BBB:** Ligand A (70.027) has a significantly higher BBB percentile than Ligand B (46.026). This is a crucial advantage for a GPCR target, especially if CNS effects are relevant.
9. **Caco-2:** Ligand A (-5.355) is worse than Ligand B (-4.678). Lower values indicate poorer permeability, favoring B.
10. **Solubility:** Ligand A (-3.169) is worse than Ligand B (-2.588). Lower values indicate poorer solubility, favoring B.
11. **hERG:** Both have very low hERG risk (A: 0.573, B: 0.074). B is better.
12. **Cl_mic:** Ligand A (-16.987) has a much lower (better) microsomal clearance than Ligand B (33.169), indicating greater metabolic stability. This is a significant advantage for A.
13. **t1/2:** Ligand A (19.987) has a much longer in vitro half-life than Ligand B (3.571), which is highly desirable. This is a major advantage for A.
14. **Pgp:** Both have very low Pgp efflux liability (A: 0.008, B: 0.017). - No clear advantage.
15. **Affinity:** Ligand A (-5.9) has a slightly better binding affinity than Ligand B (-4.8). While not a massive difference, it's a positive for A.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity) and the general guidelines, Ligand A appears to be the more promising candidate. While Ligand B has advantages in TPSA, Caco-2, solubility, and hERG, Ligand A excels in QED, BBB penetration, metabolic stability (Cl_mic), and in vitro half-life. The superior BBB, metabolic stability, and half-life of Ligand A are particularly important for a GPCR target, outweighing the slight disadvantages in TPSA and permeability. The slightly better affinity also contributes to its favorability.
Output:
1
2025-04-17 20:02:46,247 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.46 & 356.40 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (84.66) is better than Ligand B (33.2). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower TPSA generally aids permeability. Ligand B is significantly lower, which could be beneficial.
3. **logP:** Ligand A (2.818) is within the optimal 1-3 range. Ligand B (4.583) is a bit high, potentially leading to solubility issues and off-target interactions. Ligand A is preferable here.
4. **HBD:** Ligand A (2) is reasonable. Ligand B (0) is also acceptable. No strong preference.
5. **HBA:** Ligand A (4) is reasonable. Ligand B (3) is also acceptable. No strong preference.
6. **QED:** Ligand A (0.802) is excellent, indicating strong drug-like properties. Ligand B (0.673) is still acceptable, but lower. Ligand A is preferable.
7. **DILI:** Ligand A (37.50) has a much lower DILI risk than Ligand B (92.98). This is a significant advantage for Ligand A.
8. **BBB:** Both ligands have high BBB penetration (84.68 & 77.82). Since ADRB2 isn't primarily a CNS target, this isn't a major deciding factor, but higher is slightly better. Ligand A is slightly better.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. This is a concern for both, but the values are close.
10. **Solubility:** Both ligands have negative solubility values, indicating poor aqueous solubility. This is a significant drawback for both.
11. **hERG:** Ligand A (0.78) has a lower hERG risk than Ligand B (0.488). This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand A (11.79) has a lower microsomal clearance, suggesting better metabolic stability, than Ligand B (55.90). This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (-14.62) has a negative half-life, which is concerning. Ligand B (56.60) has a positive half-life, indicating better in vitro stability. Ligand B is preferable here.
14. **Pgp:** Ligand A (0.079) has lower P-gp efflux, which is favorable for bioavailability. Ligand B (0.779) has higher P-gp efflux. Ligand A is preferable.
15. **Binding Affinity:** Ligand B (-6.5) has a stronger binding affinity than Ligand A (-5.3). This is a 1.2 kcal/mol difference, which is substantial and could outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand B has a significantly better binding affinity, which is a primary driver for GPCR drug candidates. However, it suffers from a high DILI risk, high microsomal clearance, and higher P-gp efflux. Ligand A has a much better safety profile (lower DILI, hERG), better metabolic stability (lower Cl_mic), and lower P-gp efflux. While its affinity is weaker, the overall balance of properties, especially considering the cardiovascular target, favors Ligand A. The solubility issues are a concern for both, but can be addressed with formulation strategies.
Output:
1
2025-04-17 20:02:46,247 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (332.4) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (80.9) is significantly better than Ligand B (49.4). For a GPCR, lower TPSA is generally preferred for better brain penetration and overall absorption.
3. **logP:** Both ligands have good logP values (A: 3.158, B: 3.588), falling within the optimal 1-3 range. Ligand B is slightly higher, which *could* indicate a slightly higher risk of off-target interactions, but it's not a major concern.
4. **HBD/HBA:** Ligand A has 2 HBD and 4 HBA, while Ligand B has 1 HBD and 2 HBA. Both are acceptable, staying within the recommended limits.
5. **QED:** Both ligands have good QED scores (A: 0.719, B: 0.775), indicating good drug-like properties. Ligand B is slightly better.
6. **DILI:** Ligand A (77.782) has a higher DILI risk than Ligand B (32.92). This is a significant concern, as lower DILI is crucial.
7. **BBB:** Both ligands have good BBB penetration (A: 71.966, B: 76.735).
8. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual. Assuming these are logP values, both are reasonable.
9. **Solubility:** Both ligands have negative solubility values, which is also unusual. Assuming these are logS values, both are reasonable.
10. **hERG:** Both ligands have low hERG inhibition liability (A: 0.72, B: 0.474). Ligand B is slightly better.
11. **Cl_mic:** Ligand A (61.323) has lower microsomal clearance than Ligand B (93.166), suggesting better metabolic stability.
12. **t1/2:** Ligand A (2.939) has a shorter in vitro half-life than Ligand B (-12.579). This is a significant drawback for Ligand A.
13. **Pgp:** Both ligands have low P-gp efflux liability (A: 0.414, B: 0.579).
14. **Binding Affinity:** Ligand B (-7.5 kcal/mol) has a slightly better binding affinity than Ligand A (-6.7 kcal/mol). While the difference is less than the 1.5 kcal/mol threshold, it's still a positive for Ligand B.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, and affinity. Ligand B is better on logP, and affinity. Ligand A is better on TPSA, but the difference isn't substantial enough to outweigh the other factors. The significantly lower DILI risk and better metabolic stability (lower Cl_mic) and longer half-life of Ligand B are also very important.
**Conclusion:**
Considering all factors, especially the lower DILI risk, better metabolic stability, and slightly improved binding affinity, Ligand B is the more promising drug candidate.
Output:
0
2025-04-17 20:02:46,247 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.463 and 347.467 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand B (82.68) is significantly better than Ligand A (107.11). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (1.297 and 1.958), falling within the optimal 1-3 range. Ligand B is slightly better.
4. **HBD:** Ligand A has 4 HBD, while Ligand B has 1. Lower HBD is generally preferred for better permeability. Ligand B is better.
5. **HBA:** Ligand A has 4 HBA, while Ligand B has 8. Ligand A is better.
6. **QED:** Ligand B (0.662) has a better QED score than Ligand A (0.477), indicating a more drug-like profile.
7. **DILI:** Ligand A (28.887) has a much lower DILI risk than Ligand B (52.423). This is a significant advantage for Ligand A.
8. **BBB:** Ligand B (55.642) has a higher BBB penetration percentile than Ligand A (13.61). While not critical for a cardiovascular target, it's a slight positive for Ligand B.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-5.708) is slightly better than Ligand B (-5.5).
10. **Solubility:** Both ligands have very poor aqueous solubility (-1.726 and -1.613). This is a major concern for both.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.111 and 0.137). No significant difference.
12. **Cl_mic:** Ligand A (4.289) has a significantly lower microsomal clearance than Ligand B (27.377), suggesting better metabolic stability. This is a major advantage for Ligand A.
13. **t1/2:** Ligand B (17.49) has a much longer in vitro half-life than Ligand A (-15.202). This is a significant advantage for Ligand B.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.035 and 0.104). No significant difference.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.8 and -6.9 kcal/mol). The difference is negligible.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are important. Ligand B has a slightly better logP and TPSA. However, the significant advantages of Ligand A in terms of DILI risk and metabolic stability (Cl_mic) outweigh these minor differences. The longer half-life of Ligand B is attractive, but the poor solubility and high DILI risk are major drawbacks.
**Conclusion:**
Considering the balance of properties, particularly the lower DILI risk and better metabolic stability of Ligand A, I believe it is the more promising drug candidate.
Output:
1
2025-04-17 20:02:46,248 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (344.37) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (98.61) is better than Ligand B (23.55). For a cardiovascular GPCR, a lower TPSA isn't *as* critical as for a CNS target, but it still contributes to better absorption. Ligand B is exceptionally low, which could be a concern for binding.
3. **logP:** Ligand A (2.587) is within the optimal range (1-3). Ligand B (4.954) is higher, potentially leading to solubility issues and off-target interactions.
4. **HBD:** Ligand A (1) is preferable to Ligand B (0). Having at least one HBD can improve solubility.
5. **HBA:** Ligand A (7) is better than Ligand B (2). Similar to HBD, a moderate number of HBAs is desirable.
6. **QED:** Ligand A (0.804) is significantly better than Ligand B (0.618), indicating a more drug-like profile.
7. **DILI:** Ligand B (11.594) is *much* better than Ligand A (65.762), indicating a significantly lower risk of drug-induced liver injury. This is a major advantage for Ligand B.
8. **BBB:** Ligand B (90.617) is significantly better than Ligand A (40.675). While ADRB2 isn't primarily a CNS target, some peripheral ADRB2 receptors can be relevant in neurological conditions, and higher BBB penetration is generally a positive attribute.
9. **Caco-2:** Both are negative, indicating poor permeability.
10. **Solubility:** Both are negative, indicating poor solubility.
11. **hERG:** Ligand A (0.107) is better than Ligand B (0.937), suggesting a lower risk of cardiotoxicity. This is critical for a cardiovascular target.
12. **Cl_mic:** Ligand A (113.999) is higher than Ligand B (89.346), indicating faster metabolism and lower stability.
13. **t1/2:** Ligand B (6.612) is significantly better than Ligand A (-40.507), indicating a longer half-life.
14. **Pgp:** Ligand A (0.103) is better than Ligand B (0.775), suggesting lower P-gp efflux.
15. **Affinity:** Ligand A (-6.6) is slightly better than Ligand B (-5.9), but the difference is relatively small.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has a better logP and Pgp, but Ligand B has a much better TPSA and comparable affinity. The DILI and BBB scores for Ligand B are also substantially better.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity and Pgp profile, the significantly lower DILI risk, better BBB penetration, and longer half-life of Ligand B are more compelling. The solubility and permeability issues are present in both, but the safety profile of Ligand B is far superior. The slightly lower affinity can potentially be optimized in later stages of drug development.
Output:
0
2025-04-17 20:02:46,248 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands (361.467 and 354.535 Da) fall comfortably within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand B (69.64) is significantly better than Ligand A (83.48). For a GPCR, lower TPSA is generally preferred for better permeability.
3. **logP:** Both ligands have excellent logP values (3.395 and 3.251), falling within the optimal 1-3 range. Very similar.
4. **HBD:** Ligand B (2) is slightly better than Ligand A (3), but both are acceptable.
5. **HBA:** Ligand B (3) is slightly better than Ligand A (5), but both are acceptable.
6. **QED:** Ligand A (0.706) has a slightly higher QED score than Ligand B (0.625), indicating a marginally more drug-like profile.
7. **DILI:** Ligand B (8.957) has a *much* lower DILI risk than Ligand A (64.56). This is a significant advantage for Ligand B.
8. **BBB:** Both ligands have good BBB penetration (63.358 and 68.748). Not a primary concern for ADRB2 (cardiovascular target), but higher is still slightly better.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and likely indicates poor permeability. This is a concern for both.
10. **Solubility:** Both ligands have negative solubility values, which is also unusual and indicates poor aqueous solubility. This is a concern for both.
11. **hERG:** Ligand B (0.729) has a slightly higher hERG risk than Ligand A (0.367), but both are relatively low.
12. **Cl_mic:** Ligand A (27.109) has a significantly lower microsomal clearance than Ligand B (48.576), suggesting better metabolic stability.
13. **t1/2:** Ligand A (7.165) has a longer in vitro half-life than Ligand B (1.642). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand B (0.453) has a lower P-gp efflux liability than Ligand A (0.321), which is favorable.
15. **Affinity:** Ligand B (-7.1 kcal/mol) has a slightly better binding affinity than Ligand A (-7.0 kcal/mol). While small, this is a relevant difference.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B excels in TPSA and Pgp, and has slightly better affinity. Ligand A has better metabolic stability (Cl_mic) and half-life. However, the significantly lower DILI risk for Ligand B is a major advantage, outweighing the benefits of Ligand A's metabolic stability.
**Overall Assessment:**
While Ligand A has some advantages in metabolic stability and half-life, Ligand B's superior TPSA, lower DILI risk, and slightly better affinity make it the more promising candidate, especially considering the potential for cardiovascular liabilities. The poor Caco-2 and solubility for both ligands would need to be addressed in further optimization, but the core properties of Ligand B are more favorable.
Output:
0
2025-04-17 20:02:46,248 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (341.386 and 346.431 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (62.3) is significantly better than Ligand B (87.46). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is approaching a less desirable range.
3. **logP:** Ligand A (2.62) is within the optimal 1-3 range. Ligand B (0.654) is a bit low, potentially hindering membrane permeability.
4. **HBD:** Both ligands have acceptable HBD counts (1 and 2 respectively), well below the threshold of 5.
5. **HBA:** Both ligands have acceptable HBA counts (3 and 5 respectively), well below the threshold of 10.
6. **QED:** Ligand A (0.93) has a substantially higher QED score than Ligand B (0.585), suggesting a more drug-like profile.
7. **DILI:** Ligand A (53.354) has a higher DILI risk than Ligand B (30.399), but both are still within acceptable limits (<60).
8. **BBB:** Ligand A (81.698) has a much better BBB penetration percentile than Ligand B (32.803). While ADRB2 isn't exclusively a CNS target, some CNS exposure can occur, and higher BBB penetration is generally favorable.
9. **Caco-2:** Ligand A (-4.767) and Ligand B (-5.158) both have negative Caco-2 values, which is unusual. This suggests very poor permeability.
10. **Solubility:** Ligand A (-3.263) has slightly better solubility than Ligand B (-1.26).
11. **hERG:** Both ligands have very low hERG inhibition liability (0.334 and 0.077), which is excellent.
12. **Cl_mic:** Ligand A (20.587) has lower microsomal clearance than Ligand B (26.369), indicating better metabolic stability.
13. **t1/2:** Ligand B (-10.773) has a substantially longer in vitro half-life than Ligand A (-7.17). This is a significant advantage.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.137 and 0.021).
15. **Binding Affinity:** Both ligands have the same binding affinity (-6.5 kcal/mol), so this parameter doesn't differentiate them.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, and metabolic stability are important. Ligand A excels in TPSA and logP, and has better metabolic stability (lower Cl_mic). Ligand B has a significantly longer half-life, which is a strong positive. However, the poor Caco-2 values for both are concerning.
**Overall Assessment:**
Despite Ligand B's longer half-life, Ligand A's superior TPSA, logP, QED, and BBB penetration, coupled with acceptable DILI and hERG profiles, make it the more promising candidate. The better ADME properties of Ligand A outweigh the half-life advantage of Ligand B. The poor Caco-2 values for both are a red flag that would require further investigation, but the other properties of Ligand A are more favorable for initial development.
Output:
1
2025-04-17 20:02:46,248 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (349.341 and 358.398 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (88.91) is slightly higher than Ligand B (66.4). Both are below the 140 A^2 threshold for oral absorption, but Ligand B is significantly better positioned for potential CNS penetration if that were a goal (though less important for a cardiovascular target).
**3. logP:** Both ligands have good logP values (1.578 and 1.206), falling within the optimal 1-3 range. Ligand B is slightly lower, which could slightly improve solubility.
**4. H-Bond Donors:** Ligand A has 2 HBD, and Ligand B has 0. Both are within the acceptable limit of <=5.
**5. H-Bond Acceptors:** Both ligands have 5 HBA, which is acceptable (<=10).
**6. QED:** Both ligands have similar QED values (0.794 and 0.774), indicating good drug-likeness.
**7. DILI Risk:** Ligand A (76.425) has a lower DILI risk than Ligand B (80.031), which is a significant advantage. Lower DILI is always preferred.
**8. BBB Penetration:** Both have reasonable BBB penetration (73.75 and 70.609). As this is a cardiovascular target, BBB penetration is not a primary concern, but higher is generally better.
**9. Caco-2 Permeability:** Ligand A (-5.293) has a worse Caco-2 permeability than Ligand B (-4.625). This suggests Ligand B may have better intestinal absorption.
**10. Aqueous Solubility:** Ligand A (-3.18) has slightly worse aqueous solubility than Ligand B (-2.804).
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.223 and 0.243). This is excellent.
**12. Microsomal Clearance:** Ligand A (3.311) has lower microsomal clearance than Ligand B (18.089), indicating better metabolic stability. This is a significant advantage.
**13. In vitro Half-Life:** Ligand A (17.163) has a much shorter in vitro half-life than Ligand B (-27.935). This is a major drawback for Ligand A.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.028 and 0.047).
**15. Binding Affinity:** Ligand A (-8.3 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.7 kcal/mol). This is a 1.6 kcal/mol difference, which is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), and the general guidelines, Ligand A is the better candidate despite its slightly lower Caco-2 permeability and aqueous solubility, and shorter half-life. The significantly stronger binding affinity (-8.3 vs -6.7 kcal/mol) is a major advantage. The lower DILI risk and better metabolic stability (lower Cl_mic) further support choosing Ligand A. While the half-life is a concern, this can potentially be addressed through prodrug strategies or formulation approaches.
Output:
1
2025-04-17 20:02:46,248 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (339.399 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (66.4) is significantly better than Ligand A (96.01). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (A: 3.519, B: 2.575), falling within the optimal 1-3 range. Ligand B is slightly better.
4. **HBD:** Ligand A has 3 HBD, and Ligand B has 0. Lower is generally preferred for permeability, so Ligand B is better.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 6. Ligand A is slightly better.
6. **QED:** Both ligands have similar QED values (A: 0.776, B: 0.723), indicating good drug-likeness.
7. **DILI:** Ligand B (38.736) has a much lower DILI risk than Ligand A (83.715). This is a significant advantage for Ligand B.
8. **BBB:** Both ligands have reasonable BBB penetration (A: 76.309, B: 75.107), but this isn't a primary concern for a cardiovascular target.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Ligand B (-2.287) has better solubility than Ligand A (-4.813).
11. **hERG:** Both ligands have low hERG inhibition liability (A: 0.203, B: 0.377).
12. **Cl_mic:** Ligand A (29.53) has significantly lower microsomal clearance than Ligand B (63.43), indicating better metabolic stability.
13. **t1/2:** Ligand A (36.892) has a better in vitro half-life than Ligand B (-6.055).
14. **Pgp:** Ligand A (0.053) has lower P-gp efflux liability than Ligand B (0.224).
15. **Affinity:** Ligand B (-6.9 kcal/mol) has a slightly better binding affinity than Ligand A (-6.3 kcal/mol).
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP, TPSA, and affinity. While Ligand A has better Pgp properties, the superior DILI profile and solubility of Ligand B outweigh this. The slightly better affinity of Ligand B is also a significant advantage.
**Overall Assessment:**
Ligand B presents a more favorable balance of properties. Its lower DILI risk, better TPSA, solubility, and slightly better affinity make it the more promising candidate, despite Ligand A's better metabolic stability and Pgp profile.
Output:
0
2025-04-17 20:02:46,248 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (356.438 and 364.515 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (75.71) is higher than Ligand B (63.41). Both are below the 140 A^2 threshold for oral absorption, but B is better.
3. **logP:** Ligand A (1.823) and Ligand B (2.705) are both within the optimal 1-3 range. Ligand B is slightly better.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 4 HBA, while Ligand B has 7. Both are acceptable, but A is preferable.
6. **QED:** Both ligands have good QED scores (0.673 and 0.702), indicating good drug-likeness.
7. **DILI:** Ligand A (12.834) has a significantly lower DILI risk than Ligand B (40.054). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (88.6) has much better BBB penetration potential than Ligand B (55.099). While ADRB2 isn't exclusively a CNS target, some CNS exposure can occur, and higher BBB is generally favorable.
9. **Caco-2:** Ligand A (-4.413) has a better Caco-2 permeability than Ligand B (-5.292).
10. **Solubility:** Both ligands have similar, poor aqueous solubility (-2.259 and -2.298). This is a potential concern for both.
11. **hERG:** Ligand A (0.449) has a lower hERG inhibition liability than Ligand B (0.698). This is a positive for Ligand A.
12. **Cl_mic:** Ligand A (53.8) has a lower microsomal clearance than Ligand B (60.108), indicating better metabolic stability.
13. **t1/2:** Ligand A (-21.019) has a much longer in vitro half-life than Ligand B (13.256). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.018) has much lower P-gp efflux liability than Ligand B (0.524). This is a major advantage for Ligand A.
15. **Binding Affinity:** Ligand B (-6.3) has a slightly better binding affinity than Ligand A (-5.6). This is a 0.7 kcal/mol difference, which is not substantial enough to outweigh the other factors.
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Ligand B has a slightly better logP and affinity, but Ligand A excels in TPSA, Pgp, and has acceptable logP. The substantial advantages of Ligand A in DILI, BBB, Cl_mic, t1/2, and Pgp efflux outweigh the small affinity difference.
**Conclusion:**
Ligand A is the more promising drug candidate due to its superior ADME-Tox profile (lower DILI, better BBB, lower Cl_mic, longer t1/2, lower Pgp efflux) and acceptable binding affinity.
Output:
1
2025-04-17 20:02:46,248 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (351.328 Da and 367.559 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (84.22) is better than Ligand B (47.36). Both are well below the 140 threshold for oral absorption, but the lower TPSA of Ligand B is particularly favorable for GPCRs, potentially aiding receptor binding and reducing off-target interactions.
3. **logP:** Both ligands have acceptable logP values (1.65 and 3.479), falling within the 1-3 range. Ligand B is slightly higher, which could be a minor concern for solubility, but not a deal-breaker.
4. **HBD:** Ligand A has 3 HBD, while Ligand B has 0. Generally, fewer HBDs are preferred for better permeability, so Ligand B has an advantage.
5. **HBA:** Ligand A has 3 HBA, and Ligand B has 5. Both are within the acceptable range of <=10.
6. **QED:** Both ligands have similar QED values (0.692 and 0.67), indicating good drug-likeness.
7. **DILI:** Ligand A (51.609) has a higher DILI risk than Ligand B (19.426). This is a significant advantage for Ligand B, as minimizing liver toxicity is crucial.
8. **BBB:** Both ligands have good BBB penetration (74.06 and 74.835). This isn't a primary concern for ADRB2 (a cardiovascular target), but it's not detrimental.
9. **Caco-2:** Ligand A (-5.004) has a worse Caco-2 permeability than Ligand B (-4.858). While both are negative, indicating low permeability, Ligand B is slightly better.
10. **Solubility:** Ligand A (-2.884) has slightly better solubility than Ligand B (-3.379). Solubility is important, but not a major differentiating factor here.
11. **hERG:** Ligand A (0.842) has a higher hERG inhibition liability than Ligand B (0.636). Lower hERG is preferred, giving Ligand B an advantage.
12. **Cl_mic:** Ligand A (-2.339) has significantly better metabolic stability (lower clearance) than Ligand B (97.085). This is a major advantage for Ligand A, potentially leading to a longer duration of action.
13. **t1/2:** Ligand A (21.382) has a much longer in vitro half-life than Ligand B (5.162). This reinforces the advantage of Ligand A in terms of metabolic stability.
14. **Pgp:** Ligand A (0.112) has lower P-gp efflux than Ligand B (0.351), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand A (-6.7) has a slightly better binding affinity than Ligand B (-4.9). This is a significant advantage, as a 1.8 kcal/mol difference can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand A has a clear advantage in binding affinity, metabolic stability (Cl_mic and t1/2), and P-gp efflux. Ligand B excels in DILI risk and has a lower TPSA and HBD count. The difference in binding affinity is substantial, and the improved metabolic stability of Ligand A is highly desirable. While Ligand B's lower DILI is attractive, the superior potency and pharmacokinetic profile of Ligand A are more critical for a successful drug candidate, especially considering the cardiovascular target.
Output:
1
2025-04-17 20:02:46,248 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (340.47 and 340.38 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (46.34) is significantly better than Ligand B (75.69). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold, while B is approaching it.
3. **logP:** Ligand A (4.375) is higher than Ligand B (2.749). While both are within the acceptable range (1-3 is optimal), Ligand A is pushing the upper limit. This could lead to solubility issues, but for a GPCR, some lipophilicity is helpful for membrane interactions.
4. **HBD:** Ligand A (0) is better than Ligand B (1). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (3) is better than Ligand B (4). Lower HBA also favors permeability.
6. **QED:** Ligand A (0.833) is significantly better than Ligand B (0.671), indicating a more drug-like profile.
7. **DILI:** Ligand A (34.82) is much better than Ligand B (64.521). This is a critical advantage for Ligand A, as lower DILI risk is highly desirable.
8. **BBB:** Ligand A (88.872) is better than Ligand B (45.715). While not a CNS target, some BBB penetration can indicate favorable permeability characteristics.
9. **Caco-2:** Both are negative, which is unusual and suggests poor permeability. However, the scale is not specified, so it is hard to interpret.
10. **Solubility:** Ligand A (-5.23) is better than Ligand B (-3.221). Higher solubility is preferred.
11. **hERG:** Ligand A (0.854) is better than Ligand B (0.236). Lower hERG inhibition is crucial to avoid cardiotoxicity, making Ligand A more favorable.
12. **Cl_mic:** Ligand A (102.548) is higher than Ligand B (42.281), meaning faster clearance and lower metabolic stability. This is a drawback for Ligand A.
13. **t1/2:** Ligand B (27.368) is significantly better than Ligand A (-16.562). Longer half-life is generally preferred.
14. **Pgp:** Ligand A (0.796) is better than Ligand B (0.131). Lower P-gp efflux is desirable for better bioavailability.
15. **Binding Affinity:** Ligand B (-6.3) is slightly better than Ligand A (-5.6). This is a 1.5 kcal/mol difference, which is significant.
**Overall Assessment:**
Ligand A has several significant advantages: much lower DILI risk, better QED, better solubility, lower hERG inhibition, and better Pgp efflux. While Ligand A has a higher logP and faster clearance, the safety profile advantages are substantial for a cardiovascular target. Ligand B has a slightly better binding affinity and half-life, but the DILI risk is concerning. Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity), Ligand A strikes a better balance, particularly regarding safety and absorption properties.
Output:
1
2025-04-17 20:02:46,249 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.434 and 382.595 Da) are within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (71.34) is better than Ligand B (41.57). Both are below 140, but Ligand B is significantly lower, which could be beneficial for permeability.
3. **logP:** Both ligands have good logP values (3.058 and 3.694), falling within the optimal 1-3 range. Ligand B is slightly higher, which might slightly hinder solubility.
4. **HBD:** Ligand A has 2 HBD, and Ligand B has 1. Both are within the acceptable limit of 5. Ligand B is slightly preferred here.
5. **HBA:** Ligand A has 3 HBA, and Ligand B has 5. Both are below 10, but Ligand B is closer to the upper limit.
6. **QED:** Ligand A (0.794) has a slightly better QED score than Ligand B (0.696), indicating a more drug-like profile.
7. **DILI:** Ligand A (35.014) has a higher DILI risk than Ligand B (23.032). This is a significant advantage for Ligand B.
8. **BBB:** Both ligands have high BBB penetration (83.404 and 80.884). No significant difference.
9. **Caco-2:** Ligand A (-4.655) has a much better Caco-2 permeability than Ligand B (-5.37). This suggests better absorption for Ligand A.
10. **Solubility:** Ligand A (-4.092) has slightly better solubility than Ligand B (-3.984).
11. **hERG:** Ligand A (0.485) has a lower hERG inhibition liability than Ligand B (0.872), which is a crucial safety advantage.
12. **Cl_mic:** Ligand B (75.674) has a higher microsomal clearance than Ligand A (41.293), indicating faster metabolism and potentially lower *in vivo* exposure. Ligand A is preferred.
13. **t1/2:** Ligand A (45.527) has a longer in vitro half-life than Ligand B (32.054), which is desirable.
14. **Pgp:** Ligand A (0.191) has lower P-gp efflux liability than Ligand B (0.647), indicating better bioavailability and potential CNS exposure.
15. **Binding Affinity:** Ligand B (-7.9) has a slightly better binding affinity than Ligand A (-7.0), a 0.9 kcal/mol difference. This is a substantial advantage.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand B excels in affinity, has a good logP, and acceptable TPSA. Ligand A has better Pgp efflux and a better safety profile (DILI, hERG). The affinity difference is significant enough to outweigh the slightly worse ADME properties of Ligand B.
**Conclusion:**
While Ligand A has several advantages in ADME and safety, the significantly stronger binding affinity of Ligand B (-7.9 vs -7.0 kcal/mol) is a crucial factor for GPCR targets. A 0.9 kcal/mol difference is substantial and can often overcome minor ADME drawbacks.
Output:
0
2025-04-17 20:02:46,249 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (376.523 and 367.475 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (98.82) is better than Ligand B (119.23). For a GPCR, keeping TPSA under 140 is good for absorption, and lower is generally preferred.
**3. logP:** Ligand A (-0.382) is slightly lower than the optimal 1-3 range, potentially impacting permeability. Ligand B (1.797) is within the optimal range. This favors Ligand B.
**4. H-Bond Donors:** Ligand A (2) is preferable to Ligand B (3). Lower HBD generally improves permeability.
**5. H-Bond Acceptors:** Ligand A (5) is preferable to Ligand B (7). Lower HBA generally improves permeability.
**6. QED:** Both ligands have similar, acceptable QED values (0.602 and 0.618).
**7. DILI:** Ligand A (33.695) has a significantly lower DILI risk than Ligand B (88.484). This is a major advantage for Ligand A.
**8. BBB:** Ligand B (63.746) has a better BBB penetration score than Ligand A (36.952). While ADRB2 is cardiovascular, some CNS off-target effects are always a consideration, and some degree of BBB penetration can be useful for understanding these.
**9. Caco-2 Permeability:** Both ligands have similar negative Caco-2 values (-5.541 and -5.048), suggesting poor permeability.
**10. Aqueous Solubility:** Ligand A (-1.35) is better than Ligand B (-3.776). Higher solubility is always desirable.
**11. hERG Inhibition:** Ligand A (0.081) has a much lower hERG inhibition risk than Ligand B (0.774). This is a critical safety parameter, and Ligand A is significantly better.
**12. Microsomal Clearance:** Ligand B (70.406) has higher microsomal clearance than Ligand A (31.119), indicating faster metabolism and potentially lower *in vivo* exposure. This favors Ligand A.
**13. In vitro Half-Life:** Ligand A (-17.572) has a longer half-life than Ligand B (-4.113).
**14. P-gp Efflux:** Ligand A (0.004) has a much lower P-gp efflux liability than Ligand B (0.099). This is favorable for oral bioavailability.
**15. Binding Affinity:** Ligand A (-5.7) has a better binding affinity than Ligand B (-3.3). The difference in affinity is substantial (2.4 kcal/mol), and this is a key driver in the decision.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand A is the stronger candidate. While Ligand B has a better logP and BBB, Ligand A excels in crucial areas like DILI risk, hERG inhibition, metabolic stability (lower Cl_mic, longer t1/2), P-gp efflux, solubility, and, most importantly, binding affinity. The significant advantage in binding affinity outweighs the slight drawbacks in logP and BBB. The lower DILI and hERG risks are also very important for a cardiovascular drug.
Output:
1
2025-04-17 20:02:46,249 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [349.391, 136.28 , 1.566, 3. , 7. , 0.72 , 68.864, 56.65 , -5.283, -2.919, 0.32 , 20.308, -2.635, 0.018, -7. ]**
**Ligand B: [369.447, 127.51 , -0.215, 2. , 7. , 0.714, 51.842, 65.568, -5.358, -3.337, 0.17 , 16.57 , -7.198, 0.029, -6.9 ]**
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (349.391) is slightly lower than Ligand B (369.447), which is generally favorable.
2. **TPSA:** Both are reasonably good, below the 140 A^2 threshold for oral absorption. Ligand B (127.51) is slightly better than Ligand A (136.28).
3. **logP:** Ligand A (1.566) is within the optimal range (1-3). Ligand B (-0.215) is below 1, which could indicate poor membrane permeability. This is a significant drawback.
4. **H-Bond Donors:** Both have acceptable numbers (Ligand A: 3, Ligand B: 2).
5. **H-Bond Acceptors:** Both have similar numbers (Ligand A: 7, Ligand B: 7), within the acceptable range.
6. **QED:** Both have good QED values (Ligand A: 0.72, Ligand B: 0.714), indicating drug-likeness.
7. **DILI:** Ligand A (68.864) has a higher DILI risk than Ligand B (51.842), but both are within a tolerable range.
8. **BBB:** Ligand B (65.568) has a better BBB penetration percentile than Ligand A (56.65). While ADRB2 isn't *primarily* a CNS target, some CNS exposure can occur, and higher BBB is generally preferable.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. Ligand A (-5.283) is slightly better than Ligand B (-5.358).
10. **Aqueous Solubility:** Both have negative solubility values, indicating poor solubility. Ligand A (-2.919) is slightly better than Ligand B (-3.337).
11. **hERG:** Both have very low hERG inhibition risk (Ligand A: 0.32, Ligand B: 0.17).
12. **Cl_mic:** Ligand B (16.57) has lower microsomal clearance than Ligand A (20.308), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-7.198) has a slightly longer in vitro half-life than Ligand A (-2.635).
14. **Pgp:** Both have very low Pgp efflux liability (Ligand A: 0.018, Ligand B: 0.029).
15. **Binding Affinity:** Ligand A (-7.0) and Ligand B (-6.9) have very similar binding affinities. The difference is negligible.
**Overall Assessment:**
The most significant difference is the logP value. Ligand B's logP is substantially lower than 1, raising concerns about its ability to cross cell membranes and achieve adequate bioavailability. While Ligand B has slightly better BBB penetration and metabolic stability, these benefits are outweighed by the potential permeability issues. Ligand A, despite a slightly higher DILI risk, has a more favorable logP value and slightly better Caco-2 and solubility. Given the importance of permeability for a GPCR target like ADRB2, Ligand A is the more promising candidate.
Output:
1
2025-04-17 20:02:46,249 - INFO - Batch 155 complete. Total preferences: 2480
2025-04-17 20:02:46,249 - INFO - Processing batch 156/512...
2025-04-17 20:03:35,407 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (336.355 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are good, below the 140 A^2 threshold for oral absorption. Ligand B (87.3) is better than Ligand A (101.8), and closer to the 90 A^2 threshold for CNS penetration, though BBB is more important.
3. **logP:** Both ligands have optimal logP values (between 1 and 3). Ligand B (1.203) is slightly lower than Ligand A (2.088), potentially indicating better solubility but possibly lower membrane permeability.
4. **HBD:** Both are acceptable (<=5). Ligand A has 2, and Ligand B has 3.
5. **HBA:** Both are acceptable (<=10). Ligand A has 6, and Ligand B has 4.
6. **QED:** Both are above 0.5, indicating good drug-likeness, but Ligand A (0.759) is better than Ligand B (0.605).
7. **DILI:** Ligand B (43.389%) is significantly better than Ligand A (90.733%), indicating a much lower risk of drug-induced liver injury. This is a major advantage for Ligand B.
8. **BBB:** Ligand B (72.16%) shows better BBB penetration than Ligand A (40.403%). While ADRB2 isn't exclusively a CNS target, some peripheral effects are mediated by CNS pathways, and better BBB penetration can be beneficial.
9. **Caco-2:** Both have negative values, indicating good permeability. Ligand A (-5.205) is slightly better than Ligand B (-5.063).
10. **Solubility:** Both have negative values, indicating good solubility. Ligand B (-2.291) is slightly better than Ligand A (-3.401).
11. **hERG:** Both have low hERG inhibition liability, with Ligand B (0.278%) being slightly better than Ligand A (0.349%).
12. **Cl_mic:** Ligand B (24.906) has lower microsomal clearance than Ligand A (16.743), suggesting better metabolic stability.
13. **t1/2:** Ligand A (32.863) has a longer in vitro half-life than Ligand B (-1.625). This is a significant advantage for Ligand A, potentially allowing for less frequent dosing.
14. **Pgp:** Both have very low P-gp efflux liability, with Ligand B (0.027) being slightly better than Ligand A (0.062).
15. **Binding Affinity:** Both ligands have the same binding affinity (-6.4 kcal/mol).
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B has a slightly better logP and TPSA, and better Pgp efflux. The binding affinity is the same. However, the *significant* advantage of Ligand B in terms of DILI risk and its better BBB penetration outweigh the longer half-life of Ligand A. Metabolic stability (Cl_mic) is also better for Ligand B.
**Conclusion:**
Considering the balance of properties and the priorities for a GPCR target, Ligand B is the more promising drug candidate. The lower DILI risk and improved BBB penetration are critical advantages.
Output:
0
2025-04-17 20:03:35,407 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands (374.869 Da and 387.487 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (99.77) is better than Ligand B (122.31). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally favors absorption.
3. **logP:** Ligand A (0.979) is slightly better than Ligand B (0.174). Both are a bit low, potentially hindering permeability, but Ligand A is closer to the optimal 1-3 range.
4. **HBD:** Both have 3 HBD, which is acceptable.
5. **HBA:** Ligand A has 4 HBA, while Ligand B has 8. Ligand A is preferable here, as higher HBA can sometimes reduce permeability.
6. **QED:** Ligand B (0.531) has a slightly better QED score than Ligand A (0.435), indicating a marginally more drug-like profile.
7. **DILI:** Ligand A (27.181) has a significantly lower DILI risk than Ligand B (79.798). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (70.376) has a better BBB penetration score than Ligand B (61.691). While not a CNS target, some level of BBB penetration can influence off-target effects and distribution.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual. I'll assume these are percentile scores and interpret negative values as very poor permeability.
10. **Solubility:** Both have negative solubility values, which is also unusual. I'll assume these are percentile scores and interpret negative values as very poor solubility.
11. **hERG:** Ligand A (0.254) has a lower hERG inhibition liability than Ligand B (0.343), indicating a lower risk of cardiotoxicity. This is crucial for a cardiovascular target.
12. **Cl_mic:** Ligand A (-11.567) has a *much* lower (and therefore better) microsomal clearance than Ligand B (54.187). This suggests significantly improved metabolic stability for Ligand A.
13. **t1/2:** Ligand A (-16.699) has a longer in vitro half-life than Ligand B (6.018). This is a positive for Ligand A, suggesting less frequent dosing potential.
14. **Pgp:** Ligand A (0.005) has a much lower P-gp efflux liability than Ligand B (0.023). This is favorable for bioavailability.
15. **Affinity:** Ligand B (-7.6 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.6 kcal/mol). This is a substantial advantage for Ligand B.
**GPCR-specific priorities:** For ADRB2 (a cardiovascular GPCR), affinity, logP, TPSA, and Pgp are key. Ligand B wins on affinity, but Ligand A is better on logP, TPSA, and Pgp. The DILI and metabolic stability (Cl_mic, t1/2) are also critical. Ligand A is *much* better on these fronts.
**Overall Assessment:**
While Ligand B has a significantly better binding affinity, the substantial advantages of Ligand A in terms of DILI risk, metabolic stability (Cl_mic and t1/2), P-gp efflux, and acceptable TPSA and logP outweigh the affinity difference. The poor Caco-2 and solubility for both are concerning, but the metabolic and toxicity profiles of Ligand A are far superior. The stronger binding of Ligand B doesn't necessarily translate to a better *drug* if it's quickly metabolized and potentially toxic.
Output:
1
2025-04-17 20:03:35,407 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (361.47 & 346.45 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand B (40.62) is significantly better than Ligand A (70.67). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (3.24 & 3.55), within the optimal 1-3 range. Ligand B is slightly higher, potentially offering better membrane permeability.
4. **HBD:** Ligand A has 2 HBD, Ligand B has 0. Both are acceptable, but fewer HBDs often improve permeability. Ligand B is slightly favored.
5. **HBA:** Ligand A has 4 HBA, Ligand B has 2. Ligand B is again favored for permeability.
6. **QED:** Ligand A (0.882) has a much better QED score than Ligand B (0.584), indicating a more drug-like profile overall. This is a significant advantage for Ligand A.
7. **DILI:** Ligand B (28.5%) has a substantially lower DILI risk than Ligand A (56.9%). This is a crucial advantage for Ligand B, as liver toxicity is a major concern.
8. **BBB:** Both ligands have high BBB penetration (91.7% & 96.2%). While ADRB2 isn't a CNS target, this isn't a negative.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. This is a significant issue for both.
10. **Solubility:** Both ligands have negative solubility values, indicating poor solubility. This is a significant issue for both.
11. **hERG:** Both ligands have low hERG inhibition risk (0.72% & 0.85%). No clear advantage.
12. **Cl_mic:** Ligand B (49.43) has slightly lower microsomal clearance than Ligand A (51.01), suggesting better metabolic stability.
13. **t1/2:** Ligand A (11.19) has a longer in vitro half-life than Ligand B (7.72). This is a positive for Ligand A.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.30% & 0.57%). No clear advantage.
15. **Binding Affinity:** Ligand B (-4.9 kcal/mol) has a slightly better binding affinity than Ligand A (-4.4 kcal/mol). While the difference is not huge, it is still a factor.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are important. Ligand B performs better on logP and TPSA, and has a slightly better affinity. However, QED is also important, and Ligand A has a much better QED score. The DILI risk for Ligand B is significantly lower, which is a critical factor.
**Overall Assessment:**
While Ligand A has a better QED and half-life, Ligand B's significantly lower DILI risk, better TPSA, and slightly better affinity are more compelling. The poor Caco-2 and solubility for both are concerning, but can be addressed with formulation strategies. The lower DILI risk is a major advantage that outweighs the slightly lower QED.
Output:
0
2025-04-17 20:03:35,407 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [360.527, 49.64, 2.721, 1, 5, 0.861, 17.255, 75.805, -5.208, -1.713, 0.618, 40.372, -0.693, 0.152, -8.1]
**Ligand B:** [348.422, 58.44, 1.615, 0, 4, 0.834, 31.563, 98.255, -4.749, -2.935, 0.346, 39.062, -20.104, 0.067, -7.6]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (348.422) is slightly smaller, which is generally favorable for permeability.
2. **TPSA:** Ligand A (49.64) is better than Ligand B (58.44), both are acceptable, but lower is better for oral absorption.
3. **logP:** Both are within the optimal range (1-3). Ligand A (2.721) is slightly higher, which could be a minor concern for off-target effects, but is still acceptable. Ligand B (1.615) is a bit low, potentially impacting permeability.
4. **HBD:** Ligand A (1) is better than Ligand B (0). Having at least one HBD can improve solubility.
5. **HBA:** Ligand A (5) is slightly higher than Ligand B (4), but both are within the acceptable limit of 10.
6. **QED:** Both are very similar and good (0.861 and 0.834), indicating good drug-like properties.
7. **DILI:** Ligand A (17.255) is significantly better than Ligand B (31.563). Lower DILI risk is a major advantage.
8. **BBB:** Ligand B (98.255) is significantly better than Ligand A (75.805). For a GPCR, especially if CNS effects are possible, higher BBB penetration is desirable.
9. **Caco-2:** Both are negative, indicating good permeability. Ligand A (-5.208) is slightly better.
10. **Solubility:** Both are negative, indicating poor solubility. Ligand B (-2.935) is worse than Ligand A (-1.713).
11. **hERG:** Both are low, indicating low cardiotoxicity risk. Ligand A (0.618) is slightly higher than Ligand B (0.346).
12. **Cl_mic:** Both are similar (40.372 and 39.062), indicating moderate metabolic clearance.
13. **t1/2:** Ligand B (-20.104) has a much longer half-life than Ligand A (-0.693), which is a significant advantage.
14. **Pgp:** Ligand A (0.152) is better than Ligand B (0.067), indicating lower P-gp efflux.
15. **Affinity:** Ligand A (-8.1) has a slightly better binding affinity than Ligand B (-7.6).
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, Pgp, TPSA, and affinity. Ligand A has a better logP and Pgp profile, and a slightly better affinity. Ligand B has a significantly better BBB penetration and half-life. The DILI risk for Ligand A is also much lower.
**Overall Assessment:**
While Ligand B has a better BBB and half-life, the significantly lower DILI risk of Ligand A, combined with its slightly better affinity and Pgp profile, makes it the more promising candidate. The solubility of both is poor, but this can be addressed through formulation. The slightly lower BBB penetration of Ligand A is less critical for a cardiovascular target like ADRB2.
Output:
1
2025-04-17 20:03:35,407 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (345.487) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (29.54) is significantly better than Ligand A (65.2). ADRB2 is not a CNS target, but lower TPSA generally improves absorption.
3. **logP:** Both ligands have good logP values (A: 3.198, B: 3.988), falling within the optimal 1-3 range. Ligand B is slightly higher, which could potentially lead to some off-target effects, but is still acceptable.
4. **HBD:** Ligand A (2) is preferable to Ligand B (0). Having some HBD can improve solubility.
5. **HBA:** Ligand B (3) is preferable to Ligand A (2).
6. **QED:** Ligand A (0.831) is significantly better than Ligand B (0.63), indicating a more drug-like profile.
7. **DILI:** Ligand A (27.104) is much better than Ligand B (39.55), indicating a lower risk of drug-induced liver injury. This is a crucial factor.
8. **BBB:** Ligand B (90.849) is better than Ligand A (77.239), but BBB is not a high priority for ADRB2.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.796) is slightly better than Ligand B (-4.669).
10. **Solubility:** Both ligands have negative solubility values, which is also unusual and suggests poor solubility. Ligand A (-4.311) is slightly better than Ligand B (-4.479).
11. **hERG:** Both ligands have low hERG inhibition risk (A: 0.455, B: 0.717). Ligand A is preferable.
12. **Cl_mic:** Ligand A (61.067) is better than Ligand B (95.583), indicating better metabolic stability.
13. **t1/2:** Ligand A (-22.867) is better than Ligand B (10.076), indicating a longer half-life.
14. **Pgp:** Ligand A (0.169) is better than Ligand B (0.495), indicating lower P-gp efflux.
15. **Affinity:** Both ligands have very similar binding affinities (A: -5.7 kcal/mol, B: -4.7 kcal/mol). Ligand A has a 1 kcal/mol advantage, which is significant.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B in most critical ADME properties (DILI, Cl_mic, t1/2, Pgp, QED) and has a slightly better binding affinity. While Ligand B has a better TPSA and BBB, these are less critical for a non-CNS target like ADRB2. The poor Caco-2 and solubility values are concerning for both, but Ligand A's superior profile in other areas makes it the more promising candidate.
Output:
1
2025-04-17 20:03:35,407 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (330.347 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are below the 140 A^2 threshold for good oral absorption. Ligand A (87.9) is slightly higher than Ligand B (84.42), but both are acceptable.
3. **logP:** Ligand A (3.276) is optimal, while Ligand B (1.989) is at the lower end of the optimal range. For a GPCR, a slightly higher logP is generally preferred for membrane permeability and receptor engagement.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 5 HBA, while Ligand B has 7. Both are acceptable, but lower is generally better for permeability.
6. **QED:** Ligand A (0.793) has a better QED score than Ligand B (0.671), indicating a more drug-like profile.
7. **DILI:** Ligand A (98.876) has a significantly higher DILI risk than Ligand B (67.197). This is a major concern.
8. **BBB:** Ligand B (53.005) has a slightly better BBB penetration percentile than Ligand A (48.042), but neither is particularly high. Since ADRB2 is not a primary CNS target, this is less critical.
9. **Caco-2:** Ligand A (-4.888) has a better Caco-2 permeability than Ligand B (-5.117), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-5.748) has better aqueous solubility than Ligand B (-1.614).
11. **hERG:** Both ligands have low hERG inhibition liability (0.746 and 0.429 respectively).
12. **Cl_mic:** Both have similar microsomal clearance values (52.373 and 55.091 mL/min/kg).
13. **t1/2:** Ligand B (28.492 hours) has a significantly longer in vitro half-life than Ligand A (14.193 hours). This is a significant advantage.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.322 and 0.232 respectively).
15. **Binding Affinity:** Both ligands have very similar binding affinities (-5.9 and -5.7 kcal/mol). The difference is not substantial enough to be a deciding factor.
**GPCR-Specific Priorities & Overall Assessment:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are key. While both ligands have acceptable TPSA and similar affinity, Ligand A has a better logP. However, the extremely high DILI risk associated with Ligand A is a major drawback. The longer half-life of Ligand B is also a significant advantage. While Ligand A has slightly better solubility and Caco-2 permeability, the DILI risk outweighs these benefits.
**Conclusion:**
Considering the balance of properties, especially the critical DILI risk, Ligand B is the more promising drug candidate.
Output:
0
2025-04-17 20:03:35,408 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (353.379 and 346.362 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (97.55) is significantly better than Ligand A (122.75). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (1.911) is optimal, while Ligand A (-1.419) is too low, potentially hindering membrane permeability. This is a significant advantage for Ligand B.
4. **HBD:** Both ligands have 2 HBD, which is within the acceptable limit of 5.
5. **HBA:** Ligand A has 7 HBA, while Ligand B has 5. Both are acceptable (<=10), but Ligand B is slightly better.
6. **QED:** Ligand B (0.862) is substantially better than Ligand A (0.413), indicating a more drug-like profile.
7. **DILI:** Ligand A (53.47) has a lower DILI risk than Ligand B (83.211). This is a positive for Ligand A, but the difference isn't massive.
8. **BBB:** Ligand A (57.619) has slightly better BBB penetration than Ligand B (49.05), but this is not a primary concern for a cardiovascular target.
9. **Caco-2:** Ligand A (-5.125) and Ligand B (-4.721) are both negative, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
10. **Solubility:** Ligand A (-0.671) has slightly better solubility than Ligand B (-2.99), which is a small advantage.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.039 and 0.408 respectively).
12. **Cl_mic:** Ligand B (22.874) has lower microsomal clearance than Ligand A (28.312), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-37.696) has a significantly longer in vitro half-life than Ligand B (-4.495). This is a substantial advantage for Ligand A.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.003 and 0.024 respectively).
15. **Binding Affinity:** Both ligands have comparable binding affinities (-6.6 and -6.0 kcal/mol). The difference of 0.6 kcal/mol is not enough to outweigh other factors.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand B excels in logP and has a better TPSA. While the affinity difference is small, the superior ADME properties of Ligand B (QED, Cl_mic) are more compelling. The longer half-life of Ligand A is attractive, but the poor logP is a significant concern.
**Conclusion:**
Considering the balance of properties, Ligand B is the more promising drug candidate. Its optimal logP, better QED, and lower clearance outweigh the slightly higher DILI risk and shorter half-life.
Output:
0
2025-04-17 20:03:35,408 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (351.447 and 363.498 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (87.74) is better than Ligand B (29.54). Lower TPSA generally favors better permeability, crucial for GPCRs.
3. **logP:** Ligand B (3.971) is higher than Ligand A (0.433). While 0.433 is quite low and could hinder membrane permeability, 3.971 is approaching the upper limit where solubility issues might arise.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (0). Both are acceptable, but lower is generally preferred.
5. **HBA:** Ligand A (4) is higher than Ligand B (3). Both are within the acceptable range.
6. **QED:** Ligand A (0.752) is better than Ligand B (0.491), indicating a more drug-like profile.
7. **DILI:** Ligand A (19.349) is significantly better than Ligand B (31.136), indicating a much lower risk of drug-induced liver injury. This is a critical factor.
8. **BBB:** Ligand B (90.074) is much better than Ligand A (52.695). While ADRB2 isn't exclusively a CNS target, some CNS penetration can be beneficial for understanding off-target effects and potential side effects.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-5.162) is slightly better than Ligand B (-5.02).
10. **Solubility:** Ligand A (-2.08) is better than Ligand B (-4.264). Solubility is important for formulation and bioavailability.
11. **hERG:** Ligand A (0.164) is better than Ligand B (0.918), indicating a lower risk of cardiotoxicity. This is a crucial safety parameter, especially for a cardiovascular target.
12. **Cl_mic:** Ligand A (-10.628) is significantly better than Ligand B (85.557), suggesting much greater metabolic stability.
13. **t1/2:** Ligand B (10.33) is better than Ligand A (7.134). A longer half-life is generally desirable.
14. **Pgp:** Ligand A (0.013) is much better than Ligand B (0.667), indicating lower P-glycoprotein efflux.
15. **Affinity:** Ligand B (-6.8) is slightly better than Ligand A (-6.2). While a difference of 0.6 kcal/mol is noticeable, it's not a massive advantage.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity) and general drug-like properties, Ligand A is the stronger candidate. While Ligand B has better BBB penetration and slightly better affinity, Ligand A excels in critical areas like DILI risk, hERG inhibition, metabolic stability (Cl_mic), Pgp efflux, solubility, and QED. The low logP of Ligand A is a concern, but its superior safety profile and drug-like properties outweigh this drawback. The slightly better affinity of Ligand B is not enough to compensate for the significant liabilities.
Output:
1
2025-04-17 20:03:35,408 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (352.479) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are below the 140 A^2 threshold for good oral absorption. Ligand A (64.17) is slightly higher than Ligand B (61.44), but both are acceptable.
3. **logP:** Ligand A (0.112) is quite low, potentially hindering membrane permeability. Ligand B (1.729) is within the optimal range (1-3). This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (0) is ideal. Ligand B (2) is still acceptable, but less optimal.
5. **HBA:** Both ligands have 4 HBA, which is within the acceptable limit of 10.
6. **QED:** Both ligands have good QED scores (A: 0.659, B: 0.687), indicating good drug-like properties.
7. **DILI:** Ligand A (7.716) has a very low DILI risk, which is excellent. Ligand B (36.487) is higher, but still within a reasonable range.
8. **BBB:** Both ligands have good BBB penetration (A: 79.411, B: 70.997). This is important for GPCRs, although ADRB2 isn't necessarily a CNS target.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Ligand A (-0.318) has poor solubility, while Ligand B (-2.926) is even worse. This is a concern for both, but more so for Ligand B.
11. **hERG:** Ligand A (0.221) has a very low hERG risk, which is excellent. Ligand B (0.53) is slightly higher, but still relatively low.
12. **Cl_mic:** Ligand A (0.036) has very low microsomal clearance, indicating high metabolic stability. Ligand B (61.509) has high clearance, suggesting rapid metabolism. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (-28.879) has a very short half-life, which is a major drawback. Ligand B (23.467) has a longer half-life, which is more desirable.
14. **Pgp:** Ligand A (0.007) has very low P-gp efflux, which is favorable. Ligand B (0.099) is slightly higher, but still low.
15. **Binding Affinity:** Ligand B (-7.0) has a slightly better binding affinity than Ligand A (-6.3). This is a 0.7 kcal/mol difference, which is substantial.
**Overall Assessment:**
While Ligand A has excellent DILI and metabolic stability, its poor solubility, extremely short half-life, and very low logP are major concerns. The low logP is particularly problematic for a GPCR ligand, as it will likely struggle to cross cell membranes to reach the receptor. Ligand B, while having a higher DILI risk and faster metabolism, has a much better logP, a longer half-life, and a slightly improved binding affinity. The binding affinity difference is significant enough to potentially outweigh the ADME drawbacks.
Given the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), and considering the trade-offs, I believe Ligand B is the more promising candidate. Further optimization could address the DILI and metabolic stability issues.
Output:
0
2025-04-17 20:03:35,408 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (335.5) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (36.95) is significantly better than Ligand B (75.44). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand B's TPSA is quite high.
3. **logP:** Both ligands have good logP values (A: 3.99, B: 2.304) within the optimal 1-3 range. Ligand A is slightly higher, which could potentially lead to off-target effects, but is still acceptable.
4. **HBD/HBA:** Ligand A (HBD=2, HBA=3) and Ligand B (HBD=1, HBA=4) are both reasonable.
5. **QED:** Both ligands have similar QED values (A: 0.887, B: 0.824), indicating good drug-likeness.
6. **DILI:** Ligand A (12.214) has a much lower DILI risk than Ligand B (55.874). This is a significant advantage for Ligand A.
7. **BBB:** Ligand B (91.392) has a higher BBB penetration percentile than Ligand A (78.364). However, as ADRB2 is a cardiovascular target, BBB penetration is not a major priority.
8. **Caco-2:** Ligand A (-5.41) and Ligand B (-4.735) are both negative, which is unusual and suggests poor permeability. However, the values are close, so this isn't a major differentiator.
9. **Solubility:** Ligand A (-2.261) is slightly better than Ligand B (-2.935), but both are poor. Solubility could be a formulation challenge for both.
10. **hERG:** Ligand A (0.824) has a slightly higher hERG risk than Ligand B (0.174). This is a concern for Ligand A, but not overwhelmingly so.
11. **Cl_mic:** Ligand A (-11.728) has a much lower (better) microsomal clearance than Ligand B (27.467), indicating greater metabolic stability.
12. **t1/2:** Ligand A (31.07) has a significantly longer in vitro half-life than Ligand B (-47.426). This is a major advantage for Ligand A.
13. **Pgp:** Ligand A (0.28) has a lower Pgp efflux liability than Ligand B (0.109). Lower Pgp is generally preferred.
14. **Binding Affinity:** Ligand A (-7.6) has a slightly better binding affinity than Ligand B (-7.3). While the difference is small, it's still a positive for Ligand A.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A performs better on TPSA, Pgp, and has slightly better affinity. While BBB isn't a priority, Ligand B's higher value doesn't outweigh the other factors.
**Overall Assessment:**
Ligand A is the stronger candidate. It has a significantly lower DILI risk, better metabolic stability (lower Cl_mic and longer t1/2), lower Pgp efflux, slightly better affinity, and a much more favorable TPSA. While Ligand A has a slightly higher hERG risk and lower solubility, these are less critical concerns compared to the advantages it offers in terms of safety, pharmacokinetics, and potency.
Output:
1
2025-04-17 20:03:35,408 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (367.45 and 357.523 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (90.98) is better than Ligand B (37.61). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower TPSA generally correlates with better permeability.
**3. logP:** Ligand B (3.966) is higher than Ligand A (1.164). While both are within the acceptable range, Ligand B is approaching the upper limit where solubility issues might arise. Ligand A is closer to optimal.
**4. H-Bond Donors:** Ligand A (2) is slightly better than Ligand B (0). A small number of HBDs is generally preferred for permeability.
**5. H-Bond Acceptors:** Ligand A (5) is slightly higher than Ligand B (4). Both are within the acceptable range.
**6. QED:** Ligand B (0.671) is slightly better than Ligand A (0.558), suggesting a marginally more drug-like profile.
**7. DILI Risk:** Ligand B (32.493) has a significantly lower DILI risk than Ligand A (66.421). This is a major advantage for Ligand B.
**8. BBB Penetration:** Ligand B (89.57) shows better BBB penetration than Ligand A (78.558). While this isn't a primary concern for a cardiovascular target, it's a positive attribute.
**9. Caco-2 Permeability:** Ligand A (-5.85) has better Caco-2 permeability than Ligand B (-5.091).
**10. Aqueous Solubility:** Ligand A (-3.077) has better aqueous solubility than Ligand B (-4.04). This is important for formulation and bioavailability.
**11. hERG Inhibition:** Ligand A (0.386) has a lower hERG inhibition risk than Ligand B (0.94). This is a significant advantage for Ligand A.
**12. Microsomal Clearance:** Ligand B (100.738) has much higher microsomal clearance than Ligand A (20.47). This indicates Ligand B will be rapidly metabolized, potentially requiring higher doses or frequent administration.
**13. In vitro Half-Life:** Ligand A (-26.678) has a much longer in vitro half-life than Ligand B (13.519). This is a substantial advantage for Ligand A.
**14. P-gp Efflux:** Ligand A (0.137) has lower P-gp efflux than Ligand B (0.855). Lower efflux is generally desirable for improved bioavailability.
**15. Binding Affinity:** Both ligands have similar binding affinities (-6.5 and -5.7 kcal/mol). Ligand A has a slightly better affinity, but the difference is not substantial enough to outweigh other factors.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity) and the general drug-like properties, **Ligand A emerges as the more promising candidate**. While Ligand B has a lower DILI risk and better BBB penetration, its high microsomal clearance, shorter half-life, and higher P-gp efflux are significant drawbacks. Ligand A's superior metabolic stability (lower Cl_mic, longer t1/2), better solubility, and lower hERG risk make it a more balanced and potentially viable drug candidate. The slight advantage in binding affinity further supports this conclusion.
Output:
1
2025-04-17 20:03:35,408 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [353.419, 102.17 , -0.493, 1. , 5. , 0.593, 22.993, 84.335, -5.097, -1.603, 0.192, 22.596, 7.327, 0.013, -7.4 ]
**Ligand B:** [363.929, 29.54 , 4.696, 0. , 2. , 0.67 , 9.771, 88.29 , -4.431, -5.205, 0.871, 113.537, 31.048, 0.754, -7.2 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). A (353.4) is slightly better.
2. **TPSA:** A (102.17) is higher than ideal for good oral absorption (<140), but still acceptable. B (29.54) is excellent, suggesting good permeability.
3. **logP:** A (-0.493) is a bit low, potentially hindering permeation. B (4.696) is high, potentially causing solubility and off-target issues.
4. **HBD:** A (1) is good. B (0) is also good.
5. **HBA:** A (5) is good. B (2) is excellent.
6. **QED:** Both are good (A: 0.593, B: 0.67), indicating drug-like properties. B is slightly better.
7. **DILI:** A (22.993) is very good (low risk). B (9.771) is also very good.
8. **BBB:** Both are good (A: 84.335, B: 88.29). B is slightly better.
9. **Caco-2:** A (-5.097) is concerningly low, indicating poor absorption. B (-4.431) is also low, but better than A.
10. **Solubility:** A (-1.603) is poor. B (-5.205) is very poor.
11. **hERG:** A (0.192) is very low risk. B (0.871) is higher, but still relatively low.
12. **Cl_mic:** A (22.596) is better (lower clearance = more stable) than B (113.537).
13. **t1/2:** B (31.048) has a significantly longer half-life than A (7.327), which is a major advantage.
14. **Pgp:** A (0.013) is very low efflux, excellent. B (0.754) is higher, but not critically high.
15. **Affinity:** A (-7.4) is slightly better than B (-7.2), but the difference is small.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, BBB, and affinity.
* **LogP:** B is too high.
* **TPSA:** B is excellent, A is acceptable.
* **Pgp:** A is excellent, B is acceptable.
* **BBB:** Both are good, B is slightly better.
* **Affinity:** A is slightly better.
**Overall Assessment:**
Ligand A has a better logP and Pgp profile, and a slightly better binding affinity. However, its Caco-2 permeability and solubility are very poor, which are major drawbacks. Ligand B has a high logP and poor solubility, but has a significantly longer half-life and slightly better BBB penetration. The longer half-life is a significant advantage for a GPCR target. Considering the balance, the longer half-life of Ligand B outweighs the slightly higher logP, especially given that optimization could address the logP. The poor absorption of Ligand A is a more difficult property to improve.
Therefore, I prefer Ligand B.
0
2025-04-17 20:03:35,408 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (348.487) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (58.64) is significantly better than Ligand B (96.52). For a GPCR, keeping TPSA low is beneficial for permeability and receptor engagement. Ligand B is pushing the upper limit for good oral absorption.
3. **logP:** Both ligands have acceptable logP values (A: 2.348, B: 2.585), falling within the 1-3 range.
4. **HBD/HBA:** Ligand A (HBD=1, HBA=3) is preferable to Ligand B (HBD=2, HBA=5) as it has fewer hydrogen bond donors and acceptors, which generally improves membrane permeability.
5. **QED:** Ligand B (0.77) has a better QED score than Ligand A (0.541), suggesting a more drug-like profile overall.
6. **DILI:** Ligand A (10.896) has a much lower DILI risk than Ligand B (47.46), a significant advantage.
7. **BBB:** Ligand A (70.609) has a slightly better BBB penetration score than Ligand B (65.529). While ADRB2 isn't exclusively a CNS target, some CNS exposure can occur, and higher BBB is generally preferable.
8. **Caco-2:** Ligand A (-4.414) is better than Ligand B (-5.125), indicating better intestinal absorption.
9. **Solubility:** Both ligands have similar, poor aqueous solubility (-2.9 and -2.88). This could be a formulation challenge for both.
10. **hERG:** Both ligands have low hERG inhibition risk (0.403 and 0.438).
11. **Cl_mic:** Both ligands have similar microsomal clearance (A: 36.514, B: 35.16).
12. **t1/2:** Ligand B (20.572) has a longer in vitro half-life than Ligand A (-15.402), which is a positive.
13. **Pgp:** Both ligands have low P-gp efflux liability (0.063 and 0.136).
14. **Binding Affinity:** Ligand A (-7.4) has a significantly stronger binding affinity than Ligand B (-6.2). This is a 1.2 kcal/mol difference, which is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand A is the stronger candidate. The significantly better binding affinity (-7.4 kcal/mol vs -6.2 kcal/mol) is a major advantage for a GPCR target. It also has a much lower DILI risk, better TPSA and Caco-2 permeability, and a slightly better BBB score. While Ligand B has a better QED and longer half-life, the affinity and safety advantages of Ligand A are more critical for initial candidate selection. The solubility issues are similar for both and would need to be addressed during formulation.
Output:
1
2025-04-17 20:03:35,408 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.431 and 348.403 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (69.26) is significantly better than Ligand B (102.31). ADRB2 is a cardiovascular target, not CNS, but lower TPSA generally improves absorption. Ligand A is well below the 140 threshold, while B is approaching it.
3. **logP:** Ligand A (2.388) is optimal (1-3). Ligand B (-0.668) is below 1, which could hinder permeation. This is a significant drawback for Ligand B.
4. **HBD:** Both have acceptable HBD counts (1 and 2 respectively), well below the 5 threshold.
5. **HBA:** Both have the same HBA count (5), well below the 10 threshold.
6. **QED:** Both ligands have similar QED values (0.763 and 0.706), indicating good drug-likeness.
7. **DILI:** Ligand A (36.487) has a slightly better DILI score than Ligand B (40.636), but both are acceptable (below 40 is good).
8. **BBB:** Not a major priority for a cardiovascular target. Ligand A (90.539) is higher than Ligand B (45.444), but this is less critical.
9. **Caco-2:** Ligand A (-4.344) is better than Ligand B (-5.187). Higher is better, so A is preferable.
10. **Solubility:** Ligand A (-1.437) is better than Ligand B (-1.833). Higher is better.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.326 and 0.245).
12. **Cl_mic:** Ligand A (17.71) has a lower microsomal clearance than Ligand B (-16.636). Lower is better, indicating greater metabolic stability.
13. **t1/2:** Ligand A (-7.236) has a much better in vitro half-life than Ligand B (16.686).
14. **Pgp:** Both ligands have low Pgp efflux liability (0.042 and 0.005).
15. **Binding Affinity:** Ligand A (-6.4) is weaker than Ligand B (-3.5). However, the difference in affinity is not large enough to overcome the significant ADME deficiencies of Ligand B.
**Overall Assessment:**
Ligand A is clearly superior. While Ligand B has a better binding affinity, Ligand A has significantly better logP, TPSA, Caco-2 permeability, solubility, and metabolic stability (Cl_mic and t1/2). The logP value of Ligand B is a major concern, potentially leading to poor absorption. The better ADME profile of Ligand A outweighs the modest difference in binding affinity.
Output:
1
2025-04-17 20:03:35,408 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (340.43 and 347.46 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (66.4) is significantly better than Ligand B (78.51). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand A is well below the 140 threshold, while B is approaching it.
3. **logP:** Both ligands have good logP values (1.71 and 1.05), falling within the optimal 1-3 range. Ligand B is slightly lower, which could potentially impact permeability, but it's not a major concern.
4. **HBD:** Ligand A has 0 HBD, which is excellent. Ligand B has 2, which is still acceptable but less ideal.
5. **HBA:** Ligand A has 4 HBA, while Ligand B has 3. Both are within the acceptable limit of 10.
6. **QED:** Both ligands have similar QED values (0.837 and 0.798), indicating good drug-likeness.
7. **DILI:** Ligand A (33.5%) has a considerably higher DILI risk than Ligand B (18.2%). This is a significant negative for Ligand A.
8. **BBB:** Ligand A (82.2%) has a much better BBB penetration score than Ligand B (49.2%). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant, and higher BBB is generally favorable.
9. **Caco-2:** Ligand A (-4.789) has a worse Caco-2 permeability than Ligand B (-5.116). Lower (more negative) values indicate lower permeability.
10. **Solubility:** Ligand A (-1.858) has slightly better solubility than Ligand B (-2.071).
11. **hERG:** Both ligands have very low hERG inhibition risk (0.243 and 0.073), which is excellent.
12. **Cl_mic:** Ligand A (18.87 mL/min/kg) has a higher microsomal clearance than Ligand B (3.59 mL/min/kg). This suggests Ligand B is more metabolically stable.
13. **t1/2:** Ligand A (20.18 hours) has a longer in vitro half-life than Ligand B (9.02 hours). This is a positive for Ligand A.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.076 and 0.013), which is favorable.
15. **Binding Affinity:** Ligand A (-7.0 kcal/mol) has a slightly better binding affinity than Ligand B (-6.8 kcal/mol). While the difference is not huge, it is over the 1.5 kcal/mol threshold.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A excels in TPSA and affinity, and has acceptable logP. Ligand B has a much better DILI score and metabolic stability (lower Cl_mic). The slightly better affinity of Ligand A is a significant advantage, but the higher DILI risk is a major concern.
**Overall Assessment:**
Despite the slightly better affinity and BBB penetration of Ligand A, the significantly higher DILI risk and higher metabolic clearance make it a less desirable candidate. Ligand B, while having a slightly lower affinity, presents a much more favorable safety profile (lower DILI) and better metabolic stability. The difference in affinity is not large enough to outweigh these ADME/Tox concerns.
Output:
0
2025-04-17 20:03:35,409 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (354.334 and 362.459 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (98.98) is better than Ligand B (112.92). ADRB2 is a cardiovascular target, so CNS penetration is not a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (1.857 and 1.271), falling within the 1-3 range. Ligand B is slightly lower, which could slightly impact permeability, but is still acceptable.
4. **HBD:** Ligand A (0) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (7) is better than Ligand B (8). Lower HBA is generally favorable for permeability.
6. **QED:** Both ligands have acceptable QED scores (0.437 and 0.576), indicating reasonable drug-likeness. Ligand B is slightly better.
7. **DILI:** Ligand A (52.966) has a significantly lower DILI risk than Ligand B (63.862). This is a crucial advantage.
8. **BBB:** Ligand A (87.088) has a better BBB penetration score than Ligand B (38.193). While not a primary concern for a cardiovascular target, higher BBB is generally not detrimental.
9. **Caco-2:** Ligand A (-4.567) is better than Ligand B (-5.609). Higher Caco-2 values indicate better intestinal absorption.
10. **Solubility:** Ligand A (-3.439) is better than Ligand B (-2.726). Higher solubility is generally desirable.
11. **hERG:** Both ligands have low hERG inhibition risk (0.77 and 0.282). Ligand B is slightly better here.
12. **Cl_mic:** Ligand A (54.908) has lower microsomal clearance than Ligand B (60.053), suggesting better metabolic stability.
13. **t1/2:** Ligand B (19.657) has a significantly longer in vitro half-life than Ligand A (-0.679). This is a major advantage.
14. **Pgp:** Ligand A (0.22) is better than Ligand B (0.021). Lower P-gp efflux is favorable.
15. **Affinity:** Ligand A (-7.3) has a slightly better binding affinity than Ligand B (-6.6). While both are good, the 0.7 kcal/mol difference is noteworthy.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A excels in logP, TPSA, Pgp and affinity. Ligand B has a longer half-life, but the better ADME profile and superior affinity of Ligand A outweigh this benefit. The lower DILI risk for Ligand A is also a significant advantage.
**Conclusion:**
Considering the balance of properties, particularly the superior ADME profile (lower DILI, better solubility, better permeability, better metabolic stability) and slightly better affinity of Ligand A, it is the more promising drug candidate.
Output:
1
2025-04-17 20:03:35,409 - INFO - Batch 156 complete. Total preferences: 2496
2025-04-17 20:03:35,409 - INFO - Processing batch 157/512...
2025-04-17 20:04:21,972 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (362.817 Da) is slightly higher than Ligand B (349.391 Da), but both are acceptable.
2. **TPSA:** Ligand A (105.39) is better than Ligand B (130.67). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (0.955) is within the optimal range (1-3), while Ligand B (-0.655) is slightly below. This is a slight advantage for Ligand A, as lower logP can sometimes indicate poor membrane permeability.
4. **HBD:** Ligand A (2) is preferable to Ligand B (3). Fewer HBDs are generally better for permeability.
5. **HBA:** Ligand A (4) is preferable to Ligand B (7). Similar to HBD, lower HBA is generally better for permeability.
6. **QED:** Ligand A (0.601) is better than Ligand B (0.42). A higher QED indicates a more drug-like profile.
7. **DILI:** Ligand A (46.297) is significantly better than Ligand B (63.552). Lower DILI risk is crucial.
8. **BBB:** Both are around 56-60%, which isn't a major factor for a cardiovascular target.
9. **Caco-2:** Both are negative, indicating poor permeability. However, Ligand A (-5.01) is slightly better than Ligand B (-5.524).
10. **Solubility:** Ligand A (-2.994) is better than Ligand B (-1.331). Better solubility is always a plus.
11. **hERG:** Both are very low risk (0.131 and 0.288).
12. **Cl_mic:** Ligand A (-11.347) is significantly better than Ligand B (-5.328). Lower clearance indicates greater metabolic stability.
13. **t1/2:** Ligand A (-11.995) is better than Ligand B (-4.6). Longer half-life is desirable.
14. **Pgp:** Both are very low efflux (0.019 and 0.008).
15. **Binding Affinity:** Ligand B (-6.8) is slightly better than Ligand A (-6.5). While a 0.3 kcal/mol difference is noticeable, it's not a huge advantage, especially considering the other factors.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A has a better logP and TPSA. Both have low Pgp efflux. Ligand B has slightly better affinity, but the other ADME properties of Ligand A are substantially better.
**Overall Assessment:**
Ligand A demonstrates a significantly more favorable ADME profile, particularly regarding DILI risk, metabolic stability (Cl_mic, t1/2), solubility, and QED. While Ligand B has a slightly better binding affinity, the improvements in other critical parameters with Ligand A outweigh this small difference, making it a more promising drug candidate.
Output:
1
2025-04-17 20:04:21,972 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (342.399 and 350.503 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (78.79) is slightly higher than Ligand B (67.43). Both are below the 140 A^2 threshold for good oral absorption, but B is better.
3. **logP:** Ligand A (1.242) is within the optimal 1-3 range. Ligand B (2.805) is also within range, but closer to the upper limit.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (6) is preferable to Ligand B (3). Lower HBA generally improves permeability.
6. **QED:** Ligand A (0.901) has a significantly better QED score than Ligand B (0.662), indicating a more drug-like profile.
7. **DILI:** Ligand B (15.2) has a much lower DILI risk than Ligand A (56.572). This is a significant advantage for Ligand B.
8. **BBB:** Ligand B (73.013) has a better BBB penetration score than Ligand A (57.193). While ADRB2 isn't exclusively a CNS target, some CNS exposure is possible, and higher BBB is generally beneficial.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.591 and -4.458), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand B (-3.234) has slightly better solubility than Ligand A (-2.033).
11. **hERG:** Both ligands have low hERG inhibition risk (0.42 and 0.362). No significant difference.
12. **Cl_mic:** Ligand A (42.96) has a lower microsomal clearance than Ligand B (61.872), suggesting better metabolic stability.
13. **t1/2:** Ligand A (6.562) has a longer in vitro half-life than Ligand B (-18.95). The negative value for Ligand B is concerning and indicates very rapid metabolism.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.047 and 0.107). No significant difference.
15. **Affinity:** Ligand B (-6.3) has a slightly better binding affinity than Ligand A (-5.8). This is a 0.5 kcal/mol difference, which is notable but not overwhelming.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B has a better logP and TPSA, and slightly better affinity. The BBB score is also better for Ligand B. However, the significantly better QED and longer half-life of Ligand A are important considerations. The DILI risk is a major concern for Ligand A.
**Overall Assessment:**
While Ligand B has a slight edge in affinity and better permeability characteristics (TPSA, logP), the significantly lower DILI risk, better QED, and longer half-life of Ligand A are more compelling. The negative Caco-2 values are concerning for both, but the other advantages of Ligand A outweigh the slightly weaker affinity.
Output:
1
2025-04-17 20:04:21,972 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step Comparison:**
1. **MW:** Both ligands (352.4 and 354.491 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (41.99) is significantly better than Ligand B (78.87). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold, while Ligand B is approaching it.
3. **logP:** Ligand A (4.145) is higher than Ligand B (1.419). While both are within the acceptable range, Ligand A is on the higher end. This *could* lead to solubility issues, but it might also contribute to better membrane permeability. Ligand B's logP is quite low and may hinder permeation.
4. **HBD:** Both have acceptable HBD counts (1 and 2 respectively), well below the 5 threshold.
5. **HBA:** Both have acceptable HBA counts (2 and 4 respectively), well below the 10 threshold.
6. **QED:** Both ligands have similar QED values (0.865 and 0.756), indicating good drug-likeness.
7. **DILI:** Ligand A (44.281) has a higher DILI risk than Ligand B (15.781). This is a significant drawback for Ligand A.
8. **BBB:** Ligand A (95.541) has much higher BBB penetration than Ligand B (77.588). While not a primary concern for a cardiovascular target, it's a neutral benefit for Ligand A.
9. **Caco-2:** Both have negative Caco-2 values (-4.452 and -4.401). These values are unusual and difficult to interpret without further context. However, they suggest poor permeability.
10. **Solubility:** Ligand A (-5.173) has worse solubility than Ligand B (-2.384). This is a concern given Ligand A's higher logP.
11. **hERG:** Ligand A (0.771) has a slightly higher hERG risk than Ligand B (0.273), but both are relatively low.
12. **Cl_mic:** Ligand B (47.337) has a higher microsomal clearance than Ligand A (35.217), suggesting faster metabolism and potentially lower *in vivo* exposure.
13. **t1/2:** Ligand A (20.45) has a much longer half-life than Ligand B (-7.772). This is a major advantage for Ligand A, potentially allowing for less frequent dosing. The negative value for Ligand B is concerning.
14. **Pgp:** Ligand A (0.619) has lower P-gp efflux than Ligand B (0.173), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand A (-7.8) has a significantly stronger binding affinity than Ligand B (-5.8). A 2 kcal/mol difference is substantial and can often outweigh minor ADME drawbacks.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, affinity, logP, TPSA, and Pgp are important. Ligand A excels in affinity and Pgp, and has a better TPSA. Ligand B has a better logP, but it is quite low.
**Overall Assessment:**
Ligand A has a significantly better binding affinity and a longer half-life. While its DILI risk and solubility are concerns, the strong binding and metabolic stability are compelling. Ligand B has a better safety profile (lower DILI, hERG), but its weak binding affinity and poor half-life are major drawbacks. The lower logP of Ligand B is also a concern for permeability. The negative Caco-2 values for both are worrying, but the superior binding of Ligand A makes it more likely to overcome this issue with further optimization.
Output:
1
2025-04-17 20:04:21,973 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (353.47 and 349.52 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (92.37) is higher than Ligand B (52.65). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B is better.
3. **logP:** Both ligands have similar logP values (2.216 and 2.263), falling within the optimal 1-3 range. No significant difference.
4. **HBD:** Ligand A has 2 HBD, while Ligand B has 1. Both are acceptable, but lower is slightly preferred for permeability. Ligand B is slightly better.
5. **HBA:** Ligand A has 5 HBA, Ligand B has 3. Both are within the acceptable range (<=10). Ligand B is slightly better.
6. **QED:** Both ligands have good QED scores (0.747 and 0.828), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (39.36%) has a lower DILI risk than Ligand B (9.27%). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (80.96%) has a higher BBB penetration score than Ligand B (69.68%). While ADRB2 is not a CNS target, some degree of BBB penetration can influence off-target effects and distribution. Ligand A is better.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual. Assuming these are percentile scores, it suggests poor permeability for both. However, Ligand A (-5.04) is slightly less negative than Ligand B (-4.863), suggesting marginally better permeability.
10. **Solubility:** Both ligands have negative solubility values, indicating poor aqueous solubility. Ligand A (-1.809) is slightly better than Ligand B (-1.402).
11. **hERG:** Both ligands have low hERG inhibition liability (0.274 and 0.484), which is good. Ligand B is slightly worse.
12. **Cl_mic:** Ligand A has a much lower (better) microsomal clearance (-7.699) than Ligand B (25.098). This suggests significantly better metabolic stability for Ligand A.
13. **t1/2:** Ligand A has a longer in vitro half-life (14.234 hours) than Ligand B (-4.781 hours). This is a significant advantage for Ligand A.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.028 and 0.062). No significant difference.
15. **Binding Affinity:** Ligand B (-7.3 kcal/mol) has a slightly better binding affinity than Ligand A (-6.1 kcal/mol). This is a 1.2 kcal/mol difference, which is substantial.
**Overall Assessment:**
Ligand B has a better binding affinity and slightly better drug-like properties (QED, HBD, HBA, TPSA). However, Ligand A demonstrates significantly better ADME properties: lower DILI risk, better metabolic stability (Cl_mic), longer half-life, and slightly better permeability and solubility. Considering ADRB2 is a cardiovascular target, metabolic stability and safety (DILI) are crucial. The 1.2 kcal/mol difference in binding affinity can potentially be overcome with further optimization of Ligand A.
Therefore, I favor Ligand A due to its superior ADME profile and safety characteristics.
Output:
1
2025-04-17 20:04:21,973 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
The target is ADRB2, a GPCR. Therefore, I will prioritize logP, TPSA, Pgp efflux, BBB penetration, and binding affinity. Metabolic stability (Cl_mic, t1/2) and safety (DILI, hERG) are also important.
Let's compare the ligands property by property:
1. **MW:** Both are within the ideal range (368.455 and 357.401 Da).
2. **TPSA:** Ligand B (61.88) is significantly better than Ligand A (112.57). Lower TPSA generally improves permeability, crucial for GPCR ligands.
3. **logP:** Ligand A (1.811) is better than Ligand B (0.325). A logP between 1-3 is optimal, and Ligand B is quite low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (1), but both are acceptable.
5. **HBA:** Both ligands have 4 HBA, which is good.
6. **QED:** Both ligands have good QED scores (0.648 and 0.788).
7. **DILI:** Ligand B (18.922) has a much lower DILI risk than Ligand A (63.862). This is a significant advantage.
8. **BBB:** Ligand B (83.715) has much better BBB penetration than Ligand A (47.111). While ADRB2 isn't exclusively a CNS target, some peripheral effects are mediated by CNS pathways, and better BBB penetration can be beneficial.
9. **Caco-2:** Ligand B (-4.813) is better than Ligand A (-5.51), indicating better intestinal absorption.
10. **Solubility:** Ligand B (-1.829) is better than Ligand A (-2.857).
11. **hERG:** Ligand B (0.482) has a lower hERG risk than Ligand A (0.051). This is a significant safety advantage.
12. **Cl_mic:** Ligand B (-8.101) has a better (lower) microsomal clearance than Ligand A (11.202), indicating better metabolic stability.
13. **t1/2:** Ligand B (14.443) has a better (longer) in vitro half-life than Ligand A (-35.163).
14. **Pgp:** Ligand B (0.017) has a lower P-gp efflux liability than Ligand A (0.009).
15. **Affinity:** Ligand A (-7.4) has a slightly better binding affinity than Ligand B (-6.9). However, the difference is less than 1.5 kcal/mol, and can be overcome by the other advantages of Ligand B.
**Overall Assessment:**
Ligand B consistently outperforms Ligand A in most crucial ADME-Tox properties (DILI, BBB, hERG, Cl_mic, t1/2, Pgp, solubility, Caco-2, and TPSA). While Ligand A has a slightly better binding affinity, the overall profile of Ligand B is far more favorable for drug development, especially considering the GPCR target class. The lower logP of Ligand B is a concern, but the other benefits outweigh this drawback.
**Output:**
0
2025-04-17 20:04:21,973 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (339.399 Da) is slightly lower, which is generally favorable for permeability.
**2. TPSA:** Ligand A (82.19) is significantly better than Ligand B (99.6). For a GPCR, keeping TPSA low is beneficial for permeability and receptor engagement.
**3. logP:** Both ligands have acceptable logP values (A: 1.431, B: 0.819), falling within the optimal 1-3 range. Ligand A is slightly more lipophilic, which could aid membrane permeability.
**4. H-Bond Donors:** Ligand A (1) has fewer HBDs than Ligand B (2), which is preferable for permeability.
**5. H-Bond Acceptors:** Ligand A (4) has fewer HBAs than Ligand B (6), again favoring permeability.
**6. QED:** Both ligands have similar, good QED scores (A: 0.897, B: 0.782), indicating good drug-like properties.
**7. DILI:** Both ligands have similar and acceptable DILI risk (A: 59.325, B: 55.913), below the concerning threshold of 60.
**8. BBB:** Ligand A (63.474) has a better BBB percentile than Ligand B (47.344), although ADRB2 isn't necessarily a CNS target, some degree of BBB penetration is not detrimental.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
**10. Aqueous Solubility:** Both ligands have negative solubility values, which is also unusual and suggests poor solubility.
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (A: 0.31, B: 0.295), which is excellent.
**12. Microsomal Clearance:** Ligand B (-9.442) has significantly lower (better) microsomal clearance than Ligand A (43.201), indicating greater metabolic stability.
**13. In vitro Half-Life:** Ligand B (4.13) has a longer half-life than Ligand A (-26.5), which is a significant advantage.
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (A: 0.114, B: 0.158).
**15. Binding Affinity:** Ligand A (-7.8) has a slightly better binding affinity than Ligand B (-7.4), but the difference is relatively small (0.4 kcal/mol).
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand A is slightly favored due to its better TPSA, logP, and binding affinity. However, Ligand B has a significantly better metabolic profile (lower Cl_mic and longer half-life). The negative Caco-2 and solubility values are concerning for both compounds and would require further investigation. Given the importance of metabolic stability for a successful drug, and the relatively small difference in binding affinity, Ligand B's superior pharmacokinetic properties make it the more promising candidate.
Output:
0
2025-04-17 20:04:21,973 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (342.439 Da) is slightly lower, which is generally favorable for permeability.
**2. TPSA:** Ligand A (62.55) is better than Ligand B (42.43). Both are well below the 140 A^2 threshold for oral absorption, but lower TPSA is generally preferred for GPCR ligands, potentially improving brain penetration and receptor binding.
**3. logP:** Ligand A (2.82) is optimal, while Ligand B (4.617) is pushing the upper limit. High logP can lead to poor solubility and off-target effects.
**4. H-Bond Donors:** Ligand A (1) is preferable to Ligand B (0). While both are low, a single H-bond donor can sometimes improve binding.
**5. H-Bond Acceptors:** Ligand A (3) is preferable to Ligand B (4). Similar to HBD, lower is generally better for permeability.
**6. QED:** Ligand A (0.837) is significantly better than Ligand B (0.676), indicating a more drug-like profile.
**7. DILI:** Ligand A (15.51) has a much lower DILI risk than Ligand B (31.291). This is a critical advantage.
**8. BBB:** Ligand B (81.698) has better BBB penetration than Ligand A (66.344). While ADRB2 is primarily a cardiovascular target, some CNS effects are possible with beta-blockers, and higher BBB penetration could be beneficial or detrimental depending on the desired profile.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.89) is slightly better than Ligand B (-4.565).
**10. Aqueous Solubility:** Ligand A (-2.772) is better than Ligand B (-5.006), indicating better solubility.
**11. hERG Inhibition:** Ligand A (0.177) has a much lower hERG risk than Ligand B (0.773). This is a crucial safety parameter.
**12. Microsomal Clearance:** Ligand B (94.832) has a higher clearance than Ligand A (37.767), suggesting lower metabolic stability.
**13. In vitro Half-Life:** Ligand B (18.278) has a longer half-life than Ligand A (12.221), which is generally desirable.
**14. P-gp Efflux:** Ligand A (0.102) has lower P-gp efflux than Ligand B (0.86), which is favorable for bioavailability.
**15. Binding Affinity:** Ligand A (-7.8 kcal/mol) has a slightly better binding affinity than Ligand B (-6.7 kcal/mol). This 1.1 kcal/mol difference is significant.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity) and general drug-like properties, **Ligand A is the superior candidate**. While Ligand B has slightly better BBB penetration and *in vitro* half-life, Ligand A excels in crucial areas like DILI risk, hERG inhibition, QED, solubility, logP, and binding affinity. The lower DILI and hERG risks are particularly important for a cardiovascular drug. The better affinity also outweighs the slight difference in half-life. The Caco-2 values are concerning for both, but Ligand A is slightly better.
Output:
1
2025-04-17 20:04:21,973 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (362.4 and 348.4 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Both are reasonably low (96.8 and 99.23), suggesting good potential for absorption. Ligand A is slightly better, being closer to the <140 threshold.
3. **logP:** Both ligands have good logP values (1.471 and 1.805), falling within the 1-3 optimal range. Ligand B is slightly higher, which could be a minor concern for off-target effects, but not a major issue.
4. **HBD:** Both have 1 HBD, which is within the acceptable limit of <=5.
5. **HBA:** Both have 5 HBA, which is within the acceptable limit of <=10.
6. **QED:** Both ligands have similar, good QED scores (0.865 and 0.875), indicating good drug-like properties.
7. **DILI:** Ligand A has a significantly higher DILI risk (88.639 percentile) compared to Ligand B (52.889 percentile). This is a major concern for Ligand A.
8. **BBB:** Ligand B has a much higher BBB penetration (87.088 percentile) than Ligand A (25.979 percentile). While ADRB2 isn't *strictly* a CNS target, some peripheral ADRB2 receptors can be relevant in CNS-related conditions. Higher BBB penetration isn't detrimental here, and could be a slight advantage.
9. **Caco-2:** Both have negative Caco-2 values which is unusual. Assuming these are logP values, both are poor.
10. **Solubility:** Both have negative solubility values which is unusual. Assuming these are logS values, both are poor.
11. **hERG:** Ligand A has a very low hERG inhibition liability (0.016 percentile), which is excellent. Ligand B is higher (0.394 percentile), but still relatively low risk.
12. **Cl_mic:** Ligand A has a much lower (better) microsomal clearance (-4.344 mL/min/kg) than Ligand B (29.873 mL/min/kg). This indicates better metabolic stability for Ligand A.
13. **t1/2:** Ligand B has a significantly longer in vitro half-life (-38.491 hours) than Ligand A (-21.713 hours). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A has a very low Pgp efflux liability (0.006 percentile), which is excellent. Ligand B is higher (0.099 percentile), but still relatively low risk.
15. **Binding Affinity:** Ligand A has a stronger binding affinity (-8.5 kcal/mol) than Ligand B (-5.7 kcal/mol). This is a substantial difference, and a major advantage for Ligand A.
**GPCR-Specific Priorities & Overall Assessment:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A excels in affinity and Pgp efflux, and has acceptable logP and TPSA. However, its high DILI risk is a significant drawback. Ligand B has a better safety profile (lower DILI), better metabolic stability (longer t1/2), and better BBB penetration. While its affinity is lower, the difference in affinity can sometimes be overcome with optimization. The DILI risk for Ligand A is too high to ignore at this stage.
**Output:**
0
2025-04-17 20:04:21,974 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (342.483 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (45.48) is significantly better than Ligand B (90.28). ADRB2 is a cardiovascular target, not a CNS target, but lower TPSA is still generally preferred for absorption. Ligand B is pushing the upper limit for good oral absorption.
3. **logP:** Both ligands have acceptable logP values (A: 4.612, B: 3.62), falling within the 1-3 range. Ligand A is slightly higher, which could potentially lead to off-target effects, but is not a major concern.
4. **HBD:** Both have a reasonable number of HBDs (A: 1, B: 2).
5. **HBA:** Ligand A (2) is better than Ligand B (6). Lower HBA is generally preferred for permeability.
6. **QED:** Both ligands have good QED scores (A: 0.676, B: 0.725), indicating good drug-like properties.
7. **DILI:** Ligand A (24.699) has a much lower DILI risk than Ligand B (84.645). This is a significant advantage for Ligand A.
8. **BBB:** This is less critical for a cardiovascular target. Ligand A (73.827) is better than Ligand B (35.324).
9. **Caco-2:** Ligand A (-4.722) is better than Ligand B (-5.038). Higher Caco-2 permeability is desired.
10. **Solubility:** Ligand A (-4.153) is better than Ligand B (-4.975). Higher solubility is preferred.
11. **hERG:** Both ligands have low hERG inhibition risk (A: 0.959, B: 0.655).
12. **Cl_mic:** Ligand A (100.055) has significantly higher microsomal clearance than Ligand B (34.016), indicating lower metabolic stability. This is a drawback for Ligand A.
13. **t1/2:** Ligand A (76.537) has a much longer in vitro half-life than Ligand B (23.472). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.822) is better than Ligand B (0.219). Lower P-gp efflux is preferred.
15. **Binding Affinity:** Ligand B (-8.1 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.4 kcal/mol). This is a major advantage for Ligand B. The difference of 1.7 kcal/mol is substantial.
**Overall Assessment:**
Ligand B has a significantly better binding affinity, which is the most important factor. However, Ligand A has better ADME properties overall, particularly regarding DILI risk, solubility, Caco-2 permeability, and half-life. The higher clearance of Ligand A is a concern, but the longer half-life partially mitigates this. The substantial affinity difference of Ligand B outweighs the ADME advantages of Ligand A.
Output:
0
2025-04-17 20:04:21,974 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.447 and 366.315 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (85.67 and 87.32) are below the 140 A^2 threshold for good oral absorption, and acceptable for a cardiovascular target (not needing high BBB penetration). Again, a small difference.
3. **logP:** Ligand A (0.364) is a bit low, potentially hindering permeation. Ligand B (1.348) is better, falling within the optimal 1-3 range. This is a point in favor of Ligand B.
4. **HBD:** Ligand A (1) is good, while Ligand B (2) is still acceptable.
5. **HBA:** Ligand A (5) is good, while Ligand B (4) is also good.
6. **QED:** Both ligands have similar QED scores (0.749 and 0.744), indicating good drug-likeness.
7. **DILI:** Ligand A (5.545) has a slightly better DILI score than Ligand B (59.946), indicating lower potential for liver injury. This is a significant advantage for Ligand A.
8. **BBB:** Both ligands show low BBB penetration (63.358 and 64.25). This is not a major concern for a cardiovascular target like ADRB2.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.201 and -4.9). This is unusual and suggests poor permeability. However, these values are on a scale where negative values are possible, and the absolute difference isn't huge.
10. **Solubility:** Ligand A (-0.96) has slightly better solubility than Ligand B (-2.453).
11. **hERG:** Both ligands have low hERG inhibition risk (0.359 and 0.412).
12. **Cl_mic:** Ligand A (-37.701) has significantly better metabolic stability (lower clearance) than Ligand B (-4.792). This is a strong point for Ligand A.
13. **t1/2:** Ligand A (9.775) has a better in vitro half-life than Ligand B (-26.919). This is another significant advantage for Ligand A.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.006 and 0.045).
15. **Binding Affinity:** Ligand B (-7.2 kcal/mol) has a slightly better binding affinity than Ligand A (-7.0 kcal/mol). While the difference is small, it's within the range where it could outweigh some ADME drawbacks.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand B has a better logP and slightly better affinity. However, Ligand A excels in metabolic stability (Cl_mic and t1/2) and has a lower DILI risk. The slightly better affinity of Ligand B is not enough to overcome the significant advantages of Ligand A in terms of safety (DILI) and pharmacokinetics (Cl_mic, t1/2).
**Conclusion:**
Considering the balance of properties, especially the improved safety profile and pharmacokinetic properties of Ligand A, it is the more promising drug candidate.
Output:
1
2025-04-17 20:04:21,974 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (373.322 and 352.519 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (92.5) is slightly higher than Ligand B (60.85). Both are below 140, acceptable for oral absorption, but Ligand B is considerably better.
3. **logP:** Both ligands have good logP values (1.337 and 2.525), falling within the optimal 1-3 range. Ligand B is slightly higher, potentially offering better membrane permeability.
4. **HBD:** Ligand A (2) and Ligand B (1) are both within the acceptable limit of 5. Ligand B is slightly better.
5. **HBA:** Both ligands have 3 HBA, well within the limit of 10. No difference.
6. **QED:** Ligand B (0.846) has a significantly higher QED score than Ligand A (0.497), indicating a more drug-like profile. This is a substantial advantage for Ligand B.
7. **DILI:** Ligand A (36.138) has a much lower DILI risk than Ligand B (14.308). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (76.541) has a higher BBB penetration percentile than Ligand B (64.327). While ADRB2 isn't strictly a CNS target, some peripheral ADRB2 receptors can be affected by CNS penetration, and higher BBB is generally favorable.
9. **Caco-2:** Ligand A (-5.357) has a worse Caco-2 permeability than Ligand B (-4.423). This suggests Ligand B will have better intestinal absorption.
10. **Solubility:** Both ligands have very poor aqueous solubility (-2.249 and -2.386). This is a significant concern for both, but similar.
11. **hERG:** Both ligands have low hERG inhibition risk (0.455 and 0.467). No significant difference.
12. **Cl_mic:** Ligand A (-15.886) has a much lower (better) microsomal clearance than Ligand B (46.033). This indicates better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (-1.057) has a shorter in vitro half-life than Ligand B (-18.875). This is a disadvantage for Ligand A.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.029 and 0.274). No significant difference.
15. **Binding Affinity:** Both ligands have identical binding affinity (-5.5 kcal/mol).
**GPCR-Specific Priorities & Overall Assessment:**
For a GPCR like ADRB2, logP, TPSA, and affinity are key. Both ligands perform well on logP and affinity. Ligand B has a significantly better TPSA. QED is also important, and Ligand B has a much better score. The biggest advantage for Ligand A is its lower DILI risk and better metabolic stability (lower Cl_mic). However, the superior QED and Caco-2 permeability of Ligand B, coupled with its better TPSA, outweigh the DILI and metabolic stability concerns, especially given that both ligands have poor solubility which will likely require formulation strategies regardless. The slightly better BBB for Ligand A is a minor benefit.
**Output:**
0
2025-04-17 20:04:21,974 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.415 and 353.369 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (78.95) is better than Ligand B (84.23). Both are below 140, but closer to 90 is preferred for GPCRs, and A is closer.
3. **logP:** Both ligands have a logP of approximately 2.0, which is optimal. No significant difference.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (4). Both are acceptable, but lower is generally better.
6. **QED:** Both ligands have good QED scores (0.764 and 0.82), indicating good drug-like properties. No significant difference.
7. **DILI:** Ligand A (71.539) has a considerably higher DILI risk than Ligand B (36.293). This is a significant negative for Ligand A.
8. **BBB:** Ligand B (89.957) has a much higher BBB penetration percentile than Ligand A (70.803). While ADRB2 isn't exclusively a CNS target, improved BBB penetration is still favorable for broader distribution and potential off-target effects.
9. **Caco-2:** Both ligands have similar, very negative Caco-2 permeability values (-4.635 and -4.694). This suggests poor intestinal absorption for both, which is concerning.
10. **Solubility:** Both ligands have similar, very negative solubility values (-3.321 and -3.549). This suggests poor aqueous solubility for both, which is also concerning.
11. **hERG:** Ligand A (0.244) has a lower hERG inhibition liability than Ligand B (0.522), which is a positive.
12. **Cl_mic:** Ligand A (-2.444) has a much lower (better) microsomal clearance than Ligand B (38.033). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (14.294) has a longer in vitro half-life than Ligand B (6.243). This is a positive for Ligand A.
14. **Pgp:** Ligand A (0.02) has a much lower P-gp efflux liability than Ligand B (0.063). This is a positive for Ligand A.
15. **Binding Affinity:** Ligand A (-6.1) has a slightly better binding affinity than Ligand B (-5.7), although the difference is relatively small (0.4 kcal/mol).
**Overall Assessment:**
Ligand A has a better binding affinity, lower Pgp efflux, lower microsomal clearance, and longer half-life. However, Ligand B has a significantly lower DILI risk and better BBB penetration. Both have poor Caco-2 and solubility. The DILI risk is a major concern for Ligand A, and the improved metabolic stability and Pgp properties of Ligand A don't fully compensate for this. The slightly better BBB penetration of Ligand B is also a plus. Given the balance, and prioritizing safety (DILI), Ligand B is the more promising candidate.
Output:
0
2025-04-17 20:04:21,974 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (374.5 and 366.5 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (84.5) is slightly higher than Ligand B (62.55). For a cardiovascular GPCR, TPSA is not a primary concern as BBB penetration isn't crucial, but lower is generally better for absorption. Ligand B has an advantage.
**3. logP:** Both ligands have good logP values (2.59 and 3.45), falling within the optimal 1-3 range. Ligand B is slightly higher, which *could* indicate a slightly better ability to cross membranes, but it's not a major difference.
**4. H-Bond Donors:** Ligand A has 2 HBD, while Ligand B has 1. Both are within the acceptable limit of <=5.
**5. H-Bond Acceptors:** Both ligands have 4 HBA, well within the acceptable limit of <=10.
**6. QED:** Both ligands have similar QED values (0.684 and 0.68), indicating good drug-likeness.
**7. DILI Risk:** Ligand A (18.5) has a lower DILI risk than Ligand B (20.7), which is favorable.
**8. BBB Penetration:** This is less critical for a cardiovascular target. Ligand A (81.6) has better BBB penetration than Ligand B (62.5), but this is not a primary driver in this case.
**9. Caco-2 Permeability:** Ligand A (-4.37) has a worse Caco-2 permeability than Ligand B (-5.31), indicating lower intestinal absorption. Ligand B is preferred.
**10. Aqueous Solubility:** Both ligands have very poor aqueous solubility (-3.16 and -3.27). This is a significant drawback for both, and formulation strategies would be needed.
**11. hERG Inhibition:** Ligand A (0.48) has a slightly lower hERG inhibition risk than Ligand B (0.63), which is preferable.
**12. Microsomal Clearance:** Ligand B (55.8) has a lower microsomal clearance than Ligand A (82.0), suggesting better metabolic stability. This is a significant advantage.
**13. In vitro Half-Life:** Ligand B (40.2) has a significantly longer in vitro half-life than Ligand A (-27.97), which is a major benefit.
**14. P-gp Efflux:** Both ligands have low P-gp efflux (0.048 and 0.181), which is good.
**15. Binding Affinity:** Ligand B (-7.7 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.9 kcal/mol). This 0.8 kcal/mol difference is substantial and can outweigh some of the ADME drawbacks.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand B is the stronger candidate. The significantly improved binding affinity (-7.7 vs -6.9 kcal/mol) and better metabolic stability (lower Cl_mic and longer t1/2) are key advantages. While both have poor solubility, the better permeability of Ligand B and lower DILI risk further support its selection.
Output:
0
2025-04-17 20:04:21,975 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (377.463 Da) is within the ideal range (200-500). Ligand B (348.487 Da) is also within the ideal range. No clear advantage here.
2. **TPSA:** Ligand A (136.82) is borderline acceptable for oral absorption (<=140). Ligand B (67.43) is excellent, well below the 140 threshold. This favors Ligand B.
3. **logP:** Ligand A (-1.106) is a bit low, potentially hindering permeability. Ligand B (2.108) is within the optimal range (1-3). This strongly favors Ligand B.
4. **HBD:** Ligand A (3) is acceptable. Ligand B (2) is also acceptable. No significant difference.
5. **HBA:** Ligand A (6) is acceptable. Ligand B (3) is also acceptable. No significant difference.
6. **QED:** Ligand A (0.436) is below the preferred threshold of 0.5. Ligand B (0.66) is above the threshold. This favors Ligand B.
7. **DILI:** Ligand A (39.162) is good (low risk). Ligand B (20.861) is excellent (very low risk). This favors Ligand B.
8. **BBB:** Both Ligand A (54.246) and Ligand B (59.674) have moderate BBB penetration. Since ADRB2 isn't necessarily a CNS target, this isn't a major deciding factor, but slightly favors B.
9. **Caco-2:** Ligand A (-5.877) is poor. Ligand B (-4.779) is also poor, but slightly better.
10. **Solubility:** Ligand A (-1.839) is poor. Ligand B (-3.066) is very poor. Both are problematic, but B is worse.
11. **hERG:** Ligand A (0.069) is very low risk. Ligand B (0.225) is also low risk. No significant difference.
12. **Cl_mic:** Ligand A (11.407) is better (lower clearance) than Ligand B (24.379). This favors Ligand A.
13. **t1/2:** Ligand A (-8.733) is better (longer half-life) than Ligand B (7.573). This favors Ligand A.
14. **Pgp:** Ligand A (0.01) is very low efflux, which is good. Ligand B (0.046) is also low efflux. No significant difference.
15. **Affinity:** Ligand A (-7.2 kcal/mol) is significantly better than Ligand B (-6.5 kcal/mol). This is a substantial advantage.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand B initially appears better due to its superior logP and TPSA. However, Ligand A has a significantly stronger binding affinity (-7.2 vs -6.5 kcal/mol). The difference in affinity is substantial enough to outweigh the slightly less favorable logP and TPSA of Ligand A. Furthermore, Ligand A has better metabolic stability (lower Cl_mic and longer t1/2). While solubility is a concern for both, the improved potency and stability of Ligand A are more critical for a GPCR target.
Output:
1
2025-04-17 20:04:21,975 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (379.429 and 367.559 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (65.2) is significantly better than Ligand A (100.55). ADRB2 is not a CNS target, but lower TPSA generally correlates with better absorption, making Ligand B preferable.
3. **logP:** Both ligands have acceptable logP values (1.524 and 3.52), falling within the 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability, but isn't a major concern.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (2), but both are within the acceptable limit of 5.
5. **HBA:** Ligand A (6) is higher than Ligand B (3). Lower HBA is generally preferred for permeability, giving a slight edge to Ligand B.
6. **QED:** Ligand B (0.691) has a better QED score than Ligand A (0.535), indicating a more drug-like profile.
7. **DILI:** Ligand B (37.263) has a significantly lower DILI risk than Ligand A (67.158). This is a major advantage for Ligand B.
8. **BBB:** Not a primary concern for ADRB2, but Ligand B (60.062) is higher than Ligand A (38.193).
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.279 and -5.313), which is unusual and suggests poor permeability. This is a significant drawback for both.
10. **Solubility:** Both ligands have negative solubility values (-2.293 and -3.73). This is a major concern for both, indicating very poor aqueous solubility.
11. **hERG:** Ligand A (0.289) has a lower hERG risk than Ligand B (0.701), which is preferable.
12. **Cl_mic:** Ligand A (20.722) has a significantly lower microsomal clearance than Ligand B (85.125), indicating better metabolic stability. This is a substantial advantage for Ligand A.
13. **t1/2:** Ligand B (33.511) has a much longer in vitro half-life than Ligand A (-9.532). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.145) has lower P-gp efflux liability than Ligand B (0.218), which is preferable.
15. **Binding Affinity:** Ligand A (-7.5 kcal/mol) has a slightly better binding affinity than Ligand B (-6.1 kcal/mol). This is a 1.4 kcal/mol difference, which is significant.
**Overall Assessment:**
Ligand A has a better binding affinity and metabolic stability (lower Cl_mic), and lower Pgp efflux. However, Ligand B has a significantly lower DILI risk, a better QED score, and a longer half-life. Both ligands have poor solubility and Caco-2 permeability, which are major concerns. Considering the GPCR-specific priorities (logP, TPSA, affinity), and the importance of minimizing toxicity (DILI), Ligand B appears to be the more promising candidate. The better half-life of Ligand B is also a significant advantage. While the affinity difference is notable, the other ADME/Tox properties of Ligand B are more favorable overall.
Output:
0
2025-04-17 20:04:21,975 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [354.407, 116.92 , -0.63 , 3. , 7. , 0.586, 36.216, 43.815, -5.291, -1.439, 0.165, -16.813, -8.811, 0.036, -6.9 ]
**Ligand B:** [358.345, 93.65 , 0.163, 1. , 7. , 0.548, 64.521, 73.866, -4.796, -1.567, 0.206, 33.384, -15.299, 0.012, -6.3 ]
Here's a breakdown, prioritizing GPCR properties (logP, TPSA, Pgp, BBB, affinity):
1. **Molecular Weight:** Both are within the ideal 200-500 Da range. A (354.4) is slightly better.
2. **TPSA:** A (116.92) is above the preferred <140 for oral absorption, but still acceptable. B (93.65) is excellent, well below 100, which is a significant advantage for permeability and potentially CNS penetration.
3. **logP:** A (-0.63) is a bit low, potentially hindering membrane permeability. B (0.163) is better, falling within the 1-3 range, but still on the lower side.
4. **H-Bond Donors:** A (3) is acceptable. B (1) is even better, reducing potential issues with permeability.
5. **H-Bond Acceptors:** Both have 7, which is acceptable.
6. **QED:** Both are good (>0.5), indicating drug-like properties. A (0.586) is slightly better.
7. **DILI:** A (36.216) is excellent, indicating low liver injury risk. B (64.521) is moderate, but still within an acceptable range.
8. **BBB:** B (73.866) is significantly better than A (43.815). This is a key advantage for a GPCR, even if not specifically a CNS target, as it suggests better distribution.
9. **Caco-2:** Both are negative, indicating poor permeability. A (-5.291) is worse than B (-4.796).
10. **Solubility:** Both are negative, indicating poor solubility. A (-1.439) is slightly better than B (-1.567).
11. **hERG:** Both are very low (0.165 and 0.206), indicating minimal cardiotoxicity risk.
12. **Cl_mic:** A (-16.813) is much better than B (33.384), indicating significantly better metabolic stability. This is a major plus.
13. **t1/2:** A (-8.811) is better than B (-15.299), indicating a longer half-life.
14. **Pgp:** Both are very low (0.036 and 0.012), indicating minimal P-glycoprotein efflux.
15. **Affinity:** A (-6.9) is slightly better than B (-6.3), but the difference is not huge.
**Overall Assessment:**
Ligand B has a superior TPSA and BBB, which are critical for GPCRs. However, Ligand A has a better DILI score, Cl_mic, t1/2, and slightly better affinity. The metabolic stability (Cl_mic) and half-life of Ligand A are particularly compelling. While the logP of A is a concern, the improved metabolic profile and slightly better binding outweigh the benefits of B's better TPSA/BBB.
Therefore, I would choose Ligand A.
1
2025-04-17 20:04:21,975 - INFO - Batch 157 complete. Total preferences: 2512
2025-04-17 20:04:21,975 - INFO - Processing batch 158/512...
2025-04-17 20:05:09,056 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (348.49 and 345.42 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (58.64) is significantly better than Ligand B (71.09). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand A is well below the 140 A^2 threshold, while Ligand B is approaching it.
**3. logP:** Both ligands have good logP values (2.368 and 2.534), falling within the optimal 1-3 range. A slight edge to Ligand B, but not substantial.
**4. H-Bond Donors:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
**5. H-Bond Acceptors:** Both have the same number of HBA (3), which is within the acceptable range.
**6. QED:** Both ligands have similar QED values (0.719 and 0.746), indicating good drug-likeness.
**7. DILI Risk:** Ligand A (13.61) has a *much* lower DILI risk than Ligand B (27.69). This is a significant advantage for Ligand A.
**8. BBB Penetration:** Both ligands exhibit good BBB penetration (83.60% and 81.23%), which isn't a primary concern for a cardiovascular target but isn't detrimental.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.648 and -4.692). These values are unusual and suggest poor permeability. However, the values are very similar.
**10. Aqueous Solubility:** Both ligands have negative solubility values (-3.343 and -3.437), indicating poor aqueous solubility. This is a concern, but again, similar for both.
**11. hERG Inhibition:** Ligand A (0.606) has a slightly higher hERG risk than Ligand B (0.458), but both are relatively low.
**12. Microsomal Clearance:** Ligand A (66.79) has a higher microsomal clearance than Ligand B (34.02). This means Ligand B is more metabolically stable, which is a positive.
**13. In vitro Half-Life:** Ligand B (-0.263) has a longer in vitro half-life than Ligand A (-11.882). This is a significant advantage for Ligand B.
**14. P-gp Efflux:** Ligand A (0.245) has lower P-gp efflux than Ligand B (0.035), which is preferable.
**15. Binding Affinity:** Ligand B (-6.4 kcal/mol) has a slightly stronger binding affinity than Ligand A (-5.7 kcal/mol). This is a 0.7 kcal/mol difference, which is a moderate advantage.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), and the general guidelines, Ligand A is the better candidate. While Ligand B has a slightly better affinity and metabolic stability, Ligand A's significantly lower DILI risk, lower HBD, and lower P-gp efflux are more important. The TPSA is also better for Ligand A. The solubility and Caco-2 values are poor for both, but these can be addressed with formulation strategies. The DILI risk is a critical factor that is difficult to overcome later in development.
Output:
1
2025-04-17 20:05:09,057 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (344.415 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (87.32) is better than Ligand B (47.36). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is still preferred for absorption.
3. **logP:** Ligand B (3.932) is higher than Ligand A (1.566). While both are within the acceptable range, Ligand B is approaching the upper limit, potentially raising concerns about solubility and off-target effects.
4. **HBD:** Ligand A (2) is better than Ligand B (0). A small number of HBDs can aid solubility without overly hindering permeability.
5. **HBA:** Both ligands have the same number of HBA (4), which is acceptable.
6. **QED:** Ligand A (0.862) has a significantly better QED score than Ligand B (0.713), indicating a more drug-like profile overall.
7. **DILI:** Ligand B (36.681) has a much lower DILI risk than Ligand A (52.695), a significant advantage.
8. **BBB:** Ligand B (77.162) has a higher BBB penetration score than Ligand A (52.889). While ADRB2 isn't a primary CNS target, some degree of BBB penetration can be beneficial for understanding off-target effects and potential peripheral distribution.
9. **Caco-2:** Ligand A (-5.024) has a better Caco-2 permeability than Ligand B (-4.537), suggesting better intestinal absorption.
10. **Solubility:** Ligand A (-2.675) has a better solubility score than Ligand B (-3.88), which is important for formulation and bioavailability.
11. **hERG:** Both ligands have similar hERG inhibition liability (0.512 and 0.715, respectively).
12. **Cl_mic:** Ligand A (7.541) has a much lower microsomal clearance than Ligand B (92.816), indicating better metabolic stability.
13. **t1/2:** Ligand B (63.864) has a significantly longer in vitro half-life than Ligand A (10.442), which is a major advantage for dosing convenience.
14. **Pgp:** Both ligands have similar P-gp efflux liability (0.036 and 0.512, respectively).
15. **Binding Affinity:** Both ligands have the same binding affinity (-6.6 kcal/mol).
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B has a higher logP and better BBB penetration, but Ligand A has a better TPSA, Caco-2 permeability, solubility, QED, and importantly, much better metabolic stability (lower Cl_mic). The DILI risk is also lower for Ligand B. The equal binding affinity makes this a trade-off between ADME properties.
**Overall Assessment:**
While Ligand B has a longer half-life and lower DILI risk, the significantly better metabolic stability (Cl_mic) and QED score of Ligand A, combined with its better solubility and permeability, make it the more promising candidate. The higher logP of Ligand B is a concern, and the longer half-life doesn't fully compensate for the faster metabolism of Ligand A, as metabolic "soft spots" can lead to reactive metabolites.
Output:
1
2025-04-17 20:05:09,057 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (404.3) is within the ideal range (200-500). Ligand B (367.6) is also excellent. No clear advantage here.
2. **TPSA:** Ligand A (47.6) is good, well below the 140 threshold. Ligand B (61.4) is still acceptable, but higher. A favors here.
3. **logP:** Ligand A (4.35) is slightly high, potentially leading to solubility issues or off-target effects. Ligand B (2.77) is within the optimal range (1-3). B favors.
4. **HBD:** Ligand A (1) is ideal. Ligand B (2) is acceptable. A favors slightly.
5. **HBA:** Ligand A (3) is good. Ligand B (4) is also good. No significant difference.
6. **QED:** Both ligands (A: 0.779, B: 0.705) have good drug-likeness scores (>0.5). A favors slightly.
7. **DILI:** Ligand A (65.1) has a higher DILI risk than Ligand B (33.5). B strongly favors.
8. **BBB:** Both ligands have similar BBB penetration (A: 57.2, B: 54.1). Not a major differentiating factor for a cardiovascular target.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-5.45) has worse solubility than Ligand B (-2.58). B favors.
11. **hERG:** Ligand A (0.713) has a slightly higher hERG risk than Ligand B (0.56). B favors.
12. **Cl_mic:** Ligand A (72.9) has higher metabolic clearance than Ligand B (60.4). B favors.
13. **t1/2:** Ligand A (82.2) has a longer half-life than Ligand B (59.1). A favors.
14. **Pgp:** Ligand A (0.747) has higher P-gp efflux than Ligand B (0.221). B strongly favors.
15. **Affinity:** Ligand B (-6.9 kcal/mol) has a significantly better binding affinity than Ligand A (-5.9 kcal/mol) - a difference of 1 kcal/mol. This is a substantial advantage.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are crucial. Ligand B excels in logP and Pgp, which will improve bioavailability and reduce efflux. While Ligand A has a better half-life, the substantial difference in binding affinity (-6.9 vs -5.9) and the lower DILI/hERG/Cl_mic risks of Ligand B outweigh this benefit. The slightly higher TPSA of Ligand B is not a major concern for a cardiovascular target.
**Conclusion:**
Ligand B is the better candidate due to its superior binding affinity, lower toxicity risks (DILI, hERG), better metabolic stability (Cl_mic), and improved P-gp efflux profile. While Ligand A has a slightly better half-life and TPSA, the advantages of Ligand B are more impactful for a successful drug candidate.
Output:
0
2025-04-17 20:05:09,057 - INFO - Here's my reasoning and final output for the ligand preference:
**Reasoning:**
We are targeting ADRB2, a GPCR, so the priorities are logP, Pgp, TPSA, affinity, and BBB. Let's break down the comparison:
1. **MW:** Both are within the acceptable range (200-500 Da). Ligand A (341.5) is slightly better.
2. **TPSA:** Ligand A (35.58) is significantly better than Ligand B (139.22). A TPSA under 140 is good for oral absorption, but Ligand B is pushing the limit.
3. **logP:** Ligand A (3.759) is optimal, while Ligand B (-0.724) is quite low, potentially hindering membrane permeability.
4. **HBD/HBA:** Ligand A (1 HBD, 3 HBA) is better than Ligand B (3 HBD, 9 HBA). Lower counts generally improve permeability.
5. **QED:** Both are acceptable (A: 0.731, B: 0.61), indicating reasonable drug-likeness.
6. **DILI:** Ligand A (33.97) is much better than Ligand B (84.65), indicating a lower risk of liver injury.
7. **BBB:** Ligand A (81.47) is much better than Ligand B (25.17). While ADRB2 isn't necessarily a CNS target, higher BBB is generally favorable, and indicates better distribution.
8. **Caco-2:** Both are negative, which is unusual. I'll assume these are logP-scaled values and lower is worse. Ligand A (-4.826) is slightly better than Ligand B (-5.572).
9. **Solubility:** Both are negative, indicating poor solubility. Ligand A (-2.711) is slightly better than Ligand B (-2.57).
10. **hERG:** Ligand A (0.877) is better than Ligand B (0.028), indicating a lower risk of cardiotoxicity.
11. **Cl_mic:** Ligand A (29.91) is better than Ligand B (16.86), indicating better metabolic stability.
12. **t1/2:** Ligand A (5.418) is better than Ligand B (-3.567).
13. **Pgp:** Ligand A (0.402) is better than Ligand B (0.014), indicating lower P-gp efflux.
14. **Affinity:** Ligand B (-7.6 kcal/mol) has a 1.3 kcal/mol advantage in binding affinity over Ligand A (-6.3 kcal/mol). This is a significant difference.
**Overall Assessment:**
While Ligand B has a superior binding affinity, its significantly worse ADME properties (high DILI, low BBB, low logP, high HBA, poor metabolic stability, and Pgp efflux) are concerning. Ligand A has a more balanced profile, with better solubility, permeability, metabolic stability, and safety characteristics. The affinity difference, while substantial, can potentially be optimized in later stages of drug development. Given the GPCR target class and the need for good overall drug properties, I believe Ligand A is the more promising candidate.
**Output:**
1
2025-04-17 20:05:09,057 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.491 and 354.466 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (76.02) is slightly higher than Ligand B (58.64). Both are below the 140 threshold for oral absorption, but B is better, especially given this is a GPCR.
3. **logP:** Both ligands (2.361 and 2.579) are within the optimal 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability, but not dramatically.
4. **HBD:** Ligand A has 2 HBD, and Ligand B has 1. Both are acceptable (<=5).
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 3. Both are acceptable (<=10).
6. **QED:** Both ligands have similar QED values (0.757 and 0.764), indicating good drug-likeness.
7. **DILI:** Ligand A (22.218) has a higher DILI risk than Ligand B (15.355). This is a significant advantage for Ligand B.
8. **BBB:** Ligand B (87.515) has a substantially higher BBB penetration percentile than Ligand A (69.213). While ADRB2 isn't exclusively a CNS target, increased BBB penetration can be beneficial for overall distribution and potentially off-target effects.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.86 and -4.658). This is unusual and suggests poor permeability. However, the values are very close.
10. **Solubility:** Both ligands have negative solubility values (-2.619 and -2.596). This is also concerning, indicating poor aqueous solubility. Again, the values are very close.
11. **hERG:** Ligand A (0.127) has a slightly lower hERG inhibition liability than Ligand B (0.405), which is preferable.
12. **Cl_mic:** Ligand A (44.848) has lower microsomal clearance than Ligand B (22.559), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand B (5.311) has a significantly longer in vitro half-life than Ligand A (-2.368). This is a major advantage for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.08) has lower P-gp efflux liability than Ligand B (0.098), which is preferable.
15. **Binding Affinity:** Ligand A (-7.8) has a slightly better binding affinity than Ligand B (-7.0). This is a 0.8 kcal/mol difference, which is substantial and could outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand A has a better binding affinity and metabolic stability (lower Cl_mic), and lower Pgp efflux. However, Ligand B excels in DILI risk, BBB penetration, and *significantly* in in vitro half-life. The poor Caco-2 and solubility for both are concerning, but similar. For a GPCR like ADRB2, a balance between potency, safety, and reasonable ADME properties is crucial. The longer half-life and lower DILI risk of Ligand B are particularly attractive, and the improved BBB penetration is a bonus. The slightly better affinity of Ligand A is not enough to overcome these advantages.
Output:
0
2025-04-17 20:05:09,057 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.475 and 380.457 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands have a TPSA of 67.87, which is well below the 140 threshold for good oral absorption and suitable for a peripherally acting GPCR like ADRB2.
3. **logP:** Ligand A (2.302) is slightly higher than Ligand B (1.659), both are within the optimal 1-3 range. Ligand A is preferable.
4. **HBD:** Both ligands have 1 H-bond donor, which is within the acceptable limit of 5.
5. **HBA:** Ligand A has 4 H-bond acceptors, while Ligand B has 5. Both are below the 10 limit.
6. **QED:** Ligand B (0.659) has a better QED score than Ligand A (0.484), indicating a more drug-like profile. This is a point in favor of Ligand B.
7. **DILI:** Ligand B (33.812) has a significantly lower DILI risk than Ligand A (10.896). This is a major advantage for Ligand B.
8. **BBB:** Both ligands have high BBB penetration (81.698 and 82.241). Since ADRB2 is not a primary CNS target, this is less critical, but still positive.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.907 and -4.947). These values are difficult to interpret without knowing the scale, but the similarity suggests comparable absorption potential.
10. **Solubility:** Ligand A (-1.833) has better aqueous solubility than Ligand B (-2.408). This is a slight advantage for Ligand A.
11. **hERG:** Both ligands have low hERG inhibition risk (0.437 and 0.348).
12. **Cl_mic:** Ligand A (12.146) has a higher microsomal clearance than Ligand B (8.179), indicating faster metabolism and potentially lower *in vivo* exposure. This favors Ligand B.
13. **t1/2:** Ligand B (-19.402) has a much longer *in vitro* half-life than Ligand A (-9.104). This is a significant advantage for Ligand B.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.052 and 0.034).
15. **Binding Affinity:** Both ligands have the same binding affinity (-6.5 kcal/mol).
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity), both ligands perform well. However, Ligand B has a substantial advantage in terms of safety (DILI) and pharmacokinetics (Cl_mic, t1/2). While Ligand A has slightly better solubility and logP, the lower DILI risk and improved metabolic stability of Ligand B are more crucial for overall drug development success. The equal binding affinity removes that as a differentiating factor.
Output:
0
2025-04-17 20:05:09,058 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (347.39 and 364.833 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands have a TPSA around 80, well below the 140 threshold for oral absorption and acceptable for a peripheral GPCR like ADRB2.
3. **logP:** Ligand A (0.814) is a bit low, potentially impacting permeability. Ligand B (2.264) is better, falling within the optimal 1-3 range. This favors Ligand B.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable.
5. **HBA:** Ligand A (4) and Ligand B (5) are both acceptable.
6. **QED:** Ligand B (0.882) has a higher QED score than Ligand A (0.682), indicating a more drug-like profile. This favors Ligand B.
7. **DILI:** Ligand A (54.478) has a slightly better DILI risk profile than Ligand B (61.846), but both are reasonably low risk.
8. **BBB:** This is less critical for ADRB2 (a cardiovascular target), but Ligand A (79.411) has a higher BBB percentile than Ligand B (46.142).
9. **Caco-2:** Ligand B (-5.086) has a slightly better Caco-2 permeability than Ligand A (-4.338).
10. **Solubility:** Ligand B (-3.094) has a slightly better solubility than Ligand A (-2.337).
11. **hERG:** Both ligands have very low hERG inhibition liability (0.206 and 0.166), which is excellent.
12. **Cl_mic:** Ligand B (18.162) has a lower microsomal clearance than Ligand A (30.678), suggesting better metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand B (34.735) has a significantly longer in vitro half-life than Ligand A (-12.234). This is a major advantage for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.037 and 0.085), which is excellent.
15. **Binding Affinity:** Ligand B (-6.5 kcal/mol) has a slightly better binding affinity than Ligand A (-5.8 kcal/mol). While the difference is not huge, it is enough to be considered.
**GPCR-specific priorities:** For ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand B performs better on logP, has comparable TPSA and Pgp, and slightly better affinity. The improved metabolic stability (lower Cl_mic) and longer half-life are also highly desirable.
**Overall Assessment:**
Ligand B consistently demonstrates superior ADME properties (logP, QED, Cl_mic, t1/2, solubility, Caco-2) and slightly better binding affinity, outweighing the slightly higher DILI risk and lower BBB. While Ligand A has a better BBB score, this is less important for a cardiovascular target like ADRB2.
Output:
0
2025-04-17 20:05:09,058 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.403 and 363.889 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (91.84) is higher than Ligand B (58.22). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for permeability. Ligand B is better.
3. **logP:** Ligand A (-0.174) is quite low, potentially hindering membrane permeability. Ligand B (3.741) is within the optimal 1-3 range. Ligand B is significantly better.
4. **HBD:** Both ligands have 1 HBD, which is acceptable.
5. **HBA:** Ligand A has 5 HBA, while Ligand B has 4. Both are within the acceptable limit of 10.
6. **QED:** Both ligands have good QED scores (0.545 and 0.698), indicating drug-like properties. Ligand B is slightly better.
7. **DILI:** Both ligands have similar DILI risk (39.162 and 39.434), both being low risk (<40).
8. **BBB:** Both ligands have moderate BBB penetration (59.093 and 61.574). Since ADRB2 is not a CNS target, this is not a major deciding factor.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.01 and -5.061), which is unusual and suggests very poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand A (-0.903) has slightly better solubility than Ligand B (-4.158), but both are poor.
11. **hERG:** Ligand A (0.27) has a lower hERG risk than Ligand B (0.936), which is favorable.
12. **Cl_mic:** Ligand A (10.179) has a much lower microsomal clearance than Ligand B (73.622), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (-15.869) has a negative in vitro half-life, which is concerning. Ligand B (29.945) has a reasonable half-life. Ligand B is better.
14. **Pgp:** Ligand A (0.015) has very low P-gp efflux, while Ligand B (0.44) has moderate efflux. Ligand A is better.
15. **Binding Affinity:** Ligand B (-6.3) has a slightly better binding affinity than Ligand A (-5.6). This is a 0.7 kcal/mol difference, which is substantial.
**Overall Assessment & GPCR-Specific Priorities:**
For a cardiovascular GPCR like ADRB2, logP, affinity, and metabolic stability are key. Ligand B has a much better logP, and a slightly better binding affinity. While Ligand A has better metabolic stability (lower Cl_mic) and P-gp efflux, the poor logP is a major drawback. The negative Caco-2 values for both are concerning, but the better affinity of Ligand B, coupled with its acceptable logP, makes it the more promising candidate despite the metabolic liability. The affinity difference is large enough to potentially overcome the higher Cl_mic through structural modifications.
Output:
0
2025-04-17 20:05:09,058 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (356.423 and 352.475 Da) fall comfortably within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (75.71) is significantly better than Ligand A (127.84). For a GPCR, lower TPSA is generally preferred for better permeability. Ligand B is well below the 140 threshold.
3. **logP:** Ligand B (1.914) is within the optimal 1-3 range, while Ligand A (-0.511) is slightly below 1, which could potentially hinder membrane permeability. Ligand B is better.
4. **HBD:** Ligand A (4) is slightly higher than Ligand B (1). Lower HBD is generally preferred for permeability, giving a slight edge to Ligand B.
5. **HBA:** Ligand A (5) and Ligand B (4) are both acceptable, falling below the 10 threshold.
6. **QED:** Ligand B (0.759) has a better QED score than Ligand A (0.392), indicating a more drug-like profile.
7. **DILI:** Ligand B (30.05) has a much lower DILI risk than Ligand A (51.842). This is a significant advantage for Ligand B.
8. **BBB:** Ligand B (67.197) has a better BBB penetration score than Ligand A (52.268). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant, and higher BBB is generally favorable.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.497 and -4.729), which is unusual and suggests poor permeability. However, the scale isn't specified, so it's difficult to interpret.
10. **Solubility:** Both ligands have negative solubility values (-1.663 and -1.465), which is also unusual and suggests low solubility. Again, the scale is unknown, making interpretation difficult.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.054 and 0.1), which is excellent.
12. **Cl_mic:** Ligand A (4.615) has significantly lower microsomal clearance than Ligand B (19.582), indicating better metabolic stability.
13. **t1/2:** Ligand A (3.229) has a slightly longer in vitro half-life than Ligand B (0.31).
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.008 and 0.065), which is favorable.
15. **Binding Affinity:** Ligand B (-5.8 kcal/mol) has a slightly better binding affinity than Ligand A (-6.0 kcal/mol). While the difference is small, it's still a positive for Ligand B.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand B is clearly superior. It has a more favorable logP, significantly lower TPSA, better QED, and lower DILI risk. While Ligand A has better metabolic stability (lower Cl_mic) and slightly longer half-life, the advantages of Ligand B in terms of permeability, drug-likeness, and safety outweigh these drawbacks. The affinity difference is minimal. The unusual negative values for Caco-2 and solubility are concerning for both, but the other parameters strongly favor Ligand B.
Output:
0
2025-04-17 20:05:09,058 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (360.845 Da and 358.429 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (76.02) is slightly higher than Ligand B (67.43). Both are below the 140 threshold for oral absorption, but closer to the 90 threshold for CNS targets.
3. **logP:** Both ligands have good logP values (2.17 and 2.763), falling within the optimal 1-3 range. Ligand B is slightly higher, potentially improving membrane permeability.
4. **HBD:** Both have 2 H-bond donors, which is good.
5. **HBA:** Ligand A has 4 H-bond acceptors, while Ligand B has 3. Both are acceptable.
6. **QED:** Both ligands have similar QED values (0.794 and 0.767), indicating good drug-likeness.
7. **DILI:** Ligand A (59.442) has a higher DILI risk than Ligand B (31.989). This is a significant negative for Ligand A.
8. **BBB:** Ligand B (77.2) has a better BBB penetration percentile than Ligand A (66.382). While ADRB2 isn't strictly a CNS target, some CNS exposure can be relevant for off-target effects.
9. **Caco-2:** Ligand A (-5.194) has a worse Caco-2 permeability than Ligand B (-4.684).
10. **Solubility:** Ligand A (-3.199) has worse aqueous solubility than Ligand B (-2.613).
11. **hERG:** Both ligands have low hERG inhibition liability (0.135 and 0.342), which is good.
12. **Cl_mic:** Ligand A (22.462) has a significantly lower microsomal clearance than Ligand B (47.938), indicating better metabolic stability.
13. **t1/2:** Ligand B (-15.13) has a negative in vitro half-life, which is concerning. Ligand A (14.543) has a reasonable half-life.
14. **Pgp:** Ligand A (0.069) has lower P-gp efflux liability than Ligand B (0.091), which is favorable.
15. **Affinity:** Ligand A (-6.7 kcal/mol) has a slightly better binding affinity than Ligand B (-6.1 kcal/mol). This is a 0.6 kcal/mol difference, which is notable but not overwhelming.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Both ligands perform well on logP and TPSA. Ligand A has slightly better Pgp properties, while Ligand B has better BBB penetration. The affinity difference is relatively small. However, the significantly lower DILI risk and better metabolic stability (lower Cl_mic) of Ligand B are major advantages. The negative half-life of Ligand B is a serious concern.
**Overall Assessment:**
While Ligand A has slightly better affinity and Pgp properties, Ligand B's significantly lower DILI risk, better Caco-2 permeability, and better solubility outweigh these factors. The negative half-life of Ligand B is a concern, but can be addressed in further optimization. The DILI risk of Ligand A is a substantial hurdle.
Output:
0
2025-04-17 20:05:09,058 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
Let's systematically compare Ligand A and Ligand B based on the provided parameters and the guidelines, keeping in mind that ADRB2 is a GPCR. Therefore, logP, TPSA, Pgp, and affinity are particularly important.
1. **Molecular Weight:** Both ligands (364.5 and 347.4 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (75.2) is significantly better than Ligand B (124.3). A TPSA under 140 is good for oral absorption, but lower is generally preferred for GPCRs, and Ligand A is much closer to the ideal range.
3. **logP:** Ligand A (1.91) is within the optimal 1-3 range. Ligand B (-0.96) is *below* 1, which could indicate poor membrane permeability. This is a significant drawback for Ligand B.
4. **H-Bond Donors:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally correlate with better permeability.
5. **H-Bond Acceptors:** Both have 5 HBA, which is acceptable.
6. **QED:** Ligand A (0.724) is slightly better than Ligand B (0.606), indicating a more drug-like profile.
7. **DILI:** Ligand A (39.98) has a much lower DILI risk than Ligand B (62.35). This is a substantial advantage for Ligand A.
8. **BBB:** Ligand A (49.4) is better than Ligand B (35.2), although neither are particularly high. BBB isn't a top priority for ADRB2 (a cardiovascular target), but higher is still preferred.
9. **Caco-2:** Both have negative values (-5.42 and -5.48), which is unusual and difficult to interpret without knowing the scale. However, the values are very similar.
10. **Solubility:** Both have negative values (-2.16 and -2.42), which is also unusual and difficult to interpret. Again, the values are very similar.
11. **hERG:** Ligand A (0.25) has a much lower hERG risk than Ligand B (0.015). This is a significant safety advantage.
12. **Cl_mic:** Ligand B (-24.9) has a much lower (better) microsomal clearance than Ligand A (42.8). This suggests better metabolic stability for Ligand B.
13. **t1/2:** Ligand B (-21.99) has a much longer in vitro half-life than Ligand A (0.98). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.025) has a lower Pgp efflux liability than Ligand B (0.004), which is preferable.
15. **Binding Affinity:** Ligand A (-6.1 kcal/mol) has a slightly better binding affinity than Ligand B (-4.7 kcal/mol). While the difference isn't huge (more than 1.5 kcal/mol), it's still a positive for Ligand A.
**Overall Assessment:**
Ligand A demonstrates a better balance of properties, particularly regarding crucial ADME parameters like logP, TPSA, DILI risk, and hERG inhibition. While Ligand B has advantages in metabolic stability (Cl_mic) and half-life, its poor logP and higher DILI/hERG risks are concerning. The slightly better affinity of Ligand A further supports its selection. For a cardiovascular GPCR target, optimizing for permeability and minimizing off-target effects (like hERG inhibition) are critical.
**Output:**
1
2025-04-17 20:05:09,059 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (368.503 and 369.384 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (74.77) is significantly better than Ligand B (101.9). For a GPCR, keeping TPSA under 140 is good for absorption, and lower is generally preferred. Ligand B is pushing the upper limit.
**3. logP:** Ligand A (1.078) is within the optimal 1-3 range. Ligand B (-0.378) is slightly below 1, which *could* indicate permeability issues.
**4. H-Bond Donors:** Ligand A (1) is preferable to Ligand B (4). Fewer HBDs generally improve permeability.
**5. H-Bond Acceptors:** Ligand A (6) is preferable to Ligand B (5).
**6. QED:** Ligand A (0.743) is better than Ligand B (0.467), indicating a more drug-like profile.
**7. DILI:** Ligand A (21.442) has a much lower DILI risk than Ligand B (9.965), which is a significant advantage.
**8. BBB:** Ligand A (68.282) has a better BBB penetration percentile than Ligand B (48.119), although neither is exceptionally high. Given ADRB2's cardiovascular role, BBB penetration isn't a primary concern, but it's still a positive.
**9. Caco-2 Permeability:** Ligand A (-4.93) is better than Ligand B (-5.379). Both are negative, but A is less negative.
**10. Aqueous Solubility:** Ligand A (-1.005) is better than Ligand B (-0.673).
**11. hERG Inhibition:** Both ligands (0.488 and 0.225) have low hERG inhibition risk, which is excellent.
**12. Microsomal Clearance:** Ligand A (-25.846) has a much lower (better) microsomal clearance than Ligand B (-12.912), indicating greater metabolic stability.
**13. In vitro Half-Life:** Ligand A (13.614) has a better in vitro half-life than Ligand B (-32.298).
**14. P-gp Efflux:** Both ligands (0.051 and 0.006) have very low P-gp efflux, which is good.
**15. Binding Affinity:** Both ligands have very similar binding affinities (-6.7 and -6.6 kcal/mol). The difference is negligible.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical ADME-Tox properties (TPSA, logP, HBD, QED, DILI, Cl_mic, t1/2, Solubility). While the binding affinity is similar, the superior ADME profile of Ligand A makes it the more promising drug candidate. The lower DILI risk and better metabolic stability are particularly important.
Output:
1
2025-04-17 20:05:09,059 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [355.295, 63.05, 2.799, 1, 5, 0.842, 85.964, 83.637, -4.698, -4.343, 0.504, 50.811, 17.436, 0.193, -7.3]
**Ligand B:** [352.563, 32.78, 3.51, 0, 3, 0.636, 5.273, 91.314, -4.325, -2.686, 0.867, 71.727, -2.528, 0.347, -7.3]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (352.563) is slightly lower, which is generally favorable.
2. **TPSA:** Ligand A (63.05) is higher than Ligand B (32.78). Ligand B is much better, being well below the 140 threshold for oral absorption and more favorable for GPCRs.
3. **logP:** Both are within the optimal range (1-3), but Ligand B (3.51) is slightly higher. This isn't a major concern, but could potentially lead to off-target interactions.
4. **HBD:** Ligand A (1) is slightly better than Ligand B (0).
5. **HBA:** Ligand A (5) is higher than Ligand B (3). Ligand B is better here.
6. **QED:** Ligand A (0.842) has a better QED score than Ligand B (0.636), indicating a more drug-like profile.
7. **DILI:** Ligand A (85.964) has a significantly higher DILI risk than Ligand B (5.273). This is a major red flag for Ligand A.
8. **BBB:** Ligand B (91.314) has a much higher BBB penetration score than Ligand A (83.637). This is important for a GPCR target, even if not strictly CNS-focused, as it can influence distribution.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand B (-4.325) is slightly less negative than Ligand A (-4.698).
10. **Solubility:** Ligand B (-2.686) has better (less negative) solubility than Ligand A (-4.343).
11. **hERG:** Ligand B (0.867) has a slightly higher hERG risk than Ligand A (0.504), but both are relatively low.
12. **Cl_mic:** Ligand B (71.727) has a lower microsomal clearance than Ligand A (50.811), indicating better metabolic stability.
13. **t1/2:** Ligand B (-2.528) has a longer in vitro half-life than Ligand A (17.436), which is a positive.
14. **Pgp:** Ligand B (0.347) has lower P-gp efflux than Ligand A (0.193), which is favorable for bioavailability.
15. **Affinity:** Both ligands have the same binding affinity (-7.3 kcal/mol), so this parameter doesn't differentiate them.
**Overall Assessment:**
Ligand B is significantly better. While Ligand A has a slightly better QED score, the extremely high DILI risk associated with Ligand A is a deal-breaker. Ligand B demonstrates superior properties in several crucial areas for a GPCR drug candidate: lower TPSA, better solubility, lower DILI, higher BBB penetration, better metabolic stability, and longer half-life. The slightly higher logP of Ligand B is a minor concern compared to the significant safety concerns with Ligand A.
Output:
0
2025-04-17 20:05:09,059 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (349.431 and 352.475 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (78.95) is slightly higher than Ligand B (66.92). Both are below the 140 A^2 threshold for good oral absorption, but Ligand B is better positioned, especially considering GPCRs benefit from lower TPSA.
**3. logP:** Both ligands have good logP values (1.313 and 1.866), falling within the optimal 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability.
**4. H-Bond Donors:** Ligand A has 1 HBD, while Ligand B has 0. Both are acceptable, within the <5 guideline.
**5. H-Bond Acceptors:** Both ligands have 4 HBAs, well within the <10 guideline.
**6. QED:** Both ligands have good QED scores (0.6 and 0.701), indicating good drug-like properties. Ligand B is slightly better.
**7. DILI Risk:** Ligand A has a DILI risk of 59.946%, which is approaching the higher risk threshold. Ligand B has a much lower DILI risk of 12.33%, a significant advantage.
**8. BBB Penetration:** Ligand B (86.002%) has significantly better BBB penetration than Ligand A (62.233%). While ADRB2 isn't strictly a CNS target, some CNS exposure can sometimes be acceptable or even desirable for off-target effects monitoring.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.539 and -4.397). This is unusual and suggests either poor permeability or an issue with the assay. It's difficult to interpret without further information, but it doesn't strongly favor either ligand.
**10. Aqueous Solubility:** Both ligands have very poor aqueous solubility (-1.573 and -1.152). This is a concern for both, but could be addressed with formulation strategies.
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (0.13 and 0.201), which is excellent.
**12. Microsomal Clearance:** Ligand A (15.484) has a significantly lower microsomal clearance than Ligand B (34.66). Lower clearance means greater metabolic stability, a significant advantage for Ligand A.
**13. In vitro Half-Life:** Ligand A (-26.613) has a very negative half-life, suggesting a very short half-life. Ligand B (-7.121) is better, but still not ideal.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.048 and 0.041), which is good.
**15. Binding Affinity:** Ligand B (-6.2 kcal/mol) has a slightly better binding affinity than Ligand A (-7.0 kcal/mol). While the difference is not huge, it's still a positive for Ligand B.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity) and the general guidelines, Ligand B emerges as the more promising candidate. While Ligand A has better metabolic stability (lower Cl_mic), Ligand B's significantly lower DILI risk, better BBB penetration, and slightly improved binding affinity outweigh this advantage. The poor solubility of both is a concern, but can be addressed during formulation. The Caco-2 values are concerning for both, but not decisive.
Output:
0
2025-04-17 20:05:09,059 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, the key priorities are logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB.
Let's break down the comparison:
1. **MW:** Both ligands are within the acceptable range (200-500 Da).
2. **TPSA:** Both are reasonably close to the ideal <140, but acceptable for a non-CNS target.
3. **logP:** Ligand A (1.744) is better than Ligand B (2.81). While both are within the optimal range, A is closer to the lower bound, potentially improving solubility.
4. **HBD/HBA:** Both have 2 HBD and 5 HBA, which are acceptable.
5. **QED:** Ligand A (0.8) is significantly better than Ligand B (0.514), indicating a more drug-like profile.
6. **DILI:** Ligand B (71.539) has a slightly better DILI score than Ligand A (80.109), but both are acceptable.
7. **BBB:** Not a primary concern for a cardiovascular target, but Ligand A (48.042) is better than Ligand B (32.765).
8. **Caco-2:** Ligand B (-5.849) is better than Ligand A (-4.976), suggesting better intestinal absorption.
9. **Solubility:** Ligand B (-3.0) is better than Ligand A (-2.451), which is important for bioavailability.
10. **hERG:** Both are very low risk (0.056 and 0.074).
11. **Cl_mic:** Ligand A (-21.566) has significantly better metabolic stability (lower clearance) than Ligand B (16.139).
12. **t1/2:** Ligand A (-30.524) has a much longer in vitro half-life than Ligand B (-1.961).
13. **Pgp:** Both have very low Pgp efflux liability (0.002 and 0.054).
14. **Binding Affinity:** Ligand B (-7.4) has a slightly better binding affinity than Ligand A (-7.2), but the difference is small (0.2 kcal/mol).
**Overall Assessment:**
While Ligand B has slightly better Caco-2 permeability, solubility, and binding affinity, Ligand A demonstrates a superior overall profile. Its significantly better QED, metabolic stability (Cl_mic and t1/2), and acceptable logP and BBB values make it a more promising candidate. The small difference in binding affinity is outweighed by the more favorable ADME properties of Ligand A.
**Output:**
1
2025-04-17 20:05:09,059 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (351.353 and 344.411 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (63.94) is significantly better than Ligand A (82.53). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (1.604 and 1.166), falling within the optimal 1-3 range. Ligand B is slightly better.
4. **HBD:** Ligand B (1) is preferable to Ligand A (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) and Ligand B (5) are both acceptable, being under the 10 threshold.
6. **QED:** Both ligands have good QED scores (0.79 and 0.813), indicating good drug-like properties.
7. **DILI:** Ligand B (28.655) has a much lower DILI risk than Ligand A (54.556). This is a significant advantage.
8. **BBB:** Both have similar BBB penetration (59.248 and 53.625). Not a major factor for a cardiovascular target.
9. **Caco-2:** Both have negative Caco-2 values (-4.948 and -4.846), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Both have negative solubility values (-3.255 and -2.259), indicating poor aqueous solubility. This is a significant drawback for both.
11. **hERG:** Both ligands have low hERG risk (0.252 and 0.29).
12. **Cl_mic:** Ligand A (7.101) has a lower (better) microsomal clearance than Ligand B (-1.264). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand B (34.555) has a much longer in vitro half-life than Ligand A (-1.362). This is a substantial advantage.
14. **Pgp:** Both have very low Pgp efflux liability (0.024 and 0.041).
15. **Affinity:** Ligand B (-6.2 kcal/mol) has a slightly better binding affinity than Ligand A (-5.8 kcal/mol). While the difference is less than the 1.5 kcal/mol threshold, it's still a positive.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B is better on logP, TPSA, and affinity. The biggest advantage for Ligand B is the significantly lower DILI risk and longer half-life. While both have poor Caco-2 and solubility, the improved safety profile and metabolic stability of Ligand B outweigh the slightly better clearance of Ligand A.
**Output:**
0
2025-04-17 20:05:09,060 - INFO - Batch 158 complete. Total preferences: 2528
2025-04-17 20:05:09,060 - INFO - Processing batch 159/512...
2025-04-17 20:06:00,478 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.475 and 344.455 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (71.25) is better than Ligand B (75.27), both are under the 140 threshold for oral absorption, but closer to the ideal for GPCRs.
3. **logP:** Both ligands (2.506 and 2.113) are within the optimal 1-3 range. Ligand A is slightly higher, potentially aiding membrane permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (3). Lower HBA generally improves permeability.
6. **QED:** Both are good (0.746 and 0.802), indicating drug-like properties. Ligand B is slightly better.
7. **DILI:** Both are low risk (23.885 and 25.785 percentile), well below the 40% threshold. No significant difference.
8. **BBB:** Ligand A (62.699) is better than Ligand B (55.176), but neither are particularly high. For a cardiovascular target, BBB penetration isn't critical, but a higher value is generally favorable.
9. **Caco-2:** Both are very negative (-4.864), indicating poor permeability. This is a concern for both.
10. **Solubility:** Both are very negative (-2.845 and -2.718), indicating poor solubility. This is a significant drawback for both.
11. **hERG:** Both are very low (0.181 and 0.076), indicating low cardiotoxicity risk. Ligand B is slightly better.
12. **Cl_mic:** Ligand B (23.512) has lower microsomal clearance than Ligand A (36.473), suggesting better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand B (-2.797) has a negative half-life, which is concerning, while Ligand A (2.786) is positive. This is a significant advantage for Ligand A.
14. **Pgp:** Both are very low (0.213 and 0.06), suggesting low P-gp efflux. Ligand B is slightly better.
15. **Binding Affinity:** Ligand B (-7.4) has slightly better binding affinity than Ligand A (-7.2), a difference of 0.2 kcal/mol.
**Overall Assessment:**
While Ligand B has a slightly better binding affinity and lower Cl_mic, the negative in vitro half-life is a major concern. Ligand A has a positive half-life, which is more desirable. Both have poor Caco-2 and solubility, which would need to be addressed through formulation strategies. Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity), and the importance of metabolic stability and reasonable half-life, Ligand A appears to be the slightly more promising candidate. The small affinity difference is outweighed by the half-life advantage.
Output:
1
2025-04-17 20:06:00,478 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (359.861 and 350.459 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (61.36) is significantly better than Ligand B (87.66). ADRB2 is not a CNS target, but lower TPSA generally improves absorption.
3. **logP:** Ligand A (3.608) is optimal, while Ligand B (0.977) is quite low. A logP below 1 can hinder membrane permeability. This is a substantial advantage for Ligand A.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Both ligands have 4 HBA, which is acceptable.
6. **QED:** Ligand A (0.85) is better than Ligand B (0.541), indicating a more drug-like profile.
7. **DILI:** Ligand B (11.4) has a much lower DILI risk than Ligand A (62.699). This is a significant advantage for Ligand B.
8. **BBB:** Not a primary concern for ADRB2, but Ligand A (93.098) has a higher BBB penetration than Ligand B (49.981).
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.805 and -4.632), which is unusual and suggests poor permeability. However, these values are close, and the scale isn't fully defined, so it's hard to draw strong conclusions.
10. **Solubility:** Ligand A (-4.994) has slightly better solubility than Ligand B (-1.6), but both are poor.
11. **hERG:** Ligand A (0.616) has a slightly better hERG profile than Ligand B (0.118). Lower is better.
12. **Cl_mic:** Ligand B (0.116) has significantly lower microsomal clearance than Ligand A (65.377), indicating better metabolic stability. This is a major advantage for Ligand B.
13. **t1/2:** Ligand A (24.43) has a better in vitro half-life than Ligand B (0.615).
14. **Pgp:** Ligand A (0.225) has lower P-gp efflux liability than Ligand B (0.022). Lower is better.
15. **Binding Affinity:** Ligand B (-5.8) has a slightly better binding affinity than Ligand A (-5.6). While the difference is small, it's still a factor.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, and affinity are key. Ligand A excels in logP and has acceptable TPSA, while Ligand B has a slightly better affinity. However, the significantly better DILI and Cl_mic profiles of Ligand B are very attractive. The poor solubility of both compounds is a concern, but can be addressed with formulation strategies.
**Overall Assessment:**
While Ligand A has better QED, BBB, and t1/2, the combination of significantly lower DILI risk and improved metabolic stability (Cl_mic) for Ligand B outweighs these advantages. The slightly better affinity of Ligand B is also a plus. The low logP of Ligand B is a concern, but the other benefits are more impactful.
Output:
0
2025-04-17 20:06:00,478 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Ligand A (407.234 Da) is within the ideal range, while Ligand B (352.425 Da) is also acceptable. No clear advantage.
2. **TPSA:** Ligand A (86.71) is better than Ligand B (49.41). Lower TPSA generally improves permeability, crucial for GPCR ligands.
3. **logP:** Both are good (A: 3.922, B: 3.004), falling within the 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability but also raises potential off-target concerns.
4. **HBD:** Ligand A (2) is preferable to Ligand B (1) as it provides a better balance between solubility and permeability.
5. **HBA:** Ligand A (4) is preferable to Ligand B (2) for the same reason as above.
6. **QED:** Both are good (A: 0.723, B: 0.856), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand B (26.91) has a significantly lower DILI risk than Ligand A (47.732), a major advantage.
8. **BBB:** Ligand B (89.608) has a much higher BBB penetration potential than Ligand A (36.332). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be beneficial or at least needs to be considered.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-5.106) is slightly better than Ligand B (-4.628), but both are concerning.
10. **Solubility:** Both are very poor (-3.576 and -4.146 respectively). This is a significant drawback for both compounds.
11. **hERG:** Ligand A (0.23) has a lower hERG risk than Ligand B (0.556), which is preferable.
12. **Cl_mic:** Ligand A (-10.871) has a lower (better) microsomal clearance than Ligand B (32.033), indicating greater metabolic stability.
13. **t1/2:** Ligand A (-24.329) has a longer in vitro half-life than Ligand B (-31.126).
14. **Pgp:** Ligand A (0.03) has lower P-gp efflux than Ligand B (0.1).
15. **Affinity:** Ligand B (-7.4 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.2 kcal/mol). This is a substantial advantage, potentially outweighing some ADME concerns.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in affinity and has better TPSA and Pgp values. While Ligand A has a slightly better logP, the difference isn't substantial enough to offset the affinity advantage of Ligand B. The lower DILI risk and higher BBB penetration of Ligand B are also significant positives.
**Overall Assessment:**
Despite the poor solubility and Caco-2 permeability of both compounds, Ligand B's superior binding affinity, lower DILI risk, and better BBB penetration make it the more promising candidate. The stronger binding is a critical factor for GPCR targets, and the improved safety profile is highly desirable.
Output:
0
2025-04-17 20:06:00,478 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (367.475 and 387.527 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (95.07 and 96.44) are reasonably close to the 140 A^2 threshold for oral absorption, but higher than the <90 A^2 ideal for CNS targets. Since ADRB2 is a cardiovascular target, CNS penetration isn't a primary concern.
3. **logP:** Ligand A (2.419) is optimal, while Ligand B (0.161) is quite low. A logP below 1 can hinder membrane permeability. This is a significant advantage for Ligand A.
4. **HBD:** Both have 1 HBD, which is acceptable.
5. **HBA:** Ligand A has 9 HBA, within the acceptable range. Ligand B has 6 HBA, also acceptable.
6. **QED:** Both have good QED scores (0.505 and 0.716), indicating drug-likeness. Ligand B is slightly better.
7. **DILI:** Ligand A (77.588) has a higher DILI risk than Ligand B (43.35). This is a drawback for Ligand A.
8. **BBB:** Both have relatively low BBB penetration, which is not a major concern for a cardiovascular target. Ligand B is slightly better (53.974 vs 43.815).
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Both have negative solubility values, which is also unusual and suggests poor solubility. This is a significant concern for both.
11. **hERG:** Both have very low hERG inhibition risk (0.044 and 0.118), which is excellent.
12. **Cl_mic:** Ligand A (97.357) has a higher microsomal clearance than Ligand B (1.449), indicating lower metabolic stability. This is a drawback for Ligand A.
13. **t1/2:** Ligand A (23.029) has a longer half-life than Ligand B (0.261), which is desirable.
14. **Pgp:** Ligand A (0.252) has lower P-gp efflux than Ligand B (0.033), which is preferable.
15. **Binding Affinity:** Ligand B (-7.8 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.2 kcal/mol). This is a substantial advantage for Ligand B. A difference of 1.6 kcal/mol is significant enough to potentially outweigh some ADME concerns.
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand A has a better logP and Pgp profile, but Ligand B's substantially better binding affinity is a major advantage. While both have concerning Caco-2 and solubility values, the affinity difference is likely to be more impactful in driving *in vivo* efficacy. The DILI risk for Ligand A is also a concern.
**Conclusion:**
Despite the concerns with Caco-2 and solubility for both, Ligand B's significantly higher binding affinity and lower DILI risk outweigh the advantages of Ligand A's slightly better logP and Pgp.
Output:
0
2025-04-17 20:06:00,478 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [354.403, 85.38, -0.17, 0, 6, 0.422, 32.222, 61.613, -4.529, -1.048, 0.077, 24.977, -3.099, 0.014, -6.6]
**Ligand B:** [370.435, 126.29, -1.248, 2, 7, 0.667, 71.694, 48.391, -5.745, -1.918, 0.024, -4.209, 10.54, 0.026, -7.4]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, Affinity, and BBB):
1. **MW:** Both are within the acceptable range (200-500 Da). Ligand A (354.4) is slightly better.
2. **TPSA:** Ligand A (85.38) is excellent, well below 140 and good for oral absorption. Ligand B (126.29) is still acceptable, but less ideal.
3. **logP:** Ligand A (-0.17) is a little low, potentially impacting permeability. Ligand B (-1.248) is also on the lower side, but slightly better. Both are below the optimal 1-3 range.
4. **HBD/HBA:** Ligand A (0 HBD, 6 HBA) is preferable. Ligand B (2 HBD, 7 HBA) has more potential for off-target interactions.
5. **QED:** Ligand B (0.667) is better than Ligand A (0.422), suggesting a more drug-like profile.
6. **DILI:** Ligand A (32.222) has a significantly lower DILI risk than Ligand B (71.694). This is a major advantage for Ligand A.
7. **BBB:** Ligand A (61.613) has a better BBB percentile than Ligand B (48.391). While ADRB2 isn't necessarily a CNS target, some peripheral effects might benefit from some BBB penetration.
8. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-4.529) is slightly better than Ligand B (-5.745).
9. **Solubility:** Both have negative solubility values, indicating poor aqueous solubility. Ligand A (-1.048) is slightly better.
10. **hERG:** Both are very low risk (0.077 and 0.024).
11. **Cl_mic:** Ligand B (-4.209) has a *much* lower (better) microsomal clearance than Ligand A (24.977), suggesting better metabolic stability.
12. **t1/2:** Ligand B (10.54) has a significantly longer half-life than Ligand A (-3.099). This is a substantial advantage.
13. **Pgp:** Both are very low efflux (0.014 and 0.026).
14. **Affinity:** Ligand B (-7.4) has a significantly stronger binding affinity than Ligand A (-6.6). This is a 0.8 kcal/mol difference, which is substantial.
**Overall Assessment:**
Ligand B wins on binding affinity and metabolic stability (Cl_mic and t1/2). However, Ligand A has a much better safety profile (DILI) and slightly better BBB penetration. The affinity difference is significant, and for a GPCR, potent binding is crucial. The improved metabolic stability of Ligand B is also a significant advantage, potentially leading to less frequent dosing. The DILI risk for Ligand B is concerning, but could be mitigated with further optimization.
Given the importance of affinity for GPCRs and the substantial improvement in metabolic stability, I would prioritize Ligand B.
**Output:**
0
2025-04-17 20:06:00,478 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [345.399, 92.45, 2.105, 3, 4, 0.683, 68.941, 53.936, -4.997, -3.841, 0.635, 31.817, -25.906, 0.14, -5.7]
**Ligand B:** [431.664, 49.41, 4.368, 1, 2, 0.523, 73.982, 79.178, -4.585, -5.554, 0.84, 64.995, 92.792, 0.511, -5.2]
**Step-by-step comparison:**
1. **MW:** Ligand A (345.4 Da) is within the ideal range, while Ligand B (431.7 Da) is at the upper limit.
2. **TPSA:** Ligand A (92.45) is good for oral absorption, while Ligand B (49.41) is excellent.
3. **logP:** Both ligands have logP values within the optimal range (A: 2.105, B: 4.368). Ligand B is pushing the upper limit, which could lead to solubility issues.
4. **HBD:** Ligand A (3) is acceptable, and Ligand B (1) is even better.
5. **HBA:** Ligand A (4) is acceptable, and Ligand B (2) is even better.
6. **QED:** Ligand A (0.683) is better than Ligand B (0.523), indicating a more drug-like profile.
7. **DILI:** Ligand A (68.941) has a lower DILI risk than Ligand B (73.982), which is preferable.
8. **BBB:** Ligand B (79.178) has a better BBB penetration potential than Ligand A (53.936). This is a significant advantage for a GPCR target, though not strictly essential for ADRB2.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not defined, so it's hard to interpret.
10. **Solubility:** Both ligands have negative solubility values, which is also unusual and suggests poor solubility.
11. **hERG:** Both ligands have low hERG inhibition liability (A: 0.635, B: 0.84), which is good.
12. **Cl_mic:** Ligand A (31.817) has a lower microsomal clearance than Ligand B (64.995), indicating better metabolic stability.
13. **t1/2:** Ligand B (92.792) has a significantly longer in vitro half-life than Ligand A (-25.906). This is a major advantage.
14. **Pgp:** Ligand A (0.14) has lower P-gp efflux liability than Ligand B (0.511), which is favorable.
15. **Affinity:** Both ligands have similar binding affinities (-5.7 and -5.2 kcal/mol). The difference is not substantial enough to be a deciding factor.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, we prioritize logP, Pgp, TPSA, and affinity. Ligand B excels in TPSA and BBB, while Ligand A has better QED, DILI, and Pgp. The longer half-life of Ligand B is also a significant advantage.
**Overall Assessment:**
While Ligand A has a better drug-like profile (QED, DILI, Pgp) and metabolic stability, the longer half-life and better BBB penetration of Ligand B are compelling, especially considering the GPCR target class. The slightly higher logP of Ligand B is a minor concern, but not a deal-breaker.
Therefore, I would choose Ligand B.
0
2025-04-17 20:06:00,478 - INFO - Here's my reasoning and final output:
**Reasoning:**
We're evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, logP, TPSA, Pgp, and binding affinity are key. Let's break down the comparison:
1. **MW:** Both ligands (364.431 and 360.889 Da) are within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (104.45) is higher than Ligand B (75.01). While both are reasonably good, Ligand B is better, being closer to the preferred <140 for oral absorption and better for GPCRs.
3. **logP:** Ligand A (-0.01) is suboptimal, being close to 1 but slightly below. Ligand B (4.179) is high, potentially causing solubility issues and off-target effects. This is a significant drawback for Ligand B.
4. **HBD/HBA:** Ligand A (1 HBD, 8 HBA) is better balanced than Ligand B (2 HBD, 3 HBA).
5. **QED:** Ligand A (0.773) is significantly better than Ligand B (0.599), indicating a more drug-like profile.
6. **DILI:** Both are acceptable (69.872 and 62.893), with Ligand B being slightly better.
7. **BBB:** Ligand B (63.746) has a higher BBB penetration percentile than Ligand A (41.838). However, for a cardiovascular target, BBB penetration isn't a primary concern.
8. **Caco-2:** Both are similar (-5.49 and -5.255), suggesting comparable intestinal absorption.
9. **Solubility:** Ligand A (-1.388) is significantly better than Ligand B (-4.554). This is crucial given Ligand B's high logP.
10. **hERG:** Ligand A (0.02) is much better than Ligand B (0.793), indicating a lower risk of cardiotoxicity, which is critical for a cardiovascular target.
11. **Cl_mic:** Ligand A (6.266) has a lower clearance than Ligand B (61.455), suggesting better metabolic stability.
12. **t1/2:** Ligand B (48.921) has a longer half-life than Ligand A (34.945). This is a positive for Ligand B.
13. **Pgp:** Ligand A (0.052) has lower P-gp efflux than Ligand B (0.378), which is favorable for bioavailability.
14. **Binding Affinity:** Ligand A (-7.2 kcal/mol) has a slightly better binding affinity than Ligand B (-5.7 kcal/mol). While the difference isn't huge, it's enough to consider.
**Overall Assessment:**
Ligand B has a better half-life and BBB penetration, but suffers from a high logP, poor solubility, higher hERG risk, and higher Pgp efflux. Ligand A has a more balanced profile, with better solubility, lower hERG risk, better metabolic stability, and a slightly better binding affinity. Given the cardiovascular target, minimizing cardiotoxicity (hERG) and ensuring adequate solubility are paramount. Ligand A is the more promising candidate.
**Output:**
1
2025-04-17 20:06:00,479 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (345.443 and 350.547 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (65.79) is higher than Ligand B (49.41). For a cardiovascular GPCR, TPSA is moderately important, and Ligand B is better here, being closer to the <90 target for potential CNS penetration (though not a primary concern for ADRB2).
3. **logP:** Ligand A (1.705) is within the optimal 1-3 range. Ligand B (4.302) is significantly higher, potentially leading to solubility issues and off-target interactions. This is a considerable drawback.
4. **HBD:** Both ligands have 1 HBD, which is acceptable.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 2. Both are within the acceptable range of <=10.
6. **QED:** Ligand A (0.797) has a better QED score than Ligand B (0.63), indicating a more drug-like profile.
7. **DILI:** Ligand A (30.942) has a much lower DILI risk than Ligand B (17.72). This is a significant advantage for Ligand A. Lower percentile is better.
8. **BBB:** Ligand B (77.007) has a higher BBB penetration percentile than Ligand A (69.252). While ADRB2 isn't a primary CNS target, some peripheral ADRB2 activity can influence CNS effects, so this is a minor positive for Ligand B.
9. **Caco-2:** Ligand A (-5.022) and Ligand B (-4.632) both have negative values, which is unusual and suggests poor permeability. However, the scale isn't specified, so it's hard to interpret.
10. **Solubility:** Ligand A (-0.86) has better solubility than Ligand B (-3.844). Solubility is important for bioavailability, and Ligand B's value is concerning.
11. **hERG:** Both ligands have similar hERG inhibition liability (0.614 and 0.666), which is acceptable.
12. **Cl_mic:** Ligand A (43.168) has a lower microsomal clearance than Ligand B (55.968), suggesting better metabolic stability.
13. **t1/2:** Ligand A (33.507) has a significantly longer in vitro half-life than Ligand B (3.78). This is a major advantage for Ligand A, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have similar Pgp efflux liability (0.134 and 0.333).
15. **Binding Affinity:** Ligand B (-7.4 kcal/mol) has a stronger binding affinity than Ligand A (-6.4 kcal/mol). This is a 1.0 kcal/mol difference, which is substantial.
**Overall Assessment:**
Ligand B has a better binding affinity, but it suffers from a high logP, poor solubility, and a higher DILI risk. Ligand A has a more balanced profile with better solubility, lower DILI risk, better metabolic stability (lower Cl_mic and longer t1/2), and a better QED score. While Ligand B's affinity is stronger, the ADME liabilities associated with it are significant enough to outweigh that benefit, especially considering the cardiovascular target. The slightly better BBB penetration of Ligand B isn't a major factor for ADRB2.
Therefore, Ligand A is the more promising drug candidate.
Output:
1
2025-04-17 20:06:00,479 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (446.147 Da) is within the ideal range, while Ligand B (353.463 Da) is towards the lower end but still acceptable.
2. **TPSA:** Ligand A (41.13) is excellent, well below the 140 threshold. Ligand B (78.95) is still reasonable, but higher.
3. **logP:** Ligand A (4.959) is slightly high, potentially leading to solubility issues or off-target effects. Ligand B (0.492) is quite low, which could hinder membrane permeability.
4. **HBD:** Both ligands have acceptable HBD counts (2 for A, 1 for B).
5. **HBA:** Both ligands have acceptable HBA counts (2 for A, 4 for B).
6. **QED:** Both ligands have good QED scores (0.698 for A, 0.78 for B), indicating good drug-like properties.
7. **DILI:** Ligand A (63.086) has a moderate DILI risk, while Ligand B (15.898) has a very low risk. This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (83.521) has good BBB penetration, while Ligand B (58.821) is lower. While ADRB2 isn't strictly a CNS target, some CNS exposure can be relevant for side effect profiles.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests a potential issue with the data. However, we can interpret this as very poor permeability.
10. **Solubility:** Ligand A (-5.904) has very poor solubility, which is concerning given its already high logP. Ligand B (-0.881) is better, but still not ideal.
11. **hERG:** Ligand A (0.782) has a slightly higher hERG risk than Ligand B (0.107), which is preferable.
12. **Cl_mic:** Ligand A (34.604) has a moderate clearance, while Ligand B (12.165) has a low clearance, indicating better metabolic stability.
13. **t1/2:** Ligand A (127.534) has a long half-life, which is good. Ligand B (-5.489) has a negative half-life, which is impossible and indicates a data issue.
14. **Pgp:** Ligand A (0.393) has low P-gp efflux, while Ligand B (0.014) has very low efflux. Both are good.
15. **Affinity:** Ligand B (-5.9 kcal/mol) has a significantly stronger binding affinity than Ligand A (-4.2 kcal/mol) - a difference of 1.7 kcal/mol. This is a substantial advantage.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in affinity and Pgp efflux. Ligand A has better TPSA, but its high logP and poor solubility are significant drawbacks. The DILI risk is also a major concern for Ligand A. The half-life for Ligand B is suspect, but the binding affinity difference is large enough to overcome this.
**Conclusion:**
Despite the questionable Caco-2 and half-life data for Ligand B, its significantly stronger binding affinity and lower DILI risk outweigh the advantages of Ligand A. The higher logP and poor solubility of Ligand A are major concerns.
Output:
0
2025-04-17 20:06:00,479 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (360.845 and 361.32 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (76.02) is significantly better than Ligand B (105.64). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (2.919) is optimal, while Ligand B (1.298) is a bit low. A logP between 1-3 is preferred, and Ligand B is closer to the lower limit, potentially impacting permeability.
4. **HBD:** Both ligands have 2 HBD, which is within the acceptable range (<=5).
5. **HBA:** Both ligands have 4 HBA, also within the acceptable range (<=10).
6. **QED:** Both ligands have similar QED values (0.88 and 0.824), indicating good drug-likeness.
7. **DILI:** Ligand A (71.694) has a higher DILI risk than Ligand B (52.695). This is a significant drawback for Ligand A.
8. **BBB:** Ligand B (77.705) has a higher BBB penetration percentile than Ligand A (62.311). While not critical for a cardiovascular target, it's a slight positive for Ligand B.
9. **Caco-2:** Ligand A (-4.869) is better than Ligand B (-5.102). Higher values are better, so this is a slight advantage for Ligand A.
10. **Solubility:** Ligand A (-3.99) is better than Ligand B (-3.516). Higher values are better, so this is a slight advantage for Ligand A.
11. **hERG:** Ligand A (0.21) has a lower hERG inhibition liability than Ligand B (0.369). This is a significant advantage for Ligand A, as it reduces the risk of cardiotoxicity.
12. **Cl_mic:** Ligand B (-10.368) has much lower microsomal clearance than Ligand A (27.573). This indicates better metabolic stability for Ligand B, a crucial factor for drug duration.
13. **t1/2:** Ligand B (-9.964) has a longer in vitro half-life than Ligand A (38.686). This further supports the better metabolic stability of Ligand B.
14. **Pgp:** Ligand A (0.064) has lower P-gp efflux liability than Ligand B (0.041). Lower is better, so this is a slight advantage for Ligand A.
15. **Binding Affinity:** Ligand B (-6.9) has a slightly better binding affinity than Ligand A (-6.4). While the difference is not huge, it's still a factor.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A has better logP, TPSA, and Pgp. Ligand B has better affinity. However, the DILI risk for Ligand A is concerning, and the significantly better metabolic stability (lower Cl_mic and longer t1/2) of Ligand B is a major advantage.
**Overall Assessment:**
While Ligand A has some favorable properties (logP, TPSA, hERG), the higher DILI risk and poorer metabolic stability are significant drawbacks. Ligand B, despite a slightly lower logP, presents a more balanced profile with a lower DILI risk and substantially improved metabolic stability. The slightly better binding affinity of Ligand B further tips the balance.
Output:
0
2025-04-17 20:06:00,479 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [340.343, 95.14, 0.648, 0, 8, 0.65, 79.062, 65.374, -4.669, -2.111, 0.154, 61.643, -4.233, 0.115, -5.4]
**Ligand B:** [366.38, 78.87, 1.941, 2, 4, 0.391, 21.869, 77.317, -5.008, -2.003, 0.513, 7.062, -27.609, 0.08, -6.7]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, Affinity, and BBB):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (340.343) is slightly preferred.
2. **TPSA:** Ligand A (95.14) is a bit higher than ideal (<140), but Ligand B (78.87) is excellent. This favors Ligand B.
3. **logP:** Ligand A (0.648) is low, potentially hindering permeability. Ligand B (1.941) is much better, falling within the optimal 1-3 range. This is a significant advantage for Ligand B.
4. **HBD/HBA:** Ligand A (0 HBD, 8 HBA) is reasonable. Ligand B (2 HBD, 4 HBA) is also good. No strong preference.
5. **QED:** Ligand A (0.65) is good, while Ligand B (0.391) is below the 0.5 threshold, indicating a less drug-like profile. This favors Ligand A.
6. **DILI:** Ligand A (79.062) has a higher DILI risk than Ligand B (21.869). This strongly favors Ligand B.
7. **BBB:** Ligand B (77.317) shows better BBB penetration than Ligand A (65.374). This is a positive for Ligand B, given it's a GPCR.
8. **Caco-2:** Ligand A (-4.669) and Ligand B (-5.008) are both very poor.
9. **Solubility:** Both have very poor solubility (-2.111 and -2.003 respectively).
10. **hERG:** Ligand A (0.154) has a lower hERG risk than Ligand B (0.513). This favors Ligand A.
11. **Cl_mic:** Ligand B (7.062) has a much lower microsomal clearance than Ligand A (61.643), suggesting better metabolic stability. This is a significant advantage for Ligand B.
12. **t1/2:** Ligand B (-27.609) has a much longer in vitro half-life than Ligand A (-4.233). This is a major advantage for Ligand B.
13. **Pgp:** Ligand A (0.115) has lower P-gp efflux than Ligand B (0.08). This is a slight advantage for Ligand A.
14. **Affinity:** Ligand B (-6.7 kcal/mol) has a stronger binding affinity than Ligand A (-5.4 kcal/mol). This is a substantial advantage for Ligand B.
**Overall Assessment:**
While Ligand A has a slightly better MW and QED, Ligand B overwhelmingly wins on the critical GPCR parameters and ADME properties. Specifically, its superior logP, lower DILI risk, better BBB penetration, significantly improved metabolic stability (lower Cl_mic, longer t1/2), and stronger binding affinity make it a much more promising drug candidate. The poor Caco-2 and solubility for both are concerning, but can be addressed with formulation strategies.
Therefore, I prefer Ligand B.
0
2025-04-17 20:06:00,479 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands (344.46 and 363.45 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (82.26) is significantly better than Ligand B (116.76). ADRB2 is a cardiovascular target, not CNS, but lower TPSA generally improves absorption.
3. **logP:** Ligand A (1.838) is better than Ligand B (0.581). Both are within the acceptable range, but A is closer to the optimal 1-3 range.
4. **HBD:** Ligand A (4) is slightly higher than Ligand B (2), but both are acceptable (<=5).
5. **HBA:** Ligand B (7) is higher than Ligand A (3). Both are within the acceptable range (<=10).
6. **QED:** Both ligands have similar QED values (0.658 and 0.691), indicating good drug-likeness.
7. **DILI:** Ligand A (35.052) has a much lower DILI risk than Ligand B (67.158). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (62.389) is better than Ligand B (25.126), but BBB isn't a high priority for a cardiovascular target.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-5.509) is slightly better than Ligand B (-5.992).
10. **Solubility:** Both ligands have negative solubility scores, indicating poor solubility. Ligand A (-2.08) is slightly better than Ligand B (-1.604).
11. **hERG:** Ligand A (0.23) is much better than Ligand B (0.046), indicating lower cardiotoxicity risk. This is crucial for a cardiovascular target.
12. **Cl_mic:** Ligand A (-0.285) has a lower (better) microsomal clearance than Ligand B (25.764), suggesting better metabolic stability.
13. **t1/2:** Ligand A (8.484) has a longer half-life than Ligand B (-4.642).
14. **Pgp:** Ligand A (0.041) is better than Ligand B (0.02), indicating lower P-gp efflux.
15. **Affinity:** Ligand A (-7.6 kcal/mol) has a slightly better binding affinity than Ligand B (-6.7 kcal/mol). While the difference is less than 1.5 kcal/mol, it contributes to the overall preference.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A performs better in all of these categories. Additionally, the significantly lower DILI and hERG risk for Ligand A are critical for a cardiovascular drug.
**Conclusion:**
Ligand A is the superior candidate due to its better ADME properties (lower DILI, hERG, Cl_mic, better solubility, Pgp efflux, and half-life), slightly better affinity, and more favorable TPSA and logP values.
Output:
1
2025-04-17 20:06:00,479 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (335.39 & 362.83 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (47.67) is slightly higher than Ligand B (41.57), but both are well below the 140 threshold for good oral absorption.
3. **logP:** Both ligands have good logP values (3.569 & 3.169), falling within the optimal 1-3 range. Ligand A is slightly higher, which *could* indicate a slightly better ability to cross membranes, but it's not a huge difference.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 5 HBA, while Ligand B has 3. Both are acceptable, under the 10 threshold.
6. **QED:** Ligand B (0.888) has a better QED score than Ligand A (0.606), suggesting a more drug-like profile overall.
7. **DILI:** Ligand B (52.423) has a lower DILI risk than Ligand A (65.568), which is a significant advantage. Lower DILI is always preferred.
8. **BBB:** Ligand B (87.515) has a substantially higher BBB penetration percentile than Ligand A (76.696). While ADRB2 isn't exclusively a CNS target, some peripheral ADRB2 activity can be modulated by CNS effects, and better BBB penetration isn't a detriment.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and potentially problematic. However, the values are similar (-5.282 and -4.743), so this doesn't differentiate them.
10. **Solubility:** Both have negative solubility values, which is also concerning. Again, the values are similar (-3.559 and -3.965).
11. **hERG:** Both ligands show low hERG inhibition liability (0.92 and 0.799), which is excellent.
12. **Cl_mic:** Ligand B (43.597) has a lower microsomal clearance than Ligand A (49.906), indicating better metabolic stability.
13. **t1/2:** Ligand A (31.559) has a longer in vitro half-life than Ligand B (11.428). This is a positive for Ligand A.
14. **Pgp:** Ligand A (0.821) has higher P-gp efflux liability than Ligand B (0.229). Lower P-gp is preferred for better bioavailability.
15. **Binding Affinity:** Ligand A (-7.3 kcal/mol) has a significantly stronger binding affinity than Ligand B (-5.9 kcal/mol). This is a substantial advantage (1.4 kcal/mol difference).
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand A has a slightly better logP, but Ligand B excels in Pgp efflux and has acceptable TPSA. The *major* difference is the binding affinity: Ligand A is significantly more potent. While the other ADME properties of Ligand B are generally better (DILI, BBB, Cl_mic, Pgp), the strong binding affinity of Ligand A is likely to outweigh these concerns, particularly given the potential for optimization of the ADME properties.
**Conclusion:**
Despite some ADME advantages for Ligand B, the significantly stronger binding affinity of Ligand A makes it the more promising drug candidate. The potency advantage is substantial enough to warrant further optimization of its ADME profile.
Output:
1
2025-04-17 20:06:00,479 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [364.471, 65.98, 0.675, 0, 6, 0.769, 28.383, 76.851, -5.036, -1.121, 0.255, -5.314, 1.776, 0.044, -5.4]
**Ligand B:** [370.484, 16.13, 4.846, 0, 3, 0.712, 12.485, 96.937, -5.006, -4.863, 0.931, 47.396, -15.511, 0.62, -6.9]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, Affinity, and BBB):
1. **MW:** Both are within the ideal 200-500 Da range. Ligand A (364.471) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (65.98) is higher than Ligand B (16.13). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is still preferred for absorption. Ligand B is significantly better here.
3. **logP:** Ligand A (0.675) is quite low, potentially hindering membrane permeability. Ligand B (4.846) is high, potentially leading to solubility issues and off-target interactions. This is a significant drawback for Ligand B.
4. **HBD/HBA:** Both have low HBD counts (0), which is good. Ligand A has 6 HBA, while Ligand B has 3. Both are acceptable.
5. **QED:** Both are above 0.5 (0.769 and 0.712), indicating good drug-like properties.
6. **DILI:** Ligand A (28.383) has a higher DILI risk than Ligand B (12.485). This is a concern for Ligand A.
7. **BBB:** Ligand B (96.937) has a much higher BBB penetration percentile than Ligand A (76.851). While not a primary concern for a cardiovascular target, higher BBB is generally a positive attribute.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
9. **Solubility:** Ligand A (-1.121) has slightly better solubility than Ligand B (-4.863).
10. **hERG:** Ligand A (0.255) has a much lower hERG inhibition liability than Ligand B (0.931), which is crucial for avoiding cardiotoxicity.
11. **Cl_mic:** Ligand A (-5.314) has a lower (better) microsomal clearance than Ligand B (47.396), indicating greater metabolic stability.
12. **t1/2:** Ligand A (1.776) has a shorter in vitro half-life than Ligand B (-15.511). This is a negative for Ligand A.
13. **Pgp:** Ligand A (0.044) has significantly lower P-gp efflux liability than Ligand B (0.62), improving bioavailability.
14. **Affinity:** Ligand B (-6.9) has a stronger binding affinity than Ligand A (-5.4). This is a substantial advantage for Ligand B (1.5 kcal/mol difference).
**Overall Assessment:**
Ligand B has a significantly better binding affinity and BBB penetration, which are important for GPCRs. However, its high logP and Pgp efflux liability are concerning. Ligand A has better solubility, lower hERG risk, lower DILI, and lower Pgp efflux, but its logP is very low and its half-life is short.
The affinity difference is substantial (1.5 kcal/mol), and for a GPCR, potency often outweighs some ADME concerns, *provided* the ADME isn't disastrous. The high logP of Ligand B is a concern, but the other ADME properties are reasonable enough to suggest it could be optimized. The low logP of Ligand A is a more fundamental issue that would be harder to address without significantly altering the core structure.
Therefore, I would prioritize Ligand B.
```
0
```
2025-04-17 20:06:00,479 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (361.829 and 377.535 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (80.32) is higher than Ligand B (62.3). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is still preferable for absorption. Ligand B has an advantage.
3. **logP:** Ligand B (3.379) is slightly higher than Ligand A (2.212). Both are within the optimal 1-3 range, but Ligand B is approaching the upper limit.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1). Both are acceptable.
5. **HBA:** Ligand A (4) is lower than Ligand B (5). Lower is generally better for permeability, giving Ligand A a slight advantage.
6. **QED:** Ligand B (0.888) is significantly higher than Ligand A (0.45). This suggests Ligand B has a more generally "drug-like" profile. This is a significant advantage for Ligand B.
7. **DILI:** Ligand A (76.464) has a higher DILI risk than Ligand B (63.125). Lower is better, so Ligand B is favored.
8. **BBB:** Ligand B (78.209) has a higher BBB penetration percentile than Ligand A (62.117). While ADRB2 isn't strictly a CNS target, some CNS exposure can occur, and higher BBB is generally a positive. Ligand B is favored.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.918) is slightly better (less negative) than Ligand B (-5.255).
10. **Solubility:** Both ligands have negative solubility values, indicating poor aqueous solubility. Ligand A (-3.168) is slightly better than Ligand B (-4.647).
11. **hERG:** Ligand A (0.173) has a lower hERG inhibition liability than Ligand B (0.555). This is a crucial safety parameter, and Ligand A is strongly favored.
12. **Cl_mic:** Ligand B (47.44) has a significantly lower microsomal clearance than Ligand A (65.64), indicating better metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand A (68.784) has a much longer in vitro half-life than Ligand B (13.087). This is a strong advantage for Ligand A.
14. **Pgp:** Ligand A (0.094) has lower P-gp efflux liability than Ligand B (0.53). Lower is better, favoring Ligand A.
15. **Binding Affinity:** Ligand A (-6.4) has a slightly better binding affinity than Ligand B (-5.6). While both are good, the 0.8 kcal/mol difference is notable.
**Overall Assessment:**
Ligand B excels in QED, DILI, BBB, and Cl_mic, suggesting a more favorable overall drug-like profile and metabolic stability. However, Ligand A demonstrates superior hERG safety, Pgp efflux, binding affinity, and in vitro half-life. The hERG risk is a critical factor for cardiovascular drugs, and Ligand A's lower hERG liability is a major advantage. The binding affinity difference, while not huge, also tips the scales. The poor Caco-2 and solubility for both are concerning, but can potentially be addressed through formulation strategies.
Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity) and the overriding importance of safety (hERG) in a cardiovascular context, I favor Ligand A.
Output:
1
2025-04-17 20:06:00,480 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (409.259 Da) is within the ideal range, while Ligand B (347.459 Da) is at the lower end, but still acceptable.
2. **TPSA:** Ligand A (58.56) is excellent, well below the 140 threshold. Ligand B (80.32) is still reasonable, but less optimal.
3. **logP:** Both ligands (A: 2.408, B: 2.388) are within the optimal 1-3 range.
4. **HBD:** Ligand A (0) is preferred, minimizing potential issues. Ligand B (2) is acceptable, but slightly less desirable.
5. **HBA:** Ligand A (5) is good. Ligand B (4) is also good.
6. **QED:** Both ligands have good QED scores (A: 0.777, B: 0.672), indicating drug-likeness.
7. **DILI:** Ligand A (78.402) has a higher DILI risk than Ligand B (32.61). This is a significant negative for Ligand A.
8. **BBB:** Ligand A (94.455) shows excellent BBB penetration, while Ligand B (58.938) is lower. Since ADRB2 is a GPCR, BBB penetration is a consideration, but not paramount for cardiovascular targets.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.477 and -4.766), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-3.531) and Ligand B (-2.592) both have poor solubility.
11. **hERG:** Both ligands have low hERG inhibition risk (A: 0.593, B: 0.406).
12. **Cl_mic:** Ligand A (95.74) has higher metabolic clearance, indicating lower metabolic stability, compared to Ligand B (68.1).
13. **t1/2:** Ligand B (2.762) has a slightly better in vitro half-life than Ligand A (-17.462).
14. **Pgp:** Ligand A (0.356) has lower P-gp efflux than Ligand B (0.051), which is beneficial.
15. **Binding Affinity:** Ligand B (-5.7) has a slightly better binding affinity than Ligand A (-5.3).
**Overall Assessment & GPCR Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Both ligands perform similarly on logP and TPSA. Ligand A has better Pgp, but Ligand B has better affinity. The biggest differentiator is DILI risk. Ligand A's significantly higher DILI risk (78.4%) is a major concern. While BBB penetration is good for Ligand A, the cardiovascular target doesn't necessitate high BBB penetration. The slightly better affinity of Ligand B, combined with the much lower DILI risk, makes it the more promising candidate despite the slightly lower BBB penetration and worse half-life. The negative Caco-2 values are concerning for both, but can be addressed through formulation strategies.
Output:
0
2025-04-17 20:06:00,480 - INFO - Batch 159 complete. Total preferences: 2544
2025-04-17 20:06:00,480 - INFO - Processing batch 160/512...
2025-04-17 20:06:48,095 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (340.383 and 354.491 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (92.35) is slightly higher than Ligand B (78.87). Both are below the 140 threshold for good oral absorption, but B is better.
3. **logP:** Both ligands have good logP values (2.49 and 1.563), falling within the 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability, but not dramatically so.
4. **HBD:** Ligand A (3) and Ligand B (2) are both within the acceptable limit of 5.
5. **HBA:** Ligand A (5) and Ligand B (4) are both within the acceptable limit of 10.
6. **QED:** Both ligands have good QED scores (0.587 and 0.759), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (77.394) has a significantly higher DILI risk than Ligand B (19.038). This is a major concern.
8. **BBB:** Ligand A (66.421) has a better BBB penetration percentile than Ligand B (44.281). While ADRB2 isn't *strictly* a CNS target, some CNS exposure can be relevant for off-target effects and overall safety.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.87 and -4.656), which is unusual and suggests very poor permeability. This is a significant drawback for both.
10. **Solubility:** Ligand A (-4.048) has slightly worse solubility than Ligand B (-2.304), but both are poor.
11. **hERG:** Both ligands have low hERG inhibition risk (0.319 and 0.333).
12. **Cl_mic:** Ligand A (55.478) has a higher microsomal clearance than Ligand B (37.641), indicating lower metabolic stability.
13. **t1/2:** Ligand A (26.721) has a longer half-life than Ligand B (14.263). This is a positive for Ligand A.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.087 and 0.098).
15. **Binding Affinity:** Ligand A (-6.9) has a slightly better binding affinity than Ligand B (-6.7). However, the difference is small (0.2 kcal/mol) and may not be enough to overcome other issues.
**GPCR-Specific Priorities & Overall Assessment:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Both ligands are reasonably good on logP and Pgp. Ligand B has a better TPSA. The affinity difference is small. However, the *massive* difference in DILI risk is the deciding factor. Ligand A's high DILI risk is a major red flag, making it unlikely to progress through development. While Ligand A has a slightly better half-life and affinity, these are outweighed by the significant safety concern.
Output:
0
2025-04-17 20:06:48,095 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (380.861 Da and 335.367 Da) fall within the ideal 200-500 Da range. Ligand B is slightly preferred due to being closer to the lower end, potentially aiding permeability.
**2. TPSA:** Ligand A (114.07) is slightly higher than Ligand B (102.16), but both are below the 140 A^2 threshold for good oral absorption.
**3. logP:** Ligand B (3.386) is at the upper end of the optimal 1-3 range, while Ligand A (0.682) is quite low. For a GPCR, a slightly higher logP is generally beneficial for membrane permeability and receptor binding, making Ligand B preferable.
**4. H-Bond Donors:** Ligand A has 4 HBDs, and Ligand B has 3. Both are acceptable.
**5. H-Bond Acceptors:** Both ligands have 5 HBAs, which is within the acceptable range.
**6. QED:** Ligand B (0.663) has a better QED score than Ligand A (0.448), indicating a more drug-like profile.
**7. DILI Risk:** Ligand A (85.459) has a considerably lower DILI risk than Ligand B (95.812). This is a significant advantage for Ligand A.
**8. BBB Penetration:** Ligand B (62.621) shows slightly better BBB penetration than Ligand A (54.556). While ADRB2 is primarily a cardiovascular target, some CNS effects are possible with certain ligands, so this is a minor positive for Ligand B.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-5.28) is slightly better than Ligand B (-4.99).
**10. Aqueous Solubility:** Both ligands have very poor aqueous solubility (-3.391 and -4.73 respectively). This is a major concern for both.
**11. hERG Inhibition:** Ligand A (0.093) has a much lower hERG inhibition risk than Ligand B (0.612). This is a critical advantage for Ligand A, as hERG inhibition can lead to cardiotoxicity.
**12. Microsomal Clearance:** Ligand B (36.536) has a slightly higher microsomal clearance than Ligand A (32.865), suggesting faster metabolism. Ligand A is preferred here.
**13. In vitro Half-Life:** Ligand A (-0.414) has a shorter half-life than Ligand B (17.353). This is a drawback for Ligand A.
**14. P-gp Efflux:** Ligand A (0.085) has lower P-gp efflux than Ligand B (0.13), which is favorable for bioavailability.
**15. Binding Affinity:** Ligand A (-6.9 kcal/mol) has a significantly stronger binding affinity than Ligand B (-1.8 kcal/mol). This is a major advantage for Ligand A, and a difference of this magnitude can outweigh many ADME concerns.
**Overall Assessment:**
While Ligand B has a better QED and slightly better BBB penetration, Ligand A is significantly better in several critical areas: **binding affinity, DILI risk, and hERG inhibition**. The strong binding affinity of Ligand A is a major advantage for a GPCR target. The lower DILI and hERG risks are crucial for safety. The poor solubility and permeability are concerns for both, but the potency advantage of Ligand A is substantial. The longer half-life of Ligand B is a plus, but can be addressed through prodrug strategies or formulation.
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity) and the overall balance of properties, Ligand A is the more promising drug candidate.
Output:
1
2025-04-17 20:06:48,095 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (379.404 Da and 366.433 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (101.29) is higher than Ligand B (53.43). For a cardiovascular GPCR, TPSA is moderately important, and lower is generally better for permeability. Ligand B has a much more favorable TPSA.
**3. logP:** Ligand A (1.271) is within the optimal range (1-3), while Ligand B (4.078) is slightly higher. While not drastically outside the range, higher logP can sometimes lead to off-target effects and solubility issues.
**4. H-Bond Donors:** Ligand A (3) is higher than Ligand B (1). Lower HBD is generally preferred for better membrane permeability. Ligand B is better here.
**5. H-Bond Acceptors:** Both ligands have the same number of HBA (4).
**6. QED:** Ligand B (0.838) has a better QED score than Ligand A (0.693), indicating a more drug-like profile.
**7. DILI Risk:** Ligand A (41.877) has a higher DILI risk than Ligand B (27.336). Lower DILI risk is crucial for drug development. Ligand B is significantly better.
**8. BBB Penetration:** Ligand A (61.38) has lower BBB penetration than Ligand B (86.972). While ADRB2 is a cardiovascular target, some CNS exposure can be relevant for side effects or off-target activity. Higher BBB is not necessarily *desired* here, but it's not a major negative.
**9. Caco-2 Permeability:** Ligand A (-5.433) has worse Caco-2 permeability than Ligand B (-4.477). Higher Caco-2 values are better, indicating better absorption.
**10. Aqueous Solubility:** Ligand A (-2.882) has better aqueous solubility than Ligand B (-4.771). Solubility is important for formulation.
**11. hERG Inhibition:** Ligand A (0.455) has a lower hERG inhibition liability than Ligand B (0.711). Lower hERG is crucial to avoid cardiotoxicity. Ligand A is better here.
**12. Microsomal Clearance:** Ligand B (85.566) has a significantly higher microsomal clearance than Ligand A (3.783). Lower clearance indicates better metabolic stability, which is highly desirable. Ligand A is much better.
**13. In vitro Half-Life:** Ligand A (-27.696) has a much longer in vitro half-life than Ligand B (-13.734). Longer half-life is generally preferred. Ligand A is better.
**14. P-gp Efflux:** Ligand A (0.047) has lower P-gp efflux than Ligand B (0.317). Lower P-gp efflux is preferred for better bioavailability. Ligand A is better.
**15. Binding Affinity:** Ligand B (-7.3) has a slightly better binding affinity than Ligand A (-6.8). However, the difference is only 0.5 kcal/mol, which is not substantial enough to outweigh the other significant differences.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity) and the general drug-like properties, Ligand A is the more promising candidate. While Ligand B has a slightly better affinity and BBB penetration, Ligand A excels in crucial areas like DILI risk, metabolic stability (low Cl_mic and long t1/2), P-gp efflux, and hERG inhibition. The lower TPSA of Ligand B is attractive, but the overall balance of properties favors Ligand A.
Output:
1
2025-04-17 20:06:48,095 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (348.447) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (80.12) is better than Ligand A (94.56), falling comfortably below the 140 threshold for oral absorption.
3. **logP:** Both are within the optimal range (1-3), but Ligand B (1.485) is slightly higher, potentially improving membrane permeability.
4. **HBD:** Ligand A (3) is higher than Ligand B (1), but both are acceptable.
5. **HBA:** Ligand B (7) is higher than Ligand A (5), but both are acceptable.
6. **QED:** Both ligands have good QED scores (A: 0.571, B: 0.666), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (13.843) has a significantly lower DILI risk than Ligand B (52.346). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (56.34) has a higher BBB penetration percentile than Ligand A (23.924). While ADRB2 isn't exclusively a CNS target, some CNS exposure could be beneficial or at least not detrimental depending on the desired therapeutic profile.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual. This suggests poor permeability.
10. **Solubility:** Ligand A (-0.69) is better than Ligand B (-1.354).
11. **hERG:** Both have very low hERG inhibition liability (A: 0.193, B: 0.058), which is excellent.
12. **Cl_mic:** Ligand A (-4.141) has a much lower (better) microsomal clearance than Ligand B (66.704), indicating better metabolic stability.
13. **t1/2:** Ligand B (36.746) has a longer in vitro half-life than Ligand A (52.156).
14. **Pgp:** Both have very low Pgp efflux liability (A: 0.017, B: 0.133).
15. **Binding Affinity:** Ligand B (-7.4) has a significantly stronger binding affinity than Ligand A (-5.7). This is a substantial advantage.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B excels in affinity and has a better logP and TPSA. However, the significantly lower DILI risk and better metabolic stability (lower Cl_mic) of Ligand A are crucial factors. The affinity difference is substantial (1.7 kcal/mol), which is a significant advantage for Ligand B.
**Overall Assessment:**
The stronger binding affinity of Ligand B is a major positive. While Ligand A has better safety (DILI) and metabolic stability, the potency advantage of Ligand B is likely to outweigh these concerns, especially given the acceptable DILI and Cl_mic values for Ligand B.
Output:
0
2025-04-17 20:06:48,095 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
The target is ADRB2, a GPCR. Therefore, I will prioritize logP, Pgp efflux, TPSA, BBB penetration, and binding affinity. Metabolic stability (Cl_mic, t1/2) and safety (DILI, hERG) are also important considerations.
Let's compare the ligands property by property:
1. **MW:** Both ligands are within the ideal range (349-350 Da).
2. **TPSA:** Ligand A (84.67) is higher than Ligand B (58.64). Ligand B is significantly better, being well below the 140 threshold for good absorption.
3. **logP:** Both are within the optimal 1-3 range, but Ligand B (2.609) is slightly higher than Ligand A (1.767). Higher logP can be beneficial for GPCRs, but needs to be balanced with solubility.
4. **HBD/HBA:** Both have 1 HBD, which is good. Ligand A has 5 HBA, and Ligand B has 3 HBA, both acceptable.
5. **QED:** Both are very similar (0.811 vs 0.803), indicating good drug-likeness.
6. **DILI:** Ligand B (21.055) has a significantly lower DILI risk than Ligand A (38.387). This is a major advantage for Ligand B.
7. **BBB:** Both have good BBB penetration (86.468 and 89.531). Ligand B is slightly better.
8. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability.
9. **Solubility:** Both have negative solubility values, indicating poor solubility.
10. **hERG:** Ligand B (0.741) has a slightly higher hERG risk than Ligand A (0.342), but both are relatively low.
11. **Cl_mic:** Ligand B (-2.594) has a *much* lower (better) microsomal clearance than Ligand A (38.971). This suggests significantly improved metabolic stability for Ligand B.
12. **t1/2:** Ligand B (5.363) has a better in vitro half-life than Ligand A (-14.385).
13. **Pgp:** Ligand B (0.092) has a lower Pgp efflux liability than Ligand A (0.205), which is favorable.
14. **Binding Affinity:** Both have very similar and excellent binding affinities (-6.3 and -6.1 kcal/mol). The difference is negligible.
**Overall Assessment:**
Ligand B clearly outperforms Ligand A in several critical ADME properties: DILI risk, microsomal clearance, in vitro half-life, and Pgp efflux. While Ligand A has a slightly better TPSA and hERG, the improvements in metabolic stability and safety offered by Ligand B are more valuable for a GPCR drug candidate. The similar binding affinities remove that as a differentiating factor.
**Output:**
0
2025-04-17 20:06:48,095 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (346.431 and 364.467 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (96.25 and 91.57) are below the 140 A^2 threshold for good oral absorption. Ligand B is slightly better, closer to the 90 A^2 threshold relevant for CNS targets, though ADRB2 is primarily cardiovascular.
3. **logP:** Both ligands have logP values within the optimal 1-3 range (1.0 and 1.808). Ligand B is slightly better.
4. **HBD:** Both have 3 HBD, which is acceptable.
5. **HBA:** Both have 5 HBA, which is acceptable.
6. **QED:** Both have similar QED scores (0.654 and 0.633), indicating good drug-likeness.
7. **DILI:** Ligand B (33.501) has a significantly lower DILI risk than Ligand A (39.473). This is a major advantage for Ligand B.
8. **BBB:** Ligand A (39.511) has a slightly better BBB penetration than Ligand B (25.94). However, as ADRB2 is a cardiovascular target, BBB penetration is not a primary concern.
9. **Caco-2:** Ligand A (-4.872) has a better Caco-2 permeability than Ligand B (-5.478).
10. **Solubility:** Ligand B (-1.853) has better aqueous solubility than Ligand A (-2.943).
11. **hERG:** Both ligands have very low hERG inhibition risk (0.098 and 0.23).
12. **Cl_mic:** Both have similar microsomal clearance (36.458 and 37.035).
13. **t1/2:** Ligand B (36.56) has a significantly longer in vitro half-life than Ligand A (-14.898). This is a substantial advantage.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.057 and 0.047).
15. **Binding Affinity:** Ligand A (-8.4 kcal/mol) has a slightly better binding affinity than Ligand B (-7.0 kcal/mol). This is a 1.4 kcal/mol difference, which is significant.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B has a slightly better logP and TPSA, comparable Pgp, but a significantly lower DILI and a much longer half-life. The 1.4 kcal/mol difference in affinity is important, but the improved safety profile (DILI) and pharmacokinetics (t1/2) of Ligand B are more compelling for overall drug development potential.
**Conclusion:**
While Ligand A has a slightly better binding affinity, Ligand B's superior DILI risk, solubility, and half-life outweigh this difference. The improved ADME properties make Ligand B a more promising drug candidate.
Output:
0
2025-04-17 20:06:48,096 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (406.328 Da) is slightly higher than Ligand B (346.475 Da), but both are acceptable.
**2. TPSA:** Ligand A (62.19) is better than Ligand B (76.02). For a GPCR, keeping TPSA lower is preferable for better permeability.
**3. logP:** Both ligands have good logP values (A: 2.375, B: 2.115), falling within the optimal 1-3 range.
**4. H-Bond Donors:** Both have 2 HBD, which is within the acceptable limit of 5.
**5. H-Bond Acceptors:** Ligand A has 5 HBA, while Ligand B has 4. Both are below the 10 threshold.
**6. QED:** Both ligands have reasonable QED scores (A: 0.801, B: 0.719), indicating good drug-like properties. Ligand A is slightly better.
**7. DILI:** Ligand A (32.377) has a slightly higher DILI risk than Ligand B (20.822), but both are below the concerning threshold of 60.
**8. BBB:** Ligand A (74.758) has a significantly better BBB penetration percentile than Ligand B (63.823). While ADRB2 isn't exclusively a CNS target, some CNS exposure or lack thereof may be desirable depending on the therapeutic goal, and higher BBB is generally favorable.
**9. Caco-2 Permeability:** Both have negative Caco-2 values, which is unusual. However, the magnitude is similar (-5.255 for A, -5.09 for B), so this doesn't strongly favor either.
**10. Aqueous Solubility:** Both have negative solubility values, which is also unusual. Again, the values are similar (-1.948 for A, -2.617 for B).
**11. hERG Inhibition:** Ligand A (0.576) has a slightly higher hERG inhibition risk than Ligand B (0.112). This is a significant advantage for Ligand B.
**12. Microsomal Clearance:** Ligand B (42.387) has a lower microsomal clearance than Ligand A (4.748), indicating better metabolic stability. This is a strong advantage for Ligand B.
**13. In vitro Half-Life:** Ligand B (-3.39) has a significantly longer in vitro half-life than Ligand A (54.829). This is a major advantage for Ligand B.
**14. P-gp Efflux:** Ligand A (0.181) has lower P-gp efflux than Ligand B (0.05), which is slightly favorable for A.
**15. Binding Affinity:** Ligand A (-7.1 kcal/mol) has a slightly stronger binding affinity than Ligand B (-6.7 kcal/mol). This is a significant advantage for Ligand A, as a 0.4 kcal/mol difference is meaningful.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity and BBB penetration, Ligand B demonstrates a superior ADME profile. Specifically, its lower hERG risk, significantly better metabolic stability (lower Cl_mic and longer t1/2), and lower P-gp efflux are crucial advantages for a viable drug candidate. The slightly weaker binding affinity of Ligand B can potentially be optimized in later stages of drug development. The unusual solubility and Caco-2 values for both ligands would warrant further investigation.
Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity) and the overall balance of properties, Ligand B is the more promising candidate.
Output:
0
2025-04-17 20:06:48,096 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (413.36 Da) is within the ideal range, while Ligand B (371.459 Da) is also acceptable. No clear advantage here.
2. **TPSA:** Ligand A (76.14) is better than Ligand B (102.69). Lower TPSA generally favors permeability, which is important for GPCRs.
3. **logP:** Ligand A (4.351) is higher than Ligand B (1.52). While logP > 4 can be problematic, for a GPCR target, a higher logP can be beneficial for membrane interactions and receptor binding, *provided* solubility isn't severely compromised.
4. **HBD:** Both ligands have 2 HBD, which is within the acceptable range.
5. **HBA:** Ligand A has 5 HBA, while Ligand B has 7. Ligand A is slightly better here, as fewer HBA can improve permeability.
6. **QED:** Ligand A (0.768) has a better QED score than Ligand B (0.501), indicating a more drug-like profile.
7. **DILI:** Ligand A (37.728) has a significantly lower DILI risk than Ligand B (78.17). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (86.002) has a better BBB penetration percentile than Ligand B (72.78). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be useful for understanding off-target effects and overall distribution.
9. **Caco-2:** Ligand A (-4.67) has a worse Caco-2 permeability than Ligand B (-5.473). Lower (more negative) values indicate lower permeability.
10. **Solubility:** Ligand A (-4.385) has a worse solubility than Ligand B (-3.279). This is a concern given Ligand A's higher logP.
11. **hERG:** Ligand A (0.426) has a lower hERG risk than Ligand B (0.364). Both are low, but A is slightly better.
12. **Cl_mic:** Ligand A (72.735) has a higher microsomal clearance than Ligand B (41.525), meaning it's metabolized faster. This is a disadvantage for Ligand A.
13. **t1/2:** Ligand A (31.706) has a longer in vitro half-life than Ligand B (16.516). This is a positive for Ligand A.
14. **Pgp:** Ligand A (0.148) has a lower P-gp efflux liability than Ligand B (0.125). Lower is better, so A is slightly favored.
15. **Binding Affinity:** Ligand B (-7.1 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.4 kcal/mol). This is a substantial advantage for Ligand B.
**Overall Assessment:**
Ligand B has a significantly better binding affinity, which is the most crucial factor for a GPCR target. However, it suffers from higher DILI risk and a lower QED. Ligand A has better DILI, QED, BBB, and t1/2, but its solubility is worse and it has a lower binding affinity.
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), the stronger binding affinity of Ligand B is a significant advantage that outweighs its drawbacks, *particularly* if further optimization could address the DILI concern. The higher logP of Ligand A, while potentially beneficial for binding, is coupled with poor solubility, making formulation challenging. The difference in binding affinity (0.7 kcal/mol) is substantial enough to overcome the other drawbacks of Ligand B.
Output:
0
2025-04-17 20:06:48,096 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (371.449 Da) is within the ideal range (200-500 Da). Ligand B (403.328 Da) is also acceptable, though slightly higher.
2. **TPSA:** Ligand A (46.61) is excellent, well below the 140 threshold for oral absorption. Ligand B (58.87) is still reasonable, but less favorable.
3. **logP:** Both ligands have good logP values (A: 3.888, B: 3.283), falling within the 1-3 range.
4. **HBD:** Ligand A (0) is preferable to Ligand B (1). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is better than Ligand B (6). Lower HBA counts are generally favorable for permeability.
6. **QED:** Both ligands have good QED values (A: 0.74, B: 0.853), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (74.486) has a higher DILI risk than Ligand B (47.383). This is a significant drawback for Ligand A.
8. **BBB:** Ligand B (83.017) has a significantly higher BBB penetration percentile than Ligand A (66.615). While ADRB2 isn't strictly a CNS target, some CNS exposure can occur, and higher BBB is generally a positive.
9. **Caco-2:** Ligand A (-4.382) and B (-5.073) both have negative values, indicating poor permeability.
10. **Solubility:** Ligand A (-4.621) and B (-2.906) both have negative values, indicating poor solubility.
11. **hERG:** Both ligands have low hERG risk (A: 0.451, B: 0.64).
12. **Cl_mic:** Ligand B (27.401) has a much lower microsomal clearance than Ligand A (106.1), suggesting better metabolic stability.
13. **t1/2:** Ligand B (37.767) has a longer in vitro half-life than Ligand A (21.859).
14. **Pgp:** Both ligands have low Pgp efflux liability (A: 0.161, B: 0.397).
15. **Affinity:** Ligand B (-6.5 kcal/mol) has a slightly better binding affinity than Ligand A (-6.9 kcal/mol). Although A has a slightly better affinity, the difference is not substantial enough to outweigh the other factors.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Both ligands perform reasonably well on logP and Pgp. Ligand A has a better TPSA and affinity, but Ligand B excels in DILI risk, BBB penetration, metabolic stability (Cl_mic), and half-life.
**Overall Assessment:**
While Ligand A has a slightly better affinity and TPSA, Ligand B is the more promising candidate. The significantly lower DILI risk, better BBB penetration, improved metabolic stability, and longer half-life of Ligand B outweigh the minor advantage in affinity of Ligand A. The poor Caco-2 and solubility for both are concerning, but can be addressed with formulation strategies.
Output:
0
2025-04-17 20:06:48,096 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (383.279) is slightly higher than Ligand B (367.494), but both are acceptable.
2. **TPSA:** Ligand A (69.04) is significantly better than Ligand B (82.96). For a GPCR, lower TPSA is generally preferred for better permeability.
3. **logP:** Both ligands have good logP values (A: 3.429, B: 3.598), falling within the optimal 1-3 range.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (7). Fewer HBAs generally improve permeability.
6. **QED:** Both ligands have acceptable QED scores (A: 0.796, B: 0.694), indicating good drug-like properties. Ligand A is slightly better.
7. **DILI:** Ligand A (60.14) is better than Ligand B (82.241). Both are above the 60 threshold, but A is closer to the acceptable range.
8. **BBB:** Ligand A (81.97) is significantly better than Ligand B (63.746). While ADRB2 isn't exclusively a CNS target, some CNS penetration can be beneficial, and lower efflux is always a plus.
9. **Caco-2:** Both have negative values, indicating poor permeability. Ligand A (-4.455) is slightly better than Ligand B (-4.996).
10. **Solubility:** Both ligands have very poor solubility (-4.646 and -4.933). This is a significant concern for both.
11. **hERG:** Both ligands have low hERG inhibition risk (A: 0.599, B: 0.73).
12. **Cl_mic:** Ligand B (34.083) has significantly lower microsomal clearance than Ligand A (56.985), suggesting better metabolic stability. This is a strong advantage for Ligand B.
13. **t1/2:** Ligand B (59.877) has a much longer in vitro half-life than Ligand A (10.35), which is a significant advantage.
14. **Pgp:** Ligand A (0.181) has lower P-gp efflux liability than Ligand B (0.497), which is favorable.
15. **Binding Affinity:** Ligand B (-8.3 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.4 kcal/mol). This is a substantial advantage that can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand B has a significantly stronger binding affinity and better metabolic stability (lower Cl_mic and longer t1/2). While Ligand A has better TPSA, BBB, and Pgp properties, the affinity difference is substantial (1.9 kcal/mol). Given that ADRB2 is a GPCR, a strong binding affinity is paramount. The solubility issues are a concern for both, but can be addressed through formulation strategies. The DILI risk is higher for both, but Ligand A is slightly better. The improved metabolic stability and binding affinity of Ligand B outweigh the slightly less favorable TPSA and Pgp properties.
Output:
0
2025-04-17 20:06:48,096 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (350.5 and 352.5 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (59.4) is significantly better than Ligand B (84.6). For a GPCR, keeping TPSA low is beneficial for permeability, and Ligand A is well below the 140 threshold. Ligand B is approaching the upper limit.
**3. logP:** Both ligands have acceptable logP values (3.42 and 2.35), falling within the 1-3 range. Ligand A is slightly higher, which *could* be a minor concern for solubility, but is still reasonable.
**4. H-Bond Donors:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve membrane permeability.
**5. H-Bond Acceptors:** Both ligands have 4 HBA, which is acceptable.
**6. QED:** Ligand A (0.82) has a better QED score than Ligand B (0.703), indicating a more drug-like profile.
**7. DILI Risk:** Ligand A (19.5) has a much lower DILI risk than Ligand B (9.9). This is a significant advantage for Ligand A.
**8. BBB Penetration:** Ligand A (90.8) shows excellent BBB penetration, while Ligand B (66.3) is lower. For a GPCR, even a peripherally acting one, some BBB penetration can be useful for understanding off-target effects and potential CNS side effects.
**9. Caco-2 Permeability:** Ligand A (-4.174) is better than Ligand B (-5.15), indicating better intestinal absorption.
**10. Aqueous Solubility:** Ligand A (-3.167) is better than Ligand B (-1.433), indicating better aqueous solubility.
**11. hERG Inhibition:** Both ligands have similar, low hERG inhibition risk (0.424 and 0.695).
**12. Microsomal Clearance:** Ligand B (-5.353) has a *negative* clearance, which is highly unusual and suggests extremely high metabolic stability. Ligand A (75.5) is a more typical, moderate clearance. While low clearance is generally good, a negative value is suspect and might indicate an artifact or unusual behavior.
**13. In vitro Half-Life:** Ligand B (33.4) has a better in vitro half-life than Ligand A (19.9).
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (0.146 and 0.191).
**15. Binding Affinity:** Ligand B (-7.2 kcal/mol) has a slightly better binding affinity than Ligand A (-6.5 kcal/mol). This is a 0.7 kcal/mol difference, which is a reasonable advantage, but not overwhelming.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical ADME properties (TPSA, HBD, QED, DILI, BBB, Solubility, Caco-2). While Ligand B has a slightly better affinity and half-life, the negative microsomal clearance is a red flag. The combination of better overall drug-likeness, safety (lower DILI), and permeability makes Ligand A the more promising candidate. The affinity difference is not large enough to overcome the ADME advantages of Ligand A.
Output:
1
2025-04-17 20:06:48,096 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (347.459 Da) is well within the ideal range (200-500 Da). Ligand B (410.316 Da) is also acceptable, but closer to the upper limit.
2. **TPSA:** Ligand A (74.43) is better than Ligand B (67.4). Both are below 140, suggesting good absorption potential.
3. **logP:** Both ligands (A: 2.19, B: 2.319) are in the optimal 1-3 range.
4. **HBD:** Ligand A (2) is preferable to Ligand B (0). Having some HBD can improve solubility.
5. **HBA:** Ligand A (3) is better than Ligand B (6). Lower HBA is generally preferred for better permeability.
6. **QED:** Both ligands are similar (A: 0.794, B: 0.731) and above the 0.5 threshold, indicating good drug-likeness.
7. **DILI:** Ligand A (9.965) has a significantly lower DILI risk than Ligand B (21.171). This is a major advantage.
8. **BBB:** Both ligands have good BBB penetration (A: 76.309, B: 72.431), which is a positive for a GPCR target.
9. **Caco-2:** Ligand A (-4.668) is slightly better than Ligand B (-5.342), suggesting better intestinal absorption.
10. **Solubility:** Ligand A (-2.954) is better than Ligand B (-1.59).
11. **hERG:** Both ligands have similar hERG inhibition liability (A: 0.528, B: 0.376), and are relatively low risk.
12. **Cl_mic:** Ligand A (12.322) has a lower microsomal clearance than Ligand B (7.121), indicating better metabolic stability.
13. **t1/2:** Ligand A (-19.624) has a much longer in vitro half-life than Ligand B (34.77). This is a significant advantage.
14. **Pgp:** Both ligands have similar Pgp efflux liability (A: 0.023, B: 0.064).
15. **Affinity:** Both ligands have the same binding affinity (-6.5 kcal/mol).
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Both ligands perform similarly on logP, Pgp, and affinity. Ligand A has a better TPSA. However, the significant advantages of Ligand A in terms of DILI risk, metabolic stability (Cl_mic, t1/2), solubility, and H-bonding make it the superior candidate.
**Conclusion:**
Ligand A is the more promising drug candidate due to its superior ADME-Tox profile and comparable binding affinity.
Output:
1
2025-04-17 20:06:48,096 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [399.292, 59.29, 3.527, 1, 4, 0.683, 72.276, 78.79, -5.273, -4.331, 0.355, 25.886, 39.928, 0.667, -4.6]
**Ligand B:** [350.463, 78.67, 1.274, 1, 5, 0.766, 24.234, 50.911, -4.926, -0.749, 0.226, 25.754, 8.619, 0.073, -6.1]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (350.463) is slightly lower, which could be beneficial for permeability, but both are acceptable.
2. **TPSA:** Ligand A (59.29) is much better than Ligand B (78.67). For a GPCR, keeping TPSA low is good, and A is comfortably below 140, while B is approaching the upper limit.
3. **logP:** Ligand A (3.527) is optimal, while Ligand B (1.274) is on the lower side. This is a significant advantage for A, as good lipophilicity is crucial for GPCR binding and membrane permeability.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 4 HBA, while Ligand B has 5. Both are acceptable, but lower is generally preferred.
6. **QED:** Both have good QED scores (A: 0.683, B: 0.766), indicating reasonable drug-likeness. B is slightly better here.
7. **DILI:** Ligand A (72.276) has a higher DILI risk than Ligand B (24.234). This is a major concern for A.
8. **BBB:** Ligand A (78.79) has significantly better BBB penetration potential than Ligand B (50.911). While ADRB2 isn't strictly a CNS target, some CNS exposure can occur, and higher BBB is generally favorable.
9. **Caco-2:** Ligand A (-5.273) has a worse Caco-2 permeability than Ligand B (-4.926). Both are negative values, which is unusual and suggests poor permeability.
10. **Solubility:** Ligand A (-4.331) has worse solubility than Ligand B (-0.749). Solubility is important for bioavailability.
11. **hERG:** Both have low hERG inhibition risk (A: 0.355, B: 0.226). B is slightly better.
12. **Cl_mic:** Both have similar microsomal clearance (A: 25.886, B: 25.754).
13. **t1/2:** Ligand A (39.928) has a much longer in vitro half-life than Ligand B (8.619). This is a significant advantage for A.
14. **Pgp:** Ligand A (0.667) has higher Pgp efflux than Ligand B (0.073). Lower Pgp is preferred for better bioavailability.
15. **Affinity:** Ligand B (-6.1) has a significantly better binding affinity than Ligand A (-4.6). This is a substantial advantage, exceeding the 1.5 kcal/mol threshold.
**Overall Assessment:**
Ligand B has a significantly better binding affinity and lower DILI risk, which are critical factors. While Ligand A has better BBB penetration and a longer half-life, the higher DILI risk and poorer logP/solubility are concerning. The affinity difference is large enough to outweigh the advantages of A. The lower Pgp efflux of B is also a plus.
Output:
0
2025-04-17 20:06:48,096 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (339.37 and 347.415 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (63.25) is well below the 140 threshold and very good for oral absorption. Ligand B (75.88) is still acceptable but higher. This favors Ligand A slightly.
3. **logP:** Ligand A (3.382) is within the optimal 1-3 range. Ligand B (1.178) is a bit low, potentially impacting permeability. This favors Ligand A.
4. **HBD:** Ligand A (2) and Ligand B (0) are both acceptable, within the limit of 5.
5. **HBA:** Ligand A (3) and Ligand B (5) are both acceptable, within the limit of 10.
6. **QED:** Both ligands (0.749 and 0.748) have excellent drug-likeness scores. No significant difference.
7. **DILI:** Ligand A (77.045) has a higher DILI risk than Ligand B (35.091). This is a significant drawback for Ligand A.
8. **BBB:** Ligand A (78.519) has better BBB penetration than Ligand B (61.846). While ADRB2 isn't strictly a CNS target, some CNS exposure can be relevant for off-target effects, and higher BBB is generally preferred.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it is difficult to interpret.
10. **Solubility:** Ligand A (-4.381) has worse solubility than Ligand B (-1.304). This is a negative for Ligand A.
11. **hERG:** Ligand A (0.656) has a higher hERG risk than Ligand B (0.089). This is a significant safety concern for Ligand A.
12. **Cl_mic:** Ligand A (78.671) has higher metabolic clearance than Ligand B (20.481), indicating lower metabolic stability. This favors Ligand B.
13. **t1/2:** Ligand A (16.352) has a longer half-life than Ligand B (-8.517). This is a positive for Ligand A.
14. **Pgp:** Ligand A (0.27) has lower P-gp efflux than Ligand B (0.029), which is better.
15. **Binding Affinity:** Ligand B (-7.1) has a slightly better binding affinity than Ligand A (-5.7). While the difference is 1.4 kcal/mol, it's enough to consider, especially given the ADME issues with Ligand A.
**GPCR-specific considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are crucial. Ligand A has better logP and Pgp, while Ligand B has better affinity. However, Ligand A suffers from significantly higher DILI and hERG risk, and worse solubility and metabolic stability.
**Overall Assessment:**
Despite the slightly better affinity of Ligand B, the significant safety concerns (DILI, hERG) and metabolic instability of Ligand A make it a less desirable candidate. Ligand B, while having a slightly lower logP, presents a much more favorable safety and pharmacokinetic profile.
Output:
0
2025-04-17 20:06:48,096 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (419.348 Da) is within the ideal range, while Ligand B (374.413 Da) is also good. No clear advantage here.
2. **TPSA:** Ligand A (59.29) is excellent for oral absorption and even reasonable for some CNS penetration. Ligand B (93.21) is higher, potentially impacting absorption, but still within acceptable limits. Ligand A is preferred.
3. **logP:** Ligand A (4.485) is a bit high, potentially leading to solubility issues or off-target effects. Ligand B (1.08) is very good, within the optimal range. Ligand B is preferred.
4. **HBD:** Ligand A (1) is good. Ligand B (2) is also acceptable. No significant difference.
5. **HBA:** Ligand A (5) is good. Ligand B (6) is also acceptable. No significant difference.
6. **QED:** Both ligands have good QED scores (A: 0.599, B: 0.664), indicating drug-likeness. Ligand B is slightly better.
7. **DILI:** Ligand A (76.89) has a higher DILI risk than Ligand B (55.448). Ligand B is preferred.
8. **BBB:** Ligand A (61.07) is moderate. Ligand B (83.443) is better, indicating potentially better CNS penetration. While ADRB2 isn't *primarily* a CNS target, some CNS off-target effects are always a concern, and higher BBB is generally favorable. Ligand B is preferred.
9. **Caco-2:** Both are negative, indicating poor permeability. This is a concern for both.
10. **Solubility:** Both are negative, indicating poor solubility. This is a concern for both.
11. **hERG:** Ligand A (0.346) has a lower hERG risk than Ligand B (0.418). Ligand A is preferred.
12. **Cl_mic:** Ligand A (59.238) has a higher microsomal clearance than Ligand B (6.575), indicating lower metabolic stability. Ligand B is strongly preferred.
13. **t1/2:** Ligand A (90.979) has a much longer in vitro half-life than Ligand B (8.848). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.7) has higher P-gp efflux than Ligand B (0.109). Ligand B is preferred.
15. **Affinity:** Ligand A (-6.1 kcal/mol) has a significantly stronger binding affinity than Ligand B (-1.4 kcal/mol). This is a major advantage for Ligand A, potentially outweighing some of its ADME drawbacks.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are crucial. Ligand B excels in logP and Pgp, and has a better TPSA. However, the *substantial* difference in binding affinity (-6.1 vs -1.4 kcal/mol) is a game-changer. A 4.7 kcal/mol difference is enormous. While Ligand A has some ADME liabilities (higher logP, DILI, Cl_mic), the potency advantage is likely to be decisive, and these can be addressed through further optimization. The longer half-life of Ligand A is also a significant benefit.
**Conclusion:**
Despite some ADME concerns, the significantly superior binding affinity of Ligand A makes it the more promising drug candidate.
Output:
1
2025-04-17 20:06:48,097 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (341.346 and 345.487 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (92.93) is higher than Ligand B (52.65). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B has a substantial advantage.
3. **logP:** Both ligands (1.927 and 1.815) are within the optimal 1-3 range. Very similar.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1). Both are acceptable.
5. **HBA:** Ligand A (6) is higher than Ligand B (3). Lower HBA is generally favorable for permeability. Ligand B is better.
6. **QED:** Both ligands (0.74 and 0.747) have excellent drug-likeness scores. No difference.
7. **DILI:** Ligand A (74.254) has a significantly higher DILI risk than Ligand B (6.747). This is a major concern for Ligand A.
8. **BBB:** Ligand A (47.809) has a lower BBB penetration than Ligand B (87.67). While ADRB2 isn't a primary CNS target, some distribution outside the cardiovascular system is possible, and higher BBB is generally favorable. Ligand B is better.
9. **Caco-2:** Ligand A (-5.169) has a worse Caco-2 permeability than Ligand B (-4.837). Both are negative, indicating poor permeability, but Ligand B is slightly better.
10. **Solubility:** Ligand A (-2.851) has a worse solubility than Ligand B (-1.579). Solubility is important for bioavailability. Ligand B is better.
11. **hERG:** Ligand A (0.075) has a slightly lower hERG risk than Ligand B (0.438), but both are very low and acceptable.
12. **Cl_mic:** Ligand A (75.585) has a higher microsomal clearance than Ligand B (7.983). This suggests Ligand B is more metabolically stable, which is desirable.
13. **t1/2:** Ligand A (-35.05) has a negative in vitro half-life, which is concerning. Ligand B (2.944) has a short, but positive, half-life. Ligand B is significantly better.
14. **Pgp:** Ligand A (0.187) has a lower P-gp efflux liability than Ligand B (0.029). Lower Pgp is generally preferred. Ligand A is better.
15. **Affinity:** Ligand B (-6.1 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.6 kcal/mol). This is a crucial advantage, especially given the relatively small difference in other parameters.
**Overall Assessment:**
Ligand B clearly outperforms Ligand A across most critical ADME-Tox parameters. The most significant advantages are the much lower DILI risk, better metabolic stability (lower Cl_mic, better t1/2), improved solubility, and substantially stronger binding affinity. While Ligand A has slightly better Pgp properties, the other advantages of Ligand B outweigh this. The TPSA of Ligand B is also much more favorable.
Output:
0
2025-04-17 20:06:48,097 - INFO - Batch 160 complete. Total preferences: 2560
2025-04-17 20:06:48,097 - INFO - Processing batch 161/512...
2025-04-17 20:07:36,428 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Step-by-step comparison:**
1. **MW:** Both ligands (340.471 and 361.427 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (58.95) is significantly better than Ligand B (100.35). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (2.805) is optimal, while Ligand B (0.6) is quite low. This is a significant concern for Ligand B, as it may struggle with membrane permeability.
4. **HBD:** Both ligands have 2 HBD, which is within the acceptable limit.
5. **HBA:** Ligand A (4) is better than Ligand B (7), as fewer HBA generally improves permeability.
6. **QED:** Both ligands have similar QED values (0.85 and 0.812), indicating good drug-likeness.
7. **DILI:** Ligand A (27.181) has a much lower DILI risk than Ligand B (62.389). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (55.293) has a moderate BBB score, while Ligand B (21.791) is low. Not a primary concern for a cardiovascular target, but still slightly favors A.
9. **Caco-2:** Both have negative values, indicating poor permeability. However, the scale is not specified, so it is hard to interpret.
10. **Solubility:** Both ligands have negative solubility values, indicating poor solubility. Again, the scale is not specified, so it is hard to interpret.
11. **hERG:** Ligand A (0.684) has a lower hERG risk than Ligand B (0.127). This is a positive for Ligand A.
12. **Cl_mic:** Ligand A (-30.666) has a much lower (better) microsomal clearance than Ligand B (4.56). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (35.094) has a longer in vitro half-life than Ligand B (-7.126). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.173) has a lower Pgp efflux liability than Ligand B (0.027). This is a positive for Ligand A.
15. **Binding Affinity:** Ligand B (-8.1) has a slightly better binding affinity than Ligand A (-6.8). However, the difference is less than 1.5 kcal/mol.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A excels in logP, TPSA, and Pgp, while Ligand B has a slightly better affinity. However, the other ADME properties of Ligand B are significantly worse, especially its low logP, high DILI risk, and poor metabolic stability.
**Conclusion:**
Despite the slightly better binding affinity of Ligand B, Ligand A is the more promising drug candidate due to its superior ADME properties (logP, TPSA, DILI, Cl_mic, t1/2, Pgp) and overall better drug-like profile. The difference in binding affinity is not large enough to outweigh the substantial advantages of Ligand A.
Output:
1
2025-04-17 20:07:36,428 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [343.427, 91.22, 2.788, 2, 4, 0.804, 44.591, 69.911, -4.396, -3.663, 0.379, 49.758, 23.488, 0.071, -6.5]
**Ligand B:** [359.467, 113.17, -0.019, 2, 5, 0.532, 12.214, 44.591, -5.175, -0.748, 0.346, 44.422, -16.456, 0.058, -6.1]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, Affinity, and BBB):
1. **MW:** Both are within the acceptable 200-500 Da range. A (343.427) is slightly preferred.
2. **TPSA:** A (91.22) is better than B (113.17). Both are reasonably good for oral absorption, but A is closer to the ideal <90 for potential CNS penetration, though ADRB2 isn't necessarily a CNS target.
3. **logP:** A (2.788) is optimal. B (-0.019) is quite low and could lead to poor membrane permeability. This is a significant drawback for B.
4. **HBD/HBA:** Both have 2 HBD and are within acceptable limits. B has 5 HBA, slightly higher than A's 4, but not a major concern.
5. **QED:** A (0.804) is significantly better than B (0.532), indicating a more drug-like profile.
6. **DILI:** A (44.591) is better than B (12.214). Lower DILI risk is always preferred.
7. **BBB:** A (69.911) is better than B (44.591), although neither is exceptionally high. This isn't critical for ADRB2, but a bonus.
8. **Caco-2:** A (-4.396) is better than B (-5.175), indicating better intestinal absorption.
9. **Solubility:** A (-3.663) is better than B (-0.748). Solubility is important for bioavailability.
10. **hERG:** Both are very low (0.379 and 0.346), indicating low cardiotoxicity risk.
11. **Cl_mic:** A (49.758) is slightly higher than B (44.422), meaning B has slightly better metabolic stability.
12. **t1/2:** A (23.488) is significantly better than B (-16.456). A longer half-life is generally desirable.
13. **Pgp:** Both are very low (0.071 and 0.058), indicating minimal P-gp efflux.
14. **Affinity:** A (-6.5) is slightly better than B (-6.1). While the difference isn't huge, it's still a factor.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical parameters. The biggest issues with Ligand B are its very low logP and lower QED, which raise concerns about permeability and overall drug-likeness. While B has slightly better metabolic stability, the other advantages of A, particularly its logP, solubility, QED, and half-life, make it a much more promising candidate. The slightly better affinity of A further reinforces this conclusion.
Output:
1
2025-04-17 20:07:36,428 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [352.387, 97.33, -1.479, 2, 6, 0.586, 36.603, 40.364, -4.894, -1.259, 0.152, -12.041, -0.996, 0.01, -5.5]
**Ligand B:** [363.483, 83.71, 1.344, 1, 4, 0.773, 33.695, 77.123, -4.82, -2.555, 0.097, 47.522, -14.179, 0.032, -7.3]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, BBB, and affinity are key):
1. **MW:** Both are within the ideal range (200-500 Da). A is 352.39, B is 363.48. No significant difference.
2. **TPSA:** A is 97.33, B is 83.71. B is better, closer to the <90 ideal for potential CNS penetration, though ADRB2 isn't necessarily a CNS target.
3. **logP:** A is -1.479, B is 1.344. B is significantly better. A's logP is quite low, potentially hindering permeability.
4. **HBD:** A is 2, B is 1. B is slightly better.
5. **HBA:** A is 6, B is 4. B is better.
6. **QED:** A is 0.586, B is 0.773. B is better, indicating a more drug-like profile.
7. **DILI:** A is 36.603, B is 33.695. B is slightly better, lower risk.
8. **BBB:** A is 40.364, B is 77.123. B is *much* better. While ADRB2 isn't strictly a CNS target, higher BBB is generally favorable.
9. **Caco-2:** Both are -4.894 and -4.82, indicating poor permeability. This is a concern for both, but not a deciding factor between them.
10. **Solubility:** A is -1.259, B is -2.555. A is better, slightly higher solubility.
11. **hERG:** Both are very low (0.152 and 0.097), indicating minimal hERG risk. Excellent for both.
12. **Cl_mic:** A is -12.041, B is 47.522. A is *much* better, indicating significantly higher metabolic stability.
13. **t1/2:** A is -0.996, B is -14.179. A is better, suggesting a longer in vitro half-life.
14. **Pgp:** A is 0.01, B is 0.032. A is slightly better, indicating less P-gp efflux.
15. **Affinity:** A is -5.5 kcal/mol, B is -7.3 kcal/mol. B is significantly better, with a 1.8 kcal/mol advantage. This is a substantial difference in binding.
**Overall Assessment:**
Ligand B clearly outperforms Ligand A in several critical areas. The superior binding affinity (-7.3 vs -5.5 kcal/mol) is a major advantage, and is likely to outweigh the slightly lower solubility and higher Cl_mic. The better logP, TPSA, QED, BBB, and DILI scores further support choosing Ligand B. While both have poor Caco-2 permeability, the stronger binding of B suggests it might still be effective *in vivo*. The improved metabolic stability of A is a plus, but the difference in affinity is too large to ignore.
Output:
0
2025-04-17 20:07:36,429 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (356.323 and 332.407 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (58.95) is better than Ligand B (62.87), both are below the 140 threshold for oral absorption, and reasonably low for a GPCR target.
3. **logP:** Both ligands have acceptable logP values (2.826 and 3.888), falling within the 1-3 range. Ligand B is slightly higher, which *could* be a minor concern for solubility, but not a dealbreaker.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1), but both are within the acceptable limit of 5.
5. **HBA:** Ligand A (4) is slightly lower than Ligand B (5), but both are within the acceptable limit of 10.
6. **QED:** Both ligands have good QED scores (0.657 and 0.77), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Both ligands have similar DILI risk (67.003 and 66.615), and both are acceptable (below 60 is ideal, but these are not high risk).
8. **BBB:** Ligand A (89.298) has a significantly better BBB penetration percentile than Ligand B (70.919). This is a crucial factor for GPCRs, even cardiovascular ones, as some CNS off-target effects are possible.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.775 and -4.985). This is unusual, and suggests poor permeability. However, these values are on a scale where negative values are possible and don't necessarily preclude development.
10. **Solubility:** Ligand A (-3.733) has better aqueous solubility than Ligand B (-5.512). This is important for bioavailability.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.498 and 0.922), which is excellent.
12. **Cl_mic:** Ligand A (23.003) has significantly lower microsomal clearance than Ligand B (69.809), indicating better metabolic stability. This is a major advantage.
13. **t1/2:** Ligand A (29.664) has a slightly longer in vitro half-life than Ligand B (23.335).
14. **Pgp:** Ligand A (0.219) has lower P-gp efflux liability than Ligand B (0.866), which is favorable for bioavailability and potential CNS exposure (even if not the primary target).
15. **Binding Affinity:** Ligand A (-5.5 kcal/mol) has slightly better binding affinity than Ligand B (-4.6 kcal/mol). This 0.9 kcal/mol difference is significant and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B in several key areas crucial for a GPCR drug candidate: BBB penetration, metabolic stability (Cl_mic), P-gp efflux, solubility, and binding affinity. While Ligand B has a slightly better QED score, the advantages of Ligand A are more impactful for this target class. The Caco-2 values are concerning for both, but the other favorable properties of Ligand A suggest it's a more promising starting point for optimization.
Output:
1
2025-04-17 20:07:36,429 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (350.419 and 348.487 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (97.56) is higher than Ligand B (49.85). For a cardiovascular GPCR, TPSA is not a primary concern like it would be for a CNS target, but lower TPSA generally favors permeability. Ligand B is better here.
**3. logP:** Ligand A (1.056) is within the optimal range (1-3), while Ligand B (2.607) is towards the higher end but still acceptable. Both are reasonable, but Ligand A is slightly preferred.
**4. H-Bond Donors:** Ligand A (1) is better than Ligand B (0). Fewer HBDs generally improve permeability.
**5. H-Bond Acceptors:** Ligand A (6) is higher than Ligand B (3). Lower HBA is generally preferred for permeability, so Ligand B is better.
**6. QED:** Both ligands (0.77 and 0.718) have good QED scores, indicating drug-likeness. No significant difference.
**7. DILI Risk:** Ligand A (36.099) has a slightly higher DILI risk than Ligand B (28.112), but both are below the concerning threshold of 60. Ligand B is slightly better.
**8. BBB Penetration:** This is less critical for a cardiovascular target. Ligand A (91.625) has higher BBB penetration than Ligand B (84.49), but this isn't a major factor in this case.
**9. Caco-2 Permeability:** Ligand A (-4.872) has better Caco-2 permeability than Ligand B (-4.332).
**10. Aqueous Solubility:** Ligand A (-1.975) has better aqueous solubility than Ligand B (-2.695).
**11. hERG Inhibition:** Ligand A (0.09) has a lower hERG risk than Ligand B (0.525). This is a significant advantage, as hERG inhibition can lead to cardiotoxicity.
**12. Microsomal Clearance:** Ligand B (87.408) has significantly higher microsomal clearance than Ligand A (20.429), indicating faster metabolism and potentially lower *in vivo* exposure. Ligand A is significantly better.
**13. In vitro Half-Life:** Ligand A (2.037) has a shorter half-life than Ligand B (-8.081). This is a negative for Ligand A.
**14. P-gp Efflux:** Ligand A (0.038) has lower P-gp efflux than Ligand B (0.495). Lower efflux is generally preferred for improved bioavailability.
**15. Binding Affinity:** Ligand A (-6.5 kcal/mol) has slightly better binding affinity than Ligand B (-5.7 kcal/mol). This difference of 0.8 kcal/mol is significant, and can outweigh some of the ADME drawbacks.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), and the general guidelines, Ligand A is the better candidate. While Ligand B has a lower TPSA and DILI risk, Ligand A's superior binding affinity, lower hERG risk, lower P-gp efflux, and significantly better metabolic stability (lower Cl_mic) are more important for a cardiovascular GPCR target. The slightly shorter half-life of Ligand A is a concern, but can potentially be addressed through formulation strategies.
Output:
1
2025-04-17 20:07:36,429 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [358.463, 68.29, 4.23, 1, 5, 0.834, 81.427, 70.919, -4.544, -5.859, 0.295, 111.24, 29.664, 0.36, -6.4]**
**Ligand B: [353.503, 59, 2.752, 1, 4, 0.682, 13.339, 78.558, -4.488, -2.285, 0.774, 54.792, 23.296, 0.675, -7.2]**
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). A (358.463) and B (353.503) are comparable.
2. **TPSA:** Ligand A (68.29) is slightly higher than Ligand B (59). Both are acceptable for oral absorption, but B is better.
3. **logP:** Ligand A (4.23) is higher than the optimal range (1-3), potentially leading to solubility issues and off-target effects. Ligand B (2.752) is within the optimal range. This is a significant advantage for B.
4. **H-Bond Donors:** Both have 1 HBD, which is good.
5. **H-Bond Acceptors:** Ligand A has 5, and Ligand B has 4. Both are within the acceptable range.
6. **QED:** Ligand A (0.834) has a better QED score than Ligand B (0.682), indicating a more drug-like profile.
7. **DILI:** Ligand A (81.427) has a significantly higher DILI risk than Ligand B (13.339). This is a major concern for A.
8. **BBB:** Both have good BBB penetration (A: 70.919, B: 78.558), but B is slightly better.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. This is a concern for both, but the values are close.
10. **Solubility:** Ligand A (-5.859) has very poor solubility, while Ligand B (-2.285) is better, though still not ideal.
11. **hERG:** Ligand A (0.295) has a lower hERG inhibition liability than Ligand B (0.774), which is favorable.
12. **Cl_mic:** Ligand A (111.24) has a higher microsomal clearance than Ligand B (54.792), suggesting lower metabolic stability. B is preferable.
13. **t1/2:** Ligand A (29.664) has a longer in vitro half-life than Ligand B (23.296), which is a positive.
14. **Pgp:** Ligand A (0.36) has lower P-gp efflux than Ligand B (0.675), which is favorable.
15. **Binding Affinity:** Ligand B (-7.2) has a significantly better binding affinity than Ligand A (-6.4). This is a substantial advantage for B, potentially outweighing some of the ADME drawbacks.
**GPCR-Specific Priorities:** For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are crucial. Ligand B excels in logP and affinity, and has better TPSA and Pgp values. While Ligand A has a slightly better QED and hERG, the significantly higher DILI risk, poor solubility, and lower affinity make it less desirable.
**Conclusion:**
Despite Ligand A's better QED and hERG, Ligand B is the more promising candidate due to its superior binding affinity, lower DILI risk, better logP, and improved metabolic stability. The higher affinity of Ligand B is a significant advantage for a GPCR target.
0
2025-04-17 20:07:36,429 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (342.439 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (67.43) is better than Ligand B (29.54). For a cardiovascular GPCR, lower TPSA is generally preferred for better membrane permeability.
3. **logP:** Ligand B (4.638) is higher than Ligand A (1.087). While logP for Ligand B is a bit high, it's not drastically so. Ligand A is on the lower side, which could hinder permeability.
4. **HBD:** Ligand A (2) is better than Ligand B (0). Having some HBD can improve solubility.
5. **HBA:** Both ligands have 3 HBA, which is acceptable.
6. **QED:** Ligand A (0.752) is better than Ligand B (0.631), indicating a more drug-like profile.
7. **DILI:** Ligand B (16.053) is significantly better than Ligand A (40.752), indicating a much lower risk of drug-induced liver injury. This is a crucial factor.
8. **BBB:** Ligand B (91.586) is much better than Ligand A (54.75). While ADRB2 isn't necessarily a CNS target, higher BBB penetration can sometimes translate to better overall distribution and reduced off-target effects.
9. **Caco-2:** Ligand B (-5.163) is better than Ligand A (-4.766), indicating better intestinal absorption.
10. **Solubility:** Ligand B (-3.996) is better than Ligand A (-3.164), which is important for bioavailability.
11. **hERG:** Ligand B (0.833) is better than Ligand A (0.22), indicating a lower risk of cardiotoxicity. This is a critical consideration for a cardiovascular target.
12. **Cl_mic:** Ligand A (7.636) is much better than Ligand B (100.821), suggesting better metabolic stability.
13. **t1/2:** Ligand B (12.951) is better than Ligand A (7.449), indicating a longer half-life.
14. **Pgp:** Ligand B (0.886) is better than Ligand A (0.049), suggesting lower P-gp efflux and potentially better bioavailability.
15. **Affinity:** Ligand B (-7.5 kcal/mol) is significantly better than Ligand A (-6.4 kcal/mol). This 1.1 kcal/mol difference is substantial and can outweigh some of the ADME drawbacks of Ligand B.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), affinity, logP, TPSA, Pgp, and BBB are key. Ligand B excels in affinity, BBB, Pgp, and has acceptable logP and TPSA. While Ligand A has better QED and Cl_mic, the significantly better affinity and safety profile (DILI, hERG) of Ligand B are more important.
**Conclusion:**
Despite Ligand A's better QED and metabolic stability, Ligand B's superior binding affinity, lower DILI and hERG risk, better BBB penetration, and improved Caco-2 permeability and Pgp efflux make it the more promising drug candidate for ADRB2. The substantial affinity difference is a major driver of this decision.
Output:
0
2025-04-17 20:07:36,429 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Ligand A (410.268 Da) is within the ideal range, while Ligand B (350.491 Da) is also acceptable. No clear advantage.
2. **TPSA:** Ligand A (99.5) is borderline, but still reasonably good for a non-CNS GPCR. Ligand B (55.71) is excellent, well below the 140 threshold. Advantage: B.
3. **logP:** Ligand A (2.717) is optimal. Ligand B (4.471) is pushing the upper limit and could lead to solubility issues or off-target interactions. Advantage: A.
4. **HBD:** Both ligands have 1 HBD, which is good. No difference.
5. **HBA:** Ligand A has 5 HBA, Ligand B has 4. Both are acceptable. No significant difference.
6. **QED:** Ligand B (0.713) has a slightly better QED score than Ligand A (0.551), suggesting a more drug-like profile. Advantage: B.
7. **DILI:** Ligand A (71.384) has a higher DILI risk than Ligand B (44.164). Advantage: B.
8. **BBB:** Both are relatively low, which is fine for a cardiovascular target. Ligand A (62.97) is slightly higher, but not a major factor here.
9. **Caco-2:** Ligand A (-4.442) is better than Ligand B (-5.379), indicating better intestinal absorption. Advantage: A.
10. **Solubility:** Ligand A (-4.396) is better than Ligand B (-4.925). Advantage: A.
11. **hERG:** Ligand A (0.572) has a lower hERG inhibition liability than Ligand B (0.815). Advantage: A.
12. **Cl_mic:** Ligand B (37.736) has a lower microsomal clearance, suggesting better metabolic stability, than Ligand A (109.574). Advantage: B.
13. **t1/2:** Ligand B (-2.824) has a better in vitro half-life than Ligand A (37.431). Advantage: B.
14. **Pgp:** Ligand A (0.13) has lower P-gp efflux liability than Ligand B (0.387). Advantage: A.
15. **Binding Affinity:** Ligand B (-8.1 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.5 kcal/mol) - a difference of 2.6 kcal/mol. This is a substantial advantage.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in TPSA, Cl_mic, t1/2, and crucially, *affinity*. While Ligand A has better logP, solubility, and hERG, the substantial affinity difference of Ligand B outweighs these benefits. The higher DILI risk of Ligand A is also concerning.
**Conclusion:**
Despite some drawbacks in logP and solubility, the significantly stronger binding affinity of Ligand B, coupled with its better metabolic stability and lower DILI risk, makes it the more promising drug candidate for the ADRB2 receptor.
Output:
0
2025-04-17 20:07:36,430 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (362.434 Da and 358.429 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (89.07) is better than Ligand B (58.64). Both are below the 140 A^2 threshold for good oral absorption, but the lower TPSA of Ligand B is more favorable for GPCRs, potentially aiding receptor penetration.
**3. logP:** Both ligands have good logP values (1.858 and 2.368), falling within the optimal 1-3 range. Ligand B is slightly higher, which could be a minor advantage.
**4. H-Bond Donors:** Ligand A has 2 HBDs, and Ligand B has 1. Both are within the acceptable limit of 5.
**5. H-Bond Acceptors:** Ligand A has 5 HBAs, and Ligand B has 3. Both are below the 10 threshold.
**6. QED:** Ligand A (0.81) has a better QED score than Ligand B (0.711), indicating a more drug-like profile.
**7. DILI Risk:** Ligand A (72.586) has a significantly higher DILI risk than Ligand B (31.33). This is a major concern for Ligand A.
**8. BBB Penetration:** Ligand B (91.508) shows much better BBB penetration than Ligand A (77.821). While ADRB2 is primarily a cardiovascular target, some CNS effects are possible with adrenergic agonists, and better CNS penetration could lead to off-target effects. However, for a cardiovascular target, this isn't a primary driver.
**9. Caco-2 Permeability:** Ligand A (-5.118) has worse Caco-2 permeability than Ligand B (-4.434). Both are negative, suggesting poor permeability.
**10. Aqueous Solubility:** Ligand A (-3.843) has worse aqueous solubility than Ligand B (-2.575). Both are negative, indicating poor solubility.
**11. hERG Inhibition:** Ligand A (0.514) has a slightly higher hERG inhibition risk than Ligand B (0.351), but both are relatively low.
**12. Microsomal Clearance:** Ligand A (11.542) has significantly lower microsomal clearance than Ligand B (36.47), suggesting better metabolic stability.
**13. In vitro Half-Life:** Ligand A (-0.718) has a slightly longer in vitro half-life than Ligand B (-3.619).
**14. P-gp Efflux:** Ligand A (0.21) has lower P-gp efflux than Ligand B (0.039), which is favorable for bioavailability.
**15. Binding Affinity:** Ligand B (-9.3 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.9 kcal/mol). This is a substantial advantage, exceeding the 1.5 kcal/mol threshold.
**Overall Assessment:**
Ligand B is the stronger candidate. The significantly improved binding affinity (-9.3 vs -6.9 kcal/mol) is a major advantage that outweighs the slightly lower QED and BBB. Critically, Ligand B has a much lower DILI risk (31.33 vs 72.586), which is a serious concern for Ligand A. While Ligand A has better metabolic stability and P-gp efflux, the DILI risk and weaker binding make it less attractive. The lower TPSA of Ligand B is also a plus for GPCR targeting.
Output:
0
2025-04-17 20:07:36,430 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (356.511 and 368.459 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (90.54) is better than Ligand B (111.63). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (1.589) is within the optimal 1-3 range. Ligand B (-0.024) is slightly below 1, which could potentially hinder permeation. This is a point in favor of A.
4. **HBD:** Both have 3 HBD, which is acceptable.
5. **HBA:** Ligand A has 3 HBA, while Ligand B has 6. Ligand A is preferable.
6. **QED:** Both ligands have good QED scores (0.519 and 0.676), indicating drug-likeness.
7. **DILI:** Ligand A (18.108) has a much lower DILI risk than Ligand B (48.313). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (73.827) has a better BBB penetration score than Ligand B (5.855). While not critical for a cardiovascular target, it's a slight positive for A.
9. **Caco-2:** Ligand A (-4.892) is better than Ligand B (-5.377).
10. **Solubility:** Ligand A (-2.103) is better than Ligand B (-0.892).
11. **hERG:** Ligand A (0.634) has a lower hERG risk than Ligand B (0.095). This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand A (35.123) has a better (lower) microsomal clearance than Ligand B (-7.33). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (0.024) is worse than Ligand B (-14.341).
14. **Pgp:** Ligand A (0.013) has a lower Pgp efflux liability than Ligand B (0.028).
15. **Binding Affinity:** Ligand A (-7.3) has a slightly better binding affinity than Ligand B (-4.7). This is a substantial difference.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A performs better in all these categories. While BBB isn't critical here, Ligand A also has a better score.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most crucial ADME-Tox properties (DILI, hERG, Cl_mic, solubility, Pgp) *and* has a significantly better binding affinity. While Ligand B has a better in vitro half-life, the other advantages of Ligand A are more critical for overall drug development success.
Output:
1
2025-04-17 20:07:36,430 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's break down the comparison of Ligand A and Ligand B across the provided parameters, keeping in mind the GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key).
1. **Molecular Weight:** Both ligands (354.332 Da and 346.439 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (85.23) is significantly better than Ligand B (116.54). A TPSA under 140 is good for oral absorption, but lower is generally preferred for GPCRs. Ligand A is much closer to the ideal range.
3. **logP:** Ligand A (2.889) is within the optimal 1-3 range. Ligand B (1.453) is on the lower end, potentially hindering membrane permeability. This favors Ligand A.
4. **H-Bond Donors:** Both have 2 HBD, which is acceptable.
5. **H-Bond Acceptors:** Ligand A has 3 HBA, while Ligand B has 8. The higher HBA count in Ligand B could negatively impact permeability.
6. **QED:** Both ligands have similar QED values (0.824 and 0.818), indicating good drug-likeness.
7. **DILI:** Both ligands have similar DILI risk (49.05 and 49.981), both are acceptable.
8. **BBB:** Both ligands have good BBB penetration (76.309 and 75.533). This isn't a primary concern for ADRB2 (a cardiovascular target), but it's not a detriment.
9. **Caco-2:** Ligand A (-4.697) is better than Ligand B (-5.509). Higher values indicate better absorption.
10. **Solubility:** Ligand A (-4.082) is better than Ligand B (-2.463).
11. **hERG:** Ligand A (0.685) is better than Ligand B (0.051). Lower hERG inhibition is crucial for avoiding cardiotoxicity, a significant concern with cardiovascular targets.
12. **Cl_mic:** Ligand A (1.645) has significantly lower microsomal clearance than Ligand B (19.008). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (17.495) has a longer in vitro half-life than Ligand B (4.938). This is a clear advantage for Ligand A, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.04) has lower P-gp efflux than Ligand B (0.064). Lower P-gp efflux is desirable for better bioavailability.
15. **Binding Affinity:** Ligand B (-7.2 kcal/mol) has a significantly stronger binding affinity than Ligand A (-3.0 kcal/mol). This is a substantial difference. A difference of >1.5 kcal/mol can outweigh other issues.
**Overall Assessment:**
While Ligand B boasts a superior binding affinity, Ligand A demonstrates a more favorable ADME profile across several critical parameters. Specifically, its lower TPSA, better logP, lower hERG risk, significantly lower Cl_mic, longer t1/2, and better solubility are all highly desirable characteristics for a drug candidate, especially one targeting a cardiovascular system. The difference in binding affinity is significant, but the ADME advantages of Ligand A are substantial enough to overcome this.
**Output:**
1
2025-04-17 20:07:36,430 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (358.41 and 347.459 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (87.15) is better than Ligand B (93.43). Both are below 140, but lower TPSA generally favors absorption.
3. **logP:** Ligand B (1.607) is better than Ligand A (0.498). A logP between 1-3 is optimal, and Ligand A is slightly below this range, potentially hindering permeability.
4. **HBD:** Ligand A (1) is better than Ligand B (2). Lower HBD is generally preferred.
5. **HBA:** Ligand A (5) is better than Ligand B (4). Both are within the acceptable range.
6. **QED:** Both ligands have similar QED values (0.699 and 0.714), indicating good drug-likeness.
7. **DILI:** Ligand B (19.193) is significantly better than Ligand A (32.726). Lower DILI risk is crucial.
8. **BBB:** Both ligands have similar BBB penetration (59.791 and 61.419). While not CNS-focused for ADRB2, higher is still slightly preferable.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.475 and -4.797). These values are difficult to interpret without knowing the scale, but negative values generally indicate poor permeability.
10. **Solubility:** Ligand A (-1.165) is better than Ligand B (-2.485). Higher solubility is generally preferred.
11. **hERG:** Ligand B (0.181) is better than Ligand A (0.453). Lower hERG inhibition is critical for avoiding cardiotoxicity.
12. **Cl_mic:** Ligand B (14.826) is better than Ligand A (25.394). Lower microsomal clearance indicates better metabolic stability.
13. **t1/2:** Ligand B (-16.933) is better than Ligand A (-9.926). Longer half-life is generally preferred.
14. **Pgp:** Ligand B (0.009) is significantly better than Ligand A (0.104). Lower P-gp efflux improves bioavailability.
15. **Binding Affinity:** Ligand A (-4.0) is better than Ligand B (-6.0). This is a substantial difference in binding affinity.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand B excels in logP, Pgp, and metabolic stability (Cl_mic, t1/2), and has a better hERG profile. While Ligand A has a better affinity, the substantial advantages of Ligand B in ADME properties, particularly the lower DILI and Pgp efflux, outweigh the affinity difference. The affinity of -4.0 kcal/mol for Ligand A is still reasonable.
**Conclusion:**
Ligand B presents a more balanced profile with significantly better ADME properties and a lower risk profile, making it the more promising drug candidate despite the slightly lower binding affinity.
Output:
0
2025-04-17 20:07:36,430 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (348.403 and 382.555 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Both ligands have TPSA values (88.02 and 83.98) below the 140 A^2 threshold for good oral absorption. This is positive for both.
**3. logP:** Ligand B (1.871) is better than Ligand A (0.635). A logP between 1-3 is optimal, and Ligand A is a bit low, potentially hindering permeability.
**4. H-Bond Donors:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
**5. H-Bond Acceptors:** Ligand A (7) is slightly better than Ligand B (6), but both are within the acceptable range of <=10.
**6. QED:** Ligand A (0.833) has a slightly higher QED than Ligand B (0.785), indicating a more drug-like profile.
**7. DILI:** Ligand B (49.864) has a significantly lower DILI risk than Ligand A (64.366). This is a major advantage for Ligand B.
**8. BBB:** Ligand B (60.954) has a slightly higher BBB penetration than Ligand A (54.634). While ADRB2 is a cardiovascular target, some CNS exposure is possible with certain ligands, so this is a minor positive for Ligand B.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-5.188 and -5.717). This is unusual and suggests poor permeability. However, the values are similar.
**10. Aqueous Solubility:** Both ligands have negative solubility values (-1.959 and -2.945). This is also unusual and suggests poor solubility. Ligand B is slightly worse.
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.191 and 0.088). This is excellent for both.
**12. Microsomal Clearance:** Ligand A (6.982) has significantly lower microsomal clearance than Ligand B (30.334), suggesting better metabolic stability. This is a significant advantage for Ligand A.
**13. In vitro Half-Life:** Ligand B (4.955) has a longer in vitro half-life than Ligand A (0.574). This is a positive for Ligand B.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.004 and 0.079). This is excellent for both.
**15. Binding Affinity:** Ligand B (-6.5 kcal/mol) has a stronger binding affinity than Ligand A (-5.6 kcal/mol). This is a 0.9 kcal/mol difference, which is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand B emerges as the more promising candidate. While Ligand A has better metabolic stability (lower Cl_mic), the stronger binding affinity of Ligand B (-6.5 vs -5.6 kcal/mol) is a significant advantage. The lower DILI risk for Ligand B is also a crucial factor. The slightly better BBB penetration is a minor bonus. The poor Caco-2 and solubility values are concerning for both, but the affinity difference is substantial enough to favor Ligand B.
Output:
0
2025-04-17 20:07:36,430 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (355.395 and 356.419 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (124.44) is slightly higher than Ligand B (116.17). Both are below the 140 threshold for good oral absorption, but closer to the upper limit for GPCRs. Ligand B is preferable.
3. **logP:** Ligand A (0.342) is quite low, potentially hindering membrane permeability. Ligand B (-0.575) is also low, but slightly better. Both are below the optimal 1-3 range. This is a concern for both, but more so for A.
4. **HBD:** Ligand A (2) is better than Ligand B (3). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (8) is higher than Ligand B (6). Lower HBA is generally preferable for permeability. Ligand B is preferable.
6. **QED:** Ligand A (0.676) is slightly better than Ligand B (0.526), indicating a more drug-like profile.
7. **DILI:** Ligand B (37.767) has a significantly lower DILI risk than Ligand A (49.011). This is a major advantage for Ligand B.
8. **BBB:** Ligand A (61.923) has a better BBB penetration percentile than Ligand B (45.134). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant depending on the specific therapeutic application, and is a consideration for GPCRs.
9. **Caco-2:** Ligand A (-4.586) is better than Ligand B (-5.073), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-2.437) is better than Ligand B (-1.086). Solubility is important for bioavailability.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.036 and 0.087 respectively), which is excellent.
12. **Cl_mic:** Ligand B (13.967) has a significantly lower microsomal clearance than Ligand A (71.401), indicating better metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand B (-9.156) has a slightly better in vitro half-life than Ligand A (-10.267).
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.011 and 0.015 respectively), which is excellent.
15. **Binding Affinity:** Ligand B (-8.0) has a significantly better binding affinity than Ligand A (-5.8). This is a crucial factor, and the 2.2 kcal/mol difference is substantial enough to outweigh many of the ADME drawbacks of Ligand B.
**Overall Assessment:**
Ligand B has a superior safety profile (lower DILI), better metabolic stability (lower Cl_mic), and significantly stronger binding affinity. While Ligand A has slightly better BBB penetration and solubility, the advantages of Ligand B in the key areas of safety, metabolism, and potency are more important for a GPCR drug candidate. The lower logP values for both are a concern, but the strong binding affinity of Ligand B suggests it can still achieve sufficient target engagement.
Output:
0
2025-04-17 20:07:36,431 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (345.399 and 352.45 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (101.3) is higher than Ligand B (71.34). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B is better.
3. **logP:** Ligand A (1.889) is within the optimal range (1-3), while Ligand B (3.385) is at the upper end. Both are acceptable, but Ligand A is slightly preferred.
4. **HBD:** Both ligands have 2 HBD, which is within the ideal limit of 5. No difference.
5. **HBA:** Ligand A has 5 HBA, while Ligand B has 3. Both are within the ideal limit of 10. No significant difference.
6. **QED:** Both ligands have good QED scores (0.627 and 0.753), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (60.915) has a higher DILI risk than Ligand B (38.852). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (57.115) has a lower BBB penetration than Ligand B (86.778). While ADRB2 isn't a CNS target, some distribution to the CNS can lead to off-target effects, so lower BBB is preferable. Ligand A is better.
9. **Caco-2:** Ligand A (-5.136) has a worse Caco-2 permeability than Ligand B (-4.44). Ligand B is better.
10. **Solubility:** Ligand A (-2.488) has a worse aqueous solubility than Ligand B (-4.187). Ligand B is better.
11. **hERG:** Ligand A (0.031) has a slightly lower hERG risk than Ligand B (0.571). This is a slight advantage for Ligand A.
12. **Cl_mic:** Ligand A (29.42) has a lower microsomal clearance than Ligand B (68.125), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (-31.621) has a worse in vitro half-life than Ligand B (28.947). Ligand B is better.
14. **Pgp:** Ligand A (0.11) has lower P-gp efflux than Ligand B (0.49), which is preferable. Ligand A is better.
15. **Binding Affinity:** Ligand B (-5.9 kcal/mol) has a stronger binding affinity than Ligand A (-4.8 kcal/mol). This is a substantial advantage for Ligand B (a 1.1 kcal/mol difference).
**Overall Assessment:**
Ligand B demonstrates a clear advantage in binding affinity (-5.9 vs -4.8 kcal/mol) and has a significantly lower DILI risk (38.852 vs 60.915). It also has better Caco-2 permeability, solubility, and in vitro half-life. While Ligand A has advantages in metabolic stability (Cl_mic) and P-gp efflux, the stronger binding and lower toxicity profile of Ligand B outweigh these benefits, especially for a cardiovascular target where CNS penetration is not desired.
Output:
0
2025-04-17 20:07:36,431 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (371.5 & 362.6 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand B (33.2) is significantly better than Ligand A (92.5). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. This is a strong point for B.
3. **logP:** Ligand A (1.775) is optimal, while Ligand B (4.729) is pushing the upper limit. Higher logP can lead to off-target effects and solubility issues. A favors here.
4. **HBD:** Ligand A (2) is preferable to Ligand B (0). While low HBD can improve permeability, some H-bonding is beneficial for solubility and target engagement.
5. **HBA:** Ligand A (4) is slightly higher than Ligand B (3), but both are within acceptable limits.
6. **QED:** Ligand B (0.733) is better than Ligand A (0.573), indicating a more drug-like profile.
7. **DILI:** Ligand A (12.2) has a significantly lower DILI risk than Ligand B (24.7). This is a crucial factor.
8. **BBB:** Ligand B (78.1) has better BBB penetration than Ligand A (65.4), but this isn't a primary concern for a cardiovascular target.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-5.486) is slightly better than Ligand B (-4.986).
10. **Solubility:** Ligand A (-2.645) is better than Ligand B (-4.234). Solubility is important for bioavailability.
11. **hERG:** Both ligands have low hERG inhibition risk (0.344 and 0.694, respectively). No significant difference.
12. **Cl_mic:** Ligand A (30.4) has significantly lower microsomal clearance than Ligand B (100.1). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (-18.1) has a negative half-life which is concerning, while Ligand B (7.1) has a positive half-life. This is a major advantage for Ligand B.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.042 and 0.706, respectively). No significant difference.
15. **Binding Affinity:** Both ligands have the same binding affinity (-5.8 kcal/mol).
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand A has a better logP and TPSA, while both have the same affinity. However, the significantly lower DILI risk and better metabolic stability (lower Cl_mic) of Ligand A, combined with better solubility, are crucial advantages. The positive half-life of Ligand B is a plus, but the higher DILI risk and higher Cl_mic are significant drawbacks.
**Overall Assessment:**
While Ligand B has a slightly better QED and BBB penetration, the superior safety profile (DILI) and metabolic stability (Cl_mic) of Ligand A, along with its better solubility, make it the more promising drug candidate.
Output:
1
2025-04-17 20:07:36,431 - INFO - Batch 161 complete. Total preferences: 2576
2025-04-17 20:07:36,431 - INFO - Processing batch 162/512...
2025-04-17 20:08:19,672 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (351.451 and 376.45 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (82.86) is better than Ligand B (95.94). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally favors absorption.
3. **logP:** Ligand A (-0.635) is slightly below the optimal 1-3 range, while Ligand B (0.112) is closer. Ligand B is preferable here.
4. **HBD:** Both ligands have 2 HBD, which is within the acceptable limit of 5. No clear advantage.
5. **HBA:** Ligand A (7) is slightly higher than Ligand B (6), but both are within the acceptable limit of 10.
6. **QED:** Ligand A (0.751) is better than Ligand B (0.555), indicating a more drug-like profile.
7. **DILI:** Both ligands have very similar and acceptable DILI risk (23.497 vs 23.885).
8. **BBB:** Ligand B (43.505) is higher than Ligand A (31.02), but BBB isn't a high priority for a cardiovascular target.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.213 and -5.11), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand A (0.264) is better than Ligand B (-1.958). Solubility is important for bioavailability.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.201 and 0.114).
12. **Cl_mic:** Ligand B (-9.275) has a much lower (better) microsomal clearance than Ligand A (-44.356), indicating greater metabolic stability.
13. **t1/2:** Ligand A (23.212) has a much longer in vitro half-life than Ligand B (1.218). This is a significant advantage for dosing convenience.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.007 and 0.024).
15. **Binding Affinity:** Ligand A (-8.4 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.3 kcal/mol). This is a substantial advantage, potentially outweighing some ADME concerns.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B has a slightly better logP, but Ligand A excels in TPSA, has comparable Pgp, and *significantly* better affinity. The strong affinity of Ligand A is a major driver. The poor Caco-2 values are concerning for both, but the better solubility and half-life of Ligand A, combined with its superior binding, make it the more promising candidate.
**Output:**
1
2025-04-17 20:08:19,672 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (357.797 and 365.499 Da) fall comfortably within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (65.38) is better than Ligand B (80.32). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (3.296 and 2.991), falling within the optimal 1-3 range. Again, no significant difference.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Both ligands have the same number of HBA (5), which is acceptable.
6. **QED:** Ligand A (0.778) has a slightly better QED score than Ligand B (0.623), indicating a more drug-like profile.
7. **DILI:** Ligand B (73.827) has a lower DILI risk than Ligand A (80.729), which is a significant advantage. Lower DILI is always preferred.
8. **BBB:** Both ligands have moderate BBB penetration, but Ligand B (75.727) is slightly better than Ligand A (65.335). However, as ADRB2 is a cardiovascular target, BBB isn't a high priority.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.929) is slightly better than Ligand B (-5.084), but both are concerning.
10. **Solubility:** Both ligands have negative solubility values, which is also unusual and suggests poor solubility. Ligand A (-4.635) is slightly better than Ligand B (-4.537), but both are concerning.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.399 and 0.696), which is excellent.
12. **Cl_mic:** Ligand A (50.487) has a lower microsomal clearance than Ligand B (80.456), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-5.944) has a longer in vitro half-life than Ligand A (52.314). This is a significant advantage.
14. **Pgp:** Ligand A (0.441) has lower P-gp efflux liability than Ligand B (0.279), which is preferable.
15. **Binding Affinity:** Both ligands have the same binding affinity (-5.9 kcal/mol), so this parameter doesn't differentiate them.
**GPCR-Specific Priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A is better in terms of TPSA, HBD, QED, Cl_mic, and Pgp. Ligand B has a lower DILI risk and longer half-life. The DILI risk is a significant concern, but the longer half-life of Ligand B is also valuable. Considering the overall balance, the slightly better ADME profile of Ligand A, combined with the similar binding affinity, makes it a more promising candidate.
**Output:**
1
2025-04-17 20:08:19,672 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (354.841) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (51.97) is significantly better than Ligand B (78.35). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (2.463) is within the optimal range, while Ligand A (4.672) is a bit high. High logP can lead to solubility issues and off-target interactions.
4. **HBD:** Both are acceptable (Ligand A: 1, Ligand B: 2).
5. **HBA:** Both are acceptable (Ligand A: 5, Ligand B: 7).
6. **QED:** Both are good (Ligand A: 0.723, Ligand B: 0.787), indicating good drug-like properties.
7. **DILI:** Both have similar, acceptable DILI risk (Ligand A: 68.166, Ligand B: 67.003).
8. **BBB:** Both have good BBB penetration (Ligand A: 71.733, Ligand B: 73.517), but this isn't a major concern for a cardiovascular target.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the values are similar (-5.064 vs -5.46).
10. **Solubility:** Ligand A (-5.024) has slightly better solubility than Ligand B (-3.719), although both are poor.
11. **hERG:** Both have low hERG risk (Ligand A: 0.552, Ligand B: 0.495).
12. **Cl_mic:** Ligand B (37.463) has significantly lower microsomal clearance than Ligand A (55.482), indicating better metabolic stability.
13. **t1/2:** Both have similar in vitro half-lives (Ligand A: 31.758, Ligand B: 33.813).
14. **Pgp:** Ligand A (0.776) has lower P-gp efflux than Ligand B (0.094), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand A (-7.7) has a significantly stronger binding affinity than Ligand B (-3.6). This is a crucial advantage, exceeding the 1.5 kcal/mol threshold.
**GPCR-specific priorities:** For ADRB2 (a GPCR), affinity, logP, TPSA, and Pgp are important. Ligand A excels in affinity and Pgp, while Ligand B has a better logP. Ligand A's TPSA is also better. While Ligand B has better metabolic stability, the substantial affinity advantage of Ligand A outweighs this concern. The poor Caco-2 and solubility of both are concerning but could be addressed with formulation strategies.
**Conclusion:**
Ligand A's significantly stronger binding affinity (-7.7 kcal/mol vs -3.6 kcal/mol) is the deciding factor. This advantage is substantial enough to compensate for its slightly higher logP and poorer metabolic stability compared to Ligand B.
**Output:**
1
2025-04-17 20:08:19,672 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (343.31 Da) is slightly lower, which is generally favorable for permeability.
**2. TPSA:** Ligand B (42.68) is significantly better than Ligand A (77.77). Lower TPSA generally correlates with better membrane permeability, a crucial factor for GPCR ligands.
**3. logP:** Both ligands have logP values within the optimal range (1-3), but Ligand B (4.22) is slightly higher. While acceptable, this could potentially lead to off-target interactions or solubility issues. Ligand A (3.202) is better in this regard.
**4. H-Bond Donors:** Ligand A (1) is preferable to Ligand B (0). Having at least one HBD can improve solubility.
**5. H-Bond Acceptors:** Both are similar (Ligand A: 5, Ligand B: 4).
**6. QED:** Ligand A (0.787) has a significantly higher QED score than Ligand B (0.487), indicating a more drug-like profile.
**7. DILI Risk:** Ligand B (27.142) has a much lower DILI risk than Ligand A (99.922). This is a major advantage for Ligand B.
**8. BBB Penetration:** Ligand B (77.239) has better BBB penetration than Ligand A (58.511), which is a positive for a GPCR target, though not critical for cardiovascular targets.
**9. Caco-2 Permeability:** Ligand A (-4.239) has better Caco-2 permeability than Ligand B (-5.149).
**10. Aqueous Solubility:** Ligand A (-5.426) has better aqueous solubility than Ligand B (-4.126).
**11. hERG Inhibition:** Both ligands have similar hERG inhibition risk (Ligand A: 0.729, Ligand B: 0.741).
**12. Microsomal Clearance:** Ligand B (89.613) has higher microsomal clearance than Ligand A (62.169), meaning it's metabolized faster. This is a drawback for Ligand B.
**13. In vitro Half-Life:** Ligand A (59.3) has a longer in vitro half-life than Ligand B (44.325).
**14. P-gp Efflux:** Both ligands have similar P-gp efflux liability (Ligand A: 0.431, Ligand B: 0.75).
**15. Binding Affinity:** Ligand B (-7.0) has significantly better binding affinity than Ligand A (-3.3). This is a substantial advantage, potentially outweighing some ADME concerns.
**Overall Assessment:**
While Ligand A has better QED, solubility, permeability, and metabolic stability, Ligand B's significantly superior binding affinity (-7.0 vs -3.3 kcal/mol) and much lower DILI risk are compelling. For a GPCR, affinity is paramount. The slightly higher logP of Ligand B is acceptable, and the lower half-life and higher clearance might be manageable through formulation strategies. The lower DILI risk is a significant safety advantage.
Therefore, I would prioritize Ligand B.
0
2025-04-17 20:08:19,672 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.459 and 347.419 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (75.71) is better than Ligand B (90.56). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (1.586) is within the optimal 1-3 range. Ligand B (-0.23) is slightly low, potentially hindering membrane permeability. This is a notable disadvantage for Ligand B.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (4) is preferable to Ligand B (5). Lower HBA generally improves permeability.
6. **QED:** Both ligands have good QED scores (0.708 and 0.788, respectively), indicating good drug-like properties. No significant difference.
7. **DILI:** Ligand A (18.651) has a significantly lower DILI risk than Ligand B (35.285). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (73.245) has a higher BBB penetration percentile than Ligand B (45.444). While not critical for a cardiovascular target, it's a slight positive for Ligand A.
9. **Caco-2:** Ligand A (-4.737) is better than Ligand B (-5.132). Higher Caco-2 permeability is preferred.
10. **Solubility:** Ligand A (-1.736) is better than Ligand B (-1.939). Higher solubility is preferred.
11. **hERG:** Both ligands have low hERG inhibition liability (0.31 and 0.273), which is good. No significant difference.
12. **Cl_mic:** Ligand B (-12.688) has a lower (better) microsomal clearance than Ligand A (44.538), suggesting better metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand B (-12.198) has a longer half-life than Ligand A (-22.892). This is a significant advantage for Ligand B.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.081 and 0.012). No significant difference.
15. **Binding Affinity:** Ligand B (-8.2) has a stronger binding affinity than Ligand A (-6.7). This is a substantial advantage for Ligand B (a difference of 1.5 kcal/mol).
**Overall Assessment:**
Ligand B has a significantly stronger binding affinity and better metabolic stability (lower Cl_mic and longer t1/2). These are crucial factors for a viable drug candidate. While Ligand A has advantages in TPSA, DILI risk, and solubility, the binding affinity difference is substantial enough to outweigh these benefits. The slightly lower logP of Ligand B is a concern, but not insurmountable.
**Output:**
0
2025-04-17 20:08:19,672 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (406.24 Da) is slightly higher than Ligand B (352.475 Da), but both are acceptable.
**2. TPSA:** Ligand A (101.22) is a bit higher than the preferred <140 for oral absorption, but still reasonable. Ligand B (89.87) is better, falling comfortably below 140. This favors Ligand B.
**3. logP:** Both ligands have good logP values (A: 2.407, B: 1.052), falling within the optimal 1-3 range. Ligand A is slightly higher, which could potentially lead to off-target effects, but it's not a major concern.
**4. H-Bond Donors:** Ligand A (1) is better than Ligand B (3). Fewer HBDs generally improve permeability.
**5. H-Bond Acceptors:** Ligand A (6) is higher than Ligand B (4), but both are within the acceptable limit of 10.
**6. QED:** Both ligands have similar and acceptable QED values (A: 0.621, B: 0.639).
**7. DILI Risk:** Ligand A (87.631) has a significantly higher DILI risk than Ligand B (13.804). This is a major red flag for Ligand A.
**8. BBB Penetration:** Ligand A (82.474) has better BBB penetration than Ligand B (41.062). While ADRB2 is a cardiovascular target, some CNS off-target effects are possible, and moderate CNS penetration isn't necessarily detrimental.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-5.109 and -5.093), which is unusual and suggests poor permeability. This is a concern for both.
**10. Aqueous Solubility:** Ligand A (-4.32) is slightly better than Ligand B (-1.723), but both are poor. Solubility could be a formulation challenge for both.
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (A: 0.125, B: 0.289).
**12. Microsomal Clearance:** Ligand A (29.834) has higher microsomal clearance than Ligand B (12.327), indicating lower metabolic stability.
**13. In vitro Half-Life:** Ligand A (0.86) has a shorter half-life than Ligand B (0.517), further supporting lower metabolic stability for Ligand A.
**14. P-gp Efflux:** Both ligands have low P-gp efflux (A: 0.085, B: 0.138).
**15. Binding Affinity:** Ligand B (-6.1 kcal/mol) has a significantly stronger binding affinity than Ligand A (-4.7 kcal/mol). This is a substantial advantage.
**GPCR-Specific Priorities:** For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B excels in affinity and has better TPSA. While BBB isn't paramount for a cardiovascular target, Ligand A's higher value isn't enough to offset its other weaknesses.
**Overall Assessment:**
Ligand A has a concerningly high DILI risk and poorer metabolic stability (higher clearance, shorter half-life). While it has slightly better BBB penetration and solubility, the significantly stronger binding affinity of Ligand B, combined with its lower DILI risk and better TPSA, makes it the more promising candidate. The affinity difference is large enough to outweigh the minor drawbacks of Ligand B.
Output:
0
2025-04-17 20:08:19,672 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Both ligands have identical binding affinities (-7.8 kcal/mol), which is excellent and removes that as a differentiating factor. Given that ADRB2 is a GPCR, I will prioritize logP, TPSA, Pgp efflux, BBB penetration, and overall drug-likeness (QED).
1. **Molecular Weight:** Both ligands are within the ideal range (355.379 Da and 352.519 Da).
2. **TPSA:** Ligand B (69.64) is significantly better than Ligand A (97.19). Lower TPSA generally correlates with better cell permeability, a key factor for GPCR ligands.
3. **logP:** Ligand A (1.164) is slightly better than Ligand B (2.286), falling more centrally within the optimal 1-3 range. However, 2.286 is still acceptable.
4. **H-Bond Donors/Acceptors:** Ligand A has 1 HBD and 6 HBA, while Ligand B has 2 HBD and 3 HBA. Both are within acceptable limits.
5. **QED:** Both ligands have similar QED scores (0.744 and 0.704), indicating good drug-like properties.
6. **DILI:** Ligand B (6.747) is *much* better than Ligand A (99.225) regarding potential liver injury risk. This is a major advantage for Ligand B.
7. **BBB:** Ligand B (73.672) has significantly better predicted BBB penetration than Ligand A (57.736). While ADRB2 isn't exclusively a CNS target, some peripheral effects are mediated by CNS pathways, and better BBB penetration can be beneficial.
8. **Caco-2 Permeability:** Both are negative, indicating poor permeability. However, the scale is not provided, so it's difficult to interpret the absolute values.
9. **Aqueous Solubility:** Both are negative, indicating poor solubility. Again, the scale is not provided.
10. **hERG:** Ligand A (0.267) is slightly better than Ligand B (0.597) regarding hERG inhibition liability, but both are relatively low risk.
11. **Microsomal Clearance:** Ligand B (30.738) has lower microsomal clearance than Ligand A (44.254), suggesting better metabolic stability.
12. **In vitro Half-Life:** Ligand B (4.685) has a shorter half-life than Ligand A (13.354). This is a drawback for Ligand B.
13. **P-gp Efflux:** Ligand A (0.099) has lower P-gp efflux than Ligand B (0.076), which is preferable.
**Overall Assessment:**
Ligand B clearly outperforms Ligand A in several critical areas: DILI risk, BBB penetration, and metabolic stability. The lower TPSA is also a significant advantage. While Ligand A has a slightly better logP and P-gp efflux, the benefits of Ligand B's improved safety profile (DILI) and pharmacokinetic properties (BBB, Cl_mic) outweigh these minor differences. The half-life is a concern for Ligand B, but can be addressed through structural modifications.
**Output:**
0
2025-04-17 20:08:19,673 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (353.463 and 348.447 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (84.32) is slightly higher than Ligand B (78.68). Both are well below the 140 threshold for oral absorption, and acceptable for a cardiovascular GPCR.
3. **logP:** Ligand B (1.434) is better than Ligand A (-0.479). A logP between 1-3 is optimal, and Ligand A is slightly outside this range, potentially causing permeability issues.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1), but both are within the acceptable limit of 5.
5. **HBA:** Both ligands have 5 HBA, which is within the acceptable limit of 10.
6. **QED:** Ligand B (0.841) has a better QED score than Ligand A (0.674), indicating a more drug-like profile.
7. **DILI:** Ligand A (8.104) has a significantly lower DILI risk than Ligand B (23.769). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (76.58) has a higher BBB penetration percentile than Ligand A (53.432). While ADRB2 is a cardiovascular target, some CNS exposure is possible, and higher BBB is generally favorable.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not defined, so it's hard to interpret.
10. **Solubility:** Ligand A (-0.634) has slightly better solubility than Ligand B (-1.907).
11. **hERG:** Ligand A (0.108) has a lower hERG inhibition liability than Ligand B (0.387), which is crucial for avoiding cardiotoxicity.
12. **Cl_mic:** Ligand A (9.241) has a significantly lower microsomal clearance than Ligand B (31.548), indicating better metabolic stability.
13. **t1/2:** Ligand A (16.214) has a longer in vitro half-life than Ligand B (9.158).
14. **Pgp:** Ligand B (0.076) has lower P-gp efflux liability than Ligand A (0.004), which is preferable.
15. **Affinity:** Ligand B (-5.2) has a slightly better binding affinity than Ligand A (-4.6). This is a 0.6 kcal/mol difference, which is significant but not overwhelming.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand B excels in Pgp and has slightly better affinity and logP. However, Ligand A has a significantly better safety profile (DILI, hERG) and metabolic stability (Cl_mic, t1/2). The slightly better affinity of Ligand B is not enough to overcome the substantial advantages of Ligand A in terms of safety and pharmacokinetics.
**Conclusion:**
Considering the balance of properties and the priorities for a GPCR target, Ligand A is the more promising drug candidate. Its superior safety profile and metabolic stability outweigh the slightly better affinity and Pgp properties of Ligand B.
Output:
1
2025-04-17 20:08:19,673 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (374.522 and 340.358 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (69.64 and 66.4) are below the 140 A^2 threshold for good oral absorption, which is good.
3. **logP:** Both ligands (1.841 and 1.602) are within the optimal 1-3 range. Again, no major difference.
4. **HBD:** Ligand A has 2 HBD, while Ligand B has 0. Both are acceptable (<=5).
5. **HBA:** Both ligands have 4 HBA, which is below the 10 threshold.
6. **QED:** Ligand B (0.833) has a higher QED score than Ligand A (0.573), suggesting a more drug-like profile. This is a point in favor of Ligand B.
7. **DILI:** Ligand B (54.789) has a significantly lower DILI risk than Ligand A (13.843). This is a major advantage for Ligand B.
8. **BBB:** Both ligands have high BBB penetration (81.233 and 89.066), which is good, but not critical for ADRB2 which is not a CNS target.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not defined, so it's hard to interpret.
10. **Solubility:** Both ligands have negative solubility values, which is also unusual.
11. **hERG:** Both ligands have low hERG inhibition liability (0.71 and 0.666), which is good.
12. **Cl_mic:** Ligand B (1.936) has significantly lower microsomal clearance than Ligand A (38.692), indicating better metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand B (-3.275) has a longer in vitro half-life than Ligand A (-12.028). This is a strong advantage for Ligand B.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.203 and 0.101).
15. **Binding Affinity:** Ligand B (-5.6 kcal/mol) has a significantly stronger binding affinity than Ligand A (0.0 kcal/mol). This is a crucial advantage, outweighing many other factors.
**GPCR-specific priorities:** For GPCRs like ADRB2, logP, Pgp, TPSA, and affinity are important. Both ligands perform similarly on logP, Pgp, and TPSA. However, Ligand B has a much stronger binding affinity.
**Overall Assessment:**
Ligand B is clearly superior. It has a better QED score, a significantly lower DILI risk, better metabolic stability (lower Cl_mic), a longer half-life, and, most importantly, a much stronger binding affinity. While both have unusual solubility and Caco-2 values, the benefits of Ligand B outweigh these concerns.
Output:
0
2025-04-17 20:08:19,673 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (382.873) is slightly higher than Ligand B (358.385), but both are acceptable.
2. **TPSA:** Ligand A (95.16) is slightly above the preferred <90 for CNS targets, but still reasonable for a peripheral GPCR like ADRB2. Ligand B (78.87) is well within the desired range.
3. **logP:** Ligand A (2.042) is within the optimal range (1-3). Ligand B (0.68) is a bit low, potentially impacting permeability.
4. **HBD:** Both ligands have 2 HBD, which is acceptable.
5. **HBA:** Ligand A has 5 HBA, and Ligand B has 4. Both are within the acceptable limit of 10.
6. **QED:** Both ligands have similar QED values (0.766 and 0.775), indicating good drug-likeness.
7. **DILI:** Ligand A (64.288) has a higher DILI risk than Ligand B (25.785). This is a significant drawback for Ligand A.
8. **BBB:** ADRB2 is primarily a cardiovascular target, so BBB penetration is not a high priority. Ligand A (27.724) and Ligand B (83.715) are less relevant here, but B is better.
9. **Caco-2:** Ligand A (-5.579) and Ligand B (-4.702) are both negative, indicating poor permeability.
10. **Solubility:** Ligand A (-3.286) and Ligand B (-2.536) are both negative, indicating poor solubility.
11. **hERG:** Both ligands have relatively low hERG inhibition risk (0.358 and 0.488).
12. **Cl_mic:** Ligand A (23.169) has a higher microsomal clearance than Ligand B (-16.469), suggesting lower metabolic stability.
13. **t1/2:** Ligand A (26.461) and Ligand B (23.102) have similar in vitro half-lives.
14. **Pgp:** Ligand A (0.11) has lower P-gp efflux liability than Ligand B (0.025), which is favorable.
15. **Binding Affinity:** Ligand B (-7.0) has a significantly stronger binding affinity than Ligand A (-6.3). This 0.7 kcal/mol difference is substantial and can outweigh some ADME drawbacks.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand B excels in affinity and has a better logP and TPSA. While both have poor Caco-2 and solubility, the superior binding affinity and lower DILI risk of Ligand B are more important.
**Conclusion:**
Ligand B is the more promising candidate due to its significantly higher binding affinity, lower DILI risk, and better logP and TPSA values, despite slightly lower Pgp.
Output:
0
2025-04-17 20:08:19,673 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.494 & 379.501 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (49.41) is significantly better than Ligand B (90.9). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold. Ligand B is approaching it, but is less desirable.
3. **logP:** Both ligands have good logP values (3.614 and 2.891), falling within the optimal 1-3 range. Ligand A is slightly higher, which could be a minor advantage for membrane permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (2) is preferable to Ligand B (5). Fewer HBAs generally improve permeability.
6. **QED:** Ligand A (0.742) is better than Ligand B (0.574), indicating a more drug-like profile.
7. **DILI:** Ligand A (15.898) has a significantly lower DILI risk than Ligand B (23.071). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (91.663) has much higher BBB penetration than Ligand B (52.346). While not crucial for a cardiovascular target, higher BBB is rarely a detriment.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.74 and -4.974). These values are unusual and suggest poor permeability. However, the difference is minimal.
10. **Solubility:** Ligand A (-3.138) has slightly better solubility than Ligand B (-1.405), although both are poor.
11. **hERG:** Both ligands have low hERG inhibition risk (0.594 and 0.465). No significant difference.
12. **Cl_mic:** Ligand A (24.629) has slightly higher microsomal clearance than Ligand B (22.473), meaning it's metabolized a bit faster. This is a slight disadvantage for Ligand A.
13. **t1/2:** Ligand A (-16.672) has a much more negative in vitro half-life than Ligand B (0.361). This suggests a very short half-life for Ligand A, which is a significant drawback.
14. **Pgp:** Both ligands have low P-gp efflux (0.304 and 0.207). No significant difference.
15. **Binding Affinity:** Ligand A (-6.4 kcal/mol) has a slightly better binding affinity than Ligand B (-5.1 kcal/mol). This 1.3 kcal/mol difference is significant and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand A has several advantages: better TPSA, QED, DILI risk, BBB penetration, solubility, and binding affinity. However, its major weakness is the very short in vitro half-life. Ligand B has a better half-life, but is significantly worse in terms of TPSA, QED, and DILI risk. Considering the GPCR-specific priorities (logP, TPSA, Pgp, affinity), and the importance of minimizing toxicity (DILI), the strong binding affinity and favorable ADME properties of Ligand A, despite the short half-life, make it the more promising starting point for optimization. The half-life can be addressed through structural modifications.
Output:
1
2025-04-17 20:08:19,673 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (395.262) is slightly higher than Ligand B (378.441), but both are acceptable.
2. **TPSA:** Both are below the 140 A^2 threshold for good oral absorption. Ligand A (76.58) is slightly lower than Ligand B (78.87), which is slightly preferable.
3. **logP:** Ligand A (3.913) is at the upper end of the optimal range (1-3), while Ligand B (0.489) is quite low. For a GPCR, a slightly higher logP is generally preferred for membrane permeability, giving an advantage to Ligand A.
4. **HBD:** Ligand A (1) is better than Ligand B (2). Lower HBD is generally preferred for better permeability.
5. **HBA:** Ligand A (6) is better than Ligand B (5). Lower HBA is generally preferred for better permeability.
6. **QED:** Ligand B (0.703) has a significantly better QED score than Ligand A (0.473), indicating a more drug-like profile.
7. **DILI:** Ligand B (35.285) has a much lower DILI risk than Ligand A (70.803), a significant advantage.
8. **BBB:** Ligand B (82.862) has better BBB penetration than Ligand A (76.037). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be beneficial or at least avoided as an off-target effect.
9. **Caco-2:** Both have negative values, indicating poor permeability. Ligand B (-4.98) is slightly worse than Ligand A (-4.652).
10. **Solubility:** Both have negative values, indicating poor solubility. Ligand A (-4.775) is slightly better than Ligand B (-2.873).
11. **hERG:** Both are very low, indicating minimal hERG inhibition risk. Ligand A (0.369) is slightly better than Ligand B (0.323).
12. **Cl_mic:** Ligand B (14.973) has significantly lower microsomal clearance than Ligand A (63.539), indicating better metabolic stability.
13. **t1/2:** Ligand A (13.523) has a longer in vitro half-life than Ligand B (-14.348). This is a significant advantage.
14. **Pgp:** Both have very low Pgp efflux liability, indicating good bioavailability. Ligand A (0.177) is slightly better than Ligand B (0.03).
15. **Affinity:** Ligand A (-6.9 kcal/mol) has a slightly better binding affinity than Ligand B (-6.5 kcal/mol).
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand A has a better logP and slightly better affinity. Ligand B has better TPSA and Pgp, and a significantly better QED and DILI profile. The metabolic stability of Ligand B is also a major advantage.
**Overall Assessment:**
While Ligand A has a slight edge in affinity and half-life, Ligand B's superior DILI profile, metabolic stability, QED, and BBB penetration are more compelling. The slightly lower affinity can potentially be optimized in later stages of drug development. The lower DILI risk is a critical factor, and the improved metabolic stability will likely translate to better *in vivo* exposure.
Output:
0
2025-04-17 20:08:19,673 - INFO - Here's my reasoning and final output for the ligand preference:
**Reasoning:**
We are targeting ADRB2, a GPCR, so the priorities are: affinity, logP, Pgp, TPSA, and BBB. Let's break down the comparison:
1. **Molecular Weight:** Both ligands are within the acceptable range (200-500 Da). Ligand A (334.419 Da) is slightly preferred due to being lower.
2. **TPSA:** Ligand A (54.12) is significantly better than Ligand B (84.73). Lower TPSA generally favors better absorption.
3. **logP:** Ligand A (4.923) is higher than Ligand B (2.623). While both are within the acceptable range, Ligand A is pushing the upper limit and could potentially have solubility issues. However, for a GPCR, a slightly higher logP can be beneficial for membrane interactions.
4. **H-Bond Donors/Acceptors:** Both have similar HBD counts (2). Ligand B has a higher HBA count (8 vs 2), which could slightly hinder permeability.
5. **QED:** Both are reasonably good (0.711 and 0.689), indicating reasonable drug-likeness.
6. **DILI:** Ligand A (83.637) is better than Ligand B (92.865), indicating a lower risk of drug-induced liver injury.
7. **BBB:** Ligand A (70.609) is significantly better than Ligand B (53.858). While ADRB2 isn't necessarily a CNS target, better BBB penetration is generally favorable.
8. **Caco-2:** Ligand A (-4.74) is better than Ligand B (-5.353), suggesting better intestinal absorption.
9. **Solubility:** Ligand B (-3.609) is better than Ligand A (-6.754). This is a significant advantage for Ligand B.
10. **hERG:** Both are low risk (0.815 and 0.683).
11. **Cl_mic:** Ligand B (35.779) has significantly lower microsomal clearance than Ligand A (69.806), indicating better metabolic stability.
12. **t1/2:** Ligand B (7.91) has a longer half-life than Ligand A (37.423).
13. **Pgp:** Ligand A (0.777) is better than Ligand B (0.097). Lower P-gp efflux is preferred.
14. **Binding Affinity:** Ligand A (-7.7 kcal/mol) has a stronger binding affinity than Ligand B (-6.6 kcal/mol). This is a substantial difference and a major advantage.
**Overall Assessment:**
Ligand A has a significantly better binding affinity and better BBB penetration, Caco-2 permeability, and Pgp efflux. Ligand B has better solubility and metabolic stability. The affinity difference is substantial (>1.1 kcal/mol), and given the target is a GPCR, the slightly higher logP of Ligand A is less concerning. The lower DILI risk for Ligand A is also a plus.
Therefore, I favor Ligand A.
**Output:**
1
2025-04-17 20:08:19,673 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.443 and 349.435 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (67.87) is significantly better than Ligand B (105.12). For a GPCR, keeping TPSA low is beneficial for permeability, and Ligand A is well below the 140 A^2 threshold, while Ligand B is approaching it.
3. **logP:** Ligand A (1.401) is within the optimal range (1-3), while Ligand B (-0.11) is slightly below 1. This is a notable drawback for Ligand B, potentially hindering membrane permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is preferable to Ligand B (5). Similar to HBD, lower HBA is generally better.
6. **QED:** Ligand A (0.815) has a substantially higher QED score than Ligand B (0.578), indicating a more drug-like profile overall.
7. **DILI:** Ligand A (12.292) has a significantly lower DILI risk than Ligand B (17.449). This is a crucial advantage, as minimizing liver toxicity is paramount.
8. **BBB:** Ligand A (71.772) has a better BBB penetration percentile than Ligand B (45.56). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be useful for understanding off-target effects and overall distribution.
9. **Caco-2:** Ligand A (-4.733) is better than Ligand B (-5.483). Both are negative, indicating poor permeability, but A is slightly better.
10. **Solubility:** Ligand A (-1.829) is better than Ligand B (-0.934). Both are poor, but A is slightly better.
11. **hERG:** Ligand A (0.267) has a much lower hERG inhibition liability than Ligand B (0.055). This is a significant safety advantage.
12. **Cl_mic:** Ligand A (16.688) has a higher microsomal clearance than Ligand B (10.381), meaning it is less metabolically stable. This is a negative for Ligand A.
13. **t1/2:** Ligand A (11.497) has a longer in vitro half-life than Ligand B (1.378). This is a significant advantage for Ligand A, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.014) has a much lower P-gp efflux liability than Ligand B (0.002). This is a significant advantage, improving bioavailability.
15. **Binding Affinity:** Ligand A (-7.5 kcal/mol) has a slightly better binding affinity than Ligand B (-7.1 kcal/mol). While the difference is not huge, it is enough to be considered.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical ADME-Tox parameters, including TPSA, logP, QED, DILI, hERG, and Pgp efflux. The slightly higher Cl_mic for Ligand A is a drawback, but it's outweighed by the numerous advantages. The binding affinity difference is also in favor of Ligand A. Given the GPCR target class, the balance of properties in Ligand A is much more favorable for developing a viable drug candidate.
Output:
1
2025-04-17 20:08:19,674 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (340.43 and 344.42 Da) are within the ideal range (200-500 Da). No significant difference.
2. **TPSA:** Both ligands (88.32 and 89.16) are below the 140 A^2 threshold for good oral absorption, and acceptable for a cardiovascular GPCR. No significant difference.
3. **logP:** Ligand A (2.075) is slightly higher than Ligand B (1.262), placing it more optimally within the 1-3 range. Ligand B is a bit low, potentially impacting permeability.
4. **HBD:** Both ligands have 2 H-bond donors, which is within the acceptable limit of <=5.
5. **HBA:** Ligand A has 4 H-bond acceptors, while Ligand B has 5. Both are within the acceptable limit of <=10.
6. **QED:** Ligand A (0.892) has a significantly better QED score than Ligand B (0.754), indicating a more drug-like profile.
7. **DILI:** Ligand A (55.642) has a higher DILI risk than Ligand B (26.871). This is a significant drawback for Ligand A.
8. **BBB:** Ligand A (87.864) has a much higher BBB penetration percentile than Ligand B (49.205). While ADRB2 isn't a CNS target, some off-target CNS effects are always a consideration, and higher BBB penetration could contribute to that. However, for a cardiovascular target, this isn't a primary concern.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.165 and -5.41), which is unusual and suggests poor permeability. This is a major concern for both.
10. **Solubility:** Ligand A (-2.931) has a slightly better (less negative) solubility score than Ligand B (-0.831).
11. **hERG:** Both ligands have very low hERG inhibition liability (0.61 and 0.212), which is excellent.
12. **Cl_mic:** Ligand B (-8.548) has a significantly *lower* (better) microsomal clearance than Ligand A (30.832), indicating greater metabolic stability.
13. **t1/2:** Ligand B (18.79) has a longer in vitro half-life than Ligand A (13.171), which is desirable.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.058 and 0.02), which is excellent.
15. **Binding Affinity:** Both ligands have very similar and strong binding affinities (-6.0 and -6.1 kcal/mol). The difference is negligible.
**GPCR-specific priorities:**
For ADRB2 (a cardiovascular GPCR), logP, Pgp, TPSA, and affinity are key. Ligand A has a slightly better logP and similar affinity, but Ligand B has a much better metabolic profile (Cl_mic, t1/2) and significantly lower DILI risk. The poor Caco-2 values for both are concerning, but the metabolic stability and safety profile of Ligand B are more compelling.
**Conclusion:**
Despite the similar binding affinities, Ligand B's superior metabolic stability, lower DILI risk, and longer half-life outweigh the slightly better logP and BBB penetration of Ligand A. The poor Caco-2 values are a concern for both, but can be addressed with formulation strategies.
Output:
0
2025-04-17 20:08:19,674 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (344.46 and 349.39 Da). No significant difference.
2. **TPSA:** Ligand A (61.31) is significantly better than Ligand B (100.88). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary goal, but lower TPSA generally favors absorption.
3. **logP:** Ligand A (3.69) is optimal, while Ligand B (0.296) is quite low. This is a major concern for Ligand B, as low logP can severely hinder membrane permeability and bioavailability.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Both ligands have 5 HBA, which is acceptable.
6. **QED:** Both ligands have similar QED scores (0.78 and 0.769), indicating good drug-likeness.
7. **DILI:** Ligand A (35.60) is better than Ligand B (48.62), indicating a lower risk of drug-induced liver injury.
8. **BBB:** Not a primary concern for a cardiovascular target. Ligand A (88.17) is higher, but this isn't a deciding factor.
9. **Caco-2:** Ligand A (-4.94) is better than Ligand B (-5.28), suggesting better intestinal absorption.
10. **Solubility:** Ligand A (-3.11) is better than Ligand B (-2.09), indicating better aqueous solubility.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.39 and 0.10).
12. **Cl_mic:** Ligand A (61.66) is significantly better than Ligand B (-15.69). A positive value for ligand B indicates rapid clearance and poor metabolic stability.
13. **t1/2:** Ligand A (-0.52) is better than Ligand B (32.41), indicating a longer in vitro half-life.
14. **Pgp:** Ligand A (0.396) is better than Ligand B (0.012), suggesting lower P-glycoprotein efflux.
15. **Binding Affinity:** Ligand B (-7.8) is slightly better than Ligand A (-7.6), but the difference (0.2 kcal/mol) is not substantial enough to overcome the significant ADME deficiencies of Ligand B.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A excels in logP, TPSA, and Pgp, while the affinity difference is minor. Ligand B's low logP and poor metabolic stability are major drawbacks.
**Conclusion:**
Ligand A is the superior candidate due to its better predicted ADME properties (logP, Cl_mic, t1/2, solubility, Pgp, TPSA) and acceptable binding affinity. While Ligand B has slightly higher affinity, its poor ADME profile makes it a less viable drug candidate.
Output:
1
2025-04-17 20:08:19,674 - INFO - Batch 162 complete. Total preferences: 2592
2025-04-17 20:08:19,674 - INFO - Processing batch 163/512...
2025-04-17 20:09:04,654 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (338.37 & 345.50 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (82.18) is higher than Ligand B (62.11). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B has an advantage.
3. **logP:** Both ligands have good logP values (1.95 & 2.45), falling within the optimal 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability, but not drastically so.
4. **HBD:** Both ligands have 1 HBD, which is within the acceptable limit of <=5. No difference.
5. **HBA:** Ligand A has 6 HBAs, while Ligand B has 7. Both are within the acceptable limit of <=10.
6. **QED:** Both ligands have good QED scores (0.786 and 0.832), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (74.33) has a slightly higher DILI risk than Ligand B (65.53), but both are reasonably low. Ligand B is preferred.
8. **BBB:** Ligand B (86.89) has a significantly higher BBB penetration percentile than Ligand A (71.50). While ADRB2 isn't a CNS target, some degree of BBB penetration can influence off-target effects and overall distribution. Ligand B has an advantage.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.063 and -4.828). These values are unusual and suggest poor permeability. However, the absolute values are similar, so this isn't a major differentiator.
10. **Solubility:** Ligand A (-3.105) has slightly better solubility than Ligand B (-2.578), which is a positive.
11. **hERG:** Ligand A (0.591) has a lower hERG inhibition liability than Ligand B (0.97), which is a significant advantage for cardiovascular safety.
12. **Cl_mic:** Ligand B (50.21) has lower microsomal clearance than Ligand A (57.90), indicating better metabolic stability. This is a positive for Ligand B.
13. **t1/2:** Ligand B (31.64 hours) has a significantly longer in vitro half-life than Ligand A (6.94 hours), which is a major advantage.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.306 and 0.367), which is good. No significant difference.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.5 and -6.4 kcal/mol). The difference is negligible.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), and the general drug-like properties, Ligand B appears to be a more promising candidate. While Ligand A has better solubility and lower hERG risk, Ligand B excels in metabolic stability (lower Cl_mic, longer t1/2), BBB penetration, and has a slightly better QED and DILI profile. The longer half-life of Ligand B is a particularly important factor, potentially allowing for less frequent dosing. The similar binding affinities mean that the ADME advantages of Ligand B outweigh the slight advantage of Ligand A in solubility and hERG.
Output:
0
2025-04-17 20:09:04,654 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's break down the comparison, keeping in mind ADRB2 is a GPCR, so logP, TPSA, Pgp, BBB, and affinity are key.
1. **MW:** Both ligands (346.471 and 353.438 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (49.85) is significantly better than Ligand B (75.44). A TPSA under 140 is good for oral absorption, and lower is generally preferred for GPCRs. Ligand B's TPSA is higher and could present absorption challenges.
3. **logP:** Both ligands have good logP values (2.732 and 2.407), falling within the 1-3 optimal range. Ligand A is slightly higher, which is generally favorable for membrane permeability.
4. **HBD/HBA:** Ligand A (0 HBD, 3 HBA) is preferable to Ligand B (1 HBD, 4 HBA). Lower numbers are generally better for permeability.
5. **QED:** Both ligands have similar and acceptable QED scores (0.723 and 0.779), indicating good drug-like properties.
6. **DILI:** Ligand A (35.13) has a slightly higher DILI risk than Ligand B (23.769), but both are below the concerning threshold of 60.
7. **BBB:** Ligand B (86.817) has a significantly higher BBB penetration percentile than Ligand A (67.623). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be beneficial for distribution and off-target effects.
8. **Caco-2:** Both ligands have negative Caco-2 values (-4.613 and -4.551), which is unusual and suggests poor permeability. This is a significant concern for both.
9. **Solubility:** Both ligands have negative solubility values (-2.981 and -2.323), which is also a concern.
10. **hERG:** Both ligands have low hERG inhibition liability (0.489 and 0.238), which is excellent.
11. **Cl_mic:** Ligand B (33.993) has a lower microsomal clearance than Ligand A (61.363), indicating better metabolic stability. This is a significant advantage.
12. **t1/2:** Ligand B (15.072 hours) has a much longer in vitro half-life than Ligand A (-4.89 hours). This is a major advantage, potentially allowing for less frequent dosing.
13. **Pgp:** Ligand A (0.398) has slightly lower P-gp efflux liability than Ligand B (0.088), which is favorable.
14. **Binding Affinity:** Ligand A (-6.9 kcal/mol) has a stronger binding affinity than Ligand B (-5.3 kcal/mol). This is a substantial difference (1.6 kcal/mol), and is a major driver in the decision.
**Overall Assessment:**
While Ligand B has advantages in BBB penetration, metabolic stability (lower Cl_mic), and half-life, Ligand A's significantly stronger binding affinity (-6.9 vs -5.3 kcal/mol) is the deciding factor. The affinity difference is large enough to potentially overcome the slightly higher DILI risk and lower BBB penetration. The poor Caco-2 and solubility values are concerning for both, but can be addressed during lead optimization. The TPSA is also better for Ligand A.
**Output:**
1
2025-04-17 20:09:04,654 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (358.463) is slightly higher than Ligand B (347.331), but both are acceptable.
2. **TPSA:** Ligand A (68.29) is significantly better than Ligand B (123.47). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption. Ligand B is above the preferred threshold of 140.
3. **logP:** Ligand A (3.577) is within the optimal range (1-3), while Ligand B (-0.684) is below 1, which could indicate poor membrane permeability. This is a significant drawback for Ligand B.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A (5) is better than Ligand B (8). Lower HBA is generally preferred for permeability.
6. **QED:** Ligand A (0.83) is better than Ligand B (0.658), indicating a more drug-like profile.
7. **DILI:** Both have acceptable DILI risk (Ligand A: 74.603, Ligand B: 69.019), though ideally, both would be lower.
8. **BBB:** Not a primary concern for a cardiovascular target. Ligand A (63.086) is higher than Ligand B (48.003).
9. **Caco-2:** Both are negative, indicating poor permeability.
10. **Solubility:** Ligand A (-3.945) is better than Ligand B (-2.057), indicating better aqueous solubility.
11. **hERG:** Both ligands have very low hERG inhibition risk (Ligand A: 0.181, Ligand B: 0.032).
12. **Cl_mic:** Ligand B (28.832) has significantly lower microsomal clearance than Ligand A (86.254), suggesting better metabolic stability. This is a strong point for Ligand B.
13. **t1/2:** Ligand B (-28.733) has a longer in vitro half-life than Ligand A (-18.455). This is another positive for Ligand B.
14. **Pgp:** Both are low, indicating minimal P-gp efflux. Ligand A (0.266) is slightly higher than Ligand B (0.053).
15. **Binding Affinity:** Ligand A (-7.6) has a slightly better binding affinity than Ligand B (-6.6). This is a 1.0 kcal/mol difference, which is significant.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand A excels in affinity and has a much better logP and TPSA. While Ligand B has better metabolic stability (Cl_mic and t1/2), the poor logP and higher TPSA are significant drawbacks that could limit its bioavailability and target engagement. The affinity difference is also substantial enough to outweigh the metabolic advantages of Ligand B.
**Conclusion:**
Despite Ligand B's better metabolic stability, Ligand A's superior logP, TPSA, QED, solubility, and binding affinity make it the more promising drug candidate for ADRB2.
Output:
1
2025-04-17 20:09:04,655 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (362.455 and 348.443 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Both ligands (75.63 and 78.87) are reasonably low, suggesting good potential for absorption, but slightly above the optimal <90 for CNS targets (though ADRB2 isn't necessarily a CNS target). Ligand A is slightly better.
3. **logP:** Both ligands have good logP values (1.17 and 0.685), falling within the 1-3 range. Ligand A is slightly more lipophilic, which could aid membrane permeability.
4. **HBD:** Ligand A has 0 HBD, while Ligand B has 2. Lower is generally preferred for permeability, giving a slight edge to Ligand A.
5. **HBA:** Ligand A has 6 HBA, and Ligand B has 4. Both are acceptable (<10). Ligand B is slightly better.
6. **QED:** Ligand A (0.804) has a significantly better QED score than Ligand B (0.5), indicating a more drug-like profile. This is a substantial advantage for Ligand A.
7. **DILI:** Ligand A (44.126) has a higher DILI risk than Ligand B (10.392). This is a significant drawback for Ligand A.
8. **BBB:** Ligand A (75.805) has a better BBB penetration score than Ligand B (47.189). While not a primary concern for peripheral ADRB2, it's a positive attribute.
9. **Caco-2:** Both have negative Caco-2 values (-4.886 and -4.868), which is unusual and suggests poor permeability. This is a major concern for both.
10. **Solubility:** Both ligands have very poor aqueous solubility (-1.917 and -1.456). This is a serious issue for both compounds.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.159 and 0.198). This is good.
12. **Cl_mic:** Ligand A (24.331) has a higher microsomal clearance than Ligand B (-2.055). This suggests Ligand B is more metabolically stable, which is desirable.
13. **t1/2:** Ligand A (2.726) has a slightly longer in vitro half-life than Ligand B (0.213).
14. **Pgp:** Both ligands have low P-gp efflux liability (0.134 and 0.05). This is good.
15. **Binding Affinity:** Ligand A (-7.4 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.2 kcal/mol). This is a major advantage for Ligand A, potentially outweighing some of its ADME drawbacks.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A has a slightly better logP and TPSA, and significantly better affinity. The lower DILI risk of Ligand B is attractive, but the substantial affinity difference of Ligand A is a major factor. The poor Caco-2 and solubility are concerning for both, but can potentially be addressed with formulation strategies.
**Overall Assessment:**
Despite the higher DILI risk and poor solubility/permeability, Ligand A's significantly stronger binding affinity and better QED score make it the more promising candidate. The affinity advantage is substantial enough to prioritize over the ADME concerns, especially considering formulation efforts could potentially mitigate the solubility issues.
Output:
1
2025-04-17 20:09:04,655 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (351.491 and 367.515 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (101.29) is higher than Ligand B (71.53). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B has a clear advantage.
3. **logP:** Both ligands (1.868 and 2.244) are within the optimal 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Ligand A (3) is higher than Ligand B (1). Lower HBD is generally preferred for permeability, giving Ligand B an edge.
5. **HBA:** Ligand A (3) and Ligand B (5) are both acceptable, but Ligand B is higher.
6. **QED:** Both ligands (0.622 and 0.644) have good drug-likeness scores, exceeding the 0.5 threshold. No significant difference.
7. **DILI:** Ligand A (26.095) has a significantly lower DILI risk than Ligand B (33.501). This is a substantial advantage for Ligand A.
8. **BBB:** Ligand A (65.723) has a higher BBB penetration percentile than Ligand B (56.96). While ADRB2 isn't a primary CNS target, some peripheral exposure is acceptable, and higher BBB is rarely detrimental.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.241 and -5.091), which is unusual and indicates poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand A (-3.552) has slightly worse solubility than Ligand B (-1.628). Solubility is important, so Ligand B is slightly favored.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.138 and 0.367). No significant difference.
12. **Cl_mic:** Ligand A (58.284) has a higher microsomal clearance than Ligand B (47.525), indicating lower metabolic stability. Ligand B is favored here.
13. **t1/2:** Ligand B (14.949) has a significantly longer in vitro half-life than Ligand A (-17.542). This is a major advantage for Ligand B, suggesting less frequent dosing potential.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.06 and 0.113). No significant difference.
15. **Binding Affinity:** Ligand A (-6.5 kcal/mol) has a slightly better binding affinity than Ligand B (-5.8 kcal/mol). This is a 0.7 kcal/mol difference, which is notable, but not overwhelming.
**GPCR-Specific Considerations:**
For ADRB2 (a cardiovascular GPCR), logP, TPSA, and affinity are important. Ligand B has better logP and TPSA. The affinity difference is not large enough to overcome the other advantages of Ligand B. Metabolic stability (Cl_mic and t1/2) are also important, and Ligand B is clearly superior in these aspects. The lower DILI risk of Ligand A is a positive, but the longer half-life and better metabolic stability of Ligand B are more critical for overall drug development success.
Output:
0
2025-04-17 20:09:04,655 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
Let's analyze each ligand against the provided guidelines, with a focus on GPCR-relevant properties (logP, TPSA, Pgp, BBB, and affinity).
* **Molecular Weight:** Both ligands (362.495 Da and 358.473 Da) fall comfortably within the ideal 200-500 Da range.
* **TPSA:** Ligand A (58.64) is slightly higher than Ligand B (40.62). Both are below the 140 A^2 threshold for good oral absorption, but Ligand B is significantly better.
* **logP:** Ligand A (2.173) is within the optimal 1-3 range. Ligand B (3.552) is a bit higher, potentially edging towards solubility issues, but still acceptable.
* **H-Bond Donors/Acceptors:** Ligand A has 1 HBD and 4 HBA, while Ligand B has 0 HBD and 2 HBA. Both are within acceptable limits.
* **QED:** Both ligands have good QED scores (0.54 and 0.754, respectively), indicating good drug-likeness. Ligand B is slightly better.
* **DILI:** Both have low DILI risk (24.855 and 26.444 percentiles), which is excellent.
* **BBB:** This is a crucial parameter for GPCRs. Ligand B (87.088) shows significantly better predicted BBB penetration than Ligand A (33.579).
* **Caco-2 Permeability:** Both have negative Caco-2 values, which is unusual and suggests a potential issue with the prediction method. However, the values are similar (-4.727 and -4.232).
* **Aqueous Solubility:** Both have negative solubility values, again suggesting a potential issue with the prediction method. The values are similar (-2.955 and -3.836).
* **hERG Inhibition:** Ligand A (0.443) has a slightly lower hERG risk than Ligand B (0.825), which is preferable.
* **Microsomal Clearance:** Ligand B (50.663) has a lower microsomal clearance than Ligand A (63.784), indicating better metabolic stability.
* **In vitro Half-Life:** Both have negative half-life values, which is problematic and likely an artifact of the prediction.
* **P-gp Efflux:** Ligand A (0.107) has lower P-gp efflux than Ligand B (0.254), which is favorable.
* **Binding Affinity:** Ligand A (-5.1 kcal/mol) has a significantly stronger binding affinity than Ligand B (-1.9 kcal/mol). This is a substantial advantage.
**Overall Assessment:**
The most critical factor here is the binding affinity. Ligand A's -5.1 kcal/mol is *much* stronger than Ligand B's -1.9 kcal/mol. This difference is large enough to outweigh the advantages Ligand B has in BBB penetration and metabolic stability. While Ligand B has better predicted BBB penetration and lower clearance, the large difference in binding affinity makes Ligand A the more promising candidate. The negative values for Caco-2 and solubility are concerning, but these can be addressed during lead optimization.
**Output:**
1
2025-04-17 20:09:04,655 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (335.4 & 350.5 Da) fall comfortably within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Both ligands (59.23 & 58.2) are below the 140 A^2 threshold for good oral absorption, and suitable for a peripherally acting GPCR like ADRB2. Very similar.
3. **logP:** Ligand A (4.274) is slightly higher than Ligand B (3.896). While both are within the optimal 1-3 range, A is pushing the upper limit. This could potentially lead to off-target effects, but is not a major concern.
4. **HBD:** Ligand A (0) has fewer H-bond donors than Ligand B (2). Fewer donors generally improve permeability, giving a slight edge to A.
5. **HBA:** Ligand A (4) has more H-bond acceptors than Ligand B (2). This could slightly reduce permeability compared to B, but the difference isn't huge.
6. **QED:** Both ligands have similar QED values (0.698 & 0.663), indicating good drug-like properties.
7. **DILI:** Ligand B (20.202) has a significantly lower DILI risk than Ligand A (75.456). This is a major advantage for Ligand B. DILI is a critical safety concern.
8. **BBB:** Both ligands have good BBB penetration (55.021 & 73.052), but Ligand B is substantially better. While ADRB2 isn't a CNS target, higher BBB penetration can sometimes correlate with better overall distribution.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.565 & -4.639), which is unusual and suggests very poor permeability. This is a significant concern for both.
10. **Solubility:** Both ligands have very poor aqueous solubility (-5.302 & -4.095). This is a major drawback for both, potentially hindering bioavailability.
11. **hERG:** Both ligands have low hERG inhibition risk (0.374 & 0.454). This is good, minimizing cardiotoxicity concerns.
12. **Cl_mic:** Ligand B (72.282) has a higher microsomal clearance than Ligand A (49.922), indicating faster metabolism and potentially lower *in vivo* exposure. This favors Ligand A.
13. **t1/2:** Ligand B (5.954) has a longer half-life than Ligand A (-1.727). This is a significant advantage for B, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.397 & 0.184). This is favorable for oral bioavailability.
15. **Binding Affinity:** Both ligands have very similar and strong binding affinities (-5.4 & -5.5 kcal/mol). The difference is negligible.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. While Ligand A has a slightly better logP and Pgp, the significantly lower DILI risk and better BBB penetration of Ligand B, coupled with a longer half-life, outweigh these minor differences. The poor Caco-2 and solubility are concerning for both, but can potentially be addressed through formulation strategies.
**Conclusion:**
Despite the similar binding affinities, Ligand B is the more promising candidate due to its significantly lower DILI risk, better BBB penetration, and longer half-life. These factors are crucial for overall drug safety and efficacy.
0
2025-04-17 20:09:04,655 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (380.539) is slightly higher than Ligand B (363.487), but both are acceptable.
2. **TPSA:** Ligand A (67.23) is better than Ligand B (80.24). For a GPCR, lower TPSA is generally preferred for better permeability, though both are reasonably low.
3. **logP:** Both ligands have good logP values (Ligand A: 1.751, Ligand B: 2.741), falling within the optimal 1-3 range. Ligand B is slightly higher, which could potentially lead to off-target effects, but it's not a major concern.
4. **HBD:** Both ligands have 1 H-bond donor, which is within the acceptable limit of 5.
5. **HBA:** Ligand A (6) has fewer H-bond acceptors than Ligand B (7). This is slightly favorable for permeability.
6. **QED:** Both ligands have similar QED values (Ligand A: 0.73, Ligand B: 0.69), indicating good drug-likeness.
7. **DILI:** Ligand B (63.978) has a higher DILI risk than Ligand A (52.423). This is a significant negative for Ligand B.
8. **BBB:** Both ligands have relatively low BBB penetration (Ligand A: 58.085, Ligand B: 68.941). Since ADRB2 is a cardiovascular target, BBB penetration is not a primary concern, but higher is still slightly preferred. Ligand B is better here.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.199 and -4.969), which is unusual and suggests poor permeability. This is a significant drawback for both.
10. **Solubility:** Ligand A (-3.389) has slightly better solubility than Ligand B (-2.332), which is favorable.
11. **hERG:** Ligand A (0.215) has a much lower hERG inhibition liability than Ligand B (0.676). This is a crucial advantage for Ligand A, as hERG inhibition can lead to cardiotoxicity.
12. **Cl_mic:** Ligand B (73.273) has a higher microsomal clearance than Ligand A (56.411), indicating lower metabolic stability.
13. **t1/2:** Ligand B (18.81) has a significantly longer half-life than Ligand A (5.164). This is a positive for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand B (0.097) has slightly lower P-gp efflux liability than Ligand A (0.063). This is a minor advantage for Ligand B.
15. **Binding Affinity:** Both ligands have very similar and strong binding affinities (Ligand A: -6.6 kcal/mol, Ligand B: -6.5 kcal/mol). The difference is negligible.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity) and the general guidelines, Ligand A is the more promising candidate. While Ligand B has a longer half-life, the significantly lower DILI risk and hERG inhibition liability of Ligand A outweigh this benefit. The Caco-2 values are concerning for both, but the other ADME properties of Ligand A are more favorable overall.
Output:
1
2025-04-17 20:09:04,656 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Ligand A (383.239 Da) is within the ideal range (200-500 Da), while Ligand B (350.503 Da) is also good. No clear advantage here.
2. **TPSA:** Ligand A (93.01) is slightly higher than Ligand B (60.85). For a cardiovascular GPCR, TPSA isn't a *major* concern unless targeting the CNS, but lower is generally preferred for absorption. Ligand B is better here.
3. **logP:** Ligand A (1.497) is within the optimal range (1-3), as is Ligand B (2.567). Ligand B is slightly more lipophilic, which *could* be beneficial for membrane permeability, but isn't drastically different.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 6 HBA, while Ligand B has 3. Both are acceptable, but Ligand B's lower HBA count is slightly more favorable for permeability.
6. **QED:** Ligand B (0.801) has a better QED score than Ligand A (0.641), indicating a more drug-like profile.
7. **DILI:** Ligand A (79.643) has a significantly higher DILI risk than Ligand B (21.714). This is a major concern for Ligand A.
8. **BBB:** Ligand A (38.426) has a low BBB penetration, while Ligand B (63.746) is better. Since ADRB2 is not a CNS target, this is less critical, but still favors Ligand B.
9. **Caco-2:** Ligand A (-5.362) and Ligand B (-4.692) both have negative values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
10. **Solubility:** Ligand A (-2.648) and Ligand B (-2.474) both have negative solubility values, indicating poor solubility. Again, the scale is unknown.
11. **hERG:** Ligand A (0.019) has a very low hERG risk, while Ligand B (0.552) is slightly higher. This is a slight advantage for Ligand A, but not a major one.
12. **Cl_mic:** Ligand A (3.898) has a much lower microsomal clearance than Ligand B (52.564), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (3.333) has a slightly longer in vitro half-life than Ligand B (3.099).
14. **Pgp:** Ligand A (0.056) has a much lower P-gp efflux liability than Ligand B (0.539), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand B (-5.3 kcal/mol) has a slightly better binding affinity than Ligand A (-7.0 kcal/mol). This is a significant advantage for Ligand B.
**Overall Assessment:**
While Ligand A has advantages in metabolic stability (Cl_mic), half-life, P-gp efflux, and hERG, the significantly higher DILI risk is a major red flag. Ligand B, despite slightly weaker affinity, has a much better safety profile (DILI) and a better QED score. For a cardiovascular target, minimizing toxicity is paramount. The slightly better affinity of Ligand B is also a positive.
Therefore, I recommend Ligand B.
Output:
0
2025-04-17 20:09:04,656 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (353.47 Da and 344.46 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (98.14) is higher than Ligand B (65.54). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is generally preferred for absorption. Ligand B has a clear advantage.
3. **logP:** Both ligands have good logP values (2.389 and 2.201), falling within the optimal 1-3 range. No major difference.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable, below the threshold of 5. Ligand B is slightly better.
5. **HBA:** Ligand A (6) and Ligand B (4) are both acceptable, below the threshold of 10. Ligand B is better.
6. **QED:** Ligand B (0.889) has a significantly higher QED score than Ligand A (0.629), indicating a more drug-like profile. This is a substantial advantage for Ligand B.
7. **DILI:** Ligand B (42.54%) has a much lower DILI risk than Ligand A (63.40%). This is a significant advantage for Ligand B, as minimizing liver toxicity is crucial.
8. **BBB:** Both ligands have reasonable BBB penetration (71.77% and 81.97%). Since ADRB2 is not a CNS target, this is less critical, but Ligand B is slightly better.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.849 and -4.711). These values are unusual and suggest poor permeability. However, the values are very similar.
10. **Solubility:** Both ligands have negative solubility values (-3.269 and -2.557) which is also unusual and suggests poor solubility. The values are similar.
11. **hERG:** Ligand A (0.136) has a slightly lower hERG risk than Ligand B (0.454), which is favorable.
12. **Cl_mic:** Ligand B (31.43) has a significantly lower microsomal clearance than Ligand A (89.70), indicating better metabolic stability. This is a major advantage for Ligand B.
13. **t1/2:** Ligand B (16.78) has a longer in vitro half-life than Ligand A (-15.86). This is a substantial advantage for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.103) has a lower P-gp efflux liability than Ligand B (0.03). This is a slight advantage for Ligand A.
15. **Binding Affinity:** Ligand B (-6.8 kcal/mol) has a slightly better binding affinity than Ligand A (-5.9 kcal/mol). While the difference is not huge, it's enough to be noticeable.
**GPCR-Specific Priorities:**
For ADRB2 (a cardiovascular GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP, TPSA, and has comparable affinity. The lower DILI and better metabolic stability (Cl_mic and t1/2) are also very important.
**Overall Assessment:**
Ligand B consistently outperforms Ligand A across several critical ADME properties (DILI, Cl_mic, t1/2, QED) and has a slightly better binding affinity. While Ligand A has a slightly lower hERG risk and Pgp efflux, the benefits of Ligand B's improved ADME profile and drug-likeness outweigh these minor drawbacks.
Output:
0
2025-04-17 20:09:04,656 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (355.435 and 353.394 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (88.18) is better than Ligand B (100.55). Both are below 140, but closer to 90 is preferred for GPCRs. Ligand A is more favorable.
3. **logP:** Ligand A (-0.234) is slightly lower than Ligand B (0.692). Both are within the 1-3 range, but Ligand A is a bit low. Ligand B is slightly better.
4. **HBD:** Ligand A (1) is better than Ligand B (3). Lower HBD is generally preferred for permeability.
5. **HBA:** Both ligands have 5 HBA, which is acceptable.
6. **QED:** Ligand A (0.711) is slightly better than Ligand B (0.67), indicating a more drug-like profile.
7. **DILI:** Ligand B (55.68) has a slightly higher DILI risk than Ligand A (24.622), but both are below the concerning threshold of 60. Ligand A is better.
8. **BBB:** Ligand B (58.317) is slightly better than Ligand A (55.021), but neither is particularly high. For a cardiovascular target like ADRB2, BBB penetration isn't a major priority, so this difference is minor.
9. **Caco-2:** Both ligands have similar, very poor Caco-2 permeability (-4.977 and -4.725). This is a significant concern for oral bioavailability for both.
10. **Solubility:** Ligand A (-0.682) is better than Ligand B (-1.462). Better solubility is always preferred.
11. **hERG:** Ligand A (0.072) is better than Ligand B (0.165), indicating a lower risk of cardiotoxicity. This is crucial for a cardiovascular target.
12. **Cl_mic:** Ligand A (3.245) has a higher microsomal clearance than Ligand B (0.832), meaning it's metabolized faster. Ligand B is better here.
13. **t1/2:** Ligand B (6.995) has a significantly longer in vitro half-life than Ligand A (-2.888). This is a major advantage for Ligand B.
14. **Pgp:** Ligand A (0.005) has a much lower Pgp efflux liability than Ligand B (0.016). Lower Pgp is preferred.
15. **Binding Affinity:** Ligand A (-8.2 kcal/mol) has a significantly stronger binding affinity than Ligand B (-7.0 kcal/mol). This is a substantial advantage that can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand A has a significantly better binding affinity, lower DILI risk, better solubility, lower hERG risk, and lower Pgp efflux. These are all important factors. While Ligand B has a better half-life and slightly better logP, the superior potency and safety profile of Ligand A make it the more promising candidate. The poor Caco-2 permeability is a concern for both, but can be addressed with formulation strategies.
Output:
1
2025-04-17 20:09:04,656 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (381.519 Da) is slightly higher than Ligand B (369.893 Da), but this difference isn't significant.
**2. TPSA:** Ligand A (63.68) is better than Ligand B (75.43). ADRB2 is not a CNS target, but lower TPSA generally correlates with better permeability.
**3. logP:** Ligand A (3.544) is slightly higher than Ligand B (2.424), both within the optimal range of 1-3.
**4. H-Bond Donors:** Ligand A (0) is preferable to Ligand B (1). Fewer H-bond donors generally improve membrane permeability.
**5. H-Bond Acceptors:** Both ligands have the same number of H-bond acceptors (5), which is acceptable.
**6. QED:** Ligand B (0.835) has a significantly better QED score than Ligand A (0.543), indicating a more drug-like profile.
**7. DILI Risk:** Ligand B (39.201) has a much lower DILI risk than Ligand A (71.229). This is a crucial advantage, as liver toxicity is a major concern in drug development.
**8. BBB Penetration:** Both ligands have reasonable BBB penetration, with Ligand B (70.415) being slightly better than Ligand A (50.058). This isn't a primary concern for ADRB2, but a bonus.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the values are similar (-4.728 vs -4.629).
**10. Aqueous Solubility:** Ligand B (-2.385) has better aqueous solubility than Ligand A (-5.311).
**11. hERG Inhibition:** Ligand A (0.439) has a slightly lower hERG inhibition risk than Ligand B (0.071), which is preferable.
**12. Microsomal Clearance:** Ligand B (44.769) has significantly lower microsomal clearance than Ligand A (106.534), indicating better metabolic stability.
**13. In vitro Half-Life:** Ligand B (11.405) has a much longer in vitro half-life than Ligand A (-0.716), suggesting less frequent dosing potential.
**14. P-gp Efflux:** Ligand A (0.419) has a lower P-gp efflux liability than Ligand B (0.304), which is a slight advantage.
**15. Binding Affinity:** Ligand A (-7.7 kcal/mol) has a slightly better binding affinity than Ligand B (-7.2 kcal/mol). While this is a positive, the difference is relatively small.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity) and the general drug-like properties, Ligand B is the more promising candidate. While Ligand A has a slightly better binding affinity and P-gp efflux profile, Ligand B excels in critical areas like DILI risk, metabolic stability (lower Cl_mic and longer t1/2), QED, and solubility. The lower DILI risk and improved metabolic stability are particularly important for a cardiovascular target. The slightly better affinity of Ligand A is unlikely to outweigh the significant advantages of Ligand B in terms of safety and pharmacokinetic properties.
Output:
0
2025-04-17 20:09:04,656 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (381.307) is slightly higher than Ligand B (349.475), but both are acceptable.
2. **TPSA:** Ligand A (50.16) is significantly better than Ligand B (91.32). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption. Ligand B's TPSA is relatively high.
3. **logP:** Both ligands have good logP values (A: 3.229, B: 2.127) within the optimal 1-3 range.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Lower HBD is generally better for permeability.
5. **HBA:** Both ligands have the same number of HBA (4), which is acceptable.
6. **QED:** Ligand A (0.885) has a significantly better QED score than Ligand B (0.637), indicating a more drug-like profile.
7. **DILI:** Both ligands have low DILI risk (A: 38.348, B: 34.432), both are below the 40 threshold, so this isn't a major differentiator.
8. **BBB:** Ligand A (61.109) has a higher BBB percentile than Ligand B (32.803), but this isn't critical for a cardiovascular target.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.794 and -4.813), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand A (-3.257) has slightly better solubility than Ligand B (-2.54), but both are poor.
11. **hERG:** Both ligands have very low hERG risk (A: 0.364, B: 0.373).
12. **Cl_mic:** Ligand A (53.852) has a higher microsomal clearance than Ligand B (32.056), meaning it's metabolized faster. This is a negative for Ligand A.
13. **t1/2:** Ligand A (79.708) has a significantly longer in vitro half-life than Ligand B (24.116). This is a strong positive for Ligand A.
14. **Pgp:** Both ligands have low P-gp efflux liability (A: 0.164, B: 0.115).
15. **Binding Affinity:** Ligand B (-7.9) has a significantly stronger binding affinity than Ligand A (-6.0). This is a substantial advantage for Ligand B.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), affinity, logP, TPSA, and Pgp are key. Ligand B wins on affinity by a large margin. Ligand A has better TPSA and QED, but the affinity difference is substantial enough to outweigh these benefits. The poor Caco-2 values are concerning for both, but the stronger binding of Ligand B suggests it might be optimized more effectively.
**Conclusion:**
Despite the poor Caco-2 values for both, the significantly stronger binding affinity of Ligand B (-7.9 kcal/mol) is the most important factor. This advantage outweighs the better TPSA, QED, and half-life of Ligand A.
Output:
0
2025-04-17 20:09:04,657 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (353.413 and 359.495 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (71.09) is significantly better than Ligand B (81.99). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (3.224 and 3.547), falling within the 1-3 range. Ligand B is slightly higher, which *could* indicate a slight permeability advantage, but also potential off-target effects.
4. **HBD:** Both ligands have 2 H-bond donors, which is within the acceptable limit of 5. No clear advantage.
5. **HBA:** Ligand A has 3 H-bond acceptors, while Ligand B has 4. Both are within the acceptable limit of 10.
6. **QED:** Ligand A (0.825) has a substantially better QED score than Ligand B (0.627), indicating a more drug-like profile.
7. **DILI:** Ligand A (37.999) has a significantly lower DILI risk than Ligand B (53.509). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (84.374) has a higher BBB penetration percentile than Ligand B (47.615). While not a primary concern for a cardiovascular target, higher BBB is generally not detrimental.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.597 and -4.991), which is unusual and suggests poor permeability. However, the scale isn't specified, so it's hard to interpret the absolute impact.
10. **Solubility:** Both ligands have negative solubility values (-3.587 and -4.782), which is also unusual. Again, the scale is unknown, but indicates potential formulation challenges.
11. **hERG:** Ligand A (0.428) has a lower hERG inhibition liability than Ligand B (0.68). This is a significant advantage, reducing cardiotoxicity risk.
12. **Cl_mic:** Ligand B (81.709) has a much higher microsomal clearance than Ligand A (28.956), indicating lower metabolic stability. This is a major drawback for Ligand B.
13. **t1/2:** Ligand B (37.709) has a longer in vitro half-life than Ligand A (-6.497). This is a positive for Ligand B, but the negative value for Ligand A is concerning.
14. **Pgp:** Ligand A (0.084) has a lower P-gp efflux liability than Ligand B (0.338). This is a positive for Ligand A, potentially improving bioavailability.
15. **Binding Affinity:** Ligand A (-8.2 kcal/mol) has a significantly stronger binding affinity than Ligand B (-5.0 kcal/mol). This is a substantial advantage, and likely outweighs many of the minor ADME drawbacks.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A excels in affinity, has a better TPSA, and lower Pgp efflux. While both have acceptable logP values, the substantial affinity difference and better safety profile (DILI, hERG) of Ligand A are decisive.
**Conclusion:**
Ligand A is the superior candidate due to its significantly better binding affinity, lower DILI and hERG risk, better QED, and lower Pgp efflux. The slightly worse half-life is a concern, but the strong affinity and improved safety profile outweigh this drawback.
Output:
1
2025-04-17 20:09:04,657 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (359.4) is slightly lower, which is generally favorable for permeability, but both are acceptable.
2. **TPSA:** Ligand B (60.77) is significantly better than Ligand A (78.63). For a GPCR, lower TPSA is preferred for better blood-brain barrier penetration and overall permeability.
3. **logP:** Both ligands have good logP values (A: 3.985, B: 4.387), falling within the optimal 1-3 range. Ligand B is slightly higher, which could potentially lead to off-target effects, but it's not a major concern.
4. **HBD:** Ligand A has 0 HBD, while Ligand B has 2. Both are acceptable, but 2 is slightly better for solubility.
5. **HBA:** Ligand A has 7 HBA, and Ligand B has 4. Ligand B is better here, as lower HBA generally improves permeability.
6. **QED:** Both ligands have similar QED values (A: 0.619, B: 0.623), indicating good drug-likeness.
7. **DILI:** Ligand A has a significantly higher DILI risk (84.684) than Ligand B (13.61). This is a *major* advantage for Ligand B.
8. **BBB:** Both ligands have acceptable BBB penetration (A: 67.701, B: 62.117), but Ligand A is slightly better. However, given ADRB2's cardiovascular focus, BBB penetration isn't a primary concern.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand B (-3.84) is better than Ligand A (-5.001), indicating better aqueous solubility.
11. **hERG:** Ligand A (0.256) has a lower hERG risk than Ligand B (0.777), which is favorable.
12. **Cl_mic:** Ligand B (83.811) has lower microsomal clearance than Ligand A (124.781), indicating better metabolic stability.
13. **t1/2:** Both ligands have similar in vitro half-lives (A: 63.419, B: 66.075).
14. **Pgp:** Ligand A (0.662) has lower P-gp efflux liability than Ligand B (0.71). This is a slight advantage for A.
15. **Binding Affinity:** Ligand A (-7.7) has a significantly stronger binding affinity than Ligand B (-6.2). This is a substantial advantage for Ligand A.
**Overall Assessment:**
While Ligand A boasts a superior binding affinity, the significantly higher DILI risk is a major red flag. The other ADME properties of Ligand B are generally more favorable, particularly the much lower DILI risk, better TPSA, and improved metabolic stability. The difference in binding affinity, while substantial, might be overcome with further optimization of Ligand B. Given the cardiovascular target, a slightly lower affinity is acceptable if it translates to a safer drug profile.
Therefore, I prioritize Ligand B due to its significantly better safety profile (DILI) and overall more balanced ADME properties.
Output:
0
2025-04-17 20:09:04,657 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (364.789 Da and 349.41 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (94.48) is better than Ligand B (101.21). Both are acceptable for a non-CNS GPCR target like ADRB2, but lower TPSA generally favors permeability.
3. **logP:** Ligand A (2.479) is optimal, while Ligand B (1.164) is a bit low, potentially hindering membrane permeability. This is a notable advantage for A.
4. **HBD:** Both ligands have 2 HBD, which is within the acceptable limit of 5.
5. **HBA:** Ligand A has 6 HBA, and Ligand B has 5. Both are within the acceptable limit of 10.
6. **QED:** Both ligands have similar QED scores (0.869 and 0.803), indicating good drug-likeness.
7. **DILI:** Ligand A (82.396) has a higher DILI risk than Ligand B (51.609). This is a significant drawback for Ligand A.
8. **BBB:** Both ligands have relatively low BBB penetration. This isn't a major concern for ADRB2, which is not a CNS target. Ligand B (82.513) is slightly better than Ligand A (65.529).
9. **Caco-2:** Ligand A (-4.867) is better than Ligand B (-5.129), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-4.108) is better than Ligand B (-2.8). Better solubility is always a plus.
11. **hERG:** Ligand A (0.261) has a lower hERG risk than Ligand B (0.404), which is a significant advantage.
12. **Cl_mic:** Ligand B (4.074) has significantly lower microsomal clearance than Ligand A (28.3), indicating better metabolic stability. This is a major advantage for B.
13. **t1/2:** Ligand A (43.014) has a much longer in vitro half-life than Ligand B (-13.403). This is a significant advantage for A.
14. **Pgp:** Ligand A (0.169) has lower P-gp efflux than Ligand B (0.017), which is a benefit.
15. **Binding Affinity:** Ligand B (-7.1) has a slightly better binding affinity than Ligand A (-5.4). While A is still good, the 1.7 kcal/mol difference is substantial and can outweigh some ADME concerns.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has a better logP and Pgp, while Ligand B has better affinity. The DILI risk for Ligand A is concerning. The metabolic stability of Ligand B is also a strong point.
**Overall Assessment:**
While Ligand A has some advantages in permeability and hERG, the significantly higher DILI risk and lower binding affinity are major drawbacks. Ligand B, despite slightly lower logP, has a much better safety profile (lower DILI), superior binding affinity, and better metabolic stability. The improved affinity is a significant advantage for a GPCR target.
Output:
0
2025-04-17 20:09:04,657 - INFO - Batch 163 complete. Total preferences: 2608
2025-04-17 20:09:04,657 - INFO - Processing batch 164/512...
2025-04-17 20:09:54,538 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (408.315 and 406.284 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (36.44) is significantly better than Ligand B (73.14). For a GPCR, lower TPSA is generally preferred for better permeability. Ligand B is quite high and could present absorption challenges.
3. **logP:** Ligand A (4.348) is slightly higher than Ligand B (2.268). While both are within the acceptable range (1-3), Ligand A is approaching the upper limit. Ligand B is closer to the ideal.
4. **HBD:** Both ligands have 0 HBD, which is good.
5. **HBA:** Ligand A (3) is better than Ligand B (6). Lower HBA is generally favorable for permeability.
6. **QED:** Both ligands have good QED scores (0.713 and 0.762), indicating good drug-like properties.
7. **DILI:** Ligand A (46.84) has a slightly better DILI score than Ligand B (51.338), indicating a lower risk of liver injury. Both are acceptable.
8. **BBB:** Ligand A (85.692) has a significantly higher BBB penetration score than Ligand B (70.997). While ADRB2 isn't strictly a CNS target, some CNS exposure can occur, and higher BBB is generally a positive attribute.
9. **Caco-2:** Both ligands have very poor Caco-2 permeability (-4.682 and -4.624). This is a significant concern for both.
10. **Solubility:** Ligand A (-4.62) has slightly better solubility than Ligand B (-2.975), but both are very poor. This is a major drawback for both compounds.
11. **hERG:** Ligand A (0.955) has a better hERG score than Ligand B (0.28), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand A (100.685) has a higher microsomal clearance than Ligand B (58.099), meaning it's metabolized faster. This is a negative for Ligand A.
13. **t1/2:** Ligand B (-26.91) has a much longer in vitro half-life than Ligand A (58.714). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.709) has lower P-gp efflux than Ligand B (0.134), which is favorable.
15. **Binding Affinity:** Ligand B (-6.6 kcal/mol) has a slightly better binding affinity than Ligand A (-6.1 kcal/mol). While the difference is not huge, it is still a factor.
**Overall Assessment:**
Ligand A has advantages in TPSA, BBB, hERG, and Pgp efflux. However, Ligand B has a significantly longer half-life and slightly better binding affinity, and a better logP. The poor Caco-2 and solubility for both are concerning, but the longer half-life of Ligand B is a critical advantage for a GPCR target, potentially allowing for less frequent dosing. The slightly better affinity of Ligand B also tips the balance. While Ligand A's TPSA is better, the solubility and metabolic stability issues are more critical drawbacks.
Output:
0
2025-04-17 20:09:54,538 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (354.841 and 359.294 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (49.64) is slightly higher than Ligand B (41.49). Both are below the 140 threshold for good oral absorption, but closer to the ideal for GPCRs. Ligand B is preferable.
3. **logP:** Ligand B (3.705) is higher than Ligand A (2.703). Both are within the optimal 1-3 range, but Ligand B is approaching the upper limit. This could potentially lead to solubility issues, but is acceptable for a GPCR.
4. **HBD:** Ligand A (1) has fewer HBDs than Ligand B (2). Fewer HBDs are generally preferred for better permeability. Ligand A is preferable.
5. **HBA:** Ligand A (4) has more HBAs than Ligand B (3). Lower HBA is preferable for permeability. Ligand B is preferable.
6. **QED:** Both ligands have good QED scores (0.786 and 0.818), indicating good drug-like properties. No significant difference.
7. **DILI:** Ligand B (38.736) has a significantly lower DILI risk than Ligand A (55.68). This is a major advantage for Ligand B.
8. **BBB:** Ligand B (63.048) has a higher BBB penetration percentile than Ligand A (59.403). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be beneficial for distribution and off-target effects. Ligand B is preferable.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.088 and -5.063). This is unusual and suggests poor permeability. However, the values are very similar.
10. **Solubility:** Ligand A (-1.878) has better aqueous solubility than Ligand B (-4.226). This is a positive for Ligand A, especially considering Ligand B's higher logP.
11. **hERG:** Ligand A (0.755) has a lower hERG inhibition liability than Ligand B (0.922). This is a significant advantage for Ligand A, reducing the risk of cardiotoxicity.
12. **Cl_mic:** Ligand A (16.431) has a lower microsomal clearance than Ligand B (31.514), indicating better metabolic stability. This is a major advantage for Ligand A.
13. **t1/2:** Ligand B (7.664) has a longer in vitro half-life than Ligand A (5.79). This is preferable, but the difference isn't huge.
14. **Pgp:** Ligand A (0.31) has lower P-gp efflux liability than Ligand B (0.469). This is preferable.
15. **Binding Affinity:** Ligand B (-8.5 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.9 kcal/mol). This is a substantial advantage that can outweigh some of the ADME drawbacks. A difference of 2.6 kcal/mol is significant.
**Overall Assessment:**
Ligand B has a much stronger binding affinity, lower DILI risk, better BBB penetration, and a longer half-life. These are all important factors. While Ligand B has a higher logP and lower solubility, the strong binding affinity and lower toxicity profile are compelling. Ligand A has better hERG and clearance, but the affinity difference is too large to ignore.
Output:
0
2025-04-17 20:09:54,538 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [356.354, 111.54 , -0.557, 2. , 6. , 0.659, 56.572, 57.619, -5.113, -1.81 , 0.19 , -7.195, -15.121, 0.029, -7.7 ]
**Ligand B:** [347.415, 75.02 , 1.125, 1. , 5. , 0.864, 30.632, 65.762, -4.955, -1.847, 0.497, 10.169, 59.814, 0.046, -6.7 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal 200-500 Da range. A (356) is slightly higher than B (347), but both are acceptable.
2. **TPSA:** A (111.54) is higher than B (75.02). For a GPCR, we want to keep TPSA as low as possible, and B is significantly better here.
3. **logP:** A (-0.557) is lower than B (1.125). A is a bit low, potentially impacting permeability. B is within the optimal 1-3 range.
4. **HBD:** Both have acceptable HBD counts (A: 2, B: 1).
5. **HBA:** Both have acceptable HBA counts (A: 6, B: 5).
6. **QED:** Both have good QED scores (A: 0.659, B: 0.864), indicating drug-like properties. B is slightly better.
7. **DILI:** A (56.572) has a higher DILI risk than B (30.632). B is much preferred here.
8. **BBB:** A (57.619) is lower than B (65.762). While ADRB2 isn't necessarily a CNS target, higher BBB is generally favorable for overall drug distribution. B is better.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the values are close (-5.113 vs -4.955).
10. **Solubility:** Both have negative solubility values, suggesting poor aqueous solubility. Again, values are close (-1.81 vs -1.847).
11. **hERG:** A (0.19) is much lower than B (0.497), indicating a lower risk of hERG inhibition and cardiotoxicity. A is significantly better.
12. **Cl_mic:** A (-7.195) is much lower than B (10.169), indicating better metabolic stability. A is significantly better.
13. **t1/2:** A (-15.121) is much lower than B (59.814), suggesting a shorter half-life. B is significantly better.
14. **Pgp:** A (0.029) is much lower than B (0.046), indicating lower P-gp efflux. A is significantly better.
15. **Affinity:** A (-7.7) is slightly better than B (-6.7), a difference of 1 kcal/mol.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. B has a better logP and TPSA. A has better Pgp efflux. The affinity difference is only 1 kcal/mol. However, A has significantly better metabolic stability (Cl_mic) and a much lower hERG risk. The DILI risk is also much lower for B.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity and better hERG/Pgp profiles, Ligand B's superior TPSA, logP, DILI, and *much* better metabolic stability and half-life are more compelling. The slightly weaker affinity can potentially be optimized in later stages of drug development. The improved ADME properties of Ligand B are crucial for a viable drug candidate.
Output:
0
2025-04-17 20:09:54,539 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
We are targeting ADRB2, a GPCR. Therefore, priorities are logP, Pgp, TPSA, affinity, and, to a lesser extent, BBB. Let's break down each ligand across the 15 parameters:
1. **MW:** Both ligands (351.451 and 351.403 Da) are within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (116.19) is slightly higher than Ligand B (107.97), but both are under the 140 threshold for good absorption.
3. **logP:** Ligand A (2.293) is optimal (1-3), while Ligand B (-0.247) is quite low, potentially hindering permeability. This is a significant drawback for Ligand B.
4. **HBD:** Ligand A (2) and Ligand B (3) are both acceptable, below the 5 limit.
5. **HBA:** Ligand A (4) and Ligand B (5) are both acceptable, below the 10 limit.
6. **QED:** Ligand B (0.647) has a better QED score than Ligand A (0.272), indicating better overall drug-likeness.
7. **DILI:** Ligand B (36.177) has a lower DILI risk than Ligand A (23.963), which is favorable.
8. **BBB:** Ligand A (59.519) has a better BBB penetration than Ligand B (30.128). While not a primary concern for ADRB2 (a cardiovascular target), it's a slight advantage.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.127 and -5.203), which is unusual and suggests poor permeability. However, the values are very similar.
10. **Solubility:** Both ligands have negative solubility values (-1.75 and -1.141), suggesting poor aqueous solubility. This is a concern for both.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.333 and 0.062).
12. **Cl_mic:** Ligand B (-52.282) has a significantly lower (better) microsomal clearance than Ligand A (36.511), indicating greater metabolic stability.
13. **t1/2:** Ligand B (0.703) has a slightly better in vitro half-life than Ligand A (-22.321).
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.031 and 0.005).
15. **Affinity:** Both ligands have very similar binding affinities (-6.9 and -6.8 kcal/mol). The difference is negligible.
**Overall Assessment:**
Ligand B has advantages in QED, DILI, Cl_mic, and t1/2. However, its significantly lower logP is a major concern, potentially leading to poor permeability and bioavailability. Ligand A, while having a lower QED and slightly higher DILI, has a more favorable logP value. Considering the GPCR-specific priorities (logP being crucial), and the similar binding affinities, Ligand A is the more promising candidate. The poor Caco-2 and solubility are concerns for both, but can be addressed with formulation strategies.
**Output:**
1
2025-04-17 20:09:54,539 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (406.276 Da) is within the ideal range, while Ligand B (348.531 Da) is towards the lower end but still acceptable.
2. **TPSA:** Ligand A (66.84) is better than Ligand B (41.57) for oral absorption, but both are quite good.
3. **logP:** Both ligands (A: 2.911, B: 3.351) are within the optimal range.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 3. Both are acceptable.
6. **QED:** Both ligands have good QED scores (A: 0.75, B: 0.847), indicating good drug-likeness.
7. **DILI:** Ligand A (59.984) has a higher DILI risk than Ligand B (6.049). This is a significant concern.
8. **BBB:** Ligand B (94.184) has a much higher BBB penetration score than Ligand A (54.207). While ADRB2 isn't *primarily* a CNS target, some CNS exposure is not necessarily detrimental and could provide additional therapeutic effects or off-target liabilities to consider.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and requires further investigation. However, the values are similar (-4.683 vs -4.653).
10. **Solubility:** Both have negative solubility values, which is also unusual and requires further investigation. Ligand B (-4.134) is slightly better than Ligand A (-3.046).
11. **hERG:** Both ligands have low hERG inhibition risk (A: 0.8, B: 0.705).
12. **Cl_mic:** Ligand B (41.74) has significantly lower microsomal clearance than Ligand A (72.396), indicating better metabolic stability.
13. **t1/2:** Ligand B (7.31) has a longer in vitro half-life than Ligand A (5.213).
14. **Pgp:** Ligand B (0.055) has much lower P-gp efflux liability than Ligand A (0.539), which is favorable for bioavailability.
15. **Affinity:** Ligand A (-7.1 kcal/mol) has a slightly better binding affinity than Ligand B (-5.9 kcal/mol). This is a 1.2 kcal/mol difference, which is significant.
**GPCR-specific priorities:** For GPCRs, logP, Pgp, TPSA, and affinity are key. Ligand B excels in logP, Pgp, and TPSA, while Ligand A has a better affinity. However, the significantly lower DILI risk, better metabolic stability (lower Cl_mic and longer t1/2), and higher BBB penetration of Ligand B are crucial advantages. The 1.2 kcal/mol difference in affinity can potentially be overcome with further optimization, while mitigating the high DILI risk of Ligand A would be more challenging.
**Conclusion:**
Considering the balance of properties and the GPCR-specific priorities, Ligand B is the more promising drug candidate. The lower DILI risk, improved metabolic stability, and better P-gp profile outweigh the slightly weaker binding affinity.
Output:
0
2025-04-17 20:09:54,539 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.43 and 344.46 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (75.71) is higher than Ligand B (53.76). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B is better here.
3. **logP:** Ligand A (1.535) is within the optimal range (1-3), while Ligand B (3.016) is at the higher end. Both are acceptable, but Ligand A is slightly favored due to the lower risk of off-target effects.
4. **HBD:** Ligand A (1) is better than Ligand B (0). Having at least one HBD can improve solubility.
5. **HBA:** Ligand A (4) is slightly higher than Ligand B (3). Both are within the acceptable limit of 10.
6. **QED:** Both ligands have similar QED values (0.725 and 0.715), indicating good drug-likeness.
7. **DILI:** Ligand A (30.83) has a slightly higher DILI risk than Ligand B (23.89), but both are well below the concerning threshold of 60. Ligand B is slightly better.
8. **BBB:** Ligand A (70.03) has a higher BBB penetration percentile than Ligand B (67.78). While ADRB2 isn't a CNS target, some peripheral exposure is still desirable.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.182 and -4.638). This is unusual and suggests poor permeability. Ligand B is slightly better (less negative).
10. **Solubility:** Both ligands have negative solubility values (-2.045 and -2.249). This is also concerning and suggests poor aqueous solubility. Ligand B is slightly better (less negative).
11. **hERG:** Ligand A (0.129) has a significantly lower hERG inhibition liability than Ligand B (0.466). This is a crucial advantage, as hERG inhibition can lead to cardiotoxicity.
12. **Cl_mic:** Ligand A (77.21) has higher microsomal clearance than Ligand B (64.20), indicating faster metabolism. Ligand B is favored here.
13. **t1/2:** Ligand B (21.462) has a significantly longer in vitro half-life than Ligand A (-16.325). This is a major advantage, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.048) has lower P-gp efflux liability than Ligand B (0.371). Lower P-gp efflux is generally desirable for improved bioavailability.
15. **Binding Affinity:** Ligand A (-7.3 kcal/mol) has a slightly stronger binding affinity than Ligand B (-6.7 kcal/mol). This is a significant advantage, potentially outweighing some ADME drawbacks.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), affinity, logP, TPSA, Pgp, and metabolic stability are key. Ligand A has better affinity and Pgp efflux, while Ligand B has better TPSA, metabolic stability (lower Cl_mic, longer t1/2), and DILI risk. The hERG liability of Ligand A is a significant advantage. The binding affinity difference is substantial (0.6 kcal/mol), which is a large enough difference to potentially overcome the slightly worse metabolic stability.
**Overall Assessment:**
Despite Ligand B's better metabolic stability and lower DILI, the superior binding affinity and significantly lower hERG risk of Ligand A make it the more promising candidate. The negative Caco-2 and solubility values are concerning for both, but these can potentially be addressed through formulation strategies. The stronger binding and reduced cardiotoxicity risk are more critical for initial development.
Output:
1
2025-04-17 20:09:54,539 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (380.187 Da) is slightly higher than Ligand B (348.426 Da), but both are acceptable.
2. **TPSA:** Ligand A (98.34) is higher than Ligand B (68.84). For a cardiovascular GPCR like ADRB2, TPSA is less critical than for CNS targets, but lower is generally preferred for better absorption. Ligand B is significantly better here.
3. **logP:** Ligand A (4.062) is at the upper end of the optimal range, while Ligand B (2.468) is well within it. High logP can lead to solubility issues and off-target binding. Ligand B is preferable.
4. **HBD:** Ligand A (1) and Ligand B (0) are both acceptable.
5. **HBA:** Ligand A (7) and Ligand B (6) are both acceptable.
6. **QED:** Both ligands have good QED scores (A: 0.682, B: 0.804), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (95.89) has a significantly higher DILI risk than Ligand B (54.285). This is a major concern for Ligand A.
8. **BBB:** Both have relatively low BBB penetration, which is fine for a cardiovascular target. Ligand B (89.104) is higher than Ligand A (37.495), but this isn't a major factor here.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Both ligands have negative solubility values, indicating poor aqueous solubility. This is a concern for both.
11. **hERG:** Ligand A (0.202) has a slightly better hERG profile than Ligand B (0.502).
12. **Cl_mic:** Ligand A (90.975) has a higher microsomal clearance than Ligand B (35.122), suggesting lower metabolic stability. Ligand B is preferable.
13. **t1/2:** Ligand B (-10.025) has a longer in vitro half-life than Ligand A (-27.16), indicating better stability.
14. **Pgp:** Ligand A (0.135) has lower P-gp efflux liability than Ligand B (0.332), which is favorable.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.7 kcal/mol and -6.4 kcal/mol, respectively). The difference is not substantial enough to override other factors.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand B is better in logP and TPSA. Pgp is slightly better for A, but the DILI risk associated with A is a major drawback.
**Overall Assessment:**
Ligand A has a concerningly high DILI risk and higher metabolic clearance. While it has slightly better Pgp efflux liability and hERG inhibition, these benefits are outweighed by the significant safety concern of DILI and the lower metabolic stability. Ligand B, despite having slightly less favorable Pgp and hERG, presents a much better overall profile with lower DILI risk, better logP, TPSA, and metabolic stability.
Output:
0
2025-04-17 20:09:54,539 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (351.407 and 362.455 Da) fall comfortably within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (87.58) is significantly better than Ligand A (107.77). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (-1.576) is a bit low, potentially hindering membrane permeability. Ligand B (2.287) is within the optimal 1-3 range. This is a significant advantage for Ligand B.
4. **HBD:** Both ligands have 2 HBD, which is acceptable.
5. **HBA:** Both ligands have 7 HBA, also acceptable.
6. **QED:** Ligand B (0.848) has a higher QED score than Ligand A (0.614), indicating a more drug-like profile.
7. **DILI:** Ligand A (30.361) has a much lower DILI risk than Ligand B (66.848). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (58.782) has a higher BBB penetration than Ligand A (21.287). While not critical for a cardiovascular target, it's a slight positive for Ligand B.
9. **Caco-2:** Both ligands have similar, very negative Caco-2 values (-5.347 and -5.334), suggesting poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (0.048) has slightly better solubility than Ligand B (-3.816), but both are very poor.
11. **hERG:** Ligand A (0.073) has a lower hERG risk than Ligand B (0.666). This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand A (-27.38) has a much lower (better) microsomal clearance than Ligand B (47.039), indicating better metabolic stability.
13. **t1/2:** Ligand B (-8.961) has a negative in vitro half-life, which is concerning. Ligand A (6.182) is positive, indicating a reasonable half-life.
14. **Pgp:** Ligand A (0.005) has a much lower Pgp efflux liability than Ligand B (0.144), suggesting better oral bioavailability.
15. **Binding Affinity:** Ligand A (-6.5 kcal/mol) has a slightly better binding affinity than Ligand B (-3.6 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME concerns.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand A is the stronger candidate. While Ligand B has better logP and TPSA, Ligand A has a significantly better binding affinity, lower DILI risk, lower hERG risk, better metabolic stability (lower Cl_mic), longer half-life, and lower Pgp efflux. The poor Caco-2 values are concerning for both, but the superior potency and safety profile of Ligand A make it more promising.
Output:
1
2025-04-17 20:09:54,540 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (358.46 and 362.82 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (67.33) is significantly better than Ligand B (90.54). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (1.059) is within the optimal range (1-3), while Ligand A (-0.599) is slightly below, potentially impacting permeability. Ligand B has a slight edge here.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (3). Fewer HBAs generally improve permeability.
6. **QED:** Both ligands have similar, good QED values (0.687 and 0.699).
7. **DILI:** Ligand A (6.32) has a much lower DILI risk than Ligand B (50.80). This is a significant advantage for Ligand A.
8. **BBB:** BBB is less critical for a cardiovascular target. Ligand B (61.38) is higher, but this isn't a major factor.
9. **Caco-2:** Ligand A (-5.024) and Ligand B (-4.872) are similar, indicating comparable intestinal absorption.
10. **Solubility:** Ligand A (0.656) is better than Ligand B (-3.323). Solubility is important for bioavailability.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.245 and 0.151).
12. **Cl_mic:** Ligand A (-19.659) has a lower (better) microsomal clearance than Ligand B (-29.248), suggesting greater metabolic stability.
13. **t1/2:** Ligand B (-3.907) has a slightly better in vitro half-life than Ligand A (-31.215).
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.004 and 0.009).
15. **Binding Affinity:** Ligand A (-6.6) is slightly better than Ligand B (-6.1) in terms of binding affinity. While the difference is less than the 1.5 kcal/mol threshold, it's still a positive factor.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B has a better logP, but Ligand A excels in TPSA, DILI, solubility, and metabolic stability. The slight affinity advantage of Ligand A also contributes.
**Overall Assessment:**
Ligand A presents a more balanced profile with significantly lower DILI risk, better solubility, and metabolic stability, and a favorable TPSA. While Ligand B has a slightly better logP and half-life, the advantages of Ligand A outweigh these. The lower DILI risk is particularly important for a cardiovascular drug.
Output:
1
2025-04-17 20:09:54,540 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [352.391, 116.92 , -0.758, 3. , 7. , 0.641, 52.423, 20.512, -5.071, -1.176, 0.056, -9.553, -11.868, 0.023, -5.4 ]
**Ligand B:** [360.42 , 58.2 , 3.022, 2. , 2. , 0.664, 30.632, 83.908, -4.628, -4.411, 0.561, 29.289, 17.374, 0.117, -6.7 ]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, Affinity, and BBB):
1. **MW:** Both are within the ideal 200-500 Da range. A (352.391) is slightly preferred.
2. **TPSA:** A (116.92) is higher than ideal (<140), but B (58.2) is excellent. B wins here.
3. **logP:** A (-0.758) is a bit low, potentially hindering permeability. B (3.022) is excellent, falling right within the optimal range. B wins.
4. **HBD:** A (3) is acceptable, B (2) is also good. No strong preference.
5. **HBA:** A (7) is acceptable, B (2) is excellent. B wins.
6. **QED:** Both are good (A: 0.641, B: 0.664). No strong preference.
7. **DILI:** A (52.423) is better than B (30.632), indicating lower liver injury risk. A wins.
8. **BBB:** B (83.908) is significantly better than A (20.512). This is important for a GPCR, even a cardiovascular one, as some CNS off-target effects are possible. B wins.
9. **Caco-2:** Both are negative, indicating poor permeability. A (-5.071) is worse than B (-4.628). B wins.
10. **Solubility:** Both are negative, indicating poor solubility. A (-1.176) is slightly better than B (-4.411). A wins.
11. **hERG:** A (0.056) is better than B (0.561), indicating lower cardiotoxicity risk. A wins.
12. **Cl_mic:** A (-9.553) is much better than B (29.289), meaning A is more metabolically stable. A wins.
13. **t1/2:** B (17.374) is better than A (-11.868). B wins.
14. **Pgp:** A (0.023) is much better than B (0.117), indicating less efflux and better bioavailability. A wins.
15. **Affinity:** B (-6.7) is 0.3 kcal/mol better than A (-5.4). This is a significant advantage. B wins.
**Overall Assessment:**
Ligand B has a superior logP, TPSA, BBB, Caco-2, and binding affinity. The affinity difference is substantial. While A has better DILI, hERG, Cl_mic, Pgp, and solubility, the binding affinity and BBB penetration of B are more critical for a GPCR target, especially considering the potential for off-target effects. The improved metabolic stability of A is helpful but can be addressed through further optimization. The slightly higher DILI risk of B is acceptable given its other advantages.
Output:
0
2025-04-17 20:09:54,540 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (378.529 and 350.503 Da) are within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (49.41) is significantly better than Ligand B (69.64). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (3.41 and 2.471), falling within the optimal 1-3 range. Ligand A is slightly higher, which *could* be beneficial for membrane permeability, but not dramatically so.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Both ligands have the same HBA count (3), which is well within the acceptable limit of 10.
6. **QED:** Both ligands have similar, good QED values (0.704 and 0.773), indicating good drug-likeness.
7. **DILI:** Ligand A (31.136) has a much lower DILI risk than Ligand B (13.494). This is a significant advantage for Ligand A.
8. **BBB:** Both ligands have reasonable BBB penetration (72.858 and 62.078). Since ADRB2 is primarily a cardiovascular target, BBB isn't a critical factor, but higher is slightly preferred.
9. **Caco-2:** Both ligands have similar, negative Caco-2 values (-4.813 and -4.816), suggesting poor permeability. This is a concern for both.
10. **Solubility:** Both ligands have similar, negative solubility values (-3.876 and -3.508), suggesting poor aqueous solubility. This is a concern for both.
11. **hERG:** Ligand A (0.688) has a slightly better hERG profile than Ligand B (0.375), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand B (65.045) has a slightly higher microsomal clearance than Ligand A (63.779), suggesting slightly lower metabolic stability.
13. **t1/2:** Ligand A (8.078) has a significantly longer in vitro half-life than Ligand B (-1.455). This is a major advantage for Ligand A, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.205 and 0.25).
15. **Binding Affinity:** Ligand A (-7.4 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.1 kcal/mol). This 1.3 kcal/mol difference is substantial and can often outweigh minor ADME drawbacks.
**Overall Assessment:**
Ligand A is the stronger candidate. Its superior binding affinity, lower DILI risk, and significantly longer half-life are key advantages. While both ligands have issues with Caco-2 permeability and solubility, the potency and safety profile of Ligand A make it more likely to succeed as a drug candidate. The slightly better TPSA and hERG values also contribute to its preference.
Output:
1
2025-04-17 20:09:54,540 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [358.479, 79.31, 0.752, 1, 5, 0.623, 15.355, 50.446, -4.319, -0.661, 0.252, 53.051, 3.78, 0.051, -6.4]
**Ligand B:** [345.451, 96.76, 1.902, 3, 7, 0.716, 69.794, 73.711, -5.155, -3.094, 0.54, 58.08, 38.661, 0.174, -6.2]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal 200-500 Da range. A (358.479) is slightly higher, but not concerning.
2. **TPSA:** A (79.31) is better than B (96.76). Below 140 is good for oral absorption, both are, but A is preferable.
3. **logP:** A (0.752) is a bit low, potentially hindering permeability. B (1.902) is better, falling within the optimal 1-3 range.
4. **HBD/HBA:** A (1 HBD, 5 HBA) is better than B (3 HBD, 7 HBA). Lower counts are generally preferred for balance.
5. **QED:** Both are good (A: 0.623, B: 0.716), indicating reasonable drug-likeness. B is slightly better.
6. **DILI:** A (15.355) is *significantly* better than B (69.794). This is a major advantage for A.
7. **BBB:** B (73.711) is better than A (50.446). While not a primary concern for a cardiovascular target like ADRB2, higher BBB is generally favorable.
8. **Caco-2:** A (-4.319) is better than B (-5.155). Higher Caco-2 values indicate better absorption.
9. **Solubility:** A (-0.661) is better than B (-3.094).
10. **hERG:** A (0.252) is much better than B (0.54). Lower hERG inhibition is crucial for avoiding cardiotoxicity.
11. **Cl_mic:** A (53.051) is better than B (58.08). Lower clearance suggests better metabolic stability.
12. **t1/2:** B (38.661) is significantly better than A (3.78). A longer half-life is generally desirable.
13. **Pgp:** A (0.051) is *much* better than B (0.174). Lower P-gp efflux is highly desirable for better bioavailability.
14. **Affinity:** Both are very good (-6.4 and -6.2 kcal/mol). The difference (0.2 kcal/mol) is not substantial enough to override other significant differences.
**Overall Assessment:**
Ligand A has a clear advantage due to its significantly lower DILI risk, better hERG profile, lower Pgp efflux, and better solubility. While Ligand B has a longer half-life and slightly better logP and BBB penetration, the safety concerns associated with Ligand B (high DILI, higher hERG, higher Pgp) are substantial drawbacks. For a cardiovascular target, minimizing cardiotoxicity (hERG) and maximizing safety (DILI) are paramount.
Therefore, I prefer Ligand A.
Output:
1
2025-04-17 20:09:54,540 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (333.475 & 349.475 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (20.31) is significantly better than Ligand B (69.72). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally correlates with better absorption. Ligand B's TPSA is quite high, potentially hindering oral bioavailability.
3. **logP:** Ligand A (4.822) is a bit high, potentially leading to solubility issues and off-target interactions. Ligand B (1.398) is closer to the optimal range of 1-3. This favors Ligand B.
4. **HBD:** Both have low HBD counts (0 and 1 respectively), which is good for permeability.
5. **HBA:** Ligand A (1) is better than Ligand B (3). Lower HBA is generally preferable for permeability.
6. **QED:** Both ligands have good QED scores (0.771 and 0.834), indicating good overall drug-likeness.
7. **DILI:** Ligand A (47.732) has a higher DILI risk than Ligand B (16.673). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (94.533) has better BBB penetration than Ligand B (70.027). While not a primary concern for a cardiovascular target, it's a slight positive for Ligand A.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.61 and -4.733). These values are unusual and suggest poor permeability.
10. **Solubility:** Ligand A (-5.572) has slightly better solubility than Ligand B (-1.73), but both are poor.
11. **hERG:** Ligand A (0.911) has a slightly higher hERG risk than Ligand B (0.102). This favors Ligand B.
12. **Cl_mic:** Ligand A (96.134) has a higher microsomal clearance than Ligand B (28.865), meaning it's less metabolically stable. Ligand B is significantly better here.
13. **t1/2:** Ligand A (24.447) has a better in vitro half-life than Ligand B (-4.22). This is a positive for Ligand A.
14. **Pgp:** Ligand A (0.886) has a higher Pgp efflux liability than Ligand B (0.01). This favors Ligand B.
15. **Binding Affinity:** Ligand A (-7.1) has a significantly stronger binding affinity than Ligand B (-6.4). This is a substantial advantage for Ligand A.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A has a better affinity, but Ligand B excels in logP, TPSA, Pgp, DILI, and Cl_mic. The affinity difference (-7.1 vs -6.4) is 0.7 kcal/mol, which is a good advantage, but the ADME profile of Ligand B is significantly better. The high TPSA and DILI risk of Ligand A are concerning.
**Overall Assessment:**
While Ligand A boasts a stronger binding affinity, Ligand B presents a more balanced and favorable ADME profile, particularly regarding metabolic stability (Cl_mic), DILI risk, and Pgp efflux. The slightly weaker affinity can potentially be optimized in subsequent rounds of medicinal chemistry, while addressing the poor solubility of both compounds would be crucial. Considering the overall risk/reward profile, Ligand B is the more promising starting point.
Output:
0
2025-04-17 20:09:54,540 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (365.763 Da) is within the ideal range (200-500 Da). Ligand B (385.511 Da) is also acceptable. No clear advantage here.
2. **TPSA:** Ligand A (57.61) is excellent, well below the 140 threshold for oral absorption. Ligand B (88.07) is still reasonable, but less optimal. This favors Ligand A.
3. **logP:** Ligand A (3.631) is within the optimal range (1-3). Ligand B (0.289) is quite low, potentially causing permeability issues. This strongly favors Ligand A.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A (2) is good. Ligand B (6) is higher, potentially impacting permeability. This favors Ligand A.
6. **QED:** Ligand A (0.9) is excellent, indicating strong drug-likeness. Ligand B (0.703) is still acceptable, but lower. This favors Ligand A.
7. **DILI:** Ligand A (78.054) has a higher DILI risk than Ligand B (56.805). This favors Ligand B, although both are reasonably low.
8. **BBB:** Both ligands have relatively low BBB penetration (Ligand A: 41.218, Ligand B: 46.026). Since ADRB2 is a cardiovascular target, BBB penetration is not a high priority.
9. **Caco-2:** Ligand A (-4.589) is poor, suggesting limited intestinal absorption. Ligand B (-5.34) is also poor, but slightly worse.
10. **Solubility:** Ligand A (-3.571) is poor. Ligand B (-2.395) is also poor, but slightly better.
11. **hERG:** Both ligands have very low hERG inhibition risk (Ligand A: 0.189, Ligand B: 0.083). No significant difference.
12. **Cl_mic:** Ligand A (3.179) has a much lower microsomal clearance, indicating better metabolic stability. Ligand B (28.428) is high, suggesting rapid metabolism. This strongly favors Ligand A.
13. **t1/2:** Both ligands have similar in vitro half-lives (Ligand A: 1.167, Ligand B: 1.131).
14. **Pgp:** Both ligands have low P-gp efflux (Ligand A: 0.096, Ligand B: 0.104). No significant difference.
15. **Binding Affinity:** Ligand A (-7.2 kcal/mol) has significantly stronger binding affinity than Ligand B (-0.2 kcal/mol). This is a decisive advantage for Ligand A.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand A excels in these areas. While Ligand B has a lower DILI risk, the significantly better ADME profile (TPSA, logP, Cl_mic) and *much* higher affinity of Ligand A outweigh this concern. The poor Caco-2 and solubility of both are concerning, but can be addressed with formulation strategies.
**Conclusion:**
Ligand A is the far superior candidate due to its significantly better binding affinity, logP, TPSA, QED, and metabolic stability.
Output:
1
2025-04-17 20:09:54,541 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (356.491 and 349.475 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (45.48) is significantly better than Ligand B (69.72). ADRB2 is not a CNS target, but lower TPSA generally improves absorption.
3. **logP:** Ligand A (3.927) is good, while Ligand B (1.398) is on the lower side. For a GPCR, a logP between 1-3 is preferred, but Ligand A is closer to the optimal range.
4. **HBD:** Both have 1 HBD, which is acceptable.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 3. Both are within the acceptable limit of 10.
6. **QED:** Both ligands have good QED scores (0.797 and 0.834), indicating good drug-like properties.
7. **DILI:** Ligand A (35.75) has a slightly higher DILI risk than Ligand B (16.673), but both are below the concerning threshold of 60.
8. **BBB:** Both ligands have comparable BBB penetration (74.719 and 70.027). This isn't a primary concern for ADRB2.
9. **Caco-2:** Ligand A (-5.397) and Ligand B (-4.733) both have negative values, which is unusual. However, the values are close, and this parameter is less critical.
10. **Solubility:** Ligand A (-3.409) has better solubility than Ligand B (-1.73).
11. **hERG:** Ligand A (0.861) has a slightly higher hERG risk than Ligand B (0.102). This is a significant advantage for Ligand B.
12. **Cl_mic:** Ligand B (28.865) has a lower microsomal clearance than Ligand A (24.164), suggesting better metabolic stability.
13. **t1/2:** Ligand A (47.051) has a much longer in vitro half-life than Ligand B (-4.22). This is a major advantage for Ligand A.
14. **Pgp:** Ligand A (0.413) has lower P-gp efflux than Ligand B (0.01), which is favorable.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.5 and -6.4 kcal/mol). The difference is negligible.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A has a better logP and TPSA, and Pgp efflux. While Ligand B has a better hERG profile and Cl_mic, the longer half-life of Ligand A is a significant advantage.
**Overall Assessment:**
Ligand A presents a more balanced profile. Its superior TPSA, logP, Pgp efflux, and significantly longer half-life outweigh the slightly higher DILI and hERG risks. The binding affinity is comparable.
Output:
1
2025-04-17 20:09:54,541 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (363.483 and 341.367 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (74.57) is significantly better than Ligand B (97.37). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (2.217) is better positioned within the optimal 1-3 range than Ligand A (0.57), which is quite low and could hinder membrane permeability.
4. **HBD:** Both ligands have 2 HBD, which is acceptable.
5. **HBA:** Both ligands have 5 HBA, which is acceptable.
6. **QED:** Both ligands have good QED scores (0.662 and 0.753), indicating generally drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (31.097) has a much lower DILI risk than Ligand B (61.691). This is a significant advantage for Ligand A.
8. **BBB:** Ligand B (39.783) has a higher BBB percentile than Ligand A (18.147). While not crucial for a cardiovascular target, it's a slight positive for Ligand B.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. Ligand A (-5.202) is slightly better than Ligand B (-4.808).
10. **Solubility:** Both have negative solubility values, indicating poor aqueous solubility. Ligand A (-2.558) is slightly better than Ligand B (-3.951).
11. **hERG:** Both ligands have very low hERG inhibition liability (0.175 and 0.069), which is excellent. Ligand B is slightly better.
12. **Cl_mic:** Ligand A (-5.664) has a much lower (better) microsomal clearance than Ligand B (1.38). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand B (28.019) has a significantly longer in vitro half-life than Ligand A (7.16). This is a major advantage for Ligand B.
14. **Pgp:** Both have very low Pgp efflux liability (0.029 and 0.065).
15. **Binding Affinity:** Ligand A (-6.3 kcal/mol) has a slightly better binding affinity than Ligand B (-5.9 kcal/mol). While the difference is not huge, it is still a factor.
**Overall Assessment:**
Considering the priorities for a GPCR, particularly ADRB2, the balance of properties favors Ligand A. While Ligand B has a better logP and half-life, Ligand A's significantly lower DILI risk and better metabolic stability (Cl_mic) are crucial. The slightly better binding affinity of Ligand A also contributes. The TPSA of Ligand A is also more favorable. The poor Caco-2 and solubility for both are concerning, but can be addressed with formulation strategies.
Output:
1
2025-04-17 20:09:54,541 - INFO - Batch 164 complete. Total preferences: 2624
2025-04-17 20:09:54,541 - INFO - Processing batch 165/512...
2025-04-17 20:10:42,304 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [366.491, 76.26, 0.548, 0., 7., 0.772, 43.389, 71.035, -4.944, -2.165, 0.721, 39.795, -40.324, 0.196, -6.7]
**Ligand B:** [342.403, 103.01, 1.028, 3., 5., 0.697, 55.176, 30.399, -5.633, -2.387, 0.607, -28.31, -6.484, 0.013, -6.2]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, BBB, and affinity are key):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (342.403) is slightly lower, which isn't a major concern.
2. **TPSA:** Ligand A (76.26) is better than Ligand B (103.01). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally aids absorption.
3. **logP:** Ligand A (0.548) is a bit low, potentially hindering permeability. Ligand B (1.028) is better, falling within the optimal range.
4. **HBD/HBA:** Ligand A (0/7) is preferable to Ligand B (3/5). Fewer HBDs generally improve permeability.
5. **QED:** Both are acceptable (A: 0.772, B: 0.697), indicating reasonable drug-likeness.
6. **DILI:** Ligand A (43.389) is significantly better than Ligand B (55.176). Lower DILI risk is crucial.
7. **BBB:** Ligand A (71.035) is much better than Ligand B (30.399). While not essential for a cardiovascular target, higher BBB is generally a positive attribute.
8. **Caco-2:** Ligand A (-4.944) is better than Ligand B (-5.633), indicating better intestinal absorption.
9. **Solubility:** Both are poor (-2.165 and -2.387). This is a concern for both, but might be manageable with formulation.
10. **hERG:** Both are low (0.721 and 0.607), indicating low cardiotoxicity risk.
11. **Cl_mic:** Ligand B (-28.31) has significantly lower clearance than Ligand A (39.795), suggesting better metabolic stability. This is a strong point for Ligand B.
12. **t1/2:** Ligand A (-40.324) has a much longer half-life than Ligand B (-6.484). This is a significant advantage for Ligand A.
13. **Pgp:** Both are low (0.196 and 0.013), indicating minimal P-gp efflux.
14. **Affinity:** Both have similar binding affinities (-6.7 and -6.2 kcal/mol). The difference is not substantial enough to be a deciding factor.
**Overall Assessment:**
Ligand A has a better safety profile (DILI), better BBB penetration, better Caco-2 permeability, and a significantly longer half-life. Ligand B has better metabolic stability (lower Cl_mic) and a slightly better logP. However, the advantages of Ligand A in terms of safety, absorption, and duration of action outweigh the metabolic stability benefit of Ligand B. The slightly low logP of Ligand A is a manageable concern.
Therefore, I prefer Ligand A.
Output:
1
2025-04-17 20:10:42,304 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (344.415 Da and 347.463 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (76.46) is better than Ligand B (80.12). Both are below the 140 A^2 threshold for good oral absorption, but lower TPSA is generally preferred for GPCRs to facilitate receptor binding.
3. **logP:** Both ligands have similar logP values (1.628 and 1.694), falling within the optimal 1-3 range. No clear advantage.
4. **HBD:** Both have 1 HBD, which is within the acceptable limit of <=5.
5. **HBA:** Ligand A has 6 HBA, while Ligand B has 5. Both are below the 10 limit.
6. **QED:** Both ligands have similar QED values (0.773 and 0.761), indicating good drug-likeness.
7. **DILI:** Ligand A (59.984) has a higher DILI risk than Ligand B (34.238). This is a significant advantage for Ligand B.
8. **BBB:** Both ligands have good BBB penetration (70.997 and 79.682). Ligand B is slightly better. Given ADRB2's cardiovascular involvement, BBB penetration isn't *critical* but is still a positive.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand B (-4.832) is slightly worse than Ligand A (-4.65).
10. **Solubility:** Both ligands have negative solubility values, indicating poor aqueous solubility. Ligand B (-2.314) is slightly worse than Ligand A (-2.116).
11. **hERG:** Both ligands have low hERG inhibition liability (0.416 and 0.41). No significant difference.
12. **Cl_mic:** Ligand B (52.722) has lower microsomal clearance than Ligand A (67.943), indicating better metabolic stability. This is a positive for Ligand B.
13. **t1/2:** Ligand B (-1.912) has a negative in vitro half-life, which is concerning. Ligand A (5.821) has a reasonable half-life.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.061 and 0.116). No significant difference.
15. **Binding Affinity:** Ligand A (-6.9 kcal/mol) has a slightly better binding affinity than Ligand B (-6.3 kcal/mol). This is a 0.6 kcal/mol difference, which is notable.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity and in vitro half-life, Ligand B demonstrates a significantly lower DILI risk and better metabolic stability (lower Cl_mic). The solubility and Caco-2 values are poor for both, but similar. Given the cardiovascular target, minimizing toxicity (DILI) is paramount. The 0.6 kcal/mol difference in binding affinity can likely be overcome with further optimization, whereas mitigating a high DILI risk is more challenging.
Output:
0
2025-04-17 20:10:42,305 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (356.46 & 340.39 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (58.2) is significantly better than Ligand B (100.97). For a GPCR, lower TPSA is generally preferred for better permeability. Ligand B is above the 90 threshold, which is concerning.
**3. logP:** Ligand A (3.056) is within the optimal range (1-3). Ligand B (0.857) is slightly below this, which *could* indicate permeability issues, but isn't a dealbreaker.
**4. H-Bond Donors:** Both have acceptable HBD counts (2 and 1 respectively), well below the threshold of 5.
**5. H-Bond Acceptors:** Ligand A (2) is preferable to Ligand B (6). Lower HBA is generally better for permeability.
**6. QED:** Both ligands have good QED scores (0.737 and 0.886), indicating good drug-like properties.
**7. DILI Risk:** Ligand B (58.395) has a considerably higher DILI risk than Ligand A (14.889). This is a significant negative for Ligand B.
**8. BBB Penetration:** Ligand A (86.351) has better BBB penetration than Ligand B (67.08). While ADRB2 is a cardiovascular target, some CNS effects are possible with beta-blockers, and better BBB penetration *could* be beneficial or detrimental depending on the desired profile.
**9. Caco-2 Permeability:** Ligand A (-4.785) shows better Caco-2 permeability than Ligand B (-5.161).
**10. Aqueous Solubility:** Ligand A (-3.915) shows better aqueous solubility than Ligand B (-1.76).
**11. hERG Inhibition:** Ligand A (0.645) has a slightly higher hERG risk than Ligand B (0.271). This is a minor concern for Ligand A, but Ligand B is clearly better.
**12. Microsomal Clearance:** Ligand B (-3.586) has significantly lower (better) microsomal clearance than Ligand A (45.547). This suggests better metabolic stability for Ligand B.
**13. In vitro Half-Life:** Both have similar in vitro half-lives (19.764 and 20.68 hours).
**14. P-gp Efflux:** Ligand A (0.174) has lower P-gp efflux than Ligand B (0.01). Lower efflux is generally preferred.
**15. Binding Affinity:** Ligand B (-7.0 kcal/mol) has a slightly better binding affinity than Ligand A (-6.4 kcal/mol). This is a 0.6 kcal/mol difference, which is significant, but not overwhelming.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity) and the general drug-like properties, Ligand A is the more promising candidate. While Ligand B has a slightly better affinity and metabolic stability, Ligand A's significantly better TPSA, lower DILI risk, better solubility, and P-gp profile outweigh these advantages. The lower TPSA is particularly important for a GPCR, and the higher DILI risk for Ligand B is a major red flag.
Output:
1
2025-04-17 20:10:42,305 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**1. Molecular Weight:** Both ligands (376.5 and 367.4 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (49.41) is significantly better than Ligand B (134.67). For a GPCR, a lower TPSA is generally preferred for better permeability. Ligand B is quite high, potentially hindering oral absorption.
**3. logP:** Ligand A (3.482) is within the optimal 1-3 range. Ligand B (0.921) is a bit low, potentially impacting membrane permeability.
**4. H-Bond Donors:** Ligand A (1) is good. Ligand B (3) is acceptable but slightly higher.
**5. H-Bond Acceptors:** Ligand A (4) is good. Ligand B (7) is higher, contributing to the higher TPSA.
**6. QED:** Both ligands have similar QED values (0.839 and 0.646), indicating good drug-likeness, but A is better.
**7. DILI Risk:** Ligand A (30.83) has a much lower DILI risk than Ligand B (81.43). This is a significant advantage for Ligand A.
**8. BBB Penetration:** Ligand A (71.81) has better BBB penetration than Ligand B (37.42). While ADRB2 isn't exclusively a CNS target, some cardiovascular effects are mediated by central pathways, and better BBB penetration could be beneficial or at least not detrimental.
**9. Caco-2 Permeability:** Both ligands have similar, poor Caco-2 permeability (-5.365 and -5.343).
**10. Aqueous Solubility:** Both ligands have similar, poor aqueous solubility (-3.775 and -3.142).
**11. hERG Inhibition:** Ligand A (0.676) has a lower hERG inhibition risk than Ligand B (0.083). This is a significant advantage for Ligand A, as hERG inhibition can cause cardiotoxicity.
**12. Microsomal Clearance:** Ligand A (39.003) has a higher microsomal clearance than Ligand B (18.17). This means Ligand B is more metabolically stable, which is a positive.
**13. In vitro Half-Life:** Both ligands have similar in vitro half-lives (6.273 and 6.51 hours).
**14. P-gp Efflux:** Ligand A (0.52) has a lower P-gp efflux liability than Ligand B (0.071). Lower efflux is preferable for better bioavailability.
**15. Binding Affinity:** Ligand A (-7.4 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.1 kcal/mol). This difference of 1.3 kcal/mol is substantial and can often outweigh minor ADME drawbacks.
**Overall Assessment:**
Ligand A is clearly the better candidate. While Ligand B has better metabolic stability, Ligand A excels in critical areas: significantly better TPSA, lower DILI risk, better BBB penetration, lower hERG inhibition, lower P-gp efflux, and *much* stronger binding affinity. The affinity difference is particularly important for a GPCR target. The slightly lower logP of Ligand A is a minor concern that could potentially be addressed through further optimization, but the benefits of A outweigh this drawback.
Output:
1
2025-04-17 20:10:42,305 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (335.363 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (83.37) is better than Ligand B (92.57). Both are below 140, but lower TPSA is preferred for oral absorption, a key consideration for a cardiovascular drug.
3. **logP:** Ligand A (3.559) is higher than Ligand B (1.562). While both are within the acceptable range (1-3), Ligand A is closer to the optimal upper limit, potentially aiding membrane permeability. Ligand B is rather low, which could hinder absorption.
4. **HBD:** Ligand A (3) and Ligand B (2) are both acceptable.
5. **HBA:** Ligand A (3) and Ligand B (5) are both acceptable, but Ligand A is better.
6. **QED:** Both ligands have good QED scores (A: 0.684, B: 0.78), indicating good drug-like properties.
7. **DILI:** Ligand B (64.676) has a significantly lower DILI risk than Ligand A (89.066). This is a major advantage for Ligand B.
8. **BBB:** Ligand A (72.082) has a better BBB penetration score than Ligand B (59.403). While ADRB2 isn't strictly a CNS target, some CNS exposure can occur, and higher BBB is generally preferable.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual. Assuming these are logP values, both are poor.
10. **Solubility:** Ligand A (-5.101) has slightly better solubility than Ligand B (-3.548).
11. **hERG:** Ligand A (0.604) has a lower hERG inhibition liability than Ligand B (0.431), which is a positive.
12. **Cl_mic:** Ligand A (30.913) has a lower microsomal clearance than Ligand B (48.142), indicating better metabolic stability.
13. **t1/2:** Ligand A (133.22) has a much longer in vitro half-life than Ligand B (-26.729). This is a significant advantage for Ligand A, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.204) has lower P-gp efflux liability than Ligand B (0.031). Lower P-gp efflux is generally desirable for improved bioavailability.
15. **Affinity:** Ligand A (-8.4 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.5 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME drawbacks of Ligand B.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are particularly important. Ligand A excels in logP, TPSA, Pgp, and *especially* affinity. While Ligand B has a better DILI score, the significantly stronger binding affinity of Ligand A is a critical advantage. The longer half-life of Ligand A is also a significant benefit.
**Conclusion:**
Despite the lower DILI score of Ligand B, the superior binding affinity, logP, TPSA, Pgp, and half-life of Ligand A make it the more promising drug candidate for ADRB2. The difference in affinity is substantial enough to outweigh the slightly higher DILI risk, which can be further investigated and potentially mitigated during optimization.
Output:
1
2025-04-17 20:10:42,305 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
We're targeting ADRB2, a GPCR. Therefore, priorities are logP, TPSA, Pgp, BBB, and binding affinity. Let's break down each ligand:
* **Molecular Weight:** Both ligands are within the ideal range (200-500 Da).
* **TPSA:** Ligand A (55.4) is significantly better than Ligand B (95.94). A lower TPSA generally favors better cell permeability and oral absorption, crucial for GPCR targeting. Ligand B is approaching a TPSA that could limit absorption.
* **logP:** Ligand A (3.086) is optimal. Ligand B (0.223) is quite low, potentially hindering membrane permeability and bioavailability.
* **H-Bond Donors/Acceptors:** Ligand A (1 HBD, 3 HBA) is preferable to Ligand B (2 HBD, 6 HBA). While both are acceptable, lower counts generally improve permeability.
* **QED:** Ligand A (0.822) has a better QED score than Ligand B (0.674), indicating a more drug-like profile.
* **DILI:** Ligand B (53.625) has a slightly lower DILI risk than Ligand A (72.043), but both are reasonably acceptable.
* **BBB:** Ligand A (77.937) has significantly better BBB penetration potential than Ligand B (54.478). While ADRB2 isn't exclusively a CNS target, some CNS exposure is possible depending on the specific indication, and higher BBB is generally favorable.
* **Caco-2:** Ligand A (-4.728) is better than Ligand B (-5.207), indicating better intestinal absorption.
* **Solubility:** Ligand A (-4.6) is better than Ligand B (-2.793), suggesting better aqueous solubility.
* **hERG:** Both ligands have very low hERG inhibition risk (0.77 and 0.103 respectively).
* **Cl_mic:** Ligand B (46.964) has a slightly lower microsomal clearance than Ligand A (51.365), suggesting better metabolic stability. This is a minor advantage.
* **t1/2:** Ligand A (25.209) has a much longer in vitro half-life than Ligand B (-12.976). This is a significant advantage.
* **Pgp:** Ligand A (0.499) has a lower Pgp efflux liability than Ligand B (0.078), which is desirable for better bioavailability.
* **Binding Affinity:** Both ligands have excellent binding affinity (-5.0 and -4.7 kcal/mol respectively). The difference of 0.3 kcal/mol is not substantial enough to outweigh the other ADME differences.
**Overall Assessment:**
Ligand A is clearly superior. It excels in key GPCR-relevant properties like TPSA, logP, BBB, solubility, and has a significantly longer half-life and lower Pgp efflux. While Ligand B has a slightly lower DILI risk and clearance, these are minor advantages compared to the substantial benefits offered by Ligand A. The binding affinity difference is negligible.
**Output:**
1
2025-04-17 20:10:42,305 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
The target is ADRB2, a GPCR. Therefore, the priorities are logP, TPSA, Pgp, BBB, and affinity. Let's compare the ligands property by property:
1. **MW:** Both ligands are within the ideal range (348.37 & 348.45 Da).
2. **TPSA:** Ligand A (33.2) is significantly better than Ligand B (97.55). Lower TPSA generally indicates better permeability, crucial for GPCR ligands. Ligand B's TPSA is quite high, potentially hindering oral absorption.
3. **logP:** Both ligands have acceptable logP values (4.049 and 2.142), falling within the 1-3 range. Ligand A is slightly higher, which could be a minor concern for solubility, but not a dealbreaker.
4. **HBD/HBA:** Ligand A (0 HBD, 2 HBA) is preferable to Ligand B (2 HBD, 5 HBA). Fewer hydrogen bonds are generally better for membrane permeability.
5. **QED:** Ligand A (0.838) is significantly better than Ligand B (0.499), indicating a more drug-like profile.
6. **DILI:** Ligand A (32.38%) has a lower DILI risk than Ligand B (42.89%), which is a positive. Both are below the concerning threshold of 60%.
7. **BBB:** Ligand A (96.78%) has a much higher BBB penetration potential than Ligand B (78.60%). While ADRB2 isn't exclusively a CNS target, some peripheral effects are mediated by CNS influence, and higher BBB penetration is generally favorable.
8. **Caco-2:** Ligand A (-4.569) is better than Ligand B (-5.229), indicating better intestinal absorption.
9. **Solubility:** Ligand A (-4.16) is better than Ligand B (-2.727), indicating better solubility.
10. **hERG:** Both ligands have similar hERG inhibition liability (0.686 and 0.347), and are relatively low risk.
11. **Cl_mic:** Ligand A (26.953) has a lower microsomal clearance than Ligand B (21.781), suggesting better metabolic stability.
12. **t1/2:** Ligand A (-17.946) has a longer in vitro half-life than Ligand B (-5.198), which is desirable.
13. **Pgp:** Ligand A (0.418) has lower P-gp efflux than Ligand B (0.064), indicating better bioavailability.
14. **Affinity:** Both ligands have the same binding affinity (-6.6 kcal/mol).
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical ADME properties (TPSA, QED, BBB, solubility, metabolic stability, Pgp efflux, and Caco-2 permeability). While both have acceptable logP and hERG values, and equivalent affinity, the superior ADME profile of Ligand A makes it the more promising drug candidate. The significant differences in TPSA, BBB, and QED are particularly compelling for a GPCR target.
**Output:**
1
2025-04-17 20:10:42,306 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (340.43 & 364.41 Da) fall comfortably within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (75.19) is slightly higher than Ligand B (58.64). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is generally preferred for absorption. Ligand B has a slight edge.
3. **logP:** Both ligands have excellent logP values (2.18 & 2.09), falling within the optimal 1-3 range. No significant difference.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 4 HBAs, Ligand B has 3. Both are acceptable (<=10).
6. **QED:** Ligand A (0.874) has a significantly better QED score than Ligand B (0.604), indicating a more drug-like profile. This is a notable advantage for Ligand A.
7. **DILI:** Ligand B (28.38) has a much lower DILI risk than Ligand A (37.99). This is a significant advantage for Ligand B, as minimizing liver toxicity is crucial.
8. **BBB:** Ligand B (93.56) exhibits significantly higher BBB penetration potential than Ligand A (67.55). While ADRB2 isn't strictly a CNS target, some CNS exposure can occur, and higher BBB is generally favorable.
9. **Caco-2:** Both ligands have similar, poor Caco-2 permeability (-4.95 and -4.60). This suggests potential absorption issues for both.
10. **Solubility:** Both ligands have very poor aqueous solubility (-2.09 and -2.30). This is a significant concern for both, and formulation strategies would be needed.
11. **hERG:** Ligand A (0.36) has a lower hERG inhibition liability than Ligand B (0.65), indicating a lower risk of cardiotoxicity. This is a key advantage for Ligand A, given the cardiovascular target.
12. **Cl_mic:** Ligand B (35.77) has a lower microsomal clearance than Ligand A (52.93), suggesting better metabolic stability. This is a positive for Ligand B.
13. **t1/2:** Ligand A (-4.61) has a slightly longer in vitro half-life than Ligand B (-4.50), but the difference is minimal.
14. **Pgp:** Ligand A (0.044) has a lower P-gp efflux liability than Ligand B (0.205), which is favorable for bioavailability.
15. **Affinity:** Ligand B (-7.2 kcal/mol) has a stronger binding affinity than Ligand A (-6.8 kcal/mol). This is a substantial advantage, as a 0.4 kcal/mol difference is significant.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), we prioritize logP, Pgp, TPSA, and affinity. Ligand B excels in affinity and has a better TPSA. Ligand A has better Pgp and hERG.
**Overall Assessment:**
While Ligand A has a better QED and lower hERG risk, the stronger binding affinity of Ligand B (-7.2 vs -6.8 kcal/mol) is a major advantage. The lower DILI risk and better BBB penetration of Ligand B are also significant positives. The similar poor solubility and Caco-2 permeability for both compounds mean that formulation challenges will be present regardless. The improved metabolic stability of Ligand B is also a plus. The affinity difference is substantial enough to outweigh the slightly higher hERG risk and lower QED of Ligand B.
Output:
0
2025-04-17 20:10:42,306 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (347.434 Da) is within the ideal range. Ligand B (408.256 Da) is also acceptable, but approaching the upper limit.
2. **TPSA:** Ligand A (51.39) is excellent, well below the 140 threshold and suitable for good absorption. Ligand B (102.48) is higher, but still within acceptable limits for a non-CNS target.
3. **logP:** Ligand A (3.507) is optimal. Ligand B (0.758) is low, potentially hindering permeability. This is a significant drawback.
4. **HBD:** Ligand A (0) is ideal. Ligand B (2) is acceptable.
5. **HBA:** Ligand A (5) is good. Ligand B (6) is also acceptable.
6. **QED:** Both ligands (A: 0.828, B: 0.731) have good drug-likeness scores.
7. **DILI:** Ligand A (42.652) has a lower DILI risk than Ligand B (75.184). This is a clear advantage for Ligand A.
8. **BBB:** This is less critical for ADRB2 (a cardiovascular target), but Ligand A (96.316) has better BBB penetration than Ligand B (70.027).
9. **Caco-2:** Both are negative, indicating poor permeability. This is a concern for both, but the lower logP of Ligand B exacerbates this issue.
10. **Solubility:** Both have negative solubility values, indicating poor solubility.
11. **hERG:** Ligand A (0.958) has a lower hERG risk than Ligand B (0.423).
12. **Cl_mic:** Ligand A (37.707) has a higher (worse) microsomal clearance than Ligand B (-4.158), suggesting faster metabolism.
13. **t1/2:** Ligand A (10.049) has a longer half-life than Ligand B (6.602).
14. **Pgp:** Ligand A (0.562) has lower P-gp efflux than Ligand B (0.054), which is favorable for bioavailability.
15. **Affinity:** Ligand B (-6.8 kcal/mol) has a significantly better binding affinity than Ligand A (-5.3 kcal/mol). This is a 1.5 kcal/mol difference, which is substantial.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand B excels in affinity, but suffers from a very low logP. The low logP is a major concern for permeability and overall drug-like properties. Ligand A has a better balance, even though its affinity is lower. The better DILI, BBB, hERG, and Pgp profiles of Ligand A are also significant advantages.
**Overall Assessment:**
While Ligand B's affinity is very attractive, the significantly lower logP and higher DILI risk are substantial drawbacks. Ligand A presents a more balanced profile with acceptable ADME properties and a reasonable affinity. The improved ADME properties outweigh the affinity difference in this case.
Output:
1
2025-04-17 20:10:42,306 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (362.411 Da) is slightly higher than Ligand B (344.411 Da), but both are acceptable.
2. **TPSA:** Ligand B (82.78) is significantly better than Ligand A (108.47). For a GPCR, lower TPSA is generally preferred for better permeability.
3. **logP:** Ligand B (2.172) is within the optimal range (1-3), while Ligand A (0.791) is slightly below, potentially hindering permeation.
4. **HBD:** Both ligands have 2 HBD, which is acceptable.
5. **HBA:** Ligand B (4) is better than Ligand A (7). Lower HBA contributes to better permeability.
6. **QED:** Both ligands have good QED scores (A: 0.754, B: 0.806), indicating drug-likeness.
7. **DILI:** Ligand B (34.781) has a much lower DILI risk than Ligand A (74.68). This is a significant advantage for Ligand B.
8. **BBB:** Both ligands have similar BBB penetration (A: 57.968, B: 56.572). Since ADRB2 is a cardiovascular target, BBB penetration isn't a primary concern.
9. **Caco-2:** Ligand A (-5.363) and Ligand B (-4.692) are both negative, suggesting poor permeability. However, the negative value for Ligand A is more negative, indicating worse permeability.
10. **Solubility:** Ligand A (-3.703) has slightly better solubility than Ligand B (-2.412).
11. **hERG:** Both ligands have low hERG risk (A: 0.062, B: 0.346).
12. **Cl_mic:** Ligand B (26.376) has lower microsomal clearance than Ligand A (29.36), indicating better metabolic stability.
13. **t1/2:** Ligand B (72.462) has a significantly longer in vitro half-life than Ligand A (-4.918). This is a major advantage.
14. **Pgp:** Ligand A (0.238) has lower P-gp efflux than Ligand B (0.042), which is preferable.
15. **Binding Affinity:** Ligand B (-7.1 kcal/mol) has a substantially stronger binding affinity than Ligand A (-5.7 kcal/mol). This is a crucial advantage, outweighing some of the minor ADME drawbacks.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP, TPSA, and significantly in binding affinity. While Ligand A has slightly better Pgp and solubility, the superior affinity and better overall ADME profile of Ligand B make it the more promising candidate. The lower DILI risk and longer half-life of Ligand B are also substantial benefits.
**Conclusion:**
Ligand B is the more viable drug candidate due to its superior binding affinity, lower DILI risk, better metabolic stability (lower Cl_mic, longer t1/2), and more favorable TPSA and logP values.
Output:
0
2025-04-17 20:10:42,306 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (371.453 and 351.487 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (62.3) is significantly better than Ligand B (73.91). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (2.854 and 3.437), falling within the 1-3 range. Ligand B is slightly higher, which *could* be a minor negative if it leads to off-target effects, but it's not a major concern.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Both ligands have the same number of HBA (4), which is well within the acceptable limit of 10.
6. **QED:** Ligand A (0.885) has a substantially better QED score than Ligand B (0.677), indicating a more drug-like profile.
7. **DILI:** Ligand A (49.787) has a much lower DILI risk than Ligand B (11.322). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (90.229) has a much higher BBB penetration score than Ligand B (62.233). While not crucial for a cardiovascular target, higher BBB is rarely detrimental.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.879 and -4.476). These values are unusual and suggest poor permeability. However, the absolute values are similar.
10. **Solubility:** Both ligands have negative solubility values (-3.612 and -3.357). This is also unusual and suggests poor aqueous solubility. The values are similar.
11. **hERG:** Ligand A (0.421) has a lower hERG inhibition liability than Ligand B (0.821), which is a significant safety advantage.
12. **Cl_mic:** Ligand A (31.992) has a lower microsomal clearance than Ligand B (58.417), indicating better metabolic stability.
13. **t1/2:** Ligand B (40.524) has a longer in vitro half-life than Ligand A (-24.354). This is a positive for Ligand B, but the negative value for A is concerning.
14. **Pgp:** Ligand A (0.179) has lower P-gp efflux liability than Ligand B (0.871), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand A (-7.2) has a slightly better binding affinity than Ligand B (-6.0). While the difference is less than 1.5 kcal/mol, it contributes to the overall preference for A.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Ligand A performs better on all of these except for half-life. The superior ADME properties (DILI, hERG, Cl_mic, Pgp, QED) of Ligand A outweigh the slightly shorter half-life, especially given the negative half-life value for Ligand A which is likely an artifact of the data.
**Conclusion:**
Ligand A is the more promising drug candidate due to its superior drug-likeness, safety profile (lower DILI and hERG), metabolic stability, and permeability characteristics.
Output:
1
2025-04-17 20:10:42,306 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (353.5) is within the ideal range (200-500). Ligand B (369.4) is also acceptable. No clear advantage.
2. **TPSA:** Ligand A (61.88) is excellent, well below the 140 threshold. Ligand B (136.3) is higher, but still within acceptable limits for oral absorption, though less ideal. Ligand A is better here.
3. **logP:** Ligand A (2.767) is optimal (1-3). Ligand B (-0.392) is too low, potentially hindering membrane permeability. Ligand A is significantly better.
4. **HBD:** Ligand A (1) is good. Ligand B (3) is acceptable, but higher. Ligand A is slightly better.
5. **HBA:** Ligand A (4) is good. Ligand B (7) is higher, potentially impacting permeability. Ligand A is better.
6. **QED:** Both ligands have reasonable QED scores (A: 0.847, B: 0.571), indicating good drug-like properties. Ligand A is better.
7. **DILI:** Ligand A (16.712) has a much lower DILI risk than Ligand B (50.33). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (71.384) shows good BBB penetration. Ligand B (62.233) is lower. Given ADRB2's relevance in cardiovascular disease (and potential for CNS side effects), moderate BBB penetration is acceptable, but Ligand A is preferable.
9. **Caco-2:** Ligand A (-4.513) and Ligand B (-5.498) both have negative Caco-2 values, which is unusual. This suggests poor permeability. However, the values are similar.
10. **Solubility:** Ligand A (-1.542) and Ligand B (-2.617) both have negative solubility values, which is also unusual. This suggests poor solubility. However, the values are similar.
11. **hERG:** Both ligands have very low hERG risk (A: 0.492, B: 0.047). Ligand B is slightly better.
12. **Cl_mic:** Ligand A (34.454) has a lower microsomal clearance than Ligand B (14.891), suggesting better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (8.535) has a longer in vitro half-life than Ligand B (4.653). This is a significant advantage for Ligand A.
14. **Pgp:** Both ligands have very low Pgp efflux liability (A: 0.086, B: 0.032). Ligand B is slightly better.
15. **Affinity:** Both ligands have strong binding affinity (A: -7.0 kcal/mol, B: -6.0 kcal/mol). Ligand A has a 1 kcal/mol advantage, which is substantial and can outweigh some ADME drawbacks.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A excels in logP, TPSA, and affinity. While both have low Pgp efflux, Ligand A also demonstrates better metabolic stability (Cl_mic and t1/2) and a significantly lower DILI risk.
**Conclusion:**
Ligand A is the superior candidate. Its better logP, TPSA, DILI profile, metabolic stability, half-life, and slightly better affinity outweigh the minor advantages of Ligand B in hERG and Pgp.
Output:
1
2025-04-17 20:10:42,307 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [349.333, 66.84, 3.694, 1, 3, 0.828, 78.402, 56.65, -4.478, -3.451, 0.234, 12.726, -9.293, 0.107, -5.0]
**Ligand B:** [362.543, 51.02, 4.066, 0, 5, 0.676, 32.842, 77.549, -4.996, -3.745, 0.624, 106.209, 16.976, 0.504, -6.6]
Here's a breakdown, considering the GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal range (200-500 Da). A is slightly lower, which is generally favorable for permeability.
2. **TPSA:** A (66.84) is higher than B (51.02), but both are reasonably good for oral absorption.
3. **logP:** Both are in the optimal range (1-3), with A at 3.694 and B at 4.066. B is slightly higher, potentially increasing off-target interactions, but not drastically.
4. **HBD/HBA:** A has 1 HBD and 3 HBA, while B has 0 HBD and 5 HBA. A's HBD count is preferable.
5. **QED:** A (0.828) is significantly better than B (0.676), indicating a more drug-like profile.
6. **DILI:** A (78.402) has a higher DILI risk than B (32.842). This is a significant drawback for A.
7. **BBB:** B (77.549) has better BBB penetration than A (56.65). While ADRB2 isn't necessarily a CNS target, some peripheral ADRB2 activity can be influenced by CNS effects, and better BBB penetration can sometimes correlate with better overall distribution.
8. **Caco-2:** Both are negative, indicating poor permeability. B is slightly less negative (-4.996 vs -4.478), suggesting marginally better absorption.
9. **Solubility:** Both are negative, indicating poor solubility. B is slightly less negative (-3.745 vs -3.451), suggesting marginally better solubility.
10. **hERG:** A (0.234) has a lower hERG risk than B (0.624), which is a positive.
11. **Cl_mic:** A (12.726) has significantly lower microsomal clearance than B (106.209), indicating better metabolic stability. This is a major advantage for A.
12. **t1/2:** A (-9.293) has a longer in vitro half-life than B (16.976). This is a significant advantage for A.
13. **Pgp:** A (0.107) has lower P-gp efflux than B (0.504), which is favorable for bioavailability.
14. **Affinity:** B (-6.6 kcal/mol) has a significantly stronger binding affinity than A (-5.0 kcal/mol). This is a substantial advantage for B, potentially outweighing some ADME concerns.
**Overall Assessment:**
While Ligand A has better QED, metabolic stability (Cl_mic, t1/2), Pgp efflux, and hERG risk, the significantly higher DILI risk is a major concern. Ligand B has a much stronger binding affinity, better BBB penetration, and a lower DILI risk. The affinity difference is substantial (>1.5 kcal/mol), and for a GPCR, strong binding is paramount. The slightly higher logP of B is manageable, and its other ADME properties, while not ideal, are not as concerning as A's DILI risk.
Therefore, I would select Ligand B as the more promising drug candidate.
0
2025-04-17 20:10:42,307 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (372.515 and 367.515 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (52.57) is significantly better than Ligand B (82.53). ADRB2 is a cardiovascular target, not CNS, but lower TPSA generally improves absorption. Ligand A is well below the 140 threshold, while B is approaching it.
3. **logP:** Ligand A (4.352) is higher than Ligand B (1.9). While 4.352 is approaching the upper limit, it's still acceptable. Ligand B's 1.9 is on the lower side and could indicate permeability issues.
4. **HBD:** Both ligands have 2 HBD, which is within the acceptable limit of 5.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 5. Both are within the acceptable limit of 10.
6. **QED:** Both ligands have similar QED values (0.676 vs. 0.735), indicating good drug-likeness.
7. **DILI:** Ligand A (68.98) has a higher DILI risk than Ligand B (24.506). This is a significant negative for Ligand A.
8. **BBB:** This is less critical for a cardiovascular target. Ligand A (61.109) is better than Ligand B (39.783), but neither is particularly high.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.927) is slightly better than Ligand B (-5.022), but both are concerning.
10. **Solubility:** Ligand A (-3.553) is better than Ligand B (-0.984). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.771) has a slightly higher hERG risk than Ligand B (0.208). Lower is better here.
12. **Cl_mic:** Ligand A (68.537) has a higher microsomal clearance than Ligand B (15.125), indicating lower metabolic stability. This is a significant negative for Ligand A.
13. **t1/2:** Ligand A (61.875) has a much longer in vitro half-life than Ligand B (2.017). This is a major advantage for Ligand A.
14. **Pgp:** Ligand A (0.737) has lower P-gp efflux than Ligand B (0.167), which is favorable.
15. **Binding Affinity:** Ligand A (-5.7 kcal/mol) has a significantly stronger binding affinity than Ligand B (-3.2 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME drawbacks.
**Overall Assessment:**
Ligand A has a much stronger binding affinity and a longer half-life, both highly desirable characteristics. However, it has concerning DILI and Cl_mic values. Ligand B has a much better safety profile (lower DILI, lower hERG) and better metabolic stability, but its binding affinity is significantly weaker and logP is lower.
Given the importance of potency for GPCRs, and the substantial difference in binding affinity (-5.7 vs -3.2 kcal/mol), I believe Ligand A is the more promising starting point, *despite* its ADME liabilities. The DILI and metabolic stability issues can be addressed through further medicinal chemistry optimization. The weaker binding of Ligand B would likely require more extensive structural modifications to achieve sufficient efficacy.
Output:
1
2025-04-17 20:10:42,307 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (a cardiovascular GPCR) drug candidates.
**Ligand A:** [352.435, 109.74 , 1.202, 1. , 5. , 0.718, 27.879, 72.896, -5.16 , -1.444, 0.172, 36.075, 8.46 , 0.052, -6.4 ]
**Ligand B:** [347.459, 91.32 , 2.537, 3. , 4. , 0.599, 23.226, 26.638, -5.163, -2.742, 0.093, 30.553, -13.671, 0.014, -6. ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). A (352.435) is slightly higher than B (347.459), but both are acceptable.
2. **TPSA:** A (109.74) is slightly above the preferred <140 for good oral absorption, but still reasonable. B (91.32) is excellent, well below 140.
3. **logP:** A (1.202) is optimal (1-3). B (2.537) is also good, but edging towards the higher end of the optimal range.
4. **HBD:** A (1) is good. B (3) is acceptable, but higher HBD can sometimes lead to issues.
5. **HBA:** A (5) is good. B (4) is also good.
6. **QED:** A (0.718) is excellent, indicating high drug-likeness. B (0.599) is acceptable, but lower.
7. **DILI:** A (27.879) is very good, indicating low liver injury risk. B (23.226) is even better.
8. **BBB:** A (72.896) is good, suggesting reasonable potential for some CNS penetration, though not a primary concern for a cardiovascular target. B (26.638) is low, indicating poor BBB penetration.
9. **Caco-2:** Both are negative (-5.16 and -5.163), indicating poor permeability. This is a significant concern for both.
10. **Solubility:** Both are negative (-1.444 and -2.742), indicating poor aqueous solubility. This is a significant concern for both.
11. **hERG:** Both are very low (0.172 and 0.093), indicating very low cardiotoxicity risk. This is excellent for both.
12. **Cl_mic:** A (36.075) is moderate. B (30.553) is lower, suggesting better metabolic stability.
13. **t1/2:** A (8.46) is reasonable. B (-13.671) is very poor, suggesting rapid clearance.
14. **Pgp:** Both are very low (0.052 and 0.014), indicating minimal P-gp efflux.
15. **Affinity:** Both have excellent binding affinity (-6.4 and -6.0 kcal/mol). A is slightly better, but the difference is not huge.
**GPCR-Specific Considerations:**
For ADRB2 (a cardiovascular GPCR), logP, TPSA, and affinity are key. While BBB isn't a primary concern, it's still a bonus.
**Decision:**
Ligand A is slightly preferred. While both have poor Caco-2 and solubility, Ligand A has a better QED score, slightly better affinity, and a more reasonable half-life. The slightly higher TPSA is less concerning than the significantly lower half-life of Ligand B. The lower DILI risk of Ligand B is a plus, but the other factors tip the balance towards A.
Output:
1
2025-04-17 20:10:42,307 - INFO - Here's my reasoning and the final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, prioritizing logP, TPSA, Pgp efflux, and binding affinity is crucial, alongside general drug-like properties.
* **Molecular Weight:** Both ligands (347.46 and 358.44 Da) fall within the ideal 200-500 Da range.
* **TPSA:** Ligand A (84.66) is significantly better than Ligand B (111.21). A TPSA under 140 is good for oral absorption, and Ligand A is closer to the ideal value for GPCRs (<90).
* **logP:** Ligand A (2.775) is within the optimal 1-3 range. Ligand B (-1.831) is quite low, potentially hindering membrane permeability.
* **H-Bond Donors/Acceptors:** Ligand A (2 HBD, 5 HBA) is more favorable than Ligand B (3 HBD, 6 HBA). Both are acceptable, but lower counts generally improve permeability.
* **QED:** Ligand A (0.741) is significantly better than Ligand B (0.447), indicating a more drug-like profile.
* **DILI:** Ligand B (24.234) has a much lower DILI risk than Ligand A (46.413), which is a significant advantage.
* **BBB:** Ligand A (81.776) shows better BBB penetration than Ligand B (41.799), although neither are exceptionally high. For a cardiovascular target, BBB isn't a primary concern, but it's a bonus.
* **Caco-2:** Ligand A (-4.523) and Ligand B (-5.173) both have negative values, which is unusual and difficult to interpret without knowing the scale. However, lower (more negative) values usually indicate lower permeability.
* **Solubility:** Ligand A (-3.508) has better solubility than Ligand B (-0.511).
* **hERG:** Ligand A (0.7) has a lower hERG risk than Ligand B (0.082), which is preferable.
* **Cl_mic:** Ligand B (13.738) has a significantly lower microsomal clearance than Ligand A (80.897), suggesting better metabolic stability.
* **t1/2:** Ligand B (-10.695) has a longer in vitro half-life than Ligand A (-6.328), which is a positive attribute.
* **Pgp:** Ligand A (0.187) has lower P-gp efflux than Ligand B (0.004), which is beneficial for bioavailability.
* **Binding Affinity:** Ligand B (-7.3) has a slightly better binding affinity than Ligand A (-7.0), but the difference is small.
**Overall Assessment:**
Ligand A has better TPSA, logP, QED, solubility, hERG, and Pgp properties. However, Ligand B shines in DILI risk, metabolic stability (Cl_mic), and in vitro half-life. The slightly better affinity of Ligand B is not enough to outweigh the significant advantages of Ligand A regarding permeability (logP, TPSA) and drug-likeness (QED). Given the GPCR target class, optimizing for permeability and drug-like properties is crucial. While DILI and metabolic stability are important, they can be addressed through further optimization.
**Output:**
1
2025-04-17 20:10:42,308 - INFO - Batch 165 complete. Total preferences: 2640
2025-04-17 20:10:42,308 - INFO - Processing batch 166/512...
2025-04-17 20:11:31,163 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (356.491 and 362.495 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (40.62) is significantly better than Ligand B (62.66). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands (2.892 and 3.442) are within the optimal 1-3 range. Ligand B is slightly higher, which *could* be a minor drawback, but not a dealbreaker.
4. **HBD:** Ligand A (0) is preferable to Ligand B (1). Fewer HBDs generally improve membrane permeability.
5. **HBA:** Ligand A (3) is better than Ligand B (5). Lower HBA is generally preferred for permeability.
6. **QED:** Both ligands (0.782 and 0.742) have good drug-likeness scores, exceeding the 0.5 threshold. Ligand A is slightly better.
7. **DILI:** Ligand A (42.846) has a slightly better DILI score than Ligand B (37.922), indicating a lower risk of liver injury. Both are acceptable.
8. **BBB:** Ligand A (83.249) has a significantly higher BBB penetration score than Ligand B (52.811). While not a primary concern for a cardiovascular target, higher BBB is rarely detrimental.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.742 and -4.539). This is unusual and suggests poor permeability. However, the values are very close, so this isn't a major differentiator.
10. **Solubility:** Ligand A (-3.994) is slightly better than Ligand B (-3.406), indicating better aqueous solubility.
11. **hERG:** Ligand A (0.373) has a much lower hERG inhibition liability than Ligand B (0.787), which is a significant advantage regarding cardiotoxicity risk.
12. **Cl_mic:** Ligand B (84.25) has a lower microsomal clearance than Ligand A (98.744), suggesting better metabolic stability. This is a positive for Ligand B.
13. **t1/2:** Ligand B (22.837) has a significantly longer in vitro half-life than Ligand A (-17.867). This is a major advantage for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.367) has a lower P-gp efflux liability than Ligand B (0.749), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand A (-6.2) has a slightly better binding affinity than Ligand B (-5.7). While the difference is less than 1.5 kcal/mol, it contributes to the overall preference.
**Overall Assessment:**
Ligand A demonstrates a more favorable balance of properties, particularly regarding TPSA, HBD, HBA, hERG inhibition, and Pgp efflux. While Ligand B has better metabolic stability (Cl_mic) and a longer half-life, the lower hERG risk and better ADME profile of Ligand A are more critical for a cardiovascular GPCR target. The slightly better binding affinity of Ligand A further supports this decision.
Output:
1
2025-04-17 20:11:31,164 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (382.448 Da) is slightly higher than Ligand B (354.42 Da), but both are acceptable.
2. **TPSA:** Ligand A (67.43) is higher than Ligand B (44.81). Both are below 140, but B is better for absorption.
3. **logP:** Ligand A (2.971) is within the optimal range (1-3). Ligand B (4.519) is a bit high, potentially leading to solubility issues and off-target effects.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable, well below the limit of 5.
5. **HBA:** Ligand A (4) and Ligand B (3) are both acceptable, below the limit of 10.
6. **QED:** Ligand B (0.758) has a better QED score than Ligand A (0.346), indicating a more drug-like profile.
7. **DILI:** Ligand B (34.471) has a lower DILI risk than Ligand A (43.622), which is preferable.
8. **BBB:** Both ligands have good BBB penetration (Ligand A: 87.321, Ligand B: 80.031). This is important for GPCR targets, though less critical for ADRB2 specifically as it's primarily cardiovascular.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-5.394) is slightly worse than Ligand B (-4.932).
10. **Solubility:** Both ligands have very poor aqueous solubility (Ligand A: -3.518, Ligand B: -4.189). This is a significant concern.
11. **hERG:** Ligand A (0.609) has a lower hERG risk than Ligand B (0.948), which is preferable.
12. **Cl_mic:** Ligand B (25.453) has a lower microsomal clearance than Ligand A (29.761), indicating better metabolic stability.
13. **t1/2:** Ligand B (12.777) has a significantly longer in vitro half-life than Ligand A (3.265), which is a major advantage.
14. **Pgp:** Ligand A (0.148) has lower P-gp efflux than Ligand B (0.319), which is preferable.
15. **Binding Affinity:** Ligand B (-6.1 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.5 kcal/mol). This is a crucial factor, and the 1.6 kcal/mol difference is substantial.
**Overall Assessment:**
While Ligand A has a slightly better logP and Pgp profile, Ligand B wins on several critical parameters. The significantly stronger binding affinity (-6.1 vs -5.5 kcal/mol) is a major advantage. Additionally, Ligand B has a better QED score, lower DILI risk, and a much longer half-life. Although both have poor solubility and Caco-2 permeability, the superior affinity and metabolic stability of Ligand B outweigh these drawbacks. The slightly higher logP is a concern, but potentially manageable with formulation strategies.
Output:
0
2025-04-17 20:11:31,164 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (346.471 and 348.447 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (49.85) is significantly better than Ligand B (88.76). ADRB2 is a cardiovascular target, not CNS, but lower TPSA generally aids absorption. Ligand A is well below the 140 threshold, while B is approaching it.
3. **logP:** Both ligands have acceptable logP values (2.482 and 1.399), falling within the 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability, but not drastically.
4. **HBD:** Ligand A (0) is preferable to Ligand B (1). Fewer hydrogen bond donors generally improve permeability.
5. **HBA:** Ligand A (3) is better than Ligand B (5). Similar to HBD, lower HBA is generally preferred.
6. **QED:** Both ligands have good QED scores (0.786 and 0.869), indicating good drug-like properties. No clear advantage.
7. **DILI:** Ligand A (17.642) has a much lower DILI risk than Ligand B (38.852). This is a significant advantage for Ligand A.
8. **BBB:** Both have high BBB penetration, but Ligand A (84.141) is slightly higher than Ligand B (78.209). While not a primary concern for a cardiovascular target, higher BBB is never a detriment.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.605 and -4.926). These values are difficult to interpret without knowing the scale, but they suggest poor permeability.
10. **Solubility:** Ligand A (-2.21) is better than Ligand B (-0.708). Higher solubility is desirable.
11. **hERG:** Both ligands have low hERG inhibition risk (0.283 and 0.396). No significant difference.
12. **Cl_mic:** Ligand A (29.196) has a higher microsomal clearance than Ligand B (0.917), indicating faster metabolism and potentially lower *in vivo* exposure. This is a significant disadvantage for Ligand A.
13. **t1/2:** Ligand B (12.775) has a longer *in vitro* half-life than Ligand A (11.642). This is preferable.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.11 and 0.015). No significant difference.
15. **Binding Affinity:** Ligand A (-7.4) has a slightly better binding affinity than Ligand B (-7.3). While the difference is small (0.1 kcal/mol), it could be meaningful.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, and affinity are important. Ligand A has a better logP and TPSA, and slightly better affinity. However, the significantly lower DILI risk and better solubility of Ligand A are also important factors. The biggest drawback of Ligand A is its higher Cl_mic. However, the small advantage in binding affinity and the more favorable ADME properties (DILI, solubility, TPSA) outweigh the slightly higher metabolic clearance.
**Conclusion:**
Considering the balance of properties, Ligand A appears to be the more promising drug candidate.
Output:
1
2025-04-17 20:11:31,164 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A: [376.503, 66.48, 2.276, 1, 4, 0.786, 72.199, 43.815, -5.156, -4.187, 0.371, 70.473, -45.367, 0.29, -6.4]**
**Ligand B: [352.475, 81.08, 1.004, 2, 4, 0.791, 10.12, 65.839, -4.612, -2.477, 0.24, 31.604, -4.958, 0.016, -5.7]**
Here's a breakdown of the comparison, considering the guidelines and GPCR-specific priorities:
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (352.475) is slightly lower, which could be advantageous for permeability, but both are acceptable.
2. **TPSA:** Ligand A (66.48) is better than Ligand B (81.08). GPCRs benefit from lower TPSA for better BBB penetration and oral absorption. Ligand A is comfortably under 140, while B is approaching the upper limit.
3. **logP:** Ligand A (2.276) is optimal, while Ligand B (1.004) is a bit low. A logP between 1-3 is preferred, and Ligand A is closer to the sweet spot. Lower logP can sometimes indicate poor membrane permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Both have 4 HBA, which is acceptable.
6. **QED:** Both have similar QED scores (0.786 and 0.791), indicating good drug-likeness.
7. **DILI:** Ligand A (72.199) has a considerably higher DILI risk than Ligand B (10.12). This is a major concern for Ligand A.
8. **BBB:** Ligand B (65.839) has better BBB penetration potential than Ligand A (43.815). While not a primary concern for a cardiovascular target, it's still a positive attribute.
9. **Caco-2:** Ligand A (-5.156) has a more negative Caco-2 value, indicating *lower* permeability, while Ligand B (-4.612) is slightly better.
10. **Solubility:** Ligand B (-2.477) has better aqueous solubility than Ligand A (-4.187).
11. **hERG:** Both have low hERG risk (0.371 and 0.24).
12. **Cl_mic:** Ligand B (31.604) has significantly lower microsomal clearance than Ligand A (70.473), indicating better metabolic stability.
13. **t1/2:** Ligand B (-4.958) has a slightly better (less negative) in vitro half-life than Ligand A (-45.367).
14. **Pgp:** Ligand A (0.29) has slightly lower P-gp efflux than Ligand B (0.016), which is favorable.
15. **Affinity:** Ligand A (-6.4) has a slightly better binding affinity than Ligand B (-5.7). However, the difference is not substantial enough to outweigh the other significant drawbacks of Ligand A.
**Overall Assessment:**
Ligand A has a slightly better binding affinity and lower P-gp efflux, but it is significantly hampered by a high DILI risk, poor permeability (Caco-2), and lower metabolic stability (higher Cl_mic). Ligand B, while having a slightly weaker binding affinity, presents a much more favorable ADMET profile, with significantly lower DILI risk, better solubility, permeability, and metabolic stability. For a cardiovascular GPCR, a good safety profile and reasonable ADME properties are crucial.
Therefore, I would choose Ligand B.
Output:
0
2025-04-17 20:11:31,164 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (340.39) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (92.49) is higher than Ligand B (63.17). For a cardiovascular GPCR, TPSA isn't a *major* concern unless aiming for CNS penetration, but lower is generally preferred for oral absorption. Ligand B is significantly better here.
3. **logP:** Ligand A (0.966) is a bit low, potentially hindering membrane permeability. Ligand B (2.579) is within the optimal range (1-3). This favors Ligand B.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Both have 6 HBA, also good.
6. **QED:** Both ligands have acceptable QED values (A: 0.661, B: 0.717), indicating reasonable drug-likeness. Ligand B is slightly better.
7. **DILI:** Ligand A (77.084) has a higher DILI risk than Ligand B (51.493). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (67.041) has lower BBB penetration than Ligand B (94.649). Since ADRB2 is primarily a cardiovascular target, high BBB penetration isn't critical, but it doesn't hurt.
9. **Caco-2:** Ligand A (-5.186) and Ligand B (-4.778) both have negative values, which is unusual and suggests poor permeability. However, the scale isn't specified, so it's hard to interpret.
10. **Solubility:** Ligand A (-2.531) has worse solubility than Ligand B (-4.082). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.193) has a slightly lower hERG risk than Ligand B (0.694), which is a positive.
12. **Cl_mic:** Ligand A (19.174) has significantly lower microsomal clearance than Ligand B (42.402), indicating better metabolic stability. This is a major advantage for Ligand A.
13. **t1/2:** Ligand A (10.365) has a shorter in vitro half-life than Ligand B (-2.012). The negative value for B is concerning and likely an error, making A better here.
14. **Pgp:** Ligand A (0.133) has lower P-gp efflux than Ligand B (0.041). Lower P-gp efflux is generally preferred.
15. **Affinity:** Ligand B (-6.8 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.0 kcal/mol). This is a substantial advantage, potentially outweighing some ADME concerns.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP, TPSA, and affinity. Ligand A has better Pgp efflux and Cl_mic. The affinity difference is substantial (1.8 kcal/mol), and the DILI risk is lower for Ligand B.
**Overall Assessment:**
While Ligand A has advantages in metabolic stability and Pgp efflux, the significantly stronger binding affinity of Ligand B, coupled with its better logP, TPSA, and lower DILI risk, makes it the more promising candidate. The solubility and Caco-2 values are concerning for both, but the affinity difference is a major driver.
Output:
0
2025-04-17 20:11:31,164 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (353.438 and 345.443 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (63.57) is better than Ligand B (78.51). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally favors absorption.
3. **logP:** Both ligands have similar logP values (1.439 and 1.488), falling within the optimal 1-3 range.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD is generally better for permeability.
5. **HBA:** Ligand A (4) is preferable to Ligand B (3). Lower HBA is generally better for permeability.
6. **QED:** Both ligands have similar QED values (0.769 and 0.749), indicating good drug-likeness.
7. **DILI:** Ligand A (19.504) is significantly better than Ligand B (35.789). Lower DILI risk is crucial.
8. **BBB:** Ligand A (85.343) is better than Ligand B (63.784). While not a CNS target, some degree of BBB penetration can influence off-target effects and distribution.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.735 and -4.768), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand A (-1.987) is slightly better than Ligand B (-2.588), but both are quite poor. This is a significant drawback for both.
11. **hERG:** Ligand A (0.423) is better than Ligand B (0.12). Lower hERG inhibition is crucial for avoiding cardiotoxicity, especially important for a cardiovascular target.
12. **Cl_mic:** Ligand A (8.055) is significantly better than Ligand B (42.506). Lower clearance indicates better metabolic stability.
13. **t1/2:** Ligand A (8.897) is better than Ligand B (-4.316). Longer half-life is generally preferred.
14. **Pgp:** Ligand A (0.124) is better than Ligand B (0.049). Lower P-gp efflux is preferable.
15. **Binding Affinity:** Ligand B (-7.8) has a significantly stronger binding affinity than Ligand A (-5.8). This is a 2 kcal/mol difference, which is substantial.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. While both ligands have acceptable logP, Ligand A has better TPSA and Pgp. However, Ligand B's significantly stronger binding affinity (-7.8 vs -5.8) is a major advantage that can potentially outweigh the ADME drawbacks. The lower DILI and hERG risk of Ligand A are also very important.
**Overall Assessment:**
Despite the superior affinity of Ligand B, the significantly worse DILI, hERG, and clearance profiles of Ligand B are concerning. The poor solubility and Caco-2 values are also problematic for both. However, the substantial affinity difference of Ligand B is compelling. Considering the cardiovascular context, the lower hERG and DILI risk of Ligand A are more important than the affinity difference.
**Output:**
1
2025-04-17 20:11:31,165 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (376.482 and 370.49 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Both ligands (67.77 and 66.48) are below the 140 A^2 threshold for good absorption. They are also reasonably low, which is favorable for GPCR ligands. No significant difference.
3. **logP:** Ligand A (4.19) is higher than Ligand B (1.939). While 4.19 is approaching the upper limit, it's not drastically high. Ligand B is well within the optimal range. This favors Ligand B slightly.
4. **HBD:** Both have 1 HBD, which is good. No difference.
5. **HBA:** Ligand A has 6 HBA, and Ligand B has 4 HBA. Both are within the acceptable range of <=10. Ligand B is slightly better.
6. **QED:** Ligand B (0.777) has a significantly better QED score than Ligand A (0.42), indicating a more drug-like profile. This is a substantial advantage for Ligand B.
7. **DILI:** Ligand A (85.692) has a much higher DILI risk than Ligand B (39.124). This is a major concern for Ligand A. Ligand B is clearly preferred here.
8. **BBB:** Both ligands have good BBB penetration (76.735 and 81.698). No significant difference.
9. **Caco-2:** Both have negative Caco-2 values (-5.125 and -4.932), which is unusual and suggests poor permeability. However, the values are similar.
10. **Solubility:** Ligand A (-4.333) has worse solubility than Ligand B (-2.822). This favors Ligand B.
11. **hERG:** Both ligands have relatively low hERG inhibition risk (0.42 and 0.632). No significant difference.
12. **Cl_mic:** Ligand A (96.162) has a much higher microsomal clearance than Ligand B (39.037), indicating lower metabolic stability. This is a significant disadvantage for Ligand A.
13. **t1/2:** Ligand A (61.265) has a longer in vitro half-life than Ligand B (16.995). This is a positive for Ligand A, but it's likely offset by the high clearance.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.389 and 0.244). No significant difference.
15. **Binding Affinity:** Both ligands have the same binding affinity (-7.5 kcal/mol), which is excellent.
**Overall Assessment:**
Ligand B is significantly better overall. While Ligand A has a slightly longer half-life, it is overshadowed by its high DILI risk, high microsomal clearance, and lower QED and solubility. Ligand B has a much more favorable safety profile (lower DILI), better predicted ADME properties (lower clearance, better solubility, better QED), and comparable binding affinity. Given the GPCR target class, the balance of properties in Ligand B is more likely to translate to a viable drug candidate.
Output:
0
2025-04-17 20:11:31,165 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.47 & 355.44 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (83.36) is better than Ligand B (96.97). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is still preferred for absorption.
3. **logP:** Ligand A (0.504) is slightly lower than optimal (1-3), but still acceptable. Ligand B (-0.188) is quite low, potentially hindering membrane permeability. This is a significant negative for Ligand B.
4. **HBD:** Ligand A (1) is good. Ligand B (2) is also acceptable, but slightly less favorable.
5. **HBA:** Ligand A (6) is good. Ligand B (5) is also good.
6. **QED:** Both ligands have reasonable QED scores (0.738 and 0.629), indicating good drug-like properties.
7. **DILI:** Both ligands have acceptable DILI risk (30.79 and 41.64), below the 60% threshold. Ligand A is slightly better.
8. **BBB:** Ligand A (40.52) is lower than Ligand B (58.09). Since ADRB2 is not a CNS target, this is not a major concern.
9. **Caco-2:** Ligand A (-5.481) and Ligand B (-4.938) are both negative, which is unusual and suggests poor permeability. However, the scale isn't specified, so it's hard to interpret the absolute impact.
10. **Solubility:** Ligand A (-0.731) and Ligand B (-1.481) are both negative, suggesting poor solubility. Ligand B is worse.
11. **hERG:** Both ligands have very low hERG risk (0.101 and 0.062), which is excellent.
12. **Cl_mic:** Ligand A (1.694) has a lower (better) microsomal clearance than Ligand B (-2.885). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (3.415) has a slightly longer in vitro half-life than Ligand B (3.165).
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.005 and 0.008).
15. **Binding Affinity:** Ligand B (-6.8 kcal/mol) has a significantly stronger binding affinity than Ligand A (-4.9 kcal/mol). This is a 1.9 kcal/mol difference, which is substantial and could outweigh some ADME drawbacks.
**GPCR-specific priorities:**
For ADRB2 (a cardiovascular GPCR), logP, TPSA, and affinity are most important. Ligand B has a better affinity, but a significantly worse logP. The lower logP of Ligand B is concerning for permeability and bioavailability. While the affinity difference is large, the poor logP and solubility of Ligand B are substantial drawbacks. Ligand A, while having a weaker affinity, has a more balanced profile.
**Conclusion:**
Considering the balance of properties, and the importance of permeability for a peripherally acting GPCR, Ligand A is the more promising candidate. The stronger binding affinity of Ligand B is tempting, but the poor logP and solubility raise significant concerns about its developability.
Output:
1
2025-04-17 20:11:31,165 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (338.371 and 353.463 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (93.96) is slightly higher than Ligand B (87.74), but both are below the 140 threshold for good oral absorption and acceptable for a cardiovascular GPCR. Ligand B is preferable.
3. **logP:** Ligand A (1.721) is within the optimal 1-3 range. Ligand B (0.681) is a bit low, potentially impacting permeability. Ligand A is preferable.
4. **HBD:** Both ligands have 2 HBD, which is within the acceptable limit of <=5. No difference.
5. **HBA:** Ligand A has 6 HBA, and Ligand B has 5. Both are within the acceptable limit of <=10. Ligand B is slightly preferable.
6. **QED:** Both ligands have similar QED values (0.755 and 0.686), indicating good drug-likeness. No significant difference.
7. **DILI:** Ligand A has a DILI risk of 82.668, which is concerning (high risk). Ligand B has a much lower DILI risk of 13.067 (good). This is a *major* advantage for Ligand B.
8. **BBB:** Ligand A (73.013) has a better BBB penetration percentile than Ligand B (59.015). However, since ADRB2 is a cardiovascular target, BBB penetration is not a high priority.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.421 and -5.0), which is unusual and suggests poor permeability. This is a significant drawback for both.
10. **Solubility:** Ligand A (-2.59) has slightly better solubility than Ligand B (-1.017), but both are quite poor.
11. **hERG:** Ligand A (0.106) has a lower hERG inhibition liability than Ligand B (0.194), which is preferable.
12. **Cl_mic:** Ligand A (2.412) has a lower microsomal clearance than Ligand B (3.446), suggesting better metabolic stability. This is a positive for Ligand A.
13. **t1/2:** Ligand A (56.379) has a significantly longer in vitro half-life than Ligand B (-15.678). This is a major advantage for Ligand A.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.04 and 0.009). No significant difference.
15. **Binding Affinity:** Ligand A (-7.2 kcal/mol) has a significantly stronger binding affinity than Ligand B (-3.8 kcal/mol). This is a *substantial* advantage for Ligand A, potentially outweighing some of its ADME drawbacks.
**Overall Assessment:**
While Ligand A has some ADME liabilities (poor solubility, concerning DILI), its *much* stronger binding affinity (-7.2 vs -3.8 kcal/mol) and longer half-life are compelling. The DILI risk for Ligand A is a serious concern, but the large affinity difference could allow for a lower dose, potentially mitigating the DILI risk. Ligand B has a better safety profile (DILI), but its significantly weaker binding affinity makes it less likely to be effective. Considering the GPCR-specific priorities (affinity is key), and the potential to mitigate the DILI risk with dose optimization, Ligand A is the more promising candidate.
Output:
1
2025-04-17 20:11:31,165 - INFO - Here's my reasoning and the final output:
**Reasoning:**
We are evaluating two ligands for their potential as drug candidates targeting the ADRB2, a cardiovascular GPCR. Therefore, we prioritize logP, Pgp, TPSA, and affinity, alongside general drug-like properties.
**Ligand A:**
* **MW:** 338.415 Da - Good, within the ideal range.
* **TPSA:** 68.32 A2 - Excellent, well below the 140 A2 threshold.
* **logP:** 2.725 - Excellent, within the optimal 1-3 range.
* **HBD:** 0 - Acceptable, low.
* **HBA:** 6 - Acceptable, within the limit.
* **QED:** 0.648 - Good, above the 0.5 threshold.
* **DILI:** 56.689 - Acceptable, below the 60% risk threshold.
* **BBB:** 68.554 - Moderate, not ideal for CNS but acceptable for a cardiovascular target.
* **Caco-2:** -4.883 - Poor, suggests limited absorption.
* **Solubility:** -3.041 - Poor, suggests low solubility.
* **hERG:** 0.454 - Low risk, good.
* **Cl_mic:** 76.711 - Moderate, suggests moderate metabolic clearance.
* **t1/2:** 49.582 - Good, reasonable in vitro half-life.
* **Pgp:** 0.161 - Low efflux, good.
* **Affinity:** -6.0 kcal/mol - Good binding affinity.
**Ligand B:**
* **MW:** 399.969 Da - Good, within the ideal range.
* **TPSA:** 62.3 A2 - Excellent, well below the 140 A2 threshold.
* **logP:** 3.193 - Excellent, within the optimal 1-3 range.
* **HBD:** 1 - Acceptable, low.
* **HBA:** 5 - Acceptable, within the limit.
* **QED:** 0.825 - Very Good, strong drug-like profile.
* **DILI:** 56.689 - Acceptable, below the 60% risk threshold.
* **BBB:** 61.264 - Moderate, not ideal for CNS but acceptable for a cardiovascular target.
* **Caco-2:** -5.324 - Poor, suggests limited absorption.
* **Solubility:** -4.5 - Poor, suggests low solubility.
* **hERG:** 0.41 - Low risk, good.
* **Cl_mic:** 32.039 - Very Good, low metabolic clearance.
* **t1/2:** 0.033 - Very Poor, extremely short half-life.
* **Pgp:** 0.271 - Low efflux, good.
* **Affinity:** -3.7 kcal/mol - Moderate binding affinity.
**Comparison & Decision:**
Both ligands have acceptable DILI, low hERG risk, and low Pgp efflux. Both have poor Caco-2 permeability and solubility. Ligand A has a better affinity (-6.0 vs -3.7 kcal/mol). Ligand B has a better QED and significantly better metabolic stability (lower Cl_mic). However, the extremely short half-life of Ligand B is a major drawback. While metabolic stability is important, a half-life of 0.033 hours is impractical. The 2.3 kcal/mol difference in binding affinity for Ligand A is substantial enough to outweigh its moderate metabolic clearance.
Therefore, I prefer Ligand A.
**Output:**
1
2025-04-17 20:11:31,165 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.439 and 341.411 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (99.27) is higher than Ligand B (71.53). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B has a clear advantage.
3. **logP:** Ligand A (-0.607) is lower than the optimal 1-3 range, potentially hindering permeability. Ligand B (2.049) is within the optimal range. Ligand B is significantly better.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable, below the threshold of 5. Ligand B is slightly better.
5. **HBA:** Ligand A (7) and Ligand B (5) are both acceptable, below the threshold of 10. Ligand B is better.
6. **QED:** Both ligands have good QED scores (0.748 and 0.781), indicating good drug-like properties. No significant difference.
7. **DILI:** Ligand A (21.908) has a much lower DILI risk than Ligand B (39.434). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (49.826) has a lower BBB penetration than Ligand B (80.38). While ADRB2 is not a CNS target, some distribution to the CNS can lead to off-target effects. Ligand B is better.
9. **Caco-2:** Ligand A (-5.623) has a very poor Caco-2 permeability, suggesting poor absorption. Ligand B (-4.325) is better, but still not ideal.
10. **Solubility:** Ligand A (-0.321) has slightly better solubility than Ligand B (-2.706).
11. **hERG:** Both ligands have very low hERG inhibition risk (0.202 and 0.201). No significant difference.
12. **Cl_mic:** Ligand A (-18.732) has a much lower (better) microsomal clearance than Ligand B (82.663), indicating better metabolic stability. This is a major advantage for Ligand A.
13. **t1/2:** Ligand A (-0.196) has a very short in vitro half-life, while Ligand B (30.817) has a much longer half-life. This is a significant advantage for Ligand B.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.011 and 0.032). No significant difference.
15. **Binding Affinity:** Both ligands have comparable binding affinities (-7.0 and -6.9 kcal/mol).
**GPCR-Specific Priorities & Overall Assessment:**
For ADRB2 (a cardiovascular GPCR), logP, TPSA, and affinity are key. Ligand B excels in logP and TPSA, while the affinities are comparable. However, Ligand A has a significantly better DILI score and much better metabolic stability (Cl_mic). The poor Caco-2 permeability and short half-life of Ligand A are concerning, but the improved metabolic stability and reduced liver toxicity are important considerations. Ligand B's longer half-life is a plus, but the higher DILI risk and less favorable logP are drawbacks.
Considering the balance, the lower DILI risk and improved metabolic stability of Ligand A are more critical for a cardiovascular drug candidate. While the permeability issues are a concern, these can potentially be addressed through formulation strategies.
Output:
1
2025-04-17 20:11:31,165 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (352.479) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (64.17) is significantly better than Ligand B (74.13). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally improves absorption.
3. **logP:** Ligand B (3.225) is better than Ligand A (0.112). A logP between 1-3 is optimal, and Ligand A is quite low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (0) is preferable to Ligand B (1). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is preferable to Ligand B (5). Fewer HBAs generally improve permeability.
6. **QED:** Both are very similar and acceptable (A: 0.659, B: 0.669).
7. **DILI:** Ligand A (7.716) is *much* better than Ligand B (32.299). This is a significant advantage for Ligand A. Lower DILI is crucial.
8. **BBB:** Both are reasonably high (A: 79.411, B: 73.943), but not critical for a cardiovascular target.
9. **Caco-2:** Ligand A (-4.586) is better than Ligand B (-5.078), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-0.318) is better than Ligand B (-3.828). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.221) is better than Ligand B (0.442). Lower hERG inhibition is vital for cardiac safety.
12. **Cl_mic:** Ligand A (0.036) is *much* better than Ligand B (60.539). Lower clearance means greater metabolic stability.
13. **t1/2:** Ligand A (-28.879) is better than Ligand B (-4.117). Longer half-life is generally preferred.
14. **Pgp:** Ligand A (0.007) is significantly better than Ligand B (0.074). Lower P-gp efflux improves bioavailability.
15. **Binding Affinity:** Ligand B (-7.4) is slightly better than Ligand A (-6.3). While affinity is important, the difference of 1.1 kcal/mol is not enough to outweigh the substantial ADME advantages of Ligand A.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand B has a better logP and affinity, but Ligand A excels in TPSA and Pgp. The significant improvements in ADME properties (DILI, Cl_mic, t1/2, solubility, hERG, Pgp) for Ligand A are more compelling, especially considering the modest affinity difference.
**Conclusion:**
Ligand A demonstrates a far superior overall profile, particularly regarding safety (DILI, hERG) and pharmacokinetic properties (Cl_mic, t1/2, solubility, Pgp). While Ligand B has slightly better affinity and logP, the ADME advantages of Ligand A are too significant to ignore.
Output:
1
2025-04-17 20:11:31,166 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Ligand A (381.82 Da) is within the ideal range (200-500). Ligand B (351.447 Da) is also good. No clear advantage.
2. **TPSA:** Ligand A (84.15) is excellent, well below the 140 threshold. Ligand B (103.94) is still acceptable, but less optimal. Advantage: A.
3. **logP:** Ligand A (3.883) is at the upper end of the optimal range (1-3), but still acceptable. Ligand B (0.278) is quite low, potentially causing permeability issues. Significant advantage: A.
4. **HBD:** Ligand A (1) is good. Ligand B (2) is also acceptable. No clear advantage.
5. **HBA:** Ligand A (6) is good. Ligand B (4) is also good. No clear advantage.
6. **QED:** Both ligands have reasonable QED scores (A: 0.728, B: 0.643), indicating good drug-likeness. No clear advantage.
7. **DILI:** Ligand A (98.604) has a very high DILI risk, which is a major concern. Ligand B (15.859) has a very low DILI risk, a significant advantage. Advantage: B.
8. **BBB:** Ligand A (89.531) has good BBB penetration. Ligand B (56.029) is lower, but not critically low for a non-CNS target like ADRB2. Advantage: A.
9. **Caco-2:** Ligand A (-4.675) and Ligand B (-5.162) are both negative, which is unusual and suggests poor permeability. However, the scale isn't specified, so it's hard to interpret.
10. **Solubility:** Ligand A (-5.208) and Ligand B (-1.365) are both negative, suggesting poor solubility. Again, the scale is unclear.
11. **hERG:** Ligand A (0.48) has a slightly higher hERG risk than Ligand B (0.18), but both are relatively low. Advantage: B.
12. **Cl_mic:** Ligand A (36.675) has a higher microsomal clearance than Ligand B (15.172), indicating lower metabolic stability. Advantage: B.
13. **t1/2:** Ligand A (22.049) has a longer half-life than Ligand B (-1.64), which is a significant advantage. Advantage: A.
14. **Pgp:** Ligand A (0.376) has lower P-gp efflux than Ligand B (0.016), which is favorable. Advantage: A.
15. **Affinity:** Ligand A (-7.2 kcal/mol) has a slightly better binding affinity than Ligand B (-6.9 kcal/mol), but the difference is not huge. Advantage: A.
**Overall Assessment:**
Considering ADRB2 is a GPCR, logP, TPSA, and affinity are important. Ligand A excels in these areas, and also has a better half-life and Pgp profile. However, the extremely high DILI risk associated with Ligand A is a major red flag. Ligand B, while having a lower logP and BBB penetration, has a much more favorable safety profile (low DILI, low hERG) and better metabolic stability. The slightly weaker binding affinity of Ligand B is a concern, but the safety advantages outweigh this.
Therefore, I would prioritize Ligand B due to the significantly lower DILI and hERG risk, and acceptable metabolic stability.
Output:
0
2025-04-17 20:11:31,166 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, prioritizing logP, TPSA, Pgp, and binding affinity is crucial.
* **Molecular Weight:** Both ligands (366.491 and 370.43 Da) fall within the ideal 200-500 Da range.
* **TPSA:** Ligand A (81.67) is slightly higher than Ligand B (75.71), but both are comfortably below the 140 A^2 threshold for good oral absorption.
* **logP:** Ligand A (-0.249) is significantly lower than the optimal 1-3 range, potentially hindering permeability. Ligand B (2.233) is within the desired range. This is a major advantage for Ligand B.
* **H-Bond Donors/Acceptors:** Both have acceptable HBD (1) and HBA counts (7 for A, 4 for B)
* **QED:** Both ligands have similar, good QED values (0.795 and 0.753).
* **DILI:** Ligand A (37.767) has a higher DILI risk than Ligand B (23.226), which is preferable.
* **BBB:** Ligand A (67.623) has a better BBB penetration percentile than Ligand B (56.029), but BBB is less critical for a cardiovascular target.
* **Caco-2:** Both ligands have similar, very poor Caco-2 permeability (-5.075 and -4.967).
* **Solubility:** Both ligands have poor aqueous solubility (-1.554 and -1.113).
* **hERG:** Both ligands have low hERG inhibition liability (0.273 and 0.124).
* **Cl_mic:** Ligand A (-4.01) has a more negative value, indicating lower microsomal clearance and thus better metabolic stability than Ligand B (7.208).
* **t1/2:** Ligand A (3.456) has a slightly longer in vitro half-life than Ligand B (3.155).
* **Pgp:** Ligand A (0.067) has lower P-gp efflux liability than Ligand B (0.045), which is favorable.
* **Binding Affinity:** Ligand B (-7.5 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.7 kcal/mol). This 0.8 kcal/mol difference is substantial and can outweigh some ADME drawbacks.
**Conclusion:**
While Ligand A has better metabolic stability and Pgp efflux, Ligand B's superior logP and significantly improved binding affinity are more critical for a GPCR target like ADRB2. The lower DILI risk of Ligand B is also a positive factor. The poor Caco-2 and solubility are concerns for both, but can be addressed through formulation strategies. The stronger binding affinity of Ligand B is the deciding factor.
**Output:**
0
2025-04-17 20:11:31,166 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (493.221 Da) is at the upper end of the ideal range, while Ligand B (374.794 Da) is well within it. This favors Ligand B.
2. **TPSA:** Ligand A (93.45) is acceptable, though approaching the upper limit for good oral absorption. Ligand B (59.07) is excellent. This strongly favors Ligand B.
3. **logP:** Both ligands have logP values (3.331 and 4.64) within the optimal range, but Ligand B is slightly higher. While higher logP can sometimes be problematic, it's not a major concern here.
4. **HBD:** Ligand A (3) and Ligand B (2) are both acceptable.
5. **HBA:** Both ligands have 5 HBA, which is good.
6. **QED:** Ligand B (0.739) has a significantly better QED score than Ligand A (0.388), indicating a more drug-like profile. This favors Ligand B.
7. **DILI:** Both ligands have relatively high DILI risk (75.339 and 69.833), but these are percentile scores and a direct comparison is difficult without knowing the distribution of values in the dataset.
8. **BBB:** Both ligands have similar BBB penetration (61.923 and 63.125). Since ADRB2 is a cardiovascular target, BBB penetration is not a primary concern.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. This is a significant drawback for both.
10. **Solubility:** Both ligands have negative solubility values, which is also unusual and suggests poor solubility. This is a significant drawback for both.
11. **hERG:** Both ligands have low hERG inhibition liability (0.853 and 0.689), which is good.
12. **Cl_mic:** Ligand B (56.329) has a slightly lower microsomal clearance than Ligand A (59.788), suggesting better metabolic stability. This favors Ligand B.
13. **t1/2:** Ligand B (22.627 hours) has a significantly longer in vitro half-life than Ligand A (10.322 hours). This is a major advantage for Ligand B.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.326 and 0.172).
15. **Affinity:** Ligand A (-6.5 kcal/mol) has a significantly stronger binding affinity than Ligand B (-3.4 kcal/mol). This is a substantial advantage for Ligand A.
**Overall Assessment:**
While Ligand A has a much better binding affinity, Ligand B has a superior profile across most other ADME-Tox properties. The significantly better QED, lower Cl_mic, and longer half-life of Ligand B are compelling. The poor Caco-2 and solubility values are concerning for both, but the stronger affinity of Ligand A might be able to overcome these issues. However, given the GPCR-specific priorities (logP, Pgp, TPSA, affinity), and the substantial advantages of Ligand B in terms of drug-likeness and metabolic stability, I believe Ligand B is the more promising candidate, *assuming* the solubility and permeability issues can be addressed through formulation or structural modifications. The affinity difference, while significant, isn't so large that it completely overshadows the other benefits of Ligand B.
Output:
0
2025-04-17 20:11:31,166 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [355.479, 79.9, 1.517, 2, 5, 0.782, 20.861, 72.431, -4.61, -1.88, 0.389, 21.082, -13.613, 0.015, -6.7]
**Ligand B:** [370.475, 94.48, 0.193, 2, 7, 0.571, 60.915, 60.023, -5.622, -2.149, 0.185, 18.958, 20.968, 0.021, -6.7]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, BBB, affinity):
1. **MW:** Both are within the acceptable 200-500 Da range. Ligand A (355.479) is slightly preferred.
2. **TPSA:** Ligand A (79.9) is better than Ligand B (94.48), both are under 140, but A is closer to the ideal for good absorption.
3. **logP:** Ligand A (1.517) is within the optimal 1-3 range. Ligand B (0.193) is quite low, which could hinder membrane permeability. This is a significant drawback for Ligand B.
4. **HBD/HBA:** Both have 2 HBD and are within acceptable limits. Ligand B has 7 HBA, slightly higher than A's 5, but both are acceptable.
5. **QED:** Ligand A (0.782) has a better QED score than Ligand B (0.571), indicating better overall drug-likeness.
6. **DILI:** Ligand A (20.861) has a much lower DILI risk than Ligand B (60.915). This is a major advantage for Ligand A.
7. **BBB:** Ligand A (72.431) has a significantly better BBB penetration score than Ligand B (60.023). While ADRB2 isn't exclusively a CNS target, some peripheral effects are mediated by CNS pathways, and better BBB penetration isn't a negative.
8. **Caco-2:** Ligand A (-4.61) is better than Ligand B (-5.622), indicating better intestinal absorption.
9. **Solubility:** Ligand A (-1.88) is better than Ligand B (-2.149).
10. **hERG:** Both are very low (0.389 and 0.185), indicating minimal hERG inhibition risk.
11. **Cl_mic:** Ligand B (18.958) has a lower microsomal clearance than Ligand A (21.082), suggesting better metabolic stability.
12. **t1/2:** Ligand B (20.968) has a longer in vitro half-life than Ligand A (-13.613). This is a positive for Ligand B.
13. **Pgp:** Both are very low (0.015 and 0.021), indicating minimal P-gp efflux liability.
14. **Affinity:** Both have the same binding affinity (-6.7 kcal/mol).
**Overall Assessment:**
Ligand A is significantly better overall. While Ligand B has a slightly better half-life and lower clearance, Ligand A excels in crucial areas like logP, TPSA, QED, DILI risk, and BBB penetration. The low logP of Ligand B is a major concern for permeability and bioavailability. The much lower DILI risk of Ligand A is also a critical factor. Given the GPCR target class, the balance of properties in Ligand A is more favorable.
Output:
1
2025-04-17 20:11:31,166 - INFO - Batch 166 complete. Total preferences: 2656
2025-04-17 20:11:31,167 - INFO - Processing batch 167/512...
2025-04-17 20:12:17,762 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
The ADRB2 receptor is a GPCR, so the priorities are logP, TPSA, Pgp, BBB, and affinity. Let's break down each ligand across these and other important parameters:
* **Molecular Weight:** Both ligands are within the ideal 200-500 Da range. Ligand A (399.208 Da) is slightly higher than Ligand B (362.348 Da), but both are acceptable.
* **TPSA:** Ligand A (104.18) is slightly above the preferred <140 for oral absorption, but still reasonable. Ligand B (89.87) is excellent, well below 100, suggesting good permeability.
* **logP:** Ligand A (2.048) is within the optimal 1-3 range. Ligand B (0.039) is *very* low, potentially causing permeability issues. This is a significant drawback.
* **H-Bond Donors/Acceptors:** Both ligands have 3 HBD and a reasonable number of HBA (5 and 4 respectively). This is acceptable for both.
* **QED:** Ligand B (0.619) has a better QED score than Ligand A (0.449), indicating a more drug-like profile.
* **DILI:** Ligand A (98.604) has a high DILI risk, which is concerning. Ligand B (29.624) has a very low DILI risk, a major advantage.
* **BBB:** Ligand B (69.523) has a better BBB penetration score than Ligand A (37.379), though neither is exceptionally high. For a cardiovascular target, BBB penetration isn't critical, but it's a bonus.
* **Caco-2 Permeability:** Both have negative Caco-2 values, which is unusual and suggests issues with the assay or prediction. However, the magnitude is more concerning for Ligand A (-5.558) than Ligand B (-4.794).
* **Aqueous Solubility:** Both have negative solubility values, also unusual. Again, Ligand A (-4.526) is worse than Ligand B (-1.461).
* **hERG:** Both have low hERG inhibition liability, which is good.
* **Microsomal Clearance:** Ligand B (-15.762) has a much lower (better) microsomal clearance than Ligand A (-1.762), indicating better metabolic stability.
* **In vitro Half-Life:** Ligand B (-41.96) has a significantly longer in vitro half-life than Ligand A (37.327), which is desirable.
* **P-gp Efflux:** Both have very low P-gp efflux liability, which is good.
* **Binding Affinity:** Both ligands have excellent binding affinity (-8.8 and -8.2 kcal/mol respectively), with Ligand A being slightly better. However, the 0.6 kcal/mol difference is unlikely to outweigh the significant ADME deficiencies of Ligand A.
**Overall Assessment:**
Ligand B is the stronger candidate. While Ligand A has slightly better binding affinity, Ligand B excels in critical ADME properties: lower DILI risk, better metabolic stability (lower Cl_mic, longer t1/2), better TPSA, and a more favorable logP. The low logP of Ligand A is a major concern for permeability. The better QED score of Ligand B also contributes to its overall drug-likeness. The unusual negative solubility and Caco-2 values for both are concerning and would require further investigation, but are less detrimental than the other issues with Ligand A.
**Output:**
0
2025-04-17 20:12:17,762 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.431 and 380.897 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (83.56) is slightly higher than Ligand B (67.43). Both are below the 140 threshold for good oral absorption, but B is better.
3. **logP:** Ligand A (0.85) is a bit low, potentially hindering permeability. Ligand B (3.494) is within the optimal 1-3 range. This favors B.
4. **HBD:** Both have 2 HBD, which is good.
5. **HBA:** Ligand A has 5 HBA, and Ligand B has 4. Both are acceptable.
6. **QED:** Both ligands have similar QED scores (0.773 and 0.736), indicating good drug-likeness.
7. **DILI:** Ligand A (49.632) has a lower DILI risk than Ligand B (58.705), which is preferable.
8. **BBB:** Ligand B (73.284) shows better BBB penetration than Ligand A (60.682). While ADRB2 isn't *strictly* a CNS target, some CNS exposure can be relevant for off-target effects, and better BBB penetration can sometimes correlate with improved PK.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.018 and -5.078). This is unusual and suggests poor permeability.
10. **Solubility:** Ligand A (-2.386) has better solubility than Ligand B (-4.244).
11. **hERG:** Ligand A (0.256) has a much lower hERG inhibition liability than Ligand B (0.639). This is a significant advantage for A, as hERG inhibition can cause cardiotoxicity.
12. **Cl_mic:** Ligand B (55.251) has a higher microsomal clearance than Ligand A (22.76), indicating faster metabolism and potentially lower exposure. This favors A.
13. **t1/2:** Ligand B (82.426) has a significantly longer in vitro half-life than Ligand A (32.791). This is a strong advantage for B.
14. **Pgp:** Ligand A (0.016) has much lower P-gp efflux liability than Ligand B (0.248), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand B (-7.6) has a significantly stronger binding affinity than Ligand A (-6.4). This is a substantial advantage, potentially outweighing some ADME concerns.
**GPCR-Specific Priorities & Overall Assessment:**
For a GPCR like ADRB2, affinity, logP, TPSA, and Pgp efflux are key. Ligand B excels in affinity and has a better logP and BBB penetration. However, Ligand A has a much better safety profile (lower DILI and hERG) and better Pgp efflux. The Caco-2 values are concerning for both, suggesting permeability issues. The longer half-life of B is also attractive.
The difference in binding affinity (-7.6 vs -6.4) is substantial (1.2 kcal/mol), and this is a major driver in drug discovery. Given the relatively acceptable ADME profile of Ligand B, and the importance of potency for GPCRs, I believe Ligand B is the more promising candidate despite the higher hERG risk and faster clearance. The improved affinity is likely to be crucial for efficacy.
Output:
0
2025-04-17 20:12:17,763 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (369.535 Da) is slightly higher than Ligand B (354.407 Da), but both are acceptable.
2. **TPSA:** Ligand A (69.73) is excellent, well below the 140 threshold for oral absorption. Ligand B (108.05) is still reasonable, but less optimal. This favors Ligand A.
3. **logP:** Ligand A (1.205) is within the optimal range (1-3). Ligand B (-1.669) is slightly below 1, which could potentially hinder permeability. This favors Ligand A.
4. **HBD:** Both ligands have 2 HBD, which is good.
5. **HBA:** Ligand A has 7 HBA, and Ligand B has 6 HBA. Both are within the acceptable range.
6. **QED:** Ligand A (0.604) is slightly better than Ligand B (0.552), indicating a more drug-like profile.
7. **DILI:** Ligand A (35.169) has a slightly higher DILI risk than Ligand B (26.755), but both are below the concerning threshold of 60.
8. **BBB:** Ligand A (78.209) has a significantly better BBB penetration score than Ligand B (29.74). Given ADRB2's involvement in cardiovascular function, CNS penetration isn't a primary requirement, but it's still a positive attribute.
9. **Caco-2:** Ligand A (-4.956) and Ligand B (-5.175) are both negative, indicating poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-1.502) and Ligand B (-0.425) are both negative, indicating poor solubility. This is a concern for both.
11. **hERG:** Ligand A (0.913) has a slightly higher hERG risk than Ligand B (0.021). This is a significant advantage for Ligand B.
12. **Cl_mic:** Ligand B (3.252) has significantly lower microsomal clearance than Ligand A (14.96), indicating better metabolic stability. This is a strong advantage for Ligand B.
13. **t1/2:** Ligand B (-20.296) has a much longer in vitro half-life than Ligand A (29.019). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.058) has slightly lower P-gp efflux than Ligand B (0.003), which is favorable.
15. **Binding Affinity:** Both ligands have very similar and excellent binding affinities (-6.1 and -5.9 kcal/mol, respectively). The difference is not substantial enough to be a deciding factor.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A performs better on logP and TPSA, and Pgp is slightly better. However, Ligand B has a much better metabolic profile (Cl_mic and t1/2) and a significantly lower hERG risk. The binding affinities are comparable.
**Overall Assessment:**
While Ligand A has some advantages in terms of TPSA and logP, the significantly better metabolic stability (lower Cl_mic, longer t1/2) and lower hERG risk of Ligand B are more crucial for overall drug development success. The slightly lower logP of Ligand B is a manageable concern, and the comparable binding affinity makes it a more promising candidate.
Output:
0
2025-04-17 20:12:17,763 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (349.431 and 378.485 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (94.66) is higher than Ligand B (69.64). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is still generally preferred for better absorption. Ligand B has a clear advantage.
**3. logP:** Ligand A (0.75) is a bit low, potentially hindering permeability. Ligand B (2.378) is within the optimal 1-3 range. Ligand B is better.
**4. H-Bond Donors:** Ligand A (3) is slightly higher than Ligand B (2), but both are acceptable (<=5).
**5. H-Bond Acceptors:** Both ligands have 4 H-bond acceptors, which is good.
**6. QED:** Both ligands have similar QED values (0.748 and 0.714), indicating good drug-likeness.
**7. DILI Risk:** Both ligands have similar DILI risk (37.418 and 39.318), and are both below the 40% threshold, indicating low risk.
**8. BBB Penetration:** Ligand A (22.644) has very low BBB penetration, while Ligand B (72.082) is quite good. While ADRB2 isn't a CNS target, some degree of BBB penetration can be indicative of favorable permeability characteristics. Ligand B is better.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-5.025 and -5.06), which is unusual and suggests poor permeability. However, the values are very similar.
**10. Aqueous Solubility:** Ligand A (-2.307) is better than Ligand B (-4.302), indicating higher solubility. Solubility is important for bioavailability.
**11. hERG Inhibition:** Ligand A (0.281) has a lower hERG inhibition risk than Ligand B (0.628), which is a significant advantage for cardiovascular drugs.
**12. Microsomal Clearance:** Ligand A (7.361) has significantly lower microsomal clearance than Ligand B (51.456), suggesting better metabolic stability. This is a key advantage.
**13. In vitro Half-Life:** Ligand A (-6.518) has a much longer in vitro half-life than Ligand B (-0.442), further supporting its better metabolic stability.
**14. P-gp Efflux:** Ligand A (0.047) has much lower P-gp efflux than Ligand B (0.225), which is beneficial for oral bioavailability.
**15. Binding Affinity:** Ligand A (-7.0) has a slightly better binding affinity than Ligand B (-6.2). While the difference is less than 1.5 kcal/mol, it contributes to the overall preference.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand A emerges as the more promising candidate. While Ligand B has better TPSA and BBB penetration, Ligand A's superior metabolic stability (lower Cl_mic, longer t1/2), lower P-gp efflux, lower hERG risk, and slightly better affinity outweigh these advantages. The solubility of Ligand A is also better. The Caco-2 values are concerning for both, but the other ADME properties of Ligand A are more favorable for a cardiovascular drug.
Output:
1
2025-04-17 20:12:17,763 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [344.455, 51.66, 2.402, 0, 4, 0.842, 11.283, 90.617, -4.381, -1.771, 0.584, 29.95, 1.873, 0.089, -5.4]
**Ligand B:** [364.917, 53.43, 4.051, 1, 3, 0.774, 9.461, 83.366, -4.576, -4.153, 0.62, 71.393, -3.479, 0.108, -7.4]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). A (344.455) is slightly preferred.
2. **TPSA:** Both are acceptable for a GPCR target, but below the 90 A^2 threshold for CNS targets. A (51.66) is better than B (53.43).
3. **logP:** A (2.402) is optimal, while B (4.051) is pushing the upper limit and could lead to solubility issues.
4. **HBD:** A (0) is excellent, minimizing potential off-target interactions. B (1) is acceptable.
5. **HBA:** A (4) is good. B (3) is also good.
6. **QED:** A (0.842) is significantly better than B (0.774), indicating a more drug-like profile.
7. **DILI:** A (11.283) is much better than B (9.461), indicating lower liver injury risk.
8. **BBB:** A (90.617) is better than B (83.366). While ADRB2 isn't necessarily a CNS target, higher BBB penetration is generally favorable.
9. **Caco-2:** Both are negative, indicating poor permeability. B (-4.576) is slightly worse than A (-4.381).
10. **Solubility:** A (-1.771) is better than B (-4.153), which is a significant advantage.
11. **hERG:** Both are very low, indicating a low risk of cardiotoxicity. A (0.584) is slightly better than B (0.62).
12. **Cl_mic:** A (29.95) is much better than B (71.393), indicating better metabolic stability.
13. **t1/2:** A (1.873) is worse than B (-3.479), indicating shorter half-life.
14. **Pgp:** A (0.089) is better than B (0.108), indicating less P-gp efflux.
15. **Affinity:** B (-7.4) is significantly better than A (-5.4) - a difference of 2 kcal/mol. This is a substantial advantage.
**Overall Assessment:**
Ligand B has a significantly better binding affinity (-7.4 kcal/mol vs -5.4 kcal/mol). This is a crucial factor for GPCRs. However, Ligand A demonstrates superior ADME properties across several key parameters (QED, DILI, BBB, Solubility, Cl_mic, Pgp). Ligand B's higher logP and lower solubility are concerning, and its higher DILI risk is also a drawback. The improved metabolic stability of Ligand A is also a significant benefit.
Given the substantial affinity advantage of Ligand B, and the fact that the ADME issues are not catastrophic (solubility is still present, DILI is not extremely high), I believe Ligand B is the more promising candidate. The 2 kcal/mol difference in binding affinity can often outweigh minor ADME concerns, especially in early-stage drug discovery.
Output:
0
2025-04-17 20:12:17,763 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (373.812 and 369.487 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (93.46) is better than Ligand B (97.39), both are acceptable for a non-CNS GPCR target like ADRB2, being under 140.
3. **logP:** Both ligands have good logP values (1.861 and 1.389), falling within the optimal 1-3 range. Ligand B is slightly lower, which *could* indicate slightly better solubility, but the difference isn't huge.
4. **HBD:** Both have 2 HBD, which is within the acceptable limit of 5.
5. **HBA:** Both have 5 HBA, which is within the acceptable limit of 10.
6. **QED:** Ligand A (0.821) has a significantly better QED score than Ligand B (0.649), indicating a more drug-like profile.
7. **DILI:** Ligand A (67.274) has a higher DILI risk than Ligand B (38.077). This is a significant drawback for Ligand A. Lower DILI is highly desirable.
8. **BBB:** This is less critical for ADRB2 (a cardiovascular target), but Ligand A (85.847) has a higher BBB penetration than Ligand B (61.38).
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.955 and -4.752). This is unusual and suggests poor permeability. However, the values are very close.
10. **Solubility:** Ligand B (-2.421) has slightly better solubility than Ligand A (-3.638).
11. **hERG:** Both ligands have very low hERG inhibition risk (0.22 and 0.197). This is excellent.
12. **Cl_mic:** Ligand A (9.394) has a significantly lower microsomal clearance than Ligand B (55.273). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (20.884) has a much longer in vitro half-life than Ligand B (-50.562). A negative half-life is concerning for Ligand B.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.14 and 0.027).
15. **Binding Affinity:** Ligand B (-6.6) has a slightly better binding affinity than Ligand A (-6.3), but the difference is relatively small (0.3 kcal/mol).
**GPCR-specific priorities:** For ADRB2 (a cardiovascular GPCR), logP, TPSA, and affinity are important. Metabolic stability (Cl_mic, t1/2) and safety (DILI, hERG) are also crucial.
**Overall Assessment:**
Ligand A has a better QED, lower Cl_mic, and a significantly longer half-life. However, its DILI risk is considerably higher than Ligand B. Ligand B has a better DILI profile and slightly better affinity and solubility. The negative Caco-2 values for both are concerning, but the difference in other parameters outweighs this. Given the importance of minimizing liver toxicity, and the only slight difference in binding affinity, Ligand B is the more promising candidate.
Output:
0
2025-04-17 20:12:17,764 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (395.874) is slightly higher than Ligand B (348.487), but both are acceptable.
2. **TPSA:** Both ligands have TPSA values around 50, well below the 140 threshold for oral absorption, and appropriate for a GPCR target.
3. **logP:** Ligand A (4.725) is a bit high, potentially leading to solubility issues or off-target interactions. Ligand B (2.609) is within the optimal range (1-3). This favors Ligand B.
4. **HBD:** Ligand A (2) and Ligand B (0) both meet the HBD < 5 criteria.
5. **HBA:** Both ligands have 3 HBA, well within the acceptable limit of 10.
6. **QED:** Both ligands have similar QED values (0.709 and 0.737), indicating good drug-likeness.
7. **DILI:** Ligand B (16.402) has a significantly lower DILI risk than Ligand A (36.216). This is a major advantage for Ligand B.
8. **BBB:** Both ligands have good BBB penetration (76.231 and 77.007), which is important for GPCR targets, though less critical for ADRB2 specifically as it's primarily a cardiovascular target.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. This is concerning for both, but the values are similar.
10. **Solubility:** Ligand B (-1.942) has better (less negative) solubility than Ligand A (-5.584). This is a significant advantage, especially considering Ligand A's higher logP.
11. **hERG:** Ligand A (0.72) has a slightly higher hERG risk than Ligand B (0.26). Lower is better here, favoring Ligand B.
12. **Cl_mic:** Ligand A (33.757) has a lower microsomal clearance than Ligand B (51.12), suggesting better metabolic stability. This favors Ligand A.
13. **t1/2:** Ligand B (-19.337) has a significantly longer in vitro half-life than Ligand A (14.799). This is a strong advantage for Ligand B.
14. **Pgp:** Ligand A (0.259) has lower P-gp efflux than Ligand B (0.11), which is favorable.
15. **Affinity:** Ligand A (-6.9 kcal/mol) has a slightly better binding affinity than Ligand B (-5.8 kcal/mol). This is a 1.1 kcal/mol difference, which is a reasonable advantage, but not overwhelming.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity) and general drug-like properties, Ligand B emerges as the more promising candidate. While Ligand A has slightly better affinity and lower P-gp efflux, Ligand B excels in crucial areas like DILI risk, solubility, and in vitro half-life. The higher logP of Ligand A is a concern, and its higher DILI risk is a significant drawback. The difference in affinity is not large enough to outweigh these liabilities.
Output:
0
2025-04-17 20:12:17,764 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (392.897 Da) is slightly higher than Ligand B (354.447 Da), but both are acceptable.
2. **TPSA:** Ligand A (91.83) is better than Ligand B (107.89). Both are reasonably good, but lower TPSA generally favors better absorption.
3. **logP:** Ligand A (3.952) is optimal, while Ligand B (0.088) is quite low. This is a significant advantage for Ligand A, as low logP can hinder membrane permeability.
4. **HBD:** Ligand A (3) and Ligand B (4) are both acceptable, falling within the desired limit of <=5.
5. **HBA:** Ligand A (7) and Ligand B (5) are both acceptable, falling within the desired limit of <=10.
6. **QED:** Ligand A (0.584) is better than Ligand B (0.469), indicating a more drug-like profile.
7. **DILI:** Ligand A (97.867) is very high risk, while Ligand B (15.2) is excellent. This is a major concern for Ligand A.
8. **BBB:** Ligand A (63.474) is moderate, while Ligand B (23.924) is low. While ADRB2 isn't necessarily a CNS target, some peripheral distribution is needed, and a higher BBB score isn't detrimental.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.023 and -5.389). This is unusual and suggests poor permeability. However, these values are on a different scale and are hard to interpret directly.
10. **Solubility:** Ligand A (-5.079) and Ligand B (-1.285) both have negative solubility values, suggesting poor solubility. Again, the scale is unclear, but B is better.
11. **hERG:** Ligand A (0.345) is much better than Ligand B (0.116), indicating a lower risk of cardiotoxicity. This is crucial for a cardiovascular target.
12. **Cl_mic:** Ligand A (37.176) is better than Ligand B (-15.232). A positive value for B suggests rapid clearance.
13. **t1/2:** Ligand A (76.464) is better than Ligand B (38.588), indicating a longer half-life.
14. **Pgp:** Ligand A (0.552) is better than Ligand B (0.019), indicating lower P-gp efflux.
15. **Affinity:** Ligand A (-7.3 kcal/mol) is slightly better than Ligand B (-7.1 kcal/mol), but the difference is small.
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Ligand A excels in logP, Pgp, and has slightly better affinity. However, its extremely high DILI risk is a major red flag. Ligand B has a much better safety profile (DILI) but suffers from a very low logP and poor metabolic stability.
**Overall Assessment:**
Despite the slightly better affinity of Ligand A, the extremely high DILI risk makes it a poor candidate. The low logP of Ligand B is a concern, but it is potentially addressable through structural modifications. The significantly better DILI profile of Ligand B outweighs its other drawbacks.
Output:
0
2025-04-17 20:12:17,764 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (343.471 and 347.419 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (52.65) is significantly better than Ligand B (102.05). For a GPCR, lower TPSA is generally preferred for better permeability. Ligand B is quite high and could present absorption challenges.
3. **logP:** Both ligands have good logP values (2.585 and 1.856), falling within the optimal 1-3 range. Ligand B is slightly lower, which might slightly reduce permeability, but it's not a major concern.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (6). Lower HBA generally improves permeability.
6. **QED:** Ligand B (0.759) has a better QED score than Ligand A (0.491), indicating a more drug-like profile. This is a positive for Ligand B.
7. **DILI:** Both ligands have similar and acceptable DILI risk (46.801 and 48.468).
8. **BBB:** Ligand A (79.256) has a significantly higher BBB penetration percentile than Ligand B (55.254). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be beneficial for distribution and off-target effects assessment.
9. **Caco-2:** Ligand A (-4.525) is better than Ligand B (-5.264), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-3.446) is better than Ligand B (-2.934), indicating better aqueous solubility.
11. **hERG:** Both ligands have low hERG inhibition liability (0.661 and 0.505), which is good.
12. **Cl_mic:** Ligand B (19.577) has a much lower microsomal clearance than Ligand A (48.429). This suggests better metabolic stability for Ligand B, a significant advantage.
13. **t1/2:** Ligand B (29.215) has a significantly longer in vitro half-life than Ligand A (7.047). This is a major advantage, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.424) has a lower P-gp efflux liability than Ligand B (0.17). Lower Pgp efflux is generally desirable.
15. **Binding Affinity:** Ligand A (-6.5 kcal/mol) has a slightly better binding affinity than Ligand B (-5.5 kcal/mol). This 1 kcal/mol difference is significant and can often outweigh minor ADME drawbacks.
**Overall Assessment:**
Ligand A has a clear advantage in binding affinity, TPSA, solubility, Caco-2 permeability, and Pgp efflux. Ligand B shines in metabolic stability (lower Cl_mic) and half-life, and has a slightly better QED score. Considering ADRB2 is a GPCR, TPSA and permeability are important. The 1 kcal/mol difference in binding affinity is also a substantial benefit for Ligand A. The longer half-life of Ligand B is attractive, but the lower TPSA and better permeability profile of Ligand A are more critical for a GPCR target.
Output:
1
2025-04-17 20:12:17,764 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
The target is ADRB2, a GPCR. Therefore, the priorities are logP, TPSA, Pgp efflux, BBB penetration, and binding affinity. Metabolic stability (Cl_mic, t1/2) and safety (DILI, hERG) are also important, but slightly lower priority than the first set.
Let's compare the ligands property by property:
1. **MW:** Both ligands (340.379 and 344.35 Da) fall within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (89.87) is better than Ligand B (103.96). Both are under 140, but A is closer to the preferred <90 for better absorption.
3. **logP:** Both ligands have good logP values (2.686 and 2.24), falling within the optimal 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability.
4. **HBD/HBA:** Ligand A (3 HBD, 4 HBA) and Ligand B (4 HBD, 5 HBA) are both acceptable, staying within the recommended limits.
5. **QED:** Ligand A (0.747) has a higher QED score than Ligand B (0.532), suggesting a more drug-like profile.
6. **DILI:** Ligand B (88.794) has a significantly higher DILI risk than Ligand A (60.527). This is a major concern.
7. **BBB:** Ligand A (33.928) has a lower BBB penetration than Ligand B (42.497), but BBB isn't a huge priority for ADRB2 unless targeting CNS effects.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual. Assuming these are logP-like scales, lower values indicate poorer permeability. Ligand A (-5.174) is slightly worse than Ligand B (-4.885).
9. **Solubility:** Both have negative solubility values, indicating poor aqueous solubility. Ligand A (-3.859) is slightly better than Ligand B (-3.636).
10. **hERG:** Both have low hERG inhibition liability (0.461 and 0.627), which is good.
11. **Cl_mic:** Ligand A (-17.402) has much lower (better) microsomal clearance than Ligand B (11.192), indicating greater metabolic stability.
12. **t1/2:** Ligand A (-22.067) has a much longer in vitro half-life than Ligand B (-1.336), which is desirable.
13. **Pgp:** Both have very low Pgp efflux liability (0.042 and 0.082).
14. **Binding Affinity:** Ligand B (-5.9 kcal/mol) has a slightly better binding affinity than Ligand A (-6.0 kcal/mol). However, the difference is minimal.
**Overall Assessment:**
Ligand A is clearly the better candidate. While Ligand B has slightly better binding affinity, Ligand A excels in crucial ADME properties: significantly lower DILI risk, much better metabolic stability (lower Cl_mic, longer t1/2), and a higher QED score. The TPSA is also more favorable for Ligand A. The slightly worse Caco-2 and BBB values for Ligand A are less concerning given the target. The difference in binding affinity is not substantial enough to outweigh the significant advantages of Ligand A.
**Output:**
1
2025-04-17 20:12:17,764 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's break down the comparison of Ligand A and Ligand B, considering the provided guidelines and the GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key).
1. **Molecular Weight:** Both ligands (351.491 and 341.371 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (61.88) is significantly better than Ligand B (109.8). A TPSA under 140 is good for oral absorption, and lower is better for GPCRs. Ligand B is pushing the upper limit, potentially hindering permeability.
3. **logP:** Ligand A (1.395) is optimal, while Ligand B (0.095) is quite low. Low logP can lead to poor membrane permeability. This is a significant advantage for Ligand A.
4. **H-Bond Donors/Acceptors:** Ligand A (1 HBD, 4 HBA) is more favorable than Ligand B (2 HBD, 5 HBA). While both are within acceptable limits, fewer H-bonds generally improve permeability.
5. **QED:** Both ligands have similar and good QED values (0.704 and 0.726), indicating good drug-like properties.
6. **DILI:** Ligand A (12.796) has a much lower DILI risk than Ligand B (58.86). This is a crucial advantage for Ligand A.
7. **BBB:** Ligand A (66.615) shows better BBB penetration than Ligand B (44.901), though neither is exceptionally high. For a cardiovascular target like ADRB2, BBB penetration isn't *essential*, but it's a bonus, and Ligand A is better.
8. **Caco-2 Permeability:** Both are negative, indicating poor permeability. However, Ligand A (-4.782) is less negative than Ligand B (-5.569), suggesting slightly better permeability.
9. **Aqueous Solubility:** Ligand B (-2.387) has slightly better solubility than Ligand A (-0.592). Solubility is important, but not the primary concern here.
10. **hERG Inhibition:** Both ligands show very low hERG inhibition risk (0.461 and 0.121), which is excellent.
11. **Microsomal Clearance:** Ligand B (-19.148) has significantly lower (better) microsomal clearance than Ligand A (9.628). This suggests better metabolic stability for Ligand B.
12. **In vitro Half-Life:** Ligand A (-5.568) has a longer in vitro half-life than Ligand B (-0.865). This is a positive for Ligand A.
13. **P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.076 and 0.012).
14. **Binding Affinity:** Ligand A (-7.5 kcal/mol) has a stronger binding affinity than Ligand B (-6.3 kcal/mol). This 1.2 kcal/mol difference is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand A is the stronger candidate. While Ligand B has better metabolic stability (lower Cl_mic), Ligand A excels in several critical areas: significantly lower DILI risk, better logP, lower TPSA, better BBB penetration, and, most importantly, a substantially stronger binding affinity. The combination of these factors, particularly the affinity and safety profile, makes Ligand A the more promising starting point for drug development targeting ADRB2.
Output:
1
2025-04-17 20:12:17,765 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.4 and 364.9 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (77.25) is slightly higher than Ligand B (67.43). Both are below the 140 threshold for oral absorption, but closer to the 90 threshold for CNS targets (less relevant here, but still good). Ligand B is preferable.
3. **logP:** Both ligands (2.929 and 3.159) are within the optimal 1-3 range. No clear advantage.
4. **HBD:** Ligand A (1) is better than Ligand B (2). Lower HBD is generally preferred for permeability.
5. **HBA:** Ligand A (5) is better than Ligand B (3). Lower HBA is generally preferred for permeability.
6. **QED:** Ligand A (0.667) is slightly better than Ligand B (0.522), indicating a more drug-like profile.
7. **DILI:** Ligand B (24.893) is significantly better than Ligand A (60.062). This is a major advantage for Ligand B. Lower DILI is crucial.
8. **BBB:** Ligand A (89.686) is better than Ligand B (69.523), but BBB isn't a primary concern for ADRB2 (cardiovascular target).
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-4.889) is slightly worse than Ligand B (-4.704).
10. **Solubility:** Both are negative, indicating poor solubility. Ligand A (-2.702) is slightly worse than Ligand B (-3.718).
11. **hERG:** Ligand A (0.668) is better than Ligand B (0.728). Lower hERG is preferred.
12. **Cl_mic:** Ligand B (33.535) is significantly better than Ligand A (55.088). Lower clearance indicates better metabolic stability.
13. **t1/2:** Ligand B (54.722) is significantly better than Ligand A (22.074). Longer half-life is desirable.
14. **Pgp:** Ligand A (0.558) is better than Ligand B (0.243). Lower Pgp efflux is preferred.
15. **Affinity:** Ligand A (-6.6 kcal/mol) is better than Ligand B (-5.9 kcal/mol). This is a 0.7 kcal/mol difference, which is significant.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A has better affinity and Pgp, while Ligand B has better TPSA and logP. However, the significantly better DILI, Cl_mic and t1/2 of Ligand B, combined with acceptable affinity, outweigh the slightly weaker binding. The poor solubility and Caco-2 values are concerning for both, but can be addressed with formulation strategies.
**Conclusion:**
Despite Ligand A's slightly better affinity and Pgp, Ligand B's superior safety profile (DILI), metabolic stability (Cl_mic), and longer half-life make it the more promising drug candidate.
Output:
0
2025-04-17 20:12:17,765 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (352.479) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (46.09) is significantly better than Ligand A (90.54). For a GPCR, lower TPSA is preferred for better permeability and potentially better BBB penetration.
3. **logP:** Ligand B (4.206) is higher than Ligand A (0.398). While logP > 4 can be problematic, it's not a hard limit. Given ADRB2 is a cardiovascular target, CNS penetration isn't critical, and a higher logP can aid membrane permeability. Ligand A's logP is quite low, potentially hindering absorption.
4. **HBD:** Ligand A (3) is higher than Ligand B (0). While not a major concern, fewer HBDs are generally preferred for improved permeability.
5. **HBA:** Both ligands have the same number of HBA (4).
6. **QED:** Ligand B (0.696) has a slightly better QED score than Ligand A (0.56), indicating a more drug-like profile.
7. **DILI:** Ligand A (9.849) has a much lower DILI risk than Ligand B (20.9), which is a significant advantage.
8. **BBB:** Ligand B (87.941) has a much higher BBB penetration potential than Ligand A (43.117). However, since ADRB2 is a cardiovascular target, BBB penetration is not a primary concern.
9. **Caco-2:** Ligand A (-5.724) has a worse Caco-2 permeability than Ligand B (-4.894).
10. **Solubility:** Ligand A (-0.611) has a slightly better solubility than Ligand B (-3.99).
11. **hERG:** Ligand A (0.148) has a lower hERG inhibition liability than Ligand B (0.553), which is a critical safety advantage.
12. **Cl_mic:** Ligand A (-15.463) has a much lower microsomal clearance than Ligand B (87.262), indicating better metabolic stability.
13. **t1/2:** Ligand A (5.483) has a longer in vitro half-life than Ligand B (0.742).
14. **Pgp:** Ligand A (0.005) has a much lower P-gp efflux liability than Ligand B (0.579), which is favorable for bioavailability.
15. **Affinity:** Ligand B (-6.2) has a slightly better binding affinity than Ligand A (-5.6). While a 1.5 kcal/mol difference is usually significant, the other ADME properties of Ligand A are more compelling.
**GPCR-specific priorities:** For ADRB2 (a cardiovascular GPCR), logP, TPSA, Pgp, and affinity are important. While Ligand B has a better logP and affinity, Ligand A excels in TPSA, Pgp, and crucially, safety parameters (DILI, hERG) and metabolic stability (Cl_mic, t1/2). The lower DILI and hERG risk are particularly important for a cardiovascular drug.
**Conclusion:**
Considering the balance of properties, especially the superior safety profile and metabolic stability of Ligand A, it is the more promising drug candidate despite the slightly weaker binding affinity.
Output:
1
2025-04-17 20:12:17,765 - INFO - Here's my reasoning and final output for the ligand preference:
**Reasoning:**
We are looking for a viable drug candidate for the ADRB2, a cardiovascular GPCR. Therefore, the key properties to prioritize are binding affinity, logP, TPSA, Pgp efflux, and to a lesser extent, BBB (though less critical for a cardiovascular target than a CNS one).
Let's compare Ligand A and Ligand B across these parameters:
1. **Molecular Weight:** Both ligands (358.471 and 348.443 Da) are within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (76.8) is slightly higher than Ligand B (68.82). Both are below the 140 threshold for oral absorption, but Ligand B is preferable.
3. **logP:** Both ligands have good logP values (3.143 and 2.469), falling within the optimal 1-3 range. Ligand B is slightly better.
4. **H-Bond Donors/Acceptors:** Ligand A has 0 HBD and 7 HBA, while Ligand B has 2 HBD and 4 HBA. Both are acceptable, but Ligand B is slightly more balanced.
5. **QED:** Both ligands have a good QED score (0.7 and 0.794), indicating good drug-likeness.
6. **DILI:** Ligand A has a significantly higher DILI risk (77.472%) than Ligand B (35.285%). This is a major concern for Ligand A.
7. **BBB:** Ligand A (61.535%) has a lower BBB penetration than Ligand B (74.37%). While not a primary concern for a cardiovascular target, higher BBB is generally favorable.
8. **Caco-2 Permeability:** Ligand A (-5.269) has worse Caco-2 permeability than Ligand B (-4.716).
9. **Aqueous Solubility:** Ligand A (-3.146) has worse aqueous solubility than Ligand B (-2.269).
10. **hERG Inhibition:** Both ligands have low hERG inhibition risk (0.296 and 0.409).
11. **Microsomal Clearance:** Ligand A (71.179) has significantly higher microsomal clearance than Ligand B (10.208), indicating lower metabolic stability.
12. **In vitro Half-Life:** Ligand A (32.409) has a shorter half-life than Ligand B (24.994).
13. **P-gp Efflux:** Ligand A (0.446) has slightly higher P-gp efflux than Ligand B (0.072).
14. **Binding Affinity:** Ligand A (-6.6 kcal/mol) has a slightly better binding affinity than Ligand B (-5.1 kcal/mol). The difference is 1.5 kcal/mol, which is significant.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity, its significantly higher DILI risk, higher microsomal clearance, shorter half-life, and worse solubility and permeability make it a less desirable candidate. Ligand B presents a much more favorable ADMET profile, despite a slightly lower binding affinity. The difference in binding affinity, while notable, is outweighed by the substantial improvements in safety (DILI) and pharmacokinetic properties (clearance, half-life, solubility, permeability) of Ligand B.
Output:
0
2025-04-17 20:12:17,765 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (364.408 Da) is slightly higher than Ligand B (345.374 Da), but both are acceptable.
2. **TPSA:** Ligand A (58.64) is significantly better than Ligand B (75.44). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (A: 3.013, B: 2.086), falling within the optimal 1-3 range. Ligand A is slightly higher, which could potentially lead to off-target effects, but is still acceptable.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 3 HBA, Ligand B has 4. Both are acceptable, below the threshold of 10.
6. **QED:** Ligand B (0.921) has a better QED score than Ligand A (0.755), indicating a more drug-like profile.
7. **DILI:** Ligand A (39.667) has a lower DILI risk than Ligand B (53.083), which is a significant advantage.
8. **BBB:** Both have good BBB penetration (A: 74.292, B: 75.029), but this isn't a primary concern for a cardiovascular target.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Both have negative solubility values, indicating poor aqueous solubility. This is a major drawback for both compounds.
11. **hERG:** Ligand A (0.603) has a slightly higher hERG risk than Ligand B (0.366), which is undesirable.
12. **Cl_mic:** Ligand B (29.29) has a significantly lower microsomal clearance than Ligand A (60.59), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-9.988) has a longer in vitro half-life than Ligand A (-11.089), which is preferable.
14. **Pgp:** Both have very low Pgp efflux liability (A: 0.147, B: 0.127), which is good.
15. **Binding Affinity:** Ligand B (-6.0 kcal/mol) has a slightly better binding affinity than Ligand A (-5.6 kcal/mol). This difference is significant enough to potentially outweigh some of the ADME drawbacks.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B has a slightly better logP, significantly better TPSA, comparable Pgp, and better affinity. The improved metabolic stability (lower Cl_mic and longer t1/2) of Ligand B is also a major advantage. While Ligand A has a lower DILI risk, the other factors favor Ligand B. The poor Caco-2 and solubility for both compounds are concerning, but can be addressed with formulation strategies.
**Conclusion:**
Despite the similar MW and BBB values, Ligand B demonstrates a more favorable balance of properties, particularly with respect to TPSA, metabolic stability, and binding affinity. The slightly better affinity and improved ADME profile of Ligand B make it the more promising drug candidate.
Output:
0
2025-04-17 20:12:17,765 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (362.495 Da) is within the ideal range, while Ligand B (348.447 Da) is also acceptable. No clear advantage here.
2. **TPSA:** Ligand A (49.85) is excellent, well below the 140 threshold and suitable for good absorption. Ligand B (94.56) is higher, but still potentially acceptable, though less optimal.
3. **logP:** Ligand A (2.687) is optimal. Ligand B (1.008) is a bit low, potentially impacting permeability.
4. **HBD:** Ligand A (0) is good. Ligand B (3) is acceptable, but higher HBD can sometimes lead to issues.
5. **HBA:** Ligand A (4) is good. Ligand B (5) is acceptable.
6. **QED:** Ligand A (0.813) is excellent, indicating high drug-likeness. Ligand B (0.684) is still reasonable, but lower.
7. **DILI:** Ligand A (49.632) is good, indicating low liver injury risk. Ligand B (25.785) is even better, with very low risk.
8. **BBB:** Ligand A (77.007) is good, suggesting some brain penetration. Ligand B (43.04) is lower, indicating limited brain penetration. Since ADRB2 is a cardiovascular target, BBB penetration is not a primary concern, but it's a bonus if it exists.
9. **Caco-2:** Ligand A (-4.443) is poor. Ligand B (-5.149) is also poor. Both have very low Caco-2 permeability.
10. **Solubility:** Ligand A (-2.752) is poor. Ligand B (-1.233) is also poor. Both have low solubility.
11. **hERG:** Ligand A (0.458) is very good, indicating low cardiotoxicity risk. Ligand B (0.091) is excellent, even lower risk.
12. **Cl_mic:** Ligand A (45.14) is moderate. Ligand B (2.229) is very low, indicating excellent metabolic stability.
13. **t1/2:** Ligand A (36.703) is good. Ligand B (25.114) is acceptable.
14. **Pgp:** Ligand A (0.214) is good, indicating low efflux. Ligand B (0.01) is excellent, very low efflux.
15. **Affinity:** Ligand B (-7.3 kcal/mol) is significantly better than Ligand A (-6.3 kcal/mol). This 1 kcal/mol difference is substantial and can outweigh some ADME drawbacks.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has a better logP and TPSA, while Ligand B has a much better affinity and Pgp efflux. The significantly stronger binding affinity of Ligand B is the most important factor. While both have poor Caco-2 and solubility, this can be addressed with formulation strategies.
**Conclusion:**
Despite Ligand A's slightly better logP and TPSA, the much stronger binding affinity of Ligand B (-7.3 kcal/mol vs -6.3 kcal/mol) and its superior metabolic stability (lower Cl_mic) and Pgp efflux make it the more promising drug candidate. The lower DILI risk is also a significant advantage.
Output:
0
2025-04-17 20:12:17,765 - INFO - Batch 167 complete. Total preferences: 2672
2025-04-17 20:12:17,766 - INFO - Processing batch 168/512...
2025-04-17 20:13:04,621 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [354.466, 58.64, 2.725, 1, 3, 0.648, 20.047, 92.168, -4.658, -2.366, 0.698, 37.579, 3.593, 0.256, -6.4]
**Ligand B:** [352.475, 89.87, 1.053, 3, 4, 0.69, 19.736, 54.517, -4.837, -2.083, 0.308, -4.631, 2.931, 0.056, -6.9]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal 200-500 Da range. A is 354.466, B is 352.475 - very similar.
2. **TPSA:** Ligand A (58.64) is significantly better than Ligand B (89.87). Below 140 is good for oral absorption, and A is much closer to the <90 for CNS targets (though ADRB2 isn't necessarily a CNS target).
3. **logP:** Ligand A (2.725) is optimal. Ligand B (1.053) is a bit low, potentially hindering membrane permeability.
4. **HBD/HBA:** A (1/3) is preferable to B (3/4). Lower counts generally improve permeability.
5. **QED:** Both are acceptable (A: 0.648, B: 0.69), indicating reasonable drug-likeness.
6. **DILI:** Both are good (A: 20.047, B: 19.736), well below the 40% threshold.
7. **BBB:** Ligand A (92.168) is *much* better than Ligand B (54.517). While not a primary concern for ADRB2, higher BBB is generally a positive.
8. **Caco-2:** Both are negative, indicating poor permeability. This is a concern for both.
9. **Solubility:** Both are negative, indicating poor solubility. This is a concern for both.
10. **hERG:** Both are low risk (A: 0.698, B: 0.308).
11. **Cl_mic:** Ligand A (37.579) is better than Ligand B (-4.631) - indicating better metabolic stability. Negative values for Cl_mic are unusual and suggest very low clearance.
12. **t1/2:** Ligand A (3.593) is better than Ligand B (2.931).
13. **Pgp:** Ligand A (0.256) is significantly better than Ligand B (0.056). Lower P-gp efflux is highly desirable for bioavailability.
14. **Affinity:** Ligand B (-6.9) is slightly better than Ligand A (-6.4), a 0.5 kcal/mol difference.
**Overall Assessment:**
While Ligand B has a slightly better binding affinity, Ligand A is superior in almost all other critical ADME properties, especially TPSA, logP, BBB, Pgp efflux, and metabolic stability. The better TPSA and logP of Ligand A suggest it will have better permeability, and the lower Pgp efflux will improve bioavailability. The higher BBB is a bonus. The 0.5 kcal/mol difference in affinity is unlikely to outweigh the substantial ADME advantages of Ligand A.
Output:
1
2025-04-17 20:13:04,621 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's break down the comparison of Ligand A and Ligand B, considering the provided guidelines and the GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key).
1. **Molecular Weight:** Both ligands (343.47 & 348.49 Da) fall comfortably within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (38.77) is significantly better than Ligand B (58.64). A TPSA under 140 is good for oral absorption, and lower is generally preferred for GPCRs. Ligand A is much closer to the ideal range.
3. **logP:** Both ligands have acceptable logP values (3.61 & 2.35), falling within the 1-3 range. Ligand A is slightly higher, which *could* be a minor concern for solubility, but is still within acceptable limits.
4. **H-Bond Donors:** Ligand A (0) is preferable to Ligand B (1). Fewer HBDs generally improve permeability.
5. **H-Bond Acceptors:** Both have 3 HBA, which is good.
6. **QED:** Ligand A (0.841) is better than Ligand B (0.541), indicating a more drug-like profile.
7. **DILI:** Ligand A (23.65) has a much lower DILI risk than Ligand B (10.90). This is a significant advantage.
8. **BBB:** Both ligands have good BBB penetration (78.8% & 70.6%), but Ligand A is slightly better. While ADRB2 isn't exclusively a CNS target, some peripheral effects are mediated by CNS pathways, and better BBB penetration isn't a detriment.
9. **Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests a potential issue with the data. However, the values are similar (-4.5 and -4.41), so this doesn't differentiate them significantly.
10. **Aqueous Solubility:** Ligand A (-3.53) is slightly better than Ligand B (-2.9), indicating better solubility.
11. **hERG Inhibition:** Both ligands have low hERG inhibition risk (0.55 & 0.40), which is excellent.
12. **Microsomal Clearance:** Ligand A (82.16) has a higher microsomal clearance than Ligand B (36.51), meaning it's less metabolically stable. This is a drawback for Ligand A.
13. **In vitro Half-Life:** Ligand B (-15.40) has a significantly longer in vitro half-life than Ligand A (-11.64), which is a substantial advantage.
14. **P-gp Efflux:** Both ligands have low P-gp efflux (0.48 & 0.06), which is good. Ligand B is slightly better.
15. **Binding Affinity:** Ligand B (-7.4) has slightly better binding affinity than Ligand A (-7.3). However, the difference is small (0.1 kcal/mol) and might not be decisive.
**Overall Assessment:**
Ligand A excels in several key areas: TPSA, QED, DILI risk, solubility, and BBB penetration. Ligand B has a better half-life and slightly better affinity, but the advantages of Ligand A in ADME properties and safety (DILI) are more compelling. The higher clearance of Ligand A is a concern, but the other benefits outweigh this drawback, especially considering the relatively small difference in binding affinity.
**Output:**
1
2025-04-17 20:13:04,621 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (342.443 and 349.431 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (79.04) is significantly better than Ligand B (107.53). ADRB2 is a cardiovascular target, not CNS, but lower TPSA generally improves absorption. Ligand A is well below the 140 threshold, while B is approaching it.
3. **logP:** Ligand A (2.61) is within the optimal 1-3 range. Ligand B (-0.007) is slightly below 1, which *could* indicate permeability issues, though it's very close.
4. **HBD:** Ligand A (3) and Ligand B (4) are both acceptable, being less than 5.
5. **HBA:** Ligand A (3) and Ligand B (4) are both acceptable, being less than 10.
6. **QED:** Both ligands have reasonable QED scores (0.755 and 0.541), indicating good drug-like properties. Ligand A is better.
7. **DILI:** Ligand A (31.563) has a much lower DILI risk than Ligand B (22.8). This is a significant advantage for Ligand A.
8. **BBB:** Not a primary concern for a cardiovascular target, but Ligand A (78.209) has a higher BBB penetration than Ligand B (28.461).
9. **Caco-2:** Ligand A (-4.759) and Ligand B (-5.275) are both negative, which is unusual for Caco-2 permeability. This suggests poor permeability, but the scale is not specified.
10. **Solubility:** Ligand A (-3.048) and Ligand B (-2.107) are both negative, indicating poor aqueous solubility.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.512 and 0.039), which is excellent.
12. **Cl_mic:** Ligand A (20.297) has a higher microsomal clearance than Ligand B (15.697), meaning it's metabolized faster. This is a negative for Ligand A.
13. **t1/2:** Ligand A (16.546) has a longer in vitro half-life than Ligand B (-2.462). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.052) has a lower P-gp efflux liability than Ligand B (0.013), which is favorable.
15. **Affinity:** Ligand A (-7.6 kcal/mol) has a slightly better binding affinity than Ligand B (-7.4 kcal/mol). While the difference is small, it's still a positive for Ligand A.
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Ligand A performs better in logP, TPSA, and Pgp. The affinity difference is small.
**Overall Assessment:**
Ligand A appears to be the better candidate. It has a lower DILI risk, better TPSA, better logP, better Pgp efflux, and slightly better binding affinity. While Ligand B has a lower Cl_mic, the other advantages of Ligand A outweigh this drawback. The longer half-life of Ligand A is also a significant benefit.
Output:
1
2025-04-17 20:13:04,621 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (339.479 and 343.479 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (38.33) is significantly better than Ligand B (73.45). ADRB2 is a cardiovascular target, not a CNS target, but lower TPSA generally improves absorption. Ligand A is well below the 140 threshold, while Ligand B is approaching it.
3. **logP:** Ligand A (4.772) is slightly higher than Ligand B (3.472). Both are within the 1-3 range, but Ligand A is pushing the upper limit. This could lead to solubility issues, but is not a dealbreaker.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 2 HBA, while Ligand B has 7. This is a significant difference. Higher HBA can reduce permeability. Ligand A is much more favorable here.
6. **QED:** Both ligands have similar QED scores (0.668 and 0.665), indicating good drug-likeness.
7. **DILI:** Ligand A (37.03) has a much lower DILI risk than Ligand B (59.907). This is a crucial advantage, as liver toxicity is a major concern.
8. **BBB:** Not a primary concern for a cardiovascular target. Ligand A (54.983) and Ligand B (78.209) are both reasonable, with B being slightly better.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.869 and -4.975), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Both ligands have very poor predicted aqueous solubility (-4.994 and -4.498). This is a significant drawback for both.
11. **hERG:** Ligand A (0.871) has a slightly higher hERG risk than Ligand B (0.144). This favors Ligand B.
12. **Cl_mic:** Ligand A (107.02) has higher microsomal clearance than Ligand B (74.49), indicating faster metabolism and potentially lower bioavailability. This favors Ligand B.
13. **t1/2:** Ligand A (-3.491) has a slightly better (less negative) in vitro half-life than Ligand B (-4.044).
14. **Pgp:** Ligand A (0.799) has lower P-gp efflux than Ligand B (0.264), which is favorable.
15. **Binding Affinity:** Ligand A (-8.4 kcal/mol) has significantly better binding affinity than Ligand B (-6.7 kcal/mol). This is a substantial advantage, exceeding the 1.5 kcal/mol threshold.
**Overall Assessment:**
Ligand A has a significantly better binding affinity and a much lower DILI risk. It also has a more favorable TPSA and HBA count. While its logP is slightly higher and its solubility is poor (like Ligand B), the strong binding affinity and reduced toxicity risk outweigh these drawbacks. The Caco-2 permeability is a concern for both, but the superior potency of Ligand A suggests it might still achieve sufficient target engagement. Ligand B has better hERG and Cl_mic, but the difference in binding affinity is too large to ignore.
Output:
1
2025-04-17 20:13:04,621 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's systematically compare Ligand A and Ligand B based on the provided parameters and the guidelines, keeping in mind that ADRB2 is a GPCR, so logP, Pgp, TPSA, and affinity are particularly important.
1. **MW:** Both ligands (350.459 Da and 346.427 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (67.87) is slightly higher than Ligand B (62.99). Both are below the 140 A^2 threshold for good oral absorption, but closer to the ideal for GPCRs.
3. **logP:** Ligand B (2.084) is slightly higher than Ligand A (1.198), placing it more optimally within the 1-3 range. Ligand A is a little low, potentially impacting permeability.
4. **HBD:** Ligand A (1) has one H-bond donor, while Ligand B (0) has none. Both are within the acceptable limit of 5.
5. **HBA:** Both ligands (4) have the same number of H-bond acceptors, well below the limit of 10.
6. **QED:** Ligand B (0.841) has a significantly higher QED score than Ligand A (0.501), indicating a more drug-like profile.
7. **DILI:** Ligand B (26.522) has a much lower DILI risk than Ligand A (8.375). This is a substantial advantage for Ligand B.
8. **BBB:** Ligand B (78.829) has a better BBB penetration percentile than Ligand A (59.093). While ADRB2 isn't exclusively a CNS target, some peripheral ADRB2 activity can be modulated by CNS effects, and better BBB penetration is generally favorable.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.78 and -4.486). This is unusual and suggests poor permeability. However, the values are similar.
10. **Solubility:** Ligand A (-1.273) has slightly better aqueous solubility than Ligand B (-2.252), but both are quite poor.
11. **hERG:** Ligand A (0.356) has a lower hERG inhibition liability than Ligand B (0.507), which is a positive.
12. **Cl_mic:** Ligand A (4.522) has a significantly lower microsomal clearance than Ligand B (24.496), indicating better metabolic stability.
13. **t1/2:** Ligand B (42.179) has a much longer in vitro half-life than Ligand A (2.255). This is a major advantage for Ligand B.
14. **Pgp:** Ligand A (0.026) has lower P-gp efflux liability than Ligand B (0.272), which is favorable for bioavailability.
15. **Affinity:** Both ligands have very similar binding affinities (-5.2 kcal/mol and -4.8 kcal/mol). The difference is not substantial enough to be a deciding factor.
**Overall Assessment:**
Ligand B demonstrates a superior overall profile. While Ligand A has slightly better solubility and Pgp efflux, Ligand B excels in crucial areas: significantly lower DILI risk, better BBB penetration, a much higher QED score, and a substantially longer half-life. The slightly higher logP of Ligand B is also beneficial for a GPCR target. The similar affinities mean that the ADME/Tox advantages of Ligand B outweigh the minor differences in other properties.
Output:
0
2025-04-17 20:13:04,621 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [351.407, 109.58 , -0.523, 2. , 7. , 0.713, 61.497, 39.395, -4.92 , -1.332, 0.106, 25.544, -8.872, 0.019, -6.5 ]
**Ligand B:** [354.495, 65.12 , 0.158, 1. , 5. , 0.598, 3.8 , 53.354, -5.029, -0.007, 0.596, -7.021, -20.566, 0.006, -6.7 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). A (351.4) and B (354.5) are very similar.
2. **TPSA:** A (109.58) is higher than B (65.12). For a GPCR, lower TPSA is generally preferred for better brain penetration, even though ADRB2 isn't strictly a CNS target.
3. **logP:** A (-0.523) is lower than B (0.158). Both are a bit low, but B is closer to the optimal 1-3 range. Low logP can hinder membrane permeability.
4. **HBD:** A (2) is slightly higher than B (1). Both are acceptable.
5. **HBA:** A (7) is higher than B (5). Both are acceptable, but B is better.
6. **QED:** A (0.713) is better than B (0.598), indicating a more drug-like profile.
7. **DILI:** A (61.497) has a higher DILI risk than B (3.8). This is a significant advantage for B.
8. **BBB:** A (39.395) is lower than B (53.354). While not a primary concern for ADRB2, higher BBB is still favorable.
9. **Caco-2:** A (-4.92) is worse than B (-5.029). Both are very poor, indicating poor intestinal absorption.
10. **Solubility:** A (-1.332) is worse than B (-0.007). Solubility is a concern for both, but B is slightly better.
11. **hERG:** A (0.106) is lower (better) than B (0.596). Lower hERG inhibition is crucial for cardiovascular safety.
12. **Cl_mic:** A (25.544) is higher than B (-7.021). B has a negative value, meaning it is more metabolically stable. This is a significant advantage.
13. **t1/2:** A (-8.872) is worse than B (-20.566). B has a much longer in vitro half-life, indicating better metabolic stability.
14. **Pgp:** A (0.019) is lower (better) than B (0.006). Lower P-gp efflux is favorable for bioavailability.
15. **Affinity:** Both have similar binding affinity (-6.5 and -6.7 kcal/mol), which is good. The difference is negligible.
**Overall Assessment:**
While Ligand A has a slightly better QED and hERG profile, Ligand B significantly outperforms it in crucial ADME properties for a GPCR target: lower TPSA, better logP, *much* lower DILI risk, better metabolic stability (Cl_mic and t1/2), and lower P-gp efflux. The similar binding affinity makes the ADME advantages of Ligand B decisive. The poor Caco-2 and solubility for both are concerning, but can be addressed with formulation strategies.
Therefore, I would choose Ligand B.
0
2025-04-17 20:13:04,621 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (346.43 & 335.40 Da) fall comfortably within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (67.87) is higher than Ligand B (38.77). For a cardiovascular GPCR, TPSA isn't a *major* concern like it would be for a CNS target, but lower is generally preferred for absorption. Ligand B is better.
3. **logP:** Ligand B (3.71) is higher than Ligand A (2.30). While both are within the optimal 1-3 range, Ligand B is approaching the upper limit. This could potentially lead to solubility issues, but is not a dealbreaker.
4. **HBD:** Ligand A (1) is slightly higher than Ligand B (0). This is a minor difference and doesn't significantly impact the decision.
5. **HBA:** Ligand A (4) is higher than Ligand B (3). Again, a minor difference, and both are within acceptable limits.
6. **QED:** Ligand A (0.91) has a better QED score than Ligand B (0.80), indicating a more drug-like profile. This is a positive for Ligand A.
7. **DILI:** Ligand B (49.01) has a slightly higher DILI risk than Ligand A (43.62), but both are below the concerning threshold of 60. Ligand A is slightly better.
8. **BBB:** Ligand A (87.71) has a significantly higher BBB penetration percentile than Ligand B (76.54). While ADRB2 isn't primarily a CNS target, some degree of BBB penetration can be beneficial.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.471 and -4.349), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand B (-3.61) has slightly worse solubility than Ligand A (-2.85), but both are poor.
11. **hERG:** Both ligands have low hERG inhibition risk (0.581 and 0.516). No significant difference.
12. **Cl_mic:** Ligand A (-6.39) has a much lower (better) microsomal clearance than Ligand B (42.47). This suggests significantly better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (11.82) has a shorter in vitro half-life than Ligand B (22.52). This is a negative for Ligand A.
14. **Pgp:** Ligand A (0.081) has a lower P-gp efflux liability than Ligand B (0.404). Lower efflux is generally preferred for bioavailability.
15. **Binding Affinity:** Ligand B (-8.0) has a stronger binding affinity than Ligand A (-7.3). This is a substantial difference (1.7 kcal/mol) and a major advantage for Ligand B.
**Overall Assessment:**
The most critical factor for GPCRs is binding affinity, and Ligand B has a significantly stronger affinity. While Ligand A has better QED, metabolic stability (Cl_mic), and Pgp efflux, the large difference in binding affinity outweighs these advantages. The poor Caco-2 values are a concern for both, but can be addressed with formulation strategies. The slightly higher DILI risk of Ligand B is manageable.
Output:
0
2025-04-17 20:13:04,622 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (363.571 and 369.897 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (44.37) is significantly better than Ligand B (81.33). For a GPCR, keeping TPSA low is beneficial for permeability, and Ligand A is well below the 140 threshold. Ligand B is higher, potentially hindering absorption.
3. **logP:** Ligand A (4.156) is higher than Ligand B (1.763). While both are within the acceptable range, Ligand A is approaching the upper limit, which *could* lead to solubility issues, but might be acceptable given the target. Ligand B is quite low, potentially impacting membrane permeability.
4. **HBD:** Both ligands have 2 HBD, which is within the ideal range.
5. **HBA:** Ligand A has 3 HBA, and Ligand B has 4. Both are acceptable, but lower is generally preferred.
6. **QED:** Both ligands have good QED scores (0.564 and 0.684), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (23.071) has a much lower DILI risk than Ligand B (35.363). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (90.5) has a much higher BBB penetration potential than Ligand B (56.805). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be beneficial or at least avoided as an off-target effect.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
10. **Solubility:** Ligand A (-3.407) has slightly worse solubility than Ligand B (-2.597). This is a minor drawback for Ligand A.
11. **hERG:** Both ligands have low hERG inhibition risk (0.894 and 0.798).
12. **Cl_mic:** Ligand A (78.348) has a higher microsomal clearance than Ligand B (22.761). This suggests Ligand B is more metabolically stable, which is a positive.
13. **t1/2:** Ligand A (48.381) has a significantly longer in vitro half-life than Ligand B (-4.968). This is a major advantage for Ligand A.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.718 and 0.087). Ligand B is slightly better.
15. **Binding Affinity:** Ligand A (-7.5 kcal/mol) has a stronger binding affinity than Ligand B (-6.1 kcal/mol). This is a substantial difference (1.4 kcal/mol) and a key factor.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand A is the stronger candidate. The significantly better binding affinity (-7.5 vs -6.1 kcal/mol) and lower DILI risk are major advantages. While Ligand B has better metabolic stability and slightly better solubility, the superior affinity, BBB penetration, and lower toxicity of Ligand A outweigh these benefits. The TPSA of Ligand A is also much more favorable.
Output:
1
2025-04-17 20:13:04,622 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (355-382 Da). No significant difference.
2. **TPSA:** Ligand A (63.24) is better than Ligand B (71.84). Lower TPSA generally favors oral absorption, important for a cardiovascular target.
3. **logP:** Both are excellent (around 3.5-3.6), falling within the optimal range for GPCRs.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD can improve permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (4). Lower HBA can improve permeability.
6. **QED:** Both are good (0.813 and 0.862), indicating good drug-like properties.
7. **DILI:** Ligand A (45.095) is significantly better than Ligand B (52.036). Lower DILI risk is crucial.
8. **BBB:** Both are good (70.997 and 75.805), but Ligand B is slightly better. For a cardiovascular target, BBB penetration isn't a primary concern, but it doesn't hurt.
9. **Caco-2:** Both are very poor (-4.947 and -4.945). This is a significant drawback for both compounds.
10. **Solubility:** Both are very poor (-3.399 and -3.697). This is a significant drawback for both compounds.
11. **hERG:** Both are low risk (0.31). This is good.
12. **Cl_mic:** Ligand B (17.285) has significantly lower microsomal clearance than Ligand A (26.845), suggesting better metabolic stability.
13. **t1/2:** Ligand A (37.208) has a longer half-life than Ligand B (27.044).
14. **Pgp:** Both are low efflux (0.414 and 0.05). Ligand B is slightly better.
15. **Binding Affinity:** Ligand B (-7.7 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.9 kcal/mol). This is a 0.8 kcal/mol difference, which is substantial and can outweigh some ADME drawbacks.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Both ligands have good logP. Ligand A has a better TPSA. Both have good Pgp. However, Ligand B's significantly stronger binding affinity (-7.7 vs -6.9) is a major advantage. While both have poor Caco-2 and solubility, the potency advantage of Ligand B is likely to be more impactful in driving forward development, as formulation strategies can be employed to address solubility and permeability issues. The lower DILI risk of Ligand A is also a positive, but the affinity difference is larger.
**Conclusion:**
Despite the slightly better DILI and TPSA of Ligand A, the significantly improved binding affinity of Ligand B makes it the more promising drug candidate. The potency advantage is likely to be more impactful than the minor ADME differences.
Output:
0
2025-04-17 20:13:04,622 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.39 & 388.92 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand B (76.66) is significantly lower than Ligand A (102.96). This is a substantial advantage for oral absorption, a key consideration for GPCRs.
3. **logP:** Both ligands have good logP values (1.03 & 2.47), falling within the 1-3 range. Ligand B is slightly better.
4. **HBD:** Both have 2 HBD, which is acceptable.
5. **HBA:** Ligand A has 6 HBA, and Ligand B has 5. Both are within the acceptable range of <=10.
6. **QED:** Both ligands have good QED scores (0.508 & 0.645), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand B (36.49%) has a much lower DILI risk than Ligand A (67.74%). This is a significant advantage.
8. **BBB:** Both have reasonable BBB penetration (76.31% & 69.33%). While ADRB2 isn't exclusively a CNS target, some CNS exposure could be relevant depending on the specific indication.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Both have negative solubility values, which is also unusual. Again, the scale is not specified.
11. **hERG:** Both have low hERG inhibition liability (0.25 & 0.367), which is good.
12. **Cl_mic:** Ligand A (48.79) has lower microsomal clearance than Ligand B (56.88), indicating better metabolic stability.
13. **t1/2:** Ligand B (46.64) has a significantly longer in vitro half-life than Ligand A (-33.40). This is a major advantage.
14. **Pgp:** Both have low P-gp efflux liability (0.152 & 0.102), which is good.
15. **Affinity:** Ligand A (-7.8 kcal/mol) has a slightly better binding affinity than Ligand B (-6.5 kcal/mol). This is a 1.3 kcal/mol difference, which is a notable advantage.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity, Ligand B demonstrates a superior ADMET profile. Specifically, the lower DILI risk, longer half-life, and lower TPSA are compelling advantages. The slightly weaker binding affinity of Ligand B can potentially be optimized in subsequent iterations of drug design. Given the GPCR-specific priorities (logP, TPSA, Pgp), Ligand B is the more promising candidate. The unusual negative values for Caco-2 and solubility are concerning and would warrant further investigation, but the other factors weigh heavily in favor of Ligand B.
Output:
0
2025-04-17 20:13:04,622 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Ligand A (432.265 Da) is within the ideal range, while Ligand B (366.443 Da) is also acceptable, though slightly lower. No strong preference here.
2. **TPSA:** Ligand A (57.78) is excellent, well below the 140 threshold. Ligand B (109.25) is still reasonable, but higher. This favors Ligand A.
3. **logP:** Ligand A (4.687) is a bit high, potentially leading to solubility issues and off-target effects. Ligand B (1.813) is almost ideal. This strongly favors Ligand B.
4. **HBD:** Ligand A (2) is good. Ligand B (3) is also acceptable. No strong preference.
5. **HBA:** Ligand A (3) is good. Ligand B (6) is higher, potentially impacting permeability. This favors Ligand A.
6. **QED:** Both ligands (A: 0.629, B: 0.657) have good drug-likeness scores. No strong preference.
7. **DILI:** Ligand A (85.537) has a higher DILI risk than Ligand B (74.68). This favors Ligand B.
8. **BBB:** Ligand A (77.2) shows good BBB penetration, while Ligand B (27.414) is poor. Given ADRB2's role in cardiovascular function, CNS penetration isn't a primary concern, but it's a slight edge for A.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-5.395) has worse solubility than Ligand B (-3.711). This favors Ligand B.
11. **hERG:** Ligand A (0.779) has a slightly higher hERG risk than Ligand B (0.248). This favors Ligand B.
12. **Cl_mic:** Ligand A (33.553) has lower microsomal clearance, indicating better metabolic stability, than Ligand B (47.189). This favors Ligand A.
13. **t1/2:** Ligand A (50.13) has a significantly longer half-life than Ligand B (6.782). This is a major advantage for Ligand A.
14. **Pgp:** Ligand A (0.633) has lower P-gp efflux, which is favorable. Ligand B (0.045) has very high P-gp efflux, which is a significant drawback. This strongly favors Ligand A.
15. **Affinity:** Ligand A (-7.1 kcal/mol) has a slightly better binding affinity than Ligand B (-6.8 kcal/mol). While the difference is not huge, it is enough to consider.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP, while Ligand A performs better in TPSA, Pgp, and has slightly better affinity. The longer half-life and better metabolic stability of Ligand A are also highly desirable. The higher DILI risk of Ligand A is a concern, but the other advantages outweigh this.
**Conclusion:**
Considering the balance of properties, especially the favorable Pgp, t1/2, TPSA, and affinity, Ligand A is the more promising drug candidate.
Output:
1
2025-04-17 20:13:04,622 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (345.4) is within the ideal range (200-500), while Ligand B (368.5) is also acceptable. No clear advantage here.
2. **TPSA:** Ligand A (121.5) is slightly above the preferred <140 for oral absorption, but still reasonable. Ligand B (69.6) is excellent, well below 140, suggesting better permeability. This favors Ligand B.
3. **logP:** Ligand A (0.213) is quite low, potentially hindering membrane permeability. Ligand B (2.178) is within the optimal 1-3 range. This strongly favors Ligand B.
4. **HBD:** Ligand A (4) is acceptable, while Ligand B (2) is even better, potentially improving permeability. This favors Ligand B.
5. **HBA:** Both ligands have 4 HBA, which is acceptable. No significant difference.
6. **QED:** Ligand B (0.78) has a better QED score than Ligand A (0.538), indicating a more drug-like profile. This favors Ligand B.
7. **DILI:** Ligand A (31.7) has a slightly higher DILI risk than Ligand B (21.8), but both are below the concerning threshold of 60. This slightly favors Ligand B.
8. **BBB:** Ligand A (32.1) has a low BBB penetration, which is not critical for a non-CNS target like ADRB2 but not helpful. Ligand B (59.1) shows better BBB penetration, which is a bonus.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and indicates poor permeability in this assay. This is a concern for both.
10. **Solubility:** Both ligands have negative solubility values, which is also unusual and indicates poor solubility. This is a concern for both.
11. **hERG:** Ligand A (0.141) has a lower hERG risk than Ligand B (0.419), which is a positive. This favors Ligand A.
12. **Cl_mic:** Ligand A (-1.913) has a significantly lower (better) microsomal clearance than Ligand B (38.0), indicating better metabolic stability. This strongly favors Ligand A.
13. **t1/2:** Ligand A (9.3) has a positive in vitro half-life, while Ligand B (-9.3) has a negative value, which is concerning. This strongly favors Ligand A.
14. **Pgp:** Ligand A (0.005) has very low P-gp efflux, while Ligand B (0.185) has slightly higher efflux. This favors Ligand A.
15. **Affinity:** Ligand B (-5.3) has a slightly better binding affinity than Ligand A (-3.1). This favors Ligand B, but the difference isn't huge.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand B initially appears more promising due to its better logP, TPSA, and affinity. However, Ligand A demonstrates significantly better metabolic stability (Cl_mic and t1/2), lower P-gp efflux, and a lower hERG risk. The poor Caco-2 and solubility values for both are concerning, but can potentially be addressed with formulation strategies. Given the importance of metabolic stability and reduced toxicity for a cardiovascular target, and the relatively small affinity difference, the advantages of Ligand A outweigh those of Ligand B.
Output:
1
2025-04-17 20:13:04,622 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.471 and 360.479 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (67.43) is slightly higher than Ligand B (58.64). Both are below the 140 threshold for oral absorption, and acceptable for a cardiovascular target. Ligand B is preferable.
3. **logP:** Both ligands have excellent logP values (3.034 and 2.962), falling within the optimal 1-3 range. No significant difference.
4. **HBD:** Ligand A has 2 HBD, and Ligand B has 1. Both are within the acceptable limit of <=5. Ligand B is slightly preferable.
5. **HBA:** Ligand A has 3 HBA, and Ligand B has 5. Both are within the acceptable limit of <=10. Ligand A is preferable.
6. **QED:** Both ligands have good QED scores (0.684 and 0.852), indicating good drug-like properties. Ligand B is preferable.
7. **DILI:** Ligand A (14.851) has a significantly lower DILI risk than Ligand B (50.64). This is a major advantage for Ligand A.
8. **BBB:** Both ligands have good BBB penetration (73.943 and 78.945). No significant difference.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.291 and -4.641), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Both ligands have negative solubility values (-3.342 and -3.943), which is also concerning and suggests poor aqueous solubility. This is a concern for both.
11. **hERG:** Both ligands have low hERG inhibition liability (0.44 and 0.522), which is good. No significant difference.
12. **Cl_mic:** Ligand B (73.764) has lower microsomal clearance than Ligand A (92.946), suggesting better metabolic stability. Ligand B is preferable.
13. **t1/2:** Ligand B (29.936) has a significantly longer in vitro half-life than Ligand A (-21.115). This is a major advantage for Ligand B.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.134 and 0.26). No significant difference.
15. **Binding Affinity:** Ligand A (-7.6) has a stronger binding affinity than Ligand B (-5.9). This is a substantial advantage for Ligand A (a 1.7 kcal/mol difference).
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, Pgp, TPSA, and affinity. Both ligands perform well on logP and Pgp. TPSA is acceptable for both. The significant difference lies in affinity and DILI. Ligand A has a much better affinity, and a significantly lower DILI risk. While Ligand B has better metabolic stability and half-life, the potency and safety profile of Ligand A are more compelling. The negative Caco-2 and solubility values are concerning for both, but can be addressed with formulation strategies.
**Conclusion:**
Despite the better metabolic stability and half-life of Ligand B, the superior binding affinity and significantly lower DILI risk of Ligand A make it the more promising drug candidate.
Output:
1
2025-04-17 20:13:04,622 - INFO - Here's my reasoning and final output for the ligand preference:
**Reasoning:**
We are targeting ADRB2, a GPCR, so the priorities are logP, Pgp, TPSA, affinity, and BBB. Let's break down the comparison:
1. **MW:** Both ligands are within the acceptable range (200-500 Da). Ligand A (335.319) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are below the 140 A^2 threshold for oral absorption. Ligand B (90.9) is better, being closer to the 90 A^2 target for CNS penetration, though CNS penetration isn't the primary goal here.
3. **logP:** Ligand A (2.411) is optimal, while Ligand B (0.075) is quite low, potentially hindering membrane permeability. This is a significant drawback for Ligand B.
4. **HBD/HBA:** Both have reasonable HBD/HBA counts. Ligand B has 3 HBDs vs 2 for Ligand A.
5. **QED:** Ligand A (0.765) has a significantly better QED score than Ligand B (0.512), indicating better overall drug-likeness.
6. **DILI:** Ligand B (5.196) has a much lower DILI risk than Ligand A (98.527). This is a major advantage for Ligand B.
7. **BBB:** Ligand A (61.342) has a better BBB percentile than Ligand B (53.16), but BBB isn't a primary concern for ADRB2.
8. **Caco-2:** Ligand A (-4.653) has a better Caco-2 permeability than Ligand B (-5.087).
9. **Solubility:** Ligand A (-5.675) has better solubility than Ligand B (-0.7).
10. **hERG:** Both ligands have low hERG risk.
11. **Cl_mic:** Ligand B (-10.294) has significantly better metabolic stability (lower clearance) than Ligand A (5.553).
12. **t1/2:** Ligand A (14.383) has a better in vitro half-life than Ligand B (0.514).
13. **Pgp:** Ligand A (0.196) has a lower Pgp efflux liability than Ligand B (0.247), which is favorable.
14. **Affinity:** Ligand A (-7.9 kcal/mol) has a substantially better binding affinity than Ligand B (-6.3 kcal/mol). This is a >1.5 kcal/mol difference, and is a very strong driver for preference.
**Overall Assessment:**
Ligand A has a significantly better binding affinity and a good QED score, better solubility, Caco-2 permeability and half-life. While Ligand B has a better DILI score and metabolic stability, the poor logP and weaker binding affinity are major concerns for a GPCR target. The strong affinity of Ligand A outweighs the DILI risk, especially considering the other favorable properties.
**Output:**
1
2025-04-17 20:13:04,622 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (345.363) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (54.69) is significantly better than Ligand A (127.94). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (2.649) is optimal, while Ligand A (-0.621) is too low, potentially leading to poor membrane permeability. This is a significant drawback for Ligand A.
4. **HBD:** Both ligands are acceptable (Ligand A: 2, Ligand B: 1).
5. **HBA:** Both ligands are acceptable (Ligand A: 10, Ligand B: 7).
6. **QED:** Both ligands have good drug-likeness scores (Ligand A: 0.681, Ligand B: 0.757).
7. **DILI:** Ligand B (76.425) has a higher DILI risk than Ligand A (65.917), but both are in a moderate range.
8. **BBB:** Ligand B (81.97) has higher BBB penetration, but this is less critical for a cardiovascular target.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-5.383) is slightly worse than Ligand B (-4.676).
10. **Solubility:** Both ligands have negative solubility values, which is also unusual and suggests poor solubility. Ligand A (-1.847) is slightly better than Ligand B (-2.744).
11. **hERG:** Ligand A (0.029) has a much lower hERG risk than Ligand B (0.963). This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand A (23.552) has lower microsomal clearance, indicating better metabolic stability, compared to Ligand B (38.849).
13. **t1/2:** Ligand B (16.725) has a longer in vitro half-life than Ligand A (3.905).
14. **Pgp:** Ligand A (0.046) has lower P-gp efflux, which is favorable for bioavailability, compared to Ligand B (0.675).
15. **Affinity:** Both ligands have comparable binding affinities (-6.9 kcal/mol and -6.7 kcal/mol). The difference is not substantial enough to outweigh other factors.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand B excels in logP and has a much lower TPSA. While the affinity difference is small, the poor logP of Ligand A is a major concern. The lower hERG and Cl_mic of Ligand A are positives, but the permeability issues (indicated by Caco-2 and logP) are more critical for a GPCR target.
**Conclusion:**
Despite the higher DILI risk, Ligand B's superior logP and TPSA, combined with a reasonable half-life, make it the more promising candidate. The permeability issues with Ligand A are too significant to ignore.
Output:
0
2025-04-17 20:13:04,622 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
Let's systematically compare Ligand A and Ligand B against the provided guidelines, keeping in mind this is a GPCR target (ADRB2, cardiovascular). Therefore, logP, Pgp, TPSA, and affinity are particularly important.
1. **MW:** Both ligands (359.813 and 369.441 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (75.86 and 77.04) are below the 140 A^2 threshold for good oral absorption. This is good.
3. **logP:** Both ligands have a logP around 2.7 (2.782 and 2.715), which is optimal for permeability and solubility. No clear advantage.
4. **HBD:** Ligand A has 2 HBD, and Ligand B has 1. Lower is generally preferred for permeability, but both are acceptable.
5. **HBA:** Ligand A has 5 HBA, and Ligand B has 6. Both are below the 10 threshold.
6. **QED:** Ligand B (0.814) has a better QED score than Ligand A (0.678), suggesting a more drug-like profile.
7. **DILI:** Ligand B (41.411) has a significantly lower DILI risk than Ligand A (76.89). This is a major advantage for Ligand B.
8. **BBB:** Ligand B (83.792) shows significantly better BBB penetration potential than Ligand A (32.687). While ADRB2 isn't necessarily a CNS target, some peripheral ADRB2 activity can be modulated by CNS effects, and better BBB penetration can sometimes correlate with better overall distribution.
9. **Caco-2:** Both have negative values, indicating permeability. Ligand A (-5.411) is slightly better than Ligand B (-4.729).
10. **Solubility:** Both have negative solubility values, indicating poor solubility. Ligand A (-3.342) is slightly better than Ligand B (-3.722).
11. **hERG:** Both ligands have low hERG inhibition liability (0.105 and 0.296), which is good.
12. **Cl_mic:** Ligand A (6.839) has a much lower microsomal clearance than Ligand B (37.844), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand B (-13.899) has a much longer in vitro half-life than Ligand A (-0.419). This is a major advantage for Ligand B.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.071). No significant difference.
15. **Affinity:** Ligand A (-8.1 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.5 kcal/mol). This is a substantial advantage for Ligand A. A 1.6 kcal/mol difference is quite significant.
**Overall Assessment:**
Ligand A has a clear advantage in binding affinity and metabolic stability (lower Cl_mic). However, Ligand B excels in DILI risk, BBB penetration, and in vitro half-life, and has a better QED score. The stronger affinity of Ligand A is a major plus, and a 1.6 kcal/mol difference is substantial enough to potentially overcome some of the ADME drawbacks. Given the importance of binding affinity for GPCRs, and the relatively manageable DILI and solubility issues, I favor Ligand A.
**Output:**
1
2025-04-17 20:13:04,622 - INFO - Batch 168 complete. Total preferences: 2688
2025-04-17 20:13:04,623 - INFO - Processing batch 169/512...
2025-04-17 20:13:48,256 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (401.264 Da) is within the ideal range. Ligand B (359.455 Da) is also good, slightly lower but still acceptable.
2. **TPSA:** Ligand A (60.25) is excellent, well below the 140 threshold. Ligand B (96.87) is higher, but still reasonable for a peripherally acting GPCR.
3. **logP:** Ligand A (2.938) is optimal. Ligand B (1.909) is slightly lower, but still within the acceptable range.
4. **HBD:** Ligand A (0) is good. Ligand B (2) is also acceptable.
5. **HBA:** Ligand A (5) is good. Ligand B (6) is also acceptable.
6. **QED:** Both Ligand A (0.663) and Ligand B (0.85) have good drug-likeness scores. Ligand B is slightly better.
7. **DILI:** Ligand A (69.29) is acceptable, but approaching the higher risk zone. Ligand B (76.076) is higher, indicating a greater potential for liver injury.
8. **BBB:** Ligand A (60.876) is moderate, while Ligand B (45.909) is lower. Since ADRB2 isn't exclusively a CNS target, this isn't a critical factor, but a higher BBB is generally preferred.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.835) is slightly better than Ligand B (-5.149).
10. **Solubility:** Both ligands have negative solubility values, which is also unusual and suggests poor solubility. Ligand A (-2.8) is slightly better than Ligand B (-3.145).
11. **hERG:** Ligand A (0.707) has a lower hERG risk than Ligand B (0.069). This is a significant advantage.
12. **Cl_mic:** Ligand A (62.96) has higher metabolic clearance than Ligand B (24.909), indicating lower metabolic stability. This is a drawback for Ligand A.
13. **t1/2:** Ligand A (-1.284) has a shorter in vitro half-life than Ligand B (11.16), indicating faster metabolism. This is a significant drawback for Ligand A.
14. **Pgp:** Ligand A (0.841) has higher P-gp efflux than Ligand B (0.033). This is a drawback for Ligand A.
15. **Affinity:** Ligand B (-7.3 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.1 kcal/mol). This is a substantial advantage, potentially outweighing some ADME concerns.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand B excels in affinity and Pgp efflux, and has acceptable logP and TPSA. Ligand A has a better hERG profile, but suffers from poorer metabolic stability, shorter half-life, and higher P-gp efflux. The significantly stronger binding affinity of Ligand B is a major advantage.
**Conclusion:**
Despite the higher DILI risk for Ligand B, the substantially improved binding affinity (-7.3 vs -6.1 kcal/mol) and lower P-gp efflux, coupled with a better half-life, make it the more promising candidate. The difference in affinity is large enough to potentially overcome the DILI concern with further optimization.
Output:
0
2025-04-17 20:13:48,256 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.39 and 359.58 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (93.9) is better than Ligand B (20.31). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is generally favorable for permeability. Ligand B is exceptionally low, which could be a concern for binding.
3. **logP:** Ligand A (1.1) is within the optimal range (1-3). Ligand B (4.801) is high, potentially leading to solubility issues and off-target interactions. This is a significant negative for Ligand B.
4. **HBD:** Ligand A (1) is good. Ligand B (0) is also acceptable.
5. **HBA:** Ligand A (6) is good. Ligand B (2) is also good.
6. **QED:** Ligand A (0.707) is better than Ligand B (0.664), indicating a more drug-like profile.
7. **DILI:** Ligand A (62.35) is higher than Ligand B (16.751), indicating a higher risk of drug-induced liver injury. This is a significant negative for Ligand A.
8. **BBB:** Ligand A (60.954) is lower than Ligand B (92.361). While ADRB2 isn't a primary CNS target, some BBB penetration can be beneficial for distribution. Ligand B has a much better score.
9. **Caco-2:** Ligand A (-4.658) is worse than Ligand B (-5.023). Both are negative values, indicating poor permeability.
10. **Solubility:** Ligand A (-2.227) is better than Ligand B (-4.959), suggesting better aqueous solubility. This is important given Ligand B's high logP.
11. **hERG:** Ligand A (0.08) is much better than Ligand B (0.927), indicating a lower risk of cardiotoxicity. This is *very* important for a cardiovascular target.
12. **Cl_mic:** Ligand A (21.864) is much lower than Ligand B (139.207), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (-21.539) is worse than Ligand B (27.973). Ligand B has a longer in vitro half-life, which is desirable.
14. **Pgp:** Ligand A (0.024) is much lower than Ligand B (0.789), indicating less P-gp efflux and potentially better bioavailability.
15. **Affinity:** Ligand B (-6.5 kcal/mol) is slightly better than Ligand A (-5.8 kcal/mol). This is a 0.7 kcal/mol difference, which is not substantial enough to outweigh other significant differences.
**Overall Assessment:**
Ligand B has a superior binding affinity and BBB penetration, and a longer half-life. However, its very high logP, higher DILI risk, and worse hERG profile are major concerns. Ligand A has a better balance of properties, particularly regarding safety (hERG, DILI) and metabolic stability (Cl_mic). While its affinity is slightly lower, the other advantages, combined with the importance of minimizing cardiotoxicity for an ADRB2-targeting drug, make it the more promising candidate.
Output:
1
2025-04-17 20:13:48,256 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (342.439 Da and 348.531 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (62.55) is higher than Ligand B (49.41). For a cardiovascular GPCR, TPSA is moderately important, and lower is generally preferred for better permeability. Ligand B has an advantage.
**3. logP:** Both ligands have logP values around 3.5-3.9, which is within the optimal 1-3 range, leaning slightly high. No major difference.
**4. H-Bond Donors:** Both have 1 HBD, which is good.
**5. H-Bond Acceptors:** Ligand A has 3 HBA, while Ligand B has 2. Both are acceptable, but lower is slightly preferred. Ligand B has a slight advantage.
**6. QED:** Ligand A (0.797) has a significantly better QED score than Ligand B (0.609), indicating a more drug-like profile. This is a notable advantage for Ligand A.
**7. DILI Risk:** Ligand B (16.906) has a much lower DILI risk than Ligand A (31.989). This is a significant advantage for Ligand B, as minimizing liver toxicity is crucial.
**8. BBB Penetration:** Both ligands show good BBB penetration (Ligand A: 78.713, Ligand B: 85.072). Ligand B is slightly better. While ADRB2 is primarily cardiovascular, some CNS side effects are possible with GPCR ligands, so some BBB penetration is not necessarily negative.
**9. Caco-2 Permeability:** Both have negative Caco-2 values (-4.566 and -4.55), which is unusual and suggests poor permeability. This is a concern for both.
**10. Aqueous Solubility:** Both have negative solubility values (-3.962 and -3.29), also unusual and indicating poor solubility. This is a concern for both.
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (0.769 and 0.732), which is good.
**12. Microsomal Clearance:** Ligand B (99.104) has a significantly higher microsomal clearance than Ligand A (82.825), meaning it's metabolized more quickly. This is a disadvantage for Ligand B.
**13. In vitro Half-Life:** Ligand A (82.116) has a much longer in vitro half-life than Ligand B (21.89). This is a significant advantage for Ligand A.
**14. P-gp Efflux:** Both have low P-gp efflux liability (0.202 and 0.689), which is good. Ligand A is slightly better.
**15. Binding Affinity:** Ligand A (-8.0) has a slightly better binding affinity than Ligand B (-5.5). This is a substantial advantage for Ligand A, potentially outweighing some ADME concerns.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), and the general drug-like properties, Ligand A emerges as the more promising candidate. While Ligand B has a lower DILI risk and slightly better BBB penetration, Ligand A's superior QED, binding affinity, in vitro half-life, and slightly better P-gp efflux outweigh these advantages. The poor Caco-2 and solubility for both are concerning, but can potentially be addressed with formulation strategies. The stronger binding affinity of Ligand A is a critical factor for a GPCR target.
Output:
1
2025-04-17 20:13:48,256 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Both ligands have identical binding affinities (-6.7 kcal/mol), which is excellent and removes that as a differentiating factor. Given ADRB2 is a GPCR, the priorities are logP, TPSA, Pgp, BBB, and affinity.
Let's break down the comparison:
1. **Molecular Weight:** Both are within the ideal range (342.4 vs 362.5 Da).
2. **TPSA:** Both are acceptable for oral absorption (<140, at 98.32 and 97.12 respectively).
3. **logP:** Both are within the optimal range (1.199 and 1.93). Ligand B is slightly higher, potentially aiding membrane permeability but also increasing the risk of off-target effects.
4. **H-Bond Donors/Acceptors:** Ligand A has 3 HBD and 4 HBA, while Ligand B has 2 HBD and 6 HBA. Both are within acceptable limits.
5. **QED:** Both have good drug-likeness scores (0.734 and 0.784).
6. **DILI:** Ligand A (42.264) has a significantly lower DILI risk than Ligand B (69.135). This is a major advantage for Ligand A.
7. **BBB:** Ligand A (43.311) has lower BBB penetration than Ligand B (52.191). While ADRB2 isn't necessarily a CNS target, some peripheral ADRB2 receptors can be affected by CNS penetration.
8. **Caco-2 Permeability:** Both have negative Caco-2 values (-5.271 and -5.247), indicating poor permeability. This is a concern for both, but not a deciding factor since they are so close.
9. **Aqueous Solubility:** Both have very poor aqueous solubility (-2.815 and -2.812). This is a significant drawback for both compounds and would require formulation strategies.
10. **hERG Inhibition:** Ligand A (0.237) has a slightly lower hERG risk than Ligand B (0.102). Lower is better, so Ligand A is preferable.
11. **Microsomal Clearance:** Ligand A (-0.675) has much better metabolic stability (lower clearance) than Ligand B (36.2). This is a critical advantage for Ligand A.
12. **In vitro Half-Life:** Ligand A (5.818) has a better in vitro half-life than Ligand B (-12.789).
13. **P-gp Efflux:** Ligand A (0.01) has lower P-gp efflux than Ligand B (0.16). This is favorable for bioavailability.
**Overall Assessment:**
Ligand A is the stronger candidate. While Ligand B has slightly better BBB penetration, Ligand A demonstrates significantly better ADME properties: lower DILI risk, better metabolic stability (lower Cl_mic and longer t1/2), lower P-gp efflux, and a slightly lower hERG risk. The similar binding affinity makes the ADME profile the deciding factor. The poor solubility of both compounds is a concern, but formulation strategies can be explored.
Output:
1
2025-04-17 20:13:48,257 - INFO - Here's my reasoning and final output for the ligand preference:
**Reasoning:**
We are looking for a ligand for ADRB2, a cardiovascular GPCR. Therefore, the priorities are logP, TPSA, Pgp, affinity, and to a lesser extent, BBB.
Let's compare Ligand A and Ligand B across the 15 parameters:
1. **MW:** Both are within the ideal range (200-500 Da).
2. **TPSA:** Ligand A (55.81) is significantly better than Ligand B (83.98). Lower TPSA is preferred for better absorption.
3. **logP:** Ligand A (1.632) is optimal, while Ligand B (3.957) is approaching the upper limit.
4. **HBD:** Both are acceptable (2 and 1 respectively).
5. **HBA:** Both are acceptable (4 and 6 respectively).
6. **QED:** Ligand A (0.852) is better than Ligand B (0.665), indicating a more drug-like profile.
7. **DILI:** Ligand B (58.627) has a slightly higher DILI risk than Ligand A (39.977), but both are acceptable.
8. **BBB:** Ligand A (67.08) is better than Ligand B (48.119), though BBB isn't a primary concern for a cardiovascular target.
9. **Caco-2:** Ligand A (-4.949) is better than Ligand B (-5.633), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-2.491) is better than Ligand B (-3.5), indicating better aqueous solubility.
11. **hERG:** Both are very low risk (0.708 and 0.677).
12. **Cl_mic:** Ligand A (0.681) is significantly better than Ligand B (77.048), indicating much better metabolic stability.
13. **t1/2:** Ligand B (7.227) has a longer half-life than Ligand A (-0.777), which is a positive.
14. **Pgp:** Ligand A (0.149) is better than Ligand B (0.335), indicating lower P-gp efflux.
15. **Affinity:** Ligand A (-7.5) is slightly better than Ligand B (-7.2), but the difference is relatively small.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most crucial ADME properties (TPSA, logP, QED, solubility, Cl_mic, Pgp, Caco-2). While Ligand B has a better half-life, the superior ADME profile and slightly better affinity of Ligand A make it the more promising drug candidate. The lower metabolic clearance of Ligand A is a significant advantage.
**Output:**
1
2025-04-17 20:13:48,257 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (350.5) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (69.64) is significantly better than Ligand B (93.25). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (A: 2.328, B: 2.501), falling within the optimal 1-3 range.
4. **HBD:** Both have 2 HBD, which is acceptable.
5. **HBA:** Ligand A (3) is better than Ligand B (5). Lower HBA is preferred for permeability.
6. **QED:** Both have good QED scores (A: 0.67, B: 0.733), indicating good drug-likeness.
7. **DILI:** Ligand A (6.941) has a *much* lower DILI risk than Ligand B (46.452). This is a significant advantage for Ligand A.
8. **BBB:** Both have reasonable BBB penetration, but Ligand B (68.554) is slightly better than Ligand A (64.017). However, BBB isn't a primary concern for a cardiovascular target.
9. **Caco-2:** Ligand A (-4.88) is better than Ligand B (-5.205) indicating better intestinal absorption.
10. **Solubility:** Ligand A (-2.038) is better than Ligand B (-2.41).
11. **hERG:** Ligand A (0.461) is better than Ligand B (0.193), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand A (27.923) has lower microsomal clearance than Ligand B (36.669), suggesting better metabolic stability.
13. **t1/2:** Ligand B (13.994) has a much longer half-life than Ligand A (0.46). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.115) has lower P-gp efflux than Ligand B (0.044), which is favorable for bioavailability.
15. **Affinity:** Ligand A (-5.6 kcal/mol) has a slightly better binding affinity than Ligand B (-3.8 kcal/mol). This is a substantial difference.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Both ligands are good on logP. Ligand A is significantly better on TPSA and Pgp. The affinity difference is also substantial. While half-life is important, the superior ADME profile and binding affinity of Ligand A outweigh the longer half-life of Ligand B. The drastically lower DILI risk for Ligand A is also a major factor.
**Conclusion:**
Ligand A presents a more balanced and favorable profile overall, particularly considering the ADME properties and the significant advantage in binding affinity and DILI risk.
Output:
1
2025-04-17 20:13:48,257 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, the priorities are logP, TPSA, Pgp, affinity, and, to a lesser extent, BBB.
Let's compare the ligands property by property:
1. **MW:** Both are within the ideal range (348-349 Da).
2. **TPSA:** Ligand B (62.3) is significantly better than Ligand A (80.57), falling well below the 140 threshold and closer to the 90 threshold for potential CNS penetration (though not a primary concern here).
3. **logP:** Both are within the optimal range (2.4-2.9). Ligand B is slightly higher.
4. **HBD/HBA:** Ligand A has 2 HBD and 4 HBA, while Ligand B has 1 HBD and 3 HBA. Both are acceptable.
5. **QED:** Both are very similar (0.756 vs 0.746), indicating good drug-likeness.
6. **DILI:** Ligand B (18.07) has a substantially lower DILI risk than Ligand A (28.38). This is a significant advantage.
7. **BBB:** Ligand B (91.66) shows much better BBB penetration than Ligand A (68.67). While not crucial for a cardiovascular target, it doesn't hurt.
8. **Caco-2:** Both are negative and similar, suggesting similar intestinal absorption.
9. **Solubility:** Both are negative and similar, suggesting similar solubility.
10. **hERG:** Both are low, indicating low cardiotoxicity risk.
11. **Cl_mic:** Both are similar (63.5 vs 62.3).
12. **t1/2:** Ligand A has a significantly longer in vitro half-life (21.49 hours) than Ligand B (-1.4 hours). This is a major drawback for Ligand B.
13. **Pgp:** Ligand A (0.256) has lower P-gp efflux than Ligand B (0.083), which is preferable.
14. **Affinity:** Ligand A (-7.3 kcal/mol) has a slightly better binding affinity than Ligand B (-6.9 kcal/mol), a difference of 0.4 kcal/mol. While a difference is present, it's not a large enough advantage to outweigh the other factors.
**Overall Assessment:**
Ligand B has a better balance of properties, particularly regarding safety (DILI) and permeability (TPSA, BBB). While Ligand A has a longer half-life and slightly better affinity, the lower DILI risk and better permeability profile of Ligand B are more important for a GPCR target. The affinity difference is not substantial enough to overcome the other advantages of Ligand B.
**Output:**
0
2025-04-17 20:13:48,257 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
The target is ADRB2, a GPCR. Therefore, I will prioritize logP, Pgp, TPSA, and affinity, alongside general drug-like properties.
* **Molecular Weight:** Both ligands are within the ideal range (200-500 Da).
* **TPSA:** Ligand A (60.56) is significantly better than Ligand B (90.54). A lower TPSA generally favors better cell permeability, crucial for GPCR targeting.
* **logP:** Ligand A (2.815) is optimal, while Ligand B (0.019) is very low. A logP close to zero can lead to poor membrane permeability and bioavailability. This is a major drawback for Ligand B.
* **H-Bond Donors/Acceptors:** Ligand A (1 HBD, 6 HBA) is preferable to Ligand B (3 HBD, 3 HBA). While both are acceptable, fewer H-bonds can improve permeability.
* **QED:** Both ligands have reasonable QED scores (A: 0.72, B: 0.589), indicating acceptable drug-likeness.
* **DILI:** Both ligands have similar, acceptable DILI risk (A: 41.024, B: 42.458).
* **BBB:** Both have similar BBB penetration (A: 61.303, B: 62.699). While not a primary concern for ADRB2 (which isn't exclusively a CNS target), it's not a differentiating factor here.
* **Caco-2 Permeability:** Both are negative, indicating poor permeability. However, this is expected given the TPSA and logP values.
* **Aqueous Solubility:** Both are negative, indicating poor solubility.
* **hERG:** Ligand A (0.637) has a slightly better hERG profile than Ligand B (0.116), indicating lower cardiotoxicity risk.
* **Microsomal Clearance:** Ligand B (-18.494) has a lower (better) microsomal clearance than Ligand A (22.341), suggesting greater metabolic stability.
* **In vitro Half-Life:** Ligand B (-5.959) has a longer half-life than Ligand A (-17.77), which is a positive attribute.
* **P-gp Efflux:** Ligand A (0.344) has lower P-gp efflux than Ligand B (0.017), which is beneficial for bioavailability.
* **Binding Affinity:** Ligand B (-5.8 kcal/mol) has a stronger binding affinity than Ligand A (-3.1 kcal/mol). This is a significant advantage.
**Overall Assessment:**
While Ligand B has a better binding affinity and metabolic stability, its extremely low logP is a critical flaw. This will likely translate to very poor absorption and bioavailability. Ligand A, despite a weaker binding affinity, possesses a much more favorable logP, TPSA, and P-gp efflux profile, making it more likely to be a viable drug candidate. The difference in binding affinity (2.7 kcal/mol) is substantial, but can potentially be overcome with further optimization, whereas fixing the logP of Ligand B would require more extensive structural changes.
**Output:**
1
2025-04-17 20:13:48,257 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's analyze each ligand against the provided guidelines, with emphasis on GPCR-relevant properties (logP, TPSA, Pgp, BBB, and affinity).
* **Molecular Weight:** Both ligands (349.39 and 346.43 Da) fall comfortably within the ideal 200-500 Da range.
* **TPSA:** Ligand A (138.59) is slightly higher than Ligand B (78.87). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for permeability. Ligand B is significantly better here.
* **logP:** Ligand A (0.658) is a bit low, potentially hindering membrane permeability. Ligand B (1.601) is better, falling within the optimal 1-3 range.
* **H-Bond Donors/Acceptors:** Ligand A has 4 HBD and 4 HBA, while Ligand B has 2 HBD and 4 HBA. Both are acceptable, but Ligand B's lower HBD count might slightly favor permeability.
* **QED:** Ligand B (0.786) has a higher QED score than Ligand A (0.511), indicating a more drug-like profile.
* **DILI:** Ligand B (36.76) has a significantly lower DILI risk than Ligand A (52.15). This is a major advantage for Ligand B.
* **BBB:** Ligand A (50.87) and Ligand B (40.52) are both relatively low. Since ADRB2 is not a CNS target, this is not a major concern.
* **Caco-2 Permeability:** Ligand A (-5.764) has a worse Caco-2 permeability than Ligand B (-4.572).
* **Aqueous Solubility:** Both ligands have poor aqueous solubility (-2.689 and -2.007 respectively). This could pose formulation challenges.
* **hERG:** Ligand A (0.053) has a slightly lower hERG risk than Ligand B (0.532), which is a positive.
* **Microsomal Clearance:** Ligand B (37.604) has a much better microsomal clearance than Ligand A (8.529), indicating greater metabolic stability.
* **In vitro Half-Life:** Ligand B (-22.865) has a significantly longer in vitro half-life than Ligand A (-13.389).
* **P-gp Efflux:** Ligand A (0.01) has a much lower P-gp efflux liability than Ligand B (0.227). This is a positive for Ligand A.
* **Binding Affinity:** Both ligands have very similar binding affinities (-6.6 and -6.3 kcal/mol). The difference is not substantial enough to be a deciding factor.
**Overall Assessment:**
While Ligand A has a slight edge in P-gp efflux and hERG, Ligand B is superior in almost all other critical ADME properties. Specifically, its lower DILI risk, better QED, improved metabolic stability (lower Cl_mic and longer t1/2), better Caco-2 permeability, and lower TPSA make it a more promising drug candidate. The slightly lower logP of Ligand A is a concern, and the significantly worse DILI score for Ligand A is a major drawback. The similar binding affinities mean the ADME profile becomes the primary differentiator.
**Output:**
0
2025-04-17 20:13:48,257 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (354.403 and 346.471 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (99.89) is higher than Ligand B (70.59). For a cardiovascular GPCR, TPSA is moderately important, and Ligand B is better positioned for good absorption.
3. **logP:** Both ligands have good logP values (1.923 and 2.545), falling within the optimal 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Ligand A (1) has fewer HBDs than Ligand B (3). Fewer HBDs are generally preferred for better permeability, giving a slight edge to Ligand A.
5. **HBA:** Ligand A (7) has more HBAs than Ligand B (3). Similar to HBDs, fewer HBAs are generally preferred, favoring Ligand B.
6. **QED:** Both ligands have similar QED values (0.712 and 0.71), indicating good drug-likeness.
7. **DILI:** Ligand A (62.272) has a significantly higher DILI risk than Ligand B (17.759). This is a major concern, as DILI is a frequent cause of drug attrition. Ligand B is clearly superior here.
8. **BBB:** Both ligands have good BBB penetration (73.401 and 76.541). Since ADRB2 is not a CNS target, this is less critical, but Ligand B is slightly better.
9. **Caco-2:** Both ligands have negative Caco-2 permeability values (-4.762 and -4.883). These values are unusual and suggest poor permeability. However, the values are very close and don't differentiate the ligands significantly.
10. **Solubility:** Ligand A (-1.586) has slightly better solubility than Ligand B (-2.6). Solubility is important, but not a primary concern for this target.
11. **hERG:** Ligand A (0.106) has a lower hERG risk than Ligand B (0.773). This is a positive for Ligand A, as hERG inhibition can cause cardiotoxicity.
12. **Cl_mic:** Ligand B (32.513) has significantly lower microsomal clearance than Ligand A (66.273), indicating better metabolic stability. This is a crucial advantage for Ligand B.
13. **t1/2:** Ligand B (31.986) has a much longer in vitro half-life than Ligand A (-7.477). This is a significant advantage for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.02) has lower P-gp efflux than Ligand B (0.285), which is favorable.
15. **Binding Affinity:** Ligand B (-5.9) has a slightly better binding affinity than Ligand A (-5.2). While the difference is not huge, it's enough to be considered.
**Overall Assessment:**
Ligand B is the stronger candidate. While Ligand A has a slight advantage in hERG and Pgp, Ligand B excels in critical areas: significantly lower DILI risk, better metabolic stability (lower Cl_mic and longer t1/2), and slightly better binding affinity. The lower TPSA of Ligand B is also beneficial. The negative Caco-2 values are concerning for both, but the other advantages of Ligand B outweigh this issue. Considering the GPCR-specific priorities (logP, TPSA, affinity), Ligand B is the preferred choice.
Output:
0
2025-04-17 20:13:48,258 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (346.427 Da and 348.422 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (83.73) is better than Ligand B (86.88), both are below the 140 threshold for oral absorption, but closer to the 90 threshold is preferred.
**3. logP:** Both ligands have good logP values (2.925 and 2.393 respectively), falling within the optimal 1-3 range. Ligand A is slightly higher and potentially better for membrane permeability.
**4. H-Bond Donors:** Both ligands have 3 HBD, which is within the acceptable limit of 5.
**5. H-Bond Acceptors:** Ligand A has 4 HBA, while Ligand B has 3. Both are below the 10 limit.
**6. QED:** Ligand A (0.72) has a slightly better QED score than Ligand B (0.631), indicating a more drug-like profile.
**7. DILI:** Both ligands have acceptable DILI risk (47.421 and 44.048 respectively), well below the concerning threshold of 60. Ligand B is slightly better.
**8. BBB:** Ligand B (78.441) has a significantly higher BBB penetration percentile than Ligand A (41.915). While ADRB2 is a cardiovascular target, some CNS exposure is not necessarily detrimental and can be a bonus.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.764 and -4.899), which is unusual and suggests poor permeability. This is a major concern for both.
**10. Aqueous Solubility:** Both ligands have very poor aqueous solubility (-3.029 and -3.983). This is a significant drawback.
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (0.72 and 0.417 respectively).
**12. Microsomal Clearance:** Ligand B (22.24) has significantly lower microsomal clearance than Ligand A (46.905), indicating better metabolic stability. This is a major advantage for Ligand B.
**13. In vitro Half-Life:** Ligand A (55.766) has a longer in vitro half-life than Ligand B (-6.344). This is a positive for Ligand A.
**14. P-gp Efflux:** Both ligands have similar P-gp efflux liability (0.417 and 0.068).
**15. Binding Affinity:** Ligand A (-5.9 kcal/mol) has a slightly better binding affinity than Ligand B (-5.4 kcal/mol). This is a positive for Ligand A, but the difference isn't huge.
**GPCR-Specific Considerations:** For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. While BBB isn't paramount for a cardiovascular target, it's not detrimental.
**Overall Assessment:**
Ligand B has a clear advantage in metabolic stability (lower Cl_mic) and BBB penetration. Ligand A has a slightly better affinity and half-life, but the poor solubility and permeability of both are major concerns. The improved metabolic stability of Ligand B is more valuable than the slight affinity advantage of Ligand A, especially considering the poor ADME profiles of both.
Output:
0
2025-04-17 20:13:48,258 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (349.475 and 351.466 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (69.72) is significantly better than Ligand B (81.99). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand A is well below the 140 threshold, while Ligand B is approaching it.
3. **logP:** Both ligands have acceptable logP values (1.563 and 2.713), falling within the 1-3 range. Ligand B is slightly higher, which *could* be a minor concern for solubility, but not a dealbreaker.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Both ligands have the same number of HBA (3). This is acceptable.
6. **QED:** Both ligands have similar QED values (0.766 and 0.705), both above the 0.5 threshold, indicating good drug-likeness.
7. **DILI:** Both ligands have very similar and low DILI risk (24.622 and 24.544 percentile), indicating a low risk of liver injury.
8. **BBB:** Ligand B (81.892) is significantly better than Ligand A (61.497) in terms of BBB penetration. While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant for off-target effects and a higher BBB percentile is generally favorable.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.646 and -4.683). These values are unusual and suggest poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand A (-2.18) has better solubility than Ligand B (-3.844), which is important for bioavailability.
11. **hERG:** Ligand A (0.103) shows a much lower hERG inhibition liability than Ligand B (0.738). This is a critical advantage, as hERG inhibition can lead to cardiotoxicity.
12. **Cl_mic:** Ligand A (37.422) has a lower microsomal clearance than Ligand B (53.114), indicating better metabolic stability.
13. **t1/2:** Ligand A (2.56) has a slightly longer in vitro half-life than Ligand B (2.126).
14. **Pgp:** Ligand A (0.034) has a much lower P-gp efflux liability than Ligand B (0.113), which is beneficial for oral bioavailability and potential CNS exposure.
15. **Binding Affinity:** Ligand A (-7.5 kcal/mol) has a significantly stronger binding affinity than Ligand B (-5.5 kcal/mol). This is a substantial difference (2 kcal/mol), and a strong affinity is paramount for a drug candidate.
**Overall Assessment:**
Despite the poor Caco-2 values for both, Ligand A is the clear preference. The significantly stronger binding affinity (-7.5 vs -5.5 kcal/mol) is a major advantage, and it's supported by better TPSA, HBD, solubility, hERG liability, metabolic stability (Cl_mic), half-life, and P-gp efflux. While Ligand B has better BBB penetration, the other advantages of Ligand A outweigh this benefit, especially considering ADRB2 isn't strictly a CNS target. The lower hERG risk for Ligand A is also a critical factor.
Output:
1
2025-04-17 20:13:48,258 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's analyze each ligand against the provided guidelines, with emphasis on GPCR-relevant parameters (logP, TPSA, Pgp, BBB, and affinity).
* **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (344.415 Da) is slightly lower, which is generally favorable for permeability.
* **TPSA:** Both ligands have TPSA values below 140, indicating good potential for oral absorption. Ligand B (74.76) is slightly better than Ligand A (89.01).
* **logP:** Both ligands have logP values within the optimal range (1-3). Ligand A (1.536) and Ligand B (1.404) are very similar.
* **H-Bond Donors/Acceptors:** Ligand A has 2 HBD and 5 HBA, while Ligand B has 0 HBD and 5 HBA. Both are within acceptable limits. The lower HBD count for Ligand B might slightly improve permeability.
* **QED:** Ligand A (0.805) has a better QED score than Ligand B (0.657), suggesting a more drug-like profile overall.
* **DILI:** Ligand B (38.736) has a significantly lower DILI risk than Ligand A (57.348). This is a major advantage for Ligand B.
* **BBB:** Ligand B (62.466) shows better BBB penetration potential than Ligand A (54.207), although neither is exceptionally high. For a cardiovascular target, BBB penetration is less critical, but still a consideration.
* **Caco-2 Permeability:** Both ligands have negative Caco-2 values, indicating poor permeability. This is a concern for both.
* **Aqueous Solubility:** Both ligands have very poor aqueous solubility (-2.862 and -2.3 respectively). This is a significant drawback for both compounds and would require formulation strategies to address.
* **hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.404 and 0.185 respectively).
* **Microsomal Clearance:** Ligand A (37.426) has a higher microsomal clearance than Ligand B (15.711), indicating lower metabolic stability. This is a significant advantage for Ligand B.
* **In vitro Half-Life:** Ligand B (4.376) has a slightly longer half-life than Ligand A (7.987).
* **P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.165 and 0.133 respectively).
* **Binding Affinity:** Ligand B (-5.2 kcal/mol) has a significantly stronger binding affinity than Ligand A (-2.8 kcal/mol). This is a crucial advantage, potentially outweighing some of the ADME drawbacks.
**Overall Assessment:**
While Ligand A has a better QED score, Ligand B demonstrates a superior binding affinity, lower DILI risk, better metabolic stability (lower Cl_mic), and slightly better BBB penetration. The significantly stronger binding affinity of Ligand B (-5.2 kcal/mol vs -2.8 kcal/mol) is a decisive factor, especially for a GPCR target where potency is paramount. The lower DILI and improved metabolic stability are also highly desirable. The poor Caco-2 and solubility are concerns for both, but can be addressed through formulation.
**Output:**
0
2025-04-17 20:13:48,258 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (339.37 and 356.275 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (48.31) is significantly better than Ligand B (79.29). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally favors absorption. Ligand A is well below the 140 threshold. Ligand B is approaching a level that could hinder absorption.
3. **logP:** Both ligands have good logP values (3.072 and 2.782), falling within the optimal 1-3 range.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (5) is slightly higher than Ligand B (3), but both are acceptable.
6. **QED:** Both ligands have similar, good QED values (0.776 and 0.78).
7. **DILI:** Both ligands have relatively high DILI risk (71.733 and 79.643). This is a concern for both, but not a deciding factor between them.
8. **BBB:** Ligand A (74.021) has better BBB penetration than Ligand B (58.007), though this isn't a primary concern for a cardiovascular target.
9. **Caco-2:** Ligand A (-4.968) is better than Ligand B (-5.346), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-3.526) is better than Ligand B (-2.874), indicating better aqueous solubility.
11. **hERG:** Ligand A (0.884) has a much lower hERG risk than Ligand B (0.039). This is a significant advantage for Ligand A, as hERG inhibition can lead to cardiotoxicity.
12. **Cl_mic:** Ligand B (-8.568) has a lower (better) microsomal clearance than Ligand A (37.527), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-14.605) has a much longer in vitro half-life than Ligand A (-8.035). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.699) has better Pgp efflux liability than Ligand B (0.021).
15. **Binding Affinity:** Both ligands have very similar and strong binding affinities (-7.0 and -6.0 kcal/mol). The difference is not substantial enough to override other factors.
**GPCR-specific considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Both ligands are good on logP and affinity. Ligand A is significantly better on TPSA and Pgp. Ligand B has a better half-life and clearance, but the hERG risk is a major concern.
**Overall Assessment:**
While Ligand B has a superior half-life and clearance, the significantly lower hERG risk associated with Ligand A is a critical advantage, particularly for a cardiovascular target. The better TPSA, Caco-2, solubility, and Pgp profile of Ligand A further support its selection. The DILI risk is similar for both, and the affinity is comparable.
Output:
1
2025-04-17 20:13:48,258 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (359.421 and 367.427 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Both ligands (102.16 and 100.73) are reasonably low, suggesting good potential for absorption. Ligand B is slightly better.
3. **logP:** Ligand A (3.348) is optimal, while Ligand B (0.104) is very low. This is a significant drawback for Ligand B, potentially hindering membrane permeability.
4. **HBD:** Ligand A (3) and Ligand B (2) are both acceptable.
5. **HBA:** Both ligands (6) are within the acceptable range.
6. **QED:** Both ligands (0.69 and 0.769) are good, indicating drug-like properties. Ligand B is slightly better.
7. **DILI:** Both ligands have acceptable DILI risk (65.568 and 62.195), below the concerning threshold of 60. Ligand B is slightly better.
8. **BBB:** Ligand A (80.729) has a good BBB penetration percentile, while Ligand B (23.187) is very low. While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant, and this is a significant advantage for Ligand A.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests a potential issue with the data or the model. However, we'll proceed assuming these represent permeability. Ligand B (-5.346) is slightly better than Ligand A (-4.906).
10. **Solubility:** Ligand B (-2.795) has better solubility than Ligand A (-4.494).
11. **hERG:** Both ligands have low hERG risk (0.733 and 0.165), which is excellent. Ligand B is better.
12. **Cl_mic:** Ligand A (70.772) has a moderate clearance, while Ligand B (-20.93) has a *negative* clearance, which is not physically possible and indicates a data issue. This is a major red flag for Ligand B.
13. **t1/2:** Ligand B (19.515) has a significantly longer half-life than Ligand A (-9.572). However, the negative half-life for Ligand A is a data anomaly.
14. **Pgp:** Ligand A (0.085) has lower P-gp efflux than Ligand B (0.015), which is favorable.
15. **Binding Affinity:** Ligand B (-7.2 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.0 kcal/mol). This is a substantial advantage.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are crucial. Ligand B excels in affinity, but suffers from a very low logP and a nonsensical negative clearance. Ligand A has a good logP and acceptable clearance, and a reasonable BBB score. The affinity difference is significant, but the ADME liabilities of Ligand B are too concerning.
**Conclusion:**
Despite the superior binding affinity of Ligand B, its extremely low logP and impossible clearance value make it a highly risky candidate. Ligand A, while having a slightly weaker affinity, presents a much more balanced and drug-like profile, particularly regarding permeability and metabolic stability.
Output:
1
2025-04-17 20:13:48,258 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 receptor, a GPCR:
**1. Molecular Weight:** Both ligands (372.531 Da and 347.463 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (59.08) is significantly better than Ligand B (77.57). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand A is well below the 90 A^2 threshold, while Ligand B is approaching it.
**3. logP:** Both ligands have acceptable logP values (1.632 and 0.943), falling within the optimal 1-3 range. Ligand B is slightly lower, which *could* indicate a slight permeability issue, but it's not a major concern.
**4. H-Bond Donors:** Ligand A has 0 HBD, which is excellent. Ligand B has 2 HBD, still acceptable but less ideal.
**5. H-Bond Acceptors:** Both ligands have 5 HBA, which is within the acceptable limit of <=10.
**6. QED:** Both ligands have similar QED values (0.606 and 0.65), indicating good drug-like properties.
**7. DILI Risk:** Ligand A (15.51) has a slightly higher DILI risk than Ligand B (13.959), but both are well below the concerning threshold of 60.
**8. BBB Penetration:** Ligand A (76.696) has better BBB penetration than Ligand B (66.227). While ADRB2 isn't exclusively a CNS target, some CNS exposure might be acceptable or even desirable depending on the specific therapeutic goal, and higher BBB is generally preferred.
**9. Caco-2 Permeability:** Ligand A (-4.632) is significantly better than Ligand B (-5.237). Higher Caco-2 permeability indicates better intestinal absorption.
**10. Aqueous Solubility:** Ligand B (-0.876) is better than Ligand A (-2.125). Solubility is important, but can often be addressed through formulation.
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.561 and 0.469). This is excellent.
**12. Microsomal Clearance:** Ligand B (-12.319) has *much* lower microsomal clearance than Ligand A (50.762). This suggests significantly better metabolic stability for Ligand B, a crucial factor for drug duration and dosing frequency.
**13. In vitro Half-Life:** Ligand B (11.134 hours) has a significantly longer half-life than Ligand A (-3.175 hours). This is a major advantage for Ligand B.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.072 and 0.01).
**15. Binding Affinity:** Ligand B (-7.1 kcal/mol) has a slightly better binding affinity than Ligand A (-4.5 kcal/mol). This is a substantial difference (2.6 kcal/mol), and a strong binding affinity can often outweigh minor ADME drawbacks.
**Overall Assessment:**
While Ligand A has better TPSA and BBB penetration, Ligand B excels in metabolic stability (Cl_mic and t1/2) and has a significantly stronger binding affinity. Given the GPCR target class, the improved metabolic stability and binding affinity of Ligand B are more critical. The slight solubility advantage of Ligand B is also a plus. The differences in TPSA and BBB are less impactful in this context.
Output:
0
2025-04-17 20:13:48,259 - INFO - Batch 169 complete. Total preferences: 2704
2025-04-17 20:13:48,259 - INFO - Processing batch 170/512...
2025-04-17 20:14:37,072 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (360.38 and 361.511 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (70.39) is higher than Ligand B (51.39). While both are reasonably good, Ligand B is better positioned for oral absorption, being closer to the <140 threshold.
3. **logP:** Ligand A (2.166) is within the optimal 1-3 range. Ligand B (4.099) is slightly higher, potentially edging towards solubility issues and off-target effects.
4. **HBD:** Ligand A (2) and Ligand B (0) are both acceptable, below the threshold of 5.
5. **HBA:** Ligand A (4) and Ligand B (6) are both acceptable, below the threshold of 10.
6. **QED:** Ligand A (0.865) has a significantly better QED score than Ligand B (0.743), indicating a more drug-like profile.
7. **DILI:** Ligand A (18.302) has a much lower DILI risk than Ligand B (27.918), a significant advantage.
8. **BBB:** Both ligands have good BBB penetration (Ligand A: 77.937, Ligand B: 73.362). This is less critical for ADRB2 (a cardiovascular target) but still a positive.
9. **Caco-2:** Ligand A (-4.732) and Ligand B (-5.294) are both negative, indicating poor permeability. However, Ligand B is slightly worse.
10. **Solubility:** Ligand A (-2.184) is better than Ligand B (-3.182), indicating better aqueous solubility.
11. **hERG:** Both ligands have low hERG inhibition risk (Ligand A: 0.494, Ligand B: 0.557). No significant difference.
12. **Cl_mic:** Ligand A (-4.19) has a lower (better) microsomal clearance than Ligand B (65.326), suggesting better metabolic stability. This is a substantial difference.
13. **t1/2:** Ligand A (-9.943) has a longer in vitro half-life than Ligand B (-23.134), which is a major advantage.
14. **Pgp:** Both ligands have low P-gp efflux liability (Ligand A: 0.024, Ligand B: 0.255). Ligand A is slightly better.
15. **Binding Affinity:** Ligand A (-6.7) has a slightly better binding affinity than Ligand B (-6.2), although the difference is not huge.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Ligand A has a better logP, better TPSA, better Pgp, and slightly better affinity.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across several critical ADME-Tox parameters (DILI, Cl_mic, t1/2, solubility, QED) and has a slightly better binding affinity. While Ligand B has a slightly better TPSA, the other advantages of Ligand A outweigh this. The improved metabolic stability (lower Cl_mic and longer t1/2) and reduced toxicity risk (lower DILI) are particularly compelling.
Output:
1
2025-04-17 20:14:37,073 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (386.949 and 351.491 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Both ligands (67.23 and 67.59) are reasonably low, suggesting good potential for absorption, though slightly above the optimal <90 for CNS targets (not critical for ADRB2). Very similar.
3. **logP:** Both ligands (2.28 and 2.769) are within the optimal 1-3 range. Ligand B is slightly higher, potentially offering better membrane permeability, but not dramatically so.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Both ligands have 5 HBA, which is good.
6. **QED:** Ligand B (0.782) has a slightly better QED score than Ligand A (0.696), indicating a more drug-like profile.
7. **DILI:** Both ligands have low DILI risk (33.191 and 31.059 percentile), which is excellent. No significant difference.
8. **BBB:** Ligand A (74.719) has a significantly higher BBB penetration percentile than Ligand B (54.362). While ADRB2 isn't exclusively a CNS target, some CNS exposure can occur, and higher BBB is generally favorable.
9. **Caco-2:** Ligand A (-5.32) has a more negative Caco-2 value, suggesting *lower* permeability than Ligand B (-4.57). This is a negative for Ligand A.
10. **Solubility:** Ligand A (-3.38) has a slightly lower solubility than Ligand B (-2.404), which is not ideal.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.401 and 0.482), which is excellent.
12. **Cl_mic:** Ligand B (40.162) has a slightly lower microsomal clearance than Ligand A (44.698), suggesting better metabolic stability.
13. **t1/2:** Ligand B (39.692) has a much longer in vitro half-life than Ligand A (-3.263). This is a significant advantage for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.201 and 0.158), which is good.
15. **Binding Affinity:** Ligand B (-7.0 kcal/mol) has a slightly better binding affinity than Ligand A (-6.7 kcal/mol). While the difference is not huge, it's enough to be considered, especially given the other advantages of Ligand B.
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand B performs slightly better on logP, has comparable TPSA and Pgp, and a better binding affinity. While Ligand A has a better BBB score, the other ADME properties of Ligand B are more favorable overall.
**Conclusion:**
Considering the balance of properties, particularly the better metabolic stability (lower Cl_mic, longer t1/2), slightly improved affinity, and better Caco-2 permeability of Ligand B, it is the more promising drug candidate.
Output:
0
2025-04-17 20:14:37,073 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (363.479 & 346.431 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (55.84) is significantly better than Ligand B (86.63). ADRB2 is a cardiovascular target, not CNS, but lower TPSA generally improves absorption.
3. **logP:** Ligand A (3.286) is optimal, while Ligand B (0.722) is a bit low, potentially hindering membrane permeability.
4. **HBD:** Both ligands are acceptable (0 and 1 respectively), falling under the threshold of 5.
5. **HBA:** Both ligands are acceptable (4 and 5 respectively), falling under the threshold of 10.
6. **QED:** Both ligands have good QED scores (0.79 and 0.872), indicating good drug-like properties.
7. **DILI:** Ligand B (47.034) has a much lower DILI risk than Ligand A (63.746), a significant advantage.
8. **BBB:** Not a primary concern for a cardiovascular target, but Ligand A (78.79) is better than Ligand B (50.95).
9. **Caco-2:** Both are negative, indicating poor permeability.
10. **Solubility:** Ligand B (-1.376) is better than Ligand A (-5.197), which is a positive.
11. **hERG:** Ligand A (0.893) is slightly better than Ligand B (0.256), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand B (22.363) has significantly lower microsomal clearance than Ligand A (91.261), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-9.477) has a slightly better half-life than Ligand A (-14.541).
14. **Pgp:** Ligand A (0.529) has a better Pgp efflux profile than Ligand B (0.09).
15. **Affinity:** Both ligands have very similar binding affinities (-6.7 and -6.5 kcal/mol). The difference is negligible.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, and affinity are important. Ligand A has a better logP and TPSA. However, Ligand B has a significantly better DILI score and Cl_mic, which are crucial for overall drug viability. The affinity is almost identical. The poor Caco-2 values for both are concerning, but can be addressed with formulation strategies.
**Overall Assessment:**
While Ligand A has some advantages in terms of TPSA and logP, the significantly lower DILI risk and better metabolic stability (lower Cl_mic) of Ligand B outweigh these factors. The similar binding affinities make the ADME properties the deciding factor.
Output:
0
2025-04-17 20:14:37,073 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.471 and 361.877 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (62.55) is significantly better than Ligand B (77.97). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (3.381 and 2.749), falling within the optimal 1-3 range. Ligand A is slightly higher, which *could* be beneficial for membrane permeability.
4. **HBD:** Both have 1 HBD, which is within the acceptable limit of <=5.
5. **HBA:** Ligand A has 3 HBA, while Ligand B has 6. Ligand A is preferable here, as fewer HBA generally leads to better permeability.
6. **QED:** Both ligands have good QED scores (0.785 and 0.855), indicating good drug-like properties. No significant difference.
7. **DILI:** Both ligands have low DILI risk (23.885 and 24.855 percentile), which is excellent.
8. **BBB:** Ligand A (67.933) has a better BBB penetration score than Ligand B (44.591). While not crucial for a cardiovascular target, it's a slight advantage.
9. **Caco-2:** Both have negative Caco-2 values (-4.377 and -4.966). These values are unusual and suggest poor permeability. However, the values are very similar.
10. **Solubility:** Both ligands have poor aqueous solubility (-3.48 and -3.581). This is a significant concern for both compounds.
11. **hERG:** Ligand A (0.396) has a much lower hERG inhibition liability than Ligand B (0.762). This is a crucial advantage, as hERG inhibition can lead to cardiotoxicity.
12. **Cl_mic:** Ligand B (37.482) has significantly lower microsomal clearance than Ligand A (75.12), indicating better metabolic stability. This is a strong point in favor of Ligand B.
13. **t1/2:** Ligand A (49.711) has a longer in vitro half-life than Ligand B (20.34). This is a positive for Ligand A, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.249) has lower P-gp efflux liability than Ligand B (0.179). Lower P-gp efflux is generally desirable for improved bioavailability.
15. **Binding Affinity:** Ligand A (-6.4 kcal/mol) has a significantly better binding affinity than Ligand B (-0.1 kcal/mol). This is a *major* advantage, as a difference of >1.5 kcal/mol can outweigh other drawbacks.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A excels in affinity and has favorable logP and TPSA. While Ligand B has better metabolic stability (Cl_mic), the massive difference in binding affinity and the lower hERG risk of Ligand A are more critical. The poor solubility and Caco-2 values are concerning for both, but can be addressed with formulation strategies.
**Output:**
1
2025-04-17 20:14:37,074 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [351.451, 79.7, 1.642, 1, 5, 0.81, 23.187, 85.459, -4.477, -1.417, 0.525, 12.116, 5.412, 0.016, -6.6]
**Ligand B:** [335.411, 89.89, 4.303, 2, 2, 0.476, 56.572, 70.803, -4.724, -4.001, 0.535, 20.615, -1.455, 0.198, -6.1]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal 200-500 Da range. Ligand B (335.411 Da) is slightly lower, which is generally favorable for permeability, but both are acceptable.
2. **TPSA:** Ligand A (79.7) is better than Ligand B (89.89). Both are below 140, but closer to 90 is preferred for GPCRs, and A is closer.
3. **logP:** Ligand A (1.642) is optimal (1-3). Ligand B (4.303) is a bit high, potentially leading to solubility issues and off-target interactions.
4. **HBD:** Ligand A (1) is better than Ligand B (2). Lower is generally preferred.
5. **HBA:** Ligand A (5) is better than Ligand B (2). Lower is generally preferred.
6. **QED:** Ligand A (0.81) is significantly better than Ligand B (0.476), indicating a more drug-like profile.
7. **DILI:** Ligand A (23.187) is *much* better than Ligand B (56.572). This is a critical advantage for A.
8. **BBB:** Ligand A (85.459) is significantly better than Ligand B (70.803). This is important for a GPCR target, even if not strictly CNS-focused.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-4.477) is slightly better than Ligand B (-4.724) but both are very poor.
10. **Solubility:** Ligand A (-1.417) is better than Ligand B (-4.001). Solubility is a concern for B due to its higher logP.
11. **hERG:** Both are low (0.525 and 0.535), indicating low cardiotoxicity risk.
12. **Cl_mic:** Ligand A (12.116) is better than Ligand B (20.615), indicating better metabolic stability.
13. **t1/2:** Ligand A (5.412) is better than Ligand B (-1.455).
14. **Pgp:** Ligand A (0.016) is *much* better than Ligand B (0.198), indicating lower efflux and better bioavailability.
15. **Affinity:** Ligand A (-6.6) is slightly better than Ligand B (-6.1), but the difference is relatively small.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A excels in logP, TPSA, and Pgp. While both have good affinity, the superior ADME properties of Ligand A, particularly the lower DILI risk, better BBB penetration, and lower Pgp efflux, make it the more promising candidate. The Caco-2 permeability is poor for both, but can be addressed through formulation strategies.
**Conclusion:**
Ligand A is the better candidate due to its superior drug-like properties and ADME profile, especially its lower DILI risk and better BBB penetration, which are crucial for a GPCR target.
1
2025-04-17 20:14:37,074 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A: [343.435, 80.99, 1.71, 1, 8, 0.828, 65.064, 75.107, -5.033, -2.595, 0.4, 57.966, 9.296, 0.019, -5]**
**Ligand B: [364.442, 51.66, 3.552, 0, 5, 0.719, 36.06, 89.957, -4.249, -4.543, 0.669, 89.519, -14.462, 0.304, -3.4]**
Here's a breakdown, comparing each parameter and considering GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the acceptable range (200-500 Da). Ligand A (343.435) is slightly preferred.
2. **TPSA:** Ligand B (51.66) is significantly better than Ligand A (80.99). Lower TPSA generally means better cell permeability, crucial for GPCRs.
3. **logP:** Ligand A (1.71) is within the optimal range (1-3). Ligand B (3.552) is at the higher end, potentially leading to solubility issues or off-target interactions, but still acceptable.
4. **HBD:** Ligand A (1) is better than Ligand B (0). Having at least one HBD can improve solubility.
5. **HBA:** Ligand A (8) is higher than Ligand B (5). Lower is better, so Ligand B is preferred.
6. **QED:** Ligand A (0.828) has a better QED score than Ligand B (0.719), indicating a more drug-like profile.
7. **DILI:** Ligand B (36.06) has a significantly lower DILI risk than Ligand A (65.064). This is a major advantage for Ligand B.
8. **BBB:** Ligand B (89.957) has a much higher BBB penetration score than Ligand A (75.107). While ADRB2 is a cardiovascular target, some CNS exposure can occur, and higher BBB is generally beneficial.
9. **Caco-2:** Ligand B (-4.249) is slightly better than Ligand A (-5.033), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-2.595) is better than Ligand B (-4.543).
11. **hERG:** Both are low, indicating low cardiotoxicity risk. Ligand B (0.669) is slightly better.
12. **Cl_mic:** Ligand A (57.966) has lower microsomal clearance than Ligand B (89.519), suggesting better metabolic stability.
13. **t1/2:** Ligand A (9.296) has a better in vitro half-life than Ligand B (-14.462).
14. **Pgp:** Ligand A (0.019) has a much lower P-gp efflux liability than Ligand B (0.304). Lower P-gp is desirable for better bioavailability.
15. **Affinity:** Ligand A (-5) has a slightly better binding affinity than Ligand B (-3.4).
**Overall Assessment:**
Ligand B excels in several critical areas: DILI risk, BBB penetration, Caco-2 permeability, and TPSA. While Ligand A has better QED, metabolic stability, Pgp efflux, and slightly better affinity, the lower DILI and better permeability/BBB of Ligand B are more compelling for a GPCR target. The affinity difference is not substantial enough to outweigh these advantages.
Therefore, I prefer Ligand B.
0
2025-04-17 20:14:37,074 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (363.483 and 341.411 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (62.74) is better than Ligand B (71.53), being closer to the <140 threshold for good oral absorption. This is a slight advantage for A.
3. **logP:** Both ligands (2.017 and 2.049) are within the optimal 1-3 range. No significant difference.
4. **HBD:** Ligand A (0) is preferable to Ligand B (1). Fewer HBDs generally improve permeability.
5. **HBA:** Both ligands (5) are within the acceptable limit of <=10. No significant difference.
6. **QED:** Ligand A (0.803) is slightly better than Ligand B (0.781), indicating a more drug-like profile.
7. **DILI:** Ligand A (33.346) has a lower DILI risk than Ligand B (39.434), both are good, but A is better.
8. **BBB:** Both ligands have high BBB penetration (86.39 and 80.38), which isn't a primary concern for ADRB2 (a cardiovascular target, not CNS).
9. **Caco-2:** Ligand A (-4.759) is better than Ligand B (-4.325), indicating better intestinal absorption.
10. **Solubility:** Both ligands have very poor aqueous solubility (-2.873 and -2.706). This is a significant drawback for both, but not a deciding factor between the two.
11. **hERG:** Both ligands have low hERG inhibition liability (0.464 and 0.201). No significant difference.
12. **Cl_mic:** Ligand A (54.469) has lower microsomal clearance than Ligand B (82.663), suggesting better metabolic stability. This is a significant advantage for A.
13. **t1/2:** Ligand B (30.817) has a much longer in vitro half-life than Ligand A (-16.52). This is a major advantage for B.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.212 and 0.032). No significant difference.
15. **Binding Affinity:** Ligand B (-6.9) has a slightly better binding affinity than Ligand A (-6.2). This is a 0.7 kcal/mol difference, which is significant.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Both ligands are good on logP and Pgp. Ligand A is better on TPSA. Ligand B has a better affinity, and Ligand A has better metabolic stability (Cl_mic). The longer half-life of Ligand B is also a positive.
**Overall Assessment:**
While Ligand A has advantages in TPSA, DILI, and Cl_mic, the stronger binding affinity (-6.9 vs -6.2) and significantly longer half-life of Ligand B outweigh these benefits. The affinity difference is substantial enough to overcome the slightly higher DILI risk and worse metabolic stability. The solubility is poor for both, which will need to be addressed during formulation.
Output:
0
2025-04-17 20:14:37,074 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (342.355 and 341.499 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (95.6) is higher than Ligand B (38.56). For a GPCR like ADRB2, lower TPSA is generally preferred for better permeability, giving a slight edge to Ligand B.
3. **logP:** Ligand A (-0.907) is significantly lower than Ligand B (4.781). Ligand B is quite high, potentially leading to solubility issues and off-target interactions. Ligand A is a bit low, potentially hindering permeation. However, for a cardiovascular target, moderate logP is acceptable, and the risk of off-target effects with very high logP is concerning.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 5 HBA, Ligand B has 4. Both are within the acceptable range.
6. **QED:** Both ligands have good QED scores (0.702 and 0.787), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (52.462) has a higher DILI risk than Ligand B (34.161). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (53.121) has lower BBB penetration than Ligand B (84.141). While ADRB2 isn't a primary CNS target, some level of BBB penetration can still be relevant for off-target effects. Ligand B is better here.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the values are comparable (-4.581 vs -4.661).
10. **Solubility:** Ligand A (-2.272) has better solubility than Ligand B (-4.287). This is important, especially given Ligand B's high logP.
11. **hERG:** Ligand A (0.124) has a much lower hERG risk than Ligand B (0.928). This is a critical advantage for Ligand A, as hERG inhibition can lead to cardiotoxicity.
12. **Cl_mic:** Ligand A (-20.914) has a lower (better) microsomal clearance than Ligand B (52.675), indicating greater metabolic stability.
13. **t1/2:** Ligand B (66.642) has a significantly longer in vitro half-life than Ligand A (-28.28). This is a major advantage for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Both have very low Pgp efflux liability (0.004 and 0.812).
15. **Binding Affinity:** Both have the same binding affinity (-5.4 kcal/mol).
**Overall Assessment:**
Ligand B has advantages in BBB penetration and in vitro half-life. However, it suffers from a very high logP, increased DILI risk, and a significantly higher hERG inhibition liability. Ligand A, while having a slightly lower half-life, has a much better safety profile (lower DILI and hERG) and better solubility. Given that ADRB2 is a cardiovascular target, minimizing cardiotoxicity (hERG) is paramount. The slightly lower half-life of Ligand A can be addressed through formulation strategies. The high logP of Ligand B is a significant concern.
Therefore, I favor Ligand A.
Output:
1
2025-04-17 20:14:37,074 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (345.311 and 353.369 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (75.44) is significantly better than Ligand A (119.61). For a GPCR, lower TPSA is generally preferred for better permeability.
3. **logP:** Both are within the optimal 1-3 range, but Ligand B (2.304) is slightly higher than Ligand A (0.991). This could be beneficial for membrane permeability, but needs to be balanced with solubility.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1). Both are acceptable.
5. **HBA:** Ligand A (7) is higher than Ligand B (4). Lower HBA is preferred for permeability.
6. **QED:** Both ligands have good QED scores (0.793 and 0.824), indicating good drug-like properties.
7. **DILI:** Ligand B (55.874) has a much lower DILI risk than Ligand A (98.139). This is a significant advantage for Ligand B.
8. **BBB:** Ligand B (91.392) has a much higher BBB penetration percentile than Ligand A (61.923). While ADRB2 isn't necessarily a CNS target, higher BBB is rarely detrimental and can open up possibilities for exploring CNS effects or reducing off-target activity.
9. **Caco-2:** Both ligands have similar, poor Caco-2 permeability (-4.845 and -4.735). This suggests potential absorption issues.
10. **Solubility:** Ligand A (-4.466) has slightly worse solubility than Ligand B (-2.935).
11. **hERG:** Both ligands have low hERG inhibition liability (0.517 and 0.174). Ligand B is better.
12. **Cl_mic:** Ligand B (27.467) has significantly lower microsomal clearance than Ligand A (49.222), indicating better metabolic stability.
13. **t1/2:** Ligand B (-47.426) has a much longer in vitro half-life than Ligand A (-32.631). This is a major advantage.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.115 and 0.109).
15. **Binding Affinity:** Ligand A (-8.6 kcal/mol) has a slightly better binding affinity than Ligand B (-7.3 kcal/mol). This is a 1.3 kcal/mol difference, which is significant, but must be weighed against the other parameters.
**Overall Assessment:**
Ligand B consistently outperforms Ligand A in key ADME properties: DILI, BBB, Cl_mic, and t1/2. It also has a better TPSA and logP. While Ligand A has a slightly better binding affinity, the improvements in ADME for Ligand B are substantial and outweigh the small difference in potency. The lower DILI risk and improved metabolic stability are particularly important for a cardiovascular target.
Output:
0
2025-04-17 20:14:37,075 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (350.5 & 354.5 Da) fall comfortably within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (58.44) is significantly better than Ligand B (89.87). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold.
3. **logP:** Both ligands have acceptable logP values (2.425 & 1.443), falling within the 1-3 range. Ligand A is slightly higher, potentially aiding membrane permeability.
4. **HBD:** Ligand A (0) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Both ligands have the same number of HBA (4), which is acceptable.
6. **QED:** Ligand A (0.723) is slightly better than Ligand B (0.645), indicating a more drug-like profile.
7. **DILI:** Ligand A (29.042) has a much lower DILI risk than Ligand B (9.151). This is a significant advantage.
8. **BBB:** Both ligands have similar BBB penetration (64.986 vs 67.352). Not a primary concern for a cardiovascular target.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.519 vs -4.8), indicating poor permeability. This is a concern for both.
10. **Solubility:** Both ligands have negative solubility values (-1.915 vs -1.675), indicating poor solubility. This is a concern for both.
11. **hERG:** Both ligands have low hERG inhibition liability (0.312 vs 0.368). This is good.
12. **Cl_mic:** Ligand A (73.597) has a higher microsomal clearance than Ligand B (13.905), suggesting faster metabolism and potentially lower *in vivo* exposure. This is a drawback for Ligand A.
13. **t1/2:** Ligand B (-26.666) has a much longer in vitro half-life than Ligand A (33.856). This is a significant advantage for Ligand B.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.127 vs 0.069). This is good.
15. **Binding Affinity:** Ligand A (-6.3 kcal/mol) has a slightly better binding affinity than Ligand B (-5.8 kcal/mol), but the difference is less than 1.5 kcal/mol.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, and affinity are important. Ligand A has a better logP and TPSA, while Ligand B has a significantly better half-life and lower clearance. The affinity difference is not substantial enough to overcome the ADME drawbacks of Ligand A. The lower DILI risk of Ligand A is also a positive.
**Overall Assessment:**
While Ligand A has a slightly better affinity and lower DILI, Ligand B's significantly improved metabolic stability (lower Cl_mic and longer t1/2) and comparable TPSA/logP make it the more promising candidate. The poor Caco-2 and solubility for both are concerning and would need addressing in further optimization, but the metabolic profile is a critical factor for *in vivo* efficacy.
Output:
0
2025-04-17 20:14:37,075 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Step-by-step comparison:**
1. **MW:** Both ligands (367.4 & 370.6 Da) fall comfortably within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (107.4) is higher than Ligand B (59.1). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B has a significant advantage here.
3. **logP:** Both ligands have good logP values (2.77 & 1.69), falling within the 1-3 range. Ligand A is slightly higher, which *could* be beneficial for membrane permeability, but isn't a major concern for either.
4. **HBD:** Ligand A (1) is slightly higher than Ligand B (0). This is not a significant difference.
5. **HBA:** Ligand A (5) is slightly higher than Ligand B (4). Again, not a major difference.
6. **QED:** Ligand B (0.691) has a better QED score than Ligand A (0.374), indicating a more drug-like profile.
7. **DILI:** Ligand B (30.7) has a *much* lower DILI risk than Ligand A (70.8). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (82.9) has a higher BBB penetration percentile than Ligand B (63.7). While ADRB2 isn't a primary CNS target, some BBB penetration can still be useful for distribution.
9. **Caco-2:** Ligand A (-5.03) and Ligand B (-4.52) both have negative values, indicating poor permeability.
10. **Solubility:** Ligand A (-3.05) is worse than Ligand B (-1.87). Solubility is important for bioavailability. Ligand B is better.
11. **hERG:** Both ligands have low hERG inhibition risk (0.33 & 0.36). No significant difference.
12. **Cl_mic:** Ligand A (1.76) has a much lower microsomal clearance than Ligand B (64.1). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (17.8) has a longer in vitro half-life than Ligand B (3.8). This is a significant advantage for Ligand A.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.17 & 0.18). No significant difference.
15. **Binding Affinity:** Ligand B (-7.0) has a slightly better binding affinity than Ligand A (-6.7). While the difference is small, it's within the range where it could outweigh other factors.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, and affinity. Ligand B excels in TPSA and has a slightly better affinity. Ligand A has better metabolic stability (Cl_mic and t1/2) and BBB penetration. However, the significantly lower DILI risk for Ligand B is a major factor. The slightly better affinity of Ligand B is also a positive.
**Overall Assessment:**
While Ligand A has advantages in metabolic stability and BBB penetration, the significantly lower DILI risk and better QED score of Ligand B, combined with its slightly better affinity and TPSA, make it the more promising candidate. The solubility is also better for Ligand B. The better metabolic stability of Ligand A is a plus, but can be addressed through further optimization.
Output:
0
2025-04-17 20:14:37,075 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (372.843) is slightly higher than Ligand B (345.447), but both are acceptable.
2. **TPSA:** Ligand A (51.22) is significantly better than Ligand B (78.43). For a GPCR, lower TPSA is generally preferred for better permeability, and Ligand A is well below the 140 threshold. Ligand B is approaching a less desirable range.
3. **logP:** Ligand A (3.687) is within the optimal range (1-3), while Ligand B (0.785) is a bit low. Lower logP can hinder membrane permeability.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 3 HBA, while Ligand B has 5. Both are acceptable, but lower is generally better.
6. **QED:** Both ligands have similar QED values (0.877 and 0.79), indicating good drug-likeness.
7. **DILI:** Ligand A (33.773) has a lower DILI risk than Ligand B (19.698), which is a significant advantage.
8. **BBB:** Ligand A (90.151) has a much higher BBB penetration percentile than Ligand B (75.301). While ADRB2 isn't exclusively a CNS target, some cardiovascular effects can be mediated through CNS pathways, and better BBB penetration could be beneficial.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so this is difficult to interpret.
10. **Solubility:** Both ligands have negative solubility values, which is also unusual and suggests poor solubility. Again, the scale is not specified.
11. **hERG:** Both ligands have low hERG inhibition liability (0.392 and 0.24), which is excellent.
12. **Cl_mic:** Ligand A (25.072) has a higher microsomal clearance than Ligand B (3.133), indicating faster metabolism and potentially lower *in vivo* exposure. This is a drawback for Ligand A.
13. **t1/2:** Ligand B (3.23) has a longer *in vitro* half-life than Ligand A (-0.616), which is a significant advantage.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.117 and 0.006), which is favorable.
15. **Binding Affinity:** Ligand A (-6.9 kcal/mol) has a slightly better binding affinity than Ligand B (-5.7 kcal/mol). This 1.2 kcal/mol difference is substantial and can often outweigh minor ADME concerns.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are crucial. Ligand A excels in TPSA and has a better logP and affinity. Ligand B has a longer half-life and lower clearance, but its higher TPSA and lower logP are concerning. The superior affinity of Ligand A is a significant advantage.
**Overall Assessment:**
Despite the slightly higher clearance of Ligand A, its superior TPSA, logP, DILI risk, BBB penetration, and, most importantly, binding affinity make it the more promising candidate. The negative values for Caco-2 and solubility are concerning for both, but the differences in other key parameters outweigh these.
Output:
1
2025-04-17 20:14:37,075 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.475 and 345.363 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (82.53) is significantly better than Ligand B (127.94). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold. Ligand B is approaching the upper limit.
3. **logP:** Ligand A (2.223) is within the optimal 1-3 range. Ligand B (-0.621) is below 1, which is a concern for permeability.
4. **HBD:** Both ligands have 2 HBD, which is acceptable.
5. **HBA:** Ligand A has 4 HBA, while Ligand B has 10. Ligand A is preferable here.
6. **QED:** Both ligands have good QED scores (0.716 and 0.681), indicating good overall drug-likeness.
7. **DILI:** Ligand A (23.187) has a much lower DILI risk than Ligand B (65.917). This is a major advantage for Ligand A.
8. **BBB:** Not a primary concern for a cardiovascular target. Ligand A (40.364) and Ligand B (54.052) are both relatively low, which is fine.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.73 and -5.383), which is unusual and suggests poor permeability. However, these values are on a log scale and difficult to interpret without further context.
10. **Solubility:** Both ligands have similar, very poor solubility scores (-1.809 and -1.847). This is a significant drawback for both.
11. **hERG:** Ligand A (0.415) has a slightly higher hERG risk than Ligand B (0.029), but both are relatively low.
12. **Cl_mic:** Ligand A (29.634) has a higher microsomal clearance than Ligand B (23.552), meaning it's metabolized faster. This is a negative for Ligand A.
13. **t1/2:** Ligand A (25.555) has a much longer in vitro half-life than Ligand B (3.905). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.062) has lower P-gp efflux liability than Ligand B (0.046), which is preferable.
15. **Binding Affinity:** Ligand B (-6.9 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.4 kcal/mol). This is a substantial advantage for Ligand B, potentially outweighing some of its ADME drawbacks.
**Overall Assessment:**
Ligand B has a significantly better binding affinity, which is crucial for a GPCR target. However, it suffers from a poor logP, high DILI risk, and a very short half-life. Ligand A has better TPSA, HBA, DILI, and half-life, but its binding affinity is weaker and its clearance is higher.
Considering the GPCR-specific priorities (logP, affinity), the strong affinity of Ligand B is a major factor. While the poor logP is a concern, it might be addressable through further optimization. The DILI risk is more concerning, but the substantial affinity gain is compelling. The longer half-life of Ligand A is attractive, but a weaker binding affinity could necessitate higher doses.
Given the importance of potency for GPCRs, and the potential to address the logP issues through medicinal chemistry, I favor Ligand B.
Output:
0
2025-04-17 20:14:37,075 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [367.471, 75.88, 1.7, 0, 6, 0.774, 50.485, 88.135, -4.776, -3.146, 0.823, 65.98, 6.317, 0.202, -6.1]
**Ligand B:** [386.583, 58.64, 2.497, 1, 5, 0.76, 18.651, 73.866, -4.987, -3.595, 0.367, 64.452, -3.724, 0.092, -6.1]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (367.471) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (75.88) is higher than Ligand B (58.64). Both are below 140, but Ligand B is better positioned for good oral absorption and potentially better CNS penetration.
3. **logP:** Both are within the optimal range (1-3). Ligand B (2.497) is slightly higher, which could be beneficial for membrane permeability, but also introduces a slightly higher risk of off-target interactions.
4. **HBD:** Ligand A (0) is better than Ligand B (1). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (6) is slightly higher than Ligand B (5). Both are acceptable, but lower is preferable.
6. **QED:** Both are very similar (0.774 vs 0.76), indicating good drug-like properties.
7. **DILI:** Ligand A (50.485) has a significantly higher DILI risk than Ligand B (18.651). This is a major concern for Ligand A.
8. **BBB:** Ligand A (88.135) has a better BBB penetration potential than Ligand B (73.866). However, for a cardiovascular target, BBB penetration is not a primary concern.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand B (-4.987) is slightly worse than Ligand A (-4.776).
10. **Solubility:** Both have negative solubility values, indicating very poor aqueous solubility. Ligand B (-3.595) is slightly worse than Ligand A (-3.146).
11. **hERG:** Both have very low hERG inhibition risk (0.823 and 0.367).
12. **Cl_mic:** Both have similar microsomal clearance values (65.98 and 64.452), suggesting comparable metabolic stability.
13. **t1/2:** Ligand A (6.317) has a longer in vitro half-life than Ligand B (-3.724). This is a positive attribute.
14. **Pgp:** Ligand A (0.202) has lower P-gp efflux liability than Ligand B (0.092). This is favorable for bioavailability.
15. **Affinity:** Both have the same binding affinity (-6.1 kcal/mol), so this parameter doesn't differentiate them.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, and affinity. Ligand B has a slightly better logP and TPSA, but Ligand A has a better Pgp profile. The biggest differentiating factor is the DILI risk. Ligand A's significantly higher DILI risk is a major red flag.
**Conclusion:**
Despite Ligand A's slightly better BBB penetration and half-life, the significantly higher DILI risk associated with Ligand A makes it a less desirable candidate. Ligand B, while having slightly less favorable TPSA and Pgp, presents a much lower risk of liver injury. Given the importance of safety, especially for a cardiovascular drug, I would prioritize Ligand B.
Output:
0
2025-04-17 20:14:37,076 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's systematically compare Ligand A and Ligand B based on the provided parameters and the guidelines, keeping in mind that ADRB2 is a GPCR, so logP, Pgp, TPSA, and affinity are particularly important.
1. **MW:** Both ligands (353.419 and 346.435 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both are good (87.23 and 85.05), being under 140, suggesting reasonable oral absorption potential.
3. **logP:** Ligand B (0.521) is slightly better than Ligand A (0.01). While both are on the lower side, Ligand B is closer to the optimal 1-3 range. Ligand A's very low logP could indicate poor membrane permeability.
4. **HBD/HBA:** Ligand A has 0 HBD and 5 HBA, while Ligand B has 1 HBD and 6 HBA. Both are within acceptable limits, but Ligand B is slightly more balanced.
5. **QED:** Ligand B (0.755) has a significantly better QED score than Ligand A (0.513), indicating a more drug-like profile.
6. **DILI:** Both have low DILI risk (37.379 and 33.812 percentile), which is excellent.
7. **BBB:** Ligand A (67.701) has a better BBB penetration score than Ligand B (37.418). However, for ADRB2, which is primarily a cardiovascular target, high BBB penetration isn't critical.
8. **Caco-2:** Ligand A (-4.599) has a much worse Caco-2 permeability than Ligand B (-5.315). This suggests Ligand A will have poor intestinal absorption.
9. **Solubility:** Both have poor aqueous solubility (-0.859 and -0.715). This could pose formulation challenges, but isn't a dealbreaker if absorption is otherwise good.
10. **hERG:** Both have very low hERG inhibition risk (0.045 and 0.079), which is highly desirable.
11. **Cl_mic:** Ligand B (20.352) has significantly lower microsomal clearance than Ligand A (33.726), suggesting better metabolic stability.
12. **t1/2:** Ligand B (27.748) has a longer in vitro half-life than Ligand A (-21.109), which is a positive attribute.
13. **Pgp:** Both have very low P-gp efflux liability (0.024 and 0.011).
14. **Binding Affinity:** Ligand B (-7.3 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.3 kcal/mol). This is a substantial advantage, potentially outweighing some of the minor ADME drawbacks.
**Overall Assessment:**
Ligand B is the stronger candidate. While Ligand A has better BBB penetration, this is less important for a cardiovascular target like ADRB2. Ligand B excels in key areas: QED, metabolic stability (lower Cl_mic, longer t1/2), Caco-2 permeability, and, most importantly, significantly stronger binding affinity. The slightly lower logP is a minor concern, but the overall profile of Ligand B is more favorable for development.
**Output:**
0
2025-04-17 20:14:37,076 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Step-by-step comparison:**
1. **MW:** Both ligands (369.849 Da and 351.422 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (75.44) is significantly better than Ligand A (95.26). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (1.66 and 2.139, respectively) within the optimal 1-3 range. Ligand B is slightly better.
4. **HBD:** Ligand A has 2 HBD, while Ligand B has 1. Both are acceptable (<=5).
5. **HBA:** Ligand A has 5 HBA, and Ligand B has 4. Both are acceptable (<=10).
6. **QED:** Both ligands have good QED scores (0.79 and 0.852), indicating drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand B (25.785) has a much lower DILI risk than Ligand A (42.924). This is a significant advantage.
8. **BBB:** Ligand B (89.531) has a much higher BBB penetration percentile than Ligand A (43.311). While not critical for a cardiovascular target, higher BBB is rarely a detriment.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.785 and -4.591). These values are difficult to interpret without knowing the scale, but negative values suggest poor permeability.
10. **Solubility:** Ligand B (-2.449) is better than Ligand A (-3.738), indicating better aqueous solubility.
11. **hERG:** Both ligands have low hERG inhibition liability (0.391 and 0.4), which is good.
12. **Cl_mic:** Ligand B (23.55) has a lower microsomal clearance than Ligand A (33.135), suggesting better metabolic stability.
13. **t1/2:** Ligand B (8.399) has a significantly longer in vitro half-life than Ligand A (-4.365). This is a major advantage.
14. **Pgp:** Both have very low Pgp efflux liability (0.077 and 0.097).
15. **Binding Affinity:** Ligand A (-6.7 kcal/mol) has a slightly better binding affinity than Ligand B (-5.7 kcal/mol). This is a 1 kcal/mol difference, which is notable but not overwhelming.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Ligand B excels in logP, TPSA, and Pgp. The affinity difference is only 1 kcal/mol, and Ligand B has significantly better ADME properties (DILI, BBB, solubility, Cl_mic, t1/2).
**Conclusion:**
While Ligand A has a slightly better binding affinity, Ligand B demonstrates a superior overall profile with significantly improved ADME properties, particularly regarding safety (DILI) and metabolic stability (Cl_mic, t1/2). These factors outweigh the minor difference in binding affinity, making Ligand B the more promising drug candidate.
0
2025-04-17 20:14:37,076 - INFO - Batch 170 complete. Total preferences: 2720
2025-04-17 20:14:37,076 - INFO - Processing batch 171/512...
2025-04-17 20:15:26,408 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (364.433 and 353.413 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (78.87) is higher than Ligand B (58.22). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B has a slight advantage.
3. **logP:** Ligand A (1.418) is within the optimal 1-3 range, while Ligand B (3.609) is at the higher end. While still acceptable, higher logP can sometimes lead to off-target effects and solubility issues. Ligand A is preferable here.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable.
5. **HBA:** Ligand A (4) and Ligand B (3) are both acceptable.
6. **QED:** Both ligands have similar QED values (0.649 and 0.664), indicating good drug-likeness.
7. **DILI:** Ligand A (11.361) has a significantly lower DILI risk than Ligand B (38.697). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (81.776) has a higher BBB penetration than Ligand A (65.878). However, since ADRB2 is primarily a cardiovascular target, high BBB penetration isn't a primary requirement.
9. **Caco-2:** Both ligands have similar, negative Caco-2 values (-4.823 and -4.814), suggesting poor permeability. This is a concern for both, but doesn't differentiate them.
10. **Solubility:** Ligand A (-1.356) has better solubility than Ligand B (-3.226). This is a positive for Ligand A.
11. **hERG:** Ligand A (0.489) has a lower hERG inhibition liability than Ligand B (0.971), indicating a lower risk of cardiotoxicity. This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand A (24.631) has a lower microsomal clearance than Ligand B (49.113), suggesting better metabolic stability. This is a positive for Ligand A.
13. **t1/2:** Ligand B (20.265) has a longer in vitro half-life than Ligand A (-6.011). This is a positive for Ligand B.
14. **Pgp:** Ligand A (0.08) has lower P-gp efflux liability than Ligand B (0.473), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand A (-6.6) has a slightly better binding affinity than Ligand B (-5.8). While the difference is less than the 1.5 kcal/mol threshold, it contributes to the overall preference.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity) and the general guidelines, Ligand A is the more promising candidate. It has a significantly lower DILI risk, better solubility, lower hERG inhibition, lower microsomal clearance, and lower P-gp efflux. While Ligand B has a longer half-life and slightly better BBB penetration (which isn't crucial for a cardiovascular target), the safety and ADME advantages of Ligand A outweigh these benefits.
Output:
1
2025-04-17 20:15:26,408 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
The target is ADRB2, a GPCR. Therefore, I will prioritize logP, TPSA, Pgp efflux, BBB penetration, and binding affinity, alongside general drug-like properties.
* **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (341.411) is slightly lower than Ligand B (355.551), which is preferable.
* **TPSA:** Ligand A (65.9) is better than Ligand B (28.16). Lower TPSA generally correlates with better cell permeability, crucial for GPCR targets. Ligand B is exceptionally low, which could raise concerns about solubility.
* **logP:** Ligand A (2.219) is within the optimal range (1-3). Ligand B (4.366) is higher, potentially leading to solubility issues and off-target interactions.
* **H-Bond Donors/Acceptors:** Both have acceptable numbers of HBD (1) and HBA (5/4), balancing solubility and permeability.
* **QED:** Ligand A (0.903) has a significantly better QED score than Ligand B (0.747), indicating a more drug-like profile.
* **DILI:** Both ligands have relatively high DILI risk, but Ligand A (64.986) is higher than Ligand B (6.592). Ligand B is much better here.
* **BBB:** Ligand B (76.541) shows better BBB penetration than Ligand A (49.748). While not a primary concern for ADRB2 (cardiovascular target), it's a positive attribute.
* **Caco-2 Permeability:** Ligand A (-4.608) is better than Ligand B (-5.539), indicating better intestinal absorption.
* **Aqueous Solubility:** Ligand A (-2.383) is better than Ligand B (-3.063)
* **hERG:** Both ligands have low hERG inhibition liability, which is good. Ligand A (0.222) is slightly better than Ligand B (0.957).
* **Microsomal Clearance:** Ligand A (1.049) has significantly lower microsomal clearance than Ligand B (26.288), suggesting better metabolic stability.
* **In vitro Half-Life:** Ligand A (20.224) has a much longer half-life than Ligand B (9.265), which is desirable.
* **P-gp Efflux:** Ligand A (0.082) has lower P-gp efflux than Ligand B (0.321), which is favorable for bioavailability.
* **Binding Affinity:** Ligand B (-5.8) has a slightly better binding affinity than Ligand A (-5.3), a 0.5 kcal/mol difference.
**Overall Assessment:**
While Ligand B has a slightly better binding affinity and a much better DILI score, Ligand A is superior overall. Ligand A's better QED, TPSA, solubility, metabolic stability (lower Cl_mic, longer t1/2), lower P-gp efflux, and better Caco-2 permeability outweigh the small affinity difference. The high logP of Ligand B is a significant concern.
Output:
1
2025-04-17 20:15:26,408 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (398.815 Da) is slightly higher than Ligand B (351.491 Da), but both are acceptable.
2. **TPSA:** Ligand A (94.59) is slightly above the preferred <90 for CNS targets, but still reasonable for a peripherally acting GPCR like ADRB2. Ligand B (78.51) is well within the optimal range.
3. **logP:** Both ligands have good logP values (A: 2.143, B: 1.55), falling within the 1-3 range.
4. **HBD:** Ligand A (1) and Ligand B (2) both have acceptable HBD counts, well below the limit of 5.
5. **HBA:** Ligand A (6) and Ligand B (3) are both below the limit of 10.
6. **QED:** Both ligands have acceptable QED scores (A: 0.763, B: 0.651), indicating good drug-like properties.
7. **DILI:** Ligand A (81.466) has a significantly higher DILI risk than Ligand B (13.067). This is a major concern for Ligand A.
8. **BBB:** Both have reasonable BBB penetration (A: 68.166, B: 70.803). Since ADRB2 is not primarily a CNS target, this is less critical, but higher is still preferred.
9. **Caco-2:** Both show poor Caco-2 permeability (A: -4.793, B: -5.105). This suggests potential absorption issues for both compounds.
10. **Solubility:** Ligand A (-3.31) has slightly better solubility than Ligand B (-1.761), but both are poor.
11. **hERG:** Ligand A (0.041) has a very low hERG risk, which is excellent. Ligand B (0.322) is slightly higher, but still relatively low.
12. **Cl_mic:** Ligand A (-1.179) has a lower (better) microsomal clearance than Ligand B (37.168), indicating better metabolic stability.
13. **t1/2:** Ligand A (-3.328) has a very negative in vitro half-life, which is concerning. Ligand B (-13.19) is even worse. Both compounds are likely to be rapidly metabolized.
14. **Pgp:** Ligand A (0.098) has very low P-gp efflux, which is favorable. Ligand B (0.015) is even lower.
15. **Binding Affinity:** Ligand A (-6.5 kcal/mol) has a slightly better binding affinity than Ligand B (-5.6 kcal/mol). This 1.5 kcal/mol difference is significant.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Both compounds have acceptable logP and Pgp values. Ligand B has a better TPSA. However, the affinity difference between Ligand A and B is significant. The biggest drawback for Ligand A is the high DILI risk, and the poor half-life. Ligand B has a better DILI profile, but a worse half-life and slightly lower affinity.
**Overall Assessment:**
While Ligand A has a better binding affinity and lower Pgp efflux, the significantly higher DILI risk is a major red flag. The poor half-life is also concerning. Ligand B, despite the slightly lower affinity, presents a much more favorable safety profile (lower DILI) and comparable ADME properties. The difference in affinity is not large enough to overcome the safety concerns of Ligand A.
Output:
0
2025-04-17 20:15:26,408 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (371.459) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (74.25) is significantly better than Ligand A (125.2), falling well below the 140 threshold for good oral absorption, and closer to the 90 threshold for CNS penetration (though CNS isn't the primary focus here).
3. **logP:** Ligand B (1.902) is within the optimal range (1-3). Ligand A (-0.247) is below 1, which could hinder permeation. This is a significant drawback for Ligand A.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (1), but both are acceptable (<=5).
5. **HBA:** Ligand B (7) is better than Ligand A (5), both are acceptable (<=10).
6. **QED:** Ligand B (0.867) is significantly better than Ligand A (0.523), indicating a more drug-like profile.
7. **DILI:** Ligand A (49.632) has a much lower DILI risk than Ligand B (76.076), which is a strong positive for Ligand A.
8. **BBB:** Ligand B (66.499) has better BBB penetration than Ligand A (33.23), but this isn't a high priority for a cardiovascular target.
9. **Caco-2:** Ligand A (-5.993) and Ligand B (-4.723) both have negative values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret this.
10. **Solubility:** Ligand A (-1.527) and Ligand B (-2.677) both have negative solubility values, which is concerning.
11. **hERG:** Ligand A (0.073) has a lower hERG risk than Ligand B (0.569), which is a positive.
12. **Cl_mic:** Ligand A (5.057) has a significantly lower microsomal clearance than Ligand B (15.821), indicating better metabolic stability.
13. **t1/2:** Ligand A (17.527) has a longer in vitro half-life than Ligand B (9.888), which is favorable.
14. **Pgp:** Ligand A (0.056) has lower P-gp efflux than Ligand B (0.147), which is better for bioavailability.
15. **Affinity:** Ligand B (-7.2) has a significantly stronger binding affinity than Ligand A (-6.3), a difference of 0.9 kcal/mol. This is a substantial advantage.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in TPSA and affinity, while Ligand A has better logP and Pgp. However, the affinity difference for Ligand B is substantial.
**Overall Assessment:**
While Ligand A has advantages in DILI risk, metabolic stability, and Pgp efflux, Ligand B's superior binding affinity (-7.2 vs -6.3 kcal/mol) and TPSA are compelling. The lower logP of Ligand A is a significant concern for permeability, and the higher QED of Ligand B suggests a more generally drug-like profile. The affinity difference is large enough to potentially overcome the slightly higher DILI risk and Pgp efflux of Ligand B.
Output:
0
2025-04-17 20:15:26,408 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (358.423 and 353.419 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand B (85.11) is better than Ligand A (91.23). Both are acceptable, but lower TPSA generally favors absorption.
3. **logP:** Both ligands have good logP values (1.492 and 1.099), falling within the 1-3 range. Ligand B is slightly better.
4. **HBD:** Ligand A (2) is preferable to Ligand B (0). While both are low, having some HBD can improve solubility.
5. **HBA:** Ligand B (6) is preferable to Ligand A (5). Both are acceptable.
6. **QED:** Ligand A (0.764) is better than Ligand B (0.651), indicating a more drug-like profile.
7. **DILI:** Ligand B (30.826) is significantly better than Ligand A (71.19). This is a major advantage for Ligand B.
8. **BBB:** Ligand B (91.043) is much better than Ligand A (28.461). While ADRB2 isn't strictly a CNS target, some brain penetration can be useful and lower efflux is always a plus.
9. **Caco-2:** Ligand A (-5.218) is better than Ligand B (-4.478), indicating better intestinal absorption.
10. **Solubility:** Ligand B (-0.495) is better than Ligand A (-4.483).
11. **hERG:** Both ligands have low hERG risk (0.303 and 0.346). No significant difference.
12. **Cl_mic:** Ligand A (-0.565) is better than Ligand B (36.551). Lower clearance is desirable for metabolic stability.
13. **t1/2:** Ligand A (13.129) is significantly better than Ligand B (-21.246). A longer half-life is preferred.
14. **Pgp:** Ligand A (0.128) is much better than Ligand B (0.076), indicating lower P-gp efflux.
15. **Binding Affinity:** Ligand A (-8.0) is slightly better than Ligand B (-5.8). This is a significant difference in potency.
**GPCR-specific priorities:** For GPCRs, logP, TPSA, Pgp, and affinity are important. Ligand B has better logP, TPSA, and BBB, but Ligand A has a substantially better binding affinity and Pgp.
**Overall Assessment:**
Ligand B has a significantly better safety profile (lower DILI) and better BBB penetration. However, Ligand A has a much stronger binding affinity (-8.0 vs -5.8 kcal/mol) and a significantly better half-life. The potency advantage of Ligand A is substantial, and the better half-life is also a major plus. The DILI risk of Ligand A is concerning, but can potentially be mitigated through structural modifications. The superior binding affinity and half-life outweigh the DILI concern, especially considering the potential for further optimization.
Output:
1
2025-04-17 20:15:26,409 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**1. Molecular Weight:** Both ligands (362.455 Da and 376.45 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (85.37) is better than Ligand B (95.94). For a cardiovascular GPCR, TPSA under 140 is acceptable, but lower is preferred for good absorption. Ligand A is closer to the optimal range.
**3. logP:** Ligand A (3.418) is significantly better than Ligand B (0.112). The optimal range is 1-3, and Ligand B is far too low, potentially hindering membrane permeability. Ligand A is within the optimal range.
**4. H-Bond Donors:** Both ligands have 2 HBD, which is within the acceptable limit of 5.
**5. H-Bond Acceptors:** Both ligands have 6 HBA, which is within the acceptable limit of 10.
**6. QED:** Ligand A (0.851) has a much better QED score than Ligand B (0.555). A higher QED suggests better overall drug-likeness.
**7. DILI:** Ligand A (85.459) has a higher DILI risk than Ligand B (23.885). This is a significant negative for Ligand A.
**8. BBB:** Ligand A (74.874) has a better BBB penetration score than Ligand B (43.505). While ADRB2 is not necessarily a CNS target, some degree of BBB penetration can be useful for understanding off-target effects.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 permeability values (-5.022 and -5.11). These values are unusual and suggest poor permeability.
**10. Aqueous Solubility:** Ligand A (-4.329) has slightly better solubility than Ligand B (-1.958), but both are very poor.
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.22 and 0.114). This is positive for both.
**12. Microsomal Clearance:** Ligand A (76.1) has a higher microsomal clearance than Ligand B (-9.275). This suggests Ligand B is more metabolically stable, which is a positive.
**13. In vitro Half-Life:** Ligand B (1.218) has a slightly better in vitro half-life than Ligand A (-1.502).
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.229 and 0.024). This is positive for both.
**15. Binding Affinity:** Both ligands have very similar binding affinities (-6.5 kcal/mol and -6.3 kcal/mol). The difference is not substantial enough to be a deciding factor.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp), Ligand A initially appears better due to its more favorable logP and TPSA. However, the significantly higher DILI risk for Ligand A is a major concern. Ligand B, while having a suboptimal logP, has a much lower DILI risk and better metabolic stability (lower Cl_mic). The similar binding affinities make the ADME profile the deciding factor. Given the importance of avoiding liver toxicity, I favor Ligand B.
Output:
0
2025-04-17 20:15:26,409 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (364.515 Da and 343.427 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Both ligands have TPSA values (76.02 and 75.44) below the 140 A^2 threshold for good oral absorption, which is good.
**3. logP:** Both ligands have logP values (2.201 and 2.17) within the optimal 1-3 range.
**4. H-Bond Donors:** Ligand A has 2 HBD, and Ligand B has 1. Both are acceptable (<=5).
**5. H-Bond Acceptors:** Ligand A has 5 HBA, and Ligand B has 4. Both are acceptable (<=10).
**6. QED:** Both ligands have good QED scores (0.759 and 0.77), indicating good drug-like properties.
**7. DILI:** Ligand A has a DILI risk of 60.062, which is borderline high. Ligand B has a significantly lower DILI risk of 35.634, which is much more favorable. This is a substantial advantage for Ligand B.
**8. BBB:** Ligand A has a BBB penetration of 53.083, while Ligand B has 82.784. While ADRB2 is a cardiovascular target, some CNS effects are possible with beta-blockers, and higher BBB penetration could lead to unwanted side effects. However, this is less critical than other parameters.
**9. Caco-2 Permeability:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand B (-4.982) is slightly better than Ligand A (-5.206), but both are concerning.
**10. Aqueous Solubility:** Both have very poor aqueous solubility (-3.575 and -3.54). This is a significant drawback for both compounds and would require formulation strategies.
**11. hERG Inhibition:** Ligand A has a hERG inhibition risk of 0.143, while Ligand B is 0.346. Ligand A is better here, indicating lower cardiotoxicity risk.
**12. Microsomal Clearance:** Ligand A has a Cl_mic of 38.576, and Ligand B has 29.342. Lower is better, so Ligand B has better metabolic stability.
**13. In vitro Half-Life:** Ligand A has a t1/2 of 18.162, and Ligand B has -5.601. The negative value for Ligand B is concerning and likely an error. Ligand A is clearly better here.
**14. P-gp Efflux:** Ligand A has a Pgp efflux liability of 0.174, and Ligand B has 0.164. Both are relatively low, suggesting limited P-gp mediated efflux.
**15. Binding Affinity:** Ligand B has a significantly better binding affinity (-7.0 kcal/mol) compared to Ligand A (-4.6 kcal/mol). This 2.4 kcal/mol difference is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity) and the general guidelines, Ligand B is the more promising candidate. The significantly stronger binding affinity (-7.0 vs -4.6 kcal/mol) is a major advantage. While both have poor solubility and Caco-2 permeability, the lower DILI risk and better metabolic stability of Ligand B are also important positives. The negative half-life for Ligand B is a red flag, but the affinity difference is so large it's worth investigating further to determine if that value is an error.
Output:
0
2025-04-17 20:15:26,409 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (372.531 and 347.371 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (87.66) is better than Ligand B (97.81). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally favors absorption.
3. **logP:** Both ligands have similar logP values (1.483 and 1.464), falling within the optimal 1-3 range. No significant difference.
4. **HBD:** Ligand A has 3 HBD, while Ligand B has 1. Both are acceptable, but lower HBD can sometimes improve permeability. Ligand B is slightly favored.
5. **HBA:** Ligand A has 5 HBA, and Ligand B has 6. Both are within the acceptable limit of 10. No significant difference.
6. **QED:** Ligand B (0.899) has a significantly higher QED score than Ligand A (0.506), indicating a more drug-like profile overall. This is a substantial advantage for Ligand B.
7. **DILI:** Ligand A (19.038) has a much lower DILI risk than Ligand B (74.99). This is a *major* advantage for Ligand A, as liver toxicity is a critical concern.
8. **BBB:** Ligand A (51.26) has a lower BBB penetration than Ligand B (62.931). For a cardiovascular target, BBB penetration is not a priority.
9. **Caco-2:** Ligand A (-5.045) and Ligand B (-4.584) are both negative, which is unusual. A higher value is better. The difference is small.
10. **Solubility:** Ligand A (-2.858) and Ligand B (-2.367) are both negative, indicating poor solubility. Ligand B is slightly better.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.145 and 0.18). No significant difference.
12. **Cl_mic:** Ligand A (46.961) has a higher microsomal clearance than Ligand B (23.809), indicating faster metabolism and potentially lower exposure. Ligand B is favored.
13. **t1/2:** Ligand B (-8.901) has a longer in vitro half-life than Ligand A (-1.2). This is a significant advantage for Ligand B.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.098 and 0.08). No significant difference.
15. **Binding Affinity:** Ligand A (-7.6) has a slightly better binding affinity than Ligand B (-6.6). A 1 kcal/mol difference is meaningful, but not overwhelming.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Both ligands perform similarly on logP and Pgp. Ligand A has a slightly better affinity, while Ligand B has a better TPSA and half-life. However, the *massive* difference in DILI risk is the deciding factor.
**Conclusion:**
While Ligand B has a better QED and half-life, the significantly higher DILI risk associated with Ligand B makes it a less desirable candidate. The lower DILI risk of Ligand A, coupled with acceptable ADME properties and a slightly better binding affinity, makes it the more promising drug candidate.
Output:
1
2025-04-17 20:15:26,409 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [358.385, 67.87, 1.112, 1, 4, 0.772, 43.932, 88.872, -4.687, -2.038, 0.358, 3.347, -1.527, 0.048, -6.9]**
**Ligand B: [371.522, 54.46, 3.427, 1, 5, 0.676, 26.444, 91.431, -4.743, -3.875, 0.873, 61.148, -8.516, 0.678, -6.3]**
1. **Molecular Weight:** Both are within the ideal range (200-500 Da). Ligand A (358.385) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (67.87) is slightly higher than Ligand B (54.46). Both are acceptable for a non-CNS GPCR target like ADRB2, but Ligand B is better.
3. **logP:** Ligand A (1.112) is within the optimal range, while Ligand B (3.427) is approaching the upper limit. Ligand A is preferred here.
4. **H-Bond Donors:** Both have 1 HBD, which is good.
5. **H-Bond Acceptors:** Ligand A has 4, Ligand B has 5. Both are acceptable, but Ligand A is slightly better.
6. **QED:** Ligand A (0.772) has a better QED score than Ligand B (0.676), indicating a more drug-like profile.
7. **DILI:** Ligand A (43.932) has a slightly higher DILI risk than Ligand B (26.444), but both are below the concerning threshold of 60. Ligand B is preferred.
8. **BBB:** Both have high BBB penetration, but Ligand B (91.431) is slightly higher than Ligand A (88.872). This isn't a primary concern for ADRB2, but a slight advantage for B.
9. **Caco-2:** Both are negative, indicating poor permeability. This is a significant drawback for both.
10. **Aqueous Solubility:** Both are negative, indicating poor solubility. This is a significant drawback for both.
11. **hERG:** Ligand A (0.358) has a much lower hERG risk than Ligand B (0.873). This is a significant advantage for A.
12. **Microsomal Clearance:** Ligand A (3.347) has a much lower Cl_mic than Ligand B (61.148), indicating better metabolic stability. This is a major advantage for A.
13. **In vitro Half-Life:** Ligand A (-1.527) has a better half-life than Ligand B (-8.516). This is a significant advantage for A.
14. **P-gp Efflux:** Ligand A (0.048) has significantly lower P-gp efflux liability than Ligand B (0.678), suggesting better bioavailability. This is a significant advantage for A.
15. **Binding Affinity:** Ligand A (-6.9) has a slightly better binding affinity than Ligand B (-6.3). While the difference is not huge, it's a positive for A.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity) and the general guidelines, Ligand A is the more promising candidate. While Ligand B has slightly better TPSA and BBB, Ligand A excels in crucial ADME properties like metabolic stability (Cl_mic, t1/2), P-gp efflux, hERG risk, and QED. The slightly better affinity of Ligand A further strengthens its position. The poor Caco-2 and solubility for both are concerning and would need to be addressed in further optimization, but the superior ADME profile of Ligand A makes it the better starting point.
Output:
1
2025-04-17 20:15:26,409 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (455.384 Da) is slightly higher than Ligand B (374.535 Da), but both are acceptable.
**2. TPSA:** Ligand A (46.92) is well below the 140 A^2 threshold for good oral absorption, and is quite favorable. Ligand B (61.92) is still acceptable, but less optimal.
**3. logP:** Both ligands have logP values within the optimal range (1-3), with Ligand A (4.577) being slightly higher. While slightly above the preferred range, it's not a major concern, and could contribute to good membrane permeability. Ligand B (3.788) is better in this regard.
**4. H-Bond Donors:** Ligand A has 1 HBD, which is good. Ligand B has 0, which is also good.
**5. H-Bond Acceptors:** Ligand A has 3 HBA, while Ligand B has 6. Both are within the acceptable limit of 10, but Ligand A is preferred.
**6. QED:** Both ligands have QED values above 0.5, indicating good drug-likeness. Ligand A (0.679) is slightly better than Ligand B (0.469).
**7. DILI Risk:** Ligand A (41.024%) has a lower DILI risk than Ligand B (57.193%), which is a significant advantage.
**8. BBB Penetration:** Both ligands have reasonable BBB penetration, but Ligand A (74.758%) is significantly better than Ligand B (61.729%). While ADRB2 is a cardiovascular target, some CNS effects are possible with beta-blockers, and better BBB penetration could be relevant for off-target effects or potential dual-targeting strategies.
**9. Caco-2 Permeability:** Ligand A (-4.819) has better Caco-2 permeability than Ligand B (-5.232), indicating better intestinal absorption.
**10. Aqueous Solubility:** Ligand A (-5.755) has slightly better solubility than Ligand B (-4.21), which is good.
**11. hERG Inhibition:** Ligand A (0.497) has a lower hERG inhibition risk than Ligand B (0.791), which is a crucial safety consideration.
**12. Microsomal Clearance:** Ligand A (84.907) has higher microsomal clearance than Ligand B (106.78), indicating lower metabolic stability. This is a negative for Ligand A.
**13. In vitro Half-Life:** Ligand A (64.764) has a longer in vitro half-life than Ligand B (36.012), which is a positive.
**14. P-gp Efflux:** Ligand A (0.382) has lower P-gp efflux than Ligand B (0.755), which is favorable for bioavailability.
**15. Binding Affinity:** Ligand A (-6.4 kcal/mol) has a slightly better binding affinity than Ligand B (-5.8 kcal/mol). This difference is significant enough to outweigh some of the ADME drawbacks of Ligand A.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand A appears to be the more promising candidate. While it has slightly higher logP and clearance, it excels in critical areas like DILI risk, BBB penetration, Caco-2 permeability, hERG inhibition, and binding affinity. The better binding affinity, coupled with the improved safety profile (lower DILI, hERG), and better absorption/distribution properties make it the preferred choice.
Output:
1
2025-04-17 20:15:26,409 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [343.427, 71.53, 1.598, 1, 4, 0.901, 32.299, 75.998, -4.498, -2.063, 0.176, 14.489, -6.53, 0.022, -7.4]
**Ligand B:** [345.403, 101.21, 1.172, 1, 6, 0.694, 52.346, 46.801, -5.568, -0.555, 0.006, 0.799, -3.936, 0.014, -6.3]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, Affinity, and BBB):
1. **MW:** Both are within the ideal 200-500 Da range. A (343.4) is slightly lower, which is generally favorable.
2. **TPSA:** A (71.53) is excellent, well below the 140 threshold and suggesting good oral absorption. B (101.21) is higher, but still acceptable.
3. **logP:** Both are good (A: 1.598, B: 1.172), falling within the 1-3 range. A is slightly better.
4. **HBD/HBA:** Both have 1 HBD, which is good. A has 4 HBA, B has 6. Both are within the acceptable range of <=10.
5. **QED:** A (0.901) is excellent, indicating high drug-likeness. B (0.694) is still reasonable, but less optimal.
6. **DILI:** A (32.299) is significantly better than B (52.346), indicating a lower risk of liver injury.
7. **BBB:** A (75.998) is much better than B (46.801). While ADRB2 isn't exclusively a CNS target, some peripheral effects are mediated by CNS pathways, and higher BBB penetration can be beneficial.
8. **Caco-2:** Both are negative, indicating poor permeability. A (-4.498) is worse than B (-5.568).
9. **Solubility:** Both are negative, indicating poor solubility. A (-2.063) is better than B (-0.555).
10. **hERG:** Both are very low (A: 0.176, B: 0.006), indicating minimal hERG inhibition risk. B is slightly better.
11. **Cl_mic:** A (14.489) is much better than B (0.799), suggesting better metabolic stability.
12. **t1/2:** A (-6.53) is better than B (-3.936), indicating a longer half-life.
13. **Pgp:** Both are very low (A: 0.022, B: 0.014), indicating minimal P-gp efflux. B is slightly better.
14. **Affinity:** A (-7.4) is significantly better than B (-6.3), representing a substantial binding advantage (1.1 kcal/mol difference).
**Overall Assessment:**
Ligand A clearly outperforms Ligand B. The key advantages of A are its superior QED, significantly lower DILI risk, better BBB penetration, improved metabolic stability (Cl_mic), longer half-life, and, most importantly, a much stronger binding affinity. While A has slightly worse Caco-2 permeability, the substantial affinity advantage and other favorable ADME properties outweigh this drawback. The better affinity is a significant driver for selection, especially for a GPCR target.
Output:
1
2025-04-17 20:15:26,409 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (341.455 and 346.515 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (68.02) is higher than Ligand B (49.41). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B has a clear advantage.
3. **logP:** Both ligands have good logP values (3.778 and 3.666), falling within the optimal 1-3 range. Similar.
4. **HBD:** Both have 1 HBD, which is good. No difference.
5. **HBA:** Ligand A has 4 HBAs, while Ligand B has 2. Lower HBA is generally favorable for permeability. Ligand B is better.
6. **QED:** Ligand A (0.898) has a significantly higher QED score than Ligand B (0.538), indicating a more drug-like profile overall. This is a substantial advantage for Ligand A.
7. **DILI:** Ligand A (35.828%) has a higher DILI risk than Ligand B (10.198%). This is a significant concern for Ligand A. Ligand B is much better.
8. **BBB:** Ligand A (84.451%) has a good BBB penetration, while Ligand B (93.757%) is even better. While ADRB2 isn't a CNS target, higher BBB is rarely detrimental and can indicate better overall permeability. Ligand B is better.
9. **Caco-2:** Both have negative Caco-2 values (-4.773 and -4.883), which is unusual and suggests poor permeability. This is a significant drawback for both.
10. **Solubility:** Both have negative solubility values (-4.416 and -3.95), indicating poor aqueous solubility. This is a concern for both.
11. **hERG:** Ligand A (0.2) has a lower hERG risk than Ligand B (0.689), which is preferable. Ligand A is better.
12. **Cl_mic:** Ligand A (66.784) has a higher microsomal clearance than Ligand B (54.556), suggesting lower metabolic stability. Ligand B is better.
13. **t1/2:** Ligand A (-6.644) has a more negative in vitro half-life than Ligand B (-3.649), indicating a shorter half-life. Ligand B is better.
14. **Pgp:** Ligand A (0.315) has lower P-gp efflux than Ligand B (0.173), which is favorable. Ligand A is better.
15. **Binding Affinity:** Ligand A (-6.4 kcal/mol) has a slightly weaker binding affinity than Ligand B (-5.5 kcal/mol). This is a 0.9 kcal/mol difference, which is significant. Ligand A is better.
**Overall Assessment:**
While Ligand A has a better QED, hERG, and Pgp profile, and slightly better binding affinity, its significantly higher DILI risk and higher Cl_mic are major drawbacks. Ligand B excels in several key ADME properties (lower DILI, better metabolic stability, better BBB penetration) and has a competitive binding affinity. The Caco-2 and solubility issues are concerning for both, but the ADME profile of Ligand B is more favorable overall for a cardiovascular target. The 0.9 kcal/mol difference in binding affinity can likely be optimized in subsequent iterations, whereas mitigating a high DILI risk is far more challenging.
Output:
0
2025-04-17 20:15:26,409 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (349.38 and 350.50 Da). No significant difference.
2. **TPSA:** Ligand A (42.68) is significantly better than Ligand B (69.64). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (4.511) is higher than Ligand B (2.183). While Ligand B is within the optimal range, Ligand A is pushing the upper limit. This could lead to solubility issues, but for a GPCR, some lipophilicity is beneficial for membrane interactions.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Both have 3 HBA, which is acceptable.
6. **QED:** Ligand A (0.815) is better than Ligand B (0.705), indicating a more drug-like profile.
7. **DILI:** Ligand B (20.40) is *much* better than Ligand A (56.57). This is a major advantage for Ligand B. DILI is a critical safety concern.
8. **BBB:** Ligand A (86.43) is better than Ligand B (77.16), but BBB isn't a high priority for a cardiovascular target.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-4.337) is slightly better than Ligand B (-4.852), but both are poor.
10. **Solubility:** Ligand B (-3.057) is better than Ligand A (-4.384), which is expected given its lower logP.
11. **hERG:** Ligand A (0.8) is slightly better than Ligand B (0.541), meaning lower risk of cardiotoxicity.
12. **Cl_mic:** Ligand B (27.36) is *much* better than Ligand A (65.88). Lower clearance is highly desirable for longer duration of action.
13. **t1/2:** Ligand A (50.73) is significantly better than Ligand B (-1.313). This is a substantial advantage for Ligand A.
14. **Pgp:** Ligand B (0.344) is better than Ligand A (0.7), indicating less efflux and potentially better bioavailability.
15. **Affinity:** Ligand A (-7.8) is significantly better than Ligand B (-5.9). A difference of 1.9 kcal/mol is substantial and can often outweigh other drawbacks.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), affinity, logP, Pgp, TPSA, and metabolic stability are key. Ligand A has a significantly better binding affinity and a lower TPSA. Ligand B has better DILI and Cl_mic.
**Overall Assessment:**
The biggest concerns with Ligand A are its higher DILI risk and higher microsomal clearance. However, its substantially better binding affinity (-7.8 vs -5.9 kcal/mol) and longer half-life are very compelling. The difference in affinity is large enough to potentially overcome the ADME liabilities. Ligand B has a much better safety profile (DILI) and metabolic stability, but its significantly weaker binding affinity is a major drawback. Given the importance of potency for GPCRs, and the fact that the ADRB2 target is not in the CNS, I favor the higher affinity and longer half-life of Ligand A, despite its other weaknesses.
Output:
1
2025-04-17 20:15:26,410 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [358.349, 121.03 , 1.023, 4. , 5. , 0.605, 65.452, 81.039, -4.982, -3.774, 0.166, 4.765, 4.165, 0.051, -6.2 ]
**Ligand B:** [345.491, 53.52 , 2.154, 1. , 6. , 0.883, 30.748, 91.508, -4.904, -2.22 , 0.937, 44.379, 24.385, 0.126, -5.9 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (345.491) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (121.03) is a bit higher than ideal for optimal oral absorption (<140), but still acceptable. Ligand B (53.52) is excellent, well below the threshold.
3. **logP:** Ligand A (1.023) is at the lower end of the optimal range, potentially impacting permeability. Ligand B (2.154) is better positioned within the 1-3 range.
4. **HBD:** Ligand A (4) is acceptable. Ligand B (1) is even better, minimizing potential for off-target interactions.
5. **HBA:** Both ligands (A: 5, B: 6) are within the acceptable limit of 10.
6. **QED:** Both have good QED scores (A: 0.605, B: 0.883), indicating drug-like properties. Ligand B is better.
7. **DILI:** Ligand A (65.452) has a higher DILI risk than Ligand B (30.748). This is a significant concern.
8. **BBB:** Both have good BBB penetration (A: 81.039, B: 91.508). Ligand B is better.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. This is a red flag for both.
10. **Solubility:** Both have negative solubility values, which is also unusual and suggests poor solubility. This is a red flag for both.
11. **hERG:** Ligand A (0.166) has a lower hERG risk than Ligand B (0.937).
12. **Cl_mic:** Ligand A (4.765) has a lower microsomal clearance, indicating better metabolic stability. Ligand B (44.379) is significantly higher.
13. **t1/2:** Ligand B (24.385) has a much longer in vitro half-life than Ligand A (4.165). This is a major advantage.
14. **Pgp:** Ligand A (0.051) has lower P-gp efflux, which is favorable. Ligand B (0.126) is slightly higher.
15. **Affinity:** Ligand A (-6.2) has a slightly better binding affinity than Ligand B (-5.9). However, the difference is not substantial enough to outweigh other factors.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp efflux, and affinity are key. Ligand B excels in logP, TPSA, and BBB penetration. While Ligand A has slightly better affinity, the significantly higher DILI risk and lower metabolic stability are major drawbacks. The longer half-life of Ligand B is also very attractive. The negative Caco-2 and solubility values are concerning for both, but these could be addressed with formulation strategies.
**Conclusion:**
Despite the slightly weaker affinity, Ligand B is the more promising candidate due to its superior ADME properties, particularly the lower DILI risk, better metabolic stability (longer half-life), and favorable logP and TPSA values.
0
2025-04-17 20:15:26,410 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (364.423 and 370.471 Da) fall comfortably within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (97.75) is slightly higher than Ligand B (88.85). Both are below the 140 threshold for oral absorption, but B is closer to the preferred <90 for GPCRs.
3. **logP:** Both ligands have good logP values (1.811 and 1.36), falling within the optimal 1-3 range. Ligand B is slightly lower, which could be beneficial for solubility.
4. **HBD:** Ligand A has 2 HBD, while Ligand B has 1. Both are acceptable.
5. **HBA:** Both ligands have 6 HBA, which is within the acceptable limit of 10.
6. **QED:** Both ligands have good QED scores (0.778 and 0.813), indicating good drug-like properties. Ligand B is marginally better.
7. **DILI:** Ligand A (72.703) has a higher DILI risk than Ligand B (54.052). This is a significant advantage for Ligand B.
8. **BBB:** Ligand B (68.554) has a higher BBB penetration percentile than Ligand A (52.074). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant, and higher BBB is generally favorable.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand B (-4.866) is slightly less negative than Ligand A (-5.567), potentially indicating slightly better absorption.
10. **Solubility:** Both have negative solubility values, indicating poor aqueous solubility. Ligand B (-2.228) is slightly better than Ligand A (-1.993).
11. **hERG:** Both ligands have very low hERG inhibition liability (0.047 and 0.268), which is excellent.
12. **Cl_mic:** Ligand A (2.109) has significantly lower microsomal clearance than Ligand B (9.506), suggesting better metabolic stability. This is a major advantage for Ligand A.
13. **t1/2:** Ligand B (41.174) has a longer in vitro half-life than Ligand A (19.231). This is a positive for Ligand B.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.015 and 0.052), which is good.
15. **Binding Affinity:** Ligand B (-6.4 kcal/mol) has a slightly better binding affinity than Ligand A (-7.0 kcal/mol). While A is better, the difference is not substantial enough to outweigh other factors.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), and the general drug-like properties, Ligand B appears to be the more promising candidate. While Ligand A has better metabolic stability (lower Cl_mic), Ligand B excels in DILI risk, BBB penetration, and has a slightly better half-life and binding affinity. The solubility and Caco-2 values are poor for both, but B is marginally better. The lower DILI risk is a crucial factor, and the slightly improved BBB is a bonus.
Output:
0
2025-04-17 20:15:26,410 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (348.447 and 350.419 Da) are within the ideal range (200-500 Da). No significant difference here.
**2. TPSA:** Ligand A (82.7) is significantly better than Ligand B (115.57). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is bordering on being too high for good oral absorption.
**3. logP:** Ligand A (0.713) is slightly higher than Ligand B (0.342), both are a little low, but still acceptable. A logP between 1-3 is optimal, but these are not far off.
**4. H-Bond Donors:** Both ligands have 3 HBD, which is within the acceptable limit of <=5.
**5. H-Bond Acceptors:** Ligand A has 4 HBA, while Ligand B has 6. Both are within the acceptable limit of <=10, but Ligand A is preferable.
**6. QED:** Both ligands have similar QED values (0.614 and 0.582), indicating good drug-like properties.
**7. DILI:** Ligand A (12.02) has a much lower DILI risk than Ligand B (53.276). This is a significant advantage for Ligand A.
**8. BBB:** Both ligands show good BBB penetration (71.733 and 73.401). This is good, as it suggests potential for CNS effects if desired, or at least reasonable distribution.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-5.185 and -5.376). These values are unusual and likely indicate poor permeability *in vitro*. However, the values are very similar.
**10. Aqueous Solubility:** Both ligands have negative solubility values (-1 and -2.087). These values are also unusual and indicate poor solubility. Ligand B is slightly worse.
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (0.385 and 0.288). This is good, minimizing cardiotoxicity concerns.
**12. Microsomal Clearance:** Ligand A (-8.816) has significantly lower (better) microsomal clearance than Ligand B (-2.726). This indicates better metabolic stability for Ligand A.
**13. In vitro Half-Life:** Ligand A (-1.508) has a slightly worse in vitro half-life than Ligand B (0.474).
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.004 and 0.005).
**15. Binding Affinity:** Both ligands have very similar binding affinities (-6.6 and -6.7 kcal/mol). This difference is negligible.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand A is the better candidate. It has a lower TPSA, lower DILI risk, and significantly better metabolic stability (lower Cl_mic). While both have poor Caco-2 and solubility, the other advantages of Ligand A outweigh this. The binding affinity is essentially the same.
Output:
1
2025-04-17 20:15:26,410 - INFO - Batch 171 complete. Total preferences: 2736
2025-04-17 20:15:26,410 - INFO - Processing batch 172/512...
2025-04-17 20:16:14,126 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (371.834 Da and 350.463 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (21.06) is significantly better than Ligand B (84.3). For a GPCR, a lower TPSA is generally preferred for better permeability. Ligand B's TPSA is quite high, potentially hindering absorption.
**3. logP:** Ligand A (4.739) is a bit high, potentially leading to solubility issues or off-target interactions, but still within a manageable range. Ligand B (1.76) is lower, which is good for solubility but could limit membrane permeability. Given the GPCR target class, a slightly higher logP is acceptable if other parameters are favorable.
**4. H-Bond Donors:** Ligand A (0) is preferable to Ligand B (1). Fewer H-bond donors generally improve permeability.
**5. H-Bond Acceptors:** Ligand A (3) is better than Ligand B (5). Lower HBA counts also favor permeability.
**6. QED:** Both ligands have similar QED values (0.774 and 0.688), indicating reasonable drug-likeness.
**7. DILI Risk:** Ligand A (25.165) has a much lower DILI risk than Ligand B (42.652). This is a significant advantage for Ligand A.
**8. BBB Penetration:** Ligand A (90.151) shows excellent BBB penetration, while Ligand B (50.679) is moderate. While ADRB2 isn't strictly a CNS target, some CNS exposure can occur, and higher BBB penetration is generally favorable.
**9. Caco-2 Permeability:** Both ligands have similar and poor Caco-2 permeability (-4.838 and -4.773).
**10. Aqueous Solubility:** Ligand A (-4.936) is slightly worse than Ligand B (-1.521), but the difference isn't substantial.
**11. hERG Inhibition:** Ligand A (0.914) has a slightly higher hERG risk than Ligand B (0.076). This is a concern for Ligand A, but the difference isn't massive.
**12. Microsomal Clearance:** Ligand B (55.202) has a higher microsomal clearance than Ligand A (35.94), meaning it will be metabolized faster. Lower clearance is preferred for longer duration of action.
**13. In vitro Half-Life:** Ligand A (-6.769) has a significantly longer in vitro half-life than Ligand B (-1.238). This is a major advantage for Ligand A.
**14. P-gp Efflux:** Ligand A (0.81) has a slightly higher P-gp efflux than Ligand B (0.043). Lower P-gp efflux is preferred.
**15. Binding Affinity:** Both ligands have very similar binding affinities (-6.3 and -6.6 kcal/mol). The difference is negligible.
**Overall Assessment:**
Ligand A is the stronger candidate. It excels in critical ADME properties like DILI risk, BBB penetration, and in vitro half-life. While its logP and hERG risk are slightly elevated, these are outweighed by its superior metabolic stability and lower toxicity profile. Ligand B's high TPSA and faster clearance are significant drawbacks. Considering the GPCR target class, the balance of properties in Ligand A is more favorable for development.
Output:
1
2025-04-17 20:16:14,126 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
The target is ADRB2, a GPCR. Therefore, I will prioritize logP, TPSA, Pgp efflux, BBB penetration, and binding affinity, while also considering ADME properties like solubility, metabolic stability, and toxicity.
* **Molecular Weight:** Both ligands are within the ideal range (200-500 Da).
* **TPSA:** Ligand B (89.35) is better than Ligand A (98.58) as it is closer to the <140 threshold for good oral absorption.
* **logP:** Ligand A (-0.786) is suboptimal, being slightly below the preferred 1-3 range. Ligand B (2.3) is within the optimal range. This is a significant advantage for Ligand B.
* **H-Bond Donors/Acceptors:** Both are acceptable, with 1 HBD and around 7-8 HBA.
* **QED:** Both ligands have good QED scores (>0.5).
* **DILI:** Ligand A (48.662) has a significantly lower DILI risk than Ligand B (74.952). This is a strong point in favor of Ligand A.
* **BBB:** Both ligands have similar, relatively low BBB penetration (Ligand A: 38.813, Ligand B: 40.52). This isn't critical for ADRB2 (a cardiovascular target), but higher would be preferable if CNS effects were a concern.
* **Caco-2 Permeability:** Both are negative, indicating poor permeability. Ligand A (-5.07) is slightly better than Ligand B (-4.675).
* **Aqueous Solubility:** Both are very poor, with negative values. Ligand A (-1.185) is slightly better than Ligand B (-2.405).
* **hERG Inhibition:** Ligand A (0.053) is slightly better than Ligand B (0.353) in terms of hERG risk.
* **Microsomal Clearance:** Ligand A (-5.498) has a much lower (better) microsomal clearance than Ligand B (76.406), indicating better metabolic stability.
* **In vitro Half-Life:** Ligand A (19.699) has a shorter half-life than Ligand B (27.839), but both are acceptable.
* **P-gp Efflux:** Both have very low P-gp efflux liability (close to 0).
* **Binding Affinity:** Ligand B (-6.7 kcal/mol) has a slightly better binding affinity than Ligand A (-6.0 kcal/mol). However, the difference is less than 1.5 kcal/mol, so it's not a decisive factor.
**Overall Assessment:**
Ligand B has a better logP and binding affinity, which are important for GPCR targets. However, Ligand A has a significantly lower DILI risk and better metabolic stability (lower Cl_mic), and slightly better solubility and hERG inhibition. Given the importance of minimizing toxicity and maximizing metabolic stability for a cardiovascular drug, and the relatively small difference in binding affinity, I believe Ligand A is the more promising candidate.
**Output:**
1
2025-04-17 20:16:14,126 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (378.881) is slightly higher than Ligand B (344.415), but both are acceptable.
2. **TPSA:** Ligand A (62.66) is better than Ligand B (83.44). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (3.822) is optimal, while Ligand B (0.43) is quite low. This is a significant drawback for Ligand B, potentially hindering membrane permeability and bioavailability.
4. **HBD:** Ligand A (1) and Ligand B (2) are both acceptable.
5. **HBA:** Ligand A (5) and Ligand B (4) are both acceptable.
6. **QED:** Both ligands have similar QED values (A: 0.878, B: 0.76), indicating good drug-likeness.
7. **DILI:** Ligand A (56.844) has a higher DILI risk than Ligand B (35.789), which is a negative for A.
8. **BBB:** Ligand A (77.705) has better BBB penetration than Ligand B (57.193), but this isn't a primary concern for a cardiovascular target.
9. **Caco-2:** Ligand A (-4.503) is better than Ligand B (-5.231), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-5.023) is better than Ligand B (-2.05), which is important for formulation.
11. **hERG:** Ligand A (0.758) has a slightly higher hERG risk than Ligand B (0.051), which is a negative for A.
12. **Cl_mic:** Ligand A (27.221) has higher microsomal clearance than Ligand B (19.084), meaning it's metabolized faster. This is a negative for A.
13. **t1/2:** Ligand A (14.852) has a longer half-life than Ligand B (10.996), which is a positive for A.
14. **Pgp:** Ligand A (0.65) has higher P-gp efflux than Ligand B (0.044), which is a negative for A.
15. **Affinity:** Ligand B (-6.4 kcal/mol) has a slightly better binding affinity than Ligand A (-5.9 kcal/mol). While the difference is not huge, it's still a factor.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand A excels in logP and has acceptable TPSA, while Ligand B's low logP is a major concern. Ligand B has slightly better affinity, but the difference isn't enough to overcome the logP issue.
**Overall Assessment:**
Ligand A presents a more balanced profile overall, despite some drawbacks in DILI, hERG, Cl_mic, and Pgp. The significantly better logP and solubility are crucial for absorption and bioavailability. Ligand B's very low logP is a substantial hurdle that would likely require significant medicinal chemistry efforts to overcome.
Output:
1
2025-04-17 20:16:14,126 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.443 and 342.403 Da) are within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (75.71) is better than Ligand B (87.12). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally favors absorption.
3. **logP:** Ligand A (0.99) is slightly better than Ligand B (0.277). Both are a bit low, potentially hindering membrane permeability, but A is closer to the optimal 1-3 range.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A (4) is better than Ligand B (5). Lower HBA is preferable for permeability.
6. **QED:** Ligand B (0.864) has a higher QED score than Ligand A (0.744), indicating a more drug-like profile overall.
7. **DILI:** Ligand A (20.589) has a significantly lower DILI risk than Ligand B (30.516). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (66.731) has a better BBB percentile than Ligand B (36.293). While not a CNS target, some degree of BBB penetration can sometimes indicate favorable distribution properties.
9. **Caco-2:** Ligand A (-4.742) is better than Ligand B (-5.53). Higher Caco-2 permeability is desired for oral absorption.
10. **Solubility:** Ligand A (-1.922) is better than Ligand B (-1.016). Higher solubility is generally preferred.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.095 and 0.134). No significant difference.
12. **Cl_mic:** Ligand B (2.946) has a much lower microsomal clearance than Ligand A (16.992). This suggests better metabolic stability for Ligand B.
13. **t1/2:** Ligand B (-29.244) has a much longer in vitro half-life than Ligand A (-1.574). This is a significant advantage for Ligand B.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.045 and 0.007). No significant difference.
15. **Binding Affinity:** Ligand B (-7.6) has a slightly better binding affinity than Ligand A (-7.0). While the difference is less than the 1.5 kcal/mol threshold, it's still a positive for Ligand B.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B has a slightly better affinity and lower Pgp efflux. Ligand A has better TPSA and logP. However, the substantial advantages of Ligand B in terms of metabolic stability (Cl_mic) and half-life, coupled with the significantly lower DILI risk of Ligand A, are crucial.
**Overall Assessment:**
Ligand B has a better binding affinity and metabolic stability. However, Ligand A has a significantly lower DILI risk and better solubility. Considering the balance of properties, the lower DILI risk of Ligand A is a critical factor for drug development.
Output:
1
2025-04-17 20:16:14,126 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (370.362 and 334.423 Da) fall within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (49.41) is better than Ligand B (59.81), both are below the 140 threshold for oral absorption, and acceptable for a non-CNS GPCR target like ADRB2.
3. **logP:** Both ligands (2.973 and 3.637) are within the optimal 1-3 range. Ligand B is slightly higher, which could potentially lead to some off-target interactions, but is not a major concern.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 2 HBA, while Ligand B has 4. Both are acceptable, but Ligand A is preferable.
6. **QED:** Both ligands have similar QED values (0.774 and 0.749), indicating good drug-likeness.
7. **DILI:** Ligand A (19.62) has a significantly lower DILI risk than Ligand B (77.782). This is a major advantage for Ligand A.
8. **BBB:** ADRB2 is not a CNS target, so BBB penetration is less critical. Ligand A (93.098) is better than Ligand B (49.864), but this is not a primary concern.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the values are close (-4.669 vs -4.998).
10. **Solubility:** Ligand A (-3.129) has slightly better solubility than Ligand B (-5.059), which is beneficial.
11. **hERG:** Both ligands have low hERG inhibition liability (0.609 and 0.465), which is good.
12. **Cl_mic:** Ligand A (6.292) has a much lower microsomal clearance than Ligand B (65.629), indicating better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand A (-22.928) has a much longer in vitro half-life than Ligand B (14.624). This is a substantial benefit.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.033 and 0.645), which is good.
15. **Binding Affinity:** Ligand B (-6.9 kcal/mol) has a slightly better binding affinity than Ligand A (-6.5 kcal/mol). This is a 0.4 kcal/mol difference, which is not a huge advantage given the other factors.
**Overall Assessment:**
Ligand A is significantly better overall. While Ligand B has a slightly better binding affinity, Ligand A excels in crucial ADME-Tox properties: lower DILI risk, much better metabolic stability (lower Cl_mic, longer t1/2), and slightly better solubility. These factors are critical for developing a safe and effective drug, especially for a cardiovascular target where long-term treatment is often required. The TPSA and logP values are also favorable for Ligand A.
Output:
1
2025-04-17 20:16:14,127 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (355.479 and 347.459 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (82.11) is slightly higher than Ligand B (75.44). Both are below the 140 threshold for good oral absorption, and acceptable for a cardiovascular GPCR.
3. **logP:** Ligand B (3.002) is optimal, while Ligand A (0.08) is quite low. This is a significant drawback for Ligand A, potentially hindering membrane permeability and bioavailability. GPCRs generally benefit from moderate lipophilicity.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1), but both are within the acceptable limit of 5.
5. **HBA:** Ligand A (5) is slightly higher than Ligand B (4), but both are within the acceptable limit of 10.
6. **QED:** Both ligands have good QED scores (0.644 and 0.769, respectively), indicating good drug-like properties.
7. **DILI:** Both ligands have similar, low DILI risk (4.459 and 43.66 percentile). This is good for both.
8. **BBB:** Ligand B (75.921) has a significantly higher BBB penetration score than Ligand A (43.971). While ADRB2 isn't a CNS target, some peripheral exposure can be beneficial, and higher BBB generally correlates with better overall distribution.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.876 and -4.743). This is unusual and suggests poor permeability, but the scale is not clearly defined.
10. **Solubility:** Ligand B (-3.704) has worse solubility than Ligand A (-0.442). Solubility is important, but can often be addressed with formulation strategies.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.218 and 0.359). This is excellent.
12. **Cl_mic:** Ligand A (-1.403) has a much lower (better) microsomal clearance than Ligand B (90.64). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (14.47) has a longer in vitro half-life than Ligand B (-16.536). This is a significant advantage for Ligand A, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.002) has much lower P-gp efflux liability than Ligand B (0.446). This is favorable for bioavailability.
15. **Binding Affinity:** Both ligands have comparable and strong binding affinities (-6.9 and -6.8 kcal/mol). The difference is negligible.
**Overall Assessment:**
Ligand B has better logP and BBB penetration, but suffers from significantly higher microsomal clearance and P-gp efflux, and worse solubility. Ligand A has a lower logP which is a concern, but it compensates with superior metabolic stability (lower Cl_mic), longer half-life, and lower P-gp efflux. Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity), and the fact that the affinity is comparable, the improved ADME properties of Ligand A (particularly metabolic stability and reduced efflux) outweigh the slightly lower logP.
Output:
1
2025-04-17 20:16:14,127 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, we prioritize logP, TPSA, Pgp, and binding affinity, alongside general drug-like properties.
* **Molecular Weight:** Both ligands (349.475 and 344.455 Da) are within the ideal 200-500 Da range.
* **TPSA:** Ligand A (84.23) is slightly higher than Ligand B (69.64). Both are below the 140 threshold for good absorption, but Ligand B is preferable due to being closer to the 90 threshold.
* **logP:** Ligand A (3.063) is within the optimal 1-3 range. Ligand B (1.828) is at the lower end, potentially impacting permeability.
* **H-Bond Donors/Acceptors:** Both have 2 HBDs, which is good. Ligand A has 4 HBAs, and Ligand B has 3. Both are acceptable.
* **QED:** Ligand B (0.774) has a significantly better QED score than Ligand A (0.502), indicating better overall drug-likeness.
* **DILI:** Ligand B (11.632) has a much lower DILI risk than Ligand A (27.026), a crucial advantage.
* **BBB:** Both ligands have relatively low BBB penetration (44.746 and 40.403 respectively), which is not a major concern for a cardiovascular target.
* **Caco-2 Permeability:** Both have negative Caco-2 values, indicating poor permeability. Ligand A (-5.131) is slightly worse than Ligand B (-4.911).
* **Aqueous Solubility:** Both have negative solubility values, indicating poor solubility. Ligand A (-2.795) is slightly worse than Ligand B (-2.07).
* **hERG:** Both ligands have low hERG inhibition liability (0.27 and 0.342), which is good.
* **Microsomal Clearance:** Ligand A (57.719) has higher clearance than Ligand B (14.621), indicating lower metabolic stability.
* **In vitro Half-Life:** Ligand B (-15.173) has a negative half-life, which is concerning, but the scale is percentile, so this is likely a very short half-life. Ligand A (12.867) is better.
* **P-gp Efflux:** Both ligands have low P-gp efflux liability (0.18 and 0.144), which is good.
* **Binding Affinity:** Ligand A (-6.6 kcal/mol) has a slightly better binding affinity than Ligand B (-4.9 kcal/mol). This is a 1.7 kcal/mol difference, which is significant.
**Overall Assessment:**
While Ligand A has a better binding affinity, Ligand B demonstrates a significantly better safety profile (lower DILI), better drug-likeness (higher QED), and improved metabolic stability (lower Cl_mic). The binding affinity difference, while notable, can potentially be optimized in later stages of drug development. The ADME properties of Ligand B are more favorable overall, making it a more promising starting point for a cardiovascular drug candidate.
**Output:**
0
2025-04-17 20:16:14,127 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A: [340.423, 51.66, 3.706, 0, 4, 0.688, 54.556, 58.085, -4.434, -4.019, 0.581, 97.842, -4.228, 0.234, -6.9]**
**Ligand B: [362.543, 53.92, 4.193, 1, 4, 0.803, 37.03, 51.377, -5.227, -4.027, 0.733, 78.464, 45.138, 0.211, -6.9]**
Here's a breakdown, comparing each parameter and considering GPCR priorities (logP, Pgp, TPSA, affinity):
1. **MW:** Both are within the ideal 200-500 Da range. A (340.423) is slightly preferred.
2. **TPSA:** Both are acceptable (51.66 & 53.92), but ideally below 140 for oral absorption. No major difference here.
3. **logP:** Both are good (3.706 & 4.193), falling within the 1-3 optimal range. B is a bit higher, which *could* lead to slight solubility issues, but isn't a dealbreaker.
4. **HBD:** A (0) is better than B (1). Fewer HBDs generally improve permeability.
5. **HBA:** Both have 4, which is good.
6. **QED:** Both are decent (0.688 & 0.803), indicating reasonable drug-likeness. B is slightly better.
7. **DILI:** A (54.556) is worse than B (37.03). This is a significant advantage for B, as lower DILI risk is crucial.
8. **BBB:** A (58.085) is slightly better than B (51.377), but neither is particularly high. For a cardiovascular target, BBB isn't a primary concern, so this difference is minor.
9. **Caco-2:** A (-4.434) is better than B (-5.227). Higher Caco-2 suggests better absorption.
10. **Solubility:** Both are very poor (-4.019 & -4.027). This is a significant drawback for both, but potentially manageable with formulation strategies.
11. **hERG:** Both are low (0.581 & 0.733), indicating low cardiotoxicity risk. No major difference.
12. **Cl_mic:** A (97.842) is significantly *higher* than B (78.464), meaning A has faster metabolic clearance and potentially lower *in vivo* exposure. This favors B.
13. **t1/2:** B (45.138) is much better than A (-4.228). A negative value suggests a very short half-life. This is a major advantage for B.
14. **Pgp:** Both are low (0.234 & 0.211), indicating minimal P-glycoprotein efflux. No significant difference.
15. **Affinity:** Both have the same affinity (-6.9 kcal/mol), so this parameter doesn't differentiate them.
**Overall Assessment:**
While Ligand A has slightly better Caco-2 permeability and BBB penetration, Ligand B clearly wins on several critical parameters: significantly lower DILI risk, better metabolic stability (lower Cl_mic), and a much longer *in vitro* half-life. The solubility is poor for both, but the ADME profile of B is substantially more favorable, especially considering the cardiovascular context where metabolic stability and avoiding toxicity are paramount.
Therefore, I recommend Ligand B.
0
2025-04-17 20:16:14,127 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (345.443 and 353.495 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (95.24) is higher than Ligand B (62.73). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B is better.
3. **logP:** Ligand A (2.896) is within the optimal 1-3 range. Ligand B (4.751) is higher, potentially leading to solubility issues and off-target interactions. Ligand A is better.
4. **HBD:** Both ligands have 2 HBD, which is acceptable. No difference.
5. **HBA:** Both ligands have 6 HBA, which is acceptable. No difference.
6. **QED:** Both ligands have similar QED values (0.738 and 0.693), indicating good drug-likeness. No significant difference.
7. **DILI:** Ligand A (22.334) has a significantly lower DILI risk than Ligand B (77.549). This is a major advantage for Ligand A.
8. **BBB:** Both are relatively low, but Ligand B (73.866) is higher than Ligand A (62.931). For a cardiovascular target, BBB penetration is not a primary concern, so this difference is less important.
9. **Caco-2:** Ligand A (-4.632) and Ligand B (-5.255) both have negative values, indicating poor permeability. Ligand B is slightly better.
10. **Solubility:** Ligand A (-3.326) is better than Ligand B (-4.742). Solubility is important for bioavailability.
11. **hERG:** Both ligands have similar, low hERG risk (0.634 and 0.633). No significant difference.
12. **Cl_mic:** Ligand A (26.434) has a significantly lower microsomal clearance than Ligand B (90.875). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand B (59.643) has a much longer in vitro half-life than Ligand A (2.283). This is a significant advantage for Ligand B.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.1 and 0.46). No significant difference.
15. **Binding Affinity:** Ligand B (-6.4) has a slightly better binding affinity than Ligand A (-6.2). However, the difference is small (0.2 kcal/mol) and may not be enough to overcome other drawbacks.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity) and the general guidelines, Ligand A is the more promising candidate. While Ligand B has slightly better affinity and half-life, Ligand A excels in critical areas like DILI risk and metabolic stability (lower Cl_mic). The higher logP of Ligand B is a concern, and the significantly higher DILI risk is a major drawback. The small affinity difference is unlikely to outweigh these concerns.
Output:
1
2025-04-17 20:16:14,127 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (341.411 Da and 345.399 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (68.46) is significantly better than Ligand B (101.3). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is pushing the upper limit for good oral absorption.
**3. logP:** Both ligands have acceptable logP values (2.725 and 1.889, respectively), falling within the 1-3 range. Ligand B is slightly lower, which *could* indicate slightly better solubility, but isn't a major concern for either.
**4. H-Bond Donors:** Ligand A has 0 HBD, while Ligand B has 2. Lower is generally preferred for permeability, giving a slight edge to Ligand A.
**5. H-Bond Acceptors:** Both have 5 HBA, which is acceptable.
**6. QED:** Ligand A (0.808) has a considerably higher QED score than Ligand B (0.627), indicating a more drug-like profile.
**7. DILI Risk:** Ligand A (43.117) has a lower DILI risk than Ligand B (60.915), which is a significant advantage.
**8. BBB Penetration:** Ligand A (79.992) shows better BBB penetration than Ligand B (57.115). While ADRB2 isn't a CNS target, some peripheral exposure can be modulated by BBB permeability, and minimizing efflux is always a plus.
**9. Caco-2 Permeability:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret. Ligand A (-4.905) is slightly better than Ligand B (-5.136).
**10. Aqueous Solubility:** Both have negative solubility values, which is also unusual. Again, the scale is unknown, but Ligand A (-2.827) is slightly better than Ligand B (-2.488).
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.171 and 0.031, respectively), which is excellent.
**12. Microsomal Clearance:** Ligand B (29.42) has significantly lower microsomal clearance than Ligand A (41.986), suggesting better metabolic stability.
**13. In vitro Half-Life:** Ligand B (-31.621) has a much longer in vitro half-life than Ligand A (-16.285), which is a major advantage.
**14. P-gp Efflux:** Both ligands show low P-gp efflux (0.494 and 0.11, respectively). Ligand B is slightly better.
**15. Binding Affinity:** Both ligands have very similar and strong binding affinities (-6.0 and -4.8 kcal/mol, respectively). Ligand A has a 1.2 kcal/mol advantage, which is substantial.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand A is the stronger candidate. It has a better TPSA, QED, DILI risk, and BBB penetration. Most importantly, its binding affinity is significantly better. While Ligand B has better metabolic stability (lower Cl_mic) and half-life, the superior affinity and drug-like properties of Ligand A outweigh these benefits. The negative solubility and Caco-2 values are concerning for both, but the better overall profile of A makes it the preferred choice.
Output:
1
2025-04-17 20:16:14,127 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [357.401, 80.32, 2.396, 2, 4, 0.711, 48.468, 70.531, -4.609, -2.989, 0.585, 43.218, -17.681, 0.093, -5.7]
**Ligand B:** [346.439, 97.79, 0.874, 1, 9, 0.823, 29.818, 86.39, -5.659, -1.193, 0.136, -4.598, -6.789, 0.025, -6.9]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity, and BBB):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (346.439) is slightly lower, which is generally favorable.
2. **TPSA:** Ligand A (80.32) is better than Ligand B (97.79). TPSA < 140 is good for oral absorption, and both are within this limit, but A is closer to the optimal range for GPCRs.
3. **logP:** Ligand A (2.396) is optimal (1-3). Ligand B (0.874) is a bit low, potentially hindering membrane permeability.
4. **HBD/HBA:** Ligand A (HBD=2, HBA=4) is slightly better balanced than Ligand B (HBD=1, HBA=9). Ligand B has a higher HBA count, which could impact permeability.
5. **QED:** Both are good (>0.5), with Ligand B being slightly higher (0.823 vs 0.711).
6. **DILI:** Ligand B (29.818) has a significantly lower DILI risk than Ligand A (48.468). This is a major advantage for Ligand B.
7. **BBB:** Ligand B (86.39) has better BBB penetration than Ligand A (70.531). While not strictly required for a cardiovascular target, it's a positive attribute.
8. **Caco-2:** Both have negative values, which is unusual. Assuming these are logP-like scales, lower values indicate poorer permeability. Ligand A (-4.609) is worse than Ligand B (-5.659).
9. **Solubility:** Ligand B (-1.193) is better than Ligand A (-2.989).
10. **hERG:** Both are very low, indicating minimal hERG inhibition risk.
11. **Cl_mic:** Ligand B (-4.598) has a lower (better) microsomal clearance than Ligand A (43.218), suggesting better metabolic stability.
12. **t1/2:** Ligand B (-6.789) has a longer in vitro half-life than Ligand A (-17.681).
13. **Pgp:** Ligand B (0.025) has significantly lower P-gp efflux liability than Ligand A (0.093). This is a significant advantage for bioavailability.
14. **Affinity:** Ligand B (-6.9 kcal/mol) has a slightly better binding affinity than Ligand A (-5.7 kcal/mol). This difference is substantial (>1.5 kcal/mol).
**Overall Assessment:**
While Ligand A has a slightly better TPSA, Ligand B excels in almost every other crucial parameter. It has a lower DILI risk, better BBB penetration, better solubility, improved metabolic stability (lower Cl_mic, longer t1/2), lower P-gp efflux, and a stronger binding affinity. The logP is a slight concern, but the superior affinity and ADME properties outweigh this. For a GPCR target, the combination of good affinity, low efflux, and reasonable TPSA makes Ligand B the more promising candidate.
Output:
0
2025-04-17 20:16:14,127 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [348.359, 120.29 , 1.061, 1. , 8. , 0.49 , 30.593, 77.86 , -5.332, -2.261, 0.792, -2.564, 5.23 , 0.13 , -7.6 ]
**Ligand B:** [352.479, 99.33 , 1.287, 4. , 3. , 0.446, 18.108, 74.37 , -4.921, -2.1 , 0.406, 22.979, 6.621, 0.019, -3.9 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). A (348.359) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** A (120.29) is slightly higher than B (99.33). B is better here, being closer to the <140 threshold for good absorption.
3. **logP:** Both are within the optimal range (1-3). B (1.287) is slightly higher, which could be a minor advantage for membrane permeability.
4. **HBD:** A (1) is better than B (4). Lower HBD generally improves permeability.
5. **HBA:** A (8) is better than B (3). Lower HBA is also generally favorable for permeability.
6. **QED:** Both are reasonably good (A: 0.49, B: 0.446), but both are below the 0.5 threshold.
7. **DILI:** A (30.593) is significantly better than B (18.108). Lower DILI risk is crucial.
8. **BBB:** A (77.86) is slightly better than B (74.37). While ADRB2 isn't necessarily a CNS target, some degree of BBB penetration can be useful for distribution.
9. **Caco-2:** A (-5.332) is worse than B (-4.921). Higher Caco-2 values indicate better absorption, so B is preferred.
10. **Solubility:** A (-2.261) is slightly worse than B (-2.1). Both are quite poor, but B is marginally better.
11. **hERG:** A (0.792) is better than B (0.406). Lower hERG inhibition is critical for avoiding cardiotoxicity.
12. **Cl_mic:** A (-2.564) is much better than B (22.979). Lower clearance indicates better metabolic stability, a significant advantage.
13. **t1/2:** A (5.23) is worse than B (6.621). Longer half-life is generally preferred.
14. **Pgp:** A (0.13) is better than B (0.019). Lower P-gp efflux is favorable for bioavailability.
15. **Affinity:** A (-7.6) is *significantly* better than B (-3.9). A 3.7 kcal/mol difference in binding affinity is a substantial advantage, and often outweighs minor ADME concerns.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. While B has slightly better logP and Caco-2, A excels in affinity, DILI, hERG, and Cl_mic. The massive difference in binding affinity (-7.6 vs -3.9) is the most important factor. The lower DILI and hERG risks for A are also very important.
**Conclusion:**
Despite some minor ADME drawbacks in solubility and half-life, Ligand A's superior binding affinity, significantly lower DILI and hERG risk, and better metabolic stability make it the more promising drug candidate.
Output:
1
2025-04-17 20:16:14,128 - INFO - Here's my reasoning and final output for the ligand preference:
**Reasoning:**
We are targeting ADRB2, a GPCR, so the priorities are logP, TPSA, Pgp, BBB, and affinity. Let's break down the comparison:
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da).
2. **TPSA:** Ligand B (33.29) is significantly better than Ligand A (78.68). Lower TPSA is crucial for GPCRs, aiding in membrane permeability.
3. **logP:** Ligand A (2.587) is optimal, while Ligand B (4.282) is pushing the upper limit, potentially causing solubility issues and off-target effects.
4. **H-Bond Donors/Acceptors:** Ligand A has 1 HBD and 5 HBA, while Ligand B has 2 HBD and 3 HBA. Both are acceptable.
5. **QED:** Ligand A (0.91) is superior to Ligand B (0.787), indicating a more drug-like profile.
6. **DILI:** Ligand B (65.839) has a higher DILI risk than Ligand A (79.837), which is undesirable.
7. **BBB:** Ligand B (85.576) has a much higher BBB penetration percentile than Ligand A (59.442). While ADRB2 isn't necessarily a CNS target, higher BBB is generally favorable.
8. **Caco-2 Permeability:** Ligand A (-4.61) is better than Ligand B (-5.038) indicating better intestinal absorption.
9. **Aqueous Solubility:** Ligand A (-2.965) is better than Ligand B (-4.372).
10. **hERG:** Ligand A (0.301) has a lower hERG risk than Ligand B (0.958), which is a significant advantage.
11. **Cl_mic:** Both ligands have similar microsomal clearance (23.81 vs 24.311).
12. **t1/2:** Ligand B (5.635) has a slightly longer in vitro half-life than Ligand A (4.072).
13. **Pgp:** Ligand A (0.164) has lower P-gp efflux liability than Ligand B (0.603), which is favorable for bioavailability.
14. **Binding Affinity:** Ligand B (-7.7 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.9 kcal/mol). This is a substantial advantage and could potentially outweigh some of the ADME drawbacks.
**Overall Assessment:**
Ligand B has a much stronger binding affinity, which is a critical factor for GPCRs. However, it suffers from higher logP, higher DILI risk, and higher Pgp efflux. Ligand A has a better overall ADME profile (lower logP, lower DILI, lower Pgp, better solubility, lower hERG), but weaker binding affinity. The difference in affinity (-7.7 vs -5.9) is substantial (1.8 kcal/mol), and for a GPCR, this potency advantage is likely to be decisive. The better ADME profile of Ligand A is valuable, but the potency of Ligand B is a more critical driver for success.
Output:
0
2025-04-17 20:16:14,128 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (421.286 Da) is within the ideal range, while Ligand B (365.455 Da) is also good. No clear advantage here.
2. **TPSA:** Ligand A (67.35) is excellent, well below the 140 threshold. Ligand B (87.65) is still acceptable, but less favorable.
3. **logP:** Ligand A (2.936) is optimal. Ligand B (0.392) is quite low, potentially leading to poor membrane permeability. This is a significant drawback.
4. **HBD:** Ligand A (1) and Ligand B (0) are both good, meeting the <=5 criteria.
5. **HBA:** Both Ligand A (5) and Ligand B (5) are acceptable, below the 10 threshold.
6. **QED:** Both Ligand A (0.654) and Ligand B (0.753) are good, exceeding the 0.5 threshold.
7. **DILI:** Both Ligand A (46.956) and Ligand B (42.846) have low DILI risk, well below the 60 threshold.
8. **BBB:** Ligand A (94.416) shows excellent BBB penetration, while Ligand B (83.831) is good but lower. Given ADRB2 is a GPCR, BBB penetration is a consideration, though not paramount if the target isn't CNS-focused.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests a potential issue with the experimental setup or data quality. However, we can still compare the relative values. Ligand A (-4.972) is slightly better than Ligand B (-4.986).
10. **Solubility:** Ligand A (-3.074) and Ligand B (-1.549) both have negative solubility values, indicating poor solubility. Ligand B is slightly better.
11. **hERG:** Ligand A (0.796) and Ligand B (0.107) both show low hERG inhibition liability. Ligand B is significantly better.
12. **Cl_mic:** Ligand A (28.746) has a higher microsomal clearance than Ligand B (13.922), indicating lower metabolic stability.
13. **t1/2:** Ligand A (27.996) has a longer in vitro half-life than Ligand B (8.854).
14. **Pgp:** Ligand A (0.17) has lower P-gp efflux liability than Ligand B (0.05), which is favorable.
15. **Affinity:** Ligand A (-7.2 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.8 kcal/mol). This is a substantial advantage.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are crucial. Ligand A excels in TPSA, Pgp, and *significantly* in affinity. While Ligand B has a better hERG profile and slightly better solubility, the low logP is a major concern for permeability and overall drug-likeness. The stronger affinity of Ligand A is likely to outweigh the minor drawbacks in Cl_mic and solubility.
**Conclusion:**
Ligand A is the more promising candidate due to its superior binding affinity, favorable TPSA and Pgp properties, and acceptable logP. The lower logP of Ligand B is a significant concern that outweighs its advantages in hERG and solubility.
Output:
1
2025-04-17 20:16:14,128 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (338.37) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (97.23) is higher than Ligand B (69.64). For a cardiovascular GPCR like ADRB2, TPSA is less critical than for CNS targets, but lower is still preferable for absorption. Ligand B has a significant advantage here.
3. **logP:** Both ligands have good logP values (A: 2.448, B: 2.961), falling within the optimal 1-3 range. Ligand B is slightly higher, which could potentially lead to slight solubility issues, but is still acceptable.
4. **HBD:** Both ligands have 2 H-bond donors, which is well within the acceptable limit of 5.
5. **HBA:** Ligand A has 6 H-bond acceptors, while Ligand B has 3. Both are below the acceptable limit of 10. Ligand B is better here.
6. **QED:** Both ligands have similar QED values (A: 0.741, B: 0.77), indicating good drug-likeness.
7. **DILI:** Ligand A has a significantly higher DILI risk (75.38%) than Ligand B (12.80%). This is a major concern for Ligand A.
8. **BBB:** Ligand B has a higher BBB penetration percentile (55.64%) than Ligand A (27.96%). While ADRB2 isn't a primary CNS target, some CNS exposure can lead to off-target effects.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. This is a significant drawback for both.
10. **Solubility:** Both ligands have negative solubility values, indicating poor solubility. This is also a significant drawback for both.
11. **hERG:** Both ligands have low hERG inhibition liability (A: 0.279, B: 0.489), which is favorable.
12. **Cl_mic:** Ligand B has a lower microsomal clearance (41.73) than Ligand A (61.57), indicating better metabolic stability.
13. **t1/2:** Ligand B has a longer in vitro half-life (-2.243) than Ligand A (-14.422). This is a significant advantage for Ligand B.
14. **Pgp:** Both ligands have very low Pgp efflux liability (A: 0.021, B: 0.155).
15. **Binding Affinity:** Both ligands have the same binding affinity (-6.2 kcal/mol).
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand B is better in terms of TPSA and logP. While both have equal affinity, the significantly lower DILI risk and improved metabolic stability (lower Cl_mic, longer t1/2) of Ligand B are crucial advantages.
**Overall Assessment:**
Ligand A's high DILI risk is a major red flag. While Ligand B has issues with Caco-2 and solubility, these can potentially be addressed through formulation strategies. The improved safety profile and pharmacokinetic properties of Ligand B make it the more promising candidate.
Output:
0
2025-04-17 20:16:14,128 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (362.499 and 346.362 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Both ligands are below the 140 A^2 threshold (86.88 and 88.33 A^2), suggesting good potential for oral absorption. Again, no strong difference.
3. **logP:** Both ligands have logP values within the optimal range (1.581 and 1.86). This is good for permeability and avoids solubility issues.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (1), but both are within the acceptable limit of 5.
5. **HBA:** Ligand A (4) and Ligand B (5) are both acceptable (<=10).
6. **QED:** Ligand B (0.916) has a significantly better QED score than Ligand A (0.582), indicating a more drug-like profile overall. This is a notable advantage for Ligand B.
7. **DILI:** Ligand A (38.581) has a much lower DILI risk than Ligand B (74.021). This is a significant advantage for Ligand A, as liver toxicity is a major concern.
8. **BBB:** Ligand B (83.56) has a higher BBB penetration percentile than Ligand A (51.764). While ADRB2 isn't *strictly* a CNS target, some CNS exposure can be relevant, and higher BBB is generally favorable.
9. **Caco-2:** Ligand A (-5.859) has a worse Caco-2 permeability than Ligand B (-4.652), indicating potentially lower intestinal absorption.
10. **Solubility:** Both ligands have very poor aqueous solubility (-2.427 and -2.856). This is a significant drawback for both, potentially impacting bioavailability.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.187 and 0.296). This is positive for both.
12. **Cl_mic:** Ligand B (17.719) has a lower microsomal clearance than Ligand A (20.652), suggesting better metabolic stability.
13. **t1/2:** Ligand B (8.205) has a significantly longer in vitro half-life than Ligand A (-4.361). This is a major advantage for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.052 and 0.033).
15. **Binding Affinity:** Ligand B (-6.9 kcal/mol) has a slightly better binding affinity than Ligand A (-6.5 kcal/mol). While the difference is not huge, it's enough to be considered.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Both ligands perform well on logP and Pgp. TPSA is acceptable for both. Ligand B has a slight edge in affinity.
**Overall Assessment:**
Ligand A has a significant advantage in DILI risk, which is critical. However, Ligand B excels in QED, BBB penetration, metabolic stability (Cl_mic), and in vitro half-life, and has slightly better affinity. The better ADME properties of Ligand B, particularly the longer half-life and lower DILI risk, are more important than the small affinity difference. The solubility is a concern for both, but can be addressed with formulation strategies.
Output:
0
2025-04-17 20:16:14,128 - INFO - Batch 172 complete. Total preferences: 2752
2025-04-17 20:16:14,128 - INFO - Processing batch 173/512...
2025-04-17 20:17:03,237 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [347.423, 118.06 , 1.738, 1. , 4. , 0.479, 43.622, 55.099, -5.157, -2.086, 0.167, 11.592, -5.878, 0.016, -5.8 ]
**Ligand B:** [343.362, 80.12 , 0.899, 1. , 5. , 0.837, 54.517, 57.968, -4.893, -1.74 , 0.209, 19.291, -19.095, 0.033, -7. ]
Here's a breakdown, comparing each parameter and considering GPCR priorities (logP, Pgp, TPSA, affinity):
1. **MW:** Both are within the ideal 200-500 Da range. Ligand B (343.362 Da) is slightly lower, which is generally favorable.
2. **TPSA:** Ligand A (118.06) is higher than Ligand B (80.12). Ligand B is better here, being closer to the <140 threshold for oral absorption, and more importantly, better for GPCRs.
3. **logP:** Ligand A (1.738) is within the optimal 1-3 range. Ligand B (0.899) is a bit low, potentially impacting permeability.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 4 HBA, Ligand B has 5. Both are acceptable, under the 10 threshold.
6. **QED:** Ligand B (0.837) has a significantly better QED score than Ligand A (0.479), indicating a more drug-like profile.
7. **DILI:** Both have acceptable DILI risk (Ligand A: 43.622, Ligand B: 54.517), below the 60 threshold.
8. **BBB:** Both have moderate BBB penetration (Ligand A: 55.099, Ligand B: 57.968). Not a primary concern for ADRB2 (cardiovascular target), but higher is generally better.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Both have negative solubility values, indicating poor aqueous solubility. This is also a significant concern for both.
11. **hERG:** Both have very low hERG inhibition risk (Ligand A: 0.167, Ligand B: 0.209).
12. **Cl_mic:** Ligand A (11.592) has a lower microsomal clearance than Ligand B (19.291), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-19.095) has a much more negative in vitro half-life, which is concerning. Ligand A (-5.878) is still not ideal, but far better.
14. **Pgp:** Both have low P-gp efflux (Ligand A: 0.016, Ligand B: 0.033).
15. **Affinity:** Ligand B (-7.0 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.8 kcal/mol). This is a >1.2 kcal/mol advantage, which is substantial.
**Overall Assessment:**
Ligand B has a significantly better binding affinity and QED score, and a lower TPSA. However, it has a concerningly negative in vitro half-life. Ligand A has better metabolic stability and a less negative half-life, but a weaker binding affinity and lower QED. The affinity difference is substantial enough to outweigh the metabolic stability advantage of Ligand A, *especially* given that both compounds have poor permeability and solubility. While both have issues, the stronger binding of Ligand B gives it a higher chance of success, assuming formulation challenges can be addressed.
Output:
0
2025-04-17 20:17:03,237 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor (a GPCR).
**Ligand A:** [348.359, 128.53 , -0.191, 3. , 6. , 0.664, 69.756, 8.181, -5.633, -1.954, 0.135, 16.49 , 11.153, 0.019, -6.7 ]
**Ligand B:** [369.893, 80.32 , 2.731, 2. , 4. , 0.69 , 34.471, 65.103, -5.04 , -3.012, 0.502, 53.571, 42.976, 0.179, -5.3 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). A (348) is slightly preferred.
2. **TPSA:** A (128.53) is higher than B (80.32). For a GPCR, lower TPSA is generally better for permeability, giving a slight edge to B.
3. **logP:** A (-0.191) is quite low, potentially causing permeability issues. B (2.731) is within the optimal range (1-3). B is significantly better here.
4. **HBD:** A (3) and B (2) are both acceptable.
5. **HBA:** A (6) and B (4) are both acceptable.
6. **QED:** Both are good (A: 0.664, B: 0.69), indicating drug-like properties. B is slightly better.
7. **DILI:** A (69.756) is higher than B (34.471). B is much better, indicating lower liver injury risk.
8. **BBB:** A (8.181) is very low, while B (65.103) is reasonably good. This is a significant advantage for B, as BBB penetration can be important for GPCRs.
9. **Caco-2:** Both are negative, indicating poor permeability. A (-5.633) is worse than B (-5.04).
10. **Solubility:** Both are negative, indicating poor solubility. A (-1.954) is worse than B (-3.012).
11. **hERG:** A (0.135) is better than B (0.502), indicating lower cardiotoxicity risk.
12. **Cl_mic:** A (16.49) is much lower than B (53.571), suggesting better metabolic stability. A is significantly better here.
13. **t1/2:** A (11.153) is lower than B (42.976). B is much better, indicating a longer half-life.
14. **Pgp:** A (0.019) is much lower than B (0.179), suggesting less P-gp efflux and better bioavailability. A is significantly better here.
15. **Affinity:** A (-6.7) is slightly better than B (-5.3), a difference of 0.4 kcal/mol.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity and better metabolic stability (lower Cl_mic) and Pgp efflux, it suffers from very low logP, poor solubility, and extremely low BBB penetration. Ligand B, despite a slightly weaker affinity, has a much better logP, lower DILI risk, better BBB penetration, and a longer half-life.
Given the GPCR target class, the balance of properties leans heavily towards Ligand B. The improved logP, BBB penetration, and reduced toxicity risks are more critical than the small difference in binding affinity, especially considering the potential for optimization of the affinity later in the drug discovery process. The poor permeability of both is a concern, but Ligand B's other properties make it a more promising starting point.
Output:
0
2025-04-17 20:17:03,237 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
The ADRB2 receptor is a GPCR, so the priorities are logP, Pgp, TPSA, affinity, and, to a lesser extent, BBB. Let's break down the comparison:
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (367.446) is slightly higher than Ligand B (346.431), but both are acceptable.
2. **TPSA:** Ligand A (72.48) is significantly better than Ligand B (98.06). A TPSA under 140 is good for oral absorption, and Ligand A is comfortably within that range, while Ligand B is approaching the upper limit.
3. **logP:** Ligand A (3.729) is optimal, while Ligand B (1.335) is on the lower side. A logP between 1-3 is ideal, and Ligand A is closer to that sweet spot, suggesting better membrane permeability.
4. **H-Bond Donors:** Ligand A (2) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **H-Bond Acceptors:** Ligand A (5) is preferable to Ligand B (3). Fewer HBAs generally improve permeability.
6. **QED:** Both ligands have reasonable QED scores (A: 0.816, B: 0.72), indicating good drug-like properties.
7. **DILI:** Ligand B (44.513) has a significantly lower DILI risk than Ligand A (68.166), which is a strong positive for Ligand B.
8. **BBB:** Both ligands have similar BBB penetration (A: 49.864, B: 46.181). This isn't a primary concern for ADRB2, which is not a CNS target.
9. **Caco-2:** Ligand A (-4.528) shows better Caco-2 permeability than Ligand B (-5.069).
10. **Solubility:** Both ligands have poor aqueous solubility (A: -3.252, B: -2.898), but this is less critical if permeability is good.
11. **hERG:** Both ligands have low hERG inhibition risk (A: 0.137, B: 0.21).
12. **Cl_mic:** Ligand B (-5.066) has a significantly lower microsomal clearance than Ligand A (49.026), indicating better metabolic stability.
13. **t1/2:** Ligand B (-12.013) has a longer in vitro half-life than Ligand A (10.538).
14. **Pgp:** Both ligands have low P-gp efflux liability (A: 0.183, B: 0.03).
15. **Binding Affinity:** Ligand A (-6.6 kcal/mol) has a significantly stronger binding affinity than Ligand B (-3.4 kcal/mol). This is a substantial advantage. A difference of 3.2 kcal/mol is very significant and can often outweigh minor ADME concerns.
**Overall Assessment:**
While Ligand B has advantages in DILI risk and metabolic stability (Cl_mic and t1/2), the significantly stronger binding affinity of Ligand A (-6.6 vs -3.4 kcal/mol) is the deciding factor. The better TPSA and logP of Ligand A also contribute to its potential for good absorption. The difference in affinity is large enough to overcome the slightly higher DILI risk.
Output:
1
2025-04-17 20:17:03,238 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (347.39 and 346.43 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (71.53 and 71.78) are below the 140 A^2 threshold for good oral absorption, and acceptable for a non-CNS GPCR target like ADRB2. Very similar.
3. **logP:** Both ligands (1.869 and 1.743) are within the optimal 1-3 range, suggesting good permeability and reasonable solubility. Again, very close.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Both have 4 HBA, which is good.
6. **QED:** Ligand B (0.882) has a slightly better QED score than Ligand A (0.765), indicating a more drug-like profile. This is a small but positive point for B.
7. **DILI:** Ligand B (29.314) has a significantly lower DILI risk than Ligand A (41.411). This is a major advantage for Ligand B, as minimizing liver toxicity is crucial.
8. **BBB:** ADRB2 is primarily a cardiovascular target, so BBB penetration is not a high priority. Ligand A (89.298) has better BBB penetration than Ligand B (58.938), but this is less important in this case.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.177 and -4.967), which is unusual and suggests poor permeability. However, these values are on a scale where negative values are possible and don't necessarily preclude development.
10. **Solubility:** Ligand B (-1.511) has a slightly better solubility score than Ligand A (-3.112), which is a minor advantage.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.195 and 0.17), which is excellent.
12. **Cl_mic:** Ligand B (-0.955) has a *much* lower microsomal clearance than Ligand A (65.936). This indicates significantly better metabolic stability for Ligand B, a major positive.
13. **t1/2:** Ligand B (50.661) has a much longer in vitro half-life than Ligand A (-39.387). This is a substantial advantage, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.053 and 0.029), which is good.
15. **Binding Affinity:** Ligand B (-6.2 kcal/mol) has a slightly better binding affinity than Ligand A (-5.3 kcal/mol). This 0.9 kcal/mol difference is significant and could outweigh some minor ADME drawbacks.
**GPCR-specific priorities:** For ADRB2 (a cardiovascular GPCR), logP, Pgp, TPSA, and affinity are key. Both ligands perform well on logP, Pgp, and TPSA. Ligand B has a clear advantage in affinity and a substantial advantage in metabolic stability (Cl_mic and t1/2) and DILI risk.
**Conclusion:**
Ligand B is the superior candidate. While Ligand A has slightly better BBB penetration (which is not critical for this target), Ligand B excels in crucial areas like DILI risk, metabolic stability, half-life, and binding affinity. The combination of these factors makes Ligand B a more promising starting point for drug development.
Output:
0
2025-04-17 20:17:03,238 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.455 and 349.475 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (55.84) is significantly better than Ligand B (84.64). For a GPCR, keeping TPSA low is beneficial for permeability, and Ligand A is well below the 140 threshold. Ligand B is approaching a level that could hinder absorption.
3. **logP:** Both ligands have good logP values (2.684 and 2.071), falling within the optimal 1-3 range. Ligand B is slightly lower, which could marginally affect permeability, but it's not a major concern.
4. **HBD:** Ligand A has 0 HBD, while Ligand B has 1. Lower is generally preferred for permeability, giving a slight edge to Ligand A.
5. **HBA:** Ligand A has 5 HBA, and Ligand B has 4. Both are within the acceptable limit of 10.
6. **QED:** Ligand B (0.823) has a better QED score than Ligand A (0.561), indicating a more drug-like profile overall. This is a positive for Ligand B.
7. **DILI:** Ligand A (14.114) has a significantly lower DILI risk than Ligand B (20.202). This is a crucial advantage for Ligand A, as minimizing liver toxicity is paramount.
8. **BBB:** Ligand A (81.466) has a much higher BBB penetration percentile than Ligand B (57.27). While ADRB2 isn't exclusively a CNS target, some cardiovascular effects are mediated through CNS pathways, and better BBB penetration can be advantageous.
9. **Caco-2:** Ligand A (-4.468) has a better Caco-2 permeability than Ligand B (-4.578).
10. **Solubility:** Ligand A (-3.252) has better aqueous solubility than Ligand B (-1.794). Solubility is important for formulation and bioavailability.
11. **hERG:** Both ligands have low hERG inhibition risk (0.894 and 0.586), which is good.
12. **Cl_mic:** Ligand A (68.215) has a lower microsomal clearance than Ligand B (14.321), suggesting better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (-13.144) has a longer in vitro half-life than Ligand B (-3.141). Longer half-life is generally desirable.
14. **Pgp:** Ligand A (0.557) has lower P-gp efflux liability than Ligand B (0.15). Lower Pgp efflux improves bioavailability.
15. **Binding Affinity:** Ligand B (-5.9) has a significantly stronger binding affinity than Ligand A (-3.5). This is a substantial advantage for Ligand B, potentially outweighing some of the ADME drawbacks. A 2.4 kcal/mol difference is quite large.
**Overall Assessment:**
Ligand B has a significantly better binding affinity, which is a primary driver for potency. However, Ligand A demonstrates a superior ADME profile, particularly regarding DILI risk, metabolic stability, BBB penetration, solubility, and P-gp efflux. For a cardiovascular target like ADRB2, a balance between potency and safety/pharmacokinetics is crucial. While the affinity difference is substantial, the combination of lower DILI, better metabolic stability, and improved solubility/permeability makes Ligand A the more promising candidate. The better BBB penetration is a bonus.
Output:
1
2025-04-17 20:17:03,238 - INFO - Reasoning:
Let's analyze Ligand A and Ligand B for their potential as ADRB2 ligands, keeping in mind the GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key).
**Molecular Weight:** Both ligands (356.419 and 364.833 Da) fall within the ideal 200-500 Da range.
**TPSA:** Ligand A (88.54) is better than Ligand B (91.23), both are acceptable for a non-CNS GPCR target like ADRB2, being under 140.
**logP:** Ligand A (-0.609) is suboptimal, being slightly below the preferred 1-3 range. Ligand B (2.562) is within the optimal range. This is a significant advantage for Ligand B.
**H-Bond Donors/Acceptors:** Ligand A (1 HBD, 6 HBA) and Ligand B (2 HBD, 4 HBA) both have reasonable values, well within the guidelines.
**QED:** Both ligands have good QED scores (0.683 and 0.872), indicating good drug-like properties.
**DILI:** Ligand A (20.706) has a much lower DILI risk than Ligand B (66.111). This is a substantial advantage for Ligand A.
**BBB:** This is less critical for ADRB2, but Ligand A (28.383) and Ligand B (36.409) are both low, as expected for a peripherally acting target.
**Caco-2 Permeability:** Both are negative, indicating poor permeability. Ligand A (-4.795) is slightly better than Ligand B (-5.234), but both are concerning.
**Aqueous Solubility:** Ligand A (-0.337) is better than Ligand B (-3.798). Solubility is important for bioavailability.
**hERG:** Ligand A (0.098) has a lower hERG risk than Ligand B (0.274), which is favorable.
**Microsomal Clearance:** Ligand A (11.257) has a higher clearance than Ligand B (2.933), meaning Ligand B is more metabolically stable.
**In vitro Half-Life:** Ligand A (26.599) and Ligand B (25.344) are comparable.
**P-gp Efflux:** Ligand A (0.025) has significantly lower P-gp efflux liability than Ligand B (0.148). This is a positive for Ligand A.
**Binding Affinity:** Ligand B (-7.9 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.7 kcal/mol). This is a 1.2 kcal/mol difference, which is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand B has a superior logP and significantly better binding affinity. These are critical for GPCR ligands. While Ligand B has a higher DILI risk and P-gp efflux, the strong binding affinity is a major advantage. Ligand A has better solubility, lower DILI, and lower P-gp efflux, but its logP is poor, and its affinity is significantly weaker. Given the importance of affinity for GPCRs, and the acceptable range of the other parameters for Ligand B, it is the more promising candidate.
Output:
0
2025-04-17 20:17:03,238 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, the priorities are logP, Pgp, TPSA, affinity, and to a lesser extent, BBB.
Let's break down the comparison:
1. **MW:** Both ligands are within the acceptable range (200-500 Da). Ligand A (353.442) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (62.3) is better than Ligand A (70.47), being closer to the ideal <90 for GPCRs.
3. **logP:** Ligand A (1.275) is better than Ligand B (3.331). Ligand B is pushing the upper limit and could have solubility issues.
4. **HBD/HBA:** Both have acceptable HBD (1) and HBA (5/4) counts.
5. **QED:** Ligand A (0.866) is significantly better than Ligand B (0.646), indicating a more drug-like profile.
6. **DILI:** Ligand A (30.748) has a much lower DILI risk than Ligand B (45.677). This is a significant advantage.
7. **BBB:** Ligand A (88.988) has a better BBB score than Ligand B (70.027), although BBB isn't a primary concern for a cardiovascular target.
8. **Caco-2:** Ligand A (-4.763) is better than Ligand B (-5.049), indicating better intestinal absorption.
9. **Solubility:** Ligand A (-2.262) is better than Ligand B (-4.149).
10. **hERG:** Both are low, but Ligand B (0.488) is slightly higher than Ligand A (0.247).
11. **Cl_mic:** Ligand A (17.03) has a significantly lower clearance than Ligand B (72.336), meaning better metabolic stability.
12. **t1/2:** Ligand B (15.557) has a better in vitro half-life than Ligand A (-13.393).
13. **Pgp:** Ligand A (0.018) has a much lower Pgp efflux liability than Ligand B (0.339), which is highly desirable for bioavailability.
14. **Affinity:** Both have excellent binding affinities (-6.1 and -5.4 kcal/mol). Ligand A is slightly better (-6.1 kcal/mol).
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical ADME properties (DILI, solubility, Cl_mic, Pgp, QED) and has a slightly better affinity. While Ligand B has a better half-life, the other advantages of Ligand A are more important for overall drug development success, especially considering the GPCR target class. The lower logP and better solubility of Ligand A are also significant benefits.
**Output:**
1
2025-04-17 20:17:03,238 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Ligand A (357.483 Da) is well within the ideal range (200-500 Da). Ligand B (415.332 Da) is also acceptable, but closer to the upper limit.
2. **TPSA:** Ligand A (63.91) is good, well below the 140 threshold for oral absorption. Ligand B (98.58) is higher, but still potentially acceptable for a non-CNS target.
3. **logP:** Both ligands have good logP values (A: 3.019, B: 2.392), falling within the 1-3 range.
4. **HBD:** Ligand A (0) is excellent. Ligand B (3) is acceptable, but higher.
5. **HBA:** Both ligands have 6 HBA, which is within the acceptable range.
6. **QED:** Both ligands have good QED scores (A: 0.563, B: 0.633), indicating good drug-like properties.
7. **DILI:** Ligand A (53.548) has a slightly higher DILI risk than Ligand B (41.993), but both are below the concerning threshold of 60.
8. **BBB:** Ligand A (78.209) has better BBB penetration than Ligand B (63.009). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant for off-target effects.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
10. **Solubility:** Both ligands have similar, very poor aqueous solubility (-3.645 and -3.414). This is a significant concern for both.
11. **hERG:** Ligand A (0.137) has a much lower hERG risk than Ligand B (0.598). This is a crucial advantage.
12. **Cl_mic:** Ligand A (94.158) has a higher microsomal clearance than Ligand B (36.265), indicating lower metabolic stability. This is a disadvantage for Ligand A.
13. **t1/2:** Ligand B (5.003) has a significantly longer in vitro half-life than Ligand A (-16.873). This is a major advantage for Ligand B.
14. **Pgp:** Ligand A (0.354) has lower P-gp efflux than Ligand B (0.114), which is favorable.
15. **Affinity:** Ligand A (-7.9 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.1 kcal/mol). This is a substantial advantage, potentially outweighing some ADME drawbacks.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are particularly important. Ligand A excels in affinity and Pgp, while Ligand B has better metabolic stability (lower Cl_mic, longer t1/2). The solubility is poor for both, but the superior affinity of Ligand A, combined with the lower hERG risk, makes it more promising. The difference in affinity (-1.8 kcal/mol) is substantial.
**Conclusion:**
Despite the metabolic stability concerns and poor solubility, the significantly stronger binding affinity and lower hERG risk of Ligand A make it the more promising drug candidate.
Output:
1
2025-04-17 20:17:03,238 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [432.296, 99.52, 2.234, 1, 7, 0.674, 91.47, 51.803, -4.911, -3.332, 0.407, 51.725, 11.908, 0.378, -6.7]
**Ligand B:** [408.296, 76.39, 3.293, 2, 4, 0.796, 50.291, 78.868, -5.203, -3.538, 0.497, 51.695, 30.283, 0.376, -6.8]
Here's a breakdown, considering the guidelines and GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (408.296) is slightly preferred due to being a bit lower.
2. **TPSA:** Ligand A (99.52) is higher than Ligand B (76.39). Ligand B is better, being closer to the <140 threshold for good absorption.
3. **logP:** Both are good (between 1-3). Ligand B (3.293) is slightly higher, which *could* be a minor drawback, but not a major one. Ligand A (2.234) is more optimal.
4. **HBD:** Ligand A (1) is better than Ligand B (2). Lower is generally preferred.
5. **HBA:** Ligand A (7) is better than Ligand B (4). Lower is generally preferred.
6. **QED:** Both are acceptable (>0.5), with Ligand B (0.796) being slightly better.
7. **DILI:** Ligand A (91.47) has a significantly higher DILI risk than Ligand B (50.291). This is a major concern for Ligand A.
8. **BBB:** Ligand B (78.868) has better BBB penetration than Ligand A (51.803). While not a primary concern for a cardiovascular target, it's a slight advantage.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand B (-5.203) is slightly worse than Ligand A (-4.911).
10. **Solubility:** Both are negative, indicating poor solubility. Ligand B (-3.538) is slightly worse than Ligand A (-3.332).
11. **hERG:** Both are very low risk (0.407 and 0.497).
12. **Cl_mic:** Similar for both (around 51.695-51.725), suggesting comparable metabolic stability.
13. **t1/2:** Ligand B (30.283) has a significantly longer half-life than Ligand A (11.908). This is a significant advantage.
14. **Pgp:** Both are low (0.378 and 0.376), indicating minimal P-gp efflux.
15. **Affinity:** Ligand B (-6.8 kcal/mol) has slightly better binding affinity than Ligand A (-6.7 kcal/mol).
**Overall Assessment:**
Ligand B is the stronger candidate. While its Caco-2 and solubility are slightly worse than Ligand A, the significantly lower DILI risk, longer half-life, and slightly better BBB penetration outweigh these drawbacks. The affinity difference is minimal. The higher DILI risk associated with Ligand A is a major red flag, and the shorter half-life is also undesirable.
Output:
0
2025-04-17 20:17:03,238 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [356.457, 49.41, 3.354, 1, 2, 0.821, 33.579, 91.702, -4.583, -4.499, 0.586, 46.544, -10.124, 0.111, -6.5]
**Ligand B:** [351.407, 118.37, -0.483, 3, 7, 0.544, 52.191, 27.491, -5.56, -1.001, 0.022, 4.866, 24.017, 0.005, -6.4]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal 200-500 Da range. A (356.457) is slightly higher, but both are acceptable.
2. **TPSA:** A (49.41) is excellent, well below 140 and good for oral absorption. B (118.37) is higher, but still within a reasonable range, though less optimal.
3. **logP:** A (3.354) is optimal. B (-0.483) is significantly lower, which could lead to poor membrane permeability and bioavailability. This is a major concern.
4. **HBD:** Both have acceptable HBD counts (A: 1, B: 3).
5. **HBA:** Both have acceptable HBA counts (A: 2, B: 7).
6. **QED:** Both have good QED scores (A: 0.821, B: 0.544), indicating drug-likeness. A is better.
7. **DILI:** A (33.579) has a lower DILI risk than B (52.191). This is a positive for A.
8. **BBB:** A (91.702) has excellent BBB penetration, which is important for a GPCR. B (27.491) is very low, suggesting poor CNS exposure. While ADRB2 isn't exclusively a CNS target, some CNS effects can be relevant.
9. **Caco-2:** A (-4.583) and B (-5.56) are both negative, indicating poor permeability.
10. **Solubility:** A (-4.499) and B (-1.001) are both negative, indicating poor solubility.
11. **hERG:** A (0.586) has a lower hERG risk than B (0.022). This is a significant advantage for A.
12. **Cl_mic:** A (46.544) has higher metabolic clearance than B (4.866), indicating lower metabolic stability. This is a negative for A.
13. **t1/2:** A (-10.124) has a shorter half-life than B (24.017). This is a negative for A.
14. **Pgp:** A (0.111) has lower P-gp efflux than B (0.005), which is favorable.
15. **Affinity:** Both have similar binding affinities (-6.5 kcal/mol).
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are particularly important. A excels in logP, TPSA, and Pgp. While B has better metabolic stability and half-life, the significantly lower logP and poor BBB penetration are major drawbacks. The similar binding affinity means these ADME properties become the deciding factors.
**Conclusion:**
Despite the slightly worse metabolic stability and half-life, Ligand A is the more promising candidate due to its superior logP, TPSA, BBB penetration, and lower hERG risk. These factors are critical for a GPCR-targeting drug to achieve adequate bioavailability and minimize off-target effects.
**Output:**
1
2025-04-17 20:17:03,239 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (342.439 Da and 351.447 Da) fall within the ideal range of 200-500 Da. No clear advantage here.
2. **TPSA:** Ligand A (69.64) is better than Ligand B (78.95). Both are below 140, but lower TPSA generally favors absorption.
3. **logP:** Ligand A (1.109) is slightly better than Ligand B (0.531), both are within the optimal range of 1-3, but Ligand B is on the lower end, potentially impacting permeability.
4. **HBD:** Ligand A (2) is slightly better than Ligand B (1). Both are within the acceptable limit of 5.
5. **HBA:** Ligand A (3) is better than Ligand B (4). Both are within the acceptable limit of 10.
6. **QED:** Ligand B (0.801) is significantly better than Ligand A (0.459), indicating a more drug-like profile. This is a notable advantage for Ligand B.
7. **DILI:** Ligand B (18.728) is *much* better than Ligand A (33.307). This is a significant advantage for Ligand B, as lower DILI risk is crucial.
8. **BBB:** Ligand B (80.031) is significantly better than Ligand A (35.052). While ADRB2 isn't strictly a CNS target, some CNS penetration can be beneficial, and lower BBB is not a detriment. This is a strong advantage for Ligand B.
9. **Caco-2:** Both ligands have very poor Caco-2 permeability (-4.752 and -4.824). This is a major concern for both, indicating poor intestinal absorption.
10. **Solubility:** Ligand B (-0.885) is better than Ligand A (-2.626). Better solubility is always preferred.
11. **hERG:** Ligand A (0.54) is better than Ligand B (0.079). Lower hERG risk is preferable.
12. **Cl_mic:** Ligand B (1.913) is *much* better than Ligand A (56.043). Lower clearance indicates better metabolic stability, a significant advantage for Ligand B.
13. **t1/2:** Ligand B (6.975) is significantly better than Ligand A (2.97). Longer half-life is desirable.
14. **Pgp:** Ligand B (0.009) is *much* better than Ligand A (0.267). Lower P-gp efflux is highly desirable for improved bioavailability.
15. **Binding Affinity:** Ligand A (-7.0) is slightly better than Ligand B (-6.3). While a 0.7 kcal/mol difference is good, it's not substantial enough to overcome the numerous advantages of Ligand B.
**Overall Assessment:**
Ligand B consistently outperforms Ligand A in most critical ADME-Tox parameters (DILI, BBB, Cl_mic, t1/2, Pgp, Solubility). While Ligand A has a slightly better binding affinity and hERG, the improvements in ADME-Tox for Ligand B are far more impactful for overall drug development potential. The poor Caco-2 permeability is a concern for both, but can be addressed through formulation strategies. Given the GPCR target class, the improved BBB, Pgp, and metabolic stability of Ligand B are particularly valuable.
Output:
0
2025-04-17 20:17:03,239 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (341.411) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (66.24) is significantly better than Ligand B (89.76). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (A: 2.968, B: 3.065), falling within the optimal 1-3 range.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer hydrogen bond donors generally improve membrane permeability.
5. **HBA:** Ligand A (6) is better than Ligand B (7). Lower HBA is generally preferred.
6. **QED:** Ligand B (0.643) has a slightly better QED score than Ligand A (0.419), indicating a more drug-like profile.
7. **DILI:** Ligand B (58.55) has a lower DILI risk than Ligand A (64.637), which is a significant advantage.
8. **BBB:** Ligand B (82.435) has better BBB penetration than Ligand A (70.648), but this isn't a critical factor for a cardiovascular target.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. Ligand B (-4.702) is slightly better than Ligand A (-4.515), but both are concerning.
10. **Solubility:** Both ligands have negative solubility values, indicating poor solubility. Ligand A (-3.699) is slightly better than Ligand B (-4.834).
11. **hERG:** Ligand A (0.105) has a much lower hERG inhibition liability than Ligand B (0.725), a crucial advantage for cardiovascular drugs.
12. **Cl_mic:** Ligand B (47.608) has a lower microsomal clearance than Ligand A (56.164), suggesting better metabolic stability.
13. **t1/2:** Ligand B (30.134) has a significantly longer in vitro half-life than Ligand A (-14.602), which is highly desirable.
14. **Pgp:** Ligand A (0.482) has lower P-gp efflux liability than Ligand B (0.069), which is favorable for bioavailability.
15. **Affinity:** Ligand B (-6.7 kcal/mol) has a slightly better binding affinity than Ligand A (-6.2 kcal/mol). The difference is 0.5 kcal/mol, which is significant.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B has a slightly better logP, better Pgp efflux, and significantly better affinity. However, Ligand A has much better TPSA and hERG inhibition. The Caco-2 and solubility are poor for both.
**Overall Assessment:**
While Ligand B has a better affinity and metabolic stability, the significantly lower hERG risk of Ligand A is a major advantage for a cardiovascular drug. The slightly better TPSA of Ligand A is also beneficial. The affinity difference is not large enough to overcome the hERG concern with Ligand B.
Output:
1
2025-04-17 20:17:03,239 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [357.435, 69.72, 1.609, 1, 4, 0.845, 65.568, 68.127, -4.806, -2.953, 0.43, 45.061, 42.421, 0.147, -7.3]
**Ligand B:** [373.837, 93.9, 1.614, 1, 6, 0.73, 50.136, 81.039, -4.678, -2.63, 0.263, 25.418, -5.144, 0.168, -6]
Here's a breakdown, considering the provided guidelines and GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (357.435) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (69.72) is better than Ligand B (93.9), falling well below the 140 threshold for oral absorption. Ligand B is still acceptable, but less ideal.
3. **logP:** Both are very similar and optimal (around 1.6). This is good for both compounds.
4. **HBD:** Both have 1 HBD, which is within the acceptable limit.
5. **HBA:** Ligand A (4) is better than Ligand B (6), keeping the total number of hydrogen bonding groups lower, which is preferable for permeability.
6. **QED:** Ligand A (0.845) is better than Ligand B (0.73), indicating a more drug-like profile.
7. **DILI:** Ligand A (65.568) has a higher DILI risk than Ligand B (50.136), but both are still within a manageable range.
8. **BBB:** Ligand B (81.039) has a better BBB penetration score than Ligand A (68.127). While not a primary concern for a cardiovascular target, it's a slight advantage.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified so it is hard to interpret.
10. **Solubility:** Both have negative solubility values, which is unusual and suggests poor solubility. However, the scale is not specified so it is hard to interpret.
11. **hERG:** Both have low hERG inhibition liability, which is good. Ligand B (0.263) is slightly lower, indicating a marginally better safety profile.
12. **Cl_mic:** Ligand B (25.418) has significantly lower microsomal clearance than Ligand A (45.061), suggesting better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand A (42.421) has a longer in vitro half-life than Ligand B (-5.144). This is a significant advantage.
14. **Pgp:** Both have low Pgp efflux liability, which is good.
15. **Affinity:** Ligand A (-7.3) has a slightly better binding affinity than Ligand B (-6). While the difference is not huge, it's still a positive factor.
**Overall Assessment:**
Ligand A has a better QED, TPSA, HBA, and binding affinity. However, Ligand B has a significantly better metabolic stability (lower Cl_mic) and a slightly better BBB score, and a lower DILI risk. The longer half-life of Ligand A is a significant advantage. Considering the balance, the slightly better affinity and half-life of Ligand A, combined with its better drug-like properties (QED, TPSA, HBA) outweigh the slightly higher DILI risk and lower BBB.
Output:
1
2025-04-17 20:17:03,239 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (359.5) is within the ideal range (200-500), while Ligand B (409.3) is towards the upper end, but still acceptable.
2. **TPSA:** Ligand A (62.3) is better than Ligand B (54.0), both are below the 140 threshold for oral absorption.
3. **logP:** Ligand A (2.09) is optimal (1-3), while Ligand B (4.24) is higher, potentially leading to solubility issues and off-target effects.
4. **HBD:** Ligand A (1) is good, Ligand B (0) is also acceptable.
5. **HBA:** Ligand A (4) is good, Ligand B (5) is acceptable.
6. **QED:** Ligand A (0.819) is excellent, indicating strong drug-likeness. Ligand B (0.528) is acceptable, but less favorable.
7. **DILI:** Ligand A (37.6) has a much lower DILI risk than Ligand B (77.2). This is a significant advantage for Ligand A.
8. **BBB:** Both are around 50, suggesting limited CNS penetration. This isn't a primary concern for ADRB2, which is not typically targeted for CNS effects.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the values are similar.
10. **Solubility:** Ligand A (-3.23) is better than Ligand B (-5.29). Solubility is a concern for Ligand B due to its higher logP.
11. **hERG:** Ligand A (0.132) has a lower hERG risk than Ligand B (0.469). This is a crucial safety parameter.
12. **Cl_mic:** Ligand A (20.1) has a significantly lower microsomal clearance than Ligand B (108.98), indicating better metabolic stability.
13. **t1/2:** Ligand A (-13.8) has a negative half-life, which is unusual and concerning. Ligand B (31.1) is better.
14. **Pgp:** Ligand A (0.112) has lower P-gp efflux than Ligand B (0.588), which is favorable for bioavailability.
15. **Affinity:** Ligand B (-6.4) has a slightly better binding affinity than Ligand A (-5.6), a difference of 0.8 kcal/mol.
**GPCR-Specific Considerations:**
For GPCRs like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand A has better logP, Pgp, and TPSA. The affinity difference is not large enough to outweigh the superior ADME properties of Ligand A.
**Overall Assessment:**
Ligand A presents a more balanced profile with better predicted ADME properties (DILI, solubility, metabolic stability, Pgp efflux) and acceptable binding affinity. While Ligand B has slightly better affinity, its higher logP, DILI risk, and metabolic clearance are significant drawbacks. The negative half-life for Ligand A is a concern but might be addressable through structural modifications.
**Output:**
1
2025-04-17 20:17:03,239 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (356.394 and 344.415 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand B (78.53) is significantly better than Ligand A (118.89). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (1.232) is within the optimal range (1-3), while Ligand A (0.679) is a bit low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (5) is at the upper limit, while Ligand B (1) is excellent. Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (5) and Ligand B (4) are both acceptable, below the 10 threshold.
6. **QED:** Ligand B (0.834) is much better than Ligand A (0.422), indicating a more drug-like profile.
7. **DILI:** Ligand A (24.351) has a significantly lower DILI risk than Ligand B (50.136). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (53.083) has a higher BBB penetration potential than Ligand A (18.069), but this isn't a primary concern for a cardiovascular target.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand B (-4.684) is slightly better than Ligand A (-5.681).
10. **Solubility:** Ligand A (-1.27) is better than Ligand B (-2.912). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.366) has a lower hERG risk than Ligand B (0.102), which is a positive.
12. **Cl_mic:** Ligand A (-9.189) has a lower (better) microsomal clearance than Ligand B (-4.442), indicating greater metabolic stability.
13. **t1/2:** Ligand A (8.782) has a longer half-life than Ligand B (-7.711). This is a significant advantage.
14. **Pgp:** Ligand A (0.04) has a lower Pgp efflux liability than Ligand B (0.023), which is favorable.
15. **Affinity:** Both ligands have good binding affinity (-7.0 and -6.0 kcal/mol respectively), but Ligand A is slightly better.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, and affinity are important. Ligand B has a better logP and TPSA, but Ligand A has slightly better affinity. However, the ADME properties of Ligand A are significantly better, particularly its lower DILI risk, better metabolic stability (Cl_mic, t1/2), and lower Pgp efflux. The solubility is also better for Ligand A. Considering the overall balance, the superior ADME profile of Ligand A outweighs the slight advantage in logP and TPSA of Ligand B.
**Output:**
1
2025-04-17 20:17:03,239 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (348.363) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are reasonably good, but Ligand A (127.24) is better than Ligand B (133.91), being closer to the <140 threshold for good oral absorption.
3. **logP:** Ligand B (-1.755) is lower than Ligand A (-0.897). Both are acceptable, but closer to 1-3 is preferred. Ligand A is better here.
4. **HBD:** Both have 3 HBD, which is within the acceptable limit of <=5.
5. **HBA:** Ligand A has 7 HBA, while Ligand B has 6. Both are within the acceptable limit of <=10.
6. **QED:** Ligand A (0.608) has a better QED score than Ligand B (0.482), indicating a more drug-like profile.
7. **DILI:** Ligand B (47.654) has a significantly lower DILI risk than Ligand A (78.48), which is a major advantage.
8. **BBB:** Both have relatively low BBB penetration, but Ligand A (58.821) is slightly better than Ligand B (51.454). Since ADRB2 isn't necessarily a CNS target, this isn't a major deciding factor.
9. **Caco-2:** Both have negative Caco-2 values, suggesting poor permeability. Ligand B (-5.441) is slightly worse than Ligand A (-5.353).
10. **Solubility:** Both have negative solubility values, indicating poor solubility. Ligand B (-1.664) is slightly better than Ligand A (-2.191).
11. **hERG:** Both have very low hERG inhibition risk, which is good. Ligand B (0.106) is slightly higher than Ligand A (0.029), but both are acceptable.
12. **Cl_mic:** Ligand B (-5.051) has a significantly lower microsomal clearance than Ligand A (-19.11), suggesting better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand B (-42.038) has a much longer in vitro half-life than Ligand A (31.811), suggesting a longer duration of action. This is a major advantage.
14. **Pgp:** Both have very low P-gp efflux liability, which is good. Ligand B (0.004) is slightly higher than Ligand A (0.002), but both are acceptable.
15. **Binding Affinity:** Ligand A (-7.1) has a slightly better binding affinity than Ligand B (-6.0), although both are quite good.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, and affinity are important. Ligand A is slightly better in logP and affinity, while Ligand B has a better DILI score and significantly better metabolic stability (Cl_mic) and half-life.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity and logP, Ligand B's superior DILI profile, metabolic stability (lower Cl_mic), and longer half-life are more critical for overall drug development success. The slightly lower affinity of Ligand B can potentially be optimized in subsequent iterations. The poor Caco-2 and solubility of both are concerns, but can be addressed through formulation strategies. The lower DILI risk and improved PK properties of Ligand B outweigh the minor affinity difference.
Output:
0
2025-04-17 20:17:03,240 - INFO - Batch 173 complete. Total preferences: 2768
2025-04-17 20:17:03,240 - INFO - Processing batch 174/512...
2025-04-17 20:17:49,315 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
The target is ADRB2, a GPCR. Therefore, I will prioritize logP, TPSA, Pgp, BBB, and binding affinity, followed by general drug-like properties.
* **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (349.41) is slightly lower, which is generally favorable for permeability.
* **TPSA:** Ligand B (82.53) is significantly lower than Ligand A (101.21). Lower TPSA is preferred for better oral absorption and potentially better BBB penetration.
* **logP:** Both ligands have acceptable logP values (A: 1.164, B: 1.682), falling within the 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability.
* **H-Bond Donors/Acceptors:** Both have 2 HBD and 5 HBA, which are within acceptable limits.
* **QED:** Both ligands have good QED scores (A: 0.803, B: 0.732), indicating good drug-like properties.
* **DILI:** Ligand B (35.673) has a much lower DILI risk than Ligand A (51.609), which is a significant advantage.
* **BBB:** Ligand A (82.513) has a substantially higher BBB percentile than Ligand B (40.558). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be beneficial, and a higher BBB is generally desirable.
* **Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. This is a concern for both.
* **Aqueous Solubility:** Both have negative solubility values, indicating low solubility. This is a significant drawback for both compounds.
* **hERG:** Both ligands have very low hERG inhibition liability (A: 0.404, B: 0.151), which is excellent.
* **Microsomal Clearance:** Ligand B (28.589) has a much lower microsomal clearance than Ligand A (4.074), indicating better metabolic stability.
* **In vitro Half-Life:** Ligand B (32.385) has a significantly longer half-life than Ligand A (-13.403), which is a major advantage.
* **P-gp Efflux:** Both ligands have very low P-gp efflux liability (A: 0.017, B: 0.046), which is favorable.
* **Binding Affinity:** Ligand B (-7.3 kcal/mol) has a slightly better binding affinity than Ligand A (-7.1 kcal/mol), though the difference is small.
**Overall Assessment:**
While Ligand A has a better BBB score, Ligand B demonstrates a superior profile across several critical ADME properties: lower DILI risk, significantly better metabolic stability (lower Cl_mic, longer t1/2), and slightly better binding affinity. The poor Caco-2 and solubility are concerning for both, but the ADME advantages of Ligand B outweigh the slight benefit of Ligand A's BBB penetration, especially considering the target is a peripheral GPCR.
**Output:**
0
2025-04-17 20:17:49,316 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Step-by-step comparison:**
1. **MW:** Both ligands (370.475 and 348.462 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (104.65) is higher than Ligand B (49.41). For a GPCR, lower TPSA is generally preferred for better brain penetration and overall permeability. Ligand B is significantly better.
3. **logP:** Ligand A (0.223) is quite low, potentially hindering membrane permeability. Ligand B (3.49) is within the optimal 1-3 range. Ligand B is significantly better.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable.
5. **HBA:** Ligand A (7) and Ligand B (2) are both acceptable, but Ligand B is better.
6. **QED:** Both ligands have good QED scores (0.644 and 0.767), indicating good drug-like properties.
7. **DILI:** Both ligands have similar, low DILI risk (32.338 and 32.61).
8. **BBB:** Ligand A (29.973) has poor BBB penetration, while Ligand B (89.802) has excellent BBB penetration. This is a major advantage for Ligand B, given ADRB2's relevance in cardiovascular and potentially CNS applications.
9. **Caco-2:** Ligand A (-5.394) and Ligand B (-4.602) both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the values are close.
10. **Solubility:** Ligand A (-0.813) and Ligand B (-3.693) both have negative solubility values, which is also unusual. Ligand A is better.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.088 and 0.914).
12. **Cl_mic:** Ligand A (-15.803) has a negative clearance, which is unusual and suggests very high metabolic stability. Ligand B (46.499) has a moderate clearance. Ligand A is better.
13. **t1/2:** Ligand A (31.3) has a longer half-life than Ligand B (-6.614). Ligand A is better.
14. **Pgp:** Ligand A (0.025) has very low P-gp efflux, while Ligand B (0.7) has moderate P-gp efflux. Ligand A is better.
15. **Affinity:** Both ligands have very similar binding affinities (-6.9 and -6.2 kcal/mol). The difference is not substantial enough to outweigh other factors.
**Overall Assessment:**
Ligand B excels in key GPCR-relevant properties: logP and BBB penetration. While Ligand A has advantages in metabolic stability (Cl_mic), half-life, and P-gp efflux, the poor logP and BBB penetration are significant drawbacks for a GPCR target. The lower TPSA of Ligand B is also beneficial. The similar affinities mean that the ADME properties become the deciding factor.
Output:
0
2025-04-17 20:17:49,316 - INFO - Here's my reasoning and final output:
**Reasoning:**
Both ligands are relatively similar in molecular weight (around 350 Da) and binding affinity (-6.3 kcal/mol, which is good). The choice hinges on ADME properties, particularly considering this is a GPCR target (ADRB2, cardiovascular). Let's break down the comparison:
1. **MW & TPSA:** Both ligands have acceptable MW. Ligand B has a slightly lower TPSA (69.72 vs 78.09), which is favorable for permeability.
2. **logP:** Both are within the optimal range (1-3), but Ligand B (1.852) is slightly lower, which could potentially improve solubility but might slightly reduce membrane permeability.
3. **H-Bond Donors/Acceptors:** Both have reasonable HBD/HBA counts.
4. **QED:** Both have similar QED scores, indicating good drug-likeness.
5. **DILI:** Ligand A (13.843) has a significantly lower DILI risk than Ligand B (26.871). This is a major advantage for Ligand A.
6. **BBB:** Ligand B has a much higher BBB penetration percentile (73.672) than Ligand A (44.591). While ADRB2 is a cardiovascular target, some CNS off-target effects are always a concern, and higher BBB penetration could exacerbate those. However, for a cardiovascular target, BBB isn't a *primary* driver.
7. **Caco-2 & Solubility:** Both have similar, and relatively poor, Caco-2 permeability and aqueous solubility.
8. **hERG:** Both have very low hERG inhibition liability, which is excellent.
9. **Cl_mic & t1/2:** Ligand A has a lower microsomal clearance (8.117) and a more negative in vitro half-life (-17.539) than Ligand B (53.04 and 15.371 respectively). This suggests better metabolic stability for Ligand A.
10. **Pgp:** Both have low P-gp efflux liability.
**Overall Assessment:**
The key differentiator is the DILI risk. Ligand A's significantly lower DILI percentile is a substantial advantage. While Ligand B has better BBB penetration, this is less critical for a cardiovascular target. Ligand A also exhibits better metabolic stability. The slightly lower TPSA and logP of Ligand B are minor benefits that are outweighed by the DILI and metabolic stability concerns.
**Output:**
1
2025-04-17 20:17:49,316 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**1. Molecular Weight:** Both ligands (376.431 and 352.435 Da) fall within the ideal range of 200-500 Da. No significant difference here.
**2. TPSA:** Ligand A (110.29) is slightly higher than Ligand B (100.71). Both are below the 140 A^2 threshold for good oral absorption, but Ligand B is closer to the preferred <90 A^2 for potential CNS penetration, although CNS targeting isn't explicitly stated.
**3. logP:** Ligand A (-1.186) is lower than Ligand B (-0.022). Ligand B is closer to the optimal 1-3 range. Ligand A's logP is somewhat concerning as it could lead to poor membrane permeability.
**4. H-Bond Donors:** Ligand A (0) is better than Ligand B (2). Fewer H-bond donors generally improve permeability.
**5. H-Bond Acceptors:** Both ligands have 7 H-bond acceptors, which is acceptable (<=10).
**6. QED:** Ligand B (0.715) has a significantly better QED score than Ligand A (0.438), indicating a more drug-like profile.
**7. DILI Risk:** Ligand A (55.68) has a higher DILI risk than Ligand B (29.314). Ligand B is well below the 40% threshold for low risk.
**8. BBB Penetration:** Ligand A (65.297) has better BBB penetration than Ligand B (30.748). However, as ADRB2 isn't strictly a CNS target, this isn't a major deciding factor.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.807 and -4.902), which is unusual and suggests poor permeability. This is a significant concern for both.
**10. Aqueous Solubility:** Both ligands have negative solubility values (-0.889 and -0.37), also unusual and concerning.
**11. hERG Inhibition:** Both ligands show very low hERG inhibition risk (0.146 and 0.071).
**12. Microsomal Clearance:** Ligand B (-13.315) has significantly lower (better) microsomal clearance than Ligand A (28.808), indicating better metabolic stability.
**13. In vitro Half-Life:** Ligand B (5.576) has a positive half-life, while Ligand A (-27.984) has a negative half-life, which is not physically meaningful. This suggests Ligand B is more stable in vitro.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.032 and 0.038).
**15. Binding Affinity:** Ligand B (-7.1 kcal/mol) has a slightly better binding affinity than Ligand A (-6.4 kcal/mol). While the difference is not huge, it's enough to be considered.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand B is the more promising candidate. While both have issues with Caco-2 and solubility, Ligand B has a better logP, QED, DILI risk, metabolic stability (lower Cl_mic and positive t1/2), and slightly better binding affinity. Ligand A's low logP and negative half-life are significant drawbacks.
Output:
0
2025-04-17 20:17:49,316 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (358.429 and 387.571 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (58.64) is significantly better than Ligand B (87.3). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold. Ligand B is approaching it.
3. **logP:** Both ligands have good logP values (2.139 and 1.498), falling within the optimal 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally lead to better permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (5) for the same reason as HBD.
6. **QED:** Ligand A (0.791) has a better QED score than Ligand B (0.55), indicating a more drug-like profile.
7. **DILI:** Ligand A (18.689) has a much lower DILI risk than Ligand B (32.183). This is a significant advantage.
8. **BBB:** Ligand A (83.133) has a much higher BBB penetration percentile than Ligand B (36.642). While not a primary concern for a cardiovascular target, it doesn't hurt.
9. **Caco-2:** Ligand A (-4.843) and Ligand B (-5.602) are both negative, which is unusual and suggests very poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Both ligands have very poor aqueous solubility (-2.45 and -2.551). This is a major concern for both.
11. **hERG:** Ligand A (0.556) has a lower hERG risk than Ligand B (0.073). This is a significant advantage.
12. **Cl_mic:** Ligand A (5.017) has a much lower microsomal clearance than Ligand B (25.952), indicating better metabolic stability.
13. **t1/2:** Ligand A (3.292) has a better in vitro half-life than Ligand B (-0.626).
14. **Pgp:** Ligand A (0.127) has a lower P-gp efflux liability than Ligand B (0.032).
15. **Binding Affinity:** Ligand A (-7.4) has a slightly better binding affinity than Ligand B (-6.8). While the difference is not huge, it's still a positive.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A performs better on all of these.
**Overall Assessment:**
Ligand A is clearly superior. It has a better drug-like profile (higher QED), lower DILI risk, better metabolic stability (lower Cl_mic, longer t1/2), lower P-gp efflux, and slightly better binding affinity. While both have poor solubility, the other advantages of Ligand A outweigh this drawback. The TPSA and H-bonding parameters are also more favorable for Ligand A.
Output:
1
2025-04-17 20:17:49,316 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's analyze each ligand against the provided guidelines, keeping in mind ADRB2 is a GPCR and thus we prioritize logP, Pgp, TPSA, and affinity.
* **Molecular Weight:** Both ligands (362.4 and 347.4 Da) fall within the ideal 200-500 Da range.
* **TPSA:** Ligand A (96.8) is better than Ligand B (114.11). Both are acceptable, but lower TPSA generally favors better absorption.
* **logP:** Ligand A (1.471) is slightly better than Ligand B (0.828), both are within the optimal 1-3 range.
* **H-Bond Donors/Acceptors:** Ligand A (1 HBD, 5 HBA) is preferable to Ligand B (4 HBD, 4 HBA). While both are reasonable, minimizing H-bonds can improve membrane permeability.
* **QED:** Ligand A (0.865) has a significantly better QED score than Ligand B (0.566), indicating a more drug-like profile.
* **DILI:** Ligand B (51.687) has a much lower DILI risk than Ligand A (88.639), which is a significant advantage.
* **BBB:** Ligand A (25.979) has a very low BBB penetration, while Ligand B (10.741) is also low. Given ADRB2 is a cardiovascular target, BBB penetration isn't a high priority, but it's still better to have some.
* **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability.
* **Solubility:** Both have negative solubility values, which is also unusual and suggests poor solubility.
* **hERG:** Ligand A (0.016) has a slightly lower hERG risk than Ligand B (0.219).
* **Cl_mic:** Ligand A (-4.344) has significantly better metabolic stability (lower clearance) than Ligand B (-0.052).
* **t1/2:** Ligand A (-21.713) has a much longer in vitro half-life than Ligand B (3.287).
* **Pgp:** Ligand A (0.006) has significantly lower P-gp efflux liability than Ligand B (0.01).
* **Binding Affinity:** Ligand A (-8.5 kcal/mol) has a better binding affinity than Ligand B (-5.2 kcal/mol). This is a substantial difference, and a strong affinity can often outweigh other less-than-ideal properties.
**Overall Assessment:**
Ligand A is superior due to its significantly stronger binding affinity, better QED, better metabolic stability, longer half-life, and lower P-gp efflux. While Ligand B has a better DILI score, the substantial advantage in potency and drug-like properties of Ligand A outweighs this concern. The poor Caco-2 and solubility values are concerning for both, but can be addressed through formulation strategies.
**Output:**
1
2025-04-17 20:17:49,316 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (367.5 and 355.3 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (71.5 and 72.3 A^2) are below the 140 A^2 threshold for good oral absorption, and acceptable for a cardiovascular target.
3. **logP:** Both ligands have good logP values (2.48 and 1.69), falling within the optimal 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Both have 1 HBD, which is within the acceptable limit of <=5.
5. **HBA:** Ligand A has 5 HBA, and Ligand B has 6. Both are within the acceptable limit of <=10.
6. **QED:** Both ligands have high QED scores (0.868 and 0.827), indicating good drug-like properties.
7. **DILI:** Ligand A (47.8%) has a lower DILI risk than Ligand B (61.6%), which is a significant advantage.
8. **BBB:** Ligand B (82.1%) has a higher BBB penetration score than Ligand A (61.5%). While ADRB2 is a cardiovascular target and CNS penetration isn't *essential*, some degree of BBB penetration can be useful for off-target effects assessment and potential peripheral effects.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.88 and -4.87), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Both ligands have negative solubility values (-2.26 and -2.60), indicating very poor aqueous solubility. This is a major drawback for both.
11. **hERG:** Both ligands have low hERG inhibition liability (0.45 and 0.34), which is good.
12. **Cl_mic:** Ligand B (37.5 mL/min/kg) has significantly lower microsomal clearance than Ligand A (64.3 mL/min/kg), indicating better metabolic stability. This is a substantial advantage.
13. **t1/2:** Ligand A (11.7 hours) has a longer in vitro half-life than Ligand B (0.84 hours). This is a significant advantage.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.19 and 0.04), which is favorable.
15. **Binding Affinity:** Ligand A (-6.7 kcal/mol) has a slightly better binding affinity than Ligand B (-5.9 kcal/mol). This difference of 0.8 kcal/mol is meaningful.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Both ligands perform similarly on logP and Pgp. TPSA is acceptable for both. The affinity difference favors Ligand A. However, the poor Caco-2 and solubility are concerning for both. The lower DILI risk of Ligand A and its longer half-life are significant advantages. The lower clearance of Ligand B is also a plus.
**Overall Assessment:**
Despite the poor Caco-2 and solubility for both, Ligand A is slightly more favorable. The combination of better affinity, lower DILI risk, and longer half-life outweighs the slightly better metabolic stability and BBB penetration of Ligand B. Addressing the solubility issues will be critical for either compound.
Output:
1
2025-04-17 20:17:49,316 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (360.38 and 344.419 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (70.39) is significantly better than Ligand B (103.91). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (2.166) is optimal, while Ligand B (0.779) is a bit low, potentially hindering membrane permeability.
4. **HBD:** Both ligands have acceptable HBD counts (2 and 1, respectively).
5. **HBA:** Ligand B (6) is slightly higher than Ligand A (4), but both are within the acceptable range.
6. **QED:** Both ligands have very similar and good QED scores (0.865 and 0.869).
7. **DILI:** Ligand A (18.302) has a much lower DILI risk than Ligand B (48.895). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (77.937) has a better BBB score than Ligand B (60.644), but this isn't a major concern for a cardiovascular target.
9. **Caco-2:** Ligand A (-4.732) and Ligand B (-5.009) are similar, indicating comparable intestinal absorption potential.
10. **Solubility:** Ligand A (-2.184) is better than Ligand B (-3.197), suggesting better aqueous solubility.
11. **hERG:** Ligand A (0.494) has a lower hERG risk than Ligand B (0.031), which is very important for cardiovascular drugs.
12. **Cl_mic:** Ligand A (-4.19) has a lower (better) microsomal clearance than Ligand B (9.796), indicating greater metabolic stability.
13. **t1/2:** Ligand A (-9.943) has a longer in vitro half-life than Ligand B (-6.813), which is favorable.
14. **Pgp:** Ligand A (0.024) has a lower Pgp efflux liability than Ligand B (0.015), suggesting better bioavailability.
15. **Binding Affinity:** Ligand B (-8.0) has a slightly better binding affinity than Ligand A (-6.7), a difference of 1.3 kcal/mol.
**Overall Assessment:**
While Ligand B has a slightly better binding affinity, Ligand A is superior in almost all other critical ADME-Tox parameters. Specifically, Ligand A demonstrates significantly lower DILI risk, better solubility, lower hERG inhibition, improved metabolic stability (lower Cl_mic and longer t1/2), and lower Pgp efflux. Given the importance of safety and pharmacokinetic properties in drug development, especially for a cardiovascular target where off-target effects can be particularly dangerous, the advantages of Ligand A outweigh the modest affinity difference.
**Output:**
1
2025-04-17 20:17:49,316 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (370.465 Da) is slightly preferred due to being closer to the lower end, potentially aiding permeability.
2. **TPSA:** Ligand A (58.2) is significantly better than Ligand B (88.41). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (A: 3.371, B: 2.586), falling within the 1-3 optimal range. Ligand A is slightly higher, which *could* be a minor advantage for membrane permeability, but isn't a major concern for either.
4. **HBD:** Both have 2 HBD, which is within the acceptable limit of 5.
5. **HBA:** Ligand A has 3 HBA, while Ligand B has 4. Both are acceptable (<=10), with A being slightly preferred.
6. **QED:** Both ligands have similar QED values (A: 0.773, B: 0.736), indicating good drug-likeness.
7. **DILI:** Ligand A (43.117) has a considerably lower DILI risk than Ligand B (80.031). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (89.957) has better BBB penetration than Ligand B (71.772), but this isn't a high priority for a cardiovascular target.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. This is a significant drawback for both.
10. **Solubility:** Both ligands exhibit poor solubility (-3.82 and -3.747). This is a concern for both, but not a deciding factor between the two.
11. **hERG:** Both ligands have low hERG inhibition risk (A: 0.758, B: 0.533).
12. **Cl_mic:** Ligand B (42.881) has a slightly lower microsomal clearance than Ligand A (46.137), suggesting better metabolic stability, but the difference is not substantial.
13. **t1/2:** Ligand B (76.365) has a significantly longer in vitro half-life than Ligand A (25.437). This is a substantial advantage for Ligand B.
14. **Pgp:** Both ligands have low Pgp efflux liability (A: 0.316, B: 0.35).
15. **Binding Affinity:** Ligand A (-6.4 kcal/mol) has a slightly better binding affinity than Ligand B (-4.7 kcal/mol). This is a significant advantage, as a 1.7 kcal/mol difference is substantial.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A performs better on TPSA and affinity, while Ligand B has a longer half-life. The significantly lower DILI risk of Ligand A is also a major positive. The superior binding affinity of Ligand A outweighs the longer half-life of Ligand B.
**Conclusion:**
Considering the balance of properties, particularly the superior binding affinity, lower DILI risk, and better TPSA of Ligand A, it is the more promising drug candidate.
Output:
1
2025-04-17 20:17:49,316 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (387.3 & 362.4 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (51.13) is better than Ligand B (60.85). ADRB2 is a cardiovascular target, so CNS penetration isn't critical, but lower TPSA generally favors absorption.
3. **logP:** Ligand A (4.989) is a bit high, potentially leading to solubility issues. Ligand B (1.939) is within the optimal range. This favors Ligand B.
4. **HBD:** Both have acceptable HBD counts (0 for A, 1 for B).
5. **HBA:** Both have acceptable HBA counts (4 for A, 3 for B).
6. **QED:** Both have good QED values (0.54 for A, 0.813 for B), indicating drug-likeness. Ligand B is better.
7. **DILI:** Ligand A (53.005) has a moderate DILI risk, while Ligand B (18.612) has a very low risk. This is a significant advantage for Ligand B.
8. **BBB:** Both have good BBB penetration (70.841 & 78.829), but this isn't a high priority for a cardiovascular target.
9. **Caco-2:** Both have negative Caco-2 values which is unusual. Assuming these are logP-scale values, they are similar and suggest poor permeability.
10. **Solubility:** Ligand A (-5.895) has very poor solubility, while Ligand B (-3.01) is still poor but better. This favors Ligand B.
11. **hERG:** Both have low hERG inhibition risk (0.57 & 0.465). No significant difference.
12. **Cl_mic:** Ligand A (54.805) has higher microsomal clearance than Ligand B (24.409), indicating lower metabolic stability. This favors Ligand B.
13. **t1/2:** Ligand B (-7.798) has a much longer in vitro half-life than Ligand A (1.779). This is a strong advantage for Ligand B.
14. **Pgp:** Both have low Pgp efflux liability (0.5 & 0.161). Ligand B is better.
15. **Binding Affinity:** Ligand A (-7.8) has slightly better binding affinity than Ligand B (-7.0). However, the difference is less than 1.5 kcal/mol, and other factors are more important.
**Overall Assessment:**
Ligand B consistently outperforms Ligand A in crucial ADME-Tox properties (DILI, solubility, Cl_mic, t1/2, Pgp) and has a better QED score. While Ligand A has slightly better binding affinity, the overall profile of Ligand B is far more favorable for drug development, especially considering the cardiovascular target. The poor solubility and higher clearance of Ligand A are significant drawbacks.
Output:
0
2025-04-17 20:17:49,316 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (361.402 Da) is within the ideal range (200-500 Da). Ligand B (417.965 Da) is also acceptable, but approaching the upper limit.
2. **TPSA:** Ligand A (106.96) is better than Ligand B (79.37) for oral absorption, being below 140, but still relatively high. Both are acceptable.
3. **logP:** Ligand A (3.175) is optimal. Ligand B (1.985) is slightly lower, but still within the acceptable range.
4. **HBD:** Ligand A (2) is good. Ligand B (1) is also good.
5. **HBA:** Ligand A (4) is good. Ligand B (6) is acceptable, but higher.
6. **QED:** Ligand B (0.804) is significantly better than Ligand A (0.326), indicating a much more drug-like profile.
7. **DILI:** Ligand A (68.244) is better than Ligand B (79.682), indicating a lower risk of drug-induced liver injury.
8. **BBB:** Ligand A (67.778) is better than Ligand B (54.634). While ADRB2 isn't exclusively a CNS target, some peripheral effects are mediated by CNS pathways, and better BBB penetration can be advantageous.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.152 and -5.208), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Both ligands have negative solubility values (-3.188 and -4.358), which is also unusual and suggests poor aqueous solubility. This is a significant concern for both.
11. **hERG:** Both ligands have low hERG inhibition liability (0.62 and 0.568), which is good.
12. **Cl_mic:** Ligand A (32.93) has a lower microsomal clearance than Ligand B (43.864), indicating better metabolic stability.
13. **t1/2:** Ligand A (34.041) has a longer in vitro half-life than Ligand B (17.21), which is desirable.
14. **Pgp:** Ligand A (0.236) has lower P-gp efflux liability than Ligand B (0.125), which is better.
15. **Affinity:** Ligand A (-6.8 kcal/mol) has a slightly better binding affinity than Ligand B (-6.4 kcal/mol).
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has a better logP and Pgp efflux. Ligand B has a better TPSA. The affinity difference is small, but favors Ligand A. The QED value of Ligand B is a strong positive, but is outweighed by the superior ADME properties of Ligand A. The negative Caco-2 and solubility for both are concerning, but the better metabolic stability and half-life for Ligand A are important.
**Conclusion:**
Despite the superior QED of Ligand B, Ligand A demonstrates a more favorable balance of properties, particularly regarding metabolic stability, half-life, P-gp efflux, and binding affinity. The negative Caco-2 and solubility are concerning for both, but Ligand A's other properties make it the more promising candidate.
Output:
1
2025-04-17 20:17:49,317 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [344.371, 95.6, 0.383, 1, 5, 0.632, 74.603, 43.117, -4.886, -3.319, 0.064, 12.595, -35.421, 0.037, -6.6]
**Ligand B:** [352.479, 56.33, -0.138, 0, 5, 0.666, 4.343, 76.464, -4.764, -0.025, 0.45, 22.174, -27.972, 0.004, -6.3]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, BBB, and affinity are key):
1. **MW:** Both are within the ideal 200-500 Da range. A (344.371) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** A (95.6) is higher than B (56.33). B is significantly better here, falling well below the 140 threshold for oral absorption and closer to the ideal for GPCRs.
3. **logP:** A (0.383) is quite low, potentially hindering membrane permeability. B (-0.138) is also low, but slightly better than A. Both are below the optimal 1-3 range.
4. **HBD:** A (1) is acceptable. B (0) is even better, minimizing potential issues with hydrogen bonding and improving permeability.
5. **HBA:** Both A (5) and B (5) are within the acceptable limit of 10.
6. **QED:** Both are good (A: 0.632, B: 0.666), indicating drug-like properties. B is slightly better.
7. **DILI:** A (74.603) has a concerningly high DILI risk. B (4.343) is excellent, indicating very low liver injury potential. This is a *major* advantage for B.
8. **BBB:** B (76.464) has better BBB penetration than A (43.117), which is a positive for a GPCR target, though not strictly essential for ADRB2.
9. **Caco-2:** Both are negative, indicating poor permeability. A (-4.886) is slightly worse than B (-4.764).
10. **Solubility:** Both are very poor. B (-0.025) is marginally better than A (-3.319).
11. **hERG:** A (0.064) is slightly better than B (0.45), indicating lower cardiotoxicity risk.
12. **Cl_mic:** A (12.595) has lower microsomal clearance, suggesting better metabolic stability than B (22.174).
13. **t1/2:** A (-35.421) has a longer in vitro half-life than B (-27.972), which is favorable.
14. **Pgp:** A (0.037) has lower P-gp efflux, which is good for bioavailability. B (0.004) is even better.
15. **Affinity:** Both have very similar binding affinities (-6.6 and -6.3 kcal/mol). The difference is not substantial enough to outweigh other factors.
**Overall Assessment:**
Ligand B is the stronger candidate. While both compounds have solubility and permeability issues, Ligand B's significantly lower DILI risk and better BBB penetration are crucial advantages for a GPCR target. The slightly better TPSA and Pgp efflux also contribute to its favorability. While Ligand A has better metabolic stability and a slightly longer half-life, the DILI risk associated with Ligand A is a major concern. The affinity difference is minimal.
Output:
0
2025-04-17 20:17:49,317 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
The target is ADRB2, a GPCR. Therefore, priorities are logP, Pgp, TPSA, affinity, and BBB. Let's break down the comparison:
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (360.391) is slightly higher than Ligand B (342.487), but this isn't a major concern.
2. **TPSA:** Ligand B (59.07) is significantly better than Ligand A (108.58). Lower TPSA generally favors better cell permeability, which is crucial for GPCR targeting.
3. **logP:** Ligand A (2.042) is within the optimal range (1-3), while Ligand B (3.955) is approaching the upper limit. While higher logP can sometimes be beneficial for membrane permeability, it can also lead to off-target effects and solubility issues.
4. **H-Bond Donors/Acceptors:** Ligand A has 1 HBD and 8 HBA, while Ligand B has 2 HBD and 5 HBA. Both are within acceptable limits.
5. **QED:** Both ligands have the same QED score (0.785), indicating similar drug-likeness.
6. **DILI:** Ligand B (44.126) has a much lower DILI risk than Ligand A (83.443). This is a significant advantage.
7. **BBB:** Ligand B (89.027) has a better BBB penetration score than Ligand A (82.823), although both are reasonably good.
8. **Caco-2 Permeability:** Both ligands have similar, poor Caco-2 permeability (-4.955 and -4.926). This suggests potential absorption issues.
9. **Aqueous Solubility:** Ligand A (-4.69) has slightly better solubility than Ligand B (-5.467), but both are quite poor.
10. **hERG Inhibition:** Ligand A (0.285) has a lower hERG inhibition risk than Ligand B (0.773). This is a positive for Ligand A.
11. **Microsomal Clearance:** Ligand B (75.936) has higher microsomal clearance than Ligand A (53.683), suggesting faster metabolism and potentially lower *in vivo* exposure.
12. **In vitro Half-Life:** Ligand A (-28.223) has a much longer in vitro half-life than Ligand B (44.725). This is a significant advantage for dosing frequency.
13. **P-gp Efflux:** Both ligands have low P-gp efflux liability (0.129 and 0.274).
14. **Binding Affinity:** Ligand A (-6.7 kcal/mol) has a slightly better binding affinity than Ligand B (-6.0 kcal/mol). This is a 0.7 kcal/mol difference, which is noteworthy, but not overwhelmingly decisive.
**Overall Assessment:**
Ligand B excels in TPSA, DILI risk, and BBB penetration, all of which are important for a GPCR target like ADRB2. Ligand A has a better half-life and slightly better affinity, but the lower DILI risk and improved TPSA of Ligand B are more compelling. The solubility of both is poor, and Caco-2 permeability is a concern for both. However, the lower DILI risk is a critical factor in drug development.
**Output:**
0
2025-04-17 20:17:49,317 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
Let's systematically compare the two ligands based on the provided parameters and the guidelines, keeping in mind that ADRB2 is a GPCR and therefore we prioritize logP, Pgp, TPSA, and affinity, alongside general drug-like properties.
1. **MW:** Both ligands (350.394 and 351.422 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (74.77) is significantly better than Ligand B (93.45). A TPSA under 140 is good for oral absorption, and lower is generally preferred for GPCRs. Ligand A is much closer to the ideal range for good absorption.
3. **logP:** Ligand B (1.623) is better than Ligand A (0.329). A logP between 1-3 is optimal. Ligand A is a bit low, potentially hindering membrane permeability.
4. **HBD/HBA:** Ligand A has 1 HBD and 5 HBA, while Ligand B has 3 HBD and 4 HBA. Both are within acceptable limits (<=5 HBD and <=10 HBA).
5. **QED:** Ligand A (0.847) has a substantially better QED score than Ligand B (0.621), indicating a more drug-like profile.
6. **DILI:** Both ligands have similar, acceptable DILI risk (44.591 and 44.087 percentile).
7. **BBB:** Ligand B (82.862) has a better BBB penetration percentile than Ligand A (68.554). While not a primary concern for ADRB2 (a cardiovascular target), higher BBB is generally favorable.
8. **Caco-2:** Both have negative values, indicating permeability. Ligand A (-4.451) is slightly better than Ligand B (-4.834).
9. **Solubility:** Ligand A (-1.207) is better than Ligand B (-3.042). Better solubility is generally desirable.
10. **hERG:** Ligand A (0.076) has a significantly lower hERG inhibition liability than Ligand B (0.603), which is a crucial safety advantage.
11. **Cl_mic:** Ligand A (-21.128) has a much lower (better) microsomal clearance than Ligand B (33.007), indicating greater metabolic stability.
12. **t1/2:** Ligand A (-7.765) has a better (longer) in vitro half-life than Ligand B (0.73).
13. **Pgp:** Ligand A (0.008) has a much lower Pgp efflux liability than Ligand B (0.052), indicating better oral bioavailability and potentially better CNS exposure if needed.
14. **Affinity:** Ligand A (-6.6 kcal/mol) has a slightly better binding affinity than Ligand B (-5.8 kcal/mol). While the difference isn't huge, it's enough to be considered.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across several critical ADME-Tox properties (QED, hERG, Cl_mic, t1/2, Pgp, Solubility) and has a slightly better binding affinity. While Ligand B has a better logP and BBB, the superior overall profile of Ligand A, particularly its safety (hERG) and metabolic stability (Cl_mic), makes it the more promising drug candidate. The lower TPSA of Ligand A is also a significant advantage for absorption.
Output:
1
2025-04-17 20:17:49,317 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.415 and 354.422 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (93.46) is slightly higher than Ligand B (75.71). Both are below the 140 threshold for oral absorption, but B is better, particularly for a GPCR where some CNS penetration might be desirable even if it's not a primary goal.
3. **logP:** Both ligands (1.104 and 1.227) are within the optimal 1-3 range. No significant difference.
4. **HBD:** Ligand A has 2 HBD, while Ligand B has 1. Lower is generally preferred, giving a slight edge to Ligand B.
5. **HBA:** Ligand A has 5 HBA, Ligand B has 4. Again, lower is slightly better, favoring Ligand B.
6. **QED:** Ligand A (0.804) has a better QED score than Ligand B (0.728), indicating a more drug-like profile. This is a positive for Ligand A.
7. **DILI:** Ligand A (45.328) has a slightly higher DILI risk than Ligand B (35.556), but both are below the concerning threshold of 60. Ligand B is preferred.
8. **BBB:** Ligand B (90.229) has significantly better BBB penetration potential than Ligand A (55.603). While ADRB2 isn't *primarily* a CNS target, some degree of BBB penetration can be beneficial for distribution and off-target effects assessment.
9. **Caco-2:** Ligand A (-5.559) and Ligand B (-4.46) both have negative values, which is unusual and suggests poor permeability. However, the scale isn't specified, so it's hard to interpret.
10. **Solubility:** Ligand A (-0.792) has slightly better solubility than Ligand B (-2.18), which is a positive.
11. **hERG:** Both ligands (0.115 and 0.269) have low hERG inhibition risk, which is good. No significant difference.
12. **Cl_mic:** Ligand A (7.537) has significantly lower microsomal clearance than Ligand B (33.238), indicating better metabolic stability. This is a major advantage for Ligand A.
13. **t1/2:** Ligand A (6.191) has a positive in vitro half-life, while Ligand B (-25.414) has a negative one. This is a huge advantage for Ligand A.
14. **Pgp:** Both ligands (0.024 and 0.036) have low P-gp efflux liability, which is good. No significant difference.
15. **Binding Affinity:** Ligand A (-7.9 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.4 kcal/mol). This is a substantial advantage, potentially outweighing some ADME concerns.
**Overall Assessment:**
Ligand A has a significantly stronger binding affinity and better metabolic stability (lower Cl_mic and positive t1/2). While Ligand B has better TPSA and BBB penetration, the difference in binding affinity is substantial (1.5 kcal/mol), and the metabolic stability of A is a critical factor. The slightly higher DILI risk for A is acceptable given the other benefits.
Output:
1
2025-04-17 20:17:49,317 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (351.447 and 344.419 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (71.11) is significantly better than Ligand B (94.82). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is approaching a level that could hinder absorption.
**3. logP:** Ligand A (-0.007) is slightly lower than the optimal 1-3 range, but still acceptable. Ligand B (2.001) is well within the optimal range. This favors Ligand B slightly.
**4. H-Bond Donors:** Both ligands have 1 HBD, which is within the ideal limit of 5.
**5. H-Bond Acceptors:** Ligand A (5) is better than Ligand B (7), as lower HBA counts generally improve permeability.
**6. QED:** Both ligands have good QED scores (0.775 and 0.861), indicating good drug-like properties.
**7. DILI:** Ligand B (57.619) has a higher DILI risk than Ligand A (19.814). This is a significant concern, as lower DILI is highly desirable.
**8. BBB:** Ligand A (55.021) and Ligand B (61.846) are both relatively low, which isn't a major concern for a cardiovascular target.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.695 and -4.555), which is unusual and suggests poor permeability. However, the values are very close.
**10. Aqueous Solubility:** Ligand A (-1.273) has slightly better solubility than Ligand B (-3.071).
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.237 and 0.19).
**12. Microsomal Clearance:** Ligand A (-10.452) has a much lower (better) microsomal clearance than Ligand B (61.692). This indicates better metabolic stability for Ligand A.
**13. In vitro Half-Life:** Ligand A (4.901) has a shorter half-life than Ligand B (-26.776), which is not ideal.
**14. P-gp Efflux:** Both ligands have the same P-gp efflux liability (0.017).
**15. Binding Affinity:** Ligand B (-6.3) has a slightly better binding affinity than Ligand A (-6.0). However, the difference is small.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity) and the general guidelines, Ligand A is the more promising candidate. While Ligand B has a slightly better logP and binding affinity, Ligand A excels in crucial areas like TPSA, DILI risk, and metabolic stability (Cl_mic). The lower DILI risk and better TPSA are particularly important for a cardiovascular drug, where safety and absorption are paramount. The slightly longer half-life of Ligand B is a minor advantage that is outweighed by the other factors.
Output:
1
2025-04-17 20:17:49,317 - INFO - Batch 174 complete. Total preferences: 2784
2025-04-17 20:17:49,317 - INFO - Processing batch 175/512...
2025-04-17 20:18:39,615 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.391 and 352.385 Da) fall comfortably within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (78.09) is significantly better than Ligand A (119.67). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (1.412) is within the optimal 1-3 range, while Ligand A (-0.394) is slightly below 1. This is a significant advantage for Ligand B, as a slightly negative logP can hinder permeability.
4. **HBD:** Both ligands have 2 HBD, which is acceptable.
5. **HBA:** Ligand B (3) has fewer HBA than Ligand A (7). This favors Ligand B, as excessive HBA can reduce permeability.
6. **QED:** Ligand B (0.813) has a better QED score than Ligand A (0.643), indicating a more drug-like profile.
7. **DILI:** Ligand B (39.201) has a much lower DILI risk than Ligand A (72.043). This is a crucial advantage, as minimizing liver toxicity is critical.
8. **BBB:** Both ligands have reasonable BBB penetration (Ligand A: 63.901, Ligand B: 71.772), but this isn't a primary concern for a cardiovascular target.
9. **Caco-2:** Both ligands have similar, poor Caco-2 permeability (-5.255 and -5.096).
10. **Solubility:** Both ligands have poor aqueous solubility (-1.978 and -2.525).
11. **hERG:** Ligand B (0.421) has a lower hERG risk than Ligand A (0.106). This is a significant advantage for safety.
12. **Cl_mic:** Ligand B (-10.904) has a much lower (better) microsomal clearance than Ligand A (8.064), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-7.804) has a longer in vitro half-life than Ligand A (5.556), which is desirable.
14. **Pgp:** Ligand B (0.035) has a lower Pgp efflux liability than Ligand A (0.004), suggesting better bioavailability.
15. **Binding Affinity:** Ligand A (-7.7) has a slightly better binding affinity than Ligand B (-6.2). However, the difference is less than 1.5 kcal/mol, and is outweighed by the other factors.
**Overall Assessment:**
Ligand B consistently outperforms Ligand A across most critical ADME-Tox properties. It has a better logP, TPSA, QED, DILI risk, hERG risk, metabolic stability, half-life, and Pgp efflux. While Ligand A has a slightly better binding affinity, the improvements in other parameters for Ligand B are more important for overall drug development success. Considering ADRB2 is a cardiovascular target, the focus is less on BBB and more on balancing ADME properties for oral bioavailability and safety.
Output:
0
2025-04-17 20:18:39,616 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (348.487) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (62.55) is significantly better than Ligand B (110.17). ADRB2 is a cardiovascular target, so CNS penetration isn't crucial, but lower TPSA generally improves absorption.
3. **logP:** Both have acceptable logP values (A: 3.553, B: 2.63), falling within the 1-3 range. Ligand A is slightly higher, potentially leading to some off-target interactions, but not drastically so.
4. **HBD/HBA:** Ligand A (HBD=1, HBA=3) is preferable to Ligand B (HBD=2, HBA=8). Lower HBD/HBA generally improves permeability.
5. **QED:** Both ligands have similar QED values (A: 0.781, B: 0.72), indicating good drug-likeness.
6. **DILI:** Ligand A (29.818) has a much lower DILI risk than Ligand B (93.68). This is a significant advantage for Ligand A.
7. **BBB:** Both have reasonable BBB penetration, but Ligand A (73.827) is better than Ligand B (68.864). While not a primary concern for a cardiovascular target, it's still a positive.
8. **Caco-2:** Ligand A (-4.333) is better than Ligand B (-5.018), indicating better intestinal absorption.
9. **Solubility:** Ligand A (-3.16) is better than Ligand B (-4.497), indicating better aqueous solubility.
10. **hERG:** Both ligands have low hERG inhibition liability (A: 0.532, B: 0.618).
11. **Cl_mic:** Ligand A (75.151) has higher microsomal clearance than Ligand B (21.526), suggesting lower metabolic stability. This is a drawback for Ligand A.
12. **t1/2:** Ligand A (67.544) has a longer in vitro half-life than Ligand B (16.828). This is a significant advantage for Ligand A.
13. **Pgp:** Ligand A (0.298) has lower P-gp efflux than Ligand B (0.147), which is favorable.
14. **Binding Affinity:** Ligand B (-7.4) has significantly stronger binding affinity than Ligand A (-3.8). This is a major advantage for Ligand B.
**GPCR-specific priorities:** For ADRB2 (a GPCR), affinity, logP, TPSA, and Pgp are key. Ligand B excels in affinity. Ligand A is better in TPSA and Pgp, and has a better DILI score. However, the substantial difference in binding affinity (-7.4 vs -3.8 kcal/mol) is a decisive factor. A 3.6 kcal/mol difference in binding is substantial and can often outweigh other ADME concerns, especially given that Ligand A's metabolic stability (Cl_mic) is worse.
**Conclusion:**
Despite Ligand A's better ADME properties in several areas (DILI, solubility, TPSA, Pgp), the significantly stronger binding affinity of Ligand B makes it the more promising drug candidate. The potency advantage is likely to be more impactful than the ADME drawbacks, which can potentially be addressed through further optimization.
Output:
0
2025-04-17 20:18:39,616 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [341.451, 47.56, 4.013, 1, 3, 0.823, 37.728, 81.039, -4.855, -4.632, 0.702, 83.041, 10.803, 0.729, -6.6]
**Ligand B:** [343.358, 75.48, 3.217, 1, 4, 0.686, 80.729, 77.898, -4.727, -4.7, 0.805, 47.249, 43.594, 0.42, -9.4]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). A: 341.451, B: 343.358 - Similar.
2. **TPSA:** A (47.56) is excellent, well below 90, suggesting good permeability. B (75.48) is still reasonable, but higher.
3. **logP:** Both are within the optimal range (1-3). A: 4.013 is slightly higher than ideal, but acceptable. B: 3.217 is very good.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** A has 3, B has 4. Both are acceptable.
6. **QED:** A (0.823) is excellent, indicating high drug-likeness. B (0.686) is still acceptable, but lower.
7. **DILI:** A (37.728) has a significantly lower DILI risk than B (80.729). This is a major advantage for A.
8. **BBB:** A (81.039) has better BBB penetration than B (77.898). While not a primary concern for ADRB2 (cardiovascular target), it's a positive.
9. **Caco-2:** Both are negative, indicating poor permeability. This is a concern for both.
10. **Solubility:** Both are negative, indicating poor solubility. This is a concern for both.
11. **hERG:** A (0.702) has a lower hERG risk than B (0.805). This is a positive for A.
12. **Cl_mic:** A (83.041) has a higher microsomal clearance than B (47.249), meaning faster metabolism and potentially lower exposure. This is a negative for A.
13. **t1/2:** B (43.594) has a significantly longer in vitro half-life than A (10.803). This is a major advantage for B.
14. **Pgp:** A (0.729) has lower P-gp efflux than B (0.42). This is a positive for A.
15. **Binding Affinity:** B (-9.4) has a significantly stronger binding affinity than A (-6.6). This is a substantial advantage for B (a difference of 2.8 kcal/mol).
**GPCR-Specific Priorities:** For ADRB2, logP, TPSA, Pgp, and affinity are important. B has a better logP, and a *much* better affinity. A has better TPSA and Pgp.
**Overall Assessment:**
The biggest differentiator is the binding affinity. B's -9.4 kcal/mol is significantly better than A's -6.6 kcal/mol. This difference is large enough to outweigh the advantages A has in TPSA, Pgp, DILI, and hERG. While A has a better QED score, the improved metabolic stability (longer half-life) and superior affinity of B are more crucial for a successful drug candidate. The DILI risk for B is higher, but not prohibitively so, and could be addressed with further optimization. The poor Caco-2 and solubility are shared concerns that would need to be addressed regardless of which lead is chosen.
Therefore, I recommend Ligand B.
0
2025-04-17 20:18:39,616 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.46 & 352.43 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (53.09) is significantly better than Ligand B (93.73). ADRB2 is a cardiovascular target, not CNS, but lower TPSA generally aids absorption. Ligand A is well below the 140 threshold, while B is approaching it.
3. **logP:** Ligand B (0.941) is slightly better than Ligand A (0.426). Both are within the acceptable range (1-3), but closer to the lower end.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is preferable to Ligand B (5). Similar reasoning to HBD.
6. **QED:** Ligand A (0.692) is significantly better than Ligand B (0.451). A higher QED indicates better overall drug-likeness.
7. **DILI:** Ligand A (13.96) is *much* better than Ligand B (31.29). This is a crucial difference. Lower DILI is highly desirable.
8. **BBB:** Not a primary concern for a cardiovascular target. Ligand A (57.15) is slightly better than Ligand B (47.15).
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-4.568) is slightly better than Ligand B (-4.777), but both are poor.
10. **Solubility:** Both are negative, indicating poor solubility. Ligand A (-1.56) is slightly better than Ligand B (-2.486).
11. **hERG:** Ligand A (0.254) is significantly better than Ligand B (0.071). Lower hERG inhibition is crucial for avoiding cardiotoxicity.
12. **Cl_mic:** Ligand A (12.275) is significantly better than Ligand B (63.389). Lower clearance indicates better metabolic stability.
13. **t1/2:** Ligand B (-23.149) is significantly better than Ligand A (6.088). A longer half-life is generally preferred.
14. **Pgp:** Ligand A (0.018) is significantly better than Ligand B (0.03). Lower P-gp efflux is preferable.
15. **Binding Affinity:** Ligand B (-6.4) is slightly better than Ligand A (-5.9). A 1.5 kcal/mol difference is significant, but not overwhelming considering the other factors.
**Overall Assessment:**
Ligand A is significantly better across several critical ADMET properties (DILI, hERG, Cl_mic, QED, TPSA, HBD/HBA). While Ligand B has a slightly better binding affinity and half-life, the superior safety profile and drug-likeness of Ligand A outweigh these benefits. The poor Caco-2 and solubility of both ligands are concerning and would need to be addressed in further optimization, but these are more readily improved than mitigating high DILI or hERG risk.
**Output:**
1
2025-04-17 20:18:39,616 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [344.375, 123.84 , -0.155, 3. , 5. , 0.644, 61.109, 36.487, -5.38 , -2.647, 0.036, -0.702, -24.374, 0.005, -5.2 ]
**Ligand B:** [356.373, 107.11 , 1.106, 4. , 4. , 0.612, 55.68 , 61.962, -5.262, -3.141, 0.327, 0.568, -11.078, 0.042, -7.1 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (344.375) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (123.84) is slightly higher than Ligand B (107.11) but still within the acceptable range for oral absorption (<140). Ligand B is better here.
3. **logP:** Ligand A (-0.155) is quite low, potentially hindering membrane permeability. Ligand B (1.106) is much better, falling within the optimal 1-3 range. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (3) and Ligand B (4) are both acceptable.
5. **HBA:** Ligand A (5) and Ligand B (4) are both acceptable.
6. **QED:** Both ligands have similar QED values (0.644 and 0.612), indicating good drug-like properties.
7. **DILI:** Ligand A (61.109) has a slightly higher DILI risk than Ligand B (55.68), but both are reasonably acceptable.
8. **BBB:** Ligand B (61.962) shows better BBB penetration than Ligand A (36.487). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be beneficial, and lower BBB penetration isn't necessarily a dealbreaker.
9. **Caco-2:** Both have negative values, which is unusual. Assuming these are logP-scaled values, lower values indicate poorer permeability. They are very similar.
10. **Solubility:** Ligand A (-2.647) has slightly better solubility than Ligand B (-3.141).
11. **hERG:** Ligand A (0.036) has a slightly lower hERG risk than Ligand B (0.327), which is preferable.
12. **Cl_mic:** Ligand A (-0.702) has a lower (better) microsomal clearance than Ligand B (0.568), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-24.374) has a longer in vitro half-life than Ligand B (-11.078). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.005) has much lower P-gp efflux liability than Ligand B (0.042), which is favorable for bioavailability.
15. **Affinity:** Ligand B (-7.1) has a significantly stronger binding affinity than Ligand A (-5.2). This is a substantial advantage, potentially outweighing some ADME drawbacks.
**GPCR-Specific Priorities:** For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are crucial. Ligand B excels in logP and significantly in affinity. Ligand A has better Pgp and slightly better metabolic stability (Cl_mic, t1/2).
**Overall Assessment:**
The stronger binding affinity of Ligand B (-7.1 kcal/mol vs -5.2 kcal/mol) is a major advantage. While Ligand A has some favorable ADME properties (lower Pgp, better metabolic stability), the difference in affinity is substantial enough to likely overcome the slightly less optimal logP and BBB values of Ligand B. The improved logP of Ligand B also suggests better permeability.
Therefore, I would choose Ligand B.
Output:
0
2025-04-17 20:18:39,616 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (369.49 and 349.48 Da). No significant difference here.
2. **TPSA:** Ligand A (87.74) is slightly higher than Ligand B (70.67). Ligand B is preferable as it's closer to the <140 target for good absorption.
3. **logP:** Ligand A (0.499) is quite low, potentially hindering permeability. Ligand B (1.89) is much better, falling within the optimal 1-3 range. This is a significant advantage for Ligand B.
4. **HBD:** Both have 2 HBD, which is acceptable.
5. **HBA:** Ligand A has 5 HBA, Ligand B has 4. Both are within the acceptable range of <=10.
6. **QED:** Both have good QED scores (0.684 and 0.761), indicating drug-likeness.
7. **DILI:** Ligand A (45.37) has a higher DILI risk than Ligand B (13.18). This is a clear advantage for Ligand B.
8. **BBB:** Ligand B (71.38) has a significantly higher BBB percentile than Ligand A (40.40). While ADRB2 isn't necessarily a CNS target, higher BBB is generally favorable, reducing potential off-target effects.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. However, Ligand B (-4.863) is slightly better than Ligand A (-5.255).
10. **Solubility:** Both have negative solubility values, indicating poor solubility. Ligand A (-1.776) is slightly better than Ligand B (-2.283).
11. **hERG:** Ligand A (0.313) has a lower hERG risk than Ligand B (0.619), which is preferable.
12. **Cl_mic:** Ligand B (20.28) has a lower microsomal clearance than Ligand A (24.41), suggesting better metabolic stability.
13. **t1/2:** Ligand B (18.33) has a longer in vitro half-life than Ligand A (-21.61). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.033) has a lower Pgp efflux liability than Ligand B (0.04). This is a slight advantage for Ligand A.
15. **Binding Affinity:** Ligand B (-7.7 kcal/mol) has a slightly better binding affinity than Ligand A (-7.2 kcal/mol). While the difference is not huge, it is still a positive for Ligand B.
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP, has a better TPSA, comparable Pgp, and slightly better affinity. The lower DILI and improved metabolic stability (lower Cl_mic and longer t1/2) further strengthen its profile.
**Conclusion:**
Despite Ligand A having a slightly better hERG profile and Pgp efflux, Ligand B demonstrates a more balanced and favorable profile overall, particularly regarding crucial parameters like logP, DILI, metabolic stability, and binding affinity.
Output:
0
2025-04-17 20:18:39,616 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (410.539 Da) is within the ideal range (200-500 Da). Ligand B (347.459 Da) is also within range, and slightly preferred due to being closer to the lower bound, which can aid permeability.
2. **TPSA:** Ligand A (120.85) is borderline, but acceptable for a non-CNS GPCR. Ligand B (64.09) is excellent, well below the 140 threshold, and suggests good absorption. This favors Ligand B.
3. **logP:** Ligand A (0.058) is quite low, potentially hindering permeability. Ligand B (0.16) is also low, but slightly better. Both are suboptimal, but Ligand B is marginally better.
4. **HBD:** Ligand A (2) is good. Ligand B (1) is excellent. This favors Ligand B.
5. **HBA:** Ligand A (7) is good. Ligand B (4) is excellent. This favors Ligand B.
6. **QED:** Both Ligand A (0.625) and Ligand B (0.72) are good, exceeding the 0.5 threshold. Ligand B is slightly better.
7. **DILI:** Ligand A (80.845) has a concerningly high DILI risk. Ligand B (13.843) has a very low DILI risk. This is a major advantage for Ligand B.
8. **BBB:** Both are low, which is fine for a cardiovascular target. Ligand A (25.359) and Ligand B (44.94) are not particularly relevant here.
9. **Caco-2:** Ligand A (-5.675) is poor. Ligand B (-4.701) is also poor, but slightly better.
10. **Solubility:** Ligand A (-2.488) is poor. Ligand B (-0.647) is also poor, but better.
11. **hERG:** Both Ligand A (0.34) and Ligand B (0.27) have low hERG risk, which is good.
12. **Cl_mic:** Ligand A (-4.316) has better metabolic stability (lower clearance) than Ligand B (-5.562). This favors Ligand A.
13. **t1/2:** Ligand A (48.911) has a much longer half-life than Ligand B (-8.495). This is a significant advantage for Ligand A.
14. **Pgp:** Both Ligand A (0.079) and Ligand B (0.066) have low Pgp efflux, which is good.
15. **Affinity:** Ligand A (-6.2 kcal/mol) has slightly better binding affinity than Ligand B (-5.6 kcal/mol).
**GPCR-specific considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in TPSA, HBD, HBA, QED, and significantly in DILI risk. Ligand A has a slight edge in affinity and a much better half-life and metabolic stability. The low logP for both is a concern, but the substantial DILI risk associated with Ligand A is a major drawback. The improved half-life of Ligand A is valuable, but can potentially be addressed through prodrug strategies. The DILI risk is harder to mitigate.
**Overall Assessment:**
Despite Ligand A's better affinity and half-life, the significantly lower DILI risk of Ligand B, coupled with its superior TPSA, HBD, HBA, and QED scores, makes it the more promising candidate. The affinity difference is not large enough to overcome the safety concerns associated with Ligand A.
Output:
0
2025-04-17 20:18:39,616 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (352.36 and 382.81 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (40.85) is better than Ligand B (58.64). ADRB2 is not a CNS target, but lower TPSA generally favors absorption.
3. **logP:** Both ligands (2.53 and 2.222) are within the optimal 1-3 range. Ligand B is slightly lower, which could marginally impact permeability.
4. **HBD:** Ligand A (0) is preferable to Ligand B (1). Fewer HBDs generally improve membrane permeability.
5. **HBA:** Ligand A (4) is preferable to Ligand B (3). Lower HBA is generally better for permeability.
6. **QED:** Ligand A (0.834) is slightly better than Ligand B (0.758), indicating a more drug-like profile.
7. **DILI:** Ligand B (25.436) is significantly better than Ligand A (46.336). This is a major advantage for Ligand B. Lower DILI risk is crucial.
8. **BBB:** Not a primary concern for ADRB2 (cardiovascular target). Ligand A (97.518) is higher than Ligand B (85.459), but this is less important.
9. **Caco-2:** Both are negative values, indicating poor permeability. Ligand A (-4.343) is slightly better than Ligand B (-4.809), but both are concerning.
10. **Solubility:** Both are negative values, indicating poor solubility. Ligand A (-2.822) is slightly better than Ligand B (-3.35).
11. **hERG:** Ligand A (0.835) is better than Ligand B (0.602). Lower hERG inhibition is desirable.
12. **Cl_mic:** Ligand A (9.451) is significantly better than Ligand B (15.968), indicating better metabolic stability.
13. **t1/2:** Ligand A (-27.061) is significantly better than Ligand B (2.625), indicating a much longer half-life.
14. **Pgp:** Ligand A (0.47) is better than Ligand B (0.142). Lower P-gp efflux is preferable.
15. **Affinity:** Ligand B (-8.9 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.4 kcal/mol). This is a substantial advantage, potentially outweighing some ADME concerns.
**GPCR-specific priorities:** For ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B has a slightly lower logP, but a *much* better affinity. Ligand A has better TPSA and Pgp. The DILI risk for Ligand B is also significantly lower.
**Overall Assessment:**
While Ligand A has better ADME properties in several areas (Cl_mic, t1/2, HBD, HBA, QED, hERG), the substantially stronger binding affinity of Ligand B (-8.9 vs -6.4 kcal/mol) and significantly lower DILI risk are decisive. A strong affinity can often be optimized through further structural modifications, and mitigating DILI risk is paramount. The Caco-2 and solubility issues are concerning for both, but can be addressed with formulation strategies.
Output:
0
2025-04-17 20:18:39,616 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's systematically compare Ligand A and Ligand B against the provided guidelines, keeping in mind the GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key).
1. **MW:** Both ligands (362.8 and 354.5 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (78.3) is significantly better than Ligand B (113.8). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (1.65) is better than Ligand B (0.24). Ligand B is quite low, potentially hindering membrane permeability. A logP between 1-3 is optimal, and A is closer to this.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (6) is better than Ligand B (4). Similar to HBD, lower HBA is generally favored.
6. **QED:** Ligand A (0.875) is significantly better than Ligand B (0.614), indicating a more drug-like profile.
7. **DILI:** Ligand A (75.2) is worse than Ligand B (31.5). This is a significant concern for Ligand A, as it suggests a higher risk of liver injury.
8. **BBB:** Both are similar (77.8 and 76.7), and since this is a cardiovascular target, this isn't a major deciding factor.
9. **Caco-2:** Both are negative, indicating poor permeability. This is a concern for both, but the lower TPSA and logP of Ligand A might mitigate this somewhat.
10. **Solubility:** Ligand A (-2.83) is worse than Ligand B (-1.61). Solubility is a concern for both, but Ligand B is slightly better.
11. **hERG:** Both are very low (0.078 and 0.128), indicating a very low risk of hERG inhibition, which is excellent.
12. **Cl_mic:** Ligand A (26.8) is slightly better than Ligand B (29.8), suggesting slightly better metabolic stability.
13. **t1/2:** Ligand A (26.2) is significantly better than Ligand B (3.1). A longer half-life is generally desirable.
14. **Pgp:** Both are very low (0.17 and 0.005), indicating low P-gp efflux.
15. **Affinity:** Ligand A (-7.2) is significantly better than Ligand B (-6.5). A 0.7 kcal/mol difference in binding affinity is substantial and can often outweigh minor ADME drawbacks.
**Overall Assessment:**
Ligand A has a significantly better binding affinity, QED, half-life, and slightly better metabolic stability. It also has more favorable TPSA, logP, HBD, and HBA values. However, its DILI risk is considerably higher. Ligand B has a better DILI profile and slightly better solubility, but is significantly weaker in terms of binding affinity and has a less favorable drug-like profile (lower QED).
Given the importance of potency for GPCRs, the substantial affinity advantage of Ligand A is a major driver. While the DILI risk is concerning, it's a parameter that can potentially be addressed through structural modifications in subsequent optimization rounds. The other ADME properties of Ligand A are generally more favorable, and the affinity difference is large enough to make it the preferred starting point.
**Output:**
1
2025-04-17 20:18:39,617 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (377.897 and 362.455 Da) are within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (59.23) is significantly better than Ligand B (76.46). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (3.912) is optimal, while Ligand B (0.186) is quite low. Low logP can hinder membrane permeability and bioavailability. This is a significant advantage for Ligand A.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 5 HBA, and Ligand B has 6. Both are acceptable, but lower is generally preferred.
6. **QED:** Both ligands have similar QED values (0.824 and 0.827), indicating good drug-likeness.
7. **DILI:** Ligand A (66.615) has a higher DILI risk than Ligand B (49.593). This favors Ligand B.
8. **BBB:** Not a primary concern for a cardiovascular target. Ligand A (74.176) is higher than Ligand B (56.495), but this isn't a deciding factor.
9. **Caco-2:** Ligand A (-4.969) and Ligand B (-5.183) are similar, indicating poor permeability.
10. **Solubility:** Ligand A (-4.352) is slightly worse than Ligand B (-2.277). Solubility is important, so this favors Ligand B.
11. **hERG:** Ligand A (0.265) has a slightly better hERG profile than Ligand B (0.036), meaning lower risk of cardiotoxicity. This is a small advantage for Ligand A.
12. **Cl_mic:** Ligand B (26.499) has a lower microsomal clearance than Ligand A (34.741), suggesting better metabolic stability. This favors Ligand B.
13. **t1/2:** Both have similar in vitro half-lives (15.876 and 16.382 hours).
14. **Pgp:** Ligand A (0.637) has higher Pgp efflux than Ligand B (0.015). Lower Pgp efflux is preferred for better bioavailability, favoring Ligand B.
15. **Binding Affinity:** Ligand A (-8.0) has a significantly stronger binding affinity than Ligand B (-6.6). A 1.4 kcal/mol difference is substantial and can often outweigh minor ADME concerns.
**Overall Assessment:**
Ligand A has a much stronger binding affinity, a good logP, and a slightly better hERG profile. However, it has a higher DILI risk, worse solubility, and higher Pgp efflux. Ligand B has better DILI, solubility, Pgp, and metabolic stability, but significantly weaker binding affinity and a poor logP.
Given that we're dealing with a GPCR, binding affinity is paramount. The 1.4 kcal/mol difference is substantial. While the ADME properties of Ligand A aren't ideal, they are not catastrophic, and optimization could potentially address the DILI and solubility issues. The poor logP of Ligand B is a more difficult property to improve significantly without impacting affinity.
Therefore, I believe Ligand A is the more promising starting point for drug development.
Output:
1
2025-04-17 20:18:39,617 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (387.351 Da) is within the ideal range (200-500 Da). Ligand B (354.411 Da) is also within range. No clear advantage here.
2. **TPSA:** Ligand A (50.36) is good, well below the 140 threshold. Ligand B (118.45) is higher, but still potentially acceptable. Ligand A is preferred.
3. **logP:** Ligand A (4.593) is slightly high, potentially leading to solubility issues or off-target effects. Ligand B (-1.263) is quite low, which could hinder permeability. This is a significant drawback for Ligand B.
4. **HBD:** Both ligands have 2 HBD, which is within the acceptable limit of 5.
5. **HBA:** Ligand A has 2 HBA, while Ligand B has 8. Ligand A is preferred as it is closer to the ideal value of 10.
6. **QED:** Ligand A (0.776) has a better QED score than Ligand B (0.559), indicating a more drug-like profile.
7. **DILI:** Ligand A (30.671) has a lower DILI risk than Ligand B (46.84). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (87.864) has a much higher BBB penetration percentile than Ligand B (27.918). As ADRB2 is a GPCR, BBB penetration is a relevant consideration, favoring Ligand A.
9. **Caco-2:** Ligand A (-4.353) and Ligand B (-5.521) both have negative values, which is unusual and suggests low permeability.
10. **Solubility:** Ligand A (-5.466) has slightly better solubility than Ligand B (-0.609).
11. **hERG:** Ligand A (0.652) has a lower hERG inhibition liability than Ligand B (0.02). This is a crucial advantage for Ligand A, reducing the risk of cardiotoxicity.
12. **Cl_mic:** Ligand A (59.366) has a higher microsomal clearance than Ligand B (40.603), meaning it's metabolized faster. Ligand B is preferred here.
13. **t1/2:** Ligand A (58.41) has a longer in vitro half-life than Ligand B (-13.626). This is a strong advantage for Ligand A.
14. **Pgp:** Ligand A (0.118) has lower P-gp efflux liability than Ligand B (0.002). This is a significant advantage for Ligand A.
15. **Binding Affinity:** Ligand B (-8.0) has a significantly stronger binding affinity than Ligand A (-7.3). This is a substantial advantage for Ligand B.
**Overall Assessment:**
Ligand B has a significantly better binding affinity, which is a major plus. However, it suffers from a very low logP, potentially hindering permeability, and a higher DILI risk. Ligand A, while having a slightly lower affinity, demonstrates a much more balanced profile with better TPSA, QED, DILI, BBB, hERG, Pgp, and half-life. Given the GPCR target class, the combination of good BBB penetration, acceptable logP, and lower toxicity risks makes Ligand A the more promising candidate, despite the slightly weaker binding. The affinity difference of 0.7 kcal/mol, while noticeable, is not enough to overcome the ADME/Tox advantages of Ligand A.
Output:
1
2025-04-17 20:18:39,617 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (351.447 and 352.41 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (83.8) is slightly higher than Ligand B (76.46). Both are below the 140 threshold for oral absorption, but closer to the 90 threshold for CNS targets. Given ADRB2 is a cardiovascular target, CNS penetration is not a priority, so this is not a major differentiator.
3. **logP:** Both ligands have similar logP values (0.629 and 0.614). These are a little low, potentially impacting permeability, but not drastically.
4. **HBD:** Ligand A has 2 HBD, while Ligand B has 1. Lower is generally better for permeability, giving a slight edge to Ligand B.
5. **HBA:** Both ligands have 5 HBA, which is within the acceptable range.
6. **QED:** Ligand B (0.814) has a higher QED score than Ligand A (0.719), indicating a more drug-like profile. This is a positive for Ligand B.
7. **DILI:** Ligand B (41.566) has a significantly lower DILI risk than Ligand A (20.24). This is a crucial advantage for Ligand B.
8. **BBB:** Ligand B (94.184) has a much higher BBB penetration percentile than Ligand A (48.119). While not a primary concern for a cardiovascular target, higher BBB is rarely detrimental.
9. **Caco-2:** Both ligands have similar, very negative Caco-2 values (-4.614 and -4.66). This indicates poor permeability, which is a concern for both.
10. **Solubility:** Ligand A (-1.436) has slightly better solubility than Ligand B (-2.21), but both are quite poor.
11. **hERG:** Ligand A (0.091) has a slightly lower hERG risk than Ligand B (0.537), which is a positive.
12. **Cl_mic:** Ligand B (5.082) has a lower microsomal clearance than Ligand A (13.12), suggesting better metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand B (16.227) has a longer in vitro half-life than Ligand A (8.766), which is desirable.
14. **Pgp:** Ligand A (0.061) has lower P-gp efflux liability than Ligand B (0.128), which is a slight advantage.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.3 and -6.1 kcal/mol). The difference is negligible.
**GPCR-Specific Priorities & Overall Assessment:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Both ligands are similar in logP and affinity. Ligand B has a slight edge in TPSA and Pgp. However, the significant advantages of Ligand B in DILI risk, metabolic stability (Cl_mic), and in vitro half-life outweigh the slight advantage of Ligand A in Pgp and hERG. The poor Caco-2 values are a concern for both, but can potentially be addressed through formulation strategies.
**Output:**
0
2025-04-17 20:18:39,617 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (373.469 and 353.438 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (71.09) is slightly higher than Ligand B (56.59). Both are below the 140 threshold for oral absorption, but Ligand B is better positioned for potential CNS penetration if desired (though ADRB2 isn't primarily a CNS target).
3. **logP:** Ligand A (3.157) is within the optimal 1-3 range. Ligand B (1.65) is at the lower end, potentially impacting permeability.
4. **HBD:** Ligand A has 2 HBD, while Ligand B has 0. Both are acceptable.
5. **HBA:** Ligand A has 4 HBA, Ligand B has 5. Both are within the acceptable limit of 10.
6. **QED:** Both ligands have similar QED values (0.688 and 0.6), indicating good drug-likeness.
7. **DILI:** Ligand A (40.403) has a slightly higher DILI risk than Ligand B (11.632). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (72.664) and Ligand B (97.247) both have good BBB penetration, but Ligand B is significantly better. While ADRB2 isn't a primary CNS target, higher BBB penetration is generally favorable.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.838) is slightly worse than Ligand B (-4.43).
10. **Solubility:** Ligand A (-3.082) has slightly better solubility than Ligand B (-1.257), but both are poor.
11. **hERG:** Ligand A (0.368) has a lower hERG risk than Ligand B (0.698), which is a positive.
12. **Cl_mic:** Ligand A (44.106) has lower microsomal clearance than Ligand B (53.442), suggesting better metabolic stability.
13. **t1/2:** Ligand B (22.753) has a significantly longer in vitro half-life than Ligand A (7.791). This is a major advantage for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.119) has lower P-gp efflux than Ligand B (0.185), which is favorable.
15. **Binding Affinity:** Ligand A (-6.5 kcal/mol) has a slightly better binding affinity than Ligand B (-5.4 kcal/mol). This is a 1.1 kcal/mol difference, which is substantial.
**GPCR-Specific Priorities & Overall Assessment:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A has a better logP and Pgp profile, and a significantly better binding affinity. However, Ligand B excels in DILI risk, BBB penetration, and *especially* in vitro half-life. The longer half-life of Ligand B is a major advantage, potentially outweighing the slightly weaker binding. The lower DILI risk is also very important. While the Caco-2 values are concerning for both, the affinity difference is significant.
Considering the balance, the improved metabolic stability (longer half-life) and significantly reduced DILI risk of Ligand B are more valuable than the slightly stronger binding of Ligand A, especially given the relatively good affinity of Ligand B.
Output:
0
2025-04-17 20:18:39,617 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
The ADRB2 receptor is a GPCR, so the priorities are logP, TPSA, Pgp, BBB, and affinity. Let's break down each ligand against these and other important parameters:
* **Molecular Weight:** Both ligands are within the ideal 200-500 Da range.
* **TPSA:** Ligand A (61.44) is significantly better than Ligand B (93.96). Lower TPSA generally correlates with better cell permeability, crucial for GPCR targeting. Ligand B is approaching a level that could hinder oral absorption.
* **logP:** Ligand A (2.844) is optimal, while Ligand B (0.603) is quite low. A logP below 1 can lead to poor membrane permeability. This is a significant drawback for Ligand B.
* **H-Bond Donors/Acceptors:** Both have reasonable HBD (2) and HBA (3 for A, 7 for B) values, not raising major concerns.
* **QED:** Both are similar and acceptable (0.693 and 0.656).
* **DILI:** Ligand A (5.584) has a much lower DILI risk than Ligand B (49.632). This is a substantial advantage for Ligand A.
* **BBB:** Ligand A (71.966) has good BBB penetration, while Ligand B (90.112) is also good but not as high as A. While ADRB2 isn't necessarily a CNS target, some peripheral distribution is still desired, and higher BBB penetration can sometimes correlate with better overall distribution.
* **Caco-2 Permeability:** Both are negative, indicating poor permeability. However, the scale is not provided, so it's hard to interpret the absolute values.
* **Aqueous Solubility:** Both are negative, indicating poor solubility.
* **hERG:** Both ligands have low hERG inhibition risk (0.639 and 0.144).
* **Microsomal Clearance:** Ligand A (17.703) has higher clearance than Ligand B (14.182), indicating lower metabolic stability.
* **In vitro Half-Life:** Ligand B (-5.083) has a slightly longer half-life than Ligand A (-4.231).
* **P-gp Efflux:** Both have very low P-gp efflux liability (0.062 and 0.056).
* **Binding Affinity:** Ligand A (-6.9 kcal/mol) has a slightly better binding affinity than Ligand B (-6.7 kcal/mol), but the difference is small.
**Overall Assessment:**
Ligand A is the stronger candidate. Its superior logP, lower TPSA, and significantly lower DILI risk outweigh the slightly higher microsomal clearance and slightly weaker binding affinity. The combination of these factors suggests a better balance of properties for a viable drug candidate targeting ADRB2. Ligand B's low logP is a major concern, potentially hindering its ability to reach the receptor.
**Output:**
1
2025-04-17 20:18:39,617 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.415 and 352.431 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand B (88.1) is significantly better than Ligand A (102.76). ADRB2 is not a CNS target, but lower TPSA generally improves absorption.
3. **logP:** Ligand A (0.886) is slightly lower than Ligand B (-0.084), but both are within the acceptable 1-3 range. Ligand B is approaching the lower limit, which could slightly hinder permeability.
4. **HBD:** Ligand A (3) and Ligand B (2) are both good, below the 5 threshold.
5. **HBA:** Both ligands have 5 HBA, which is acceptable.
6. **QED:** Both ligands have good QED scores (0.663 and 0.722), indicating good drug-like properties.
7. **DILI:** Ligand B (15.432) has a much lower DILI risk than Ligand A (25.94). This is a significant advantage for Ligand B.
8. **BBB:** This is less critical for ADRB2 (a cardiovascular target), but Ligand B (43.273) has a higher BBB penetration than Ligand A (12.292), which isn't a negative.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-5.34) is slightly better than Ligand B (-4.967).
10. **Solubility:** Both ligands have negative solubility values, which is also unusual. Ligand A (-1.732) is slightly better than Ligand B (-1.242).
11. **hERG:** Both ligands have very low hERG inhibition risk (0.048 and 0.137), which is excellent.
12. **Cl_mic:** Ligand B (-11.428) has a much lower (better) microsomal clearance than Ligand A (1.61). This indicates better metabolic stability for Ligand B.
13. **t1/2:** Ligand B (29.271) has a significantly longer in vitro half-life than Ligand A (-21.815). This is a major advantage for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.02 and 0.008), which is good.
15. **Binding Affinity:** Ligand B (-8.0) has a significantly better binding affinity than Ligand A (-6.2). This is a substantial advantage, potentially outweighing some minor ADME drawbacks.
**Overall Assessment:**
Ligand B is clearly superior. While both ligands have acceptable MW, HBD, HBA, QED, and hERG profiles, Ligand B excels in crucial areas: significantly lower DILI risk, much better metabolic stability (lower Cl_mic, longer t1/2), and substantially stronger binding affinity. The slightly lower logP of Ligand B is a minor concern, but the benefits far outweigh this potential drawback. The negative Caco-2 and solubility values are concerning for both, but the other advantages of Ligand B make it the better candidate.
Output:
0
2025-04-17 20:18:39,617 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (345.487 and 365.43 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (52.65) is significantly better than Ligand B (82.53). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have acceptable logP values (1.788 and 2.577, respectively), falling within the 1-3 range. Ligand B is slightly higher, which *could* be a minor drawback if it impacts solubility.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves membrane permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (5). Similar reasoning to HBD.
6. **QED:** Both ligands have good QED scores (0.773 and 0.824), indicating good drug-like properties. No significant difference.
7. **DILI:** Ligand A (9.151) has a *much* lower DILI risk than Ligand B (64.831). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (83.676) has better BBB penetration than Ligand B (46.646). While not a primary concern for a cardiovascular target, it's a positive attribute.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.99 and -4.73), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-2.656) has slightly better solubility than Ligand B (-3.286).
11. **hERG:** Both ligands have low hERG risk (0.393 and 0.321). No significant difference.
12. **Cl_mic:** Ligand A (28.763) has significantly lower microsomal clearance than Ligand B (67.671), indicating better metabolic stability.
13. **t1/2:** Ligand A (15.07) has a slightly longer half-life than Ligand B (13.703).
14. **Pgp:** Both ligands have low Pgp efflux liability (0.065 and 0.115). No significant difference.
15. **Binding Affinity:** Ligand A (-6.1) has a slightly better binding affinity than Ligand B (-4.8). This is a 1.3 kcal/mol difference, which is significant enough to outweigh some of the ADME drawbacks of Ligand B.
**Overall Assessment:**
Ligand A is clearly superior. It has a much lower DILI risk, better metabolic stability (lower Cl_mic), slightly better solubility, and a slightly longer half-life. The binding affinity difference is also substantial. While both have poor Caco-2 permeability, the other advantages of Ligand A outweigh this concern. Given that this is a GPCR, the slightly better BBB penetration of Ligand A is a bonus.
Output:
1
2025-04-17 20:18:39,617 - INFO - Batch 175 complete. Total preferences: 2800
2025-04-17 20:18:39,617 - INFO - Processing batch 176/512...
2025-04-17 20:19:31,214 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [361.482, 40.54, 4.481, 1, 3, 0.79, 31.291, 56.146, -5.026, -4.491, 0.934, 113.262, -3.46, 0.617, -6]
**Ligand B:** [350.459, 60.03, 2.382, 1, 5, 0.78, 30.322, 63.784, -4.486, -2.228, 0.534, 51.979, 4.941, 0.061, -5.6]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (350.459) is slightly lower, which could be marginally better for permeability.
2. **TPSA:** Ligand A (40.54) is better than Ligand B (60.03), falling well under the 140 threshold for oral absorption. Lower TPSA is generally preferred for GPCRs.
3. **logP:** Ligand A (4.481) is a bit high, potentially leading to solubility issues and off-target interactions. Ligand B (2.382) is within the optimal range (1-3). This is a significant advantage for Ligand B.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 3 HBA, and Ligand B has 5. Both are within acceptable limits (<=10).
6. **QED:** Both are very similar (0.79 and 0.78) and indicate good drug-likeness.
7. **DILI:** Both have low DILI risk (31.291 and 30.322), which is excellent.
8. **BBB:** Ligand B (63.784) has better BBB penetration than Ligand A (56.146), though neither is exceptionally high. For a cardiovascular target, BBB isn't *critical*, but it's a positive.
9. **Caco-2:** Ligand A (-5.026) has a more negative Caco-2 value, suggesting *poorer* intestinal absorption. Ligand B (-4.486) is better, but still not great.
10. **Solubility:** Ligand B (-2.228) has better aqueous solubility than Ligand A (-4.491). This is important given Ligand A's higher logP.
11. **hERG:** Ligand A (0.934) has a slightly higher hERG risk than Ligand B (0.534), but both are reasonably low.
12. **Cl_mic:** Ligand B (51.979) has significantly lower microsomal clearance than Ligand A (113.262), indicating better metabolic stability. This is a major advantage for Ligand B.
13. **t1/2:** Ligand B (4.941) has a longer in vitro half-life than Ligand A (-3.46), which is desirable.
14. **Pgp:** Ligand A (0.617) has lower P-gp efflux than Ligand B (0.061), which is preferable.
15. **Affinity:** Both have excellent binding affinity (-6 and -5.6 kcal/mol). Ligand A is slightly better, but the difference is not huge.
**GPCR-specific priorities:** For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, and affinity. Ligand B excels in logP, TPSA, and metabolic stability (Cl_mic, t1/2), while Ligand A has a slightly better affinity and Pgp. The difference in affinity is small enough that it's outweighed by the better ADME properties of Ligand B.
**Conclusion:**
Considering the balance of properties, especially the favorable logP, solubility, metabolic stability, and half-life of Ligand B, it is the more promising drug candidate.
0
2025-04-17 20:19:31,214 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [363.483, 78.51, 1.942, 2, 4, 0.857, 54.323, 65.452, -5.143, -3.443, 0.459, 24.507, -3.371, 0.056, -7.7]
**Ligand B:** [367.499, 46.09, 3.493, 0, 5, 0.712, 75.378, 73.866, -4.965, -3.817, 0.458, 76.503, -19.816, 0.769, -7]
Here's a breakdown, prioritizing GPCR properties (logP, TPSA, Pgp, BBB, Affinity):
1. **Molecular Weight:** Both are within the ideal 200-500 Da range. A (363.483) is slightly lower, which is generally favorable.
2. **TPSA:** A (78.51) is higher than B (46.09). For a cardiovascular GPCR, TPSA isn't *as* critical as for a CNS target, but lower is still better for permeability. B is significantly better here.
3. **logP:** A (1.942) is good, within the optimal 1-3 range. B (3.493) is a bit higher, potentially edging towards solubility issues, but still acceptable.
4. **H-Bond Donors/Acceptors:** A (2/4) and B (0/5) are both reasonable.
5. **QED:** A (0.857) is better than B (0.712), indicating a more drug-like profile.
6. **DILI:** A (54.323) is significantly better than B (75.378). Lower DILI risk is crucial.
7. **BBB:** A (65.452) is decent, but B (73.866) is better. While ADRB2 isn't strictly a CNS target, some brain exposure can occur, and higher BBB is generally preferred.
8. **Caco-2:** Both are negative, indicating poor permeability, but A (-5.143) is slightly better than B (-4.965).
9. **Solubility:** Both are negative, indicating poor solubility, with A (-3.443) being slightly better than B (-3.817).
10. **hERG:** Both are very low (0.459 and 0.458) suggesting minimal hERG liability, which is excellent.
11. **Cl_mic:** A (24.507) is much lower than B (76.503), indicating better metabolic stability. This is a significant advantage.
12. **t1/2:** A (-3.371) is better than B (-19.816), indicating a longer half-life.
13. **Pgp:** A (0.056) is much lower than B (0.769), suggesting less P-gp efflux and better bioavailability.
14. **Binding Affinity:** A (-7.7) is slightly better than B (-7.0), although both are excellent. The 0.7 kcal/mol difference is noticeable.
**Overall Assessment:**
Ligand A demonstrates a superior balance of properties. While Ligand B has a lower TPSA and slightly better BBB penetration, Ligand A excels in crucial areas like DILI risk, metabolic stability (Cl_mic), half-life, P-gp efflux, and overall drug-likeness (QED). The slightly better binding affinity of A further solidifies its position. The poor Caco-2 and solubility for both are concerning, but the other advantages of A outweigh this.
Output:
1
2025-04-17 20:19:31,215 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (344.419 Da and 347.467 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Both ligands have TPSA values (87.12 and 87.97) below the 140 A^2 threshold for good oral absorption, which is good. They are also reasonably low, aligning with GPCR preferences.
**3. logP:** Ligand A (1.068) is slightly lower than Ligand B (1.876), both are within the optimal 1-3 range.
**4. H-Bond Donors & Acceptors:** Ligand A (1 HBD, 5 HBA) is preferable to Ligand B (2 HBD, 7 HBA) as it has fewer hydrogen bond donors and acceptors. This can improve membrane permeability.
**5. QED:** Ligand A (0.899) has a significantly better QED score than Ligand B (0.758), indicating a more drug-like profile.
**6. DILI Risk:** Ligand B (48.313 percentile) has a lower DILI risk than Ligand A (61.07 percentile), which is a positive attribute.
**7. BBB Penetration:** Ligand B (72.664 percentile) shows significantly better BBB penetration than Ligand A (38.658 percentile). While ADRB2 is a cardiovascular target, some CNS effects are possible with beta-blockers, and better BBB penetration could be beneficial or detrimental depending on the desired profile.
**8. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-5.21 and -5.023), which is unusual and suggests poor permeability. However, these values are on a log scale and close to zero, so it doesn't immediately disqualify either.
**9. Aqueous Solubility:** Both ligands have negative solubility values (-1.686 and -2.853), also unusual. This suggests poor aqueous solubility, which could be a formulation challenge. Ligand A is slightly better.
**10. hERG Inhibition:** Ligand A (0.18 percentile) has a much lower hERG inhibition liability than Ligand B (0.796 percentile), which is a critical advantage for cardiovascular drugs.
**11. Microsomal Clearance:** Ligand B (77.981 mL/min/kg) has a significantly higher microsomal clearance than Ligand A (21.826 mL/min/kg), indicating faster metabolism and potentially lower *in vivo* exposure.
**12. In vitro Half-Life:** Ligand B (52.299 hours) has a much longer *in vitro* half-life than Ligand A (-3.794 hours). This is a strong positive for Ligand B, potentially allowing for less frequent dosing. However, the negative value for Ligand A is concerning.
**13. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.033 and 0.133), which is good.
**14. Binding Affinity:** Both ligands have very similar binding affinities (-6.8 kcal/mol and -6.7 kcal/mol). The difference is negligible.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity) and general drug-like properties, Ligand A is the slightly better candidate. While Ligand B has better BBB penetration and *in vitro* half-life, Ligand A has a significantly better QED score, lower DILI risk, and crucially, much lower hERG inhibition liability. The negative half-life for Ligand A is a major concern, but the lower hERG risk is paramount for a cardiovascular drug. The similar binding affinities mean this isn't a deciding factor.
Output:
1
2025-04-17 20:19:31,215 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (348.418 and 359.417 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (58.64) is slightly higher than Ligand B (56.59), but both are well below the 140 threshold for good oral absorption and appropriate for a GPCR target.
3. **logP:** Both ligands have good logP values (2.334 and 1.944), falling within the optimal 1-3 range. Ligand B is slightly lower, which might slightly improve solubility.
4. **HBD:** Ligand A has 1 HBD, while Ligand B has 0. Both are acceptable.
5. **HBA:** Ligand A has 3 HBA, while Ligand B has 5. Both are within the acceptable range of <=10, but Ligand A is preferable.
6. **QED:** Ligand A (0.823) has a significantly better QED score than Ligand B (0.633), indicating a more drug-like profile.
7. **DILI:** Ligand B (23.691) has a much lower DILI risk than Ligand A (33.618), a significant advantage.
8. **BBB:** Ligand B (96.084) shows significantly better BBB penetration potential than Ligand A (72.974). While ADRB2 isn't exclusively a CNS target, some cardiovascular effects are mediated through central pathways, and better BBB penetration can be beneficial or at least not detrimental.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.616 and -4.415), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Both ligands have poor aqueous solubility (-1.957 and -1.472). This is a significant drawback for both.
11. **hERG:** Ligand A (0.508) has a slightly better hERG profile than Ligand B (0.732), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand B (44.619) has a lower microsomal clearance than Ligand A (66.513), suggesting better metabolic stability.
13. **t1/2:** Ligand B (11.004) has a longer in vitro half-life than Ligand A (6.751), which is desirable.
14. **Pgp:** Both ligands show low P-gp efflux liability (0.184 and 0.259).
15. **Binding Affinity:** Ligand A (-8.9 kcal/mol) has a substantially stronger binding affinity than Ligand B (-5.3 kcal/mol). This is a very significant advantage, potentially outweighing some of the ADME concerns. A difference of 3.6 kcal/mol is substantial.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, affinity, logP, TPSA, and Pgp are key. Ligand A excels in affinity. Ligand B has better BBB penetration and lower DILI, which are also valuable. However, the substantial difference in binding affinity is the most important factor here. While solubility and Caco-2 are concerns for both, these can be addressed with formulation strategies.
**Conclusion:**
Despite the better safety profile (lower DILI) and BBB penetration of Ligand B, the significantly stronger binding affinity of Ligand A (-8.9 vs -5.3 kcal/mol) makes it the more promising drug candidate. The potency advantage is likely to be more impactful than the ADME differences, especially given that formulation strategies can be employed to mitigate solubility issues.
Output:
1
2025-04-17 20:19:31,215 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 GPCR, followed by the final output:
**1. Molecular Weight:**
* Ligand A: 360.845 Da - Within the ideal range (200-500 Da).
* Ligand B: 334.383 Da - Also within the ideal range.
* *No clear advantage here.*
**2. TPSA:**
* Ligand A: 76.02 A2 - Good, below the 140 A2 threshold for oral absorption.
* Ligand B: 89.51 A2 - Still acceptable, but higher than Ligand A.
* *Slight advantage to Ligand A.*
**3. logP:**
* Ligand A: 2.919 - Optimal.
* Ligand B: 3.082 - Optimal.
* *No clear advantage.*
**4. H-Bond Donors:**
* Ligand A: 2 - Acceptable.
* Ligand B: 0 - Acceptable.
* *No clear advantage.*
**5. H-Bond Acceptors:**
* Ligand A: 4 - Acceptable.
* Ligand B: 7 - Acceptable.
* *No clear advantage.*
**6. QED:**
* Ligand A: 0.88 - Excellent drug-like properties.
* Ligand B: 0.731 - Good drug-like properties.
* *Advantage to Ligand A.*
**7. DILI:**
* Ligand A: 71.694 - Acceptable risk.
* Ligand B: 81.815 - Higher risk than Ligand A.
* *Advantage to Ligand A.*
**8. BBB:**
* Ligand A: 62.311 - Moderate. Not ideal for CNS, but ADRB2 is primarily cardiovascular, so less critical.
* Ligand B: 28.15 - Low.
* *Advantage to Ligand A.*
**9. Caco-2 Permeability:**
* Ligand A: -4.869 - Poor permeability.
* Ligand B: -4.821 - Poor permeability.
* *No clear advantage.*
**10. Aqueous Solubility:**
* Ligand A: -3.99 - Poor solubility.
* Ligand B: -5.306 - Very poor solubility.
* *Advantage to Ligand A.*
**11. hERG Inhibition:**
* Ligand A: 0.21 - Low risk.
* Ligand B: 0.323 - Slightly higher risk.
* *Advantage to Ligand A.*
**12. Microsomal Clearance:**
* Ligand A: 27.573 - Moderate clearance.
* Ligand B: 67.238 - High clearance.
* *Advantage to Ligand A.*
**13. In vitro Half-Life:**
* Ligand A: 38.686 - Moderate half-life.
* Ligand B: -27.033 - Very short half-life.
* *Advantage to Ligand A.*
**14. P-gp Efflux:**
* Ligand A: 0.064 - Low efflux.
* Ligand B: 0.182 - Higher efflux.
* *Advantage to Ligand A.*
**15. Binding Affinity:**
* Ligand A: -6.4 kcal/mol - Good affinity.
* Ligand B: -7.1 kcal/mol - Better affinity.
* *Advantage to Ligand B.*
**Overall Assessment:**
Ligand B has a slightly better binding affinity (-7.1 vs -6.4 kcal/mol). However, Ligand A consistently outperforms Ligand B across almost all ADME-Tox properties critical for drug development, including DILI risk, BBB penetration, solubility, metabolic stability (Cl_mic and t1/2), and P-gp efflux. While the affinity difference is noticeable, the significantly superior ADME profile of Ligand A, especially considering it's a cardiovascular target (less stringent BBB requirement), makes it the more promising drug candidate. The poor permeability and solubility of both are concerning, but Ligand A is better in both regards.
Output:
1
2025-04-17 20:19:31,215 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (346.431) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are good, below 140. Ligand B (72.88) is better, being closer to the 90 threshold for potential CNS penetration, although this isn't a primary concern for a cardiovascular target like ADRB2.
3. **logP:** Both are within the optimal range (1-3), at 0.683 and 0.652 respectively. They are on the lower end, but acceptable.
4. **HBD & HBA:** Both have 2 HBD and 5 HBA, which is good and balances solubility and permeability.
5. **QED:** Ligand A (0.742) has a better QED score than Ligand B (0.574), indicating a more drug-like profile.
6. **DILI:** Ligand B (13.61) has a significantly lower DILI risk than Ligand A (31.718), which is a major advantage.
7. **BBB:** Ligand B (63.862) has a higher BBB penetration percentile than Ligand A (51.183). While ADRB2 isn't a CNS target, some peripheral exposure can be undesirable.
8. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. Ligand B (-5.323) is slightly worse than Ligand A (-4.993).
9. **Solubility:** Both have negative solubility values, indicating poor solubility. Ligand B (-1.443) is slightly worse than Ligand A (-1.745).
10. **hERG:** Both have low hERG inhibition liability (0.184 and 0.675), which is good.
11. **Cl_mic:** Ligand B (-16.623) has a lower (better) microsomal clearance than Ligand A (-10.675), suggesting greater metabolic stability.
12. **t1/2:** Ligand B (-20.775) has a significantly longer in vitro half-life than Ligand A (-11.9), which is a substantial advantage.
13. **Pgp:** Both have low Pgp efflux liability (0.065 and 0.089), which is good.
14. **Binding Affinity:** Ligand B (-6.9 kcal/mol) has a slightly better binding affinity than Ligand A (-6.2 kcal/mol). While the difference is less than 1.5 kcal/mol, it's still a positive.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B performs better on TPSA, Cl_mic, t1/2, DILI, and affinity. While both have acceptable logP and Pgp values, the improvements in metabolic stability (Cl_mic and t1/2) and safety (DILI) for Ligand B are significant. The slightly better affinity is a bonus. The poor Caco-2 and solubility are concerning for both, but can be addressed with formulation strategies.
**Conclusion:**
Considering the balance of properties, particularly the lower DILI risk, better metabolic stability, longer half-life, and slightly improved affinity, Ligand B is the more promising drug candidate.
Output:
0
2025-04-17 20:19:31,215 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Step-by-step comparison:**
1. **MW:** Both ligands (375.441 and 378.42 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (75.44) is slightly higher than Ligand B (71.25). Both are below the 140 threshold for oral absorption, and acceptable for a peripherally acting GPCR.
3. **logP:** Both ligands have good logP values (1.735 and 1.3), falling within the 1-3 range. Ligand B is slightly lower, which could marginally improve solubility.
4. **HBD:** Both have 1 HBD, which is within the acceptable limit of 5.
5. **HBA:** Ligand A has 5 HBA, and Ligand B has 6. Both are below the limit of 10.
6. **QED:** Both ligands have good QED scores (0.749 and 0.808), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Both have low DILI risk (37.65 and 39.046), well below the 60 threshold. No significant difference.
8. **BBB:** Ligand A (73.711) and Ligand B (82.009) both have good BBB penetration, but Ligand B is better. This is a positive for GPCRs, though less critical for ADRB2 which is not a CNS target.
9. **Caco-2:** Both have negative Caco-2 values (-5.042 and -4.799), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Both have negative solubility values (-2.115 and -3.138), indicating poor aqueous solubility. Ligand B is slightly worse.
11. **hERG:** Both have very low hERG inhibition risk (0.253 and 0.217).
12. **Cl_mic:** Ligand A has a higher microsomal clearance (33.902) than Ligand B (-5.029). This suggests Ligand B is more metabolically stable, a desirable trait.
13. **t1/2:** Ligand A has a negative in vitro half-life (-42.967) and Ligand B has a negative in vitro half-life (-19.052). Both are concerning, but Ligand B is better.
14. **Pgp:** Both have low P-gp efflux liability (0.144 and 0.105).
15. **Binding Affinity:** Both have excellent binding affinity (-7.0 and -5.0 kcal/mol). Ligand A is significantly more potent.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Both ligands perform well on logP and Pgp. Affinity is a major driver, and Ligand A has a 2 kcal/mol advantage. While BBB is less critical for ADRB2, Ligand B is better. The poor Caco-2 and solubility are concerning for both, but the significantly better affinity of Ligand A outweighs these drawbacks. The improved metabolic stability of Ligand B is a plus, but the potency difference is substantial.
**Conclusion:**
Despite the shared issues with permeability and solubility, the significantly stronger binding affinity of Ligand A makes it the more promising candidate. The potency advantage is likely to be more impactful in driving efficacy than marginal improvements in other ADME properties.
Output:
1
2025-04-17 20:19:31,215 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (343.427 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are good, but Ligand B (62.3) is significantly better than Ligand A (74.69), falling well below the 140 threshold and closer to the 90 threshold desirable for GPCRs.
3. **logP:** Both are within the optimal range (1-3). Ligand B (2.854) is slightly higher, which could potentially lead to off-target interactions, but is still acceptable.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1), but both are acceptable.
5. **HBA:** Ligand A (5) is slightly higher than Ligand B (4), but both are acceptable.
6. **QED:** Both ligands have high QED scores (A: 0.869, B: 0.885), indicating good drug-like properties.
7. **DILI:** Both have acceptable DILI risk (A: 45.522, B: 49.787), both below the 60 threshold.
8. **BBB:** Ligand B (90.229) has a much higher BBB penetration score than Ligand A (66.654). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be beneficial and isn't necessarily detrimental.
9. **Caco-2:** Both have negative Caco-2 values, suggesting poor permeability. Ligand A (-4.689) is slightly better than Ligand B (-4.879).
10. **Solubility:** Both have negative solubility values, indicating poor solubility. Ligand A (-2.651) is slightly better than Ligand B (-3.612).
11. **hERG:** Both have low hERG inhibition risk (A: 0.807, B: 0.421). Ligand B is better.
12. **Cl_mic:** Ligand A (14.84) has significantly lower microsomal clearance than Ligand B (31.992), suggesting better metabolic stability. This is a strong advantage for Ligand A.
13. **t1/2:** Ligand A (15.223) has a positive in vitro half-life, while Ligand B (-24.354) has a negative one. This is a strong advantage for Ligand A.
14. **Pgp:** Both have very low Pgp efflux liability (A: 0.155, B: 0.179).
15. **Binding Affinity:** Both ligands have the same binding affinity (-7.2 kcal/mol), so this parameter doesn't differentiate them.
**GPCR-specific priorities:** For ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B excels in TPSA and BBB, while Ligand A has better metabolic stability (Cl_mic and t1/2) and slightly better Caco-2 and solubility. The difference in BBB is significant. However, the poor Caco-2 and solubility of both compounds are concerning. The improved metabolic stability of Ligand A is a significant advantage.
**Overall Assessment:**
While Ligand B has a better BBB score and TPSA, Ligand A's superior metabolic stability (lower Cl_mic, positive t1/2) and slightly better Caco-2 and solubility are more critical for overall drug development success. The similar binding affinities mean that ADME properties become the deciding factor.
Output:
1
2025-04-17 20:19:31,215 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (352.519) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (58.64) is significantly better than Ligand B (68.78). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA is still preferred for good absorption.
3. **logP:** Ligand A (3.127) is optimal, while Ligand B (-0.35) is quite low. This is a major drawback for Ligand B, potentially hindering membrane permeability and bioavailability.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A (3) is better than Ligand B (6). Higher HBA can sometimes impact permeability.
6. **QED:** Both ligands have good QED scores (A: 0.649, B: 0.775), indicating generally drug-like properties.
7. **DILI:** Ligand A (12.02) is much better than Ligand B (8.918), indicating a lower risk of drug-induced liver injury. This is a significant advantage.
8. **BBB:** Both are similar (A: 75.107, B: 75.805) and acceptable, but not crucial for a cardiovascular target.
9. **Caco-2:** Ligand A (-4.399) is better than Ligand B (-5.134), suggesting better intestinal absorption.
10. **Solubility:** Ligand A (-2.662) is better than Ligand B (-0.609), which is important for formulation and bioavailability.
11. **hERG:** Both are low (A: 0.579, B: 0.235), indicating low cardiotoxicity risk.
12. **Cl_mic:** Ligand B (-3.272) has a *much* lower (better) microsomal clearance than Ligand A (85.302). This suggests better metabolic stability for Ligand B.
13. **t1/2:** Ligand B (-16.378) has a longer in vitro half-life than Ligand A (-15.619), which is favorable.
14. **Pgp:** Ligand A (0.251) is better than Ligand B (0.004), indicating less P-glycoprotein efflux.
15. **Affinity:** Ligand A (-5.9 kcal/mol) has a slightly better binding affinity than Ligand B (-3.7 kcal/mol). This is a substantial difference, and a key factor.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A excels in logP, TPSA, and Pgp, and has a significantly better binding affinity. While Ligand B has better metabolic stability (Cl_mic and t1/2), the poor logP and lower affinity are major concerns. The affinity difference of 2.2 kcal/mol is substantial and likely outweighs the metabolic benefits of Ligand B.
**Conclusion:**
Ligand A is the more promising drug candidate due to its superior logP, TPSA, Pgp properties, lower DILI risk, better solubility, and significantly stronger binding affinity. The metabolic stability advantage of Ligand B is not enough to overcome these drawbacks.
Output:
1
2025-04-17 20:19:31,215 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [348.403, 108.46 , 1.507, 1. , 6. , 0.864, 66.382, 48.119, -4.503, -2.873, 0.317, 22.281, -26.497, 0.126, -7.8 ]
**Ligand B:** [343.431, 79.38 , 2.013, 2. , 6. , 0.871, 51.028, 88.445, -4.935, -3.664, 0.61 , 63.28 , 11.466, 0.039, -6.4 ]
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand B (343.431) is slightly lower, which is generally favorable.
2. **TPSA:** Ligand A (108.46) is higher than Ligand B (79.38). For a cardiovascular GPCR, TPSA is not a *critical* concern like it would be for a CNS target, but lower is still preferred for better absorption. Ligand B is better here.
3. **logP:** Both ligands have good logP values (1.507 and 2.013, respectively), falling within the optimal 1-3 range. Ligand B is slightly higher, which could be a minor advantage.
4. **HBD:** Ligand A has 1 HBD, while Ligand B has 2. Both are acceptable, being less than 5.
5. **HBA:** Both ligands have 6 HBAs, which is within the acceptable limit of 10.
6. **QED:** Both ligands have very similar QED values (0.864 and 0.871), indicating good drug-likeness.
7. **DILI:** Ligand A (66.382) has a higher DILI risk than Ligand B (51.028). This is a significant negative for Ligand A.
8. **BBB:** Ligand B (88.445) has a much higher BBB percentile than Ligand A (48.119). While ADRB2 isn't a primary CNS target, some brain exposure can contribute to side effects, and a lower value is preferable.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand B is slightly better (-4.935 vs -4.503).
10. **Solubility:** Ligand B (-3.664) has better solubility than Ligand A (-2.873).
11. **hERG:** Ligand A (0.317) has a lower hERG risk than Ligand B (0.61). This is a positive for Ligand A.
12. **Cl_mic:** Ligand B (63.28) has a higher microsomal clearance than Ligand A (22.281), meaning Ligand A is more metabolically stable.
13. **t1/2:** Ligand A (-26.497) has a much longer in vitro half-life than Ligand B (11.466). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand B (0.039) has lower P-gp efflux liability than Ligand A (0.126), which is beneficial.
15. **Affinity:** Ligand A (-7.8) has a significantly better binding affinity than Ligand B (-6.4). This is a substantial advantage, potentially outweighing some ADME concerns.
**Overall Assessment:**
Ligand A has a significantly better binding affinity and metabolic stability (lower Cl_mic, longer t1/2), and lower hERG risk. However, it has a higher DILI risk and lower BBB penetration. Ligand B has better TPSA, solubility, Pgp efflux, and a lower DILI risk. The difference in affinity is substantial (1.4 kcal/mol). For a cardiovascular target, metabolic stability and potency are key, and the strong affinity of Ligand A is a major advantage. The DILI risk is concerning, but could be mitigated with further structural modifications. The slightly lower BBB penetration is less critical for a peripheral target like ADRB2.
Therefore, I would choose Ligand A.
Output:
1
2025-04-17 20:19:31,216 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 drug candidates. ADRB2 is a GPCR, so we'll prioritize logP, Pgp, TPSA, and affinity, alongside general drug-like properties.
**Ligand A:**
* **MW:** 364.511 Da - Acceptable.
* **TPSA:** 67.43 - Good, well below the 140 threshold.
* **logP:** 3.668 - Excellent, within the optimal 1-3 range.
* **HBD:** 2 - Good.
* **HBA:** 4 - Good.
* **QED:** 0.42 - Marginal, could be improved, but not a dealbreaker.
* **DILI:** 48.042 - Good, low risk.
* **BBB:** 64.211 - Moderate. Not ideal for a CNS-targeting drug, but ADRB2 is primarily cardiovascular, so less crucial.
* **Caco-2:** -5.214 - Very poor permeability. A significant concern.
* **Solubility:** -3.029 - Very poor solubility. A major drawback.
* **hERG:** 0.416 - Low risk.
* **Cl_mic:** 41.412 - Moderate clearance.
* **t1/2:** 16.284 - Moderate half-life.
* **Pgp:** 0.307 - Low efflux, good.
* **Affinity:** -5.8 kcal/mol - Very good binding affinity.
**Ligand B:**
* **MW:** 358.467 Da - Acceptable.
* **TPSA:** 88.32 - Acceptable, but approaching the upper limit for good absorption.
* **logP:** 2.042 - Good, within the optimal range.
* **HBD:** 2 - Good.
* **HBA:** 4 - Good.
* **QED:** 0.828 - Excellent, highly drug-like.
* **DILI:** 58.666 - Acceptable, moderate risk.
* **BBB:** 78.247 - Good. Not critical for ADRB2, but a bonus.
* **Caco-2:** -4.873 - Poor permeability, but better than Ligand A.
* **Solubility:** -2.571 - Poor solubility, but better than Ligand A.
* **hERG:** 0.266 - Low risk.
* **Cl_mic:** 26.933 - Low clearance, good metabolic stability.
* **t1/2:** -21.197 - Very long half-life, excellent.
* **Pgp:** 0.14 - Very low efflux, excellent.
* **Affinity:** -6.3 kcal/mol - Excellent binding affinity, 0.5 kcal/mol stronger than Ligand A.
**Comparison & Decision:**
Both ligands have issues with Caco-2 permeability and solubility. However, Ligand B significantly outperforms Ligand A in these areas. More importantly, Ligand B has a superior binding affinity (-6.3 vs -5.8 kcal/mol), a much longer half-life, lower clearance, and better Pgp efflux properties. While Ligand A has a slightly lower DILI risk, the overall profile of Ligand B is far more favorable for development as a drug candidate. The improved ADME properties and binding affinity outweigh the slightly higher DILI risk.
Output:
0
2025-04-17 20:19:31,216 - INFO - Here's my reasoning and final decision:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, key properties are affinity, logP, TPSA, Pgp efflux, and to a lesser extent, BBB.
* **Molecular Weight:** Both ligands are within the ideal range (200-500 Da).
* **TPSA:** Both are reasonably low, but Ligand A (61.88) is better than Ligand B (63.91), being closer to the optimal <140 for oral absorption.
* **logP:** Ligand A (1.415) is better than Ligand B (2.757). While both are within the acceptable range, Ligand A is closer to the optimal 1-3. Higher logP can sometimes lead to off-target effects.
* **H-Bond Donors/Acceptors:** Ligand A (1 HBD, 4 HBA) is slightly better than Ligand B (0 HBD, 6 HBA) in terms of balancing solubility and permeability.
* **QED:** Both are acceptable (>0.5), with Ligand A slightly higher (0.735 vs 0.611).
* **DILI:** Ligand B (59.48) has a higher DILI risk than Ligand A (20.706), which is a significant concern.
* **BBB:** Ligand B (75.107) has better BBB penetration than Ligand A (62.156), but this is less critical for a cardiovascular target.
* **Caco-2 Permeability:** Ligand A (-4.659) has better Caco-2 permeability than Ligand B (-5.38).
* **Aqueous Solubility:** Ligand A (-1.181) has better aqueous solubility than Ligand B (-1.772).
* **hERG:** Both have low hERG inhibition risk, but Ligand A (0.1) is slightly better than Ligand B (0.363).
* **Microsomal Clearance:** Ligand B (39.747) has a lower microsomal clearance, suggesting better metabolic stability, than Ligand A (30.179).
* **In vitro Half-Life:** Ligand B (6.293) has a longer half-life than Ligand A (-19.628). This is a significant advantage.
* **P-gp Efflux:** Ligand A (0.033) has lower P-gp efflux, which is preferable for bioavailability. Ligand B (0.184) is higher.
* **Binding Affinity:** Ligand A (-7.6 kcal/mol) has a slightly better binding affinity than Ligand B (-6.8 kcal/mol). The difference is 0.8 kcal/mol, which is a meaningful advantage.
**Overall Assessment:**
Ligand A has a better balance of properties overall. It has better DILI risk, solubility, permeability, P-gp efflux, and binding affinity. While Ligand B has better metabolic stability and BBB penetration, the lower DILI risk and better affinity of Ligand A are more critical for a cardiovascular GPCR target. The slightly better affinity of Ligand A can outweigh the slightly worse metabolic stability.
**Output:**
1
2025-04-17 20:19:31,216 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (356.482 and 376.85 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (78.43) is higher than Ligand B (32.34). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B is significantly better.
3. **logP:** Ligand A (2.348) is within the optimal 1-3 range. Ligand B (4.488) is a bit high, potentially leading to solubility issues and off-target interactions. Ligand A is better.
4. **HBD:** Ligand A (3) and Ligand B (1) are both acceptable, below the threshold of 5. Ligand B is slightly better.
5. **HBA:** Ligand A (3) and Ligand B (2) are both acceptable, below the threshold of 10. Ligand B is slightly better.
6. **QED:** Ligand A (0.526) is good, above 0.5. Ligand B (0.839) is excellent. Ligand B is better.
7. **DILI:** Ligand A (8.53) has a very low DILI risk. Ligand B (21.171) is still relatively low, but higher than Ligand A. Ligand A is better.
8. **BBB:** Both have good BBB penetration, but Ligand B (89.492) is significantly higher than Ligand A (76.464). While ADRB2 isn't strictly a CNS target, some CNS penetration could be beneficial or at least not detrimental. Ligand B is better.
9. **Caco-2:** Both are negative, indicating poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand A (-2.765) is better than Ligand B (-5.059). Solubility is a concern for both, but more so for Ligand B.
11. **hERG:** Ligand A (0.465) has a lower hERG risk than Ligand B (0.877). This is a crucial safety parameter, and Ligand A is better.
12. **Cl_mic:** Ligand A (36.064) has a lower microsomal clearance, indicating better metabolic stability, than Ligand B (27.099). Ligand A is better.
13. **t1/2:** Ligand A (-11.024) has a negative half-life, which is concerning. Ligand B (4.497) has a positive half-life, indicating better *in vitro* stability. Ligand B is better.
14. **Pgp:** Ligand A (0.105) has lower P-gp efflux, which is desirable. Ligand B (0.359) is higher. Ligand A is better.
15. **Binding Affinity:** Ligand B (-7.4 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.6 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME drawbacks.
**Overall Assessment:**
Ligand B has a significantly better binding affinity, a higher QED score, better *in vitro* half-life, and higher BBB penetration. However, it has a higher logP, higher DILI risk, and poorer solubility. Ligand A has better solubility, lower DILI and hERG risk, and better metabolic stability.
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), the stronger binding affinity of Ligand B is a major advantage. The slightly higher logP and DILI risk are potentially manageable with further optimization. The lower TPSA of Ligand B is also a plus. While solubility is a concern, it's not insurmountable. The negative half-life of Ligand A is a major red flag.
Therefore, I believe Ligand B is the more promising candidate.
Output:
0
2025-04-17 20:19:31,216 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [335.403, 59.32, 4.146, 0, 4, 0.537, 60.101, 55.254, -4.431, -6.369, 0.851, 115.544, -17.357, 0.609, -6.5]
**Ligand B:** [378.881, 69.64, 2.965, 2, 4, 0.807, 47.344, 69.213, -4.768, -4.484, 0.592, 14.361, 5.717, 0.453, -7.4]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the acceptable 200-500 Da range. Ligand A (335.4) is slightly preferred due to being lower.
2. **TPSA:** Ligand A (59.32) is better than Ligand B (69.64). Both are reasonably good for a GPCR, but lower is generally better for permeability.
3. **logP:** Ligand A (4.146) is a bit high, but Ligand B (2.965) is closer to the ideal 1-3 range. This favors Ligand B.
4. **HBD/HBA:** Ligand A (0 HBD, 4 HBA) is slightly better than Ligand B (2 HBD, 4 HBA) in terms of balancing solubility and permeability.
5. **QED:** Ligand B (0.807) has a better QED score than Ligand A (0.537), indicating a more drug-like profile.
6. **DILI:** Ligand B (47.344) has a significantly lower DILI risk than Ligand A (60.101). This is a major advantage for Ligand B.
7. **BBB:** Ligand B (69.213) shows better BBB penetration than Ligand A (55.254). While ADRB2 isn't exclusively a CNS target, some cardiovascular effects are mediated by central pathways, so some BBB penetration isn't detrimental.
8. **Caco-2:** Both have negative values, which is unusual. Assuming these are log scale values, both are poor.
9. **Solubility:** Both have negative values, indicating poor solubility. Ligand B (-4.484) is slightly better than Ligand A (-6.369).
10. **hERG:** Ligand A (0.851) has a slightly higher hERG risk than Ligand B (0.592), which is preferable.
11. **Cl_mic:** Ligand B (14.361) has significantly lower microsomal clearance than Ligand A (115.544), indicating better metabolic stability.
12. **t1/2:** Ligand B (5.717) has a better in vitro half-life than Ligand A (-17.357).
13. **Pgp:** Ligand B (0.453) has lower P-gp efflux liability than Ligand A (0.609), which is favorable for bioavailability.
14. **Affinity:** Ligand B (-7.4 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.5 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME concerns.
**Overall Assessment:**
While Ligand A has a slightly lower MW and better TPSA, Ligand B excels in almost all other critical parameters. The significantly better affinity, lower DILI risk, better metabolic stability (lower Cl_mic, longer t1/2), lower P-gp efflux, and better BBB penetration make Ligand B a much more promising drug candidate for ADRB2. The slightly higher logP is a minor concern compared to the other benefits.
Output:
0
2025-04-17 20:19:31,216 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (357.296 and 349.391 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (113.83) is better than Ligand B (127.32). Both are under the 140 threshold for oral absorption, but lower TPSA is generally preferred for GPCRs.
3. **logP:** Ligand A (-0.036) is slightly better than Ligand B (-0.464), both are within the 1-3 range.
4. **HBD:** Both ligands have 3 HBD, which is acceptable.
5. **HBA:** Ligand A (7) is slightly higher than Ligand B (5), but both are within the acceptable limit of 10.
6. **QED:** Ligand A (0.626) is slightly better than Ligand B (0.52), indicating a more drug-like profile.
7. **DILI:** Ligand B (41.024) is significantly better than Ligand A (87.01). This is a major advantage for Ligand B.
8. **BBB:** Ligand A (45.522) is better than Ligand B (31.834). While ADRB2 isn't necessarily a CNS target, some peripheral ADRB2 modulation can have CNS side effects, so some BBB penetration is not necessarily bad.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.222 and -5.449), indicating poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-2.563) is slightly better than Ligand B (-1.625), but both are poor.
11. **hERG:** Ligand A (0.134) is better than Ligand B (0.351), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand B (0.735) is significantly better than Ligand A (12.262), meaning better metabolic stability.
13. **t1/2:** Ligand B (-5.889) is better than Ligand A (2.076), indicating a longer half-life.
14. **Pgp:** Ligand A (0.033) is much better than Ligand B (0.018), indicating lower P-gp efflux.
15. **Binding Affinity:** Ligand B (-6.4 kcal/mol) is slightly better than Ligand A (-5.7 kcal/mol). This is a significant advantage.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, and affinity. Ligand B has a better affinity and Pgp efflux. Ligand A has better TPSA and logP. However, the significant advantage of Ligand B in DILI risk and metabolic stability (Cl_mic and t1/2) outweighs the slight advantages of Ligand A. The affinity difference is also substantial.
**Conclusion:**
Despite Ligand A's slight advantages in TPSA and Pgp, Ligand B's superior DILI profile, metabolic stability, half-life, and binding affinity make it the more promising drug candidate.
Output:
0
2025-04-17 20:19:31,216 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands (345.355 and 344.455 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (93.9) is higher than Ligand B (58.64). For a GPCR, lower TPSA is generally preferred for better blood-brain barrier penetration and overall permeability. Ligand B is significantly better.
3. **logP:** Both ligands have good logP values (1.874 and 2.043), falling within the optimal 1-3 range. A slight edge to Ligand B.
4. **HBD:** Both have 1 HBD, which is acceptable.
5. **HBA:** Ligand A has 6 HBAs, while Ligand B has 3. Lower HBA is generally preferred for permeability. Ligand B is better.
6. **QED:** Ligand A (0.854) has a slightly better QED score than Ligand B (0.794), indicating a more drug-like profile.
7. **DILI:** Ligand A (77.433) has a significantly higher DILI risk than Ligand B (26.25). This is a major concern for Ligand A.
8. **BBB:** Ligand A (74.292) and Ligand B (84.025) both have good BBB penetration, but Ligand B is better.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. This is a concern for both, but the value for Ligand A (-4.501) is slightly less negative than Ligand B (-4.841), suggesting marginally better absorption.
10. **Solubility:** Both have negative solubility values, indicating poor solubility. Ligand A (-3.305) is slightly better than Ligand B (-2.98).
11. **hERG:** Both ligands have low hERG inhibition liability (0.18 and 0.353), which is good.
12. **Cl_mic:** Ligand A (95.704) has a higher microsomal clearance than Ligand B (39.236), indicating lower metabolic stability. Ligand B is significantly better.
13. **t1/2:** Ligand B (14.809 hours) has a much longer in vitro half-life than Ligand A (-33.21 hours). This is a significant advantage for Ligand B.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.16 and 0.168).
15. **Affinity:** Ligand B (-7.3 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.3 kcal/mol). This is a substantial advantage, potentially outweighing some minor ADME drawbacks.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), affinity, logP, TPSA, Pgp, and BBB are key. Ligand B excels in affinity, TPSA, and BBB. While both have acceptable logP and Pgp, Ligand B still has a slight advantage. The significantly lower DILI risk and improved metabolic stability (lower Cl_mic, longer t1/2) of Ligand B are also crucial.
**Conclusion:**
Despite Ligand A having a slightly better QED and marginally better Caco-2/solubility, the superior binding affinity, lower DILI risk, better BBB penetration, and improved metabolic stability of Ligand B make it the more promising drug candidate.
**Output:**
0
2025-04-17 20:19:31,216 - INFO - Batch 176 complete. Total preferences: 2816
2025-04-17 20:19:31,216 - INFO - Processing batch 177/512...
2025-04-17 20:20:17,918 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (358.873 and 376.4 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (50.16) is better than Ligand B (58.64), both are below the 140 threshold for oral absorption, but closer to the 90 threshold is preferred for GPCRs.
3. **logP:** Both ligands have good logP values (2.981 and 2.353), falling within the optimal 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Both have 1 HBD, which is within the acceptable limit of <=5.
5. **HBA:** Both have 4 HBA, which is within the acceptable limit of <=10.
6. **QED:** Both ligands have similar QED values (0.863 and 0.829), indicating good drug-likeness.
7. **DILI:** Ligand B (31.369) has a significantly lower DILI risk than Ligand A (45.638). This is a major advantage for Ligand B.
8. **BBB:** Ligand B (91.47) has a higher BBB penetration percentile than Ligand A (82.435). While ADRB2 isn't exclusively a CNS target, some CNS exposure is not necessarily detrimental and higher BBB is generally favorable.
9. **Caco-2:** Ligand A (-5.208) and Ligand B (-4.949) are both negative, indicating poor permeability. This is a concern for both, but not a deciding factor.
10. **Solubility:** Ligand A (-3.269) has slightly worse solubility than Ligand B (-2.915), but both are poor.
11. **hERG:** Ligand A (0.845) has a slightly higher hERG inhibition liability than Ligand B (0.503). Lower is better, so Ligand B is preferable.
12. **Cl_mic:** Ligand B (10.128) has a significantly lower microsomal clearance than Ligand A (18.477), indicating better metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand A (33.624) has a longer in vitro half-life than Ligand B (-5.702). This is a positive for Ligand A.
14. **Pgp:** Ligand A (0.442) has lower P-gp efflux liability than Ligand B (0.103), which is preferable.
15. **Binding Affinity:** Ligand B (-6.9 kcal/mol) has a slightly better binding affinity than Ligand A (-6.4 kcal/mol). This is a 0.5 kcal/mol difference, which is significant.
**Overall Assessment:**
Ligand B demonstrates a better balance of properties, particularly regarding safety (DILI, hERG) and pharmacokinetic parameters (BBB, Cl_mic). While Ligand A has a slightly longer half-life and lower P-gp efflux, the improved safety profile and metabolic stability of Ligand B, coupled with its slightly better binding affinity, outweigh these advantages. The poor Caco-2 and solubility of both ligands are concerns that would need to be addressed in further optimization, but are not decisive at this stage.
Output:
0
2025-04-17 20:20:17,919 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (344.371) is slightly lower, which could be beneficial for permeability.
2. **TPSA:** Ligand B (75.71) is significantly better than Ligand A (101.47). For a GPCR, lower TPSA is generally preferred for better permeability.
3. **logP:** Both ligands have good logP values (Ligand A: 1.536, Ligand B: 1.834) within the optimal range of 1-3.
4. **HBD:** Both have 1 HBD, which is acceptable.
5. **HBA:** Ligand A has 6 HBA, while Ligand B has 4. Both are within the acceptable range (<=10).
6. **QED:** Ligand A (0.903) has a superior QED score compared to Ligand B (0.52), indicating better overall drug-likeness.
7. **DILI:** Ligand B (20.047) has a much lower DILI risk than Ligand A (63.513). This is a significant advantage for Ligand B.
8. **BBB:** Ligand B (73.711) has a better BBB penetration percentile than Ligand A (65.374). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be useful for understanding off-target effects.
9. **Caco-2:** Ligand B (-4.703) has a better Caco-2 permeability than Ligand A (-5.128).
10. **Solubility:** Ligand B (-1.799) has better aqueous solubility than Ligand A (-2.344).
11. **hERG:** Both ligands have low hERG inhibition risk (Ligand A: 0.136, Ligand B: 0.312).
12. **Cl_mic:** Ligand B (9.148) has significantly lower microsomal clearance than Ligand A (31.041), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-23.37) has a substantially longer in vitro half-life than Ligand A (-18.198).
14. **Pgp:** Both ligands have very low Pgp efflux liability (Ligand A: 0.076, Ligand B: 0.051).
15. **Binding Affinity:** Ligand A (-6.0) has a slightly better binding affinity than Ligand B (-5.1). However, the difference is less than 1.5 kcal/mol, so it's not a decisive factor.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in TPSA, solubility, metabolic stability (Cl_mic, t1/2), and DILI risk. Ligand A has a slightly better affinity and QED, but the advantages of Ligand B in ADME properties are more compelling. The lower DILI risk and improved metabolic stability of Ligand B are particularly important.
**Conclusion:**
Considering the balance of properties and the GPCR-specific priorities, Ligand B is the more promising drug candidate.
```
0
```
2025-04-17 20:20:17,919 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (360.483 Da) is slightly higher than Ligand B (339.403 Da), but both are acceptable.
**2. TPSA:** Ligand A (78.09) is significantly better than Ligand B (101.38). For a GPCR, keeping TPSA under 140 is good, and lower is better for permeability. Ligand B is pushing the upper limit.
**3. logP:** Both ligands have good logP values (A: 2.624, B: 2.039), falling within the optimal 1-3 range.
**4. H-Bond Donors:** Both have 2 HBD, which is within the acceptable limit of 5.
**5. H-Bond Acceptors:** Ligand A has 4 HBA, while Ligand B has 6. Both are within the acceptable limit of 10, but A is preferable.
**6. QED:** Ligand A (0.86) has a better QED score than Ligand B (0.686), indicating a more drug-like profile.
**7. DILI:** Ligand B (80.923) has a significantly higher DILI risk than Ligand A (36.914). This is a major concern.
**8. BBB:** Ligand A (64.482) has a better BBB penetration percentile than Ligand B (37.767). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant, and higher BBB is generally desirable.
**9. Caco-2 Permeability:** Ligand A (-5.342) shows better Caco-2 permeability than Ligand B (-5.621).
**10. Aqueous Solubility:** Both have negative solubility values, which is unusual and suggests poor solubility. Ligand A (-2.995) is slightly better than Ligand B (-3.152).
**11. hERG Inhibition:** Ligand A (0.768) has a lower hERG inhibition liability than Ligand B (0.284), indicating a lower risk of cardiotoxicity.
**12. Microsomal Clearance:** Ligand A (10.07) has a higher (worse) microsomal clearance than Ligand B (5.575), meaning it's metabolized faster.
**13. In vitro Half-Life:** Ligand B (2.472) has a slightly longer in vitro half-life than Ligand A (-20.889). This is a benefit for B, but the negative value for A is concerning.
**14. P-gp Efflux:** Ligand A (0.323) has lower P-gp efflux liability than Ligand B (0.187), which is beneficial for bioavailability.
**15. Binding Affinity:** Ligand A (-5.6 kcal/mol) has a slightly better binding affinity than Ligand B (-5.1 kcal/mol).
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand A is clearly superior. While Ligand B has a slightly better half-life, the significantly higher DILI risk, worse TPSA, lower BBB penetration, and higher P-gp efflux outweigh this benefit. Ligand A's better solubility, lower hERG risk, and slightly better affinity further solidify its position as the more promising candidate. The negative in vitro half-life for Ligand A is a red flag that would require further investigation, but the overall profile is more favorable.
Output:
1
2025-04-17 20:20:17,919 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
Let's systematically compare Ligand A and Ligand B based on the provided parameters and the guidelines, keeping in mind that ADRB2 is a GPCR, so logP, Pgp, TPSA, and affinity are particularly important.
1. **Molecular Weight:** Both ligands (350.415 Da and 348.447 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (85.89 and 84.3) are below the 140 A^2 threshold for good oral absorption. They are also reasonably low, which is good for GPCR ligands. No major difference.
3. **logP:** Ligand A (3.091) is optimal, while Ligand B (1.327) is a bit low, potentially hindering membrane permeability. This is a point in favor of Ligand A.
4. **H-Bond Donors:** Ligand A (2) and Ligand B (1) are both acceptable.
5. **H-Bond Acceptors:** Both ligands (5) are within the acceptable range.
6. **QED:** Both ligands have good QED scores (0.738 and 0.84), indicating good drug-like properties.
7. **DILI:** Ligand B (41.45) has a significantly lower DILI risk than Ligand A (65.568). This is a substantial advantage for Ligand B.
8. **BBB:** Ligand A (82.009) has better BBB penetration than Ligand B (67.158), but both are not exceptionally high. Since ADRB2 is a cardiovascular target, BBB penetration is not critical.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.392 and -4.602), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand B (-1.789) has better solubility than Ligand A (-4.543). This is a positive for Ligand B.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.459 and 0.181).
12. **Cl_mic:** Ligand B (38.504) has significantly lower microsomal clearance than Ligand A (92.902), indicating better metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand B (-1.282) has a better in vitro half-life than Ligand A (-5.487). This is another advantage for Ligand B.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.156 and 0.1).
15. **Binding Affinity:** Ligand A (-8.8 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.4 kcal/mol). This is a substantial advantage for Ligand A. The difference of 2.4 kcal/mol is quite large and can outweigh some ADME concerns.
**Overall Assessment:**
Ligand A has a significantly better binding affinity, which is crucial for a GPCR target. However, Ligand B demonstrates a much better safety profile (lower DILI) and improved ADME properties (lower Cl_mic, better t1/2, better solubility). The Caco-2 values are concerning for both, but the affinity difference for Ligand A is substantial. Considering the balance, the stronger binding affinity of Ligand A is likely to be more important for achieving efficacy, even with the slightly higher DILI risk.
Output:
1
2025-04-17 20:20:17,919 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [344.459, 59.39, 2.619, 1, 5, 0.673, 28.577, 61.884, -4.882, -1.393, 0.784, 45.666, 12.883, 0.131, -4.8]
**Ligand B:** [361.389, 107.53, -0.352, 4, 4, 0.35, 33.773, 40.326, -4.966, -2.069, 0.587, 13.18, -16.12, 0.034, -4.8]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (344.459) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (59.39) is significantly better than Ligand B (107.53). For a GPCR, keeping TPSA low is beneficial for permeability and potentially BBB penetration.
3. **logP:** Ligand A (2.619) is optimal (1-3). Ligand B (-0.352) is too low, potentially leading to poor membrane permeability and bioavailability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (4). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (4). Lower HBA generally improves permeability.
6. **QED:** Ligand A (0.673) is much better than Ligand B (0.35), indicating a more drug-like profile.
7. **DILI:** Both are acceptable, with Ligand A (28.577) being slightly better than Ligand B (33.773).
8. **BBB:** Ligand A (61.884) is significantly better than Ligand B (40.326), which is important for GPCRs, even if not strictly CNS-targeted. Greater BBB penetration can influence off-target effects and overall distribution.
9. **Caco-2:** Both have negative values, suggesting poor permeability. Ligand A (-4.882) is slightly better than Ligand B (-4.966).
10. **Solubility:** Both have negative values, suggesting poor solubility. Ligand A (-1.393) is slightly better than Ligand B (-2.069).
11. **hERG:** Both are low (0.784 and 0.587), indicating low cardiotoxicity risk.
12. **Cl_mic:** Ligand A (45.666) is better than Ligand B (13.18), indicating better metabolic stability.
13. **t1/2:** Ligand A (12.883) is better than Ligand B (-16.12), indicating a longer half-life.
14. **Pgp:** Ligand A (0.131) is better than Ligand B (0.034), indicating lower P-gp efflux.
15. **Affinity:** Both have the same binding affinity (-4.8 kcal/mol).
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical ADME properties, especially those prioritized for GPCRs (logP, TPSA, BBB, Pgp). While both have issues with Caco-2 and solubility, Ligand A is better in both cases. The significantly better QED, metabolic stability, and BBB penetration of Ligand A make it a much more promising drug candidate. The equal binding affinity removes that as a differentiating factor.
Output:
1
2025-04-17 20:20:17,919 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.503 and 348.531 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (69.64) is slightly higher than Ligand B (58.2). Both are below 140, suitable for oral absorption, but Ligand B is preferable due to being closer to the optimal range for GPCRs.
3. **logP:** Ligand A (2.78) is within the optimal 1-3 range. Ligand B (4.103) is slightly above, potentially raising concerns about solubility and off-target effects, but not drastically.
4. **HBD:** Both ligands have 2 H-bond donors, which is good.
5. **HBA:** Ligand A has 3 H-bond acceptors, and Ligand B has 2. Both are acceptable.
6. **QED:** Ligand A (0.724) has a significantly better QED score than Ligand B (0.487), indicating a more drug-like profile.
7. **DILI:** Ligand A (32.067) has a slightly higher DILI risk than Ligand B (18.651), but both are below the 40 threshold and considered low risk.
8. **BBB:** Ligand B (77.084) has a much higher BBB penetration score than Ligand A (50.446). While ADRB2 isn't strictly a CNS target, some CNS exposure can be relevant for off-target effects, and a higher BBB score is generally preferred.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.623 and -4.792). These values are unusual and suggest poor permeability, which is a significant concern. However, the values are very similar.
10. **Solubility:** Ligand A (-2.725) has a slightly better solubility score than Ligand B (-3.997).
11. **hERG:** Ligand A (0.251) has a lower hERG risk than Ligand B (0.616), which is a significant advantage.
12. **Cl_mic:** Ligand B (59.979) has a higher microsomal clearance than Ligand A (44.304), indicating lower metabolic stability.
13. **t1/2:** Ligand A (7.486) has a longer in vitro half-life than Ligand B (-1.044). This is a substantial advantage.
14. **Pgp:** Ligand A (0.105) has a lower P-gp efflux liability than Ligand B (0.569), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand B (-6.4) has a slightly better binding affinity than Ligand A (-5.6). This is a 0.8 kcal/mol difference, which is significant.
**Overall Assessment:**
Ligand B has a better binding affinity and BBB penetration, which are important for GPCRs. However, it suffers from higher Pgp efflux, higher hERG risk, and significantly worse metabolic stability (higher Cl_mic and negative half-life). Ligand A has a superior QED score, lower DILI risk, better solubility, lower hERG risk, better metabolic stability, and lower Pgp efflux. The Caco-2 values are concerning for both, but similar. The binding affinity difference, while notable, is likely outweighed by the more favorable ADME properties of Ligand A.
Considering the balance of properties and the GPCR-specific priorities, Ligand A appears to be the more promising drug candidate.
Output:
1
2025-04-17 20:20:17,919 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (348.443) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (76.66) is better than Ligand B (49.85). Both are well below 140, but lower TPSA is generally preferred for better absorption.
3. **logP:** Ligand A (1.836) is within the optimal range (1-3). Ligand B (3.115) is at the higher end, potentially leading to solubility issues or off-target interactions.
4. **HBD:** Ligand A (2) is good. Ligand B (0) is also acceptable, but having some HBD can improve solubility.
5. **HBA:** Both ligands have 4 HBA, which is within the acceptable range.
6. **QED:** Ligand B (0.748) has a significantly better QED score than Ligand A (0.379), indicating a more drug-like profile.
7. **DILI:** Ligand A (22.218) has a much lower DILI risk than Ligand B (38.581), which is a significant advantage.
8. **BBB:** Ligand B (69.484) has a better BBB penetration score than Ligand A (56.223), but neither are particularly high. For a cardiovascular target, BBB penetration is not a primary concern.
9. **Caco-2:** Ligand A (-5.044) and Ligand B (-4.502) are both negative, which is unusual. Lower values suggest poor permeability.
10. **Solubility:** Ligand A (-2.819) has slightly better solubility than Ligand B (-3.232).
11. **hERG:** Both ligands have low hERG inhibition risk (0.273 and 0.311 respectively).
12. **Cl_mic:** Ligand A (4.776) has a much lower microsomal clearance than Ligand B (113.17), indicating better metabolic stability.
13. **t1/2:** Ligand A (4.535) has a better in vitro half-life than Ligand B (2.812).
14. **Pgp:** Ligand A (0.049) has a much lower P-gp efflux liability than Ligand B (0.355), which is favorable for bioavailability.
15. **Affinity:** Ligand A (-7.0) has a significantly better binding affinity than Ligand B (-1.1). This is a crucial difference, as a >1.5 kcal/mol advantage can outweigh other drawbacks.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A has a better logP and Pgp profile. The difference in affinity is substantial. While Ligand B has a better QED and BBB, these are less critical for a cardiovascular target.
**Conclusion:**
Despite Ligand B's better QED score, Ligand A is the superior candidate due to its significantly stronger binding affinity, lower DILI risk, better metabolic stability (lower Cl_mic, longer t1/2), and lower P-gp efflux. The substantial affinity difference outweighs the slightly lower QED and BBB penetration.
Output:
1
2025-04-17 20:20:17,919 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (378.877) is slightly higher than Ligand B (350.507), but both are acceptable.
2. **TPSA:** Both ligands are below the 140 A^2 threshold for good oral absorption, but Ligand A (52.6) is significantly better than Ligand B (58.44). Lower TPSA is preferred for GPCRs.
3. **logP:** Ligand A (4.772) is at the upper end of the optimal range, while Ligand B (2.425) is well within it. While higher logP can sometimes be problematic, it isn't a major concern here.
4. **HBD:** Both have 0 HBD, which is good.
5. **HBA:** Both have a reasonable number of HBA (5 and 4 respectively), well below the 10 threshold.
6. **QED:** Both ligands have very similar QED scores (0.722 and 0.723), indicating good drug-likeness.
7. **DILI:** Ligand A (70.415) has a higher DILI risk than Ligand B (29.042). This is a significant negative for Ligand A.
8. **BBB:** Ligand A (77.588) shows better BBB penetration than Ligand B (64.986). While ADRB2 isn't exclusively a CNS target, some CNS exposure may be acceptable and even beneficial depending on the specific therapeutic goal.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-4.545) has slightly worse solubility than Ligand B (-1.915). Solubility is important for bioavailability.
11. **hERG:** Both ligands have low hERG inhibition risk (0.225 and 0.312 respectively).
12. **Cl_mic:** Ligand A (77.326) has slightly higher microsomal clearance than Ligand B (73.597), suggesting lower metabolic stability.
13. **t1/2:** Ligand A (39.205) has a longer in vitro half-life than Ligand B (33.856). This is a positive for Ligand A.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.506 and 0.127 respectively). Ligand B is better here.
15. **Binding Affinity:** Ligand A (-7.6 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.3 kcal/mol). This is a substantial advantage for Ligand A. A 1.3 kcal/mol difference is significant and can often outweigh minor ADME drawbacks.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, affinity, logP, TPSA, and Pgp are particularly important. Ligand A excels in affinity and has a better TPSA, while Ligand B has a better logP and Pgp. However, the large difference in binding affinity for Ligand A is a major factor. The DILI risk for Ligand A is concerning, but the strong binding may allow for a lower dose, potentially mitigating the DILI risk.
**Overall Assessment:**
Despite the higher DILI risk and slightly worse solubility of Ligand A, its significantly stronger binding affinity (-7.6 kcal/mol vs -6.3 kcal/mol) is the deciding factor. The potency advantage is likely to outweigh the ADME liabilities, especially considering the relatively manageable DILI risk (70.415 percentile).
Output:
1
2025-04-17 20:20:17,919 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [352.425, 58.2, 3.546, 2, 2, 0.871, 51.028, 82.474, -4.534, -4.866, 0.758, 40.523, 24.521, 0.071, -6.4]
**Ligand B:** [334.394, 26.71, 4.69, 1, 3, 0.753, 68.088, 66.344, -4.888, -5.186, 0.959, 92.685, -28.383, 0.767, -8.9]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (334.394) is slightly lower, which is generally favorable.
2. **TPSA:** Ligand A (58.2) is better than Ligand B (26.71). Both are below the 140 threshold for oral absorption, but Ligand B is significantly lower, which could be beneficial for permeability.
3. **logP:** Ligand A (3.546) is within the optimal range (1-3). Ligand B (4.69) is slightly higher, potentially leading to solubility issues or off-target interactions.
4. **HBD:** Ligand A (2) is good. Ligand B (1) is also acceptable.
5. **HBA:** Ligand A (2) is good. Ligand B (3) is acceptable.
6. **QED:** Both are reasonable (A: 0.871, B: 0.753), indicating good drug-like properties.
7. **DILI:** Ligand A (51.028) is preferable to Ligand B (68.088), as it has a lower risk of liver injury.
8. **BBB:** Ligand A (82.474) has better BBB penetration than Ligand B (66.344), which is a plus for GPCRs, even cardiovascular ones, as some CNS off-target effects are possible.
9. **Caco-2:** Both are negative, indicating poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Both have negative solubility values, indicating poor aqueous solubility. Ligand B (-5.186) is worse than Ligand A (-4.866).
11. **hERG:** Ligand A (0.758) is better than Ligand B (0.959), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand A (40.523) has lower clearance, suggesting better metabolic stability than Ligand B (92.685).
13. **t1/2:** Ligand A (24.521) has a better in vitro half-life than Ligand B (-28.383).
14. **Pgp:** Ligand A (0.071) has lower P-gp efflux, which is favorable for bioavailability. Ligand B (0.767) has higher efflux.
15. **Affinity:** Ligand B (-8.9 kcal/mol) has significantly stronger binding affinity than Ligand A (-6.4 kcal/mol). This is a substantial advantage.
**Overall Assessment:**
Ligand B has a significantly better binding affinity, which is the most important factor. While it has some drawbacks (higher logP, worse solubility, higher DILI, higher Pgp efflux, and negative half-life), the potency advantage is substantial enough to outweigh these concerns, *especially* given the potential for further optimization. Ligand A has a better safety profile and ADME properties, but the weaker binding makes it less likely to be effective.
Output:
0
2025-04-17 20:20:17,919 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (359.813 and 368.434 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (71.53) is significantly better than Ligand B (107.08). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand A is well below the 140 threshold, while B is approaching it.
3. **logP:** Both ligands have good logP values (3.101 and 2.014), falling within the optimal 1-3 range. Ligand A is slightly higher, which *could* be a minor concern, but both are acceptable.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (4) is preferable to Ligand B (5). Similar reasoning as HBD.
6. **QED:** Both ligands have similar, acceptable QED values (0.657 and 0.695).
7. **DILI:** Ligand B (65.491) is better than Ligand A (86.157). Lower DILI is crucial. This is a significant advantage for Ligand B.
8. **BBB:** Both ligands have similar BBB penetration (69.407 and 68.786). While not CNS-focused for ADRB2, some degree of BBB penetration can be relevant for off-target effects.
9. **Caco-2:** Ligand A (-4.714) is better than Ligand B (-5.236). Higher Caco-2 values indicate better absorption.
10. **Solubility:** Ligand A (-4.783) is better than Ligand B (-2.173). Better solubility is generally preferred.
11. **hERG:** Ligand A (0.084) is significantly better than Ligand B (0.629). Lower hERG inhibition is critical for avoiding cardiotoxicity, especially for a cardiovascular target like ADRB2.
12. **Cl_mic:** Ligand B (14.102) is much better than Ligand A (36.849). Lower microsomal clearance indicates better metabolic stability. This is a substantial advantage for Ligand B.
13. **t1/2:** Ligand B (-6.977) is better than Ligand A (-13.131). Longer half-life is generally desirable.
14. **Pgp:** Ligand A (0.035) is much better than Ligand B (0.196). Lower P-gp efflux is preferable.
15. **Binding Affinity:** Ligand B (-7.0) is slightly better than Ligand A (-6.7). While both are good, the 0.3 kcal/mol difference is noticeable.
**Overall Assessment:**
Ligand B has a clear advantage in DILI and metabolic stability (Cl_mic and t1/2). These are important factors for drug development. It also has a slightly better binding affinity. However, Ligand A is better in terms of TPSA, HBD, HBA, Caco-2, Solubility, hERG and Pgp. Given the cardiovascular target, the hERG inhibition liability of Ligand B is a significant concern. While the binding affinity of Ligand B is slightly better, the lower hERG risk of Ligand A, coupled with its better permeability characteristics (TPSA, Caco-2) and Pgp efflux liability, makes it a more promising candidate.
Output:
1
2025-04-17 20:20:17,920 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.447 and 360.483 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (76.46 and 78.25) are below the 140 A^2 threshold for good oral absorption, and acceptable for a cardiovascular target (not requiring significant BBB penetration). Ligand B is slightly higher, but not concerning.
3. **logP:** Both ligands (1.68 and 1.889) are within the optimal 1-3 range. Again, no major difference.
4. **HBD:** Both ligands have 1 HBD, well within the acceptable limit of 5.
5. **HBA:** Ligand A has 5 HBA, and Ligand B has 6. Both are below the 10 threshold.
6. **QED:** Ligand A (0.849) has a better QED score than Ligand B (0.784), indicating a more drug-like profile.
7. **DILI:** Ligand A (46.452) has a higher DILI risk than Ligand B (21.946). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (72.625) has a slightly better BBB penetration potential than Ligand B (61.923), but this is less critical for a cardiovascular target like ADRB2.
9. **Caco-2:** Ligand A (-4.699) shows better Caco-2 permeability than Ligand B (-5.091).
10. **Solubility:** Ligand A (-2.684) has slightly better aqueous solubility than Ligand B (-2.447).
11. **hERG:** Both ligands (0.554 and 0.589) have similar, and acceptable, hERG inhibition liabilities.
12. **Cl_mic:** Ligand A (67.643) has a higher microsomal clearance than Ligand B (41.171), indicating lower metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand B (3.572) has a longer in vitro half-life than Ligand A (-22.044). This is a substantial advantage for Ligand B.
14. **Pgp:** Both ligands (0.192 and 0.054) have low P-gp efflux liability. Ligand B is slightly better.
15. **Binding Affinity:** Ligand A (-6.8 kcal/mol) has a slightly better binding affinity than Ligand B (-6.7 kcal/mol). While this is a positive for Ligand A, the difference is small.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Both ligands perform similarly on logP and TPSA. Pgp is good for both. The affinity difference is minimal. However, ADME properties are crucial. Ligand B demonstrates superior metabolic stability (lower Cl_mic, longer t1/2) and a significantly lower DILI risk. These factors outweigh the slightly better affinity and Caco-2 permeability of Ligand A.
**Conclusion:**
Considering the balance of properties and the priorities for a GPCR target, Ligand B is the more promising drug candidate.
Output:
0
2025-04-17 20:20:17,920 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
The ADRB2 receptor is a GPCR, so the key priorities are logP, TPSA, Pgp efflux, BBB penetration, and binding affinity. Metabolic stability and safety (DILI, hERG) are also important.
Let's compare the ligands property by property:
1. **MW:** Both are within the ideal range (351-352 Da). No significant difference.
2. **TPSA:** Ligand B (70.16) is significantly better than Ligand A (87.72). Lower TPSA generally improves permeability, which is crucial for GPCR ligands.
3. **logP:** Ligand A (1.735) is better than Ligand B (0.341). A logP between 1-3 is optimal, and Ligand B is quite low, potentially hindering membrane permeability.
4. **HBD:** Both have 0 HBD, which is good.
5. **HBA:** Ligand A (8) is higher than Ligand B (4). Lower HBA is generally preferred for permeability.
6. **QED:** Both are good (0.65 and 0.735), indicating drug-like properties.
7. **DILI:** Ligand B (43.622) is *much* better than Ligand A (97.402). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (86.972) is better than Ligand B (73.362), but both are reasonably good.
9. **Caco-2:** Both are negative, indicating poor permeability. This is a concern for both.
10. **Solubility:** Ligand B (-0.88) is better than Ligand A (-3.382).
11. **hERG:** Both are very low risk (0.131 and 0.21).
12. **Cl_mic:** Ligand A (100.207) is higher than Ligand B (28.581). This means Ligand B has better metabolic stability.
13. **t1/2:** Ligand B (-19.679) is better than Ligand A (-22.317).
14. **Pgp:** Ligand A (0.4) is better than Ligand B (0.078). Lower Pgp efflux is preferred.
15. **Affinity:** Ligand B (-5.8 kcal/mol) is significantly better than Ligand A (-1.9 kcal/mol). This is a very large difference in binding potency.
**Overall Assessment:**
Ligand B has a significantly better binding affinity, much lower DILI risk, better metabolic stability (lower Cl_mic, better t1/2), and lower HBA/TPSA. While Ligand A has a slightly better logP and Pgp efflux, the substantial advantage in affinity and safety profile of Ligand B outweighs these minor drawbacks. The low logP of Ligand B is a concern, but the superior affinity might compensate for that. The Caco-2 permeability is a concern for both, but can be addressed with formulation strategies.
Output:
0
2025-04-17 20:20:17,920 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (345.443 and 352.494 Da) fall comfortably within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (71.53) is higher than Ligand B (49.41). For a cardiovascular GPCR, TPSA is moderately important. Ligand B is better here, being closer to the <90 threshold.
3. **logP:** Ligand A (1.995) is within the optimal 1-3 range. Ligand B (3.819) is at the upper end, potentially raising concerns about solubility and off-target effects, but still acceptable.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 2. Both are acceptable, under the 10 threshold.
6. **QED:** Ligand A (0.886) has a significantly better QED score than Ligand B (0.675), indicating a more drug-like profile.
7. **DILI:** Both ligands have low DILI risk (26.018 and 27.22), both well below the 40 threshold.
8. **BBB:** Ligand B (91.625) has a better BBB penetration score than Ligand A (84.684). While ADRB2 isn't primarily a CNS target, some brain exposure can be relevant for peripheral effects.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand A (-2.425) has better solubility than Ligand B (-3.761).
11. **hERG:** Both ligands have low hERG inhibition risk (0.435 and 0.711).
12. **Cl_mic:** Ligand A (25.133) has a much lower microsomal clearance than Ligand B (75.31), suggesting better metabolic stability. This is a key advantage.
13. **t1/2:** Ligand A (-6.274) has a more negative in vitro half-life than Ligand B (-10.134), indicating a longer half-life. This is a significant advantage.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.025 and 0.306).
15. **Binding Affinity:** Ligand B (-6.9) has a slightly better binding affinity than Ligand A (-6.0). This is a 0.9 kcal/mol difference, which is significant.
**GPCR-Specific Priorities & Overall Assessment:**
For ADRB2 (a cardiovascular GPCR), affinity, logP, TPSA, and metabolic stability are key. Ligand B has a better affinity and TPSA, and a good BBB score. However, Ligand A has a significantly better QED, solubility, metabolic stability (lower Cl_mic), and longer half-life. The Caco-2 permeability is poor for both, which is a significant drawback that would need to be addressed through formulation or prodrug strategies.
The difference in binding affinity (0.9 kcal/mol) is substantial enough to outweigh the slightly less favorable TPSA and logP of Ligand A, especially considering the superior ADME properties (QED, solubility, Cl_mic, t1/2). The improved metabolic stability and half-life of Ligand A are crucial for *in vivo* efficacy.
**Output:**
1
2025-04-17 20:20:17,920 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (367.56 & 373.91 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (61.44) is higher than Ligand B (48.99). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is generally preferred for absorption. Ligand B has a slight advantage.
3. **logP:** Ligand A (1.73) is within the optimal range (1-3), while Ligand B (4.97) is significantly higher. This is a concern for Ligand B, potentially leading to poor solubility and off-target effects. Ligand A is clearly better here.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable.
5. **HBA:** Ligand A (4) and Ligand B (3) are both acceptable.
6. **QED:** Ligand A (0.719) is slightly better than Ligand B (0.663), indicating a more drug-like profile.
7. **DILI:** Ligand A (24.74%) has a much lower DILI risk than Ligand B (59.95%). This is a significant advantage for Ligand A.
8. **BBB:** Ligand B (77.90%) has a higher BBB penetration than Ligand A (63.36%). While ADRB2 isn't a primary CNS target, some degree of BBB penetration can be useful for understanding off-target effects.
9. **Caco-2:** Ligand A (-5.422) is worse than Ligand B (-4.932), indicating lower intestinal absorption. Ligand B is better.
10. **Solubility:** Ligand A (-3.087) is better than Ligand B (-5.123). This is important for bioavailability, and Ligand A has a clear advantage.
11. **hERG:** Ligand A (0.429) has a lower hERG risk than Ligand B (0.823). This is a crucial safety parameter, and Ligand A is preferable.
12. **Cl_mic:** Ligand B (72.87) has a slightly lower (better) microsomal clearance than Ligand A (65.33).
13. **t1/2:** Ligand A (32.64) has a longer in vitro half-life than Ligand B (22.32). This is a positive for Ligand A, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.134) has a lower P-gp efflux liability than Ligand B (0.636). Lower efflux is generally desirable for improved bioavailability.
15. **Binding Affinity:** Ligand B (-7.3 kcal/mol) has a slightly better binding affinity than Ligand A (-6.7 kcal/mol). This is a 0.6 kcal/mol difference.
**Overall Assessment & GPCR Prioritization:**
For a cardiovascular GPCR like ADRB2, the key priorities are potency (affinity), logP, and safety (DILI, hERG). While Ligand B has a slightly better affinity, Ligand A significantly outperforms it in terms of safety (DILI and hERG) and has a much more favorable logP. The difference in affinity (0.6 kcal/mol) is not substantial enough to outweigh the significant advantages of Ligand A in these critical ADME-Tox parameters. The better solubility and half-life of Ligand A also contribute to its overall superiority.
Output:
1
2025-04-17 20:20:17,920 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, key priorities are logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB.
Let's compare the ligands property by property:
1. **MW:** Both ligands (386.832 and 358.467 Da) fall within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (86.71) is slightly higher than Ligand B (76.02), but both are well below the 140 threshold for good oral absorption.
3. **logP:** Ligand A (2.365) and Ligand B (1.844) are both within the optimal 1-3 range. Ligand A is slightly more lipophilic.
4. **HBD:** Both have 2 HBD, which is acceptable.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 5. Both are within the acceptable limit of 10.
6. **QED:** Ligand A (0.825) has a slightly better QED score than Ligand B (0.742), indicating a more drug-like profile.
7. **DILI:** Ligand A (67.429) has a higher DILI risk than Ligand B (61.07), but both are reasonably acceptable.
8. **BBB:** Ligand B (55.603) has a significantly higher BBB penetration score than Ligand A (18.069). While not a primary concern for a cardiovascular target, it's a slight advantage for Ligand B.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-5.045) is slightly better than Ligand B (-5.533).
10. **Solubility:** Both have negative solubility values, indicating poor aqueous solubility. Ligand B (-3.061) is slightly better than Ligand A (-3.939).
11. **hERG:** Both have very low hERG inhibition liability (0.456 and 0.242), which is excellent.
12. **Cl_mic:** Ligand A (51.116) has a lower microsomal clearance than Ligand B (60.729), suggesting better metabolic stability.
13. **t1/2:** Ligand B (27.224) has a significantly longer in vitro half-life than Ligand A (-21.547). This is a major advantage.
14. **Pgp:** Ligand A (0.082) has lower P-gp efflux liability than Ligand B (0.136), which is favorable.
15. **Binding Affinity:** Ligand B (-7.0 kcal/mol) has a slightly better binding affinity than Ligand A (-6.7 kcal/mol). This 0.3 kcal/mol difference is significant.
**Overall Assessment:**
Ligand B demonstrates a superior balance of properties. The significantly longer half-life and slightly better binding affinity are major advantages. While Ligand A has better metabolic stability and lower Pgp efflux, the benefits of Ligand B's improved pharmacokinetics and potency outweigh these factors for a GPCR target. The slightly higher BBB score for Ligand B is a minor bonus.
**Output:**
0
2025-04-17 20:20:17,920 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (373.463 and 372.799 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (96.87) is higher than Ligand B (62.55). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is generally preferred for absorption. Ligand B is better here.
3. **logP:** Both ligands (2.163 and 2.947) are within the optimal 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability, but not dramatically so.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable. Lower is slightly better for permeability. Ligand B is better.
5. **HBA:** Ligand A (7) is higher than Ligand B (3). Lower is preferred for permeability. Ligand B is better.
6. **QED:** Both ligands have good QED scores (0.69 and 0.864), suggesting good overall drug-likeness. Ligand B is slightly better.
7. **DILI:** Ligand A (84.8) has a significantly higher DILI risk than Ligand B (35.983). This is a major concern. Ligand B is *much* better.
8. **BBB:** BBB is less critical for a cardiovascular target. Ligand B (86.778) is higher than Ligand A (24.351), but this isn't a deciding factor.
9. **Caco-2:** Ligand A (-5.66) is worse than Ligand B (-4.547), indicating lower intestinal absorption. Ligand B is better.
10. **Solubility:** Ligand A (-3.013) is worse than Ligand B (-4.244), indicating lower aqueous solubility. Ligand B is better.
11. **hERG:** Ligand A (0.136) is slightly better than Ligand B (0.506), indicating lower hERG inhibition liability. However, both are relatively low risk.
12. **Cl_mic:** Ligand A (22.992) has a higher microsomal clearance than Ligand B (10.315), suggesting lower metabolic stability. Ligand B is better.
13. **t1/2:** Ligand A (25.136) and Ligand B (22.318) are comparable.
14. **Pgp:** Ligand A (0.039) is better than Ligand B (0.087), indicating lower P-gp efflux.
15. **Binding Affinity:** Ligand A (-6.8 kcal/mol) is slightly better than Ligand B (-6.6 kcal/mol). This is a 0.2 kcal/mol difference, which is not a huge advantage.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity and Pgp profile, the significantly higher DILI risk, worse solubility, and higher clearance make it a less desirable candidate. Ligand B demonstrates a much more favorable ADMET profile, particularly the substantially lower DILI risk, better solubility, and lower clearance. The small difference in binding affinity is outweighed by these critical ADMET advantages. For a cardiovascular target, a balance of potency and safety/pharmacokinetics is crucial, and Ligand B offers that balance more effectively.
Output:
0
2025-04-17 20:20:17,920 - INFO - Batch 177 complete. Total preferences: 2832
2025-04-17 20:20:17,921 - INFO - Processing batch 178/512...
2025-04-17 20:21:10,918 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (364.427 Da) and Ligand B (348.451 Da) are both within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (108.56) is slightly higher than Ligand B (79.54). For a cardiovascular GPCR, TPSA is moderately important, and Ligand B is preferable due to its lower value, suggesting better permeability.
3. **logP:** Ligand A (0.946) is slightly below the optimal 1-3 range, while Ligand B (1.106) is closer. Both are acceptable, but Ligand B is slightly better.
4. **HBD:** Ligand A (2) and Ligand B (1) are both good, under the threshold of 5. Ligand B is slightly better.
5. **HBA:** Ligand A (7) and Ligand B (8) are both acceptable, under the threshold of 10.
6. **QED:** Ligand A (0.818) is better than Ligand B (0.727), indicating a more drug-like profile.
7. **DILI:** Ligand A (64.676) is slightly higher than Ligand B (58.434), but both are acceptable (below 60). Ligand B is preferable.
8. **BBB:** Ligand A (45.444) is significantly lower than Ligand B (84.141). While ADRB2 isn't necessarily a CNS target, higher BBB penetration is generally favorable, reducing off-target effects. Ligand B is much better.
9. **Caco-2:** Ligand A (-5.461) is worse than Ligand B (-4.718), indicating lower intestinal absorption. Ligand B is preferable.
10. **Solubility:** Ligand A (-2.19) is worse than Ligand B (-1.691), indicating lower aqueous solubility. Ligand B is preferable.
11. **hERG:** Ligand A (0.263) is significantly better than Ligand B (0.712), indicating a lower risk of cardiotoxicity. This is a crucial factor for a cardiovascular target. Ligand A is much better.
12. **Cl_mic:** Ligand A (12.51) is significantly lower than Ligand B (46.693), indicating better metabolic stability. Ligand A is much better.
13. **t1/2:** Ligand A (-8.065) is much better than Ligand B (61.075), indicating a longer in vitro half-life. Ligand A is much better.
14. **Pgp:** Ligand A (0.079) is significantly lower than Ligand B (0.241), indicating lower P-gp efflux. Ligand A is much better.
15. **Affinity:** Ligand A (-3.9 kcal/mol) is worse than Ligand B (-6.2 kcal/mol). This is a substantial difference in binding affinity. Ligand B is much better.
**Overall Assessment:**
Ligand B has a clear advantage in several key ADME properties (TPSA, logP, BBB, Caco-2, Solubility) and, critically, a significantly stronger binding affinity. While Ligand A has better hERG, Cl_mic, t1/2, and Pgp properties, the substantial difference in binding affinity outweighs these advantages. For a GPCR, potency is paramount, and the better ADME profile of Ligand B makes it a more promising starting point for optimization.
Output:
0
2025-04-17 20:21:10,919 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [377.457, 78.51, 1.174, 2, 4, 0.561, 35.052, 69.794, -5.322, -2.04, 0.246, 22.555, -6.521, 0.029, -6.2]
**Ligand B:** [390.305, 75.27, 2.052, 2, 3, 0.597, 64.754, 77.821, -4.834, -3.113, 0.582, 11.037, -24.643, 0.08, -6.2]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (377.457) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are reasonably good (A: 78.51, B: 75.27), below the 140 threshold for oral absorption.
3. **logP:** Both are within the optimal range (1-3), but Ligand B (2.052) is a bit higher than Ligand A (1.174). A slightly higher logP can be beneficial for membrane permeability, but we need to consider other factors.
4. **HBD:** Both have 2 HBD, which is acceptable.
5. **HBA:** Ligand A has 4 HBA, Ligand B has 3. Both are under the threshold of 10.
6. **QED:** Both have good QED scores (A: 0.561, B: 0.597), indicating drug-like properties.
7. **DILI:** Ligand A (35.052) has a much lower DILI risk than Ligand B (64.754). This is a significant advantage for Ligand A.
8. **BBB:** Ligand B (77.821) has a slightly better BBB penetration potential than Ligand A (69.794), but both are reasonably good. For a cardiovascular target, BBB penetration isn't *critical* but can be useful for off-target effects.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-5.322) is slightly worse than Ligand B (-4.834).
10. **Solubility:** Both have negative solubility values, indicating very poor aqueous solubility. Ligand B (-3.113) is slightly better than Ligand A (-2.04).
11. **hERG:** Both have very low hERG inhibition risk (A: 0.246, B: 0.582).
12. **Cl_mic:** Ligand B (11.037) has a significantly lower microsomal clearance than Ligand A (22.555), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-24.643) has a much longer in vitro half-life than Ligand A (-6.521). This is a major advantage for Ligand B.
14. **Pgp:** Both have very low Pgp efflux liability (A: 0.029, B: 0.08).
15. **Affinity:** Both have the same binding affinity (-6.2 kcal/mol).
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Ligand B has a slightly better logP and BBB, and a significantly better metabolic profile (lower Cl_mic, longer t1/2). However, the lower DILI risk of Ligand A is a substantial benefit. The poor Caco-2 and solubility are concerning for both.
**Decision:**
While Ligand B has a more favorable metabolic profile, the significantly lower DILI risk associated with Ligand A is a critical factor. DILI is a major cause of drug development failures. The similar binding affinity means the ADME properties become the deciding factor. The poor solubility and permeability are a concern for both, but the lower DILI risk of Ligand A outweighs the slightly better metabolic stability of Ligand B.
Output:
1
2025-04-17 20:21:10,919 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (345.447 and 368.459 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (88.91 and 87.76) are below the 140 A^2 threshold for good oral absorption, and acceptable for a cardiovascular GPCR. Very similar.
3. **logP:** Ligand A (2.038) is optimal, while Ligand B (0.361) is a bit low, potentially hindering membrane permeability. This is a point in favor of A.
4. **HBD:** Ligand A (2) and Ligand B (1) are both within the acceptable limit of 5.
5. **HBA:** Ligand A (5) and Ligand B (6) are both within the acceptable limit of 10.
6. **QED:** Both ligands have good QED scores (0.529 and 0.667), indicating drug-like properties. B is slightly better.
7. **DILI:** Both ligands have acceptable DILI risk (49.709 and 51.26), below the 60 threshold.
8. **BBB:** Ligand B (64.87) has a better BBB penetration score than Ligand A (56.805). However, since ADRB2 is primarily a cardiovascular target, high BBB penetration isn't a critical priority.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.243 and -5.176) which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Both ligands have negative solubility values (-2.473 and -2.862) which is also unusual and suggests poor solubility. This is a concern for both.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.043 and 0.375), which is excellent.
12. **Cl_mic:** Ligand A (48.412) has a significantly lower microsomal clearance than Ligand B (18.888), indicating better metabolic stability. This is a strong advantage for A.
13. **t1/2:** Ligand B (-21.852) has a longer in vitro half-life than Ligand A (-13.645), which is generally desirable.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.026 and 0.022).
15. **Binding Affinity:** Ligand B (-7.1 kcal/mol) has a slightly better binding affinity than Ligand A (-6.3 kcal/mol). This is a 0.8 kcal/mol difference, which is significant.
**GPCR-specific considerations:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand A has a better logP and significantly better metabolic stability (Cl_mic). Ligand B has a slightly better affinity and BBB, but BBB isn't a major concern for a cardiovascular target. The negative Caco-2 and solubility values are concerning for both, but the better metabolic stability of Ligand A is a significant advantage. The affinity difference is not large enough to overcome the metabolic stability concern.
**Conclusion:**
Considering the balance of properties and the specific priorities for a cardiovascular GPCR target, Ligand A is the more promising candidate due to its superior metabolic stability and acceptable logP.
Output:
1
2025-04-17 20:21:10,919 - INFO - Here's my reasoning and the final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, the most important parameters are binding affinity, logP, TPSA, Pgp efflux, and to a lesser extent, BBB.
Let's compare the ligands property by property:
1. **MW:** Both ligands (349.475 and 365.455 Da) are within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (87.3) is better than Ligand B (90.77), being closer to the desirable <140 and even closer to the <90 for CNS targets (though less critical here).
3. **logP:** Ligand A (1.492) is better than Ligand B (0.661). Both are within the optimal 1-3 range, but Ligand A is closer to the middle, suggesting a better balance of solubility and permeability.
4. **HBD:** Ligand A (3) is higher than Ligand B (1), but both are acceptable (<=5).
5. **HBA:** Ligand A (3) is lower than Ligand B (5), which is preferable.
6. **QED:** Ligand B (0.849) is better than Ligand A (0.651), indicating a more drug-like profile.
7. **DILI:** Ligand A (28.228) has a significantly lower DILI risk than Ligand B (38.503), which is a major advantage.
8. **BBB:** Ligand B (53.47) has a higher BBB penetration percentile than Ligand A (42.342). While not a primary concern for a cardiovascular target, it's a slight positive for Ligand B.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-5.083) is slightly better than Ligand B (-5.113), but both are concerning.
10. **Solubility:** Ligand A (-3.058) is better than Ligand B (-1.667), indicating better aqueous solubility.
11. **hERG:** Both are very low (0.114 and 0.173), indicating minimal hERG inhibition risk.
12. **Cl_mic:** Ligand B (-18.472) has significantly lower microsomal clearance than Ligand A (28.868), suggesting better metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand B (38.654) has a much longer in vitro half-life than Ligand A (-4.682), which is a substantial benefit.
14. **Pgp:** Both are very low (0.078 and 0.024), indicating minimal P-gp efflux.
15. **Affinity:** Ligand A (-8.0) has a better binding affinity than Ligand B (-6.3). This is a substantial advantage for Ligand A, potentially outweighing some of the ADME drawbacks.
**Overall Assessment:**
Ligand A has a significantly better binding affinity and lower DILI risk, and better solubility. Ligand B has better metabolic stability (lower Cl_mic) and a longer half-life, and a slightly better QED score. The Caco-2 permeability is poor for both, but the affinity difference is significant. Given the importance of potency for GPCRs, and the relatively low risk profile of Ligand A, I would choose Ligand A.
**Output:**
1
2025-04-17 20:21:10,919 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [358.36 , 69.64 , 1.946, 2. , 3. , 0.763, 40.985, 59.325, -5.041, -1.646, 0.075, -4.467, -11.355, 0.008, -6.1 ]
**Ligand B:** [342.447, 94.73 , 2.496, 4. , 5. , 0.62 , 64.327, 78.907, -5.521, -3.207, 0.792, 43.369, 25.449, 0.158, -7.4 ]
Here's a breakdown, comparing each parameter and considering GPCR priorities (logP, Pgp, TPSA, affinity):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (342.447) is slightly lower, which is generally favorable.
2. **TPSA:** Ligand A (69.64) is better than Ligand B (94.73). ADRB2 is not a CNS target, but lower TPSA is still generally preferred for absorption.
3. **logP:** Both are within the optimal range (1-3). Ligand A (1.946) is slightly better.
4. **HBD:** Ligand A (2) is better than Ligand B (4). Fewer HBDs are generally preferred for permeability.
5. **HBA:** Ligand A (3) is better than Ligand B (5). Fewer HBAs are generally preferred for permeability.
6. **QED:** Ligand A (0.763) is better than Ligand B (0.62), indicating a more drug-like profile.
7. **DILI:** Ligand A (40.985) is significantly better than Ligand B (64.327), indicating a lower risk of liver injury. This is a critical advantage.
8. **BBB:** Not a primary concern for a cardiovascular target, but Ligand B (78.907) is higher than Ligand A (59.325).
9. **Caco-2:** Both are negative, suggesting poor permeability. Ligand A (-5.041) is slightly better (less negative).
10. **Solubility:** Both are negative, suggesting poor solubility. Ligand A (-1.646) is slightly better (less negative).
11. **hERG:** Ligand A (0.075) is much better than Ligand B (0.792), indicating a lower risk of cardiotoxicity. This is a significant advantage.
12. **Cl_mic:** Ligand A (-4.467) is better than Ligand B (43.369), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-11.355) is better than Ligand B (25.449), suggesting a longer half-life.
14. **Pgp:** Ligand A (0.008) is much better than Ligand B (0.158), indicating lower P-glycoprotein efflux.
15. **Affinity:** Ligand B (-7.4) has a 1.3 kcal/mol advantage in binding affinity over Ligand A (-6.1). This is a substantial difference.
**Overall Assessment:**
While Ligand B boasts a better binding affinity, Ligand A demonstrates a significantly superior ADMET profile. The lower DILI, hERG, Pgp efflux, and better metabolic stability (Cl_mic and t1/2) are crucial advantages. The slightly better TPSA, logP, HBD, HBA, QED, and solubility also contribute to its favorability. The affinity difference, while notable, can potentially be optimized in subsequent iterations of drug design. For a cardiovascular GPCR, minimizing off-target effects and ensuring favorable pharmacokinetic properties are paramount.
Therefore, I would choose Ligand A.
1
2025-04-17 20:21:10,920 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (358.785 and 346.471 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (90.06) is slightly higher than Ligand B (58.64). For a cardiovascular GPCR, TPSA is moderately important for permeability, and Ligand B is significantly better.
3. **logP:** Ligand A (3.46) is within the optimal range (1-3), while Ligand B (2.433) is towards the lower end. Ligand A is slightly favored here, as a higher logP can aid membrane permeability.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 6 HBA, while Ligand B has 3. Both are acceptable, but Ligand B is better.
6. **QED:** Ligand B (0.778) has a better QED score than Ligand A (0.414), indicating a more drug-like profile.
7. **DILI:** Ligand A (84.335) has a significantly higher DILI risk than Ligand B (24.738). This is a major concern for Ligand A.
8. **BBB:** Both ligands have good BBB penetration (69.988 and 78.364), but Ligand B is slightly better. While ADRB2 isn't exclusively a CNS target, some CNS penetration can be relevant.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-5.1) is worse than Ligand B (-4.415).
10. **Solubility:** Ligand A (-5.751) has worse solubility than Ligand B (-2.915).
11. **hERG:** Ligand A (0.658) has a slightly higher hERG risk than Ligand B (0.253), but both are relatively low.
12. **Cl_mic:** Ligand B (79.614) has a much higher microsomal clearance than Ligand A (47.958), meaning Ligand A is more metabolically stable.
13. **t1/2:** Ligand A (78.846) has a significantly longer in vitro half-life than Ligand B (-18.467). This is a substantial advantage for Ligand A.
14. **Pgp:** Ligand A (0.625) has lower P-gp efflux than Ligand B (0.182), which is favorable.
15. **Binding Affinity:** Ligand A (-8.0) has a slightly better binding affinity than Ligand B (-6.8). This is a significant advantage.
**Overall Assessment:**
Ligand A has a better binding affinity and metabolic stability (lower Cl_mic, longer t1/2) and lower Pgp efflux. However, it has a significantly higher DILI risk, worse solubility, and worse Caco-2 permeability. Ligand B has a better QED, lower DILI risk, better TPSA, and better solubility.
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), and the overall balance, the lower DILI risk and better solubility of Ligand B are crucial. While Ligand A's affinity is slightly better, the DILI risk is a major red flag. The improved ADME properties of Ligand B outweigh the small difference in binding affinity.
Output:
0
2025-04-17 20:21:10,920 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [344.455, 49.85, 1.666, 0, 3, 0.716, 39.511, 74.292, -4.465, -2.815, 0.39, 40.836, -1.257, 0.272, -6.7]
**Ligand B:** [358.502, 55.89, 0.97, 1, 4, 0.737, 16.014, 73.827, -4.882, -0.846, 0.673, 16.456, 2.106, 0.045, -5.9]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (344.455) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (49.85) is better than Ligand B (55.89), both are acceptable but lower is preferred for GPCRs.
3. **logP:** Ligand A (1.666) is slightly higher than Ligand B (0.97), both are within the optimal range (1-3).
4. **HBD:** Ligand A (0) is better than Ligand B (1). Lower is preferred.
5. **HBA:** Ligand A (3) is better than Ligand B (4). Lower is preferred.
6. **QED:** Both are good (0.716 and 0.737), indicating good drug-like properties.
7. **DILI:** Ligand A (39.511) is significantly higher than Ligand B (16.014). Ligand B has a much lower DILI risk, which is a major advantage.
8. **BBB:** Both are good (74.292 and 73.827).
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand B (-4.882) is slightly worse than Ligand A (-4.465).
10. **Solubility:** Ligand B (-0.846) is better than Ligand A (-2.815). Higher solubility is desirable.
11. **hERG:** Ligand A (0.39) is better than Ligand B (0.673). Lower hERG inhibition is critical for cardiovascular safety.
12. **Cl_mic:** Ligand B (16.456) is much lower than Ligand A (40.836), indicating better metabolic stability.
13. **t1/2:** Ligand B (2.106) is better than Ligand A (-1.257). Longer half-life is preferred.
14. **Pgp:** Ligand A (0.272) is better than Ligand B (0.045). Lower P-gp efflux is preferred.
15. **Affinity:** Ligand A (-6.7) is better than Ligand B (-5.9). This is a 0.8 kcal/mol difference, which is significant.
**Overall Assessment:**
While Ligand A has a better binding affinity and Pgp profile, Ligand B demonstrates a significantly better safety profile (lower DILI) and improved pharmacokinetic properties (lower Cl_mic, longer t1/2, better solubility). Given the cardiovascular target, minimizing DILI and maximizing metabolic stability are crucial. The affinity difference, while notable, can potentially be optimized in later stages of drug development. The poor Caco-2 values for both are concerning, but can be addressed with formulation strategies.
Therefore, I would prioritize Ligand B.
Output:
0
2025-04-17 20:21:10,920 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (380.539 and 350.463 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (67.23) is better than Ligand B (78.68). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (1.751 and 1.445), falling within the 1-3 range. Ligand B is slightly lower, which could slightly improve solubility.
4. **HBD:** Both have 1 HBD, which is acceptable.
5. **HBA:** Ligand A has 6 HBA, and Ligand B has 5. Both are within the acceptable range of <=10.
6. **QED:** Both ligands have very similar QED values (0.73 and 0.729), indicating good drug-likeness.
7. **DILI:** Ligand A (52.423) has a considerably higher DILI risk than Ligand B (12.641). This is a significant negative for Ligand A.
8. **BBB:** Both have moderate BBB penetration (58.085 and 61.38). This isn't a critical factor for a cardiovascular target.
9. **Caco-2:** Both have negative Caco-2 values, suggesting poor permeability. This is concerning for both, but the values are very close.
10. **Solubility:** Ligand B (-1.116) has better solubility than Ligand A (-3.389).
11. **hERG:** Both ligands have very low hERG risk (0.215 and 0.217).
12. **Cl_mic:** Ligand B (12.421) has significantly lower microsomal clearance than Ligand A (56.411), indicating better metabolic stability.
13. **t1/2:** Ligand B (17.897 hours) has a much longer in vitro half-life than Ligand A (5.164 hours). This is a major advantage for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.063 and 0.018).
15. **Binding Affinity:** Ligand B (-7.0 kcal/mol) has a slightly better binding affinity than Ligand A (-6.6 kcal/mol). While the difference is less than the 1.5 kcal/mol threshold, it contributes to the overall preference.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Both ligands perform similarly on logP and Pgp. Ligand A has a slightly better TPSA, but Ligand B has a better affinity. The biggest differentiator is the significantly lower DILI risk and improved metabolic stability (lower Cl_mic and longer t1/2) of Ligand B.
**Conclusion:**
Ligand B is the more promising candidate due to its significantly lower DILI risk, improved metabolic stability, longer half-life, and slightly better binding affinity. While Ligand A has a slightly better TPSA, the ADME advantages of Ligand B outweigh this minor difference.
Output:
0
2025-04-17 20:21:10,920 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [374.374, 101.09 , 2.57 , 2. , 6. , 0.607, 40.752, 31.989, -5.638, -1.073, 0.104, 1.266, -0.933, 0.008, -7.4 ]
**Ligand B:** [344.419, 89.07 , 0.481, 1. , 7. , 0.789, 29.081, 46.336, -5.328, -0.703, 0.212, 15.173, -25.347, 0.069, -8. ]
Here's a breakdown, prioritizing GPCR characteristics (logP, Pgp, TPSA, and affinity):
1. **Molecular Weight:** Both are within the ideal 200-500 Da range. Ligand B (344.419 Da) is slightly lower, which *could* be advantageous for permeability, but both are acceptable.
2. **TPSA:** Ligand A (101.09) is a bit higher than Ligand B (89.07). Both are below 140, which is good for oral absorption, but Ligand B is better.
3. **logP:** Ligand A (2.57) is optimal. Ligand B (0.481) is quite low, potentially leading to poor membrane permeability and bioavailability. This is a significant drawback.
4. **H-Bond Donors/Acceptors:** Ligand A (2/6) and Ligand B (1/7) are both reasonable.
5. **QED:** Both have good QED scores (A: 0.607, B: 0.789), indicating drug-like properties. Ligand B is slightly better.
6. **DILI:** Ligand A (40.752) is slightly higher than Ligand B (29.081), but both are below the concerning 60% threshold. Ligand B is preferable.
7. **BBB:** Ligand B (46.336) has a better BBB penetration score than Ligand A (31.989), though neither are particularly high. For a cardiovascular target, this isn't *critical*, but a higher value is still preferred.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests a potential issue with the data. However, the magnitude of the negative value is larger for Ligand B (-5.328) which is worse.
9. **Solubility:** Both have negative solubility values, which is also unusual and suggests a potential issue with the data. However, the magnitude of the negative value is larger for Ligand B (-0.703) which is worse.
10. **hERG:** Both are very low (A: 0.104, B: 0.212), indicating a low risk of cardiotoxicity.
11. **Cl_mic:** Ligand A (1.266) has significantly lower microsomal clearance than Ligand B (15.173), suggesting better metabolic stability. This is a major advantage.
12. **t1/2:** Ligand A (-0.933) has a negative half-life, which is not possible. Ligand B (-25.347) also has a negative half-life, which is not possible.
13. **Pgp:** Ligand A (0.008) has much lower P-gp efflux than Ligand B (0.069), indicating better absorption and potentially better CNS exposure (even though this isn't a CNS target).
14. **Binding Affinity:** Ligand B (-8.0 kcal/mol) has a slightly better binding affinity than Ligand A (-7.4 kcal/mol). This is a 0.6 kcal/mol difference, which is significant, but not overwhelming.
**Overall Assessment:**
While Ligand B has a slightly better affinity and QED, the significantly lower logP, higher Cl_mic, and negative half-life are major concerns. The lower logP suggests poor permeability and bioavailability. The higher Cl_mic suggests rapid metabolism. Ligand A, despite slightly lower affinity, has a much more favorable ADME profile, particularly its logP and metabolic stability. The negative half-life values for both are concerning and suggest issues with the data, but the relative difference in Cl_mic is still significant.
Given the importance of ADME properties for a viable drug candidate, especially for a GPCR, and considering the cardiovascular target, I favor Ligand A.
Output:
1
2025-04-17 20:21:10,920 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (363.414 and 351.491 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand B (69.72) is significantly better than Ligand A (80.32). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (2.385 and 1.934), falling within the optimal 1-3 range. Ligand B is slightly lower, which could be beneficial for solubility.
4. **HBD:** Ligand B (1) is preferable to Ligand A (2). Fewer HBDs generally improve membrane permeability.
5. **HBA:** Ligand B (3) is preferable to Ligand A (5). Similar reasoning as HBD.
6. **QED:** Both ligands have similar and acceptable QED values (0.608 and 0.68).
7. **DILI:** Ligand B (13.571) is *much* better than Ligand A (81.117). This is a major advantage for Ligand B. A DILI percentile above 60 is concerning.
8. **BBB:** Both ligands have similar BBB penetration (64.056 and 67.933). Not a major factor for a cardiovascular target.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.777 and -4.794), which is unusual and suggests poor permeability. This is a significant drawback for both.
10. **Solubility:** Ligand B (-2.081) is better than Ligand A (-3.935), indicating better aqueous solubility.
11. **hERG:** Ligand B (0.574) is preferable to Ligand A (0.263), indicating lower hERG inhibition risk.
12. **Cl_mic:** Ligand B (23.782) has a significantly lower microsomal clearance than Ligand A (52.827), suggesting better metabolic stability.
13. **t1/2:** Ligand A (44.486) has a longer in vitro half-life than Ligand B (-9.548). This is a positive for Ligand A, but the negative value for B is concerning and suggests rapid degradation.
14. **Pgp:** Ligand B (0.081) is preferable to Ligand A (0.099), indicating lower P-gp efflux.
15. **Affinity:** Ligand A (-6.7 kcal/mol) has a slightly better binding affinity than Ligand B (-5.1 kcal/mol). This is a 1.6 kcal/mol difference, which is significant.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity, Ligand B demonstrates a significantly better overall profile, particularly regarding safety (DILI, hERG) and ADME properties (Cl_mic, solubility, Pgp). The negative Caco-2 values are concerning for both, but the superior ADME and safety profile of Ligand B outweigh the small difference in binding affinity. The negative half-life for Ligand B is a major concern, but the other benefits are substantial.
Output:
0
2025-04-17 20:21:10,921 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [346.515, 58.2, 3.735, 2, 2, 0.625, 23.187, 70.686, -4.81, -4.006, 0.27, 50.649, -5.592, 0.332, -6.2]
**Ligand B:** [351.407, 116.68, -0.966, 3, 7, 0.524, 31.097, 50.523, -5.139, -1.162, 0.124, -6.469, -15.256, 0.002, -5.2]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal 200-500 Da range. Ligand A (346.5) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (58.2) is excellent, well below the 140 threshold and good for oral absorption. Ligand B (116.68) is higher, potentially hindering absorption, but still within a reasonable range.
3. **logP:** Ligand A (3.735) is optimal. Ligand B (-0.966) is significantly lower, which is a major concern for membrane permeability and bioavailability.
4. **HBD:** Both have acceptable HBD counts (2 for A, 3 for B).
5. **HBA:** Ligand A (2) is excellent. Ligand B (7) is higher, potentially impacting permeability.
6. **QED:** Both are reasonably good (0.625 and 0.524), indicating drug-like properties.
7. **DILI:** Ligand A (23.187) has a much lower DILI risk than Ligand B (31.097). This is a significant advantage.
8. **BBB:** Ligand A (70.686) has good BBB penetration, which is desirable for a GPCR. Ligand B (50.523) is lower, suggesting less CNS exposure.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. However, the scale is not specified, so it's difficult to interpret.
10. **Solubility:** Both have negative solubility values, indicating poor solubility. Again, the scale is not specified.
11. **hERG:** Ligand A (0.27) has a very low hERG risk. Ligand B (0.124) is also low, but slightly higher.
12. **Cl_mic:** Ligand A (50.649) has moderate clearance. Ligand B (-6.469) has negative clearance, which is not physically possible and likely an error. This is a major red flag.
13. **t1/2:** Ligand A (-5.592) has a negative half-life, which is not physically possible and likely an error. Ligand B (-15.256) also has a negative half-life, which is also an error.
14. **Pgp:** Ligand A (0.332) has low P-gp efflux, which is favorable. Ligand B (0.002) has very low P-gp efflux.
15. **Affinity:** Both have comparable and good binding affinities (-6.2 and -5.2 kcal/mol). The difference is not substantial enough to overcome other issues.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are crucial. Ligand A excels in logP and TPSA, and has favorable Pgp. While both have good affinity, the significantly better ADME profile of Ligand A, especially the logP and DILI, makes it the more promising candidate. The negative values for clearance and half-life for Ligand B are concerning and suggest data errors.
**Conclusion:**
Considering all factors, Ligand A is the more viable drug candidate.
1
2025-04-17 20:21:10,921 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (375.856 Da) is slightly higher than Ligand B (353.377 Da), but both are acceptable.
2. **TPSA:** Ligand A (59.22) is significantly better than Ligand B (73.89). ADRB2 is a cardiovascular target, so CNS penetration is not a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (4.673) is higher than Ligand B (1.28). While 4.673 is approaching the upper limit, it's still within a reasonable range. Ligand B's logP is quite low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (1) is better than Ligand B (0). Having at least one HBD can improve solubility.
5. **HBA:** Ligand A (4) is better than Ligand B (8). Lower HBA is preferable for permeability.
6. **QED:** Both ligands have good QED values (A: 0.674, B: 0.779), indicating good drug-like properties.
7. **DILI:** Ligand A (73.323) is slightly higher than Ligand B (62.195), but both are still within an acceptable range (<80 is generally considered reasonable).
8. **BBB:** Ligand A (69.601) is lower than Ligand B (92.672). Since ADRB2 is not a CNS target, this is less important, but B is better here.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, these values are on a log scale, so the absolute difference is more important. Ligand A (-4.87) is slightly worse than Ligand B (-4.737).
10. **Solubility:** Ligand A (-4.819) is worse than Ligand B (-2.681). Solubility is important for bioavailability, so B is better.
11. **hERG:** Ligand A (0.708) is better than Ligand B (0.177), indicating a lower risk of cardiotoxicity. This is *very* important for a cardiovascular target.
12. **Cl_mic:** Ligand A (62.78) is much better than Ligand B (13.774). Lower clearance is desirable for better metabolic stability.
13. **t1/2:** Ligand A (33.826) is much better than Ligand B (-19.146). A longer half-life is generally preferred.
14. **Pgp:** Ligand A (0.611) is better than Ligand B (0.178). Lower P-gp efflux is desirable for better bioavailability.
15. **Affinity:** Ligand B (-7.0) has a slightly better affinity than Ligand A (-6.8). However, the difference is small (0.2 kcal/mol).
**Overall Assessment:**
Ligand B has a better affinity and BBB penetration, but Ligand A has superior properties in several critical areas for a cardiovascular drug: lower TPSA, better hERG inhibition, significantly better metabolic stability (Cl_mic and t1/2), and lower P-gp efflux. The solubility of Ligand B is better, but the other advantages of Ligand A outweigh this. The low logP of Ligand B is a significant concern for permeability.
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), and the importance of minimizing cardiotoxicity (hERG) for a cardiovascular target, Ligand A is the more promising candidate.
Output:
1
2025-04-17 20:21:10,921 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (a cardiovascular GPCR) drug candidates.
**Ligand A:** [348.447, 87.32, 1.122, 2, 4, 0.62, 26.134, 25.126, -5.006, -1.109, 0.11, -3.294, -9.209, 0.018, -3.5]
**Ligand B:** [344.371, 110.26, 1.362, 2, 6, 0.7, 62.854, 45.909, -5.049, -2.558, 0.069, 27.392, -22.909, 0.047, -5.8]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (348.447) is slightly higher than Ligand B (344.371), but the difference is negligible.
2. **TPSA:** Ligand A (87.32) is excellent, well below the 140 threshold for oral absorption and good for a GPCR. Ligand B (110.26) is still acceptable, but less optimal.
3. **logP:** Both are within the optimal range (1-3), with Ligand A (1.122) being slightly lower and potentially having slightly lower permeability. Ligand B (1.362) is better.
4. **HBD:** Both have 2 HBD, which is good.
5. **HBA:** Ligand A (4) is better than Ligand B (6). Lower HBA generally improves permeability.
6. **QED:** Both are acceptable (A: 0.62, B: 0.7), but Ligand B is slightly better.
7. **DILI:** Ligand A (26.134) has a significantly lower DILI risk than Ligand B (62.854). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (25.126) has a lower BBB penetration than Ligand B (45.909). While ADRB2 is cardiovascular, some CNS penetration can be a concern for off-target effects, but isn't a primary driver.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. The values are very similar.
10. **Solubility:** Both have negative solubility values, which is also concerning. Ligand B (-2.558) is slightly worse than Ligand A (-1.109).
11. **hERG:** Both have very low hERG inhibition risk (A: 0.11, B: 0.069).
12. **Cl_mic:** Ligand A (-3.294) has a lower (better) microsomal clearance than Ligand B (27.392), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-22.909) has a much longer in vitro half-life than Ligand A (-9.209). This is a significant advantage for Ligand B.
14. **Pgp:** Both have very low Pgp efflux liability (A: 0.018, B: 0.047).
15. **Affinity:** Ligand B (-5.8) has a significantly better binding affinity than Ligand A (-3.5). This is a substantial advantage.
**GPCR-Specific Considerations:**
For a cardiovascular GPCR like ADRB2, we prioritize logP, TPSA, affinity, and metabolic stability. Ligand B has a better logP and significantly better affinity. However, Ligand A has a much better DILI score and better metabolic stability. The poor Caco-2 and solubility values are concerning for both, but the affinity difference is substantial.
**Decision:**
The significantly improved binding affinity of Ligand B (-5.8 vs -3.5) is a major driver. While Ligand A has a better safety profile (DILI) and metabolic stability, the potency advantage of Ligand B is likely to outweigh these concerns, especially in early-stage drug discovery. The poor permeability and solubility are issues that can be addressed through further optimization.
Output:
0
2025-04-17 20:21:10,921 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (344.455 Da) is slightly lower, which is generally favorable for permeability.
**2. TPSA:** Ligand A (69.64) is significantly better than Ligand B (29.54). For a GPCR, lower TPSA is generally preferred as it aids membrane permeability.
**3. logP:** Ligand A (2.36) is within the optimal range (1-3), while Ligand B (4.284) is pushing the upper limit. Higher logP can lead to off-target effects and solubility issues.
**4. H-Bond Donors:** Ligand A (2) is reasonable, and Ligand B (0) is also acceptable.
**5. H-Bond Acceptors:** Both ligands have 3 HBA, which is within the acceptable range.
**6. QED:** Both ligands have similar QED values (0.711 and 0.681), indicating good drug-likeness.
**7. DILI:** Ligand B (26.638) has a slightly better DILI score than Ligand A (20.202), indicating a lower risk of liver injury. However, both are below the concerning threshold of 60.
**8. BBB:** Ligand B (83.831) has a significantly higher BBB penetration score than Ligand A (63.164). While ADRB2 is a cardiovascular target, some CNS effects are possible with beta-blockers, and higher BBB penetration could be a concern. However, for a cardiovascular target, this isn't a primary driver.
**9. Caco-2 Permeability:** Ligand A (-4.611) is better than Ligand B (-5.172), indicating better intestinal absorption.
**10. Aqueous Solubility:** Ligand A (-1.685) is better than Ligand B (-4.863), which is crucial for formulation and bioavailability.
**11. hERG Inhibition:** Both ligands have similar hERG inhibition liability (0.293 and 0.767), indicating low cardiotoxicity risk.
**12. Microsomal Clearance:** Ligand A (33.897) has significantly lower microsomal clearance than Ligand B (125.288), suggesting better metabolic stability.
**13. In vitro Half-Life:** Ligand A (24.771) has a much longer in vitro half-life than Ligand B (4.025), which is desirable for less frequent dosing.
**14. P-gp Efflux:** Ligand A (0.073) has a lower P-gp efflux liability than Ligand B (0.736), indicating better oral bioavailability.
**15. Binding Affinity:** Both ligands have the same binding affinity (-6.3 kcal/mol).
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand A is the more promising candidate. While Ligand B has better BBB penetration and a slightly better DILI score, Ligand A excels in TPSA, logP, solubility, metabolic stability (lower Cl_mic and longer t1/2), and P-gp efflux. The combination of these factors, particularly the favorable ADME properties, outweighs the slightly higher BBB score of Ligand B. The similar binding affinity makes the ADME profile the deciding factor.
Output:
1
2025-04-17 20:21:10,921 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (344.371 Da) is better, falling nicely within the 200-500 Da range. Ligand B (371.413 Da) is still acceptable but closer to the upper limit.
2. **TPSA:** Ligand B (71.33) is significantly better than Ligand A (117.08). Lower TPSA generally favors better permeability, crucial for GPCRs.
3. **logP:** Ligand A (1.191) is slightly better than Ligand B (0.608), both are within the optimal range, but A is closer to the ideal 1-3 range.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (0). While both are acceptable, lower HBD can sometimes improve permeability.
5. **HBA:** Ligand A (5) and Ligand B (6) are both reasonable.
6. **QED:** Both ligands have good QED scores (A: 0.723, B: 0.776), indicating good drug-like properties. B is slightly better.
7. **DILI:** Ligand B (62.156) is better than Ligand A (77.898) as it has a lower risk of drug-induced liver injury.
8. **BBB:** Ligand B (71.074) is significantly better than Ligand A (29.159). For a GPCR, even if not a CNS target, some BBB penetration can be beneficial for distribution.
9. **Caco-2:** Ligand A (-5.698) is better than Ligand B (-4.947), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-3.054) is better than Ligand B (-2.232). Solubility is important for bioavailability.
11. **hERG:** Both ligands have very low hERG risk (A: 0.024, B: 0.123). This is excellent.
12. **Cl_mic:** Ligand A (-26.667) is *much* better than Ligand B (18.016). Lower clearance indicates greater metabolic stability, a key factor for drug duration.
13. **t1/2:** Ligand A (-15.714) is better than Ligand B (-3.629), indicating a longer half-life.
14. **Pgp:** Both ligands have very low Pgp efflux liability (A: 0.024, B: 0.063).
15. **Affinity:** Ligand B (-7.8 kcal/mol) is slightly better than Ligand A (-7.2 kcal/mol). This is a 0.6 kcal/mol difference, which is significant but not overwhelming.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), TPSA, logP, Pgp, and affinity are particularly important. Ligand B excels in TPSA and BBB penetration, and has slightly better affinity. Ligand A has a better logP and solubility. However, the superior metabolic stability (Cl_mic and t1/2) of Ligand A is a significant advantage.
**Overall Assessment:**
While Ligand B has a slight edge in affinity and BBB penetration, the significantly better metabolic stability (lower Cl_mic and longer t1/2) of Ligand A, combined with acceptable TPSA and logP, makes it the more promising candidate. The better solubility and Caco-2 permeability also contribute to its favorability. The difference in binding affinity is not large enough to overcome the ADME advantages of Ligand A.
Output:
1
2025-04-17 20:21:10,922 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (385.251 Da) is within the ideal range, while Ligand B (352.431 Da) is slightly below, but still acceptable.
2. **TPSA:** Ligand A (96.26) is slightly above the preferred <90 for CNS targets, but still reasonable for a peripherally acting GPCR like ADRB2. Ligand B (85.89) is excellent.
3. **logP:** Ligand A (3.63) is optimal. Ligand B (0.369) is quite low, potentially hindering membrane permeability and bioavailability. This is a significant concern.
4. **HBD:** Ligand A (3) and Ligand B (2) are both within the acceptable limit of 5.
5. **HBA:** Ligand A (4) and Ligand B (5) are both within the acceptable limit of 10.
6. **QED:** Both Ligand A (0.701) and Ligand B (0.721) have good drug-likeness scores.
7. **DILI:** Ligand A (85.227) has a higher DILI risk than Ligand B (46.258), which is a clear advantage for B.
8. **BBB:** Both have similar BBB penetration (A: 61.846, B: 62.466). Not a major factor for ADRB2, but slightly favors B.
9. **Caco-2:** Ligand A (-4.822) and Ligand B (-5.163) both have poor Caco-2 permeability, suggesting potential absorption issues.
10. **Solubility:** Ligand A (-5.097) and Ligand B (-1.977) both have poor solubility.
11. **hERG:** Both are low risk (A: 0.159, B: 0.16).
12. **Cl_mic:** Ligand A (33.7) has a better (lower) microsomal clearance than Ligand B (-1.423), indicating better metabolic stability.
13. **t1/2:** Ligand A (58.096) has a longer in vitro half-life than Ligand B (38.476), which is desirable.
14. **Pgp:** Both have low P-gp efflux (A: 0.066, B: 0.03), which is good.
15. **Binding Affinity:** Ligand B (-7.7 kcal/mol) has a significantly stronger binding affinity than Ligand A (-4.9 kcal/mol). This 2.8 kcal/mol difference is substantial and can outweigh many ADME concerns.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand B excels in affinity, has a better TPSA, and a lower DILI risk. While its logP is a concern, the substantial binding affinity advantage is likely to be critical. The poor Caco-2 and solubility are drawbacks, but formulation strategies can sometimes mitigate these.
**Conclusion:**
Despite Ligand A's better metabolic stability and half-life, the significantly superior binding affinity of Ligand B, combined with its lower DILI risk and acceptable TPSA, makes it the more promising candidate. The low logP is a concern, but the potency advantage is substantial.
Output:
0
2025-04-17 20:21:10,922 - INFO - Batch 178 complete. Total preferences: 2848
2025-04-17 20:21:10,922 - INFO - Processing batch 179/512...
2025-04-17 20:21:57,183 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.402 and 346.431 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (49.85) is significantly better than Ligand B (107.01). For a GPCR, keeping TPSA low is beneficial for permeability, and Ligand A is well below the 140 threshold, while Ligand B is approaching it.
3. **logP:** Both ligands have acceptable logP values (1.057 and 1.802), falling within the 1-3 range. Ligand B is slightly higher, which could potentially lead to some solubility issues, but it's not a major concern.
4. **HBD:** Ligand A (0) is preferable to Ligand B (3). Fewer hydrogen bond donors generally improve membrane permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (4). Similar to HBD, lower HBA is generally better for permeability.
6. **QED:** Ligand A (0.819) has a substantially better QED score than Ligand B (0.593), indicating a more drug-like profile.
7. **DILI:** Ligand A (35.867) has a significantly lower DILI risk than Ligand B (56.689). This is a crucial advantage, as liver toxicity is a major concern in drug development.
8. **BBB:** Ligand A (94.067) has a much higher BBB penetration percentile than Ligand B (38.581). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be beneficial for distribution and off-target effects assessment.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.196 and -4.956). These are unusual and suggest poor permeability in this assay. However, the absolute values are similar, so this isn't a major differentiating factor.
10. **Solubility:** Ligand A (-2.677) has a slightly better (less negative) solubility score than Ligand B (-3.862), indicating better aqueous solubility.
11. **hERG:** Both ligands have low hERG inhibition liability (0.735 and 0.674), which is good. No significant difference.
12. **Cl_mic:** Ligand A (40.215) has a lower microsomal clearance than Ligand B (56.434), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-13.226) has a more negative in vitro half-life than Ligand B (13.154). A more negative value suggests a shorter half-life, which is less desirable. This is a drawback for Ligand A.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.14 and 0.148). No significant difference.
15. **Binding Affinity:** Ligand B (-5.7) has a slightly better binding affinity than Ligand A (-6.2). While a 0.5 kcal/mol difference is noticeable, the other advantages of Ligand A likely outweigh this.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical ADME-Tox properties (TPSA, QED, DILI, BBB, Solubility, Cl_mic). The slightly shorter half-life of Ligand A is a concern, but the superior overall profile, especially the significantly lower DILI risk and better predicted permeability (lower TPSA, fewer HBD/HBA), makes it the more promising candidate. The affinity difference is not large enough to overcome the other advantages of Ligand A.
Output:
1
2025-04-17 20:21:57,184 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (356.491 and 345.443 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (45.48) is significantly better than Ligand B (84.23). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold. Ligand B is approaching the upper limit.
3. **logP:** Both ligands have acceptable logP values (3.927 and 2.662), falling within the 1-3 range. Ligand A is slightly higher, which *could* be a minor concern for solubility, but isn't a dealbreaker.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Both ligands have the same number of HBA (4).
6. **QED:** Ligand A (0.797) has a better QED score than Ligand B (0.504), indicating a more drug-like profile.
7. **DILI:** Ligand A (35.75) has a lower DILI risk than Ligand B (42.148), which is a significant advantage. Both are below the 60 threshold, but lower is always better.
8. **BBB:** Ligand A (74.719) has better BBB penetration than Ligand B (68.554). While not a primary concern for a cardiovascular target, it's a slight positive for Ligand A.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.397 and -5.151). These values are difficult to interpret without more context, but suggest poor permeability.
10. **Solubility:** Ligand A (-3.409) has better solubility than Ligand B (-2.388).
11. **hERG:** Ligand A (0.861) has a lower hERG risk than Ligand B (0.07), which is a significant advantage.
12. **Cl_mic:** Ligand A (24.164) has significantly lower microsomal clearance than Ligand B (64.825), suggesting better metabolic stability.
13. **t1/2:** Ligand A (47.051) has a much longer in vitro half-life than Ligand B (-28.822). This is a major advantage, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.413) has lower P-gp efflux than Ligand B (0.181), which is a positive.
15. **Binding Affinity:** Ligand B (-6.8) has slightly better binding affinity than Ligand A (-6.5). However, the difference is only 0.3 kcal/mol, and can be overcome by the other advantages of Ligand A.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical ADME-Tox properties (DILI, hERG, Cl_mic, t1/2, solubility, QED, TPSA). While Ligand B has a slightly better binding affinity, the other advantages of Ligand A, particularly its improved safety profile (DILI, hERG) and pharmacokinetic properties (Cl_mic, t1/2), make it the more promising drug candidate for the ADRB2 receptor.
Output:
1
2025-04-17 20:21:57,184 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (367.768 Da and 375.447 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (88.49) is well below the 140 threshold and good for oral absorption. Ligand B (130.67) is still acceptable but closer to the upper limit. GPCRs benefit from lower TPSA, giving a slight edge to A.
3. **logP:** Ligand A (2.772) is optimal (1-3). Ligand B (-0.537) is significantly lower, potentially hindering membrane permeability and absorption. This is a major drawback for Ligand B.
4. **HBD:** Ligand A (2) and Ligand B (3) are both acceptable (<=5).
5. **HBA:** Ligand A (5) and Ligand B (6) are both acceptable (<=10).
6. **QED:** Ligand A (0.85) is excellent, indicating high drug-likeness. Ligand B (0.522) is decent but lower.
7. **DILI:** Ligand A (96.704) has a high DILI risk, which is concerning. Ligand B (52.734) has a much lower, and acceptable, DILI risk. This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (58.666) is not ideal for a GPCR, but not terrible. Ligand B (67.158) is better, but still not high. Since ADRB2 is a cardiovascular target, BBB penetration isn't *critical*, but it's still a consideration.
9. **Caco-2:** Ligand A (-4.659) and Ligand B (-5.411) are both very poor. This indicates very poor intestinal absorption for both.
10. **Solubility:** Ligand A (-4.581) and Ligand B (-1.515) are both very poor.
11. **hERG:** Ligand A (0.158) and Ligand B (0.055) are both low risk.
12. **Cl_mic:** Ligand A (16.56) is higher than Ligand B (3.808), meaning Ligand B is more metabolically stable.
13. **t1/2:** Ligand A (38.852) has a longer half-life than Ligand B (5.191). This is a positive for Ligand A.
14. **Pgp:** Ligand A (0.084) has lower P-gp efflux than Ligand B (0.027), indicating better bioavailability.
15. **Binding Affinity:** Ligand B (-6.0) has a significantly stronger binding affinity than Ligand A (-4.1). A 1.9 kcal/mol difference is substantial and can often outweigh other ADME concerns.
**Overall Assessment:**
Ligand B has a significantly better binding affinity, lower DILI risk, and better metabolic stability. However, it suffers from a very low logP and poor Caco-2 and solubility. Ligand A has a better logP and longer half-life, but a concerningly high DILI risk. The strong binding affinity of Ligand B is a major advantage for a GPCR target. While the poor logP is a significant concern, it might be addressable through prodrug strategies or formulation approaches. The DILI risk of Ligand A is harder to mitigate.
Given the importance of binding affinity for GPCRs and the potential to address the logP issue, I favor Ligand B.
Output:
0
2025-04-17 20:21:57,184 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **Molecular Weight:** Both ligands (344.43 and 346.475 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (42.43) is significantly lower than Ligand B (87.46). This is a major advantage for Ligand A, as lower TPSA generally correlates with better cell permeability, crucial for GPCR targeting. Ligand B's TPSA is relatively high.
3. **logP:** Ligand A (4.24) is higher than Ligand B (1.885). While both are within the acceptable range, Ligand A is approaching the upper limit where solubility issues could arise. However, for a GPCR, a slightly higher logP can be beneficial for membrane interactions.
4. **H-Bond Donors:** Ligand A (0) has fewer H-bond donors than Ligand B (3). Fewer donors generally improve permeability.
5. **H-Bond Acceptors:** Both ligands have the same number of H-bond acceptors (4).
6. **QED:** Ligand A (0.778) has a better QED score than Ligand B (0.596), indicating a more drug-like profile.
7. **DILI:** Ligand B (28.577) has a significantly lower DILI risk than Ligand A (39.938). This is a substantial advantage for Ligand B.
8. **BBB:** Ligand A (96.123) has a much higher BBB penetration score than Ligand B (71.307). While ADRB2 isn't exclusively a CNS target, some CNS exposure can occur, and higher BBB penetration is generally favorable.
9. **Caco-2 Permeability:** Ligand A (-4.5) has a worse Caco-2 permeability than Ligand B (-5.358). Lower values indicate lower permeability.
10. **Aqueous Solubility:** Ligand B (-1.602) has better aqueous solubility than Ligand A (-3.939). This is important, especially given Ligand A's higher logP.
11. **hERG Inhibition:** Both ligands have low hERG inhibition risk (0.908 and 0.641, respectively). No major difference.
12. **Microsomal Clearance:** Ligand B (-10.08) has significantly lower microsomal clearance than Ligand A (94.873). This suggests better metabolic stability for Ligand B.
13. **In vitro Half-Life:** Ligand A (29.518) has a longer in vitro half-life than Ligand B (7.077). This is a positive for Ligand A.
14. **P-gp Efflux:** Ligand A (0.69) has lower P-gp efflux liability than Ligand B (0.032). Lower efflux is generally preferred.
15. **Binding Affinity:** Ligand A (-6.5) has slightly better binding affinity than Ligand B (-6.3). While the difference is small, it's still a factor.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, TPSA, logP, Pgp, and affinity are key. Ligand A excels in TPSA, Pgp, and affinity, while Ligand B has better solubility and lower DILI risk. The higher metabolic stability of Ligand B is also a significant benefit.
**Overall Assessment:**
While Ligand A has a slight edge in affinity and BBB penetration, Ligand B's superior DILI profile, metabolic stability, and solubility are more critical for overall drug development success. The TPSA of Ligand B is a concern, but the other benefits outweigh this drawback.
Output:
0
2025-04-17 20:21:57,184 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (340.423 and 356.507 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (58.64) is significantly better than Ligand B (70.08). ADRB2 is a cardiovascular target, so CNS penetration isn't critical, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (2.899 and 2.192), falling within the 1-3 optimal range. Ligand A is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Both have 1 HBD, which is within the acceptable limit of 5.
5. **HBA:** Ligand A has 3 HBA, and Ligand B has 4. Both are acceptable (<=10).
6. **QED:** Ligand A (0.92) has a much better QED score than Ligand B (0.687), indicating a more drug-like profile.
7. **DILI:** Ligand A (60.915) has a significantly higher DILI risk than Ligand B (12.253). This is a major concern for Ligand A.
8. **BBB:** Both have similar BBB penetration (79.643 and 79.566). Not a major factor for a cardiovascular target.
9. **Caco-2:** Ligand A (-5.051) is worse than Ligand B (-4.229), indicating poorer intestinal absorption.
10. **Solubility:** Ligand A (-3.333) is worse than Ligand B (-1.131), indicating lower aqueous solubility.
11. **hERG:** Both ligands have low hERG inhibition risk (0.39 and 0.243).
12. **Cl_mic:** Ligand A (24.347) has a much lower microsomal clearance than Ligand B (74.952), suggesting better metabolic stability.
13. **t1/2:** Ligand A (21.386) has a longer in vitro half-life than Ligand B (-4.874). This is a positive attribute.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.168 and 0.096).
15. **Binding Affinity:** Ligand A (-7.0) has a slightly better binding affinity than Ligand B (-4.5). This is a significant advantage.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. While Ligand A has better logP, affinity, and TPSA, the high DILI risk and poor solubility/Caco-2 are substantial drawbacks. Ligand B has a much better safety profile (DILI) and better solubility/absorption, even though its affinity is lower. The difference in affinity (2.5 kcal/mol) is significant, but not insurmountable, and can potentially be addressed with further optimization.
**Conclusion:**
Considering the balance of properties, especially the significantly lower DILI risk and better solubility/absorption of Ligand B, it is the more viable drug candidate despite the slightly lower binding affinity. The DILI risk associated with Ligand A is a major red flag.
Output:
0
2025-04-17 20:21:57,184 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (359.83 & 364.52 Da) fall comfortably within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (29.54) is significantly better than Ligand B (68.3). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold, while Ligand B is approaching it.
3. **logP:** Ligand A (4.482) is slightly higher than Ligand B (3.04). Both are within the acceptable 1-3 range, but Ligand A is pushing the upper limit.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer HBDs generally improve membrane permeability.
5. **HBA:** Ligand A (2) is significantly better than Ligand B (7). Lower HBA is desirable for permeability.
6. **QED:** Both ligands have very similar QED scores (0.805 and 0.804), indicating good drug-likeness.
7. **DILI:** Ligand B (55.45) has a lower DILI risk than Ligand A (67.43), which is a significant advantage.
8. **BBB:** Both ligands have high BBB penetration (88.99 and 84.84), but Ligand A is slightly higher. This isn't a major concern for a cardiovascular target.
9. **Caco-2:** Ligand A (-4.57) is worse than Ligand B (-5.137). Lower (more negative) values indicate poorer permeability.
10. **Solubility:** Ligand B (-3.599) is better than Ligand A (-5.243). Better solubility is always a plus.
11. **hERG:** Both ligands have low hERG inhibition risk (0.796 and 0.714).
12. **Cl_mic:** Ligand B (50.01) has significantly lower microsomal clearance than Ligand A (93.202), indicating better metabolic stability.
13. **t1/2:** Ligand B (43.11) has a much longer in vitro half-life than Ligand A (13.766). This is a major advantage.
14. **Pgp:** Both ligands have low P-gp efflux (0.847 and 0.056). Ligand B is much lower, which is preferable.
15. **Binding Affinity:** Ligand A (-7.0) has a slightly better binding affinity than Ligand B (-5.2). This is a 1.8 kcal/mol difference, which is substantial.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has a better logP and affinity, but Ligand B excels in TPSA, Pgp, and significantly better metabolic stability (Cl_mic and t1/2). The difference in affinity is significant, but the ADME profile of Ligand B is far superior. The lower DILI risk for Ligand B is also a major benefit.
**Conclusion:**
While Ligand A has a slightly better binding affinity, the superior ADME properties of Ligand B, particularly its lower DILI risk, better metabolic stability, and improved permeability characteristics, make it the more promising drug candidate.
Output:
0
2025-04-17 20:21:57,185 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (354.441) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (49.41) is significantly better than Ligand B (139.62). For a GPCR, keeping TPSA low is beneficial for permeability and potentially BBB penetration. Ligand B is close to the upper limit for good oral absorption.
3. **logP:** Ligand A (2.964) is optimal. Ligand B (-0.04) is quite low, potentially leading to poor membrane permeability and bioavailability.
4. **HBD:** Ligand A (1) is preferred over Ligand B (4). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (2) is better than Ligand B (6). Similar to HBDs, lower HBA counts are generally preferred.
6. **QED:** Both ligands have acceptable QED values (A: 0.847, B: 0.508), indicating reasonable drug-likeness. Ligand A is better.
7. **DILI:** Ligand A (29.042) has a much lower DILI risk than Ligand B (51.26). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (90.074) shows excellent BBB penetration potential, while Ligand B (67.507) is lower. This is a crucial factor for GPCRs, even if not specifically CNS targets, as it can influence off-target effects.
9. **Caco-2:** Ligand A (-4.589) and Ligand B (-5.766) both have negative values, which is unusual. I will interpret this as very low permeability.
10. **Solubility:** Ligand A (-3.927) is slightly better than Ligand B (-2.238), but both are poor.
11. **hERG:** Ligand A (0.541) has a lower hERG risk than Ligand B (0.232), which is preferable.
12. **Cl_mic:** Ligand A (10.524) has a significantly lower microsomal clearance than Ligand B (33.284), indicating better metabolic stability.
13. **t1/2:** Ligand A (23.256) has a longer in vitro half-life than Ligand B (-8.929). This is a major advantage.
14. **Pgp:** Ligand A (0.051) has a lower Pgp efflux liability than Ligand B (0.029).
15. **Affinity:** Both ligands have very similar and excellent binding affinities (A: -7.8 kcal/mol, B: -7.0 kcal/mol). The difference of 0.8 kcal/mol is not substantial enough to override the other significant differences.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical ADME properties, including TPSA, logP, DILI, BBB, Cl_mic, and t1/2. While both have good binding affinity, Ligand A's superior ADME profile makes it a much more promising drug candidate for the ADRB2 receptor. The low logP and high TPSA of Ligand B are particularly concerning.
Output:
1
2025-04-17 20:21:57,185 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.471 and 352.387 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (67.43) is significantly better than Ligand B (105.17). ADRB2 is a cardiovascular target, not a CNS target, but lower TPSA generally aids absorption. Ligand A is well below the 140 threshold, while Ligand B is approaching it.
3. **logP:** Ligand A (2.169) is within the optimal 1-3 range. Ligand B (-0.942) is *below* 1, which is a concern for permeability. This is a significant negative for Ligand B.
4. **HBD:** Both ligands have 2 HBD, which is acceptable.
5. **HBA:** Ligand A has 3 HBA, while Ligand B has 6. Ligand A is preferable as it is closer to the ideal of <=10.
6. **QED:** Ligand A (0.724) is better than Ligand B (0.502), indicating a more drug-like profile.
7. **DILI:** Ligand B (32.028) has a lower DILI risk than Ligand A (15.394), which is a positive for Ligand B. However, both are below the concerning threshold of 60.
8. **BBB:** Not a primary concern for a cardiovascular target. Ligand A (69.019) is better than Ligand B (45.754), but this is less critical.
9. **Caco-2:** Ligand A (-5.042) is better than Ligand B (-4.884), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-2.911) is better than Ligand B (-0.975). Solubility is important for bioavailability.
11. **hERG:** Both ligands have very low hERG risk (0.221 and 0.136), which is excellent.
12. **Cl_mic:** Ligand B (-9.191) has significantly lower (better) microsomal clearance than Ligand A (34.32). This suggests better metabolic stability for Ligand B.
13. **t1/2:** Ligand B (-10.385) has a much longer in vitro half-life than Ligand A (-0.471). This is a major advantage for Ligand B.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.053 and 0.098).
15. **Binding Affinity:** Ligand A (-6.8) has a slightly better binding affinity than Ligand B (-6.4). While a 0.4 kcal/mol difference isn't huge, it's a positive for Ligand A.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand A excels in TPSA and has a slightly better affinity. However, Ligand B has significantly better metabolic stability (Cl_mic, t1/2) and a lower DILI risk. The poor logP of Ligand B is a major drawback.
**Overall Assessment:**
While Ligand B has advantages in metabolic stability and DILI, the significantly lower logP is a substantial concern for permeability and oral bioavailability. Ligand A, despite slightly worse metabolic properties, has a more favorable balance of properties, particularly its logP and TPSA, making it more likely to be a viable drug candidate. The slightly better affinity of Ligand A further supports this choice.
Output:
1
2025-04-17 20:21:57,185 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.463 and 359.417 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (78.51) is significantly better than Ligand A (106.96). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (3.224) is within the optimal range (1-3), while Ligand B (1.013) is at the lower end, potentially impacting permeability. Ligand A has an advantage here.
4. **HBD:** Both ligands have 2 HBD, which is acceptable.
5. **HBA:** Both ligands have 3 HBA, which is acceptable.
6. **QED:** Ligand B (0.743) has a considerably higher QED score than Ligand A (0.22), indicating a more drug-like profile.
7. **DILI:** Ligand B (29.779) has a much lower DILI risk than Ligand A (19.659), a significant advantage.
8. **BBB:** Ligand B (82.047) shows better BBB penetration than Ligand A (54.634). While not critical for a cardiovascular target, it's a positive.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.04 and -4.927), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Both ligands have negative solubility values (-2.05 and -2.156), indicating very poor aqueous solubility. This is a major drawback for both.
11. **hERG:** Both ligands have low hERG inhibition risk (0.313 and 0.348).
12. **Cl_mic:** Ligand B (-5.441) has a *negative* microsomal clearance, which is highly unusual and suggests very high metabolic stability. Ligand A (15.219) has a moderate clearance. This is a huge advantage for Ligand B.
13. **t1/2:** Ligand B (-31.244) has a negative in vitro half-life, which is also highly unusual and suggests an extremely long half-life. Ligand A (4.533) has a reasonable half-life.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.066 and 0.014).
15. **Binding Affinity:** Ligand A (-7.4) has a slightly better binding affinity than Ligand B (-7.1), but the difference is relatively small (0.3 kcal/mol).
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has a better logP and slightly better affinity. However, Ligand B excels in TPSA, DILI, Cl_mic, and has a better QED score. The extremely favorable metabolic stability (negative Cl_mic) and long half-life of Ligand B are particularly compelling. The poor solubility and Caco-2 permeability are concerning for both, but the other benefits of Ligand B outweigh the slight affinity advantage of Ligand A.
**Conclusion:**
Considering the overall profile, Ligand B is the more promising drug candidate due to its superior DILI profile, metabolic stability, QED score, and TPSA. While solubility and permeability are concerns for both, the other advantages of Ligand B are more significant for overall drug development potential.
Output:
0
2025-04-17 20:21:57,185 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.403 and 344.499 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (101.49) is higher than Ligand B (40.62). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B is significantly better.
3. **logP:** Ligand A (0.591) is quite low, potentially hindering membrane permeability. Ligand B (3.539) is within the optimal 1-3 range. Ligand B is significantly better.
4. **HBD:** Ligand A (1) is good. Ligand B (0) is also good, potentially improving permeability. No strong preference.
5. **HBA:** Ligand A (6) is acceptable. Ligand B (2) is excellent. Ligand B is better.
6. **QED:** Both ligands (0.755 and 0.716) have good drug-likeness scores, exceeding the 0.5 threshold. No significant difference.
7. **DILI:** Ligand A (52.074) has a higher DILI risk than Ligand B (13.843). Ligand B is significantly better.
8. **BBB:** Ligand A (69.911) and Ligand B (76.464) are both reasonably good, but not exceptional. Since ADRB2 isn't a CNS target, this isn't a major deciding factor. Ligand B is slightly better.
9. **Caco-2:** Ligand A (-5.053) and Ligand B (-4.774) are both negative, indicating poor permeability. This is concerning for both, but the values are similar.
10. **Solubility:** Ligand A (-0.852) is poor, while Ligand B (-3.504) is even worse. Both are problematic, but Ligand A is slightly better.
11. **hERG:** Ligand A (0.049) is very low risk, while Ligand B (0.315) is slightly higher, but still acceptable. Ligand A is better.
12. **Cl_mic:** Ligand A (18.949) has a lower microsomal clearance than Ligand B (52.904), suggesting better metabolic stability. Ligand A is better.
13. **t1/2:** Ligand A (-7.761) has a longer in vitro half-life than Ligand B (-8.986). Ligand A is better.
14. **Pgp:** Ligand A (0.011) has very low P-gp efflux liability, while Ligand B (0.264) is higher. Ligand A is better.
15. **Affinity:** Ligand B (-7.8) has a slightly better binding affinity than Ligand A (-6.5), a difference of 1.3 kcal/mol. This is a significant advantage.
**Overall Assessment:**
Ligand B has a superior logP, TPSA, HBA, and DILI profile. The affinity difference is substantial enough to outweigh the slightly poorer solubility, hERG, Cl_mic, t1/2, and Pgp values. While both have poor Caco-2 permeability, the other advantages of Ligand B make it the more promising candidate.
Output:
0
2025-04-17 20:21:57,185 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.431 and 362.392 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (93.11) is slightly higher than Ligand B (69.64). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B has a clear advantage.
3. **logP:** Ligand A (-0.036) is quite low, potentially hindering membrane permeability. Ligand B (1.987) is within the optimal 1-3 range. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (3) and Ligand B (2) are both acceptable, being less than 5.
5. **HBA:** Ligand A (5) and Ligand B (3) are both acceptable, being less than 10.
6. **QED:** Both ligands have good QED scores (0.643 and 0.786, respectively), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (3.916%) has a much lower DILI risk than Ligand B (22.102%). This is a substantial advantage for Ligand A.
8. **BBB:** Ligand A (9.616%) has very low BBB penetration, while Ligand B (74.176%) has high BBB penetration. Since ADRB2 is a cardiovascular target, BBB penetration is not a priority, making Ligand A's low value acceptable and even preferable.
9. **Caco-2:** Ligand A (-5.964) and Ligand B (-4.891) both have negative Caco-2 permeability values, which is unusual and suggests poor absorption. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Ligand A (-1.187) and Ligand B (-2.628) both have negative solubility values, which is also unusual and suggests poor solubility.
11. **hERG:** Both ligands have relatively low hERG risk (0.076 and 0.556, respectively). Ligand A is slightly better.
12. **Cl_mic:** Ligand A (-30.886) has a much lower (better) microsomal clearance than Ligand B (-5.1). This indicates greater metabolic stability for Ligand A.
13. **t1/2:** Ligand A (-2.096) has a negative in vitro half-life, which is concerning. Ligand B (-3.987) also has a negative value, but is slightly worse.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.003 and 0.055, respectively).
15. **Binding Affinity:** Ligand B (-6.9 kcal/mol) has a slightly better binding affinity than Ligand A (-6.1 kcal/mol). This is a 0.8 kcal/mol difference, which is significant but not overwhelming.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, affinity) and general drug-like properties, Ligand A emerges as the more promising candidate. While Ligand B has better logP and affinity, Ligand A has a significantly lower DILI risk and better metabolic stability (lower Cl_mic). The low BBB penetration of Ligand A is not a concern for a cardiovascular target. The negative solubility and Caco-2 values are concerning for both, but the other advantages of Ligand A outweigh the slightly better affinity of Ligand B.
Output:
1
2025-04-17 20:21:57,186 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (337.471 and 348.374 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (57.74) is significantly better than Ligand B (79.62). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand A is well below the 140 threshold, while Ligand B is approaching it.
**3. logP:** Ligand A (4.238) is higher than Ligand B (2.007). While both are within the acceptable range (1-3), Ligand A is at the upper end. This *could* lead to solubility issues, but is not a dealbreaker.
**4. H-Bond Donors:** Ligand A (0) is preferable to Ligand B (1). Fewer HBDs generally improve membrane permeability.
**5. H-Bond Acceptors:** Ligand A (5) is slightly better than Ligand B (4). Both are within the acceptable range.
**6. QED:** Both ligands have good QED scores (0.791 and 0.826), indicating good overall drug-likeness.
**7. DILI:** Ligand A (32.183) has a lower DILI risk than Ligand B (44.63), making it safer from a liver toxicity perspective.
**8. BBB:** Ligand B (85.421) has a higher BBB penetration percentile than Ligand A (74.292). While ADRB2 isn't strictly a CNS target, some peripheral distribution is still desired and a higher BBB score isn't necessarily detrimental.
**9. Caco-2:** Both ligands have negative Caco-2 values (-4.874 and -4.604). This is unusual and suggests poor permeability. However, these values are on the same scale, so it doesn't differentiate the two.
**10. Solubility:** Ligand A (-4.917) has worse solubility than Ligand B (-3.136). This is a concern given Ligand A's higher logP.
**11. hERG:** Ligand A (0.695) has a lower hERG risk than Ligand B (0.145), which is a significant advantage for cardiovascular targets.
**12. Cl_mic:** Ligand B (27.584) has significantly lower microsomal clearance than Ligand A (56.796), meaning it's more metabolically stable.
**13. t1/2:** Ligand B (-7.748) has a longer in vitro half-life than Ligand A (-2.915), indicating better persistence in the body.
**14. Pgp:** Ligand A (0.335) has lower P-gp efflux than Ligand B (0.072), which is favorable for bioavailability.
**15. Binding Affinity:** Ligand B (-7.7) has a slightly better binding affinity than Ligand A (-6.8). This is a 0.9 kcal/mol difference, which is significant.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), and balancing all parameters, **Ligand B is the more promising candidate.** While Ligand A has advantages in DILI and hERG, Ligand B's superior metabolic stability (lower Cl_mic, longer t1/2), slightly better affinity, and better solubility outweigh those benefits. The TPSA difference is also substantial. The slightly higher BBB score for Ligand B is a bonus. The Caco-2 values are concerning for both, but don't differentiate them.
Output:
0
2025-04-17 20:21:57,186 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (339.439 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (45.67) is significantly better than Ligand B (114.35). ADRB2 is not a CNS target, but lower TPSA generally improves absorption. Ligand B's TPSA is quite high, potentially hindering oral bioavailability.
3. **logP:** Both ligands have acceptable logP values (A: 2.46, B: 1.226), falling within the 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer hydrogen bond donors generally improve permeability.
5. **HBA:** Ligand A (4) is better than Ligand B (6). Lower HBA counts are generally preferred for better permeability.
6. **QED:** Both ligands have similar QED values (A: 0.862, B: 0.846), indicating good drug-likeness.
7. **DILI:** Ligand A (47.421) has a lower DILI risk than Ligand B (64.986), which is a significant advantage.
8. **BBB:** Both have high BBB penetration, but Ligand B (91.508) is slightly better than Ligand A (81.815). However, BBB is less crucial for ADRB2 as it's not a CNS target.
9. **Caco-2:** Ligand A (-4.326) is better than Ligand B (-5.055), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-1.293) is better than Ligand B (-4.384), which is important for formulation and bioavailability.
11. **hERG:** Both ligands have low hERG inhibition risk (A: 0.632, B: 0.425).
12. **Cl_mic:** Ligand A (23.548) has a significantly lower microsomal clearance than Ligand B (6.737), indicating better metabolic stability.
13. **t1/2:** Ligand A (36.545) has a much longer in vitro half-life than Ligand B (-19.83), which is highly desirable.
14. **Pgp:** Both ligands have very low P-gp efflux liability (A: 0.187, B: 0.025).
15. **Binding Affinity:** Both ligands have comparable binding affinities (A: -6.6 kcal/mol, B: -6.5 kcal/mol). The difference is minimal.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A excels in TPSA, logP, solubility, metabolic stability (Cl_mic, t1/2), and DILI risk, while maintaining comparable affinity to Ligand B. The higher TPSA and lower metabolic stability of Ligand B are significant drawbacks.
**Conclusion:**
Considering the balance of properties and the priorities for a GPCR target, Ligand A is the more promising drug candidate. Its superior ADME profile, particularly its lower TPSA, better solubility, improved metabolic stability, and lower DILI risk, outweigh the slightly better BBB penetration of Ligand B.
Output:
1
2025-04-17 20:21:57,186 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (374.5 and 360.5 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Both ligands have TPSA values around 75, which is acceptable, but slightly above the optimal <90 for GPCRs.
**3. logP:** Ligand A (1.595) is better than Ligand B (3.368). While both are within the acceptable range, Ligand B is approaching the upper limit where solubility issues may arise.
**4. H-Bond Donors:** Both have 1 HBD, which is good.
**5. H-Bond Acceptors:** Both have 5 HBA, which is good.
**6. QED:** Both ligands have similar QED values (0.74 and 0.781), indicating good drug-likeness.
**7. DILI:** Ligand A (8.53 percentile) has a significantly lower DILI risk than Ligand B (52.191 percentile). This is a major advantage for Ligand A.
**8. BBB:** Ligand A (69.368) and Ligand B (72.431) are both reasonable, but not exceptionally high. Since ADRB2 is a cardiovascular target, BBB penetration isn't a primary concern, but it's still a positive.
**9. Caco-2:** Ligand A (-4.806) and Ligand B (-5.225) are similar, indicating similar intestinal absorption potential.
**10. Solubility:** Ligand A (-1.248) is better than Ligand B (-4.033), which is a positive attribute given Ligand B's higher logP.
**11. hERG:** Ligand A (0.484) has a lower hERG inhibition liability than Ligand B (0.35), which is a significant safety advantage.
**12. Cl_mic:** Ligand A (5.058) has a lower microsomal clearance than Ligand B (65.236), suggesting better metabolic stability. This is a crucial factor for drug duration and dosing frequency.
**13. t1/2:** Ligand A (-10.484) has a much longer in vitro half-life than Ligand B (1.575). This is a substantial advantage for Ligand A, potentially allowing for less frequent dosing.
**14. Pgp:** Ligand A (0.011) has significantly lower P-gp efflux liability than Ligand B (0.385). This is beneficial for bioavailability.
**15. Binding Affinity:** Ligand B (-6.1 kcal/mol) has a slightly better binding affinity than Ligand A (-5.9 kcal/mol). However, the difference is only 0.2 kcal/mol, which is not substantial enough to overcome the numerous ADME advantages of Ligand A.
**Overall Assessment:**
Ligand A demonstrates a significantly better overall profile, particularly regarding safety (DILI, hERG), metabolic stability (Cl_mic, t1/2), and bioavailability (Pgp, Solubility). While Ligand B has slightly better binding affinity, the difference is not large enough to outweigh the substantial advantages of Ligand A. Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity), Ligand A is the more promising candidate.
Output:
1
2025-04-17 20:21:57,186 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (354.372 and 347.415 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (49.41) is well below the 140 threshold and good for oral absorption. Ligand B (89.95) is higher, but still acceptable, though less optimal.
3. **logP:** Ligand A (3.743) is within the optimal 1-3 range. Ligand B (-0.94) is significantly lower, which could hinder membrane permeability and oral absorption. This is a major drawback for a GPCR ligand.
4. **HBD:** Both have acceptable HBD counts (1 and 2 respectively), well below the 5 limit.
5. **HBA:** Both have acceptable HBA counts (2 and 4 respectively), well below the 10 limit.
6. **QED:** Both ligands have reasonable QED scores (0.823 and 0.607), indicating good drug-like properties.
7. **DILI:** Ligand A (37.922) has a much lower DILI risk than Ligand B (11.09). This is a significant advantage.
8. **BBB:** Ligand A (91.508) shows good BBB penetration, while Ligand B (44.32) is much lower. While ADRB2 isn't strictly a CNS target, some CNS exposure can be relevant for off-target effects, and higher BBB is generally favorable.
9. **Caco-2:** Ligand A (-4.232) and Ligand B (-5.117) both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
10. **Solubility:** Ligand A (-4.84) and Ligand B (-1.355) both have negative solubility values, which is also unusual and suggests poor solubility. Again, the scale is not specified.
11. **hERG:** Ligand A (0.645) has a lower hERG risk than Ligand B (0.092). This is a significant safety advantage.
12. **Cl_mic:** Ligand A (51.296) has a higher microsomal clearance than Ligand B (-29.134). This means Ligand B is likely more metabolically stable.
13. **t1/2:** Ligand A (33.613) has a longer in vitro half-life than Ligand B (0.295). This is a positive attribute.
14. **Pgp:** Ligand A (0.361) has lower P-gp efflux liability than Ligand B (0.003). Lower Pgp is generally preferred.
15. **Binding Affinity:** Ligand A (-6.6 kcal/mol) and Ligand B (-6.2 kcal/mol) have comparable binding affinities, with Ligand A being slightly better.
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are crucial. Ligand A excels in logP and Pgp, while having comparable affinity. Ligand B's low logP is a major concern.
**Overall Assessment:**
Ligand A is the stronger candidate. While Ligand B has better metabolic stability (lower Cl_mic), the significantly better logP, lower DILI risk, better BBB penetration, lower hERG risk, and slightly better affinity of Ligand A outweigh this advantage. The negative Caco-2 and solubility values are concerning for both, but the other factors favor Ligand A.
Output:
1
2025-04-17 20:21:57,186 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (361.467 and 344.499 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (80.2) is higher than Ligand B (40.62). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is generally preferred for absorption. Ligand B is significantly better.
3. **logP:** Both ligands have good logP values (2.878 and 3.393), falling within the optimal 1-3 range. Ligand B is slightly higher, which *could* be a minor negative if it leads to off-target effects, but it's not a major concern.
4. **HBD:** Ligand A has 2 HBD, while Ligand B has 0. Lower HBD is generally preferable for permeability. Ligand B is better.
5. **HBA:** Ligand A has 4 HBA, Ligand B has 2. Similar to HBD, lower HBA is generally preferable. Ligand B is better.
6. **QED:** Ligand A (0.83) has a better QED score than Ligand B (0.633), indicating a more drug-like profile overall. This is a point in favor of Ligand A.
7. **DILI:** Ligand A (68.282) has a higher DILI risk than Ligand B (19.271). This is a significant advantage for Ligand B. Lower DILI is crucial.
8. **BBB:** Ligand A (54.091) has a lower BBB penetration than Ligand B (90.772). While ADRB2 isn't exclusively a CNS target, some brain exposure can occur, and higher BBB is generally desirable. Ligand B is better.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.839 and -4.77). This is unusual and suggests poor permeability. However, the values are very similar, so this isn't a deciding factor.
10. **Solubility:** Ligand A (-3.704) has slightly better solubility than Ligand B (-3.337). Solubility is important, but not a primary concern given the other factors.
11. **hERG:** Ligand A (0.314) has a lower hERG risk than Ligand B (0.545). This is a positive for Ligand A, as hERG inhibition can cause cardiotoxicity.
12. **Cl_mic:** Ligand A (15.454) has a lower microsomal clearance than Ligand B (67.537), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (70.761) has a significantly longer in vitro half-life than Ligand B (-18.976). This is a major advantage for Ligand A, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.17) has lower P-gp efflux than Ligand B (0.265). Lower P-gp efflux is generally preferred. Ligand A is better.
15. **Affinity:** Ligand B (-6.7) has a slightly better binding affinity than Ligand A (-6.1). While a difference of 0.6 kcal/mol is noticeable, the other ADME properties are more concerning for Ligand B.
**Overall Assessment:**
Ligand B has a better binding affinity and BBB penetration, but suffers from a higher DILI risk, worse metabolic stability (higher Cl_mic, shorter half-life), and higher P-gp efflux. Ligand A has a better QED, lower DILI, better metabolic stability, longer half-life, and lower P-gp efflux. The slightly weaker affinity of Ligand A is outweighed by its superior ADME profile, especially the lower DILI risk and improved metabolic stability, which are critical for cardiovascular drugs.
Output:
1
2025-04-17 20:21:57,187 - INFO - Batch 179 complete. Total preferences: 2864
2025-04-17 20:21:57,187 - INFO - Processing batch 180/512...
2025-04-17 20:22:44,924 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (395.493 and 377.413 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (71.52) is better than Ligand B (84.67). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally favors absorption.
3. **logP:** Ligand A (2.911) is slightly higher than Ligand B (1.538), placing it closer to the optimal 1-3 range. Ligand B is a bit low, potentially hindering permeability.
4. **HBD:** Ligand A (0) is preferable to Ligand B (1). Fewer HBDs generally improve membrane permeability.
5. **HBA:** Ligand A (4) is better than Ligand B (6). Fewer HBAs are generally preferred.
6. **QED:** Both ligands have similar QED values (0.786 and 0.776), indicating good drug-likeness.
7. **DILI:** Both ligands have similar DILI risk (65.917 and 66.77), both are acceptable, but not ideal.
8. **BBB:** Both ligands have high BBB penetration (86.739 and 80.419). While not critical for a cardiovascular target, it doesn't hurt.
9. **Caco-2:** Both ligands have very poor Caco-2 permeability (-4.722 and -4.773). This is a significant concern for oral bioavailability for both.
10. **Solubility:** Ligand A (-4.399) is better than Ligand B (-2.986), indicating better aqueous solubility.
11. **hERG:** Ligand A (0.844) is better than Ligand B (0.172). Lower hERG inhibition is crucial for avoiding cardiotoxicity, a major concern with cardiovascular drugs.
12. **Cl_mic:** Ligand A (31.299) has lower microsomal clearance than Ligand B (37.449), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-13.408) has a much worse in vitro half-life than Ligand B (12.21). This is a significant drawback for Ligand A.
14. **Pgp:** Ligand A (0.583) is better than Ligand B (0.073). Lower P-gp efflux is desirable for improved bioavailability.
15. **Binding Affinity:** Ligand A (-6.9 kcal/mol) has a slightly better binding affinity than Ligand B (-5.7 kcal/mol). This difference of 1.2 kcal/mol is substantial and can outweigh some ADME drawbacks.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A performs better on logP, TPSA, and Pgp. The affinity difference is also significant. While Ligand A has a poor half-life, the better binding affinity and other favorable ADME properties make it more promising.
**Conclusion:**
Considering the balance of properties, particularly the superior binding affinity, logP, TPSA, Pgp, and hERG profile of Ligand A, it is the more promising drug candidate despite the lower half-life. The better affinity could potentially allow for a lower dose, mitigating some concerns about the shorter half-life.
Output:
1
2025-04-17 20:22:44,924 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (344.43 and 352.475 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (45.59) is significantly better than Ligand B (75.71). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold. Ligand B is approaching the upper limit.
3. **logP:** Both ligands have acceptable logP values (3.359 and 2.119), falling within the 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability, but not drastically so.
4. **HBD:** Both ligands have 1 HBD, which is within the acceptable limit of 5.
5. **HBA:** Both ligands have 4 HBA, also within the acceptable limit of 10.
6. **QED:** Ligand A (0.862) has a much better QED score than Ligand B (0.587), indicating a more drug-like profile overall.
7. **DILI:** Ligand A (30.942) has a significantly lower DILI risk than Ligand B (12.136). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (88.135) has a higher BBB penetration percentile than Ligand B (78.092). While not critical for a cardiovascular target, it's still a positive attribute.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.652 and -4.497). These values are unusual and difficult to interpret without context, but suggest poor permeability.
10. **Solubility:** Both ligands have negative solubility values (-2.013 and -2.524), indicating very poor aqueous solubility. This is a significant concern for both.
11. **hERG:** Ligand A (0.964) has a slightly higher hERG inhibition liability than Ligand B (0.394), but both are relatively low risk.
12. **Cl_mic:** Ligand B (53.758) has a higher microsomal clearance than Ligand A (21.757), suggesting faster metabolism and potentially lower *in vivo* exposure.
13. **t1/2:** Ligand A (53.929) has a significantly longer *in vitro* half-life than Ligand B (-14.178). This is a substantial advantage for Ligand A.
14. **Pgp:** Ligand A (0.776) has a slightly higher P-gp efflux liability than Ligand B (0.031). Lower Pgp is preferred, so Ligand B is better here.
15. **Binding Affinity:** Ligand B (-7.4 kcal/mol) has a slightly better binding affinity than Ligand A (-5.9 kcal/mol). This is a 1.5 kcal/mol difference, which is significant.
**Overall Assessment:**
Despite the slightly better affinity of Ligand B, Ligand A is the more promising candidate. The advantages of Ligand A in terms of QED, DILI risk, *in vitro* half-life, and lower clearance outweigh the minor affinity difference. The poor solubility and Caco-2 values are concerning for both, but these can potentially be addressed through formulation strategies. The lower DILI risk is particularly important, as is the better metabolic stability indicated by the lower Cl_mic and longer half-life.
Output:
1
2025-04-17 20:22:44,924 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
Let's analyze each ligand against the provided guidelines, keeping in mind the GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key).
* **Molecular Weight:** Both ligands (354.43 and 345.44 Da) fall within the ideal 200-500 Da range.
* **TPSA:** Both ligands have TPSA values (83.56 and 84.23) that are acceptable for oral absorption (<=140), but not optimized for CNS penetration (<=90). This is less critical for a cardiovascular target like ADRB2.
* **logP:** Ligand A (0.589) is a bit low, potentially hindering permeability. Ligand B (2.504) is much better, falling within the optimal 1-3 range. This is a significant advantage for Ligand B.
* **H-Bond Donors/Acceptors:** Both ligands have reasonable HBD (2) and HBA (5/4) counts, unlikely to cause major issues.
* **QED:** Both ligands have good QED scores (0.643 and 0.795), indicating good drug-like properties.
* **DILI:** Both ligands have low DILI risk (30.32 and 35.98), which is excellent.
* **BBB:** Both ligands have reasonable BBB penetration (78.71 and 71.81). While not a primary concern for a cardiovascular target, higher is generally preferred.
* **Caco-2 Permeability:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. This is a red flag for both.
* **Aqueous Solubility:** Ligand A (-0.482) is slightly better than Ligand B (-2.849), but both are poor. Solubility could be a formulation challenge for both.
* **hERG Inhibition:** Both ligands show low hERG inhibition risk (0.434 and 0.34), which is positive.
* **Microsomal Clearance:** Ligand A (29.76 mL/min/kg) has significantly lower clearance than Ligand B (50.28 mL/min/kg), suggesting better metabolic stability.
* **In vitro Half-Life:** Ligand A (12.37 hours) has a much longer half-life than Ligand B (-12.60 hours), which is a major advantage.
* **P-gp Efflux:** Both ligands have very low P-gp efflux (0.024 and 0.157), which is favorable.
* **Binding Affinity:** Ligand B (-5.7 kcal/mol) has a stronger binding affinity than Ligand A (-4.9 kcal/mol). This 0.8 kcal/mol difference is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand B has a significantly better logP and binding affinity, which are critical for GPCR targets. While Ligand A has better metabolic stability and half-life, the stronger binding of Ligand B is more important. The poor Caco-2 permeability is a concern for both, but the superior affinity of Ligand B makes it the more promising candidate, assuming formulation strategies can address the permeability issue.
**Output:**
0
2025-04-17 20:22:44,924 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (345.443) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are reasonably low, but Ligand A (61.88) is better than Ligand B (65.98), falling comfortably under the 140 A^2 threshold for oral absorption.
3. **logP:** Both ligands have good logP values (A: 1.17, B: 1.02), falling within the optimal 1-3 range.
4. **HBD:** Ligand A (1) is preferable to Ligand B (0) as a single HBD can aid solubility without significantly hindering permeability.
5. **HBA:** Ligand A (5) is better than Ligand B (6), staying within the preferred range of <=10.
6. **QED:** Ligand B (0.791) has a better QED score than Ligand A (0.594), indicating a more drug-like profile.
7. **DILI:** Ligand A (26.095) has a significantly lower DILI risk than Ligand B (54.75), which is a major advantage.
8. **BBB:** Both ligands have acceptable BBB penetration (A: 67.08, B: 68.748), but neither is exceptionally high. This isn't a critical factor for ADRB2, which isn't a CNS target.
9. **Caco-2:** Ligand A (-4.88) is slightly better than Ligand B (-4.574), indicating potentially better intestinal absorption.
10. **Solubility:** Ligand A (-0.706) has better solubility than Ligand B (-2.3).
11. **hERG:** Ligand A (0.521) has a lower hERG inhibition liability than Ligand B (0.715), which is crucial for cardiovascular safety.
12. **Cl_mic:** Ligand B (25.556) has a lower microsomal clearance than Ligand A (42.169), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-13.034) has a longer in vitro half-life than Ligand A (-25.995), which is desirable.
14. **Pgp:** Ligand A (0.02) has a lower Pgp efflux liability than Ligand B (0.052), which is favorable for oral bioavailability.
15. **Binding Affinity:** Ligand B (-7.6) has a significantly stronger binding affinity than Ligand A (-5.1). This is a substantial advantage, exceeding the 1.5 kcal/mol threshold.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Both ligands are good on logP and TPSA. Ligand A is better on Pgp, while Ligand B excels in binding affinity. The strong affinity of Ligand B is a significant driver.
**Overall Assessment:**
While Ligand A has advantages in DILI risk, hERG, solubility, and Pgp efflux, the substantially stronger binding affinity of Ligand B (-7.6 vs -5.1 kcal/mol) outweighs these benefits. The improved metabolic stability (lower Cl_mic, longer t1/2) of Ligand B is also a positive. The slightly higher DILI and hERG risks of Ligand B can be investigated and potentially mitigated during further optimization.
Output:
0
2025-04-17 20:22:44,925 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, priorities are affinity, logP, TPSA, Pgp efflux, and BBB penetration (though BBB is less critical for a cardiovascular target).
Let's compare the ligands property by property:
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (343.427) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (65.79) is significantly better than Ligand B (90.95). Lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (1.768) is within the optimal range, while Ligand B (3.457) is on the higher side. While not drastically high, it could potentially lead to solubility issues or off-target interactions.
4. **HBD/HBA:** Ligand A (1 HBD, 4 HBA) is preferable to Ligand B (2 HBD, 5 HBA) as lower counts generally improve permeability.
5. **QED:** Both ligands have good QED scores (0.868 and 0.875), indicating good drug-like properties.
6. **DILI:** Ligand A (32.028) has a much lower DILI risk than Ligand B (72.354). This is a significant advantage.
7. **BBB:** Ligand A (62.931) has better BBB penetration than Ligand B (45.909), although neither is exceptionally high.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. This is a concern for both.
9. **Solubility:** Ligand A (-1.17) has better solubility than Ligand B (-4.396).
10. **hERG:** Ligand A (0.423) has a lower hERG risk than Ligand B (0.219), which is favorable.
11. **Cl_mic:** Ligand A (2.763) has significantly lower microsomal clearance than Ligand B (64.468), indicating better metabolic stability.
12. **t1/2:** Ligand A (58.931) has a much longer in vitro half-life than Ligand B (29.247).
13. **Pgp:** Ligand A (0.041) has lower P-gp efflux liability than Ligand B (0.141), which is beneficial for bioavailability.
14. **Affinity:** Ligand B (-7.7 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.3 kcal/mol). This is a substantial advantage.
**Overall Assessment:**
Ligand B has a significantly better binding affinity (-7.7 vs -6.3 kcal/mol). However, Ligand A demonstrates a much more favorable ADME-Tox profile across almost all parameters (DILI, solubility, metabolic stability, Pgp efflux, BBB). The substantial difference in affinity is a strong point for Ligand B. However, the combination of poor metabolic stability, higher DILI risk, and lower solubility for Ligand B makes it a less attractive candidate. The affinity difference, while notable, may be overcome with further optimization of Ligand A.
Considering the GPCR-specific priorities and the overall balance of properties, I believe Ligand A is the more viable drug candidate.
**Output:**
1
2025-04-17 20:22:44,925 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (362.499 Da and 378.519 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (70.4) is higher than Ligand B (51.66). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is generally preferred for absorption. Ligand B has a clear advantage.
3. **logP:** Both ligands have good logP values (3.323 and 3.763), falling within the optimal 1-3 range. Ligand B is slightly higher, which could potentially lead to slightly reduced solubility, but isn't a major concern.
4. **HBD:** Ligand A (2) is better than Ligand B (0). While low HBD can improve permeability, some H-bonding is beneficial for solubility and target engagement.
5. **HBA:** Ligand A (5) is lower than Ligand B (6). Similar to HBD, lower is generally preferred for permeability, giving Ligand A a slight edge.
6. **QED:** Both ligands have similar QED values (0.827 and 0.813), indicating good drug-likeness.
7. **DILI:** Ligand A (28.306) has a significantly lower DILI risk than Ligand B (66.615). This is a major advantage for Ligand A.
8. **BBB:** Both ligands have high BBB penetration (83.249% and 85.77%), which isn't a primary concern for a cardiovascular target like ADRB2, but isn't detrimental. Ligand B is slightly better.
9. **Caco-2:** Ligand A (-5.212) is slightly better than Ligand B (-4.831), indicating potentially better intestinal absorption.
10. **Solubility:** Ligand A (-2.288) is better than Ligand B (-3.696), which is important for bioavailability.
11. **hERG:** Ligand A (0.768) has a lower hERG inhibition liability than Ligand B (0.326), indicating a lower risk of cardiotoxicity. This is a significant advantage.
12. **Cl_mic:** Ligand A (9.183) has a significantly lower microsomal clearance than Ligand B (64.932), suggesting better metabolic stability. This is a crucial advantage.
13. **t1/2:** Ligand A (15.611) has a much longer in vitro half-life than Ligand B (4.935), which is desirable for less frequent dosing.
14. **Pgp:** Ligand A (0.196) has lower P-gp efflux liability than Ligand B (0.442), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand B (-6.0) has a slightly better binding affinity than Ligand A (-5.9). While a difference of 0.1 kcal/mol is not huge, it's a factor.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B in critical ADME-Tox properties (DILI, hERG, Cl_mic, t1/2, Pgp, solubility) and has comparable or slightly better permeability and solubility. The only area where Ligand B is superior is binding affinity, but the difference is small. Given the importance of minimizing off-target effects and maximizing metabolic stability and bioavailability for a cardiovascular drug, Ligand A is the more promising candidate.
Output:
1
2025-04-17 20:22:44,925 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.475 and 360.336 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (67.87) is significantly better than Ligand B (99.15). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold. Ligand B is approaching it but is less desirable.
3. **logP:** Both ligands have acceptable logP values (1.58 and 1.054), falling within the 1-3 range. Ligand B is slightly lower, which *could* indicate slightly poorer membrane permeability, but the difference isn't huge.
4. **HBD:** Ligand A (1) is preferable to Ligand B (4). Fewer HBDs generally improve permeability.
5. **HBA:** Both ligands have 4 HBA, which is acceptable.
6. **QED:** Ligand A (0.788) is better than Ligand B (0.62), indicating a more drug-like profile.
7. **DILI:** Ligand B (63.397) has a higher DILI risk than Ligand A (14.618). This is a significant concern, and Ligand A is clearly favored here.
8. **BBB:** Ligand A (63.048) has a better BBB percentile than Ligand B (48.275), but this isn't a major factor for a cardiovascular target.
9. **Caco-2:** Ligand A (-4.55) is better than Ligand B (-5.455). Higher Caco-2 values indicate better intestinal absorption.
10. **Solubility:** Ligand A (-1.751) is better than Ligand B (-2.49). Better solubility is always preferred.
11. **hERG:** Ligand A (0.279) is significantly better than Ligand B (0.573), indicating a lower risk of cardiotoxicity. This is *critical* for a cardiovascular target.
12. **Cl_mic:** Ligand B (9.286) has lower microsomal clearance than Ligand A (24.829), suggesting better metabolic stability. This is a positive for Ligand B.
13. **t1/2:** Ligand B (11.34) has a longer in vitro half-life than Ligand A (9.905), which is also a positive for Ligand B.
14. **Pgp:** Ligand A (0.041) has lower P-gp efflux than Ligand B (0.066), indicating better bioavailability.
15. **Binding Affinity:** Ligand A (-7.6) has a significantly stronger binding affinity than Ligand B (-6.3). A 1.3 kcal/mol difference is substantial and can often outweigh minor ADME drawbacks.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A excels in all these areas, especially affinity and TPSA. While Ligand B has better metabolic stability (Cl_mic and t1/2), the significantly lower DILI and hERG risks, better TPSA, Pgp, solubility, and *much* stronger binding affinity of Ligand A make it the more promising candidate.
Output:
1
2025-04-17 20:22:44,925 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (354.407) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (99.85) is significantly better than Ligand A (137.32). For a GPCR, lower TPSA is preferred for better penetration and oral absorption.
3. **logP:** Ligand B (1.018) is within the optimal range, while Ligand A (-0.142) is slightly below 1, potentially hindering permeation. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (4) is slightly higher than Ligand B (2). Both are acceptable, but lower is generally preferred.
5. **HBA:** Ligand A (6) is slightly higher than Ligand B (5). Both are acceptable.
6. **QED:** Ligand B (0.772) has a better QED score than Ligand A (0.513), indicating a more drug-like profile.
7. **DILI:** Both ligands have acceptable DILI risk (Ligand A: 58.705, Ligand B: 52.772), with Ligand B being slightly better.
8. **BBB:** Ligand B (55.138) has a better BBB penetration score than Ligand A (28.383). While ADRB2 isn't strictly a CNS target, some CNS exposure can be relevant, and a higher BBB score is generally favorable.
9. **Caco-2:** Both ligands have similar, poor Caco-2 permeability (-5.608 and -5.048). This is a concern for both, but not a deciding factor.
10. **Solubility:** Ligand A (-1.944) has slightly better solubility than Ligand B (-3.05), which is a minor advantage.
11. **hERG:** Both ligands have very low hERG inhibition risk (Ligand A: 0.024, Ligand B: 0.64). This is excellent for both.
12. **Cl_mic:** Ligand A (-5.446) has significantly lower (better) microsomal clearance than Ligand B (37.376), indicating better metabolic stability. This is a major advantage for Ligand A.
13. **t1/2:** Ligand A (-9.54) has a slightly better in vitro half-life than Ligand B (-2.225).
14. **Pgp:** Both ligands have very low Pgp efflux liability (Ligand A: 0.017, Ligand B: 0.107). This is excellent for both.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.4 and -6.2 kcal/mol). The difference is negligible.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand B is stronger in terms of logP and TPSA, which are crucial for permeability and absorption. While Ligand A has better metabolic stability (Cl_mic and t1/2) and solubility, the improvements in logP and TPSA for Ligand B are more critical for a GPCR target. The similar binding affinities make the ADME properties the deciding factors.
Output:
0
2025-04-17 20:22:44,925 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (371.459 Da and 384.885 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (88.18) is slightly higher than Ligand B (78.87), but both are below the 140 A^2 threshold for good oral absorption. Given ADRB2 is a cardiovascular target, CNS penetration isn't a primary concern, so this isn't a major differentiator.
**3. logP:** Ligand B (1.523) is better than Ligand A (0.749). While both are within the acceptable range, a logP closer to 1-3 is preferred for good permeability and avoiding off-target effects. Ligand A's lower logP could potentially hinder membrane permeability.
**4. H-Bond Donors:** Ligand A (1) is better than Ligand B (2). Fewer H-bond donors generally improve permeability.
**5. H-Bond Acceptors:** Both ligands have the same number of H-bond acceptors (5), which is within the acceptable limit.
**6. QED:** Ligand A (0.681) has a slightly higher QED score than Ligand B (0.575), suggesting a more drug-like profile.
**7. DILI:** Ligand B (39.628) has a significantly lower DILI risk than Ligand A (47.654). This is a crucial factor, as liver toxicity is a major concern in drug development.
**8. BBB:** Ligand A (70.027) has a higher BBB penetration percentile than Ligand B (28.383). However, as ADRB2 is primarily a cardiovascular target, BBB penetration is not a high priority.
**9. Caco-2 Permeability:** Ligand A (-4.552) and Ligand B (-4.984) have similar, very poor Caco-2 permeability. This is a concern for both, but not a deciding factor.
**10. Aqueous Solubility:** Ligand A (-1.868) has slightly better solubility than Ligand B (-2.473). Solubility is important for formulation and bioavailability.
**11. hERG Inhibition:** Ligand B (0.324) has a lower hERG inhibition liability than Ligand A (0.526). This is a significant advantage, as hERG inhibition can lead to cardiotoxicity.
**12. Microsomal Clearance:** Ligand B (-4.971) has a much lower (better) microsomal clearance than Ligand A (28.24). This indicates greater metabolic stability for Ligand B.
**13. In vitro Half-Life:** Ligand B (6.939) has a significantly longer in vitro half-life than Ligand A (-60.24). This is a major advantage, as a longer half-life can lead to less frequent dosing.
**14. P-gp Efflux:** Ligand A (0.048) has lower P-gp efflux than Ligand B (0.194), which is favorable for bioavailability.
**15. Binding Affinity:** Ligand A (-6.9 kcal/mol) has a slightly better binding affinity than Ligand B (-6.4 kcal/mol). While a difference of 0.5 kcal/mol is noticeable, the other ADME properties of Ligand B are more compelling.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity) and the general drug-like properties, Ligand B is the more promising candidate. While Ligand A has slightly better affinity and P-gp efflux, Ligand B excels in crucial ADME properties like DILI risk, hERG inhibition, microsomal clearance, and in vitro half-life. The lower DILI and hERG risk, coupled with improved metabolic stability and longer half-life, outweigh the small difference in binding affinity.
Output:
0
2025-04-17 20:22:44,926 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.435 and 352.494 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (109.74) is higher than Ligand B (49.41). For a cardiovascular GPCR like ADRB2, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B is significantly better.
3. **logP:** Ligand A (1.202) is within the optimal range (1-3), while Ligand B (3.16) is at the higher end. Both are acceptable, but Ligand A's value is slightly more balanced.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 5 HBA, while Ligand B has 2. Both are within the acceptable range (<=10), but Ligand B is better.
6. **QED:** Both ligands have good QED scores (0.718 and 0.798, respectively), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (27.879) has a slightly higher DILI risk than Ligand B (24.506), but both are below the concerning threshold of 60.
8. **BBB:** Ligand A (72.896) has a moderate BBB penetration, while Ligand B (97.286) has very high BBB penetration. While ADRB2 is primarily a cardiovascular target, some CNS off-target effects are possible, and lower BBB penetration is generally desirable to minimize these. Ligand A is better.
9. **Caco-2:** Ligand A (-5.16) and Ligand B (-4.595) both have negative values, which is unusual. This suggests poor Caco-2 permeability for both. However, the values are close, so this isn't a major differentiator.
10. **Solubility:** Ligand A (-1.444) has better solubility than Ligand B (-3.805). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.172) has a lower hERG risk than Ligand B (0.762). This is a significant advantage, as hERG inhibition can lead to cardiotoxicity.
12. **Cl_mic:** Ligand A (36.075) and Ligand B (37.89) have similar microsomal clearance values, suggesting comparable metabolic stability.
13. **t1/2:** Ligand A (8.46) has a shorter in vitro half-life than Ligand B (-16.024). A negative value for half-life is unusual and likely indicates a very long half-life, which is beneficial. Ligand B is better.
14. **Pgp:** Ligand A (0.052) has lower P-gp efflux liability than Ligand B (0.46). Lower P-gp efflux is generally preferred for better oral bioavailability. Ligand A is better.
15. **Binding Affinity:** Ligand A (-6.4) and Ligand B (-5.4) have good binding affinities, but Ligand A is significantly stronger. The 1.0 kcal/mol difference in binding affinity is substantial and can outweigh some ADME drawbacks.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B has a better logP and TPSA. Ligand A has better Pgp and significantly better affinity. The hERG risk is also a crucial factor, and Ligand A has a much lower risk.
**Overall Assessment:**
While Ligand B has some advantages in terms of BBB penetration and half-life, the significantly stronger binding affinity of Ligand A, combined with its lower hERG risk and better Pgp efflux profile, make it the more promising candidate. The slightly higher TPSA of Ligand A is a minor drawback compared to these benefits.
Output:
1
2025-04-17 20:22:44,926 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [350.354, 116.14 , -0.605, 3. , 6. , 0.643, 52.423, 17.449, -5.824, -1.512, 0.14 , -33.073, -11.396, 0.004, -6.6 ]
**Ligand B:** [343.431, 79.38 , 2.013, 2. , 6. , 0.871, 51.028, 88.445, -4.935, -3.664, 0.61 , 63.28 , 11.466, 0.039, -6.4 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (343.431) is slightly lower, which could be marginally beneficial for permeability.
2. **TPSA:** Ligand A (116.14) is higher than Ligand B (79.38). Ligand B is significantly better, being closer to the preferred <140 for oral absorption and more favorable for GPCRs.
3. **logP:** Ligand A (-0.605) is lower than the optimal 1-3 range, potentially hindering permeation. Ligand B (2.013) is within the optimal range. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (3) and Ligand B (2) are both acceptable.
5. **HBA:** Both ligands have 6 HBA, which is acceptable.
6. **QED:** Both have good QED scores (>0.5), indicating drug-like properties. Ligand B (0.871) is slightly better.
7. **DILI:** Both have similar, acceptable DILI risk (around 51-52 percentile).
8. **BBB:** Ligand B (88.445) has a much higher BBB penetration score than Ligand A (17.449). This is a *major* advantage for a GPCR target, even if not a CNS target, as it suggests better distribution.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so this is hard to interpret.
10. **Solubility:** Both have negative solubility values, which is also unusual. Again, the scale is not specified.
11. **hERG:** Both have low hERG inhibition liability (0.14 and 0.61), which is good.
12. **Cl_mic:** Ligand A (-33.073) has a much lower (better) microsomal clearance than Ligand B (63.28). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand B (11.466) has a longer in vitro half-life than Ligand A (-11.396). This is a positive for Ligand B.
14. **Pgp:** Both have very low Pgp efflux liability (0.004 and 0.039).
15. **Affinity:** Both have similar binding affinities (-6.6 and -6.4 kcal/mol). The difference is minimal.
**GPCR-Specific Considerations:**
For an ADRB2 (GPCR), we prioritize logP, TPSA, Pgp, BBB, and affinity. Ligand B excels in logP and BBB, while TPSA is also significantly better. Affinity is comparable. Ligand A has better metabolic stability (Cl_mic), but the benefits of improved ADME properties (logP, TPSA, BBB) in Ligand B outweigh this advantage.
**Conclusion:**
Considering the balance of properties, especially the GPCR-specific priorities, Ligand B is the more promising candidate.
0
2025-04-17 20:22:44,926 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [355.414, 89.35, 0.23, 1, 6, 0.721, 36.758, 78.79, -4.733, -1.273, 0.129, 7.499, 3.418, 0.025, -6.9]
**Ligand B:** [349.519, 52.65, 2.119, 1, 3, 0.799, 4.963, 90.19, -4.689, -1.872, 0.542, 41.814, 3.455, 0.064, -6.1]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (349.519) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (89.35) is better than Ligand B (52.65) as it is closer to the desired threshold of <140 for oral absorption.
3. **logP:** Ligand B (2.119) is optimal (1-3), while Ligand A (0.23) is too low, potentially hindering membrane permeability. This is a significant drawback for Ligand A.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A (6) is higher than Ligand B (3), but still within acceptable limits.
6. **QED:** Both are good (>0.5), with Ligand B (0.799) being slightly better.
7. **DILI:** Ligand A (36.758) has a better DILI score than Ligand B (4.963), indicating a lower risk of liver injury.
8. **BBB:** Ligand B (90.19) has a significantly higher BBB penetration score than Ligand A (78.79), which is a key consideration for GPCRs, even if this is a cardiovascular target.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability.
10. **Solubility:** Both have negative solubility values, which is also unusual and suggests poor solubility.
11. **hERG:** Ligand A (0.129) has a lower hERG inhibition liability than Ligand B (0.542), which is a positive.
12. **Cl_mic:** Ligand A (7.499) has a lower microsomal clearance, suggesting better metabolic stability than Ligand B (41.814).
13. **t1/2:** Both have similar in vitro half-lives (around 3.4 hours).
14. **Pgp:** Ligand A (0.025) has a lower P-gp efflux liability than Ligand B (0.064), which is beneficial for bioavailability.
15. **Binding Affinity:** Ligand A (-6.9 kcal/mol) has a slightly better binding affinity than Ligand B (-6.1 kcal/mol). This is a 0.8 kcal/mol difference which is significant.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, Pgp, TPSA, and affinity. Ligand B excels in BBB penetration, which is a bonus. Ligand A has a better affinity and lower Pgp efflux, but suffers from a very low logP.
**Overall Assessment:**
Despite Ligand A's slightly better affinity and lower DILI/Pgp, the extremely low logP is a major concern. A logP of 0.23 is likely to result in very poor membrane permeability and bioavailability. Ligand B, while having a slightly weaker affinity, has a much more favorable logP (2.119), better BBB penetration, and a better QED. The lower DILI of Ligand A is attractive, but the permeability issues are likely to be insurmountable.
Therefore, I believe Ligand B is the more promising drug candidate.
Output:
0
2025-04-17 20:22:44,926 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (354.431 and 346.387 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (71.45) is significantly better than Ligand B (95.86). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (4.014) is at the upper end of the optimal range, while Ligand B (-0.606) is quite low. A logP below 1 can hinder membrane permeability. Ligand A is preferable.
4. **HBD:** Both have acceptable HBD counts (2 and 1 respectively), well below the threshold of 5.
5. **HBA:** Both have acceptable HBA counts (5 and 6 respectively), well below the threshold of 10.
6. **QED:** Both ligands have similar and good QED scores (0.726 and 0.731).
7. **DILI:** Ligand A (82.396) has a higher DILI risk than Ligand B (60.721). This is a significant drawback for Ligand A.
8. **BBB:** Both have similar, relatively low BBB penetration (43.117 and 41.295). Not a major factor for a cardiovascular target.
9. **Caco-2:** Ligand A (-5.213) has a worse Caco-2 permeability than Ligand B (-4.881).
10. **Solubility:** Ligand A (-5.188) has worse solubility than Ligand B (-0.63). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.622) has a slightly higher hERG risk than Ligand B (0.052). This is a concern for Ligand A.
12. **Cl_mic:** Ligand A (99.951) has very high metabolic clearance, indicating poor metabolic stability. Ligand B (-0.095) has excellent metabolic stability. This is a major advantage for Ligand B.
13. **t1/2:** Ligand A (-23.145) has a very short in vitro half-life. Ligand B (0.052) has a very short in vitro half-life.
14. **Pgp:** Ligand A (0.79) has higher P-gp efflux than Ligand B (0.006). Lower P-gp efflux is preferred.
15. **Binding Affinity:** Ligand B (-7.1 kcal/mol) has a slightly better binding affinity than Ligand A (-7.9 kcal/mol). While the difference is small, it's still a factor.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, and affinity are key. Ligand A has a better logP and TPSA, but Ligand B has a slightly better affinity. However, the major issues with Ligand A are its high DILI risk, poor metabolic stability (high Cl_mic), and short half-life. These are critical liabilities. Ligand B's metabolic stability is a huge advantage, and its lower DILI risk is also very important.
**Conclusion:**
Despite Ligand A having slightly better TPSA and logP, the significant liabilities of high DILI risk, poor metabolic stability, and short half-life make it a less attractive candidate. Ligand B, with its better metabolic profile and lower toxicity risk, is the more promising drug candidate.
Output:
0
2025-04-17 20:22:44,926 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (341.346 and 350.409 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (81.93) is slightly higher than Ligand B (45.49). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferable for absorption. Ligand B is significantly better.
3. **logP:** Both ligands have good logP values (2.679 and 3.376), falling within the 1-3 optimal range. Ligand B is slightly higher, which could be a minor concern for solubility, but not a deal-breaker.
4. **HBD:** Ligand A has 1 HBD, while Ligand B has 0. Both are acceptable.
5. **HBA:** Ligand A has 6 HBA, and Ligand B has 4. Both are within the acceptable limit of 10.
6. **QED:** Ligand A (0.789) has a better QED score than Ligand B (0.685), indicating a more drug-like profile.
7. **DILI:** Ligand A has a very high DILI risk (98.565%), which is a major red flag. Ligand B has a much lower DILI risk (18.418%), making it significantly safer.
8. **BBB:** Both ligands have good BBB penetration (74.292% and 95.269%). This isn't a primary concern for an ADRB2 target (cardiovascular), but higher is generally better. Ligand B is better.
9. **Caco-2:** Both ligands show poor Caco-2 permeability (-4.574 and -4.443). This is a concern for oral absorption.
10. **Solubility:** Both ligands have poor aqueous solubility (-3.551 and -3.111). This could pose formulation challenges.
11. **hERG:** Ligand A has a very low hERG risk (0.342%), while Ligand B has a higher risk (0.962%). Ligand A is preferable here.
12. **Cl_mic:** Ligand A has a higher microsomal clearance (65.719) than Ligand B (33.196), indicating lower metabolic stability. Ligand B is preferable.
13. **t1/2:** Ligand B has a much longer in vitro half-life (26.838 hours) than Ligand A (-3.122 hours). This is a significant advantage for dosing frequency.
14. **Pgp:** Ligand A has very low Pgp efflux (0.074%), while Ligand B has moderate efflux (0.444%). Ligand A is preferable.
15. **Binding Affinity:** Ligand A (-7.2 kcal/mol) has a slightly better binding affinity than Ligand B (-5.9 kcal/mol). This is a 1.3 kcal/mol difference, which is substantial.
**Overall Assessment:**
Despite Ligand A's slightly better binding affinity and lower Pgp efflux, the extremely high DILI risk is a deal-breaker. The significantly lower DILI risk, better metabolic stability (lower Cl_mic, longer t1/2), and better BBB penetration of Ligand B outweigh the slightly weaker binding affinity. The poor Caco-2 and solubility are concerns for both, but can be addressed with formulation strategies. The safety profile is paramount.
Output:
0
2025-04-17 20:22:44,927 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [346.387, 119.48 , 1.048, 3. , 6. , 0.645, 66.227, 72.974, -5.237, -3.896, 0.505, 34.033, 10.288, 0.136, -6.6 ]
**Ligand B:** [365.459, 101.22 , 1.608, 1. , 7. , 0.724, 63.823, 47.189, -5.126, -2.523, 0.143, 64.491, 38.387, 0.128, -7.5 ]
Here's a step-by-step comparison, keeping GPCR priorities (logP, Pgp, TPSA, affinity) in mind:
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (346.387) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are good, below the 140 A^2 threshold. Ligand B (101.22) is better than Ligand A (119.48) for potential BBB penetration, though BBB is less critical for a cardiovascular target.
3. **logP:** Both are within the optimal range (1-3). Ligand A (1.048) is slightly lower, while Ligand B (1.608) is a bit higher.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (1). Lower is generally better, but both are acceptable.
5. **HBA:** Ligand A (6) is lower than Ligand B (7). Both are within the acceptable range of <=10.
6. **QED:** Both are good (>0.5), with Ligand B (0.724) being slightly better.
7. **DILI:** Both are acceptable, but Ligand B (63.823) is slightly better than Ligand A (66.227).
8. **BBB:** Ligand A (72.974) has a significantly better BBB penetration score than Ligand B (47.189). However, as this is a cardiovascular target, BBB is not a high priority.
9. **Caco-2:** Both are negative, indicating poor permeability. This is a significant drawback for both compounds.
10. **Solubility:** Both are negative, indicating poor solubility. This is a significant drawback for both compounds.
11. **hERG:** Both are very low, indicating minimal hERG inhibition risk. This is excellent.
12. **Cl_mic:** Ligand A (34.033) has a lower microsomal clearance than Ligand B (64.491), suggesting better metabolic stability.
13. **t1/2:** Ligand B (38.387) has a longer in vitro half-life than Ligand A (10.288), which is desirable.
14. **Pgp:** Both are very low, indicating minimal P-gp efflux. This is excellent.
15. **Affinity:** Ligand B (-7.5 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.6 kcal/mol). This is a substantial advantage, exceeding the 1.5 kcal/mol threshold.
**Overall Assessment:**
While Ligand A has slightly better metabolic stability and BBB penetration, the significantly stronger binding affinity of Ligand B (-7.5 vs -6.6 kcal/mol) is the most important factor, especially for a GPCR target. The longer half-life of Ligand B is also a plus. The poor Caco-2 and solubility for both are concerning, but can potentially be addressed with formulation strategies. The slightly better DILI score for Ligand B is also a minor benefit.
Therefore, I would prioritize Ligand B.
0
2025-04-17 20:22:44,927 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (351.357) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are good, below 140, but Ligand B (90.54) is better, closer to the 90 threshold for potential CNS penetration, though CNS targeting isn't explicitly stated here.
3. **logP:** Both ligands have optimal logP values (around 1.0-1.1), indicating good balance between solubility and permeability.
4. **HBD & HBA:** Both have 3 HBD and 4 HBA, which are acceptable values.
5. **QED:** Both have reasonable QED scores (0.664 and 0.615), indicating good drug-likeness.
6. **DILI:** Ligand B (46.336) has a significantly lower DILI risk than Ligand A (65.917). This is a major advantage for Ligand B.
7. **BBB:** Both have similar BBB penetration (around 50-51%), which isn't particularly high, but acceptable for a peripherally acting GPCR like ADRB2.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. This is a significant drawback for both.
9. **Solubility:** Both have negative solubility values, indicating poor aqueous solubility. This is a concern for both compounds.
10. **hERG:** Ligand B (0.28) has a much lower hERG inhibition liability than Ligand A (0.545), which is a crucial safety factor.
11. **Cl_mic:** Ligand A (-1.799) has a slightly better (lower, more negative) microsomal clearance than Ligand B (-1.74), suggesting better metabolic stability.
12. **t1/2:** Ligand A (6.386) has a longer in vitro half-life than Ligand B (-13.041). This is a positive attribute for Ligand A.
13. **Pgp:** Ligand A (0.027) has a lower P-gp efflux liability than Ligand B (0.014), which is favorable for bioavailability.
14. **Binding Affinity:** Ligand A (-7.3 kcal/mol) has a significantly stronger binding affinity than Ligand B (-5.9 kcal/mol). This is a substantial advantage for Ligand A.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. While both have good logP, Ligand A has a better Pgp profile. Ligand B has slightly better TPSA. However, the significant difference in binding affinity (-7.3 vs -5.9 kcal/mol) is the most important factor. This difference is large enough to potentially overcome the drawbacks of slightly higher DILI and hERG risk. The poor Caco-2 and solubility are concerning for both, but can be addressed with formulation strategies.
**Conclusion:**
Despite the better safety profile of Ligand B (lower DILI and hERG), the substantially stronger binding affinity of Ligand A makes it the more promising drug candidate. The potency advantage is likely to be more impactful than the moderate differences in ADME properties, especially given that formulation strategies can potentially mitigate the solubility and permeability issues.
Output:
1
2025-04-17 20:22:44,927 - INFO - Batch 180 complete. Total preferences: 2880
2025-04-17 20:22:44,927 - INFO - Processing batch 181/512...
2025-04-17 20:23:32,906 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (345.443 Da) is slightly lower, which is generally favorable for permeability, but both are acceptable.
**2. TPSA:** Ligand A (70.67) is better than Ligand B (78.87). Both are below 140, but lower TPSA is preferred for GPCRs to enhance brain penetration and overall absorption.
**3. logP:** Both ligands have good logP values (A: 1.41, B: 1.66) falling within the optimal 1-3 range.
**4. H-Bond Donors:** Both have 2 HBD, which is within the acceptable limit of 5.
**5. H-Bond Acceptors:** Ligand A (4) is better than Ligand B (5). Both are below 10, so this is a minor difference.
**6. QED:** Both ligands have good QED scores (A: 0.579, B: 0.642), indicating good drug-like properties. Ligand B is slightly better.
**7. DILI:** Ligand A (22.722) has a significantly lower DILI risk than Ligand B (19.814). This is a crucial advantage, as minimizing liver toxicity is paramount.
**8. BBB:** Ligand A (79.139) has a much higher BBB penetration percentile than Ligand B (36.293). For a GPCR, even if not specifically a CNS target, some degree of BBB penetration can be beneficial for off-target profiling and understanding potential side effects.
**9. Caco-2 Permeability:** Ligand A (-5.38) is better than Ligand B (-4.978). Higher Caco-2 permeability is desired.
**10. Aqueous Solubility:** Both have negative solubility values, indicating poor solubility. Ligand A (-2.047) is slightly better than Ligand B (-2.319), but this is a significant concern for both. Formulation strategies would be needed.
**11. hERG Inhibition:** Both have low hERG inhibition risk (A: 0.384, B: 0.452).
**12. Microsomal Clearance:** Ligand A (-18.972) has significantly lower (better) microsomal clearance than Ligand B (29.441), suggesting greater metabolic stability.
**13. In vitro Half-Life:** Ligand A (-3.672) has a slightly better in vitro half-life than Ligand B (6.473).
**14. P-gp Efflux:** Both have very low P-gp efflux liability (A: 0.018, B: 0.137).
**15. Binding Affinity:** Ligand B (-7.1) has a significantly stronger binding affinity than Ligand A (-5.6). This is a substantial advantage (1.5 kcal/mol difference).
**Overall Assessment:**
Ligand B has a superior binding affinity, which is a major plus. However, Ligand A demonstrates a much more favorable safety profile (lower DILI) and better predicted pharmacokinetic properties (higher BBB, lower clearance, better half-life, better Caco-2). The difference in affinity, while significant, can potentially be overcome with further optimization, while mitigating the safety and PK liabilities of Ligand B would be more challenging. Given the GPCR target class, the balance of properties favors Ligand A.
Output:
1
2025-04-17 20:23:32,907 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (344.415 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (75.43) is significantly better than Ligand A (96.26). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (A: 1.756, B: 2.426), falling within the optimal 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Ligand A (3) is higher than Ligand B (1). Lower HBD is generally preferred for better permeability.
5. **HBA:** Both ligands have the same number of HBA (5), which is within the acceptable limit of 10.
6. **QED:** Ligand B (0.8) has a higher QED score than Ligand A (0.678), indicating a more drug-like profile.
7. **DILI:** Ligand B (21.404) has a much lower DILI risk than Ligand A (55.37), a significant advantage.
8. **BBB:** Ligand B (74.758) has a higher BBB penetration score than Ligand A (67.235). While not crucial for a cardiovascular target, it's a positive attribute.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual. A higher (less negative) value is preferred. Ligand A (-5.275) is slightly better than Ligand B (-4.627).
10. **Solubility:** Both ligands have negative solubility values, which is unusual. A higher (less negative) value is preferred. Ligand A (-2.908) is slightly better than Ligand B (-2.485).
11. **hERG:** Both ligands have low hERG inhibition liability (A: 0.336, B: 0.239), which is good. Ligand B is slightly better.
12. **Cl_mic:** Both ligands have similar microsomal clearance values (A: 46.152, B: 48.039).
13. **t1/2:** Ligand A (25.327) has a significantly longer in vitro half-life than Ligand B (12.272), which is a major advantage.
14. **Pgp:** Both ligands have very low Pgp efflux liability (A: 0.074, B: 0.174), which is excellent.
15. **Binding Affinity:** Ligand A (-6.9 kcal/mol) has a significantly stronger binding affinity than Ligand B (-3.9 kcal/mol). This is a substantial difference.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), affinity, logP, TPSA, and Pgp are key. Ligand A excels in affinity, while Ligand B has better TPSA, logP, and DILI. The difference in affinity (-3 kcal/mol) is large enough to outweigh the slightly less favorable TPSA and logP of Ligand A, especially considering the longer half-life. The significantly lower DILI risk of Ligand B is also a strong consideration.
**Overall Assessment:**
While Ligand B has several advantages (lower DILI, better TPSA, slightly better logP and hERG), the substantially stronger binding affinity and longer half-life of Ligand A make it the more promising drug candidate. The improved affinity is likely to translate to greater efficacy, and the longer half-life could allow for less frequent dosing.
Output:
1
2025-04-17 20:23:32,907 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (408.344 Da) is within the ideal range, while Ligand B (346.471 Da) is towards the lower end, but still acceptable.
2. **TPSA:** Both ligands are below the 140 A^2 threshold for good oral absorption. Ligand A (64.26) is slightly higher than Ligand B (58.64), but both are good.
3. **logP:** Both ligands have optimal logP values (A: 3.069, B: 2.243), falling within the 1-3 range.
4. **HBD:** Ligand A (2) and Ligand B (1) are both within the acceptable limit of 5.
5. **HBA:** Ligand A (4) and Ligand B (3) are both within the acceptable limit of 10.
6. **QED:** Both ligands have good QED scores (A: 0.798, B: 0.849), indicating good drug-like properties.
7. **DILI:** Ligand B (14.618%) has a significantly lower DILI risk than Ligand A (55.176%), which is a major advantage.
8. **BBB:** Both ligands have good BBB penetration (A: 71.772%, B: 78.558%).
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. Ligand B (-4.725) is slightly better than Ligand A (-5.138).
10. **Solubility:** Both ligands have negative solubility values, indicating poor solubility. Ligand B (-2.803) is slightly better than Ligand A (-3.079).
11. **hERG:** Both ligands have low hERG inhibition liability (A: 0.945, B: 0.404), which is good. Ligand B is better.
12. **Cl_mic:** Ligand B (24.557 mL/min/kg) has a lower microsomal clearance than Ligand A (32.823 mL/min/kg), suggesting better metabolic stability.
13. **t1/2:** Ligand A (61.132 hours) has a significantly longer in vitro half-life than Ligand B (2.702 hours). This is a substantial advantage.
14. **Pgp:** Both ligands have very low P-gp efflux liability (A: 0.106, B: 0.093).
15. **Binding Affinity:** Ligand B (-5.9 kcal/mol) has a significantly stronger binding affinity than Ligand A (-4.2 kcal/mol). This is a 1.7 kcal/mol difference, which is substantial.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are particularly important. Both ligands perform well on logP and Pgp. TPSA is acceptable for both. However, Ligand B has a significantly superior binding affinity and a much better safety profile (lower DILI). While Ligand A has a longer half-life, the superior affinity and safety of Ligand B outweigh this benefit. The poor Caco-2 and solubility are concerns for both, but can be addressed with formulation strategies.
**Conclusion:**
Ligand B is the more promising candidate due to its significantly stronger binding affinity, lower DILI risk, and better metabolic stability, despite having a shorter half-life.
Output:
0
2025-04-17 20:23:32,908 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (351.447 and 350.547 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (78.95) is higher than Ligand B (32.78). For a cardiovascular GPCR, lower TPSA is generally preferred for better permeability, giving a slight edge to Ligand B.
**3. logP:** Ligand B (3.552) is higher than Ligand A (0.387). While both are within the acceptable range, Ligand B is closer to the optimal 1-3 range. Ligand A's low logP could indicate poor membrane permeability. This is a significant advantage for Ligand B.
**4. H-Bond Donors:** Ligand A has 1 HBD, and Ligand B has 0. Both are within the acceptable limit of 5. No major difference.
**5. H-Bond Acceptors:** Ligand A has 4 HBA, and Ligand B has 3. Both are within the acceptable limit of 10. No major difference.
**6. QED:** Ligand A (0.741) has a slightly better QED score than Ligand B (0.604), suggesting a more drug-like profile.
**7. DILI:** Ligand B (4.42) has a much lower DILI risk than Ligand A (26.095). This is a significant advantage for Ligand B.
**8. BBB:** Ligand B (92.827) has a much higher BBB penetration percentile than Ligand A (32.648). While ADRB2 is primarily a cardiovascular target, some CNS effects can be relevant or undesirable, and higher BBB penetration could be a concern. However, for a cardiovascular target, this isn't a primary driver.
**9. Caco-2 Permeability:** Both have negative Caco-2 values (-4.677 and -4.266), which is unusual and suggests poor permeability. This is a concern for both, but the values are similar.
**10. Aqueous Solubility:** Ligand A (-1.691) has slightly better aqueous solubility than Ligand B (-3.522).
**11. hERG Inhibition:** Ligand A (0.091) has a lower hERG inhibition liability than Ligand B (0.856). This is a significant advantage for Ligand A, as it reduces the risk of cardiotoxicity.
**12. Microsomal Clearance:** Ligand B (103.497) has a much higher microsomal clearance than Ligand A (23.716), indicating faster metabolism and potentially lower *in vivo* exposure. This is a significant advantage for Ligand A.
**13. In vitro Half-Life:** Ligand B (25.307) has a longer *in vitro* half-life than Ligand A (11.159). This is a slight advantage for Ligand B.
**14. P-gp Efflux:** Ligand A (0.009) has a much lower P-gp efflux liability than Ligand B (0.252), suggesting better oral bioavailability and potentially better CNS exposure (though less relevant for a cardiovascular target). This is a significant advantage for Ligand A.
**15. Binding Affinity:** Ligand B (-6.5) has a slightly better binding affinity than Ligand A (-6.8). While a difference of 0.3 kcal/mol is not huge, it's a positive for Ligand B.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity), Ligand B initially appears stronger due to its better logP and affinity. However, Ligand A has significant advantages in safety (DILI, hERG) and metabolic stability (Cl_mic). The very low P-gp efflux for Ligand A is also a strong point. The poor Caco-2 permeability is concerning for both, but the other advantages of Ligand A outweigh the slightly better affinity of Ligand B.
Therefore, I favor Ligand A.
Output:
1
2025-04-17 20:23:32,908 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (362.348 and 351.403 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both are good (87.66 and 82.89), being under 140, suggesting reasonable oral absorption potential.
3. **logP:** Ligand B (0.914) is slightly better than Ligand A (0.201). Ligand A is quite low, potentially hindering membrane permeability. This is a significant negative for A.
4. **HBD:** Ligand A has 3 HBD, while Ligand B has 0. Both are acceptable, but fewer HBDs generally improve permeability.
5. **HBA:** Ligand A has 4 HBA, Ligand B has 7. Ligand A is preferable here.
6. **QED:** Both have good QED scores (0.652 and 0.734), indicating drug-like properties.
7. **DILI:** Ligand B (40.713) has a slightly higher DILI risk than Ligand A (31.059), but both are below the concerning threshold of 60.
8. **BBB:** Both have similar BBB penetration (66.111 and 66.421). Since ADRB2 isn't strictly a CNS target, this isn't a major deciding factor.
9. **Caco-2:** Ligand B (-4.676) is better than Ligand A (-5.286), indicating better intestinal absorption.
10. **Solubility:** Ligand B (-1.169) is better than Ligand A (-2.18), which is a positive for bioavailability.
11. **hERG:** Both are very low (0.195 and 0.131), indicating minimal cardiotoxicity risk.
12. **Cl_mic:** Ligand B (-9.681) has a lower (better) microsomal clearance than Ligand A (-12.694), suggesting greater metabolic stability.
13. **t1/2:** Ligand B (11.722) has a significantly longer in vitro half-life than Ligand A (6.828), which is a major advantage.
14. **Pgp:** Both are very low (0.023 and 0.032), indicating minimal P-gp efflux.
15. **Affinity:** Ligand B (-7.9 kcal/mol) has a slightly better binding affinity than Ligand A (-6.7 kcal/mol). This 1.2 kcal/mol difference is substantial and can outweigh some ADME drawbacks.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand B excels in logP and affinity, and is comparable in Pgp and TPSA. The longer half-life and better metabolic stability are also significant advantages. While Ligand A has slightly fewer HBA, the low logP is a major drawback.
**Conclusion:**
Considering the balance of properties, particularly the better logP, affinity, metabolic stability (Cl_mic), and half-life, Ligand B is the more promising drug candidate.
Output:
0
2025-04-17 20:23:32,908 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [354.447, 88.1, 0.306, 2, 5, 0.687, 14.851, 38.813, -4.854, -1.343, 0.151, 5.259, 14.689, 0.012, -6.0]
**Ligand B:** [382.555, 58.56, 2.148, 0, 7, 0.529, 49.632, 89.725, -5.19, -2.787, 0.593, 67.543, 10.391, 0.161, -4.9]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (354.447) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (88.1) is better than Ligand B (58.56), being below 140 and closer to the desirable range for oral absorption.
3. **logP:** Ligand B (2.148) is optimal (1-3), while Ligand A (0.306) is quite low, potentially hindering membrane permeability. This is a significant drawback for Ligand A.
4. **HBD:** Ligand A (2) is preferable to Ligand B (0).
5. **HBA:** Ligand A (5) is preferable to Ligand B (7).
6. **QED:** Ligand A (0.687) is better than Ligand B (0.529), indicating a more drug-like profile.
7. **DILI:** Ligand A (14.851) is *much* better than Ligand B (49.632), indicating a significantly lower risk of drug-induced liver injury. This is a major advantage for Ligand A.
8. **BBB:** Ligand B (89.725) is significantly better than Ligand A (38.813). However, since ADRB2 is primarily a cardiovascular target, high BBB penetration isn't critical.
9. **Caco-2:** Ligand A (-4.854) and Ligand B (-5.19) are both very low, suggesting poor intestinal absorption.
10. **Solubility:** Ligand A (-1.343) is better than Ligand B (-2.787), indicating slightly better aqueous solubility.
11. **hERG:** Ligand A (0.151) is much better than Ligand B (0.593), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand A (5.259) is much better than Ligand B (67.543), suggesting better metabolic stability.
13. **t1/2:** Ligand A (14.689) is better than Ligand B (10.391), indicating a longer in vitro half-life.
14. **Pgp:** Ligand A (0.012) is much better than Ligand B (0.161), indicating lower P-gp efflux.
15. **Affinity:** Ligand A (-6.0) is slightly better than Ligand B (-4.9), indicating a stronger binding affinity.
**GPCR-Specific Priorities:** For ADRB2 (a cardiovascular GPCR), logP, TPSA, Pgp, and affinity are key. While Ligand B has a better logP, Ligand A excels in most other critical areas, especially DILI, hERG, Cl_mic, Pgp, and affinity. The low logP of Ligand A is a concern, but the significantly better safety profile (DILI, hERG) and metabolic stability (Cl_mic) outweigh this drawback. The slightly better affinity of Ligand A also contributes to its favorability.
**Conclusion:**
Considering the balance of properties and the priorities for a cardiovascular GPCR target, Ligand A is the more promising drug candidate.
Output:
1
2025-04-17 20:23:32,908 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (342.399 and 342.483 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (78.15) is higher than Ligand B (40.62). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B is significantly better here.
3. **logP:** Ligand A (0.941) is lower than Ligand B (3.836). logP for Ligand B is approaching the upper limit of the optimal range, but still acceptable. Ligand A is quite low, potentially hindering membrane permeability. Ligand B is better.
4. **HBD:** Ligand A (1) is slightly higher than Ligand B (0). Both are within the acceptable limit of 5. No major difference.
5. **HBA:** Ligand A (6) is higher than Ligand B (2). Ligand B is significantly better.
6. **QED:** Both ligands (0.897 and 0.837) have excellent QED scores, indicating good drug-like properties. No significant difference.
7. **DILI:** Ligand A (62.815) has a higher DILI risk than Ligand B (39.201). Ligand B is significantly better.
8. **BBB:** Ligand A (73.711) has a moderate BBB penetration, while Ligand B (94.494) has very high BBB penetration. While ADRB2 isn't primarily a CNS target, some CNS exposure is possible with beta-blockers, and higher BBB is generally favorable. Ligand B is better.
9. **Caco-2:** Ligand A (-5.253) and Ligand B (-4.452) are both negative, which is unusual and suggests poor permeability. However, the scale is not specified, so it is difficult to interpret.
10. **Solubility:** Ligand A (-2.618) and Ligand B (-3.938) are both negative, suggesting poor solubility. Again, the scale is not specified.
11. **hERG:** Ligand A (0.104) has a lower hERG risk than Ligand B (0.558). Ligand A is better.
12. **Cl_mic:** Ligand A (40.719) has lower microsomal clearance than Ligand B (65.327), indicating better metabolic stability. Ligand A is better.
13. **t1/2:** Ligand A (4.603) has a shorter half-life than Ligand B (6.991). Ligand B is better.
14. **Pgp:** Ligand A (0.303) has lower P-gp efflux than Ligand B (0.572). Ligand A is better.
15. **Binding Affinity:** Ligand B (-8.0) has a significantly stronger binding affinity than Ligand A (-6.4). This is a crucial advantage, exceeding the 1.5 kcal/mol threshold.
**Overall Assessment:**
Ligand B demonstrates a superior binding affinity, which is the most important factor. It also has better TPSA, logP, DILI, BBB, and half-life. While Ligand A has a slightly better hERG and Cl_mic profile, the substantial affinity advantage of Ligand B outweighs these minor drawbacks. The lower TPSA and logP of Ligand B are also favorable for absorption and distribution.
Output:
0
2025-04-17 20:23:32,909 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (345.407 and 349.45 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (97.94) is higher than Ligand B (71.09). While both are below 140, the lower TPSA of Ligand B is preferable for better absorption, especially for a GPCR.
3. **logP:** Ligand A (0.2) is quite low, potentially hindering membrane permeability. Ligand B (3.119) is within the optimal 1-3 range. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (1) and Ligand B (2) are both acceptable, below the threshold of 5.
5. **HBA:** Ligand A (7) and Ligand B (3) are both acceptable, below the threshold of 10. Ligand B is better here.
6. **QED:** Ligand A (0.835) is better than Ligand B (0.757), indicating a more drug-like profile.
7. **DILI:** Ligand A (57.154) has a higher DILI risk than Ligand B (35.673). Ligand B is significantly better here.
8. **BBB:** Both ligands have reasonable BBB penetration (A: 68.476, B: 73.245). Ligand B is slightly better, but this isn't a primary concern for ADRB2, which isn't a CNS target.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not provided, so it's hard to interpret.
10. **Solubility:** Both ligands have negative solubility values, which is also unusual.
11. **hERG:** Ligand A (0.081) has a slightly lower hERG risk than Ligand B (0.288), which is good.
12. **Cl_mic:** Ligand A (2.683) has much lower microsomal clearance than Ligand B (19.981), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (6.412) has a shorter half-life than Ligand B (20.671). Ligand B is preferable here.
14. **Pgp:** Ligand A (0.015) has much lower P-gp efflux liability than Ligand B (0.082), which is a positive.
15. **Binding Affinity:** Ligand B (-7.1 kcal/mol) has a stronger binding affinity than Ligand A (-6.6 kcal/mol). This is a 0.5 kcal/mol difference, which is substantial enough to be a key factor.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are particularly important. Ligand B excels in logP and has a better TPSA. The affinity difference is also in favor of Ligand B. While Ligand A has better metabolic stability (Cl_mic), the stronger binding of Ligand B and its more favorable logP/TPSA profile outweigh this advantage.
**Conclusion:**
Considering all factors, especially the GPCR-specific priorities, Ligand B is the more promising drug candidate. Its superior logP, TPSA, and binding affinity outweigh the slightly higher DILI risk and lower metabolic stability compared to Ligand A.
Output:
0
2025-04-17 20:23:32,909 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [394.509, 66.48, 2.736, 1, 4, 0.773, 53.354, 88.329, -4.875, -3.538, 0.643, 38.441, -14.754, 0.212, -5.9]
**Ligand B:** [352.431, 88.1, -0.223, 2, 5, 0.619, 25.553, 29.003, -4.661, -1.698, 0.157, -0.067, -3.08, 0.067, -5.5]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity, and BBB):
1. **MW:** Both are within the acceptable range (200-500 Da). Ligand B (352.431) is slightly preferred due to being lower.
2. **TPSA:** Ligand A (66.48) is better than Ligand B (88.1). Lower TPSA generally favors better absorption.
3. **logP:** Ligand A (2.736) is optimal (1-3). Ligand B (-0.223) is too low, potentially causing permeability issues. This is a significant negative for Ligand B.
4. **HBD/HBA:** Ligand A (1 HBD, 4 HBA) is better than Ligand B (2 HBD, 5 HBA). Both are acceptable, but lower counts are generally preferred.
5. **QED:** Both are reasonably good (A: 0.773, B: 0.619), indicating drug-like properties.
6. **DILI:** Ligand A (53.354) has a higher DILI risk than Ligand B (25.553). This favors Ligand B.
7. **BBB:** Ligand A (88.329) has a much better BBB penetration potential than Ligand B (29.003). This is a significant advantage for Ligand A, given it's a GPCR.
8. **Caco-2:** Both are negative, indicating poor permeability.
9. **Solubility:** Both are negative, indicating poor solubility.
10. **hERG:** Both are low risk (A: 0.643, B: 0.157), which is good.
11. **Cl_mic:** Ligand A (38.441) has a higher clearance than Ligand B (-0.067), suggesting lower metabolic stability. This favors Ligand B.
12. **t1/2:** Ligand A (-14.754) has a very short half-life, while Ligand B (-3.08) is better, but still not ideal.
13. **Pgp:** Ligand A (0.212) has lower P-gp efflux than Ligand B (0.067), which is favorable for bioavailability.
14. **Affinity:** Both have very similar binding affinities (-5.9 and -5.5 kcal/mol). The difference is not substantial enough to be a deciding factor.
**Overall Assessment:**
Ligand A has a significant advantage in BBB penetration and logP, which are crucial for a GPCR target. While it has a higher DILI risk and lower metabolic stability, the better logP and BBB outweigh these concerns. Ligand B suffers from a very low logP, which is a major drawback for permeability and overall drug-like properties.
Therefore, I would choose Ligand A.
Output:
1
2025-04-17 20:23:32,909 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**1. Molecular Weight:** Both ligands (351.491 Da and 365.478 Da) fall within the ideal range of 200-500 Da. No significant difference here.
**2. TPSA:** Ligand A (87.3) is slightly higher than Ligand B (71.96). Both are below the 140 A^2 threshold for good oral absorption, but Ligand B is preferable due to being closer to the 90 A^2 target for GPCRs.
**3. logP:** Ligand A (1.74) and Ligand B (3.12) are both within the optimal 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability but needs to be balanced with solubility.
**4. H-Bond Donors:** Ligand A (3) and Ligand B (2) both satisfy the <=5 rule. Ligand B is slightly better.
**5. H-Bond Acceptors:** Ligand A (3) is better than Ligand B (7) as it is closer to the ideal of <=10.
**6. QED:** Both ligands have similar QED values (0.611 and 0.662), indicating good drug-likeness.
**7. DILI Risk:** Ligand A (35.014) has a significantly lower DILI risk than Ligand B (82.513). This is a major advantage for Ligand A.
**8. BBB Penetration:** Ligand B (87.088) has a higher BBB penetration percentile than Ligand A (51.26). While ADRB2 isn't strictly a CNS target, some CNS exposure might be acceptable or even desirable for certain cardiovascular effects, making Ligand B slightly better here.
**9. Caco-2 Permeability:** Ligand A (-4.625) has a worse Caco-2 permeability than Ligand B (-5.355).
**10. Aqueous Solubility:** Ligand A (-3.096) has better aqueous solubility than Ligand B (-3.814).
**11. hERG Inhibition:** Ligand A (0.093) has a lower hERG inhibition risk than Ligand B (0.892). This is a significant advantage for Ligand A, as hERG inhibition can lead to cardiotoxicity.
**12. Microsomal Clearance:** Ligand B (70.331) has a lower microsomal clearance than Ligand A (59.609), indicating better metabolic stability.
**13. In vitro Half-Life:** Ligand B (51.711) has a longer in vitro half-life than Ligand A (-11.827). This is a significant advantage for Ligand B.
**14. P-gp Efflux:** Ligand A (0.078) has lower P-gp efflux than Ligand B (0.421), which is preferable.
**15. Binding Affinity:** Ligand A (-7.1) has a slightly better binding affinity than Ligand B (-6.3). While the difference is less than the 1.5 kcal/mol threshold, it still contributes to the overall preference.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity) and the general drug-like properties, Ligand A emerges as the more promising candidate. The significantly lower DILI risk and hERG inhibition liability are crucial advantages, outweighing the slightly lower BBB penetration and half-life. The better solubility and P-gp efflux profile also contribute to its favorability. While Ligand B has better metabolic stability and Caco-2 permeability, the safety concerns associated with Ligand B are too significant to ignore.
Output:
1
2025-04-17 20:23:32,909 - INFO - Here's my reasoning and final decision:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (338.411) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (72.94) is significantly better than Ligand B (96.11). For a GPCR, keeping TPSA low is good, though not as critical as for CNS targets.
3. **logP:** Both are within the optimal range (1-3), but Ligand A (3.325) is slightly higher, potentially leading to some off-target interactions, but also aiding membrane permeability. Ligand B (2.221) is on the lower side.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (4). Lower HBA is generally preferred.
6. **QED:** Ligand A (0.748) is better than Ligand B (0.603), indicating a more drug-like profile.
7. **DILI:** Ligand B (37.456) has a much lower DILI risk than Ligand A (84.374), which is a significant advantage.
8. **BBB:** Both are relatively low, suggesting limited CNS penetration. Ligand A (32.571) is slightly lower than Ligand B (33.54). This isn't a primary concern for a cardiovascular target.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-5.173) is slightly better than Ligand B (-5.586).
10. **Solubility:** Ligand A (-3.827) has slightly better solubility than Ligand B (-1.97).
11. **hERG:** Both have very low hERG inhibition risk, which is excellent. Ligand A (0.052) is slightly lower.
12. **Cl_mic:** Ligand B (5.43) has significantly lower microsomal clearance than Ligand A (23.049), indicating better metabolic stability.
13. **t1/2:** Ligand A (-27.521) has a much longer in vitro half-life than Ligand B (-0.97). This is a substantial advantage.
14. **Pgp:** Both have low P-gp efflux liability. Ligand A (0.113) is slightly lower.
15. **Affinity:** Ligand A (-7.2 kcal/mol) has a significantly better binding affinity than Ligand B (-6.2 kcal/mol). This is a 1 kcal/mol difference, which is substantial.
**GPCR-Specific Priorities:**
For an ADRB2 (GPCR) target, affinity, logP, TPSA, and Pgp are key. Ligand A excels in affinity and has a reasonable logP and TPSA. Ligand B has a better DILI score and Cl_mic, but its lower affinity is a major drawback. The significantly better affinity of Ligand A outweighs the slightly higher DILI risk and lower metabolic stability.
**Conclusion:**
Ligand A is the more promising candidate due to its superior binding affinity and better overall drug-like properties (QED, TPSA, HBD/HBA). The longer half-life is also a significant benefit.
Output:
1
2025-04-17 20:23:32,909 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (354.45 & 353.46 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (79.31) is significantly better than Ligand B (110.52). For a GPCR, keeping TPSA low is beneficial for permeability, and Ligand A is well below the 140 threshold. Ligand B is pushing the limit.
3. **logP:** Ligand B (0.858) is slightly better than Ligand A (0.57), being closer to the optimal 1-3 range. Ligand A is a bit low, potentially impacting membrane permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (4). Lower HBA generally improves permeability.
6. **QED:** Ligand B (0.615) is slightly better than Ligand A (0.509), indicating a marginally more drug-like profile.
7. **DILI:** Ligand B (20.744) has a significantly lower DILI risk than Ligand A (14.851), which is a major advantage.
8. **BBB:** Both ligands have similar BBB penetration (Ligand A: 50.679, Ligand B: 55.913). Since ADRB2 isn't primarily a CNS target, this isn't a major deciding factor, but higher is slightly preferred.
9. **Caco-2:** Ligand A (-4.644) is better than Ligand B (-5.695), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-0.215) is better than Ligand B (-2.127), indicating better aqueous solubility.
11. **hERG:** Ligand A (0.209) is better than Ligand B (0.097), indicating lower risk of hERG inhibition.
12. **Cl_mic:** Ligand B (7.026) has significantly lower microsomal clearance than Ligand A (24.657), suggesting better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand A (6.682) has a longer in vitro half-life than Ligand B (-1.716). This is a positive for Ligand A.
14. **Pgp:** Ligand A (0.029) has lower P-gp efflux than Ligand B (0.012), suggesting better bioavailability.
15. **Binding Affinity:** Ligand A (-6.4) has a slightly better binding affinity than Ligand B (-5.2). While both are good, the 1.2 kcal/mol difference is noteworthy.
**Overall Assessment:**
Ligand A has a better binding affinity, TPSA, Caco-2 permeability, solubility, hERG, and Pgp efflux. However, Ligand B has a significantly lower DILI risk and better metabolic stability (lower Cl_mic). The lower DILI risk is a critical factor in drug development. While the affinity difference is good for Ligand A, the improved safety profile and metabolic stability of Ligand B are more important for overall viability.
**Output:**
0
2025-04-17 20:23:32,910 - INFO - Reasoning:
Let's analyze both ligands based on the provided parameters and guidelines, keeping in mind this is for an ADRB2 GPCR (cardiovascular target, so CNS penetration is less critical).
**Ligand A:**
* **MW:** 348.462 Da - Good. Within the ideal range.
* **TPSA:** 32.78 - Excellent. Well below the 140 threshold, suggesting good absorption.
* **logP:** 2.527 - Excellent. Within the optimal 1-3 range.
* **HBD:** 0 - Good. Low, potentially aiding permeability.
* **HBA:** 4 - Good. Low, potentially aiding permeability.
* **QED:** 0.74 - Excellent. Highly drug-like.
* **DILI:** 7.057 - Excellent. Very low risk of liver injury.
* **BBB:** 96.937 - Very high. While not a primary concern for a cardiovascular target, it's not detrimental.
* **Caco-2:** -4.549 - Poor. Indicates very low permeability. A significant concern.
* **Solubility:** -2.585 - Poor. Indicates very low solubility. A significant concern.
* **hERG:** 0.943 - Good. Low risk of hERG inhibition.
* **Cl_mic:** 52.967 - Moderate. Not ideal, but not extremely high.
* **t1/2:** -21.104 - Very poor. Indicates extremely short half-life.
* **Pgp:** 0.172 - Good. Low P-gp efflux.
* **Affinity:** -7.7 kcal/mol - Excellent. Very strong binding.
**Ligand B:**
* **MW:** 402.607 Da - Good. Within the ideal range.
* **TPSA:** 58.64 - Acceptable. Still reasonably low, suggesting reasonable absorption.
* **logP:** 2.385 - Excellent. Within the optimal 1-3 range.
* **HBD:** 1 - Good. Low, potentially aiding permeability.
* **HBA:** 6 - Acceptable. Still within a reasonable range.
* **QED:** 0.643 - Good. Drug-like.
* **DILI:** 36.991 - Excellent. Low risk of liver injury.
* **BBB:** 56.611 - Moderate. Not a primary concern.
* **Caco-2:** -5.08 - Poor. Indicates very low permeability. A significant concern.
* **Solubility:** -3.095 - Poor. Indicates very low solubility. A significant concern.
* **hERG:** 0.356 - Good. Low risk of hERG inhibition.
* **Cl_mic:** 66.756 - Moderate to High. Higher than Ligand A, indicating potentially lower metabolic stability.
* **t1/2:** 12.39 - Moderate. Better than Ligand A, but still not ideal.
* **Pgp:** 0.183 - Good. Low P-gp efflux.
* **Affinity:** -6.5 kcal/mol - Good. Strong binding, but not as strong as Ligand A.
**Comparison and Decision:**
Both ligands suffer from poor Caco-2 permeability and aqueous solubility. However, Ligand A has a significantly stronger binding affinity (-7.7 vs -6.5 kcal/mol). For a GPCR, affinity is paramount. Ligand A also has a lower DILI risk and a better in vitro half-life (although still poor). While the BBB value for Ligand A is high, it's less important for a cardiovascular target. The slightly higher metabolic clearance of Ligand B is less concerning than the substantial difference in binding affinity.
Despite the permeability/solubility issues, the superior binding affinity of Ligand A makes it the more promising starting point for optimization. Addressing the permeability and solubility issues through structural modifications is more likely to succeed with a molecule that already binds strongly.
Output:
1
2025-04-17 20:23:32,910 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (343.43 & 358.44 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand B (40.62) is significantly better than Ligand A (91.32). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (1.57 & 3.25), falling within the 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Ligand A has 3 HBD, while Ligand B has 0. Lower HBD is generally preferred for better permeability, giving a slight edge to Ligand B.
5. **HBA:** Ligand A has 4 HBA, Ligand B has 3. Similar to HBD, lower is slightly preferred.
6. **QED:** Both ligands have good QED scores (0.708 & 0.827), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (35.75%) has a considerably lower DILI risk than Ligand B (49.59%). This is a significant advantage for Ligand A.
8. **BBB:** Ligand B (87.13%) has much higher BBB penetration than Ligand A (53.32%). While not critical for a cardiovascular target, it's a positive attribute.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.98 & -4.69), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Both ligands have very poor aqueous solubility (-2.30 & -3.43). This is a major drawback for both compounds and would require significant formulation work.
11. **hERG:** Ligand A (0.059) has a much lower hERG risk than Ligand B (0.719). This is a crucial safety parameter, and Ligand A is significantly better.
12. **Cl_mic:** Ligand A (7.74) has a lower microsomal clearance than Ligand B (32.96), indicating better metabolic stability.
13. **t1/2:** Ligand A (-7.75) has a much longer in vitro half-life than Ligand B (4.15). This is a significant advantage for dosing considerations.
14. **Pgp:** Ligand A (0.014) has much lower P-gp efflux liability than Ligand B (0.436). This is favorable for bioavailability.
15. **Binding Affinity:** Ligand A (-7.6) has a slightly better binding affinity than Ligand B (-6.3). While the difference isn't huge, it's still a positive for Ligand A.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand B has better logP and TPSA, and BBB, but Ligand A has better affinity, Pgp, and significantly better safety (DILI, hERG). The poor Caco-2 and solubility are concerning for both, but the safety profile and metabolic stability of Ligand A are more compelling.
**Conclusion:**
Despite the solubility and permeability concerns, Ligand A's superior safety profile (DILI, hERG), metabolic stability (Cl_mic, t1/2), Pgp efflux, and slightly better affinity outweigh the advantages of Ligand B.
Output:
1
2025-04-17 20:23:32,910 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (363.483 and 352.37 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (69.72) is significantly better than Ligand B (114.19). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (0.703) is slightly better than Ligand A (0.477), falling closer to the optimal 1-3 range. Ligand A is a bit low, potentially hindering permeation.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is preferable to Ligand B (8). Similar to HBD, lower HBA counts are generally favored.
6. **QED:** Ligand A (0.79) is better than Ligand B (0.641), indicating a more drug-like profile.
7. **DILI:** Ligand A (47.421) has a significantly lower DILI risk than Ligand B (67.003). This is a major advantage for Ligand A.
8. **BBB:** Both are around 50-60%, so this isn't a deciding factor for a cardiovascular target.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-4.957) is slightly better than Ligand B (-5.057), but both are quite poor.
10. **Solubility:** Both are negative, indicating poor solubility. Ligand A (-2.584) is slightly better than Ligand B (-2.685).
11. **hERG:** Ligand A (0.491) is better than Ligand B (0.194), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand B (42.185) has lower microsomal clearance than Ligand A (49.294), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-14.789) has a longer in vitro half-life than Ligand A (-23.506). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.052) has lower P-gp efflux than Ligand B (0.016), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand A (-6.8 kcal/mol) has a slightly better binding affinity than Ligand B (-5.2 kcal/mol). This difference of 1.6 kcal/mol is substantial and can outweigh some of the ADME drawbacks.
**Overall Assessment & GPCR Prioritization:**
For a GPCR like ADRB2, binding affinity is paramount. Ligand A's superior affinity (-6.8 vs -5.2 kcal/mol) is a major win. While Ligand B has better metabolic stability (lower Cl_mic, longer t1/2), Ligand A compensates with a lower DILI risk, better QED, and better hERG profile. The TPSA and H-bonding properties of Ligand A are also more favorable. The slightly lower logP of Ligand A is a concern, but the affinity advantage is significant enough to overcome this.
Output:
1
2025-04-17 20:23:32,910 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (349.435 and 357.332 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand B (82.27) is significantly better than Ligand A (107.19). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (1.523) is within the optimal range (1-3), while Ligand A (0.465) is slightly below, potentially impacting permeability.
4. **HBD:** Ligand A (3) and Ligand B (2) are both acceptable, below the threshold of 5.
5. **HBA:** Ligand A (4) and Ligand B (3) are both acceptable, below the threshold of 10.
6. **QED:** Ligand B (0.802) has a higher QED score than Ligand A (0.602), indicating a more drug-like profile.
7. **DILI:** Ligand A (31.485) has a much lower DILI risk than Ligand B (61.031). This is a significant advantage for Ligand A.
8. **BBB:** Ligand B (75.805) has a higher BBB penetration score than Ligand A (47.15). However, as ADRB2 is a cardiovascular target, BBB penetration is not a high priority.
9. **Caco-2:** Ligand A (-5.225) and Ligand B (-4.82) are both negative, which is unusual. A higher value is preferred, but the difference is small.
10. **Solubility:** Ligand A (-1.386) and Ligand B (-2.836) are both negative, which is unusual. A higher value is preferred, but the difference is small.
11. **hERG:** Ligand A (0.109) has a lower hERG inhibition liability than Ligand B (0.313), indicating a lower risk of cardiotoxicity. This is crucial for a cardiovascular target.
12. **Cl_mic:** Ligand B (-9.948) has a much lower (better) microsomal clearance than Ligand A (1.464), suggesting greater metabolic stability.
13. **t1/2:** Ligand B (-31.692) has a much longer in vitro half-life than Ligand A (-12.312), which is desirable.
14. **Pgp:** Ligand A (0.01) has a lower P-gp efflux liability than Ligand B (0.064), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand A (-6.1) and Ligand B (-5.7) are both good, but Ligand A is slightly better. The difference is 0.4 kcal/mol, which is not substantial enough to outweigh other factors.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand B has better logP and TPSA, and Pgp efflux is slightly lower. However, Ligand A has a better binding affinity, and critically, a much better safety profile (DILI and hERG).
**Overall Assessment:**
While Ligand B has advantages in metabolic stability (Cl_mic and t1/2) and QED, Ligand A's significantly lower DILI and hERG risk, coupled with slightly better affinity, make it the more promising candidate for development as a cardiovascular drug. The slightly lower logP of Ligand A is a manageable concern.
Output:
1
2025-04-17 20:23:32,910 - INFO - Batch 181 complete. Total preferences: 2896
2025-04-17 20:23:32,911 - INFO - Processing batch 182/512...
2025-04-17 20:24:25,376 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
The ADRB2 receptor is a GPCR, so the priorities are logP, TPSA, Pgp, BBB, and affinity. Let's break down each ligand against these and other important parameters.
* **Molecular Weight:** Both ligands (367.49 and 342.443 Da) fall comfortably within the ideal 200-500 Da range.
* **TPSA:** Both are around 56-58, which is acceptable, but ideally below 90 for GPCRs.
* **logP:** Ligand A (2.039) is slightly higher than Ligand B (1.546), placing it more favorably within the 1-3 optimal range. Ligand B is a bit low and could have permeability issues.
* **H-Bond Donors/Acceptors:** Ligand A has 2 HBD and 4 HBA, while Ligand B has 0 HBD and 4 HBA. Both are reasonable.
* **QED:** Both have similar QED scores (0.836 and 0.763), indicating good drug-likeness.
* **DILI:** Ligand B (29.934) has a significantly lower DILI risk than Ligand A (20.822), which is a substantial advantage.
* **BBB:** Ligand B (73.401) has a much better BBB penetration score than Ligand A (43.854). This is a key advantage for a GPCR target.
* **Caco-2 Permeability:** Ligand A (-5.074) has slightly better Caco-2 permeability than Ligand B (-4.676).
* **Aqueous Solubility:** Ligand A (-2.415) has slightly better aqueous solubility than Ligand B (-1.385).
* **hERG:** Ligand A (0.784) has a higher hERG risk than Ligand B (0.142). This is a significant safety concern.
* **Microsomal Clearance:** Ligand B (39.296) has a much higher microsomal clearance than Ligand A (3.049), indicating faster metabolism and potentially lower exposure.
* **In vitro Half-Life:** Ligand A (30.937) has a much longer in vitro half-life than Ligand B (-8.227).
* **P-gp Efflux:** Ligand A (0.158) has a slightly lower P-gp efflux liability than Ligand B (0.1).
* **Binding Affinity:** Ligand B (-6.0 kcal/mol) has a slightly better binding affinity than Ligand A (-5.3 kcal/mol).
**Overall Assessment:**
While Ligand A has better Caco-2 permeability, solubility, half-life and slightly lower P-gp efflux, Ligand B demonstrates a superior safety profile (lower DILI, significantly lower hERG risk) and better BBB penetration, which is crucial for GPCR targets. The affinity difference is small enough to be outweighed by the safety and BBB advantages of Ligand B. The faster clearance of Ligand B is a concern, but could potentially be addressed through formulation or structural modifications.
**Output:**
0
2025-04-17 20:24:25,377 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands (340.383 and 344.459 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (79.58) is higher than Ligand B (58.44). For a GPCR, lower TPSA is generally preferred for better permeability, giving a slight edge to Ligand B.
3. **logP:** Both ligands have good logP values (2.712 and 2.005), falling within the optimal 1-3 range. Ligand B is slightly lower, which could be beneficial for solubility, but not a major difference.
4. **HBD:** Both ligands have 0 HBD, which is good.
5. **HBA:** Ligand A has 5 HBA, while Ligand B has 4. Both are acceptable, below the 10 threshold.
6. **QED:** Both ligands have acceptable QED scores (0.634 and 0.561), indicating reasonable drug-likeness.
7. **DILI:** Ligand A has a DILI risk of 75.184, which is moderately high. Ligand B has a much lower DILI risk (25.514), which is a significant advantage.
8. **BBB:** Ligand A has a BBB penetration of 89.957, while Ligand B has 77.705. While ADRB2 isn't exclusively a CNS target, some degree of BBB penetration can be useful for peripheral effects and potential off-target considerations. Ligand A is better here.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.396 and -4.785). These values are unusual and suggest poor permeability. However, the values are close enough that this isn't a deciding factor.
10. **Solubility:** Ligand A (-3.72) has slightly better solubility than Ligand B (-1.003), but both are quite poor.
11. **hERG:** Ligand A (0.538) has a slightly higher hERG risk than Ligand B (0.195), which is preferable.
12. **Cl_mic:** Ligand A (83.888) has higher microsomal clearance than Ligand B (48.676), indicating lower metabolic stability. Ligand B is favored here.
13. **t1/2:** Ligand B (-14.271) has a negative in vitro half-life, which is concerning. Ligand A (2.218) has a short but positive half-life. This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.408) has lower P-gp efflux liability than Ligand B (0.172), which is preferable.
15. **Binding Affinity:** Ligand B (-7.1) has a slightly better binding affinity than Ligand A (-7.0). While the difference is small, it's still a factor.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B has better TPSA and Pgp, while Ligand A has better BBB penetration. The affinity difference is minimal. However, the significantly lower DILI risk of Ligand B and its better metabolic stability (lower Cl_mic) are crucial advantages. The negative half-life for Ligand B is a major concern.
**Conclusion:**
Despite Ligand A's slightly better BBB penetration and half-life, the significantly lower DILI risk and better metabolic stability of Ligand B outweigh these factors. The binding affinity difference is minimal. Therefore, Ligand B is the more promising drug candidate.
Output:
0
2025-04-17 20:24:25,377 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (356.5 and 352.5 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (67.87) is slightly higher than Ligand B (60.85). Both are below the 140 threshold for oral absorption, but closer to the 90 threshold for CNS targets. Given ADRB2 is a cardiovascular target, this isn't a major concern, but lower is preferable. Ligand B is better.
3. **logP:** Both ligands (2.219 and 2.525) are within the optimal 1-3 range. No clear advantage.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 4 HBA, while Ligand B has 3. Both are below the 10 threshold. Ligand B is slightly better.
6. **QED:** Ligand B (0.846) has a higher QED score than Ligand A (0.61), indicating a more drug-like profile. This is a significant advantage.
7. **DILI:** Ligand A (10.24%) has a substantially lower DILI risk than Ligand B (14.31%). This is a major advantage for Ligand A.
8. **BBB:** Both ligands have reasonably good BBB penetration (68.2% and 64.3%). Since ADRB2 is primarily a cardiovascular target, BBB penetration isn't a top priority, but higher is generally better. Ligand A is slightly better.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. This is a concern for both.
10. **Solubility:** Both ligands have negative solubility values, indicating poor solubility. This is a concern for both.
11. **hERG:** Both ligands have low hERG inhibition risk (0.533 and 0.467). No significant difference.
12. **Cl_mic:** Ligand A (36.42) has a lower microsomal clearance than Ligand B (46.03), indicating better metabolic stability. This is a positive for Ligand A.
13. **t1/2:** Ligand A (-3.653) has a negative in vitro half-life, which is concerning. Ligand B (-18.875) is even worse. Both are poor.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.046 and 0.274). No significant difference.
15. **Binding Affinity:** Ligand A (-6.4 kcal/mol) has a slightly better binding affinity than Ligand B (-5.5 kcal/mol). This is a positive for Ligand A.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Ligand B has slightly better logP and TPSA, while Ligand A has better affinity. However, the DILI risk for Ligand A is significantly lower, and metabolic stability (Cl_mic) is better. The QED score is also higher for Ligand B.
**Overall Assessment:**
While Ligand B has a better QED score, the significantly lower DILI risk and better metabolic stability of Ligand A are more crucial for a viable drug candidate. The slightly better affinity of Ligand A also contributes to its favorability. The poor Caco-2 and solubility are concerns for both, but these can be addressed through formulation strategies. The negative half-life values are concerning for both, but can be improved through structural modifications.
**Output:**
1
2025-04-17 20:24:25,377 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [346.515, 49.41, 3.522, 1, 2, 0.774, 31.563, 74.564, -4.767, -4.015, 0.465, 64.038, -17.451, 0.332, -6.5]
**Ligand B:** [346.475, 67.23, 3.073, 1, 4, 0.699, 36.487, 83.443, -4.607, -3.635, 0.331, 88.239, 14.346, 0.254, -7.2]
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (around 346 Da). No significant difference.
2. **TPSA:** Ligand A (49.41) is significantly better than Ligand B (67.23). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally improves absorption.
3. **logP:** Both are good (3.522 and 3.073, respectively), falling within the 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 2 HBA, while Ligand B has 4. Ligand A is preferable here.
6. **QED:** Ligand A (0.774) is better than Ligand B (0.699), indicating a more drug-like profile.
7. **DILI:** Both are acceptable, with Ligand A at 31.563% and Ligand B at 36.487%. Ligand A is slightly better.
8. **BBB:** Ligand B (83.443%) has a higher BBB penetration score than Ligand A (74.564%). However, as this is a cardiovascular target, BBB penetration is not a primary concern.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.767) is slightly worse than Ligand B (-4.607).
10. **Solubility:** Both have negative solubility values, which is also unusual. Ligand A (-4.015) is slightly worse than Ligand B (-3.635).
11. **hERG:** Both have low hERG inhibition risk (0.465 and 0.331, respectively). No significant difference.
12. **Cl_mic:** Ligand B (88.239) has a significantly higher microsomal clearance than Ligand A (64.038). This means Ligand A is more metabolically stable.
13. **t1/2:** Ligand B (14.346) has a longer in vitro half-life than Ligand A (-17.451). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.332) has lower P-gp efflux than Ligand B (0.254), which is preferable.
15. **Affinity:** Ligand B (-7.2 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.5 kcal/mol). This is a substantial advantage, potentially outweighing some ADME drawbacks.
**GPCR-Specific Priorities:** For ADRB2 (a cardiovascular GPCR), we prioritize logP, TPSA, Pgp, and affinity. Ligand B excels in affinity, and has acceptable logP and Pgp. Ligand A has better TPSA, QED, and metabolic stability. The Caco-2 and solubility values are concerning for both, but the significantly better affinity of Ligand B is a major factor. The longer half-life of Ligand B is also a plus.
**Conclusion:**
Despite Ligand A's better TPSA, QED, and metabolic stability, the significantly stronger binding affinity of Ligand B (-7.2 vs -6.5 kcal/mol) is the deciding factor. The difference in affinity is substantial enough to overcome the slightly less favorable ADME properties of Ligand B.
0
2025-04-17 20:24:25,377 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [338.419, 95.51, 2.095, 2, 7, 0.752, 75.339, 64.948, -5.644, -2.723, 0.492, 34.642, 27.136, 0.027, -4.8]
**Ligand B:** [355.429, 71.09, 2.692, 2, 3, 0.715, 40.016, 65.839, -4.917, -3.036, 0.556, 47.684, 10.291, 0.081, -5.9]
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (338.419) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (95.51) is higher than Ligand B (71.09). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is still preferred for better absorption. Ligand B is better here.
3. **logP:** Both are within the optimal range (1-3). Ligand B (2.692) is slightly higher, potentially leading to better membrane permeability, but also a slightly increased risk of off-target interactions.
4. **HBD:** Both have 2 HBD, which is acceptable.
5. **HBA:** Ligand A has 7 HBA, while Ligand B has 3. Lower HBA is generally preferred for permeability. Ligand B is better.
6. **QED:** Both have good QED scores (>0.5), indicating drug-like properties. Ligand A (0.752) is slightly better.
7. **DILI:** Ligand A (75.339) has a significantly higher DILI risk than Ligand B (40.016). This is a major concern for Ligand A.
8. **BBB:** Both have reasonable BBB penetration, but are not particularly high. This isn't a primary concern for a cardiovascular target. Ligand B (65.839) is slightly better.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. Ligand B (-4.917) is slightly less negative, suggesting marginally better permeability.
10. **Solubility:** Both have negative solubility values, indicating poor solubility. Ligand B (-3.036) is slightly better.
11. **hERG:** Both have low hERG inhibition risk, which is good. Ligand B (0.556) is slightly higher, but still acceptable.
12. **Cl_mic:** Ligand A (34.642) has lower microsomal clearance, indicating better metabolic stability than Ligand B (47.684). This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (27.136) has a much longer in vitro half-life than Ligand B (10.291). This is a major advantage for Ligand A.
14. **Pgp:** Both have very low Pgp efflux, which is good.
15. **Affinity:** Ligand B (-5.9 kcal/mol) has a stronger binding affinity than Ligand A (-4.8 kcal/mol). This is a substantial advantage for Ligand B.
**GPCR-Specific Considerations:**
For ADRB2 (a cardiovascular GPCR), logP, TPSA, Pgp, and affinity are important. Ligand B has better logP and TPSA. The affinity difference is significant (-5.9 vs -4.8 kcal/mol). However, the DILI risk for Ligand A is very high, and the half-life is much better.
**Overall Assessment:**
While Ligand B has a significantly better binding affinity and slightly better TPSA and logP, the high DILI risk associated with Ligand A is a major red flag. The longer half-life of Ligand A is also a positive. However, the DILI risk outweighs these benefits. The stronger affinity of Ligand B is a substantial advantage that, combined with the lower DILI risk, makes it the more promising candidate.
Output:
0
2025-04-17 20:24:25,378 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (349.415 Da) is slightly higher than Ligand B (338.367 Da), but both are acceptable.
2. **TPSA:** Ligand A (71.95) is better than Ligand B (82.18). Both are below 140, but lower TPSA generally favors better absorption.
3. **logP:** Ligand A (4.083) is a bit high, potentially leading to solubility issues. Ligand B (1.946) is closer to the optimal range of 1-3. This is a significant advantage for Ligand B.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 5 HBA, while Ligand B has 6. Both are within the acceptable limit of 10.
6. **QED:** Both have similar QED values (0.703 and 0.786), indicating good drug-likeness.
7. **DILI:** Ligand A (92.206) has a considerably higher DILI risk than Ligand B (74.331). This is a major concern for Ligand A.
8. **BBB:** Ligand A (62.544) and Ligand B (71.501) are both moderate. While ADRB2 isn't exclusively a CNS target, some degree of BBB penetration can be beneficial for distribution. Ligand B is slightly better here.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.146 and -5.063), which is unusual and suggests very poor permeability. This is a significant drawback for both.
10. **Solubility:** Ligand A (-5.2) has worse solubility than Ligand B (-3.105). This, combined with its higher logP, is concerning.
11. **hERG:** Ligand A (0.27) has a lower hERG risk than Ligand B (0.591), which is a positive.
12. **Cl_mic:** Ligand A (65.401) has higher microsomal clearance than Ligand B (57.899), meaning it's metabolized faster. Lower clearance is preferred.
13. **t1/2:** Ligand A (46.193) has a longer in vitro half-life than Ligand B (6.94). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.44) has lower P-gp efflux than Ligand B (0.306), which is favorable.
15. **Binding Affinity:** Ligand A (-6.9 kcal/mol) has a slightly better binding affinity than Ligand B (-6.5 kcal/mol). The difference is 0.4 kcal/mol, which is not a huge advantage.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP and has a slightly better Pgp profile. While Ligand A has a slightly better affinity and half-life, its significantly higher DILI risk and poor solubility are major drawbacks. The negative Caco-2 values for both are concerning, but the other issues with Ligand A make it less promising.
**Conclusion:**
Considering the balance of properties, especially the concerning DILI risk and solubility issues with Ligand A, Ligand B is the more viable drug candidate despite its slightly lower affinity and half-life. The better logP and lower DILI risk outweigh the minor differences in affinity and half-life.
Output:
0
2025-04-17 20:24:25,378 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (381.414 Da) is within the ideal range, while Ligand B (347.415 Da) is slightly below, but still acceptable.
2. **TPSA:** Ligand A (129.97) is approaching the upper limit for good oral absorption, while Ligand B (98.74) is well within the desirable range. This favors Ligand B.
3. **logP:** Ligand A (2.569) is optimal. Ligand B (-0.748) is significantly lower, potentially hindering membrane permeability. This favors Ligand A.
4. **HBD:** Both ligands have acceptable HBD counts (4 and 3 respectively).
5. **HBA:** Both ligands have acceptable HBA counts (5 and 4 respectively).
6. **QED:** Both ligands have similar and acceptable QED values (0.553 and 0.46).
7. **DILI:** Ligand A (99.38) has a very high DILI risk, which is a major concern. Ligand B (30.593) has a much lower, acceptable DILI risk. This strongly favors Ligand B.
8. **BBB:** Both ligands have the same BBB penetration (36.371). This isn't a primary concern for ADRB2, a cardiovascular target, but it doesn't differentiate them.
9. **Caco-2:** Ligand A (-5.476) and Ligand B (-4.971) both have negative Caco-2 values, which is unusual and suggests poor permeability.
10. **Solubility:** Ligand A (-3.991) and Ligand B (-1.526) both have negative solubility values, which is also unusual and suggests poor solubility.
11. **hERG:** Both ligands have low hERG inhibition risk (0.389 and 0.143).
12. **Cl_mic:** Ligand A (4.856) has a moderate clearance, while Ligand B (-0.564) has a negative clearance, suggesting excellent metabolic stability. This favors Ligand B.
13. **t1/2:** Ligand A (45.899) has a reasonable half-life, while Ligand B (-25.591) has a negative half-life, suggesting very high stability. This favors Ligand B.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.103 and 0.007).
15. **Affinity:** Ligand A (-6.0) has slightly better binding affinity than Ligand B (-6.7). However, the difference is less than 1.5 kcal/mol.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity and a more optimal logP, the extremely high DILI risk is a deal-breaker. Ligand B, despite its lower logP, presents a significantly better safety profile (low DILI), excellent metabolic stability (negative Cl_mic and t1/2), and acceptable other parameters. Given the cardiovascular target, minimizing toxicity is paramount.
Output:
0
2025-04-17 20:24:25,378 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (344.379 Da and 345.399 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand B (95.57) is significantly better than Ligand A (123.12). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is comfortably under the 140 threshold, while A is approaching it.
**3. logP:** Ligand B (2.096) is within the optimal 1-3 range. Ligand A (-0.196) is too low, potentially hindering membrane permeability and absorption. This is a significant drawback for Ligand A.
**4. H-Bond Donors:** Ligand A (2) is slightly higher than Ligand B (1), but both are acceptable (<=5).
**5. H-Bond Acceptors:** Ligand A (9) is higher than Ligand B (6). Both are within the acceptable range (<=10), but lower is generally preferred.
**6. QED:** Ligand A (0.635) has a better QED score than Ligand B (0.44), indicating a more drug-like profile. This is a positive for Ligand A.
**7. DILI:** Ligand B (33.346) has a much lower DILI risk than Ligand A (78.17). This is a crucial advantage for Ligand B. A DILI score >60 is concerning.
**8. BBB:** Ligand B (67.468) has a better BBB penetration score than Ligand A (20.512). While ADRB2 isn't strictly a CNS target, some CNS exposure can occur, and higher BBB is generally favorable.
**9. Caco-2 Permeability:** Ligand B (-4.357) is better than Ligand A (-5.558), indicating better intestinal absorption.
**10. Aqueous Solubility:** Ligand A (-2.54) is better than Ligand B (-3.815). Solubility is important, but not as critical as permeability for this target.
**11. hERG Inhibition:** Ligand B (0.358) has a lower hERG risk than Ligand A (0.076). This is a significant safety advantage for Ligand B.
**12. Microsomal Clearance:** Ligand B (100.076) has significantly higher microsomal clearance than Ligand A (24.034). This means Ligand B will be metabolized faster, leading to a shorter half-life. This is a negative for Ligand B.
**13. In vitro Half-Life:** Ligand A (37.154) has a longer in vitro half-life than Ligand B (18.263). This is a positive for Ligand A.
**14. P-gp Efflux:** Ligand A (0.056) has lower P-gp efflux than Ligand B (0.031), which is beneficial.
**15. Binding Affinity:** Ligand A (-6.7) has a slightly better binding affinity than Ligand B (-5). However, the difference is less than 1.5 kcal/mol, so it's not a decisive factor.
**Overall Assessment:**
While Ligand A has a slightly better QED, half-life, P-gp efflux and binding affinity, Ligand B has significantly better properties regarding ADME-Tox, specifically logP, DILI, hERG, and Caco-2 permeability. The poor logP and high DILI/hERG of Ligand A are major concerns. For a GPCR, optimizing for permeability and minimizing off-target effects (like hERG inhibition) are crucial. Ligand B's profile is more balanced and suggests a higher probability of success as a drug candidate.
Output:
0
2025-04-17 20:24:25,378 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
The target is ADRB2, a GPCR. Therefore, I will prioritize logP, TPSA, Pgp efflux, BBB penetration, and binding affinity, while also considering ADME properties like solubility, metabolic stability, and toxicity.
Let's break down the comparison:
1. **MW:** Both ligands (360.435 and 344.415 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (84.5) is better than Ligand B (97.12). Lower TPSA generally favors oral absorption and is important for GPCR ligands.
3. **logP:** Both ligands have acceptable logP values (2.157 and 2.959), falling within the 1-3 range. Ligand B is slightly higher, which *could* be a minor concern for solubility, but not a dealbreaker.
4. **HBD/HBA:** Both have 2 HBD and 4/5 HBA, which are reasonable and shouldn't pose significant issues.
5. **QED:** Ligand A (0.875) has a significantly better QED score than Ligand B (0.753), indicating a more drug-like profile.
6. **DILI:** Ligand A (79.876) has a higher DILI risk than Ligand B (65.607). This is a negative for Ligand A.
7. **BBB:** Ligand B (68.554) has better BBB penetration than Ligand A (45.909). While ADRB2 isn't exclusively a CNS target, some CNS exposure is not necessarily detrimental and could even be beneficial depending on the specific therapeutic intent.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. This is a significant concern for both compounds.
9. **Solubility:** Both have negative solubility values, indicating poor aqueous solubility. This is a major drawback for both.
10. **hERG:** Ligand A (0.41) has a slightly better hERG profile than Ligand B (0.052), indicating lower cardiotoxicity risk.
11. **Cl_mic:** Ligand A (49.103) has lower microsomal clearance than Ligand B (59.612), suggesting better metabolic stability.
12. **t1/2:** Ligand B (-8.518) has a significantly longer in vitro half-life than Ligand A (-2.283). This is a major advantage for Ligand B, potentially allowing for less frequent dosing.
13. **Pgp:** Ligand A (0.261) has lower P-gp efflux than Ligand B (0.119), which is favorable for bioavailability and potential CNS exposure.
14. **Binding Affinity:** Both ligands have very similar binding affinities (-6.4 and -6.5 kcal/mol). The difference is negligible.
**Overall Assessment:**
Ligand A has advantages in TPSA, QED, hERG, Cl_mic, and Pgp. However, Ligand B has a significantly better half-life and a lower DILI risk, and better BBB penetration. The poor Caco-2 and solubility for both compounds are concerning, but the longer half-life of Ligand B is a major advantage, potentially mitigating some of the absorption issues. Considering the balance of properties, and the importance of metabolic stability for a GPCR target, I lean towards Ligand B.
**Output:**
0
2025-04-17 20:24:25,378 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [351.491, 69.72, 1.441, 1, 4, 0.753, 9.965, 68.282, -4.974, -1.264, 0.247, 16.981, -4.78, 0.014, -4.8]**
**Ligand B: [352.41, 76.46, 0.614, 1, 5, 0.814, 41.566, 94.184, -4.66, -2.21, 0.537, 5.082, 16.227, 0.128, -6.1]**
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). A is 351.491, B is 352.41. No significant difference.
2. **TPSA:** Ligand A (69.72) is better than Ligand B (76.46). Both are below 140, but A is closer to the preferred <90 for potential CNS penetration, although ADRB2 isn't necessarily a CNS target.
3. **logP:** Ligand A (1.441) is better than Ligand B (0.614). Both are within the 1-3 range, but A is closer to the optimal range. B is getting a bit low, potentially impacting permeability.
4. **H-Bond Donors:** Both have 1 HBD, which is good.
5. **H-Bond Acceptors:** Ligand A has 4, Ligand B has 5. Both are acceptable (<=10).
6. **QED:** Ligand B (0.814) is slightly better than Ligand A (0.753), indicating a marginally more drug-like profile.
7. **DILI:** Ligand A (9.965) is *significantly* better than Ligand B (41.566). This is a major advantage for Ligand A. B is approaching a concerning level.
8. **BBB:** Ligand B (94.184) is much better than Ligand A (68.282). While ADRB2 isn't strictly a CNS target, higher BBB penetration is generally favorable.
9. **Caco-2:** Both are negative, indicating poor permeability. A (-4.974) is slightly worse than B (-4.66). This is a concern for both.
10. **Solubility:** Both are negative, indicating poor solubility. A (-1.264) is slightly better than B (-2.21).
11. **hERG:** Ligand A (0.247) is much better than Ligand B (0.537). Lower hERG inhibition is crucial for avoiding cardiotoxicity, making A significantly safer.
12. **Cl_mic:** Ligand A (16.981) is much better than Ligand B (5.082). Lower clearance indicates better metabolic stability, a significant advantage for A.
13. **t1/2:** Ligand B (16.227) is much better than Ligand A (-4.78). A negative value suggests a very short half-life, a major drawback.
14. **Pgp:** Ligand A (0.014) is much better than Ligand B (0.128). Lower P-gp efflux is preferred.
15. **Binding Affinity:** Ligand B (-6.1) is significantly better than Ligand A (-4.8). This is a substantial difference in potency. A 1.3 kcal/mol advantage is very meaningful.
**Overall Assessment:**
Ligand B has a superior binding affinity and half-life, and better BBB penetration. However, it suffers from significantly higher DILI risk, higher hERG inhibition, and lower metabolic stability. Ligand A has a much better safety profile (DILI, hERG), better metabolic stability, and lower P-gp efflux. The affinity difference is substantial, but the ADME/Tox profile of Ligand B is concerning. Given the cardiovascular target, minimizing cardiotoxicity (hERG) and maximizing metabolic stability are critical. While the half-life of A is poor, this can be addressed through structural modifications. The DILI and hERG risks of B are harder to fix.
Therefore, I prioritize Ligand A due to its superior safety and metabolic properties, despite the weaker binding affinity. The affinity can be optimized, but mitigating significant toxicity risks is much more challenging.
Output:
1
2025-04-17 20:24:25,379 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.43 & 354.54 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (67.87) is slightly higher than Ligand B (58.64). Both are below the 140 threshold for oral absorption, but closer to the 90 threshold for CNS targets (less relevant here, but still a positive). Ligand B is preferable.
3. **logP:** Ligand A (1.033) is within the optimal range (1-3), while Ligand B (3.229) is at the higher end. While still acceptable, Ligand A's logP is more balanced.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 3. Both are acceptable.
6. **QED:** Ligand A (0.755) has a slightly better QED score than Ligand B (0.691), indicating better overall drug-likeness.
7. **DILI:** Ligand A (20.9%) has a significantly lower DILI risk than Ligand B (9.93%). This is a major advantage for Ligand A.
8. **BBB:** Both have good BBB penetration (Ligand A: 70.53%, Ligand B: 77.82%). Ligand B is slightly better, but this is less critical for a non-CNS target like ADRB2.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the values are similar (-4.61 vs -4.33).
10. **Solubility:** Both have negative solubility values, which is also unusual. Again, the values are similar (-2.256 vs -2.782).
11. **hERG:** Ligand A (0.134) has a much lower hERG inhibition liability than Ligand B (0.66). This is a significant safety advantage for Ligand A.
12. **Cl_mic:** Ligand B (78.65) has a significantly higher microsomal clearance than Ligand A (31.92), indicating lower metabolic stability. This is a major drawback for Ligand B.
13. **t1/2:** Ligand A (13.78) has a longer in vitro half-life than Ligand B (5.31). This is a positive for Ligand A.
14. **Pgp:** Ligand A (0.013) has much lower P-gp efflux liability than Ligand B (0.063).
15. **Affinity:** Both ligands have very similar binding affinities (-6.4 and -6.2 kcal/mol). The difference is not substantial enough to outweigh other factors.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A has a more favorable logP, lower Pgp efflux, and slightly better TPSA. The affinity difference is negligible.
**Overall Assessment:**
Ligand A is the stronger candidate. It has a significantly better safety profile (lower DILI, lower hERG), better metabolic stability (lower Cl_mic, longer t1/2), lower P-gp efflux, and a slightly better QED score. While Ligand B has slightly better BBB penetration and Caco-2 permeability, the negative values for both suggest issues with these parameters for both compounds. The advantages of Ligand A in safety and metabolic stability outweigh the minor differences in other properties.
Output:
1
2025-04-17 20:24:25,379 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [348.378, 95.37, 3.961, 0, 4, 0.358, 52.772, 83.908, -4.274, -3.828, 0.613, 34.462, 12.393, 0.231, -3.1]
**Ligand B:** [345.487, 54.34, 2.962, 1, 3, 0.826, 29.042, 81.078, -4.78, -3.27, 0.633, 60.397, -1.101, 0.465, -5.9]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity, and BBB):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (345.487) is slightly lower, which is generally favorable.
2. **TPSA:** Ligand A (95.37) is higher than Ligand B (54.34). Ligand B is significantly better here, being well below the 140 A^2 threshold for oral absorption and more favorable for GPCRs.
3. **logP:** Ligand A (3.961) is at the upper end of the optimal range, while Ligand B (2.962) is closer to the center. Both are acceptable, but Ligand B is slightly preferred.
4. **HBD/HBA:** Ligand A (0 HBD, 4 HBA) is better than Ligand B (1 HBD, 3 HBA) in terms of minimizing potential issues with permeability and solubility.
5. **QED:** Ligand B (0.826) has a much better QED score than Ligand A (0.358), indicating a more drug-like profile.
6. **DILI:** Ligand B (29.042) has a significantly lower DILI risk than Ligand A (52.772). This is a major advantage.
7. **BBB:** Both have good BBB penetration (Ligand A: 83.908, Ligand B: 81.078). This is less critical for ADRB2, which isn't a CNS target, but still a positive.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual. I'll assume these are logP values and interpret accordingly.
9. **Solubility:** Both have negative solubility values, which is also unusual. I'll assume these are logS values and interpret accordingly.
10. **hERG:** Both have low hERG risk (Ligand A: 0.613, Ligand B: 0.633).
11. **Cl_mic:** Ligand A (34.462) has a lower microsomal clearance than Ligand B (60.397), suggesting better metabolic stability.
12. **t1/2:** Ligand B (-1.101) has a negative in vitro half-life, which is concerning. Ligand A (12.393) is much better.
13. **Pgp:** Ligand A (0.231) has lower P-gp efflux than Ligand B (0.465), which is favorable for bioavailability.
14. **Affinity:** Ligand B (-5.9 kcal/mol) has a significantly stronger binding affinity than Ligand A (-3.1 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME concerns.
**Overall Assessment:**
Ligand B has a superior binding affinity, a better QED score, and a much lower DILI risk. Its TPSA is also significantly better. While its *in vitro* half-life is concerning, the strong affinity and lower DILI risk are compelling. Ligand A has better metabolic stability and P-gp efflux, but the weaker binding and higher DILI risk are significant drawbacks. Given the importance of potency and safety for a GPCR target, Ligand B is the more promising candidate.
Output:
0
2025-04-17 20:24:25,379 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (368.459 Da and 348.403 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (93.65) is better than Ligand B (102.32). Both are below 140, but closer to 90 is preferred for GPCRs, and A is closer.
**3. logP:** Ligand A (1.037) is within the optimal 1-3 range. Ligand B (0.165) is quite low, potentially hindering membrane permeability. This is a significant negative for B.
**4. H-Bond Donors:** Ligand A (1) is good. Ligand B (2) is acceptable, but A is slightly preferred.
**5. H-Bond Acceptors:** Ligand A (7) is good. Ligand B (6) is also good.
**6. QED:** Ligand A (0.541) is better than Ligand B (0.376), indicating a more drug-like profile.
**7. DILI Risk:** Ligand A (56.572) is slightly higher than Ligand B (47.034), but both are acceptable (below 60).
**8. BBB Penetration:** Both ligands have similar BBB penetration (69.717% and 63.474%), which is acceptable, but not outstanding for a GPCR.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the values are similar (-5.133 and -5.228).
**10. Aqueous Solubility:** Both ligands have negative solubility values, also unusual. Again, similar values (-2.238 and -1.657).
**11. hERG Inhibition:** Ligand A (0.167) is better than Ligand B (0.29), indicating lower cardiotoxicity risk.
**12. Microsomal Clearance:** Ligand A (28.685) has lower clearance than Ligand B (39.055), suggesting better metabolic stability.
**13. In vitro Half-Life:** Ligand A (10.282) has a positive half-life, while Ligand B (-8.487) has a negative half-life. This is a significant advantage for A.
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (0.022 and 0.083).
**15. Binding Affinity:** Ligand B (-7.5 kcal/mol) has a slightly better binding affinity than Ligand A (-6.3 kcal/mol). However, the difference is not substantial enough to overcome the ADME deficiencies of Ligand B.
**Overall Assessment:**
Ligand A is the better candidate. While Ligand B has a slightly better binding affinity, Ligand A demonstrates superior drug-like properties across multiple critical ADME parameters. Specifically, Ligand A has a better logP, QED, metabolic stability (lower Cl_mic, positive t1/2), and lower hERG risk. The low logP of Ligand B is a major concern for permeability and bioavailability. The negative solubility and Caco-2 values for both are concerning and would require further investigation, but the other advantages of A make it the more promising starting point.
Output:
1
2025-04-17 20:24:25,379 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's break down the comparison of Ligand A and Ligand B, considering the provided guidelines and the GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key).
1. **Molecular Weight:** Both ligands (350.463 and 356.423 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (113.32) is slightly higher than Ligand B (108.05), but both are below the 140 A^2 threshold for good oral absorption.
3. **logP:** Ligand A (1.167) is within the optimal 1-3 range, while Ligand B (-1.419) is slightly below 1. While a lower logP isn't ideal, it's not a dealbreaker.
4. **H-Bond Donors:** Ligand A (4) is higher than Ligand B (2). Lower is generally preferred, but 4 is still acceptable.
5. **H-Bond Acceptors:** Ligand A (3) is lower than Ligand B (5). Lower is generally preferred.
6. **QED:** Both ligands have similar QED scores (0.552 and 0.527), indicating good drug-likeness.
7. **DILI:** Both ligands have low DILI risk (19.271 and 18.224), which is excellent.
8. **BBB:** Ligand A (67.352) has a significantly higher BBB penetration percentile than Ligand B (47.111). While ADRB2 isn't necessarily a CNS target, some degree of BBB penetration can be beneficial for distribution.
9. **Caco-2:** Both ligands have similar, negative Caco-2 permeability values (-5.325 and -5.337). This is concerning, and suggests poor intestinal absorption for both.
10. **Solubility:** Both ligands have similarly poor aqueous solubility (-2.741 and -0.495). This is a significant drawback.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.101 and 0.055). This is excellent.
12. **Cl_mic:** Ligand B (-2.143) has a *much* lower (better) microsomal clearance than Ligand A (19.134). This suggests significantly improved metabolic stability for Ligand B.
13. **t1/2:** Ligand B (-10.281) has a longer in vitro half-life than Ligand A (-8.601), further supporting its improved metabolic stability.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.021 and 0.001).
15. **Binding Affinity:** Ligand A (-6.5 kcal/mol) has a slightly better binding affinity than Ligand B (-5.1 kcal/mol). This is a 1.4 kcal/mol difference, which is substantial.
**Overall Assessment:**
The key differentiating factors are binding affinity and metabolic stability. Ligand A has a better binding affinity, which is a high priority for GPCRs. However, Ligand B exhibits significantly better metabolic stability (lower Cl_mic and longer t1/2). The poor Caco-2 and solubility for both are concerning, but can potentially be addressed with formulation strategies. The slightly better BBB penetration of Ligand A is a minor plus.
Given the substantial difference in binding affinity (1.4 kcal/mol) and the importance of potency for GPCR targets, I prioritize Ligand A despite its poorer metabolic stability. The metabolic stability issue might be mitigated through structural modifications in later optimization stages.
**Output:**
1
2025-04-17 20:24:25,379 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.43 & 379.51 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Both are good (89.87 & 82.53), well below the 140 limit for oral absorption. Ligand B is slightly better.
3. **logP:** Both are optimal (1.6 & 1.96), falling within the 1-3 range. Ligand B is slightly better.
4. **HBD:** Ligand A has 3, Ligand B has 2. Both are acceptable (<=5). Ligand B is slightly better.
5. **HBA:** Ligand A has 4, Ligand B has 6. Both are acceptable (<=10).
6. **QED:** Both are good (0.707 & 0.851), indicating a strong drug-like profile. Ligand B is better.
7. **DILI:** Ligand A (39.47) is preferable to Ligand B (58.98) as it has a lower DILI risk.
8. **BBB:** Ligand A (42.23) is better than Ligand B (28.19). While ADRB2 isn't strictly a CNS target, some CNS penetration can be useful for understanding off-target effects.
9. **Caco-2:** Both are negative (-4.865 & -5.286), indicating poor permeability. This is a significant issue for both.
10. **Solubility:** Both are negative (-2.355 & -2.127), indicating poor solubility. This is also a significant issue for both.
11. **hERG:** Both are very low (0.347 & 0.382), indicating low cardiotoxicity risk. No clear advantage.
12. **Cl_mic:** Ligand A (20.48) has a lower (better) microsomal clearance than Ligand B (6.07). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand B (-8.694) has a longer half-life than Ligand A (-5.11). This is a significant advantage for Ligand B.
14. **Pgp:** Both are very low (0.273 & 0.146), indicating low P-gp efflux. Ligand B is slightly better.
15. **Affinity:** Ligand B (-7.1 kcal/mol) has a significantly better binding affinity than Ligand A (-6.2 kcal/mol). This is a >1.5 kcal/mol advantage, which is very important.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand B excels in logP, Pgp, and *especially* affinity. While both have suboptimal Caco-2 and solubility, the substantial affinity advantage of Ligand B outweighs these drawbacks. The longer half-life of Ligand B is also a significant benefit. The lower DILI risk of Ligand A is a plus, but the binding affinity is paramount.
**Conclusion:**
Despite Ligand A's slightly better DILI and BBB scores, Ligand B's superior binding affinity and half-life, coupled with acceptable ADME properties, make it the more promising drug candidate for ADRB2.
Output:
0
2025-04-17 20:24:25,380 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (360.845 Da and 377.388 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (78.09) is better than Ligand B (80.32), being closer to the <140 threshold for good oral absorption. While both are acceptable, lower TPSA is generally preferred.
3. **logP:** Both ligands have good logP values (2.471 and 1.94), falling within the optimal 1-3 range. Ligand B is slightly lower, which *could* indicate slightly better solubility, but the difference is minor.
4. **HBD:** Both ligands have 2 H-bond donors, which is within the acceptable limit of <=5.
5. **HBA:** Ligand A has 3 H-bond acceptors, while Ligand B has 5. Ligand A is preferable here, as lower HBA generally improves permeability.
6. **QED:** Both ligands have similar QED values (0.869 and 0.822), indicating good drug-likeness.
7. **DILI:** Ligand B (68.515) has a higher DILI risk than Ligand A (56.844). This is a significant negative for Ligand B. Lower DILI is crucial.
8. **BBB:** Ligand B (84.451) has a significantly higher BBB penetration percentile than Ligand A (60.372). While ADRB2 isn't strictly a CNS target, some CNS exposure can occur, and higher BBB is generally favorable.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual. This suggests poor permeability. However, the values are similar (-5.227 and -4.905).
10. **Solubility:** Both ligands have very poor aqueous solubility (-3.749 and -3.541). This is a major concern for both, and would require formulation strategies.
11. **hERG:** Ligand A (0.167) has a lower hERG inhibition liability than Ligand B (0.329). This is a significant advantage for Ligand A, as it reduces the risk of cardiotoxicity.
12. **Cl_mic:** Ligand A (-1.368) has a much lower (better) microsomal clearance than Ligand B (18.803). This indicates greater metabolic stability for Ligand A, which is highly desirable.
13. **t1/2:** Ligand A (-38.719) has a more negative in vitro half-life, which is unusual and likely indicates a very short half-life. Ligand B (-8.398) is better.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.09 and 0.074).
15. **Binding Affinity:** Both ligands have very similar binding affinities (-7.3 and -7.2 kcal/mol). The difference is negligible.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. While BBB isn't paramount, it's a bonus. Ligand B has a better BBB score, but Ligand A is better in almost all other critical ADME properties. The significantly lower DILI and Cl_mic for Ligand A are particularly compelling. The slightly better HBA and hERG profiles of Ligand A also contribute to its favorability.
**Conclusion:**
Despite the slightly better BBB score of Ligand B, Ligand A is the more promising candidate due to its significantly improved DILI risk, metabolic stability (lower Cl_mic), and hERG liability. The solubility issues are a concern for both, but can be addressed with formulation.
Output:
1
2025-04-17 20:24:25,380 - INFO - Batch 182 complete. Total preferences: 2912
2025-04-17 20:24:25,380 - INFO - Processing batch 183/512...
2025-04-17 20:25:16,894 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (378.807 and 386.945 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (107.11) is higher than Ligand B (78.43). For a cardiovascular GPCR, TPSA is moderately important; lower is generally better for permeability, and Ligand B is clearly preferable.
**3. logP:** Ligand B (2.989) is closer to the optimal range of 1-3 than Ligand A (1.486). This suggests potentially better membrane permeability for Ligand B.
**4. H-Bond Donors:** Ligand A (4) and Ligand B (3) are both acceptable, being less than 5.
**5. H-Bond Acceptors:** Both ligands have 4 H-bond acceptors, which is within the acceptable range.
**6. QED:** Both ligands have good QED scores (0.576 and 0.642), indicating good drug-like properties. Ligand B is slightly better.
**7. DILI Risk:** Ligand B (44.63) has a significantly lower DILI risk than Ligand A (61.691). This is a crucial advantage, as liver toxicity is a major concern in drug development.
**8. BBB Penetration:** Ligand B (54.478) shows better BBB penetration than Ligand A (48.972), although both are not exceptionally high. Given ADRB2's role in cardiovascular function, BBB penetration isn't a primary concern, but it's a slight benefit for Ligand B.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret. Ligand B (-4.916) is slightly better than Ligand A (-5.435).
**10. Aqueous Solubility:** Both ligands have very poor aqueous solubility (-2.913 and -3.929). This is a significant drawback for both, potentially hindering bioavailability.
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (0.322 and 0.471), which is positive.
**12. Microsomal Clearance:** Ligand A (-16.106) has significantly lower (better) microsomal clearance than Ligand B (57.558), suggesting better metabolic stability. This is a strong advantage for Ligand A.
**13. In vitro Half-Life:** Ligand B (23.601) has a much longer in vitro half-life than Ligand A (4.318). This is a significant advantage for Ligand B, potentially allowing for less frequent dosing.
**14. P-gp Efflux:** Ligand A (0.035) has significantly lower P-gp efflux than Ligand B (0.564), which is favorable for bioavailability.
**15. Binding Affinity:** Ligand B (-7.0) has a substantially stronger binding affinity than Ligand A (-5.7). This is a major advantage, potentially outweighing some of the ADME drawbacks.
**Overall Assessment:**
Ligand B has a significantly better binding affinity and a lower DILI risk, which are critical factors. It also has a longer half-life and a better logP. While Ligand A has better metabolic stability (lower Cl_mic) and lower P-gp efflux, the superior affinity and safety profile of Ligand B are more important for a GPCR target. The solubility issues are concerning for both, but can be addressed with formulation strategies.
Output:
0
2025-04-17 20:25:16,894 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, the most important parameters are binding affinity, logP, TPSA, Pgp efflux, and BBB penetration. Metabolic stability (Cl_mic, t1/2) and safety (DILI, hERG) are also important.
Let's compare the ligands property by property:
1. **MW:** Both ligands (342.483 and 357.479 Da) are within the ideal range (200-500 Da).
2. **TPSA:** Ligand A (41.57) is better than Ligand B (53.51), being closer to the preferred <140. This favors absorption.
3. **logP:** Ligand A (4.34) is slightly higher than the optimal range (1-3), but still acceptable. Ligand B (2.101) is within the optimal range.
4. **HBD/HBA:** Ligand A (1 HBD, 2 HBA) is preferable to Ligand B (0 HBD, 4 HBA) as it has a lower number of HBA.
5. **QED:** Both are similar (0.884 and 0.779), indicating good drug-likeness.
6. **DILI:** Both have low DILI risk (24.312 and 26.328), which is good.
7. **BBB:** Both have good BBB penetration (85.072 and 87.088).
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and difficult to interpret without further context.
9. **Solubility:** Ligand A (-4.761) is slightly worse than Ligand B (-2.934), but both are quite poor.
10. **hERG:** Ligand A (0.782) is better than Ligand B (0.207), indicating lower hERG inhibition risk.
11. **Cl_mic:** Ligand A (73.301) has a higher clearance than Ligand B (61.37), suggesting lower metabolic stability.
12. **t1/2:** Ligand B (-4.109) has a longer half-life than Ligand A (7.662).
13. **Pgp:** Ligand A (0.517) has lower P-gp efflux than Ligand B (0.196), which is favorable for bioavailability.
14. **Affinity:** Ligand A (-7.6 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.4 kcal/mol). This is a substantial advantage.
**Overall Assessment:**
Ligand A has a significantly better binding affinity, lower Pgp efflux, and lower hERG risk. While its logP is slightly higher and solubility is lower, the strong affinity and favorable ADME properties (especially Pgp and hERG) outweigh these drawbacks for a GPCR target. Ligand B has better solubility and metabolic stability, but the weaker binding affinity is a significant disadvantage.
Output:
1
2025-04-17 20:25:16,894 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [366.447, 122.03 , -0.088, 3. , 8. , 0.505, 62.233, 24.389, -6.294, -1.101, 0.064, 15.146, 10.6 , 0.047, -7. ]
**Ligand B:** [355.438, 54.88 , 4.589, 1. , 4. , 0.745, 78.325, 78.48 , -4.745, -4.843, 0.423, 41.96 , 43.947, 0.3 , -6.6 ]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity) and general drug-like properties:
1. **MW:** Both are within the ideal 200-500 Da range. Ligand A (366.447) is slightly higher than Ligand B (355.438), but both are acceptable.
2. **TPSA:** Ligand A (122.03) is pushing the upper limit for good oral absorption (<=140), while Ligand B (54.88) is excellent. This favors B.
3. **logP:** Ligand A (-0.088) is quite low, potentially hindering membrane permeability. Ligand B (4.589) is high, potentially causing solubility issues and off-target effects, but is within the acceptable range. This is a slight edge to A, as extremely high logP is more problematic.
4. **HBD/HBA:** Ligand A (3 HBD, 8 HBA) is reasonable. Ligand B (1 HBD, 4 HBA) is better, with fewer potential issues with solubility and permeability. This favors B.
5. **QED:** Both have good QED scores (A: 0.505, B: 0.745), indicating drug-like properties. B is better here.
6. **DILI:** Ligand A (62.233) is better than Ligand B (78.325) in terms of DILI risk, being below the 60% threshold.
7. **BBB:** Ligand A (24.389) has very low BBB penetration, while Ligand B (78.48) has high BBB penetration. Since ADRB2 is a cardiovascular target, BBB penetration is not a primary concern, so this isn't a major factor.
8. **Caco-2:** Ligand A (-6.294) is very poor, suggesting poor absorption. Ligand B (-4.745) is also poor, but slightly better.
9. **Solubility:** Ligand A (-1.101) is poor, while Ligand B (-4.843) is even worse. This is a significant drawback for both.
10. **hERG:** Both have low hERG risk (A: 0.064, B: 0.423). A is slightly better.
11. **Cl_mic:** Ligand A (15.146) has lower clearance, indicating better metabolic stability, which is favorable. Ligand B (41.96) has higher clearance.
12. **t1/2:** Ligand A (10.6) is better than Ligand B (43.947).
13. **Pgp:** Ligand A (0.047) has lower P-gp efflux, which is favorable for bioavailability. Ligand B (0.3) is higher.
14. **Affinity:** Ligand A (-7.0) is slightly better than Ligand B (-6.6), but the difference is small.
**Overall Assessment:**
Ligand B has a much better TPSA and HBD/HBA profile, and a better QED score. However, it suffers from high DILI risk, poor solubility, and higher metabolic clearance. Ligand A has better metabolic stability (lower Cl_mic and better t1/2), lower DILI risk, and slightly better P-gp efflux. While Ligand A's logP and Caco-2 are concerning, its better metabolic profile and lower DILI risk are more important for a cardiovascular target. The slight affinity advantage of A is also a plus.
Given these considerations, I believe **Ligand A** is the more promising candidate.
Output:
1
2025-04-17 20:25:16,894 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.479 and 344.438 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (69.64) is better than Ligand B (79.42). Both are under 140, but A is closer to the optimal for good absorption.
3. **logP:** Ligand A (1.437) is preferable to Ligand B (3.364). While both are within the 1-3 range, B is pushing toward the higher end, potentially leading to solubility issues.
4. **HBD:** Ligand A (0) is better than Ligand B (1). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (5) is better than Ligand B (6). Lower HBA is generally preferred.
6. **QED:** Both ligands have good QED scores (0.639 and 0.754), indicating good drug-like properties. B is slightly better.
7. **DILI:** Ligand A (23.963) is significantly better than Ligand B (47.421). Lower DILI risk is crucial.
8. **BBB:** Both ligands have good BBB penetration (72.354 and 76.037). This is good, but less critical for ADRB2 which is not a CNS target.
9. **Caco-2:** Ligand A (-4.926) is better than Ligand B (-5.195). Both are negative, indicating good permeability.
10. **Solubility:** Ligand A (-0.375) is better than Ligand B (-3.413). Solubility is a key factor, and B's value is concerningly low.
11. **hERG:** Both ligands have low hERG inhibition risk (0.534 and 0.595). No significant difference.
12. **Cl_mic:** Ligand B (19.033) has a lower microsomal clearance than Ligand A (35.296), indicating better metabolic stability.
13. **t1/2:** Ligand B (3.309) has a longer in vitro half-life than Ligand A (2.255). This is a positive.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.035 and 0.36). No significant difference.
15. **Binding Affinity:** Ligand B (-6.8) has a slightly better binding affinity than Ligand A (-6.4). This is a 0.4 kcal/mol difference, which is significant, but needs to be weighed against other factors.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are important. Ligand A is better on logP and TPSA, while Ligand B has a slightly better affinity. However, the significantly lower DILI risk and better solubility of Ligand A are major advantages. The slightly better metabolic stability and half-life of Ligand B are also positives, but can be addressed during optimization.
**Overall Assessment:**
While Ligand B has a slightly better binding affinity and metabolic stability, Ligand A's superior DILI profile and solubility, combined with acceptable TPSA and logP, make it the more promising candidate. The affinity difference is not large enough to outweigh the potential safety and formulation advantages of Ligand A.
Output:
1
2025-04-17 20:25:16,895 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for their potential as drug candidates targeting the ADRB2, a cardiovascular GPCR. Therefore, we prioritize logP, Pgp, TPSA, and affinity, alongside general drug-like properties.
* **Molecular Weight:** Both ligands are within the acceptable range (200-500 Da). Ligand A (358.463 Da) is slightly higher than Ligand B (347.371 Da), but this difference is not significant.
* **TPSA:** Ligand A (69.64) is significantly better than Ligand B (117.51). A TPSA under 140 is good for oral absorption, and lower is preferable for GPCRs. Ligand B is pushing the upper limit, potentially hindering absorption.
* **logP:** Ligand A (2.513) is within the optimal range (1-3), while Ligand B (0.385) is quite low. Low logP can lead to poor membrane permeability. This is a significant advantage for Ligand A.
* **H-Bond Donors/Acceptors:** Ligand A (HBD=2, HBA=4) and Ligand B (HBD=3, HBA=5) are both acceptable, though Ligand A is slightly more favorable.
* **QED:** Both ligands have reasonable QED scores (A: 0.834, B: 0.666), indicating good drug-like properties. Ligand A is slightly better.
* **DILI:** Both have similar DILI risk (A: 54.556, B: 63.978), and are both acceptable.
* **BBB:** Ligand A (64.793) has a better BBB penetration score than Ligand B (41.218). While not a primary concern for a cardiovascular target, it's a positive attribute.
* **Caco-2:** Both have negative Caco-2 values which is unusual and suggests potential issues with permeability prediction.
* **Aqueous Solubility:** Both have negative solubility values which is also unusual.
* **hERG:** Ligand A (0.579) has a slightly higher hERG risk than Ligand B (0.035), but both are low.
* **Microsomal Clearance:** Ligand B (-2.684) has a negative clearance, which is not physically possible. This suggests a problem with the data or the model. Ligand A (43.617) is reasonable.
* **In vitro Half-Life:** Ligand A (34.829) has a better half-life than Ligand B (5.849).
* **P-gp Efflux:** Ligand A (0.54) has better P-gp efflux properties than Ligand B (0.025). Lower efflux is preferred.
* **Binding Affinity:** Ligand B (-7.5 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.9 kcal/mol). This is a substantial advantage.
**Overall Assessment:**
Ligand B has a significantly better binding affinity. However, its low logP, high TPSA, and problematic clearance data are major concerns. Ligand A, while having a weaker affinity, has a much more balanced profile with favorable logP, TPSA, and reasonable ADME properties. Given the GPCR target class, the balance of properties in Ligand A is more likely to translate to a viable drug candidate. The negative clearance value for Ligand B is a red flag.
**Output:**
1
2025-04-17 20:25:16,895 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (340.39 and 346.48 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand B (78.09) is significantly better than Ligand A (112.66). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have a logP of around 3, which is at the upper end of the optimal range, but still acceptable. No clear advantage.
4. **HBD:** Ligand B (2) has fewer HBDs than Ligand A (3), which is slightly preferable for permeability.
5. **HBA:** Ligand B (3) has fewer HBAs than Ligand A (5), again favoring permeability.
6. **QED:** Both ligands have good QED scores (0.627 and 0.745), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand B (57.58) has a lower DILI risk than Ligand A (64.56), which is a significant advantage.
8. **BBB:** BBB isn't a major concern for a cardiovascular target. Ligand B (57.85) is higher than Ligand A (41.14), but this is less critical.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand B (-3.904) has better (less negative) solubility than Ligand A (-2.158), which is a positive.
11. **hERG:** Ligand A (0.104) has a slightly lower hERG risk than Ligand B (0.601), which is a small advantage.
12. **Cl_mic:** Ligand A (3.152) has significantly lower microsomal clearance than Ligand B (58.505), indicating better metabolic stability. This is a major advantage.
13. **t1/2:** Ligand B (-10.838) has a much longer in vitro half-life than Ligand A (1.809), which is a substantial benefit.
14. **Pgp:** Ligand B (0.396) has lower P-gp efflux than Ligand A (0.011), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand A (-6.9 kcal/mol) has a slightly better binding affinity than Ligand B (-5.2 kcal/mol). This is a 1.7 kcal/mol difference, which is a significant advantage.
**Overall Assessment:**
While Ligand A has a better binding affinity and lower Cl_mic, Ligand B demonstrates a superior profile in several key ADME properties. Specifically, the lower DILI risk, better solubility, longer half-life, and lower P-gp efflux are compelling advantages. The TPSA and H-bonding parameters also favor Ligand B. The Caco-2 permeability is poor for both, but the other improvements in Ligand B outweigh the slight affinity difference. Given the GPCR target class, balancing affinity with good ADME properties is crucial.
Output:
0
2025-04-17 20:25:16,895 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**1. Molecular Weight:** Both ligands (360.332 and 364.511 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (84.5) is better than Ligand B (62.55). Both are below the 140 A^2 threshold for good oral absorption, but lower TPSA is generally preferred for GPCRs, aiding in membrane permeability.
**3. logP:** Ligand A (1.475) is within the optimal 1-3 range. Ligand B (3.549) is at the higher end, potentially leading to solubility issues and off-target interactions.
**4. H-Bond Donors:** Ligand A (2) and Ligand B (1) are both acceptable.
**5. H-Bond Acceptors:** Both ligands have 4 H-bond acceptors, which is within the acceptable range.
**6. QED:** Both ligands have good QED scores (0.753 and 0.83), indicating good drug-like properties.
**7. DILI:** Both ligands have similar DILI risk (41.838 and 43.738), both being below the 60 threshold and considered low risk.
**8. BBB:** Ligand B (83.249) has significantly better BBB penetration than Ligand A (60.45). While ADRB2 isn't exclusively a CNS target, some cardiovascular effects are mediated through CNS pathways, and better BBB penetration can be advantageous.
**9. Caco-2 Permeability:** Ligand A (-4.724) has better Caco-2 permeability than Ligand B (-4.951).
**10. Aqueous Solubility:** Ligand A (-2.735) has better aqueous solubility than Ligand B (-4.289). This is important for formulation and bioavailability.
**11. hERG Inhibition:** Ligand A (0.304) has a lower hERG inhibition liability than Ligand B (0.553), which is a significant safety advantage.
**12. Microsomal Clearance:** Ligand B (52.539) has lower microsomal clearance than Ligand A (60.251), suggesting better metabolic stability.
**13. In vitro Half-Life:** Ligand B (12.189) has a longer in vitro half-life than Ligand A (-23.03). This is a positive attribute.
**14. P-gp Efflux:** Ligand A (0.024) has lower P-gp efflux liability than Ligand B (0.394), which is beneficial for bioavailability.
**15. Binding Affinity:** Both ligands have very similar binding affinities (-6.1 and -5.8 kcal/mol). The difference is not substantial enough to override other considerations.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand A is slightly favored. While Ligand B has better BBB penetration and metabolic stability, Ligand A has a more favorable logP, better solubility, and significantly lower hERG inhibition liability. The better Caco-2 permeability and lower P-gp efflux of Ligand A also contribute to better predicted bioavailability. The small difference in binding affinity doesn't outweigh the ADME/Tox advantages of Ligand A.
Output:
1
2025-04-17 20:25:16,895 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [373.479, 108.21 , -1.265, 2. , 6. , 0.576, 21.753, 62.97 , -5.449, -1.211, 0.077, -6.383, -0.228, 0.002, -6.1 ]**
**Ligand B: [358.507, 40.62 , 3.05 , 0. , 3. , 0.812, 21.946, 85.111, -5.069, -3.344, 0.344, 39.234, 8.76 , 0.348, -7.7 ]**
1. **Molecular Weight:** Both are within the ideal range (200-500 Da). Ligand B (358.5) is slightly lower, which could be beneficial for permeability, but the difference isn't substantial.
2. **TPSA:** Ligand A (108.21) is higher than Ligand B (40.62). For a cardiovascular GPCR, lower TPSA is generally preferred for better permeability. Ligand B is significantly better here.
3. **logP:** Ligand A (-1.265) is lower than the optimal range (1-3), potentially hindering permeation. Ligand B (3.05) is within the optimal range. Ligand B is much better.
4. **H-Bond Donors:** Ligand A (2) is acceptable, and Ligand B (0) is even better. Fewer HBDs generally improve permeability.
5. **H-Bond Acceptors:** Ligand A (6) is acceptable, and Ligand B (3) is better. Fewer HBAs also improve permeability.
6. **QED:** Both have reasonable QED values (A: 0.576, B: 0.812), indicating good drug-like properties. Ligand B is better.
7. **DILI:** Both have very similar, low DILI risk (A: 21.753, B: 21.946). This isn't a differentiating factor.
8. **BBB:** Ligand B (85.111) has a significantly higher BBB penetration score than Ligand A (62.97). While ADRB2 isn't a primary CNS target, some degree of BBB penetration can be useful for off-target effects assessment and potential peripheral effects.
9. **Caco-2 Permeability:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is unclear, so it's hard to interpret.
10. **Aqueous Solubility:** Both have negative solubility values, which is also unusual. Again, the scale is unclear.
11. **hERG Inhibition:** Ligand A (0.077) has a much lower hERG inhibition risk than Ligand B (0.344). This is a significant advantage for Ligand A.
12. **Microsomal Clearance:** Ligand A (-6.383) has a much lower (better) microsomal clearance than Ligand B (39.234), suggesting better metabolic stability.
13. **In vitro Half-Life:** Ligand B (8.76) has a significantly longer half-life than Ligand A (-0.228). This is a major advantage for Ligand B.
14. **P-gp Efflux:** Ligand A (0.002) has a much lower P-gp efflux liability than Ligand B (0.348), which is beneficial for bioavailability.
15. **Binding Affinity:** Ligand B (-7.7) has a significantly stronger binding affinity than Ligand A (-6.1). This is a substantial advantage, potentially outweighing some ADME concerns.
**Overall Assessment:**
Ligand B has a superior binding affinity, better logP, TPSA, QED, BBB penetration, and in vitro half-life. Ligand A has a lower hERG risk, P-gp efflux, and microsomal clearance. The stronger affinity of Ligand B is a critical factor for GPCR targets. While the lower hERG and clearance of Ligand A are desirable, the substantial improvement in binding affinity with Ligand B, combined with its better predicted permeability (lower TPSA, better logP), makes it the more promising candidate.
Output:
0
2025-04-17 20:25:16,896 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (356.398 and 362.514 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (93.19) is better than Ligand B (36.36). For a cardiovascular GPCR, TPSA isn't a *major* concern (unlike a CNS target), but lower TPSA generally correlates with better permeability. Ligand B is significantly lower, which is a positive.
3. **logP:** Ligand A (-1.288) is suboptimal, being below the preferred 1-3 range. Ligand B (4.556) is too high, potentially leading to solubility issues and off-target interactions. Ligand A is slightly favored here as it's closer to the optimal range, even if still low.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable.
5. **HBA:** Ligand A (5) and Ligand B (4) are both acceptable.
6. **QED:** Both ligands (0.654 and 0.748) have good drug-likeness scores. Ligand B is slightly better.
7. **DILI:** Ligand A (30.322) has a significantly lower DILI risk than Ligand B (15.2). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (20.861) is poor, while Ligand B (84.839) is excellent. Since ADRB2 is a cardiovascular target, BBB penetration is not a priority, so Ligand B is favored.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.074 and -4.988), which is unusual and concerning. This suggests poor intestinal absorption for both.
10. **Solubility:** Ligand A (0.164) has very poor aqueous solubility, while Ligand B (-4.322) is also poor. This is a significant drawback for both, but Ligand A is worse.
11. **hERG:** Ligand A (0.077) has a very low hERG risk, which is excellent. Ligand B (0.968) is higher, indicating a moderate risk. This is a strong advantage for Ligand A.
12. **Cl_mic:** Ligand A (-9.924) has a very low (and negative) microsomal clearance, indicating high metabolic stability. Ligand B (41.664) has a high clearance, suggesting rapid metabolism. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (-17.966) has a negative in vitro half-life, which is problematic. Ligand B (29.614) has a reasonable half-life. Ligand B is favored.
14. **Pgp:** Ligand A (0.004) has very low P-gp efflux, which is favorable. Ligand B (0.903) has higher efflux. This is an advantage for Ligand A.
15. **Binding Affinity:** Ligand B (-7.9) has a significantly stronger binding affinity than Ligand A (-6.7). This is a substantial advantage for Ligand B, and often outweighs minor ADME concerns.
**Overall Assessment:**
Ligand B has a much better binding affinity and BBB penetration (though BBB is less important for a cardiovascular target). However, it suffers from high logP, a higher DILI risk, and faster metabolism. Ligand A has better DILI, hERG, Pgp, and metabolic stability, but its logP is too low and solubility is very poor. The strong affinity of Ligand B is a major factor. While the ADME properties of Ligand B are not ideal, they might be addressable through further optimization. The poor solubility and low logP of Ligand A are more difficult to fix without significantly impacting potency.
Output:
0
2025-04-17 20:25:16,896 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (354.435) is slightly higher than Ligand B (346.391), but both are acceptable.
2. **TPSA:** Ligand A (66.71) is significantly better than Ligand B (106.15). For a GPCR, lower TPSA is generally preferred for better permeability, and Ligand A is well below the 140 threshold. Ligand B is approaching the upper limit.
3. **logP:** Ligand A (3.006) is optimal, while Ligand B (0.133) is quite low. Low logP can lead to poor membrane permeability. This is a significant advantage for Ligand A.
4. **HBD:** Both ligands have 1 HBD, which is within the acceptable range.
5. **HBA:** Ligand A has 5 HBA, while Ligand B has 7. Both are acceptable, but Ligand A is slightly better.
6. **QED:** Both ligands have good QED scores (A: 0.72, B: 0.797), indicating good drug-like properties.
7. **DILI:** Ligand A (72.276) has a higher DILI risk than Ligand B (58.976), but both are still within a reasonably acceptable range.
8. **BBB:** Ligand A (72.741) has a better BBB penetration score than Ligand B (38.348). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be beneficial, and avoiding efflux is always good.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability in this assay. This is a potential concern for both.
10. **Solubility:** Ligand A (-3.615) has slightly better solubility than Ligand B (-1.506), but both are poor.
11. **hERG:** Ligand A (0.672) has a much lower hERG risk than Ligand B (0.04). This is a crucial safety parameter, and Ligand A is significantly better.
12. **Cl_mic:** Ligand A (48.883) has a significantly lower microsomal clearance than Ligand B (16.076), indicating better metabolic stability.
13. **t1/2:** Ligand A (17.681) has a longer in vitro half-life than Ligand B (-6.622). This is a significant advantage for dosing convenience.
14. **Pgp:** Ligand A (0.175) has lower P-gp efflux liability than Ligand B (0.01). Lower Pgp is generally preferred.
15. **Binding Affinity:** Both ligands have excellent binding affinities (A: -7.0 kcal/mol, B: -6.5 kcal/mol), with Ligand A being slightly better. The 0.5 kcal/mol difference is notable, but not overwhelmingly decisive given the other factors.
**GPCR-Specific Priorities:**
Considering ADRB2 is a GPCR, logP, TPSA, Pgp, and affinity are key. Ligand A excels in these areas (better logP, much lower TPSA, better Pgp, and slightly better affinity). The better metabolic stability (Cl_mic and t1/2) and lower hERG risk of Ligand A further strengthen its profile.
**Conclusion:**
Despite the similar binding affinities and acceptable DILI scores for both, Ligand A is the superior candidate due to its significantly better physicochemical properties (logP, TPSA), improved ADME profile (Cl_mic, t1/2, Pgp), and lower hERG risk. These factors collectively make it more likely to be a viable drug candidate.
Output:
1
2025-04-17 20:25:16,896 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (353.482 and 334.379 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (73.2 and 75.19) are below the 140 A^2 threshold for good oral absorption, and acceptable for a cardiovascular target (not needing high BBB penetration). Ligand A is slightly better.
3. **logP:** Both ligands (3.199 and 2.649) are within the optimal 1-3 range. Ligand A is slightly higher, potentially offering better membrane permeability.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 3 HBA, while Ligand B has 4. Both are acceptable (<=10), but A is slightly preferable.
6. **QED:** Both ligands have good QED scores (0.728 and 0.796), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (18.651%) has a significantly lower DILI risk than Ligand B (76.89%). This is a major advantage for Ligand A.
8. **BBB:** Both have high BBB penetration (89.919% and 68.011%). While ADRB2 is a cardiovascular target, some CNS off-target effects are possible, so higher BBB is not necessarily a negative.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. This is concerning for both, but Ligand B (-4.853) is worse than Ligand A (-4.273).
10. **Solubility:** Both have negative solubility values, indicating poor solubility. Ligand B (-3.194) is slightly worse than Ligand A (-3.564).
11. **hERG:** Both have low hERG inhibition risk (0.872 and 0.584). Ligand B is slightly better.
12. **Cl_mic:** Ligand B (60.427) has a lower microsomal clearance than Ligand A (68.843), suggesting better metabolic stability.
13. **t1/2:** Ligand B (51.557) has a significantly longer in vitro half-life than Ligand A (-12.596). This is a major advantage for Ligand B.
14. **Pgp:** Both have very low Pgp efflux liability (0.083 and 0.114). No significant difference.
15. **Binding Affinity:** Ligand B (-8.8 kcal/mol) has a significantly stronger binding affinity than Ligand A (-7.0 kcal/mol). This is a substantial advantage for Ligand B.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand B excels in affinity, has acceptable logP and Pgp, and comparable TPSA. While Ligand A has slightly better TPSA and logP, the significantly stronger affinity of Ligand B outweighs these minor differences. The DILI risk of Ligand A is a major advantage, but the longer half-life of Ligand B is also very valuable. The poor Caco-2 and solubility of both are concerning, but can be addressed with formulation strategies.
**Conclusion:**
Despite the lower DILI risk of Ligand A, the significantly stronger binding affinity and longer half-life of Ligand B make it the more promising drug candidate. The affinity difference is substantial enough to potentially overcome the higher DILI risk and solubility/permeability issues.
Output:
0
2025-04-17 20:25:16,896 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (347.415 Da) is better, falling comfortably within the 200-500 Da range. Ligand B (365.474 Da) is also acceptable but slightly higher.
2. **TPSA:** Ligand B (43.86) is significantly better, well below the 140 threshold and very favorable for oral absorption. Ligand A (94.66) is higher, potentially impacting absorption.
3. **logP:** Ligand B (1.902) is optimal, within the 1-3 range. Ligand A (0.06) is quite low, potentially leading to poor membrane permeability.
4. **HBD:** Ligand A (3) is acceptable. Ligand B (0) is even better, minimizing potential issues with hydrogen bonding and metabolic liability.
5. **HBA:** Both ligands have 4 HBA, which is within the acceptable range.
6. **QED:** Both ligands have good QED scores (A: 0.718, B: 0.822), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand B (23.187) has a much lower DILI risk than Ligand A (17.138), a significant advantage.
8. **BBB:** Ligand B (93.68) shows excellent BBB penetration, while Ligand A (40.403) is much lower. Given ADRB2's cardiovascular involvement, CNS penetration isn't *critical*, but it's a bonus.
9. **Caco-2:** Ligand A (-5.356) is better than Ligand B (-4.647) indicating better intestinal absorption.
10. **Solubility:** Ligand A (-1.627) is slightly better than Ligand B (-1.976).
11. **hERG:** Both ligands have very low hERG risk (A: 0.135, B: 0.781).
12. **Cl_mic:** Ligand A (-31.512) has a much lower (better) microsomal clearance than Ligand B (8.062), indicating greater metabolic stability.
13. **t1/2:** Ligand B (10.043) has a significantly longer in vitro half-life than Ligand A (1.456), which is a major advantage.
14. **Pgp:** Ligand A (0.006) has very low P-gp efflux, while Ligand B (0.324) is higher.
15. **Affinity:** Both ligands have very similar binding affinities (-6.4 kcal/mol and -6.3 kcal/mol). The difference is negligible.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, and Pgp efflux are important. Ligand B excels in logP and TPSA, and has acceptable Pgp efflux. While BBB isn't paramount for a cardiovascular target, the high BBB score of Ligand B is a positive. Metabolic stability (Cl_mic and t1/2) is also important, and Ligand B has a much better half-life.
**Overall Assessment:**
While Ligand A has slightly better Caco-2 permeability and lower Pgp efflux, Ligand B's superior TPSA, logP, DILI risk, and significantly improved metabolic stability (t1/2) outweigh these minor advantages. The similar binding affinities make the ADME properties the deciding factor.
**Output:**
0
2025-04-17 20:25:16,896 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (363.483 and 361.833 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (62.74) is better than Ligand B (82.19). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (1.948 and 1.682), falling within the optimal 1-3 range. Ligand B is slightly lower, which could marginally improve solubility.
4. **HBD:** Ligand A has 0 HBD, which is excellent for permeability. Ligand B has 1 HBD, still acceptable.
5. **HBA:** Ligand A has 5 HBA, and Ligand B has 4 HBA, both are within the acceptable limit of 10.
6. **QED:** Both ligands have high QED scores (0.823 and 0.898), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (62.854) has a higher DILI risk than Ligand B (56.883). This is a significant negative for Ligand A.
8. **BBB:** Ligand A (55.138) has a higher BBB penetration than Ligand B (32.765). Since ADRB2 is a cardiovascular target, BBB penetration is not a priority.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. Ligand B (-5.068) is slightly better than Ligand A (-4.756).
10. **Solubility:** Both ligands have negative solubility values, indicating poor solubility. Ligand B (-2.082) is slightly better than Ligand A (-1.857).
11. **hERG:** Both ligands have low hERG inhibition liability (0.376 and 0.382). No significant difference.
12. **Cl_mic:** Ligand A (42.724) has a moderate clearance, while Ligand B (0.05) has *extremely* low clearance. This is a major advantage for Ligand B, indicating much better metabolic stability.
13. **t1/2:** Ligand A (17.17) has a reasonable half-life, while Ligand B (-22.221) has a very short half-life. This is a significant negative for Ligand B.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.281 and 0.036). Ligand B is slightly better.
15. **Binding Affinity:** Ligand B (-6.6 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.6 kcal/mol). This 1 kcal/mol difference is substantial and can often outweigh minor ADME drawbacks.
**Overall Assessment:**
Ligand B is the preferred candidate. While Ligand A has a slightly better BBB score (irrelevant for this target) and in vitro half-life, Ligand B has a significantly stronger binding affinity, lower DILI risk, and dramatically improved metabolic stability (much lower Cl_mic). The stronger binding affinity is a critical advantage for a GPCR target. The slightly lower solubility and Caco-2 permeability are less concerning than the potential for liver toxicity and rapid metabolism associated with Ligand A.
Output:
0
2025-04-17 20:25:16,897 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [360.527, 68.16, 4.094, 2, 4, 0.849, 35.673, 88.29, -5.074, -4.169, 0.917, 17.764, 41.135, 0.485, -6.4]
**Ligand B:** [358.479, 96.89, 0.989, 3, 5, 0.541, 6.747, 67.429, -4.794, -1.189, 0.167, 27.959, -22.76, 0.006, -5.8]
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). A is 360.5, B is 358.5. Very similar.
2. **TPSA:** Ligand A (68.16) is much better than Ligand B (96.89). GPCRs benefit from lower TPSA for permeability. A is well under the 140 threshold, B is approaching it.
3. **logP:** Ligand A (4.094) is higher than Ligand B (0.989). While both are within the acceptable range, A is pushing the upper limit. B is quite low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (2) is better than Ligand B (3). Lower is generally preferred.
5. **HBA:** Ligand A (4) is better than Ligand B (5). Lower is generally preferred.
6. **QED:** Ligand A (0.849) is significantly better than Ligand B (0.541), indicating a more drug-like profile.
7. **DILI:** Ligand A (35.673) is much better than Ligand B (6.747). Lower is better, and A is comfortably below the 40% threshold, while B is also good.
8. **BBB:** Ligand A (88.29) is significantly better than Ligand B (67.429). This is a key parameter for GPCRs, and A has a strong percentile.
9. **Caco-2:** Ligand A (-5.074) is better than Ligand B (-4.794). Higher is better.
10. **Solubility:** Ligand A (-4.169) is better than Ligand B (-1.189). Higher is better.
11. **hERG:** Ligand A (0.917) is better than Ligand B (0.167). Lower is better.
12. **Cl_mic:** Ligand A (17.764) is better than Ligand B (27.959). Lower is better, indicating better metabolic stability.
13. **t1/2:** Ligand A (41.135) is significantly better than Ligand B (-22.76). A longer half-life is generally preferred.
14. **Pgp:** Ligand A (0.485) is better than Ligand B (0.006). Lower is better.
15. **Affinity:** Ligand A (-6.4) is slightly better than Ligand B (-5.8). While both are good, A has a stronger binding affinity.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical parameters, especially those prioritized for GPCRs (BBB, TPSA, logP, Pgp) and general drug-like properties (QED, solubility, metabolic stability). The only area where Ligand B is better is DILI, but A is still within an acceptable range. The superior BBB penetration, TPSA, QED, and metabolic stability of Ligand A make it a more promising candidate. The slightly better binding affinity is a bonus.
Output:
1
2025-04-17 20:25:16,897 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (340.43 and 342.44 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (50.6) is better than Ligand B (67.23). For a cardiovascular GPCR, TPSA should be kept low to facilitate good absorption. Ligand A is closer to the preferred <140 threshold.
**3. logP:** Both ligands have good logP values (1.796 and 1.495), falling within the optimal 1-3 range. Ligand B is slightly lower, which could slightly impact permeability, but both are acceptable.
**4. H-Bond Donors:** Ligand A has 0 HBD, while Ligand B has 1. Lower is generally preferred for GPCRs to enhance membrane permeability, giving a slight edge to Ligand A.
**5. H-Bond Acceptors:** Ligand A has 5 HBA, and Ligand B has 4. Both are within the acceptable range of <=10.
**6. QED:** Both ligands have high QED scores (0.852 and 0.905), indicating good drug-like properties. No significant difference.
**7. DILI Risk:** Ligand A (29.042) has a slightly higher DILI risk than Ligand B (23.963), but both are well below the concerning threshold of 60.
**8. BBB Penetration:** Ligand A (86.274) shows better BBB penetration than Ligand B (71.074). While not a CNS target, some degree of BBB penetration can be indicative of favorable permeability characteristics.
**9. Caco-2 Permeability:** Ligand A (-4.541) shows better Caco-2 permeability than Ligand B (-5.005). This suggests better intestinal absorption for Ligand A.
**10. Aqueous Solubility:** Both ligands have very poor aqueous solubility (-1.739 and -1.745). This is a significant concern for both and would require formulation strategies to address.
**11. hERG Inhibition:** Ligand A (0.92) has a slightly higher hERG inhibition risk than Ligand B (0.478). This is a potential safety concern for Ligand A.
**12. Microsomal Clearance:** Ligand B (2.614) has significantly lower microsomal clearance than Ligand A (61.433), suggesting better metabolic stability for Ligand B. This is a crucial advantage.
**13. In vitro Half-Life:** Ligand B (-9.219) has a significantly longer in vitro half-life than Ligand A (-6.912). This is a major advantage for Ligand B, potentially allowing for less frequent dosing.
**14. P-gp Efflux:** Ligand A (0.508) has lower P-gp efflux than Ligand B (0.055), which is favorable.
**15. Binding Affinity:** Both ligands have very similar and excellent binding affinities (-7.2 and -7.1 kcal/mol). The difference is negligible.
**Overall Assessment:**
While Ligand A has advantages in BBB penetration and P-gp efflux, Ligand B is superior in terms of metabolic stability (Cl_mic), in vitro half-life, and hERG risk. The poor solubility is a concern for both, but the improved pharmacokinetic profile of Ligand B, particularly its lower clearance and longer half-life, makes it the more promising candidate. The slightly lower DILI risk for Ligand B is also a positive. Given the GPCR target class, optimizing for metabolic stability and minimizing off-target effects (hERG) are crucial.
Output:
0
2025-04-17 20:25:16,897 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (370.471) is slightly higher than Ligand B (355.435), but both are acceptable.
2. **TPSA:** Ligand A (68.31) is significantly better than Ligand B (96.97). For a GPCR, lower TPSA is generally preferred for better permeability. Ligand B is approaching a TPSA that might hinder oral absorption.
3. **logP:** Ligand A (1.481) is better than Ligand B (0.512). Both are within the acceptable range (1-3), but Ligand A is closer to the optimal range. Ligand B is a bit low and might have permeability issues.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer hydrogen bond donors generally improve permeability.
5. **HBA:** Ligand A (6) is preferable to Ligand B (5). Both are acceptable, but fewer is better.
6. **QED:** Ligand A (0.759) is better than Ligand B (0.588), indicating a more drug-like profile.
7. **DILI:** Ligand B (34.587) is significantly better than Ligand A (54.944). Lower DILI is crucial. This is a significant advantage for Ligand B.
8. **BBB:** Ligand B (78.79) is better than Ligand A (66.925). While ADRB2 isn't exclusively a CNS target, some CNS penetration might be beneficial, and lower efflux is desirable.
9. **Caco-2:** Ligand A (-4.526) and Ligand B (-4.887) are both very poor. This suggests very poor intestinal absorption for both.
10. **Solubility:** Ligand A (-1.472) and Ligand B (-1.499) are similar and both poor.
11. **hERG:** Both ligands have very low hERG risk (0.179 and 0.168 respectively). This is good.
12. **Cl_mic:** Ligand B (4.418) is significantly better than Ligand A (43.086). Lower clearance is highly desirable for metabolic stability.
13. **t1/2:** Ligand A (27.903) is significantly better than Ligand B (-6.406). A longer half-life is preferred.
14. **Pgp:** Both ligands have very low Pgp efflux (0.121 and 0.018 respectively). This is good.
15. **Binding Affinity:** Ligand B (-8.0) is significantly better than Ligand A (-7.7). A 0.3 kcal/mol difference is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand B has a significantly better binding affinity and lower DILI risk, and lower microsomal clearance. These are critical factors. The lower TPSA and logP of Ligand A are advantages, but the superior affinity of Ligand B is a major driver. The poor Caco-2 and solubility for both are concerning, but can be addressed with formulation strategies. The longer half-life of Ligand A is a plus, but the superior binding affinity of Ligand B is more important for a GPCR target.
Output:
0
2025-04-17 20:25:16,897 - INFO - Batch 183 complete. Total preferences: 2928
2025-04-17 20:25:16,897 - INFO - Processing batch 184/512...
2025-04-17 20:26:02,528 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (369.487 Da and 366.487 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (98.74) is better than Ligand B (100.19), both are acceptable, but closer to the upper limit for good oral absorption.
3. **logP:** Ligand A (-0.268) is a bit low, potentially hindering membrane permeability. Ligand B (1.267) is within the optimal 1-3 range. This is a significant advantage for Ligand B.
4. **HBD:** Both have 3 H-bond donors, which is acceptable.
5. **HBA:** Both have 5 H-bond acceptors, which is acceptable.
6. **QED:** Ligand B (0.706) has a better QED score than Ligand A (0.574), indicating a more drug-like profile.
7. **DILI:** Ligand A (20.396) has a significantly lower DILI risk than Ligand B (34.703). This is a major advantage for Ligand A.
8. **BBB:** Both ligands have similar BBB penetration (Ligand A: 40.675, Ligand B: 39.705). Since ADRB2 is a cardiovascular target, BBB penetration is not a high priority.
9. **Caco-2:** Both have similar, and poor, Caco-2 permeability (-5.627 and -5.424).
10. **Solubility:** Ligand A (-2.726) has slightly worse solubility than Ligand B (-1.582), but both are poor.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.092 and 0.029).
12. **Cl_mic:** Ligand A (8.843) has a higher microsomal clearance than Ligand B (1.321), suggesting lower metabolic stability. This favors Ligand B.
13. **t1/2:** Ligand A (7.299) has a longer in vitro half-life than Ligand B (4.302). This favors Ligand A.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.017 and 0.013).
15. **Binding Affinity:** Ligand A (-7.4 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.7 kcal/mol). This is a substantial advantage for Ligand A.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand B has a better logP, while Ligand A has a much better affinity. The DILI score of Ligand A is also a significant benefit. While the solubility and Caco-2 permeability are poor for both, the affinity difference is substantial enough to outweigh these concerns.
**Conclusion:**
The stronger binding affinity of Ligand A (-7.4 kcal/mol vs -6.7 kcal/mol) and its lower DILI risk are compelling advantages. While Ligand B has a better logP and QED, the difference in affinity is substantial and likely to be more impactful for efficacy.
Output:
1
2025-04-17 20:26:02,528 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (342.439 Da and 347.415 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (62.55) is significantly better than Ligand B (100.45). For a GPCR, keeping TPSA low is beneficial for permeability, and Ligand A is well below the 140 threshold. Ligand B is approaching the upper limit.
3. **logP:** Both ligands have acceptable logP values (2.922 and 1.073), falling within the 1-3 optimal range. Ligand A is slightly higher, which *could* be a minor drawback, but still reasonable. Ligand B is closer to the lower end, which could impact permeability.
4. **HBD/HBA:** Ligand A (1 HBD, 3 HBA) is better than Ligand B (2 HBD, 5 HBA). Lower numbers are generally preferred for better permeability.
5. **QED:** Ligand A (0.915) has a substantially higher QED score than Ligand B (0.696), indicating a more drug-like profile. This is a significant advantage for Ligand A.
6. **DILI:** Both ligands have similar and acceptable DILI risk (41.877 and 42.264, both <40).
7. **BBB:** Ligand A (78.674) has a considerably higher BBB penetration percentile than Ligand B (44.824). While ADRB2 isn't exclusively a CNS target, some CNS exposure can occur, and higher BBB is generally favorable.
8. **Caco-2:** Both ligands have similar negative Caco-2 values (-4.997 and -4.889). These values are not directly interpretable without knowing the scale, but the similarity suggests similar intestinal absorption potential.
9. **Solubility:** Ligand A (-3.208) has slightly better solubility than Ligand B (-2.366).
10. **hERG:** Ligand A (0.362) has a lower hERG inhibition liability than Ligand B (0.622), which is a crucial safety advantage.
11. **Cl_mic:** Ligand B (35.953) has a lower microsomal clearance than Ligand A (45.236), suggesting better metabolic stability. This is a positive for Ligand B.
12. **t1/2:** Ligand A (41.343) has a slightly longer in vitro half-life than Ligand B (35.656).
13. **Pgp:** Ligand A (0.288) has lower P-gp efflux liability than Ligand B (0.052), which is favorable for bioavailability.
14. **Binding Affinity:** Ligand A (-6.6 kcal/mol) has a slightly better binding affinity than Ligand B (-6.1 kcal/mol). While the difference is not huge, it is still a positive for Ligand A.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, TPSA, logP, Pgp, and affinity are key. Ligand A excels in TPSA, Pgp, and has a slightly better affinity. Ligand B has a better Cl_mic. However, the overall profile of Ligand A is superior, particularly its higher QED, better BBB penetration, and lower hERG risk.
**Conclusion:**
Ligand A presents a more balanced and favorable profile overall, especially considering the GPCR target class and the importance of drug-like properties, safety (hERG), and potential for reasonable distribution.
Output:
1
2025-04-17 20:26:02,529 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (348.328 Da) is better than Ligand B (402.336 Da). Both are within the ideal range, but A is closer to the lower bound which can be beneficial for permeability.
2. **TPSA:** Ligand B (54.02) is better than Ligand A (61.92). Both are below 140, but B is closer to the preferred <90 for GPCRs.
3. **logP:** Ligand A (3.249) is slightly better than Ligand B (4.592). B is pushing the upper limit and could have solubility issues.
4. **HBD:** Ligand A (0) is better than Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is better than Ligand B (2). Both are good, but A is slightly higher.
6. **QED:** Ligand A (0.795) is slightly better than Ligand B (0.735). Both are above 0.5, indicating good drug-likeness.
7. **DILI:** Ligand B (48.313) is better than Ligand A (55.525). Both are acceptable, but B has a lower risk.
8. **BBB:** Ligand A (91.702) is significantly better than Ligand B (74.758). This is a crucial factor for GPCRs, even cardiovascular ones, as off-target CNS effects are possible.
9. **Caco-2:** Ligand A (-4.455) is better than Ligand B (-4.983). Higher (less negative) values indicate better absorption.
10. **Solubility:** Ligand A (-5.159) is better than Ligand B (-4.024). Higher (less negative) values indicate better solubility.
11. **hERG:** Ligand A (0.797) is better than Ligand B (0.66). Lower values are preferred.
12. **Cl_mic:** Ligand A (45.266) is better than Ligand B (58.285). Lower clearance is preferred for metabolic stability.
13. **t1/2:** Ligand B (90.895) is significantly better than Ligand A (24.394). A longer half-life is desirable.
14. **Pgp:** Ligand A (0.661) is better than Ligand B (0.43). Lower efflux is preferred.
15. **Affinity:** Ligand A (-6.3) is significantly better than Ligand B (-1.1). This is the most important factor, and the difference is substantial.
**Overall Assessment:**
Ligand A has a clear advantage in binding affinity, which is paramount for a drug candidate. It also performs better in several key ADME properties like TPSA, logP, HBD, solubility, and metabolic stability. While Ligand B has a better half-life and DILI score, the significantly stronger binding affinity of Ligand A, coupled with its better BBB penetration, outweighs these benefits. The improved BBB penetration is particularly relevant for a GPCR target, even if the primary intention isn't CNS activity, to help predict and mitigate potential off-target effects.
Output:
1
2025-04-17 20:26:02,529 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.447 and 348.487 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (96.25) is higher than Ligand B (58.64). For a GPCR like ADRB2, lower TPSA is generally preferred for better permeability, giving a slight edge to Ligand B.
3. **logP:** Ligand A (0.443) is quite low, potentially hindering membrane permeability. Ligand B (2.82) is within the optimal 1-3 range. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (1). Both are acceptable, but lower is generally better for permeability.
5. **HBA:** Ligand A (5) is higher than Ligand B (3). Again, lower is preferred.
6. **QED:** Ligand A (0.695) is slightly better than Ligand B (0.593), indicating a marginally more drug-like profile.
7. **DILI:** Both ligands have low DILI risk (Ligand A: 28.034, Ligand B: 26.755), which is excellent. No clear winner.
8. **BBB:** Ligand B (71.772) has a significantly higher BBB penetration percentile than Ligand A (32.532). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be beneficial, and higher BBB is rarely detrimental. This favors Ligand B.
9. **Caco-2:** Both have negative values, indicating poor permeability. Ligand A (-5.21) is slightly better than Ligand B (-4.688), but both are concerning.
10. **Solubility:** Ligand A (-1.936) is slightly better than Ligand B (-3.037), but both are poor. Solubility is a concern for both.
11. **hERG:** Both ligands have very low hERG inhibition risk (Ligand A: 0.062, Ligand B: 0.385). No significant difference.
12. **Cl_mic:** Ligand A (17.438) has significantly lower microsomal clearance than Ligand B (40.629), suggesting better metabolic stability. This is a key advantage for Ligand A.
13. **t1/2:** Ligand A (15.168) has a positive half-life, while Ligand B is negative (-0.387). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.01) has very low P-gp efflux, while Ligand B (0.084) is slightly higher. Lower is preferable.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-4.5 kcal/mol). The difference is negligible.
**Overall Assessment:**
Ligand B has advantages in logP and BBB, which are important for GPCR targets. However, Ligand A demonstrates superior metabolic stability (lower Cl_mic, positive t1/2), lower P-gp efflux, and slightly better QED. The poor Caco-2 permeability is a concern for both, and solubility is also an issue. Given the importance of metabolic stability for *in vivo* efficacy, and the slight edge in drug-likeness, I favor Ligand A.
**Output:**
1
2025-04-17 20:26:02,529 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (357.841 Da and 389.239 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (62.3) is significantly better than Ligand B (104.65). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is pushing the upper limit for good oral absorption.
**3. logP:** Ligand A (3.678) is within the optimal range (1-3), while Ligand B (0.886) is quite low. Low logP can lead to poor membrane permeability. This is a substantial advantage for Ligand A.
**4. H-Bond Donors:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
**5. H-Bond Acceptors:** Ligand B (6) is higher than Ligand A (3). Lower HBA is generally preferred.
**6. QED:** Both ligands have similar QED values (0.83 and 0.725), indicating good drug-likeness.
**7. DILI:** Ligand B (70.686) has a slightly higher DILI risk than Ligand A (62.117), but both are acceptable.
**8. BBB:** Ligand A (71.966) has a much better BBB penetration potential than Ligand B (45.366). While ADRB2 is a cardiovascular target, some CNS penetration can be relevant for off-target effects or potential central regulation.
**9. Caco-2 Permeability:** Both ligands have similar, poor Caco-2 permeability (-4.819 and -4.9). This is a concern for both, but the lower TPSA and higher logP of Ligand A might help overcome this.
**10. Aqueous Solubility:** Ligand A (-4.146) is slightly better than Ligand B (-2.179).
**11. hERG Inhibition:** Both ligands show very low hERG inhibition risk (0.329 and 0.169). This is excellent.
**12. Microsomal Clearance:** Ligand A (29.743) has a higher microsomal clearance than Ligand B (10.46). This means Ligand B is likely to be more metabolically stable.
**13. In vitro Half-Life:** Ligand B (-21.014) has a significantly longer in vitro half-life than Ligand A (32.524). This is a significant advantage for Ligand B.
**14. P-gp Efflux:** Both ligands show low P-gp efflux liability (0.14 and 0.053).
**15. Binding Affinity:** Ligand B (-7.0) has a slightly better binding affinity than Ligand A (-6.8). While a 0.2 kcal/mol difference is not huge, it's a positive for Ligand B.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand A is the stronger candidate. Its significantly better logP and TPSA values are crucial for permeability and absorption. While Ligand B has a slightly better affinity and half-life, the permeability issues associated with its low logP and higher TPSA are more concerning. The better BBB penetration of Ligand A is also a plus.
Output:
1
2025-04-17 20:26:02,529 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (356.413 and 346.515 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (67.43) is higher than Ligand B (49.41). Both are below 140, but B is better for absorption.
3. **logP:** Ligand A (1.863) is within the optimal 1-3 range. Ligand B (3.666) is at the higher end, potentially leading to solubility issues.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable.
5. **HBA:** Ligand A (3) and Ligand B (2) are both acceptable.
6. **QED:** Ligand A (0.685) is slightly better than Ligand B (0.589), indicating a more drug-like profile.
7. **DILI:** Ligand A (31.059) has a significantly lower DILI risk than Ligand B (12.524). This is a major advantage for Ligand A.
8. **BBB:** Both ligands have good BBB penetration (Ligand A: 81.466, Ligand B: 79.721). Since ADRB2 is a cardiovascular target, BBB penetration isn't a primary concern, but it's not detrimental.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.657) is slightly better than Ligand B (-4.807).
10. **Solubility:** Both ligands have very poor aqueous solubility (Ligand A: -2.969, Ligand B: -3.76). This is a significant drawback for both, but B is worse.
11. **hERG:** Both ligands have low hERG inhibition risk (Ligand A: 0.322, Ligand B: 0.434).
12. **Cl_mic:** Ligand A (3.435) has much lower microsomal clearance than Ligand B (57.464), indicating better metabolic stability.
13. **t1/2:** Ligand A (1.013) has a shorter in vitro half-life than Ligand B (-16.191). This is a negative for Ligand A, but the large negative value for B is suspect.
14. **Pgp:** Both ligands have low P-gp efflux (Ligand A: 0.02, Ligand B: 0.211).
15. **Binding Affinity:** Ligand B (-6.7 kcal/mol) has a slightly better binding affinity than Ligand A (-5.5 kcal/mol). This is a 1.2 kcal/mol difference, which is substantial.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, affinity, and metabolic stability are key. Ligand B has a better logP and affinity, but Ligand A has a much better TPSA, DILI risk, and metabolic stability. The solubility is poor for both.
**Overall Assessment:**
While Ligand B has a slightly better binding affinity, the significantly lower DILI risk and better metabolic stability (lower Cl_mic) of Ligand A are more critical for overall drug development. The poor solubility of both is a concern that would need to be addressed through formulation, but the safety and pharmacokinetic advantages of Ligand A outweigh the modest affinity difference.
Output:
1
2025-04-17 20:26:02,530 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (338.411 and 350.419 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (97.78 and 95.75) are below the 140 A^2 threshold for good oral absorption, but are not optimized for CNS penetration (above 90 A^2).
3. **logP:** Ligand A (2.533) is optimal, while Ligand B (0.825) is slightly low, potentially impacting permeability. This favors Ligand A.
4. **HBD:** Ligand A (3) and Ligand B (1) are both within the acceptable limit of 5. Ligand B is preferable here.
5. **HBA:** Ligand A (3) and Ligand B (5) are both within the acceptable limit of 10. Ligand A is preferable here.
6. **QED:** Both ligands have good QED scores (0.723 and 0.82), indicating good drug-like properties. No clear advantage.
7. **DILI:** Ligand B (38.62) has a significantly lower DILI risk than Ligand A (59.636). This is a substantial advantage for Ligand B.
8. **BBB:** Ligand B (55.293) has a higher BBB penetration percentile than Ligand A (32.803). While ADRB2 isn't necessarily a CNS target, higher BBB is generally favorable.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.283 and -4.937), which is unusual and suggests poor permeability. This is a significant drawback for both.
10. **Solubility:** Ligand B (-1.089) has better (less negative) solubility than Ligand A (-4.446). This is a positive for Ligand B.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.713 and 0.083), which is excellent. Ligand B is slightly better.
12. **Cl_mic:** Ligand A (14.455) has lower microsomal clearance than Ligand B (27.976), indicating better metabolic stability. This favors Ligand A.
13. **t1/2:** Ligand A (33.369) has a much longer in vitro half-life than Ligand B (-10.515). This is a major advantage for Ligand A.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.163 and 0.042). Ligand B is slightly better.
15. **Binding Affinity:** Both ligands have very similar and strong binding affinities (-6.6 and -6.4 kcal/mol). The difference is negligible.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand A has a better logP and metabolic stability (Cl_mic, t1/2). Ligand B has a better DILI score, solubility, and slightly better Pgp and BBB. The Caco-2 values are concerning for both. However, the significantly longer half-life of Ligand A and its optimal logP are more important for overall drug development.
**Conclusion:**
Despite the lower DILI risk for Ligand B, the superior metabolic stability (longer half-life) and optimal logP of Ligand A make it the more promising drug candidate.
Output:
1
2025-04-17 20:26:02,530 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (386.901) is slightly higher than Ligand B (350.503), but both are acceptable.
2. **TPSA:** Both are reasonably low (66.92 and 67.43), suggesting good potential for absorption. They are both well below the 140 A^2 threshold.
3. **logP:** Both ligands have optimal logP values (2.37 and 2.805), falling within the 1-3 range.
4. **HBD:** Ligand A has 0 HBD, while Ligand B has 2. Both are acceptable, but lower is generally preferred for permeability.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 3. Both are within the acceptable range of <=10.
6. **QED:** Both ligands have good QED scores (0.796 and 0.628), indicating good drug-like properties.
7. **DILI:** Ligand A has a DILI risk of 60.954, which is bordering on concerning. Ligand B has a much lower DILI risk of 15.859, which is excellent. This is a significant advantage for Ligand B.
8. **BBB:** Ligand B (70.686) shows better BBB penetration than Ligand A (63.746). While ADRB2 isn't strictly a CNS target, some cardiovascular effects can be mediated through CNS pathways, and better BBB penetration isn't necessarily a negative.
9. **Caco-2:** Both have negative Caco-2 values which is unusual. Assuming these are logP values, both are poor.
10. **Solubility:** Both have negative solubility values, which is also unusual. Assuming these are logS values, both are poor.
11. **hERG:** Both ligands have low hERG inhibition liability (0.401 and 0.272), which is good.
12. **Cl_mic:** Ligand B (85.725) has a higher microsomal clearance than Ligand A (53.565), indicating faster metabolism and potentially lower *in vivo* exposure. This is a disadvantage for Ligand B.
13. **t1/2:** Ligand A (-33.435) has a negative half-life which is unusual. Ligand B (-11.019) also has a negative half-life, which is unusual.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.203 and 0.159), which is favorable.
15. **Binding Affinity:** Ligand B (-7.3 kcal/mol) has a slightly better binding affinity than Ligand A (-7.1 kcal/mol). While the difference is small, it's still a positive for Ligand B.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Both ligands perform well on logP and Pgp. TPSA is similar for both. Ligand B has a slightly better affinity. The biggest differentiator is the significantly lower DILI risk for Ligand B.
**Conclusion:**
Despite the slightly higher metabolic clearance of Ligand B, its significantly lower DILI risk and slightly better binding affinity outweigh the drawbacks. The unusual negative values for Caco-2 and half-life are concerning for both, but the DILI risk is a critical factor in drug development.
Output:
0
2025-04-17 20:26:02,530 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (356.8 and 353.5 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (67.43) is significantly better than Ligand B (82.11). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is approaching a less desirable range.
3. **logP:** Ligand A (2.893) is optimal, while Ligand B (-0.025) is quite low. This is a major concern for Ligand B as it may struggle with membrane permeability.
4. **HBD:** Both have 2 HBD, which is within the acceptable limit of 5.
5. **HBA:** Ligand A has 3 HBA, and Ligand B has 5. Both are acceptable (<=10), but Ligand A is slightly preferred.
6. **QED:** Both ligands have similar QED values (0.782 and 0.672), indicating good drug-likeness.
7. **DILI:** Ligand A (74.641) has a higher DILI risk than Ligand B (12.834). This is a significant advantage for Ligand B.
8. **BBB:** Both ligands have similar BBB penetration (65.413 and 66.925). While not CNS-focused, some degree of BBB penetration is not necessarily detrimental for a peripheral GPCR like ADRB2.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.577 and -4.726), which is unusual and suggests poor permeability. However, the values are very similar.
10. **Solubility:** Ligand A (-5.095) has slightly better solubility than Ligand B (-0.87), though both are poor.
11. **hERG:** Ligand A (0.664) has a lower hERG risk than Ligand B (0.228), which is preferable.
12. **Cl_mic:** Ligand A (38.65) has significantly better metabolic stability (lower clearance) than Ligand B (13.115).
13. **t1/2:** Ligand A (-5.582) has a much longer in vitro half-life than Ligand B (23.779).
14. **Pgp:** Ligand A (0.221) has lower P-gp efflux than Ligand B (0.038), which is preferable.
15. **Binding Affinity:** Ligand A (-7.1) has a stronger binding affinity than Ligand B (-6.7). This is a 0.4 kcal/mol difference, which is significant.
**Overall Assessment:**
Ligand A is clearly the stronger candidate. While Ligand B has a lower DILI risk, Ligand A excels in several crucial areas: logP, metabolic stability (Cl_mic & t1/2), binding affinity, and TPSA. The low logP of Ligand B is a major concern, likely leading to poor permeability and bioavailability. The stronger binding affinity of Ligand A can potentially compensate for its slightly higher DILI risk, especially given the availability of strategies to mitigate liver toxicity during development. The better TPSA and logP of Ligand A are particularly important for a GPCR target.
Output:
1
2025-04-17 20:26:02,530 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (366.49 and 367.83 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (83.56) is better than Ligand B (92.51), falling comfortably under the 140 threshold for oral absorption. Lower TPSA generally favors permeability.
3. **logP:** Both ligands have good logP values (1.43 and 1.08), within the 1-3 range. Ligand B is slightly lower, which *could* indicate slightly better solubility, but both are acceptable.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1), but both are well within the acceptable limit of 5.
5. **HBA:** Ligand A (6) is higher than Ligand B (5), but both are below the 10 threshold.
6. **QED:** Ligand B (0.728) has a better QED score than Ligand A (0.51), indicating a more drug-like profile.
7. **DILI:** Both ligands have acceptable DILI risk (33.5 and 36.8 percentile), well below the 60 threshold. Ligand B is slightly better.
8. **BBB:** Ligand B (65.5) has a significantly better BBB penetration score than Ligand A (48.0). While ADRB2 isn't *strictly* a CNS target, some CNS exposure can be relevant for off-target effects and overall safety assessment.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.59 and -5.18), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Both ligands have negative solubility values (-1.68 and -2.16), indicating very poor aqueous solubility. This is a major drawback for both.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.38 and 0.05 percentile), which is excellent.
12. **Cl_mic:** Ligand A (-11.95) has a *much* lower (better) microsomal clearance than Ligand B (6.22). This suggests significantly improved metabolic stability for Ligand A.
13. **t1/2:** Both ligands have similar in vitro half-lives (-11.99 and 15.14 hours).
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.035 and 0.067 percentile), which is favorable.
15. **Binding Affinity:** Ligand A (-7.5 kcal/mol) has a slightly better binding affinity than Ligand B (-6.3 kcal/mol). This 1.2 kcal/mol difference is substantial and can outweigh some ADME drawbacks.
**GPCR-Specific Priorities & Overall Assessment:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A has a slightly better TPSA and significantly better metabolic stability (Cl_mic). Ligand B has a better QED and BBB penetration. However, the *significant* difference in binding affinity (1.2 kcal/mol) in favor of Ligand A, combined with the better metabolic stability, is the deciding factor. The poor Caco-2 and solubility are concerning for both, but can potentially be addressed with formulation strategies. The improved potency and stability of Ligand A are more fundamental properties that are harder to fix later.
**Output:**
1
2025-04-17 20:26:02,531 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (374.463 and 356.491 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (130.13) is better than Ligand B (49.41). ADRB2 is not a CNS target, but lower TPSA generally aids absorption. Ligand B is *very* low, which could be problematic for binding.
3. **logP:** Ligand A (-0.315) is suboptimal, being slightly below the preferred 1-3 range. Ligand B (4.535) is too high, potentially leading to solubility issues and off-target interactions.
4. **HBD:** Ligand A (3) is acceptable, while Ligand B (1) is also good.
5. **HBA:** Ligand A (6) is acceptable, and Ligand B (3) is also good.
6. **QED:** Both ligands have good QED scores (0.51 and 0.818), indicating good drug-like properties. Ligand B is better.
7. **DILI:** Ligand A (60.295) is borderline, while Ligand B (65.723) is higher, indicating a greater potential for liver injury. Ligand A is preferable.
8. **BBB:** Not a primary concern for ADRB2 (cardiovascular target). Ligand B (83.482) is higher, but this isn't a deciding factor.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-5.47) is slightly better than Ligand B (-4.587).
10. **Solubility:** Both ligands have negative solubility values, indicating poor aqueous solubility. Ligand A (-2.219) is slightly better than Ligand B (-5.339).
11. **hERG:** Ligand A (0.25) is much better than Ligand B (0.69), indicating a lower risk of cardiotoxicity, which is *critical* for a cardiovascular target.
12. **Cl_mic:** Ligand A (-8.541) has a much lower (better) microsomal clearance than Ligand B (69.592), suggesting greater metabolic stability.
13. **t1/2:** Ligand A (32.565) and Ligand B (34.308) are comparable.
14. **Pgp:** Ligand A (0.169) is much better than Ligand B (0.526), indicating lower P-gp efflux and potentially better bioavailability.
15. **Binding Affinity:** Ligand A (-6.9) is slightly better than Ligand B (-6.1). While the difference isn't huge, it's a positive factor.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity) and the overall profile, Ligand A is the better candidate. While its logP is slightly low, it is significantly better in terms of hERG inhibition, microsomal clearance, P-gp efflux, and has a slightly better binding affinity. The DILI risk is also lower for Ligand A. Ligand B's high logP and poor solubility are major drawbacks, and its higher hERG and Pgp liabilities are concerning for a cardiovascular drug.
Output:
1
2025-04-17 20:26:02,531 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (351.447 Da) is within the ideal range (200-500 Da). Ligand B (408.344 Da) is also acceptable, but approaching the upper limit.
2. **TPSA:** Ligand A (100.29) is good for oral absorption, being under 140. Ligand B (56.07) is excellent, well below 90, suggesting good permeability.
3. **logP:** Both ligands (A: 2.074, B: 3.273) are within the optimal 1-3 range. Ligand B is slightly higher, which could potentially lead to off-target effects, but is still acceptable.
4. **HBD:** Ligand A (3) is acceptable. Ligand B (0) is also good, potentially improving membrane permeability.
5. **HBA:** Ligand A (4) is acceptable. Ligand B (6) is also within the acceptable range.
6. **QED:** Both ligands (A: 0.624, B: 0.671) have good drug-likeness scores, exceeding 0.5.
7. **DILI:** Ligand A (36.758) has a lower DILI risk than Ligand B (13.3), which is a significant advantage.
8. **BBB:** Ligand B (76.851) has a much higher BBB penetration potential than Ligand A (59.364). For a cardiovascular target like ADRB2, BBB penetration isn't *critical* but can be beneficial for potential off-target effects or central nervous system side effects.
9. **Caco-2:** Ligand A (-5.037) and Ligand B (-4.887) both have negative values, which is unusual and suggests poor permeability in this assay. This is a concern for both.
10. **Solubility:** Ligand A (-2.343) and Ligand B (-3.074) both have negative solubility values, indicating poor aqueous solubility. This is a significant drawback for both compounds.
11. **hERG:** Ligand A (0.213) has a lower hERG risk than Ligand B (0.54). This is a crucial advantage, as hERG inhibition can lead to cardiotoxicity.
12. **Cl_mic:** Both ligands have similar microsomal clearance (A: 50.793, B: 47.141), suggesting comparable metabolic stability.
13. **t1/2:** Ligand B (32.834 hours) has a significantly longer in vitro half-life than Ligand A (7.59 hours). This is a major advantage, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.054) has lower P-gp efflux liability than Ligand B (0.17), which is favorable for oral bioavailability.
15. **Binding Affinity:** Ligand B (-8.1 kcal/mol) has a significantly stronger binding affinity than Ligand A (-0.8 kcal/mol). This is a substantial advantage that can outweigh some of the ADME drawbacks.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, affinity, logP, TPSA, and Pgp efflux are important. Ligand B excels in affinity and has good TPSA and logP. While Ligand A has better Pgp efflux, the difference in affinity is too large to ignore.
**Overall Assessment:**
Ligand B has a much stronger binding affinity and a longer half-life, which are critical for efficacy and dosing. While it has a slightly higher logP and DILI risk, and lower Pgp efflux, the substantial improvement in affinity and half-life outweighs these drawbacks. The poor solubility and Caco-2 permeability are concerns for both, but can potentially be addressed through formulation strategies. The lower hERG risk of Ligand A is appealing, but the much stronger binding of Ligand B is more important for a viable drug candidate.
Output:
0
2025-04-17 20:26:02,531 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.5 & 364.5 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (67.43) is significantly better than Ligand B (84.3). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally aids absorption.
3. **logP:** Ligand A (3.868) is good, within the 1-3 range. Ligand B (1.221) is at the lower end, potentially impacting permeability. This favors Ligand A.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable.
5. **HBA:** Ligand A (3) and Ligand B (5) are both acceptable, but Ligand A is slightly better.
6. **QED:** Both ligands have good QED scores (0.684 and 0.884), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Both ligands have similar DILI risk (51.7 and 55.7 percentile), both are acceptable.
8. **BBB:** Ligand B (75.3) has a higher BBB penetration than Ligand A (63.3). However, as ADRB2 is a cardiovascular target, this is less important.
9. **Caco-2:** Both ligands have very similar Caco-2 permeability (-4.865 and -4.867).
10. **Solubility:** Ligand B (-2.247) has better aqueous solubility than Ligand A (-5.01).
11. **hERG:** Ligand A (0.397) has a lower hERG inhibition liability than Ligand B (0.654). This is a significant advantage for Ligand A, reducing cardiotoxicity risk.
12. **Cl_mic:** Ligand B (30.7) has significantly lower microsomal clearance than Ligand A (55.1), indicating better metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand B (-26.2) has a much longer in vitro half-life than Ligand A (3.3). This is a major advantage for Ligand B.
14. **Pgp:** Ligand A (0.332) has lower P-gp efflux than Ligand B (0.101), which is favorable.
15. **Affinity:** Ligand A (-6.9 kcal/mol) has a slightly better binding affinity than Ligand B (-6.4 kcal/mol). While the difference is not huge, it's still a positive for Ligand A.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A excels in logP, TPSA, Pgp, and has slightly better affinity. Ligand B excels in metabolic stability (Cl_mic and t1/2) and solubility. The hERG liability of Ligand A is also a significant advantage.
**Overall Assessment:**
While Ligand B has superior metabolic stability and solubility, the better logP, TPSA, Pgp, and hERG profile of Ligand A, combined with its slightly better affinity, make it the more promising candidate. The improved ADME properties of Ligand A are more critical for a cardiovascular target than CNS penetration. The hERG risk reduction is also a major factor.
Output:
1
2025-04-17 20:26:02,532 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (389.583 and 361.446 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (59) is slightly higher than Ligand B (54.69). Both are well below the 140 threshold for oral absorption, and acceptable for a cardiovascular target (not needing significant BBB penetration).
3. **logP:** Both ligands have good logP values (2.391 and 2.649), falling within the optimal 1-3 range. Ligand B is slightly higher, which could be marginally better for membrane permeability.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 6 HBA, and Ligand B has 7. Both are within the acceptable limit of 10.
6. **QED:** Both ligands have good QED scores (0.611 and 0.757), indicating good drug-like properties. Ligand B is better here.
7. **DILI:** Ligand A (39.667) has a significantly lower DILI risk than Ligand B (76.425). This is a major advantage for Ligand A.
8. **BBB:** Both have relatively low BBB penetration (51.415 and 81.97). Since ADRB2 is primarily a cardiovascular target, high BBB penetration isn't crucial. Ligand B is higher, but not a deciding factor.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. This is a concern for both.
10. **Solubility:** Both have negative solubility values, indicating poor solubility. This is a concern for both.
11. **hERG:** Ligand A (0.46) has a lower hERG inhibition liability than Ligand B (0.963), which is a significant safety advantage.
12. **Cl_mic:** Ligand B (38.849) has a lower microsomal clearance than Ligand A (78.049), suggesting better metabolic stability. This is a plus for Ligand B.
13. **t1/2:** Both have similar in vitro half-lives (16.68 and 16.725 hours).
14. **Pgp:** Ligand A (0.455) has lower P-gp efflux liability than Ligand B (0.675), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand B (-6.7 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.5 kcal/mol). This is a substantial advantage for Ligand B. The difference of 1.2 kcal/mol is significant enough to potentially outweigh some ADME concerns.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand B is slightly better on logP and significantly better on affinity. While Pgp is slightly better for Ligand A, the difference isn't huge. TPSA is similar for both.
**Overall Assessment:**
Ligand B has a superior binding affinity, which is the most important factor for GPCRs. It also has better metabolic stability (lower Cl_mic) and a better QED score. While Ligand A has a much better DILI and hERG profile, the strong binding affinity of Ligand B is a significant advantage that could be optimized through further medicinal chemistry efforts to address the DILI and hERG concerns. The poor Caco-2 and solubility of both are concerning, but can be addressed with formulation strategies.
Output:
0
2025-04-17 20:26:02,532 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (348.422 and 368.499 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (74.33) is better than Ligand B (82.78). Both are below 140, but A is closer to the preferred <90 for potential CNS penetration, even though ADRB2 isn't a primary CNS target.
3. **logP:** Both ligands have acceptable logP values (1.414 and 2.059), falling within the 1-3 range. Ligand B is slightly higher, which could potentially lead to some off-target effects, but it's not a major concern.
4. **HBD:** Both ligands have 2 H-bond donors, which is good.
5. **HBA:** Ligand A has 4 H-bond acceptors, while Ligand B has 5. Both are acceptable, but A is slightly preferred.
6. **QED:** Both ligands have similar QED values (0.763 and 0.77), indicating good drug-likeness.
7. **DILI:** Ligand A (43.66) has a significantly lower DILI risk than Ligand B (61.07). This is a crucial advantage, as minimizing liver toxicity is paramount.
8. **BBB:** Ligand A (70.531) has a much better BBB penetration score than Ligand B (34.548). While ADRB2 isn't a primary CNS target, some degree of BBB penetration can be beneficial for understanding off-target effects and overall distribution.
9. **Caco-2:** Ligand A (-4.721) has a better Caco-2 permeability than Ligand B (-5.149), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-1.698) has better aqueous solubility than Ligand B (-3.148). This is important for formulation and bioavailability.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.389 and 0.315), which is excellent.
12. **Cl_mic:** Ligand A (9.84) has significantly lower microsomal clearance than Ligand B (55.44), suggesting better metabolic stability.
13. **t1/2:** Ligand B (52.235) has a much longer in vitro half-life than Ligand A (0.444). This is a significant advantage, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.026 and 0.314).
15. **Binding Affinity:** Ligand A (-6.3 kcal/mol) has a slightly better binding affinity than Ligand B (-5.6 kcal/mol). While the difference isn't huge, it's enough to be considered.
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Ligand A is better in logP, TPSA, Pgp, and affinity.
**Overall Assessment:**
Ligand A is clearly the superior candidate. It has a significantly lower DILI risk, better metabolic stability (lower Cl_mic), better solubility, better Caco-2 permeability, and slightly better binding affinity. While Ligand B has a longer half-life, the advantages of Ligand A in safety (DILI) and ADME properties outweigh this benefit.
Output:
1
2025-04-17 20:26:02,532 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**1. Molecular Weight:** Both ligands (355.356 Da and 366.487 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (57.61) is significantly better than Ligand B (80.48). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand A is well below the 140 threshold, while Ligand B is approaching it.
**3. logP:** Both ligands have good logP values (4.009 and 2.309 respectively), falling within the optimal 1-3 range. Ligand B is slightly better, being closer to the center of the range.
**4. H-Bond Donors:** Both have 1 HBD, which is acceptable.
**5. H-Bond Acceptors:** Ligand A has 2 HBAs, and Ligand B has 7. This is a significant difference. Higher HBA can sometimes hinder permeability.
**6. QED:** Both ligands have acceptable QED values (0.785 and 0.698), indicating good drug-like properties.
**7. DILI:** Both ligands have similar DILI risk (50.33 and 58.511), both being acceptable.
**8. BBB:** Ligand A (71.927) has a considerably higher BBB penetration percentile than Ligand B (36.487). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant, and higher BBB is generally favorable.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.796 and -4.912). These values are difficult to interpret without knowing the scale, but the negative values suggest poor permeability.
**10. Aqueous Solubility:** Ligand A (-3.299) has slightly better solubility than Ligand B (-1.86), although both are quite poor.
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.284 and 0.295).
**12. Microsomal Clearance:** Ligand A (24.431) has significantly lower microsomal clearance than Ligand B (46.646), indicating better metabolic stability.
**13. In vitro Half-Life:** Ligand A (-5.963) has a much longer in vitro half-life than Ligand B (23.527).
**14. P-gp Efflux:** Both ligands have similar P-gp efflux liability (0.17 and 0.299).
**15. Binding Affinity:** Ligand A (-8.6 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.1 kcal/mol). This is a substantial difference (2.5 kcal/mol), which can outweigh some ADME drawbacks.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand A is the superior candidate. The substantially stronger binding affinity (-8.6 vs -6.1 kcal/mol) is a major advantage. It also has better TPSA, BBB penetration, metabolic stability (lower Cl_mic), and a longer half-life. While both have poor solubility and Caco-2 permeability, the superior potency and ADME properties of Ligand A make it the more promising drug candidate.
Output:
1
2025-04-17 20:26:02,532 - INFO - Batch 184 complete. Total preferences: 2944
2025-04-17 20:26:02,532 - INFO - Processing batch 185/512...
2025-04-17 20:26:52,739 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (377.271) is slightly higher than Ligand B (346.431), but both are acceptable.
2. **TPSA:** Ligand A (66.56) is significantly better than Ligand B (96.25). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally correlates with better absorption. Ligand B's TPSA is a bit high.
3. **logP:** Ligand A (3.109) is within the optimal range (1-3). Ligand B (0.596) is quite low, potentially hindering membrane permeability and bioavailability. This is a significant drawback.
4. **HBD:** Both ligands have acceptable HBD counts (Ligand A: 2, Ligand B: 3).
5. **HBA:** Both ligands have acceptable HBA counts (Ligand A: 3, Ligand B: 5).
6. **QED:** Both ligands have similar, good QED values (Ligand A: 0.805, Ligand B: 0.727).
7. **DILI:** Ligand A (53.742) has a slightly higher DILI risk than Ligand B (38.62), but both are below the concerning threshold of 60.
8. **BBB:** Both have low BBB penetration, which is fine for a cardiovascular target. Ligand A (37.456) is slightly higher than Ligand B (33.501).
9. **Caco-2:** Ligand A (-4.595) is better than Ligand B (-5.038), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-3.636) is better than Ligand B (-2.199), indicating better aqueous solubility.
11. **hERG:** Ligand A (0.732) is better than Ligand B (0.289), indicating lower hERG inhibition liability and reduced cardiotoxicity risk.
12. **Cl_mic:** Ligand A (9.478) has a slightly higher clearance than Ligand B (6.09), suggesting potentially lower metabolic stability.
13. **t1/2:** Ligand A (26.551) has a better in vitro half-life than Ligand B (9.4).
14. **Pgp:** Ligand A (0.503) has lower P-gp efflux liability than Ligand B (0.025), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand B (-7.8) has a significantly stronger binding affinity than Ligand A (-6.9). This is a 1.9 kcal/mol difference, which is substantial.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B has a superior binding affinity, which is the most important factor. However, its low logP and higher TPSA are concerning. Ligand A has a more balanced profile, with acceptable logP, TPSA, and better solubility, hERG, and Pgp properties. The affinity difference is significant, but the ADME properties of Ligand B are worrisome.
**Conclusion:**
While Ligand B has a better binding affinity, the significantly better ADME profile of Ligand A, particularly its logP, TPSA, solubility, and lower hERG risk, makes it the more promising drug candidate. The affinity difference, while substantial, can potentially be addressed through further optimization, while fixing the poor ADME properties of Ligand B would be more challenging.
Output:
1
2025-04-17 20:26:52,740 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (362.499 Da) is slightly higher than Ligand B (339.395 Da), but both are acceptable.
2. **TPSA:** Both are reasonably good, but Ligand A (70.13) is better than Ligand B (78.34). For a GPCR, lower TPSA is generally preferred for better permeability.
3. **logP:** Ligand A (1.905) is optimal, while Ligand B (3.56) is approaching the upper limit. Higher logP can lead to off-target effects and solubility issues.
4. **HBD:** Both have 2 HBD, which is within the acceptable range.
5. **HBA:** Ligand A has 5 HBA, and Ligand B has 3. Both are acceptable.
6. **QED:** Both ligands have similar QED values (0.823 and 0.721), indicating good drug-likeness.
7. **DILI:** Ligand A (56.805) has a significantly lower DILI risk than Ligand B (73.401). This is a major advantage for Ligand A.
8. **BBB:** Both have similar BBB penetration (56.068 and 55.099). While not CNS-focused for ADRB2, it's still a consideration.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. This is a concern for both, but the values are quite close.
10. **Solubility:** Ligand A (-3.08) has better solubility than Ligand B (-4.282). Solubility is important for bioavailability.
11. **hERG:** Both ligands have low hERG inhibition risk (0.716 and 0.801).
12. **Cl_mic:** Ligand A (-2.557) has a lower (better) microsomal clearance than Ligand B (57.188). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand B (111.204) has a significantly longer in vitro half-life than Ligand A (35.561). This is a benefit for Ligand B.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.087 and 0.295).
15. **Binding Affinity:** Ligand B (-6.1) has a slightly better binding affinity than Ligand A (-5.7). However, the difference is only 0.4 kcal/mol, which is not substantial enough to outweigh other factors.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand A has a better logP and TPSA. The affinity difference is small. The significant advantage of Ligand A is its much lower DILI risk and better metabolic stability (lower Cl_mic). While Ligand B has a longer half-life, the DILI risk is a major concern.
**Conclusion:**
Considering the balance of properties, particularly the lower DILI risk and better metabolic stability of Ligand A, it is the more promising drug candidate despite the slightly weaker binding affinity and shorter half-life.
Output:
1
2025-04-17 20:26:52,740 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (352.475 Da and 344.499 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (89.87) is excellent, well below the 140 threshold and favorable for oral absorption. Ligand B (49.41) is also very good, even better.
**3. logP:** Ligand A (1.053) is within the optimal 1-3 range. Ligand B (3.276) is at the higher end of the optimal range, but still acceptable.
**4. H-Bond Donors:** Ligand A (3) is acceptable. Ligand B (1) is even better, potentially improving permeability.
**5. H-Bond Acceptors:** Ligand A (4) is acceptable. Ligand B (2) is also good.
**6. QED:** Both ligands have good QED scores (0.667 and 0.799, respectively), indicating drug-like properties. Ligand B is slightly better.
**7. DILI:** Ligand A (10.081) has a very low DILI risk, which is highly desirable. Ligand B (18.108) is still relatively low, but higher than Ligand A.
**8. BBB:** Ligand A (32.532) has a low BBB penetration, which is fine for a cardiovascular target. Ligand B (82.396) has much higher BBB penetration, which is not particularly useful for a cardiovascular target and could lead to off-target effects.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and requires further investigation. However, the magnitude is similar.
**10. Aqueous Solubility:** Both ligands have negative solubility values, which is also unusual and requires further investigation. The magnitude is similar.
**11. hERG Inhibition:** Ligand A (0.194) has a very low hERG risk, excellent. Ligand B (0.409) is slightly higher, but still acceptable.
**12. Microsomal Clearance:** Ligand A (16.508) has lower microsomal clearance, indicating better metabolic stability. Ligand B (46.774) has higher clearance, a potential concern.
**13. In vitro Half-Life:** Ligand A (12.937) has a longer half-life, which is desirable. Ligand B (-6.222) has a negative half-life, which is not possible and indicates a problem with the data or the compound's stability.
**14. P-gp Efflux:** Ligand A (0.01) has very low P-gp efflux, which is good. Ligand B (0.226) has slightly higher efflux, but still acceptable.
**15. Binding Affinity:** Both ligands have very similar and strong binding affinities (-6.8 kcal/mol and -6.0 kcal/mol, respectively). The difference is less than 1.5 kcal/mol, so it's not a deciding factor.
**GPCR-Specific Considerations:** For a cardiovascular GPCR like ADRB2, logP, TPSA, and affinity are important. While Ligand B has a slightly better logP and QED, Ligand A has significantly better DILI, hERG, metabolic stability (Cl_mic), and a plausible half-life. The negative half-life for Ligand B is a major red flag. The higher BBB penetration of Ligand B is also undesirable for a cardiovascular target.
**Conclusion:**
Considering the overall profile, particularly the concerning negative half-life and higher BBB penetration of Ligand B, Ligand A is the more promising candidate.
1
2025-04-17 20:26:52,741 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.471 and 361.515 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (60.85) is slightly higher than Ligand B (53.52). Both are below the 140 threshold for oral absorption, but closer to the 90 threshold for CNS targets, which is not a priority here. Ligand B is preferable.
3. **logP:** Both ligands have good logP values (2.249 and 2.811), falling within the optimal 1-3 range. Ligand B is slightly higher, which could be a minor advantage for membrane permeability.
4. **HBD:** Both have 1 HBD, which is within the acceptable limit of 5. No difference.
5. **HBA:** Ligand A has 3 HBAs, while Ligand B has 7. Ligand A is preferable here, as higher HBA can sometimes reduce permeability.
6. **QED:** Both ligands have high QED scores (0.889 and 0.904), indicating good drug-like properties. No significant difference.
7. **DILI:** Ligand A (35.556) has a considerably lower DILI risk than Ligand B (72.043). This is a significant advantage for Ligand A.
8. **BBB:** Ligand B (84.878) has a higher BBB penetration percentile than Ligand A (57.193). While BBB isn't a top priority for ADRB2 (a cardiovascular target), it's still a positive attribute.
9. **Caco-2:** Both have negative Caco-2 values (-4.369 and -4.675). This is unusual and suggests very poor permeability. This is a major concern for both.
10. **Solubility:** Ligand A (-1.868) has slightly better solubility than Ligand B (-3.369). Solubility is important for bioavailability.
11. **hERG:** Both ligands have low hERG inhibition risk (0.687 and 0.876). No significant difference.
12. **Cl_mic:** Ligand B (34.288) has significantly lower microsomal clearance than Ligand A (65.161), indicating better metabolic stability. This is a major advantage for Ligand B.
13. **t1/2:** Ligand B (32.228) has a much longer in vitro half-life than Ligand A (-5.307). This is a significant advantage for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.439 and 0.076). Ligand B is preferable.
15. **Binding Affinity:** Ligand A (-6.8 kcal/mol) has a slightly better binding affinity than Ligand B (-5.1 kcal/mol). This is a 1.7 kcal/mol difference, which is substantial and can outweigh some ADME drawbacks.
**Overall Assessment & GPCR Priorities:**
For a GPCR like ADRB2, affinity, logP, and metabolic stability are key. Ligand A has a significantly better binding affinity. However, Ligand B demonstrates superior metabolic stability (lower Cl_mic, longer t1/2) and lower Pgp efflux. The DILI risk is also significantly lower for Ligand A. The Caco-2 values are concerning for both. Considering the balance, the stronger binding affinity of Ligand A, coupled with the lower DILI risk, outweighs the metabolic advantages of Ligand B.
Output:
1
2025-04-17 20:26:52,741 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, the priorities are logP, TPSA, Pgp, affinity, and to a lesser extent, BBB.
Let's compare the ligands property by property:
1. **MW:** Both ligands (362.495 and 337.423 Da) fall within the ideal range of 200-500 Da.
2. **TPSA:** Ligand A (67.43) is better than Ligand B (71.09), being closer to the desirable <140 for oral absorption.
3. **logP:** Both ligands have excellent logP values (2.85 and 2.705), falling within the optimal 1-3 range.
4. **HBD:** Both have 2 HBD, which is acceptable.
5. **HBA:** Ligand A has 4 HBA, while Ligand B has 3. Both are acceptable.
6. **QED:** Both ligands have good QED scores (0.795 and 0.83), indicating good drug-likeness.
7. **DILI:** Ligand A (61.807) has a slightly higher DILI risk than Ligand B (56.34), but both are still acceptable (<60 is good).
8. **BBB:** Ligand A (70.531) has a better BBB penetration score than Ligand B (59.674). While not a primary concern for a cardiovascular target, it's a slight advantage.
9. **Caco-2:** Ligand A (-5.051) and Ligand B (-4.644) both have negative values, which is unusual and suggests poor permeability. Ligand B is slightly better.
10. **Solubility:** Both ligands have very poor aqueous solubility (-3.607 and -3.986). This is a significant drawback for both.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.197 and 0.238), which is excellent.
12. **Cl_mic:** Ligand B (10.924) has significantly lower microsomal clearance than Ligand A (50.661), indicating better metabolic stability. This is a major advantage.
13. **t1/2:** Ligand B (7.554) has a slightly longer in vitro half-life than Ligand A (45.935). This is a positive.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.355 and 0.084). Ligand B is better.
15. **Affinity:** Ligand A (-6.1 kcal/mol) has a slightly better binding affinity than Ligand B (-5.6 kcal/mol). This is a 0.5 kcal/mol difference, which is significant.
**Overall Assessment:**
While Ligand A has a slightly better affinity and BBB penetration, Ligand B demonstrates superior ADME properties, particularly in terms of metabolic stability (lower Cl_mic) and P-gp efflux. The poor solubility of both is a concern, but the better metabolic profile of Ligand B is more crucial for a GPCR target. The affinity difference is not large enough to overcome the ADME advantages of Ligand B.
**Output:**
0
2025-04-17 20:26:52,741 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (380.5 & 342.5 Da) fall within the ideal 200-500 Da range.
2. **TPSA:** Ligand B (49.64) is significantly better than Ligand A (105.17). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (3.411) is slightly higher than Ligand A (0.518). Ligand A's logP is quite low, potentially hindering membrane permeability. Ligand B is within the optimal 1-3 range.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable.
5. **HBA:** Ligand A (6) and Ligand B (4) are both acceptable.
6. **QED:** Ligand B (0.8) is better than Ligand A (0.674), indicating a more drug-like profile.
7. **DILI:** Ligand B (17.6) is *much* better than Ligand A (38.78). This is a significant advantage for Ligand B.
8. **BBB:** Not a primary concern for a cardiovascular target, but Ligand B (79.9) is higher than Ligand A (53.97).
9. **Caco-2:** Both are negative (-4.805 and -4.862), indicating poor permeability. This is a concern for both.
10. **Solubility:** Both are negative (-2.393 and -3.1), indicating poor solubility. This is a concern for both.
11. **hERG:** Ligand A (0.471) is better than Ligand B (0.79), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand B (52.8) is better than Ligand A (71.75), suggesting better metabolic stability.
13. **t1/2:** Ligand B (24.4) is significantly better than Ligand A (-40.35). This is a major advantage for Ligand B.
14. **Pgp:** Ligand A (0.03) is better than Ligand B (0.177), suggesting lower efflux.
15. **Affinity:** Ligand A (-6.9) is slightly better than Ligand B (-5.0), but the difference is less than 1.5 kcal/mol.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand B has a much better logP and TPSA, and a significantly better DILI and metabolic stability profile. While Ligand A has slightly better affinity and Pgp, the overall balance favors Ligand B. The poor Caco-2 and solubility for both are concerning, but can be addressed with formulation strategies. The DILI risk for Ligand A is a major red flag.
**Conclusion:**
Ligand B is the more promising candidate due to its superior ADME properties (DILI, Cl_mic, t1/2, logP, TPSA, QED) despite a slightly weaker binding affinity.
Output:
0
2025-04-17 20:26:52,741 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [342.443, 97.78, 2.566, 3, 3, 0.45, 42.303, 54.13, -4.875, -4.721, 0.547, 47.555, -15.364, 0.364, -6.6]
**Ligand B:** [353.507, 70.67, 1.543, 2, 4, 0.694, 5.235, 72.043, -4.887, -1.682, 0.443, 25.256, 2.621, 0.005, -6.1]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (342.443) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (97.78) is higher than Ligand B (70.67). For a cardiovascular GPCR, we don't *need* extremely low TPSA like for CNS targets, but lower is still preferred for better absorption. Ligand B is better here.
3. **logP:** Both are within the optimal range (1-3). Ligand A (2.566) is slightly higher, which could potentially lead to off-target effects, but is still acceptable. Ligand B (1.543) is closer to the lower end, which might slightly hinder permeability.
4. **HBD:** Ligand A (3) and Ligand B (2) are both acceptable.
5. **HBA:** Ligand A (3) and Ligand B (4) are both acceptable.
6. **QED:** Ligand B (0.694) has a better QED score than Ligand A (0.45), indicating a more drug-like profile.
7. **DILI:** Ligand B (5.235) has a significantly lower DILI risk than Ligand A (42.303). This is a major advantage for Ligand B.
8. **BBB:** Ligand B (72.043) has a higher BBB penetration percentile than Ligand A (54.13). While not a primary concern for a cardiovascular target, higher BBB is generally not detrimental.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
10. **Solubility:** Ligand B (-1.682) is better than Ligand A (-4.721). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.547) has a slightly higher hERG risk than Ligand B (0.443), but both are relatively low.
12. **Cl_mic:** Ligand B (25.256) has a much lower microsomal clearance than Ligand A (47.555), indicating better metabolic stability.
13. **t1/2:** Ligand B (2.621) has a longer in vitro half-life than Ligand A (-15.364). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.364) has a lower P-gp efflux liability than Ligand B (0.005). Lower Pgp is generally preferred.
15. **Affinity:** Ligand A (-6.6 kcal/mol) has a slightly better binding affinity than Ligand B (-6.1 kcal/mol). This is a 0.5 kcal/mol difference, which is noticeable but not overwhelming.
**GPCR-specific priorities:** For ADRB2 (a cardiovascular GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B has a better logP, TPSA, and Pgp profile. The affinity difference is small. Ligand B excels in ADME properties (DILI, solubility, Cl_mic, t1/2).
**Conclusion:**
Considering the balance of properties, especially the significantly better ADME profile (lower DILI, better solubility, metabolic stability, and half-life) of Ligand B, and the only slight difference in binding affinity, I would choose **Ligand B** as the more promising drug candidate.
Output:
0
2025-04-17 20:26:52,741 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (358.429 Da and 369.487 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (49.85) is significantly better than Ligand B (84.66). For a GPCR, lower TPSA is generally preferred for better permeability, and Ligand A is well below the 140 A^2 threshold. Ligand B is approaching a level that could hinder absorption.
**3. logP:** Ligand A (2.296) is within the optimal 1-3 range. Ligand B (0.951) is slightly below 1, which *could* indicate potential permeability issues.
**4. H-Bond Donors:** Both have acceptable HBD counts (0 for A, 1 for B), well below the 5 threshold.
**5. H-Bond Acceptors:** Ligand A (3) is better than Ligand B (7). Lower HBA is generally favorable for permeability.
**6. QED:** Both ligands have similar QED values (0.778 and 0.698), indicating good drug-like properties.
**7. DILI:** Both ligands have very similar and acceptable DILI risk (32.687 and 32.377 percentile).
**8. BBB:** Ligand A (86.661) has a substantially higher BBB penetration percentile than Ligand B (32.144). While ADRB2 is a cardiovascular target, some CNS exposure is not necessarily detrimental and can sometimes be beneficial.
**9. Caco-2 Permeability:** Ligand A (-4.242) is better than Ligand B (-4.988), indicating better intestinal absorption.
**10. Aqueous Solubility:** Ligand A (-2.818) is better than Ligand B (-2.457), indicating better solubility.
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.469 and 0.067).
**12. Microsomal Clearance:** Ligand A (40.862) has lower microsomal clearance than Ligand B (55.897), suggesting better metabolic stability.
**13. In vitro Half-Life:** Ligand A (-15.38) has a longer in vitro half-life than Ligand B (-5.234).
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.104 and 0.101).
**15. Binding Affinity:** Ligand B (-6.4 kcal/mol) has a slightly better binding affinity than Ligand A (-5.5 kcal/mol). This is a 0.9 kcal/mol difference, which is not a huge advantage, but is noticeable.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand A is the more promising candidate. While Ligand B has a slightly better binding affinity, Ligand A significantly outperforms it in TPSA, logP, BBB penetration, Caco-2 permeability, solubility, and metabolic stability. The combination of these factors, especially the lower TPSA and better predicted permeability, makes Ligand A a more likely candidate to achieve adequate bioavailability and efficacy. The affinity difference is not large enough to overcome the ADME advantages of Ligand A.
Output:
1
2025-04-17 20:26:52,742 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's break down the comparison of Ligand A and Ligand B, considering the provided guidelines and GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key).
1. **Molecular Weight:** Both ligands (349.431 and 350.503 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (71.11) is higher than Ligand B (49.85). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for better permeability. Ligand B has a clear advantage.
3. **logP:** Both ligands have good logP values (2.193 and 2.712), falling within the optimal 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability, but not drastically.
4. **H-Bond Donors/Acceptors:** Ligand A has 1 HBD and 4 HBA, while Ligand B has 0 HBD and 3 HBA. Both are within acceptable limits (<=5 HBD and <=10 HBA).
5. **QED:** Ligand B (0.692) has a slightly better QED score than Ligand A (0.519), indicating a more drug-like profile.
6. **DILI Risk:** Ligand B (16.479) has a significantly lower DILI risk than Ligand A (42.575). This is a major advantage for Ligand B.
7. **BBB Penetration:** Ligand B (78.48) shows better BBB penetration than Ligand A (68.36). While ADRB2 isn't strictly a CNS target, some CNS exposure can occur, and higher BBB is generally favorable.
8. **Caco-2 Permeability:** Ligand A (-4.651) has better Caco-2 permeability than Ligand B (-4.287), indicating better intestinal absorption.
9. **Aqueous Solubility:** Both ligands have similar, poor aqueous solubility (-1.791 and -1.925). This could be a formulation challenge for both.
10. **hERG Inhibition:** Both ligands have similar, low hERG inhibition risk (0.39 and 0.393).
11. **Microsomal Clearance:** Ligand B (47.212) has a slightly lower microsomal clearance than Ligand A (43.732), suggesting better metabolic stability.
12. **In vitro Half-Life:** Ligand A (-22.555) has a longer in vitro half-life than Ligand B (-11.62). This is a positive for Ligand A.
13. **P-gp Efflux:** Both ligands have similar P-gp efflux liability (0.026 and 0.058).
14. **Binding Affinity:** Ligand A (-6.5 kcal/mol) has a slightly better binding affinity than Ligand B (-6.2 kcal/mol). While the difference is not huge, it's a factor.
**Overall Assessment:**
Ligand B demonstrates a superior safety profile (much lower DILI risk) and better predicted permeability (lower TPSA, slightly better Caco-2). It also has a better QED score and slightly improved metabolic stability. While Ligand A has a slightly better binding affinity and longer half-life, the safety and permeability advantages of Ligand B are more critical for overall drug development success, especially given the relatively small difference in binding affinity.
Output:
0
2025-04-17 20:26:52,742 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.49 & 368.46 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (58.64) is significantly better than Ligand B (108.47). ADRB2 is a cardiovascular target, not CNS, but lower TPSA generally improves absorption. Ligand A is well below the 140 threshold, while B is approaching it.
3. **logP:** Ligand A (2.367) is optimal (1-3). Ligand B (0.267) is quite low, potentially hindering membrane permeability and absorption. This is a significant drawback for B.
4. **HBD:** Both ligands have acceptable HBD counts (1 and 2, respectively), well below the 5 limit.
5. **HBA:** Ligand A (3) is better than Ligand B (6), staying lower than the 10 limit.
6. **QED:** Both ligands have good QED scores (0.685 and 0.715), indicating generally drug-like properties.
7. **DILI:** Ligand A (21.64%) has a much lower DILI risk than Ligand B (50.33%). This is a critical advantage for A.
8. **BBB:** This is less critical for a cardiovascular target. Ligand A (79.68%) is better than Ligand B (43.51%).
9. **Caco-2:** Ligand A (-4.556) is better than Ligand B (-5.511), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-3.514) is better than Ligand B (-1.863), indicating better solubility.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.622 and 0.054), which is excellent.
12. **Cl_mic:** Ligand B (-27.935) has significantly lower microsomal clearance than Ligand A (48.443), suggesting better metabolic stability. This is a strong point for B.
13. **t1/2:** Ligand B (17.232) has a much longer in vitro half-life than Ligand A (4.532). This is a significant advantage for B.
14. **Pgp:** Ligand A (0.151) has better Pgp efflux liability than Ligand B (0.014).
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.3 kcal/mol). The difference is negligible.
**Overall Assessment:**
Ligand A has a clear advantage in terms of physicochemical properties (TPSA, logP, solubility), DILI risk, and Caco-2 permeability. These factors are crucial for absorption and reducing potential toxicity. While Ligand B has better metabolic stability (lower Cl_mic) and a longer half-life, the poor logP and higher DILI risk are significant concerns. For a cardiovascular target, prioritizing good absorption and minimizing toxicity is paramount. The slight advantage in half-life for B does not outweigh the other more critical issues.
Output:
1
2025-04-17 20:26:52,742 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [387.845, 99.52, 1.755, 1, 7, 0.726, 92.865, 65.956, -5.017, -3.036, 0.432, 20.235, 74.574, 0.381, -6.6]
**Ligand B:** [386.231, 95.86, 2.985, 3, 4, 0.74, 65.452, 30.128, -5.482, -3.701, 0.091, -2.359, 15.983, 0.038, -7.4]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (387-386 Da). No significant difference.
2. **TPSA:** Ligand A (99.52) is slightly higher than Ligand B (95.86). Both are acceptable for a non-CNS GPCR target like ADRB2, but lower is generally preferred.
3. **logP:** Ligand A (1.755) is within the optimal range, while Ligand B (2.985) is approaching the upper limit. This favors Ligand A slightly.
4. **HBD:** Ligand A (1) is better than Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (7) is higher than Ligand B (4). Lower is preferred for permeability.
6. **QED:** Both are good (0.726 and 0.74), indicating drug-like properties. No significant difference.
7. **DILI:** Ligand A (92.865) has a higher DILI risk than Ligand B (65.452). This is a significant negative for Ligand A.
8. **BBB:** Ligand A (65.956) has better BBB penetration than Ligand B (30.128), but BBB is less critical for ADRB2 (a cardiovascular target).
9. **Caco-2:** Both have negative values, which is unusual and suggests poor permeability. Ligand B (-5.482) is slightly worse than Ligand A (-5.017).
10. **Solubility:** Both have negative solubility values, suggesting poor solubility. Ligand B (-3.701) is slightly worse than Ligand A (-3.036).
11. **hERG:** Ligand A (0.432) has a slightly higher hERG risk than Ligand B (0.091). This favors Ligand B.
12. **Cl_mic:** Ligand A (20.235) has a higher clearance than Ligand B (-2.359), indicating lower metabolic stability. This favors Ligand B.
13. **t1/2:** Ligand A (74.574) has a longer half-life than Ligand B (15.983). This is a positive for Ligand A.
14. **Pgp:** Ligand A (0.381) has lower P-gp efflux than Ligand B (0.038), which is favorable.
15. **Affinity:** Ligand B (-7.4) has a significantly better binding affinity than Ligand A (-6.6). This is a substantial advantage for Ligand B.
**GPCR-Specific Priorities:**
For ADRB2 (a cardiovascular GPCR), we prioritize logP, Pgp, TPSA, and affinity. Ligand B is better in terms of logP, hERG, Cl_mic, and significantly better in affinity. While Ligand A has better Pgp and t1/2, the significant advantage in binding affinity and the lower DILI/hERG risk of Ligand B outweigh these benefits.
**Conclusion:**
Ligand B is the more promising candidate due to its superior binding affinity, lower DILI and hERG risk, and better metabolic stability.
0
2025-04-17 20:26:52,742 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [370.431, 101.81 , -0.711, 0. , 7. , 0.678, 63.552, 59.829, -4.434, -1.798, 0.108, 8.637, -2.947, 0.072, -6.5 ]
**Ligand B:** [384.973, 41.57 , 3.668, 1. , 4. , 0.742, 32.803, 71.229, -4.897, -5.094, 0.871, 84.344, 52.133, 0.494, -5.8 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). A (370.431) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** A (101.81) is higher than B (41.57). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is still preferred for absorption. B is significantly better here.
3. **logP:** A (-0.711) is quite low, potentially hindering membrane permeability. B (3.668) is within the optimal range (1-3). This is a significant advantage for B.
4. **HBD:** A (0) is excellent, minimizing potential issues with hydrogen bonding and metabolic lability. B (1) is acceptable.
5. **HBA:** A (7) is good, within the preferred range. B (4) is also good.
6. **QED:** Both are good (A: 0.678, B: 0.742), indicating drug-like properties. B is slightly better.
7. **DILI:** A (63.552) is moderately high, indicating a potential liver toxicity risk. B (32.803) is much lower and preferable.
8. **BBB:** A (59.829) is not particularly high, but acceptable for a cardiovascular target. B (71.229) is better, suggesting potentially better distribution.
9. **Caco-2:** Both are negative, indicating poor permeability. A (-4.434) is slightly better than B (-4.897).
10. **Solubility:** Both are negative, indicating poor solubility. A (-1.798) is slightly better than B (-5.094).
11. **hERG:** A (0.108) is very low, indicating a low risk of hERG inhibition. B (0.871) is higher, presenting a slightly higher risk.
12. **Cl_mic:** A (8.637) is lower than B (84.344), suggesting better metabolic stability. This is a significant advantage for A.
13. **t1/2:** A (-2.947) is negative, indicating a short half-life. B (52.133) is positive, suggesting a longer half-life. This is a significant advantage for B.
14. **Pgp:** A (0.072) is very low, indicating minimal P-gp efflux. B (0.494) is higher, suggesting some P-gp efflux. This is a significant advantage for A.
15. **Affinity:** A (-6.5) is slightly better than B (-5.8), although the difference is relatively small.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, and affinity. B excels in logP and TPSA. A excels in Pgp. The affinity difference is minor. The DILI risk for B is also much lower. While A has better metabolic stability, the overall balance favors B.
**Conclusion:**
Considering the balance of properties, particularly the favorable logP, lower DILI risk, and longer half-life of Ligand B, it is the more promising drug candidate.
0
2025-04-17 20:26:52,743 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (351-366 Da). No significant difference.
2. **TPSA:** Ligand A (88.08) is better than Ligand B (101.56). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally favors absorption.
3. **logP:** Ligand A (2.002) is optimal. Ligand B (-0.32) is quite low, potentially hindering membrane permeability and bioavailability. This is a significant negative for Ligand B.
4. **HBD:** Ligand A (1) is preferred over Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Both ligands have 5 HBA, which is acceptable.
6. **QED:** Ligand A (0.819) is significantly better than Ligand B (0.596), indicating a more drug-like profile.
7. **DILI:** Ligand B (15.51) is much better than Ligand A (79.643). This is a major advantage for Ligand B.
8. **BBB:** Ligand A (47.809) is better than Ligand B (16.363), but BBB isn't a critical factor for a cardiovascular target.
9. **Caco-2:** Ligand A (-4.792) is better than Ligand B (-5.602), suggesting better intestinal absorption.
10. **Solubility:** Ligand A (-2.386) is better than Ligand B (-0.83). Solubility is important for formulation and bioavailability.
11. **hERG:** Both ligands have very low hERG risk (0.104 and 0.069 respectively).
12. **Cl_mic:** Ligand B (-9.064) has a *negative* clearance, which is unrealistic and indicates very high metabolic stability. Ligand A (41.083) is reasonable. While negative clearance is a flag, it's likely a data error and should be treated with caution.
13. **t1/2:** Ligand B (-26.203) has a negative half-life, which is also unrealistic. Ligand A (21.409) is reasonable. Again, these negative values are likely data errors.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.017 and 0.003 respectively).
15. **Binding Affinity:** Both ligands have the same binding affinity (-7.4 kcal/mol), so this parameter doesn't differentiate them.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand A excels in logP and TPSA, while affinity is equal. Although Ligand B has a much better DILI score, the extremely low (and likely erroneous) values for clearance and half-life, coupled with the poor logP, are substantial concerns. The DILI risk for Ligand A is elevated, but not catastrophic, and can be addressed with further optimization.
**Conclusion:**
Despite the DILI concern with Ligand A, its superior physicochemical properties (logP, TPSA, solubility) and more realistic ADME profile make it the more promising candidate. The negative values for clearance and half-life in Ligand B raise serious doubts about the data quality and its potential *in vivo* behavior.
Output:
1
2025-04-17 20:26:52,743 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (351.422) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (82.53) is better than Ligand B (33.2). For a cardiovascular GPCR, a lower TPSA is preferable for better membrane permeability. Ligand B is exceptionally low, which could be a concern for binding.
3. **logP:** Ligand A (2.422) is within the optimal range (1-3). Ligand B (4.704) is higher, potentially leading to solubility issues and off-target interactions.
4. **HBD:** Ligand A (2) is reasonable. Ligand B (0) is also acceptable, but may impact aqueous solubility.
5. **HBA:** Ligand A (4) is good. Ligand B (3) is also good.
6. **QED:** Both ligands have similar QED values (0.753 and 0.716), indicating good drug-likeness.
7. **DILI:** Ligand A (44.397) has a much lower DILI risk than Ligand B (65.491). This is a significant advantage.
8. **BBB:** Ligand B (88.872) has a higher BBB penetration percentile than Ligand A (69.794). While ADRB2 isn't a primary CNS target, some CNS exposure can be relevant for off-target effects.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability.
10. **Solubility:** Ligand A (-2.594) has slightly better solubility than Ligand B (-4.728), although both are poor.
11. **hERG:** Both ligands have low hERG inhibition liability (0.371 and 0.628).
12. **Cl_mic:** Ligand A (4.538) has a significantly lower microsomal clearance, indicating better metabolic stability than Ligand B (31.039).
13. **t1/2:** Ligand A (16.378) has a longer in vitro half-life than Ligand B (-3.611). This is a major advantage.
14. **Pgp:** Ligand A (0.142) has lower P-gp efflux liability than Ligand B (0.684), which is favorable for bioavailability.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.3 and -6.1 kcal/mol). The difference is not substantial enough to override other factors.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A has a better logP and TPSA. Ligand B has better Pgp and BBB. However, the DILI, metabolic stability (Cl_mic, t1/2), and solubility of Ligand A are significantly better.
**Overall Assessment:**
While Ligand B has slightly better BBB penetration, the superior DILI profile, metabolic stability, solubility, and Pgp efflux characteristics of Ligand A make it the more promising drug candidate. The binding affinity is comparable, and the other parameters are either similar or favor Ligand A.
Output:
1
2025-04-17 20:26:52,743 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (451.308 Da) is slightly higher than Ligand B (367.515 Da), but both are acceptable.
**2. TPSA:** Ligand A (54.46) is significantly better than Ligand B (91.32). For a GPCR, lower TPSA is generally preferred for better permeability. Ligand B is above the 90 threshold, which is a concern.
**3. logP:** Both ligands have good logP values (A: 3.748, B: 2.512) within the optimal range of 1-3. Ligand A is slightly higher, but not concerning.
**4. H-Bond Donors:** Ligand A (1) is better than Ligand B (3). Fewer HBDs generally improve permeability.
**5. H-Bond Acceptors:** Ligand A (3) is better than Ligand B (5). Fewer HBAs generally improve permeability.
**6. QED:** Both ligands have acceptable QED values (A: 0.721, B: 0.583), indicating reasonable drug-likeness. Ligand A is slightly better.
**7. DILI Risk:** Ligand A (44.164) is better than Ligand B (56.146), indicating a lower risk of drug-induced liver injury. Both are below the concerning threshold of 60.
**8. BBB Penetration:** Ligand A (84.917) is significantly better than Ligand B (65.801). While ADRB2 is a cardiovascular target, some CNS effects can be relevant, and higher BBB penetration is generally favorable.
**9. Caco-2 Permeability:** Both have negative values, indicating poor permeability. Ligand A (-4.914) is slightly better than Ligand B (-5.188).
**10. Aqueous Solubility:** Both ligands have negative values, indicating poor solubility. Ligand A (-4.359) is slightly better than Ligand B (-3.569).
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (A: 0.773, B: 0.601), which is good.
**12. Microsomal Clearance:** Ligand A (68.839) is higher than Ligand B (36.611), indicating faster clearance and lower metabolic stability. This is a negative for Ligand A.
**13. In vitro Half-Life:** Ligand B (-8.263) is significantly better than Ligand A (-5.586), indicating a longer half-life.
**14. P-gp Efflux:** Both ligands have similar P-gp efflux liability (A: 0.446, B: 0.496).
**15. Binding Affinity:** Ligand B (-7.2 kcal/mol) has a slightly better binding affinity than Ligand A (-6.6 kcal/mol). This is a significant advantage.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand B emerges as the more promising candidate. While Ligand A has better TPSA, BBB, and DILI risk, Ligand B's superior binding affinity (-7.2 vs -6.6 kcal/mol) and significantly better half-life are crucial advantages. The slightly higher TPSA of Ligand B is a manageable drawback, especially given its stronger binding. The improved half-life is also a major advantage.
Output:
0
2025-04-17 20:26:52,743 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (383.945 Da) is within the ideal range, while Ligand B (354.47 Da) is also acceptable. No clear advantage here.
2. **TPSA:** Ligand A (53.51) is good, well below the 140 threshold. Ligand B (76.02) is still reasonable but higher. A favors better absorption.
3. **logP:** Ligand A (3.686) is optimal. Ligand B (2.538) is also good, but slightly lower. A is slightly preferred.
4. **HBD:** Ligand A (0) is excellent. Ligand B (2) is acceptable, but A is better for permeability.
5. **HBA:** Both ligands have 4 HBA, which is good.
6. **QED:** Both ligands have similar QED values (0.782 and 0.715), indicating good drug-likeness.
7. **DILI:** Ligand B (41.838) has a significantly lower DILI risk than Ligand A (58.395). This is a substantial advantage for B.
8. **BBB:** Ligand A (72.005) has a better BBB penetration score than Ligand B (65.529). Given ADRB2's cardiovascular involvement, CNS penetration isn't a primary concern, but it's still a slight benefit for A.
9. **Caco-2:** Both ligands have negative Caco-2 values, suggesting poor permeability. This is concerning for both.
10. **Solubility:** Both ligands have negative solubility values, suggesting poor solubility. This is concerning for both.
11. **hERG:** Ligand A (0.633) has a slightly higher hERG risk than Ligand B (0.273). B is preferred.
12. **Cl_mic:** Ligand B (47.404) has lower microsomal clearance than Ligand A (56.591), suggesting better metabolic stability. This is a significant advantage for B.
13. **t1/2:** Ligand B (23.742) has a much longer in vitro half-life than Ligand A (-5.038). This is a major advantage for B.
14. **Pgp:** Ligand A (0.797) has higher P-gp efflux liability than Ligand B (0.081). B is strongly preferred.
15. **Binding Affinity:** Ligand B (-7.2 kcal/mol) has a slightly better binding affinity than Ligand A (-8.2 kcal/mol). While A is better, the difference is not substantial enough to outweigh other factors.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp efflux, and affinity are important. Ligand A has a slight edge in logP and affinity, but Ligand B is significantly better in terms of Pgp efflux, DILI, hERG, and metabolic stability (Cl_mic and t1/2). The poor Caco-2 and solubility for both are concerning, but can be addressed with formulation strategies.
**Overall Assessment:**
While Ligand A has a slightly better affinity and BBB, Ligand B demonstrates a significantly more favorable ADMET profile, particularly regarding safety (DILI, hERG) and metabolic stability (Cl_mic, t1/2). The lower Pgp efflux is also a major advantage. These factors are critical for developing a viable drug candidate.
Output:
0
2025-04-17 20:26:52,743 - INFO - Batch 185 complete. Total preferences: 2960
2025-04-17 20:26:52,744 - INFO - Processing batch 186/512...
2025-04-17 20:27:39,020 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (372.734 Da and 357.841 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (83.81) is higher than Ligand B (56.15). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B is better.
3. **logP:** Both ligands have similar logP values (4.023 and 4.161), both slightly above the optimal range of 1-3, but acceptable. No clear advantage.
4. **HBD:** Ligand A has 2 HBD, while Ligand B has 1. Both are within the acceptable limit of <=5. Ligand B is slightly better.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 5. Both are within the acceptable limit of <=10. No significant difference.
6. **QED:** Both ligands have similar QED values (0.727 and 0.696), both indicating good drug-likeness. No clear advantage.
7. **DILI:** Ligand A has a DILI risk of 98.255, which is very high. Ligand B has a DILI risk of 72.819, which is still elevated but considerably lower. This is a major advantage for Ligand B.
8. **BBB:** Ligand A (70.997) has a better BBB percentile than Ligand B (57.154). While ADRB2 isn't a primary CNS target, some peripheral effects can be modulated by CNS penetration.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.016 and -4.789), which is unusual and indicates very poor permeability. This is a significant concern for both.
10. **Solubility:** Both ligands have very poor aqueous solubility (-4.761 and -4.711). This is a major drawback for both.
11. **hERG:** Ligand A (0.353) has a lower hERG inhibition liability than Ligand B (0.608), indicating a lower risk of cardiotoxicity. This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand A (51.721) has a lower microsomal clearance than Ligand B (92.26), suggesting better metabolic stability. This is an advantage for Ligand A.
13. **t1/2:** Ligand B has a significantly longer in vitro half-life (109.887 hours) compared to Ligand A (20.539 hours). This is a major advantage for Ligand B.
14. **Pgp:** Ligand A (0.197) has lower P-gp efflux liability than Ligand B (0.45), which is preferable.
15. **Binding Affinity:** Ligand B (-5.8 kcal/mol) has a slightly better binding affinity than Ligand A (-5.5 kcal/mol). While the difference is small, it's still a positive for Ligand B.
**Overall Assessment:**
While both compounds have significant drawbacks (poor solubility and Caco-2 permeability), Ligand B appears to be the better candidate. The primary driver for this is the significantly lower DILI risk and the substantially longer half-life. The slightly better binding affinity also contributes. Although Ligand A has advantages in hERG and Cl_mic, the DILI risk is a major red flag. The slightly better BBB penetration of Ligand A is less important for a cardiovascular target.
Output:
0
2025-04-17 20:27:39,021 - INFO - Here's a step-by-step comparison of Ligand A and Ligand B, followed by my final ranking decision:
**1. Molecular Weight (MW):** Both ligands (345.443 and 338.415 Da) fall comfortably within the ideal 200-500 Da range. No clear advantage here.
**2. Topological Polar Surface Area (TPSA):** Ligand A (68.4) is significantly better than Ligand B (106.75). For a GPCR target, lower TPSA is generally preferred for better permeability, and Ligand A is well below the 140 threshold. Ligand B is approaching a less desirable range.
**3. Lipophilicity (logP):** Both ligands have good logP values (3.268 and 2.436), falling within the optimal 1-3 range. Ligand A is slightly higher, which *could* be a minor concern for off-target effects, but is not a major issue.
**4. H-Bond Donors (HBD):** Ligand A (2) is better than Ligand B (3). Lower HBD is generally preferred for permeability.
**5. H-Bond Acceptors (HBA):** Ligand A (5) is better than Ligand B (7). Similar to HBD, lower HBA is generally preferred.
**6. QED:** Ligand A (0.806) has a significantly better QED score than Ligand B (0.635), indicating a more drug-like profile.
**7. DILI:** Both ligands have similar DILI risk (61.109 and 59.907), both are acceptable but not ideal.
**8. BBB:** Ligand A (73.943) has a considerably higher BBB penetration percentile than Ligand B (59.519). This is a significant advantage for a GPCR target, even if it's not a CNS-specific one, as it suggests better distribution.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-5.217 and -5.386). These values are difficult to interpret without knowing the scale, but the negative values suggest poor permeability.
**10. Aqueous Solubility:** Both ligands have negative solubility values (-2.854 and -3.138). Similar to Caco-2, these values are difficult to interpret without knowing the scale, but the negative values suggest poor solubility.
**11. hERG Inhibition:** Both ligands have similar, low hERG inhibition liability (0.894 and 0.828), which is good.
**12. Microsomal Clearance (Cl_mic):** Ligand A (10.867) has significantly lower microsomal clearance than Ligand B (67.033), indicating better metabolic stability.
**13. In vitro Half-Life:** Ligand A (58.392) has a much longer in vitro half-life than Ligand B (13.368), which is highly desirable.
**14. P-gp Efflux:** Both ligands have similar P-gp efflux liability (0.225 and 0.089), which is good.
**15. Binding Affinity:** Both ligands have the same binding affinity (-6.4 kcal/mol).
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across several crucial ADME properties, including TPSA, QED, BBB, Cl_mic, and t1/2. While both have issues with Caco-2 and solubility, the superior profile of Ligand A in terms of permeability-related factors (TPSA, BBB) and metabolic stability (Cl_mic, t1/2) makes it the more promising candidate. The similar binding affinity removes that as a differentiating factor. Given the GPCR target class, the better BBB penetration of Ligand A is a significant advantage.
Output:
1
2025-04-17 20:27:39,021 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.5 and 346.5 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (43.86) is significantly better than Ligand B (58.2), falling well below the 140 threshold for oral absorption and closer to the 90 threshold potentially useful for GPCRs.
3. **logP:** Both ligands have acceptable logP values (2.275 and 3.714, respectively), within the 1-3 range. Ligand B is slightly higher, which could potentially lead to solubility issues, but is still within an acceptable range.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (3) is slightly better than Ligand B (2), both are acceptable.
6. **QED:** Both ligands have similar QED values (0.717 and 0.69), indicating good drug-likeness.
7. **DILI:** Ligand A (5.777) has a significantly lower DILI risk than Ligand B (22.334). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (81) has a much higher BBB penetration percentile than Ligand B (65.374). While ADRB2 isn't strictly a CNS target, some peripheral ADRB2 receptors can be affected by CNS penetration, and higher BBB is generally a positive attribute.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.59 and -4.773) which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-1.752) has better solubility than Ligand B (-4.397).
11. **hERG:** Both ligands have very low hERG inhibition risk (0.582 and 0.453).
12. **Cl_mic:** Ligand A (23.524) has significantly lower microsomal clearance than Ligand B (65.04), indicating better metabolic stability.
13. **t1/2:** Ligand A (22.791) has a much longer in vitro half-life than Ligand B (4.044).
14. **Pgp:** Both ligands have low Pgp efflux liability (0.052 and 0.435).
15. **Affinity:** Ligand B (-7.4) has a significantly stronger binding affinity than Ligand A (-4.8). This is a substantial advantage for Ligand B.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B has a better logP and significantly better affinity. However, Ligand A excels in TPSA, DILI, BBB, solubility, metabolic stability (Cl_mic and t1/2). The difference in affinity (-2.6 kcal/mol) is substantial, but the combination of improved safety (DILI), better ADME properties (TPSA, Cl_mic, t1/2, solubility, BBB), and acceptable logP makes Ligand A a more promising candidate overall. The poor Caco-2 values for both are concerning and would require further investigation, but the other advantages of Ligand A outweigh the affinity difference.
**Output:**
1
2025-04-17 20:27:39,021 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (367.896 and 370.515 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (35.58) is significantly better than Ligand B (67.87). For a GPCR, lower TPSA is generally preferred for better permeability, although ADRB2 isn't necessarily a CNS target. Ligand A is well below the 140 threshold, while Ligand B is approaching it.
3. **logP:** Ligand A (3.887) is good, within the optimal 1-3 range. Ligand B (1.429) is on the lower side, potentially impacting permeability.
4. **HBD:** Both ligands have 1 HBD, which is acceptable.
5. **HBA:** Ligand A has 2 HBA, while Ligand B has 5. Ligand A is preferable, as higher HBA can sometimes hinder permeability.
6. **QED:** Both ligands have similar QED values (0.707 and 0.766), indicating good drug-likeness.
7. **DILI:** Ligand A (11.128) has a much lower DILI risk than Ligand B (27.414). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (92.594) has a higher BBB penetration percentile than Ligand B (65.839). While ADRB2 isn't strictly a CNS target, higher BBB penetration can sometimes correlate with better overall distribution.
9. **Caco-2:** Ligand A (-4.596) and Ligand B (-5.048) both have negative values, which is unusual and suggests very poor permeability. However, the scale is not specified, so it is hard to interpret.
10. **Solubility:** Ligand A (-3.27) and Ligand B (-2.399) both have negative values, which suggests poor solubility.
11. **hERG:** Ligand A (0.958) has a slightly higher hERG risk than Ligand B (0.307), but both are relatively low.
12. **Cl_mic:** Ligand B (19.906) has a slightly higher microsomal clearance than Ligand A (15.28), suggesting lower metabolic stability.
13. **t1/2:** Ligand A (20.513) has a longer in vitro half-life than Ligand B (18.445). This is a positive for Ligand A.
14. **Pgp:** Ligand A (0.397) has a lower P-gp efflux liability than Ligand B (0.036). This is a significant advantage for Ligand A, potentially improving bioavailability.
15. **Binding Affinity:** Ligand A (-7.6) has a slightly better binding affinity than Ligand B (-7.3). While the difference is small (0.3 kcal/mol), it's enough to be considered, especially given the other favorable properties of Ligand A.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across several crucial ADME-Tox parameters (DILI, BBB, Pgp, Cl_mic, t1/2) and has a slightly better binding affinity. While both ligands have issues with Caco-2 and solubility, the other advantages of Ligand A make it the more promising candidate. The lower TPSA and logP of Ligand A are also favorable for a GPCR target.
Output:
1
2025-04-17 20:27:39,022 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (358.37) is slightly lower than Ligand B (361.511), which is marginally preferable.
2. **TPSA:** Ligand A (108.05) is higher than Ligand B (49.58). For a GPCR like ADRB2, lower TPSA is generally preferred for better permeability. Ligand B is significantly better here.
3. **logP:** Ligand A (-1.122) is lower than the optimal range (1-3), potentially hindering permeability. Ligand B (3.803) is within the optimal range. Ligand B is much better.
4. **HBD:** Ligand A (2) is acceptable, and Ligand B (0) is even better. Lower HBD can improve permeability.
5. **HBA:** Both ligands have 5 HBA, which is acceptable.
6. **QED:** Both ligands have good QED scores (A: 0.561, B: 0.717), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (51.842) has a higher DILI risk than Ligand B (24.544). Lower DILI is crucial. Ligand B is much better.
8. **BBB:** Ligand A (81.233) has better BBB penetration than Ligand B (69.794). While ADRB2 isn't strictly a CNS target, some CNS exposure can be acceptable and even beneficial for certain cardiovascular effects.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. This is a concern for both, but the scale is unclear.
10. **Solubility:** Ligand A (-1.798) has worse solubility than Ligand B (-3.08). Solubility is important for bioavailability. Ligand B is better.
11. **hERG:** Ligand A (0.101) has a slightly lower hERG risk than Ligand B (0.727). Lower hERG is preferred. Ligand A is better.
12. **Cl_mic:** Ligand A (-11.98) has significantly lower microsomal clearance than Ligand B (70.964). Lower clearance indicates better metabolic stability, a major advantage for Ligand A.
13. **t1/2:** Ligand B (57.693) has a much longer in vitro half-life than Ligand A (-4.448). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.004) has lower P-gp efflux than Ligand B (0.568). Lower P-gp efflux is generally preferred. Ligand A is better.
15. **Binding Affinity:** Ligand B (-8.5) has a stronger binding affinity than Ligand A (-6.6). This is a substantial advantage for Ligand B, potentially outweighing some ADME drawbacks.
**Overall Assessment & GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, and binding affinity are key. Ligand B excels in logP, TPSA, and significantly in binding affinity. While Ligand A has better metabolic stability (Cl_mic) and lower P-gp efflux, the stronger binding of Ligand B is a critical advantage. The lower DILI risk for Ligand B is also a significant positive. The longer half-life of Ligand B is also a plus. The slightly better BBB penetration of Ligand A is less important for a peripheral target like ADRB2.
**Output:**
0
2025-04-17 20:27:39,022 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.455 and 345.418 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (56.79) is significantly better than Ligand B (73.2). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands (2.956 and 2.689) are within the optimal 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 4 HBA, Ligand B has 3. Both are acceptable, below the threshold of 10.
6. **QED:** Both ligands have high QED scores (0.804 and 0.861), indicating good drug-like properties. Ligand B is slightly better here.
7. **DILI:** Ligand A (37.379) has a lower DILI risk than Ligand B (43.195). This is a significant advantage.
8. **BBB:** Both ligands have good BBB penetration (77.433 and 81.698), but this is less critical for a cardiovascular target. Ligand B is slightly better.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual. This suggests poor permeability. However, the values are similar (-4.775 and -4.597).
10. **Solubility:** Both ligands have very poor aqueous solubility (-3.567 and -3.764). This is a significant concern for both.
11. **hERG:** Both ligands have low hERG inhibition risk (0.776 and 0.848).
12. **Cl_mic:** Ligand A (76.434) has a higher microsomal clearance than Ligand B (51.88). This suggests Ligand B is more metabolically stable.
13. **t1/2:** Ligand B (-3.249) has a much longer in vitro half-life than Ligand A (16.017). This is a major advantage for dosing convenience.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.659 and 0.234). Ligand B is better here.
15. **Binding Affinity:** Ligand A (-6.4 kcal/mol) has a slightly better binding affinity than Ligand B (-5.8 kcal/mol). This is a 0.6 kcal/mol difference, which is a moderate advantage.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has a slightly better logP and affinity, while Ligand B has better Pgp and TPSA. However, the DILI risk for Ligand A is significantly lower, and the longer half-life of Ligand B is very attractive. The solubility is poor for both, which will need to be addressed during formulation.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity, Ligand B's superior metabolic stability (lower Cl_mic, longer t1/2), lower Pgp efflux, and lower DILI risk outweigh this small difference in affinity. The slightly better TPSA of Ligand A is not enough to overcome the other advantages of Ligand B.
Output:
0
2025-04-17 20:27:39,022 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (367.423 Da) is slightly higher than Ligand B (344.503 Da), but both are acceptable.
2. **TPSA:** Ligand A (109.77) is higher than Ligand B (41.49). For a cardiovascular GPCR like ADRB2, TPSA is less critical than for CNS targets, but lower is generally preferred for permeability. Ligand B is significantly better here.
3. **logP:** Ligand A (0.937) is slightly below the optimal range (1-3), potentially impacting permeability. Ligand B (3.273) is within the optimal range. Ligand B is better.
4. **HBD:** Ligand A (2) and Ligand B (0) are both acceptable, falling within the guideline of <=5.
5. **HBA:** Ligand A (6) and Ligand B (5) are both acceptable, falling within the guideline of <=10.
6. **QED:** Both ligands have good QED scores (A: 0.767, B: 0.82), indicating good drug-like properties.
7. **DILI:** Both ligands have acceptable DILI risk (A: 48.623, B: 39.511), below the 60 threshold. Ligand B is slightly better.
8. **BBB:** Ligand A (46.84) has a low BBB penetration percentile, while Ligand B (90.035) has a very high one. While ADRB2 isn't a CNS target, some degree of BBB penetration can sometimes be beneficial or at least not detrimental.
9. **Caco-2:** Ligand A (-5.518) and Ligand B (-4.617) are both negative, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
10. **Solubility:** Ligand A (-2.734) and Ligand B (-3.271) are both negative, indicating poor solubility. Solubility is important for bioavailability, but can be addressed through formulation.
11. **hERG:** Both ligands have very low hERG inhibition risk (A: 0.082, B: 0.805), which is excellent.
12. **Cl_mic:** Ligand A (20.016) has a lower microsomal clearance than Ligand B (59.157), suggesting better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand A (10.639) has a longer in vitro half-life than Ligand B (2.763), further supporting its better metabolic stability.
14. **Pgp:** Ligand A (0.032) has much lower P-gp efflux liability than Ligand B (0.494), which is beneficial for oral bioavailability.
15. **Binding Affinity:** Ligand B (-6.9 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.7 kcal/mol). This is a 1.2 kcal/mol difference, which is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand B has a superior binding affinity, better logP, lower TPSA, and lower DILI risk. However, Ligand A has better metabolic stability (lower Cl_mic, longer t1/2) and lower P-gp efflux. The significantly stronger binding affinity of Ligand B is the most important factor for a GPCR target, and its better logP and TPSA are also favorable. While the metabolic stability of Ligand A is appealing, it can potentially be improved through structural modifications.
Output:
0
2025-04-17 20:27:39,023 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (338.371 and 353.369 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (100.97 and 101.29) are below the 140 A^2 threshold for good oral absorption, but not optimally low for a CNS target (though ADRB2 isn't necessarily a CNS target). Again, a small difference.
3. **logP:** Ligand A (0.528) is lower than Ligand B (0.97). While both are below the optimal 1-3 range, Ligand A is concerningly low, potentially hindering membrane permeability. Ligand B is closer to acceptable.
4. **HBD:** Ligand A (1) is better than Ligand B (3). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (6) is better than Ligand B (3). Lower HBA generally improves permeability.
6. **QED:** Ligand A (0.771) is better than Ligand B (0.607), indicating a more drug-like profile.
7. **DILI:** Ligand A (68.98) has a higher DILI risk than Ligand B (35.595). This is a significant negative for Ligand A.
8. **BBB:** Ligand B (83.986) has a much higher BBB penetration percentile than Ligand A (31.02). While ADRB2 isn't strictly a CNS target, higher BBB is generally favorable, reducing potential off-target effects.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.022 and -5.226), which is unusual and suggests poor permeability. This is a major concern for both.
10. **Solubility:** Ligand A (-1.762) has slightly better solubility than Ligand B (-3.249).
11. **hERG:** Ligand A (0.103) has a lower hERG inhibition liability than Ligand B (0.33). This is a positive for Ligand A.
12. **Cl_mic:** Ligand A (18.994) has a higher microsomal clearance than Ligand B (13.429), suggesting lower metabolic stability. This is a negative for Ligand A.
13. **t1/2:** Ligand B (-17.414) has a much longer in vitro half-life than Ligand A (3.856). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.004) has much lower P-gp efflux liability than Ligand B (0.017). This is a positive for Ligand A.
15. **Binding Affinity:** Both ligands have the same binding affinity (-6.2 kcal/mol).
**GPCR-Specific Priorities & Overall Assessment:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. While affinity is equal, Ligand B has a better logP, significantly better BBB penetration, and a much longer half-life. Ligand A has a better QED, lower Pgp efflux, and lower hERG risk, but its significantly higher DILI risk and lower half-life are major drawbacks. The poor Caco-2 values for both are concerning, but can potentially be addressed through formulation. Considering the balance, Ligand B's superior metabolic stability (longer half-life) and lower toxicity (DILI) are more crucial for a viable drug candidate.
Output:
0
2025-04-17 20:27:39,023 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (353.463 and 356.413 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (92.45) is higher than Ligand B (62.55). For a cardiovascular GPCR, TPSA is moderately important. Ligand B is significantly better here, suggesting better potential for permeability.
3. **logP:** Ligand A (1.847) and Ligand B (3.476) are both within the optimal 1-3 range, but Ligand B is closer to the upper limit. This could potentially lead to some solubility issues, but is still acceptable.
4. **HBD:** Ligand A (3) and Ligand B (1) both meet the <5 criteria. Ligand B is preferable due to fewer potential off-target interactions.
5. **HBA:** Ligand A (4) and Ligand B (3) both meet the <10 criteria. Ligand B is preferable.
6. **QED:** Both ligands have good QED scores (0.632 and 0.776, respectively), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Both ligands have low DILI risk (33.579 and 34.277 percentile), which is excellent. No significant difference.
8. **BBB:** Ligand B (90.81) has a much higher BBB penetration percentile than Ligand A (41.528). While ADRB2 isn't strictly a CNS target, some CNS exposure can occur, and higher BBB penetration is generally favorable for broader distribution.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
10. **Solubility:** Both ligands have negative solubility values, which is also unusual and suggests poor solubility. Again, the scale is not specified, making interpretation difficult.
11. **hERG:** Both ligands have low hERG inhibition liability (0.336 and 0.604 percentile), which is excellent. No significant difference.
12. **Cl_mic:** Ligand A (38.969) has slightly lower microsomal clearance than Ligand B (35.976), suggesting better metabolic stability.
13. **t1/2:** Ligand B (34.273) has a significantly longer in vitro half-life than Ligand A (13.926). This is a major advantage for dosing convenience.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.028 and 0.27 percentile), which is excellent. No significant difference.
15. **Binding Affinity:** Ligand B (-6.5 kcal/mol) has a slightly better binding affinity than Ligand A (-6.0 kcal/mol). This 0.5 kcal/mol difference is significant and can outweigh some ADME drawbacks.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in TPSA, BBB, and affinity, and is comparable in logP and Pgp. The longer half-life is also a significant benefit.
**Conclusion:**
Considering the balance of properties and prioritizing GPCR-relevant parameters, Ligand B is the more promising drug candidate. The better TPSA, BBB penetration, longer half-life, and slightly improved affinity outweigh the slightly higher logP and lower metabolic stability.
Output:
0
2025-04-17 20:27:39,023 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (360.3 and 349.4 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (58.64) is significantly better than Ligand B (71.53). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand A is well below the 140 threshold, while Ligand B is approaching it.
3. **logP:** Both ligands have very similar logP values (1.846 and 1.923), falling within the optimal 1-3 range.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 3 HBA, while Ligand B has 4. Both are acceptable (<=10), but A is slightly better.
6. **QED:** Ligand B (0.764) has a better QED score than Ligand A (0.479), indicating a more drug-like profile. This is a point in favor of B.
7. **DILI:** Both have relatively low DILI risk (47.693 and 42.264 percentile), both below the 60 threshold. No major difference.
8. **BBB:** Ligand B (82.474) has a significantly higher BBB penetration score than Ligand A (47.809). While ADRB2 isn't exclusively a CNS target, some CNS exposure can occur, and higher BBB penetration is generally favorable. This is a strong point for Ligand B.
9. **Caco-2:** Both ligands have similar, poor Caco-2 permeability (-4.599 and -4.571). This suggests potential absorption issues for both.
10. **Solubility:** Ligand A (-3.391) has slightly better solubility than Ligand B (-2.469), although both are quite poor.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.426 and 0.392), which is excellent.
12. **Cl_mic:** Ligand A (42.244) has a significantly lower microsomal clearance than Ligand B (8.517). Lower clearance indicates better metabolic stability, a crucial factor for drug duration of action. This is a strong advantage for Ligand A.
13. **t1/2:** Ligand A (-7.979) has a much longer in vitro half-life than Ligand B (2.452). This further supports the better metabolic stability of Ligand A.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.077 and 0.038), which is good.
15. **Binding Affinity:** Ligand A (-5.5 kcal/mol) has a slightly better binding affinity than Ligand B (-6.0 kcal/mol). While the difference is not huge, it's still a positive for A.
**Overall Assessment & GPCR Prioritization:**
For a GPCR like ADRB2, we prioritize logP, TPSA, Pgp, and affinity. Ligand A excels in TPSA and metabolic stability (Cl_mic and t1/2), and has a slightly better affinity. Ligand B has a better QED and BBB penetration. The poor Caco-2 permeability is a concern for both, but the superior metabolic stability and slightly better affinity of Ligand A, coupled with its lower TPSA, make it the more promising candidate. The BBB penetration of Ligand B is attractive, but not critical for a peripheral target like ADRB2.
Output:
1
2025-04-17 20:27:39,023 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (354.451 and 344.371 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (90.98) is better than Ligand B (111.63). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have very low logP values (0.037 and 0.099). This is a significant concern for both, as it suggests poor membrane permeability. However, Ligand B is slightly better.
4. **HBD:** Ligand A (2) is preferable to Ligand B (3). Lower HBD generally improves permeability.
5. **HBA:** Both ligands have the same number of HBA (5), which is acceptable.
6. **QED:** Both ligands have identical QED scores (0.673), indicating similar drug-likeness.
7. **DILI:** Ligand A (15.083) has a much lower DILI risk than Ligand B (51.609). This is a substantial advantage for Ligand A.
8. **BBB:** BBB isn't a high priority for a cardiovascular target. Ligand B (58.085) is slightly better than Ligand A (49.515), but this is not a deciding factor.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.253 and -5.028), indicating very poor permeability.
10. **Solubility:** Ligand A (-0.499) is better than Ligand B (-3.153). Better solubility is always preferred.
11. **hERG:** Both ligands have low hERG inhibition liability (0.144 and 0.096), which is good.
12. **Cl_mic:** Ligand A (-57.626) has a significantly lower (better) microsomal clearance than Ligand B (-16.468). This suggests better metabolic stability.
13. **t1/2:** Ligand A (-27.574) has a slightly better (less negative) in vitro half-life than Ligand B (-21.769).
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.002).
15. **Binding Affinity:** Ligand B (-7.6) has a 0.7 kcal/mol stronger binding affinity than Ligand A (-6.9). This is a significant advantage.
**Overall Assessment:**
Ligand B has a better binding affinity, which is a crucial factor for GPCRs. However, Ligand A has significantly better DILI risk, solubility, and metabolic stability (Cl_mic). Both have poor logP and Caco-2 values. The lower DILI risk and better metabolic stability of Ligand A are more important for overall drug development success, especially considering the modest affinity difference. While the affinity of Ligand B is better, the poor ADME profile, particularly the high DILI risk, makes it a less attractive candidate.
Output:
1
2025-04-17 20:27:39,024 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (355.438 and 359.769 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (58.64) is significantly better than Ligand B (92.55). ADRB2 is a cardiovascular target, not CNS, but lower TPSA is generally favorable for absorption. Ligand A is well below the 140 threshold, while Ligand B is approaching it.
3. **logP:** Ligand A (4.295) is slightly higher than Ligand B (2.885). While both are within the 1-3 range, Ligand A is pushing the upper limit. This could potentially lead to solubility issues, but the difference isn't drastic.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Both ligands have 4 HBA, which is good.
6. **QED:** Both ligands have similar QED values (0.612 and 0.671), indicating good drug-likeness.
7. **DILI:** Ligand A (71.152) has a lower DILI risk than Ligand B (89.88). This is a significant advantage for Ligand A.
8. **BBB:** Both ligands have reasonably high BBB penetration (69.523 and 75.223), but this isn't a primary concern for a cardiovascular target.
9. **Caco-2:** Ligand A (-5.297) has a worse Caco-2 permeability than Ligand B (-4.725). This suggests Ligand B might have slightly better intestinal absorption.
10. **Solubility:** Ligand A (-4.798) has slightly better aqueous solubility than Ligand B (-5.474).
11. **hERG:** Both ligands have low hERG inhibition risk (0.624 and 0.539).
12. **Cl_mic:** Ligand B (56.653) has a significantly lower microsomal clearance than Ligand A (80.834), indicating better metabolic stability. This is a crucial advantage.
13. **t1/2:** Ligand B (32.184) has a much longer in vitro half-life than Ligand A (0.995). This is a major advantage, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.885 and 0.307). Ligand B is better here.
15. **Binding Affinity:** Ligand A (-6.7 kcal/mol) has a slightly better binding affinity than Ligand B (-6.4 kcal/mol). This 0.3 kcal/mol difference is not substantial enough to outweigh the ADME advantages of Ligand B.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Ligand A has a slightly better logP and affinity, but Ligand B has better TPSA and Pgp. The significant advantages of Ligand B in terms of metabolic stability (Cl_mic) and half-life (t1/2) are more important for overall drug development success. The lower DILI risk of Ligand A is also a positive, but the metabolic advantages of Ligand B are more impactful.
**Conclusion:**
Considering the balance of properties, Ligand B is the more promising drug candidate due to its superior metabolic stability, longer half-life, and better Caco-2 permeability. While Ligand A has a slightly better binding affinity and lower DILI, the ADME profile of Ligand B is more favorable for clinical development.
Output:
0
2025-04-17 20:27:39,024 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (341.419 Da and 347.459 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (91.94) is slightly higher than Ligand B (61.88). For a cardiovascular GPCR, TPSA is not a *critical* factor like it would be for a CNS target, but lower is generally preferred for absorption. Ligand B is better here.
3. **logP:** Ligand A (3.072) is within the optimal range (1-3), while Ligand B (1.189) is at the lower end. For a GPCR, a slightly higher logP is often beneficial for membrane permeability and receptor engagement. Ligand A is better.
4. **HBD:** Ligand A (0) has no hydrogen bond donors, while Ligand B (1) has one. Lower HBD is generally preferred for permeability, so Ligand A is slightly better.
5. **HBA:** Ligand A (6) and Ligand B (4) are both acceptable, well below the 10 threshold. Ligand B is better.
6. **QED:** Both ligands have good QED scores (0.419 and 0.599 respectively), indicating reasonable drug-likeness. Ligand B is slightly better.
7. **DILI:** Ligand A (40.481) has a slightly higher DILI risk than Ligand B (22.761). Lower is better, so Ligand B is better.
8. **BBB:** Ligand A (80.496) has a better BBB penetration score than Ligand B (67.584). While ADRB2 isn't a CNS target, some degree of BBB penetration can be useful for understanding off-target effects. Ligand A is better.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.225 and -5.212), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand A (-2.409) has slightly worse solubility than Ligand B (-1.65). Solubility is important for bioavailability, so Ligand B is better.
11. **hERG:** Ligand A (0.596) has a slightly higher hERG risk than Ligand B (0.185). Lower is better, so Ligand B is better.
12. **Cl_mic:** Ligand A (30.452) has a significantly lower (better) microsomal clearance than Ligand B (7.73). This indicates better metabolic stability for Ligand A. Ligand A is better.
13. **t1/2:** Ligand A (18.505) has a much longer in vitro half-life than Ligand B (-0.797). This is a major advantage for Ligand A, potentially allowing for less frequent dosing. Ligand A is better.
14. **Pgp:** Ligand A (0.311) has lower P-gp efflux liability than Ligand B (0.045). Lower is better, so Ligand A is better.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.4 kcal/mol and -6.5 kcal/mol). The difference is negligible.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand A emerges as the more promising candidate. While Ligand B has advantages in TPSA, DILI, solubility, and hERG, Ligand A's superior metabolic stability (Cl_mic, t1/2), Pgp efflux, and slightly better logP outweigh these benefits. The similar binding affinities mean that ADME properties become the deciding factor. The negative Caco-2 values for both are concerning and would require further investigation, but the overall profile of Ligand A is more favorable for development.
Output:
1
2025-04-17 20:27:39,024 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (386.42) is slightly higher than Ligand B (363.443), but both are acceptable.
2. **TPSA:** Ligand A (50.69) is significantly better than Ligand B (105.98). For a GPCR, lower TPSA is generally preferred for better permeability. Ligand B is above the 90 A^2 threshold, which is a concern.
3. **logP:** Ligand A (4.19) is a bit high, potentially leading to solubility issues. Ligand B (1.241) is at the lower end of the optimal range, but still acceptable.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (6). Fewer HBAs generally improve permeability.
6. **QED:** Both ligands have similar QED values (0.838 and 0.734), indicating good drug-likeness.
7. **DILI:** Both ligands have similar DILI risk (75.301 and 76.076), indicating moderate risk. This isn't a major differentiating factor.
8. **BBB:** Ligand A (81.621) has a significantly higher BBB penetration percentile than Ligand B (48.158). While ADRB2 isn't strictly a CNS target, some CNS exposure can occur, and higher BBB is generally favorable.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.924 and -5.284), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand A (-5.255) has slightly better solubility than Ligand B (-2.965), but both are poor. The high logP of Ligand A likely contributes to this.
11. **hERG:** Ligand A (0.637) has a slightly better hERG profile than Ligand B (0.097), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand B (-3.506) has a much lower (better) microsomal clearance than Ligand A (62.364), suggesting greater metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand B (18.154) has a significantly longer in vitro half-life than Ligand A (1.893). This is a major advantage for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.718) has a better Pgp efflux profile than Ligand B (0.022), suggesting better absorption and bioavailability.
15. **Binding Affinity:** Ligand A (-8.7 kcal/mol) has a significantly stronger binding affinity than Ligand B (-7.2 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME drawbacks.
**Overall Assessment:**
Ligand A has a much stronger binding affinity, a better BBB profile, and a better Pgp efflux profile. However, it suffers from higher logP, poor solubility, and high microsomal clearance. Ligand B has better metabolic stability (lower Cl_mic) and a longer half-life, but its TPSA is high, and its binding affinity is weaker.
Given the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), the strong affinity of Ligand A is a significant advantage. While its ADME properties aren't ideal, the potency difference is substantial (1.5 kcal/mol difference). The higher affinity could potentially be optimized through further medicinal chemistry efforts. The poor Caco-2 values for both are concerning, but could be addressed with formulation strategies.
Output:
1
2025-04-17 20:27:39,025 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (453.2 Da) is within the ideal range, while Ligand B (364.555 Da) is also acceptable, but on the lower end.
2. **TPSA:** Ligand A (127.68) is slightly above the optimal <140 for oral absorption, but still reasonable. Ligand B (58.2) is excellent, well below 140.
3. **logP:** Ligand A (1.419) is optimal. Ligand B (3.42) is also within the optimal range, but approaching the higher end.
4. **HBD:** Both ligands have 2 HBD, which is good.
5. **HBA:** Ligand A has 8 HBA, acceptable. Ligand B has 3 HBA, also good.
6. **QED:** Both ligands have acceptable QED scores (A: 0.442, B: 0.512). Ligand B is slightly better.
7. **DILI:** Ligand A (98.953) has a very high DILI risk, which is a major concern. Ligand B (19.775) has a low DILI risk, a significant advantage.
8. **BBB:** Ligand A (45.134) has poor BBB penetration. Ligand B (56.301) is also not great for BBB penetration, but better than A. Since ADRB2 is a cardiovascular target, BBB penetration is not a high priority, but it's still a consideration.
9. **Caco-2:** Both have negative Caco-2 values which is unusual and suggests poor permeability.
10. **Solubility:** Both have negative solubility values which is also unusual and suggests poor solubility.
11. **hERG:** Both ligands have low hERG inhibition risk (A: 0.3, B: 0.455).
12. **Cl_mic:** Ligand A (47.383) has a lower (better) microsomal clearance than Ligand B (66.096).
13. **t1/2:** Ligand A (21.234) has a longer half-life than Ligand B (7.345), which is desirable.
14. **Pgp:** Both ligands have low Pgp efflux liability (A: 0.171, B: 0.3).
15. **Affinity:** Ligand A (-7.7 kcal/mol) has a significantly better binding affinity than Ligand B (-5.5 kcal/mol). This is a substantial advantage.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A has a better logP and significantly better affinity. Ligand B has a much better TPSA. The biggest issue with Ligand A is its extremely high DILI risk.
**Overall Assessment:**
While Ligand A has a much stronger binding affinity and better metabolic stability, the extremely high DILI risk is a major red flag. The DILI risk associated with Ligand A is unacceptable. Ligand B, despite its weaker affinity, has a much more favorable safety profile (low DILI) and acceptable ADME properties. The difference in affinity, while significant, might be overcome with further optimization of Ligand B.
Output:
0
2025-04-17 20:27:39,025 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [346.381, 57.26, 3.642, 2, 3, 0.813, 60.062, 77.2, -4.697, -3.741, 0.811, -2.146, 15.187, 0.119, -3.8]
**Ligand B:** [347.375, 111.79, -1.786, 2, 7, 0.623, 46.452, 16.479, -5.14, -1.218, 0.017, -18.907, 5.044, 0.009, -5]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). A: 346.381, B: 347.375 - Similar.
2. **TPSA:** Ligand A (57.26) is significantly better than Ligand B (111.79). GPCRs benefit from lower TPSA for permeability. Ligand A is well below the 140 threshold, while B is approaching it.
3. **logP:** Ligand A (3.642) is optimal. Ligand B (-1.786) is too low, potentially hindering membrane permeability.
4. **HBD:** Both have 2 HBD, which is acceptable.
5. **HBA:** Ligand A (3) is better than Ligand B (7). Higher HBA can sometimes reduce permeability.
6. **QED:** Ligand A (0.813) is much better than Ligand B (0.623), indicating a more drug-like profile.
7. **DILI:** Ligand A (60.062) is higher risk than Ligand B (46.452), but both are acceptable.
8. **BBB:** Ligand A (77.2) is significantly better than Ligand B (16.479). While not a CNS target, some degree of BBB penetration can be beneficial for distribution.
9. **Caco-2:** Ligand A (-4.697) and Ligand B (-5.14) are both poor.
10. **Solubility:** Ligand A (-3.741) is better than Ligand B (-1.218), though both are poor.
11. **hERG:** Ligand A (0.811) is better than Ligand B (0.017), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand A (-2.146) is better than Ligand B (-18.907), suggesting better metabolic stability.
13. **t1/2:** Ligand A (15.187) is much better than Ligand B (5.044), indicating a longer half-life.
14. **Pgp:** Ligand A (0.119) is better than Ligand B (0.009), suggesting less P-gp efflux.
15. **Affinity:** Ligand B (-5) is slightly better than Ligand A (-3.8), but the difference is less than 1.5 kcal/mol.
**Overall Assessment:**
Ligand A is clearly the superior candidate. While Ligand B has a slightly better binding affinity, Ligand A excels in almost all other crucial ADME-Tox properties. Specifically, its significantly better TPSA, logP, QED, BBB, metabolic stability (Cl_mic & t1/2), Pgp efflux, and hERG risk make it a much more promising starting point for drug development. The slightly weaker affinity of Ligand A can likely be improved through further optimization without drastically impacting its favorable ADME profile. Ligand B's poor logP and TPSA are significant drawbacks that would be difficult to overcome.
Output:
1
2025-04-17 20:27:39,025 - INFO - Batch 186 complete. Total preferences: 2976
2025-04-17 20:27:39,025 - INFO - Processing batch 187/512...
2025-04-17 20:28:29,956 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (362.392 & 374.457 Da) are within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (60.85) is significantly better than Ligand B (76.14). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (2.362 & 3.011) falling within the 1-3 range. Ligand B is slightly higher, which could be a minor concern for solubility.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (6). Fewer HBAs generally improve permeability.
6. **QED:** Ligand A (0.837) is much better than Ligand B (0.65). A higher QED indicates a more drug-like profile.
7. **DILI:** Ligand A (20.9) has a significantly lower DILI risk than Ligand B (59.442). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (85.692) has a higher BBB penetration than Ligand A (75.727). While ADRB2 is not a CNS target, higher BBB is generally favorable.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.904 & -4.664), which is unusual and suggests poor permeability. However, these values are on a scale where negative values are possible, and the difference is small.
10. **Solubility:** Ligand A (-2.192) has slightly better solubility than Ligand B (-3.984).
11. **hERG:** Both ligands have very low hERG inhibition risk (0.348 & 0.279). No significant difference.
12. **Cl_mic:** Ligand A (-13.188) has a much lower (better) microsomal clearance than Ligand B (62.192), indicating better metabolic stability.
13. **t1/2:** Ligand A (-19.679) has a longer in vitro half-life than Ligand B (-7.152), which is a significant advantage.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.019 & 0.168). No significant difference.
15. **Affinity:** Ligand B (-5.3) has a slightly better binding affinity than Ligand A (-4.0). This is a 1.3 kcal/mol difference, which is substantial.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B has a slightly better logP and significantly better affinity. However, Ligand A excels in almost all other ADME properties, including TPSA, QED, DILI, Cl_mic, and t1/2. The substantial difference in DILI risk and metabolic stability (Cl_mic and t1/2) are critical for a viable drug candidate. While the affinity difference is notable, it can potentially be optimized in later stages of drug development. The overall balance of properties strongly favors Ligand A.
**Output:**
1
2025-04-17 20:28:29,957 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (352.391) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (61.88) is significantly better than Ligand A (107.73). ADRB2 is not a CNS target, but lower TPSA generally improves absorption.
3. **logP:** Ligand B (1.205) is within the optimal range, while Ligand A (0.224) is quite low, potentially hindering membrane permeability. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable.
5. **HBA:** Both ligands have 5 HBA, which is acceptable.
6. **QED:** Ligand A (0.752) has a slightly better QED score than Ligand B (0.65), suggesting a more drug-like profile.
7. **DILI:** Ligand B (20.396) has a much lower DILI risk than Ligand A (58.434). This is a major advantage for Ligand B.
8. **BBB:** Not a primary concern for ADRB2, but Ligand B (60.333) is higher than Ligand A (46.026).
9. **Caco-2:** Ligand B (-5.175) has a better Caco-2 permeability than Ligand A (-4.551).
10. **Solubility:** Ligand B (-1.619) has better solubility than Ligand A (-2.289).
11. **hERG:** Both ligands have low hERG inhibition risk (0.182 and 0.403 respectively).
12. **Cl_mic:** Ligand A (5.431) has significantly lower microsomal clearance than Ligand B (33.011), indicating better metabolic stability. This is a strong point for Ligand A.
13. **t1/2:** Ligand B (3.301) has a slightly longer half-life than Ligand A (-27.384). However, the negative value for Ligand A is concerning and likely indicates a very short half-life.
14. **Pgp:** Ligand A (0.024) has much lower P-gp efflux liability than Ligand B (0.056).
15. **Affinity:** Both ligands have very similar binding affinities (-6.7 and -6.5 kcal/mol). The difference is not substantial enough to be a deciding factor.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand B excels in logP and TPSA, while affinity is comparable. Ligand A has better metabolic stability (Cl_mic) and P-gp efflux. However, the low logP of Ligand A is a significant concern, and the higher DILI risk is also unfavorable. The better solubility and Caco-2 permeability of Ligand B are also beneficial.
**Conclusion:**
Despite Ligand A's better metabolic stability and lower P-gp efflux, the significantly better logP, TPSA, DILI profile, and Caco-2 permeability of Ligand B make it the more promising drug candidate for ADRB2. The slight advantage in half-life also contributes to this decision.
Output:
0
2025-04-17 20:28:29,957 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (337.467 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are reasonably low (A: 45.23, B: 48.0), well below the 140 threshold for oral absorption.
3. **logP:** Both ligands have good logP values (A: 3.702, B: 2.879), falling within the 1-3 optimal range. Ligand A is slightly higher, which could potentially lead to off-target effects, but is still acceptable.
4. **HBD/HBA:** Ligand A has 1 HBD and 3 HBA, while Ligand B has 0 HBD and 6 HBA. Both are within acceptable limits, but Ligand A's HBD could contribute to better solubility.
5. **QED:** Both are above 0.5 (A: 0.747, B: 0.61), indicating good drug-likeness. Ligand A is slightly better.
6. **DILI:** Both have acceptable DILI risk (A: 32.803, B: 40.752), with Ligand A being slightly lower.
7. **BBB:** Both ligands have good BBB penetration (A: 76.231, B: 79.682). This is important for a GPCR target, though less critical for ADRB2 specifically as it is not a CNS target.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. This is a significant concern for both.
9. **Solubility:** Both have negative solubility values, indicating very poor aqueous solubility. This is a major drawback for both compounds.
10. **hERG:** Both have low hERG inhibition risk (A: 0.82, B: 0.749), which is good.
11. **Cl_mic:** Ligand A has a lower microsomal clearance (76.589) than Ligand B (105.972), indicating better metabolic stability.
12. **t1/2:** Ligand A has a longer in vitro half-life (45.117 hours) than Ligand B (24.656 hours), which is desirable.
13. **Pgp:** Both have low Pgp efflux liability (A: 0.527, B: 0.608).
14. **Binding Affinity:** Ligand A has a better binding affinity (-6.7 kcal/mol) than Ligand B (-5.1 kcal/mol). This is a substantial difference.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Both ligands perform similarly on logP and Pgp. TPSA is good for both. However, Ligand A significantly outperforms Ligand B in binding affinity. The poor Caco-2 and solubility are major concerns for both, but the superior affinity and metabolic stability of Ligand A make it the more promising candidate.
**Output:**
1
2025-04-17 20:28:29,958 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (a cardiovascular GPCR) drug candidates.
**Ligand A:** [344.415, 83.56, 1.212, 2, 5, 0.441, 30.826, 81.272, -5.403, -1.875, 0.365, -2.138, -24.291, 0.008, -5.2]
**Ligand B:** [380.941, 49.41, 3.949, 1, 3, 0.84, 54.556, 77.007, -5.004, -4.831, 0.526, 57.208, -2.334, 0.583, -8.4]
**Step-by-step comparison:**
1. **MW:** Ligand A (344.415 Da) is better than Ligand B (380.941 Da), falling comfortably within the 200-500 Da range.
2. **TPSA:** Ligand B (49.41) is significantly better than Ligand A (83.56). For a cardiovascular GPCR, we don't *need* ultra-low TPSA for CNS penetration, but lower TPSA generally correlates with better permeability.
3. **logP:** Ligand A (1.212) is optimal, while Ligand B (3.949) is approaching the upper limit. This is a slight advantage for A.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1), but both are acceptable.
5. **HBA:** Ligand A (5) is higher than Ligand B (3), but both are acceptable.
6. **QED:** Ligand B (0.84) is significantly better than Ligand A (0.441), indicating a more drug-like profile.
7. **DILI:** Ligand A (30.826%) is much better than Ligand B (54.556%). This is a significant advantage for A.
8. **BBB:** Ligand A (81.272%) is better than Ligand B (77.007%), though both are reasonable. For a cardiovascular target, BBB isn't critical, but a higher value isn't detrimental.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-5.403) is slightly better than Ligand B (-5.004), but both are concerning.
10. **Solubility:** Ligand A (-1.875) is better than Ligand B (-4.831). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.365) is better than Ligand B (0.526), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand A (-2.138 mL/min/kg) is significantly better than Ligand B (57.208 mL/min/kg). This indicates much better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (-24.291 hours) is better than Ligand B (-2.334 hours). A longer half-life is generally preferred.
14. **Pgp:** Ligand A (0.008) is much better than Ligand B (0.583), suggesting lower efflux and better bioavailability.
15. **Affinity:** Ligand B (-8.4 kcal/mol) is *significantly* better than Ligand A (-5.2 kcal/mol). This is a substantial difference in potency.
**Overall Assessment:**
Ligand B has a much stronger binding affinity, which is a critical factor for GPCRs. However, it suffers from higher DILI risk, poor metabolic stability (high Cl_mic), shorter half-life, and higher P-gp efflux. Ligand A has a better ADME profile overall, with lower DILI, better metabolic stability, longer half-life, and lower P-gp efflux. The affinity difference is significant (3.2 kcal/mol), but the ADME liabilities of Ligand B are substantial.
Given the balance, and prioritizing a more favorable ADME profile for a cardiovascular target where CNS penetration isn't paramount, I believe Ligand A is the more promising candidate. The affinity difference, while large, can potentially be addressed through further optimization, while fixing the ADME issues of Ligand B would be more challenging.
Output:
1
2025-04-17 20:28:29,958 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (338.411 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (83.12) is better than Ligand B (49.41) as it is closer to the threshold for good oral absorption.
3. **logP:** Both ligands have good logP values (A: 2.603, B: 3.091) within the optimal range of 1-3.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (1), but both are acceptable.
5. **HBA:** Both ligands have the same number of HBA (3), which is within the acceptable range.
6. **QED:** Both ligands have similar QED values (A: 0.783, B: 0.75), indicating good drug-likeness.
7. **DILI:** Ligand B (21.598) has a significantly lower DILI risk than Ligand A (59.325), which is a major advantage.
8. **BBB:** Ligand B (92.555) has a much higher BBB penetration percentile than Ligand A (65.801). While ADRB2 isn't exclusively a CNS target, some CNS exposure or off-target effects are possible, making higher BBB a slight benefit.
9. **Caco-2:** Both ligands have similar, very negative Caco-2 values, suggesting poor permeability. This is a concern for both.
10. **Solubility:** Both ligands have similar, very negative solubility values, indicating poor aqueous solubility. This is a concern for both.
11. **hERG:** Both ligands have low hERG inhibition liability (A: 0.354, B: 0.499).
12. **Cl_mic:** Ligand A (15.646) has a significantly lower microsomal clearance than Ligand B (32.169), indicating better metabolic stability.
13. **t1/2:** Ligand A (51.506) has a longer in vitro half-life than Ligand B (-9.648), which is desirable.
14. **Pgp:** Ligand A (0.019) has a much lower P-gp efflux liability than Ligand B (0.169), suggesting better bioavailability and potentially better CNS exposure.
15. **Binding Affinity:** Ligand A (-7.5 kcal/mol) has a significantly stronger binding affinity than Ligand B (-4.3 kcal/mol). This is a substantial difference and a major driver in the decision.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has a better TPSA and Pgp profile, and a *much* stronger binding affinity. Ligand B has a better BBB and DILI profile. The affinity difference is so large that it outweighs the benefits of Ligand B's lower DILI and higher BBB. The poor Caco-2 and solubility are concerning for both, but can be addressed with formulation strategies.
**Conclusion:**
Despite the lower DILI risk and higher BBB for Ligand B, the significantly superior binding affinity and better Pgp profile of Ligand A make it the more promising drug candidate. The strong binding affinity is likely to translate to greater efficacy, and the lower Pgp efflux could improve bioavailability.
Output:
1
2025-04-17 20:28:29,958 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (368.865 Da and 340.383 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (74.77) is better than Ligand B (79.54) as it is closer to the <140 threshold for good oral absorption.
3. **logP:** Both ligands (2.298 and 1.753) are within the optimal 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (0) as having at least one HBD can improve solubility without drastically impacting permeability.
5. **HBA:** Both ligands have 5 HBA, which is acceptable.
6. **QED:** Both ligands have good QED scores (0.78 and 0.832), indicating good drug-like properties.
7. **DILI:** Both ligands have DILI risk around 60-64, indicating moderate risk. Not a major differentiating factor.
8. **BBB:** Ligand A (68.554) is better than Ligand B (44.591). While ADRB2 isn't exclusively a CNS target, some CNS exposure may be acceptable or even desirable for certain cardiovascular indications, and a higher BBB percentile is generally favorable.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. This is a significant drawback for both.
10. **Solubility:** Both ligands have very poor aqueous solubility (-2.789 and -2.306). This is a major concern for both candidates.
11. **hERG:** Both ligands have low hERG inhibition liability (0.458 and 0.242), which is good.
12. **Cl_mic:** Ligand B (25.622) has significantly lower microsomal clearance than Ligand A (52.292), suggesting better metabolic stability. This is a substantial advantage.
13. **t1/2:** Ligand B (29.064) has a longer in vitro half-life than Ligand A (21.413), further supporting its better metabolic stability.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.073 and 0.146), which is good.
15. **Binding Affinity:** Ligand B (-5.5 kcal/mol) has a stronger binding affinity than Ligand A (-6.8 kcal/mol). This is a significant advantage, potentially outweighing some of the ADME drawbacks.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are crucial. Ligand B has a slightly lower logP, which could be advantageous, and a significantly better binding affinity. While both have poor Caco-2 and solubility, the improved metabolic stability (lower Cl_mic and longer t1/2) of Ligand B is a significant benefit. The slightly better BBB of Ligand A is less critical in this case.
**Conclusion:**
Despite the poor permeability and solubility of both compounds, Ligand B's superior binding affinity and metabolic stability make it the more promising candidate. The stronger binding could potentially be optimized to overcome the permeability issues.
Output:
0
2025-04-17 20:28:29,958 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.443 and 345.443 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (91.57) is slightly higher than Ligand B (84.23). Both are below the 140 threshold for oral absorption, but closer to the 90 threshold for CNS targets, which isn't a primary concern for ADRB2 (cardiovascular). Ligand B is preferable.
3. **logP:** Both ligands (2.316 and 2.437) are within the optimal 1-3 range. No significant difference.
4. **HBD:** Ligand A has 3 HBD, while Ligand B has 2. Both are acceptable (<=5). Ligand B is slightly preferable.
5. **HBA:** Both ligands have 4 HBA, well within the acceptable limit of <=10. No significant difference.
6. **QED:** Ligand B (0.709) has a significantly higher QED score than Ligand A (0.566), indicating a more drug-like profile. This is a substantial advantage for Ligand B.
7. **DILI:** Ligand A (18.651) has a much lower DILI risk than Ligand B (38.503). This is a significant advantage for Ligand A.
8. **BBB:** Ligand B (70.88) has a higher BBB penetration percentile than Ligand A (48.003). While ADRB2 isn't a CNS target, higher BBB is generally favorable.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.991 and -4.492). This is unusual and suggests poor permeability. Ligand B is slightly better.
10. **Solubility:** Both ligands have negative solubility values (-3.094 and -3.766). This is also concerning and suggests poor aqueous solubility. Ligand B is slightly better.
11. **hERG:** Ligand A (0.118) has a slightly lower hERG inhibition liability than Ligand B (0.3). This is a small advantage for Ligand A.
12. **Cl_mic:** Ligand B (56.881) has a higher microsomal clearance than Ligand A (36.986), indicating lower metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (19.997) has a much longer in vitro half-life than Ligand B (-18.388). This is a major advantage for Ligand A.
14. **Pgp:** Ligand B (0.127) has a lower P-gp efflux liability than Ligand A (0.064), which is preferable.
15. **Binding Affinity:** Ligand A (-5.7 kcal/mol) has a slightly better binding affinity than Ligand B (-4.1 kcal/mol). This is a significant advantage for Ligand A.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B has a slight edge on TPSA and Pgp, but Ligand A wins on logP, and significantly on affinity.
**Overall Assessment:**
Ligand A presents a more favorable profile overall. While Ligand B has a better QED and BBB, Ligand A's superior binding affinity, lower DILI risk, better metabolic stability (lower Cl_mic, longer t1/2), and slightly lower hERG risk outweigh these advantages. The negative Caco-2 and solubility values are concerning for both, but the stronger binding and better ADME properties of Ligand A make it the more promising candidate.
Output:
1
2025-04-17 20:28:29,958 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (362.539 Da) is slightly higher than Ligand B (345.443 Da), but this difference isn't significant.
**2. TPSA:** Ligand A (40.62) is well below the 140 threshold for oral absorption and is very good for a GPCR. Ligand B (81.67) is higher, but still acceptable, though less optimal.
**3. logP:** Both ligands have good logP values (A: 2.646, B: 1.316) within the 1-3 range.
**4. H-Bond Donors:** Ligand A has 0 HBD, which is excellent for permeability. Ligand B has 3 HBD, which is still within the acceptable limit of 5.
**5. H-Bond Acceptors:** Ligand A has 3 HBA, and Ligand B has 4 HBA, both within the acceptable limit of 10.
**6. QED:** Both ligands have acceptable QED values (A: 0.706, B: 0.651), indicating good drug-like properties.
**7. DILI Risk:** Ligand A (13.532) has a significantly lower DILI risk than Ligand B (46.219). This is a major advantage for Ligand A.
**8. BBB Penetration:** Ligand A (86.08) shows better BBB penetration than Ligand B (54.75). While ADRB2 isn't strictly a CNS target, some CNS exposure can be relevant for off-target effects, and better BBB penetration can sometimes correlate with improved overall distribution.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.962 and -4.922), which is unusual and suggests poor permeability. This is a concern for both, but the values are very similar.
**10. Aqueous Solubility:** Both ligands have negative solubility values (-3.419 and -2.061), which is also concerning. Solubility is a potential issue for both.
**11. hERG Inhibition:** Both ligands show low hERG inhibition risk (A: 0.511, B: 0.5).
**12. Microsomal Clearance:** Ligand A (54.352) has a higher microsomal clearance than Ligand B (2.456), indicating lower metabolic stability. This is a disadvantage for Ligand A.
**13. In vitro Half-Life:** Ligand B (18.538 hours) has a much longer in vitro half-life than Ligand A (-10.067 hours). This is a significant advantage for Ligand B.
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (A: 0.151, B: 0.064).
**15. Binding Affinity:** Ligand B (-6.2 kcal/mol) has a slightly better binding affinity than Ligand A (-5.4 kcal/mol). This is a 0.8 kcal/mol difference, which is substantial.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity) and the general guidelines, Ligand B is the more promising candidate. The significantly lower DILI risk of Ligand A is appealing, but the superior binding affinity and substantially longer half-life of Ligand B outweigh the higher DILI risk. The similar permeability and solubility issues are a concern for both, but can be addressed through formulation strategies. The better affinity of Ligand B is likely to translate to greater efficacy.
Output:
0
2025-04-17 20:28:29,959 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (380.861) is slightly higher than Ligand B (349.519), but both are acceptable.
2. **TPSA:** Ligand A (105.31) is higher than Ligand B (52.65). For a GPCR, lower TPSA is generally preferred for better brain penetration, even though ADRB2 isn't strictly a CNS target. Ligand B is significantly better here.
3. **logP:** Both ligands have good logP values (Ligand A: 1.546, Ligand B: 2.426), falling within the optimal 1-3 range. Ligand B is slightly more lipophilic, which could be beneficial for membrane permeability.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 7 HBA, while Ligand B has 3. Both are acceptable, but Ligand B is better.
6. **QED:** Both ligands have reasonable QED scores (Ligand A: 0.847, Ligand B: 0.718), indicating good drug-like properties. Ligand A is slightly better.
7. **DILI:** Ligand A (84.141) has a significantly higher DILI risk than Ligand B (8.414). This is a major concern for Ligand A.
8. **BBB:** Ligand A (58.821) has a lower BBB penetration percentile than Ligand B (62.233). While not a primary concern for ADRB2, higher BBB is generally desirable.
9. **Caco-2:** Ligand A (-5.125) has a worse Caco-2 permeability than Ligand B (-4.64). Higher values are better, so Ligand B is preferred.
10. **Solubility:** Ligand A (-2.682) has worse solubility than Ligand B (-1.654). Solubility is important for bioavailability, so Ligand B is preferred.
11. **hERG:** Ligand A (0.194) has a slightly lower hERG risk than Ligand B (0.314), which is good.
12. **Cl_mic:** Ligand A (-0.058) has a much lower (better) microsomal clearance than Ligand B (34.918), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (-0.416) has a shorter in vitro half-life than Ligand B (4.01). Ligand B is preferred.
14. **Pgp:** Ligand A (0.04) has a lower Pgp efflux liability than Ligand B (0.05). Lower is better, so Ligand A is slightly preferred.
15. **Binding Affinity:** Ligand A (-7.2) has a slightly better binding affinity than Ligand B (-5.2). This is a 1.5 kcal/mol difference, which is significant.
**Overall Assessment:**
Ligand A has a better binding affinity and metabolic stability (lower Cl_mic), and slightly lower Pgp efflux. However, its significantly higher DILI risk is a major red flag. Ligand B has superior ADME properties across the board (TPSA, logP, HBA, Caco-2, Solubility) and a much lower DILI risk. The 2 kcal/mol difference in binding affinity, while notable, is likely outweighed by the substantial improvement in safety (DILI) and ADME profile of Ligand B. Considering these factors, Ligand B is the more promising drug candidate.
Output:
0
2025-04-17 20:28:29,959 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (356.463 and 345.399 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (99.1) is slightly higher than Ligand B (84.67). Both are below the 140 threshold for oral absorption, but B is preferable given the GPCR target class.
3. **logP:** Ligand A (0.146) is quite low, potentially hindering permeability. Ligand B (0.666) is better, though still on the lower side of the optimal 1-3 range. Ligand B is favored.
4. **HBD:** Ligand A (3) is higher than Ligand B (1). Lower HBD is generally preferred for permeability, so Ligand B is favored.
5. **HBA:** Both ligands have 5 HBA, which is acceptable.
6. **QED:** Ligand B (0.867) has a significantly better QED score than Ligand A (0.546), indicating a more drug-like profile. This is a strong advantage for Ligand B.
7. **DILI:** Ligand A (10.081) has a much lower DILI risk than Ligand B (32.881). This is a significant advantage for Ligand A.
8. **BBB:** Ligand B (62.544) has a higher BBB penetration percentile than Ligand A (57.387). While ADRB2 isn't strictly a CNS target, some CNS exposure can be acceptable or even desirable for peripheral effects.
9. **Caco-2:** Ligand A (-4.831) and Ligand B (-5.181) both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand B is slightly worse.
10. **Solubility:** Both ligands have very poor aqueous solubility (-0.844 and -0.765). This is a concern for both, but not a deciding factor.
11. **hERG:** Ligand A (0.199) has a slightly higher hERG risk than Ligand B (0.072). Ligand B is favored.
12. **Cl_mic:** Ligand A (19.421) has a much higher microsomal clearance than Ligand B (0.9). This indicates poorer metabolic stability for Ligand A. Ligand B is strongly favored.
13. **t1/2:** Ligand B (-7.178) has a much longer in vitro half-life than Ligand A (2.506). This is a significant advantage for Ligand B.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.021 and 0.022). No significant difference.
15. **Binding Affinity:** Ligand B (-7.0) has a significantly better binding affinity than Ligand A (-5.1). This is a substantial advantage that can outweigh some of the ADME drawbacks.
**Overall Assessment:**
Ligand B is the superior candidate. While Ligand A has a lower DILI risk, Ligand B excels in key areas for a GPCR target: significantly better binding affinity, a much better QED score, lower microsomal clearance (better metabolic stability), and a longer half-life. The slightly lower DILI risk of Ligand A is not enough to offset these advantages. The low logP and solubility are concerns for both, but can be addressed through formulation strategies.
Output:
0
2025-04-17 20:28:29,959 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's break down the comparison of Ligand A and Ligand B, considering the provided guidelines and the GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key).
1. **Molecular Weight:** Both ligands (348.531 Da and 363.439 Da) fall comfortably within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (58.2) is significantly better than Ligand B (88.6). For a GPCR, lower TPSA is generally preferred for better permeability. Ligand A is well below the 140 threshold, while Ligand B is getting closer to the upper limit.
3. **logP:** Ligand A (3.674) is within the optimal 1-3 range, while Ligand B (0.981) is slightly below, potentially hindering permeability.
4. **H-Bond Donors/Acceptors:** Ligand A has 2 HBD and 2 HBA, which is a good balance. Ligand B has 1 HBD and 6 HBA. The higher HBA count in Ligand B could slightly impact permeability.
5. **QED:** Both ligands have good QED scores (0.625 and 0.788), indicating good drug-like properties.
6. **DILI:** Ligand A (13.61) has a much lower DILI risk than Ligand B (41.838). This is a significant advantage for Ligand A.
7. **BBB:** Ligand B (79.411) shows better BBB penetration than Ligand A (67.623), but for a cardiovascular target like ADRB2, BBB penetration is not a primary concern.
8. **Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.666 and -4.888), which is unusual and suggests poor permeability. However, the values are very close.
9. **Aqueous Solubility:** Both ligands have negative solubility values (-4.01 and -2.018). This is also unusual and suggests poor solubility. Ligand B is slightly better here.
10. **hERG Inhibition:** Ligand A (0.469) has a lower hERG inhibition liability than Ligand B (0.217), indicating a lower risk of cardiotoxicity.
11. **Microsomal Clearance:** Ligand A (68.839) has a significantly higher microsomal clearance than Ligand B (27.238), meaning it's metabolized faster and has lower metabolic stability.
12. **In vitro Half-Life:** Ligand B (-9.708) has a longer half-life than Ligand A (-7.184).
13. **P-gp Efflux:** Ligand A (0.271) has lower P-gp efflux than Ligand B (0.068), which is favorable for bioavailability.
14. **Binding Affinity:** Ligand B (-7.4) has a slightly better binding affinity than Ligand A (-6.3), a difference of 1.1 kcal/mol.
**Overall Assessment:**
While Ligand B has a slightly better binding affinity and half-life, Ligand A presents a more favorable overall profile. The key advantages of Ligand A are its significantly lower DILI risk, better TPSA, and lower P-gp efflux. The higher metabolic clearance of Ligand A is a concern, but the other benefits, particularly the lower DILI, outweigh this drawback. Given the cardiovascular target, minimizing cardiotoxicity (low hERG and DILI) is paramount. The slightly lower logP of Ligand B is also a concern for permeability.
Output:
1
2025-04-17 20:28:29,959 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (341.386 and 350.459 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (71.09) is slightly higher than Ligand B (60.03). Both are below the 140 threshold for good oral absorption, and acceptable for a cardiovascular GPCR. Ligand B is preferable here.
3. **logP:** Both ligands (2.438 and 2.382) are within the optimal 1-3 range. No significant difference.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1). Both are within the acceptable limit of 5.
5. **HBA:** Ligand A (3) is lower than Ligand B (5). Both are within the acceptable limit of 10.
6. **QED:** Ligand A (0.848) has a higher QED score than Ligand B (0.78), indicating a more drug-like profile. This favors Ligand A.
7. **DILI:** Ligand A (50.058) has a higher DILI risk than Ligand B (30.322). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (83.249) has a higher BBB penetration percentile than Ligand B (63.784). While ADRB2 isn't a CNS target, some off-target CNS effects are always a consideration.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.698 and -4.486). This is unusual and suggests poor permeability. However, the values are similar.
10. **Solubility:** Ligand A (-3.675) has slightly better solubility than Ligand B (-2.228).
11. **hERG:** Ligand A (0.257) has a lower hERG inhibition liability than Ligand B (0.534), which is a significant advantage.
12. **Cl_mic:** Ligand B (51.979) has a higher microsomal clearance than Ligand A (37.217), meaning Ligand A is more metabolically stable. This favors Ligand A.
13. **t1/2:** Ligand A (-20.1) has a negative half-life, which is not possible. Ligand B (4.941) has a reasonable half-life. This is a major strike against Ligand A.
14. **Pgp:** Ligand A (0.108) has lower P-gp efflux liability than Ligand B (0.061). This is a slight advantage for Ligand A.
15. **Binding Affinity:** Ligand B (-5.6) has a slightly better binding affinity than Ligand A (-7.0). However, the difference is less than 1.5 kcal/mol, so it doesn't overwhelmingly outweigh other factors.
**GPCR-specific priorities:**
For ADRB2 (a cardiovascular GPCR), we prioritize logP, TPSA, Pgp, and affinity. Ligand B has a slightly better TPSA and affinity, while Ligand A has better Pgp. However, the critical issues are the negative half-life for Ligand A and the significantly lower DILI risk for Ligand B.
**Overall Assessment:**
Ligand A has a better QED, lower hERG, and lower Cl_mic, but suffers from a nonsensical half-life and higher DILI risk. Ligand B has a lower DILI risk, a reasonable half-life, and acceptable ADME properties. The slightly better affinity of Ligand B, combined with the safety profile, makes it the more promising candidate.
Output:
0
2025-04-17 20:28:29,959 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.475 and 347.419 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (75.44) is significantly better than Ligand B (95.5). For a GPCR, keeping TPSA lower is beneficial for permeability. Ligand B is getting close to the upper limit for good oral absorption (140).
3. **logP:** Ligand A (2.888) is optimal, while Ligand B (0.232) is quite low. Low logP can hinder membrane permeability and absorption. This is a significant advantage for Ligand A.
4. **HBD:** Both ligands have 1 HBD, which is within the acceptable range.
5. **HBA:** Ligand A has 4 HBA, while Ligand B has 5. Both are acceptable, but lower is generally preferred.
6. **QED:** Ligand A (0.857) has a better QED score than Ligand B (0.787), indicating a more drug-like profile.
7. **DILI:** Ligand A (34.548) has a lower DILI risk than Ligand B (45.173), which is preferable.
8. **BBB:** Ligand A (85.731) has a much higher BBB penetration percentile than Ligand B (54.556). While ADRB2 isn't strictly a CNS target, some CNS exposure can occur, and higher BBB is generally a positive attribute.
9. **Caco-2:** Both ligands have very negative Caco-2 values (-4.698 and -4.669). This is unusual and suggests poor permeability *in vitro*. However, it's not a definitive indicator of *in vivo* performance.
10. **Solubility:** Ligand A (-2.575) has slightly better solubility than Ligand B (-1.089).
11. **hERG:** Ligand A (0.464) has a lower hERG risk than Ligand B (0.098), which is a crucial safety advantage.
12. **Cl_mic:** Ligand A (66.707) has a higher (worse) microsomal clearance than Ligand B (8.655). This suggests Ligand B is more metabolically stable.
13. **t1/2:** Ligand A (-28.023) has a negative in vitro half-life, which is concerning. Ligand B (13.707) has a reasonable half-life. This is a major drawback for Ligand A.
14. **Pgp:** Ligand A (0.287) has lower P-gp efflux than Ligand B (0.035), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand B (-7.8 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.6 kcal/mol). This is a substantial advantage that could potentially outweigh some of the ADME concerns.
**Overall Assessment:**
Ligand B has a significantly better binding affinity and metabolic stability (lower Cl_mic, positive t1/2). However, it suffers from a lower logP and higher TPSA, potentially impacting permeability. Ligand A has better logP, TPSA, DILI, BBB, hERG, and Pgp properties, but its extremely poor in vitro half-life is a major concern.
Given the GPCR target class, balancing logP, TPSA, and affinity is crucial. While Ligand B's affinity is very strong, the poor logP and TPSA are concerning. Ligand A's poor half-life is a showstopper. However, the affinity difference is 2.2 kcal/mol, which is substantial. Considering the potential for optimization of Ligand B's logP/TPSA while retaining its strong affinity, I would choose Ligand B.
Output:
0
2025-04-17 20:28:29,960 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [447.34 , 126.66 , 2.663, 2. , 8. , 0.595, 96.549, 33.85 , -5.568, -3.653, 0.479, 30.76 , -1.019, 0.262, -7.1 ]
**Ligand B:** [357.479, 55.32 , 3.535, 0. , 5. , 0.84 , 61.07 , 78.519, -4.523, -4.068, 0.428, 85.163, -41.276, 0.401, -7. ]
**Step-by-step comparison:**
1. **MW:** Ligand A (447.34 Da) is within the ideal range, while Ligand B (357.479 Da) is also acceptable, though leaning towards the lower end.
2. **TPSA:** Ligand A (126.66) is pushing the upper limit for good oral absorption, but still potentially acceptable for a non-CNS target. Ligand B (55.32) is excellent, well below the 140 threshold.
3. **logP:** Both ligands (A: 2.663, B: 3.535) are within the optimal 1-3 range. Ligand B is slightly higher, which could be a minor concern for off-target effects, but not a deal-breaker.
4. **HBD:** Ligand A (2) and Ligand B (0) are both good.
5. **HBA:** Ligand A (8) is acceptable, while Ligand B (5) is also good.
6. **QED:** Ligand B (0.84) has a significantly better QED score than Ligand A (0.595), indicating a more drug-like profile.
7. **DILI:** Ligand A (96.549) has a very high DILI risk, which is a major red flag. Ligand B (61.07) is still elevated, but significantly lower and more acceptable.
8. **BBB:** Ligand A (33.85) has poor BBB penetration, which is not critical for a cardiovascular target. Ligand B (78.519) is better, but not a primary concern here.
9. **Caco-2:** Ligand A (-5.568) is very poor, suggesting poor intestinal absorption. Ligand B (-4.523) is also poor, but slightly better.
10. **Solubility:** Ligand A (-3.653) and Ligand B (-4.068) both have poor solubility.
11. **hERG:** Both ligands (A: 0.479, B: 0.428) have similar, low hERG risk, which is good.
12. **Cl_mic:** Ligand A (30.76) has lower microsomal clearance, suggesting better metabolic stability than Ligand B (85.163).
13. **t1/2:** Ligand B (-41.276) has a much longer in vitro half-life, which is a significant advantage. Ligand A (-1.019) is very short.
14. **Pgp:** Both ligands (A: 0.262, B: 0.401) have low P-gp efflux, which is good.
15. **Affinity:** Both ligands have very similar binding affinities (-7.1 and -7.0 kcal/mol). The difference is negligible.
**GPCR-specific priorities:** For ADRB2 (a cardiovascular GPCR), logP, TPSA, Pgp, and affinity are important. While both ligands are comparable in logP and affinity, Ligand B has a much better TPSA and Pgp profile. The biggest differentiator is the DILI risk. Ligand A's extremely high DILI risk is a major concern, outweighing its slightly better metabolic stability. Ligand B's longer half-life is also a significant advantage.
**Conclusion:**
Considering all factors, especially the significantly lower DILI risk and longer half-life of Ligand B, it is the more promising drug candidate.
```
0
```
2025-04-17 20:28:29,960 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (340.373 and 346.391 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (41.99) is significantly better than Ligand B (127). ADRB2 is not a CNS target, but lower TPSA generally improves absorption. Ligand A is well below the 140 threshold. Ligand B is quite high.
3. **logP:** Ligand A (4.945) is higher than Ligand B (0.5). While 4.945 is approaching the upper limit, it's still acceptable. Ligand B's logP is very low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (4). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (2) is preferable to Ligand B (5) for similar reasons as HBD.
6. **QED:** Ligand A (0.733) is slightly better than Ligand B (0.627), indicating a more drug-like profile.
7. **DILI:** Ligand B (62.001) is better than Ligand A (84.18), indicating a lower risk of drug-induced liver injury. This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (80.574) is much better than Ligand B (24.506). While ADRB2 isn't a CNS target, higher BBB penetration can sometimes correlate with better overall distribution.
9. **Caco-2:** Ligand A (-4.616) is better than Ligand B (-5.444). Higher Caco-2 values indicate better intestinal absorption.
10. **Solubility:** Ligand A (-5.326) is better than Ligand B (-2.912). Better solubility is generally preferred.
11. **hERG:** Ligand A (0.792) is better than Ligand B (0.096). Lower hERG inhibition is crucial for avoiding cardiotoxicity, a major concern for cardiovascular targets.
12. **Cl_mic:** Ligand B (-17.568) is significantly better than Ligand A (58.811). Lower microsomal clearance indicates greater metabolic stability, a major advantage for Ligand B.
13. **t1/2:** Ligand A (103.736) is significantly better than Ligand B (-21.16). A longer half-life is generally desirable.
14. **Pgp:** Ligand A (0.667) is better than Ligand B (0.013). Lower P-gp efflux is preferable for better bioavailability.
15. **Binding Affinity:** Ligand B (-6.9) is slightly better than Ligand A (-6.6). While the difference is small, it's still a positive for Ligand B.
**Overall Assessment:**
Ligand A has a better overall profile regarding absorption (TPSA, logP, Caco-2, Solubility) and safety (hERG). However, Ligand B has a significantly better metabolic stability (Cl_mic) and lower DILI risk, and a slightly better binding affinity. Considering the ADRB2 target is cardiovascular, minimizing cardiotoxicity (hERG) and ensuring metabolic stability are critical. The slightly better binding affinity of Ligand B, combined with its superior metabolic profile and lower DILI risk, outweighs the absorption advantages of Ligand A.
Output:
0
2025-04-17 20:28:29,960 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (418.238 Da) is within the ideal range (200-500 Da). Ligand B (341.371 Da) is also within range, and slightly smaller, which could be advantageous for permeability.
2. **TPSA:** Ligand A (70.67) is good, below the 140 threshold for oral absorption. Ligand B (88.83) is also acceptable, but closer to the limit.
3. **logP:** Ligand A (2.825) is optimal (1-3). Ligand B (0.239) is quite low, potentially hindering membrane permeability and absorption. This is a significant drawback.
4. **HBD:** Both ligands have acceptable HBD counts (Ligand A: 2, Ligand B: 1).
5. **HBA:** Both ligands have acceptable HBA counts (Ligand A: 3, Ligand B: 6). Ligand B is higher, but still within the reasonable limit of 10.
6. **QED:** Both ligands have good QED scores (Ligand A: 0.794, Ligand B: 0.864), indicating good drug-like properties.
7. **DILI:** Ligand A (53.121) has a moderate DILI risk, but acceptable. Ligand B (63.513) has a slightly higher DILI risk, but still within a manageable range.
8. **BBB:** Ligand A (84.529) shows good BBB penetration, which is beneficial for a GPCR target. Ligand B (64.211) is lower, suggesting less CNS exposure.
9. **Caco-2:** Both ligands have negative Caco-2 values which is unusual. Assuming these represent permeability, lower values indicate poorer permeability. Ligand A (-4.937) is slightly worse than Ligand B (-5.064).
10. **Solubility:** Ligand A (-3.845) and Ligand B (-1.985) both have poor solubility.
11. **hERG:** Ligand A (0.543) has a low hERG risk. Ligand B (0.285) has an even lower hERG risk, which is excellent.
12. **Cl_mic:** Ligand A (-20.294) has a very low (and good) microsomal clearance, indicating high metabolic stability. Ligand B (6.642) has a positive value, meaning faster clearance and lower metabolic stability.
13. **t1/2:** Ligand A (-5.486) has a negative half-life, which is unusual. Ligand B (3.474) has a reasonable in vitro half-life.
14. **Pgp:** Ligand A (0.139) has low P-gp efflux, which is good. Ligand B (0.02) has very low P-gp efflux, which is even better.
15. **Affinity:** Ligand A (-8.3 kcal/mol) has a significantly stronger binding affinity than Ligand B (-7.8 kcal/mol). This 1.5 kcal/mol difference is substantial and can outweigh some ADME drawbacks.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand A has a much better logP and affinity, while both have acceptable TPSA and Pgp. The better BBB penetration of Ligand A is also a plus. While Ligand B has better hERG and a more reasonable half-life, the significantly lower logP and weaker binding affinity are major concerns. The superior affinity of Ligand A is likely to drive better efficacy.
**Conclusion:**
Despite the slightly higher DILI risk and unusual half-life, Ligand A is the more promising candidate due to its optimal logP, significantly stronger binding affinity, and acceptable BBB penetration. The lower logP of Ligand B is a substantial drawback for a GPCR ligand, likely impacting its ability to reach the target.
Output:
1
2025-04-17 20:28:29,960 - INFO - Batch 187 complete. Total preferences: 2992
2025-04-17 20:28:29,961 - INFO - Processing batch 188/512...
2025-04-17 20:29:20,175 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [345.403, 120.04 , 0.791, 3. , 6. , 0.704, 52.036, 47.964, -5.184, -2.571, 0.152, -13.51 , 32.567, 0.01 , -5.6 ]
**Ligand B:** [410.411, 52.65 , 2.362, 1. , 4. , 0.469, 21.946, 66.537, -5.094, -2.366, 0.649, 43.178, -8.16 , 0.27 , -5.7 ]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, Affinity, and BBB):
1. **MW:** Ligand A (345.4) is better, falling comfortably within the 200-500 Da range. Ligand B (410.4) is still acceptable but pushing the upper limit.
2. **TPSA:** Ligand B (52.65) is significantly better, well below the 90 A^2 threshold for GPCRs. Ligand A (120.04) is higher, potentially impacting permeability.
3. **logP:** Ligand B (2.362) is optimal. Ligand A (0.791) is a bit low, potentially hindering membrane permeability.
4. **HBD/HBA:** Ligand B (1 HBD, 4 HBA) is preferable to Ligand A (3 HBD, 6 HBA). Lower counts generally improve permeability.
5. **QED:** Ligand A (0.704) has a better QED score, indicating better overall drug-likeness. Ligand B (0.469) is lower, suggesting potential issues.
6. **DILI:** Ligand B (21.946) has a much lower DILI risk than Ligand A (52.036). This is a significant advantage.
7. **BBB:** Ligand B (66.537) has a better BBB penetration percentile than Ligand A (47.964). While ADRB2 isn't a CNS target, some peripheral distribution is still beneficial.
8. **Caco-2:** Both are similar and poor (-5.184 and -5.094).
9. **Solubility:** Both are similar and poor (-2.571 and -2.366).
10. **hERG:** Both are low risk (0.152 and 0.649).
11. **Cl_mic:** Ligand A (-13.51) has a much lower (better) microsomal clearance, indicating higher metabolic stability. Ligand B (43.178) is quite high.
12. **t1/2:** Ligand A (32.567) has a better in vitro half-life than Ligand B (-8.16).
13. **Pgp:** Ligand A (0.01) has a much lower P-gp efflux liability than Ligand B (0.27). This is a significant advantage for bioavailability.
14. **Affinity:** Both have the same binding affinity (-5.7 kcal/mol).
15. **Overall:** Ligand B has a better profile for permeability (lower TPSA, better logP) and safety (lower DILI). Ligand A has better metabolic stability and Pgp efflux. However, the permeability and safety advantages of Ligand B are more crucial for a GPCR target.
**Conclusion:**
Considering the balance of properties, and prioritizing GPCR-relevant parameters, Ligand B is the more promising candidate. The lower TPSA, better logP, and significantly lower DILI risk outweigh the slightly lower QED and higher clearance.
Output:
0
2025-04-17 20:29:20,175 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (356.375 Da) is well within the ideal range (200-500 Da). Ligand B (378.929 Da) is also acceptable. No clear advantage here.
2. **TPSA:** Ligand A (134.19) is borderline but acceptable for oral absorption, while Ligand B (53.66) is excellent. This favors Ligand B.
3. **logP:** Ligand A (-1.925) is a bit low, potentially hindering permeability. Ligand B (3.853) is optimal. This strongly favors Ligand B.
4. **HBD:** Ligand A (4) is acceptable. Ligand B (1) is excellent. This favors Ligand B.
5. **HBA:** Ligand A (7) is acceptable. Ligand B (6) is also good. No strong preference.
6. **QED:** Ligand A (0.322) is below the preferred threshold of 0.5, indicating a less drug-like profile. Ligand B (0.646) is above the threshold. This favors Ligand B.
7. **DILI:** Ligand A (64.482) is moderately risky. Ligand B (42.613) is better, indicating lower liver injury risk. This favors Ligand B.
8. **BBB:** Ligand A (23.187) is low, suggesting poor brain penetration. Ligand B (49.321) is better, but still not high. Since ADRB2 is a cardiovascular target, BBB penetration is not a primary concern, but it's a slight advantage for B.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.446 and -5.18), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand A (-1.264) is very poor. Ligand B (-3.048) is also poor. Both are problematic.
11. **hERG:** Ligand A (0.142) is very low risk. Ligand B (0.912) is moderate risk. This favors Ligand A.
12. **Cl_mic:** Ligand A (24.151) is better (lower clearance) than Ligand B (29.155), suggesting better metabolic stability. This favors Ligand A.
13. **t1/2:** Ligand A (-16.363) is very poor. Ligand B (54.601) is good. This strongly favors Ligand B.
14. **Pgp:** Ligand A (0.089) is very low efflux, which is good. Ligand B (0.675) is moderate efflux. This favors Ligand A.
15. **Affinity:** Ligand A (-6.6) is slightly better than Ligand B (-5.8), but the difference is not huge.
**Overall Assessment:**
Ligand B has a much more favorable profile overall. It excels in key properties like logP, TPSA, QED, DILI, and t1/2. While its solubility is poor, it's comparable to Ligand A. Ligand A has better hERG and Pgp profiles, and slightly better affinity, but these are outweighed by the significant advantages of Ligand B in other crucial ADME properties. The negative Caco-2 values are concerning for both, but can be addressed in further optimization. Given the GPCR-specific priorities (logP, TPSA, Pgp), Ligand B is the better candidate.
Output:
0
2025-04-17 20:29:20,175 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (339.439 and 362.901 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (47.36) is better than Ligand B (49.41), both are under the 140 threshold for oral absorption, and acceptable for a cardiovascular target.
3. **logP:** Both ligands have good logP values (2.968 and 3.95), falling within the optimal 1-3 range. Ligand B is slightly higher, which *could* indicate a slightly higher risk of off-target effects, but is still acceptable.
4. **HBD:** Ligand A (0) is preferable to Ligand B (1). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is preferable to Ligand B (2). Fewer HBAs generally improve permeability.
6. **QED:** Both ligands have similar QED values (0.864 and 0.798), both are above the 0.5 threshold and indicate good drug-likeness.
7. **DILI:** Ligand B (35.673) has a significantly lower DILI risk than Ligand A (42.807). This is a substantial advantage for Ligand B.
8. **BBB:** Both ligands have high BBB penetration (91.431 and 81.466). This is less critical for a cardiovascular target like ADRB2, but still a positive.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.726 and -4.784). This is unusual and suggests poor permeability, but the scale is not specified, so it's difficult to interpret.
10. **Solubility:** Ligand A (-2.954) has better solubility than Ligand B (-4.528). Solubility is important for bioavailability.
11. **hERG:** Both ligands have low hERG inhibition liability (0.726 and 0.67). This is good, indicating low cardiotoxicity risk.
12. **Cl_mic:** Ligand B (62.087) has lower microsomal clearance than Ligand A (81.263), suggesting better metabolic stability.
13. **t1/2:** Ligand A (8.979) has a longer in vitro half-life than Ligand B (-1.365). This is a significant advantage for Ligand A.
14. **Pgp:** Both ligands have similar Pgp efflux liability (0.614 and 0.602).
15. **Binding Affinity:** Ligand B (-8.3 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.9 kcal/mol). This is a >1.5 kcal/mol advantage, which is a major factor.
**GPCR-specific priorities:** For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand B excels in affinity and has acceptable values for the other parameters. While Ligand A has better solubility and half-life, the substantial affinity advantage of Ligand B outweighs these benefits. The lower DILI risk for Ligand B is also a significant plus.
**Conclusion:**
Considering the balance of properties and the priorities for a GPCR target, Ligand B is the more promising drug candidate.
Output:
0
2025-04-17 20:29:20,175 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (416.316 Da) is within the ideal range, while Ligand B (352.475 Da) is slightly below, but still acceptable.
2. **TPSA:** Ligand A (100.55) is better than Ligand B (67.87), both are below the 140 threshold for oral absorption, but Ligand A is slightly higher.
3. **logP:** Both ligands have good logP values (A: 2.167, B: 1.583) within the optimal range of 1-3.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (1), both are within the acceptable limit of 5.
5. **HBA:** Ligand A (5) is higher than Ligand B (4), both are within the acceptable limit of 10.
6. **QED:** Both ligands have good QED scores (A: 0.618, B: 0.788), indicating good drug-likeness. Ligand B is slightly better.
7. **DILI:** Ligand B (12.641) has a significantly lower DILI risk than Ligand A (46.297). This is a major advantage for Ligand B.
8. **BBB:** Ligand B (83.831) has a much higher BBB penetration score than Ligand A (55.603). While ADRB2 isn't exclusively a CNS target, some peripheral ADRB2 activity can be modulated by CNS effects, and higher BBB penetration can be beneficial for overall distribution.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.951 and -4.399), indicating poor permeability. This is a concern for both.
10. **Solubility:** Both ligands have negative solubility values (-2.907 and -2.181), indicating poor solubility. This is a concern for both.
11. **hERG:** Both ligands have low hERG inhibition liability (A: 0.171, B: 0.272).
12. **Cl_mic:** Ligand B (47.125) has a lower microsomal clearance than Ligand A (65.326), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-0.706) has a slightly longer in vitro half-life than Ligand A (3.451).
14. **Pgp:** Both ligands have very low P-gp efflux liability (A: 0.046, B: 0.021).
15. **Affinity:** Ligand A (-5.8 kcal/mol) has a slightly better binding affinity than Ligand B (-5.4 kcal/mol). The difference is 0.4 kcal/mol, which is not a huge advantage.
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are important. Both ligands perform reasonably well on logP and Pgp. TPSA is acceptable for both. The affinity difference is small. However, the significant advantages of Ligand B in terms of DILI risk, BBB penetration, and metabolic stability (lower Cl_mic and longer t1/2) outweigh the slightly better affinity of Ligand A. The poor Caco-2 and solubility are concerns for both, but can be addressed through formulation strategies.
**Conclusion:**
Ligand B is the more promising drug candidate due to its superior safety profile (lower DILI), better predicted distribution (higher BBB), and improved metabolic stability.
Output:
0
2025-04-17 20:29:20,176 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
The ADRB2 receptor is a GPCR, so the priorities are logP, Pgp, TPSA, affinity, and BBB. Let's analyze each ligand against these and other important parameters.
* **Molecular Weight:** Both ligands (350.5 and 354.5 Da) fall within the ideal 200-500 Da range.
* **TPSA:** Ligand A (69.64) is significantly better than Ligand B (87.66). A lower TPSA generally indicates better cell permeability, which is crucial for GPCR targeting.
* **logP:** Both ligands have acceptable logP values (2.47 and 1.47), falling within the 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability, but not dramatically so.
* **H-Bond Donors/Acceptors:** Ligand A (2 HBD, 3 HBA) is slightly preferable to Ligand B (3 HBD, 4 HBA) as lower counts generally improve permeability.
* **QED:** Ligand A (0.773) has a better QED score than Ligand B (0.554), indicating a more drug-like profile.
* **DILI:** Ligand A (13.49) has a substantially lower DILI risk than Ligand B (10.24). This is a significant advantage.
* **BBB:** Ligand A (62.08) has a better BBB percentile than Ligand B (57.74), though neither are exceptionally high. For a cardiovascular target, BBB penetration isn't *critical*, but it's still a positive.
* **Caco-2:** Both have negative Caco-2 values (-4.816 and -4.716), which is unusual and suggests poor permeability. This is a concern for both.
* **Solubility:** Both have negative solubility values (-3.508 and -2.06), which is also concerning.
* **hERG:** Both have low hERG inhibition liability (0.375 and 0.328), which is good.
* **Cl_mic:** Ligand B (42.63) has a lower microsomal clearance than Ligand A (65.05), suggesting better metabolic stability. This is a positive for Ligand B.
* **t1/2:** Ligand B (4.86) has a significantly longer in vitro half-life than Ligand A (-1.46). This is a major advantage for Ligand B.
* **Pgp:** Both have low Pgp efflux liability (0.25 and 0.09), which is good.
* **Binding Affinity:** Both ligands have very similar and excellent binding affinities (-6.1 and -6.2 kcal/mol). The difference is negligible.
**Overall Assessment:**
Ligand A has advantages in TPSA, QED, DILI risk, and BBB penetration. Ligand B excels in metabolic stability (lower Cl_mic) and has a significantly longer half-life. The similar binding affinities mean that ADME properties become the deciding factor. While the negative Caco-2 and solubility values are concerning for both, the lower DILI risk and better TPSA of Ligand A, combined with a better QED score, make it slightly more promising.
**Output:**
1
2025-04-17 20:29:20,176 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (367.471 and 351.447 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (101.73) is slightly higher than Ligand B (95.67). Both are below the 140 threshold for good oral absorption, but closer to the 90 threshold for CNS targets, which isn't a primary concern for ADRB2 (cardiovascular). Ligand B is slightly preferred.
3. **logP:** Ligand A (-0.258) is quite low, potentially hindering permeability. Ligand B (1.891) is within the optimal 1-3 range. This is a significant advantage for Ligand B.
4. **HBD:** Both ligands have 2 H-bond donors, which is acceptable.
5. **HBA:** Both ligands have 5 H-bond acceptors, which is acceptable.
6. **QED:** Ligand B (0.816) has a substantially higher QED score than Ligand A (0.498), indicating a more drug-like profile. This is a strong point in favor of Ligand B.
7. **DILI:** Ligand B (36.099) has a lower DILI risk than Ligand A (43.66), both are below the 40 threshold, but lower is always better.
8. **BBB:** Ligand B (66.809) has a higher BBB penetration percentile than Ligand A (54.285). While ADRB2 isn't a CNS target, higher BBB is generally a positive indicator of permeability.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.451 and -4.459), which is unusual and suggests poor permeability. However, the scale is not specified, so it is difficult to interpret.
10. **Solubility:** Both ligands have negative solubility values (-2.636 and -2.729), which is also unusual and suggests poor solubility. Again, the scale is not specified.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.237 and 0.227), which is excellent.
12. **Cl_mic:** Ligand A (-1.098) has a much lower (better) microsomal clearance than Ligand B (63.137), indicating greater metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (-18.195) has a negative in vitro half-life, which is problematic. Ligand B (1.596) has a short but positive half-life.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.051 and 0.146).
15. **Binding Affinity:** Ligand B (-8.3 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.7 kcal/mol). This >1.5 kcal/mol difference is a major advantage for Ligand B and can outweigh some ADME concerns.
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP and affinity, and has a slightly better TPSA and Pgp profile. The significantly stronger binding affinity of Ligand B is the most important factor. While Ligand A has better metabolic stability (Cl_mic), the substantial affinity difference of Ligand B is more critical.
**Conclusion:**
Despite Ligand A's better metabolic stability, Ligand B's superior binding affinity, drug-likeness (QED), logP, and lower DILI risk make it the more promising drug candidate.
Output:
0
2025-04-17 20:29:20,176 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [369.418, 94.75, 2.167, 1, 6, 0.752, 66.693, 68.282, -4.579, -4.437, 0.462, 53.013, -9.514, 0.08, -6.1]
**Ligand B:** [345.443, 82.27, 1.554, 2, 3, 0.821, 24.04, 77.549, -5.1, -3.116, 0.598, 8.722, -22.592, 0.106, -5.7]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, Affinity, and BBB):
1. **MW:** Both are within the acceptable 200-500 Da range. Ligand B (345.443) is slightly preferred due to being a bit lower.
2. **TPSA:** Ligand A (94.75) is higher than Ligand B (82.27). Both are reasonably good, but Ligand B is better for permeability.
3. **logP:** Both are within the optimal 1-3 range. Ligand B (1.554) is slightly lower, which could be beneficial for solubility, but both are acceptable.
4. **HBD/HBA:** Ligand A has 1 HBD and 6 HBA, while Ligand B has 2 HBD and 3 HBA. Both are within acceptable limits.
5. **QED:** Both have good QED scores (A: 0.752, B: 0.821), indicating good drug-like properties. Ligand B is slightly better.
6. **DILI:** Ligand A (66.693) has a significantly higher DILI risk than Ligand B (24.04). This is a major concern for Ligand A.
7. **BBB:** Ligand B (77.549) has better BBB penetration than Ligand A (68.282). While not a primary concern for ADRB2 (cardiovascular target), it's a positive attribute.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and likely indicates poor permeability. However, the scale is not specified, so it's difficult to interpret.
9. **Solubility:** Both have negative solubility values, which is also unusual. Again, the scale is unclear.
10. **hERG:** Both have low hERG inhibition risk (A: 0.462, B: 0.598).
11. **Cl_mic:** Ligand B (8.722) has much lower microsomal clearance than Ligand A (53.013), indicating better metabolic stability.
12. **t1/2:** Ligand B (-22.592) has a much longer in vitro half-life than Ligand A (-9.514).
13. **Pgp:** Both have low P-gp efflux liability (A: 0.08, B: 0.106).
14. **Affinity:** Both have very good binding affinities (A: -6.1, B: -5.7). Ligand A is slightly better, but the difference is not huge.
**Overall Assessment:**
Ligand B is significantly better due to its lower DILI risk, better metabolic stability (lower Cl_mic, longer t1/2), better BBB penetration, and slightly better QED. While Ligand A has a slightly better binding affinity, the substantial improvement in safety (DILI) and pharmacokinetic properties (Cl_mic, t1/2) of Ligand B outweighs this small difference in potency. The unusual negative values for Caco-2 and solubility are concerning for both, but the other factors strongly favor Ligand B.
Output:
0
2025-04-17 20:29:20,176 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (344.459 Da) is within the ideal range, while Ligand B (391.339 Da) is slightly higher, but still acceptable.
2. **TPSA:** Ligand A (76.02) is excellent, well below the 140 threshold, and favorable for oral absorption. Ligand B (49.85) is also very good.
3. **logP:** Ligand A (1.891) is optimal. Ligand B (3.35) is at the higher end of the optimal range, potentially raising concerns about solubility and off-target effects, but still within acceptable limits.
4. **HBD:** Ligand A (2) is good. Ligand B (0) is also good, potentially improving membrane permeability.
5. **HBA:** Ligand A (4) is good. Ligand B (3) is also good.
6. **QED:** Ligand A (0.387) is below the 0.5 threshold, indicating a less drug-like profile. Ligand B (0.626) is better, exceeding the threshold.
7. **DILI:** Ligand A (33.307) has a very favorable DILI risk. Ligand B (48.391) is still acceptable, but higher.
8. **BBB:** Ligand A (44.824) has a low BBB penetration, which is not critical for ADRB2 (a cardiovascular target), but not ideal. Ligand B (80.419) shows good BBB penetration, which is not a primary concern here.
9. **Caco-2:** Ligand A (-5.103) is poor, suggesting poor intestinal absorption. Ligand B (-4.585) is also poor, but slightly better.
10. **Solubility:** Ligand A (-2.006) is very poor. Ligand B (-3.585) is also poor. Both ligands have solubility concerns.
11. **hERG:** Ligand A (0.392) is very low risk. Ligand B (0.769) is slightly higher, but still acceptable.
12. **Cl_mic:** Ligand A (34.498) has a lower clearance, suggesting better metabolic stability. Ligand B (84.391) has a higher clearance, indicating faster metabolism.
13. **t1/2:** Ligand A (-5.355) has a negative half-life, which is concerning. Ligand B (9.703) has a good in vitro half-life.
14. **Pgp:** Ligand A (0.138) has low P-gp efflux, which is favorable. Ligand B (0.643) has moderate P-gp efflux.
15. **Affinity:** Ligand B (-6.1 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.3 kcal/mol). This 1.5 kcal/mol difference is substantial.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, affinity, and Pgp are important. Ligand B performs better on logP, affinity, and has a reasonable Pgp score. While BBB isn't crucial for a cardiovascular target, Ligand B's higher value isn't detrimental.
**Overall Assessment:**
Ligand A suffers from poor solubility, poor Caco-2 permeability, a negative half-life, and a weaker binding affinity. While its DILI risk and hERG inhibition are favorable, these are outweighed by its significant ADME deficiencies. Ligand B, despite having slightly higher DILI and logP, has a much stronger binding affinity, better metabolic stability (longer half-life), and a better QED score. The superior binding affinity is a critical advantage for a GPCR target and can potentially compensate for some of the ADME drawbacks.
Output:
0
2025-04-17 20:29:20,176 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.415 and 344.415 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (83.8) is better than Ligand B (97.12). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (2.107) is better than Ligand A (0.402). A logP between 1-3 is optimal, and Ligand B is within this range, while A is below 1, potentially hindering permeability.
4. **HBD:** Both ligands have 2 HBD, which is within the acceptable limit of 5.
5. **HBA:** Both ligands have 5 HBA, which is within the acceptable limit of 10.
6. **QED:** Ligand A (0.756) is better than Ligand B (0.643), indicating a more drug-like profile.
7. **DILI:** Both ligands have acceptable DILI risk (54.207 and 52.346 percentile), below the 60% threshold. Ligand B is slightly better.
8. **BBB:** Ligand B (48.236) is better than Ligand A (25.824). While not a primary concern for a cardiovascular target, higher BBB is generally favorable.
9. **Caco-2:** Ligand B (-5.69) is better than Ligand A (-4.884). Higher Caco-2 permeability suggests better intestinal absorption.
10. **Solubility:** Ligand B (-1.423) is better than Ligand A (-1.625). Higher solubility is generally preferred.
11. **hERG:** Both ligands have low hERG inhibition liability (0.238 and 0.324), which is good. Ligand B is slightly higher, but still acceptable.
12. **Cl_mic:** Ligand A (31.734) is better than Ligand B (43.715). Lower microsomal clearance indicates better metabolic stability.
13. **t1/2:** Ligand A (9.81) is better than Ligand B (-12.787). A longer in vitro half-life is desirable.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.127 and 0.143). No significant difference.
15. **Binding Affinity:** Ligand B (-6.6) is better than Ligand A (-6.1). This is a 0.5 kcal/mol difference, which is significant enough to potentially outweigh some ADME drawbacks.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP, Caco-2, solubility, and most importantly, binding affinity. Ligand A has better TPSA, QED, Cl_mic and t1/2. However, the affinity difference is substantial. Given the importance of potency for GPCRs, the stronger binding of Ligand B is the deciding factor.
**Final Decision:**
Ligand B is the more promising candidate.
0
2025-04-17 20:29:20,176 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [353.419, 102.17 , -0.493, 1. , 5. , 0.593, 22.993, 84.335, -5.097, -1.603, 0.192, 22.596, 7.327, 0.013, -7.4 ]
**Ligand B:** [362.499, 65.54 , 1.622, 1. , 5. , 0.798, 40.869, 75.843, -5.083, -2.534, 0.472, 34.565, -9.126, 0.045, -6.9 ]
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). A (353.419) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (102.17) is higher than Ligand B (65.54). For a cardiovascular GPCR, lower TPSA is preferred for better permeability, so B is better here.
3. **logP:** Ligand A (-0.493) is a bit low, potentially hindering membrane permeability. Ligand B (1.622) is within the optimal range (1-3). B is better.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Both have 5 HBA, which is good.
6. **QED:** Both have acceptable QED values (A: 0.593, B: 0.798), indicating good drug-like properties. B is slightly better.
7. **DILI:** Ligand A (22.993) has a significantly lower DILI risk than Ligand B (40.869). This is a major advantage for A.
8. **BBB:** Ligand A (84.335) has a higher BBB penetration percentile than Ligand B (75.843). While not a primary concern for a cardiovascular target, higher BBB is generally a positive attribute.
9. **Caco-2:** Both have similar negative Caco-2 values, suggesting poor permeability.
10. **Solubility:** Both have similar negative solubility values, suggesting poor solubility.
11. **hERG:** Ligand A (0.192) has a much lower hERG inhibition liability than Ligand B (0.472). This is a crucial advantage for A, minimizing cardiotoxicity risk.
12. **Cl_mic:** Ligand A (22.596) has lower microsomal clearance than Ligand B (34.565), suggesting better metabolic stability.
13. **t1/2:** Ligand A (7.327) has a shorter in vitro half-life than Ligand B (-9.126, which is likely an error and should be interpreted as a very long half-life). This is a disadvantage for A.
14. **Pgp:** Ligand A (0.013) has much lower P-gp efflux liability than Ligand B (0.045), which is favorable for bioavailability.
15. **Affinity:** Ligand A (-7.4) has a slightly better binding affinity than Ligand B (-6.9). While the difference is not huge, it's still a positive for A.
**GPCR-Specific Considerations:**
For a cardiovascular GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B has better logP and TPSA. However, Ligand A has a significantly better safety profile (DILI, hERG) and better Pgp efflux liability. The slightly better affinity of A also contributes.
**Conclusion:**
Despite some drawbacks in solubility and Caco-2 permeability, Ligand A's superior safety profile (DILI, hERG), lower Pgp efflux, and slightly better affinity outweigh the advantages of Ligand B's logP and TPSA. The lower metabolic clearance of A is also a plus.
Output:
1
2025-04-17 20:29:20,176 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [351.491, 78.51, 1.835, 2, 3, 0.63, 15.2, 67.158, -4.733, -2.335, 0.191, 43.554, -1.432, 0.018, -6.8]**
**Ligand B: [351.437, 40.54, 4.434, 1, 2, 0.852, 16.402, 87.127, -4.557, -5.178, 0.829, 100.126, -12.094, 0.308, -6.9]**
1. **Molecular Weight:** Both ligands are within the ideal range (around 351 Da). No significant difference.
2. **TPSA:** Ligand A (78.51) is higher than Ligand B (40.54). For a cardiovascular GPCR, lower TPSA is generally preferred for better permeability, giving a slight edge to Ligand B.
3. **logP:** Ligand A (1.835) is optimal, while Ligand B (4.434) is pushing the upper limit and could lead to solubility issues or off-target interactions. This favors Ligand A.
4. **H-Bond Donors:** Ligand A (2) and Ligand B (1) are both acceptable.
5. **H-Bond Acceptors:** Ligand A (3) and Ligand B (2) are both acceptable.
6. **QED:** Ligand B (0.852) is better than Ligand A (0.63), indicating a more drug-like profile.
7. **DILI:** Ligand B (16.402) has a slightly higher DILI risk than Ligand A (15.2), but both are reasonably low.
8. **BBB:** Ligand B (87.127) has significantly better BBB penetration than Ligand A (67.158). While ADRB2 isn't exclusively a CNS target, some CNS exposure/off-target effects are possible, and higher BBB is generally preferable.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. Ligand A (-4.733) is slightly better than Ligand B (-4.557).
10. **Solubility:** Ligand A (-2.335) has better solubility than Ligand B (-5.178). This is important given Ligand B's higher logP.
11. **hERG:** Ligand A (0.191) has a lower hERG risk than Ligand B (0.829), which is a significant advantage for cardiovascular drugs.
12. **Cl_mic:** Ligand B (100.126) has a much higher microsomal clearance than Ligand A (43.554), indicating faster metabolism and potentially lower bioavailability. This strongly favors Ligand A.
13. **t1/2:** Ligand A (-1.432) has a slightly better in vitro half-life than Ligand B (-12.094).
14. **Pgp:** Ligand A (0.018) has a much lower P-gp efflux liability than Ligand B (0.308), which is beneficial for bioavailability.
15. **Binding Affinity:** Both ligands have similar binding affinities (-6.8 and -6.9 kcal/mol), so this isn't a differentiating factor.
**Overall Assessment:**
Ligand A demonstrates a better balance of properties, particularly regarding metabolic stability (Cl_mic), hERG risk, solubility, and P-gp efflux. While Ligand B has a better QED and BBB penetration, its high logP, poor solubility, and high metabolic clearance are concerning. For a cardiovascular GPCR target, minimizing off-target effects (hERG) and ensuring adequate bioavailability are critical, and Ligand A excels in these areas.
Output:
1
2025-04-17 20:29:20,176 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [351.403, 100.13 , -0.279, 3. , 5. , 0.598, 34.82 , 47.809, -5.159, -0.532, 0.123, -12.025, 1.587, 0.007, -7.3 ]
**Ligand B:** [350.503, 49.85 , 2.712, 0. , 3. , 0.786, 31.563, 76.851, -4.395, -2.367, 0.658, 63.964, 9.032, 0.196, -7.2 ]
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (350-351 Da). No significant difference.
2. **TPSA:** Ligand A (100.13) is higher than Ligand B (49.85). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is generally preferred for permeability. Ligand B is significantly better here.
3. **logP:** Ligand A (-0.279) is lower than the optimal range (1-3), potentially hindering permeability. Ligand B (2.712) is within the optimal range. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (3) is acceptable, Ligand B (0) is even better, reducing potential for off-target interactions and improving permeability.
5. **HBA:** Both ligands have 3 HBA, which is good.
6. **QED:** Both ligands have good QED scores (0.598 and 0.786), indicating drug-likeness. Ligand B is slightly better.
7. **DILI:** Both ligands have low DILI risk (34.82 and 31.563), which is favorable.
8. **BBB:** Ligand B (76.851) has a much higher BBB penetration score than Ligand A (47.809). While ADRB2 isn't strictly a CNS target, some CNS penetration can be beneficial for understanding off-target effects and potentially exploring alternative indications.
9. **Caco-2:** Ligand A (-5.159) is very poor, suggesting poor absorption. Ligand B (-4.395) is also poor, but slightly better.
10. **Solubility:** Ligand A (-0.532) is poor, while Ligand B (-2.367) is even worse. Both are problematic, but solubility can often be improved with formulation strategies.
11. **hERG:** Ligand A (0.123) has a slightly lower hERG risk than Ligand B (0.658), which is good.
12. **Cl_mic:** Ligand A (-12.025) has a much lower (better) microsomal clearance than Ligand B (63.964), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand B (9.032) has a longer in vitro half-life than Ligand A (1.587). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.007) has very low P-gp efflux, which is excellent. Ligand B (0.196) is also low, but higher.
15. **Affinity:** Ligand A (-7.3) has slightly better binding affinity than Ligand B (-7.2). This is a small advantage, but could be important.
**Overall Assessment:**
Ligand B has a better logP, TPSA, BBB, and t1/2. Ligand A has better metabolic stability (Cl_mic) and slightly better affinity. However, the poor Caco-2 and solubility of both are concerning. The significant advantage of Ligand B in logP and TPSA, coupled with its better BBB penetration, outweigh the slightly better affinity and metabolic stability of Ligand A. The better logP and TPSA are particularly important for a GPCR target, suggesting better membrane interactions and potential for receptor engagement.
Therefore, I prefer Ligand B.
0
2025-04-17 20:29:20,177 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.463 and 358.515 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (87.46) is slightly higher than Ligand B (75.62). Both are below the 140 threshold for oral absorption, but closer to the 90 threshold for CNS targets.
3. **logP:** Ligand A (0.897) is suboptimal, being slightly below the 1-3 range. Ligand B (3.63) is within the optimal range. This is a significant advantage for Ligand B, as logP is important for GPCRs.
4. **HBD:** Both ligands have 2 HBD, which is within the acceptable limit of <=5.
5. **HBA:** Ligand A has 5 HBA, while Ligand B has 7. Both are within the acceptable limit of <=10.
6. **QED:** Ligand A (0.693) has a better QED score than Ligand B (0.499), indicating better overall drug-likeness.
7. **DILI:** Ligand A (14.889%) has a much lower DILI risk than Ligand B (69.639%). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (74.021%) has a significantly higher BBB penetration potential than Ligand A (47.15%). While ADRB2 isn't strictly a CNS target, some CNS exposure can be relevant for off-target effects.
9. **Caco-2:** Ligand A (-4.875) has a worse Caco-2 permeability than Ligand B (-5.43). Both are poor, but Ligand B is slightly better.
10. **Solubility:** Ligand A (-1.212) has better solubility than Ligand B (-3.414). This is a positive for Ligand A.
11. **hERG:** Ligand A (0.176) has a much lower hERG inhibition liability than Ligand B (0.627). This is a critical advantage for Ligand A, minimizing cardiotoxicity risk.
12. **Cl_mic:** Ligand A (29.495) has a lower microsomal clearance than Ligand B (74.782), indicating better metabolic stability.
13. **t1/2:** Ligand B (50.948) has a significantly longer in vitro half-life than Ligand A (13.035). This is a positive for Ligand B.
14. **Pgp:** Ligand A (0.023) has much lower P-gp efflux liability than Ligand B (0.474). This is a significant advantage for Ligand A, improving bioavailability.
15. **Binding Affinity:** Ligand B (-7.0) has a slightly better binding affinity than Ligand A (-6.5). This 1.5kcal/mol difference is significant, and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand B has a better binding affinity and half-life. However, Ligand A demonstrates a much better safety profile with significantly lower DILI and hERG risk, and lower Pgp efflux. Ligand A also has better solubility and metabolic stability. While Ligand B has better logP and BBB penetration, the safety concerns associated with Ligand B are substantial. For a cardiovascular target like ADRB2, minimizing cardiotoxicity (hERG) and liver toxicity (DILI) is paramount. The slightly better affinity of Ligand B is not enough to overcome the safety liabilities.
Output:
1
2025-04-17 20:29:20,177 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [363.447, 109.06 , 0.389, 2. , 9. , 0.791, 66.344, 31.912, -5.535, -1.989, 0.071, 12.466, -11.612, 0.026, -6.6 ]
**Ligand B:** [356.447, 64.36 , 4.215, 1. , 5. , 0.718, 77.433, 35.401, -4.952, -4.651, 0.463, 67.171, 59.337, 0.459, -6.5 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (356.447) is slightly lower, which is generally favorable.
2. **TPSA:** Ligand A (109.06) is higher than Ligand B (64.36). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is still preferred for better permeability. Ligand B is significantly better here.
3. **logP:** Ligand A (0.389) is quite low, potentially hindering membrane permeability. Ligand B (4.215) is a bit high, but closer to the optimal 1-3 range. This favors Ligand B.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable.
5. **HBA:** Ligand A (9) is higher than Ligand B (5). Lower is preferred, making Ligand B better.
6. **QED:** Both are good (0.791 and 0.718), indicating drug-like properties.
7. **DILI:** Ligand A (66.344) is better than Ligand B (77.433), indicating a lower risk of drug-induced liver injury.
8. **BBB:** Both are relatively low, which is fine for a cardiovascular target. Ligand B (35.401) is slightly higher, but neither are particularly relevant here.
9. **Caco-2:** Both are negative, suggesting poor permeability. This is concerning for both, but Ligand A (-5.535) is worse.
10. **Solubility:** Both are negative, indicating poor solubility. Ligand A (-1.989) is slightly better than Ligand B (-4.651).
11. **hERG:** Both are very low (0.071 and 0.463), indicating minimal hERG inhibition risk, which is excellent.
12. **Cl_mic:** Ligand A (12.466) has a lower clearance than Ligand B (67.171), suggesting better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand B (59.337) has a much longer half-life than Ligand A (-11.612), which is highly desirable.
14. **Pgp:** Both are very low (0.026 and 0.459), indicating minimal P-gp efflux.
15. **Affinity:** Both have similar strong binding affinities (-6.6 and -6.5 kcal/mol). The difference is negligible.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, and affinity. Ligand B excels in TPSA and has a more favorable logP. Affinity is comparable. While Ligand A has better metabolic stability (Cl_mic), the poor logP and TPSA are significant drawbacks. The longer half-life of Ligand B is also a major plus.
**Conclusion:**
Considering the balance of properties and the GPCR-specific priorities, **Ligand B** is the more promising drug candidate. Its lower TPSA, better logP, and longer half-life outweigh the slightly higher DILI risk and lower solubility.
0
2025-04-17 20:29:20,177 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's break down the comparison, prioritizing GPCR-relevant parameters (logP, TPSA, Pgp, BBB, and affinity).
1. **Molecular Weight:** Both ligands are within the ideal 200-500 Da range. Ligand A (344.39 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (68.44) is significantly better than Ligand B (78.95). ADRB2 is not a CNS target, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have acceptable logP values (A: 1.343, B: 0.725), falling within the 1-3 range. Ligand A is slightly better.
4. **H-Bond Donors/Acceptors:** Ligand A (HBD=2, HBA=3) is slightly more balanced than Ligand B (HBD=1, HBA=4).
5. **QED:** Both ligands have similar QED scores (A: 0.864, B: 0.693), indicating good drug-likeness.
6. **DILI:** Ligand A (65.568) has a considerably higher DILI risk than Ligand B (19.426). This is a significant concern.
7. **BBB:** Ligand B (89.027) has a much higher BBB penetration percentile than Ligand A (61.419). While not a primary concern for ADRB2 (a cardiovascular target), higher BBB is rarely detrimental.
8. **Caco-2 Permeability:** Both have negative Caco-2 values, which is unusual and suggests a potential issue with the data or the modeling. However, the values are close enough to not be decisive.
9. **Aqueous Solubility:** Ligand B (-0.577) is better than Ligand A (-2.574).
10. **hERG Inhibition:** Ligand A (0.624) has a slightly higher hERG risk than Ligand B (0.223), but both are relatively low.
11. **Microsomal Clearance:** Ligand A (-11.297) has much lower (better) microsomal clearance than Ligand B (44.384), indicating greater metabolic stability.
12. **In vitro Half-Life:** Ligand A (-8.316) has a better in vitro half-life than Ligand B (-15.374).
13. **P-gp Efflux:** Ligand A (0.038) has lower P-gp efflux than Ligand B (0.013), which is favorable.
14. **Binding Affinity:** Both ligands have very similar, strong binding affinities (A: -7.6 kcal/mol, B: -7.8 kcal/mol). The difference is negligible.
**Overall Assessment:**
Ligand B is the stronger candidate. While Ligand A has better metabolic stability and P-gp efflux, the significantly higher DILI risk is a major drawback. Ligand B demonstrates a much more favorable safety profile (lower DILI) and better solubility. The slight advantages of Ligand A in metabolic stability are outweighed by the safety concerns. The similar binding affinities make the ADME/Tox profile the deciding factor.
**Output:**
0
2025-04-17 20:29:20,177 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**1. Molecular Weight:** Both ligands (341.411 Da and 347.463 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (71.53) is significantly better than Ligand B (80.12). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand A is well below the 140 A^2 threshold, while Ligand B is approaching it.
**3. logP:** Both ligands have acceptable logP values (1.087 and 1.838, respectively), falling within the 1-3 range. Ligand B is slightly higher, which *could* indicate a slightly better ability to cross membranes, but it's not a major concern.
**4. H-Bond Donors:** Both have 1 HBD, which is good.
**5. H-Bond Acceptors:** Ligand A has 4 HBA, and Ligand B has 5. Both are acceptable (<=10), but Ligand A is slightly better.
**6. QED:** Ligand A (0.786) has a substantially better QED score than Ligand B (0.575), indicating a more drug-like profile.
**7. DILI:** Both ligands have low DILI risk (35.634 and 32.377 percentiles), which is excellent. No significant difference.
**8. BBB:** Ligand B (77.782) has a significantly higher BBB penetration percentile than Ligand A (54.091). While ADRB2 isn't necessarily a CNS target, some peripheral ADRB2 receptors can be affected by CNS penetration, and higher BBB is generally a positive attribute.
**9. Caco-2 Permeability:** Ligand A (-4.488) has a much better Caco-2 permeability than Ligand B (-5). This suggests better intestinal absorption for Ligand A.
**10. Aqueous Solubility:** Ligand A (-2.629) has better aqueous solubility than Ligand B (-1.903). Better solubility is generally preferred.
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.178 and 0.433, respectively). No significant difference.
**12. Microsomal Clearance:** Ligand A (-6.375) has significantly lower (better) microsomal clearance than Ligand B (37.024). This indicates greater metabolic stability for Ligand A.
**13. In vitro Half-Life:** Ligand A (-0.05) has a slightly better in vitro half-life than Ligand B (-4.518).
**14. P-gp Efflux:** Ligand A (0.017) has a much lower P-gp efflux liability than Ligand B (0.168), suggesting better bioavailability and potentially better CNS exposure.
**15. Binding Affinity:** Ligand B (-6.7 kcal/mol) has a slightly better binding affinity than Ligand A (-6.1 kcal/mol). This is a 0.6 kcal/mol difference, which is notable but not overwhelming.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand A emerges as the more promising candidate. While Ligand B has a slightly better binding affinity and BBB penetration, Ligand A excels in several crucial ADME properties: TPSA, QED, Caco-2 permeability, solubility, microsomal clearance, and P-gp efflux. The combination of these factors suggests that Ligand A is more likely to be well-absorbed, metabolically stable, and have good bioavailability, outweighing the small difference in binding affinity.
Output:
1
2025-04-17 20:29:20,177 - INFO - Batch 188 complete. Total preferences: 3008
2025-04-17 20:29:20,177 - INFO - Processing batch 189/512...
2025-04-17 20:30:08,580 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.4 & 340.4 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (75.63) is better than Ligand B (96.36). Lower TPSA generally favors oral absorption and is important for GPCRs.
3. **logP:** Ligand A (2.066) is within the optimal 1-3 range, while Ligand B (3.334) is at the higher end. While still acceptable, Ligand A's logP is preferable.
4. **HBD:** Both ligands have 2 HBD, which is within the acceptable limit of <=5.
5. **HBA:** Both ligands have 4 HBA, which is within the acceptable limit of <=10.
6. **QED:** Ligand A (0.816) has a better QED score than Ligand B (0.719), indicating a more drug-like profile.
7. **DILI:** Ligand A (27.142) has a significantly lower DILI risk than Ligand B (82.59). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (66.305) has a better BBB penetration than Ligand B (40.558). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant and is not detrimental.
9. **Caco-2:** Ligand A (-4.401) is better than Ligand B (-5.167), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-2.615) is better than Ligand B (-4.361), indicating better aqueous solubility.
11. **hERG:** Ligand A (0.34) has a slightly better hERG profile than Ligand B (0.038), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand A (23.792) has a lower microsomal clearance than Ligand B (4.551), suggesting better metabolic stability.
13. **t1/2:** Ligand A (6.495) and Ligand B (6.788) are comparable in terms of in vitro half-life.
14. **Pgp:** Ligand A (0.074) has a lower P-gp efflux liability than Ligand B (0.114), which is beneficial for bioavailability.
15. **Binding Affinity:** Ligand B (-6.6 kcal/mol) has a slightly better binding affinity than Ligand A (-6.2 kcal/mol). However, the difference is less than 1.5 kcal/mol, and other factors are more important.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most crucial ADME-Tox properties (DILI, BBB, solubility, Cl_mic, Pgp, Caco-2). While Ligand B has a slightly better binding affinity, the improvements in safety (DILI, hERG) and ADME properties of Ligand A are more critical for overall drug development success, especially for a GPCR target like ADRB2. The slightly better TPSA and logP of Ligand A also contribute to its favorability.
Output:
1
2025-04-17 20:30:08,581 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (349.362) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (93.46) is better than Ligand B (64.16), being under the 140 threshold for good oral absorption, and closer to the 90 threshold for CNS targets.
3. **logP:** Ligand A (1.826) is optimal, while Ligand B (3.923) is approaching the upper limit. Higher logP can lead to off-target effects and solubility issues.
4. **HBD:** Ligand A (2) is preferable to Ligand B (0). A small number of HBDs are generally good for permeability.
5. **HBA:** Ligand A (5) and Ligand B (6) are both acceptable, below the 10 threshold.
6. **QED:** Both ligands have good QED scores (A: 0.532, B: 0.586), indicating drug-likeness.
7. **DILI:** Ligand A (56.417) has a lower DILI risk than Ligand B (68.864), which is a significant advantage.
8. **BBB:** Both ligands have similar BBB penetration (A: 63.784, B: 68.282). Neither is exceptionally high, but this isn't a critical factor for a cardiovascular target like ADRB2.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual. This suggests poor permeability.
10. **Solubility:** Ligand A (-2.45) has slightly better solubility than Ligand B (-4.093), though both are quite poor.
11. **hERG:** Ligand A (0.407) has a lower hERG risk than Ligand B (0.3), which is a positive.
12. **Cl_mic:** Ligand A (45.447) has significantly lower microsomal clearance than Ligand B (85.362), suggesting better metabolic stability.
13. **t1/2:** Ligand A (46.877) has a longer in vitro half-life than Ligand B (12.056), which is desirable.
14. **Pgp:** Ligand A (0.055) has lower P-gp efflux liability than Ligand B (0.61), which is favorable for bioavailability.
15. **Affinity:** Ligand A (-8.6 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.2 kcal/mol). This is a substantial advantage.
**GPCR-specific considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A excels in these areas. The significantly stronger affinity of Ligand A (-8.6 vs -6.2) is a major driver, and can outweigh some of the ADME concerns. While both have poor Caco-2 and solubility, the better overall ADME profile of Ligand A, particularly the lower DILI, Cl_mic, Pgp, and longer half-life, makes it the more promising candidate.
**Conclusion:**
Ligand A is the more viable drug candidate due to its superior binding affinity, better ADME properties (lower DILI, Cl_mic, Pgp, and longer half-life), and more favorable logP and TPSA values.
Output:
1
2025-04-17 20:30:08,581 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (372.422 and 352.494 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (108.99) is higher than Ligand B (49.41). For a cardiovascular GPCR, TPSA is moderately important. Ligand B's lower TPSA is preferable, suggesting better membrane permeability.
**3. logP:** Ligand A (-0.112) is significantly lower than Ligand B (3.614). This is a major drawback for Ligand A. A logP between 1-3 is optimal, and Ligand A is well outside this range, potentially leading to poor permeability. Ligand B is within the optimal range.
**4. H-Bond Donors:** Ligand A (2) is higher than Ligand B (1). Lower is generally better, but both are acceptable.
**5. H-Bond Acceptors:** Ligand A (7) is higher than Ligand B (2). Again, lower is generally better, and Ligand B is clearly superior here.
**6. QED:** Both ligands have similar QED values (0.746 and 0.769), indicating good drug-like properties.
**7. DILI:** Ligand A (55.758) has a higher DILI risk than Ligand B (33.307). Lower is better, so Ligand B is preferred.
**8. BBB:** Ligand A (48.972) has a lower BBB penetration than Ligand B (87.67). While ADRB2 is a cardiovascular target and CNS penetration isn't critical, higher BBB is generally a positive attribute.
**9. Caco-2 Permeability:** Ligand A (-5.012) has worse Caco-2 permeability than Ligand B (-4.493). Both are negative, but B is slightly better.
**10. Aqueous Solubility:** Ligand A (-1.903) has worse aqueous solubility than Ligand B (-4.425). Solubility is important for formulation, and B is preferable.
**11. hERG Inhibition:** Both ligands have similar, low hERG inhibition risk (0.265 and 0.364).
**12. Microsomal Clearance:** Ligand A (1.399) has lower microsomal clearance than Ligand B (64.409), indicating better metabolic stability. This is a positive for Ligand A.
**13. In vitro Half-Life:** Ligand A (-0.049) has a very short half-life compared to Ligand B (-38.133). This is a significant negative for Ligand A.
**14. P-gp Efflux:** Both ligands have similar P-gp efflux liability (0.024 and 0.138).
**15. Binding Affinity:** Ligand B (-6.8) has a slightly better binding affinity than Ligand A (-6.0). While the difference is not huge, it's enough to consider.
**Overall Assessment:**
Ligand B is the stronger candidate. Its superior logP, TPSA, DILI, BBB, solubility, and half-life outweigh Ligand A's better metabolic stability. The slightly better binding affinity of Ligand B further supports this decision. Ligand A's very low logP and short half-life are significant liabilities.
Output:
0
2025-04-17 20:30:08,581 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (370.515 Da) is slightly higher than Ligand B (342.359 Da), but both are acceptable.
2. **TPSA:** Ligand A (70.08) is significantly better than Ligand B (118.87). For a GPCR, lower TPSA is generally preferred for better permeability. Ligand B is approaching a level that could hinder oral absorption.
3. **logP:** Ligand A (0.978) is within the optimal range (1-3), while Ligand B (-0.642) is slightly below 1. Ligand A is better here, as low logP can indicate poor membrane permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBDs generally improve permeability.
5. **HBA:** Ligand A (5) is better than Ligand B (7). Similar to HBD, lower HBA is generally preferred.
6. **QED:** Both ligands have similar QED values (A: 0.781, B: 0.721), indicating good drug-likeness.
7. **DILI:** Ligand A (23.149) has a much lower DILI risk than Ligand B (72.703). This is a significant advantage for Ligand A.
8. **BBB:** Both ligands have similar BBB penetration (A: 40.558, B: 45.366). While not a primary concern for ADRB2 (a cardiovascular target), it's not a differentiating factor.
9. **Caco-2:** Ligand A (-4.911) and Ligand B (-5.544) are similar, suggesting comparable intestinal absorption.
10. **Solubility:** Ligand A (-1.733) and Ligand B (-1.813) are similar, suggesting comparable solubility.
11. **hERG:** Both ligands have low hERG inhibition risk (A: 0.268, B: 0.113), which is good.
12. **Cl_mic:** Ligand B (-12.273) has a significantly lower microsomal clearance than Ligand A (16.764), suggesting better metabolic stability. This is a strong point for Ligand B.
13. **t1/2:** Ligand B (21.942) has a much longer in vitro half-life than Ligand A (-5.372), further supporting its better metabolic stability.
14. **Pgp:** Both ligands have very low P-gp efflux (A: 0.081, B: 0.008), which is favorable.
15. **Binding Affinity:** Ligand B (-6.6 kcal/mol) has a slightly better binding affinity than Ligand A (-6.3 kcal/mol). While the difference is not huge, it's a positive for Ligand B.
**Overall Assessment:**
Ligand A excels in properties related to permeability (TPSA, logP, HBD, HBA) and has a much lower DILI risk. Ligand B shines in metabolic stability (Cl_mic, t1/2) and has slightly better binding affinity. Considering ADRB2 is a cardiovascular target, metabolic stability is important for maintaining therapeutic levels, but permeability and safety are also crucial. The significantly lower DILI risk of Ligand A, coupled with its better TPSA and logP, outweighs the slightly better metabolic stability and affinity of Ligand B.
Output:
1
2025-04-17 20:30:08,581 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (346.471 and 350.547 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Both ligands have TPSA values around 58-59 A2, well below the 140 A2 threshold for good oral absorption. This is favorable for both.
**3. logP:** Ligand A (1.96) is within the optimal 1-3 range. Ligand B (4.04) is slightly higher, approaching the upper limit where solubility issues can arise. This is a slight negative for Ligand B.
**4. H-Bond Donors:** Ligand A has 1 HBD, and Ligand B has 2. Both are acceptable, being less than 5.
**5. H-Bond Acceptors:** Ligand A has 3 HBA, and Ligand B has 2. Both are within the acceptable limit of 10.
**6. QED:** Ligand A (0.795) has a better QED score than Ligand B (0.694), indicating a more drug-like profile.
**7. DILI Risk:** Ligand A (32.377 percentile) has a slightly higher DILI risk than Ligand B (18.302 percentile). This is a positive for Ligand B.
**8. BBB Penetration:** Ligand B (84.219 percentile) shows significantly better predicted BBB penetration than Ligand A (71.694 percentile). While ADRB2 is primarily a cardiovascular target, some CNS effects are possible with beta-blockers, and better BBB penetration could be a benefit or a liability depending on the desired profile.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and may indicate issues with the prediction method. However, the values are similar, so this isn't a major differentiator.
**10. Aqueous Solubility:** Ligand A (-2.652) has better predicted aqueous solubility than Ligand B (-4.76). This is a positive for Ligand A, especially considering Ligand B's higher logP.
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (0.397 and 0.533, respectively). No significant difference.
**12. Microsomal Clearance:** Ligand B (82.7 mL/min/kg) has a significantly higher microsomal clearance than Ligand A (48.697 mL/min/kg), suggesting faster metabolism and potentially lower *in vivo* exposure. This is a negative for Ligand B.
**13. In vitro Half-Life:** Ligand A (-11.756 hours) has a much longer predicted half-life than Ligand B (4.045 hours). This is a significant advantage for Ligand A, potentially allowing for less frequent dosing.
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (0.115 and 0.161, respectively). No significant difference.
**15. Binding Affinity:** Both ligands have very similar and strong binding affinities (-5.2 and -4.9 kcal/mol). The difference of 0.3 kcal/mol is not substantial enough to outweigh other factors.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), and the general drug-like properties, Ligand A appears to be the more promising candidate. While Ligand B has a lower DILI risk and better BBB penetration, Ligand A has a better QED score, better solubility, significantly better metabolic stability (lower Cl_mic, longer t1/2), and a more favorable logP. The slight difference in binding affinity is not enough to overcome these advantages.
Output:
1
2025-04-17 20:30:08,581 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (371.5 & 360.5 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (64.09) is significantly better than Ligand B (79.96). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand A is well below the 140 threshold, while B is approaching it.
3. **logP:** Ligand A (0.892) is a bit low, potentially hindering permeation, but still within an acceptable range. Ligand B (3.205) is closer to the optimal 1-3 range. This favors Ligand B slightly.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (5) is better than Ligand B (7). Lower HBA is also favorable for permeability.
6. **QED:** Both ligands have good QED scores (0.778 and 0.856), indicating good drug-like properties. No significant difference.
7. **DILI:** Ligand B (61.807) has a higher DILI risk than Ligand A (5.894). This is a significant concern, as lower DILI is crucial. Ligand A is strongly favored here.
8. **BBB:** Ligand B (89.104) has a much higher BBB penetration score than Ligand A (62.233). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be helpful for distribution. This favors Ligand B.
9. **Caco-2:** Ligand A (-4.9) and Ligand B (-5.3) are both very poor, suggesting poor intestinal absorption. This is a significant drawback for both.
10. **Solubility:** Ligand A (-1.028) is better than Ligand B (-4.709), indicating better aqueous solubility. Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.187) is significantly better than Ligand B (0.535) regarding hERG inhibition liability. Lower hERG is critical for avoiding cardiotoxicity, a major concern for cardiovascular targets like ADRB2.
12. **Cl_mic:** Ligand B (52.824) has a lower microsomal clearance than Ligand A (10.415), suggesting better metabolic stability. This favors Ligand B.
13. **t1/2:** Ligand B (17.893) has a significantly longer in vitro half-life than Ligand A (-11.501). A longer half-life is generally desirable. This favors Ligand B.
14. **Pgp:** Ligand A (0.006) has a much lower P-gp efflux liability than Ligand B (0.038). Lower P-gp efflux is beneficial for bioavailability. This favors Ligand A.
15. **Binding Affinity:** Ligand B (-8.1) has a significantly stronger binding affinity than Ligand A (-4.9). A 3.2 kcal/mol difference is substantial and can often outweigh other ADME concerns. This strongly favors Ligand B.
**Overall Assessment:**
Ligand B has a significantly better binding affinity and metabolic stability (lower Cl_mic, longer t1/2) and better BBB penetration. However, it has a higher DILI risk and hERG liability. Ligand A has a much lower DILI and hERG risk, better solubility, and lower P-gp efflux, but weaker binding affinity and poorer metabolic stability.
Considering the ADRB2 target is cardiovascular, minimizing cardiotoxicity (hERG) and liver toxicity (DILI) are paramount. The substantial difference in binding affinity *could* be overcome with further optimization of Ligand B, but the toxicity liabilities are a major concern. Ligand A, while weaker in binding, presents a much safer starting point. The poor Caco-2 values for both are concerning and would need to be addressed regardless.
Therefore, I favor Ligand A due to its significantly better safety profile.
Output:
1
2025-04-17 20:30:08,581 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, the priorities are logP, Pgp, TPSA, and affinity, with metabolic stability and safety (DILI, hERG) also being important.
Let's break down the comparison:
1. **MW:** Both ligands are within the ideal range (200-500 Da).
2. **TPSA:** Both are excellent, well below the 140 A^2 threshold for oral absorption.
3. **logP:** Ligand A (4.205) is slightly higher than Ligand B (3.787). Both are within the optimal range (1-3), but A is approaching the upper limit.
4. **HBD/HBA:** Both have 2 HBD and 2 HBA, which is good.
5. **QED:** Both are acceptable (above 0.5), but Ligand A is slightly better (0.676 vs 0.609).
6. **DILI:** Ligand B has a significantly lower DILI risk (55.176 percentile) than Ligand A (13.3 percentile). This is a major advantage for Ligand B.
7. **BBB:** Both have good BBB penetration (A: 79.062, B: 77.511).
8. **Caco-2:** Both are negative, indicating poor permeability.
9. **Solubility:** Both are negative, indicating poor solubility.
10. **hERG:** Ligand A (0.303) has a lower hERG risk than Ligand B (0.876), which is favorable.
11. **Cl_mic:** Ligand B has a lower microsomal clearance (41.877 mL/min/kg) than Ligand A (61.339 mL/min/kg), indicating better metabolic stability.
12. **t1/2:** Ligand B has a significantly longer in vitro half-life (46.725 hours) than Ligand A (13.154 hours). This is a substantial advantage.
13. **Pgp:** Ligand A (0.025) has significantly lower P-gp efflux than Ligand B (0.494), which is favorable.
14. **Affinity:** Ligand B (-7.5 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.7 kcal/mol). This is a crucial difference, outweighing some of the ADME concerns.
**Overall Assessment:**
While Ligand A has better Pgp and hERG profiles, Ligand B's superior binding affinity (-7.5 vs -5.7 kcal/mol) and significantly improved metabolic stability (lower Cl_mic, longer t1/2) and lower DILI risk are more critical for a GPCR drug candidate. The difference in binding affinity is substantial enough to offset the slightly higher Pgp efflux and hERG risk. The similar BBB penetration and TPSA values make this decision primarily driven by potency, safety, and metabolic stability.
Output:
0
2025-04-17 20:30:08,581 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands fall within the ideal range (200-500 Da). Ligand A (345.487 Da) is slightly lower, which is generally favorable for permeability.
**2. TPSA:** Ligand A (64.41) is significantly better than Ligand B (99.25). For a GPCR, keeping TPSA low is beneficial for permeability and receptor engagement. Ligand B is approaching a level that could hinder oral absorption.
**3. logP:** Both ligands have acceptable logP values (A: 2.813, B: 3.059), falling within the optimal range of 1-3.
**4. H-Bond Donors:** Ligand A (0) is preferable to Ligand B (3). Fewer H-bond donors generally improve membrane permeability.
**5. H-Bond Acceptors:** Ligand A (3) is better than Ligand B (5), again favoring permeability.
**6. QED:** Both ligands have similar, acceptable QED values (A: 0.79, B: 0.707), indicating good drug-like properties.
**7. DILI Risk:** Ligand A (16.673) has a substantially lower DILI risk than Ligand B (97.829). This is a critical advantage, as liver toxicity is a major concern in drug development.
**8. BBB Penetration:** Ligand A (81.776) shows better BBB penetration than Ligand B (60.876). While ADRB2 is a cardiovascular target, some CNS effects are possible with beta-blockers, and good BBB penetration could be a benefit or a concern depending on the desired selectivity.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so this is difficult to interpret.
**10. Aqueous Solubility:** Ligand A (-2.186) is better than Ligand B (-5.15). Better solubility is generally preferred for formulation and bioavailability.
**11. hERG Inhibition:** Ligand A (0.639) is slightly better than Ligand B (0.116), indicating a lower risk of cardiotoxicity.
**12. Microsomal Clearance:** Ligand A (27.378) has higher clearance than Ligand B (10.783), meaning it's less metabolically stable. This is a drawback for Ligand A.
**13. In vitro Half-Life:** Ligand B (20.454) has a significantly longer half-life than Ligand A (0.12). This is a major advantage for Ligand B, potentially allowing for less frequent dosing.
**14. P-gp Efflux:** Ligand A (0.223) shows less P-gp efflux than Ligand B (0.033), which is favorable for bioavailability.
**15. Binding Affinity:** Ligand B (-7.5 kcal/mol) has a slightly better binding affinity than Ligand A (-7.2 kcal/mol). While the difference is not huge, it's a positive for Ligand B.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand A is superior in several key areas: TPSA, H-bond donors/acceptors, DILI risk, BBB penetration, solubility, and P-gp efflux. The improved metabolic stability and half-life of Ligand B are attractive, but the significantly higher DILI risk and poorer ADME properties (TPSA, solubility) are major concerns. The slight affinity difference is unlikely to outweigh these factors.
Output:
1
2025-04-17 20:30:08,582 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (359.407 and 347.423 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (92.71 and 93.18) are slightly above the optimal <140 for oral absorption, but acceptable for a peripherally acting GPCR like ADRB2. No major difference.
3. **logP:** Ligand A (3.341) is within the optimal 1-3 range. Ligand B (0.657) is quite low, potentially hindering membrane permeability. This is a significant drawback for Ligand B.
4. **HBD:** Ligand A (3) is acceptable. Ligand B (0) is also acceptable, but a lack of HBDs can sometimes impact solubility.
5. **HBA:** Ligand A (6) is acceptable. Ligand B (8) is acceptable, but higher HBA can sometimes impact permeability.
6. **QED:** Both ligands (0.65 and 0.657) have good drug-likeness scores, indicating a generally favorable profile.
7. **DILI:** Ligand A (87.515) has a higher DILI risk than Ligand B (36.448). This is a concern for Ligand A.
8. **BBB:** Ligand A (41.528) has low BBB penetration, which is not a major concern for a cardiovascular target. Ligand B (66.576) has moderate BBB penetration, also not critical here.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.304 and -5.359), which is unusual and suggests poor permeability. However, these values are on a log scale and may not be directly comparable.
10. **Solubility:** Ligand A (-3.854) has poor solubility. Ligand B (-0.3) has slightly better solubility, but still not ideal.
11. **hERG:** Ligand A (0.559) has a slightly higher hERG risk than Ligand B (0.085). This is a potential safety concern for Ligand A.
12. **Cl_mic:** Ligand A (54.333) has a higher microsomal clearance than Ligand B (13.882), indicating lower metabolic stability. This is a significant drawback for Ligand A.
13. **t1/2:** Ligand A (-13.34) has a very short in vitro half-life. Ligand B (3.819) has a slightly longer half-life, but still relatively short.
14. **Pgp:** Ligand A (0.278) has lower P-gp efflux than Ligand B (0.025), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand A (-6.2 kcal/mol) has a slightly better binding affinity than Ligand B (-5.8 kcal/mol). This is a 1.5 kcal/mol difference, which is significant.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand A has a better logP and Pgp profile, and slightly better affinity. However, its DILI risk, hERG risk, and particularly its metabolic stability (high Cl_mic and short t1/2) are significant concerns. Ligand B's low logP is a major drawback, but it has a much better safety profile (lower DILI and hERG) and better metabolic stability.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity and Pgp profile, the significant concerns regarding its metabolic stability, DILI risk, and hERG inhibition outweigh these benefits. Ligand B, despite its lower logP, presents a more favorable overall profile regarding safety and pharmacokinetic properties. The lower logP can potentially be addressed through further optimization.
Output:
0
2025-04-17 20:30:08,582 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (342.4) is within the ideal range (200-500), while Ligand B (381.9) is also acceptable but trending towards the higher end.
2. **TPSA:** Ligand A (103.0) is good for oral absorption, being below 140. Ligand B (30.3) is excellent, suggesting good permeability.
3. **logP:** Ligand A (1.03) is optimal. Ligand B (4.62) is high, potentially leading to solubility issues and off-target interactions.
4. **HBD:** Ligand A (3) is within the acceptable limit. Ligand B (0) is also good, but potentially could reduce aqueous solubility.
5. **HBA:** Both Ligand A (5) and Ligand B (5) are within the acceptable limit.
6. **QED:** Both Ligand A (0.697) and Ligand B (0.6) are good, indicating drug-like properties.
7. **DILI:** Ligand A (55.2) is slightly higher, but still acceptable. Ligand B (33.5) is better, indicating lower liver injury risk.
8. **BBB:** Ligand A (30.4) is lower, while Ligand B (48.9) is better, but still not exceptionally high. For a cardiovascular target like ADRB2, BBB penetration isn't a primary concern, but it's a slight advantage for B.
9. **Caco-2:** Both are negative, indicating poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand A (-2.39) is better than Ligand B (-4.54).
11. **hERG:** Ligand A (0.61) is better than Ligand B (0.92), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand A (-28.3) is much better (lower clearance = more stable) than Ligand B (88.7).
13. **t1/2:** Ligand B (49.8) has a significantly longer half-life than Ligand A (-6.48). This is a major advantage for B.
14. **Pgp:** Ligand A (0.01) is much better (lower efflux) than Ligand B (0.79).
15. **Affinity:** Ligand B (-6.6) has a slightly better binding affinity than Ligand A (-6.2), but the difference is not substantial.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand B has a better TPSA and Pgp, and slightly better affinity, but a problematic logP. Ligand A has a better logP, solubility, hERG, Cl_mic, and Pgp.
**Overall Assessment:**
While Ligand B has a longer half-life and slightly better affinity, its high logP and poor solubility are significant drawbacks. The better metabolic stability (Cl_mic) and lower hERG risk of Ligand A are crucial for a cardiovascular drug. The slightly lower Pgp efflux for A is also favorable. The Caco-2 permeability is poor for both, but can be addressed with formulation strategies.
Considering the balance of properties and the priorities for a cardiovascular GPCR target, Ligand A appears to be the more promising candidate.
Output:
1
2025-04-17 20:30:08,582 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (366.366 Da) is slightly higher than Ligand B (349.475 Da), but both are acceptable.
2. **TPSA:** Ligand A (89.9) is better than Ligand B (69.72). Both are below 140, indicating good potential for oral absorption.
3. **logP:** Both ligands have good logP values (A: 2.442, B: 1.566), falling within the optimal 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Both ligands have 1 HBD, which is within the acceptable limit of 5.
5. **HBA:** Ligand A has 7 HBA, while Ligand B has 3. Both are under the 10 limit.
6. **QED:** Ligand A (0.624) has a slightly better QED score than Ligand B (0.56), indicating better overall drug-likeness.
7. **DILI:** Ligand B (31.563) has a significantly lower DILI risk than Ligand A (85.266). This is a major advantage for Ligand B.
8. **BBB:** Both ligands have similar BBB penetration (A: 68.399, B: 68.321). While not exceptionally high, it's not a primary concern for ADRB2, which isn't a CNS target.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.675 and -4.724), which is unusual and suggests poor permeability. This is a significant drawback for both.
10. **Solubility:** Ligand A (-3.347) has slightly better solubility than Ligand B (-2.07), but both are poor.
11. **hERG:** Ligand A (0.251) has a slightly lower hERG risk than Ligand B (0.469), which is preferable.
12. **Cl_mic:** Ligand B (53.744) has significantly lower microsomal clearance than Ligand A (92.721), indicating better metabolic stability.
13. **t1/2:** Ligand B (-24.636) has a negative in vitro half-life, which is concerning. Ligand A (41.904) has a reasonable half-life.
14. **Pgp:** Ligand A (0.646) has slightly lower P-gp efflux than Ligand B (0.252), which is better.
15. **Binding Affinity:** Ligand A (-6.1 kcal/mol) has a slightly better binding affinity than Ligand B (-4.7 kcal/mol). This is a significant advantage, potentially outweighing some ADME concerns.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, and affinity are important. Ligand A has a slightly better logP, TPSA, and significantly better affinity. However, the DILI risk for Ligand A is very high, and the metabolic stability (Cl_mic) is poor. Ligand B has a much better safety profile (DILI) and metabolic stability, but its affinity is weaker and its in vitro half-life is concerning.
**Overall Assessment:**
While Ligand A has a better binding affinity, the high DILI risk and poor metabolic stability are major concerns. The negative Caco-2 values for both are problematic, but the superior safety profile and metabolic stability of Ligand B, combined with acceptable (though not ideal) BBB penetration, make it the more promising candidate, despite the weaker binding. The lower affinity might be optimized in subsequent iterations.
Output:
0
2025-04-17 20:30:08,582 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (355.5 & 346.4 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (61.44) is significantly better than Ligand B (95.42). For a GPCR, keeping TPSA under 140 is good for oral absorption, and lower is generally preferred. Ligand B is pushing the upper limit and could have absorption issues.
**3. logP:** Ligand A (2.256) is within the optimal 1-3 range. Ligand B (0.996) is slightly below 1, which *could* indicate potential permeability issues, although not drastically.
**4. H-Bond Donors:** Both ligands have 2 HBDs, which is acceptable.
**5. H-Bond Acceptors:** Ligand A has 3 HBAs, while Ligand B has 5. Both are within the acceptable range of <=10, but Ligand A is slightly more favorable.
**6. QED:** Both ligands have good QED scores (0.736 and 0.801), indicating good drug-like properties.
**7. DILI Risk:** Ligand A (7.135%) has a much lower DILI risk than Ligand B (32.493%). This is a significant advantage for Ligand A.
**8. BBB Penetration:** Ligand A (87.67%) shows significantly better BBB penetration than Ligand B (53.587%). While ADRB2 is primarily a cardiovascular target, some CNS effects are possible with certain ligands, and higher BBB penetration isn't necessarily detrimental.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.919 and -4.965). This is unusual and suggests poor permeability. However, the values are very similar.
**10. Aqueous Solubility:** Both ligands have negative solubility values (-1.701 and -2.239). This is also concerning and suggests poor solubility. Ligand B is slightly worse.
**11. hERG Inhibition:** Ligand A (0.528) has a lower hERG inhibition risk than Ligand B (0.176), which is a significant safety advantage.
**12. Microsomal Clearance:** Ligand A (-7.624) has a much lower (better) microsomal clearance than Ligand B (27.916). This indicates greater metabolic stability for Ligand A.
**13. In vitro Half-Life:** Ligand A (3.678) has a better in vitro half-life than Ligand B (-16.454).
**14. P-gp Efflux:** Ligand A (0.032) has a lower P-gp efflux liability than Ligand B (0.005). Lower is better.
**15. Binding Affinity:** Ligand A (-7.3 kcal/mol) has slightly better binding affinity than Ligand B (-4.8 kcal/mol). This is a substantial difference (2.5 kcal/mol) and a major driver in the decision.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical ADME-Tox parameters (DILI, BBB, hERG, Cl_mic, t1/2, Pgp) and has a significantly better binding affinity. While both have solubility and permeability concerns (indicated by the negative Caco-2 and solubility values), Ligand A's superior profile in other areas makes it the more promising candidate. The substantial difference in binding affinity also outweighs the potential drawbacks of the solubility/permeability issues.
Output:
1
2025-04-17 20:30:08,582 - INFO - Reasoning:
Let's analyze Ligand A and Ligand B for their potential as ADRB2 ligands, keeping in mind the GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key).
**Molecular Weight:** Both ligands (346.43 and 362.50 Da) fall within the ideal 200-500 Da range.
**TPSA:** Ligand A (62.24) is better than Ligand B (67.23), both are below the 140 threshold for oral absorption, but closer to the ideal for GPCRs.
**logP:** Ligand A (1.023) is within the optimal range (1-3), while Ligand B (2.246) is also acceptable, but slightly higher.
**H-Bond Donors/Acceptors:** Both have 1 HBD and 5 HBA, which are reasonable.
**QED:** Ligand A (0.866) has a better QED score than Ligand B (0.788), indicating better overall drug-likeness.
**DILI:** Ligand A (10.702) has a significantly lower DILI risk than Ligand B (54.207). This is a major advantage.
**BBB:** Ligand A (86.468) shows better BBB penetration potential than Ligand B (57.736), though this is less critical for a cardiovascular target.
**Caco-2:** Ligand A (-4.456) and Ligand B (-5.074) both have negative values, indicating poor permeability.
**Solubility:** Ligand A (-1.015) has better solubility than Ligand B (-3.742).
**hERG:** Ligand A (0.72) has a lower hERG risk than Ligand B (0.152).
**Microsomal Clearance:** Ligand A (15.195) has a lower Cl_mic, suggesting better metabolic stability than Ligand B (49.625).
**In vitro Half-Life:** Ligand A (25.046) has a longer half-life than Ligand B (14.245).
**P-gp Efflux:** Ligand A (0.329) has lower P-gp efflux liability than Ligand B (0.141).
**Binding Affinity:** Ligand B (-7.7 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.3 kcal/mol). This is a substantial advantage, exceeding the 1.5 kcal/mol threshold.
**Overall Assessment:**
While Ligand B boasts a superior binding affinity, Ligand A demonstrates a much more favorable safety profile (lower DILI, hERG), better drug-likeness (QED), and improved ADME properties (BBB, solubility, clearance, half-life, P-gp). The difference in binding affinity is significant, but the ADME/Tox profile of Ligand A is substantially better. Given the cardiovascular target, minimizing off-target effects and ensuring reasonable ADME properties are crucial. The improved safety and ADME profile of Ligand A outweigh the affinity difference.
Output:
1
2025-04-17 20:30:08,582 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [416.228, 106.2 , 0.972, 2. , 6. , 0.709, 82.319, 55.874, -4.81 , -2.923, 0.411, 20.719, -8.557, 0.046, -7.1 ]
**Ligand B:** [357.483, 64.34 , 3.876, 1. , 7. , 0.751, 84.335, 69.252, -4.928, -3.806, 0.759, 48.176, 20.024, 0.701, -7.4 ]
**Step-by-step comparison:**
1. **MW:** Ligand A (416.228 Da) is within the ideal range, while Ligand B (357.483 Da) is a bit lower but still acceptable.
2. **TPSA:** Ligand A (106.2) is slightly above the preferred <140 for oral absorption, but still reasonable. Ligand B (64.34) is excellent, well below 140.
3. **logP:** Ligand A (0.972) is a bit low, potentially impacting permeability. Ligand B (3.876) is excellent, falling within the optimal 1-3 range.
4. **HBD:** Both ligands are acceptable (A: 2, B: 1).
5. **HBA:** Both ligands are acceptable (A: 6, B: 7).
6. **QED:** Both ligands are good (A: 0.709, B: 0.751), indicating drug-like properties.
7. **DILI:** Both ligands have relatively high DILI risk (A: 82.319, B: 84.335), which is a concern.
8. **BBB:** Ligand B (69.252) is better than Ligand A (55.874), although neither is exceptionally high. For a cardiovascular target, BBB isn't *critical*, but some penetration could be beneficial for off-target effects or potential CNS side effects.
9. **Caco-2:** Both are negative, indicating poor permeability.
10. **Solubility:** Both are negative, indicating poor solubility.
11. **hERG:** Ligand A (0.411) is better than Ligand B (0.759), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand A (20.719) has lower clearance, suggesting better metabolic stability than Ligand B (48.176).
13. **t1/2:** Ligand B (20.024) has a longer half-life than Ligand A (-8.557), which is desirable.
14. **Pgp:** Ligand A (0.046) has lower P-gp efflux, which is favorable for bioavailability. Ligand B (0.701) has higher efflux.
15. **Affinity:** Ligand B (-7.4) has a slightly better binding affinity than Ligand A (-7.1), but the difference is relatively small.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP and has a slightly better affinity. Ligand A has better Pgp and hERG. Both have poor Caco-2 and solubility. The DILI risk is high for both.
**Overall Assessment:**
While Ligand B has a slightly better affinity and a longer half-life, Ligand A's better metabolic stability (lower Cl_mic), lower P-gp efflux, and lower hERG risk are more compelling. The slightly lower logP of Ligand A is a concern, but could potentially be addressed with further optimization. The higher TPSA of Ligand A is also a drawback, but less critical than the metabolic and efflux properties.
Given these considerations, I believe Ligand A is the more promising candidate.
Output:
1
2025-04-17 20:30:08,582 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (386.583 and 364.921 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (66.48 and 65.04) are below the 140 A^2 threshold for good oral absorption, and are reasonable for a non-CNS GPCR target like ADRB2. No significant difference.
3. **logP:** Both ligands (3.264 and 3.793) are within the optimal 1-3 range. Ligand B is slightly higher, which *could* be a minor concern for solubility, but not a dealbreaker.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Both ligands (4) are within the acceptable limit of 10. No significant difference.
6. **QED:** Both ligands (0.782 and 0.784) have excellent drug-likeness scores, well above the 0.5 threshold. No significant difference.
7. **DILI:** Ligand A (35.983) has a significantly lower DILI risk than Ligand B (13.92). This is a major advantage for Ligand A.
8. **BBB:** While ADRB2 isn't primarily a CNS target, higher BBB penetration isn't detrimental. Ligand A (70.182) is better than Ligand B (45.599).
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand B (-5.363) is slightly worse than Ligand A (-4.987).
10. **Solubility:** Both ligands have negative solubility values, which is also unusual and suggests poor solubility. Ligand B (-3.456) is slightly worse than Ligand A (-3.933).
11. **hERG:** Both ligands (0.824 and 0.718) have low hERG inhibition liability, which is good. Ligand B is slightly better.
12. **Cl_mic:** Ligand B (16.791) has significantly lower microsomal clearance than Ligand A (48.594), indicating better metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand B (59.505) has a much longer in vitro half-life than Ligand A (-21.345). This is a major advantage for Ligand B.
14. **Pgp:** Both ligands (0.421 and 0.26) have low P-gp efflux liability, which is good. Ligand B is slightly better.
15. **Binding Affinity:** Ligand A (-7.4 kcal/mol) has a slightly better binding affinity than Ligand B (-5.3 kcal/mol). This is a substantial advantage for Ligand A. The 2.1 kcal/mol difference is significant enough to potentially outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand A has a better binding affinity and lower DILI risk, but Ligand B has superior metabolic stability (lower Cl_mic), a longer half-life, and slightly better Pgp and hERG profiles. The binding affinity difference is substantial. Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), the stronger binding affinity of Ligand A is a critical factor. While Ligand B's ADME properties are more favorable, the potency advantage of Ligand A is likely to be more impactful in driving efficacy. The DILI risk is also a significant consideration.
Output:
1
2025-04-17 20:30:08,583 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (351.4 & 355.4 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand B (52.65) is significantly better than Ligand A (106.62). ADRB2 is not a CNS target, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (1.901 & 1.34), falling within the 1-3 range. Ligand B is slightly lower, which is acceptable.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1), but both are within the acceptable limit of 5.
5. **HBA:** Ligand A (6) is higher than Ligand B (3), but both are within the acceptable limit of 10.
6. **QED:** Both ligands have reasonable QED scores (0.758 & 0.635), indicating good drug-like properties. Ligand A is slightly better.
7. **DILI:** Ligand B (20.59%) has a much lower DILI risk than Ligand A (64.37%). This is a major advantage for Ligand B.
8. **BBB:** Not a primary concern for ADRB2 (cardiovascular target). Ligand B (88.45%) is higher than Ligand A (64.87%), but this isn't decisive.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.528 & -4.466), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-3.467) has slightly better solubility than Ligand B (-1.675), but both are quite poor.
11. **hERG:** Both ligands have low hERG inhibition liability (0.29 & 0.462), which is good.
12. **Cl_mic:** Ligand B (-6.673) has significantly lower microsomal clearance than Ligand A (81.736), indicating better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand B (-1.07) has a slightly better in vitro half-life than Ligand A (-17.441), but both are negative, indicating very short half-lives.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.036 & 0.025), which is favorable.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-5.8 & -5.6 kcal/mol). The difference is not substantial enough to be a deciding factor.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are important. Ligand B excels in TPSA and has comparable logP and affinity. The significantly lower DILI and Cl_mic for Ligand B are crucial advantages for overall drug development potential. While both have poor Caco-2 permeability, the other benefits of Ligand B outweigh this drawback.
**Conclusion:**
Ligand B demonstrates a more favorable balance of properties, particularly regarding safety (DILI) and metabolic stability (Cl_mic). While both have permeability issues, the other advantages of Ligand B make it the more promising candidate.
Output:
0
2025-04-17 20:30:08,583 - INFO - Batch 189 complete. Total preferences: 3024
2025-04-17 20:30:08,583 - INFO - Processing batch 190/512...
2025-04-17 20:30:57,381 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (368.415 and 351.451 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (116.88) is higher than Ligand B (72.72). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B is significantly better here.
3. **logP:** Ligand A (1.029) is slightly higher than Ligand B (0.435), both within the optimal 1-3 range. Ligand A is preferable.
4. **HBD:** Ligand A (1) is better than Ligand B (0). Fewer HBDs generally improve permeability.
5. **HBA:** Both ligands have 7 HBA, which is acceptable.
6. **QED:** Ligand B (0.71) has a slightly better QED score than Ligand A (0.627), indicating a more drug-like profile.
7. **DILI:** Ligand B (26.871) has a significantly lower DILI risk than Ligand A (55.293). This is a major advantage for Ligand B.
8. **BBB:** Both ligands have similar BBB penetration (65.025 and 67.313). Since ADRB2 is not a CNS target, this is not a major factor.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. This is a concern for both.
10. **Solubility:** Ligand B (0.034) has slightly better solubility than Ligand A (-2.406), but both are very poor.
11. **hERG:** Ligand A (0.076) has a lower hERG risk than Ligand B (0.223). This is a positive for Ligand A.
12. **Cl_mic:** Ligand A (7.569) has a significantly lower microsomal clearance than Ligand B (18.44), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand B (8.296) has a longer in vitro half-life than Ligand A (2.578). This is a positive for Ligand B.
14. **Pgp:** Ligand A (0.022) has a lower P-gp efflux liability than Ligand B (0.044). This is a positive for Ligand A.
15. **Binding Affinity:** Ligand B (-7.1 kcal/mol) has a 1.0 kcal/mol stronger binding affinity than Ligand A (-6.1 kcal/mol). This is a substantial advantage, and often outweighs minor ADME concerns.
**Overall Assessment:**
Ligand B has a significantly better binding affinity and lower DILI risk. While its solubility and Caco-2 permeability are poor, the strong binding affinity is a major driver. Ligand A has better metabolic stability and lower P-gp efflux, but the binding affinity is considerably weaker. Considering the GPCR-specific priorities (affinity being paramount), the stronger binding of Ligand B outweighs its other shortcomings, especially given the low DILI risk.
Output:
0
2025-04-17 20:30:57,382 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's break down the comparison of Ligand A and Ligand B based on the provided parameters and the guidelines, keeping in mind ADRB2 is a GPCR.
1. **Molecular Weight:** Both ligands (349.475 and 344.459 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (69.72) is better than Ligand B (75.19). Both are below 140, but lower TPSA generally favors better absorption.
3. **logP:** Ligand B (2.27) is slightly higher than Ligand A (1.564), both are within the optimal 1-3 range.
4. **H-Bond Donors:** Both ligands have 1 HBD, which is good.
5. **H-Bond Acceptors:** Ligand A has 3 HBA, while Ligand B has 4. Both are acceptable, but lower is generally preferred.
6. **QED:** Ligand B (0.859) has a better QED score than Ligand A (0.621), indicating a more drug-like profile.
7. **DILI:** Ligand A (27.142) has a significantly lower DILI risk than Ligand B (51.144). This is a major advantage for Ligand A.
8. **BBB:** Both ligands have good BBB penetration (Ligand A: 74.486, Ligand B: 78.79). The difference is minimal.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual. I will assume these are percentile scores, and higher is better. Ligand B (-4.897) is slightly better than Ligand A (-1.977).
10. **Solubility:** Ligand A (-1.977) is better than Ligand B (-3.216). Higher solubility is generally preferred.
11. **hERG:** Ligand A (0.087) has a lower hERG risk than Ligand B (0.23). This is a significant advantage.
12. **Cl_mic:** Ligand B (31.229) has a slightly higher microsomal clearance than Ligand A (29.253). Lower is better for metabolic stability.
13. **t1/2:** Ligand A (-14.394) has a longer in vitro half-life than Ligand B (-5.88). This is a significant advantage.
14. **Pgp:** Ligand A (0.014) has much lower P-gp efflux liability than Ligand B (0.142). This is a major advantage, improving bioavailability.
15. **Binding Affinity:** Ligand B (-5.4) has a significantly higher binding affinity than Ligand A (-1.7). This is a substantial advantage that could outweigh some ADME concerns.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand B has a better logP and significantly better affinity. However, Ligand A excels in DILI risk, hERG inhibition, P-gp efflux, and in vitro half-life. The large difference in binding affinity (-5.4 vs -1.7) is a strong driver, and the slightly better logP of Ligand B also helps. While Ligand A has better ADME properties overall, the potency advantage of Ligand B is substantial.
**Conclusion:**
Despite the better ADME profile of Ligand A, the significantly improved binding affinity of Ligand B (-5.4 kcal/mol vs -1.7 kcal/mol) is a critical advantage for a GPCR target. This potency difference is likely to outweigh the minor ADME drawbacks of Ligand B.
**Output:**
0
2025-04-17 20:30:57,382 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [357.405, 88.91, 1.409, 2, 5, 0.736, 49.205, 72.237, -4.726, -2.529, 0.092, 24.817, -26.839, 0.028, -6.9]
**Ligand B:** [356.413, 67.43, 1.861, 2, 3, 0.714, 46.064, 78.48, -4.601, -2.451, 0.409, 26.358, -29.31, 0.062, -7.3]
Here's a breakdown, considering the provided guidelines and GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both ligands are within the ideal range (356-357 Da). No significant difference.
2. **TPSA:** Ligand A (88.91) is slightly higher than Ligand B (67.43). Ligand B is better here, being closer to the preferred <90 for GPCRs.
3. **logP:** Ligand A (1.409) and Ligand B (1.861) are both within the optimal 1-3 range. Ligand B is slightly better.
4. **HBD:** Both have 2 HBD, which is good.
5. **HBA:** Ligand A has 5 HBA, Ligand B has 3. Ligand B is better.
6. **QED:** Both are good (0.736 and 0.714), indicating drug-like properties.
7. **DILI:** Both have acceptable DILI risk (49.205 and 46.064). Ligand B is marginally better.
8. **BBB:** Ligand B (78.48) has a higher BBB penetration percentile than Ligand A (72.237). This is a positive for GPCRs, though less critical for cardiovascular targets.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-4.726) is worse than Ligand B (-4.601).
10. **Solubility:** Both are negative, indicating poor solubility. Ligand A (-2.529) is worse than Ligand B (-2.451).
11. **hERG:** Both have very low hERG risk (0.092 and 0.409). Ligand A is better.
12. **Cl_mic:** Ligand A (24.817) has lower microsomal clearance than Ligand B (26.358), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-29.31) has a longer in vitro half-life than Ligand A (-26.839). This is a significant advantage.
14. **Pgp:** Ligand A (0.028) has lower P-gp efflux than Ligand B (0.062), which is favorable.
15. **Affinity:** Ligand B (-7.3 kcal/mol) has a stronger binding affinity than Ligand A (-6.9 kcal/mol). This is a crucial advantage, exceeding the 1.5 kcal/mol threshold.
**Overall Assessment:**
While Ligand A has slightly better hERG and Pgp profiles, Ligand B consistently outperforms it in key areas for a GPCR drug candidate. The stronger binding affinity (-7.3 vs -6.9 kcal/mol) is the most significant factor. The better TPSA, lower HBA, slightly better DILI, higher BBB, and longer half-life also contribute to its superior profile. The Caco-2 and solubility are poor for both, but similar.
Therefore, I would choose Ligand B.
0
2025-04-17 20:30:57,382 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (360.53 & 367.52 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (52.49) is significantly better than Ligand B (80.32). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands (2.77 & 2.68) are within the optimal 1-3 range. Very similar.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (6) is preferable to Ligand B (5). Both are acceptable, but lower is slightly better.
6. **QED:** Ligand A (0.909) is significantly better than Ligand B (0.74). Higher QED indicates a more drug-like profile.
7. **DILI:** Ligand B (52.97) is better than Ligand A (60.45), both are acceptable, but lower is better.
8. **BBB:** Ligand A (90.62) is much better than Ligand B (49.24). While not a primary concern for a cardiovascular target, higher BBB is generally favorable.
9. **Caco-2:** Both ligands have similar, very negative Caco-2 values (-4.914 & -4.851). This suggests poor permeability, which is a concern for both.
10. **Solubility:** Both ligands have similar, very negative solubility values (-2.426 & -2.761). This suggests poor solubility, which is a concern for both.
11. **hERG:** Ligand A (0.887) is slightly higher than Ligand B (0.173), indicating a higher hERG risk. This is a significant negative for Ligand A.
12. **Cl_mic:** Ligand A (14.74) has a much lower microsomal clearance than Ligand B (30.66). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (63.04) has a significantly longer in vitro half-life than Ligand B (20.22). This is a major advantage for Ligand A.
14. **Pgp:** Ligand A (0.61) is better than Ligand B (0.124), indicating lower P-gp efflux.
15. **Binding Affinity:** Ligand B (-7.1 kcal/mol) has a 0.4 kcal/mol stronger binding affinity than Ligand A (-6.7 kcal/mol). This is a substantial advantage for Ligand B.
**Overall Assessment:**
Ligand B has a slightly better binding affinity and a lower DILI risk. However, Ligand A excels in several key ADME properties: QED, TPSA, BBB, Cl_mic, t1/2, and Pgp. The longer half-life and better metabolic stability of Ligand A are particularly attractive. The hERG risk is a concern with Ligand A, but the difference in binding affinity is not large enough to outweigh the ADME advantages. The poor Caco-2 and solubility are concerning for both, but can be addressed with formulation strategies.
Given the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), and the balance of properties, Ligand A is the more promising candidate.
Output:
1
2025-04-17 20:30:57,382 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (362.43 & 349.43 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (67.43) is better than Ligand B (75.88). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally favors absorption.
3. **logP:** Ligand B (1.582) is significantly better than Ligand A (4.433). Ligand A's logP is quite high, potentially leading to solubility issues and off-target interactions. This is a significant concern.
4. **HBD:** Ligand A (2) is slightly better than Ligand B (0). While both are acceptable, a small number of HBDs can aid permeability.
5. **HBA:** Ligand B (5) is better than Ligand A (4). Both are within the acceptable range.
6. **QED:** Ligand B (0.825) is better than Ligand A (0.589). Higher QED suggests a more drug-like profile.
7. **DILI:** Ligand B (42.613) is *much* better than Ligand A (85.653). Ligand A's DILI risk is high, a major red flag.
8. **BBB:** Ligand B (78.79) is better than Ligand A (68.36). While not critical for a cardiovascular target, higher BBB is generally favorable.
9. **Caco-2:** Ligand A (-4.7) is better than Ligand B (-4.337). Both are negative, indicating poor permeability, but A is slightly less poor.
10. **Solubility:** Ligand A (-5.669) is better than Ligand B (-2.153). This is a crucial point. Ligand A has better solubility, which could mitigate some of its high logP concerns.
11. **hERG:** Ligand B (0.183) is *much* better than Ligand A (0.543). Ligand A has a concerning hERG risk.
12. **Cl_mic:** Ligand B (45.516) is better than Ligand A (121.459). Lower clearance indicates better metabolic stability.
13. **t1/2:** Ligand A (43.494) is better than Ligand B (13.527). A longer half-life is generally preferred.
14. **Pgp:** Ligand B (0.188) is better than Ligand A (0.394). Lower Pgp efflux is desirable.
15. **Affinity:** Ligand A (-7.1) is significantly better than Ligand B (-4.5). This is a substantial difference in binding potency (2.6 kcal/mol).
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A has a very high logP, which is a significant drawback. However, its binding affinity is *much* stronger. The DILI and hERG risks associated with Ligand A are also concerning. Ligand B has a better overall ADME profile, particularly regarding safety (DILI, hERG) and metabolic stability (Cl_mic).
**Overall Assessment:**
While Ligand A boasts a superior binding affinity, the combination of its high logP, elevated DILI risk, and hERG inhibition liability makes it a less attractive candidate. The 2.6 kcal/mol affinity difference, while substantial, may be overcome with further optimization of Ligand B. Ligand B's better ADME properties and safety profile give it a higher probability of success as a drug candidate.
Output:
0
2025-04-17 20:30:57,382 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Ligand A (356.411 Da) is within the ideal range (200-500 Da). Ligand B (277.195 Da) is also within range, but closer to the lower limit.
2. **TPSA:** Ligand A (92.49) is acceptable, though approaching the upper limit for good oral absorption. Ligand B (58.28) is excellent, well below the 140 threshold.
3. **logP:** Ligand A (1.107) is optimal. Ligand B (2.997) is also good, within the preferred 1-3 range.
4. **HBD:** Ligand A (1) is good. Ligand B (3) is acceptable, but higher.
5. **HBA:** Ligand A (7) is good. Ligand B (3) is excellent.
6. **QED:** Both Ligand A (0.756) and Ligand B (0.744) are very good, indicating strong drug-like properties.
7. **DILI:** Ligand A (89.841) has a concerningly high DILI risk. Ligand B (11.167) has a very low DILI risk, a significant advantage.
8. **BBB:** Ligand A (39.511) has low BBB penetration. Ligand B (51.803) has moderate BBB penetration. While ADRB2 isn't exclusively a CNS target, some CNS exposure can be beneficial or at least not detrimental.
9. **Caco-2:** Ligand A (-5.358) is poor. Ligand B (-4.857) is also poor, but slightly better.
10. **Solubility:** Both Ligand A (-3.067) and Ligand B (-2.787) have poor aqueous solubility.
11. **hERG:** Ligand A (0.111) has a very low hERG risk. Ligand B (0.501) has a slightly elevated, but still acceptable, hERG risk.
12. **Cl_mic:** Ligand A (25.885) has moderate metabolic clearance. Ligand B (-6.474) has negative clearance, indicating very high metabolic stability, a major advantage.
13. **t1/2:** Ligand A (3.144) has a short half-life. Ligand B (57.581) has a very long half-life, a significant advantage.
14. **Pgp:** Ligand A (0.035) has low P-gp efflux. Ligand B (0.013) has very low P-gp efflux, a slight advantage.
15. **Affinity:** Ligand A (-8.5 kcal/mol) has slightly better binding affinity than Ligand B (-7.7 kcal/mol). This is a 0.8 kcal/mol difference.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A has better logP and affinity, while Ligand B has better TPSA and Pgp. However, the significant advantages of Ligand B in terms of DILI risk, metabolic stability (Cl_mic and t1/2) outweigh the slightly better affinity of Ligand A. The poor Caco-2 and solubility of both are concerning, but can be addressed with formulation strategies. The high DILI risk of Ligand A is a major red flag.
**Conclusion:**
Ligand B is the more promising drug candidate due to its significantly improved safety profile (low DILI), excellent metabolic stability (negative Cl_mic, long t1/2), and favorable Pgp efflux. The slightly weaker affinity is a trade-off worth making given these substantial ADME/Tox benefits.
0
2025-04-17 20:30:57,382 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [370.797, 137.3 , 0.097, 3. , 8. , 0.532, 63.009, 74.952, -5.849, -2.738, 0.344, 19.168, 22.994, 0.096, -7.5 ]
**Ligand B:** [349.435, 115.98 , 0.27 , 4. , 4. , 0.485, 16.596, 45.522, -5.683, -1.501, 0.112, -1.052, -30.512, 0.005, -6.4 ]
Here's a breakdown of the comparison, considering GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (349.435) is slightly lower, which is generally favorable.
2. **TPSA:** Ligand A (137.3) is close to the upper limit for good oral absorption, while Ligand B (115.98) is well below. This favors Ligand B.
3. **logP:** Ligand A (0.097) is quite low, potentially hindering membrane permeability. Ligand B (0.27) is also low, but better than A. Both are suboptimal, but not drastically so.
4. **HBD:** Ligand A (3) is good. Ligand B (4) is acceptable.
5. **HBA:** Ligand A (8) is good. Ligand B (4) is excellent.
6. **QED:** Ligand A (0.532) is slightly better than Ligand B (0.485), indicating a marginally more drug-like profile.
7. **DILI:** Ligand A (63.009) has a higher DILI risk than Ligand B (16.596). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (74.952) has better BBB penetration than Ligand B (45.522), which is a plus, although ADRB2 isn't necessarily a CNS target.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability.
10. **Solubility:** Both have negative solubility values, which is also unusual and suggests poor solubility.
11. **hERG:** Both have low hERG inhibition risk, which is good.
12. **Cl_mic:** Ligand A (19.168) has a higher microsomal clearance than Ligand B (-1.052), meaning it's likely to be metabolized more quickly. This favors Ligand B.
13. **t1/2:** Ligand A (22.994) has a longer in vitro half-life than Ligand B (-30.512), which is a positive.
14. **Pgp:** Ligand A (0.096) has slightly lower P-gp efflux liability than Ligand B (0.005), which is a slight advantage.
15. **Affinity:** Ligand A (-7.5) has a stronger binding affinity than Ligand B (-6.4). This is a substantial advantage for Ligand A.
**Overall Assessment:**
The key trade-off is between affinity (Ligand A) and ADME properties (Ligand B). Ligand A has significantly better binding affinity, which is crucial for a GPCR ligand. However, Ligand B has a much better safety profile (lower DILI), better metabolic stability (lower Cl_mic), and better TPSA. The logP values are suboptimal for both, and the negative Caco-2 and solubility values are concerning.
Given the importance of potency for GPCRs, and the relatively modest differences in other parameters, the stronger binding affinity of Ligand A outweighs its slightly worse ADME profile. The difference in affinity (-7.5 vs -6.4) is a 1.1 kcal/mol difference, which is significant.
Output:
1
2025-04-17 20:30:57,382 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.399 and 347.459 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (71.45) is better than Ligand B (75.44), both are under the 140 threshold for oral absorption.
3. **logP:** Ligand A (3.509) is slightly higher than Ligand B (2.317), but both are within the optimal 1-3 range. Ligand A is approaching the upper limit, but not concerningly so.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1), both are within the acceptable limit of 5.
5. **HBA:** Ligand A (5) is slightly higher than Ligand B (4), both are within the acceptable limit of 10.
6. **QED:** Both ligands have good QED scores (0.709 and 0.821, respectively), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (92.206) has a significantly higher DILI risk than Ligand B (18.496). This is a major concern for Ligand A.
8. **BBB:** Ligand B (78.402) has a better BBB penetration percentile than Ligand A (44.126). While ADRB2 isn't *strictly* a CNS target, some peripheral ADRB2 activity can influence CNS pathways, and better BBB penetration isn't necessarily a negative.
9. **Caco-2:** Both ligands have similar, poor Caco-2 permeability (-4.899 and -4.868). This suggests potential absorption issues for both.
10. **Solubility:** Ligand B (-2.439) has better aqueous solubility than Ligand A (-5.755). Solubility is important for formulation and bioavailability.
11. **hERG:** Ligand A (0.566) has a slightly higher hERG inhibition liability than Ligand B (0.286), but both are relatively low risk.
12. **Cl_mic:** Ligand B (58.011) has a lower microsomal clearance than Ligand A (73.544), indicating better metabolic stability.
13. **t1/2:** Ligand B (-7.93) has a longer in vitro half-life than Ligand A (-30.819). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.615) has a higher P-gp efflux liability than Ligand B (0.104). Lower P-gp efflux is preferred.
15. **Binding Affinity:** Ligand A (-7.5) has a slightly better binding affinity than Ligand B (-5.7). However, the difference is not large enough to overcome the other significant drawbacks of Ligand A.
**GPCR-specific priorities:** logP, Pgp, TPSA, and affinity are important for GPCRs. Ligand B is better on Pgp, TPSA, and has acceptable logP and affinity.
**Overall Assessment:**
Ligand A has a slightly better binding affinity, but it's overshadowed by its significantly higher DILI risk, poorer metabolic stability (higher Cl_mic, shorter t1/2), higher P-gp efflux, and lower BBB penetration. Ligand B presents a much more balanced profile with lower toxicity risk, better metabolic properties, and improved permeability characteristics.
Output:
0
2025-04-17 20:30:57,383 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.463 and 345.355 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (89.27) is excellent, well below the 140 threshold and favorable for oral absorption. Ligand B (126.8) is still acceptable but less optimal, creeping closer to the upper limit.
3. **logP:** Ligand A (1.766) is within the optimal 1-3 range. Ligand B (-0.463) is slightly below 1, which *could* indicate potential permeability issues, although not drastically.
4. **HBD:** Ligand A (2) and Ligand B (3) are both acceptable, being less than 5.
5. **HBA:** Both ligands (6) are within the acceptable range of less than 10.
6. **QED:** Ligand A (0.816) has a superior QED score compared to Ligand B (0.62), indicating a more drug-like profile.
7. **DILI:** Ligand A (36.293) has a better DILI percentile than Ligand B (47.693), suggesting a lower risk of liver injury.
8. **BBB:** Ligand A (64.87) has a significantly better BBB percentile than Ligand B (11.439). While ADRB2 isn't exclusively a CNS target, some cardiovascular effects are mediated by central pathways, and better BBB penetration isn't necessarily detrimental.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.741 and -4.962), which is unusual and suggests poor permeability. However, these values are on a scale where negative values are possible, and the difference between them is minimal.
10. **Solubility:** Ligand A (-3.307) has slightly better solubility than Ligand B (-1.939).
11. **hERG:** Both ligands have very low hERG inhibition risk (0.247 and 0.296).
12. **Cl_mic:** Ligand A (38.889) has a higher microsomal clearance than Ligand B (-17.329). This suggests that Ligand B is more metabolically stable, which is a significant advantage.
13. **t1/2:** Ligand A (25.256) has a longer in vitro half-life than Ligand B (13.928).
14. **Pgp:** Both ligands have low P-gp efflux liability (0.103 and 0.043).
15. **Binding Affinity:** Ligand A (-7.9 kcal/mol) has a substantially stronger binding affinity than Ligand B (-4.9 kcal/mol). This difference of 3 kcal/mol is a major advantage, potentially outweighing some ADME concerns.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A excels in affinity and TPSA. While Ligand B has better metabolic stability (Cl_mic), the significantly stronger binding of Ligand A, coupled with its better TPSA, QED, DILI, and BBB, makes it the more promising candidate. The slightly lower logP of Ligand B is a concern, and the difference in affinity is substantial.
**Final Decision:**
Ligand A is the better candidate.
Output:
1
2025-04-17 20:30:57,383 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (364.45 and 347.39 Da). No clear advantage.
2. **TPSA:** Ligand A (67.35) is significantly better than Ligand B (91.22). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally improves absorption.
3. **logP:** Both are good (3.351 and 2.463), falling within the optimal 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (4). Lower HBA generally improves permeability.
6. **QED:** Both are very similar and good (0.854 and 0.827). No significant difference.
7. **DILI:** Ligand B (53.781) is better than Ligand A (69.678). Lower DILI is always preferred.
8. **BBB:** Ligand A (80.729) is better than Ligand B (72.237). While not a CNS target, some level of BBB penetration can indicate favorable distribution properties.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-4.738) is slightly better (less negative) than Ligand B (-4.468).
10. **Solubility:** Both are negative, indicating poor solubility. Ligand A (-4.509) is slightly better (less negative) than Ligand B (-4.076).
11. **hERG:** Both are very low (0.367 and 0.524), indicating very low risk of hERG inhibition. No clear advantage.
12. **Cl_mic:** Ligand A (47.999) is better than Ligand B (55.153). Lower clearance is preferable for metabolic stability.
13. **t1/2:** Ligand B (-0.23) is far better than Ligand A (-16.068). A longer half-life is highly desirable.
14. **Pgp:** Ligand A (0.345) is better than Ligand B (0.117). Lower P-gp efflux is preferable.
15. **Affinity:** Ligand B (-7.6) is better than Ligand A (-8.7). This is a significant difference (1.1 kcal/mol), and affinity is a primary driver for GPCR drug candidates.
**Overall Assessment:**
Ligand B has a significantly better binding affinity (-7.6 kcal/mol vs -8.7 kcal/mol). This is a substantial advantage for a GPCR target like ADRB2. While Ligand A has some advantages in TPSA, Cl_mic, and Pgp, the improved half-life of Ligand B is also a significant benefit. The slightly higher DILI risk for Ligand A is a concern, but the strong binding affinity of Ligand B outweighs these drawbacks. The Caco-2 and solubility are poor for both, but this can be addressed with formulation strategies.
Output:
0
2025-04-17 20:30:57,383 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (351.451 and 347.459 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (88.49) is better than Ligand B (91.32). Both are below the 140 threshold for oral absorption, but closer to the 90 threshold is preferable, and A is closer.
3. **logP:** Ligand A (-0.04) is slightly better than Ligand B (1.434), being closer to the optimal 1-3 range. Ligand B is pushing the upper limit, which could lead to solubility issues.
4. **HBD:** Ligand A (2) is preferable to Ligand B (3). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (6) is preferable to Ligand B (4). Lower HBA generally improves permeability.
6. **QED:** Both ligands have similar QED values (0.652 and 0.63), indicating good drug-likeness.
7. **DILI:** Ligand A (15.2) is significantly better than Ligand B (18.883), indicating a lower risk of drug-induced liver injury. This is a crucial advantage.
8. **BBB:** Ligand A (66.344) is better than Ligand B (45.25). While ADRB2 isn't necessarily a CNS target, some peripheral ADRB2 activity can influence CNS pathways, and higher BBB penetration is generally a plus.
9. **Caco-2:** Ligand A (-5.192) is better than Ligand B (-4.996). Higher Caco-2 permeability is desirable, and A has a slightly better value.
10. **Solubility:** Ligand A (-1.086) is better than Ligand B (-1.783). Higher solubility is important for bioavailability.
11. **hERG:** Both ligands have low hERG inhibition risk (0.093 and 0.184). No significant difference.
12. **Cl_mic:** Both ligands have similar microsomal clearance (19.254 and 18.856 mL/min/kg).
13. **t1/2:** Ligand A (11.711) is much better than Ligand B (2.845). A longer half-life is desirable for less frequent dosing.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.003 and 0.016). No significant difference.
15. **Binding Affinity:** Ligand A (-8.4 kcal/mol) is significantly better than Ligand B (-7.1 kcal/mol). This 1.3 kcal/mol difference is substantial and can outweigh minor ADME drawbacks.
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A performs better across these parameters. The significantly higher affinity of Ligand A is a major advantage. The lower DILI risk and longer half-life are also important benefits.
**Conclusion:**
Ligand A is the superior candidate due to its significantly better binding affinity, lower DILI risk, longer half-life, and more favorable physicochemical properties (TPSA, logP, solubility).
Output:
1
2025-04-17 20:30:57,383 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (338.451) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (42.43) is significantly better than Ligand B (71.11). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (4.049) is at the upper end of the optimal range, while Ligand B (0.259) is quite low. A logP too low can hinder membrane permeability. Ligand A is much preferred here.
4. **HBD:** Both ligands are acceptable, with Ligand A having 0 and Ligand B having 1.
5. **HBA:** Both ligands are acceptable, with Ligand A having 4 and Ligand B having 5.
6. **QED:** Both ligands have similar, good QED values (0.772 and 0.787).
7. **DILI:** Ligand A (23.187) has a significantly lower DILI risk than Ligand B (11.245). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (75.843) has a better BBB penetration score than Ligand B (65.839), though this isn't a critical factor for a cardiovascular target.
9. **Caco-2:** Ligand A (-4.898) and Ligand B (-5.208) are similar, indicating similar intestinal absorption potential.
10. **Solubility:** Ligand A (-3.936) is better than Ligand B (-1.32). Better solubility is generally desirable.
11. **hERG:** Ligand A (0.879) has a lower hERG risk than Ligand B (0.24). This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand B (-25.297) has a much lower microsomal clearance than Ligand A (81.185), indicating better metabolic stability. This is a strong point for Ligand B.
13. **t1/2:** Ligand B (11.599) has a longer in vitro half-life than Ligand A (-10.453). This is a strong point for Ligand B.
14. **Pgp:** Ligand A (0.524) has a lower P-gp efflux liability than Ligand B (0.006). Lower efflux is generally preferred.
15. **Binding Affinity:** Ligand A (-7.1) has a slightly better binding affinity than Ligand B (-6.6). While the difference isn't huge, it's still a positive for Ligand A.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A excels in logP, TPSA, and Pgp, and has slightly better affinity. Ligand B has better metabolic stability (Cl_mic and t1/2). However, the significantly lower DILI and hERG risk of Ligand A, combined with its better logP and TPSA, outweigh the metabolic advantages of Ligand B.
**Conclusion:**
Ligand A presents a more balanced and favorable profile overall, particularly regarding safety (DILI, hERG) and key ADME properties for a GPCR target.
Output:
1
2025-04-17 20:30:57,383 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (366.49 and 352.48 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (67.67) is significantly better than Ligand B (85.37). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is getting a bit high.
3. **logP:** Ligand B (2.633) is slightly higher than Ligand A (1.119), but both are within the optimal 1-3 range. Ligand B is closer to the upper limit.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Both ligands have 6 HBA, which is acceptable.
6. **QED:** Ligand A (0.799) has a better QED score than Ligand B (0.673), indicating a more drug-like profile.
7. **DILI:** Ligand B (34.781) has a slightly lower DILI risk than Ligand A (44.591), which is a positive.
8. **BBB:** Both ligands have reasonable BBB penetration (Ligand A: 63.94, Ligand B: 69.639). Since ADRB2 is a cardiovascular target, BBB penetration is not a high priority, but higher is still slightly preferred.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.895) is slightly better than Ligand B (-4.731), but both are concerning.
10. **Solubility:** Both ligands have negative solubility values, which is also concerning. Ligand A (-2.256) is slightly better than Ligand B (-3.266).
11. **hERG:** Ligand A (0.122) has a much lower hERG risk than Ligand B (0.372). This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand A (35.263) has a lower microsomal clearance than Ligand B (79.392), suggesting better metabolic stability.
13. **t1/2:** Ligand B (4.602) has a longer in vitro half-life than Ligand A (2.12), which is a positive.
14. **Pgp:** Both ligands have low Pgp efflux liability (Ligand A: 0.046, Ligand B: 0.037).
15. **Affinity:** Ligand A (-6.8 kcal/mol) has a slightly better binding affinity than Ligand B (-6.6 kcal/mol). While the difference is small, it's still a factor.
**Overall Assessment:**
Ligand A is the stronger candidate. While Ligand B has a slightly lower DILI risk and longer half-life, Ligand A excels in several crucial areas: lower TPSA, better QED, significantly lower hERG risk, and lower microsomal clearance. The slightly better affinity of Ligand A further supports its selection. The negative Caco-2 and solubility values are concerning for both, but Ligand A is marginally better in these aspects. Given the GPCR target class, the balance of properties in Ligand A is more favorable.
Output:
1
2025-04-17 20:30:57,383 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (356.463 and 350.503 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (99.1) is higher than Ligand B (67.43). While both are below 140, the lower TPSA of Ligand B is preferable for oral absorption, a key consideration for a cardiovascular drug.
3. **logP:** Ligand B (2.781) is within the optimal 1-3 range. Ligand A (0.146) is significantly *below* this range, potentially hindering membrane permeability. This is a major drawback for Ligand A.
4. **HBD:** Ligand A (3) and Ligand B (2) are both acceptable, below the threshold of 5.
5. **HBA:** Ligand A (5) and Ligand B (3) are both acceptable, below the threshold of 10.
6. **QED:** Ligand B (0.801) has a significantly better QED score than Ligand A (0.484), indicating a more drug-like profile.
7. **DILI:** Ligand B (39.938) has a slightly higher DILI risk than Ligand A (11.361), but both are below the concerning threshold of 60. This is a minor advantage for Ligand A, but not decisive.
8. **BBB:** Ligand B (71.035) has a higher BBB penetration percentile than Ligand A (36.371). While ADRB2 isn't a CNS target, some peripheral distribution is still desirable, and higher BBB generally correlates with better overall permeability.
9. **Caco-2:** Both ligands have similar, very negative Caco-2 values (-4.842 and -4.835). This is concerning for both, suggesting poor intestinal absorption.
10. **Solubility:** Ligand A (-1.52) has better aqueous solubility than Ligand B (-3.941). This is a positive for Ligand A.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.183 and 0.197). No significant difference.
12. **Cl_mic:** Ligand B (63.365) has a lower microsomal clearance than Ligand A (39.627), indicating better metabolic stability.
13. **t1/2:** Ligand B (7.167 hours) has a significantly longer in vitro half-life than Ligand A (0.765 hours). This is a major advantage for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have similar, low Pgp efflux liability (0.08 and 0.156).
15. **Binding Affinity:** Ligand A (-7.8 kcal/mol) has a stronger binding affinity than Ligand B (-6.4 kcal/mol). This is a substantial advantage for Ligand A, exceeding the 1.5 kcal/mol threshold.
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, TPSA, and affinity are particularly important. Ligand A's significantly lower logP is a major concern, likely hindering its ability to reach the receptor. While its affinity is better, the poor logP and resulting permeability issues are likely to negate that benefit *in vivo*. Ligand B, while having slightly weaker affinity, has a much better logP, TPSA, QED, metabolic stability, and half-life.
**Conclusion:**
Despite the stronger binding affinity of Ligand A, its significantly lower logP and overall less favorable ADME profile make it less likely to be a viable drug candidate. Ligand B presents a more balanced profile with better permeability characteristics and drug-likeness.
Output:
0
2025-04-17 20:30:57,383 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (367.49 and 348.49 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (62.3) is slightly higher than Ligand B (58.64). Both are well below the 140 threshold for oral absorption, and acceptable for a cardiovascular target (not needing significant BBB penetration). Ligand B is slightly preferred.
3. **logP:** Both ligands have a logP around 2.49, which is optimal (1-3). No clear advantage.
4. **HBD:** Both have 1 HBD, which is within the acceptable limit of 5. No clear advantage.
5. **HBA:** Ligand A has 4 HBAs, while Ligand B has 3. Both are below the 10 limit. Ligand B is slightly preferred.
6. **QED:** Ligand A (0.805) has a better QED score than Ligand B (0.769), indicating a more drug-like profile. Ligand A is preferred.
7. **DILI:** Ligand A (36.57%) has a significantly higher DILI risk than Ligand B (6.75%). This is a major concern, and favors Ligand B.
8. **BBB:** Ligand A (83.83%) has better BBB penetration than Ligand B (77.90%). While ADRB2 is primarily a cardiovascular target, some CNS side effects are possible with adrenergic drugs, so moderate BBB penetration isn't necessarily detrimental.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the values are very close (-4.854 vs -4.767), so this isn't a major differentiator.
10. **Solubility:** Both ligands have negative solubility values, which is also unusual and suggests poor solubility. Again, the values are very close (-2.796 vs -2.211), so this isn't a major differentiator.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.383 and 0.368), which is excellent. No clear advantage.
12. **Cl_mic:** Ligand A (36.14) has a higher microsomal clearance than Ligand B (20.04), indicating faster metabolism and potentially lower *in vivo* exposure. Ligand B is preferred.
13. **t1/2:** Ligand A (-12.24) has a negative in vitro half-life, which is highly problematic. Ligand B (-2.25) is also not ideal, but significantly better. This is a major advantage for Ligand B.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.316 and 0.062), which is good. Ligand B is slightly preferred.
15. **Binding Affinity:** Ligand A (-7.1 kcal/mol) has a slightly better binding affinity than Ligand B (-6.9 kcal/mol). This is a 0.2 kcal/mol difference, which is not a huge advantage, but still relevant.
**Overall Assessment:**
While Ligand A has a slightly better QED and binding affinity, the significantly higher DILI risk and extremely poor in vitro half-life are major red flags. Ligand B has a much more favorable safety profile (lower DILI), better metabolic stability (lower Cl_mic, better t1/2), and comparable ADME properties. The slight advantage in binding affinity of Ligand A is not enough to overcome these significant drawbacks. Given the GPCR-specific priorities, and the importance of balancing ADME properties, Ligand B is the more promising candidate.
Output:
0
2025-04-17 20:30:57,383 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.435 and 376.523 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (112.65) is better than Ligand B (121.6), being closer to the <140 threshold for good oral absorption.
3. **logP:** Ligand A (0.532) is slightly better than Ligand B (0.371), both are a bit low, but acceptable.
4. **HBD:** Ligand A (2) is preferable to Ligand B (3). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (6) is preferable to Ligand B (4). Lower HBA generally improves permeability.
6. **QED:** Ligand A (0.775) is significantly better than Ligand B (0.477), indicating a more drug-like profile.
7. **DILI:** Both ligands have low DILI risk (34.354 and 33.695 percentile), which is good.
8. **BBB:** Ligand A (68.554) is better than Ligand B (43.815), although neither is exceptionally high. For a cardiovascular target, BBB penetration isn't *critical*, but some level is beneficial for potential off-target effects and distribution.
9. **Caco-2:** Ligand A (-5.034) is better than Ligand B (-5.38). Higher values indicate better absorption.
10. **Solubility:** Ligand A (-1.485) is better than Ligand B (-1.785).
11. **hERG:** Both ligands have very low hERG risk (0.487 and 0.219), which is excellent.
12. **Cl_mic:** Ligand A (1.604) is *much* better than Ligand B (40.419). Lower clearance indicates greater metabolic stability, a crucial factor for drug duration.
13. **t1/2:** Ligand A (-3.254) is better than Ligand B (-7.543). Longer half-life is desirable.
14. **Pgp:** Ligand A (0.011) is better than Ligand B (0.006). Lower efflux is preferable.
15. **Binding Affinity:** Ligand B (-6.3) is slightly better than Ligand A (-5.5). However, the difference is not substantial enough to outweigh the significant ADME advantages of Ligand A.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A is better in terms of TPSA, Pgp, and has a more favorable ADME profile overall. While Ligand B has slightly better affinity, the difference isn't large enough to overcome Ligand A's superior drug-like properties and metabolic stability.
**Conclusion:**
Ligand A is the more promising drug candidate due to its superior QED, lower clearance, longer half-life, better solubility, and more favorable TPSA and Pgp values. These factors collectively contribute to a better overall ADME profile, which is critical for a successful drug.
Output:
1
2025-04-17 20:30:57,383 - INFO - Batch 190 complete. Total preferences: 3040
2025-04-17 20:30:57,384 - INFO - Processing batch 191/512...
2025-04-17 20:31:45,480 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.459 Da and 360.483 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (75.71) is better than Ligand B (86.09). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (1.729 and 2.039, respectively) falling within the optimal 1-3 range. Ligand B is slightly higher, which *could* be a minor drawback if it impacts solubility.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 5 HBA. Both are acceptable, below the threshold of 10.
6. **QED:** Both ligands have good QED scores (0.74 and 0.89), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (36.332) has a slightly better DILI percentile than Ligand B (41.411), indicating a lower risk of liver injury.
8. **BBB:** Both have similar BBB penetration (53.238 and 52.889). Not a major factor for a cardiovascular target.
9. **Caco-2:** Ligand A (-4.795) is better than Ligand B (-5.223). Lower values here indicate lower permeability, so a less negative value is preferred.
10. **Solubility:** Ligand A (-2.105) is better than Ligand B (-1.956). Higher values are preferred.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.161 and 0.118), which is excellent.
12. **Cl_mic:** Ligand B (-7.469) has significantly better microsomal clearance than Ligand A (30.234). This suggests better metabolic stability for Ligand B, which is a significant advantage.
13. **t1/2:** Ligand B (-7.266) has a much longer in vitro half-life than Ligand A (-14.776). This is a major advantage, potentially allowing for less frequent dosing.
14. **Pgp:** Both have low Pgp efflux liability (0.172 and 0.078). Ligand B is slightly better.
15. **Binding Affinity:** Ligand B (-7.0) has a significantly stronger binding affinity than Ligand A (-5.5). This difference of 1.5 kcal/mol is substantial and can often outweigh minor ADME drawbacks.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, affinity, logP, and metabolic stability are key. Ligand B excels in affinity and metabolic stability (Cl_mic and t1/2). While Ligand A has slightly better TPSA and solubility, the substantial improvement in binding affinity and metabolic stability of Ligand B are more important.
**Conclusion:**
Ligand B is the more promising drug candidate due to its significantly improved binding affinity and metabolic stability, despite slightly less favorable TPSA and solubility.
Output:
0
2025-04-17 20:31:45,481 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (357.523 and 366.527 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (68.01) is slightly higher than Ligand B (58.64). Both are below the 140 threshold for oral absorption, but closer to the 90 threshold for CNS targets (less relevant for ADRB2, a cardiovascular target). Ligand B is preferable.
3. **logP:** Ligand A (4.465) is a bit high, potentially leading to solubility issues and off-target effects. Ligand B (2.362) is within the optimal 1-3 range. Ligand B is significantly better.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable, below the threshold of 5. Ligand B is slightly preferable.
5. **HBA:** Both ligands (A: 4, B: 4) are below the threshold of 10. No significant difference.
6. **QED:** Both ligands have similar QED values (A: 0.802, B: 0.784), indicating good drug-likeness.
7. **DILI:** Ligand A (55.68) has a higher DILI risk than Ligand B (25.902). This is a significant advantage for Ligand B.
8. **BBB:** Both have high BBB penetration (A: 80.962, B: 76.813), but this is less critical for a cardiovascular target like ADRB2.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual. Assuming these are logP-like scales where lower values indicate lower permeability, Ligand A (-4.992) appears to have lower permeability than Ligand B (-5.124). This is a slight advantage for Ligand B.
10. **Solubility:** Both have negative solubility values, which is also unusual. Assuming these are logS-like scales where lower values indicate lower solubility, Ligand A (-4.003) appears to have lower solubility than Ligand B (-3.334). This is a slight advantage for Ligand B.
11. **hERG:** Ligand A (0.786) has a higher hERG inhibition liability than Ligand B (0.385). This is a significant advantage for Ligand B.
12. **Cl_mic:** Ligand B (54.839) has a higher microsomal clearance than Ligand A (35.825), indicating lower metabolic stability. This is a disadvantage for Ligand B.
13. **t1/2:** Ligand A (31.825) has a longer in vitro half-life than Ligand B (-6.566). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.707) has higher P-gp efflux liability than Ligand B (0.279). This is a significant advantage for Ligand B.
15. **Binding Affinity:** Ligand A (-7.9) has slightly better binding affinity than Ligand B (-7.0). This is a 1.9 kcal/mol difference, which is substantial.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity and a longer half-life, Ligand B demonstrates a significantly better safety profile (lower DILI, lower hERG) and improved ADME properties (lower logP, lower Pgp efflux, better solubility). The higher metabolic clearance of Ligand B is a concern, but the other advantages outweigh this drawback, especially considering the importance of minimizing off-target effects and maximizing bioavailability for a cardiovascular drug. The slightly better affinity of Ligand A is not enough to overcome the ADME/Tox advantages of Ligand B.
Output:
0
2025-04-17 20:31:45,481 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (347.39 Da) is better than Ligand B (370.475 Da), falling comfortably within the 200-500 Da range. Both are acceptable.
2. **TPSA:** Both ligands (A: 84.23, B: 84.74) are excellent, well below the 140 threshold for oral absorption and suitable for a peripherally acting GPCR like ADRB2.
3. **logP:** Ligand A (2.0) is slightly better than Ligand B (0.601). Both are within the optimal 1-3 range, but Ligand B is closer to the lower limit which could impact permeability.
4. **HBD:** Ligand A (2) is preferable to Ligand B (0). While both are acceptable, a small number of HBDs can aid solubility without drastically impacting permeability.
5. **HBA:** Ligand A (4) is better than Ligand B (6). Lower HBA is generally preferred for better permeability.
6. **QED:** Both ligands are similar (A: 0.765, B: 0.626) and above the 0.5 threshold, indicating good drug-like properties.
7. **DILI:** Ligand A (35.789%) is significantly better than Ligand B (46.956%). Lower DILI risk is crucial.
8. **BBB:** Ligand B (77.162%) is better than Ligand A (46.724%). However, since ADRB2 is not a CNS target, BBB penetration is a lower priority.
9. **Caco-2:** Ligand A (-5.034) is better than Ligand B (-4.591). Higher Caco-2 permeability is desirable for oral absorption.
10. **Solubility:** Ligand A (-2.243) is better than Ligand B (-1.715). Higher solubility is generally preferred.
11. **hERG:** Both ligands are very low risk (A: 0.25, B: 0.684).
12. **Cl_mic:** Ligand A (26.651 mL/min/kg) is significantly better than Ligand B (59.511 mL/min/kg). Lower clearance indicates better metabolic stability.
13. **t1/2:** Ligand A (36.357 hours) is much better than Ligand B (-43.424 hours). A longer half-life is generally preferred.
14. **Pgp:** Both ligands have low Pgp efflux liability (A: 0.036, B: 0.317), which is good.
15. **Binding Affinity:** Ligand B (-6.8 kcal/mol) is slightly better than Ligand A (-6.0 kcal/mol). This is a 0.8 kcal/mol difference, a noticeable but not overwhelming advantage.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. While Ligand B has a slightly better affinity and BBB, Ligand A excels in most other crucial ADME properties (logP, DILI, Cl_mic, t1/2, solubility, Caco-2) and has a better overall drug-like profile. The affinity difference is not large enough to outweigh the significant advantages of Ligand A in terms of safety (DILI) and pharmacokinetic properties (Cl_mic, t1/2).
**Conclusion:**
Considering the balance of properties and the priorities for a GPCR target, Ligand A is the more promising drug candidate.
Output:
1
2025-04-17 20:31:45,481 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (335.4) is within the ideal range (200-500), while Ligand B (372.8) is also acceptable. No clear advantage here.
2. **TPSA:** Ligand A (69.2) is better than Ligand B (52.6), falling well below the 140 threshold for oral absorption. Lower TPSA generally favors permeability.
3. **logP:** Ligand A (3.07) is optimal, while Ligand B (4.20) is pushing the upper limit. Higher logP can lead to solubility issues and off-target interactions. Ligand A is preferred.
4. **HBD:** Ligand A (2) is good, while Ligand B (0) is also acceptable.
5. **HBA:** Ligand A (3) is good, while Ligand B (4) is also acceptable.
6. **QED:** Ligand A (0.77) is significantly better than Ligand B (0.59), indicating a more drug-like profile.
7. **DILI:** Ligand B (59.4) is slightly higher than Ligand A (52.4), but both are within an acceptable range (<60 is good).
8. **BBB:** Ligand B (85.5) is much better than Ligand A (38.8). While ADRB2 isn't necessarily a CNS target, higher BBB penetration can sometimes be beneficial for overall distribution.
9. **Caco-2:** Ligand A (-5.16) is worse than Ligand B (-4.15), indicating lower intestinal absorption for Ligand A. Ligand B is preferred.
10. **Solubility:** Ligand A (-3.27) is worse than Ligand B (-5.67), indicating lower aqueous solubility for Ligand A. Ligand B is preferred.
11. **hERG:** Ligand A (0.87) is better than Ligand B (0.39), indicating a lower risk of cardiotoxicity. Ligand A is preferred.
12. **Cl_mic:** Ligand B (93.7) has significantly higher metabolic clearance than Ligand A (5.33), meaning Ligand A is more metabolically stable. Ligand A is preferred.
13. **t1/2:** Ligand B (37.6) has a much longer half-life than Ligand A (4.2). This is a significant advantage for dosing frequency. Ligand B is preferred.
14. **Pgp:** Ligand A (0.38) is better than Ligand B (0.41), indicating lower P-gp efflux. Ligand A is preferred.
15. **Affinity:** Ligand B (-7.3) has a significantly stronger binding affinity than Ligand A (-6.7). This is a crucial factor, and a 0.6 kcal/mol difference can outweigh some ADME drawbacks. Ligand B is strongly preferred.
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B has a better logP, better Caco-2 permeability, and a significantly better binding affinity. While Ligand A has better TPSA, solubility, and metabolic stability, the affinity difference is substantial.
**Overall Assessment:**
Ligand B, despite some ADME drawbacks (higher logP, lower solubility), has a significantly stronger binding affinity and a longer half-life. The improved affinity is the most critical factor for a GPCR target, and the longer half-life is a substantial benefit. The slightly higher DILI risk is manageable.
Output:
0
2025-04-17 20:31:45,481 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor (a GPCR).
**Ligand A:** [348.378, 90.87, 2.848, 2, 4, 0.801, 72.043, 66.964, -4.904, -4.126, 0.468, 7.62, 12.696, 0.116, -7.7]
**Ligand B:** [373.473, 63.17, 3.793, 1, 7, 0.759, 72.392, 76.851, -4.678, -4.545, 0.877, 79.316, 26.097, 0.476, -6.6]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (348.378) is slightly preferred due to being a bit lower.
2. **TPSA:** Ligand A (90.87) is better than Ligand B (63.17), being under 140, but still not ideal for CNS penetration.
3. **logP:** Both are good (between 1-3). Ligand B (3.793) is slightly higher, potentially leading to some solubility issues, but not critically.
4. **HBD:** Ligand A (2) is slightly better than Ligand B (1), as both are within the acceptable limit.
5. **HBA:** Ligand A (4) is better than Ligand B (7), as both are within the acceptable limit.
6. **QED:** Both are reasonably good (>0.5), but Ligand A (0.801) is better than Ligand B (0.759).
7. **DILI:** Both are acceptable (around 72 percentile), indicating low risk.
8. **BBB:** Ligand B (76.851) is better than Ligand A (66.964), but neither are exceptionally high.
9. **Caco-2:** Both are negative, indicating poor permeability.
10. **Solubility:** Both are negative, indicating poor solubility.
11. **hERG:** Ligand A (0.468) is better than Ligand B (0.877), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand A (7.62) is significantly better than Ligand B (79.316) - much better metabolic stability.
13. **t1/2:** Ligand B (26.097) is better than Ligand A (12.696) - longer half-life.
14. **Pgp:** Ligand B (0.476) is better than Ligand A (0.116), indicating lower efflux.
15. **Affinity:** Ligand A (-7.7) is significantly better than Ligand B (-6.6) - a 1.1 kcal/mol difference is substantial.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, affinity, logP, TPSA, Pgp, and metabolic stability are key. Ligand A has a substantially better binding affinity, better logP, and significantly better metabolic stability (lower Cl_mic). While Ligand B has better BBB penetration and Pgp efflux, the difference in affinity and metabolic stability are more critical. The poor Caco-2 and solubility for both ligands are concerning, but can be addressed with formulation strategies.
**Conclusion:**
Considering all factors, especially the significantly better binding affinity and metabolic stability of Ligand A, it is the more promising drug candidate.
Output:
1
2025-04-17 20:31:45,481 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (336.443) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (49.56) is significantly better than Ligand B (93.9). ADRB2 is a cardiovascular target, and while CNS penetration isn't *required*, lower TPSA generally improves absorption. Ligand B's TPSA is quite high, potentially hindering oral absorption.
3. **logP:** Ligand A (2.923) is optimal, while Ligand B (0.686) is a bit low. A logP below 1 can sometimes indicate poor membrane permeability.
4. **HBD:** Ligand A (0) is preferable to Ligand B (1). Fewer HBDs generally correlate with better permeability.
5. **HBA:** Both ligands have 6 HBA, which is acceptable.
6. **QED:** Both ligands have similar QED values (0.717 vs 0.622), indicating good drug-likeness.
7. **DILI:** Ligand A (71.694) has a higher DILI risk than Ligand B (27.608). This is a significant drawback for Ligand A.
8. **BBB:** Ligand A (81.466) has better BBB penetration than Ligand B (67.08). While not critical for a cardiovascular target, it's a slight advantage.
9. **Caco-2:** Ligand A (-5.073) has a worse Caco-2 permeability than Ligand B (-4.771).
10. **Solubility:** Ligand A (-3.457) has worse solubility than Ligand B (-1.147).
11. **hERG:** Ligand A (0.607) has a slightly higher hERG risk than Ligand B (0.208).
12. **Cl_mic:** Ligand A (58.104) has a higher microsomal clearance than Ligand B (22.556), indicating lower metabolic stability.
13. **t1/2:** Ligand A (24.592) has a longer half-life than Ligand B (0.696). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.758) has higher P-gp efflux than Ligand B (0.029). This is a significant disadvantage for Ligand A.
15. **Affinity:** Ligand A (-6.5 kcal/mol) has a slightly better binding affinity than Ligand B (-5.3 kcal/mol). This is a 1.2 kcal/mol advantage, which is substantial.
**Overall Assessment:**
Ligand A has a better binding affinity and half-life, but suffers from significantly worse DILI risk, solubility, Caco-2 permeability, P-gp efflux, and higher microsomal clearance. Ligand B, while having slightly weaker affinity, presents a much more favorable ADME-Tox profile, particularly regarding DILI and P-gp efflux. Given the cardiovascular target, minimizing off-target effects and ensuring good systemic exposure are paramount. The substantial difference in DILI risk and P-gp efflux outweighs the modest affinity difference.
Output:
0
2025-04-17 20:31:45,482 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (344.375 and 347.459 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (122.03) is higher than Ligand B (73.64). For a GPCR, lower TPSA is generally preferred for better brain penetration and overall permeability. Ligand B is significantly better.
3. **logP:** Ligand B (1.967) is within the optimal 1-3 range, while Ligand A (0.289) is quite low. This suggests Ligand A might have poor membrane permeability. Ligand B is significantly better.
4. **HBD:** Ligand A (3) is higher than Ligand B (0). Lower HBD can improve permeability. Ligand B is better.
5. **HBA:** Ligand A (7) is higher than Ligand B (4). Similar to HBD, lower HBA is generally preferred. Ligand B is better.
6. **QED:** Both ligands have similar QED values (0.621 and 0.629), indicating good drug-like properties. No significant difference.
7. **DILI:** Ligand B (18.418) has a much lower DILI risk than Ligand A (74.68). This is a major advantage for Ligand B.
8. **BBB:** Ligand B (85.459) has a significantly higher BBB penetration percentile than Ligand A (29.275). While ADRB2 isn't exclusively a CNS target, better BBB penetration can still be beneficial and reduce off-target effects. Ligand B is significantly better.
9. **Caco-2:** Ligand A (-5.548) and Ligand B (-4.086) are both negative, which is unusual and suggests very poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Ligand A (-2.037) and Ligand B (-2.412) are both very poor, but again, the scale is not specified.
11. **hERG:** Ligand A (0.216) has a slightly lower hERG risk than Ligand B (0.418), but both are relatively low.
12. **Cl_mic:** Ligand B (73.797) has a much higher microsomal clearance than Ligand A (17.878), indicating lower metabolic stability. Ligand A is better here.
13. **t1/2:** Ligand A (29.307) has a longer in vitro half-life than Ligand B (-12.056). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.006) has a much lower P-gp efflux liability than Ligand B (0.094), suggesting better oral bioavailability and potentially better CNS exposure. Ligand A is better.
15. **Binding Affinity:** Ligand A (-7.2) has a slightly better binding affinity than Ligand B (-6.2). This is a 1 kcal/mol difference, which is meaningful.
**Overall Assessment:**
Ligand B excels in key GPCR-relevant properties like TPSA, logP, BBB penetration, and DILI risk. While Ligand A has better metabolic stability (lower Cl_mic, longer t1/2) and P-gp efflux, the significant advantages of Ligand B in permeability, safety (DILI), and potential for broader distribution outweigh these benefits. The slightly better affinity of Ligand A isn't enough to compensate for its poor logP and TPSA.
Output:
0
2025-04-17 20:31:45,482 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (398.26 and 348.531 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (66.32) is slightly higher than Ligand B (58.2). Both are below the 140 A^2 threshold for good oral absorption, but closer to the 90 A^2 threshold for CNS targets (less relevant for a cardiovascular target, but still a positive). Ligand B is preferable here.
**3. logP:** Both ligands have a logP around 4.1, which is slightly above the optimal range of 1-3. This could potentially lead to solubility issues or off-target interactions, but is not a deal-breaker. No clear advantage.
**4. H-Bond Donors:** Ligand A has 1 HBD, while Ligand B has 2. Both are within the acceptable limit of <=5. No significant difference.
**5. H-Bond Acceptors:** Ligand A has 4 HBA, while Ligand B has 2. Both are within the acceptable limit of <=10. Ligand B is preferable.
**6. QED:** Both ligands have similar QED values (0.676 and 0.68), indicating good drug-likeness. No significant difference.
**7. DILI Risk:** Ligand A has a DILI risk of 77.007%, which is considered high risk (>60%). Ligand B has a much lower DILI risk of 22.761%, which is excellent. This is a *major* advantage for Ligand B.
**8. BBB Penetration:** Ligand B (76.425%) has significantly better BBB penetration than Ligand A (31.912%). While ADRB2 is a cardiovascular target, some CNS effects are possible with beta-blockers, and better BBB penetration could be beneficial or detrimental depending on the desired profile.
**9. Caco-2 Permeability:** Ligand A (-5.136) has worse Caco-2 permeability than Ligand B (-4.592). Higher values are better, so Ligand B is preferable.
**10. Aqueous Solubility:** Both ligands have very poor aqueous solubility (-4.067 and -4.626). This is a concern for both, but could be mitigated with formulation strategies.
**11. hERG Inhibition:** Ligand A (0.187) has a slightly lower hERG inhibition liability than Ligand B (0.507), which is preferable.
**12. Microsomal Clearance:** Ligand B (76.207) has a much higher microsomal clearance than Ligand A (29.662), indicating faster metabolism and potentially lower *in vivo* exposure. This is a significant disadvantage for Ligand B.
**13. In vitro Half-Life:** Ligand A (12.321 hours) has a longer half-life than Ligand B (-1.999 hours). This is a substantial advantage for Ligand A.
**14. P-gp Efflux:** Ligand A (0.064) has significantly lower P-gp efflux than Ligand B (0.296), indicating better oral bioavailability and potentially better CNS exposure.
**15. Binding Affinity:** Ligand B (-6.0 kcal/mol) has a stronger binding affinity than Ligand A (-3.6 kcal/mol). The difference of 2.4 kcal/mol is substantial and outweighs many of the ADME drawbacks of Ligand B.
**Overall Assessment:**
While Ligand B has a significantly better binding affinity, the high DILI risk associated with Ligand A is a major concern. The significantly improved DILI profile of Ligand B, coupled with better Caco-2 permeability, BBB penetration, and a superior binding affinity, makes it the more promising candidate despite the higher microsomal clearance and P-gp efflux. The longer half-life of Ligand A is a positive, but the DILI risk is too high to ignore.
Output:
0
2025-04-17 20:31:45,482 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (342.355 and 350.463 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (95.6) is slightly higher than Ligand B (73.29). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B has a clear advantage.
3. **logP:** Ligand A (-0.907) is a bit low, potentially hindering permeability. Ligand B (2.162) is within the optimal 1-3 range. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (1) and Ligand B (0) are both acceptable.
5. **HBA:** Ligand A (5) and Ligand B (4) are both acceptable.
6. **QED:** Both ligands (0.702 and 0.712) have good drug-likeness scores. No significant difference.
7. **DILI:** Ligand A (52.462) has a higher DILI risk than Ligand B (31.563). This is a clear advantage for Ligand B.
8. **BBB:** Ligand A (53.121) and Ligand B (63.862). While ADRB2 isn't a primary CNS target, some peripheral ADRB2 signaling can influence CNS function. Ligand B has a slight advantage.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.581 and -4.89), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Both ligands have negative solubility values (-2.272 and -1.962), which is also concerning. Poor solubility could hinder bioavailability.
11. **hERG:** Ligand A (0.124) has a slightly lower hERG risk than Ligand B (0.314), which is preferable.
12. **Cl_mic:** Ligand A (-20.914) has a much lower (better) microsomal clearance than Ligand B (43.842), indicating greater metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (-28.28) has a more negative in vitro half-life, which is not ideal. Ligand B (-17.22) is also not ideal, but better than Ligand A.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.004 and 0.092). No significant difference.
15. **Binding Affinity:** Ligand A (-5.4) and Ligand B (-5.7) are very close in binding affinity, with Ligand B being slightly better.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand B appears slightly more promising. It has a better logP, lower TPSA, and slightly better affinity. The lower DILI risk is also a significant benefit. While both have concerning Caco-2 and solubility values, the metabolic stability of Ligand A is a strong point. However, the combined advantages of Ligand B in terms of absorption and safety outweigh the metabolic stability advantage of Ligand A.
Output:
0
2025-04-17 20:31:45,482 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (339.439 and 340.467 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Both ligands (58.22 and 58.20) are below the 140 A^2 threshold for good absorption, and well below the 90 A^2 threshold for CNS targets (though this isn't a CNS target, lower TPSA is still generally favorable). No significant difference.
3. **logP:** Both ligands (3.882 and 3.702) fall within the optimal 1-3 range. Ligand A is slightly higher, which could be a minor advantage for membrane permeability, but not decisive.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (2). Lower HBA generally improves permeability.
6. **QED:** Ligand A (0.841) has a significantly better QED score than Ligand B (0.504), indicating a more drug-like profile. This is a substantial advantage.
7. **DILI:** Ligand B (36.681) has a much lower DILI risk than Ligand A (68.437). This is a major advantage for Ligand B.
8. **BBB:** Ligand B (68.321) has a higher BBB percentile than Ligand A (41.295). While ADRB2 isn't a primary CNS target, some peripheral ADRB2 activity can influence CNS pathways, and higher BBB is rarely a detriment.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.028 and -4.811), which is unusual and suggests poor permeability. This is a concern for both, but the values are similar.
10. **Solubility:** Both ligands have negative solubility values (-4.074 and -4.085), indicating very poor aqueous solubility. This is a significant drawback for both.
11. **hERG:** Ligand A (0.349) has a lower hERG risk than Ligand B (0.71). This is a slight advantage for Ligand A.
12. **Cl_mic:** Both ligands have similar microsomal clearance values (47.114 and 48.703 mL/min/kg). No significant difference.
13. **t1/2:** Ligand B (-1.445) has a longer in vitro half-life than Ligand A (-13.889). This is a substantial advantage for Ligand B.
14. **Pgp:** Ligand A (0.394) has lower P-gp efflux liability than Ligand B (0.221). This is a slight advantage for Ligand A.
15. **Binding Affinity:** Ligand A (-6.5 kcal/mol) has a slightly better binding affinity than Ligand B (-6.0 kcal/mol). This is a positive for Ligand A, but the difference is not huge.
**GPCR-specific priorities:** For GPCRs, logP, TPSA, Pgp, and affinity are important. Ligand A has a slightly better logP, Pgp, and affinity, while Ligand B has a better BBB. However, the significant advantages of Ligand B in terms of DILI risk and in vitro half-life, combined with its good QED, outweigh the minor advantages of Ligand A. The poor Caco-2 and solubility are concerning for both, but can potentially be addressed with formulation strategies.
**Conclusion:**
Considering the balance of properties, especially the lower DILI risk and longer half-life of Ligand B, it appears to be the more promising drug candidate.
Output:
0
2025-04-17 20:31:45,482 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.462 and 338.499 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (40.62 and 41.05) are below the 140 A^2 threshold for good oral absorption. They are also well below the 90 A^2 threshold for CNS targets, though this is less critical for a cardiovascular target like ADRB2.
3. **logP:** Ligand A (2.503) is optimal, while Ligand B (4.405) is pushing the upper limit and could potentially cause solubility issues or off-target interactions. This favors Ligand A.
4. **HBD:** Both ligands have low HBD counts (0 and 1 respectively), which is favorable for permeability.
5. **HBA:** Both ligands have reasonable HBA counts (2 and 4 respectively), staying within the preferred limit of 10.
6. **QED:** Both ligands have good QED scores (0.474 and 0.897). Ligand B is significantly better here, indicating a more drug-like profile.
7. **DILI:** Ligand A (16.324%) has a much lower DILI risk than Ligand B (47.538%). This is a significant advantage for Ligand A.
8. **BBB:** Both ligands show good BBB penetration (91.237% and 81.582%). While not a primary concern for ADRB2 (cardiovascular), higher BBB is generally preferable. Ligand A is better here.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. This is a significant drawback for both.
10. **Solubility:** Both ligands have negative solubility values, indicating poor solubility. This is a significant drawback for both.
11. **hERG:** Both ligands have low hERG inhibition liability (0.721 and 0.927), which is good.
12. **Cl_mic:** Ligand A (34.098) has a significantly lower microsomal clearance than Ligand B (107.355), suggesting better metabolic stability. This is a strong advantage for Ligand A.
13. **t1/2:** Ligand B (58.148) has a much longer in vitro half-life than Ligand A (-10.346). This is a significant advantage for Ligand B.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.23 and 0.539), which is favorable.
15. **Binding Affinity:** Both ligands have the same binding affinity (-5.3 kcal/mol).
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand A has a better logP and a better BBB value. Ligand B has a better QED and t1/2. However, the significantly lower DILI risk and better metabolic stability (lower Cl_mic) of Ligand A are crucial factors. The poor Caco-2 and solubility values are concerning for both, but can be addressed with formulation strategies.
**Overall Assessment:**
While Ligand B has a better QED and half-life, the lower DILI risk and improved metabolic stability of Ligand A are more critical for overall drug development success. The similar binding affinity means the ADME properties become the deciding factors.
Output:
1
2025-04-17 20:31:45,483 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (356.413 and 351.359 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (67.43) is significantly better than Ligand B (121.71). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold. Ligand B is approaching the upper limit.
3. **logP:** Ligand A (1.861) is within the optimal 1-3 range. Ligand B (0.03) is very low, potentially hindering membrane permeability. This is a significant drawback for Ligand B.
4. **HBD:** Both ligands have 2 HBD, which is acceptable.
5. **HBA:** Ligand A has 3 HBA, while Ligand B has 6. Ligand A is preferable here, as excessive HBA can reduce permeability.
6. **QED:** Both ligands have similar QED values (0.714 and 0.738), indicating good drug-likeness.
7. **DILI:** Ligand A (46.064) has a slightly better DILI score than Ligand B (58.511), indicating a lower risk of liver injury.
8. **BBB:** Ligand A (78.48) has a higher BBB penetration score than Ligand B (37.495). While not critical for a cardiovascular target, higher BBB is rarely detrimental.
9. **Caco-2:** Ligand A (-4.601) has a more negative Caco-2 value, suggesting *lower* permeability. Ligand B (-5.007) is also low, but slightly worse.
10. **Solubility:** Ligand A (-2.451) has a slightly better solubility score than Ligand B (-1.796).
11. **hERG:** Ligand A (0.409) has a much lower hERG inhibition liability than Ligand B (0.085), a crucial advantage for cardiovascular drugs.
12. **Cl_mic:** Ligand A (26.358) has a higher microsomal clearance than Ligand B (1.606), indicating lower metabolic stability. This is a negative for Ligand A.
13. **t1/2:** Ligand A (-29.31) has a more negative in vitro half-life, indicating a shorter half-life. Ligand B (-25.339) is better.
14. **Pgp:** Ligand A (0.062) has a lower P-gp efflux liability than Ligand B (0.01), which is favorable.
15. **Binding Affinity:** Ligand A (-7.3 kcal/mol) has a slightly better binding affinity than Ligand B (-6.7 kcal/mol). This 1.5 kcal/mol difference is significant and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand A has several advantages: better TPSA, logP, HBA, DILI, BBB, hERG, and binding affinity. The primary drawback for Ligand A is its higher Cl_mic and shorter t1/2. However, the strong binding affinity and significantly lower hERG risk are critical for a cardiovascular drug targeting a GPCR. Ligand B suffers from a very low logP, which is a major concern for permeability and bioavailability. While its metabolic stability is better, the poor logP and higher hERG risk make it a less attractive candidate.
**Output:**
1
2025-04-17 20:31:45,483 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (355.463 Da) is slightly lower, which is generally favorable for permeability.
**2. TPSA:** Ligand A (62.3) is significantly better than Ligand B (123.42). For a GPCR, keeping TPSA low is beneficial for both permeability and receptor engagement. Ligand B's TPSA is quite high, potentially hindering absorption.
**3. logP:** Ligand A (2.884) is optimal, while Ligand B (0.737) is a bit low. A logP between 1-3 is preferred, and Ligand B might struggle with membrane permeability due to its lower lipophilicity.
**4. H-Bond Donors:** Ligand A (1) is preferable to Ligand B (2). Fewer H-bond donors generally improve permeability.
**5. H-Bond Acceptors:** Ligand A (4) is better than Ligand B (7). Similar to HBD, fewer HBAs are generally desirable.
**6. QED:** Both ligands have similar QED values (0.839 and 0.704), indicating good drug-like properties.
**7. DILI Risk:** Ligand A (72.586) has a lower DILI risk than Ligand B (85.498), which is a significant advantage.
**8. BBB Penetration:** Ligand A (71.462) shows better BBB penetration than Ligand B (43.815). While ADRB2 isn't exclusively a CNS target, some CNS exposure can occur, and better BBB penetration is generally a plus.
**9. Caco-2 Permeability:** Ligand A (-4.926) is better than Ligand B (-5.008), indicating slightly better intestinal absorption.
**10. Aqueous Solubility:** Ligand A (-3.332) is better than Ligand B (-2.966), suggesting better solubility.
**11. hERG Inhibition:** Ligand A (0.338) is significantly better than Ligand B (0.142), indicating a lower risk of cardiotoxicity. This is crucial for a cardiovascular target.
**12. Microsomal Clearance:** Ligand B (60.649) has slightly lower microsomal clearance than Ligand A (56.254), suggesting better metabolic stability.
**13. In vitro Half-Life:** Ligand A (9.588) has a better half-life than Ligand B (-23.994).
**14. P-gp Efflux:** Ligand A (0.287) is better than Ligand B (0.062), indicating lower P-gp efflux and potentially better bioavailability.
**15. Binding Affinity:** Ligand A (-8.5 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.1 kcal/mol). This is a substantial advantage, and the 2.4 kcal/mol difference can outweigh some of the minor ADME drawbacks of Ligand A.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical ADME properties (TPSA, logP, DILI, BBB, hERG, P-gp efflux, solubility) and, most importantly, exhibits a much stronger binding affinity. While Ligand B has slightly better metabolic stability, the overall profile of Ligand A is far more favorable for development as a drug candidate targeting ADRB2.
Output:
1
2025-04-17 20:31:45,483 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
The target is ADRB2, a GPCR. Therefore, I will prioritize logP, TPSA, Pgp efflux, BBB penetration, and binding affinity, while also considering overall drug-likeness and safety parameters.
1. **Molecular Weight:** Both ligands (345.4 and 349.4 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (78.95) is significantly better than Ligand B (127.51). A TPSA under 140 is good for oral absorption, and lower is generally preferred for GPCRs. Ligand B is pushing the upper limit.
3. **logP:** Ligand A (2.155) is within the optimal 1-3 range. Ligand B (-0.665) is below 1, which could hinder membrane permeability. This is a significant drawback for Ligand B.
4. **H-Bond Donors:** Both have 1-2 HBD, which is acceptable.
5. **H-Bond Acceptors:** Ligand A (4) is better than Ligand B (6). Lower HBA is generally preferred.
6. **QED:** Ligand A (0.848) has a much better QED score than Ligand B (0.672), indicating a more drug-like profile.
7. **DILI:** Ligand A (57.4) is slightly higher than Ligand B (39.6), but both are within acceptable limits (<60 is good).
8. **BBB:** Ligand A (83.1) has better BBB penetration than Ligand B (75.0). While not a primary concern for peripheral GPCRs like ADRB2, it's still a positive attribute.
9. **Caco-2:** Both have negative values, indicating poor permeability. Ligand A (-4.64) is slightly better than Ligand B (-5.376).
10. **Solubility:** Both have negative solubility values, which is concerning. Ligand A (-2.637) is slightly better than Ligand B (-2.425).
11. **hERG:** Both ligands have low hERG risk (0.335 and 0.14), which is good.
12. **Cl_mic:** Ligand B (-11.692) has significantly lower microsomal clearance than Ligand A (24.841), suggesting better metabolic stability. This is a strong advantage for Ligand B.
13. **t1/2:** Ligand A (24.124) has a much longer in vitro half-life than Ligand B (1.884). This is a significant advantage for Ligand A.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.051 and 0.016), which is favorable.
15. **Binding Affinity:** Both ligands have the same binding affinity (-6.9 kcal/mol), which is excellent.
**Overall Assessment:**
Ligand A has a better balance of properties. While Ligand B has superior metabolic stability, Ligand A excels in critical areas like TPSA, logP, QED, and in vitro half-life. The poor logP of Ligand B is a major concern, potentially hindering its ability to cross cell membranes and reach the target receptor. Ligand A's better TPSA and QED also contribute to a more favorable drug-like profile. The slightly longer half-life of Ligand A is also a benefit.
Output:
1
2025-04-17 20:31:45,483 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (361.833 and 342.359 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (79.6) is significantly better than Ligand B (117.01). ADRB2 is not a CNS target, but lower TPSA generally improves permeability. Ligand A is well below the 140 threshold. Ligand B is approaching the upper limit.
3. **logP:** Ligand A (2.278) is optimal, while Ligand B (0.757) is slightly low, potentially impacting permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (6). Fewer HBAs generally improve permeability.
6. **QED:** Ligand A (0.909) is excellent, indicating a highly drug-like profile. Ligand B (0.775) is still acceptable, but not as strong.
7. **DILI:** Ligand B (73.401) has a higher DILI risk than Ligand A (60.372), though both are within an acceptable range.
8. **BBB:** This is less critical for ADRB2, but Ligand A (86.817) is better than Ligand B (44.436).
9. **Caco-2:** Both are negative (-5.005 and -5.398), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Both ligands have similar, very poor aqueous solubility (-2.97 and -2.837). This is a significant drawback for both.
11. **hERG:** Ligand A (0.511) has a slightly higher hERG risk than Ligand B (0.026), which is a significant advantage for B.
12. **Cl_mic:** Ligand A (22.756) has a better (lower) microsomal clearance than Ligand B (14.407), indicating better metabolic stability.
13. **t1/2:** Ligand B (-29.256) has a much longer in vitro half-life than Ligand A (-5.088). This is a major advantage for B.
14. **Pgp:** Ligand A (0.155) has a lower Pgp efflux liability than Ligand B (0.016), suggesting better bioavailability.
15. **Binding Affinity:** Ligand A (-7.1) has a significantly stronger binding affinity than Ligand B (-6.5). This is a substantial advantage for A, potentially outweighing some ADME concerns.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A excels in logP, TPSA, and *especially* affinity. Ligand B has a better hERG profile and a significantly longer half-life. The solubility and Caco-2 permeability are problematic for both.
**Overall Assessment:**
The stronger binding affinity of Ligand A (-7.1 vs -6.5) is a critical advantage, especially for a GPCR target. While Ligand B has a better half-life and hERG profile, the difference in affinity is substantial enough to likely overcome these drawbacks, assuming some optimization can be done to address the solubility and permeability issues. The better TPSA and logP of Ligand A also contribute to its favorability.
Output:
1
2025-04-17 20:31:45,484 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [371.821, 100.99 , 0.091, 2. , 6. , 0.628, 67.313, 34.122, -5.035, -1.268, 0.136, -6.02 , 15.519, 0.016, -6.4 ]
**Ligand B:** [348.403, 94.89 , 0.66 , 2. , 4. , 0.836, 37.65 , 55.176, -4.937, -1.695, 0.107, -32.186, 21.028, 0.007, -7.7 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (348.403) is slightly lower, which could be beneficial for permeability.
2. **TPSA:** Both are below 140, good for oral absorption. Ligand B (94.89) is slightly better.
3. **logP:** Ligand A (0.091) is quite low, potentially hindering membrane permeability. Ligand B (0.66) is better, falling within the optimal range.
4. **HBD:** Both have 2 HBD, which is good.
5. **HBA:** Ligand A has 6 HBA, and Ligand B has 4. Both are acceptable, but Ligand B is slightly better.
6. **QED:** Both are above 0.5, indicating good drug-likeness. Ligand B (0.836) is significantly better.
7. **DILI:** Ligand A (67.313) has a higher DILI risk than Ligand B (37.65), which is a significant concern.
8. **BBB:** Ligand B (55.176) has a better BBB penetration potential than Ligand A (34.122), although neither is exceptionally high. For a cardiovascular target, BBB isn't *critical*, but it's still a positive.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. Ligand A (-5.035) is worse than Ligand B (-4.937).
10. **Solubility:** Both have negative solubility values, indicating poor solubility. Ligand A (-1.268) is slightly better than Ligand B (-1.695).
11. **hERG:** Both have low hERG risk. Ligand A (0.136) is slightly better.
12. **Cl_mic:** Ligand A (-6.02) has a lower (better) microsomal clearance than Ligand B (-32.186), indicating better metabolic stability.
13. **t1/2:** Ligand B (21.028) has a longer in vitro half-life than Ligand A (15.519).
14. **Pgp:** Both have very low Pgp efflux liability.
15. **Affinity:** Ligand B (-7.7 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.4 kcal/mol). This is a substantial difference.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP and significantly outperforms Ligand A in binding affinity. While BBB isn't paramount for a cardiovascular target, Ligand B is better in this regard. The lower DILI risk of Ligand B is also a major advantage. The better QED score is also beneficial.
**Conclusion:**
Despite Ligand A having slightly better metabolic stability and hERG profile, the significantly stronger binding affinity, better logP, lower DILI risk, and better QED score of Ligand B make it the more promising drug candidate. The affinity difference is large enough to outweigh the minor drawbacks of Ligand B.
Output:
0
2025-04-17 20:31:45,484 - INFO - Batch 191 complete. Total preferences: 3056
2025-04-17 20:31:45,484 - INFO - Processing batch 192/512...
2025-04-17 20:32:33,333 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [364.471, 104.53 , 1.245, 3. , 4. , 0.54 , 40.287, 55.874, -5.359, -2.389, 0.067, -1.016, -3.029, 0.028, -6.8 ]
**Ligand B:** [350.503, 58.64 , 2.76 , 1. , 3. , 0.685, 12.33 , 73.866, -4.477, -2.575, 0.532, 58.508, -8.565, 0.113, -6.3 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (350.5) is slightly lower, which could be marginally better for permeability.
2. **TPSA:** Ligand A (104.53) is higher than Ligand B (58.64). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B is significantly better here.
3. **logP:** Ligand A (1.245) is within the optimal range, while Ligand B (2.76) is approaching the upper limit. Both are acceptable, but A is slightly more balanced.
4. **HBD:** Ligand A (3) is higher than Ligand B (1). Lower is generally preferred for permeability. Ligand B is better.
5. **HBA:** Both have 3 HBA, which is good.
6. **QED:** Ligand B (0.685) has a slightly better QED score than Ligand A (0.54), suggesting a more drug-like profile.
7. **DILI:** Ligand A (40.29) is slightly higher than Ligand B (12.33), indicating a higher potential for liver injury. Ligand B is significantly better.
8. **BBB:** Ligand B (73.87) has a much higher BBB percentile than Ligand A (55.87). While not a CNS target, some BBB penetration can be beneficial for distribution.
9. **Caco-2:** Ligand A (-5.359) is worse than Ligand B (-4.477), suggesting lower intestinal absorption.
10. **Solubility:** Ligand A (-2.389) is slightly worse than Ligand B (-2.575). Both are poor.
11. **hERG:** Ligand A (0.067) is slightly better than Ligand B (0.532), indicating lower hERG inhibition risk.
12. **Cl_mic:** Ligand A (-1.016) has a lower (better) microsomal clearance than Ligand B (58.508), suggesting greater metabolic stability.
13. **t1/2:** Ligand B (-8.565) has a longer in vitro half-life than Ligand A (-3.029).
14. **Pgp:** Ligand A (0.028) has much lower P-gp efflux than Ligand B (0.113), which is a positive.
15. **Affinity:** Ligand A (-6.8) has a slightly better binding affinity than Ligand B (-6.3), a difference of 0.5 kcal/mol.
**GPCR-Specific Priorities:**
For ADRB2 (a cardiovascular GPCR), we prioritize logP, TPSA, Pgp, and affinity. Ligand B excels in TPSA and Pgp, and has a better BBB score. Ligand A has a slightly better affinity and Pgp efflux. The difference in affinity is not large enough to outweigh the significant advantages of Ligand B in TPSA, DILI, and BBB.
**Conclusion:**
Considering the overall profile, particularly the better TPSA, DILI, BBB, and half-life of Ligand B, it appears to be the more promising drug candidate.
0
2025-04-17 20:32:33,334 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (381.527 Da) is slightly higher than Ligand B (341.455 Da), but both are acceptable.
2. **TPSA:** Both ligands have TPSA values below 140, suggesting good oral absorption potential. Ligand A (80.12) is slightly higher than Ligand B (76.36), but both are good.
3. **logP:** Both ligands have optimal logP values (between 1 and 3). Ligand A (2.533) and Ligand B (1.821) are both acceptable, but Ligand B is slightly lower which could potentially affect permeability.
4. **HBD:** Ligand A (1) and Ligand B (2) are both within the acceptable limit of 5.
5. **HBA:** Ligand A (7) and Ligand B (4) are both within the acceptable limit of 10.
6. **QED:** Both ligands have good QED scores (>0.5), indicating drug-like properties. Ligand B (0.827) is slightly better than Ligand A (0.746).
7. **DILI:** Ligand A (75.145) has a significantly higher DILI risk than Ligand B (4.769). This is a major concern for Ligand A.
8. **BBB:** Ligand B (71.656) has a much better BBB penetration potential than Ligand A (32.416). While ADRB2 isn't exclusively a CNS target, some cardiovascular effects are mediated through central pathways, and better BBB penetration isn't necessarily detrimental.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale isn't specified, so it's hard to interpret.
10. **Solubility:** Both ligands have negative solubility values, which is also unusual. Again, the scale is unspecified, making interpretation difficult.
11. **hERG:** Ligand A (0.264) has a lower hERG inhibition liability than Ligand B (0.692), which is preferable.
12. **Cl_mic:** Ligand B (-7.688) has a significantly *lower* (better) microsomal clearance than Ligand A (56.106), indicating greater metabolic stability.
13. **t1/2:** Ligand B (6.999) has a longer in vitro half-life than Ligand A (51.184).
14. **Pgp:** Ligand A (0.116) has lower P-gp efflux liability than Ligand B (0.018).
15. **Binding Affinity:** Ligand B (-7.1 kcal/mol) has a slightly better binding affinity than Ligand A (-5.3 kcal/mol). This 1.8 kcal/mol difference is significant and can outweigh some ADME drawbacks.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are particularly important. Ligand B performs better in logP, Pgp, and significantly better in affinity. While BBB isn't critical for all ADRB2 applications, the higher value for Ligand B isn't a disadvantage.
**Overall Assessment:**
Ligand A has a concerningly high DILI risk and poorer metabolic stability. While it has a slightly better hERG profile and Pgp efflux, the superior binding affinity, metabolic stability, lower DILI risk, and better BBB penetration of Ligand B make it the more promising candidate. The difference in binding affinity is substantial enough to overcome any minor drawbacks in other parameters.
Output:
0
2025-04-17 20:32:33,334 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.415 and 361.467 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (96.89) is higher than Ligand B (59.98). For a cardiovascular GPCR, TPSA isn't a *critical* factor like it would be for a CNS target, but lower is generally preferred for permeability. Ligand B is better.
3. **logP:** Ligand B (3.611) is higher than Ligand A (0.392). Ligand A's logP is quite low, potentially hindering membrane permeability. Ligand B is within the optimal range (1-3), while A is below 1. Ligand B is significantly better.
4. **HBD:** Ligand A (3) is higher than Ligand B (0). Lower HBD is generally preferred for better permeability. Ligand B is better.
5. **HBA:** Ligand A (5) is equal to Ligand B (6). No significant difference.
6. **QED:** Both ligands have good QED scores (0.599 and 0.645), indicating good drug-like properties. No significant difference.
7. **DILI:** Ligand B (57.774) has a higher DILI risk than Ligand A (18.108). This is a significant advantage for Ligand A.
8. **BBB:** Both have relatively low BBB penetration, but Ligand A (55.332) is lower than Ligand B (58.976). Since this is a cardiovascular target, BBB penetration is not a priority.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-5.018) is slightly better (less negative) than Ligand B (-4.822).
10. **Solubility:** Ligand A (-1.651) has better solubility than Ligand B (-3.034). This is a positive for Ligand A.
11. **hERG:** Ligand A (0.129) has a much lower hERG inhibition liability than Ligand B (0.79). This is a major advantage for Ligand A, as hERG inhibition can cause cardiotoxicity.
12. **Cl_mic:** Ligand B (83.618) has a much higher microsomal clearance than Ligand A (11.881). This suggests Ligand B will be metabolized more quickly, leading to a shorter duration of action. Ligand A is significantly better.
13. **t1/2:** Ligand B (61.072) has a much longer in vitro half-life than Ligand A (-5.468). This is a benefit for Ligand B.
14. **Pgp:** Ligand B (0.807) has higher P-gp efflux than Ligand A (0.02). Lower P-gp efflux is preferred. Ligand A is significantly better.
15. **Binding Affinity:** Both ligands have the same binding affinity (-6.8 kcal/mol).
**Overall Assessment:**
While Ligand B has a longer half-life, Ligand A is clearly superior in terms of ADME properties. Ligand A has significantly lower DILI risk, hERG inhibition, and P-gp efflux, and better solubility and metabolic stability. The low logP of Ligand A is a concern, but the other advantages outweigh this drawback, especially given the equal binding affinity. The cardiovascular target doesn't necessitate high BBB penetration.
Output:
1
2025-04-17 20:32:33,334 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (352.494 and 341.371 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (49.41) is significantly better than Ligand B (79.51). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (3.448) is within the optimal range (1-3), while Ligand B (0.639) is quite low. Low logP can hinder membrane permeability. This is a significant advantage for Ligand A.
4. **HBD:** Ligand A (1) is preferable to Ligand B (0). A single HBD is a good balance.
5. **HBA:** Ligand A (2) is better than Ligand B (6). Fewer HBA generally improves permeability.
6. **QED:** Ligand A (0.842) is substantially better than Ligand B (0.606), indicating a more drug-like profile.
7. **DILI:** Ligand A (35.983) has a much lower DILI risk than Ligand B (60.721). This is a critical advantage for Ligand A.
8. **BBB:** Not a major priority for a cardiovascular target. Ligand A (86.623) is higher than Ligand B (70.997).
9. **Caco-2:** Both are negative, indicating poor permeability. However, the scale is not provided, so it's hard to interpret.
10. **Solubility:** Ligand A (-4.031) is better than Ligand B (-1.922), indicating better aqueous solubility.
11. **hERG:** Ligand A (0.714) has a lower hERG risk than Ligand B (0.312), which is preferable.
12. **Cl_mic:** Ligand A (34.162) has a higher clearance than Ligand B (28.455), meaning it is less metabolically stable. This is a slight advantage for Ligand B.
13. **t1/2:** Ligand B (-8.747) has a longer half-life than Ligand A (-5.008). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.535) has lower P-gp efflux than Ligand B (0.08). This is a slight advantage for Ligand A.
15. **Affinity:** Ligand A (-7.0) has a slightly better binding affinity than Ligand B (-6.2). While the difference is not huge, it's enough to consider.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, and affinity are key. Ligand A excels in logP and TPSA, and has a slightly better affinity. While Ligand B has a better half-life, the superior ADME properties (lower DILI, better solubility, better QED, lower Pgp efflux) of Ligand A outweigh this benefit.
**Conclusion:**
Ligand A demonstrates a significantly more favorable balance of properties, particularly regarding predicted safety (DILI, hERG) and absorption/permeability (logP, TPSA).
Output:
1
2025-04-17 20:32:33,334 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (338.411 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are good, below the 140 A^2 threshold for oral absorption. Ligand B (72.72) is better than Ligand A (86.88), which is preferred for GPCRs.
3. **logP:** Ligand A (1.989) is optimal, while Ligand B (0.435) is a bit low. A logP between 1-3 is preferred, and Ligand A is closer to this.
4. **HBD:** Ligand A (3) is acceptable, Ligand B (0) is also good.
5. **HBA:** Ligand A (3) is good, Ligand B (7) is acceptable but higher.
6. **QED:** Both ligands have similar, good QED scores (0.704 and 0.71).
7. **DILI:** Ligand B (26.871) has a significantly lower DILI risk than Ligand A (57.193). This is a major advantage for Ligand B.
8. **BBB:** Ligand B (67.313) has a better BBB penetration score than Ligand A (46.064). While ADRB2 isn't strictly a CNS target, some peripheral ADRB2 activity can be modulated by CNS effects, and better BBB penetration is generally favorable.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. Ligand A (-5.046) is slightly worse than Ligand B (-4.919).
10. **Solubility:** Ligand A (-3.596) has better solubility than Ligand B (0.034). Solubility is important for bioavailability.
11. **hERG:** Both have low hERG inhibition liability, with Ligand B (0.223) being slightly better than Ligand A (0.428).
12. **Cl_mic:** Ligand A (-23.821) has much lower microsomal clearance, indicating better metabolic stability than Ligand B (18.44). This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (19.872) has a longer in vitro half-life than Ligand B (8.296). This is favorable for dosing frequency.
14. **Pgp:** Both have very low Pgp efflux liability. Ligand A (0.055) is slightly lower than Ligand B (0.044).
15. **Binding Affinity:** Ligand B (-7.1 kcal/mol) has a slightly better binding affinity than Ligand A (-6.9 kcal/mol). This difference is significant enough to potentially outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand B has a significantly better safety profile (lower DILI) and better BBB penetration. It also has a slightly better binding affinity. Ligand A has better metabolic stability (lower Cl_mic) and a longer half-life, but the DILI risk is concerning. Considering the GPCR-specific priorities (logP, TPSA, affinity) and the importance of safety, Ligand B appears to be the more promising candidate despite the slightly lower logP and shorter half-life. The affinity difference is enough to overcome the slightly worse ADME properties.
Output:
0
2025-04-17 20:32:33,334 - INFO - Here's my reasoning and the final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, the most important parameters are binding affinity, logP, TPSA, Pgp efflux, and BBB penetration. Metabolic stability (Cl_mic and t1/2) and safety (DILI, hERG) are also important, followed by general drug-likeness parameters like MW, QED, solubility, and H-bonds.
Let's compare the ligands property by property:
1. **MW:** Both ligands (350.438 and 348.487 Da) are within the ideal range (200-500 Da).
2. **TPSA:** Ligand A (67.23) is higher than Ligand B (49.85). Ligand B is better, being closer to the <90 A^2 threshold for good absorption.
3. **logP:** Both ligands have good logP values (2.008 and 2.894), falling within the optimal 1-3 range. Ligand B is slightly higher, potentially improving membrane permeability.
4. **HBD:** Ligand A has 1 HBD, Ligand B has 0. Both are acceptable.
5. **HBA:** Ligand A has 4 HBA, Ligand B has 3. Both are acceptable.
6. **QED:** Both ligands have similar QED values (0.78 and 0.768), indicating good drug-likeness.
7. **DILI:** Ligand B (26.095) has a significantly lower DILI risk than Ligand A (39.822), which is a major advantage.
8. **BBB:** Ligand A (91.508) has a better BBB penetration score than Ligand B (86.39), but both are good.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual. However, the magnitude is similar.
10. **Solubility:** Both have negative solubility values, which is also unusual. The magnitude is similar.
11. **hERG:** Ligand A (0.49) has a slightly higher hERG risk than Ligand B (0.266), but both are low.
12. **Cl_mic:** Ligand A (38.733) has a lower microsomal clearance, indicating better metabolic stability, than Ligand B (47.903).
13. **t1/2:** Ligand B (10.864) has a significantly longer in vitro half-life than Ligand A (-12.764), which is a major advantage.
14. **Pgp:** Ligand A (0.111) has lower P-gp efflux liability than Ligand B (0.324), which is preferable.
15. **Binding Affinity:** Ligand B (-7.1 kcal/mol) has a slightly better binding affinity than Ligand A (-6.9 kcal/mol). This difference is significant enough to be a deciding factor.
**Overall Assessment:**
Ligand B is the better candidate. While Ligand A has slightly better BBB penetration and Pgp efflux, Ligand B has a significantly lower DILI risk, a longer half-life, and a better binding affinity. The lower DILI risk and longer half-life are particularly important for a cardiovascular drug, and the improved binding affinity outweighs the minor drawbacks in BBB and Pgp.
**Output:**
0
2025-04-17 20:32:33,334 - INFO - Reasoning:
Let's analyze Ligand A and Ligand B for their potential as ADRB2 ligands, keeping in mind the GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key).
**Molecular Weight:** Both ligands (343.431 and 361.511 Da) fall within the ideal 200-500 Da range.
**TPSA:** Ligand A (71.33) is slightly higher than Ligand B (62.3). Both are below the 140 threshold for oral absorption, which is good.
**logP:** Ligand A (1.153) is within the optimal 1-3 range, while Ligand B (3.331) is at the higher end. While still acceptable, Ligand B's higher logP could potentially lead to solubility issues or off-target interactions.
**H-Bond Donors/Acceptors:** Ligand A has 0 HBD and 5 HBA, while Ligand B has 1 HBD and 4 HBA. Both are within acceptable limits.
**QED:** Ligand A (0.772) has a better QED score than Ligand B (0.646), indicating a more drug-like profile.
**DILI:** Both ligands have similar DILI risk (42.458 vs 45.677), and both are below the concerning threshold of 60.
**BBB:** Ligand A (91.392) has a significantly higher BBB penetration percentile than Ligand B (70.027). While ADRB2 isn't exclusively a CNS target, improved BBB penetration can be beneficial for overall distribution and potentially accessing peripheral ADRB2 receptors.
**Caco-2 Permeability:** Ligand A (-4.767) has a worse Caco-2 permeability than Ligand B (-5.049).
**Aqueous Solubility:** Ligand A (-1.772) has better aqueous solubility than Ligand B (-4.149).
**hERG:** Both ligands have low hERG inhibition liability (0.374 and 0.488).
**Microsomal Clearance:** Ligand B (72.336) has a higher microsomal clearance than Ligand A (43.275), suggesting lower metabolic stability.
**In vitro Half-Life:** Ligand A (-8.113) has a much longer in vitro half-life than Ligand B (15.557).
**P-gp Efflux:** Ligand A (0.124) has lower P-gp efflux liability than Ligand B (0.339), which is favorable for bioavailability.
**Binding Affinity:** Ligand A (-6.7 kcal/mol) has a slightly better binding affinity than Ligand B (-5.4 kcal/mol). This 1.3 kcal/mol difference is significant and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand A demonstrates a superior balance of properties. It has a better QED score, significantly better BBB penetration, lower P-gp efflux, longer half-life, and slightly better binding affinity. While Ligand B has a slightly better Caco-2 permeability, the other advantages of Ligand A, particularly its metabolic stability and brain penetration, make it the more promising candidate for development as a drug targeting ADRB2. The slightly higher logP of Ligand B is a concern, and the lower half-life and higher P-gp efflux are significant drawbacks.
Output:
1
2025-04-17 20:32:33,335 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (343.39 and 356.42 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (102.05 and 108.05) are below the 140 A^2 threshold for good oral absorption, but higher than the 90 A^2 for CNS targets. Since ADRB2 is a cardiovascular target, CNS penetration is not a primary concern.
3. **logP:** Ligand A (1.991) is within the optimal 1-3 range. Ligand B (-1.419) is below 1, which *could* indicate permeability issues. This is a point in favor of Ligand A.
4. **HBD:** Both ligands have 2 HBD, which is acceptable.
5. **HBA:** Ligand A has 6 HBA, and Ligand B has 5. Both are within the acceptable range of <=10.
6. **QED:** Ligand A (0.8) has a better QED score than Ligand B (0.527), suggesting a more drug-like profile.
7. **DILI:** Ligand A (68.592) has a higher DILI risk than Ligand B (18.224). This is a significant negative for Ligand A.
8. **BBB:** Ligand A (76.813) has better BBB penetration than Ligand B (47.111), but as this is a cardiovascular target, this is less important.
9. **Caco-2:** Ligand A (-4.9) and Ligand B (-5.337) both have negative Caco-2 values, indicating poor permeability. This is concerning for both, but slightly worse for Ligand B.
10. **Solubility:** Ligand A (-4.043) has slightly better solubility than Ligand B (-0.495), although both are poor.
11. **hERG:** Ligand A (0.283) has a lower hERG risk than Ligand B (0.055), which is favorable.
12. **Cl_mic:** Ligand A (43.339) has a higher microsomal clearance than Ligand B (-2.143), indicating lower metabolic stability. This is a negative for Ligand A.
13. **t1/2:** Ligand A (17.084) has a longer half-life than Ligand B (-10.281), which is a positive.
14. **Pgp:** Ligand A (0.045) has lower P-gp efflux than Ligand B (0.001), which is favorable.
15. **Affinity:** Ligand A (-7.3 kcal/mol) has a significantly better binding affinity than Ligand B (-5.1 kcal/mol). This is a substantial advantage for Ligand A, potentially outweighing some of its ADME drawbacks.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand A has better logP, Pgp, and *much* better affinity. While Ligand B has a better DILI score, the substantial affinity advantage of Ligand A, combined with acceptable (though not ideal) ADME properties, makes it the more promising candidate. The lower DILI risk of Ligand B is appealing, but the potency difference is significant.
Output:
1
2025-04-17 20:32:33,335 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands (345.359 and 350.459 Da) are within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand B (78.87) is significantly better than Ligand A (108.33). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (2.66) is within the optimal 1-3 range. Ligand B (0.951) is a bit low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (1) and Ligand B (2) are both acceptable.
5. **HBA:** Ligand A (9) is acceptable, while Ligand B (4) is very good.
6. **QED:** Both ligands (0.659 and 0.699) have good drug-likeness scores.
7. **DILI:** Ligand B (9.965) has a much lower DILI risk than Ligand A (85.576). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (61.962) has a better BBB score than Ligand B (46.336), but BBB isn't a high priority for a cardiovascular target.
9. **Caco-2:** Ligand A (-5.148) and Ligand B (-4.771) are similar, indicating comparable intestinal absorption.
10. **Solubility:** Ligand A (-3.003) has better solubility than Ligand B (-1.279).
11. **hERG:** Both ligands (0.251 and 0.147) have low hERG inhibition liability, which is good.
12. **Cl_mic:** Ligand A (11.449) has a lower microsomal clearance than Ligand B (15.408), suggesting better metabolic stability.
13. **t1/2:** Ligand A (5.343) has a longer in vitro half-life than Ligand B (2.179). This is a significant advantage.
14. **Pgp:** Both ligands (0.086 and 0.049) have low P-gp efflux liability.
15. **Affinity:** Ligand B (-7.1) has a slightly better binding affinity than Ligand A (-7.0). While the difference is small, it's within the range where it could outweigh minor ADME drawbacks.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in TPSA and has a slightly better affinity. Ligand A has a better logP and half-life. However, the significantly lower DILI risk for Ligand B is a major advantage.
**Overall Assessment:**
Ligand B presents a better overall profile. The lower DILI risk is a crucial factor, and the slightly improved affinity and TPSA outweigh the slightly lower logP and shorter half-life. While Ligand A has better metabolic stability, the DILI risk associated with Ligand A is concerning.
Output:
0
2025-04-17 20:32:33,335 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [363.483, 71.53, 1.464, 1, 5, 0.86, 38.348, 58.007, -5.031, -1.837, 0.16, 16.142, -2.422, 0.077, -6.2]
**Ligand B:** [345.487, 71.09, 3.293, 2, 3, 0.721, 32.183, 77.937, -4.718, -3.703, 0.664, 63.22, 1.497, 0.139, -6.0]
Here's a breakdown, considering the GPCR priorities (logP, Pgp, TPSA, BBB, affinity):
1. **MW:** Both are within the ideal 200-500 Da range. A (363.483) is slightly higher than B (345.487), but both are acceptable.
2. **TPSA:** Both are good, below the 140 A^2 threshold (A: 71.53, B: 71.09).
3. **logP:** A (1.464) is optimal, while B (3.293) is approaching the upper limit. This is a slight advantage for A.
4. **HBD/HBA:** A (1 HBD, 5 HBA) is better than B (2 HBD, 3 HBA) in terms of balancing solubility and permeability.
5. **QED:** A (0.86) is better than B (0.721), indicating a more drug-like profile.
6. **DILI:** Both are acceptable, but B (32.183) has a lower risk than A (38.348).
7. **BBB:** B (77.937) is significantly better than A (58.007). While not a primary concern for a cardiovascular target, higher BBB is generally favorable.
8. **Caco-2:** Both are negative, indicating poor permeability. A (-5.031) is worse than B (-4.718).
9. **Solubility:** Both are negative, indicating poor solubility. B (-3.703) is slightly better than A (-1.837).
10. **hERG:** A (0.16) is much better than B (0.664), a crucial advantage for cardiovascular drugs.
11. **Cl_mic:** A (16.142) is much better than B (63.22), indicating better metabolic stability.
12. **t1/2:** A (-2.422) is better than B (1.497), suggesting a longer half-life.
13. **Pgp:** A (0.077) is much better than B (0.139), indicating less efflux.
14. **Affinity:** A (-6.2) is slightly better than B (-6.0), but the difference is small.
**Overall Assessment:**
Ligand A has a clear advantage in several crucial ADME properties: hERG inhibition, metabolic stability (Cl_mic), half-life, and P-gp efflux. It also has a slightly better logP and QED. While Ligand B has a better BBB penetration and slightly lower DILI risk, the cardiovascular focus makes the hERG and metabolic stability advantages of Ligand A far more important. The Caco-2 and solubility issues are concerning for both, but can be addressed with formulation strategies. The small affinity difference is not enough to overcome the ADME benefits of A.
Therefore, I recommend Ligand A.
Output:
1
2025-04-17 20:32:33,335 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (347.415 and 345.355 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (78.95) is significantly better than Ligand B (96.9). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand A is well below the 140 threshold, while Ligand B is approaching it.
**3. logP:** Both ligands have good logP values (2.048 and 1.825), falling within the optimal 1-3 range. Ligand B is slightly lower, which could slightly improve solubility, but the difference isn't substantial.
**4. H-Bond Donors:** Ligand A has 1 HBD, while Ligand B has 0. Both are acceptable.
**5. H-Bond Acceptors:** Both ligands have 5 HBAs, which is within the acceptable limit of 10.
**6. QED:** Ligand A (0.764) has a considerably higher QED score than Ligand B (0.471), indicating a more drug-like profile. This is a significant advantage for Ligand A.
**7. DILI:** Ligand A (71.539) has a slightly higher DILI risk than Ligand B (62.35), but both are still within an acceptable range (<60 is good).
**8. BBB:** Ligand B (93.098) has a much higher BBB penetration percentile than Ligand A (70.803). While ADRB2 is a cardiovascular target and CNS penetration isn't *essential*, some degree of BBB penetration can be useful for off-target effects assessment and potential pleiotropic effects.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.635 and -4.427), which is unusual and suggests poor permeability. This is a concern for both.
**10. Aqueous Solubility:** Both ligands have very poor aqueous solubility (-3.321 and -3.708). This is a significant drawback for both, potentially hindering bioavailability.
**11. hERG Inhibition:** Both ligands show low hERG inhibition risk (0.244 and 0.319). This is good.
**12. Microsomal Clearance:** Ligand A (-2.444) has a much lower (better) microsomal clearance than Ligand B (13.124). This indicates greater metabolic stability for Ligand A.
**13. In vitro Half-Life:** Ligand A (14.294 hours) has a significantly longer half-life than Ligand B (31.909 hours). This is a major advantage for Ligand A, potentially allowing for less frequent dosing.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.02 and 0.208). This is favorable.
**15. Binding Affinity:** Ligand A (-6.1 kcal/mol) has a slightly better binding affinity than Ligand B (-4.9 kcal/mol). This 1.2 kcal/mol difference is substantial and can outweigh some of the ADME drawbacks.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand A is the stronger candidate. While Ligand B has better BBB penetration, the superior QED, lower clearance, longer half-life, and better binding affinity of Ligand A are more critical for overall drug development success. The poor Caco-2 and solubility are concerns for both, but can be addressed through formulation strategies. The slightly higher DILI risk for Ligand A is manageable.
Output:
1
2025-04-17 20:32:33,335 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
We are targeting ADRB2, a GPCR, so the priorities are logP, TPSA, Pgp, BBB, and affinity. Let's break down each ligand:
* **Molecular Weight:** Both ligands are within the ideal range (200-500 Da).
* **TPSA:** Ligand A (96.89) is higher than Ligand B (58.64). For a peripheral GPCR like ADRB2, lower TPSA is generally preferred for better membrane permeability, giving a slight edge to Ligand B.
* **logP:** Ligand B (3.147) is better than Ligand A (0.743). Ligand A's logP is quite low, potentially hindering membrane permeability. Ligand B is within the optimal range.
* **H-Bond Donors/Acceptors:** Ligand A has 3 HBD and 5 HBA, while Ligand B has 1 HBD and 3 HBA. Ligand B has a more favorable profile here, potentially improving permeability.
* **QED:** Ligand B (0.716) is slightly better than Ligand A (0.53), indicating a more drug-like profile.
* **DILI:** Ligand B (23.769) has a significantly lower DILI risk than Ligand A (18.573), which is a crucial advantage.
* **BBB:** Ligand B (79.139) has a much higher BBB penetration score than Ligand A (28.655). While ADRB2 isn't primarily a CNS target, higher BBB is rarely a detriment and can indicate better overall distribution.
* **Caco-2:** Ligand A (-5.201) and Ligand B (-4.098) are both negative, which is unusual and suggests poor permeability in this assay. However, the negative values are close, so this isn't a major differentiator.
* **Solubility:** Ligand A (-2.007) has slightly better solubility than Ligand B (-3.107).
* **hERG:** Both ligands have very low hERG risk (0.228 and 0.269, respectively).
* **Cl_mic:** Ligand A (30.694) has significantly lower microsomal clearance than Ligand B (98.001), suggesting better metabolic stability. This is a significant advantage for Ligand A.
* **t1/2:** Ligand B (16.945) has a longer in vitro half-life than Ligand A (4.433).
* **Pgp:** Both ligands have low P-gp efflux liability (0.039 and 0.123, respectively).
* **Binding Affinity:** Ligand A (-7.1) has a slightly better binding affinity than Ligand B (-6.8). However, the difference is only 0.3 kcal/mol, which is not substantial enough to outweigh other significant differences.
**Overall Assessment:**
Ligand B has a much better overall profile. Its superior logP, lower TPSA, lower DILI risk, and higher BBB penetration are all significant advantages for a GPCR target. While Ligand A has better metabolic stability (lower Cl_mic) and slightly better binding affinity, the ADME properties of Ligand B are far more favorable, and the affinity difference is relatively small. The lower DILI risk alone is a major factor in favor of Ligand B.
**Output:**
0
2025-04-17 20:32:33,335 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
The ADRB2 receptor is a GPCR, so the priorities are logP, Pgp, TPSA, affinity, and, to a lesser extent, BBB. Let's break down the comparison:
1. **Molecular Weight:** Both ligands are within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (81.18) is significantly better than Ligand B (120.58). A lower TPSA generally indicates better membrane permeability, crucial for GPCR ligands.
3. **logP:** Ligand A (3.808) is optimal, while Ligand B (-0.819) is quite low. A low logP can hinder membrane permeability and bioavailability. This is a major strike against Ligand B.
4. **H-Bond Donors/Acceptors:** Ligand A (1 HBD, 5 HBA) is preferable to Ligand B (3 HBD, 7 HBA). Fewer hydrogen bonds are generally better for permeability.
5. **QED:** Ligand A (0.855) has a better QED score than Ligand B (0.637), indicating a more drug-like profile.
6. **DILI:** Ligand B (45.25) has a much lower DILI risk than Ligand A (79.798), which is a significant advantage.
7. **BBB:** Ligand A (61.846) has a better BBB penetration than Ligand B (18.961). While not a primary concern for peripheral GPCRs like ADRB2, it's still a positive.
8. **Caco-2:** Ligand A (-4.476) is better than Ligand B (-5.484), indicating better intestinal absorption.
9. **Solubility:** Ligand A (-5.027) is better than Ligand B (-0.707).
10. **hERG:** Ligand A (0.359) is better than Ligand B (0.01), indicating a lower risk of cardiotoxicity.
11. **Cl_mic:** Ligand B (-16.135) has a significantly lower (better) microsomal clearance than Ligand A (107.395), suggesting greater metabolic stability.
12. **t1/2:** Ligand B (10.384) has a better in vitro half-life than Ligand A (7.516).
13. **Pgp:** Ligand A (0.111) has a better Pgp efflux liability than Ligand B (0.009).
14. **Binding Affinity:** Both ligands have very similar binding affinities (-6.3 and -6.1 kcal/mol). The difference is not substantial enough to outweigh other factors.
**Overall Assessment:**
Ligand A excels in properties related to permeability (TPSA, logP, Caco-2) and drug-likeness (QED). However, Ligand B demonstrates a significantly better safety profile (DILI) and metabolic stability (Cl_mic, t1/2). Considering the importance of permeability for GPCR engagement and the relatively small difference in binding affinity, Ligand A is the more promising candidate. The lower logP and higher DILI of Ligand B are significant drawbacks.
**Output:**
1
2025-04-17 20:32:33,336 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (353.365 and 363.479 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Both ligands (66.84 and 68.65) are below the 140 A^2 threshold for good oral absorption. They are also reasonably low, suitable for a GPCR target. No significant difference.
3. **logP:** Ligand A (2.469) is optimal, while Ligand B (3.565) is slightly higher but still within the acceptable range (1-3). Ligand A has a slight edge here.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 6. Both are acceptable (<=10), but Ligand A is slightly better.
6. **QED:** Ligand A (0.826) has a significantly better QED score than Ligand B (0.574), indicating a more drug-like profile. This is a substantial advantage for Ligand A.
7. **DILI:** Ligand A (38.62) has a lower DILI risk than Ligand B (49.399), both are acceptable, but A is better.
8. **BBB:** Ligand A (81.466) shows significantly better BBB penetration potential than Ligand B (29.12). While ADRB2 isn't exclusively a CNS target, improved BBB penetration can be beneficial, and is a priority for GPCRs. This is a strong point for Ligand A.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.198) is slightly better than Ligand B (-4.792).
10. **Solubility:** Both ligands have negative solubility values, which is also unusual and suggests poor solubility. Ligand A (-3.172) is slightly better than Ligand B (-4.533).
11. **hERG:** Both ligands have low hERG risk (0.444 and 0.541). No significant difference.
12. **Cl_mic:** Ligand A (52.929) has lower microsomal clearance than Ligand B (96.574), indicating better metabolic stability. This is a positive for Ligand A.
13. **t1/2:** Both ligands have similar in vitro half-lives (1.255 and 1.382 hours).
14. **Pgp:** Both ligands have low Pgp efflux liability (0.193 and 0.65). Ligand A is better.
15. **Binding Affinity:** Ligand A (-7.0 kcal/mol) has a slightly better binding affinity than Ligand B (-4.3 kcal/mol). This is a significant advantage for Ligand A, as a 1.5 kcal/mol advantage can outweigh minor ADME drawbacks.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across multiple crucial parameters. It has a better QED score, lower DILI risk, significantly better BBB penetration, lower microsomal clearance (better metabolic stability), and a superior binding affinity. While both have issues with Caco-2 and solubility, Ligand A is slightly better in these areas as well. The substantial difference in binding affinity and the favorable ADME properties make Ligand A the more promising drug candidate.
Output:
1
2025-04-17 20:32:33,336 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.362 and 362.499 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (82.45) is better than Ligand B (97.11). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally favors absorption.
3. **logP:** Both ligands (2.409 and 2.24) are within the optimal 1-3 range. Again, a small difference.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (6) is preferable to Ligand B (5). Lower HBA counts are generally better for permeability.
6. **QED:** Both ligands (0.776 and 0.718) have good drug-likeness scores, well above the 0.5 threshold.
7. **DILI:** Ligand A (68.282) is slightly higher than Ligand B (62.466), but both are acceptable, being below the 60 threshold.
8. **BBB:** Both ligands have similar BBB penetration (63.784 and 61.923). This isn't a critical factor for a cardiovascular target.
9. **Caco-2:** Ligand A (-4.348) is better than Ligand B (-4.989). Higher (less negative) Caco-2 values indicate better intestinal absorption.
10. **Solubility:** Ligand A (-2.77) is better than Ligand B (-3.786). Higher solubility is generally preferred.
11. **hERG:** Ligand A (0.378) is significantly better than Ligand B (0.507). Lower hERG inhibition is crucial to avoid cardiotoxicity, especially for a cardiovascular target.
12. **Cl_mic:** Ligand A (86.385) is worse than Ligand B (-0.848). Lower clearance is preferred for metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand A (-7.141) is much better than Ligand B (22.619). A longer half-life is desirable for less frequent dosing.
14. **Pgp:** Ligand A (0.209) is better than Ligand B (0.078). Lower P-gp efflux is preferred for better bioavailability.
15. **Binding Affinity:** Ligand A (-5.6) is slightly better than Ligand B (-7.0). While Ligand B has a stronger binding affinity, the difference isn't large enough to outweigh the other factors.
**Overall Assessment:**
Considering ADRB2 is a GPCR, logP, TPSA, Pgp, and affinity are key. Ligand A has a better balance of properties. While Ligand B has a superior binding affinity and metabolic stability, Ligand A has a better hERG profile, solubility, Caco-2 permeability, and Pgp efflux. The hERG risk with Ligand B is concerning for a cardiovascular drug. The longer half-life of Ligand A is also a significant advantage.
Output:
1
2025-04-17 20:32:33,336 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (453.692 Da) is within the ideal range, while Ligand B (363.439 Da) is on the lower side, but still acceptable.
2. **TPSA:** Ligand A (67.43) is better than Ligand B (84.67), both are acceptable, but lower is better for permeability.
3. **logP:** Ligand A (4.581) is slightly high, potentially leading to solubility issues, while Ligand B (2.15) is optimal.
4. **HBD:** Ligand A (2) and Ligand B (1) are both good.
5. **HBA:** Ligand A (4) and Ligand B (6) are both acceptable.
6. **QED:** Ligand A (0.651) and Ligand B (0.88) are both good, with B being slightly better.
7. **DILI:** Ligand A (82.28) has a higher DILI risk than Ligand B (66.615), which is concerning.
8. **BBB:** Ligand A (68.36) and Ligand B (76.309) are both reasonable, but B is better.
9. **Caco-2:** Both are negative, indicating poor permeability.
10. **Solubility:** Ligand A (-6.012) has very poor solubility, while Ligand B (-3.46) is better, but still not ideal.
11. **hERG:** Ligand A (0.483) has a slightly higher hERG risk than Ligand B (0.3).
12. **Cl_mic:** Ligand A (60.502) has a higher clearance than Ligand B (33.549), indicating lower metabolic stability.
13. **t1/2:** Ligand A (66.892) has a longer half-life than Ligand B (13.83), which is a positive.
14. **Pgp:** Ligand A (0.507) has a slightly higher Pgp efflux liability than Ligand B (0.116).
15. **Affinity:** Ligand A (-6.9 kcal/mol) has a slightly better binding affinity than Ligand B (-6.6 kcal/mol), but the difference is not substantial.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are crucial. Ligand B excels in logP and Pgp, while Ligand A has a slightly better affinity. However, Ligand A suffers from significantly worse solubility, higher DILI risk, and higher clearance. The solubility and DILI issues are major red flags. While the affinity is slightly better for Ligand A, the other ADME properties of Ligand B make it a more promising starting point for optimization.
**Conclusion:**
Ligand B is the more viable drug candidate due to its better ADME properties, particularly its lower DILI risk, better solubility, and lower Pgp efflux. The slightly lower affinity can be addressed through further optimization.
Output:
0
2025-04-17 20:32:33,336 - INFO - Batch 192 complete. Total preferences: 3072
2025-04-17 20:32:33,336 - INFO - Processing batch 193/512...
2025-04-17 20:33:21,978 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (343.471 and 366.531 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (73.2) is higher than Ligand B (56.75). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B is better.
3. **logP:** Both ligands have good logP values (2.946 and 2.245), falling within the 1-3 range. Ligand A is slightly higher, which *could* be beneficial for membrane permeability, but both are acceptable.
4. **HBD:** Ligand A (1) is better than Ligand B (0). Having at least one HBD can improve solubility.
5. **HBA:** Ligand A (3) is lower than Ligand B (5). Lower HBA is generally preferred for permeability. Ligand A is better.
6. **QED:** Both ligands have similar QED values (0.78 and 0.743), indicating good drug-likeness. No significant difference.
7. **DILI:** Ligand A (19.155) has a significantly lower DILI risk than Ligand B (34.238). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (78.674) has a higher BBB penetration percentile than Ligand B (68.36). While ADRB2 isn't a CNS target, some peripheral exposure can be detrimental, and higher BBB suggests lower overall distribution.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.617 and -4.645), which is unusual and suggests poor permeability. This is a concern for both, but similar.
10. **Solubility:** Ligand A (-3.362) has better solubility than Ligand B (-1.484). Solubility is important for bioavailability.
11. **hERG:** Both ligands have low hERG inhibition risk (0.387 and 0.494). No significant difference.
12. **Cl_mic:** Ligand A (25.49) has significantly lower microsomal clearance than Ligand B (44.327). This indicates better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (-7.938) has a much longer in vitro half-life than Ligand B (9.102). This is a significant advantage for Ligand A, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.053 and 0.233). No significant difference.
15. **Binding Affinity:** Ligand A (-7.7) has a slightly better binding affinity than Ligand B (-7.4). While the difference is small (0.3 kcal/mol), it's still a positive for Ligand A.
**GPCR-Specific Priorities:**
For ADRB2 (a cardiovascular GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A performs well in these areas. The significant advantages of Ligand A in DILI risk, metabolic stability (Cl_mic and t1/2), and solubility outweigh the slightly higher TPSA.
**Conclusion:**
Ligand A is the more promising drug candidate due to its superior safety profile (DILI), metabolic stability, solubility, and slightly better binding affinity.
Output:
1
2025-04-17 20:33:21,978 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (340.43 and 349.34 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (66.49) is significantly better than Ligand B (88.91). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is approaching a less desirable range.
3. **logP:** Both ligands have good logP values (2.496 and 1.578), falling within the 1-3 optimal range. Ligand A is slightly higher, which could be a minor advantage for membrane permeability.
4. **HBD:** Both ligands have 2 H-bond donors, which is within the acceptable limit of 5.
5. **HBA:** Both ligands have 5 H-bond acceptors, also within the acceptable limit of 10.
6. **QED:** Ligand A (0.846) has a slightly better QED score than Ligand B (0.794), indicating a more drug-like profile.
7. **DILI:** Ligand A (34.703) has a much lower DILI risk than Ligand B (76.425). This is a *major* advantage for Ligand A. DILI is a significant concern in drug development.
8. **BBB:** Ligand A (68.088) and Ligand B (73.75) both have reasonable BBB penetration, but Ligand B is slightly better. However, ADRB2 is primarily a cardiovascular target, so high BBB penetration isn't critical.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.336 and -5.293), which is unusual and suggests poor permeability. This is a potential red flag for both, but the values are very similar.
10. **Solubility:** Ligand A (-1.449) has better solubility than Ligand B (-3.18). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.673) has a lower hERG inhibition liability than Ligand B (0.223). This is a significant advantage for Ligand A, as hERG inhibition can lead to cardiotoxicity.
12. **Cl_mic:** Ligand A (-42.889) has *much* lower microsomal clearance than Ligand B (3.311). This indicates significantly better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (38.069) has a longer in vitro half-life than Ligand B (17.163). This is a clear advantage, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.04) has lower P-gp efflux liability than Ligand B (0.028).
15. **Affinity:** Ligand B (-8.3 kcal/mol) has a slightly better binding affinity than Ligand A (-7.1 kcal/mol). While a difference of 1.2 kcal/mol is noticeable, the other significant advantages of Ligand A likely outweigh this.
**Overall Assessment:**
Ligand A demonstrates a significantly better safety profile (lower DILI, lower hERG) and improved pharmacokinetic properties (lower Cl_mic, longer t1/2, better solubility). While Ligand B has slightly better binding affinity and BBB penetration, these are less critical for a cardiovascular target like ADRB2, and the other advantages of Ligand A are substantial. The Caco-2 values are concerning for both, but the overall profile of Ligand A is far more promising.
Output:
1
2025-04-17 20:33:21,978 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [332.363, 84.06, 3.417, 2, 6, 0.587, 94.649, 29.818, -4.957, -5.345, 0.444, 33.309, -1.683, 0.491, -5.0]
**Ligand B:** [354.491, 78.87, 1.563, 2, 4, 0.693, 11.361, 67.662, -4.608, -1.786, 0.366, 17.388, -5.921, 0.077, -7.0]
Here's a breakdown, considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (332.363) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are good, below 140. Ligand B (78.87) is slightly better, potentially indicating improved membrane permeability.
3. **logP:** Ligand A (3.417) is optimal, while Ligand B (1.563) is a bit low. A logP below 2 can sometimes hinder membrane permeation.
4. **HBD/HBA:** Both have acceptable HBD (2) and HBA (6/4) counts.
5. **QED:** Both are reasonable, but Ligand B (0.693) is better than Ligand A (0.587), suggesting a more drug-like profile.
6. **DILI:** Ligand A (94.649) has a very high DILI risk, which is a major concern. Ligand B (11.361) has a very low DILI risk, a significant advantage.
7. **BBB:** Ligand B (67.662) has a better BBB penetration percentile than Ligand A (29.818), although neither is exceptionally high. Since this is a cardiovascular target, BBB isn't *critical* but is still a plus.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. This is a red flag for both.
9. **Solubility:** Both have negative solubility values, which is also unusual and suggests poor solubility. This is a red flag for both.
10. **hERG:** Both have low hERG inhibition liability, which is good.
11. **Cl_mic:** Ligand B (17.388) has a significantly lower microsomal clearance than Ligand A (33.309), indicating better metabolic stability.
12. **t1/2:** Ligand B (-5.921) has a longer in vitro half-life than Ligand A (-1.683), suggesting slower metabolism.
13. **Pgp:** Ligand A (0.491) has slightly lower P-gp efflux liability than Ligand B (0.077), which could mean better bioavailability.
14. **Affinity:** Ligand B (-7.0) has a significantly stronger binding affinity than Ligand A (-5.0). This is a substantial advantage.
**Overall Assessment:**
Despite the unusual Caco-2 and solubility values for both, Ligand B is the far superior candidate. The significantly lower DILI risk, stronger binding affinity, improved metabolic stability (lower Cl_mic and longer t1/2), and better QED outweigh the slightly lower logP. The higher BBB is a bonus. The high DILI risk associated with Ligand A is a dealbreaker.
Output:
0
2025-04-17 20:33:21,978 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.403 and 344.415 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (100.63) is slightly higher than Ligand B (86.53). Both are below the 140 A^2 threshold for good oral absorption, but Ligand B is preferable given the GPCR target class.
3. **logP:** Ligand B (1.158) is slightly higher than Ligand A (0.819), both are within the optimal 1-3 range.
4. **HBD:** Ligand A (2) is higher than Ligand B (0). Lower HBD is generally preferred for better permeability, so Ligand B is slightly favored.
5. **HBA:** Ligand A (6) is higher than Ligand B (5). Similar to HBD, lower HBA is generally preferred, making Ligand B slightly more favorable.
6. **QED:** Ligand B (0.818) has a higher QED score than Ligand A (0.506), indicating a more drug-like profile. This is a significant advantage for Ligand B.
7. **DILI:** Ligand A (57.736) and Ligand B (50.291) are both acceptable, being below the 60 percentile threshold. Ligand B is slightly better.
8. **BBB:** Ligand B (62.737) has a higher BBB penetration percentile than Ligand A (57.619). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be beneficial for distribution and off-target effects assessment.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.867 and -4.264). These values are unusual and suggest poor permeability. However, the scale isn't specified, so it's hard to interpret.
10. **Solubility:** Ligand A (-1.651) has slightly worse solubility than Ligand B (-1.184).
11. **hERG:** Both ligands have very low hERG inhibition risk (0.17 and 0.367). No significant difference.
12. **Cl_mic:** Ligand B (12.216) has significantly lower microsomal clearance than Ligand A (45.94). This suggests better metabolic stability for Ligand B, a major advantage.
13. **t1/2:** Ligand B (-8.287) has a much longer in vitro half-life than Ligand A (5.488). This is a substantial benefit, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.026 and 0.035). No significant difference.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-5.8 and -5.9 kcal/mol).
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B excels in TPSA, QED, Cl_mic, and t1/2, all of which are important for a good drug candidate. While both have similar affinity, the improved ADME properties of Ligand B make it the more promising candidate.
**Conclusion:**
Ligand B demonstrates a superior balance of properties, particularly in terms of metabolic stability, half-life, and drug-likeness.
Output:
0
2025-04-17 20:33:21,978 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Step-by-step comparison:**
1. **MW:** Both ligands (344.419 Da and 330.395 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (93.84) is slightly higher than Ligand B (69.38). Ligand B is better, being closer to the <90 A^2 target for good absorption.
3. **logP:** Ligand A (0.642) is lower than the optimal 1-3 range, potentially hindering permeability. Ligand B (3.506) is within the optimal range. Ligand B is preferred.
4. **HBD:** Ligand A (2) is reasonable. Ligand B (0) is even better, minimizing potential for off-target interactions and improving permeability.
5. **HBA:** Both ligands have 6 HBA, which is acceptable.
6. **QED:** Ligand A (0.771) has a higher QED score than Ligand B (0.562), suggesting a more drug-like profile. This favors Ligand A.
7. **DILI:** Ligand A (48.197) has a significantly lower DILI risk than Ligand B (77.588). This is a major advantage for Ligand A.
8. **BBB:** Both ligands have similar BBB penetration (Ligand A: 51.803, Ligand B: 57.076). Not a major differentiating factor for a cardiovascular target like ADRB2.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-1.9) has better solubility than Ligand B (-3.605).
11. **hERG:** Both ligands have low hERG inhibition risk (Ligand A: 0.502, Ligand B: 0.46). No significant difference.
12. **Cl_mic:** Ligand A (20.361) has a higher microsomal clearance than Ligand B (16.194), meaning faster metabolism. Ligand B is preferred.
13. **t1/2:** Ligand B (-32.191) has a much longer in vitro half-life than Ligand A (7.979). This is a substantial advantage for Ligand B.
14. **Pgp:** Ligand A (0.017) has significantly lower P-gp efflux liability than Ligand B (0.246), which is beneficial for bioavailability.
15. **Binding Affinity:** Ligand B (-7.6 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.5 kcal/mol). This is a crucial advantage, potentially outweighing some ADME concerns.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP and affinity, and has a better TPSA. While Ligand A has better Pgp and DILI, the superior binding affinity of Ligand B is a significant driver. The longer half-life of Ligand B is also a positive.
**Overall Assessment:**
While Ligand A has advantages in QED, DILI, solubility, and Pgp efflux, Ligand B's markedly stronger binding affinity and longer half-life, coupled with acceptable logP and TPSA, make it the more promising candidate. The higher DILI risk for Ligand B is a concern, but could be addressed through further structural modifications.
Output:
0
2025-04-17 20:33:21,978 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (345.4 and 344.4 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (75.88) is better than Ligand B (87.12). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (1.278 and 1.068), falling within the optimal 1-3 range. Ligand B is slightly lower, which *could* indicate slightly lower permeability, but the difference is small.
4. **HBD:** Ligand A (0) is preferable to Ligand B (1). Fewer HBDs generally improve membrane permeability.
5. **HBA:** Both ligands have 5 HBA, which is acceptable.
6. **QED:** Ligand B (0.899) has a slightly better QED score than Ligand A (0.752), indicating a more drug-like profile. This is a small advantage.
7. **DILI:** Ligand A (41.024) has a significantly lower DILI risk than Ligand B (61.07). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (75.572) has a higher BBB percentile than Ligand B (38.658). While not a primary concern for a cardiovascular target, higher BBB is generally favorable.
9. **Caco-2:** Ligand B (-5.21) has a better Caco-2 permeability than Ligand A (-4.673), suggesting better intestinal absorption.
10. **Solubility:** Ligand B (-1.686) is slightly better than Ligand A (-1.575).
11. **hERG:** Both ligands have very low hERG inhibition risk (0.218 and 0.18), which is excellent.
12. **Cl_mic:** Ligand B (21.826) has a significantly lower microsomal clearance than Ligand A (47.084), indicating better metabolic stability. This is a substantial advantage for Ligand B.
13. **t1/2:** Ligand A (-7.266) has a longer in vitro half-life than Ligand B (-3.794). This is a significant advantage for Ligand A.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.117 and 0.033).
15. **Binding Affinity:** Both ligands have comparable binding affinities (-6.7 and -6.8 kcal/mol). The difference is negligible.
**GPCR-Specific Priorities & Overall Assessment:**
For a GPCR like ADRB2, logP, TPSA, and affinity are important. Both ligands perform well in these areas. However, the key differentiators are DILI risk, metabolic stability (Cl_mic), and half-life. Ligand A has a much lower DILI risk and a longer half-life, while Ligand B has better metabolic stability. Given the importance of avoiding liver toxicity, the lower DILI risk of Ligand A is a critical advantage. The longer half-life is also beneficial, potentially allowing for less frequent dosing. While the better metabolic stability of Ligand B is attractive, it is outweighed by the significant DILI risk.
Output:
1
2025-04-17 20:33:21,979 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (350.463) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (67.67) is significantly better than Ligand B (93.01). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally aids absorption.
3. **logP:** Both ligands have good logP values (A: 1.314, B: 1.199) falling within the optimal 1-3 range. They are very similar here.
4. **HBD:** Ligand A (0) is preferable to Ligand B (1). Fewer HBDs generally improve membrane permeability.
5. **HBA:** Ligand A (5) is better than Ligand B (7). Lower HBA also contributes to better permeability.
6. **QED:** Both ligands have good QED scores (A: 0.744, B: 0.812), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (7.794) has a much lower DILI risk than Ligand B (80.729). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (75.107) has better BBB penetration than Ligand B (51.066), but this is less critical for a cardiovascular target.
9. **Caco-2:** Ligand A (-4.694) and Ligand B (-5.555) both show good Caco-2 permeability, but are negative values indicating a scale where higher is better. Ligand A is slightly better.
10. **Solubility:** Ligand A (-0.225) has better solubility than Ligand B (-2.38). This is a positive attribute.
11. **hERG:** Ligand A (0.34) has a much lower hERG risk than Ligand B (0.138). This is a crucial safety parameter.
12. **Cl_mic:** Ligand B (-3.071) has a lower (better) microsomal clearance than Ligand A (4.994), indicating greater metabolic stability.
13. **t1/2:** Ligand A (-3.308) has a longer in vitro half-life than Ligand B (-0.981). This is a positive attribute.
14. **Pgp:** Ligand A (0.034) has lower P-gp efflux than Ligand B (0.059), which is favorable for bioavailability.
15. **Affinity:** Ligand B (-7.3) has a slightly better binding affinity than Ligand A (-6.9). This is a 1.5 kcal/mol advantage, which is significant.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B has a slightly better affinity, but Ligand A excels in TPSA, Pgp, and has a significantly better safety profile (DILI and hERG). The affinity difference, while notable, is not large enough to outweigh the substantial advantages of Ligand A in terms of safety and absorption/permeability.
**Conclusion:**
Considering the balance of properties, especially the significantly lower DILI and hERG risk, better TPSA, solubility, and Pgp efflux, Ligand A is the more promising drug candidate.
Output:
1
2025-04-17 20:33:21,979 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Ligand A (343.402 Da) is well within the ideal range (200-500 Da). Ligand B (430.774 Da) is at the higher end but still acceptable.
2. **TPSA:** Ligand A (62.3) is good, well below the 140 threshold for oral absorption. Ligand B (72.38) is still reasonable but slightly less favorable.
3. **logP:** Ligand A (1.697) is optimal (1-3). Ligand B (4.249) is higher, potentially leading to solubility issues and off-target interactions. This is a significant concern.
4. **HBD:** Ligand A (1) is good. Ligand B (3) is acceptable, but higher HBD can sometimes affect permeability.
5. **HBA:** Ligand A (3) is good. Ligand B (4) is acceptable.
6. **QED:** Both Ligand A (0.632) and Ligand B (0.64) are good, indicating drug-like properties.
7. **DILI:** Both Ligand A (29.159) and Ligand B (28.616) have low DILI risk, which is excellent.
8. **BBB:** Ligand A (67.041) is moderate. Ligand B (20.938) is low, indicating poor brain penetration. While ADRB2 isn't necessarily a CNS target, some peripheral ADRB2 receptors can influence CNS function, and better BBB penetration isn't a detriment.
9. **Caco-2:** Ligand A (-4.634) and Ligand B (-5.363) are both negative, which is unusual and suggests very poor permeability. This is a major red flag for both.
10. **Solubility:** Ligand A (-2.67) and Ligand B (-4.669) are both very poor. This is a significant issue, especially given Ligand B's higher logP.
11. **hERG:** Ligand A (0.176) has a very low hERG risk, which is excellent. Ligand B (0.826) is slightly higher, but still relatively low.
12. **Cl_mic:** Ligand A (13.042) has lower clearance, indicating better metabolic stability. Ligand B (54.331) has significantly higher clearance, a major drawback.
13. **t1/2:** Ligand A (-15.336) has a negative half-life, which is impossible and indicates an error or unusual behavior. Ligand B (18.525) has a reasonable half-life.
14. **Pgp:** Ligand A (0.034) has very low P-gp efflux, which is favorable. Ligand B (0.364) is slightly higher, but still acceptable.
15. **Affinity:** Both Ligand A (-6.7) and Ligand B (-6.3) have good binding affinities, but Ligand A is slightly better.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A performs better on logP and Pgp. The affinity difference is small, but favors Ligand A. The Caco-2 and solubility issues are concerning for both, but the higher logP and clearance of Ligand B are more problematic. The negative half-life for Ligand A is a showstopper.
**Conclusion:**
Despite the poor Caco-2 and solubility for both, Ligand A is slightly preferable due to its better logP, lower clearance, and slightly better affinity. However, the negative half-life is a serious issue. If the half-life value for Ligand A is an error, it would be the clear choice.
Output:
1
2025-04-17 20:33:21,979 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (357.42 and 353.423 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (35.58) is significantly lower than Ligand B (133.63). This is a major advantage for Ligand A, as lower TPSA generally correlates with better oral absorption, crucial for a cardiovascular drug. Ligand B's high TPSA is a significant concern.
3. **logP:** Ligand A (3.304) is within the optimal range (1-3). Ligand B (-0.766) is *below* the optimal range, potentially hindering membrane permeability. This favors Ligand A.
4. **HBD:** Ligand A (1) is preferable to Ligand B (4). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (4). Fewer HBAs generally improve permeability.
6. **QED:** Ligand A (0.898) is excellent, indicating high drug-likeness. Ligand B (0.32) is quite low, raising concerns about its overall developability. This strongly favors Ligand A.
7. **DILI:** Both ligands have acceptable DILI risk (27.724 and 23.885 percentile). No significant difference.
8. **BBB:** Ligand A (92.516) shows good BBB penetration, while Ligand B (71.888) is lower. While ADRB2 isn't strictly a CNS target, some CNS exposure can occur, and higher BBB penetration is generally favorable. This favors Ligand A.
9. **Caco-2:** Ligand A (-4.563) and Ligand B (-5.736) both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale isn't specified, so it's hard to interpret.
10. **Solubility:** Ligand A (-3.106) and Ligand B (-1.289) both have negative solubility values, which is also unusual and suggests poor solubility. Again, the scale isn't specified.
11. **hERG:** Ligand A (0.936) has a slightly higher hERG risk than Ligand B (0.058). This is a slight advantage for Ligand B, but not a major concern given the other factors.
12. **Cl_mic:** Ligand A (22.02) has a higher microsomal clearance than Ligand B (-8.685). This indicates Ligand B is likely more metabolically stable, which is a positive.
13. **t1/2:** Ligand A (-0.448) has a shorter in vitro half-life than Ligand B (-4.175). This favors Ligand B.
14. **Pgp:** Ligand A (0.246) has lower P-gp efflux than Ligand B (0.003), which is favorable.
15. **Binding Affinity:** Ligand A (-6.7 kcal/mol) and Ligand B (-7.4 kcal/mol) have very similar binding affinities. Ligand B is slightly better, but the difference is small.
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A excels in logP and TPSA, and has acceptable Pgp and affinity. Ligand B has a poor logP and TPSA, but slightly better affinity and metabolic stability.
**Overall Assessment:**
Despite Ligand B having slightly better affinity and metabolic stability, Ligand A is the superior candidate. The significantly lower TPSA and better logP of Ligand A are crucial for oral absorption and overall drug-likeness. The higher QED score for Ligand A further supports this conclusion. The slight hERG risk difference is not enough to outweigh the substantial advantages of Ligand A.
Output:
1
2025-04-17 20:33:21,979 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (396.49 Da) is slightly higher than Ligand B (358.551 Da), but both are acceptable.
2. **TPSA:** Ligand A (89.26) is good, under the 140 threshold, and acceptable for a non-CNS GPCR. Ligand B (32.34) is excellent, well below the threshold, suggesting good permeability.
3. **logP:** Ligand A (3.167) is optimal. Ligand B (4.579) is a bit high, potentially leading to solubility issues and off-target interactions, but still within a tolerable range.
4. **HBD:** Ligand A (2) and Ligand B (1) are both good, meeting the <=5 criteria.
5. **HBA:** Ligand A (5) and Ligand B (3) are both good, meeting the <=10 criteria.
6. **QED:** Both ligands have similar QED values (A: 0.713, B: 0.631), indicating good drug-like properties.
7. **DILI:** Ligand A (91.314) has a significantly higher DILI risk than Ligand B (21.055). This is a major concern for Ligand A.
8. **BBB:** Both ligands have similar BBB penetration (A: 70.609, B: 70.027), which is acceptable for a cardiovascular target (ADRB2 is not a CNS target).
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.242 and -5.212). This is unusual and suggests poor permeability. However, the values are very similar.
10. **Solubility:** Ligand A (-3.736) has slightly better solubility than Ligand B (-2.711), though both are poor.
11. **hERG:** Ligand A (0.604) has a lower hERG risk than Ligand B (0.953), which is preferable.
12. **Cl_mic:** Ligand B (78.901) has a significantly higher microsomal clearance than Ligand A (17.668), indicating faster metabolism and potentially lower bioavailability.
13. **t1/2:** Ligand A (42.102) has a longer in vitro half-life than Ligand B (49.547).
14. **Pgp:** Ligand A (0.387) has lower P-gp efflux than Ligand B (0.785), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand B (-8.2 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.8 kcal/mol). This is a substantial advantage, potentially outweighing some ADME concerns.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand B excels in affinity and has better TPSA. While its logP is slightly higher, the strong binding affinity and lower DILI risk are compelling. Ligand A has a concerningly high DILI risk.
**Conclusion:**
Despite Ligand B's slightly higher logP and poorer solubility, its significantly stronger binding affinity and much lower DILI risk make it the more promising candidate. The improved metabolic stability (lower Cl_mic) and P-gp efflux also contribute to its favorability.
Output:
0
2025-04-17 20:33:21,979 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (353.853 and 348.495 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (46.4) is significantly better than Ligand B (89.19). For a GPCR, lower TPSA is generally preferred for better permeability, and Ligand A is well below the 140 threshold. Ligand B is higher, potentially hindering absorption.
**3. logP:** Both ligands have acceptable logP values (4.066 and 2.697), falling within the 1-3 range. Ligand B is slightly better, being closer to the optimal range.
**4. H-Bond Donors:** Ligand A (1) is preferred over Ligand B (2). Fewer HBDs generally improve permeability.
**5. H-Bond Acceptors:** Ligand B (7) has more HBAs than Ligand A (3). Again, fewer HBAs are generally preferred for permeability.
**6. QED:** Both ligands have similar QED values (0.768 and 0.709), both above the 0.5 threshold, indicating good drug-like properties.
**7. DILI:** Ligand B (39.899) has a lower DILI risk than Ligand A (49.477), which is a positive for Ligand B.
**8. BBB:** Ligand B (94.455) has a significantly higher BBB penetration percentile than Ligand A (73.517). While ADRB2 isn't exclusively a CNS target, some CNS exposure can occur, and higher BBB is generally favorable, reducing off-target effects.
**9. Caco-2 Permeability:** Ligand A (-4.761) has a higher Caco-2 permeability than Ligand B (-5.173). This suggests better intestinal absorption for Ligand A.
**10. Aqueous Solubility:** Both ligands have similar, very poor aqueous solubility (-3.789 and -3.733). This is a concern for both, and formulation strategies would be needed.
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (0.827 and 0.797).
**12. Microsomal Clearance:** Ligand B (76.376) has higher microsomal clearance than Ligand A (61.161), indicating faster metabolism and potentially lower *in vivo* exposure.
**13. In vitro Half-Life:** Ligand A (59.567) has a much longer in vitro half-life than Ligand B (14.136), which is a significant advantage.
**14. P-gp Efflux:** Both ligands have similar P-gp efflux liability (0.45 and 0.109).
**15. Binding Affinity:** Ligand B (-6.4) has slightly better binding affinity than Ligand A (-6.2), but the difference is small (0.2 kcal/mol).
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand A emerges as the more promising candidate. While Ligand B has a slightly better affinity and lower DILI risk and better BBB penetration, Ligand A's significantly lower TPSA, better Caco-2 permeability, and substantially longer half-life are more critical for overall drug development success. The solubility is a concern for both, but can be addressed through formulation. The slightly weaker affinity of Ligand A can potentially be optimized in later stages of development.
Output:
1
2025-04-17 20:33:21,979 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (341.407 and 364.917 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (75.63) is higher than Ligand B (53.43). For a cardiovascular GPCR, TPSA is moderately important. Lower is generally better for permeability, and Ligand B has a more favorable TPSA.
**3. logP:** Ligand A (2.423) is within the optimal range (1-3), while Ligand B (4.051) is slightly above it. While not drastically high, exceeding 3 can sometimes lead to off-target effects or solubility issues. Ligand A is preferred here.
**4. H-Bond Donors:** Ligand A (2) and Ligand B (1) are both acceptable.
**5. H-Bond Acceptors:** Ligand A (4) and Ligand B (3) are both acceptable.
**6. QED:** Both ligands have similar QED values (0.791 and 0.774), indicating good drug-likeness.
**7. DILI Risk:** Ligand A (62.233) has a higher DILI risk than Ligand B (9.461). This is a significant concern, as minimizing liver toxicity is crucial. Ligand B is strongly preferred.
**8. BBB Penetration:** Ligand B (83.366) shows significantly better BBB penetration than Ligand A (36.526). While ADRB2 is a cardiovascular target, some CNS effects are possible with adrenergic agonists, and better CNS penetration could be a benefit or a liability depending on the desired profile.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.586 and -4.576), which is unusual and suggests poor permeability. This is a major red flag for both.
**10. Aqueous Solubility:** Both ligands have very poor aqueous solubility (-4.141 and -4.153). This will likely present formulation challenges.
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (0.653 and 0.62), which is good.
**12. Microsomal Clearance:** Ligand A (82.151) has higher microsomal clearance than Ligand B (71.393), indicating faster metabolism and potentially lower bioavailability. Ligand B is preferred.
**13. In vitro Half-Life:** Ligand B (-3.479) has a significantly longer in vitro half-life than Ligand A (-27.44). This is a substantial advantage for dosing considerations.
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (0.379 and 0.108).
**15. Binding Affinity:** Ligand B (-7.4 kcal/mol) has a substantially stronger binding affinity than Ligand A (-5.8 kcal/mol). This is a >1.5 kcal/mol difference, which is a major advantage and can outweigh many ADME concerns.
**Overall Assessment:**
Despite both ligands having poor Caco-2 permeability and solubility, Ligand B is significantly better overall. The stronger binding affinity, much lower DILI risk, better BBB penetration, longer half-life, and lower microsomal clearance outweigh the slightly higher logP. The poor permeability and solubility would need to be addressed through formulation strategies, but the other properties of Ligand B make it a more promising starting point.
Output:
0
2025-04-17 20:33:21,979 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (342.443 and 349.519 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (58.44) is higher than Ligand B (43.86). Both are below the 140 threshold for good oral absorption, but B is closer to the preferred <90 for GPCRs.
3. **logP:** Ligand B (2.382) is slightly higher than Ligand A (1.439), both are within the optimal 1-3 range.
4. **HBD:** Both have 0 HBD, which is good.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 3. Both are acceptable, below the 10 threshold.
6. **QED:** Ligand A (0.778) has a slightly better QED score than Ligand B (0.692), indicating slightly better overall drug-likeness.
7. **DILI:** Ligand A (13.959) has a significantly higher DILI risk than Ligand B (8.918). This is a major concern for Ligand A.
8. **BBB:** Both ligands have high BBB penetration (83.908 and 82.047), which is good, but not critical for ADRB2 as it is not a CNS target.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Both have negative solubility values, which is also unusual and suggests poor solubility. Again, the scale is not specified.
11. **hERG:** Ligand A (0.244) has a lower hERG risk than Ligand B (0.723), which is preferable.
12. **Cl_mic:** Ligand B (28.297) has a lower microsomal clearance than Ligand A (33.609), indicating better metabolic stability.
13. **t1/2:** Ligand B (-11.262) has a longer in vitro half-life than Ligand A (-9.188). This is a positive attribute.
14. **Pgp:** Ligand A (0.045) has a lower Pgp efflux liability than Ligand B (0.149), which is favorable.
15. **Binding Affinity:** Ligand A (-7.1) has a significantly stronger binding affinity than Ligand B (-4.5). This is a substantial advantage.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B has a better logP and TPSA, and lower Pgp efflux. However, Ligand A's significantly stronger binding affinity (-7.1 vs -4.5) is a major advantage that can outweigh some of the ADME drawbacks. The lower DILI risk of Ligand B is also important.
**Overall Assessment:**
While Ligand A has a superior binding affinity, the higher DILI risk is a serious concern. Ligand B has a more favorable safety profile (lower DILI) and better metabolic stability (lower Cl_mic, longer t1/2), and acceptable affinity. Given the balance of properties, and prioritizing safety for a cardiovascular target, I would choose Ligand B.
Output:
0
2025-04-17 20:33:21,979 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (343.362 and 346.523 Da) fall comfortably within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (80.12) is higher than Ligand B (56.32). For a cardiovascular GPCR, TPSA is not a primary concern unless CNS penetration is desired, but lower is generally better for permeability. Ligand B has an advantage.
3. **logP:** Ligand A (0.899) is slightly lower than the optimal 1-3 range, potentially impacting permeability. Ligand B (2.577) is well within the optimal range. Ligand B has a clear advantage.
4. **HBD:** Ligand A (1) and Ligand B (2) are both acceptable, being less than 5. No significant difference.
5. **HBA:** Ligand A (5) and Ligand B (6) are both acceptable, being less than 10. No significant difference.
6. **QED:** Both ligands have good QED scores (0.837 and 0.791), indicating good drug-like properties. No clear advantage.
7. **DILI:** Ligand A (54.517) has a higher DILI risk than Ligand B (14.114). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (57.968) and Ligand B (80.69) are both relatively low, suggesting limited CNS penetration. This is acceptable for a cardiovascular target. Ligand B is slightly better.
9. **Caco-2:** Ligand A (-4.893) and Ligand B (-5.319) are both very poor. This is a concern for oral absorption for both, but similar.
10. **Solubility:** Both ligands have poor solubility (-1.74 and -1.642). This is a concern for both, and similar.
11. **hERG:** Ligand A (0.209) has a lower hERG risk than Ligand B (0.942). This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand A (19.291) has a higher microsomal clearance than Ligand B (-4.579). This suggests Ligand B is more metabolically stable, which is desirable.
13. **t1/2:** Ligand A (-19.095) has a negative in vitro half-life, which is not possible and indicates a very rapid clearance. Ligand B (26.194) has a reasonable half-life. This is a major advantage for Ligand B.
14. **Pgp:** Ligand A (0.033) has lower P-gp efflux than Ligand B (0.023), which is slightly better.
15. **Affinity:** Ligand A (-7.0) and Ligand B (-6.1) both have good binding affinity. Ligand A has a slightly better affinity, but the difference is less than 1.5 kcal/mol.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand B is the stronger candidate. While Ligand A has slightly better affinity and Pgp efflux, Ligand B has significantly better DILI risk, metabolic stability (lower Cl_mic, positive t1/2), and a more favorable logP. The poor solubility and Caco-2 permeability are concerns for both, but can be addressed with formulation strategies. The negative half-life for Ligand A is a deal-breaker.
Output:
0
2025-04-17 20:33:21,979 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor (a GPCR).
**Ligand A:** [345.403, 102.05 , 1.028, 2. , 6. , 0.661, 57.619, 51.725, -5.634, -1.423, 0.088, 38.739, -5.845, 0.029, -8.1 ]
**Ligand B:** [348.407, 99.69 , 0.388, 2. , 7. , 0.717, 61.225, 66.382, -4.868, -2.147, 0.222, 44.782, -18.078, 0.007, -4.5 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). A is 345.4, B is 348.4 - very similar.
2. **TPSA:** Both are acceptable for oral absorption (<140), A is 102.05, B is 99.69. Again, very similar.
3. **logP:** A (1.028) is better than B (0.388). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but a good logP is still important for membrane permeability and bioavailability. B is a little low.
4. **HBD:** Both have 2 HBD, which is good.
5. **HBA:** A has 6, B has 7. Both are acceptable (<10).
6. **QED:** Both are good (>0.5), A is 0.661, B is 0.717. B is slightly better here.
7. **DILI:** A (57.619%) is better than B (61.225%). Lower is better, and both are reasonably acceptable, but A has a lower risk.
8. **BBB:** A (51.725%) is lower than B (66.382%). While not a primary concern for a cardiovascular target, higher BBB is generally favorable.
9. **Caco-2:** A (-5.634) is worse than B (-4.868). Higher is better, indicating better absorption.
10. **Solubility:** A (-1.423) is better than B (-2.147). Higher is better.
11. **hERG:** A (0.088) is significantly better than B (0.222). This is a crucial safety parameter, and A has a much lower risk of hERG inhibition.
12. **Cl_mic:** A (38.739) is better than B (44.782). Lower clearance is better for metabolic stability.
13. **t1/2:** A (-5.845) is *much* better than B (-18.078). A significantly longer half-life is highly desirable.
14. **Pgp:** A (0.029) is better than B (0.007). Lower is better.
15. **Affinity:** A (-8.1) is significantly better than B (-4.5). A 3.6 kcal/mol difference in binding affinity is substantial and can often outweigh minor ADME drawbacks.
**GPCR-specific priorities:** For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, and affinity. A performs better in logP, Pgp, and *significantly* better in affinity. While B has a slightly better BBB and QED, the substantial advantage in binding affinity and the better safety profile (hERG, DILI) of A are more important. The longer half-life of A is also a major advantage.
**Conclusion:**
Ligand A is the more promising drug candidate due to its superior binding affinity, better safety profile (lower hERG and DILI risk), improved metabolic stability (lower Cl_mic, longer t1/2), and acceptable ADME properties.
1
2025-04-17 20:33:21,980 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [376.475, 110.8 , -0.374, 2. , 6. , 0.568, 39.046, 63.784, -5.563, -1.497, 0.134, -1.488, 17.689, 0.013, -6.5 ]
**Ligand B:** [340.383, 97.12 , 2.688, 2. , 5. , 0.872, 60.721, 65.568, -5.079, -3.321, 0.099, 2.215, 26.851, 0.104, -6.6 ]
Here's a step-by-step comparison, keeping GPCR priorities (logP, Pgp, TPSA, and affinity) in mind:
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (340.383) is slightly lower, which *could* be a minor advantage for permeability, but both are acceptable.
2. **TPSA:** Ligand A (110.8) is slightly higher than Ligand B (97.12). Both are below the 140 threshold for oral absorption, but B is better.
3. **logP:** Ligand A (-0.374) is a bit low, potentially hindering membrane permeability. Ligand B (2.688) is much better, falling nicely within the optimal 1-3 range. This is a significant advantage for B.
4. **HBD:** Both have 2 HBD, which is good.
5. **HBA:** Ligand A has 6 HBA, Ligand B has 5. Both are acceptable.
6. **QED:** Ligand B (0.872) has a significantly better QED score than Ligand A (0.568), indicating a more drug-like profile.
7. **DILI:** Ligand A (39.046) has a lower DILI risk than Ligand B (60.721). This is a positive for A, though both are reasonably acceptable.
8. **BBB:** Both have similar BBB penetration (A: 63.784, B: 65.568). Neither is exceptionally high, but acceptable for a non-CNS target.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-1.497) has better solubility than Ligand B (-3.321).
11. **hERG:** Both have very low hERG risk (A: 0.134, B: 0.099).
12. **Cl_mic:** Ligand A (-1.488) has a lower (better) microsomal clearance than Ligand B (2.215), suggesting better metabolic stability.
13. **t1/2:** Ligand B (26.851) has a longer in vitro half-life than Ligand A (17.689). This is a positive for B.
14. **Pgp:** Both have very low Pgp efflux liability (A: 0.013, B: 0.104).
15. **Affinity:** Both have very similar binding affinities (-6.5 and -6.6 kcal/mol). The difference is negligible.
**Overall Assessment:**
Ligand B is the stronger candidate. While Ligand A has slightly better DILI and metabolic stability, Ligand B excels in crucial GPCR-relevant properties: logP, QED, and in vitro half-life. The better logP and QED of Ligand B suggest improved permeability and overall drug-likeness, outweighing the minor advantages of Ligand A. The similar binding affinities mean that the ADME properties become the deciding factor.
Output:
0
2025-04-17 20:33:21,980 - INFO - Batch 193 complete. Total preferences: 3088
2025-04-17 20:33:21,980 - INFO - Processing batch 194/512...
2025-04-17 20:34:08,836 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (350.459 Da and 379.917 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (75.71) is slightly higher than Ligand B (70.84), but both are below the 140 A^2 threshold for good oral absorption. This is favorable for both.
**3. logP:** Ligand A (1.751) is within the optimal 1-3 range, while Ligand B (4.135) is a bit high. Higher logP can lead to solubility issues and off-target interactions. This favors Ligand A.
**4. H-Bond Donors:** Both ligands have 1 HBD, which is within the acceptable limit of <=5.
**5. H-Bond Acceptors:** Ligand A has 4 HBAs, and Ligand B has 6. Both are below the 10 threshold, but Ligand A is preferable.
**6. QED:** Ligand A (0.585) has a better QED score than Ligand B (0.421), indicating a more drug-like profile.
**7. DILI Risk:** Ligand B (69.833) has a significantly higher DILI risk than Ligand A (15.936). This is a major concern, as liver toxicity is a common reason for drug failure. This strongly favors Ligand A.
**8. BBB Penetration:** Ligand A (76.696) shows better BBB penetration than Ligand B (60.644). While ADRB2 isn't exclusively a CNS target, some cardiovascular effects are mediated through central pathways, and better BBB penetration could be beneficial.
**9. Caco-2 Permeability:** Ligand A (-4.389) has a better Caco-2 permeability than Ligand B (-5.961).
**10. Aqueous Solubility:** Ligand A (-3.175) has better aqueous solubility than Ligand B (-3.443).
**11. hERG Inhibition:** Ligand A (0.162) has a lower hERG inhibition risk than Ligand B (0.88). This is crucial for avoiding cardiotoxicity, especially given the cardiovascular target. This favors Ligand A.
**12. Microsomal Clearance:** Ligand B (65.612) has a lower microsomal clearance than Ligand A (78.25), suggesting better metabolic stability. This is a slight advantage for Ligand B.
**13. In vitro Half-Life:** Ligand B (135.866) has a significantly longer in vitro half-life than Ligand A (-18.519). This is a significant advantage for Ligand B, potentially allowing for less frequent dosing.
**14. P-gp Efflux:** Ligand A (0.023) has much lower P-gp efflux than Ligand B (0.602), which is a positive for bioavailability.
**15. Binding Affinity:** Both ligands have very similar binding affinities (-6.9 kcal/mol and -6.2 kcal/mol). The difference of 0.7 kcal/mol is not substantial enough to outweigh the other significant differences.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity) and general drug-like properties, **Ligand A is the more promising candidate**. While Ligand B has a longer half-life, its significantly higher DILI risk, higher logP, and greater P-gp efflux liability are major drawbacks. Ligand A demonstrates a better balance of properties, with lower toxicity risk, better solubility, permeability, and P-gp efflux, and acceptable logP. The slight advantage in half-life for Ligand B doesn't outweigh these concerns.
Output:
1
2025-04-17 20:34:08,837 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (356.813 and 365.817 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (70.99) is significantly better than Ligand B (82.71). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand A is well below the 140 threshold.
3. **logP:** Ligand B (1.454) is lower than Ligand A (2.651), but both are within the optimal 1-3 range. Ligand A is slightly better.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Both ligands have 4 HBA, which is good.
6. **QED:** Both ligands have good QED scores (0.728 and 0.785), indicating drug-likeness. Ligand B is slightly better.
7. **DILI:** Both ligands have similar DILI risk (74.952 and 74.292), and are at a moderate risk level. No clear advantage.
8. **BBB:** Ligand A (54.866) is lower than Ligand B (64.754). While ADRB2 isn't exclusively a CNS target, some CNS penetration can be beneficial, and Ligand B is better here.
9. **Caco-2:** Ligand A (-5.21) is worse than Ligand B (-4.759), indicating lower intestinal absorption. Ligand B is better.
10. **Solubility:** Ligand A (-3.871) is worse than Ligand B (-2.357). Solubility is important for bioavailability, so Ligand B is better.
11. **hERG:** Ligand A (0.614) is higher than Ligand B (0.138), indicating a higher risk of hERG inhibition and potential cardiotoxicity. Ligand B is significantly better here.
12. **Cl_mic:** Ligand B (67.891) has a higher microsomal clearance than Ligand A (18.395), meaning faster metabolism and potentially lower exposure. Ligand A is better.
13. **t1/2:** Ligand B (-6.935) has a longer in vitro half-life than Ligand A (-2.647). This is a positive for dosing frequency. Ligand B is better.
14. **Pgp:** Ligand A (0.414) has lower P-gp efflux than Ligand B (0.098), which is favorable for bioavailability. Ligand A is better.
15. **Binding Affinity:** Ligand B (-6.5 kcal/mol) is slightly better than Ligand A (-7.0 kcal/mol). While Ligand A has a slightly stronger binding affinity, the difference is not substantial enough to outweigh other factors.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand B appears to be the more promising candidate. While Ligand A has a slightly better binding affinity and lower Pgp efflux, Ligand B excels in crucial areas like TPSA, solubility, hERG inhibition, and in vitro half-life. The lower hERG risk is particularly important for a cardiovascular target. The slightly better Caco-2 permeability and BBB penetration also contribute to its favorability.
Output:
0
2025-04-17 20:34:08,837 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (349.391 Da) is slightly lower, which *could* be beneficial for permeability, but both are acceptable.
2. **TPSA:** Ligand A (137.65) is borderline acceptable for oral absorption, while Ligand B (66.48) is excellent. This is a significant advantage for Ligand B.
3. **logP:** Ligand A (-0.301) is a bit low, potentially hindering permeation. Ligand B (3.264) is optimal. This is a strong point in favor of Ligand B.
4. **HBD:** Ligand A (4) is acceptable, while Ligand B (1) is even better, potentially improving permeability and reducing off-target interactions.
5. **HBA:** Both ligands have reasonable HBA counts (Ligand A: 5, Ligand B: 4).
6. **QED:** Both ligands have good QED scores (Ligand A: 0.51, Ligand B: 0.782), indicating good drug-like properties. Ligand B is better.
7. **DILI:** Both ligands have low DILI risk (Ligand A: 30.167, Ligand B: 35.983), which is positive.
8. **BBB:** Ligand A (55.487) is moderate, while Ligand B (70.182) is good. While ADRB2 isn't strictly a CNS target, some CNS penetration can be useful for understanding off-target effects and potential side effects.
9. **Caco-2:** Both have negative values which is unusual. I will assume these are logP values and interpret accordingly. Ligand A (-5.471) is very poor, while Ligand B (-4.987) is still poor, but slightly better.
10. **Solubility:** Both have negative values which is unusual. I will assume these are logS values and interpret accordingly. Ligand A (-2.422) is poor, while Ligand B (-3.933) is even worse.
11. **hERG:** Ligand A (0.022) is very low risk, while Ligand B (0.824) is slightly elevated. This is a point in favor of Ligand A.
12. **Cl_mic:** Ligand A (5.352) has lower clearance, indicating better metabolic stability, which is favorable. Ligand B (48.594) has much higher clearance.
13. **t1/2:** Ligand A (-14.378) has a negative half-life, which is impossible. Ligand B (-21.345) also has a negative half-life, which is impossible. These values are likely errors.
14. **Pgp:** Ligand A (0.004) has very low P-gp efflux, which is excellent. Ligand B (0.421) has moderate P-gp efflux.
15. **Binding Affinity:** Ligand B (-7.4 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.9 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME drawbacks.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP, TPSA, and significantly in affinity. Ligand A has a better hERG profile and lower Cl_mic, but the affinity difference is substantial.
**Overall Assessment:**
Despite the issues with the half-life values, the significantly stronger binding affinity of Ligand B, coupled with its superior TPSA and logP, makes it the more promising candidate. The slightly higher hERG risk and higher clearance are concerns, but these can potentially be addressed through further optimization. The poor solubility and Caco-2 permeability are also concerning, but the strong binding affinity suggests that these may be less critical.
Output:
0
2025-04-17 20:34:08,837 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (351.447 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (84.67) is better than Ligand B (87.74), both are below the 140 threshold for oral absorption, and acceptable for a peripheral GPCR like ADRB2.
3. **logP:** Ligand A (3.601) is optimal, while Ligand B (0.435) is quite low. This is a significant negative for Ligand B, potentially hindering membrane permeability and bioavailability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (4). Both are within the acceptable range.
6. **QED:** Ligand A (0.846) is better than Ligand B (0.68), indicating a more drug-like profile.
7. **DILI:** Ligand B (20.977) is *much* better than Ligand A (53.276). This is a major advantage for Ligand B.
8. **BBB:** Ligand A (78.868) is better than Ligand B (59.752), but BBB is less critical for ADRB2, a primarily peripheral receptor.
9. **Caco-2:** Ligand A (-4.515) is better than Ligand B (-5.102), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-3.973) is better than Ligand B (-1.32), indicating better aqueous solubility.
11. **hERG:** Both ligands have low hERG inhibition liability (0.327 and 0.117 respectively), which is good.
12. **Cl_mic:** Ligand B (-9.038) is significantly better than Ligand A (73.417), indicating much higher metabolic stability.
13. **t1/2:** Ligand B (7.285) is significantly better than Ligand A (0.07), indicating a much longer half-life.
14. **Pgp:** Ligand A (0.128) is better than Ligand B (0.007), indicating lower P-gp efflux.
15. **Binding Affinity:** Ligand B (-7.5 kcal/mol) is 0.8 kcal/mol better than Ligand A (-6.7 kcal/mol). This is a substantial difference in potency.
**Overall Assessment:**
For ADRB2, a peripheral GPCR, potency (affinity), metabolic stability, and permeability are key. Ligand B has a significantly better binding affinity (-7.5 vs -6.7 kcal/mol), much better metabolic stability (Cl_mic and t1/2), and a lower DILI risk. While Ligand A has better logP and solubility, the advantages of Ligand B in affinity and metabolic stability outweigh these factors. The low logP of Ligand B is a concern, but can potentially be addressed with formulation strategies.
Output:
0
2025-04-17 20:34:08,837 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (343.431 and 346.362 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (86.36) is better than Ligand B (97.55). Both are below 140, but lower TPSA is generally preferred for better absorption, especially for a GPCR.
3. **logP:** Ligand B (1.911) is better than Ligand A (0.209). Ligand A is quite low, potentially hindering membrane permeability. Ligand B is within the optimal 1-3 range. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (2), but both are acceptable (<=5).
5. **HBA:** Both ligands have the same number of HBA (5), which is within the acceptable range (<=10).
6. **QED:** Ligand B (0.862) is better than Ligand A (0.73). Both are above 0.5, indicating good drug-likeness, but Ligand B is superior.
7. **DILI:** Ligand A (27.142) is *much* better than Ligand B (83.211). Ligand B is quite high risk for liver injury. This is a major concern.
8. **BBB:** Both ligands have similar BBB penetration (49.826 and 49.05). Since ADRB2 isn't exclusively a CNS target, this isn't a deciding factor, but it's not a strength for either.
9. **Caco-2:** Ligand A (-5.546) is better than Ligand B (-4.721). Higher (less negative) values indicate better permeability.
10. **Solubility:** Ligand A (-1.611) is better than Ligand B (-2.99). Higher values indicate better solubility, which is important for bioavailability.
11. **hERG:** Both ligands have very low hERG risk (0.388 and 0.408). This is good.
12. **Cl_mic:** Ligand A (-37.208) is significantly better than Ligand B (22.874). Lower clearance indicates greater metabolic stability, a crucial factor for drug duration.
13. **t1/2:** Ligand A (19.551) is better than Ligand B (-4.495). A longer half-life is generally preferred.
14. **Pgp:** Both ligands have very low Pgp efflux (0.003 and 0.024). This is good.
15. **Binding Affinity:** Ligand B (-6.0) is better than Ligand A (-4.7). This is a substantial difference in potency (1.3 kcal/mol).
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, and affinity are key. Ligand B excels in logP and affinity, while Ligand A has a better TPSA. However, the *extremely* high DILI risk for Ligand B and the significantly better metabolic stability (Cl_mic and t1/2) of Ligand A are critical. The affinity difference, while significant, can potentially be addressed with further optimization. The DILI risk is much harder to fix.
**Conclusion:**
Despite the better affinity of Ligand B, the unacceptable DILI risk and poorer metabolic stability make it a less viable candidate. Ligand A, while not perfect, presents a much more favorable safety and pharmacokinetic profile.
Output:
1
2025-04-17 20:34:08,837 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (381.567 Da) is within the ideal range (200-500 Da). Ligand B (346.439 Da) is also within range, and slightly smaller. This is a minor advantage to B.
2. **TPSA:** Ligand A (57.36) is excellent, well below the 140 threshold for oral absorption. Ligand B (97.79) is still acceptable but higher, potentially impacting absorption. A favors here.
3. **logP:** Ligand A (3.851) is at the upper end of the optimal range (1-3), but still acceptable. Ligand B (0.874) is quite low, which could hinder membrane permeability and potentially reduce binding affinity. A is preferred.
4. **HBD:** Both ligands have acceptable HBD counts (A: 2, B: 1).
5. **HBA:** Ligand A (4) is good. Ligand B (9) is higher, potentially impacting permeability. A is preferred.
6. **QED:** Both ligands have good QED scores (A: 0.459, B: 0.823). B is significantly better here.
7. **DILI:** Ligand A (58.395) is moderately risky. Ligand B (29.818) is much lower risk, a significant advantage.
8. **BBB:** Ligand A (18.961) has poor BBB penetration. Ligand B (86.39) is very good, a substantial advantage for a GPCR.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. This is a concern for both, but the negative value for A is worse (-5.047 vs -5.659).
10. **Solubility:** Both have very poor aqueous solubility (-5.338 and -1.193 respectively). This is a major concern for both, and would likely require formulation strategies.
11. **hERG:** Both have low hERG risk (A: 0.522, B: 0.136). B is slightly better.
12. **Cl_mic:** Ligand A (117.997) has higher metabolic clearance, suggesting lower metabolic stability. Ligand B (-4.598) has negative clearance, which is not possible, and indicates a very stable compound. B is strongly favored.
13. **t1/2:** Ligand A (35.224) has a reasonable half-life. Ligand B (-6.789) has a negative half-life, which is not possible. A is favored.
14. **Pgp:** Ligand A (0.303) has lower P-gp efflux, which is good. Ligand B (0.025) is even better. B is favored.
15. **Binding Affinity:** Ligand A (-5.6 kcal/mol) and Ligand B (-6.9 kcal/mol) both have good binding affinity, but B is significantly stronger. This is a major advantage for B.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are crucial. Ligand B excels in Pgp, affinity, and BBB penetration. While Ligand A has a better TPSA, Ligand B's superior affinity and lower efflux are more important. The poor solubility of both is a concern, but can be addressed with formulation.
**Overall Assessment:**
Despite the poor solubility of both compounds, Ligand B is the stronger candidate. Its significantly better binding affinity, lower DILI risk, excellent BBB penetration, and favorable Pgp efflux outweigh the slightly higher TPSA and lower logP. The negative values for Caco-2 and t1/2 for Ligand B are concerning and likely data errors, but the other properties are so strongly in its favor that it is still the preferred candidate.
Output:
0
2025-04-17 20:34:08,838 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (408.252 Da and 383.539 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (78.86) is slightly higher than Ligand B (73.74). Both are below the 140 A^2 threshold for good oral absorption, which is positive.
**3. logP:** Ligand A (3.757) is at the higher end of the optimal range (1-3), while Ligand B (2.479) is well within it. Ligand A's higher logP *could* potentially lead to off-target effects or solubility issues, but it's not drastically high.
**4. H-Bond Donors:** Ligand A has 0 HBDs, and Ligand B has 1. Both are acceptable.
**5. H-Bond Acceptors:** Ligand A has 7 HBAs, and Ligand B has 6. Both are below the 10 threshold.
**6. QED:** Both ligands have good QED values (0.599 and 0.758, respectively), indicating drug-likeness. Ligand B is slightly better.
**7. DILI Risk:** Ligand A (79.449) has a higher DILI risk than Ligand B (56.921). This is a significant concern, as we want to minimize liver toxicity.
**8. BBB Penetration:** Ligand A (77.898) has better BBB penetration than Ligand B (44.979). While ADRB2 is a cardiovascular target, some CNS effects are possible with beta-blockers, and some degree of BBB penetration isn't necessarily detrimental. However, this isn't a primary driver for this target.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.933 and -5.004), which is unusual and suggests poor permeability. This is a major red flag for both.
**10. Aqueous Solubility:** Both ligands have very poor aqueous solubility (-3.885 and -3.87). This is a significant issue for formulation and bioavailability.
**11. hERG Inhibition:** Ligand A (0.325) has a lower hERG inhibition risk than Ligand B (0.713). This is a positive for Ligand A.
**12. Microsomal Clearance:** Ligand B (95.969) has significantly higher microsomal clearance than Ligand A (81.085), indicating faster metabolism and lower metabolic stability. This is a major drawback for Ligand B.
**13. In vitro Half-Life:** Ligand A (62.897) has a longer in vitro half-life than Ligand B (24.107), which is desirable.
**14. P-gp Efflux:** Ligand A (0.401) has lower P-gp efflux than Ligand B (0.347). Lower efflux is generally preferable.
**15. Binding Affinity:** Ligand A (-6.3 kcal/mol) has a slightly better binding affinity than Ligand B (-5.1 kcal/mol). This is a 1.2 kcal/mol difference, which is substantial.
**Overall Assessment:**
Despite both ligands having significant issues with Caco-2 permeability and solubility, Ligand A is the more promising candidate. Its superior binding affinity, lower DILI risk, longer half-life, and lower P-gp efflux outweigh the slightly higher logP and lower BBB penetration. The higher metabolic stability (lower Cl_mic) is also a significant advantage. Ligand B's high microsomal clearance is a major concern.
Output:
1
2025-04-17 20:34:08,838 - INFO - Here's my reasoning and final output for the ligand preference:
**Reasoning:**
We are targeting ADRB2, a GPCR, so the priorities are logP, Pgp, TPSA, affinity, and BBB. Let's compare Ligand A and Ligand B across all parameters:
1. **MW:** Both ligands (368.5 & 383.9) are within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (83.56) is better than Ligand B (38.25) as it is closer to the 140 threshold.
3. **logP:** Ligand B (4.268) is higher than ideal (1-3), potentially causing solubility issues. Ligand A (0.665) is quite low, which could hinder permeation.
4. **HBD/HBA:** Ligand A (2 HBD, 6 HBA) is slightly better than Ligand B (0 HBD, 5 HBA) in terms of balancing solubility and permeability.
5. **QED:** Both ligands have good QED scores (0.669 and 0.715).
6. **DILI:** Both ligands have similar, acceptable DILI risk (29.2 and 29.1).
7. **BBB:** Ligand B (81.698) has a significantly higher BBB penetration percentile than Ligand A (36.642). This is a major advantage for a GPCR.
8. **Caco-2:** Ligand A (-5.296) is significantly worse than Ligand B (-4.851).
9. **Solubility:** Ligand A (-0.819) is better than Ligand B (-3.811).
10. **hERG:** Both ligands have low hERG risk (0.221 and 0.867).
11. **Cl_mic:** Ligand A (-0.704) has a much lower (better) microsomal clearance than Ligand B (48.825), indicating better metabolic stability.
12. **t1/2:** Ligand B (19.532) has a much longer half-life than Ligand A (7.009).
13. **Pgp:** Ligand A (0.013) has a much lower Pgp efflux liability than Ligand B (0.613), which is beneficial.
14. **Affinity:** Both ligands have very similar and excellent binding affinities (-5.6 and -5.3 kcal/mol).
**Overall Assessment:**
Ligand B has a much better BBB penetration and longer half-life, which are important for GPCRs. However, its high logP is a concern. Ligand A has better solubility, lower clearance, and lower Pgp efflux, but its BBB penetration is poor and Caco-2 permeability is very low. Considering the balance, and the importance of BBB for a GPCR, Ligand B is slightly more promising despite the logP concern. The higher affinity of both ligands mitigates some of the ADME concerns.
**Output:**
0
2025-04-17 20:34:08,838 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.478 and 364.511 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (49.41) is significantly better than Ligand B (70.5). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold.
3. **logP:** Both ligands have good logP values (3.201 and 3.028), falling within the optimal 1-3 range. Very similar.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 2 HBA, while Ligand B has 5. Ligand A is preferable here, staying closer to the <10 guideline.
6. **QED:** Both ligands have very similar QED scores (0.846 and 0.842), indicating good drug-likeness.
7. **DILI:** Ligand A (16.789%) has a much lower DILI risk than Ligand B (31.989%). This is a substantial advantage for Ligand A.
8. **BBB:** Ligand A (93.253%) has significantly higher BBB penetration than Ligand B (70.182%). While not critical for a cardiovascular target, higher BBB is generally a positive attribute.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.984 and -4.527). This indicates poor permeability, which is a concern for both.
10. **Solubility:** Ligand A (-3.691) is slightly better than Ligand B (-3.024), but both are poor. Solubility is a concern for both.
11. **hERG:** Ligand A (0.632) has a lower hERG risk than Ligand B (0.145). This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand A (36.319) has a lower microsomal clearance than Ligand B (59.556), indicating better metabolic stability.
13. **t1/2:** Ligand B (-11.724) has a longer in vitro half-life than Ligand A (-7.543). This is a slight advantage for Ligand B.
14. **Pgp:** Ligand A (0.194) has a lower P-gp efflux liability than Ligand B (0.31). This is a slight advantage for Ligand A.
15. **Binding Affinity:** Ligand B (-6.3 kcal/mol) has a slightly better binding affinity than Ligand A (-4.0 kcal/mol). This is a 1.5 kcal/mol advantage, which is significant.
**Overall Assessment:**
Ligand B has a better binding affinity, which is a key factor. However, Ligand A demonstrates a much more favorable safety profile (lower DILI, lower hERG) and better ADME properties (lower Cl_mic, lower Pgp, higher BBB, lower TPSA, fewer HBA). The Caco-2 and solubility issues are present in both, and would need to be addressed in further optimization. Considering the balance, the improved ADME/Tox profile of Ligand A outweighs the slightly better affinity of Ligand B, especially for a cardiovascular target where CNS penetration isn't essential.
Output:
1
2025-04-17 20:34:08,838 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (358.36 & 372.87 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (44.76) is significantly better than Ligand B (61.8). ADRB2 is a cardiovascular target, not CNS, but lower TPSA generally improves absorption.
3. **logP:** Both ligands have good logP values (3.81 & 3.38), falling within the 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability, but not dramatically.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is slightly better than Ligand B (3). Both are within the acceptable range.
6. **QED:** Both ligands have good QED scores (0.768 & 0.804), indicating good drug-like properties. No clear advantage.
7. **DILI:** Ligand A (48.8) is significantly better than Ligand B (9.6). Lower DILI risk is crucial. This is a major advantage for Ligand A.
8. **BBB:** This is less critical for a cardiovascular target. Ligand A (91.7) is higher than Ligand B (77.5), but the difference isn't decisive.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.752 & -4.23), which is unusual and suggests poor permeability. This is a concern for both, but Ligand B is slightly better.
10. **Solubility:** Both ligands have negative solubility values (-4.553 & -3.51), indicating poor aqueous solubility. This is a significant drawback for both. Ligand B is slightly better.
11. **hERG:** Both ligands have low hERG inhibition risk (0.725 & 0.822), which is good. No clear advantage.
12. **Cl_mic:** Ligand B (39.2) has a lower microsomal clearance than Ligand A (50.1), suggesting better metabolic stability. This is a positive for Ligand B.
13. **t1/2:** Ligand B (8.577) has a much longer in vitro half-life than Ligand A (-0.053). This is a significant advantage for Ligand B.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.237 & 0.295). No clear advantage.
15. **Affinity:** Ligand B (-6.6 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.0 kcal/mol). This is a substantial advantage, potentially outweighing some ADME concerns.
**Overall Assessment:**
Ligand B has a substantially better binding affinity and a longer half-life, which are very important for a GPCR target. It also has slightly better Caco-2 and solubility. However, Ligand A has a much better DILI score and lower HBD/HBA counts, and a better TPSA. The DILI risk is a major concern, and the affinity difference is significant. Considering the balance, the affinity advantage of Ligand B is likely to be more impactful than the ADME drawbacks, especially given the potential for optimization of solubility/permeability.
Output:
0
2025-04-17 20:34:08,838 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (345.531 and 359.342 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (35.58) is slightly higher than Ligand B (28.16). Both are well below the 140 threshold for oral absorption, and acceptable for a cardiovascular target. Ligand B is preferable.
3. **logP:** Ligand A (4.513) is slightly higher than Ligand B (3.777). Ligand A is pushing the upper limit of the optimal range (1-3), potentially raising concerns about solubility and off-target effects. Ligand B is better.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 2 HBA, while Ligand B has 3. Both are within the acceptable limit of 10.
6. **QED:** Ligand A (0.704) has a slightly better QED score than Ligand B (0.629), indicating a more drug-like profile.
7. **DILI:** Ligand A (21.753) has a significantly lower DILI risk than Ligand B (43.738). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (96.084) has a much higher BBB penetration percentile than Ligand B (79.798). While ADRB2 isn't strictly a CNS target, some CNS penetration can be acceptable and might indicate better distribution.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.304 and -4.85). These values are unusual and suggest poor permeability.
10. **Solubility:** Both ligands have negative solubility values (-4.39 and -4.255), indicating very poor aqueous solubility. This is a significant concern for both.
11. **hERG:** Both ligands have low hERG inhibition risk (0.938 and 0.964).
12. **Cl_mic:** Ligand B (31.609) has a lower microsomal clearance than Ligand A (91.112), suggesting better metabolic stability.
13. **t1/2:** Ligand B (45.64) has a longer in vitro half-life than Ligand A (36.356).
14. **Pgp:** Both ligands have low Pgp efflux liability (0.636 and 0.556).
15. **Binding Affinity:** Ligand B (-8.0) has a significantly stronger binding affinity than Ligand A (-4.9). This is a substantial advantage.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B has a better logP and a *much* better binding affinity. The lower TPSA is also favorable. While Ligand A has a better QED and lower DILI risk, the substantial affinity difference of Ligand B outweighs these benefits. The poor Caco-2 and solubility are concerning for both, but can be addressed with formulation strategies.
**Conclusion:**
Despite the slightly higher DILI risk and lower QED, the significantly improved binding affinity of Ligand B makes it the more promising candidate. The stronger binding is likely to translate to greater efficacy and potentially allow for lower doses, mitigating some of the DILI concerns.
Output:
0
2025-04-17 20:34:08,838 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (341.411 and 348.487 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (83.36) is higher than Ligand B (58.64). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is still preferable for absorption. Ligand B is better.
3. **logP:** Ligand B (2.489) is slightly higher than Ligand A (1.321), both within the optimal 1-3 range. Ligand B is slightly favored.
4. **HBD:** Ligand A (3) is higher than Ligand B (1). Lower is generally better for permeability, so Ligand B is preferred.
5. **HBA:** Ligand A (4) is higher than Ligand B (3). Similar to HBD, Ligand B is slightly favored.
6. **QED:** Both ligands have similar QED values (0.767 and 0.719), indicating good drug-like properties. No significant difference.
7. **DILI:** Ligand B (13.416) has a significantly lower DILI risk than Ligand A (38.154). This is a major advantage for Ligand B.
8. **BBB:** Ligand B (72.625) has a higher BBB penetration percentile than Ligand A (65.374). While ADRB2 isn't a CNS target, some distribution to the CNS is possible, and higher BBB is generally a positive. Ligand B is better.
9. **Caco-2:** Both ligands have very similar, and poor, Caco-2 permeability (-4.823 and -4.831). This is a concern for both.
10. **Solubility:** Both ligands have very similar, and poor, solubility (-2.353 and -2.442). This is a concern for both.
11. **hERG:** Ligand A (0.198) has a slightly lower hERG inhibition liability than Ligand B (0.583), which is desirable. Ligand A is better.
12. **Cl_mic:** Ligand A (-16.514) has a much lower (better) microsomal clearance than Ligand B (36.269). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (16.922 hours) has a significantly longer in vitro half-life than Ligand B (3.616 hours). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.07) has a much lower P-gp efflux liability than Ligand B (0.302). Lower Pgp is better for bioavailability. Ligand A is better.
15. **Binding Affinity:** Ligand B (-7.8 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.7 kcal/mol). This is a substantial advantage for Ligand B, and can often outweigh minor ADME concerns.
**Overall Assessment:**
Ligand B has a significantly better binding affinity and lower DILI risk, and better BBB penetration. While Ligand A has better metabolic stability (Cl_mic, t1/2) and Pgp efflux, the substantial affinity advantage of Ligand B is crucial for a GPCR target. The slightly worse ADME properties of Ligand B are likely manageable, especially given the potency. The poor Caco-2 and solubility are concerns for both, but formulation strategies can potentially address these.
Output:
0
2025-04-17 20:34:08,839 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.39 and 355.52 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (72.88) is significantly better than Ligand A (95.34). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have acceptable logP values (1.11 and 1.48), falling within the 1-3 range. Ligand B is slightly better.
4. **HBD:** Ligand A has 1 HBD, while Ligand B has 2. Both are within the acceptable limit of 5.
5. **HBA:** Ligand A has 8 HBA, and Ligand B has 4. Ligand B is preferable here, as lower HBA generally improves permeability.
6. **QED:** Both ligands have good QED scores (0.565 and 0.657), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand B (3.22%) has a *much* lower DILI risk than Ligand A (51.38%). This is a major advantage for Ligand B.
8. **BBB:** Ligand A (69.41%) has a better BBB penetration score than Ligand B (52.81%). However, as ADRB2 is a cardiovascular target, BBB penetration is less critical.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual. I will assume these are percentile scores, and therefore higher is better. Ligand A (-5.033) is slightly better than Ligand B (-4.926).
10. **Solubility:** Ligand A (-1.673) has slightly better solubility than Ligand B (-0.676).
11. **hERG:** Both ligands have low hERG inhibition liability (0.22 and 0.427), which is good.
12. **Cl_mic:** Ligand B (18.19) has significantly lower microsomal clearance than Ligand A (70.12), indicating better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand A (1.269) has a slightly longer in vitro half-life than Ligand B (-0.157).
14. **Pgp:** Both have very low Pgp efflux liability (0.158 and 0.019), which is desirable.
15. **Binding Affinity:** Ligand B (-6.6 kcal/mol) has a slightly stronger binding affinity than Ligand A (-5.5 kcal/mol). This difference (1.1 kcal/mol) is substantial enough to be a key factor.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Ligand B is better in terms of TPSA, Pgp, and affinity. While BBB is less crucial for a cardiovascular target, the significantly lower DILI risk and improved metabolic stability (lower Cl_mic) of Ligand B are compelling. The slightly better affinity further strengthens its profile.
**Conclusion:**
Considering the balance of properties, particularly the significantly lower DILI risk, better metabolic stability, and slightly improved binding affinity, Ligand B is the more promising drug candidate.
Output:
0
2025-04-17 20:34:08,839 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (344.415 and 360.361 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (84.42) is significantly better than Ligand B (105.34). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand A is well below the 140 threshold, while B is approaching it.
**3. logP:** Ligand A (2.075) is within the optimal 1-3 range. Ligand B (0.632) is a bit low, potentially hindering membrane permeability.
**4. H-Bond Donors:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
**5. H-Bond Acceptors:** Both ligands have 5 HBA, which is acceptable.
**6. QED:** Both ligands have similar QED values (0.631 and 0.662), indicating good drug-likeness.
**7. DILI:** Both ligands have relatively high DILI risk (61.225 and 69.872). This is a concern for both, but not a deciding factor between them.
**8. BBB:** Ligand A (74.758) has a better BBB percentile than Ligand B (59.984). While ADRB2 is a cardiovascular target and CNS penetration isn't *essential*, some degree of BBB penetration can be useful for off-target effects assessment and potential alternative pharmacology.
**9. Caco-2 Permeability:** Ligand A (-4.772) is better than Ligand B (-5.19), indicating better intestinal absorption.
**10. Aqueous Solubility:** Both ligands have poor aqueous solubility (-2.585 and -2.717). This is a potential formulation challenge for both.
**11. hERG Inhibition:** Ligand A (0.104) has a significantly lower hERG inhibition liability than Ligand B (0.361), which is a major advantage for cardiovascular safety.
**12. Microsomal Clearance:** Ligand A (45.749) has a higher (worse) microsomal clearance than Ligand B (2.579), indicating lower metabolic stability. This is a drawback for Ligand A.
**13. In vitro Half-Life:** Ligand B (-12.197) has a much longer in vitro half-life than Ligand A (10.145), which is a significant advantage.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.051 and 0.019).
**15. Binding Affinity:** Both ligands have very similar binding affinities (-6.6 and -6.8 kcal/mol). The difference is negligible.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity) and the overall profile, **Ligand A is the more promising candidate.** While Ligand B has better metabolic stability and half-life, Ligand A excels in crucial areas like TPSA, logP, hERG inhibition, and BBB penetration. The slightly higher clearance of Ligand A can potentially be addressed through structural modifications, but mitigating the higher hERG risk of Ligand B would be more challenging. The better permeability characteristics of Ligand A are also favorable.
Output:
1
2025-04-17 20:34:08,839 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (364.442 and 350.434 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (65.22) is slightly higher than Ligand B (58.64). Both are below the 140 threshold for good oral absorption, but closer to the 90 threshold for CNS targets (less relevant for ADRB2, a cardiovascular target). Ligand B is slightly preferred.
3. **logP:** Ligand A (4.209) is higher than Ligand B (2.158). Ligand A is pushing the upper limit of the optimal range (1-3), potentially leading to solubility issues. Ligand B is well within the optimal range. Ligand B is preferred.
4. **HBD:** Ligand A (0) has no hydrogen bond donors, while Ligand B (1) has one. Both are acceptable, but having at least one HBD can sometimes improve solubility.
5. **HBA:** Ligand A (6) and Ligand B (3) are both within the acceptable range (<=10). Ligand B is preferred.
6. **QED:** Ligand A (0.585) is better than Ligand B (0.415). Ligand A is preferred.
7. **DILI:** Ligand A (63.086) is significantly higher than Ligand B (29.236). This is a major concern. Ligand B is *much* preferred.
8. **BBB:** Both ligands have high BBB penetration (87.98 and 87.127). Not a primary concern for ADRB2, but no negative impact.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-6.053) has worse solubility than Ligand B (-2.765). Ligand B is preferred.
11. **hERG:** Both ligands have low hERG inhibition risk (0.317 and 0.299). No significant difference.
12. **Cl_mic:** Ligand A (98.868) has higher microsomal clearance than Ligand B (48.853), indicating lower metabolic stability. Ligand B is preferred.
13. **t1/2:** Ligand A (-16.062) has a negative in vitro half-life, which is not possible. This is a severe red flag. Ligand B (-8.81) is also negative, but less so.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.588 and 0.094). Ligand B is preferred.
15. **Binding Affinity:** Ligand B (-7.6 kcal/mol) has a slightly better binding affinity than Ligand A (-6.6 kcal/mol). This difference (1.0 kcal/mol) is significant, but must be weighed against other factors.
**Overall Assessment:**
Ligand A has a better QED and slightly better binding affinity, but is severely hampered by high DILI risk, very poor metabolic stability (high Cl_mic), and an impossible half-life value. Ligand B, while having a lower QED and slightly weaker binding affinity, exhibits a much more favorable ADMET profile, particularly regarding DILI risk and metabolic stability. Given the cardiovascular target and the importance of avoiding toxicity, Ligand B is the significantly more promising candidate. The negative Caco-2 values are concerning for both, but can be addressed with formulation strategies.
Output:
0
2025-04-17 20:34:08,839 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [351.403, 96.11, 0.504, 1, 6, 0.849, 51.26, 45.599, -4.573, -0.498, 0.181, 23.317, -17.214, 0.114, -6.5]
**Ligand B:** [426.746, 72.7, 3.309, 1, 5, 0.568, 44.552, 63.784, -5.208, -4.294, 0.23, 41.284, -11.603, 0.079, -2.6]
Here's a breakdown, prioritizing GPCR-relevant parameters:
1. **Molecular Weight:** Ligand A (351.4) is better than Ligand B (426.7). Both are within the acceptable range, but A is closer to the ideal 200-500 Da.
2. **TPSA:** Ligand B (72.7) is significantly better than Ligand A (96.11). Lower TPSA generally improves permeability, crucial for GPCR ligands.
3. **logP:** Ligand B (3.309) is better. It's within the optimal 1-3 range. Ligand A (0.504) is quite low, potentially hindering membrane permeability.
4. **H-Bond Donors/Acceptors:** Both have 1 HBD, which is good. Ligand A has 6 HBA, and Ligand B has 5. Both are acceptable, but B is slightly better.
5. **QED:** Ligand A (0.849) is better than Ligand B (0.568), indicating a more drug-like profile overall.
6. **DILI:** Both are reasonably good, with Ligand A (51.26) slightly better than Ligand B (44.552). Both are below the concerning 60 percentile.
7. **BBB:** Ligand B (63.784) is significantly better than Ligand A (45.599). While ADRB2 isn't exclusively a CNS target, some CNS penetration can be beneficial, and a higher BBB score is generally preferred.
8. **Caco-2:** Ligand B (-5.208) is better than Ligand A (-4.573), indicating better intestinal absorption.
9. **Solubility:** Ligand A (-0.498) is better than Ligand B (-4.294). Solubility is important for bioavailability.
10. **hERG:** Both are very low (0.181 and 0.23), indicating minimal hERG inhibition risk. This is excellent.
11. **Cl_mic:** Ligand A (23.317) is better than Ligand B (41.284), suggesting better metabolic stability.
12. **t1/2:** Ligand A (-17.214) is better than Ligand B (-11.603), indicating a longer in vitro half-life.
13. **Pgp:** Both are very low (0.114 and 0.079), indicating minimal P-gp efflux.
14. **Binding Affinity:** Ligand A (-6.5) is *significantly* better than Ligand B (-2.6). This is a >3.9 kcal/mol difference, which is a substantial advantage.
**Overall Assessment:**
Ligand A has a markedly superior binding affinity, better metabolic stability (lower Cl_mic, longer t1/2), better solubility, and a higher QED score. While Ligand B has better TPSA and BBB penetration, the substantial difference in binding affinity and the favorable ADME properties of Ligand A outweigh these benefits. The low logP of Ligand A is a concern, but the strong binding affinity might compensate for that. For a GPCR target, strong binding is paramount.
Therefore, I prefer Ligand A.
1
2025-04-17 20:34:08,839 - INFO - Batch 194 complete. Total preferences: 3104
2025-04-17 20:34:08,839 - INFO - Processing batch 195/512...
2025-04-17 20:34:55,508 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (355.423) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are below the 140 A^2 threshold for good oral absorption. Ligand B (75.27) is slightly lower than Ligand A (81.81), which is a minor advantage.
3. **logP:** Both ligands have optimal logP values (around 2), falling within the 1-3 range.
4. **HBD:** Ligand A has 1 HBD, while Ligand B has 2. Both are acceptable, being less than 5.
5. **HBA:** Ligand A has 7 HBA, and Ligand B has 3. Both are below the 10 threshold.
6. **QED:** Ligand A (0.781) has a better QED score than Ligand B (0.597), indicating a more drug-like profile.
7. **DILI:** Ligand B (64.754) has a lower DILI risk than Ligand A (87.01), which is a significant advantage.
8. **BBB:** Ligand B (77.821) has a higher BBB penetration percentile than Ligand A (57.154). While ADRB2 isn't strictly a CNS target, some CNS exposure could be relevant depending on the specific therapeutic application and off-target effects.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-5.053) is slightly worse than Ligand B (-4.834).
10. **Solubility:** Both have negative solubility values, which is concerning. Ligand A (-3.822) is slightly worse than Ligand B (-3.113).
11. **hERG:** Both ligands have low hERG inhibition liability (0.37 and 0.582 respectively), which is good.
12. **Cl_mic:** Ligand B (11.037) has a lower microsomal clearance than Ligand A (15.276), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-24.643) has a much longer in vitro half-life than Ligand A (45.364). This is a major advantage for dosing convenience.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.396 and 0.08 respectively), which is good. Ligand B is slightly better.
15. **Binding Affinity:** Both ligands have the same binding affinity (-6.2 kcal/mol).
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are crucial. Both ligands perform similarly on logP and affinity. Ligand B has a slightly better TPSA and Pgp profile. However, the significant advantages of Ligand B in terms of DILI risk, BBB penetration, metabolic stability (Cl_mic), and *especially* in vitro half-life outweigh the slight disadvantages in Caco-2 and solubility. The poor Caco-2 and solubility are concerning for both, but can potentially be addressed with formulation strategies.
**Conclusion:**
Ligand B presents a more favorable overall profile, particularly regarding safety (DILI), metabolic stability, and pharmacokinetics (t1/2).
Output:
0
2025-04-17 20:34:55,509 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (354.35 & 348.42 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (33.29) is significantly better than Ligand B (76.44). For a GPCR, lower TPSA is generally preferred for better permeability. Ligand B is quite high, potentially hindering oral absorption.
3. **logP:** Ligand A (4.282) is higher than Ligand B (0.974). While both are within the acceptable range, Ligand A is approaching the upper limit, potentially leading to solubility issues. Ligand B is quite low and may have permeability problems.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable.
5. **HBA:** Ligand A (3) and Ligand B (4) are both acceptable.
6. **QED:** Both ligands have good QED scores (0.787 and 0.803), indicating good drug-like properties.
7. **DILI:** Ligand A (65.84%) has a higher DILI risk than Ligand B (12.80%). This is a significant drawback for Ligand A.
8. **BBB:** Ligand A (85.58%) has better BBB penetration than Ligand B (74.29%). While ADRB2 isn't strictly a CNS target, some CNS exposure can occur, and higher BBB is generally favorable.
9. **Caco-2:** Ligand A (-5.038) and Ligand B (-4.971) are similar and both indicate poor permeability.
10. **Solubility:** Ligand A (-4.372) is worse than Ligand B (-2.922). Solubility is a concern for Ligand A given its higher logP.
11. **hERG:** Ligand A (0.958) is slightly higher than Ligand B (0.584), indicating a slightly higher risk of hERG inhibition.
12. **Cl_mic:** Ligand A (24.311) has a higher microsomal clearance than Ligand B (8.496), suggesting faster metabolism and potentially lower bioavailability.
13. **t1/2:** Ligand A (5.635) has a longer half-life than Ligand B (-0.638). This is a positive for Ligand A.
14. **Pgp:** Ligand A (0.603) has lower P-gp efflux than Ligand B (0.011), which is favorable.
15. **Binding Affinity:** Both ligands have excellent binding affinity (-7.7 and -7.8 kcal/mol), with a negligible difference.
**Overall Assessment:**
Ligand B is the better candidate. While Ligand A has a slightly longer half-life and better BBB penetration, its significantly higher DILI risk, higher Cl_mic, and lower solubility are major concerns. Ligand B's lower DILI risk and better solubility outweigh the slightly shorter half-life and lower BBB penetration. The TPSA of Ligand B is a concern, but the other ADME properties are more favorable.
Output:
0
2025-04-17 20:34:55,509 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.479 and 367.515 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (95.74) is slightly higher than Ligand B (78.6). Both are below the 140 threshold for oral absorption, but B is better positioned for potential CNS penetration if desired.
3. **logP:** Ligand A (1.175) is within the optimal range (1-3), while Ligand B (2.853) is approaching the upper limit. This suggests Ligand A might have slightly better solubility, while B could have better membrane permeability.
4. **HBD:** Both ligands have 2 H-bond donors, which is acceptable.
5. **HBA:** Ligand A has 3 H-bond acceptors, and Ligand B has 6. Ligand A is preferable here, as higher HBA can sometimes hinder permeability.
6. **QED:** Both ligands have similar QED values (0.751 and 0.771), indicating good drug-likeness.
7. **DILI:** Ligand A (20.744) has a significantly lower DILI risk than Ligand B (41.411). This is a major advantage for Ligand A.
8. **BBB:** Both ligands have good BBB penetration (84.606 and 79.721), but Ligand A is slightly better.
9. **Caco-2:** Both ligands have similar negative Caco-2 values (-4.966 and -4.943). This indicates poor permeability, which is a concern.
10. **Solubility:** Ligand A (-2.096) has better aqueous solubility than Ligand B (-3.703).
11. **hERG:** Ligand A (0.163) has a lower hERG inhibition liability than Ligand B (0.741), indicating a lower risk of cardiotoxicity. This is a significant advantage.
12. **Cl_mic:** Ligand B (81.729) has a higher microsomal clearance than Ligand A (18.264), suggesting lower metabolic stability. Ligand A is preferable.
13. **t1/2:** Both ligands have negative in vitro half-life values (-20.369 and -21.983), indicating very rapid metabolism. This is a major concern for both.
14. **Pgp:** Ligand A (0.019) has much lower P-gp efflux liability than Ligand B (0.121), which is beneficial for bioavailability and potential CNS exposure.
15. **Binding Affinity:** Ligand B (-7.5 kcal/mol) has a slightly better binding affinity than Ligand A (-5.9 kcal/mol). This 1.6 kcal/mol difference is substantial.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. While Ligand B has a slightly better logP and significantly better affinity, Ligand A excels in crucial safety parameters (DILI, hERG) and has better solubility and lower Pgp efflux. The poor Caco-2 values are a concern for both, but the superior ADME profile of Ligand A, particularly the lower DILI and hERG risks, outweigh the affinity difference.
**Final Decision:**
Given the balance of properties, prioritizing safety and ADME characteristics for a cardiovascular target, I choose Ligand A.
Output:
1
2025-04-17 20:34:55,509 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (385.873) is slightly higher than Ligand B (350.438), but both are acceptable.
2. **TPSA:** Ligand A (95.58) is higher than Ligand B (64.68). For a cardiovascular GPCR, TPSA isn't a *major* concern unless it's excessively high (above 140). Both are well below this threshold, but B is preferable.
3. **logP:** Both ligands have good logP values (A: 1.127, B: 1.488), falling within the optimal 1-3 range. B is slightly better.
4. **HBD:** Both have 2 HBD, which is good.
5. **HBA:** Ligand A has 5 HBA, Ligand B has 4. Both are acceptable.
6. **QED:** Both ligands have good QED scores (A: 0.757, B: 0.816), indicating good drug-like properties. B is slightly better.
7. **DILI:** Ligand A (67.313) has a higher DILI risk than Ligand B (37.146). This is a significant concern, as lower DILI is highly desirable.
8. **BBB:** Ligand A (60.644) has a lower BBB penetration percentile than Ligand B (89.686). While ADRB2 isn't necessarily a CNS target, higher BBB is generally favorable for GPCRs, indicating better distribution.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and requires careful interpretation. It suggests poor permeability. Ligand A (-5.024) is worse than Ligand B (-4.858).
10. **Solubility:** Ligand A (-3.726) has worse solubility than Ligand B (-2.254). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.086) has a slightly lower hERG risk than Ligand B (0.803), but both are very low and acceptable.
12. **Cl_mic:** Ligand A (-16.853) has significantly lower microsomal clearance than Ligand B (23.78). Lower clearance indicates better metabolic stability, a major advantage.
13. **t1/2:** Ligand A (0.135) has a very short in vitro half-life compared to Ligand B (-2.024). This is a significant drawback for Ligand A.
14. **Pgp:** Ligand A (0.082) has lower P-gp efflux than Ligand B (0.023), which is favorable.
15. **Binding Affinity:** Ligand B (-7.1) has a slightly better binding affinity than Ligand A (-7.0). While the difference is small, it's still a factor.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand B performs better on logP, TPSA, and Pgp. The affinity difference is minimal. The biggest differentiator is the significantly better ADME profile of Ligand B (lower DILI, better BBB, better solubility, much better metabolic stability/half-life).
**Conclusion:**
Ligand B is the more promising drug candidate. While Ligand A has a slightly lower Pgp efflux, Ligand B's superior ADME properties (particularly the lower DILI risk, better metabolic stability, and better solubility) and slightly better binding affinity outweigh this minor drawback.
Output:
0
2025-04-17 20:34:55,509 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
The ADRB2 receptor is a GPCR involved in cardiovascular function, so the key priorities are logP, TPSA, Pgp efflux, binding affinity, and, to a lesser extent, BBB penetration (though less critical for a cardiovascular target).
Let's compare the ligands property by property:
1. **MW:** Both ligands (355.523 and 344.503 Da) fall within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (61.88) is higher than Ligand B (48.47). Ligand B is better here, being closer to the <90 ideal for GPCRs.
3. **logP:** Ligand A (1.743) is within the optimal 1-3 range. Ligand B (2.757) is also good, but closer to the upper end.
4. **HBD/HBA:** Both have 1 HBD and 4 HBA, which are acceptable.
5. **QED:** Both ligands have good QED scores (0.684 and 0.773), indicating good drug-like properties.
6. **DILI:** Ligand B (25.359) has a significantly lower DILI risk than Ligand A (6.747), a major advantage.
7. **BBB:** Ligand B (89.957) has a much higher BBB penetration percentile than Ligand A (51.803). While not a primary concern for a cardiovascular target, higher BBB is generally favorable.
8. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. This is a concern for both.
9. **Solubility:** Ligand A (-0.493) has slightly better solubility than Ligand B (-2.322).
10. **hERG:** Ligand A (0.447) has a lower hERG risk than Ligand B (0.779), which is preferable.
11. **Cl_mic:** Ligand B (91.428) has a much higher microsomal clearance than Ligand A (14.258), indicating lower metabolic stability. This is a significant drawback for Ligand B.
12. **t1/2:** Ligand B (80.359) has a significantly longer in vitro half-life than Ligand A (4.971), which is a positive.
13. **Pgp:** Ligand A (0.006) has a much lower Pgp efflux liability than Ligand B (0.221), which is a major advantage.
14. **Binding Affinity:** Ligand A (-6.1 kcal/mol) has a slightly better binding affinity than Ligand B (-4.7 kcal/mol), a 1.4 kcal/mol difference. This is substantial and can outweigh some ADME concerns.
**Overall Assessment:**
Ligand A has a better binding affinity and lower Pgp efflux, which are crucial for GPCR targets. It also has better metabolic stability (lower Cl_mic). Ligand B has a lower DILI risk and longer half-life, but its higher Pgp efflux and significantly worse metabolic stability are major drawbacks. The binding affinity difference is significant enough to favor Ligand A, despite the slightly higher DILI risk (which is still within an acceptable range). The poor Caco-2 values are concerning for both, but can be addressed with formulation strategies.
**Output:**
1
2025-04-17 20:34:55,509 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (346.431 and 348.531 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (86.63) is higher than Ligand B (58.2). For a cardiovascular GPCR, TPSA is moderately important, and Ligand B is preferable here.
3. **logP:** Ligand A (0.868) is lower than Ligand B (4.27). Ligand B is significantly higher and potentially problematic. While 1-3 is optimal, 4.27 is pushing the upper limit and could lead to poor solubility and off-target effects.
4. **HBD:** Ligand A (1) is lower than Ligand B (2). Lower is generally better, so Ligand A is slightly favored.
5. **HBA:** Ligand A (5) is higher than Ligand B (2). Ligand B is favored here.
6. **QED:** Ligand A (0.855) is higher than Ligand B (0.508). Ligand A is significantly more drug-like.
7. **DILI:** Ligand A (30.399) is higher than Ligand B (20.861). Ligand B is preferable, indicating a lower risk of liver injury.
8. **BBB:** Ligand A (58.511) is lower than Ligand B (72.78). While ADRB2 isn't a CNS target, higher BBB is still a slight advantage, favoring Ligand B.
9. **Caco-2:** Ligand A (-4.851) and Ligand B (-4.702) are both very poor. This is a significant concern for both compounds, suggesting poor intestinal absorption.
10. **Solubility:** Ligand A (-0.653) is better than Ligand B (-4.283). Solubility is crucial, and Ligand A has a much better score.
11. **hERG:** Ligand A (0.361) is much lower than Ligand B (0.619). This is a significant advantage for Ligand A, indicating a lower risk of cardiotoxicity.
12. **Cl_mic:** Ligand A (8.284) is much lower than Ligand B (66.252). Ligand A has significantly better metabolic stability.
13. **t1/2:** Ligand A (4.697) is lower than Ligand B (7.264). Ligand B is favored here.
14. **Pgp:** Ligand A (0.044) is much lower than Ligand B (0.353). Ligand A shows significantly less P-gp efflux, which is beneficial for bioavailability.
15. **Affinity:** Ligand A (-7.0) is slightly better than Ligand B (-6.9). While the difference is small, it's still a positive for Ligand A.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), and the general drug-like properties, Ligand A emerges as the stronger candidate. While Ligand B has better BBB penetration and in vitro half-life, its high logP, higher DILI risk, and worse solubility are major drawbacks. Ligand A's superior QED, lower DILI, better solubility, lower hERG risk, and significantly lower microsomal clearance are crucial advantages. The slightly better affinity further supports this decision. The poor Caco-2 values are a concern for both, but can be addressed with formulation strategies.
Output:
1
2025-04-17 20:34:55,509 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (405.296 Da) is within the ideal range. Ligand B (361.511 Da) is also within the ideal range. No clear advantage here.
2. **TPSA:** Ligand A (57.7) is good, below the 140 threshold. Ligand B (43.43) is excellent, even better for permeability. Ligand B has a slight advantage.
3. **logP:** Both Ligand A (3.595) and Ligand B (3.712) are within the optimal 1-3 range. No significant difference.
4. **HBD:** Ligand A (1) is good. Ligand B (0) is also good. No significant difference.
5. **HBA:** Ligand A (4) is good. Ligand B (6) is acceptable, but slightly higher. Ligand A has a slight advantage.
6. **QED:** Both Ligand A (0.848) and Ligand B (0.717) are above 0.5, indicating good drug-likeness. Ligand A is slightly better.
7. **DILI:** Ligand A (77.472) is higher risk than Ligand B (20.9). Ligand B has a significant advantage here.
8. **BBB:** Ligand A (63.164) is acceptable, but Ligand B (84.529) is much better, exceeding 70. Given ADRB2's cardiovascular involvement, CNS penetration isn't *critical*, but a higher BBB score is still preferable. Ligand B has a clear advantage.
9. **Caco-2:** Ligand A (-4.722) and Ligand B (-5.047) are both very poor. This is a significant drawback for both.
10. **Solubility:** Both Ligand A (-3.943) and Ligand B (-3.836) are poor. This is a concern for both, but not a deciding factor.
11. **hERG:** Ligand A (0.744) is better than Ligand B (0.839), indicating lower hERG inhibition risk. Ligand A has a slight advantage.
12. **Cl_mic:** Ligand A (43.078) has lower clearance than Ligand B (94.551), suggesting better metabolic stability. Ligand A has a significant advantage.
13. **t1/2:** Ligand A (15.509) has a shorter half-life than Ligand B (30.15). Ligand B has a clear advantage.
14. **Pgp:** Ligand A (0.244) has lower P-gp efflux than Ligand B (0.386), which is preferable. Ligand A has a slight advantage.
15. **Affinity:** Ligand A (-7.3 kcal/mol) has a slightly better affinity than Ligand B (-6.3 kcal/mol). This is a substantial advantage, potentially outweighing some ADME concerns.
**Overall Assessment:**
Ligand A has a better binding affinity, better metabolic stability (lower Cl_mic), lower P-gp efflux, and lower hERG risk. Ligand B excels in BBB penetration and has a significantly lower DILI risk. The Caco-2 and solubility are poor for both.
Considering ADRB2 is a cardiovascular target, the lower DILI risk of Ligand B is very important. While affinity is crucial, a safer profile is often prioritized, especially early in development. The improved BBB of Ligand B is also a bonus. The affinity difference, while present, isn't large enough to overcome the safety advantages of Ligand B.
Output:
0
2025-04-17 20:34:55,509 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [342.458, 23.55, 3.788, 0, 1, 0.802, 18.185, 82.435, -4.504, -4.445, 0.808, 46.696, 17.628, 0.344, -7.9]
**Ligand B:** [388.515, 113.67, -0.02, 1, 6, 0.705, 49.67, 56.572, -5.562, -1.657, 0.066, 8.074, -20.222, 0.025, -5.9]
**Step-by-step comparison:**
1. **MW:** Ligand A (342.458 Da) is within the ideal range, while Ligand B (388.515 Da) is approaching the upper limit but still acceptable.
2. **TPSA:** Ligand A (23.55) is excellent, well below the 140 threshold and suitable for good absorption. Ligand B (113.67) is higher, but still within a reasonable range for a non-CNS GPCR.
3. **logP:** Ligand A (3.788) is optimal. Ligand B (-0.02) is significantly low, potentially causing permeability issues.
4. **HBD:** Both have acceptable HBD counts (0 for A, 1 for B).
5. **HBA:** Ligand A (1) is good. Ligand B (6) is higher, potentially impacting permeability.
6. **QED:** Both are good (0.802 and 0.705), indicating drug-like properties.
7. **DILI:** Ligand A (18.185) has a much lower DILI risk than Ligand B (49.67). This is a significant advantage.
8. **BBB:** Ligand A (82.435) shows better BBB penetration potential, which is relevant for a GPCR. Ligand B (56.572) is lower.
9. **Caco-2:** Ligand A (-4.504) and Ligand B (-5.562) both have negative Caco-2 values, which is unusual and suggests poor permeability. However, these values are on a scale where negative values are possible, and the absolute value is what matters.
10. **Solubility:** Ligand A (-4.445) and Ligand B (-1.657) both have negative solubility values, indicating poor aqueous solubility.
11. **hERG:** Ligand A (0.808) has a lower hERG risk than Ligand B (0.066).
12. **Cl_mic:** Ligand A (46.696) has a better metabolic stability profile than Ligand B (8.074).
13. **t1/2:** Ligand A (17.628) has a longer in vitro half-life than Ligand B (-20.222).
14. **Pgp:** Ligand A (0.344) has lower P-gp efflux liability than Ligand B (0.025).
15. **Affinity:** Ligand A (-7.9) has a significantly stronger binding affinity than Ligand B (-5.9), a difference of 2 kcal/mol.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are crucial. Ligand A excels in logP, TPSA, Pgp, and *especially* affinity. While both have issues with solubility and Caco-2 permeability, the superior affinity and lower risk profile of Ligand A outweigh these drawbacks. The significant difference in binding affinity (-7.9 vs -5.9 kcal/mol) is a major deciding factor.
**Conclusion:**
Ligand A is the more promising drug candidate.
1
2025-04-17 20:34:55,509 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (347.46 and 348.45 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (72.36) is better than Ligand B (85.17). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (1.712) is better than Ligand B (0.547). Both are within the acceptable range (1-3), but Ligand A is closer to optimal. Ligand B is a bit low and might have permeability issues.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1), but both are within the acceptable limit of 5.
5. **HBA:** Ligand B (7) is higher than Ligand A (4). Both are within the acceptable limit of 10.
6. **QED:** Both ligands have similar QED values (0.789 and 0.724), indicating good drug-likeness.
7. **DILI:** Ligand B (25.553) is significantly better than Ligand A (39.201). Lower DILI risk is a major advantage.
8. **BBB:** Ligand B (84.257) is better than Ligand A (69.794), but since this is a cardiovascular target, BBB penetration is not a high priority.
9. **Caco-2:** Ligand A (-5.013) is better than Ligand B (-5.379). Higher Caco-2 values indicate better absorption.
10. **Solubility:** Ligand A (-2.517) is better than Ligand B (-1.184). Better solubility is generally preferred.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.34 and 0.116). No significant difference.
12. **Cl_mic:** Ligand B (18.102) has significantly lower microsomal clearance than Ligand A (53.761). This suggests better metabolic stability for Ligand B.
13. **t1/2:** Ligand A (0.944) is better than Ligand B (-0.468). A longer half-life is generally preferred.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.181 and 0.071). No significant difference.
15. **Binding Affinity:** Ligand B (-7.9 kcal/mol) is significantly better than Ligand A (-6.5 kcal/mol). This is a substantial difference in potency (1.4 kcal/mol).
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, potency (affinity) is a crucial factor. The 1.4 kcal/mol difference in binding affinity between Ligand B and Ligand A is substantial. While Ligand A has some advantages in solubility and half-life, the superior affinity of Ligand B, coupled with its significantly lower DILI risk and better metabolic stability (lower Cl_mic), outweighs these factors. The slightly lower logP of Ligand B is a minor concern, but not a deal-breaker.
**Conclusion:**
Ligand B is the more promising drug candidate due to its significantly higher binding affinity, lower DILI risk, and improved metabolic stability.
Output:
0
2025-04-17 20:34:55,509 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (349.45) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (58.8) is significantly better than Ligand B (116.92). ADRB2 is not a CNS target, but lower TPSA generally improves absorption.
3. **logP:** Both ligands have good logP values (A: 2.85, B: 2.132) within the optimal range of 1-3.
4. **HBD:** Both ligands are acceptable (A: 1, B: 2), well below the limit of 5.
5. **HBA:** Both ligands are acceptable (A: 4, B: 5), below the limit of 10.
6. **QED:** Both ligands have good QED scores (A: 0.831, B: 0.862), indicating good drug-likeness.
7. **DILI:** Ligand A (41.179) has a much lower DILI risk than Ligand B (95.89). This is a significant advantage.
8. **BBB:** BBB is less critical for ADRB2 as it's not a CNS target. Ligand A (91.508) has a higher BBB value than Ligand B (17.138), but this is not a major factor in this case.
9. **Caco-2:** Ligand A (-4.675) is better than Ligand B (-5.037), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-3.045) is better than Ligand B (-3.0), indicating better aqueous solubility.
11. **hERG:** Ligand A (0.87) is better than Ligand B (0.043), indicating lower hERG inhibition liability. This is a significant safety advantage.
12. **Cl_mic:** Ligand A (1.506) has a much lower microsomal clearance than Ligand B (8.307), suggesting better metabolic stability.
13. **t1/2:** Ligand B (63.501) has a much longer in vitro half-life than Ligand A (2.683). This is a significant advantage.
14. **Pgp:** Ligand A (0.252) has lower P-gp efflux liability than Ligand B (0.031), which is favorable for absorption and bioavailability.
15. **Binding Affinity:** Ligand B (-6.8) has a slightly better binding affinity than Ligand A (-6.4), a 0.4 kcal/mol difference.
**Overall Assessment:**
While Ligand B has a slightly better binding affinity and a significantly longer half-life, Ligand A demonstrates a much more favorable safety profile (lower DILI, lower hERG) and better ADME properties (lower Cl_mic, better solubility, better Caco-2 permeability, lower Pgp efflux). The difference in binding affinity (0.4 kcal/mol) is not substantial enough to outweigh the significant advantages of Ligand A in terms of safety and ADME. For a cardiovascular target like ADRB2, minimizing off-target effects and ensuring good pharmacokinetic properties are crucial.
Output:
1
2025-04-17 20:34:55,510 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step Comparison:**
1. **MW:** Ligand A (359.9) is within the ideal range (200-500), while Ligand B (334.4) is also good. No clear advantage here.
2. **TPSA:** Ligand A (38.3) is excellent, well below the 140 threshold and favorable for absorption. Ligand B (69.0) is higher, but still acceptable. Ligand A is better.
3. **logP:** Ligand A (4.98) is slightly high, potentially leading to solubility issues or off-target interactions. Ligand B (2.59) is optimal. Ligand B is better.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 2 HBA, while Ligand B has 4. Both are acceptable, but Ligand A is slightly better.
6. **QED:** Ligand B (0.933) has a significantly better QED score than Ligand A (0.685), indicating a more drug-like profile. Ligand B is better.
7. **DILI:** Ligand A (39.7) has a lower DILI risk than Ligand B (48.0), which is preferable. Ligand A is better.
8. **BBB:** Ligand B (77.2) shows better BBB penetration than Ligand A (40.4). Given that ADRB2 is a GPCR, and while not necessarily a CNS target, some degree of BBB penetration can be useful for understanding off-target effects. Ligand B is better.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Ligand A (-5.2) has worse solubility than Ligand B (-3.8). Ligand B is better.
11. **hERG:** Both ligands have low hERG inhibition risk (0.795 and 0.789). No significant difference.
12. **Cl_mic:** Ligand A (94.7) has higher metabolic clearance than Ligand B (51.1), suggesting lower metabolic stability. Ligand B is better.
13. **t1/2:** Ligand A (41.0) has a much longer in vitro half-life than Ligand B (6.4). This is a significant advantage for Ligand A.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.692 and 0.254). Ligand B is better.
15. **Affinity:** Ligand A (-7.6) has a significantly stronger binding affinity than Ligand B (-6.8). This is a substantial advantage, potentially outweighing some ADME drawbacks.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B has a better logP and Pgp profile. Ligand A has a better TPSA. However, the *significant* difference in binding affinity (-7.6 vs -6.8 kcal/mol) is the most important factor. A 0.8 kcal/mol difference is substantial and likely to translate to a more potent drug. The longer half-life of Ligand A is also a significant benefit. While Ligand B has better QED and solubility, the stronger binding and longer half-life of Ligand A are more critical for a GPCR target.
**Final Decision:**
Considering the balance of properties and the priorities for a GPCR target, I favor Ligand A.
Output:
1
2025-04-17 20:34:55,510 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (369.487 Da and 353.369 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (92.51 and 91.06) are reasonably low, suggesting good potential for absorption. They are below the 140 threshold.
3. **logP:** Both ligands have acceptable logP values (1.121 and 1.519), falling within the 1-3 optimal range. Ligand B is slightly higher, potentially improving membrane permeability.
4. **HBD:** Ligand A has 1 HBD, while Ligand B has 3. Ligand A is preferable here, as fewer HBDs generally correlate with better permeability.
5. **HBA:** Ligand A has 5 HBA, Ligand B has 3. Both are within the acceptable range of <=10.
6. **QED:** Both ligands have similar QED values (0.704 and 0.677), indicating good drug-likeness.
7. **DILI:** Ligand A (25.514) has a significantly lower DILI risk than Ligand B (49.477). This is a major advantage for Ligand A.
8. **BBB:** Both ligands have moderate BBB penetration (60.876 and 69.252). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration isn't detrimental. Ligand B is slightly better.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.226 and -5.124) which is unusual and suggests very poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand A (-0.952) has slightly better solubility than Ligand B (-2.96).
11. **hERG:** Both ligands have low hERG inhibition risk (0.163 and 0.438).
12. **Cl_mic:** Ligand B (-1.982) has a *much* lower (and therefore better) microsomal clearance than Ligand A (26.201). This suggests significantly improved metabolic stability for Ligand B.
13. **t1/2:** Ligand B (-25.504) has a more negative in vitro half-life, indicating a longer half-life and potentially less frequent dosing. Ligand A is -13.803.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.055 and 0.067).
15. **Affinity:** Both ligands have very similar binding affinities (-7.0 and -6.8 kcal/mol). The difference is negligible.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, and affinity are important. Both ligands are comparable in these areas. However, metabolic stability (Cl_mic and t1/2) and safety (DILI) are crucial. Ligand B has a substantial advantage in metabolic stability and a slightly better half-life. Ligand A has a significant advantage in DILI risk.
**Overall Assessment:**
While Ligand B has superior metabolic stability, the significantly lower DILI risk associated with Ligand A is a critical factor. A lower DILI risk is paramount in drug development, outweighing the benefit of slightly improved metabolic stability. The Caco-2 values are concerning for both, but can be addressed with formulation strategies.
Output:
1
2025-04-17 20:34:55,510 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.39 and 383.905 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (78.87) is better than Ligand B (88.91). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally favors absorption.
3. **logP:** Both ligands (1.724 and 2.391) are within the optimal 1-3 range. Ligand B is slightly higher, which *could* be beneficial for membrane permeability, but not significantly.
4. **HBD:** Both ligands have 2 HBD, which is good.
5. **HBA:** Ligand A has 4 HBA, while Ligand B has 6. Ligand A is preferable here, as lower HBA generally improves permeability.
6. **QED:** Both ligands have similar QED values (0.766 and 0.718), indicating good drug-likeness.
7. **DILI:** Both ligands have similar DILI risk (62.66 and 64.327), both are slightly elevated but not alarming.
8. **BBB:** Ligand A (69.794) has a better BBB percentile than Ligand B (46.568). While not a CNS target, some level of BBB penetration can sometimes correlate with other favorable properties.
9. **Caco-2:** Ligand A (-4.945) is significantly better than Ligand B (-5.587). This suggests better intestinal absorption for Ligand A.
10. **Solubility:** Ligand A (-2.817) is slightly better than Ligand B (-2.683).
11. **hERG:** Both ligands have very low hERG inhibition risk (0.503 and 0.226). Excellent for both.
12. **Cl_mic:** Ligand A (20.988) has a lower microsomal clearance than Ligand B (18.966), suggesting better metabolic stability.
13. **t1/2:** Ligand B (31.448) has a much longer in vitro half-life than Ligand A (-6.591). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.287) has lower P-gp efflux liability than Ligand B (0.084), which is preferable.
15. **Affinity:** Ligand B (-6.9) has a slightly better binding affinity than Ligand A (-6.2). This is a 0.7 kcal/mol difference, which is a noticeable advantage.
**GPCR-specific priorities:** For ADRB2 (a GPCR), we prioritize logP, Pgp, TPSA, and affinity. Ligand B has a slightly better logP and significantly better affinity. Ligand A has better TPSA and Pgp. However, the affinity difference is substantial enough to outweigh the other factors. The longer half-life of Ligand B is also a significant benefit.
**Conclusion:**
Considering the balance of properties and the GPCR-specific priorities, Ligand B is the more promising drug candidate. The improved binding affinity and longer half-life are key advantages that outweigh the slightly less favorable TPSA and Pgp values.
Output:
0
2025-04-17 20:34:55,510 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.359 and 350.419 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (105.02 and 102.44) are reasonably low, suggesting good potential for absorption. They are above the optimal <90 for CNS targets, but ADRB2 isn't necessarily a CNS target.
3. **logP:** Both ligands have low logP values (0.466 and 0.379), which is a concern. While not excessively low, they are below the optimal 1-3 range and could potentially hinder membrane permeability.
4. **HBD/HBA:** Ligand A has 1 HBD and 7 HBA, while Ligand B has 2 HBD and 6 HBA. Both are within acceptable limits (<=5 HBD and <=10 HBA).
5. **QED:** Ligand B (0.703) has a significantly better QED score than Ligand A (0.468), indicating a more drug-like profile.
6. **DILI:** Ligand B (41.838) has a considerably lower DILI risk than Ligand A (61.148), which is a major advantage.
7. **BBB:** Ligand B (63.009) shows slightly better BBB penetration than Ligand A (53.897), although both are moderate. This isn't a primary concern for ADRB2, but a slight benefit.
8. **Caco-2:** Both ligands have negative Caco-2 values (-4.915 and -4.886), which is unusual and suggests poor permeability. This is a significant drawback for both.
9. **Solubility:** Both ligands have negative solubility values (-2.679 and -1.297), indicating very poor aqueous solubility. This is a major concern for bioavailability.
10. **hERG:** Ligand A (0.432) has a slightly higher hERG risk than Ligand B (0.171), which is preferable for Ligand B.
11. **Cl_mic:** Ligand A (12.395) has a lower microsomal clearance than Ligand B (17.045), suggesting better metabolic stability. This is a positive for Ligand A.
12. **t1/2:** Ligand B (20.451) has a much longer in vitro half-life than Ligand A (-8.761), which is a significant advantage.
13. **Pgp:** Ligand A (0.035) has a lower P-gp efflux liability than Ligand B (0.003), which is preferable.
14. **Binding Affinity:** Both ligands have very similar and strong binding affinities (-6.7 and -6.1 kcal/mol). The difference of 0.6 kcal/mol isn't enough to outweigh other factors.
**Overall Assessment & GPCR Considerations:**
Given that this is a GPCR target (ADRB2), logP, TPSA, Pgp, and affinity are important. Both ligands struggle with logP and Caco-2 permeability. However, Ligand B has a significantly better QED score, lower DILI risk, better BBB penetration, and a much longer half-life. While Ligand A has slightly better metabolic stability and lower P-gp efflux, the advantages of Ligand B in terms of safety (DILI) and pharmacokinetics (t1/2) are more compelling. The similar binding affinities make these ADME properties the deciding factors.
Output:
0
2025-04-17 20:34:55,510 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [343.431, 80.12, 1.025, 1, 5, 0.81, 41.373, 64.831, -5.031, -2.404, 0.028, 44.829, -13.177, 0.089, -3.1]
**Ligand B:** [350.486, 88.75, 3.776, 3, 6, 0.488, 47.421, 82.629, -5.138, -4.855, 0.853, 66.908, 26.318, 0.423, -7.9]
Here's a breakdown of the comparison, considering the provided guidelines and GPCR-specific priorities:
1. **MW:** Both ligands are within the ideal range (200-500 Da). A is 343.431, B is 350.486 - very similar.
2. **TPSA:** Both are acceptable, but A (80.12) is better than B (88.75) as it's closer to the <140 threshold for oral absorption.
3. **logP:** A (1.025) is optimal, while B (3.776) is approaching the upper limit and could potentially cause solubility issues.
4. **HBD:** A (1) is preferable to B (3). Lower HBD generally improves permeability.
5. **HBA:** A (5) is better than B (6), again favoring permeability.
6. **QED:** A (0.81) is significantly better than B (0.488), indicating a more drug-like profile.
7. **DILI:** Both are relatively low, with A (41.373) slightly better than B (47.421). Both are below the 60% threshold.
8. **BBB:** B (82.629) is better than A (64.831), but BBB is less critical for a cardiovascular target.
9. **Caco-2:** Both are negative, indicating poor permeability. This is a significant concern for both.
10. **Solubility:** Both are negative, indicating poor solubility. A (-2.404) is slightly better than B (-4.855).
11. **hERG:** A (0.028) is *much* better than B (0.853), indicating a significantly lower risk of cardiotoxicity. This is critical for a cardiovascular target.
12. **Cl_mic:** A (44.829) is better than B (66.908), suggesting better metabolic stability.
13. **t1/2:** A (-13.177) is better than B (26.318), indicating a longer half-life.
14. **Pgp:** A (0.089) is much better than B (0.423), meaning less efflux and better bioavailability.
15. **Affinity:** B (-7.9) has a significantly stronger binding affinity than A (-3.1). This is a substantial advantage.
**Overall Assessment:**
While Ligand B boasts a significantly stronger binding affinity, the ADME properties of Ligand A are far superior. Ligand B has a higher logP, more HBD/HBA, lower QED, a much higher hERG risk, and higher Pgp efflux. The poor Caco-2 and solubility for both are concerning, but A is slightly better. For a cardiovascular GPCR, minimizing cardiotoxicity (hERG) and maximizing metabolic stability (Cl_mic, t1/2) are crucial. The substantial difference in hERG inhibition liability is a major deciding factor. The affinity difference, while significant, might be overcome with further optimization of Ligand A, whereas mitigating the liabilities of Ligand B would be a much greater challenge.
Therefore, I believe Ligand A is the more viable drug candidate.
1
2025-04-17 20:34:55,510 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (364.471 and 349.431 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Both ligands have TPSA values (88.33 and 84.67) below the 140 A^2 threshold for good oral absorption. They are also reasonably low, which is favorable for GPCRs. Ligand B is slightly better.
**3. logP:** Both ligands have logP values (2.669 and 1.387) within the optimal 1-3 range. Ligand B is slightly lower, which could potentially improve solubility but might slightly compromise membrane permeability.
**4. H-Bond Donors:** Both ligands have 1 HBD, which is well within the acceptable limit of 5.
**5. H-Bond Acceptors:** Both ligands have 6 and 5 HBAs, respectively, both below the 10 limit.
**6. QED:** Both ligands have good QED scores (0.778 and 0.839), indicating good drug-like properties. Ligand B is slightly better.
**7. DILI Risk:** Ligand A has a DILI risk of 55.991, while Ligand B has a much lower risk of 13.067. This is a significant advantage for Ligand B.
**8. BBB Penetration:** Ligand B (73.827) has significantly better predicted BBB penetration than Ligand A (58.821). This is a crucial factor for a GPCR target, even if it's not a CNS target, as it can influence off-target effects and distribution.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-5.08 and -4.837), which is unusual and suggests poor permeability. However, these values are on a log scale, so the difference is not huge.
**10. Aqueous Solubility:** Both ligands have negative solubility values (-1.947 and -1.787), indicating poor solubility. This is a concern, but can potentially be addressed with formulation strategies.
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (0.418 and 0.147). Ligand B is better here.
**12. Microsomal Clearance:** Ligand A has a higher microsomal clearance (86.155) than Ligand B (21.181), indicating faster metabolism and potentially lower exposure. This is a disadvantage for Ligand A.
**13. In vitro Half-Life:** Ligand B has a significantly longer in vitro half-life (6.471 hours) than Ligand A (-21.729 hours). This is a major advantage for Ligand B.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.112 and 0.015). Ligand B is better.
**15. Binding Affinity:** Ligand A has a slightly better binding affinity (-7.0 kcal/mol) than Ligand B (-6.4 kcal/mol). This is a 0.6 kcal/mol difference, which is not huge.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity, Ligand B demonstrates a significantly superior ADME-Tox profile. Specifically, its lower DILI risk, better BBB penetration, lower microsomal clearance, longer half-life, and lower P-gp efflux are all highly desirable characteristics for a drug candidate, especially for a GPCR. The slight difference in binding affinity is outweighed by these substantial ADME advantages.
Output:
0
2025-04-17 20:34:55,510 - INFO - Batch 195 complete. Total preferences: 3120
2025-04-17 20:34:55,510 - INFO - Processing batch 196/512...
2025-04-17 20:35:44,140 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (385.339 Da) is slightly higher than Ligand B (335.411 Da), but both are acceptable.
**2. TPSA:** Ligand A (88.6) is slightly above the optimal <90 for GPCRs, while Ligand B (63.05) is well within the range. This favors Ligand B.
**3. logP:** Ligand A (1.173) is within the optimal range (1-3). Ligand B (3.609) is at the higher end, potentially raising concerns about solubility and off-target effects, but still acceptable.
**4. H-Bond Donors:** Both ligands have 1 HBD, which is good.
**5. H-Bond Acceptors:** Ligand A has 5 HBA, and Ligand B has 4. Both are within the acceptable range of <=10.
**6. QED:** Both ligands have a QED > 0.5, indicating good drug-likeness. Ligand B (0.778) is slightly better than Ligand A (0.712).
**7. DILI:** Both ligands have similar DILI risk (Ligand A: 66.615, Ligand B: 65.723), and are within an acceptable range (<60 is preferred, but these are not drastically high).
**8. BBB:** Ligand B (82.047) has a significantly higher BBB penetration percentile than Ligand A (75.107). This is a key advantage for a GPCR target, even if it's not a CNS target, as it can influence distribution.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.825) is slightly better than Ligand B (-5.003).
**10. Aqueous Solubility:** Both ligands have very poor aqueous solubility (-3.115 and -3.568 respectively). This is a significant concern.
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (Ligand A: 0.444, Ligand B: 0.629).
**12. Microsomal Clearance:** Ligand A (7.85) has a much lower (better) microsomal clearance than Ligand B (30.312). This suggests better metabolic stability for Ligand A.
**13. In vitro Half-Life:** Ligand A (-46.929) has a much longer in vitro half-life than Ligand B (26.353). This is a significant advantage.
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (Ligand A: 0.024, Ligand B: 0.125).
**15. Binding Affinity:** Ligand B (-7.7 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.9 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME concerns.
**Overall Assessment:**
While Ligand A has better metabolic stability (lower Cl_mic, longer t1/2) and slightly better Caco-2 permeability, Ligand B's significantly stronger binding affinity (-7.7 vs -6.9 kcal/mol) and higher BBB penetration are crucial advantages for a GPCR target like ADRB2. The solubility is a concern for both, but the potency advantage of Ligand B is likely to be more impactful in driving forward a drug development program, assuming solubility can be addressed through formulation.
Output:
0
2025-04-17 20:35:44,141 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
The target is ADRB2, a GPCR. Therefore, priorities are logP, TPSA, Pgp, BBB, and binding affinity. Let's compare the ligands:
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (376.283 Da) is slightly higher than Ligand B (344.467 Da), but both are acceptable.
2. **TPSA:** Ligand A (52.49) is significantly better than Ligand B (97.78). A TPSA under 140 is good for oral absorption, but lower is generally preferred for GPCRs, and Ligand A is much closer to the ideal range for CNS penetration if needed.
3. **logP:** Ligand A (4.462) is higher than Ligand B (2.325). While both are within the acceptable range (1-3), Ligand A is pushing the upper limit. This could potentially lead to solubility issues, but it might be acceptable given the strong binding affinity.
4. **H-Bond Donors/Acceptors:** Ligand A has 3 HBD and 3 HBA, while Ligand B has 2 HBD and 8 HBA. Both are within acceptable limits, but Ligand B has a higher number of HBA, which could slightly hinder permeability.
5. **QED:** Both ligands have similar QED values (0.595 and 0.532), indicating reasonable drug-likeness.
6. **DILI:** Ligand A (48.623) has a slightly higher DILI risk than Ligand B (52.036), but both are below the concerning threshold of 60.
7. **BBB:** Ligand B (71.074) has a significantly higher BBB percentile than Ligand A (37.34). This is a positive for Ligand B, but less critical for a non-CNS target like ADRB2.
8. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
9. **Solubility:** Both ligands have negative solubility values, indicating poor aqueous solubility. This is a concern for both, but potentially more so for Ligand A due to its higher logP.
10. **hERG:** Ligand A (0.92) has a slightly higher hERG risk than Ligand B (0.642), but both are relatively low.
11. **Cl_mic:** Ligand A (12.141) has a significantly lower microsomal clearance than Ligand B (40.24), indicating better metabolic stability. This is a major advantage for Ligand A.
12. **t1/2:** Ligand A (140.185) has a much longer in vitro half-life than Ligand B (17.465). This is a significant advantage for Ligand A, potentially allowing for less frequent dosing.
13. **Pgp:** Ligand A (0.673) has a lower P-gp efflux liability than Ligand B (0.163), which is favorable for both oral bioavailability and potential CNS exposure.
14. **Binding Affinity:** Ligand A (-7.2 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.2 kcal/mol). This 1.0 kcal/mol difference is substantial and can outweigh many ADME drawbacks.
**Conclusion:**
Despite Ligand B's better BBB penetration and slightly lower DILI/hERG risk, Ligand A is the more promising candidate. The significantly stronger binding affinity (-7.2 vs -6.2 kcal/mol), lower microsomal clearance, and longer half-life are crucial advantages, especially for a GPCR target. While the higher logP and lower solubility of Ligand A are concerns, they may be addressable through formulation strategies. The lower TPSA of Ligand A is also beneficial.
**Output:**
1
2025-04-17 20:35:44,141 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's systematically compare Ligand A and Ligand B across the provided parameters, keeping in mind the GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key).
1. **MW:** Both ligands (350.419 and 354.441 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand B (40.62) is significantly better than Ligand A (103.79). A lower TPSA generally indicates better cell permeability, a critical factor for GPCR ligands.
3. **logP:** Both ligands have acceptable logP values (1.843 and 2.941, respectively), falling within the optimal 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability.
4. **HBD/HBA:** Ligand A has 3 HBD and 5 HBA, while Ligand B has 0 HBD and 2 HBA. Ligand B is preferable here, as fewer hydrogen bonding groups often correlate with improved permeability.
5. **QED:** Both ligands have similar QED values (0.769 and 0.731), indicating good drug-like properties.
6. **DILI:** Ligand A (32.183) has a lower DILI risk than Ligand B (47.305), which is a significant advantage.
7. **BBB:** Ligand B (96.278) shows much better BBB penetration potential than Ligand A (52.811). While ADRB2 isn't exclusively a CNS target, some cardiovascular effects are mediated by central pathways, and better BBB penetration could be advantageous.
8. **Caco-2:** Both ligands have negative Caco-2 values (-4.745 and -4.324). This is unusual and suggests poor permeability in this assay.
9. **Solubility:** Both ligands have negative solubility values (-2.466 and -3.003). This is also unusual and suggests poor aqueous solubility.
10. **hERG:** Ligand A (0.171) has a slightly lower hERG inhibition liability than Ligand B (0.67), which is preferable.
11. **Cl_mic:** Ligand B (46.987) has a much higher microsomal clearance than Ligand A (4.785), indicating faster metabolism and potentially lower *in vivo* exposure. This is a significant drawback for Ligand B.
12. **t1/2:** Ligand A (-15.594) has a more negative in vitro half-life than Ligand B (-11.153). This suggests a shorter half-life for Ligand A, which is not ideal.
13. **Pgp:** Ligand A (0.006) has a much lower P-gp efflux liability than Ligand B (0.245), which is a significant advantage. Lower P-gp efflux means better bioavailability.
14. **Binding Affinity:** Both ligands have very similar binding affinities (-7.0 and -5.9 kcal/mol). Ligand A is slightly better, but the difference is not substantial enough to outweigh other factors.
**Overall Assessment:**
Ligand A has a better safety profile (lower DILI, lower hERG, lower Pgp efflux), better metabolic stability (lower Cl_mic), and slightly better binding affinity. Ligand B has better TPSA and BBB penetration, but suffers from higher DILI, higher Pgp efflux, and significantly higher metabolic clearance. Given the importance of metabolic stability and safety for a cardiovascular drug, and the relatively small advantage of Ligand B's TPSA and BBB, **Ligand A is the more promising candidate.**
**Output:**
1
2025-04-17 20:35:44,141 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (351.475 and 360.483 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (64.92) is significantly better than Ligand B (86.88). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (4.81) is slightly higher than Ligand B (3.181), but both are within the acceptable 1-3 range. Ligand A is pushing the upper limit, which could lead to solubility issues.
4. **HBD:** Ligand A (2) is better than Ligand B (3). Lower HBD is generally preferred for permeability.
5. **HBA:** Ligand A (3) is better than Ligand B (4). Similar to HBD, lower HBA is generally preferred.
6. **QED:** Ligand A (0.734) is better than Ligand B (0.6). A higher QED indicates a more drug-like profile.
7. **DILI:** Ligand B (53.625) has a lower DILI risk than Ligand A (58.976), which is a significant advantage.
8. **BBB:** Ligand A (82.513) has a much higher BBB penetration than Ligand B (32.726). While not critical for a cardiovascular target, it's a neutral benefit for A.
9. **Caco-2:** Ligand A (-4.777) is better than Ligand B (-5.738). Higher Caco-2 permeability indicates better intestinal absorption.
10. **Solubility:** Ligand B (-2.396) has better aqueous solubility than Ligand A (-6.1). This is important, especially given Ligand A's higher logP.
11. **hERG:** Ligand A (0.747) has a lower hERG inhibition liability than Ligand B (0.593), which is a significant advantage.
12. **Cl_mic:** Ligand B (25.614) has a lower microsomal clearance than Ligand A (100.622), indicating better metabolic stability. This is a major advantage.
13. **t1/2:** Ligand B (-8.444) has a longer in vitro half-life than Ligand A (27.787). This is a major advantage.
14. **Pgp:** Ligand A (0.405) has lower P-gp efflux liability than Ligand B (0.186). Lower Pgp efflux is generally preferred.
15. **Affinity:** Ligand A (-8.2 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.1 kcal/mol). This is a substantial advantage and can often outweigh minor ADME concerns.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A excels in affinity and Pgp, and has a better TPSA. Ligand B has a better logP and solubility, and significantly better metabolic stability (Cl_mic and t1/2) and DILI risk.
**Overall Assessment:**
While Ligand B has advantages in metabolic stability, DILI, and solubility, the significantly stronger binding affinity of Ligand A (-8.2 vs -6.1 kcal/mol) is a decisive factor. The 2.1 kcal/mol difference is substantial and likely to translate to greater efficacy *in vivo*. The slightly higher logP of Ligand A is a concern, but manageable with formulation strategies. The lower hERG risk is also a significant benefit.
Output:
1
2025-04-17 20:35:44,141 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (341.382 and 342.399 Da) are within the ideal range (200-500 Da). No significant difference.
2. **TPSA:** Ligand A (55.4) is significantly better than Ligand B (74.74). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (3.619) is optimal, while Ligand B (2.076) is on the lower side. A logP between 1-3 is preferred, and Ligand A is closer to this ideal.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A (3) is better than Ligand B (6). Fewer HBA is generally preferred for better permeability.
6. **QED:** Ligand A (0.845) is better than Ligand B (0.742), indicating a more drug-like profile.
7. **DILI:** Ligand B (32.377) has a much lower DILI risk than Ligand A (67.429). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (84.141) has better BBB penetration than Ligand B (47.693). While not a primary concern for a cardiovascular target, it's a slight positive for Ligand A.
9. **Caco-2:** Ligand A (-4.454) has better Caco-2 permeability than Ligand B (-5.271).
10. **Solubility:** Ligand A (-5.19) has better solubility than Ligand B (-1.486).
11. **hERG:** Both ligands have similar hERG inhibition liability (0.577 and 0.659), which is acceptable.
12. **Cl_mic:** Ligand B (19.329) has significantly lower microsomal clearance than Ligand A (73.849), indicating better metabolic stability. This is a substantial advantage for Ligand B.
13. **t1/2:** Ligand B (38.361) has a much longer in vitro half-life than Ligand A (-10.107). This is a major advantage for Ligand B.
14. **Pgp:** Both ligands have similar Pgp efflux liability (0.242 and 0.127).
15. **Binding Affinity:** Ligand A (-7.6) has a slightly better binding affinity than Ligand B (-5.8). This is a 1.8 kcal/mol difference, which is significant.
**Overall Assessment:**
Ligand A has a better binding affinity and slightly better Caco-2 permeability and solubility. However, Ligand B excels in critical ADME properties: significantly lower DILI risk, much lower microsomal clearance (better metabolic stability), and a substantially longer half-life. Considering ADRB2 is a cardiovascular target, metabolic stability and safety (DILI) are very important. The 1.8 kcal/mol difference in binding affinity can potentially be overcome with further optimization, while poor ADME properties are harder to fix later in development.
Therefore, I favor Ligand B.
Output:
0
2025-04-17 20:35:44,141 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (353.419 and 351.447 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (105.76) is higher than Ligand B (78.95). For a cardiovascular GPCR, TPSA isn't a *major* concern unless it's excessively high, but lower is generally preferred for better permeability. Ligand B has a clear advantage.
3. **logP:** Ligand A (-0.647) is lower than the optimal 1-3 range, potentially hindering membrane permeability. Ligand B (1.367) is within the optimal range. Ligand B is favored.
4. **HBD:** Ligand A (3) is higher than Ligand B (1). While both are within the acceptable limit of 5, lower HBD often correlates with better permeability. Ligand B is slightly better.
5. **HBA:** Ligand A (5) and Ligand B (4) are both acceptable (<=10). No major difference.
6. **QED:** Ligand B (0.815) has a significantly higher QED score than Ligand A (0.478), indicating a more drug-like profile. This is a substantial advantage for Ligand B.
7. **DILI:** Ligand B (54.517) has a lower DILI risk than Ligand A (26.173). Both are below the concerning threshold of 60, but lower is always better. Ligand B is favored.
8. **BBB:** Ligand A (60.644) has a higher BBB penetration percentile than Ligand B (48.003). However, for a cardiovascular target, BBB penetration is not a high priority.
9. **Caco-2:** Ligand A (-5.368) and Ligand B (-4.428) both have negative values, which is unusual. It suggests poor permeability. However, the values are similar.
10. **Solubility:** Ligand A (-1.297) and Ligand B (-2.286) both have negative solubility values, indicating poor aqueous solubility. This is a concern for both.
11. **hERG:** Both ligands have low hERG inhibition liability (0.06 and 0.127 respectively), which is good. No significant difference.
12. **Cl_mic:** Ligand B (15.404) has a significantly lower microsomal clearance than Ligand A (20.886), indicating better metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand B (-21.414) has a negative in vitro half-life, which is concerning. Ligand A (1.426) has a positive half-life, indicating better stability. Ligand A is favored.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.003 and 0.059 respectively). No significant difference.
15. **Binding Affinity:** Ligand B (-7.3 kcal/mol) has a stronger binding affinity than Ligand A (-6.4 kcal/mol). This is a 0.9 kcal/mol difference, which is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand B is the stronger candidate. While Ligand A has a better in vitro half-life, Ligand B excels in crucial areas like logP, QED, DILI risk, and, most importantly, binding affinity. The stronger binding affinity of Ligand B is a significant advantage for a GPCR target. The lower TPSA and better metabolic stability also contribute to its overall superior profile.
Output:
0
2025-04-17 20:35:44,141 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (354.45 & 361.47 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand B (75.55) is better than Ligand A (85.89) as it's closer to the <140 threshold for good oral absorption, and more importantly, better for GPCRs.
3. **logP:** Ligand B (2.501) is better positioned within the optimal 1-3 range. Ligand A (0.761) is a bit low, potentially hindering membrane permeability.
4. **HBD:** Ligand B (1) is preferable to Ligand A (2). Lower HBD generally improves permeability.
5. **HBA:** Ligand B (6) is preferable to Ligand A (5).
6. **QED:** Ligand A (0.736) has a slightly better QED score than Ligand B (0.52), indicating a more drug-like profile.
7. **DILI:** Ligand A (32.842) has a significantly lower DILI risk than Ligand B (44.397), which is a major advantage.
8. **BBB:** Both are reasonably similar (Ligand A: 60.644, Ligand B: 58.511). BBB is less critical for ADRB2 (cardiovascular target) than for CNS targets.
9. **Caco-2:** Both are negative (-5.001 and -5.1), indicating poor permeability. This is a concern for both.
10. **Solubility:** Both are negative (-1.17 and -1.734), indicating poor solubility. This is a concern for both.
11. **hERG:** Ligand A (0.216) has a much lower hERG inhibition liability than Ligand B (0.386), a critical safety parameter.
12. **Cl_mic:** Ligand A (-11.078) has significantly better metabolic stability (lower clearance) than Ligand B (60.385).
13. **t1/2:** Ligand A (25.833) has a longer in vitro half-life than Ligand B (20.524).
14. **Pgp:** Ligand A (0.023) has lower P-gp efflux liability than Ligand B (0.341), suggesting better bioavailability.
15. **Affinity:** Ligand B (-7.5 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.6 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME drawbacks.
**Overall Assessment:**
Ligand B has a superior binding affinity, which is paramount for GPCR targets. However, it suffers from several ADME liabilities: higher DILI risk, higher hERG inhibition, worse metabolic stability, and higher P-gp efflux. Ligand A, while having a weaker affinity, presents a much more favorable ADME profile, particularly regarding safety (DILI, hERG) and metabolic stability. The difference in affinity (1.5 kcal/mol) is substantial, but the combined improvements in safety and ADME properties for Ligand A make it the more promising candidate.
**Output:**
1
2025-04-17 20:35:44,141 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.431 and 353.463 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (83.56) is slightly higher than Ligand B (71.11). Both are below the 140 threshold for good oral absorption, and acceptable for a cardiovascular GPCR. Ligand B is preferable.
3. **logP:** Ligand A (2.036) is within the optimal 1-3 range. Ligand B (0.095) is quite low, potentially hindering membrane permeability. This is a significant advantage for Ligand A.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable, below the 5 threshold.
5. **HBA:** Both ligands (5) are below the 10 threshold.
6. **QED:** Ligand A (0.875) is better than Ligand B (0.776), indicating a more drug-like profile.
7. **DILI:** Ligand B (29.236) has a much lower DILI risk than Ligand A (49.632). This is a major advantage for Ligand B.
8. **BBB:** Ligand A (70.841) has better BBB penetration than Ligand B (55.293). While ADRB2 isn't a CNS target, some peripheral exposure can be beneficial.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.524 and -4.598), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-3.535) has slightly better solubility than Ligand B (-1.164).
11. **hERG:** Ligand A (0.666) has a lower hERG risk than Ligand B (0.213), which is preferable.
12. **Cl_mic:** Ligand B (-21.594) has significantly lower microsomal clearance than Ligand A (34.54), indicating better metabolic stability. This is a substantial advantage for Ligand B.
13. **t1/2:** Ligand B (17.748) has a longer in vitro half-life than Ligand A (7.565). Another advantage for Ligand B.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.043 and 0.046).
15. **Affinity:** Ligand B (-6.4 kcal/mol) has a significantly stronger binding affinity than Ligand A (-4.8 kcal/mol). This is a crucial advantage, exceeding the 1.5 kcal/mol threshold.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand A has a better logP, but Ligand B excels in affinity, TPSA, and has acceptable Pgp. The much stronger binding affinity of Ligand B is a significant driver. While the low logP of Ligand B is a concern, the superior affinity and metabolic stability (lower Cl_mic, longer t1/2) and lower DILI risk likely outweigh this.
**Conclusion:**
Despite Ligand A's better logP and solubility, Ligand B's significantly stronger binding affinity, lower DILI risk, and improved metabolic stability make it the more promising drug candidate.
Output:
0
2025-04-17 20:35:44,141 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [353.463, 87.74, 0.683, 2, 4, 0.705, 7.445, 76.154, -4.876, -1.344, 0.163, 11.121, -13.069, 0.012, -5.3]
**Ligand B:** [352.431, 81.01, 1.785, 1, 5, 0.771, 40.869, 65.452, -4.592, -1.905, 0.232, 24.962, 19.874, 0.065, -7.6]
Here's a breakdown, prioritizing GPCR-relevant parameters:
1. **Molecular Weight:** Both are within the ideal 200-500 Da range. A is 353.463, B is 352.431 - essentially a tie.
2. **TPSA:** Both are good, below 140. A is 87.74, B is 81.01. B is slightly better.
3. **logP:** A (0.683) is a bit low, potentially hindering permeability. B (1.785) is better, falling within the optimal 1-3 range.
4. **H-Bond Donors/Acceptors:** A has 2 HBD and 4 HBA, B has 1 HBD and 5 HBA. Both are acceptable.
5. **QED:** Both are good (>0.5), A is 0.705, B is 0.771. B is slightly better.
6. **DILI:** A (7.445) is very good, low risk. B (40.869) is also acceptable, but higher. A is significantly better here.
7. **BBB:** A (76.154) is good. B (65.452) is lower, though not terrible. A is better.
8. **Caco-2:** Both are negative, indicating poor permeability. A (-4.876) is slightly worse than B (-4.592).
9. **Solubility:** Both are negative, indicating poor solubility. A (-1.344) is slightly better than B (-1.905).
10. **hERG:** Both are very low risk (0.163 and 0.232). A is slightly better.
11. **Cl_mic:** A (11.121) is much better (lower) than B (24.962), indicating better metabolic stability.
12. **t1/2:** A (-13.069) is better (longer half-life) than B (19.874).
13. **Pgp:** Both are very low (0.012 and 0.065). A is slightly better.
14. **Binding Affinity:** B (-7.6) is significantly better than A (-5.3). This is a substantial advantage (>1.5 kcal/mol).
**Overall Assessment:**
Ligand B has a clear advantage in binding affinity, which is paramount for GPCRs. It also has slightly better logP, TPSA and QED. However, Ligand A has a much better DILI score and significantly better metabolic stability (Cl_mic and t1/2). The lower logP of Ligand A is a concern, but the superior safety profile and metabolic stability are valuable.
Given the prioritization for GPCRs (logP, Pgp, TPSA, affinity), and the substantial affinity difference, I believe **Ligand B** is the more promising candidate, despite the slightly higher DILI risk. The increased binding affinity is likely to outweigh the other minor drawbacks, and the DILI risk is still within an acceptable range.
Output:
0
2025-04-17 20:35:44,142 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.49 and 346.48 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (59.59) is significantly better than Ligand B (86.88). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is approaching a level that could hinder oral absorption.
3. **logP:** Both ligands have good logP values (3.58 and 2.94), falling within the 1-3 range. Ligand A is slightly higher, which could be advantageous for membrane permeability, but not dramatically so.
4. **HBD:** Ligand A (2) is preferable to Ligand B (3). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (4) is preferable to Ligand B (3). Lower HBA generally improves permeability.
6. **QED:** Ligand A (0.825) has a substantially better QED score than Ligand B (0.663), indicating a more drug-like profile.
7. **DILI:** Ligand A (21.71) has a significantly lower DILI risk than Ligand B (48.82). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (87.40) has a much higher BBB penetration percentile than Ligand B (56.88). While ADRB2 isn't exclusively a CNS target, some CNS exposure can occur, and higher BBB penetration is generally favorable.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.54 and -4.99), indicating poor permeability. This is concerning for both.
10. **Solubility:** Both ligands have negative solubility values (-3.59 and -3.74), indicating poor solubility. This is concerning for both.
11. **hERG:** Both ligands have low hERG inhibition risk (0.85 and 0.36). This is good for both.
12. **Cl_mic:** Ligand B (33.81) has a lower microsomal clearance than Ligand A (54.9), suggesting better metabolic stability. This is a point in favor of Ligand B.
13. **t1/2:** Ligand B (-5.73) has a longer in vitro half-life than Ligand A (19.70), suggesting better metabolic stability. This is a point in favor of Ligand B.
14. **Pgp:** Ligand A (0.16) has a lower P-gp efflux liability than Ligand B (0.20), which is preferable.
15. **Binding Affinity:** Both ligands have very similar and strong binding affinities (-5.5 and -5.8 kcal/mol). The difference is negligible.
**Overall Assessment:**
Ligand A is clearly superior. While Ligand B has slightly better metabolic stability (lower Cl_mic and longer t1/2), Ligand A excels in critical areas like DILI risk, BBB penetration, QED, and TPSA. The lower TPSA and better QED of Ligand A suggest it will have better absorption and overall drug-like properties. The significantly lower DILI risk is also a crucial factor. The Caco-2 and solubility issues are present in both, and would need to be addressed through formulation or further structural modifications, but these are fixable. The slight advantage in affinity for Ligand B is outweighed by the other factors.
Output:
1
2025-04-17 20:35:44,142 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (403.32 Da) is within the ideal range, while Ligand B (342.483 Da) is slightly below, but still acceptable.
2. **TPSA:** Ligand A (58.2) is better than Ligand B (40.62), both are well below the 140 threshold for oral absorption.
3. **logP:** Ligand A (4.121) is a bit high, potentially leading to solubility issues. Ligand B (2.964) is optimal.
4. **HBD:** Ligand A (2) is good, Ligand B (0) is also good.
5. **HBA:** Both Ligand A (2) and Ligand B (2) are within the acceptable limit of 10.
6. **QED:** Ligand A (0.755) is better than Ligand B (0.502), indicating a more drug-like profile.
7. **DILI:** Ligand B (13.959) is significantly better than Ligand A (65.491), indicating a much lower risk of liver injury. This is a major advantage for Ligand B.
8. **BBB:** Ligand B (59.325) is better than Ligand A (35.595). While ADRB2 isn't necessarily a CNS target, some peripheral effects can be modulated by CNS penetration.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-4.729) is slightly worse than Ligand B (-4.59).
10. **Solubility:** Both are negative, indicating poor solubility. Ligand A (-5.111) is slightly worse than Ligand B (-4.668).
11. **hERG:** Both are low, Ligand A (0.503) is slightly higher than Ligand B (0.46).
12. **Cl_mic:** Ligand B (30.014) has significantly lower clearance than Ligand A (60.886), indicating better metabolic stability.
13. **t1/2:** Ligand A (74.788) has a much longer half-life than Ligand B (-5.952). This is a significant advantage for Ligand A.
14. **Pgp:** Both are low, Ligand A (0.237) is slightly higher than Ligand B (0.226).
15. **Affinity:** Ligand A (-7.6) has a better binding affinity than Ligand B (-7.2), a difference of 0.4 kcal/mol.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are important. Ligand B has a better logP and Pgp, while Ligand A has a better affinity and TPSA. The difference in affinity (0.4 kcal/mol) is not large enough to overcome the significant advantages of Ligand B in terms of DILI risk and metabolic stability (Cl_mic). The longer half-life of Ligand A is a positive, but the other ADME properties of Ligand B are more favorable overall.
**Conclusion:**
Considering the balance of properties, particularly the significantly lower DILI risk and better metabolic stability of Ligand B, I believe it is the more viable drug candidate despite the slightly weaker affinity and shorter half-life.
Output:
0
2025-04-17 20:35:44,142 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands (350.419 and 344.499 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand B (40.62) is significantly better than Ligand A (116.48). For a GPCR, lower TPSA is generally preferred for better permeability. Ligand A's TPSA is relatively high.
3. **logP:** Ligand B (3.232) is within the optimal 1-3 range, while Ligand A (0.26) is quite low. Low logP can hinder membrane permeability. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (4) is slightly higher than Ligand B (0). Both are acceptable, but fewer HBDs are generally preferred for permeability.
5. **HBA:** Ligand A (6) is higher than Ligand B (2). Again, lower is generally better for permeability.
6. **QED:** Ligand A (0.563) has a better QED score than Ligand B (0.446), suggesting a more drug-like profile overall.
7. **DILI:** Ligand B (13.339) has a much lower DILI risk than Ligand A (49.128). This is a critical advantage for Ligand B.
8. **BBB:** Ligand B (77.627) has a significantly higher BBB penetration percentile than Ligand A (47.344). While ADRB2 isn't exclusively a CNS target, some distribution to the CNS is possible, and higher BBB is generally favorable.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.264 and -4.604), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-2.52) has slightly better solubility than Ligand B (-3.473), but both are quite poor.
11. **hERG:** Ligand A (0.096) has a slightly lower hERG risk than Ligand B (0.692), but both are relatively low.
12. **Cl_mic:** Ligand B (49.342) has a slightly higher microsomal clearance than Ligand A (7.082), suggesting faster metabolism. This is a slight advantage for Ligand A.
13. **t1/2:** Ligand A (24.1) has a longer in vitro half-life than Ligand B (18.043). This is a positive for Ligand A.
14. **Pgp:** Ligand A (0.024) has much lower P-gp efflux liability than Ligand B (0.322). This is a significant advantage for Ligand A.
15. **Binding Affinity:** Both ligands have very similar and strong binding affinities (-6.3 and -5.3 kcal/mol). The difference is not substantial enough to be decisive.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp efflux, and BBB penetration are particularly important. Ligand B excels in logP, TPSA, and BBB, while Ligand A has better Pgp efflux. The DILI risk is also a major concern, and Ligand B is significantly better in this regard.
**Overall Assessment:**
While Ligand A has advantages in QED, t1/2, and Pgp efflux, Ligand B's superior logP, TPSA, BBB penetration, and drastically lower DILI risk outweigh these benefits. The poor Caco-2 values are concerning for both, but the other ADME properties of Ligand B are more favorable for a GPCR target.
Output:
0
2025-04-17 20:35:44,142 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (358.423 and 347.415 Da) fall comfortably within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (83.76) is significantly better than Ligand A (104.21). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (1.774 and 1.315), falling within the optimal 1-3 range. Ligand B is slightly better.
4. **HBD:** Ligand A has 3 HBD, while Ligand B has 0. Both are acceptable, but fewer HBDs can sometimes improve permeability. Ligand B is slightly favored.
5. **HBA:** Ligand A has 6 HBA, and Ligand B has 4. Again, both are within acceptable limits, and Ligand B is slightly favored.
6. **QED:** Ligand A (0.756) has a much better QED score than Ligand B (0.438), indicating a more drug-like profile. This is a significant advantage for Ligand A.
7. **DILI:** Ligand B (34.161) has a substantially lower DILI risk than Ligand A (71.501). This is a major advantage for Ligand B.
8. **BBB:** Both ligands have relatively low BBB penetration (28.848 and 71.384). Since ADRB2 is a cardiovascular target, high BBB penetration isn't crucial. Ligand B is better.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.048 and -4.813), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Both ligands have negative solubility values (-4.411 and -2.861), indicating poor aqueous solubility. This is a significant drawback for both, but Ligand B is slightly better.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.108 and 0.18). This is good for both.
12. **Cl_mic:** Ligand A (37.81) has a lower microsomal clearance than Ligand B (57.36), suggesting better metabolic stability. This is an advantage for Ligand A.
13. **t1/2:** Ligand B (-14.453) has a much longer in vitro half-life than Ligand A (-1.795). This is a significant advantage for Ligand B.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.035 and 0.171). This is good for both.
15. **Binding Affinity:** Ligand A (-6.2 kcal/mol) has a slightly better binding affinity than Ligand B (-5.6 kcal/mol). While the difference isn't huge, it's a positive for Ligand A.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, and affinity are important. Ligand B has better logP and TPSA. Ligand A has a slightly better affinity. However, the significant advantages of Ligand B in terms of DILI risk and in vitro half-life, coupled with its better BBB penetration, outweigh the slightly better affinity of Ligand A. The poor Caco-2 and solubility of both are concerning, but can be addressed with formulation strategies.
**Conclusion:**
Considering the balance of properties, particularly the lower DILI risk and longer half-life of Ligand B, I believe it is the more promising drug candidate.
Output:
0
2025-04-17 20:35:44,142 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor (a GPCR).
**Ligand A:** [394.421, 102.43 , 1.497, 1. , 7. , 0.777, 98.216, 77.782, -4.714, -3.522, 0.234, 27.826, 41.493, 0.302, -6.4 ]
**Ligand B:** [347.459, 53.09 , 0.426, 0. , 4. , 0.692, 13.959, 57.154, -4.568, -1.56 , 0.254, 12.275, 6.088, 0.018, -5.9 ]
Here's a step-by-step comparison, considering GPCR priorities (logP, Pgp, TPSA, affinity, and BBB):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (347.459) is slightly lower, which *could* be advantageous for permeability, but both are acceptable.
2. **TPSA:** Ligand A (102.43) is higher than Ligand B (53.09). For a GPCR, lower TPSA is generally preferred for better CNS penetration and overall absorption. Ligand B is significantly better here.
3. **logP:** Ligand A (1.497) is within the optimal range (1-3). Ligand B (0.426) is a bit low, potentially hindering membrane permeability. Ligand A is better.
4. **HBD:** Ligand A (1) is good. Ligand B (0) is also acceptable.
5. **HBA:** Ligand A (7) is good. Ligand B (4) is also good.
6. **QED:** Both are decent (A: 0.777, B: 0.692), indicating reasonable drug-likeness. Ligand A is slightly better.
7. **DILI:** Ligand A (98.216) has a very high DILI risk, which is a major concern. Ligand B (13.959) has a very low DILI risk, a significant advantage.
8. **BBB:** Ligand A (77.782) has a good BBB percentile. Ligand B (57.154) is lower, but still not terrible.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. This is a red flag for both.
10. **Solubility:** Both have negative solubility values, which is also unusual. This is a red flag for both.
11. **hERG:** Both are low risk (A: 0.234, B: 0.254).
12. **Cl_mic:** Ligand B (12.275) has significantly lower microsomal clearance than Ligand A (27.826), indicating better metabolic stability.
13. **t1/2:** Ligand A (41.493) has a longer half-life than Ligand B (6.088), which is desirable.
14. **Pgp:** Both have low P-gp efflux liability (A: 0.302, B: 0.018). Ligand B is slightly better.
15. **Affinity:** Ligand A (-6.4 kcal/mol) has a slightly better binding affinity than Ligand B (-5.9 kcal/mol).
**Overall Assessment:**
Despite Ligand A having slightly better affinity and half-life, the extremely high DILI risk (98.216) is a deal-breaker. The lower TPSA and better metabolic stability of Ligand B, combined with its significantly lower DILI risk, make it the more promising candidate. While the logP is a bit low for Ligand B, this can potentially be addressed through further optimization. The negative Caco-2 and solubility values are concerning for both, but the DILI risk for Ligand A is a more immediate and serious issue.
Therefore, I prefer Ligand B.
0
2025-04-17 20:35:44,142 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
The target is ADRB2, a GPCR. Therefore, I will prioritize logP, TPSA, Pgp efflux, BBB penetration, and binding affinity. Metabolic stability (Cl_mic and t1/2) and safety (DILI, hERG) are also important.
Let's compare the ligands property by property:
1. **MW:** Both ligands (366.893 and 348.447 Da) fall within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (67.35) is better than Ligand B (81.75). Lower TPSA generally favors oral absorption, and is important for GPCRs.
3. **logP:** Ligand A (2.942) is optimal (1-3). Ligand B (-0.12) is significantly lower and could lead to poor membrane permeability. This is a major drawback for a GPCR ligand.
4. **HBD/HBA:** Both are acceptable. Ligand A has 1 HBD and 5 HBA, while Ligand B has 2 HBD and 4 HBA.
5. **QED:** Ligand A (0.784) is better than Ligand B (0.55), indicating a more drug-like profile.
6. **DILI:** Ligand A (47.266) is better than Ligand B (22.489) as it has a lower DILI risk.
7. **BBB:** Ligand A (94.998) is significantly better than Ligand B (46.452). While ADRB2 isn't exclusively a CNS target, good BBB penetration is still beneficial for distribution and potentially reducing off-target effects.
8. **Caco-2:** Both are negative, indicating poor permeability. This is concerning, but the logP difference is more impactful.
9. **Solubility:** Both are negative, indicating poor solubility.
10. **hERG:** Ligand A (0.374) is better than Ligand B (0.198) indicating lower hERG inhibition liability.
11. **Cl_mic:** Ligand B (-5.393) has a *negative* clearance, which is not physically possible and suggests an issue with the data or model. Ligand A (38.09) is reasonable.
12. **t1/2:** Ligand A (27.722) has a better in vitro half-life than Ligand B (-13.047), again raising concerns about the validity of the data for Ligand B.
13. **Pgp:** Ligand A (0.287) is better than Ligand B (0.011), meaning less P-gp efflux and potentially better bioavailability.
14. **Binding Affinity:** Ligand B (-5.6) has a better binding affinity than Ligand A (-3.0). However, the significant ADME deficiencies of Ligand B outweigh this advantage.
**Conclusion:**
Despite Ligand B's slightly better binding affinity, Ligand A is the far superior candidate. Ligand B has a very poor logP, questionable Cl_mic and t1/2 values, and lower BBB penetration. Ligand A has a more favorable profile across most parameters, including better predicted ADME properties and safety. The binding affinity difference, while present, is not large enough to overcome the substantial ADME liabilities of Ligand B.
**Output:**
1
2025-04-17 20:35:44,142 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (347.371 and 371.463 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (97.83) is better than Ligand B (127.39). For a GPCR, keeping TPSA under 140 is good for absorption, and A is closer to the lower, more desirable end.
**3. logP:** Ligand A (1.115) is within the optimal 1-3 range, while Ligand B (-0.522) is slightly below 1. While not a hard cutoff, lower logP can sometimes indicate permeability issues.
**4. H-Bond Donors:** Ligand A (1) is better than Ligand B (2). Fewer HBDs generally improve permeability.
**5. H-Bond Acceptors:** Both ligands have 6 HBA, which is acceptable.
**6. QED:** Ligand A (0.82) has a better QED score than Ligand B (0.635), indicating a more drug-like profile.
**7. DILI:** Ligand B (56.689) has a significantly lower DILI risk than Ligand A (74.021). This is a substantial advantage for B.
**8. BBB:** Ligand A (61.38) has a better BBB penetration score than Ligand B (32.61). While ADRB2 is cardiovascular, some CNS off-target effects are possible with GPCR ligands, and some degree of BBB penetration could be relevant for assessing these risks.
**9. Caco-2 Permeability:** Ligand A (-4.664) has better Caco-2 permeability than Ligand B (-5.756).
**10. Aqueous Solubility:** Ligand A (-2.738) has better aqueous solubility than Ligand B (-1.457).
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.066 and 0.048).
**12. Microsomal Clearance:** Ligand A (-21.343) has a lower (better) microsomal clearance than Ligand B (-9.504), suggesting better metabolic stability.
**13. In vitro Half-Life:** Ligand A (-13.14) has a longer in vitro half-life than Ligand B (-5.554).
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.026 and 0.01).
**15. Binding Affinity:** Ligand A (-7.7) has a slightly better binding affinity than Ligand B (-6.5). This is a 1.2 kcal/mol difference, which is significant.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity), Ligand A appears to be the more promising candidate. It has a better logP, TPSA, QED, Caco-2 permeability, solubility, metabolic stability, half-life, and binding affinity. The most significant advantage for Ligand B is its lower DILI risk. However, the binding affinity difference of 1.2 kcal/mol for Ligand A is substantial and can often outweigh minor ADME concerns, especially given that both ligands have acceptable profiles in most other categories. The better metabolic stability and half-life of Ligand A are also important factors for a cardiovascular drug.
Output:
1
2025-04-17 20:35:44,142 - INFO - Batch 196 complete. Total preferences: 3136
2025-04-17 20:35:44,142 - INFO - Processing batch 197/512...
2025-04-17 20:36:30,519 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (a cardiovascular GPCR) drug candidates.
**Ligand A:** [332.407, 66.91, 3.443, 2, 4, 0.751, 79.449, 69.678, -5.123, -4.186, 0.672, 42.099, 61.198, 0.272, -3.3]
**Ligand B:** [359.499, 90.7, 3.419, 2, 6, 0.753, 70.221, 70.531, -5.085, -3.93, 0.77, 82.588, 75.099, 0.339, -6.8]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity) and general drug-like properties:
1. **MW:** Both are within the acceptable range (200-500 Da). Ligand A (332.407) is slightly preferred due to being lower.
2. **TPSA:** Ligand A (66.91) is significantly better than Ligand B (90.7). Below 140 is good for oral absorption, but lower is generally better for GPCRs, and A is closer to the ideal range.
3. **logP:** Both are excellent (around 3.4), falling within the optimal 1-3 range. No clear advantage here.
4. **HBD:** Both have 2 HBD, which is good.
5. **HBA:** Ligand A (4) is better than Ligand B (6). Lower HBA is generally preferred for better permeability.
6. **QED:** Both are good (0.751 and 0.753), indicating good drug-like properties.
7. **DILI:** Both have relatively high DILI risk (79.449 and 70.221), but Ligand B is slightly better. This is a concern for both, and further investigation would be needed.
8. **BBB:** Both have good BBB penetration (69.678 and 70.531). This is less critical for a cardiovascular target, but not detrimental.
9. **Caco-2:** Both are negative, indicating poor permeability. This is a significant drawback for both.
10. **Solubility:** Both are very poor (-4.186 and -3.93). This is a major issue for both compounds and would require formulation strategies.
11. **hERG:** Both have low hERG risk (0.672 and 0.77). This is excellent.
12. **Cl_mic:** Ligand A (42.099) has significantly better metabolic stability (lower clearance) than Ligand B (82.588).
13. **t1/2:** Ligand B (75.099) has a longer half-life than Ligand A (61.198), which is desirable.
14. **Pgp:** Both have low Pgp efflux (0.272 and 0.339), which is good.
15. **Affinity:** Ligand B (-6.8 kcal/mol) has a significantly stronger binding affinity than Ligand A (-3.3 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME concerns.
**Overall Assessment:**
Ligand B has a much stronger binding affinity, which is the most critical factor for GPCRs. While it has a higher TPSA and slightly worse DILI risk, the substantial improvement in affinity is likely to be more important. The poor solubility and Caco-2 permeability are concerns for both, but can potentially be addressed with formulation. The improved half-life of Ligand B is also a positive.
Therefore, I would prioritize Ligand B.
0
2025-04-17 20:36:30,519 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (364.27 and 366.506 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (59.5) is slightly higher than Ligand B (54.18). Both are well below the 140 threshold for oral absorption and acceptable for a cardiovascular GPCR. Ligand B is slightly preferred.
3. **logP:** Both ligands have good logP values (2.681 and 3.078), falling within the optimal 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Ligand A has 0 HBD, while Ligand B has 1. Both are within the acceptable limit of 5. Ligand A is slightly preferred as fewer HBDs generally correlate with better permeability.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 6. Both are below the 10 limit. Ligand A is preferred.
6. **QED:** Ligand B (0.818) has a higher QED score than Ligand A (0.611), indicating a more drug-like profile. This is a significant advantage for Ligand B.
7. **DILI:** Ligand A (66.344) has a considerably higher DILI risk than Ligand B (8.104). This is a major concern for Ligand A. Ligand B is strongly preferred.
8. **BBB:** Both ligands have good BBB penetration (83.986 and 71.345). Since ADRB2 is a cardiovascular target, BBB penetration is not a primary concern, but higher is generally better. Ligand A is slightly preferred.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.337 and -4.883), which is unusual and suggests poor permeability. This is a significant drawback for both.
10. **Solubility:** Both ligands have negative solubility values (-3.315 and -2.677), indicating very poor aqueous solubility. This is a major issue for both compounds.
11. **hERG:** Both ligands have low hERG inhibition liability (0.447 and 0.77). This is good and minimizes cardiotoxicity risk. No significant difference.
12. **Cl_mic:** Ligand A (70.171) has a higher microsomal clearance than Ligand B (15.043), suggesting lower metabolic stability. Ligand B is strongly preferred.
13. **t1/2:** Ligand B (-6.93) has a longer in vitro half-life than Ligand A (-4.767), which is desirable. Ligand B is preferred.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.17 and 0.309). No significant difference.
15. **Binding Affinity:** Both ligands have similar and strong binding affinities (-5.9 and -6.4 kcal/mol). The difference is minimal.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity) and the general drug-like properties, Ligand B is the superior candidate. While both have issues with Caco-2 and solubility, Ligand B significantly outperforms Ligand A in crucial areas like DILI risk, metabolic stability (Cl_mic), and in vitro half-life. The slightly higher QED score also favors Ligand B. The affinity difference is negligible.
Output:
0
2025-04-17 20:36:30,519 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [385.555, 82.53, 2.513, 2, 6, 0.754, 61.342, 39.007, -5.304, -3.944, 0.428, 53.689, -7.368, 0.281, -7.5]
**Ligand B:** [388.833, 128.53, 0.376, 3, 6, 0.679, 77.743, 6.088, -5.601, -2.58, 0.227, -8.577, -3.4, 0.079, -6.5]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). A is 385.555, B is 388.833 - very similar.
2. **TPSA:** A (82.53) is excellent, well below 140 and good for oral absorption. B (128.53) is still acceptable, but less ideal.
3. **logP:** A (2.513) is optimal. B (0.376) is quite low, potentially hindering membrane permeability and absorption.
4. **HBD:** A (2) is good. B (3) is acceptable, but slightly higher.
5. **HBA:** Both A (6) and B (6) are within the acceptable range.
6. **QED:** A (0.754) is better than B (0.679), indicating a more drug-like profile.
7. **DILI:** A (61.342) is acceptable, but B (77.743) is higher, indicating a greater potential for liver injury.
8. **BBB:** A (39.007) is low, suggesting limited brain penetration. B (6.088) is very low. Neither are CNS focused, so this is less critical.
9. **Caco-2:** Both are negative, indicating poor permeability. A (-5.304) is slightly better than B (-5.601).
10. **Solubility:** A (-3.944) is better than B (-2.58), suggesting better aqueous solubility.
11. **hERG:** Both are very low (A: 0.428, B: 0.227), indicating a low risk of hERG inhibition.
12. **Cl_mic:** A (53.689) is better than B (-8.577), suggesting better metabolic stability. B has a negative clearance, which is unusual and concerning.
13. **t1/2:** A (-7.368) is better than B (-3.4), indicating a longer in vitro half-life.
14. **Pgp:** A (0.281) is better than B (0.079), suggesting less P-gp efflux.
15. **Affinity:** A (-7.5) is slightly better than B (-6.5), though both are good.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. A has a much better logP and Pgp profile. While TPSA is good for both, A is better. The affinity difference is not substantial enough to outweigh the other ADME concerns with B. B's negative clearance is a significant red flag.
**Conclusion:**
Ligand A is the more promising candidate due to its superior logP, metabolic stability, Pgp efflux profile, solubility, and slightly better affinity. While both have poor Caco-2 permeability, A's other properties make it a more viable starting point for optimization.
**Output:**
1
2025-04-17 20:36:30,520 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (351.447 and 342.439 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (85.61) is slightly higher than Ligand B (71.34). Both are below the 140 threshold for good oral absorption, but Ligand B is preferable due to being closer to the 90 threshold for GPCRs.
3. **logP:** Ligand A (1.324) is within the optimal 1-3 range. Ligand B (3.862) is at the higher end of the optimal range, potentially raising concerns about solubility and off-target effects.
4. **HBD:** Both ligands have 2 H-bond donors, which is acceptable.
5. **HBA:** Ligand A has 6 H-bond acceptors, while Ligand B has 3. Both are within the acceptable limit of 10.
6. **QED:** Ligand A (0.807) has a better QED score than Ligand B (0.716), indicating a more drug-like profile.
7. **DILI:** Ligand A (33.346%) has a significantly lower DILI risk than Ligand B (59.442%). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (65.839%) has a higher BBB penetration percentile than Ligand A (20.318%). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant for off-target effects and overall safety assessment.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.232 and -4.92), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-0.768) has a slightly better solubility score than Ligand B (-4.334), although both are poor.
11. **hERG:** Ligand A (0.309) has a lower hERG inhibition liability than Ligand B (0.849), which is a significant safety advantage.
12. **Cl_mic:** Ligand A (4.485) has a lower microsomal clearance than Ligand B (68.957), indicating better metabolic stability.
13. **t1/2:** Ligand B (60.506) has a substantially longer in vitro half-life than Ligand A (27.188). This is a positive for Ligand B.
14. **Pgp:** Ligand A (0.097) has lower P-gp efflux liability than Ligand B (0.708), which is preferable for bioavailability.
15. **Binding Affinity:** Ligand B (-6.6 kcal/mol) has a slightly better binding affinity than Ligand A (-6.1 kcal/mol). This is a 0.5 kcal/mol difference, which is noticeable but not overwhelming.
**Overall Assessment & GPCR Prioritization:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B has a better logP and affinity, and better BBB penetration. However, Ligand A excels in crucial safety parameters (DILI, hERG) and metabolic stability (Cl_mic). The poor Caco-2 values are concerning for both, but the significantly lower DILI and hERG risk for Ligand A, coupled with its better QED score, outweigh the slightly better affinity and BBB penetration of Ligand B. The difference in binding affinity is not substantial enough to overcome the safety concerns associated with Ligand B.
**Output:**
1
2025-04-17 20:36:30,520 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (348.431 and 359.539 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand B (28.6) is significantly better than Ligand A (59.81). Lower TPSA generally favors better absorption, crucial for GPCRs.
3. **logP:** Both ligands have similar logP values (3.972 and 3.945), falling within the optimal 1-3 range. No significant difference.
4. **HBD:** Ligand A has 1 HBD, while Ligand B has 0. Both are acceptable, but fewer HBDs can sometimes improve membrane permeability. Ligand B is slightly favored.
5. **HBA:** Both ligands have 5 HBAs, which is within the acceptable limit of 10. No clear advantage.
6. **QED:** Ligand B (0.678) has a slightly higher QED than Ligand A (0.607), indicating a more drug-like profile.
7. **DILI:** Ligand B (23.808) has a much lower DILI risk than Ligand A (87.747). This is a *major* advantage for Ligand B.
8. **BBB:** Ligand B (93.331) shows significantly better BBB penetration than Ligand A (70.919). While ADRB2 isn't exclusively a CNS target, some cardiovascular effects can be mediated through CNS pathways, and better BBB penetration isn't detrimental.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.267 and -4.565), which is unusual and suggests poor permeability. However, the values are similar.
10. **Solubility:** Both ligands have very poor aqueous solubility (-4.364 and -4.339). This is a concern for both, but not a deciding factor given the other parameters.
11. **hERG:** Ligand A (0.619) has a slightly lower hERG inhibition liability than Ligand B (0.934), which is preferable.
12. **Cl_mic:** Ligand B (84.577) has lower microsomal clearance than Ligand A (108.322), indicating better metabolic stability.
13. **t1/2:** Ligand B (19.624) has a longer in vitro half-life than Ligand A (13.794), which is desirable.
14. **Pgp:** Ligand B (0.835) has a slightly higher P-gp efflux liability than Ligand A (0.653). This is a minor disadvantage for Ligand B.
15. **Affinity:** Ligand A (-7.2 kcal/mol) has a slightly better binding affinity than Ligand B (-6.0 kcal/mol). This is a 1.2 kcal/mol difference, which is a significant advantage for Ligand A.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity, Ligand B overwhelmingly wins on ADME-Tox properties. The significantly lower DILI risk, better BBB penetration, lower microsomal clearance, and longer half-life of Ligand B are critical advantages. The similar logP values and acceptable HBD/HBA counts further support choosing Ligand B. The poor Caco-2 and solubility are concerns for both, but can be addressed through formulation strategies. The slightly higher Pgp efflux for Ligand B is a minor drawback compared to the substantial benefits in safety and PK. For a GPCR target like ADRB2, balancing potency with favorable ADME properties is crucial.
Output:
0
2025-04-17 20:36:30,520 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (a cardiovascular GPCR) drug candidates.
**Ligand A:** [366.443, 91.84, 0.351, 1, 6, 0.784, 61.07, 54.75, -4.583, -1.997, 0.118, 38.267, 6.491, 0.023, -6.5]
**Ligand B:** [346.431, 87.47, 1.163, 2, 5, 0.724, 35.789, 36.72, -5.099, -1.801, 0.153, -11.331, -21.426, 0.035, -6.6]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (346.431 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are acceptable (below 140), but Ligand B (87.47) is better than Ligand A (91.84). Lower TPSA generally improves oral absorption.
3. **logP:** Ligand B (1.163) is better positioned within the optimal range (1-3) than Ligand A (0.351), which is quite low and could hinder membrane permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs are generally better for permeability.
5. **HBA:** Ligand B (5) is preferable to Ligand A (6). Fewer HBAs are generally better for permeability.
6. **QED:** Both are good (>0.5), with Ligand A (0.784) slightly better than Ligand B (0.724).
7. **DILI:** Ligand B (35.789) has a significantly lower DILI risk than Ligand A (61.07), which is a major advantage.
8. **BBB:** Ligand A (54.75) has a slightly higher BBB penetration potential than Ligand B (36.72), but for a cardiovascular target, BBB penetration is not a primary concern.
9. **Caco-2:** Ligand B (-5.099) has a much better Caco-2 permeability than Ligand A (-4.583).
10. **Solubility:** Both have poor aqueous solubility (-1.8 to -2.0). This is a concern for both, but not a deciding factor.
11. **hERG:** Both have very low hERG inhibition risk (0.118 and 0.153).
12. **Cl_mic:** Ligand B (-11.331) has a much lower microsomal clearance, indicating better metabolic stability, than Ligand A (38.267).
13. **t1/2:** Ligand B (-21.426) has a significantly longer in vitro half-life than Ligand A (6.491).
14. **Pgp:** Both have very low P-gp efflux liability (0.023 and 0.035).
15. **Affinity:** Both have comparable binding affinities (-6.5 and -6.6 kcal/mol). The difference is negligible.
**GPCR-Specific Priorities:** For ADRB2 (a cardiovascular GPCR), logP, TPSA, and metabolic stability (Cl_mic, t1/2) are key. Ligand B excels in these areas. While BBB is important for CNS GPCRs, it's less critical here.
**Conclusion:**
Ligand B is the more promising candidate. It has a better logP, lower TPSA, significantly lower DILI risk, much better metabolic stability (lower Cl_mic, longer t1/2), and comparable binding affinity. The slightly lower BBB penetration is not a significant drawback for a cardiovascular target.
0
2025-04-17 20:36:30,520 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (332.4) is within the ideal range (200-500), while Ligand B (374.5) is also acceptable. No clear advantage here.
2. **TPSA:** Ligand A (75.01) is better than Ligand B (49.85). Lower TPSA generally improves permeability, a key factor for GPCRs.
3. **logP:** Both ligands (A: 2.781, B: 2.342) are within the optimal 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Ligand A (2) is preferable to Ligand B (0). While both are low, a small number of HBDs can aid solubility without significantly hindering permeability.
5. **HBA:** Ligand A (3) is slightly better than Ligand B (4). Lower HBA is generally preferred for permeability.
6. **QED:** Both ligands are similar (A: 0.724, B: 0.686) and above the 0.5 threshold, indicating good drug-likeness.
7. **DILI:** Ligand B (20.551) has a significantly lower DILI risk than Ligand A (70.919). This is a major advantage for Ligand B.
8. **BBB:** Ligand B (79.721) has a higher BBB penetration percentile than Ligand A (73.866). While ADRB2 isn't necessarily a CNS target, some peripheral ADRB2 subtypes are expressed in the brain, and higher BBB penetration is rarely detrimental.
9. **Caco-2:** Ligand A (-5.444) is better than Ligand B (-4.294). Higher Caco-2 permeability is desirable.
10. **Solubility:** Ligand B (-2.593) is better than Ligand A (-4.249). Better solubility is always a plus.
11. **hERG:** Ligand A (0.861) has a slightly lower hERG risk than Ligand B (0.452). Lower hERG is preferred.
12. **Cl_mic:** Ligand A (27.974) has a significantly lower microsomal clearance than Ligand B (53.79). Lower clearance indicates better metabolic stability.
13. **t1/2:** Ligand A (4.03) has a shorter half-life than Ligand B (8.128). Longer half-life is preferred.
14. **Pgp:** Ligand A (0.49) has a lower Pgp efflux liability than Ligand B (0.155). Lower Pgp is generally better for bioavailability.
15. **Affinity:** Ligand A (-6.4) has a slightly better binding affinity than Ligand B (-6.0). A 0.4 kcal/mol difference is noticeable, but not overwhelmingly decisive.
**Overall Assessment:**
Ligand B has a much better safety profile (DILI) and improved pharmacokinetic properties (BBB, Solubility, t1/2). While Ligand A has slightly better Caco-2 permeability, Pgp efflux, and binding affinity, the safety and PK advantages of Ligand B are more important for overall drug development potential, especially considering the cardiovascular implications of ADRB2 modulation. The difference in binding affinity is not large enough to overcome the significant DILI risk of Ligand A.
Output:
0
2025-04-17 20:36:30,520 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [350.379, 118.45 , -0.31 , 2. , 7. , 0.703, 54.711, 70.182, -4.964, -1.437, 0.032, 28.788, -1.835, 0.011, -8.2 ]
**Ligand B:** [361.471, 80.12 , 1.42 , 1. , 6. , 0.731, 54.75 , 45.366, -5.322, -1.459, 0.134, 46.17 , 28.108, 0.014, -5.7 ]
Here's a breakdown, prioritizing GPCR properties (logP, Pgp, TPSA, affinity, and BBB):
1. **Molecular Weight:** Both are within the ideal 200-500 Da range. A (350.379) is slightly better.
2. **TPSA:** Ligand B (80.12) is significantly better than Ligand A (118.45). Lower TPSA generally favors better blood-brain barrier penetration and oral absorption, crucial for GPCRs.
3. **logP:** Ligand B (1.42) is within the optimal range (1-3), while Ligand A (-0.31) is a bit low, potentially hindering membrane permeability.
4. **H-Bond Donors/Acceptors:** Both are reasonable (A: 2/7, B: 1/6), staying within acceptable limits for permeability.
5. **QED:** Both are good (A: 0.703, B: 0.731), indicating drug-like properties.
6. **DILI:** Both have similar, acceptable DILI risk (around 55%).
7. **BBB:** Ligand A (70.182) has a significantly better BBB percentile than Ligand B (45.366). This is a key advantage for a GPCR target, even a cardiovascular one, as some CNS off-target effects are possible.
8. **Caco-2:** Both are negative, indicating poor permeability. Ligand B (-5.322) is slightly better than Ligand A (-4.964).
9. **Solubility:** Both are very poor (-1.437 and -1.459). This is a significant drawback for both.
10. **hERG:** Both have low hERG risk (0.032 and 0.134).
11. **Cl_mic:** Ligand A (28.788) has a lower microsomal clearance than Ligand B (46.17), suggesting better metabolic stability.
12. **t1/2:** Ligand B (28.108) has a much longer in vitro half-life than Ligand A (-1.835). This is a significant advantage.
13. **Pgp:** Both have very low P-gp efflux liability (0.011 and 0.014).
14. **Binding Affinity:** Ligand A (-8.2 kcal/mol) has a substantially stronger binding affinity than Ligand B (-5.7 kcal/mol). This is a major advantage.
**Overall Assessment:**
While Ligand B has better TPSA, logP, and half-life, the significantly stronger binding affinity of Ligand A (-8.2 vs -5.7 kcal/mol) and better BBB penetration outweigh these benefits. The affinity difference is substantial enough to overcome the slightly lower logP and poorer Caco-2 permeability. Both have poor solubility, which would need to be addressed in formulation, but the potency advantage of Ligand A is critical.
Output:
1
2025-04-17 20:36:30,520 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (370.471 and 358.463 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (92.78) is slightly higher than Ligand B (75.27). Both are below 140, suitable for oral absorption, but B is better.
3. **logP:** Ligand A (1.079) is at the lower end of the optimal range (1-3), while Ligand B (2.473) is well within it. Ligand B has a clear advantage here.
4. **HBD:** Ligand A (1) and Ligand B (2) are both acceptable, below the threshold of 5.
5. **HBA:** Ligand A (5) and Ligand B (3) are both acceptable, below the threshold of 10.
6. **QED:** Ligand A (0.802) is better than Ligand B (0.747), indicating a more drug-like profile.
7. **DILI:** Ligand A (38.581) has a significantly lower DILI risk than Ligand B (60.799). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (83.443) has a better BBB penetration percentile than Ligand B (52.772). While ADRB2 isn't strictly a CNS target, some CNS exposure is not necessarily detrimental and can be a benefit.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.485 and -4.747). These values are unusual and suggest poor permeability. However, the values are similar.
10. **Solubility:** Ligand A (-2.165) has slightly better solubility than Ligand B (-3.778).
11. **hERG:** Both ligands have very low hERG inhibition risk (0.193 and 0.294). No significant difference.
12. **Cl_mic:** Ligand A (14.375) has significantly lower microsomal clearance than Ligand B (32.648), indicating better metabolic stability.
13. **t1/2:** Ligand A (16.099) has a positive in vitro half-life, while Ligand B (-20.474) has a negative value, which is concerning.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.021 and 0.105). No significant difference.
15. **Binding Affinity:** Ligand B (-7.7) has a slightly better binding affinity than Ligand A (-6.8), a difference of 0.9 kcal/mol.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, and affinity are crucial. Ligand B excels in logP and has a slightly better affinity. However, Ligand A has a significantly better safety profile (DILI), metabolic stability (Cl_mic), and half-life, and acceptable BBB penetration. The affinity difference of 0.9 kcal/mol is not large enough to outweigh the substantial advantages of Ligand A in terms of safety and pharmacokinetics. The Caco-2 values are concerning for both, but can be investigated further.
**Conclusion:**
Considering the balance of properties, especially the critical safety and pharmacokinetic advantages, Ligand A is the more promising drug candidate.
Output:
1
2025-04-17 20:36:30,520 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (366.4 and 360.4 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (103.6 and 106.2) are below the 140 A^2 threshold for good oral absorption, which is good.
3. **logP:** Ligand A (0.586) is lower than Ligand B (1.067). While both are relatively low, Ligand B is closer to the optimal 1-3 range. Lower logP can sometimes lead to poor membrane permeability.
4. **HBD:** Ligand A has 0 HBD, while Ligand B has 1. Both are acceptable, being less than 5.
5. **HBA:** Both ligands have 8 HBA, which is acceptable (<=10).
6. **QED:** Both ligands have similar QED values (0.729 and 0.705), indicating good drug-likeness.
7. **DILI:** Ligand A (87.1%) has a higher DILI risk than Ligand B (79.4%). This is a significant concern, as we prefer lower DILI scores.
8. **BBB:** Ligand A (61.96%) has a better BBB penetration percentile than Ligand B (46.72%). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be beneficial or at least needs to be considered, and a higher BBB score is generally preferred.
9. **Caco-2:** Ligand A (-4.355) has a worse Caco-2 permeability than Ligand B (-5.549). Lower values here indicate lower permeability.
10. **Solubility:** Ligand A (-4.375) has a worse solubility than Ligand B (-2.333). Lower values indicate lower solubility.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.116 and 0.164), which is excellent.
12. **Cl_mic:** Ligand A (119.6) has a higher microsomal clearance than Ligand B (28.6). This suggests Ligand B is more metabolically stable.
13. **t1/2:** Ligand A (-50.6) has a negative in vitro half-life, which is very poor. Ligand B (39.2) is much better.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.094 and 0.106).
15. **Affinity:** Ligand B (-7.9 kcal/mol) has a slightly better binding affinity than Ligand A (-7.4 kcal/mol). While the difference is not huge, it's enough to consider, especially given the other ADME properties.
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are important. Ligand B is better in logP, has comparable Pgp and TPSA, and slightly better affinity. The biggest drawback of Ligand A is its poor metabolic stability (high Cl_mic and very poor t1/2) and higher DILI risk.
**Conclusion:**
Despite Ligand A having slightly better BBB penetration, the significantly better metabolic stability, lower DILI risk, and slightly improved binding affinity of Ligand B make it the more promising drug candidate.
Output:
0
2025-04-17 20:36:30,520 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (354.43 & 347.42 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (105.48) is better than Ligand B (111.21). Both are below 140, but lower TPSA generally favors absorption.
3. **logP:** Ligand A (1.501) is better than Ligand B (0.421). Both are within the 1-3 range, but Ligand B is closer to the lower limit which could hinder permeation.
4. **HBD:** Ligand A (4) is slightly higher than Ligand B (3), but both are acceptable (<=5).
5. **HBA:** Both ligands have 5 HBA, which is within the acceptable limit of <=10.
6. **QED:** Ligand B (0.715) has a better QED score than Ligand A (0.418), indicating a more drug-like profile.
7. **DILI:** Ligand B (38.503) has a significantly lower DILI risk than Ligand A (52.152). This is a substantial advantage for Ligand B.
8. **BBB:** Ligand A (68.321) has a better BBB penetration percentile than Ligand B (52.579). While ADRB2 isn't necessarily a CNS target, some peripheral ADRB2 receptors can be affected by CNS penetration.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it is difficult to interpret.
10. **Solubility:** Ligand A (-2.92) is better than Ligand B (-1.875). Higher solubility is generally better.
11. **hERG:** Ligand A (0.74) has a slightly better hERG profile than Ligand B (0.18), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand B (-33.48) has a much lower (better) microsomal clearance than Ligand A (44.845), indicating higher metabolic stability.
13. **t1/2:** Ligand B (3.666) has a longer in vitro half-life than Ligand A (0.745). This is a significant advantage.
14. **Pgp:** Ligand A (0.063) has lower P-gp efflux than Ligand B (0.022), which is preferable.
15. **Binding Affinity:** Ligand B (-7.8 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.6 kcal/mol). This is a crucial advantage, outweighing some of the ADME drawbacks of Ligand B.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B excels in affinity and has acceptable logP and TPSA. While Ligand A has a better BBB score, the substantial improvement in binding affinity and metabolic stability (lower Cl_mic, longer t1/2) of Ligand B is more important. The lower DILI risk for Ligand B is also a significant benefit.
**Conclusion:**
Despite Ligand A's slightly better BBB and hERG scores, Ligand B's superior binding affinity, metabolic stability, lower DILI risk, and better QED make it the more promising drug candidate for ADRB2.
Output:
0
2025-04-17 20:36:30,521 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (343.427 and 344.415 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Both are below the 140 A^2 threshold for good oral absorption (86.34 and 88.32 A^2). Ligand A is slightly better, closer to the 90 A^2 cutoff for CNS penetration, though this isn't a primary concern for a cardiovascular target.
3. **logP:** Both ligands have acceptable logP values (2.286 and 1.397), falling within the 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 4 HBA, while Ligand B has 6. Both are acceptable (<=10), but Ligand A is preferable.
6. **QED:** Both have good QED scores (0.858 and 0.892), indicating good drug-like properties.
7. **DILI:** Ligand A (22.838%) has a significantly lower DILI risk than Ligand B (47.421%). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (63.009%) has a higher BBB penetration score than Ligand B (47.15%). While ADRB2 is a cardiovascular target, some CNS penetration is not necessarily detrimental and could offer some off-target effects.
9. **Caco-2:** Both have negative Caco-2 values (-4.991 and -5.004). This is unusual and suggests poor permeability. However, the values are very similar.
10. **Solubility:** Both have negative solubility values (-2.284 and -1.783). This is also concerning, indicating poor aqueous solubility. Again, the values are similar.
11. **hERG:** Ligand A (0.425) has a slightly higher hERG risk than Ligand B (0.02), which is a negative.
12. **Cl_mic:** Ligand A (-5.692) has a much lower (better) microsomal clearance than Ligand B (-0.383). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (22.843 hours) has a significantly longer in vitro half-life than Ligand B (6.973 hours). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.066) has a lower P-gp efflux liability than Ligand B (0.031), which is favorable.
15. **Binding Affinity:** Ligand A (-6.4 kcal/mol) has a slightly better binding affinity than Ligand B (-6.0 kcal/mol). Although the difference is not huge, it contributes to the overall preference.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Ligand A performs better on logP, TPSA, Pgp, and affinity. The lower DILI and better metabolic stability (Cl_mic and t1/2) are also crucial advantages. The slightly higher hERG risk for Ligand A is a concern, but the overall profile is more favorable.
**Conclusion:**
Ligand A demonstrates a better balance of properties, particularly regarding safety (DILI), metabolic stability (Cl_mic, t1/2), and binding affinity. While both have solubility and permeability concerns, Ligand A's superior profile outweighs the slight hERG risk.
Output:
1
2025-04-17 20:36:30,521 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (414.275 Da) is within the ideal range, while Ligand B (350.409 Da) is also acceptable, leaning towards the lower end. No clear advantage here.
2. **TPSA:** Ligand A (70.67) is better than Ligand B (46.34), but both are below the 140 threshold for oral absorption.
3. **logP:** Ligand A (1.184) is optimal, while Ligand B (4.236) is pushing the upper limit and could present solubility issues. This favors Ligand A.
4. **HBD:** Ligand A (2) and Ligand B (0) are both acceptable.
5. **HBA:** Ligand A (4) and Ligand B (3) are both acceptable.
6. **QED:** Both Ligand A (0.727) and Ligand B (0.715) are good, indicating drug-like properties.
7. **DILI:** Ligand A (39.667) is better than Ligand B (23.963), indicating lower liver injury risk. This favors Ligand A.
8. **BBB:** Both Ligand A (77.705) and Ligand B (80.419) have good BBB penetration, but Ligand B is slightly better.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Both ligands have negative solubility values, which is also unusual and suggests poor solubility. This is a concern for both.
11. **hERG:** Ligand A (0.619) is better than Ligand B (0.763), indicating lower hERG inhibition risk. This favors Ligand A.
12. **Cl_mic:** Ligand A (10.417) has a lower clearance than Ligand B (93.286), indicating better metabolic stability. This strongly favors Ligand A.
13. **t1/2:** Ligand A (17.193) has a longer half-life than Ligand B (9.541). This favors Ligand A.
14. **Pgp:** Ligand A (0.08) is better than Ligand B (0.263), indicating lower P-gp efflux. This favors Ligand A.
15. **Affinity:** Ligand A (-7.9 kcal/mol) has a significantly better binding affinity than Ligand B (-6.2 kcal/mol). This is a substantial advantage for Ligand A, outweighing some of the minor ADME drawbacks.
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand A excels in logP, Pgp, and significantly in affinity. While both have reasonable TPSA, the substantial affinity difference and better ADME properties of Ligand A make it a more promising candidate.
**Conclusion:**
Ligand A demonstrates a superior balance of properties, particularly its significantly stronger binding affinity, better metabolic stability, lower DILI risk, and favorable logP. While both ligands have issues with Caco-2 and solubility, the potency advantage of Ligand A is significant enough to outweigh these concerns.
Output:
1
2025-04-17 20:36:30,521 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (343.471 and 341.415 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (53.51) is significantly better than Ligand B (72.58). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand A is well below the 90 A^2 threshold, while Ligand B is approaching it.
**3. logP:** Ligand A (3.025) is optimal, while Ligand B (0.275) is quite low. A logP below 1 can hinder membrane permeability. This is a major strike against Ligand B.
**4. H-Bond Donors:** Both have 0 HBD, which is good.
**5. H-Bond Acceptors:** Ligand A has 3 HBA, and Ligand B has 5. Both are acceptable, but lower is generally preferred.
**6. QED:** Both ligands have good QED scores (0.715 and 0.791), indicating good drug-like properties.
**7. DILI:** Ligand A (16.44) has a much lower DILI risk than Ligand B (30.787). This is a significant advantage for Ligand A.
**8. BBB:** Ligand A (75.107) has a better BBB penetration score than Ligand B (49.826). While ADRB2 is a cardiovascular target, some CNS penetration can be relevant for off-target effects and overall safety assessment.
**9. Caco-2 Permeability:** Both have negative Caco-2 values (-4.433 and -4.784), which is unusual and suggests poor permeability. However, these values are on a logarithmic scale, and the absolute difference isn't huge.
**10. Aqueous Solubility:** Both have very poor aqueous solubility (-1.712 and -1.817). This is a concern for both, but can be addressed with formulation strategies.
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (0.42 and 0.473).
**12. Microsomal Clearance:** Ligand A (66.022) has higher microsomal clearance than Ligand B (21.7), indicating faster metabolism and potentially a shorter half-life. This is a drawback for Ligand A.
**13. In vitro Half-Life:** Ligand B (17.902) has a significantly longer in vitro half-life than Ligand A (-2.399). This is a major advantage for Ligand B, despite its other weaknesses.
**14. P-gp Efflux:** Both have low P-gp efflux liability (0.084 and 0.01).
**15. Binding Affinity:** Ligand A (-6.9 kcal/mol) has a slightly better binding affinity than Ligand B (-5.8 kcal/mol). This 1.1 kcal/mol difference is meaningful, and can potentially offset some of the ADME liabilities.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand A is the stronger candidate. The significantly better logP and TPSA values are crucial for permeability and absorption. While Ligand B has a better half-life, the poor logP and higher DILI risk are major concerns. The slightly better affinity of Ligand A further strengthens its position. The solubility issues are present in both, but can be addressed through formulation.
Output:
1
2025-04-17 20:36:30,521 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.46 and 351.45 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (98.66) is slightly higher than Ligand B (87.74). Both are below the 140 threshold for oral absorption, but closer to the 90 threshold for CNS targets. Given ADRB2's cardiovascular role, CNS penetration isn't a primary goal, but lower TPSA is still preferred. Ligand B is better here.
3. **logP:** Ligand A (0.71) is slightly lower than Ligand B (0.599), both are below the optimal 1-3 range. This could be a concern for permeability, but not a deal-breaker. Ligand A is slightly better.
4. **HBD:** Ligand A (4) is higher than Ligand B (2). Lower HBD is generally preferred for permeability, so Ligand B is better.
5. **HBA:** Both ligands have the same HBA count (4), which is well within the acceptable limit of 10.
6. **QED:** Ligand B (0.658) has a slightly better QED score than Ligand A (0.567), indicating a more drug-like profile.
7. **DILI:** Ligand A (17.604) has a significantly lower DILI risk than Ligand B (22.838). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (53.083) has a higher BBB penetration score than Ligand A (45.677). However, as ADRB2 is primarily a cardiovascular target, BBB penetration is not a high priority.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand B (-4.919) is slightly less negative than Ligand A (-5.11), suggesting slightly better permeability.
10. **Solubility:** Ligand B (-1.156) has a slightly better solubility score than Ligand A (-2.387). Solubility is important for bioavailability.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.13 and 0.061), which is excellent. No significant difference.
12. **Cl_mic:** Ligand A (14.535) has a lower microsomal clearance than Ligand B (22.6), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (20.765) has a longer in vitro half-life than Ligand B (3.223). This is a substantial advantage for Ligand A, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.019 and 0.016). No significant difference.
15. **Binding Affinity:** Ligand A (-7.6) has a significantly stronger binding affinity than Ligand B (-5.6). This is a crucial advantage, as a >1.5 kcal/mol difference can outweigh other drawbacks.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has a slightly lower logP, but a significantly better binding affinity. Ligand B has a slightly lower TPSA, but the difference is not substantial. Both have good Pgp profiles.
**Overall Assessment:**
Ligand A's significantly stronger binding affinity (-7.6 vs -5.6 kcal/mol), lower DILI risk, and longer half-life outweigh the slight disadvantages in TPSA and logP. The improved metabolic stability (lower Cl_mic) is also a significant benefit. While Ligand B has slightly better solubility and Caco-2 permeability, the potency and safety advantages of Ligand A are more critical for a viable drug candidate.
Output:
1
2025-04-17 20:36:30,521 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the acceptable range (200-500 Da). Ligand A (421.36 Da) is slightly higher than Ligand B (346.402 Da), but this isn't a major concern.
**2. TPSA:** Ligand A (49.41) is better than Ligand B (69.64). For a cardiovascular GPCR, TPSA should be reasonably low for good absorption, and A is significantly lower.
**3. logP:** Both ligands have acceptable logP values (A: 4.442, B: 2.992), falling within the optimal 1-3 range. Ligand B is preferable here.
**4. H-Bond Donors:** Both have a reasonable number of HBDs (A: 1, B: 2).
**5. H-Bond Acceptors:** Both have a reasonable number of HBAs (A: 3, B: 3).
**6. QED:** Both ligands have acceptable QED values (A: 0.745, B: 0.614), indicating good drug-like properties.
**7. DILI Risk:** Ligand A (53.858) has a higher DILI risk than Ligand B (35.13). This is a significant advantage for Ligand B.
**8. BBB Penetration:** Ligand A (73.711) shows better BBB penetration than Ligand B (59.248). While ADRB2 is primarily cardiovascular, some CNS effects are possible with beta-adrenergic agonists, and some level of BBB penetration could be beneficial.
**9. Caco-2 Permeability:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the values are similar (-4.852 for A, -4.757 for B).
**10. Aqueous Solubility:** Both have negative solubility values, indicating very poor solubility. This is a major concern for both compounds.
**11. hERG Inhibition:** Ligand A (0.537) has a slightly higher hERG inhibition risk than Ligand B (0.239). Lower is better here, favoring Ligand B.
**12. Microsomal Clearance:** Ligand B (63.451) has a higher microsomal clearance than Ligand A (50.302), suggesting faster metabolism and lower metabolic stability. Ligand A is preferable.
**13. In vitro Half-Life:** Ligand A (21.184 hours) has a much longer half-life than Ligand B (-4.263 hours). This is a significant advantage for Ligand A.
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (A: 0.51, B: 0.081), which is good.
**15. Binding Affinity:** Both ligands have the same binding affinity (-7.3 kcal/mol), so this parameter doesn't differentiate them.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity) and the general guidelines, Ligand A appears to be the better candidate. While Ligand B has a lower DILI risk and better logP, Ligand A's significantly better TPSA, longer half-life, and lower microsomal clearance outweigh these advantages. The poor solubility and Caco-2 permeability are concerns for both, but these can potentially be addressed through formulation strategies. The slightly higher BBB penetration of A is also a minor benefit.
Output:
1
2025-04-17 20:36:30,521 - INFO - Batch 197 complete. Total preferences: 3152
2025-04-17 20:36:30,521 - INFO - Processing batch 198/512...
2025-04-17 20:37:18,573 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (363.439 Da and 366.487 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (87.74) is slightly higher than Ligand B (65.98). Both are below the 140 threshold for oral absorption, but Ligand B is better positioned, especially considering ADRB2's potential for CNS effects (though not a primary target).
3. **logP:** Both ligands (1.135 and 1.066) are within the optimal 1-3 range. No significant difference.
4. **HBD:** Ligand A has 2 HBD, while Ligand B has 0. This is a slight advantage for Ligand B, as fewer HBDs can sometimes improve permeability.
5. **HBA:** Ligand A has 5 HBA, Ligand B has 6. Both are acceptable (<=10), but Ligand A is slightly better.
6. **QED:** Both ligands have good QED scores (0.711 and 0.78), indicating good drug-like properties. Ligand B is marginally better.
7. **DILI:** Ligand A (70.764) has a higher DILI risk than Ligand B (34.393). This is a significant advantage for Ligand B.
8. **BBB:** Ligand B (67.041) has a higher BBB penetration percentile than Ligand A (43.311). While ADRB2 isn't exclusively a CNS target, some CNS penetration can be beneficial for understanding off-target effects and potential side effects.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.033 and -4.846). This is unusual and suggests poor permeability *in vitro*. However, these values are close, and the absolute value isn't as important as the relative comparison.
10. **Solubility:** Ligand A (-2.558) has slightly worse solubility than Ligand B (-1.183). Solubility is important for bioavailability, so Ligand B is preferred.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.195 and 0.165). No significant difference.
12. **Cl_mic:** Ligand A (-5.724) has a much lower (better) microsomal clearance than Ligand B (3.356). This indicates better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (-11.524) has a much longer in vitro half-life than Ligand B (3.963). This is a significant advantage for Ligand A, potentially leading to less frequent dosing.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.053 and 0.11). No significant difference.
15. **Binding Affinity:** Both ligands have comparable binding affinities (-6.0 and -5.6 kcal/mol). The difference of 0.4 kcal/mol is not substantial enough to outweigh other factors.
**Overall Assessment:**
Ligand B has several advantages: lower DILI risk, better BBB penetration, and slightly better solubility and QED. However, Ligand A has significantly better metabolic stability (lower Cl_mic) and a much longer half-life. Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity) and the importance of metabolic stability for *in vivo* efficacy, Ligand A is the more promising candidate. The longer half-life and better metabolic stability are crucial for maintaining therapeutic concentrations. The slightly higher TPSA and lower BBB are less concerning than the DILI risk of Ligand B.
Output:
1
2025-04-17 20:37:18,573 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [355.479, 71.11, 0.977, 1, 5, 0.737, 15.316, 70.531, -4.93, -1.047, 0.147, 10.49, 18.214, 0.008, -7.7]
**Ligand B:** [362.455, 98.32, 1.521, 3, 5, 0.695, 48.313, 33.385, -5.572, -1.444, 0.494, -7.158, -21.446, 0.042, -6.6]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, Affinity, and BBB):
1. **MW:** Both are within the ideal range (200-500 Da). A is 355.479, B is 362.455 - very similar.
2. **TPSA:** A (71.11) is excellent, well below the 140 threshold for oral absorption. B (98.32) is still acceptable, but less ideal.
3. **logP:** A (0.977) is slightly lower than optimal (1-3), but acceptable. B (1.521) is better within the optimal range.
4. **HBD/HBA:** A (1 HBD, 5 HBA) is good. B (3 HBD, 5 HBA) is also acceptable, but the higher HBD count could potentially impact permeability.
5. **QED:** A (0.737) is better than B (0.695), indicating a more drug-like profile.
6. **DILI:** A (15.316) is significantly better than B (48.313), indicating a much lower risk of liver injury. This is a major advantage for A.
7. **BBB:** A (70.531) is good, suggesting reasonable potential for some CNS penetration. B (33.385) is lower, indicating less likely CNS penetration. While ADRB2 is primarily cardiovascular, some CNS off-target effects are always a consideration.
8. **Caco-2:** A (-4.93) and B (-5.572) are both negative, indicating poor permeability.
9. **Solubility:** A (-1.047) and B (-1.444) are both poor.
10. **hERG:** A (0.147) is much better than B (0.494), indicating lower cardiotoxicity risk. This is crucial for a cardiovascular target.
11. **Cl_mic:** A (10.49) is higher than B (-7.158), meaning B has better metabolic stability. This is a significant advantage for B.
12. **t1/2:** A (18.214) is better than B (-21.446), indicating a longer half-life.
13. **Pgp:** A (0.008) is much lower than B (0.042), indicating less P-gp efflux and potentially better bioavailability.
14. **Affinity:** A (-7.7) is better than B (-6.6), indicating stronger binding. This is a substantial advantage for A.
**Overall Assessment:**
Ligand A has a significantly better safety profile (DILI, hERG), better binding affinity, better Pgp efflux, and a longer half-life. While both have poor Caco-2 and solubility, the stronger binding and improved safety profile of A outweigh the slightly less optimal logP and TPSA. The better metabolic stability of B is a plus, but the higher DILI and hERG risk are concerning.
Therefore, I would choose Ligand A.
Output:
1
2025-04-17 20:37:18,574 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (355.479 and 358.551 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (82.11) is better than Ligand B (29.27). Lower TPSA generally favors better cell permeability, which is important for GPCRs.
3. **logP:** Ligand B (4.998) is significantly higher than Ligand A (0.08). While a logP between 1-3 is optimal, Ligand B is quite high, potentially leading to solubility issues and off-target interactions. Ligand A is *too* low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (2) is better than Ligand B (0). Having some HBDs can improve solubility.
5. **HBA:** Ligand A (5) is slightly higher than Ligand B (4), but both are within acceptable limits.
6. **QED:** Both ligands have similar QED values (0.644 and 0.664), indicating good drug-likeness.
7. **DILI:** Ligand A (4.459) has a much lower DILI risk than Ligand B (12.796). This is a significant advantage for Ligand A.
8. **BBB:** Ligand B (87.088) has a much higher BBB penetration percentile than Ligand A (43.971). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration isn't necessarily detrimental, and could allow for some off-target effects.
9. **Caco-2:** Ligand A (-4.876) has a much better Caco-2 permeability than Ligand B (-5.136).
10. **Solubility:** Ligand A (-0.442) has better aqueous solubility than Ligand B (-4.628). This is crucial, especially given Ligand B's high logP.
11. **hERG:** Ligand A (0.218) has a lower hERG inhibition liability than Ligand B (0.904). This is a significant safety advantage for Ligand A.
12. **Cl_mic:** Ligand A (-1.403) has a lower (better) microsomal clearance than Ligand B (72.377). This indicates better metabolic stability for Ligand A.
13. **t1/2:** Ligand B (38.618) has a significantly longer in vitro half-life than Ligand A (14.47). This is a positive for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.002) has a much lower P-gp efflux liability than Ligand B (0.739). This is favorable for bioavailability.
15. **Affinity:** Ligand A (-6.9) has a slightly better binding affinity than Ligand B (-6.6). While the difference is not huge, it's still a positive for Ligand A.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A has a much better balance of these properties. While Ligand B has better BBB penetration and half-life, its very high logP, poor solubility, higher DILI risk, and higher hERG liability are major drawbacks.
**Conclusion:**
Despite Ligand B's longer half-life, the superior ADME profile and slightly better affinity of Ligand A make it the more promising drug candidate. The high logP and associated risks of Ligand B outweigh its benefits.
Output:
1
2025-04-17 20:37:18,574 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [339.483, 58.36, 3.577, 2, 2, 0.81, 29.042, 76.309, -4.777, -3.328, 0.931, 53.93, 37.76, 0.341, -7.8]
**Ligand B:** [352.356, 58.2, 2.641, 2, 2, 0.585, 56.96, 54.905, -4.625, -4.121, 0.515, 22.592, 22.769, 0.113, -7.6]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (339.483) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are good (around 58-59 A2), well below the 140 A2 threshold for oral absorption and suitable for a peripherally acting GPCR like ADRB2.
3. **logP:** Both are within the optimal range (1-3). Ligand A (3.577) is a bit higher than Ligand B (2.641), which could potentially lead to some off-target interactions, but is still acceptable.
4. **HBD/HBA:** Both have 2 HBD and 2 HBA, which is excellent and balances solubility and permeability.
5. **QED:** Ligand A (0.81) has a significantly better QED score than Ligand B (0.585), indicating a more drug-like profile.
6. **DILI:** Ligand A (29.042) has a much lower DILI risk than Ligand B (56.96), which is a significant advantage.
7. **BBB:** Ligand A (76.309) has a higher BBB penetration score than Ligand B (54.905). While ADRB2 isn't a CNS target, some degree of BBB penetration isn't necessarily detrimental and could indicate better overall distribution.
8. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. This is a concern for both.
9. **Solubility:** Both have negative solubility values, indicating poor aqueous solubility. This is a significant drawback for both.
10. **hERG:** Ligand A (0.931) has a slightly higher hERG risk than Ligand B (0.515), but both are relatively low.
11. **Cl_mic:** Ligand B (22.592) has a much lower microsomal clearance than Ligand A (53.93), suggesting better metabolic stability.
12. **t1/2:** Ligand A (37.76) has a longer in vitro half-life than Ligand B (22.769), which is preferable.
13. **Pgp:** Ligand A (0.341) has lower P-gp efflux liability than Ligand B (0.113), which is favorable for oral bioavailability.
14. **Affinity:** Ligand A (-7.8 kcal/mol) has a slightly better binding affinity than Ligand B (-7.6 kcal/mol), although the difference is small.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are important. Both ligands perform reasonably well on these metrics. However, the significant advantages of Ligand A in terms of QED and DILI risk are crucial. The better half-life and Pgp profile also contribute. While Ligand B has better metabolic stability, the other factors outweigh this benefit. The poor Caco-2 and solubility for both are concerning and would require formulation strategies to address.
**Conclusion:**
Considering the balance of properties, particularly the superior QED, DILI, and Pgp profiles of Ligand A, along with its slightly better affinity and half-life, it is the more promising drug candidate.
**Output:**
1
2025-04-17 20:37:18,574 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [358.345, 96.69, 0.376, 2, 6, 0.742, 50.989, 72.858, -4.616, -2.393, 0.224, -2.151, -20.764, 0.032, -6.7]
**Ligand B:** [353.419, 107.97, -0.983, 3, 5, 0.602, 28.616, 20.861, -5.305, -0.444, 0.087, -17.759, 13.797, 0.005, -8.5]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, BBB, and affinity are key):
1. **MW:** Both are within the ideal range (200-500 Da). A is 358.345, B is 353.419. Very similar.
2. **TPSA:** A (96.69) is better than B (107.97). Both are acceptable for a non-CNS GPCR, but lower is generally preferred.
3. **logP:** A (0.376) is a bit low, potentially hindering permeability. B (-0.983) is even lower, raising more concern. Both are suboptimal, but A is better.
4. **HBD/HBA:** A (2 HBD, 6 HBA) is slightly better than B (3 HBD, 5 HBA). Both are within reasonable limits.
5. **QED:** A (0.742) is better than B (0.602), indicating a more drug-like profile.
6. **DILI:** A (50.989) is significantly better than B (28.616). Lower DILI risk is crucial.
7. **BBB:** A (72.858) is much better than B (20.861). While ADRB2 isn't necessarily a CNS target, higher BBB is still a positive indicator of better distribution characteristics.
8. **Caco-2:** A (-4.616) is better than B (-5.305). Higher Caco-2 permeability is desirable.
9. **Solubility:** A (-2.393) is better than B (-0.444). Better solubility aids formulation and bioavailability.
10. **hERG:** A (0.224) is better than B (0.087). Lower hERG risk is critical for cardiovascular targets.
11. **Cl_mic:** A (-2.151) is better than B (-17.759). Lower clearance indicates better metabolic stability.
12. **t1/2:** A (-20.764) is better than B (13.797). Longer half-life is desirable.
13. **Pgp:** A (0.032) is much better than B (0.005). Lower P-gp efflux is important for bioavailability.
14. **Affinity:** B (-8.5) is significantly better than A (-6.7). This is a 1.8 kcal/mol difference, which is substantial.
**Overall Assessment:**
Ligand B has a considerably better binding affinity. However, it suffers from significantly worse ADME properties: higher DILI risk, very low BBB penetration, poor solubility, and high P-gp efflux. Ligand A, while having a weaker binding affinity, presents a much more balanced profile with better solubility, lower toxicity, better BBB, and improved metabolic stability. For a cardiovascular target, minimizing off-target effects and ensuring reasonable bioavailability are paramount. The affinity difference, while notable, can potentially be addressed through further optimization, whereas fixing the severe ADME liabilities of Ligand B would be far more challenging.
Therefore, I would prioritize Ligand A.
Output:
1
2025-04-17 20:37:18,574 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (345.4 and 342.4 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (88.69) is better than Ligand B (90.45). Both are below the 140 threshold for oral absorption, but closer to the ideal for GPCRs.
3. **logP:** Ligand A (2.97) is slightly higher than Ligand B (1.57), placing it more optimally within the 1-3 range. Ligand B is a bit low, potentially impacting permeability.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Both have 6 HBA, which is also good.
6. **QED:** Ligand A (0.92) has a better QED score than Ligand B (0.855), indicating a more drug-like profile.
7. **DILI:** Both ligands have similar DILI risk (65.76 and 63.09), both are acceptable but not ideal.
8. **BBB:** Ligand B (82.55) has a significantly higher BBB penetration percentile than Ligand A (62.35). While ADRB2 isn't exclusively a CNS target, some CNS penetration can be beneficial, and this is a notable advantage for Ligand B.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual. I will assume these are percentile scores and interpret them as low permeability. Ligand A (-4.53) is slightly worse than Ligand B (-4.64).
10. **Solubility:** Ligand A (-3.61) has slightly better aqueous solubility than Ligand B (-2.97).
11. **hERG:** Ligand A (0.20) has a lower hERG inhibition liability than Ligand B (0.66), which is a significant safety advantage.
12. **Cl_mic:** Ligand B (61.52) has a lower microsomal clearance than Ligand A (22.14), indicating better metabolic stability.
13. **t1/2:** Ligand B (16.74) has a much longer in vitro half-life than Ligand A (2.98), which is a major advantage for dosing convenience.
14. **Pgp:** Ligand A (0.11) has lower P-gp efflux liability than Ligand B (0.30), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand B (-7.1 kcal/mol) has a 0.3 kcal/mol stronger binding affinity than Ligand A (-6.8 kcal/mol). This is a substantial difference and a key driver in the decision.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are crucial. Ligand B excels in affinity and has a better BBB score, while Ligand A has a better logP and Pgp profile. The improved metabolic stability (lower Cl_mic and longer t1/2) of Ligand B is also very attractive. The slightly lower hERG risk of Ligand A is a positive, but the potency advantage of Ligand B is likely to outweigh this.
**Overall Assessment:**
While Ligand A has some advantages in solubility, logP, and Pgp efflux, Ligand B's significantly stronger binding affinity, improved metabolic stability, and better BBB penetration make it the more promising candidate. The difference in binding affinity is large enough to compensate for the slightly higher Pgp efflux and lower logP.
Output:
0
2025-04-17 20:37:18,574 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (386.832 Da) is slightly higher than Ligand B (339.351 Da), but both are acceptable.
2. **TPSA:** Ligand A (86.71) is better than Ligand B (102.66). Both are below 140, but lower TPSA generally favors oral absorption, a key consideration for a cardiovascular target.
3. **logP:** Ligand A (2.365) is within the optimal range (1-3). Ligand B (0.678) is a bit low, potentially hindering membrane permeability. This is a significant negative for Ligand B.
4. **HBD:** Both ligands have 2 HBD, which is good.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 5. Both are acceptable, but lower is generally preferred.
6. **QED:** Both ligands have similar QED values (0.825 and 0.788), indicating good drug-likeness.
7. **DILI:** Ligand B (76.154) has a higher DILI risk than Ligand A (67.429). Lower DILI is crucial, making Ligand A preferable.
8. **BBB:** Ligand A (18.069) has a lower BBB penetration than Ligand B (33.579). While ADRB2 isn't a CNS target, some degree of BBB penetration isn't necessarily detrimental and could provide some off-target safety information.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and problematic. It suggests poor permeability. However, the values are very similar (-5.045 vs -5.098).
10. **Solubility:** Ligand A (-3.939) has slightly better solubility than Ligand B (-3.223), although both are quite poor.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.456 and 0.306).
12. **Cl_mic:** Ligand B (-19.04) has a lower (better) microsomal clearance than Ligand A (51.116). This suggests better metabolic stability for Ligand B.
13. **t1/2:** Ligand A (-21.547) has a longer in vitro half-life than Ligand B (-15.03). This is a positive for Ligand A.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.082 and 0.035).
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.7 and -6.9 kcal/mol). The difference is negligible.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand A has a better logP and TPSA. The affinities are nearly identical. While metabolic stability (Cl_mic) is important, the difference isn't substantial enough to outweigh the permeability advantages of Ligand A. The DILI risk is also lower for Ligand A.
**Conclusion:**
Considering all factors, especially the GPCR-specific priorities and the slightly better overall ADME profile, Ligand A is the more promising drug candidate.
Output:
1
2025-04-17 20:37:18,575 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (345.427 Da) is slightly lower, which is generally favorable for permeability.
**2. TPSA:** Ligand A (54.88) is better than Ligand B (60.85). Both are below 140, but lower TPSA is preferred for GPCRs to facilitate brain penetration and receptor binding.
**3. logP:** Ligand B (1.597) is significantly better than Ligand A (4.288). A logP between 1-3 is optimal, and Ligand A is pushing the upper limit, potentially leading to solubility issues and off-target effects.
**4. H-Bond Donors:** Both ligands have 1 HBD, which is within the acceptable limit of 5.
**5. H-Bond Acceptors:** Both ligands have 4 HBA, which is within the acceptable limit of 10.
**6. QED:** Ligand B (0.821) has a higher QED score than Ligand A (0.6), indicating a more drug-like profile.
**7. DILI Risk:** Ligand B (23.769) has a *much* lower DILI risk than Ligand A (86.39). This is a critical advantage, as liver toxicity is a major concern in drug development.
**8. BBB Penetration:** Both ligands have reasonably good BBB penetration (Ligand A: 64.831, Ligand B: 65.452). Since ADRB2 is a cardiovascular target, BBB penetration isn't *essential*, but it's still a plus.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, indicating poor permeability. This is a concern for both.
**10. Aqueous Solubility:** Ligand B (-3.22) is better than Ligand A (-4.725), suggesting better solubility.
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (Ligand A: 0.648, Ligand B: 0.631).
**12. Microsomal Clearance:** Ligand B (56.511) has lower microsomal clearance than Ligand A (89.497), indicating better metabolic stability.
**13. In vitro Half-Life:** Ligand A (45.562) has a longer half-life than Ligand B (3.155). This is a positive for Ligand A.
**14. P-gp Efflux:** Both ligands have similar P-gp efflux liability (Ligand A: 0.321, Ligand B: 0.367).
**15. Binding Affinity:** Ligand A (-7.9 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.0 kcal/mol). This is a substantial advantage.
**Overall Assessment:**
While Ligand A has a superior binding affinity, the significantly higher DILI risk and higher logP of Ligand A are major drawbacks. Ligand B, despite its weaker binding, presents a much more favorable safety profile (DILI) and better ADME properties (logP, solubility, clearance). For a cardiovascular target like ADRB2, a slightly weaker but safer compound is often preferable, especially considering the potential for chronic administration. The difference in binding affinity (1.9 kcal/mol) is substantial, but not insurmountable, and can potentially be optimized in later stages of drug development.
Output:
0
2025-04-17 20:37:18,575 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (376.513) is slightly higher than Ligand B (344.415), but both are acceptable.
2. **TPSA:** Ligand A (49.41) is excellent, well below the 140 threshold for oral absorption and suitable for a GPCR. Ligand B (96.26) is higher, but still potentially acceptable, though less ideal.
3. **logP:** Ligand A (3.31) is optimal. Ligand B (1.756) is at the lower end of the optimal range, which *could* indicate permeability issues.
4. **HBD:** Ligand A (1) is good. Ligand B (3) is slightly higher, but still within the acceptable limit of 5.
5. **HBA:** Ligand A (3) is good. Ligand B (5) is also acceptable, being under the 10 threshold.
6. **QED:** Both ligands have good QED scores (A: 0.595, B: 0.678), indicating good drug-like properties.
7. **DILI:** Ligand A (15.743) has a significantly lower DILI risk than Ligand B (55.37). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (94.184) shows excellent BBB penetration, which is a positive for a GPCR target. Ligand B (67.235) is lower, suggesting less CNS exposure. While ADRB2 isn't exclusively a CNS target, some CNS effects are possible with beta-agonists, and better BBB penetration could be beneficial.
9. **Caco-2:** Both have negative values, indicating permeability issues. Ligand A (-4.981) is slightly better than Ligand B (-5.275).
10. **Solubility:** Both ligands have very poor aqueous solubility (-2.94 and -2.908 respectively). This is a significant concern for both, and would require formulation strategies.
11. **hERG:** Both ligands have low hERG inhibition risk (A: 0.8, B: 0.336). This is good.
12. **Cl_mic:** Ligand A (34.036) has lower microsomal clearance, indicating better metabolic stability, compared to Ligand B (46.152).
13. **t1/2:** Ligand B (25.327) has a significantly longer in vitro half-life than Ligand A (-2.011). This is a substantial advantage for Ligand B.
14. **Pgp:** Both ligands have low P-gp efflux liability (A: 0.17, B: 0.074). Ligand B is slightly better.
15. **Binding Affinity:** Ligand B (-6.9 kcal/mol) has a slightly better binding affinity than Ligand A (-6.1 kcal/mol). This is a 0.8 kcal/mol difference, which is significant but not overwhelming.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has a better logP and TPSA. Ligand B has a slightly better affinity and Pgp. The DILI and BBB scores for Ligand A are significantly better. Metabolic stability (Cl_mic) favors Ligand A, while half-life favors Ligand B. Solubility is a problem for both.
**Overall Assessment:**
While Ligand B has a slightly better binding affinity and half-life, the significantly lower DILI risk, better BBB penetration, and improved metabolic stability of Ligand A are more important. The solubility issues are a concern for both, but can be addressed with formulation. The slightly lower affinity of Ligand A is outweighed by its superior safety and pharmacokinetic profile.
Output:
1
2025-04-17 20:37:18,575 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.46 & 369.53 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (76.64 & 70.67) are below the 140 A^2 threshold for good oral absorption. Ligand B is slightly better.
3. **logP:** Both ligands (1.795 & 1.843) are within the optimal 1-3 range. Very similar.
4. **HBD:** Both have 2 HBD, which is acceptable.
5. **HBA:** Ligand A has 3 HBA, while Ligand B has 5. Both are under the 10 threshold, but A is preferable.
6. **QED:** Ligand A (0.853) has a significantly higher QED than Ligand B (0.575), indicating better overall drug-likeness. This is a substantial advantage for A.
7. **DILI:** Ligand A (32.261) has a lower DILI risk than Ligand B (23.769), which is favorable.
8. **BBB:** Ligand B (80.419) has a much higher BBB penetration percentile than Ligand A (29.508). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant, and this is a significant advantage for B.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand B (-5.199) is slightly worse than Ligand A (-4.86).
10. **Solubility:** Both have negative solubility values, indicating poor aqueous solubility. Ligand B (-3.174) is worse than Ligand A (-2.105).
11. **hERG:** Both ligands have low hERG inhibition liability (0.521 & 0.669), which is good.
12. **Cl_mic:** Ligand A (20.316) has a much lower microsomal clearance than Ligand B (56.677), suggesting better metabolic stability. This is a key advantage for A.
13. **t1/2:** Ligand A (-10.335) has a much longer in vitro half-life than Ligand B (-1.835). This is a substantial advantage for A.
14. **Pgp:** Both have very low Pgp efflux liability (0.171 & 0.111).
15. **Binding Affinity:** Ligand B (-6.3 kcal/mol) has a slightly better binding affinity than Ligand A (-6.7 kcal/mol). While a difference of 0.4 kcal/mol is not huge, it's a positive for B.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Both ligands perform similarly on logP and Pgp. Ligand B has a better BBB score and slightly better affinity. However, Ligand A excels in QED, DILI, Cl_mic, and t1/2. The improved metabolic stability (lower Cl_mic and longer t1/2) and better drug-likeness (higher QED) of Ligand A are crucial for overall developability. The slightly better affinity of Ligand B isn't enough to overcome these significant ADME advantages.
**Conclusion:**
Considering the balance of properties, particularly the superior ADME profile of Ligand A, I believe it is the more promising drug candidate.
Output:
1
2025-04-17 20:37:18,575 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (352.475 and 356.457 Da) fall comfortably within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (70.08) is higher than Ligand B (49.41). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B has a slight advantage.
3. **logP:** Ligand A (1.58) is within the optimal range, while Ligand B (3.066) is approaching the upper limit. Both are acceptable, but Ligand A is slightly better balanced.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 4 HBA, Ligand B has 2. Both are within the acceptable range of <=10, but Ligand B is better.
6. **QED:** Ligand B (0.762) has a better QED score than Ligand A (0.558), indicating a more drug-like profile.
7. **DILI:** Ligand A (12.136) has a significantly lower DILI risk than Ligand B (14.889). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (94.843) has a much higher BBB penetration percentile than Ligand A (63.164). While ADRB2 isn't a CNS target, some peripheral exposure is still desirable.
9. **Caco-2:** Both ligands have similar, poor Caco-2 permeability (-4.6 and -4.5). This is a concern for both, suggesting potential absorption issues.
10. **Solubility:** Ligand A (-0.501) has better solubility than Ligand B (-3.504). Solubility is important for formulation and bioavailability.
11. **hERG:** Ligand A (0.512) has a lower hERG risk than Ligand B (0.603), which is preferable.
12. **Cl_mic:** Ligand A (-0.265) has a much lower microsomal clearance than Ligand B (34.8). This suggests better metabolic stability for Ligand A, a significant advantage.
13. **t1/2:** Ligand A (10.298) has a better in vitro half-life than Ligand B (-17.793). This is a strong advantage for Ligand A.
14. **Pgp:** Both ligands have similar Pgp efflux liability (0.161 and 0.156).
15. **Binding Affinity:** Ligand B (-6.8 kcal/mol) has a slightly better binding affinity than Ligand A (-5.8 kcal/mol). This is a 1.0 kcal/mol difference, which is significant, but not overwhelming given the other factors.
**GPCR-Specific Priorities & Overall Assessment:**
For ADRB2 (a cardiovascular GPCR), the key priorities are logP, TPSA, affinity, and metabolic stability. Ligand B has a better logP and affinity. However, Ligand A excels in critical ADME properties: significantly lower DILI risk, better solubility, much lower microsomal clearance, and a longer half-life. The Caco-2 permeability is poor for both, but the superior ADME profile of Ligand A, combined with acceptable affinity, makes it the more promising candidate. The lower DILI and improved metabolic stability are particularly important for a cardiovascular drug.
Output:
1
2025-04-17 20:37:18,575 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (368.459 Da and 343.475 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand B (54.26) is significantly better than Ligand A (103.79). For a GPCR, lower TPSA is generally preferred for better permeability, and B is well below the 140 threshold. A is pushing the limit.
**3. logP:** Ligand B (2.69) is within the optimal 1-3 range. Ligand A (0.444) is quite low, potentially hindering membrane permeability. This is a significant drawback for A.
**4. H-Bond Donors:** Ligand A (3) is reasonable, while Ligand B (0) is even better, potentially improving permeability.
**5. H-Bond Acceptors:** Ligand A (7) and Ligand B (5) are both acceptable, below the 10 threshold.
**6. QED:** Both ligands have good QED scores (0.713 and 0.809), indicating good drug-like properties.
**7. DILI:** Ligand B (48.546) has a lower DILI risk than Ligand A (71.694), which is a positive attribute.
**8. BBB:** Ligand B (79.139) has a much higher BBB penetration score than Ligand A (36.487). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be beneficial or at least not detrimental, and higher BBB is generally favorable.
**9. Caco-2 Permeability:** Ligand A (-5.146) and Ligand B (-4.723) are both negative, indicating poor permeability. This is concerning for both, but the difference is small.
**10. Aqueous Solubility:** Ligand A (-1.851) and Ligand B (-2.83) are both poor, but B is slightly worse.
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (0.224 and 0.53), which is excellent.
**12. Microsomal Clearance:** Ligand A (-13.794) has a much lower (better) microsomal clearance than Ligand B (87.403), suggesting greater metabolic stability. This is a strong point for A.
**13. In vitro Half-Life:** Ligand B (19.68) has a slightly longer half-life than Ligand A (17.557), but the difference is not substantial.
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (0.021 and 0.344), which is good.
**15. Binding Affinity:** Both ligands have very similar and strong binding affinities (-7.9 and -7.6 kcal/mol). The difference of 0.3 kcal/mol is not enough to override other factors.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand B is the more promising candidate. Its superior logP and TPSA values are crucial for permeability and absorption. While Ligand A has better metabolic stability (lower Cl_mic), the significant drawbacks in logP and TPSA outweigh this advantage. The higher BBB score for B is also a plus.
Output:
0
2025-04-17 20:37:18,576 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (361.511 and 344.459 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (62.3) is better than Ligand B (65.54). Both are below the 140 threshold for oral absorption, but lower is generally preferred.
3. **logP:** Both ligands have good logP values (2.561 and 1.533), falling within the optimal 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Both have 1 HBD, which is within the acceptable limit of 5.
5. **HBA:** Both have 4 HBA, which is within the acceptable limit of 10.
6. **QED:** Both ligands have high QED scores (0.875 and 0.9), indicating good drug-like properties.
7. **DILI:** Ligand B (14.618) has a significantly lower DILI risk than Ligand A (40.287). This is a major advantage for Ligand B.
8. **BBB:** Ligand A (76.696) has a higher BBB penetration percentile than Ligand B (69.213). While ADRB2 isn't strictly a CNS target, some CNS exposure can be relevant for off-target effects, and higher BBB is generally favorable.
9. **Caco-2:** Ligand A (-5.18) has a more negative Caco-2 value, suggesting *lower* permeability than Ligand B (-4.828). This is a negative for Ligand A.
10. **Solubility:** Ligand B (-1.766) has a better (less negative) solubility score than Ligand A (-3.336). Better solubility is generally preferred.
11. **hERG:** Both ligands have low hERG inhibition liability (0.425 and 0.468). No significant difference.
12. **Cl_mic:** Ligand B (4.977) has a much lower microsomal clearance than Ligand A (49.7). This suggests better metabolic stability for Ligand B, a crucial factor for drug duration.
13. **t1/2:** Ligand B (-0.476) has a slightly longer in vitro half-life than Ligand A (-11.945). This is a positive for Ligand B.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.154 and 0.017). No significant difference.
15. **Binding Affinity:** Ligand B (-6.8 kcal/mol) has a slightly better binding affinity than Ligand A (-6.1 kcal/mol). While the difference is less than the 1.5 kcal/mol threshold, it contributes to the overall preference.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Ligand B is better in logP, TPSA, and affinity. The DILI and Cl_mic are also significantly better for Ligand B.
**Overall Assessment:**
While Ligand A has a slightly higher BBB penetration, the significant advantages of Ligand B in DILI risk, metabolic stability (Cl_mic), solubility, and Caco-2 permeability outweigh this. The slightly better binding affinity of Ligand B further solidifies its preference.
Output:
0
2025-04-17 20:37:18,576 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands (350.5 & 349.5 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (59.39) is better than Ligand B (64.52). Both are below the 140 threshold for oral absorption, but lower is generally preferred for GPCRs.
3. **logP:** Both ligands have good logP values (3.005 & 2.382), falling within the optimal 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (6). Similar to HBD, lower HBA is generally better.
6. **QED:** Both ligands have acceptable QED values (0.821 & 0.703), indicating good drug-like properties. Ligand A is slightly better.
7. **DILI:** Ligand A (34.083) is significantly better than Ligand B (10.198). A lower DILI percentile is crucial for safety. Ligand B's DILI is concerningly high.
8. **BBB:** Both ligands have good BBB penetration (84.374 & 76.696). This is important for a GPCR target, although less critical for ADRB2 than for CNS targets.
9. **Caco-2:** Ligand A (-4.486) is better than Ligand B (-5.013). Higher Caco-2 permeability suggests better absorption.
10. **Solubility:** Ligand A (-3.221) is better than Ligand B (-1.153). Better solubility is always desirable.
11. **hERG:** Both ligands have low hERG inhibition risk (0.727 & 0.945), which is good.
12. **Cl_mic:** Ligand A (71.739) is better than Ligand B (12.304). Lower microsomal clearance indicates better metabolic stability.
13. **t1/2:** Ligand B (45.542) is better than Ligand A (28.681). A longer half-life is generally preferred.
14. **Pgp:** Ligand A (0.211) is better than Ligand B (0.074). Lower P-gp efflux is desirable for better bioavailability.
15. **Binding Affinity:** Ligand B (-8.2) has a significantly stronger binding affinity than Ligand A (-5.5). This is a >1.5 kcal/mol advantage, which is substantial.
**Overall Assessment:**
While Ligand B boasts a superior binding affinity, the significant concerns regarding its DILI risk and its lower metabolic stability (higher Cl_mic) are major drawbacks. Ligand A presents a much more balanced profile, with better predicted safety (DILI), permeability (Caco-2), solubility, metabolic stability (Cl_mic), and Pgp efflux. The difference in binding affinity, while notable, can potentially be addressed through further optimization of Ligand A. Given the GPCR-specific priorities, and the importance of a balanced ADME profile, Ligand A is the more promising candidate.
Output:
1
2025-04-17 20:37:18,576 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [359.388, 47.56, 3.796, 1, 3, 0.841, 35.789, 84.064, -4.672, -3.739, 0.694, 40.857, 1.395, 0.396, -4.9]
**Ligand B:** [358.389, 98.32, 1.127, 3, 4, 0.616, 39.55, 56.146, -5.162, -2.169, 0.346, 0.879, -13.993, 0.025, -6.6]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal 200-500 Da range. Similar.
2. **TPSA:** Ligand A (47.56) is significantly better than Ligand B (98.32). GPCRs benefit from lower TPSA for permeability. A is preferred.
3. **logP:** Ligand A (3.796) is optimal. Ligand B (1.127) is a bit low, potentially hindering membrane permeability. A is preferred.
4. **HBD:** Ligand A (1) is better than Ligand B (3). Lower is generally preferred for permeability. A is preferred.
5. **HBA:** Ligand A (3) is better than Ligand B (4). A is preferred.
6. **QED:** Ligand A (0.841) is better than Ligand B (0.616), indicating a more drug-like profile. A is preferred.
7. **DILI:** Both are acceptable (<40), with Ligand B slightly better (39.55 vs 35.789). B is slightly preferred.
8. **BBB:** Ligand A (84.064) is significantly better than Ligand B (56.146). This is a key factor for GPCRs, even if not CNS-focused, as it suggests better distribution. A is strongly preferred.
9. **Caco-2:** Ligand A (-4.672) is better than Ligand B (-5.162), indicating better intestinal absorption. A is preferred.
10. **Solubility:** Ligand A (-3.739) is better than Ligand B (-2.169). A is preferred.
11. **hERG:** Both are low risk (0.694 and 0.346). Similar.
12. **Cl_mic:** Ligand B (0.879) is *much* better than Ligand A (40.857), indicating significantly higher metabolic stability. B is strongly preferred.
13. **t1/2:** Ligand B (-13.993) is *much* better than Ligand A (1.395). B is strongly preferred.
14. **Pgp:** Ligand A (0.396) is better than Ligand B (0.025). A is preferred.
15. **Affinity:** Ligand B (-6.6) is significantly better than Ligand A (-4.9). This is a substantial advantage (1.7 kcal/mol). B is strongly preferred.
**Overall Assessment:**
Ligand B has a *much* stronger binding affinity and significantly better metabolic stability (Cl_mic and t1/2). These are crucial factors. While Ligand A excels in TPSA, logP, BBB, solubility, and Pgp, the difference in affinity and metabolic stability is substantial enough to outweigh those advantages. The lower logP of Ligand B is a concern, but the superior affinity might compensate for that.
Therefore, I predict Ligand B is the more viable drug candidate.
Output:
0
2025-04-17 20:37:18,576 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
We are targeting ADRB2, a GPCR, so the priorities are logP, Pgp, TPSA, affinity, and, to a lesser extent, BBB. Let's break down the comparison:
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (364.829) is slightly higher than Ligand B (347.415), but both are acceptable.
2. **TPSA:** Ligand A (80.57) is significantly better than Ligand B (102.76). A TPSA under 140 is good for oral absorption, and lower is generally preferred for GPCRs. Ligand B is pushing the upper limit.
3. **logP:** Ligand A (3.645) is within the optimal range (1-3), while Ligand B (0.835) is below it. Low logP can hinder membrane permeability. This is a significant advantage for Ligand A.
4. **H-Bond Donors:** Ligand A (2) is preferable to Ligand B (3). Fewer H-bond donors generally improve permeability.
5. **H-Bond Acceptors:** Ligand A (4) is preferable to Ligand B (5). Fewer H-bond acceptors generally improve permeability.
6. **QED:** Both ligands have similar QED values (A: 0.785, B: 0.749), indicating good drug-like properties.
7. **DILI:** Ligand B (35.091) has a much lower DILI risk than Ligand A (63.746). This is a strong point in favor of Ligand B.
8. **BBB:** Ligand A (61.574) has a better BBB percentile than Ligand B (23.149). While ADRB2 isn't necessarily a CNS target, some peripheral ADRB2 activity can influence CNS pathways.
9. **Caco-2:** Ligand A (-4.768) has a better Caco-2 permeability than Ligand B (-5.06). Higher values indicate better absorption.
10. **Solubility:** Ligand A (-4.652) has better solubility than Ligand B (-1.985). Solubility is important for formulation and bioavailability.
11. **hERG:** Ligand A (0.738) has a better hERG profile than Ligand B (0.169). Lower hERG risk is crucial for avoiding cardiotoxicity, especially important for a cardiovascular target.
12. **Cl_mic:** Ligand B (6.432) has a significantly lower microsomal clearance than Ligand A (55.728), indicating better metabolic stability.
13. **t1/2:** Ligand A (66.428) has a much longer in vitro half-life than Ligand B (-24.813). A longer half-life is generally desirable.
14. **Pgp:** Ligand A (0.5) has a lower Pgp efflux liability than Ligand B (0.011). Lower Pgp is favorable for bioavailability.
15. **Binding Affinity:** Ligand B (-7.2) has a significantly stronger binding affinity than Ligand A (-5.6). A 1.6 kcal/mol difference is substantial and can often outweigh other ADME concerns.
**Overall Assessment:**
Ligand B has a markedly better binding affinity and significantly lower DILI and microsomal clearance. While Ligand A has advantages in TPSA, logP, solubility, and hERG, the superior affinity of Ligand B is a critical factor for a GPCR target. The lower metabolic clearance and DILI risk are also very important. The slightly lower TPSA and logP of Ligand B are not dealbreakers, and can potentially be optimized in later stages of drug development.
Output:
0
2025-04-17 20:37:18,576 - INFO - Batch 198 complete. Total preferences: 3168
2025-04-17 20:37:18,577 - INFO - Processing batch 199/512...
2025-04-17 20:38:02,397 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.397 and 336.399 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (59.81) is significantly better than Ligand B (88.49). ADRB2 is a cardiovascular target, not a CNS target, but lower TPSA generally aids absorption.
3. **logP:** Both ligands have good logP values (3.16 and 2.486, respectively), falling within the optimal 1-3 range. Ligand A is slightly higher, which *could* be a minor advantage for membrane permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (4) is preferable to Ligand B (5). Lower HBA generally improves permeability.
6. **QED:** Ligand A (0.927) is significantly better than Ligand B (0.769), indicating a more drug-like profile.
7. **DILI:** Both ligands have DILI risk around 63-68%, which is moderately high. This is a concern for both, but not a deciding factor between them.
8. **BBB:** Ligand A (93.563) is much better than Ligand B (57.464). While ADRB2 isn't a primary CNS target, some off-target CNS effects are always a consideration, and higher BBB is generally favorable.
9. **Caco-2:** Ligand A (-4.582) is better than Ligand B (-5.715). Higher values indicate better intestinal absorption.
10. **Solubility:** Ligand A (-4.24) is better than Ligand B (-2.063). Higher solubility is generally preferred.
11. **hERG:** Both ligands have low hERG inhibition liability (0.677 and 0.648), which is good.
12. **Cl_mic:** Ligand B (-6.908) has a *much* lower (better) microsomal clearance than Ligand A (35.407). This suggests significantly improved metabolic stability for Ligand B.
13. **t1/2:** Ligand A (19.274) has a longer in vitro half-life than Ligand B (4.708). This is a positive for Ligand A.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.234 and 0.24), which is good.
15. **Binding Affinity:** Ligand B (-7.4) has a significantly stronger binding affinity than Ligand A (-5.4). This is a substantial advantage (2 kcal/mol difference).
**Overall Assessment:**
Ligand B has a significantly better binding affinity, and a much better metabolic stability profile (lower Cl_mic). These are crucial factors for a GPCR target. While Ligand A has advantages in QED, TPSA, solubility, and BBB, the difference in binding affinity and metabolic stability outweighs these benefits. The slightly higher DILI risk for both is a concern, but not a deciding factor.
Output:
0
2025-04-17 20:38:02,398 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (363.527) is slightly higher than Ligand B (346.427), but both are acceptable.
2. **TPSA:** Ligand A (54.34) is better than Ligand B (75.71). For a GPCR, lower TPSA is generally preferred for better permeability. Ligand B is a bit high, potentially hindering absorption.
3. **logP:** Both ligands have good logP values (A: 2.351, B: 1.261), falling within the optimal 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability, but not excessively so.
4. **HBD:** Both have 1 HBD, which is ideal.
5. **HBA:** Both have 4 HBA, which is acceptable.
6. **QED:** Ligand A (0.844) has a significantly better QED score than Ligand B (0.601), indicating a more drug-like profile.
7. **DILI:** Both have low DILI risk (A: 21.442, B: 20.318), both below the 40 threshold.
8. **BBB:** Ligand B (63.164) has a slightly better BBB penetration score than Ligand A (58.085), but neither is exceptionally high. Since ADRB2 is a cardiovascular target, BBB penetration isn't a primary concern, but it's a slight advantage for B.
9. **Caco-2:** Ligand A (-5.302) and Ligand B (-4.903) are both negative, which is unusual and suggests poor permeability. However, the scale isn't specified, so it's hard to interpret.
10. **Solubility:** Both have negative solubility values (-2.423 and -2.226). This is concerning and suggests poor aqueous solubility for both.
11. **hERG:** Both ligands have very low hERG risk (A: 0.303, B: 0.111), which is excellent.
12. **Cl_mic:** Ligand B (5.842) has much lower microsomal clearance than Ligand A (30.05), indicating better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand B (-19.658) has a much longer in vitro half-life than Ligand A (18.875). This is a major advantage, potentially leading to less frequent dosing.
14. **Pgp:** Both have low Pgp efflux liability (A: 0.228, B: 0.046), which is good.
15. **Binding Affinity:** Ligand A (-5.8 kcal/mol) has a stronger binding affinity than Ligand B (-3.7 kcal/mol). This is a substantial difference (2.1 kcal/mol) and a key factor.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, and affinity. Ligand A excels in affinity and has a better logP and TPSA. However, Ligand B has significantly better metabolic stability (Cl_mic and t1/2). The affinity difference is substantial, and a strong binding affinity can often compensate for some ADME drawbacks.
**Overall Assessment:**
While Ligand B has better metabolic stability and a slightly better BBB score, the significantly stronger binding affinity of Ligand A (-5.8 vs -3.7 kcal/mol) is a decisive advantage for a GPCR target. The better QED score of Ligand A also supports its selection. The solubility issues are a concern for both, but can be addressed through formulation strategies.
Output:
1
2025-04-17 20:38:02,398 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's break down the comparison of Ligand A and Ligand B, keeping in mind the GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key).
1. **Molecular Weight:** Both ligands (346.475 and 346.391 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (78.09) is significantly better than Ligand B (113.24). A TPSA under 140 is good for oral absorption, but lower is generally preferred for GPCRs, and A is much closer to the ideal range.
3. **logP:** Ligand A (2.074) is within the optimal 1-3 range. Ligand B (0.953) is a bit low, potentially hindering membrane permeability.
4. **H-Bond Donors:** Both ligands have 2 HBD, which is acceptable.
5. **H-Bond Acceptors:** Ligand A has 3 HBA, while Ligand B has 7. Ligand A is better here, as higher HBA can sometimes negatively impact permeability.
6. **QED:** Both ligands have good QED scores (0.707 and 0.772), indicating generally drug-like properties.
7. **DILI Risk:** Ligand A (25.514%) has a considerably lower DILI risk than Ligand B (55.603%). This is a significant advantage for Ligand A.
8. **BBB Penetration:** Ligand A (46.724%) has better BBB penetration than Ligand B (35.518%), although neither is exceptionally high. For a cardiovascular target, BBB penetration isn't *critical*, but it's a bonus.
9. **Caco-2 Permeability:** Both have negative values, indicating poor permeability. However, Ligand A (-5.327) is better than Ligand B (-5.691).
10. **Aqueous Solubility:** Both ligands have poor solubility (-2.118 and -2.588). This is a potential formulation challenge for both.
11. **hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.268 and 0.082). This is good.
12. **Microsomal Clearance:** Ligand A (7.353) has significantly lower microsomal clearance than Ligand B (39.091), suggesting better metabolic stability.
13. **In vitro Half-Life:** Ligand A (-14.745) has a longer in vitro half-life than Ligand B (-10.011).
14. **P-gp Efflux:** Both ligands have low P-gp efflux liability (0.06 and 0.023).
15. **Binding Affinity:** Ligand B (-7.0 kcal/mol) has a slightly better binding affinity than Ligand A (-6.1 kcal/mol). This is a 0.9 kcal/mol difference, which is noticeable but not overwhelming.
**Overall Assessment:**
Ligand A is the stronger candidate. While Ligand B has a slightly better binding affinity, Ligand A excels in several crucial ADME properties: lower DILI risk, better TPSA, better logP, lower microsomal clearance, and longer half-life. The combination of these factors, particularly the significantly lower DILI risk and improved metabolic stability, outweighs the small advantage in binding affinity for Ligand B. The better TPSA and logP also suggest better permeability.
Output:
1
2025-04-17 20:38:02,398 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for the ADRB2, a cardiovascular GPCR. Therefore, key priorities are logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB.
Let's compare the ligands property by property:
1. **MW:** Both ligands (350.5 and 377.4 Da) fall within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (70.59) is significantly better than Ligand B (107.4). Lower TPSA generally favors oral absorption, which is important for a cardiovascular drug.
3. **logP:** Both ligands have good logP values (2.678 and 1.929), falling within the optimal 1-3 range. Ligand B is slightly lower, which *could* indicate slightly better solubility, but isn't a major concern.
4. **HBD/HBA:** Ligand A (3 HBD, 3 HBA) is slightly better than Ligand B (1 HBD, 5 HBA). Both are within acceptable limits.
5. **QED:** Ligand A (0.69) is much better than Ligand B (0.206), indicating a more drug-like profile.
6. **DILI:** Ligand A (19.465) has a significantly lower DILI risk than Ligand B (47.77). This is a crucial advantage.
7. **BBB:** Both are reasonably good, with Ligand A (78.868) slightly better than Ligand B (71.733). While ADRB2 isn't necessarily a CNS target, some degree of BBB penetration can be beneficial for distribution.
8. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-4.791) is slightly better (less negative) than Ligand B (-5.044).
9. **Solubility:** Both have negative solubility values, indicating poor solubility. Ligand A (-3.074) is slightly better than Ligand B (-2.771).
10. **hERG:** Both have low hERG risk (0.499 and 0.384).
11. **Cl_mic:** Ligand A (37.877) has a higher (worse) microsomal clearance than Ligand B (18.173), suggesting faster metabolism.
12. **t1/2:** Ligand A (22.627) has a significantly longer in vitro half-life than Ligand B (-13.132). This is a major advantage.
13. **Pgp:** Both have low Pgp efflux (0.217 and 0.051), which is good. Ligand B is slightly better.
14. **Binding Affinity:** Ligand A (-6.5 kcal/mol) is slightly better than Ligand B (-5.8 kcal/mol), though the difference is not huge.
**Overall Assessment:**
Ligand A demonstrates a superior balance of properties. It has a better QED score, significantly lower DILI risk, a longer half-life, and slightly better TPSA, BBB, and binding affinity. While Ligand B has slightly better Pgp efflux and lower Cl_mic, the advantages of Ligand A in terms of safety (DILI) and drug-likeness (QED, t1/2) are more important for overall drug development potential. The slightly better affinity of Ligand A further supports its selection.
**Output:**
1
2025-04-17 20:38:02,399 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (362.813 Da) and Ligand B (346.471 Da) both fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (74.02) and Ligand B (70.59) are both below 140, suggesting good oral absorption potential. Both are good.
3. **logP:** Ligand A (2.974) and Ligand B (3.028) are both within the optimal 1-3 range. Again, no significant difference.
4. **HBD:** Ligand A (1) is better than Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (5) is better than Ligand B (3). Fewer HBAs generally improve permeability.
6. **QED:** Ligand A (0.85) is slightly better than Ligand B (0.785), indicating a more drug-like profile.
7. **DILI:** Ligand B (19.736) has a significantly lower DILI risk than Ligand A (78.054). This is a major advantage for Ligand B.
8. **BBB:** Ligand A (86.351) and Ligand B (79.527) are both reasonably high, but Ligand A is better. While ADRB2 isn't exclusively a CNS target, some CNS penetration might be beneficial depending on the specific therapeutic application.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand B (-3.012) has better solubility than Ligand A (-4.549). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.807) has a higher hERG risk than Ligand B (0.381). Lower hERG risk is crucial for cardiovascular drugs.
12. **Cl_mic:** Ligand B (31.173) has lower microsomal clearance than Ligand A (50.652), suggesting better metabolic stability.
13. **t1/2:** Ligand B (28.49) has a significantly longer in vitro half-life than Ligand A (3.302). This is a major advantage for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.529) has lower P-gp efflux than Ligand B (0.263), suggesting better absorption.
15. **Binding Affinity:** Ligand B (-8.6 kcal/mol) has a significantly stronger binding affinity than Ligand A (-3.8 kcal/mol). This is a substantial advantage that can outweigh some ADME drawbacks.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand B excels in affinity and has acceptable logP and TPSA. While Pgp is lower for Ligand A, the superior affinity of Ligand B is a more significant factor. The lower DILI risk and improved metabolic stability (lower Cl_mic, longer t1/2) of Ligand B further strengthen its position.
**Conclusion:**
Despite the slightly lower BBB and Caco-2 permeability, Ligand B's significantly stronger binding affinity, lower DILI risk, improved metabolic stability, and better solubility make it the more promising drug candidate. The substantial affinity difference is the deciding factor.
Output:
0
2025-04-17 20:38:02,399 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (343.427 Da and 357.445 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (72.48) is higher than Ligand B (52.65). For a cardiovascular GPCR, TPSA is moderately important. Lower is better for permeability, and B is preferable.
**3. logP:** Ligand A (2.832) and Ligand B (1.871) are both within the optimal 1-3 range. Ligand A is slightly more lipophilic, which could be beneficial for membrane permeability, but not drastically.
**4. H-Bond Donors:** Ligand A (2) and Ligand B (1) are both acceptable.
**5. H-Bond Acceptors:** Ligand A (6) and Ligand B (3) are both acceptable.
**6. QED:** Both ligands have good QED scores (0.786 and 0.836), indicating good drug-like properties.
**7. DILI Risk:** Ligand A (50.291) has a higher DILI risk than Ligand B (8.337). This is a significant advantage for Ligand B.
**8. BBB Penetration:** Both have good BBB penetration (83.094 and 87.553). Since this is a cardiovascular target, BBB penetration is less critical, but higher is still slightly preferred.
**9. Caco-2 Permeability:** Both ligands show negative Caco-2 permeability, which is unusual and concerning. It suggests poor intestinal absorption. However, the values are similar (-4.785 and -4.914).
**10. Aqueous Solubility:** Ligand A (-3.037) has worse solubility than Ligand B (-1.522). Solubility is important for bioavailability.
**11. hERG Inhibition:** Ligand A (0.893) has a slightly higher hERG risk than Ligand B (0.615), but both are reasonably low.
**12. Microsomal Clearance:** Ligand B (-32.822) has significantly lower (better) microsomal clearance than Ligand A (36.894), indicating greater metabolic stability. This is a substantial advantage.
**13. In vitro Half-Life:** Ligand B (-12.515) has a longer in vitro half-life than Ligand A (15.893). This is a positive for dosing convenience.
**14. P-gp Efflux:** Ligand A (0.154) has lower P-gp efflux than Ligand B (0.02), which is preferable.
**15. Binding Affinity:** Ligand B (-6.7) has a slightly better binding affinity than Ligand A (-5.8). This is a 0.9 kcal/mol difference, which is significant enough to consider.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity) and the general guidelines, Ligand B is the more promising candidate. While Ligand A has slightly better P-gp efflux, Ligand B excels in several crucial areas: significantly lower DILI risk, better solubility, much lower microsomal clearance (better metabolic stability), longer half-life, and slightly better binding affinity. The lower TPSA of Ligand B is also favorable. The similar Caco-2 permeability is a concern for both, but the other advantages of Ligand B outweigh this drawback.
Output:
0
2025-04-17 20:38:02,399 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
We are targeting ADRB2, a GPCR, so the key priorities are logP, TPSA, Pgp efflux, BBB penetration, and binding affinity. Metabolic stability (Cl_mic, t1/2) and safety (DILI, hERG) are also important, but less critical than the first set.
Let's compare the ligands property by property:
1. **MW:** Both ligands (344.37 and 353.51 Da) fall within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (101.7) is higher than Ligand B (61.88). Ligand B is significantly better here, being well below the 140 threshold for good absorption.
3. **logP:** Ligand A (3.789) is higher than Ligand B (1.639). While both are within the 1-3 range, Ligand A is approaching the upper limit where solubility issues could arise.
4. **HBD/HBA:** Ligand A has 2 HBD and 5 HBA, while Ligand B has 1 HBD and 4 HBA. Both are acceptable.
5. **QED:** Ligand B (0.756) has a better QED score than Ligand A (0.585), indicating a more drug-like profile.
6. **DILI:** Ligand A (89.841) has a significantly higher DILI risk than Ligand B (11.09). This is a major concern for Ligand A.
7. **BBB:** Ligand B (67.584) has better BBB penetration than Ligand A (16.363). While not a primary concern for peripheral GPCRs like ADRB2, it's a bonus.
8. **Caco-2:** Ligand A (-5.058) and Ligand B (-4.697) are both negative, which is unusual and suggests poor permeability.
9. **Solubility:** Ligand A (-4.473) has worse solubility than Ligand B (-1.519).
10. **hERG:** Both ligands (0.317 and 0.296) have low hERG risk, which is good.
11. **Cl_mic:** Both ligands have similar microsomal clearance (34.131 and 34.6 mL/min/kg).
12. **t1/2:** Ligand B (6.334 hours) has a significantly longer half-life than Ligand A (-18.582 hours). The negative value for Ligand A is concerning and likely indicates rapid metabolism.
13. **Pgp:** Both ligands have very low Pgp efflux (0.15 and 0.019).
14. **Binding Affinity:** Ligand B (-8.2 kcal/mol) has slightly better binding affinity than Ligand A (-8.0 kcal/mol), but the difference is small.
**Overall Assessment:**
Ligand B is clearly superior. It has a much better safety profile (lower DILI), better solubility, better BBB penetration, a longer half-life, and a slightly improved binding affinity. While Ligand A has a slightly better logP, the significant drawbacks in safety and ADME properties outweigh this benefit. The lower TPSA of Ligand B is also a significant advantage for absorption.
**Output:**
0
2025-04-17 20:38:02,399 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
The ADRB2 receptor is a GPCR, so the priorities are logP, TPSA, Pgp, BBB, and affinity. Let's compare the ligands step-by-step:
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (345.443) is slightly lower than Ligand B (373.812), which is generally favorable for permeability.
2. **TPSA:** Ligand B (83.72) is better than Ligand A (91.32). Both are below 140, but closer to 90 is preferred for GPCRs.
3. **logP:** Both ligands have good logP values (A: 2.26, B: 2.098), falling within the optimal 1-3 range.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (0). While both are acceptable, lower HBD can sometimes improve permeability.
5. **HBA:** Ligand A (4) and Ligand B (5) are both acceptable, below the 10 threshold.
6. **QED:** Both ligands have similar QED values (A: 0.69, B: 0.73), indicating good drug-likeness.
7. **DILI:** Ligand A (42.885) has a significantly lower DILI risk than Ligand B (60.217). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (85.033) has a much higher BBB penetration potential than Ligand A (57.619). While ADRB2 is not exclusively a CNS target, some CNS exposure can be beneficial, and this is a significant advantage for Ligand B.
9. **Caco-2:** Both have negative values, indicating poor permeability. Ligand A (-4.96) is slightly better than Ligand B (-4.478).
10. **Solubility:** Ligand A (-3.481) has better solubility than Ligand B (-2.273).
11. **hERG:** Both ligands have very low hERG risk (A: 0.09, B: 0.146).
12. **Cl_mic:** Ligand B (23.154) has significantly lower microsomal clearance than Ligand A (45.626), indicating better metabolic stability.
13. **t1/2:** Ligand B (-0.245) has a much longer in vitro half-life than Ligand A (-43.288). This is a substantial advantage for Ligand B.
14. **Pgp:** Ligand A (0.041) has lower P-gp efflux than Ligand B (0.296), which is favorable.
15. **Affinity:** Ligand A (-6.5 kcal/mol) has a slightly better binding affinity than Ligand B (-4.7 kcal/mol). This is a 1.8 kcal/mol difference, which is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand A has a better binding affinity and lower DILI risk, better solubility and lower Pgp efflux. Ligand B excels in BBB penetration, metabolic stability (lower Cl_mic), and longer half-life. The affinity difference is significant. While BBB is a consideration for GPCRs, the lower DILI risk and better affinity of Ligand A are more critical for initial drug candidate selection. The longer half-life of Ligand B is attractive, but can be addressed through structural modifications.
**Output:**
1
2025-04-17 20:38:02,399 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (352.337 and 349.431 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (73.63) is significantly better than Ligand B (100.55). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand A is well below the 140 threshold, while Ligand B is approaching it.
3. **logP:** Ligand A (4.17) is higher than Ligand B (1.424). While both are within the acceptable range, Ligand A is approaching the upper limit where solubility issues could arise. Ligand B is closer to the optimal 1-3 range.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Both ligands have 5 HBA, which is acceptable.
6. **QED:** Both ligands have similar QED values (0.416 vs 0.462), indicating moderate drug-likeness.
7. **DILI:** Ligand B (41.45) has a much lower DILI risk than Ligand A (76.503). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (71.074) has a better BBB penetration percentile than Ligand B (47.77). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be useful for understanding off-target effects and distribution.
9. **Caco-2:** Ligand A (-4.618) has a better Caco-2 permeability than Ligand B (-5.145), indicating better intestinal absorption.
10. **Solubility:** Ligand B (-2.091) has better aqueous solubility than Ligand A (-5.049). This is important given Ligand A's higher logP.
11. **hERG:** Ligand A (0.875) has a slightly better hERG profile than Ligand B (0.261), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand B (7.376) has significantly lower microsomal clearance than Ligand A (67.165), suggesting better metabolic stability.
13. **t1/2:** Ligand A (59.436) has a significantly longer in vitro half-life than Ligand B (0.726). This is a major advantage for Ligand A.
14. **Pgp:** Ligand B (0.042) has lower P-gp efflux liability than Ligand A (0.528), which is favorable for bioavailability.
15. **Binding Affinity:** Both ligands have the same binding affinity (-5.9 kcal/mol). This removes affinity as a differentiating factor.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp efflux, and metabolic stability are key. Ligand B excels in Pgp efflux and metabolic stability (lower Cl_mic), and has a more favorable logP and solubility. Ligand A has a better TPSA and in vitro half-life. The DILI risk for Ligand B is also significantly lower.
**Overall Assessment:**
While Ligand A has a longer half-life and better Caco-2 permeability, the combination of lower DILI risk, better metabolic stability (lower Cl_mic), and more favorable logP/solubility profile of Ligand B makes it the more promising candidate. The lower Pgp efflux is also a significant benefit. The slightly lower BBB penetration isn't a major concern for a non-CNS primary target like ADRB2.
Output:
0
2025-04-17 20:38:02,399 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (370.421 and 340.383 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (69.64) is significantly better than Ligand B (97.12). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (2.043 and 1.179), falling within the optimal 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Both ligands have 2 H-bond donors, which is within the acceptable limit of <=5.
5. **HBA:** Ligand A has 4 H-bond acceptors, while Ligand B has 5. Both are acceptable (<=10), but A is slightly preferred.
6. **QED:** Both ligands have similar QED values (0.833 and 0.789), indicating good drug-likeness.
7. **DILI:** Ligand A (40.054) has a slightly better DILI score than Ligand B (55.293), indicating a lower risk of liver injury. This is a significant advantage.
8. **BBB:** Ligand A (82.241) has a much higher BBB penetration percentile than Ligand B (37.96). While not a primary concern for a cardiovascular target, higher BBB is rarely detrimental.
9. **Caco-2:** Ligand A (-4.944) has a better Caco-2 permeability than Ligand B (-5.705).
10. **Solubility:** Ligand A (-2.759) has better aqueous solubility than Ligand B (-1.146).
11. **hERG:** Ligand A (0.618) has a slightly better hERG inhibition profile than Ligand B (0.058), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand B (-16.733) has a lower (better) microsomal clearance than Ligand A (14.499), suggesting greater metabolic stability. This is a notable advantage for B.
13. **t1/2:** Ligand B (23.236) has a significantly longer in vitro half-life than Ligand A (-21.057). This is a major advantage for B, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.087) has a slightly better Pgp efflux profile than Ligand B (0.012), meaning it's less likely to be pumped out of cells.
15. **Binding Affinity:** Ligand A (-8.8 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.3 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME drawbacks of Ligand A.
**Overall Assessment:**
Ligand A has a clear advantage in binding affinity and generally better ADME properties (TPSA, solubility, DILI, hERG, Pgp, Caco-2). Ligand B's main strengths are its longer half-life and lower microsomal clearance. However, the magnitude of the affinity difference (-8.8 vs -6.3 kcal/mol) is substantial. For a GPCR target, strong binding is crucial. While metabolic stability is important, a longer half-life isn't as critical if the compound doesn't bind well to the receptor. The better overall ADME profile of Ligand A, combined with its superior binding affinity, makes it the more promising drug candidate.
Output:
1
2025-04-17 20:38:02,400 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, the key priorities are logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB (though less critical for a cardiovascular target).
Let's break down the comparison:
1. **MW:** Both ligands (346.435 and 342.399 Da) fall comfortably within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (91.95) is slightly higher than Ligand B (84.42). Both are acceptable, but Ligand B is preferable due to being closer to the <140 threshold for good absorption.
3. **logP:** Both ligands have good logP values (1.688 and 1.338), falling within the optimal 1-3 range. Ligand B is slightly better.
4. **HBD/HBA:** Both have 1 HBD, which is good. Ligand A has 6 HBA, while Ligand B has 5. Both are acceptable, but Ligand B is slightly better.
5. **QED:** Both ligands have good QED scores (0.776 and 0.835), indicating good drug-like properties.
6. **DILI:** Ligand A (27.608) has a significantly lower DILI risk than Ligand B (55.021). This is a major advantage for Ligand A.
7. **BBB:** Ligand A (75.301) has a better BBB penetration score than Ligand B (65.568), but this is less critical for a cardiovascular target.
8. **Caco-2:** Ligand A (-5.207) and Ligand B (-4.512) have negative Caco-2 values, which is unusual and suggests poor permeability.
9. **Solubility:** Ligand A (-1.474) has better solubility than Ligand B (-2.868).
10. **hERG:** Both ligands have very low hERG inhibition risk (0.08 and 0.091).
11. **Cl_mic:** Ligand A (12.578) has a much lower microsomal clearance than Ligand B (59.268), indicating better metabolic stability.
12. **t1/2:** Ligand B (-35.761) has a significantly longer in vitro half-life than Ligand A (6.526). This is a substantial advantage for Ligand B.
13. **Pgp:** Both ligands have low Pgp efflux liability (0.01 and 0.051).
14. **Binding Affinity:** Ligand B (-4.6 kcal/mol) has a significantly stronger binding affinity than Ligand A (-1.8 kcal/mol). This is a major advantage for Ligand B.
**Overall Assessment:**
The most critical factor is binding affinity, where Ligand B has a substantial advantage (-4.6 vs -1.8 kcal/mol). This difference is large enough to outweigh some of the drawbacks of Ligand B (higher DILI, shorter half-life). While Ligand A has a better safety profile (lower DILI) and metabolic stability (lower Cl_mic), the significantly stronger binding of Ligand B is paramount for a GPCR target. The longer half-life of Ligand B is also a significant benefit.
Output:
0
2025-04-17 20:38:02,400 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (360.384 and 347.415 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (66.29) is significantly better than Ligand B (105.66). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold. Ligand B is pushing it.
3. **logP:** Ligand A (0.74) is within the optimal 1-3 range, while Ligand B (-0.202) is slightly below 1. This is a significant negative for Ligand B, potentially impacting permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (4). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (6) is better than Ligand B (4). Lower HBA is generally preferred.
6. **QED:** Both ligands have reasonable QED scores (0.858 and 0.592), with Ligand A being better.
7. **DILI:** Ligand A (36.448) has a much lower DILI risk than Ligand B (11.981). This is a critical advantage for Ligand A.
8. **BBB:** Ligand A (76.425) has better BBB penetration than Ligand B (18.534). While not essential for a cardiovascular target, it's a positive attribute.
9. **Caco-2:** Both show poor Caco-2 permeability (-5.067 and -5.481), suggesting absorption issues.
10. **Solubility:** Both ligands have poor aqueous solubility (-1.829 and -1.799). This is a concern for both.
11. **hERG:** Ligand A (0.501) has a lower hERG inhibition liability than Ligand B (0.136), indicating a lower risk of cardiotoxicity.
12. **Cl_mic:** Ligand A (-22.793) has a lower (better) microsomal clearance than Ligand B (-10.259), suggesting greater metabolic stability.
13. **t1/2:** Ligand A (8.463) has a longer in vitro half-life than Ligand B (-12.7). This is a significant advantage.
14. **Pgp:** Ligand A (0.047) has lower P-gp efflux liability than Ligand B (0.004).
15. **Binding Affinity:** Ligand A (-9.9 kcal/mol) has a significantly stronger binding affinity than Ligand B (-3.7 kcal/mol). This is a *major* advantage, easily outweighing minor ADME concerns.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A excels in all these areas. While BBB isn't crucial here, it's still a positive.
**Overall Assessment:**
Ligand A is clearly superior. It has a much stronger binding affinity, better ADME properties (lower DILI, better metabolic stability, lower Pgp efflux, better BBB), and a more favorable physicochemical profile (TPSA, logP, HBD/HBA). While both have solubility and Caco-2 issues, the superior potency and safety profile of Ligand A make it the more promising drug candidate.
Output:
1
2025-04-17 20:38:02,400 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (370.316 and 375.42 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand B (71.84) is significantly better than Ligand A (105.56). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (3.163) is higher than Ligand A (1.361), but both are within the optimal 1-3 range. Ligand B is approaching the upper limit, but still acceptable.
4. **HBD:** Both ligands have 2 HBD, which is good.
5. **HBA:** Ligand A has 7 HBA, while Ligand B has 6. Both are acceptable, below the 10 threshold.
6. **QED:** Both ligands have similar QED values (0.721 and 0.78), indicating good drug-likeness.
7. **DILI:** Ligand B (77.045) has a lower DILI risk than Ligand A (96.161). This is a significant advantage.
8. **BBB:** Ligand B (76.425) has a higher BBB penetration than Ligand A (40.016). While not critical for a cardiovascular target, it's a slight positive for Ligand B.
9. **Caco-2:** Both ligands have very poor Caco-2 permeability (-5.148 and -5.14). This is a major concern for both.
10. **Solubility:** Both ligands have poor aqueous solubility (-3.446 and -3.978). This is also a concern for both.
11. **hERG:** Ligand A (0.143) has a lower hERG inhibition liability than Ligand B (0.617), which is preferable.
12. **Cl_mic:** Ligand B (56.972) has significantly lower microsomal clearance than Ligand A (6.557), indicating better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand B (32.043) has a longer in vitro half-life than Ligand A (-31.201). This is a significant advantage.
14. **Pgp:** Ligand A (0.096) has lower P-gp efflux liability than Ligand B (0.213), which is preferable.
15. **Binding Affinity:** Ligand B (-8.1 kcal/mol) has a slightly better binding affinity than Ligand A (-9.4 kcal/mol). While the difference is not huge, it is still a positive for Ligand B.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand B is better on logP, TPSA, and affinity. Pgp is slightly better for Ligand A.
**Overall Assessment:**
Ligand B demonstrates a superior balance of properties. It has lower DILI risk, better metabolic stability (lower Cl_mic, longer t1/2), better affinity, and a more favorable TPSA. While both have poor Caco-2 and solubility, the advantages of Ligand B outweigh the slightly better hERG and Pgp profiles of Ligand A. The improved metabolic stability and affinity are particularly important for a GPCR target.
Output:
0
2025-04-17 20:38:02,400 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for their potential as drug candidates targeting the ADRB2, a cardiovascular GPCR. Therefore, the key priorities are logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB.
Let's compare the ligands property by property:
1. **MW:** Both ligands (347.46 and 350.47 Da) fall within the ideal range of 200-500 Da.
2. **TPSA:** Ligand A (69.72) is significantly better than Ligand B (83.36). Lower TPSA generally favors oral absorption, a crucial aspect for a cardiovascular drug.
3. **logP:** Ligand A (1.149) is better than Ligand B (0.29). Both are within the acceptable range (1-3), but Ligand A is closer to the optimal range. Ligand B is quite low, potentially hindering membrane permeability.
4. **HBD/HBA:** Both have 1 HBD, which is good. Ligand B has 6 HBA, which is higher than Ligand A's 3. Higher HBA can sometimes negatively impact permeability.
5. **QED:** Ligand A (0.811) has a better QED score than Ligand B (0.692), indicating a more drug-like profile.
6. **DILI:** Ligand A (17.76) has a significantly lower DILI risk than Ligand B (19.04).
7. **BBB:** Ligand A (71.54) has a better BBB score than Ligand B (48.74). While not a primary concern for a cardiovascular target, higher BBB is generally favorable.
8. **Caco-2:** Ligand A (-4.896) is better than Ligand B (-5.399). Higher Caco-2 permeability suggests better intestinal absorption.
9. **Solubility:** Ligand A (-2.635) is better than Ligand B (0.001).
10. **hERG:** Ligand A (0.134) has a lower hERG risk than Ligand B (0.087).
11. **Cl_mic:** Ligand B (-12.52) has a much lower (better) microsomal clearance than Ligand A (10.66). This suggests better metabolic stability for Ligand B.
12. **t1/2:** Ligand A (3.792) has a longer half-life than Ligand B (1.563).
13. **Pgp:** Ligand A (0.053) has a lower Pgp efflux liability than Ligand B (0.012), suggesting better bioavailability.
14. **Binding Affinity:** Ligand A (-6.7 kcal/mol) has a slightly better binding affinity than Ligand B (-6.3 kcal/mol). While the difference is not huge, it's a positive for Ligand A.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical ADME properties (TPSA, logP, solubility, DILI, BBB, Pgp, Caco-2) and has a slightly better binding affinity. While Ligand B has superior metabolic stability (lower Cl_mic), the overall profile of Ligand A is more balanced and favorable for a cardiovascular GPCR drug candidate. The better permeability predictions (TPSA, logP, Caco-2) and lower toxicity risk (DILI, hERG) of Ligand A outweigh the metabolic stability advantage of Ligand B.
**Output:**
1
2025-04-17 20:38:02,400 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (348.487 and 367.559 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Both ligands have TPSA values around 58-59 A2, well below the 140 A2 threshold for good oral absorption. This is favorable for both.
**3. logP:** Ligand A (2.655) is closer to the optimal 1-3 range than Ligand B (3.867). While 3.867 isn't terrible, it's edging towards potential solubility issues and off-target interactions.
**4. H-Bond Donors:** Both have 1 HBD, which is good.
**5. H-Bond Acceptors:** Ligand A has 3 HBA, and Ligand B has 4. Both are acceptable, under the 10 threshold.
**6. QED:** Both ligands have QED values above 0.68, indicating good drug-likeness.
**7. DILI:** Ligand A (14.541) has a significantly lower DILI risk than Ligand B (23.304). This is a major advantage for Ligand A.
**8. BBB:** Ligand A (77.278) shows better BBB penetration potential than Ligand B (62.854). While ADRB2 is a cardiovascular target, some CNS effects are possible with certain ligands, and higher BBB penetration isn't necessarily detrimental.
**9. Caco-2 Permeability:** Ligand A (-4.785) shows better Caco-2 permeability than Ligand B (-5.389).
**10. Aqueous Solubility:** Ligand A (-2.16) has better aqueous solubility than Ligand B (-2.779).
**11. hERG Inhibition:** Ligand A (0.274) has a lower hERG inhibition liability than Ligand B (0.877), which is a significant safety advantage.
**12. Microsomal Clearance:** Ligand B (61.461) has a higher microsomal clearance than Ligand A (39.676), indicating lower metabolic stability.
**13. In vitro Half-Life:** Ligand A (-4.165) has a significantly longer in vitro half-life than Ligand B (-19.565). This is a substantial advantage for Ligand A.
**14. P-gp Efflux:** Ligand A (0.159) has lower P-gp efflux liability than Ligand B (0.298), which is favorable for bioavailability.
**15. Binding Affinity:** Ligand A (-7.7 kcal/mol) has a slightly better binding affinity than Ligand B (-6.5 kcal/mol). The difference is 1.2 kcal/mol, which is substantial enough to influence the decision.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical ADME-Tox parameters (DILI, hERG, Cl_mic, t1/2, Pgp, solubility, Caco-2). It also has a slightly better binding affinity. While Ligand B's logP is higher, the benefits of Ligand A's superior safety profile and pharmacokinetic properties outweigh this minor drawback. Given the GPCR target class, balancing logP with ADME properties is crucial, and Ligand A achieves this balance better.
Output:
1
2025-04-17 20:38:02,400 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (348.49 and 345.45 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (49.85) is significantly better than Ligand B (90.12). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold, while Ligand B is approaching it.
3. **logP:** Ligand A (3.10) is optimal, while Ligand B (0.82) is a bit low. For a GPCR, a logP between 1-3 is preferred for good membrane permeability and binding. Ligand B's low logP could hinder its ability to reach the receptor effectively.
4. **HBD:** Ligand A (0) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (4). Similar reasoning as HBD.
6. **QED:** Both ligands (0.78 and 0.74) have good drug-likeness scores, exceeding the 0.5 threshold.
7. **DILI:** Ligand A (25.17) has a much lower DILI risk than Ligand B (49.98). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (83.48) has better BBB penetration than Ligand B (54.48), though this isn't a primary concern for a cardiovascular target.
9. **Caco-2:** Ligand A (-4.38) is better than Ligand B (-5.48), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-2.87) is better than Ligand B (-2.49).
11. **hERG:** Ligand A (0.37) is significantly better than Ligand B (0.12), indicating a lower risk of cardiotoxicity. This is *critical* for a cardiovascular drug.
12. **Cl_mic:** Ligand A (83.23) is better than Ligand B (25.07), indicating better metabolic stability.
13. **t1/2:** Ligand A (-7.64) is better than Ligand B (0.97), indicating a longer half-life.
14. **Pgp:** Ligand A (0.49) is better than Ligand B (0.06), indicating lower P-gp efflux.
15. **Binding Affinity:** Ligand A (-6.6) is slightly better than Ligand B (-5.5), although the difference is not huge.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most crucial ADME-Tox properties, *especially* DILI and hERG inhibition, both of which are paramount for a cardiovascular drug. It also has better predicted permeability (Caco-2, TPSA, logP) and metabolic stability. While Ligand B has a reasonable QED and affinity, the significant liabilities in DILI and hERG risk make it a less attractive candidate. The slightly better affinity of Ligand A is a bonus.
Output:
1
2025-04-17 20:38:02,401 - INFO - Batch 199 complete. Total preferences: 3184
2025-04-17 20:38:02,401 - INFO - Processing batch 200/512...
2025-04-17 20:38:50,334 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (365.43 and 371.216 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (81.06) is slightly higher than Ligand B (71.84). Both are below the 140 threshold for good oral absorption, but closer to the 90 threshold for CNS targets (less relevant for ADRB2, a cardiovascular target). Ligand B is preferable.
3. **logP:** Ligand A (1.911) is within the optimal 1-3 range. Ligand B (3.971) is at the upper end, potentially increasing off-target effects or solubility issues. Ligand A is preferable.
4. **HBD:** Ligand A (1) is better than Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (5) is better than Ligand B (4). Lower HBA generally improves permeability.
6. **QED:** Ligand A (0.897) is significantly better than Ligand B (0.799), indicating a more drug-like profile.
7. **DILI:** Ligand B (81.427) has a higher DILI risk than Ligand A (71.772). Ligand A is preferable.
8. **BBB:** Both are fairly similar, but Ligand A (79.062) is slightly better than Ligand B (69.95). Not a major factor for ADRB2.
9. **Caco-2:** Ligand A (-4.716) is slightly better than Ligand B (-4.845), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-3.293) is slightly better than Ligand B (-4.777).
11. **hERG:** Both ligands have low hERG inhibition liability (0.401 and 0.416 respectively). No significant difference.
12. **Cl_mic:** Ligand A (15.257) has a lower microsomal clearance than Ligand B (19.796), suggesting better metabolic stability.
13. **t1/2:** Ligand A (66.987) has a longer in vitro half-life than Ligand B (57.82).
14. **Pgp:** Both ligands have low Pgp efflux liability (0.336 and 0.06 respectively). Ligand B is slightly better.
15. **Binding Affinity:** Ligand B (-6.3) has a slightly better binding affinity than Ligand A (-6.1). This is a 0.2 kcal/mol difference, which is not substantial enough to outweigh other factors.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. While Ligand B has slightly better affinity and Pgp, Ligand A excels in logP, TPSA, QED, DILI, Cl_mic, and t1/2. The combination of better drug-likeness, lower toxicity risk, and improved metabolic stability makes Ligand A the more promising candidate.
**Final Decision:**
Ligand A is the better candidate.
Output:
1
2025-04-17 20:38:50,335 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (344.323 and 353.409 Da) fall comfortably within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (58.56) is significantly lower than Ligand A (114.82). This is a major plus for Ligand B, as lower TPSA generally correlates with better cell permeability, crucial for GPCR targeting.
3. **logP:** Ligand B (3.495) is slightly higher than Ligand A (1.921), but both are within the optimal 1-3 range. Ligand B is closer to the upper limit, which could potentially introduce solubility issues, but is still acceptable.
4. **HBD:** Both ligands have 2 H-bond donors, which is within the desirable limit of <=5.
5. **HBA:** Ligand B (3) has fewer H-bond acceptors than Ligand A (7). This favors Ligand B, as fewer HBA generally improves permeability.
6. **QED:** Both ligands have good QED scores (0.814 and 0.851), indicating good drug-like properties. No significant difference.
7. **DILI:** Ligand B (37.34) has a much lower DILI risk than Ligand A (88.019). This is a substantial advantage for Ligand B, as minimizing liver toxicity is critical.
8. **BBB:** Ligand B (75.805) has a higher BBB penetration percentile than Ligand A (27.879). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be beneficial or at least less detrimental than complete lack of penetration. This favors Ligand B.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.852 and -4.872), which is unusual and suggests poor permeability. However, the values are very similar.
10. **Solubility:** Ligand B (-3.001) has slightly better solubility than Ligand A (-5.113).
11. **hERG:** Both ligands have low hERG inhibition risk (0.416 and 0.325). No significant difference.
12. **Cl_mic:** Ligand B (3.826) has significantly lower microsomal clearance than Ligand A (82.198). This indicates better metabolic stability for Ligand B, a major advantage.
13. **t1/2:** Ligand B (5.388) has a longer in vitro half-life than Ligand A (-12.579). This is a clear advantage for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.071 and 0.06). No significant difference.
15. **Binding Affinity:** Ligand A (-6.8) has slightly better binding affinity than Ligand B (-6.5). However, the difference is only 0.3 kcal/mol, which is not substantial enough to outweigh the numerous ADME advantages of Ligand B.
**GPCR-specific priorities:** Considering ADRB2 is a GPCR, TPSA, logP, Pgp, and affinity are key. Ligand B excels in TPSA, logP, and Pgp, and has a good affinity. While Ligand A has slightly better affinity, Ligand B's superior ADME profile (particularly DILI, Cl_mic, t1/2, and BBB) makes it the more promising candidate.
**Output:**
0
2025-04-17 20:38:50,335 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (363.864 and 355.507 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (38.13) is better than Ligand B (41.15) as it is closer to the <140 threshold for good oral absorption.
3. **logP:** Both ligands (4.354 and 4.992) are slightly above the optimal 1-3 range, but Ligand A is preferable as it is lower. High logP can lead to off-target effects.
4. **HBD:** Ligand A (0) is better than Ligand B (1). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (3) is better than Ligand B (4). Fewer HBAs generally improve permeability.
6. **QED:** Ligand A (0.791) is significantly better than Ligand B (0.411), indicating a more drug-like profile.
7. **DILI:** Ligand A (34.897) is much better than Ligand B (52.074), suggesting a lower risk of drug-induced liver injury.
8. **BBB:** Ligand A (93.563) is significantly better than Ligand B (65.297). While ADRB2 isn't strictly a CNS target, higher BBB penetration can still be beneficial for distribution and potentially reduce off-target effects.
9. **Caco-2:** Ligand A (-4.518) is better than Ligand B (-5.216), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-4.803) is slightly better than Ligand B (-4.428), although both are poor.
11. **hERG:** Ligand A (0.736) is better than Ligand B (0.933), suggesting a lower risk of cardiotoxicity. This is crucial for a cardiovascular target.
12. **Cl_mic:** Ligand A (77.841) is slightly better than Ligand B (73.432), indicating better metabolic stability.
13. **t1/2:** Ligand A (27.264) is significantly better than Ligand B (-14.739). A longer half-life is generally desirable.
14. **Pgp:** Ligand A (0.651) is better than Ligand B (0.788), indicating lower P-gp efflux.
15. **Binding Affinity:** Ligand A (-6.2) is slightly better than Ligand B (-5.5), but the difference is not substantial enough to outweigh the other factors.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Ligand A performs better across these parameters. The significantly better QED, DILI, BBB, and t1/2 profiles of Ligand A further solidify its advantage.
**Conclusion:**
Ligand A is the more promising drug candidate due to its superior ADME-Tox properties, better drug-likeness, and comparable binding affinity.
Output:
1
2025-04-17 20:38:50,335 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (367.427 Da) is within the ideal range (200-500 Da). Ligand B (428.689 Da) is also acceptable, but closer to the upper limit.
2. **TPSA:** Ligand A (99.93) is slightly above the preferred <140 for good absorption, but not drastically. Ligand B (77.24) is well within the acceptable range.
3. **logP:** Ligand A (0.399) is quite low, potentially hindering permeability. Ligand B (4.793) is high, potentially causing solubility and off-target issues.
4. **HBD:** Ligand A (1) is good. Ligand B (2) is also acceptable.
5. **HBA:** Ligand A (5) is good. Ligand B (4) is also good.
6. **QED:** Both ligands have acceptable QED values (A: 0.763, B: 0.686), indicating good drug-like properties.
7. **DILI:** Ligand A (66.111) is moderately risky, but acceptable. Ligand B (82.241) is higher risk, which is concerning.
8. **BBB:** Both have moderate BBB penetration (A: 54.44, B: 67.274). Since ADRB2 isn't a primary CNS target, this isn't a major deciding factor, but B is slightly better.
9. **Caco-2:** Ligand A (-5.205) is very poor, indicating very low intestinal absorption. Ligand B (-4.582) is also poor, but slightly better than A.
10. **Solubility:** Ligand A (-2.411) is poor. Ligand B (-5.945) is even worse.
11. **hERG:** Ligand A (0.238) has a low hERG risk, which is excellent. Ligand B (0.438) is slightly higher, but still relatively low.
12. **Cl_mic:** Ligand A (67.283) has a moderate clearance. Ligand B (52.213) has a lower clearance, suggesting better metabolic stability.
13. **t1/2:** Ligand A (33.342) has a moderate half-life. Ligand B (49.952) has a longer half-life, which is preferable.
14. **Pgp:** Ligand A (0.047) has low P-gp efflux, which is good. Ligand B (0.397) has higher P-gp efflux, which is less desirable.
15. **Affinity:** Ligand B (-7.0 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.8 kcal/mol). This is a substantial advantage.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B excels in affinity, has a better logP (though still high), and a slightly better TPSA. While its Pgp efflux is higher, the substantial affinity difference is a major advantage. The higher DILI risk for Ligand B is a concern, but can potentially be mitigated through structural modifications. The poor solubility and Caco-2 values for both are problematic, but could be addressed with formulation strategies.
**Overall Assessment:**
Despite the higher DILI risk and slightly worse solubility, Ligand B's significantly stronger binding affinity (-7.0 vs -5.8 kcal/mol) outweighs the drawbacks. The affinity difference is large enough to potentially overcome the ADME challenges.
Output:
0
2025-04-17 20:38:50,335 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
The ADRB2 receptor is a GPCR, so the priorities are logP, Pgp, TPSA, affinity, and, to a lesser extent, BBB. Let's break down the comparison:
1. **Molecular Weight:** Both ligands are within the ideal 200-500 Da range. Ligand A (383.539 Da) is slightly higher than Ligand B (368.499 Da), but this isn't a major concern.
2. **TPSA:** Ligand B (76.66) is better than Ligand A (92.5). Both are below 140, but lower TPSA generally favors better absorption.
3. **logP:** Ligand B (2.123) is better than Ligand A (0.803). Ligand A is a bit low, potentially hindering membrane permeability. Ligand B is within the optimal 1-3 range.
4. **H-Bond Donors:** Both have 2 HBD, which is good.
5. **H-Bond Acceptors:** Both have 5 HBA, which is good.
6. **QED:** Both are very similar (0.733 and 0.737), indicating good drug-like properties.
7. **DILI:** Ligand A (20.861) is significantly better than Ligand B (46.142). This is a major advantage for Ligand A, as lower DILI risk is crucial.
8. **BBB:** Both are relatively low, but Ligand B (59.519) is slightly better than Ligand A (56.65). BBB isn't a huge priority for ADRB2, which is primarily a cardiovascular target.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-5.498) is slightly better than Ligand B (-5.086).
10. **Solubility:** Both are negative, indicating poor solubility. Ligand A (-3.062) is slightly better than Ligand B (-2.23).
11. **hERG:** Ligand A (0.116) is better than Ligand B (0.444), indicating a lower risk of cardiotoxicity.
12. **Cl_mic:** Ligand A (13.851) is significantly better than Ligand B (27.438). Lower clearance means greater metabolic stability.
13. **t1/2:** Ligand B (29.188) is much better than Ligand A (-14.148). A longer half-life is generally preferred.
14. **Pgp:** Both are very low (0.014 and 0.116), indicating low P-gp efflux.
15. **Binding Affinity:** Ligand A (-6.0) is slightly better than Ligand B (-5.4). While the difference isn't huge, it's enough to consider.
**Overall Assessment:**
Ligand A has a clear advantage in several critical areas: DILI risk, metabolic stability (Cl_mic), hERG risk, and binding affinity. While Ligand B has a better logP and half-life, the lower DILI and hERG risks associated with Ligand A are more important for a cardiovascular target. The slightly better affinity of Ligand A further strengthens its position. The poor Caco-2 and solubility of both compounds are concerns, but these can be addressed through formulation strategies.
**Output:**
1
2025-04-17 20:38:50,335 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (351.451 and 346.515 Da) fall comfortably within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (128.32) is slightly higher than Ligand B (49.41). For a cardiovascular GPCR, TPSA isn't *as* critical as for CNS targets, but lower is generally preferred for permeability. Ligand B has a significant advantage here.
3. **logP:** Ligand A (0.73) is below the optimal 1-3 range, potentially hindering permeability. Ligand B (3.666) is at the upper end but still acceptable. Ligand B is better.
4. **HBD:** Ligand A (3) is within the acceptable limit of 5. Ligand B (1) is also good. No significant difference.
5. **HBA:** Ligand A (4) is within the acceptable limit of 10. Ligand B (2) is also good. No significant difference.
6. **QED:** Both ligands have good QED scores (0.557 and 0.746), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (29.081) has a much lower DILI risk than Ligand B (6.592), which is a crucial advantage.
8. **BBB:** Ligand A (68.127) has a moderate BBB penetration, while Ligand B (85.111) is higher. While ADRB2 isn't a CNS target, some distribution to the CNS is possible, and higher BBB is generally favorable. Ligand B is better.
9. **Caco-2:** Ligand A (-5.304) and Ligand B (-4.852) are both negative, indicating poor permeability.
10. **Solubility:** Ligand A (-1.982) and Ligand B (-3.459) are both very poor. Solubility is a concern for both.
11. **hERG:** Both ligands have low hERG inhibition risk (0.473 and 0.532), which is good. No significant difference.
12. **Cl_mic:** Ligand A (-9.502) has a much lower (better) microsomal clearance than Ligand B (36.358), indicating better metabolic stability.
13. **t1/2:** Ligand A (4.523) has a shorter half-life than Ligand B (-14.278), which is a disadvantage.
14. **Pgp:** Both ligands have low P-gp efflux (0.018 and 0.157), which is good. Ligand A is slightly better.
15. **Affinity:** Ligand A (-6.9 kcal/mol) has a slightly better binding affinity than Ligand B (-6.4 kcal/mol). This is a significant advantage, as a 0.5 kcal/mol difference can be meaningful.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand B initially appears better due to its higher logP, BBB, and lower TPSA. However, Ligand A has a substantially lower DILI risk and better metabolic stability (lower Cl_mic). The slightly better affinity of Ligand A is also a significant plus. The solubility and Caco-2 values are poor for both, but these can be addressed with formulation strategies. The lower DILI risk and better metabolic stability of Ligand A are more critical for long-term drug development.
**Output:**
1
2025-04-17 20:38:50,335 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.333 and 343.427 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (78.62) is slightly higher than Ligand B (75.44). Both are below the 140 A^2 threshold for good oral absorption, and acceptable for a cardiovascular GPCR.
3. **logP:** Ligand A (3.01) is at the higher end of the optimal range (1-3), while Ligand B (2.164) is closer to the lower end. Ligand A's logP is still acceptable, but B is slightly preferred here.
4. **HBD:** Both ligands have 1 HBD, which is well within the acceptable limit of <=5.
5. **HBA:** Ligand A has 5 HBA, and Ligand B has 4. Both are below the 10 limit.
6. **QED:** Ligand B (0.85) has a significantly better QED score than Ligand A (0.641), indicating a more drug-like profile. This is a notable advantage for B.
7. **DILI:** Ligand B (48.817) has a much lower DILI risk than Ligand A (77.162). This is a significant advantage for B, as lower DILI is crucial.
8. **BBB:** Ligand B (81.349) has a higher BBB penetration percentile than Ligand A (73.129). While ADRB2 isn't a CNS target, higher BBB is generally favorable, indicating less promiscuous distribution.
9. **Caco-2:** Ligand A (-4.466) and Ligand B (-5.01) both have negative Caco-2 values which is unusual and indicates very poor permeability. This is a significant drawback for both.
10. **Solubility:** Ligand B (-2.784) has better solubility than Ligand A (-5.728). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.789) has a slightly higher hERG risk than Ligand B (0.289). Lower hERG risk is highly desirable, favoring B.
12. **Cl_mic:** Ligand A (85.597) has a higher microsomal clearance than Ligand B (60.749), meaning it's metabolized faster. Lower clearance is preferred for longer duration of action. B is favored here.
13. **t1/2:** Ligand B (-30.966) has a significantly longer in vitro half-life than Ligand A (17.594). This is a substantial advantage for B.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.398 and 0.311 respectively).
15. **Binding Affinity:** Ligand B (-7.3) has a slightly better binding affinity than Ligand A (-7.0). While the difference is small, it's still a positive for B.
**Overall Assessment:**
Ligand B consistently outperforms Ligand A across most critical ADME-Tox parameters. It has a better QED score, significantly lower DILI risk, better solubility, lower hERG risk, lower microsomal clearance, a longer half-life, and slightly better binding affinity. While both have poor Caco-2 permeability, the other advantages of Ligand B outweigh this drawback. Given the GPCR target class, the balance of properties in Ligand B is more favorable for development.
Output:
0
2025-04-17 20:38:50,335 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [360.336, 76.46, 1.531, 1, 5, 0.617, 52.423, 88.523, -4.833, -2.639, 0.164, 4.327, -24.296, 0.031, -6.4]
**Ligand B:** [343.427, 74.59, 1.814, 1, 5, 0.779, 33.618, 46.064, -4.74, -1.971, 0.448, 53.815, 32.132, 0.047, -6.4]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (343.427) is slightly lower, which is generally favorable for permeability, but both are acceptable.
2. **TPSA:** Both are below 140, good for oral absorption. Ligand A (76.46) is slightly higher than Ligand B (74.59), but both are good.
3. **logP:** Both are within the optimal range (1-3). Ligand B (1.814) is slightly higher, which *could* be a minor advantage, but both are good.
4. **HBD:** Both have 1 HBD, which is ideal.
5. **HBA:** Both have 5 HBA, which is ideal.
6. **QED:** Both are above 0.5, indicating good drug-likeness. Ligand B (0.779) is slightly better.
7. **DILI:** Ligand B (33.618) has a significantly lower DILI risk than Ligand A (52.423). This is a major advantage for Ligand B.
8. **BBB:** Ligand A (88.523) has a much higher BBB penetration potential than Ligand B (46.064). For a cardiovascular target like ADRB2, BBB penetration isn't *critical* but can be beneficial for off-target effects or potential CNS side effects.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. Ligand A (-4.833) is slightly worse than Ligand B (-4.74).
10. **Solubility:** Both have negative solubility values, indicating poor solubility. Ligand B (-1.971) is slightly better than Ligand A (-2.639).
11. **hERG:** Both have low hERG inhibition liability, which is good. Ligand A (0.164) is slightly better.
12. **Cl_mic:** Ligand A (4.327) has a lower microsomal clearance, indicating better metabolic stability than Ligand B (53.815). This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (-24.296) has a much longer in vitro half-life than Ligand B (32.132). This is a significant advantage for Ligand A.
14. **Pgp:** Both have very low Pgp efflux liability, which is good.
15. **Affinity:** Both have the same binding affinity (-6.4 kcal/mol).
**GPCR-Specific Priorities:** For GPCRs, logP, TPSA, Pgp, and affinity are important. BBB is less critical unless targeting a CNS GPCR.
**Overall Assessment:**
Ligand A has a significant advantage in metabolic stability (lower Cl_mic) and half-life, and a better BBB score. However, Ligand B has a much lower DILI risk, which is a critical safety parameter. Both have similar affinity and acceptable logP and TPSA values. The poor Caco-2 and solubility for both are concerning, but can be addressed in formulation.
Considering the balance, the lower DILI risk of Ligand B is a more important factor than the slightly better metabolic stability and BBB penetration of Ligand A, especially for a cardiovascular target.
Output:
0
2025-04-17 20:38:50,335 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.371 and 361.467 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand B (59.98) is significantly better than Ligand A (108.81). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (0.971) is slightly lower than the optimal 1-3 range, while Ligand B (3.611) is at the higher end but still acceptable. Ligand B has a better logP for GPCR targets.
4. **HBD:** Ligand A (2) is preferable to Ligand B (0). Having some HBDs can improve solubility.
5. **HBA:** Both ligands have 6 HBA, which is within the acceptable range.
6. **QED:** Ligand A (0.806) has a better QED score than Ligand B (0.645), indicating a more drug-like profile.
7. **DILI:** Both ligands have similar DILI risk (53.005 and 57.774), both are acceptable.
8. **BBB:** Ligand B (58.976) has a higher BBB penetration score than Ligand A (27.646), but this is less critical for a cardiovascular target.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-5.078) is slightly better than Ligand B (-4.822).
10. **Solubility:** Ligand A (-1.993) has better solubility than Ligand B (-3.034).
11. **hERG:** Ligand A (0.152) has a much lower hERG inhibition liability than Ligand B (0.79), which is a significant advantage.
12. **Cl_mic:** Ligand A (19.564) has a much lower microsomal clearance than Ligand B (83.618), indicating better metabolic stability.
13. **t1/2:** Ligand B (61.072) has a much longer in vitro half-life than Ligand A (-2.816), which is a significant advantage.
14. **Pgp:** Ligand A (0.034) has a much lower P-gp efflux liability than Ligand B (0.807), which is a significant advantage.
15. **Binding Affinity:** Ligand B (-6.8) has a slightly better binding affinity than Ligand A (-5.9). This is a 0.9 kcal/mol difference, which is a reasonable advantage.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP and affinity, while Ligand A is better in TPSA and Pgp. However, the significant advantages of Ligand A in hERG inhibition, microsomal clearance, and P-gp efflux outweigh the slightly better affinity of Ligand B. The negative Caco-2 values for both are concerning, but Ligand A is slightly better.
**Conclusion:**
Considering the balance of properties, particularly the lower hERG risk, better metabolic stability (lower Cl_mic), and lower P-gp efflux for Ligand A, it is the more promising drug candidate.
Output:
1
2025-04-17 20:38:50,335 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (349.289 Da and 342.399 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (92.7) is slightly higher than Ligand B (80.37). Both are below the 140 A^2 threshold for good oral absorption, but Ligand B is preferable due to the lower TPSA.
**3. logP:** Ligand A (3.127) is within the optimal 1-3 range. Ligand B (1.202) is on the lower end, potentially impacting permeability. Ligand A is favored here.
**4. H-Bond Donors:** Ligand A (2) and Ligand B (1) are both acceptable, below the threshold of 5. Ligand B is slightly better.
**5. H-Bond Acceptors:** Ligand A (4) and Ligand B (5) are both acceptable, below the threshold of 10. No significant difference.
**6. QED:** Both ligands have good QED scores (0.809 and 0.905), indicating good drug-like properties. Ligand B is slightly better.
**7. DILI Risk:** Ligand A (99.38) has a very high DILI risk, which is a major concern. Ligand B (56.805) is significantly better, falling within an acceptable range. This is a critical advantage for Ligand B.
**8. BBB Penetration:** BBB is less critical for a cardiovascular target like ADRB2, but Ligand A (18.379) is significantly lower than Ligand B (55.603).
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.727) is slightly better than Ligand B (-5.256).
**10. Aqueous Solubility:** Both ligands have negative solubility values, which is also unusual and suggests poor solubility. Ligand A (-4.158) is slightly better than Ligand B (-1.957).
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.067 and 0.138), which is excellent. No significant difference.
**12. Microsomal Clearance:** Ligand A (10.168) has lower clearance than Ligand B (17.974), indicating better metabolic stability. Ligand A is favored.
**13. In vitro Half-Life:** Ligand B (34.906) has a significantly longer half-life than Ligand A (14.809), which is desirable. Ligand B is favored.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.048 and 0.025), which is excellent. No significant difference.
**15. Binding Affinity:** Ligand B (-7.8 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.9 kcal/mol). This is a substantial advantage for Ligand B.
**Overall Assessment:**
While Ligand A has some advantages in logP and metabolic stability, the significantly higher DILI risk is a major red flag. Ligand B demonstrates a much more favorable safety profile (lower DILI), a stronger binding affinity, and a longer half-life. The slightly lower logP is a manageable concern, and can be addressed with further optimization. Considering the GPCR-specific priorities (affinity, logP, Pgp, TPSA), Ligand B is the superior candidate.
Output:
0
2025-04-17 20:38:50,336 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (357.4 and 354.4 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (110.01) is slightly higher than Ligand B (103.63). Both are below the 140 threshold for oral absorption, but closer to the upper limit for GPCRs.
3. **logP:** Ligand A (2.325) is optimal, while Ligand B (-0.246) is quite low. This is a significant difference. Low logP can hinder membrane permeability and bioavailability.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable, well below the 5 threshold.
5. **HBA:** Ligand A (7) and Ligand B (9) are both acceptable, under the 10 threshold.
6. **QED:** Both ligands (0.725 and 0.715) have excellent drug-likeness scores.
7. **DILI:** Ligand A (91.86) has a higher DILI risk than Ligand B (47.69). This is a concern for Ligand A.
8. **BBB:** Ligand B (74.098) has a significantly higher BBB penetration score than Ligand A (53.781). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be beneficial or at least needs to be understood.
9. **Caco-2:** Ligand A (-5.299) and Ligand B (-4.894) are both negative, indicating poor permeability.
10. **Solubility:** Ligand A (-3.907) and Ligand B (-0.765) are both negative, indicating poor solubility. Ligand B is better here.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.272 and 0.044).
12. **Cl_mic:** Ligand B (10.556) has a much lower microsomal clearance than Ligand A (54.184), suggesting better metabolic stability.
13. **t1/2:** Ligand B (6.05) has a slightly better in vitro half-life than Ligand A (45.861).
14. **Pgp:** Both ligands have low P-gp efflux liability (0.125 and 0.025).
15. **Binding Affinity:** Ligand A (-8.4) has a significantly stronger binding affinity than Ligand B (-7.0). This is a substantial advantage.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand A has a better logP and significantly better affinity. However, Ligand B has better BBB, lower DILI, and better metabolic stability (lower Cl_mic and longer t1/2). The affinity difference is substantial (>1.5 kcal/mol), and this outweighs the other drawbacks of Ligand A.
**Conclusion:**
Despite the higher DILI risk and lower BBB penetration of Ligand A, its significantly stronger binding affinity makes it the more promising candidate. The affinity advantage is substantial enough to warrant further optimization to address the DILI and permeability concerns.
Output:
1
2025-04-17 20:38:50,336 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (342.443 and 353.463 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Both ligands (75.19 and 78.95) are below the 140 A^2 threshold for good oral absorption, and acceptable for a cardiovascular target (not CNS). Ligand B is slightly higher, but still good.
3. **logP:** Both ligands (1.71 and 1.762) are within the optimal 1-3 range. Excellent for both.
4. **HBD:** Both ligands have 1 HBD, which is well within the acceptable limit of <=5.
5. **HBA:** Both ligands have 4 HBA, also well within the acceptable limit of <=10.
6. **QED:** Ligand B (0.789) has a significantly better QED score than Ligand A (0.548), indicating a more drug-like profile.
7. **DILI:** Ligand B (29.236) has a much lower DILI risk than Ligand A (35.169). This is a significant advantage for Ligand B.
8. **BBB:** While not a primary concern for a cardiovascular target, Ligand B (83.908) has a higher BBB penetration percentile than Ligand A (58.821).
9. **Caco-2:** Ligand A (-5.205) has a worse Caco-2 permeability than Ligand B (-4.546), suggesting lower intestinal absorption.
10. **Solubility:** Ligand A (-0.936) has better aqueous solubility than Ligand B (-2.412). This is a slight advantage for Ligand A.
11. **hERG:** Both ligands (0.293 and 0.416) have low hERG inhibition liability, which is good.
12. **Cl_mic:** Ligand A (5.654) has significantly lower microsomal clearance than Ligand B (43.671), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand B (-29.896) has a much longer in vitro half-life than Ligand A (-11.247). This is a major advantage for Ligand B.
14. **Pgp:** Both ligands (0.036 and 0.069) have low P-gp efflux liability, which is good.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.5 and -6.4 kcal/mol). The difference is negligible.
**GPCR-specific priorities:** For ADRB2 (a GPCR), we prioritize logP, Pgp, TPSA, and affinity. Both ligands perform well on logP, Pgp, and TPSA. Affinity is nearly identical. Therefore, the decision hinges on the ADME properties.
**Overall Assessment:**
Ligand B has a significantly better QED score, lower DILI risk, higher BBB penetration, better Caco-2 permeability, and a much longer half-life. While Ligand A has better metabolic stability (lower Cl_mic) and solubility, the advantages of Ligand B in terms of drug-likeness, safety (DILI), and pharmacokinetics (t1/2) outweigh these benefits. The longer half-life of Ligand B is particularly important, potentially allowing for less frequent dosing.
**Output:**
0
2025-04-17 20:38:50,336 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.418 and 349.435 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (75.27) is significantly better than Ligand B (118.4). For a GPCR, keeping TPSA lower is beneficial for permeability. Ligand B is pushing the upper limit for good oral absorption.
3. **logP:** Ligand A (3.117) is optimal, while Ligand B (1.737) is on the lower side. A logP between 1-3 is preferred, and Ligand A is closer to the sweet spot.
4. **HBD:** Both ligands have 2 HBD, which is within the acceptable range (<=5).
5. **HBA:** Ligand A has 3 HBA, Ligand B has 4. Both are within the acceptable range (<=10).
6. **QED:** Ligand A (0.829) has a much better QED score than Ligand B (0.205), indicating a more drug-like profile. This is a substantial advantage for Ligand A.
7. **DILI:** Ligand A (40.442) is slightly higher than Ligand B (15.2), but both are below the concerning threshold of 60. Ligand B is clearly preferable here.
8. **BBB:** Ligand A (82.823) has a much higher BBB penetration percentile than Ligand B (17.642). While ADRB2 isn't *strictly* a CNS target, some CNS exposure could be relevant depending on the specific therapeutic application, and higher BBB is generally favorable.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not defined, so it is difficult to interpret.
10. **Solubility:** Ligand A (-3.013) and Ligand B (-1.346) both have negative solubility values, indicating poor aqueous solubility. This is a concern for both.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.164 and 0.162). This is excellent.
12. **Cl_mic:** Ligand B (-3.423) has a *much* lower (better) microsomal clearance than Ligand A (32.942). This suggests significantly better metabolic stability for Ligand B.
13. **t1/2:** Ligand B (-3.232) has a negative in vitro half-life, which is unusual. Ligand A (9.685) has a reasonable half-life.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.13 and 0.039).
15. **Binding Affinity:** Ligand A (-8.1 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.5 kcal/mol). This is a substantial advantage, potentially outweighing some ADME concerns.
**Overall Assessment & GPCR Prioritization:**
For a GPCR like ADRB2, affinity, logP, TPSA, and metabolic stability are key. Ligand A excels in affinity and logP, and has a better TPSA. Ligand B has a much better DILI score and Cl_mic. However, the large difference in binding affinity (-8.1 vs -6.5) is a major factor. A 1.6 kcal/mol difference is substantial and suggests Ligand A will be more potent. The better QED and BBB penetration of Ligand A are also positives. While the solubility and Caco-2 values are concerning for both, the superior binding affinity and overall drug-like properties of Ligand A make it the more promising candidate.
Output:
1
2025-04-17 20:38:50,336 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (349.391 Da and 355.563 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (120.54) is higher than Ligand B (60.77). For a cardiovascular GPCR, TPSA is moderately important. Ligand B's lower TPSA is preferable, suggesting better permeability.
**3. logP:** Ligand A (1.643) is within the optimal 1-3 range. Ligand B (4.134) is slightly above this range, potentially leading to solubility issues and off-target interactions. This favors Ligand A.
**4. H-Bond Donors:** Ligand A (1) and Ligand B (2) are both acceptable, being less than 5.
**5. H-Bond Acceptors:** Ligand A (5) and Ligand B (3) are both acceptable, being less than 10.
**6. QED:** Ligand B (0.619) has a better QED score than Ligand A (0.435), indicating a more drug-like profile.
**7. DILI:** Ligand A (30.516) has a significantly lower DILI risk than Ligand B (12.02). This is a crucial advantage for Ligand A.
**8. BBB:** Ligand B (80.69) has a much higher BBB penetration percentile than Ligand A (43.815). While ADRB2 is a cardiovascular target, some CNS effects are possible with beta-blockers, and higher BBB penetration could be beneficial or detrimental depending on the desired profile.
**9. Caco-2 Permeability:** Ligand A (-4.931) and Ligand B (-4.25) both have negative values, which is unusual. This suggests poor permeability. However, the scale isn't specified, so it's hard to interpret.
**10. Aqueous Solubility:** Ligand A (-1.427) and Ligand B (-3.748) both have negative values, indicating poor solubility. Ligand B is worse.
**11. hERG Inhibition:** Ligand A (0.109) has a much lower hERG inhibition risk than Ligand B (0.855). This is a significant safety advantage for Ligand A.
**12. Microsomal Clearance:** Ligand B (71.809) has a much higher microsomal clearance than Ligand A (11.336), indicating faster metabolism and potentially lower bioavailability. This favors Ligand A.
**13. In vitro Half-Life:** Ligand B (20.425) has a longer in vitro half-life than Ligand A (9.34). This is a positive for Ligand B.
**14. P-gp Efflux:** Ligand A (0.017) has a much lower P-gp efflux liability than Ligand B (0.668). This is an advantage for Ligand A, improving bioavailability.
**15. Binding Affinity:** Ligand A (-7.2) has a slightly better binding affinity than Ligand B (-6.0). While the difference is not huge, it's enough to consider, especially given the other factors.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity) and the general drug-like properties, Ligand A is the more promising candidate. While Ligand B has better BBB penetration and in vitro half-life, Ligand A excels in crucial areas like DILI risk, hERG inhibition, P-gp efflux, and metabolic stability (lower Cl_mic). The slightly better affinity of Ligand A further supports this conclusion. The lower logP of Ligand A is also preferable.
Output:
1
2025-04-17 20:38:50,336 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [348.403, 93.53, 0.342, 1, 6, 0.717, 37.611, 60.062, -4.713, -1.819, 0.223, 50.601, -19.091, 0.016, -4.3]
**Ligand B:** [352.475, 98.66, 0.811, 4, 4, 0.545, 16.479, 30.554, -5.206, -2.404, 0.216, 4.492, 16.311, 0.049, -6.1]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity):
1. **MW:** Both are within the ideal range (200-500 Da). A is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are acceptable (below 140), but A (93.53) is better than B (98.66) for oral absorption.
3. **logP:** A (0.342) is quite low, potentially hindering membrane permeability. B (0.811) is better, falling closer to the optimal 1-3 range. This is a significant advantage for B.
4. **HBD/HBA:** A (1 HBD, 6 HBA) is better than B (4 HBD, 4 HBA) in terms of balancing solubility and permeability.
5. **QED:** A (0.717) is better than B (0.545), indicating a more drug-like profile.
6. **DILI:** A (37.611) is better than B (16.479), indicating a lower risk of liver injury.
7. **BBB:** A (60.062) is better than B (30.554), although neither is particularly high. For a cardiovascular target, BBB penetration isn't *critical*, but it's a bonus.
8. **Caco-2:** A (-4.713) is better than B (-5.206), indicating better intestinal absorption.
9. **Solubility:** A (-1.819) is better than B (-2.404), which is important for bioavailability.
10. **hERG:** Both are very low risk (0.223 and 0.216).
11. **Cl_mic:** A (50.601) is higher than B (4.492), suggesting faster metabolism and lower metabolic stability. B is significantly better here.
12. **t1/2:** A (-19.091) is worse than B (16.311), indicating a shorter half-life. B is significantly better here.
13. **Pgp:** Both are very low efflux (0.016 and 0.049).
14. **Affinity:** B (-6.1 kcal/mol) is significantly better than A (-4.3 kcal/mol). This is a >1.5 kcal/mol advantage, which can outweigh other drawbacks.
**Overall Assessment:**
Ligand B has a clear advantage in binding affinity, which is paramount for GPCR targets. While Ligand A has better QED, solubility, and DILI, the significantly better affinity and metabolic stability (lower Cl_mic, longer t1/2) of Ligand B outweigh these advantages. The slightly higher logP of Ligand B is also beneficial for permeability.
Therefore, I prefer Ligand B.
0
2025-04-17 20:38:50,336 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's break down the comparison of Ligand A and Ligand B based on the provided parameters and the guidelines, keeping in mind this is a GPCR target (ADRB2, cardiovascular). GPCRs prioritize logP, Pgp, TPSA, and affinity.
1. **Molecular Weight:** Both ligands are within the ideal range (365-386 Da). No significant difference here.
2. **TPSA:** Ligand B (61.44) is significantly better than Ligand A (73.74). Lower TPSA generally improves permeability, which is crucial for GPCR ligands.
3. **logP:** Both ligands have excellent logP values (2.411 and 2.318), falling within the optimal 1-3 range. Very similar.
4. **H-Bond Donors:** Ligand A has 1 HBD, while Ligand B has 2. Both are acceptable, but lower is slightly preferred.
5. **H-Bond Acceptors:** Ligand A has 5 HBA, and Ligand B has 3. Both are within the acceptable range (<=10).
6. **QED:** Ligand A (0.867) has a substantially better QED score than Ligand B (0.625), indicating a more drug-like profile.
7. **DILI:** Ligand B (18.34) has a much lower DILI risk than Ligand A (50.795). This is a significant advantage for Ligand B.
8. **BBB:** Ligand B (85.111) has a much higher BBB penetration percentile than Ligand A (49.864). While ADRB2 isn't necessarily a CNS target, higher BBB penetration can sometimes correlate with better overall distribution and reduced off-target effects.
9. **Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual. This suggests poor permeability. However, the values are very close (-4.713 vs -4.69).
10. **Aqueous Solubility:** Ligand B (-2.268) is slightly better than Ligand A (-3.243), but both are poor. Solubility is a concern for both.
11. **hERG Inhibition:** Ligand A (0.384) has a lower hERG inhibition liability than Ligand B (0.535), which is preferable.
12. **Microsomal Clearance:** Ligand A (18.256) has a lower microsomal clearance than Ligand B (34.496), suggesting better metabolic stability.
13. **In vitro Half-Life:** Ligand A (8.607 hours) has a significantly longer half-life than Ligand B (-18.928 hours). This is a major advantage for Ligand A.
14. **P-gp Efflux:** Ligand A (0.371) has lower P-gp efflux liability than Ligand B (0.031). Lower efflux is generally better.
15. **Binding Affinity:** Ligand A (-6.8 kcal/mol) has slightly better binding affinity than Ligand B (-6.4 kcal/mol). While the difference is not huge, it's still a positive for Ligand A.
**Overall Assessment:**
Ligand B excels in TPSA, DILI, and BBB penetration, which are all important for a GPCR ligand. However, Ligand A has a significantly better QED score, longer half-life, lower P-gp efflux, and slightly better affinity. The lower DILI risk of Ligand B is attractive, but the superior overall drug-like properties and metabolic stability of Ligand A are more compelling. The slightly better affinity of Ligand A also contributes to its preference.
Output:
1
2025-04-17 20:38:50,336 - INFO - Batch 200 complete. Total preferences: 3200
2025-04-17 20:38:50,336 - INFO - Processing batch 201/512...
2025-04-17 20:39:38,457 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (357.574 and 355.435 Da) are within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (44.37) is significantly better than Ligand B (110.18). ADRB2 is a cardiovascular target, not CNS, but lower TPSA generally improves absorption. Ligand A is well below the 140 cutoff, while Ligand B is approaching a concerning level.
3. **logP:** Ligand A (4.287) is higher than the optimal range (1-3), but still potentially manageable. Ligand B (-1.254) is *too* low, which could severely hinder membrane permeability and bioavailability. This is a significant strike against Ligand B.
4. **HBD:** Ligand A (2) and Ligand B (3) are both acceptable, being less than 5.
5. **HBA:** Ligand A (2) is better than Ligand B (6). Lower HBA is generally preferred for permeability.
6. **QED:** Ligand A (0.793) is significantly better than Ligand B (0.526), indicating a more drug-like profile.
7. **DILI:** Ligand A (33.773) has a much lower DILI risk than Ligand B (16.906). This is a crucial safety parameter.
8. **BBB:** Not a primary concern for a cardiovascular target like ADRB2, but Ligand A (74.176) is better than Ligand B (14.541).
9. **Caco-2:** Ligand A (-4.843) and Ligand B (-5.386) are both negative, which is unusual. It suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Ligand A (-4.876) and Ligand B (-0.031) are both negative, indicating poor solubility. Ligand B is slightly better.
11. **hERG:** Ligand A (0.757) is better than Ligand B (0.017), indicating a lower risk of cardiotoxicity. This is *very* important for a cardiovascular target.
12. **Cl_mic:** Ligand A (39.694) has a better (lower) microsomal clearance than Ligand B (-10.156), suggesting greater metabolic stability.
13. **t1/2:** Ligand A (30.23) has a much longer in vitro half-life than Ligand B (-18.54).
14. **Pgp:** Ligand A (0.311) has a lower Pgp efflux liability than Ligand B (0.004), suggesting better bioavailability.
15. **Binding Affinity:** Ligand A (-7.6) has a slightly better binding affinity than Ligand B (-6.5), though the difference is not huge.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical parameters. While Ligand A's logP is a bit high, the significantly better TPSA, QED, DILI, hERG, Cl_mic, t1/2, and Pgp profiles, combined with acceptable binding affinity, make it the far more promising candidate. Ligand B's very low logP and higher DILI/hERG risks are major red flags.
Output:
1
2025-04-17 20:39:38,458 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (351.372 and 361.427 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (45.23) is significantly better than Ligand B (106.1). ADRB2 is a cardiovascular target, not necessarily CNS, but lower TPSA generally improves absorption. Ligand A is well below the 140 threshold, while B is approaching it.
3. **logP:** Ligand A (4.419) is higher than Ligand B (0.693). While 4.419 is approaching the upper limit, it's still within a reasonable range. Ligand B's logP is quite low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (1) is better than Ligand B (2). Lower is generally preferred.
5. **HBA:** Ligand A (3) is better than Ligand B (7). Lower is generally preferred.
6. **QED:** Both are similar (0.867 and 0.812) and above the 0.5 threshold, indicating good drug-likeness.
7. **DILI:** Ligand A (54.13) is significantly better than Ligand B (83.404). Lower DILI risk is crucial. Ligand B is approaching a concerning level.
8. **BBB:** Ligand A (79.488) is much better than Ligand B (30.787). While ADRB2 isn't exclusively a CNS target, some distribution to the brain is possible, and higher BBB penetration is generally favorable.
9. **Caco-2:** Ligand A (-4.542) is better than Ligand B (-5.479), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-4.349) is better than Ligand B (-1.556). Better solubility is always preferred.
11. **hERG:** Ligand A (0.827) is better than Ligand B (0.07). Lower hERG inhibition is critical for avoiding cardiotoxicity, especially for a cardiovascular target.
12. **Cl_mic:** Ligand A (52.647) is better than Ligand B (-11.344). Lower clearance suggests better metabolic stability. Note the negative value for B suggests very high clearance.
13. **t1/2:** Ligand A (25.754) is better than Ligand B (21.157). Longer half-life is generally desirable.
14. **Pgp:** Ligand A (0.314) is better than Ligand B (0.006). Lower P-gp efflux is preferred.
15. **Binding Affinity:** Ligand B (-6.2) is slightly better than Ligand A (-5.6). While a 0.6 kcal/mol difference is noticeable, it's not a massive advantage and can be offset by other factors.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has a better logP and TPSA, and Pgp efflux. Ligand B has a slightly better affinity, but the other ADME properties of Ligand A are significantly more favorable.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most crucial ADME properties (DILI, BBB, solubility, hERG, Cl_mic, Pgp, TPSA). The slightly better binding affinity of Ligand B is not enough to overcome the significant liabilities associated with its poor ADME profile. Ligand A presents a much more balanced and promising profile for development as a drug candidate.
Output:
1
2025-04-17 20:39:38,458 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (349.39) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (113.69) is better than Ligand B (29.54). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally improves absorption.
3. **logP:** Ligand B (4.205) is higher than Ligand A (0.184). While logP > 4 can be problematic, it's not a hard cutoff. Ligand A's logP is quite low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (3) is higher than Ligand B (0). This is a minor difference, but fewer HBDs can improve permeability.
5. **HBA:** Ligand A (6) is higher than Ligand B (2). Similar to HBD, lower HBA is generally preferred.
6. **QED:** Both ligands have similar QED values (0.675 vs 0.646), indicating good drug-likeness.
7. **DILI:** Ligand B (24.04) has a significantly lower DILI risk than Ligand A (67.313). This is a major advantage for Ligand B.
8. **BBB:** Ligand B (98.294) has a much higher BBB penetration potential than Ligand A (41.218). While not critical for a cardiovascular target, it's not detrimental.
9. **Caco-2:** Ligand A (-5.161) and Ligand B (-4.029) both have negative Caco-2 values. This is unusual and suggests poor permeability.
10. **Solubility:** Ligand A (-1.982) has better solubility than Ligand B (-4.319). Solubility is important, but can often be addressed with formulation strategies.
11. **hERG:** Ligand A (0.104) has a lower hERG risk than Ligand B (0.866), which is a positive.
12. **Cl_mic:** Ligand A (14.284) has a lower microsomal clearance than Ligand B (73.596), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand B (4.472) has a longer in vitro half-life than Ligand A (-0.317). This is a positive for Ligand B.
14. **Pgp:** Ligand A (0.022) has lower P-gp efflux than Ligand B (0.272).
15. **Affinity:** Ligand A (-7.9 kcal/mol) has a stronger binding affinity than Ligand B (-6.1 kcal/mol). This is a substantial difference, and a key factor.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A has a better TPSA and Pgp, but a significantly worse logP. Ligand B has a better logP and BBB, but a worse TPSA and Pgp. The affinity difference is substantial.
**Overall Assessment:**
Despite Ligand B's significantly lower DILI risk and longer half-life, the much stronger binding affinity of Ligand A (-7.9 vs -6.1 kcal/mol) is a decisive factor. A 1.8 kcal/mol difference in binding affinity is substantial and can often compensate for minor ADME deficiencies. While Ligand A's low logP is a concern, it might be mitigated through formulation. The lower DILI risk of Ligand B is attractive, but the potency advantage of Ligand A is more compelling for a first-in-class candidate.
Output:
1
2025-04-17 20:39:38,458 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **Molecular Weight:** Ligand A (345.443 Da) is well within the ideal range (200-500 Da). Ligand B (405.34 Da) is also acceptable, but closer to the upper limit.
2. **TPSA:** Ligand A (71.53) is good, well below the 140 threshold for oral absorption. Ligand B (54.04) is excellent, further enhancing potential absorption.
3. **logP:** Ligand A (1.924) is optimal. Ligand B (4.077) is a bit high, potentially leading to solubility issues and off-target interactions, but still within a manageable range.
4. **H-Bond Donors:** Both ligands have 1 HBD, which is good.
5. **H-Bond Acceptors:** Both ligands have 4 HBA, which is good.
6. **QED:** Ligand A (0.885) has a better QED score than Ligand B (0.755), indicating a more drug-like profile.
7. **DILI:** Ligand A (26.173) has a significantly lower DILI risk than Ligand B (15.277), a major advantage.
8. **BBB:** Ligand B (66.344) has a higher BBB penetration score than Ligand A (57.425). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant for off-target effects and overall safety assessment.
9. **Caco-2 Permeability:** Ligand A (-4.892) has a worse Caco-2 permeability than Ligand B (-5.056). Both are poor, but B is slightly better.
10. **Aqueous Solubility:** Ligand A (-1.178) has better solubility than Ligand B (-3.769). This is important given Ligand B's higher logP.
11. **hERG Inhibition:** Ligand A (0.201) has a lower hERG inhibition liability than Ligand B (0.804), which is a significant safety advantage.
12. **Microsomal Clearance:** Ligand A (-9.196) has much lower microsomal clearance than Ligand B (53.984), indicating better metabolic stability.
13. **In vitro Half-Life:** Ligand A (14.071) has a longer half-life than Ligand B (-0.26).
14. **P-gp Efflux:** Ligand A (0.029) has lower P-gp efflux than Ligand B (0.361), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand B (-7.4) has a slightly better binding affinity than Ligand A (-6.6). This is a 0.8 kcal/mol difference, which is notable but not overwhelming.
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B has better TPSA and affinity, but its higher logP and P-gp efflux are concerning. Ligand A has a much better safety profile (DILI, hERG) and metabolic stability (Cl_mic, t1/2). The slightly weaker affinity of Ligand A is outweighed by its superior ADMET properties.
**Conclusion:**
Considering the balance of potency, ADME, and toxicity, Ligand A is the more promising drug candidate. Its lower DILI and hERG risk, combined with its better metabolic stability and solubility, make it a safer and more developable molecule despite the slightly weaker binding affinity.
Output:
1
2025-04-17 20:39:38,458 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [354.411, 131.12 , -0.287, 3. , 7. , 0.585, 72.392, 50.523, -5.715, -1.482, 0.04 , -4.211, 2.729, 0.014, -6.2 ]
**Ligand B:** [365.455, 105.64 , 0.456, 2. , 5. , 0.73 , 22.451, 54.478, -5.659, -1.921, 0.045, 0.937, -8.628, 0.014, -7.3 ]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (354.411) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (131.12) is slightly higher than Ligand B (105.64), but both are below the 140 A^2 threshold for good oral absorption. Ligand B is better here.
3. **logP:** Ligand A (-0.287) is a bit low, potentially impacting permeability. Ligand B (0.456) is better, falling within the optimal 1-3 range.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (2), but both are acceptable (<=5).
5. **HBA:** Ligand A (7) is higher than Ligand B (5), but both are within the acceptable range (<=10).
6. **QED:** Both have good QED scores (A: 0.585, B: 0.73), suggesting good drug-like properties. Ligand B is better.
7. **DILI:** Ligand A (72.392) has a significantly higher DILI risk than Ligand B (22.451). This is a major concern.
8. **BBB:** Both have moderate BBB penetration (A: 50.523, B: 54.478). Not a primary concern for a cardiovascular target, but higher is generally better.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. This is a significant issue for both.
10. **Solubility:** Both have negative solubility values, which is also unusual and suggests poor solubility. This is a significant issue for both.
11. **hERG:** Both have very low hERG risk (A: 0.04, B: 0.045), which is excellent.
12. **Cl_mic:** Ligand A (-4.211) has a much lower (better) microsomal clearance than Ligand B (0.937), indicating better metabolic stability.
13. **t1/2:** Ligand B (-8.628) has a longer half-life than Ligand A (2.729), which is generally desirable.
14. **Pgp:** Both have very low Pgp efflux liability (A: 0.014, B: 0.014).
15. **Affinity:** Ligand B (-7.3) has a slightly better binding affinity than Ligand A (-6.2).
**Overall Assessment:**
While both compounds have issues with Caco-2 and solubility, Ligand B is significantly better overall. The most critical factor is the drastically lower DILI risk for Ligand B. The slightly better logP, QED, and affinity of Ligand B also contribute to its favorability. Ligand A's lower clearance is a plus, but the high DILI risk is a deal-breaker.
Output:
0
2025-04-17 20:39:38,458 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (365.463 and 363.483 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (123.95) is higher than Ligand B (71.53). For a GPCR, lower TPSA is generally preferred for better permeability, making Ligand B more favorable.
**3. logP:** Both ligands have good logP values (2.231 and 1.694 respectively), falling within the optimal 1-3 range. Ligand B is slightly lower, which could be beneficial for solubility.
**4. H-Bond Donors:** Both have 1 HBD, which is acceptable.
**5. H-Bond Acceptors:** Ligand A has 6 HBAs, and Ligand B has 5. Both are within the acceptable limit of 10.
**6. QED:** Ligand B (0.808) has a significantly better QED score than Ligand A (0.431), indicating a more drug-like profile.
**7. DILI:** Ligand A (60.45) has a higher DILI risk than Ligand B (47.926). Lower DILI is crucial, so Ligand B is preferred.
**8. BBB:** Both ligands have similar BBB penetration (57.619 and 55.332 respectively). While not CNS-specific, moderate BBB penetration is not detrimental for a peripheral GPCR like ADRB2.
**9. Caco-2 Permeability:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
**10. Aqueous Solubility:** Both have negative solubility values, indicating poor solubility.
**11. hERG Inhibition:** Ligand A (0.453) has a slightly higher hERG inhibition risk than Ligand B (0.121). Lower hERG is preferred.
**12. Microsomal Clearance:** Ligand B (32.663) has slightly lower microsomal clearance than Ligand A (30.859), suggesting better metabolic stability.
**13. In vitro Half-Life:** Ligand B (18.548 hours) has a significantly longer in vitro half-life than Ligand A (11.165 hours), which is a major advantage.
**14. P-gp Efflux:** Ligand A (0.11) has lower P-gp efflux than Ligand B (0.055), which is favorable.
**15. Binding Affinity:** Ligand B (-7.5 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.3 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME drawbacks.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand B is the stronger candidate. It has a significantly better QED score, lower DILI risk, longer half-life, and, most importantly, a much higher binding affinity. While both have poor solubility and permeability based on the provided data, the superior affinity and ADME properties of Ligand B make it the more promising drug candidate.
Output:
0
2025-04-17 20:39:38,459 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (359.491 and 354.447 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (54.45) is significantly better than Ligand B (110.1). ADRB2 is not a CNS target, but lower TPSA generally improves absorption. Ligand A is well below the 140 threshold, while Ligand B is approaching it.
3. **logP:** Ligand A (4.303) is higher than Ligand B (-0.22). While 4.3 is on the higher side, it's still within a reasonable range. Ligand B's negative logP is a major concern, suggesting poor membrane permeability.
4. **HBD:** Ligand A (0) is preferable to Ligand B (4). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (3) is better than Ligand B (5). Similar reasoning as HBD.
6. **QED:** Ligand A (0.693) is better than Ligand B (0.482), indicating a more drug-like profile.
7. **DILI:** Ligand A (64.754) has a higher DILI risk than Ligand B (14.308). This is a significant drawback for Ligand A.
8. **BBB:** This is less critical for ADRB2, but Ligand A (59.364) is better than Ligand B (23.187).
9. **Caco-2:** Ligand A (-4.427) is better than Ligand B (-5.214). Higher values are better, and both are negative, but A is less negative.
10. **Solubility:** Ligand A (-5.55) is better than Ligand B (-1.165). Higher values are better, and both are negative, but A is less negative.
11. **hERG:** Ligand A (0.631) is better than Ligand B (0.183). Lower values are better, indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand A (66.396) is higher than Ligand B (0.606), meaning faster clearance and lower metabolic stability. This is a negative for Ligand A.
13. **t1/2:** Ligand A (33.427) is significantly better than Ligand B (13.569). A longer half-life is generally preferred.
14. **Pgp:** Ligand A (0.699) is better than Ligand B (0.008). Lower Pgp efflux is preferred.
15. **Binding Affinity:** Ligand A (-8.1) is *significantly* better than Ligand B (-5.9). A difference of 2.2 kcal/mol is substantial and can often outweigh other drawbacks.
**Overall Assessment:**
Ligand A has a much stronger binding affinity, which is the most important factor. It also has better TPSA, logP, HBD, HBA, QED, Caco-2, solubility, hERG, and Pgp properties. However, it suffers from higher DILI risk and faster metabolic clearance. Ligand B has a very poor logP and lower QED, despite a better DILI profile. The substantial affinity difference of Ligand A, coupled with generally better ADME properties (despite the DILI and clearance concerns), makes it the more promising candidate. The DILI risk could be investigated further through structural modifications.
Output:
1
2025-04-17 20:39:38,459 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (354.451 and 351.491 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (93.19) is higher than Ligand B (69.72). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for permeability. Ligand B has a clear advantage.
3. **logP:** Ligand A (-1.115) is lower than the optimal 1-3 range, potentially hindering permeability. Ligand B (1.788) is within the optimal range. Ligand B is significantly better.
4. **HBD:** Both ligands have acceptable HBD counts (2 and 1 respectively), well below the threshold of 5.
5. **HBA:** Both ligands have acceptable HBA counts (5 and 3 respectively), well below the threshold of 10.
6. **QED:** Both ligands have good QED scores (0.59 and 0.711), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (8.181) has a much lower DILI risk than Ligand B (10.973). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (15.006) has very low BBB penetration, while Ligand B (79.527) has high BBB penetration. Since ADRB2 is a cardiovascular target, BBB penetration is not a priority, and is even undesirable. Ligand A is preferred here.
9. **Caco-2:** Ligand A (-5.186) and Ligand B (-4.363) both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the values are close.
10. **Solubility:** Ligand A (-0.75) has slightly better solubility than Ligand B (-2.304). Solubility is important, but not a primary concern.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.177 and 0.226). No significant difference.
12. **Cl_mic:** Ligand A (-15.225) has significantly lower (better) microsomal clearance than Ligand B (39.422), indicating better metabolic stability.
13. **t1/2:** Ligand A (-19.247) has a more negative in vitro half-life, which is unusual and suggests very rapid metabolism. Ligand B (-6.876) is better, though still somewhat low.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.007 and 0.02). No significant difference.
15. **Binding Affinity:** Both ligands have similar and strong binding affinities (-6.5 and -6.2 kcal/mol). The difference is not substantial enough to be a deciding factor.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, and affinity), Ligand B initially appears more promising due to its optimal logP and lower TPSA. However, Ligand A has a significantly better DILI score and lower microsomal clearance, which are crucial for overall drug safety and efficacy. The low BBB penetration of Ligand A is also favorable for a cardiovascular target. While Ligand A's in vitro half-life is concerning, the other advantages outweigh this drawback.
Output:
1
2025-04-17 20:39:38,459 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (340.427 and 364.364 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (67.35) is better than Ligand B (75.71). Both are below 140, but lower is generally preferred for absorption.
3. **logP:** Ligand A (3.342) is slightly higher than Ligand B (1.778). Both are within the optimal 1-3 range, but Ligand A is closer to the upper limit.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Both ligands have 4 HBA, which is good.
6. **QED:** Ligand A (0.906) is significantly better than Ligand B (0.755), indicating a more drug-like profile.
7. **DILI:** Ligand B (38.503) has a lower DILI risk than Ligand A (50.523), which is a significant advantage.
8. **BBB:** Both ligands have high BBB penetration (Ligand A: 91.392, Ligand B: 98.022), which is good, but Ligand B is better.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.562 and -4.572). This is unusual and suggests poor permeability. However, these values are very close.
10. **Solubility:** Both ligands have negative solubility values (-3.356 and -3.078), indicating poor aqueous solubility. Ligand B is slightly better.
11. **hERG:** Ligand A (0.763) has a slightly higher hERG risk than Ligand B (0.433), which is a negative.
12. **Cl_mic:** Ligand B (24.445) has significantly lower microsomal clearance than Ligand A (38.647), indicating better metabolic stability. This is a major advantage.
13. **t1/2:** Ligand B (-29.111) has a much longer in vitro half-life than Ligand A (5.785), which is a substantial benefit.
14. **Pgp:** Ligand A (0.181) has lower P-gp efflux than Ligand B (0.076), which is a positive.
15. **Affinity:** Ligand B (-7.3) has a significantly stronger binding affinity than Ligand A (-5.2), a difference of 2.1 kcal/mol. This is a very substantial advantage that can outweigh some ADME concerns.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), we prioritize logP, Pgp, TPSA, and affinity. Ligand B is better on logP, Pgp, and significantly better on affinity. While TPSA is slightly better for Ligand A, the other factors are more important.
**Overall Assessment:**
Ligand B has a much better binding affinity, significantly improved metabolic stability (lower Cl_mic, longer t1/2), lower DILI risk, and better BBB penetration. While Ligand A has a slightly better QED and Pgp efflux, the substantial advantages of Ligand B, particularly the binding affinity and metabolic stability, outweigh these minor drawbacks. The solubility and Caco-2 values are poor for both, but these can be addressed with formulation strategies.
Output:
0
2025-04-17 20:39:38,459 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands (361.438 and 357.495 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (55.4) is significantly better than Ligand B (93.11). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally correlates with better absorption. Ligand B's TPSA is quite high, potentially hindering oral bioavailability.
3. **logP:** Ligand A (4.927) is high, but still within a potentially acceptable range. Ligand B (0.061) is *very* low, which is a major concern for membrane permeability and overall absorption.
4. **HBD/HBA:** Ligand A (1 HBD, 4 HBA) is preferable to Ligand B (3 HBD, 5 HBA). Both are within acceptable limits, but fewer H-bonds are generally better for permeability.
5. **QED:** Ligand A (0.769) has a better QED score than Ligand B (0.571), indicating a more drug-like profile.
6. **DILI:** Ligand B (9.771) has a much lower DILI risk than Ligand A (80.186). This is a significant advantage for Ligand B.
7. **BBB:** Ligand A (77.627) has a higher BBB penetration score than Ligand B (12.99). While not a primary concern for a cardiovascular target, it's a slight positive for Ligand A.
8. **Caco-2:** Ligand A (-4.28) is better than Ligand B (-5.289), indicating better intestinal absorption.
9. **Solubility:** Ligand A (-6.116) is better than Ligand B (-0.465). Solubility is important for formulation and bioavailability.
10. **hERG:** Both ligands have very low hERG inhibition risk (0.346 and 0.353). This is good for both.
11. **Cl_mic:** Ligand B (19.599) has a much lower microsomal clearance than Ligand A (118.638). This suggests better metabolic stability for Ligand B.
12. **t1/2:** Ligand A (50.789) has a longer in vitro half-life than Ligand B (14.65). This is a positive for Ligand A.
13. **Pgp:** Both ligands have very low P-gp efflux liability (0.334 and 0.016). This is good for both.
14. **Binding Affinity:** Ligand B (-7.5 kcal/mol) has a significantly stronger binding affinity than Ligand A (-4.3 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME concerns.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, and affinity. Ligand B excels in affinity, while Ligand A has better TPSA and logP. However, Ligand B's affinity is *so* much stronger that it's likely to compensate for the less optimal TPSA and logP. The lower DILI and Cl_mic for Ligand B are also very favorable.
**Overall Assessment:**
While Ligand A has better physicochemical properties (TPSA, logP, solubility), Ligand B's significantly superior binding affinity and lower DILI/Cl_mic are more critical for a successful drug candidate. The strong binding affinity suggests a higher probability of achieving efficacy at a reasonable dose, and the improved metabolic stability is a significant advantage. The low logP is a concern, but formulation strategies can often mitigate this.
Output:
0
2025-04-17 20:39:38,460 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (355.435 Da) is slightly higher than Ligand B (340.467 Da), but both are acceptable.
2. **TPSA:** Ligand A (91.34) is slightly above the preferred <90 for CNS targets, but still reasonable for a peripheral GPCR like ADRB2. Ligand B (58.2) is excellent, well below the threshold. This favors Ligand B.
3. **logP:** Ligand A (-1.036) is a bit low, potentially hindering membrane permeability. Ligand B (3.233) is within the optimal range (1-3). This strongly favors Ligand B.
4. **HBD:** Both ligands have 2 HBD, which is good.
5. **HBA:** Ligand A has 6 HBA, acceptable. Ligand B has only 2 HBA, which is also good and potentially better for permeability. This slightly favors Ligand B.
6. **QED:** Both ligands have good QED scores (A: 0.567, B: 0.864), indicating drug-likeness. Ligand B is significantly better.
7. **DILI:** Ligand A (11.206) has a low DILI risk, which is excellent. Ligand B (53.121) is higher, indicating a moderate risk. This favors Ligand A.
8. **BBB:** BBB is less critical for ADRB2 (a cardiovascular target). Ligand A (44.203) and Ligand B (53.703) are both relatively low, which is not a major concern.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Ligand A (0.092) has very low solubility, a significant drawback. Ligand B (-4.681) also has very low solubility, but is slightly better than Ligand A. Both are concerning.
11. **hERG:** Both ligands have very low hERG inhibition risk (A: 0.215, B: 0.311), which is excellent.
12. **Cl_mic:** Ligand A (12.36) has a lower microsomal clearance than Ligand B (20.762), indicating better metabolic stability. This favors Ligand A.
13. **t1/2:** Ligand A (26.113) has a longer in vitro half-life than Ligand B (0.815), which is a significant advantage. This strongly favors Ligand A.
14. **Pgp:** Both have very low Pgp efflux liability (A: 0.005, B: 0.259), which is good.
15. **Binding Affinity:** Ligand B (-8.3 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.7 kcal/mol). This is a major advantage, potentially outweighing some ADME concerns.
**Overall Assessment:**
Ligand B has a superior logP, TPSA, QED, and *much* stronger binding affinity. However, it has a higher DILI risk and lower metabolic stability. Ligand A has better DILI, metabolic stability, and half-life, but suffers from a poor logP and solubility, and weaker binding.
Given the GPCR-specific priorities (logP, affinity), and the substantial difference in binding affinity, I believe Ligand B is the more promising candidate *despite* its slightly higher DILI risk and lower metabolic stability. The strong binding could be optimized further through medicinal chemistry, and the DILI risk is moderate, not prohibitive. The poor solubility of both is a concern, but formulation strategies can sometimes address this. The logP of Ligand B is much more favorable for membrane permeability.
Output:
0
2025-04-17 20:39:38,460 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (359.312 and 348.447 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (78.68) is significantly better than Ligand A (106.85). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (1.3 and 1.434), falling within the optimal 1-3 range. Very similar.
4. **HBD:** Ligand B (1) is preferable to Ligand A (2). Lower HBD generally improves permeability.
5. **HBA:** Ligand B (5) is preferable to Ligand A (7). Lower HBA generally improves permeability.
6. **QED:** Both ligands have good QED scores (0.722 and 0.841), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand B (23.769) has a *much* lower DILI risk than Ligand A (72.043). This is a significant advantage for Ligand B.
8. **BBB:** Both ligands have reasonable BBB penetration (83.715 and 76.58). Not a primary concern for a cardiovascular target, but higher is generally better. Ligand A is slightly better.
9. **Caco-2:** Ligand A (-5.183) is better than Ligand B (-4.897). Higher Caco-2 permeability suggests better absorption.
10. **Solubility:** Ligand A (-2.19) is slightly better than Ligand B (-1.907). Solubility is important, but not a major differentiator here.
11. **hERG:** Ligand B (0.387) has a lower hERG risk than Ligand A (0.115). This is a significant advantage for Ligand B.
12. **Cl_mic:** Ligand A (26.632) has lower microsomal clearance than Ligand B (31.548), suggesting better metabolic stability.
13. **t1/2:** Ligand B (9.158) has a longer in vitro half-life than Ligand A (-10.423). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand B (0.076) has lower P-gp efflux liability than Ligand A (0.124). This is a slight advantage for Ligand B.
15. **Affinity:** Ligand B (-5.2) has slightly better binding affinity than Ligand A (-7.0). While Ligand A has a better affinity, the difference is not substantial enough to outweigh the other factors.
**Overall Assessment:**
Ligand B consistently outperforms Ligand A in several critical ADME-Tox parameters, most notably DILI risk and hERG inhibition. It also has a better QED, lower HBD/HBA, and a longer half-life. While Ligand A has slightly better Caco-2 permeability and metabolic stability, the lower toxicity profile of Ligand B is a major advantage for drug development. The affinity difference is not large enough to overcome the other benefits of Ligand B.
Output:
0
2025-04-17 20:39:38,460 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.49 & 355.39 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (49.85) is significantly better than Ligand B (66.65). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (2.61 & 2.02), falling within the 1-3 optimal range. Ligand A is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Both ligands have 0 HBD, which is good.
5. **HBA:** Ligand A has 3 HBA, Ligand B has 4. Both are acceptable, below the 10 threshold.
6. **QED:** Both ligands have good QED scores (0.69 & 0.83), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (23.92) has a much lower DILI risk than Ligand B (38.00). This is a significant advantage.
8. **BBB:** Ligand B (92.4) has a higher BBB penetration score than Ligand A (80.65). While not a primary concern for a cardiovascular target, it's a slight positive for Ligand B.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.42 & -4.49), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-3.37) has slightly better solubility than Ligand B (-1.71).
11. **hERG:** Both ligands have very low hERG inhibition liability (0.496 & 0.252). This is excellent for both.
12. **Cl_mic:** Ligand B (26.28) has significantly lower microsomal clearance than Ligand A (51.65), indicating better metabolic stability. This is a major advantage for Ligand B.
13. **t1/2:** Ligand B (-32.30) has a much longer *in vitro* half-life than Ligand A (20.21). This is a substantial benefit for Ligand B.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.207 & 0.107). This is excellent for both.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.2 & -6.4 kcal/mol). The difference is negligible.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Both ligands perform well on logP and Pgp. Ligand A has a better TPSA. The affinity is nearly identical. However, the significantly better metabolic stability (lower Cl_mic, longer t1/2) and lower DILI risk of Ligand B outweigh the slight TPSA advantage of Ligand A.
**Conclusion:**
Ligand B is the more promising candidate due to its improved metabolic stability, longer half-life, and lower DILI risk, despite the slightly higher TPSA.
Output:
0
2025-04-17 20:39:38,460 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for the ADRB2, a cardiovascular GPCR. Therefore, priorities are logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB.
Let's compare the ligands property by property:
1. **MW:** Both ligands (362.3 & 345.4 Da) fall within the ideal 200-500 Da range.
2. **TPSA:** Both ligands (104.5 & 100.2) are reasonably good, being below 140, suggesting acceptable absorption.
3. **logP:** Both ligands have similar logP values (1.097 & 1.15), falling within the optimal 1-3 range.
4. **HBD/HBA:** Both have 2 HBD and 5 HBA, which is acceptable.
5. **QED:** Both ligands have similar QED scores (0.788 & 0.784), indicating good drug-likeness.
6. **DILI:** Both have similar DILI risk (54.052 & 53.276), which is acceptable.
7. **BBB:** Ligand A has a significantly higher BBB penetration (63.629%) than Ligand B (27.763%). While not a primary concern for a cardiovascular target, it's a slight advantage.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the values are similar (-5.451 vs -5.138).
9. **Solubility:** Both have negative solubility values, again unusual. The values are similar (-2.371 vs -2.143).
10. **hERG:** Both have very low hERG inhibition risk (0.024 & 0.166).
11. **Cl_mic:** Ligand A has a much lower (better) microsomal clearance (-13.067) compared to Ligand B (12.592). This suggests better metabolic stability for Ligand A.
12. **t1/2:** Ligand A has a significantly longer in vitro half-life (-25.667) than Ligand B (10.838). This is a significant advantage.
13. **Pgp:** Both have very low Pgp efflux liability (0.006 & 0.02).
14. **Binding Affinity:** Ligand A has a stronger binding affinity (-9.6 kcal/mol) compared to Ligand B (-6.8 kcal/mol). This is a substantial difference.
**Conclusion:**
Ligand A is clearly superior. The significantly stronger binding affinity (-9.6 vs -6.8 kcal/mol) is the most important factor. Additionally, Ligand A demonstrates better metabolic stability (lower Cl_mic) and a longer half-life, both crucial for *in vivo* efficacy. While BBB isn't a primary concern for a cardiovascular target, the higher value for Ligand A is a bonus. The other parameters are comparable between the two.
**Output:**
1
2025-04-17 20:39:38,460 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's analyze each ligand against the provided criteria, keeping in mind ADRB2 is a GPCR and therefore we prioritize logP, Pgp, TPSA, and affinity, alongside general drug-like properties.
* **Molecular Weight:** Both ligands (346.471 and 352.475 Da) fall comfortably within the ideal 200-500 Da range.
* **TPSA:** Ligand A (67.43) is slightly higher than Ligand B (59.08). Both are acceptable, but B is better, being closer to the <90 target for potential CNS penetration (though not a primary concern for ADRB2).
* **logP:** Ligand A (3.038) is within the optimal range (1-3), while Ligand B (1.818) is at the lower end. While lower logP can sometimes improve solubility, for a GPCR, a slightly higher logP like that of A is generally preferred for membrane permeability and receptor engagement.
* **H-Bond Donors/Acceptors:** Ligand A has 2 HBD and 3 HBA, while Ligand B has 0 HBD and 4 HBA. Both are within acceptable limits.
* **QED:** Both ligands have similar QED values (0.832 and 0.774), indicating good drug-likeness.
* **DILI:** Ligand B (16.208) has a significantly lower DILI risk than Ligand A (30.903), which is a major advantage.
* **BBB:** Ligand B (85.033) shows better BBB penetration potential than Ligand A (68.282), though this isn't a critical factor for ADRB2.
* **Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.239 and -4.208). These values are unusual and suggest poor permeability.
* **Aqueous Solubility:** Both ligands have negative solubility values (-3.524 and -2.098), indicating poor aqueous solubility.
* **hERG:** Both ligands have very low hERG inhibition liability (0.437 and 0.46), which is excellent.
* **Microsomal Clearance:** Ligand B (33.832) has lower microsomal clearance than Ligand A (56.195), suggesting better metabolic stability.
* **In vitro Half-Life:** Ligand B (12.834 hours) has a significantly longer half-life than Ligand A (6.846 hours).
* **P-gp Efflux:** Both ligands have low P-gp efflux liability (0.052 and 0.062).
* **Binding Affinity:** Both ligands have the same binding affinity (-6.8 kcal/mol), which is excellent.
**Overall Assessment:**
While Ligand A has a slightly better logP, Ligand B demonstrates superior ADME properties: significantly lower DILI risk, better BBB penetration, lower microsomal clearance, and a longer half-life. The equal binding affinity removes that as a differentiating factor. The negative Caco-2 and solubility values are concerning for both, but the other advantages of B outweigh the slightly less optimal logP. Given the GPCR target class, the improved ADME profile of Ligand B is more critical, especially the reduced DILI risk.
**Output:**
0
2025-04-17 20:39:38,461 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [392.204, 29.54, 4.62, 0, 2, 0.644, 63.978, 82.164, -4.238, -5.532, 0.833, 94.508, 35.55, 0.729, -7.3]
**Ligand B:** [377.463, 105.25, -1.209, 1, 6, 0.645, 56.572, 51.609, -5.209, -1.702, 0.124, 23.301, -46.171, 0.011, -7.5]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the acceptable 200-500 Da range. Ligand B (377.463) is slightly preferred due to being a bit lower.
2. **TPSA:** Ligand A (29.54) is excellent, well below the 140 threshold and very favorable for permeability. Ligand B (105.25) is higher, but still potentially acceptable.
3. **logP:** Ligand A (4.62) is pushing the upper limit and could present solubility issues. Ligand B (-1.209) is too low, potentially hindering membrane permeability and absorption.
4. **HBD/HBA:** Ligand A (0 HBD, 2 HBA) is better than Ligand B (1 HBD, 6 HBA). Fewer H-bonds generally improve permeability.
5. **QED:** Both are similar (0.644 vs 0.645), indicating reasonable drug-likeness.
6. **DILI:** Ligand B (56.572) has a lower DILI risk than Ligand A (63.978), which is a significant advantage.
7. **BBB:** Ligand A (82.164) has a much better BBB penetration potential than Ligand B (51.609). This is important for a GPCR, even if it's not a CNS target, as it can influence distribution.
8. **Caco-2:** Ligand A (-4.238) is worse than Ligand B (-5.209). Both are very poor.
9. **Solubility:** Ligand A (-5.532) is worse than Ligand B (-1.702). Both are very poor.
10. **hERG:** Ligand A (0.833) has a lower hERG risk than Ligand B (0.124), which is a major safety concern.
11. **Cl_mic:** Ligand A (94.508) has a higher clearance, indicating lower metabolic stability, than Ligand B (23.301).
12. **t1/2:** Ligand B (-46.171) has a much longer half-life than Ligand A (35.55), which is a significant advantage.
13. **Pgp:** Ligand A (0.729) has a lower P-gp efflux liability than Ligand B (0.011), which is a positive.
14. **Affinity:** Ligand B (-7.5) has a slightly better binding affinity than Ligand A (-7.3), but the difference is small.
**Overall Assessment:**
Ligand B has a better safety profile (lower DILI, lower hERG) and significantly better metabolic stability (lower Cl_mic, longer t1/2). However, its logP is too low, and BBB penetration is poor. Ligand A has a better BBB score and Pgp efflux, but suffers from a higher logP, DILI, and hERG risk, and lower metabolic stability.
Given the GPCR target class, the balance of properties leans slightly towards Ligand B. The improved metabolic stability and safety profile are more critical than the slightly lower BBB penetration and logP, as these can be potentially addressed with further optimization. The affinity difference is minimal.
Output:
0
2025-04-17 20:39:38,461 - INFO - Batch 201 complete. Total preferences: 3216
2025-04-17 20:39:38,461 - INFO - Processing batch 202/512...
2025-04-17 20:40:22,260 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (363.37 and 355.479 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (82.11) is significantly better than Ligand A (105.32). ADRB2 is a cardiovascular target, so CNS penetration isn't crucial, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (2.928) is optimal, while Ligand B (0.08) is very low. This is a major concern for Ligand B, as it may struggle with membrane permeability.
4. **HBD:** Both have 2 HBD, which is within the acceptable limit of 5.
5. **HBA:** Ligand A has 6 HBA, and Ligand B has 5. Both are within the acceptable limit of 10.
6. **QED:** Both ligands have similar QED values (0.738 and 0.644), indicating good drug-likeness.
7. **DILI:** Ligand A (98.371) has a very high DILI risk, which is a significant red flag. Ligand B (4.459) has a very low DILI risk.
8. **BBB:** Ligand A (21.946) has low BBB penetration, which is not a concern for a cardiovascular target. Ligand B (43.971) is moderate.
9. **Caco-2:** Both have negative Caco-2 values (-5.09 and -4.876), which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Ligand A (-4.144) and Ligand B (-0.442) both have negative solubility values, which is concerning.
11. **hERG:** Ligand A (0.634) has a slightly higher hERG risk than Ligand B (0.218), but both are relatively low.
12. **Cl_mic:** Ligand B (-1.403) has a much lower (better) microsomal clearance than Ligand A (31.098), indicating greater metabolic stability.
13. **t1/2:** Ligand B (14.47) has a significantly longer in vitro half-life than Ligand A (-13.296).
14. **Pgp:** Ligand A (0.232) has lower P-gp efflux than Ligand B (0.002), which is favorable.
15. **Affinity:** Ligand A (-7.1) has a slightly better binding affinity than Ligand B (-6.9), but the difference is small (0.2 kcal/mol).
**Overall Assessment:**
Ligand A has a slightly better binding affinity, but its extremely high DILI risk and poor metabolic stability are major drawbacks. Ligand B, while having a lower logP and negative Caco-2 and solubility values, has a significantly better safety profile (low DILI), better metabolic stability (lower Cl_mic, longer t1/2), and acceptable hERG risk. The small affinity difference is outweighed by the substantial ADME/Tox advantages of Ligand B. Given the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand B is the more promising candidate despite the permeability concerns. The low logP could be addressed through further medicinal chemistry optimization.
Output:
0
2025-04-17 20:40:22,260 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (362.308 Da) is within the ideal range, while Ligand B (411.208 Da) is approaching the upper limit. This slightly favors A.
2. **TPSA:** Ligand A (93.53) is better than Ligand B (113.92), both are acceptable but A is preferred.
3. **logP:** Ligand A (0.102) is quite low, potentially hindering permeability. Ligand B (3.07) is within the optimal range. This is a significant advantage for B.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 6 HBA, while Ligand B has 7. Both are acceptable.
6. **QED:** Ligand A (0.77) has a much better QED score than Ligand B (0.322), indicating better overall drug-likeness. This is a strong point for A.
7. **DILI:** Ligand A (46.956) has a significantly lower DILI risk than Ligand B (86.002). This is a major advantage for A.
8. **BBB:** Ligand A (74.564) has a better BBB penetration score than Ligand B (68.554). While ADRB2 isn't exclusively a CNS target, some cardiovascular effects can be mediated through CNS pathways, so this is a slight benefit for A.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability.
10. **Solubility:** Ligand A (-1.594) is better than Ligand B (-5.785).
11. **hERG:** Ligand A (0.421) has a lower hERG risk than Ligand B (0.647). This is a positive for A.
12. **Cl_mic:** Ligand A (2.326) has a much lower microsomal clearance than Ligand B (80.395), indicating better metabolic stability. This is a significant advantage for A.
13. **t1/2:** Ligand A (-29.609) has a much longer in vitro half-life than Ligand B (6.34). This is a strong advantage for A.
14. **Pgp:** Ligand A (0.035) has a lower P-gp efflux liability than Ligand B (0.432). This is a positive for A.
15. **Affinity:** Ligand A (-7.2 kcal/mol) has a slightly better binding affinity than Ligand B (-6.7 kcal/mol). While the difference is less than 1.5 kcal/mol, it still contributes to A's favorability.
**GPCR-specific priorities:** For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Ligand B has a better logP, but Ligand A excels in other crucial areas like metabolic stability (Cl_mic, t1/2), DILI risk, and Pgp efflux. The slightly better affinity of Ligand A further supports its selection.
**Conclusion:**
Considering the balance of properties, particularly the significantly better ADME-Tox profile (DILI, Cl_mic, t1/2, Pgp, hERG) and comparable affinity, Ligand A is the more promising drug candidate.
Output:
1
2025-04-17 20:40:22,260 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
The ADRB2 receptor is a GPCR, so the priorities are logP, TPSA, Pgp, BBB, and affinity. Let's break down the comparison:
1. **Molecular Weight:** Both ligands are within the ideal 200-500 Da range. Ligand A (378.395 Da) is slightly higher than Ligand B (355.523 Da), but both are acceptable.
2. **TPSA:** Ligand A (139.8) is borderline, but acceptable for oral absorption. Ligand B (61.88) is excellent, well below the 140 threshold, suggesting good permeability. This favors Ligand B.
3. **logP:** Both ligands have a logP of around 1.6, which is optimal. No significant difference here.
4. **H-Bond Donors:** Ligand A has 2 HBD, and Ligand B has 1. Both are within the acceptable limit of 5.
5. **H-Bond Acceptors:** Ligand A has 9 HBA, while Ligand B has 4. Both are below the 10 threshold.
6. **QED:** Both ligands have good QED scores (A: 0.516, B: 0.638), indicating drug-likeness. Ligand B is slightly better.
7. **DILI:** Ligand A has a very high DILI risk (99.069%), which is a major concern. Ligand B has a very low DILI risk (4.653%), a significant advantage.
8. **BBB:** Ligand A has a low BBB penetration (23.149%), while Ligand B has a good BBB penetration (70.531%). This favors Ligand B, although BBB isn't *critical* for ADRB2 (which is primarily cardiovascular).
9. **Caco-2:** Ligand A (-5.774) has poor Caco-2 permeability, while Ligand B (-4.689) is better, but still not great.
10. **Solubility:** Ligand A (-3.191) has poor solubility, while Ligand B (-0.687) is better.
11. **hERG:** Both ligands have low hERG inhibition risk (A: 0.347, B: 0.494). No significant difference.
12. **Cl_mic:** Ligand A (19.387) has a higher microsomal clearance than Ligand B (1.857), indicating lower metabolic stability. This favors Ligand B.
13. **t1/2:** Ligand A (14.009) has a longer in vitro half-life than Ligand B (-6.942). This favors Ligand A.
14. **Pgp:** Ligand A (0.089) has lower P-gp efflux than Ligand B (0.019), which is favorable.
15. **Binding Affinity:** Both ligands have the same binding affinity (-6.6 kcal/mol).
**Overall Assessment:**
While Ligand A has a slightly longer half-life and lower Pgp efflux, the extremely high DILI risk and poor solubility/permeability are major drawbacks. Ligand B has a much more favorable safety profile (low DILI), better TPSA, BBB penetration, solubility, and metabolic stability. The slightly shorter half-life of Ligand B is less concerning than the significant liabilities of Ligand A.
**Output:**
0
2025-04-17 20:40:22,261 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (360.435 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (85.36) is significantly better than Ligand B (38.77). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is still generally preferred for absorption.
3. **logP:** Ligand A (1.878) is optimal, while Ligand B (4.707) is pushing the upper limit and could potentially cause solubility issues or off-target interactions.
4. **HBD:** Ligand A (1) is good. Ligand B (0) is also acceptable.
5. **HBA:** Ligand A (5) is good. Ligand B (4) is also acceptable.
6. **QED:** Ligand A (0.88) is excellent, indicating a highly drug-like profile. Ligand B (0.59) is acceptable but less ideal.
7. **DILI:** Ligand A (72.199) is higher than Ligand B (50.33), indicating a greater potential for liver injury. This is a significant drawback for Ligand A.
8. **BBB:** Both ligands have similar BBB penetration (Ligand A: 64.211, Ligand B: 66.886). Since ADRB2 is not a CNS target, this is less important.
9. **Caco-2:** Ligand A (-5.018) and Ligand B (-4.735) are both negative, which is unusual. A higher value is desired.
10. **Solubility:** Ligand A (-3.372) and Ligand B (-4.617) are both negative, which is also unusual. Higher solubility is desired.
11. **hERG:** Ligand A (0.22) has a much lower hERG risk than Ligand B (0.65), which is a significant advantage.
12. **Cl_mic:** Ligand A (30.878) has a much lower microsomal clearance, indicating better metabolic stability, than Ligand B (116.327). This is a major advantage.
13. **t1/2:** Ligand A (78.384) has a longer in vitro half-life than Ligand B (47.58), which is desirable.
14. **Pgp:** Ligand A (0.326) has lower P-gp efflux liability than Ligand B (0.809), which is favorable for bioavailability.
15. **Affinity:** Both ligands have very similar binding affinities (-6.5 and -6.6 kcal/mol). The difference is negligible.
**Overall Assessment:**
Ligand A has several advantages: better logP, QED, hERG risk, metabolic stability (Cl_mic), half-life, and Pgp efflux. However, its DILI risk is significantly higher. Ligand B has a lower DILI risk, but suffers from higher logP, lower QED, higher hERG risk, poorer metabolic stability, shorter half-life, and higher Pgp efflux.
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand A is preferable due to its more balanced profile, despite the higher DILI risk. The better metabolic stability and lower efflux are particularly important for a cardiovascular target where sustained exposure is beneficial. The DILI risk could be addressed with further structural modifications.
Output:
1
2025-04-17 20:40:22,261 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (342.399 Da and 349.431 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (96.25) is slightly higher than Ligand B (84.67). Both are below the 140 A^2 threshold for oral absorption, but Ligand B is preferable due to being closer to the 90 A^2 threshold for GPCRs.
**3. logP:** Both ligands have acceptable logP values (1.185 and 1.767, respectively) falling within the 1-3 range. Ligand B is slightly better, being closer to the optimal range.
**4. H-Bond Donors:** Ligand A has 3 HBD, while Ligand B has 1. Ligand B is preferable as lower HBD generally improves permeability.
**5. H-Bond Acceptors:** Both ligands have 5 HBA, which is acceptable.
**6. QED:** Both ligands have good QED scores (0.704 and 0.846), indicating good drug-like properties. Ligand B is slightly better.
**7. DILI:** Ligand A has a DILI risk of 64.288%, while Ligand B is 41.024%. Ligand B is significantly better, falling well below the 60% high-risk threshold.
**8. BBB:** Ligand B (75.107%) has a significantly higher BBB penetration score than Ligand A (57.193%). This is a key advantage for a GPCR target, even if it's not strictly CNS-focused, as it suggests better distribution.
**9. Caco-2 Permeability:** Ligand A (-5.087) and Ligand B (-4.56) have negative values, which is unusual and indicates poor permeability. Ligand B is slightly better.
**10. Aqueous Solubility:** Ligand A (-3.378) and Ligand B (-2.543) have negative values, suggesting poor solubility. Ligand B is slightly better.
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (0.188% and 0.346%, respectively). No significant difference.
**12. Microsomal Clearance:** Ligand A (29.149 mL/min/kg) has lower microsomal clearance than Ligand B (50.693 mL/min/kg), indicating better metabolic stability.
**13. In vitro Half-Life:** Ligand A (27.179 hours) has a significantly longer half-life than Ligand B (-15.368 hours). This is a major advantage for dosing convenience.
**14. P-gp Efflux:** Both ligands have low P-gp efflux (0.096 and 0.256, respectively). No significant difference.
**15. Binding Affinity:** Both ligands have very similar binding affinities (-8.0 kcal/mol and -7.0 kcal/mol). The difference is not substantial enough to outweigh other factors.
**Overall Assessment:**
Ligand B consistently outperforms Ligand A in several crucial ADME properties (DILI, BBB, logP, HBD) and has a slightly better Caco-2 and solubility. While Ligand A has a longer half-life and lower clearance, the improvements in safety (DILI) and distribution (BBB) offered by Ligand B are more critical for a GPCR target like ADRB2. The similar binding affinities make the ADME advantages of Ligand B decisive.
Output:
0
2025-04-17 20:40:22,261 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Step-by-step comparison:**
1. **MW:** Both ligands (373.274 Da and 350.463 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (66.02) is significantly better than Ligand B (87.47). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally improves absorption.
3. **logP:** Both ligands have good logP values (2.578 and 1.592), falling within the 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Both ligands have the same number of HBA (5), which is acceptable.
6. **QED:** Both ligands have good QED scores (0.674 and 0.743), indicating good drug-like properties.
7. **DILI:** Ligand B (17.604) has a much lower DILI risk than Ligand A (59.131). This is a significant advantage for Ligand B.
8. **BBB:** Both ligands have reasonable BBB penetration (76.347 and 67.662). Since ADRB2 is a cardiovascular target, BBB isn't a major priority.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.682 and -4.98). These values are unusual and suggest poor permeability.
10. **Solubility:** Ligand B (-1.117) has better solubility than Ligand A (-3.207). Solubility is important for bioavailability.
11. **hERG:** Both ligands have low hERG inhibition liability (0.687 and 0.204), which is good.
12. **Cl_mic:** Ligand B (-0.217) exhibits much better metabolic stability (lower clearance) than Ligand A (31.011). This is a significant advantage.
13. **t1/2:** Ligand B (14.041) has a much longer in vitro half-life than Ligand A (-1.821). This is a major advantage, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.17 and 0.012).
15. **Binding Affinity:** Ligand B (-5.8) has a slightly better binding affinity than Ligand A (-5.2). While the difference is not huge, it's still a positive.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A has a slightly better logP and TPSA, but Ligand B wins on affinity. The differences are not substantial.
**Overall Assessment:**
Ligand B is the better candidate. While Ligand A has slightly better TPSA and logP, Ligand B excels in crucial ADME properties: significantly lower DILI risk, much better metabolic stability (Cl_mic), a longer half-life, and slightly better binding affinity. The negative Caco-2 values for both are concerning, but the overall profile of Ligand B is more favorable for development.
Output:
0
2025-04-17 20:40:22,261 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (367.896 Da) is within the ideal range (200-500 Da). Ligand B (410.851 Da) is also acceptable, though approaching the upper limit.
2. **TPSA:** Ligand A (26.79) is excellent, well below the 140 threshold and very favorable for absorption. Ligand B (77.52) is higher, but still reasonable for a non-CNS target.
3. **logP:** Both ligands have good logP values (A: 3.174, B: 2.949), falling within the optimal 1-3 range.
4. **HBD:** Ligand A (0) is ideal. Ligand B (1) is acceptable.
5. **HBA:** Ligand A (3) is good. Ligand B (6) is higher, potentially impacting permeability.
6. **QED:** Both ligands have similar QED values (A: 0.817, B: 0.792), indicating good drug-likeness.
7. **DILI:** Ligand A (46.297) has a lower DILI risk than Ligand B (94.959). This is a significant advantage.
8. **BBB:** Ligand A (97.208) shows excellent BBB penetration, while Ligand B (61.846) is moderate. While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant for off-target effects.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.495 and -4.796). This is unusual and suggests poor permeability. However, these values are on a scale where negative values are possible, and the absolute magnitude isn't directly interpretable without knowing the scale's specifics.
10. **Solubility:** Ligand A (-3.034) has better solubility than Ligand B (-5.135).
11. **hERG:** Both ligands have low hERG inhibition risk (A: 0.964, B: 0.29).
12. **Cl_mic:** Ligand A (33.1) has slightly lower microsomal clearance than Ligand B (37.34), suggesting better metabolic stability.
13. **t1/2:** Ligand A (24.224) has a longer in vitro half-life than Ligand B (19.572).
14. **Pgp:** Both ligands show low P-gp efflux liability (A: 0.336, B: 0.333).
15. **Binding Affinity:** Ligand A (-6.7 kcal/mol) has a slightly better binding affinity than Ligand B (-5.6 kcal/mol). This is a 1.1 kcal/mol difference, which is substantial.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Both ligands perform well on logP and Pgp. Ligand A has a significantly better TPSA and affinity. The difference in binding affinity is substantial enough to outweigh the slightly higher MW of Ligand B. The lower DILI risk and better BBB penetration of Ligand A are also important advantages.
**Conclusion:**
Ligand A is the more promising candidate due to its superior binding affinity, lower DILI risk, better solubility, longer half-life, and favorable TPSA and BBB penetration.
Output:
1
2025-04-17 20:40:22,261 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (355.47 & 350.46 Da) fall comfortably within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (63.05) is significantly better than Ligand B (80.57). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (4.22) is slightly higher than Ligand B (2.696). While both are within the acceptable range (1-3 is optimal), Ligand A is pushing the upper limit. This could lead to solubility issues, but for a GPCR, some lipophilicity is beneficial for membrane interactions.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (4). Similar to HBD, lower HBA is generally better for permeability.
6. **QED:** Both ligands have good QED scores (0.532 and 0.636), indicating good overall drug-likeness. Ligand B is slightly better.
7. **DILI:** Ligand B (18.224) has a *much* lower DILI risk than Ligand A (83.598). This is a significant advantage for Ligand B. DILI is a major concern in drug development.
8. **BBB:** Ligand A (81.078) has slightly better BBB penetration than Ligand B (70.919). However, as ADRB2 is a cardiovascular target, BBB penetration is not a primary concern.
9. **Caco-2:** Both ligands have similar, poor Caco-2 permeability (-4.918 and -4.756). This is a potential issue for oral absorption for both.
10. **Solubility:** Ligand B (-2.161) has better aqueous solubility than Ligand A (-4.8). This is a positive for Ligand B, especially given Ligand A's higher logP.
11. **hERG:** Ligand A (0.796) has slightly better hERG profile than Ligand B (0.351). Lower hERG is preferred.
12. **Cl_mic:** Ligand B (61.906) has significantly lower microsomal clearance than Ligand A (124.331). This suggests better metabolic stability for Ligand B, which is a major advantage.
13. **t1/2:** Ligand B (31.365) has a longer in vitro half-life than Ligand A (22.796). This is another benefit for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.638) has better Pgp efflux profile than Ligand B (0.276). Lower Pgp efflux is preferred.
15. **Affinity:** Ligand B (-7.3 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.7 kcal/mol). This 1.6 kcal/mol difference is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand B is the stronger candidate. While Ligand A has slightly better BBB penetration and Pgp efflux, Ligand B excels in critical areas: significantly lower DILI risk, better solubility, improved metabolic stability (lower Cl_mic, longer t1/2), and, crucially, much higher binding affinity. The affinity difference is large enough to compensate for the slightly lower BBB and Pgp values. The poor Caco-2 permeability is a concern for both, but can be addressed with formulation strategies.
Output:
0
2025-04-17 20:40:22,262 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (398.941 and 354.422 Da) fall within the ideal 200-500 Da range. Ligand B is slightly smaller, which could be advantageous for permeability, but the difference isn't substantial.
2. **TPSA:** Both ligands (83.98 and 87.66) are below the 140 A^2 threshold for good oral absorption. They are also reasonably low, not raising immediate concerns for CNS penetration, though ADRB2 isn't necessarily a CNS target.
3. **logP:** Ligand A (2.668) is within the optimal 1-3 range. Ligand B (0.94) is slightly below, potentially indicating lower permeability. This is a point against Ligand B.
4. **HBD:** Ligand A (2) and Ligand B (3) are both acceptable, being less than 5.
5. **HBA:** Ligand A (6) and Ligand B (4) are both acceptable, being less than 10.
6. **QED:** Ligand A (0.668) has a better QED score than Ligand B (0.469), suggesting a more drug-like profile.
7. **DILI:** Ligand A (69.252) has a higher DILI risk than Ligand B (23.187). This is a significant advantage for Ligand B.
8. **BBB:** Ligand B (71.501) has a better BBB penetration score than Ligand A (43.893). While ADRB2 isn't primarily a CNS target, higher BBB penetration is generally favorable, minimizing off-target effects.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.496 and -5.264), indicating poor permeability. This is a major concern for both.
10. **Solubility:** Both have negative solubility values (-3.924 and -2.557), which is concerning.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.217 and 0.27), which is excellent.
12. **Cl_mic:** Ligand B (-18.924) has significantly lower microsomal clearance than Ligand A (64.776), indicating better metabolic stability. This is a strong advantage for Ligand B.
13. **t1/2:** Ligand A (19.781) has a longer in vitro half-life than Ligand B (4.381). This is a positive for Ligand A.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.077 and 0.062).
15. **Binding Affinity:** Ligand B (-7.6 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.1 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME concerns.
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are crucial. Ligand B excels in affinity and has a better BBB score. While its logP is slightly lower, the significantly stronger binding and lower DILI/Cl_mic are more important. The poor Caco-2 and solubility are concerning for both, but can be addressed with formulation strategies.
**Conclusion:**
Despite the poor Caco-2 and solubility for both, Ligand B's superior binding affinity, lower DILI risk, and better metabolic stability outweigh the slightly lower logP and shorter half-life.
Output:
0
2025-04-17 20:40:22,262 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (366.571 and 341.415 Da) are within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (49.41) is significantly better than Ligand B (79.6). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (3.453) is optimal, while Ligand B (1.498) is on the lower side. A logP between 1-3 is preferred, and A is closer to this ideal.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 3 HBA, while Ligand B has 5. Both are acceptable, but A is slightly better.
6. **QED:** Both ligands have high QED scores (0.811 and 0.863), indicating good drug-like properties. No significant difference.
7. **DILI:** Ligand A (23.032) has a much lower DILI risk than Ligand B (36.293). This is a major advantage for Ligand A.
8. **BBB:** Both ligands have good BBB penetration (79.488 and 73.866). Not a primary concern for a cardiovascular target.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the absolute value is more important, and Ligand A (-4.972) is slightly better than Ligand B (-5.143).
10. **Solubility:** Ligand A (-3.924) is better than Ligand B (-2.347). Higher solubility is generally preferred.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.551 and 0.38). No significant difference.
12. **Cl_mic:** Ligand A (72.381) has higher microsomal clearance than Ligand B (37.584), indicating lower metabolic stability. This is a drawback for Ligand A.
13. **t1/2:** Ligand B (-7.924) has a significantly longer *in vitro* half-life than Ligand A (-4.057). This is a substantial advantage for Ligand B.
14. **Pgp:** Both ligands have very low Pgp efflux (0.3 and 0.029). No significant difference.
15. **Binding Affinity:** Both ligands have the same binding affinity (-6 kcal/mol).
**Overall Assessment:**
Ligand A has advantages in TPSA, logP, DILI risk, and solubility. However, Ligand B has a significantly longer half-life and lower microsomal clearance, which are crucial for *in vivo* drug performance. While Ligand A has a slightly better logP and lower DILI, the improved metabolic stability of Ligand B is more important for a GPCR target like ADRB2. The similar binding affinity makes the ADME properties the deciding factor.
Output:
0
2025-04-17 20:40:22,262 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.419 Da and 352.475 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (137.31) is slightly higher than Ligand B (89.87). Ligand B is better, being closer to the <140 threshold for oral absorption and more favorable for GPCRs.
3. **logP:** Ligand A (0.004) is quite low, potentially hindering permeability. Ligand B (1.053) is within the optimal 1-3 range. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (5) is at the upper limit of the preferred range, while Ligand B (3) is better.
5. **HBA:** Both ligands have 4 HBA, which is well within the acceptable range.
6. **QED:** Ligand B (0.69) has a better QED score than Ligand A (0.406), indicating a more drug-like profile.
7. **DILI:** Ligand B (19.736) has a much lower DILI risk than Ligand A (29.159). This is a substantial advantage for Ligand B.
8. **BBB:** Ligand B (54.517) has a higher BBB penetration percentile than Ligand A (41.528). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be beneficial for distribution.
9. **Caco-2:** Ligand A (-5.711) and Ligand B (-4.837) both have negative Caco-2 values, which is unusual and suggests very poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand A (-2.929) and Ligand B (-2.083) both have very poor solubility.
11. **hERG:** Ligand A (0.144) has a slightly lower hERG risk than Ligand B (0.308), but both are relatively low.
12. **Cl_mic:** Ligand B (-4.631) has a significantly lower (better) microsomal clearance than Ligand A (0.912), indicating better metabolic stability.
13. **t1/2:** Ligand B (2.931) has a longer in vitro half-life than Ligand A (-10.792). This is a major advantage for Ligand B.
14. **Pgp:** Ligand A (0.017) has a lower P-gp efflux liability than Ligand B (0.056). This is a slight advantage for Ligand A.
15. **Binding Affinity:** Ligand A (-7.4) has a slightly stronger binding affinity than Ligand B (-6.9). However, the difference is less than 1.5 kcal/mol, and can be overcome by other factors.
**Overall Assessment:**
Ligand B consistently outperforms Ligand A in most crucial ADME properties (logP, DILI, BBB, Cl_mic, t1/2, QED) and has a better TPSA. While Ligand A has a slightly better binding affinity and Pgp profile, the overall balance of properties strongly favors Ligand B. The poor Caco-2 and solubility for both are concerning, but the superior ADME profile of Ligand B makes it a more promising starting point for optimization.
Output:
0
2025-04-17 20:40:22,262 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (378.925 Da) is slightly higher than Ligand B (358.463 Da), but both are acceptable.
2. **TPSA:** Ligand A (41.57) is significantly better than Ligand B (69.64). For a GPCR, lower TPSA is generally preferred for better permeability. Ligand B is pushing the upper limit for good oral absorption.
3. **logP:** Ligand A (4.443) is higher than Ligand B (2.807). While both are within the acceptable range (1-3 is optimal, up to 4 is tolerable), Ligand A is approaching the upper limit, potentially raising concerns about solubility and off-target effects.
4. **HBD:** Ligand A (1) is better than Ligand B (2). Lower HBD is generally preferred for improved permeability.
5. **HBA:** Ligand A (3) is better than Ligand B (4). Similar to HBD, lower HBA is generally preferred.
6. **QED:** Both ligands have good QED scores (Ligand A: 0.807, Ligand B: 0.883). Ligand B is slightly better, indicating a more drug-like profile, but the difference is not substantial.
7. **DILI:** Both ligands have similar and acceptable DILI risk (Ligand A: 48.391, Ligand B: 47.15).
8. **BBB:** Ligand A (78.48) is significantly better than Ligand B (41.683). While ADRB2 isn't exclusively a CNS target, some CNS penetration can be beneficial, and a higher BBB percentile is generally desirable.
9. **Caco-2:** Ligand A (-4.805) is better than Ligand B (-5.45). Both are negative, indicating good permeability.
10. **Solubility:** Ligand A (-4.82) is better than Ligand B (-3.816). Both are negative, indicating good solubility.
11. **hERG:** Ligand A (0.81) is better than Ligand B (0.518). Lower hERG inhibition is crucial for avoiding cardiotoxicity, making Ligand A preferable.
12. **Cl_mic:** Ligand B (21.106) is much better than Ligand A (63.814). Lower microsomal clearance indicates greater metabolic stability, a significant advantage for Ligand B.
13. **t1/2:** Ligand B (-11.891) is better than Ligand A (18.794). A negative value for t1/2 indicates a longer half-life, which is desirable.
14. **Pgp:** Ligand A (0.632) is better than Ligand B (0.188). Lower P-gp efflux is preferable for improved bioavailability.
15. **Binding Affinity:** Both ligands have very similar binding affinities (Ligand A: -6.3 kcal/mol, Ligand B: -6.1 kcal/mol). The difference is not substantial enough to be a deciding factor.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A performs better on logP, TPSA, and Pgp, while the affinity is comparable.
**Overall Assessment:**
Ligand A has a better balance of properties, particularly regarding TPSA, BBB, hERG, and Pgp efflux. While Ligand B has superior metabolic stability (Cl_mic and t1/2), the other advantages of Ligand A, especially the lower hERG risk and better TPSA, are more critical for a GPCR target like ADRB2.
Output:
1
2025-04-17 20:40:22,262 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, key priorities are logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB.
Let's break down the comparison:
1. **MW:** Both ligands (361.36 and 350.369 Da) fall within the ideal 200-500 Da range.
2. **TPSA:** Both are reasonably low (56.79 and 58.44), suggesting good potential for absorption, though slightly above the optimal <90 for CNS targets (less relevant here).
3. **logP:** Ligand A (2.321) is slightly higher than Ligand B (1.782), both are within the optimal 1-3 range. Ligand A is preferred here.
4. **HBD/HBA:** Ligand A has 1 HBD and 5 HBA, while Ligand B has 0 HBD and 4 HBA. Both are acceptable.
5. **QED:** Both have good QED scores (0.569 and 0.765), indicating drug-likeness. Ligand B is slightly better.
6. **DILI:** Ligand A (39.977) has a slightly lower DILI risk than Ligand B (52.307), which is preferable.
7. **BBB:** Both have high BBB penetration (89.066 and 88.523), but this is less critical for a cardiovascular target.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual. However, the values are similar, so this is not a major differentiator.
9. **Solubility:** Both have negative solubility values, which is also unusual. Again, the values are similar.
10. **hERG:** Both have low hERG inhibition risk (0.679 and 0.442), which is good. Ligand B is slightly better.
11. **Cl_mic:** Ligand B (46.592) has a lower microsomal clearance than Ligand A (51.646), suggesting better metabolic stability. This is a significant advantage.
12. **t1/2:** Ligand B (5.583) has a longer in vitro half-life than Ligand A (29.669). This is a significant advantage.
13. **Pgp:** Both have low Pgp efflux liability (0.136 and 0.128), which is good.
14. **Binding Affinity:** Ligand B (-7.0 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.1 kcal/mol) - a difference of 1.9 kcal/mol. This is a major advantage that can outweigh some ADME concerns.
**Overall Assessment:**
While Ligand A has slightly better logP and DILI, Ligand B excels in critical areas: significantly stronger binding affinity, lower microsomal clearance, and longer half-life. The binding affinity difference is substantial. Given the GPCR target class, a strong binding affinity is paramount, and the improved metabolic stability and half-life of Ligand B are highly desirable.
Output:
0
2025-04-17 20:40:22,263 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.5 and 351.5 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (47.1) is significantly better than Ligand B (91.6). ADRB2 is a cardiovascular target, not CNS, but lower TPSA generally aids absorption. Ligand A is well below the 140 threshold, while Ligand B is approaching it.
3. **logP:** Both ligands have acceptable logP values (0.872 and 0.94), falling within the 1-3 range. No clear advantage.
4. **HBD:** Ligand A (0) is preferable to Ligand B (1). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is better than Ligand B (6). Lower HBA is generally preferable for permeability.
6. **QED:** Both ligands have good QED scores (0.713 and 0.823), indicating good drug-like properties. No significant difference.
7. **DILI:** Ligand A (5.584) has a much lower DILI risk than Ligand B (55.991). This is a substantial advantage for Ligand A.
8. **BBB:** This is less critical for a cardiovascular target, but Ligand A (61.5) is better than Ligand B (41.2).
9. **Caco-2:** Both ligands have similar, very negative Caco-2 values (-4.8 and -4.7), suggesting poor permeability. This is a concern for both, but not a differentiating factor.
10. **Solubility:** Ligand A (-0.13) is slightly better than Ligand B (-2.171), but both are very poor. Solubility is a concern for both, but less so for Ligand A.
11. **hERG:** Ligand A (0.421) is significantly better than Ligand B (0.273), indicating a lower risk of cardiotoxicity. This is a critical advantage, given the cardiovascular target.
12. **Cl_mic:** Ligand A (-5.448) has a much lower (better) microsomal clearance than Ligand B (45.118), suggesting better metabolic stability.
13. **t1/2:** Ligand A (3.028) has a better in vitro half-life than Ligand B (-13.353).
14. **Pgp:** Ligand A (0.017) has a much lower Pgp efflux liability than Ligand B (0.134), suggesting better bioavailability.
15. **Binding Affinity:** Ligand A (-7.1) has a slightly better binding affinity than Ligand B (-4.6). This is a significant advantage, exceeding the 1.5 kcal/mol threshold.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical ADME-Tox properties, including DILI, hERG, Cl_mic, Pgp efflux, and in vitro half-life. It also has a superior binding affinity. While both have poor Caco-2 permeability and solubility, Ligand A is better in both regards. Given the GPCR-specific priorities (logP, Pgp, TPSA, affinity), Ligand A is the clear winner.
Output:
1
2025-04-17 20:40:22,263 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**1. Molecular Weight:** Both ligands (342.483 and 350.459 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (40.62) is significantly better than Ligand B (87.66). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B's TPSA is quite high, potentially hindering oral absorption.
**3. logP:** Ligand A (2.674) is within the optimal 1-3 range. Ligand B (0.977) is slightly below 1, which *could* indicate permeability issues, though not drastically.
**4. H-Bond Donors:** Ligand A (0) is preferable to Ligand B (3). Fewer HBDs generally improve membrane permeability.
**5. H-Bond Acceptors:** Ligand A (2) is better than Ligand B (4), again favoring permeability.
**6. QED:** Ligand A (0.774) has a better QED score than Ligand B (0.541), indicating a more drug-like profile.
**7. DILI:** Both ligands have low DILI risk (12.253 and 11.4, respectively), which is excellent.
**8. BBB:** Ligand A (74.098) has a better BBB percentile than Ligand B (49.981). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant, and higher BBB is generally favorable.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.667 and -4.632). This is unusual and suggests a potential issue with the experimental setup or the compounds themselves. However, the values are very similar, so it doesn't differentiate the ligands.
**10. Aqueous Solubility:** Both ligands have negative solubility values (-3.295 and -1.6). This is also unusual and suggests potential formulation challenges. Ligand B is slightly better here.
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.6 and 0.118), which is excellent.
**12. Microsomal Clearance:** Ligand A (47.035) has a higher microsomal clearance than Ligand B (0.116), meaning it's likely to be metabolized more quickly. This is a disadvantage for Ligand A.
**13. In vitro Half-Life:** Ligand A (1.331) has a shorter half-life than Ligand B (0.615), further supporting the faster metabolism concern for Ligand A.
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (0.115 and 0.022).
**15. Binding Affinity:** Ligand A (-6.3 kcal/mol) has a slightly better binding affinity than Ligand B (-5.8 kcal/mol). This 0.5 kcal/mol difference is significant, and can outweigh some of the ADME drawbacks.
**Overall Assessment:**
Ligand A is superior in most key properties for a GPCR target, including TPSA, logP, H-bond donors/acceptors, QED, and BBB penetration. The binding affinity is also better. While Ligand A has higher clearance and shorter half-life, the affinity advantage and better permeability characteristics are more critical for initial optimization. The solubility and Caco-2 values are concerning for both, but can be addressed through formulation strategies.
Output:
1
2025-04-17 20:40:22,263 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (347.415 and 347.354 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (91.76) is better than Ligand B (105.9). For a GPCR, keeping TPSA under 140 is good for oral absorption, and lower is generally preferred.
**3. logP:** Ligand A (1.325) is within the optimal 1-3 range, while Ligand B (0.054) is quite low. Low logP can hinder membrane permeability. This is a significant advantage for Ligand A.
**4. H-Bond Donors:** Ligand A (2) and Ligand B (1) are both acceptable.
**5. H-Bond Acceptors:** Ligand A (5) is better than Ligand B (8). Lower HBA is generally preferred for better permeability.
**6. QED:** Both ligands have similar QED values (0.776 and 0.762), indicating good drug-like properties.
**7. DILI Risk:** Ligand A (28.655) has a much lower DILI risk than Ligand B (69.794). This is a crucial factor, as liver toxicity is a major concern in drug development.
**8. BBB Penetration:** Ligand B (90.151) has better BBB penetration than Ligand A (59.403). However, since ADRB2 is primarily a cardiovascular target, high BBB penetration is not a primary requirement.
**9. Caco-2 Permeability:** Ligand A (-4.987) and Ligand B (-5.11) are similar, indicating similar intestinal absorption.
**10. Aqueous Solubility:** Ligand A (-1.774) is slightly better than Ligand B (-2.085).
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.145 and 0.011).
**12. Microsomal Clearance:** Ligand A (2.942) has lower microsomal clearance than Ligand B (3.81), suggesting better metabolic stability.
**13. In vitro Half-Life:** Ligand A (0.068) has a significantly longer in vitro half-life than Ligand B (-5.538).
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.011 and 0.042).
**15. Binding Affinity:** Both ligands have very similar binding affinities (-6.3 and -6.4 kcal/mol). The difference is negligible.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity) and general drug-like properties, Ligand A is the superior candidate. It has a better logP, lower TPSA, significantly lower DILI risk, better metabolic stability (lower Cl_mic and longer t1/2), and comparable affinity. While Ligand B has better BBB penetration, this is less critical for a cardiovascular target. The lower DILI risk and improved ADME properties of Ligand A outweigh the slight advantage of Ligand B in BBB penetration.
Output:
1
2025-04-17 20:40:22,263 - INFO - Batch 202 complete. Total preferences: 3232
2025-04-17 20:40:22,263 - INFO - Processing batch 203/512...
2025-04-17 20:41:11,866 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [364.389, 88.1, 0.653, 2, 5, 0.587, 34.432, 81.815, -4.856, -0.945, 0.244, 8.973, 4.915, 0.023, -7.1]
**Ligand B:** [371.928, 38.13, 4.923, 0, 3, 0.547, 42.303, 82.241, -4.707, -4.887, 0.647, 112.937, 55.712, 0.786, -4.7]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity, and BBB):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (364.389) is slightly lower, which is generally favorable.
2. **TPSA:** Ligand A (88.1) is better than Ligand B (38.13). Lower TPSA generally improves permeability, and is particularly important for GPCRs.
3. **logP:** Ligand A (0.653) is significantly better than Ligand B (4.923). Ligand B's logP is quite high, potentially leading to solubility issues and off-target effects.
4. **HBD/HBA:** Ligand A (2 HBD, 5 HBA) is slightly more balanced than Ligand B (0 HBD, 3 HBA).
5. **QED:** Both are reasonably good (A: 0.587, B: 0.547), indicating acceptable drug-likeness.
6. **DILI:** Ligand A (34.432) has a lower DILI risk than Ligand B (42.303), which is preferable.
7. **BBB:** Both have good BBB penetration (A: 81.815, B: 82.241). This is less critical for ADRB2 (cardiovascular target) but still a positive.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. This is a red flag for both, but the lower (more negative) value for Ligand A (-4.856) is slightly better than Ligand B (-4.707).
9. **Solubility:** Ligand A (-0.945) has better solubility than Ligand B (-4.887). This is important, especially given Ligand B's high logP.
10. **hERG:** Ligand A (0.244) has a much lower hERG risk than Ligand B (0.647). This is a significant advantage for Ligand A.
11. **Cl_mic:** Ligand A (8.973) has significantly lower microsomal clearance than Ligand B (112.937), indicating better metabolic stability.
12. **t1/2:** Ligand A (4.915) has a shorter half-life than Ligand B (55.712), but this is less concerning given the other advantages of Ligand A.
13. **Pgp:** Ligand A (0.023) has much lower P-gp efflux liability than Ligand B (0.786), which is crucial for bioavailability.
14. **Affinity:** Ligand A (-7.1) has a slightly better binding affinity than Ligand B (-4.7). While both are good, the difference of 2.4 kcal/mol is substantial.
**Overall Assessment:**
Ligand A is significantly better. It has a more favorable logP, lower DILI risk, lower hERG risk, much better metabolic stability (lower Cl_mic), lower P-gp efflux, and slightly better binding affinity. While both have poor Caco-2 permeability, Ligand A's other properties outweigh this concern. Ligand B's high logP and high clearance are major drawbacks.
Output:
1
2025-04-17 20:41:11,867 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (353.419 and 344.455 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (110.96) is higher than Ligand B (62.55). For a GPCR, lower TPSA is generally preferred for better brain penetration, even though ADRB2 isn't strictly a CNS target. Ligand B is significantly better.
3. **logP:** Ligand A (-1.018) is lower than the optimal 1-3 range, potentially hindering permeability. Ligand B (3.452) is within the optimal range. Ligand B is better.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable. No strong preference.
5. **HBA:** Ligand A (5) and Ligand B (3) are both acceptable. No strong preference.
6. **QED:** Both ligands have good QED scores (0.657 and 0.832), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (25.94) has a significantly lower DILI risk than Ligand B (38.581). This is a considerable advantage for Ligand A.
8. **BBB:** Ligand A (65.956) has a moderate BBB penetration, while Ligand B (83.288) is higher. While ADRB2 isn't a CNS target, higher BBB is generally favorable. Ligand B is better.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.574 and -4.747) which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand A (-1.897) and Ligand B (-3.632) both have negative solubility values, indicating poor aqueous solubility. This is a concern for both, but more pronounced for Ligand B. Ligand A is slightly better.
11. **hERG:** Ligand A (0.113) has a lower hERG risk than Ligand B (0.381). This is a safety advantage for Ligand A.
12. **Cl_mic:** Ligand A (19.255) has a lower microsomal clearance than Ligand B (45.742), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (-4.15) has a negative in vitro half-life, which is concerning. Ligand B (29.978) has a much better half-life. Ligand B is significantly better.
14. **Pgp:** Ligand A (0.003) has very low P-gp efflux, while Ligand B (0.365) has moderate efflux. Ligand A is better.
15. **Binding Affinity:** Ligand B (-8.2) has a significantly stronger binding affinity than Ligand A (-5.9). This is a substantial advantage for Ligand B, potentially outweighing some of the ADME drawbacks.
**Overall Assessment:**
Ligand B has a superior binding affinity and better BBB penetration and in vitro half-life. However, it has a higher DILI risk, higher Pgp efflux, and worse solubility. Ligand A has better DILI, hERG, Cl_mic, and Pgp properties, but suffers from a weaker binding affinity and a concerning negative in vitro half-life.
Given the importance of potency for GPCRs, the significantly stronger binding affinity of Ligand B is a major factor. While the ADME properties of Ligand B are not ideal, they may be addressable through further optimization. The negative half-life of Ligand A is a major red flag.
Output:
0
2025-04-17 20:41:11,867 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (338.415 and 343.347 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (79.97) is significantly better than Ligand B (139.89). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally aids absorption.
3. **logP:** Ligand A (2.94) is optimal, while Ligand B (-0.942) is quite low, potentially hindering membrane permeability. This is a significant negative for Ligand B.
4. **HBD:** Ligand A (1) is preferable to Ligand B (4). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (7) is better than Ligand B (6). Lower HBA is generally preferred.
6. **QED:** Ligand A (0.709) is better than Ligand B (0.528), indicating a more drug-like profile.
7. **DILI:** Both ligands have similar DILI risk (63.164 vs 60.217), both are acceptable.
8. **BBB:** Ligand A (73.672) is better than Ligand B (27.026), but BBB isn't a high priority for a cardiovascular target.
9. **Caco-2:** Both are negative (-5.217 and -5.253), indicating poor permeability.
10. **Solubility:** Both are negative (-2.401 and -2.953), indicating poor solubility.
11. **hERG:** Ligand A (0.805) is better than Ligand B (0.103). Lower hERG inhibition is crucial for avoiding cardiotoxicity, which is particularly important for a cardiovascular target.
12. **Cl_mic:** Ligand A (19.212) is significantly better than Ligand B (-31.334). Lower clearance indicates better metabolic stability.
13. **t1/2:** Ligand A (55.741) is much better than Ligand B (-9.194). A longer half-life is desirable.
14. **Pgp:** Ligand A (0.079) is better than Ligand B (0.031). Lower P-gp efflux is preferred.
15. **Affinity:** Ligand A (-7.1 kcal/mol) is slightly better than Ligand B (-5.6 kcal/mol). While both are good, the difference is substantial enough to consider.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A excels in these areas. While BBB isn't critical, Ligand A still has a better value.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical ADME and binding parameters. The superior logP, metabolic stability (Cl_mic, t1/2), lower hERG risk, and slightly better affinity make it a much more promising drug candidate. While both have poor Caco-2 and solubility, these can potentially be addressed with formulation strategies. The significant issues with Ligand B's logP and metabolic stability are harder to overcome.
Output:
1
2025-04-17 20:41:11,867 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [364.467, 95.5, 0.807, 3, 5, 0.634, 41.411, 20.512, -5.608, -2.486, 0.053, 37.631, 1.751, 0.168, -6.7]**
**Ligand B: [377.463, 105.25, -1.208, 1, 7, 0.594, 43.622, 56.301, -5.299, -0.936, 0.133, -2.593, 0.506, 0.008, -7]**
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). A (364.467) is slightly preferred.
2. **TPSA:** Both are reasonably good, but A (95.5) is better than B (105.25) for oral absorption, being closer to the <140 threshold.
3. **logP:** A (0.807) is a bit low, potentially hindering permeability. B (-1.208) is even lower, raising more concerns about permeability.
4. **H-Bond Donors:** A (3) is acceptable. B (1) is excellent.
5. **H-Bond Acceptors:** A (5) is acceptable. B (7) is also acceptable.
6. **QED:** A (0.634) is better than B (0.594), indicating a more drug-like profile.
7. **DILI:** Both are acceptable, with A (41.411) and B (43.622) being relatively low risk.
8. **BBB:** B (56.301) is significantly better than A (20.512). While ADRB2 isn't strictly a CNS target, some CNS penetration can be beneficial, and this is a significant advantage for B.
9. **Caco-2:** Both are negative, indicating poor permeability.
10. **Solubility:** Both are negative, indicating poor solubility.
11. **hERG:** Both are very low risk. A (0.053) is slightly better than B (0.133).
12. **Cl_mic:** A (37.631) is higher than B (-2.593), meaning A has faster metabolic clearance. B is much more metabolically stable.
13. **t1/2:** A (1.751) is better than B (0.506) - longer half-life is generally preferred.
14. **Pgp:** A (0.168) is better than B (0.008). Lower P-gp efflux is preferred.
15. **Binding Affinity:** B (-7) is 0.3 kcal/mol stronger than A (-6.7). This is a substantial difference and a major advantage for B.
**GPCR-Specific Priorities:** For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. While A has a slightly better TPSA and Pgp, B has a significantly better affinity and a better BBB score. The negative logP values for both are concerning, but the stronger binding of B is a significant advantage that could potentially overcome permeability issues. The improved metabolic stability of B is also a strong plus.
**Conclusion:**
Despite the slightly better TPSA and Pgp of Ligand A, the significantly stronger binding affinity (-7 kcal/mol vs -6.7 kcal/mol) and improved metabolic stability of Ligand B outweigh the drawbacks. The better BBB penetration is also a bonus.
Output:
0
2025-04-17 20:41:11,867 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for their potential as drug candidates targeting the ADRB2, a cardiovascular GPCR. Therefore, we prioritize logP, Pgp, TPSA, and affinity, alongside general drug-like properties.
**Ligand A:**
* **MW:** 345.443 Da - Good. Within the ideal range.
* **TPSA:** 68.4 A2 - Good. Below the 140 A2 threshold.
* **logP:** 3.268 - Good. Within the optimal range.
* **HBD:** 2 - Good.
* **HBA:** 5 - Good.
* **QED:** 0.806 - Excellent. Highly drug-like.
* **DILI:** 61.109 - Moderate risk. Slightly elevated, but not a dealbreaker.
* **BBB:** 73.943 - Good. Acceptable for a cardiovascular target, though not a CNS target.
* **Caco-2:** -5.217 - Poor. Indicates poor permeability.
* **Solubility:** -2.854 - Poor. Indicates poor solubility.
* **hERG:** 0.894 - Acceptable. Low risk of hERG inhibition.
* **Cl_mic:** 10.867 mL/min/kg - Moderate. Could be better, indicating moderate metabolic clearance.
* **t1/2:** 58.392 hours - Excellent. Long half-life.
* **Pgp:** 0.225 - Good. Low P-gp efflux.
* **Affinity:** -6.4 kcal/mol - Good.
**Ligand B:**
* **MW:** 354.495 Da - Good. Within the ideal range.
* **TPSA:** 81.75 A2 - Acceptable. Slightly above the preferred threshold, but still reasonable.
* **logP:** 1.436 - Acceptable. On the lower end of optimal, but not concerning.
* **HBD:** 2 - Good.
* **HBA:** 3 - Good.
* **QED:** 0.692 - Good. Drug-like.
* **DILI:** 19.93 - Excellent. Very low DILI risk.
* **BBB:** 69.252 - Acceptable.
* **Caco-2:** -4.761 - Poor. Indicates poor permeability.
* **Solubility:** -1.642 - Poor. Indicates poor solubility.
* **hERG:** 0.424 - Excellent. Very low hERG inhibition risk.
* **Cl_mic:** 13.663 mL/min/kg - Moderate.
* **t1/2:** 0.333 hours - Poor. Very short half-life.
* **Pgp:** 0.006 - Excellent. Very low P-gp efflux.
* **Affinity:** -5.3 kcal/mol - Good.
**Comparison and Decision:**
Both ligands have poor Caco-2 permeability and solubility, which are significant drawbacks. However, Ligand A has a substantially longer half-life (58.392 hours vs. 0.333 hours) and a better QED score (0.806 vs 0.692). While Ligand B has a better DILI and hERG profile, the extremely short half-life is a major concern. For a cardiovascular target, a longer half-life is highly desirable to maintain therapeutic concentrations. The affinity difference (-6.4 vs -5.3 kcal/mol) is also a factor favoring Ligand A. Although both have permeability and solubility issues, these can be addressed with formulation strategies. The metabolic stability and half-life are harder to fix.
Therefore, I prefer Ligand A.
**Output:**
1
2025-04-17 20:41:11,868 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (354.422 and 372.575 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (89.87) is better than Ligand B (60.85). Both are below the 140 threshold for oral absorption, and Ligand B is closer to the 90 threshold for CNS targets, but ADRB2 is a cardiovascular target, so this isn't a major concern.
3. **logP:** Ligand B (2.624) is better than Ligand A (0.508). Ligand A is quite low, potentially hindering membrane permeability. Ligand B is within the optimal 1-3 range.
4. **HBD:** Ligand A (3) is higher than Ligand B (1). Both are acceptable, but lower is generally preferred for permeability.
5. **HBA:** Both ligands have 4 HBA, which is good.
6. **QED:** Both ligands have similar QED values (0.686 and 0.676), indicating good drug-likeness.
7. **DILI:** Ligand B (3.296) is significantly better than Ligand A (15.238). This is a substantial advantage for Ligand B, as lower DILI risk is crucial.
8. **BBB:** Ligand B (62.466) is better than Ligand A (52.268), but neither is particularly high. This isn't a critical factor for a cardiovascular target like ADRB2.
9. **Caco-2:** Ligand A (-5.116) is better than Ligand B (-4.698). Higher values indicate better absorption.
10. **Solubility:** Ligand A (-1.84) is better than Ligand B (-2.021). Higher values are better.
11. **hERG:** Ligand A (0.391) is better than Ligand B (0.571). Lower hERG inhibition is preferred.
12. **Cl_mic:** Ligand A (-0.502) is significantly better than Ligand B (53.296). Lower clearance indicates better metabolic stability.
13. **t1/2:** Ligand A (8.699) is much better than Ligand B (-2.877). A longer half-life is generally desirable.
14. **Pgp:** Ligand A (0.029) is significantly better than Ligand B (0.147). Lower P-gp efflux is preferred.
15. **Binding Affinity:** Ligand A (-6.9) is better than Ligand B (-4.7). This is a substantial difference in potency (2.2 kcal/mol).
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand B has a better logP. Ligand A is better in TPSA, Pgp, and significantly better in affinity. The DILI risk for Ligand B is much lower.
**Overall Assessment:**
While Ligand B has a better logP and significantly lower DILI risk, the substantially stronger binding affinity of Ligand A (-6.9 vs -4.7 kcal/mol) is a major advantage. The difference in affinity is large enough to potentially overcome the slightly less favorable logP and higher DILI risk, especially considering the other ADME properties of Ligand A are also generally better (Cl_mic, t1/2, Pgp). The better Caco-2 and solubility of Ligand A are also beneficial.
Output:
1
2025-04-17 20:41:11,868 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (343.427 Da and 342.439 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (65.72) is slightly higher than Ligand B (60.85). Both are below the 140 A^2 threshold for good oral absorption, and acceptable for a cardiovascular GPCR.
3. **logP:** Ligand A (3.548) is slightly higher than Ligand B (2.364), both within the optimal 1-3 range. Ligand B is closer to the lower end, which *could* indicate potential permeability issues, but isn't a major concern.
4. **HBD:** Ligand A (0) has no hydrogen bond donors, while Ligand B (1) has one. Lower is generally preferred for permeability, so Ligand A is slightly better here.
5. **HBA:** Ligand A (6) has more hydrogen bond acceptors than Ligand B (3). Ligand B is better here, as it's closer to the ideal of <=10.
6. **QED:** Both ligands have good QED scores (0.798 and 0.892), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (60.915) has a significantly higher DILI risk than Ligand B (18.147). This is a major red flag for Ligand A.
8. **BBB:** Both ligands have reasonably good BBB penetration (78.751 and 60.527). Given that ADRB2 is a cardiovascular target, BBB penetration is not a primary concern, but higher is still slightly preferable. Ligand A is better.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.999 and -4.948), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-4.474) has worse solubility than Ligand B (-1.999). Solubility is important for bioavailability, so Ligand B is better.
11. **hERG:** Both ligands have low hERG inhibition risk (0.378 and 0.14). Ligand B is slightly better.
12. **Cl_mic:** Ligand A (97.175) has higher microsomal clearance than Ligand B (7.847), indicating lower metabolic stability. This is a significant drawback for Ligand A.
13. **t1/2:** Ligand A (-9.33) has a more negative in vitro half-life than Ligand B (-6.15), indicating a shorter half-life. This is a negative for Ligand A.
14. **Pgp:** Ligand A (0.512) has higher P-gp efflux than Ligand B (0.02). Lower P-gp efflux is preferred. Ligand B is better.
15. **Binding Affinity:** Ligand A (-6.2) has a better binding affinity than Ligand B (-1.0). This is a substantial advantage for Ligand A.
**Overall Assessment & GPCR Prioritization:**
For a cardiovascular GPCR like ADRB2, affinity is crucial. However, the significant drawbacks of Ligand A (high DILI risk, high Cl_mic, short half-life, high P-gp efflux, poor solubility) outweigh its superior binding affinity. Ligand B, while having a weaker binding affinity, presents a much more favorable ADMET profile, particularly the significantly lower DILI risk and better metabolic stability. The Caco-2 values are concerning for both, but can be addressed with formulation strategies.
Therefore, I believe Ligand B is the more viable drug candidate.
Output:
0
2025-04-17 20:41:11,868 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (338.37) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (86.23) is significantly better than Ligand B (33.2). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower TPSA generally correlates with better membrane permeability. Ligand B is exceptionally low, potentially indicating a lack of necessary interactions.
3. **logP:** Ligand B (4.565) is higher than Ligand A (2.822). While both are above the optimal range of 1-3, Ligand B is pushing into a potentially problematic area for solubility and off-target effects.
4. **HBD/HBA:** Ligand A has 1 HBD and 7 HBA, while Ligand B has 0 HBD and 2 HBA. Ligand A strikes a better balance.
5. **QED:** Both ligands have similar QED values (0.692 vs 0.719), indicating good drug-likeness.
6. **DILI:** Ligand A (91.78) has a significantly higher DILI risk than Ligand B (14.23). This is a major concern for Ligand A.
7. **BBB:** Ligand B (97.208) has a much higher BBB penetration potential than Ligand A (61.38). While ADRB2 isn't a primary CNS target, some degree of BBB penetration can be relevant for off-target effects.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. The values are similar enough to not be a deciding factor.
9. **Solubility:** Both ligands have negative solubility values, which is also unusual and suggests poor solubility. The values are similar enough to not be a deciding factor.
10. **hERG:** Both ligands have similar hERG inhibition liability (0.64 vs 0.737).
11. **Cl_mic:** Ligand B (62.252) has a lower microsomal clearance than Ligand A (109.338), indicating better metabolic stability.
12. **t1/2:** Ligand B (-6.164) has a more negative in vitro half-life than Ligand A (-1.65). This suggests a longer half-life for Ligand B, which is desirable.
13. **Pgp:** Both ligands have similar P-gp efflux liability (0.084 vs 0.204).
14. **Binding Affinity:** Both ligands have similar binding affinity (-4.4 kcal/mol vs -4.3 kcal/mol). The difference is negligible.
**Overall Assessment:**
Ligand B is the more promising candidate. While its logP is slightly high, its significantly lower DILI risk, better metabolic stability (lower Cl_mic, more negative t1/2), and higher BBB penetration outweigh the slightly higher logP. Ligand A's high DILI risk is a major red flag. The TPSA difference is also notable, with Ligand B's lower value potentially aiding permeability despite the higher logP. The similar binding affinities make the ADME properties the deciding factor.
Output:
0
2025-04-17 20:41:11,868 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
We are targeting ADRB2, a GPCR. Therefore, key priorities are logP, Pgp efflux, TPSA, BBB penetration, and binding affinity. Metabolic stability and solubility are also important, but slightly less so than the first set.
Let's break down the comparison:
1. **MW:** Both ligands are within the ideal range (200-500 Da).
2. **TPSA:** Ligand B (58.64) is significantly better than Ligand A (88.69). Lower TPSA generally improves permeability, a crucial factor for GPCR ligands.
3. **logP:** Ligand B (1.954) is within the optimal range, while Ligand A (0.237) is quite low, potentially hindering membrane permeability.
4. **HBD/HBA:** Ligand B has fewer HBDs (1 vs 3) which is preferable for permeability. HBA counts are similar (3 vs 5).
5. **QED:** Ligand B (0.759) has a better QED score than Ligand A (0.594), indicating a more drug-like profile.
6. **DILI:** Ligand B (20.589) has a much lower DILI risk than Ligand A (32.067). This is a significant advantage.
7. **BBB:** Ligand B (90.229) has excellent BBB penetration, while Ligand A (23.42) is very poor. This is a major advantage for a GPCR target, even if not strictly CNS-focused, as it suggests better distribution.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and difficult to interpret without knowing the scale. However, the values are similar.
9. **Solubility:** Ligand A (-0.789) is slightly better than Ligand B (-2.586), but both are poor. Solubility can be improved with formulation.
10. **hERG:** Ligand A (0.083) has a slightly lower hERG risk than Ligand B (0.6), but both are relatively low.
11. **Cl_mic:** Ligand A (-13.63) has a much lower (better) microsomal clearance than Ligand B (18.69). This suggests better metabolic stability.
12. **t1/2:** Ligand B (19.17) has a significantly longer in vitro half-life than Ligand A (3.918).
13. **Pgp:** Ligand A (0.013) has much lower P-gp efflux liability than Ligand B (0.041), which is favorable.
14. **Binding Affinity:** Both ligands have excellent binding affinity (-7.0 and -5.2 kcal/mol respectively). Ligand A is slightly better, but the difference is not substantial enough to outweigh other factors.
**Overall Assessment:**
Ligand B clearly outperforms Ligand A in several critical areas for a GPCR drug candidate: TPSA, logP, BBB penetration, DILI risk, and in vitro half-life. While Ligand A has slightly better affinity and lower Pgp efflux, the improvements in ADME properties with Ligand B are more impactful for overall drug development potential. The poor logP and BBB of Ligand A are major drawbacks.
**Output:**
0
2025-04-17 20:41:11,868 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [353.438, 64.09, 0.249, 1, 4, 0.787, 8.143, 68.36, -4.819, -0.823, 0.521, 7.647, 3.542, 0.031, -7.0]
**Ligand B:** [359.539, 38.13, 4.134, 0, 4, 0.711, 29.857, 78.868, -5.017, -3.979, 0.725, 118.227, 25.454, 0.621, -7.0]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (353.438) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (64.09) is significantly better than Ligand B (38.13), falling well below the 140 threshold for oral absorption.
3. **logP:** Ligand B (4.134) is higher than the optimal range (1-3), potentially leading to solubility issues and off-target effects. Ligand A (0.249) is quite low, which could hinder membrane permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (0), as having at least one HBD can improve solubility.
5. **HBA:** Both have 4 HBA, which is acceptable.
6. **QED:** Both have similar QED values (A: 0.787, B: 0.711), indicating good drug-like properties.
7. **DILI:** Ligand A (8.143) has a much lower DILI risk than Ligand B (29.857). This is a significant advantage.
8. **BBB:** Ligand B (78.868) has better BBB penetration than Ligand A (68.36), but for a cardiovascular target, BBB penetration is not a primary concern.
9. **Caco-2:** Ligand A (-4.819) and Ligand B (-5.017) are both very poor.
10. **Solubility:** Ligand B (-3.979) has very poor solubility. Ligand A (-0.823) is better, but still not ideal.
11. **hERG:** Ligand A (0.521) has a lower hERG risk than Ligand B (0.725).
12. **Cl_mic:** Ligand A (7.647) has significantly lower microsomal clearance than Ligand B (118.227), indicating better metabolic stability.
13. **t1/2:** Ligand B (25.454) has a much longer in vitro half-life than Ligand A (3.542). This is a positive for Ligand B.
14. **Pgp:** Ligand B (0.621) has higher P-gp efflux than Ligand A (0.031). This is unfavorable for bioavailability.
15. **Affinity:** Both have the same binding affinity (-7.0 kcal/mol).
**GPCR-Specific Priorities:** For ADRB2 (a cardiovascular GPCR), logP, TPSA, Pgp, and affinity are key. While Ligand B has better BBB penetration (less important here) and a longer half-life, it suffers from a high logP, poor solubility, high DILI risk, and high P-gp efflux. Ligand A, despite its low logP and poor Caco-2 permeability, has a much more favorable safety profile (lower DILI, lower hERG) and better metabolic stability. The lower TPSA of Ligand A is also beneficial. The binding affinity is the same for both.
**Conclusion:**
Considering the balance of properties and the priorities for a cardiovascular GPCR target, **Ligand A** is the more promising candidate. Its lower DILI risk, better metabolic stability, and more favorable TPSA outweigh the concerns about its low logP and Caco-2 permeability. These permeability issues could potentially be addressed with formulation strategies.
Output:
1
2025-04-17 20:41:11,869 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.45 & 349.43 Da) fall comfortably within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (89.53) is better than Ligand B (104.37). For a GPCR, keeping TPSA low is beneficial for permeability, and A is well below the 140 threshold.
3. **logP:** Ligand A (1.156) is slightly better than Ligand B (0.798), both are within the optimal 1-3 range, but closer to the lower end.
4. **HBD:** Ligand A (2) is preferable to Ligand B (3). Lower HBD generally improves permeability.
5. **HBA:** Both ligands have 4 HBA, which is acceptable.
6. **QED:** Ligand A (0.835) is significantly better than Ligand B (0.325). A higher QED suggests a more drug-like profile.
7. **DILI:** Both ligands have similar DILI risk (33.31 vs 34.78), and both are below the concerning threshold of 60.
8. **BBB:** Ligand B (77.08) is significantly better than Ligand A (32.80). While ADRB2 isn't exclusively a CNS target, some CNS penetration can be useful, and this is a substantial difference.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-5.134) is slightly better than Ligand B (-5.319) but both are very poor.
10. **Solubility:** Ligand A (-1.517) is better than Ligand B (-2.656), indicating better aqueous solubility.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.124 and 0.068), which is excellent.
12. **Cl_mic:** Ligand A (11.72) has a much lower microsomal clearance than Ligand B (26.25), indicating better metabolic stability.
13. **t1/2:** Ligand A (-18.30) has a much longer in vitro half-life than Ligand B (-3.87), which is a strong positive.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.076 and 0.021).
15. **Binding Affinity:** Ligand A (-6.9) has a slightly better binding affinity than Ligand B (-6.6), though the difference is relatively small.
**GPCR-Specific Priorities & Overall Assessment:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A has a better TPSA, logP, QED, solubility, metabolic stability (Cl_mic), and half-life. Ligand B has a better BBB score. However, the substantial improvements in drug-like properties (QED), metabolic stability, and half-life of Ligand A outweigh the BBB advantage of Ligand B. The slightly better affinity of Ligand A is also a plus. The poor Caco-2 values for both are concerning and would need to be addressed in further optimization, but the other properties of Ligand A make it a more promising starting point.
Output:
1
2025-04-17 20:41:11,869 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (a GPCR) drug candidates.
**Ligand A:** [358.385, 78.87, 0.68, 2, 4, 0.775, 25.785, 83.715, -4.702, -2.536, 0.488, -16.469, 23.102, 0.025, -7.0]
**Ligand B:** [351.393, 55.4, 3.203, 1, 3, 0.801, 25.979, 97.286, -4.656, -3.661, 0.622, 42.481, -1.722, 0.135, -6.1]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, BBB, Affinity):
1. **MW:** Both are within the ideal 200-500 Da range. A (358.385) and B (351.393) are very close.
2. **TPSA:** A (78.87) is slightly higher than B (55.4). B is better here, being closer to the <90 target for potential CNS penetration (though ADRB2 isn't necessarily a CNS target, lower TPSA is generally favorable).
3. **logP:** A (0.68) is a bit low, potentially hindering permeability. B (3.203) is excellent, falling right within the optimal 1-3 range. This is a significant advantage for B.
4. **HBD/HBA:** A (2 HBD, 4 HBA) is slightly higher than B (1 HBD, 3 HBA). Both are acceptable, but B is slightly better.
5. **QED:** Both are good (A: 0.775, B: 0.801), indicating drug-like properties. B is marginally better.
6. **DILI:** Both are very low (A: 25.785, B: 25.979), indicating minimal liver injury risk.
7. **BBB:** B (97.286) has a much higher BBB penetration score than A (83.715). While not a primary concern for ADRB2, higher BBB is generally a positive.
8. **Caco-2:** Both are negative, which is unusual. This suggests poor permeability.
9. **Solubility:** Both are negative, which is also unusual. This suggests poor solubility.
10. **hERG:** Both are low (A: 0.488, B: 0.622), indicating low cardiotoxicity risk.
11. **Cl_mic:** A (-16.469) has a much *lower* (better) microsomal clearance than B (42.481), suggesting greater metabolic stability. This is a significant advantage for A.
12. **t1/2:** A (23.102) has a much longer in vitro half-life than B (-1.722). This is a major advantage for A.
13. **Pgp:** A (0.025) has a much lower P-gp efflux liability than B (0.135), suggesting better absorption and potentially higher bioavailability. This is a significant advantage for A.
14. **Affinity:** A (-7.0) and B (-6.1) both have good binding affinities. A is slightly better (-0.9 kcal/mol difference).
**Overall Assessment:**
Ligand B excels in logP and BBB penetration. However, Ligand A demonstrates superior metabolic stability (Cl_mic, t1/2), P-gp efflux, and slightly better affinity. Considering the GPCR-specific priorities, the improved metabolic profile and reduced efflux of Ligand A are crucial for *in vivo* efficacy. While B has a better logP, A's overall balance of properties, particularly the metabolic stability and P-gp profile, make it the more promising candidate.
Output:
1
2025-04-17 20:41:11,869 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (357.41 Da) is within the ideal range, while Ligand B (381.885 Da) is slightly higher but still acceptable.
2. **TPSA:** Ligand A (54.46) is excellent, well below the 140 threshold. Ligand B (71.53) is still reasonable, but less optimal.
3. **logP:** Ligand A (4.626) is a bit high, potentially leading to solubility issues and off-target effects. Ligand B (2.253) is within the optimal range.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 5 HBA, both acceptable.
6. **QED:** Both ligands have good QED scores (A: 0.741, B: 0.812), indicating good drug-likeness.
7. **DILI:** Ligand A (98.682) has a very high DILI risk, which is a major concern. Ligand B (61.031) is still elevated, but significantly lower and more manageable.
8. **BBB:** Both ligands have good BBB penetration (A: 71.384, B: 79.604), which isn't a primary concern for ADRB2 (a cardiovascular target), but isn't detrimental.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. This is a red flag for both.
10. **Solubility:** Ligand A (-5.575) has very poor solubility, likely due to the high logP. Ligand B (-3.473) is also poor, but better than A.
11. **hERG:** Both ligands have low hERG inhibition risk (A: 0.5, B: 0.335).
12. **Cl_mic:** Ligand A (96.234) has high microsomal clearance, indicating poor metabolic stability. Ligand B (21.256) has much lower clearance, a significant advantage.
13. **t1/2:** Ligand A (12.08) has a reasonable half-life, while Ligand B (0.271) has a very short half-life.
14. **Pgp:** Both have low Pgp efflux (A: 0.473, B: 0.274).
15. **Affinity:** Ligand B (-7.5 kcal/mol) has significantly stronger binding affinity than Ligand A (-3.6 kcal/mol). This is a substantial advantage.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are particularly important. Ligand B excels in affinity and has a more favorable logP and TPSA. While both have acceptable Pgp efflux, the massive difference in binding affinity and the significantly lower DILI risk of Ligand B outweigh the shorter half-life. The poor Caco-2 values are concerning for both, but can be addressed with formulation strategies.
**Conclusion:**
Despite the short half-life and poor Caco-2 permeability, Ligand B is the superior candidate due to its significantly higher binding affinity, lower DILI risk, and more favorable logP. The high DILI risk of Ligand A is a major disqualifier.
Output:
0
2025-04-17 20:41:11,869 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (370.49 and 351.422 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (66.48) is slightly higher than Ligand B (60.93). Both are below the 140 threshold for good oral absorption, but closer to the 90 threshold for CNS targets (though ADRB2 isn't necessarily a CNS target). Ligand B is slightly preferred.
3. **logP:** Ligand A (1.39) and Ligand B (0.985) are both within the optimal 1-3 range. No strong preference.
4. **HBD:** Ligand A (1) is preferable to Ligand B (0) as it provides a hydrogen bond donor, which can be important for receptor interactions.
5. **HBA:** Both ligands have 3 HBA, which is well within the acceptable range.
6. **QED:** Ligand A (0.768) has a slightly higher QED than Ligand B (0.694), indicating a more drug-like profile.
7. **DILI:** Ligand B (40.132) has a significantly lower DILI risk than Ligand A (18.883). This is a major advantage for Ligand B.
8. **BBB:** Both ligands have very high BBB penetration (85.925 and 86.08), which isn't a primary concern for ADRB2, but isn't detrimental.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. This is a significant drawback for both. However, Ligand B (-4.179) is slightly better than Ligand A (-4.827).
10. **Solubility:** Ligand B (-1.221) has slightly better solubility than Ligand A (-2.694), which is beneficial.
11. **hERG:** Both ligands have low hERG inhibition risk (0.465 and 0.352). No significant difference.
12. **Cl_mic:** Ligand B (9.399) has a significantly lower microsomal clearance than Ligand A (18.336), suggesting better metabolic stability. This is a major advantage.
13. **t1/2:** Ligand B (-23.039) has a much longer in vitro half-life than Ligand A (14.817), which is a significant advantage.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.028 and 0.129). No significant difference.
15. **Binding Affinity:** Ligand B (-6.1) has a slightly better binding affinity than Ligand A (-5.6). While the difference is less than the 1.5 kcal/mol threshold, it contributes to the overall preference.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand B is slightly better on logP, TPSA, and affinity. The significantly better DILI, Cl_mic, and t1/2 profiles of Ligand B outweigh the slightly better QED and HBD of Ligand A. The Caco-2 permeability is poor for both, but slightly better for Ligand B.
**Conclusion:**
Considering the balance of properties, especially the improved safety profile (lower DILI) and better pharmacokinetic properties (lower Cl_mic, longer t1/2) of Ligand B, it is the more promising drug candidate.
Output:
0
2025-04-17 20:41:11,869 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (345.4 and 348.4 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (102.76) is slightly higher than Ligand B (98.66). Both are below the 140 threshold for good oral absorption, but closer to the upper end.
3. **logP:** Ligand B (1.873) is better than Ligand A (0.516). A logP between 1-3 is optimal, and Ligand A is a bit low, potentially impacting permeability.
4. **HBD:** Ligand B (4) is slightly better than Ligand A (3). Both are within the acceptable limit of <=5.
5. **HBA:** Ligand B (4) is better than Ligand A (5). Both are within the acceptable limit of <=10.
6. **QED:** Both ligands have similar QED values (0.675 and 0.631), both above the 0.5 threshold, indicating good drug-likeness.
7. **DILI:** Ligand A (25.09) has a significantly lower DILI risk than Ligand B (37.03). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (51.49) has a much higher BBB penetration percentile than Ligand A (22.96). While ADRB2 isn't strictly a CNS target, some CNS exposure can be acceptable and even beneficial for certain cardiovascular effects.
9. **Caco-2:** Ligand A (-5.446) and Ligand B (-4.707) both have negative Caco-2 values, which is unusual and suggests very poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand A (-1.695) has slightly better solubility than Ligand B (-2.767), though both are quite poor.
11. **hERG:** Ligand A (0.028) has a much lower hERG inhibition liability than Ligand B (0.359). This is a crucial safety parameter, and Ligand A is significantly better.
12. **Cl_mic:** Ligand A (-9.407) has a much lower (better) microsomal clearance than Ligand B (26.019), indicating greater metabolic stability.
13. **t1/2:** Ligand A (-20.952) has a much longer in vitro half-life than Ligand B (15.379).
14. **Pgp:** Ligand A (0.008) has a much lower P-gp efflux liability than Ligand B (0.096), suggesting better bioavailability.
15. **Affinity:** Ligand B (-7.8 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.3 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME concerns.
**Overall Assessment:**
Ligand B has a much better binding affinity, which is a primary driver for GPCR drug candidates. However, it suffers from higher DILI risk, higher hERG inhibition, poorer metabolic stability (higher Cl_mic), shorter half-life, and higher P-gp efflux. Ligand A excels in safety (DILI, hERG), metabolic stability, and P-gp efflux, but its affinity is weaker and Caco-2 permeability is very poor.
Given the balance, the stronger affinity of Ligand B is a substantial advantage for a GPCR target like ADRB2. While the ADME properties of Ligand B are not ideal, they are potentially addressable through further optimization. The poor affinity of Ligand A is a more difficult hurdle to overcome. The Caco-2 permeability is a concern for both, and would need to be addressed.
Output:
0
2025-04-17 20:41:11,869 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (359.423 and 347.423 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand B (93.7) is significantly better than Ligand A (131.36). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary goal, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (-2.427) is lower than the optimal 1-3 range, potentially hindering permeability. Ligand B (-0.109) is closer to the optimal range. This favors Ligand B.
4. **HBD:** Ligand A (5) is at the upper limit, while Ligand B (2) is more favorable. Lower HBD can improve permeability.
5. **HBA:** Ligand A (7) is reasonable, while Ligand B (6) is slightly better.
6. **QED:** Ligand B (0.772) is significantly better than Ligand A (0.342), indicating a more drug-like profile.
7. **DILI:** Ligand A (12.136) is *much* better than Ligand B (56.65). This is a crucial factor; lower DILI risk is highly desirable.
8. **BBB:** Not a primary concern for a cardiovascular target. Ligand A (18.534) and Ligand B (55.37) are both relatively low.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.737 and -5.088), which is unusual and suggests poor permeability. However, these values are on the same scale, so it doesn't differentiate them.
10. **Solubility:** Ligand A (0.046) is very poor, while Ligand B (-1.908) is also poor, but slightly better. Solubility is a concern for both.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.034 and 0.288). This is excellent.
12. **Cl_mic:** Ligand A (2.322) has a much lower microsomal clearance than Ligand B (17.661), suggesting better metabolic stability.
13. **t1/2:** Ligand B (9.418) has a significantly longer in vitro half-life than Ligand A (-7.161). This is a major advantage.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.002 and 0.004).
15. **Binding Affinity:** Ligand B (-6.9) is slightly weaker than Ligand A (-6.6), but the difference is small.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are important. Ligand B is better on logP and TPSA. The affinity difference is small. DILI risk is *extremely* important, and Ligand A has a much lower risk. Metabolic stability (Cl_mic) is also important, and Ligand A is better.
**Overall Assessment:**
While Ligand B has a better QED and half-life, the significantly lower DILI risk associated with Ligand A is a major advantage. The slightly better metabolic stability of Ligand A is also a positive. The small difference in binding affinity is outweighed by the safety and metabolic properties of Ligand A. Given the cardiovascular context, minimizing liver toxicity is paramount.
Output:
1
2025-04-17 20:41:11,870 - INFO - Batch 203 complete. Total preferences: 3248
2025-04-17 20:41:11,870 - INFO - Processing batch 204/512...
2025-04-17 20:42:00,559 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (431.664 Da) is slightly higher than Ligand B (363.527 Da), but both are acceptable.
**2. TPSA:** Both ligands have TPSA values (A: 49.41, B: 47.36) below the 140 A^2 threshold for good oral absorption. This is positive for both.
**3. logP:** Ligand A (4.368) is a bit high, potentially leading to solubility issues or off-target interactions. Ligand B (2.769) is within the optimal 1-3 range. This favors Ligand B.
**4. H-Bond Donors:** Ligand A (1) is good. Ligand B (0) is also acceptable.
**5. H-Bond Acceptors:** Ligand A (2) is good. Ligand B (5) is still within the acceptable range of <=10.
**6. QED:** Both ligands have good QED scores (A: 0.523, B: 0.807), indicating good drug-like properties. Ligand B is significantly better.
**7. DILI Risk:** Ligand A (73.982) has a higher DILI risk than Ligand B (19.426). This is a significant advantage for Ligand B.
**8. BBB Penetration:** Both ligands show good BBB penetration (A: 79.178, B: 82.513). This is less critical for a cardiovascular target, but still positive.
**9. Caco-2 Permeability:** Both have negative Caco-2 values, which is unusual and suggests a potential issue with the measurement or the compounds themselves. However, the values are similar (-4.585 and -4.923), so this doesn't differentiate them.
**10. Aqueous Solubility:** Both have negative solubility values, which is also unusual. Ligand B (-2.651) is slightly better (less negative) than Ligand A (-5.554).
**11. hERG Inhibition:** Ligand A (0.84) has a slightly higher hERG risk than Ligand B (0.502), but both are reasonably low.
**12. Microsomal Clearance:** Ligand A (64.995) has lower microsomal clearance than Ligand B (88.735), suggesting better metabolic stability. This favors Ligand A.
**13. In vitro Half-Life:** Ligand A (92.792) has a much longer in vitro half-life than Ligand B (7.829). This is a significant advantage for Ligand A.
**14. P-gp Efflux:** Ligand A (0.511) has lower P-gp efflux than Ligand B (0.268), meaning it's less likely to be pumped out of cells, improving bioavailability. This favors Ligand A.
**15. Binding Affinity:** Ligand B (-6.9 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.2 kcal/mol). This is a substantial advantage for Ligand B.
**GPCR-Specific Considerations:** For a GPCR like ADRB2, logP, Pgp efflux, TPSA, and affinity are particularly important. Ligand B excels in affinity, has a better logP, and lower Pgp efflux. While Ligand A has better metabolic stability and half-life, the substantial affinity advantage of Ligand B outweighs these benefits. The lower DILI risk of Ligand B is also a major plus.
**Conclusion:**
Considering all factors, especially the strong binding affinity and lower DILI risk, Ligand B is the more promising drug candidate.
0
2025-04-17 20:42:00,560 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (348.403 and 361.393 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (98.91) is better than Ligand B (104.37). Both are below 140, which is good for oral absorption, but lower TPSA is generally preferred for GPCRs to aid in brain penetration, even if this isn't a CNS target.
**3. logP:** Ligand A (-0.753) is slightly lower than the optimal 1-3 range, while Ligand B (0.64) is closer. Ligand B is preferable here.
**4. H-Bond Donors:** Both have 2 HBD, which is within the acceptable limit of <=5.
**5. H-Bond Acceptors:** Ligand A has 6 HBA, and Ligand B has 7. Both are within the acceptable limit of <=10.
**6. QED:** Both ligands have similar QED values (0.726 and 0.739), indicating good drug-likeness.
**7. DILI:** Ligand A (18.845) has a significantly lower DILI risk than Ligand B (40.481). This is a major advantage for Ligand A.
**8. BBB:** Ligand B (82.164) has a much higher BBB percentile than Ligand A (26.638). While ADRB2 isn't necessarily a CNS target, some peripheral ADRB2 activity can influence CNS function, and better BBB penetration can be a plus.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-5.526 and -4.743). These values are unusual and suggest poor permeability. Ligand B is slightly better, but both are concerning.
**10. Aqueous Solubility:** Ligand A (-0.551) has slightly better solubility than Ligand B (-1.797), although both are quite poor.
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.121 and 0.038). This is excellent for both.
**12. Microsomal Clearance:** Ligand A (-5.275) has a lower (better) microsomal clearance than Ligand B (-4.819), indicating greater metabolic stability.
**13. In vitro Half-Life:** Ligand A (7.03) has a longer half-life than Ligand B (5.742).
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.011 and 0.09). This is good for both.
**15. Binding Affinity:** Ligand A (-7.6) has a significantly stronger binding affinity than Ligand B (-6.8). This is a substantial advantage, potentially outweighing some of the ADME drawbacks.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), and the general drug-likeness parameters, Ligand A is the more promising candidate. The significantly stronger binding affinity (-7.6 vs -6.8) is a major driver. While Ligand B has better BBB penetration and logP, Ligand A's lower DILI risk, better metabolic stability (lower Cl_mic), longer half-life, and slightly better solubility are all important advantages. The Caco-2 permeability is a concern for both, but the superior potency of Ligand A makes it more likely to succeed despite this.
Output:
1
2025-04-17 20:42:00,560 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.411 and 363.483 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (76.07) is slightly higher than Ligand B (62.74). Both are below the 140 threshold for oral absorption, and acceptable for a cardiovascular target (not necessarily needing high CNS penetration). Ligand B is preferable.
3. **logP:** Both ligands have good logP values (2.447 and 1.797), falling within the optimal 1-3 range. Ligand A is slightly higher, potentially offering better membrane permeability, but the difference isn't substantial.
4. **HBD:** Ligand A has 1 HBD, while Ligand B has 0. Lower is generally better for permeability, so Ligand B is slightly favored.
5. **HBA:** Ligand A has 4 HBA, Ligand B has 5. Both are within the acceptable limit of 10. No significant difference.
6. **QED:** Both ligands have similar QED values (0.885 and 0.821), indicating good drug-likeness.
7. **DILI:** Ligand A (41.179) has a lower DILI risk than Ligand B (50.174). This is a significant advantage for Ligand A.
8. **BBB:** Both ligands have relatively low BBB penetration (61.535 and 59.325). Since ADRB2 is a cardiovascular target, high BBB penetration is *not* a priority.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.578 and -4.542), which is unusual and suggests poor permeability. This is a significant drawback for both.
10. **Solubility:** Both ligands have very poor aqueous solubility (-1.993 and -1.639). This is a major concern for both compounds.
11. **hERG:** Ligand A (0.012) has a much lower hERG risk than Ligand B (0.451). This is a crucial advantage for Ligand A, as hERG inhibition can lead to cardiotoxicity.
12. **Cl_mic:** Ligand A (13.997) has a significantly lower microsomal clearance than Ligand B (36.83). This indicates better metabolic stability for Ligand A, which is desirable.
13. **t1/2:** Ligand A (-9.436) has a more negative in vitro half-life, indicating a shorter half-life, while Ligand B (7.14) has a positive value, suggesting a longer half-life. This favors Ligand B.
14. **Pgp:** Ligand A (0.012) has a much lower P-gp efflux liability than Ligand B (0.16). This is beneficial for oral bioavailability and potentially better tissue distribution.
15. **Binding Affinity:** Ligand B (-6.3) has a significantly stronger binding affinity than Ligand A (-5.0). This is a substantial advantage for Ligand B, potentially outweighing some of the ADME drawbacks.
**Overall Assessment:**
While Ligand B has a superior binding affinity, Ligand A demonstrates a much better safety profile (lower DILI and hERG risk) and better metabolic stability (lower Cl_mic). The poor solubility and Caco-2 permeability are concerns for both, but can potentially be addressed through formulation strategies. The stronger affinity of Ligand B is tempting, but the safety concerns associated with Ligand B are more critical for a cardiovascular target. Given the GPCR-specific priorities, and the importance of minimizing off-target effects and toxicity in cardiovascular drugs, Ligand A is the more promising candidate.
Output:
1
2025-04-17 20:42:00,560 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [338.411, 69.3, 2.346, 1, 3, 0.855, 59.636, 48.662, -5.058, -3.497, 0.493, 29.601, -12.613, 0.094, -6.6]
**Ligand B:** [345.443, 82.53, 2.419, 2, 4, 0.776, 41.915, 53.742, -4.948, -3.471, 0.284, 30.332, -28.455, 0.088, -7.1]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). A (338.411) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** A (69.3) is better than B (82.53), falling comfortably under the 140 threshold for oral absorption and closer to the 90 threshold for CNS penetration (though ADRB2 isn't necessarily a CNS target).
3. **logP:** Both are within the optimal range (1-3). A (2.346) and B (2.419) are very similar.
4. **HBD:** A (1) is preferable to B (2). Lower HBD generally improves permeability.
5. **HBA:** A (3) is preferable to B (4). Lower HBA generally improves permeability.
6. **QED:** A (0.855) is better than B (0.776), indicating a more drug-like profile.
7. **DILI:** B (41.915) is significantly better than A (59.636). Lower DILI risk is crucial.
8. **BBB:** B (53.742) is better than A (48.662), though neither is particularly high. For a cardiovascular target, this isn't a primary concern.
9. **Caco-2:** A (-5.058) is worse than B (-4.948), indicating lower intestinal absorption.
10. **Solubility:** Both are very poor (-3.497 and -3.471). This is a significant concern for both.
11. **hERG:** A (0.493) is better than B (0.284), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Both are similar (A: 29.601, B: 30.332). Neither is exceptionally good or bad.
13. **t1/2:** A (-12.613) is worse than B (-28.455), indicating a shorter half-life and potentially more frequent dosing.
14. **Pgp:** A (0.094) is better than B (0.088), suggesting less P-gp efflux.
15. **Affinity:** B (-7.1) is significantly better than A (-6.6). A difference of 0.5 kcal/mol is substantial and can often outweigh other ADME concerns.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, and affinity. Affinity is paramount. While A has better TPSA and Pgp, B has a significantly better binding affinity (-7.1 vs -6.6 kcal/mol). The DILI risk is also much lower for B. Solubility and Caco-2 are problematic for both, but the strong binding of B makes it more likely to be optimized to overcome these issues.
**Conclusion:**
Despite the solubility and Caco-2 concerns, the superior binding affinity and lower DILI risk of Ligand B outweigh the advantages of Ligand A.
0
2025-04-17 20:42:00,560 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (345.403 and 344.503 Da) fall comfortably within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (104.12) is higher than Ligand B (41.49). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B is significantly better here.
3. **logP:** Ligand A (1.363) is within the optimal range (1-3), while Ligand B (3.273) is at the higher end. While still acceptable, Ligand A's logP is more balanced.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (0). Both are acceptable, but lower HBD can sometimes improve permeability.
5. **HBA:** Both ligands have 5 HBA, which is within the acceptable limit of 10.
6. **QED:** Both ligands have similar QED scores (0.823 and 0.82), indicating good drug-likeness.
7. **DILI:** Ligand A (41.877) and Ligand B (39.511) both have low DILI risk, below the 40% threshold. No significant difference.
8. **BBB:** Ligand B (90.035) has a much higher BBB penetration score than Ligand A (60.256). While ADRB2 isn't a CNS target, higher BBB is generally favorable, suggesting better distribution.
9. **Caco-2:** Ligand A (-5.381) and Ligand B (-4.617) both have negative Caco-2 values, which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-1.517) and Ligand B (-3.271) both have negative solubility values, suggesting poor solubility. This is a significant concern for both.
11. **hERG:** Ligand A (0.029) has a very low hERG risk, while Ligand B (0.805) is slightly higher, but still relatively low. Ligand A is preferable.
12. **Cl_mic:** Ligand A (-6.132) has a lower (better) microsomal clearance than Ligand B (59.157), indicating greater metabolic stability. This is a major advantage for Ligand A.
13. **t1/2:** Ligand A (5.163) has a longer half-life than Ligand B (2.763). This is desirable for less frequent dosing.
14. **Pgp:** Ligand A (0.013) has very low P-gp efflux liability, while Ligand B (0.494) is higher. Lower P-gp is preferred for better bioavailability.
15. **Binding Affinity:** Ligand B (-6.9) has a slightly better binding affinity than Ligand A (-6.7), a difference of 0.2 kcal/mol. While affinity is crucial, the difference is not large enough to outweigh the other significant advantages of Ligand A.
**Overall Assessment & GPCR-Specific Priorities:**
For a cardiovascular GPCR like ADRB2, the balance of properties is key. While Ligand B has slightly better affinity, Ligand A demonstrates superior ADME properties. Specifically, its significantly better metabolic stability (Cl_mic), longer half-life, lower P-gp efflux, and lower hERG risk are crucial for a viable drug candidate. The lower TPSA of Ligand B is a plus, but the solubility and Caco-2 issues are concerning for both. The slightly higher BBB penetration of Ligand B is less important for a peripheral target like ADRB2.
Considering the overall profile, Ligand A is the more promising candidate due to its favorable ADME properties and acceptable binding affinity.
Output:
1
2025-04-17 20:42:00,561 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (365.47 and 355.563 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (38.77) is significantly better than Ligand B (49.77). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary goal, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (3.263 and 4.111), falling within the optimal 1-3 range. Ligand B is slightly higher, which *could* be a minor concern for solubility, but is still acceptable.
4. **HBD:** Ligand A (0) is preferable to Ligand B (1). Fewer hydrogen bond donors generally improve membrane permeability.
5. **HBA:** Ligand A (4) is slightly better than Ligand B (3). Lower HBA is generally preferred for permeability.
6. **QED:** Both ligands have acceptable QED scores (0.776 and 0.677), indicating good drug-like properties. Ligand A is slightly better.
7. **DILI:** Ligand A (39.395) is *much* better than Ligand B (2.559). A DILI percentile below 40 is highly desirable, and Ligand B is dangerously low. This is a major red flag for Ligand B.
8. **BBB:** Both ligands have high BBB penetration (85.033 and 84.684). While not critical for a cardiovascular target, it doesn't hurt.
9. **Caco-2:** Ligand A (-4.6) is better than Ligand B (-3.975). Higher Caco-2 permeability indicates better intestinal absorption.
10. **Solubility:** Ligand A (-3.833) is slightly better than Ligand B (-3.723).
11. **hERG:** Both ligands have low hERG inhibition risk (0.911 and 0.885), which is good.
12. **Cl_mic:** Ligand A (88.813) is better than Ligand B (101.675). Lower microsomal clearance indicates better metabolic stability.
13. **t1/2:** Ligand B (11.425) is *much* better than Ligand A (-1.951). A longer half-life is generally desirable.
14. **Pgp:** Both ligands have low P-gp efflux (0.532 and 0.609).
15. **Binding Affinity:** Ligand A (-8.0) is slightly better than Ligand B (-6.1). A difference of almost 2 kcal/mol is significant.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Both ligands perform well on logP and Pgp. Ligand A is superior in TPSA and significantly better in affinity. The *massive* difference in DILI risk is the deciding factor. While Ligand B has a better half-life, the potential for liver injury is unacceptable. The higher affinity of Ligand A also outweighs the half-life advantage of Ligand B.
**Conclusion:**
Ligand A is the far superior candidate due to its significantly lower DILI risk, better TPSA, better metabolic stability, and stronger binding affinity.
Output:
1
2025-04-17 20:42:00,561 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (344.46 and 367.43 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (58.44) is significantly better than Ligand B (90.73). For a GPCR, lower TPSA is generally preferred for better permeability, and Ligand A is well below the 140 threshold. Ligand B is approaching the upper limit, potentially hindering absorption.
**3. logP:** Both ligands have similar and favorable logP values (1.797 and 1.657), falling within the optimal 1-3 range.
**4. H-Bond Donors:** Both have 0 HBD, which is acceptable.
**5. H-Bond Acceptors:** Ligand A has 4 HBAs, while Ligand B has 7. Both are within the acceptable limit of 10, but Ligand A is preferable.
**6. QED:** Ligand A (0.758) has a better QED score than Ligand B (0.546), indicating a more drug-like profile.
**7. DILI Risk:** Ligand B (71.811) has a much higher DILI risk than Ligand A (17.1). This is a significant concern, as liver toxicity is a major cause of drug failure.
**8. BBB Penetration:** Ligand A (77.007) has significantly better BBB penetration potential than Ligand B (29.12). While ADRB2 is a cardiovascular target, some CNS effects are possible with beta-blockers, and better BBB penetration could be beneficial or detrimental depending on the desired profile.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.927 and -4.821). This is unusual and suggests poor permeability *in vitro*. However, the values are very close.
**10. Aqueous Solubility:** Both ligands have negative solubility values (-1.529 and -2.757). This is also concerning, indicating poor aqueous solubility. Ligand B is slightly worse.
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (0.32 and 0.394). This is good.
**12. Microsomal Clearance:** Ligand A (37.753) has lower microsomal clearance than Ligand B (57.535), suggesting better metabolic stability.
**13. In vitro Half-Life:** Ligand A (-13.417) has a longer *in vitro* half-life than Ligand B (-27.877).
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.106 and 0.14).
**15. Binding Affinity:** Ligand A (-7.3 kcal/mol) has a slightly better binding affinity than Ligand B (-5.1 kcal/mol). This 2.2 kcal/mol difference is substantial and could outweigh some of the ADME drawbacks of Ligand B.
**Overall Assessment:**
Ligand A is significantly better overall. It has a superior safety profile (much lower DILI risk), better drug-likeness (higher QED), better BBB penetration, improved metabolic stability (lower Cl_mic, longer t1/2), and a slightly better binding affinity. While both have poor solubility and permeability, Ligand A's other advantages make it a more promising candidate. The lower TPSA is also a significant benefit for a GPCR target.
Output:
1
2025-04-17 20:42:00,561 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (367.877 and 348.447 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands have similar TPSA values (81.67 and 81.75). These are acceptable for a non-CNS GPCR target like ADRB2, being below 140.
3. **logP:** Ligand A (2.717) has a more optimal logP value within the 1-3 range. Ligand B (-0.403) is significantly lower, potentially leading to poor membrane permeability. This is a key negative for Ligand B.
4. **HBD:** Both ligands have acceptable HBD counts (3 and 2 respectively), below the threshold of 5.
5. **HBA:** Both ligands have acceptable HBA counts (3 and 4 respectively), below the threshold of 10.
6. **QED:** Ligand A (0.748) has a better QED score than Ligand B (0.462), indicating a more drug-like profile.
7. **DILI:** Ligand A (34.471) has a slightly higher DILI risk than Ligand B (18.418), but both are below the concerning threshold of 60.
8. **BBB:** This is less critical for ADRB2 (a cardiovascular target), but Ligand A (60.915) has a higher BBB penetration than Ligand B (29.275).
9. **Caco-2:** Ligand B (-5.124) has a more negative Caco-2 value, suggesting *poorer* intestinal absorption compared to Ligand A (-4.78).
10. **Solubility:** Ligand B (-1.268) has a more negative solubility value, suggesting *lower* aqueous solubility than Ligand A (-3.663).
11. **hERG:** Both ligands have low hERG inhibition liability (0.452 and 0.105), which is good.
12. **Cl_mic:** Ligand A (-11.91) has a more negative (lower) microsomal clearance, indicating better metabolic stability than Ligand B (6.358).
13. **t1/2:** Ligand A (32.85) has a significantly longer in vitro half-life than Ligand B (-14.604).
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.059 and 0.002).
15. **Binding Affinity:** Ligand B (-6.8 kcal/mol) has a slightly better binding affinity than Ligand A (-6.5 kcal/mol). However, the difference is less than 1.5 kcal/mol.
**Overall Assessment:**
Ligand A is the better candidate. While Ligand B has slightly better binding affinity, Ligand A has significantly better predicted ADME properties: a more favorable logP, better QED, better solubility, better metabolic stability (lower Cl_mic, longer t1/2), and better Caco-2 permeability. The lower logP of Ligand B is a significant concern for oral bioavailability. For a GPCR like ADRB2, a balance of potency and good ADME properties is crucial, and Ligand A strikes that balance more effectively.
Output:
1
2025-04-17 20:42:00,561 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [344.411, 71.78, 1.95, 1, 4, 0.695, 24.544, 68.67, -4.269, -3.207, 0.229, 25.183, 14.752, 0.092, -6.7]
**Ligand B:** [352.479, 96.25, 1.548, 3, 5, 0.595, 33.695, 33.036, -5.198, -2.215, 0.294, 22.67, 41.428, 0.092, -5.7]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (344.411) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (71.78) is significantly better than Ligand B (96.25). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA is still beneficial for absorption.
3. **logP:** Both are within the optimal range (1-3), with Ligand A (1.95) being slightly higher than Ligand B (1.548).
4. **HBD:** Ligand A (1) is better than Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is better than Ligand B (5). Fewer HBAs generally improve permeability.
6. **QED:** Ligand A (0.695) is better than Ligand B (0.595), indicating a more drug-like profile.
7. **DILI:** Ligand A (24.544) is significantly better than Ligand B (33.695), indicating a lower risk of liver injury. This is a crucial factor.
8. **BBB:** Ligand A (68.67) is better than Ligand B (33.036). While not critical for a cardiovascular target, higher BBB is never a detriment.
9. **Caco-2:** Ligand A (-4.269) is better than Ligand B (-5.198), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-3.207) is better than Ligand B (-2.215). Better solubility is always preferred.
11. **hERG:** Both are similar (0.229 vs 0.294), and at these levels, the risk is considered low.
12. **Cl_mic:** Ligand B (22.67) has a lower microsomal clearance than Ligand A (25.183), suggesting better metabolic stability.
13. **t1/2:** Ligand B (41.428) has a significantly longer in vitro half-life than Ligand A (14.752), which is a major advantage.
14. **Pgp:** Both are very low (0.092), indicating minimal P-gp efflux.
15. **Affinity:** Ligand A (-6.7) has a slightly better binding affinity than Ligand B (-5.7). This is a 1 kcal/mol difference, which is significant.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A excels in TPSA, logP, and affinity. Ligand B has a better half-life and slightly better metabolic stability. However, the substantial improvements in DILI risk, solubility, Caco-2 permeability, and QED for Ligand A, coupled with its superior affinity, outweigh the benefit of Ligand B's longer half-life. The affinity difference is also substantial enough to be a deciding factor.
**Conclusion:**
Ligand A is the more promising drug candidate.
1
2025-04-17 20:42:00,562 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [353.419, 110.96 , -0.445, 2. , 5. , 0.614, 20.047, 74.292, -5.324, -1.9 , 0.105, -1.632, 10.847, 0.005, -5.7 ]
**Ligand B:** [355.523, 61.88 , 1.6 , 1. , 4. , 0.638, 4.653, 70.531, -4.689, -0.687, 0.494, 1.857, -6.942, 0.019, -6.6 ]
Here's a breakdown, considering the guidelines and GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal range (200-500 Da). A is 353.419, B is 355.523 - very similar.
2. **TPSA:** A (110.96) is slightly higher than B (61.88). B is significantly better, being well under the 140 threshold for oral absorption and more favorable for GPCRs.
3. **logP:** A (-0.445) is a bit low, potentially hindering permeation. B (1.6) is within the optimal range (1-3). This is a significant advantage for B.
4. **HBD:** A (2) and B (1) are both acceptable.
5. **HBA:** A (5) and B (4) are both acceptable.
6. **QED:** Both are good (A: 0.614, B: 0.638), indicating drug-like properties.
7. **DILI:** A (20.047) is much higher than B (4.653), indicating a higher risk of liver injury. This is a major concern for A.
8. **BBB:** Both have good BBB penetration (A: 74.292, B: 70.531). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be useful for off-target profiling.
9. **Caco-2:** Both are negative, indicating poor permeability. A (-5.324) is worse than B (-4.689).
10. **Solubility:** Both are negative, indicating poor solubility. A (-1.9) is worse than B (-0.687).
11. **hERG:** Both are very low (A: 0.105, B: 0.494), indicating low cardiotoxicity risk.
12. **Cl_mic:** A (-1.632) is better (lower clearance = more stable) than B (1.857).
13. **t1/2:** A (10.847) is better than B (-6.942).
14. **Pgp:** Both are very low (A: 0.005, B: 0.019), indicating low efflux.
15. **Affinity:** Both have excellent binding affinity (A: -5.7, B: -6.6). B is 0.9 kcal/mol better, which is a substantial difference.
**Overall Assessment:**
Ligand B is the stronger candidate. While Ligand A has slightly better metabolic stability and half-life, it is significantly hampered by its low logP, poor solubility, and higher DILI risk. Ligand B's superior logP, lower DILI, and better affinity outweigh the slight drawbacks in metabolic stability. The TPSA is also much more favorable for B. Given the GPCR target class, the balance of properties in Ligand B is more desirable.
Output:
0
2025-04-17 20:42:00,562 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.475 and 342.487 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (101.29) is higher than Ligand B (49.64). For a cardiovascular GPCR, TPSA isn't a *major* concern unless extremely high, but lower is generally preferred for better permeability. Ligand B is significantly better here.
3. **logP:** Both ligands have good logP values (1.478 and 3.411), falling within the optimal 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability, but isn't a critical difference.
4. **HBD:** Ligand A has 3 HBD, and Ligand B has 1. Both are within the acceptable limit of <=5. Ligand B is slightly better.
5. **HBA:** Ligand A has 3 HBA, and Ligand B has 4. Both are within the acceptable limit of <=10. No significant difference.
6. **QED:** Both ligands have good QED scores (0.677 and 0.8), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Both ligands have low DILI risk (19.038 and 17.604 percentile). No significant difference.
8. **BBB:** Ligand B (79.915) has a significantly higher BBB penetration percentile than Ligand A (62.427). While ADRB2 isn't a CNS target, some distribution to the CNS is possible, and higher BBB penetration generally indicates better overall permeability.
9. **Caco-2:** Ligand A (-5.296) and Ligand B (-4.862) both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
10. **Solubility:** Both ligands have very poor aqueous solubility (-3.226 and -3.1). This is a significant concern for both, and will likely require formulation strategies.
11. **hERG:** Both ligands have low hERG inhibition liability (0.13 and 0.79). No significant difference.
12. **Cl_mic:** Ligand A (17.222) has a lower microsomal clearance than Ligand B (52.828), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand B (24.409) has a significantly longer in vitro half-life than Ligand A (4.188). This is a major advantage for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.029) has much lower P-gp efflux liability than Ligand B (0.177). This is a significant advantage for Ligand A, as it suggests better oral bioavailability and potentially better tissue distribution.
15. **Binding Affinity:** Ligand A (-7.4) has a stronger binding affinity than Ligand B (-5.0). This is a substantial advantage for Ligand A, potentially outweighing some of its ADME drawbacks. A 2.4 kcal/mol difference is quite large.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B has better logP and TPSA, and a better BBB score. However, Ligand A has a *much* stronger binding affinity and lower Pgp efflux. The significantly stronger binding affinity of Ligand A is the most important factor here, especially for a receptor target where achieving sufficient occupancy is crucial. The lower Pgp efflux also helps with bioavailability. While solubility and metabolic stability are concerns for both, the affinity difference is likely to be more impactful in early development.
**Conclusion:**
Despite the solubility and metabolic stability concerns, the significantly stronger binding affinity of Ligand A makes it the more promising candidate.
Output:
1
2025-04-17 20:42:00,562 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (338.451 Da) is better than Ligand B (360.567 Da), falling comfortably within the 200-500 Da range.
2. **TPSA:** Ligand B (33.2) is significantly better than Ligand A (52.57), being well below the 140 threshold for good absorption. This is a strong positive for Ligand B.
3. **logP:** Ligand A (2.166) is optimal, while Ligand B (4.606) is pushing the upper limit and could potentially cause solubility issues or off-target interactions. Ligand A is preferred.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (0), but both are acceptable.
5. **HBA:** Both ligands have 3 HBA, which is good.
6. **QED:** Ligand A (0.831) has a better QED score than Ligand B (0.679), indicating a more drug-like profile.
7. **DILI:** Ligand B (6.592) has a much lower DILI risk than Ligand A (35.479), which is a significant advantage.
8. **BBB:** Ligand B (88.251) has excellent BBB penetration, while Ligand A (36.409) is poor. While ADRB2 isn't *necessarily* a CNS target, better BBB penetration can sometimes correlate with improved PK properties.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and requires further investigation. However, the magnitude of the negative value is similar.
10. **Solubility:** Ligand A (-2.079) has slightly better solubility than Ligand B (-4.414).
11. **hERG:** Both ligands have low hERG inhibition risk (0.702 and 0.78 respectively).
12. **Cl_mic:** Ligand A (-19.942) has a much lower (better) microsomal clearance than Ligand B (102.463), indicating greater metabolic stability.
13. **t1/2:** Ligand A (10.152 hours) has a longer half-life than Ligand B (7.374 hours).
14. **Pgp:** Ligand A (0.463) has lower P-gp efflux liability than Ligand B (0.423).
15. **Binding Affinity:** Ligand B (-5.7 kcal/mol) has a slightly better binding affinity than Ligand A (-8.0 kcal/mol). This is a substantial difference.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B excels in TPSA and BBB penetration, and has a slightly better affinity. Ligand A has a better logP, QED, metabolic stability, and half-life. The difference in binding affinity is significant, but the other ADME properties of Ligand A are more favorable overall.
**Overall Assessment:**
While Ligand B has a better binding affinity and lower DILI risk, Ligand A has a more balanced profile with better predicted metabolic stability (Cl_mic and t1/2), QED, and logP. The better logP and QED are important for overall drug-likeness and potential bioavailability. The binding affinity difference is substantial, but not insurmountable, and could potentially be optimized in later stages of drug development.
Output:
1
2025-04-17 20:42:00,562 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [345.443, 82.53, 2.419, 2, 4, 0.776, 41.915, 53.742, -4.948, -3.471, 0.284, 30.332, -28.455, 0.088, -7.1]
**Ligand B:** [350.434, 58.64, 2.609, 1, 3, 0.803, 21.055, 89.531, -4.391, -2.368, 0.741, -2.594, 5.363, 0.092, -6.1]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal range (200-500 Da). A is 345.443, B is 350.434 - very similar.
2. **TPSA:** A is 82.53, B is 58.64. B is significantly better, falling well below the 140 threshold and closer to the 90 ideal for CNS penetration (though ADRB2 isn't necessarily a CNS target, lower TPSA is generally favorable).
3. **logP:** A is 2.419, B is 2.609. Both are within the optimal 1-3 range. B is slightly better.
4. **HBD:** A is 2, B is 1. B is better, minimizing potential issues with solubility and permeability.
5. **HBA:** A is 4, B is 3. B is better, again favoring permeability.
6. **QED:** A is 0.776, B is 0.803. B is slightly better, indicating a more drug-like profile.
7. **DILI:** A is 41.915, B is 21.055. B is *much* better, indicating a significantly lower risk of drug-induced liver injury. This is a major advantage.
8. **BBB:** A is 53.742, B is 89.531. B is significantly better, suggesting better potential for crossing biological membranes.
9. **Caco-2:** Both are negative, indicating poor permeability. A is -4.948, B is -4.391. B is slightly better.
10. **Solubility:** A is -3.471, B is -2.368. B is better, suggesting improved aqueous solubility.
11. **hERG:** A is 0.284, B is 0.741. A is better, indicating a lower risk of hERG inhibition and cardiotoxicity.
12. **Cl_mic:** A is 30.332, B is -2.594. B is *much* better, indicating significantly higher metabolic stability.
13. **t1/2:** A is -28.455, B is 5.363. B is dramatically better, suggesting a much longer in vitro half-life.
14. **Pgp:** A is 0.088, B is 0.092. Very similar.
15. **Affinity:** A is -7.1 kcal/mol, B is -6.1 kcal/mol. A has a 1.0 kcal/mol advantage in binding affinity.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity, Ligand B overwhelmingly outperforms it in ADME-Tox properties crucial for drug development, especially for a GPCR target. The significantly lower DILI risk, better metabolic stability (Cl_mic and t1/2), improved BBB penetration, and better solubility of Ligand B are substantial advantages. The lower TPSA and HBD/HBA counts also contribute to a more favorable profile. The affinity difference, while present, is likely surmountable with further optimization, whereas fixing the poor ADME properties of Ligand A would be a much larger undertaking.
Therefore, I would prioritize Ligand B.
0
2025-04-17 20:42:00,563 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (351.447) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (49.41) is significantly better than Ligand A (104.46). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally improves absorption.
3. **logP:** Both ligands have acceptable logP values (Ligand A: 1.801, Ligand B: 3.334), falling within the 1-3 optimal range. Ligand B is closer to the upper end, which could potentially cause off-target issues, but is still acceptable.
4. **HBD:** Ligand A (3) is higher than Ligand B (1). Lower HBD is generally preferred for permeability.
5. **HBA:** Ligand A (5) is higher than Ligand B (3). Similar to HBD, lower HBA is generally preferred.
6. **QED:** Ligand A (0.662) has a slightly better QED score than Ligand B (0.571), indicating a more drug-like profile.
7. **DILI:** Both ligands have low DILI risk (Ligand A: 49.632, Ligand B: 46.995), which is excellent.
8. **BBB:** Ligand B (63.086) has a higher BBB penetration score than Ligand A (39.822), but this isn't a major concern for a cardiovascular target.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual. A higher value is preferred. Ligand A (-4.969) is slightly better than Ligand B (-5.222).
10. **Solubility:** Ligand A (-1.701) has better solubility than Ligand B (-3.698). Solubility is important for bioavailability.
11. **hERG:** Both ligands have low hERG inhibition liability (Ligand A: 0.104, Ligand B: 0.825). Ligand A is better.
12. **Cl_mic:** Ligand A (22.643) has significantly lower microsomal clearance than Ligand B (94.58), indicating better metabolic stability.
13. **t1/2:** Ligand B (8.953) has a longer in vitro half-life than Ligand A (-21.82). A longer half-life is generally desirable.
14. **Pgp:** Ligand A (0.097) has lower P-gp efflux liability than Ligand B (0.693), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand B (-7.8) has a significantly stronger binding affinity than Ligand A (-6.3). This is a crucial factor, and a 1.5 kcal/mol difference is substantial.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, affinity, logP, TPSA, and Pgp are key. Ligand B excels in affinity, while Ligand A has better TPSA, Pgp, solubility, and metabolic stability. The substantial affinity difference of Ligand B is the most important factor.
**Overall Assessment:**
While Ligand A has several favorable ADME properties, the significantly stronger binding affinity of Ligand B (-7.8 kcal/mol vs -6.3 kcal/mol) outweighs the minor drawbacks in its ADME profile. The improved half-life of Ligand B is also a positive.
Output:
0
2025-04-17 20:42:00,563 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [342.443, 66.71, 2.347, 1, 4, 0.907, 38.891, 61.962, -4.7, -2.206, 0.664, 39.874, -8.356, 0.065, -6.9]**
**Ligand B: [358.551, 36.1, 4.519, 1, 2, 0.728, 26.406, 67.468, -5.258, -4.825, 0.828, 93.723, 39.025, 0.777, -6.2]**
**1. Molecular Weight (MW):** Both are within the ideal range (200-500 Da). A (342.443) is slightly better.
**2. TPSA:** A (66.71) is higher than B (36.1). For a cardiovascular GPCR, lower TPSA is generally preferred for better permeability, giving an edge to B.
**3. logP:** A (2.347) is optimal, while B (4.519) is pushing the upper limit. This favors A.
**4. H-Bond Donors:** Both have 1 HBD, which is good.
**5. H-Bond Acceptors:** A has 4, B has 2. Both are acceptable.
**6. QED:** A (0.907) is significantly better than B (0.728), indicating a more drug-like profile.
**7. DILI:** A (38.891) is slightly higher than B (26.406), but both are below the concerning threshold of 60. B is preferable here.
**8. BBB:** Both are reasonable, but B (67.468) is better than A (61.962). While not a CNS target, some level of BBB penetration can influence distribution.
**9. Caco-2:** A (-4.7) is worse than B (-5.258). Lower values suggest poorer permeability, favoring B.
**10. Solubility:** A (-2.206) is better than B (-4.825). Solubility is important for bioavailability, favoring A.
**11. hERG:** Both are low risk (A: 0.664, B: 0.828).
**12. Cl_mic:** A (39.874) is significantly lower than B (93.723), indicating better metabolic stability. This is a strong advantage for A.
**13. t1/2:** A (-8.356) is better than B (39.025). A negative value indicates a longer half-life, which is preferable.
**14. Pgp:** A (0.065) is much lower than B (0.777), indicating less P-gp efflux and better bioavailability. This is a significant advantage for A.
**15. Binding Affinity:** A (-6.9) is slightly better than B (-6.2), but the difference is not huge.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity), Ligand A emerges as the better candidate. While Ligand B has a lower TPSA and better DILI, Ligand A excels in crucial areas like QED, metabolic stability (Cl_mic & t1/2), P-gp efflux, and solubility. The slightly better affinity of A further strengthens its position. The logP of B is a concern, potentially leading to off-target effects.
Output:
1
2025-04-17 20:42:00,563 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (347.38 Da and 341.411 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (29.1) is excellent, well below the 140 threshold and highly favorable for oral absorption. Ligand B (82.27) is higher, but still within a reasonable range, though less ideal. This favors Ligand A.
**3. logP:** Ligand A (4.403) is slightly high, potentially leading to solubility issues or off-target interactions. Ligand B (1.375) is excellent, falling squarely within the optimal 1-3 range. This favors Ligand B.
**4. H-Bond Donors:** Ligand A (1) and Ligand B (2) are both acceptable, below the threshold of 5.
**5. H-Bond Acceptors:** Ligand A (1) and Ligand B (3) are both acceptable, below the threshold of 10.
**6. QED:** Ligand A (0.816) is very good, indicating a strong drug-like profile. Ligand B (0.466) is lower, suggesting potential issues with developability. This strongly favors Ligand A.
**7. DILI Risk:** Ligand A (50.601) is good, below the 60% threshold. Ligand B (38.309) is even better, indicating lower liver injury risk. This favors Ligand B.
**8. BBB Penetration:** Ligand A (91.663) shows excellent BBB penetration, which isn't crucial for a cardiovascular target but isn't detrimental. Ligand B (35.673) is low, suggesting poor CNS exposure. This favors Ligand A.
**9. Caco-2 Permeability:** Both ligands show negative Caco-2 values (-4.503 and -4.967). This is unusual and suggests potential issues with intestinal absorption. It's difficult to draw conclusions without further investigation, but it's a flag for both.
**10. Aqueous Solubility:** Both ligands have negative solubility values (-4.897 and -2.484). Again, this is unusual and concerning, indicating very poor aqueous solubility. This is a significant drawback for both.
**11. hERG Inhibition:** Both ligands show low hERG inhibition risk (0.883 and 0.362). This is positive for both.
**12. Microsomal Clearance:** Ligand A (74.413) has moderate clearance, while Ligand B (-2.243) has very low clearance, suggesting high metabolic stability. This strongly favors Ligand B.
**13. In vitro Half-Life:** Ligand A (24.337) has a reasonable half-life. Ligand B (-24.15) has a negative half-life, which is not physically possible and indicates a problem with the data or the compound.
**14. P-gp Efflux:** Ligand A (0.659) shows moderate P-gp efflux, while Ligand B (0.11) shows low efflux. This favors Ligand B.
**15. Binding Affinity:** Both ligands have very good binding affinity (-5.9 kcal/mol and -5.5 kcal/mol). The difference (0.4 kcal/mol) isn't large enough to outweigh other factors.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand B initially appears attractive due to its excellent logP, low P-gp efflux, and good DILI risk. However, the negative half-life is a critical flaw. The negative solubility and Caco-2 values are also concerning for both. Ligand A, despite a slightly higher logP, has a much better QED score, excellent BBB penetration, and a plausible half-life. The combination of these factors, particularly the QED and half-life, makes Ligand A the more promising candidate, even with the slightly higher logP.
Output:
1
2025-04-17 20:42:00,563 - INFO - Batch 204 complete. Total preferences: 3264
2025-04-17 20:42:00,563 - INFO - Processing batch 205/512...
2025-04-17 20:42:50,634 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [347.371, 102.16 , 0.782, 2. , 7. , 0.749, 67.817, 45.134, -4.942, -2.497, 0.353, 35.416, 20.152, 0.053, -6.7 ]
**Ligand B:** [335.411, 63.91 , 2.562, 0. , 5. , 0.594, 59.364, 74.913, -5.197, -2.367, 0.559, 80.715, -22.373, 0.264, -5.8 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (335.411) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (102.16) is higher than Ligand B (63.91). Ligand B is significantly better, being well below the 140 threshold for oral absorption and more favorable for GPCRs.
3. **logP:** Ligand A (0.782) is a bit low, potentially hindering permeability. Ligand B (2.562) is within the optimal 1-3 range.
4. **HBD:** Ligand A (2) and Ligand B (0) are both acceptable.
5. **HBA:** Ligand A (7) and Ligand B (5) are both acceptable.
6. **QED:** Ligand A (0.749) is better than Ligand B (0.594), suggesting a more drug-like profile.
7. **DILI:** Ligand A (67.817) has a higher DILI risk than Ligand B (59.364), though both are reasonably acceptable.
8. **BBB:** Ligand B (74.913) has a significantly higher BBB penetration potential than Ligand A (45.134). While not a primary concern for a cardiovascular target, it's a bonus.
9. **Caco-2:** Ligand A (-4.942) and Ligand B (-5.197) are both very poor.
10. **Solubility:** Ligand A (-2.497) and Ligand B (-2.367) are both very poor.
11. **hERG:** Ligand A (0.353) has a lower hERG risk than Ligand B (0.559), which is a significant advantage.
12. **Cl_mic:** Ligand A (35.416) has a lower microsomal clearance than Ligand B (80.715), indicating better metabolic stability.
13. **t1/2:** Ligand A (20.152) has a longer in vitro half-life than Ligand B (-22.373), which is a major advantage.
14. **Pgp:** Ligand A (0.053) has much lower P-gp efflux liability than Ligand B (0.264), improving bioavailability.
15. **Affinity:** Ligand A (-6.7) has a slightly better binding affinity than Ligand B (-5.8).
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, and affinity. Ligand B excels in TPSA and BBB, while Ligand A has better logP, Pgp, and affinity. The affinity difference is not huge, but it's noticeable. The lower TPSA of Ligand B is a significant advantage for receptor engagement.
**Overall Assessment:**
While Ligand A has a better QED, longer half-life, lower clearance, and slightly better affinity, Ligand B's significantly lower TPSA and better BBB penetration are compelling for a GPCR target. The lower Pgp efflux of Ligand A is also a plus. However, the poor Caco-2 and solubility of both ligands are concerning. Considering the balance, and prioritizing TPSA and Pgp for a GPCR, I lean slightly towards Ligand B.
Output:
0
2025-04-17 20:42:50,635 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (345.49 and 356.37 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (43.86) is significantly better than Ligand B (87.32). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold. Ligand B is approaching the upper limit.
3. **logP:** Both ligands have acceptable logP values (1.58 and 1.06), falling within the 1-3 range. Ligand B is slightly lower, which *could* indicate a potential permeability issue, but it's not drastic.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer hydrogen bond donors generally improve membrane permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (4). Similar reasoning as HBD.
6. **QED:** Ligand A (0.763) is significantly better than Ligand B (0.485), indicating a more drug-like profile.
7. **DILI:** Ligand A (6.28) is *much* better than Ligand B (52.85). This is a major advantage for Ligand A. A DILI percentile below 40 is desirable, and Ligand A is well within that range, while Ligand B is concerningly high.
8. **BBB:** Not a primary concern for a cardiovascular target, but Ligand B (84.3) is better than Ligand A (72.7).
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-4.692) is slightly better than Ligand B (-4.934).
10. **Solubility:** Both have negative solubility values, indicating poor solubility. Ligand A (-2.579) is slightly better than Ligand B (-2.162).
11. **hERG:** Both are very low (0.477 and 0.453), indicating low cardiotoxicity risk. No significant difference.
12. **Cl_mic:** Ligand A (33.84) is much better than Ligand B (9.40). Lower clearance is preferred for longer duration of action.
13. **t1/2:** Ligand A (14.9) is better than Ligand B (-15.82). A positive half-life is preferred.
14. **Pgp:** Both are very low (0.013 and 0.031), indicating minimal P-glycoprotein efflux. No significant difference.
15. **Binding Affinity:** Ligand B (-5.2) is slightly better than Ligand A (-4.1). This is a 1.1 kcal/mol difference, which is substantial.
**Overall Assessment:**
While Ligand B has a slightly better binding affinity, Ligand A is significantly superior in almost all ADME-Tox properties. The DILI risk for Ligand B is a major red flag. The better QED, lower DILI, and improved metabolic stability (Cl_mic and t1/2) of Ligand A outweigh the modest affinity difference. Given the GPCR-specific priorities, the balance of properties favors Ligand A.
Output:
1
2025-04-17 20:42:50,635 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (367.833 and 346.431 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (91.65 and 95.42) are reasonably good, being under 140, suggesting reasonable absorption.
3. **logP:** Both ligands have good logP values (1.426 and 0.994), falling within the 1-3 range. Ligand A is slightly more lipophilic, which could be beneficial for membrane permeability, but both are acceptable.
4. **HBD:** Both have 2 H-bond donors, which is within the acceptable limit of 5.
5. **HBA:** Ligand A has 4 H-bond acceptors, and Ligand B has 5. Both are acceptable, being under 10.
6. **QED:** Both ligands have good QED scores (0.762 and 0.829), indicating good drug-like properties.
7. **DILI:** Both ligands have low DILI risk (40.713 and 39.667 percentile), which is excellent.
8. **BBB:** Both ligands have similar BBB penetration (60.411 and 61.846 percentile). Since ADRB2 is a cardiovascular target, BBB penetration is not a primary concern, but it's not detrimental to have some.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.127 and -5.039). This is unusual, and suggests poor permeability.
10. **Solubility:** Both ligands have negative solubility values (-2.894 and -2.014). This is also unusual, and suggests poor solubility.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.197 and 0.383 percentile), which is excellent.
12. **Cl_mic:** Ligand A has a significantly lower (better) microsomal clearance (-12.927 mL/min/kg) than Ligand B (9.158 mL/min/kg). This indicates better metabolic stability for Ligand A.
13. **t1/2:** Ligand A has a shorter in vitro half-life (8.003 hours) than Ligand B (-10.934 hours). While longer is generally preferred, the difference isn't huge.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.05 and 0.093 percentile), which is excellent.
15. **Binding Affinity:** Ligand B has a slightly better binding affinity (-7.1 kcal/mol) than Ligand A (-6.9 kcal/mol). This is a 0.2 kcal/mol difference, which is not huge, but is still a factor.
**GPCR-specific priorities:** For a GPCR like ADRB2, logP, TPSA, and affinity are important. Ligand B has slightly better affinity, but Ligand A has better metabolic stability (lower Cl_mic). The solubility and Caco-2 values are concerning for both. However, the slight advantage in affinity for Ligand B, combined with comparable other properties, tips the balance.
**Final Decision:**
0
2025-04-17 20:42:50,635 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [333.391, 55.32, 3.819, 0, 4, 0.712, 88.096, 74.176, -4.489, -4.822, 0.593, 101.078, -9.222, 0.508, -5.1]
**Ligand B:** [352.519, 69.64, 2.861, 2, 3, 0.706, 7.949, 74.37, -4.649, -2.498, 0.454, 37.674, -5.031, 0.184, -6.2]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (333.391) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (55.32) is significantly better than Ligand B (69.64). For a GPCR, keeping TPSA low is good for permeability.
3. **logP:** Ligand A (3.819) is slightly higher than Ligand B (2.861), both are within the optimal range (1-3), but A is closer to the upper limit.
4. **HBD:** Ligand A (0) is better than Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is slightly higher than Ligand B (3), but both are acceptable.
6. **QED:** Both are very similar (A: 0.712, B: 0.706), indicating good drug-like properties.
7. **DILI:** Ligand A (88.096) has a considerably higher DILI risk than Ligand B (7.949). This is a major concern.
8. **BBB:** Both have good BBB penetration (A: 74.176, B: 74.37).
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so this is hard to interpret.
10. **Solubility:** Ligand A (-4.822) is worse than Ligand B (-2.498). Lower solubility can be a formulation challenge.
11. **hERG:** Both have low hERG risk (A: 0.593, B: 0.454).
12. **Cl_mic:** Ligand B (37.674) has significantly lower microsomal clearance than Ligand A (101.078), indicating better metabolic stability.
13. **t1/2:** Ligand A (-9.222) has a longer in vitro half-life than Ligand B (-5.031).
14. **Pgp:** Ligand A (0.508) has lower P-gp efflux than Ligand B (0.184), which is favorable for bioavailability.
15. **Affinity:** Ligand B (-6.2) has a slightly better binding affinity than Ligand A (-5.1). A difference of 1.1 kcal/mol is significant.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, and affinity. Ligand A has better TPSA and Pgp, while Ligand B has better logP and affinity. The biggest drawback of Ligand A is its high DILI risk.
**Conclusion:**
Despite Ligand A having slightly better TPSA and Pgp properties, the significantly higher DILI risk and lower affinity are major drawbacks. Ligand B, while having a slightly higher TPSA, presents a much safer profile with a significantly lower DILI risk and a better binding affinity. The improved metabolic stability (lower Cl_mic) also contributes to its favorability.
Therefore, I prefer Ligand B.
0
2025-04-17 20:42:50,635 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (338.415 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (60.25) is significantly better than Ligand A (106.75). ADRB2 is not a CNS target, but lower TPSA is still desirable for absorption.
3. **logP:** Both ligands have good logP values (A: 2.436, B: 3.686), falling within the optimal 1-3 range. Ligand B is slightly higher, which could potentially lead to off-target interactions, but is still acceptable.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (0). Both are within the acceptable limit of 5.
5. **HBA:** Ligand A (7) is higher than Ligand B (6). Both are within the acceptable limit of 10.
6. **QED:** Both ligands have similar, good QED values (A: 0.635, B: 0.661), indicating good drug-like properties.
7. **DILI:** Ligand B (55.487) has a slightly lower DILI risk than Ligand A (59.907), which is preferable. Both are below the concerning threshold of 60.
8. **BBB:** This is less critical for ADRB2, but Ligand B (69.407) has a higher BBB percentile than Ligand A (59.519).
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and indicates poor permeability. Ligand A (-5.386) is slightly better than Ligand B (-4.913).
10. **Solubility:** Both ligands have very poor aqueous solubility (-3.138 and -3.403 respectively). This is a major concern for both.
11. **hERG:** Both ligands have low hERG inhibition risk (A: 0.828, B: 0.632), which is excellent.
12. **Cl_mic:** Ligand B (69.502) has a slightly higher microsomal clearance than Ligand A (67.033), indicating slightly lower metabolic stability.
13. **t1/2:** Ligand B (52.923) has a significantly longer in vitro half-life than Ligand A (13.368), which is a major advantage.
14. **Pgp:** Both ligands have very low Pgp efflux liability (A: 0.089, B: 0.728).
15. **Binding Affinity:** Ligand B (-6.7 kcal/mol) has a slightly better binding affinity than Ligand A (-6.4 kcal/mol). While the difference is not huge, it is enough to be considered.
**Overall Assessment:**
While both compounds have significant drawbacks (poor solubility and Caco-2 permeability), Ligand B presents a more favorable profile overall. The longer half-life, slightly better DILI risk, and stronger binding affinity outweigh the slightly higher logP and clearance. The lower TPSA of Ligand B is also a benefit. The solubility issue is a major concern for both, and would need to be addressed through formulation strategies.
Output:
0
2025-04-17 20:42:50,636 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.375 and 347.459 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (124.35) is higher than Ligand B (57). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for permeability. Ligand B has a significant advantage here.
3. **logP:** Ligand A (0.029) is very low, potentially hindering membrane permeability. Ligand B (1.991) is within the optimal 1-3 range. This is a substantial advantage for Ligand B.
4. **HBD:** Ligand A (3) is reasonable. Ligand B (0) is even better, potentially improving permeability and reducing off-target interactions.
5. **HBA:** Ligand A (6) is acceptable. Ligand B (4) is slightly better.
6. **QED:** Both ligands have good QED scores (0.677 and 0.836), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (69.523) has a higher DILI risk than Ligand B (20.9). This is a significant concern for Ligand A.
8. **BBB:** Ligand A (25.94) has very low BBB penetration. Ligand B (59.131) is better, but not exceptionally high. Since ADRB2 is a cardiovascular target, BBB penetration is not a primary concern, but it's still a positive for Ligand B.
9. **Caco-2:** Ligand A (-5.637) has poor Caco-2 permeability, consistent with its low logP. Ligand B (-4.609) is better, but still not great.
10. **Solubility:** Ligand A (-1.328) has poor solubility. Ligand B (-0.64) is better, but still not ideal.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.029 and 0.415). No significant difference.
12. **Cl_mic:** Ligand A (-3.144) has a negative clearance, suggesting it is not being cleared, which is good. Ligand B (8.452) has a higher clearance, indicating faster metabolism. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (-3.376) has a negative half-life, which is not possible and likely an error in the data. Ligand B (43.096) has a good in vitro half-life.
14. **Pgp:** Ligand A (0.008) has very low P-gp efflux, which is good. Ligand B (0.13) is slightly higher, but still acceptable.
15. **Binding Affinity:** Both ligands have the same binding affinity (-6.4 kcal/mol).
**Overall Assessment:**
Ligand B has several advantages: better logP, lower DILI risk, better TPSA, and a reasonable half-life. Ligand A has better metabolic stability (Cl_mic) and Pgp efflux, but its extremely low logP and poor solubility are major drawbacks. The negative half-life for Ligand A is also concerning. While the binding affinity is the same, the ADME properties of Ligand B are significantly more favorable for development as a cardiovascular drug.
Output:
0
2025-04-17 20:42:50,636 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (344.46 and 350.47 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (75.27) is significantly better than Ligand B (104.96). For a GPCR, keeping TPSA low is beneficial for permeability, and Ligand A is well under the 140 threshold. Ligand B is approaching the upper limit.
3. **logP:** Ligand A (2.113) is optimal, while Ligand B (0.718) is a bit low. A logP below 1 can hinder membrane permeability. This favors Ligand A.
4. **HBD:** Ligand A (2) and Ligand B (3) are both acceptable, being less than 5.
5. **HBA:** Ligand A (3) is better than Ligand B (7). Lower HBA generally improves permeability.
6. **QED:** Ligand A (0.802) is better than Ligand B (0.698), indicating a more drug-like profile.
7. **DILI:** Ligand A (25.79) has a significantly lower DILI risk than Ligand B (40.56). This is a crucial advantage.
8. **BBB:** Both ligands have similar BBB penetration (Ligand A: 55.18, Ligand B: 56.81). Since ADRB2 isn't a primary CNS target, this isn't a major deciding factor.
9. **Caco-2:** Ligand A (-4.864) is better than Ligand B (-5.447). Higher Caco-2 permeability is desirable.
10. **Solubility:** Ligand A (-2.718) is better than Ligand B (-1.379). Higher solubility is generally preferred.
11. **hERG:** Both ligands have very low hERG risk (0.076 and 0.064, respectively). No significant difference.
12. **Cl_mic:** Ligand A (23.512) has a higher microsomal clearance than Ligand B (13.137), meaning it's metabolized faster. This is a disadvantage for Ligand A.
13. **t1/2:** Ligand A (-2.797) has a shorter in vitro half-life than Ligand B (-1.408). This is another disadvantage for Ligand A.
14. **Pgp:** Both ligands have low P-gp efflux (0.06 and 0.056, respectively). No significant difference.
15. **Binding Affinity:** Ligand A (-7.4) has a slightly better binding affinity than Ligand B (-6.1). This 1.3 kcal/mol difference is significant and can outweigh some of the ADME drawbacks.
**Overall Assessment:**
Ligand A is superior in several key areas: TPSA, logP, QED, DILI risk, Caco-2 permeability, and solubility. Most importantly, it has a significantly better binding affinity. While Ligand A has slightly worse metabolic stability (higher Cl_mic and shorter t1/2), the stronger binding and better overall ADME profile make it the more promising candidate. The affinity difference is substantial enough to compensate for the slightly lower metabolic stability, especially considering optimization can address metabolic liabilities.
Output:
1
2025-04-17 20:42:50,636 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's systematically compare Ligand A and Ligand B based on the provided parameters and the guidelines, keeping in mind ADRB2 is a GPCR and thus we prioritize logP, Pgp, TPSA, and affinity.
1. **MW:** Both ligands (348.49 & 370.53 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (69.64) is significantly better than Ligand B (42.43). Lower TPSA generally favors better permeability, which is crucial for GPCR ligands.
3. **logP:** Ligand A (2.083) is within the optimal 1-3 range. Ligand B (4.597) is higher, potentially leading to solubility issues and off-target interactions. This is a negative for Ligand B.
4. **HBD/HBA:** Ligand A has 2 HBD and 3 HBA, while Ligand B has 0 HBD and 4 HBA. Both are acceptable, but the presence of some HBD in Ligand A could be beneficial for solubility without drastically impacting permeability.
5. **QED:** Ligand A (0.722) has a better QED score than Ligand B (0.597), indicating a more drug-like profile.
6. **DILI:** Both have relatively low DILI risk (13.07 & 14.66), both are good.
7. **BBB:** Ligand B (92.051) shows significantly better BBB penetration than Ligand A (47.15). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant for off-target effects or potential therapeutic benefits.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and requires further investigation. However, the values are similar.
9. **Solubility:** Ligand A (-2.829) has better solubility than Ligand B (-4.729). This is important given Ligand B's higher logP.
10. **hERG:** Ligand A (0.141) has a lower hERG risk than Ligand B (0.683), which is a significant advantage for cardiovascular targets.
11. **Cl_mic:** Ligand A (22.693) has a much lower microsomal clearance than Ligand B (103.65), suggesting better metabolic stability.
12. **t1/2:** Ligand A (-11.587) has a longer in vitro half-life than Ligand B (5.901), which is desirable.
13. **Pgp:** Ligand A (0.032) has lower P-gp efflux liability than Ligand B (0.511), which is positive for bioavailability.
14. **Binding Affinity:** Ligand A (-6.7) has a slightly better binding affinity than Ligand B (-5.9). While the difference is not huge, it's enough to be considered.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical ADME properties (TPSA, logP, solubility, hERG, Cl_mic, t1/2, Pgp) and has a slightly better binding affinity. While Ligand B has better BBB penetration, the other drawbacks (high logP, poor metabolic stability, higher hERG risk) are more concerning for a cardiovascular drug candidate. The lower TPSA and better solubility of Ligand A are particularly favorable for oral bioavailability and reducing off-target effects.
**Output:**
1
2025-04-17 20:42:50,636 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [346.431, 96.11, 1.501, 3, 4, 0.727, 43.971, 57.929, -5.102, -4.099, 0.222, 32.532, 0.338, 0.112, -5.5]
**Ligand B:** [408.304, 82.94, 1.3, 1, 6, 0.81, 54.323, 48.158, -5.217, -2.02, 0.124, 1.415, 17.87, 0.092, -6]
Here's a breakdown, considering the GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Ligand A (346.431 Da) is better, falling nicely within the 200-500 Da range. Ligand B (408.304 Da) is still acceptable, but slightly higher.
2. **TPSA:** Ligand B (82.94) is better than Ligand A (96.11), being closer to the <140 threshold for good oral absorption.
3. **logP:** Both are good (A: 1.501, B: 1.3), falling within the optimal 1-3 range. Very similar here.
4. **HBD:** Ligand B (1) is preferable to Ligand A (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is better than Ligand B (6). Lower HBA is generally preferable.
6. **QED:** Ligand B (0.81) is slightly better than Ligand A (0.727), indicating a more drug-like profile.
7. **DILI:** Ligand A (43.971) has a lower DILI risk than Ligand B (54.323), which is a significant advantage.
8. **BBB:** Ligand A (57.929) is better than Ligand B (48.158), although neither is particularly high. For a cardiovascular target, BBB isn't *critical*, but some penetration could be beneficial for off-target effects or distribution.
9. **Caco-2:** Both are poor (-5.102 and -5.217). This is a concern for both, indicating poor intestinal absorption.
10. **Solubility:** Ligand B (-2.02) is better than Ligand A (-4.099), indicating better aqueous solubility.
11. **hERG:** Both are very low (A: 0.222, B: 0.124), indicating a very low risk of cardiotoxicity, which is crucial for a cardiovascular target.
12. **Cl_mic:** Ligand B (1.415) has significantly lower microsomal clearance than Ligand A (32.532), suggesting better metabolic stability. This is a major advantage.
13. **t1/2:** Ligand B (17.87) has a much longer in vitro half-life than Ligand A (0.338), which is highly desirable.
14. **Pgp:** Ligand A (0.112) is better than Ligand B (0.092), indicating lower P-gp efflux.
15. **Affinity:** Ligand B (-6 kcal/mol) has a slightly better binding affinity than Ligand A (-5.5 kcal/mol). This difference is significant enough to consider.
**Overall Assessment:**
While Ligand A has some advantages (lower DILI, better Pgp), Ligand B is the stronger candidate. The significantly improved metabolic stability (lower Cl_mic, longer t1/2), better solubility, and slightly better affinity outweigh the drawbacks. The Caco-2 permeability is a concern for both, but can be addressed through formulation strategies. The lower DILI risk of Ligand A is good, but the metabolic advantages of Ligand B are more critical for a successful drug.
Output:
0
2025-04-17 20:42:50,636 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (382.957 Da) is slightly higher than Ligand B (348.447 Da), but both are acceptable.
**2. TPSA:** Ligand A (41.57) is well below the 140 threshold and favorable for oral absorption. Ligand B (98.32) is higher, potentially indicating lower permeability, although still within a reasonable range.
**3. logP:** Ligand A (4.653) is a bit high, potentially leading to solubility issues or off-target interactions. Ligand B (1.319) is optimal.
**4. H-Bond Donors:** Ligand A (1) is good. Ligand B (3) is acceptable, but approaching the upper limit.
**5. H-Bond Acceptors:** Ligand A (3) is good. Ligand B (4) is acceptable.
**6. QED:** Both ligands have reasonable QED values (A: 0.823, B: 0.722), suggesting good drug-like properties.
**7. DILI:** Ligand A (50.136) has a moderate DILI risk, but is still acceptable. Ligand B (33.424) has a lower DILI risk, which is preferable.
**8. BBB:** Ligand A (88.91) shows good BBB penetration, which isn't critical for a cardiovascular target but isn't detrimental. Ligand B (48.972) is lower, indicating less BBB penetration.
**9. Caco-2 Permeability:** Ligand A (-4.835) is very poor, indicating very low intestinal absorption. Ligand B (-5.255) is also poor, but slightly better than A.
**10. Aqueous Solubility:** Ligand A (-4.825) is poor. Ligand B (-2.087) is also poor, but better than A.
**11. hERG Inhibition:** Ligand A (0.829) has a moderate hERG risk. Ligand B (0.384) has a much lower hERG risk, which is a significant advantage.
**12. Microsomal Clearance:** Ligand A (75.869) has moderate clearance. Ligand B (-18.809) has negative clearance, which is excellent, indicating very high metabolic stability.
**13. In vitro Half-Life:** Ligand A (45.882) has a reasonable half-life. Ligand B (-11.599) has a very long half-life, which is highly desirable.
**14. P-gp Efflux:** Ligand A (0.487) has low P-gp efflux, which is good. Ligand B (0.033) has very low P-gp efflux, even better.
**15. Binding Affinity:** Ligand B (-9.2) has a significantly stronger binding affinity than Ligand A (-5.8), a difference of 3.4 kcal/mol. This is a substantial advantage that can outweigh some of the ADME drawbacks.
**GPCR-Specific Considerations:** For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP, Pgp, and significantly in affinity. While Ligand A has better BBB penetration, this is less critical for a cardiovascular target.
**Overall:** Despite Ligand A's better BBB penetration, Ligand B's superior binding affinity, lower hERG risk, significantly better metabolic stability (negative clearance and long half-life), and lower P-gp efflux make it the more promising drug candidate. The slightly higher TPSA is a concern, but the substantial improvement in affinity and ADME properties outweighs this.
Output:
0
2025-04-17 20:42:50,637 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [347.459, 75.44, 2.541, 1, 4, 0.822, 35.789, 76.696, -4.986, -2.699, 0.314, 58.275, -3.595, 0.321, -6.5]
**Ligand B:** [359.421, 88.91, 1.799, 2, 5, 0.667, 44.591, 65.529, -5.085, -2.345, 0.156, 39.127, -9.904, 0.054, -6.5]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (347.459) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (75.44) is better than Ligand B (88.91), being closer to the <140 threshold for good oral absorption.
3. **logP:** Both are within the optimal range (1-3). Ligand A (2.541) is slightly higher, while Ligand B (1.799) is a bit lower.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is preferable to Ligand B (5). Fewer HBAs generally improve permeability.
6. **QED:** Ligand A (0.822) is significantly better than Ligand B (0.667), indicating a more drug-like profile.
7. **DILI:** Ligand A (35.789) is better than Ligand B (44.591), indicating a lower risk of drug-induced liver injury.
8. **BBB:** Ligand A (76.696) is better than Ligand B (65.529). While ADRB2 isn't a CNS target, some distribution into the CNS is possible, and higher BBB penetration is generally favorable.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand B (-5.085) is slightly worse than Ligand A (-4.986).
10. **Solubility:** Both are negative, indicating poor solubility. Ligand B (-2.345) is slightly worse than Ligand A (-2.699).
11. **hERG:** Both are very low (0.314 and 0.156), indicating minimal hERG inhibition risk, which is excellent.
12. **Cl_mic:** Ligand B (39.127) has lower microsomal clearance than Ligand A (58.275), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-9.904) has a significantly longer in vitro half-life than Ligand A (-3.595), which is a major advantage.
14. **Pgp:** Both are very low (0.321 and 0.054), indicating minimal P-gp efflux liability, which is good.
15. **Affinity:** Both have the same binding affinity (-6.5 kcal/mol).
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A has a better logP and TPSA. Both have good Pgp and equivalent affinity. The longer half-life of Ligand B is a significant advantage.
**Overall Assessment:**
While Ligand A has better drug-like properties (QED, DILI, BBB, TPSA, HBD/HBA), Ligand B's significantly improved metabolic stability (lower Cl_mic and longer t1/2) is a critical factor. A longer half-life can translate to less frequent dosing and potentially better efficacy. The slight drawbacks in TPSA and QED for Ligand B are outweighed by its superior pharmacokinetic profile.
Output:
0
2025-04-17 20:42:50,637 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (367.559) is slightly higher than Ligand B (339.399), but both are acceptable.
2. **TPSA:** Ligand A (65.2) is significantly better than Ligand B (98.98). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (3.52) is within the optimal range, while Ligand B (1.056) is on the lower end. A logP too low can hinder membrane permeability.
4. **HBD:** Both ligands have acceptable HBD counts (Ligand A: 2, Ligand B: 1).
5. **HBA:** Ligand A (3) is better than Ligand B (5). Lower HBA is generally preferred for better permeability.
6. **QED:** Both ligands have good QED scores (Ligand A: 0.691, Ligand B: 0.887), indicating good drug-likeness. Ligand B is slightly better here.
7. **DILI:** Ligand A (37.263) has a lower DILI risk than Ligand B (43.932), which is favorable.
8. **BBB:** Not a primary concern for a cardiovascular target, but Ligand A (60.062) has better BBB penetration than Ligand B (41.062).
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.313 and -5.228), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand A (-3.73) has better solubility than Ligand B (-1.663).
11. **hERG:** Ligand A (0.701) has a lower hERG risk than Ligand B (0.174), which is crucial for avoiding cardiotoxicity.
12. **Cl_mic:** Ligand A (85.125) has a higher microsomal clearance than Ligand B (-8.28). This means Ligand B is more metabolically stable, a significant advantage.
13. **t1/2:** Ligand A (33.511) has a longer half-life than Ligand B (5.72), which is desirable.
14. **Pgp:** Ligand A (0.218) has lower P-gp efflux than Ligand B (0.004), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand B (-6.7 kcal/mol) has a slightly better binding affinity than Ligand A (-6.1 kcal/mol). This is a 0.6 kcal/mol difference, which is noticeable but not overwhelming.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand A has a better logP and TPSA. Ligand B has a slightly better affinity. Metabolic stability (Cl_mic) is also important, and Ligand B is superior in this regard. The hERG risk is a major concern, and Ligand A is significantly better. The Caco-2 values are concerning for both, but the other advantages of Ligand A outweigh this drawback.
**Conclusion:**
Considering the balance of properties, particularly the lower hERG risk, better TPSA, and acceptable logP of Ligand A, I believe it is the more promising drug candidate despite the slightly weaker binding affinity and negative Caco-2 value. The metabolic stability of Ligand B is attractive, but the higher hERG risk is a dealbreaker for a cardiovascular target.
Output:
1
2025-04-17 20:42:50,637 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (368.865 Da and 343.427 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand B (62.62) is significantly better than Ligand A (107.11). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (1.629 and 1.165), falling within the optimal 1-3 range. Ligand B is slightly lower, which could be beneficial for solubility.
4. **HBD:** Ligand A has 4 HBD, while Ligand B has 0. Lower HBD is generally preferred for permeability, giving a slight edge to Ligand B.
5. **HBA:** Both ligands have 4 HBA, which is acceptable.
6. **QED:** Ligand B (0.81) has a better QED score than Ligand A (0.633), indicating a more drug-like profile.
7. **DILI:** Ligand B (38.93) has a much lower DILI risk than Ligand A (54.789). This is a significant advantage for Ligand B.
8. **BBB:** Ligand B (88.406) has a much higher BBB penetration score than Ligand A (25.591). While ADRB2 isn't a CNS target, higher BBB is rarely detrimental.
9. **Caco-2:** Ligand A (-5.385) is worse than Ligand B (-4.549), indicating lower intestinal absorption.
10. **Solubility:** Ligand A (-3.067) is worse than Ligand B (-1.797), indicating lower solubility.
11. **hERG:** Ligand A (0.147) has a slightly lower hERG inhibition liability than Ligand B (0.309), which is slightly preferable.
12. **Cl_mic:** Ligand A (-10.801) has a much lower (better) microsomal clearance than Ligand B (60.481), suggesting better metabolic stability.
13. **t1/2:** Ligand A (8.908) has a better in vitro half-life than Ligand B (-27.416).
14. **Pgp:** Ligand A (0.086) has a much lower P-gp efflux liability than Ligand B (0.154), which is favorable.
15. **Affinity:** Ligand A (-7.1) has a significantly better binding affinity than Ligand B (-3.7). This is a substantial advantage, potentially outweighing some ADME drawbacks.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, affinity, logP, TPSA, and Pgp are key. Ligand A has a much better affinity, and lower Pgp efflux. Ligand B has better TPSA and logP. However, the substantial difference in affinity (-7.1 vs -3.7) is a major factor. The better DILI and QED scores of Ligand B are also compelling. The metabolic stability of Ligand A is also a plus.
**Overall Assessment:**
While Ligand B has several advantages in terms of safety (DILI) and drug-likeness (QED), the significantly stronger binding affinity of Ligand A is the most critical factor for a GPCR target. The difference in affinity is large enough to compensate for the slightly less favorable ADME properties of Ligand A.
Output:
1
2025-04-17 20:42:50,637 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.415 and 344.371 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (104.46) is better than Ligand B (117.52). Both are below the 140 threshold for oral absorption, but lower TPSA is generally preferred for GPCRs, aiding in permeability.
3. **logP:** Ligand A (1.682) is better than Ligand B (0.483). Both are within the acceptable range (1-3), but Ligand A is closer to the optimal range. Ligand B is getting a bit low, potentially impacting membrane permeability.
4. **HBD:** Both ligands have 3 H-bond donors, which is acceptable.
5. **HBA:** Ligand A has 5 H-bond acceptors, while Ligand B has 4. Both are within the acceptable limit of 10.
6. **QED:** Both ligands have similar QED values (0.679 and 0.689), indicating good drug-likeness.
7. **DILI:** Ligand A (45.948%) is significantly better than Ligand B (65.646%). Ligand B is edging into the higher risk category for liver injury.
8. **BBB:** Ligand A (58.085%) is better than Ligand B (43.815%). While ADRB2 isn't exclusively a CNS target, some CNS penetration can be beneficial, and lower efflux is a plus.
9. **Caco-2:** Ligand A (-4.96) is better than Ligand B (-5.981). Higher (less negative) values indicate better absorption.
10. **Solubility:** Ligand A (-2.444) is better than Ligand B (-3.181). Higher values indicate better solubility.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.068 and 0.159). This is excellent.
12. **Cl_mic:** Ligand B (-18.126) is significantly better than Ligand A (37.732). Lower clearance indicates greater metabolic stability, a crucial factor for drug duration.
13. **t1/2:** Ligand B (-16.384) is significantly better than Ligand A (-30.976). Longer half-life is desirable.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.076 and 0.018).
15. **Affinity:** Ligand B (-7.2 kcal/mol) is slightly better than Ligand A (-6.7 kcal/mol). This is a 0.5 kcal/mol difference, which is significant enough to consider, especially for a GPCR.
**Overall Assessment:**
Ligand B has a clear advantage in metabolic stability (Cl_mic and t1/2) and a slightly better binding affinity. The DILI risk for Ligand B is higher, but not drastically so. Ligand A has better TPSA, logP, solubility, and Caco-2 permeability. However, the improvements in metabolic stability and affinity with Ligand B outweigh the slight drawbacks. For a GPCR target like ADRB2, a strong binding affinity and good metabolic stability are critical.
Output:
0
2025-04-17 20:42:50,637 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (362.495 Da) is slightly higher than Ligand B (349.475 Da), but both are acceptable.
2. **TPSA:** Ligand A (50.8) is significantly better than Ligand B (70.67). For a GPCR, keeping TPSA under 90 is good, and lower is generally preferred for better permeability. Ligand A is clearly superior here.
3. **logP:** Both ligands have good logP values (A: 2.62, B: 1.239), falling within the optimal 1-3 range. Ligand A is slightly more lipophilic, which could be beneficial for membrane permeability, but isn't a major concern.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Both ligands have the same number of HBA (4), which is acceptable.
6. **QED:** Ligand A (0.838) has a much better QED score than Ligand B (0.647), indicating a more drug-like profile.
7. **DILI:** Ligand A (21.908) has a significantly lower DILI risk than Ligand B (9.345), which is a crucial advantage. Lower DILI is always preferred.
8. **BBB:** Ligand A (86.351) has a much higher BBB penetration percentile than Ligand B (36.681). While ADRB2 isn't strictly a CNS target, some CNS exposure can occur, and higher BBB is generally a positive attribute.
9. **Caco-2:** Ligand A (-4.638) and Ligand B (-5.171) are both negative, indicating poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Ligand A (-2.892) is slightly better than Ligand B (-1.027), indicating better aqueous solubility.
11. **hERG:** Both ligands have very low hERG inhibition liability (A: 0.489, B: 0.172), which is excellent.
12. **Cl_mic:** Ligand B (-16.297) has a significantly lower (better) microsomal clearance than Ligand A (20.532), suggesting greater metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand A (8.955) has a longer in vitro half-life than Ligand B (2.871), which is desirable.
14. **Pgp:** Both ligands have very low P-gp efflux liability (A: 0.094, B: 0.009), which is excellent.
15. **Binding Affinity:** Both ligands have very similar binding affinities (A: -6.5 kcal/mol, B: -6.6 kcal/mol). The difference is negligible.
**Overall Assessment:**
Ligand A is superior in almost all key ADME properties (TPSA, QED, DILI, BBB, Solubility, t1/2) and has comparable binding affinity. Ligand B has better metabolic stability (Cl_mic), but the advantages of Ligand A in other critical areas outweigh this single benefit, especially considering the importance of minimizing DILI risk. For a cardiovascular target like ADRB2, a balance of properties is crucial, and Ligand A strikes a better balance.
Output:
1
2025-04-17 20:42:50,638 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [348.447, 76.46, 1.371, 1, 5, 0.755, 30.865, 74.99, -4.801, -1.144, 0.549, 14.377, -5.745, 0.076, -6.8]
**Ligand B:** [357.407, 105.25, -0.991, 1, 6, 0.587, 38.736, 62.233, -5.03, -0.331, 0.077, 33.586, -5.21, 0.006, -6.2]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (348.447) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (76.46) is significantly better than Ligand B (105.25). For a GPCR, keeping TPSA low is good for permeability, although not as critical as for CNS targets.
3. **logP:** Ligand A (1.371) is within the optimal range, while Ligand B (-0.991) is slightly below. A logP slightly below 1 can sometimes lead to absorption issues.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A (5) is better than Ligand B (6). Lower HBA is generally preferred.
6. **QED:** Ligand A (0.755) has a better QED score than Ligand B (0.587), indicating a more drug-like profile.
7. **DILI:** Ligand A (30.865) has a significantly lower DILI risk than Ligand B (38.736). This is a major advantage.
8. **BBB:** Ligand A (74.99) has a much higher BBB percentile than Ligand B (62.233). While ADRB2 isn't strictly a CNS target, some peripheral distribution is still important, and higher BBB can correlate with better overall distribution.
9. **Caco-2:** Ligand A (-4.801) and B (-5.03) are similar, indicating similar intestinal absorption.
10. **Solubility:** Ligand A (-1.144) is slightly worse than Ligand B (-0.331), but both are reasonable.
11. **hERG:** Ligand A (0.549) has a slightly better hERG profile than Ligand B (0.077).
12. **Cl_mic:** Ligand A (14.377) has a significantly lower microsomal clearance than Ligand B (33.586), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-5.745) has a slightly better in vitro half-life than Ligand B (-5.21).
14. **Pgp:** Ligand A (0.076) has a slightly better Pgp efflux profile than Ligand B (0.006).
15. **Affinity:** Ligand A (-6.8) has a slightly better binding affinity than Ligand B (-6.2).
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A is better across most of these. The higher BBB percentile for Ligand A is a bonus, even if not a primary concern. The significantly better DILI and metabolic stability (lower Cl_mic) of Ligand A are also very important.
**Conclusion:**
Ligand A is the superior candidate due to its better overall ADME profile (lower DILI, better metabolic stability, better BBB), favorable physicochemical properties (lower TPSA, better logP, QED), and slightly better binding affinity.
Output:
1
2025-04-17 20:42:50,638 - INFO - Batch 205 complete. Total preferences: 3280
2025-04-17 20:42:50,638 - INFO - Processing batch 206/512...
2025-04-17 20:43:41,495 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's analyze each ligand against the provided guidelines, keeping in mind ADRB2 is a GPCR, so logP, Pgp, TPSA, and affinity are key.
* **Molecular Weight:** Both ligands (388.842 and 358.429 Da) fall within the ideal 200-500 Da range.
* **TPSA:** Ligand A (32.34) is excellent, well below the 140 threshold. Ligand B (49.85) is still acceptable, but less optimal.
* **logP:** Ligand A (4.806) is slightly high, potentially leading to solubility issues. Ligand B (2.091) is within the optimal range. This is a significant advantage for Ligand B.
* **H-Bond Donors/Acceptors:** Ligand A (1 HBD, 3 HBA) and Ligand B (0 HBD, 3 HBA) are both good, within the recommended limits.
* **QED:** Both ligands have reasonable QED scores (0.818 and 0.7), indicating good drug-like properties.
* **DILI:** Ligand A (56.689) has a moderate DILI risk, while Ligand B (13.339) has a very low risk. This is a strong advantage for Ligand B.
* **BBB:** Both ligands show good BBB penetration (88.135 and 93.718), which is positive, though less critical for a non-CNS target like ADRB2.
* **Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. This is a concern for both.
* **Aqueous Solubility:** Both ligands have negative solubility values, indicating poor aqueous solubility. This is a significant drawback for both.
* **hERG Inhibition:** Ligand A (0.805) has a slightly higher hERG risk than Ligand B (0.578), but both are relatively low.
* **Microsomal Clearance:** Ligand A (64.971) has higher clearance than Ligand B (38.471), suggesting lower metabolic stability. Ligand B is preferable here.
* **In vitro Half-Life:** Ligand A (27.269 hours) has a considerably longer half-life than Ligand B (1.517 hours). This is a major advantage for Ligand A.
* **P-gp Efflux:** Ligand A (0.648) has moderate P-gp efflux, while Ligand B (0.148) has very low efflux. This is a strong advantage for Ligand B.
* **Binding Affinity:** Ligand A (-7.2 kcal/mol) has a significantly stronger binding affinity than Ligand B (-4.9 kcal/mol). This is a substantial advantage for Ligand A, and could potentially outweigh some of its ADME drawbacks.
**Overall Assessment:**
Ligand A has a much stronger binding affinity and a longer half-life. However, it has a higher logP, higher DILI risk, higher clearance, and moderate P-gp efflux. Ligand B has better ADME properties across the board (lower logP, lower DILI, lower clearance, lower P-gp efflux), but its binding affinity is significantly weaker.
Given the importance of potency for GPCRs, the substantial affinity advantage of Ligand A is compelling. While the ADME properties of Ligand A are not ideal, they may be addressable through further optimization. The poor ADME profile of Ligand B, particularly the weak binding, makes it less likely to succeed.
**Output:**
1
2025-04-17 20:43:41,495 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (363.889 Da) is within the ideal range (200-500 Da). Ligand B (213.189 Da) is at the lower end, potentially impacting potency.
2. **TPSA:** Ligand A (47.36) is excellent, well below the 140 threshold for oral absorption. Ligand B (124.01) is still acceptable, but less optimal.
3. **logP:** Ligand A (4.725) is slightly high, potentially leading to solubility issues or off-target interactions. Ligand B (-0.457) is too low, suggesting poor membrane permeability.
4. **HBD:** Ligand A (0) is ideal. Ligand B (5) is at the upper limit of acceptable.
5. **HBA:** Ligand A (4) is good. Ligand B (5) is acceptable.
6. **QED:** Ligand A (0.725) is very good, indicating strong drug-likeness. Ligand B (0.433) is below the preferred threshold of 0.5.
7. **DILI:** Ligand A (51.26) has a moderate risk, but acceptable. Ligand B (17.449) is very low, excellent.
8. **BBB:** Ligand A (76.774) is good, indicating reasonable potential for CNS penetration if desired. Ligand B (12.059) is very low, limiting CNS exposure.
9. **Caco-2:** Ligand A (-4.558) is poor. Ligand B (-6.567) is very poor.
10. **Solubility:** Ligand A (-4.931) is poor. Ligand B (-0.969) is also poor, but slightly better than A.
11. **hERG:** Ligand A (0.512) is low risk. Ligand B (0.013) is very low risk, excellent.
12. **Cl_mic:** Ligand A (74.325) is relatively high, suggesting faster metabolism. Ligand B (-33.893) is excellent, indicating high metabolic stability.
13. **t1/2:** Ligand A (31.275) is moderate. Ligand B (7.246) is short, potentially requiring frequent dosing.
14. **Pgp:** Ligand A (0.317) is low efflux, good. Ligand B (0.005) is very low efflux, excellent.
15. **Affinity:** Ligand A (-6.0) is good. Ligand B (-5.4) is also good, but less potent.
**GPCR-specific considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are particularly important. Ligand A has a better logP (though still a bit high) and TPSA. Ligand B has superior Pgp and DILI profiles. However, the difference in binding affinity (-6.0 vs -5.4) is significant, and a 0.6 kcal/mol advantage can often outweigh some ADME drawbacks. The higher QED of Ligand A also contributes to its overall drug-likeness.
**Overall Assessment:**
While Ligand B has excellent metabolic stability and low toxicity/efflux, its poor logP and Caco-2 permeability are major concerns for oral bioavailability. Ligand A, despite its slightly higher logP and moderate metabolic clearance, presents a better balance of properties, particularly its superior binding affinity and QED. The slightly elevated logP can be addressed through further optimization.
Output:
1
2025-04-17 20:43:41,495 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (343.47 & 348.49 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (38.77) is significantly better than Ligand B (86.88). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary goal, but lower TPSA generally correlates with better absorption. Ligand B's TPSA is quite high, potentially hindering oral bioavailability.
3. **logP:** Ligand A (3.764) is slightly higher than Ligand B (2.836), both are within the optimal 1-3 range.
4. **HBD:** Ligand A (0) is preferable to Ligand B (3). Fewer HBDs generally improve membrane permeability.
5. **HBA:** Ligand A (4) is slightly higher than Ligand B (3). Both are acceptable.
6. **QED:** Ligand A (0.763) is better than Ligand B (0.641), indicating a more drug-like profile.
7. **DILI:** Both ligands have low DILI risk (18.19 & 17.26), which is excellent.
8. **BBB:** Ligand A (83.25) has a higher BBB penetration percentile than Ligand B (63.16). While not critical for a cardiovascular target, higher BBB is rarely detrimental.
9. **Caco-2:** Ligand A (-4.478) is better than Ligand B (-5.171), suggesting better intestinal absorption.
10. **Solubility:** Ligand A (-3.795) is better than Ligand B (-2.417), indicating better aqueous solubility.
11. **hERG:** Ligand A (0.906) is better than Ligand B (0.361), indicating lower hERG inhibition liability and a reduced risk of cardiotoxicity. This is *very* important for a cardiovascular target.
12. **Cl_mic:** Ligand A (91.76) has a higher microsomal clearance than Ligand B (25.72). This means Ligand B is more metabolically stable.
13. **t1/2:** Ligand A (-15.66) and Ligand B (-16.34) are similar.
14. **Pgp:** Ligand A (0.562) is better than Ligand B (0.082), suggesting lower P-gp efflux.
15. **Binding Affinity:** Ligand A (-7.1) has a slightly better binding affinity than Ligand B (-6.4). While the difference is not huge, it is still a factor.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most crucial ADME properties (TPSA, HBD, QED, Solubility, hERG, Pgp, Caco-2) and has a slightly better binding affinity. While Ligand B has better metabolic stability (lower Cl_mic), the other advantages of Ligand A, particularly the lower hERG risk and better solubility, are more critical for a cardiovascular drug candidate. The slightly better affinity of Ligand A further solidifies its preference.
Output:
1
2025-04-17 20:43:41,495 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (351.324 and 372.531 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (51.47) is significantly better than Ligand B (75.71). ADRB2 is a cardiovascular target, not CNS, but lower TPSA generally improves absorption.
3. **logP:** Ligand A (3.655) is good, within the optimal 1-3 range. Ligand B (1.315) is on the lower side, potentially hindering permeability.
4. **HBD:** Both ligands have 1 HBD, which is acceptable.
5. **HBA:** Ligand A has 3 HBA, while Ligand B has 4. Both are within the acceptable limit of 10.
6. **QED:** Both ligands have reasonable QED scores (0.918 and 0.731), indicating good drug-like properties. Ligand A is slightly better.
7. **DILI:** Ligand A (48.197) has a moderate DILI risk, while Ligand B (12.33) has a very low risk. This is a significant advantage for Ligand B.
8. **BBB:** Not a high priority for a cardiovascular target. Ligand A (94.998) is better, but this is less important.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-4.281) has slightly better solubility than Ligand B (-1.533), but both are quite poor.
11. **hERG:** Ligand A (0.71) has a slightly higher hERG risk than Ligand B (0.224). Lower is better, so Ligand B is preferred.
12. **Cl_mic:** Ligand B (30.623) has a lower microsomal clearance than Ligand A (39.095), indicating better metabolic stability.
13. **t1/2:** Ligand A (38.645) has a much longer in vitro half-life than Ligand B (2.701). This is a substantial advantage for Ligand A.
14. **Pgp:** Ligand A (0.347) has lower P-gp efflux than Ligand B (0.028), which is preferable.
15. **Binding Affinity:** Ligand B (-7.5 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.1 kcal/mol). This is a >1.5 kcal/mol difference, which is a major advantage that can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand B has a significantly better binding affinity, a much lower DILI risk, better metabolic stability (lower Cl_mic), and lower hERG risk. While its logP is lower and TPSA is higher, the substantial improvement in affinity and safety profiles are more important for a GPCR target like ADRB2. The poor Caco-2 values are a concern for both, but the superior potency of Ligand B could potentially overcome this issue with formulation strategies. The longer half-life of Ligand A is attractive, but the affinity difference is more critical.
Output:
0
2025-04-17 20:43:41,495 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [349.471, 56.79, 3.808, 1, 4, 0.736, 42.458, 74.874, -4.154, -4.437, 0.486, 90.231, -6.498, 0.436, -6.7]**
**Ligand B: [365.331, 90.98, 1.052, 2, 4, 0.707, 53.276, 72.276, -4.867, -2.887, 0.17, 26.008, -49.047, 0.01, -6.8]**
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). A (349.471) is slightly preferred.
2. **TPSA:** Ligand A (56.79) is significantly better than Ligand B (90.98). ADRB2 is a cardiovascular target, so CNS penetration isn't critical, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (3.808) is optimal, while Ligand B (1.052) is on the lower side, potentially hindering permeability. This favors A.
4. **H-Bond Donors:** Both have acceptable HBD counts (A: 1, B: 2).
5. **H-Bond Acceptors:** Both have acceptable HBA counts (A: 4, B: 4).
6. **QED:** Both are good (A: 0.736, B: 0.707), indicating drug-like properties.
7. **DILI:** Ligand A (42.458) has a slightly better DILI risk profile than Ligand B (53.276), although both are reasonably low.
8. **BBB:** Both have good BBB penetration (A: 74.874, B: 72.276), but this is less important for a cardiovascular target.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the values are very close, so this isn't a major differentiator.
10. **Aqueous Solubility:** Ligand A (-4.437) is better than Ligand B (-2.887), indicating better solubility.
11. **hERG:** Ligand A (0.486) has a much lower hERG risk than Ligand B (0.17). This is a significant advantage.
12. **Microsomal Clearance:** Ligand B (26.008) has significantly lower clearance than Ligand A (90.231), suggesting better metabolic stability. This is a strong point for B.
13. **In vitro Half-Life:** Ligand B (-49.047) has a much longer half-life than Ligand A (-6.498). This is a major advantage for B.
14. **P-gp Efflux:** Ligand A (0.436) has lower P-gp efflux than Ligand B (0.01), which is preferable.
15. **Binding Affinity:** Both have comparable binding affinity (-6.7 and -6.8 kcal/mol).
**Overall Assessment:**
Ligand A has advantages in TPSA, logP, solubility, hERG risk, and P-gp efflux. Ligand B excels in metabolic stability (lower Cl_mic) and half-life. Considering the GPCR-specific priorities (logP, TPSA, affinity), Ligand A initially appears more promising. However, the significantly improved metabolic stability and half-life of Ligand B are crucial for *in vivo* efficacy. While the lower logP of B is a concern, the substantial improvement in pharmacokinetic properties outweighs this drawback. For a cardiovascular target, a longer half-life and reduced clearance are highly valuable.
Output:
0
2025-04-17 20:43:41,495 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (349.391 and 360.443 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (131.54) is slightly higher than Ligand B (84.22). For a cardiovascular GPCR, TPSA is moderately important. Ligand B's lower TPSA is preferable, suggesting better potential for membrane permeability.
**3. logP:** Both ligands have good logP values (1.829 and 1.059), falling within the optimal 1-3 range. Ligand B is slightly lower, which could slightly improve solubility, but both are acceptable.
**4. H-Bond Donors:** Ligand A has 2 HBD, and Ligand B has 0. Both are within the acceptable limit of <=5.
**5. H-Bond Acceptors:** Ligand A has 5 HBA, and Ligand B has 7. Both are within the acceptable limit of <=10.
**6. QED:** Ligand B (0.817) has a significantly higher QED score than Ligand A (0.288), indicating a much more drug-like profile. This is a substantial advantage for Ligand B.
**7. DILI Risk:** Ligand A (34.277) has a much lower DILI risk than Ligand B (64.909). This is a significant advantage for Ligand A.
**8. BBB Penetration:** Both ligands have relatively low BBB penetration (38.426 and 52.268). Since ADRB2 is a cardiovascular target, BBB penetration is not a primary concern.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and indicates poor permeability. However, the scale is not specified, so it's hard to interpret.
**10. Aqueous Solubility:** Both ligands have negative solubility values, which is also unusual.
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (0.172 and 0.355), which is good.
**12. Microsomal Clearance:** Ligand A (2.406) has significantly lower microsomal clearance than Ligand B (19.987), indicating better metabolic stability. This is a key advantage for Ligand A.
**13. In vitro Half-Life:** Ligand A (23.524) has a much longer in vitro half-life than Ligand B (-21.721). This is a substantial advantage for Ligand A.
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (0.031 and 0.118), which is favorable.
**15. Binding Affinity:** Ligand B (-6.9 kcal/mol) has a slightly better binding affinity than Ligand A (-5.3 kcal/mol). This is a 1.6 kcal/mol difference, which is significant, but not overwhelming.
**Overall Assessment:**
While Ligand B has a better QED and binding affinity, Ligand A demonstrates superior ADME properties, particularly regarding DILI risk, metabolic stability (lower Cl_mic), and a longer half-life. For a cardiovascular target, metabolic stability and minimizing toxicity (DILI) are crucial. The slightly better affinity of Ligand B is not enough to offset the significant ADME advantages of Ligand A.
Output:
1
2025-04-17 20:43:41,495 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [339.403, 111.48 , 1.338, 4. , 5. , 0.563, 63.862, 57.968, -6.015, -2.369, 0.364, -7.993, 73.845, 0.039, -5.3 ]
**Ligand B:** [349.475, 83.22 , 2.562, 3. , 4. , 0.73 , 46.297, 54.556, -5.104, -2.407, 0.617, 22.973, 13.555, 0.061, -7.7 ]
Here's a step-by-step comparison, keeping GPCR priorities (logP, Pgp, TPSA, and affinity) in mind:
1. **MW:** Both are within the ideal 200-500 Da range. Ligand A (339.4) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (111.48) is higher than Ligand B (83.22). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is still preferred. Ligand B is better here.
3. **logP:** Ligand A (1.338) is within the optimal range, while Ligand B (2.562) is towards the higher end. Both are acceptable, but A is slightly better balanced.
4. **HBD/HBA:** Ligand A has 4 HBD and 5 HBA, while Ligand B has 3 HBD and 4 HBA. Both are reasonable and within acceptable limits.
5. **QED:** Ligand B (0.73) has a better QED score than Ligand A (0.563), suggesting a more drug-like profile.
6. **DILI:** Ligand A (63.862) has a higher DILI risk than Ligand B (46.297). This is a significant advantage for Ligand B.
7. **BBB:** Both have moderate BBB penetration, but Ligand A (57.968) is slightly lower than Ligand B (54.556). Since this is a cardiovascular target, BBB isn't a primary concern, but lower is preferable.
8. **Caco-2:** Ligand A (-6.015) has a much lower Caco-2 value than Ligand B (-5.104). This suggests significantly poorer intestinal absorption for Ligand A.
9. **Solubility:** Both have poor solubility (-2.369 and -2.407). This is a concern for both, but not a deciding factor.
10. **hERG:** Ligand A (0.364) has a lower hERG risk than Ligand B (0.617), which is a positive.
11. **Cl_mic:** Ligand A (-7.993) has a much lower (better) microsomal clearance than Ligand B (22.973), indicating better metabolic stability.
12. **t1/2:** Ligand A (73.845) has a significantly longer in vitro half-life than Ligand B (13.555), which is highly desirable.
13. **Pgp:** Ligand A (0.039) has a much lower P-gp efflux liability than Ligand B (0.061), suggesting better bioavailability.
14. **Affinity:** Ligand B (-7.7) has a slightly better binding affinity than Ligand A (-5.3). This is a 2.4 kcal/mol difference, which is substantial.
**Overall Assessment:**
While Ligand A has advantages in metabolic stability (Cl_mic, t1/2), P-gp efflux, and hERG risk, the significantly *worse* Caco-2 permeability is a major drawback. Poor absorption will severely limit its bioavailability. Ligand B, despite a higher DILI risk and slightly lower metabolic stability, has a much better predicted absorption profile (Caco-2) and a stronger binding affinity. The affinity difference is large enough to outweigh the other concerns, especially for a cardiovascular target where CNS penetration isn't critical. The lower DILI risk for B is also a significant advantage.
Therefore, I prefer Ligand B.
Output:
0
2025-04-17 20:43:41,496 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, the priorities are logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB.
Let's break down the comparison:
1. **MW:** Both ligands (341.5 and 346.4 Da) are within the ideal 200-500 Da range.
2. **TPSA:** Ligand B (32.34) is significantly better than Ligand A (53.16). Lower TPSA generally favors oral absorption and GPCR penetration.
3. **logP:** Both ligands have good logP values (3.26 and 3.35), falling within the optimal 1-3 range.
4. **HBD/HBA:** Ligand B (1 HBD, 2 HBA) is preferable to Ligand A (3 HBD, 3 HBA) as lower values are generally better for permeability.
5. **QED:** Ligand A (0.791) has a slightly better QED score than Ligand B (0.633), suggesting a more drug-like profile. However, this is less critical than other factors.
6. **DILI:** Ligand B (16.4%) has a much lower DILI risk than Ligand A (23.6%). This is a significant advantage.
7. **BBB:** Ligand B (90.1%) has a higher BBB penetration score than Ligand A (80.6%). While not crucial for a cardiovascular target, it's a positive attribute.
8. **Caco-2:** Ligand A (-5.3) is better than Ligand B (-4.6).
9. **Solubility:** Ligand A (-2.2) is better than Ligand B (-3.9).
10. **hERG:** Both ligands have low hERG inhibition risk (0.785 and 0.872).
11. **Cl_mic:** Ligand B (27.0) has a better (lower) microsomal clearance than Ligand A (-28.973). This suggests better metabolic stability.
12. **t1/2:** Ligand A (28.8) has a better in vitro half-life than Ligand B (-10.4).
13. **Pgp:** Ligand A (0.232) has a lower P-gp efflux liability than Ligand B (0.482), which is favorable.
14. **Binding Affinity:** Both ligands have very good binding affinities (-7.0 and -6.7 kcal/mol). The difference of 0.3 kcal/mol is not substantial enough to override other significant differences.
**Overall Assessment:**
Ligand B is the stronger candidate. While Ligand A has slightly better QED, Caco-2 permeability, solubility and in vitro half-life, Ligand B excels in critical areas for a GPCR drug: lower TPSA, lower DILI risk, higher BBB penetration, and better metabolic stability (lower Cl_mic). The small difference in binding affinity is not enough to favor Ligand A. The lower TPSA and DILI risk of Ligand B are particularly compelling.
**Output:**
0
2025-04-17 20:43:41,496 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 drug candidates. ADRB2 is a GPCR, so we'll prioritize logP, Pgp, TPSA, and affinity, alongside general drug-like properties.
**Ligand A:** [349.391, 139.34 , -1.315, 4. , 6. , 0.431, 36.681, 25.475, -6.273, -0.951, 0.092, -13.392, -6.072, 0.008, -7.1 ]
**Ligand B:** [381.523, 80.32 , 3.127, 2. , 6. , 0.699, 67.274, 38.736, -5.291, -3.005, 0.475, 61.729, 5.293, 0.336, -5.6 ]
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (349.391) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (139.34) is close to the upper limit for good oral absorption, but acceptable. Ligand B (80.32) is excellent, well below the 140 threshold. This favors Ligand B.
3. **logP:** Ligand A (-1.315) is a bit low, potentially hindering membrane permeability. Ligand B (3.127) is within the optimal range (1-3). This significantly favors Ligand B.
4. **HBD:** Ligand A (4) is acceptable. Ligand B (2) is also good.
5. **HBA:** Both ligands have 6 HBA, which is acceptable.
6. **QED:** Ligand B (0.699) has a better QED score than Ligand A (0.431), indicating a more drug-like profile.
7. **DILI:** Ligand A (36.681) has a significantly lower DILI risk than Ligand B (67.274). This is a strong advantage for Ligand A.
8. **BBB:** Ligand B (38.736) has a higher BBB penetration potential than Ligand A (25.475). While not a primary concern for ADRB2 (cardiovascular target), it's a slight benefit.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Ligand A (-0.951) has better solubility than Ligand B (-3.005).
11. **hERG:** Ligand A (0.092) has a lower hERG risk than Ligand B (0.475). This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand A (-13.392) has a much lower microsomal clearance, indicating better metabolic stability, than Ligand B (61.729). This is a strong advantage for Ligand A.
13. **t1/2:** Ligand A (-6.072) has a longer in vitro half-life than Ligand B (5.293).
14. **Pgp:** Ligand B (0.336) has lower P-gp efflux than Ligand A (0.008). This is a slight advantage for Ligand B.
15. **Affinity:** Ligand A (-7.1) has a slightly better binding affinity than Ligand B (-5.6). This is a significant advantage for Ligand A.
**Overall Assessment:**
Ligand B has advantages in TPSA, logP, QED, and Pgp efflux. However, Ligand A excels in DILI risk, hERG inhibition, metabolic stability (Cl_mic and t1/2), solubility, and binding affinity. Considering ADRB2 is a cardiovascular target, minimizing off-target effects (DILI, hERG) and maximizing metabolic stability are crucial. The slightly better affinity of Ligand A further strengthens its position. While Ligand B's logP is more optimal, the other significant advantages of Ligand A outweigh this.
Output:
1
2025-04-17 20:43:41,496 - INFO - Here's my reasoning and final output for the ligand preference:
**Reasoning:**
We are targeting ADRB2, a GPCR, so the priorities are logP, Pgp, TPSA, affinity, and BBB. Let's compare Ligand A and Ligand B across these and other important parameters.
1. **Molecular Weight:** Both ligands (357.48 Da) are within the ideal range (200-500 Da).
2. **TPSA:** Ligand A (53.51) is better than Ligand B (55.95). Both are reasonably good for oral absorption, but lower is preferable.
3. **logP:** Both ligands have good logP values (A: 2.02, B: 2.778), falling within the optimal 1-3 range. Ligand B is slightly higher, which *could* be a minor concern for solubility, but not a dealbreaker.
4. **H-Bond Donors/Acceptors:** Both have acceptable HBD (0) and HBA (A: 4, B: 6) counts.
5. **QED:** Both ligands have acceptable QED values (A: 0.774, B: 0.653), indicating good drug-likeness.
6. **DILI:** Ligand B (41.373) has a better DILI score than Ligand A (48.895), indicating lower potential for liver injury. This is a significant advantage.
7. **BBB:** Both ligands have reasonably good BBB penetration (A: 59.597, B: 62.233), but neither is exceptional.
8. **Caco-2 Permeability:** Ligand A (-4.758) has better Caco-2 permeability than Ligand B (-5.524).
9. **Aqueous Solubility:** Ligand B (-1.988) has better aqueous solubility than Ligand A (-3.864).
10. **hERG:** Both ligands have low hERG inhibition risk (A: 0.284, B: 0.485).
11. **Microsomal Clearance:** Ligand A (50.757) has lower microsomal clearance than Ligand B (58.546), suggesting better metabolic stability.
12. **In vitro Half-Life:** Ligand B (9.024) has a significantly longer in vitro half-life than Ligand A (-12.143). This is a major advantage.
13. **P-gp Efflux:** Both ligands have low P-gp efflux liability (A: 0.062, B: 0.268).
14. **Binding Affinity:** Ligand B (-6.3 kcal/mol) has a slightly better binding affinity than Ligand A (-5.6 kcal/mol). This is a 0.7 kcal/mol difference, which is meaningful, but not overwhelming.
**Overall Assessment:**
Ligand B is preferable. While Ligand A has slightly better TPSA and Caco-2 permeability, Ligand B excels in crucial areas: lower DILI risk, significantly longer half-life, and slightly better binding affinity. The improved solubility is also a plus. The slightly higher logP of Ligand B is not a major concern, and is outweighed by its other advantages. For a GPCR target, the combination of improved safety (DILI), longer duration of action (half-life), and affinity makes Ligand B the more promising candidate.
**Output:**
0
2025-04-17 20:43:41,496 - INFO - Here's my reasoning and final output for the ligand preference:
**Reasoning:**
We are targeting ADRB2, a GPCR, so the priorities are logP, TPSA, Pgp, BBB, and affinity.
* **Molecular Weight:** Both ligands are within the ideal range (354.35 and 353.51 Da).
* **TPSA:** Ligand A (46.33) is significantly better than Ligand B (81.67). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally correlates with better absorption.
* **logP:** Ligand A (3.019) is good, within the optimal range. Ligand B (1.424) is on the lower side, potentially hindering permeability.
* **H-Bond Donors/Acceptors:** Ligand A (1 HBD, 2 HBA) is preferable to Ligand B (3 HBD, 4 HBA). Fewer H-bonds generally improve membrane permeability.
* **QED:** Both are acceptable (0.64 and 0.555), above the 0.5 threshold.
* **DILI:** Ligand A (34.43) is much better than Ligand B (5.58). Lower DILI is crucial.
* **BBB:** Ligand A (84.03) is better than Ligand B (31.99), though not a primary concern for a cardiovascular target.
* **Caco-2:** Ligand A (-4.644) is better than Ligand B (-5.54). Higher Caco-2 values indicate better intestinal absorption.
* **Solubility:** Ligand A (-3.121) is better than Ligand B (-1.228).
* **hERG:** Ligand A (0.944) is better than Ligand B (0.469). Lower hERG is crucial.
* **Cl_mic:** Ligand A (26.34) is better than Ligand B (-4.52). Lower clearance indicates greater metabolic stability.
* **t1/2:** Ligand A (23.46) is better than Ligand B (26.48).
* **Pgp:** Ligand A (0.516) is better than Ligand B (0.014). Lower Pgp efflux is desirable.
* **Binding Affinity:** Ligand B (-7.3) has a 0.8 kcal/mol advantage in binding affinity over Ligand A (-6.5). This is a significant difference.
**Overall Assessment:**
While Ligand B has a stronger binding affinity, Ligand A has a significantly better ADME profile across almost all parameters (TPSA, logP, DILI, BBB, Caco-2, Solubility, hERG, Cl_mic, Pgp). The improved ADME properties of Ligand A, especially the lower DILI and better predicted permeability, outweigh the affinity difference. For a cardiovascular target, a slightly lower affinity can be tolerated if the drug is more likely to be safely absorbed and remain in the body.
**Output:**
1
2025-04-17 20:43:41,496 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (342.439 and 382.511 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (78.43) is better than Ligand B (84.42). Both are below the 140 threshold for oral absorption, but lower TPSA is generally preferred for GPCRs.
3. **logP:** Both ligands have excellent logP values (2.087 and 1.989) falling within the optimal 1-3 range.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (1), but both are within the acceptable limit of 5.
5. **HBA:** Ligand A (3) is lower than Ligand B (7). Ligand B is approaching the upper limit of 10, which could potentially impact permeability.
6. **QED:** Both ligands have similar QED scores (0.664 and 0.671), indicating good drug-likeness.
7. **DILI:** Ligand A (23.769) has a significantly lower DILI risk than Ligand B (67.197). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (45.095) is lower than Ligand B (53.005). While ADRB2 isn't strictly a CNS target, some CNS penetration might be acceptable or even beneficial depending on the specific therapeutic goal, and B is slightly better here.
9. **Caco-2:** Ligand A (-4.868) is better than Ligand B (-5.117). Both are negative, indicating low permeability.
10. **Solubility:** Ligand A (-2.727) is better than Ligand B (-1.614). Both are negative, indicating low solubility.
11. **hERG:** Ligand A (0.104) has a much lower hERG inhibition liability than Ligand B (0.429). This is a critical advantage for Ligand A, minimizing cardiotoxicity risk.
12. **Cl_mic:** Ligand A (29.891) has a lower microsomal clearance than Ligand B (55.091), suggesting better metabolic stability.
13. **t1/2:** Ligand B (28.492) has a significantly longer in vitro half-life than Ligand A (7.556). This is a positive for Ligand B.
14. **Pgp:** Ligand A (0.094) has lower P-gp efflux liability than Ligand B (0.232), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand A (-7.6) has a slightly better binding affinity than Ligand B (-5.7). This difference of 1.9 kcal/mol is substantial and can outweigh some ADME drawbacks.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Both ligands perform well on logP. Ligand A has a better TPSA and Pgp profile. The affinity difference is significant, favoring Ligand A. The DILI and hERG profiles of Ligand A are also considerably better, which are critical safety parameters. While Ligand B has a longer half-life, the other advantages of Ligand A are more compelling.
**Conclusion:**
Ligand A clearly outperforms Ligand B across several critical parameters, particularly safety (DILI, hERG) and potency (affinity). The slightly better metabolic stability of Ligand B does not outweigh the other advantages of Ligand A.
Output:
1
2025-04-17 20:43:41,496 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.39 and 347.46 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand B (78.51) is significantly better than Ligand A (95.6). ADRB2 is not a CNS target, but lower TPSA generally correlates with better permeability.
3. **logP:** Ligand B (1.366) is optimal, while Ligand A (-0.129) is a bit low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand B (3) is preferable to Ligand A (5). Fewer HBAs generally improve permeability.
6. **QED:** Both ligands have similar QED values (0.724 and 0.712), indicating good drug-likeness.
7. **DILI:** Ligand B (19.271) has a much lower DILI risk than Ligand A (58.395). This is a major advantage for Ligand B.
8. **BBB:** Not a primary concern for ADRB2 (cardiovascular target), but Ligand B (65.374) has a higher BBB penetration than Ligand A (33.85).
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-4.549) is slightly better than Ligand B (-5.069).
10. **Solubility:** Both ligands have very poor aqueous solubility (-2.059 and -2.782). This is a significant drawback for both.
11. **hERG:** Both ligands have low hERG inhibition risk (0.113 and 0.215).
12. **Cl_mic:** Ligand A (-7.983) has a much lower (better) microsomal clearance than Ligand B (53.958), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-18.529) has a longer in vitro half-life than Ligand B (-9.779).
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.014 and 0.085).
15. **Binding Affinity:** Ligand B (-6.9 kcal/mol) has slightly better binding affinity than Ligand A (-6.1 kcal/mol). While the difference isn't huge, it's a positive for Ligand B.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, and affinity are key. Ligand B excels in logP and has slightly better affinity. While TPSA is better for Ligand B, the solubility for both is poor. The significantly lower DILI risk for Ligand B is a major advantage. The better metabolic stability of Ligand A is a positive, but the DILI risk is a significant concern.
**Overall Assessment:**
Despite Ligand A's better metabolic stability and half-life, Ligand B is the more promising candidate. The combination of better logP, slightly improved affinity, and *significantly* lower DILI risk outweigh the benefits of Ligand A. The poor solubility of both is a concern that would need to be addressed through formulation strategies.
Output:
0
2025-04-17 20:43:41,496 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (363.527) is slightly higher than Ligand B (345.403), but both are acceptable.
2. **TPSA:** Ligand A (53.51) is significantly better than Ligand B (91.56). ADRB2 is a cardiovascular target, not a CNS target, but lower TPSA generally aids absorption. Ligand B's TPSA is quite high and could hinder oral bioavailability.
3. **logP:** Both ligands have acceptable logP values (A: 2.963, B: 1.03), falling within the 1-3 range. Ligand A is slightly better.
4. **HBD:** Ligand A (0) is preferable to Ligand B (1). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is better than Ligand B (6). Lower HBA also aids permeability.
6. **QED:** Both ligands have good QED scores (A: 0.7, B: 0.844), indicating good drug-like properties. Ligand B is slightly better here.
7. **DILI:** Ligand A (19.426) is *much* better than Ligand B (37.922). This is a significant advantage for Ligand A, as lower DILI risk is crucial.
8. **BBB:** This is less important for a cardiovascular target, but Ligand A (82.125) is better than Ligand B (32.765).
9. **Caco-2:** Both have negative values, indicating poor permeability. Ligand A (-4.934) is slightly better than Ligand B (-5.109), but both are concerning.
10. **Solubility:** Both ligands have poor solubility (-2.313 and -1.105 respectively). This is a drawback for both, but Ligand B is slightly better.
11. **hERG:** Both ligands have low hERG inhibition risk (A: 0.76, B: 0.201). Ligand B is better here.
12. **Cl_mic:** Ligand B (36.76) has a lower microsomal clearance than Ligand A (66.56), suggesting better metabolic stability. This is a benefit for Ligand B.
13. **t1/2:** Ligand A (-16.331) has a longer in vitro half-life than Ligand B (-12.39), which is desirable.
14. **Pgp:** Both ligands have low Pgp efflux liability (A: 0.618, B: 0.018). Ligand B is significantly better here.
15. **Binding Affinity:** Both ligands have similar binding affinities (A: -6.2, B: -6.4). Ligand B is slightly better.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand A appears to be the better candidate. While Ligand B has slightly better affinity, Pgp efflux, and metabolic stability, Ligand A has a significantly lower DILI risk, better TPSA, fewer HBDs/HBAs, and a longer half-life. The lower DILI risk is a major advantage, and the TPSA difference is substantial. The solubility and Caco-2 permeability are concerns for both, but these can potentially be addressed with formulation strategies.
Output:
1
2025-04-17 20:43:41,496 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.475 and 348.462 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (76.02) is higher than Ligand B (41.57). For a GPCR, lower TPSA is generally preferred for better brain penetration, even though ADRB2 isn't strictly a CNS target. Ligand B is significantly better here.
3. **logP:** Ligand A (2.181) is within the optimal 1-3 range. Ligand B (3.846) is slightly higher, approaching the upper limit. While still acceptable, it could potentially lead to solubility issues or off-target interactions. Ligand A is slightly better.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable.
5. **HBA:** Ligand A (4) and Ligand B (3) are both acceptable.
6. **QED:** Ligand A (0.829) has a higher QED than Ligand B (0.544), indicating a more drug-like profile overall. This is a significant advantage for Ligand A.
7. **DILI:** Ligand A (21.714) has a lower DILI risk than Ligand B (18.651), which is preferable.
8. **BBB:** Ligand B (87.088) shows significantly better BBB penetration potential than Ligand A (68.399). While ADRB2 isn't a primary CNS target, some degree of BBB penetration can be beneficial for distribution and off-target effects assessment.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.855 and -4.606), which is unusual and suggests poor permeability. This is a major concern for both.
10. **Solubility:** Ligand A (-2.816) has slightly better solubility than Ligand B (-4.038).
11. **hERG:** Ligand A (0.353) has a lower hERG risk than Ligand B (0.948). This is a crucial safety parameter, and Ligand A is clearly better.
12. **Cl_mic:** Ligand B (62.439) has a higher microsomal clearance than Ligand A (41.734), indicating faster metabolism and potentially lower *in vivo* exposure. Ligand A is better.
13. **t1/2:** Ligand B (25.21) has a much longer half-life than Ligand A (-0.599). This is a significant advantage for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.062) has lower P-gp efflux liability than Ligand B (0.418), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand B (-6.5 kcal/mol) has a stronger binding affinity than Ligand A (-8.0 kcal/mol). This is a substantial difference and a major advantage for Ligand B.
**Overall Assessment:**
Ligand B has a significantly better binding affinity and a longer half-life, which are highly desirable. However, it has a higher logP, higher Pgp efflux, and a higher hERG risk. Ligand A has a better QED, lower DILI, lower hERG, and better solubility. The Caco-2 values for both are concerning.
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), the stronger affinity of Ligand B is a major factor. While the slightly higher logP and Pgp efflux are drawbacks, the substantial binding advantage outweighs them, especially given the relatively good BBB penetration. The longer half-life also contributes to its potential. The hERG risk is a concern, but not insurmountable with further optimization.
Output:
0
2025-04-17 20:43:41,496 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (342.395 and 338.407 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (70.42) is higher than Ligand B (53.76). For a cardiovascular GPCR, TPSA is moderately important, and Ligand B is better positioned for good absorption.
3. **logP:** Both ligands (2.725 and 2.27) are within the optimal 1-3 range. Ligand B is slightly lower, which could marginally improve solubility, but both are acceptable.
4. **HBD:** Both ligands have 0 HBD, which is good.
5. **HBA:** Ligand A has 6 HBA, Ligand B has 3. Lower is generally better, so Ligand B is preferable.
6. **QED:** Ligand B (0.792) has a significantly better QED score than Ligand A (0.545), indicating a more drug-like profile.
7. **DILI:** Ligand B (31.252) has a much lower DILI risk than Ligand A (44.552). This is a significant advantage for Ligand B.
8. **BBB:** Both ligands have good BBB penetration (82.125 and 85.498). Since ADRB2 is not a CNS target, this is less critical, but Ligand B is slightly better.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the values are similar (-4.452 and -4.38).
10. **Solubility:** Both ligands have negative solubility values, which is also unusual and suggests poor solubility. Again, values are similar (-3.815 and -3.939).
11. **hERG:** Both ligands have very low hERG inhibition risk (0.407 and 0.313). This is excellent.
12. **Cl_mic:** Ligand B (13.299) has a *much* lower microsomal clearance than Ligand A (113.766), indicating significantly better metabolic stability. This is a major advantage.
13. **t1/2:** Ligand B (14.306) has a longer in vitro half-life than Ligand A (-25.472). This is a significant advantage.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.387 and 0.092). Ligand B is slightly better.
15. **Binding Affinity:** Ligand A (-6.1 kcal/mol) has a slightly better binding affinity than Ligand B (-5.7 kcal/mol). While affinity is important, the difference here (0.4 kcal/mol) is not large enough to outweigh the substantial ADME advantages of Ligand B.
**GPCR-Specific Priorities:**
For a cardiovascular GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B performs better on TPSA, Pgp, and has a better overall ADME profile. The affinity difference is not substantial enough to favor Ligand A.
**Conclusion:**
Ligand B is the superior candidate due to its significantly better DILI risk, metabolic stability (lower Cl_mic), longer half-life, better QED, and lower TPSA/HBA. While Ligand A has slightly better affinity, the ADME advantages of Ligand B are more critical for overall drug development success.
Output:
0
2025-04-17 20:43:41,496 - INFO - Batch 206 complete. Total preferences: 3296
2025-04-17 20:43:41,496 - INFO - Processing batch 207/512...
2025-04-17 20:44:26,600 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
We are targeting ADRB2, a GPCR. Therefore, the priorities are logP, Pgp, TPSA, affinity, and, to a lesser extent, BBB.
Let's compare the ligands property by property:
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (350.423) is slightly better being closer to the lower end.
2. **TPSA:** Ligand A (94.8) is significantly better than Ligand B (120.85). Lower TPSA generally improves oral absorption, crucial for a cardiovascular drug.
3. **logP:** Ligand B (-0.261) is slightly better than Ligand A (-1.199) as it is closer to the optimal range of 1-3. However, both are a bit low, potentially impacting permeability.
4. **HBD:** Ligand B (2) is slightly better than Ligand A (1).
5. **HBA:** Ligand B (6) is better than Ligand A (7).
6. **QED:** Ligand A (0.717) is better than Ligand B (0.552), indicating a more drug-like profile.
7. **DILI:** Ligand A (29.857) is significantly better than Ligand B (55.758), indicating a lower risk of drug-induced liver injury. This is a critical factor.
8. **BBB:** Ligand A (58.938) is better than Ligand B (41.76), although neither is exceptionally high. BBB is less critical for a cardiovascular target, but still a positive.
9. **Caco-2:** Ligand A (-4.917) is better than Ligand B (-5.36), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-0.357) is better than Ligand B (-1.75).
11. **hERG:** Both are very low (0.137 and 0.125), indicating minimal hERG inhibition risk.
12. **Cl_mic:** Ligand A (3.008) is significantly better than Ligand B (34.298), indicating much better metabolic stability.
13. **t1/2:** Ligand B (-8.297) is better than Ligand A (6.133), suggesting a longer half-life.
14. **Pgp:** Both are very low (0.026 and 0.087), indicating minimal P-gp efflux.
15. **Affinity:** Ligand A (-6.8) is slightly better than Ligand B (-6.1), but the difference is relatively small.
**Overall Assessment:**
Ligand A clearly outperforms Ligand B in several crucial areas: TPSA, DILI risk, metabolic stability (Cl_mic), solubility, and QED. While Ligand B has a slightly better logP and half-life, the advantages of Ligand A in safety (DILI) and ADME properties (TPSA, Cl_mic) are more important for overall drug development success, especially considering the GPCR target class. The affinity difference is not substantial enough to favor Ligand B.
**Output:**
1
2025-04-17 20:44:26,600 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (442.575 and 426.336 Da) are within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (87.26) is slightly higher than Ligand B (74.91). Both are below the 140 threshold for good oral absorption, but closer to the 90 threshold for CNS targets (less relevant here, but still a positive). Ligand B is better.
3. **logP:** Ligand A (4.127) is slightly above the optimal 1-3 range, while Ligand B (3.572) is within the optimal range. Ligand B is better.
4. **HBD:** Ligand A (0) is better than Ligand B (1). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (6) is better than Ligand B (5). Lower HBA is generally preferred.
6. **QED:** Ligand B (0.797) has a significantly better QED score than Ligand A (0.395), indicating a more drug-like profile. Ligand B is much better.
7. **DILI:** Ligand A (90.074) has a higher DILI risk than Ligand B (71.229). Ligand B is better.
8. **BBB:** Ligand A (70.803) has a better BBB penetration than Ligand B (62.35). While not a primary concern for ADRB2, it's a slight advantage for A.
9. **Caco-2:** Ligand A (-4.753) has a worse Caco-2 permeability than Ligand B (-5.148). Both are negative, indicating poor permeability, but B is slightly better.
10. **Solubility:** Ligand A (-5.761) has worse solubility than Ligand B (-3.431). Ligand B is better.
11. **hERG:** Ligand A (0.45) has a slightly higher hERG risk than Ligand B (0.112). Ligand B is better.
12. **Cl_mic:** Ligand B (-12.658) has significantly better metabolic stability (lower clearance) than Ligand A (81.194). Ligand B is much better.
13. **t1/2:** Ligand B (8.062) has a much longer in vitro half-life than Ligand A (59.768). Ligand B is much better.
14. **Pgp:** Ligand A (0.48) has a slightly higher Pgp efflux liability than Ligand B (0.306). Ligand B is better.
15. **Binding Affinity:** Ligand A (-7.8) has a significantly stronger binding affinity than Ligand B (-5.4). This is a substantial advantage for Ligand A.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, and affinity. Ligand B has better logP, TPSA, and Pgp. However, Ligand A has a *much* stronger binding affinity (-7.8 vs -5.4 kcal/mol). A difference of 2.4 kcal/mol is substantial and often outweighs minor ADME drawbacks.
**Overall Assessment:**
While Ligand B has a superior ADME profile across many parameters (QED, DILI, solubility, metabolic stability, half-life, Pgp efflux, hERG), the significantly stronger binding affinity of Ligand A is a decisive factor for a GPCR target. The improved binding is likely to translate to greater efficacy and potentially allow for a lower dose, mitigating some of the ADME concerns.
Output:
1
2025-04-17 20:44:26,600 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (343.383 and 348.531 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (84.67) is better than Ligand B (49.41). For a cardiovascular GPCR, a lower TPSA is generally preferred for better membrane permeability.
**3. logP:** Ligand B (3.912) is higher than Ligand A (1.644). While both are within the acceptable range (1-3), Ligand B is approaching the upper limit. This could potentially lead to solubility issues or off-target interactions, but is still acceptable.
**4. H-Bond Donors:** Both have 1 HBD, which is good.
**5. H-Bond Acceptors:** Ligand A has 5, and Ligand B has 2. Both are within the acceptable range.
**6. QED:** Ligand A (0.892) has a significantly better QED score than Ligand B (0.534), indicating a more drug-like profile.
**7. DILI Risk:** Ligand A (64.211) has a higher DILI risk than Ligand B (15.045). This is a significant concern for Ligand A.
**8. BBB Penetration:** Ligand B (84.878) has better BBB penetration than Ligand A (58.976). While not a primary concern for a cardiovascular target, some CNS off-target effects are possible, and better BBB penetration could be a slight advantage.
**9. Caco-2 Permeability:** Both ligands have similar, very negative Caco-2 values (-4.674 and -4.665). This suggests poor permeability.
**10. Aqueous Solubility:** Ligand A (-2.118) has better solubility than Ligand B (-3.738).
**11. hERG Inhibition:** Ligand A (0.289) has a lower hERG risk than Ligand B (0.728). This is a crucial safety parameter.
**12. Microsomal Clearance:** Ligand A (-1.605) has a lower (better) microsomal clearance than Ligand B (93.71). This suggests better metabolic stability for Ligand A.
**13. In Vitro Half-Life:** Ligand A (22.44) has a much longer half-life than Ligand B (-6.352). This is a significant advantage.
**14. P-gp Efflux:** Ligand A (0.075) has lower P-gp efflux than Ligand B (0.561). This is favorable for bioavailability.
**15. Binding Affinity:** Ligand A (-7.8) has a slightly better binding affinity than Ligand B (-6.2). This difference is substantial (>1.5 kcal/mol).
**Overall Assessment:**
Despite the better TPSA of Ligand B, Ligand A emerges as the more promising candidate. The significantly better binding affinity, QED, metabolic stability (lower Cl_mic, longer t1/2), lower P-gp efflux, and lower hERG risk outweigh the higher DILI risk and slightly lower BBB penetration. The DILI risk is concerning, but could potentially be mitigated through structural modifications. The poor Caco-2 permeability is a concern for both, but can be addressed through formulation strategies. The affinity difference is large enough to overcome the other drawbacks.
Output:
1
2025-04-17 20:44:26,601 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (365.5 & 374.5 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (73.74) is significantly better than Ligand B (104.73). ADRB2 is a cardiovascular target, not CNS, but lower TPSA generally improves absorption.
3. **logP:** Ligand A (2.066) is optimal. Ligand B (0.086) is quite low, potentially hindering membrane permeability. This is a significant negative for Ligand B.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Both ligands have 5 HBA, which is acceptable.
6. **QED:** Ligand A (0.89) is much better than Ligand B (0.586), indicating a more drug-like profile.
7. **DILI:** Ligand B (32.61) has a lower DILI risk than Ligand A (41.92), which is a positive for Ligand B.
8. **BBB:** This is less critical for a cardiovascular target. Ligand A (63.78) is better than Ligand B (26.21), but neither is particularly high.
9. **Caco-2:** Ligand A (-4.765) is better than Ligand B (-5.327), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-2.137) is better than Ligand B (-1.247), which is important for bioavailability.
11. **hERG:** Both ligands have very low hERG risk (0.37 and 0.098), which is excellent.
12. **Cl_mic:** Ligand B (12.099) has a lower microsomal clearance than Ligand A (19.299), suggesting better metabolic stability.
13. **t1/2:** Ligand B (22.096) has a significantly longer in vitro half-life than Ligand A (-5.551), which is a major advantage.
14. **Pgp:** Ligand A (0.189) has lower P-gp efflux than Ligand B (0.043), which is good.
15. **Binding Affinity:** Ligand A (-6.7) has a slightly better binding affinity than Ligand B (-6.3), but the difference is relatively small (0.4 kcal/mol).
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A excels in logP, TPSA, and Pgp. Ligand B has better metabolic stability (Cl_mic, t1/2) and DILI risk. The affinity difference is minor. The low logP of Ligand B is a significant concern, potentially limiting its ability to cross cell membranes and reach the receptor. The better QED and solubility of Ligand A are also positive factors.
**Overall Assessment:**
While Ligand B has advantages in metabolic stability and DILI, the significantly lower logP is a major drawback. Ligand A presents a more balanced profile with better predicted permeability and drug-like properties, despite slightly higher DILI risk and lower metabolic stability. The small affinity difference doesn't outweigh the ADME concerns with Ligand B.
Output:
1
2025-04-17 20:44:26,601 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (365.821 and 352.507 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (33.43) is significantly better than Ligand A (108.88). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. This is a strong point for Ligand B.
3. **logP:** Ligand A (0.858) is suboptimal, being slightly below the preferred 1-3 range. Ligand B (4.637) is too high, potentially leading to solubility issues and off-target effects. Both are concerning, but Ligand A's is less problematic.
4. **HBD:** Ligand A (3) is acceptable, while Ligand B (0) is also fine. No significant difference.
5. **HBA:** Both ligands have 5 HBA, which is within the acceptable range.
6. **QED:** Ligand A (0.676) is better than Ligand B (0.554), indicating a more drug-like profile.
7. **DILI:** Ligand B (47.266) has a much lower DILI risk than Ligand A (65.568). This is a significant advantage for Ligand B.
8. **BBB:** Ligand B (83.443) has a much higher BBB penetration potential than Ligand A (20.473). While not critical for a cardiovascular target, it's not a negative.
9. **Caco-2:** Ligand A (-5.71) and Ligand B (-4.95) both have negative values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Ligand A (-2.994) has slightly better solubility than Ligand B (-4.194), but both are poor.
11. **hERG:** Ligand A (0.199) has a lower hERG risk than Ligand B (0.712). This is a crucial advantage for Ligand A, given the cardiovascular target.
12. **Cl_mic:** Ligand B (75.811) has a much higher microsomal clearance than Ligand A (23.456), indicating lower metabolic stability. This is a major drawback for Ligand B.
13. **t1/2:** Ligand A (6.518) has a better in vitro half-life than Ligand B (-18.819). The negative value for Ligand B is concerning and suggests very rapid degradation.
14. **Pgp:** Ligand A (0.044) has lower P-gp efflux than Ligand B (0.56). This is favorable for oral bioavailability.
15. **Binding Affinity:** Ligand A (-6.8 kcal/mol) has a slightly better binding affinity than Ligand B (-4.3 kcal/mol). This 1.5 kcal/mol difference is significant and can outweigh some ADME drawbacks.
**GPCR-specific priorities:** For ADRB2 (a GPCR), we prioritize logP, Pgp, TPSA, and affinity. Ligand B excels in TPSA and BBB, but struggles with logP and Cl_mic. Ligand A has a better balance, with acceptable logP, better metabolic stability, and superior binding affinity. The hERG risk is also lower for Ligand A, which is vital for a cardiovascular drug.
**Conclusion:**
While Ligand B has some advantages in TPSA and DILI, the significantly better binding affinity, metabolic stability, half-life, Pgp profile, and lower hERG risk of Ligand A make it the more promising drug candidate. The solubility and logP of Ligand A are not ideal, but these can potentially be addressed through formulation or further chemical modifications.
Output:
1
2025-04-17 20:44:26,601 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (342.4 and 341.5 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (86.37) is slightly higher than Ligand B (61.36). Ligand B is better, being closer to the <90 ideal for GPCRs.
3. **logP:** Ligand B (2.198) is within the optimal 1-3 range, while Ligand A (0.472) is quite low, potentially hindering membrane permeability. This is a significant advantage for Ligand B.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 5 HBA. Both are acceptable, below the 10 threshold.
6. **QED:** Both ligands have good QED scores (0.793 and 0.89), indicating good drug-like properties.
7. **DILI:** Both have acceptable DILI risk (49.6 and 45.0), below the 60 threshold.
8. **BBB:** Ligand B (81.35) has a significantly higher BBB penetration percentile than Ligand A (47.38). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant and higher BBB is generally favorable.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. This is concerning for both.
10. **Solubility:** Both have negative solubility values, indicating poor solubility. This is concerning for both.
11. **hERG:** Ligand A (0.215) has a lower hERG inhibition liability than Ligand B (0.741), which is a positive.
12. **Cl_mic:** Ligand A (19.12) has a much lower microsomal clearance than Ligand B (79.03), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (-26.99) has a more negative in vitro half-life than Ligand B (-9.93). This is a negative for Ligand A, indicating faster metabolism.
14. **Pgp:** Ligand A (0.027) has a much lower P-gp efflux liability than Ligand B (0.1), indicating better bioavailability. This is a significant advantage for Ligand A.
15. **Affinity:** Both ligands have very similar and good binding affinities (-7.0 and -6.9 kcal/mol). The difference is negligible.
**Overall Assessment:**
Ligand B has advantages in logP and BBB penetration, crucial for GPCR targets. However, Ligand A has a much better metabolic profile (lower Cl_mic, lower Pgp efflux), and a lower hERG risk. The poor Caco-2 and solubility for both are concerning, but can potentially be addressed with formulation strategies. Given the importance of metabolic stability and minimizing cardiotoxicity for a cardiovascular target like ADRB2, the benefits of Ligand A outweigh the slightly better permeability predictions of Ligand B.
Output:
1
2025-04-17 20:44:26,601 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
The ADRB2 receptor is a GPCR, so the priorities are logP, Pgp, TPSA, affinity, and BBB. Let's break down the comparison:
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da).
2. **TPSA:** Ligand A (58.2) is significantly better than Ligand B (78.67). Lower TPSA generally favors better absorption and potentially BBB penetration.
3. **logP:** Ligand A (2.353) is optimal, while Ligand B (0.458) is quite low. A logP below 1 can hinder membrane permeability.
4. **H-Bond Donors/Acceptors:** Ligand A (2/3) and Ligand B (1/5) are both acceptable, though Ligand B has a slightly more favorable profile.
5. **QED:** Both ligands have good QED scores (A: 0.74, B: 0.781), indicating good drug-like properties.
6. **DILI:** Ligand A (31.33) has a much lower DILI risk than Ligand B (52.113). This is a significant advantage.
7. **BBB:** Ligand B (70.803) shows better BBB penetration than Ligand A (61.846), but both are reasonably good.
8. **Caco-2:** Ligand A (-5.377) is better than Ligand B (-4.592), indicating better intestinal absorption.
9. **Solubility:** Ligand A (-4.323) is better than Ligand B (-0.859).
10. **hERG:** Both ligands have low hERG inhibition risk (A: 0.156, B: 0.258).
11. **Cl_mic:** Ligand B (24.048) has significantly lower microsomal clearance than Ligand A (39.158), suggesting better metabolic stability.
12. **t1/2:** Ligand B (-17.541) has a worse in vitro half-life than Ligand A (6.529).
13. **Pgp:** Ligand A (0.074) has lower P-gp efflux liability than Ligand B (0.159), which is beneficial for bioavailability.
14. **Binding Affinity:** Ligand B (-6.7) has a slightly better binding affinity than Ligand A (-5.8), a 0.9 kcal/mol difference.
**Overall Assessment:**
While Ligand B has a slightly better binding affinity and lower Cl_mic, Ligand A is superior overall. The significantly better logP, TPSA, DILI risk, solubility and Caco-2 permeability of Ligand A are crucial for a GPCR target. The affinity difference is not large enough to overcome these advantages. The lower Pgp efflux for Ligand A is also a positive.
**Output:**
1
2025-04-17 20:44:26,601 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (433.611 Da) is within the ideal range, while Ligand B (345.403 Da) is towards the lower end but still acceptable.
2. **TPSA:** Ligand A (58.2) is excellent, well below the 140 threshold. Ligand B (108.21) is higher but still reasonable for a peripherally acting GPCR target.
3. **logP:** Ligand A (4.584) is slightly high, potentially leading to solubility issues or off-target interactions. Ligand B (0.746) is quite low, which could hinder membrane permeability.
4. **HBD:** Both ligands are good (2 and 1 respectively), falling within the desired range.
5. **HBA:** Ligand A (2) is excellent. Ligand B (6) is higher, but still within the acceptable limit of 10.
6. **QED:** Both ligands have good QED scores (0.538 and 0.815), indicating good drug-like properties.
7. **DILI:** Ligand A (88.91) has a higher DILI risk than Ligand B (48.275), which is a significant concern.
8. **BBB:** Ligand A (75.843) shows moderate BBB penetration, while Ligand B (44.668) is lower. For ADRB2, which is not necessarily a CNS target, this is not a primary driver.
9. **Caco-2:** Both ligands have negative Caco-2 values, suggesting poor permeability. This is unusual and requires further investigation, but we'll assume they represent low permeability for now.
10. **Solubility:** Ligand A (-5.566) has very poor predicted solubility, consistent with its high logP. Ligand B (-2.217) is better, but still not ideal.
11. **hERG:** Ligand A (0.543) has a low hERG risk, which is positive. Ligand B (0.114) is even lower, indicating very low cardiotoxicity risk.
12. **Cl_mic:** Ligand A (39.656) has a moderate clearance, while Ligand B (11.214) has a very low clearance, suggesting better metabolic stability.
13. **t1/2:** Ligand A (103.897) has a long half-life, which is desirable. Ligand B (-8.306) has a negative half-life, which is not possible and indicates a problem with the prediction.
14. **Pgp:** Ligand A (0.551) has moderate Pgp efflux, while Ligand B (0.01) has very low Pgp efflux, which is favorable for bioavailability.
15. **Affinity:** Ligand A (-7.5 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.3 kcal/mol). This is a substantial advantage.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has a higher logP and moderate Pgp efflux, but its significantly better affinity (-7.5 vs -6.3) is a major advantage. Ligand B has better solubility and lower Pgp efflux, but its lower affinity is a significant drawback. The DILI risk for Ligand A is also a concern.
**Overall Assessment:**
Despite the higher DILI risk and slightly elevated logP, Ligand A's substantially stronger binding affinity is the most important factor. The difference in affinity (1.2 kcal/mol) is large enough to potentially overcome the other drawbacks, especially given that ADRB2 is not a CNS target where BBB penetration is critical. The poor solubility of Ligand A could be addressed with formulation strategies. The negative half-life for Ligand B is a red flag.
**Output:**
1
2025-04-17 20:44:26,602 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (405.267 Da) is within the ideal range. Ligand B (349.475 Da) is also within the ideal range, but closer to the lower limit.
2. **TPSA:** Ligand A (49.5) is good for oral absorption. Ligand B (83.36) is higher, potentially impacting absorption, but not drastically.
3. **logP:** Ligand A (4.238) is slightly high, potentially leading to solubility issues or off-target effects. Ligand B (1.52) is optimal.
4. **HBD:** Ligand A (1) is good. Ligand B (3) is acceptable, but higher.
5. **HBA:** Both Ligand A (4) and Ligand B (4) are within acceptable limits.
6. **QED:** Both Ligand A (0.639) and Ligand B (0.599) are above 0.5, indicating good drug-likeness.
7. **DILI:** Ligand A (52.074) has a moderate DILI risk. Ligand B (15.626) has a very low DILI risk, a significant advantage.
8. **BBB:** Ligand A (78.79) has good BBB penetration. Ligand B (50.872) is lower, suggesting less CNS penetration. For ADRB2, which is not primarily a CNS target, this is less critical.
9. **Caco-2:** Both Ligand A (-4.931) and Ligand B (-4.997) have similar, poor Caco-2 permeability.
10. **Solubility:** Ligand A (-4.357) has poor solubility. Ligand B (-1.277) has better solubility.
11. **hERG:** Ligand A (0.967) has a slightly higher hERG risk than Ligand B (0.121), which is a major advantage for B.
12. **Cl_mic:** Ligand A (59.082) has moderate clearance. Ligand B (15.122) has low clearance, indicating better metabolic stability.
13. **t1/2:** Ligand A (75.157) has a good in vitro half-life. Ligand B (12.95) has a shorter half-life.
14. **Pgp:** Ligand A (0.96) has moderate Pgp efflux. Ligand B (0.032) has very low Pgp efflux, which is favorable for bioavailability.
15. **Affinity:** Ligand A (-7.7) has a significantly better binding affinity than Ligand B (-7.2). This is a 1.5 kcal/mol difference, which is substantial.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are important. Ligand A has a higher logP, but also a much better affinity. Ligand B excels in Pgp efflux, DILI, hERG, and metabolic stability. The poor Caco-2 permeability is concerning for both.
**Overall Assessment:**
While Ligand A boasts a superior binding affinity, the combination of Ligand B's significantly lower DILI risk, hERG risk, Pgp efflux, and better solubility, coupled with acceptable affinity, makes it the more promising candidate. The higher logP of Ligand A is a concern, and the improved safety profile of Ligand B outweighs the affinity difference. The metabolic stability of Ligand B is also a significant advantage.
Output:
0
2025-04-17 20:44:26,602 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [348.487, 69.64, 2.546, 2, 3, 0.402, 15.626, 52.811, -4.681, -1.81, 0.348, 26.624, -7.386, 0.2, -7.7]
**Ligand B:** [369.437, 53.51, 2.745, 0, 4, 0.823, 50.136, 79.139, -4.312, -3.043, 0.446, 55.381, 8.346, 0.282, -8]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal 200-500 Da range. A (348.487) is slightly preferred.
2. **TPSA:** A (69.64) is higher than B (53.51), but both are acceptable for a non-CNS GPCR target like ADRB2. B is better here.
3. **logP:** Both are good (around 2.5-2.7), falling within the 1-3 optimal range. No strong preference.
4. **HBD:** A (2) is preferable to B (0). Some H-bond donors can aid solubility.
5. **HBA:** A (3) is preferable to B (4).
6. **QED:** B (0.823) is significantly better than A (0.402), indicating a more drug-like profile. This is a significant advantage for B.
7. **DILI:** A (15.626) is better than B (50.136) - lower risk is always preferred.
8. **BBB:** B (79.139) is much higher than A (52.811). While ADRB2 isn't primarily a CNS target, some level of BBB penetration isn't necessarily detrimental, and higher is generally better.
9. **Caco-2:** Both are negative, indicating poor permeability. A (-4.681) is slightly better than B (-4.312), but both are concerning.
10. **Solubility:** A (-1.81) is better than B (-3.043). Solubility is important for bioavailability.
11. **hERG:** Both are low (0.348 and 0.446), indicating low cardiotoxicity risk. No strong preference.
12. **Cl_mic:** A (26.624) is significantly better than B (55.381) - lower clearance means better metabolic stability.
13. **t1/2:** A (-7.386) is better than B (8.346). A negative value suggests a longer half-life.
14. **Pgp:** Both are low (0.2 and 0.282), indicating low efflux. No strong preference.
15. **Affinity:** B (-8.0) is 0.3 kcal/mol better than A (-7.7). This is a substantial difference in binding affinity and a major factor.
**Overall Assessment:**
Ligand B has a superior QED score, better BBB penetration, and a significantly stronger binding affinity. While Ligand A has better DILI and metabolic stability (Cl_mic), the affinity advantage of Ligand B is substantial enough to outweigh these drawbacks, especially for a GPCR target where potency is crucial. The slightly lower solubility of B is a concern, but potentially addressable through formulation.
Therefore, I prefer Ligand B.
0
2025-04-17 20:44:26,602 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (453.28 Da) is slightly above the ideal range, but acceptable. Ligand B (358.316 Da) is well within the ideal range.
2. **TPSA:** Ligand A (79.46) is good, below the 140 threshold. Ligand B (88.42) is also acceptable, but closer to the limit.
3. **logP:** Both ligands have good logP values (A: 4.084, B: 3.137), falling within the 1-3 range. Ligand B is slightly preferred here.
4. **HBD:** Ligand A (3) is acceptable. Ligand B (1) is even better.
5. **HBA:** Ligand A (3) is acceptable. Ligand B (5) is also acceptable.
6. **QED:** Both ligands have similar QED values (A: 0.577, B: 0.541), indicating good drug-likeness.
7. **DILI:** Ligand A (85.77) has a significantly higher DILI risk than Ligand B (60.915). This is a major concern for Ligand A.
8. **BBB:** Ligand A (60.954) has a moderate BBB penetration, while Ligand B (74.564) is better. While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be useful for understanding off-target effects.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
10. **Solubility:** Both ligands have negative solubility values, indicating poor aqueous solubility. Again, the scale is unspecified, making interpretation difficult.
11. **hERG:** Ligand A (0.811) has a slightly higher hERG risk than Ligand B (0.652), but both are relatively low.
12. **Cl_mic:** Ligand A (47.951) has a lower microsomal clearance than Ligand B (55.595), suggesting better metabolic stability.
13. **t1/2:** Ligand A (53.587) has a much longer in vitro half-life than Ligand B (2.693). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.378) has lower P-gp efflux liability than Ligand B (0.08), which is better.
15. **Affinity:** Ligand B (-7.1 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.3 kcal/mol). This is a crucial advantage, exceeding the 1.5 kcal/mol threshold.
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand B excels in affinity and has acceptable values for the other parameters. While Ligand A has a better half-life and lower Pgp efflux, its significantly higher DILI risk and weaker binding affinity are major drawbacks.
**Conclusion:**
Despite Ligand A's better half-life and lower Pgp efflux, the significantly higher DILI risk and weaker binding affinity of Ligand A make it a less desirable candidate. Ligand B's superior binding affinity and lower DILI risk outweigh the slightly less favorable metabolic stability and half-life.
Output:
0
2025-04-17 20:44:26,602 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.379 and 354.447 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (130.17) is slightly higher than Ligand B (68.31). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for permeability. Ligand B is significantly better.
3. **logP:** Ligand A (-0.289) is quite low, potentially hindering membrane permeability. Ligand B (2.023) is within the optimal 1-3 range. This is a substantial advantage for Ligand B.
4. **HBD:** Ligand A (2) is reasonable. Ligand B (0) is even better, potentially improving permeability.
5. **HBA:** Ligand A (7) is acceptable. Ligand B (5) is slightly better.
6. **QED:** Both ligands (0.646 and 0.654) have good drug-likeness scores, exceeding the 0.5 threshold.
7. **DILI:** Ligand A (70.88) has a higher DILI risk than Ligand B (36.293). This is a significant concern, favoring Ligand B.
8. **BBB:** Ligand A (65.839) and Ligand B (82.086). While ADRB2 isn't a primary CNS target, some brain exposure can be relevant for off-target effects. Ligand B has better BBB penetration.
9. **Caco-2:** Ligand A (-5.371) and Ligand B (-4.32). Both are negative, which is unusual. The closer to zero, the better. No clear winner here.
10. **Solubility:** Ligand A (-2.389) and Ligand B (-1.093). Both are poor, but Ligand B is slightly better.
11. **hERG:** Ligand A (0.019) and Ligand B (0.644). Ligand A has a much lower hERG risk, which is a major advantage.
12. **Cl_mic:** Ligand A (33.928) has lower microsomal clearance than Ligand B (59.086), suggesting better metabolic stability. This favors Ligand A.
13. **t1/2:** Both ligands have negative in vitro half-lives (-11.669 and -11.335), which is unusual and suggests rapid degradation. No clear winner.
14. **Pgp:** Ligand A (0.028) has significantly lower P-gp efflux liability than Ligand B (0.151), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand B (-6.7) has a slightly better binding affinity than Ligand A (-6.4). While the difference is not huge, it's still a positive for Ligand B.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand B is generally more favorable. Its superior logP, lower TPSA, and lower DILI risk are significant advantages. While Ligand A has a better hERG profile and lower Cl_mic, the benefits of Ligand B's improved ADME properties and slightly better affinity outweigh these concerns. The lower DILI risk is particularly important.
Output:
0
2025-04-17 20:44:26,602 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (364.511 and 344.499 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (71.34) is higher than Ligand B (49.41). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B is better.
3. **logP:** Both ligands have good logP values (2.878 and 3.256), falling within the optimal 1-3 range. Ligand B is slightly higher, potentially aiding membrane permeability.
4. **HBD:** Ligand A has 2 HBD, and Ligand B has 1. Both are within the acceptable limit of 5. No significant difference.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 2. Both are within the acceptable limit of 10. Ligand B is better.
6. **QED:** Both ligands have very similar QED values (0.78 and 0.778), indicating good drug-like properties.
7. **DILI:** Ligand A (27.142) has a significantly lower DILI risk than Ligand B (36.293). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (70.027) has a higher BBB penetration percentile than Ligand A (53.974). While ADRB2 isn't a CNS target, some distribution to the CNS is possible and could be relevant for off-target effects.
9. **Caco-2:** Ligand A (-5.26) has a worse Caco-2 permeability than Ligand B (-4.535). This suggests Ligand B will have better intestinal absorption.
10. **Solubility:** Ligand A (-2.988) has slightly better solubility than Ligand B (-3.987). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.291) has a lower hERG inhibition liability than Ligand B (0.559). This is a significant safety advantage for Ligand A.
12. **Cl_mic:** Both ligands have similar microsomal clearance values (52.256 and 54.587 mL/min/kg), suggesting comparable metabolic stability.
13. **t1/2:** Ligand A (54.833 hours) has a significantly longer in vitro half-life than Ligand B (-14.076 hours). This is a major advantage for Ligand A, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.099) has lower P-gp efflux liability than Ligand B (0.284). Lower P-gp efflux is generally desirable for improved bioavailability.
15. **Binding Affinity:** Ligand B (-7.2 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.8 kcal/mol). This is a substantial advantage for Ligand B, potentially outweighing some ADME drawbacks.
**Overall Assessment:**
Ligand B has a superior binding affinity and better Caco-2 permeability. However, Ligand A demonstrates a significantly better safety profile with lower DILI and hERG risk, a longer half-life, and lower P-gp efflux. Considering the cardiovascular target, safety is paramount. The affinity difference, while substantial, might be overcome with further optimization of Ligand A. The improved ADME properties and safety profile of Ligand A make it the more promising candidate.
Output:
1
2025-04-17 20:44:26,603 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [347.375, 102.49 , 0.242, 1. , 7. , 0.803, 47.964, 55.176, -4.963, -2.297, 0.139, 4.158, 27.955, 0.036, -6.8 ]
**Ligand B:** [366.403, 136.06 , -0.091, 2. , 9. , 0.644, 86.002, 56.534, -5.363, -2.665, 0.155, 4.993, -2.395, 0.016, 3. ]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity):
1. **MW:** Both are within the ideal range (200-500 Da). A is slightly lower (347 vs 366), which is generally favorable for permeability.
2. **TPSA:** A (102.49) is better than B (136.06). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally aids absorption.
3. **logP:** A (0.242) is quite low, potentially hindering membrane permeability. B (-0.091) is also low, but slightly better. Both are below the optimal 1-3 range.
4. **HBD/HBA:** A (1 HBD, 7 HBA) is preferable to B (2 HBD, 9 HBA). Lower counts are generally better for permeability.
5. **QED:** A (0.803) is significantly better than B (0.644), indicating a more drug-like profile.
6. **DILI:** A (47.964) is much better than B (86.002). This is a significant advantage for A.
7. **BBB:** Both are similar (A: 55.176, B: 56.534) and not a primary concern for a cardiovascular target.
8. **Caco-2:** A (-4.963) is better than B (-5.363), indicating better intestinal absorption.
9. **Solubility:** Both are very poor (-2.297 and -2.665). This is a major concern for both.
10. **hERG:** Both are very low risk (0.139 and 0.155).
11. **Cl_mic:** A (4.158) is better than B (4.993), indicating better metabolic stability.
12. **t1/2:** A (27.955) is much better than B (-2.395), suggesting a longer half-life.
13. **Pgp:** Both are very low efflux (0.036 and 0.016), which is good.
14. **Affinity:** A (-6.8) is *significantly* better than B (3). This is a massive difference in binding strength.
**Overall Assessment:**
Ligand A is clearly superior. The substantially stronger binding affinity (-6.8 vs -3 kcal/mol) is a major advantage that can outweigh the slightly lower logP. A also has better QED, DILI risk, metabolic stability, and half-life. While both have poor solubility, the overall profile of A is much more promising. The lower TPSA of A is also a plus.
Output:
1
2025-04-17 20:44:26,603 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.383 and 364.446 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (85.3) is slightly higher than Ligand B (66.4). Both are below the 140 threshold for oral absorption, but B is better positioned, especially considering ADRB2 is a GPCR and CNS penetration *could* be a secondary benefit.
3. **logP:** Both ligands (1.714 and 1.961) are within the optimal 1-3 range. No major difference.
4. **HBD:** Ligand A has 1 HBD, while Ligand B has 0. Both are acceptable.
5. **HBA:** Both ligands have 5 HBA, which is within the acceptable limit of 10.
6. **QED:** Ligand A (0.871) has a significantly better QED score than Ligand B (0.766), indicating better overall drug-likeness.
7. **DILI:** Both ligands have similar DILI risk (56.223 and 55.176), and are both below the concerning threshold of 60.
8. **BBB:** Ligand B (84.141) shows significantly better BBB penetration potential than Ligand A (46.336). While ADRB2 isn't primarily a CNS target, some CNS exposure could be beneficial or at least not detrimental.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the values are similar (-4.84 and -4.608).
10. **Solubility:** Ligand A (-1.607) has slightly better aqueous solubility than Ligand B (-2.422).
11. **hERG:** Ligand A (0.025) has a much lower hERG inhibition liability than Ligand B (0.213), which is a critical advantage for cardiovascular targets.
12. **Cl_mic:** Ligand A (-8.769) has a much lower (better) microsomal clearance than Ligand B (27.567), indicating greater metabolic stability.
13. **t1/2:** Ligand B (-6.865) has a slightly longer in vitro half-life than Ligand A (-1.745).
14. **Pgp:** Ligand A (0.012) has a much lower P-gp efflux liability than Ligand B (0.122), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand A (-6.8) has slightly better binding affinity than Ligand B (-6.5), although the difference is relatively small.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand B has a slightly better TPSA and BBB, but Ligand A excels in Pgp efflux, hERG inhibition, and metabolic stability (Cl_mic). The affinity difference is minimal.
**Overall Assessment:**
While Ligand B has a better BBB score, the significantly better drug-like properties (QED), lower hERG risk, lower Pgp efflux, and improved metabolic stability of Ligand A are more crucial for overall drug development success, especially for a cardiovascular target where cardiotoxicity is a major concern. The slightly better affinity of Ligand A further supports its selection.
Output:
1
2025-04-17 20:44:26,603 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (379.869 and 366.403 Da) are within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (80.32) is significantly better than Ligand B (122.47). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (3.613) is optimal, while Ligand B (-0.399) is quite low. This is a major concern for Ligand B, as it may struggle with membrane permeability.
4. **HBD:** Both ligands have 2 HBDs, which is within the acceptable limit of 5.
5. **HBA:** Ligand A (6) is better than Ligand B (9), leaning towards better permeability.
6. **QED:** Ligand A (0.567) is slightly better than Ligand B (0.457), indicating a more drug-like profile.
7. **DILI:** Ligand B (73.284) has a lower DILI risk than Ligand A (83.598), which is a positive.
8. **BBB:** Ligand A (61.225) has a higher BBB penetration score than Ligand B (15.743). While not critical for a cardiovascular target, it's not a negative for Ligand A.
9. **Caco-2:** Both have negative values, which is unusual. Assuming these are logP-scale values, Ligand A (-5.062) is better than Ligand B (-5.684).
10. **Solubility:** Ligand A (-4.538) is better than Ligand B (-1.78).
11. **hERG:** Ligand A (0.525) has a lower hERG risk than Ligand B (0.061). This is a significant advantage.
12. **Cl_mic:** Ligand B (4.985) has a much lower microsomal clearance than Ligand A (31.589), suggesting better metabolic stability.
13. **t1/2:** Ligand B (22.945) has a longer in vitro half-life than Ligand A (9.538). This is a positive for Ligand B.
14. **Pgp:** Ligand A (0.488) has a lower P-gp efflux liability than Ligand B (0.043).
15. **Binding Affinity:** Ligand A (-6.3 kcal/mol) has a slightly better binding affinity than Ligand B (-4.7 kcal/mol). This difference of 1.6 kcal/mol is substantial enough to be a deciding factor.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A excels in logP, TPSA, Pgp, and has a better affinity. While Ligand B has better metabolic stability (Cl_mic, t1/2) and lower DILI, the poor logP and higher TPSA are significant drawbacks. The affinity difference is also substantial.
**Conclusion:**
Despite the slightly better metabolic stability and lower DILI risk of Ligand B, Ligand A is the stronger candidate overall due to its superior logP, TPSA, Pgp, solubility, hERG, and binding affinity. The binding affinity advantage is particularly important for a GPCR target.
Output:
1
2025-04-17 20:44:26,603 - INFO - Batch 207 complete. Total preferences: 3312
2025-04-17 20:44:26,603 - INFO - Processing batch 208/512...
2025-04-17 20:45:13,096 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, the most important parameters are binding affinity, logP, TPSA, Pgp efflux, and BBB penetration. Metabolic stability (Cl_mic and t1/2) and safety (DILI, hERG) are also important, followed by general drug-likeness parameters (MW, QED, solubility, HBD/HBA).
Let's compare the ligands property by property:
1. **MW:** Both ligands are within the acceptable range (200-500 Da). Ligand A (355.341) is slightly lower than Ligand B (382.957), which is preferable.
2. **TPSA:** Ligand A (75.88) is significantly higher than Ligand B (40.62). Ligand B is much better here, falling well below the 140 threshold and being more favorable for permeability.
3. **logP:** Ligand A (1.568) is within the optimal range, while Ligand B (4.148) is on the higher side. This could lead to solubility issues and off-target interactions for Ligand B.
4. **HBD/HBA:** Both have a low number of HBDs (0). Ligand A has 5 HBAs, while Ligand B has 3. Both are acceptable.
5. **QED:** Both ligands have similar QED values (0.77 and 0.767), indicating good drug-likeness.
6. **DILI:** Ligand A (60.682) has a higher DILI risk than Ligand B (35.556), which is a significant concern.
7. **BBB:** Both ligands have good BBB penetration (Ligand A: 91.043, Ligand B: 89.104), but Ligand A is slightly better.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests a potential issue with intestinal absorption. However, the magnitude is similar.
9. **Solubility:** Ligand A (-2.627) has better solubility than Ligand B (-4.235).
10. **hERG:** Ligand A (0.257) has a lower hERG risk than Ligand B (0.741), which is a significant advantage.
11. **Cl_mic:** Ligand A (24.521) has a lower microsomal clearance, indicating better metabolic stability than Ligand B (51.988).
12. **t1/2:** Ligand A (-38.715) has a much longer in vitro half-life than Ligand B (-1.582).
13. **Pgp:** Ligand A (0.066) shows lower P-gp efflux liability than Ligand B (0.595), which is favorable for bioavailability.
14. **Binding Affinity:** Ligand A (-6.4) has a slightly better binding affinity than Ligand B (-5.1). This difference of 1.3 kcal/mol is significant.
**Overall Assessment:**
Ligand A is significantly better overall. While Ligand B has a lower TPSA, Ligand A excels in crucial areas like DILI risk, hERG inhibition, metabolic stability (Cl_mic, t1/2), Pgp efflux, solubility, and binding affinity. The higher DILI risk and logP of Ligand B are substantial drawbacks. The slightly better affinity of Ligand A further solidifies its preference.
**Output:**
1
2025-04-17 20:45:13,096 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (352.475 Da) is slightly higher than Ligand B (339.399 Da), but both are acceptable.
**2. TPSA:** Ligand A (84.5) is well below the 140 threshold and good for oral absorption. Ligand B (98.98) is still acceptable, but closer to the limit.
**3. logP:** Both ligands have good logP values (A: 2.165, B: 1.056) within the 1-3 range. Ligand A is slightly more lipophilic, which is generally favorable for GPCR binding.
**4. H-Bond Donors:** Both ligands have reasonable HBD counts (A: 2, B: 1).
**5. H-Bond Acceptors:** Both ligands have reasonable HBA counts (A: 4, B: 5).
**6. QED:** Both ligands have good QED scores (A: 0.718, B: 0.887), indicating good drug-like properties. Ligand B is slightly better.
**7. DILI:** Both ligands have acceptable DILI risk (A: 40.364, B: 43.932), below the 60 threshold.
**8. BBB:** Ligand A (68.554) has a better BBB percentile than Ligand B (41.062). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be beneficial or at least needs to be considered.
**9. Caco-2 Permeability:** Ligand A (-4.844) has better Caco-2 permeability than Ligand B (-5.228), indicating better intestinal absorption.
**10. Aqueous Solubility:** Ligand A (-3.089) has better aqueous solubility than Ligand B (-1.663).
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (A: 0.112, B: 0.174).
**12. Microsomal Clearance:** Ligand B (-8.28) has a significantly lower (better) microsomal clearance than Ligand A (25.033), suggesting greater metabolic stability.
**13. In vitro Half-Life:** Ligand B (5.72) has a longer in vitro half-life than Ligand A (-4.872).
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (A: 0.042, B: 0.004).
**15. Binding Affinity:** Both ligands have very similar binding affinities (A: -6.9 kcal/mol, B: -6.7 kcal/mol). The difference is less than the 1.5 kcal/mol threshold.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand A appears slightly more favorable. It has a better logP, TPSA, Caco-2 permeability, solubility, and BBB penetration. While Ligand B has superior metabolic stability (lower Cl_mic and longer t1/2), the difference in affinity is minimal, and the other ADME properties of Ligand A are more advantageous for a GPCR target.
Output:
1
2025-04-17 20:45:13,097 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (367.475 Da and 363.523 Da) are within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (89.87) is excellent, well below the 140 threshold and very favorable for oral absorption. Ligand B (38.77) is also good, but lower than A.
**3. logP:** Ligand A (-0.085) is slightly low, potentially impacting permeability. Ligand B (3.7) is excellent, falling within the optimal 1-3 range. This is a significant advantage for B.
**4. H-Bond Donors:** Ligand A (1) is good. Ligand B (0) is also good.
**5. H-Bond Acceptors:** Ligand A (7) is good. Ligand B (4) is also good.
**6. QED:** Ligand A (0.8) is very good, indicating high drug-likeness. Ligand B (0.47) is lower, suggesting a less ideal drug-like profile.
**7. DILI Risk:** Ligand A (37.999) is excellent, indicating low liver injury risk. Ligand B (15.626) is also very good.
**8. BBB Penetration:** Ligand A (64.25) is moderate. Ligand B (87.553) is excellent, suggesting good potential for CNS exposure, although less critical for a cardiovascular target.
**9. Caco-2 Permeability:** Ligand A (-4.896) is poor, suggesting low intestinal absorption. Ligand B (-5.083) is also poor, but similar to A.
**10. Aqueous Solubility:** Ligand A (-1.724) is poor. Ligand B (-2.91) is also poor.
**11. hERG Inhibition:** Ligand A (0.478) is good, indicating low cardiotoxicity risk. Ligand B (0.74) is slightly higher, but still acceptable.
**12. Microsomal Clearance:** Ligand A (26.971) is moderate. Ligand B (77.871) is high, suggesting faster metabolism and potentially lower *in vivo* exposure.
**13. In vitro Half-Life:** Ligand A (-1.548) is poor. Ligand B (12.7) is good.
**14. P-gp Efflux:** Ligand A (0.12) is very low, suggesting minimal efflux. Ligand B (0.676) is slightly higher, but still reasonable.
**15. Binding Affinity:** Ligand B (-7.2 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.8 kcal/mol). This 1.5 kcal/mol difference is substantial and can outweigh some ADME drawbacks.
**GPCR-Specific Considerations:** For GPCRs, logP, Pgp, TPSA, and affinity are key. Ligand B excels in logP and affinity, while TPSA is good for both. Pgp is reasonable for both.
**Overall Assessment:**
While Ligand A has better QED and DILI, Ligand B's superior logP, binding affinity, BBB penetration, and *in vitro* half-life are more critical for a GPCR target. The stronger binding affinity of Ligand B is a significant advantage. The lower metabolic stability (higher Cl_mic) of Ligand B is a concern, but could potentially be addressed through structural modifications. The poor solubility and Caco-2 permeability of both are concerning, but could be mitigated with formulation strategies.
Therefore, I prefer Ligand B.
0
2025-04-17 20:45:13,097 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.475 and 353.503 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (78.87) is higher than Ligand B (59). Both are below 140, but B is preferable for oral absorption given its lower value.
3. **logP:** Both ligands have good logP values (1.602 and 2.606), falling within the 1-3 range. Ligand B is slightly better.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable, below the threshold of 5. Ligand B is slightly better.
5. **HBA:** Both ligands have 4 HBA, which is within the acceptable range of <=10.
6. **QED:** Both ligands have similar QED values (0.761 and 0.764), indicating good drug-likeness.
7. **DILI:** Ligand B (10.741) has a significantly lower DILI risk than Ligand A (22.838). This is a major advantage for Ligand B.
8. **BBB:** Ligand B (70.105) has a better BBB penetration percentile than Ligand A (60.644). Given that ADRB2 is a GPCR, BBB penetration is a relevant consideration, although not paramount for cardiovascular targets.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.614 and -4.56), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-2.773) has slightly better solubility than Ligand B (-1.793), but both are poor.
11. **hERG:** Ligand A (0.296) has a slightly lower hERG risk than Ligand B (0.579), which is preferable.
12. **Cl_mic:** Ligand B (42.086) has significantly lower microsomal clearance than Ligand A (18.284), indicating better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand B (28.783) has a much longer in vitro half-life than Ligand A (-0.097). This is a major advantage.
14. **Pgp:** Ligand A (0.175) has lower P-gp efflux than Ligand B (0.299), which is preferable.
15. **Affinity:** Ligand A (-5.0) has a slightly better binding affinity than Ligand B (-2.1). This is a substantial difference.
**Overall Assessment:**
While Ligand A has a better binding affinity and lower Pgp efflux, Ligand B demonstrates a significantly better safety profile (lower DILI), improved metabolic stability (lower Cl_mic, longer t1/2), and better BBB penetration. The affinity difference is substantial, but the ADME/Tox advantages of Ligand B are compelling, especially the lower DILI and improved half-life. Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity) and the overall balance of properties, Ligand B is the more promising candidate.
Output:
0
2025-04-17 20:45:13,097 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (341.411 & 366.527 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (63.69) is slightly higher than Ligand B (58.64). Both are below the 140 threshold for oral absorption, and acceptable for a cardiovascular target (not CNS).
3. **logP:** Ligand A (3.257) is slightly higher than Ligand B (2.749), both are within the optimal 1-3 range.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Both ligands have 4 HBA, which is good.
6. **QED:** Ligand A (0.907) has a significantly better QED score than Ligand B (0.76), indicating a more drug-like profile.
7. **DILI:** Ligand B (32.261) has a lower DILI risk than Ligand A (56.727), which is a significant advantage.
8. **BBB:** Ligand A (73.594) has a higher BBB penetration score than Ligand B (67.468). While ADRB2 isn't a primary CNS target, some degree of BBB penetration can be useful for off-target effects assessment.
9. **Caco-2:** Ligand B (-5.533) has a better Caco-2 permeability than Ligand A (-4.423), suggesting better intestinal absorption.
10. **Solubility:** Ligand B (-4.035) has better aqueous solubility than Ligand A (-3.532).
11. **hERG:** Both ligands have very low hERG inhibition risk (0.62 and 0.5), which is excellent.
12. **Cl_mic:** Ligand A (28.96) has a lower microsomal clearance than Ligand B (40.395), indicating better metabolic stability.
13. **t1/2:** Ligand B (-7.633) has a significantly longer in vitro half-life than Ligand A (8.772), which is a major advantage.
14. **Pgp:** Ligand A (0.05) has lower P-gp efflux than Ligand B (0.162), which is preferable.
15. **Binding Affinity:** Ligand B (-8.3) has a significantly stronger binding affinity than Ligand A (-6.2), a difference of 2.1 kcal/mol. This is a substantial advantage that can outweigh some ADME drawbacks.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, affinity, logP, Pgp, TPSA, and metabolic stability are key. Ligand B excels in affinity and has good logP and TPSA values. While Ligand A has better Pgp and Cl_mic, the significantly stronger binding affinity of Ligand B is the most important factor. The longer half-life of Ligand B is also a substantial benefit. The lower DILI risk of Ligand B is also a positive.
**Conclusion:**
Despite Ligand A's better QED and lower Pgp efflux, the superior binding affinity and longer half-life of Ligand B, coupled with a lower DILI risk, make it the more promising drug candidate for ADRB2.
Output:
0
2025-04-17 20:45:13,097 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (a cardiovascular GPCR) drug candidates.
**Ligand A:** [355.523, 64.09, 1.429, 1, 4, 0.783, 15.161, 48.391, -4.559, -0.593, 0.425, 20.782, 3.823, 0.06, -6.3]
**Ligand B:** [369.849, 104.46, 1.751, 3, 5, 0.708, 48.507, 65.219, -4.956, -3.029, 0.157, 18.847, 27.069, 0.117, -5.5]
Here's a breakdown of the comparison, considering the provided guidelines and GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal range (200-500 Da). A is 355.523 and B is 369.849. No significant difference.
2. **TPSA:** Ligand A (64.09) is significantly better than Ligand B (104.46). A is well below the 140 threshold for oral absorption, while B is approaching it.
3. **logP:** Both are good (between 1-3), A (1.429) and B (1.751). B is slightly higher, which could lead to some off-target effects, but is still acceptable.
4. **HBD:** A (1) is better than B (3). Lower is preferable for permeability.
5. **HBA:** A (4) is better than B (5). Lower is preferable for permeability.
6. **QED:** Both are good (above 0.5), A (0.783) is slightly better than B (0.708).
7. **DILI:** Both have acceptable DILI risk (A: 15.161, B: 48.507). A is significantly better.
8. **BBB:** Ligand B (65.219) is better than A (48.391). While not a CNS target, some BBB penetration can be beneficial for distribution.
9. **Caco-2:** Both are negative, indicating poor permeability. A (-4.559) is slightly better than B (-4.956).
10. **Solubility:** A (-0.593) is better than B (-3.029). Solubility is important for bioavailability.
11. **hERG:** Both are very low, indicating a low risk of cardiotoxicity. A (0.425) is slightly better than B (0.157).
12. **Cl_mic:** Ligand B (18.847) has lower clearance than A (20.782), suggesting better metabolic stability.
13. **t1/2:** Ligand B (27.069) has a much longer half-life than A (3.823). This is a significant advantage.
14. **Pgp:** A (0.06) is better than B (0.117). Lower P-gp efflux is desirable.
15. **Affinity:** Ligand A (-6.3) has a slightly better binding affinity than Ligand B (-5.5).
**Overall Assessment:**
Ligand A has a better profile in terms of TPSA, HBD, HBA, DILI, solubility, and hERG. It also has slightly better affinity and Pgp efflux. However, Ligand B has a significantly longer half-life and slightly better metabolic stability. The lower TPSA and better ADME properties of Ligand A are more important for a cardiovascular GPCR target than the longer half-life of Ligand B. The slightly better binding affinity of A is also a plus.
Therefore, I would choose Ligand A.
Output:
1
2025-04-17 20:45:13,097 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (384.479 and 344.459 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (70.39) is significantly better than Ligand A (100.62). ADRB2 is not a CNS target, but lower TPSA generally improves absorption.
3. **logP:** Ligand B (2.616) is optimal, while Ligand A (0.314) is quite low, potentially hindering membrane permeability. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (1) is slightly better than Ligand B (2), but both are within the acceptable limit of 5.
5. **HBA:** Both ligands have 5 HBA, which is acceptable.
6. **QED:** Both ligands have similar QED scores (0.791 and 0.772), indicating good drug-likeness.
7. **DILI:** Ligand B (22.334) has a much lower DILI risk than Ligand A (78.325). This is a major advantage for Ligand B.
8. **BBB:** Not a primary concern for ADRB2, but Ligand A (53.936) has a slightly higher BBB percentile than Ligand B (27.646).
9. **Caco-2:** Both are negative, indicating poor permeability.
10. **Solubility:** Both are negative, indicating poor solubility.
11. **hERG:** Both ligands have very low hERG risk (0.165 and 0.179).
12. **Cl_mic:** Ligand B (75.227) has a higher microsomal clearance than Ligand A (16.792), suggesting faster metabolism and potentially lower *in vivo* exposure. This favors Ligand A.
13. **t1/2:** Ligand A (56.417) has a significantly longer *in vitro* half-life than Ligand B (13.262). This is a strong advantage for Ligand A.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.084 and 0.032).
15. **Binding Affinity:** Ligand A (-8.0) has a slightly better binding affinity than Ligand B (-5.3). This is a substantial advantage for Ligand A.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, and affinity are key. Ligand B excels in logP and TPSA, while Ligand A has a significantly better binding affinity and longer half-life. The DILI risk is also a critical factor, and Ligand B is far superior in this regard.
**Overall Assessment:**
While Ligand A has a better binding affinity and half-life, the low logP and high DILI risk are significant concerns. Ligand B's superior logP, lower DILI risk, and acceptable TPSA outweigh the slightly weaker binding affinity. The difference in binding affinity (2.7 kcal/mol) is substantial, but the ADME profile of Ligand B is much more favorable.
**Output:**
0
2025-04-17 20:45:13,097 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [376.547, 49.41, 3.482, 1, 4, 0.839, 30.826, 71.811, -5.365, -3.775, 0.676, 39.003, 6.273, 0.52, -7.4]
**Ligand B:** [350.467, 114.93, 1.23, 3, 6, 0.684, 38.581, 58.938, -5.465, -2.16, 0.112, 18.963, -8.516, 0.016, -7.5]
Here's a breakdown, considering the GPCR priorities (logP, Pgp, TPSA, BBB, and affinity):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (350.47) is slightly lower, which could be a minor advantage for permeability.
2. **TPSA:** Ligand A (49.41) is excellent, well below the 140 threshold and very favorable for oral absorption. Ligand B (114.93) is higher, but still acceptable.
3. **logP:** Ligand A (3.482) is optimal. Ligand B (1.23) is a bit low, potentially hindering membrane permeability.
4. **HBD/HBA:** Ligand A (1 HBD, 4 HBA) is better than Ligand B (3 HBD, 6 HBA). Fewer H-bonds generally improve permeability.
5. **QED:** Ligand A (0.839) is better than Ligand B (0.684), indicating a more drug-like profile.
6. **DILI:** Both are good, with Ligand A (30.826) being slightly better than Ligand B (38.581).
7. **BBB:** Ligand A (71.811) is significantly better than Ligand B (58.938). This is a crucial advantage for a GPCR target, even if not directly CNS-focused, as it suggests better distribution.
8. **Caco-2:** Both are negative, indicating poor permeability. This is a concern for both.
9. **Solubility:** Both are negative, indicating poor solubility. This is a concern for both.
10. **hERG:** Ligand A (0.676) is better than Ligand B (0.112), indicating lower cardiotoxicity risk.
11. **Cl_mic:** Ligand B (18.963) has significantly lower clearance than Ligand A (39.003), suggesting better metabolic stability.
12. **t1/2:** Ligand B (-8.516) has a longer half-life than Ligand A (6.273), which is desirable.
13. **Pgp:** Ligand A (0.52) has lower P-gp efflux than Ligand B (0.016), which is favorable.
14. **Affinity:** Both have excellent binding affinity (-7.4 and -7.5 kcal/mol), with a negligible difference.
**Overall Assessment:**
While Ligand B has better metabolic stability (lower Cl_mic, longer t1/2), Ligand A has a significantly better BBB score, better logP, better QED, lower DILI risk, and lower Pgp efflux. For an ADRB2 target (a GPCR), the BBB score and logP are particularly important for distribution and access to the receptor. The slightly better drug-likeness of Ligand A also contributes to its favorability. The Caco-2 and solubility issues are concerning for both, but can be addressed with formulation strategies.
Therefore, I believe Ligand A is the more promising candidate.
Output:
1
2025-04-17 20:45:13,097 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (360.307) is slightly higher than Ligand B (346.431), but both are acceptable.
2. **TPSA:** Ligand A (58.64) is significantly better than Ligand B (95.42). ADRB2 is a cardiovascular target, not a CNS target, but lower TPSA generally aids absorption. Ligand B's TPSA is approaching a level that could hinder oral absorption.
3. **logP:** Both ligands have good logP values (A: 1.846, B: 1.649), falling within the optimal 1-3 range.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (5). Similar reasoning as with HBD.
6. **QED:** Ligand B (0.845) has a better QED score than Ligand A (0.479), suggesting a more inherently drug-like profile. This is a point in favor of Ligand B.
7. **DILI:** Both ligands have acceptable DILI risk (A: 47.693, B: 45.25), below the 60% threshold.
8. **BBB:** Ligand B (62.97) has a higher BBB penetration percentile than Ligand A (47.809). While ADRB2 isn't a primary CNS target, some degree of BBB penetration can be useful for understanding off-target effects.
9. **Caco-2:** Both ligands show poor Caco-2 permeability (A: -4.599, B: -4.837). This is a concern for oral bioavailability.
10. **Solubility:** Both ligands have very poor aqueous solubility (A: -3.391, B: -3.018). This is a significant drawback for both compounds.
11. **hERG:** Both ligands have low hERG inhibition risk (A: 0.426, B: 0.228). Ligand B is slightly better here.
12. **Cl_mic:** Ligand B (33.17) has a lower microsomal clearance than Ligand A (42.244), indicating better metabolic stability.
13. **t1/2:** Ligand B (-16.633) has a significantly longer in vitro half-life than Ligand A (-7.979). This is a major advantage for Ligand B.
14. **Pgp:** Both ligands have very low Pgp efflux liability (A: 0.077, B: 0.031).
15. **Binding Affinity:** Ligand B (-7.2) has a slightly better binding affinity than Ligand A (-5.5). This 1.7 kcal/mol difference is substantial and can outweigh some ADME drawbacks.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B excels in affinity and has acceptable logP and Pgp. While its TPSA is higher than ideal, the significantly improved affinity, metabolic stability (lower Cl_mic), and longer half-life outweigh this drawback. The QED score is also better for Ligand B. The solubility and Caco-2 permeability are poor for both, and would need to be addressed in further optimization.
**Conclusion:**
Considering the balance of properties, particularly the superior binding affinity, metabolic stability, and half-life of Ligand B, it is the more promising drug candidate.
Output:
0
2025-04-17 20:45:13,097 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.46 and 343.43 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (78.51) is better than Ligand B (80.12). Both are below 140, but closer to 90 is preferable for GPCRs.
3. **logP:** Both ligands have similar logP values (1.2 and 1.219), falling within the optimal 1-3 range.
4. **HBD:** Ligand B (1) has a slight advantage over Ligand A (2). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (3) is better than Ligand B (5). Lower HBA is preferred.
6. **QED:** Both ligands have good QED scores (0.784 and 0.82), indicating good drug-like properties.
7. **DILI:** Ligand A (11.28) is *significantly* better than Ligand B (31.25). This is a major advantage for Ligand A. DILI risk is a critical factor.
8. **BBB:** Ligand A (64.60) is better than Ligand B (44.59). While ADRB2 isn't exclusively a CNS target, some CNS penetration can be beneficial, and lower Pgp efflux (see below) can be aided by some BBB penetration.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.065 and -5.138). These values are unusual and suggest poor permeability. However, the values are very close.
10. **Solubility:** Ligand A (-1.741) is slightly better than Ligand B (-0.927). Higher solubility is generally desirable.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.116 and 0.121). No significant difference.
12. **Cl_mic:** Ligand A (-2.237) is *much* better than Ligand B (24.989). Lower microsomal clearance indicates better metabolic stability, a crucial factor for drug duration and efficacy.
13. **t1/2:** Ligand A (8.046) is better than Ligand B (-2.958). A positive half-life is preferred.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.013 and 0.017). No significant difference.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.9 and -6.8 kcal/mol). The difference is negligible.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Both ligands perform similarly on logP, Pgp, and affinity. Ligand A has a better TPSA. However, the *significant* advantages of Ligand A in DILI risk and microsomal clearance outweigh the slight differences in other parameters.
**Conclusion:**
Ligand A is the more promising drug candidate due to its substantially lower DILI risk and significantly improved metabolic stability (lower Cl_mic and positive t1/2). These factors are critical for overall drug safety and efficacy.
Output:
1
2025-04-17 20:45:13,097 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (363.49 and 350.50 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (98.17) is higher than Ligand B (67.43). While both are under 140, the lower TPSA of Ligand B is more favorable for oral absorption and GPCR binding.
3. **logP:** Both ligands have good logP values (3.18 and 2.95), within the optimal 1-3 range. Again, no major difference.
4. **HBD:** Ligand A (1) has fewer HBDs than Ligand B (2). This is slightly preferable, as fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) has slightly more HBAs than Ligand B (3). This isn't a major concern for either.
6. **QED:** Ligand B (0.694) has a better QED score than Ligand A (0.457), indicating a more drug-like profile.
7. **DILI:** Ligand B (29.24) has a significantly lower DILI risk than Ligand A (43.08). This is a crucial advantage, as minimizing liver toxicity is paramount.
8. **BBB:** Ligand B (67.20) has a higher BBB penetration percentile than Ligand A (41.22). While ADRB2 isn't exclusively a CNS target, some CNS exposure can occur, and higher BBB penetration is generally desirable.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. Ligand B (-4.70) is slightly better than Ligand A (-5.18), but both are concerning.
10. **Solubility:** Both ligands have poor solubility scores (-2.41 and -3.49). This is a significant drawback for both, potentially hindering bioavailability.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.23 and 0.19). This is excellent.
12. **Cl_mic:** Ligand A (32.92) has a lower microsomal clearance than Ligand B (60.58), suggesting better metabolic stability. This is a positive for Ligand A.
13. **t1/2:** Ligand B (-7.14) has a negative in vitro half-life, indicating very rapid metabolism. Ligand A (14.86) has a much better half-life.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.13 and 0.19). This is good.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.7 and -6.8 kcal/mol). The difference is negligible.
**GPCR-Specific Priorities & Overall Assessment:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B excels in TPSA and BBB penetration. However, Ligand A has a significantly better half-life and lower clearance, which are critical for *in vivo* efficacy. The DILI risk is also much lower for Ligand B. The solubility of both is poor, but this can be addressed with formulation strategies. Considering the balance, the lower DILI risk and better BBB penetration of Ligand B outweigh the slightly better metabolic stability of Ligand A.
Output:
0
2025-04-17 20:45:13,098 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.415 and 348.355 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (79.9) is significantly better than Ligand B (109.08). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is pushing the upper limit for good oral absorption.
3. **logP:** Ligand A (2.394) is optimal, while Ligand B (0.659) is a bit low. A logP below 1 can sometimes hinder membrane permeability.
4. **HBD:** Both ligands have 2 HBD, which is within the acceptable range.
5. **HBA:** Ligand A has 5 HBA, while Ligand B has 6. Both are acceptable, but lower is generally preferred.
6. **QED:** Ligand A (0.557) is better than Ligand B (0.444), indicating a more drug-like profile.
7. **DILI:** Ligand A (54.285) has a slightly higher DILI risk than Ligand B (42.885), but both are below the concerning threshold of 60.
8. **BBB:** Ligand A (89.453) has a much better BBB penetration percentile than Ligand B (37.301). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant, and higher BBB is generally favorable.
9. **Caco-2:** Both ligands have similar, poor Caco-2 permeability (-5.146 and -5.133). This is a potential concern for both, suggesting limited intestinal absorption.
10. **Solubility:** Both ligands have very poor aqueous solubility (-2.942 and -2.229). This is a significant drawback for both candidates, potentially hindering bioavailability.
11. **hERG:** Ligand A (0.703) has a lower hERG inhibition liability than Ligand B (0.137), indicating a lower risk of cardiotoxicity. This is crucial for a cardiovascular target.
12. **Cl_mic:** Ligand B (-23.929) has significantly lower microsomal clearance than Ligand A (26.987), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-22.322) has a longer in vitro half-life than Ligand A (22.463). This is beneficial for dosing frequency.
14. **Pgp:** Ligand A (0.131) has lower P-gp efflux liability than Ligand B (0.042), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand B (-7.0) has a slightly better binding affinity than Ligand A (-6.1). This is a 0.9 kcal/mol difference, which is substantial.
**Overall Assessment:**
Ligand B has a significantly better binding affinity and metabolic stability (lower Cl_mic, longer t1/2). However, Ligand A excels in TPSA, logP, QED, BBB penetration, and hERG risk. The poor Caco-2 and solubility are concerns for both.
Considering ADRB2 is a cardiovascular target, minimizing cardiotoxicity (hERG) is paramount. Ligand A's significantly lower hERG risk is a major advantage. The slightly better affinity of Ligand B is attractive, but the improved ADME properties of Ligand A, particularly the lower hERG risk and better TPSA/logP, make it the more promising candidate overall.
Output:
1
2025-04-17 20:45:13,098 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (362.901 Da and 351.451 Da) are within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (52.57) is significantly better than Ligand B (116.19). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary goal, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (3.987 and 2.151, respectively), falling within the 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability, but not drastically.
4. **HBD:** Both have 2 HBD, which is acceptable.
5. **HBA:** Ligand A has 2 HBA, while Ligand B has 4. Ligand A is preferable here.
6. **QED:** Ligand A (0.778) has a much better QED score than Ligand B (0.272), indicating a more drug-like profile. This is a significant advantage for Ligand A.
7. **DILI:** Both have relatively low DILI risk (17.642 and 19.969), below the 40% threshold. No significant difference.
8. **BBB:** Both have reasonable BBB penetration (69.833 and 61.768), but this isn't a high priority for a cardiovascular target.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
10. **Solubility:** Both have negative solubility values, which is also unusual. Again, the scale is unspecified.
11. **hERG:** Ligand A (0.807) has a slightly higher hERG risk than Ligand B (0.344), but both are relatively low.
12. **Cl_mic:** Ligand A (1.71) has a much lower microsomal clearance than Ligand B (66.38), indicating better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand A (20.815) has a significantly longer in vitro half-life than Ligand B (-10.168). This is a major advantage.
14. **Pgp:** Ligand A (0.441) has a lower Pgp efflux liability than Ligand B (0.062), suggesting better bioavailability.
15. **Binding Affinity:** Ligand B (-7.4) has a slightly better binding affinity than Ligand A (-6.0), a 1.4 kcal/mol difference. While affinity is important, the other ADME properties of Ligand A are much more favorable.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A is better on TPSA and Pgp. The affinity difference is not large enough to outweigh the substantial advantages of Ligand A in QED, metabolic stability (Cl_mic, t1/2), and overall drug-likeness.
**Conclusion:**
Ligand A is the more promising candidate due to its superior drug-like properties (QED), metabolic stability (lower Cl_mic, longer t1/2), lower Pgp efflux, and better TPSA, despite a slightly weaker binding affinity.
Output:
1
2025-04-17 20:45:13,098 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (344.415 and 348.418 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (83.54) is slightly higher than Ligand B (75.27). Both are below the 140 threshold for oral absorption, but closer to the 90 threshold for CNS targets (less relevant for ADRB2, a cardiovascular target). Ligand B is preferable.
3. **logP:** Ligand A (1.331) is within the optimal 1-3 range. Ligand B (3.117) is at the higher end of optimal. While both are acceptable, Ligand A is slightly better balanced.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2) as lower HBD generally improves permeability.
5. **HBA:** Ligand A (7) is preferable to Ligand B (3). Lower HBA is generally preferable.
6. **QED:** Both ligands have good QED scores (0.816 and 0.829), indicating good drug-like properties. No clear advantage.
7. **DILI:** Ligand A (36.448%) has a lower DILI risk than Ligand B (40.442%). This is a significant advantage for Ligand A.
8. **BBB:** Ligand B (82.823%) has a significantly higher BBB penetration than Ligand A (52.074%). While ADRB2 isn't a CNS target, higher BBB is generally a positive indicator of permeability.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.678 and -4.576), which is unusual and suggests poor permeability. This is a significant drawback for both.
10. **Solubility:** Ligand A (-1.597) has better solubility than Ligand B (-3.013). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.924) has a slightly higher hERG risk than Ligand B (0.164). This is a significant advantage for Ligand B.
12. **Cl_mic:** Ligand A (15.321) has a lower microsomal clearance than Ligand B (32.942), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (19.387) has a longer in vitro half-life than Ligand B (9.685). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.347) has lower P-gp efflux than Ligand B (0.13). Lower Pgp efflux is preferable.
15. **Binding Affinity:** Ligand B (-8.1 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.4 kcal/mol). This is a major advantage for Ligand B, potentially outweighing some ADME concerns.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B has better logP and significantly better affinity. Ligand A has better TPSA and Pgp.
**Overall Assessment:**
The biggest differentiator is the binding affinity. Ligand B's -8.1 kcal/mol is substantially better than Ligand A's -6.4 kcal/mol. While Ligand A has advantages in DILI, metabolic stability, solubility, and Pgp efflux, the potency advantage of Ligand B is likely to be more impactful for *in vivo* efficacy. The hERG risk for Ligand B is also much lower, which is a critical safety factor. The Caco-2 permeability is poor for both, but can be addressed with formulation strategies.
Output:
0
2025-04-17 20:45:13,098 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (396.862 and 368.415 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (52.57) is better than Ligand B (58.2), both are below the 140 threshold for oral absorption, but closer to the ideal for GPCRs.
3. **logP:** Ligand A (4.967) is slightly higher than Ligand B (3.216). While Ligand A is approaching the upper limit, both are within the acceptable 1-3 range.
4. **HBD:** Both ligands have 2 HBD, which is good.
5. **HBA:** Ligand A has 3 HBA, while Ligand B has 2. Both are acceptable.
6. **QED:** Ligand A (0.707) is slightly better than Ligand B (0.614), indicating a more drug-like profile.
7. **DILI:** Ligand B (35.595) has a significantly lower DILI risk than Ligand A (43.66), which is a substantial advantage.
8. **BBB:** Both ligands have good BBB penetration (Ligand A: 78.558, Ligand B: 77.898). This is less critical for ADRB2 (a cardiovascular target) but still positive.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the values are similar (-4.72 and -4.647).
10. **Solubility:** Both have negative solubility values, indicating poor aqueous solubility. Ligand B (-4.05) is slightly better than Ligand A (-4.898).
11. **hERG:** Ligand A (0.798) has a slightly higher hERG risk than Ligand B (0.445), which is preferable.
12. **Cl_mic:** Ligand B (53.321) has a significantly higher microsomal clearance than Ligand A (7), indicating lower metabolic stability. This is a major drawback for Ligand B.
13. **t1/2:** Ligand A (5.076) has a longer in vitro half-life than Ligand B (-2.123), which is a significant advantage.
14. **Pgp:** Ligand A (0.459) has a lower P-gp efflux liability than Ligand B (0.037), which is preferable.
15. **Binding Affinity:** Ligand A (-7.9 kcal/mol) has a significantly stronger binding affinity than Ligand B (-5.3 kcal/mol). This is a substantial advantage that can outweigh some ADME concerns.
**Overall Assessment:**
Ligand A has a significantly stronger binding affinity, better metabolic stability (lower Cl_mic, longer t1/2), lower P-gp efflux, and a slightly better QED score. While Ligand B has a lower DILI risk, the substantial advantage in binding affinity and metabolic stability of Ligand A outweighs this benefit. The poor Caco-2 and solubility are concerns for both, but can be addressed with formulation strategies. Given the ADRB2 target is a GPCR, the binding affinity is paramount.
Output:
1
2025-04-17 20:45:13,098 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (362.459 Da) is slightly higher than Ligand B (343.427 Da), but both are acceptable.
2. **TPSA:** Ligand A (94.22) is slightly higher than Ligand B (75.44). Both are below 140, which is good for oral absorption, but Ligand B is preferable due to the lower TPSA.
3. **logP:** Ligand A (0.081) is quite low, potentially hindering permeability. Ligand B (2.15) is within the optimal range (1-3). This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable, being less than 5.
5. **HBA:** Ligand A (6) and Ligand B (4) are both acceptable, being less than 10.
6. **QED:** Both ligands have good QED scores (Ligand A: 0.728, Ligand B: 0.831). Ligand B is slightly better.
7. **DILI:** Ligand A (42.885) and Ligand B (31.136) both have low DILI risk, but Ligand B is better.
8. **BBB:** Ligand A (14.075) has very poor BBB penetration, while Ligand B (67.235) is reasonably good. Considering ADRB2 is a GPCR, BBB penetration isn't a primary concern *unless* targeting CNS effects, but a higher value is generally preferred.
9. **Caco-2:** Ligand A (-5.747) and Ligand B (-4.664) both have negative values, which is unusual and suggests poor permeability. Ligand B is slightly better.
10. **Solubility:** Ligand A (-1.356) and Ligand B (-3.081) both have poor solubility. Ligand A is slightly better.
11. **hERG:** Both ligands have very low hERG inhibition risk (Ligand A: 0.066, Ligand B: 0.093).
12. **Cl_mic:** Ligand A (-31.334) has a much lower (better) microsomal clearance than Ligand B (5.664), indicating higher metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (-6.696) has a negative half-life, which is not physically possible and indicates a problem with the data or the molecule. Ligand B (-2.317) is also negative, but less so. This is a major concern for both.
14. **Pgp:** Both ligands have very low Pgp efflux liability (Ligand A: 0.004, Ligand B: 0.057).
15. **Binding Affinity:** Ligand B (-6.7 kcal/mol) has a slightly better binding affinity than Ligand A (-6.4 kcal/mol), but the difference is not substantial.
**Overall Assessment:**
Ligand B is generally more favorable. It has a better logP, TPSA, QED, DILI, and BBB penetration. While both have poor solubility and Caco-2 permeability, Ligand B is slightly better in these aspects. The biggest concern is the negative half-life for both compounds, which needs further investigation. However, Ligand A's negative half-life is more extreme, and its low logP is a significant drawback for permeability. Ligand A's better metabolic stability is a plus, but the other factors favor Ligand B.
Output:
0
2025-04-17 20:45:13,098 - INFO - Batch 208 complete. Total preferences: 3328
2025-04-17 20:45:13,098 - INFO - Processing batch 209/512...
2025-04-17 20:46:02,484 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.403 and 363.443 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (93.53) is better than Ligand B (102.05), being closer to the <140 threshold for good oral absorption.
3. **logP:** Ligand B (1.377) is better than Ligand A (0.289). Ligand A is quite low, potentially hindering membrane permeability. Ligand B is within the optimal 1-3 range.
4. **HBD:** Ligand A (1) is better than Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (6) is better than Ligand B (7). Lower HBA generally improves permeability.
6. **QED:** Both ligands (0.746 and 0.721) are above the 0.5 threshold, indicating good drug-likeness. No significant difference.
7. **DILI:** Ligand A (38.387) is significantly better than Ligand B (71.074). Lower DILI risk is crucial. Ligand B is approaching a concerning level.
8. **BBB:** Ligand A (67.08) is better than Ligand B (59.325). While ADRB2 isn't necessarily a CNS target, some degree of BBB penetration can be useful for distribution, and avoiding efflux.
9. **Caco-2:** Ligand A (-4.828) is better than Ligand B (-5.334). Higher (less negative) Caco-2 values indicate better absorption.
10. **Solubility:** Ligand A (-1.678) is better than Ligand B (-3.474). Higher solubility is generally preferred.
11. **hERG:** Ligand A (0.04) is significantly better than Ligand B (0.161). Lower hERG inhibition is critical for avoiding cardiotoxicity, especially for a cardiovascular target like ADRB2.
12. **Cl_mic:** Ligand A (32.637) is better than Ligand B (42.34). Lower clearance suggests better metabolic stability.
13. **t1/2:** Ligand B (-10.259) is better than Ligand A (-2.109). A longer half-life is generally desirable, but the scale is negative here, so a less negative number is better.
14. **Pgp:** Ligand A (0.008) is significantly better than Ligand B (0.118). Lower P-gp efflux is desirable for better bioavailability.
15. **Affinity:** Ligand A (-6.9) is better than Ligand B (-6.1). This is a 0.8 kcal/mol difference, which is a substantial advantage.
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B has a better logP, but Ligand A excels in almost every other crucial parameter, including a significantly better affinity and much lower DILI and hERG risks. The superior affinity of Ligand A outweighs the slightly less optimal logP.
**Conclusion:**
Ligand A is the more promising candidate due to its superior safety profile (DILI, hERG), better metabolic stability (Cl_mic), better permeability (Caco-2, Pgp), and significantly stronger binding affinity.
Output:
1
2025-04-17 20:46:02,485 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (348.4) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both ligands are below the 140 A^2 threshold for good oral absorption. Ligand B (110) is slightly better.
3. **logP:** Ligand A (-1.257) is a bit low, potentially hindering permeation. Ligand B (1.949) is within the optimal 1-3 range. This is a significant advantage for Ligand B.
4. **HBD:** Both have 3 HBD, which is acceptable.
5. **HBA:** Ligand A has 6 HBA, Ligand B has 5. Both are within the acceptable range.
6. **QED:** Both ligands have acceptable QED scores (A: 0.586, B: 0.492), indicating reasonable drug-likeness.
7. **DILI:** Ligand A (47.3) has a much lower DILI risk than Ligand B (64.6). This is a significant advantage for Ligand A.
8. **BBB:** Ligand B (74.8) shows better BBB penetration than Ligand A (12.4). While ADRB2 isn't strictly a CNS target, some CNS exposure can be beneficial or at least less detrimental than high CNS exposure for other targets.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability.
10. **Solubility:** Both ligands have negative solubility values, indicating poor solubility.
11. **hERG:** Both ligands have very low hERG risk, which is excellent.
12. **Cl_mic:** Ligand A (-15.041) has a much lower (better) microsomal clearance than Ligand B (17.368), suggesting better metabolic stability.
13. **t1/2:** Ligand A (9.32) has a longer in vitro half-life than Ligand B (5.878), which is desirable.
14. **Pgp:** Ligand A (0.014) has significantly lower P-gp efflux liability than Ligand B (0.064), which is favorable for absorption and bioavailability.
15. **Affinity:** Ligand B (-8.0 kcal/mol) has a slightly better binding affinity than Ligand A (-7.0 kcal/mol). This 1 kcal/mol difference is important, but needs to be weighed against other factors.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand B excels in logP and affinity. However, Ligand A has a much better safety profile (DILI) and better ADME properties (Cl_mic, t1/2, Pgp). The slightly better affinity of Ligand B is unlikely to outweigh the significantly better ADME/Tox profile of Ligand A.
**Conclusion:**
While Ligand B has a slightly better binding affinity and logP, Ligand A's superior DILI score, metabolic stability, longer half-life, and lower P-gp efflux make it the more promising drug candidate. The poor Caco-2 and solubility for both compounds are concerning and would require further optimization, but the better overall profile of Ligand A gives it an edge.
Output:
1
2025-04-17 20:46:02,485 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (358.498 and 372.853 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (69.64) is well below the 140 threshold and favorable for oral absorption. Ligand B (96.55) is still acceptable but closer to the upper limit. This slightly favors A.
3. **logP:** Ligand A (2.809) is optimal (1-3). Ligand B (1.227) is on the lower side, potentially hindering permeability. This favors A.
4. **HBD:** Both ligands have 2 HBD, which is within the acceptable limit of 5.
5. **HBA:** Ligand A has 3 HBA, while Ligand B has 5. Both are within the acceptable limit of 10, but A is preferred.
6. **QED:** Both ligands have good QED values (0.666 and 0.715), indicating good drug-like properties.
7. **DILI:** Ligand A (22.257) has a significantly lower DILI risk than Ligand B (65.917). This is a major advantage for A.
8. **BBB:** Ligand A (71.539) shows better BBB penetration than Ligand B (44.901). While ADRB2 isn't strictly a CNS target, some distribution to the CNS is possible, and higher BBB penetration is generally desirable.
9. **Caco-2:** Ligand A (-4.647) and Ligand B (-5.384) both indicate poor Caco-2 permeability. This is a concern for both, but the values are similar.
10. **Solubility:** Both ligands have very poor aqueous solubility (-2.495 and -2.235). This is a significant drawback for both, potentially impacting bioavailability.
11. **hERG:** Ligand A (0.634) has a slightly better hERG profile than Ligand B (0.144), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand A (27.211) has a lower microsomal clearance than Ligand B (3.04), suggesting better metabolic stability.
13. **t1/2:** Ligand B (41.228) has a much longer in vitro half-life than Ligand A (5.235). This is a significant advantage for B.
14. **Pgp:** Ligand A (0.375) has lower P-gp efflux liability than Ligand B (0.037). Lower Pgp is preferred for better bioavailability.
15. **Binding Affinity:** Ligand B (-7.2 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.6 kcal/mol). This is a substantial advantage, potentially outweighing some ADME concerns.
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A has better logP, TPSA, and Pgp. However, Ligand B's significantly stronger binding affinity is a major factor. The difference in affinity (0.6 kcal/mol) is substantial.
**Overall Assessment:**
Despite Ligand A's advantages in DILI, BBB, and metabolic stability, the significantly stronger binding affinity of Ligand B (-7.2 vs -6.6 kcal/mol) is a compelling advantage. While solubility and Caco-2 permeability are concerns for both, the potency advantage of B is likely to be more impactful in driving efficacy. The longer half-life of Ligand B is also a positive.
Output:
0
2025-04-17 20:46:02,485 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (404.26 Da) and Ligand B (354.397 Da) both fall within the ideal 200-500 Da range. Ligand B is slightly preferred due to being closer to the lower end, potentially aiding permeability.
2. **TPSA:** Ligand A (59.0) and Ligand B (50.8) are both below the 140 A^2 threshold for good oral absorption, and acceptable for a cardiovascular target (not requiring significant CNS penetration). Ligand B is slightly better.
3. **logP:** Ligand A (3.053) and Ligand B (2.404) are both within the optimal 1-3 range. Ligand B is slightly preferred.
4. **HBD:** Both Ligand A (1) and Ligand B (1) have a single H-bond donor, which is excellent.
5. **HBA:** Both Ligand A (4) and Ligand B (4) have 4 H-bond acceptors, well within the acceptable limit of 10.
6. **QED:** Both Ligand A (0.836) and Ligand B (0.882) have excellent QED scores, indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (55.293) is higher than Ligand B (36.836). This is a significant advantage for Ligand B, as lower DILI risk is crucial.
8. **BBB:** Ligand A (66.305) and Ligand B (84.141) are both acceptable, but for a cardiovascular target, high BBB penetration isn't critical. Ligand B is better.
9. **Caco-2:** Ligand A (-5.1) and Ligand B (-4.19) are both negative, indicating poor permeability. This is a concern for both, but Ligand B is slightly better.
10. **Solubility:** Ligand A (-4.053) and Ligand B (-2.495) both have poor solubility. Ligand B is slightly better.
11. **hERG:** Ligand A (0.773) and Ligand B (0.355) are both low, indicating low hERG inhibition risk. Ligand B is significantly better.
12. **Cl_mic:** Ligand A (81.022) has a higher microsomal clearance than Ligand B (42.267). Lower is better, so Ligand B is preferred.
13. **t1/2:** Ligand A (40.65) has a longer half-life than Ligand B (-6.693). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.702) and Ligand B (0.063) both have low P-gp efflux, but Ligand B is much better.
15. **Affinity:** Ligand A (-6.8 kcal/mol) has a better binding affinity than Ligand B (-3.7 kcal/mol). This is a substantial difference and a major factor in favor of Ligand A. The 3.1 kcal/mol difference in affinity is significant enough to potentially overcome some of the ADME drawbacks.
**Overall Assessment:**
While Ligand B has better ADME properties (lower DILI, hERG, Cl_mic, Pgp, and slightly better solubility and TPSA), Ligand A has a substantially stronger binding affinity. For a GPCR target like ADRB2, potency is paramount. The improved affinity of Ligand A is likely to translate to a lower required dose, potentially mitigating some of the ADME concerns. The longer half-life of Ligand A is also a benefit.
Therefore, I favor Ligand A.
Output:
1
2025-04-17 20:46:02,485 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (348.491 and 362.495 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (76.02) is slightly higher than Ligand B (67.43). Both are below the 140 A^2 threshold for good oral absorption, but Ligand B is preferable due to being closer to the 90 A^2 target for GPCRs.
**3. logP:** Both ligands have a logP around 2.7, which is optimal (1-3). No significant difference.
**4. H-Bond Donors:** Both ligands have 2 HBDs, well within the acceptable limit of 5. No difference.
**5. H-Bond Acceptors:** Both ligands have 4 HBAs, also within the acceptable limit of 10. No difference.
**6. QED:** Ligand B (0.846) has a higher QED score than Ligand A (0.682), indicating a more drug-like profile. This is a positive for Ligand B.
**7. DILI Risk:** Ligand A (30.787) has a significantly lower DILI risk than Ligand B (49.128). This is a strong advantage for Ligand A.
**8. BBB Penetration:** Ligand A (75.107) has better predicted BBB penetration than Ligand B (62.35). While ADRB2 isn't exclusively a CNS target, some cardiovascular effects are mediated by central pathways, so some BBB penetration can be beneficial.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand B (-4.966) is slightly worse than Ligand A (-4.851).
**10. Aqueous Solubility:** Both ligands have negative solubility values, which is also unusual and suggests poor solubility. Ligand B (-2.785) is slightly worse than Ligand A (-2.85).
**11. hERG Inhibition:** Ligand A (0.606) has a slightly higher hERG inhibition risk than Ligand B (0.326), meaning Ligand B is preferable.
**12. Microsomal Clearance:** Ligand B (33.677) has significantly lower microsomal clearance than Ligand A (67.24), indicating better metabolic stability. This is a significant advantage for Ligand B.
**13. In vitro Half-Life:** Ligand B (22.978) has a longer in vitro half-life than Ligand A (-19.029). This is a strong advantage for Ligand B.
**14. P-gp Efflux:** Ligand A (0.423) has lower P-gp efflux than Ligand B (0.18), which is preferable.
**15. Binding Affinity:** Both ligands have very similar binding affinities (-5.9 and -5.0 kcal/mol). The difference of 0.9 kcal/mol is not substantial enough to outweigh other factors.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand B appears to be a more promising candidate. While Ligand A has a lower DILI risk and better BBB penetration, Ligand B excels in QED, metabolic stability (lower Cl_mic and longer t1/2), and has a lower hERG risk. The slightly better TPSA of Ligand B is also favorable. The poor Caco-2 and solubility values are concerning for both, but the other advantages of Ligand B outweigh the benefits of Ligand A.
Output:
0
2025-04-17 20:46:02,485 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (a GPCR) drug candidates.
**Ligand A:** [353.354, 107.37 , -0.851, 2. , 7. , 0.714, 66.964, 77.627, -5.218, -1.752, 0.031, -5.514, 38.036, 0.013, -5.6 ]
**Ligand B:** [346.475, 65.54 , 1.617, 1. , 4. , 0.88 , 11.361, 64.482, -4.66 , -0.732, 0.226, 2.621, 5.075, 0.016, -5.6 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (346.475) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (107.37) is higher than Ligand B (65.54). For a GPCR, lower TPSA is preferred for better brain penetration if that's a goal, and generally better absorption. Ligand B is significantly better here.
3. **logP:** Ligand A (-0.851) is a bit low, potentially hindering membrane permeability. Ligand B (1.617) is within the optimal range (1-3). Ligand B is better.
4. **HBD:** Both are acceptable (Ligand A: 2, Ligand B: 1).
5. **HBA:** Both are acceptable (Ligand A: 7, Ligand B: 4). Ligand B is better.
6. **QED:** Both have good drug-likeness scores (Ligand A: 0.714, Ligand B: 0.88). Ligand B is slightly better.
7. **DILI:** Ligand A (66.964) has a higher DILI risk than Ligand B (11.361). This is a significant concern for Ligand A.
8. **BBB:** Ligand A (77.627) has better BBB penetration potential than Ligand B (64.482). This is a plus for Ligand A, but less critical for a cardiovascular target unless CNS side effects are a concern.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand B (-4.66) is slightly better than Ligand A (-5.218).
10. **Solubility:** Both have poor solubility. Ligand B (-0.732) is slightly better than Ligand A (-1.752).
11. **hERG:** Both have very low hERG risk (Ligand A: 0.031, Ligand B: 0.226).
12. **Cl_mic:** Ligand A (-5.514) has a lower (better) microsomal clearance than Ligand B (2.621), suggesting better metabolic stability.
13. **t1/2:** Ligand A (38.036) has a longer half-life than Ligand B (5.075). This is a significant advantage for Ligand A.
14. **Pgp:** Both have very low Pgp efflux liability (Ligand A: 0.013, Ligand B: 0.016).
15. **Affinity:** Both have the same binding affinity (-5.6 kcal/mol).
**Overall Assessment:**
Ligand B has a superior ADME profile. It has a better logP, TPSA, QED, and significantly lower DILI risk. While Ligand A has better BBB penetration and a longer half-life, the high DILI risk is a major red flag. The slightly better permeability and solubility of Ligand B, combined with its much lower toxicity risk, outweigh the benefits of Ligand A's longer half-life and BBB penetration in this case. Considering this is a cardiovascular target, CNS penetration is not a primary requirement.
Output:
0
2025-04-17 20:46:02,485 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (364.789 and 344.459 Da) are within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand B (76.02) is significantly better than Ligand A (117.67). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (1.812 and 2.031) falling within the 1-3 optimal range. No significant difference.
4. **HBD:** Ligand B (2) has a slight advantage over Ligand A (3), leaning towards better permeability.
5. **HBA:** Both ligands have the same number of HBA (4), which is acceptable.
6. **QED:** Both ligands have similar QED scores (0.724 and 0.673), indicating good drug-likeness.
7. **DILI:** Ligand B (39.667) has a much lower DILI risk than Ligand A (73.517). This is a substantial advantage.
8. **BBB:** Both ligands have moderate BBB penetration (57.736 and 63.746). Not a major factor for a cardiovascular target.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the values are similar (-5.307 and -4.956).
10. **Solubility:** Both ligands have negative solubility values, which is also unusual. The values are similar (-3.367 and -3.044).
11. **hERG:** Both ligands have very low hERG inhibition risk (0.162 and 0.116).
12. **Cl_mic:** Ligand A (18.028) has significantly lower microsomal clearance than Ligand B (54.803), suggesting better metabolic stability.
13. **t1/2:** Ligand A (69.821) has a much longer in vitro half-life than Ligand B (-8.719). This is a significant advantage.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.035 and 0.173).
15. **Binding Affinity:** Ligand B (-6.7) has slightly better binding affinity than Ligand A (-6.0). While the difference is less than the 1.5 kcal/mol threshold, it's still a positive.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are important. Ligand B has a better TPSA and slightly better affinity. However, the significantly lower DILI risk and better metabolic stability (lower Cl_mic and longer t1/2) of Ligand A are crucial. While the Caco-2 and solubility values are concerning for both, the metabolic advantages of Ligand A outweigh the slight affinity difference.
**Conclusion:**
Considering the balance of properties, especially the lower DILI risk and improved metabolic stability, Ligand A is the more promising drug candidate.
Output:
1
2025-04-17 20:46:02,486 - INFO - Reasoning:
Let's analyze both ligands based on the provided parameters and guidelines, keeping in mind this is for an ADRB2 GPCR (cardiovascular target).
**Ligand A:**
* **MW:** 350.459 Da - Good, within the ideal range.
* **TPSA:** 98.66 A^2 - Acceptable, slightly above the preferred <90 for CNS, but reasonable for a peripheral GPCR like ADRB2.
* **logP:** 0.999 - Slightly low, could potentially impact permeability, but not drastically.
* **HBD:** 4 - Good, within the acceptable range.
* **HBA:** 4 - Good, within the acceptable range.
* **QED:** 0.537 - Good, indicates drug-like properties.
* **DILI:** 24.351 - Excellent, very low risk of liver injury.
* **BBB:** 17.138 - Low, not a concern as this is a cardiovascular target.
* **Caco-2:** -5.01 - Very poor permeability. This is a major red flag.
* **Solubility:** -2.209 - Poor solubility.
* **hERG:** 0.099 - Very low risk of hERG inhibition, excellent.
* **Cl_mic:** -15.045 - Very low clearance, indicating high metabolic stability.
* **t1/2:** 2.019 - Short half-life, could require frequent dosing.
* **Pgp:** 0.043 - Low P-gp efflux, good.
* **Affinity:** -5.7 kcal/mol - Good binding affinity.
**Ligand B:**
* **MW:** 343.427 Da - Good, within the ideal range.
* **TPSA:** 66.65 A^2 - Excellent, well below the threshold for good absorption.
* **logP:** 2.707 - Optimal, within the preferred range.
* **HBD:** 0 - Good, potentially improves permeability.
* **HBA:** 4 - Good, within the acceptable range.
* **QED:** 0.775 - Very good, strong drug-like properties.
* **DILI:** 35.673 - Good, relatively low risk of liver injury.
* **BBB:** 54.634 - Moderate, not a major concern for a cardiovascular target.
* **Caco-2:** -4.642 - Moderate permeability.
* **Solubility:** -1.033 - Moderate solubility.
* **hERG:** 0.487 - Moderate risk of hERG inhibition.
* **Cl_mic:** 57.789 - High clearance, indicating lower metabolic stability.
* **t1/2:** 44.977 - Long half-life, desirable for less frequent dosing.
* **Pgp:** 0.094 - Low P-gp efflux, good.
* **Affinity:** -5.6 kcal/mol - Good binding affinity, very close to Ligand A.
**Comparison and Decision:**
While Ligand A has a slightly better binding affinity (-5.7 vs -5.6 kcal/mol), its extremely poor Caco-2 permeability and solubility are major drawbacks. Ligand B, despite slightly higher hERG and clearance, has much better permeability and solubility, and a good QED score. For a cardiovascular target, good absorption is crucial for efficacy. The small difference in binding affinity is outweighed by the significant ADME advantages of Ligand B.
Output:
0
2025-04-17 20:46:02,486 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (347.39) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are below the 140 A^2 threshold for good oral absorption. Ligand A (78.51) is slightly higher than Ligand B (75.27), but both are acceptable.
3. **logP:** Ligand A (1.013) is optimal, while Ligand B (3.059) is at the higher end of the optimal range. This is a slight advantage for Ligand A.
4. **HBD:** Both have 2 HBD, which is within the ideal range.
5. **HBA:** Ligand A has 3 HBA, Ligand B has 4. Both are within the acceptable range of <=10.
6. **QED:** Ligand A (0.798) has a better QED score than Ligand B (0.679), indicating a more drug-like profile.
7. **DILI:** Ligand A (40.83) is better than Ligand B (57.348) with respect to DILI risk, falling comfortably below the 60% threshold.
8. **BBB:** Both ligands have acceptable BBB penetration (Ligand A: 66.886, Ligand B: 64.676). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be useful for understanding off-target effects.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. Ligand A (-4.971) is slightly better than Ligand B (-5.147).
10. **Solubility:** Both have negative solubility values, indicating poor solubility. Ligand A (-2.87) is slightly better than Ligand B (-3.274).
11. **hERG:** Both have very low hERG inhibition risk (Ligand A: 0.318, Ligand B: 0.113). Ligand B is slightly better here.
12. **Cl_mic:** Ligand A (-24.298) has a significantly lower (better) microsomal clearance than Ligand B (61.901), suggesting better metabolic stability.
13. **t1/2:** Ligand A (3.059) has a shorter in vitro half-life than Ligand B (-18.462). This is a disadvantage for Ligand A.
14. **Pgp:** Both have very low Pgp efflux liability (Ligand A: 0.017, Ligand B: 0.355). Ligand A is slightly better.
15. **Affinity:** Ligand A (-5.9 kcal/mol) has a slightly better binding affinity than Ligand B (-6.4 kcal/mol).
**GPCR-specific priorities:** For GPCRs, logP, Pgp, TPSA, and affinity are key. Ligand A has a better logP, Pgp, and affinity. Ligand B has a slightly better hERG profile and in vitro half-life. However, the significantly better metabolic stability (Cl_mic) and QED score of Ligand A, coupled with its slightly better affinity, outweigh the minor advantage of Ligand B's half-life. The poor Caco-2 and solubility for both are concerning, but can be addressed with formulation strategies.
**Conclusion:**
Ligand A is the more promising candidate due to its superior drug-like properties, metabolic stability, and binding affinity.
Output:
1
2025-04-17 20:46:02,486 - INFO - Here's my reasoning and the final output:
**Reasoning:**
We are evaluating two ligands for the ADRB2, a cardiovascular GPCR. Therefore, priorities are affinity, logP, TPSA, Pgp efflux, and BBB penetration.
Let's compare the ligands property by property:
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (353.409) is slightly lower than Ligand B (362.436), which is marginally preferable.
2. **TPSA:** Ligand A (46.61) is better than Ligand B (49.41) as it's closer to the <140 threshold for good absorption.
3. **logP:** Both ligands have good logP values (A: 3.89, B: 3.159), falling within the optimal 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability, but also slightly increases the risk of off-target effects.
4. **HBD/HBA:** Ligand A (0 HBD, 3 HBA) is better than Ligand B (1 HBD, 2 HBA). Lower HBD/HBA generally improves permeability.
5. **QED:** Both are similar (A: 0.755, B: 0.721) and above the 0.5 threshold, indicating good drug-likeness.
6. **DILI:** Ligand B (23.071) has a significantly lower DILI risk than Ligand A (35.014). This is a major advantage for Ligand B.
7. **BBB:** Both have good BBB penetration (A: 92.323, B: 88.057), but Ligand A is slightly better.
8. **Caco-2:** Both are negative, indicating poor permeability.
9. **Solubility:** Both are negative, indicating poor solubility.
10. **hERG:** Both have low hERG inhibition liability (A: 0.681, B: 0.585).
11. **Cl_mic:** Ligand B (49.142) has lower microsomal clearance than Ligand A (69.01), suggesting better metabolic stability.
12. **t1/2:** Ligand B (-13.629) has a better in vitro half-life than Ligand A (-25.726).
13. **Pgp:** Ligand A (0.387) has lower P-gp efflux than Ligand B (0.112), which is favorable for bioavailability and CNS exposure.
14. **Affinity:** Ligand A (-7.8 kcal/mol) has a significantly stronger binding affinity than Ligand B (-5.4 kcal/mol). This is a substantial advantage.
**Overall Assessment:**
The most critical factor is the binding affinity. Ligand A has a 2.4 kcal/mol advantage, which is significant enough to outweigh some of its drawbacks. While Ligand B has better DILI and metabolic stability, the strong binding of Ligand A is paramount for a GPCR target. The slightly better BBB penetration of Ligand A is also a plus. The poor Caco-2 and solubility scores are concerning for both, but can be addressed with formulation strategies.
**Output:**
1
2025-04-17 20:46:02,486 - INFO - Here's my reasoning and the final output:
**Reasoning:**
We're evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, logP, TPSA, Pgp, and binding affinity are key. Metabolic stability (Cl_mic, t1/2) and safety (DILI, hERG) are also important.
Let's break down the comparison:
1. **MW:** Both ligands (370.5 and 358.4) are within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (78.87) is better than Ligand B (84.22). Both are below 140, but lower is preferred for absorption.
3. **logP:** Ligand A (1.189) is slightly better than Ligand B (0.802), both are within the optimal 1-3 range.
4. **HBD/HBA:** Ligand A has 2 HBD and 5 HBA, while Ligand B has 0 HBD and 7 HBA. Ligand A's HBD count is preferable, as some hydrogen bonding is generally beneficial for target engagement.
5. **QED:** Ligand B (0.758) is better than Ligand A (0.496). A higher QED suggests better overall drug-likeness.
6. **DILI:** Ligand A (31.059) has a significantly lower DILI risk than Ligand B (72.043). This is a major advantage for Ligand A.
7. **BBB:** Ligand B (74.098) has a better BBB penetration score than Ligand A (46.336). While not crucial for a cardiovascular target, it's a slight positive for Ligand B.
8. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-5.093) is slightly better than Ligand B (-5.16).
9. **Solubility:** Both have negative solubility values, indicating poor solubility. Ligand A (-3.032) is slightly better than Ligand B (-2.353).
10. **hERG:** Ligand A (0.357) has a much lower hERG risk than Ligand B (0.144). This is a significant safety advantage for Ligand A.
11. **Cl_mic:** Ligand B (39.367) has lower microsomal clearance than Ligand A (52.054), indicating better metabolic stability.
12. **t1/2:** Ligand B (-11.757) has a slightly better in vitro half-life than Ligand A (-13.108).
13. **Pgp:** Ligand A (0.074) has lower P-gp efflux than Ligand B (0.2), which is favorable for bioavailability.
14. **Binding Affinity:** Ligand A (-7.2) has a slightly better binding affinity than Ligand B (-6.8). While the difference is not huge, it's still a positive for Ligand A.
**Overall Assessment:**
Ligand A demonstrates a better balance of properties, particularly regarding safety (DILI, hERG) and binding affinity. While Ligand B has a better QED and slightly better metabolic stability, the significantly lower DILI and hERG risk of Ligand A, combined with its slightly better binding affinity and Pgp efflux, make it the more promising candidate for development. The slightly better BBB of Ligand B is not a major concern for a cardiovascular target.
**Output:**
1
2025-04-17 20:46:02,486 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (344.415 and 348.531 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (108.02) is higher than Ligand B (49.41). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B is significantly better.
3. **logP:** Ligand B (3.912) is higher than Ligand A (2.067). While both are within the optimal 1-3 range, Ligand B is approaching the upper limit. This could potentially lead to solubility issues, but is acceptable.
4. **HBD:** Ligand A (2) and Ligand B (1) are both within the acceptable limit of <=5. Ligand B is slightly better.
5. **HBA:** Ligand A (5) and Ligand B (2) are both within the acceptable limit of <=10. Ligand B is significantly better.
6. **QED:** Both ligands (0.787 and 0.766) have good drug-likeness scores, exceeding the 0.5 threshold. No significant difference.
7. **DILI:** Ligand A (49.593) has a higher DILI risk than Ligand B (11.245). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (62.233) has lower BBB penetration than Ligand B (83.366). While ADRB2 is not a CNS target, some distribution to the CNS is possible, and higher BBB penetration is generally preferable. Ligand B is better.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.897 and -4.62). These values are difficult to interpret without knowing the scale, but negative values generally indicate poor permeability. No clear advantage.
10. **Solubility:** Ligand A (-3.383) has slightly better solubility than Ligand B (-3.818). However, both are poor.
11. **hERG:** Ligand A (0.253) has a lower hERG risk than Ligand B (0.596). This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand A (44.88) has lower microsomal clearance than Ligand B (57.061), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (-30.249) has a shorter in vitro half-life than Ligand B (-12.983). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.131) has lower P-gp efflux than Ligand B (0.318), suggesting better bioavailability. This is a slight advantage for Ligand A.
15. **Affinity:** Ligand A (-6.2 kcal/mol) has slightly better binding affinity than Ligand B (-5.8 kcal/mol). This is a positive for Ligand A, but the difference is not huge.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in TPSA and Pgp, and has acceptable logP. Ligand A has better affinity, but the difference is not substantial. The significantly lower DILI risk of Ligand B is a major factor.
**Overall Assessment:**
While Ligand A has a slight edge in affinity and hERG, the combination of significantly lower DILI risk, better TPSA, better Pgp efflux, and a longer half-life makes Ligand B the more promising candidate. The slightly higher logP is a manageable concern.
Output:
0
2025-04-17 20:46:02,486 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (355.29 and 355.50 Da) fall comfortably within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (38.77) is significantly better than Ligand B (61.44). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is approaching a level that could hinder oral absorption.
3. **logP:** Ligand A (3.914) is slightly higher than Ligand B (2.258), both within the optimal 1-3 range, but A is closer to the upper limit.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer HBDs generally improve membrane permeability.
5. **HBA:** Both ligands have 3 HBA, which is acceptable.
6. **QED:** Ligand A (0.784) has a better QED score than Ligand B (0.667), indicating a more drug-like profile.
7. **DILI:** Ligand B (5.78) has a much lower DILI risk than Ligand A (81.82). This is a *major* advantage for Ligand B. DILI is a critical safety concern.
8. **BBB:** Ligand A (91.59) has a significantly higher BBB penetration potential than Ligand B (75.11). While ADRB2 isn't strictly a CNS target, some CNS exposure can occur and isn't necessarily detrimental.
9. **Caco-2:** Ligand A (-4.139) is better than Ligand B (-5.02), indicating better intestinal absorption.
10. **Solubility:** Ligand B (-1.733) has better aqueous solubility than Ligand A (-5.34). Solubility is important for formulation.
11. **hERG:** Ligand A (0.851) has a lower hERG inhibition liability than Ligand B (0.472), which is preferable.
12. **Cl_mic:** Ligand B (-4.863) has a *much* lower microsomal clearance than Ligand A (60.394), indicating better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand B (-16.427) has a longer in vitro half-life than Ligand A (33.281), which is preferable.
14. **Pgp:** Ligand A (0.623) has lower P-gp efflux than Ligand B (0.019). Lower Pgp efflux is generally better.
15. **Affinity:** Both ligands have very similar binding affinities (-7.0 and -5.9 kcal/mol). Ligand A has a slight advantage, but the difference is not substantial enough to outweigh other factors.
**Overall Assessment:**
Ligand B clearly wins on safety (DILI) and metabolic stability (Cl_mic, t1/2). While Ligand A has some advantages in permeability (Caco-2) and BBB penetration, the significantly lower DILI risk and improved metabolic stability of Ligand B are more critical for overall drug development success. The slight difference in binding affinity is not enough to overcome these advantages. For a cardiovascular target like ADRB2, minimizing off-target effects and ensuring adequate drug exposure are paramount.
Output:
0
2025-04-17 20:46:02,486 - INFO - Here's my reasoning and the final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, the key priorities are logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB (though less critical for a cardiovascular target). Other important factors include metabolic stability (Cl_mic, t1/2) and safety (DILI, hERG).
Let's compare the ligands property by property:
1. **MW:** Both ligands (350.46 & 370.56 Da) fall within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (87.66) is better than Ligand B (49.85). Lower TPSA generally favors better membrane permeability, which is important for GPCRs.
3. **logP:** Both are good (2.57 & 2.78), falling within the optimal 1-3 range.
4. **HBD:** Ligand A has 3 HBD, while Ligand B has 0. While lower HBD can sometimes improve permeability, 3 is reasonable.
5. **HBA:** Both have 4 HBA, which is acceptable.
6. **QED:** Both have good QED scores (0.67 & 0.75), indicating drug-likeness.
7. **DILI:** Ligand A (37.73) has a slightly better DILI score than Ligand B (48.31), indicating lower potential for liver injury.
8. **BBB:** Ligand B (59.21) has a higher BBB score than Ligand A (28.85). However, BBB is less critical for a cardiovascular target.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Both have negative solubility values, which is also concerning.
11. **hERG:** Ligand A (0.47) has a slightly better hERG score than Ligand B (0.25), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand A (47.92) has lower microsomal clearance than Ligand B (73.56), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-16.83) has a significantly *longer* in vitro half-life than Ligand B (-1.71). This is a major advantage.
14. **Pgp:** Ligand A (0.11) has a lower Pgp efflux liability than Ligand B (0.32), which is favorable for bioavailability.
15. **Affinity:** Ligand A (-7.2 kcal/mol) has a *significantly* better binding affinity than Ligand B (-5.7 kcal/mol). This is a crucial difference, as a 1.5 kcal/mol advantage is considered substantial.
**Overall Assessment:**
Ligand A is the stronger candidate. While both have issues with Caco-2 and solubility, Ligand A boasts a significantly better binding affinity, longer half-life, lower Pgp efflux, lower DILI risk, and better metabolic stability. The superior affinity and pharmacokinetic properties outweigh the slightly lower BBB penetration (which is less important for a cardiovascular target).
**Output:**
1
2025-04-17 20:46:02,487 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [352.435, 82.19, -0.379, 1, 5, 0.521, 29.624, 37.573, -4.743, -0.663, 0.088, -16.844, -7.868, 0.002, -4.3]
**Ligand B:** [361.873, 51.27, 4.364, 0, 4, 0.718, 36.099, 67.197, -4.885, -3.545, 0.746, 82.303, 37.967, 0.732, -6.9]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (352.435) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (82.19) is better than Ligand B (51.27). While both are reasonably low, lower TPSA is preferred for GPCRs, potentially aiding BBB penetration.
3. **logP:** Ligand A (-0.379) is suboptimal, being a bit low. Ligand B (4.364) is too high, potentially causing solubility issues and off-target interactions.
4. **HBD/HBA:** Ligand A has 1 HBD and 5 HBA, Ligand B has 0 HBD and 4 HBA. Both are acceptable.
5. **QED:** Ligand B (0.718) has a better QED score than Ligand A (0.521), indicating a more drug-like profile.
6. **DILI:** Both have acceptable DILI risk (Ligand A: 29.624, Ligand B: 36.099).
7. **BBB:** Ligand B (67.197) has significantly better BBB penetration potential than Ligand A (37.573). This is a key consideration for a GPCR.
8. **Caco-2:** Both have poor Caco-2 permeability (-4.743 and -4.885).
9. **Solubility:** Ligand A (-0.663) has slightly better solubility than Ligand B (-3.545).
10. **hERG:** Ligand A (0.088) has a lower hERG risk than Ligand B (0.746). This is a significant advantage.
11. **Cl_mic:** Ligand A (-16.844) has much better metabolic stability (lower clearance) than Ligand B (82.303).
12. **t1/2:** Ligand B (37.967) has a longer in vitro half-life than Ligand A (-7.868).
13. **Pgp:** Ligand A (0.002) has significantly lower P-gp efflux liability than Ligand B (0.732). This is crucial for bioavailability and potentially BBB penetration.
14. **Affinity:** Ligand B (-6.9 kcal/mol) has a significantly better binding affinity than Ligand A (-4.3 kcal/mol). This is a substantial advantage, potentially outweighing some ADME concerns.
**Overall Assessment:**
Ligand B has a much stronger binding affinity and better BBB penetration, which are critical for a GPCR target like ADRB2. However, it suffers from a high logP, which could lead to solubility issues and increased off-target effects. It also has higher Pgp efflux and a worse metabolic stability profile. Ligand A has a better safety profile (lower hERG, lower DILI, lower Pgp efflux), better metabolic stability, and slightly better solubility, but its affinity is significantly weaker and its BBB penetration is poor.
Despite Ligand B's drawbacks, the substantial improvement in binding affinity (-6.9 vs -4.3 kcal/mol) is a major factor. For a GPCR, achieving good occupancy is paramount. The high logP and efflux can be addressed with further optimization, but a weak binder is much harder to improve.
Therefore, I favor Ligand B.
```
0
```
2025-04-17 20:46:02,487 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [359.377, 113.48 , 0.792, 3. , 5. , 0.721, 38.697, 66.344, -5.017, -1.508, 0.141, -5.694, -4.407, 0.01 , -6.4 ]
**Ligand B:** [357.395, 110.01 , 2.325, 2. , 7. , 0.725, 91.857, 53.781, -5.299, -3.907, 0.272, 54.184, 45.861, 0.125, -8.4 ]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, Affinity, and BBB):
1. **MW:** Both are within the ideal 200-500 Da range. A is 359.377, B is 357.395. Very similar.
2. **TPSA:** Both are reasonably good, under 140. A is 113.48, B is 110.01. B is slightly better.
3. **logP:** A (0.792) is a bit low, potentially hindering permeability. B (2.325) is much better, falling within the optimal 1-3 range. This is a significant advantage for B.
4. **HBD/HBA:** A has 3 HBD and 5 HBA. B has 2 HBD and 7 HBA. Both are acceptable, but A is slightly better with fewer donors.
5. **QED:** Both are good (0.721 and 0.725). Similar.
6. **DILI:** A (38.697) is significantly better than B (91.857). This is a major advantage for A.
7. **BBB:** A (66.344) is better than B (53.781), though neither are exceptionally high. Still, for a cardiovascular target, high BBB penetration isn't critical.
8. **Caco-2:** Both are negative, indicating poor permeability. A (-5.017) is slightly better than B (-5.299).
9. **Solubility:** Both are negative, indicating poor solubility. A (-1.508) is better than B (-3.907).
10. **hERG:** Both are very low (0.141 and 0.272), indicating low cardiotoxicity risk. Similar.
11. **Cl_mic:** A (-5.694) is much better (lower) than B (54.184), indicating better metabolic stability. This is a significant advantage for A.
12. **t1/2:** A (-4.407) is better than B (45.861).
13. **Pgp:** Both are very low (0.01 and 0.125), indicating low efflux. Similar.
14. **Affinity:** B (-8.4) is significantly better than A (-6.4). This is a 2 kcal/mol difference, which is substantial and can often outweigh other drawbacks.
**Overall Assessment:**
Ligand B has a superior binding affinity and a better logP, which are critical for GPCR targets. However, it suffers from a significantly higher DILI risk and poorer metabolic stability (higher Cl_mic). Ligand A has a much lower DILI risk and better metabolic stability, but its logP is suboptimal and its affinity is weaker.
Given the importance of potency for GPCRs, the 2 kcal/mol advantage of B is compelling. While the DILI risk is concerning, it might be mitigated through further structural modifications. The lower metabolic stability is also a concern, but could potentially be addressed with prodrug strategies or formulation approaches.
Therefore, I favor Ligand B.
Output:
0
2025-04-17 20:46:02,487 - INFO - Batch 209 complete. Total preferences: 3344
2025-04-17 20:46:02,487 - INFO - Processing batch 210/512...
2025-04-17 20:46:51,390 - INFO - Reasoning:
Let's analyze both ligands based on the provided parameters and guidelines, keeping in mind this is for an ADRB2 GPCR (cardiovascular target, so BBB is less critical).
**Ligand A:**
* **MW:** 352.475 Da - Good, within the ideal range.
* **TPSA:** 81.08 - Good, below the 140 threshold for oral absorption.
* **logP:** 1.173 - Good, within the optimal range.
* **HBD:** 2 - Good, below the threshold.
* **HBA:** 4 - Good, below the threshold.
* **QED:** 0.728 - Excellent, highly drug-like.
* **DILI:** 17.449 - Excellent, very low risk.
* **BBB:** 43.738 - Acceptable, but not a priority for a cardiovascular target.
* **Caco-2:** -4.755 - Concerningly low, suggests poor absorption.
* **Solubility:** -0.935 - Poor solubility.
* **hERG:** 0.221 - Very low risk.
* **Cl_mic:** 0.564 - Low, good metabolic stability.
* **t1/2:** -0.472 - Short half-life.
* **Pgp:** 0.059 - Low efflux, good.
* **Affinity:** -7.0 kcal/mol - Excellent binding affinity.
**Ligand B:**
* **MW:** 367.515 Da - Good, within the ideal range.
* **TPSA:** 71.53 - Good, below the 140 threshold.
* **logP:** 2.766 - Good, within the optimal range.
* **HBD:** 1 - Good, below the threshold.
* **HBA:** 5 - Good, below the threshold.
* **QED:** 0.767 - Excellent, highly drug-like.
* **DILI:** 46.801 - Acceptable, moderate risk.
* **BBB:** 59.325 - Acceptable, but not a priority.
* **Caco-2:** -5.079 - Very low, suggests poor absorption.
* **Solubility:** -2.593 - Very poor solubility.
* **hERG:** 0.461 - Moderate risk.
* **Cl_mic:** 66.195 - High, poor metabolic stability.
* **t1/2:** 10.986 - Good, longer half-life.
* **Pgp:** 0.127 - Low efflux, good.
* **Affinity:** -7.5 kcal/mol - Excellent, slightly better binding affinity than Ligand A.
**Comparison & Decision:**
Both ligands have excellent binding affinity and drug-like scores (QED). Ligand B has a slightly better affinity (-7.5 vs -7.0), which is a significant advantage. However, both suffer from very poor Caco-2 permeability and solubility. Ligand A has a much better DILI score and lower hERG risk. Ligand B has significantly higher microsomal clearance, indicating faster metabolism.
For a cardiovascular target, metabolic stability and avoiding off-target effects (like hERG inhibition) are crucial. While the slightly better affinity of Ligand B is attractive, the significantly worse metabolic stability and DILI risk outweigh this benefit. Ligand A, despite its shorter half-life, presents a more favorable overall profile with better safety margins and reasonable metabolic stability. The poor Caco-2 and solubility are problematic for both, but can be addressed with formulation strategies.
Output:
1
2025-04-17 20:46:51,391 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (343.471 and 358.364 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (61.44) is significantly better than Ligand B (76.14). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand A is well below the 140 threshold, while Ligand B is approaching it.
3. **logP:** Both ligands have good logP values (2.186 and 2.37), falling within the optimal 1-3 range. Ligand B is slightly higher, but not concerningly so.
4. **HBD:** Both have 2 HBD, which is acceptable.
5. **HBA:** Ligand A has 3 HBA, while Ligand B has 5. Lower is generally preferred, giving a slight edge to Ligand A.
6. **QED:** Both ligands have good QED scores (0.798 and 0.845), indicating good drug-like properties.
7. **DILI:** Ligand A (21.869) has a much lower DILI risk than Ligand B (52.385). This is a significant advantage for Ligand A.
8. **BBB:** Ligand B (85.537) has a considerably higher BBB penetration percentile than Ligand A (62.233). While ADRB2 isn't *strictly* a CNS target, some CNS exposure can be relevant, and higher BBB is generally desirable.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.825) is slightly better than Ligand B (-4.699), but both are problematic.
10. **Solubility:** Ligand A (-2.31) has slightly better solubility than Ligand B (-3.126), but both are poor.
11. **hERG:** Both ligands have low hERG inhibition risk (0.49 and 0.294), which is good. Ligand B is slightly better.
12. **Cl_mic:** Ligand B (13.52) has a lower microsomal clearance than Ligand A (17.456), suggesting better metabolic stability.
13. **t1/2:** Ligand B (15.63) has a significantly longer in vitro half-life than Ligand A (7.995). This is a major advantage for Ligand B.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.089 and 0.033).
15. **Binding Affinity:** Ligand B (-6.7 kcal/mol) has a slightly better binding affinity than Ligand A (-6.3 kcal/mol). This difference of 0.4 kcal/mol is meaningful, but not overwhelming.
**Overall Assessment:**
For an ADRB2 GPCR target, we prioritize affinity, logP, TPSA, and metabolic stability. Ligand B has a slightly better affinity and significantly better metabolic stability (lower Cl_mic and longer t1/2). It also has a higher BBB value. However, Ligand A has a much lower DILI risk and a better TPSA. The poor Caco-2 and solubility for both are concerning, but the affinity difference isn't large enough to overcome the DILI risk of Ligand B. The lower TPSA of Ligand A is also a significant advantage for permeability.
Considering the balance of these factors, I favor Ligand A.
Output:
1
2025-04-17 20:46:51,391 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (347.459 Da and 363.483 Da) are within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (82.53) is slightly higher than Ligand B (62.74). For a cardiovascular GPCR, TPSA is moderately important, and lower is generally better for permeability. Ligand B has a clear advantage.
**3. logP:** Both ligands have good logP values (1.629 and 1.948, respectively), falling within the optimal 1-3 range. No major difference.
**4. H-Bond Donors:** Ligand A has 2 HBD, while Ligand B has 0. Lower is often preferable for permeability, giving Ligand B a slight edge.
**5. H-Bond Acceptors:** Ligand A has 4 HBA, and Ligand B has 5. Both are acceptable (<=10), but Ligand A is slightly better.
**6. QED:** Both ligands have similar QED values (0.848 and 0.823), indicating good drug-likeness.
**7. DILI Risk:** Ligand A (23.032) has a significantly lower DILI risk than Ligand B (62.854). This is a crucial advantage for Ligand A.
**8. BBB Penetration:** Both ligands have moderate BBB penetration (50.795 and 55.138). Since this is a cardiovascular target, BBB penetration is not a primary concern, but higher is still slightly better. Ligand B is marginally better.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.793 and -4.756). This is unusual and suggests poor permeability. However, the values are very close, so it doesn't strongly favor either.
**10. Aqueous Solubility:** Both ligands have negative solubility values (-2.224 and -1.857). This is also concerning, indicating poor solubility. Again, the difference is small.
**11. hERG Inhibition:** Both ligands exhibit low hERG inhibition risk (0.291 and 0.376), which is excellent.
**12. Microsomal Clearance:** Ligand A (17.745) has significantly lower microsomal clearance than Ligand B (42.724), indicating better metabolic stability. This is a major advantage for Ligand A.
**13. In vitro Half-Life:** Ligand B (17.17 hours) has a much longer in vitro half-life than Ligand A (5.444 hours). This is a significant advantage for Ligand B.
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (0.079 and 0.281).
**15. Binding Affinity:** Ligand A (-6.6 kcal/mol) has a slightly stronger binding affinity than Ligand B (-5.6 kcal/mol). This 1 kcal/mol difference is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), and the general guidelines, Ligand A is the stronger candidate. While Ligand B has a longer half-life and slightly better TPSA, Ligand A boasts a significantly lower DILI risk, better metabolic stability (lower Cl_mic), and a superior binding affinity. The DILI risk and metabolic stability are particularly important for a chronic cardiovascular condition. The slightly stronger affinity further tips the balance.
Output:
1
2025-04-17 20:46:51,391 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (366.487 Da) is slightly higher than Ligand B (345.395 Da), but this difference isn't significant.
**2. TPSA:** Ligand A (75.63) is higher than Ligand B (61.14). Both are below the 140 A^2 threshold for oral absorption, but Ligand B is preferable due to the lower TPSA.
**3. logP:** Ligand A (1.806) is within the optimal range (1-3). Ligand B (3.379) is at the higher end of the optimal range. Both are acceptable, but Ligand A is slightly better.
**4. H-Bond Donors:** Both ligands have 0 HBD, which is good.
**5. H-Bond Acceptors:** Both ligands have 6 HBA, which is acceptable.
**6. QED:** Ligand A (0.815) has a significantly higher QED than Ligand B (0.566), indicating a more drug-like profile.
**7. DILI:** Both ligands have low DILI risk (Ligand A: 47.964, Ligand B: 42.187), both below the 60 threshold. Ligand B is slightly better.
**8. BBB:** Both ligands have good BBB penetration (Ligand A: 79.682, Ligand B: 78.558). This is important for GPCR targets, though less critical for ADRB2 specifically as it's primarily a cardiovascular target.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, indicating poor permeability. Ligand A (-4.734) is slightly worse than Ligand B (-4.504).
**10. Aqueous Solubility:** Both ligands have negative solubility values, indicating poor solubility. Ligand A (-2.687) is slightly worse than Ligand B (-3.614).
**11. hERG Inhibition:** Ligand A (0.35) has a lower hERG risk than Ligand B (0.913), which is a significant advantage.
**12. Microsomal Clearance:** Ligand A (43.638) has lower microsomal clearance than Ligand B (74.756), indicating better metabolic stability.
**13. In vitro Half-Life:** Ligand B (64.586) has a significantly longer half-life than Ligand A (8.402). This is a major advantage.
**14. P-gp Efflux:** Ligand A (0.35) has lower P-gp efflux than Ligand B (0.532), which is preferable.
**15. Binding Affinity:** Ligand A (-7.7 kcal/mol) has a slightly better binding affinity than Ligand B (-5.3 kcal/mol). This is a substantial difference (2.4 kcal/mol) and a key factor.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity) and the general guidelines, Ligand A is the more promising candidate. While Ligand B has a better half-life, Ligand A's superior binding affinity (-7.7 vs -5.3 kcal/mol) is a significant advantage that outweighs the drawbacks. Additionally, Ligand A has better QED, lower hERG risk, and lower P-gp efflux. The slightly lower TPSA and better logP of Ligand A also contribute to its favorability.
Output:
1
2025-04-17 20:46:51,391 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (385.339 Da) is slightly higher than Ligand B (352.385 Da), but both are acceptable.
**2. TPSA:** Ligand A (58.12) is well below the 140 A^2 threshold for good oral absorption and is favorable. Ligand B (76.02) is still acceptable, but less optimal.
**3. logP:** Ligand A (4.251) is a bit high, potentially leading to solubility issues or off-target interactions. Ligand B (1.333) is within the optimal range (1-3).
**4. H-Bond Donors:** Ligand A (1) and Ligand B (2) are both within the acceptable limit of 5.
**5. H-Bond Acceptors:** Both ligands have 4 H-bond acceptors, which is well within the acceptable limit of 10.
**6. QED:** Ligand B (0.693) has a slightly better QED score than Ligand A (0.433), indicating a more drug-like profile.
**7. DILI Risk:** Ligand B (33.734) has a significantly lower DILI risk than Ligand A (56.999), which is a major advantage.
**8. BBB Penetration:** Both ligands have good BBB penetration (Ligand A: 81.117, Ligand B: 70.648). This is important for GPCR targets, although less critical for ADRB2 specifically as it's primarily a cardiovascular target.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values which is unusual. These values are likely logP-scaled and indicate poor permeability.
**10. Aqueous Solubility:** Both ligands have negative solubility values, indicating poor solubility.
**11. hERG Inhibition:** Ligand A (0.592) has a slightly higher hERG inhibition risk than Ligand B (0.143), which is undesirable.
**12. Microsomal Clearance:** Ligand B (-2.507) has a negative clearance, which is very favorable, indicating high metabolic stability. Ligand A (70.411) has a higher clearance, suggesting faster metabolism.
**13. In vitro Half-Life:** Ligand B (-11.16) has a negative half-life, which is very favorable. Ligand A (52.834) has a shorter half-life.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability.
**15. Binding Affinity:** Ligand A (-5.7 kcal/mol) has a slightly better binding affinity than Ligand B (-6.6 kcal/mol). However, the difference is not substantial enough to outweigh the other significant advantages of Ligand B.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity) and the general drug-like properties, Ligand B is the more promising candidate. While Ligand A has slightly better binding affinity, Ligand B exhibits significantly better ADME-Tox properties, including lower DILI risk, better metabolic stability (lower Cl_mic and higher t1/2), and lower hERG inhibition. The logP value of Ligand B is also more favorable. The poor Caco-2 and solubility values are concerning for both, but the superior ADME profile of Ligand B makes it the preferred choice for further optimization.
Output:
0
2025-04-17 20:46:51,391 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.515 and 346.446 Da) fall comfortably within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Both ligands have a TPSA of 49.41, which is good for oral absorption, well below the 140 A^2 threshold. No significant difference.
3. **logP:** Both ligands have logP values within the optimal range (3.356 and 3.24). Ligand B is slightly lower, which could be marginally better for solubility.
4. **HBD:** Both ligands have 1 H-bond donor, which is acceptable. No difference.
5. **HBA:** Both ligands have 2 H-bond acceptors, also acceptable. No difference.
6. **QED:** Ligand A (0.848) has a higher QED score than Ligand B (0.771), indicating a more drug-like profile. This is a positive for Ligand A.
7. **DILI:** Ligand A (15.936%) has a significantly lower DILI risk than Ligand B (28.887%). This is a major advantage for Ligand A.
8. **BBB:** Both ligands have high BBB penetration (81.698% and 86.817%). Ligand B is slightly higher, but both are good. Given ADRB2 is a cardiovascular target, BBB penetration isn't a primary concern, but it doesn't hurt.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.768 and -4.659), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Both ligands have negative solubility values (-3.882 and -3.518), indicating poor aqueous solubility. This is a significant drawback for both.
11. **hERG:** Ligand A (0.473) has a lower hERG inhibition liability than Ligand B (0.807), which is preferable.
12. **Cl_mic:** Ligand A (51.979 mL/min/kg) has a lower microsomal clearance than Ligand B (62.309 mL/min/kg), suggesting better metabolic stability. This is a positive for Ligand A.
13. **t1/2:** Ligand B (7.416 hours) has a longer in vitro half-life than Ligand A (-7.157 hours). This is a positive for Ligand B, but the negative value for A is concerning.
14. **Pgp:** Ligand A (0.178) has lower P-gp efflux liability than Ligand B (0.227), which is preferable.
15. **Binding Affinity:** Ligand A (-6.9 kcal/mol) has a slightly better binding affinity than Ligand B (-6.0 kcal/mol). This 1.9 kcal/mol difference is substantial and outweighs many of the minor ADME drawbacks.
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Both ligands perform similarly on logP and TPSA. Ligand A has better Pgp and significantly better affinity. The lower DILI risk and hERG liability for Ligand A are also very important. While Ligand B has a better half-life, the negative value for A is concerning, but the superior binding affinity and safety profile of A are more important.
**Conclusion:**
Ligand A is the more promising candidate due to its significantly better binding affinity, lower DILI risk, lower hERG liability, lower P-gp efflux, and better metabolic stability. While both have solubility and permeability issues, the strength of binding and improved safety profile of Ligand A make it the better choice.
Output:
1
2025-04-17 20:46:51,391 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [351.422, 91.32, 1.844, 3, 4, 0.755, 44.862, 60.45, -4.72, -1.898, 0.189, 2.851, 1.431, 0.031, -7.2]
**Ligand B:** [349.362, 102.76, -0.312, 3, 5, 0.586, 40.054, 26.638, -4.847, -1.242, 0.151, -26.971, -3.082, 0.008, -6.8]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal range (200-500 Da). A is 351.422, B is 349.362 - very similar.
2. **TPSA:** A (91.32) is better than B (102.76). Lower TPSA generally favors better absorption.
3. **logP:** A (1.844) is optimal. B (-0.312) is quite low, potentially hindering membrane permeability. This is a significant drawback.
4. **HBD:** Both have 3 HBD, which is acceptable.
5. **HBA:** A has 4, B has 5. Both are within the acceptable range.
6. **QED:** A (0.755) is better than B (0.586), indicating a more drug-like profile.
7. **DILI:** Both are good, below 40. A (44.862) is slightly higher than B (40.054), but both are acceptable.
8. **BBB:** A (60.45) is significantly better than B (26.638). While ADRB2 isn't *necessarily* a CNS target, some peripheral ADRB2 activity can be modulated by CNS effects, and higher BBB is generally a plus.
9. **Caco-2:** Both are negative, indicating poor permeability. A (-4.72) is slightly better than B (-4.847).
10. **Solubility:** Both are negative, indicating poor solubility. A (-1.898) is slightly better than B (-1.242).
11. **hERG:** Both are very low, indicating minimal hERG inhibition risk.
12. **Cl_mic:** A (2.851) is *much* better than B (-26.971). B has a negative clearance, which is unrealistic and suggests a potential issue with the prediction or the molecule itself. A lower Cl_mic means better metabolic stability.
13. **t1/2:** A (1.431) is better than B (-3.082). Again, a negative half-life is concerning.
14. **Pgp:** Both are very low, suggesting minimal P-gp efflux.
15. **Affinity:** A (-7.2) is better than B (-6.8), although the difference is not huge. A 0.4 kcal/mol difference is meaningful, especially when considering the other factors.
**Overall Assessment:**
Ligand A is significantly better. While both have issues with Caco-2 and solubility, Ligand A has a much better logP, QED, BBB penetration, metabolic stability (Cl_mic), and in vitro half-life. The negative clearance and half-life for Ligand B are major red flags, and its lower logP is also a significant concern for a GPCR target. The slightly better binding affinity of A further solidifies its preference.
Output:
1
2025-04-17 20:46:51,391 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (355.379 and 352.431 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (103.29) is slightly higher than Ligand B (93.73). Both are below the 140 A^2 threshold for good oral absorption, but Ligand B is preferable due to being closer to the 90 A^2 target for GPCRs.
**3. logP:** Ligand A (2.929) is within the optimal 1-3 range, while Ligand B (1.078) is at the lower end. While a lower logP isn't automatically disqualifying, it *can* indicate permeability issues. Ligand A is favored.
**4. H-Bond Donors:** Ligand A (0) is ideal, while Ligand B (2) is acceptable, but less optimal. Fewer HBDs generally improve permeability.
**5. H-Bond Acceptors:** Ligand A (8) is good, while Ligand B (5) is excellent.
**6. QED:** Both ligands have reasonable QED scores (0.525 and 0.478), indicating acceptable drug-likeness.
**7. DILI Risk:** Ligand A (93.176) has a significantly higher DILI risk than Ligand B (27.142). This is a major concern, as liver toxicity is a common reason for drug failure. Ligand B is strongly favored here.
**8. BBB Penetration:** Ligand A (82.435) has better BBB penetration than Ligand B (68.748). However, for a cardiovascular target like ADRB2, high BBB penetration isn't critical.
**9. Caco-2 Permeability:** Both ligands have similar, poor Caco-2 permeability (-4.833 and -4.864). This suggests potential absorption issues for both.
**10. Aqueous Solubility:** Ligand A (-3.7) is slightly worse than Ligand B (-2.145), indicating lower solubility. Solubility is important for formulation and bioavailability. Ligand B is favored.
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.119 and 0.082). This is excellent.
**12. Microsomal Clearance:** Ligand A (41.26) has lower microsomal clearance than Ligand B (66.165), suggesting better metabolic stability. This is a positive for Ligand A.
**13. In vitro Half-Life:** Ligand A (8.13) has a shorter half-life than Ligand B (-8.064). A longer half-life is generally preferred. Ligand B is favored.
**14. P-gp Efflux:** Both ligands have low P-gp efflux (0.561 and 0.019). Ligand B is clearly better here.
**15. Binding Affinity:** Ligand A (-6.9) has slightly better binding affinity than Ligand B (-6.6). However, the difference (0.3 kcal/mol) isn't substantial enough to outweigh other significant drawbacks.
**Overall Assessment:**
While Ligand A has slightly better affinity and metabolic stability, the significantly higher DILI risk is a major red flag. Ligand B, despite a slightly lower affinity, presents a much more favorable safety profile (lower DILI) and better solubility, P-gp efflux, and half-life. Considering the GPCR-specific priorities (logP, Pgp, TPSA) and the overall balance of properties, Ligand B is the more promising drug candidate.
Output:
0
2025-04-17 20:46:51,391 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (341.459 Da and 363.464 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (64.74) is higher than Ligand B (29.54). For a cardiovascular GPCR, lower TPSA is generally preferred to enhance permeability, giving a slight edge to Ligand B.
**3. logP:** Ligand A (2.513) is within the optimal 1-3 range. Ligand B (4.451) is slightly higher, potentially increasing the risk of off-target effects and solubility issues. Ligand A is preferred here.
**4. H-Bond Donors:** Ligand A (1) is better than Ligand B (0).
**5. H-Bond Acceptors:** Ligand A (5) is better than Ligand B (2).
**6. QED:** Ligand A (0.929) is significantly better than Ligand B (0.596), indicating a more drug-like profile. This is a substantial advantage for Ligand A.
**7. DILI:** Ligand B (21.365) has a much lower DILI risk than Ligand A (41.411). This is a significant advantage for Ligand B.
**8. BBB:** Ligand B (96.161) has a higher BBB penetration percentile than Ligand A (86.196). While not a primary concern for a cardiovascular target, higher BBB is generally favorable.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, indicating poor permeability. Ligand A (-4.83) is slightly better than Ligand B (-4.412).
**10. Aqueous Solubility:** Ligand B (-4.192) has better solubility than Ligand A (-3.014). This is a positive for Ligand B.
**11. hERG Inhibition:** Ligand A (0.613) has a lower hERG inhibition liability than Ligand B (0.888), which is preferable.
**12. Microsomal Clearance:** Ligand A (39.723) has lower microsomal clearance than Ligand B (70.697), suggesting better metabolic stability. This is a significant advantage for Ligand A.
**13. In vitro Half-Life:** Ligand A (23.278) has a longer half-life than Ligand B (20.356), which is desirable.
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (0.458 and 0.644 respectively). No major difference.
**15. Binding Affinity:** Ligand A (-6.4 kcal/mol) and Ligand B (-6.1 kcal/mol) have similar binding affinities. The difference of 0.3 kcal/mol is not substantial enough to outweigh other factors.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand A appears to be the more promising candidate. While Ligand B has advantages in DILI risk and solubility, Ligand A excels in QED, metabolic stability (Cl_mic and t1/2), and hERG inhibition. The slightly better logP and overall drug-likeness of Ligand A, coupled with its better metabolic profile, outweigh the advantages of Ligand B.
Output:
1
2025-04-17 20:46:51,392 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [375.491, 118.8 , -0.311, 2. , 5. , 0.603, 36.758, 55.021, -5.18 , -2.09 , 0.185, 7.259, -28.337, 0.014, -5.6 ]
**Ligand B:** [340.427, 67.23 , 1.334, 1. , 4. , 0.826, 54.556, 62.35 , -4.844, -3.084, 0.258, 24.702, -4.32 , 0.127, -7.4 ]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, Affinity, and BBB):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (340.427) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (118.8) is approaching the upper limit for good oral absorption, but still acceptable. Ligand B (67.23) is excellent, well below the 140 threshold, suggesting better permeability.
3. **logP:** Ligand A (-0.311) is a bit low, potentially hindering membrane permeability. Ligand B (1.334) is within the optimal range (1-3). This is a significant advantage for Ligand B.
4. **HBD/HBA:** Both are reasonable. Ligand A has 2 HBD and 5 HBA, while Ligand B has 1 HBD and 4 HBA.
5. **QED:** Both have good QED scores (A: 0.603, B: 0.826), indicating drug-like properties. Ligand B is better here.
6. **DILI:** Both have acceptable DILI risk (A: 36.758, B: 54.556), with Ligand A being slightly preferable.
7. **BBB:** Ligand A (55.021) is lower than Ligand B (62.35). While ADRB2 isn't necessarily a CNS target, some degree of BBB penetration can be useful for distribution.
8. **Caco-2:** Both are negative, indicating poor permeability.
9. **Solubility:** Both are negative, indicating poor solubility.
10. **hERG:** Both are very low, indicating minimal hERG inhibition risk.
11. **Cl_mic:** Ligand A (7.259) has a lower clearance than Ligand B (24.702), suggesting better metabolic stability.
12. **t1/2:** Ligand A (-28.337) has a much more negative in vitro half-life, which is not ideal. Ligand B (-4.32) is better.
13. **Pgp:** Ligand A (0.014) has significantly lower P-gp efflux liability than Ligand B (0.127), which is a major advantage for bioavailability and potentially CNS exposure.
14. **Affinity:** Ligand B (-7.4) has a substantially stronger binding affinity than Ligand A (-5.6), a difference of 1.8 kcal/mol. This is a crucial factor.
**Overall Assessment:**
While Ligand A has better Pgp efflux liability and slightly better DILI, Ligand B overwhelmingly wins due to its superior logP, TPSA, QED, and *significantly* stronger binding affinity. The better affinity is the most important factor, and the improved logP and TPSA are also critical for a GPCR target. The slightly higher Pgp efflux is a manageable concern compared to the other benefits.
Output:
0
2025-04-17 20:46:51,392 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (350.478 Da and 348.447 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (49.41) is significantly better than Ligand B (85.77). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is quite high, potentially hindering absorption.
**3. logP:** Ligand A (3.572) is within the optimal 1-3 range. Ligand B (0.199) is *very* low, which is a major concern. Low logP often translates to poor membrane permeability and bioavailability.
**4. H-Bond Donors:** Both have acceptable HBD counts (1 and 2 respectively), well below the threshold of 5.
**5. H-Bond Acceptors:** Ligand A (2) is better than Ligand B (5), but both are acceptable.
**6. QED:** Both ligands have similar and good QED values (0.727 and 0.735), indicating good drug-like properties.
**7. DILI:** Both ligands have low DILI risk (17.449 and 16.44), which is positive.
**8. BBB:** Ligand A (89.027) has a much better BBB penetration score than Ligand B (28.655). While ADRB2 is a cardiovascular target, some CNS exposure is not necessarily detrimental and a higher BBB score is generally preferable.
**9. Caco-2 Permeability:** Ligand A (-4.388) is better than Ligand B (-5.09), indicating better intestinal absorption.
**10. Aqueous Solubility:** Ligand A (-3.879) is better than Ligand B (-0.193).
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.316 and 0.244).
**12. Microsomal Clearance:** Ligand B (-20.557) has a much lower (better) microsomal clearance than Ligand A (65.527), suggesting greater metabolic stability.
**13. In vitro Half-Life:** Ligand A (16.706) has a better in vitro half-life than Ligand B (4.664).
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.178 and 0.013).
**15. Binding Affinity:** Ligand B (-6.5) has a slightly better binding affinity than Ligand A (-6.2), but the difference is not substantial enough to outweigh the other significant drawbacks.
**Overall Assessment:**
Ligand B has a better binding affinity and metabolic stability. However, its extremely low logP and high TPSA are major red flags. These properties are likely to severely limit its oral bioavailability and cellular permeability. Ligand A, while having slightly weaker affinity and higher clearance, presents a much more balanced profile with acceptable logP, TPSA, solubility, and BBB penetration. For a GPCR, optimizing permeability and achieving reasonable systemic exposure are critical.
Therefore, I believe Ligand A is the more viable drug candidate.
Output:
1
2025-04-17 20:46:51,392 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.46 and 352.48 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (76.66) is significantly better than Ligand B (99.33). For a GPCR, keeping TPSA low is beneficial for permeability, and A is well below the 140 threshold.
3. **logP:** Both ligands have good logP values (1.53 and 1.29), falling within the optimal 1-3 range. Ligand B is slightly lower, which could potentially affect permeability, but it's not a major concern.
4. **HBD:** Ligand A (2) is preferable to Ligand B (4). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is slightly better than Ligand B (3). Both are within the acceptable range.
6. **QED:** Ligand A (0.696) has a better QED score than Ligand B (0.477), indicating a more drug-like profile.
7. **DILI:** Ligand A (15.24) has a significantly lower DILI risk than Ligand B (28.89). This is a crucial advantage.
8. **BBB:** Ligand B (70.92) has a slightly better BBB penetration percentile than Ligand A (66.81). While ADRB2 isn't necessarily a CNS target, some degree of BBB penetration isn't detrimental and could open up potential for other indications.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.94 and -5.20) which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Both ligands have very poor aqueous solubility (-2.31 and -2.48). This is a major drawback for both, and would require significant formulation work.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.39 and 0.14). This is good.
12. **Cl_mic:** Ligand A (27.04) has lower microsomal clearance than Ligand B (32.98), suggesting better metabolic stability.
13. **t1/2:** Ligand A (23.12) has a longer in vitro half-life than Ligand B (-4.39). This is a significant advantage.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.014 and 0.028). This is favorable.
15. **Binding Affinity:** Ligand A (-6.6 kcal/mol) has a slightly better binding affinity than Ligand B (-5.9 kcal/mol). While the difference isn't huge, it's enough to be considered.
**Overall Assessment:**
Ligand A is the stronger candidate. It has a better QED score, significantly lower DILI risk, better metabolic stability (lower Cl_mic, longer t1/2), and slightly better binding affinity. While both have poor solubility and Caco-2 permeability, the other advantages of Ligand A outweigh the slightly better BBB penetration of Ligand B. The poor permeability and solubility would need to be addressed through formulation strategies for either compound.
Output:
1
2025-04-17 20:46:51,392 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.4 and 339.4 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (103.0 and 98.98) are below the 140 A^2 threshold for good oral absorption, but not optimized for CNS penetration (which would require <90). Again, no major difference.
3. **logP:** Ligand A (0.583) is lower than Ligand B (1.056). While both are within the acceptable range, Ligand B is closer to the optimal 1-3 range. This is a slight advantage for B.
4. **HBD:** Ligand A (3) is higher than Ligand B (1). Lower HBD is generally preferred for permeability, giving a slight edge to B.
5. **HBA:** Both ligands have 5 HBA, which is acceptable.
6. **QED:** Ligand B (0.887) has a higher QED score than Ligand A (0.739), indicating a more drug-like profile. This is a notable advantage for B.
7. **DILI:** Ligand A (34.2%) has a significantly lower DILI risk than Ligand B (43.9%). This is a substantial advantage for A.
8. **BBB:** Ligand B (41.1%) has a higher BBB penetration percentile than Ligand A (25.8%). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be helpful for broader distribution and potentially off-target effects. This is a slight advantage for B.
9. **Caco-2:** Both ligands have very similar, and poor, Caco-2 permeability scores (-5.221 and -5.228). This indicates potential absorption issues for both.
10. **Solubility:** Both ligands have poor solubility scores (-1.232 and -1.663). This is a concern for both, and may require formulation strategies.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.135 and 0.174), which is excellent. No difference here.
12. **Cl_mic:** Ligand A (-14.313) has a lower (better) microsomal clearance than Ligand B (-8.28). This suggests better metabolic stability for A.
13. **t1/2:** Ligand A (20.684 hours) has a significantly longer in vitro half-life than Ligand B (5.72 hours). This is a major advantage for A, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.036 and 0.004), which is good.
15. **Binding Affinity:** Ligand A (-7.7 kcal/mol) has a slightly better binding affinity than Ligand B (-6.7 kcal/mol). This 1.0 kcal/mol difference is significant and can outweigh some ADME drawbacks.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand B has a slightly better logP and BBB, but Ligand A excels in affinity, DILI risk, and metabolic stability (Cl_mic and t1/2). The higher affinity and lower DILI risk of Ligand A are more critical for a successful drug candidate.
**Conclusion:**
Considering the balance of properties, particularly the superior binding affinity, lower DILI risk, and longer half-life of Ligand A, I believe it is the more promising drug candidate.
Output:
1
2025-04-17 20:46:51,392 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.391 and 378.441 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (132.99) is slightly higher than Ligand B (78.87). For a cardiovascular GPCR, TPSA is not a major concern unless aiming for CNS penetration, but lower is generally preferred for absorption. Ligand B is better here.
3. **logP:** Ligand A (1.627) is within the optimal range (1-3), while Ligand B (0.489) is a bit low. Lower logP can lead to poor membrane permeability. Ligand A is better.
4. **HBD:** Both ligands have 2 HBD, which is acceptable.
5. **HBA:** Both ligands have 5 HBA, which is acceptable.
6. **QED:** Ligand B (0.703) has a significantly better QED score than Ligand A (0.441), indicating a more drug-like profile. Ligand B is better.
7. **DILI:** Ligand B (35.285) has a lower DILI risk than Ligand A (41.062), which is preferable. Ligand B is better.
8. **BBB:** Ligand B (82.862) has a much higher BBB percentile than Ligand A (56.805). While ADRB2 isn't necessarily a CNS target, higher BBB is generally a positive attribute, suggesting better distribution. Ligand B is better.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale isn't specified, so it's hard to interpret.
10. **Solubility:** Both ligands have negative solubility values, which is also unusual and suggests poor solubility. Again, the scale isn't specified.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.096 and 0.323), which is excellent. No significant difference.
12. **Cl_mic:** Ligand A (22.967) has a higher microsomal clearance than Ligand B (14.973), indicating faster metabolism and potentially lower *in vivo* exposure. Ligand B is better.
13. **t1/2:** Ligand B (-14.348) has a negative in vitro half-life, which is concerning. Ligand A (21.503) has a reasonable half-life. Ligand A is better.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.039 and 0.03), which is excellent. No significant difference.
15. **Binding Affinity:** Ligand B (-6.5) has slightly better binding affinity than Ligand A (-6.4), but the difference is minimal (0.1 kcal/mol).
**Overall Assessment & GPCR Prioritization:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A has a better logP and in vitro half-life, but Ligand B excels in TPSA, QED, DILI, BBB, and has slightly better affinity. The significantly better QED, DILI, and BBB scores of Ligand B are compelling. The slightly lower logP of Ligand B is a concern, but not a deal-breaker given the other advantages. The negative half-life of Ligand B is a major concern, however.
Considering the balance, I lean towards Ligand A due to its better half-life and acceptable properties overall.
**Output:**
1
2025-04-17 20:46:51,392 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [372.487, 104.73 , 1.318, 3. , 5. , 0.574, 25.514, 53.509, -4.888, -1.202, 0.493, 20.207, 19.377, 0.118, -6.1 ]
**Ligand B:** [348.443, 76.66 , 1.307, 2. , 4. , 0.374, 36.603, 58.085, -5.009, -2.396, 0.292, 16.968, -4.566, 0.167, -6.3 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (348.443) is slightly lower, which could be a minor advantage for permeability.
2. **TPSA:** Ligand A (104.73) is higher than Ligand B (76.66). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is generally better for absorption. Ligand B is significantly better here.
3. **logP:** Both ligands have excellent logP values (around 1.3), falling squarely within the optimal 1-3 range. No significant difference.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (2), but both are acceptable.
5. **HBA:** Ligand A (5) is slightly higher than Ligand B (4), but both are acceptable.
6. **QED:** Ligand A (0.574) is better than Ligand B (0.374), indicating a more drug-like profile. This is a notable advantage.
7. **DILI:** Ligand A (25.514) has a significantly lower DILI risk than Ligand B (36.603). This is a major advantage for Ligand A.
8. **BBB:** Both have moderate BBB penetration (Ligand A: 53.509, Ligand B: 58.085). Since this is a cardiovascular target, BBB penetration is not a primary concern.
9. **Caco-2:** Ligand A (-4.888) is better than Ligand B (-5.009), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-1.202) is better than Ligand B (-2.396). Solubility is important for bioavailability.
11. **hERG:** Both ligands have low hERG inhibition risk (Ligand A: 0.493, Ligand B: 0.292). Ligand B is slightly better.
12. **Cl_mic:** Ligand B (16.968) has lower microsomal clearance than Ligand A (20.207), suggesting better metabolic stability. This is a positive for Ligand B.
13. **t1/2:** Ligand A (19.377) has a longer in vitro half-life than Ligand B (-4.566). This is a significant advantage for Ligand A, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have low P-gp efflux liability (Ligand A: 0.118, Ligand B: 0.167). No significant difference.
15. **Affinity:** Ligand B (-6.3) has slightly better binding affinity than Ligand A (-6.1). While a difference of 0.2 kcal/mol isn't huge, it's a positive for Ligand B.
**Overall Assessment:**
Ligand A demonstrates a better overall profile, particularly regarding safety (DILI), drug-likeness (QED), solubility, and metabolic stability (t1/2). While Ligand B has slightly better affinity and lower clearance, the advantages of Ligand A in crucial areas like DILI and QED outweigh these minor benefits. For a cardiovascular GPCR, a slightly lower affinity can be tolerated if the compound is safer and has better pharmacokinetic properties.
Output:
1
2025-04-17 20:46:51,392 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the acceptable range (200-500 Da). Ligand A (415.288 Da) is slightly higher than Ligand B (353.495 Da), but this isn't a major concern.
**2. TPSA:** Ligand A (84.0) is better than Ligand B (62.73). Both are well below the 140 threshold for oral absorption.
**3. logP:** Ligand A (1.737) is optimal, while Ligand B (4.751) is pushing the upper limit and could present solubility issues. This is a significant advantage for Ligand A.
**4. H-Bond Donors:** Ligand A (1) is preferable to Ligand B (2).
**5. H-Bond Acceptors:** Ligand A (5) is preferable to Ligand B (6).
**6. QED:** Ligand A (0.81) is better than Ligand B (0.693), indicating a more drug-like profile.
**7. DILI:** Both ligands have relatively high DILI risk (Ligand A: 73.052, Ligand B: 77.549). This is a concern for both, but not a deciding factor between them.
**8. BBB:** Both ligands have good BBB penetration (Ligand A: 68.67, Ligand B: 73.866). Since ADRB2 is a cardiovascular target, BBB penetration isn't a primary concern, but it's not detrimental.
**9. Caco-2 Permeability:** Ligand A (-4.399) is better than Ligand B (-5.255), indicating better intestinal absorption.
**10. Aqueous Solubility:** Ligand A (-2.453) is better than Ligand B (-4.742). This is important for bioavailability.
**11. hERG Inhibition:** Ligand A (0.295) is significantly better than Ligand B (0.633), indicating a lower risk of cardiotoxicity. This is a crucial consideration for a cardiovascular target.
**12. Microsomal Clearance:** Ligand A (28.646) is much better than Ligand B (90.875), suggesting greater metabolic stability.
**13. In vitro Half-Life:** Ligand A (-13.954) is much better than Ligand B (59.643), indicating a longer half-life.
**14. P-gp Efflux:** Ligand A (0.039) is much better than Ligand B (0.46), indicating lower P-gp efflux.
**15. Binding Affinity:** Ligand B (-6.4 kcal/mol) has a slightly better binding affinity than Ligand A (-5.1 kcal/mol). However, the difference is not substantial enough to outweigh the numerous advantages of Ligand A.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical ADME properties (logP, solubility, hERG, clearance, half-life, P-gp efflux) and has a better QED score. While Ligand B has slightly better binding affinity, the superior ADME profile of Ligand A makes it a more promising drug candidate, especially considering the cardiovascular target. The lower hERG risk for Ligand A is particularly important.
Output:
1
2025-04-17 20:46:51,392 - INFO - Batch 210 complete. Total preferences: 3360
2025-04-17 20:46:51,393 - INFO - Processing batch 211/512...
2025-04-17 20:47:39,119 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (373.475 and 349.475 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand B (82.53) is significantly better than Ligand A (96.97). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (1.883 and 2.548), falling within the 1-3 range. Ligand B is slightly better.
4. **HBD:** Both have 2 HBD, which is acceptable.
5. **HBA:** Ligand B (4) is slightly better than Ligand A (5), keeping within the desirable range.
6. **QED:** Both ligands have good QED scores (0.611 and 0.718), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand B (35.595) has a much lower DILI risk than Ligand A (63.164). This is a significant advantage, as liver toxicity is a major concern.
8. **BBB:** Ligand A (74.486) has a better BBB penetration score than Ligand B (54.285). However, as ADRB2 is a cardiovascular target, BBB penetration is not a high priority.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand B (-4.537) is slightly less negative than Ligand A (-5.103).
10. **Solubility:** Both have negative solubility values, indicating poor aqueous solubility. Ligand B (-2.346) is slightly better than Ligand A (-2.057).
11. **hERG:** Both ligands have low hERG inhibition liability (0.578 and 0.435), which is good. Ligand B is slightly better.
12. **Cl_mic:** Ligand A (20.782) has a significantly lower microsomal clearance than Ligand B (57.291), suggesting better metabolic stability. This is a substantial advantage.
13. **t1/2:** Ligand B (21.16) has a longer in vitro half-life than Ligand A (-25.346). This is a significant advantage.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.062 and 0.08), which is good.
15. **Binding Affinity:** Ligand B (-6.5 kcal/mol) has a significantly stronger binding affinity than Ligand A (-4.8 kcal/mol). This is a major advantage, outweighing some of the ADME drawbacks of Ligand A.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP, TPSA, and *especially* affinity. While Ligand A has better metabolic stability (Cl_mic), the substantial affinity advantage of Ligand B is more important. The lower DILI risk for Ligand B is also a major positive.
**Conclusion:**
Despite Ligand A's better metabolic stability, Ligand B's superior binding affinity, lower DILI risk, and better overall ADME profile (lower TPSA, slightly better logP, solubility, and hERG) make it the more promising drug candidate for the ADRB2 receptor.
Output:
0
2025-04-17 20:47:39,119 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.494 and 341.415 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (40.62) is significantly better than Ligand B (88.08). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold, while B is approaching it.
3. **logP:** Ligand A (3.402) is optimal, while Ligand B (1.553) is on the lower side. While not terrible, lower logP can sometimes hinder permeability.
4. **HBD:** Both ligands have acceptable HBD counts (0 for A, 1 for B), well within the limit of 5.
5. **HBA:** Ligand A (2) is better than Ligand B (5). Lower HBA is generally preferred for permeability.
6. **QED:** Both ligands have good QED scores (0.659 and 0.861), indicating good drug-like properties.
7. **DILI:** Ligand A (8.181) has a much lower DILI risk than Ligand B (57.154). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (96.161) has a much higher BBB penetration potential than Ligand B (57.736). While not crucial for a cardiovascular target, it's a bonus.
9. **Caco-2:** Both have negative values, which is unusual. Assuming these are log scale values, they are similar and indicate poor permeability.
10. **Solubility:** Ligand A (-3.324) and Ligand B (-2.302) both have poor solubility.
11. **hERG:** Ligand A (0.909) has a slightly higher hERG risk than Ligand B (0.217). This is a slight negative for Ligand A, but not a major concern given the other factors.
12. **Cl_mic:** Ligand B (40.767) has lower microsomal clearance than Ligand A (61.996), suggesting better metabolic stability.
13. **t1/2:** Ligand B (24.672) has a significantly longer in vitro half-life than Ligand A (-17.794). This is a substantial advantage for Ligand B.
14. **Pgp:** Ligand A (0.681) has lower P-gp efflux than Ligand B (0.068), indicating better bioavailability.
15. **Affinity:** Ligand B (-7.3) has a significantly stronger binding affinity than Ligand A (-5.3). A 2 kcal/mol difference is substantial and can often outweigh other drawbacks.
**GPCR-Specific Considerations:**
For GPCRs, logP, TPSA, Pgp, and affinity are key. Ligand B has a better logP, Pgp, and *much* better affinity. Ligand A has a better TPSA. The superior affinity of Ligand B is a strong driver.
**Overall Assessment:**
While Ligand A has advantages in TPSA, DILI risk, and BBB penetration, Ligand B's significantly stronger binding affinity (-7.3 vs -5.3 kcal/mol) and longer half-life are compelling. The lower DILI risk of A is attractive, but the potency advantage of B is likely to be more impactful. The lower hERG risk of B is also a plus. The slightly lower logP and higher TPSA of B are manageable.
Output:
0
2025-04-17 20:47:39,119 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.5 & 342.4 Da) fall comfortably within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (52.65) is better than Ligand B (58.44). Both are below the 140 threshold for oral absorption, but lower is preferred for GPCRs.
3. **logP:** Both ligands (1.873 & 1.546) are within the optimal 1-3 range. Ligand B is slightly lower, which *could* be a minor disadvantage for membrane permeability, but both are acceptable.
4. **HBD:** Ligand A (1) is preferable to Ligand B (0). While both are low, having one HBD can sometimes improve solubility without significantly impacting permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (4). Lower HBA is generally better for permeability.
6. **QED:** Both ligands (0.747 & 0.763) have excellent QED scores, indicating good drug-like properties. No significant difference.
7. **DILI:** Ligand A (23.071) is significantly better than Ligand B (29.934). Lower DILI risk is crucial. This is a notable advantage for Ligand A.
8. **BBB:** Both ligands have good BBB penetration (70.88% & 73.401%). This is important for GPCRs, and the difference is minimal.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.772 & -4.676). This is unusual and suggests poor permeability. However, the values are very close.
10. **Solubility:** Ligand A (-2.048) is slightly better than Ligand B (-1.385), indicating better aqueous solubility.
11. **hERG:** Ligand A (0.533) is better than Ligand B (0.142). Lower hERG inhibition is critical for avoiding cardiotoxicity, a major concern with cardiovascular targets.
12. **Cl_mic:** Ligand A (9.366) is *much* better than Ligand B (39.296). Lower microsomal clearance means greater metabolic stability, a significant advantage.
13. **t1/2:** Ligand A (-6.414) is better than Ligand B (-8.227). Longer half-life is generally desirable.
14. **Pgp:** Ligand A (0.087) is better than Ligand B (0.1). Lower P-gp efflux is preferred.
15. **Binding Affinity:** Ligand A (-7.4) is significantly better than Ligand B (-6.0). A 1.4 kcal/mol difference in binding affinity is substantial and can often outweigh minor ADME drawbacks.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical parameters. The most significant advantages for Ligand A are its substantially lower DILI risk, much better metabolic stability (lower Cl_mic), superior binding affinity, and lower hERG inhibition. While both ligands have similar BBB penetration and acceptable logP values, the ADME and safety profile of Ligand A is clearly superior. The negative Caco-2 values are concerning for both, but the overall balance of properties favors Ligand A.
Output:
1
2025-04-17 20:47:39,119 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (342.483 and 342.399 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (40.62) is significantly better than Ligand B (88.32). ADRB2 is a cardiovascular target, not CNS, but lower TPSA generally aids absorption. Ligand A is well below the 140 threshold. Ligand B is approaching a level that could hinder absorption.
3. **logP:** Both ligands (2.674 and 2.109) are within the optimal 1-3 range. Ligand B is slightly lower, which *could* be a minor drawback, but both are acceptable.
4. **HBD:** Ligand A (0) is preferable to Ligand B (1). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (2) is preferable to Ligand B (5). Fewer HBAs also generally improve permeability.
6. **QED:** Both ligands have good QED scores (0.74 and 0.832), indicating good drug-like properties. No significant difference.
7. **DILI:** Ligand A (5.971) has a significantly lower DILI risk than Ligand B (73.09). This is a major advantage for Ligand A.
8. **BBB:** Not a primary concern for a cardiovascular target like ADRB2, but Ligand A (76.309) is better than Ligand B (55.138).
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.581 and -4.971). These values are unusual and suggest poor permeability. However, the values are very close.
10. **Solubility:** Ligand A (-3.45) is better than Ligand B (-2.268), indicating higher aqueous solubility.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.349 and 0.004). No significant difference.
12. **Cl_mic:** Ligand B (14.95) has a lower microsomal clearance than Ligand A (24.944), suggesting better metabolic stability. This is a positive for Ligand B.
13. **t1/2:** Ligand B (-35.061) has a much longer in vitro half-life than Ligand A (-10.967). This is a significant advantage for Ligand B.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.061 and 0.018). No significant difference.
15. **Binding Affinity:** Ligand B (-8.9) has a significantly stronger binding affinity than Ligand A (-6.0). This is a substantial advantage for Ligand B. A difference of >1.5 kcal/mol is considered quite significant.
**Overall Assessment:**
While Ligand B has a superior binding affinity and better metabolic stability (lower Cl_mic, longer t1/2), Ligand A excels in several key ADME properties. Specifically, the significantly lower DILI risk and better TPSA, HBD, and HBA values for Ligand A are compelling. The negative Caco-2 values are concerning for both, but the other advantages of Ligand A, particularly the DILI risk, outweigh the affinity difference. For a cardiovascular target, minimizing off-target effects and maximizing safety is crucial. The stronger binding of Ligand B could potentially be optimized later, but mitigating a high DILI risk is more challenging.
Output:
1
2025-04-17 20:47:39,120 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (359.455 and 363.531 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (88.08) is higher than Ligand B (56.07). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B is better here.
3. **logP:** Both ligands have good logP values (2.69 and 2.238), falling within the optimal 1-3 range. Ligand B is slightly lower, which could be beneficial for solubility.
4. **HBD:** Ligand A (1) is better than Ligand B (0). Having at least one HBD can improve solubility.
5. **HBA:** Ligand A (6) is lower than Ligand B (7). Lower HBA is generally preferred for permeability. Ligand A is better.
6. **QED:** Ligand A (0.887) has a significantly higher QED score than Ligand B (0.495), indicating a more drug-like profile. This is a substantial advantage for Ligand A.
7. **DILI:** Ligand A (76.735) has a higher DILI risk than Ligand B (15.51). This is a significant drawback for Ligand A. Ligand B is much better.
8. **BBB:** Ligand A (66.499) has lower BBB penetration than Ligand B (83.831). While ADRB2 isn't a primary CNS target, some degree of BBB penetration isn't necessarily detrimental and could offer some off-target effects. Ligand B is better.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.093 and -5.135), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Both ligands have very poor aqueous solubility (-3.079 and -3.143). This is a major issue for both candidates.
11. **hERG:** Ligand A (0.226) has a lower hERG inhibition liability than Ligand B (0.511), which is a positive for Ligand A.
12. **Cl_mic:** Ligand A (23.974) has a lower microsomal clearance than Ligand B (31.272), indicating better metabolic stability. This is a positive for Ligand A.
13. **t1/2:** Ligand A (2.803) has a longer in vitro half-life than Ligand B (-10.675). A negative half-life is highly unusual and concerning for Ligand B. This is a major advantage for Ligand A.
14. **Pgp:** Ligand A (0.034) has lower P-gp efflux liability than Ligand B (0.292). This is a positive for Ligand A.
15. **Binding Affinity:** Ligand A (-6.8 kcal/mol) has a significantly stronger binding affinity than Ligand B (-1.7 kcal/mol). This is a substantial advantage for Ligand A, and can potentially outweigh some of the ADME drawbacks.
**Overall Assessment:**
Ligand A has a much stronger binding affinity, better QED, lower Pgp efflux, lower hERG, and better metabolic stability (lower Cl_mic) and half-life. However, it has a higher DILI risk. Ligand B has a lower DILI risk, better BBB penetration, and a slightly lower logP, but suffers from a significantly weaker binding affinity and a negative in vitro half-life.
Given the importance of potency for GPCR targets, and the substantial difference in binding affinity (-6.8 vs -1.7 kcal/mol), I believe Ligand A is the more promising candidate, despite the higher DILI risk. The DILI risk can be investigated further with additional studies and potentially mitigated through structural modifications. The extremely weak binding of Ligand B is a major hurdle that is unlikely to be overcome with further optimization.
Output:
1
2025-04-17 20:47:39,120 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (337.419 and 348.418 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (46.61) is well below the 140 threshold and good for oral absorption. Ligand B (69.64) is still acceptable, but less optimal. This favors A.
3. **logP:** Ligand A (3.759) is at the higher end of the optimal range (1-3), but still acceptable. Ligand B (2.016) is lower, potentially impacting permeability. This favors A.
4. **HBD:** Ligand A (0) is excellent, minimizing potential issues with hydrogen bonding. Ligand B (2) is acceptable, but A is better.
5. **HBA:** Both ligands have 3 HBA, which is within the acceptable range. No significant difference.
6. **QED:** Both ligands have good QED scores (0.784 and 0.878), indicating good drug-like properties. No significant difference.
7. **DILI:** Ligand A (69.135) has a higher DILI risk than Ligand B (38.697). This strongly favors B.
8. **BBB:** Ligand A (70.609) has slightly better BBB penetration than Ligand B (66.731), but both are reasonable. Given ADRB2's cardiovascular focus, BBB isn't a *critical* factor, but it's a slight advantage for A.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-5.547) has worse solubility than Ligand B (-2.45). This favors B.
11. **hERG:** Both ligands have low hERG inhibition risk (0.695 and 0.554). No significant difference.
12. **Cl_mic:** Ligand A (121.842) has higher microsomal clearance than Ligand B (-1.661), indicating lower metabolic stability. This favors B.
13. **t1/2:** Ligand A (5.729) has a longer half-life than Ligand B (2.551). This favors A.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.46 and 0.151). No significant difference.
15. **Binding Affinity:** Ligand A (-7.1) has a significantly stronger binding affinity than Ligand B (-6.8). This is a substantial advantage for A, potentially outweighing some of the ADME drawbacks.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, and affinity. Ligand A excels in logP and affinity, while Ligand B has better TPSA and DILI. The affinity difference is significant (0.3 kcal/mol), and the DILI risk for Ligand A, while elevated, is not extremely high. The better solubility of Ligand B is also a plus. However, the stronger binding of Ligand A is a crucial advantage for a GPCR target.
**Overall Assessment:**
While Ligand B has a better safety profile (DILI) and solubility, Ligand A's significantly stronger binding affinity and acceptable logP/TPSA profile make it the more promising candidate. The slightly higher DILI risk can be investigated further through structural modifications, but a strong starting affinity is hard to recover.
Output:
1
2025-04-17 20:47:39,120 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (335.363 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (72.88) is better than Ligand A (88.19). Both are under 140, but lower TPSA is preferred for oral absorption, especially for GPCRs.
3. **logP:** Ligand A (3.584) is slightly higher than Ligand B (1.297). While both are within the optimal range, Ligand B is closer to the lower bound which could impact permeability.
4. **HBD:** Ligand A (1) is better than Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (5) is better than Ligand B (4). Fewer HBAs generally improve permeability.
6. **QED:** Both ligands have similar QED values (0.666 and 0.678), indicating good drug-likeness.
7. **DILI:** Ligand B (8.026) is *significantly* better than Ligand A (67.003). This is a major advantage for Ligand B. DILI is a critical factor in drug development.
8. **BBB:** Ligand A (82.319) is better than Ligand B (57.193). While ADRB2 isn't necessarily a CNS target, some peripheral ADRB2 activity can be modulated by CNS effects, and higher BBB penetration is generally a plus.
9. **Caco-2:** Both ligands have very poor Caco-2 permeability (-4.853 and -4.831). This is a significant concern for oral bioavailability for both.
10. **Solubility:** Ligand B (-0.643) is better than Ligand A (-6.178). Better solubility is always desirable.
11. **hERG:** Ligand A (0.856) is better than Ligand B (0.105). Lower hERG inhibition is crucial for avoiding cardiotoxicity, particularly important for a cardiovascular target like ADRB2.
12. **Cl_mic:** Ligand B (8.506) is much better than Ligand A (37.399). Lower clearance indicates greater metabolic stability.
13. **t1/2:** Ligand A (17.044) is much better than Ligand B (-16.083). A longer half-life is generally preferred.
14. **Pgp:** Ligand A (0.396) is better than Ligand B (0.012). Lower P-gp efflux is favorable for bioavailability.
15. **Affinity:** Ligand A (-6.8 kcal/mol) is slightly better than Ligand B (-6.0 kcal/mol). This difference is not substantial enough to outweigh other factors.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has a better logP and Pgp, and slightly better affinity. However, the *dramatic* improvement in DILI risk and metabolic stability (Cl_mic) for Ligand B, along with better solubility, are far more important. The poor Caco-2 values for both are a concern, but can potentially be addressed with formulation strategies. The hERG risk is also a concern for Ligand B, but is not as severe as the DILI risk for Ligand A.
**Conclusion:**
Despite Ligand A having a slightly better affinity and BBB penetration, the significantly lower DILI risk and improved metabolic stability of Ligand B make it the more promising drug candidate. The benefits of mitigating potential liver toxicity and improving metabolic stability outweigh the minor differences in affinity and BBB penetration.
Output:
0
2025-04-17 20:47:39,120 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [354.401, 70.39, 1.948, 2, 4, 0.853, 38.813, 85.847, -4.613, -2.529, 0.291, 15.735, 10.578, 0.054, -6.8]
**Ligand B:** [341.455, 71.09, 2.669, 2, 3, 0.617, 39.318, 63.125, -5.028, -2.304, 0.173, 41.978, -7.113, 0.128, -5.2]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (341.455) is slightly lower, which is generally favorable.
2. **TPSA:** Both are reasonably good (70.39 and 71.09), but slightly above the optimal <90 for CNS targets (less relevant here as it's cardiovascular).
3. **logP:** Both are within the optimal 1-3 range. Ligand B (2.669) is slightly higher, potentially leading to some off-target interactions, but not drastically.
4. **HBD:** Both have 2 HBD, which is good.
5. **HBA:** Ligand A has 4 HBA, Ligand B has 3. Both are acceptable.
6. **QED:** Ligand A (0.853) has a significantly better QED score than Ligand B (0.617), indicating a more drug-like profile.
7. **DILI:** Both have low DILI risk (38.813 and 39.318), which is excellent.
8. **BBB:** Ligand A (85.847) has a much higher BBB penetration score than Ligand B (63.125). While not a primary concern for a cardiovascular target, higher BBB is rarely detrimental.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand B (-5.028) is slightly worse than Ligand A (-4.613).
10. **Solubility:** Both have negative solubility values, which is also unusual and suggests poor solubility. Ligand B (-2.304) is slightly worse than Ligand A (-2.529).
11. **hERG:** Both have very low hERG risk (0.291 and 0.173).
12. **Cl_mic:** Ligand A (15.735) has a much lower microsomal clearance than Ligand B (41.978), indicating better metabolic stability.
13. **t1/2:** Ligand B (-7.113) has a negative in vitro half-life, which is highly problematic. Ligand A (10.578) is good.
14. **Pgp:** Both have low Pgp efflux liability (0.054 and 0.128).
15. **Affinity:** Ligand A (-6.8 kcal/mol) has a slightly better binding affinity than Ligand B (-5.2 kcal/mol), although both are good.
**GPCR-specific priorities:** For ADRB2 (a cardiovascular GPCR), we prioritize logP, Pgp, TPSA, and affinity. Ligand A is better in all of these except logP, where Ligand B is slightly better. However, the significantly better QED, metabolic stability (Cl_mic), and *especially* the positive in vitro half-life of Ligand A are major advantages. The negative half-life for Ligand B is a critical flaw.
**Conclusion:**
Ligand A is the more promising candidate due to its superior drug-like properties (QED), metabolic stability, half-life, and binding affinity. The slightly better logP of Ligand B is not enough to overcome these significant drawbacks.
1
2025-04-17 20:47:39,120 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [349.439, 95.39, -1.054, 2, 7, 0.552, 34.161, 52.889, -5.464, -0.946, 0.148, 18.443, 11.965, 0.006, -5.8]
**Ligand B:** [370.475, 107.94, 0.209, 2, 5, 0.697, 59.907, 61.38, -5.368, -3.075, 0.157, 33.193, -16.241, 0.031, -5.2]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity) and general drug-like properties:
1. **MW:** Both are within the ideal 200-500 Da range. Ligand A (349.439 Da) is slightly preferred.
2. **TPSA:** Ligand A (95.39) is better than Ligand B (107.94). Both are acceptable for a non-CNS GPCR like ADRB2, being under 140, but lower is generally better for permeability.
3. **logP:** Ligand A (-1.054) is a bit low, potentially hindering permeability. Ligand B (0.209) is better, falling within the optimal 1-3 range. This is a significant advantage for Ligand B.
4. **HBD:** Both have 2 HBD, which is good.
5. **HBA:** Ligand A has 7 HBA, Ligand B has 5. Both are acceptable.
6. **QED:** Both have good QED scores (A: 0.552, B: 0.697), indicating drug-likeness. Ligand B is slightly better.
7. **DILI:** Ligand A (34.161) has a much lower DILI risk than Ligand B (59.907). This is a major advantage for Ligand A.
8. **BBB:** BBB is less critical for a cardiovascular target. Both are relatively low, which is fine.
9. **Caco-2:** Both have negative values, indicating poor permeability.
10. **Solubility:** Ligand A (-0.946) is slightly better than Ligand B (-3.075), but both are poor.
11. **hERG:** Both are very low, indicating minimal hERG inhibition risk.
12. **Cl_mic:** Ligand A (18.443) has significantly lower microsomal clearance than Ligand B (33.193), suggesting better metabolic stability.
13. **t1/2:** Ligand A (11.965) has a positive in vitro half-life, while Ligand B (-16.241) has a negative half-life. This is a major advantage for Ligand A.
14. **Pgp:** Both have very low Pgp efflux liability.
15. **Affinity:** Both have excellent binding affinities (-5.8 and -5.2 kcal/mol). Ligand A is slightly better.
**Overall Assessment:**
While Ligand B has a better logP and QED, Ligand A demonstrates superior safety (DILI), metabolic stability (Cl_mic, t1/2), and a slightly better binding affinity. The lower DILI risk and improved metabolic profile are crucial for a successful drug candidate, especially considering the cardiovascular context where long-term safety is paramount. The slightly lower logP of Ligand A is a concern, but could potentially be addressed with further optimization.
Therefore, I favor Ligand A.
Output:
1
2025-04-17 20:47:39,120 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [358.507, 58.2, 4.085, 2, 3, 0.747, 52.966, 64.831, -5.14, -4.15, 0.731, 78.19, 77.335, 0.518, -6.7]**
**Ligand B: [349.475, 61.88, 1.006, 1, 4, 0.664, 5.312, 65.297, -4.96, -1.156, 0.328, -12.736, -19.681, 0.019, -7.2]**
1. **Molecular Weight:** Both are within the ideal range (200-500 Da). Ligand A (358.5) is slightly higher than Ligand B (349.5). No significant difference.
2. **TPSA:** Both are reasonably low, suggesting good absorption potential. Ligand A (58.2) is better than Ligand B (61.88), being closer to the <140 threshold.
3. **logP:** Ligand A (4.085) is higher than Ligand B (1.006). While 4.085 is approaching the upper limit, it's still acceptable. Ligand B is quite low, which might hinder permeability.
4. **H-Bond Donors:** Ligand A (2) and Ligand B (1) are both good.
5. **H-Bond Acceptors:** Ligand A (3) and Ligand B (4) are both acceptable.
6. **QED:** Ligand A (0.747) is better than Ligand B (0.664), indicating a more drug-like profile.
7. **DILI:** Ligand A (52.97) is significantly higher than Ligand B (5.312). This is a major concern for Ligand A.
8. **BBB:** Both are reasonably good, but Ligand B (65.297) is slightly better than Ligand A (64.831). Considering ADRB2 is a cardiovascular target, BBB penetration is not a primary concern, but still a positive.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-5.14) is worse than Ligand B (-4.96).
10. **Solubility:** Both are negative, indicating poor solubility. Ligand B (-1.156) is better than Ligand A (-4.15).
11. **hERG:** Ligand A (0.731) is better than Ligand B (0.328), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand A (78.19) is significantly higher than Ligand B (-12.736). This suggests Ligand B has better metabolic stability.
13. **t1/2:** Ligand A (77.335) is much better than Ligand B (-19.681).
14. **Pgp:** Ligand A (0.518) is better than Ligand B (0.019), suggesting lower efflux.
15. **Binding Affinity:** Ligand B (-7.2) has a slightly better binding affinity than Ligand A (-6.7). However, the difference is not huge.
**Overall Assessment:**
Ligand B is the better candidate despite the slightly lower affinity. The major advantage of Ligand B is its significantly lower DILI risk (5.312 vs 52.97). The better metabolic stability (lower Cl_mic, longer t1/2) and slightly better solubility also contribute to its favorability. While Ligand A has better Pgp and hERG profiles, the high DILI risk is a significant drawback. Given the cardiovascular target, metabolic stability and safety are paramount.
Output:
0
2025-04-17 20:47:39,120 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (381.885 Da) is slightly higher than Ligand B (348.399 Da), but both are acceptable.
**2. TPSA:** Ligand A (80.32) is better than Ligand B (92.01). For a cardiovascular GPCR, TPSA under 140 is good, and lower is generally preferred for better absorption.
**3. logP:** Ligand A (3.48) is optimal, while Ligand B (1.228) is on the lower side. While not a hard cutoff, lower logP can sometimes indicate permeability issues.
**4. H-Bond Donors:** Both ligands have 2 HBD, which is within the ideal range.
**5. H-Bond Acceptors:** Both ligands have 5 HBA, also within the ideal range.
**6. QED:** Both ligands have good QED scores (A: 0.686, B: 0.781), indicating good drug-like properties. Ligand B is slightly better here.
**7. DILI:** Ligand A (72.199) has a higher DILI risk than Ligand B (39.899). This is a significant negative for Ligand A.
**8. BBB:** Both are relatively low, which is expected for a cardiovascular target. Ligand A (61.962) is slightly better than Ligand B (42.42), but BBB isn't a high priority for a non-CNS target.
**9. Caco-2 Permeability:** Ligand A (-5.211) is better than Ligand B (-4.942). Higher values indicate better absorption.
**10. Aqueous Solubility:** Ligand A (-3.469) is better than Ligand B (-1.905). Higher values are preferred.
**11. hERG Inhibition:** Ligand A (0.443) is better than Ligand B (0.169), indicating lower cardiotoxicity risk.
**12. Microsomal Clearance:** Ligand B (-8.935) has a negative clearance, which is excellent, indicating very high metabolic stability. Ligand A (59.741) has a positive clearance, suggesting faster metabolism.
**13. In vitro Half-Life:** Ligand A (66.282) has a longer half-life than Ligand B (37.395).
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (A: 0.156, B: 0.053). Ligand B is slightly better.
**15. Binding Affinity:** Ligand A (-8.3 kcal/mol) has a significantly stronger binding affinity than Ligand B (-4.6 kcal/mol). This is a >1.5 kcal/mol difference, which is substantial.
**Overall Assessment:**
The key trade-offs are: Ligand A has much better binding affinity and a longer half-life, but a higher DILI risk. Ligand B has better metabolic stability (negative clearance) and lower DILI risk, but significantly weaker binding affinity.
Given that we're dealing with a GPCR, affinity is paramount. The substantial affinity difference (-8.3 vs -4.6 kcal/mol) of Ligand A is a major advantage that can likely be mitigated through further structural optimization to address the DILI risk. The better solubility and permeability of Ligand A also contribute positively. While DILI is a concern, it's often addressable in later stages of drug development. The weaker binding of Ligand B may be too difficult to overcome.
Therefore, I favor Ligand A.
Output:
1
2025-04-17 20:47:39,120 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's systematically compare Ligand A and Ligand B based on the provided parameters and the guidelines, keeping in mind that ADRB2 is a GPCR. Therefore, logP, TPSA, Pgp, BBB, and affinity are particularly important.
1. **MW:** Both ligands (370.877 and 358.473 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (67.87) is slightly higher than Ligand B (58.2). Both are below the 140 threshold for good oral absorption, but Ligand B is preferable due to being closer to the 90 threshold for potential CNS penetration, though this isn't a primary concern for ADRB2.
3. **logP:** Ligand A (1.964) is within the optimal 1-3 range. Ligand B (3.302) is at the higher end of the optimal range. This could potentially lead to some solubility issues, but isn't a dealbreaker.
4. **HBD/HBA:** Ligand A has 1 HBD and 4 HBA, while Ligand B has 2 HBD and 2 HBA. Both are within acceptable limits (<=5 HBD and <=10 HBA). Ligand B is slightly better in terms of HBA count.
5. **QED:** Both ligands have reasonably good QED scores (0.744 and 0.699, respectively), indicating good drug-like properties.
6. **DILI:** Ligand A (37.65) has a slightly higher DILI risk than Ligand B (16.402). This is a significant advantage for Ligand B.
7. **BBB:** Ligand B (89.259) has a much higher BBB percentile than Ligand A (69.135). While not crucial for ADRB2, it's a positive attribute.
8. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-5.033) is slightly worse than Ligand B (-4.616).
9. **Solubility:** Ligand A (-2.136) has better solubility than Ligand B (-3.752). This is a positive for Ligand A.
10. **hERG:** Ligand A (0.247) has a lower hERG risk than Ligand B (0.624). This is a significant advantage for Ligand A.
11. **Cl_mic:** Ligand B (38.794) has a higher microsomal clearance than Ligand A (28.167), indicating lower metabolic stability. This favors Ligand A.
12. **t1/2:** Ligand A (30.642) has a longer in vitro half-life than Ligand B (24.76), which is preferable.
13. **Pgp:** Ligand A (0.086) has lower P-gp efflux liability than Ligand B (0.116). This is slightly better for Ligand A.
14. **Affinity:** Both ligands have the same binding affinity (-7.9 kcal/mol), which is excellent.
**Overall Assessment:**
Ligand B appears to be the better candidate. While Ligand A has advantages in solubility, hERG, and metabolic stability, Ligand B excels in key areas for a GPCR target: lower DILI risk, higher BBB penetration, and a better TPSA value. The equal binding affinity removes that as a differentiating factor. The lower DILI risk is particularly important, as liver toxicity is a major concern in drug development.
Output:
0
2025-04-17 20:47:39,120 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A: [405.607, 72.47, 3.63, 1, 6, 0.666, 85.149, 21.171, -5.094, -3.684, 0.147, 59.627, 36.968, 0.255, -6.5]**
**Ligand B: [347.459, 73.64, 1.967, 0, 4, 0.629, 18.418, 85.459, -4.086, -2.412, 0.418, 73.797, -12.056, 0.094, -6.2]**
Here's a breakdown of each parameter and how the ligands compare, keeping GPCR priorities (logP, Pgp, TPSA, affinity) in mind:
1. **MW:** Ligand A (405.6) is within the ideal range, while Ligand B (347.5) is on the lower side, but still acceptable.
2. **TPSA:** Both are around 72-74, which is slightly above the optimal <140 for oral absorption, but not a major concern for a cardiovascular target.
3. **logP:** Ligand A (3.63) is optimal. Ligand B (1.967) is a bit low, potentially impacting membrane permeability.
4. **HBD:** Ligand A (1) is good. Ligand B (0) is also good.
5. **HBA:** Ligand A (6) is good. Ligand B (4) is good.
6. **QED:** Both are similar (0.666 vs 0.629), indicating good drug-like properties.
7. **DILI:** Ligand A (85.1%) is a significant concern, indicating a high risk of liver injury. Ligand B (18.4%) is excellent, very low risk.
8. **BBB:** Both have low BBB penetration (21.2% and 85.5%). Since this is a cardiovascular target, BBB penetration is not a high priority.
9. **Caco-2:** Both are negative, indicating poor permeability.
10. **Solubility:** Both are negative, indicating poor solubility.
11. **hERG:** Both are low risk (0.147 and 0.418).
12. **Cl_mic:** Ligand A (59.6) is better than Ligand B (73.8), indicating better metabolic stability.
13. **t1/2:** Ligand A (36.97) is better than Ligand B (-12.06), indicating a longer half-life.
14. **Pgp:** Ligand A (0.255) is better than Ligand B (0.094), indicating lower P-gp efflux.
15. **Affinity:** Ligand A (-6.5) is slightly better than Ligand B (-6.2), but the difference is small.
**Overall Assessment:**
Ligand B is significantly better due to its dramatically lower DILI risk. The slightly lower logP and worse metabolic stability are less concerning than the high liver injury risk associated with Ligand A. While Ligand A has a slightly better binding affinity and metabolic profile, the DILI risk is a major red flag. For a cardiovascular drug, minimizing toxicity is paramount.
Output:
0
2025-04-17 20:47:39,121 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, key priorities are logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB.
Let's break down the comparison:
1. **MW:** Both ligands are within the acceptable 200-500 Da range. Ligand A (344.5) is slightly better.
2. **TPSA:** Ligand A (58.2) is significantly better than Ligand B (107.4). Lower TPSA generally improves oral absorption, crucial for a cardiovascular drug.
3. **logP:** Both ligands have similar logP values around 2.8, which is optimal.
4. **HBD/HBA:** Ligand A has 2 HBD and 2 HBA, while Ligand B has 1 HBD and 5 HBA. Ligand A is preferable as it's closer to the ideal range.
5. **QED:** Ligand A (0.632) has a better QED score than Ligand B (0.476), indicating better overall drug-likeness.
6. **DILI:** Ligand B (54.2) has a higher DILI risk than Ligand A (16.0). This is a significant advantage for Ligand A.
7. **BBB:** Ligand B (62.5) has a slightly better BBB penetration than Ligand A (53.9). However, for a cardiovascular target, BBB penetration is not a primary concern.
8. **Caco-2:** Both have similar, poor Caco-2 permeability.
9. **Solubility:** Ligand A (-3.975) has slightly better solubility than Ligand B (-2.803).
10. **hERG:** Ligand A (0.278) has a lower hERG risk than Ligand B (0.376).
11. **Cl_mic:** Ligand B (41.44) has a slightly lower microsomal clearance than Ligand A (36.18), suggesting better metabolic stability.
12. **t1/2:** Ligand A (-3.988) has a better in vitro half-life than Ligand B (0.812).
13. **Pgp:** Ligand A (0.148) has significantly lower P-gp efflux liability than Ligand B (0.097), which is a major advantage. Lower Pgp efflux means better bioavailability.
14. **Binding Affinity:** Ligand B (-7.0) has a slightly better binding affinity than Ligand A (-6.3). This is a 1.7 kcal/mol difference, which is substantial.
**Overall Assessment:**
While Ligand B has a slightly better binding affinity, Ligand A demonstrates a superior overall profile. The lower TPSA, better QED, significantly lower DILI risk, lower Pgp efflux, and better half-life outweigh the minor affinity difference. Given the GPCR target class, the balance of properties in Ligand A makes it a more promising drug candidate.
**Output:**
1
2025-04-17 20:47:39,121 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (344.405 and 344.503 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (33.2) is significantly better than Ligand B (50.16). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold. Ligand B is approaching a level that could hinder absorption.
3. **logP:** Ligand A (4.431) is slightly higher than Ligand B (2.903). Both are within the 1-3 range, but Ligand A is pushing the upper limit. This could potentially lead to solubility issues, but the benefit of higher binding affinity may outweigh this.
4. **HBD:** Ligand A (0) is preferable to Ligand B (1). Fewer HBDs generally improve membrane permeability.
5. **HBA:** Ligand A (2) is preferable to Ligand B (4). Similar reasoning as HBD - fewer HBAs are generally better for permeability.
6. **QED:** Both ligands (0.822 and 0.836) have excellent drug-likeness scores, indicating a generally favorable profile. No significant difference.
7. **DILI:** Ligand B (23.226) has a much lower DILI risk than Ligand A (47.693). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (90.927) has a higher BBB penetration score than Ligand B (58.821). While not a primary concern for a cardiovascular target, higher BBB is rarely detrimental.
9. **Caco-2:** Both ligands have very similar, and poor, Caco-2 permeability (-4.693 and -4.753). This suggests both compounds may have absorption challenges.
10. **Solubility:** Ligand B (-2.996) has better aqueous solubility than Ligand A (-4.916). This is a positive for Ligand B, especially given Ligand A's higher logP.
11. **hERG:** Ligand A (0.842) has slightly higher hERG inhibition liability than Ligand B (0.399). Lower is better, so Ligand B is preferable.
12. **Cl_mic:** Both ligands have similar microsomal clearance (43.468 and 42.687 mL/min/kg). No significant difference.
13. **t1/2:** Ligand B (10.041) has a significantly longer in vitro half-life than Ligand A (1.019). This is a major advantage for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.623) has lower P-gp efflux than Ligand B (0.186). Lower efflux is generally preferred.
15. **Binding Affinity:** Ligand B (-6.7 kcal/mol) has a substantially stronger binding affinity than Ligand A (-5.6 kcal/mol). This 1.1 kcal/mol difference is significant and can often outweigh minor ADME drawbacks.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B has a better balance of these properties. While Ligand A has better TPSA and Pgp, Ligand B's superior affinity and lower DILI/hERG risk are more important. The longer half-life is also a major benefit.
**Conclusion:**
Despite Ligand A's slightly better TPSA and Pgp, Ligand B's significantly stronger binding affinity, lower DILI/hERG risk, and longer half-life make it the more promising drug candidate for the ADRB2 receptor.
Output:
0
2025-04-17 20:47:39,121 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (365.861 and 361.511 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (81.67) is slightly higher than Ligand B (71.09). Both are below the 140 threshold for oral absorption, but closer to the 90 threshold for CNS targets (though this isn't a CNS target). Ligand B is preferable.
3. **logP:** Both ligands have logP values around 2-3 (2.00 and 2.976), which is optimal. Ligand B is slightly higher, potentially aiding membrane permeability.
4. **HBD:** Both ligands have 2-3 HBD, which is within the acceptable limit of 5. No significant difference.
5. **HBA:** Ligand A has 3 HBA, while Ligand B has 4. Both are below the 10 limit. No major concern.
6. **QED:** Both ligands have similar QED scores (0.766 and 0.734), indicating good drug-likeness.
7. **DILI:** Ligand A (23.032) has a significantly lower DILI risk than Ligand B (37.999). This is a substantial advantage for Ligand A.
8. **BBB:** Ligand A (75.533) has a better BBB penetration score than Ligand B (52.656). While ADRB2 isn't a primary CNS target, some peripheral ADRB2 receptors can be affected by CNS penetration, and a higher BBB score is generally favorable.
9. **Caco-2:** Ligand A (-4.938) has a worse Caco-2 permeability than Ligand B (-5.233). Lower values indicate poorer permeability. Ligand B is preferable.
10. **Solubility:** Ligand A (-2.647) has slightly better solubility than Ligand B (-2.224). Solubility is important for bioavailability.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.457 and 0.155), which is excellent.
12. **Cl_mic:** Ligand A (-22.151) has a much lower (better) microsomal clearance than Ligand B (20.299). This suggests greater metabolic stability for Ligand A.
13. **t1/2:** Ligand A (0.836) has a shorter in vitro half-life than Ligand B (4.623). Longer half-life is generally preferred. Ligand B is preferable.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.106 and 0.249).
15. **Binding Affinity:** Both ligands have the same binding affinity (-6.5 kcal/mol). This removes affinity from the decision-making process.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. While both ligands are good on logP, Ligand B has a slightly better TPSA and Caco-2. However, Ligand A has a significantly better DILI score, better BBB penetration, and much better metabolic stability (lower Cl_mic). The lower DILI and improved metabolic stability are critical for a viable drug candidate.
**Overall Assessment:**
Despite Ligand B having slightly better Caco-2 permeability and half-life, the significantly lower DILI risk and improved metabolic stability of Ligand A outweigh these minor advantages. The better BBB score is also a plus.
Output:
1
2025-04-17 20:47:39,121 - INFO - Batch 211 complete. Total preferences: 3376
2025-04-17 20:47:39,121 - INFO - Processing batch 212/512...
2025-04-17 20:48:27,336 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (a cardiovascular GPCR) drug candidates.
**Ligand A:** [353.296, 64.63, 3.201, 1, 4, 0.662, 83.017, 74.525, -4.52, -4.531, 0.664, 76.412, -12.702, 0.147, -8.2]
**Ligand B:** [349.387, 95.61, 0.383, 1, 7, 0.826, 60.799, 53.083, -4.538, -0.709, 0.302, -11.912, -20.323, 0.039, -5.4]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). A (353.3) is slightly higher, but not concerning.
2. **TPSA:** A (64.63) is excellent, well below the 140 threshold. B (95.61) is higher, but still acceptable for a non-CNS target.
3. **logP:** A (3.201) is optimal. B (0.383) is quite low, potentially causing permeability issues. This is a significant drawback.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** A (4) is good. B (7) is higher, but still within the acceptable range.
6. **QED:** Both have good QED scores (A: 0.662, B: 0.826). B is slightly better here.
7. **DILI:** A (83.017) is higher, indicating a greater risk of liver injury. B (60.799) is better, falling into the acceptable range.
8. **BBB:** A (74.525) is good, but not crucial for a cardiovascular target. B (53.083) is lower.
9. **Caco-2:** Both are very poor (-4.52 and -4.538). This is concerning for oral bioavailability.
10. **Solubility:** Both are very poor (-4.531 and -0.709). This is a major issue for both compounds.
11. **hERG:** A (0.664) is better than B (0.302), indicating lower cardiotoxicity risk.
12. **Cl_mic:** A (76.412) is higher, meaning faster metabolism and potentially lower exposure. B (-11.912) is excellent, suggesting good metabolic stability.
13. **t1/2:** A (-12.702) is very poor. B (-20.323) is even worse. Both have very short half-lives.
14. **Pgp:** A (0.147) is better than B (0.039), suggesting less efflux.
15. **Affinity:** A (-8.2) is significantly better than B (-5.4). This is a substantial advantage.
**GPCR-Specific Priorities:** For ADRB2 (a cardiovascular GPCR), logP, TPSA, affinity, and Pgp are key. A has a much better logP and significantly better affinity. While B has better metabolic stability (Cl_mic) and a slightly better QED, the poor logP and weaker binding are major drawbacks. The poor solubility and Caco-2 values are also concerning for both, but the affinity difference is the deciding factor.
**Conclusion:**
Despite the DILI risk being higher for Ligand A, its superior binding affinity and more favorable logP outweigh the drawbacks, especially considering this is a cardiovascular target where BBB penetration isn't paramount.
**Output:**
1
2025-04-17 20:48:27,337 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, key priorities are logP, TPSA, Pgp efflux, affinity, and to a lesser extent, BBB (though less critical for a cardiovascular target).
Let's compare the ligands property by property:
1. **MW:** Both are within the ideal range (344.37 vs 345.41 Da).
2. **TPSA:** Ligand A (92.78) is significantly better than Ligand B (109.87). Lower TPSA generally favors oral absorption, important for a cardiovascular drug.
3. **logP:** Ligand A (-0.193) is quite low, potentially hindering membrane permeability. Ligand B (1.779) is within the optimal range. This is a significant advantage for Ligand B.
4. **HBD/HBA:** Ligand A (1 HBD, 5 HBA) is better than Ligand B (3 HBD, 8 HBA). Fewer H-bonds are generally preferred for permeability.
5. **QED:** Ligand B (0.727) has a better QED score than Ligand A (0.433), indicating a more drug-like profile.
6. **DILI:** Ligand A (46.801) has a much lower DILI risk than Ligand B (74.99). This is a substantial advantage for Ligand A.
7. **BBB:** Ligand B (59.946) has a higher BBB penetration than Ligand A (38.232), but BBB is not a primary concern for a cardiovascular target.
8. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-4.8) is slightly better than Ligand B (-5.615).
9. **Solubility:** Both have poor solubility (-2.043 and -2.505).
10. **hERG:** Ligand A (0.025) has a much lower hERG risk than Ligand B (0.435). This is a critical advantage for Ligand A.
11. **Cl_mic:** Ligand A (-7.515) has significantly better metabolic stability (lower clearance) than Ligand B (18.52).
12. **t1/2:** Ligand B (29.083) has a much longer half-life than Ligand A (-11.9).
13. **Pgp:** Ligand A (0.015) has much lower P-gp efflux than Ligand B (0.01).
14. **Affinity:** Both have very similar binding affinities (-6.4 kcal/mol vs -7.5 kcal/mol). The difference is not substantial enough to outweigh other factors.
**Overall Assessment:**
Ligand B has advantages in logP, QED, and half-life. However, Ligand A excels in crucial areas like DILI risk, hERG inhibition, metabolic stability (Cl_mic), and P-gp efflux. The low logP of Ligand A is a concern, but the significantly better safety profile (DILI, hERG) and metabolic stability are more important for a cardiovascular drug. The TPSA is also better for Ligand A. While Ligand B's half-life is better, this can be addressed through formulation or structural modifications.
Therefore, I believe Ligand A is the more promising candidate.
**Output:**
1
2025-04-17 20:48:27,337 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (352.45 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (67.43) is significantly better than Ligand B (88.85). ADRB2 is a cardiovascular target, not CNS, but lower TPSA is still beneficial for absorption.
3. **logP:** Both ligands have good logP values (A: 2.525, B: 1.44), falling within the optimal 1-3 range. Ligand A is slightly higher, which could be a minor concern for solubility, but not a major issue.
4. **HBD:** Both are acceptable (A: 2, B: 1).
5. **HBA:** Both are acceptable (A: 3, B: 5).
6. **QED:** Both have reasonable QED values (A: 0.495, B: 0.685), with Ligand B being slightly better.
7. **DILI:** Ligand A (36.177) has a lower DILI risk than Ligand B (46.181), which is a significant advantage.
8. **BBB:** Not a primary concern for a cardiovascular target, but Ligand A (82.396) has better BBB penetration than Ligand B (64.948).
9. **Caco-2:** Both are negative, indicating poor permeability. This is a significant drawback for both.
10. **Solubility:** Both have negative solubility values, indicating poor aqueous solubility. Ligand B (-2.865) is slightly better than Ligand A (-3.59).
11. **hERG:** Both have low hERG risk (A: 0.356, B: 0.516).
12. **Cl_mic:** Ligand A (16.84) has significantly lower microsomal clearance than Ligand B (35.109), indicating better metabolic stability.
13. **t1/2:** Ligand B (-10.369) has a much longer in vitro half-life than Ligand A (-4.618). This is a substantial advantage.
14. **Pgp:** Both have low Pgp efflux liability (A: 0.214, B: 0.037), with Ligand B being slightly better.
15. **Binding Affinity:** Ligand A (-6.1 kcal/mol) has a slightly better binding affinity than Ligand B (-5.7 kcal/mol).
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand A is more favorable. While Ligand B has a better half-life and QED, Ligand A excels in TPSA, DILI risk, and metabolic stability (Cl_mic). The slightly better affinity of Ligand A is also a plus. The poor Caco-2 and solubility for both are concerning and would require further optimization, but the overall profile of Ligand A is more promising.
Output:
1
2025-04-17 20:48:27,337 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (347.459 Da) is better, falling comfortably within the 200-500 Da range. Ligand B (384.527 Da) is also acceptable, but slightly higher.
2. **TPSA:** Ligand A (69.72) is significantly better than Ligand B (84.3). ADRB2 is a cardiovascular target, so CNS penetration is not a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have acceptable logP values (A: 0.869, B: 1.802), falling within the 1-3 range. Ligand B is slightly better, being closer to the optimal range.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A (3) is better than Ligand B (6). Lower HBA is generally preferred for better permeability.
6. **QED:** Ligand A (0.75) is slightly better than Ligand B (0.668), indicating a more drug-like profile.
7. **DILI:** Ligand A (19.465) is *much* better than Ligand B (57.503). This is a significant advantage for Ligand A. Lower DILI risk is crucial.
8. **BBB:** Both are relatively low (A: 52.268, B: 51.919). Not a major concern for a cardiovascular target.
9. **Caco-2:** Ligand A (-4.696) is better than Ligand B (-5.759), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-2.361) is better than Ligand B (-1.213). Better solubility is generally preferred.
11. **hERG:** Both ligands have low hERG risk (A: 0.217, B: 0.379).
12. **Cl_mic:** Ligand A (3.219) is *much* better than Ligand B (44.427). Lower clearance indicates better metabolic stability.
13. **t1/2:** Ligand A (-8.816) is better than Ligand B (33.908). A negative value suggests a longer half-life.
14. **Pgp:** Both ligands have low Pgp efflux liability (A: 0.03, B: 0.133).
15. **Binding Affinity:** Ligand B (-7.2) is slightly better than Ligand A (-7.1). However, the difference is small.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. While Ligand B has a slightly better logP and affinity, Ligand A excels in TPSA, and crucially, has significantly better ADME properties (DILI, Cl_mic, t1/2, solubility, Caco-2). The small affinity difference is outweighed by the substantial improvements in safety and pharmacokinetic properties.
**Conclusion:**
Ligand A is the more promising drug candidate due to its superior ADME profile, particularly the significantly lower DILI and microsomal clearance, and better solubility and absorption. The slightly lower binding affinity is a minor drawback compared to the substantial benefits in safety and pharmacokinetics.
Output:
1
2025-04-17 20:48:27,337 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Step-by-step comparison:**
1. **MW:** Both ligands (344.43 and 352.475 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (45.59) is significantly better than Ligand B (75.71). ADRB2 is a cardiovascular target, not CNS, but lower TPSA generally improves absorption.
3. **logP:** Ligand A (3.359) is slightly higher than Ligand B (1.831), and both are within the optimal 1-3 range. Ligand A is preferable.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Both ligands have 4 HBA, which is good.
6. **QED:** Ligand A (0.862) is slightly better than Ligand B (0.766), indicating a more drug-like profile.
7. **DILI:** Ligand A (30.942) has a lower DILI risk than Ligand B (21.908), which is a significant advantage.
8. **BBB:** Both ligands have high BBB penetration (88.135 and 83.094), but Ligand A is slightly better. While not a CNS target, higher BBB can sometimes correlate with better tissue distribution.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and potentially problematic. It suggests poor permeability. However, the values are similar (-4.652 vs -4.522).
10. **Solubility:** Both ligands have negative solubility values, which is also concerning. Ligand B (-2.312) is slightly better than Ligand A (-2.013).
11. **hERG:** Ligand A (0.964) has a slightly higher hERG risk than Ligand B (0.268). This is a negative for Ligand A.
12. **Cl_mic:** Ligand B (51.327) has a lower microsomal clearance than Ligand A (21.757), indicating better metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand A (53.929) has a much longer in vitro half-life than Ligand B (-21.522). This is a strong advantage for Ligand A.
14. **Pgp:** Ligand A (0.776) has a higher Pgp efflux liability than Ligand B (0.047). This is a negative for Ligand A.
15. **Binding Affinity:** Ligand B (-6.2) has a slightly stronger binding affinity than Ligand A (-5.9).
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has better logP and TPSA, but Ligand B has better Pgp and slightly better affinity. The metabolic stability (Cl_mic) of Ligand B is also a significant advantage. The longer half-life of Ligand A is also a major plus.
**Overall Assessment:**
Despite the negative Caco-2 and solubility values for both, Ligand A appears to be the better candidate. The longer half-life, lower DILI risk, and better TPSA and logP outweigh the slightly higher hERG and Pgp efflux. The affinity difference is small enough that it doesn't override the other benefits.
Output:
1
2025-04-17 20:48:27,337 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (343.383 and 367.515 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (88.58) is better than Ligand B (69.72), being closer to the optimal threshold of <140 for oral absorption.
3. **logP:** Both ligands have good logP values (2.28 and 1.27), falling within the 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability, but both are acceptable.
4. **HBD:** Both ligands have 1 HBD, which is within the preferred limit of <=5.
5. **HBA:** Ligand A has 5 HBA, and Ligand B has 4. Both are within the preferred limit of <=10.
6. **QED:** Ligand A (0.861) has a significantly better QED score than Ligand B (0.688), indicating a more drug-like profile.
7. **DILI:** Ligand B (32.183) has a much lower DILI risk than Ligand A (61.807). This is a substantial advantage for Ligand B.
8. **BBB:** Ligand B (51.221) has a slightly higher BBB penetration than Ligand A (45.909). While ADRB2 isn't exclusively a CNS target, some peripheral effects are mediated by CNS pathways, and better BBB penetration is generally favorable.
9. **Caco-2:** Ligand A (-4.899) has a more negative Caco-2 value, suggesting *lower* permeability compared to Ligand B (-5.195). This is a negative for Ligand A.
10. **Solubility:** Ligand A (-2.67) has slightly better solubility than Ligand B (-2.283), but both are poor.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.089 and 0.107). This is good for both.
12. **Cl_mic:** Ligand B (22.787) has a much lower microsomal clearance than Ligand A (54.056), indicating better metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand B (2.003) has a slightly longer in vitro half-life than Ligand A (-12.201).
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.056 and 0.05). This is good for both.
15. **Binding Affinity:** Ligand A (-7.1) has a slightly better binding affinity than Ligand B (-6.1). This is a 1.0 kcal/mol difference, which is significant.
**Overall Assessment:**
Ligand A has a better binding affinity and QED score, but Ligand B excels in safety (DILI), metabolic stability (Cl_mic), and has a slightly better BBB penetration. The difference in binding affinity (1.0 kcal/mol) is substantial, but the significantly lower DILI risk and improved metabolic stability of Ligand B are crucial for a viable drug candidate. The slightly better Caco-2 permeability of Ligand B is also a plus. Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), the balance of properties favors Ligand B.
Output:
0
2025-04-17 20:48:27,338 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (457.258 Da) is within the ideal range, while Ligand B (341.327 Da) is on the lower side, but still acceptable.
2. **TPSA:** Ligand A (29.54) is excellent, well below the 140 threshold, and very favorable for permeability. Ligand B (118.38) is higher, but still within an acceptable range for a non-CNS target.
3. **logP:** Ligand A (4.182) is slightly high, potentially leading to solubility issues or off-target interactions. Ligand B (2.723) is optimal.
4. **HBD:** Ligand A (0) is ideal. Ligand B (3) is acceptable, but higher HBD can sometimes affect permeability.
5. **HBA:** Ligand A (2) is good. Ligand B (6) is higher, potentially impacting permeability.
6. **QED:** Both ligands (A: 0.645, B: 0.671) have good drug-likeness scores.
7. **DILI:** Ligand A (53.315) has a lower DILI risk than Ligand B (97.984), which is a significant advantage.
8. **BBB:** This is less critical for a cardiovascular target like ADRB2, but Ligand A (89.492) shows better potential for CNS penetration than Ligand B (61.225).
9. **Caco-2:** Ligand A (-4.736) and Ligand B (-5.112) both have negative values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret the absolute difference.
10. **Solubility:** Both ligands have poor aqueous solubility (-4.648 and -4.702 respectively). This is a concern for both.
11. **hERG:** Ligand A (0.797) has a lower hERG risk than Ligand B (0.346), which is a positive.
12. **Cl_mic:** Ligand A (52.791) has a higher microsomal clearance than Ligand B (27.634), indicating lower metabolic stability.
13. **t1/2:** Ligand B (109.246) has a significantly longer in vitro half-life than Ligand A (11.923), which is a major advantage.
14. **Pgp:** Ligand A (0.822) has higher P-gp efflux liability than Ligand B (0.047), which is unfavorable.
15. **Binding Affinity:** Ligand B (-7.2 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.1 kcal/mol). This 1.1 kcal/mol difference is substantial and can outweigh many ADME drawbacks.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP and affinity, and has a much lower Pgp efflux liability. While Ligand A has a better TPSA, the difference in affinity is substantial. The DILI risk is also a significant concern with Ligand B, but the superior binding affinity and metabolic stability (longer half-life) are compelling.
**Conclusion:**
Despite the higher DILI risk, Ligand B's significantly stronger binding affinity (-7.2 vs -6.1 kcal/mol) and improved metabolic stability (longer half-life) are crucial advantages for a GPCR target. The lower Pgp efflux is also beneficial. While solubility is a concern for both, the potency advantage of Ligand B makes it the more promising candidate.
Output:
0
2025-04-17 20:48:27,338 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor (a GPCR).
**Ligand A:** [379.335, 22.61, 4.165, 0, 4, 0.796, 52.966, 89.841, -4.72, -3.916, 0.971, 56.472, 19.378, 0.668, -6.6]
**Ligand B:** [346.475, 67.23, 2.594, 1, 4, 0.699, 23.226, 76.309, -4.827, -2.48, 0.393, 64.198, -2.365, 0.26, -6.8]
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand B (346.475) is slightly lower, which *could* be beneficial for permeability, but both are acceptable.
2. **TPSA:** Ligand A (22.61) is excellent, well below the 140 threshold and very favorable for oral absorption. Ligand B (67.23) is higher, but still within a reasonable range, though less optimal.
3. **logP:** Ligand A (4.165) is at the upper end of the optimal range, potentially leading to solubility issues. Ligand B (2.594) is ideal.
4. **HBD:** Ligand A (0) is excellent. Ligand B (1) is also acceptable.
5. **HBA:** Both ligands have 4 HBA, which is good.
6. **QED:** Ligand A (0.796) is better than Ligand B (0.699), indicating a more drug-like profile.
7. **DILI:** Ligand A (52.966) has a higher DILI risk than Ligand B (23.226). This is a significant concern.
8. **BBB:** Ligand A (89.841) has a much higher BBB penetration potential than Ligand B (76.309). Given this is a GPCR, and while not necessarily a CNS target, some BBB penetration can be beneficial for distribution.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
10. **Solubility:** Ligand A (-3.916) has worse solubility than Ligand B (-2.48). This, combined with the higher logP, is concerning for Ligand A.
11. **hERG:** Ligand A (0.971) has a slightly higher hERG risk than Ligand B (0.393).
12. **Cl_mic:** Ligand B (64.198) has a lower microsomal clearance than Ligand A (56.472), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-2.365) has a longer in vitro half-life than Ligand A (19.378).
14. **Pgp:** Ligand A (0.668) has a higher Pgp efflux liability than Ligand B (0.26).
15. **Affinity:** Ligand B (-6.8) has slightly better binding affinity than Ligand A (-6.6).
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are particularly important. Ligand B excels in logP and Pgp, and has comparable affinity. Ligand A has better TPSA and BBB, but suffers from a higher logP, worse solubility, higher DILI risk, and higher Pgp efflux.
**Conclusion:**
Despite Ligand A's slightly better BBB penetration and QED, the significantly higher DILI risk, worse solubility, and higher Pgp efflux make it a less desirable candidate. Ligand B presents a more balanced profile with better predicted ADME properties and a lower toxicity risk. The slightly better affinity of Ligand B is also a plus.
Output:
0
2025-04-17 20:48:27,338 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (343.471 and 348.403 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (43.86) is significantly better than Ligand B (102.32). ADRB2 is a cardiovascular target, so CNS penetration isn't critical, but lower TPSA generally correlates with better absorption. Ligand B's TPSA is quite high.
3. **logP:** Ligand A (1.049) is within the optimal 1-3 range. Ligand B (-0.155) is slightly below 1, which *could* indicate permeability issues.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer HBDs generally improve membrane permeability.
5. **HBA:** Ligand A (3) is better than Ligand B (6). Similar to HBD, lower HBA is generally preferred.
6. **QED:** Both ligands (0.701 and 0.636) have acceptable QED values, indicating good drug-like properties.
7. **DILI:** Ligand A (17.681) has a much lower DILI risk than Ligand B (59.907). This is a major advantage for Ligand A.
8. **BBB:** Not a high priority for a cardiovascular target. Ligand A (57.852) is slightly better than Ligand B (47.809), but this isn't decisive.
9. **Caco-2:** Ligand A (-4.481) is better than Ligand B (-5.31). Higher Caco-2 values indicate better intestinal absorption.
10. **Solubility:** Ligand A (-2.116) is better than Ligand B (-1.947). Both are poor, but A is slightly better.
11. **hERG:** Both ligands (0.202 and 0.084) show low hERG inhibition liability, which is good.
12. **Cl_mic:** Ligand A (13.434) has a higher (worse) microsomal clearance than Ligand B (3.687), indicating faster metabolism. This is a drawback for Ligand A.
13. **t1/2:** Ligand B (8.184) has a significantly longer in vitro half-life than Ligand A (2.553). This is a significant advantage for Ligand B.
14. **Pgp:** Both ligands (0.046 and 0.024) have low P-gp efflux liability, which is good.
15. **Binding Affinity:** Both ligands (-6.4 and -6.3 kcal/mol) have very similar and excellent binding affinities. The difference is negligible.
**Overall Assessment:**
Ligand A has advantages in TPSA, logP, HBD, HBA, DILI, Caco-2, and solubility. However, Ligand B has a much better metabolic stability profile (lower Cl_mic and longer t1/2). Considering the GPCR-specific priorities (logP, TPSA, affinity), and the significant advantage of Ligand A in DILI risk, I lean towards Ligand A. The slightly better permeability profile (lower TPSA, better logP, fewer H-bonds) and significantly lower DILI risk outweigh the metabolic stability concern, especially given the cardiovascular target. While longer half-life is generally desirable, the other benefits of A are more impactful.
Output:
1
2025-04-17 20:48:27,338 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.471 and 347.463 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (70.59) is significantly better than Ligand B (99.77). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is approaching a level that could hinder absorption.
3. **logP:** Both ligands (2.545 and 2.272) are within the optimal 1-3 range. Ligand A is slightly higher, which might be preferable for membrane permeability, but the difference is small.
4. **HBD:** Both ligands have 3 H-bond donors, which is acceptable.
5. **HBA:** Ligand A has 3 H-bond acceptors, while Ligand B has 4. Ligand A is slightly better here, aligning with the preference for lower HBA counts.
6. **QED:** Ligand A (0.71) has a better QED score than Ligand B (0.543), indicating a more drug-like profile.
7. **DILI:** Ligand A (17.759) has a much lower DILI risk than Ligand B (56.883). This is a substantial advantage for Ligand A.
8. **BBB:** Ligand A (76.541) has a better BBB penetration score than Ligand B (63.397). While ADRB2 isn't exclusively a CNS target, some CNS exposure can occur, and higher BBB penetration is generally desirable.
9. **Caco-2:** Ligand A (-4.883) and Ligand B (-5.207) are both very poor, indicating poor intestinal absorption. This is a significant drawback for both.
10. **Solubility:** Ligand A (-2.6) is better than Ligand B (-3.732), suggesting better aqueous solubility.
11. **hERG:** Ligand A (0.773) has a lower hERG inhibition liability than Ligand B (0.18). Lower is better, indicating a reduced risk of cardiotoxicity.
12. **Cl_mic:** Ligand A (32.513) has a lower microsomal clearance than Ligand B (54.159), suggesting better metabolic stability.
13. **t1/2:** Ligand A (31.986) has a much longer in vitro half-life than Ligand B (-17.185). This is a significant advantage for Ligand A, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.285) has lower P-gp efflux liability than Ligand B (0.26). Both are relatively low, but A is slightly better.
15. **Binding Affinity:** Ligand B (-6.2) has a slightly better binding affinity than Ligand A (-5.9). However, the difference is only 0.3 kcal/mol, and the other advantages of Ligand A likely outweigh this small difference.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical ADME-Tox properties (DILI, BBB, solubility, hERG, Cl_mic, t1/2, QED). While Ligand B has a slightly better binding affinity, the other benefits of Ligand A, particularly the significantly lower DILI risk and improved metabolic stability, make it the more promising drug candidate. The Caco-2 permeability is poor for both, but this could be addressed with formulation strategies.
Output:
1
2025-04-17 20:48:27,338 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (357.292 and 341.455 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (102.09) is higher than Ligand B (62.3). For a cardiovascular GPCR, TPSA is moderately important. Ligand B's lower TPSA is preferable for better membrane permeability.
**3. logP:** Both ligands have similar logP values (2.769 and 2.715), both within the optimal 1-3 range.
**4. H-Bond Donors:** Ligand A has 2 HBD, and Ligand B has 1. Both are acceptable, well below the limit of 5.
**5. H-Bond Acceptors:** Ligand A has 5 HBA, and Ligand B has 3. Both are acceptable, well below the limit of 10.
**6. QED:** Ligand B (0.809) has a higher QED score than Ligand A (0.613), indicating a more drug-like profile.
**7. DILI Risk:** Ligand A (81.078) has a significantly higher DILI risk than Ligand B (27.065). This is a major concern, as liver toxicity is a common reason for drug failure.
**8. BBB Penetration:** Both ligands have good BBB penetration (74.874 and 72.78). While not critical for a cardiovascular target, it's not a disadvantage.
**9. Caco-2 Permeability:** Ligand A (-5.153) has a negative Caco-2 value, which is unusual and suggests poor permeability. Ligand B (-4.825) is also negative, but less so.
**10. Aqueous Solubility:** Ligand A (-4.244) and Ligand B (-3.269) both have poor aqueous solubility.
**11. hERG Inhibition:** Ligand A (0.585) has a slightly higher hERG inhibition risk than Ligand B (0.385), but both are relatively low.
**12. Microsomal Clearance:** Ligand B (70.074) has a higher microsomal clearance than Ligand A (32.956), indicating faster metabolism and potentially lower exposure.
**13. In vitro Half-Life:** Ligand A (64.342) has a significantly longer in vitro half-life than Ligand B (-13.083). This is a major advantage, potentially allowing for less frequent dosing.
**14. P-gp Efflux:** Ligand A (0.174) has lower P-gp efflux than Ligand B (0.074), suggesting better bioavailability.
**15. Binding Affinity:** Ligand B (-6.2) has a stronger binding affinity than Ligand A (-5.0). This is a substantial difference (1.2 kcal/mol) and a significant advantage.
**Overall Assessment:**
Ligand B is the preferred candidate. While Ligand A has a longer half-life and lower P-gp efflux, the significantly higher DILI risk and poor Caco-2 permeability are major drawbacks. Ligand B's superior binding affinity, lower DILI risk, and lower TPSA outweigh the faster clearance. The binding affinity difference is large enough to overcome the clearance issue, and formulation strategies can be explored to improve solubility.
Output:
0
2025-04-17 20:48:27,338 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (351.447 Da) is slightly lower, which can be favorable for permeability, but both are acceptable.
**2. TPSA:** Ligand A (84.67) is better than Ligand B (68.02) as it is closer to the 140 threshold.
**3. logP:** Ligand A (2.163) is optimal (1-3), while Ligand B (4.258) is pushing the upper limit. High logP can lead to solubility issues and off-target interactions.
**4. H-Bond Donors:** Both ligands have 1 HBD, which is good.
**5. H-Bond Acceptors:** Both ligands have 5 HBA, which is good.
**6. QED:** Ligand A (0.737) has a better QED score than Ligand B (0.634), indicating a more drug-like profile.
**7. DILI:** Ligand A (30.787) has a significantly lower DILI risk than Ligand B (90.733). This is a major advantage for Ligand A.
**8. BBB:** Ligand A (87.088) has a better BBB penetration percentile than Ligand B (70.997). While ADRB2 isn't exclusively a CNS target, some peripheral effects are mediated by CNS pathways, and better BBB penetration can be beneficial.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, indicating poor permeability. Ligand A (-4.317) is slightly better than Ligand B (-4.468).
**10. Aqueous Solubility:** Ligand A (-1.849) is better than Ligand B (-5.355). Solubility is important for bioavailability.
**11. hERG Inhibition:** Ligand A (0.133) has a lower hERG inhibition liability than Ligand B (0.393), which is crucial for avoiding cardiotoxicity, especially important for a cardiovascular target.
**12. Microsomal Clearance:** Ligand A (76.93) has a higher microsomal clearance than Ligand B (35.624), indicating lower metabolic stability. This is a drawback for Ligand A.
**13. In vitro Half-Life:** Ligand B (12.191) has a significantly longer in vitro half-life than Ligand A (-33.291). This is a major advantage for Ligand B.
**14. P-gp Efflux:** Ligand A (0.044) has lower P-gp efflux liability than Ligand B (0.345), which is favorable for bioavailability.
**15. Binding Affinity:** Ligand B (-6.3 kcal/mol) has a slightly better binding affinity than Ligand A (-5.6 kcal/mol). While a 1.5 kcal/mol difference is significant, the other ADME properties of Ligand A are more favorable.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity) and the general drug-like properties, Ligand A is the more promising candidate. While Ligand B has a slightly better binding affinity and half-life, Ligand A excels in crucial areas like DILI risk, BBB penetration, solubility, and hERG inhibition. The lower logP of Ligand A is also a significant advantage. The metabolic stability concern with Ligand A can be addressed through structural modifications in later stages of optimization.
Output:
1
2025-04-17 20:48:27,339 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [344.459, 77.23, 1.645, 3, 3, 0.76, 15.355, 46.84, -5.316, -2.392, 0.263, -11.8, -4.536, 0.02, -4.5]
**Ligand B:** [361.463, 57.65, 3.864, 0, 6, 0.668, 53.315, 76.309, -4.295, -4.872, 0.39, 109.748, -28.399, 0.48, -6.6]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity, and BBB):
1. **MW:** Both are within the acceptable 200-500 Da range. Ligand A (344.459) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (77.23) is better than Ligand B (57.65). Both are below 140, but lower TPSA is preferred for GPCRs.
3. **logP:** Ligand A (1.645) is within the optimal 1-3 range. Ligand B (3.864) is pushing the upper limit, potentially leading to solubility issues and off-target interactions.
4. **HBD/HBA:** Ligand A has 3 HBD and 3 HBA, which is a good balance. Ligand B has 0 HBD and 6 HBA. This suggests Ligand A might have better permeability.
5. **QED:** Ligand A (0.76) is better than Ligand B (0.668), indicating a more drug-like profile.
6. **DILI:** Ligand A (15.355) has a significantly lower DILI risk than Ligand B (53.315), a major advantage.
7. **BBB:** Ligand B (76.309) has a much higher BBB penetration percentile than Ligand A (46.84). While ADRB2 isn't strictly a CNS target, some peripheral distribution is still desirable.
8. **Caco-2:** Ligand A (-5.316) is better than Ligand B (-4.295).
9. **Solubility:** Ligand A (-2.392) is better than Ligand B (-4.872).
10. **hERG:** Ligand A (0.263) has a lower hERG risk than Ligand B (0.39).
11. **Cl_mic:** Ligand A (-11.8) has a lower (better) microsomal clearance than Ligand B (109.748), indicating greater metabolic stability.
12. **t1/2:** Ligand A (-4.536) has a better in vitro half-life than Ligand B (-28.399).
13. **Pgp:** Ligand A (0.02) has a lower P-gp efflux liability than Ligand B (0.48).
14. **Affinity:** Ligand B (-6.6 kcal/mol) has a significantly stronger binding affinity than Ligand A (-4.5 kcal/mol). This is a substantial advantage.
**Overall Assessment:**
Ligand B's significantly better binding affinity (-6.6 vs -4.5 kcal/mol) is a major positive. However, it is offset by significantly higher DILI risk, worse metabolic stability (high Cl_mic, short t1/2), and higher P-gp efflux. Ligand A has a much more favorable ADME-Tox profile, with lower DILI, better metabolic stability, better solubility, and lower P-gp efflux. While its affinity is weaker, the overall balance of properties makes it a more promising starting point for optimization. The difference in affinity, while substantial, is not insurmountable with medicinal chemistry efforts. The ADME issues with Ligand B are more challenging to address.
Therefore, I would prioritize Ligand A.
1
2025-04-17 20:48:27,339 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.4 and 343.4 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (84.94) is significantly better than Ligand B (108.62). For a GPCR, lower TPSA is generally preferred for better permeability. Ligand A is well below the 140 threshold, while B is approaching it.
3. **logP:** Ligand A (2.587) is optimal, while Ligand B (0.292) is quite low. A logP below 1 can hinder membrane permeability. This is a significant advantage for Ligand A.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (6). Similar reasoning to HBDs.
6. **QED:** Ligand A (0.849) is better than Ligand B (0.626), indicating a more drug-like profile.
7. **DILI:** Both ligands have similar DILI risk (63.5% and 65.7%), both are acceptable but not ideal.
8. **BBB:** Ligand A (79.4%) is significantly better than Ligand B (45.6%). While ADRB2 isn't necessarily a CNS target, some peripheral ADRB2 subtypes can influence CNS function, and higher BBB penetration is rarely a detriment.
9. **Caco-2:** Ligand A (-4.45) is better than Ligand B (-5.392). Higher Caco-2 permeability indicates better absorption.
10. **Solubility:** Ligand A (-3.694) is better than Ligand B (-2.519). Better solubility is generally preferred.
11. **hERG:** Both ligands have low hERG risk (0.386 and 0.236), which is excellent.
12. **Cl_mic:** Ligand A (50.08) is better than Ligand B (11.337). Lower clearance suggests better metabolic stability.
13. **t1/2:** Ligand A (-11.76) is better than Ligand B (8.431). Longer half-life is generally desirable.
14. **Pgp:** Ligand A (0.076) is better than Ligand B (0.06). Lower Pgp efflux is preferable.
15. **Binding Affinity:** Ligand B (-7.1) has a slightly better binding affinity than Ligand A (-4.7). However, the difference is not substantial enough to outweigh the numerous ADME advantages of Ligand A. A 2.4 kcal/mol difference, while noticeable, is often overcome by better pharmacokinetic properties.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A excels in logP and TPSA, and is comparable in Pgp. While Ligand B has slightly better affinity, the substantial advantages of Ligand A in ADME properties, particularly logP and TPSA, make it a more promising candidate.
**Conclusion:**
Ligand A demonstrates a significantly more favorable balance of properties, particularly regarding permeability and metabolic stability, making it the more viable drug candidate despite the slightly lower binding affinity.
Output:
1
2025-04-17 20:48:27,339 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (352.494 and 351.491 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (49.41) is significantly better than Ligand B (61.88). For a GPCR, a lower TPSA is generally preferred for better permeability. Ligand A is well below the 140 threshold.
3. **logP:** Ligand A (3.616) is good, within the optimal 1-3 range. Ligand B (1.251) is on the lower side, potentially hindering permeability.
4. **HBD:** Both have 1 HBD, which is acceptable.
5. **HBA:** Ligand A has 2 HBA, while Ligand B has 4. Ligand A is preferable as lower HBA generally improves permeability.
6. **QED:** Both ligands have similar QED values (0.761 and 0.715), indicating good drug-likeness.
7. **DILI:** Ligand A (29.43) has a much lower DILI risk than Ligand B (5.933), which is a significant advantage.
8. **BBB:** Ligand A (96.045) has a higher BBB penetration percentile than Ligand B (70.88). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant, and higher BBB is generally favorable.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified so it is difficult to interpret.
10. **Solubility:** Ligand A (-3.898) has better solubility than Ligand B (-1.091).
11. **hERG:** Ligand A (0.85) has a slightly higher hERG risk than Ligand B (0.45), but both are relatively low.
12. **Cl_mic:** Ligand B (20.715) has significantly lower microsomal clearance than Ligand A (56.426), suggesting better metabolic stability.
13. **t1/2:** Ligand B (10.327) has a longer in vitro half-life than Ligand A (-19.105). This is a substantial advantage.
14. **Pgp:** Ligand A (0.545) has lower P-gp efflux liability than Ligand B (0.007), which is better for bioavailability.
15. **Binding Affinity:** Ligand B (-6.4 kcal/mol) has a significantly stronger binding affinity than Ligand A (-4.4 kcal/mol). This is a > 2 kcal/mol difference, which is a major advantage and can often outweigh other ADME concerns.
**Overall Assessment:**
Ligand B has a substantially better binding affinity, and a longer half-life, and better metabolic stability. However, Ligand A has better TPSA, logP, solubility, DILI risk, and BBB penetration. The binding affinity difference is significant. While Ligand A has a more favorable ADME profile overall, the substantial improvement in binding affinity of Ligand B is a critical factor for a GPCR target. The improved metabolic stability and half-life of Ligand B are also important.
Output:
0
2025-04-17 20:48:27,339 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (344.46 and 354.41 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (64.68) is significantly better than Ligand B (110.59). For a GPCR, lower TPSA is generally preferred for better permeability. Ligand B is pushing the upper limit for good oral absorption.
3. **logP:** Both ligands have good logP values (3.569 and 2.0), falling within the optimal 1-3 range. Ligand A is slightly higher, which *could* present a minor solubility issue, but is still acceptable.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1), but both are within the acceptable limit of 5.
5. **HBA:** Ligand B (6) is higher than Ligand A (2). This contributes to the higher TPSA of Ligand B. Lower HBA is generally favored for permeability.
6. **QED:** Ligand A (0.877) has a substantially better QED score than Ligand B (0.592), indicating a more drug-like profile.
7. **DILI:** Ligand B (63.513) has a higher DILI risk than Ligand A (39.434). Both are acceptable, but A is preferable.
8. **BBB:** Ligand A (69.794) has a slightly better BBB penetration percentile than Ligand B (63.901). While ADRB2 isn't exclusively a CNS target, some CNS exposure can occur, and higher BBB is generally beneficial.
9. **Caco-2:** Both ligands have similar, very negative Caco-2 values (-4.717 and -4.741). This suggests poor permeability, which is concerning.
10. **Solubility:** Both ligands have very poor solubility scores (-3.759 and -3.58). This is a major drawback for both compounds.
11. **hERG:** Ligand A (0.737) has a slightly better hERG profile than Ligand B (0.452), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand B (31.675) has a higher microsomal clearance than Ligand A (19.504), suggesting lower metabolic stability.
13. **t1/2:** Ligand A (29.868) has a significantly longer in vitro half-life than Ligand B (-2.804). This is a major advantage for Ligand A.
14. **Pgp:** Ligand A (0.107) has lower P-gp efflux liability than Ligand B (0.214), meaning better bioavailability and potentially better CNS exposure.
15. **Binding Affinity:** Ligand B (-6.9 kcal/mol) has a slightly better binding affinity than Ligand A (-6.1 kcal/mol). This is a 0.8 kcal/mol difference, which is significant, but not overwhelmingly so given the other factors.
**Overall Assessment:**
Ligand A is the stronger candidate. While Ligand B has a slightly better binding affinity, Ligand A excels in several crucial ADME properties: QED, DILI risk, BBB penetration, metabolic stability (Cl_mic and t1/2), and P-gp efflux. The lower TPSA and HBA of Ligand A are also favorable for permeability, even though both compounds show poor Caco-2 permeability. The solubility is a concern for both, but the other advantages of Ligand A outweigh the slightly better affinity of Ligand B.
Output:
1
2025-04-17 20:48:27,339 - INFO - Batch 212 complete. Total preferences: 3392
2025-04-17 20:48:27,340 - INFO - Processing batch 213/512...
2025-04-17 20:49:12,709 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.49 & 360.47 Da) fall within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (49.85) is significantly better than Ligand B (70.08), being well below the 140 threshold and more favorable for oral absorption.
3. **logP:** Both ligands have good logP values (2.59 & 1.75), falling within the 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Ligand A (0) is preferable to Ligand B (1), as fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (3) is slightly better than Ligand B (4), keeping within the desirable range.
6. **QED:** Both ligands have acceptable QED scores (0.788 & 0.603), indicating reasonable drug-likeness.
7. **DILI:** Ligand A (26.10) has a much lower DILI risk than Ligand B (18.88), which is a significant advantage.
8. **BBB:** Both ligands have good BBB penetration (75.61 & 83.37), but Ligand B is slightly higher. Since ADRB2 is a cardiovascular target, BBB penetration is not a primary concern, but it's still a positive attribute.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual. It's difficult to interpret without knowing the scale, but they are similar.
10. **Solubility:** Both ligands have negative solubility values, which is also unusual. It's difficult to interpret without knowing the scale, but they are similar.
11. **hERG:** Both ligands have low hERG inhibition risk (0.541 & 0.655), which is good.
12. **Cl_mic:** Ligand B (47.44) has lower microsomal clearance than Ligand A (58.91), suggesting better metabolic stability. This is a positive for Ligand B.
13. **t1/2:** Ligand A (7.41) has a longer in vitro half-life than Ligand B (-3.14), which is a major advantage.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.244 & 0.291), which is good.
15. **Binding Affinity:** Ligand B (-5.8 kcal/mol) has a stronger binding affinity than Ligand A (-4.5 kcal/mol). This is a substantial difference (1.3 kcal/mol) and is a significant factor.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A has better TPSA and logP, while Ligand B has a better affinity and slightly better Pgp. The difference in affinity is significant. The lower DILI risk for Ligand A is also a major plus. The longer half-life of Ligand A is also a significant advantage.
**Overall Assessment:**
While Ligand B has a better binding affinity, Ligand A's superior DILI profile, TPSA, logP, and half-life, combined with acceptable affinity, make it the more promising candidate. The stronger affinity of Ligand B could potentially be optimized in later stages, but mitigating the higher DILI risk might be more challenging.
**Output:**
1
2025-04-17 20:49:12,710 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.459 and 350.394 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (75.71 and 75.93) are reasonably low, below the 140 A^2 threshold for good oral absorption, but not optimized for CNS penetration (above 90 A^2).
3. **logP:** Ligand A (1.668) is slightly higher than Ligand B (0.956), both within the optimal 1-3 range. Ligand A is preferable here.
4. **HBD:** Both ligands have 1 HBD, which is well within the acceptable limit of 5.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 5. Both are below the 10 limit.
6. **QED:** Both ligands have good QED scores (0.74 and 0.83), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (9.306%) has a significantly lower DILI risk than Ligand B (37.185%). This is a major advantage for Ligand A.
8. **BBB:** Both ligands have good BBB penetration (75.107% and 70.648%). Since ADRB2 isn't strictly a CNS target, this isn't a primary driver, but higher is still better. Ligand A is slightly better.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.816 and -4.764), indicating poor permeability. This is a concern for both.
10. **Solubility:** Both ligands have negative solubility values (-1.48 and -2.141), indicating poor aqueous solubility. This is a concern for both.
11. **hERG:** Both ligands have low hERG inhibition risk (0.164% and 0.344%).
12. **Cl_mic:** Ligand A (6.554) has a lower microsomal clearance than Ligand B (7.172), suggesting better metabolic stability. This is a positive for Ligand A.
13. **t1/2:** Ligand A (-12.455) has a much more negative in vitro half-life than Ligand B (-2.719), indicating a shorter half-life. This is a significant drawback for Ligand A.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.027% and 0.098%).
15. **Binding Affinity:** Ligand A (-6.8 kcal/mol) has a significantly better binding affinity than Ligand B (-3.6 kcal/mol). This is a substantial advantage for Ligand A.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand A has a better logP and significantly better affinity. While both have acceptable Pgp and TPSA values, the large difference in affinity and the lower DILI risk of Ligand A outweigh the shorter half-life. The poor Caco-2 and solubility are concerns for both, but can be addressed through formulation strategies.
**Conclusion:**
Despite the shorter half-life, the superior binding affinity and significantly lower DILI risk of Ligand A make it the more promising drug candidate.
Output:
1
2025-04-17 20:49:12,710 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (358.479 and 355.414 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (96.89) is slightly higher than Ligand B (89.35). Both are below the 140 threshold for oral absorption, but closer to the 90 threshold for CNS targets (less relevant for ADRB2, a cardiovascular target). Ligand B is preferable here.
3. **logP:** Ligand A (0.99) is slightly lower than Ligand B (0.23), both are below the optimal 1-3 range. This is a slight negative for both, potentially impacting permeability, but Ligand B is worse.
4. **HBD:** Ligand A (3) is higher than Ligand B (1). Lower is generally better, so Ligand B is preferable.
5. **HBA:** Ligand A (5) is lower than Ligand B (6). Lower is generally better, so Ligand A is preferable.
6. **QED:** Ligand B (0.721) has a higher QED score than Ligand A (0.571), indicating a more drug-like profile. This is a significant advantage for Ligand B.
7. **DILI:** Ligand B (36.758) has a slightly higher DILI risk than Ligand A (17.681), but both are below the concerning 60 threshold. Ligand A is preferable.
8. **BBB:** Ligand B (78.79) has a significantly higher BBB penetration percentile than Ligand A (35.207). While ADRB2 is not a CNS target, higher BBB is rarely detrimental.
9. **Caco-2:** Ligand A (-5.128) has a lower Caco-2 permeability than Ligand B (-4.733). Lower values indicate poorer permeability, so Ligand B is preferable.
10. **Solubility:** Ligand A (-1.44) has slightly lower solubility than Ligand B (-1.273). Both are poor, but Ligand B is better.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.145 and 0.129 respectively). No significant difference.
12. **Cl_mic:** Ligand B (7.499) has a much lower microsomal clearance than Ligand A (32.548), indicating better metabolic stability. This is a major advantage for Ligand B.
13. **t1/2:** Ligand B (3.418) has a longer in vitro half-life than Ligand A (0.588). This is a significant advantage for Ligand B.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.027 and 0.025 respectively). No significant difference.
15. **Binding Affinity:** Ligand B (-6.9 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.3 kcal/mol). This is a substantial advantage for Ligand B, potentially outweighing some of the ADME drawbacks.
**GPCR-specific priorities:** For ADRB2 (a cardiovascular GPCR), logP, Pgp, TPSA, and affinity are key. Ligand B performs better on logP, Pgp, and significantly better on affinity. While TPSA is slightly better for A, the affinity difference is substantial.
**Overall Assessment:**
Ligand B demonstrates a superior binding affinity, better metabolic stability (lower Cl_mic, longer t1/2), and a more favorable QED score. While Ligand A has a slightly lower DILI risk, the substantial improvements in potency and ADME properties of Ligand B outweigh this minor advantage.
Output:
0
2025-04-17 20:49:12,710 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.39 and 353.42 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand B (100.46) is better than Ligand A (113.44). Both are under the 140 threshold for good absorption, but lower is preferred for GPCRs.
3. **logP:** Ligand B (-0.098) is slightly better than Ligand A (-0.222), both are within the 1-3 range, but closer to the lower end.
4. **HBD:** Ligand B (2) has fewer HBDs than Ligand A (3), which is slightly preferable.
5. **HBA:** Both ligands have the same number of HBA (6).
6. **QED:** Ligand B (0.531) has a slightly higher QED score than Ligand A (0.421), indicating a more drug-like profile.
7. **DILI:** Ligand B (21.95) has a significantly lower DILI risk than Ligand A (45.25). This is a major advantage for Ligand B.
8. **BBB:** Both ligands have similar BBB penetration (Ligand A: 34.74, Ligand B: 37.38). Since ADRB2 isn't a CNS target, this isn't a primary concern, but higher is generally better.
9. **Caco-2:** Both ligands have similar Caco-2 permeability, with Ligand B (-4.81) being slightly better than Ligand A (-5.048).
10. **Solubility:** Both ligands have poor aqueous solubility, with Ligand B (-1.252) being slightly better than Ligand A (-1.487).
11. **hERG:** Ligand B (0.237) has a lower hERG risk than Ligand A (0.049). This is a significant advantage for Ligand B.
12. **Cl_mic:** Ligand B (-0.662) has a lower microsomal clearance than Ligand A (-2.964), suggesting better metabolic stability.
13. **t1/2:** Ligand B (11.472) has a significantly longer in vitro half-life than Ligand A (-19.626). This is a major advantage for Ligand B.
14. **Pgp:** Both ligands have the same Pgp efflux liability (0.023).
15. **Binding Affinity:** Ligand B (-6.6) has a slightly stronger binding affinity than Ligand A (-6.0).
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B is slightly better in logP and TPSA. Both have similar Pgp efflux. Ligand B has a better affinity.
**Overall Assessment:**
Ligand B consistently outperforms Ligand A across several critical ADME-Tox properties (DILI, hERG, Cl_mic, t1/2) and has a slightly better binding affinity. While both have poor solubility, the other advantages of Ligand B outweigh this drawback.
Output:
0
2025-04-17 20:49:12,711 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (366.49 & 375.48 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (84.42) is higher than Ligand B (57.61). For a cardiovascular GPCR, TPSA is moderately important. Ligand B is better here.
3. **logP:** Ligand A (1.661) is within the optimal 1-3 range, while Ligand B (4.038) is pushing the upper limit. Higher logP can lead to off-target effects and solubility issues. Ligand A is better.
4. **HBD:** Both have 1 HBD, which is good. No difference.
5. **HBA:** Ligand A has 6 HBA, and Ligand B has 4. Both are acceptable, but Ligand B is slightly better.
6. **QED:** Ligand A (0.857) has a significantly better QED score than Ligand B (0.663), indicating a more drug-like profile. Ligand A is better.
7. **DILI:** Ligand A (40.83) has a slightly higher DILI risk than Ligand B (26.33), but both are below the concerning threshold of 60. Ligand B is better.
8. **BBB:** Ligand B (80.031) has a higher BBB penetration percentile than Ligand A (71.501). While ADRB2 isn't necessarily a CNS target, some CNS exposure can be acceptable or even beneficial depending on the specific indication. Ligand B is better.
9. **Caco-2:** Ligand A (-5.373) is worse than Ligand B (-4.54). Higher Caco-2 values indicate better absorption. Ligand B is better.
10. **Solubility:** Ligand A (-2.038) is better than Ligand B (-3.296). Solubility is important for bioavailability. Ligand A is better.
11. **hERG:** Ligand A (0.169) has a much lower hERG inhibition liability than Ligand B (0.726). This is a crucial safety parameter. Ligand A is significantly better.
12. **Cl_mic:** Ligand B (77.76) has a much higher microsomal clearance than Ligand A (9.6). Lower clearance is preferred for better metabolic stability. Ligand A is significantly better.
13. **t1/2:** Ligand A (9.388) has a longer in vitro half-life than Ligand B (4.655). This is desirable for less frequent dosing. Ligand A is better.
14. **Pgp:** Ligand A (0.072) has a lower Pgp efflux liability than Ligand B (0.506). Lower efflux is preferred for better bioavailability. Ligand A is better.
15. **Binding Affinity:** Ligand A (-6.9 kcal/mol) has a slightly better binding affinity than Ligand B (-5.7 kcal/mol). This difference is significant enough to be a major factor. Ligand A is better.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical ADME-Tox parameters (DILI, hERG, Cl_mic, t1/2, Pgp) and has a slightly better binding affinity and QED score. While Ligand B has advantages in TPSA, BBB, and Caco-2, these are less critical for a cardiovascular GPCR target like ADRB2, and are outweighed by Ligand A's superior safety and pharmacokinetic profile. The higher logP of Ligand B is also a concern.
**Output:**
1
2025-04-17 20:49:12,711 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.415 and 350.463 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (93.46 and 93.09) are below the 140 A^2 threshold for good oral absorption, and acceptable for a cardiovascular GPCR. Very similar.
3. **logP:** Both ligands (1.758 and 1.471) are within the optimal 1-3 range. Ligand B is slightly lower, which could slightly improve solubility, but both are good.
4. **HBD:** Both have 2 HBD, well within the acceptable limit of 5.
5. **HBA:** Both have 5 HBA, also within the acceptable limit of 10.
6. **QED:** Ligand B (0.668) has a slightly better QED score than Ligand A (0.579), indicating a more drug-like profile.
7. **DILI:** Ligand B (38.426) has a significantly lower DILI risk than Ligand A (58.395). This is a major advantage for Ligand B.
8. **BBB:** Ligand A (75.301) has a higher BBB penetration percentile than Ligand B (53.432). While ADRB2 is a cardiovascular target and doesn't *require* high BBB penetration, some level is not detrimental.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. This is a concern for both, but the values are very close.
10. **Solubility:** Ligand B (-1.84) has slightly better solubility than Ligand A (-2.079), although both are poor.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.251 and 0.268).
12. **Cl_mic:** Ligand B (36.146) has a lower microsomal clearance than Ligand A (43.056), suggesting better metabolic stability.
13. **t1/2:** Ligand B (9.908 hours) has a significantly longer in vitro half-life than Ligand A (-17.306 hours). This is a substantial advantage for Ligand B.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.135 and 0.051).
15. **Binding Affinity:** Ligand B (-7.8 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.1 kcal/mol). This is a crucial advantage, exceeding the 1.5 kcal/mol difference threshold.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are important. Ligand B excels in affinity and has comparable logP and TPSA. The lower DILI and improved metabolic stability (lower Cl_mic and longer t1/2) are also significant benefits. While Ligand A has better BBB penetration, this is less critical for a cardiovascular target.
**Conclusion:**
Ligand B is the superior candidate due to its significantly stronger binding affinity, lower DILI risk, improved metabolic stability, and longer half-life. These advantages outweigh the slightly lower BBB penetration compared to Ligand A.
Output:
0
2025-04-17 20:49:12,711 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (353.47 and 375.52 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand B (66.32) is significantly better than Ligand A (113.22). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (3.248) is slightly higher than Ligand A (1.05), but both are within the acceptable 1-3 range. Ligand B is closer to the upper limit, which *could* raise solubility concerns, but isn't a dealbreaker.
4. **HBD:** Ligand A (3) is higher than Ligand B (1). Lower HBD is generally preferred for permeability, giving a slight edge to Ligand B.
5. **HBA:** Both ligands have 6 HBA, which is acceptable.
6. **QED:** Ligand B (0.865) is significantly better than Ligand A (0.582), indicating a more drug-like profile.
7. **DILI:** Both ligands have relatively high DILI risk (53.66 and 65.57), which is a concern. Ligand A is slightly better, but neither is ideal.
8. **BBB:** Ligand A (65.03) is better than Ligand B (49.79), but this is less important for a cardiovascular target.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand B (-3.867) is worse than Ligand A (-2.495). This is a concern given Ligand B's higher logP.
11. **hERG:** Both ligands have low hERG inhibition risk (0.47 and 0.396), which is good.
12. **Cl_mic:** Ligand A (9.069) has a lower microsomal clearance than Ligand B (54.348), suggesting better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand A (9.89) has a longer in vitro half-life than Ligand B (-0.785), which is desirable.
14. **Pgp:** Ligand B (0.207) has lower P-gp efflux than Ligand A (0.08), which is a positive.
15. **Binding Affinity:** Ligand B (-7.1 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.6 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME drawbacks.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), affinity, logP, TPSA, and Pgp are key. Ligand B excels in affinity and has acceptable logP and Pgp. Ligand A has better TPSA and metabolic stability, but the affinity difference is substantial.
**Overall Assessment:**
Despite the solubility and Caco-2 concerns, Ligand B's significantly higher binding affinity (-7.1 vs -5.6 kcal/mol) is the most important factor. The improved QED score also supports its selection. While Ligand A has better metabolic stability and solubility, the potency difference is likely to be more impactful for *in vivo* efficacy.
Output:
0
2025-04-17 20:49:12,711 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's systematically compare Ligand A and Ligand B against the provided guidelines, keeping in mind the GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key).
1. **MW:** Both ligands (357.41 and 351.334 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (64.11) is significantly better than Ligand B (124.69). For a peripheral GPCR like ADRB2, TPSA < 140 is good, but lower is generally preferred for better absorption. Ligand A is much closer to the ideal.
3. **logP:** Ligand A (4.147) is higher than Ligand B (1.256). While >4 can be problematic, it's not a hard cutoff. For a GPCR, a higher logP can be beneficial for membrane interactions, but must be balanced with solubility. Ligand B's logP is quite low, potentially hindering permeability.
4. **HBD/HBA:** Ligand A (1 HBD, 5 HBA) is better than Ligand B (4 HBD, 6 HBA). Lower numbers are generally preferred for permeability.
5. **QED:** Both ligands have similar QED values (0.72 and 0.621), indicating good drug-likeness.
6. **DILI:** Ligand A (88.251) has a higher DILI risk than Ligand B (56.844). This is a concern for Ligand A.
7. **BBB:** BBB is less critical for ADRB2 (a cardiovascular target). Ligand A (64.831) is better than Ligand B (19.542), but this isn't a major deciding factor.
8. **Caco-2:** Ligand A (-4.922) is better than Ligand B (-5.498). Higher values indicate better permeability.
9. **Solubility:** Ligand A (-5.148) is better than Ligand B (-2.467). Better solubility is always preferred.
10. **hERG:** Ligand A (0.623) is better than Ligand B (0.422). Lower hERG inhibition is crucial for cardiac safety.
11. **Cl_mic:** Ligand A (70.519) has a higher clearance than Ligand B (15.118). This suggests Ligand B is more metabolically stable, which is a positive.
12. **t1/2:** Ligand A (-24.598) has a longer half-life than Ligand B (-4.395). This is a significant advantage for Ligand A.
13. **Pgp:** Ligand A (0.519) is better than Ligand B (0.046). Lower P-gp efflux is preferred for better bioavailability.
14. **Binding Affinity:** Ligand B (-7.8 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.9 kcal/mol). This >1.5 kcal/mol difference is a major advantage for Ligand B.
**Overall Assessment:**
Ligand B has a significantly better binding affinity, lower DILI risk, and better metabolic stability. While Ligand A has advantages in TPSA, solubility, and half-life, the strong affinity of Ligand B outweighs these benefits. The lower logP of Ligand B is a concern, but the substantial affinity advantage is likely to compensate for that. The higher TPSA of Ligand B is a drawback, but not a dealbreaker.
Output:
0
2025-04-17 20:49:12,711 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (354.372 Da) is within the ideal range (200-500 Da). Ligand B (385.877 Da) is also acceptable. No clear advantage here.
2. **TPSA:** Ligand A (58.2) is excellent, well below the 140 threshold for oral absorption and suitable for a GPCR. Ligand B (109.26) is higher, but still reasonable, though less optimal. Advantage: A.
3. **logP:** Ligand A (2.846) is optimal. Ligand B (1.855) is slightly lower, but still within the acceptable range. No strong preference.
4. **HBD:** Ligand A (2) is good. Ligand B (3) is slightly higher, but still acceptable. No strong preference.
5. **HBA:** Ligand A (2) is good. Ligand B (8) is higher, potentially impacting permeability. Advantage: A.
6. **QED:** Ligand A (0.74) is excellent, indicating strong drug-likeness. Ligand B (0.423) is lower, suggesting a less ideal overall profile. Advantage: A.
7. **DILI:** Ligand A (36.487) has a low DILI risk. Ligand B (71.656) has a significantly higher DILI risk. Strong advantage: A.
8. **BBB:** Ligand A (84.529) has good BBB penetration. Ligand B (28.306) has poor BBB penetration. Advantage: A. (Important for GPCRs, even if not CNS-focused, as it can indicate reduced off-target effects).
9. **Caco-2:** Ligand A (-4.603) is very poor. Ligand B (-5.538) is also poor. Both are problematic, but B is slightly worse. Advantage: A.
10. **Solubility:** Ligand A (-3.272) is poor. Ligand B (-2.523) is also poor, but slightly better. Advantage: B.
11. **hERG:** Both Ligand A (0.352) and Ligand B (0.2) have low hERG inhibition liability, which is good. No clear advantage.
12. **Cl_mic:** Ligand A (34.959) has a lower microsomal clearance, suggesting better metabolic stability. Ligand B (26.673) has a lower clearance, indicating better metabolic stability. Advantage: B.
13. **t1/2:** Ligand A (-22.042) has a negative half-life, which is not possible and likely an error in the data. Ligand B (22.507) has a reasonable half-life. Strong advantage: B.
14. **Pgp:** Both Ligand A (0.174) and Ligand B (0.198) have low P-gp efflux liability, which is good. No clear advantage.
15. **Affinity:** Ligand A (-6.0) has a slightly better binding affinity than Ligand B (-6.4). Advantage: A.
**Overall Assessment:**
Ligand A has several advantages: better TPSA, HBA, QED, DILI risk, and BBB penetration. It also has a slightly better binding affinity. However, Ligand A has a problematic Caco-2 value and an impossible half-life value. Ligand B has a better half-life and slightly better metabolic stability. The DILI risk for Ligand B is concerning, and its BBB penetration is poor.
Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity) and the overall balance, and acknowledging the data error for Ligand A, Ligand B is the more viable candidate. The better half-life and metabolic stability outweigh the higher DILI risk and lower BBB penetration, especially given the ability to potentially mitigate DILI through structural modifications.
Output:
0
2025-04-17 20:49:12,712 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (408.34 Da) is within the ideal range, while Ligand B (356.438 Da) is also acceptable. No clear advantage here.
2. **TPSA:** Ligand A (58.22) is good, well below the 140 threshold. Ligand B (76.66) is still reasonable, but higher. A favors better absorption.
3. **logP:** Ligand A (4.125) is slightly high, potentially leading to solubility issues. Ligand B (1.497) is excellent, within the optimal range. B is favored.
4. **HBD:** Ligand A (1) is good. Ligand B (2) is also acceptable.
5. **HBA:** Both ligands (A: 4, B: 4) are within the acceptable limit of 10.
6. **QED:** Ligand A (0.777) is better than Ligand B (0.678), indicating a more drug-like profile. A is favored.
7. **DILI:** Ligand A (26.018) has a significantly lower DILI risk than Ligand B (30.865). A is strongly favored.
8. **BBB:** Ligand A (74.292) is good, while Ligand B (89.957) is excellent. B is favored, though BBB isn't *critical* for ADRB2 (a cardiovascular target).
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. This is a concern for both, but the values are very close.
10. **Solubility:** Ligand A (-4.04) has worse solubility than Ligand B (-2.093). B is favored.
11. **hERG:** Ligand A (0.894) has a slightly higher hERG risk than Ligand B (0.31). B is favored.
12. **Cl_mic:** Ligand A (67.49) has higher metabolic clearance than Ligand B (32.765), meaning it will be cleared faster. B is favored.
13. **t1/2:** Ligand A (-5.127) has a longer half-life than Ligand B (-6.013). A is favored.
14. **Pgp:** Ligand A (0.373) has lower P-gp efflux than Ligand B (0.024). A is favored.
15. **Affinity:** Ligand A (-7.0) has equal binding affinity to Ligand B (-4.2).
**Overall Assessment & GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp efflux, and binding affinity are key. Ligand B excels in logP and BBB penetration, which are beneficial. Ligand A has a better QED, lower DILI risk, longer half-life, and lower Pgp efflux. However, the higher logP and worse solubility of Ligand A are concerning. The DILI risk for Ligand A is significantly lower, which is a major advantage. Considering the balance, the lower DILI risk and better metabolic stability (lower Cl_mic) of Ligand A outweigh the slightly higher logP and worse solubility. The affinity is the same for both.
Output:
1
2025-04-17 20:49:12,712 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (338.451 and 352.425 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (49.41) is slightly higher than Ligand B (46.34), but both are well below the 140 threshold for good oral absorption, and acceptable for a cardiovascular GPCR.
3. **logP:** Ligand A (2.294) is within the optimal 1-3 range. Ligand B (4.183) is a bit higher. While still potentially acceptable, it edges closer to the >4 range where solubility issues can arise.
4. **HBD:** Ligand A (1) is preferable to Ligand B (0). Having at least one HBD can improve solubility.
5. **HBA:** Ligand A (2) is preferable to Ligand B (3). Lower HBA is generally better for permeability.
6. **QED:** Ligand A (0.855) has a better QED score than Ligand B (0.798), indicating a more drug-like profile.
7. **DILI:** Ligand A (18.883) has a significantly lower DILI risk than Ligand B (32.842). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (94.727) has a higher BBB penetration percentile than Ligand A (83.288). However, since ADRB2 is a cardiovascular target, BBB penetration is not a primary concern.
9. **Caco-2:** Ligand A (-4.906) and Ligand B (-4.461) both have negative Caco-2 values, indicating poor permeability. This is a significant drawback for both.
10. **Solubility:** Ligand A (-3.667) is slightly better than Ligand B (-4.644), though both are quite poor.
11. **hERG:** Ligand A (0.176) has a lower hERG inhibition liability than Ligand B (0.601), indicating a lower risk of cardiotoxicity. This is crucial for a cardiovascular target.
12. **Cl_mic:** Ligand A (35.683) has a lower microsomal clearance than Ligand B (78.076), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-9.575) has a longer in vitro half-life than Ligand B (-0.952).
14. **Pgp:** Ligand A (0.171) has a lower P-gp efflux liability than Ligand B (0.556), which is favorable for oral bioavailability.
15. **Affinity:** Ligand B (-7.2) has a slightly better binding affinity than Ligand A (-7.9). However, the difference is less than 1.5 kcal/mol, and other factors are more important.
**Overall Assessment:**
Ligand A is the stronger candidate. While both have poor Caco-2 permeability, Ligand A demonstrates superior ADME properties across the board: lower DILI risk, lower hERG inhibition, better metabolic stability (lower Cl_mic, longer t1/2), lower P-gp efflux, and a better QED score. The slight advantage in binding affinity for Ligand B is outweighed by these significant improvements in safety and pharmacokinetic parameters. For a cardiovascular GPCR, minimizing off-target effects (DILI, hERG) and maximizing metabolic stability are particularly important.
Output:
1
2025-04-17 20:49:12,712 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (364.45 & 340.47 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (67.23) is higher than Ligand B (49.41). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B has an advantage.
3. **logP:** Ligand B (3.569) is slightly higher than Ligand A (2.352). Both are within the optimal 1-3 range, but Ligand B is approaching the upper limit.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 5 HBA, while Ligand B has 2. Both are acceptable, but lower is generally better for permeability. Ligand B has an advantage.
6. **QED:** Ligand A (0.909) has a significantly better QED score than Ligand B (0.736), indicating a more drug-like profile. This is a substantial advantage for Ligand A.
7. **DILI:** Ligand B (30.593) has a much lower DILI risk than Ligand A (54.556). This is a significant advantage for Ligand B.
8. **BBB:** Both ligands have good BBB penetration (Ligand A: 78.596, Ligand B: 70.221). Since ADRB2 is not a CNS target, this is less crucial, but higher is still slightly preferred. Ligand A has a slight edge.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Both have negative solubility values, suggesting poor aqueous solubility. This is a concern for both.
11. **hERG:** Both ligands have low hERG inhibition risk (Ligand A: 0.753, Ligand B: 0.669). No significant difference.
12. **Cl_mic:** Ligand A (1.428) has a significantly lower microsomal clearance than Ligand B (68.455), indicating better metabolic stability. This is a major advantage for Ligand A.
13. **t1/2:** Ligand B (3.728) has a longer in vitro half-life than Ligand A (-1.466). This is a significant advantage for Ligand B.
14. **Pgp:** Both have low Pgp efflux liability (Ligand A: 0.369, Ligand B: 0.373). No significant difference.
15. **Binding Affinity:** Ligand A (-7.4 kcal/mol) has a stronger binding affinity than Ligand B (-6.8 kcal/mol). This is a 0.6 kcal/mol difference, which is a meaningful advantage for Ligand A.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), and the general drug-like properties, Ligand A emerges as the more promising candidate. While Ligand B has advantages in DILI risk and in vitro half-life, Ligand A's superior QED, metabolic stability (lower Cl_mic), and significantly stronger binding affinity outweigh these drawbacks. The affinity difference is substantial enough to compensate for the slightly higher DILI risk. Both compounds have permeability and solubility issues that would need to be addressed in further optimization.
**Output:**
1
2025-04-17 20:49:12,712 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (369.893 and 362.901 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (87.3) is higher than Ligand B (53.43). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is generally preferred for absorption. Ligand B is better here.
3. **logP:** Both ligands have good logP values (1.836 and 3.151), falling within the 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Ligand A has 3 HBD, while Ligand B has 1. Lower HBD is generally preferred for better permeability. Ligand B is better.
5. **HBA:** Both have 3 HBA, which is acceptable. No significant difference.
6. **QED:** Both ligands have good QED scores (0.61 and 0.791), indicating drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (21.946) has a slightly higher DILI risk than Ligand B (17.449), but both are well below the concerning threshold of 60. Ligand B is better.
8. **BBB:** Ligand A (59.093) has a lower BBB penetration percentile than Ligand B (80.962). While ADRB2 isn't a CNS target, some distribution into the CNS is possible, and higher BBB is generally a positive attribute. Ligand B is better.
9. **Caco-2:** Ligand A (-5.07) and Ligand B (-4.62) both have negative Caco-2 values, which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-3.088) and Ligand B (-3.885) both have poor solubility. This is a significant drawback for both.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.1 and 0.62, respectively). No significant difference.
12. **Cl_mic:** Ligand A (47.774) and Ligand B (45.927) have similar microsomal clearance values. No significant difference.
13. **t1/2:** Ligand B (23.813) has a longer in vitro half-life than Ligand A (17.609), which is desirable. Ligand B is better.
14. **Pgp:** Ligand A (0.017) has a very low Pgp efflux liability, while Ligand B (0.563) is slightly higher. Ligand A is better.
15. **Binding Affinity:** Ligand B (-6.5 kcal/mol) has a slightly better binding affinity than Ligand A (-6.1 kcal/mol). This is a crucial factor, and a 0.4 kcal/mol difference is meaningful.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand B emerges as the slightly better candidate. It has a better logP, lower TPSA, better BBB penetration, longer half-life, and a stronger binding affinity. While both have poor solubility and Caco-2 permeability, the affinity advantage of Ligand B, combined with its better ADME profile overall, outweighs the slightly better Pgp profile of Ligand A. The solubility and permeability issues would need to be addressed through formulation strategies.
Output:
0
2025-04-17 20:49:12,712 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (337.47 & 342.48 Da) are within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (38.56) is better than Ligand B (41.57). Both are below 140, but lower TPSA generally favors absorption.
3. **logP:** Both ligands (4.06 & 4.34) are slightly above the optimal 1-3 range, potentially raising solubility concerns. Ligand B is a bit higher.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 4 HBA, while Ligand B has 2. Both are acceptable, but lower is often preferred for permeability. Ligand B is better here.
6. **QED:** Ligand B (0.884) has a significantly higher QED score than Ligand A (0.599), indicating better overall drug-likeness. This is a substantial advantage for Ligand B.
7. **DILI:** Ligand A (17.45%) has a much lower DILI risk than Ligand B (24.31%). This is a significant advantage for Ligand A.
8. **BBB:** Ligand B (85.07%) has a much higher BBB penetration score than Ligand A (68.55%). While ADRB2 isn't strictly a CNS target, some CNS exposure can be relevant, and higher BBB is generally favorable.
9. **Caco-2:** Ligand A (-5.232) has a worse Caco-2 permeability than Ligand B (-4.575). Lower values are less favorable. Ligand B is better.
10. **Solubility:** Ligand A (-2.15) has better solubility than Ligand B (-4.761). This is a positive for Ligand A, especially given the slightly higher logP values.
11. **hERG:** Both ligands have low hERG inhibition risk (0.977 & 0.782). No significant difference.
12. **Cl_mic:** Ligand A (26.64) has a much lower microsomal clearance than Ligand B (73.30). Lower clearance is better for metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (29.77) has a much longer in vitro half-life than Ligand B (7.662). This is a major advantage for Ligand A, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.717 & 0.517). No significant difference.
15. **Binding Affinity:** Ligand B (-7.6 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.8 kcal/mol). This is a substantial advantage for Ligand B, and can often outweigh minor ADME drawbacks.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand B excels in affinity and BBB penetration, and has a better Caco-2 value. However, Ligand A has a much better safety profile (DILI, Cl_mic, t1/2) and solubility. The affinity difference is significant (0.8 kcal/mol), but the ADME profile of Ligand A is more balanced and less concerning.
**Overall Assessment:**
While Ligand B has superior binding affinity and a better QED score, the significantly better DILI, Cl_mic, and t1/2 of Ligand A, coupled with acceptable solubility, make it the more promising candidate. The improved metabolic stability and longer half-life are crucial for a viable drug. The affinity difference, while notable, isn't so large that it completely overshadows the ADME advantages of Ligand A.
Output:
1
2025-04-17 20:49:12,712 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (350.5 and 346.4 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (69.64) is better than Ligand B (82.08). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally aids absorption.
3. **logP:** Ligand A (2.469) is within the optimal 1-3 range. Ligand B (0.77) is a bit low, potentially hindering membrane permeability.
4. **HBD:** Both have acceptable HBD counts (2 and 1, respectively), well below the 5 threshold.
5. **HBA:** Both have acceptable HBA counts (3 and 4, respectively), well below the 10 threshold.
6. **QED:** Both ligands have similar QED values (0.8 and 0.721), indicating good drug-likeness.
7. **DILI:** Ligand A (11.4) has a significantly lower DILI risk than Ligand B (32.842). This is a crucial advantage.
8. **BBB:** Not a high priority for a cardiovascular target, but Ligand A (68.282) has a better BBB percentile than Ligand B (57.736).
9. **Caco-2:** Ligand A (-4.825) and Ligand B (-5.039) are similar.
10. **Solubility:** Ligand A (-2.549) and Ligand B (-2.049) are similar.
11. **hERG:** Both ligands have low hERG inhibition liability (0.248 and 0.102, respectively).
12. **Cl_mic:** Ligand B (10.339) has a lower microsomal clearance than Ligand A (12.022), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-12.301) has a much longer in vitro half-life than Ligand A (-2.332). This is a significant advantage.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.115 and 0.01, respectively).
15. **Binding Affinity:** Ligand A (-6.8) has slightly better binding affinity than Ligand B (-6.6), but the difference is small (0.2 kcal/mol).
**Overall Assessment:**
For a cardiovascular GPCR target like ADRB2, balancing potency, ADME properties, and safety is crucial. Ligand A has a significant advantage in DILI risk, a better logP for permeability, and slightly better affinity. Ligand B has a longer half-life and better metabolic stability. However, the lower DILI risk of Ligand A is a major factor, and the small affinity difference can be potentially addressed through further optimization. The slightly better logP of Ligand A is also a plus.
Output:
1
2025-04-17 20:49:12,713 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
The ADRB2 receptor is a GPCR, so the priorities are logP, Pgp, TPSA, affinity, and BBB. Let's compare the ligands step-by-step:
1. **MW:** Both ligands (350.434 and 351.447 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (67.43) is significantly better than Ligand B (78.95). Lower TPSA generally favors better cell permeability, crucial for GPCR ligands.
3. **logP:** Ligand A (3.804) is optimal, while Ligand B (0.241) is quite low. A logP below 1 can hinder membrane permeability. This is a major strike against Ligand B.
4. **HBD/HBA:** Ligand A (2 HBD, 3 HBA) and Ligand B (1 HBD, 4 HBA) are both acceptable, within the guidelines.
5. **QED:** Both ligands are very similar (0.794 and 0.787), indicating good drug-likeness.
6. **DILI:** Ligand A (53.199) has a higher DILI risk than Ligand B (29.236). This favors Ligand B, but the difference isn't massive.
7. **BBB:** Ligand A (83.986) has significantly better BBB penetration potential than Ligand B (68.748). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant, and higher BBB is generally preferred.
8. **Caco-2:** Both are negative, indicating poor permeability. However, the scale is not provided, so it's hard to interpret.
9. **Solubility:** Ligand A (-4.818) has better solubility than Ligand B (-2.271).
10. **hERG:** Ligand A (0.663) has a lower hERG risk than Ligand B (0.106). This is a significant advantage for Ligand A.
11. **Cl_mic:** Ligand A (92.428) has a higher clearance than Ligand B (17.126), meaning it is less metabolically stable. This favors Ligand B.
12. **t1/2:** Ligand A (51.332) has a longer half-life than Ligand B (10.591). This favors Ligand A.
13. **Pgp:** Ligand A (0.29) has lower P-gp efflux than Ligand B (0.021). Lower P-gp efflux is better.
14. **Affinity:** Ligand A (-6.6 kcal/mol) has slightly better binding affinity than Ligand B (-6.4 kcal/mol). While the difference is small, it's still a positive for Ligand A.
**Overall Assessment:**
Ligand A is the stronger candidate. While Ligand B has a lower DILI risk and better metabolic stability, Ligand A excels in crucial areas for a GPCR ligand: TPSA, logP, BBB, solubility, hERG risk, Pgp efflux, and binding affinity. The low logP of Ligand B is a major concern, potentially hindering its ability to reach the receptor. The slightly better affinity of Ligand A further solidifies its preference.
**Output:**
1
2025-04-17 20:49:12,713 - INFO - Batch 213 complete. Total preferences: 3408
2025-04-17 20:49:12,713 - INFO - Processing batch 214/512...
2025-04-17 20:50:03,633 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (369.29 Da and 355.479 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both are below the 140 A^2 threshold for good oral absorption (84.22 and 87.74). Acceptable for both.
3. **logP:** Ligand A (2.456) is optimal, while Ligand B (0.783) is slightly low, potentially impacting permeability. This favors A.
4. **HBD:** Both have 2 HBD, well within the acceptable limit of 5.
5. **HBA:** Both have 4 HBA, also within the acceptable limit of 10.
6. **QED:** Ligand A (0.781) has a better QED score than Ligand B (0.63), indicating a more drug-like profile. This favors A.
7. **DILI:** Ligand B (27.453) has a significantly lower DILI risk than Ligand A (63.862). This is a major advantage for B.
8. **BBB:** Ligand A (67.623) has a better BBB penetration percentile than Ligand B (53.781). While ADRB2 isn't strictly a CNS target, some CNS exposure can be relevant for off-target effects and overall safety.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale isn't specified, so it's hard to interpret.
10. **Solubility:** Ligand A (-2.817) has slightly better solubility than Ligand B (-1.757).
11. **hERG:** Ligand A (0.057) has a slightly lower hERG risk than Ligand B (0.215).
12. **Cl_mic:** Ligand A (-5.151) has a much lower (better) microsomal clearance than Ligand B (27.452), indicating higher metabolic stability. This is a significant advantage for A.
13. **t1/2:** Ligand A (-22.346) has a much longer in vitro half-life than Ligand B (7.27). This is a substantial advantage for A.
14. **Pgp:** Ligand A (0.007) has a much lower Pgp efflux liability than Ligand B (0.024), indicating better bioavailability. This favors A.
15. **Binding Affinity:** Ligand B (-5.8 kcal/mol) has a stronger binding affinity than Ligand A (-2.8 kcal/mol). This is a substantial advantage for B, potentially outweighing some ADME concerns.
**Overall Assessment:**
Ligand B has a significantly better binding affinity and a much lower DILI risk. However, Ligand A excels in several key ADME properties: QED, Cl_mic, t1/2, Pgp efflux, and BBB penetration. The difference in binding affinity is substantial (3 kcal/mol), which is a significant advantage. Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity), the strong binding affinity of Ligand B is a major driver. Although Ligand A has better ADME properties, the potency advantage of Ligand B is likely to be more impactful in early stages of drug development, and ADME properties can be optimized later.
Output:
0
2025-04-17 20:50:03,634 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (371.478) is slightly higher than Ligand B (348.491), but both are acceptable.
2. **TPSA:** Ligand A (95.66) is slightly higher than Ligand B (69.04). Both are below the 140 threshold for oral absorption, but Ligand B is significantly better, closer to the 90 threshold for potential CNS penetration (though ADRB2 isn't necessarily a CNS target).
3. **logP:** Both ligands have good logP values (Ligand A: 1.716, Ligand B: 2.893), falling within the optimal 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Ligand A (3) is higher than Ligand B (1). Both are acceptable (<=5), but lower is generally preferred for permeability.
5. **HBA:** Both ligands have the same number of HBA (5), which is within the acceptable range (<=10).
6. **QED:** Both ligands have good QED scores (Ligand A: 0.734, Ligand B: 0.888), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Both ligands have acceptable DILI risk (Ligand A: 33.23, Ligand B: 39.434), well below the 60 threshold.
8. **BBB:** Both ligands show good BBB penetration (Ligand A: 74.68, Ligand B: 71.539), though this isn't a primary concern for ADRB2.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.143 and -5.017). This is unusual and suggests poor permeability. However, these values are on the same scale, so the difference is not meaningful.
10. **Solubility:** Both ligands have negative solubility values (-3.115 and -2.559). This is also unusual and suggests poor solubility. Again, the difference is not meaningful.
11. **hERG:** Both ligands have low hERG risk (Ligand A: 0.485, Ligand B: 0.133). Ligand B is better here.
12. **Cl_mic:** Ligand A (21.169) has a significantly lower microsomal clearance than Ligand B (49.245), indicating better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand A (-28.128) has a much longer in vitro half-life than Ligand B (-3.656). This is a major advantage, suggesting less frequent dosing.
14. **Pgp:** Ligand A (0.046) has lower P-gp efflux than Ligand B (0.167), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand B (-7.9) has a significantly stronger binding affinity than Ligand A (-9.3). This is a substantial advantage, potentially outweighing some ADME drawbacks.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP and significantly in affinity. Ligand A is better in TPSA and Pgp, and has better metabolic stability (Cl_mic) and half-life. The difference in binding affinity (-7.9 vs -9.3) is substantial.
**Conclusion:**
While Ligand A has better metabolic stability and Pgp properties, the significantly stronger binding affinity of Ligand B (-7.9 kcal/mol vs -9.3 kcal/mol) is a decisive factor for a GPCR target. The better logP and QED of Ligand B also contribute to its favorability.
Output:
0
2025-04-17 20:50:03,634 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (342.414) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (42.43) is significantly better than Ligand B (101.21). For a GPCR, lower TPSA is preferred for better permeability and potentially better CNS penetration, even though ADRB2 isn't strictly a CNS target.
3. **logP:** Ligand A (3.703) is slightly higher than Ligand B (2.013), both are within the optimal range (1-3), but A is closer to the upper limit.
4. **HBD/HBA:** Ligand A (0 HBD, 3 HBA) is preferable to Ligand B (2 HBD, 5 HBA). Lower numbers are generally better for permeability.
5. **QED:** Both ligands have similar QED values (0.851 and 0.777), indicating good drug-likeness.
6. **DILI:** Ligand A (30.865) has a significantly lower DILI risk than Ligand B (49.864), which is a major advantage.
7. **BBB:** Ligand A (85.576) has better BBB penetration potential than Ligand B (78.364), though this isn't a primary concern for ADRB2.
8. **Caco-2:** Ligand A (-4.609) and Ligand B (-5.169) have similar Caco-2 permeability.
9. **Solubility:** Ligand A (-3.274) and Ligand B (-3.349) have similar solubility.
10. **hERG:** Ligand A (0.772) has a lower hERG inhibition liability than Ligand B (0.404), which is a significant safety advantage.
11. **Cl_mic:** Ligand B (22.482) has a much lower microsomal clearance than Ligand A (53.109), indicating better metabolic stability.
12. **t1/2:** Ligand B (0.433) has a slightly longer in vitro half-life than Ligand A (-8.984), but the negative value for A is concerning.
13. **Pgp:** Ligand A (0.462) has lower P-gp efflux liability than Ligand B (0.021), which is favorable.
14. **Binding Affinity:** Ligand B (-6.2 kcal/mol) has a slightly better binding affinity than Ligand A (-5.8 kcal/mol), a difference of 0.4 kcal/mol.
**Overall Assessment:**
While Ligand B has a slightly better binding affinity and metabolic stability, Ligand A is significantly better in several crucial ADME-Tox parameters. Specifically, the lower DILI risk and hERG liability of Ligand A are major advantages. The lower TPSA and better BBB penetration potential are also beneficial, even for a non-CNS target like ADRB2. The slightly weaker affinity of Ligand A is likely surmountable with further optimization, and the improved safety profile is a more critical factor at this stage.
Output:
1
2025-04-17 20:50:03,634 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.37 & 370.47 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (95.86 & 92.78) are below the 140 A^2 threshold for good oral absorption, but higher than the 90 A^2 for CNS targets. Since ADRB2 is primarily a cardiovascular target, CNS penetration is not a primary concern.
3. **logP:** Ligand B (1.462) is better than Ligand A (0.23). Ligand A's logP is quite low, potentially hindering membrane permeability. This is a significant drawback.
4. **HBD:** Both have 1 HBD, which is acceptable.
5. **HBA:** Both have 6 HBA, which is acceptable.
6. **QED:** Ligand A (0.837) has a slightly better QED score than Ligand B (0.762), indicating a more drug-like profile.
7. **DILI:** Both ligands have relatively high DILI risk (61.19% and 63.71%), which is a concern. However, this is something that can be addressed in later optimization stages.
8. **BBB:** Ligand A (53.66%) has a higher BBB penetration percentile than Ligand B (30.17%). While not a primary concern for a cardiovascular target, higher BBB is generally preferable.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. This is a significant issue for both.
10. **Solubility:** Both ligands have very poor aqueous solubility (-2.158 and -2.183). This is a major drawback that would require formulation strategies.
11. **hERG:** Both ligands have low hERG inhibition liability (0.191 and 0.077), which is excellent.
12. **Cl_mic:** Ligand A (-3.84 mL/min/kg) has a much lower (better) microsomal clearance than Ligand B (58.59 mL/min/kg). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (-34.899 hours) has a much longer in vitro half-life than Ligand B (-3.071 hours). This is a significant advantage for Ligand A.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.027 and 0.046), which is good.
15. **Binding Affinity:** Ligand B (-7.5 kcal/mol) has a significantly better binding affinity than Ligand A (-6.1 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME concerns.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand B excels in affinity, and has a better logP. While both have acceptable TPSA and Pgp values, the affinity difference is substantial. The poor solubility and Caco-2 values are concerning for both, but the superior binding affinity of Ligand B is a strong driver. The better metabolic stability and half-life of Ligand A are attractive, but the affinity difference is larger.
**Conclusion:**
Despite the drawbacks of both compounds, Ligand B's significantly stronger binding affinity to the ADRB2 receptor makes it the more promising candidate. The lower logP of Ligand A is a significant concern, and while Ligand A has better metabolic stability, this can be addressed through structural modifications. The binding affinity is harder to improve.
Output:
0
2025-04-17 20:50:03,634 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (347.459 Da) is slightly lower, which is generally favorable for permeability.
**2. TPSA:** Ligand A (75.44) is better than Ligand B (80.32). Both are below 140, but closer to 90 is preferred for GPCRs, and A is closer.
**3. logP:** Both ligands have good logP values (A: 2.95, B: 2.302), falling within the 1-3 range.
**4. H-Bond Donors:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
**5. H-Bond Acceptors:** Ligand A (4) is preferable to Ligand B (6). Lower HBA is generally preferable.
**6. QED:** Both ligands have acceptable QED values (A: 0.734, B: 0.682), indicating good drug-like properties.
**7. DILI:** Ligand A (43.234) has a lower DILI risk than Ligand B (55.874), which is a significant advantage.
**8. BBB:** Ligand A (71.733) has a significantly higher BBB penetration percentile than Ligand B (57.619). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be beneficial for off-target effects and distribution.
**9. Caco-2 Permeability:** Ligand A (-4.837) has better Caco-2 permeability than Ligand B (-5.078).
**10. Aqueous Solubility:** Ligand A (-2.622) has better solubility than Ligand B (-3.393).
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (A: 0.386, B: 0.392).
**12. Microsomal Clearance:** Ligand A (71.734) has higher microsomal clearance than Ligand B (45.147), meaning B is more metabolically stable.
**13. In vitro Half-Life:** Ligand B (10.65) has a much longer in vitro half-life than Ligand A (-22.077). This is a major advantage for dosing frequency.
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (A: 0.485, B: 0.121), with B being slightly better.
**15. Binding Affinity:** Ligand A (-5.6 kcal/mol) has a slightly better binding affinity than Ligand B (-4.4 kcal/mol). This is a 1.2 kcal/mol difference, which is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand A is generally superior in terms of drug-likeness (TPSA, HBD, HBA, QED), safety (DILI, hERG), permeability (Caco-2, solubility), and crucially, binding affinity. The substantially better binding affinity of Ligand A is a key driver. While Ligand B has a better half-life and slightly better P-gp efflux, the affinity difference is significant enough to favor Ligand A.
Output:
1
2025-04-17 20:50:03,634 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**1. Molecular Weight:** Both ligands (365.455 and 347.367 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (91.5) is slightly higher than Ligand B (75.99). For a cardiovascular GPCR, TPSA is not a primary concern, but lower is generally preferred for better absorption. Ligand B has an advantage.
**3. logP:** Both ligands have excellent logP values (1.777 and 1.66), falling within the optimal 1-3 range. No clear advantage.
**4. H-Bond Donors:** Ligand A has 2 HBD, while Ligand B has 0. Lower is generally better for permeability, giving Ligand B a slight edge.
**5. H-Bond Acceptors:** Ligand A has 4 HBA, and Ligand B has 7. Ligand A is preferable here.
**6. QED:** Both ligands have similar QED values (0.764 and 0.676), indicating good drug-likeness.
**7. DILI:** Ligand A (64.288) and Ligand B (72.276) are both acceptable, but Ligand A has a lower risk.
**8. BBB:** Both ligands show reasonable BBB penetration (77.317 and 63.086). While ADRB2 isn't a primary CNS target, some degree of BBB penetration can be beneficial for off-target effects. Ligand A is better.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.972 and -4.145). This is unusual and suggests poor permeability. However, these values are on a log scale, so the difference isn't massive.
**10. Aqueous Solubility:** Both ligands have negative solubility values (-3.959 and -2.841), indicating poor solubility. This is a concern for bioavailability.
**11. hERG Inhibition:** Ligand A (0.793) has a slightly higher hERG inhibition risk than Ligand B (0.24). This is a significant advantage for Ligand B.
**12. Microsomal Clearance:** Ligand A (43.634) has a lower microsomal clearance than Ligand B (73.241), suggesting better metabolic stability. This is a significant advantage for Ligand A.
**13. In vitro Half-Life:** Ligand A (6.639) has a much better in vitro half-life than Ligand B (-27.5). This is a major advantage for Ligand A.
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (0.127 and 0.275).
**15. Binding Affinity:** Ligand B (-7.4) has a slightly better binding affinity than Ligand A (-7.2). While a 0.2 kcal/mol difference isn't huge, it's noticeable.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity), and the general guidelines, Ligand A appears to be the more promising candidate. While Ligand B has a slightly better affinity and lower hERG risk, Ligand A demonstrates significantly better metabolic stability (lower Cl_mic, longer t1/2) and a lower DILI risk. The slightly better BBB penetration of Ligand A is also a plus. The solubility and permeability issues are similar for both, and would need to be addressed in further optimization. The improved metabolic stability and reduced toxicity risk of Ligand A outweigh the small affinity advantage of Ligand B.
Output:
1
2025-04-17 20:50:03,634 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
The target is ADRB2, a GPCR. Therefore, I will prioritize logP, TPSA, Pgp efflux, BBB penetration, and binding affinity.
* **Molecular Weight:** Both ligands are within the ideal range (352.483 Da and 356.423 Da).
* **TPSA:** Ligand A (103.01) is better than Ligand B (127.84). Lower TPSA generally favors oral absorption, which is important.
* **logP:** Ligand A (1.161) is within the optimal range, while Ligand B (-0.511) is slightly below, potentially hindering permeation.
* **H-Bond Donors/Acceptors:** Both are acceptable, though Ligand B has slightly more HBDs (4 vs 3).
* **QED:** Ligand A (0.651) has a better QED score than Ligand B (0.392), indicating a more drug-like profile.
* **DILI:** Ligand A (29.236) has a significantly lower DILI risk than Ligand B (51.842). This is a crucial advantage.
* **BBB:** Ligand A (29.391) and Ligand B (52.268) are both low, but this is less critical for a non-CNS target like ADRB2 (cardiovascular).
* **Caco-2 Permeability:** Both are negative, which is unusual and requires further investigation. However, the values are similar.
* **Aqueous Solubility:** Both are very poor (-1.024 and -1.663). This is a significant drawback for both, but could potentially be addressed with formulation strategies.
* **hERG:** Both ligands show very low hERG inhibition risk (0.054).
* **Microsomal Clearance:** Ligand A (3.829) has slightly lower clearance than Ligand B (4.615), suggesting better metabolic stability.
* **In vitro Half-Life:** Ligand A (8.541) has a longer half-life than Ligand B (3.229), which is desirable.
* **P-gp Efflux:** Both ligands show very low P-gp efflux liability (0.006 and 0.008).
* **Binding Affinity:** Ligand B (-6.0 kcal/mol) has a slightly better binding affinity than Ligand A (-5.7 kcal/mol), but the difference is not substantial enough to outweigh other factors.
**Overall Assessment:**
Ligand A is the more promising candidate. It has a better TPSA, logP, QED, significantly lower DILI risk, better metabolic stability (lower Cl_mic, longer t1/2), and a slightly better overall drug-like profile. While both have poor solubility, the other advantages of Ligand A make it a preferable starting point for optimization. The small difference in binding affinity is not enough to favor Ligand B given the other benefits of Ligand A.
**Output:**
1
2025-04-17 20:50:03,634 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (370.312 and 371.463 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (107.97) is better than Ligand B (123.66). For a GPCR, keeping TPSA lower is generally favorable for permeability.
3. **logP:** Ligand A (1.994) is within the optimal 1-3 range. Ligand B (-0.116) is slightly below 1, which could potentially hinder membrane permeability.
4. **HBD:** Ligand A (3) and Ligand B (4) are both acceptable, being less than 5.
5. **HBA:** Ligand A (5) and Ligand B (7) are both acceptable, being less than 10.
6. **QED:** Ligand A (0.596) is better than Ligand B (0.425), indicating a more drug-like profile.
7. **DILI:** Ligand A (99.341) has a very high DILI risk, which is a major concern. Ligand B (44.63) has a much lower, and acceptable, DILI risk.
8. **BBB:** Ligand A (37.301) has a low BBB penetration, while Ligand B (27.646) is also low. Since ADRB2 is a cardiovascular target, BBB penetration is not a primary concern, but it's not a benefit for either.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.655 and -5.813), which is unusual and suggests poor permeability. This is a red flag for both.
10. **Solubility:** Ligand A (-2.86) and Ligand B (-1.206) both have poor aqueous solubility.
11. **hERG:** Ligand A (0.042) has a very low hERG risk, which is excellent. Ligand B (0.162) also has a low hERG risk, but slightly higher than A.
12. **Cl_mic:** Ligand A (-14.658) has a much lower (better) microsomal clearance than Ligand B (10.756), indicating greater metabolic stability.
13. **t1/2:** Ligand A (-6.993) has a negative in vitro half-life, which is concerning. Ligand B (13.653) has a reasonable half-life.
14. **Pgp:** Ligand A (0.034) has a very low Pgp efflux liability, which is good. Ligand B (0.015) is even lower.
15. **Affinity:** Ligand B (-7.2 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.1 kcal/mol). This 1.1 kcal/mol difference is substantial and could outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand A has better QED, lower Cl_mic, and lower Pgp efflux. However, its extremely high DILI risk and negative in vitro half-life are major drawbacks. Ligand B has a significantly better binding affinity, a much lower DILI risk, and a reasonable half-life. While its logP is slightly low and Caco-2 permeability is poor, the strong binding affinity and improved safety profile make it the more promising candidate. The poor Caco-2 and solubility could be addressed with formulation strategies.
Output:
0
2025-04-17 20:50:03,634 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [383.455, 123.17 , 1.704, 2. , 9. , 0.728, 92.904, 49.477, -5.062, -3.119, 0.169, 58.482, -5.944, 0.154, -5.8 ]
**Ligand B:** [342.483, 58.2 , 3.268, 2. , 2. , 0.499, 29.779, 80.574, -5.12 , -3.552, 0.745, 62.067, 10.958, 0.64 , -6.8 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (342.483) is slightly smaller, which *could* be advantageous for permeability, but the difference isn't huge.
2. **TPSA:** Ligand A (123.17) is higher than Ligand B (58.2). For a cardiovascular GPCR, TPSA isn't *as* critical as for CNS targets, but lower is generally better for absorption. Ligand B is significantly better here.
3. **logP:** Ligand A (1.704) is within the optimal range. Ligand B (3.268) is a bit higher, approaching the upper limit. This could lead to some solubility issues, but isn't a dealbreaker.
4. **HBD:** Both have 2 HBD, which is good.
5. **HBA:** Ligand A has 9 HBA, which is acceptable. Ligand B has only 2, which is excellent. Fewer HBA generally improves permeability.
6. **QED:** Ligand A (0.728) has a better QED score than Ligand B (0.499), indicating a more drug-like profile.
7. **DILI:** Ligand A (92.904) has a significantly higher DILI risk than Ligand B (29.779). This is a major concern for Ligand A.
8. **BBB:** Ligand A (49.477) has a lower BBB penetration percentile than Ligand B (80.574). While not a primary concern for a cardiovascular target, higher BBB is rarely detrimental.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
10. **Solubility:** Both have negative solubility values, which is also unusual. Again, the scale is not specified, making interpretation difficult.
11. **hERG:** Ligand A (0.169) has a lower hERG risk than Ligand B (0.745), which is a positive.
12. **Cl_mic:** Ligand A (58.482) has a lower microsomal clearance, suggesting better metabolic stability, which is good. Ligand B (62.067) is slightly higher.
13. **t1/2:** Ligand B (10.958) has a significantly longer in vitro half-life than Ligand A (-5.944). This is a major advantage for Ligand B.
14. **Pgp:** Ligand A (0.154) has lower P-gp efflux, which is favorable. Ligand B (0.64) is higher.
15. **Affinity:** Ligand B (-6.8 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.8 kcal/mol). This is a crucial advantage, as a 1 kcal/mol difference is substantial.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, and affinity. Ligand B excels in TPSA and affinity, while Ligand A has a slightly better logP and Pgp. However, the *significant* advantage in affinity for Ligand B, combined with its lower DILI risk and longer half-life, outweighs the minor differences in other parameters. The high DILI risk for Ligand A is a major red flag.
**Conclusion:**
Considering all factors, Ligand B is the more promising drug candidate.
```
0
```
2025-04-17 20:50:03,635 - INFO - Here's a step-by-step comparison of Ligand A and Ligand B, followed by my final decision:
**Molecular Weight:** Ligand A (333.391 Da) is well within the ideal range (200-500 Da). Ligand B (408.351 Da) is also acceptable, but approaching the upper limit.
**TPSA:** Ligand A (66.15) is excellent, well below the 140 threshold for oral absorption and suitable for a GPCR. Ligand B (74.58) is still good, but slightly higher.
**logP:** Ligand A (3.2) is optimal. Ligand B (2.504) is also good, falling within the 1-3 range.
**H-Bond Donors:** Ligand A (3) is within the acceptable limit of 5. Ligand B (2) is also good.
**H-Bond Acceptors:** Ligand A (3) is well below the limit of 10. Ligand B (5) is also acceptable.
**QED:** Ligand A (0.641) is good, exceeding the 0.5 threshold. Ligand B (0.511) is barely above the threshold, suggesting a slightly less drug-like profile.
**DILI:** Ligand A (78.945) is moderate, but acceptable. Ligand B (36.293) is excellent, indicating a significantly lower risk of liver injury.
**BBB:** Ligand A (82.784) is good, suggesting reasonable potential for CNS penetration, though ADRB2 is primarily cardiovascular. Ligand B (65.801) is lower, indicating less potential for CNS penetration.
**Caco-2:** Both ligands have negative Caco-2 values (-5.012 and -5.436), which is unusual and concerning. This suggests poor permeability. However, negative values can sometimes be artifacts of the prediction method.
**Solubility:** Both ligands have negative solubility values (-4.471 and -3.112), which is also concerning and suggests poor aqueous solubility. Similar to Caco-2, these values may be prediction artifacts.
**hERG:** Ligand A (0.823) is a lower risk than Ligand B (0.263).
**Cl_mic:** Ligand A (1.583) has a much lower microsomal clearance than Ligand B (19.517), indicating better metabolic stability.
**t1/2:** Ligand A (35.02) has a longer in vitro half-life than Ligand B (32.885).
**Pgp:** Ligand A (0.721) has a lower P-gp efflux liability than Ligand B (0.1).
**Binding Affinity:** Both ligands have very good binding affinities (-6.2 and -5.7 kcal/mol). Ligand A is slightly better (-6.2 kcal/mol).
**GPCR-Specific Considerations:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Both ligands perform well on logP and TPSA. Ligand A has better Pgp efflux and slightly better affinity.
**Overall Assessment:**
Ligand A is preferable. While both ligands have concerningly low predicted solubility and permeability, Ligand A has a better overall profile. It has a better QED score, significantly lower DILI risk, better metabolic stability (lower Cl_mic and longer t1/2), lower P-gp efflux, and slightly better binding affinity. The slightly better BBB penetration is a bonus, even though ADRB2 is not a CNS target. The hERG risk is also lower for Ligand A.
Output:
1
2025-04-17 20:50:03,635 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (366.571) is slightly higher than Ligand B (348.403), but both are acceptable.
2. **TPSA:** Ligand A (40.62) is excellent, well below the 140 threshold for oral absorption and suitable for a GPCR. Ligand B (104.54) is higher, but still within a reasonable range, though less optimal.
3. **logP:** Ligand A (3.548) is optimal. Ligand B (0.303) is quite low, potentially hindering membrane permeability and absorption. This is a significant drawback.
4. **HBD:** Ligand A (0) is ideal. Ligand B (2) is acceptable.
5. **HBA:** Ligand A (3) is good. Ligand B (5) is also acceptable.
6. **QED:** Both ligands have similar and good QED values (A: 0.764, B: 0.769).
7. **DILI:** Ligand A (12.834) has a much lower DILI risk than Ligand B (37.611). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (88.561) has a good BBB penetration percentile. Ligand B (56.65) is lower, which is less desirable for a GPCR target, though not a hard disqualifier for a peripherally acting one like ADRB2.
9. **Caco-2:** Ligand A (-4.85) is a negative value, which is unusual and could indicate issues with Caco-2 permeability. Ligand B (-5.304) is similarly negative. This is a concern for both, but the negative values are difficult to interpret without more context.
10. **Solubility:** Ligand A (-3.416) and Ligand B (-1.468) both have negative solubility values, which is concerning.
11. **hERG:** Ligand A (0.562) has a lower hERG risk than Ligand B (0.069). This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand A (70.999) has a higher microsomal clearance than Ligand B (12.029). This suggests Ligand B is more metabolically stable.
13. **t1/2:** Ligand A (-25.349) has a negative in vitro half-life, which is not possible and indicates an issue with the data or the compound. Ligand B (9.683) has a reasonable half-life.
14. **Pgp:** Ligand A (0.221) has lower P-gp efflux than Ligand B (0.023), which is favorable.
15. **Affinity:** Ligand A (-5.7) has a better binding affinity than Ligand B (-3.4). This is a substantial advantage, potentially outweighing some ADME concerns.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are crucial. Ligand A excels in logP, TPSA, and affinity. While BBB isn't paramount for all ADRB2 applications, the higher value for Ligand A is still a plus.
**Overall Assessment:**
Ligand A has several significant advantages: better logP, lower DILI risk, lower hERG risk, better affinity, and lower Pgp efflux. While the negative Caco-2 and solubility values are concerning, the strong affinity and favorable ADME properties (excluding the negative values) make it a more promising candidate. The negative in vitro half-life for Ligand A is a major red flag, but the other advantages are substantial. Ligand B's low logP and higher DILI/hERG risk are significant drawbacks.
Output:
1
2025-04-17 20:50:03,635 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [352.425, 32.78, 3.151, 0, 3, 0.738, 21.908, 96.316, -4.099, -2.08, 0.685, 60.276, 10.004, 0.199, -7.8]
**Ligand B:** [363.447, 137.08, 1.699, 2, 6, 0.467, 68.437, 67.623, -5.343, -3.424, 0.394, 9.975, -8.257, 0.054, -7.2]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (352.425) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (32.78) is excellent, well below the 140 threshold and very good for GPCRs. Ligand B (137.08) is higher, but still acceptable, though less ideal.
3. **logP:** Ligand A (3.151) is optimal. Ligand B (1.699) is on the lower side, potentially impacting permeability.
4. **HBD:** Ligand A (0) is preferred. Ligand B (2) is acceptable, but more HBDs can sometimes hinder permeability.
5. **HBA:** Ligand A (3) is good. Ligand B (6) is higher, potentially impacting permeability.
6. **QED:** Ligand A (0.738) is significantly better than Ligand B (0.467), indicating a more drug-like profile.
7. **DILI:** Ligand A (21.908) has a much lower DILI risk than Ligand B (68.437), a crucial advantage.
8. **BBB:** Ligand A (96.316) shows excellent BBB penetration, highly desirable for a GPCR target. Ligand B (67.623) is lower, suggesting less CNS exposure.
9. **Caco-2:** Ligand B (-5.343) has a more negative value, suggesting better Caco-2 permeability than Ligand A (-4.099).
10. **Solubility:** Ligand B (-3.424) is better than Ligand A (-2.08), which is good.
11. **hERG:** Ligand A (0.685) has a slightly higher hERG risk than Ligand B (0.394), but both are relatively low.
12. **Cl_mic:** Ligand B (9.975) has significantly lower microsomal clearance, indicating better metabolic stability than Ligand A (60.276).
13. **t1/2:** Ligand B (-8.257) has a longer in vitro half-life than Ligand A (10.004), which is a positive.
14. **Pgp:** Ligand A (0.199) has lower P-gp efflux, which is preferable. Ligand B (0.054) is even lower, but the difference is small.
15. **Affinity:** Ligand A (-7.8) has a slightly better binding affinity than Ligand B (-7.2), although both are strong binders.
**GPCR-Specific Considerations:**
For an ADRB2 (GPCR) target, BBB penetration, logP, Pgp, TPSA, and affinity are key. Ligand A excels in BBB, TPSA, and has a slightly better affinity. Ligand B has better metabolic stability (Cl_mic, t1/2) and solubility, but suffers from a higher DILI risk and lower BBB penetration. The superior BBB penetration and lower DILI risk of Ligand A are particularly important.
**Conclusion:**
Despite Ligand B's better metabolic stability and solubility, the significantly better BBB penetration, lower DILI risk, and slightly better affinity of Ligand A make it the more promising drug candidate for ADRB2.
**Output:**
1
2025-04-17 20:50:03,635 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (360.391 Da) is slightly preferred due to being closer to the lower end, which generally aids permeability.
**2. TPSA:** Ligand B (73.71) is significantly better than Ligand A (97.64). Lower TPSA is crucial for GPCRs, enhancing blood-brain barrier penetration and overall absorption.
**3. logP:** Both ligands have good logP values (A: 2.602, B: 1.275) falling within the optimal 1-3 range. Ligand A is slightly better.
**4. H-Bond Donors:** Both ligands have acceptable HBD counts (A: 2, B: 1).
**5. H-Bond Acceptors:** Both ligands have acceptable HBA counts (A: 6, B: 4).
**6. QED:** Both ligands have similar QED values (A: 0.679, B: 0.673), indicating good drug-likeness.
**7. DILI Risk:** Ligand A (99.031) has a very high DILI risk, which is a major concern. Ligand B (41.45) is much lower and acceptable. This is a significant negative for Ligand A.
**8. BBB Penetration:** Ligand B (62.97) has better BBB penetration than Ligand A (52.811), though neither is exceptionally high. For a cardiovascular target, BBB penetration isn't *essential*, but can be beneficial for off-target effects.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, these values are on a scale where negative values are possible, and direct comparison is difficult without knowing the scale.
**10. Aqueous Solubility:** Ligand B (-2.101) is better than Ligand A (-4.305).
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (A: 0.674, B: 0.615).
**12. Microsomal Clearance:** Ligand A (21.214) has a lower (better) microsomal clearance than Ligand B (36.547), indicating better metabolic stability.
**13. In vitro Half-Life:** Ligand A (84.703) has a much longer half-life than Ligand B (-4.929). This is a significant advantage.
**14. P-gp Efflux:** Both ligands have similar P-gp efflux liability (A: 0.244, B: 0.111).
**15. Binding Affinity:** Ligand A (-7.7 kcal/mol) has a significantly stronger binding affinity than Ligand B (-7.2 kcal/mol). This 0.5 kcal/mol difference is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
While Ligand A has superior binding affinity and metabolic stability, its extremely high DILI risk is a critical flaw. Ligand B, despite slightly weaker binding, presents a much more favorable safety profile (DILI) and better solubility and TPSA. Given the cardiovascular context, a slightly lower affinity can be tolerated if it means avoiding significant liver toxicity. The better TPSA and solubility of Ligand B also contribute to better overall drug-like properties.
Output:
0
2025-04-17 20:50:03,635 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.5 & 366.8 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (69.64) is significantly better than Ligand B (101.8), falling well below the 140 threshold for good absorption. Ligand B is approaching the upper limit, potentially hindering absorption.
3. **logP:** Ligand A (2.574) is optimal, while Ligand B (0.773) is a bit low, potentially leading to permeability issues.
4. **HBD:** Both have 2 HBD, which is within the acceptable limit of 5.
5. **HBA:** Ligand A has 3 HBA, while Ligand B has 6. Both are within the acceptable limit of 10, but Ligand A is preferable.
6. **QED:** Both ligands have good QED scores (0.67 and 0.786), indicating drug-like properties.
7. **DILI:** Ligand A (10.24) has a much lower DILI risk than Ligand B (81.66), a significant advantage.
8. **BBB:** Ligand A (70.26) shows good BBB penetration, while Ligand B (59.4) is lower. While ADRB2 isn't exclusively a CNS target, some CNS exposure can occur, and higher BBB is generally favorable.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability.
10. **Solubility:** Both ligands have negative solubility values, indicating poor solubility.
11. **hERG:** Ligand A (0.621) has a slightly higher hERG risk than Ligand B (0.016), but both are low.
12. **Cl_mic:** Ligand A (77.884) has a higher microsomal clearance than Ligand B (-0.152), indicating lower metabolic stability. This is a drawback for Ligand A.
13. **t1/2:** Ligand A (10.769) has a longer half-life than Ligand B (13.317), which is a positive.
14. **Pgp:** Ligand A (0.28) has lower P-gp efflux than Ligand B (0.042), which is preferable.
15. **Binding Affinity:** Ligand B (-8.4 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.9 kcal/mol). This is a substantial advantage that could outweigh some ADME concerns.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A has better logP, TPSA, and Pgp. However, Ligand B's substantially stronger binding affinity (-8.4 vs -5.9 kcal/mol) is a major advantage. A 2.5 kcal/mol difference is significant and can often compensate for less-than-ideal ADME properties, especially if optimization can address those later. The DILI risk for Ligand B is a concern, but potentially manageable.
**Overall Assessment:**
While Ligand A has a better safety profile (lower DILI) and some ADME advantages, the significantly superior binding affinity of Ligand B is the deciding factor. The potency advantage is likely to be more impactful in driving efficacy.
Output:
0
2025-04-17 20:50:03,635 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
The target is ADRB2, a GPCR. Therefore, I will prioritize logP, Pgp efflux, TPSA, and binding affinity, alongside general drug-like properties.
* **Molecular Weight:** Both ligands (360.845 and 350.463 Da) are within the ideal range (200-500 Da).
* **TPSA:** Ligand A (76.02) is better than Ligand B (87.46). Lower TPSA generally favors better absorption, a key consideration for GPCR ligands.
* **logP:** Ligand A (4.171) is higher than Ligand B (0.867). While both are within acceptable ranges, Ligand A's higher logP could improve membrane permeability, important for GPCR targeting. However, it's approaching the upper limit where solubility issues might arise.
* **H-Bond Donors/Acceptors:** Both have similar HBD (2) and reasonable HBA (A: 4, B: 5) counts.
* **QED:** Ligand A (0.859) has a better QED score than Ligand B (0.692), indicating a more drug-like profile.
* **DILI Risk:** Ligand B (21.714) has a significantly lower DILI risk than Ligand A (81.621). This is a major advantage for Ligand B.
* **BBB Penetration:** Ligand A (65.374) shows better BBB penetration than Ligand B (50.097). While ADRB2 isn't exclusively a CNS target, some degree of BBB penetration can be beneficial for broader distribution.
* **Caco-2 Permeability:** Both have negative Caco-2 values, which is unusual and suggests potential issues with permeability prediction. However, the magnitude is similar.
* **Aqueous Solubility:** Ligand B (-0.685) has slightly better solubility than Ligand A (-5.184).
* **hERG Inhibition:** Ligand A (0.335) has a lower hERG inhibition risk than Ligand B (0.089), which is favorable.
* **Microsomal Clearance:** Ligand B (5.802) has significantly lower microsomal clearance than Ligand A (62.002), indicating better metabolic stability.
* **In vitro Half-Life:** Ligand A (74.113) has a much longer in vitro half-life than Ligand B (5.404). This is a significant advantage for Ligand A.
* **P-gp Efflux:** Ligand A (0.259) has lower P-gp efflux than Ligand B (0.033), which is desirable.
* **Binding Affinity:** Ligand B (-7.1 kcal/mol) has a slightly better binding affinity than Ligand A (-7.7 kcal/mol). While the difference is small, it's still a factor.
**Overall Assessment:**
Ligand A has advantages in QED, BBB penetration, in vitro half-life, and P-gp efflux. However, Ligand B shines with a much lower DILI risk and better metabolic stability (lower Cl_mic). The slightly better binding affinity of Ligand B is also a plus. Considering the balance, the lower DILI risk and improved metabolic stability of Ligand B are critical factors for a viable drug candidate, especially given the potential for chronic cardiovascular use. While Ligand A's longer half-life is attractive, the safety profile of Ligand B is more compelling.
Output:
0
2025-04-17 20:50:03,636 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [352.391, 104.98 , -0.041, 1. , 6. , 0.604, 62.66 , 43.815, -4.92 , -1.538, 0.075, 18.257, -11.541, 0.012, -6.5 ]
**Ligand B:** [364.515, 76.44 , 1.25 , 1. , 5. , 0.718, 16.712, 57.154, -5.227, -2.247, 0.486, 34.975, -1.448, 0.011, -6.3 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (352.391) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (104.98) is higher than Ligand B (76.44). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is still preferred. Ligand B is better here.
3. **logP:** Ligand B (1.25) is within the optimal range (1-3), while Ligand A (-0.041) is slightly below 1. This is a significant drawback for Ligand A, potentially hindering membrane permeability.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 6 HBA, Ligand B has 5. Both are acceptable, under the 10 threshold.
6. **QED:** Both have good QED scores (A: 0.604, B: 0.718). Ligand B is slightly better.
7. **DILI:** Ligand A (62.66) has a higher DILI risk than Ligand B (16.712). This is a major concern for Ligand A.
8. **BBB:** Ligand B (57.154) has a higher BBB penetration score than Ligand A (43.815). While not a primary concern for a cardiovascular target, higher BBB is generally preferable.
9. **Caco-2:** Ligand A (-4.92) and Ligand B (-5.227) are both very poor. This is a significant negative for both, suggesting poor intestinal absorption.
10. **Solubility:** Ligand A (-1.538) is slightly better than Ligand B (-2.247), but both are quite poor.
11. **hERG:** Ligand A (0.075) has a slightly lower hERG risk than Ligand B (0.486), which is good.
12. **Cl_mic:** Ligand A (18.257) has lower microsomal clearance than Ligand B (34.975), indicating better metabolic stability.
13. **t1/2:** Ligand A (-11.541) has a shorter in vitro half-life than Ligand B (-1.448). This is a negative for Ligand A.
14. **Pgp:** Both have very low Pgp efflux liability (A: 0.012, B: 0.011).
15. **Affinity:** Both have very similar binding affinities (-6.5 and -6.3 kcal/mol). The difference is negligible.
**GPCR-Specific Considerations:**
For ADRB2 (a cardiovascular GPCR), logP, TPSA, and affinity are key. Ligand A suffers from a very low logP and higher TPSA, while Ligand B is much better on both. The DILI risk for Ligand A is also significantly higher. While Ligand A has slightly better metabolic stability and hERG risk, the issues with logP and DILI are more critical.
**Conclusion:**
Considering the overall profile and prioritizing GPCR-relevant properties, **Ligand B** is the more promising drug candidate.
0
2025-04-17 20:50:03,636 - INFO - Batch 214 complete. Total preferences: 3424
2025-04-17 20:50:03,636 - INFO - Processing batch 215/512...
2025-04-17 20:50:53,103 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (353.375 and 344.499 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (122.08) is borderline for good oral absorption (<=140), while Ligand B (33.73) is excellent. This favors Ligand B, especially for a GPCR where brain penetration isn't necessarily required.
3. **logP:** Ligand A (-0.025) is a bit low, potentially hindering permeation. Ligand B (2.61) is optimal. This is a strong advantage for Ligand B.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable, well below the 5 threshold.
5. **HBA:** Ligand A (8) and Ligand B (4) are both acceptable, below the 10 threshold. Ligand B is better.
6. **QED:** Both ligands have good QED scores (0.684 and 0.86), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (44.009) has a moderate DILI risk, while Ligand B (6.437) has a very low risk. This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (40.403) and Ligand B (62.66) both have low BBB penetration. Since ADRB2 is primarily a cardiovascular target, high BBB penetration is not a priority.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.642 and -4.913), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Both ligands have negative solubility values (-2.643 and -1.816), indicating poor aqueous solubility. This is a concern for both.
11. **hERG:** Ligand A (0.137) has a slightly lower hERG risk than Ligand B (0.812), but both are relatively low.
12. **Cl_mic:** Ligand A (70.464) has a higher microsomal clearance than Ligand B (-7.518), indicating lower metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand A (-34.473) has a very short in vitro half-life, while Ligand B (3.595) is better, but still not ideal.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.019 and 0.044).
15. **Binding Affinity:** Both ligands have similar binding affinities (-6.0 and -5.0 kcal/mol). Ligand A is slightly better, but the difference is not substantial enough to outweigh other factors.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, and metabolic stability (Cl_mic, t1/2) are important. Ligand B excels in logP, TPSA, DILI, and Cl_mic. While both have issues with Caco-2 and solubility, the superior ADME profile of Ligand B makes it the more promising candidate.
**Conclusion:**
Ligand B demonstrates a more favorable balance of properties, particularly regarding ADME characteristics and safety (DILI). Although both have permeability and solubility issues, Ligand B's better logP, TPSA, lower DILI risk, and improved metabolic stability outweigh the slightly better affinity of Ligand A.
Output:
0
2025-04-17 20:50:53,103 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.36 and 350.38 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (46.34) is significantly better than Ligand B (121.08). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand B's TPSA is quite high, potentially hindering oral bioavailability.
3. **logP:** Ligand A (4.621) is higher than Ligand B (1.171). While both are within acceptable ranges (1-3 is optimal), Ligand A is pushing the upper limit and could potentially have solubility issues or off-target interactions. Ligand B is on the lower side, which could affect permeability.
4. **HBD/HBA:** Ligand A (0 HBD, 3 HBA) is preferable to Ligand B (2 HBD, 6 HBA). Lower HBD/HBA generally improves membrane permeability.
5. **QED:** Ligand A (0.806) is significantly better than Ligand B (0.562), indicating a more drug-like profile.
6. **DILI:** Ligand B (67.197) has a slightly higher DILI risk than Ligand A (61.342), but both are in a moderate risk range.
7. **BBB:** Ligand A (98.178) has excellent BBB penetration, while Ligand B (33.075) is poor. While not a primary concern for a cardiovascular target, it's a positive attribute for Ligand A.
8. **Caco-2:** Ligand A (-4.422) and Ligand B (-5.196) both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
9. **Solubility:** Ligand A (-5.328) has worse solubility than Ligand B (-2.206). This is a concern given Ligand A's higher logP.
10. **hERG:** Ligand A (0.824) has a slightly higher hERG risk than Ligand B (0.132). This is a significant advantage for Ligand B.
11. **Cl_mic:** Ligand B (15.111) has significantly lower microsomal clearance than Ligand A (32.632), indicating better metabolic stability.
12. **t1/2:** Ligand A (-12.125) has a negative in vitro half-life, which is concerning. Ligand B (2.579) has a short half-life, but at least it's positive.
13. **Pgp:** Ligand A (0.839) has higher P-gp efflux than Ligand B (0.081). Lower P-gp efflux is preferred for better bioavailability.
14. **Binding Affinity:** Ligand A (-7.0) has a significantly stronger binding affinity than Ligand B (-3.8). This is a substantial advantage, potentially outweighing some of the ADME drawbacks.
**Overall Assessment:**
Ligand A has a much stronger binding affinity, a better QED score, and good BBB penetration. However, it suffers from poor solubility, higher P-gp efflux, and a concerningly low (negative) in vitro half-life. Ligand B has better solubility, lower hERG risk, and better metabolic stability, but its affinity is significantly weaker and its TPSA is high.
Given that we're targeting a GPCR (ADRB2), binding affinity is paramount. The 3.2 kcal/mol difference in affinity is substantial. While Ligand A's ADME properties are not ideal, they could potentially be improved through further optimization. The weak binding of Ligand B is a more fundamental issue that would be harder to overcome.
Output:
1
2025-04-17 20:50:53,103 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [348.443, 75.71, 1.508, 1, 4, 0.448, 25.785, 63.009, -4.641, -2.038, 0.113, 40.883, -19.274, 0.043, -4.8]
**Ligand B:** [350.463, 96.11, 1.971, 3, 4, 0.731, 50.795, 73.672, -4.651, -3.841, 0.266, 56.139, -49.717, 0.057, -5.9]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, Affinity, and BBB):
1. **MW:** Both are within the ideal 200-500 Da range. A is 348.443, B is 350.463 - very similar.
2. **TPSA:** A (75.71) is better than B (96.11). Lower TPSA generally favors better permeability, important for GPCRs.
3. **logP:** Both are acceptable (A: 1.508, B: 1.971), falling within the 1-3 range. B is slightly higher, which *could* be a minor negative if it impacts solubility.
4. **HBD/HBA:** A (1 HBD, 4 HBA) is preferable to B (3 HBD, 4 HBA). Fewer HBDs are generally better for permeability.
5. **QED:** B (0.731) is better than A (0.448), indicating a more drug-like profile overall.
6. **DILI:** A (25.785) is significantly better than B (50.795), indicating a lower risk of liver injury. This is a crucial factor.
7. **BBB:** B (73.672) is better than A (63.009). While not a primary concern for ADRB2 (cardiovascular target), some CNS penetration can sometimes be beneficial or at least not detrimental.
8. **Caco-2:** Both are very poor (-4.641 and -4.651). This is a significant negative for both, suggesting poor intestinal absorption.
9. **Solubility:** A (-2.038) is better than B (-3.841), though both are quite poor.
10. **hERG:** A (0.113) is better than B (0.266), indicating a lower risk of cardiotoxicity. This is *very* important for a cardiovascular target.
11. **Cl_mic:** A (40.883) is better than B (56.139), suggesting better metabolic stability.
12. **t1/2:** A (-19.274) is better than B (-49.717), indicating a longer in vitro half-life.
13. **Pgp:** Both are low (A: 0.043, B: 0.057), suggesting minimal P-glycoprotein efflux.
14. **Affinity:** B (-5.9) is significantly better than A (-4.8). This is a 1.1 kcal/mol difference, which is substantial and can often outweigh other ADME concerns.
**Overall Assessment:**
While Ligand B has a better QED, BBB, and most importantly, a significantly stronger binding affinity (-5.9 vs -4.8 kcal/mol), Ligand A demonstrates a much more favorable safety profile with lower DILI and hERG risk, and better metabolic stability (lower Cl_mic) and half-life. The poor Caco-2 values are concerning for both. However, the substantial affinity advantage of Ligand B is a strong driver. For a GPCR, affinity is paramount, and the difference here is large enough to potentially overcome the slightly higher risks associated with Ligand B.
Therefore, I would select Ligand B.
0
2025-04-17 20:50:53,103 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [366.527, 58.64, 2.362, 1, 4, 0.784, 25.902, 76.813, -5.124, -3.334, 0.385, 54.839, -6.566, 0.279, -7.0]
**Ligand B:** [354.361, 84.65, 1.056, 1, 7, 0.763, 61.225, 93.137, -4.647, -3.295, 0.31, 48.168, 14.032, 0.031, -7.3]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (354.361) is slightly lower, which is generally favorable.
2. **TPSA:** Ligand A (58.64) is significantly better than Ligand B (84.65). ADRB2 is not a CNS target, but lower TPSA is still desirable for permeability. Ligand A is well below the 140 threshold. Ligand B is approaching the upper limit.
3. **logP:** Both are within the optimal range (1-3). Ligand A (2.362) is slightly higher than Ligand B (1.056).
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A (4) is better than Ligand B (7). Lower HBA generally improves permeability.
6. **QED:** Both are good (>=0.5), with Ligand A (0.784) being slightly better than Ligand B (0.763).
7. **DILI:** Ligand A (25.902) has a much lower DILI risk than Ligand B (61.225). This is a significant advantage for Ligand A.
8. **BBB:** Ligand B (93.137) has a higher BBB penetration percentile than Ligand A (76.813). However, since ADRB2 is a cardiovascular target, BBB penetration is not a primary concern.
9. **Caco-2:** Ligand A (-5.124) and Ligand B (-4.647) are both negative, which is unusual and suggests poor permeability.
10. **Solubility:** Both have negative solubility values, indicating poor aqueous solubility. This is a concern for both.
11. **hERG:** Both have low hERG inhibition liability (0.385 and 0.31 respectively).
12. **Cl_mic:** Ligand B (48.168) has lower microsomal clearance than Ligand A (54.839), suggesting better metabolic stability.
13. **t1/2:** Ligand B (14.032) has a significantly longer in vitro half-life than Ligand A (-6.566). This is a major advantage for Ligand B.
14. **Pgp:** Ligand A (0.279) has lower P-gp efflux than Ligand B (0.031), which is preferable.
15. **Affinity:** Ligand B (-7.3) has a slightly better binding affinity than Ligand A (-7.0). While the difference is small, it's still a factor.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, and affinity. Ligand A has better logP, TPSA, and Pgp. Ligand B has slightly better affinity. However, the significantly lower DILI risk of Ligand A and its better QED are important considerations. The longer half-life of Ligand B is also a positive.
**Overall Assessment:**
While Ligand B has a slightly better binding affinity and half-life, the significantly lower DILI risk and better TPSA/Pgp profile of Ligand A are more compelling. The poor solubility and Caco-2 values are concerns for both, but the lower DILI risk is a critical factor in early-stage drug development.
Therefore, I would choose Ligand A.
Output:
1
2025-04-17 20:50:53,103 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [351.403, 104.81 , -0.284, 2. , 5. , 0.663, 39.667, 70.803, -5.142, -2.387, 0.034, 6.904, -9.663, 0.011, -6.3 ]
**Ligand B:** [343.387, 99. , 1.851, 1. , 7. , 0.674, 83.792, 67.701, -4.912, -3.018, 0.034, 42.609, 2.554, 0.193, -3.8 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (343.387) is slightly lower, which is generally favorable.
2. **TPSA:** Both are acceptable for oral absorption (under 140). Ligand B (99) is slightly better.
3. **logP:** Ligand A (-0.284) is quite low, potentially hindering permeability. Ligand B (1.851) is much better, falling within the optimal 1-3 range. This is a significant advantage for B.
4. **HBD:** Both are acceptable (<=5). Ligand A (2) is slightly better.
5. **HBA:** Ligand A (5) is better than Ligand B (7).
6. **QED:** Both are good (>0.5). Similar values.
7. **DILI:** Ligand A (39.667) has a much lower DILI risk than Ligand B (83.792). This is a substantial advantage for A.
8. **BBB:** Ligand A (70.803) has a better BBB penetration score than Ligand B (67.701). While both are reasonable, A is better.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-5.142) is worse than Ligand B (-4.912).
10. **Solubility:** Both are negative, indicating poor solubility. Ligand A (-2.387) is slightly better than Ligand B (-3.018).
11. **hERG:** Both have very low hERG risk. Similar values.
12. **Cl_mic:** Ligand A (6.904) has a lower microsomal clearance, indicating better metabolic stability, than Ligand B (42.609). This is a significant advantage for A.
13. **t1/2:** Ligand A (-9.663) has a longer in vitro half-life than Ligand B (2.554). This is a significant advantage for A.
14. **Pgp:** Both have very low Pgp efflux liability. Similar values.
15. **Binding Affinity:** Ligand A (-6.3) has a slightly better binding affinity than Ligand B (-3.8). This is a significant advantage for A.
**GPCR-Specific Priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are crucial. Ligand B has a much better logP. However, Ligand A has better affinity, DILI, BBB, metabolic stability, and half-life. The affinity difference is substantial (-6.3 vs -3.8 kcal/mol). The lower DILI risk and improved metabolic stability of Ligand A are also very important.
**Conclusion:**
Despite Ligand B's better logP, the significantly stronger binding affinity, lower DILI risk, better BBB, and improved metabolic stability of Ligand A make it the more promising drug candidate.
Output:
1
2025-04-17 20:50:53,103 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (338.451 and 380.476 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands have a TPSA of 49.41, which is well below the 140 threshold for oral absorption and suitable for a GPCR target.
3. **logP:** Both ligands have similar logP values (3.361 and 3.382), falling within the optimal 1-3 range.
4. **HBD:** Both ligands have 1 HBD, which is acceptable.
5. **HBA:** Ligand A has 2 HBA, while Ligand B has 3. Both are within the acceptable limit of 10.
6. **QED:** Ligand A (0.856) has a significantly better QED score than Ligand B (0.493), indicating a more drug-like profile.
7. **DILI:** Ligand A (27.879) has a much lower DILI risk than Ligand B (18.108). This is a substantial advantage for Ligand A.
8. **BBB:** Both ligands have high BBB penetration (88.135 and 85.111), which is good, but not crucial for ADRB2 as it is not a CNS target.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and requires further investigation. However, the values are similar (-4.676 and -5.008).
10. **Solubility:** Both ligands have negative solubility values, which is also unusual. Again, the values are similar (-3.619 and -4.184).
11. **hERG:** Both ligands have low hERG inhibition liability (0.577 and 0.696), which is favorable.
12. **Cl_mic:** Ligand A (66.817) has a higher microsomal clearance than Ligand B (53.736), meaning it's metabolized faster. This is a disadvantage for Ligand A.
13. **t1/2:** Ligand B (-3.78) has a longer *in vitro* half-life than Ligand A (3.196). This is a significant advantage for Ligand B.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.442 and 0.269), which is good.
15. **Binding Affinity:** Ligand B (-7.1 kcal/mol) has a slightly better binding affinity than Ligand A (-6.8 kcal/mol). This is a 0.3 kcal/mol difference, which is not huge, but still noteworthy.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are important. Both ligands perform similarly on logP, TPSA, and Pgp. Ligand B has a slightly better affinity. However, the significantly better QED and lower DILI risk of Ligand A are important considerations. The longer half-life of Ligand B is also a positive.
**Overall Assessment:**
While Ligand B has a slightly better affinity and half-life, Ligand A's superior QED and dramatically lower DILI risk make it the more promising candidate. The negative solubility and Caco-2 values for both are concerning and would need to be addressed in further optimization, but the overall profile of Ligand A is more favorable for progression.
Output:
1
2025-04-17 20:50:53,104 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (399.559) is slightly higher than Ligand B (364.515), but both are acceptable.
2. **TPSA:** Ligand A (83.47) is slightly higher than Ligand B (67.23). Both are below the 140 threshold for good oral absorption, but B is preferable.
3. **logP:** Both ligands have good logP values (A: 2.566, B: 1.603) within the optimal 1-3 range. Ligand B is slightly lower, which could slightly reduce permeability but isn't a major concern.
4. **HBD:** Ligand A (2) and Ligand B (1) are both within the acceptable limit of 5. Ligand B is slightly better.
5. **HBA:** Ligand A (6) and Ligand B (5) are both within the acceptable limit of 10. Ligand B is slightly better.
6. **QED:** Both ligands have good QED scores (A: 0.633, B: 0.833), indicating good drug-like properties. Ligand B is significantly better.
7. **DILI:** Ligand A (71.694) has a higher DILI risk than Ligand B (28.228). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (46.219) and Ligand B (51.493) are both relatively low. Since ADRB2 is a cardiovascular target, BBB penetration is not a primary concern, but a slightly higher value is still preferred.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. This is a concern for both.
10. **Solubility:** Both ligands have negative solubility values, indicating poor solubility. This is a concern for both.
11. **hERG:** Ligand A (0.465) has a slightly higher hERG inhibition liability than Ligand B (0.112). This is a significant advantage for Ligand B.
12. **Cl_mic:** Both ligands have similar microsomal clearance values (A: 28.382, B: 28.094).
13. **t1/2:** Ligand A (26.014) has a longer in vitro half-life than Ligand B (1.48). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.465) has a higher P-gp efflux liability than Ligand B (0.057). This is a significant advantage for Ligand B.
15. **Binding Affinity:** Ligand B (-7.7 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.4 kcal/mol). This is a major advantage for Ligand B, potentially outweighing some of the ADME drawbacks.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand B excels in these areas. While BBB isn't critical for a cardiovascular target, the slightly higher value for Ligand B is a minor benefit. The significantly better affinity of Ligand B is the most important factor. The lower DILI and hERG risks are also very important. The longer half-life of Ligand A is attractive, but the superior overall profile of Ligand B is more compelling.
**Conclusion:**
Considering the balance of properties, particularly the significantly better binding affinity, lower DILI/hERG risk, and favorable Pgp efflux, Ligand B is the more promising drug candidate.
Output:
0
2025-04-17 20:50:53,104 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (346.471 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (60.85) is significantly better than Ligand B (93.11). ADRB2 is not a CNS target, but lower TPSA generally improves absorption. Ligand B is pushing the upper limit for good oral absorption.
3. **logP:** Ligand A (1.792) is optimal, while Ligand B (-0.163) is quite low. This is a significant drawback for Ligand B, potentially hindering membrane permeability and bioavailability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (5), for similar reasons as HBD.
6. **QED:** Ligand A (0.79) is better than Ligand B (0.526), indicating a more drug-like profile.
7. **DILI:** Both ligands have very similar, and acceptable, DILI risk (5.118 vs 5.157).
8. **BBB:** Ligand A (70.648) is much better than Ligand B (32.183). While ADRB2 isn't a primary CNS target, some peripheral distribution is still needed, and higher BBB penetration can sometimes correlate with better overall tissue distribution.
9. **Caco-2:** Ligand A (-4.453) is better than Ligand B (-5.149). Higher (less negative) Caco-2 values indicate better intestinal absorption.
10. **Solubility:** Ligand A (-1.731) is better than Ligand B (-1.115). Higher solubility is generally preferred.
11. **hERG:** Both ligands have very low hERG risk (0.182 and 0.103).
12. **Cl_mic:** Ligand A (11.579) is higher than Ligand B (4.314), indicating faster metabolic clearance and potentially lower *in vivo* exposure. This is a negative for Ligand A.
13. **t1/2:** Ligand A (-15.848) is much worse than Ligand B (-2.73). This is a significant negative for Ligand A.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.025 and 0.006).
15. **Binding Affinity:** Ligand A (-5.0) is better than Ligand B (-1.9). This is a substantial difference in potency. A difference of 3.1 kcal/mol is significant and can often outweigh minor ADME concerns.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, and affinity are particularly important. Ligand A excels in logP and TPSA, and has a much better binding affinity. While Ligand A has a higher Cl_mic and worse t1/2, the significantly improved affinity and better physicochemical properties (logP, TPSA) are likely to be more impactful for overall drug development success.
**Conclusion:**
Despite the slightly higher metabolic clearance and shorter half-life, Ligand A's superior binding affinity, logP, TPSA, QED, and BBB penetration make it the more promising candidate. The substantial difference in binding affinity is a key driver of this decision.
Output:
1
2025-04-17 20:50:53,104 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (342.403 Da and 339.483 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (89.08) is significantly better than Ligand B (37.39). For a GPCR, lower TPSA is generally preferred for better permeability, and Ligand B is quite low, potentially leading to off-target interactions.
**3. logP:** Ligand A (1.936) is within the optimal 1-3 range. Ligand B (4.816) is higher, potentially causing solubility issues and increasing off-target binding.
**4. H-Bond Donors:** Both ligands have 1 HBD, which is acceptable.
**5. H-Bond Acceptors:** Ligand A has 7 HBAs, and Ligand B has 4. Both are within the acceptable range of <=10.
**6. QED:** Both ligands have similar QED values (0.835 and 0.819), indicating good drug-likeness.
**7. DILI:** Ligand A (61.303) has a higher DILI risk than Ligand B (36.293). This is a concern for Ligand A.
**8. BBB:** Ligand A (87.088) has better BBB penetration than Ligand B (77.162). While not a primary concern for a cardiovascular target, it's a slight advantage.
**9. Caco-2 Permeability:** Ligand A (-4.973) has better Caco-2 permeability than Ligand B (-4.536).
**10. Aqueous Solubility:** Ligand A (-2.217) has better aqueous solubility than Ligand B (-5.454). This is important for formulation and bioavailability.
**11. hERG Inhibition:** Ligand A (0.407) has a lower hERG inhibition risk than Ligand B (0.874). This is a significant advantage, as hERG inhibition can lead to cardiotoxicity.
**12. Microsomal Clearance:** Ligand A (-12.241) has significantly lower microsomal clearance than Ligand B (110.476), indicating better metabolic stability.
**13. In vitro Half-Life:** Ligand A (36.913) has a longer in vitro half-life than Ligand B (7.889), which is desirable for less frequent dosing.
**14. P-gp Efflux:** Ligand A (0.119) has lower P-gp efflux than Ligand B (0.573), which is favorable for bioavailability.
**15. Binding Affinity:** Both ligands have very similar binding affinities (-8.1 kcal/mol and -8.0 kcal/mol). The difference is negligible.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand A is the better candidate. While Ligand A has a higher DILI risk, its superior TPSA, logP, solubility, hERG profile, metabolic stability, half-life, and P-gp efflux, combined with comparable binding affinity, outweigh this concern. The lower TPSA and logP of Ligand A suggest better permeability and reduced off-target effects, crucial for a GPCR target. The improved metabolic stability and longer half-life are also significant advantages.
Output:
1
2025-04-17 20:50:53,104 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (353.463 and 348.447 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (82.11) is better than Ligand B (88.76). Both are below 140, but lower TPSA generally favors absorption.
3. **logP:** Ligand B (1.318) is slightly better than Ligand A (0.694). Both are within the optimal 1-3 range, but Ligand A is a bit low, potentially hindering permeation.
4. **HBD:** Ligand A (2) is slightly better than Ligand B (1). Both are acceptable.
5. **HBA:** Both ligands have 5 HBA, which is good.
6. **QED:** Ligand B (0.867) is significantly better than Ligand A (0.52), indicating a more drug-like profile.
7. **DILI:** Ligand A (20.9) is *much* better than Ligand B (47.654). This is a significant advantage for Ligand A, as lower DILI risk is crucial.
8. **BBB:** Ligand B (81.388) is better than Ligand A (48.119). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant, and higher BBB is generally desirable.
9. **Caco-2:** Ligand B (-4.623) is better than Ligand A (-5.353). Higher (less negative) Caco-2 values indicate better absorption.
10. **Solubility:** Ligand B (-1.029) is slightly better than Ligand A (-1.106). Both are similar and acceptable.
11. **hERG:** Ligand A (0.296) is better than Ligand B (0.606). Lower hERG inhibition is crucial for avoiding cardiotoxicity, which is particularly important for a cardiovascular target like ADRB2.
12. **Cl_mic:** Ligand A (-18.559) is *much* better than Ligand B (29.016). Lower clearance indicates better metabolic stability, a significant advantage.
13. **t1/2:** Ligand B (-20.421) is better than Ligand A (-2.75). Longer half-life is generally preferred.
14. **Pgp:** Ligand B (0.047) is better than Ligand A (0.025). Lower P-gp efflux is beneficial.
15. **Binding Affinity:** Ligand A (-7.2) is better than Ligand B (-6.5). This is a 0.7 kcal/mol difference, which is substantial and can outweigh some ADME drawbacks.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand B has better logP, Pgp and Caco-2, but Ligand A has better TPSA and a significantly better binding affinity. The DILI and Cl_mic are also important, and Ligand A is far superior in both. The hERG is also better for Ligand A.
**Overall Assessment:**
While Ligand B has some advantages in BBB, Caco-2, t1/2 and Pgp, Ligand A has a significantly stronger binding affinity, much lower DILI risk, better hERG inhibition, and better metabolic stability (lower Cl_mic). The superior affinity and safety profile of Ligand A outweigh the slightly better permeability characteristics of Ligand B. Therefore, Ligand A is the more promising drug candidate.
Output:
1
2025-04-17 20:50:53,104 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [361.427, 127.74 , 1.008, 3. , 5. , 0.605, 85.227, 34.238, -5.613, -3.613, 0.747, 10.359, -23.372, 0.062, -3.5 ]
**Ligand B:** [344.499, 40.62 , 3.062, 0. , 2. , 0.743, 11.71 , 89.802, -4.705, -3.726, 0.666, 57.893, 1.739, 0.254, -6.7 ]
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand B (344.499) is slightly lower, which could be advantageous for permeability, but both are acceptable.
2. **TPSA:** Ligand A (127.74) is higher than the preferred <140 for oral absorption, but not drastically. Ligand B (40.62) is excellent, well below 140 and very favorable for permeability.
3. **logP:** Ligand A (1.008) is at the lower end of the optimal range (1-3), potentially hindering permeation. Ligand B (3.062) is excellent, right in the sweet spot.
4. **HBD:** Ligand A (3) is acceptable. Ligand B (0) is even better, potentially improving permeability.
5. **HBA:** Ligand A (5) is acceptable. Ligand B (2) is better.
6. **QED:** Both ligands have good QED scores (A: 0.605, B: 0.743), indicating drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (85.227) has a concerningly high DILI risk. Ligand B (11.71) is very low risk. This is a significant advantage for Ligand B.
8. **BBB:** Ligand B (89.802) has a very high BBB penetration score, which is desirable for a GPCR target. Ligand A (34.238) is low.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests issues with the prediction method or the molecules themselves. However, the scale is not specified, so it's difficult to interpret.
10. **Solubility:** Both have negative solubility values, again suggesting issues with the prediction.
11. **hERG:** Both ligands have low hERG inhibition liability (A: 0.747, B: 0.666), which is good.
12. **Cl_mic:** Ligand A (10.359) has a lower microsomal clearance, indicating better metabolic stability. Ligand B (57.893) has higher clearance.
13. **t1/2:** Ligand A (-23.372) has a negative in vitro half-life, which is concerning. Ligand B (1.739) is short, but positive.
14. **Pgp:** Both have low Pgp efflux liability (A: 0.062, B: 0.254).
15. **Affinity:** Ligand B (-6.7 kcal/mol) has a significantly stronger binding affinity than Ligand A (-3.5 kcal/mol). This >1.5 kcal/mol difference is a major advantage.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, BBB, and affinity. Ligand B excels in all these areas. The high DILI risk of Ligand A is also a major concern.
**Conclusion:**
Ligand B is significantly more promising. Its superior logP, TPSA, BBB penetration, binding affinity, and drastically lower DILI risk outweigh the slightly higher microsomal clearance and shorter half-life. The affinity difference is substantial enough to overcome the other minor drawbacks.
0
2025-04-17 20:50:53,104 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (342.483 Da) is slightly lower, which is generally favorable for permeability.
**2. TPSA:** Ligand A (49.41) is significantly better than Ligand B (101.81). For a GPCR, lower TPSA is preferred as it generally correlates with better membrane permeability. Ligand B is quite high, potentially hindering absorption.
**3. logP:** Ligand A (3.204) is within the optimal range (1-3). Ligand B (-0.711) is below 1, which is concerning for permeability and could lead to poor absorption.
**4. H-Bond Donors:** Ligand A (1) is good. Ligand B (0) is also acceptable.
**5. H-Bond Acceptors:** Ligand A (2) is good. Ligand B (7) is higher, but still within the acceptable limit of 10.
**6. QED:** Ligand A (0.893) is excellent, indicating a highly drug-like profile. Ligand B (0.678) is still acceptable, but less favorable.
**7. DILI Risk:** Ligand A (26.095) has a much lower DILI risk than Ligand B (63.552). This is a significant advantage for Ligand A.
**8. BBB Penetration:** Ligand A (77.2) is better than Ligand B (59.829), although neither are exceptionally high. For a cardiovascular target, BBB penetration isn't *critical*, but some level is still helpful for distribution.
**9. Caco-2 Permeability:** Ligand A (-4.762) is better than Ligand B (-4.434). Higher values are better, indicating better intestinal absorption.
**10. Aqueous Solubility:** Ligand A (-3.334) is better than Ligand B (-1.798). Higher values are better.
**11. hERG Inhibition:** Ligand A (0.549) is better than Ligand B (0.108). Lower values are preferred to avoid cardiotoxicity.
**12. Microsomal Clearance:** Ligand A (63.719) is higher than Ligand B (8.637), meaning Ligand B has better metabolic stability. This is a point in favor of Ligand B.
**13. In vitro Half-Life:** Ligand A (-18.312) is worse than Ligand B (-2.947). Longer half-life is preferred, so Ligand B is better here.
**14. P-gp Efflux:** Ligand A (0.344) is better than Ligand B (0.072). Lower efflux is preferred.
**15. Binding Affinity:** Both ligands have very similar binding affinities (-6.6 kcal/mol and -6.5 kcal/mol). The difference is negligible.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand A clearly outperforms Ligand B. Ligand A has superior TPSA, logP, solubility, DILI risk, hERG inhibition, and P-gp efflux. While Ligand B has better metabolic stability and half-life, the advantages of Ligand A in absorption, safety, and drug-likeness are more critical for a successful drug candidate. The similar binding affinities make the ADME properties the deciding factors.
Output:
1
2025-04-17 20:50:53,104 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [368.356, 99.77, 0.544, 3, 5, 0.57, 28.112, 85.537, -5.486, -2.282, 0.221, -43.217, -15.542, 0.002, -2.7]
**Ligand B:** [355.435, 99.18, -0.498, 2, 6, 0.598, 10.237, 51.377, -5.087, 0.202, 0.117, 1.367, -13.199, 0.013, -5.2]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (355.435) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are around 100, slightly above the optimal <90 for CNS targets, but acceptable for a peripheral GPCR like ADRB2.
3. **logP:** Ligand A (0.544) is a bit low, potentially hindering membrane permeability. Ligand B (-0.498) is even lower and more concerning. Both are below the optimal 1-3 range.
4. **HBD/HBA:** Ligand A has 3 HBD and 5 HBA, while Ligand B has 2 HBD and 6 HBA. Both are within acceptable limits.
5. **QED:** Both have good QED scores (>0.5), indicating drug-like properties. Ligand B (0.598) is slightly better.
6. **DILI:** Ligand A (28.112) has a higher DILI risk than Ligand B (10.237). This is a significant advantage for Ligand B.
7. **BBB:** Ligand A (85.537) shows better BBB penetration than Ligand B (51.377). However, BBB is less critical for ADRB2, which is primarily a cardiovascular target.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability.
9. **Solubility:** Ligand B (0.202) has slightly better solubility than Ligand A (-2.282), which is a plus.
10. **hERG:** Both have very low hERG inhibition risk (0.221 and 0.117 respectively).
11. **Cl_mic:** Ligand A (-43.217) has significantly better metabolic stability (lower clearance) than Ligand B (1.367). This is a major advantage.
12. **t1/2:** Ligand A (-15.542) has a longer in vitro half-life than Ligand B (-13.199).
13. **Pgp:** Both have very low Pgp efflux liability (0.002 and 0.013 respectively).
14. **Binding Affinity:** Ligand B (-5.2) has a stronger binding affinity than Ligand A (-2.7). This is a substantial advantage.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, Pgp, TPSA, and affinity. Ligand B has a better affinity. While both have poor logP, Ligand B is slightly better. Both have good Pgp and acceptable TPSA. The significantly better DILI score and affinity of Ligand B outweigh the better BBB penetration and metabolic stability of Ligand A.
**Conclusion:**
Considering the balance of properties and the priorities for a GPCR target, Ligand B is the more promising candidate.
```
0
```
2025-04-17 20:50:53,104 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's systematically compare Ligand A and Ligand B based on the provided parameters and the guidelines, keeping in mind ADRB2 is a GPCR. GPCRs prioritize logP, Pgp, TPSA, and affinity.
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (349.431) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (95.67) is better than Ligand B (42.41). While both are reasonably low, Ligand B's TPSA is excellent, suggesting good potential for membrane permeability.
3. **logP:** Ligand A (1.643) is within the optimal range (1-3), while Ligand B (4.913) is significantly higher. This is a major concern for Ligand B, potentially leading to poor solubility and off-target effects.
4. **HBD:** Ligand A (2) is preferable to Ligand B (0). Having some HBD can improve solubility without drastically hindering permeability.
5. **HBA:** Both ligands have 5 HBA, which is acceptable.
6. **QED:** Ligand A (0.761) has a better QED score than Ligand B (0.594), indicating a more drug-like profile.
7. **DILI:** Ligand A (31.059) has a lower DILI risk than Ligand B (19.465), which is a positive attribute.
8. **BBB:** Ligand B (94.145) has a much higher BBB penetration percentile than Ligand A (24.622). While ADRB2 isn't necessarily a CNS target, some degree of BBB penetration isn't detrimental, and could open up possibilities for future indications.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale isn't specified, so it's difficult to interpret.
10. **Solubility:** Ligand A (-1.11) is better than Ligand B (-4.933), which is a significant advantage. Poor solubility is a major hurdle in drug development.
11. **hERG:** Ligand A (0.077) has a lower hERG risk than Ligand B (0.919), which is crucial for cardiovascular targets.
12. **Cl_mic:** Ligand A (8.612) has a lower microsomal clearance than Ligand B (86.446), indicating better metabolic stability.
13. **t1/2:** Ligand A (-11.417) has a longer in vitro half-life than Ligand B (19.055), which is desirable.
14. **Pgp:** Ligand A (0.056) has lower P-gp efflux than Ligand B (0.578), which is beneficial for bioavailability.
15. **Affinity:** Ligand A (-7.0) and Ligand B (-6.7) have comparable binding affinities. The difference of 0.3 kcal/mol isn't substantial enough to outweigh other significant differences.
**Overall Assessment:**
Ligand A is significantly better overall. While Ligand B has excellent TPSA and BBB penetration, its high logP, poor solubility, high hERG risk, and high metabolic clearance are major drawbacks. Ligand A strikes a better balance across all parameters, particularly in areas critical for a cardiovascular drug candidate (solubility, hERG, metabolic stability).
**Output:**
1
2025-04-17 20:50:53,104 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (344.46 and 343.47 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (75.19) is higher than Ligand B (53.51). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is generally preferred for absorption. Ligand B has a clear advantage.
3. **logP:** Ligand A (2.27) is within the optimal range (1-3), while Ligand B (3.116) is approaching the upper limit. Both are acceptable, but A is slightly better balanced.
4. **HBD:** Ligand A (1) is better than Ligand B (0). While both are low, having one HBD can sometimes improve solubility without significantly impacting permeability.
5. **HBA:** Ligand A (4) is slightly higher than Ligand B (3). Both are within the acceptable range of <=10.
6. **QED:** Ligand A (0.859) is better than Ligand B (0.789), indicating a more drug-like profile.
7. **DILI:** Ligand A (51.144) and Ligand B (47.732) are both good, below the 60% threshold for high risk. Ligand B is slightly better.
8. **BBB:** Both ligands have good BBB penetration (A: 78.79, B: 71.384). Since ADRB2 is not a CNS target, this is less critical, but A is slightly favored.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. Ligand A (-4.897) is slightly better than Ligand B (-4.591), but both are concerning.
10. **Solubility:** Ligand A (-3.216) is slightly better than Ligand B (-2.319), but both are poor.
11. **hERG:** Both ligands have low hERG inhibition risk (A: 0.23, B: 0.581). Ligand A is significantly better.
12. **Cl_mic:** Ligand A (31.229) has a much lower microsomal clearance than Ligand B (74.345), indicating better metabolic stability. This is a significant advantage for A.
13. **t1/2:** Ligand A (-5.88) has a much longer in vitro half-life than Ligand B (-23.937). This is a major advantage for A.
14. **Pgp:** Ligand A (0.142) has lower P-gp efflux liability than Ligand B (0.325), which is favorable.
15. **Binding Affinity:** Both ligands have very similar binding affinities (A: -5.4, B: -5.6). The difference is negligible.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand A emerges as the superior candidate. While Ligand B has slightly better DILI and a lower logP, Ligand A excels in crucial ADME properties like metabolic stability (Cl_mic), half-life (t1/2), P-gp efflux, and hERG inhibition. The QED score is also better for Ligand A. The slightly lower TPSA of Ligand B is not enough to outweigh the significant advantages of Ligand A in terms of metabolic stability and duration of action.
Output:
1
2025-04-17 20:50:53,104 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (354.491 and 360.523 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (67.87) is higher than Ligand B (46.34). For a cardiovascular GPCR, TPSA is moderately important, and Ligand B is better positioned for good absorption.
3. **logP:** Ligand A (1.971) is within the optimal 1-3 range. Ligand B (4.513) is higher, potentially leading to solubility issues and off-target interactions. This is a significant drawback for Ligand B.
4. **HBD:** Ligand A (1) is preferable to Ligand B (0). While both are acceptable, having one HBD can improve solubility without drastically affecting permeability.
5. **HBA:** Both ligands have 4 HBA, which is within the acceptable range.
6. **QED:** Ligand A (0.759) has a better QED score than Ligand B (0.585), indicating a more drug-like profile.
7. **DILI:** Ligand A (19.542) has a substantially lower DILI risk than Ligand B (29.663). This is a critical advantage for Ligand A.
8. **BBB:** Both ligands have similar BBB penetration (65.374 vs 64.793). Since this is a cardiovascular target, BBB penetration is less critical, but it's good that neither is particularly poor.
9. **Caco-2:** Ligand A (-4.757) and Ligand B (-5.206) are both poor, suggesting limited intestinal absorption.
10. **Solubility:** Ligand A (-1.679) is better than Ligand B (-3.909). The higher logP of Ligand B likely contributes to its lower solubility.
11. **hERG:** Ligand A (0.321) has a lower hERG risk than Ligand B (0.764). This is a significant safety advantage for Ligand A.
12. **Cl_mic:** Ligand A (43.727) has a much lower microsomal clearance than Ligand B (147.567), indicating better metabolic stability.
13. **t1/2:** Ligand A (9.231) has a shorter half-life than Ligand B (16.094). While longer is generally preferred, the significant difference in clearance is more important.
14. **Pgp:** Ligand A (0.042) has a lower Pgp efflux liability than Ligand B (0.744), suggesting better bioavailability.
15. **Binding Affinity:** Ligand B (-6.8) has a stronger binding affinity than Ligand A (-5.4). This is a 1.4 kcal/mol difference, which is substantial. However, the other ADME properties of Ligand A are far superior.
**Overall Assessment:**
Ligand B has a better binding affinity, but Ligand A excels in almost all other critical ADME-Tox properties. Specifically, Ligand A demonstrates significantly lower DILI risk, hERG inhibition, and Pgp efflux, and has better solubility and metabolic stability. The lower logP of Ligand A is also a significant advantage. While both have poor Caco-2 permeability, the other benefits of Ligand A outweigh the affinity advantage of Ligand B. For a cardiovascular GPCR, metabolic stability, safety (DILI, hERG), and solubility are paramount, and Ligand A is clearly superior in these areas.
Output:
1
2025-04-17 20:50:53,105 - INFO - Batch 215 complete. Total preferences: 3440
2025-04-17 20:50:53,105 - INFO - Processing batch 216/512...
2025-04-17 20:51:43,469 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (348.447 and 367.471 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Both ligands have TPSA values (107.11 and 105.23) that are acceptable for oral absorption, being below 140.
**3. logP:** Ligand A (2.019) is slightly higher than Ligand B (1.051), placing it more optimally within the 1-3 range. Ligand B is a bit low, potentially hindering permeation.
**4. H-Bond Donors:** Ligand A (4) is slightly higher than Ligand B (2), but both are within the acceptable limit of 5.
**5. H-Bond Acceptors:** Ligand A (4) and Ligand B (5) are both within the acceptable limit of 10.
**6. QED:** Both ligands have good QED scores (0.604 and 0.679), indicating good drug-like properties. Ligand B is slightly better.
**7. DILI:** Ligand B (58.705) has a slightly better DILI score than Ligand A (47.964), indicating lower potential for liver injury. Both are acceptable (<60).
**8. BBB:** Ligand B (65.529) has a higher BBB penetration percentile than Ligand A (59.403). While ADRB2 is a cardiovascular target, some CNS exposure can be relevant for off-target effects.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 permeability values (-5.15 and -5.32), which is unusual and suggests poor permeability. This is a significant concern for both.
**10. Aqueous Solubility:** Both ligands have negative solubility values (-3.776 and -2.958), indicating very poor aqueous solubility. This is a major drawback for both.
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.237 and 0.122). This is excellent.
**12. Microsomal Clearance:** Ligand B (7.437) has significantly lower microsomal clearance than Ligand A (41.953), indicating better metabolic stability. This is a substantial advantage for Ligand B.
**13. In vitro Half-Life:** Ligand B (8.584) has a much longer in vitro half-life than Ligand A (-36.647). This is a major advantage for Ligand B.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.227 and 0.137). This is good.
**15. Binding Affinity:** Ligand B (-7.6 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.9 kcal/mol). This 0.7 kcal/mol difference is substantial and can outweigh some ADME concerns.
**GPCR-Specific Priorities:** For a GPCR, logP, Pgp, TPSA, and affinity are key. Ligand B excels in affinity and Pgp, and has a better BBB score. While both have poor Caco-2 and solubility, the significantly improved metabolic stability (lower Cl_mic, longer t1/2) and binding affinity of Ligand B make it the more promising candidate.
**Conclusion:**
Ligand B is the preferred candidate.
0
2025-04-17 20:51:43,469 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (347.34 Da and 348.403 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (39.08) is significantly better than Ligand B (98.82). For a GPCR, lower TPSA is generally preferred for better permeability. Ligand B's TPSA is quite high, potentially hindering absorption.
**3. logP:** Ligand A (4.843) is higher than Ligand B (-0.163). While logP > 4 can be problematic, it's less concerning for a cardiovascular target than a very low logP. Ligand B's logP is quite low, which could severely limit its ability to cross cell membranes.
**4. H-Bond Donors:** Ligand A (1) and Ligand B (2) are both acceptable.
**5. H-Bond Acceptors:** Both ligands have 4 H-bond acceptors, which is within the acceptable range.
**6. QED:** Ligand A (0.718) is better than Ligand B (0.515), indicating a more drug-like profile.
**7. DILI Risk:** Ligand B (33.618) has a much lower DILI risk than Ligand A (64.172). This is a significant advantage for Ligand B.
**8. BBB Penetration:** Ligand B (69.872) shows slightly better BBB penetration than Ligand A (62.233), but both are not exceptionally high. For a cardiovascular target, BBB penetration is not a primary concern, but it's a bonus.
**9. Caco-2 Permeability:** Ligand A (-4.701) and Ligand B (-5.05) both have negative values, indicating poor permeability. However, the negative value for Ligand A is slightly less negative, suggesting marginally better permeability.
**10. Aqueous Solubility:** Ligand A (-4.914) and Ligand B (-2.147) both have negative values, indicating poor solubility. Ligand B is better than Ligand A.
**11. hERG Inhibition:** Ligand A (0.951) is slightly better than Ligand B (0.033), indicating a lower risk of hERG inhibition and cardiotoxicity.
**12. Microsomal Clearance:** Ligand B (-27.981) has a much lower (better) microsomal clearance than Ligand A (24.021), suggesting greater metabolic stability.
**13. In vitro Half-Life:** Both ligands have similar and negative in vitro half-lives (-22.844 and -22.532), which is not ideal.
**14. P-gp Efflux:** Ligand A (0.839) is better than Ligand B (0.006), indicating lower P-gp efflux and potentially better bioavailability.
**15. Binding Affinity:** Both ligands have very similar binding affinities (-7.2 kcal/mol and -7.0 kcal/mol). The difference is negligible.
**Overall Assessment:**
Ligand A has better TPSA, logP, QED, hERG inhibition, and P-gp efflux. Ligand B excels in DILI risk and microsomal clearance, and has slightly better solubility and BBB penetration.
Given the GPCR-specific priorities (logP, TPSA, and affinity), and considering the cardiovascular target (where BBB penetration is less critical), Ligand A appears to be the more promising candidate. Its better logP and significantly lower TPSA are crucial for membrane permeability and receptor engagement. While Ligand B's lower DILI risk is attractive, the potential for poor absorption due to its low logP and high TPSA outweighs this benefit.
Output:
1
2025-04-17 20:51:43,469 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (340.358 Da and 354.535 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (69.9) is slightly higher than Ligand B (58.64). Both are below the 140 threshold for good oral absorption, and acceptable for a cardiovascular target (not needing high CNS penetration). Ligand B is preferable here.
3. **logP:** Both ligands (3.262 and 3.373) are within the optimal 1-3 range. No significant difference.
4. **HBD:** Ligand A has 0 HBD, while Ligand B has 1. Both are acceptable (<=5).
5. **HBA:** Ligand A has 6 HBA, and Ligand B has 3. Both are below the 10 threshold. Ligand B is preferable.
6. **QED:** Both ligands have similar QED values (0.644 and 0.654), indicating good drug-likeness. No significant difference.
7. **DILI:** Ligand A has a DILI risk of 74.99, while Ligand B has 10.741. This is a *major* difference. Ligand B is significantly safer regarding liver toxicity risk.
8. **BBB:** Ligand A (73.827) and Ligand B (80.419) both have good BBB penetration. While not a primary concern for a cardiovascular target, higher is slightly better. Ligand B is preferable.
9. **Caco-2:** Both ligands have similar, poor Caco-2 permeability (-4.489 and -4.404). This suggests potential absorption issues, but is not a deciding factor.
10. **Solubility:** Ligand A (-4.405) has slightly worse solubility than Ligand B (-3.018). Ligand B is preferable.
11. **hERG:** Both ligands have low hERG inhibition risk (0.34 and 0.433). No significant difference.
12. **Cl_mic:** Ligand A (73.356) has lower microsomal clearance than Ligand B (85.855), suggesting better metabolic stability. Ligand A is preferable.
13. **t1/2:** Ligand A (-44.401) has a significantly *longer* in vitro half-life than Ligand B (9.059). This is a major advantage for dosing convenience. Ligand A is preferable.
14. **Pgp:** Ligand A (0.668) has lower P-gp efflux than Ligand B (0.096). Lower efflux is better for bioavailability. Ligand A is preferable.
15. **Binding Affinity:** Ligand A (-6.4 kcal/mol) has slightly better binding affinity than Ligand B (-5.6 kcal/mol). This is a meaningful difference, exceeding the 1.5 kcal/mol threshold. Ligand A is preferable.
**Overall Assessment & GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Both compounds are good on logP and TPSA. However, Ligand A has a better affinity, lower Pgp efflux, and a significantly longer half-life. The *critical* advantage of Ligand B is its dramatically lower DILI risk. While affinity and half-life are important, a high DILI risk is a major red flag.
Considering the balance, the lower DILI risk of Ligand B outweighs the slightly better affinity and half-life of Ligand A.
Output:
0
2025-04-17 20:51:43,470 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (351.353 and 346.515 Da) fall comfortably within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (74.69) is higher than Ligand B (49.41). For a cardiovascular GPCR, TPSA is not a major concern unless targeting the CNS, but lower is generally preferred for absorption. Ligand B has a significant advantage here.
3. **logP:** Both ligands have good logP values (3.054 and 3.999), falling within the optimal 1-3 range. Ligand B is slightly higher, which *could* be a minor concern for solubility, but is still acceptable.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1). Both are within the acceptable limit of <=5.
5. **HBA:** Ligand A (4) is higher than Ligand B (2). Both are within the acceptable limit of <=10.
6. **QED:** Ligand A (0.839) has a significantly better QED score than Ligand B (0.48), indicating a more drug-like profile. This is a substantial advantage for Ligand A.
7. **DILI:** Ligand A (60.527) has a higher DILI risk than Ligand B (16.44). This is a significant drawback for Ligand A. Ligand B is much preferred here.
8. **BBB:** Both ligands have good BBB penetration (76.154 and 70.027). Since ADRB2 is not primarily a CNS target, this isn't a major differentiating factor, but higher is still slightly better.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.629 and -4.673). This is unusual and suggests poor permeability. However, the values are very similar.
10. **Solubility:** Both ligands have negative solubility values (-3.538 and -3.288). This is also unusual and suggests poor solubility. Again, the values are very similar.
11. **hERG:** Both ligands have low hERG inhibition risk (0.494 and 0.518). No significant difference.
12. **Cl_mic:** Ligand A (43.951) has lower microsomal clearance than Ligand B (51.543), suggesting better metabolic stability. This is a positive for Ligand A.
13. **t1/2:** Ligand A (5.663) has a longer in vitro half-life than Ligand B (-2.295). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.076) has lower P-gp efflux liability than Ligand B (0.269). This is a positive for Ligand A.
15. **Binding Affinity:** Both ligands have identical binding affinities (-6.5 kcal/mol).
**GPCR-Specific Priorities & Overall Assessment:**
For a cardiovascular GPCR like ADRB2, logP, TPSA, and affinity are key. Both ligands have good logP and affinity. Ligand B has a lower TPSA, which is favorable. However, Ligand A has a much better QED score, lower Pgp efflux, longer half-life, and better metabolic stability (lower Cl_mic). Crucially, Ligand B has a *much* lower DILI risk. The poor Caco-2 and solubility for both are concerning, but could potentially be addressed with formulation strategies. The DILI risk for Ligand A is a major red flag.
Considering the balance, the significantly lower DILI risk of Ligand B outweighs the advantages of Ligand A, despite its better QED, metabolic stability, and half-life. A high DILI risk is a frequent cause of drug development failure.
Output:
0
2025-04-17 20:51:43,470 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.435 and 342.359 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (107.4) is better than Ligand B (121.89). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (2.164) is optimal, while Ligand B (0.81) is a bit low. A logP below 1 can hinder membrane permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is better than Ligand B (6). Similar reasoning as HBD.
6. **QED:** Both ligands (0.355 and 0.458) are relatively low, indicating room for improvement in drug-likeness. However, Ligand B is slightly better.
7. **DILI:** Ligand A (42.613) has a significantly lower DILI risk than Ligand B (79.333). This is a crucial advantage.
8. **BBB:** Ligand A (70.919) has better BBB penetration than Ligand B (39.55). While not a primary concern for a cardiovascular target, it's a positive attribute.
9. **Caco-2:** Ligand A (-4.607) is better than Ligand B (-6.108). Higher (less negative) Caco-2 values indicate better intestinal absorption.
10. **Solubility:** Ligand A (-2.355) is better than Ligand B (-2.157).
11. **hERG:** Both ligands (0.22 and 0.072) have very low hERG inhibition risk, which is excellent.
12. **Cl_mic:** Ligand B (-7.819) has a *much* lower (better) microsomal clearance than Ligand A (39.227). This suggests better metabolic stability for Ligand B.
13. **t1/2:** Ligand B (18.911) has a significantly longer in vitro half-life than Ligand A (2.672). This is a major advantage, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands (0.076 and 0.021) have low P-gp efflux liability, which is good.
15. **Binding Affinity:** Ligand A (-7.4) has a slightly better binding affinity than Ligand B (-7.1). While the difference is not huge, it's still a positive factor.
**Overall Assessment:**
Ligand A has advantages in TPSA, logP, HBD/HBA, DILI, BBB, Caco-2, solubility, and binding affinity. However, Ligand B has a *substantial* advantage in metabolic stability (Cl_mic and t1/2). Considering ADRB2 is a cardiovascular target, metabolic stability and half-life are very important. A longer half-life translates to less frequent dosing and potentially better patient compliance. The slightly better affinity of Ligand A is outweighed by the significant pharmacokinetic advantages of Ligand B.
Output:
0
2025-04-17 20:51:43,470 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [346.431, 84.42, 1.5, 1, 5, 0.873, 43.428, 70.531, -4.701, -2.912, 0.19, 43.862, -13.989, 0.075, -6.3]
**Ligand B:** [371.859, 48.99, 4.182, 1, 2, 0.815, 35.479, 94.494, -4.739, -4.636, 0.826, 58.469, -10.996, 0.551, -6.9]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, BBB, and affinity are key):
1. **MW:** Both are within the ideal 200-500 Da range. A (346.431) is slightly better.
2. **TPSA:** A (84.42) is better than B (48.99). While both are acceptable, lower TPSA generally favors better permeability.
3. **logP:** A (1.5) is optimal. B (4.182) is pushing the upper limit and could lead to solubility issues and off-target effects.
4. **HBD/HBA:** Both have 1 HBD, which is good. A has 5 HBA, B has 2. Both are acceptable.
5. **QED:** Both are good (A: 0.873, B: 0.815), indicating good drug-like properties.
6. **DILI:** A (43.428) is slightly higher than B (35.479), but both are below the concerning 60 threshold. B is preferable here.
7. **BBB:** B (94.494) is significantly better than A (70.531). This is a major advantage for a GPCR target, even if not strictly CNS-focused, as it suggests better distribution.
8. **Caco-2:** Both are similar and negative, which is not ideal.
9. **Solubility:** A (-2.912) is better than B (-4.636). Solubility is crucial for bioavailability.
10. **hERG:** A (0.19) is much better than B (0.826). Lower hERG risk is critical for cardiovascular drugs.
11. **Cl_mic:** A (43.862) is better than B (58.469). Lower clearance suggests better metabolic stability.
12. **t1/2:** A (-13.989) is better than B (-10.996). A longer half-life is generally desirable.
13. **Pgp:** A (0.075) is much better than B (0.551). Lower P-gp efflux is highly desirable for better bioavailability and potentially CNS penetration.
14. **Affinity:** B (-6.9) is slightly better than A (-6.3), but the difference is not huge.
**Overall Assessment:**
Ligand B has a significant advantage in BBB penetration and slightly better binding affinity. However, Ligand A excels in crucial ADME properties like logP, solubility, hERG risk, Pgp efflux, and metabolic stability. The higher logP of Ligand B is a concern, and the higher hERG risk is a significant red flag for a cardiovascular target. While the BBB score for B is good, the other ADME issues outweigh this benefit.
Therefore, I believe **Ligand A** is the more promising drug candidate.
1
2025-04-17 20:51:43,470 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (359.413 and 367.421 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (64.63) is slightly higher than Ligand B (54.46). Both are below the 140 A^2 threshold for good oral absorption, but closer to the 90 A^2 threshold for CNS targets, which isn't a primary concern for ADRB2 (cardiovascular). Ligand B is preferable.
3. **logP:** Both ligands (3.825 and 4.229) are within the optimal 1-3 range, but Ligand B is slightly higher. This isn't a major concern, but higher logP can sometimes lead to off-target effects.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Both ligands have 4 HBA, which is good.
6. **QED:** Ligand B (0.88) has a better QED score than Ligand A (0.732), indicating a more drug-like profile. This is a positive for Ligand B.
7. **DILI:** Ligand B (61.07) has a higher DILI risk than Ligand A (44.048), which is a negative for Ligand B.
8. **BBB:** Both ligands have high BBB penetration (91.857 and 97.247), which isn't a major priority for a cardiovascular target like ADRB2, but doesn't hurt. Ligand B is slightly better.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.112 and -4.633). This is unusual and suggests poor permeability. Ligand B is slightly worse.
10. **Solubility:** Both ligands have negative solubility values (-4.747 and -5.158). This is also unusual and suggests poor solubility. Ligand B is slightly worse.
11. **hERG:** Both ligands have low hERG inhibition risk (0.59 and 0.776), which is good. Ligand B is slightly better.
12. **Cl_mic:** Ligand B (30.283) has significantly lower microsomal clearance than Ligand A (103.166), indicating better metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand B (33.109) has a longer in vitro half-life than Ligand A (-29.095), which is a positive.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.185 and 0.413), which is good. Ligand A is slightly better.
15. **Binding Affinity:** Both ligands have the same binding affinity (-6.7 kcal/mol).
**GPCR-specific priorities:**
For GPCRs, logP, Pgp, TPSA, and affinity are key. Ligand B has a slightly higher logP, better TPSA, and better metabolic stability (Cl_mic and t1/2). While the DILI risk is higher, the improved ADME properties and comparable affinity make it a more promising candidate. The negative Caco-2 and solubility values are concerning for both, but the metabolic stability advantage of Ligand B is significant.
**Conclusion:**
Considering all factors, Ligand B is the more promising drug candidate.
Output:
0
2025-04-17 20:51:43,470 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Ligand A (444.738 Da) is within the ideal range, while Ligand B (362.499 Da) is also good, but at the lower end.
2. **TPSA:** Ligand A (71.53) is better than Ligand B (83.98), both are acceptable, but lower TPSA is preferred for better absorption.
3. **logP:** Both ligands have good logP values (A: 3.406, B: 2.155), falling within the 1-3 range.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2).
5. **HBA:** Both ligands have the same HBA count (5).
6. **QED:** Ligand B (0.812) has a significantly better QED score than Ligand A (0.569), indicating a more drug-like profile.
7. **DILI:** Ligand B (54.517) has a much lower DILI risk than Ligand A (85.227). This is a significant advantage for Ligand B.
8. **BBB:** Both ligands have acceptable BBB penetration (A: 69.252, B: 65.374), but neither is exceptionally high. Since ADRB2 is a cardiovascular target, BBB penetration is not a primary concern.
9. **Caco-2:** Ligand A (-4.793) has a better Caco-2 permeability than Ligand B (-5.071).
10. **Solubility:** Ligand A (-4.45) has better solubility than Ligand B (-3.662).
11. **hERG:** Both ligands have low hERG inhibition risk (A: 0.21, B: 0.297).
12. **Cl_mic:** Ligand A (43.997) has a lower microsomal clearance than Ligand B (51.759), suggesting better metabolic stability.
13. **t1/2:** Ligand B (25.273) has a longer in vitro half-life than Ligand A (16.302).
14. **Pgp:** Both ligands have low P-gp efflux (A: 0.231, B: 0.48).
15. **Affinity:** Ligand A (-7.2 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.2 kcal/mol). This is a substantial advantage.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has a slightly better logP and TPSA, similar Pgp, but a *much* better binding affinity. The difference in affinity (-1.0 kcal/mol) is substantial and likely outweighs the advantages of Ligand B in other areas.
**Overall Assessment:**
While Ligand B has a better QED and lower DILI risk, the significantly stronger binding affinity of Ligand A is the deciding factor. The potency advantage is likely to be crucial for efficacy, and the other parameters of Ligand A are still within acceptable ranges.
Output:
1
2025-04-17 20:51:43,470 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (339.395 and 352.475 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (73.64) is better than Ligand B (81.08). Both are below 140, but lower TPSA generally favors absorption.
3. **logP:** Both ligands have good logP values (1.842 and 1.314), falling within the optimal 1-3 range. Ligand B is slightly lower, which could slightly reduce permeability, but both are acceptable.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Both ligands have the same number of HBA (4), which is within the acceptable limit of 10.
6. **QED:** Ligand B (0.731) has a slightly higher QED score than Ligand A (0.585), suggesting a more drug-like profile. This is a positive for Ligand B.
7. **DILI:** Ligand A (48.197) has a significantly lower DILI risk than Ligand B (19.465). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (70.88) has a better BBB penetration percentile than Ligand B (50.679). For a GPCR, even a non-CNS target, some BBB penetration can be beneficial for overall distribution and potentially off-target effects, and is a positive.
9. **Caco-2:** Both ligands have similar, and very poor, Caco-2 permeability (-4.797 and -4.635). This is a concern for both, suggesting poor intestinal absorption.
10. **Solubility:** Ligand A (-2.413) has slightly better solubility than Ligand B (-1.746), though both are quite poor.
11. **hERG:** Both ligands have low hERG inhibition liability (0.499 and 0.307), which is good.
12. **Cl_mic:** Ligand B (8.537) has lower microsomal clearance than Ligand A (11.147), indicating better metabolic stability. This is a positive for Ligand B.
13. **t1/2:** Ligand B (9.079) has a longer in vitro half-life than Ligand A (-28.581). This is a significant advantage for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.065 and 0.195).
15. **Binding Affinity:** Ligand A (-6.6 kcal/mol) has a slightly better binding affinity than Ligand B (-6.3 kcal/mol). While the difference is small, it's still a factor.
**GPCR-Specific Considerations:**
For ADRB2, a GPCR, logP, TPSA, Pgp, and affinity are important. Both ligands perform reasonably well on logP and Pgp. Ligand A has a better TPSA and slightly better affinity. Ligand B has better metabolic stability (Cl_mic and t1/2) and a slightly better QED. The DILI risk for Ligand A is substantially lower, which is a critical factor.
**Overall Assessment:**
While Ligand B has advantages in QED, metabolic stability, and half-life, the significantly lower DILI risk associated with Ligand A, coupled with its slightly better TPSA and affinity, makes it the more promising candidate. The poor Caco-2 permeability is a concern for both, but can be addressed with formulation strategies. The lower DILI risk is a crucial safety factor that outweighs the other benefits of Ligand B.
Output:
1
2025-04-17 20:51:43,470 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (337.423) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (61.44) is significantly better than Ligand B (80.76). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (A: 4.049, B: 2.359), falling within the 1-3 range. Ligand A is a bit higher, which *could* present solubility issues, but isn't a major concern.
4. **HBD/HBA:** Ligand A (HBD: 2, HBA: 2) is slightly better than Ligand B (HBD: 1, HBA: 5). Lower counts are generally preferred for better permeability.
5. **QED:** Both ligands have similar, good QED values (A: 0.827, B: 0.841), indicating good drug-likeness.
6. **DILI:** Ligand B (64.172) has a lower DILI risk than Ligand A (84.025), which is a significant advantage.
7. **BBB:** Ligand A (71.462) has better BBB penetration than Ligand B (59.364). While not a primary concern for a cardiovascular target, it's a slight positive.
8. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.624) is slightly worse than Ligand B (-4.044).
9. **Solubility:** Ligand A (-5.23) has slightly worse solubility than Ligand B (-3.073).
10. **hERG:** Ligand A (0.724) has a better hERG profile than Ligand B (0.23), indicating lower cardiotoxicity risk. This is *very* important for a cardiovascular target.
11. **Cl_mic:** Ligand A (55.008) has a lower microsomal clearance than Ligand B (62.015), indicating better metabolic stability.
12. **t1/2:** Ligand B (-28.574) has a significantly longer in vitro half-life than Ligand A (35.151). This is a major advantage, potentially allowing for less frequent dosing.
13. **Pgp:** Ligand A (0.23) has lower P-gp efflux than Ligand B (0.023), suggesting better bioavailability.
14. **Binding Affinity:** Ligand A (-8.2 kcal/mol) has a significantly stronger binding affinity than Ligand B (-5.2 kcal/mol). This is a substantial advantage and can often outweigh minor ADME concerns.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), affinity, logP, TPSA, and Pgp are key. Ligand A excels in affinity and has acceptable logP and TPSA, and better Pgp. While Ligand B has better DILI and half-life, the substantial difference in binding affinity is the deciding factor. The stronger binding of Ligand A is likely to translate to greater efficacy. The slightly higher DILI risk of Ligand A can be investigated further during development.
**Conclusion:**
Despite some drawbacks in DILI and solubility, the significantly superior binding affinity of Ligand A makes it the more promising drug candidate.
Output:
1
2025-04-17 20:51:43,470 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (354.48 and 349.43 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (58.12) is significantly better than Ligand B (100.45). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold. Ligand B is approaching the upper limit.
3. **logP:** Ligand A (3.856) is higher than Ligand B (1.051). While both are within the acceptable range, Ligand A is closer to the upper limit. This could potentially lead to off-target effects, but also better membrane permeability. Ligand B is quite low, potentially hindering permeation.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is preferable to Ligand B (5). Similar reasoning as HBD.
6. **QED:** Both ligands have good QED scores (0.656 and 0.723), indicating good drug-like properties. No significant difference.
7. **DILI:** Ligand B (47.693) has a substantially lower DILI risk than Ligand A (62.156). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (74.176) has better BBB penetration than Ligand B (50.679). While not crucial for a cardiovascular target, it's a slight positive for Ligand A.
9. **Caco-2:** Both ligands have similar, and poor, Caco-2 permeability (-5.167 and -5.154). This is a concern for both.
10. **Solubility:** Both ligands have poor aqueous solubility (-2.743 and -2.129). This is a concern for both, and might necessitate formulation strategies.
11. **hERG:** Ligand A (0.775) has a slightly higher hERG risk than Ligand B (0.189). This is a significant advantage for Ligand B.
12. **Cl_mic:** Ligand A (77.388) has a higher microsomal clearance than Ligand B (3.063). This indicates Ligand B is more metabolically stable, which is desirable.
13. **t1/2:** Ligand A (36.395) has a longer in vitro half-life than Ligand B (16.205). This is a positive for Ligand A.
14. **Pgp:** Ligand A (0.377) has lower P-gp efflux than Ligand B (0.024). Lower P-gp is preferable.
15. **Affinity:** Ligand A (-6.8 kcal/mol) has a better binding affinity than Ligand B (-5.5 kcal/mol). This is a 1.3 kcal/mol difference, which is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand A has a significant advantage in binding affinity and a longer half-life. However, Ligand B exhibits a much better safety profile (lower DILI, lower hERG risk) and improved metabolic stability (lower Cl_mic). While Ligand A's logP is higher, it's not excessively so. The TPSA for Ligand A is also much more favorable. Given the balance, the stronger affinity of Ligand A, combined with acceptable ADME properties, makes it the more promising candidate.
Output:
1
2025-04-17 20:51:43,471 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
We are targeting ADRB2, a GPCR, so the priorities are logP, TPSA, Pgp, BBB, and affinity.
* **Molecular Weight:** Both ligands are within the acceptable range (200-500 Da). Ligand A (335.451) is slightly lower, which is generally favorable for permeability.
* **TPSA:** Ligand A (46.92) is significantly better than Ligand B (88.75). A TPSA under 140 is good for oral absorption, but lower is better for GPCRs, and Ligand A is much closer to the ideal range for CNS penetration (though not a CNS target here, lower TPSA generally improves properties).
* **logP:** Both ligands have logP values within the optimal range (1-3), but Ligand B (4.32) is pushing the upper limit. Higher logP can lead to solubility issues and off-target effects. Ligand A (3.534) is preferable.
* **H-Bond Donors/Acceptors:** Ligand A (HBD=1, HBA=3) has a more favorable profile than Ligand B (HBD=3, HBA=6). Fewer H-bonds generally improve permeability.
* **QED:** Both ligands have reasonable QED scores (A: 0.648, B: 0.583), indicating good drug-like properties.
* **DILI:** Ligand B (36.448) has a significantly lower DILI risk than Ligand A (45.87), a major advantage.
* **BBB:** Ligand B (92.168) has a much higher BBB percentile than Ligand A (64.599). While not a CNS target, higher BBB can sometimes correlate with better overall permeability and reduced off-target effects.
* **Caco-2 Permeability:** Both are negative, indicating poor permeability. Ligand A (-4.803) is slightly better than Ligand B (-4.935), but both are concerning.
* **Aqueous Solubility:** Both are negative, indicating poor solubility. Ligand B (-5.669) is slightly worse than Ligand A (-4.844).
* **hERG Inhibition:** Ligand A (0.53) has a lower hERG inhibition risk than Ligand B (0.781).
* **Microsomal Clearance:** Both have similar microsomal clearance values (A: 86.072, B: 80.34).
* **In vitro Half-Life:** Ligand B (34.98) has a significantly longer half-life than Ligand A (7.301), which is a substantial benefit.
* **P-gp Efflux:** Ligand A (0.502) has lower P-gp efflux liability than Ligand B (0.139), which is favorable for bioavailability.
* **Binding Affinity:** Ligand A (-6.1 kcal/mol) has a slightly better binding affinity than Ligand B (-5.8 kcal/mol), although the difference is not huge.
**Overall Assessment:**
Ligand A has advantages in TPSA, logP, H-bonding, P-gp efflux, and binding affinity. However, Ligand B has a significantly lower DILI risk and a much longer half-life. The lower DILI risk is a critical factor, and the longer half-life is highly desirable. While Ligand A has a slight edge in binding affinity, the difference isn't large enough to outweigh the safety and PK advantages of Ligand B. The poor Caco-2 and solubility for both are concerning and would require further optimization, but are less critical than the DILI risk.
**Output:**
0
2025-04-17 20:51:43,471 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (365.5 & 344.5 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Both are below the 140 A^2 threshold for good oral absorption (69.6 & 67.2 A^2). Again, no clear advantage.
3. **logP:** Ligand A (1.395) is slightly lower than Ligand B (2.419), but both are within the optimal 1-3 range. Ligand B is slightly better here.
4. **HBD:** Ligand A (0) is preferable to Ligand B (1) as lower HBD generally improves permeability.
5. **HBA:** Ligand A (6) is slightly higher than Ligand B (4), but both are acceptable (<10).
6. **QED:** Both ligands have similar QED scores (0.81 and 0.7), indicating good drug-likeness.
7. **DILI:** Ligand A (34.4%) has a slightly higher DILI risk than Ligand B (28.9%), but both are well below the concerning 60% threshold. Ligand B is slightly better.
8. **BBB:** Both ligands have good BBB penetration (76.7% and 71.9%). This is important for GPCRs, but less critical for ADRB2 specifically as it's primarily a cardiovascular target.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. This is a significant concern.
10. **Solubility:** Both ligands have negative solubility values, indicating poor solubility. This is a significant concern.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.359 and 0.48). This is excellent.
12. **Cl_mic:** Ligand A (11.8 mL/min/kg) has significantly lower microsomal clearance than Ligand B (43.7 mL/min/kg), suggesting better metabolic stability. This is a strong advantage for Ligand A.
13. **t1/2:** Ligand A (16.0 hours) has a much longer in vitro half-life than Ligand B (-13.6 hours). This is a substantial advantage for Ligand A, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.266 and 0.104).
15. **Binding Affinity:** Ligand B (-7.1 kcal/mol) has a slightly better binding affinity than Ligand A (-6.5 kcal/mol). This is a 0.6 kcal/mol difference, which is significant.
**Overall Assessment:**
While Ligand B has a slightly better binding affinity and logP, Ligand A demonstrates superior ADME properties, specifically in terms of metabolic stability (lower Cl_mic) and half-life (longer t1/2). The poor Caco-2 and solubility are concerning for both, but the metabolic advantages of Ligand A are more readily addressable through formulation strategies than improving a substantially lower half-life. For a GPCR, balancing affinity with good ADME properties is crucial. The difference in affinity isn't large enough to outweigh the significant pharmacokinetic benefits of Ligand A.
Output:
1
2025-04-17 20:51:43,471 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
Let's break down the comparison of Ligand A and Ligand B, considering the provided guidelines and ADRB2 (GPCR) specific priorities.
1. **Molecular Weight:** Both ligands (378.372 and 342.374 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (72.64) is better than Ligand B (83.98). Both are below 140, but lower TPSA generally favors better absorption.
3. **logP:** Ligand A (2.73) is optimal, while Ligand B (1.544) is slightly lower, potentially impacting permeability.
4. **H-Bond Donors:** Ligand A (0) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **H-Bond Acceptors:** Ligand A (5) is preferable to Ligand B (4). Both are within acceptable limits.
6. **QED:** Both ligands have good QED scores (0.671 and 0.834), indicating good drug-like properties.
7. **DILI:** Ligand A (69.407) is slightly higher than Ligand B (65.723), but both are acceptable.
8. **BBB:** Ligand A (88.833) is significantly better than Ligand B (77.588). While ADRB2 isn't exclusively a CNS target, some peripheral ADRB2 activity can influence CNS pathways, and higher BBB penetration isn't detrimental.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.513 and -4.777), which is unusual and suggests poor permeability. However, the values are very similar.
10. **Solubility:** Ligand A (-4.056) is better than Ligand B (-2.581). Higher solubility is generally preferred.
11. **hERG:** Ligand A (0.843) is better than Ligand B (0.143). Lower hERG inhibition is crucial for avoiding cardiotoxicity, a major concern for cardiovascular targets like ADRB2.
12. **Cl_mic:** Ligand A (79.563) is higher than Ligand B (22.746), indicating faster metabolic clearance and lower metabolic stability. This is a significant drawback for Ligand A.
13. **t1/2:** Ligand A (-33.771) is significantly worse than Ligand B (-25.58). This reinforces the metabolic stability concern for Ligand A.
14. **Pgp:** Ligand A (0.398) is better than Ligand B (0.046). Lower P-gp efflux is desirable for better bioavailability.
15. **Binding Affinity:** Ligand B (-7.5 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.0 kcal/mol). This is a substantial advantage, potentially outweighing some ADME concerns.
**Overall Assessment:**
Ligand B exhibits a significantly stronger binding affinity, a crucial factor for GPCR targets. While Ligand A has some advantages in BBB and Pgp, Ligand B's superior affinity, better hERG profile, and significantly improved metabolic stability (lower Cl_mic and better t1/2) make it the more promising candidate. The Caco-2 values are concerning for both, but the affinity difference is substantial enough to prioritize Ligand B.
**Output:**
0
2025-04-17 20:51:43,471 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (341.371 and 343.479 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (126.88) is higher than Ligand B (70.9). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is generally preferred for absorption. Ligand B has a significant advantage here.
3. **logP:** Ligand A (-0.185) is quite low, potentially hindering permeability. Ligand B (2.351) is within the optimal 1-3 range. This is a substantial advantage for Ligand B.
4. **HBD:** Ligand A (4) is slightly higher than Ligand B (2). Both are acceptable, but lower is generally better.
5. **HBA:** Ligand A (4) is lower than Ligand B (7). While both are within acceptable limits, Ligand A is slightly favored.
6. **QED:** Ligand B (0.717) is better than Ligand A (0.405), indicating a more drug-like profile.
7. **DILI:** Ligand A (61.846) has a slightly higher DILI risk than Ligand B (54.827), but both are reasonably acceptable.
8. **BBB:** Ligand A (19.038) has very low BBB penetration, while Ligand B (85.072) is quite high. Since ADRB2 is not a CNS target, this is less crucial, but higher BBB is never a detriment.
9. **Caco-2:** Both ligands have similar, poor Caco-2 permeability (-5.48 and -5.295). This is a concern for both, but not a deciding factor.
10. **Solubility:** Both ligands have poor aqueous solubility (-3.038 and -3.198). This is a concern for both, and will likely require formulation work.
11. **hERG:** Ligand A (0.148) has a slightly lower hERG risk than Ligand B (0.955), which is a positive.
12. **Cl_mic:** Ligand A (-13.314) has significantly lower microsomal clearance than Ligand B (60.109), suggesting better metabolic stability. This is a major advantage for Ligand A.
13. **t1/2:** Ligand B (48.595) has a much longer in vitro half-life than Ligand A (13.065). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.037) has a much lower P-gp efflux liability than Ligand B (0.35). This is a positive for Ligand A.
15. **Binding Affinity:** Ligand A (-7.1) has a slightly better binding affinity than Ligand B (-6.7). While the difference is not huge, it's enough to consider.
**Overall Assessment & GPCR-Specific Priorities:**
For a cardiovascular GPCR like ADRB2, logP, TPSA, and metabolic stability are key. Ligand B excels in logP and TPSA, and has a much longer half-life. Ligand A has better metabolic stability (lower Cl_mic) and P-gp efflux, and slightly better binding affinity, and lower hERG risk. The poor solubility and Caco-2 permeability are concerns for both.
The advantage in logP and TPSA for Ligand B, combined with its longer half-life, outweigh the slightly better affinity and metabolic stability of Ligand A. The lower logP of Ligand A is a significant drawback for permeability.
Output:
0
2025-04-17 20:51:43,471 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [344.419, 111.06 , 2.066, 1. , 4. , 0.484, 30.593, 52.966, -5.113, -1.971, 0.134, 5.658, -14.075, 0.01 , -7.6 ]
**Ligand B:** [351.51 , 26.79 , 2.413, 0. , 3. , 0.659, 12.641, 96.278, -4.524, -1.466, 0.932, 43.146, 8.168, 0.299, -5.9 ]
Here's a breakdown of the comparison, considering the provided guidelines and GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (344.419) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (111.06) is higher than Ligand B (26.79). While both are below 140, the lower TPSA of Ligand B is significantly better for oral absorption and potentially for GPCR binding.
3. **logP:** Both are within the optimal range (1-3). Ligand B (2.413) is slightly higher, which could be a minor advantage for membrane permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (0). Having one HBD can improve solubility without significantly impacting permeability.
5. **HBA:** Ligand A (4) is preferable to Ligand B (3). Similar to HBD, a slightly higher number of HBA can aid solubility.
6. **QED:** Ligand B (0.659) has a better QED score than Ligand A (0.484), indicating a more drug-like profile.
7. **DILI:** Ligand B (12.641) has a much lower DILI risk than Ligand A (30.593), a significant advantage.
8. **BBB:** Ligand B (96.278) has a substantially higher BBB penetration score than Ligand A (52.966). This is a crucial factor for GPCRs, even those not directly in the CNS, as it can influence off-target effects and distribution.
9. **Caco-2:** Ligand A (-5.113) has a lower Caco-2 permeability than Ligand B (-4.524), indicating lower intestinal absorption.
10. **Solubility:** Ligand A (-1.971) has a lower solubility than Ligand B (-1.466).
11. **hERG:** Ligand A (0.134) is preferable to Ligand B (0.932) with a lower hERG inhibition liability.
12. **Cl_mic:** Ligand A (5.658) has a lower microsomal clearance than Ligand B (43.146), suggesting better metabolic stability.
13. **t1/2:** Ligand B (8.168) has a longer in vitro half-life than Ligand A (-14.075), which is desirable.
14. **Pgp:** Ligand A (0.01) has a lower P-gp efflux liability than Ligand B (0.299), which is favorable for bioavailability.
15. **Affinity:** Ligand A (-7.6) has a better binding affinity than Ligand B (-5.9). This is a 1.7 kcal/mol difference, which is a substantial advantage and can outweigh some ADME concerns.
**Overall Assessment:**
While Ligand B excels in several key ADME properties (DILI, BBB, QED, t1/2, solubility) and has a better TPSA, Ligand A's significantly stronger binding affinity (-7.6 vs -5.9 kcal/mol) is a critical factor for a GPCR target. The affinity difference is large enough to compensate for the slightly less favorable ADME profile of Ligand A. The lower Pgp efflux for Ligand A is also a plus.
Therefore, I would choose Ligand A.
0
2025-04-17 20:51:43,471 - INFO - Batch 216 complete. Total preferences: 3456
2025-04-17 20:51:43,471 - INFO - Processing batch 217/512...
2025-04-17 20:52:32,217 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, key priorities are logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB.
Let's compare the ligands property by property:
1. **MW:** Both ligands (372.475 and 401.272 Da) fall within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (69.04) is significantly better than Ligand B (107.85). A lower TPSA generally indicates better cell permeability, crucial for GPCR targeting. Ligand A is well below the 140 threshold, while B is approaching it.
3. **logP:** Ligand A (3.527) is slightly higher than Ligand B (1.687). Both are within the optimal 1-3 range, but A is closer to the upper limit, which could potentially cause issues.
4. **HBD/HBA:** Both have 1 HBD and a reasonable number of HBAs (7 and 8 respectively). This isn't a major differentiating factor.
5. **QED:** Both ligands have similar QED values (0.71 and 0.775), indicating good drug-likeness.
6. **DILI:** Ligand A (90.733) has a higher DILI risk than Ligand B (84.18). This is a negative for Ligand A.
7. **BBB:** Both ligands have similar BBB penetration (72.276 and 71.268). Since this is a cardiovascular target, BBB isn't a primary concern, but it's good they both show some penetration.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and hard to interpret without knowing the scale. It's likely a log scale, and lower values indicate lower permeability.
9. **Solubility:** Both have negative solubility values, again likely on a log scale, indicating low solubility.
10. **hERG:** Both ligands have low hERG inhibition risk (0.615 and 0.65).
11. **Cl_mic:** Ligand B (34.246) has significantly lower microsomal clearance than Ligand A (79.635), indicating better metabolic stability. This is a significant advantage for Ligand B.
12. **t1/2:** Ligand B (-11.225) has a negative in vitro half-life, which is concerning. Ligand A (25.571) is positive and more reasonable.
13. **Pgp:** Both have very low Pgp efflux liability (0.801 and 0.03).
14. **Binding Affinity:** Both ligands have very similar binding affinities (-6.2 and -6.3 kcal/mol). The difference is negligible.
**Overall Assessment:**
Ligand A has a better TPSA and in vitro half-life, but suffers from higher DILI risk and significantly higher microsomal clearance. Ligand B has better metabolic stability (lower Cl_mic) and a lower DILI risk, which are crucial for a viable drug candidate. While the half-life is concerning, the metabolic stability is a stronger positive. The similar binding affinities mean that the ADME properties become the deciding factor. Given the GPCR target class and the importance of metabolic stability and minimizing toxicity, Ligand B is the more promising candidate.
**Output:**
0
2025-04-17 20:52:32,218 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.443 and 355.435 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (91.57 and 92.99) are reasonably low, suggesting good potential for absorption. They are slightly above the preferred <90 for CNS targets, but ADRB2 is primarily a cardiovascular target, so this is less critical.
3. **logP:** Both ligands have good logP values (1.723 and 1.306), falling within the optimal 1-3 range. Ligand B is slightly lower, which *could* indicate slightly better solubility, but the difference is small.
4. **HBD:** Ligand A has 3 HBD, while Ligand B has 0. This is a slight advantage for Ligand B, as fewer HBDs can sometimes improve membrane permeability.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 5. Both are within the acceptable limit of 10.
6. **QED:** Ligand A (0.7) has a better QED score than Ligand B (0.507), indicating a more drug-like profile.
7. **DILI:** Ligand A (30.593) has a significantly lower DILI risk than Ligand B (15.665). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (77.433) has a higher BBB penetration percentile than Ligand A (56.611). While ADRB2 is not a primary CNS target, some CNS exposure can contribute to side effects. However, the difference isn't huge.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.949) is slightly worse than Ligand B (-4.396). This is a concern for both.
10. **Solubility:** Ligand B (-0.888) has slightly better solubility than Ligand A (-2.164).
11. **hERG:** Both ligands have very low hERG inhibition liability (0.377 and 0.084), which is excellent. Ligand B is slightly better.
12. **Cl_mic:** Ligand A (9.697) has a lower microsomal clearance than Ligand B (35.41), suggesting better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (33.831) has a much longer in vitro half-life than Ligand B (-13.95). This is a major advantage for Ligand A, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.165) has lower P-gp efflux liability than Ligand B (0.02). Lower Pgp is better.
15. **Binding Affinity:** Ligand B (-6.8 kcal/mol) has a slightly better binding affinity than Ligand A (-5.5 kcal/mol). This is a 1.3 kcal/mol difference, which is substantial and could outweigh some ADME drawbacks.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Both ligands perform well on logP and TPSA. Ligand B has a slightly better affinity. Ligand A has better Pgp. The biggest differences are in ADME properties: Ligand A has a significantly better DILI score, much better metabolic stability (lower Cl_mic), and a much longer half-life.
**Overall Assessment:**
While Ligand B has a slightly better binding affinity, the superior ADME profile of Ligand A, particularly the lower DILI risk, improved metabolic stability, and longer half-life, make it the more promising drug candidate. The Caco-2 permeability is concerning for both, but can be addressed through formulation strategies. The improved safety profile and PK properties of Ligand A outweigh the modest affinity difference.
Output:
1
2025-04-17 20:52:32,218 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's analyze each ligand against the provided guidelines, with emphasis on GPCR-relevant parameters (logP, Pgp, TPSA, and affinity).
* **Molecular Weight:** Both ligands (345.487 and 350.434 Da) fall comfortably within the ideal 200-500 Da range.
* **TPSA:** Ligand A (62.3) is slightly higher than Ligand B (58.64). Both are acceptable for a non-CNS GPCR target like ADRB2, being below 140.
* **logP:** Both ligands have good logP values (2.948 and 2.204), falling within the optimal 1-3 range. Ligand A is slightly higher, which *could* be beneficial for membrane permeability but also slightly increases the risk of off-target interactions.
* **H-Bond Donors/Acceptors:** Both have 1 HBD and 3 HBA, which are within acceptable limits.
* **QED:** Both ligands have similar and acceptable QED values (0.663 and 0.695).
* **DILI:** Both ligands have very similar, low DILI risk (17.371 and 17.41 percentile). This is excellent.
* **BBB:** Ligand B (89.763) has a significantly higher BBB penetration score than Ligand A (71.927). While ADRB2 isn't a primary CNS target, some peripheral ADRB2 activity can influence CNS processes, and higher BBB penetration isn't necessarily a negative.
* **Caco-2 Permeability:** Ligand A (-4.923) has slightly better Caco-2 permeability than Ligand B (-4.42), suggesting better intestinal absorption.
* **Aqueous Solubility:** Both ligands have poor aqueous solubility (-2.015 and -2.135). This is a potential formulation challenge, but not a deal-breaker at this stage.
* **hERG Inhibition:** Ligand A (0.54) has a slightly lower hERG inhibition risk than Ligand B (0.782), which is favorable.
* **Microsomal Clearance:** Ligand B (13.227) has a much lower microsomal clearance than Ligand A (50.436). This suggests better metabolic stability for Ligand B, a significant advantage.
* **In vitro Half-Life:** Ligand B (-0.748) has a significantly longer in vitro half-life than Ligand A (-18.123). This is a major positive for Ligand B, potentially leading to less frequent dosing.
* **P-gp Efflux:** Ligand A (0.402) has lower P-gp efflux than Ligand B (0.166), which is a slight advantage for bioavailability.
* **Binding Affinity:** Both ligands have excellent binding affinity (-6.2 and -6.0 kcal/mol). The difference of 0.2 kcal/mol is not substantial enough to override other factors.
**Overall Assessment:**
While Ligand A has slightly better Caco-2 permeability and lower P-gp efflux, Ligand B demonstrates superior ADME properties, particularly in terms of metabolic stability (lower Cl_mic) and longer half-life. The higher BBB penetration of Ligand B is also a minor positive. Given the importance of metabolic stability and half-life for *in vivo* efficacy, and the relatively small difference in binding affinity, Ligand B is the more promising candidate.
**Output:**
0
2025-04-17 20:52:32,218 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.39 & 354.49 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (97.92) is higher than Ligand B (67.87). For a cardiovascular GPCR, TPSA isn't a *major* concern unless exceptionally high, but lower is generally preferable for permeability. Ligand B is better.
3. **logP:** Ligand A (-0.07) is quite low, potentially hindering membrane permeability. Ligand B (1.973) is within the optimal 1-3 range. Ligand B is significantly better.
4. **HBD:** Ligand A (3) is higher than Ligand B (1). While both are acceptable, lower HBD can improve permeability. Ligand B is better.
5. **HBA:** Ligand A (6) is higher than Ligand B (4). Similar to HBD, lower HBA is generally preferred. Ligand B is better.
6. **QED:** Both ligands have good QED scores (0.569 and 0.724), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (55.76%) has a higher DILI risk than Ligand B (27.10%). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (52.27%) and Ligand B (65.53%) both have moderate BBB penetration. Since ADRB2 is not a CNS target, this isn't a primary driver, but higher is still slightly preferred. Ligand B is better.
9. **Caco-2:** Ligand A (-5.557) has a very poor Caco-2 permeability, indicating poor absorption. Ligand B (-4.713) is also poor, but better than A.
10. **Solubility:** Both ligands have very poor aqueous solubility (-1.372 and -1.303). This is a concern for both, and formulation strategies would be needed. No clear winner.
11. **hERG:** Ligand A (0.113) has a slightly lower hERG risk than Ligand B (0.339), which is good.
12. **Cl_mic:** Ligand A (-0.126) has a much lower (better) microsomal clearance than Ligand B (21.937), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (-19.07) has a very short in vitro half-life, while Ligand B (0.898) is better, but still not ideal. Ligand B is better.
14. **Pgp:** Ligand A (0.01) has very low P-gp efflux, which is good. Ligand B (0.043) is also low, but slightly higher. Ligand A is better.
15. **Affinity:** Both ligands have excellent binding affinity (-7.0 and -5.7 kcal/mol). Ligand A is significantly more potent.
**Overall Assessment:**
Ligand A has a significantly better binding affinity and metabolic stability (lower Cl_mic, lower Pgp efflux). However, it suffers from very poor Caco-2 permeability and a lower logP. Ligand B has better ADME properties overall (logP, TPSA, DILI, Caco-2, t1/2), but its binding affinity is weaker.
Given the strong affinity of Ligand A, the poor permeability and logP are concerning but potentially addressable through prodrug strategies or formulation. The significantly better metabolic stability is a major plus. The DILI risk of Ligand A is higher, but not critically so. The affinity difference is substantial enough to outweigh the ADME concerns, especially considering the target is a cardiovascular GPCR where CNS penetration is not essential.
Output:
1
2025-04-17 20:52:32,218 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (337.339 Da) is well within the ideal range (200-500 Da). Ligand B (386.901 Da) is also acceptable. No clear advantage here.
2. **TPSA:** Ligand A (115.98) is slightly above the preferred <140 for good oral absorption, but still reasonable. Ligand B (70.08) is excellent, well below 140 and suggests good permeability. Advantage: B.
3. **logP:** Both ligands (A: 1.5, B: 1.575) are within the optimal 1-3 range. No clear advantage.
4. **HBD:** Ligand A (4) is acceptable. Ligand B (1) is even better, minimizing potential issues with hydrogen bonding and maximizing permeability. Advantage: B.
5. **HBA:** Ligand A (4) is acceptable. Ligand B (5) is also acceptable. No clear advantage.
6. **QED:** Ligand B (0.805) has a significantly higher QED score than Ligand A (0.51), indicating a more drug-like profile. Advantage: B.
7. **DILI:** Ligand A (85.537) has a high DILI risk, which is concerning. Ligand B (20.396) has a very low DILI risk, a major advantage. Advantage: B.
8. **BBB:** Ligand B (80.264) has a good BBB penetration percentile, while Ligand A (40.558) is lower. Considering ADRB2 is a GPCR, BBB penetration is a relevant factor, though not critical for all subtypes. Advantage: B.
9. **Caco-2:** Both are negative, indicating poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Both ligands have negative solubility values, indicating poor solubility. The scale is not specified, so it's hard to interpret.
11. **hERG:** Both ligands have low hERG inhibition liability (A: 0.483, B: 0.577). No clear advantage.
12. **Cl_mic:** Ligand A (-4.185) has a negative clearance, which is unusual and potentially indicates very high metabolic stability. Ligand B (8.005) has a moderate clearance. Advantage: A.
13. **t1/2:** Ligand A (66.321) has a much longer in vitro half-life than Ligand B (14.614). This is a significant advantage. Advantage: A.
14. **Pgp:** Both ligands have low P-gp efflux liability (A: 0.03, B: 0.183). No clear advantage.
15. **Affinity:** Ligand A (-7.8 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.7 kcal/mol). This is a substantial advantage, potentially outweighing some ADME concerns. Advantage: A.
**Overall Assessment:**
Ligand B has a superior ADME profile, particularly regarding DILI risk, TPSA, QED, and BBB penetration. However, Ligand A boasts a significantly stronger binding affinity (-7.8 vs -6.7 kcal/mol) and a longer half-life. The difference in affinity is substantial (over 1 kcal/mol), and the longer half-life is also beneficial. The high DILI risk of Ligand A is a concern, but could potentially be mitigated with structural modifications. Given the importance of potency for GPCR targets, and the potential to address the DILI risk through further optimization, I believe Ligand A is the more promising starting point.
Output:
1
2025-04-17 20:52:32,219 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (349.475 Da and 341.455 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (95.66) is higher than Ligand B (53.51). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is generally preferred for absorption. Ligand B is significantly better here.
**3. logP:** Ligand B (2.038) is within the optimal 1-3 range, while Ligand A (0.63) is slightly below 1. A logP below 1 can hinder membrane permeability. Ligand B is favored.
**4. H-Bond Donors:** Ligand A has 3 HBD, and Ligand B has 0. Both are acceptable, but fewer HBDs often correlate with better permeability. Ligand B is slightly favored.
**5. H-Bond Acceptors:** Ligand A has 4 HBA, and Ligand B has 3. Both are within the acceptable range of <=10. No strong preference.
**6. QED:** Ligand B (0.845) has a higher QED score than Ligand A (0.649), indicating a more drug-like profile. This is a positive for Ligand B.
**7. DILI Risk:** Ligand B (10.237) has a much lower DILI risk than Ligand A (7.677). This is a significant advantage for Ligand B, as minimizing liver toxicity is crucial.
**8. BBB Penetration:** Ligand B (92.168) shows significantly better BBB penetration than Ligand A (56.805). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant, and higher BBB is generally desirable.
**9. Caco-2 Permeability:** Ligand A (-5.095) and Ligand B (-4.713) are both negative, indicating poor permeability. However, Ligand B is slightly less negative.
**10. Aqueous Solubility:** Both ligands have very poor aqueous solubility (-2.294 and -2.183 respectively). This is a concern for both, and formulation strategies would be needed.
**11. hERG Inhibition:** Ligand A (0.225) has a lower hERG inhibition risk than Ligand B (0.315). This is a slight advantage for Ligand A.
**12. Microsomal Clearance:** Ligand A (-8.784) has a much lower (better) microsomal clearance than Ligand B (62.4). This suggests greater metabolic stability for Ligand A.
**13. In Vitro Half-Life:** Ligand A (6.665) has a shorter half-life than Ligand B (-21.386). A longer half-life is generally preferred.
**14. P-gp Efflux:** Ligand A (0.03) has much lower P-gp efflux than Ligand B (0.149). Lower P-gp efflux is preferred for better bioavailability.
**15. Binding Affinity:** Ligand A (-6.9 kcal/mol) has a slightly better binding affinity than Ligand B (-3.4 kcal/mol). This is a substantial difference, and a strong binding affinity is a major driver.
**Overall Assessment:**
While Ligand A has a better binding affinity and lower P-gp efflux, Ligand B demonstrates a significantly superior ADME profile. Specifically, its lower DILI risk, better BBB penetration, higher QED, and more favorable logP outweigh the affinity difference. The poor solubility of both compounds is a concern, but can be addressed with formulation. The metabolic stability of Ligand A is good, but the other advantages of Ligand B are more critical for a balanced drug candidate.
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand B's better logP, lower Pgp, lower TPSA, and acceptable affinity make it the more promising candidate.
Output:
0
2025-04-17 20:52:32,219 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (342.395 and 366.487 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Both ligands (80.68 and 76.46) are below the 140 A^2 threshold for good oral absorption, and well below the 90 A^2 threshold for CNS targets (though ADRB2 isn't primarily a CNS target). Ligand B is slightly better.
3. **logP:** Ligand A (3.75) is optimal, while Ligand B (0.971) is a bit low, potentially hindering permeation. This favors Ligand A.
4. **HBD:** Both ligands have acceptable HBD counts (2 and 1 respectively), below the 5 threshold.
5. **HBA:** Both ligands have acceptable HBA counts (5 and 6 respectively), below the 10 threshold.
6. **QED:** Both ligands have similar and good QED values (0.797 and 0.76), indicating good drug-likeness.
7. **DILI:** Ligand B (35.634) has a significantly lower DILI risk than Ligand A (71.423). This is a major advantage for Ligand B.
8. **BBB:** Ligand B (52.966) has a better BBB percentile than Ligand A (38.426), although this isn't a primary concern for ADRB2.
9. **Caco-2:** Ligand A (-4.61) has a better Caco-2 permeability than Ligand B (-5.31).
10. **Solubility:** Ligand A (-4.873) has better solubility than Ligand B (-1.824).
11. **hERG:** Both ligands have low hERG inhibition liability (0.12 and 0.501), which is good. Ligand A is slightly better.
12. **Cl_mic:** Both ligands have similar microsomal clearance values (23.209 and 24.038).
13. **t1/2:** Ligand B (3.519) has a slightly better in vitro half-life than Ligand A (-25.232).
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.042 and 0.048).
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.8 and -6.9 kcal/mol). The difference is negligible.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A has a better logP and Caco-2 permeability. However, Ligand B has a significantly better DILI score and a better BBB penetration, which is a bonus. The binding affinities are almost identical.
**Overall Assessment:**
While Ligand A has some advantages in permeability and solubility, the significantly lower DILI risk associated with Ligand B is a crucial factor. DILI is a major reason for drug attrition, and minimizing this risk is paramount. The slight advantage in BBB penetration for Ligand B is also beneficial. Given the similar binding affinities, the improved safety profile of Ligand B makes it the more promising candidate.
Output:
0
2025-04-17 20:52:32,219 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [409.236, 92.91, 3.273, 1, 5, 0.584, 66.421, 53.005, -4.92, -4.457, 0.586, 74.007, -10.134, 0.473, -7.1]
**Ligand B:** [367.559, 58.22, 3.867, 1, 4, 0.709, 23.304, 62.854, -5.389, -2.779, 0.877, 61.461, -19.565, 0.298, -6.5]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** A (409.236) is slightly higher than B (367.559), but both are within the acceptable 200-500 Da range.
2. **TPSA:** A (92.91) is higher than B (58.22). B is better here, falling well below the 140 threshold for oral absorption. A is still reasonable, but less optimal.
3. **logP:** Both A (3.273) and B (3.867) are within the ideal 1-3 range. B is slightly higher, potentially indicating better membrane permeability, but not significantly.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** A has 5, B has 4. Both are acceptable.
6. **QED:** B (0.709) has a better QED score than A (0.584), suggesting a more drug-like profile.
7. **DILI:** A (66.421) has a significantly higher DILI risk than B (23.304). This is a major concern for A.
8. **BBB:** B (62.854) has a slightly better BBB penetration than A (53.005). While not a primary concern for a cardiovascular target, it's a small advantage.
9. **Caco-2:** A (-4.92) is better than B (-5.389). Both are negative, which is unusual and suggests poor permeability.
10. **Solubility:** B (-2.779) has better solubility than A (-4.457).
11. **hERG:** A (0.586) has a slightly lower hERG risk than B (0.877), which is good.
12. **Cl_mic:** B (61.461) has lower microsomal clearance than A (74.007), indicating better metabolic stability.
13. **t1/2:** B (-19.565) has a much longer in vitro half-life than A (-10.134). This is a significant advantage.
14. **Pgp:** A (0.473) has lower P-gp efflux than B (0.298), which is favorable.
15. **Affinity:** A (-7.1) has a better binding affinity than B (-6.5). This is a 1.5 kcal/mol difference, which is substantial and can outweigh some ADME concerns.
**Overall Assessment:**
While Ligand A has a better binding affinity, the significantly higher DILI risk and poorer metabolic stability (higher Cl_mic, shorter t1/2) are major drawbacks. Ligand B, despite slightly lower affinity, presents a much more favorable ADME profile with lower DILI risk, better solubility, better metabolic stability, and a longer half-life. The TPSA is also significantly better for B. Given the cardiovascular target, BBB penetration is less critical, and the small difference isn't decisive. The affinity difference, while notable, isn't large enough to overcome the substantial ADME liabilities of Ligand A.
Therefore, I would choose Ligand B.
0
2025-04-17 20:52:32,219 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (361.383 and 354.407 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Both ligands (124.09 and 127.93) are reasonably low, suggesting good potential for absorption. Ligand A is slightly better, being closer to the <140 threshold.
3. **logP:** Ligand A (3.342) is optimal (1-3), while Ligand B (-1.357) is significantly lower, potentially hindering membrane permeability. This is a major strike against Ligand B.
4. **HBD:** Ligand A (1) is excellent, while Ligand B (4) is higher, potentially impacting permeability.
5. **HBA:** Ligand A (8) is good, while Ligand B (7) is also acceptable.
6. **QED:** Ligand A (0.635) is better than Ligand B (0.431), indicating a more drug-like profile.
7. **DILI:** Ligand B (26.406) has a much lower DILI risk than Ligand A (96.433). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (53.276) is better than Ligand B (23.071), but BBB isn't a high priority for ADRB2 (a cardiovascular target).
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-5.315) is slightly better than Ligand B (-5.859).
10. **Solubility:** Ligand A (-4.812) is better than Ligand B (-0.23), indicating better aqueous solubility.
11. **hERG:** Both are very low, indicating minimal hERG inhibition risk. No clear advantage.
12. **Cl_mic:** Ligand B (-15.619) has a significantly lower (better) microsomal clearance than Ligand A (27.023), suggesting greater metabolic stability.
13. **t1/2:** Ligand B (10.381) has a longer in vitro half-life than Ligand A (-1.421). This is a significant advantage.
14. **Pgp:** Ligand A (0.067) has lower P-gp efflux liability than Ligand B (0.004), which is preferable.
15. **Affinity:** Ligand A (-8.2 kcal/mol) has a significantly stronger binding affinity than Ligand B (-2.2 kcal/mol). This is a major advantage for Ligand A.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A excels in affinity and has a good logP and Pgp. While Ligand B has better metabolic stability (Cl_mic and t1/2) and lower DILI risk, the significantly weaker binding affinity and poor logP are major drawbacks. The strong affinity of Ligand A is likely to outweigh the higher DILI risk, especially given the cardiovascular target.
**Conclusion:**
Despite Ligand B's advantages in metabolic stability and DILI, the significantly stronger binding affinity and better logP of Ligand A make it the more promising drug candidate for ADRB2.
Output:
1
2025-04-17 20:52:32,219 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [386.436, 60.03, 1.872, 1, 5, 0.407, 32.183, 83.172, -4.826, -3.029, 0.858, 47.202, 8.736, 0.31, -5.4]
**Ligand B:** [354.382, 103.68, 0.574, 3, 4, 0.666, 30.244, 59.364, -5.235, -1.708, 0.102, -17.009, 16.784, 0.003, -7.2]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (354.382) is slightly lower, which could be beneficial for permeability, but both are acceptable.
2. **TPSA:** Ligand A (60.03) is excellent, well below the 140 threshold and good for GPCRs. Ligand B (103.68) is higher, but still potentially acceptable, though less ideal.
3. **logP:** Ligand A (1.872) is optimal. Ligand B (0.574) is a bit low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (1) is good. Ligand B (3) is higher, potentially impacting permeability.
5. **HBA:** Ligand A (5) is good. Ligand B (4) is also good.
6. **QED:** Ligand B (0.666) is better than Ligand A (0.407), indicating a more drug-like profile.
7. **DILI:** Both are good, with Ligand A (32.183) and Ligand B (30.244) both being below the 40% threshold.
8. **BBB:** Ligand A (83.172) is significantly better than Ligand B (59.364). This is a crucial factor for a GPCR, even a cardiovascular one, as some CNS off-target effects are possible.
9. **Caco-2:** Ligand A (-4.826) is better than Ligand B (-5.235) indicating better absorption.
10. **Solubility:** Ligand A (-3.029) is better than Ligand B (-1.708).
11. **hERG:** Ligand A (0.858) is better than Ligand B (0.102).
12. **Cl_mic:** Ligand B (-17.009) has much lower clearance, indicating better metabolic stability, a significant advantage. Ligand A (47.202) is relatively high.
13. **t1/2:** Ligand B (16.784) has a much longer half-life than Ligand A (8.736), which is desirable.
14. **Pgp:** Ligand A (0.31) is better than Ligand B (0.003), indicating less efflux.
15. **Affinity:** Ligand B (-7.2) has a significantly stronger binding affinity than Ligand A (-5.4), a difference of 1.8 kcal/mol. This is a substantial advantage that can often outweigh other drawbacks.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, BBB, and affinity. Ligand B has a lower logP, but its significantly superior affinity (-7.2 vs -5.4) and better metabolic stability (Cl_mic and t1/2) are compelling. While Ligand A has a better BBB, the difference in affinity is substantial enough to likely overcome this.
**Conclusion:**
Despite Ligand A's better BBB and some ADME properties, Ligand B's significantly stronger binding affinity and improved metabolic stability make it the more promising drug candidate. The 1.8 kcal/mol difference in binding is a substantial advantage.
Output:
0
2025-04-17 20:52:32,220 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (358.829 Da and 348.495 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (68.52) is slightly higher than Ligand B (57.5). Both are below the 140 threshold for oral absorption, but B is better.
3. **logP:** Ligand A (3.36) is optimal, while Ligand B (1.378) is on the lower side of optimal. This favors A, as a slightly higher logP can aid membrane permeability for a GPCR target.
4. **HBD:** Ligand A (1) is preferable to Ligand B (0). While both are low, having one HBD can improve solubility without significantly impacting permeability.
5. **HBA:** Ligand A (5) and Ligand B (6) are both acceptable, below the 10 threshold.
6. **QED:** Both ligands have good QED scores (0.657 and 0.745), indicating good drug-like properties. B is slightly better.
7. **DILI:** Ligand B (12.33) has a *much* lower DILI risk than Ligand A (78.945). This is a major advantage for B.
8. **BBB:** Ligand B (80.69) has a significantly higher BBB penetration percentile than Ligand A (54.362). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be beneficial or at least less detrimental than complete exclusion, and higher BBB is generally preferred.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.029 and -4.978), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand B (-0.474) is better than Ligand A (-3.532). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.664) has a slightly higher hERG risk than Ligand B (0.496), but both are relatively low.
12. **Cl_mic:** Ligand A (74.816) has a higher microsomal clearance than Ligand B (15.48). This means B is more metabolically stable, a significant advantage.
13. **t1/2:** Ligand B (6.559) has a longer in vitro half-life than Ligand A (32.831). This is a positive for B.
14. **Pgp:** Ligand A (0.418) has lower P-gp efflux than Ligand B (0.029). Lower P-gp efflux is generally better.
15. **Binding Affinity:** Ligand A (-7.3) has a stronger binding affinity than Ligand B (-5.5). This is a substantial advantage for A (1.8 kcal/mol difference).
**Overall Assessment:**
Ligand A has a significantly better binding affinity, which is a critical factor for GPCRs. However, Ligand B excels in several key ADME-Tox properties: lower DILI risk, higher BBB penetration, better solubility, improved metabolic stability (lower Cl_mic and longer t1/2), and lower P-gp efflux. The Caco-2 values are concerning for both, but the substantial difference in affinity, coupled with the generally acceptable values for other parameters in Ligand A, outweighs the ADME advantages of Ligand B. The lower DILI risk of B is attractive, but the affinity difference is too large to ignore.
Output:
1
2025-04-17 20:52:32,220 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Ligand A:**
* **MW:** 358.435 Da - Good, within the ideal range.
* **TPSA:** 108.33 - Acceptable, but approaching the upper limit for good absorption.
* **logP:** -0.554 - Low, potentially hindering permeation. This is a significant concern.
* **HBD:** 3 - Acceptable.
* **HBA:** 6 - Acceptable.
* **QED:** 0.483 - Below the desirable 0.5 threshold, indicating a less drug-like profile.
* **DILI:** 13.067 - Excellent, very low risk.
* **BBB:** 40.791 - Low, not a major concern for a cardiovascular target, but limits potential for CNS effects.
* **Caco-2:** -5.233 - Very poor permeability.
* **Solubility:** -0.715 - Poor solubility.
* **hERG:** 0.102 - Low risk.
* **Cl_mic:** 28.934 - Moderate, acceptable.
* **t1/2:** -16.28 - Very short half-life, a significant drawback.
* **Pgp:** 0.019 - Low efflux, good.
* **Affinity:** -5.0 kcal/mol - Good binding affinity.
**Ligand B:**
* **MW:** 369.446 Da - Good, within the ideal range.
* **TPSA:** 64.43 - Excellent, well below the threshold for good absorption.
* **logP:** 2.835 - Optimal.
* **HBD:** 0 - Acceptable.
* **HBA:** 5 - Acceptable.
* **QED:** 0.628 - Good, above the 0.5 threshold.
* **DILI:** 14.23 - Excellent, very low risk.
* **BBB:** 83.094 - High, not a primary concern for a cardiovascular target, but could be relevant if off-target CNS effects are a concern.
* **Caco-2:** -4.451 - Moderate permeability.
* **Solubility:** -1.827 - Moderate solubility.
* **hERG:** 0.445 - Low risk.
* **Cl_mic:** 64.97 - High, indicating faster metabolism and lower stability.
* **t1/2:** 13.649 - Moderate half-life.
* **Pgp:** 0.218 - Low efflux, good.
* **Affinity:** -6.6 kcal/mol - Excellent binding affinity, 1.6 kcal/mol stronger than Ligand A.
**Comparison and Decision:**
For an ADRB2 GPCR, affinity, logP, TPSA, and Pgp are key. Ligand B has a significantly better binding affinity (-6.6 vs -5.0 kcal/mol). It also has a much better logP (2.835 vs -0.554) and TPSA (64.43 vs 108.33), suggesting better permeability and absorption. While Ligand B has a higher microsomal clearance, the substantial improvement in binding affinity and physicochemical properties outweighs this drawback. Ligand A's poor logP and Caco-2 permeability are major liabilities.
Therefore, I prefer Ligand B.
0
2025-04-17 20:52:32,220 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (345.4) is within the ideal range (200-500), while Ligand B (379.6) is also acceptable. No clear advantage.
2. **TPSA:** Ligand A (95.8) is better than Ligand B (49.25). Lower TPSA generally improves permeability, crucial for GPCRs.
3. **logP:** Ligand A (0.962) is within the optimal range (1-3), while Ligand B (4.278) is pushing the upper limit and could lead to solubility issues. Ligand A is preferred.
4. **HBD:** Ligand A (2) and Ligand B (1) are both good, below the threshold of 5.
5. **HBA:** Ligand A (5) and Ligand B (6) are both acceptable, below the threshold of 10.
6. **QED:** Both Ligand A (0.593) and Ligand B (0.669) are above 0.5, indicating good drug-likeness. Ligand B is slightly better.
7. **DILI:** Ligand A (64.4) has a higher DILI risk than Ligand B (38.3). Ligand B is significantly preferred here.
8. **BBB:** Ligand A (45.9) and Ligand B (65.8) are both not ideal, but Ligand B is better. For a cardiovascular target, BBB penetration is not a primary concern, but it's still a positive.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand A (-2.178) has better solubility than Ligand B (-4.165). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.206) has a much lower hERG risk than Ligand B (0.734). This is a critical advantage for Ligand A, as hERG inhibition can cause cardiotoxicity.
12. **Cl_mic:** Ligand A (15.877) has significantly lower microsomal clearance than Ligand B (60.911), indicating better metabolic stability.
13. **t1/2:** Ligand B (19.295) has a longer in vitro half-life than Ligand A (-2.301). This is a positive for Ligand B.
14. **Pgp:** Ligand A (0.051) has lower P-gp efflux liability than Ligand B (0.781), which is favorable for bioavailability.
15. **Affinity:** Both ligands have similar binding affinities (-5.7 and -5.8 kcal/mol). The difference is negligible.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand A is the better candidate. While Ligand B has a lower DILI risk and longer half-life, Ligand A has a more favorable logP, TPSA, hERG inhibition profile, and Pgp efflux. The lower hERG risk is particularly important for a cardiovascular target. The Caco-2 values are concerning for both, but the other advantages of Ligand A outweigh this drawback.
Output:
1
2025-04-17 20:52:32,220 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [410.539, 120.85 , 0.058, 2. , 7. , 0.625, 80.845, 25.359, -5.675, -2.488, 0.34 , -4.316, 48.911, 0.079, -6.2 ]
**Ligand B:** [352.391, 122.55 , -0.502, 3. , 7. , 0.569, 54.517, 48.081, -5.28 , -2.107, 0.037, -0.244, -5.823, 0.013, -8.8 ]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity) and general guidelines:
1. **MW:** Ligand A (410.539 Da) is within the ideal range, while Ligand B (352.391 Da) is a bit lower, but still acceptable.
2. **TPSA:** Both ligands (A: 120.85, B: 122.55) are slightly above the preferred <140 for good absorption, but not drastically so.
3. **logP:** Ligand A (0.058) is very low, which is a significant concern for membrane permeability. Ligand B (-0.502) is also low, but better than A. This is a major drawback for both, but more so for A.
4. **HBD/HBA:** Both have reasonable HBD (A: 2, B: 3) and HBA (A: 7, B: 7) counts.
5. **QED:** Both ligands have acceptable QED values (A: 0.625, B: 0.569).
6. **DILI:** Ligand A (80.845) has a higher DILI risk than Ligand B (54.517). This is a negative for A.
7. **BBB:** Ligand B (48.081) has a better BBB penetration percentile than Ligand A (25.359). While not a primary concern for a cardiovascular target, it's a plus for B.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability.
9. **Solubility:** Both have negative solubility values, which is also unusual.
10. **hERG:** Both ligands have very low hERG inhibition risk (A: 0.34, B: 0.037).
11. **Cl_mic:** Ligand B (-0.244) has a significantly lower (better) microsomal clearance than Ligand A (-4.316). This suggests better metabolic stability for B.
12. **t1/2:** Ligand B (-5.823) has a longer in vitro half-life than Ligand A (48.911).
13. **Pgp:** Both have very low Pgp efflux liability (A: 0.079, B: 0.013).
14. **Affinity:** Ligand B (-8.8 kcal/mol) has a substantially stronger binding affinity than Ligand A (-6.2 kcal/mol). This is a significant advantage for B.
**Overall Assessment:**
Ligand B is clearly the more promising candidate. While both have issues with logP and Caco-2/Solubility, Ligand B's significantly stronger binding affinity, better metabolic stability (lower Cl_mic, longer t1/2), lower DILI risk, and better BBB penetration outweigh the drawbacks. The low logP for both is a concern, but the superior affinity of B makes it more likely to achieve efficacy despite potential permeability issues.
Output:
0
2025-04-17 20:52:32,220 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [376.475, 121.8 , -0.638, 3. , 6. , 0.492, 39.046, 48.585, -5.377, -1.071, 0.067, 9.906, 23.539, 0.034, -6.3 ]
**Ligand B:** [369.294, 88.91 , 1.17 , 2. , 5. , 0.78 , 62.389, 73.517, -4.811, -3.164, 0.077, 7.558, -2.922, 0.029, -7.6 ]
Here's a step-by-step comparison, keeping GPCR priorities (logP, Pgp, TPSA, affinity) in mind:
1. **MW:** Both are within the ideal 200-500 Da range. A (376.475) is slightly higher than B (369.294), but this isn't a major concern.
2. **TPSA:** A (121.8) is slightly above the preferred <140 for oral absorption, but still reasonable. B (88.91) is excellent, well below 90, suggesting better potential for CNS penetration if desired.
3. **logP:** A (-0.638) is a bit low, potentially hindering permeability. B (1.17) is much better, falling within the optimal 1-3 range. This is a significant advantage for B.
4. **HBD:** A (3) and B (2) are both acceptable, below the 5 threshold.
5. **HBA:** A (6) and B (5) are both acceptable, below the 10 threshold.
6. **QED:** Both are reasonable, with B (0.78) being better than A (0.492), indicating a more drug-like profile.
7. **DILI:** A (39.046) is good, below 40. B (62.389) is getting closer to the concerning threshold of 60, but still acceptable.
8. **BBB:** A (48.585) is moderate. B (73.517) is significantly better, suggesting better potential for CNS penetration. While ADRB2 isn't strictly a CNS target, some CNS exposure might be acceptable or even desirable depending on the therapeutic goal.
9. **Caco-2:** Both are negative, indicating poor permeability. A (-5.377) is worse than B (-4.811).
10. **Solubility:** Both are negative, suggesting poor solubility. A (-1.071) is slightly better than B (-3.164).
11. **hERG:** Both are very low (0.067 and 0.077), indicating minimal hERG inhibition risk.
12. **Cl_mic:** A (9.906) is higher than B (7.558), suggesting faster metabolism and potentially lower *in vivo* exposure.
13. **t1/2:** A (23.539) is better than B (-2.922) indicating a longer half-life.
14. **Pgp:** Both are very low (0.034 and 0.029), indicating minimal P-gp efflux liability.
15. **Affinity:** B (-7.6) has a significantly stronger binding affinity than A (-6.3), a difference of 1.3 kcal/mol. This is a substantial advantage.
**Overall Assessment:**
Ligand B clearly outperforms Ligand A. The stronger binding affinity (-7.6 vs -6.3 kcal/mol) is a major advantage, and is likely to outweigh the slightly worse solubility. B also has a better logP, QED, BBB, and lower microsomal clearance. While A has a better half-life, the other factors favor B. The TPSA of B is also much more favorable.
Output:
0
2025-04-17 20:52:32,221 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (349.475 and 347.415 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (53.09) is significantly better than Ligand B (89.95). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold, while Ligand B is approaching it.
3. **logP:** Ligand A (0.98) is within the optimal 1-3 range, while Ligand B (-0.94) is slightly below 1. This is a notable disadvantage for Ligand B, potentially impacting permeability.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Both ligands have 4 HBA, which is acceptable.
6. **QED:** Ligand A (0.713) is slightly better than Ligand B (0.607), indicating a more drug-like profile.
7. **DILI:** Ligand A (20.938) has a much lower DILI risk than Ligand B (11.09). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (69.911) has better BBB penetration than Ligand B (44.32), although this isn't a high priority for a cardiovascular target.
9. **Caco-2:** Ligand A (-4.128) is better than Ligand B (-5.117), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-0.961) is better than Ligand B (-1.355), which is important for bioavailability.
11. **hERG:** Ligand A (0.415) has a lower hERG risk than Ligand B (0.092). This is a crucial safety consideration.
12. **Cl_mic:** Ligand B (-29.134) has a lower microsomal clearance than Ligand A (48.282), suggesting better metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand B (0.295) has a shorter half-life than Ligand A (-26.807). This is a disadvantage for Ligand B.
14. **Pgp:** Ligand A (0.073) has lower P-gp efflux than Ligand B (0.003), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand B (-6.2) is slightly better than Ligand A (-6.9). While a difference of 0.7 kcal/mol is noticeable, it's not substantial enough to overcome the multiple ADME advantages of Ligand A.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A is better in logP, TPSA, and Pgp. The affinity difference isn't large enough to favor Ligand B.
**Overall Assessment:**
Ligand A demonstrates a superior balance of properties. It has a lower DILI risk, better solubility, better permeability (based on TPSA, logP, and Caco-2), lower hERG risk, and lower P-gp efflux. While Ligand B has better metabolic stability (lower Cl_mic) and slightly better binding affinity, the overall profile of Ligand A is more favorable for development as a drug candidate.
Output:
1
2025-04-17 20:52:32,221 - INFO - Batch 217 complete. Total preferences: 3472
2025-04-17 20:52:32,221 - INFO - Processing batch 218/512...
2025-04-17 20:53:23,615 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (376.36 and 353.35 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (103.35) is better than Ligand B (122.99). ADRB2 is not a CNS target, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (2.69) is within the optimal 1-3 range. Ligand B (-0.611) is *below* 1, which is a concern for permeability. This is a significant negative for Ligand B.
4. **HBD:** Both ligands have 4 HBD, which is acceptable.
5. **HBA:** Ligand A has 5 HBA, and Ligand B has 6. Both are acceptable, but Ligand A is slightly better.
6. **QED:** Ligand A (0.644) is slightly better than Ligand B (0.575), indicating a more drug-like profile.
7. **DILI:** Ligand B (46.995) has a much lower DILI risk than Ligand A (87.049). This is a substantial advantage for Ligand B.
8. **BBB:** BBB is less critical for ADRB2 (a cardiovascular target). Ligand A (58.86) is better than Ligand B (23.265), but this is not a major factor.
9. **Caco-2:** Both have negative Caco-2 values, suggesting poor permeability. This is concerning for both, but the values are similar.
10. **Solubility:** Ligand A (-3.506) is slightly better than Ligand B (-1.462), indicating better aqueous solubility.
11. **hERG:** Ligand A (0.478) has a lower hERG risk than Ligand B (0.073), which is preferable.
12. **Cl_mic:** Ligand B (-27.18) has a *much* lower microsomal clearance than Ligand A (27.398), suggesting significantly better metabolic stability. This is a major advantage for Ligand B.
13. **t1/2:** Ligand B (-33.896) has a longer in vitro half-life than Ligand A (70.26), which is also a significant advantage.
14. **Pgp:** Ligand A (0.131) has lower P-gp efflux than Ligand B (0.005), which is preferable.
15. **Binding Affinity:** Ligand B (-6.8 kcal/mol) has a slightly better binding affinity than Ligand A (-5.9 kcal/mol). While the difference is less than the 1.5 kcal/mol threshold, it still contributes to the overall preference.
**Overall Assessment:**
Ligand B has several key advantages: significantly lower DILI risk, much better metabolic stability (lower Cl_mic), and a longer half-life. While Ligand A has slightly better TPSA, solubility, and Pgp efflux, the ADME advantages of Ligand B are more critical for overall drug development success. The slightly lower logP of Ligand B is a concern, but the strong metabolic stability and reduced toxicity outweigh this drawback. The binding affinity difference is minor.
Output:
0
2025-04-17 20:53:23,616 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, priorities are logP, TPSA, Pgp, affinity, and to a lesser extent, BBB.
Let's compare the ligands property by property:
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (344.459) is slightly better.
2. **TPSA:** Ligand A (56.84) is significantly better than Ligand B (108.49). Lower TPSA is preferred for GPCRs, aiding permeability.
3. **logP:** Both are within the optimal range (1-3). Ligand A (2.535) is slightly higher than Ligand B (1.913), which is acceptable.
4. **HBD:** Ligand A (2) is preferable to Ligand B (3).
5. **HBA:** Both have 4 HBA, a neutral point.
6. **QED:** Ligand A (0.806) is better than Ligand B (0.725), indicating a more drug-like profile.
7. **DILI:** Ligand A (54.556) is significantly better than Ligand B (89.841). Lower DILI is crucial.
8. **BBB:** Ligand A (78.558) is much better than Ligand B (26.638). While not a CNS target, some BBB penetration can be beneficial for distribution.
9. **Caco-2:** Ligand A (-4.764) is better than Ligand B (-5.549), indicating better absorption.
10. **Solubility:** Ligand A (-2.107) is better than Ligand B (-3.232).
11. **hERG:** Ligand A (0.737) is much better than Ligand B (0.033). Lower hERG risk is critical for cardiovascular drugs.
12. **Cl_mic:** Ligand A (14.694) is better than Ligand B (-24.739). Lower clearance is preferred for metabolic stability.
13. **t1/2:** Ligand A (9.634) is better than Ligand B (-17.296). Longer half-life is desirable.
14. **Pgp:** Ligand A (0.083) is better than Ligand B (0.043). Lower Pgp efflux is preferred.
15. **Affinity:** Ligand A (-7.2) is significantly better than Ligand B (-5.5). A 1.7 kcal/mol difference is substantial and can outweigh minor ADME drawbacks.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across almost all parameters, especially in critical areas like DILI, hERG, metabolic stability (Cl_mic, t1/2), and most importantly, binding affinity. Ligand B has a concerningly high DILI risk and poor metabolic stability. While Ligand B has a slightly lower logP, the benefits of Ligand A far outweigh this minor difference.
**Output:**
1
2025-04-17 20:53:23,616 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (340.354 and 340.467 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (62.56) is slightly higher than Ligand B (58.2). Both are below the 140 threshold for good oral absorption, and acceptable for a cardiovascular target (not requiring significant BBB penetration).
3. **logP:** Ligand A (3.373) is slightly higher than Ligand B (2.38). Both are within the optimal 1-3 range, but Ligand A is closer to the upper limit.
4. **HBD:** Ligand A (0) has no hydrogen bond donors, while Ligand B (2) has two. Lower HBD can be beneficial for membrane permeability.
5. **HBA:** Ligand A (4) has more hydrogen bond acceptors than Ligand B (2). Lower HBA is generally preferred for permeability.
6. **QED:** Both ligands have similar QED values (0.859 and 0.73), indicating good drug-likeness.
7. **DILI:** Ligand A (67.429) has a significantly higher DILI risk than Ligand B (19.698). This is a major concern.
8. **BBB:** Ligand A (76.541) has a higher BBB penetration percentile than Ligand B (36.138). While ADRB2 is a cardiovascular target and doesn't *require* high BBB penetration, a moderate level isn't detrimental.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.089 and -4.797), which is unusual and suggests poor permeability. This is a significant drawback for both.
10. **Solubility:** Both ligands have very poor predicted aqueous solubility (-4.179 and -3.951). This is a major formulation challenge.
11. **hERG:** Ligand A (0.708) has a slightly higher hERG inhibition risk than Ligand B (0.145). Lower is better, and Ligand B is much better here.
12. **Cl_mic:** Ligand B (1.329) has significantly lower microsomal clearance than Ligand A (10.231), indicating better metabolic stability.
13. **t1/2:** Ligand B (6.647) has a longer in vitro half-life than Ligand A (-17.866). This is a significant advantage.
14. **Pgp:** Ligand A (0.314) has lower P-gp efflux liability than Ligand B (0.073). Lower P-gp efflux is generally preferred.
15. **Affinity:** Ligand A (-7.0) has slightly better binding affinity than Ligand B (-6.1). The difference is 0.9 kcal/mol, which is not a large advantage.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Both ligands have acceptable logP and TPSA values. Ligand A has a slightly better affinity, but the difference isn't substantial enough to overcome its significant drawbacks. Ligand A has a higher Pgp efflux liability.
**Overall Assessment:**
Ligand A has a slightly better affinity and BBB penetration, but it suffers from significantly higher DILI risk, higher hERG risk, much higher metabolic clearance, shorter half-life, and higher P-gp efflux. Ligand B, while having slightly lower affinity, has a much more favorable safety profile (DILI, hERG), better metabolic stability (Cl_mic, t1/2), and lower P-gp efflux. The poor Caco-2 and solubility are concerns for both, but can potentially be addressed with formulation strategies. Given the importance of safety and metabolic stability in drug development, Ligand B is the more promising candidate.
Output:
0
2025-04-17 20:53:23,616 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (345.45 & 358.43 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (77.57) is slightly higher than Ligand B (69.64). Both are below the 140 threshold for oral absorption, but closer to the 90 threshold for CNS targets. Ligand B is slightly preferred.
3. **logP:** Ligand B (2.102) is within the optimal 1-3 range, while Ligand A (0.408) is below 1, potentially hindering permeation. This is a significant advantage for Ligand B.
4. **HBD:** Both ligands have 2 H-bond donors, satisfying the <=5 guideline.
5. **HBA:** Ligand A has 5 H-bond acceptors, while Ligand B has 3. Both are below the 10 guideline.
6. **QED:** Ligand A (0.808) has a slightly better QED score than Ligand B (0.715), indicating a marginally more drug-like profile.
7. **DILI:** Ligand A (19.16%) has a significantly lower DILI risk than Ligand B (28.15%). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (65.84%) has a better BBB penetration score than Ligand A (43.27%). While ADRB2 isn't necessarily a CNS target, some peripheral ADRB2 signaling can influence CNS function, and better BBB penetration isn't necessarily a negative.
9. **Caco-2:** Ligand A (-5.166) and Ligand B (-4.664) both have negative values, which is unusual and suggests very poor permeability. This is a concern for both, but the values are close.
10. **Solubility:** Ligand A (-1.051) has slightly better solubility than Ligand B (-2.055), but both are poor.
11. **hERG:** Ligand A (0.19) has a much lower hERG inhibition liability than Ligand B (0.468), indicating a lower risk of cardiotoxicity. This is a critical advantage for Ligand A, given the cardiovascular implications of ADRB2 modulation.
12. **Cl_mic:** Ligand A (-34.371) has a much lower (better) microsomal clearance than Ligand B (14.792), suggesting greater metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand B (-16.596) has a longer in vitro half-life than Ligand A (13.053), which is desirable.
14. **Pgp:** Ligand A (0.005) has much lower P-gp efflux liability than Ligand B (0.131), suggesting better oral bioavailability and potentially better tissue distribution. This is a significant advantage for Ligand A.
15. **Binding Affinity:** Ligand A (-7.2 kcal/mol) has a slightly better binding affinity than Ligand B (-6.7 kcal/mol). While the difference is less than 1.5 kcal/mol, it contributes to the overall preference.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp efflux, and affinity are important. Ligand B excels in logP and BBB, while Ligand A excels in TPSA, Pgp, Cl_mic, hERG, and affinity. The superior affinity and significantly improved ADME properties (DILI, hERG, Cl_mic, Pgp) of Ligand A outweigh the slightly better logP and BBB of Ligand B. The poor Caco-2 values for both are concerning but can be addressed with formulation strategies.
**Conclusion:**
Considering the balance of properties, particularly the lower DILI, hERG, and Pgp efflux, combined with better metabolic stability and slightly improved affinity, Ligand A is the more promising drug candidate.
Output:
1
2025-04-17 20:53:23,616 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (a cardiovascular GPCR) drug candidates.
**Ligand A:** [353.394, 100.55 , 0.692, 3. , 5. , 0.67 , 55.68 , 58.317, -4.725, -1.462, 0.165, 0.832, 6.995, 0.016, -7. ]
**Ligand B:** [392.298, 38.77 , 4.064, 0. , 3. , 0.657, 42.924, 86.778, -4.511, -5.037, 0.758, 66.447, 36.98 , 0.54 , -7.1 ]
**Step-by-step comparison:**
1. **MW:** Ligand A (353.394 Da) is better, falling nicely within the 200-500 Da range. Ligand B (392.298 Da) is still acceptable, but closer to the upper limit.
2. **TPSA:** Ligand B (38.77) is significantly better than Ligand A (100.55). For a cardiovascular GPCR, lower TPSA is generally preferred for better permeability.
3. **logP:** Ligand B (4.064) is higher than Ligand A (0.692). While 4.064 is approaching the upper limit, it's still within a reasonable range and could contribute to better membrane permeability. Ligand A's logP is quite low, potentially hindering permeability.
4. **HBD:** Ligand A (3) is higher than Ligand B (0). Lower is generally preferred, but 3 is acceptable.
5. **HBA:** Both ligands have a similar number of HBA (5 and 3 respectively) which are both within the acceptable range.
6. **QED:** Both ligands are similar (0.67 vs 0.657), indicating good drug-likeness.
7. **DILI:** Ligand B (42.924) has a lower DILI risk than Ligand A (55.68), which is a significant advantage.
8. **BBB:** Ligand B (86.778) has a much higher BBB penetration potential than Ligand A (58.317). While not a primary concern for a cardiovascular target, higher BBB is rarely detrimental.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual. Assuming these are logP-scale values, they suggest poor permeability.
10. **Solubility:** Ligand A (-1.462) has better solubility than Ligand B (-5.037). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.165) has a lower hERG risk than Ligand B (0.758), which is a major advantage.
12. **Cl_mic:** Ligand A (0.832) has a significantly lower microsomal clearance than Ligand B (66.447), suggesting better metabolic stability.
13. **t1/2:** Ligand B (36.98) has a much longer in vitro half-life than Ligand A (6.995), which is a significant advantage.
14. **Pgp:** Ligand A (0.016) has a lower P-gp efflux liability than Ligand B (0.54), which is a positive.
15. **Affinity:** Ligand B (-7.1 kcal/mol) has a slightly better binding affinity than Ligand A (-7.0 kcal/mol). This difference is relatively small, but could be meaningful.
**GPCR-Specific Priorities:** For ADRB2 (a cardiovascular GPCR), we prioritize logP, TPSA, Pgp, and affinity. Ligand B excels in logP, TPSA, and affinity, while Ligand A has better Pgp and hERG.
**Overall Assessment:**
Ligand B has a superior profile overall. While Ligand A has advantages in hERG and metabolic stability, Ligand B's better TPSA, logP, DILI, BBB, and half-life outweigh these concerns. The slightly better affinity of Ligand B further supports its selection. The solubility of Ligand A is better, but formulation strategies can often address solubility issues.
Output:
0
2025-04-17 20:53:23,616 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (364.471 and 347.39 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (79.96) is slightly higher than Ligand B (73.74). Both are below the 140 A^2 threshold for good oral absorption, but closer to the 90 A^2 threshold for CNS targets. Since ADRB2 is cardiovascular, TPSA is less critical.
**3. logP:** Ligand A (2.439) is within the optimal 1-3 range. Ligand B (0.768) is a bit low, potentially impacting membrane permeability. This favors Ligand A.
**4. H-Bond Donors:** Both ligands have 1 HBD, which is good.
**5. H-Bond Acceptors:** Ligand A has 7 HBAs, while Ligand B has 4. Both are within the acceptable limit of 10.
**6. QED:** Both ligands have high QED scores (0.821 and 0.854), indicating good drug-like properties.
**7. DILI Risk:** Ligand B (26.599) has a significantly lower DILI risk than Ligand A (56.146). This is a major advantage for Ligand B.
**8. BBB Penetration:** Ligand B (84.257) shows better BBB penetration than Ligand A (69.639). While ADRB2 is cardiovascular, some CNS off-target effects are always a concern, and higher BBB penetration could exacerbate these. However, for a cardiovascular target, BBB is less critical than for a CNS target.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.764 and -4.421). This is unusual and suggests poor permeability. However, negative values are often artifacts of the prediction method.
**10. Aqueous Solubility:** Both ligands have negative solubility values (-2.833 and -1.732). Similar to Caco-2, these are likely prediction artifacts, and solubility isn't a major concern given the logP values.
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (0.586 and 0.445).
**12. Microsomal Clearance:** Ligand B (-22.476) has significantly lower microsomal clearance than Ligand A (54.479), indicating better metabolic stability. This is a significant advantage for Ligand B.
**13. In vitro Half-Life:** Ligand B (8.328 hours) has a much longer half-life than Ligand A (-24.638 hours). This is a substantial advantage for Ligand B, potentially allowing for less frequent dosing.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.331 and 0.054).
**15. Binding Affinity:** Both ligands have very similar binding affinities (-6.7 and -6.6 kcal/mol). The difference is negligible.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand A has a slight edge in logP, but Ligand B excels in critical ADME properties like DILI risk, microsomal clearance, and half-life. The similar binding affinities mean these ADME improvements are decisive. While the negative Caco-2 and solubility values are concerning, they are likely prediction artifacts. The lower DILI risk and improved metabolic stability of Ligand B are particularly important for a cardiovascular drug.
Output:
0
2025-04-17 20:53:23,616 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (382.51 and 344.499 Da) fall within the ideal 200-500 Da range. Ligand B is slightly preferred due to its lower molecular weight.
2. **TPSA:** Ligand A (49.41) is slightly higher than Ligand B (40.62). Both are acceptable for a non-CNS GPCR target like ADRB2, being below 140. Ligand B is slightly favored.
3. **logP:** Both ligands have good logP values (4.664 and 3.372), falling within the 1-3 range. Ligand B is slightly preferred here.
4. **HBD:** Ligand A has 1 HBD, while Ligand B has 0. Both are within the acceptable limit of 5. No strong preference.
5. **HBA:** Ligand A has 3 HBA, and Ligand B has 2. Both are within the acceptable limit of 10. No strong preference.
6. **QED:** Both ligands have good QED values (0.424 and 0.734), indicating reasonable drug-likeness. Ligand B is significantly better.
7. **DILI:** Both ligands have low DILI risk (28.383 and 25.281), both well below the 40 threshold. No strong preference.
8. **BBB:** Both ligands have similar BBB penetration (79.294 and 78.945). Since ADRB2 is primarily a cardiovascular target, BBB penetration is not a high priority.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.961 and -4.81). This is unusual and suggests poor permeability. However, it's a relative comparison, and the values are very close.
10. **Solubility:** Both ligands have very poor aqueous solubility (-3.569 and -3.531). This is a significant concern for both.
11. **hERG:** Both ligands have low hERG inhibition liability (0.838 and 0.513). This is good, minimizing cardiotoxicity risk. Ligand B is slightly better.
12. **Cl_mic:** Ligand A has a lower microsomal clearance (52.864) than Ligand B (66.288), suggesting better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand B has a longer in vitro half-life (-5.114) than Ligand A (-2.668). This is a significant advantage for Ligand B.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.728 and 0.585). No strong preference.
15. **Binding Affinity:** Ligand A has a stronger binding affinity (-7.8 kcal/mol) than Ligand B (-6.8 kcal/mol). This is a substantial difference (1 kcal/mol) and a major advantage for Ligand A.
**Overall Assessment:**
The most critical factors for a GPCR like ADRB2 are affinity, logP, and metabolic stability. Ligand A has a significantly better binding affinity (-7.8 vs -6.8 kcal/mol) and better metabolic stability (lower Cl_mic). While Ligand B has a better QED and half-life, the substantial affinity advantage of Ligand A outweighs these benefits. The poor solubility and Caco-2 values are concerning for both, but can be addressed through formulation strategies.
Output:
1
2025-04-17 20:53:23,616 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
Let's analyze each ligand against the provided guidelines, keeping in mind ADRB2 is a GPCR, so logP, Pgp, TPSA, and affinity are key.
* **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (346.431) is slightly preferred due to being lower.
* **TPSA:** Ligand A (72.96) is significantly better than Ligand B (110.28). A TPSA under 140 is good for oral absorption, but lower is generally better for GPCRs, and A is well within a desirable range. B is approaching a less favorable range.
* **logP:** Ligand A (-0.844) is a bit low, potentially hindering permeability. Ligand B (1.007) is within the optimal range of 1-3. This favors B.
* **H-Bond Donors/Acceptors:** Ligand A (1 HBD, 4 HBA) is better than Ligand B (2 HBD, 7 HBA). Lower counts generally improve permeability.
* **QED:** Both ligands have similar and acceptable QED values (A: 0.674, B: 0.702).
* **DILI:** Ligand A (21.442) has a much lower DILI risk than Ligand B (63.746). This is a significant advantage for A.
* **BBB:** Ligand B (68.748) has a better BBB penetration percentile than Ligand A (43.04). While ADRB2 isn't necessarily a CNS target, some peripheral ADRB2 activity can be influenced by CNS effects, so this is a slight advantage for B.
* **Caco-2 Permeability:** Both are very poor (-5.093 and -5.073). This is a concern for both, but doesn't heavily sway the decision as they are so similar.
* **Aqueous Solubility:** Both are very poor (-1.114 and -2.713). This is a concern for both, but doesn't heavily sway the decision as they are so similar.
* **hERG:** Ligand A (0.057) has a much lower hERG risk than Ligand B (0.219). This is a significant advantage for A, as hERG inhibition can lead to cardiotoxicity.
* **Microsomal Clearance:** Ligand A (-3.29) has a much lower (better) microsomal clearance than Ligand B (25.545), indicating greater metabolic stability.
* **In vitro Half-Life:** Ligand A (-1.144) has a slightly better in vitro half-life than Ligand B (-6.2).
* **P-gp Efflux:** Ligand A (0.006) has a much lower P-gp efflux liability than Ligand B (0.024). This is a significant advantage for A, improving bioavailability.
* **Binding Affinity:** Both ligands have excellent binding affinities (-6.6 and -5.9 kcal/mol). Ligand A is slightly better, but the difference is not huge.
**Overall Assessment:**
Ligand A demonstrates a significantly better safety profile (lower DILI, lower hERG), better metabolic stability (lower Cl_mic), and lower P-gp efflux. While Ligand B has a slightly better logP and BBB penetration, the advantages of Ligand A in ADME-Tox properties are more critical for overall drug development success, especially given the cardiovascular implications of ADRB2 modulation. The slightly better TPSA of Ligand A is also beneficial. The affinity difference is minimal.
Output:
1
2025-04-17 20:53:23,616 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [349.781, 93.79, 3.666, 2, 5, 0.576, 99.38, 56.146, -5.08, -5.019, 0.67, 58.364, 64.07, 0.106, -6.4]
**Ligand B:** [382.507, 75.71, 1.556, 1, 5, 0.81, 49.632, 69.911, -4.703, -3.085, 0.237, 58.637, 1.176, 0.158, -4.6]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal 200-500 Da range. Ligand A (349.781) is slightly preferred due to being closer to the lower end, potentially aiding permeability.
2. **TPSA:** Ligand A (93.79) is slightly higher than Ligand B (75.71). For a cardiovascular GPCR, TPSA isn't *as* critical as for CNS targets, but lower is generally better for absorption. Ligand B is better here.
3. **logP:** Ligand A (3.666) is within the optimal range, while Ligand B (1.556) is on the lower side. For a GPCR, a higher logP is generally preferred for membrane permeability and receptor engagement. Ligand A is better.
4. **HBD:** Ligand A (2) is slightly better than Ligand B (1). Both are acceptable.
5. **HBA:** Both ligands have 5 HBA, which is acceptable.
6. **QED:** Ligand B (0.81) has a better QED score than Ligand A (0.576), indicating a more drug-like profile. Ligand B is better.
7. **DILI:** Ligand A (99.38) has a very high DILI risk, which is a major concern. Ligand B (49.632) has a much lower, and acceptable, DILI risk. Ligand B is *significantly* better.
8. **BBB:** Both have reasonable BBB penetration, but Ligand B (69.911) is better than Ligand A (56.146). While not a CNS target, some BBB penetration can be beneficial for distribution.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand B (-4.703) is slightly better than Ligand A (-5.08).
10. **Solubility:** Ligand B (-3.085) has better solubility than Ligand A (-5.019).
11. **hERG:** Both have low hERG inhibition risk (0.67 and 0.237 respectively). Ligand B is better.
12. **Cl_mic:** Both have similar microsomal clearance (58.364 and 58.637).
13. **t1/2:** Ligand A (64.07) has a significantly longer in vitro half-life than Ligand B (1.176). This is a major advantage for dosing frequency.
14. **Pgp:** Ligand A (0.106) has lower P-gp efflux than Ligand B (0.158). Lower efflux is preferable. Ligand A is better.
15. **Binding Affinity:** Ligand A (-6.4) has a better binding affinity than Ligand B (-4.6). This is a substantial difference (1.8 kcal/mol), and a strong driver for selection.
**Overall Assessment:**
The key differentiating factors are DILI risk and binding affinity. Ligand A has a *very* high DILI risk, which is a major red flag. Ligand B has a much more acceptable DILI profile. However, Ligand A has significantly better binding affinity. The 1.8 kcal/mol difference in binding is substantial and could potentially overcome some ADME liabilities *if* the DILI risk could be mitigated through structural modifications. However, given the severity of the DILI risk, and the acceptable (though not ideal) ADME profile of Ligand B, I would prioritize Ligand B. The better solubility, lower DILI, and better BBB penetration of Ligand B outweigh the affinity difference, especially considering the potential for further optimization of Ligand B's affinity.
Output:
0
2025-04-17 20:53:23,616 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (355.385 and 349.475 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (84.23) is higher than Ligand B (53.09). For a cardiovascular GPCR, TPSA isn't *as* critical as for a CNS target, but lower is generally preferred for absorption. Ligand B is better.
3. **logP:** Ligand A (2.524) and Ligand B (1.121) are both within the optimal 1-3 range, but Ligand A is closer to the upper end. Ligand B is slightly better.
4. **HBD:** Ligand A (2) and Ligand B (0) both are acceptable. Lower HBD can sometimes improve permeability, so Ligand B is slightly favored.
5. **HBA:** Both ligands have 4 HBA, which is within the acceptable range.
6. **QED:** Ligand A (0.736) is slightly better than Ligand B (0.698), indicating a marginally more drug-like profile.
7. **DILI:** Ligand B (8.143) has a *much* lower DILI risk than Ligand A (56.146). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (86.506) has a higher BBB penetration percentile than Ligand B (73.866). While ADRB2 isn't a primary CNS target, some degree of BBB penetration can be useful for understanding off-target effects and overall distribution.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.609 and -4.5), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-3.318) has slightly better solubility than Ligand B (-0.331), but both are poor.
11. **hERG:** Ligand A (0.142) has a slightly lower hERG risk than Ligand B (0.314), which is favorable.
12. **Cl_mic:** Ligand B (6.459) has significantly lower microsomal clearance than Ligand A (37.35), indicating better metabolic stability. This is a major advantage for Ligand B.
13. **t1/2:** Ligand A (-29.739) has a negative in vitro half-life, which is concerning. Ligand B (-1.736) is also low, but much better than Ligand A.
14. **Pgp:** Ligand A (0.106) has lower P-gp efflux than Ligand B (0.019), which is favorable.
15. **Binding Affinity:** Ligand A (-7.0) has a slightly better binding affinity than Ligand B (-6.3), but the difference is only 0.7 kcal/mol.
**Overall Assessment:**
While Ligand A has slightly better binding affinity and BBB penetration, Ligand B has a significantly better safety profile (much lower DILI risk), better metabolic stability (lower Cl_mic), and a less negative in vitro half-life. The poor Caco-2 values are a concern for both, but the ADME properties of Ligand B are substantially more favorable overall, especially the DILI and metabolic stability. For a cardiovascular target, minimizing off-target effects and ensuring reasonable metabolic stability are crucial. The 0.7 kcal/mol difference in binding affinity is unlikely to outweigh the substantial ADME advantages of Ligand B.
Output:
0
2025-04-17 20:53:23,617 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (368.5 and 364.5 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (104.21) is higher than Ligand B (64.8). For a GPCR, lower TPSA is generally preferred for better brain penetration and overall permeability, giving a slight edge to Ligand B.
3. **logP:** Ligand B (3.511) is higher than Ligand A (1.74). While both are within the optimal 1-3 range, Ligand B is approaching the upper limit. This could potentially lead to solubility issues, but for a GPCR, a slightly higher logP isn't as detrimental as it might be for other targets.
4. **HBD:** Ligand A (3) is higher than Ligand B (0). Fewer HBDs are generally preferred for permeability, favoring Ligand B.
5. **HBA:** Both ligands have 6 HBA, which is acceptable.
6. **QED:** Ligand B (0.717) has a slightly higher QED than Ligand A (0.616), indicating a more drug-like profile.
7. **DILI:** Both ligands have similar DILI risk (44.552 vs 46.297), and both are below the concerning threshold of 60.
8. **BBB:** Ligand B (82.396) has significantly better predicted BBB penetration than Ligand A (36.409). This is a crucial advantage for a GPCR, even if it's not a CNS target, as it can indicate better distribution properties.
9. **Caco-2:** Ligand A (-5.275) shows better Caco-2 permeability than Ligand B (-4.455).
10. **Solubility:** Ligand A (-2.487) has better predicted aqueous solubility than Ligand B (-3.922). This is important, especially given Ligand B's higher logP.
11. **hERG:** Both ligands have very low hERG risk (0.169 and 0.503), which is excellent.
12. **Cl_mic:** Ligand A (5.844) has significantly lower microsomal clearance than Ligand B (119.755). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (18.346) has a much longer in vitro half-life than Ligand B (-12.147). This is a significant advantage, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.195 and 0.483).
15. **Binding Affinity:** Ligand B (-6.1) has a slightly better binding affinity than Ligand A (-6.0). While the difference is small, it's still a factor.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand B initially appears stronger due to its lower TPSA, better BBB penetration, and slightly better affinity. However, Ligand A has a substantial advantage in metabolic stability (lower Cl_mic) and a significantly longer half-life. The solubility of Ligand A is also better. The small affinity difference is likely less important than the ADME benefits of Ligand A. Given the cardiovascular target, CNS penetration isn't a primary concern, making the BBB advantage of Ligand B less critical. The metabolic stability and half-life of Ligand A are more valuable for a successful drug candidate.
Output:
1
2025-04-17 20:53:23,617 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (360.445 & 363.523 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (58.64) is better than Ligand B (38.77). Both are below 140, but Ligand B is significantly lower, potentially improving permeability.
3. **logP:** Ligand B (3.65) is slightly higher than Ligand A (2.387), edging towards the upper limit of the optimal range. Ligand A is well within the optimal range.
4. **HBD:** Ligand A (1) is better than Ligand B (0). A single HBD can be beneficial for solubility without significantly impacting permeability.
5. **HBA:** Ligand A (3) is better than Ligand B (4). Lower HBA is generally preferable for permeability.
6. **QED:** Ligand A (0.687) is significantly better than Ligand B (0.47). A higher QED suggests a more drug-like profile.
7. **DILI:** Ligand B (16.712) is much better than Ligand A (30.748). Lower DILI risk is a critical advantage.
8. **BBB:** Both ligands have high BBB penetration (Ligand A: 87.088, Ligand B: 88.29). This is good, but less critical for ADRB2 than for CNS targets.
9. **Caco-2:** Ligand B (-4.999) is better than Ligand A (-4.567). Higher Caco-2 permeability suggests better intestinal absorption.
10. **Solubility:** Ligand B (-3.152) is better than Ligand A (-2.425). Better solubility is always a plus.
11. **hERG:** Both ligands have low hERG inhibition liability (Ligand A: 0.656, Ligand B: 0.758). No significant difference.
12. **Cl_mic:** Ligand A (20.315) is much better than Ligand B (92.546). Lower microsomal clearance indicates greater metabolic stability, a significant advantage.
13. **t1/2:** Ligand B (9.323) is better than Ligand A (6.965). A longer half-life is generally desirable.
14. **Pgp:** Ligand B (0.72) is better than Ligand A (0.294). Lower P-gp efflux suggests better bioavailability.
15. **Binding Affinity:** Ligand A (-6.5) is better than Ligand B (-5.7). A 0.8 kcal/mol difference in binding affinity is substantial and can often outweigh minor ADME drawbacks.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B has a slightly higher logP, better Caco-2, solubility, Pgp, and half-life. However, Ligand A has a substantially better QED, significantly lower DILI risk, and a much stronger binding affinity. The binding affinity difference is the most important factor.
**Overall Assessment:**
While Ligand B has some advantages in ADME properties, the significantly stronger binding affinity of Ligand A (-6.5 vs -5.7 kcal/mol) and its better QED and lower DILI risk make it the more promising drug candidate. The improved metabolic stability (lower Cl_mic) is also a significant benefit.
Output:
1
2025-04-17 20:53:23,617 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.435 and 352.414 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (88.81) is slightly higher than Ligand B (78.07). Both are below the 140 threshold for good oral absorption, but closer to the 90 threshold for CNS targets. Given ADRB2's cardiovascular role, CNS penetration isn't a primary concern, so this isn't a major differentiator.
3. **logP:** Ligand B (1.452) is better positioned within the optimal 1-3 range than Ligand A (0.098), which is quite low and could indicate poor membrane permeability. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A has 1 HBD, while Ligand B has 0. Both are acceptable.
5. **HBA:** Ligand A has 6 HBA, and Ligand B has 7. Both are within the acceptable limit of 10.
6. **QED:** Both ligands have similar QED values (0.762 and 0.719), indicating good drug-likeness.
7. **DILI:** Ligand B (41.411) has a slightly higher DILI risk than Ligand A (31.912), but both are below the concerning threshold of 60.
8. **BBB:** Ligand B (74.564) has a substantially higher BBB penetration percentile than Ligand A (46.375). While not crucial for a cardiovascular target, higher BBB is generally a positive attribute.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.878 and -4.533). This is unusual and suggests poor permeability. However, the values are very close.
10. **Solubility:** Both ligands have similar, very poor aqueous solubility scores (-0.902 and -0.91). This is a potential issue for both, requiring formulation strategies.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.138 and 0.228), which is excellent.
12. **Cl_mic:** Ligand A (6.228) has a significantly lower microsomal clearance than Ligand B (48.389), indicating better metabolic stability. This is a major advantage for Ligand A.
13. **t1/2:** Ligand A (15.816 hours) has a much longer in vitro half-life than Ligand B (5.27 hours). This is a significant advantage for Ligand A, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.012 and 0.133).
15. **Binding Affinity:** Both ligands have the same binding affinity (-6.2 kcal/mol).
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand B has a better logP, but Ligand A has superior metabolic stability (Cl_mic) and half-life. The binding affinity is identical. Given the importance of metabolic stability and half-life for *in vivo* efficacy, and the relatively poor permeability indicated by the Caco-2 values for both, the improved PK profile of Ligand A is more valuable.
Output:
1
2025-04-17 20:53:23,617 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (408.252 Da) is within the ideal range, while Ligand B (364.555 Da) is also acceptable. No clear advantage here.
2. **TPSA:** Ligand A (78.86) is better than Ligand B (42.43). Both are well below the 140 threshold for oral absorption, but Ligand B is significantly lower, potentially indicating better permeability.
3. **logP:** Both ligands have good logP values (A: 3.757, B: 4.361), falling within the 1-3 range. Ligand B is slightly higher, which could be a minor concern for solubility.
4. **HBD:** Both have 0 HBD, which is good.
5. **HBA:** Ligand A has 7 HBA, and Ligand B has 4 HBA. Both are within the acceptable limit of 10.
6. **QED:** Both ligands have good QED scores (A: 0.599, B: 0.688), indicating good drug-likeness. Ligand B is slightly better.
7. **DILI:** Ligand A has a DILI risk of 79.449, which is concerning (approaching the high-risk threshold of >60). Ligand B has a much lower DILI risk of 8.143, a significant advantage.
8. **BBB:** Ligand A (77.898) and Ligand B (90.539) both have good BBB penetration. Ligand B is better.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.933 and -4.492). This is unusual and suggests poor permeability. However, negative values are often artifacts of the prediction method, and the absolute value is less important than the overall profile.
10. **Solubility:** Both ligands have negative solubility values (-3.885 and -4.502). Similar to Caco-2, these are likely prediction artifacts.
11. **hERG:** Ligand A (0.325) has a lower hERG risk than Ligand B (0.704), which is preferable.
12. **Cl_mic:** Ligand A (81.085) has a lower microsomal clearance than Ligand B (93.933), suggesting better metabolic stability.
13. **t1/2:** Ligand A (62.897) has a much longer in vitro half-life than Ligand B (11.063), a significant advantage.
14. **Pgp:** Ligand A (0.401) has lower P-gp efflux than Ligand B (0.1), which is preferable.
15. **Affinity:** Both ligands have very similar binding affinities (-6.3 kcal/mol and -6.2 kcal/mol). The difference is negligible.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are important. Ligand B has a slightly higher logP and better BBB penetration, but Ligand A has better TPSA and Pgp efflux. The most significant difference is the DILI risk, where Ligand B is *much* better. The longer half-life of Ligand A is also a substantial benefit.
**Overall Assessment:**
While Ligand B has slightly better BBB penetration and QED, the significantly lower DILI risk, better metabolic stability (lower Cl_mic), longer half-life, and lower Pgp efflux of Ligand A outweigh these minor advantages. The binding affinities are essentially the same. The negative Caco-2 and solubility values are concerning but likely artifacts of the prediction method.
**Output:**
1
2025-04-17 20:53:23,617 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (a cardiovascular GPCR) drug candidates.
**Ligand A:** [354.491, 77.92, 1.85, 1, 4, 0.685, 28.228, 54.905, -4.383, -1.48, 0.19, 39.441, 4.091, 0.113, -6.3]
**Ligand B:** [348.487, 58.64, 2.824, 1, 3, 0.515, 8.918, 80.07, -4.533, -2.003, 0.539, 64.763, -10.729, 0.093, -6]
Here's a breakdown of the comparison, considering the provided guidelines and GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (348.487) is slightly lower, which is generally favorable.
2. **TPSA:** Ligand A (77.92) is higher than Ligand B (58.64). Both are acceptable for a cardiovascular target, but Ligand B is better.
3. **logP:** Ligand A (1.85) is within the optimal range, while Ligand B (2.824) is towards the higher end but still acceptable.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A (4) has more HBAs than Ligand B (3). Lower is better for permeability.
6. **QED:** Ligand A (0.685) has a better QED score than Ligand B (0.515), indicating better overall drug-likeness.
7. **DILI:** Ligand A (28.228) has a significantly lower DILI risk than Ligand B (8.918), which is a major advantage.
8. **BBB:** Ligand B (80.07) has a much higher BBB penetration score than Ligand A (54.905). While not critical for a cardiovascular target, it's a slight positive for B.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. Ligand A (-4.383) is slightly better than Ligand B (-4.533).
10. **Solubility:** Ligand A (-1.48) is slightly better than Ligand B (-2.003)
11. **hERG:** Ligand A (0.19) has a much lower hERG risk than Ligand B (0.539), a crucial safety parameter.
12. **Cl_mic:** Ligand A (39.441) has a lower microsomal clearance than Ligand B (64.763), suggesting better metabolic stability.
13. **t1/2:** Ligand A (4.091) has a longer in vitro half-life than Ligand B (-10.729).
14. **Pgp:** Ligand A (0.113) has lower P-gp efflux liability than Ligand B (0.093).
15. **Affinity:** Both have very similar binding affinities (-6.3 and -6 kcal/mol). The difference is negligible.
**Overall Assessment:**
Ligand A is the stronger candidate. While Ligand B has better BBB penetration and a slightly lower TPSA, Ligand A excels in crucial areas like DILI risk, hERG inhibition, metabolic stability (Cl_mic and t1/2), and QED. The similar binding affinities make these differences decisive. The lower DILI and hERG risks are particularly important for a cardiovascular drug.
Output:
1
2025-04-17 20:53:23,617 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (365.543 and 361.463 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (61.44) is slightly higher than Ligand B (57.65). Both are below the 140 A^2 threshold for good oral absorption, and acceptable for a cardiovascular target (not requiring significant CNS penetration).
**3. logP:** Ligand A (1.793) is within the optimal 1-3 range. Ligand B (3.864) is pushing the upper limit, potentially raising concerns about solubility and off-target effects, but is still within an acceptable range.
**4. H-Bond Donors:** Ligand A has 2 HBD, and Ligand B has 0. Both are within the acceptable limit of <=5.
**5. H-Bond Acceptors:** Ligand A has 4 HBA, and Ligand B has 6. Both are within the acceptable limit of <=10.
**6. QED:** Both ligands have similar QED values (0.722 and 0.668), indicating good drug-like properties.
**7. DILI:** Ligand A (16.44) has a considerably lower DILI risk than Ligand B (53.315). This is a significant advantage for Ligand A.
**8. BBB:** Both ligands have good BBB penetration (70.415 and 76.309). While ADRB2 is primarily a cardiovascular target, some CNS off-target effects are possible, and moderate BBB penetration isn't necessarily detrimental.
**9. Caco-2 Permeability:** Ligand A (-5.235) has a worse Caco-2 permeability than Ligand B (-4.295). While both are negative, indicating poor permeability, Ligand B is slightly better.
**10. Aqueous Solubility:** Ligand A (-2.939) has better aqueous solubility than Ligand B (-4.872). This is a positive for Ligand A, particularly given Ligand B's higher logP.
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.348 and 0.39). This is excellent for both.
**12. Microsomal Clearance:** Ligand A (74.94) has a lower microsomal clearance than Ligand B (109.748), suggesting better metabolic stability.
**13. In vitro Half-Life:** Ligand A (24.657) has a longer in vitro half-life than Ligand B (-28.399). This is a significant advantage for Ligand A.
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (0.1 and 0.48).
**15. Binding Affinity:** Ligand A (-6.8) has slightly better binding affinity than Ligand B (-6.6). While the difference is small (0.2 kcal/mol), it's still a positive for Ligand A.
**GPCR-Specific Considerations:** For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Ligand B has a slightly better logP and Caco-2 permeability, but Ligand A excels in DILI risk, metabolic stability (Cl_mic and t1/2), solubility, and has a slightly better binding affinity. The lower DILI risk and improved metabolic stability of Ligand A are particularly valuable.
**Conclusion:**
Considering the balance of properties, and prioritizing metabolic stability and safety (DILI) alongside binding affinity, **Ligand A is the more promising drug candidate.**
1
2025-04-17 20:53:23,617 - INFO - Batch 218 complete. Total preferences: 3488
2025-04-17 20:53:23,617 - INFO - Processing batch 219/512...
2025-04-17 20:54:11,332 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (348.359 Da) is within the ideal range (200-500 Da). Ligand B (239.315 Da) is slightly below, potentially raising concerns about potency, though not disqualifying.
2. **TPSA:** Ligand A (120.29) is acceptable, though approaching the upper limit for good oral absorption. Ligand B (72.72) is excellent, suggesting good permeability.
3. **logP:** Both ligands (A: 1.061, B: 1.306) are within the optimal 1-3 range.
4. **HBD:** Ligand A (1) is good. Ligand B (4) is higher, potentially impacting permeability.
5. **HBA:** Ligand A (8) is good. Ligand B (4) is excellent.
6. **QED:** Both ligands have acceptable QED values (A: 0.49, B: 0.639), with B being slightly more drug-like.
7. **DILI:** Ligand A (30.593) has a low DILI risk, which is excellent. Ligand B (0.853) is also very low risk.
8. **BBB:** Ligand A (77.86) is reasonable, while Ligand B (8.104) is very low. Since ADRB2 is a cardiovascular target, BBB penetration is not a high priority.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.332 and -5.233), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Both ligands have negative solubility values (-2.261 and -1.252), which is also concerning.
11. **hERG:** Ligand A (0.792) has a slightly higher hERG risk than Ligand B (0.095), which is a significant advantage for B.
12. **Cl_mic:** Ligand A (-2.564) has a lower (better) microsomal clearance than Ligand B (-8.038), indicating better metabolic stability.
13. **t1/2:** Ligand A (5.23) has a longer half-life than Ligand B (-6.514), which is desirable.
14. **Pgp:** Ligand A (0.13) has lower P-gp efflux liability than Ligand B (0.007), which is preferable.
15. **Affinity:** Ligand A (-7.6 kcal/mol) has a slightly better binding affinity than Ligand B (-6.7 kcal/mol). This is a 0.9 kcal/mol difference, which is substantial.
**GPCR-specific considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Both ligands have acceptable logP values. Ligand B has a better TPSA. Ligand A has better Pgp efflux. The affinity difference is significant, favoring Ligand A. The negative Caco-2 and solubility values are concerning for both, but the superior affinity and metabolic stability of Ligand A are more important.
**Conclusion:**
Despite the concerning Caco-2 and solubility values, Ligand A's superior binding affinity, better metabolic stability (lower Cl_mic), and longer half-life outweigh the advantages of Ligand B. The slightly higher hERG risk of Ligand A is manageable given the overall profile.
Output:
1
2025-04-17 20:54:11,332 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [448.364, 88.6, 2.53, 1, 6, 0.704, 79.721, 77.2, -4.823, -3.455, 0.342, 71.612, 18.564, 0.279, -6.1]
**Ligand B:** [352.494, 49.41, 3.819, 1, 2, 0.722, 33.773, 84.141, -4.378, -3.84, 0.68, 77.284, 13.066, 0.462, -5.6]
**Step-by-step comparison:**
1. **MW:** Ligand A (448.364 Da) is within the ideal range, while Ligand B (352.494 Da) is a bit lower, but still acceptable.
2. **TPSA:** Ligand A (88.6) is good, but approaching the upper limit for good oral absorption. Ligand B (49.41) is excellent, well below the 140 threshold.
3. **logP:** Both are good (A: 2.53, B: 3.819), within the optimal 1-3 range. Ligand B is slightly higher, which could potentially lead to off-target effects, but isn't a major concern.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 6 HBA, acceptable. Ligand B has 2 HBA, which is even better.
6. **QED:** Both have good QED scores (A: 0.704, B: 0.722).
7. **DILI:** Ligand A (79.721) has a significantly higher DILI risk than Ligand B (33.773). This is a major concern for Ligand A.
8. **BBB:** Both have good BBB penetration (A: 77.2, B: 84.141). Ligand B is slightly better.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. This is a concern for both.
10. **Solubility:** Both have negative solubility values, indicating poor solubility. This is a concern for both.
11. **hERG:** Ligand A (0.342) has a slightly better hERG profile than Ligand B (0.68), but both are acceptable.
12. **Cl_mic:** Both have similar microsomal clearance (A: 71.612, B: 77.284).
13. **t1/2:** Ligand A (18.564) has a longer half-life than Ligand B (13.066), which is preferable.
14. **Pgp:** Ligand A (0.279) has lower Pgp efflux than Ligand B (0.462), which is better.
15. **Affinity:** Ligand A (-6.1 kcal/mol) has a slightly better binding affinity than Ligand B (-5.6 kcal/mol).
**GPCR-specific priorities:** For ADRB2 (a GPCR), we prioritize logP, Pgp, TPSA, and affinity. Ligand B excels in TPSA and has a slightly better BBB penetration. Ligand A has a slightly better affinity and Pgp efflux. However, the significantly higher DILI risk for Ligand A is a major drawback.
**Conclusion:**
Despite the slightly better affinity and Pgp efflux of Ligand A, the substantially higher DILI risk associated with it makes Ligand B the more promising candidate. The lower DILI risk, combined with good TPSA, BBB, and acceptable logP, outweighs the small difference in binding affinity. The poor Caco-2 and solubility are concerns for both, but can be addressed with formulation strategies.
Output:
0
2025-04-17 20:54:11,333 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (364.515 Da and 350.459 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Both ligands (65.54 and 67.87) are reasonably low, suggesting good potential for absorption. They are below the 140 A^2 threshold.
**3. logP:** Both ligands have logP values (1.624 and 1.501) within the optimal 1-3 range, indicating a good balance between hydrophobicity and hydrophilicity.
**4. H-Bond Donors:** Both have 1 HBD, which is acceptable.
**5. H-Bond Acceptors:** Ligand A has 5 HBA, and Ligand B has 4. Both are within the acceptable limit of <=10.
**6. QED:** Ligand A (0.862) has a better QED score than Ligand B (0.737), indicating a more drug-like profile.
**7. DILI:** Ligand A (47.499) has a higher DILI risk than Ligand B (21.636). This is a significant advantage for Ligand B.
**8. BBB:** Ligand A (75.107) has a slightly better BBB penetration score than Ligand B (65.801). While ADRB2 is a cardiovascular target, some CNS exposure can occur, and higher BBB is generally preferred.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.937 and -4.662). This is unusual and suggests poor permeability. However, the values are very close.
**10. Aqueous Solubility:** Both ligands have negative solubility values (-2.162 and -1.925). This is also concerning, indicating poor solubility. Again, the values are similar.
**11. hERG Inhibition:** Ligand A (0.474) has a slightly lower hERG inhibition risk than Ligand B (0.129), which is favorable.
**12. Microsomal Clearance:** Ligand A (63.717) has a higher microsomal clearance than Ligand B (45.253), meaning it's metabolized faster. Ligand B has better metabolic stability.
**13. In vitro Half-Life:** Ligand B (24.288 hours) has a significantly longer in vitro half-life than Ligand A (-1.659 hours). This is a major advantage for Ligand B, potentially allowing for less frequent dosing.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.313 and 0.03).
**15. Binding Affinity:** Ligand A (-6.8 kcal/mol) has a slightly better binding affinity than Ligand B (-6.5 kcal/mol). This 0.3 kcal/mol difference is not substantial enough to outweigh other factors.
**GPCR-Specific Considerations:** For GPCRs, logP, Pgp, TPSA, and affinity are important. Both ligands perform similarly on logP, TPSA, and Pgp. Affinity is slightly better for Ligand A, but the difference isn't large.
**Overall Assessment:**
Ligand B is the more promising candidate. While Ligand A has slightly better affinity and BBB penetration, Ligand B exhibits a significantly lower DILI risk and a much longer in vitro half-life. The poor Caco-2 and solubility values are concerning for both, but the improved safety profile and pharmacokinetic properties of Ligand B make it the better choice for further development.
Output:
0
2025-04-17 20:54:11,333 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A: [358.454, 76.66, 2.274, 2, 4, 0.464, 31.601, 84.529, -4.935, -2.928, 0.513, 37.016, -10.856, 0.153, -6.2]**
**Ligand B: [366.487, 95.74, 1.486, 2, 4, 0.826, 34.626, 80.264, -5.115, -1.946, 0.22, -5.751, -0.565, 0.021, -5.5]**
Here's a breakdown, comparing each parameter and considering GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal range (200-500 Da). A is 358.454, B is 366.487. Very similar.
2. **TPSA:** A (76.66) is better than B (95.74). ADRB2 is not a CNS target, but lower TPSA generally aids absorption.
3. **logP:** A (2.274) is optimal, while B (1.486) is slightly lower, potentially impacting permeability.
4. **HBD:** Both have 2, which is good.
5. **HBA:** Both have 4, which is good.
6. **QED:** B (0.826) is significantly better than A (0.464), indicating a more drug-like profile. This is a notable advantage for B.
7. **DILI:** Both are good, with A at 31.6% and B at 34.6%. Similar and low risk.
8. **BBB:** A (84.529) is slightly better than B (80.264), but BBB isn't critical for a cardiovascular target.
9. **Caco-2:** A (-4.935) is worse than B (-5.115). Lower values indicate better permeability.
10. **Solubility:** A (-2.928) is worse than B (-1.946). B has better aqueous solubility.
11. **hERG:** A (0.513) is better than B (0.22). Lower hERG risk is crucial.
12. **Cl_mic:** A (37.016) is worse than B (-5.751). B has better metabolic stability.
13. **t1/2:** A (-10.856) is worse than B (-0.565). B has a longer in vitro half-life.
14. **Pgp:** A (0.153) is better than B (0.021). Lower P-gp efflux is preferred.
15. **Affinity:** A (-6.2) is slightly better than B (-5.5). This is a 0.7 kcal/mol difference, which is significant.
**Overall Assessment:**
Ligand A has a slightly better binding affinity and Pgp efflux profile, and a better hERG profile. However, Ligand B excels in QED, solubility, metabolic stability (Cl_mic and t1/2), and Caco-2 permeability. The QED score and improved ADME properties of Ligand B are compelling. While the affinity difference is noticeable, a 0.7 kcal/mol advantage can often be overcome with optimization, especially given the superior overall profile of Ligand B. For a cardiovascular GPCR, metabolic stability and good absorption are very important, and B has a clear advantage in these areas.
Therefore, I prefer Ligand B.
0
2025-04-17 20:54:11,333 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (343.511 and 351.422 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (38.33) is significantly better than Ligand B (93.45). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold. Ligand B is pushing the upper limit.
3. **logP:** Ligand A (4.788) is a bit high, potentially leading to solubility issues or off-target interactions. Ligand B (1.705) is within the optimal 1-3 range. This favors Ligand B.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (2) is preferable to Ligand B (4). Fewer HBAs generally improve permeability.
6. **QED:** Ligand A (0.655) is better than Ligand B (0.466), indicating a more drug-like profile.
7. **DILI:** Ligand A (29.081) has a significantly lower DILI risk than Ligand B (39.977). This is a major advantage for Ligand A.
8. **BBB:** Both ligands have similar BBB penetration (82.28 and 83.986). Not a deciding factor here.
9. **Caco-2:** Both ligands have similar, poor Caco-2 permeability (-5.051 and -5.005). This is a concern for both.
10. **Solubility:** Ligand A (-4.658) is slightly better than Ligand B (-2.774), but both are poor.
11. **hERG:** Both ligands have low hERG risk (0.787 and 0.687). No significant difference.
12. **Cl_mic:** Ligand A (84.139) has a higher microsomal clearance than Ligand B (22.687), indicating faster metabolism and potentially lower *in vivo* exposure. This favors Ligand B.
13. **t1/2:** Ligand A (13.514) has a longer half-life than Ligand B (9.827). This is a positive for Ligand A.
14. **Pgp:** Both ligands have similar Pgp efflux liability (0.895 and 0.094).
15. **Binding Affinity:** Ligand A (-6.1) has a slightly better binding affinity than Ligand B (-5.9). While the difference is small (0.2 kcal/mol), it's still a positive for Ligand A.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand B has better logP, but Ligand A excels in TPSA, DILI, QED, and has comparable affinity. The higher metabolic clearance of Ligand A is a concern, but the better overall profile, especially the significantly lower DILI risk, outweighs this.
**Conclusion:**
Considering the balance of properties, and prioritizing a favorable safety profile (low DILI) alongside reasonable ADME and binding affinity, Ligand A appears to be the more promising drug candidate.
Output:
1
2025-04-17 20:54:11,333 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.431 and 349.435 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (79.9) is slightly better than Ligand B (80.56), both are below the 140 threshold for oral absorption, and acceptable for a peripheral GPCR like ADRB2.
3. **logP:** Ligand A (2.096) is optimal (1-3), while Ligand B (0.704) is a bit low, potentially hindering membrane permeability. This is a point in favor of A.
4. **HBD:** Ligand A (2) and Ligand B (0) are both acceptable.
5. **HBA:** Ligand A (4) and Ligand B (6) are both acceptable, though A is slightly preferred.
6. **QED:** Both ligands (0.79 and 0.782) have excellent drug-likeness scores.
7. **DILI:** Both ligands are at acceptable risk levels (47.77 and 49.942 percentile).
8. **BBB:** Both ligands have good BBB penetration (71.384 and 72.082 percentile), though this is less critical for ADRB2 (a non-CNS target).
9. **Caco-2:** Both ligands have negative Caco-2 values which is unusual and suggests poor permeability.
10. **Solubility:** Both ligands have negative solubility values which is unusual and suggests poor solubility.
11. **hERG:** Both ligands have low hERG inhibition liability (0.34 and 0.25), which is excellent.
12. **Cl_mic:** Ligand A (4.354) has a lower microsomal clearance than Ligand B (28.05), indicating better metabolic stability. This is a significant advantage for A.
13. **t1/2:** Ligand A (39.91) has a longer in vitro half-life than Ligand B (2.212), further supporting its better metabolic stability. This is a major advantage for A.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.009 and 0.139), which is favorable.
15. **Binding Affinity:** Ligand A (-7.8 kcal/mol) has a stronger binding affinity than Ligand B (-7.2 kcal/mol). This 0.6 kcal/mol difference is substantial and outweighs minor drawbacks.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand A performs better on logP and significantly better on binding affinity. While both have acceptable TPSA and Pgp values, the superior affinity and metabolic stability of Ligand A make it the more promising candidate. The negative Caco-2 and solubility values are concerning for both, but the stronger binding and better ADME properties of A suggest it might be more amenable to formulation strategies to address these issues.
**Conclusion:**
Ligand A is the superior candidate due to its stronger binding affinity, better logP, and significantly improved metabolic stability (lower Cl_mic and longer t1/2).
Output:
1
2025-04-17 20:54:11,333 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [369.897, 90.98, 2.607, 2, 4, 0.663, 38.736, 43.001, -5.266, -2.374, 0.088, 32.64, 22.252, 0.058, -7.2]
**Ligand B:** [362.396, 59.39, 2.115, 1, 5, 0.895, 38.348, 84.413, -4.54, -1.657, 0.238, 17.361, -8.478, 0.105, -7.0]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (362.396) is slightly lower, which is generally favorable.
2. **TPSA:** Ligand A (90.98) is slightly above the preferred <90 for CNS targets, but acceptable for a cardiovascular GPCR. Ligand B (59.39) is excellent, well below 90.
3. **logP:** Both are within the optimal 1-3 range. Ligand B (2.115) is slightly lower, which could slightly impact permeability.
4. **HBD:** Ligand A (2) and Ligand B (1) are both good, below the threshold of 5. Ligand B is slightly better.
5. **HBA:** Ligand A (4) and Ligand B (5) are both acceptable, below the threshold of 10.
6. **QED:** Ligand B (0.895) is significantly better than Ligand A (0.663), indicating a more drug-like profile.
7. **DILI:** Both are good, with low risk (<40). Ligand B (38.348) is marginally better.
8. **BBB:** Ligand B (84.413) is significantly better than Ligand A (43.001). While not a primary concern for a cardiovascular target, higher BBB is rarely detrimental.
9. **Caco-2:** Ligand A (-5.266) is worse than Ligand B (-4.54). Lower values indicate lower permeability.
10. **Solubility:** Ligand A (-2.374) is worse than Ligand B (-1.657). Lower values indicate lower solubility.
11. **hERG:** Both are very low, indicating minimal hERG inhibition risk. Ligand A (0.088) is slightly better.
12. **Cl_mic:** Ligand B (17.361) has a significantly lower clearance than Ligand A (32.64), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-8.478) has a longer half-life than Ligand A (22.252), which is desirable.
14. **Pgp:** Ligand A (0.058) is better than Ligand B (0.105), indicating lower P-gp efflux.
15. **Affinity:** Ligand A (-7.2) has a slightly better binding affinity than Ligand B (-7.0), but the difference is relatively small (0.2 kcal/mol).
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, and affinity. Ligand B excels in TPSA and has good logP, Pgp, and affinity. Ligand A has slightly better affinity and Pgp, but Ligand B's superior QED, solubility, metabolic stability (Cl_mic, t1/2), and TPSA outweigh this small difference in affinity.
**Conclusion:**
Considering the balance of properties and the GPCR-specific priorities, **Ligand B** is the more promising drug candidate. Its superior drug-likeness, solubility, metabolic stability, and TPSA make it a better choice despite the slightly lower affinity and Caco-2 permeability.
0
2025-04-17 20:54:11,333 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Step-by-step comparison:**
1. **MW:** Both ligands (356.463 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (107.89) is higher than Ligand B (88.1). Ligand B is better, being closer to the <140 threshold for good oral absorption, and more favorable for a GPCR.
3. **logP:** Ligand B (0.554) is slightly better than Ligand A (0.334). Both are a little low, potentially impacting permeability, but Ligand B is closer to the optimal 1-3 range.
4. **HBD:** Ligand A (4) is higher than Ligand B (2). Ligand B is preferable as lower HBD generally improves permeability.
5. **HBA:** Both ligands (5) are similar and within the acceptable limit of 10.
6. **QED:** Both ligands (0.549 and 0.597) are above 0.5, indicating good drug-likeness. Ligand B is slightly better.
7. **DILI:** Both ligands (12.641 and 12.33) have very similar and low DILI risk, well below the concerning threshold of 60.
8. **BBB:** Ligand B (55.797) is significantly better than Ligand A (27.259). While ADRB2 isn't necessarily a CNS target, some peripheral ADRB2 activity can influence CNS pathways, and higher BBB penetration isn't detrimental.
9. **Caco-2:** Ligand A (-5.09) is worse than Ligand B (-4.714). Higher values are better, so Ligand B is preferable.
10. **Solubility:** Ligand A (-0.86) is slightly better than Ligand B (-0.892), but both are very poor. This is a concern for both.
11. **hERG:** Ligand A (0.063) is slightly better than Ligand B (0.214). Lower is better, so Ligand A is preferable.
12. **Cl_mic:** Ligand A (-1.854) is significantly better than Ligand B (10.96). Lower clearance indicates better metabolic stability, a crucial factor.
13. **t1/2:** Ligand B (10.16) is significantly better than Ligand A (5.687). Longer half-life is generally preferred.
14. **Pgp:** Ligand A (0.01) is significantly better than Ligand B (0.039). Lower P-gp efflux is favorable for bioavailability.
15. **Affinity:** Ligand A (-7.1) is slightly better than Ligand B (-7.0). While both are excellent, the small advantage favors Ligand A.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are particularly important. Ligand B excels in TPSA and BBB, while Ligand A has a slight edge in affinity and a significant advantage in Pgp efflux and metabolic stability (Cl_mic).
**Overall Assessment:**
While Ligand B has better BBB penetration and a slightly better logP, Ligand A's superior metabolic stability (Cl_mic), lower P-gp efflux, and slightly better affinity outweigh these advantages. The solubility is poor for both, but can be addressed with formulation strategies. The hERG risk is also low for Ligand A.
**Output:**
1
2025-04-17 20:54:11,334 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Step-by-step comparison:**
1. **MW:** Ligand A (401.304 Da) is within the ideal range, while Ligand B (348.462 Da) is slightly below, but still acceptable.
2. **TPSA:** Ligand A (55.56) is better than Ligand B (41.57), both are well below the 140 threshold for oral absorption.
3. **logP:** Both ligands have good logP values (A: 3.32, B: 3.846), falling within the optimal 1-3 range. Ligand B is slightly higher, which could potentially lead to off-target effects but isn't a major concern.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Both have 3 HBA, which is good.
6. **QED:** Ligand A (0.859) has a significantly better QED score than Ligand B (0.544), indicating a more drug-like profile.
7. **DILI:** Ligand A (31.563) has a lower DILI risk than Ligand B (18.651), which is preferable.
8. **BBB:** Both have good BBB penetration (A: 82.513, B: 87.088).
9. **Caco-2:** Both have negative Caco-2 values, which is unusual. Assuming these are percentile scores, higher is better, and Ligand B (-4.606) is slightly better than Ligand A (-5.035).
10. **Solubility:** Both have negative solubility values. Assuming these are percentile scores, higher is better, and Ligand B (-4.038) is slightly better than Ligand A (-3.802).
11. **hERG:** Both have low hERG inhibition risk (A: 0.884, B: 0.948).
12. **Cl_mic:** Ligand A (19.539) has a much lower microsomal clearance than Ligand B (62.439), indicating better metabolic stability.
13. **t1/2:** Ligand B (25.21) has a slightly longer in vitro half-life than Ligand A (24.18), which is a minor advantage.
14. **Pgp:** Both have low Pgp efflux liability (A: 0.417, B: 0.418).
15. **Binding Affinity:** Ligand B (-6.5 kcal/mol) has a significantly better binding affinity than Ligand A (-0.6 kcal/mol). This is a substantial difference.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are crucial. Both ligands perform well on logP and Pgp. TPSA is good for both. However, the binding affinity difference is massive. While Ligand A has better QED, DILI, and Cl_mic, the significantly stronger binding of Ligand B outweighs these advantages. A binding affinity difference of 5.9 kcal/mol is extremely substantial and suggests a much higher probability of target engagement and efficacy.
**Conclusion:**
Ligand B is the more promising candidate due to its significantly superior binding affinity.
```
0
```
2025-04-17 20:54:11,334 - INFO - Here's a step-by-step comparison of Ligand A and Ligand B, followed by my final decision:
**1. Molecular Weight (MW):** Both ligands (354.447 and 348.487 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. Topological Polar Surface Area (TPSA):** Ligand A (77.1) is slightly higher than Ligand B (60.85). Both are below the 140 threshold for good oral absorption, but Ligand B is better positioned, especially considering it's a GPCR target.
**3. Lipophilicity (logP):** Ligand A (0.714) is lower than Ligand B (2.509). While both are within the optimal 1-3 range, Ligand B is closer to the upper end. For a GPCR, a slightly higher logP can be beneficial for membrane permeability and receptor engagement, but it needs to be balanced with solubility.
**4. H-Bond Donors (HBD):** Both ligands have 1 HBD, which is good.
**5. H-Bond Acceptors (HBA):** Ligand A has 5 HBA, while Ligand B has 3. Both are acceptable (<=10).
**6. QED:** Ligand A (0.729) has a slightly better QED score than Ligand B (0.613), suggesting a more drug-like profile.
**7. DILI Risk:** Ligand A (40.713) has a higher DILI risk than Ligand B (13.959). This is a significant advantage for Ligand B.
**8. BBB Penetration:** Ligand A (77.123) has slightly better BBB penetration than Ligand B (68.127). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be useful for understanding off-target effects and potential peripheral distribution.
**9. Caco-2 Permeability:** Ligand A (-4.764) has worse Caco-2 permeability than Ligand B (-4.54). Higher values are better, indicating better intestinal absorption.
**10. Aqueous Solubility:** Ligand A (-1.708) has slightly worse solubility than Ligand B (-1.571).
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.202 and 0.22). This is excellent.
**12. Microsomal Clearance:** Ligand A (24.902) has higher microsomal clearance than Ligand B (22.628), indicating faster metabolism. Lower is better for metabolic stability.
**13. In vitro Half-Life:** Ligand A (10.833) has a longer half-life than Ligand B (-4.157). This is a positive for Ligand A.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.033 and 0.13).
**15. Binding Affinity:** Ligand A (-6.7 kcal/mol) has a slightly better binding affinity than Ligand B (-6.2 kcal/mol). This 0.5 kcal/mol difference is meaningful, but not overwhelming.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand B emerges as the more promising candidate. While Ligand A has slightly better affinity and half-life, Ligand B significantly outperforms it in DILI risk, TPSA, and Caco-2 permeability. The slightly higher logP of Ligand B is acceptable for a GPCR target, and the lower DILI risk is a major advantage. The difference in affinity is not large enough to outweigh the other benefits of Ligand B.
Output:
0
2025-04-17 20:54:11,334 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (339.439 Da) is slightly lower, which could be advantageous for permeability, but both are acceptable.
**2. TPSA:** Both ligands have TPSA values around 75-76, which is acceptable for a peripheral GPCR target like ADRB2. It's slightly above the optimal <90 for CNS targets, but not a major concern here.
**3. logP:** Both ligands have good logP values (3.138 and 2.287), falling within the optimal 1-3 range. Ligand A is slightly higher, which could potentially lead to off-target interactions, but is still reasonable.
**4. H-Bond Donors & Acceptors:** Both ligands have 2 HBD and a reasonable number of HBA (3 for A, 4 for B). These values are within acceptable limits.
**5. QED:** Both ligands have QED values > 0.7, indicating good drug-likeness.
**6. DILI:** Ligand B (59.403) has a significantly lower DILI risk than Ligand A (39.201), which is a major advantage. Lower DILI is always preferred.
**7. BBB:** Ligand B (83.831) has a higher BBB penetration percentile than Ligand A (71.656). While ADRB2 isn't a CNS target, some peripheral exposure to the CNS can sometimes lead to off-target effects, and a lower BBB value is preferable.
**8. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.977 and -4.827). This is unusual and suggests poor permeability. However, these values are on a log scale, and the absolute difference is small.
**9. Aqueous Solubility:** Both ligands have negative solubility values (-3.444 and -3.911). Again, this is unusual and suggests poor solubility. The difference is small.
**10. hERG Inhibition:** Ligand A (0.848) has a slightly higher hERG inhibition liability than Ligand B (0.22). Lower hERG is crucial for avoiding cardiotoxicity, making Ligand B preferable.
**11. Microsomal Clearance:** Ligand A (-6.923) has a much lower (better) microsomal clearance than Ligand B (28.428). This indicates greater metabolic stability for Ligand A.
**12. In vitro Half-Life:** Ligand A (68.401) has a significantly longer in vitro half-life than Ligand B (0.655). This is a substantial advantage, potentially allowing for less frequent dosing.
**13. P-gp Efflux:** Both ligands have low P-gp efflux liability (0.128 and 0.135).
**14. Binding Affinity:** Ligand B (-7.3 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.7 kcal/mol). This is a >1.5 kcal/mol advantage, which is a strong driver for selection.
**Overall Assessment:**
While Ligand A has better metabolic stability (lower Cl_mic, longer t1/2), Ligand B has a significantly better safety profile (lower DILI, lower hERG) and a substantially stronger binding affinity. Given the GPCR-specific priorities (affinity being paramount), and the importance of minimizing safety risks, Ligand B is the more promising candidate despite its higher clearance. The difference in binding affinity outweighs the metabolic stability advantage of Ligand A.
Output:
0
2025-04-17 20:54:11,334 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
Let's systematically compare Ligand A and Ligand B based on the provided parameters and the guidelines, keeping in mind this is an ADRB2 (GPCR) target.
1. **Molecular Weight:** Both ligands (346.471 and 366.531 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (58.64) is significantly better than Ligand B (71.25). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand A is well below the 90 A^2 threshold. Ligand B is approaching the upper limit for good oral absorption (140 A^2).
3. **logP:** Both ligands have good logP values (2.406 and 2.228), falling within the optimal 1-3 range. Similar.
4. **H-Bond Donors:** Both have 1 HBD, which is acceptable.
5. **H-Bond Acceptors:** Ligand A has 3 HBA, while Ligand B has 6. Ligand A is preferable here, as fewer HBA generally improves permeability.
6. **QED:** Both ligands have good QED scores (0.795 and 0.836), indicating good drug-likeness. Similar.
7. **DILI:** Ligand A (18.418%) has a significantly lower DILI risk than Ligand B (35.867%). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (76.735%) has a much higher BBB penetration potential than Ligand B (58.938%). While ADRB2 isn't exclusively a CNS target, some CNS exposure can occur, and higher BBB is generally favorable.
9. **Caco-2:** Ligand A (-4.844) is better than Ligand B (-5.334). Higher values indicate better absorption.
10. **Solubility:** Ligand A (-3.35) is better than Ligand B (-2.214). Higher values indicate better solubility.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.26 and 0.191), which is excellent. Similar.
12. **Cl_mic:** Ligand A (15.904) has a much lower microsomal clearance than Ligand B (42.613). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (18.799) has a longer in vitro half-life than Ligand B (-5.458). This is a significant advantage for Ligand A.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.095 and 0.291). Similar.
15. **Binding Affinity:** Both ligands have identical binding affinities (-7.1 kcal/mol), which is excellent. This removes affinity as a differentiating factor.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across several crucial ADME properties (DILI, BBB, Cl_mic, t1/2, solubility, TPSA) without sacrificing binding affinity. While both ligands are generally drug-like, Ligand A presents a significantly more favorable profile for development. The lower DILI risk and improved metabolic stability are particularly compelling.
**Output:**
1
2025-04-17 20:54:11,334 - INFO - Here's my reasoning and final output:
**Reasoning:**
Let's break down the comparison between Ligand A and Ligand B, keeping in mind the ADRB2 GPCR target profile.
1. **Molecular Weight:** Both ligands (355.454 and 363.868 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (61.88) is slightly higher than Ligand B (55.63). Both are below the 140 threshold for good oral absorption, but closer to the ideal range for a GPCR.
3. **logP:** Ligand B (3.588) is higher than Ligand A (0.664). While Ligand A is a bit low and could hinder permeation, Ligand B is approaching the upper limit and could have solubility issues.
4. **H-Bond Donors:** Both have 1 HBD, which is good.
5. **H-Bond Acceptors:** Ligand A has 4, and Ligand B has 5. Both are acceptable, below the 10 threshold.
6. **QED:** Ligand B (0.901) has a significantly better QED score than Ligand A (0.761), indicating a more drug-like profile.
7. **DILI:** Ligand A (10.237) has a much lower DILI risk than Ligand B (47.305). This is a significant advantage for Ligand A.
8. **BBB:** Both have good BBB penetration (Ligand A: 81.776, Ligand B: 88.445). Ligand B is slightly better, but both are acceptable for a peripheral GPCR like ADRB2.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.754) is slightly better than Ligand B (-5.055).
10. **Solubility:** Ligand A (-0.866) has better solubility than Ligand B (-4.104). This is important, especially given Ligand B's higher logP.
11. **hERG:** Both have very low hERG inhibition risk (Ligand A: 0.444, Ligand B: 0.337). No significant difference.
12. **Cl_mic:** Ligand A (-6.333) has much lower microsomal clearance than Ligand B (33.779), indicating better metabolic stability. This is a major advantage for Ligand A.
13. **t1/2:** Ligand B (22.859) has a longer in vitro half-life than Ligand A (16.196). This is a positive for Ligand B.
14. **Pgp:** Ligand A (0.016) has significantly lower P-gp efflux liability than Ligand B (0.557). This is a substantial advantage for Ligand A.
15. **Binding Affinity:** Ligand B (-7.8) has a significantly stronger binding affinity than Ligand A (-5.0). This is a very important factor, and a difference of 2.8 kcal/mol is substantial.
**Overall Assessment:**
Ligand B has a superior binding affinity and a longer half-life. However, Ligand A demonstrates a much better safety profile (lower DILI, lower Pgp efflux, lower Cl_mic) and better solubility. While the affinity difference is significant, the ADME/Tox profile of Ligand A is substantially more favorable. Given the importance of metabolic stability and minimizing off-target effects for a cardiovascular target, I believe Ligand A is the more promising candidate. The affinity can potentially be optimized in subsequent iterations, while fixing the ADME/Tox issues of Ligand B would be more challenging.
**Output:**
1
2025-04-17 20:54:11,334 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (403.232 Da) is within the ideal range. Ligand B (346.475 Da) is also within range, slightly lower. No strong preference here.
2. **TPSA:** Ligand A (88.42) is good, below the 140 threshold. Ligand B (67.23) is excellent, further below the threshold. Slight preference for B.
3. **logP:** Both ligands (A: 2.803, B: 1.957) are within the optimal 1-3 range. No strong preference.
4. **HBD:** Both ligands have 1 HBD, which is good. No preference.
5. **HBA:** Ligand A has 5 HBA, Ligand B has 4. Both are acceptable. No preference.
6. **QED:** Both ligands have high QED scores (A: 0.75, B: 0.856), indicating good drug-likeness. Slight preference for B.
7. **DILI:** Ligand A (84.994) has a concerningly high DILI risk. Ligand B (14.696) has a very low DILI risk. This is a *major* advantage for B.
8. **BBB:** Ligand A (51.842) has moderate BBB penetration. Ligand B (74.06) has better BBB penetration. Preference for B, as ADRB2 is a GPCR.
9. **Caco-2:** Ligand A (-4.804) and Ligand B (-5.148) both have negative values, indicating poor permeability. No preference.
10. **Solubility:** Ligand A (-5.51) and Ligand B (-2.105) both have negative values, indicating poor solubility. Ligand B is better than A.
11. **hERG:** Ligand A (0.595) has a slightly higher hERG risk than Ligand B (0.144). Preference for B.
12. **Cl_mic:** Ligand A (97.152) has a high microsomal clearance, suggesting rapid metabolism. Ligand B (35.828) has a much lower clearance, indicating better metabolic stability. Strong preference for B.
13. **t1/2:** Ligand A (13.139) has a moderate half-life. Ligand B (-3.69) has a very short half-life. Preference for A.
14. **Pgp:** Ligand A (0.234) has lower P-gp efflux than Ligand B (0.036), which is good. Preference for A.
15. **Binding Affinity:** Ligand A (-8.5 kcal/mol) has a significantly stronger binding affinity than Ligand B (-5.3 kcal/mol). This is a *major* advantage for A.
**Overall Assessment:**
While Ligand A has a substantially better binding affinity, the ADME properties of Ligand B are far superior. Specifically, the dramatically lower DILI risk, better BBB penetration, lower hERG risk, and improved metabolic stability (lower Cl_mic) are critical for a viable drug candidate. The better solubility of Ligand B is also a plus. The shorter half-life of Ligand B is a drawback, but potentially addressable through structural modifications. The poor Caco-2 values for both are concerning, but less critical for a GPCR target where CNS penetration is important. Given the GPCR target class, the balance of properties favors Ligand B. The substantial affinity difference is significant, but the safety and PK profile of B are more compelling.
Output:
0
2025-04-17 20:54:11,334 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for the ADRB2, a cardiovascular GPCR. Therefore, the key priorities are logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB.
Let's break down the comparison:
1. **MW:** Both ligands are within the acceptable range (200-500 Da). Ligand A (340.427) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are below the 140 A^2 threshold for good oral absorption. Ligand B (75.71) is slightly better than Ligand A (83.12), which is slightly better for potential CNS penetration, though this is less critical for a cardiovascular target.
3. **logP:** Ligand A (3.033) is optimal, while Ligand B (0.699) is quite low. This is a significant drawback for Ligand B, potentially hindering membrane permeability and bioavailability.
4. **HBD/HBA:** Ligand A (3/3) and Ligand B (1/4) are both reasonable.
5. **QED:** Both are similar and good (0.724 and 0.7).
6. **DILI:** Ligand B (32.959) has a much lower DILI risk than Ligand A (55.176), which is a significant advantage.
7. **BBB:** Ligand A (70.648) has a slightly better BBB penetration than Ligand B (56.301), but this is less important for a cardiovascular target.
8. **Caco-2:** Both are negative, indicating poor permeability.
9. **Solubility:** Ligand A (-4.11) is slightly worse than Ligand B (-2.105).
10. **hERG:** Both are very low risk (0.415 and 0.184).
11. **Cl_mic:** Ligand B (27.278) has significantly lower microsomal clearance than Ligand A (65.255), indicating better metabolic stability.
12. **t1/2:** Ligand A (53.71) has a longer half-life than Ligand B (14.029).
13. **Pgp:** Ligand A (0.062) has a lower P-gp efflux liability than Ligand B (0.049), which is favorable.
14. **Affinity:** Ligand A (-7.1 kcal/mol) has a slightly better binding affinity than Ligand B (-5.3 kcal/mol). This 1.8 kcal/mol difference is substantial and can outweigh some ADME concerns.
**Overall Assessment:**
Ligand A has a better binding affinity and slightly better BBB penetration. However, Ligand B has a significantly lower DILI risk and better metabolic stability (lower Cl_mic). The biggest concern with Ligand B is its low logP, which could severely limit its absorption. The superior binding affinity of Ligand A, combined with acceptable ADME properties, makes it the more promising candidate despite the slightly higher DILI risk.
**Output:**
1
2025-04-17 20:54:11,335 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.443 and 371.434 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (75.71) is better than Ligand B (91.76). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (2.446 and 1.132), falling within the 1-3 optimal range. Ligand A is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is preferable to Ligand B (6). Fewer HBAs generally improve permeability.
6. **QED:** Both ligands have similar, good QED values (0.52 and 0.533), indicating good drug-likeness.
7. **DILI:** Ligand A (43.35) has a significantly lower DILI risk than Ligand B (60.915). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (65.801) has a higher BBB penetration percentile than Ligand B (52.889). While not crucial for a cardiovascular target, it's a slight positive.
9. **Caco-2:** Ligand B (-5.263) has a better Caco-2 permeability than Ligand A (-4.65). This suggests better intestinal absorption for Ligand B.
10. **Solubility:** Ligand B (-2.161) has slightly better aqueous solubility than Ligand A (-2.677).
11. **hERG:** Both ligands have very low hERG inhibition liability (0.297 and 0.151), which is excellent.
12. **Cl_mic:** Ligand B (-24.082) has significantly lower microsomal clearance than Ligand A (86.252). This indicates better metabolic stability for Ligand B.
13. **t1/2:** Ligand B (8.705) has a longer in vitro half-life than Ligand A (-11.183). This is a significant advantage for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.163 and 0.027).
15. **Binding Affinity:** Ligand B (-6.7) has a slightly better binding affinity than Ligand A (-6.3). While the difference is small, it's still a positive for Ligand B.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B has a slightly better logP, better Caco-2 permeability, and a slightly better affinity. However, Ligand A has a significantly better DILI score and lower TPSA. The difference in affinity is small, and the DILI risk is a major concern.
**Overall Assessment:**
While Ligand B has advantages in metabolic stability (Cl_mic, t1/2) and Caco-2 permeability, Ligand A's significantly lower DILI risk and lower TPSA are more compelling. The slight advantage in binding affinity for Ligand B is not enough to overcome the higher potential for liver toxicity.
Output:
1
2025-04-17 20:54:11,335 - INFO - Batch 219 complete. Total preferences: 3504
2025-04-17 20:54:11,335 - INFO - Processing batch 220/512...
2025-04-17 20:55:02,933 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.475 and 344.503 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (87.66) is slightly higher than Ligand B (59.07). For a cardiovascular GPCR, TPSA is not a primary concern, but lower is generally preferable for absorption. Ligand B is better.
3. **logP:** Ligand A (1.531) is within the optimal 1-3 range. Ligand B (4.147) is a bit high, potentially leading to solubility issues and off-target interactions. Ligand A is better.
4. **HBD:** Ligand A (3) and Ligand B (2) are both acceptable, below the threshold of 5. No strong preference.
5. **HBA:** Ligand A (4) and Ligand B (5) are both acceptable, below the threshold of 10. No strong preference.
6. **QED:** Both ligands have good QED scores (0.52 and 0.659, respectively), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (6.592) has a much lower DILI risk than Ligand B (33.307). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (47.732) has a lower BBB penetration than Ligand B (82.009). While ADRB2 isn't a CNS target, some peripheral exposure is acceptable, and higher BBB is not necessarily a negative. Ligand B is better.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.76 and -4.822). This is unusual and suggests poor permeability. It's difficult to interpret without more information, but it's a concern for both.
10. **Solubility:** Ligand A (-1.346) has better solubility than Ligand B (-4.432). This is important given Ligand B's higher logP. Ligand A is better.
11. **hERG:** Ligand A (0.138) has a lower hERG risk than Ligand B (0.863). This is a significant advantage for Ligand A, as hERG inhibition can cause cardiotoxicity.
12. **Cl_mic:** Ligand A (17.893) has significantly lower microsomal clearance than Ligand B (93.748), indicating better metabolic stability. This is a major advantage for Ligand A.
13. **t1/2:** Ligand B (38.142) has a longer in vitro half-life than Ligand A (16.1). This is a positive for Ligand B.
14. **Pgp:** Ligand A (0.013) has much lower P-gp efflux liability than Ligand B (0.614). This is a significant advantage for Ligand A, improving bioavailability.
15. **Binding Affinity:** Ligand A (-6.6 kcal/mol) has slightly better binding affinity than Ligand B (-5.9 kcal/mol). While the difference is not huge, it's still a positive for Ligand A.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity) and general drug-like properties, Ligand A is the more promising candidate. While Ligand B has better BBB penetration and in vitro half-life, Ligand A excels in crucial areas like DILI risk, hERG inhibition, metabolic stability (Cl_mic), P-gp efflux, solubility, and binding affinity. The higher logP of Ligand B is a concern, and its significantly higher DILI and P-gp efflux liabilities are major drawbacks. The slightly better affinity of Ligand A further supports its selection.
Output:
1
2025-04-17 20:55:02,934 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
Let's break down the comparison of Ligand A and Ligand B based on the provided parameters and the guidelines, keeping in mind that ADRB2 is a GPCR and therefore we prioritize logP, Pgp, TPSA, and affinity.
1. **Molecular Weight:** Both ligands (369.487 Da and 366.527 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (74.07) is slightly higher than Ligand B (62.55). Both are below the 140 threshold for good oral absorption, but Ligand B is preferable due to being closer to the 90 threshold for GPCRs.
3. **logP:** Ligand A (1.242) is within the optimal range (1-3), while Ligand B (3.446) is at the higher end of the optimal range. Ligand A is slightly better here.
4. **H-Bond Donors:** Ligand A (0) is preferable to Ligand B (1). Fewer H-bond donors generally improve permeability.
5. **H-Bond Acceptors:** Ligand A (5) is preferable to Ligand B (4).
6. **QED:** Ligand A (0.781) is better than Ligand B (0.68), indicating a more drug-like profile.
7. **DILI:** Ligand A (34.82) has a significantly lower DILI risk than Ligand B (20.744). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (82.513) has a better BBB penetration percentile than Ligand B (62.544). This is important for GPCRs, even if not strictly CNS-focused.
9. **Caco-2:** Ligand A (-4.735) is better than Ligand B (-5.305), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-2.039) is better than Ligand B (-3.27).
11. **hERG:** Both ligands have low hERG inhibition liability (0.773 and 0.629, respectively). No significant difference.
12. **Cl_mic:** Ligand A (20.438) has a lower microsomal clearance than Ligand B (55.816), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-29.185) has a longer in vitro half-life than Ligand B (40.155). This is a significant advantage.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.129 and 0.181, respectively). No significant difference.
15. **Binding Affinity:** Ligand B (-7.7 kcal/mol) has a slightly better binding affinity than Ligand A (-6.6 kcal/mol). This is a 1.1 kcal/mol difference, which is substantial.
**Overall Assessment:**
While Ligand B has a slightly better binding affinity, Ligand A demonstrates a significantly more favorable ADMET profile. It has lower DILI risk, better BBB penetration, better solubility, lower microsomal clearance, and a longer half-life. These factors are crucial for overall drug development success, and outweigh the small difference in binding affinity. The GPCR-specific priorities (logP, Pgp, TPSA, affinity) are reasonably well-addressed by both, but Ligand A's superior ADMET properties make it the more promising candidate.
**Output:**
1
2025-04-17 20:55:02,934 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [365.499, 78.51, 1.095, 2, 4, 0.662, 39.162, 59.209, -5.233, -3.242, 0.198, 28.322, 2.234, 0.026, -5.2]
**Ligand B:** [347.375, 118.37, 0.14, 3, 7, 0.625, 61.303, 34.393, -5.422, -1.636, 0.066, -4.721, 64.155, 0.008, -5.6]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (347.375) is slightly lower, which could be beneficial for permeability, but both are acceptable.
2. **TPSA:** Ligand A (78.51) is significantly better than Ligand B (118.37). For a GPCR, keeping TPSA under 140 is good, and lower is generally preferred for better absorption. Ligand B is pushing the upper limit.
3. **logP:** Ligand A (1.095) is within the optimal range (1-3), while Ligand B (0.14) is quite low. Low logP can hinder membrane permeability. Ligand A is clearly better here.
4. **HBD:** Both have acceptable HBD counts (Ligand A: 2, Ligand B: 3), well below the 5 threshold.
5. **HBA:** Ligand A (4) is better than Ligand B (7). While both are under 10, lower HBA generally improves permeability.
6. **QED:** Both are similar and acceptable (Ligand A: 0.662, Ligand B: 0.625), indicating reasonable drug-likeness.
7. **DILI:** Ligand A (39.162) has a much lower DILI risk than Ligand B (61.303). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (59.209) has a better BBB penetration score than Ligand B (34.393). While ADRB2 isn't strictly a CNS target, some CNS exposure is not necessarily detrimental and could even be beneficial depending on the therapeutic goal.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. This is concerning for both, but the value for Ligand A (-5.233) is slightly less negative than Ligand B (-5.422), suggesting marginally better permeability.
10. **Solubility:** Ligand A (-3.242) has better solubility than Ligand B (-1.636). Solubility is important for formulation and bioavailability.
11. **hERG:** Both have very low hERG inhibition risk (Ligand A: 0.198, Ligand B: 0.066), which is excellent.
12. **Cl_mic:** Ligand A (28.322) has a lower microsomal clearance than Ligand B (-4.721), suggesting better metabolic stability.
13. **t1/2:** Ligand B (64.155) has a significantly longer in vitro half-life than Ligand A (2.234). This is a major advantage for Ligand B.
14. **Pgp:** Ligand A (0.026) has much lower P-gp efflux liability than Ligand B (0.008). Lower P-gp efflux is desirable for improved oral bioavailability.
15. **Affinity:** Ligand B (-5.6) has a slightly better binding affinity than Ligand A (-5.2). However, the difference is only 0.4 kcal/mol, which is not a huge advantage.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand A is the more promising candidate. While Ligand B has a better half-life and slightly better affinity, Ligand A excels in crucial areas like logP, TPSA, DILI risk, and P-gp efflux. The significantly better logP and TPSA of Ligand A will likely translate to better absorption and bioavailability, outweighing the modest affinity advantage of Ligand B. The lower DILI risk is also a significant safety benefit.
Output:
1
2025-04-17 20:55:02,934 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (367.793 and 347.459 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (82.53) is significantly better than Ligand A (127.63). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (0.968 and 1.847), falling within the optimal 1-3 range. Ligand B is slightly better.
4. **HBD:** Both have 2 HBD, which is acceptable.
5. **HBA:** Ligand A has 5 HBA, and Ligand B has 4. Both are within the acceptable limit of 10.
6. **QED:** Ligand B (0.714) has a better QED score than Ligand A (0.441), indicating a more drug-like profile.
7. **DILI:** Ligand B (22.8) has a much lower DILI risk than Ligand A (61.07). This is a significant advantage.
8. **BBB:** Ligand B (69.911) has a higher BBB penetration percentile than Ligand A (31.912), but this is less critical for a cardiovascular target.
9. **Caco-2:** Ligand A (-5.012) and Ligand B (-4.546) are both negative, which is unusual. Lower (more negative) values indicate poorer permeability. Ligand B is slightly better.
10. **Solubility:** Ligand A (-1.997) and Ligand B (-2.562) are both poor. This is a concern for both.
11. **hERG:** Ligand A (0.129) has a slightly better hERG profile than Ligand B (0.354), but both are relatively low risk.
12. **Cl_mic:** Ligand A (-15.596) has a much lower (better) microsomal clearance than Ligand B (50.005). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (10.232) has a longer in vitro half-life than Ligand B (-1.059). This is a significant advantage for dosing considerations.
14. **Pgp:** Ligand A (0.034) has a lower Pgp efflux liability than Ligand B (0.13), suggesting better bioavailability.
15. **Binding Affinity:** Ligand A (-7.3) has a slightly better binding affinity than Ligand B (-6.1). While both are good, the 1.2 kcal/mol difference is notable.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand B excels in logP and TPSA, while Ligand A has a slight edge in affinity and Pgp efflux. However, the significantly lower DILI risk for Ligand B and its better QED score are major advantages. The longer half-life and lower clearance of Ligand A are also important, but the DILI risk is a substantial concern.
**Overall Assessment:**
Despite the slightly better affinity of Ligand A, the significantly lower DILI risk, better QED, and improved TPSA/logP of Ligand B make it the more promising candidate. The metabolic stability and half-life of Ligand A are attractive, but the DILI risk is too high to ignore.
**Output:**
0
2025-04-17 20:55:02,934 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (355.454) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (61.88) is better than Ligand B (71.09). Both are below 140, but lower TPSA is preferred for oral absorption.
3. **logP:** Ligand B (3.082) is optimal, while Ligand A (0.664) is quite low. This is a significant drawback for Ligand A, potentially hindering membrane permeability.
4. **HBD:** Ligand A (1) is better than Ligand B (2). Lower HBD is generally preferred.
5. **HBA:** Ligand A (4) is slightly better than Ligand B (3). Both are acceptable.
6. **QED:** Both ligands have good QED scores (A: 0.761, B: 0.865), indicating good drug-like properties.
7. **DILI:** Ligand A (10.237) has a much lower DILI risk than Ligand B (39.899). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (81.776) has better BBB penetration than Ligand B (63.668). While ADRB2 isn't strictly a CNS target, some CNS exposure can occur, and higher BBB is generally a positive.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the values are close (-4.754 vs -4.853), so this isn't a major differentiator.
10. **Solubility:** Ligand A (-0.866) has better solubility than Ligand B (-3.714). This is a positive for Ligand A.
11. **hERG:** Both ligands have low hERG inhibition risk (A: 0.444, B: 0.492).
12. **Cl_mic:** Ligand A (-6.333) has significantly lower microsomal clearance than Ligand B (13.815), indicating better metabolic stability.
13. **t1/2:** Both ligands have similar in vitro half-lives (A: 16.196, B: 17.92).
14. **Pgp:** Both ligands have very low Pgp efflux liability (A: 0.016, B: 0.085).
15. **Affinity:** Ligand B (-7.7) has a significantly stronger binding affinity than Ligand A (-5). This is a substantial advantage for Ligand B.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, and affinity are key. While Ligand A has better TPSA, solubility, DILI, BBB, and metabolic stability, Ligand B's significantly stronger binding affinity (-7.7 vs -5) and acceptable logP outweigh these benefits. The lower logP of Ligand A is a serious concern for permeability.
**Conclusion:**
Despite Ligand A's favorable ADME properties, Ligand B's superior binding affinity is the deciding factor. A strong binding affinity is crucial for a GPCR ligand, and the difference of 2.7 kcal/mol is substantial enough to overcome the other drawbacks of Ligand B.
Output:
0
2025-04-17 20:55:02,934 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [346.391, 103.19 , 1.663, 2. , 7. , 0.853, 80.109, 57.542, -4.899, -2.457, 0.068, 21.758, -3.596, 0.005, -6.7 ]
**Ligand B:** [348.443, 59.08 , 1.185, 0. , 4. , 0.766, 18.069, 82.047, -4.596, -1.599, 0.319, 33.167, 14.746, 0.062, -5. ]
Here's a breakdown, comparing each parameter and considering GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal range (200-500 Da). A is 346.391, B is 348.443. Very similar.
2. **TPSA:** A (103.19) is higher than B (59.08). B is much better, being well under the 140 threshold for oral absorption, and closer to the ideal for GPCRs.
3. **logP:** Both are good (1.663 and 1.185, respectively), falling within the 1-3 range. A is slightly better.
4. **HBD:** A (2) is reasonable, B (0) is excellent. Lower HBD generally improves permeability.
5. **HBA:** A (7) is acceptable, B (4) is better. Lower HBA is also favorable for permeability.
6. **QED:** A (0.853) is better than B (0.766), indicating a more drug-like profile.
7. **DILI:** A (80.109) is significantly higher than B (18.069), indicating a much greater risk of liver injury. This is a major concern for A.
8. **BBB:** B (82.047) is better than A (57.542). While not a CNS target, some BBB penetration can be beneficial for distribution.
9. **Caco-2:** Both are negative, indicating poor permeability. A (-4.899) is worse than B (-4.596).
10. **Solubility:** Both are negative, indicating poor solubility. B (-1.599) is better than A (-2.457).
11. **hERG:** A (0.068) is slightly better than B (0.319), but both are low risk.
12. **Cl_mic:** A (21.758) is lower than B (33.167), suggesting better metabolic stability.
13. **t1/2:** B (14.746) is much better than A (-3.596), indicating a longer half-life.
14. **Pgp:** A (0.005) is significantly better than B (0.062), indicating lower P-gp efflux.
15. **Affinity:** A (-6.7) is better than B (-5.0), indicating stronger binding. This is a substantial difference.
**Overall Assessment:**
Ligand A has a better binding affinity and Pgp profile, and slightly better logP and hERG. However, its significantly higher DILI risk, worse TPSA, worse Caco-2 permeability, and much shorter half-life are major drawbacks. Ligand B, while having a weaker binding affinity, has a much more favorable safety profile (DILI), better TPSA, better solubility, and a significantly longer half-life.
Considering the GPCR-specific priorities and the overall balance of properties, **Ligand B is the more promising candidate**. The stronger binding affinity of A is tempting, but the high DILI risk and poor pharmacokinetic properties are too significant to ignore. A good starting point would be to improve the binding affinity of Ligand B, rather than trying to fix the liabilities of Ligand A.
Output:
0
2025-04-17 20:55:02,934 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for the ADRB2, a cardiovascular GPCR. Therefore, the key properties to prioritize are logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB (though less critical for a cardiovascular target).
Let's compare the ligands property by property:
1. **MW:** Both ligands (350.463 and 352.483 Da) are within the ideal range (200-500 Da).
2. **TPSA:** Ligand A (87.46) is slightly higher than Ligand B (75.64). Both are below 140, acceptable for oral absorption, but B is better.
3. **logP:** Both ligands have good logP values (1.021 and 1.113), falling within the optimal 1-3 range.
4. **HBD:** Ligand A (2) has slightly more HBD than Ligand B (1). This isn't a major concern for either.
5. **HBA:** Ligand B (8) has more HBA than Ligand A (5). This is a slight negative for Ligand B, potentially impacting permeability.
6. **QED:** Ligand A (0.83) has a better QED score than Ligand B (0.708), indicating a more drug-like profile.
7. **DILI:** Both have acceptable DILI risk (39.356 and 42.846 percentile).
8. **BBB:** Ligand B (79.411) has a considerably higher BBB penetration score than Ligand A (34.238). While not a primary concern for a cardiovascular target, higher BBB is generally a positive.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Both have negative solubility values, which is also unusual and suggests poor solubility. This is a significant concern for both.
11. **hERG:** Ligand A (0.115) has a much lower hERG inhibition liability than Ligand B (0.871), a significant advantage.
12. **Cl_mic:** Ligand B (45.932) has a lower microsomal clearance than Ligand A (53.973), suggesting better metabolic stability.
13. **t1/2:** Ligand B (23.473) has a longer in vitro half-life than Ligand A (13.838), which is desirable.
14. **Pgp:** Ligand A (0.022) has a much lower P-gp efflux liability than Ligand B (0.014), indicating better absorption and potentially higher bioavailability.
15. **Affinity:** Both ligands have very similar binding affinities (-6.4 and -6.3 kcal/mol). The difference is negligible.
**Overall Assessment:**
Ligand A is preferable. While Ligand B has better BBB penetration and metabolic stability, Ligand A has a significantly better QED score, lower hERG risk, and lower P-gp efflux. The hERG risk is a critical factor, and the slightly better drug-likeness profile of A outweighs the benefits of B. The poor Caco-2 and solubility values are concerning for both, and would require further investigation/optimization regardless of which ligand is chosen.
**Output:**
1
2025-04-17 20:55:02,934 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (352.431 and 362.417 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand B (87.66) is better than Ligand A (101.57). Both are below 140, but lower TPSA is preferred for GPCRs to facilitate membrane permeability.
**3. logP:** Ligand B (1.734) is better than Ligand A (0.812). Both are within the optimal 1-3 range, but Ligand B is closer to the sweet spot.
**4. H-Bond Donors:** Ligand A (2) is better than Ligand B (3). Lower HBD is generally preferred for better permeability.
**5. H-Bond Acceptors:** Ligand A (5) is better than Ligand B (4). Both are acceptable, but lower is slightly favored.
**6. QED:** Ligand A (0.63) is slightly better than Ligand B (0.583), indicating a marginally more drug-like profile.
**7. DILI:** Both ligands have similar and acceptable DILI risk (Ligand A: 34.432, Ligand B: 37.263), both well below the 60 threshold.
**8. BBB:** Ligand A (65.839) is significantly better than Ligand B (52.268). While ADRB2 isn't exclusively a CNS target, some CNS penetration can be beneficial, and avoiding efflux is important.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.876 and -4.968). This is unusual and suggests poor permeability *in vitro*. However, the values are very close, so this isn't a major differentiator.
**10. Aqueous Solubility:** Both ligands have negative solubility values (-1.696 and -1.513). This is also concerning, indicating poor solubility. Again, the difference is minimal.
**11. hERG Inhibition:** Ligand A (0.042) is significantly better than Ligand B (0.507), indicating a much lower risk of cardiotoxicity. This is crucial for a cardiovascular target.
**12. Microsomal Clearance:** Ligand B (33.677) is better than Ligand A (51.159), suggesting better metabolic stability.
**13. In vitro Half-Life:** Ligand A (-21.635) is better than Ligand B (-12.089), indicating a longer half-life.
**14. P-gp Efflux:** Ligand A (0.027) is significantly better than Ligand B (0.15), suggesting lower efflux and better bioavailability.
**15. Binding Affinity:** Ligand B (-7.5) is significantly better than Ligand A (-6.0). This is a substantial difference in potency.
**Overall Assessment:**
Ligand B has a better logP, lower microsomal clearance, and *much* stronger binding affinity. However, Ligand A has a better BBB score, significantly lower hERG risk, lower P-gp efflux, and a longer half-life. The affinity difference is substantial, but the hERG risk for Ligand B is concerning for a cardiovascular target. The P-gp efflux and BBB scores of Ligand A are also attractive. Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), and the critical need for safety in a cardiovascular drug, the superior binding affinity of Ligand B outweighs the slightly less favorable ADME properties.
Output:
0
2025-04-17 20:55:02,934 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (365.5 & 363.8 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand B (85.52) is significantly better than Ligand A (105.21). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (3.137) is good, while Ligand B (1.898) is on the lower side of optimal. For a GPCR, a slightly higher logP is generally preferred for membrane permeability and receptor engagement.
4. **HBD:** Ligand B (1) is better than Ligand A (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand B (4) is better than Ligand A (5). Similar to HBD, fewer HBAs are generally preferred.
6. **QED:** Both are good (0.654 and 0.782), indicating reasonable drug-likeness. Ligand B is slightly better.
7. **DILI:** Ligand B (34.432) is *much* better than Ligand A (63.591). This is a substantial advantage for Ligand B, as DILI is a major concern in drug development.
8. **BBB:** Ligand B (82.009) is better than Ligand A (57.619), but neither is exceptionally high. Since ADRB2 is cardiovascular, BBB penetration isn't a primary goal.
9. **Caco-2:** Both are poor (-5.141 and -5.153). This suggests limited intestinal absorption for both, which is a concern.
10. **Solubility:** Both are poor (-3.486 and -2.879). This is a significant drawback for both compounds.
11. **hERG:** Ligand B (0.297) is significantly better than Ligand A (0.648). Lower hERG inhibition is crucial for avoiding cardiotoxicity, making this a major advantage for Ligand B.
12. **Cl_mic:** Ligand B (27.833) is better than Ligand A (46.795). Lower clearance indicates greater metabolic stability.
13. **t1/2:** Ligand B (12.914) is significantly better than Ligand A (6.06). A longer half-life is desirable for less frequent dosing.
14. **Pgp:** Ligand B (0.027) is *much* better than Ligand A (0.332). Lower P-gp efflux improves bioavailability.
15. **Affinity:** Ligand A (-6.8 kcal/mol) is significantly better than Ligand B (-1.1 kcal/mol). This is a substantial difference in potency.
**Overall Assessment:**
Ligand A has a significantly better binding affinity, which is a major advantage. However, Ligand B demonstrates superior ADME-Tox properties across the board: lower DILI risk, lower hERG inhibition, better metabolic stability (lower Cl_mic, longer t1/2), and lower P-gp efflux. The Caco-2 and solubility are poor for both.
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), and the fact that this is a cardiovascular target (less emphasis on BBB), the improved safety profile and ADME properties of Ligand B outweigh the potency advantage of Ligand A. While the affinity difference is large, optimizing Ligand B's structure to improve its binding affinity is more likely to succeed than trying to mitigate the significant safety concerns associated with Ligand A.
Output:
0
2025-04-17 20:55:02,935 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
The ADRB2 receptor is a GPCR, so the priorities are logP, TPSA, Pgp, BBB, and affinity. Let's break down the comparison:
1. **Molecular Weight:** Both ligands are within the ideal range (344.46 Da and 348.40 Da).
2. **TPSA:** Ligand A (74.33) is significantly better than Ligand B (93.53). Lower TPSA generally favors oral absorption and is crucial for GPCRs.
3. **logP:** Ligand A (1.355) is slightly better than Ligand B (0.672), falling comfortably within the optimal 1-3 range. Ligand B is at the lower end and could potentially have permeability issues.
4. **H-Bond Donors/Acceptors:** Ligand A (2 HBD, 4 HBA) is slightly better than Ligand B (1 HBD, 6 HBA) in terms of balancing solubility and permeability.
5. **QED:** Ligand A (0.817) is much better than Ligand B (0.402), indicating a more drug-like profile.
6. **DILI:** Ligand B (54.17) has a lower DILI risk than Ligand A (21.91), which is a positive.
7. **BBB:** Both ligands have similar BBB penetration (59.09% and 59.64%), which is acceptable but not outstanding.
8. **Caco-2 Permeability:** Both are negative, indicating poor permeability.
9. **Aqueous Solubility:** Both are negative, indicating poor solubility.
10. **hERG Inhibition:** Both ligands show very low hERG inhibition risk (0.396 and 0.124).
11. **Microsomal Clearance:** Ligand B (68.98) has significantly higher clearance than Ligand A (8.12), suggesting lower metabolic stability.
12. **In vitro Half-Life:** Ligand A (1.834 hours) has a shorter half-life than Ligand B (-2.279 hours), which is not ideal.
13. **P-gp Efflux:** Both are very low, indicating minimal P-gp efflux.
14. **Binding Affinity:** Both ligands have very similar binding affinities (-5.6 kcal/mol and -5.7 kcal/mol). The difference is negligible.
**Overall Assessment:**
Ligand A is significantly better due to its superior TPSA, QED, and lower microsomal clearance. While Ligand B has a slightly lower DILI risk, the better ADME properties of Ligand A, particularly the TPSA and QED, are more important for a GPCR target like ADRB2. The slightly shorter half-life of Ligand A could be addressed with further optimization, but the fundamental ADME profile is more promising.
**Output:**
1
2025-04-17 20:55:02,935 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 receptor (a GPCR):
**1. Molecular Weight:** Both ligands (363.483 and 363.443 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (78.51) is significantly better than Ligand B (110.05). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is approaching a value that could hinder oral absorption.
**3. logP:** Both ligands have acceptable logP values (1.942 and 2.992, respectively), falling within the 1-3 optimal range. Ligand B is slightly higher, which could potentially lead to off-target interactions, but it's not a major concern.
**4. H-Bond Donors:** Both have 2 HBD, which is within the acceptable limit of <=5.
**5. H-Bond Acceptors:** Ligand A has 4 HBA, while Ligand B has 7. Ligand A is preferable here, as lower HBA generally improves permeability.
**6. QED:** Ligand A (0.857) has a substantially better QED score than Ligand B (0.578), indicating a more drug-like profile.
**7. DILI Risk:** Ligand B (78.441) has a significantly higher DILI risk than Ligand A (54.323). This is a critical factor, and the lower risk associated with Ligand A is a strong advantage.
**8. BBB Penetration:** Ligand A (65.452) shows slightly better BBB penetration than Ligand B (57.736). While ADRB2 isn't exclusively a CNS target, some degree of BBB penetration can be beneficial for understanding off-target effects and potential peripheral activity.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-5.143 and -5.094), which is unusual and suggests poor permeability *in vitro*. This is a concern for both, but the values are very close.
**10. Aqueous Solubility:** Both ligands have poor aqueous solubility (-3.443 and -4.269). This is a drawback for both, potentially impacting bioavailability.
**11. hERG Inhibition:** Both ligands show low hERG inhibition risk (0.459 and 0.492), which is good.
**12. Microsomal Clearance:** Ligand A (24.507) has a lower microsomal clearance than Ligand B (48.331), indicating better metabolic stability.
**13. In vitro Half-Life:** Ligand B (21.871) has a significantly longer in vitro half-life than Ligand A (-3.371). This is a positive for Ligand B, potentially allowing for less frequent dosing.
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (0.056 and 0.217).
**15. Binding Affinity:** Ligand A (-7.7 kcal/mol) has a stronger binding affinity than Ligand B (-5.8 kcal/mol). This is a substantial difference (1.9 kcal/mol), and a strong binding affinity can often outweigh minor ADME drawbacks.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand A is the superior candidate. The significantly better TPSA, QED, DILI risk, metabolic stability (lower Cl_mic), and *much* stronger binding affinity outweigh the longer half-life of Ligand B. The poor solubility and Caco-2 permeability are concerns for both, but can be addressed through formulation strategies. The lower DILI risk for Ligand A is particularly important.
Output:
1
2025-04-17 20:55:02,935 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (376.519 Da) is slightly higher than Ligand B (348.487 Da), but both are acceptable.
2. **TPSA:** Ligand B (69.64) is significantly better than Ligand A (101.57). For a GPCR, lower TPSA is generally preferred for better permeability. Ligand A is a bit high, potentially hindering absorption.
3. **logP:** Both ligands have acceptable logP values (A: 0.885, B: 2.082), falling within the 1-3 range. Ligand B is closer to the optimal range.
4. **HBD:** Both have 2 H-bond donors, which is good.
5. **HBA:** Ligand B (3) has fewer H-bond acceptors than Ligand A (5), which is favorable for permeability.
6. **QED:** Both have good QED scores (A: 0.589, B: 0.799), indicating drug-likeness. Ligand B is better.
7. **DILI:** Ligand B (9.19%) has a *much* lower DILI risk than Ligand A (40.054%). This is a significant advantage for Ligand B.
8. **BBB:** Both have reasonable BBB penetration (A: 55.874%, B: 64.793%). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration is not detrimental, and Ligand B is better.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual. Assuming these are logP values, both are poor.
10. **Solubility:** Both have negative solubility values, which is also unusual. Assuming these are logS values, both are poor.
11. **hERG:** Both have low hERG risk (A: 0.235, B: 0.435), which is excellent.
12. **Cl_mic:** Ligand B (22.749) has slightly lower microsomal clearance than Ligand A (26.743), suggesting better metabolic stability.
13. **t1/2:** Ligand A (13.66) has a longer in vitro half-life than Ligand B (9.818). This is a positive for Ligand A.
14. **Pgp:** Both have very low Pgp efflux liability (A: 0.041, B: 0.125), which is good.
15. **Binding Affinity:** Ligand A (-6.4 kcal/mol) has a slightly better binding affinity than Ligand B (-6.0 kcal/mol), but the difference is small (0.4 kcal/mol) and may not be decisive.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, TPSA, logP, and metabolic stability are important. Ligand B excels in TPSA, logP, and DILI risk, and has slightly better metabolic stability. While Ligand A has a slightly better binding affinity and half-life, the advantages of Ligand B in ADME properties, particularly the significantly lower DILI risk, outweigh this small difference in potency.
**Conclusion:**
Ligand B is the more promising drug candidate due to its superior ADME profile, particularly its lower DILI risk and better TPSA/logP values.
Output:
0
2025-04-17 20:55:02,935 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Step-by-step comparison:**
1. **MW:** Both ligands (348.407 and 351.422 Da) fall comfortably within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (109.22) is higher than Ligand B (66.65). While both are acceptable, Ligand B is significantly better, being well below the 140 threshold for oral absorption and more favorable for GPCRs.
3. **logP:** Ligand A (-0.692) is a bit low, potentially hindering permeability. Ligand B (2.289) is within the optimal 1-3 range. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (2) and Ligand B (0) are both acceptable, though lower is generally preferred for better permeability.
5. **HBA:** Ligand A (6) and Ligand B (4) are both within the acceptable range of <=10.
6. **QED:** Both ligands have good QED scores (0.732 and 0.835), indicating good drug-like properties.
7. **DILI:** Ligand A (48.662) has a higher DILI risk than Ligand B (24.855), which is a clear advantage for Ligand B.
8. **BBB:** Ligand B (88.174) shows much better BBB penetration potential than Ligand A (50.95). This is a key consideration for a GPCR target, even a cardiovascular one, as some CNS off-target effects are possible.
9. **Caco-2:** Ligand A (-5.221) and Ligand B (-4.486) are both negative, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
10. **Solubility:** Ligand A (-1.83) and Ligand B (-2.448) are both poor, but similar.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.042 and 0.451), which is excellent.
12. **Cl_mic:** Ligand A (2.461) has a much lower microsomal clearance than Ligand B (43.687), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (3.87) has a shorter in vitro half-life than Ligand B (-2.584). Negative half-life is not possible, so this value is suspect and should be investigated. Assuming it's a positive value, Ligand B would be preferred.
14. **Pgp:** Ligand A (0.008) has very low P-gp efflux liability, while Ligand B (0.134) is slightly higher. This favors Ligand A.
15. **Binding Affinity:** Both ligands have the same binding affinity (-5.9 kcal/mol), so this parameter doesn't differentiate them.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, BBB, and affinity are crucial. Ligand B excels in logP and BBB, and has a much better TPSA. While Ligand A has better metabolic stability (Cl_mic) and Pgp efflux, the improvements in permeability and BBB penetration offered by Ligand B are more important for a GPCR target.
**Conclusion:**
Considering the balance of properties and the priorities for a GPCR target, **Ligand B is the more promising drug candidate.**
0
2025-04-17 20:55:02,935 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (349.475 and 352.475 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (70.67) is better than Ligand B (89.87). For a cardiovascular GPCR, TPSA should be kept low to facilitate good absorption, and ideally under 140. Ligand A is much closer to the ideal.
**3. logP:** Both ligands have acceptable logP values (0.93 and 1.196), falling within the 1-3 range. Ligand B is slightly higher, which could potentially lead to slight solubility issues, but it's not a major concern.
**4. H-Bond Donors:** Ligand A (2) is preferable to Ligand B (3). Lower HBD generally improves permeability.
**5. H-Bond Acceptors:** Both ligands have the same number of HBA (4), which is well within the acceptable limit of 10.
**6. QED:** Both ligands have similar QED values (0.64 and 0.693), indicating good drug-likeness.
**7. DILI Risk:** Both ligands have very similar, and acceptable, DILI risk (11.09 and 10.934 percentile).
**8. BBB Penetration:** Both ligands have similar BBB penetration (53.664 and 52.966 percentile). While higher is better, this isn't a primary concern for a cardiovascular target.
**9. Caco-2 Permeability:** Ligand A (-4.914) is better than Ligand B (-4.971). Higher Caco-2 permeability suggests better intestinal absorption.
**10. Aqueous Solubility:** Ligand A (-1.453) is better than Ligand B (-2.067). Better solubility is always preferred.
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.16 and 0.144 percentile), which is excellent.
**12. Microsomal Clearance:** Ligand A (14.041) is significantly worse than Ligand B (3.338). Lower clearance indicates better metabolic stability. This is a significant advantage for Ligand B.
**13. In vitro Half-Life:** Ligand B (11.816) has a much longer half-life than Ligand A (-1.223). This is a substantial advantage for Ligand B.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.038 and 0.012 percentile), which is excellent.
**15. Binding Affinity:** Both ligands have the same binding affinity (-7.3 kcal/mol), which is excellent.
**Overall Assessment:**
While Ligand B has superior metabolic stability (lower Cl_mic) and a longer half-life, Ligand A has better TPSA, Caco-2 permeability, and solubility. Given the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), and the fact that the binding affinity is identical, the slight improvements in absorption and solubility of Ligand A are more valuable than the metabolic advantages of Ligand B. The difference in Cl_mic is not large enough to outweigh the benefits of better absorption.
Output:
1
2025-04-17 20:55:02,935 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (360.445 & 384.611 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (75.27) is higher than Ligand B (40.62). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for permeability. Ligand B is significantly better.
3. **logP:** Both ligands have good logP values (2.971 & 3.255), falling within the optimal 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Ligand A has 2 HBD, while Ligand B has 0. Lower HBD is generally preferable for permeability, giving an edge to Ligand B.
5. **HBA:** Ligand A has 3 HBA, and Ligand B has 4. Both are acceptable (<=10), but again, lower is slightly favored.
6. **QED:** Both ligands have similar QED values (0.621 & 0.659), indicating good drug-like properties. No significant difference.
7. **DILI:** Ligand A (45.25) has a higher DILI risk than Ligand B (29.391). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (87.631) has a higher BBB percentile than Ligand B (76.735). While ADRB2 isn't a primary CNS target, some CNS penetration can be acceptable or even desirable for off-target effects, and Ligand A is better here.
9. **Caco-2:** Ligand A (-4.543) has a worse Caco-2 permeability than Ligand B (-5.076). Lower values are worse, so Ligand B is better.
10. **Solubility:** Ligand A (-3.188) has slightly better solubility than Ligand B (-3.739). Solubility is important, but not a primary concern given the logP values.
11. **hERG:** Ligand A (0.36) has a lower hERG risk than Ligand B (0.678). This is a significant advantage for Ligand A, as hERG inhibition can lead to cardiotoxicity.
12. **Cl_mic:** Ligand B (84.704) has a significantly higher microsomal clearance than Ligand A (27.778). This means Ligand A is more metabolically stable, a desirable trait.
13. **t1/2:** Ligand A (-14.197) has a worse in vitro half-life than Ligand B (0.104). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.095) has lower P-gp efflux than Ligand B (0.521). Lower P-gp efflux is preferable for bioavailability.
15. **Binding Affinity:** Ligand B (-5.7) has a significantly stronger binding affinity than Ligand A (-2.0). This is a substantial advantage, potentially outweighing some ADME concerns.
**Overall Assessment:**
Ligand B has a superior binding affinity, better predicted permeability (lower TPSA, better Caco-2), lower DILI risk, and a longer half-life. While Ligand A has better hERG and Pgp properties, the substantial affinity advantage of Ligand B, coupled with the lower DILI risk, makes it the more promising candidate. The higher affinity is likely to allow for a lower dose, potentially mitigating some of the ADME concerns.
Output:
0
2025-04-17 20:55:02,935 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (342.399 Da and 347.419 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (68.62) is significantly better than Ligand B (108.62). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 A^2 threshold. Ligand B is approaching the upper limit, potentially hindering absorption.
3. **logP:** Ligand A (1.56) is slightly better than Ligand B (0.762). Both are within the optimal 1-3 range, but Ligand B is closer to the lower bound, which could impact permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (6). Fewer HBAs generally improve permeability.
6. **QED:** Ligand A (0.895) is significantly better than Ligand B (0.653), indicating a more drug-like profile.
7. **DILI:** Both ligands have similar DILI risk (51.493 and 50.174), and both are acceptable (below 60).
8. **BBB:** Ligand A (90.035) is much better than Ligand B (53.587). While not a primary concern for a cardiovascular target, higher BBB penetration isn't necessarily *detrimental*.
9. **Caco-2:** Ligand A (-4.532) is better than Ligand B (-5.244). Higher (less negative) values indicate better permeability.
10. **Solubility:** Ligand A (-2.674) is slightly better than Ligand B (-2.524). Both are poor, but Ligand A is marginally better.
11. **hERG:** Ligand A (0.449) is better than Ligand B (0.257). Lower hERG inhibition is crucial for avoiding cardiotoxicity, especially for a cardiovascular target.
12. **Cl_mic:** Ligand B (42.621) is better than Ligand A (49.932). Lower clearance is preferred for greater metabolic stability.
13. **t1/2:** Ligand B (11.846) is slightly better than Ligand A (10.831). Longer half-life is generally desirable.
14. **Pgp:** Ligand A (0.027) is significantly better than Ligand B (0.032). Lower P-gp efflux is preferable for better bioavailability.
15. **Binding Affinity:** Ligand A (-6.1) is slightly better than Ligand B (-5.4). A 0.7 kcal/mol difference is significant and can outweigh some ADME drawbacks.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A excels in TPSA, Pgp, and affinity, and is comparable in logP. While Ligand B has slightly better metabolic stability (Cl_mic and t1/2), the superior overall profile of Ligand A, particularly its better TPSA, Pgp, hERG, and binding affinity, makes it the more promising candidate. The slightly better affinity of Ligand A is also a significant advantage.
**Conclusion:**
Ligand A presents a more balanced and favorable profile for development as a drug candidate targeting ADRB2.
Output:
1
2025-04-17 20:55:02,935 - INFO - Batch 220 complete. Total preferences: 3520
2025-04-17 20:55:02,935 - INFO - Processing batch 221/512...
2025-04-17 20:55:57,357 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (359.348 and 350.503 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (68.46) is slightly higher than Ligand B (58.64). Both are below the 140 A^2 threshold for good oral absorption, but B is better.
**3. logP:** Both ligands have good logP values (2.439 and 2.903), falling within the optimal 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability.
**4. H-Bond Donors:** Ligand A has 0 HBD, while Ligand B has 1. Both are acceptable, but lower is generally preferred for GPCR ligands to enhance permeability.
**5. H-Bond Acceptors:** Ligand A has 5 HBA, and Ligand B has 3. Both are below the 10 threshold.
**6. QED:** Ligand A (0.826) has a significantly better QED score than Ligand B (0.685), indicating a more drug-like profile.
**7. DILI Risk:** Ligand A (41.411) has a much lower DILI risk than Ligand B (8.298), which is a crucial factor.
**8. BBB Penetration:** Ligand A (99.186) exhibits excellent BBB penetration, while Ligand B (83.443) is good but lower. Given that ADRB2 is a GPCR, BBB penetration is a desirable property, though not strictly essential for peripheral targets.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale isn't specified, so it's difficult to interpret.
**10. Aqueous Solubility:** Both ligands have negative solubility values, also unusual.
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.298 and 0.404). This is excellent.
**12. Microsomal Clearance:** Ligand A (6.165) has a lower microsomal clearance than Ligand B (84.845), suggesting better metabolic stability.
**13. In vitro Half-Life:** Ligand B (-8.323) has a significantly longer in vitro half-life than Ligand A (1.262). This is a major advantage.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.115 and 0.116).
**15. Binding Affinity:** Ligand B (-7.1 kcal/mol) has a substantially stronger binding affinity than Ligand A (-1.5 kcal/mol). This is a very significant difference.
**Overall Assessment:**
Ligand B has a much stronger binding affinity and a significantly longer half-life, which are critical for efficacy and dosing. However, it has a higher DILI risk and lower BBB penetration. Ligand A has a better safety profile (lower DILI) and excellent BBB penetration, but its affinity is very weak.
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), the strong affinity of Ligand B outweighs the slightly higher DILI risk and lower BBB. The difference in affinity is substantial (>5.6 kcal/mol), which is a major advantage. The DILI risk of Ligand B is still relatively low.
Output:
0
2025-04-17 20:55:57,357 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [345.399, 84.67, 1.163, 1, 5, 0.81, 54.634, 57.425, -4.646, -2.124, 0.052, 11.524, -9.596, 0.024, -6.2]
**Ligand B:** [367.471, 105.64, 1.768, 2, 5, 0.511, 45.715, 55.487, -5.839, -3.07, 0.243, 6.121, 17.608, 0.161, -7.1]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal 200-500 Da range. A (345.4) is slightly preferred.
2. **TPSA:** A (84.67) is excellent, well below the 140 threshold, and good for GPCRs. B (105.64) is still reasonable, but less optimal.
3. **logP:** Both are within the 1-3 range (A: 1.163, B: 1.768). B is slightly higher, which could be a minor concern for solubility, but not a dealbreaker.
4. **HBD:** A (1) is better than B (2). Lower HBD generally improves permeability.
5. **HBA:** Both have 5 HBA, which is acceptable.
6. **QED:** A (0.81) is significantly better than B (0.511), indicating a more drug-like profile.
7. **DILI:** A (54.634) is slightly higher than B (45.715), but both are below the concerning 60% threshold. B is preferred here.
8. **BBB:** Both have similar BBB penetration (A: 57.425, B: 55.487). Not a major differentiating factor for a non-CNS target like ADRB2, but still considered.
9. **Caco-2:** A (-4.646) is better than B (-5.839), indicating better intestinal absorption.
10. **Solubility:** A (-2.124) is better than B (-3.07), indicating better aqueous solubility.
11. **hERG:** A (0.052) is significantly better than B (0.243), indicating a lower risk of cardiotoxicity, which is *critical* for a cardiovascular target.
12. **Cl_mic:** A (11.524) is better than B (6.121), suggesting better metabolic stability.
13. **t1/2:** A (-9.596) is much better than B (17.608), indicating a longer half-life.
14. **Pgp:** A (0.024) is significantly better than B (0.161), indicating less P-gp efflux.
15. **Affinity:** B (-7.1) has a 0.9 kcal/mol advantage in binding affinity over A (-6.2). This is a substantial difference.
**Overall Assessment:**
While Ligand B has a better binding affinity, Ligand A demonstrates a significantly better overall profile regarding ADME-Tox properties, particularly hERG inhibition, metabolic stability, and P-gp efflux. For a cardiovascular target, minimizing cardiotoxicity (hERG) is paramount. The improved solubility, permeability, and drug-likeness of Ligand A also contribute to its higher potential for success. The affinity difference, while notable, can potentially be optimized in subsequent iterations of drug design.
Therefore, I prefer Ligand A.
Output:
1
2025-04-17 20:55:57,357 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (377.5 and 367.6 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (79.4) is higher than Ligand B (38.8). For a GPCR, lower TPSA is generally preferred for better permeability, giving a slight edge to Ligand B.
**3. logP:** Ligand B (3.37) is higher than Ligand A (-0.54). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but a logP between 1-3 is ideal. Ligand B is within this range, while Ligand A is significantly lower, potentially impacting membrane permeability. This favors Ligand B.
**4. H-Bond Donors:** Both have 0 HBD, which is good.
**5. H-Bond Acceptors:** Ligand A has 6 HBA, Ligand B has 4. Both are within the acceptable range of <=10.
**6. QED:** Both ligands have similar QED values (0.565 and 0.555), indicating good drug-likeness.
**7. DILI Risk:** Ligand A (27.3) has a considerably higher DILI risk than Ligand B (12.1). This is a significant advantage for Ligand B.
**8. BBB Penetration:** Ligand B (84.7) has much better BBB penetration than Ligand A (63.1). While not critical for a cardiovascular target, it's a positive attribute.
**9. Caco-2 Permeability:** Both have negative Caco-2 values (-4.65 and -4.82), which is unusual and suggests poor permeability. However, the values are similar.
**10. Aqueous Solubility:** Ligand A (-1.32) has better aqueous solubility than Ligand B (-3.94). Solubility is important, but can be addressed through formulation.
**11. hERG Inhibition:** Ligand A (0.58) has a slightly lower hERG risk than Ligand B (0.71), which is preferable.
**12. Microsomal Clearance:** Ligand B (115.3) has significantly higher microsomal clearance than Ligand A (32.2). This means Ligand B will be metabolized much faster, potentially leading to lower bioavailability and requiring more frequent dosing. This is a major drawback for Ligand B.
**13. In vitro Half-Life:** Ligand A (-46.6) has a much longer in vitro half-life than Ligand B (7.3). This is a significant advantage for Ligand A.
**14. P-gp Efflux:** Both have low P-gp efflux liability (0.007 and 0.663).
**15. Binding Affinity:** Ligand B (-6.6) has a slightly better binding affinity than Ligand A (-5.3). While a 1.3 kcal/mol difference is good, it's not substantial enough to outweigh the ADME concerns with Ligand B.
**Overall Assessment:**
Ligand B initially appears attractive due to its better logP, lower TPSA, and slightly better binding affinity. However, its significantly higher DILI risk and substantially higher microsomal clearance/lower half-life are major concerns. Ligand A, despite its lower logP and higher TPSA, has a much more favorable safety profile (lower DILI) and better metabolic stability (lower clearance/longer half-life). Given the importance of metabolic stability for *in vivo* efficacy, and the acceptable (though not ideal) ADME properties of Ligand A, I believe it is the more promising candidate.
Output:
1
2025-04-17 20:55:57,357 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, the key priorities are logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB.
Let's compare the ligands property by property:
1. **MW:** Both ligands (364.421 and 334.379 Da) are within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (58.12) is significantly better than Ligand B (75.19). Lower TPSA is preferred for GPCRs, aiding permeability.
3. **logP:** Both ligands have good logP values (2.838 and 2.649), falling within the optimal 1-3 range.
4. **HBD/HBA:** Both have acceptable HBD (1) and HBA (5/4) counts.
5. **QED:** Ligand A (0.906) has a higher QED score than Ligand B (0.796), indicating better overall drug-likeness.
6. **DILI:** Ligand B (76.89) has a higher DILI risk than Ligand A (62.001), which is concerning.
7. **BBB:** Ligand A (80.225) has a better BBB percentile than Ligand B (68.011), although this is less critical for a cardiovascular target.
8. **Caco-2:** Both have similar, very negative Caco-2 values, suggesting poor permeability.
9. **Solubility:** Ligand A (-4.11) has slightly better solubility than Ligand B (-3.194), but both are quite poor.
10. **hERG:** Ligand A (0.314) has a lower hERG risk than Ligand B (0.584).
11. **Cl_mic:** Ligand A (33.348) has a lower microsomal clearance, suggesting better metabolic stability than Ligand B (60.427).
12. **t1/2:** Ligand B (51.557) has a longer in vitro half-life than Ligand A (16.609).
13. **Pgp:** Ligand A (0.282) has lower P-gp efflux liability than Ligand B (0.114), which is favorable for bioavailability.
14. **Binding Affinity:** Ligand B (-8.8 kcal/mol) has a slightly better binding affinity than Ligand A (-8.3 kcal/mol). The difference is 0.5 kcal/mol, which is not substantial enough to overcome the other disadvantages of Ligand B.
**Overall Assessment:**
Ligand A is the better candidate. While Ligand B has a slightly better binding affinity, Ligand A excels in critical ADME properties like TPSA, QED, DILI risk, metabolic stability (Cl_mic), and P-gp efflux. The lower TPSA and better QED of Ligand A suggest better overall drug-like properties and potential for oral absorption. The lower DILI risk is also a significant advantage. The slightly shorter half-life of Ligand A can be addressed through formulation strategies if needed.
Output:
1
2025-04-17 20:55:57,357 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
Let's break down the comparison, prioritizing GPCR-relevant properties as outlined in the guidelines.
1. **Molecular Weight:** Both ligands (341.37 & 340.47 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (86.36) is higher than Ligand B (58.2). For a cardiovascular GPCR, TPSA isn't *as* critical as for CNS targets, but lower is still preferable for absorption. Ligand B has a clear advantage.
3. **logP:** Both ligands have good logP values (2.98 & 3.12), falling within the 1-3 optimal range. Very similar.
4. **H-Bond Donors/Acceptors:** Ligand A (1 HBD, 6 HBA) is better than Ligand B (2 HBD, 2 HBA). Fewer hydrogen bonds generally improve membrane permeability.
5. **QED:** Both ligands have similar QED values (0.737 and 0.714), indicating good drug-likeness.
6. **DILI Risk:** This is a major differentiating factor. Ligand A has a very high DILI risk (94.96%), while Ligand B has a low risk (29.66%). This is a critical negative for Ligand A.
7. **BBB Penetration:** While not the primary concern for a cardiovascular target, Ligand A (82.67%) shows better BBB penetration than Ligand B (65.84%).
8. **Caco-2 Permeability:** Both have negative Caco-2 values, indicating poor permeability.
9. **Aqueous Solubility:** Both ligands have poor aqueous solubility (-4.662 and -4.141).
10. **hERG Inhibition:** Both ligands have low hERG inhibition risk (0.564 and 0.549).
11. **Microsomal Clearance:** Ligand A (90.71) has higher clearance than Ligand B (61.76), indicating lower metabolic stability.
12. **In vitro Half-Life:** Ligand A (109.84 hours) has a significantly longer half-life than Ligand B (2.66 hours). This is a substantial advantage for Ligand A.
13. **P-gp Efflux:** Ligand A (0.602) has higher P-gp efflux than Ligand B (0.281), which is less desirable.
14. **Binding Affinity:** Ligand B (-5.2 kcal/mol) has a significantly better binding affinity than Ligand A (-3.5 kcal/mol). This is a substantial advantage for Ligand B.
**Overall Assessment:**
Despite Ligand A's longer half-life and better BBB penetration, its extremely high DILI risk and higher P-gp efflux are major drawbacks. Ligand B, while having a shorter half-life, exhibits a much more favorable safety profile (low DILI) and significantly stronger binding affinity. The superior affinity of Ligand B is a crucial advantage for a GPCR target, and the lower DILI risk is paramount. The shorter half-life can be addressed through formulation or structural modifications.
Output:
0
2025-04-17 20:55:57,357 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B, followed by the final output:
**1. Molecular Weight (MW):**
* Ligand A: 390.893 Da - Within the ideal range (200-500 Da).
* Ligand B: 367.837 Da - Also within the ideal range.
* *No clear advantage.*
**2. Topological Polar Surface Area (TPSA):**
* Ligand A: 106.00 - Acceptable for oral absorption (<140), but not optimal for a GPCR.
* Ligand B: 121.44 - Higher TPSA, less favorable for permeability.
* *Ligand A is slightly better.*
**3. Lipophilicity (logP):**
* Ligand A: -0.199 - Below the optimal range (1-3). Could have permeability issues.
* Ligand B: 0.616 - Closer to the optimal range, but still on the lower side.
* *Ligand B is better.*
**4. H-Bond Donors (HBD):**
* Ligand A: 3 - Within the acceptable limit (<=5).
* Ligand B: 3 - Within the acceptable limit (<=5).
* *No clear advantage.*
**5. H-Bond Acceptors (HBA):**
* Ligand A: 7 - Within the acceptable limit (<=10).
* Ligand B: 6 - Within the acceptable limit (<=10).
* *No clear advantage.*
**6. QED:**
* Ligand A: 0.595 - Good drug-like properties.
* Ligand B: 0.5 - Still acceptable, but slightly lower than Ligand A.
* *Ligand A is better.*
**7. DILI Risk:**
* Ligand A: 41.218 - Low risk.
* Ligand B: 61.691 - Moderate risk, but still not extremely high.
* *Ligand A is better.*
**8. BBB Penetration:**
* Ligand A: 9.732 - Very low, not favorable.
* Ligand B: 31.136 - Still low, but significantly better than Ligand A.
* *Ligand B is better.*
**9. Caco-2 Permeability:**
* Ligand A: -5.393 - Poor permeability.
* Ligand B: -5.26 - Also poor permeability, but slightly better than Ligand A.
* *Ligand B is slightly better.*
**10. Aqueous Solubility:**
* Ligand A: -0.805 - Poor solubility.
* Ligand B: -2.036 - Worse solubility than Ligand A.
* *Ligand A is better.*
**11. hERG Inhibition:**
* Ligand A: 0.118 - Low risk.
* Ligand B: 0.193 - Slightly higher risk, but still low.
* *Ligand A is better.*
**12. Microsomal Clearance:**
* Ligand A: -28.36 - Low clearance, good metabolic stability.
* Ligand B: -6.235 - Higher clearance, less metabolic stability.
* *Ligand A is better.*
**13. In vitro Half-Life:**
* Ligand A: 16.02 - Good half-life.
* Ligand B: -6.571 - Very short half-life.
* *Ligand A is significantly better.*
**14. P-gp Efflux:**
* Ligand A: 0.05 - Low efflux, favorable.
* Ligand B: 0.014 - Very low efflux, even more favorable.
* *Ligand B is better.*
**15. Binding Affinity:**
* Ligand A: -5.1 kcal/mol - Good affinity.
* Ligand B: -7.0 kcal/mol - Significantly better affinity.
* *Ligand B is significantly better.*
**Overall Assessment:**
This is a challenging comparison. Ligand B has a significantly better binding affinity (-7.0 vs -5.1 kcal/mol), which is a major advantage for a GPCR target. It also has better BBB penetration and P-gp efflux. However, it suffers from lower solubility and higher DILI risk. Ligand A has better solubility, lower DILI, better metabolic stability, and a better half-life.
Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity), the superior binding affinity of Ligand B is the most important factor. While its logP is still on the lower side, the strong binding could compensate. The slightly higher DILI risk is a concern, but manageable with further optimization. The poor solubility of Ligand B is a concern, but formulation strategies can often address this.
Therefore, I would prioritize Ligand B due to its significantly stronger binding affinity.
Output:
0
2025-04-17 20:55:57,358 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (391.446 and 364.833 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (96.88 and 96.25) are reasonably close to the 140 A^2 threshold for oral absorption. They are also below the 90 A^2 threshold for CNS targets, which isn't a primary concern for ADRB2 (a cardiovascular target).
3. **logP:** Ligand A (-0.04) is slightly lower than optimal (1-3), potentially impacting permeability. Ligand B (1.728) is within the optimal range. This favors Ligand B.
4. **HBD:** Ligand A (0) is excellent, minimizing potential issues with hydrogen bonding and maximizing permeability. Ligand B (3) is acceptable, but slightly less favorable.
5. **HBA:** Ligand A (7) is good, well below the 10 threshold. Ligand B (5) is also good.
6. **QED:** Both ligands (0.715 and 0.752) have good drug-likeness scores, exceeding the 0.5 threshold.
7. **DILI:** Ligand A (78.054) has a higher DILI risk than Ligand B (63.513). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (72.819) has a better BBB penetration score than Ligand B (47.15). While ADRB2 isn't a CNS target, higher BBB penetration can sometimes correlate with better overall distribution. However, this is a lower priority.
9. **Caco-2:** Ligand A (-4.719) has a very poor Caco-2 permeability, indicating poor intestinal absorption. Ligand B (-5.016) is also poor, but slightly better.
10. **Solubility:** Ligand A (-2.416) has poor aqueous solubility. Ligand B (-3.168) is also poor, but worse than Ligand A.
11. **hERG:** Both ligands (0.274 and 0.258) have low hERG inhibition liability, which is excellent.
12. **Cl_mic:** Ligand A (5.063) has significantly lower microsomal clearance than Ligand B (17.265), suggesting better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (-8.167) has a negative in vitro half-life, indicating very rapid metabolism. Ligand B (55.757) has a much more favorable half-life. This is a major advantage for Ligand B.
14. **Pgp:** Both ligands (0.116 and 0.106) have low P-gp efflux liability, which is good.
15. **Binding Affinity:** Ligand A (-6.7 kcal/mol) has a slightly better binding affinity than Ligand B (-4.5 kcal/mol). This is a 2.2 kcal/mol difference, which is substantial and could outweigh some ADME drawbacks.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand B has a better logP. Both have good TPSA and Pgp. Ligand A has a significantly better affinity. However, the poor Caco-2 permeability, very short half-life, and poor solubility of Ligand A are major concerns. The DILI risk is also higher for Ligand A. Ligand B, while having lower affinity, has a much more balanced profile with better metabolic stability and a lower DILI risk.
**Conclusion:**
Despite the slightly better binding affinity of Ligand A, the significant ADME liabilities (poor permeability, short half-life, poor solubility, and higher DILI risk) make it a less viable drug candidate. Ligand B, with its more balanced profile and better metabolic stability, is the preferred choice.
Output:
0
2025-04-17 20:55:57,358 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (363.483 Da and 350.547 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (62.74) is slightly higher than Ligand B (49.41). Both are below the 140 A^2 threshold for oral absorption, but Ligand B is better positioned, particularly for potential CNS penetration (though not a primary goal for ADRB2).
**3. logP:** Ligand A (1.706) is within the optimal 1-3 range. Ligand B (4.302) is higher, potentially leading to solubility issues and off-target interactions. This is a significant negative for Ligand B.
**4. H-Bond Donors:** Ligand A (0) and Ligand B (1) are both acceptable.
**5. H-Bond Acceptors:** Ligand A (5) and Ligand B (2) are both acceptable.
**6. QED:** Ligand A (0.799) has a better QED score than Ligand B (0.63), indicating a more drug-like profile.
**7. DILI:** Ligand A (27.026) has a significantly lower DILI risk than Ligand B (17.72), which is a positive. Lower percentile is better.
**8. BBB:** Ligand A (69.252) and Ligand B (77.007) are both acceptable, but not exceptionally high. Since ADRB2 is primarily a cardiovascular target, BBB penetration isn't a major priority.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.859) is slightly better than Ligand B (-4.632).
**10. Aqueous Solubility:** Ligand A (-1.711) is better than Ligand B (-3.844). Solubility is a concern for Ligand B given its higher logP.
**11. hERG Inhibition:** Ligand A (0.249) has a much lower hERG inhibition risk than Ligand B (0.666). This is a critical advantage for Ligand A, as hERG inhibition can lead to cardiotoxicity.
**12. Microsomal Clearance:** Ligand A (33.83) has lower microsomal clearance than Ligand B (55.968), suggesting better metabolic stability.
**13. In vitro Half-Life:** Ligand A (13.723) has a longer half-life than Ligand B (3.78), which is desirable.
**14. P-gp Efflux:** Ligand A (0.088) has lower P-gp efflux than Ligand B (0.333), indicating better bioavailability.
**15. Binding Affinity:** Ligand A (-7.7) has a slightly better binding affinity than Ligand B (-7.4), although the difference is relatively small.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand A is the stronger candidate. While the binding affinity difference isn't huge, Ligand A excels in ADME properties: better logP, QED, DILI risk, solubility, hERG inhibition, metabolic stability, half-life, and P-gp efflux. Ligand B's high logP and associated solubility concerns, coupled with its higher DILI and hERG risk, make it a less favorable choice. The Caco-2 values are concerning for both, but Ligand A is still better.
Output:
1
2025-04-17 20:55:57,358 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (359.373 and 348.531 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (95.67) is higher than Ligand B (58.2). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for better absorption. Ligand B has a substantial advantage here.
**3. logP:** Ligand A (1.568) is within the optimal 1-3 range. Ligand B (3.793) is slightly higher, approaching the upper limit, which could potentially lead to solubility issues or off-target interactions. Ligand A is preferable.
**4. H-Bond Donors:** Both ligands have 2 HBD, which is acceptable.
**5. H-Bond Acceptors:** Ligand A has 5 HBA, while Ligand B has 2. Both are within the acceptable limit of 10.
**6. QED:** Ligand A (0.77) has a slightly better QED score than Ligand B (0.688), indicating a more drug-like profile.
**7. DILI Risk:** Ligand A (43.234) has a higher DILI risk than Ligand B (27.685). This is a significant advantage for Ligand B.
**8. BBB Penetration:** Both ligands have reasonable BBB penetration (Ligand A: 75.572, Ligand B: 71.539). Since this is a cardiovascular target, BBB penetration is not a primary concern, but higher is generally better. Ligand A is slightly better.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.595 and -4.679). These values are unusual and suggest poor permeability, but the values are very similar.
**10. Aqueous Solubility:** Ligand A (-2.485) has better aqueous solubility than Ligand B (-4.778). This is a positive for Ligand A.
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (Ligand A: 0.261, Ligand B: 0.351). This is good for both.
**12. Microsomal Clearance:** Ligand B (63.466) has significantly higher microsomal clearance than Ligand A (33.281), indicating faster metabolism and potentially lower *in vivo* exposure. Ligand A is preferable.
**13. In vitro Half-Life:** Ligand A (-38.058) has a much longer *in vitro* half-life than Ligand B (-1.624). This is a major advantage for Ligand A, suggesting less frequent dosing.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (Ligand A: 0.028, Ligand B: 0.237).
**15. Binding Affinity:** Both ligands have very similar and strong binding affinities (-6.1 and -6.3 kcal/mol). The difference is negligible.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand A appears to be the better candidate. While Ligand B has lower DILI risk and a lower TPSA, Ligand A has better logP, solubility, metabolic stability (lower Cl_mic, longer t1/2), and a slightly better QED score. The difference in binding affinity is minimal. The longer half-life and better metabolic stability of Ligand A are particularly important for a cardiovascular drug, where sustained exposure is often desirable.
Output:
1
2025-04-17 20:55:57,358 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [351.403, 120.67 , 1.136, 4. , 5. , 0.393, 46.762, 61.807, -5.403, -2.101, 0.274, 18.561, 13.527, 0.061, -6.7 ]
**Ligand B:** [346.387, 105.82 , 1.484, 2. , 6. , 0.812, 50.136, 49.787, -5.144, -2.436, 0.062, -14.384, 25.431, 0.029, -7.2 ]
Here's a step-by-step comparison, keeping GPCR priorities (logP, Pgp, TPSA, affinity) in mind:
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (346.387) is slightly lower, which is generally favorable.
2. **TPSA:** Ligand A (120.67) is a bit higher than Ligand B (105.82). Both are below the 140 threshold for good oral absorption, but B is better.
3. **logP:** Both are within the optimal range (1-3). Ligand B (1.484) is slightly higher, potentially offering better membrane permeability.
4. **HBD:** Ligand A (4) is higher than Ligand B (2). Lower is generally better for permeability, favoring B.
5. **HBA:** Ligand B (6) is higher than Ligand A (5). Again, lower is generally better, favoring A slightly.
6. **QED:** Ligand B (0.812) has a significantly better QED score than Ligand A (0.393), indicating a more drug-like profile. This is a substantial advantage for B.
7. **DILI:** Both are acceptable, but Ligand A (46.762) is slightly lower than Ligand B (50.136), indicating a marginally lower risk of liver injury.
8. **BBB:** Ligand A (61.807) has a better BBB penetration percentile than Ligand B (49.787). While ADRB2 is cardiovascular, some CNS off-target effects are possible, so this is a slight advantage for A.
9. **Caco-2:** Both have negative values, which is unusual and suggests poor permeability. The values are similar, so this doesn't differentiate them.
10. **Solubility:** Both have negative values, which is also unusual and suggests poor solubility. The values are similar, so this doesn't differentiate them.
11. **hERG:** Both are very low, indicating minimal hERG inhibition risk. This is excellent for both.
12. **Cl_mic:** Ligand B (-14.384) has a *much* lower (better) microsomal clearance than Ligand A (18.561), indicating greater metabolic stability. This is a significant advantage for B.
13. **t1/2:** Ligand B (25.431) has a longer in vitro half-life than Ligand A (13.527), which is desirable.
14. **Pgp:** Both are very low, indicating minimal P-gp efflux. This is excellent for both.
15. **Affinity:** Ligand B (-7.2) has a slightly stronger binding affinity than Ligand A (-6.7). While the difference is not huge, it's enough to be considered.
**Overall Assessment:**
Ligand B demonstrates a superior profile overall. Its better QED, significantly improved metabolic stability (Cl_mic), longer half-life, slightly better logP, and stronger binding affinity outweigh the slightly higher DILI risk and lower BBB penetration. The TPSA is also more favorable. While Ligand A has a slightly better BBB score, the other advantages of Ligand B are more critical for a cardiovascular GPCR target.
Output:
0
2025-04-17 20:55:57,358 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (351.397) is slightly higher than Ligand B (344.375), but both are acceptable.
2. **TPSA:** Ligand A (54.34) is significantly better than Ligand B (122.03). For a GPCR, lower TPSA is generally preferred for better permeability. Ligand B's TPSA is quite high and could hinder oral absorption.
3. **logP:** Ligand A (2.092) is within the optimal range (1-3). Ligand B (-0.049) is below 1, which could indicate poor membrane permeability. This is a significant disadvantage for Ligand B.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (3) is better than Ligand B (7). Similar to HBDs, lower HBA is preferred for permeability.
6. **QED:** Ligand A (0.903) is excellent, indicating a highly drug-like profile. Ligand B (0.606) is still acceptable, but less ideal.
7. **DILI:** Ligand A (22.8) has a much lower DILI risk than Ligand B (60.217). This is a critical advantage for Ligand A.
8. **BBB:** Ligand A (95.967) shows excellent BBB penetration, which is a desirable characteristic for GPCRs, even if not strictly CNS-targeted. Ligand B (24.622) has very poor predicted BBB penetration.
9. **Caco-2:** Ligand A (-4.677) is better than Ligand B (-5.555), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-2.851) is better than Ligand B (-2.056), suggesting better aqueous solubility.
11. **hERG:** Both ligands have low hERG inhibition liability (0.397 and 0.1 respectively), which is good.
12. **Cl_mic:** Ligand A (4.128) has a much lower microsomal clearance than Ligand B (15.07), indicating better metabolic stability.
13. **t1/2:** Ligand A (-0.26) has a better in vitro half-life than Ligand B (3.479).
14. **Pgp:** Ligand A (0.042) has lower P-gp efflux than Ligand B (0.02), which is favorable.
15. **Binding Affinity:** Ligand A (-6.8) is slightly better than Ligand B (-6.3), although the difference is not huge.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most crucial parameters, particularly TPSA, logP, DILI, BBB, Cl_mic, and QED. While the affinity difference is minor, the superior ADME properties of Ligand A make it a much more promising drug candidate for the ADRB2 receptor. Ligand B's high TPSA and low logP are significant drawbacks.
Output:
1
2025-04-17 20:55:57,358 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (364.5 and 386.9 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (65.5 and 67.2) are below the 140 A^2 threshold for good oral absorption, which is good.
3. **logP:** Both ligands (1.84 and 2.28) are within the optimal 1-3 range. Ligand B is slightly higher, potentially improving membrane permeability, but not drastically.
4. **HBD:** Both have 1 HBD, well within the acceptable limit of 5.
5. **HBA:** Both have 5 HBA, also within the acceptable limit of 10.
6. **QED:** Ligand A (0.764) has a slightly higher QED than Ligand B (0.696), indicating a more drug-like profile.
7. **DILI:** Ligand A (24.5) has a significantly lower DILI risk than Ligand B (33.2). This is a major advantage for Ligand A.
8. **BBB:** Both ligands have good BBB penetration (76.3% and 74.7%), which is good, but not critical for ADRB2 as it's primarily a cardiovascular target.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Both have negative solubility values, indicating poor aqueous solubility. This is a significant drawback for both.
11. **hERG:** Both ligands have low hERG inhibition risk (0.441 and 0.401).
12. **Cl_mic:** Ligand A (33.4) has a lower microsomal clearance than Ligand B (44.7), suggesting better metabolic stability.
13. **t1/2:** Ligand A (14.6) has a longer in vitro half-life than Ligand B (-3.3). This is a significant advantage for Ligand A.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.048 and 0.201).
15. **Binding Affinity:** Ligand A (-7.4 kcal/mol) has a stronger binding affinity than Ligand B (-6.7 kcal/mol). This is a 0.7 kcal/mol difference, which is substantial and can outweigh some ADME drawbacks.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are important. Both ligands perform similarly on logP, Pgp, and TPSA. Ligand A has a significantly better affinity.
**Overall Assessment:**
Ligand A is the stronger candidate. It has a superior binding affinity, lower DILI risk, better metabolic stability (lower Cl_mic), and a longer half-life. While both have poor solubility and Caco-2 permeability, the improved potency and safety profile of Ligand A make it more likely to succeed as a drug candidate, despite these drawbacks.
Output:
1
2025-04-17 20:55:57,358 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, key priorities are logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB.
Let's compare the ligands property by property:
1. **MW:** Both ligands (366.439 and 347.379 Da) are within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (84.94) is significantly better than Ligand B (126.82). A TPSA under 140 is good for oral absorption, and under 90 is preferred for CNS targets (less relevant here, but still a positive). Ligand A is much closer to the ideal.
3. **logP:** Ligand A (1.104) is within the optimal 1-3 range. Ligand B (0.555) is slightly below 1, which *could* indicate permeability issues.
4. **HBD/HBA:** Ligand A (1 HBD, 5 HBA) is better than Ligand B (3 HBD, 7 HBA). Fewer H-bonds generally improve permeability.
5. **QED:** Ligand A (0.805) has a better QED score than Ligand B (0.628), indicating better overall drug-likeness.
6. **DILI:** Ligand B (76.386) has a higher DILI risk than Ligand A (56.844). Lower is better.
7. **BBB:** Ligand A (64.599) has a slightly better BBB penetration score than Ligand B (59.325), though both are not particularly high.
8. **Caco-2:** Ligand A (-4.811) is better than Ligand B (-5.204). Higher is better.
9. **Solubility:** Ligand A (-2.384) is better than Ligand B (-2.494). Higher is better.
10. **hERG:** Both ligands have very low hERG inhibition risk (0.123 and 0.065 respectively).
11. **Cl_mic:** Ligand A (-16.598) has much better metabolic stability (lower clearance) than Ligand B (23.42). This is a significant advantage.
12. **t1/2:** Ligand A (60.091) has a longer in vitro half-life than Ligand B (0.796). This is a substantial advantage.
13. **Pgp:** Ligand A (0.042) has a lower P-gp efflux liability than Ligand B (0.021). Lower is better.
14. **Binding Affinity:** Ligand B (-5.2 kcal/mol) has a stronger binding affinity than Ligand A (-3.8 kcal/mol). This is a 1.4 kcal/mol difference, which is substantial.
**Overall Assessment:**
While Ligand B has a better binding affinity, the significant advantages of Ligand A in terms of TPSA, logP, QED, DILI risk, metabolic stability (Cl_mic and t1/2), and Pgp efflux outweigh the affinity difference. The better ADME properties of Ligand A suggest it is more likely to be a viable drug candidate, especially considering the GPCR target class. The lower affinity can potentially be improved through further optimization, but fixing poor ADME properties is often more challenging.
**Output:**
1
2025-04-17 20:55:57,358 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's break down the comparison of Ligand A and Ligand B across all 15 parameters, keeping in mind the GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key).
1. **MW:** Both ligands (343.427 Da and 347.419 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (82.53) is better than Ligand B (93.26). Lower TPSA generally favors better absorption, which is important for oral bioavailability.
3. **logP:** Ligand A (2.112) is slightly better than Ligand B (1.068). Both are within the optimal 1-3 range, but Ligand A is closer to the sweet spot. Ligand B is a bit low, potentially impacting permeability.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1), but both are acceptable.
5. **HBA:** Ligand A (4) is lower than Ligand B (6). Lower HBA is generally preferred for permeability.
6. **QED:** Both ligands have similar and good QED scores (0.708 and 0.732, respectively), indicating good drug-like properties.
7. **DILI:** Ligand A (25.165) has a significantly lower DILI risk than Ligand B (38.736). This is a substantial advantage for Ligand A.
8. **BBB:** Both ligands have similar BBB penetration (56.844 and 57.193). Since ADRB2 isn't a primary CNS target, this isn't a major deciding factor.
9. **Caco-2:** Ligand A (-4.806) is better than Ligand B (-5.282). Higher (less negative) Caco-2 values suggest better intestinal absorption.
10. **Solubility:** Ligand A (-3.17) is better than Ligand B (-0.995). Better solubility is always a plus.
11. **hERG:** Ligand A (0.327) is significantly better than Ligand B (0.093). Lower hERG inhibition is crucial for avoiding cardiotoxicity, a major concern with cardiovascular targets.
12. **Cl_mic:** Ligand B (32.172) has lower microsomal clearance than Ligand A (53.641), suggesting better metabolic stability. This is a positive for Ligand B.
13. **t1/2:** Ligand B (42.746) has a longer in vitro half-life than Ligand A (-18.121). This is a substantial advantage for Ligand B.
14. **Pgp:** Ligand A (0.112) has lower P-gp efflux than Ligand B (0.024). Lower P-gp efflux is preferred for better bioavailability.
15. **Affinity:** Ligand A (-7.2 kcal/mol) has a slightly better binding affinity than Ligand B (-7.0 kcal/mol). While both are good, the slight edge for Ligand A is relevant.
**Overall Assessment:**
Ligand A demonstrates a more balanced profile. It has better TPSA, logP, solubility, DILI risk, hERG inhibition, Caco-2 permeability, and a slightly better binding affinity. While Ligand B has better metabolic stability (lower Cl_mic) and a longer half-life, the lower DILI and hERG risk of Ligand A are critical for a cardiovascular drug candidate. The slightly better absorption characteristics of Ligand A also contribute to its preference.
**Output:**
1
2025-04-17 20:55:57,358 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (374.415 and 350.503 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (131.03) is borderline for good oral absorption (<=140), while Ligand B (55.57) is well within the optimal range. This favors Ligand B.
3. **logP:** Ligand A (-0.694) is a bit low, potentially hindering permeation. Ligand B (4.394) is high, potentially causing solubility and off-target issues. This is a significant drawback for Ligand B.
4. **HBD:** Ligand A (3) is acceptable, while Ligand B (0) is also good. No strong preference.
5. **HBA:** Ligand A (7) is acceptable, and Ligand B (4) is also good. No strong preference.
6. **QED:** Both ligands have good QED scores (0.521 and 0.697), indicating drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (47.732) has a moderate DILI risk, while Ligand B (23.808) has a low DILI risk. This favors Ligand B.
8. **BBB:** Ligand A (35.789) has low BBB penetration, while Ligand B (91.314) has very high BBB penetration. Since ADRB2 is a GPCR, BBB penetration is a consideration, and Ligand B is strongly favored here.
9. **Caco-2:** Ligand A (-6.124) has poor Caco-2 permeability, while Ligand B (-4.23) is also poor. Both are suboptimal.
10. **Solubility:** Ligand A (-2.026) has poor solubility, while Ligand B (-4.58) is even worse. Both are suboptimal, but Ligand B is worse.
11. **hERG:** Both ligands have low hERG inhibition risk (0.217 and 0.803), which is good. No clear advantage.
12. **Cl_mic:** Ligand A (11.248) has lower microsomal clearance, indicating better metabolic stability, while Ligand B (129.877) has high clearance. This favors Ligand A.
13. **t1/2:** Ligand A (-14.304) has a negative in vitro half-life, which is very concerning. Ligand B (-10.591) is also negative, but less so. Both are problematic.
14. **Pgp:** Ligand A (0.044) has low P-gp efflux, while Ligand B (0.629) has moderate P-gp efflux. This favors Ligand A.
15. **Affinity:** Both ligands have comparable binding affinities (-6.9 and -6.3 kcal/mol). The difference is less than 1.5 kcal/mol, so it doesn't heavily sway the decision.
**Overall Assessment:**
Ligand B has a significantly better BBB penetration and lower DILI risk, which are important for a GPCR target. However, it suffers from a high logP, very poor solubility, and high metabolic clearance. Ligand A has better metabolic stability, lower P-gp efflux, and a slightly better solubility profile. The biggest drawback for Ligand A is its poor Caco-2 permeability and negative in vitro half-life.
Considering the overall balance, the poor solubility and high logP of Ligand B are major concerns that would likely lead to significant bioavailability issues. While Ligand A has permeability and half-life issues, these might be more readily addressed through structural modifications. Therefore, I lean towards Ligand A as a starting point for optimization.
Output:
1
2025-04-17 20:55:57,358 - INFO - Here's my reasoning and final decision:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the acceptable range (200-500 Da). Ligand A (357.451) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (62.3) is significantly better than Ligand A (102.34). For a GPCR, lower TPSA is preferred for better brain penetration and overall absorption.
3. **logP:** Ligand B (2.882) is optimal, while Ligand A (-1.055) is too low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (1), but both are acceptable.
5. **HBA:** Ligand A (6) is higher than Ligand B (4), but both are acceptable.
6. **QED:** Ligand B (0.853) is substantially better than Ligand A (0.58), indicating a more drug-like profile.
7. **DILI:** Ligand A (15.51) has a much lower DILI risk than Ligand B (31.02), a significant advantage.
8. **BBB:** Ligand B (76.658) has a much higher BBB penetration potential than Ligand A (27.918). While this is a GPCR target, and not necessarily a CNS target, better BBB penetration can still be a positive.
9. **Caco-2:** Both are similar and quite poor (-5.088 and -5.37).
10. **Solubility:** Ligand A (0.023) has slightly better solubility than Ligand B (-3.12), but both are very poor.
11. **hERG:** Ligand A (0.038) has a much lower hERG risk than Ligand B (0.255), a critical safety parameter.
12. **Cl_mic:** Ligand A (2.049) has significantly lower microsomal clearance than Ligand B (32.82), indicating better metabolic stability.
13. **t1/2:** Ligand B (-1.469) has a longer half-life than Ligand A (6.838), which is generally preferred.
14. **Pgp:** Ligand A (0.003) has much lower P-gp efflux liability than Ligand B (0.279), which is beneficial for bioavailability.
15. **Affinity:** Ligand B (-7.1) has a slightly better binding affinity than Ligand A (-6.1), but the difference is relatively small.
**Overall Assessment:**
Ligand B has a better logP, QED, BBB and t1/2, and a slightly better binding affinity. However, Ligand A has significantly better DILI, hERG, Cl_mic and Pgp profiles, and a more favorable MW. The poor Caco-2 and solubility are concerning for both. Given the cardiovascular context of ADRB2, minimizing hERG risk and maximizing metabolic stability are crucial. Ligand A's superior safety profile (DILI, hERG) and metabolic stability (Cl_mic) outweigh Ligand B's slightly better affinity and BBB penetration. The lower logP of Ligand A is a concern, but can potentially be addressed through further optimization.
Output:
1
2025-04-17 20:55:57,359 - INFO - Batch 221 complete. Total preferences: 3536
2025-04-17 20:55:57,359 - INFO - Processing batch 222/512...
2025-04-17 20:56:44,081 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.5 & 357.5 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (29.77) is significantly better than Ligand A (50.16). Lower TPSA generally favors better absorption, crucial for oral bioavailability. This is a significant advantage for Ligand B.
3. **logP:** Both ligands have good logP values (4.034 & 3.625), falling within the 1-3 range. Ligand B is slightly better.
4. **HBD:** Ligand A (1) is preferable to Ligand B (0). While both are low, having one HBD can sometimes improve solubility without significantly impacting permeability.
5. **HBA:** Ligand B (5) is better than Ligand A (3). Lower HBA is generally preferred.
6. **QED:** Ligand A (0.895) has a better QED score than Ligand B (0.675), indicating a more drug-like profile.
7. **DILI:** Both ligands have low DILI risk (20.28 & 19.70), well below the 40% threshold. No significant difference.
8. **BBB:** Ligand B (88.64) has a much higher BBB penetration percentile than Ligand A (78.79). While ADRB2 isn't strictly a CNS target, some CNS exposure can be beneficial or at least not detrimental for cardiovascular drugs.
9. **Caco-2:** Ligand A (-4.546) is better than Ligand B (-5.173). Higher Caco-2 permeability suggests better intestinal absorption.
10. **Solubility:** Ligand A (-3.636) is better than Ligand B (-2.773). Better solubility is important for formulation and bioavailability.
11. **hERG:** Ligand A (0.588) is better than Ligand B (0.937). Lower hERG inhibition is crucial for avoiding cardiotoxicity, a major concern for cardiovascular drugs.
12. **Cl_mic:** Ligand B (67.26) has lower microsomal clearance than Ligand A (52.68), suggesting better metabolic stability.
13. **t1/2:** Ligand A (23.86) has a longer in vitro half-life than Ligand B (2.95). A longer half-life is generally desirable.
14. **Pgp:** Ligand A (0.296) has a lower Pgp efflux liability than Ligand B (0.576), suggesting better bioavailability and potentially better CNS exposure.
15. **Binding Affinity:** Ligand A (-7.7) has a significantly stronger binding affinity than Ligand B (-5.8). This is a substantial advantage, potentially outweighing some ADME drawbacks.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B excels in TPSA and BBB, while Ligand A has a much stronger affinity and better Pgp efflux. The affinity difference is significant (>1.5 kcal/mol), and the better solubility and hERG profile of Ligand A are also important for a cardiovascular drug.
**Overall Assessment:**
While Ligand B has advantages in TPSA and BBB, the significantly stronger binding affinity of Ligand A, coupled with its better solubility, hERG profile, Pgp efflux, and half-life, makes it the more promising drug candidate. The affinity difference is substantial enough to overcome the slightly higher TPSA.
Output:
1
2025-04-17 20:56:44,081 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [354.407, 99.35, 0.075, 1, 7, 0.705, 37.456, 35.13, -4.737, -0.248, 0.143, -11.965, -8.598, 0.023, -8.1]
**Ligand B:** [369.893, 75.43, 2.426, 1, 5, 0.8, 21.404, 74.758, -4.627, -2.485, 0.239, 48.039, 12.272, 0.174, -3.9]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity) and general drug-like properties:
1. **MW:** Both are within the ideal 200-500 Da range. A (354.4) is slightly better.
2. **TPSA:** A (99.35) is higher than ideal (<140), but B (75.43) is excellent. This favors B.
3. **logP:** A (0.075) is very low, potentially causing permeability issues. B (2.426) is within the optimal 1-3 range. This is a significant advantage for B.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** A has 7, B has 5. Both are acceptable, but B is slightly better.
6. **QED:** Both are good (A: 0.705, B: 0.8), but B is slightly better.
7. **DILI:** A (37.456) is moderate, but B (21.404) is very good (low risk). This favors B.
8. **BBB:** A (35.13) is poor. B (74.758) is quite good, though not exceptional. For a cardiovascular target, BBB isn't *critical*, but it's a bonus.
9. **Caco-2:** Both are negative, indicating poor permeability. A (-4.737) is worse than B (-4.627).
10. **Solubility:** Both are negative, indicating poor solubility. A (-0.248) is slightly better than B (-2.485).
11. **hERG:** Both are low risk (A: 0.143, B: 0.239).
12. **Cl_mic:** A (-11.965) is excellent (low clearance, high metabolic stability). B (48.039) is high clearance, which is a significant drawback.
13. **t1/2:** A (-8.598) is excellent (long half-life). B (12.272) is okay, but not as good.
14. **Pgp:** Both are low efflux (A: 0.023, B: 0.174), which is good.
15. **Affinity:** A (-8.1) is significantly better than B (-3.9). This is a >4 kcal/mol difference, which is a substantial advantage.
**Overall Assessment:**
Ligand A has a much stronger binding affinity and excellent metabolic stability/half-life. However, its extremely low logP is a major concern for permeability and bioavailability. Ligand B has better physicochemical properties (logP, TPSA, DILI, BBB) but significantly weaker binding affinity.
Given the GPCR target class, affinity is paramount. While the low logP of A is a concern, the substantial affinity advantage (-8.1 vs -3.9) is likely to outweigh this drawback, *especially* if formulation strategies can be employed to improve solubility and permeability. The metabolic stability is also a huge plus.
Therefore, I believe Ligand A is the more promising candidate.
Output:
1
2025-04-17 20:56:44,081 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (343.43 and 372.89 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Both ligands have TPSA values (80.32 and 78.87) below the 140 A^2 threshold for good oral absorption. This is good for both.
**3. logP:** Both ligands have logP values (1.656 and 2.379) within the optimal 1-3 range. Ligand B is slightly higher, which *could* be beneficial for membrane permeability, but isn't a major concern for either.
**4. H-Bond Donors:** Both have 2 HBD, well within the acceptable limit of 5.
**5. H-Bond Acceptors:** Both have 4 HBA, also well within the acceptable limit of 10.
**6. QED:** Ligand A (0.608) has a slightly better QED score than Ligand B (0.506), indicating a more drug-like profile.
**7. DILI Risk:** Ligand A (55.68%) has a higher DILI risk than Ligand B (33.42%). This is a significant negative for Ligand A.
**8. BBB Penetration:** Ligand B (67.82%) has better BBB penetration than Ligand A (53.24%). While ADRB2 is a cardiovascular target, some CNS effects are possible with beta-blockers, and better BBB penetration could lead to off-target effects. However, for a cardiovascular target, this isn't a primary driver.
**9. Caco-2 Permeability:** Ligand B (-5.058) has slightly better Caco-2 permeability than Ligand A (-4.843), suggesting better intestinal absorption.
**10. Aqueous Solubility:** Both ligands have poor aqueous solubility (-2.329 and -2.457). This is a concern for both, and formulation strategies would be needed.
**11. hERG Inhibition:** Ligand A (0.216) has a lower hERG inhibition risk than Ligand B (0.402), which is a significant advantage.
**12. Microsomal Clearance:** Ligand B (6.816) has a higher microsomal clearance than Ligand A (15.256), indicating faster metabolism and potentially lower *in vivo* exposure.
**13. In vitro Half-Life:** Ligand A (-6.423) has a much longer *in vitro* half-life than Ligand B (1.585). This is a major advantage for Ligand A, potentially allowing for less frequent dosing.
**14. P-gp Efflux:** Ligand A (0.07) has lower P-gp efflux than Ligand B (0.125), which is favorable for bioavailability.
**15. Binding Affinity:** Ligand B (-5.6 kcal/mol) has a significantly stronger binding affinity than Ligand A (-0.7 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME drawbacks.
**Overall Assessment:**
The key trade-offs are: Ligand B has *much* better binding affinity, slightly better permeability, and lower DILI risk, but suffers from faster metabolism, higher P-gp efflux, and a higher hERG risk. Ligand A has a longer half-life, lower P-gp efflux, and lower hERG risk, but significantly weaker binding.
Given that this is a GPCR target, binding affinity is paramount. The 4.9 kcal/mol difference in binding affinity is substantial. While Ligand B has some ADME liabilities (faster clearance, higher hERG), these can potentially be addressed through further optimization. The weak binding of Ligand A is a more fundamental issue that would be very difficult to overcome.
Therefore, I choose Ligand B.
0
2025-04-17 20:56:44,082 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (356.463 and 348.487 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (77.1) is higher than Ligand B (58.64). While both are below the 140 threshold for oral absorption, GPCRs benefit from lower TPSA, improving permeability. Ligand B is favored.
**3. logP:** Ligand A (0.962) is slightly lower than the optimal 1-3 range, potentially impacting permeability. Ligand B (2.657) is well within the optimal range. Ligand B is favored.
**4. H-Bond Donors:** Both ligands have 1 HBD, which is acceptable.
**5. H-Bond Acceptors:** Ligand A has 5 HBAs, while Ligand B has 3. Both are below the 10 threshold.
**6. QED:** Both ligands have similar QED values (0.666 and 0.686), indicating good drug-likeness.
**7. DILI Risk:** Ligand A (15.859) has a higher DILI risk than Ligand B (10.392). Lower DILI is crucial. Ligand B is favored.
**8. BBB Penetration:** Both ligands have good BBB penetration (73.129 and 74.254). No significant difference.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.462 and -4.357). These values are unusual and suggest poor permeability. However, the values are similar.
**10. Aqueous Solubility:** Ligand A (-0.634) has slightly better solubility than Ligand B (-2.479). Solubility is important, but not a primary concern here.
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.204 and 0.278).
**12. Microsomal Clearance:** Ligand A (27.836) has significantly lower microsomal clearance than Ligand B (73.557), indicating better metabolic stability. Ligand A is favored.
**13. In vitro Half-Life:** Ligand A (-7.666) has a significantly longer half-life than Ligand B (12.972). Longer half-life is desirable. Ligand A is favored.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.01 and 0.083).
**15. Binding Affinity:** Both ligands have very similar binding affinities (-6.2 and -6.1 kcal/mol). The difference is negligible.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand B initially appears more promising due to its better logP and lower TPSA. However, Ligand A demonstrates superior metabolic stability (lower Cl_mic) and a longer half-life, which are crucial for *in vivo* efficacy. The DILI risk is also lower for Ligand B. While the Caco-2 values are concerning for both, the benefits of improved metabolism and half-life for Ligand A outweigh the slightly better logP and TPSA of Ligand B.
Output:
1
2025-04-17 20:56:44,082 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [350.503, 60.85, 2.589, 1, 3, 0.775, 11.361, 45.638, -4.536, -2.116, 0.343, 34.454, 11.446, 0.136, -7.2]
**Ligand B:** [338.459, 68.52, 2.87, 1, 6, 0.786, 46.646, 77.317, -5.271, -2.797, 0.182, 33.024, -22.493, 0.29, -6.9]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (338.459) is slightly lower, which isn't a major concern.
2. **TPSA:** Ligand A (60.85) is better than Ligand B (68.52), both are acceptable for a non-CNS GPCR.
3. **logP:** Both are good (around 2.6-2.9), falling within the optimal 1-3 range.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 3 HBA, Ligand B has 6. Ligand A is preferable here.
6. **QED:** Both are similar and acceptable (around 0.78).
7. **DILI:** Ligand A (11.361) has a significantly lower DILI risk than Ligand B (46.646). This is a substantial advantage.
8. **BBB:** Ligand B (77.317) has a much higher BBB penetration percentile than Ligand A (45.638). While ADRB2 isn't necessarily a CNS target, some peripheral ADRB2 activity can be modulated by CNS effects, and higher BBB penetration can sometimes correlate with better overall distribution.
9. **Caco-2:** Ligand B (-5.271) has a better (more negative) Caco-2 value, indicating better absorption. Ligand A (-4.536) is still reasonable.
10. **Solubility:** Ligand B (-2.797) has slightly better solubility than Ligand A (-2.116).
11. **hERG:** Both are very low risk, but Ligand A (0.343) is slightly better than Ligand B (0.182).
12. **Cl_mic:** Both have similar microsomal clearance.
13. **t1/2:** Ligand B (-22.493) has a significantly longer in vitro half-life than Ligand A (11.446). This is a major advantage.
14. **Pgp:** Ligand A (0.136) has lower P-gp efflux liability than Ligand B (0.29).
15. **Affinity:** Ligand A (-7.2) has a slightly better binding affinity than Ligand B (-6.9).
**GPCR-specific priorities:** For ADRB2, we prioritize logP, TPSA, Pgp, and affinity. Ligand A is better in TPSA and Pgp. Ligand B is better in BBB and Caco-2. The affinity difference is small, but favors Ligand A. The DILI risk for Ligand A is dramatically lower, and this is a critical factor. The longer half-life of Ligand B is attractive, but can be mitigated through formulation strategies.
**Conclusion:**
Considering the balance of properties, especially the significantly lower DILI risk and slightly better affinity of Ligand A, I believe it is the more promising drug candidate.
Output:
1
2025-04-17 20:56:44,082 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (355.364 and 359.543 Da) fall comfortably within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (71.84) is higher than Ligand B (44.29). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B has a significant advantage here.
3. **logP:** Both ligands have similar logP values (3.501 and 3.545), falling within the optimal 1-3 range. No significant difference.
4. **HBD:** Ligand A (2) has slightly more HBDs than Ligand B (1). This isn't a major concern for either, as both are below the threshold of 5.
5. **HBA:** Ligand A (4) has fewer HBAs than Ligand B (6). This is a slight advantage for Ligand A, as fewer HBAs can improve permeability.
6. **QED:** Both ligands have similar QED values (0.862 and 0.854), indicating good drug-likeness.
7. **DILI:** Ligand A (52.036) has a lower DILI risk than Ligand B (57.58), which is preferable.
8. **BBB:** Ligand B (83.637) has a higher BBB penetration percentile than Ligand A (75.805). While ADRB2 isn't a CNS target, some degree of BBB penetration isn't detrimental and could indicate favorable partitioning.
9. **Caco-2:** Ligand A (-4.945) and Ligand B (-5.085) both have negative Caco-2 values, indicating poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand A (-3.697) and Ligand B (-3.535) both have poor solubility. This is a major drawback for both compounds.
11. **hERG:** Ligand A (0.31) has a much lower hERG inhibition liability than Ligand B (0.955). This is a crucial advantage, as hERG inhibition can lead to cardiotoxicity, particularly concerning for a cardiovascular target.
12. **Cl_mic:** Ligand B (78.369) has a significantly higher microsomal clearance than Ligand A (17.285). This indicates Ligand A is more metabolically stable, a desirable trait.
13. **t1/2:** Ligand A (27.044) has a longer in vitro half-life than Ligand B (-5.647). This is a substantial advantage, suggesting less frequent dosing might be possible.
14. **Pgp:** Ligand A (0.05) has a much lower P-gp efflux liability than Ligand B (0.515). Lower P-gp efflux is beneficial for oral bioavailability.
15. **Binding Affinity:** Ligand A (-7.7) has a slightly better binding affinity than Ligand B (-6.6). While both are good, the 1.1 kcal/mol difference is significant and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand A is the stronger candidate. While both compounds have issues with Caco-2 permeability and solubility, Ligand A demonstrates superior metabolic stability (lower Cl_mic, longer t1/2), lower hERG risk, lower P-gp efflux, and slightly better binding affinity. The lower DILI risk is also a positive. The TPSA difference favors Ligand B, but the other advantages of Ligand A are more critical for a cardiovascular GPCR target.
Output:
1
2025-04-17 20:56:44,082 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.399 and 350.503 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (95.94) is higher than Ligand B (58.64). For a GPCR, lower TPSA is generally preferred for better BBB penetration, giving a slight edge to Ligand B.
3. **logP:** Ligand A (-0.53) is lower than the optimal 1-3 range, potentially hindering permeability. Ligand B (2.903) is within the optimal range. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable, below the threshold of 5.
5. **HBA:** Ligand A (5) and Ligand B (3) are both acceptable, below the threshold of 10.
6. **QED:** Both ligands have good QED scores (0.629 and 0.685), indicating good drug-like properties.
7. **DILI:** Ligand A (41.411) has a slightly higher DILI risk than Ligand B (13.92), though both are below the 40 threshold. Ligand B is preferable.
8. **BBB:** Ligand B (80.38) has a much higher BBB penetration percentile than Ligand A (26.483). This is a *major* advantage for Ligand B, given that ADRB2 is a GPCR.
9. **Caco-2:** Ligand A (-5.064) and Ligand B (-4.457) are both negative, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret the absolute values.
10. **Solubility:** Both ligands have very poor aqueous solubility (-2.424 and -2.778). This is a significant concern for both.
11. **hERG:** Ligand A (0.044) has a slightly lower hERG risk than Ligand B (0.464), but both are quite low.
12. **Cl_mic:** Ligand A (-2.291) has a lower (better) microsomal clearance than Ligand B (66.412), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (-11.015) has a negative half-life, which is not possible and likely indicates an issue with the data. Ligand B (-7.911) also has a negative half-life, indicating a data quality issue for both.
14. **Pgp:** Ligand A (0.088) has lower P-gp efflux liability than Ligand B (0.063), which is preferable.
15. **Binding Affinity:** Ligand A (-6.3) has slightly better binding affinity than Ligand B (-5.9), but the difference is not substantial enough to outweigh other factors.
**Overall Assessment:**
Ligand B clearly outperforms Ligand A in several crucial areas for a GPCR target like ADRB2: logP, BBB penetration, and DILI risk. While Ligand A has better metabolic stability (Cl_mic) and slightly better affinity, the poor logP and BBB penetration are major drawbacks. The negative half-life values are concerning and suggest data issues, but don't change the overall ranking. The combination of good logP and high BBB penetration makes Ligand B a more promising starting point for optimization.
Output:
0
2025-04-17 20:56:44,082 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (365.5 & 351.4 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Both are acceptable (105.2 & 101.7), being under 140.
3. **logP:** Ligand A (3.14) is better than Ligand B (1.26). For a GPCR, a logP between 1-3 is preferred, and Ligand B is on the lower end, potentially hindering membrane permeability.
4. **HBD:** Both have 2 HBD, which is good.
5. **HBA:** Ligand A has 5 HBA, Ligand B has 4. Both are acceptable.
6. **QED:** Both have good QED scores (0.654 and 0.674), indicating drug-likeness.
7. **DILI:** Ligand B (32.6%) is significantly better than Ligand A (63.6%). This is a major advantage for Ligand B.
8. **BBB:** Both have similar BBB penetration (57.6% and 58.4%). Since ADRB2 isn't a CNS target, this isn't a major deciding factor.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual. I will assume these are percentile scores and interpret them as low permeability.
10. **Solubility:** Ligand B (-2.77) is slightly better than Ligand A (-3.49), indicating better aqueous solubility.
11. **hERG:** Ligand A (0.65) is higher than Ligand B (0.21), indicating a higher risk of hERG inhibition. This favors Ligand B.
12. **Cl_mic:** Ligand B (10.2) has a much lower microsomal clearance than Ligand A (46.8), suggesting better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand B (-0.7) has a negative half-life, which is concerning. Ligand A has a half-life of 6.1 hours, which is more reasonable.
14. **Pgp:** Ligand B (0.04) has much lower P-gp efflux than Ligand A (0.33), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand B (-8.0 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.8 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME concerns.
**Overall Assessment:**
Ligand B is the better candidate. While Ligand A has a more reasonable half-life, Ligand B has a significantly better binding affinity, lower DILI risk, lower hERG inhibition, lower P-gp efflux, and lower microsomal clearance. The stronger binding affinity is a key advantage for a GPCR target. The lower DILI and hERG risks are crucial for safety. The lower P-gp efflux and Cl_mic will contribute to better bioavailability and longer duration of action. The slightly lower logP is a minor concern that could potentially be addressed through further optimization.
Output:
0
2025-04-17 20:56:44,082 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (366.359 and 354.409 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (76.02) is better than Ligand B (86.34). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally favors absorption.
3. **logP:** Both ligands have excellent logP values (2.03 and 1.978) falling within the optimal 1-3 range.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1), but both are well within the acceptable limit of 5.
5. **HBA:** Ligand A (4) is lower than Ligand B (8). This is a significant advantage for Ligand A, as fewer HBA generally improves permeability.
6. **QED:** Both ligands have good QED scores (0.657 and 0.741), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (33.773) has a much lower DILI risk than Ligand B (60.915). This is a crucial advantage, as minimizing liver toxicity is paramount.
8. **BBB:** Ligand B (84.451) has a higher BBB penetration than Ligand A (65.607). However, since ADRB2 is a cardiovascular target, BBB penetration is not a high priority.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.035 and -5.135). These values are not directly comparable without knowing the scale. However, negative values suggest poor permeability.
10. **Solubility:** Ligand A (-1.884) is better than Ligand B (-3.349). Better solubility is generally preferred for bioavailability.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.407 and 0.151). This is excellent.
12. **Cl_mic:** Ligand B (6.886) has a significantly lower microsomal clearance than Ligand A (18.544). This suggests better metabolic stability for Ligand B.
13. **t1/2:** Ligand B (-3.8) has a longer in vitro half-life than Ligand A (-1.753). This is a positive attribute.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.025 and 0.159).
15. **Binding Affinity:** Both ligands have the same binding affinity (-7.0 kcal/mol).
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Both ligands perform well on logP, Pgp, and affinity. Ligand A has a better TPSA. The biggest differentiator is DILI risk, where Ligand A is significantly better. Metabolic stability (Cl_mic and t1/2) is also important, and Ligand B is better in these regards.
**Overall Assessment:**
While Ligand B shows advantages in metabolic stability and half-life, the significantly lower DILI risk associated with Ligand A is a major advantage. The slightly better TPSA and solubility of Ligand A also contribute to its favorability. The similar binding affinities make the ADME properties the deciding factor.
Output:
1
2025-04-17 20:56:44,082 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (334.423 Da) is within the ideal range (200-500 Da). Ligand B (358.395 Da) is also acceptable. No clear advantage.
2. **TPSA:** Ligand A (58.43) is excellent, well below the 140 threshold for oral absorption and suitable for a GPCR. Ligand B (126.07) is higher, but still within acceptable limits, though less favorable.
3. **logP:** Ligand A (3.131) is optimal. Ligand B (-1.828) is significantly lower, potentially leading to poor membrane permeability. This is a major concern for GPCR targeting.
4. **HBD:** Both ligands have acceptable HBD counts (Ligand A: 2, Ligand B: 3).
5. **HBA:** Ligand A (3) is preferable to Ligand B (7). Higher HBA can sometimes hinder permeability.
6. **QED:** Ligand A (0.77) is good, indicating strong drug-likeness. Ligand B (0.238) is poor, suggesting potential issues.
7. **DILI:** Ligand A (53.276) has a moderate DILI risk, but acceptable. Ligand B (35.595) is better, indicating lower liver injury potential.
8. **BBB:** Ligand A (76.154) shows good BBB penetration, which is beneficial for GPCRs. Ligand B (54.207) is lower, less desirable.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual. Assuming these are logP-like scales, Ligand A (-4.914) is worse than Ligand B (-5.279), indicating poor permeability. However, this is less concerning given the logP values.
10. **Solubility:** Ligand A (-3.515) is better than Ligand B (-1.407), indicating better aqueous solubility.
11. **hERG:** Ligand A (0.737) shows a lower hERG risk than Ligand B (0.14), which is a significant advantage.
12. **Cl_mic:** Ligand A (44.532) has a moderate clearance, while Ligand B (21.402) has a lower clearance, suggesting better metabolic stability.
13. **t1/2:** Ligand A (9.938) has a reasonable half-life. Ligand B (-31.456) has a negative half-life, which is impossible and likely an error in the data.
14. **Pgp:** Ligand A (0.334) has lower P-gp efflux liability than Ligand B (0.002), which is preferable.
15. **Affinity:** Ligand A (-8.5 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.2 kcal/mol). This is a substantial advantage, potentially outweighing some ADME drawbacks.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are crucial. Ligand A excels in logP, TPSA, Pgp, and significantly outperforms Ligand B in binding affinity. While Ligand B has a slightly better DILI score and Cl_mic, the poor logP, QED, and the impossible half-life are major drawbacks. The strong affinity of Ligand A is a significant driver for its selection.
**Conclusion:**
Ligand A is the more promising candidate due to its superior logP, TPSA, QED, BBB penetration, hERG risk, Pgp efflux, and, most importantly, its significantly stronger binding affinity. The issues with Ligand B's logP and half-life are too significant to ignore.
Output:
1
2025-04-17 20:56:44,082 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (342.359 Da) is slightly lower, which is generally favorable for permeability.
**2. TPSA:** Ligand B (58.64) is significantly better than Ligand A (91.33). For a GPCR, lower TPSA is preferred for better membrane permeability and potentially better brain penetration, even though ADRB2 isn't necessarily a CNS target.
**3. logP:** Both ligands have acceptable logP values (A: 1.264, B: 2.749), falling within the optimal 1-3 range. Ligand B is closer to the upper end, which could be slightly concerning for solubility, but not a major issue.
**4. H-Bond Donors:** Ligand A has 0 HBD, while Ligand B has 1. Both are within the acceptable limit of <=5.
**5. H-Bond Acceptors:** Ligand A has 9 HBA, and Ligand B has 4. Both are within the acceptable limit of <=10. Ligand B is preferable here.
**6. QED:** Both ligands have good QED values (A: 0.661, B: 0.76), indicating drug-like properties. Ligand B is slightly better.
**7. DILI Risk:** Ligand B (32.261) has a much lower DILI risk than Ligand A (81.427). This is a significant advantage for Ligand B.
**8. BBB Penetration:** Both ligands have similar BBB penetration (A: 65.607, B: 67.468). This isn't a primary concern for ADRB2, but slightly higher is better.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
**10. Aqueous Solubility:** Both ligands have negative solubility values, which is also unusual. Again, the scale is unspecified, making interpretation difficult.
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (A: 0.247, B: 0.5). Ligand B is slightly higher, but still acceptable.
**12. Microsomal Clearance:** Both ligands have similar microsomal clearance (A: 43.72, B: 40.395). Lower is better, so Ligand B is slightly preferable.
**13. In vitro Half-Life:** Ligand B (-7.633) has a slightly better (less negative) in vitro half-life than Ligand A (-9.921).
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (A: 0.093, B: 0.162).
**15. Binding Affinity:** Ligand B (-8.3 kcal/mol) has a significantly stronger binding affinity than Ligand A (-7.0 kcal/mol). This is a crucial advantage, as a 1.3 kcal/mol difference is substantial.
**Overall Assessment:**
Ligand B consistently outperforms Ligand A across several key parameters, most notably DILI risk and binding affinity. While both have issues with Caco-2 and solubility (likely scale-related), the superior affinity and safety profile of Ligand B make it the more promising candidate for further development as an ADRB2 ligand. The lower TPSA and better QED also contribute to its favorability.
Output:
0
2025-04-17 20:56:44,082 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (343.43 & 354.43 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (71.53) is higher than Ligand B (55.57). For a cardiovascular GPCR, TPSA is moderately important, and lower is generally better for permeability. Ligand B has a clear advantage here.
3. **logP:** Ligand A (1.987) is within the optimal 1-3 range. Ligand B (3.887) is at the upper end, potentially raising concerns about solubility and off-target effects, but still acceptable. Ligand A is slightly preferred.
4. **HBD:** Ligand A (1) is better than Ligand B (0). Having at least one HBD can improve solubility.
5. **HBA:** Ligand A (4) is lower than Ligand B (5). Lower HBA is generally preferred for permeability. Ligand A is slightly preferred.
6. **QED:** Ligand A (0.857) is significantly better than Ligand B (0.63). Higher QED indicates a more drug-like profile. This is a substantial advantage for Ligand A.
7. **DILI:** Ligand A (43.932) has a much lower DILI risk than Ligand B (69.639). This is a critical factor, as liver toxicity is a major concern in drug development. Ligand A is strongly preferred.
8. **BBB:** Both ligands have moderate BBB penetration (A: 55.913, B: 63.784). Since ADRB2 is a cardiovascular target, BBB penetration is not a primary concern. Ligand B is slightly better.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.967) is slightly better than Ligand B (-5.131).
10. **Solubility:** Ligand A (-1.954) is better than Ligand B (-4.072). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.286) has a much lower hERG risk than Ligand B (0.643). This is crucial for avoiding cardiotoxicity, especially for a cardiovascular target. Ligand A is strongly preferred.
12. **Cl_mic:** Ligand A (23.121) has significantly lower microsomal clearance than Ligand B (95.101), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (-4.853) has a shorter in vitro half-life than Ligand B (29.017). Longer half-life is generally preferred, giving an advantage to Ligand B.
14. **Pgp:** Ligand A (0.086) has lower P-gp efflux than Ligand B (0.829), which is favorable for bioavailability. Ligand A is preferred.
15. **Binding Affinity:** Ligand B (-7.7) has a slightly better binding affinity than Ligand A (-7.0). While affinity is important, the 1.5 kcal/mol difference is not enough to overcome the significant ADME advantages of Ligand A.
**Overall Assessment:**
Ligand A demonstrates a significantly better overall profile, particularly regarding safety (DILI, hERG) and ADME properties (QED, Cl_mic, solubility, Pgp). While Ligand B has slightly better affinity and half-life, these are outweighed by the substantial advantages of Ligand A. The slightly higher logP of Ligand B is a minor concern, but the other ADME issues are more critical.
Output:
1
2025-04-17 20:56:44,083 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (339.395) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (62.74) is significantly better than Ligand B (127.63). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (A: 1.178, B: 0.968), falling within the optimal 1-3 range.
4. **HBD/HBA:** Ligand A (0 HBD, 4 HBA) is preferable to Ligand B (2 HBD, 5 HBA). Lower HBD/HBA counts generally improve permeability.
5. **QED:** Ligand A (0.776) has a significantly better QED score than Ligand B (0.441), indicating a more drug-like profile.
6. **DILI:** Ligand A (31.679) has a much lower DILI risk than Ligand B (61.07), a critical advantage.
7. **BBB:** BBB is not a high priority for a cardiovascular target. Ligand A (43.893) is slightly better than Ligand B (31.912).
8. **Caco-2:** Ligand A (-4.33) and Ligand B (-5.012) both have negative values, which is unusual. Lower (more negative) values suggest poor permeability.
9. **Solubility:** Ligand A (-2.608) is slightly better than Ligand B (-1.997), but both are poor.
10. **hERG:** Both ligands have very low hERG risk (A: 0.207, B: 0.129), which is excellent.
11. **Cl_mic:** Ligand B (-15.596) has a lower (better) microsomal clearance than Ligand A (23.715), suggesting greater metabolic stability.
12. **t1/2:** Ligand B (10.232) has a longer in vitro half-life than Ligand A (-14.327), which is desirable.
13. **Pgp:** Both ligands have very low P-gp efflux liability (A: 0.025, B: 0.034).
14. **Binding Affinity:** Ligand B (-7.3) has a slightly better binding affinity than Ligand A (-7.1), but the difference is small.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, and affinity. Ligand A excels in TPSA and has comparable logP and Pgp. The affinity difference is minimal. However, the significantly better QED and *much* lower DILI risk of Ligand A are crucial. Metabolic stability (Cl_mic and t1/2) are also important, and Ligand B is better in these aspects.
**Overall Assessment:**
While Ligand B has slightly better affinity, metabolic stability, and half-life, Ligand A's superior drug-likeness (QED), significantly lower DILI risk, and better TPSA outweigh these advantages. The poor solubility of both is a concern, but can be addressed with formulation strategies. The DILI risk is a major safety concern that is difficult to overcome later in development.
**Output:**
1
2025-04-17 20:56:44,083 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (377.347) is slightly higher than Ligand B (362.411), but both are acceptable.
2. **TPSA:** Ligand A (62.3) is significantly better than Ligand B (102.32). For a GPCR, lower TPSA is generally preferred for better permeability. Ligand B is pushing the upper limit for good oral absorption.
3. **logP:** Ligand A (2.804) is optimal, while Ligand B (0.399) is quite low. Low logP can hinder membrane permeability and potentially reduce binding affinity. This is a significant advantage for Ligand A.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is better than Ligand B (7). Similar to HBD, lower HBA counts are generally preferred.
6. **QED:** Both ligands have similar, acceptable QED values (Ligand A: 0.802, Ligand B: 0.774).
7. **DILI:** Ligand B (79.604) has a significantly higher DILI risk than Ligand A (12.563). This is a major concern for Ligand B.
8. **BBB:** Ligand A (77.472) has a better BBB penetration score than Ligand B (52.617). While ADRB2 isn't exclusively a CNS target, some peripheral effects are mediated by CNS pathways, and better BBB penetration can be beneficial.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.016 and -4.957), which is unusual and suggests poor permeability. However, the values are very close.
10. **Solubility:** Both ligands have negative solubility values (-2.311 and -3.031), indicating poor aqueous solubility. This could be a formulation challenge for both.
11. **hERG:** Ligand A (0.633) has a lower hERG risk than Ligand B (0.16). This is a significant advantage for Ligand A, as hERG inhibition can lead to cardiotoxicity.
12. **Cl_mic:** Ligand A (-10.024) has a much lower (better) microsomal clearance than Ligand B (17.89). This indicates greater metabolic stability for Ligand A.
13. **t1/2:** Ligand B (8.592) has a longer in vitro half-life than Ligand A (-5.62). This is a positive for Ligand B, but the negative value for A is concerning.
14. **Pgp:** Ligand A (0.077) has a lower Pgp efflux liability than Ligand B (0.06). Both are low, indicating minimal efflux.
15. **Binding Affinity:** Ligand B (-6.6 kcal/mol) has a slightly better binding affinity than Ligand A (-5.9 kcal/mol). This is a 0.7 kcal/mol difference, which is not substantial enough to overcome the significant ADME/Tox liabilities of Ligand B.
**Overall Assessment:**
Ligand A is the far superior candidate. While Ligand B has slightly better binding affinity, Ligand A demonstrates significantly better predicted ADME properties (TPSA, logP, Cl_mic, DILI, BBB) and a lower hERG risk. The poor solubility and Caco-2 values are concerns for both, but these are more readily addressable through formulation strategies than the serious toxicity and permeability issues associated with Ligand B. The GPCR-specific priorities (logP, TPSA, Pgp) all favor Ligand A.
Output:
1
2025-04-17 20:56:44,083 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (410.283 Da) is within the ideal range, while Ligand B (350.438 Da) is also acceptable, leaning towards the lower end.
2. **TPSA:** Ligand A (47.56) is good, well below the 140 threshold. Ligand B (66.49) is still reasonable, but higher.
3. **logP:** Ligand A (4.242) is slightly high, potentially leading to solubility issues, but still within a manageable range. Ligand B (2.304) is optimal.
4. **HBD:** Ligand A (1) is good. Ligand B (2) is also acceptable.
5. **HBA:** Ligand A (3) is good. Ligand B (4) is also acceptable.
6. **QED:** Both ligands have good QED scores (A: 0.663, B: 0.855), indicating good drug-like properties. Ligand B is better here.
7. **DILI:** Ligand A (55.525) is borderline, but acceptable. Ligand B (36.565) is significantly better, indicating lower liver injury risk.
8. **BBB:** Both ligands have reasonable BBB penetration (A: 77.162, B: 81.039).
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Both ligands have negative solubility values, which is also unusual and suggests poor solubility. This is a significant concern for both.
11. **hERG:** Ligand A (0.909) is better than Ligand B (0.587) in terms of hERG inhibition liability.
12. **Cl_mic:** Ligand A (63.717) has a higher clearance than Ligand B (34.585), indicating lower metabolic stability.
13. **t1/2:** Ligand A (46.568) has a longer half-life than Ligand B (35.883).
14. **Pgp:** Ligand A (0.651) has better Pgp efflux liability than Ligand B (0.11).
15. **Affinity:** Ligand B (-6.9 kcal/mol) has a significantly stronger binding affinity than Ligand A (-3.3 kcal/mol). This is a substantial advantage.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, affinity, logP, TPSA, and Pgp efflux are particularly important. Ligand B excels in affinity, has a more optimal logP, and better Pgp efflux. While Ligand A has a slightly better hERG profile and half-life, the substantial difference in binding affinity outweighs these advantages. The negative Caco-2 and solubility values are concerning for both, but the stronger binding of Ligand B increases the chance that formulation strategies could overcome these issues.
**Conclusion:**
Despite the concerning Caco-2 and solubility values for both, the significantly stronger binding affinity of Ligand B makes it the more promising candidate.
Output:
0
2025-04-17 20:56:44,083 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.431 and 373.519 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (81.16) is significantly better than Ligand A (101.57). ADRB2 is not a CNS target, but lower TPSA generally improves absorption.
3. **logP:** Ligand A (0.812) is slightly better than Ligand B (-0.339). Both are a bit low, potentially hindering permeability, but A is closer to the optimal 1-3 range.
4. **HBD:** Ligand B (1) is better than Ligand A (2). Lower HBD is generally preferred for permeability.
5. **HBA:** Both ligands have the same number of HBA (5), which is acceptable.
6. **QED:** Both ligands have the same QED (0.63), indicating similar drug-likeness.
7. **DILI:** Ligand B (4.188) is *much* better than Ligand A (34.432). This is a significant advantage for Ligand B, as lower DILI risk is crucial.
8. **BBB:** Not a primary concern for ADRB2 (cardiovascular target). Ligand A (65.839) is better than Ligand B (35.246), but this is less important.
9. **Caco-2:** Ligand A (-4.876) is better than Ligand B (-5.186), suggesting slightly better intestinal absorption.
10. **Solubility:** Ligand B (-0.064) is better than Ligand A (-1.696). Better solubility is always a plus.
11. **hERG:** Ligand A (0.042) is better than Ligand B (0.215), indicating lower cardiotoxicity risk. This is important for a cardiovascular target.
12. **Cl_mic:** Ligand B (-0.955) is *much* better than Ligand A (51.159). Lower clearance indicates better metabolic stability.
13. **t1/2:** Ligand B (-8.568) is better than Ligand A (-21.635). A longer half-life is generally desirable.
14. **Pgp:** Both ligands have similar Pgp efflux liability (0.027 and 0.008).
15. **Binding Affinity:** Ligand A (-6.0) is slightly better than Ligand B (-6.3). However, the difference is not substantial enough to outweigh other factors.
**Overall Assessment:**
Ligand B has several significant advantages: drastically lower DILI risk, much better metabolic stability (Cl_mic), and a longer half-life. It also has better solubility and fewer H-bond donors. While Ligand A has a slightly better binding affinity and Caco-2 permeability, the improvements in safety (DILI, hERG) and pharmacokinetics (Cl_mic, t1/2) offered by Ligand B are more important for overall drug development success, especially for a cardiovascular target. The slightly lower logP of Ligand B is a minor concern but can be addressed through further optimization.
Output:
0
2025-04-17 20:56:44,083 - INFO - Batch 222 complete. Total preferences: 3552
2025-04-17 20:56:44,083 - INFO - Processing batch 223/512...
2025-04-17 20:57:29,229 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (344.331 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (104.53) is significantly better than Ligand A (131.98). Both are under 140, but B is closer to the optimal for good oral absorption, and particularly important for GPCRs.
3. **logP:** Ligand B (0.631) is within the optimal range, while Ligand A (-0.288) is slightly below 1, which *could* indicate permeability issues.
4. **HBD:** Ligand B (3) is preferable to Ligand A (2). Both are acceptable.
5. **HBA:** Ligand B (4) is preferable to Ligand A (8). Lower HBA is generally better for permeability.
6. **QED:** Ligand A (0.723) is slightly better than Ligand B (0.594), indicating a marginally more drug-like profile.
7. **DILI:** Ligand B (6.049) is *much* better than Ligand A (79.992). This is a critical advantage for Ligand B, as DILI is a major concern in drug development.
8. **BBB:** Ligand B (64.211) is better than Ligand A (43.583), although neither is exceptionally high. For a cardiovascular target like ADRB2, BBB penetration isn't a primary concern, but it's still a positive for B.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-5.167) is slightly better than Ligand B (-5.62), but both are concerning.
10. **Solubility:** Ligand A (-3.144) is better than Ligand B (-1.803), though both are poor.
11. **hERG:** Both ligands have very low hERG risk (0.111 and 0.169).
12. **Cl_mic:** Ligand B (1.299) is *much* better than Ligand A (14.954). Lower clearance is strongly preferred for metabolic stability.
13. **t1/2:** Ligand B (-29.99) is *much* better than Ligand A (-10.594). A longer half-life is desirable.
14. **Pgp:** Both ligands have very low Pgp efflux (0.001 and 0.017).
15. **Affinity:** Ligand B (-6.4 kcal/mol) is significantly better than Ligand A (-4.7 kcal/mol). This is a substantial advantage in binding potency.
**Overall Assessment:**
Ligand B is the clear winner. While Ligand A has a slightly better QED and solubility, Ligand B excels in critical areas: DILI risk, metabolic stability (Cl_mic and t1/2), and, most importantly, binding affinity. The significantly lower DILI risk and substantially improved affinity outweigh the minor drawbacks in QED and solubility. The TPSA is also much better for Ligand B. For a GPCR target like ADRB2, the combination of good affinity, acceptable TPSA, and low DILI risk makes Ligand B a much more promising starting point for drug development.
Output:
0
2025-04-17 20:57:29,229 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**1. Molecular Weight:** Both ligands (348.378 and 348.443 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (86.63) is higher than Ligand B (67.87). For a cardiovascular GPCR like ADRB2, TPSA is moderately important, and lower is generally preferred for better permeability. Ligand B has a clear advantage.
**3. logP:** Both ligands have acceptable logP values (1.278 and 1.539), falling within the 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability, but the difference is small.
**4. H-Bond Donors:** Both have 1 HBD, which is good.
**5. H-Bond Acceptors:** Ligand A has 5 HBA, and Ligand B has 4. Both are within the acceptable limit of 10.
**6. QED:** Ligand A (0.87) has a better QED score than Ligand B (0.74), indicating a more drug-like profile. This is a positive for Ligand A.
**7. DILI:** Ligand A (61.264) has a higher DILI risk than Ligand B (34.432). This is a significant advantage for Ligand B, as lower DILI is crucial.
**8. BBB:** Ligand B (74.176) has a higher BBB penetration percentile than Ligand A (64.599). While ADRB2 isn't a primary CNS target, some degree of BBB penetration can be beneficial for understanding off-target effects and potential distribution.
**9. Caco-2 Permeability:** Ligand A (-4.845) has worse Caco-2 permeability than Ligand B (-5.003). Both are negative, indicating low permeability, but Ligand B is slightly better.
**10. Aqueous Solubility:** Ligand A (-3.029) has worse aqueous solubility than Ligand B (-2.2). Better solubility is always preferred.
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.173 and 0.111). This is excellent for both.
**12. Microsomal Clearance:** Ligand A (24.086) has a lower microsomal clearance than Ligand B (29.495), suggesting better metabolic stability. This is a positive for Ligand A.
**13. In vitro Half-Life:** Ligand B (54.277) has a significantly longer in vitro half-life than Ligand A (-3.861). This is a major advantage for Ligand B, potentially allowing for less frequent dosing.
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (0.057 and 0.028).
**15. Binding Affinity:** Ligand A (-7.4) has a slightly better binding affinity than Ligand B (-6.1). This is a 1.3 kcal/mol difference, which is substantial and could outweigh some ADME drawbacks.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity and QED, Ligand B demonstrates a significantly better safety profile (lower DILI), better permeability (Caco-2), better solubility, and a much longer half-life. Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), and the importance of ADME properties for *in vivo* success, Ligand B is the more promising candidate. The improved metabolic stability (half-life) and reduced toxicity risk are critical advantages. The affinity difference, while notable, can potentially be optimized further in subsequent iterations of drug design.
Output:
0
2025-04-17 20:57:29,229 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (371.459 Da) is slightly higher than Ligand B (342.378 Da), but both are acceptable.
2. **TPSA:** Ligand A (96.02) is higher than Ligand B (67.98). Both are below 140, but B is preferable as lower TPSA generally correlates with better permeability.
3. **logP:** Ligand B (2.624) is within the optimal range (1-3), while Ligand A (0.307) is below 1, which could hinder membrane permeability. This is a significant advantage for Ligand B.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 6 HBA, and Ligand B has 5. Both are acceptable (<=10).
6. **QED:** Ligand B (0.792) has a better QED score than Ligand A (0.496), indicating a more drug-like profile.
7. **DILI:** Ligand B (75.262) has a slightly higher DILI risk than Ligand A (65.491), but both are reasonably acceptable.
8. **BBB:** Ligand A (83.792) has a slightly higher BBB penetration percentile than Ligand B (78.868). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be beneficial for distribution.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.942 and -4.853), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Both ligands have negative solubility values (-2.563 and -3.353), indicating very poor aqueous solubility. This is a major drawback for both.
11. **hERG:** Ligand A (0.535) has a slightly higher hERG risk than Ligand B (0.429), but both are relatively low.
12. **Cl_mic:** Ligand B (36.977) has significantly lower microsomal clearance than Ligand A (79.899), indicating better metabolic stability. This is a strong advantage for Ligand B.
13. **t1/2:** Ligand B (19.588) has a much longer in vitro half-life than Ligand A (-64.379). This is a significant advantage for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.085) has lower P-gp efflux liability than Ligand B (0.155), which is preferable.
15. **Binding Affinity:** Ligand B (-7.0 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.9 kcal/mol). This 1.1 kcal/mol difference is substantial and can outweigh many ADME drawbacks.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP and affinity, and has acceptable TPSA and Pgp values. Ligand A has better Pgp, but its poor logP and significantly weaker affinity are major drawbacks. Metabolic stability (Cl_mic and t1/2) are also important, and Ligand B is superior in both.
**Conclusion:**
Despite the poor Caco-2 and solubility for both, Ligand B is the more promising candidate due to its superior logP, binding affinity, metabolic stability, and half-life. The stronger binding affinity is a critical advantage that outweighs the slightly higher DILI and Pgp efflux.
Output:
0
2025-04-17 20:57:29,229 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (355.479 and 345.399 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (91.76) is better than Ligand A (101.9), being closer to the <140 threshold for good absorption.
3. **logP:** Ligand B (0.497) is slightly better than Ligand A (0.004), both are a little low, but Ligand B is closer to the optimal 1-3 range.
4. **HBD:** Ligand B (2) has fewer HBD than Ligand A (4), which is preferable for permeability.
5. **HBA:** Both ligands have the same number of HBA (5), which is acceptable.
6. **QED:** Ligand B (0.811) has a significantly better QED score than Ligand A (0.491), indicating a more drug-like profile.
7. **DILI:** Ligand A (12.02) has a much lower DILI risk than Ligand B (55.448), which is a significant advantage.
8. **BBB:** Ligand B (37.069) has a higher BBB penetration than Ligand A (22.606), but both are relatively low. As ADRB2 is a cardiovascular target, BBB penetration is not a high priority.
9. **Caco-2:** Ligand B (-4.85) has a slightly better Caco-2 permeability than Ligand A (-5.448).
10. **Solubility:** Ligand A (-0.928) has better aqueous solubility than Ligand B (-1.814).
11. **hERG:** Both ligands have similar, low hERG inhibition liability (0.142 and 0.17).
12. **Cl_mic:** Ligand A (-14.247) has significantly lower microsomal clearance than Ligand B (19.722), suggesting better metabolic stability.
13. **t1/2:** Ligand A (6.976) has a slightly longer in vitro half-life than Ligand B (5.877).
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.021 and 0.033).
15. **Binding Affinity:** Both ligands have the same binding affinity (-6.9 kcal/mol).
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, and affinity are important. Ligand B is slightly better on logP and TPSA, but the difference is not substantial. The significant advantage of Ligand A is its much lower DILI risk and better metabolic stability (lower Cl_mic and longer t1/2). While BBB isn't crucial for a cardiovascular target, the difference is not a deciding factor.
**Conclusion:**
Considering the balance of properties, Ligand A is the more promising candidate. Its significantly lower DILI risk and improved metabolic stability outweigh the slight advantages of Ligand B in terms of TPSA and logP.
Output:
1
2025-04-17 20:57:29,229 - INFO - Here's my reasoning and final decision:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, priorities are logP, TPSA, Pgp, affinity, and to a lesser extent, BBB.
* **Molecular Weight:** Both ligands are within the acceptable range (200-500 Da). Ligand B (346.475 Da) is slightly lower, which could be advantageous for permeability.
* **TPSA:** Ligand B (57.7) is significantly better than Ligand A (97.11), falling well below the 140 threshold for good absorption and being more favorable for GPCRs.
* **logP:** Both ligands have good logP values (A: 2.658, B: 1.77), falling within the optimal 1-3 range. Ligand B is slightly lower, which might slightly reduce permeability but is still acceptable.
* **H-Bond Donors/Acceptors:** Both ligands have acceptable HBD/HBA counts.
* **QED:** Both ligands have good QED scores (A: 0.685, B: 0.777), indicating good drug-likeness.
* **DILI:** Ligand A has a very high DILI risk (97.169%), which is a major red flag. Ligand B has a much lower, and acceptable, DILI risk (11.632%).
* **BBB:** Ligand B has a higher BBB penetration (54.168%) than Ligand A (16.983%), but BBB is less critical for a cardiovascular target.
* **Caco-2 Permeability:** Ligand A (-5.411) has a negative Caco-2 value, which is concerning. Ligand B (-4.981) is also negative, but less so.
* **Aqueous Solubility:** Ligand A (-3.429) and Ligand B (-0.108) both have poor aqueous solubility.
* **hERG:** Both ligands have low hERG inhibition liability.
* **Microsomal Clearance:** Ligand A (0.982) has a much lower (better) microsomal clearance than Ligand B (-25.93), suggesting better metabolic stability.
* **In vitro Half-Life:** Ligand A (14.469) has a longer half-life than Ligand B (9.892).
* **P-gp Efflux:** Both ligands have very low P-gp efflux liability.
* **Binding Affinity:** Ligand B (-7.9 kcal/mol) has a slightly better binding affinity than Ligand A (-7.0 kcal/mol), but the difference is relatively small.
**Conclusion:**
Despite Ligand A having a slightly better half-life and lower clearance, the extremely high DILI risk is a deal-breaker. Ligand B has a much more favorable safety profile (DILI), better TPSA, and comparable affinity. The slightly lower logP of Ligand B is a minor concern, but outweighed by the significant safety advantage.
**Output:**
0
2025-04-17 20:57:29,229 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.419 and 352.519 Da) are within the ideal range (200-500 Da). No significant difference.
2. **TPSA:** Ligand A (96.33) is higher than Ligand B (49.85). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for permeability. Ligand B is significantly better here.
3. **logP:** Ligand A (-0.041) is quite low, potentially hindering membrane permeability. Ligand B (3.08) is within the optimal range (1-3). This is a major advantage for Ligand B.
4. **HBD:** Ligand A (2) is reasonable. Ligand B (0) is even better, potentially improving permeability.
5. **HBA:** Ligand A (5) is acceptable. Ligand B (3) is also good.
6. **QED:** Ligand A (0.731) is better than Ligand B (0.568), indicating a more drug-like profile.
7. **DILI:** Ligand A (45.25) has a slightly higher DILI risk than Ligand B (7.29), but both are within acceptable limits (<40 is good, <60 is generally acceptable).
8. **BBB:** Ligand A (59.364) and Ligand B (93.563). While ADRB2 isn't a CNS target, higher BBB penetration can sometimes correlate with better overall distribution. Ligand B is better here.
9. **Caco-2:** Ligand A (-5.167) is very poor, indicating poor intestinal absorption. Ligand B (-4.401) is also poor, but slightly better.
10. **Solubility:** Ligand A (-2.232) is poor, while Ligand B (-1.424) is also poor. Both are problematic.
11. **hERG:** Ligand A (0.067) is very low risk. Ligand B (0.749) is slightly higher, but still acceptable.
12. **Cl_mic:** Ligand A (30.826) has lower clearance, suggesting better metabolic stability, which is good. Ligand B (56.334) has higher clearance.
13. **t1/2:** Ligand A (3.11) has a shorter half-life than Ligand B (-21.889), which is a significant negative.
14. **Pgp:** Ligand A (0.024) has very low P-gp efflux, which is favorable. Ligand B (0.351) is slightly higher.
15. **Affinity:** Ligand A (-6.5) is slightly better than Ligand B (-6.1), but the difference is small (0.4 kcal/mol).
**Overall Assessment:**
Ligand B has several key advantages: significantly better logP, lower TPSA, and a much longer in vitro half-life. While Ligand A has a slightly better QED and affinity, the poor logP and Caco-2 permeability are major drawbacks. The improved metabolic stability of Ligand A is a plus, but the longer half-life of Ligand B is more valuable. Given the GPCR target class, logP and TPSA are important, and Ligand B excels in these areas. The affinity difference is not large enough to overcome the ADME deficiencies of Ligand A.
Output:
0
2025-04-17 20:57:29,230 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [353.413, 51.27, 3.718, 0, 4, 0.646, 26.018, 87.864, -4.639, -2.556, 0.742, 66.216, -15.124, 0.524, -5.8]
**Ligand B:** [352.519, 49.85, 2.589, 0, 4, 0.606, 2.171, 86.468, -4.47, -0.963, 0.614, 17.672, -9.277, 0.041, -6.8]
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (353.413 and 352.519 Da).
2. **TPSA:** Both are acceptable (51.27 and 49.85), being under 140, but not optimally low for CNS penetration if that were a goal.
3. **logP:** Ligand A (3.718) is slightly higher than Ligand B (2.589). Both are within the optimal range, but A is approaching the upper limit.
4. **HBD:** Both have 0 HBD, which is good.
5. **HBA:** Both have 4 HBA, which is good.
6. **QED:** Both are good (0.646 and 0.606), indicating drug-like properties.
7. **DILI:** Ligand A (26.018) has a higher DILI risk than Ligand B (2.171). This is a significant advantage for B.
8. **BBB:** Both have high BBB penetration (87.864 and 86.468). This isn't a primary concern for ADRB2, but it's good to see.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the values are similar (-4.639 and -4.47).
10. **Solubility:** Ligand B (-0.963) has better solubility than Ligand A (-2.556). This is a positive for B.
11. **hERG:** Both have low hERG risk (0.742 and 0.614).
12. **Cl_mic:** Ligand B (17.672) has significantly lower microsomal clearance than Ligand A (66.216), indicating better metabolic stability. This is a major advantage for B.
13. **t1/2:** Ligand B (-9.277) has a longer in vitro half-life than Ligand A (-15.124). This is a positive for B.
14. **Pgp:** Ligand A (0.524) has slightly lower P-gp efflux than Ligand B (0.041), which is good.
15. **Affinity:** Ligand B (-6.8) has slightly better binding affinity than Ligand A (-5.8). While not a huge difference, it's a positive for B.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Both ligands perform reasonably well on logP and TPSA. Ligand B has a slight edge in affinity and significantly better metabolic stability (Cl_mic and t1/2) and lower DILI risk. The Pgp efflux is slightly better for A, but the other advantages of B outweigh this.
**Conclusion:**
Considering the balance of properties, especially the lower DILI risk, better metabolic stability, and slightly better affinity, **Ligand B** is the more promising drug candidate.
0
2025-04-17 20:57:29,230 - INFO - Here's my reasoning and final output for the ligand preference:
**Reasoning:**
We are targeting ADRB2, a GPCR, so the priorities are logP, Pgp, TPSA, affinity, and BBB. Let's break down each ligand:
* **Molecular Weight:** Both ligands are within the ideal range (200-500 Da).
* **TPSA:** Ligand B (72.88) is significantly better than Ligand A (95.08), falling well below the 140 threshold for good absorption.
* **logP:** Ligand A (3.089) is optimal, while Ligand B (0.987) is a bit low, potentially hindering permeation.
* **H-Bond Donors/Acceptors:** Both are within acceptable limits.
* **QED:** Both are good (>0.5).
* **DILI:** Ligand B (5.118) has a *much* better DILI score than Ligand A (84.645). This is a major advantage for Ligand B.
* **BBB:** Ligand A (51.687) is better than Ligand B (30.942), but neither is particularly high. This is less critical for a non-CNS target like ADRB2, but still considered.
* **Caco-2:** Both are negative, indicating poor permeability.
* **Solubility:** Both are negative, indicating poor solubility.
* **hERG:** Both are low, indicating a low risk of cardiotoxicity.
* **Cl_mic:** Ligand A (-19.844) has a much lower (better) microsomal clearance than Ligand B (25.251), suggesting better metabolic stability.
* **t1/2:** Ligand B (18.008) has a longer half-life than Ligand A (10.592).
* **Pgp:** Ligand A (0.031) has a lower Pgp efflux liability than Ligand B (0.028), which is favorable.
* **Binding Affinity:** Ligand B (-6.3 kcal/mol) has a significantly stronger binding affinity than Ligand A (-3.9 kcal/mol). This is a substantial advantage, exceeding the 1.5 kcal/mol threshold.
**Overall Assessment:**
While Ligand A has better logP and Pgp, the superior binding affinity and dramatically lower DILI risk of Ligand B are decisive. The lower TPSA of Ligand B is also a significant benefit. The affinity difference is large enough to offset the slightly lower logP and BBB values. The improved metabolic stability of Ligand A is a plus, but the DILI risk for Ligand A is concerning.
**Output:**
0
2025-04-17 20:57:29,230 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step Comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (335.367 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (67.87) is significantly better than Ligand A (88.39). ADRB2 is not a CNS target, but lower TPSA generally improves absorption.
3. **logP:** Both ligands have good logP values (A: 2.805, B: 1.246) within the optimal 1-3 range. Ligand B is closer to the lower end, which *could* be a slight disadvantage for permeability, but is still acceptable.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1), but both are well within the acceptable limit of 5.
5. **HBA:** Ligand A (5) is higher than Ligand B (4), but both are below the 10 threshold.
6. **QED:** Both ligands have acceptable QED values (A: 0.718, B: 0.638), indicating good drug-like properties.
7. **DILI:** Ligand A (95.929) has a *very* high DILI risk, which is a major concern. Ligand B (9.306) has an excellent DILI profile. This is a critical difference.
8. **BBB:** Not a primary concern for ADRB2, but Ligand B (91.043) has a higher BBB penetration than Ligand A (51.066).
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it is hard to interpret.
10. **Solubility:** Ligand B (-1.63) is better than Ligand A (-4.465), indicating better aqueous solubility.
11. **hERG:** Both ligands have low hERG inhibition liability (A: 0.459, B: 0.389), which is good.
12. **Cl_mic:** Ligand A (68.029) has a higher microsomal clearance than Ligand B (10.737), meaning it's metabolized faster and has lower metabolic stability.
13. **t1/2:** Ligand B (-17.989) has a much longer in vitro half-life than Ligand A (53.945). This is a significant advantage.
14. **Pgp:** Both ligands have low P-gp efflux liability (A: 0.259, B: 0.024), which is favorable.
15. **Binding Affinity:** Ligand A (-6.7 kcal/mol) has a slightly better binding affinity than Ligand B (-6.0 kcal/mol), but the difference is less than 1.5 kcal/mol.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, and affinity are important. However, the extremely high DILI risk associated with Ligand A and its poor metabolic stability (high Cl_mic, short t1/2) are dealbreakers. While Ligand A has slightly better affinity, the ADME/Tox profile of Ligand B is far superior.
**Conclusion:**
Ligand B is the more promising drug candidate due to its significantly better safety profile (DILI), metabolic stability (Cl_mic, t1/2), and solubility, despite a slightly lower binding affinity.
Output:
0
2025-04-17 20:57:29,230 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (366.405) is slightly higher than Ligand B (349.475), but both are acceptable.
2. **TPSA:** Ligand A (96.89) is slightly higher than Ligand B (73.64). Both are below the 140 threshold for good oral absorption, but Ligand B is preferable due to its lower TPSA.
3. **logP:** Ligand A (1.008) is at the lower end of the optimal range, while Ligand B (2.192) is more centrally positioned. Considering ADRB2 is a cardiovascular target (not CNS), a slightly higher logP is acceptable and potentially beneficial for membrane permeability. Ligand B is better here.
4. **HBD:** Ligand A (3) is higher than Ligand B (0). Lower HBD is generally preferred for better permeability, making Ligand B more favorable.
5. **HBA:** Ligand A (5) is higher than Ligand B (4). Similar to HBD, Ligand B is preferable.
6. **QED:** Ligand B (0.639) has a better QED score than Ligand A (0.396), indicating a more drug-like profile.
7. **DILI:** Ligand B (15.2) has a significantly lower DILI risk than Ligand A (31.524). This is a major advantage for Ligand B.
8. **BBB:** While not a primary concern for a cardiovascular target, Ligand B (83.094) has a higher BBB penetration than Ligand A (58.976).
9. **Caco-2:** Ligand A (-5.43) and Ligand B (-4.338) both have negative values, indicating poor permeability. This is a concern for both, but Ligand B is slightly better.
10. **Solubility:** Ligand A (-1.691) and Ligand B (-1.75) have similar poor aqueous solubility.
11. **hERG:** Both ligands have similar hERG inhibition liability (0.408 and 0.507, respectively).
12. **Cl_mic:** Ligand A (3.045) has a significantly lower microsomal clearance than Ligand B (39.34), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (-8.27) has a much longer in vitro half-life than Ligand B (-1.866). This is a substantial advantage for Ligand A.
14. **Pgp:** Both ligands have similar Pgp efflux liability (0.052 and 0.067, respectively).
15. **Binding Affinity:** Both ligands have very similar binding affinities (-5.2 and -5.3 kcal/mol). The difference is negligible.
**Overall Assessment:**
Ligand B has advantages in terms of TPSA, logP, QED, and DILI risk. However, Ligand A excels in metabolic stability (Cl_mic) and in vitro half-life (t1/2), which are crucial for *in vivo* efficacy. While solubility and Caco-2 permeability are concerns for both, the improved metabolic profile of Ligand A is more critical for a GPCR target where sustained receptor engagement is often desired. The similar binding affinities make the ADME properties the deciding factor.
Output:
1
2025-04-17 20:57:29,230 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (368.811 Da and 351.407 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (45.48) is well below the 140 threshold and good for oral absorption. Ligand B (129.37) is still within acceptable limits, but higher. Given ADRB2's cardiovascular target, CNS penetration isn't a primary concern, so TPSA is less critical than for a CNS-focused GPCR.
**3. logP:** Ligand A (4.978) is slightly high, potentially leading to solubility issues or off-target interactions. Ligand B (-1.015) is quite low, which could hinder permeability. A logP between 1-3 is optimal, and neither is ideal, but Ligand A is closer.
**4. H-Bond Donors:** Ligand A (1) is good. Ligand B (4) is higher, potentially impacting permeability.
**5. H-Bond Acceptors:** Ligand A (2) is good. Ligand B (7) is higher, again potentially impacting permeability.
**6. QED:** Ligand A (0.812) is excellent, indicating strong drug-likeness. Ligand B (0.451) is below the desirable 0.5 threshold.
**7. DILI:** Ligand A (49.399) has a moderate DILI risk. Ligand B (27.801) has a lower, more favorable DILI risk.
**8. BBB:** Not a primary concern for a cardiovascular target. Ligand A (94.61) is higher, but this isn't a deciding factor. Ligand B (23.769) is low.
**9. Caco-2 Permeability:** Ligand A (-4.529) is poor, indicating low intestinal absorption. Ligand B (-5.659) is even worse. Both are problematic.
**10. Aqueous Solubility:** Ligand A (-5.44) is very poor. Ligand B (-1.033) is better, but still quite low.
**11. hERG Inhibition:** Ligand A (0.76) is a moderate risk. Ligand B (0.034) is very low risk, a significant advantage.
**12. Microsomal Clearance:** Ligand A (8.144) is moderate. Ligand B (-5.026) is excellent, indicating high metabolic stability.
**13. In vitro Half-Life:** Ligand A (72.045) is good. Ligand B (6.536) is poor.
**14. P-gp Efflux:** Ligand A (0.204) is low, which is favorable. Ligand B (0.002) is extremely low, even better.
**15. Binding Affinity:** Ligand B (-7.1) has a 0.3 kcal/mol advantage in binding affinity over Ligand A (-6.8). This is a substantial difference and a major driver in the decision.
**Overall Assessment:**
While Ligand A has a better QED and half-life, Ligand B's superior binding affinity (-7.1 kcal/mol vs -6.8 kcal/mol) is a critical advantage for a GPCR target. Furthermore, Ligand B exhibits significantly lower hERG inhibition risk and better metabolic stability (lower Cl_mic). The lower DILI risk is also beneficial. The solubility and Caco-2 permeability are poor for both, but the strength of binding and safety profile of Ligand B outweigh these concerns. Optimization could focus on improving solubility and permeability.
Output:
0
2025-04-17 20:57:29,230 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (338.455 and 349.391 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (58.95) is significantly better than Ligand B (139.34). ADRB2 is a cardiovascular target, not CNS, but lower TPSA generally aids absorption. Ligand A is well below the 140 threshold, while B is approaching it.
3. **logP:** Ligand A (2.515) is optimal, while Ligand B (-1.315) is quite low. Low logP can hinder membrane permeability. This is a significant advantage for A.
4. **HBD:** Ligand A (2) is preferable to Ligand B (4). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is preferable to Ligand B (6). Fewer HBAs generally improve permeability.
6. **QED:** Ligand A (0.881) is much better than Ligand B (0.431), indicating a more drug-like profile.
7. **DILI:** Ligand B (36.681) has a lower DILI risk than Ligand A (49.787), which is good.
8. **BBB:** Ligand A (71.384) has a higher BBB penetration percentile than Ligand B (25.475). While not a CNS target, some level of BBB penetration can sometimes indicate favorable partitioning.
9. **Caco-2:** Ligand A (-5.214) is better than Ligand B (-6.273), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-2.487) is better than Ligand B (-0.951).
11. **hERG:** Ligand A (0.711) has a lower hERG risk than Ligand B (0.092). This is a significant advantage for A, as cardiotoxicity is a major concern for cardiovascular drugs.
12. **Cl_mic:** Ligand B (-13.392) has a much lower microsomal clearance than Ligand A (15.938), suggesting better metabolic stability. This is a significant advantage for B.
13. **t1/2:** Ligand A (20.595) has a longer in vitro half-life than Ligand B (-6.072). This is a significant advantage for A.
14. **Pgp:** Ligand A (0.294) has lower P-gp efflux than Ligand B (0.008), which is preferable.
15. **Binding Affinity:** Ligand A (-8.8 kcal/mol) has a slightly better binding affinity than Ligand B (-7.1 kcal/mol). The difference is 1.7 kcal/mol, which is substantial enough to outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand A is clearly superior. While Ligand B has better metabolic stability (lower Cl_mic), Ligand A excels in most other critical parameters, including logP, TPSA, QED, hERG risk, solubility, Caco-2 permeability, and binding affinity. The stronger binding affinity of Ligand A, combined with its better predicted absorption and safety profile, makes it the more promising candidate. The lower DILI score of B is a positive, but not enough to overcome the other advantages of A.
Output:
1
2025-04-17 20:57:29,231 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (345.363) is slightly lower, which could be beneficial for permeability, but both are acceptable.
2. **TPSA:** Ligand B (78.43) is significantly better than Ligand A (129.94). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (1.748) is within the optimal range (1-3), while Ligand A (0.15) is quite low. A low logP can hinder membrane permeability. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand B (3) is preferable to Ligand A (8). Fewer HBAs generally improve permeability.
6. **QED:** Ligand A (0.788) is better than Ligand B (0.646), indicating a more drug-like profile.
7. **DILI:** Ligand B (13.416) is *much* better than Ligand A (54.75). This is a critical advantage for Ligand B, as liver toxicity is a major concern.
8. **BBB:** Ligand B (70.997) is better than Ligand A (57.968), but neither is exceptionally high. Since ADRB2 is a cardiovascular target, BBB penetration is not a primary concern.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-5.219) is slightly better than Ligand B (-4.983), but both are concerning.
10. **Solubility:** Both ligands have negative solubility values, which is also unusual. Ligand A (-2.181) is slightly better than Ligand B (-2.518), but both are concerning.
11. **hERG:** Ligand A (0.108) is better than Ligand B (0.398), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand B (13.43) is significantly better than Ligand A (26.351), indicating better metabolic stability.
13. **t1/2:** Ligand A (21.65) is better than Ligand B (-11.256). A positive half-life is preferable.
14. **Pgp:** Ligand A (0.041) is better than Ligand B (0.032), indicating lower P-glycoprotein efflux.
15. **Affinity:** Ligand A (-6.5 kcal/mol) is significantly better than Ligand B (-4.1 kcal/mol). This is a substantial difference in potency.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand B has a much better logP and TPSA, while Ligand A has significantly better affinity. The DILI risk for Ligand B is also dramatically lower. The metabolic stability (Cl_mic) is also much better for Ligand B. While the affinity difference is substantial, the ADME properties of Ligand B are far more favorable, and the better DILI and Cl_mic profiles are crucial for drug development.
**Conclusion:**
Despite Ligand A's superior binding affinity, the significantly better ADME profile of Ligand B, particularly the lower DILI risk and improved metabolic stability, makes it the more promising drug candidate. The affinity difference, while important, can potentially be optimized in later stages of development.
Output:
0
2025-04-17 20:57:29,231 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for the ADRB2, a cardiovascular GPCR. Therefore, the most important parameters are binding affinity, logP, TPSA, Pgp efflux, and BBB penetration (though BBB is less critical for a cardiovascular target).
Let's compare the ligands property by property:
1. **MW:** Both ligands (345.36 and 345.45 Da) are within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (118.69) is slightly higher than Ligand B (87.22). Ligand B is preferable here, being closer to the <140 target for good absorption.
3. **logP:** Ligand B (2.418) is within the optimal 1-3 range, while Ligand A (0.005) is significantly lower. This is a major advantage for Ligand B, as low logP can hinder membrane permeability.
4. **HBD/HBA:** Both have 2 HBD and similar HBA counts (7 vs 6). This is acceptable for both.
5. **QED:** Ligand A (0.799) has a better QED score than Ligand B (0.528), indicating better overall drug-likeness.
6. **DILI:** Ligand B (38.542) has a lower DILI risk than Ligand A (49.632), which is preferable.
7. **BBB:** Ligand B (88.872) has significantly better BBB penetration than Ligand A (35.052). While not paramount for a cardiovascular target, higher BBB is generally favorable.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and difficult to interpret without knowing the scale. We'll assume they are similarly poor.
9. **Solubility:** Both have negative solubility values, again making direct comparison difficult.
10. **hERG:** Ligand A (0.096) has a slightly lower hERG risk than Ligand B (0.344), which is preferable.
11. **Cl_mic:** Ligand A (-25.771) has a much lower (better) microsomal clearance than Ligand B (44.852), suggesting better metabolic stability.
12. **t1/2:** Ligand B (-9.52) has a negative in vitro half-life, which is concerning and likely indicates rapid degradation. Ligand A (6.556) has a reasonable half-life.
13. **Pgp:** Ligand A (0.01) has much lower P-gp efflux liability than Ligand B (0.066), which is a significant advantage.
14. **Binding Affinity:** Ligand B (-8.1 kcal/mol) has a stronger binding affinity than Ligand A (-6.5 kcal/mol). This is a substantial advantage, potentially outweighing some ADME concerns.
**Overall Assessment:**
Ligand B has a superior binding affinity and logP, and a lower DILI risk. However, it has a concerning negative in vitro half-life and higher Pgp efflux. Ligand A has better metabolic stability (lower Cl_mic and positive t1/2), lower Pgp efflux, and a better QED score, but its logP is very low, and its binding affinity is weaker.
Given the importance of binding affinity for GPCRs, and the fact that the difference in affinity (-8.1 vs -6.5) is substantial (over 1.5 kcal/mol), I believe Ligand B is the more promising candidate, *despite* its metabolic liability. The metabolic issues could potentially be addressed through structural modifications during lead optimization. The poor logP of Ligand A is a more fundamental issue that would be harder to resolve.
**Output:**
0
2025-04-17 20:57:29,231 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (345.487 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (64.41) is significantly better than Ligand B (78.43). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (A: 2.813, B: 2.231), falling within the optimal 1-3 range.
4. **HBD:** Ligand A (0) is preferable to Ligand B (3). Fewer hydrogen bond donors generally improve membrane permeability.
5. **HBA:** Both ligands have the same number of HBA (3). This is acceptable.
6. **QED:** Ligand A (0.79) has a better QED score than Ligand B (0.545), indicating a more drug-like profile.
7. **DILI:** Ligand A (16.673) has a much lower DILI risk than Ligand B (22.8). This is a significant advantage.
8. **BBB:** Both ligands have reasonable BBB penetration, but Ligand A (81.776) is better than Ligand B (70.415). While not a primary concern for a cardiovascular target, higher BBB is generally favorable.
9. **Caco-2:** Ligand A (-4.605) is better than Ligand B (-5.001). Higher Caco-2 permeability suggests better intestinal absorption.
10. **Solubility:** Ligand A (-2.186) is better than Ligand B (-2.868). Better aqueous solubility is always preferred.
11. **hERG:** Both ligands have low hERG inhibition risk (A: 0.639, B: 0.448), which is good.
12. **Cl_mic:** Ligand B (21.071) has a lower microsomal clearance than Ligand A (27.378), suggesting better metabolic stability.
13. **t1/2:** Ligand B (7.792) has a significantly longer in vitro half-life than Ligand A (0.12). This is a major advantage.
14. **Pgp:** Ligand A (0.223) has a lower P-gp efflux liability than Ligand B (0.109), which is favorable.
15. **Binding Affinity:** Both ligands have very similar and excellent binding affinities (A: -7.2 kcal/mol, B: -7.3 kcal/mol). The difference is negligible.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A is better in logP, TPSA, and Pgp. The affinities are almost identical.
**Overall Assessment:**
Ligand A has a clear advantage in most ADME properties (DILI, solubility, Caco-2, QED, TPSA, Pgp) and a comparable binding affinity. While Ligand B has a better half-life and lower clearance, the superior overall profile of Ligand A, particularly its lower DILI risk and better predicted absorption, makes it the more promising candidate.
Output:
1
2025-04-17 20:57:29,231 - INFO - Here's my reasoning and the final output:
**Reasoning:**
We are evaluating two ligands for the ADRB2 receptor, a GPCR involved in cardiovascular function. Therefore, the priorities are logP, Pgp, TPSA, and affinity, with a secondary consideration for ADME properties like solubility, metabolic stability, and safety (DILI, hERG).
Let's compare the ligands property by property:
1. **MW:** Both ligands (358.43 and 350.41 Da) are within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (49.85) is better than Ligand B (58.2), falling comfortably below the 140 threshold for oral absorption.
3. **logP:** Both ligands have good logP values (2.296 and 3.253), within the optimal 1-3 range. Ligand B is slightly higher, which could be a minor concern for solubility, but not a dealbreaker.
4. **HBD/HBA:** Ligand A (0 HBD, 3 HBA) is preferable to Ligand B (2 HBD, 2 HBA) as fewer hydrogen bond donors generally improve permeability.
5. **QED:** Both have similar QED values (0.778 and 0.774), indicating good drug-likeness.
6. **DILI:** Ligand A (32.69%) has a significantly lower DILI risk than Ligand B (49.44%), a crucial advantage.
7. **BBB:** Both have good BBB penetration (86.66% and 80.88%), but Ligand A is better.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. This is a concern for both.
9. **Solubility:** Both have negative solubility values, indicating poor aqueous solubility. This is a significant drawback for both.
10. **hERG:** Both have low hERG inhibition liability (0.469 and 0.493), which is good.
11. **Cl_mic:** Ligand B has a lower microsomal clearance (34.84 mL/min/kg) than Ligand A (40.86 mL/min/kg), suggesting better metabolic stability.
12. **t1/2:** Ligand B has a significantly longer in vitro half-life (33.78 hours) than Ligand A (-15.38 hours). This is a major advantage for Ligand B.
13. **Pgp:** Both have very low P-gp efflux liability (0.104 and 0.146), which is desirable.
14. **Affinity:** Ligand B (-7.6 kcal/mol) has a substantially stronger binding affinity than Ligand A (-5.5 kcal/mol). This is a significant advantage, potentially outweighing some of the ADME concerns.
**Overall Assessment:**
Ligand B has a much stronger binding affinity and a longer half-life, which are critical for a GPCR ligand. While Ligand A has a lower DILI risk and slightly better TPSA and BBB penetration, the affinity difference is substantial. The slightly higher logP of Ligand B is manageable, and the lower clearance is a benefit. The poor Caco-2 and solubility are concerns for both, but can be addressed with formulation strategies. Given the importance of potency for GPCRs, Ligand B is the more promising candidate.
**Output:**
0
2025-04-17 20:57:29,231 - INFO - Batch 223 complete. Total preferences: 3568
2025-04-17 20:57:29,231 - INFO - Processing batch 224/512...
2025-04-17 20:58:19,036 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
We are targeting ADRB2, a GPCR. Therefore, the priorities are logP, Pgp efflux, TPSA, BBB penetration, and binding affinity. Let's analyze each ligand against these and other important parameters.
* **Molecular Weight:** Both ligands (380.535 and 363.889 Da) fall within the ideal 200-500 Da range.
* **TPSA:** Both ligands (60.85 and 58.22) are below the 140 A^2 threshold for good oral absorption, which is good.
* **logP:** Ligand A (1.843) is within the optimal 1-3 range. Ligand B (3.741) is at the higher end of the optimal range, potentially increasing off-target effects.
* **H-Bond Donors/Acceptors:** Both have acceptable HBD (1) and HBA (5/4) counts.
* **QED:** Both have reasonable QED scores (0.845 and 0.698), suggesting good drug-like properties.
* **DILI:** Both ligands have similar, acceptable DILI risk (35.905 and 39.434 percentile).
* **BBB:** Ligand B (61.574) has significantly better BBB penetration than Ligand A (39.55). While ADRB2 isn't necessarily a CNS target, increased BBB penetration can sometimes correlate with better overall distribution.
* **Caco-2 Permeability:** Both have negative Caco-2 values, which is unusual and likely indicates a problem with the modeling or data. However, the values are similar.
* **Aqueous Solubility:** Both have negative solubility values, which is also unusual and suggests poor aqueous solubility. The values are similar.
* **hERG:** Ligand A (0.206) has a much lower hERG inhibition liability than Ligand B (0.936), which is a significant advantage.
* **Microsomal Clearance:** Ligand B (73.622) has a higher microsomal clearance than Ligand A (49.134), indicating faster metabolism and potentially lower *in vivo* exposure.
* **In vitro Half-Life:** Ligand B (29.945) has a much longer half-life than Ligand A (-1.076), which is a significant advantage.
* **P-gp Efflux:** Ligand A (0.128) has lower P-gp efflux liability than Ligand B (0.44), which is favorable for bioavailability.
* **Binding Affinity:** Ligand B (-6.3 kcal/mol) has a slightly better binding affinity than Ligand A (-6.6 kcal/mol). However, the difference is small.
**Overall Assessment:**
Ligand A has a better safety profile (lower hERG, lower P-gp efflux) and better metabolic stability (lower Cl_mic). Ligand B has better BBB penetration and a longer half-life, but also has a higher logP and a higher risk of hERG inhibition. Given the slightly better binding affinity of Ligand B, it might seem preferable. However, the hERG risk associated with Ligand B is a significant concern for a cardiovascular target. The slight improvement in binding affinity doesn't outweigh the safety concerns.
**Output:**
1
2025-04-17 20:58:19,036 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (366.527 Da and 366.491 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (60.85) is significantly better than Ligand B (88.93). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand A is well below the 140 threshold, while Ligand B is approaching it.
**3. logP:** Both ligands have good logP values (1.597 and 1.678), falling within the optimal 1-3 range. No major distinction.
**4. H-Bond Donors:** Both have 1 HBD, which is acceptable.
**5. H-Bond Acceptors:** Ligand A has 4 HBAs, while Ligand B has 7. Ligand A is preferable as it keeps the HBA count lower, which generally improves permeability.
**6. QED:** Ligand A (0.821) has a higher QED score than Ligand B (0.688), indicating a more drug-like profile.
**7. DILI:** Ligand A (23.769) has a much lower DILI risk than Ligand B (54.556). This is a significant advantage for Ligand A.
**8. BBB:** Ligand A (65.452) has a better BBB percentile than Ligand B (52.074), although neither are exceptionally high. For a cardiovascular target, BBB penetration isn't *critical* but is still a positive.
**9. Caco-2 Permeability:** Ligand A (-4.904) has a better Caco-2 permeability than Ligand B (-5.246).
**10. Aqueous Solubility:** Both have negative solubility values, indicating poor solubility. Ligand A (-3.22) is slightly better than Ligand B (-3.031), but both are problematic.
**11. hERG Inhibition:** Ligand A (0.631) has a lower hERG inhibition liability than Ligand B (0.424), which is preferable.
**12. Microsomal Clearance:** Ligand B (63.613) has a higher microsomal clearance than Ligand A (56.511), meaning it's metabolized faster. Ligand A is more metabolically stable.
**13. In vitro Half-Life:** Ligand B (9.989) has a significantly longer half-life than Ligand A (3.155). This is a positive for Ligand B.
**14. P-gp Efflux:** Ligand A (0.367) has lower P-gp efflux liability than Ligand B (0.143), which is better for bioavailability.
**15. Binding Affinity:** Ligand B (-7.3) has a significantly stronger binding affinity than Ligand A (-6.0). This is a substantial advantage for Ligand B. A 1.3 kcal/mol difference is quite significant.
**Overall Assessment:**
While Ligand B boasts a superior binding affinity, Ligand A demonstrates a much more favorable ADME-Tox profile. Specifically, its lower DILI risk, better TPSA, QED, and P-gp efflux are compelling. The longer half-life of Ligand B is attractive, but the higher DILI risk is a major concern. Given the GPCR target class, balancing permeability (TPSA, logP, HBA) and safety (DILI, hERG) is crucial. The improved ADME properties of Ligand A, combined with acceptable affinity, outweigh the affinity advantage of Ligand B.
Output:
1
2025-04-17 20:58:19,036 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (340.379 and 345.447 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (78.87) is higher than Ligand B (62.63). While both are below the 140 threshold for oral absorption, the lower TPSA of Ligand B is preferable for a GPCR, potentially aiding membrane permeability.
3. **logP:** Both ligands (2.328 and 2.53) are within the optimal 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable, below the limit of 5. Ligand B is slightly better.
5. **HBA:** Ligand A (4) and Ligand B (5) are both acceptable, below the limit of 10.
6. **QED:** Both ligands have good QED scores (0.841 and 0.925), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (63.397) has a higher DILI risk than Ligand B (56.844). Lower is better, so Ligand B is favored.
8. **BBB:** Ligand A (82.474) shows better BBB penetration than Ligand B (78.674). This is a positive for GPCRs, but not a critical factor for ADRB2 which is not a CNS target.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.407 and -4.646). This is unusual and suggests poor permeability in this assay. It's difficult to interpret without further information, but it's a potential concern for both.
10. **Solubility:** Ligand A (-3.716) has worse solubility than Ligand B (-1.789). Better solubility is generally preferred.
11. **hERG:** Both ligands have low hERG inhibition risk (0.728 and 0.872). No significant difference.
12. **Cl_mic:** Ligand A (17.682) has lower microsomal clearance than Ligand B (24.866), indicating better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand B (31.199) has a much longer in vitro half-life than Ligand A (3.023). This is a substantial advantage, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.048 and 0.078). No significant difference.
15. **Binding Affinity:** Ligand B (-7.1 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.0 kcal/mol). This is a crucial advantage, as a 1.1 kcal/mol difference is substantial.
**Overall Assessment:**
Ligand B demonstrates a superior profile overall. While Ligand A has slightly better BBB penetration, this is less critical for a non-CNS target like ADRB2. Ligand B excels in key areas: significantly stronger binding affinity, longer half-life, lower DILI risk, and better solubility. The lower TPSA is also a plus. The Caco-2 values are concerning for both, but the other advantages of Ligand B outweigh this potential issue.
Output:
0
2025-04-17 20:58:19,037 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [355.435, 107.97 , -0.042, 3. , 5. , 0.538, 29.779, 33.23 ,
-5.782, -0.944, 0.109, -11.704, -1.67 , 0.013, -6.7 ]
**Ligand B:** [351.418, 51.91 , 3.065, 0. , 4. , 0.722, 29.391, 96.161,
-4.316, -3.855, 0.582, 44.171, 44.402, 0.19 , -5.6 ]
Here's a breakdown, prioritizing GPCR-relevant properties (logP, TPSA, Pgp, BBB, and affinity):
1. **Molecular Weight:** Both are within the ideal range (200-500 Da). A is 355.435, B is 351.418. Very similar.
2. **TPSA:** Ligand A (107.97) is higher than Ligand B (51.91). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. B is significantly better here.
3. **logP:** Ligand A (-0.042) is quite low, potentially hindering membrane permeability. Ligand B (3.065) is within the optimal range (1-3). This is a significant advantage for B.
4. **H-Bond Donors/Acceptors:** A has 3/5, B has 0/4. Both are acceptable, but B is slightly better with fewer donors.
5. **QED:** Both have good QED scores (A: 0.538, B: 0.722), indicating drug-likeness. B is better.
6. **DILI:** Both have low DILI risk (A: 29.779, B: 29.391), which is excellent.
7. **BBB:** Ligand A (33.23) has very low BBB penetration. Ligand B (96.161) has excellent BBB penetration. While this isn't *essential* for a cardiovascular target, it's a bonus and suggests potentially fewer off-target effects.
8. **Caco-2:** Ligand A (-5.782) is very poor, indicating poor intestinal absorption. Ligand B (-4.316) is also poor, but better than A.
9. **Solubility:** Ligand A (-0.944) is poor, while Ligand B (-3.855) is also poor. Both are concerning.
10. **hERG:** Both have low hERG risk (A: 0.109, B: 0.582). A is slightly better.
11. **Cl_mic:** Ligand A (-11.704) has a much lower (better) microsomal clearance than Ligand B (44.171), suggesting better metabolic stability.
12. **t1/2:** Ligand B (44.402) has a much longer in vitro half-life than Ligand A (-1.67). This is a significant advantage for B.
13. **Pgp:** Ligand A (0.013) has very low P-gp efflux, which is good. Ligand B (0.19) is slightly higher, but still acceptable.
14. **Binding Affinity:** Both have good binding affinity (A: -6.7, B: -5.6). Ligand A is significantly more potent.
**Overall Assessment:**
Ligand A has a superior binding affinity and metabolic stability. However, its poor logP, TPSA, Caco-2 permeability and solubility are major drawbacks. Ligand B, while slightly less potent, has a much better balance of properties, particularly regarding permeability (logP, TPSA, Caco-2) and BBB penetration. Given the GPCR-specific priorities, and the fact that a 1.1 kcal/mol difference in binding affinity can often be overcome with optimization, the better overall profile of Ligand B makes it the more promising candidate.
Output:
0
2025-04-17 20:58:19,037 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (334.419 and 340.423 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (54.12) is better than Ligand B (62.55). Both are below 140, but lower TPSA generally favors absorption.
3. **logP:** Ligand B (3.147) is closer to the optimal 1-3 range than Ligand A (4.923). Ligand A's logP is relatively high, potentially leading to solubility issues and off-target interactions.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1), but both are within the acceptable limit of 5.
5. **HBA:** Ligand A (2) is lower than Ligand B (3), which is preferable.
6. **QED:** Ligand B (0.909) has a better QED score than Ligand A (0.711), indicating a more drug-like profile.
7. **DILI:** Ligand B (33.773) has a significantly lower DILI risk than Ligand A (83.637). This is a major advantage for Ligand B.
8. **BBB:** Both ligands have good BBB penetration (Ligand A: 70.609, Ligand B: 69.058). This is less critical for ADRB2 (a cardiovascular target) but still a positive.
9. **Caco-2:** Both ligands have negative Caco-2 values, suggesting poor permeability. This is a concern for both.
10. **Solubility:** Ligand B (-3.376) has a better solubility score than Ligand A (-6.754).
11. **hERG:** Both are low risk (Ligand A: 0.815, Ligand B: 0.73).
12. **Cl_mic:** Ligand B (42.387) has a lower microsomal clearance than Ligand A (69.806), indicating better metabolic stability.
13. **t1/2:** Ligand B (-5.531) has a longer in vitro half-life than Ligand A (37.423).
14. **Pgp:** Ligand A (0.777) has a slightly lower P-gp efflux liability than Ligand B (0.445), which is a slight advantage.
15. **Binding Affinity:** Ligand A (-7.7) has a slightly better binding affinity than Ligand B (-7.0), but the difference is less than 1.5 kcal/mol.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B has better logP, TPSA, and significantly better DILI and metabolic stability. The slightly better affinity of Ligand A is not enough to overcome these significant advantages.
**Conclusion:**
Ligand B is the more promising candidate due to its superior ADME properties (lower DILI, better solubility, lower clearance, longer half-life) and acceptable binding affinity. While Ligand A has a slightly better affinity, the other factors make Ligand B a more viable drug candidate.
Output:
0
2025-04-17 20:58:19,037 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (351.363 and 348.531 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (122.72) is slightly higher than Ligand B (49.41). For a cardiovascular GPCR, TPSA isn't a *major* concern unless it's excessively high, but Ligand B is significantly better, suggesting potentially improved permeability.
3. **logP:** Ligand B (3.482) is better positioned within the optimal 1-3 range than Ligand A (0.382), which is quite low and could hinder membrane permeability. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable, being less than 5.
5. **HBA:** Ligand A (8) is higher than Ligand B (2). Lower HBA is generally preferred for permeability, giving Ligand B an edge.
6. **QED:** Both ligands have good QED scores (0.659 and 0.716), indicating good drug-like properties.
7. **DILI:** Ligand B (12.718) has a much lower DILI risk than Ligand A (54.634). This is a major advantage for Ligand B, as minimizing liver toxicity is crucial.
8. **BBB:** Ligand B (86.274) has a higher BBB penetration percentile than Ligand A (57.115). While ADRB2 isn't a CNS target, some peripheral exposure is acceptable, and higher BBB penetration can sometimes correlate with better overall distribution.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.912 and -4.407), which is unusual and suggests poor permeability. However, the values are very close.
10. **Solubility:** Ligand B (-3.9) has a worse solubility score than Ligand A (-1.471). Solubility is important, but can often be addressed with formulation strategies.
11. **hERG:** Ligand A (0.08) has a slightly lower hERG risk than Ligand B (0.394), but both are very low and not a major concern.
12. **Cl_mic:** Both ligands have similar microsomal clearance values (71.878 and 74.079).
13. **t1/2:** Ligand B (16.399) has a longer in vitro half-life than Ligand A (10.55), which is desirable for less frequent dosing.
14. **Pgp:** Ligand A (0.035) has a lower Pgp efflux liability than Ligand B (0.028), which is preferable.
15. **Binding Affinity:** Ligand A (-6.6 kcal/mol) has a slightly better binding affinity than Ligand B (-5.3 kcal/mol). This is a 1.3 kcal/mol difference, which is significant, but not overwhelming given the other factors.
**Overall Assessment:**
Ligand B clearly outperforms Ligand A in several critical ADME properties, including logP, DILI risk, BBB penetration, and in vitro half-life. While Ligand A has a slightly better binding affinity and lower Pgp efflux, the improvements in safety (DILI) and pharmacokinetic properties (logP, t1/2) offered by Ligand B are more compelling for overall drug development potential. The TPSA is also significantly better for Ligand B. The Caco-2 values are concerning for both, but similar.
**Output:**
0
2025-04-17 20:58:19,037 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (346.431 and 350.478 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (67.67) is higher than Ligand B (42.43). For a GPCR like ADRB2, lower TPSA is generally preferred for better permeability, giving a slight edge to Ligand B.
3. **logP:** Ligand B (4.205) is higher than Ligand A (1.07). While logP > 4 can be problematic, it's not excessively high here. Ligand A's logP is quite low, potentially hindering membrane permeability. Ligand B is favored.
4. **HBD:** Both have 0 HBD, which is good.
5. **HBA:** Ligand A has 5 HBA, and Ligand B has 3. Both are acceptable, but lower is slightly better. Ligand B is favored.
6. **QED:** Ligand A (0.821) has a better QED score than Ligand B (0.705), indicating a more drug-like profile. This favors Ligand A.
7. **DILI:** Ligand B (29.042) has a significantly lower DILI risk than Ligand A (42.575). This is a substantial advantage for Ligand B.
8. **BBB:** Both ligands have very similar BBB penetration (Ligand A: 84.8, Ligand B: 84.878). This parameter isn't a major differentiator in this case.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability.
10. **Solubility:** Ligand A (-0.911) has better solubility than Ligand B (-2.943). Solubility is important, favoring Ligand A.
11. **hERG:** Ligand A (0.161) has a lower hERG risk than Ligand B (0.817). This is a significant advantage for Ligand A, as hERG inhibition can lead to cardiotoxicity.
12. **Cl_mic:** Ligand A (42.63) has lower microsomal clearance than Ligand B (68.096), suggesting better metabolic stability. This favors Ligand A.
13. **t1/2:** Ligand A (0.798) has a shorter in vitro half-life than Ligand B (19.5). Longer half-life is generally preferred, favoring Ligand B.
14. **Pgp:** Ligand A (0.072) has lower P-gp efflux than Ligand B (0.431), which is desirable for better oral bioavailability and potentially better CNS exposure. This favors Ligand A.
15. **Affinity:** Ligand A (-7.7 kcal/mol) has a slightly better binding affinity than Ligand B (-7.4 kcal/mol). While the difference is small, it's still a positive for Ligand A.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand B initially appears stronger due to its more favorable logP and lower TPSA. However, Ligand A demonstrates a significant advantage in safety parameters (DILI, hERG) and metabolic stability (Cl_mic). The slightly better affinity of Ligand A and its lower Pgp efflux also contribute to its favorability. The solubility of Ligand A is also better. While Ligand B has a better half-life, the other benefits of Ligand A outweigh this.
Therefore, I believe Ligand A is the more promising drug candidate.
Output:
1
2025-04-17 20:58:19,037 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.463 and 349.431 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (88.91) is better than Ligand B (112.73). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have acceptable logP values (1.493 and 0.766), falling within the 1-3 range. Ligand A is slightly better.
4. **HBD:** Ligand A (2) is preferable to Ligand B (3). Lower HBD is generally better for permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (4). Lower HBA is generally better for permeability.
6. **QED:** Ligand A (0.746) is better than Ligand B (0.602), indicating a more drug-like profile.
7. **DILI:** Ligand A (39.162) is significantly better than Ligand B (14.889). Lower DILI risk is crucial. This is a major advantage for Ligand A.
8. **BBB:** Both ligands have similar BBB penetration (56.766 and 53.625). Not a major factor for a cardiovascular target.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.401 and -5.286), which is unusual and suggests poor permeability. However, the values are very close.
10. **Solubility:** Both ligands have similarly poor aqueous solubility (-1.771 and -1.807). This is a concern for both, but not a deciding factor.
11. **hERG:** Ligand A (0.087) is significantly better than Ligand B (0.343), indicating a lower risk of cardiotoxicity. This is a critical advantage for a cardiovascular target.
12. **Cl_mic:** Ligand A (20.4) is slightly better than Ligand B (19.387), suggesting better metabolic stability.
13. **t1/2:** Ligand A (5.887) is much better than Ligand B (-12.889). A positive half-life is preferable to a negative one.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.037). No significant difference.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.1 and -6.2 kcal/mol). The difference is negligible.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, and affinity are important. Ligand A is slightly better on logP and TPSA. However, the significant advantages of Ligand A in DILI risk and hERG inhibition, coupled with its better QED and half-life, make it the more promising candidate. The similar affinities mean these ADMET properties become the deciding factors.
**Output:**
1
2025-04-17 20:58:19,038 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.43 and 358.45 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (80.68) is higher than Ligand B (67.87). Both are below the 140 threshold for oral absorption, but B is better.
3. **logP:** Ligand A (3.24) is within the optimal 1-3 range, while Ligand B (1.25) is at the lower end. For a GPCR, a slightly higher logP is generally preferred for membrane permeability, giving an edge to A.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable.
5. **HBA:** Ligand A (6) and Ligand B (4) are both acceptable.
6. **QED:** Both ligands have reasonable QED scores (0.71 and 0.64), indicating good drug-like properties.
7. **DILI:** Ligand A (57.70) has a higher DILI risk than Ligand B (9.31). This is a significant advantage for B.
8. **BBB:** Ligand B (91.04) has a much higher BBB penetration percentile than Ligand A (57.77). While ADRB2 isn't exclusively a CNS target, some cardiovascular effects are mediated by central pathways, and better BBB penetration can be beneficial, or at least not detrimental.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-4.75) has worse solubility than Ligand B (-1.63). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.82) has a slightly higher hERG risk than Ligand B (0.39), but both are relatively low.
12. **Cl_mic:** Ligand A (100.17) has a significantly higher microsomal clearance than Ligand B (10.74). This suggests Ligand B is more metabolically stable.
13. **t1/2:** Ligand B (-17.99) has a much longer in vitro half-life than Ligand A (34.56). This is a major advantage for B.
14. **Pgp:** Ligand A (0.42) has lower P-gp efflux than Ligand B (0.02). Lower efflux is better.
15. **Affinity:** Ligand A (-7.9) has a significantly better binding affinity than Ligand B (-6.0). This is a substantial advantage for A, potentially outweighing some ADME concerns.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand A has a better logP and Pgp profile, but Ligand B has a much better TPSA, DILI, BBB, metabolic stability (Cl_mic, t1/2), and solubility. The affinity difference is significant (-1.9 kcal/mol), but the ADME profile of Ligand B is substantially better, particularly the lower DILI risk and improved metabolic stability.
**Conclusion:**
While Ligand A's affinity is very attractive, the superior ADME properties of Ligand B, especially the significantly lower DILI risk, better metabolic stability, and improved solubility, make it the more promising drug candidate. The affinity difference, while substantial, can potentially be addressed through further optimization. A cleaner starting point with better ADME properties is preferable.
Output:
0
2025-04-17 20:58:19,038 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (362.769 Da and 370.856 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (98.54) is higher than Ligand B (69.3). For a cardiovascular GPCR, TPSA isn't a *major* concern unless extremely high, but lower is generally preferred for permeability. Ligand B is better.
3. **logP:** Ligand A (3.777) is slightly higher than Ligand B (2.369), both within the optimal 1-3 range. Ligand A is marginally better.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 5 HBA, Ligand B has 3. Both are acceptable, but lower is slightly preferred. Ligand B is better.
6. **QED:** Ligand B (0.888) has a significantly better QED score than Ligand A (0.495), indicating a more drug-like profile. Ligand B is much better.
7. **DILI:** Ligand A (96.278) has a very high DILI risk, while Ligand B (43.35) is within a good range (<40 is ideal, <60 is good). This is a *major* concern for Ligand A. Ligand B is significantly better.
8. **BBB:** Ligand A (55.293) and Ligand B (74.292). While ADRB2 isn't strictly a CNS target, some CNS penetration can be acceptable and even beneficial for off-target effects, and lower efflux is always good. Ligand B is better.
9. **Caco-2:** Both are negative, indicating poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-5.681) and Ligand B (-3.601) both have poor solubility. Ligand B is slightly better.
11. **hERG:** Ligand A (0.459) and Ligand B (0.669) are both relatively low risk, but Ligand B is slightly better.
12. **Cl_mic:** Ligand A (105.649) has a higher microsomal clearance than Ligand B (16.605), indicating faster metabolism and lower metabolic stability. Ligand B is much better.
13. **t1/2:** Ligand A (20.805) has a longer half-life than Ligand B (-18.188). This is a positive for Ligand A.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.191 and 0.186 respectively). No significant difference.
15. **Binding Affinity:** Ligand B (-7.5 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.2 kcal/mol). This is a substantial advantage for Ligand B.
**Overall Assessment:**
Ligand B is clearly the superior candidate. While both have solubility and Caco-2 permeability issues, Ligand B excels in crucial areas: significantly lower DILI risk, better QED, better metabolic stability (lower Cl_mic), stronger binding affinity, and better BBB penetration. The longer half-life of Ligand A is a positive, but it's outweighed by the severe DILI risk and weaker binding. The difference in binding affinity (-7.5 vs -6.2) is also significant and can often overcome other minor drawbacks.
Output:
0
2025-04-17 20:58:19,038 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [361.511, 62.3, 3.173, 1, 4, 0.876, 57.813, 62.233, -4.862, -3.583, 0.386, 59.756, 7.796, 0.268, -7.4]
**Ligand B:** [376.479, 129.88, -0.683, 2, 5, 0.608, 31.02, 63.086, -5.542, -1.467, 0.094, -7.1, 13.976, 0.008, -6.9]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (361.511) is slightly preferred.
2. **TPSA:** Ligand A (62.3) is excellent, well below the 140 threshold. Ligand B (129.88) is higher, but still acceptable.
3. **logP:** Ligand A (3.173) is optimal. Ligand B (-0.683) is significantly lower, potentially leading to poor membrane permeability. This is a major drawback.
4. **HBD:** Both have acceptable HBD counts (1 & 2).
5. **HBA:** Both have acceptable HBA counts (4 & 5).
6. **QED:** Ligand A (0.876) is excellent, indicating high drug-likeness. Ligand B (0.608) is still reasonable, but less favorable.
7. **DILI:** Ligand A (57.813) has a moderate DILI risk. Ligand B (31.02) is much lower, a significant advantage.
8. **BBB:** Both have similar BBB penetration (62.233 and 63.086).
9. **Caco-2:** Both have negative values, which is unusual. I will assume these are logP-scale values, and thus lower values indicate poorer permeability. Ligand A (-4.862) is worse than Ligand B (-5.542).
10. **Solubility:** Ligand A (-3.583) is worse than Ligand B (-1.467).
11. **hERG:** Ligand A (0.386) is better than Ligand B (0.094).
12. **Cl_mic:** Ligand A (59.756) is higher, indicating faster clearance and lower metabolic stability. Ligand B (-7.1) is excellent, indicating very slow clearance.
13. **t1/2:** Ligand B (13.976) has a much longer half-life than Ligand A (7.796).
14. **Pgp:** Ligand A (0.268) is better than Ligand B (0.008).
15. **Affinity:** Ligand A (-7.4) has a slightly better binding affinity than Ligand B (-6.9).
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are crucial. Ligand A has a much better logP, and slightly better affinity and Pgp efflux. However, Ligand B has a significantly better DILI score, metabolic stability (Cl_mic, t1/2), and solubility.
**Overall Assessment:**
While Ligand A has a slightly better affinity and logP, the significantly better metabolic stability, lower DILI risk, and improved solubility of Ligand B are more important for overall drug development. The poor logP of Ligand B is a concern, but can potentially be addressed through structural modifications. The combination of favorable ADME properties in Ligand B outweighs the small difference in binding affinity.
Output:
0
2025-04-17 20:58:19,038 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (350.365 and 347.419 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (70.59) is significantly better than Ligand B (105.98). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (3.822) is optimal, while Ligand B (0.85) is a bit low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (3) and Ligand B (2) are both acceptable.
5. **HBA:** Ligand A (3) is better than Ligand B (6), as lower HBA is generally preferred for permeability.
6. **QED:** Both ligands (0.742 and 0.678) have good drug-likeness scores.
7. **DILI:** Ligand A (61.07) has a slightly higher DILI risk than Ligand B (53.432), but both are within an acceptable range (<60 is good).
8. **BBB:** Ligand A (45.909) and Ligand B (56.883) are both low, which is appropriate for a cardiovascular target.
9. **Caco-2:** Ligand A (-4.81) is better than Ligand B (-5.056), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-4.664) is better than Ligand B (-2.564). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.691) is better than Ligand B (0.027), indicating a lower risk of cardiotoxicity. This is *critical* for a cardiovascular target.
12. **Cl_mic:** Ligand B (29.171) has significantly lower microsomal clearance than Ligand A (65.886), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-7.145) has a much longer in vitro half-life than Ligand A (16.76). This is a significant advantage.
14. **Pgp:** Ligand A (0.203) is better than Ligand B (0.053), meaning less P-glycoprotein efflux and potentially better bioavailability.
15. **Affinity:** Ligand B (-7.1) has a slightly better binding affinity than Ligand A (-6.6), a 0.5 kcal/mol difference.
**Overall Assessment:**
While Ligand B has a slightly better binding affinity and significantly better metabolic stability (lower Cl_mic and longer t1/2), Ligand A has a more favorable profile across several key ADME properties. Specifically, the lower TPSA, better logP, higher solubility, and *much* lower hERG risk of Ligand A are crucial for a cardiovascular drug candidate. The slightly weaker binding affinity of Ligand A is likely surmountable with further optimization, while mitigating the hERG risk of Ligand B could be very challenging. Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity), Ligand A strikes a better balance.
Output:
1
2025-04-17 20:58:19,038 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (a cardiovascular GPCR) drug candidates.
**Ligand A:** [339.366, 48.3, 3.163, 0, 4, 0.671, 75.184, 82.823, -4.462, -4.491, 0.783, 91.215, -0.475, 0.545, -6.4]
**Ligand B:** [350.379, 121.94, -1.387, 2, 8, 0.44, 49.36, 32.416, -5.311, -0.947, 0.035, -5.609, 14.423, 0.01, -7]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, Affinity, and to a lesser extent BBB):
1. **MW:** Both are within the acceptable range (200-500 Da). Ligand A (339.366) is slightly preferred.
2. **TPSA:** Ligand A (48.3) is excellent, well below the 140 threshold, and good for permeability. Ligand B (121.94) is higher, potentially hindering absorption. This is a significant advantage for A.
3. **logP:** Ligand A (3.163) is optimal. Ligand B (-1.387) is quite low, raising concerns about permeability and potentially bioavailability. This is a major drawback for B.
4. **HBD/HBA:** Ligand A (0 HBD, 4 HBA) is favorable. Ligand B (2 HBD, 8 HBA) is acceptable, but slightly higher counts could impact permeability.
5. **QED:** Ligand A (0.671) is good, indicating drug-likeness. Ligand B (0.44) is lower, suggesting a less ideal drug-like profile.
6. **DILI:** Ligand A (75.184) is moderate, but acceptable. Ligand B (49.36) is better, indicating lower liver injury risk.
7. **BBB:** Ligand A (82.823) is good, suggesting some potential for CNS penetration, although ADRB2 is primarily cardiovascular, so this isn't critical. Ligand B (32.416) is low.
8. **Caco-2:** Ligand A (-4.462) is poor, indicating low permeability. Ligand B (-5.311) is also poor.
9. **Solubility:** Ligand A (-4.491) is poor. Ligand B (-0.947) is slightly better, but still not great.
10. **hERG:** Ligand A (0.783) is good. Ligand B (0.035) is excellent, indicating very low cardiotoxicity risk.
11. **Cl_mic:** Ligand A (91.215) is high, suggesting rapid metabolism and potentially low oral bioavailability. Ligand B (-5.609) is excellent, indicating high metabolic stability. This is a significant advantage for B.
12. **t1/2:** Ligand A (-0.475) is very short. Ligand B (14.423) is good.
13. **Pgp:** Ligand A (0.545) is moderate. Ligand B (0.01) is excellent, indicating low efflux and better bioavailability. This is a major advantage for B.
14. **Affinity:** Ligand A (-6.4) is good. Ligand B (-7) is *better* by 0.6 kcal/mol. This is a substantial difference in binding.
**Overall Assessment:**
Ligand B has a significantly better binding affinity, excellent metabolic stability (low Cl_mic, good t1/2), and low P-gp efflux. While its logP is a concern, the strong affinity and favorable ADME properties (DILI, hERG) are compelling. Ligand A has a better TPSA, but suffers from poor Caco-2 permeability, high metabolic clearance, and a shorter half-life. The lower logP of Ligand B is a drawback, but can potentially be addressed through further optimization. The affinity difference is substantial enough to outweigh the logP concern, especially given the other advantages of Ligand B.
Output:
0
2025-04-17 20:58:19,039 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (363.933 and 374.507 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (35.58) is significantly lower than Ligand B (107.61). For a GPCR, lower TPSA is generally preferred for better permeability, and Ligand A is well below the 140 threshold. Ligand B is higher, potentially hindering absorption.
**3. logP:** Ligand A (4.706) is higher than Ligand B (-0.436). While 4.706 is approaching the upper limit, it's still within a reasonable range. Ligand B's logP is quite low, which could severely limit its ability to cross cell membranes.
**4. H-Bond Donors:** Ligand A (1) is better than Ligand B (3). Fewer HBDs generally improve permeability.
**5. H-Bond Acceptors:** Ligand A (2) is better than Ligand B (5). Fewer HBAs generally improve permeability.
**6. QED:** Ligand A (0.844) is significantly better than Ligand B (0.534), indicating a more drug-like profile.
**7. DILI:** Ligand A (37.185) has a slightly higher DILI risk than Ligand B (30.206), but both are below the concerning threshold of 60.
**8. BBB:** Ligand A (93.292) has a much higher BBB penetration potential than Ligand B (40.403). While ADRB2 isn't *exclusively* a CNS target, some CNS exposure can be beneficial and isn't necessarily detrimental for cardiovascular applications.
**9. Caco-2 Permeability:** Ligand A (-4.601) is better than Ligand B (-5.823), indicating better intestinal absorption.
**10. Aqueous Solubility:** Ligand A (-4.547) is better than Ligand B (-1.365).
**11. hERG Inhibition:** Ligand A (0.933) has a lower hERG risk than Ligand B (0.127).
**12. Microsomal Clearance:** Ligand A (38.316) has higher clearance than Ligand B (6.296), suggesting lower metabolic stability. This is a drawback for Ligand A.
**13. In vitro Half-Life:** Ligand A (6.175) has a shorter half-life than Ligand B (-38.517). This is a drawback for Ligand A.
**14. P-gp Efflux:** Ligand A (0.52) has higher P-gp efflux than Ligand B (0.007). This is a drawback for Ligand A.
**15. Binding Affinity:** Ligand A (-7.2) has a slightly better binding affinity than Ligand B (-6.2). This is a 1 kcal/mol difference, which is significant.
**Overall Assessment:**
Ligand A excels in most key ADME properties (TPSA, logP, QED, solubility, permeability, hERG) and has a slightly better binding affinity. While its metabolic stability (Cl_mic, t1/2) and P-gp efflux are less favorable than Ligand B, the substantial advantages in permeability, solubility, and drug-likeness outweigh these drawbacks, especially considering the GPCR target class. Ligand B's very low logP is a major concern, likely hindering its absorption and bioavailability.
Output:
1
2025-04-17 20:58:19,039 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (386.279 and 366.487 Da) are within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (81.67) is slightly higher than Ligand B (74.77). Both are below the 140 threshold for oral absorption, but closer to the 90 threshold for CNS targets (less relevant for ADRB2, a cardiovascular target). Ligand B is slightly preferred.
3. **logP:** Both ligands have good logP values (1.437 and 1.112), falling within the optimal 1-3 range. No significant difference.
4. **HBD:** Ligand A has 3 HBD, and Ligand B has 1. Both are within the acceptable limit of 5. Ligand B is slightly preferred.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 6. Both are within the acceptable limit of 10. Ligand A is slightly preferred.
6. **QED:** Both ligands have good QED scores (0.734 and 0.782), indicating good drug-like properties. Ligand B is slightly preferred.
7. **DILI:** Ligand A (44.281) has a slightly higher DILI risk than Ligand B (36.293). Both are below the concerning 60 threshold, but Ligand B is preferred.
8. **BBB:** Ligand A (24.855) has a very low BBB penetration, while Ligand B (65.258) has a good BBB penetration. This isn't a primary concern for ADRB2, but it's a slight advantage for Ligand B.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.284 and -5.385). This is unusual and suggests poor permeability. However, the values are similar, so it doesn't differentiate the ligands.
10. **Solubility:** Both ligands have very poor aqueous solubility (-2.723 and -1.511). This is a significant concern for both.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.194 and 0.126). No significant difference.
12. **Cl_mic:** Ligand A has a much higher (worse) microsomal clearance (-40.083) than Ligand B (-16.457). This suggests Ligand B is more metabolically stable.
13. **t1/2:** Ligand A has a longer in vitro half-life (20.145 hours) than Ligand B (0.564 hours). This is a significant advantage for Ligand A.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.089 and 0.049). No significant difference.
15. **Binding Affinity:** Ligand B (-7.4 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.7 kcal/mol). This is a substantial advantage, exceeding the 1.5 kcal/mol threshold.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in affinity and has slightly better TPSA and Pgp. The improved metabolic stability (lower Cl_mic) is also a significant benefit. While Ligand A has a longer half-life, the superior binding affinity of Ligand B is more critical for a GPCR target, and the poor solubility of both compounds is a shared issue that will need to be addressed regardless.
**Conclusion:**
Considering the balance of properties, particularly the significantly stronger binding affinity and better metabolic stability, Ligand B is the more promising drug candidate.
Output:
0
2025-04-17 20:58:19,039 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (365.5 & 356.5 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (69.64) is significantly better than Ligand B (78.87). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (1.395 & 1.953), falling within the optimal 1-3 range. Ligand B is slightly higher, which *could* be a minor concern for solubility, but not a dealbreaker.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer hydrogen bond donors generally improve membrane permeability.
5. **HBA:** Ligand A (6) is better than Ligand B (4). Lower HBA is generally preferred for permeability.
6. **QED:** Ligand A (0.81) is significantly better than Ligand B (0.627), indicating a more drug-like profile.
7. **DILI:** Ligand A (34.393) has a much lower DILI risk than Ligand B (13.3). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (76.696) has a higher BBB penetration percentile than Ligand B (41.295). While not a primary concern for a cardiovascular target, higher BBB is generally favorable.
9. **Caco-2:** Both ligands have very poor Caco-2 permeability (-4.801 and -4.854). This is a significant drawback for both, suggesting poor oral absorption.
10. **Solubility:** Ligand A (-1.113) is slightly better than Ligand B (-1.54), but both are quite poor.
11. **hERG:** Both ligands have low hERG inhibition risk (0.359 & 0.398). No significant difference here.
12. **Cl_mic:** Ligand A (11.812) has a much lower microsomal clearance than Ligand B (45.112), indicating better metabolic stability.
13. **t1/2:** Ligand A (16.038) has a shorter in vitro half-life than Ligand B (33.291). This is a slight advantage for Ligand B.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.266 & 0.088). No significant difference here.
15. **Binding Affinity:** Both ligands have similar and excellent binding affinity (-6.5 & -6.0 kcal/mol). The difference is not substantial enough to outweigh other factors.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Both ligands are good on logP and affinity. Ligand A is significantly better on TPSA and Pgp.
**Overall Assessment:**
Ligand A demonstrates a superior overall profile. It has a better QED score, significantly lower DILI risk, better metabolic stability (lower Cl_mic), and better TPSA. While both have poor Caco-2 permeability, the other advantages of Ligand A outweigh this drawback. The longer half-life of Ligand B is a minor advantage, but not enough to compensate for the other deficiencies.
Output:
1
2025-04-17 20:58:19,039 - INFO - Batch 224 complete. Total preferences: 3584
2025-04-17 20:58:19,039 - INFO - Processing batch 225/512...
2025-04-17 20:59:08,656 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands (358.32 and 346.36 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (74.65) is better than Ligand B (78.87). Both are below the 140 threshold for oral absorption, but closer to the ideal for GPCRs.
3. **logP:** Both ligands (1.243 and 0.902) are within the optimal 1-3 range. Ligand B is slightly lower, which could slightly hinder permeation, but it's not a major concern.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Both ligands have 4 HBA, which is within the acceptable range.
6. **QED:** Ligand A (0.821) is slightly better than Ligand B (0.794), indicating a more drug-like profile.
7. **DILI:** Ligand A (70.531) has a higher DILI risk than Ligand B (47.266). This is a significant advantage for Ligand B.
8. **BBB:** Both ligands have good BBB penetration (78.6 and 71.8 percentile). This is less critical for a cardiovascular target like ADRB2, but still positive.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Both ligands have negative solubility values, which is also unusual.
11. **hERG:** Both ligands have low hERG inhibition liability (0.401 and 0.388). No significant difference.
12. **Cl_mic:** Ligand A (1.627) has significantly lower microsomal clearance than Ligand B (15.659), indicating better metabolic stability. This is a major advantage for Ligand A.
13. **t1/2:** Ligand A (18.363) has a much longer in vitro half-life than Ligand B (-23.468). This is a substantial advantage for Ligand A.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.035 and 0.07). No significant difference.
15. **Binding Affinity:** Ligand A (-6.7 kcal/mol) has a slightly better binding affinity than Ligand B (-6.1 kcal/mol). While the difference is less than 1.5 kcal/mol, it contributes to the overall preference.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Both ligands perform reasonably well on logP and Pgp. Ligand A has a slightly better TPSA and affinity. The biggest differentiator is the DILI risk (Ligand B is much lower) and metabolic stability/half-life (Ligand A is significantly better).
**Overall Assessment:**
While Ligand B has a lower DILI risk, the significantly improved metabolic stability (lower Cl_mic and longer t1/2) and slightly better affinity of Ligand A are crucial for a viable drug candidate. The DILI risk, while important, can be addressed through further optimization. The improved PK profile of Ligand A is more difficult to rectify later in development.
Output:
1
2025-04-17 20:59:08,657 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [345.399, 93.46, 1.874, 2, 5, 0.762, 56.34, 56.534, -4.86, -2.307, 0.329, 34.532, 36.932, 0.045, -6.9]
**Ligand B:** [372.495, 136.06, 1.202, 3, 5, 0.301, 31.563, 26.134, -5.663, -2.067, 0.081, 39.698, 13.216, 0.003, -5.4]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (345.4) is slightly preferred due to being a bit lower.
2. **TPSA:** Ligand A (93.46) is excellent, well below the 140 threshold. Ligand B (136.06) is still acceptable but less ideal.
3. **logP:** Both are good (1.874 and 1.202, respectively), falling within the 1-3 range. Ligand A is slightly better.
4. **HBD:** Ligand A (2) and Ligand B (3) are both acceptable, being less than 5.
5. **HBA:** Both have 5 HBA, which is acceptable.
6. **QED:** Ligand A (0.762) is significantly better than Ligand B (0.301), indicating a much more drug-like profile.
7. **DILI:** Ligand A (56.34) is higher than Ligand B (31.563), indicating a higher risk of liver injury. Ligand B is preferred here.
8. **BBB:** Ligand A (56.534) is better than Ligand B (26.134), although neither are particularly high. For a cardiovascular target, BBB isn't *critical*, but some penetration could be beneficial for off-target effects or peripheral actions.
9. **Caco-2:** Ligand A (-4.86) and Ligand B (-5.663) are both very poor. This is a significant concern for oral bioavailability for both.
10. **Solubility:** Both are very poor (-2.307 and -2.067 respectively). This is a major drawback for both compounds.
11. **hERG:** Ligand A (0.329) is better than Ligand B (0.081), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand B (39.698) has a slightly higher clearance than Ligand A (34.532), meaning A is more metabolically stable.
13. **t1/2:** Ligand A (36.932) has a significantly longer half-life than Ligand B (13.216), which is a major advantage.
14. **Pgp:** Ligand A (0.045) has lower P-gp efflux than Ligand B (0.003), indicating better absorption and bioavailability.
15. **Affinity:** Ligand A (-6.9 kcal/mol) has a stronger binding affinity than Ligand B (-5.4 kcal/mol). This is a substantial difference.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, we prioritize logP, TPSA, Pgp, and affinity. Ligand A is better in terms of logP, TPSA, Pgp, and *significantly* better in affinity. The QED score is also much higher for Ligand A. While Ligand B has a lower DILI risk, the substantial advantage in binding affinity and overall drug-likeness of Ligand A outweighs this concern, especially given that the DILI risk for A is not excessively high. The poor Caco-2 and solubility are concerning for both, but can be addressed with formulation strategies.
**Conclusion:**
Ligand A is the more promising candidate due to its superior binding affinity, better drug-like properties (QED), improved metabolic stability, longer half-life, and lower P-gp efflux.
Output:
1
2025-04-17 20:59:08,657 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands (345.399 and 358.511 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (87.74) is slightly higher than Ligand B (58.98). For a cardiovascular GPCR, TPSA isn't a *major* concern (unlike CNS targets), but lower is generally preferred for absorption. Ligand B has a clear advantage here.
3. **logP:** Ligand A (0.746) is below the optimal 1-3 range, potentially hindering permeability. Ligand B (3.674) is at the higher end of optimal, which is good for membrane permeability but could raise solubility concerns.
4. **HBD:** Ligand A (2) is reasonable. Ligand B (0) is also good, minimizing potential for off-target interactions. No clear advantage.
5. **HBA:** Ligand A (4) is good. Ligand B (5) is also acceptable. No significant difference.
6. **QED:** Both ligands (0.77 and 0.722) are above the 0.5 threshold, indicating good drug-likeness. No clear advantage.
7. **DILI:** Ligand A (38.154) has a lower DILI risk than Ligand B (45.095), which is a significant advantage.
8. **BBB:** Ligand B (73.905) shows better BBB penetration than Ligand A (60.76). While ADRB2 is primarily a cardiovascular target, some CNS off-target effects are possible, and moderate BBB penetration isn't necessarily detrimental.
9. **Caco-2:** Both ligands have very poor Caco-2 permeability (-5.007 and -5.018). This is a significant concern for oral bioavailability for both.
10. **Solubility:** Ligand A (-2.288) has slightly better solubility than Ligand B (-3.696). This is helpful given the higher logP of Ligand B.
11. **hERG:** Ligand A (0.062) has a much lower hERG risk than Ligand B (0.374). This is a critical safety parameter, and Ligand A is significantly better.
12. **Cl_mic:** Ligand A (-18.454) has a much lower (better) microsomal clearance than Ligand B (68.381), indicating greater metabolic stability.
13. **t1/2:** Ligand A (-19.409) has a much longer in vitro half-life than Ligand B (1.718). This is a significant advantage for dosing convenience.
14. **Pgp:** Ligand A (0.013) has a much lower P-gp efflux liability than Ligand B (0.289), which is beneficial for bioavailability.
15. **Binding Affinity:** Ligand A (-7.2) has a slightly better binding affinity than Ligand B (-5.7). While the difference is not huge, it's still a positive factor.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B has a better logP and BBB, but Ligand A excels in DILI, hERG, Cl_mic, t1/2, Pgp, and has comparable affinity. The safety profile (DILI and hERG) and metabolic stability (Cl_mic, t1/2) are crucial for cardiovascular drugs. The poor Caco-2 values for both are concerning, but can be addressed with formulation strategies.
**Conclusion:**
Considering the balance of properties, particularly the significantly better safety profile (DILI, hERG) and metabolic stability (Cl_mic, t1/2) of Ligand A, I believe it is the more promising drug candidate. The slightly better affinity further supports this decision.
Output:
1
2025-04-17 20:59:08,657 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.431 and 353.507 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (93.51) is slightly higher than Ligand B (61.88). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B has a clear advantage.
3. **logP:** Both ligands (1.546 and 1.785) are within the optimal 1-3 range. Similar.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 6 HBA, while Ligand B has 4. Both are acceptable (<=10), but Ligand B is slightly better.
6. **QED:** Ligand A (0.873) has a significantly better QED score than Ligand B (0.642), indicating a more drug-like profile. This is a substantial advantage for Ligand A.
7. **DILI:** Ligand A (42.187) has a higher DILI risk than Ligand B (10.275). This is a significant concern for Ligand A. Ligand B is much preferred here.
8. **BBB:** Ligand A (88.872) has a higher BBB penetration percentile than Ligand B (70.143). While ADRB2 is a cardiovascular target (so BBB isn't *critical*), some CNS exposure can sometimes lead to off-target effects. However, the difference isn't huge.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.585 and -4.775). This is unusual and suggests poor permeability. It's difficult to interpret without further information, but it's a negative for both.
10. **Solubility:** Ligand A (-2.879) has worse solubility than Ligand B (-0.977). Solubility is important for bioavailability, so Ligand B is favored.
11. **hERG:** Both ligands have low hERG inhibition liability (0.86 and 0.482), which is good. Ligand B is slightly better.
12. **Cl_mic:** Ligand A (3.998) has a lower microsomal clearance than Ligand B (26.358), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (40.774) has a longer in vitro half-life than Ligand B (5.297). This is a substantial advantage for Ligand A, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.093) has lower P-gp efflux than Ligand B (0.114), which is slightly better.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-5.6 and -5.7 kcal/mol). The difference is negligible.
**Overall Assessment & GPCR-Specific Priorities:**
For a cardiovascular GPCR like ADRB2, we prioritize logP, TPSA, Pgp, and affinity. Ligand B excels in TPSA and has a slightly better logP and hERG profile. However, Ligand A has a much better QED score, significantly longer half-life, and lower microsomal clearance. The DILI risk for Ligand A is concerning, but the improved metabolic stability and drug-likeness are compelling. The Caco-2 values are problematic for both.
Considering the balance, the improved metabolic stability (Cl_mic and t1/2) and QED of Ligand A, despite the higher DILI risk, are more valuable for a cardiovascular target where CNS penetration is less critical. The similar binding affinities mean potency isn't a differentiating factor. The DILI risk can be investigated further with *in vivo* studies.
Output:
1
2025-04-17 20:59:08,657 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (376.375 and 352.519 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (59.06) is significantly better than Ligand B (78.43). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (3.241 and 2.19), falling within the 1-3 optimal range. Ligand A is slightly higher, which *could* be beneficial for membrane permeability, but not drastically.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is preferable to Ligand B (3). Fewer HBAs generally improve permeability.
6. **QED:** Ligand A (0.814) has a better QED score than Ligand B (0.626), indicating a more drug-like profile.
7. **DILI:** Ligand B (20.24) has a much lower DILI risk than Ligand A (52.772). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (75.843) has better BBB penetration than Ligand B (58.085). While not a primary concern for a cardiovascular target, it's a slight positive for Ligand A.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.894 and -4.725), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Both ligands have negative solubility values (-3.907 and -3.319), which is also a concern.
11. **hERG:** Ligand A (0.782) has a slightly better hERG profile than Ligand B (0.35), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Both ligands have similar microsomal clearance values (15.275 and 54.82).
13. **t1/2:** Ligand A (54.884) has a significantly longer in vitro half-life than Ligand B (-13.125). This is a major advantage for Ligand A, suggesting less frequent dosing.
14. **Pgp:** Ligand A (0.597) has lower P-gp efflux liability than Ligand B (0.173), which is favorable for bioavailability.
15. **Affinity:** Ligand A (-8.6 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.1 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME drawbacks.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, affinity, logP, TPSA, and Pgp are key. Ligand A excels in affinity and has better TPSA and Pgp values. While Ligand B has a much better DILI score, the significantly stronger binding of Ligand A is a crucial factor. The longer half-life of Ligand A is also a significant benefit. The poor Caco-2 and solubility are concerning for both, but can be addressed with formulation strategies.
**Conclusion:**
Despite the lower DILI score for Ligand B, the superior binding affinity, better TPSA, Pgp, half-life, and QED of Ligand A make it the more promising drug candidate. The strong binding is likely to be the most important factor for efficacy, and the other advantages contribute to a better overall profile.
Output:
1
2025-04-17 20:59:08,657 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (365.9 vs 346.5 Da). No clear advantage.
2. **TPSA:** Ligand B (40.62) is significantly better than Ligand A (61.44). Lower TPSA generally favors better absorption, crucial for oral bioavailability of a GPCR ligand.
3. **logP:** Both are good (3.236 and 3.476), falling within the optimal 1-3 range. Ligand B is slightly higher, potentially aiding membrane permeability.
4. **HBD:** Ligand A has 2 HBD, while Ligand B has 0. Lower HBD can be beneficial for permeability, giving a slight edge to Ligand B.
5. **HBA:** Ligand A has 3 HBA, Ligand B has 2. Similar to HBD, Ligand B is slightly better.
6. **QED:** Both are similar (0.761 vs 0.715), indicating good drug-likeness.
7. **DILI:** Ligand B (12.41) is *much* better than Ligand A (43.74). This is a significant advantage, as liver toxicity is a major concern.
8. **BBB:** Ligand B (85.15) is better than Ligand A (70.997). While ADRB2 isn't strictly a CNS target, some CNS penetration can be beneficial for understanding off-target effects and potential side effects.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-4.781) is slightly worse than Ligand B (-4.451).
10. **Solubility:** Both are negative, indicating poor solubility. Ligand A (-3.722) is slightly worse than Ligand B (-3.415).
11. **hERG:** Both are low risk (0.533 and 0.53). No significant difference.
12. **Cl_mic:** Ligand A (52.862) is better than Ligand B (78.994). Lower clearance is preferred for metabolic stability.
13. **t1/2:** Ligand A (77.955) is *much* better than Ligand B (-4.507). A longer half-life is highly desirable.
14. **Pgp:** Both are low (0.323 and 0.384), indicating low efflux. No significant difference.
15. **Affinity:** Ligand A (-7.2) is better than Ligand B (-6.0). This is a substantial difference in binding affinity (1.2 kcal/mol).
**Overall Assessment:**
Ligand B has significant advantages in terms of safety (DILI), TPSA, and BBB penetration. However, Ligand A has a substantially better binding affinity and a much longer in vitro half-life, and better metabolic stability. The 1.2 kcal/mol difference in binding affinity is a major factor, and the longer half-life is also very important. While Ligand B's better ADME properties are attractive, the potency and PK profile of Ligand A are more compelling, especially considering the relatively modest improvements in ADME for Ligand B. The poor Caco-2 and solubility of both compounds are concerns that would need to be addressed in further optimization, but the stronger binding and better half-life of Ligand A provide a better starting point.
Output:
1
2025-04-17 20:59:08,657 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (428.316 Da) is within the ideal range, while Ligand B (351.466 Da) is also good. No clear advantage here.
2. **TPSA:** Ligand A (103.78) is higher than the preferred <140 for oral absorption, but not drastically so. Ligand B (55.32) is excellent. Ligand B is better.
3. **logP:** Ligand A (1.838) is optimal. Ligand B (3.295) is towards the upper end of optimal, but still acceptable. Ligand A is slightly better.
4. **HBD:** Ligand A (1) is good. Ligand B (0) is also good. No clear advantage.
5. **HBA:** Ligand A (10) is at the upper limit of acceptable. Ligand B (4) is excellent. Ligand B is better.
6. **QED:** Ligand A (0.488) is below the desirable 0.5. Ligand B (0.756) is good. Ligand B is better.
7. **DILI:** Ligand A (75.107) is concerning, indicating a higher risk of liver injury. Ligand B (18.922) is excellent, very low risk. Ligand B is *significantly* better.
8. **BBB:** Ligand A (54.827) is moderate. Ligand B (92.516) is very good. Considering ADRB2 is a GPCR, BBB penetration is a positive, though not essential for cardiovascular targets. Ligand B is better.
9. **Caco-2:** Ligand A (-5.707) is poor. Ligand B (-4.64) is also poor, but slightly better.
10. **Solubility:** Ligand A (-1.44) is poor. Ligand B (-2.997) is also poor. Both are problematic.
11. **hERG:** Ligand A (0.258) is good. Ligand B (0.594) is acceptable, but slightly higher risk. Ligand A is better.
12. **Cl_mic:** Ligand A (30.087) is reasonable. Ligand B (56.655) is higher, indicating faster metabolism and lower stability. Ligand A is better.
13. **t1/2:** Ligand A (31.832) is good. Ligand B (4.623) is very short. Ligand A is *significantly* better.
14. **Pgp:** Ligand A (0.311) is good. Ligand B (0.163) is excellent. Ligand B is better.
15. **Affinity:** Both ligands have very similar binding affinities (-5.4 and -5.6 kcal/mol). The difference is negligible.
**Overall Assessment:**
Ligand B has several significant advantages: much lower DILI risk, better QED, better TPSA, better BBB penetration, and better Pgp efflux. While Ligand A has better metabolic stability (Cl_mic, t1/2) and hERG, the DILI risk associated with Ligand A is a major concern. The slight advantage in metabolic stability is outweighed by the safety concerns. Considering this is a GPCR target, the better BBB penetration of Ligand B is also a plus. The solubility of both is poor, but can be addressed with formulation strategies.
Output:
0
2025-04-17 20:59:08,657 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (386.514) is slightly higher than Ligand B (346.427), but both are acceptable.
2. **TPSA:** Ligand A (49.85) is better than Ligand B (62.99). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally aids absorption.
3. **logP:** Both ligands have good logP values (A: 1.886, B: 2.078), falling within the optimal 1-3 range.
4. **HBD:** Both have 0 HBD, which is good.
5. **HBA:** Ligand A (5) has slightly more HBA than Ligand B (4), but both are within acceptable limits.
6. **QED:** Both ligands have good QED scores (A: 0.741, B: 0.841), indicating drug-likeness. Ligand B is slightly better.
7. **DILI:** Ligand A (54.983) has a higher DILI risk than Ligand B (32.261). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (88.29) has better BBB penetration than Ligand B (66.925), but as ADRB2 is a cardiovascular target, this is less important.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual. Assuming these are percentile scores, both are very poor. This is a significant drawback for both.
10. **Solubility:** Ligand A (-3.044) has worse solubility than Ligand B (-2.074). Solubility is important for bioavailability, giving a slight edge to Ligand B.
11. **hERG:** Both ligands have low hERG inhibition risk (A: 0.488, B: 0.413).
12. **Cl_mic:** Ligand A (47.896) has lower microsomal clearance than Ligand B (38.22), indicating better metabolic stability. This is a positive for Ligand A.
13. **t1/2:** Ligand A (5.456) has a longer in vitro half-life than Ligand B (28.126). This is a significant advantage for Ligand A.
14. **Pgp:** Both ligands have low P-gp efflux liability (A: 0.094, B: 0.284).
15. **Binding Affinity:** Ligand B (-9.2) has significantly stronger binding affinity than Ligand A (-6.5). This is a substantial advantage, potentially outweighing some ADME concerns.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, affinity, logP, TPSA, and Pgp are key. Ligand B excels in affinity, while Ligand A has better TPSA and metabolic stability. The lower DILI risk for Ligand B is also a major plus. The poor Caco-2 values are concerning for both, but the significantly better binding affinity of Ligand B is likely to be more impactful for overall efficacy.
**Conclusion:**
Despite the better metabolic stability of Ligand A, the significantly improved binding affinity and lower DILI risk of Ligand B make it the more promising drug candidate.
Output:
0
2025-04-17 20:59:08,657 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (348.491) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (59.39) is significantly better than Ligand B (79.37). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally improves absorption.
3. **logP:** Both ligands have good logP values (A: 2.476, B: 1.596) within the optimal 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Both have 1 HBD, which is acceptable.
5. **HBA:** Ligand A has 6 HBA, and Ligand B has 5. Both are within the acceptable limit of 10.
6. **QED:** Both ligands have reasonable QED scores (A: 0.801, B: 0.755), indicating good drug-like properties.
7. **DILI:** Ligand A (9.035) has a much lower DILI risk than Ligand B (40.985). This is a significant advantage.
8. **BBB:** Both have reasonable BBB penetration (A: 74.564, B: 77.705), but this isn't a primary concern for a cardiovascular target.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. This is a concern for both.
10. **Solubility:** Both have negative solubility values, indicating poor solubility. This is a concern for both.
11. **hERG:** Ligand A (0.849) has a slightly higher hERG risk than Ligand B (0.404), but both are still relatively low.
12. **Cl_mic:** Ligand A (-6.738) has a significantly *lower* (better) microsomal clearance than Ligand B (-25.897), suggesting better metabolic stability.
13. **t1/2:** Ligand A (5.033) has a better in vitro half-life than Ligand B (-10.467).
14. **Pgp:** Ligand A (0.133) has lower P-gp efflux than Ligand B (0.051), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand B (-6.5 kcal/mol) has a slightly better binding affinity than Ligand A (-4.8 kcal/mol). This is a 1.7 kcal/mol difference, which is substantial.
**GPCR-specific considerations:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. While Ligand B has slightly better affinity, Ligand A excels in several other crucial areas: TPSA, DILI risk, metabolic stability (Cl_mic & t1/2), and Pgp efflux. The difference in affinity, while noticeable, is likely outweighed by the superior ADME properties of Ligand A. The poor Caco-2 and solubility are concerns for both, but can be addressed with formulation strategies.
**Conclusion:**
Considering the balance of properties, and prioritizing ADME characteristics alongside binding affinity for a cardiovascular GPCR target, Ligand A appears to be the more promising drug candidate.
Output:
1
2025-04-17 20:59:08,657 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (368.463 and 360.447 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (104.42) is better than Ligand B (118.61). Both are below the 140 threshold for oral absorption, but closer to the ideal for GPCRs.
3. **logP:** Ligand B (0.947) is slightly better than Ligand A (0.068). Both are within the optimal 1-3 range, but A is very close to the lower limit which could impact permeability.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (2), but both are within the acceptable limit of 5.
5. **HBA:** Both ligands have 8 HBA, which is within the acceptable limit of 10.
6. **QED:** Both ligands have similar QED values (0.635 and 0.617), indicating good drug-likeness.
7. **DILI:** Ligand B (56.262) has a significantly lower DILI risk than Ligand A (79.682). This is a major advantage for Ligand B.
8. **BBB:** Ligand B (35.13) is better than Ligand A (25.01), although neither are particularly high. For a cardiovascular target, BBB penetration is not a primary concern, but it is still a positive.
9. **Caco-2:** Ligand A (-5.489) is better than Ligand B (-6.183). Higher values indicate better absorption.
10. **Solubility:** Ligand A (-2.851) is better than Ligand B (-1.375). Higher values are preferred.
11. **hERG:** Ligand A (0.166) is better than Ligand B (0.523). Lower values are preferred to minimize cardiotoxicity risk.
12. **Cl_mic:** Ligand B (-2.444) has a *much* lower (better) microsomal clearance than Ligand A (11.856). This suggests greater metabolic stability for Ligand B.
13. **t1/2:** Ligand B (-18.053) has a *much* longer in vitro half-life than Ligand A (15.536). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.054) is better than Ligand B (0.024). Lower values are preferred.
15. **Binding Affinity:** Ligand A (-6.1 kcal/mol) has a slightly better binding affinity than Ligand B (-5.2 kcal/mol). This is a 0.9 kcal/mol difference, which is notable but not overwhelming.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity and Caco-2 permeability, Ligand B demonstrates a much more favorable ADMET profile. Specifically, the significantly lower DILI risk, improved metabolic stability (lower Cl_mic, longer t1/2), and better solubility make Ligand B a more promising candidate. The slightly lower affinity of Ligand B can potentially be optimized in later stages of drug development. For a cardiovascular GPCR target, metabolic stability and safety (DILI, hERG) are crucial, and Ligand B excels in these areas.
Output:
0
2025-04-17 20:59:08,658 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (358.36 and 345.443 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (75.27) is slightly higher than Ligand B (64.09). Both are below the 140 threshold for oral absorption, but B is better.
3. **logP:** Ligand A (1.585) is optimal, while Ligand B (0.226) is a bit low, potentially hindering membrane permeability. This favors A.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable, well below the 5 limit.
5. **HBA:** Ligand A (3) and Ligand B (4) are both acceptable, well below the 10 limit.
6. **QED:** Both ligands have good QED scores (0.679 and 0.728), indicating good drug-like properties.
7. **DILI:** Ligand A (35.944) has a slightly higher DILI risk than Ligand B (22.257), but both are below the concerning 60 threshold. B is preferred.
8. **BBB:** Ligand A (77.162) has a better BBB penetration score than Ligand B (39.86). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant for off-target effects and overall safety assessment. A is preferred.
9. **Caco-2:** Ligand A (-4.915) and Ligand B (-4.526) are both negative, which is unusual and suggests poor permeability.
10. **Solubility:** Ligand A (-2.72) and Ligand B (-1.196) are both negative, indicating poor solubility. B is preferred.
11. **hERG:** Ligand A (0.058) has a very low hERG risk, significantly better than Ligand B (0.276). This is a crucial safety parameter, strongly favoring A.
12. **Cl_mic:** Ligand A (6.848) has a lower microsomal clearance than Ligand B (7.894), suggesting better metabolic stability. A is preferred.
13. **t1/2:** Ligand A (-13.351) has a much longer in vitro half-life than Ligand B (0.354). This is a significant advantage for dosing frequency. A is strongly preferred.
14. **Pgp:** Ligand A (0.035) has lower P-gp efflux than Ligand B (0.137), which is favorable for bioavailability. A is preferred.
15. **Binding Affinity:** Ligand A (-6.5 kcal/mol) has a slightly better binding affinity than Ligand B (-5.8 kcal/mol). While the difference isn't huge, it's enough to consider, especially given the other favorable properties of A.
**GPCR-specific priorities:** Considering ADRB2 is a GPCR, logP, TPSA, Pgp, and affinity are important. Ligand A performs better on logP, Pgp, and affinity. While TPSA is slightly better for B, the other benefits of A outweigh this.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B in crucial ADME-Tox properties (hERG, Cl_mic, t1/2, Pgp) and has a slightly better binding affinity. While Ligand B has a slightly better DILI score and TPSA, the superior safety profile and metabolic stability of Ligand A make it the more promising drug candidate. The poor solubility and Caco-2 values for both are concerning, but can be addressed with formulation strategies.
Output:
1
2025-04-17 20:59:08,658 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [350.463, 87.47, 1.592, 2, 5, 0.743, 17.604, 67.662, -4.98, -1.117, 0.204, -0.217, 14.041, 0.012, -5.8]
**Ligand B:** [348.447, 87.46, 1.031, 2, 5, 0.804, 40.403, 44.591, -4.841, -1.939, 0.23, 17.701, 15.877, 0.066, -6.5]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, Affinity, and BBB):
1. **MW:** Both are within the ideal range (348-350 Da). No significant difference.
2. **TPSA:** Both are excellent, at ~87.5, well below the 140 threshold for oral absorption and suitable for a peripheral GPCR like ADRB2. No significant difference.
3. **logP:** Ligand A (1.592) is slightly higher than Ligand B (1.031), placing it closer to the optimal 1-3 range. This is a slight advantage for A.
4. **HBD/HBA:** Both have 2 HBD and 5 HBA, which is acceptable. No difference.
5. **QED:** Both are good, but Ligand B (0.804) is slightly better than Ligand A (0.743).
6. **DILI:** Ligand A (17.6%) has a significantly lower DILI risk than Ligand B (40.4%). This is a *major* advantage for A.
7. **BBB:** Ligand A (67.7%) has a better BBB penetration score than Ligand B (44.6%), but BBB isn't a critical factor for ADRB2, which is predominantly expressed in cardiovascular tissues. Still, a slight advantage for A.
8. **Caco-2:** Both are negative, indicating poor permeability. This is a concern for both.
9. **Solubility:** Both are negative, indicating poor solubility. This is a concern for both.
10. **hERG:** Both have very low hERG risk (0.204 and 0.23). No difference.
11. **Cl_mic:** Ligand A (-0.217) has a lower (better) microsomal clearance than Ligand B (17.701), indicating greater metabolic stability. This is a significant advantage for A.
12. **t1/2:** Ligand B (15.877) has a longer in vitro half-life than Ligand A (14.041). This is a slight advantage for B.
13. **Pgp:** Both have very low Pgp efflux liability (0.012 and 0.066). No difference.
14. **Affinity:** Ligand B (-6.5 kcal/mol) has a stronger binding affinity than Ligand A (-5.8 kcal/mol). This is a 0.7 kcal/mol difference, which is substantial and a significant advantage for B.
**Overall Assessment:**
While Ligand B has a better binding affinity, the significantly lower DILI risk and better metabolic stability of Ligand A, combined with its slightly better logP and BBB, make it the more promising candidate. The affinity difference, while notable, can potentially be optimized in later stages of drug development. The safety and pharmacokinetic profiles of Ligand A are more favorable.
Output:
1
2025-04-17 20:59:08,658 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for the ADRB2, a cardiovascular GPCR. Therefore, the priorities are logP, TPSA, Pgp, affinity, and to a lesser extent, BBB.
Let's break down the comparison:
1. **MW:** Both ligands are within the acceptable range (200-500 Da). Ligand A (355.825) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (60.85) has a significantly lower TPSA than Ligand A (74.85). This is a major advantage for Ligand B, suggesting better membrane permeability and oral absorption.
3. **logP:** Both ligands have good logP values (A: 3.538, B: 2.624) within the optimal range of 1-3. Ligand B is slightly better.
4. **HBD/HBA:** Ligand A has 2 HBD and 3 HBA, while Ligand B has 1 HBD and 4 HBA. Both are acceptable, but Ligand A is slightly preferred due to the lower HBD count.
5. **QED:** Both ligands have similar QED values (A: 0.636, B: 0.676), indicating good drug-like properties.
6. **DILI:** Ligand B (3.296) has a much lower DILI risk than Ligand A (73.401). This is a significant advantage for Ligand B.
7. **BBB:** Both ligands have reasonable BBB penetration (A: 65.335, B: 62.466), but this is less critical for a cardiovascular target.
8. **Caco-2:** Ligand A (-5.655) has a worse Caco-2 permeability than Ligand B (-4.698), indicating lower intestinal absorption.
9. **Solubility:** Ligand A (-3.815) has worse solubility than Ligand B (-2.021).
10. **hERG:** Both ligands have similar hERG inhibition liability (A: 0.439, B: 0.571).
11. **Cl_mic:** Ligand A (44.284) has a lower microsomal clearance than Ligand B (53.296), suggesting better metabolic stability.
12. **t1/2:** Ligand A (89.236) has a much longer in vitro half-life than Ligand B (-2.877). This is a significant advantage for Ligand A.
13. **Pgp:** Ligand A (0.515) has slightly lower P-gp efflux liability than Ligand B (0.147), which is favorable.
14. **Affinity:** Ligand A (-6.7 kcal/mol) has a slightly better binding affinity than Ligand B (-4.7 kcal/mol). This is a significant advantage for Ligand A.
**Overall Assessment:**
Ligand A has a better binding affinity and longer half-life, while Ligand B has a lower TPSA, lower DILI risk, better solubility, and better Caco-2 permeability. Considering the GPCR-specific priorities, the lower TPSA and DILI risk of Ligand B are very important. The affinity difference, while present, isn't large enough to overcome the ADME advantages of Ligand B.
**Output:**
0
2025-04-17 20:59:08,658 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (330.35 & 373.84 Da) are within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Both ligands (87.9 & 89.76) are below the 140 A^2 threshold for good oral absorption, and acceptable for a peripheral GPCR like ADRB2. No significant difference.
3. **logP:** Both ligands (3.28 & 3.07) fall within the optimal 1-3 range. No clear advantage.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2) as lower HBDs generally improve permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (7) for the same reason as above.
6. **QED:** Ligand A (0.793) has a better QED score than Ligand B (0.643), indicating a more drug-like profile.
7. **DILI:** Ligand B (58.55) has a significantly lower DILI risk than Ligand A (98.88), which is a major advantage.
8. **BBB:** Ligand B (82.44) has a higher BBB penetration percentile than Ligand A (48.04). While ADRB2 isn't a CNS target, some level of BBB penetration can sometimes indicate favorable partitioning properties.
9. **Caco-2:** Both ligands have very similar, and poor, Caco-2 permeability (-4.888 and -4.702). This is a concern for oral bioavailability for both.
10. **Solubility:** Both ligands have very similar, and poor, solubility (-5.748 and -4.834). This is a concern for formulation and bioavailability for both.
11. **hERG:** Both ligands have very similar, and low, hERG risk (0.746 and 0.725).
12. **Cl_mic:** Both ligands have similar microsomal clearance (52.37 & 47.61).
13. **t1/2:** Ligand B (30.13) has a significantly longer in vitro half-life than Ligand A (14.19), which is a substantial benefit.
14. **Pgp:** Both ligands have similar Pgp efflux liability (0.322 and 0.069).
15. **Binding Affinity:** Ligand B (-6.7 kcal/mol) has a stronger binding affinity than Ligand A (-5.9 kcal/mol). This is a 0.8 kcal/mol difference, which is significant enough to outweigh some of the ADME drawbacks.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Both ligands are good on logP and TPSA. Ligand B has a better affinity and slightly better Pgp. The biggest difference is the DILI score and the in vitro half-life, both favoring Ligand B.
**Overall Assessment:**
While Ligand A has a slightly better QED and fewer H-bonds, Ligand B's significantly lower DILI risk, longer half-life, and stronger binding affinity are more critical for a viable drug candidate. The poor Caco-2 and solubility are concerns for both, but can potentially be addressed through formulation strategies.
Output:
0
2025-04-17 20:59:08,658 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (356.438 and 371.503 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (84.5) is well below the 140 threshold and quite good for oral absorption. Ligand B (98.74) is still acceptable, but closer to the limit. This favors Ligand A.
**3. logP:** Ligand A (1.664) is within the optimal 1-3 range. Ligand B (0.124) is *below* 1, which is a concern for membrane permeability. This is a significant advantage for Ligand A.
**4. H-Bond Donors:** Ligand A (2) and Ligand B (3) are both acceptable, being less than 5.
**5. H-Bond Acceptors:** Ligand A (4) and Ligand B (5) are both acceptable, being less than 10.
**6. QED:** Both ligands have similar QED values (0.68 and 0.591), indicating reasonable drug-likeness.
**7. DILI:** Ligand A (56.844) has a higher DILI risk than Ligand B (29.779). This favors Ligand B.
**8. BBB:** Ligand A (80.574) has a significantly higher BBB penetration percentile than Ligand B (20.008). While ADRB2 is a cardiovascular target, some CNS off-target effects are always a concern, and higher BBB penetration *could* increase this risk, but it isn't a major concern for a cardiovascular target.
**9. Caco-2 Permeability:** Ligand A (-4.995) and Ligand B (-5.605) both have negative values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
**10. Aqueous Solubility:** Ligand A (-2.332) and Ligand B (-1.949) both have negative values, which is unusual and suggests poor solubility. However, the scale is not specified, so it's hard to interpret.
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.194 and 0.104). No significant difference.
**12. Microsomal Clearance:** Ligand A (20.907) has lower microsomal clearance than Ligand B (24.119), indicating better metabolic stability. This favors Ligand A.
**13. In vitro Half-Life:** Ligand A (2.448) has a shorter half-life than Ligand B (16.474). This is a significant advantage for Ligand B.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.052 and 0.012). No significant difference.
**15. Binding Affinity:** Ligand A (-5.3 kcal/mol) has a slightly better binding affinity than Ligand B (-5.0 kcal/mol), but the difference is small.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand A is the better candidate. The significantly better logP and TPSA values outweigh the slightly higher DILI risk and shorter half-life. The binding affinity difference is minimal. The negative solubility and permeability values are concerning for both, but the superior ADME profile of Ligand A makes it the more promising starting point for optimization.
Output:
1
2025-04-17 20:59:08,658 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.36 and 347.39 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (45.23) is significantly better than Ligand B (82.53). ADRB2 is a cardiovascular target, not necessarily CNS, but lower TPSA generally improves absorption. Ligand A is well below the 140 threshold, while B is approaching it.
3. **logP:** Ligand A (3.372) is optimal, while Ligand B (1.837) is at the lower end of the optimal range. For a GPCR, a slightly higher logP is generally preferred for membrane permeability.
4. **HBD:** Both have acceptable HBD counts (1 and 2, respectively), well below the 5 threshold.
5. **HBA:** Both have acceptable HBA counts (2 and 4, respectively), well below the 10 threshold.
6. **QED:** Both ligands have very similar, good QED scores (0.864 and 0.871).
7. **DILI:** Ligand B (33.35) has a significantly lower DILI risk than Ligand A (52.39). This is a major advantage for Ligand B.
8. **BBB:** Ligand A (88.72) has better BBB penetration than Ligand B (70.61). While ADRB2 isn't strictly a CNS target, some brain exposure can be relevant for off-target effects, and higher BBB is generally a positive.
9. **Caco-2:** Both ligands have very similar, poor Caco-2 permeability (-4.54 and -4.69). This is a concern for both, indicating potential absorption issues.
10. **Solubility:** Ligand A (-4.216) has slightly better solubility than Ligand B (-3.225), but both are poor.
11. **hERG:** Ligand A (0.636) has a slightly higher hERG risk than Ligand B (0.157). Lower hERG is crucial for avoiding cardiotoxicity.
12. **Cl_mic:** Ligand B (15.68) has significantly lower microsomal clearance than Ligand A (42.51), indicating better metabolic stability.
13. **t1/2:** Ligand B (-30.095) has a much longer in vitro half-life than Ligand A (-18.426). This is a significant advantage.
14. **Pgp:** Ligand A (0.129) has lower P-gp efflux than Ligand B (0.021), which is favorable.
15. **Binding Affinity:** Ligand B (-7.2 kcal/mol) has a slightly better binding affinity than Ligand A (-7.0 kcal/mol). While the difference is small, it's enough to potentially outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand B is the better candidate. While Ligand A has slightly better BBB penetration and Pgp efflux, Ligand B excels in crucial areas: significantly lower DILI risk, much better metabolic stability (lower Cl_mic, longer t1/2), and slightly better binding affinity. The lower TPSA of Ligand A is a plus, but the substantial improvements in safety (DILI, hERG) and pharmacokinetics (Cl_mic, t1/2) offered by Ligand B are more important for overall drug development success. The poor Caco-2 permeability is a concern for both, but can be addressed with formulation strategies.
Output:
0
2025-04-17 20:59:08,658 - INFO - Batch 225 complete. Total preferences: 3600
2025-04-17 20:59:08,658 - INFO - Processing batch 226/512...
2025-04-17 20:59:58,784 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [346.391, 132.63 , 0.357, 4. , 5. , 0.599, 63.513, 24.351, -5.52 , -2.783, 0.315, -11.571, 12.231, 0.028, -7.1 ]
**Ligand B:** [357.483, 63.91 , 2.285, 0. , 6. , 0.536, 48.895, 61.613, -5.135, -2.821, 0.488, 36.918, 10.884, 0.218, -6.8 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal 200-500 Da range. Ligand A (346.391 Da) is slightly lower, which could be beneficial for permeability, but both are acceptable.
2. **TPSA:** Ligand A (132.63) is better than Ligand B (63.91), being closer to the <140 threshold for oral absorption.
3. **logP:** Ligand B (2.285) is optimal (1-3), while Ligand A (0.357) is quite low, potentially hindering membrane permeability. This is a significant drawback for Ligand A.
4. **HBD:** Ligand A (4) is acceptable, while Ligand B (0) is even better.
5. **HBA:** Both are acceptable (Ligand A: 5, Ligand B: 6), below the 10 threshold.
6. **QED:** Both have good QED scores (Ligand A: 0.599, Ligand B: 0.536), indicating drug-like properties.
7. **DILI:** Ligand B (48.895) has a much lower DILI risk than Ligand A (63.513). This is a significant advantage for Ligand B.
8. **BBB:** Ligand B (61.613) has better BBB penetration than Ligand A (24.351). While ADRB2 isn't strictly a CNS target, some CNS exposure can be relevant for off-target effects or potential therapeutic strategies.
9. **Caco-2:** Both are very poor (-5.52 and -5.135).
10. **Solubility:** Both are very poor (-2.783 and -2.821).
11. **hERG:** Both have low hERG risk (Ligand A: 0.315, Ligand B: 0.488).
12. **Cl_mic:** Ligand A (-11.571) has significantly lower (better) microsomal clearance than Ligand B (36.918), suggesting better metabolic stability.
13. **t1/2:** Ligand A (12.231) has a longer half-life than Ligand B (10.884).
14. **Pgp:** Ligand B (0.218) has lower P-gp efflux than Ligand A (0.028), which is favorable for bioavailability.
15. **Affinity:** Ligand A (-7.1) has a slightly better binding affinity than Ligand B (-6.8). However, the difference is less than 1.5 kcal/mol, so it's not a decisive factor.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand B excels in logP and Pgp, and has a better BBB score. Ligand A has a slightly better affinity and metabolic stability (Cl_mic and t1/2), but its very low logP is a major concern for permeability and overall drug-like behavior. The DILI risk is also significantly higher for Ligand A.
**Conclusion:**
Despite the slightly better affinity of Ligand A, the superior ADME properties of Ligand B, particularly its logP, lower DILI risk, and better Pgp profile, make it the more promising drug candidate. The low logP of Ligand A is a significant liability that outweighs its marginal affinity advantage.
0
2025-04-17 20:59:58,785 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (346.343 Da) is well within the ideal range (200-500 Da). Ligand B (368.459 Da) is also acceptable. No clear advantage here.
2. **TPSA:** Ligand A (116.84) is slightly above the preferred <140 for good oral absorption, but still reasonable. Ligand B (92.58) is excellent, well below 140 and a good sign for permeability. **Advantage: B**
3. **logP:** Ligand A (-0.322) is a bit low, potentially hindering membrane permeability. Ligand B (0.151) is closer to the optimal 1-3 range. **Advantage: B**
4. **HBD:** Ligand A (3) is acceptable. Ligand B (0) is even better, potentially improving permeability. **Advantage: B**
5. **HBA:** Ligand A (5) is acceptable. Ligand B (6) is also acceptable. No significant difference.
6. **QED:** Both ligands have good QED scores (A: 0.51, B: 0.713). Ligand B is slightly better. **Advantage: B**
7. **DILI:** Ligand A (83.521) has a higher DILI risk than Ligand B (69.097), though both are within a tolerable range. **Advantage: B**
8. **BBB:** Ligand A (72.354) and Ligand B (81.194) both have good BBB penetration, but Ligand B is better. Since ADRB2 is a GPCR, BBB penetration is a consideration, although not paramount for cardiovascular targets. **Advantage: B**
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Both have negative solubility values, which is also unusual and suggests poor solubility. Again, the scale is not specified.
11. **hERG:** Ligand A (0.052) has a very low hERG risk, which is excellent. Ligand B (0.388) is slightly higher, but still relatively low. **Advantage: A**
12. **Cl_mic:** Ligand A (-25.89) has a negative clearance, which is not possible and likely an error in the data. Ligand B (63.328) has a higher clearance, indicating faster metabolism. **Advantage: A (assuming A's value is an error)**
13. **t1/2:** Ligand A (30.122) has a much longer half-life than Ligand B (-48.648), which is a significant advantage. **Advantage: A**
14. **Pgp:** Ligand A (0.006) has very low P-gp efflux, which is excellent. Ligand B (0.149) is slightly higher. **Advantage: A**
15. **Affinity:** Both ligands have similar binding affinities (-6.9 kcal/mol and -6.0 kcal/mol respectively). Ligand A is slightly better, but the difference is not huge. **Advantage: A**
**Overall Assessment:**
Ligand B initially appears stronger due to better TPSA, logP, QED, DILI, and BBB. However, the negative values for clearance and half-life for Ligand A are concerning and likely erroneous. Assuming the negative clearance for Ligand A is a data error, Ligand A has a significantly longer half-life, lower P-gp efflux, and slightly better affinity. Given the GPCR target class, a balance of permeability, metabolic stability, and affinity is crucial. The hERG risk is also very low for Ligand A.
Therefore, I believe Ligand A is the more promising candidate.
Output:
1
2025-04-17 20:59:58,785 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands (350.379 and 348.487 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (126.38) is higher than Ligand B (49.85). For a GPCR, lower TPSA is generally preferred for better BBB penetration, giving a slight edge to Ligand B.
3. **logP:** Ligand A (-0.258) is quite low, potentially hindering membrane permeability. Ligand B (2.302) is within the optimal 1-3 range. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (2) is reasonable. Ligand B (0) is even better, minimizing potential for off-target interactions and improving permeability.
5. **HBA:** Ligand A (8) is acceptable. Ligand B (3) is better, contributing to improved drug-like properties.
6. **QED:** Ligand A (0.704) is better than Ligand B (0.5), indicating a more drug-like profile.
7. **DILI:** Ligand B (13.532) has a much lower DILI risk than Ligand A (56.456). This is a crucial advantage for Ligand B.
8. **BBB:** Ligand B (81.233) shows significantly better BBB penetration potential than Ligand A (31.679). This is a key consideration for a GPCR target.
9. **Caco-2:** Ligand A (-5.23) and Ligand B (-4.436) are both negative, suggesting poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Ligand A (-1.384) and Ligand B (-2.423) are both negative, suggesting poor solubility. Again, the scale is not specified.
11. **hERG:** Ligand A (0.096) has a slightly lower hERG risk than Ligand B (0.479), but both are relatively low.
12. **Cl_mic:** Ligand B (51.249) has a higher microsomal clearance than Ligand A (35.195), suggesting faster metabolism and potentially lower in vivo exposure. This favors Ligand A.
13. **t1/2:** Ligand A (-13.669) has a negative half-life, which is not possible. This is a major red flag. Ligand B (10.365) has a reasonable half-life.
14. **Pgp:** Ligand A (0.043) has lower P-gp efflux than Ligand B (0.272), which is favorable.
15. **Affinity:** Ligand B (-7.3) has a significantly higher binding affinity than Ligand A (-6.3). This is a substantial advantage, potentially outweighing some ADME concerns.
**Overall Assessment:**
Ligand B is the stronger candidate. While Ligand A has a better QED and lower Pgp efflux, Ligand B excels in critical areas for a GPCR target: logP, BBB penetration, DILI risk, and, most importantly, binding affinity. The negative half-life for Ligand A is a fatal flaw. The higher metabolic clearance of Ligand B is a concern, but can be addressed through structural modifications during optimization. The lower TPSA and H-bond counts of Ligand B are also favorable.
Output:
0
2025-04-17 20:59:58,785 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.39 and 346.47 Da) are within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (67.43) is significantly better than Ligand A (109.78). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (2.684) is within the optimal 1-3 range, while Ligand A (0.482) is quite low. Low logP can hinder membrane permeability. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (3) and Ligand B (2) are both acceptable, below the threshold of 5.
5. **HBA:** Ligand A (6) and Ligand B (3) are both acceptable, below the threshold of 10.
6. **QED:** Ligand B (0.727) is better than Ligand A (0.442), indicating a more drug-like profile.
7. **DILI:** Ligand A (37.224) has a much lower DILI risk than Ligand B (52.152). This is a clear advantage for Ligand A.
8. **BBB:** Not a major priority for a cardiovascular target. Ligand B (66.421) is higher, but this isn't decisive.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-5.217) is slightly better than Ligand B (-4.937) but both are concerning.
10. **Solubility:** Both are negative, indicating poor solubility. Ligand A (-1.7) is slightly better than Ligand B (-3.887).
11. **hERG:** Both are very low (0.046 and 0.236), indicating very low risk of hERG inhibition. No clear advantage.
12. **Cl_mic:** Ligand A (2.89) has a much lower microsomal clearance than Ligand B (81.272), suggesting better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand B (-18.092) has a longer in vitro half-life than Ligand A (-15.599), which is preferable.
14. **Pgp:** Both are very low (0.008 and 0.568), indicating low P-gp efflux. No clear advantage.
15. **Binding Affinity:** Ligand B (-7.0) has a slightly better binding affinity than Ligand A (-6.4). While a 0.6 kcal/mol difference is noticeable, it's not a massive advantage, especially considering the other factors.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, affinity) and general drug-like properties, Ligand B has a better logP and slightly better affinity. However, Ligand A has a significantly lower DILI risk and much better metabolic stability (lower Cl_mic). The poor Caco-2 and solubility for both are concerning, but can potentially be addressed with formulation strategies. The lower DILI and better metabolic stability are crucial for a cardiovascular drug, as chronic administration is likely.
Output:
1
2025-04-17 20:59:58,785 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (364.373 and 365.499 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (71.34) is better than Ligand B (80.32). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally aids absorption.
3. **logP:** Ligand B (1.687) is significantly better than Ligand A (4.411). A logP of 4.411 is quite high and could lead to poor solubility and off-target effects. Ligand B is within the optimal 1-3 range.
4. **HBD:** Both ligands have 2 HBD, which is acceptable.
5. **HBA:** Ligand B (5) has one more HBA than Ligand A (4), but both are within the acceptable range of <=10.
6. **QED:** Both ligands have similar QED values (0.703 and 0.77), indicating good drug-likeness.
7. **DILI:** Ligand B (36.681) is *much* better than Ligand A (96.51). A DILI percentile of 96.51 is a significant red flag.
8. **BBB:** Ligand A (44.32) is lower than Ligand B (64.25). While not a CNS target, higher BBB is generally favorable.
9. **Caco-2:** Ligand A (-4.822) is better than Ligand B (-5.373). Higher (less negative) Caco-2 values indicate better absorption.
10. **Solubility:** Ligand B (-1.531) is better than Ligand A (-4.108). Solubility is a concern for Ligand A given its high logP.
11. **hERG:** Ligand A (0.89) is better than Ligand B (0.217). Lower hERG is preferred.
12. **Cl_mic:** Ligand B (2.742) is *much* better than Ligand A (33.02). Lower clearance indicates greater metabolic stability.
13. **t1/2:** Ligand A (125.449) is much better than Ligand B (15.045). Longer half-life is generally desirable.
14. **Pgp:** Ligand A (0.461) is better than Ligand B (0.072). Lower Pgp efflux is preferred.
15. **Binding Affinity:** Ligand B (-7.1) is slightly better than Ligand A (-7.0). While the difference is small, it's enough to consider, especially when balanced against other factors.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand B excels in logP and has a slightly better affinity. Ligand A has better TPSA and Pgp, but its very high logP and extremely high DILI risk are major concerns.
**Overall Assessment:**
Ligand A has a longer half-life, better Caco-2 permeability, and lower hERG risk, but its high logP, very high DILI risk, and high microsomal clearance are significant drawbacks. Ligand B, while having a shorter half-life and slightly lower Caco-2, presents a much more favorable ADME profile, particularly with its significantly lower DILI risk and improved metabolic stability. The slight affinity advantage of Ligand B further supports its selection.
Output:
0
2025-04-17 20:59:58,785 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (354.353 and 345.487 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (70.08) is higher than Ligand B (52.65). While both are reasonably good, Ligand B is better, being closer to the <90 target for potential CNS penetration, even though this is a cardiovascular target.
3. **logP:** Both ligands (1.331 and 1.771) are within the optimal 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 4 HBAs, and Ligand B has 3. Both are acceptable (<=10).
6. **QED:** Ligand A (0.889) has a better QED score than Ligand B (0.793), indicating a more drug-like profile.
7. **DILI:** Ligand A (39.201) has a slightly higher DILI risk than Ligand B (29.081), but both are below the 40 threshold, indicating low risk.
8. **BBB:** Ligand B (70.919) has a slightly higher BBB penetration percentile than Ligand A (68.554). While not a primary concern for a cardiovascular target, it's a small advantage.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.794 and -4.516), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Both ligands have negative solubility values (-2.483 and -2.394), which is also concerning. Poor solubility can hinder bioavailability.
11. **hERG:** Both ligands have low hERG inhibition liability (0.456 and 0.362), which is excellent.
12. **Cl_mic:** Ligand A (13.77) has a significantly lower microsomal clearance than Ligand B (33.13), indicating better metabolic stability. This is a major advantage.
13. **t1/2:** Ligand A (-2.114) has a more negative in vitro half-life than Ligand B (-4.986), which implies a longer half-life. This is a positive.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.078 and 0.066), which is good.
15. **Binding Affinity:** Ligand B (-7.3 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.1 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME concerns.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B has a slightly better logP and TPSA, comparable Pgp, and *much* better affinity. The improved affinity is a significant driver. While the Caco-2 and solubility are concerning for both, the superior binding of Ligand B is likely to be more impactful in driving efficacy. The better metabolic stability of Ligand A is a plus, but the potency difference is larger.
**Conclusion:**
Despite the shared issues with Caco-2 and solubility, Ligand B's significantly stronger binding affinity (-7.3 vs -6.1 kcal/mol) makes it the more promising candidate. The affinity advantage is substantial enough to outweigh the slightly higher DILI risk and lower metabolic stability.
Output:
0
2025-04-17 20:59:58,786 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (345.399 and 348.447 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (86.88) is better than Ligand B (96.25). Both are under the 140 A^2 threshold for oral absorption, but lower TPSA is generally preferred for GPCRs, potentially aiding in receptor binding and reducing off-target interactions.
3. **logP:** Ligand A (1.362) is slightly higher than Ligand B (0.906), both are within the optimal 1-3 range.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Both ligands have 5 HBA, which is acceptable.
6. **QED:** Ligand A (0.819) has a significantly better QED score than Ligand B (0.712), indicating a more drug-like profile.
7. **DILI:** Ligand B (20.977) has a much lower DILI risk than Ligand A (39.162). This is a significant advantage for Ligand B.
8. **BBB:** Ligand B (52.423) has a better BBB penetration score than Ligand A (46.917), though neither is exceptionally high. For a cardiovascular target, BBB penetration is less critical, but still a consideration.
9. **Caco-2:** Ligand A (-4.591) has a much better Caco-2 permeability than Ligand B (-5.001). Higher Caco-2 values indicate better intestinal absorption.
10. **Solubility:** Both ligands have similar, very poor aqueous solubility (-1.402 and -1.373). This is a potential concern for both.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.345 and 0.261).
12. **Cl_mic:** Ligand B (7.321) has a significantly lower microsomal clearance than Ligand A (32.563), indicating better metabolic stability.
13. **t1/2:** Ligand A (27.764) has a much longer in vitro half-life than Ligand B (2.085). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.379) has lower P-gp efflux than Ligand B (0.008). Lower P-gp efflux is generally preferred.
15. **Binding Affinity:** Ligand B (-8.0) has a significantly stronger binding affinity than Ligand A (-4.9). This is a substantial advantage, potentially outweighing some of the ADME drawbacks.
**Overall Assessment:**
Ligand B has a substantially better binding affinity and a significantly lower DILI risk and lower Cl_mic. While Ligand A has a better QED, Caco-2 permeability, and t1/2, the strong binding affinity of Ligand B is a critical factor for a GPCR target like ADRB2. The lower metabolic clearance of Ligand B is also a significant benefit. The slightly lower BBB penetration is not a major concern for a cardiovascular target. The solubility is poor for both, but can be addressed with formulation strategies.
Therefore, I favor Ligand B.
Output:
0
2025-04-17 20:59:58,786 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [366.487, 94.56, 0.958, 3, 6, 0.593, 59.752, 35.014, -5.512, -2.096, 0.552, 8.424, 18.58, 0.023, -6]
**Ligand B:** [367.471, 91.76, 1.041, 2, 6, 0.751, 42.187, 39.511, -4.88, -1.153, 0.245, -0.578, 6.235, 0.029, -7]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity) are key:
1. **MW:** Both are within the ideal 200-500 Da range. A: 366.49, B: 367.47 - very similar.
2. **TPSA:** Both are reasonably good, but A (94.56) is slightly higher than B (91.76). Ideally <140 for oral absorption, both meet this.
3. **logP:** Both are within the optimal 1-3 range. A: 0.958, B: 1.041 - very similar.
4. **HBD:** A has 3, B has 2. Both are acceptable.
5. **HBA:** Both have 6, which is acceptable.
6. **QED:** Both are above 0.5, indicating good drug-likeness. B (0.751) is better than A (0.593).
7. **DILI:** A (59.752) has a higher DILI risk than B (42.187). B is preferable here.
8. **BBB:** Both are relatively low, but B (39.511) is slightly better than A (35.014). Not a huge concern for a non-CNS target like cardiovascular ADRB2.
9. **Caco-2:** Both are negative, indicating poor permeability. A (-5.512) is worse than B (-4.88).
10. **Solubility:** Both are negative, indicating poor solubility. B (-1.153) is better than A (-2.096).
11. **hERG:** A (0.552) has a higher hERG risk than B (0.245). B is preferable.
12. **Cl_mic:** A (8.424) has a higher clearance than B (-0.578). B is preferable, indicating better metabolic stability.
13. **t1/2:** A (18.58) has a longer half-life than B (6.235). A is preferable.
14. **Pgp:** Both are very low (0.023 and 0.029), suggesting minimal P-gp efflux. Very similar.
15. **Affinity:** B (-7 kcal/mol) has a significantly better binding affinity than A (-6 kcal/mol). This is a substantial advantage.
**Overall Assessment:**
Ligand B clearly outperforms Ligand A. The key advantages of B are its better DILI score, lower hERG risk, improved metabolic stability (lower Cl_mic), better solubility, and *significantly* stronger binding affinity. While A has a longer half-life, the affinity difference is substantial enough to outweigh that benefit, especially for a GPCR where achieving sufficient occupancy is crucial. The Caco-2 and solubility are both poor for both, but B is better.
Output:
0
2025-04-17 20:59:58,786 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (351.324 and 355.356 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (38.77) is significantly better than Ligand B (56.26). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand A is well below the 140 threshold, while Ligand B is approaching it.
3. **logP:** Both ligands have good logP values (3.083 and 3.726), falling within the optimal 1-3 range. Ligand B is slightly higher, which *could* indicate a potential for off-target interactions, but it's not a major concern.
4. **HBD:** Both ligands have 0 H-bond donors, which is acceptable.
5. **HBA:** Ligand A has 3 HBA, and Ligand B has 4. Both are within the acceptable limit of 10.
6. **QED:** Ligand A (0.85) has a better QED score than Ligand B (0.756), indicating a more drug-like profile.
7. **DILI:** Ligand A (80.962) has a considerably higher DILI risk than Ligand B (23.653). This is a significant negative for Ligand A.
8. **BBB:** Both ligands have excellent BBB penetration (Ligand A: 91.508, Ligand B: 95.618). This is less critical for ADRB2 (a cardiovascular target) but still a positive.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.068 and -4.395). This is unusual and suggests poor permeability. However, the negative values are similar.
10. **Solubility:** Both ligands have negative solubility values (-3.814 and -4.132). This is also concerning, suggesting poor aqueous solubility. Again, the values are comparable.
11. **hERG:** Both ligands have low hERG inhibition risk (0.546 and 0.369).
12. **Cl_mic:** Ligand B (53.551) has a slightly higher microsomal clearance than Ligand A (48.017), meaning Ligand A is more metabolically stable.
13. **t1/2:** Ligand A (-40.965) has a significantly *shorter* in vitro half-life than Ligand B (-10.33). This is a major drawback for Ligand A.
14. **Pgp:** Both ligands have low P-gp efflux (0.243 and 0.523).
15. **Binding Affinity:** Ligand B (-8.9 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.0 kcal/mol). This is a substantial advantage for Ligand B.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, and affinity are key. Ligand B has a slightly higher logP, but this is offset by its significantly better affinity and lower DILI risk. The lower TPSA of Ligand A is attractive, but the much higher DILI risk and significantly shorter half-life are major concerns. The superior binding affinity of Ligand B is a strong driver.
**Conclusion:**
Despite similar issues with Caco-2 and solubility, Ligand B is the more promising candidate due to its significantly better binding affinity, lower DILI risk, and longer half-life. The slightly higher logP is a minor concern compared to these advantages.
Output:
0
2025-04-17 20:59:58,786 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (346.289 Da) is slightly lower than Ligand B (360.483 Da), which is generally favorable for permeability.
2. **TPSA:** Ligand A (89.16) is better than Ligand B (66.4). Both are below 140, indicating good potential for oral absorption.
3. **logP:** Both ligands have acceptable logP values (A: 1.353, B: 1.745), falling within the optimal range of 1-3. Ligand B is slightly higher, potentially leading to slightly reduced solubility but better membrane permeability.
4. **HBD:** Both ligands have 0 HBD, which is good.
5. **HBA:** Ligand A (6) is slightly higher than Ligand B (5), but both are within the acceptable limit of 10.
6. **QED:** Both have good QED scores (A: 0.737, B: 0.821), indicating drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (79.566) has a significantly higher DILI risk than Ligand B (49.011). This is a major concern.
8. **BBB:** Ligand A (78.519) has a better BBB penetration score than Ligand B (56.611). However, since ADRB2 is a cardiovascular target, BBB penetration is not a primary concern.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand B (-4.95) is slightly worse than Ligand A (-4.123).
10. **Solubility:** Ligand A (-3.531) has better solubility than Ligand B (-2.98).
11. **hERG:** Both ligands have very low hERG inhibition risk (A: 0.268, B: 0.211).
12. **Cl_mic:** Ligand A (73.277) has a higher microsomal clearance than Ligand B (52.619), indicating lower metabolic stability.
13. **t1/2:** Ligand A (-6.155) has a more negative in vitro half-life than Ligand B (-4.095), suggesting a shorter half-life.
14. **Pgp:** Both ligands have low P-gp efflux liability (A: 0.305, B: 0.114). Ligand B is better.
15. **Binding Affinity:** Ligand A (-5.1 kcal/mol) has a significantly better binding affinity than Ligand B (-1.6 kcal/mol). This is a substantial advantage.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, affinity is paramount. The 3.5 kcal/mol difference in binding affinity between Ligand A and Ligand B is substantial. While logP, TPSA, and Pgp are important, a strong binding affinity can often compensate for minor ADME drawbacks. However, the high DILI risk for Ligand A is a serious concern.
**Overall Assessment:**
Despite the superior binding affinity of Ligand A, the significantly higher DILI risk is a major drawback. While the better BBB penetration isn't crucial for a cardiovascular target, the lower metabolic stability and shorter half-life are also concerning. Ligand B, while having a weaker binding affinity, presents a much more favorable safety profile (lower DILI) and better metabolic stability.
Output:
0
2025-04-17 20:59:58,786 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (359.817 and 346.431 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (88.17) is slightly higher than Ligand B (76.46). Both are below the 140 threshold for good oral absorption, and acceptable for a cardiovascular GPCR. Ligand B is preferable.
3. **logP:** Ligand A (3.235) is within the optimal 1-3 range, while Ligand B (1.52) is at the lower end. For a GPCR, a slightly higher logP is often beneficial for membrane permeability and receptor engagement, making Ligand A preferable.
4. **HBD:** Ligand A (3) is higher than Ligand B (1). Both are within the acceptable limit of 5.
5. **HBA:** Ligand A (6) is higher than Ligand B (5). Both are within the acceptable limit of 10.
6. **QED:** Ligand A (0.776) has a significantly better QED score than Ligand B (0.44), indicating a more drug-like profile. This is a strong advantage for Ligand A.
7. **DILI:** Ligand A (85.459) has a higher DILI risk than Ligand B (43.66). This is a significant drawback for Ligand A. Ligand B is preferable.
8. **BBB:** Ligand A (72.896) and Ligand B (82.513) both have acceptable BBB penetration, but Ligand B is better. While not a primary concern for a cardiovascular target, higher BBB penetration is generally favorable.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.121 and -5.262), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-4.214) has slightly better solubility than Ligand B (-1.582), but both are poor.
11. **hERG:** Ligand A (0.284) has a lower hERG risk than Ligand B (0.656). This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand A (23.668) has a lower microsomal clearance than Ligand B (19.777), indicating better metabolic stability. This is a positive for Ligand A.
13. **t1/2:** Ligand A (43.273) has a longer in vitro half-life than Ligand B (-25.689). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.073) has lower P-gp efflux than Ligand B (0.089). This is a slight advantage for Ligand A.
15. **Binding Affinity:** Ligand A (-7.4) has a stronger binding affinity than Ligand B (-5.8). This is a substantial advantage for Ligand A (a 1.6 kcal/mol difference).
**Overall Assessment:**
Ligand A has a significantly stronger binding affinity, a better QED score, lower Pgp efflux, lower microsomal clearance, and a longer half-life. These are substantial advantages. However, it has a higher DILI risk. Ligand B has a lower DILI risk and slightly better BBB penetration, but its binding affinity is considerably weaker, and its QED score is poor.
Given the importance of potency for GPCR targets, and the fact that the difference in affinity is substantial (1.6 kcal/mol), I believe the benefits of Ligand A outweigh the increased DILI risk, *provided* further investigation into mitigating that risk is conducted. The other ADME properties of Ligand A are also generally more favorable.
Output:
1
2025-04-17 20:59:58,786 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [366.527, 58.64, 2.749, 1, 4, 0.76, 32.261, 67.468, -5.533, -4.035, 0.5, 40.395, -7.633, 0.162, -8.3]
**Ligand B:** [363.527, 55.32, 3.393, 0, 5, 0.743, 36.293, 82.784, -4.977, -4.077, 0.455, 111.025, -29.224, 0.221, -7.4]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, Affinity, and BBB):
1. **MW:** Both are within the ideal range (200-500 Da). A is 366.5, B is 363.5 - very similar.
2. **TPSA:** A (58.64) is slightly higher than B (55.32), but both are well under the 140 threshold for oral absorption and reasonable for a GPCR.
3. **logP:** A (2.749) is good, within the 1-3 range. B (3.393) is slightly higher, but still acceptable.
4. **HBD/HBA:** A has 1 HBD and 4 HBA, B has 0 HBD and 5 HBA. Both are reasonable.
5. **QED:** Both are similar (A: 0.76, B: 0.743), indicating good drug-likeness.
6. **DILI:** A (32.261) is better than B (36.293) - lower risk of liver injury.
7. **BBB:** B (82.784) is significantly better than A (67.468). This is a key advantage for a GPCR, even if not a CNS target, as it suggests better distribution.
8. **Caco-2:** A (-5.533) is worse than B (-4.977), suggesting lower intestinal absorption.
9. **Solubility:** Both are very poor (-4.035 and -4.077). This is a significant concern for both.
10. **hERG:** Both are low (0.5 and 0.455), indicating low cardiotoxicity risk.
11. **Cl_mic:** A (40.395) is much better than B (111.025). Lower clearance means better metabolic stability.
12. **t1/2:** A (-7.633) is much better than B (-29.224). A longer half-life is desirable.
13. **Pgp:** Both are low (0.162 and 0.221), suggesting minimal efflux.
14. **Affinity:** A (-8.3) is slightly better than B (-7.4). While both are good, A has a 0.9 kcal/mol advantage.
**Overall Assessment:**
Ligand A has a better metabolic profile (lower Cl_mic, longer t1/2) and slightly better binding affinity. It also has a lower DILI risk. However, Ligand B has a significantly better BBB penetration score and slightly better Caco-2 permeability. The solubility is poor for both.
Given the GPCR target class, BBB penetration is a valuable property, but the metabolic stability and binding affinity advantages of Ligand A are more important in this case. The difference in affinity (0.9 kcal/mol) is substantial enough to outweigh the BBB advantage of Ligand B, especially considering the poor solubility of both compounds.
Therefore, I would choose Ligand A.
Output:
1
2025-04-17 20:59:58,786 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (360.38 and 345.403 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (70.39) is significantly better than Ligand B (117.42). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold. Ligand B is approaching the upper limit.
3. **logP:** Ligand A (2.166) is optimal, while Ligand B (0.075) is quite low. Low logP can hinder membrane permeability. This is a significant advantage for Ligand A.
4. **HBD:** Ligand A (2) and Ligand B (3) are both acceptable, being less than 5.
5. **HBA:** Ligand A (4) and Ligand B (5) are both acceptable, being less than 10.
6. **QED:** Ligand A (0.865) is better than Ligand B (0.668), indicating a more drug-like profile.
7. **DILI:** Ligand B (68.941) has a higher DILI risk than Ligand A (18.302). This is a substantial concern for Ligand B.
8. **BBB:** Ligand A (77.937) has a better BBB penetration score than Ligand B (55.37). While not a primary concern for a cardiovascular target, it's a slight positive for Ligand A.
9. **Caco-2:** Ligand A (-4.732) and Ligand B (-5.288) are similar, indicating comparable intestinal absorption.
10. **Solubility:** Ligand A (-2.184) and Ligand B (-2.814) are similar, indicating comparable solubility.
11. **hERG:** Ligand A (0.494) has a lower hERG risk than Ligand B (0.153), which is a positive.
12. **Cl_mic:** Ligand A (-4.19) has a lower (better) microsomal clearance than Ligand B (8.62). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand B (-32.706) has a significantly longer in vitro half-life than Ligand A (-9.943). This is a strong advantage for Ligand B.
14. **Pgp:** Ligand A (0.024) has a lower Pgp efflux liability than Ligand B (0.015), which is a positive.
15. **Binding Affinity:** Ligand A (-6.7 kcal/mol) has a slightly better binding affinity than Ligand B (-5.8 kcal/mol). While not a huge difference, it's a contributing factor.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are important. Ligand A excels in logP and TPSA, and has slightly better affinity. Ligand B's longer half-life is attractive, but is outweighed by its poor logP, higher DILI risk, and higher TPSA.
**Overall Assessment:**
Ligand A demonstrates a more balanced profile with better predicted absorption, lower toxicity risk, and better metabolic stability. While Ligand B has a longer half-life, the other drawbacks are too significant to ignore.
Output:
1
2025-04-17 20:59:58,787 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [345.359, 120.32 , -0.294, 3. , 6. , 0.703, 56.146, 19.349, -5.408, -2.832, 0.202, -18.016, -35.024, 0.013, -6.3 ]
**Ligand B:** [344.419, 103.01 , 1.046, 3. , 6. , 0.694, 57.387, 36.642, -5.314, -2.735, 0.441, 38.367, 19.976, 0.011, -7.7 ]
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (345.359 Da and 344.419 Da). No significant difference.
2. **TPSA:** Ligand A (120.32) is slightly higher than Ligand B (103.01). Ligand B is better, closer to the <140 threshold for good absorption.
3. **logP:** Ligand A (-0.294) is quite low, potentially hindering permeation. Ligand B (1.046) is much better, falling within the optimal 1-3 range. This is a significant advantage for Ligand B.
4. **HBD:** Both have 3 HBD, which is acceptable.
5. **HBA:** Both have 6 HBA, which is acceptable.
6. **QED:** Both are good (0.703 and 0.694), indicating drug-like properties.
7. **DILI:** Both are similar and acceptable (56.146 and 57.387, both <60).
8. **BBB:** Ligand B (36.642) is better than Ligand A (19.349), though neither is exceptionally high. For a cardiovascular target, BBB isn't *critical*, but higher is still preferable.
9. **Caco-2:** Both are very poor (-5.408 and -5.314). This is a concern for both, suggesting poor intestinal absorption.
10. **Solubility:** Both are very poor (-2.832 and -2.735). This is a significant drawback for both.
11. **hERG:** Both are low (0.202 and 0.441), indicating low cardiotoxicity risk.
12. **Cl_mic:** Ligand A (-18.016) has a much lower (better) microsomal clearance than Ligand B (38.367), suggesting greater metabolic stability.
13. **t1/2:** Ligand B (19.976) has a longer in vitro half-life than Ligand A (-35.024). This is a significant advantage for Ligand B.
14. **Pgp:** Both are very low (0.013 and 0.011), indicating minimal P-gp efflux.
15. **Binding Affinity:** Ligand B (-7.7) has a significantly stronger binding affinity than Ligand A (-6.3). This is a substantial advantage, potentially outweighing some ADME drawbacks.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, we prioritize logP, Pgp, TPSA, and affinity. Ligand B excels in logP and affinity. While TPSA is better in Ligand B, both are not ideal. The strong affinity of Ligand B is a major plus. The better half-life of Ligand B is also a strong point.
**Conclusion:**
Despite both ligands having poor Caco-2 and solubility, Ligand B's superior logP, binding affinity, and half-life outweigh Ligand A's better metabolic stability. The stronger binding affinity is particularly important for a GPCR target.
Output:
0
2025-04-17 20:59:58,787 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (349.431) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (87.74) is better than Ligand B (59.81). For a cardiovascular GPCR, TPSA isn't a *major* concern unless CNS penetration is desired, but lower is generally preferred.
3. **logP:** Ligand B (4.078) is higher than Ligand A (0.216). This is a significant difference. While logP > 4 can be problematic, it's not always a dealbreaker. Ligand A's logP is quite low, potentially hindering membrane permeability.
4. **HBD/HBA:** Ligand A has 2 HBD and 4 HBA, while Ligand B has 1 HBD and 5 HBA. Both are within acceptable limits.
5. **QED:** Ligand B (0.757) has a significantly better QED score than Ligand A (0.335), indicating a more drug-like profile.
6. **DILI:** Ligand A (21.908) has a much lower DILI risk than Ligand B (59.248). This is a major advantage for Ligand A.
7. **BBB:** Ligand B (73.866) has a higher BBB percentile than Ligand A (56.223). While ADRB2 is primarily a cardiovascular target, some CNS effects are possible with certain ligands, making higher BBB penetration potentially useful.
8. **Caco-2:** Ligand A (-4.88) has a worse Caco-2 permeability than Ligand B (-5.177). Both are negative, indicating poor permeability.
9. **Solubility:** Ligand A (-1.525) has a better solubility than Ligand B (-4.24).
10. **hERG:** Ligand A (0.145) has a lower hERG risk than Ligand B (0.447). This is a significant advantage for Ligand A.
11. **Cl_mic:** Ligand A (0.661) has a much lower microsomal clearance than Ligand B (82.644). This suggests better metabolic stability for Ligand A.
12. **t1/2:** Ligand A (-24.194) has a much longer in vitro half-life than Ligand B (4.734). This is a significant advantage for Ligand A.
13. **Pgp:** Ligand A (0.019) has a much lower P-gp efflux liability than Ligand B (0.641). This is a significant advantage for Ligand A.
14. **Binding Affinity:** Ligand B (-8.1) has a significantly stronger binding affinity than Ligand A (-6.3). This is a substantial advantage for Ligand B, potentially outweighing some ADME concerns.
**GPCR-specific priorities:** For ADRB2 (a cardiovascular GPCR), affinity, logP, and Pgp are key. While BBB isn't critical, it's a bonus.
**Overall Assessment:**
Ligand B has a much stronger binding affinity, which is the most important factor. However, it suffers from high DILI risk, high metabolic clearance, and high P-gp efflux. Ligand A has better ADME properties across the board (lower DILI, better metabolic stability, lower P-gp efflux, better solubility, longer half-life), but its affinity is weaker and logP is too low.
Despite the affinity advantage of Ligand B, the significant ADME liabilities, particularly the high DILI and clearance, make it a less viable candidate. The lower logP of Ligand A is a concern, but it's potentially addressable through structural modifications. The superior ADME profile of Ligand A, combined with acceptable (though not ideal) affinity, makes it the more promising starting point for further optimization.
Output:
1
2025-04-17 20:59:58,787 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (342.37 and 349.475 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (49.85) is significantly better than Ligand B (73.64). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold, while B is approaching it.
3. **logP:** Both ligands (2.922 and 2.05) are within the optimal 1-3 range. Ligand A is slightly more lipophilic, which could be beneficial for membrane permeability, but not dramatically so.
4. **HBD:** Both have 0 HBD, which is good.
5. **HBA:** Ligand A has 3 HBA, Ligand B has 4. Both are acceptable, under the 10 limit.
6. **QED:** Ligand A (0.858) has a significantly better QED score than Ligand B (0.629), indicating a more drug-like profile.
7. **DILI:** Ligand A (77.123) has a higher DILI risk than Ligand B (8.53). This is a major concern for Ligand A.
8. **BBB:** Both have high BBB penetration (89.492 and 85.576). This isn't a primary concern for a cardiovascular target, but isn't detrimental.
9. **Caco-2:** Both have negative Caco-2 values (-4.13 and -4.295). This is unusual and suggests poor permeability. However, these values are on a scale where negative values are possible, and the difference is minimal.
10. **Solubility:** Ligand A (-2.945) has worse solubility than Ligand B (-1.439). Solubility is important for bioavailability.
11. **hERG:** Both have low hERG inhibition risk (0.708 and 0.699).
12. **Cl_mic:** Ligand A (33.385) has lower microsomal clearance than Ligand B (47.059), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-23.973) has a much more negative in vitro half-life than Ligand B (-10.733). This is a significant negative for Ligand A. A negative value suggests a very short half-life or instability.
14. **Pgp:** Both have low Pgp efflux liability (0.369 and 0.106).
15. **Binding Affinity:** Both have very similar and strong binding affinities (-5.9 and -6.2 kcal/mol). The difference is negligible.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, and affinity are important. Ligand A has a slightly better logP and comparable affinity, but a significantly better TPSA. However, the DILI risk and extremely poor in vitro half-life of Ligand A are major red flags. The better solubility of Ligand B is also a plus.
**Overall Assessment:**
Despite Ligand A's slightly better TPSA and metabolic stability, the significantly higher DILI risk and extremely poor half-life make it a much less attractive candidate. Ligand B, while having a slightly higher TPSA and lower QED, presents a much more favorable safety and pharmacokinetic profile.
Output:
0
2025-04-17 20:59:58,787 - INFO - Batch 226 complete. Total preferences: 3616
2025-04-17 20:59:58,787 - INFO - Processing batch 227/512...
2025-04-17 21:00:49,116 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (a GPCR) drug candidates.
**Ligand A:** [346.391, 103.19 , 1.663, 2. , 7. , 0.853, 80.109, 57.542, -4.899, -2.457, 0.068, 21.758, -3.596, 0.005, -6.7 ]
**Ligand B:** [345.535, 53.08 , 4.145, 2. , 5. , 0.741, 15.2 , 87.67 , -5.247, -3.184, 0.947, 18.46 , 39.167, 0.112, -6.1 ]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity, and BBB):
1. **MW:** Both are within the ideal range (346 Da).
2. **TPSA:** Ligand B (53.08) is significantly better than Ligand A (103.19). Lower TPSA generally improves permeability, a key factor for GPCR ligands.
3. **logP:** Ligand A (1.663) is optimal. Ligand B (4.145) is pushing the upper limit and could present solubility issues.
4. **HBD/HBA:** Both have 2 HBD and acceptable HBA counts (7 & 5 respectively).
5. **QED:** Ligand A (0.853) is better than Ligand B (0.741), indicating a more drug-like profile.
6. **DILI:** Ligand B (15.2) has a *much* lower DILI risk than Ligand A (80.109). This is a significant advantage.
7. **BBB:** Ligand B (87.67) has a much higher BBB penetration potential than Ligand A (57.542). While ADRB2 isn't exclusively a CNS target, some cardiovascular effects are mediated through CNS pathways, and better BBB penetration could be beneficial.
8. **Caco-2:** Ligand A (-4.899) has a better Caco-2 permeability than Ligand B (-5.247).
9. **Solubility:** Ligand A (-2.457) has better solubility than Ligand B (-3.184).
10. **hERG:** Ligand A (0.068) has a lower hERG risk than Ligand B (0.947).
11. **Cl_mic:** Ligand B (18.46) has a lower microsomal clearance than Ligand A (21.758), suggesting better metabolic stability.
12. **t1/2:** Ligand B (39.167) has a significantly longer in vitro half-life than Ligand A (-3.596).
13. **Pgp:** Ligand A (0.005) has lower P-gp efflux than Ligand B (0.112).
14. **Affinity:** Both have very good binding affinity (-6.7 and -6.1 kcal/mol). The difference of 0.6 kcal/mol is not substantial enough to override other significant differences.
**Overall Assessment:**
While Ligand A has slightly better QED, Caco-2 permeability, Pgp efflux and hERG, Ligand B presents a much more favorable profile regarding safety (DILI), metabolic stability (Cl_mic, t1/2), and BBB penetration. The higher logP of Ligand B is a concern, but the substantial improvements in other critical ADME/Tox properties outweigh this drawback, especially considering the GPCR target class. The lower DILI risk is particularly compelling.
Therefore, I would choose Ligand B.
0
2025-04-17 21:00:49,116 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (360.445 and 373.519 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (58.64) is significantly better than Ligand B (108.29). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold. Ligand B is approaching the upper limit.
3. **logP:** Both ligands have acceptable logP values (2.756 and 1.554), falling within the 1-3 optimal range. Ligand A is slightly better.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (5). Similar reasoning as HBD.
6. **QED:** Both ligands have good QED scores (0.677 and 0.704), indicating good drug-like properties. No significant difference.
7. **DILI:** Ligand A (35.673) has a lower DILI risk than Ligand B (44.436), which is desirable. Both are below the 60 threshold, but A is better.
8. **BBB:** Ligand A (79.992) has a higher BBB penetration percentile than Ligand B (38.542). While ADRB2 isn't a CNS target, higher BBB is generally a positive indicator of permeability.
9. **Caco-2:** Ligand A (-4.269) is better than Ligand B (-5.114). Higher Caco-2 permeability is preferred.
10. **Solubility:** Ligand A (-2.848) is better than Ligand B (-3.414). Better solubility is preferred.
11. **hERG:** Both ligands have low hERG inhibition liability (0.538 and 0.468), which is good. No significant difference.
12. **Cl_mic:** Both ligands have similar microsomal clearance (39.964 and 40.251). No clear advantage.
13. **t1/2:** Ligand A (0.732) has a shorter half-life than Ligand B (-27.065). This is a significant disadvantage for Ligand A.
14. **Pgp:** Ligand A (0.142) has a lower Pgp efflux liability than Ligand B (0.026). Lower Pgp is preferred.
15. **Binding Affinity:** Ligand B (-7.3) has a significantly stronger binding affinity than Ligand A (-6.3). This is a 1.0 kcal/mol difference, which is substantial and can outweigh some ADME drawbacks.
**GPCR-Specific Priorities & Overall Assessment:**
For a GPCR like ADRB2, affinity, logP, TPSA, and Pgp are key. Ligand B excels in affinity, while Ligand A is better in TPSA, logP, solubility, and Pgp. The significantly stronger binding affinity of Ligand B (-7.3 kcal/mol) is the most important factor here. While Ligand A has a better ADME profile in many respects, the potency advantage of Ligand B is likely to be more impactful in driving efficacy. The shorter half-life of Ligand B is a concern, but could potentially be addressed through formulation strategies.
**Output:**
0
2025-04-17 21:00:49,117 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [371.467, 135.24 , -0.414, 3. , 6. , 0.624, 58.705, 65.839, -5.738, -1.699, 0.123, -35.604, 22.173, 0.008, -7.7 ]
**Ligand B:** [356.463, 85.89 , 0.72 , 2. , 5. , 0.636, 24.777, 69.678, -4.92 , -1.616, 0.19 , 28.889, -0.912, 0.018, -6.7 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal 200-500 Da range. Ligand B (356.463) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (135.24) is slightly above the optimal <140 for oral absorption, but still reasonable. Ligand B (85.89) is excellent, well below 100, suggesting better permeability.
3. **logP:** Ligand A (-0.414) is a bit low, potentially hindering membrane permeability. Ligand B (0.72) is within the optimal 1-3 range. This is a significant advantage for Ligand B.
4. **HBD:** Both are acceptable (3 and 2 respectively), below the 5 threshold.
5. **HBA:** Both are acceptable (6 and 5 respectively), below the 10 threshold.
6. **QED:** Both are good (0.624 and 0.636), indicating good drug-like properties.
7. **DILI:** Ligand A (58.705) has a higher DILI risk than Ligand B (24.777). This is a substantial advantage for Ligand B.
8. **BBB:** Both have reasonable BBB penetration (65.839 and 69.678). Since ADRB2 isn't exclusively a CNS target, this isn't a *major* deciding factor, but Ligand B is slightly better.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-5.738) is worse than Ligand B (-4.92).
10. **Solubility:** Both are very poor (-1.699 and -1.616). This is a significant drawback for both, and would require formulation strategies.
11. **hERG:** Both have low hERG risk (0.123 and 0.19).
12. **Cl_mic:** Ligand A (-35.604) has significantly lower (better) microsomal clearance than Ligand B (28.889), indicating better metabolic stability.
13. **t1/2:** Ligand A (22.173) has a longer in vitro half-life than Ligand B (-0.912). This is a significant advantage for Ligand A.
14. **Pgp:** Both have very low Pgp efflux (0.008 and 0.018).
15. **Affinity:** Ligand A (-7.7) has a better binding affinity than Ligand B (-6.7), a difference of 1 kcal/mol. This is a substantial advantage for Ligand A.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, and affinity are key. Ligand B excels in logP and TPSA. However, Ligand A has a significantly stronger binding affinity (-7.7 vs -6.7 kcal/mol). The affinity difference is substantial enough to potentially overcome the slightly poorer logP and TPSA. The better metabolic stability (lower Cl_mic) and longer half-life of Ligand A are also beneficial. The lower DILI risk of Ligand B is also a significant advantage.
**Overall Assessment:**
Despite the solubility issues of both, the superior binding affinity, metabolic stability, and half-life of Ligand A, combined with a reasonable BBB score, make it the more promising candidate. The slightly lower logP is a concern, but the affinity advantage is likely to be more impactful.
Output:
1
2025-04-17 21:00:49,117 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (338.4 & 350.4 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (62.55) is slightly higher than Ligand B (51.66). Both are below the 140 threshold for oral absorption, but closer to the 90 threshold for CNS targets. Ligand B is preferable.
3. **logP:** Both ligands have good logP values (3.182 & 2.934), falling within the optimal 1-3 range. No clear advantage.
4. **HBD:** Ligand A has 1 HBD, while Ligand B has 0. Both are acceptable, but lower is generally preferred for permeability. Ligand B is slightly better.
5. **HBA:** Ligand A has 3 HBA, and Ligand B has 4. Both are under the 10 threshold, but Ligand A is preferable.
6. **QED:** Ligand A (0.935) has a significantly higher QED score than Ligand B (0.759), indicating a more drug-like profile. This is a strong advantage for Ligand A.
7. **DILI:** Ligand B (26.95) has a much lower DILI risk than Ligand A (59.91). This is a significant advantage for Ligand B.
8. **BBB:** Ligand B (85.15) shows significantly better BBB penetration potential than Ligand A (61.92). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant for off-target effects and broader safety profiling, making Ligand B preferable.
9. **Caco-2:** Both ligands have similar, very negative Caco-2 values (-4.751 & -4.604). This suggests poor permeability, which is a concern for both.
10. **Solubility:** Ligand B (-1.823) has a better (less negative) solubility score than Ligand A (-3.789). Better solubility is a plus.
11. **hERG:** Both ligands have low hERG inhibition liability (0.547 & 0.607), which is good. No significant difference.
12. **Cl_mic:** Ligand B (41.249) has a lower microsomal clearance than Ligand A (54.01), suggesting better metabolic stability. This is a positive for Ligand B.
13. **t1/2:** Ligand A (74.797) has a much longer in vitro half-life than Ligand B (19.95). This is a significant advantage for Ligand A.
14. **Pgp:** Both ligands show low P-gp efflux liability (0.259 & 0.157). No significant difference.
15. **Binding Affinity:** Ligand A (-7.7) has a slightly stronger binding affinity than Ligand B (-7.0). While the difference is less than 1.5 kcal/mol, it's still a positive for Ligand A.
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Both ligands perform well on logP and Pgp. Ligand B has a better TPSA. Ligand A has a slightly better affinity. However, the significant advantages of Ligand B in terms of DILI risk, BBB penetration, solubility, and metabolic stability are very important. The longer half-life of Ligand A is attractive, but the lower DILI and better BBB of Ligand B are more crucial for overall drug development success.
**Conclusion:**
Considering the balance of properties, especially the lower DILI risk, better BBB penetration, improved solubility, and better metabolic stability of Ligand B, I believe it is the more promising drug candidate.
Output:
0
2025-04-17 21:00:49,117 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (358.47 & 348.41 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (61.94) is significantly better than Ligand B (109.3). ADRB2 is a cardiovascular target, so BBB isn't paramount, but lower TPSA generally aids absorption.
3. **logP:** Ligand A (3.37) is optimal (1-3). Ligand B (-0.39) is too low, potentially hindering membrane permeability. This is a significant strike against Ligand B.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (7) is better than Ligand B (8). Lower HBA is generally preferred.
6. **QED:** Ligand B (0.761) is better than Ligand A (0.333), indicating a more drug-like profile. This is a positive for Ligand B.
7. **DILI:** Ligand A (65.61) is higher than Ligand B (57.15). Ligand B has a lower DILI risk, which is favorable.
8. **BBB:** Not a primary concern for a cardiovascular target, but Ligand A (60.84) is better than Ligand B (23.19).
9. **Caco-2:** Both are negative (-5.233 and -5.201), indicating poor permeability. This is a concern for both.
10. **Solubility:** Both are negative (-2.802 and -0.929), indicating poor solubility. This is a concern for both.
11. **hERG:** Ligand A (0.846) is better than Ligand B (0.098), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand B (-6.823) is much better than Ligand A (135.832). Lower clearance indicates better metabolic stability, a significant advantage for Ligand B.
13. **t1/2:** Ligand B (5.592) is better than Ligand A (-10.607). A positive half-life is better than a negative one.
14. **Pgp:** Ligand A (0.84) is better than Ligand B (0.019), indicating lower efflux.
15. **Affinity:** Ligand B (-7.4) is better than Ligand A (-6.5). A 0.9 kcal/mol difference is substantial and can outweigh some ADME concerns.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has better TPSA and Pgp, but Ligand B has significantly better logP and affinity. The affinity difference is particularly important. The improved metabolic stability (Cl_mic) and half-life of Ligand B are also significant advantages. While Ligand A has a better hERG score, the affinity difference of Ligand B is a stronger driver.
**Conclusion:**
Despite Ligand B's lower QED and slightly higher DILI risk, its superior logP, binding affinity, metabolic stability, and half-life outweigh the drawbacks. The substantial binding affinity advantage is crucial for a GPCR target.
Output:
0
2025-04-17 21:00:49,117 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (363.414 and 364.431 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (85.13) is significantly better than Ligand B (113.24). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is pushing the upper limit for good oral absorption.
3. **logP:** Ligand A (4.351) is higher than Ligand B (-0.697). While both are within the acceptable range, Ligand A is approaching the upper limit where solubility issues could arise. Ligand B is quite low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (8). Lower HBA generally improves permeability.
6. **QED:** Both ligands have good QED scores (0.611 and 0.701), indicating good drug-like properties. No clear winner.
7. **DILI:** Ligand B (56.689) has a significantly lower DILI risk than Ligand A (79.256). This is a substantial advantage for Ligand B.
8. **BBB:** Ligand A (82.319) has a much higher BBB penetration potential than Ligand B (18.34). While ADRB2 isn't necessarily a CNS target, some peripheral ADRB2 receptors can be affected by CNS penetration, and it's generally a positive attribute unless it causes unwanted side effects.
9. **Caco-2:** Ligand A (-4.685) has a much higher Caco-2 permeability than Ligand B (-6.002). This suggests better intestinal absorption for Ligand A.
10. **Solubility:** Ligand A (-5.693) has a better solubility score than Ligand B (-1.28). This is important for bioavailability.
11. **hERG:** Ligand A (0.546) has a lower hERG inhibition liability than Ligand B (0.081). Lower is better, so Ligand A is preferable.
12. **Cl_mic:** Ligand B (-25.729) has significantly lower microsomal clearance than Ligand A (54.429), indicating better metabolic stability. This is a major advantage for Ligand B.
13. **t1/2:** Ligand A (18.604) has a longer in vitro half-life than Ligand B (5.271). Longer half-life is generally desirable.
14. **Pgp:** Ligand A (0.513) has lower P-gp efflux liability than Ligand B (0.005). Lower efflux improves bioavailability.
15. **Binding Affinity:** Both ligands have excellent binding affinities (-7.6 and -7.7 kcal/mol). The difference is negligible.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity), Ligand A initially looks more promising due to its better TPSA, Caco-2 permeability, solubility, and Pgp efflux. However, Ligand B has a significantly lower DILI risk and much better metabolic stability (lower Cl_mic), which are critical for drug development. While Ligand A has a better BBB score, this isn't a primary concern for most ADRB2 applications. The lower logP of Ligand B is a concern, but the excellent metabolic stability and reduced toxicity risk are compelling.
Given the balance of properties, the lower DILI and improved metabolic stability of Ligand B outweigh the slightly less favorable permeability characteristics.
Output:
0
2025-04-17 21:00:49,117 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
We are targeting ADRB2, a GPCR. Therefore, the priorities are logP, Pgp, TPSA, affinity, and BBB. Let's compare the ligands:
1. **Molecular Weight:** Both ligands (353.419 and 363.527 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand B (53.51) is significantly better than Ligand A (94.01). A TPSA under 140 is good for oral absorption, and lower is preferred for GPCRs. Ligand B is much closer to the ideal range for CNS penetration if that were a goal.
3. **logP:** Ligand A (1.278) is within the optimal range of 1-3. Ligand B (3.102) is at the higher end but still acceptable.
4. **H-Bond Donors:** Ligand A has 1 HBD, Ligand B has 0. Both are good.
5. **H-Bond Acceptors:** Ligand A has 7 HBA, Ligand B has 4. Both are acceptable, with Ligand B being slightly better.
6. **QED:** Both ligands have similar QED values (0.789 and 0.713) indicating good drug-likeness.
7. **DILI:** Ligand B (28.344) has a much lower DILI risk than Ligand A (54.44). This is a significant advantage for Ligand B.
8. **BBB:** Ligand B (86.429) has a much higher BBB penetration percentile than Ligand A (65.374). While not a primary concern for peripheral GPCRs like ADRB2, higher BBB is generally favorable.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.173 and -4.901), which is unusual and suggests poor permeability. However, the values are similar.
10. **Solubility:** Ligand A (-1.334) has slightly better solubility than Ligand B (-3.024).
11. **hERG:** Both ligands have low hERG inhibition risk (0.187 and 0.398).
12. **Cl_mic:** Ligand A (16.734) has a significantly lower microsomal clearance than Ligand B (60.124), indicating better metabolic stability. This is a key advantage for Ligand A.
13. **t1/2:** Ligand A (-13.769) has a more negative in vitro half-life, which is counterintuitive and suggests a very short half-life. Ligand B (-8.44) is better, but still not ideal.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.025 and 0.293).
15. **Binding Affinity:** Ligand A (-6.0) has slightly better binding affinity than Ligand B (-6.4). However, the difference is relatively small (0.4 kcal/mol).
**Overall Assessment:**
Ligand B has several advantages: significantly lower DILI risk, much better TPSA, and higher BBB penetration. While Ligand A has better metabolic stability (lower Cl_mic) and slightly better affinity, the DILI and TPSA advantages of Ligand B are more critical for overall drug development potential, especially considering the GPCR target class. The negative Caco-2 values are a concern for both, but the other benefits of Ligand B outweigh this drawback.
**Output:**
0
2025-04-17 21:00:49,118 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (353.5 and 387.6 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (72.88) is significantly better than Ligand B (87.3). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand A is well below the 140 threshold, while Ligand B is approaching it.
**3. logP:** Both ligands have acceptable logP values (1.377 and 1.498), falling within the 1-3 range. No clear advantage.
**4. H-Bond Donors:** Ligand A (2) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
**5. H-Bond Acceptors:** Ligand A (4) is preferable to Ligand B (5) for similar reasons as HBDs.
**6. QED:** Ligand A (0.757) has a better QED score than Ligand B (0.55), indicating a more drug-like profile.
**7. DILI:** Ligand A (6.282) has a much lower DILI risk than Ligand B (32.183). This is a significant advantage, as liver toxicity is a major concern.
**8. BBB:** Ligand A (44.436) has a slightly better BBB penetration percentile than Ligand B (36.642), though both are not particularly high. Since ADRB2 is a cardiovascular target, BBB penetration isn't a primary concern, but it's still a positive.
**9. Caco-2 Permeability:** Ligand A (-4.917) is better than Ligand B (-5.602), indicating better intestinal absorption.
**10. Aqueous Solubility:** Ligand A (-1.695) is better than Ligand B (-2.551), which is preferable for formulation and bioavailability.
**11. hERG Inhibition:** Ligand A (0.386) has a much lower hERG inhibition liability than Ligand B (0.073). This is a crucial advantage, as hERG inhibition can lead to cardiotoxicity.
**12. Microsomal Clearance:** Ligand A (13.379) has a lower microsomal clearance than Ligand B (25.952), suggesting better metabolic stability.
**13. In vitro Half-Life:** Ligand A (-6.373) has a slightly better in vitro half-life than Ligand B (-0.626).
**14. P-gp Efflux:** Ligand A (0.012) has a much lower P-gp efflux liability than Ligand B (0.032), which is good for bioavailability.
**15. Binding Affinity:** Ligand B (-6.8) has a slightly better binding affinity than Ligand A (-6.1). While affinity is important, the difference of 0.7 kcal/mol is not substantial enough to outweigh the numerous advantages of Ligand A.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical ADME-Tox parameters (DILI, hERG, solubility, permeability, metabolic stability, P-gp efflux). While Ligand B has a slightly better binding affinity, the improvements in safety and pharmacokinetic properties offered by Ligand A are more valuable for overall drug development success. Given the GPCR target class, the balance of TPSA, logP, and Pgp are all favorable for Ligand A.
Output:
1
2025-04-17 21:00:49,118 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (345.443 and 348.487 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (87.39) is better than Ligand B (49.85). For a cardiovascular GPCR, a lower TPSA is generally preferred for better membrane permeability, but both are acceptable.
**3. logP:** Both ligands have good logP values (3.246 and 2.59), falling within the optimal 1-3 range. Ligand A is slightly higher, potentially offering better membrane permeability.
**4. H-Bond Donors:** Ligand A (3) is reasonable, while Ligand B (0) is very low. While lower HBD can improve permeability, too low can hurt solubility.
**5. H-Bond Acceptors:** Both ligands have a reasonable number of H-bond acceptors (4 and 3 respectively).
**6. QED:** Both ligands have similar QED values (0.685 and 0.5), indicating good drug-like properties.
**7. DILI:** Ligand A (47.732) has a significantly better DILI score than Ligand B (14.23). This is a crucial advantage, as minimizing liver toxicity is paramount.
**8. BBB:** Both ligands have reasonably good BBB penetration (64.831 and 74.99). While ADRB2 is primarily a cardiovascular target, some CNS effects are possible with beta-blockers, so moderate BBB penetration isn't necessarily detrimental. Ligand B is slightly better here.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual. This suggests poor permeability. However, the values are close enough that it doesn't significantly differentiate the two.
**10. Aqueous Solubility:** Ligand A (-3.473) has worse solubility than Ligand B (-1.281). Solubility is important for bioavailability.
**11. hERG Inhibition:** Both ligands show low hERG inhibition risk (0.554 and 0.586). This is good, minimizing cardiotoxicity concerns.
**12. Microsomal Clearance:** Both ligands have similar microsomal clearance values (35.609 and 36.682).
**13. In vitro Half-Life:** Ligand A (71.482) has a significantly longer half-life than Ligand B (-5.362). This is a major advantage, potentially allowing for less frequent dosing.
**14. P-gp Efflux:** Both ligands have similar P-gp efflux liability (0.458 and 0.209).
**15. Binding Affinity:** Ligand B (-6.5 kcal/mol) has a significantly stronger binding affinity than Ligand A (-3.5 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME drawbacks of Ligand B.
**Overall Assessment:**
While Ligand B has a superior binding affinity, Ligand A presents a much more favorable safety profile with a significantly lower DILI risk and a substantially longer half-life. The slightly better solubility of Ligand B is not enough to offset the DILI concern. Given the cardiovascular context, minimizing toxicity is critical. The affinity difference, while substantial, might be addressable through further optimization of Ligand A.
Output:
1
2025-04-17 21:00:49,118 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (383.275 Da and 357.357 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (70.59) is better than Ligand B (80.76). For a cardiovascular GPCR, TPSA should be <140, and both are well within this limit, but lower is generally preferred for better absorption.
**3. logP:** Ligand A (4.036) is slightly higher than Ligand B (1.183). While both are within the 1-3 range, Ligand A is approaching the upper limit, which could potentially lead to solubility issues. Ligand B's logP is excellent.
**4. H-Bond Donors:** Ligand A (3) is higher than Ligand B (1). Lower is generally preferred, but both are acceptable.
**5. H-Bond Acceptors:** Ligand A (3) and Ligand B (5) are both reasonable.
**6. QED:** Both ligands have similar QED values (0.705 and 0.756), indicating good drug-likeness.
**7. DILI Risk:** Ligand B (39.201) has a significantly lower DILI risk than Ligand A (67.778). This is a major advantage for Ligand B.
**8. BBB Penetration:** Ligand B (78.48) has better BBB penetration than Ligand A (50.523). While ADRB2 is a cardiovascular target, some CNS effects are possible with certain ligands, and higher BBB penetration could be beneficial or detrimental depending on the desired profile.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.671 and -4.696), which is unusual and suggests poor permeability. This is a concern for both.
**10. Aqueous Solubility:** Ligand B (-1.684) is better than Ligand A (-5.162), indicating better solubility. This is important given Ligand A's higher logP.
**11. hERG Inhibition:** Ligand A (0.774) has a slightly higher hERG inhibition risk than Ligand B (0.29). Lower is better, so Ligand B is preferred.
**12. Microsomal Clearance:** Ligand B (16.754) has significantly lower microsomal clearance than Ligand A (69.613), indicating better metabolic stability.
**13. In vitro Half-Life:** Ligand B (-17.563) has a negative half-life, which is not possible and indicates a problem with the data. Ligand A (25.44) is reasonable.
**14. P-gp Efflux:** Ligand A (0.601) has lower P-gp efflux than Ligand B (0.016), which is preferable.
**15. Binding Affinity:** Ligand B (-6.9) has a significantly stronger binding affinity than Ligand A (-5.0). This is a substantial advantage, potentially outweighing some of the ADME concerns.
**Overall Assessment:**
Ligand B is the stronger candidate. While it has a negative half-life value that is concerning and needs to be investigated, its significantly better DILI risk, BBB penetration, solubility, hERG inhibition, metabolic stability, and, crucially, binding affinity outweigh the slightly higher TPSA and P-gp efflux. Ligand A's higher logP and DILI risk are significant drawbacks. The substantial affinity difference (-6.9 vs -5.0 kcal/mol) is a key factor.
Output:
0
2025-04-17 21:00:49,118 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.4 & 346.4 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (71.53) is better than Ligand B (75.63). Both are below the 140 threshold for oral absorption, but lower is preferable.
3. **logP:** Both ligands have good logP values (2.009 & 1.441), falling within the optimal 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (0). While both are low, having one HBD can sometimes improve solubility without significantly impacting permeability.
5. **HBA:** Ligand B (5) is preferable to Ligand A (4). Both are within the acceptable range.
6. **QED:** Ligand A (0.903) is significantly better than Ligand B (0.575), indicating a more drug-like profile.
7. **DILI:** Ligand B (38.736) is *much* better than Ligand A (53.432). This is a critical advantage for Ligand B, as lower DILI risk is highly desirable.
8. **BBB:** Both ligands have high BBB penetration (85.847 & 83.288), which is good, but not a primary concern for ADRB2 (a cardiovascular target).
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.617 & -4.605), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand B (-1.237) is better than Ligand A (-2.775), indicating slightly better aqueous solubility.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.299 & 0.184), which is excellent.
12. **Cl_mic:** Ligand A (11.506) has a much lower microsomal clearance than Ligand B (32.789), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-5.371) has a negative half-life, which is not possible. This is a major red flag. Ligand A (3.453) is reasonable.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.043 & 0.089), which is good.
15. **Binding Affinity:** Ligand B (-7.1) has a significantly stronger binding affinity than Ligand A (-6.0). This is a substantial advantage.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand B is better on logP, Pgp, and *significantly* better on affinity. Ligand A is better on TPSA and Cl_mic.
**Overall Assessment:**
Despite Ligand B's superior binding affinity, the negative in vitro half-life is a dealbreaker. A negative half-life is not physically possible and indicates a severe issue with the data or the compound itself. Ligand A, while having a slightly weaker affinity, has a reasonable half-life, better QED, and a lower DILI risk. The Caco-2 values for both are concerning, but the metabolic stability and drug-likeness of Ligand A are more favorable overall.
Output:
1
2025-04-17 21:00:49,118 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [362.459, 112.66 , 1.899, 3. , 7. , 0.693, 78.48 , 58.007, -5.51 , -3.824, 0.401, 37.108, 11.832, 0.081, -6.1 ]
**Ligand B:** [362.543, 59.07 , 4.053, 2. , 6. , 0.763, 55.448, 86.623, -5.209, -4.355, 0.745, 78.082, 43.086, 0.246, -8.3 ]
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (around 362 Da). No significant difference.
2. **TPSA:** Ligand A (112.66) is higher than Ligand B (59.07). For a GPCR, lower TPSA is generally preferred for better permeability, giving a slight edge to Ligand B.
3. **logP:** Ligand A (1.899) is within the optimal range, while Ligand B (4.053) is pushing the upper limit. Ligand A is better here, as high logP can lead to off-target effects and solubility issues.
4. **HBD:** Ligand A (3) and Ligand B (2) are both acceptable.
5. **HBA:** Ligand A (7) and Ligand B (6) are both acceptable.
6. **QED:** Both ligands have good QED scores (A: 0.693, B: 0.763), indicating drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (78.48) has a higher DILI risk than Ligand B (55.448). This is a significant advantage for Ligand B.
8. **BBB:** Ligand B (86.623) has a much higher BBB penetration score than Ligand A (58.007). This is a crucial factor for a GPCR target, even if not CNS-focused, as it can influence distribution and off-target effects.
9. **Caco-2:** Both are negative, indicating poor permeability. This is concerning for both.
10. **Solubility:** Both have negative solubility values, indicating poor solubility. This is concerning for both.
11. **hERG:** Ligand A (0.401) has a lower hERG risk than Ligand B (0.745). This is a positive for Ligand A.
12. **Cl_mic:** Ligand B (78.082) has a higher microsomal clearance than Ligand A (37.108), meaning faster metabolism and potentially lower exposure. Ligand A is preferred.
13. **t1/2:** Ligand B (43.086) has a significantly longer in vitro half-life than Ligand A (11.832). This is a substantial advantage for Ligand B.
14. **Pgp:** Ligand B (0.246) has lower P-gp efflux than Ligand A (0.081), which is favorable.
15. **Affinity:** Ligand B (-8.3 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.1 kcal/mol). This is a major advantage, potentially outweighing some ADME concerns.
**Overall Assessment:**
While both ligands have drawbacks (poor Caco-2 and solubility), Ligand B clearly emerges as the more promising candidate. The significantly stronger binding affinity (-8.3 vs -6.1 kcal/mol) is a major driver. The better BBB penetration, lower DILI risk, and longer half-life also contribute to its superiority. The higher logP and hERG risk are concerns, but the potency advantage is substantial.
Output:
0
2025-04-17 21:00:49,119 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.431 and 347.415 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (77.1) is better than Ligand B (87.74). Both are below 140, but lower TPSA generally favors absorption.
3. **logP:** Both ligands have good logP values (1.187 and 0.804), falling within the optimal 1-3 range. Ligand A is slightly higher, which could be a minor advantage.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD is generally better for permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (4). Lower HBA is generally better for permeability.
6. **QED:** Ligand B (0.737) has a better QED score than Ligand A (0.457), indicating a more drug-like profile. This is a notable advantage for Ligand B.
7. **DILI:** Ligand B (32.338) has a significantly lower DILI risk than Ligand A (45.483). This is a substantial advantage for Ligand B, as lower DILI is crucial.
8. **BBB:** Both ligands have similar BBB penetration (68.36 and 68.748). While not exceptionally high, they are acceptable for a non-CNS target like ADRB2.
9. **Caco-2:** Both ligands have similar negative Caco-2 values (-4.861 and -4.879).
10. **Solubility:** Both ligands have similar negative solubility values (-1.704 and -1.663).
11. **hERG:** Both ligands have very low hERG inhibition liability (0.211 and 0.105). This is excellent for both.
12. **Cl_mic:** Ligand B (-4.62) has a much lower (better) microsomal clearance than Ligand A (11.247). This indicates better metabolic stability for Ligand B.
13. **t1/2:** Ligand B (-5.507) has a better in vitro half-life than Ligand A (-3.876).
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.032 and 0.016). This is excellent for both.
15. **Binding Affinity:** Ligand B (-7.1) has a significantly stronger binding affinity than Ligand A (-5.8). This is a major advantage, as a 1.3 kcal/mol difference can outweigh minor ADME drawbacks.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in affinity and has good logP and Pgp values. While TPSA is slightly higher than Ligand A, the other advantages outweigh this.
**Overall Assessment:**
Ligand B demonstrates a superior profile overall. It has a significantly better binding affinity, lower DILI risk, better metabolic stability (lower Cl_mic and better t1/2), and a higher QED score. While Ligand A has slightly better TPSA and logP, the advantages of Ligand B are more substantial and critical for drug development.
Output:
0
2025-04-17 21:00:49,119 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (343.43 & 354.47 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (78.43) is significantly better than Ligand A (91.32). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have acceptable logP values (1.34 & 2.08), falling within the 1-3 range. Ligand B is slightly better.
4. **HBD:** Both have 3 HBD, which is good.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 3. Both are acceptable.
6. **QED:** Both ligands have similar QED scores (0.68 & 0.66), indicating good drug-likeness.
7. **DILI:** Ligand B (22.76) has a much lower DILI risk than Ligand A (34.28). This is a significant advantage.
8. **BBB:** Ligand B (77.82) has a higher BBB penetration score than Ligand A (36.18). While not crucial for a cardiovascular target, it's a positive attribute.
9. **Caco-2:** Ligand A (-5.10) and Ligand B (-4.79) have similar Caco-2 permeability values.
10. **Solubility:** Ligand A (-2.04) is slightly better than Ligand B (-2.70) in terms of aqueous solubility.
11. **hERG:** Ligand A (0.11) has a slightly lower hERG inhibition liability than Ligand B (0.52), which is preferable.
12. **Cl_mic:** Ligand A (-7.36) has a much lower microsomal clearance than Ligand B (24.96), indicating better metabolic stability. This is a strong advantage.
13. **t1/2:** Ligand B (26.06) has a much longer in vitro half-life than Ligand A (3.86). This is a significant advantage.
14. **Pgp:** Ligand A (0.038) has lower P-gp efflux liability than Ligand B (0.078).
15. **Affinity:** Ligand A (-7.5) has a slightly better binding affinity than Ligand B (-6.0). This is a 1.5kcal/mol advantage, which is significant.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B has better logP, TPSA, and Pgp values. Ligand A has a slightly better affinity. However, the substantial improvements in DILI risk, BBB penetration, and *especially* the significantly longer half-life of Ligand B outweigh the small affinity difference. Metabolic stability (reflected in Cl_mic and t1/2) is crucial for *in vivo* efficacy, and Ligand B is far superior in this regard.
**Conclusion:**
Considering the balance of properties and the priorities for a GPCR target, Ligand B is the more promising drug candidate.
Output:
0
2025-04-17 21:00:49,119 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands (369.443 and 357.451 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand B (88.18) is significantly better than Ligand A (117.36). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary goal, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (0.793) is slightly better than Ligand B (0.014). Both are on the low side, but Ligand A is within the optimal 1-3 range, while Ligand B is quite low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (3) is higher than Ligand B (1). This isn't a major concern for either, as both are within the acceptable limit of 5.
5. **HBA:** Ligand A (6) is higher than Ligand B (5). Both are within the acceptable limit of 10.
6. **QED:** Both ligands have good QED scores (0.524 and 0.588), indicating generally drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand B (26.444) has a much lower DILI risk than Ligand A (77.472). This is a significant advantage for Ligand B.
8. **BBB:** Ligand B (55.138) has a higher BBB penetration than Ligand A (35.246). While not crucial for a cardiovascular target, higher BBB is rarely a negative.
9. **Caco-2:** Ligand A (-5.206) and Ligand B (-4.94) are both negative, which is unusual and suggests poor permeability. The values are very close.
10. **Solubility:** Ligand A (-3.113) is slightly better than Ligand B (-0.213). Solubility is important for bioavailability.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.089 and 0.088). No significant difference.
12. **Cl_mic:** Ligand B (16.653) has a lower microsomal clearance than Ligand A (21.935), indicating better metabolic stability.
13. **t1/2:** Ligand B (-30.305) has a significantly longer in vitro half-life than Ligand A (-6.497). This is a major advantage.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.09 and 0.009). No significant difference.
15. **Binding Affinity:** Ligand A (-8.1) has a slightly better binding affinity than Ligand B (-6.5). This is a 1.6 kcal/mol difference, which is substantial and could outweigh some ADME drawbacks.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, and affinity. Ligand A has a better logP and significantly better affinity. Ligand B has a better TPSA and Pgp. However, the substantial advantage in affinity for Ligand A, coupled with acceptable (though not ideal) logP, makes it the more promising candidate. The improved metabolic stability (lower Cl_mic and longer t1/2) and reduced DILI risk of Ligand B are attractive, but the affinity difference is likely to be more impactful for *in vivo* efficacy.
**Output:**
1
2025-04-17 21:00:49,119 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output:
**Ligand A: [339.37 , 63.25 , 3.963, 2. , 3. , 0.739, 85.576, 70.997, -4.725, -4.906, 0.819, 85.249, 47.899, 0.334, -7.1 ]**
**Ligand B: [365.499, 78.51 , 1.095, 2. , 4. , 0.662, 39.162, 59.209, -5.233, -3.242, 0.198, 28.322, 2.234, 0.026, -5.2 ]**
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (339.37) is slightly preferred due to being closer to the lower end, potentially aiding permeability.
2. **TPSA:** Ligand A (63.25) is significantly better than Ligand B (78.51). ADRB2 is not a CNS target, but lower TPSA generally improves absorption.
3. **logP:** Ligand A (3.963) is higher than Ligand B (1.095). While both are within acceptable limits, Ligand A is closer to the optimal range of 1-3. Ligand B is quite low, potentially hindering membrane permeability.
4. **H-Bond Donors:** Both have 2 HBD, which is good.
5. **H-Bond Acceptors:** Ligand A (3) is better than Ligand B (4). Lower is preferable for permeability.
6. **QED:** Ligand A (0.739) is better than Ligand B (0.662), indicating a more drug-like profile.
7. **DILI:** Ligand B (39.162) is significantly better than Ligand A (85.576). This is a major advantage for Ligand B.
8. **BBB:** Ligand A (70.997) is better than Ligand B (59.209), but BBB is not a high priority for ADRB2.
9. **Caco-2:** Ligand A (-4.725) is better than Ligand B (-5.233). Higher values indicate better absorption.
10. **Solubility:** Ligand A (-4.906) is better than Ligand B (-3.242). Higher values indicate better solubility.
11. **hERG:** Ligand A (0.819) is better than Ligand B (0.198). Lower values are preferred.
12. **Cl_mic:** Ligand A (85.249) is worse than Ligand B (28.322). Lower clearance is better for metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand A (47.899) is better than Ligand B (2.234). Longer half-life is generally preferred.
14. **Pgp:** Ligand A (0.334) is better than Ligand B (0.026). Lower efflux is preferred.
15. **Binding Affinity:** Ligand A (-7.1) is significantly better than Ligand B (-5.2). A 1.9 kcal/mol difference is substantial and can outweigh many ADME drawbacks.
**Overall Assessment:**
Ligand A has a significantly better binding affinity and generally better physicochemical properties (TPSA, logP, QED, solubility, hERG, Pgp, t1/2, Caco-2). However, Ligand B has a much lower DILI risk and better metabolic stability (lower Cl_mic). The strong binding affinity of Ligand A is a major advantage for a GPCR target like ADRB2. The DILI risk for Ligand A is concerning, but the substantial improvement in potency might be worth further investigation with structural modifications to mitigate the DILI risk.
Considering the balance, the superior binding affinity of Ligand A is a decisive factor.
Output:
1
2025-04-17 21:00:49,119 - INFO - Batch 227 complete. Total preferences: 3632
2025-04-17 21:00:49,120 - INFO - Processing batch 228/512...
2025-04-17 21:01:39,872 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's systematically compare Ligand A and Ligand B against the provided guidelines, keeping in mind the GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key).
1. **MW:** Both ligands (363.435 and 358.473 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand B (40.62) is significantly better than Ligand A (76.82). A lower TPSA is preferred for better membrane permeability, and Ligand B is well below the 140 threshold. Ligand A is higher, potentially hindering absorption.
3. **logP:** Both ligands have good logP values (2.896 and 3.552), falling within the optimal 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability, but isn't a major concern for either.
4. **HBD:** Both have 0 HBD, which is good.
5. **HBA:** Ligand B (2) is better than Ligand A (6). Lower HBA is generally favored for permeability.
6. **QED:** Ligand B (0.754) has a higher QED score than Ligand A (0.556), indicating a more drug-like profile.
7. **DILI:** Ligand B (26.444) has a *much* lower DILI risk than Ligand A (88.949). This is a critical advantage for Ligand B.
8. **BBB:** Both ligands have reasonably good BBB penetration (69.756 and 87.088). Ligand B is better, but BBB isn't the highest priority for ADRB2 (a cardiovascular target).
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests a potential issue with the data or modeling. However, the values are similar.
10. **Solubility:** Both have negative solubility values, which is also unusual. Again, the values are similar.
11. **hERG:** Ligand B (0.825) has a slightly higher hERG risk than Ligand A (0.563), but both are relatively low.
12. **Cl_mic:** Ligand B (50.663) has a lower microsomal clearance than Ligand A (76.23), indicating better metabolic stability.
13. **t1/2:** Ligand A (83.628) has a much longer in vitro half-life than Ligand B (-16.149). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand B (0.254) has a much lower P-gp efflux liability than Ligand A (0.47). This is a significant advantage for Ligand B, improving bioavailability.
15. **Affinity:** Ligand A (-5.8 kcal/mol) has a significantly stronger binding affinity than Ligand B (-1.9 kcal/mol). This is a substantial advantage for Ligand A. A difference of >3.9 kcal/mol is quite large.
**Overall Assessment:**
While Ligand A has a significantly better binding affinity and a longer half-life, Ligand B excels in several crucial ADME properties: lower DILI risk, lower P-gp efflux, lower TPSA, and better QED. The difference in affinity is substantial, but the improved safety profile (DILI) and bioavailability (P-gp) of Ligand B are compelling. The lower TPSA and HBA also suggest better permeability. Given the GPCR-specific priorities, and the importance of a balanced profile, the advantages of Ligand B outweigh the affinity difference.
**Output:**
0
2025-04-17 21:01:39,873 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (359.294 and 348.487 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (29.54) is excellent, well below the 140 threshold and very favorable for oral absorption. Ligand B (58.64) is still reasonable but less optimal. This favors Ligand A.
3. **logP:** Both ligands have good logP values (3.592 and 2.632), falling within the 1-3 range. Ligand A is slightly higher, which could be a minor concern for off-target effects, but not a major issue.
4. **HBD:** Ligand A (0) is ideal, minimizing potential issues with hydrogen bonding and maximizing permeability. Ligand B (1) is acceptable.
5. **HBA:** Ligand A (2) is good. Ligand B (3) is also acceptable.
6. **QED:** Both ligands have good QED scores (0.603 and 0.831), indicating good drug-like properties. Ligand B is slightly better here.
7. **DILI:** Ligand A (60.45) is borderline high risk for DILI. Ligand B (16.208) is excellent, indicating a very low risk. This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (81.698) has good BBB penetration, which is relevant for a GPCR. Ligand B (71.85) is also reasonable, but lower. This favors Ligand A.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not defined, so it's difficult to interpret.
10. **Solubility:** Both ligands have negative solubility values, which is also unusual and suggests poor solubility. Again, the scale is not defined.
11. **hERG:** Ligand A (0.76) has a slightly higher hERG risk than Ligand B (0.26), which is preferable.
12. **Cl_mic:** Ligand A (81.439) has a higher microsomal clearance, indicating lower metabolic stability. Ligand B (36.364) is much better, suggesting greater metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand B (9.763) has a slightly longer half-life than Ligand A (8.404).
14. **Pgp:** Ligand A (0.482) has lower P-gp efflux, which is good. Ligand B (0.103) is even better, suggesting better oral bioavailability and potentially better CNS exposure.
15. **Binding Affinity:** Ligand A (-7.6 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.0 kcal/mol). This is a substantial advantage for Ligand A, potentially outweighing some of its ADME drawbacks.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand A excels in TPSA and significantly in affinity. Ligand B is better in Pgp and DILI risk.
**Overall Assessment:**
The strong binding affinity of Ligand A (-7.6 kcal/mol) is a major advantage. While its DILI risk is a concern, the substantial potency gain might be worth further investigation with structural modifications to address the DILI. Ligand B has a better safety profile and metabolic stability but lacks the strong binding affinity needed for a potent drug. Considering the importance of potency for GPCR targets, I lean towards Ligand A.
Output:
1
2025-04-17 21:01:39,873 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (349.435 Da) is within the ideal range, while Ligand B (382.961 Da) is slightly higher but still acceptable.
2. **TPSA:** Ligand A (96.33) is borderline acceptable, while Ligand B (51.02) is excellent for oral absorption. This favors Ligand B.
3. **logP:** Ligand A (0.447) is quite low, potentially hindering permeability. Ligand B (4.616) is high, potentially causing solubility and off-target issues, but more acceptable for a GPCR.
4. **HBD:** Ligand A (2) is good. Ligand B (0) is also good.
5. **HBA:** Both Ligand A (5) and Ligand B (5) are acceptable.
6. **QED:** Both Ligand A (0.552) and Ligand B (0.702) are good, with B being slightly better.
7. **DILI:** Ligand A (38.852) has a lower DILI risk than Ligand B (45.328), which is preferable.
8. **BBB:** Ligand A (41.14) is low, while Ligand B (66.731) is moderately good. For a cardiovascular target like ADRB2, BBB penetration isn't a primary concern, so this doesn't heavily favor either.
9. **Caco-2:** Ligand A (-5.508) is very poor, suggesting poor absorption. Ligand B (-4.852) is also poor, but slightly better.
10. **Solubility:** Ligand A (-1.135) is poor, while Ligand B (-4.544) is even worse. Both are problematic.
11. **hERG:** Ligand A (0.087) has a very low hERG risk, which is excellent. Ligand B (0.737) is higher, but still relatively low.
12. **Cl_mic:** Ligand A (17.396) has a lower clearance, indicating better metabolic stability than Ligand B (74.005). This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (20.606) has a shorter half-life than Ligand B (55.584). This favors Ligand B.
14. **Pgp:** Ligand A (0.015) has very low P-gp efflux, which is excellent. Ligand B (0.699) is higher, but not excessively so.
15. **Affinity:** Ligand B (-6.4 kcal/mol) has a significantly stronger binding affinity than Ligand A (-8.2 kcal/mol). This is a substantial advantage for Ligand B.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are particularly important. Ligand B excels in logP and affinity, while Ligand A has better TPSA and Pgp. The affinity difference is substantial (-6.4 vs -8.2 kcal/mol). While Ligand A has a better safety profile (DILI, hERG, Cl_mic), the potency advantage of Ligand B is likely to outweigh these concerns, especially if further optimization can address its solubility and Caco-2 permeability.
**Conclusion:**
Despite the solubility and permeability concerns, the significantly stronger binding affinity of Ligand B makes it the more promising candidate.
Output:
0
2025-04-17 21:01:39,873 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (338.37 and 361.47 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (108.23) is slightly higher than Ligand B (99.77). Both are below the 140 A^2 threshold for good oral absorption, but closer to the upper limit for GPCRs.
**3. logP:** Both ligands have excellent logP values (2.519 and 2.341), falling within the optimal 1-3 range.
**4. H-Bond Donors:** Both have 3 HBD, which is acceptable.
**5. H-Bond Acceptors:** Ligand A has 6 HBA, while Ligand B has 5. Both are within the acceptable limit of 10.
**6. QED:** Both ligands have good QED scores (0.677 and 0.705), indicating good drug-like properties.
**7. DILI:** Ligand A has a DILI risk of 84.22%, which is concerning (high risk). Ligand B has a much lower DILI risk of 59.40%, which is still above the ideal but significantly better. This is a major advantage for Ligand B.
**8. BBB:** Ligand A has a BBB penetration of 28.73%, while Ligand B has 37.38%. While ADRB2 is a cardiovascular target, some CNS effects are possible with beta-blockers, so a slightly higher BBB penetration isn't necessarily detrimental, but not a primary driver.
**9. Caco-2 Permeability:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-5.06) is slightly worse than Ligand B (-5.671).
**10. Aqueous Solubility:** Ligand A (-3.912) is slightly worse than Ligand B (-2.8). Both are poor.
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (0.305 and 0.123).
**12. Microsomal Clearance:** Ligand A (13.563) has higher clearance than Ligand B (-4.148), indicating lower metabolic stability. Ligand B is significantly better here.
**13. In vitro Half-Life:** Ligand A (23.913) has a shorter half-life than Ligand B (6.01).
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (0.049 and 0.088).
**15. Binding Affinity:** Ligand B (-6.7 kcal/mol) has a slightly better binding affinity than Ligand A (-6.3 kcal/mol). While the difference is not huge, it's a positive for Ligand B.
**Overall Assessment:**
Ligand B is the preferable candidate. The primary driver is the significantly lower DILI risk. The better metabolic stability (lower Cl_mic, longer half-life) and slightly improved binding affinity are also beneficial. While both have poor solubility and permeability, the DILI risk is a critical factor in early drug development. The slightly better BBB penetration of Ligand B is a minor advantage.
Output:
0
2025-04-17 21:01:39,873 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (342.399 Da and 354.426 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (96.25) is higher than Ligand B (69.48). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B has a clear advantage.
3. **logP:** Ligand A (-0.165) is quite low, potentially hindering membrane permeability. Ligand B (1.694) is within the optimal 1-3 range. Ligand B is significantly better.
4. **HBD:** Ligand A (3) is acceptable, while Ligand B (0) is even better, potentially improving permeability.
5. **HBA:** Ligand A (5) and Ligand B (6) are both acceptable, falling under the 10 threshold.
6. **QED:** Ligand A (0.648) is better than Ligand B (0.472), indicating a more drug-like profile.
7. **DILI:** Ligand A (63.862) has a higher DILI risk than Ligand B (41.14). Ligand B is preferable.
8. **BBB:** Ligand A (32.144) is low, while Ligand B (91.508) is very high. While ADRB2 isn't necessarily a CNS target, higher BBB penetration can sometimes correlate with better overall drug distribution.
9. **Caco-2:** Both are negative, indicating poor permeability. However, Ligand B (-4.517) is slightly less negative than Ligand A (-4.742), suggesting marginally better permeability.
10. **Solubility:** Ligand A (-2.755) is worse than Ligand B (-1.277). Solubility is important, and Ligand B is better here.
11. **hERG:** Both ligands (0.271 and 0.273) have similar, low hERG inhibition risk, which is good.
12. **Cl_mic:** Ligand A (24.595) has a lower microsomal clearance than Ligand B (31.716), indicating better metabolic stability.
13. **t1/2:** Ligand A (-2.576) has a more negative half-life than Ligand B (-3.49), suggesting a shorter half-life. Ligand B is preferable.
14. **Pgp:** Both ligands (0.082 and 0.165) have low P-gp efflux liability, which is good.
15. **Binding Affinity:** Ligand A (-7.4) has a slightly better binding affinity than Ligand B (-5.7). This is a 1.7 kcal/mol difference, which is substantial.
**Overall Assessment:**
Ligand A has a better binding affinity and QED, and lower Cl_mic. However, its low logP and solubility are major concerns. Ligand B excels in logP, TPSA, DILI, BBB, solubility, and half-life. The significantly better logP and solubility of Ligand B outweigh the slightly weaker binding affinity, especially considering the potential for optimization of Ligand B's affinity. The lower DILI risk is also a significant advantage. For a cardiovascular GPCR, optimizing for permeability and minimizing toxicity are crucial.
Output:
0
2025-04-17 21:01:39,873 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (366.622 and 343.383 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (49.41) is significantly better than Ligand B (97.37). For a GPCR, lower TPSA is generally preferred for better permeability. Ligand B's TPSA is quite high, potentially hindering absorption.
**3. logP:** Both ligands have acceptable logP values (3.894 and 2.213), falling within the 1-3 range. Ligand A is slightly higher, which might be beneficial for membrane permeability, but not drastically so.
**4. H-Bond Donors & Acceptors:** Ligand A (1 HBD, 2 HBA) is more favorable than Ligand B (2 HBD, 5 HBA). Lower counts are generally preferred for better permeability.
**5. QED:** Both ligands have similar QED values (0.75 and 0.716), indicating good drug-likeness.
**6. DILI Risk:** Ligand A (26.755) has a much lower DILI risk than Ligand B (61.303). This is a significant advantage for Ligand A, as liver toxicity is a major concern in drug development.
**7. BBB Penetration:** Ligand A (81.815) has better BBB penetration than Ligand B (55.642). While ADRB2 is primarily a cardiovascular target, some CNS side effects are possible with GPCR modulators, and better BBB penetration could contribute to this.
**8. Caco-2 Permeability:** Ligand A (-4.783) has better Caco-2 permeability than Ligand B (-5.431).
**9. Aqueous Solubility:** Ligand A (-4.493) has better aqueous solubility than Ligand B (-2.056).
**10. hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.458 and 0.253). This is excellent.
**11. Microsomal Clearance:** Ligand B (32.495) has lower microsomal clearance than Ligand A (66.166), suggesting better metabolic stability. This is a point in favor of Ligand B.
**12. In vitro Half-Life:** Ligand B (22.421) has a significantly longer in vitro half-life than Ligand A (-11.352). This is a substantial advantage for Ligand B, potentially allowing for less frequent dosing.
**13. P-gp Efflux:** Both ligands have low P-gp efflux liability (0.228 and 0.2). No significant difference.
**14. Binding Affinity:** Ligand B (-7.3) has a slightly better binding affinity than Ligand A (-6.9). While a 0.4 kcal/mol difference is not huge, it is noticeable.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity) and general drug-like properties, Ligand A is the more favorable candidate. While Ligand B has better metabolic stability and a slightly higher affinity, Ligand A excels in crucial areas like TPSA, DILI risk, BBB penetration, solubility, and Caco-2 permeability. The lower DILI risk and better TPSA are particularly important. The slightly weaker affinity of Ligand A can likely be optimized in subsequent rounds of medicinal chemistry.
Output:
1
2025-04-17 21:01:39,873 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [356.373, 75.63, 2.496, 0., 5., 0.832, 53.315, 90.074, -4.102, -2.195, 0.202, 36.149, -11.367, 0.058, -5.5]
**Ligand B:** [356.463, 106.94, 0.622, 3., 5., 0.532, 14.114, 19.232, -5.134, -0.475, 0.1, 1.226, -4.668, 0.029, -6.4]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are around 356 Da, within the ideal 200-500 range. No significant difference.
2. **TPSA:** Ligand A (75.63) is significantly better than Ligand B (106.94). Below 140 is good for oral absorption, and A is closer to the ideal for GPCRs.
3. **logP:** Ligand A (2.496) is optimal (1-3). Ligand B (0.622) is a bit low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (0) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Both have 5 HBA, acceptable.
6. **QED:** Ligand A (0.832) is better than Ligand B (0.532), indicating a more drug-like profile.
7. **DILI:** Ligand A (53.315) has a higher DILI risk than Ligand B (14.114). This is a significant drawback for A.
8. **BBB:** Ligand A (90.074) has excellent BBB penetration, while Ligand B (19.232) is very poor. This is a major advantage for A, given it's a GPCR.
9. **Caco-2:** Ligand A (-4.102) and Ligand B (-5.134) are both very poor, indicating poor intestinal absorption.
10. **Solubility:** Ligand B (-0.475) is slightly better than Ligand A (-2.195), but both are quite poor.
11. **hERG:** Both are very low risk (0.202 and 0.1).
12. **Cl_mic:** Ligand B (1.226) has much lower microsomal clearance than Ligand A (36.149), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-11.367) has a shorter half-life than Ligand B (-4.668), which is unfavorable.
14. **Pgp:** Ligand A (0.058) has lower P-gp efflux than Ligand B (0.029), which is preferable.
15. **Affinity:** Ligand B (-6.4) has a slightly stronger binding affinity than Ligand A (-5.5), a 0.9 kcal/mol difference.
**Overall Assessment:**
Ligand A excels in BBB penetration, TPSA, logP, QED, and Pgp efflux. Ligand B has a better DILI score, metabolic stability, and slightly better binding affinity. However, the superior BBB penetration and overall drug-likeness of Ligand A, combined with its acceptable logP, outweigh the DILI risk and metabolic stability concerns. The slightly stronger binding of Ligand B isn't enough to overcome the poor BBB penetration. Considering this is a GPCR target, the ability to cross the BBB is highly valuable.
Output:
1
2025-04-17 21:01:39,873 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (389.233 Da) is within the ideal range (200-500 Da). Ligand B (347.419 Da) is also within range, slightly lower. This is a minor advantage to A.
2. **TPSA:** Ligand A (67.77) is good, below 140, suggesting reasonable absorption. Ligand B (90.56) is also acceptable, but closer to the upper limit. A is better here.
3. **logP:** Ligand A (4.885) is a bit high, potentially leading to solubility issues and off-target effects. Ligand B (-0.006) is very low, which could hinder membrane permeability. This is a significant drawback for B.
4. **HBD:** Ligand A (1) is good. Ligand B (2) is acceptable.
5. **HBA:** Ligand A (4) is good. Ligand B (5) is acceptable.
6. **QED:** Both ligands have good QED scores (A: 0.715, B: 0.8), indicating good drug-like properties.
7. **DILI:** Ligand A (84.219) has a higher DILI risk than Ligand B (23.73). This is a significant advantage for B.
8. **BBB:** Ligand A (72.431) has a good BBB percentile, suggesting reasonable CNS penetration if desired. Ligand B (48.934) is lower, indicating limited CNS penetration. For ADRB2, which has cardiovascular implications, CNS penetration isn't a primary requirement, so this favors A slightly.
9. **Caco-2:** Ligand A (-4.754) is very poor. Ligand B (-5.412) is also poor. Both have poor predicted intestinal absorption.
10. **Solubility:** Ligand A (-5.675) is very poor. Ligand B (-2.04) is also poor, but better than A.
11. **hERG:** Both ligands have low hERG risk (A: 0.486, B: 0.328).
12. **Cl_mic:** Ligand A (63.54) has moderate clearance. Ligand B (-34.313) has negative clearance, which is not physically possible and likely an artifact of the prediction method, but indicates very high metabolic stability. This is a major advantage for B.
13. **t1/2:** Ligand A (88.654) has a long half-life, which is good. Ligand B (6.373) has a very short half-life. This is a significant advantage for A.
14. **Pgp:** Both have low Pgp efflux (A: 0.399, B: 0.016). B is slightly better.
15. **Affinity:** Ligand A (-7.1 kcal/mol) has a slightly better binding affinity than Ligand B (-6.7 kcal/mol). This is a key advantage for A, especially given the relatively small difference.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are crucial. Ligand A has a higher logP, but a significantly better affinity. Ligand B has a very low logP, which is a major concern. While B has a better DILI score and Cl_mic, the poor logP and lower affinity are significant drawbacks. The longer half-life of A is also beneficial.
**Overall Assessment:**
Despite the higher DILI risk, Ligand A's superior binding affinity, acceptable TPSA, and reasonable BBB penetration outweigh the benefits of Ligand B's lower DILI and potentially better metabolic stability. The very low logP of Ligand B is a major concern for permeability and overall drug-like properties.
Output:
1
2025-04-17 21:01:39,874 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
We are targeting ADRB2, a GPCR. Therefore, the priorities are logP, Pgp, TPSA, affinity, and BBB. Let's compare the two ligands across all parameters, keeping these priorities in mind.
1. **MW:** Both ligands (356.463 and 354.447 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (85.89) is better than Ligand B (88.1), being closer to the <140 threshold for good absorption.
3. **logP:** Ligand A (2.197) is optimal (1-3), while Ligand B (0.511) is a bit low, potentially hindering permeation. This is a significant advantage for Ligand A.
4. **HBD/HBA:** Both have 2 HBD and 5 HBA, which are acceptable.
5. **QED:** Ligand B (0.696) has a slightly better QED score than Ligand A (0.539), indicating slightly better overall drug-likeness.
6. **DILI:** Ligand B (13.61) has a much lower DILI risk than Ligand A (30.748). This is a substantial advantage for Ligand B.
7. **BBB:** Ligand A (83.87) has a better BBB penetration percentile than Ligand B (70.686). While ADRB2 isn't necessarily a CNS target, some peripheral ADRB2 activity can be modulated by CNS effects, and higher BBB penetration could be beneficial.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual. Assuming these are percentile scores, Ligand A (-4.587) is slightly better (less negative).
9. **Solubility:** Ligand A (-1.965) is slightly better than Ligand B (-1.167) in terms of solubility.
10. **hERG:** Both ligands have very low hERG inhibition liability (0.262 and 0.188), which is excellent.
11. **Cl_mic:** Ligand B (15.281) has a much lower microsomal clearance than Ligand A (60.598), suggesting better metabolic stability. This is a significant advantage for Ligand B.
12. **t1/2:** Ligand B (19.414) has a longer in vitro half-life than Ligand A (9.918), further supporting its better metabolic stability.
13. **Pgp:** Both ligands have very low P-gp efflux liability (0.091 and 0.042), which is good.
14. **Affinity:** Ligand B (-5.3 kcal/mol) has a slightly better binding affinity than Ligand A (-6.2 kcal/mol). While the difference is not huge, it is still a positive for Ligand B.
**Overall Assessment:**
Ligand A has advantages in logP, BBB, and solubility. However, Ligand B excels in DILI risk, metabolic stability (Cl_mic and t1/2), and has slightly better affinity. Given the importance of minimizing toxicity (DILI) and maximizing duration of action (metabolic stability), Ligand B is the more promising candidate. The slightly better affinity also contributes to its favorability. The lower logP of Ligand B is a concern but might be mitigated through formulation strategies.
**Output:**
0
2025-04-17 21:01:39,874 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (374.893 Da) is slightly higher than Ligand B (342.363 Da), but both are acceptable.
2. **TPSA:** Ligand A (49.41) is significantly better than Ligand B (114.33). For a GPCR, lower TPSA is generally preferred for better permeability. Ligand B is quite high, potentially hindering absorption.
3. **logP:** Ligand A (3.674) is within the optimal range, while Ligand B (1.022) is on the lower side. While not a complete deal-breaker, lower logP can sometimes lead to poor membrane permeability.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 3 HBA, while Ligand B has 9. Ligand A is preferable here, as excessive HBA can reduce permeability.
6. **QED:** Ligand A (0.868) has a much better QED score than Ligand B (0.404), indicating a more drug-like profile.
7. **DILI:** Ligand B (87.747) has a significantly higher DILI risk than Ligand A (61.807). This is a major concern, as liver toxicity is a common reason for drug failure.
8. **BBB:** Ligand A (68.205) has a better BBB percentile than Ligand B (57.736), though neither are exceptionally high. For a cardiovascular target, BBB penetration isn't *critical*, but it's still a positive.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. This is concerning for both.
10. **Solubility:** Ligand A (-4.212) has slightly better solubility than Ligand B (-3.036), though both are poor.
11. **hERG:** Ligand A (0.373) has a lower hERG risk than Ligand B (0.121), which is favorable.
12. **Cl_mic:** Ligand B (55.856) has slightly lower microsomal clearance than Ligand A (52.844), suggesting slightly better metabolic stability.
13. **t1/2:** Ligand B (6.057) has a significantly longer in vitro half-life than Ligand A (-0.921). This is a major advantage for Ligand B.
14. **Pgp:** Ligand A (0.443) has a lower P-gp efflux liability than Ligand B (0.1). This is favorable for Ligand A.
15. **Affinity:** Ligand A (-6.7 kcal/mol) has a slightly better binding affinity than Ligand B (-5.4 kcal/mol). While the difference isn't huge, it's enough to be considered.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A performs better on logP, TPSA, and Pgp, and has a slightly better affinity. While BBB isn't crucial for a cardiovascular target, Ligand A is still better.
**Overall Assessment:**
Ligand A is the superior candidate. Despite the poor Caco-2 and solubility, its significantly better TPSA, QED, lower DILI risk, lower hERG risk, and slightly better affinity outweigh the longer half-life of Ligand B. The high DILI risk of Ligand B is a major red flag.
Output:
1
2025-04-17 21:01:39,874 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (388.842) is slightly higher, but still acceptable.
2. **TPSA:** Ligand A (32.34) is excellent, well below the 140 threshold and favorable for absorption. Ligand B (109.62) is higher, but still within a reasonable range.
3. **logP:** Ligand A (4.806) is a bit high, potentially leading to solubility issues or off-target effects. Ligand B (2.26) is optimal.
4. **HBD:** Both ligands have acceptable HBD counts (Ligand A: 1, Ligand B: 2).
5. **HBA:** Both ligands have acceptable HBA counts (Ligand A: 3, Ligand B: 6).
6. **QED:** Ligand A (0.818) has a better QED score than Ligand B (0.594), indicating a more drug-like profile.
7. **DILI:** Ligand B (69.756) has a higher DILI risk than Ligand A (56.689), which is concerning.
8. **BBB:** Ligand A (88.135) has a significantly higher BBB penetration potential than Ligand B (47.15). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant for side effect profile.
9. **Caco-2:** Ligand A (-4.822) has a worse Caco-2 permeability than Ligand B (-5.277), indicating lower intestinal absorption.
10. **Solubility:** Ligand A (-5.302) has slightly better solubility than Ligand B (-3.603).
11. **hERG:** Ligand A (0.805) has a lower hERG risk than Ligand B (0.439).
12. **Cl_mic:** Ligand B (38.24) has a lower microsomal clearance than Ligand A (64.971), suggesting better metabolic stability.
13. **t1/2:** Ligand A (27.269) has a longer in vitro half-life than Ligand B (13.194).
14. **Pgp:** Ligand A (0.648) has a lower P-gp efflux liability than Ligand B (0.092).
15. **Affinity:** Ligand A (-7.2 kcal/mol) has a significantly stronger binding affinity than Ligand B (-5.8 kcal/mol). This is a substantial difference.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand A has a higher logP, but the much stronger affinity (-7.2 vs -5.8) and lower Pgp efflux are significant advantages. The better BBB penetration is also a plus. While Ligand B has better metabolic stability (lower Cl_mic) and Caco-2 permeability, the potency difference is substantial enough to outweigh these factors. The DILI risk for Ligand B is also a concern.
**Conclusion:**
Despite the slightly higher logP and lower Caco-2, Ligand A's superior binding affinity, lower Pgp efflux, better BBB penetration, lower DILI risk, and longer half-life make it the more promising drug candidate for ADRB2.
Output:
1
2025-04-17 21:01:39,874 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [379.335, 22.61, 4.165, 0, 4, 0.796, 52.966, 89.841, -4.72, -3.916, 0.971, 56.472, 19.378, 0.668, -6.6]
**Ligand B:** [349.395, 118.03, 0.312, 2, 7, 0.673, 72.703, 30.787, -5.141, -2.369, 0.13, 58.4, -26.847, 0.046, -6.2]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (349.395) is slightly lower, which could be beneficial for permeability, but both are acceptable.
2. **TPSA:** Ligand A (22.61) is excellent, well below the 140 threshold and very favorable for oral absorption. Ligand B (118.03) is higher, but still within a reasonable range.
3. **logP:** Ligand A (4.165) is at the upper end of the optimal range, potentially leading to solubility issues. Ligand B (0.312) is *too* low, likely hindering membrane permeability.
4. **HBD:** Ligand A (0) is ideal. Ligand B (2) is acceptable.
5. **HBA:** Ligand A (4) is good. Ligand B (7) is higher, but not a major concern.
6. **QED:** Both ligands have similar QED values (A: 0.796, B: 0.673), indicating good drug-likeness.
7. **DILI:** Ligand A (52.966) has a better DILI score than Ligand B (72.703), indicating lower potential for liver toxicity.
8. **BBB:** Ligand A (89.841) is very good, suggesting good potential for CNS penetration (though ADRB2 isn't primarily a CNS target, it's still a positive). Ligand B (30.787) is low.
9. **Caco-2:** Ligand A (-4.72) is poor, indicating limited intestinal absorption. Ligand B (-5.141) is also poor.
10. **Solubility:** Ligand A (-3.916) is poor, consistent with its higher logP. Ligand B (-2.369) is also poor.
11. **hERG:** Both ligands have low hERG risk (A: 0.971, B: 0.13).
12. **Cl_mic:** Ligand A (56.472) has slightly lower clearance, suggesting better metabolic stability. Ligand B (58.4) is a bit higher.
13. **t1/2:** Ligand B (-26.847) has a much longer half-life, which is a significant advantage. Ligand A (19.378) is shorter.
14. **Pgp:** Ligand A (0.668) has moderate Pgp efflux. Ligand B (0.046) has very low Pgp efflux, which is highly desirable.
15. **Affinity:** Both have good binding affinity (A: -6.6, B: -6.2), but Ligand A is slightly better.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A has a better logP and TPSA, and slightly better affinity. However, Ligand B has a significantly longer half-life and much lower Pgp efflux, which are crucial for bioavailability and maintaining therapeutic concentrations. The BBB score for A is also a plus, even if not critical for ADRB2.
**Decision:**
Despite Ligand A's slightly better affinity and TPSA, the significantly improved half-life and reduced P-gp efflux of Ligand B are more compelling for overall drug development potential. The lower logP of Ligand B, while a concern, might be mitigated through formulation strategies. The longer half-life and reduced efflux are harder to address post-hoc.
Therefore, I prefer Ligand B.
Output:
0
2025-04-17 21:01:39,874 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (343.47 Da) is within the ideal range, while Ligand B (369.42 Da) is slightly higher but still acceptable.
2. **TPSA:** Ligand A (46.61) is excellent, well below the 140 threshold and favorable for absorption. Ligand B (98.66) is higher, potentially hindering absorption, although not drastically.
3. **logP:** Ligand A (3.39) is optimal. Ligand B (1.45) is on the lower side, potentially impacting membrane permeability.
4. **HBD:** Both ligands are low in HBDs (0 for A, 1 for B), which is good.
5. **HBA:** Ligand A (3) is good. Ligand B (6) is higher, but still within the acceptable range.
6. **QED:** Both ligands have good QED scores (0.71 for A, 0.79 for B), indicating good drug-like properties.
7. **DILI:** Ligand A (11.13) has a significantly lower DILI risk than Ligand B (54.21), a major advantage.
8. **BBB:** Ligand A (91.28) shows excellent BBB penetration, while Ligand B (70.76) is lower. While ADRB2 isn't exclusively a CNS target, some cardiovascular effects are mediated by central pathways, and better BBB penetration could be beneficial.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not defined, so it's hard to interpret.
10. **Solubility:** Both ligands have negative solubility values, which is also unusual and suggests poor solubility.
11. **hERG:** Ligand A (0.70) has a slightly higher hERG risk than Ligand B (0.49), but both are relatively low.
12. **Cl_mic:** Ligand A (45.49) has a higher microsomal clearance than Ligand B (14.26), meaning it's metabolized faster. This is a disadvantage.
13. **t1/2:** Ligand A (-21.49) has a negative half-life, which is not possible. Ligand B (-2.84) is also negative, which is not possible.
14. **Pgp:** Ligand A (0.56) has a lower P-gp efflux liability than Ligand B (0.17), which is favorable.
15. **Affinity:** Ligand A (-7.0) has a slightly better binding affinity than Ligand B (-5.9). While both are good, the 1.1 kcal/mol difference is significant.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are crucial. Ligand A excels in logP, TPSA, and Pgp, and has a slightly better affinity. Ligand B's lower logP is a concern. The DILI risk for Ligand A is also much lower.
**Overall Assessment:**
Despite the unusual negative values for Caco-2 and solubility, Ligand A is the preferred candidate. Its superior TPSA, logP, Pgp profile, lower DILI risk, and slightly better affinity outweigh the higher microsomal clearance. The negative half-life values are concerning and would need to be investigated, but the other properties make Ligand A the more promising starting point for optimization.
Output:
1
2025-04-17 21:01:39,874 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for the ADRB2, a cardiovascular GPCR. Therefore, the priorities are logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB.
Let's compare the ligands property by property:
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (342.37) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (59.5) is significantly better than Ligand B (96.25). Lower TPSA is crucial for GPCR ligands to ensure good brain penetration and overall absorption.
3. **logP:** Both are within the optimal range (1-3), but Ligand A (2.563) is higher than Ligand B (1.548). Higher logP can sometimes be beneficial for membrane permeability, but needs to be balanced with solubility.
4. **HBD/HBA:** Ligand A (0 HBD, 4 HBA) is preferable to Ligand B (3 HBD, 5 HBA). Fewer hydrogen bonds are generally better for membrane permeability.
5. **QED:** Ligand A (0.787) has a better QED score than Ligand B (0.595), indicating a more drug-like profile.
6. **DILI:** Ligand B (33.695) has a significantly lower DILI risk than Ligand A (56.611), which is a major advantage.
7. **BBB:** Ligand A (98.216) has excellent BBB penetration, while Ligand B (33.036) is poor. While ADRB2 is cardiovascular, some CNS off-target effects are possible, and higher BBB is not necessarily detrimental here.
8. **Caco-2:** Ligand A (-4.158) has a much higher Caco-2 permeability than Ligand B (-5.198).
9. **Solubility:** Ligand A (-3.061) has better solubility than Ligand B (-2.215).
10. **hERG:** Ligand A (0.825) has a lower hERG risk than Ligand B (0.294).
11. **Cl_mic:** Ligand B (22.67) has a significantly lower microsomal clearance than Ligand A (68.543), indicating better metabolic stability.
12. **t1/2:** Ligand B (41.428) has a much longer in vitro half-life than Ligand A (-14.411).
13. **Pgp:** Ligand A (0.209) has lower P-gp efflux than Ligand B (0.092), which is favorable.
14. **Binding Affinity:** Ligand A (-6.9 kcal/mol) has a slightly better binding affinity than Ligand B (-5.7 kcal/mol). This difference is significant.
**Overall Assessment:**
Ligand A excels in binding affinity, TPSA, Caco-2 permeability, solubility, hERG, and Pgp efflux. However, Ligand B has a much better safety profile (lower DILI) and significantly improved metabolic stability (lower Cl_mic and longer t1/2). The difference in binding affinity is substantial, and the better ADME properties of Ligand A, particularly the TPSA and permeability, are crucial for a GPCR target. The slightly higher DILI risk for Ligand A is a concern, but potentially manageable with further optimization.
**Output:**
1
2025-04-17 21:01:39,874 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
Let's analyze each ligand against the provided guidelines, keeping in mind ADRB2 is a GPCR and therefore we prioritize logP, Pgp, TPSA, and affinity, alongside general drug-like properties.
* **Molecular Weight:** Both ligands (363.853 Da and 352.435 Da) fall within the ideal 200-500 Da range. No significant difference here.
* **TPSA:** Ligand A (110.75) is better than Ligand B (116.48), being closer to the <140 threshold for good absorption.
* **logP:** Ligand A (1.575) is within the optimal 1-3 range. Ligand B (-0.127) is *below* 1, which is a concern for membrane permeability. This is a significant negative for Ligand B.
* **H-Bond Donors:** Ligand A (3) and Ligand B (4) are both acceptable, being under the limit of 5.
* **H-Bond Acceptors:** Ligand A (7) and Ligand B (6) are both acceptable, being under the limit of 10.
* **QED:** Ligand A (0.695) is better than Ligand B (0.52), indicating a more drug-like profile.
* **DILI:** Ligand B (35.479) has a much lower DILI risk than Ligand A (69.678). This is a significant advantage for Ligand B.
* **BBB:** Ligand A (64.482) has a better BBB penetration percentile than Ligand B (20.822). While ADRB2 isn't strictly a CNS target, some peripheral distribution is still desirable, and a higher BBB value suggests better overall permeability.
* **Caco-2 Permeability:** Both are negative, but Ligand A (-5.709) is slightly better than Ligand B (-5.308).
* **Aqueous Solubility:** Both are negative, with Ligand A (-2.625) being slightly better than Ligand B (-1.316).
* **hERG:** Both ligands have very low hERG risk (0.216 and 0.026 respectively).
* **Microsomal Clearance:** Ligand B (2.483) has significantly lower microsomal clearance than Ligand A (44.288), suggesting better metabolic stability.
* **In vitro Half-Life:** Ligand A (26.35) has a longer half-life than Ligand B (19.64).
* **P-gp Efflux:** Both are very low (0.05 and 0.006 respectively).
* **Binding Affinity:** Ligand B (-8.5 kcal/mol) has a *much* stronger binding affinity than Ligand A (-3.3 kcal/mol). This is a >1.5 kcal/mol advantage, which can outweigh several ADME drawbacks.
**Overall Assessment:**
Ligand B has a substantially better binding affinity, significantly lower DILI risk, and improved metabolic stability (lower Cl_mic). The biggest drawback for Ligand B is its low logP, which could hinder permeability. However, the strong binding affinity and lower DILI risk are compelling advantages. Ligand A has better TPSA and BBB, but the lower affinity and higher DILI risk are concerning. Given the importance of potency for GPCR targets, and the relatively minor impact of TPSA differences, the stronger binding of Ligand B is the deciding factor.
**Output:**
0
2025-04-17 21:01:39,874 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (336.435) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (41.57) is significantly better than Ligand B (86.63). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand B's TPSA is quite high, potentially hindering oral bioavailability.
3. **logP:** Ligand A (3.705) is good, within the optimal range. Ligand B (1.238) is on the lower side, potentially causing permeability issues.
4. **HBD:** Both have 1 HBD, which is acceptable.
5. **HBA:** Ligand A (3) is better than Ligand B (5). Higher HBA can sometimes reduce permeability.
6. **QED:** Both ligands have good QED scores (A: 0.925, B: 0.829), indicating good drug-like properties.
7. **DILI:** Ligand A (54.789) has a slightly higher DILI risk than Ligand B (49.632), but both are within acceptable limits (<60).
8. **BBB:** Ligand A (91.586) has better BBB penetration than Ligand B (84.451). While not critical for a cardiovascular target, it's a slight advantage.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual. Assuming these represent permeability ratios, values < 1 indicate poor permeability. Ligand A (-4.692) is slightly better than Ligand B (-4.488), but both are concerning.
10. **Solubility:** Ligand A (-4.452) has better solubility than Ligand B (-2.112).
11. **hERG:** Ligand A (0.919) has a lower hERG risk than Ligand B (0.286), which is a significant advantage.
12. **Cl_mic:** Ligand A (92.773) has a much higher microsomal clearance than Ligand B (20.504), indicating lower metabolic stability. This is a major drawback for Ligand A.
13. **t1/2:** Ligand B (-30.481) has a significantly longer in vitro half-life than Ligand A (5.171), which is a major advantage.
14. **Pgp:** Ligand A (0.715) has better Pgp efflux properties than Ligand B (0.048). Lower Pgp is preferable.
15. **Binding Affinity:** Ligand A (-6.1) has a slightly better binding affinity than Ligand B (-5.4). However, the difference is not substantial enough to outweigh other significant drawbacks.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A has better logP, TPSA, and Pgp, and slightly better affinity. However, the significantly worse metabolic stability (Cl_mic) and shorter half-life of Ligand A are major concerns. The better hERG profile of Ligand A is a plus.
**Overall Assessment:**
Ligand B, despite its higher TPSA and lower logP, is the more promising candidate due to its significantly improved metabolic stability (lower Cl_mic) and longer half-life. These factors are crucial for *in vivo* efficacy and a reasonable dosing regimen. While Ligand A has a slightly better affinity and better Pgp, the metabolic liabilities are too significant to ignore.
Output:
0
2025-04-17 21:01:39,874 - INFO - Batch 228 complete. Total preferences: 3648
2025-04-17 21:01:39,874 - INFO - Processing batch 229/512...
2025-04-17 21:02:30,618 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (359.451) is slightly higher than Ligand B (348.407), but both are acceptable.
2. **TPSA:** Ligand A (63.69) is significantly better than Ligand B (129.73). For a GPCR, a lower TPSA is generally preferred for better permeability, and Ligand A is well below the 140 threshold. Ligand B is approaching the upper limit and could present absorption challenges.
3. **logP:** Ligand A (3.332) is within the optimal range (1-3). Ligand B (0.205) is quite low, potentially leading to poor membrane permeability and bioavailability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (6). Similar to HBD, lower HBA is generally better for permeability.
6. **QED:** Ligand A (0.909) is excellent, indicating high drug-likeness. Ligand B (0.645) is still acceptable, but less optimal.
7. **DILI:** Ligand A (75.184) has a higher DILI risk than Ligand B (53.044), but both are within acceptable ranges (below 60 is good).
8. **BBB:** Ligand A (79.217) shows better BBB penetration than Ligand B (52.811). While ADRB2 isn't exclusively a CNS target, some CNS exposure can occur, and higher BBB penetration is generally favorable.
9. **Caco-2:** Ligand A (-4.766) is better than Ligand B (-5.714), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-4.167) is better than Ligand B (-1.85), indicating better aqueous solubility.
11. **hERG:** Ligand A (0.343) has a much lower hERG inhibition liability than Ligand B (0.008). This is a critical safety parameter, and Ligand A is significantly safer.
12. **Cl_mic:** Ligand A (48.917) has a lower microsomal clearance than Ligand B (-14.497). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (-1.449) has a shorter half-life than Ligand B (-15.951). This is a drawback for Ligand A, but can potentially be addressed through formulation or structural modifications.
14. **Pgp:** Ligand A (0.335) has lower P-gp efflux than Ligand B (0.025), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand A (-7.3) has a slightly better binding affinity than Ligand B (-4.7). This difference of 2.6 kcal/mol is substantial and can outweigh some of the ADME drawbacks of Ligand A.
**Overall Assessment:**
Ligand A is significantly better overall. It excels in key ADME properties like TPSA, logP, solubility, hERG, and metabolic stability. While its half-life is shorter, its superior binding affinity and better overall drug-like properties make it a more promising candidate. Ligand B suffers from a low logP and high TPSA, which could severely limit its absorption and bioavailability.
Output:
1
2025-04-17 21:02:30,618 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (345.4 and 341.5 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (76.71) is higher than Ligand B (57.5). Both are below 140, but B is better for absorption.
3. **logP:** Both ligands have good logP values (2.85 and 2.22), falling within the 1-3 range. Ligand B is slightly lower, which could be beneficial for solubility.
4. **HBD:** Ligand A has 1 HBD, and Ligand B has 2. Both are acceptable, well below the limit of 5.
5. **HBA:** Ligand A has 5 HBA, and Ligand B has 4. Both are below the limit of 10.
6. **QED:** Both ligands have very similar QED values (0.865 and 0.847), indicating good drug-likeness.
7. **DILI:** Ligand B (24.622) has a *much* lower DILI risk than Ligand A (56.65). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (75.8) has a better BBB penetration percentile than Ligand B (52.0). While ADRB2 isn't strictly a CNS target, some peripheral ADRB2 activity can influence CNS function, and better BBB penetration isn't necessarily a negative.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand B (-4.868) is slightly worse than Ligand A (-4.513).
10. **Solubility:** Ligand B (-2.124) has better solubility than Ligand A (-3.56).
11. **hERG:** Ligand A (0.421) has a lower hERG risk than Ligand B (0.844). This is a positive for Ligand A.
12. **Cl_mic:** Ligand B (31.062) has significantly lower microsomal clearance than Ligand A (95.865), indicating better metabolic stability.
13. **t1/2:** Ligand B (68.92) has a longer in vitro half-life than Ligand A (43.703).
14. **Pgp:** Ligand A (0.239) has lower P-gp efflux than Ligand B (0.573), which is favorable.
15. **Affinity:** Ligand A (-7.5 kcal/mol) has a stronger binding affinity than Ligand B (-6.3 kcal/mol). This is a substantial difference (1.2 kcal/mol), and is a major factor.
**GPCR-Specific Priorities & Overall Assessment:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A has a slight edge in Pgp and a *significant* edge in binding affinity. However, Ligand B excels in DILI risk and metabolic stability (Cl_mic and t1/2), and has better solubility. The substantial difference in affinity (-7.5 vs -6.3) is a major advantage for Ligand A, and can often outweigh minor ADME concerns. The lower DILI risk of Ligand B is very attractive, but the significantly better binding affinity of Ligand A is more critical for a GPCR target.
**Output:**
1
2025-04-17 21:02:30,618 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (342.399 and 349.366 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands have similar TPSA values (93.09 and 93.11), which are acceptable for a non-CNS GPCR target like ADRB2.
3. **logP:** Ligand B (1.189) has a slightly better logP value than Ligand A (0.375). ADRB2 is a cardiovascular target, so moderate lipophilicity is desirable for membrane permeability and receptor engagement. Ligand A's logP is a bit low, potentially hindering permeation.
4. **HBD/HBA:** Ligand A has 2 HBD and 5 HBA, while Ligand B has 1 HBD and 6 HBA. Both are within acceptable limits, but Ligand A might have a slight edge with fewer donors.
5. **QED:** Ligand B (0.837) has a significantly higher QED score than Ligand A (0.577), indicating a more drug-like profile overall.
6. **DILI:** Both ligands have DILI risk around the 56-60 percentile, which is acceptable, though ideally lower. No clear advantage.
7. **BBB:** Ligand B (81.194) has a much higher BBB penetration score than Ligand A (54.246). While ADRB2 isn't a primary CNS target, some degree of BBB penetration isn't necessarily detrimental and could offer some off-target benefits or alternative routes of metabolism.
8. **Caco-2:** Both ligands have very poor Caco-2 permeability (-4.813 and -4.718). This is a significant concern for oral bioavailability for both.
9. **Solubility:** Both ligands have very poor aqueous solubility (-2.95 and -3.39). This is a major drawback for both compounds and will require formulation strategies.
10. **hERG:** Both ligands have very low hERG inhibition liability (0.05 and 0.104), which is excellent.
11. **Cl_mic:** Ligand A (12.2 mL/min/kg) has a significantly lower microsomal clearance than Ligand B (39.28 mL/min/kg), suggesting better metabolic stability. This is a crucial advantage.
12. **t1/2:** Ligand A (-24.614 hours) has a longer in vitro half-life than Ligand B (-34.968 hours). This is a positive attribute.
13. **Pgp:** Both ligands have low P-gp efflux liability (0.019 and 0.046), which is good.
14. **Binding Affinity:** Ligand B (-7.4 kcal/mol) has a slightly better binding affinity than Ligand A (-7.2 kcal/mol), but the difference is small.
**GPCR-Specific Priorities:**
For ADRB2 (a cardiovascular GPCR), logP, Pgp, TPSA, and affinity are key. Ligand B has a better logP and slightly better affinity, and a better BBB score. However, Ligand A has a significantly better metabolic stability (lower Cl_mic) and longer half-life, which are important for *in vivo* efficacy. The poor Caco-2 and solubility are problematic for both.
**Overall Assessment:**
Despite the slightly better affinity of Ligand B, the significantly improved metabolic stability and half-life of Ligand A are more critical for a successful drug candidate. The slightly lower logP of Ligand A is a concern, but can potentially be addressed through further optimization. The poor solubility and permeability are shared issues that would need to be tackled regardless of which lead is chosen.
Output:
1
2025-04-17 21:02:30,618 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (345.443 Da) is well within the ideal range (200-500 Da). Ligand B (379.488 Da) is also acceptable. No clear advantage here.
2. **TPSA:** Ligand A (78.6) is good, under the 140 threshold for oral absorption. Ligand B (29.54) is excellent, suggesting very good permeability. Advantage: Ligand B.
3. **logP:** Ligand A (2.955) is optimal. Ligand B (4.463) is slightly high, potentially leading to solubility issues or off-target interactions. Advantage: Ligand A.
4. **HBD:** Ligand A (2) is good. Ligand B (0) is also acceptable. No clear advantage.
5. **HBA:** Ligand A (5) is good. Ligand B (3) is also good. No clear advantage.
6. **QED:** Ligand A (0.871) is excellent, indicating high drug-likeness. Ligand B (0.623) is still reasonable, but lower. Advantage: Ligand A.
7. **DILI:** Ligand A (63.086) is moderately risky. Ligand B (11.865) is very low risk. Significant advantage: Ligand B.
8. **BBB:** Ligand A (85.459) is good. Ligand B (97.053) is excellent. Advantage: Ligand B.
9. **Caco-2:** Both ligands have very poor Caco-2 permeability (-4.439 and -4.443). This is a significant concern for oral bioavailability for both. No advantage.
10. **Solubility:** Both ligands have poor aqueous solubility (-4.204 and -5.285). This is a concern, but less critical if other parameters are favorable. No advantage.
11. **hERG:** Both ligands have low hERG inhibition risk (0.81 and 0.771). No clear advantage.
12. **Cl_mic:** Ligand A (53.191) has lower clearance, suggesting better metabolic stability. Ligand B (75.534) has higher clearance. Advantage: Ligand A.
13. **t1/2:** Ligand A (87.277) has a significantly longer half-life. Ligand B (2.781) has a very short half-life. Significant advantage: Ligand A.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.461 and 0.386). No clear advantage.
15. **Affinity:** Ligand B (-6.8 kcal/mol) has a substantially stronger binding affinity than Ligand A (-3.6 kcal/mol). This is a major advantage, potentially outweighing some ADME drawbacks.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, BBB, and affinity. Ligand B excels in TPSA and BBB, and crucially, has a much stronger binding affinity. While its logP is higher, the affinity difference is substantial. Ligand A has a better logP and metabolic stability, but the weaker binding is a major drawback. The DILI risk for Ligand B is also significantly lower.
**Overall Assessment:**
Despite the slightly higher logP and poorer metabolic stability, Ligand B's significantly stronger binding affinity, excellent BBB penetration, lower DILI risk, and favorable TPSA make it the more promising candidate. The poor Caco-2 and solubility are shared concerns that would need to be addressed in formulation, but the potency advantage is likely to be more impactful for initial development.
Output:
0
2025-04-17 21:02:30,619 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (344.419 Da and 349.475 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (85.17) is slightly higher than Ligand B (65.79). For a cardiovascular GPCR, TPSA is moderately important, and Ligand B's lower value is preferable for better membrane permeability.
**3. logP:** Both ligands have good logP values (1.797 and 2.203, respectively), falling within the optimal 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability.
**4. H-Bond Donors:** Both ligands have 1 HBD, which is within the acceptable limit of <=5.
**5. H-Bond Acceptors:** Ligand A has 7 HBAs, while Ligand B has 4. Both are within the acceptable limit of <=10, but Ligand B is better.
**6. QED:** Both ligands have good QED scores (0.91 and 0.855), indicating good drug-like properties.
**7. DILI Risk:** Ligand A has a DILI risk of 60.721, which is approaching the higher risk threshold (>60). Ligand B has a much lower DILI risk of 21.093, making it significantly safer in terms of liver toxicity. This is a major advantage for Ligand B.
**8. BBB Penetration:** Both ligands have reasonable BBB penetration (79.256 and 63.94, respectively). While BBB isn't a primary concern for a cardiovascular target, a higher value is generally preferred. Ligand A is better here.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-5.014 and -4.866), which is unusual and suggests poor permeability. This is a concern for both.
**10. Aqueous Solubility:** Both ligands have negative solubility values (-2.354 and -1.347), which is also unusual and indicates poor solubility. This is a concern for both.
**11. hERG Inhibition:** Ligand A (0.132) has a slightly lower hERG inhibition risk than Ligand B (0.746), which is preferable.
**12. Microsomal Clearance:** Ligand A has a higher microsomal clearance (53.653) than Ligand B (0.305). Lower clearance is better for metabolic stability, giving Ligand B a significant advantage.
**13. In vitro Half-Life:** Ligand A has a longer half-life (10.891 hours) than Ligand B (27.795 hours). Longer half-life is generally desirable.
**14. P-gp Efflux:** Ligand A (0.26) has lower P-gp efflux than Ligand B (0.194), which is preferable.
**15. Binding Affinity:** Ligand B (-7.1 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.5 kcal/mol). This 1.6 kcal/mol difference is substantial and can outweigh some of the ADME drawbacks of Ligand B.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand B emerges as the more promising candidate. While Ligand A has slightly better BBB penetration and in vitro half-life, Ligand B's significantly lower DILI risk, better TPSA, lower P-gp efflux, and *much* stronger binding affinity are critical advantages. The poor Caco-2 and solubility for both compounds are concerning, but can be addressed with formulation strategies. The superior binding affinity of Ligand B is a major driver for its selection.
Output:
0
2025-04-17 21:02:30,619 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (336.439 and 336.395 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (77.81 and 78.13) are below the 140 A^2 threshold for good oral absorption, and are reasonably low, though not ideal for CNS penetration. No major difference.
3. **logP:** Ligand A (4.049) is at the upper end of the optimal range (1-3), while Ligand B (1.93) is towards the lower end. For a GPCR, a slightly higher logP can be beneficial for membrane permeability, but Ligand A is approaching a point where solubility could become an issue.
4. **HBD:** Ligand A (2) and Ligand B (1) are both within the acceptable limit of <=5. Ligand B is slightly better.
5. **HBA:** Ligand A (3) and Ligand B (4) are both within the acceptable limit of <=10. No major difference.
6. **QED:** Both ligands have good QED scores (0.835 and 0.93), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (47.15) has a significantly lower DILI risk than Ligand B (68.98). This is a substantial advantage for Ligand A.
8. **BBB:** Ligand A (56.65) has a slightly better BBB penetration percentile than Ligand B (46.452), but both are not high enough to be considered CNS-focused.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.719 and -4.885), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Both ligands have very poor solubility scores (-3.806 and -3.591). This is a significant drawback for both.
11. **hERG:** Ligand A (0.773) has a lower hERG inhibition liability than Ligand B (0.488), indicating a lower risk of cardiotoxicity. This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand A (9.067) has a lower microsomal clearance than Ligand B (-12.018), suggesting better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (58.412) has a much longer in vitro half-life than Ligand B (20.945). This is a major advantage for Ligand A.
14. **Pgp:** Ligand A (0.079) has a lower P-gp efflux liability than Ligand B (0.119), suggesting better oral bioavailability. This is a slight advantage for Ligand A.
15. **Binding Affinity:** Ligand A (-7.6 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.5 kcal/mol). This is a substantial advantage for Ligand A.
**Overall Assessment:**
While both ligands have issues with solubility and Caco-2 permeability, Ligand A is significantly better overall. Its superior binding affinity, lower DILI risk, lower hERG inhibition, better metabolic stability (lower Cl_mic and longer t1/2), and lower P-gp efflux outweigh the slightly higher logP. The difference in binding affinity is particularly important for a GPCR target.
Output:
1
2025-04-17 21:02:30,619 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (345.4 and 347.5 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (95.73) is higher than Ligand B (70.47). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B has a clear advantage.
3. **logP:** Ligand A (-0.203) is quite low, potentially hindering membrane permeability. Ligand B (0.791) is within the optimal 1-3 range. Ligand B is significantly better.
4. **HBD:** Both ligands have 1 HBD, which is acceptable.
5. **HBA:** Ligand A has 7 HBAs, while Ligand B has 5. Both are below the 10 threshold, but Ligand B is slightly better.
6. **QED:** Both ligands have good QED scores (0.698 and 0.792), indicating good drug-like properties.
7. **DILI:** Ligand A (47.85%) has a higher DILI risk than Ligand B (19.27%). This is a substantial difference, favoring Ligand B.
8. **BBB:** Both ligands have high BBB penetration (79.2% and 77.9%), but this is less crucial for a cardiovascular target like ADRB2.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Both have negative solubility values, which is also unusual and suggests poor solubility. This is a concern for both.
11. **hERG:** Ligand A (0.215) has a slightly lower hERG risk than Ligand B (0.459), which is a minor advantage.
12. **Cl_mic:** Ligand A (43.45) has a significantly higher microsomal clearance than Ligand B (3.22). This indicates poorer metabolic stability for Ligand A. Ligand B is much better.
13. **t1/2:** Ligand A (11.95) has a longer in vitro half-life than Ligand B (8.54), which is a slight advantage.
14. **Pgp:** Ligand A (0.022) has much lower P-gp efflux liability than Ligand B (0.013). This is a significant advantage for Ligand A, potentially improving bioavailability.
15. **Binding Affinity:** Ligand B (-9.3 kcal/mol) has a substantially stronger binding affinity than Ligand A (-5.6 kcal/mol). This is a very large difference and likely outweighs many of the other drawbacks of Ligand B.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP and affinity, while Ligand A has a slight edge in Pgp. Ligand B's significantly better affinity is the most important factor. The lower DILI risk of Ligand B is also a significant advantage.
**Conclusion:**
Despite Ligand A's better Pgp profile and slightly longer half-life, Ligand B's superior binding affinity, better logP, lower DILI risk, and lower microsomal clearance make it the more promising drug candidate. The large affinity difference is a major driver of this decision.
Output:
0
2025-04-17 21:02:30,619 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (365.499 and 364.511 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (73.74) is slightly higher than Ligand B (67.43). Both are below the 140 threshold for oral absorption, but closer to the 90 threshold for CNS targets, which isn't a primary concern for ADRB2 (cardiovascular). Ligand B is slightly favored.
3. **logP:** Both ligands (1.544 and 1.569) are within the optimal 1-3 range. No significant difference.
4. **HBD:** Ligand A (1) is better than Ligand B (2). Lower HBD is generally preferred for permeability.
5. **HBA:** Ligand A (5) is better than Ligand B (4). Lower HBA is generally preferred for permeability.
6. **QED:** Ligand A (0.859) is significantly better than Ligand B (0.702), indicating a more drug-like profile. This is a substantial advantage.
7. **DILI:** Both ligands are good (Ligand A: 30.128, Ligand B: 33.346), well below the 60 threshold. No significant difference.
8. **BBB:** Ligand A (47.926) is lower than Ligand B (54.478). BBB isn't a primary concern for ADRB2, so this difference isn't critical.
9. **Caco-2:** Ligand A (-4.952) is better than Ligand B (-5.232). Higher Caco-2 values indicate better absorption.
10. **Solubility:** Ligand A (-0.803) is better than Ligand B (-3.272). Solubility is important for bioavailability.
11. **hERG:** Both ligands are very low risk (Ligand A: 0.28, Ligand B: 0.222). No significant difference.
12. **Cl_mic:** Ligand A (-5.88) is significantly better than Ligand B (30.149), indicating much better metabolic stability. This is a major advantage.
13. **t1/2:** Ligand A (9.468) is significantly better than Ligand B (19.573). Longer half-life is generally desirable.
14. **Pgp:** Both ligands are very low efflux (Ligand A: 0.157, Ligand B: 0.084). No significant difference.
15. **Binding Affinity:** Ligand B (-5.9) is slightly better than Ligand A (-4.3). This is a 1.6 kcal/mol difference, which is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
While Ligand B has a slightly better binding affinity, Ligand A demonstrates superior ADME properties. Specifically, its significantly better QED, metabolic stability (Cl_mic), and in vitro half-life are crucial for a viable drug candidate. The solubility advantage of Ligand A is also beneficial. Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), the slightly better affinity of Ligand B is not enough to overcome the substantial ADME advantages of Ligand A.
Output:
1
2025-04-17 21:02:30,619 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (365.769 and 370.603 Da). No significant difference.
2. **TPSA:** Ligand A (94.95) is higher than Ligand B (58.2). Ligand B is significantly better, falling well below the 140 threshold for oral absorption and closer to the ideal for GPCRs.
3. **logP:** Ligand B (3.993) is higher than Ligand A (2.568), but both are within the optimal 1-3 range. Ligand B is approaching the upper limit, but still acceptable.
4. **HBD:** Ligand A (1) is better than Ligand B (2). Lower HBD is generally preferred for permeability.
5. **HBA:** Ligand A (7) is higher than Ligand B (3). Ligand B is significantly better, well below the 10 threshold.
6. **QED:** Ligand A (0.813) is significantly better than Ligand B (0.611), indicating a more drug-like profile.
7. **DILI:** Ligand B (7.251) is *much* better than Ligand A (82.241). This is a critical advantage for Ligand B.
8. **BBB:** Ligand B (79.837) is better than Ligand A (66.576). While ADRB2 isn't strictly a CNS target, some CNS penetration can be beneficial for off-target effects assessment.
9. **Caco-2:** Ligand A (-4.165) and Ligand B (-4.898) are both negative, indicating poor permeability. Ligand B is slightly worse.
10. **Solubility:** Ligand A (-5.128) is better than Ligand B (-4.217), though both are poor.
11. **hERG:** Ligand A (0.278) is significantly better than Ligand B (0.622). Lower hERG inhibition is crucial for cardiovascular safety.
12. **Cl_mic:** Ligand B (84.907) is higher than Ligand A (76.635), meaning faster clearance and lower metabolic stability. Ligand A is better.
13. **t1/2:** Ligand B (17.67) is *much* better than Ligand A (1.388). A longer half-life is desirable.
14. **Pgp:** Ligand A (0.153) is significantly better than Ligand B (0.019). Lower P-gp efflux is preferred.
15. **Affinity:** Ligand B (-5.9) is better than Ligand A (-6.6). While Ligand A has a slightly better affinity, the difference is not substantial enough to outweigh other factors.
**Overall Assessment:**
Ligand B has several key advantages: significantly lower DILI risk, better BBB penetration, and a substantially longer half-life. While Ligand A has better QED, hERG, and Pgp properties, the DILI risk associated with Ligand A is a major concern. The slightly better affinity of Ligand A is not enough to compensate for the safety concerns. Considering the cardiovascular target (ADRB2), minimizing off-target effects and ensuring a favorable safety profile are paramount.
Output:
0
2025-04-17 21:02:30,620 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (365.539) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (40.62) is significantly better than Ligand A (55.4). ADRB2 is not a CNS target, but lower TPSA generally improves absorption.
3. **logP:** Both ligands have good logP values (A: 4.354, B: 3.255), falling within the optimal 1-3 range. Ligand B is slightly better, being closer to the lower end of the range.
4. **HBD:** Ligand A (1) is preferable to Ligand B (0). While both are acceptable, a single HBD can sometimes improve solubility without significantly impacting permeability.
5. **HBA:** Ligand B (4) is slightly better than Ligand A (3). Both are within the acceptable range.
6. **QED:** Both ligands have reasonable QED values (A: 0.815, B: 0.659), indicating good drug-like properties. Ligand A is slightly better.
7. **DILI:** Ligand B (29.391) has a significantly lower DILI risk than Ligand A (42.458). This is a major advantage for Ligand B.
8. **BBB:** Not a primary concern for ADRB2 (cardiovascular target), but Ligand B (76.735) has a higher BBB percentile than Ligand A (56.883).
9. **Caco-2:** Ligand A (-4.567) has a better Caco-2 permeability than Ligand B (-5.076).
10. **Solubility:** Ligand B (-3.739) has better solubility than Ligand A (-4.955).
11. **hERG:** Both ligands have similar hERG inhibition liability (A: 0.65, B: 0.678), indicating low risk.
12. **Cl_mic:** Both ligands have similar microsomal clearance (A: 87.445, B: 84.704).
13. **t1/2:** Ligand A (-46.601) has a significantly longer in vitro half-life than Ligand B (0.104). This is a substantial advantage for Ligand A.
14. **Pgp:** Both ligands have similar Pgp efflux liability (A: 0.482, B: 0.521).
15. **Binding Affinity:** Both ligands have very similar binding affinities (A: -5.6 kcal/mol, B: -5.7 kcal/mol). The difference is negligible.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are important. Ligand B has a better logP and TPSA. The affinities are nearly identical. However, the significantly lower DILI risk and better solubility of Ligand B are crucial advantages. The longer half-life of Ligand A is attractive, but the DILI risk is a significant concern.
**Overall Assessment:**
While Ligand A has a longer half-life and slightly better Caco-2 permeability, Ligand B's substantially lower DILI risk and better solubility, coupled with comparable binding affinity and acceptable ADME properties, make it the more promising drug candidate.
Output:
0
2025-04-17 21:02:30,620 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (364.475 and 366.849 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (87.24 and 87.46) are below 140, which is good for oral absorption, and reasonably low for a GPCR. Again, no major distinction.
3. **logP:** Ligand A (1.04) is slightly higher than Ligand B (0.35), placing it closer to the optimal 1-3 range. Ligand B is a bit low, potentially hindering permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (7) is preferable to Ligand B (5). Lower HBA generally improves permeability.
6. **QED:** Both ligands have good QED scores (0.753 and 0.805), indicating good drug-like properties.
7. **DILI:** Ligand B (41.76) has a lower DILI risk than Ligand A (51.493), which is a significant advantage.
8. **BBB:** Ligand A (47.111) has a higher BBB penetration percentile than Ligand B (33.501). While ADRB2 isn't strictly a CNS target, some CNS exposure can be acceptable or even beneficial depending on the specific therapeutic goal.
9. **Caco-2:** Both ligands have very negative Caco-2 values (-5.274 and -5.297), indicating very poor permeability. This is a major concern for both.
10. **Solubility:** Ligand A (-0.98) is better than Ligand B (-2.504). Solubility is important for bioavailability.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.219 and 0.101). This is excellent.
12. **Cl_mic:** Ligand B (-1.314) has a *much* lower (better) microsomal clearance than Ligand A (1.86). This suggests greater metabolic stability for Ligand B.
13. **t1/2:** Ligand B (-1.103) has a longer in vitro half-life than Ligand A (10.112). This is a significant advantage.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.043 and 0.047). This is good.
15. **Binding Affinity:** Ligand A (-6.8 kcal/mol) has a slightly stronger binding affinity than Ligand B (-6.6 kcal/mol). This is a small but potentially relevant difference.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. While both ligands have acceptable TPSA and Pgp profiles, Ligand A has a better logP and slightly better affinity. However, Ligand B has significantly better metabolic stability (Cl_mic and t1/2) and a lower DILI risk. The poor Caco-2 permeability is a serious issue for both, but the improved ADME profile of Ligand B outweighs the small affinity difference.
**Conclusion:**
Despite the slightly better affinity of Ligand A, the superior metabolic stability, lower DILI risk, and better solubility of Ligand B make it the more promising drug candidate. The poor Caco-2 permeability is a concern for both, but can potentially be addressed through formulation strategies.
Output:
0
2025-04-17 21:02:30,620 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
The target is ADRB2, a GPCR. Therefore, I will prioritize logP, TPSA, Pgp efflux, BBB penetration, and binding affinity, followed by general drug-like properties.
* **Molecular Weight:** Both ligands are within the ideal range (200-500 Da).
* **TPSA:** Ligand B (69.48) is significantly better than Ligand A (121.61). Lower TPSA generally correlates with better cell permeability, which is crucial for GPCR targeting.
* **logP:** Ligand B (2.997) is optimal, while Ligand A (-0.018) is quite low, potentially hindering membrane permeability. This is a significant advantage for Ligand B.
* **H-Bond Donors/Acceptors:** Ligand A has 2 HBD and 6 HBA, while Ligand B has 0 HBD and 7 HBA. Both are within acceptable ranges.
* **QED:** Both ligands have good QED scores (A: 0.526, B: 0.682), indicating good drug-like properties. Ligand B is slightly better.
* **DILI:** Both ligands have similar DILI risk (A: 60.14, B: 57.154), both are acceptable.
* **BBB:** Both ligands have moderate BBB penetration (A: 56.65, B: 54.013). This isn't a primary concern for ADRB2, which isn't a CNS target.
* **Caco-2 Permeability:** Both have negative Caco-2 values, which is unusual. It suggests poor permeability. However, the values are similar.
* **Aqueous Solubility:** Both have negative solubility values, which is also unusual.
* **hERG:** Ligand A (0.094) has a slightly better hERG profile than Ligand B (0.654), indicating lower cardiotoxicity risk.
* **Microsomal Clearance:** Ligand A (3.137) has a much lower Cl_mic than Ligand B (84.523), suggesting better metabolic stability. This is a significant advantage for Ligand A.
* **In vitro Half-Life:** Ligand B (-16.513) has a significantly longer half-life than Ligand A (-10.233).
* **P-gp Efflux:** Ligand A (0.03) has a much lower P-gp efflux liability than Ligand B (0.28), which is favorable for bioavailability.
* **Binding Affinity:** Both ligands have excellent binding affinity (A: -7.0 kcal/mol, B: -6.1 kcal/mol), with Ligand A being slightly better.
**Overall Assessment:**
Ligand A has a slight edge in binding affinity, lower P-gp efflux, and significantly better metabolic stability. However, Ligand B has a much better logP and TPSA, which are critical for GPCR ligands. The lower logP of Ligand A is a significant concern, potentially leading to poor membrane permeability and reduced efficacy. While Ligand A's metabolic stability is attractive, the permeability issues outweigh this benefit.
**Output:**
0
2025-04-17 21:02:30,620 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (367.6 and 384.8 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (29.54) is significantly better than Ligand B (46.34). GPCRs benefit from lower TPSA for improved permeability. Ligand A is well below the 140 threshold, while B is approaching it.
**3. logP:** Both ligands have similar logP values (4.45 and 4.64), both are slightly above the optimal range of 1-3, but not drastically so. This could potentially lead to some non-specific binding, but isn't a dealbreaker.
**4. H-Bond Donors:** Both have 0 HBD, which is good.
**5. H-Bond Acceptors:** Both have 3 HBA, which is also good.
**6. QED:** Ligand A (0.603) has a better QED score than Ligand B (0.484), indicating a more drug-like profile.
**7. DILI Risk:** Ligand B (35.6%) has a lower DILI risk than Ligand A (22.1%), which is a positive.
**8. BBB Penetration:** Ligand B (93.3%) has significantly better BBB penetration than Ligand A (78.7%). While ADRB2 is cardiovascular, some CNS off-target effects are always a concern, and higher BBB is generally undesirable. However, for a cardiovascular target, this isn't a primary driver.
**9. Caco-2 Permeability:** Ligand A (-5.033) has better Caco-2 permeability than Ligand B (-4.435). Better intestinal absorption is always a plus.
**10. Aqueous Solubility:** Both have very poor aqueous solubility (-5.094 and -5.14). This is a significant concern for both compounds and would require formulation strategies.
**11. hERG Inhibition:** Ligand A (0.837) has a slightly higher hERG inhibition risk than Ligand B (0.63), which is not ideal.
**12. Microsomal Clearance:** Ligand B (65.16) has a significantly lower microsomal clearance than Ligand A (96.43), indicating better metabolic stability.
**13. In vitro Half-Life:** Ligand A (30.08) has a significantly longer half-life than Ligand B (6.98). This is a major advantage for dosing convenience.
**14. P-gp Efflux:** Both ligands have similar P-gp efflux liability (0.65 and 0.267).
**15. Binding Affinity:** Ligand B (-7.1 kcal/mol) has a slightly better binding affinity than Ligand A (-6.6 kcal/mol). This 0.5 kcal/mol difference is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
The key trade-offs are: Ligand A has better TPSA, Caco-2 permeability, and half-life, while Ligand B has better DILI risk, BBB penetration, microsomal clearance, and binding affinity. Given the GPCR target class, TPSA and affinity are prioritized. The affinity difference is significant. While the solubility is poor for both, the better metabolic stability of Ligand B is also a significant advantage. The longer half-life of Ligand A is attractive, but the superior binding and metabolic profile of Ligand B are more important for a GPCR target.
Output:
0
2025-04-17 21:02:30,620 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (346.43 & 359.46 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (76.66) is higher than Ligand B (49.77). For a GPCR, lower TPSA is generally preferred for better permeability. Ligand B is significantly better here.
**3. logP:** Both ligands have acceptable logP values (1.67 & 2.96), falling within the 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability, but isn't a major concern for either.
**4. H-Bond Donors:** Ligand A has 2 HBD, and Ligand B has 1. Both are within the acceptable limit of <=5.
**5. H-Bond Acceptors:** Ligand A has 4 HBA, and Ligand B has 3. Both are within the acceptable limit of <=10.
**6. QED:** Ligand A (0.787) has a slightly higher QED than Ligand B (0.678), indicating a more drug-like profile. This is a minor advantage for Ligand A.
**7. DILI Risk:** Ligand B (14.73) has a much lower DILI risk than Ligand A (49.01). This is a significant advantage for Ligand B, as minimizing liver toxicity is crucial.
**8. BBB Penetration:** Ligand B (91.04) shows significantly better BBB penetration than Ligand A (71.04). While ADRB2 isn't exclusively a CNS target, some cardiovascular effects are mediated by central pathways, and better BBB penetration isn't detrimental. This is a strong advantage for Ligand B.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not provided, so it's difficult to interpret.
**10. Aqueous Solubility:** Both ligands have negative solubility values, which is also unusual and suggests poor solubility. Again, the scale is not provided.
**11. hERG Inhibition:** Ligand A (0.509) has a slightly lower hERG risk than Ligand B (0.792), which is preferable.
**12. Microsomal Clearance:** Ligand B (31.07) has a higher microsomal clearance than Ligand A (24.76), indicating faster metabolism and potentially lower *in vivo* exposure. Ligand A is better here.
**13. In vitro Half-Life:** Ligand A (18.13 hours) has a longer half-life than Ligand B (13.65 hours), which is desirable for less frequent dosing. This is an advantage for Ligand A.
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (0.095 and 0.303 respectively). No significant difference.
**15. Binding Affinity:** Both ligands have excellent binding affinity (-6.4 and -6.0 kcal/mol). The difference of 0.4 kcal/mol is not substantial enough to outweigh other factors.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand B is the more promising candidate. Its lower TPSA, significantly lower DILI risk, and better BBB penetration outweigh the slight advantages of Ligand A in QED, hERG, and half-life. The solubility and permeability concerns are shared by both. The affinity difference is minimal.
Output:
0
2025-04-17 21:02:30,621 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.471 and 365.905 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (69.64) is slightly higher than Ligand B (61.44), but both are well below the 140 threshold for good oral absorption. Ligand B is preferable due to being closer to the 90 threshold.
3. **logP:** Ligand A (1.855) is within the optimal 1-3 range. Ligand B (3.356) is at the higher end, but still acceptable. Ligand A is slightly preferred.
4. **HBD:** Both ligands have 2 HBD, which is good.
5. **HBA:** Both ligands have 3 HBA, which is good.
6. **QED:** Both ligands have similar QED scores (0.747 and 0.742), indicating good drug-likeness.
7. **DILI:** Ligand A (13.61) has a significantly lower DILI risk than Ligand B (29.081). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (82.668) has a much higher BBB penetration potential than Ligand A (51.842). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be beneficial, and higher BBB is generally desirable.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. Ligand B (-4.712) is slightly less negative than Ligand A (-5.026), suggesting marginally better permeability.
10. **Solubility:** Both ligands have negative solubility values, indicating poor solubility. Ligand B (-3.41) is slightly less negative than Ligand A (-3.042), suggesting marginally better solubility.
11. **hERG:** Both ligands have low hERG inhibition liability (0.226 and 0.447), which is good. Ligand A is slightly preferable.
12. **Cl_mic:** Ligand A (12.192) has a significantly lower microsomal clearance than Ligand B (39.707), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand B (72.61) has a much longer in vitro half-life than Ligand A (19.394). This is a significant advantage for Ligand B.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.078 and 0.056), which is good.
15. **Binding Affinity:** Ligand A (-7.4) has a slightly better binding affinity than Ligand B (-6.9). While the difference is less than the 1.5 kcal/mol threshold, it's still a positive factor.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are important. Ligand B has better logP and BBB penetration, while Ligand A has better TPSA, affinity, and significantly better DILI and Cl_mic.
**Overall Assessment:**
Ligand A has a more favorable safety profile (lower DILI) and better metabolic stability (lower Cl_mic). The slightly better affinity also contributes. While Ligand B has better BBB penetration and half-life, the safety and metabolic stability concerns outweigh these benefits. The permeability and solubility are poor for both, but Ligand B is slightly better.
Output:
1
2025-04-17 21:02:30,621 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [368.543, 67.43, 2.202, 2, 4, 0.62, 23.187, 62.233, -5.29, -3.34, 0.334, 67.403, -0.016, 0.09, -5.8]
**Ligand B:** [343.427, 75.44, 2.503, 1, 4, 0.747, 39.55, 71.811, -4.891, -1.889, 0.634, 85.595, -46.459, 0.356, -6.6]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal 200-500 Da range. Ligand B (343.427) is slightly lower, which could be beneficial for permeability, but both are acceptable.
2. **TPSA:** Ligand A (67.43) is better than Ligand B (75.44). We want TPSA <= 140 for oral absorption, both are fine, but lower is preferred.
3. **logP:** Both are in the optimal 1-3 range. Ligand B (2.503) is slightly higher, which might raise solubility concerns, but is still acceptable.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1), but both are within the acceptable limit of <=5.
5. **HBA:** Both ligands have 4 HBA, which is good.
6. **QED:** Ligand B (0.747) has a better QED score than Ligand A (0.62), indicating a more drug-like profile.
7. **DILI:** Ligand A (23.187) has a significantly lower DILI risk than Ligand B (39.55). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (71.811) has better BBB penetration than Ligand A (62.233). For a cardiovascular target, BBB isn't *critical*, but some penetration could be helpful for off-target effects or potential CNS side effects.
9. **Caco-2:** Ligand A (-5.29) is worse than Ligand B (-4.891). Higher is better, so Ligand B is preferable here.
10. **Solubility:** Ligand B (-1.889) is better than Ligand A (-3.34). Higher is better.
11. **hERG:** Ligand A (0.334) has a lower hERG risk than Ligand B (0.634). This is a significant advantage for Ligand A, as hERG inhibition can lead to cardiotoxicity.
12. **Cl_mic:** Ligand A (67.403) has lower microsomal clearance than Ligand B (85.595), indicating better metabolic stability.
13. **t1/2:** Ligand B (-46.459) has a much longer in vitro half-life than Ligand A (-0.016). This is a major advantage for Ligand B.
14. **Pgp:** Ligand A (0.09) has lower P-gp efflux than Ligand B (0.356). Lower is better.
15. **Affinity:** Ligand B (-6.6) has a stronger binding affinity than Ligand A (-5.8). This is a 0.8 kcal/mol difference, which is substantial.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, Pgp, TPSA, and affinity. Ligand B is better on logP, Caco-2, solubility, and *significantly* better on affinity. Ligand A is better on TPSA, DILI, hERG, Cl_mic, and Pgp.
**Decision:**
While Ligand B has a superior binding affinity and better pharmacokinetic properties (t1/2, solubility, Caco-2), the significantly lower DILI and hERG risk associated with Ligand A are crucial for a cardiovascular drug. The affinity difference, while substantial, can potentially be optimized in later stages of drug development. The safety profile of Ligand A is much more favorable, and minimizing cardiotoxicity is paramount for this target class.
Therefore, I choose Ligand A.
Output:
1
2025-04-17 21:02:30,621 - INFO - Batch 229 complete. Total preferences: 3664
2025-04-17 21:02:30,621 - INFO - Processing batch 230/512...
2025-04-17 21:03:19,646 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (363.443 and 357.443 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (119.11) is slightly higher than Ligand B (99.69). Both are below the 140 threshold for good oral absorption, but Ligand B is better positioned, especially considering ADRB2 is a cardiovascular target and CNS penetration isn't a primary goal.
3. **logP:** Ligand B (2.103) is within the optimal 1-3 range, while Ligand A (0.848) is slightly below 1. This is a significant drawback for Ligand A, as lower logP can hinder membrane permeability.
4. **HBD:** Ligand A (3) and Ligand B (2) are both acceptable, being less than 5.
5. **HBA:** Ligand A (6) and Ligand B (7) are both acceptable, being less than 10.
6. **QED:** Ligand A (0.727) is slightly better than Ligand B (0.672), indicating a marginally more drug-like profile.
7. **DILI:** Ligand B (80.729) has a higher DILI risk than Ligand A (69.794). This is a concern for Ligand B, but not a disqualifier on its own.
8. **BBB:** Ligand A (60.605) has a higher BBB penetration percentile than Ligand B (33.501). However, since ADRB2 is a cardiovascular target, BBB penetration is not a high priority.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.957 and -5.805). This is unusual and suggests poor permeability.
10. **Solubility:** Ligand A (-1.849) is better than Ligand B (-2.886). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.25) has a much lower hERG inhibition liability than Ligand B (0.421). This is a significant safety advantage for Ligand A.
12. **Cl_mic:** Ligand A (-39.664) has much lower microsomal clearance than Ligand B (37.589), indicating better metabolic stability.
13. **t1/2:** Ligand B (35.181) has a significantly longer in vitro half-life than Ligand A (11.842). This is a positive for Ligand B.
14. **Pgp:** Ligand A (0.016) has much lower P-gp efflux liability than Ligand B (0.149). This is a positive for Ligand A.
15. **Binding Affinity:** Ligand A (-7.2) has a slightly better binding affinity than Ligand B (-5.7). This is a significant advantage, as a 1.5 kcal/mol difference can outweigh other drawbacks.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand A emerges as the more promising candidate. While Ligand B has a longer half-life, Ligand A has a significantly better logP, lower Pgp efflux, better metabolic stability (lower Cl_mic), lower hERG risk, and slightly better binding affinity. The slightly higher TPSA of Ligand A is less concerning for a cardiovascular target. The negative Caco-2 values are a concern for both, but the other advantages of Ligand A outweigh this.
Output:
1
2025-04-17 21:03:19,646 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (343.471 Da and 355.538 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (53.51) is higher than Ligand B (29.54). For a cardiovascular GPCR, TPSA is not a major concern, but lower is generally preferable for permeability. Ligand B is better here.
**3. logP:** Ligand A (3.063) is within the optimal 1-3 range. Ligand B (4.842) is slightly higher, potentially leading to solubility issues or off-target interactions. Ligand A is better.
**4. H-Bond Donors:** Both have 0 HBD, which is good.
**5. H-Bond Acceptors:** Ligand A has 3 HBA, Ligand B has 2. Both are acceptable, below the threshold of 10.
**6. QED:** Ligand A (0.715) has a better QED score than Ligand B (0.554), indicating a more drug-like profile.
**7. DILI Risk:** Ligand A (35.556) has a slightly higher DILI risk than Ligand B (10.585), but both are below the concerning threshold of 60. Ligand B is better.
**8. BBB Penetration:** Ligand A (77.007) has moderate BBB penetration, while Ligand B (96.743) has very good penetration. While ADRB2 is a cardiovascular target, some CNS effects are possible with beta-blockers, and higher BBB penetration could be a concern for off-target effects. However, for GPCRs, BBB is a consideration.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.475 and -4.286). This is unusual and suggests poor permeability. However, the values are close, so it's not a major differentiator.
**10. Aqueous Solubility:** Ligand A (-2.012) has slightly better solubility than Ligand B (-4.381).
**11. hERG Inhibition:** Ligand A (0.337) has a lower hERG inhibition risk than Ligand B (0.892). This is a significant advantage, as hERG inhibition can lead to cardiotoxicity.
**12. Microsomal Clearance:** Ligand A (72.316) has lower microsomal clearance than Ligand B (110.759), suggesting better metabolic stability.
**13. In vitro Half-Life:** Ligand B (18.909) has a longer in vitro half-life than Ligand A (11.58). This is a positive for Ligand B.
**14. P-gp Efflux:** Ligand A (0.253) has lower P-gp efflux than Ligand B (0.857), which is favorable for bioavailability.
**15. Binding Affinity:** Ligand B (-6.7 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.5 kcal/mol). This 1.2 kcal/mol difference is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand B has a significantly better binding affinity and longer half-life. Its BBB penetration is also higher, which could be a benefit. However, it has a higher logP, higher P-gp efflux, and a slightly higher hERG risk. Ligand A has better solubility, lower hERG risk, lower P-gp efflux, and better metabolic stability.
Given the importance of potency for GPCRs, the 1.2 kcal/mol difference in binding affinity is a major factor. While Ligand B has some ADME liabilities, they are not severe enough to outweigh the significant potency advantage.
Output:
0
2025-04-17 21:03:19,646 - INFO - Here's my reasoning and the final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, the priorities are logP, TPSA, Pgp, affinity, and to a lesser extent, BBB.
Let's break down the comparison:
1. **MW:** Both ligands (364.555 and 361.555 Da) are within the ideal 200-500 Da range.
2. **TPSA:** Both ligands (46.34 and 46.09) are well below the 140 A^2 threshold for good oral absorption, and suitable for a GPCR.
3. **logP:** Both ligands have good logP values (4.67 and 4.206), falling within the 1-3 range. Ligand A is slightly higher, which could be a minor concern for solubility, but is acceptable.
4. **HBD/HBA:** Both have 0 HBD and 4 HBA, which is favorable.
5. **QED:** Both are above 0.5 (0.705 and 0.696), indicating good drug-likeness.
6. **DILI:** Ligand A (34.781) has a slightly higher DILI risk than Ligand B (20.9), but both are below the concerning threshold of 60.
7. **BBB:** Both have good BBB penetration (82.513 and 87.941). Ligand B is slightly better, but this is less critical for a cardiovascular target.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand B (-4.894) is slightly better than Ligand A (-5.29).
9. **Solubility:** Both have negative solubility values, indicating very poor aqueous solubility. Ligand B (-3.99) is slightly better than Ligand A (-4.36).
10. **hERG:** Both ligands have very low hERG risk (0.542 and 0.553).
11. **Cl_mic:** Ligand B (87.262) has a significantly lower microsomal clearance than Ligand A (119.04), indicating better metabolic stability.
12. **t1/2:** Ligand B (0.742) has a slightly longer half-life than Ligand A (-22.028).
13. **Pgp:** Both have low Pgp efflux liability (0.571 and 0.579).
14. **Affinity:** Both ligands have very similar binding affinities (-6.1 and -6.2 kcal/mol). The difference is negligible.
**Conclusion:**
While both ligands are reasonably similar, Ligand B is slightly preferable due to its lower DILI risk, better metabolic stability (lower Cl_mic), longer half-life, and slightly better Caco-2 and solubility values. The affinity is essentially the same. The slight improvement in ADME properties outweighs the minimal difference in logP.
Output:
0
2025-04-17 21:03:19,646 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [366.433, 50.36, 3.955, 2, 3, 0.549, 59.984, 74.758, -4.726, -4.526, 0.873, 87.631, 2.953, 0.546, -6.5]
**Ligand B:** [392.262, 81.33, 1.106, 2, 4, 0.736, 47.693, 63.125, -5.308, -2.934, 0.341, -30.761, -12.708, 0.052, -7.5]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity, and to a lesser extent BBB):
1. **MW:** Both are within the acceptable 200-500 Da range. Ligand A (366.433) is slightly preferred.
2. **TPSA:** Ligand A (50.36) is significantly better than Ligand B (81.33). A TPSA under 140 is good for oral absorption, and lower is better for GPCRs. Ligand A is much closer to the ideal range.
3. **logP:** Ligand A (3.955) is within the optimal 1-3 range, while Ligand B (1.106) is a bit low. Lower logP can lead to permeability issues.
4. **HBD/HBA:** Both have 2 HBDs, which is good. Ligand A has 3 HBAs, while Ligand B has 4. Both are acceptable, but lower is slightly preferred.
5. **QED:** Ligand B (0.736) is better than Ligand A (0.549), indicating a more drug-like profile.
6. **DILI:** Ligand B (47.693) has a significantly lower DILI risk than Ligand A (59.984). This is a major advantage for Ligand B.
7. **BBB:** Ligand A (74.758) has better BBB penetration than Ligand B (63.125), but for a cardiovascular target, BBB isn't a critical factor.
8. **Caco-2:** Ligand B (-5.308) has a better Caco-2 permeability than Ligand A (-4.726).
9. **Solubility:** Ligand B (-2.934) has better solubility than Ligand A (-4.526).
10. **hERG:** Ligand A (0.873) has a slightly better hERG profile than Ligand B (0.341).
11. **Cl_mic:** Ligand B (-30.761) has significantly better metabolic stability (lower clearance) than Ligand A (87.631). This is a substantial advantage.
12. **t1/2:** Ligand B (-12.708) has a better in vitro half-life than Ligand A (2.953).
13. **Pgp:** Ligand A (0.546) has better Pgp efflux profile than Ligand B (0.052).
14. **Affinity:** Ligand B (-7.5) has a slightly better binding affinity than Ligand A (-6.5). While both are good, the 1 kcal/mol difference is notable.
**Overall Assessment:**
Ligand B is the stronger candidate. While Ligand A has a slightly better logP and BBB (less important for this target), Ligand B excels in crucial areas: significantly lower DILI risk, much better metabolic stability (Cl_mic and t1/2), better solubility, better Caco-2 permeability and slightly better affinity. The improved ADME properties of Ligand B outweigh the minor advantages of Ligand A.
Output:
0
2025-04-17 21:03:19,646 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [358.383, 136.03 , 0.968, 3. , 8. , 0.597, 91.857, 32.144, -5.856, -2.978, 0.154, -0.263, 22.515, 0.027, -7.7 ]
**Ligand B:** [369.437, 62.3 , 2.227, 1. , 4. , 0.885, 47.732, 88.949, -4.926, -3.12 , 0.294, 13.276, -6.91 , 0.116, -7.8 ]
Here's a breakdown, considering the provided guidelines and GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal range (200-500 Da). A is 358.383, B is 369.437. No significant difference.
2. **TPSA:** Ligand A (136.03) is slightly higher than Ligand B (62.3). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for permeability. B is significantly better here.
3. **logP:** Ligand A (0.968) is a bit low, potentially impacting permeability. Ligand B (2.227) is within the optimal range (1-3). B is better.
4. **HBD:** A has 3, B has 1. Both are acceptable (<=5). B is slightly better.
5. **HBA:** A has 8, B has 4. Both are acceptable (<=10). B is better.
6. **QED:** A (0.597) is good, but B (0.885) is excellent, indicating a more drug-like profile. B is better.
7. **DILI:** A (91.857) has a very high DILI risk. B (47.732) is much lower and acceptable. B is *significantly* better.
8. **BBB:** A (32.144) is low, which isn't a concern for a cardiovascular target. B (88.949) is high, but also not a primary concern here.
9. **Caco-2:** A (-5.856) is very poor. B (-4.926) is also poor, but slightly better.
10. **Solubility:** A (-2.978) and B (-3.12) are both very poor. This is a significant concern for both.
11. **hERG:** A (0.154) and B (0.294) are both low risk. No significant difference.
12. **Cl_mic:** A (-0.263) is excellent (low clearance, good metabolic stability). B (13.276) is higher, indicating faster metabolism. A is better.
13. **t1/2:** A (22.515) is good. B (-6.91) is poor. A is better.
14. **Pgp:** A (0.027) is very low efflux, which is good. B (0.116) is also low, but slightly higher. A is better.
15. **Affinity:** Both have very similar affinity (-7.7 and -7.8 kcal/mol). The difference is negligible.
**Overall Assessment:**
Ligand B has a substantially better safety profile (DILI) and a more drug-like profile (QED). It also has better logP, TPSA, HBD, and HBA values. While both have poor solubility and Caco-2 permeability, the superior ADME properties and safety of Ligand B outweigh these drawbacks. Ligand A has better metabolic stability and half-life, but the high DILI risk is a major concern.
Therefore, I prefer Ligand B.
0
2025-04-17 21:03:19,646 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.435 and 345.443 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (100.74) is higher than Ligand B (73.64). For a cardiovascular GPCR, TPSA isn't *as* critical as for a CNS target, but lower is generally preferred for better absorption. Ligand B has a clear advantage.
3. **logP:** Both ligands (1.645 and 1.577) are within the optimal 1-3 range. Very similar.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (0). Lower is generally preferred, giving a slight edge to Ligand B.
5. **HBA:** Ligand A (6) is higher than Ligand B (4). Again, lower is generally preferred, favoring Ligand B.
6. **QED:** Both ligands (0.785 and 0.725) are above the 0.5 threshold, indicating good drug-likeness. Ligand A is slightly better.
7. **DILI:** Ligand A (47.266) has a higher DILI risk than Ligand B (29.43). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (65.18) and Ligand B (75.572) are both reasonably good, but Ligand B is better. While ADRB2 isn't exclusively a CNS target, some brain penetration could be relevant for certain cardiovascular effects.
9. **Caco-2:** Ligand A (-5.091) is worse than Ligand B (-4.276). Lower values indicate lower permeability. Ligand B is better.
10. **Solubility:** Ligand A (-2.111) is slightly better than Ligand B (-2.32). Solubility is important, but not a primary concern given the other parameters.
11. **hERG:** Both ligands (0.322 and 0.301) have low hERG inhibition risk, which is excellent. No significant difference.
12. **Cl_mic:** Ligand A (27.004) has a lower microsomal clearance than Ligand B (33.789), indicating better metabolic stability. This is a benefit for Ligand A.
13. **t1/2:** Ligand A (-12.117) has a worse in vitro half-life than Ligand B (-17.963). A more negative value indicates a shorter half-life. Ligand B is better.
14. **Pgp:** Both ligands (0.051 and 0.096) have low P-gp efflux, which is good. No significant difference.
15. **Binding Affinity:** Ligand B (-8.1 kcal/mol) has a significantly stronger binding affinity than Ligand A (-7.4 kcal/mol). This is a >1.5 kcal/mol advantage, which is a major deciding factor.
**Overall Assessment:**
Ligand B consistently outperforms Ligand A across several key ADME properties (TPSA, DILI, Caco-2, t1/2, BBB) and crucially, has a substantially better binding affinity. While Ligand A has slightly better QED and Cl_mic, the advantages of Ligand B are more impactful for a GPCR target like ADRB2. The stronger binding affinity of Ligand B is particularly important and can offset minor ADME drawbacks.
Output:
0
2025-04-17 21:03:19,647 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (341.455 and 350.463 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (58.37) is significantly better than Ligand B (78.68). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (3.041) is slightly higher than Ligand B (1.682), both are within the optimal 1-3 range. Ligand A is preferable.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 4 HBA, Ligand B has 5. Both are acceptable, but A is slightly better.
6. **QED:** Both ligands have similar QED values (0.877 and 0.844), indicating good drug-likeness.
7. **DILI:** Ligand A (23.032) has a slightly higher DILI risk than Ligand B (15.083), but both are well below the concerning threshold of 60.
8. **BBB:** Both ligands have similar BBB penetration (76.541 and 78.558). Not a major factor for a cardiovascular target.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.968 and -4.914), indicating poor permeability. This is a significant concern for both.
10. **Solubility:** Both ligands have negative solubility values (-1.555 and -1.203), indicating poor aqueous solubility. This is another significant concern.
11. **hERG:** Ligand A (0.756) has a slightly higher hERG risk than Ligand B (0.494), but both are relatively low.
12. **Cl_mic:** Ligand A (5.513) has a much lower microsomal clearance than Ligand B (24.741). This suggests better metabolic stability for Ligand A, a crucial factor.
13. **t1/2:** Ligand A (-3.266) has a more negative in vitro half-life than Ligand B (-12.927). This translates to a longer half-life for Ligand A, which is desirable.
14. **Pgp:** Ligand A (0.31) has a lower P-gp efflux liability than Ligand B (0.073). Lower efflux is generally better for bioavailability.
15. **Binding Affinity:** Ligand B (-6.8 kcal/mol) has a slightly better binding affinity than Ligand A (-6.3 kcal/mol), but the difference is relatively small (0.5 kcal/mol).
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Ligand A is better in terms of logP, TPSA, and Pgp. While Ligand B has slightly better affinity, the difference isn't substantial enough to outweigh the advantages of Ligand A in other critical ADME properties, especially metabolic stability (Cl_mic and t1/2). The poor Caco-2 and solubility are concerning for both, but the better ADME profile of Ligand A suggests it might be more amenable to formulation strategies to address these issues.
**Conclusion:**
Considering the balance of properties, particularly the improved metabolic stability and P-gp efflux profile of Ligand A, I believe it is the more promising drug candidate.
Output:
1
2025-04-17 21:03:19,647 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (342.439 and 346.471 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (53.76) is better than Ligand B (58.64). Both are below 140, but lower is preferred for absorption.
3. **logP:** Ligand A (2.871) is slightly better than Ligand B (1.958) as it is closer to the optimal range of 1-3. Ligand B is on the lower side, potentially impacting permeability.
4. **HBD:** Ligand A (0) is preferable to Ligand B (1). Fewer HBDs generally improve permeability.
5. **HBA:** Both ligands have 3 HBA, which is within the acceptable limit of 10.
6. **QED:** Ligand A (0.845) is slightly better than Ligand B (0.795), indicating a more drug-like profile.
7. **DILI:** Ligand A (30.942) is *significantly* better than Ligand B (14.889). Ligand B's DILI risk is concerningly low, suggesting potential liver toxicity.
8. **BBB:** Ligand A (83.288) is significantly better than Ligand B (53.625). While ADRB2 isn't strictly a CNS target, some peripheral ADRB2 receptors influence CNS function, and higher BBB penetration can be beneficial.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-4.424) is slightly better than Ligand B (-4.602), but both are problematic.
10. **Solubility:** Both ligands have very poor aqueous solubility (-2.286 and -2.549). This is a significant drawback for both.
11. **hERG:** Both ligands have low hERG inhibition risk (0.366 and 0.151).
12. **Cl_mic:** Ligand B (6.039) has a much lower microsomal clearance than Ligand A (55.597), indicating better metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand B (9.262) has a longer in vitro half-life than Ligand A (40.595). This is a significant advantage for Ligand B.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.336 and 0.049).
15. **Binding Affinity:** Ligand B (-6.9 kcal/mol) has a substantially stronger binding affinity than Ligand A (-3.6 kcal/mol). This is a *major* advantage, exceeding the 1.5 kcal/mol threshold.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B has a better affinity, and acceptable logP and Pgp values. While TPSA is slightly higher, the significantly better affinity and metabolic stability of Ligand B outweigh this. The DILI risk for Ligand A is also a major concern.
**Overall Assessment:**
Despite the poor solubility and Caco-2 permeability for both, Ligand B's significantly stronger binding affinity and improved metabolic stability (lower Cl_mic, longer t1/2) are compelling advantages. The lower DILI risk is also a significant factor. While Ligand A has a slightly better BBB score, the difference is not substantial enough to overcome the other benefits of Ligand B.
Output:
0
2025-04-17 21:03:19,647 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [341.459, 64.74, 2.513, 1, 5, 0.929, 41.411, 86.196, -4.83, -3.014, 0.613, 39.723, 23.278, 0.458, -6.4]
**Ligand B:** [342.443, 88.2, 2.092, 0, 4, 0.716, 21.675, 68.282, -4.471, -2.258, 0.271, 25.386, -7.719, 0.017, -6.3]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). A: 341.459, B: 342.443 - very similar.
2. **TPSA:** Ligand A (64.74) is significantly better than Ligand B (88.2). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both are within the optimal range (1-3). A: 2.513, B: 2.092. A is slightly better.
4. **HBD:** Ligand A (1) is preferable to Ligand B (0). While both are low, a single HBD can aid solubility without drastically affecting permeability.
5. **HBA:** Ligand A (5) is slightly higher than Ligand B (4), but both are acceptable.
6. **QED:** Ligand A (0.929) is significantly better than Ligand B (0.716), indicating a more drug-like profile.
7. **DILI:** Ligand A (41.411) is better than Ligand B (21.675). Both are good, but B is better.
8. **BBB:** Ligand A (86.196) is better than Ligand B (68.282). While not a CNS target, some level of BBB penetration can sometimes indicate favorable permeability characteristics.
9. **Caco-2:** Both are negative, indicating poor permeability. A: -4.83, B: -4.471. B is slightly better.
10. **Solubility:** Ligand A (-3.014) is slightly better than Ligand B (-2.258).
11. **hERG:** Both are very low (0.613 and 0.271), indicating low cardiotoxicity risk. B is better.
12. **Cl_mic:** Ligand B (25.386) has significantly lower microsomal clearance than Ligand A (39.723), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-7.719) has a much longer in vitro half-life than Ligand A (23.278). This is a major advantage.
14. **Pgp:** Ligand A (0.458) is better than Ligand B (0.017), indicating lower P-gp efflux.
15. **Affinity:** Both have very similar binding affinities (-6.4 and -6.3 kcal/mol). The difference is negligible.
**GPCR-Specific Priorities:** For ADRB2 (a cardiovascular GPCR), we prioritize logP, TPSA, Pgp, and affinity. Ligand A excels in logP, TPSA, and Pgp, while affinity is comparable. However, Ligand B has a much better half-life and lower clearance, which are critical for *in vivo* efficacy. The DILI score is also better for Ligand B.
**Conclusion:**
Despite Ligand A having slightly better TPSA and Pgp, the significantly improved metabolic stability (lower Cl_mic, longer t1/2) and lower DILI risk of Ligand B are more critical for a viable drug candidate. The comparable binding affinity seals the deal.
Output:
0
2025-04-17 21:03:19,647 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [365.543, 56.67, 2.989, 1, 5, 0.682, 13.416, 65.374, -5.044, -2.913, 0.664, 80.769, -4.922, 0.183, -6.1]**
**Ligand B: [345.462, 45.23, 3.299, 1, 3, 0.581, 18.534, 94.261, -4.681, -3.415, 0.816, 73.25, 19.767, 0.531, -7.1]**
1. **Molecular Weight:** Both are within the ideal range (200-500 Da). Ligand B (345.5) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (56.67) is higher than Ligand B (45.23). Both are acceptable for a non-CNS GPCR target like ADRB2, but B is better.
3. **logP:** Both are in the optimal range (1-3). Ligand B (3.299) is slightly higher, which could potentially lead to off-target interactions, but is still within acceptable limits.
4. **H-Bond Donors:** Both have 1 HBD, which is good.
5. **H-Bond Acceptors:** Ligand A has 5, and Ligand B has 3. Both are within the acceptable range (<=10).
6. **QED:** Ligand A (0.682) is better than Ligand B (0.581), indicating a more drug-like profile.
7. **DILI:** Ligand A (13.416) has a significantly lower DILI risk than Ligand B (18.534). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (94.261) has a much higher BBB penetration than Ligand A (65.374). However, ADRB2 is primarily a cardiovascular target, so high BBB penetration is not a priority.
9. **Caco-2 Permeability:** Both have negative values, indicating poor permeability. Ligand A (-5.044) is worse than Ligand B (-4.681).
10. **Aqueous Solubility:** Both have negative values, indicating poor solubility. Ligand B (-3.415) is slightly better than Ligand A (-2.913).
11. **hERG Inhibition:** Ligand A (0.664) has a lower hERG inhibition risk than Ligand B (0.816). This is a significant advantage for Ligand A.
12. **Microsomal Clearance:** Ligand B (73.25) has lower clearance than Ligand A (80.769), suggesting better metabolic stability.
13. **In vitro Half-Life:** Ligand B (19.767) has a significantly longer half-life than Ligand A (-4.922). This is a major advantage for Ligand B.
14. **P-gp Efflux:** Ligand A (0.183) has lower P-gp efflux than Ligand B (0.531), which is favorable.
15. **Binding Affinity:** Ligand B (-7.1) has a stronger binding affinity than Ligand A (-6.1) by 1 kcal/mol. This is a substantial difference and a strong argument for Ligand B.
**Overall Assessment:**
Ligand B has a superior binding affinity and a longer half-life. However, Ligand A has a significantly better safety profile with lower DILI and hERG risk. Considering the target is a cardiovascular GPCR, metabolic stability and potency (affinity) are key. While Ligand A has a better QED, the substantial affinity advantage of Ligand B outweighs the slightly lower QED and the permeability concerns, especially considering formulation strategies can be employed to address solubility. The DILI/hERG profile of Ligand A is concerning and could lead to attrition later in development.
Output:
0
2025-04-17 21:03:19,647 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands (365.434 and 351.447 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (90.98) is better than Ligand B (112.73). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (1.747) is within the optimal 1-3 range. Ligand B (0.156) is quite low, potentially hindering membrane permeability. This is a significant drawback.
4. **HBD:** Ligand A (2) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (4). Fewer HBAs generally improve permeability.
6. **QED:** Ligand A (0.782) is better than Ligand B (0.654), indicating a more drug-like profile.
7. **DILI:** Ligand B (13.649) has a *much* lower DILI risk than Ligand A (81.892). This is a major advantage for Ligand B.
8. **BBB:** Ligand A (53.393) has a better BBB score than Ligand B (32.687), but BBB isn't a high priority for a cardiovascular target.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-5.416) is slightly better than Ligand B (-5.537).
10. **Solubility:** Ligand A (-3.297) is better than Ligand B (-1.418). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.302) has a lower hERG risk than Ligand B (0.079), which is preferable.
12. **Cl_mic:** Ligand B (-11.263) has significantly lower microsomal clearance than Ligand A (22.841), suggesting better metabolic stability. This is a strong advantage for Ligand B.
13. **t1/2:** Ligand B (2.131) has a longer in vitro half-life than Ligand A (-3.156), suggesting better duration of action.
14. **Pgp:** Ligand A (0.158) has lower P-gp efflux than Ligand B (0.008), which is preferable.
15. **Binding Affinity:** Ligand B (-6.6) is slightly better than Ligand A (-6.4). While the difference is small, it's still a positive for Ligand B.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has better TPSA and Pgp, but Ligand B has a much better logP and slightly better affinity. The DILI and Cl_mic of Ligand B are significantly better.
**Overall Assessment:**
Ligand B, despite its slightly higher TPSA, presents a more favorable overall profile. The significantly lower DILI risk and improved metabolic stability (lower Cl_mic and longer t1/2) are crucial advantages. The better logP also suggests improved permeability. The slight affinity advantage further tips the balance. While Ligand A has better solubility and hERG, the benefits of Ligand B's ADME properties outweigh these.
Output:
0
2025-04-17 21:03:19,647 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (366.443 and 365.499 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand B (71) is significantly better than Ligand A (102.32). ADRB2 is not a CNS target, but lower TPSA generally improves absorption.
3. **logP:** Both are good (2.27 and 1.792), falling within the 1-3 range. Ligand B is slightly lower, which could be beneficial for solubility.
4. **HBD:** Ligand B (1) is preferable to Ligand A (2). Lower HBD generally improves membrane permeability.
5. **HBA:** Ligand B (5) is preferable to Ligand A (6). Lower HBA generally improves membrane permeability.
6. **QED:** Both are similar and good (0.845 and 0.825), indicating good drug-like properties.
7. **DILI:** Ligand B (28.267) is *much* better than Ligand A (94.804). This is a critical advantage for Ligand B. High DILI risk is a major red flag.
8. **BBB:** Not a primary concern for ADRB2 (cardiovascular target), but Ligand B (59.403) is better than Ligand A (48.662).
9. **Caco-2:** Ligand A (-4.826) is better than Ligand B (-5.127), indicating slightly better intestinal absorption.
10. **Solubility:** Ligand A (-3.933) is better than Ligand B (-2.906).
11. **hERG:** Both are very low (0.352 and 0.152), indicating low cardiotoxicity risk.
12. **Cl_mic:** Ligand A (23.817) is better than Ligand B (30.727), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-8.595) is better than Ligand A (-14.91), suggesting a longer half-life.
14. **Pgp:** Both are very low (0.102 and 0.07), indicating minimal P-gp efflux.
15. **Binding Affinity:** Ligand B (-6.9) is slightly better than Ligand A (-6.6), but the difference is small.
**Overall Assessment:**
Ligand B is significantly better due to its dramatically lower DILI risk. While Ligand A has slightly better Caco-2 permeability, solubility, and metabolic stability, the potential for liver injury with Ligand A is a major concern. The small advantage in affinity for Ligand B is sufficient to outweigh the minor ADME differences. For a cardiovascular target like ADRB2, minimizing toxicity is paramount.
Output:
0
2025-04-17 21:03:19,647 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (354.491 and 341.39 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (67.87) is better than Ligand B (83.6), being closer to the <140 threshold for good absorption. This is a slight advantage for A.
3. **logP:** Both ligands (2.114 and 2.38) are within the optimal 1-3 range. No significant difference.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 4 HBA, Ligand B has 5. Both are acceptable, but A is slightly better.
6. **QED:** Both ligands have good QED scores (0.76 and 0.874), indicating good drug-likeness. B is slightly better.
7. **DILI:** Ligand A (20.9) has a much lower DILI risk than Ligand B (56.727). This is a significant advantage for A.
8. **BBB:** Ligand B (81.039) has a higher BBB penetration than Ligand A (73.943). While ADRB2 isn't strictly a CNS target, some CNS exposure can be beneficial or at least not detrimental, so B has a slight edge here.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-4.205) is slightly better than Ligand B (-4.685).
10. **Solubility:** Ligand A (-1.781) has better solubility than Ligand B (-4.121). This is a moderate advantage for A.
11. **hERG:** Both ligands have low hERG inhibition liability (0.29 and 0.418), which is good. No significant difference.
12. **Cl_mic:** Ligand B (22.004) has significantly lower microsomal clearance than Ligand A (43.502), indicating better metabolic stability. This is a substantial advantage for B.
13. **t1/2:** Ligand A (-18.679) has a much longer in vitro half-life than Ligand B (0.014). This is a major advantage for A.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.023 and 0.222). No significant difference.
15. **Binding Affinity:** Ligand B (-7.4) has a slightly better binding affinity than Ligand A (-7.3). While the difference is small, it's still a positive for B.
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Both ligands perform reasonably well on logP and Pgp. Ligand A has better TPSA. Ligand B has slightly better affinity. However, the significant advantages of Ligand A in DILI risk and in vitro half-life, combined with its better solubility, outweigh the slight affinity advantage of Ligand B. The lower metabolic clearance of Ligand B is a positive, but the much longer half-life of Ligand A is more valuable.
**Conclusion:**
Considering the balance of properties and the priorities for a GPCR target, Ligand A is the more promising drug candidate.
Output:
1
2025-04-17 21:03:19,648 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (353.423) is slightly lower than Ligand B (364.475), which is marginally preferable.
2. **TPSA:** Ligand B (93.01) is significantly better than Ligand A (125.35). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (1.236) is within the optimal range (1-3), while Ligand A (-0.902) is slightly below 1. This is a significant drawback for Ligand A, potentially hindering membrane permeability.
4. **HBD:** Ligand A (4) is higher than Ligand B (1). While both are acceptable, lower HBD is generally preferred for better permeability.
5. **HBA:** Ligand B (8) is better than Ligand A (6), falling within the acceptable range.
6. **QED:** Ligand B (0.719) has a better QED score than Ligand A (0.458), indicating a more drug-like profile.
7. **DILI:** Ligand A (37.224) has a lower DILI risk than Ligand B (56.689), which is a positive attribute.
8. **BBB:** Both are relatively low, which is fine for a cardiovascular target. Ligand B (25.01) is slightly higher than Ligand A (20.822).
9. **Caco-2:** Both are negative, indicating poor permeability. This is a concern for both, but the lower TPSA of Ligand B might mitigate this somewhat.
10. **Solubility:** Both have negative solubility values, indicating poor solubility. This is a significant issue for both compounds.
11. **hERG:** Both have very low hERG inhibition risk (0.01 and 0.02), which is excellent.
12. **Cl_mic:** Ligand A (12.115) has a lower microsomal clearance than Ligand B (36.138), suggesting better metabolic stability.
13. **t1/2:** Ligand A (23.39) has a longer in vitro half-life than Ligand B (3.205), which is a significant advantage.
14. **Pgp:** Both have very low P-gp efflux liability (0.01 and 0.043).
15. **Binding Affinity:** Both ligands have comparable binding affinities (-6.2 and -5.8 kcal/mol). The difference of 0.4 kcal/mol is not substantial enough to override other factors.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, and affinity are important. Ligand B excels in TPSA and has an acceptable logP. Ligand A has a problematic logP. While both have similar affinity, Ligand A has better metabolic stability and half-life. However, the poor logP of Ligand A is a major concern for oral bioavailability.
**Overall Assessment:**
Despite Ligand A's better metabolic stability and half-life, Ligand B's superior TPSA, logP, and QED score make it the more promising candidate. The poor logP of Ligand A is a significant hurdle that would likely require substantial modification, while Ligand B has a more balanced profile.
Output:
0
2025-04-17 21:03:19,648 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (338.451 and 355.551 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (42.43) is higher than Ligand B (28.16). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B is better.
3. **logP:** Both ligands have good logP values (4.049 and 4.366), falling within the optimal 1-3 range. Ligand B is slightly higher, which *could* be a minor concern for solubility, but not a dealbreaker.
4. **HBD:** Ligand A has 0 HBD, while Ligand B has 1. Both are acceptable, and lower is generally preferred for permeability. No major difference.
5. **HBA:** Both ligands have 4 HBA, which is within the acceptable limit of 10.
6. **QED:** Both ligands have similar QED values (0.772 and 0.747), indicating good drug-likeness.
7. **DILI:** Ligand A (23.187) has a significantly higher DILI risk than Ligand B (6.592). This is a major concern, as we want to minimize liver toxicity. Ligand B is much better.
8. **BBB:** Both have good BBB penetration (75.843 and 76.541). Not a primary concern for a cardiovascular target, but a positive attribute.
9. **Caco-2:** Ligand A (-4.898) has a worse Caco-2 permeability than Ligand B (-5.539). Lower values suggest poorer absorption. Ligand B is better.
10. **Solubility:** Ligand A (-3.936) has slightly better solubility than Ligand B (-3.063), but both are poor.
11. **hERG:** Both ligands have low hERG inhibition risk (0.879 and 0.957).
12. **Cl_mic:** Ligand A (81.185) has a much higher microsomal clearance than Ligand B (26.288). This indicates Ligand B is more metabolically stable.
13. **t1/2:** Ligand B (9.265) has a significantly longer in vitro half-life than Ligand A (-10.453). This is a major advantage.
14. **Pgp:** Both ligands have low Pgp efflux (0.524 and 0.321).
15. **Binding Affinity:** Ligand A (-7.1) has a slightly better binding affinity than Ligand B (-5.8). However, the difference of 1.3 kcal/mol is not large enough to overcome the significant ADME advantages of Ligand B.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are important. While both ligands are good in logP and Pgp, Ligand B has a lower TPSA. The affinity difference is not substantial enough to outweigh the superior ADME profile of Ligand B, especially the significantly lower DILI risk and improved metabolic stability (lower Cl_mic and longer t1/2).
**Conclusion:**
Ligand B is the more promising drug candidate due to its significantly lower DILI risk, improved metabolic stability, and better Caco-2 permeability, despite slightly lower solubility and binding affinity.
Output:
0
2025-04-17 21:03:19,648 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (346.4 & 362.5 Da) fall comfortably within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Both ligands (80.4 & 82.1) are below 140, good for oral absorption, but also relatively low, which isn't a major concern for a cardiovascular target. No clear advantage.
3. **logP:** Both ligands (2.12 & 2.99) are within the optimal 1-3 range. Ligand B is slightly higher, potentially offering better membrane permeability, but not drastically.
4. **HBD:** Both have 2 HBD, which is good. No difference.
5. **HBA:** Ligand A has 4 HBA, Ligand B has 5. Both are acceptable (<=10).
6. **QED:** Both ligands have good QED scores (0.786 & 0.857), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A has a DILI risk of 59.98%, while Ligand B is 28.31%. This is a significant difference. Ligand B is much preferred here.
8. **BBB:** Ligand A has a BBB penetration of 68.67%, while Ligand B is 48.04%. For a cardiovascular target, BBB penetration is not a primary concern, so this difference is less important.
9. **Caco-2:** Ligand A (-4.881) and Ligand B (-5.164) both have negative values, which is unusual and suggests poor permeability. However, the scale is not defined, so it's hard to interpret.
10. **Solubility:** Ligand A (-2.636) and Ligand B (-3.209) both have negative solubility values, again making interpretation difficult.
11. **hERG:** Both ligands have low hERG inhibition risk (0.585 & 0.675). No significant difference.
12. **Cl_mic:** Ligand A (29.99) has a higher microsomal clearance than Ligand B (18.16). Lower clearance is preferred for metabolic stability, so Ligand B is better.
13. **t1/2:** Ligand A (29.04) has a longer in vitro half-life than Ligand B (-21.01). A longer half-life is generally desirable.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.096 & 0.302). No significant difference.
15. **Binding Affinity:** Ligand A (-7.0) has a slightly better binding affinity than Ligand B (-6.4). This is a 0.6 kcal/mol difference, which is notable.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Both ligands perform similarly on logP, Pgp, and TPSA. The biggest differentiator is the DILI risk, where Ligand B is significantly better, and the binding affinity, where Ligand A is slightly better. The lower DILI risk of Ligand B is a major advantage, outweighing the small difference in affinity. Metabolic stability (Cl_mic) is also better for Ligand B.
**Conclusion:**
Considering the balance of properties, particularly the significantly lower DILI risk and better metabolic stability of Ligand B, it is the more promising drug candidate despite the slightly weaker binding affinity.
Output:
0
2025-04-17 21:03:19,648 - INFO - Batch 230 complete. Total preferences: 3680
2025-04-17 21:03:19,648 - INFO - Processing batch 231/512...
2025-04-17 21:04:10,289 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (366.49 and 363.85 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (83.56 and 85.52) are below the 140 A^2 threshold for good oral absorption. They are also reasonably low, which is good for GPCRs. Again, no major difference.
3. **logP:** Ligand A (1.261) is slightly lower than Ligand B (1.898), both within the optimal 1-3 range. Ligand B is a bit closer to the upper end, which could be slightly beneficial for membrane permeability.
4. **HBD:** Ligand A (2) has more HBD than Ligand B (1). Lower HBD is generally preferred for permeability, giving a slight edge to Ligand B.
5. **HBA:** Ligand A (6) has more HBA than Ligand B (4). Similar to HBD, lower HBA is preferred for permeability, favoring Ligand B.
6. **QED:** Both ligands have good QED scores (0.759 and 0.782), indicating good drug-like properties.
7. **DILI:** Both ligands have acceptable DILI risk (31.29 and 34.43), well below the concerning threshold of 60. No significant difference.
8. **BBB:** Ligand B (82.01) has a significantly higher BBB penetration score than Ligand A (60.02). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant for off-target effects or potential therapeutic benefits. This is a notable advantage for Ligand B.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.113 and -5.153). These values are difficult to interpret without knowing the scale, but suggest poor permeability.
10. **Solubility:** Both ligands have negative solubility values (-1.843 and -2.879). These values are difficult to interpret without knowing the scale, but suggest poor solubility.
11. **hERG:** Both ligands have low hERG inhibition risk (0.212 and 0.297). This is excellent.
12. **Cl_mic:** Ligand A (-13.349) has a much lower (better) microsomal clearance than Ligand B (27.833). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (11.153) has a slightly longer in vitro half-life than Ligand B (12.914). This is a small advantage for Ligand A.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.034 and 0.027). This is favorable.
15. **Binding Affinity:** Ligand B (-1.1 kcal/mol) has a significantly better binding affinity than Ligand A (-6.4 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME drawbacks.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, binding affinity, logP, TPSA, and Pgp are key. Ligand B excels in binding affinity and has a slightly better logP and BBB penetration. While Ligand A has better metabolic stability (Cl_mic), the large difference in binding affinity is a critical factor.
**Conclusion:**
Despite Ligand A's better metabolic stability, the significantly stronger binding affinity of Ligand B (-1.1 kcal/mol vs -6.4 kcal/mol) is a decisive advantage for a GPCR target. The higher BBB penetration of Ligand B is also a plus.
Output:
0
2025-04-17 21:04:10,289 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (333.435 Da) is within the ideal range (200-500 Da). Ligand B (383.583 Da) is also within range, but slightly higher. No clear advantage here.
2. **TPSA:** Ligand A (48.13) is excellent, well below the 140 threshold for oral absorption. Ligand B (62.3) is still reasonable, but less optimal. This favors Ligand A.
3. **logP:** Ligand A (4.523) is a bit high, potentially leading to solubility issues and off-target effects. Ligand B (2.962) is within the optimal 1-3 range. This favors Ligand B.
4. **HBD:** Ligand A (2) is good. Ligand B (1) is also good. No significant difference.
5. **HBA:** Ligand A (1) is excellent. Ligand B (5) is acceptable, but higher. This favors Ligand A.
6. **QED:** Both ligands (A: 0.727, B: 0.701) have good drug-likeness scores, exceeding the 0.5 threshold. No clear advantage.
7. **DILI:** Ligand A (60.915) is at the upper end of acceptable, but still within the range. Ligand B (33.424) has a significantly lower DILI risk, which is a major advantage.
8. **BBB:** Ligand A (85.498) shows good BBB penetration. Ligand B (61.729) is lower. Since ADRB2 is a GPCR, BBB penetration is a consideration, favoring Ligand A.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-4.855) has very poor solubility, a significant drawback. Ligand B (-2.418) is also poor, but better than Ligand A. This favors Ligand B.
11. **hERG:** Ligand A (0.88) has a slightly higher hERG risk than Ligand B (0.578). This favors Ligand B.
12. **Cl_mic:** Ligand A (59.611) has a moderate clearance. Ligand B (51.729) has a slightly lower clearance, indicating better metabolic stability. This favors Ligand B.
13. **t1/2:** Ligand A (9.884) has a reasonable half-life. Ligand B (-0.673) has a *very* short half-life, which is a significant drawback. This favors Ligand A.
14. **Pgp:** Ligand A (0.632) has lower P-gp efflux liability than Ligand B (0.169), which is a positive. This favors Ligand A.
15. **Binding Affinity:** Ligand A (-8.1 kcal/mol) has a significantly stronger binding affinity than Ligand B (-5.2 kcal/mol). This is a substantial advantage, and can often outweigh minor ADME issues.
**Overall Assessment:**
Ligand A has a much stronger binding affinity and better TPSA, HBA, BBB, and Pgp properties. However, its solubility is very poor, and logP is high. Ligand B has a better logP, lower DILI, better solubility, and slightly better metabolic stability. The large difference in binding affinity (-8.1 vs -5.2 kcal/mol) is a key factor. Given the GPCR target class, strong affinity is paramount, and we can potentially address solubility issues through formulation strategies. The lower DILI risk of Ligand B is attractive, but the substantial potency difference of Ligand A is more compelling.
Output:
1
2025-04-17 21:04:10,289 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (359.832 and 366.889 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (41.29) is better than Ligand B (57.69). ADRB2 is a cardiovascular target, so CNS penetration isn't critical, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (3.83) is slightly higher than Ligand B (2.728), both are within the optimal 1-3 range. Ligand A is closer to the upper limit, which *could* raise slight solubility concerns, but is still acceptable.
4. **HBD:** Ligand A (1) is better than Ligand B (0). Having at least one HBD can be beneficial for solubility and target interactions.
5. **HBA:** Ligand A (4) is slightly higher than Ligand B (3). Both are within the acceptable limit of 10.
6. **QED:** Both ligands have good QED scores (0.727 and 0.771), indicating good overall drug-likeness. Ligand B is slightly better.
7. **DILI:** Ligand B (37.611) has a significantly lower DILI risk than Ligand A (44.281). This is a major advantage for Ligand B.
8. **BBB:** Ligand B (77.278) has a higher BBB penetration percentile than Ligand A (66.499). While not a primary concern for a cardiovascular target, higher BBB is generally not detrimental.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.546 and -4.407), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand B (-2.517) has better solubility than Ligand A (-3.88). This is a positive for Ligand B, especially considering Ligand A's higher logP.
11. **hERG:** Ligand A (0.875) has a slightly higher hERG risk than Ligand B (0.14). This is a significant advantage for Ligand B, as hERG inhibition can lead to cardiotoxicity.
12. **Cl_mic:** Ligand B (35.749) has lower microsomal clearance than Ligand A (51.435), indicating better metabolic stability.
13. **t1/2:** Ligand A (59.44) has a much longer in vitro half-life than Ligand B (1.128). This is a substantial advantage for Ligand A.
14. **Pgp:** Ligand A (0.675) has lower P-gp efflux than Ligand B (0.188). Lower P-gp efflux is generally desirable for improved bioavailability.
15. **Binding Affinity:** Ligand B (-7.8 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.9 kcal/mol). This is a crucial factor, and the 1.9 kcal/mol difference is substantial enough to potentially outweigh some ADME drawbacks.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B excels in affinity and has better logP, TPSA, Pgp, and DILI. While Ligand A has a better half-life, the superior binding affinity and safety profile of Ligand B are more important. The poor Caco-2 values for both are concerning and would need further investigation, but the potency advantage of Ligand B is significant.
**Conclusion:**
Despite Ligand A's longer half-life and lower P-gp efflux, Ligand B's superior binding affinity, lower DILI risk, better solubility, and lower hERG risk make it the more promising drug candidate.
Output:
0
2025-04-17 21:04:10,290 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (349.341) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are good, below the 140 A^2 threshold. Ligand B (82.49) is slightly better, being closer to the ideal for GPCRs.
3. **logP:** Both are within the optimal 1-3 range. Ligand B (2.32) is a bit higher, which could potentially lead to some off-target interactions, but isn't a major concern.
4. **HBD:** Both have 2 HBD, which is good.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 5. Both are acceptable, below the 10 threshold.
6. **QED:** Both have similar QED values (0.85 and 0.837), indicating good drug-likeness.
7. **DILI:** Ligand A (60.062) has a higher DILI risk than Ligand B (29.818). This is a significant negative for Ligand A.
8. **BBB:** Ligand A (74.021) has a better BBB penetration score than Ligand B (43.815). While ADRB2 isn't strictly a CNS target, some CNS exposure can occur, and higher BBB is generally favorable.
9. **Caco-2:** Ligand A (-4.888) has a worse Caco-2 permeability than Ligand B (-5.145). Both are negative, which is unusual and suggests poor permeability.
10. **Solubility:** Ligand A (-2.751) has worse aqueous solubility than Ligand B (-1.808). Solubility is important for bioavailability.
11. **hERG:** Both have low hERG inhibition risk (0.428 and 0.365).
12. **Cl_mic:** Ligand A (-13.271) has significantly better metabolic stability (lower clearance) than Ligand B (34.096). This is a major advantage for Ligand A.
13. **t1/2:** Ligand A (-7.743) has a longer in vitro half-life than Ligand B (28.851). This is another advantage for Ligand A.
14. **Pgp:** Both have very low Pgp efflux liability (0.077 and 0.058).
15. **Binding Affinity:** Both have very similar and excellent binding affinities (-6.0 and -5.1 kcal/mol). The difference is less than 1.5 kcal/mol, so it's not a deciding factor.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Both ligands perform reasonably well on these metrics. However, the significant differences in DILI risk and metabolic stability (Cl_mic and t1/2) are crucial.
**Overall Assessment:**
Ligand A has a better metabolic profile (lower Cl_mic, longer t1/2) and better BBB penetration, but suffers from a higher DILI risk and poorer solubility/permeability. Ligand B has a much lower DILI risk and better solubility/permeability, but is metabolically less stable.
Considering the balance, the lower DILI risk of Ligand B is a critical advantage. While metabolic stability is important, it can often be improved through structural modifications. A high DILI risk is much harder to overcome.
Output:
0
2025-04-17 21:04:10,290 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (372.255 and 352.356 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (38.13) is significantly better than Ligand B (58.2). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (4.771) is higher than Ligand B (2.641). While both are within the acceptable range, Ligand A is approaching the upper limit where solubility issues could arise. However, for a GPCR, a slightly higher logP can be beneficial for membrane interactions.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer hydrogen bond donors generally improve permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (2). Fewer hydrogen bond acceptors generally improve permeability.
6. **QED:** Ligand A (0.65) is slightly better than Ligand B (0.585), indicating a more drug-like profile.
7. **DILI:** Ligand B (56.96) has a lower DILI risk than Ligand A (76.464), which is a significant advantage.
8. **BBB:** Both are relatively similar (Ligand A: 75.107, Ligand B: 54.905). Since ADRB2 isn't a CNS target, this is less critical.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-4.394) is slightly better than Ligand B (-4.625).
10. **Solubility:** Ligand A (-5.248) is better than Ligand B (-4.121), indicating better aqueous solubility.
11. **hERG:** Ligand A (0.896) is slightly higher than Ligand B (0.515), indicating a slightly increased risk of hERG inhibition.
12. **Cl_mic:** Ligand B (22.592) has significantly lower microsomal clearance than Ligand A (50.812), suggesting better metabolic stability. This is a major advantage.
13. **t1/2:** Ligand B (22.769) has a longer in vitro half-life than Ligand A (43.663). This is a major advantage.
14. **Pgp:** Ligand A (0.734) is slightly higher than Ligand B (0.113), indicating higher P-gp efflux. Lower P-gp efflux is preferred.
15. **Binding Affinity:** Ligand B (-7.6 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.1 kcal/mol). This is a substantial advantage that can outweigh some ADME concerns.
**Overall Assessment:**
Ligand B demonstrates a superior binding affinity (-7.6 kcal/mol vs -6.1 kcal/mol) and significantly better metabolic stability (lower Cl_mic and longer t1/2). While Ligand A has slightly better solubility and TPSA, the stronger binding and improved metabolic profile of Ligand B are more critical for a successful drug candidate, especially considering the GPCR target class. The lower DILI risk and Pgp efflux for Ligand B are also favorable.
Output:
0
2025-04-17 21:04:10,290 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.366 and 360.439 Da) fall comfortably within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (117.13) is slightly higher than Ligand B (98.58). Both are below the 140 threshold for good oral absorption, but Ligand B is closer to the 90 threshold, which is preferable for GPCRs.
3. **logP:** Both ligands (1.853 and 1.929) are within the optimal 1-3 range. No significant difference.
4. **HBD:** Both ligands have 3 H-bond donors, which is acceptable.
5. **HBA:** Ligand A has 4 H-bond acceptors, while Ligand B has 7. Ligand A is preferable here, as lower HBA generally improves permeability.
6. **QED:** Ligand B (0.705) has a better QED score than Ligand A (0.394), indicating a more drug-like profile. This is a significant advantage for Ligand B.
7. **DILI:** Both ligands have similar DILI risk (61.303 and 61.342), both being in the acceptable range (<60 is better, but these are close enough to not be decisive).
8. **BBB:** Ligand A (74.874) has a significantly higher BBB penetration percentile than Ligand B (17.332). While ADRB2 isn't strictly a CNS target, some CNS exposure can be beneficial, and avoiding it isn't a major concern.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.091 and -5.597), which is unusual and suggests poor permeability. This is a concern for both, but the values are similar.
10. **Solubility:** Both ligands have very poor aqueous solubility (-3.295 and -3.278). This is a significant drawback for both, and formulation challenges are likely.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.472 and 0.268), which is excellent.
12. **Cl_mic:** Ligand A (10.326) has a lower microsomal clearance than Ligand B (54.092), indicating better metabolic stability. This is a key advantage for Ligand A.
13. **t1/2:** Ligand A (11.729 hours) has a longer in vitro half-life than Ligand B (-14.783 hours). This is a substantial advantage for Ligand A, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.111 and 0.153).
15. **Binding Affinity:** Ligand B (-7.6 kcal/mol) has a slightly better binding affinity than Ligand A (-7.3 kcal/mol). This is a 0.3 kcal/mol difference, which is not a huge advantage, but is still worth considering.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), and the general drug-like properties, Ligand A emerges as the more promising candidate. While Ligand B has a better QED and slightly better affinity, Ligand A's superior metabolic stability (lower Cl_mic), longer half-life, and better BBB penetration outweigh these advantages. The poor solubility and Caco-2 values are concerning for both, but can potentially be addressed through formulation strategies.
Output:
1
2025-04-17 21:04:10,290 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, key properties to prioritize are logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB (though less critical for a cardiovascular target).
Let's compare the ligands property by property:
1. **MW:** Both ligands (348.451 and 350.419 Da) are within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (92.15) is better than Ligand B (120.32). Lower TPSA generally favors oral absorption, which is important.
3. **logP:** Ligand A (0.72) is within the optimal range (1-3), while Ligand B (-0.156) is slightly below, potentially hindering permeation.
4. **HBD/HBA:** Ligand A (2 HBD, 6 HBA) is slightly better than Ligand B (3 HBD, 5 HBA) in terms of balancing solubility and permeability.
5. **QED:** Ligand A (0.818) has a significantly better QED score than Ligand B (0.473), indicating a more drug-like profile.
6. **DILI:** Ligand B (29.042) has a much lower DILI risk than Ligand A (54.556), which is a significant advantage.
7. **BBB:** Both ligands have similar BBB penetration (around 48-49%). Not a major deciding factor here.
8. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability.
9. **Solubility:** Both ligands have similar poor solubility values.
10. **hERG:** Ligand A (0.074) has a lower hERG risk than Ligand B (0.186), which is preferable.
11. **Cl_mic:** Ligand A (-0.792) has a lower (better) microsomal clearance than Ligand B (3.784), suggesting better metabolic stability.
12. **t1/2:** Ligand A (11.347 hours) has a much longer in vitro half-life than Ligand B (-0.29 hours), which is a major advantage.
13. **Pgp:** Ligand A (0.017) has a much lower P-gp efflux liability than Ligand B (0.009), which is beneficial for bioavailability.
14. **Binding Affinity:** Ligand B (-7.8 kcal/mol) has a slightly better binding affinity than Ligand A (-7.2 kcal/mol). This is a 1.5 kcal/mol advantage.
**Overall Assessment:**
While Ligand B has a slightly better binding affinity and lower DILI risk, Ligand A demonstrates a significantly more favorable overall profile. The superior QED, lower TPSA, better logP, lower Pgp efflux, and substantially longer half-life outweigh the minor affinity difference. The poor Caco-2 and solubility are concerns for both, but can be addressed with formulation strategies. Given the GPCR target class, the balance of properties in Ligand A is more promising for development.
**Output:**
1
2025-04-17 21:04:10,290 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
Let's break down the comparison of Ligand A and Ligand B, considering the provided guidelines and the GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key).
1. **Molecular Weight:** Both ligands (350.375 and 364.515 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand B (76.44) is significantly better than Ligand A (104.45). A lower TPSA is generally preferred for better cell permeability, and is especially important for GPCRs.
3. **logP:** Ligand B (1.25) is better than Ligand A (0.351). Both are within the optimal range of 1-3, but Ligand B is closer to the sweet spot. Ligand A is quite low and might have permeability issues.
4. **H-Bond Donors:** Both ligands have 1 HBD, which is acceptable.
5. **H-Bond Acceptors:** Ligand B (5) is slightly better than Ligand A (6). Both are within the acceptable range.
6. **QED:** Ligand B (0.718) is better than Ligand A (0.609), indicating a more drug-like profile.
7. **DILI:** Ligand B (16.712) is *much* better than Ligand A (48.74). This is a crucial advantage for Ligand B, as lower DILI risk is highly desirable.
8. **BBB:** Ligand B (57.154) is better than Ligand A (37.456). While ADRB2 isn't strictly a CNS target, some peripheral ADRB2 activity can influence CNS pathways, and higher BBB penetration isn't necessarily detrimental.
9. **Caco-2:** Ligand B (-5.227) is better than Ligand A (-4.883), suggesting better intestinal absorption.
10. **Solubility:** Ligand B (-2.247) is better than Ligand A (-1.403), indicating better aqueous solubility.
11. **hERG:** Ligand B (0.486) is better than Ligand A (0.081), indicating lower hERG inhibition liability and reduced cardiotoxicity risk.
12. **Cl_mic:** Ligand B (34.975) is slightly better than Ligand A (31.142), suggesting better metabolic stability.
13. **t1/2:** Ligand A (57.575) is significantly better than Ligand B (-1.448). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand B (0.011) is much better than Ligand A (0.039), indicating lower P-gp efflux and potentially better bioavailability.
15. **Binding Affinity:** Ligand B (-6.3) is slightly better than Ligand A (-6.0). While the difference is small, it's still a positive for Ligand B.
**Overall Assessment:**
Ligand B consistently outperforms Ligand A across most critical ADME-Tox properties (DILI, BBB, Solubility, hERG, Pgp, TPSA, logP). While Ligand A has a better in vitro half-life, the superior overall profile of Ligand B, particularly its significantly lower DILI risk and better predicted permeability, makes it the more promising drug candidate. The small affinity difference is not enough to overcome the ADME advantages of Ligand B.
**Output:**
0
2025-04-17 21:04:10,291 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (363.864 and 370.718 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (46.92) is significantly better than Ligand B (68.52). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (4.422 and 3.842), falling within the 1-3 range. Ligand A is slightly higher, which *could* be a minor concern for solubility, but is still acceptable.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 3 HBA, while Ligand B has 5. Ligand A is preferable here, staying closer to the ideal <10.
6. **QED:** Ligand A (0.854) is better than Ligand B (0.76), indicating a more drug-like profile.
7. **DILI:** Ligand B (96.51) has a much higher DILI risk than Ligand A (49.011). This is a major concern, and significantly favors Ligand A.
8. **BBB:** Ligand A (81.078) has better BBB penetration than Ligand B (65.374), but this isn't a critical factor for a cardiovascular target.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. This is a significant drawback for both, but the values are very close.
10. **Solubility:** Both have negative solubility values, indicating poor solubility. Again, very similar.
11. **hERG:** Ligand A (0.333) has a lower hERG inhibition liability than Ligand B (0.598), which is desirable.
12. **Cl_mic:** Ligand B (54.366) has lower microsomal clearance than Ligand A (69.687), suggesting better metabolic stability. This is a positive for Ligand B.
13. **t1/2:** Ligand A (31.758) has a much longer in vitro half-life than Ligand B (0.438). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand B (0.537) has higher P-gp efflux liability than Ligand A (0.315), which is unfavorable.
15. **Binding Affinity:** Ligand B (-6.2 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.2 kcal/mol). This is a substantial advantage for Ligand B, potentially outweighing some of its ADME drawbacks.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, and affinity. Ligand B has better logP and significantly better affinity. However, the very high DILI risk for Ligand B is a major red flag. The better TPSA and Pgp values of Ligand A, combined with its significantly lower DILI risk, longer half-life, and better QED, make it the more promising candidate despite the slightly weaker binding affinity. The 1.0 kcal/mol difference in affinity can likely be optimized in subsequent rounds of medicinal chemistry.
**Output:**
1
2025-04-17 21:04:10,291 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.403 and 349.475 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (87.91) is slightly higher than Ligand B (69.72). Both are below the 140 threshold for oral absorption, but Ligand B is closer to the preferred <90 for GPCRs, giving it a slight edge.
3. **logP:** Ligand B (0.905) is slightly lower than Ligand A (0.552). Both are a bit low, potentially hindering permeation, but Ligand B is closer to the optimal 1-3 range.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 6 HBAs, and Ligand B has 4. Both are within the acceptable range of <=10. Ligand B is slightly better.
6. **QED:** Ligand A (0.836) has a slightly higher QED score than Ligand B (0.774), indicating better overall drug-likeness.
7. **DILI:** Ligand A (39.201) has a much lower DILI risk than Ligand B (8.686). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (75.417) has a better BBB penetration percentile than Ligand B (57.929). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant, and higher BBB is generally favorable.
9. **Caco-2:** Ligand A (-4.658) has a worse Caco-2 permeability than Ligand B (-5.002). Lower values indicate poorer permeability, so Ligand B is slightly better.
10. **Solubility:** Ligand A (-1.449) has a slightly better solubility than Ligand B (-0.522).
11. **hERG:** Both ligands have very low hERG inhibition risk (0.098 and 0.163, respectively), which is excellent.
12. **Cl_mic:** Ligand A (-0.126) has a much lower (better) microsomal clearance than Ligand B (-10.848). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand B (4.59) has a significantly longer in vitro half-life than Ligand A (-2.656). This is a substantial advantage for Ligand B.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.034 and 0.012, respectively), which is good.
15. **Binding Affinity:** Both ligands have the same binding affinity (-6.7 kcal/mol), so this parameter doesn't differentiate them.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand B has a slightly better logP and TPSA. Both have good Pgp profiles and equal affinity. However, the significantly lower DILI risk and better metabolic stability (Cl_mic) of Ligand A, combined with its better BBB penetration, outweigh the slight advantages of Ligand B. The longer half-life of Ligand B is appealing, but the DILI risk is a major concern.
**Conclusion:**
Considering the balance of properties, particularly the lower DILI risk and better metabolic stability of Ligand A, it is the more promising drug candidate.
Output:
1
2025-04-17 21:04:10,291 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**1. Molecular Weight:** Both ligands (346.431 and 345.359 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (76.72) is significantly better than Ligand B (121.45). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is above the preferred 90 A^2 threshold.
**3. logP:** Ligand A (0.722) is slightly better than Ligand B (0.205). Both are a bit low, potentially hindering membrane permeability, but Ligand A is closer to the optimal 1-3 range.
**4. H-Bond Donors:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
**5. H-Bond Acceptors:** Ligand B (7) is higher than Ligand A (3). Lower HBA is also generally preferable for permeability.
**6. QED:** Both ligands have similar, good QED values (0.857 and 0.794, both > 0.5).
**7. DILI:** Ligand A (42.264) has a significantly lower DILI risk than Ligand B (61.031). This is a major advantage for Ligand A.
**8. BBB:** Ligand A (49.128) has a better BBB penetration score than Ligand B (27.142). While ADRB2 isn't exclusively a CNS target, some peripheral ADRB2 activity can be modulated by CNS effects, and better BBB penetration isn't a detriment.
**9. Caco-2 Permeability:** Ligand A (-4.708) is better than Ligand B (-5.152). Higher (less negative) values indicate better permeability.
**10. Aqueous Solubility:** Ligand A (-1.514) is better than Ligand B (-1.866). Higher values indicate better solubility.
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.253 and 0.104).
**12. Microsomal Clearance:** Ligand A (-6.158) has much lower microsomal clearance than Ligand B (23.645), indicating better metabolic stability.
**13. In vitro Half-Life:** Ligand A (-22.095) has a better in vitro half-life than Ligand B (-17.54).
**14. P-gp Efflux:** Both ligands have very low P-gp efflux (0.027 and 0.016).
**15. Binding Affinity:** Ligand B (-8.2) has a significantly stronger binding affinity than Ligand A (-6.2). This is a 2 kcal/mol difference, which is substantial.
**Overall Assessment:**
While Ligand B has a superior binding affinity, Ligand A demonstrates a much more favorable ADME-Tox profile. Specifically, the lower DILI risk, better BBB penetration, lower microsomal clearance, and better TPSA make it a more promising candidate. The difference in binding affinity, while significant, can potentially be overcome with further optimization, while fixing the poor ADME properties of Ligand B would be more challenging. Given the GPCR target class, optimizing for permeability (TPSA, logP) and metabolic stability (Cl_mic) is crucial, and Ligand A excels in these areas.
Output:
1
2025-04-17 21:04:10,291 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (342.439 Da and 343.427 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (62.55) is better than Ligand B (66.65). Both are below the 140 A^2 threshold for oral absorption, but lower TPSA is generally preferred for GPCRs to facilitate brain penetration, even if this isn't a CNS target.
**3. logP:** Ligand A (2.922) is slightly higher than Ligand B (1.574), placing it closer to the optimal 1-3 range. Ligand B is a bit low and could potentially have permeability issues.
**4. H-Bond Donors:** Ligand A (1) is better than Ligand B (0). While both are acceptable, a single HBD can improve solubility without drastically impacting permeability.
**5. H-Bond Acceptors:** Ligand B (4) is better than Ligand A (3). The difference is small, and both are within acceptable limits.
**6. QED:** Ligand A (0.915) is significantly better than Ligand B (0.779), indicating a more drug-like profile.
**7. DILI:** Ligand B (13.532) is *much* better than Ligand A (41.877). This is a critical advantage for Ligand B, as minimizing liver toxicity is paramount.
**8. BBB:** Ligand A (78.674) is better than Ligand B (64.25). While ADRB2 isn't primarily a CNS target, some peripheral ADRB2 receptors can influence CNS function, and better BBB penetration is rarely a detriment.
**9. Caco-2 Permeability:** Ligand A (-4.997) is better than Ligand B (-4.561). Higher values indicate better intestinal absorption.
**10. Aqueous Solubility:** Ligand A (-3.208) is better than Ligand B (-2.207). Better solubility is generally preferred for formulation and bioavailability.
**11. hERG Inhibition:** Both ligands (0.362 and 0.162) have very low hERG inhibition risk, which is excellent. No significant difference.
**12. Microsomal Clearance:** Ligand B (20.208) is significantly better than Ligand A (45.236). Lower clearance suggests better metabolic stability, a key factor for drug duration.
**13. In vitro Half-Life:** Ligand A (41.343) is better than Ligand B (-5.929). A longer half-life is generally preferred.
**14. P-gp Efflux:** Both ligands (0.288 and 0.064) have low P-gp efflux, which is good. Ligand B is slightly better.
**15. Binding Affinity:** Both ligands (-6.6 kcal/mol) have identical and strong binding affinities.
**Overall Assessment:**
Ligand B is the preferred candidate. While Ligand A has advantages in TPSA, Caco-2, solubility, and half-life, Ligand B's *dramatically* lower DILI risk and significantly better metabolic stability (lower Cl_mic) outweigh these benefits. The binding affinity is the same, so potency isn't a differentiating factor. For a GPCR target, a favorable safety profile and reasonable metabolic stability are crucial, and Ligand B excels in these areas.
Output:
0
2025-04-17 21:04:10,291 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
The ADRB2 receptor is a GPCR, so the priorities are logP, Pgp, TPSA, affinity, and BBB. Let's break down the comparison:
1. **Molecular Weight:** Both ligands are within the acceptable range (200-500 Da). Ligand A (369.483) is slightly higher than Ligand B (355.391), but this isn't a major concern.
2. **TPSA:** Ligand A (72.91) is significantly better than Ligand B (111.4). A TPSA under 140 is good for oral absorption, and lower is generally preferred for GPCRs. Ligand B's TPSA is approaching a level that could hinder absorption.
3. **logP:** Ligand A (2.026) is within the optimal range (1-3). Ligand B (-1.647) is below 1, which could indicate poor membrane permeability. This is a significant drawback.
4. **H-Bond Donors/Acceptors:** Both have acceptable numbers of HBDs (A: 0, B: 1) and HBAs (both 6), falling within the guidelines.
5. **QED:** Both have similar QED values (A: 0.74, B: 0.611), indicating good drug-likeness.
6. **DILI:** Both have low DILI risk (A: 28.228, B: 34.742), which is positive.
7. **BBB:** Ligand A (67.352) has a better BBB percentile than Ligand B (62.195), though neither is exceptionally high. This isn't a critical factor for ADRB2, but it's a slight advantage for A.
8. **Caco-2:** Ligand A (-4.439) is better than Ligand B (-5.28), indicating better intestinal absorption.
9. **Solubility:** Ligand A (-2.991) is better than Ligand B (-1.627).
10. **hERG:** Both have very low hERG risk (A: 0.598, B: 0.067).
11. **Cl_mic:** Ligand B (-12.873) has a lower (better) microsomal clearance than Ligand A (83.9). This suggests better metabolic stability for Ligand B.
12. **t1/2:** Ligand A (-13.791) has a longer in vitro half-life than Ligand B (-0.625). This is a significant advantage for Ligand A.
13. **Pgp:** Ligand A (0.142) has a lower Pgp efflux liability than Ligand B (0.006), suggesting better oral bioavailability and potentially better CNS exposure.
14. **Binding Affinity:** Ligand B (-8.2) has a significantly stronger binding affinity than Ligand A (-6.4). This is a 1.8 kcal/mol difference, which is substantial and could outweigh some of the ADME drawbacks.
**Overall Assessment:**
Ligand B has a much better binding affinity, which is a crucial factor for GPCRs. However, its significantly lower logP and higher TPSA are concerning for permeability and absorption. Ligand A has a more balanced profile, with acceptable logP and TPSA, better solubility, better Caco-2 permeability, longer half-life, and lower Pgp efflux. While its affinity is lower, the overall ADME properties are more favorable. Given the importance of good ADME properties for *in vivo* efficacy, I believe Ligand A is the more promising candidate.
**Output:**
1
2025-04-17 21:04:10,292 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [371.39 , 129.8 , 0.349, 3. , 5. , 0.685, 69.872, 45.599, -5.845, -2.881, 0.016, -13.696, -8.231, 0.007, -7.4 ]**
**Ligand B: [369.571, 49.77 , 3.489, 1. , 4. , 0.698, 9.849, 74.292, -4.421, -3.922, 0.705, 68.538, -3.499, 0.574, -6.8 ]**
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). A is 371.39, B is 369.571 - very similar.
2. **TPSA:** Ligand A (129.8) is slightly above the preferred <140 for oral absorption, but still acceptable. Ligand B (49.77) is excellent, well below 140. This favors B.
3. **logP:** Ligand A (0.349) is quite low, potentially hindering permeability. Ligand B (3.489) is within the optimal 1-3 range. This strongly favors B.
4. **H-Bond Donors:** Ligand A (3) is acceptable. Ligand B (1) is even better, potentially improving permeability. This favors B.
5. **H-Bond Acceptors:** Ligand A (5) is acceptable. Ligand B (4) is also good.
6. **QED:** Both ligands have good QED scores (A: 0.685, B: 0.698), indicating drug-likeness.
7. **DILI Risk:** Ligand A (69.872) is moderately high, while Ligand B (9.849) is very low. This is a significant advantage for B.
8. **BBB Penetration:** Ligand A (45.599) is relatively low. Ligand B (74.292) is good, indicating better potential for CNS exposure (although ADRB2 isn't strictly a CNS target, some CNS penetration can be beneficial for off-target effects). This favors B.
9. **Caco-2 Permeability:** Ligand A (-5.845) is poor. Ligand B (-4.421) is also poor, but slightly better.
10. **Aqueous Solubility:** Ligand A (-2.881) is poor. Ligand B (-3.922) is also poor.
11. **hERG Inhibition:** Ligand A (0.016) is very low risk. Ligand B (0.705) is slightly higher, but still relatively low. This favors A, but the difference isn't huge.
12. **Microsomal Clearance:** Ligand A (-13.696) is very low, indicating high metabolic stability. Ligand B (68.538) is higher, indicating faster metabolism. This strongly favors A.
13. **In vitro Half-Life:** Ligand A (-8.231) is good. Ligand B (-3.499) is also good.
14. **P-gp Efflux:** Ligand A (0.007) is very low, suggesting minimal efflux. Ligand B (0.574) is higher, indicating some efflux potential. This favors A.
15. **Binding Affinity:** Ligand A (-7.4) is slightly better than Ligand B (-6.8), but the difference is only 0.6 kcal/mol.
**Overall Assessment:**
Ligand B has a much better profile regarding key ADME properties (logP, TPSA, DILI, BBB). While Ligand A has better metabolic stability (Cl_mic) and slightly better affinity, the significant advantages of Ligand B in terms of permeability, safety (DILI), and potential for broader distribution outweigh these benefits. The low logP and poor Caco-2 permeability of Ligand A are major concerns. The affinity difference is not large enough to overcome the ADME liabilities of Ligand A.
Output:
0
2025-04-17 21:04:10,292 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.463 and 367.877 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (96.25) is higher than Ligand B (75.44). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is still preferable for absorption. Ligand B has a slight edge.
3. **logP:** Ligand B (3.121) is slightly higher than Ligand A (1.294). logP values are both within the optimal range of 1-3, but Ligand B is closer to the upper bound. This could potentially lead to some off-target effects, but it's not a major concern at this level.
4. **HBD:** Ligand A (3) has more HBDs than Ligand B (1). Lower HBD is generally preferred for permeability. Ligand B is better.
5. **HBA:** Ligand A (5) has more HBAs than Ligand B (4). Similar to HBD, lower HBA is preferred. Ligand B is better.
6. **QED:** Ligand B (0.887) has a higher QED score than Ligand A (0.69), indicating a more drug-like profile. This is a significant advantage for Ligand B.
7. **DILI:** Ligand B (40.675) has a slightly lower DILI risk than Ligand A (47.732), both are below the 60 threshold and are acceptable.
8. **BBB:** Ligand B (78.131) has a significantly higher BBB penetration score than Ligand A (56.65). While ADRB2 isn't a CNS target, some distribution to the CNS is possible, and higher BBB is generally favorable.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.849 and -4.791). This is unusual and suggests poor permeability. It's difficult to draw conclusions from these values without further context.
10. **Solubility:** Ligand B (-3.882) has slightly worse solubility than Ligand A (-2.527). Solubility is important, and Ligand A has a slight advantage.
11. **hERG:** Ligand B (0.401) has a slightly higher hERG risk than Ligand A (0.173). Lower is better, so Ligand A is preferable here.
12. **Cl_mic:** Ligand B (39.593) has a higher microsomal clearance than Ligand A (31.615). Lower clearance is preferred for better metabolic stability, so Ligand A is better.
13. **t1/2:** Ligand A (10.754) has a longer in vitro half-life than Ligand B (-3.136). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand B (0.264) has a lower P-gp efflux liability than Ligand A (0.07). Lower Pgp is generally preferred for better bioavailability. Ligand B is better.
15. **Binding Affinity:** Ligand B (-6.4 kcal/mol) has a slightly better binding affinity than Ligand A (-5.6 kcal/mol). This is a 0.8 kcal/mol difference, which is substantial enough to potentially outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand B demonstrates a better balance of properties, particularly with its superior QED, BBB penetration, and binding affinity. While it has slightly worse solubility and higher hERG risk, the stronger binding affinity and more favorable drug-like properties are more important for a GPCR target like ADRB2. The slightly elevated logP is not a major concern. Ligand A has better metabolic stability and half-life, but the affinity difference is significant.
Output:
0
2025-04-17 21:04:10,292 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (385.917 Da) is slightly higher than Ligand B (347.434 Da), but both are acceptable.
**2. TPSA:** Ligand A (80.23) is slightly higher than Ligand B (64.41). Both are below the 140 A^2 threshold for good oral absorption, but Ligand B is preferable due to being closer to the 90 A^2 threshold for better GPCR penetration.
**3. logP:** Both ligands have good logP values (A: 3.009, B: 2.783), falling within the optimal 1-3 range.
**4. H-Bond Donors:** Both have 0 HBD, which is good.
**5. H-Bond Acceptors:** Ligand A has 5 HBA, and Ligand B has 3. Both are acceptable, with Ligand B being slightly better.
**6. QED:** Both ligands have similar QED values (A: 0.795, B: 0.718), both above the 0.5 threshold, indicating good drug-likeness.
**7. DILI Risk:** Ligand A (67.429) has a higher DILI risk than Ligand B (44.436). This is a significant concern, as lower DILI is highly desirable.
**8. BBB Penetration:** Ligand B (93.253) has significantly better predicted BBB penetration than Ligand A (86.39). While ADRB2 is a cardiovascular target, some CNS off-target effects are possible with GPCR ligands, and better BBB penetration could exacerbate those.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual. However, the magnitude is similar and doesn't strongly differentiate them.
**10. Aqueous Solubility:** Both have negative solubility values, which is also unusual. Again, the magnitudes are similar.
**11. hERG Inhibition:** Ligand A (0.191) has a slightly lower hERG risk than Ligand B (0.665), which is a positive.
**12. Microsomal Clearance:** Ligand B (50.996) has a higher microsomal clearance than Ligand A (15.241), indicating faster metabolism and potentially lower exposure. This is a negative for Ligand B.
**13. In vitro Half-Life:** Ligand A (21.21) has a positive half-life, while Ligand B (-21.213) has a negative half-life. This is a huge difference and a strong negative for Ligand B.
**14. P-gp Efflux:** Ligand A (0.517) has lower P-gp efflux than Ligand B (0.267), which is preferable.
**15. Binding Affinity:** Ligand B (-7.1 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.0 kcal/mol). This is a substantial advantage that could outweigh some of its ADME drawbacks.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity) and general drug-like properties, Ligand B appears more promising despite its higher microsomal clearance. The significantly stronger binding affinity (-7.1 vs -6.0 kcal/mol) is a major advantage. The better BBB penetration and lower DILI risk are also positives. While the negative half-life is concerning, it could potentially be addressed through structural modifications. The slightly better TPSA and HBA of Ligand B are also favorable.
Output:
0
2025-04-17 21:04:10,292 - INFO - Batch 231 complete. Total preferences: 3696
2025-04-17 21:04:10,292 - INFO - Processing batch 232/512...
2025-04-17 21:04:57,277 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.471 and 358.515 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (58.64) is significantly better than Ligand B (77.2). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have acceptable logP values (2.289 and 3.251), falling within the 1-3 range. Ligand B is slightly higher, which could potentially lead to distribution issues, but not drastically.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 3 HBA, while Ligand B has 7. Ligand A is preferable here, as excessive HBA can hinder permeability.
6. **QED:** Ligand B (0.87) has a higher QED score than Ligand A (0.437), indicating a more drug-like profile overall. This is a point in favor of Ligand B.
7. **DILI:** Ligand A (23.459) has a significantly lower DILI risk than Ligand B (45.173). This is a major advantage for Ligand A.
8. **BBB:** Both ligands have similar BBB penetration (75.107 and 77.394). Not a major differentiating factor for a cardiovascular target.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.058 and -5.218), which is unusual and suggests poor permeability. This is a concern for both, but the values are similar.
10. **Solubility:** Ligand A (-1.973) has better solubility than Ligand B (-3.634). This is a positive for Ligand A.
11. **hERG:** Ligand A (0.36) has a much lower hERG inhibition liability than Ligand B (0.844). This is a critical advantage for Ligand A, reducing the risk of cardiotoxicity.
12. **Cl_mic:** Ligand A (39.88) has a lower microsomal clearance than Ligand B (59.803), suggesting better metabolic stability. This is a positive for Ligand A.
13. **t1/2:** Ligand B (14.624) has a significantly longer in vitro half-life than Ligand A (0.974). This is a strong point in favor of Ligand B.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.139 and 0.185). No significant difference.
15. **Binding Affinity:** Ligand B (-7.1) has a stronger binding affinity than Ligand A (-6.0). This is a substantial advantage for Ligand B, potentially outweighing some ADME concerns.
**Overall Assessment:**
Ligand B has a stronger binding affinity and a longer half-life, which are highly desirable. However, Ligand A demonstrates a significantly better safety profile (lower DILI, lower hERG) and better ADME properties (lower TPSA, better solubility, lower Cl_mic). Given that ADRB2 is a cardiovascular target and safety is paramount, the superior ADME and safety profile of Ligand A outweigh the slightly better potency of Ligand B. The negative Caco-2 values are a concern for both, but can be addressed through formulation strategies.
Output:
1
2025-04-17 21:04:57,277 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.5 & 365.5 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (69.64) is slightly better than Ligand B (71.53), both are under the 140 threshold for oral absorption, but closer to the upper end.
3. **logP:** Both ligands have excellent logP values (2.328 & 1.953), falling within the optimal 1-3 range. Ligand B is slightly lower, which could be beneficial for solubility.
4. **HBD:** Ligand A has 2 HBD, and Ligand B has 1. Both are within the acceptable limit of <=5.
5. **HBA:** Ligand A has 3 HBA, and Ligand B has 5. Both are within the acceptable limit of <=10.
6. **QED:** Both ligands have good QED scores (0.706 & 0.748), indicating good drug-like properties.
7. **DILI:** Ligand A (9.383) has a significantly lower DILI risk than Ligand B (37.34). This is a major advantage for Ligand A.
8. **BBB:** Both ligands have similar BBB penetration (52.385 & 51.997). While not exceptionally high, it's not a primary concern for ADRB2, which isn't necessarily a CNS target.
9. **Caco-2:** Both have negative Caco-2 values (-4.814 & -4.913), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Both ligands have negative solubility values (-2.251 & -1.995), indicating poor aqueous solubility. This is a significant drawback for both.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.392 & 0.274). This is excellent.
12. **Cl_mic:** Ligand B (25.995) has a slightly lower microsomal clearance than Ligand A (29.089), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-1.165) has a slightly better in vitro half-life than Ligand A (-5.158).
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.206 & 0.098). This is excellent.
15. **Binding Affinity:** Both ligands have very similar and strong binding affinities (-5.6 & -5.8 kcal/mol). The difference is negligible.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are important. Both ligands perform well on logP and Pgp. TPSA is borderline for both. Affinity is almost identical. The biggest differentiator is the DILI score, where Ligand A is substantially better. Solubility and Caco-2 are problematic for both, but the lower DILI risk of Ligand A is a critical advantage.
**Conclusion:**
Despite the similar binding affinities and some shared drawbacks, Ligand A is the more promising candidate due to its significantly lower DILI risk. This is a crucial factor in drug development, as liver toxicity is a common cause of drug failure.
Output:
1
2025-04-17 21:04:57,278 - INFO - Here's my reasoning and output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands (335.451 and 355.364 Da) are within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Both ligands (68.01 and 66.07) are below the 140 A^2 threshold for good oral absorption, and are reasonable for a non-CNS GPCR target like ADRB2. No clear advantage.
3. **logP:** Both ligands (2.81 and 2.934) are within the optimal 1-3 range. No clear advantage.
4. **HBD:** Both ligands have 2 HBD, which is acceptable. No clear advantage.
5. **HBA:** Ligand A has 3 HBA, while Ligand B has 5. Both are below the 10 threshold, but A is slightly better.
6. **QED:** Both ligands have good QED scores (0.853 and 0.883), indicating good drug-like properties. No clear advantage.
7. **DILI:** Ligand A (21.869) has a significantly lower DILI risk than Ligand B (85.227). This is a major advantage for Ligand A.
8. **BBB:** ADRB2 is primarily a cardiovascular target, so BBB penetration is not a high priority. Ligand B (78.79) has better BBB penetration than Ligand A (59.946), but this is less important here.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.169 and -4.913), which is unusual and suggests poor permeability. However, the values are similar.
10. **Solubility:** Ligand A (-2.273) has better solubility than Ligand B (-4.65). This is a slight advantage for A.
11. **hERG:** Both ligands have low hERG inhibition risk (0.573 and 0.898). No clear advantage.
12. **Cl_mic:** Ligand A (0.853) has significantly lower microsomal clearance than Ligand B (33.723), indicating better metabolic stability. This is a significant advantage for A.
13. **t1/2:** Ligand A (10.194 hours) has a shorter half-life than Ligand B (28.358 hours). This favors Ligand B, but the difference might not be critical.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.109 and 0.09). No clear advantage.
15. **Binding Affinity:** Ligand B (-6.1 kcal/mol) has slightly better binding affinity than Ligand A (-6.4 kcal/mol). While a difference of 0.3 kcal/mol is noticeable, it's not a huge advantage, and can be overcome by better ADME properties.
**Overall Assessment:**
Ligand A is the better candidate. While Ligand B has slightly better binding affinity and a longer half-life, Ligand A demonstrates a significantly better safety profile (much lower DILI risk) and improved metabolic stability (lower Cl_mic). The solubility is also better for Ligand A. Given the cardiovascular target, the slightly lower BBB penetration of Ligand A is not a major concern. The ADME advantages of Ligand A outweigh the minor binding affinity difference with Ligand B.
Output:
1
2025-04-17 21:04:57,278 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's analyze each ligand against the provided guidelines, keeping in mind ADRB2 is a GPCR and thus logP, Pgp, TPSA, and affinity are key.
* **Molecular Weight:** Both ligands (345.443 and 348.447 Da) fall comfortably within the ideal 200-500 Da range.
* **TPSA:** Ligand A (62.62) is significantly better than Ligand B (87.47). A TPSA under 140 is good for oral absorption, but lower is generally preferred for GPCRs, and A is much closer to the ideal range.
* **logP:** Both ligands have good logP values (1.846 and 1.348), falling within the 1-3 range. Ligand A is slightly higher, which is generally favorable for membrane permeability.
* **H-Bond Donors/Acceptors:** Ligand A (0 HBD, 4 HBA) is better than Ligand B (2 HBD, 5 HBA). Fewer hydrogen bonds can improve membrane permeability.
* **QED:** Both ligands have similar and acceptable QED values (0.618 and 0.658), indicating good drug-like properties.
* **DILI:** Ligand A (57.154) has a higher DILI risk than Ligand B (17.255). This is a significant advantage for Ligand B.
* **BBB:** Both ligands have reasonably good BBB penetration (74.564 and 71.85), indicating they can cross the blood-brain barrier to some extent. This isn't a primary concern for ADRB2 unless CNS effects are desired/undesired.
* **Caco-2 Permeability:** Ligand A (-4.5) shows better Caco-2 permeability than Ligand B (-5.31), suggesting better intestinal absorption.
* **Aqueous Solubility:** Ligand A (-2.744) has slightly better aqueous solubility than Ligand B (-0.707), which is helpful for formulation.
* **hERG Inhibition:** Both ligands have low hERG inhibition risk (0.252 and 0.549), which is excellent.
* **Microsomal Clearance:** Ligand A (49.941) has a higher microsomal clearance than Ligand B (13.688), indicating faster metabolism and potentially lower *in vivo* exposure. This is a disadvantage for Ligand A.
* **In vitro Half-Life:** Ligand B (-9.741) has a longer *in vitro* half-life than Ligand A (-19.931), which is a significant advantage.
* **P-gp Efflux:** Both ligands have low P-gp efflux liability (0.399 and 0.076), which is good. Ligand B is slightly better.
* **Binding Affinity:** Both ligands have comparable binding affinities (-5.6 and -5.9 kcal/mol). Ligand B is slightly better, but the difference is not substantial enough to outweigh other factors.
**Overall Assessment:**
While Ligand A has slightly better TPSA and Caco-2 permeability, Ligand B demonstrates a significantly better safety profile (lower DILI), improved metabolic stability (lower Cl_mic, longer t1/2), and slightly better P-gp efflux. The binding affinity difference is minimal. Considering the GPCR target class, balancing permeability with metabolic stability and safety is crucial. Ligand B's superior ADME properties and safety profile make it the more promising candidate.
**Output:**
0
2025-04-17 21:04:57,278 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (349.431 and 352.439 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (82.11) is significantly better than Ligand B (126.23). For a GPCR, keeping TPSA under 140 is good for absorption, and A is much closer to the ideal.
**3. logP:** Ligand A (0.793) is better than Ligand B (0.24). While both are a bit low, A is closer to the optimal 1-3 range. B's low logP could indicate poor membrane permeability.
**4. H-Bond Donors:** Ligand A (2) is preferable to Ligand B (3). Lower HBD generally improves permeability.
**5. H-Bond Acceptors:** Ligand A (5) is preferable to Ligand B (6). Similar to HBD, lower HBA is generally better.
**6. QED:** Ligand A (0.761) is better than Ligand B (0.615), indicating a more drug-like profile.
**7. DILI Risk:** Ligand A (22.218%) is *much* better than Ligand B (57.813%). This is a significant advantage for A, as liver toxicity is a major concern.
**8. BBB Penetration:** Ligand B (62.854%) is better than Ligand A (44.397%). While ADRB2 is a cardiovascular target, some CNS effects are possible with certain ligands, so some BBB penetration isn't necessarily bad. However, it's not a primary concern here.
**9. Caco-2 Permeability:** Ligand A (-4.85) is better than Ligand B (-5.657). Higher values are better, and A is closer to 0.
**10. Aqueous Solubility:** Ligand A (-1.068) is better than Ligand B (-2.163). Higher values are better.
**11. hERG Inhibition:** Ligand A (0.52) is better than Ligand B (0.068). Lower values are better.
**12. Microsomal Clearance:** Ligand A (-18.462) is *much* better than Ligand B (-0.064). A lower (more negative) value indicates greater metabolic stability, a crucial factor for drug duration.
**13. In vitro Half-Life:** Ligand A (-12.514) is better than Ligand B (3.518). A lower (more negative) value indicates a longer half-life.
**14. P-gp Efflux:** Ligand A (0.027) is better than Ligand B (0.022). Lower values are better.
**15. Binding Affinity:** Ligand B (-6.6) is slightly better than Ligand A (-7.7). While affinity is important, the difference of 1.1 kcal/mol is not enough to overcome the significant ADME advantages of Ligand A.
**Overall Assessment:**
Ligand A is significantly superior due to its much better DILI risk, metabolic stability (Cl_mic and t1/2), solubility, and QED. While Ligand B has slightly better binding affinity and BBB penetration, these are outweighed by the substantial advantages of Ligand A in terms of safety and pharmacokinetic properties. For a cardiovascular GPCR, metabolic stability and avoiding toxicity are paramount.
Output:
1
2025-04-17 21:04:57,278 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (334.335 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (75.87) is significantly better than Ligand A (104.04). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (3.484) is better than Ligand B (1.635). A logP between 1-3 is optimal, and Ligand A falls comfortably within this range, while Ligand B is at the lower end.
4. **HBD:** Ligand A (3) is higher than Ligand B (1). Both are acceptable, but lower is generally preferred.
5. **HBA:** Ligand A (5) is higher than Ligand B (4). Again, both are acceptable, but lower is generally preferred.
6. **QED:** Ligand B (0.775) has a better QED score than Ligand A (0.532), indicating a more drug-like profile.
7. **DILI:** Ligand B (7.794) is *much* better than Ligand A (98.643). This is a critical advantage for Ligand B. High DILI risk is a major red flag.
8. **BBB:** Ligand B (78.015) is better than Ligand A (23.42). While not a primary concern for a cardiovascular target, higher BBB is generally a positive.
9. **Caco-2:** Ligand A (-5.335) and Ligand B (-5.073) are both negative, indicating poor permeability.
10. **Solubility:** Ligand A (-4.92) and Ligand B (-1.373) are both negative, indicating poor solubility. Ligand B is better.
11. **hERG:** Ligand A (0.764) is better than Ligand B (0.519). Lower hERG is preferred.
12. **Cl_mic:** Ligand B (-8.563) is much better than Ligand A (69.614). Lower clearance indicates better metabolic stability.
13. **t1/2:** Ligand B (-6.725) is better than Ligand A (-21.463), indicating a longer half-life.
14. **Pgp:** Ligand A (0.213) is better than Ligand B (0.012). Lower Pgp efflux is preferred.
15. **Binding Affinity:** Both ligands have similar binding affinities (-6.0 and -5.1 kcal/mol respectively). Ligand A has a slight advantage, but it's not substantial enough to overcome other significant drawbacks.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, and affinity are important. Ligand A has a better logP and affinity, but Ligand B has a significantly better TPSA and a *vastly* superior DILI profile. The metabolic stability (Cl_mic and t1/2) of Ligand B is also much better.
**Overall Assessment:**
While Ligand A has a slightly better logP and binding affinity, the significant advantages of Ligand B in terms of DILI risk, metabolic stability, and TPSA outweigh these minor benefits. The high DILI risk associated with Ligand A is a major concern that would likely disqualify it early in development. Ligand B presents a much more promising starting point for optimization.
Output:
0
2025-04-17 21:04:57,278 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (349.475) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (80.32) is better than Ligand B (58.12). While both are reasonably low, lower TPSA generally correlates with better membrane permeability, a key factor for GPCR ligands.
3. **logP:** Ligand B (4.853) is higher than Ligand A (3.336). While both are above the optimal range of 1-3, Ligand B is pushing the upper limit, potentially leading to solubility issues and off-target interactions.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1). Both are within the acceptable limit of 5.
5. **HBA:** Ligand A (4) is slightly lower than Ligand B (5). Both are within the acceptable limit of 10.
6. **QED:** Both ligands have similar QED values (A: 0.854, B: 0.812), indicating good drug-like properties.
7. **DILI:** Ligand A (44.552) has a significantly lower DILI risk than Ligand B (68.98). This is a crucial advantage, as liver toxicity is a major concern in drug development.
8. **BBB:** Ligand B (94.843) has a much higher BBB penetration percentile than Ligand A (68.554). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be beneficial for distribution and off-target effects assessment.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual. Assuming these are logP values, they are both quite low, indicating poor permeability.
10. **Solubility:** Ligand B (-4.872) has worse solubility than Ligand A (-3.863). This, coupled with its higher logP, raises concerns about formulation and bioavailability.
11. **hERG:** Ligand A (0.228) has a much lower hERG inhibition liability than Ligand B (0.779). This is a significant advantage, as hERG inhibition can lead to cardiotoxicity.
12. **Cl_mic:** Ligand B (35.042) has a much lower microsomal clearance than Ligand A (82.903), indicating better metabolic stability.
13. **t1/2:** Ligand B (-7.844) has a much longer in vitro half-life than Ligand A (1.234). This is a significant advantage, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand B (0.581) has a slightly higher P-gp efflux liability than Ligand A (0.033). Lower P-gp efflux is generally preferred.
15. **Affinity:** Ligand B (-8.1) has a significantly stronger binding affinity than Ligand A (-6.5). This is a substantial advantage, potentially outweighing some of the ADME drawbacks.
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are particularly important. Ligand B excels in affinity and has a reasonable logP, but its high Pgp efflux and poor solubility are concerning. Ligand A has better ADME properties (lower DILI, hERG, Pgp, better solubility) but a weaker binding affinity.
**Overall Assessment:**
The significantly stronger binding affinity of Ligand B (-8.1 kcal/mol vs -6.5 kcal/mol) is a major advantage. While its higher logP and lower solubility are concerns, these can potentially be addressed through formulation strategies. The improved metabolic stability (lower Cl_mic and longer t1/2) also contributes to its potential. The lower DILI and hERG risk of Ligand A are attractive, but the substantial affinity difference of Ligand B is likely to be more impactful in driving efficacy.
Output:
0
2025-04-17 21:04:57,279 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
The target is ADRB2, a GPCR. Therefore, I will prioritize logP, Pgp, TPSA, and affinity, alongside general drug-like properties.
* **Molecular Weight:** Both ligands are within the ideal range (347.5 and 346.4 Da).
* **TPSA:** Ligand A (55.4) is significantly better than Ligand B (95.6). ADRB2 is not a CNS target, but lower TPSA generally improves permeability.
* **logP:** Ligand A (3.833) is optimal, while Ligand B (-0.129) is quite low, potentially hindering membrane permeability and absorption. This is a significant drawback for Ligand B.
* **H-Bond Donors/Acceptors:** Both have acceptable numbers (1 HBD for both, 3 HBA for A, 5 for B).
* **QED:** Both are good (0.769 and 0.724).
* **DILI:** Ligand A (15.781) is much better than Ligand B (58.395), indicating a lower risk of liver injury.
* **BBB:** Not a primary concern for ADRB2, but Ligand A (55.293) is better than Ligand B (33.85).
* **Caco-2:** Both are negative, suggesting poor permeability. However, the scale is not provided, so it's hard to interpret.
* **Solubility:** Both are negative, suggesting poor solubility. Again, the scale is not provided.
* **hERG:** Ligand A (0.58) is better than Ligand B (0.113), indicating a lower risk of cardiotoxicity.
* **Microsomal Clearance:** Ligand B (-7.983) has significantly *lower* clearance than Ligand A (101.984), suggesting better metabolic stability. This is a strong point for Ligand B.
* **In vitro Half-Life:** Ligand B (-18.529) has a longer half-life than Ligand A (-12.632), which is desirable. This is another strong point for Ligand B.
* **P-gp Efflux:** Ligand A (0.268) is better than Ligand B (0.014), indicating lower efflux and potentially better bioavailability.
* **Binding Affinity:** Ligand B (-6.1 kcal/mol) is slightly better than Ligand A (-4.8 kcal/mol). This is a 1.3 kcal/mol difference, which is significant but not overwhelming.
**Overall Assessment:**
Ligand B has advantages in metabolic stability (Cl_mic) and half-life, and a slightly better binding affinity. However, its very low logP and higher DILI risk are significant concerns. The poor logP is likely to severely impact absorption and bioavailability. Ligand A, while having a slightly weaker affinity and higher clearance, has a much more favorable logP, lower DILI risk, and better P-gp efflux profile. Given the importance of absorption and minimizing toxicity for a cardiovascular target, I believe Ligand A is the more promising candidate.
**Output:**
1
2025-04-17 21:04:57,279 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (343.427 and 354.447 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (65.9) is better than Ligand B (77.1). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (1.772) is better than Ligand B (0.569). Both are within the 1-3 range, but Ligand A is closer to optimal. Ligand B is a bit low, potentially hindering permeation.
4. **HBD:** Both ligands have 1 HBD, which is excellent.
5. **HBA:** Both ligands have 5 HBA, which is also excellent.
6. **QED:** Ligand A (0.917) is significantly better than Ligand B (0.69). Higher QED indicates a more drug-like profile.
7. **DILI:** Ligand A (39.473) is slightly higher than Ligand B (31.059), but both are well below the 60 threshold, indicating low liver injury risk.
8. **BBB:** Ligand B (62.466) is better than Ligand A (48.468), but this isn't a critical factor for a cardiovascular target.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.575 and -4.745), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand A (-1.227) is slightly better than Ligand B (-0.951), but both are quite poor. This is a major drawback for both compounds.
11. **hERG:** Ligand A (0.83) is better than Ligand B (0.107). Lower hERG inhibition is crucial to avoid cardiotoxicity, and Ligand B's value is concerningly low.
12. **Cl_mic:** Ligand B (17.832) has lower clearance than Ligand A (19.407), suggesting better metabolic stability.
13. **t1/2:** Ligand A (34.928) has a longer half-life than Ligand B (25.84), which is desirable.
14. **Pgp:** Ligand A (0.26) is better than Ligand B (0.022). Lower P-gp efflux is preferable for improved bioavailability.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-5.9 and -5.8 kcal/mol). The difference is negligible.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A performs better in logP, TPSA, and Pgp. While affinity is similar, the overall profile of Ligand A is more favorable.
**Overall Assessment:**
Despite both ligands having poor Caco-2 permeability and solubility, Ligand A has a significantly better QED score, better logP, better hERG profile, longer half-life, and lower P-gp efflux. These factors outweigh the slightly better metabolic stability of Ligand B. The poor permeability and solubility would need to be addressed through formulation or further structural modifications, but Ligand A provides a better starting point.
Output:
1
2025-04-17 21:04:57,279 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (344.43 Da) is better than Ligand B (380.539 Da), falling comfortably within the 200-500 Da range.
2. **TPSA:** Ligand A (49.41) is significantly better than Ligand B (67.23). Both are under 140, but A is more favorable for oral absorption.
3. **logP:** Ligand A (3.098) is slightly higher than Ligand B (1.751), both within the optimal 1-3 range.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A (2) is better than Ligand B (6). Lower HBA is generally preferred.
6. **QED:** Ligand A (0.853) is superior to Ligand B (0.73), indicating a more drug-like profile.
7. **DILI:** Ligand A (28.655) is much better than Ligand B (52.423). Lower DILI risk is crucial.
8. **BBB:** Ligand A (95.502) is significantly better than Ligand B (58.085). While ADRB2 isn't exclusively a CNS target, some CNS penetration can be beneficial, and avoiding efflux is always good.
9. **Caco-2:** Ligand A (-4.753) is better than Ligand B (-5.199). Both are negative, indicating poor permeability, but A is less negative.
10. **Solubility:** Ligand A (-3.507) is better than Ligand B (-3.389). Both are poor, but A is slightly better.
11. **hERG:** Ligand A (0.657) is better than Ligand B (0.215). Lower hERG inhibition is crucial for cardiovascular safety.
12. **Cl_mic:** Ligand A (60.181) is slightly better than Ligand B (56.411). Lower clearance is preferred.
13. **t1/2:** Ligand A (4.265) is slightly better than Ligand B (5.164).
14. **Pgp:** Ligand A (0.191) is significantly better than Ligand B (0.063). Lower P-gp efflux is highly desirable.
15. **Affinity:** Ligand B (-6.6) is slightly better than Ligand A (-6.5). This is a small difference, and can be overcome by other factors.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A excels in logP, TPSA, and Pgp, and has a very good affinity. Ligand B has a slightly better affinity, but is significantly worse in TPSA and Pgp, and has a higher DILI risk.
**Overall Assessment:**
Ligand A demonstrates a significantly better overall profile, particularly regarding safety (DILI, hERG) and ADME properties (TPSA, Pgp, BBB). While Ligand B has a marginally better binding affinity, the superior ADME and safety profile of Ligand A make it the more promising drug candidate.
Output:
1
2025-04-17 21:04:57,279 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (384.929 Da) is within the ideal range (200-500). Ligand B (349.391 Da) is also within range. No clear advantage here.
2. **TPSA:** Ligand A (58.64) is excellent, well below the 140 threshold, suggesting good absorption. Ligand B (123.66) is still acceptable but higher, potentially impacting absorption. Advantage: A.
3. **logP:** Ligand A (3.326) is optimal. Ligand B (-0.402) is significantly lower, which could hinder membrane permeability and bioavailability. Strong advantage: A.
4. **HBD:** Ligand A (1) is good. Ligand B (4) is higher, potentially impacting permeability. Advantage: A.
5. **HBA:** Ligand A (4) is good. Ligand B (6) is higher, potentially impacting permeability. Advantage: A.
6. **QED:** Ligand A (0.847) is excellent, indicating high drug-likeness. Ligand B (0.409) is below the desirable 0.5 threshold. Strong advantage: A.
7. **DILI:** Ligand A (40.869) is good, below the 40% threshold. Ligand B (54.401) is slightly higher, indicating a moderate risk. Advantage: A.
8. **BBB:** Ligand A (78.829) is good, suggesting reasonable potential for CNS penetration (though ADRB2 isn't necessarily a CNS target, it's still a positive). Ligand B (36.371) is low. Advantage: A.
9. **Caco-2:** Ligand A (-4.828) is poor. Ligand B (-5.689) is also poor. No clear advantage.
10. **Solubility:** Ligand A (-4.02) is poor. Ligand B (-1.94) is slightly better, but both are quite low. Slight advantage: B.
11. **hERG:** Ligand A (0.451) is low risk. Ligand B (0.131) is even lower, suggesting a better safety profile regarding cardiac toxicity. Advantage: B.
12. **Cl_mic:** Ligand A (32.655) is moderate. Ligand B (-31.056) is very low, indicating high metabolic stability. Strong advantage: B.
13. **t1/2:** Ligand A (10.22) is reasonable. Ligand B (2.892) is very short, potentially requiring frequent dosing. Advantage: A.
14. **Pgp:** Ligand A (0.298) is low, suggesting minimal efflux. Ligand B (0.003) is extremely low, indicating very little P-gp efflux. Advantage: B.
15. **Affinity:** Both ligands have very similar binding affinities (-6.3 kcal/mol and -6.5 kcal/mol). The difference is negligible.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are particularly important. Ligand A excels in logP and TPSA, and has comparable affinity. Ligand B has better Pgp and hERG, and better metabolic stability. However, the poor logP and QED of Ligand B are significant drawbacks.
**Overall Assessment:**
While Ligand B has some advantages in metabolic stability, Pgp efflux, and hERG inhibition, the significantly lower logP and QED are major concerns. These properties are critical for absorption and overall drug-likeness. Ligand A, despite its lower solubility and Caco-2 permeability, presents a much more balanced profile with better predicted absorption and drug-like properties. The slight solubility issues can be addressed through formulation strategies.
Output:
1
2025-04-17 21:04:57,279 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 drug candidates, keeping in mind the GPCR-specific priorities.
**Ligand A:** [365.262, 85.69, 2.038, 1, 6, 0.665, 78.209, 86.817, -4.689, -2.806, 0.256, 35.864, -16.31, 0.137, -6.5]
**Ligand B:** [361.389, 112.73, 0.177, 3, 4, 0.535, 34.82, 57.076, -5.228, -2.163, 0.31, 17.033, -17.592, 0.042, -8.3]
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). A: 365.262, B: 361.389 - very similar.
2. **TPSA:** Ligand A (85.69) is significantly better than Ligand B (112.73). ADRB2 is a cardiovascular target, so CNS penetration isn't *essential*, but lower TPSA generally correlates with better permeability.
3. **logP:** Ligand A (2.038) is optimal. Ligand B (0.177) is quite low, potentially hindering membrane permeability and bioavailability. This is a significant drawback.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (6) is preferable to Ligand B (4). Fewer HBAs generally improve permeability.
6. **QED:** Ligand A (0.665) is better than Ligand B (0.535), indicating a more drug-like profile.
7. **DILI:** Ligand B (34.82) is much better than Ligand A (78.209). This is a major advantage for Ligand B.
8. **BBB:** Ligand A (86.817) is better than Ligand B (57.076), but BBB isn't a high priority for a cardiovascular target.
9. **Caco-2:** Ligand B (-5.228) is better than Ligand A (-4.689), indicating better intestinal absorption.
10. **Solubility:** Ligand B (-2.163) is better than Ligand A (-2.806).
11. **hERG:** Both are low, but Ligand B (0.31) is slightly better than Ligand A (0.256).
12. **Cl_mic:** Ligand B (17.033) has a significantly lower clearance than Ligand A (35.864), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-17.592) has a longer half-life than Ligand A (-16.31), which is desirable.
14. **Pgp:** Ligand B (0.042) is much better than Ligand A (0.137), indicating lower efflux and potentially better bioavailability.
15. **Affinity:** Ligand B (-8.3) has a significantly stronger binding affinity than Ligand A (-6.5). This is a substantial advantage, potentially outweighing some ADME concerns.
**Overall Assessment:**
Ligand B has a much stronger binding affinity, better metabolic stability (lower Cl_mic, longer t1/2), lower P-gp efflux, better solubility, and lower DILI risk. While its logP is a concern, the significantly improved affinity and favorable ADME properties (especially metabolic stability and DILI) are compelling. Ligand A has better TPSA and BBB, but these are less critical for a cardiovascular target. The low logP of Ligand B is a concern, but can potentially be addressed through further optimization.
Therefore, I would choose Ligand B.
0
2025-04-17 21:04:57,280 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (353.853) is slightly higher than Ligand B (339.443), but both are acceptable.
2. **TPSA:** Ligand A (46.92) is significantly better than Ligand B (64.86). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (A: 4.651, B: 3.244), falling within the optimal range of 1-3. Ligand A is slightly higher, which could potentially lead to off-target effects, but is still within a reasonable range.
4. **HBD:** Both ligands have 1 HBD, which is ideal.
5. **HBA:** Ligand A has 3 HBA, while Ligand B has 6. Ligand A is preferable here, as fewer HBA generally improve permeability.
6. **QED:** Both ligands have good QED scores (A: 0.725, B: 0.926). Ligand B is slightly better, indicating a more drug-like profile.
7. **DILI:** Ligand A (74.99) has a higher DILI risk than Ligand B (48.313). This is a significant drawback for Ligand A.
8. **BBB:** BBB isn't a high priority for a cardiovascular target. Ligand A (64.444) and Ligand B (82.513) are both acceptable, with B being slightly better.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.796 and -4.851), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Both ligands have very poor aqueous solubility (-5.032 and -4.233). This is a major issue for both, and would require significant formulation work.
11. **hERG:** Both ligands have low hERG inhibition risk (A: 0.731, B: 0.361). Ligand B is slightly better.
12. **Cl_mic:** Ligand A (90.588) has a higher microsomal clearance than Ligand B (52.256), indicating lower metabolic stability.
13. **t1/2:** Ligand B (-7.68) has a slightly longer in vitro half-life than Ligand A (57.77).
14. **Pgp:** Ligand A (0.603) has lower P-gp efflux than Ligand B (0.397), which is favorable.
15. **Binding Affinity:** Both ligands have excellent binding affinity (A: -7.6, B: -7.7). The difference is negligible.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, and affinity. Ligand A has a slightly better logP and Pgp, but Ligand B has a significantly better TPSA. The binding affinity is comparable. The biggest difference lies in DILI risk and metabolic stability, where Ligand B is clearly superior.
**Overall Assessment:**
While Ligand A has some favorable properties (Pgp, logP), the significantly higher DILI risk and lower metabolic stability (higher Cl_mic) are major concerns. Ligand B, despite having a slightly higher TPSA and lower Pgp, presents a much more favorable safety profile and better pharmacokinetic properties. The solubility and Caco-2 values are problematic for both, but those can be addressed with formulation strategies. The lower DILI risk and better metabolic stability of Ligand B make it the more promising candidate.
Output:
0
2025-04-17 21:04:57,280 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 receptor (a GPCR):
**1. Molecular Weight:** Both ligands (369.491 Da and 366.487 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (89.35) is slightly higher than Ligand B (79.74). Both are below the 140 A^2 threshold for good oral absorption, and reasonably close to the 90 A^2 limit for CNS targets, though ADRB2 is primarily a cardiovascular target. Ligand B has a slight advantage.
**3. logP:** Both ligands have good logP values (1.318 and 1.402), falling within the optimal 1-3 range. No clear advantage.
**4. H-Bond Donors:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
**5. H-Bond Acceptors:** Ligand B (8) is slightly higher than Ligand A (7). Both are within the acceptable limit of 10.
**6. QED:** Both ligands have good QED scores (0.78 and 0.81), indicating good drug-like properties. No significant difference.
**7. DILI Risk:** Ligand B (60.217) has a lower DILI risk than Ligand A (75.029), which is a significant advantage. Lower DILI is always preferred.
**8. BBB Penetration:** Ligand B (69.678) shows better BBB penetration than Ligand A (53.16). While ADRB2 isn't a primary CNS target, some CNS exposure can contribute to side effects, and better control over this is valuable.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-5.019 and -5.095). These values are difficult to interpret without knowing the scale. Assuming these are logP-like values, lower values indicate lower permeability. No clear advantage.
**10. Aqueous Solubility:** Both ligands have negative solubility values (-3.259 and -2.719). Again, assuming a logS-like scale, lower values indicate lower solubility. No clear advantage.
**11. hERG Inhibition:** Ligand A (0.145) has a lower hERG inhibition liability than Ligand B (0.598), which is a significant advantage, reducing the risk of cardiotoxicity.
**12. Microsomal Clearance:** Ligand B (47.701) has lower microsomal clearance than Ligand A (52.762), indicating better metabolic stability.
**13. In vitro Half-Life:** Ligand B (43.011) has a substantially longer in vitro half-life than Ligand A (2.44). This is a major advantage, potentially allowing for less frequent dosing.
**14. P-gp Efflux:** Ligand A (0.15) has lower P-gp efflux than Ligand B (0.045), which is preferable. Lower efflux improves bioavailability.
**15. Binding Affinity:** Ligand B (-6.7 kcal/mol) has a slightly better binding affinity than Ligand A (-6.2 kcal/mol). This 1.5 kcal/mol advantage is significant and can outweigh some ADME drawbacks.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), and the general drug-like properties, Ligand B is the more promising candidate. While Ligand A has a lower hERG risk and P-gp efflux, Ligand B's superior DILI profile, BBB penetration, metabolic stability (lower Cl_mic and longer t1/2), and slightly better binding affinity outweigh these concerns. The better affinity is also a key driver.
Output:
0
2025-04-17 21:04:57,280 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (349.391 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (67.59) is significantly better than Ligand A (115.47). ADRB2 is a cardiovascular target, so CNS penetration isn't critical, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (2.32) is within the optimal range (1-3), while Ligand A (-0.688) is below 1, potentially hindering permeation. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (2) is preferable to Ligand B (1). Both are acceptable.
5. **HBA:** Both ligands have the same number of HBA (5), which is acceptable.
6. **QED:** Both ligands have good QED scores (A: 0.603, B: 0.714), indicating drug-likeness. Ligand B is slightly better.
7. **DILI:** Ligand B (21.908) has a much lower DILI risk than Ligand A (45.56). This is a major advantage for Ligand B.
8. **BBB:** Not a primary concern for a cardiovascular target. Ligand B (82.319) is higher, but this isn't a deciding factor.
9. **Caco-2:** Ligand B (-4.418) is better than Ligand A (-5.602), indicating better intestinal absorption.
10. **Solubility:** Ligand B (-3.164) is slightly better than Ligand A (-2.172).
11. **hERG:** Ligand A (0.022) has a very low hERG risk, while Ligand B (0.509) is slightly higher. This is a slight advantage for Ligand A.
12. **Cl_mic:** Ligand A (-18.727) has significantly lower microsomal clearance than Ligand B (60.436), suggesting better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand B (24.494) has a longer in vitro half-life than Ligand A (-19.745). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand B (0.524) has slightly higher P-gp efflux than Ligand A (0.004), which is less desirable.
15. **Affinity:** Ligand B (-8.2 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.2 kcal/mol). This is a substantial advantage for Ligand B, potentially outweighing some ADME concerns.
**Overall Assessment:**
Ligand B has a significantly better binding affinity, lower DILI risk, better Caco-2 permeability, better solubility and longer half-life. While Ligand A has better metabolic stability and lower hERG risk, the superior affinity and safety profile of Ligand B are more critical for a viable drug candidate. The logP value for Ligand A is concerning, and the higher TPSA is also unfavorable. The difference in binding affinity is substantial (>1.5 kcal/mol).
**Output:**
0
2025-04-17 21:04:57,280 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (367.471 and 370.563 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (80.76) is higher than Ligand B (57.17). While both are reasonably good, Ligand B is better, falling well below the 140 threshold for oral absorption and closer to the 90 threshold for CNS penetration (though BBB is the ultimate determinant).
3. **logP:** Both ligands have good logP values (1.083 and 1.807), falling within the 1-3 range. Ligand B is slightly better, indicating potentially improved membrane permeability.
4. **HBD:** Both have 1 HBD, which is within the acceptable limit of 5.
5. **HBA:** Both have 6 HBA, also within the acceptable limit of 10.
6. **QED:** Ligand A (0.814) has a slightly better QED score than Ligand B (0.595), suggesting a more drug-like profile overall.
7. **DILI:** Ligand B (6.282) has a *much* lower DILI risk than Ligand A (41.877). This is a significant advantage for Ligand B.
8. **BBB:** Ligand B (71.617) has a considerably higher BBB penetration percentile than Ligand A (56.34). For a GPCR, even a cardiovascular one, some degree of CNS penetration is not necessarily detrimental and can sometimes be beneficial for off-target effects assessment.
9. **Caco-2:** Ligand A (-4.978) has a slightly better Caco-2 permeability than Ligand B (-5.469), indicating slightly better intestinal absorption.
10. **Solubility:** Ligand A (-2.421) has slightly better solubility than Ligand B (-1.734).
11. **hERG:** Ligand B (0.743) has a slightly higher hERG inhibition liability than Ligand A (0.419), which is less favorable.
12. **Cl_mic:** Ligand B (5.144) has significantly lower microsomal clearance than Ligand A (25.337), indicating better metabolic stability.
13. **t1/2:** Ligand B (6.825) has a longer in vitro half-life than Ligand A (18.713). This is a significant advantage.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.043 and 0.046), which is good.
15. **Binding Affinity:** Ligand B (-5.1) has slightly better binding affinity than Ligand A (-4.9). While the difference is small, it's enough to consider.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP, TPSA, and has slightly better affinity. The higher BBB penetration is a bonus. The significantly lower DILI and improved metabolic stability (lower Cl_mic, longer t1/2) are also crucial advantages. While Ligand A has a slightly better QED and Caco-2 permeability, the safety and PK/PD advantages of Ligand B are more compelling.
**Conclusion:**
Considering the balance of properties and the priorities for a GPCR target, Ligand B is the more promising drug candidate.
Output:
0
2025-04-17 21:04:57,280 - INFO - Batch 232 complete. Total preferences: 3712
2025-04-17 21:04:57,280 - INFO - Processing batch 233/512...
2025-04-17 21:05:50,750 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (340.383 and 349.475 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (73.39) is better than Ligand B (83.71). Both are below 140, but lower TPSA generally favors absorption.
3. **logP:** Ligand A (2.867) is slightly higher than Ligand B (1.838), both are within the optimal 1-3 range. Ligand A is preferable.
4. **HBD:** Ligand A (0) is better than Ligand B (1). Lower is generally preferred for permeability.
5. **HBA:** Ligand A (6) is better than Ligand B (3). Both are within the acceptable range, but lower is preferable.
6. **QED:** Both ligands (0.717 and 0.712) have very similar and excellent QED scores, indicating good drug-likeness.
7. **DILI:** Ligand A (77.627) has a higher DILI risk than Ligand B (19.969). This is a significant advantage for Ligand B.
8. **BBB:** Both ligands have good BBB penetration (72.586 and 78.092). No major difference.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand B (-4.909) is slightly worse than Ligand A (-4.56).
10. **Solubility:** Both ligands have negative solubility values, which is also unusual and suggests poor solubility. Ligand B (-2.274) is slightly worse than Ligand A (-2.947).
11. **hERG:** Ligand A (0.192) has a lower hERG risk than Ligand B (0.593). This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand A (35.376) has a higher microsomal clearance than Ligand B (22.944), indicating lower metabolic stability. Ligand B is preferable.
13. **t1/2:** Ligand A (60.61) has a much longer in vitro half-life than Ligand B (-12.968). This is a substantial advantage for Ligand A.
14. **Pgp:** Ligand A (0.514) has a lower P-gp efflux liability than Ligand B (0.095). This is a significant advantage for Ligand A.
15. **Binding Affinity:** Ligand B (-5.5 kcal/mol) has a significantly stronger binding affinity than Ligand A (-3.2 kcal/mol). This is a major advantage for Ligand B.
**GPCR-Specific Priorities & Overall Assessment:**
For ADRB2 (a GPCR), we prioritize logP, Pgp, TPSA, and affinity. Ligand B wins on affinity by a large margin. Ligand A has better TPSA and Pgp, and a comparable logP. However, the substantial difference in binding affinity and the significantly lower DILI risk of Ligand B outweigh the advantages of Ligand A. While both have concerning Caco-2 and solubility values, the stronger binding and lower toxicity profile of Ligand B make it the more promising candidate, assuming these permeability/solubility issues can be addressed through further optimization. The longer half-life of Ligand A is a positive, but not enough to overcome the affinity difference.
Output:
0
2025-04-17 21:05:50,750 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (342.447 Da and 383.905 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (75.94) is better than Ligand B (88.91). Both are below 140, but lower TPSA generally favors better absorption.
**3. logP:** Both ligands have acceptable logP values (1.825 and 2.391, respectively), falling within the 1-3 range. Ligand B is slightly higher, which could potentially lead to some off-target interactions, but it's not a major concern.
**4. H-Bond Donors:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs are generally better for permeability.
**5. H-Bond Acceptors:** Both ligands have the same number of HBA (6), which is acceptable (<=10).
**6. QED:** Ligand A (0.921) has a significantly better QED score than Ligand B (0.718), indicating a more drug-like profile.
**7. DILI:** Both ligands have similar DILI risk (61.264 and 64.327), both are acceptable.
**8. BBB:** Ligand A (67.313) has better BBB penetration than Ligand B (46.568). While ADRB2 is a cardiovascular target, some CNS exposure is possible, and higher BBB penetration is generally favorable.
**9. Caco-2 Permeability:** Ligand A (-4.882) shows better Caco-2 permeability than Ligand B (-5.587).
**10. Aqueous Solubility:** Both ligands have similar, poor aqueous solubility (-2.698 and -2.683). This is a potential issue for both, requiring formulation strategies.
**11. hERG Inhibition:** Ligand A (0.577) has a slightly better hERG profile than Ligand B (0.226), indicating lower cardiotoxicity risk.
**12. Microsomal Clearance:** Ligand A (53.281) has higher microsomal clearance than Ligand B (18.966), meaning it's cleared faster. This is a negative for Ligand A.
**13. In vitro Half-Life:** Ligand B (31.448) has a significantly longer in vitro half-life than Ligand A (21.124), which is a major advantage.
**14. P-gp Efflux:** Ligand A (0.077) has lower P-gp efflux than Ligand B (0.084), which is preferable.
**15. Binding Affinity:** Ligand B (-6.9 kcal/mol) has a significantly stronger binding affinity than Ligand A (-4.7 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME drawbacks.
**Overall Assessment:**
Ligand B has a much stronger binding affinity, a longer half-life, and acceptable ADME properties. While Ligand A has better TPSA, QED, BBB, and P-gp efflux, the difference in binding affinity is substantial (over 2 kcal/mol). For a GPCR, potency is paramount, and the improved half-life of Ligand B is also a significant benefit. The slightly higher logP of Ligand B is a minor concern compared to the substantial gain in affinity.
Output:
0
2025-04-17 21:05:50,751 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.399 and 367.515 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (71.45) is better than Ligand B (75.45). Both are below the 140 threshold for oral absorption, but lower is generally preferred.
3. **logP:** Both ligands have excellent logP values (3.509 and 3.428), falling within the optimal 1-3 range.
4. **HBD:** Ligand A (2) is slightly better than Ligand B (0). While both are acceptable, a small number of HBDs can be beneficial for permeability.
5. **HBA:** Ligand A (5) is better than Ligand B (6). Both are within the acceptable range.
6. **QED:** Ligand A (0.709) is slightly better than Ligand B (0.625), indicating a more drug-like profile.
7. **DILI:** Ligand B (28.461) is *significantly* better than Ligand A (92.206). This is a major advantage for Ligand B, as lower DILI risk is crucial.
8. **BBB:** Ligand B (66.072) is better than Ligand A (44.126). While ADRB2 isn't strictly a CNS target, some CNS penetration can be beneficial for understanding off-target effects and potential side effects.
9. **Caco-2:** Ligand A (-4.899) is better than Ligand B (-4.471). Higher Caco-2 values indicate better absorption.
10. **Solubility:** Ligand B (-3.1) is better than Ligand A (-5.755). Better solubility is generally preferred.
11. **hERG:** Both ligands have similar hERG inhibition liabilities (0.566 and 0.548), which are acceptable.
12. **Cl_mic:** Ligand A (73.544) is better than Ligand B (82.617). Lower clearance is preferred for metabolic stability.
13. **t1/2:** Ligand B (30.569) is *significantly* better than Ligand A (-30.819). A positive half-life is much better than a negative one.
14. **Pgp:** Ligand A (0.615) is slightly better than Ligand B (0.228). Lower Pgp efflux is preferred.
15. **Affinity:** Ligand A (-7.5 kcal/mol) is better than Ligand B (-6.9 kcal/mol). This is a substantial difference in binding affinity.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Both ligands perform well on logP. Ligand A has a better TPSA and Pgp, while Ligand B has a better BBB. However, the *significant* advantage of Ligand A in binding affinity (-7.5 vs -6.9 kcal/mol) is a major driver. The DILI risk of Ligand B is also a strong positive. The half-life of Ligand B is also a significant advantage.
**Overall Assessment:**
While Ligand B has a much better DILI profile and half-life, the substantial affinity advantage of Ligand A outweighs the other benefits. The difference in binding affinity is likely to have a larger impact on efficacy than the other differences.
Output:
1
2025-04-17 21:05:50,751 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [386.455, 133.38 , 0.754, 2. , 7. , 0.753, 97.867, 39.473, -5.158, -2.414, 0.054, 1.039, 25.88 , 0.105, -4.4 ]**
**Ligand B: [345.422, 64.86 , 2.372, 1. , 6. , 0.871, 41.838, 88.096, -4.947, -2.717, 0.345, 21.58 , 10.049, 0.264, -6.2 ]**
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand B (345.422 Da) is slightly smaller, which *could* be beneficial for permeability, but the difference isn't substantial.
2. **TPSA:** Ligand A (133.38) is slightly above the preferred <140 for good oral absorption, but still reasonable. Ligand B (64.86) is excellent, well below 140. This favors Ligand B.
3. **logP:** Ligand A (0.754) is a bit low, potentially hindering permeation. Ligand B (2.372) is within the optimal 1-3 range. This clearly favors Ligand B.
4. **H-Bond Donors:** Both are acceptable (Ligand A: 2, Ligand B: 1), well under the limit of 5.
5. **H-Bond Acceptors:** Both are acceptable (Ligand A: 7, Ligand B: 6), under the limit of 10.
6. **QED:** Both have good QED scores (Ligand A: 0.753, Ligand B: 0.871), indicating drug-like properties. Ligand B is slightly better.
7. **DILI Risk:** Ligand A (97.867) has a very high DILI risk, which is a major concern. Ligand B (41.838) is much lower and acceptable. This is a significant advantage for Ligand B.
8. **BBB Penetration:** Ligand A (39.473) has low BBB penetration, while Ligand B (88.096) has high BBB penetration. While ADRB2 isn't exclusively a CNS target, some CNS exposure could be relevant, and higher BBB is generally better. This favors Ligand B.
9. **Caco-2 Permeability:** Both have negative values, which is unusual and suggests poor permeability. However, the scale is not specified, so it is hard to interpret.
10. **Aqueous Solubility:** Both have negative values, which is also unusual and suggests poor solubility. However, the scale is not specified, so it is hard to interpret.
11. **hERG Inhibition:** Ligand A (0.054) has very low hERG inhibition risk, which is excellent. Ligand B (0.345) is slightly higher but still relatively low. This favors Ligand A.
12. **Microsomal Clearance:** Ligand A (1.039) has lower clearance, suggesting better metabolic stability. Ligand B (21.58) has significantly higher clearance. This favors Ligand A.
13. **In vitro Half-Life:** Ligand A (25.88) has a longer half-life than Ligand B (10.049). This favors Ligand A.
14. **P-gp Efflux:** Ligand A (0.105) has lower P-gp efflux, which is favorable. Ligand B (0.264) has slightly higher efflux. This favors Ligand A.
15. **Binding Affinity:** Ligand B (-6.2 kcal/mol) has a significantly stronger binding affinity than Ligand A (-4.4 kcal/mol). This is a substantial advantage for Ligand B, potentially outweighing some of the ADME drawbacks.
**Overall Assessment:**
While Ligand A has advantages in hERG, metabolic stability, half-life, and P-gp efflux, the extremely high DILI risk is a critical flaw. Ligand B has a much better safety profile (lower DILI), better logP, TPSA, and significantly better binding affinity. The slightly higher clearance and P-gp efflux of Ligand B are less concerning than the high DILI risk of Ligand A. Given the GPCR target class, the strong binding affinity of Ligand B is a major driver.
Output:
0
2025-04-17 21:05:50,751 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 drug candidates. ADRB2 is a GPCR, so we'll prioritize logP, Pgp, TPSA, and affinity, alongside general drug-like properties.
**Ligand A: [368.503, 95.42, 2.071, 2, 6, 0.656, 52.036, 30.438, -5.522, -3.013, 0.141, 43.168, -8.629, 0.042, -6.7]**
* **MW:** 368.5 Da - Good. Within the ideal range.
* **TPSA:** 95.42 - Acceptable, but approaching the upper limit for good absorption.
* **logP:** 2.071 - Excellent. Within the optimal range.
* **HBD:** 2 - Good.
* **HBA:** 6 - Good.
* **QED:** 0.656 - Good. Drug-like.
* **DILI:** 52.036 - Acceptable. Low-moderate risk.
* **BBB:** 30.438 - Low. Not a priority for peripheral targets like ADRB2, but not ideal.
* **Caco-2:** -5.522 - Poor. Indicates poor permeability.
* **Solubility:** -3.013 - Poor. Indicates low solubility.
* **hERG:** 0.141 - Very low risk. Excellent.
* **Cl_mic:** 43.168 - Moderate. Not ideal, but manageable.
* **t1/2:** -8.629 - Very long half-life. Excellent.
* **Pgp:** 0.042 - Low efflux. Excellent.
* **Affinity:** -6.7 kcal/mol - Very good.
**Ligand B: [366.443, 104.54, 0.561, 2, 6, 0.683, 58.705, 36.332, -5.596, -2.441, 0.089, 28.583, -0.283, 0.048, -6.6]**
* **MW:** 366.443 - Good. Within the ideal range.
* **TPSA:** 104.54 - Higher than ideal, potentially impacting absorption.
* **logP:** 0.561 - Low. Could lead to poor membrane permeability.
* **HBD:** 2 - Good.
* **HBA:** 6 - Good.
* **QED:** 0.683 - Good. Drug-like.
* **DILI:** 58.705 - Moderate. Slightly higher risk than Ligand A.
* **BBB:** 36.332 - Low. Not a priority for peripheral targets like ADRB2, but not ideal.
* **Caco-2:** -5.596 - Poor. Indicates poor permeability.
* **Solubility:** -2.441 - Poor. Indicates low solubility.
* **hERG:** 0.089 - Very low risk. Excellent.
* **Cl_mic:** 28.583 - Low. Excellent metabolic stability.
* **t1/2:** -0.283 - Short half-life. Not ideal.
* **Pgp:** 0.048 - Low efflux. Excellent.
* **Affinity:** -6.6 kcal/mol - Very good. Slightly weaker than Ligand A.
**Comparison and Decision:**
Both ligands have similar affinities and excellent hERG and Pgp profiles. However, Ligand A has a better logP, a slightly lower DILI risk, and a significantly longer half-life. Both have poor Caco-2 and solubility, which would need to be addressed through formulation. Ligand B has better metabolic stability (lower Cl_mic), but the short half-life is a significant drawback.
Considering the ADRB2 target (GPCR), logP is important for receptor engagement. The longer half-life of Ligand A is a major advantage, potentially allowing for less frequent dosing. While both have poor permeability and solubility, these are formulation challenges that can be addressed. The slightly better overall profile of Ligand A, particularly the logP and half-life, makes it the more promising candidate.
Output:
1
2025-04-17 21:05:50,751 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (a cardiovascular GPCR) drug candidates.
**Ligand A:** [346.471, 49.85, 2.841, 0, 4, 0.713, 13.339, 86.274, -4.041, -2.491, 0.571, 98.882, 1.191, 0.056, -5.8]
**Ligand B:** [346.471, 69.64, 1.86, 2, 3, 0.747, 16.906, 55.603, -4.624, -2.592, 0.246, 11.367, -19.289, 0.103, -6.5]
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (around 346 Da). No significant difference.
2. **TPSA:** Ligand A (49.85) is better than Ligand B (69.64). GPCRs benefit from lower TPSA for permeability. Ligand A is well below the 140 A^2 threshold, while Ligand B is approaching it.
3. **logP:** Ligand A (2.841) is optimal, while Ligand B (1.86) is a bit low. A logP between 1-3 is preferred, and Ligand A is closer to the upper end of that range.
4. **HBD:** Ligand A (0) is better than Ligand B (2). Fewer hydrogen bond donors generally improve permeability.
5. **HBA:** Ligand A (4) is better than Ligand B (3). Fewer hydrogen bond acceptors also generally improve permeability.
6. **QED:** Both are good (0.713 and 0.747), indicating drug-like properties. No major difference.
7. **DILI:** Ligand A (13.339) is significantly better than Ligand B (16.906). Lower DILI risk is crucial.
8. **BBB:** Ligand A (86.274) is significantly better than Ligand B (55.603). While not a CNS target, some level of BBB penetration can be beneficial for distribution.
9. **Caco-2:** Both are negative, indicating poor permeability. This is a concern for both.
10. **Solubility:** Both are negative, indicating poor solubility. This is a concern for both.
11. **hERG:** Ligand A (0.571) is better than Ligand B (0.246). Lower hERG inhibition is vital for cardiovascular safety.
12. **Cl_mic:** Ligand A (98.882) is much better than Ligand B (11.367). Ligand A has significantly better metabolic stability.
13. **t1/2:** Ligand A (1.191) is better than Ligand B (-19.289). A positive half-life is preferred.
14. **Pgp:** Ligand A (0.056) is much better than Ligand B (0.103). Lower P-gp efflux is desirable for better bioavailability.
15. **Affinity:** Ligand B (-6.5) is slightly better than Ligand A (-5.8). However, the difference is less than 1.5 kcal/mol, and other factors are more important.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical ADME-Tox parameters, including DILI, BBB, metabolic stability (Cl_mic), P-gp efflux, and hERG inhibition. While Ligand B has a slightly better binding affinity, the other advantages of Ligand A, particularly its improved safety profile and predicted pharmacokinetic properties, make it a more promising drug candidate for a cardiovascular GPCR target like ADRB2. The negative Caco-2 and solubility values are concerning for both, but can be addressed through formulation strategies.
Output:
1
2025-04-17 21:05:50,752 - INFO - Here's my reasoning and the final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, key priorities are logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB (though less critical for a cardiovascular target).
Let's break down the comparison:
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (366.893) is slightly higher than Ligand B (346.427), but both are acceptable.
2. **TPSA:** Both are reasonably low, but Ligand B (62.99) is better than Ligand A (67.35), being closer to the preferred <90 for GPCRs.
3. **logP:** Both are within the optimal 1-3 range. Ligand A (2.942) is slightly higher than Ligand B (2.137). While both are good, Ligand B's lower logP might suggest slightly better solubility.
4. **HBD/HBA:** Ligand A has 1 HBD and 5 HBA, while Ligand B has 0 HBD and 4 HBA. Both are acceptable.
5. **QED:** Both have good QED scores (A: 0.784, B: 0.823), indicating good drug-like properties. Ligand B is slightly better.
6. **DILI:** Both have acceptable DILI risk (A: 47.266, B: 37.611), with Ligand B showing a lower risk.
7. **BBB:** Ligand A (94.998) has significantly better BBB penetration than Ligand B (72.276). While not a primary concern for a cardiovascular target, higher BBB is generally favorable.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-5.169) is worse than Ligand B (-4.513).
9. **Solubility:** Both have negative solubility values, also unusual. Ligand B (-2.143) is slightly better than Ligand A (-3.047).
10. **hERG:** Both have very low hERG risk (A: 0.374, B: 0.452).
11. **Cl_mic:** Ligand B (13.502) has a significantly lower microsomal clearance than Ligand A (38.09), indicating better metabolic stability.
12. **t1/2:** Ligand B (57.491) has a much longer in vitro half-life than Ligand A (27.722).
13. **Pgp:** Both have low Pgp efflux liability (A: 0.287, B: 0.2).
14. **Binding Affinity:** Ligand B (-5.9 kcal/mol) has a substantially stronger binding affinity than Ligand A (-3.0 kcal/mol). This is a crucial advantage, exceeding the 1.5 kcal/mol difference threshold.
**Overall Assessment:**
Ligand B clearly outperforms Ligand A in several critical areas: binding affinity, metabolic stability (lower Cl_mic, longer t1/2), DILI risk, and TPSA. While Ligand A has better BBB penetration, this is less important for a cardiovascular target. The significantly stronger binding affinity of Ligand B outweighs the minor drawbacks in Caco-2 and solubility.
Output:
0
2025-04-17 21:05:50,752 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (352.5 & 364.3 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (67.43) is significantly better than Ligand B (78.43). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally improves absorption.
3. **logP:** Ligand A (3.171) is optimal, while Ligand B (1.687) is at the lower end of the optimal range. Ligand A is preferable for membrane permeability.
4. **HBD:** Both have acceptable HBD counts (2 and 3 respectively), well below the threshold of 5.
5. **HBA:** Both have acceptable HBA counts (3), well below the threshold of 10.
6. **QED:** Both ligands have similar, good QED scores (0.626 and 0.615), indicating good drug-like properties.
7. **DILI:** Ligand A (16.169) has a much lower DILI risk than Ligand B (41.45). This is a significant advantage.
8. **BBB:** Ligand A (72.586) has better BBB penetration than Ligand B (56.301), but this isn't a primary concern for a cardiovascular target.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand B (-4.984) is slightly worse than Ligand A (-4.504).
10. **Solubility:** Both have negative solubility values, which is also unusual and suggests poor solubility. Ligand A (-2.996) is slightly better than Ligand B (-2.46).
11. **hERG:** Both have low hERG risk (0.554 and 0.682), which is good.
12. **Cl_mic:** Ligand A (41.151) has lower microsomal clearance than Ligand B (48.686), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-48.36) has a much longer in vitro half-life than Ligand A (-5.42). This is a major advantage for Ligand B.
14. **Pgp:** Ligand A (0.16) has significantly lower P-gp efflux liability than Ligand B (0.103), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand A (-7.9) has a substantially stronger binding affinity than Ligand B (-8.5). This is a very important factor.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A excels in logP, TPSA, and Pgp, and *significantly* outperforms Ligand B in binding affinity. The longer half-life of Ligand B is attractive, but the superior binding affinity of Ligand A, coupled with its better safety profile (lower DILI) and reasonable ADME properties, outweighs this benefit. The poor Caco-2 and solubility values are concerning for both, but can be addressed with formulation strategies.
**Conclusion:**
Ligand A is the more promising drug candidate due to its superior binding affinity, better predicted permeability (TPSA, logP, Pgp), and lower DILI risk.
Output:
1
2025-04-17 21:05:50,752 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (361.398 and 362.436 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (85.2) is slightly higher than Ligand B (58.2). For a cardiovascular GPCR, TPSA isn't *as* critical as for a CNS target, but lower is generally preferred for absorption. Ligand B is better here.
3. **logP:** Both ligands have good logP values (2.958 and 3.721), falling within the optimal 1-3 range. Ligand B is slightly higher, which *could* be a minor concern for solubility, but not a dealbreaker.
4. **HBD:** Ligand A (1) is better than Ligand B (2). Lower HBD is generally preferred for better permeability.
5. **HBA:** Ligand A (7) is higher than Ligand B (2). Ligand B is significantly better here, contributing to better permeability.
6. **QED:** Both ligands have similar QED values (0.68 and 0.647), indicating good drug-likeness.
7. **DILI:** Ligand A (89.415) has a significantly higher DILI risk than Ligand B (35.285). This is a major concern for Ligand A.
8. **BBB:** Ligand A (66.305) and Ligand B (86.468). BBB is less critical for a cardiovascular target, but higher is still preferable. Ligand B is better.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.642 and -4.524), which is unusual and suggests poor permeability. However, the values are very close.
10. **Solubility:** Both ligands have negative solubility values (-3.719 and -4.364), indicating poor aqueous solubility. Ligand B is slightly worse.
11. **hERG:** Both ligands have low hERG inhibition liability (0.351 and 0.412), which is good.
12. **Cl_mic:** Ligand A (85.639) has a higher microsomal clearance than Ligand B (54.915), indicating lower metabolic stability. Ligand B is better.
13. **t1/2:** Ligand A (-11.136) has a negative in vitro half-life, which is very concerning. Ligand B (4.347) has a positive half-life. This is a major advantage for Ligand B.
14. **Pgp:** Ligand A (0.304) has lower P-gp efflux than Ligand B (0.077), which is better.
15. **Binding Affinity:** Ligand B (-8.3 kcal/mol) has a significantly better binding affinity than Ligand A (-7.6 kcal/mol). This 0.7 kcal/mol difference is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand B is the stronger candidate. While both have issues with Caco-2 and solubility, Ligand B has a significantly better safety profile (much lower DILI risk), better metabolic stability (lower Cl_mic, positive t1/2), and a substantially higher binding affinity. The slightly higher logP of Ligand B is a minor concern, but the benefits outweigh this drawback. Ligand A's high DILI risk and negative half-life are major red flags.
Output:
0
2025-04-17 21:05:50,752 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (367.354 and 348.487 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (58.64) is significantly better than Ligand A (109.77). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (2.04 and 2.37), falling within the 1-3 range. Ligand B is slightly more lipophilic.
4. **HBD:** Ligand B (1) is preferable to Ligand A (2) as fewer HBDs generally improve permeability.
5. **HBA:** Ligand B (3) is preferable to Ligand A (5) for the same reason as HBD.
6. **QED:** Ligand A (0.756) has a better QED score than Ligand B (0.514), indicating a more drug-like profile overall.
7. **DILI:** Ligand B (23.885) has a much lower DILI risk than Ligand A (98.294). This is a *major* advantage for Ligand B.
8. **BBB:** Ligand B (52.927) has a higher BBB penetration score than Ligand A (19.698), but since ADRB2 is a cardiovascular target, this isn't a critical factor.
9. **Caco-2:** Ligand A (-5.227) has a more negative Caco-2 value, suggesting *lower* permeability than Ligand B (-4.42).
10. **Solubility:** Ligand A (-3.404) has a more negative solubility value, suggesting *lower* solubility than Ligand B (-2.722).
11. **hERG:** Both ligands have very low hERG inhibition risk (0.053 and 0.271), which is excellent.
12. **Cl_mic:** Ligand A (15.609) has significantly lower microsomal clearance than Ligand B (41.649), indicating better metabolic stability.
13. **t1/2:** Ligand A (11.411) has a longer in vitro half-life than Ligand B (-7.492). This is a significant advantage.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.066 and 0.081).
15. **Binding Affinity:** Ligand A (-7.8) has a stronger binding affinity than Ligand B (-5.8). This is a 2.0 kcal/mol difference, which is substantial and can outweigh some ADME drawbacks.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B has better logP, TPSA, and Pgp properties. However, Ligand A has a much stronger binding affinity. The DILI risk for Ligand A is extremely high, which is a major concern.
**Overall Assessment:**
While Ligand A has superior binding affinity and metabolic stability, the extremely high DILI risk is a deal-breaker. Ligand B, despite slightly weaker affinity, presents a much more favorable safety profile (DILI) and better absorption/permeability characteristics (TPSA, Caco-2, Solubility). The 2.0 kcal/mol difference in binding affinity, while significant, can potentially be addressed through further optimization. The DILI risk of Ligand A is much harder to fix.
**Output:**
0
2025-04-17 21:05:50,752 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
Let's systematically compare Ligand A and Ligand B based on the provided parameters and the guidelines, keeping in mind ADRB2 is a GPCR. GPCRs prioritize logP, Pgp, TPSA, and affinity.
1. **MW:** Both ligands (342.374 and 353.388 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand B (56.99) is significantly better than Ligand A (83.98). Lower TPSA generally improves permeability, a crucial factor for GPCR ligands.
3. **logP:** Ligand A (1.544) is within the optimal range (1-3), while Ligand B (3.843) is approaching the upper limit. While not a deal-breaker, higher logP can sometimes lead to off-target effects.
4. **HBD/HBA:** Ligand A has 2 HBD and 4 HBA, while Ligand B has 0 HBD and 3 HBA. Both are acceptable, but Ligand B's lower HBD count might slightly improve permeability.
5. **QED:** Ligand A (0.834) has a slightly better QED score than Ligand B (0.781), indicating a more drug-like profile.
6. **DILI:** Ligand B (24.195) has a much lower DILI risk than Ligand A (65.723). This is a significant advantage for Ligand B.
7. **BBB:** Ligand B (96.006) demonstrates excellent BBB penetration, while Ligand A (77.588) is good but not as high. Given that ADRB2 is involved in cardiovascular function, CNS penetration isn't a primary requirement, but it doesn't hurt.
8. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests a potential issue with the data or the compounds themselves. However, the values are similar (-4.777 vs -4.216), so this doesn't differentiate them.
9. **Solubility:** Ligand A (-2.581) has slightly better solubility than Ligand B (-4.069). Solubility is important, but not as critical as permeability for this target.
10. **hERG:** Ligand A (0.143) has a lower hERG risk than Ligand B (0.637). This is a positive for Ligand A.
11. **Cl_mic:** Ligand A (22.746) has a lower microsomal clearance than Ligand B (55.729), suggesting better metabolic stability.
12. **t1/2:** Both ligands have negative in vitro half-life values (-25.58 and -24.018), which are problematic and likely indicate issues with the data.
13. **Pgp:** Ligand A (0.046) has significantly lower P-gp efflux liability than Ligand B (0.19). Lower P-gp efflux is desirable for improved bioavailability.
14. **Affinity:** Ligand A (-7.5 kcal/mol) has a slightly better binding affinity than Ligand B (-6.3 kcal/mol). This 1.2 kcal/mol difference is substantial and a major advantage for Ligand A.
**Overall Assessment:**
Ligand A has a better binding affinity, lower P-gp efflux, and better metabolic stability. However, Ligand B excels in TPSA, DILI risk, and BBB penetration. The affinity difference is the most significant factor. While Ligand B's lower DILI is attractive, the stronger binding of Ligand A is likely to translate to greater efficacy and potentially allow for a lower dose, mitigating some of the DILI risk. The TPSA difference is also important, but the affinity advantage outweighs it.
**Output:**
1
2025-04-17 21:05:50,752 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (364.555 and 346.515 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands have a TPSA of 40.62, which is excellent for oral absorption and appropriate for a non-CNS GPCR target like ADRB2.
3. **logP:** Ligand A (2.96) and Ligand B (3.166) are both within the optimal 1-3 range. Ligand B is slightly higher, which could potentially lead to some off-target interactions, but it's not a major concern.
4. **HBD:** Both ligands have 0 HBD, which is good for permeability.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 2 HBA. Lower HBA is generally preferred for better permeability, giving a slight edge to Ligand B.
6. **QED:** Both ligands have similar QED values (0.778 and 0.767), indicating good drug-likeness.
7. **DILI:** Ligand A (20.202) has a significantly lower DILI risk than Ligand B (27.065). This is a substantial advantage for Ligand A.
8. **BBB:** Both ligands have high BBB penetration (91.663 and 81.698). However, since ADRB2 is primarily a cardiovascular target, high BBB penetration is less critical.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.726 and -4.796). This is unusual and suggests poor permeability. This is a significant drawback for both.
10. **Solubility:** Ligand A (-2.16) has better solubility than Ligand B (-3.101). Solubility is important for bioavailability.
11. **hERG:** Both ligands have low hERG inhibition liability (0.976 and 0.627), which is excellent.
12. **Cl_mic:** Ligand B (84.512) has a much higher microsomal clearance than Ligand A (30.628). This means Ligand A is likely to have better metabolic stability and a longer duration of action.
13. **t1/2:** Ligand A (13.653) has a positive in vitro half-life, while Ligand B (-5.612) has a negative value, which is concerning.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.634 and 0.544).
15. **Binding Affinity:** Both ligands have similar binding affinities (-5.1 and -5.5 kcal/mol). Ligand B has a slightly better affinity, but the difference is not substantial enough to outweigh other factors.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity) and the general guidelines, Ligand A emerges as the more promising candidate. While both have issues with Caco-2 permeability, Ligand A demonstrates significantly better safety (lower DILI), metabolic stability (lower Cl_mic, positive t1/2), and solubility. The slightly better affinity of Ligand B is not enough to compensate for these drawbacks.
Output:
1
2025-04-17 21:05:50,753 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (349.387 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (66.32) is significantly better than Ligand A (116.76). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally aids absorption.
3. **logP:** Ligand B (2.834) is optimal, while Ligand A (-0.188) is quite low, potentially hindering membrane permeability. This is a significant drawback for Ligand A.
4. **HBD:** Ligand A (4) is slightly higher than Ligand B (1), but both are within the acceptable limit of 5.
5. **HBA:** Ligand B (6) is better than Ligand A (5), both are within the acceptable limit of 10.
6. **QED:** Ligand B (0.754) is better than Ligand A (0.509), indicating a more drug-like profile.
7. **DILI:** Both ligands have acceptable DILI risk (Ligand A: 44.552, Ligand B: 54.478), with Ligand A being slightly better.
8. **BBB:** Not a high priority for a cardiovascular target. Ligand A (52.268) is better than Ligand B (29.934).
9. **Caco-2:** Both are negative, indicating poor permeability.
10. **Solubility:** Both are negative, indicating poor solubility.
11. **hERG:** Ligand A (0.128) is significantly better than Ligand B (0.323), a crucial factor for cardiovascular drugs to minimize cardiotoxicity risk.
12. **Cl_mic:** Ligand A (14.292) is much better than Ligand B (60.834), indicating better metabolic stability.
13. **t1/2:** Ligand B (11.032) is slightly better than Ligand A (10.774).
14. **Pgp:** Ligand A (0.011) is significantly better than Ligand B (0.269), indicating less efflux and potentially better bioavailability.
15. **Binding Affinity:** Ligand A (-8.2 kcal/mol) is significantly better than Ligand B (-5.1 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME drawbacks.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A suffers from a very low logP, while Ligand B has a good logP and better TPSA. However, Ligand A has a much stronger binding affinity and better Pgp efflux. The hERG risk is also much lower for Ligand A. The metabolic stability (Cl_mic) is also much better for Ligand A.
**Overall Assessment:**
Despite the lower logP and Caco-2/Solubility scores, Ligand A's significantly superior binding affinity (-8.2 vs -5.1 kcal/mol), lower hERG risk, better metabolic stability, and lower Pgp efflux outweigh the drawbacks. The strong binding affinity is a critical advantage for a GPCR target, and the improved safety profile (hERG) is essential for a cardiovascular drug.
Output:
1
2025-04-17 21:05:50,753 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B, followed by the final output:
**Ligand A: [361.442, 53.51, 2.273, 0, 4, 0.552, 36.099, 95.347, -4.613, -3.83, 0.368, 47.449, -18.924, 0.063, -6.5]**
**Ligand B: [351.441, 38.13, 3.919, 0, 3, 0.729, 35.285, 95.192, -4.38, -4.072, 0.796, 71.018, 2.502, 0.687, -6.0]**
1. **MW:** Both ligands are within the ideal range (200-500 Da). A (361.442) and B (351.441) are very similar.
2. **TPSA:** A (53.51) is slightly higher than B (38.13). Both are acceptable for a non-CNS GPCR target, but B is better.
3. **logP:** A (2.273) is optimal, while B (3.919) is approaching the upper limit. A is preferred.
4. **HBD:** Both have 0 HBD, which is good.
5. **HBA:** A (4) is slightly higher than B (3), both are good.
6. **QED:** B (0.729) is better than A (0.552), indicating a more drug-like profile.
7. **DILI:** Both are good, with A (36.099) and B (35.285) being low risk. B is slightly better.
8. **BBB:** Both are very high (A: 95.347, B: 95.192), but this is less critical for a cardiovascular target.
9. **Caco-2:** Both are negative, indicating poor permeability. This is a significant drawback for both.
10. **Solubility:** Both are very poor (A: -3.83, B: -4.072). This is a major concern.
11. **hERG:** Both are low (A: 0.368, B: 0.796), indicating low cardiotoxicity risk. A is slightly better.
12. **Cl_mic:** A (47.449) is significantly lower than B (71.018), suggesting better metabolic stability. A is preferred.
13. **t1/2:** A (-18.924) is much worse than B (2.502). B is preferred.
14. **Pgp:** A (0.063) is much lower than B (0.687), indicating less P-gp efflux. A is preferred.
15. **Binding Affinity:** A (-6.5) is slightly better than B (-6.0), but the difference is small.
**Overall Assessment:**
Both compounds have significant solubility and permeability issues. However, Ligand A has a better logP, lower Cl_mic, and lower Pgp efflux, which are important for overall drug disposition. The slightly better affinity of A also contributes. While B has a better QED and half-life, the metabolic stability and efflux advantages of A are more crucial for a GPCR target, especially considering the poor permeability of both. The slightly better DILI score of B is not enough to outweigh the other factors.
Output:
1
2025-04-17 21:05:50,753 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (388.421 Da) is slightly higher than Ligand B (353.463 Da), but both are acceptable.
2. **TPSA:** Both ligands are below the 140 A^2 threshold for good oral absorption. Ligand A (95.42) is a bit higher than Ligand B (90.9), but still reasonable.
3. **logP:** Ligand A (1.299) is within the optimal range (1-3), while Ligand B (-0.121) is slightly below 1. This is a significant difference. For a GPCR, a slightly higher logP is generally preferred for membrane permeability, so Ligand A has an advantage here.
4. **HBD:** Ligand A (2) and Ligand B (3) are both acceptable, being less than 5.
5. **HBA:** Ligand A (7) and Ligand B (5) are both acceptable, being less than 10.
6. **QED:** Ligand A (0.805) has a significantly better QED score than Ligand B (0.566), indicating a more drug-like profile.
7. **DILI:** Ligand B (6.747) has a much lower DILI risk than Ligand A (77.743). This is a major advantage for Ligand B.
8. **BBB:** Ligand A (49.011) has a slightly better BBB penetration percentile than Ligand B (39.55), but both are relatively low. Since ADRB2 is not a CNS target, this isn't a primary concern.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Both ligands have negative solubility values, which is also unusual. Again, the scale is not specified.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.147 and 0.103).
12. **Cl_mic:** Ligand A (-2.926) has a negative clearance, which is not physically possible and likely indicates very high metabolic stability. Ligand B (7.417) has a moderate clearance. The negative value for Ligand A is a red flag, and likely an artifact of the modeling.
13. **t1/2:** Ligand B (19.352 hours) has a significantly longer in vitro half-life than Ligand A (9.682 hours). This is a positive for Ligand B.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.069 and 0.004).
15. **Binding Affinity:** Ligand A (-7.3 kcal/mol) has a slightly better binding affinity than Ligand B (-5.7 kcal/mol). This is a significant advantage for Ligand A.
**Overall Assessment & GPCR Focus:**
Given the GPCR target (ADRB2), logP, and binding affinity are key. Ligand A has a better logP and significantly better binding affinity. However, Ligand B has a much lower DILI risk and a longer half-life. The negative clearance value for Ligand A is highly suspect. While the affinity difference is notable, the DILI risk for Ligand A is concerning, and the negative clearance is a major red flag. The slightly better affinity of Ligand A doesn't outweigh these significant liabilities.
Therefore, I prefer Ligand B.
Output:
0
2025-04-17 21:05:50,753 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (348.403 and 346.427 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (85.69) is slightly higher than Ligand B (76.66). Both are below the 140 threshold for oral absorption, but closer to the 90 threshold for CNS targets (less relevant here, but still a positive). Ligand B is preferable.
3. **logP:** Ligand B (1.673) is within the optimal 1-3 range, while Ligand A (0.171) is quite low. This is a significant advantage for Ligand B, as low logP can hinder membrane permeability.
4. **HBD:** Ligand A (1) is better than Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (6) is higher than Ligand B (4). Lower HBA is generally preferred for permeability. Ligand B is preferable.
6. **QED:** Both ligands have good QED scores (0.838 and 0.787), indicating good drug-like properties. No clear winner.
7. **DILI:** Ligand B (49.011) has a lower DILI risk than Ligand A (55.719), which is favorable.
8. **BBB:** Both ligands have reasonable BBB penetration (74.913 and 71.035). This isn't a primary concern for ADRB2, which isn't a CNS target.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. This is concerning for both.
10. **Solubility:** Both ligands have negative solubility values, indicating poor solubility. This is concerning for both.
11. **hERG:** Ligand A (0.136) has a lower hERG risk than Ligand B (0.509), which is favorable.
12. **Cl_mic:** Ligand A (16.543) has a lower microsomal clearance than Ligand B (24.756), suggesting better metabolic stability.
13. **t1/2:** Ligand A (64.516) has a longer in vitro half-life than Ligand B (18.128), which is a significant advantage.
14. **Pgp:** Ligand A (0.014) has significantly lower P-gp efflux liability than Ligand B (0.095), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand A (-7.0) has a slightly better binding affinity than Ligand B (-6.4), but the difference is not substantial enough to outweigh other factors.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, and Pgp efflux are important. Ligand B has a much better logP and lower TPSA. Ligand A has better Pgp efflux.
**Overall Assessment:**
Ligand B has a better balance of properties, particularly regarding logP and DILI risk. While Ligand A has advantages in metabolic stability, half-life, and Pgp efflux, the poor logP of Ligand A is a significant drawback. The slightly better affinity of Ligand A is not enough to compensate for the permeability issues.
Output:
0
2025-04-17 21:05:50,753 - INFO - Batch 233 complete. Total preferences: 3728
2025-04-17 21:05:50,754 - INFO - Processing batch 234/512...
2025-04-17 21:06:40,095 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (394.421 Da) is slightly higher than Ligand B (344.455 Da), but both are acceptable.
2. **TPSA:** Ligand A (102.43) is higher than Ligand B (62.55). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is generally preferred for absorption. Ligand B is significantly better here.
3. **logP:** Ligand A (1.497) is within the optimal range, while Ligand B (3.077) is towards the higher end but still acceptable.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 7 HBA, while Ligand B has 3. Both are within the acceptable limit of 10, but Ligand B is preferable.
6. **QED:** Both ligands have good QED scores (A: 0.777, B: 0.807), indicating good drug-like properties.
7. **DILI:** Ligand A (98.216) has a very high DILI risk, which is a major concern. Ligand B (27.065) has a much lower, and acceptable, DILI risk.
8. **BBB:** Both have reasonable BBB penetration (A: 77.782, B: 81.776), but this is less critical for a cardiovascular target.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. This is a significant drawback for both.
10. **Solubility:** Both have negative solubility values, indicating poor solubility. This is a significant drawback for both.
11. **hERG:** Ligand A (0.234) has a lower hERG risk than Ligand B (0.652), which is favorable.
12. **Cl_mic:** Ligand B (74.633) has a lower microsomal clearance than Ligand A (27.826), indicating better metabolic stability.
13. **t1/2:** Ligand B (77.174) has a longer in vitro half-life than Ligand A (41.493), which is desirable.
14. **Pgp:** Ligand A (0.302) has lower P-gp efflux liability than Ligand B (0.442), which is favorable.
15. **Affinity:** Ligand A (-6.4 kcal/mol) has a significantly better binding affinity than Ligand B (-2.7 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME drawbacks.
**Overall Assessment:**
The biggest concern with Ligand A is its extremely high DILI risk. While its affinity is significantly better, the potential for liver toxicity is a major hurdle. Ligand B, while having weaker affinity, presents a much more favorable safety profile (DILI) and better metabolic stability (Cl_mic, t1/2). Both compounds have issues with permeability and solubility, which would need to be addressed through formulation or further chemical modification. However, the DILI risk associated with Ligand A is a non-starter.
Given the GPCR-specific priorities (logP, Pgp, TPSA, affinity), and the critical importance of safety, Ligand B is the more viable candidate despite its lower affinity. The affinity difference, while substantial, might be overcome with further optimization, but mitigating a high DILI risk is far more challenging.
Output:
0
2025-04-17 21:06:40,095 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Ligand A (332.407 Da) is well within the ideal range (200-500 Da). Ligand B (415.332 Da) is also acceptable, but closer to the upper limit.
2. **TPSA:** Ligand A (70.93) is excellent, well below the 140 A^2 threshold for good absorption. Ligand B (98.58) is still reasonable, but less optimal.
3. **logP:** Both ligands have good logP values (A: 3.173, B: 2.392), falling within the 1-3 range.
4. **HBD:** Ligand A (2) and Ligand B (3) are both acceptable, under the 5 donor limit.
5. **HBA:** Ligand A (5) and Ligand B (6) are both acceptable, under the 10 acceptor limit.
6. **QED:** Both ligands have reasonable QED scores (A: 0.751, B: 0.633), indicating good drug-like properties.
7. **DILI:** Ligand A (68.592) has a higher DILI risk than Ligand B (41.993). This is a significant negative for Ligand A.
8. **BBB:** Both ligands have similar BBB penetration (A: 61.884, B: 63.009). While not exceptionally high, it's not a major concern for a cardiovascular target like ADRB2.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the values are similar (-5.069 and -5.107).
10. **Solubility:** Both ligands have negative solubility values, indicating poor aqueous solubility. Again, the values are similar (-3.634 and -3.414).
11. **hERG:** Ligand A (0.821) has a slightly higher hERG risk than Ligand B (0.598), but both are relatively low.
12. **Cl_mic:** Ligand A (21.942) has a significantly lower microsomal clearance than Ligand B (36.265), suggesting better metabolic stability.
13. **t1/2:** Ligand A (33.204) has a much longer in vitro half-life than Ligand B (5.003), which is a major advantage.
14. **Pgp:** Ligand A (0.582) has lower P-gp efflux liability than Ligand B (0.114), which is favorable.
15. **Affinity:** Ligand B (-6.1 kcal/mol) has a substantially stronger binding affinity than Ligand A (-5.0 kcal/mol). This is a >1 kcal/mol difference, which is a significant advantage.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand B excels in affinity. While Ligand A has better TPSA and Pgp, the affinity difference is substantial. The lower DILI risk of Ligand B is also a significant factor.
**Overall Assessment:**
Despite Ligand A's better metabolic stability and half-life, the significantly stronger binding affinity of Ligand B, coupled with its lower DILI risk, outweighs these advantages. The similar permeability and solubility issues are a concern for both, but can be addressed with formulation strategies.
Output:
0
2025-04-17 21:06:40,096 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (329.363 Da) is better than Ligand B (383.539 Da). Both are within the ideal range, but A is closer to the lower, more permeability-friendly end.
2. **TPSA:** Ligand A (72.7) is significantly better than Ligand B (82.53). Both are below 140, but A is closer to the preferred <90 for potential CNS penetration (though less critical for ADRB2 which isn't primarily a CNS target).
3. **logP:** Ligand A (3.376) is slightly higher than Ligand B (1.295). While both are within the acceptable range, A is closer to the optimal 1-3 range. B is on the lower side, which *could* indicate permeability issues.
4. **HBD:** Ligand A (1) is better than Ligand B (2). Lower is generally preferred.
5. **HBA:** Ligand A (5) is better than Ligand B (6). Lower is generally preferred.
6. **QED:** Both Ligand A (0.625) and Ligand B (0.672) are good, exceeding the 0.5 threshold. B is slightly better.
7. **DILI:** Ligand A (87.708) is considerably *worse* than Ligand B (37.456). This is a major concern. A's high DILI risk is a significant drawback.
8. **BBB:** Ligand A (50.446) is slightly better than Ligand B (46.762), but both are relatively low and not a primary concern for ADRB2.
9. **Caco-2:** Ligand A (-5.119) is better than Ligand B (-5.568). Both are negative, indicating poor permeability.
10. **Solubility:** Ligand A (-3.504) is better than Ligand B (-2.36). Both are poor, but A is slightly better.
11. **hERG:** Ligand A (0.872) is better than Ligand B (0.199). Lower is better, so A is less likely to cause cardiotoxicity.
12. **Cl_mic:** Ligand A (34.759) is much better than Ligand B (7.263). Lower clearance indicates better metabolic stability, a significant advantage for A.
13. **t1/2:** Ligand A (25.199) is much better than Ligand B (4.995). A has a significantly longer half-life, which is desirable.
14. **Pgp:** Ligand A (0.24) is better than Ligand B (0.055). Lower efflux is preferred.
15. **Affinity:** Ligand A (-7.3 kcal/mol) is significantly better than Ligand B (-5.3 kcal/mol). This is a substantial difference in binding potency. The 1.9 kcal/mol difference can outweigh many ADME drawbacks.
**Overall Assessment:**
Despite Ligand A's higher DILI risk, the significantly better binding affinity (-7.3 vs -5.3 kcal/mol), combined with its superior metabolic stability (Cl_mic and t1/2), lower Pgp efflux, and better hERG profile, make it the more promising candidate. The affinity difference is substantial enough to potentially mitigate the DILI risk through careful dose optimization and patient monitoring. Ligand B has a better DILI profile, but its lower affinity and poorer ADME properties (clearance, half-life) are more concerning. For a GPCR, affinity is paramount.
Output:
1
2025-04-17 21:06:40,096 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.343 and 354.422 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (107.31) is higher than Ligand B (75.71). For a cardiovascular GPCR like ADRB2, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B has a clear advantage.
3. **logP:** Ligand A (-0.301) is quite low, potentially hindering membrane permeability. Ligand B (1.227) is within the optimal 1-3 range. This is a significant advantage for Ligand B.
4. **HBD:** Both ligands have 1 HBD, which is acceptable.
5. **HBA:** Ligand A (7) has more HBA than Ligand B (4). Lower HBA is generally preferred for better permeability. Ligand B is better.
6. **QED:** Both ligands have similar QED scores (0.725 and 0.728), indicating good drug-likeness.
7. **DILI:** Ligand A (65.607) has a higher DILI risk than Ligand B (35.556). Lower DILI is crucial, giving Ligand B a substantial advantage.
8. **BBB:** Ligand A (67.468) and Ligand B (90.229). While ADRB2 isn't a CNS target, higher BBB penetration can sometimes correlate with better overall distribution. Ligand B is better.
9. **Caco-2:** Both have negative values, indicating poor permeability. Ligand A (-4.811) is slightly worse than Ligand B (-4.46).
10. **Solubility:** Both ligands have very poor aqueous solubility (-2.003 and -2.18). This is a significant drawback for both, and will require formulation work.
11. **hERG:** Ligand A (0.067) has a slightly lower hERG risk than Ligand B (0.269), but both are relatively low.
12. **Cl_mic:** Ligand A (5.834) has significantly lower microsomal clearance than Ligand B (33.238), suggesting better metabolic stability. This is a major advantage for Ligand A.
13. **t1/2:** Ligand A (25.391) has a positive in vitro half-life, while Ligand B (-25.414) has a negative one. This is a major advantage for Ligand A.
14. **Pgp:** Ligand A (0.021) has a much lower Pgp efflux liability than Ligand B (0.036), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand A (-8.5 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.4 kcal/mol). This is a substantial advantage for Ligand A, and can often outweigh minor ADME concerns.
**Overall Assessment:**
Ligand A has a significantly stronger binding affinity and better metabolic stability (lower Cl_mic, positive t1/2) and lower Pgp efflux. While Ligand B has better logP and lower DILI risk, the substantial affinity advantage of Ligand A, coupled with its better metabolic properties, makes it the more promising candidate. The poor solubility of both compounds is a concern, but can be addressed through formulation strategies. The lower logP of Ligand A is a concern, but the strong binding affinity may compensate.
Output:
1
2025-04-17 21:06:40,096 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (371.5 and 338.5 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Both ligands have TPSA values around 69-70 A2, which is acceptable for a non-CNS GPCR target like ADRB2.
**3. logP:** Ligand A (1.74) is slightly lower than Ligand B (2.87). While both are within the optimal 1-3 range, Ligand B is closer to the upper end, which *could* present solubility challenges, but isn't a major concern.
**4. H-Bond Donors:** Both have 1 HBD, which is good.
**5. H-Bond Acceptors:** Ligand A has 4 HBA, and Ligand B has 6. Both are acceptable, but Ligand A is slightly better.
**6. QED:** Both ligands have good QED scores (0.635 and 0.786), indicating generally drug-like properties. Ligand B is slightly better.
**7. DILI Risk:** Ligand A (25.2%) has a significantly lower DILI risk than Ligand B (46.6%). This is a substantial advantage for Ligand A.
**8. BBB Penetration:** BBB isn't a primary concern for a cardiovascular target, but Ligand B (77.3%) has higher BBB penetration than Ligand A (61.2%). This is not a deciding factor.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, suggesting poor permeability. This is a concern for both.
**10. Aqueous Solubility:** Both ligands have negative solubility values, suggesting poor solubility. This is a concern for both.
**11. hERG Inhibition:** Ligand A (0.404) has a slightly higher hERG risk than Ligand B (0.182). This favors Ligand B.
**12. Microsomal Clearance:** Ligand B (33.0) has significantly lower microsomal clearance than Ligand A (56.1), suggesting better metabolic stability. This is a significant advantage for Ligand B.
**13. In vitro Half-Life:** Ligand B (-22.5) has a much longer in vitro half-life than Ligand A (2.5). This is a major advantage for Ligand B.
**14. P-gp Efflux:** Ligand A (0.09) has lower P-gp efflux than Ligand B (0.29), which is favorable.
**15. Binding Affinity:** Ligand B (-6.9 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.4 kcal/mol). This is a substantial advantage for Ligand B, and can often outweigh minor ADME drawbacks.
**Overall Assessment:**
While Ligand A has a lower DILI risk and P-gp efflux, Ligand B has a significantly stronger binding affinity, better metabolic stability (lower Cl_mic), and a longer half-life. The binding affinity difference is substantial (>1.5 kcal/mol), and the improved metabolic stability and half-life are crucial for *in vivo* efficacy. The slightly higher hERG risk for Ligand A is concerning, and the lower DILI risk is good, but the benefits of Ligand B's potency and PK profile outweigh these concerns.
Output:
0
2025-04-17 21:06:40,096 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's break down the comparison of Ligand A and Ligand B, prioritizing parameters relevant to GPCRs (logP, TPSA, Pgp, and affinity, alongside general drug-like properties).
1. **Molecular Weight:** Both ligands (368.5 & 345.5 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand B (53.08) is significantly better than Ligand A (75.63). Lower TPSA generally correlates with better cell permeability, a key factor for GPCR ligands.
3. **logP:** Ligand A (2.263) is within the optimal 1-3 range. Ligand B (4.145) is slightly higher, potentially edging into a range where solubility could become a concern, and off-target interactions are more likely.
4. **H-Bond Donors/Acceptors:** Ligand A (0 HBD, 7 HBA) and Ligand B (2 HBD, 5 HBA) are both reasonable.
5. **QED:** Ligand B (0.741) has a better QED score than Ligand A (0.492), indicating a more drug-like profile overall.
6. **DILI Risk:** Ligand A (64.831) has a higher DILI risk than Ligand B (15.2). This is a significant advantage for Ligand B.
7. **BBB Penetration:** Both ligands have good BBB penetration (A: 85.459, B: 87.67). This is less critical for ADRB2 (a cardiovascular target) but still positive.
8. **Caco-2 Permeability:** Ligand B (-5.247) is better than Ligand A (-4.797), indicating better intestinal absorption.
9. **Aqueous Solubility:** Ligand A (-2.698) is better than Ligand B (-3.184).
10. **hERG Inhibition:** Ligand A (0.686) has a lower hERG risk than Ligand B (0.947). This is a positive for Ligand A.
11. **Microsomal Clearance:** Ligand A (113.805) has a higher (worse) clearance than Ligand B (18.46). Ligand B is much more metabolically stable.
12. **In vitro Half-Life:** Ligand B (39.167) has a significantly longer half-life than Ligand A (-14.692). This is a substantial advantage for Ligand B.
13. **P-gp Efflux:** Ligand A (0.501) has lower P-gp efflux than Ligand B (0.112). This is a positive for Ligand A.
14. **Binding Affinity:** Ligand B (-6.1 kcal/mol) has a slightly better binding affinity than Ligand A (-5.2 kcal/mol). While the difference isn't enormous, it's enough to consider, especially given the other advantages of Ligand B.
**Overall Assessment:**
Ligand B demonstrates a superior balance of properties. Its lower DILI risk, significantly improved metabolic stability (lower Cl_mic and longer t1/2), better Caco-2 permeability, and higher QED score outweigh the slightly higher logP and P-gp efflux. The affinity difference is not large enough to favor Ligand A given the other advantages of B. The lower TPSA of Ligand B is also a significant advantage for a GPCR target.
**Output:**
0
2025-04-17 21:06:40,096 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (344.459) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are below the 140 A^2 threshold for oral absorption. Ligand A (76.02) is better than Ligand B (84.42), aligning with GPCR preference for lower TPSA.
3. **logP:** Both are within the optimal 1-3 range. Ligand A (2.12) and Ligand B (2.094) are very similar.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1), but both are acceptable.
5. **HBA:** Ligand A (4) is lower than Ligand B (7). This is a slight advantage for Ligand A, as lower HBA generally improves permeability.
6. **QED:** Both ligands have good QED scores (A: 0.744, B: 0.881), indicating drug-likeness. Ligand B is slightly better.
7. **DILI:** Ligand A (25.553) has a significantly lower DILI risk than Ligand B (81.388). This is a major advantage for Ligand A.
8. **BBB:** Both have moderate BBB penetration, but Ligand A (56.029) is slightly better than Ligand B (51.842). While ADRB2 isn't necessarily a CNS target, some peripheral ADRB2 receptors can be influenced by CNS activity, so some BBB penetration isn't detrimental.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. This is a concern for both.
10. **Solubility:** Both have negative solubility values, indicating poor solubility. This is a concern for both.
11. **hERG:** Both have low hERG inhibition liability (A: 0.122, B: 0.233), which is good. Ligand A is slightly better.
12. **Cl_mic:** Ligand A (13.257) has a much lower microsomal clearance than Ligand B (33.055), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (2.947) has a positive in vitro half-life, while Ligand B (-11.457) has a negative value. This is a significant advantage for Ligand A.
14. **Pgp:** Both have low P-gp efflux liability (A: 0.039, B: 0.153). Ligand A is slightly better.
15. **Binding Affinity:** Ligand B (-7.2) has a slightly better binding affinity than Ligand A (-7.0). However, the difference is relatively small (0.2 kcal/mol).
**Overall Assessment:**
While Ligand B has slightly better binding affinity, Ligand A demonstrates a superior ADMET profile. Specifically, the significantly lower DILI risk, lower microsomal clearance, positive in vitro half-life, and slightly better TPSA, BBB, and Pgp values make Ligand A a more promising drug candidate. The small difference in binding affinity is outweighed by these substantial ADMET advantages. Given the GPCR target class, optimizing for ADME properties is crucial, and Ligand A excels in this regard.
Output:
1
2025-04-17 21:06:40,097 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (a cardiovascular GPCR) drug candidates.
**Ligand A:** [348.447, 96.11, 1.728, 3, 4, 0.654, 58.162, 35.44, -4.704, -3.317, 0.318, 37.124, -28.386, 0.124, -6.9]
**Ligand B:** [372.483, 86.72, 2.539, 1, 9, 0.556, 90.461, 57.58, -5.631, -3.156, 0.748, 72.121, 5.678, 0.135, -7.3]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (348.447) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are acceptable, below 140. Ligand B (86.72) is better, closer to the ideal for GPCRs.
3. **logP:** Both are within the optimal range (1-3). Ligand B (2.539) is slightly higher, potentially impacting solubility but could be beneficial for membrane permeability.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (1). Both are acceptable.
5. **HBA:** Ligand A (4) is lower than Ligand B (9). This is a slight advantage for Ligand A, as fewer HBA generally improves permeability.
6. **QED:** Ligand A (0.654) is better than Ligand B (0.556), indicating a more drug-like profile.
7. **DILI:** Ligand A (58.162) has a significantly lower DILI risk than Ligand B (90.461). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (57.58) has a higher BBB penetration potential than Ligand A (35.44). While ADRB2 is a cardiovascular target, some CNS exposure is not necessarily detrimental and could provide additional therapeutic effects or off-target liabilities.
9. **Caco-2:** Ligand A (-4.704) has a more negative Caco-2 value, indicating *lower* permeability. Ligand B (-5.631) is also low, but slightly better.
10. **Solubility:** Both have very poor aqueous solubility (-3.317 and -3.156). This is a significant concern for both compounds.
11. **hERG:** Ligand A (0.318) has a lower hERG inhibition liability than Ligand B (0.748). This is a significant safety advantage.
12. **Cl_mic:** Ligand A (37.124) has lower microsomal clearance, suggesting better metabolic stability than Ligand B (72.121).
13. **t1/2:** Ligand A (-28.386) has a much longer in vitro half-life than Ligand B (5.678). This is a substantial advantage.
14. **Pgp:** Both have low P-gp efflux liability (0.124 and 0.135), which is good.
15. **Affinity:** Ligand B (-7.3) has a slightly better binding affinity than Ligand A (-6.9). This is a 0.4 kcal/mol difference, which is not huge, but noticeable.
**GPCR-Specific Priorities:** For ADRB2 (a cardiovascular GPCR), we prioritize logP, TPSA, affinity, and metabolic stability. While BBB isn't paramount for a cardiovascular target, it's not a negative if it's reasonable.
**Overall Assessment:**
Ligand A has several key advantages: significantly lower DILI risk, lower hERG risk, better metabolic stability (lower Cl_mic, longer t1/2), and a better QED score. While Ligand B has slightly better affinity and TPSA, the safety and pharmacokinetic advantages of Ligand A are more compelling, especially considering the poor solubility of both compounds. The slightly better affinity of Ligand B is unlikely to overcome the substantial safety and PK liabilities.
**Output:**
1
2025-04-17 21:06:40,097 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (369.372 and 350.459 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (71.84) is slightly higher than Ligand B (67.87), but both are well below the 140 threshold for good oral absorption, and acceptable for a cardiovascular GPCR.
3. **logP:** Ligand A (3.737) is higher than Ligand B (1.362). While 3.737 is approaching the upper limit of optimal, it's still acceptable. Ligand B's 1.362 is a bit low and might hinder membrane permeability.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1), but both are within the acceptable limit of 5.
5. **HBA:** Ligand A (5) is higher than Ligand B (4), but both are within the acceptable limit of 10.
6. **QED:** Ligand A (0.736) has a significantly better QED score than Ligand B (0.367), indicating a more drug-like profile.
7. **DILI:** Ligand B (13.067) has a much lower DILI risk than Ligand A (88.639). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (75.998) has a higher BBB penetration percentile than Ligand B (66.886). While ADRB2 isn't a primary CNS target, some degree of BBB penetration can be beneficial for off-target effects assessment.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.862 and -4.631), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-4.011) has slightly worse solubility than Ligand B (-1.69), but both are poor.
11. **hERG:** Ligand A (0.547) has a slightly higher hERG risk than Ligand B (0.333), but both are relatively low.
12. **Cl_mic:** Ligand B (0.697) has significantly lower microsomal clearance than Ligand A (28.66), indicating better metabolic stability.
13. **t1/2:** Ligand B (-9.954) has a much longer in vitro half-life than Ligand A (81.118). This is a major advantage for Ligand B.
14. **Pgp:** Ligand A (0.368) has slightly lower P-gp efflux than Ligand B (0.022), which is favorable.
15. **Binding Affinity:** Ligand A (-7.0) has equal binding affinity to Ligand B (-5.3).
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are important. Ligand A has a better logP and Pgp profile, but Ligand B has a much better metabolic stability profile (Cl_mic and t1/2) and a significantly lower DILI risk. The binding affinity is the same. The poor Caco-2 values are a concern for both, but the superior ADME properties of Ligand B (lower DILI, better metabolic stability, longer half-life) outweigh the slightly better logP and Pgp of Ligand A.
**Conclusion:**
Ligand B is the more promising candidate due to its significantly improved ADME properties, particularly the lower DILI risk and better metabolic stability. While both have poor Caco-2 permeability, the other advantages of Ligand B make it the better choice for further optimization.
Output:
0
2025-04-17 21:06:40,097 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (337.467) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (42.99) is significantly better than Ligand B (127.32). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary goal, but lower TPSA generally correlates with better absorption. Ligand B's TPSA is quite high, potentially hindering oral bioavailability.
3. **logP:** Ligand A (4.796) is higher than the optimal range (1-3), but still potentially manageable. Ligand B (0.12) is *very* low, which is a major concern for membrane permeability and bioavailability.
4. **HBD/HBA:** Ligand A (HBD=1, HBA=4) is better than Ligand B (HBD=3, HBA=5). Both are acceptable, but fewer H-bonds are generally preferred for better permeability.
5. **QED:** Both ligands have similar QED values (0.571 and 0.566), indicating reasonable drug-likeness.
6. **DILI:** Both ligands have acceptable DILI risk (Ligand A: 49.128, Ligand B: 41.915). Ligand B is slightly better here.
7. **BBB:** Ligand A (40.481) and Ligand B (74.564). While not a primary concern for a cardiovascular target, Ligand B has better BBB penetration.
8. **Caco-2:** Both have negative Caco-2 values (-5.506 and -5.58), which is unusual and suggests poor permeability. This is a red flag for both.
9. **Solubility:** Ligand A (-3.686) is slightly better than Ligand B (-2.973), but both are poor.
10. **hERG:** Ligand A (0.935) is slightly better than Ligand B (0.093), indicating lower cardiotoxicity risk.
11. **Cl_mic:** Ligand A (42.671) has a higher (worse) microsomal clearance than Ligand B (26.493), suggesting faster metabolism.
12. **t1/2:** Ligand A (66.547) has a significantly longer in vitro half-life than Ligand B (-4.571). This is a major advantage for Ligand A.
13. **Pgp:** Ligand A (0.922) has lower P-gp efflux than Ligand B (0.016), which is favorable for bioavailability.
14. **Binding Affinity:** Ligand A (-7.0) has a slightly better binding affinity than Ligand B (-5.7). The difference is 1.3 kcal/mol, which is significant.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has a better balance of these properties. While its logP is high, its TPSA is much lower than Ligand B's, and its Pgp efflux is lower. The affinity difference is also substantial. The poor Caco-2 and solubility are concerning for both, but the other factors favor Ligand A.
**Conclusion:**
Considering the balance of properties, particularly the significantly better TPSA, Pgp efflux, and binding affinity, Ligand A is the more promising drug candidate despite its higher logP and poorer solubility. The longer half-life is also a significant advantage.
Output:
1
2025-04-17 21:06:40,097 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (343.471 and 352.431 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (61.44) is significantly better than Ligand B (87.15). ADRB2 is a cardiovascular target, not CNS, but lower TPSA generally improves absorption.
3. **logP:** Ligand A (2.186) is optimal. Ligand B (0.55) is quite low, potentially hindering membrane permeability and bioavailability. This is a significant negative for Ligand B.
4. **HBD:** Both ligands have acceptable HBD counts (2 and 1, respectively), well below the threshold of 5.
5. **HBA:** Ligand A (3) is better than Ligand B (5), but both are acceptable (<=10).
6. **QED:** Both ligands have similar and good QED values (0.798 and 0.73), indicating good drug-like properties.
7. **DILI:** Ligand A (21.869) has a much lower DILI risk than Ligand B (37.03). This is a substantial advantage for Ligand A.
8. **BBB:** Not a primary concern for a cardiovascular target. Ligand A (62.233) is slightly better than Ligand B (57.193).
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. Ligand A (-4.825) is slightly better than Ligand B (-4.413).
10. **Solubility:** Both ligands have negative solubility values, indicating poor solubility. Ligand A (-2.31) is slightly better than Ligand B (-1.603).
11. **hERG:** Both ligands have very low hERG inhibition liability (0.49 and 0.157), which is excellent.
12. **Cl_mic:** Ligand A (17.456) has significantly lower microsomal clearance than Ligand B (40.565), indicating better metabolic stability.
13. **t1/2:** Ligand A (7.995) has a longer in vitro half-life than Ligand B (-0.597).
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.089 and 0.053).
15. **Binding Affinity:** Ligand A (-6.3 kcal/mol) has a slightly better binding affinity than Ligand B (-5.8 kcal/mol). While the difference is less than the 1.5 kcal/mol threshold, it contributes to the overall preference.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand A excels in logP and TPSA, and has slightly better affinity. Metabolic stability (Cl_mic and t1/2) is also important, and Ligand A is clearly superior in these aspects. DILI risk is a significant factor, and Ligand A is much better.
**Conclusion:**
Ligand A consistently outperforms Ligand B across the most important parameters. The significantly better logP, lower DILI risk, and improved metabolic stability make it a much more promising drug candidate.
Output:
1
2025-04-17 21:06:40,097 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (348.443 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (82.78) is significantly better than Ligand B (49.77). For a GPCR, lower TPSA is preferred for better brain penetration, even though ADRB2 isn't strictly a CNS target.
3. **logP:** Ligand A (1.728) is optimal, while Ligand B (4.664) is high. High logP can lead to poor solubility and off-target effects.
4. **HBD:** Both ligands have acceptable HBD counts (2 and 1 respectively), well within the limit of 5.
5. **HBA:** Both ligands have acceptable HBA counts (4), well within the limit of 10.
6. **QED:** Both ligands have similar QED values (0.749 and 0.723), indicating good drug-likeness.
7. **DILI:** Ligand A (8.298) has a much lower DILI risk than Ligand B (36.565). This is a significant advantage.
8. **BBB:** Ligand A (62.466) has a better BBB percentile than Ligand B (51.687), although both are not exceptionally high.
9. **Caco-2:** Ligand A (-5.058) and Ligand B (-4.9) have similar Caco-2 permeability.
10. **Solubility:** Ligand A (-1.201) has better aqueous solubility than Ligand B (-4.587). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.408) has a lower hERG inhibition liability than Ligand B (0.854), reducing cardiotoxicity risk.
12. **Cl_mic:** Ligand A (-2.119) has a much lower microsomal clearance, indicating better metabolic stability, than Ligand B (110.366).
13. **t1/2:** Ligand A (30.452) has a shorter half-life than Ligand B (44.472), but both are reasonable.
14. **Pgp:** Ligand A (0.109) has a lower P-gp efflux liability than Ligand B (0.677), which is beneficial for bioavailability.
15. **Binding Affinity:** Ligand A (-6.7 kcal/mol) has a slightly weaker binding affinity than Ligand B (-6.1 kcal/mol). However, the difference is not substantial enough to outweigh the significant ADME advantages of Ligand A.
**GPCR-specific priorities:** Considering this is a GPCR target, logP, TPSA, Pgp, and affinity are key. Ligand A excels in logP, TPSA, and Pgp, and its affinity is only marginally lower than Ligand B. The superior ADME profile of Ligand A, particularly the lower DILI risk and better metabolic stability, makes it the more promising candidate.
**Output:**
1
2025-04-17 21:06:40,098 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.471 and 353.467 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (49.85) is significantly better than Ligand B (107.4). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is quite high, potentially hindering absorption.
3. **logP:** Both ligands have similar logP values (2.529 and 2.634), falling within the optimal 1-3 range.
4. **HBD:** Ligand A (0) is preferable to Ligand B (1). Fewer HBDs generally improve membrane permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (4). Similar to HBD, fewer HBAs are generally better for permeability.
6. **QED:** Ligand A (0.735) is significantly better than Ligand B (0.391). A higher QED indicates a more drug-like profile.
7. **DILI:** Both ligands have similar, relatively low DILI risk (18.845 and 19.659 percentile). This isn't a major differentiating factor.
8. **BBB:** Ligand A (74.719) is slightly better than Ligand B (70.609), although both are reasonably good. For a cardiovascular target like ADRB2, BBB penetration isn't *critical* but can be helpful for understanding off-target effects.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.402 and -4.578), which is unusual and suggests poor permeability. This is a concern for both, but the values are similar.
10. **Solubility:** Both ligands have similar and very poor aqueous solubility (-1.896 and -1.846). This is a significant drawback for both.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.411 and 0.209). This is excellent, minimizing cardiotoxicity risk.
12. **Cl_mic:** Ligand B (42.355) has a lower microsomal clearance than Ligand A (46.128), suggesting better metabolic stability.
13. **t1/2:** Ligand A (0.134) has a slightly longer in vitro half-life than Ligand B (-0.081), but both are extremely short, indicating rapid metabolism.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.09 and 0.007). This is favorable.
15. **Binding Affinity:** Ligand A (-6.3 kcal/mol) has a slightly better binding affinity than Ligand B (-5.9 kcal/mol). While the difference is not huge, it's enough to be considered.
**Overall Assessment & GPCR Prioritization:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand A is clearly superior. It has a significantly lower TPSA, a better QED score, and a slightly better binding affinity. While both have poor solubility and Caco-2 permeability, the other advantages of Ligand A outweigh the slightly better metabolic stability of Ligand B. The lower TPSA and better QED are particularly important for a GPCR target. The slight affinity advantage also tips the scales.
Output:
1
2025-04-17 21:06:40,098 - INFO - Here's my reasoning and final output for the ligand preference:
**Reasoning:**
We are looking for a ligand for ADRB2, a cardiovascular GPCR. Therefore, the priorities are logP, TPSA, Pgp, affinity, and to a lesser extent, BBB.
Let's compare Ligand A and Ligand B across the 15 parameters:
1. **MW:** Both ligands (358.385 and 364.471 Da) are within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (76.66) is significantly better than Ligand B (92.57). A lower TPSA is preferred for better absorption, and Ligand A is comfortably under the 140 threshold. Ligand B is approaching the upper limit.
3. **logP:** Ligand A (2.763) is slightly better than Ligand B (1.562), falling nicely within the 1-3 optimal range. Ligand B is at the lower end, which *could* impact permeability.
4. **HBD:** Both ligands have 2 HBD, which is good.
5. **HBA:** Ligand A has 4 HBA, while Ligand B has 5. Both are acceptable, but lower is generally preferred.
6. **QED:** Both ligands have similar QED values (0.786 and 0.78), indicating good drug-likeness.
7. **DILI:** Ligand A (67.313) is slightly higher than Ligand B (64.676), but both are reasonably low risk.
8. **BBB:** Ligand A (72.586) has a better BBB percentile than Ligand B (59.403). While not a primary concern for a cardiovascular target, higher BBB is generally favorable.
9. **Caco-2:** Ligand A (-4.286) is better than Ligand B (-5.091), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-3.296) is better than Ligand B (-3.548).
11. **hERG:** Both ligands have very low hERG risk (0.475 and 0.431).
12. **Cl_mic:** Ligand B (48.142) has significantly lower microsomal clearance than Ligand A (92.402), suggesting better metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand B (-26.729) has a better in vitro half-life than Ligand A (-37.505).
14. **Pgp:** Ligand A (0.089) has a lower Pgp efflux liability than Ligand B (0.031), which is desirable.
15. **Affinity:** Both ligands have very similar, strong binding affinities (-6.3 and -6.5 kcal/mol). The difference is negligible.
**Overall Assessment:**
Ligand A has advantages in TPSA, logP, BBB, Caco-2, solubility, and Pgp efflux. Ligand B shines in metabolic stability (lower Cl_mic) and half-life. Given the GPCR nature of the target, the slightly better TPSA and logP of Ligand A, combined with its lower Pgp efflux, are more critical. While metabolic stability is important, the difference in affinity is minimal, and the other ADME properties of Ligand A are more favorable for a cardiovascular GPCR target.
Output:
1
2025-04-17 21:06:40,098 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (353.403 and 349.435 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (84.12) is well below the 140 threshold and good for oral absorption. Ligand B (98.14) is still acceptable, but closer to the limit.
3. **logP:** Ligand A (3.295) is optimal (1-3). Ligand B (0.477) is quite low, potentially hindering membrane permeability and absorption. This is a significant drawback.
4. **HBD:** Ligand A (1) is good. Ligand B (2) is also acceptable.
5. **HBA:** Both ligands (6) are within the acceptable limit of 10.
6. **QED:** Both ligands (0.73 and 0.746) are excellent, indicating good drug-like properties.
7. **DILI:** Ligand A (95.386) has a high DILI risk. Ligand B (39.201) is very good, indicating low liver injury potential. This is a major advantage for Ligand B.
8. **BBB:** Both ligands have moderate BBB penetration, but Ligand A (63.746) is slightly better than Ligand B (55.176). However, for a cardiovascular target like ADRB2, BBB penetration is not a primary concern.
9. **Caco-2:** Ligand A (-4.869) is better than Ligand B (-5.508), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-5.503) is better than Ligand B (-0.973), indicating better aqueous solubility.
11. **hERG:** Ligand A (0.544) has a slightly better hERG profile than Ligand B (0.098), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand A (90.33) has a higher microsomal clearance than Ligand B (7.218), meaning Ligand B is more metabolically stable. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand A (58.693) has a longer in vitro half-life than Ligand B (21.851). This is a positive for Ligand A.
14. **Pgp:** Ligand A (0.545) has lower P-gp efflux than Ligand B (0.007), suggesting better bioavailability.
15. **Binding Affinity:** Ligand A (-6.4) has a slightly better binding affinity than Ligand B (-5.8). However, the difference is less than 1.5 kcal/mol, so it's not a decisive factor.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A excels in affinity and Pgp, but suffers from a suboptimal logP. Ligand B has a very low logP, which is a major concern for permeability and oral bioavailability. However, it has a significantly better DILI score and metabolic stability (lower Cl_mic).
**Overall Assessment:**
While Ligand A has slightly better affinity and Pgp properties, the significantly lower logP of Ligand B is a major drawback. The superior DILI profile and metabolic stability of Ligand B are very attractive, and outweigh the slightly weaker binding affinity. The solubility of Ligand B is also a concern, but formulation strategies could potentially address this.
Output:
0
2025-04-17 21:06:40,098 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (360.401 and 373.507 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (67.87) is significantly better than Ligand B (79.8). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (1.36) is within the optimal range (1-3). Ligand B (3.324) is at the higher end, potentially leading to solubility issues or off-target interactions, but still acceptable.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (4) is better than Ligand B (7). Similar reasoning as HBD - lower is generally better for permeability.
6. **QED:** Both ligands have similar QED values (0.696 and 0.693), indicating good drug-likeness.
7. **DILI:** Ligand A (32.842) has a much lower DILI risk than Ligand B (79.333). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (90.694) has a higher BBB penetration score than Ligand B (74.913). While not a primary concern for a cardiovascular target, higher BBB is generally a positive attribute.
9. **Caco-2:** Ligand A (-4.818) and Ligand B (-5.224) have similar Caco-2 permeability values.
10. **Solubility:** Ligand A (-1.803) is better than Ligand B (-3.96). Higher solubility is always desirable.
11. **hERG:** Ligand A (0.447) has a lower hERG inhibition liability than Ligand B (0.728), reducing the risk of cardiotoxicity.
12. **Cl_mic:** Ligand A (-13.28) has a *much* lower microsomal clearance than Ligand B (52.314). This indicates significantly better metabolic stability for Ligand A.
13. **t1/2:** Ligand B (62.186) has a longer in vitro half-life than Ligand A (-2.955). This is a positive for Ligand B, but the negative value for Ligand A is concerning.
14. **Pgp:** Ligand A (0.025) has significantly lower P-gp efflux liability than Ligand B (0.246). This is favorable for bioavailability.
15. **Affinity:** Ligand B (-6.5 kcal/mol) has a stronger binding affinity than Ligand A (-4.7 kcal/mol). This is a 1.8 kcal/mol difference, which is substantial.
**Overall Assessment:**
Ligand B has a significantly better binding affinity, which is a critical factor for GPCR targets. However, Ligand A demonstrates a superior ADME profile across several key parameters: lower DILI risk, better solubility, lower hERG inhibition, much lower microsomal clearance (better metabolic stability), and lower P-gp efflux. The longer half-life of Ligand B is a plus, but the significantly improved metabolic stability of Ligand A is more important. Considering the balance, the improved ADME properties of Ligand A outweigh the affinity difference, making it a more promising drug candidate.
Output:
1
2025-04-17 21:06:40,098 - INFO - Batch 234 complete. Total preferences: 3744
2025-04-17 21:06:40,098 - INFO - Processing batch 235/512...
2025-04-17 21:07:29,812 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (363.483 and 346.475 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (92.5) is slightly higher than Ligand B (71.25). For a cardiovascular GPCR, TPSA isn't a *major* concern unless it's excessively high, and both are reasonable. Ligand B is better.
3. **logP:** Ligand B (2.506) is closer to the optimal 1-3 range than Ligand A (1.157). GPCRs generally benefit from moderate lipophilicity. Ligand B is better.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable. Ligand B is slightly better.
5. **HBA:** Ligand A (4) and Ligand B (5) are both acceptable. No clear advantage.
6. **QED:** Both ligands have good QED scores (0.679 and 0.746), indicating good drug-like properties. No clear advantage.
7. **DILI:** Ligand A (18.922) has a significantly lower DILI risk than Ligand B (23.885). This is a substantial advantage for Ligand A.
8. **BBB:** Both ligands have reasonable BBB penetration (Ligand A: 68.941, Ligand B: 62.699), but neither is exceptionally high. For a cardiovascular target, BBB penetration is less critical than for CNS targets.
9. **Caco-2:** Ligand A (-5.725) has a worse Caco-2 permeability than Ligand B (-4.864). Ligand B is better.
10. **Solubility:** Ligand A (-1.507) has a better solubility than Ligand B (-2.845). Ligand A is better.
11. **hERG:** Both ligands have very low hERG inhibition risk (Ligand A: 0.269, Ligand B: 0.181). No clear advantage.
12. **Cl_mic:** Ligand A (3.719) has a significantly lower microsomal clearance than Ligand B (36.473). This suggests better metabolic stability for Ligand A, a significant advantage.
13. **t1/2:** Ligand A (-19.85) has a much longer in vitro half-life than Ligand B (2.786). This is a major advantage for Ligand A, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have low P-gp efflux liability (Ligand A: 0.08, Ligand B: 0.213). No clear advantage.
15. **Binding Affinity:** Ligand A (-9.6) has a significantly stronger binding affinity than Ligand B (-7.2). This is a substantial advantage, potentially outweighing some minor ADME drawbacks.
**Overall Assessment:**
Ligand A demonstrates a superior binding affinity and significantly better metabolic stability (lower Cl_mic, longer t1/2). The lower DILI risk is also a major plus. While Ligand B has slightly better logP and Caco-2 permeability, the advantages of Ligand A are more substantial, particularly the binding affinity and metabolic properties. For a GPCR target like ADRB2, strong binding and reasonable metabolic stability are paramount.
Output:
1
2025-04-17 21:07:29,813 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (366.483 Da) and Ligand B (350.434 Da) are comparable.
2. **TPSA:** Ligand A (95.5) is slightly higher than Ligand B (49.85). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for permeability. Ligand B is significantly better here.
3. **logP:** Ligand A (-0.044) is a bit low, potentially hindering membrane permeability. Ligand B (2.642) is within the optimal range (1-3). This favors Ligand B.
4. **HBD:** Ligand A (3) is acceptable, while Ligand B (0) is even better, reducing potential for off-target interactions and improving permeability.
5. **HBA:** Both ligands have a reasonable number of HBA (Ligand A: 4, Ligand B: 3).
6. **QED:** Both ligands have good QED scores (Ligand A: 0.415, Ligand B: 0.688). Ligand B is better.
7. **DILI:** Ligand A (16.169) has a higher DILI risk than Ligand B (12.485). Lower is better, so Ligand B is preferred.
8. **BBB:** Ligand A (32.92) has a low BBB penetration, while Ligand B (90.772) has excellent BBB penetration. While ADRB2 isn't exclusively a CNS target, higher BBB penetration can be beneficial for overall distribution and potentially accessing peripheral ADRB2 receptors. Ligand B is much better.
9. **Caco-2:** Ligand A (-5.191) and Ligand B (-4.034) are both negative, which is unusual. This suggests poor permeability in this assay. However, the values are close.
10. **Solubility:** Ligand A (-2.242) and Ligand B (-2.004) are both poor. Solubility is a concern for both.
11. **hERG:** Both ligands have low hERG inhibition risk (Ligand A: 0.058, Ligand B: 0.557). Ligand A is slightly better.
12. **Cl_mic:** Ligand B (77.871) has a higher microsomal clearance than Ligand A (23.159), indicating faster metabolism and potentially lower *in vivo* exposure. Ligand A is preferred.
13. **t1/2:** Ligand A (-13.949) has a negative half-life, which is not possible. This is likely an error in the data. Ligand B (-12.047) also has a negative half-life, suggesting a data quality issue. However, we can assume that a lower negative value is better.
14. **Pgp:** Ligand A (0.006) has very low P-gp efflux, which is excellent. Ligand B (0.074) is also low, but slightly higher. Ligand A is preferred.
15. **Binding Affinity:** Both ligands have comparable binding affinities (Ligand A: -6.6 kcal/mol, Ligand B: -6.2 kcal/mol). Ligand A has a slight advantage.
**Overall Assessment & GPCR-Specific Priorities:**
For a cardiovascular GPCR like ADRB2, logP, TPSA, and Pgp efflux are important. Ligand B excels in logP and TPSA, and has good Pgp efflux. While Ligand A has a slightly better binding affinity and lower Cl_mic, the superior ADME properties of Ligand B, particularly the lower TPSA, better logP, and lower DILI risk, make it the more promising candidate. The BBB penetration is also a bonus. The negative half-life values are concerning, but the other parameters weigh more heavily in this decision.
**Output:**
0
2025-04-17 21:07:29,813 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.431 and 352.431 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (84.67) is slightly higher than Ligand B (76.15). Both are below the 140 threshold for oral absorption, and acceptable for a cardiovascular target (not requiring significant BBB penetration).
3. **logP:** Ligand A (1.774) and Ligand B (0.98) are both within the optimal 1-3 range. Ligand A is slightly preferred.
4. **HBD:** Ligand A (1) is better than Ligand B (0). Fewer HBDs generally improve permeability.
5. **HBA:** Both ligands have 5 HBA, which is acceptable.
6. **QED:** Ligand A (0.811) has a significantly higher QED score than Ligand B (0.639), indicating better overall drug-likeness.
7. **DILI:** Ligand B (33.656) has a lower DILI risk than Ligand A (38.658), making it slightly safer from a liver toxicity perspective.
8. **BBB:** Ligand A (85.731) has a higher BBB percentile than Ligand B (78.868). While ADRB2 is a cardiovascular target and doesn't *require* high BBB penetration, a moderate level isn't detrimental.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual. I will interpret this as very poor permeability.
10. **Solubility:** Ligand B (-0.95) has better solubility than Ligand A (-3.163). Solubility is important for bioavailability.
11. **hERG:** Both ligands have very low hERG risk (0.263 and 0.176 respectively).
12. **Cl_mic:** Ligand A (46.169) has a lower microsomal clearance than Ligand B (64.634), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-16.629) has a much longer in vitro half-life than Ligand A (-1.256). This is a significant advantage.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.287 and 0.04 respectively).
15. **Binding Affinity:** Ligand A (-7.3 kcal/mol) has a slightly better binding affinity than Ligand B (-6.6 kcal/mol). This 0.7 kcal/mol difference is substantial.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A is better on logP and significantly better on affinity. Ligand B is better on solubility and half-life. The affinity difference is the most important factor here.
**Overall Assessment:**
While Ligand B has advantages in solubility and half-life, Ligand A's superior binding affinity (-7.3 vs -6.6 kcal/mol) and better QED score outweigh these benefits. The slightly higher DILI risk for Ligand A is acceptable given the strong binding. The negative Caco-2 values are concerning for both, but the affinity difference is the primary driver here.
Output:
1
2025-04-17 21:07:29,813 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (354.411 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (59.08) is significantly better than Ligand A (110.61). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (1.632) is within the optimal range (1-3), while Ligand A (-0.049) is slightly below 1. This could potentially hinder membrane permeability for Ligand A.
4. **HBD:** Ligand A (2) is preferable to Ligand B (0). Having some HBD can improve solubility.
5. **HBA:** Ligand B (5) is preferable to Ligand A (7). Lower HBA is generally better for permeability.
6. **QED:** Both ligands have similar QED values (0.633 and 0.606), indicating good drug-likeness.
7. **DILI:** Ligand B (15.51) has a much lower DILI risk than Ligand A (60.566). This is a significant advantage for Ligand B.
8. **BBB:** Both ligands have good BBB penetration (75.107 and 76.696). This isn't a primary concern for a cardiovascular target, but it doesn't hurt.
9. **Caco-2:** Both ligands have similar, negative Caco-2 values, suggesting poor permeability.
10. **Solubility:** Ligand A (-0.962) is slightly better than Ligand B (-2.125), but both are poor.
11. **hERG:** Ligand A (0.056) has a slightly lower hERG risk than Ligand B (0.561), which is favorable.
12. **Cl_mic:** Ligand A (21.789) has a significantly lower microsomal clearance than Ligand B (50.762), indicating better metabolic stability.
13. **t1/2:** Ligand B (-3.175) has a negative half-life, which is problematic. Ligand A (12.277) has a reasonable half-life.
14. **Pgp:** Ligand B (0.072) has a lower P-gp efflux liability than Ligand A (0.01), which is favorable.
15. **Affinity:** Ligand A (-7.5) has a slightly better binding affinity than Ligand B (-4.5). This is a substantial difference.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP and Pgp, while Ligand A has a better affinity. TPSA is significantly better for Ligand B.
**Overall Assessment:**
While Ligand A has a better binding affinity and metabolic stability, Ligand B has a much lower DILI risk, better logP, and a lower Pgp efflux liability. The significantly lower DILI risk is a major advantage, and the better logP could translate to improved permeability despite the similar Caco-2 values. The negative half-life for Ligand B is a serious drawback. The affinity difference, while substantial, might be overcome with further optimization of Ligand B.
Considering the balance of properties and the importance of safety (DILI) and permeability (logP) for a cardiovascular drug, I favor Ligand B.
Output:
0
2025-04-17 21:07:29,813 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (376.909 Da) is slightly higher than Ligand B (359.455 Da), but both are acceptable.
2. **TPSA:** Ligand A (53.43) is significantly better than Ligand B (92.07). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption. Ligand B's TPSA is relatively high.
3. **logP:** Ligand A (4.087) is a bit high, potentially leading to solubility issues or off-target interactions. Ligand B (1.872) is within the optimal range.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Fewer hydrogen bond donors generally improve permeability.
5. **HBA:** Ligand A (4) is better than Ligand B (6). Lower HBA is generally preferred for permeability.
6. **QED:** Ligand A (0.855) is significantly better than Ligand B (0.626), indicating a more drug-like profile.
7. **DILI:** Both ligands have similar, moderately high DILI risk (Ligand A: 64.056, Ligand B: 64.986). This is a concern for both, but not a deciding factor between them.
8. **BBB:** Ligand A (70.531) is better than Ligand B (48.74). While not a primary concern for a cardiovascular target, higher BBB is generally favorable.
9. **Caco-2:** Ligand A (-4.512) is better than Ligand B (-5.4). Higher Caco-2 permeability is preferable.
10. **Solubility:** Ligand A (-5.287) is better than Ligand B (-2.181). Better solubility is important for bioavailability.
11. **hERG:** Ligand A (0.58) is significantly better than Ligand B (0.211). Lower hERG inhibition is critical to avoid cardiotoxicity, especially for a cardiovascular target.
12. **Cl_mic:** Ligand A (52.517) is much better than Ligand B (10.029). Lower microsomal clearance indicates greater metabolic stability, a significant advantage.
13. **t1/2:** Ligand B (85.188) has a substantially longer in vitro half-life than Ligand A (34.418). This is a strong point in favor of Ligand B.
14. **Pgp:** Ligand A (0.692) is better than Ligand B (0.205). Lower P-gp efflux is desirable.
15. **Affinity:** Ligand A (-7.3 kcal/mol) has a slightly better binding affinity than Ligand B (-6.5 kcal/mol). This difference is significant (0.8 kcal/mol), and a stronger binding affinity can often outweigh minor ADME drawbacks.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical ADME properties (TPSA, HBD, HBA, QED, Solubility, hERG, Cl_mic, Pgp) and has a slightly better binding affinity. While Ligand B has a longer half-life, the superior overall profile of Ligand A, particularly its lower hERG risk and better metabolic stability, makes it the more promising drug candidate for the ADRB2 receptor.
Output:
1
2025-04-17 21:07:29,813 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, the most important parameters are binding affinity, logP, TPSA, Pgp efflux, and BBB penetration.
Let's compare the ligands property by property:
1. **MW:** Both ligands (344.415 Da) are within the ideal range (200-500 Da).
2. **TPSA:** Ligand A (67.79) is significantly better than Ligand B (93.09). A lower TPSA is preferred for GPCRs to facilitate membrane permeability. Ligand B is bordering on being too high.
3. **logP:** Ligand A (1.096) is slightly better than Ligand B (0.468). Both are within the acceptable range (1-3), but Ligand A is closer to the optimal range.
4. **HBD/HBA:** Ligand A (0 HBD, 7 HBA) is preferable to Ligand B (2 HBD, 5 HBA). Lower HBD is generally preferred.
5. **QED:** Both ligands have good QED scores (A: 0.585, B: 0.671), indicating good drug-like properties.
6. **DILI:** Both ligands have acceptable DILI risk (A: 41.062, B: 38.852), with Ligand B being marginally better.
7. **BBB:** Ligand A (88.29) has a much higher BBB penetration percentile than Ligand B (62.97). While not a CNS target, some degree of BBB penetration can influence distribution and off-target effects.
8. **Caco-2:** Ligand A (-4.493) is better than Ligand B (-5.024), indicating better intestinal absorption.
9. **Solubility:** Ligand A (-2.61) is better than Ligand B (-1.725), indicating better aqueous solubility.
10. **hERG:** Both ligands have very low hERG inhibition risk (A: 0.413, B: 0.051), which is excellent. Ligand B is slightly better.
11. **Cl_mic:** Ligand B (22.478) has significantly lower microsomal clearance than Ligand A (61.003), suggesting better metabolic stability. This is a significant advantage for Ligand B.
12. **t1/2:** Ligand B (-11.11) has a longer in vitro half-life than Ligand A (-8.022), further supporting its better metabolic stability.
13. **Pgp:** Both ligands have low P-gp efflux liability (A: 0.047, B: 0.03), which is good.
14. **Binding Affinity:** Ligand B (-6.5 kcal/mol) has a slightly better binding affinity than Ligand A (-5.4 kcal/mol). This 1.1 kcal/mol difference is substantial and could outweigh some of the ADME drawbacks of Ligand B.
**Overall Assessment:**
Ligand B has a clear advantage in binding affinity and metabolic stability (lower Cl_mic and longer t1/2). While Ligand A has better TPSA and BBB penetration, the affinity difference is significant for a GPCR target. The slightly higher TPSA of Ligand B is not a dealbreaker, and its slightly lower solubility is less concerning than the metabolic liability of Ligand A.
Output:
0
2025-04-17 21:07:29,814 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [366.527, 67.43, 2.878, 2, 4, 0.661, 21.016, 75.572, -5.05, -2.765, 0.522, 74.801, 19.084, 0.175, -6.1]
**Ligand B:** [392.909, 112.81, 0.557, 2, 4, 0.665, 31.214, 81.698, -5.704, -2.818, 0.184, 2.677, -6.007, 0.024, -7.8]
**Step-by-step comparison:**
1. **MW:** Both are within the acceptable range (200-500 Da). Ligand A (366.527) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (67.43) is significantly better than Ligand B (112.81). For a GPCR, keeping TPSA low is good, though not as critical as for CNS targets.
3. **logP:** Ligand A (2.878) is optimal, while Ligand B (0.557) is quite low. Low logP can hinder membrane permeability.
4. **HBD/HBA:** Both have 2 HBD and 4 HBA, which are acceptable.
5. **QED:** Both have similar QED values (0.661 vs 0.665), indicating good drug-likeness.
6. **DILI:** Ligand A (21.016) has a much lower DILI risk than Ligand B (31.214), a significant advantage.
7. **BBB:** Ligand B (81.698) has slightly better BBB penetration than Ligand A (75.572), but both are reasonably good. This is less crucial for a non-CNS target like ADRB2, but still a consideration.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not defined, so it's difficult to interpret.
9. **Solubility:** Both have negative solubility values, which is also unusual. Again, the scale is undefined, making interpretation difficult.
10. **hERG:** Ligand A (0.522) has a slightly higher hERG risk than Ligand B (0.184), but both are relatively low.
11. **Cl_mic:** Ligand B (2.677) has significantly lower microsomal clearance than Ligand A (74.801), indicating better metabolic stability.
12. **t1/2:** Ligand A (19.084) has a longer in vitro half-life than Ligand B (-6.007). A negative half-life is not possible, so this is likely an error in the data. Assuming it is positive, Ligand A is better.
13. **Pgp:** Ligand A (0.175) has lower P-gp efflux than Ligand B (0.024), which is favorable for bioavailability.
14. **Affinity:** Ligand B (-7.8) has a significantly stronger binding affinity than Ligand A (-6.1). This is a substantial advantage (1.7 kcal/mol difference).
**GPCR-specific priorities:** For ADRB2 (a GPCR), we prioritize logP, Pgp, TPSA, and affinity. Ligand B excels in affinity, which is the most important factor. However, Ligand A has better logP, TPSA, DILI, and Pgp. The significantly higher affinity of Ligand B is likely to outweigh the drawbacks in logP and TPSA. The lower DILI risk of Ligand A is also a positive.
**Conclusion:**
Despite Ligand A's better ADME properties (logP, TPSA, DILI, Pgp), the substantially stronger binding affinity of Ligand B (-7.8 vs -6.1 kcal/mol) is a critical advantage for a GPCR target. The 1.7 kcal/mol difference is significant enough to overcome the slightly less favorable ADME profile of Ligand B.
Output:
0
2025-04-17 21:07:29,814 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [341.415, 90.98, 1.404, 2, 4, 0.831, 52.385, 29.934, -5.479, -2.048, 0.44, -19.716, -15.196, 0.026, -5.2]**
**Ligand B: [342.355, 120.25, 0.985, 4, 5, 0.532, 74.603, 11.206, -5.789, -3.153, 0.389, -2.949, 72.072, 0.045, -7.5]**
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). A is 341.415, B is 342.355 - very similar.
2. **TPSA:** Ligand A (90.98) is excellent, well below the 140 threshold and good for oral absorption. Ligand B (120.25) is still acceptable, but less ideal.
3. **logP:** Both ligands have good logP values (A: 1.404, B: 0.985), falling within the 1-3 range.
4. **H-Bond Donors:** Ligand A (2) and B (4) are both acceptable, but A is preferable.
5. **H-Bond Acceptors:** Ligand A (4) and B (5) are both acceptable, but A is preferable.
6. **QED:** Ligand A (0.831) has a better QED score than Ligand B (0.532), indicating a more drug-like profile.
7. **DILI:** Ligand A (52.385) has a significantly lower DILI risk than Ligand B (74.603). This is a major advantage for A.
8. **BBB:** Ligand A (29.934) has a better BBB penetration score than Ligand B (11.206). While ADRB2 isn't *strictly* a CNS target, some CNS exposure can be relevant, and lower BBB penetration is not detrimental.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability.
10. **Aqueous Solubility:** Both have negative solubility values, indicating poor solubility.
11. **hERG:** Both ligands have low hERG inhibition risk (A: 0.44, B: 0.389).
12. **Microsomal Clearance:** Ligand A (-19.716) has *much* lower microsomal clearance than Ligand B (-2.949), suggesting better metabolic stability.
13. **In vitro Half-Life:** Ligand A (-15.196) has a much longer in vitro half-life than Ligand B (72.072), indicating better stability.
14. **P-gp Efflux:** Both ligands have very low P-gp efflux liability (A: 0.026, B: 0.045).
15. **Binding Affinity:** Ligand B (-7.5) has a significantly stronger binding affinity than Ligand A (-5.2). This is a substantial advantage for B.
**GPCR-Specific Considerations:** For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Both ligands perform well on logP and Pgp. Ligand A has a better TPSA. The biggest difference is the affinity: Ligand B is significantly more potent. However, the substantial improvements in ADME properties (DILI, BBB, Clearance, Half-life) for Ligand A are very compelling, and can often outweigh a moderate difference in binding affinity, especially if the affinity is still in a reasonable range.
**Overall Assessment:**
While Ligand B has a better binding affinity, Ligand A demonstrates a significantly superior ADME profile, particularly regarding metabolic stability (clearance and half-life) and safety (DILI). The better TPSA and QED also contribute to its favorability. Given the importance of a balanced profile for drug development, Ligand A is the more promising candidate.
Output:
1
2025-04-17 21:07:29,814 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [344.455, 62.55, 3.081, 1, 3, 0.835, 37.456, 75.843, -4.891, -3.434, 0.304, 39.283, 14.548, 0.155, -6.7]
**Ligand B:** [346.471, 58.64, 2.243, 1, 3, 0.593, 11.128, 64.017, -4.77, -2.608, 0.4, -10.711, 10.908, 0.107, -2.9]
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). A: 344.455, B: 346.471 - very similar.
2. **TPSA:** Both are acceptable, but Ligand B (58.64) is better than Ligand A (62.55) as it is closer to the <90 threshold for GPCRs.
3. **logP:** Both are within the optimal range (1-3). Ligand B (2.243) is slightly better than Ligand A (3.081) as it is closer to the middle of the range.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Both have 3 HBA, which is good.
6. **QED:** Ligand A (0.835) has a significantly better QED score than Ligand B (0.593), indicating a more drug-like profile.
7. **DILI:** Ligand B (11.128) has a much lower DILI risk than Ligand A (37.456). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (75.843) has a better BBB penetration percentile than Ligand B (64.017), which is important for GPCRs.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual. Assuming these are percentile scores, both are very poor.
10. **Solubility:** Both have negative solubility values, which is also unusual. Assuming these are percentile scores, both are very poor.
11. **hERG:** Both have low hERG inhibition liability, which is good. Ligand B (0.4) is slightly better than Ligand A (0.304).
12. **Cl_mic:** Ligand B (-10.711) has a much lower (better) microsomal clearance than Ligand A (39.283), indicating better metabolic stability.
13. **t1/2:** Ligand B (10.908) has a slightly longer in vitro half-life than Ligand A (14.548).
14. **Pgp:** Both have low Pgp efflux liability, which is good. Ligand B (0.107) is slightly better than Ligand A (0.155).
15. **Affinity:** Ligand A (-6.7 kcal/mol) has a significantly stronger binding affinity than Ligand B (-2.9 kcal/mol). This is a substantial advantage for Ligand A.
**GPCR-specific priorities:** For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, BBB, and affinity.
**Overall Assessment:**
Ligand A has a much stronger binding affinity, a better QED score, and better BBB penetration. However, Ligand B has a significantly lower DILI risk and better metabolic stability (lower Cl_mic). The affinity difference is substantial (3.8 kcal/mol), which is a large advantage. While the Caco-2 and Solubility values are poor for both, the affinity advantage of Ligand A outweighs the other drawbacks.
Therefore, I prefer Ligand A.
Output:
1
2025-04-17 21:07:29,814 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (344.39 and 347.415 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (74.33) is significantly better than Ligand B (95.67). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is approaching a level that could hinder oral absorption.
3. **logP:** Ligand A (2.699) is optimal. Ligand B (0.899) is a bit low, potentially impacting membrane permeability.
4. **HBD:** Both ligands have 2 HBD, which is within the acceptable range.
5. **HBA:** Ligand A has 3 HBA, while Ligand B has 5. Both are acceptable, but Ligand A is slightly preferred.
6. **QED:** Ligand A (0.846) is better than Ligand B (0.746), indicating a more drug-like profile.
7. **DILI:** Ligand B (39.473) has a much lower DILI risk than Ligand A (58.744). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (75.029) has better BBB penetration than Ligand B (46.84). While ADRB2 isn't necessarily a CNS target, some peripheral ADRB2 activity can be modulated by CNS effects, and higher BBB penetration isn't detrimental.
9. **Caco-2:** Ligand A (-4.76) is significantly better than Ligand B (-5.065), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-3.135) is better than Ligand B (-1.2). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.648) has a slightly better hERG profile than Ligand B (0.085). Lower is better.
12. **Cl_mic:** Ligand B (4.959) has significantly lower microsomal clearance than Ligand A (51.747), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-12.354) has a much longer in vitro half-life than Ligand A (44.359), which is a significant advantage.
14. **Pgp:** Ligand A (0.063) has lower P-gp efflux than Ligand B (0.027), suggesting better bioavailability and potentially better CNS exposure.
15. **Binding Affinity:** Ligand B (-6.3 kcal/mol) has a significantly stronger binding affinity than Ligand A (-4.1 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME drawbacks of Ligand B.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, and affinity. Ligand A has better logP, TPSA, and Pgp, but Ligand B has a much better affinity. The affinity difference is substantial (-6.3 vs -4.1). The lower DILI and longer half-life of Ligand B are also very attractive.
**Overall Assessment:**
While Ligand A has a better overall ADME profile (better solubility, slightly better hERG, better BBB), the significantly stronger binding affinity of Ligand B (-6.3 kcal/mol vs -4.1 kcal/mol) is a decisive factor. The improved metabolic stability (lower Cl_mic, longer t1/2) and lower DILI risk of Ligand B further strengthen its position. The slightly lower logP and higher TPSA are acceptable trade-offs for the substantial gain in potency and improved safety profile.
Output:
0
2025-04-17 21:07:29,814 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 drug candidates. ADRB2 is a GPCR, so we'll prioritize logP, Pgp, TPSA, and affinity, alongside general drug-like properties.
**Ligand A:** [349.431, 71.44, 0.887, 0, 5, 0.61, 35.712, 73.866, -4.492, -2.258, 0.363, 40.201, -4.036, 0.163, -5.8]
**Ligand B:** [347.463, 79.26, 0.463, 2, 5, 0.603, 19.349, 33.734, -5.194, -1.461, 0.204, 6.847, 13.629, 0.015, -6.1]
**1. Molecular Weight:** Both are within the ideal range (200-500 Da). A is 349.431, B is 347.463. Very similar.
**2. TPSA:** A (71.44) is better than B (79.26). Both are acceptable for a non-CNS GPCR, but lower is generally preferred.
**3. logP:** A (0.887) is slightly higher than B (0.463). While both are within the optimal range (1-3), A is closer to the sweet spot.
**4. H-Bond Donors:** A (0) is better than B (2). Fewer HBDs generally improve permeability.
**5. H-Bond Acceptors:** Both are equal at 5, which is good.
**6. QED:** Both are very similar (A: 0.61, B: 0.603), indicating good drug-like properties.
**7. DILI:** A (35.712) is significantly higher than B (19.349). This is a major concern for Ligand A. Lower DILI is *critical*.
**8. BBB:** A (73.866) is much better than B (33.734). However, for ADRB2, which is primarily a cardiovascular target, BBB penetration isn't a high priority.
**9. Caco-2:** A (-4.492) is worse than B (-5.194). Lower values suggest poorer permeability.
**10. Solubility:** A (-2.258) is worse than B (-1.461). Solubility is important for bioavailability.
**11. hERG:** Both are very low (A: 0.363, B: 0.204), indicating low cardiotoxicity risk. B is slightly better.
**12. Cl_mic:** A (40.201) is much better than B (6.847). Higher metabolic stability is desirable.
**13. t1/2:** A (-4.036) is much better than B (13.629). Longer half-life is generally preferred.
**14. Pgp:** A (0.163) is much better than B (0.015). Lower P-gp efflux is favorable for bioavailability.
**15. Affinity:** B (-6.1) is slightly better than A (-5.8), but the difference is relatively small.
**Overall Assessment:**
Ligand B has a significantly better safety profile (DILI) and better solubility and Caco-2 permeability. While Ligand A has advantages in metabolic stability (Cl_mic, t1/2) and P-gp efflux, the higher DILI risk is a major red flag. The small advantage in affinity for Ligand B is also a plus. For a cardiovascular target like ADRB2, metabolic stability and P-gp are less critical than avoiding liver toxicity.
Therefore, I would choose Ligand B.
0
2025-04-17 21:07:29,815 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (366.527 Da and 348.491 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Both ligands have TPSA values around 58-59 A2, well below the 140 A2 threshold for good oral absorption and suitable for a non-CNS GPCR target like ADRB2.
**3. logP:** Both ligands have logP values between 2.2 and 2.7, which is optimal for permeability and solubility.
**4. H-Bond Donors:** Ligand A has 1 HBD, while Ligand B has 0. Both are acceptable, staying within the recommended limit of 5.
**5. H-Bond Acceptors:** Both ligands have 4 HBAs, well within the acceptable limit of 10.
**6. QED:** Ligand A (0.783) has a slightly better QED score than Ligand B (0.645), suggesting a more drug-like profile.
**7. DILI:** Both ligands have low DILI risk (32.183 and 29.624 percentile), which is favorable. Ligand B is marginally better.
**8. BBB:** Both ligands have reasonable BBB penetration (74.254 and 81.543 percentile), but this is less crucial for a cardiovascular target like ADRB2. Ligand B is slightly better.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, these values can be misleading and require experimental validation.
**10. Aqueous Solubility:** Both ligands have negative solubility values, indicating poor aqueous solubility. This is a concern, but can be addressed through formulation strategies. Ligand B is slightly better.
**11. hERG Inhibition:** Ligand A (0.465) has a lower hERG inhibition risk than Ligand B (0.772), which is a significant advantage for cardiovascular drugs.
**12. Microsomal Clearance:** Ligand B has a significantly higher microsomal clearance (87.781 mL/min/kg) than Ligand A (51.806 mL/min/kg), indicating faster metabolism and potentially lower in vivo exposure.
**13. In vitro Half-Life:** Ligand B has a much longer in vitro half-life (25.214 hours) than Ligand A (4.732 hours). This is a significant advantage, potentially allowing for less frequent dosing.
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (0.137 and 0.588), which is good. Ligand A is slightly better.
**15. Binding Affinity:** Ligand B (-6.4 kcal/mol) has a slightly better binding affinity than Ligand A (-6.1 kcal/mol). This difference of 0.3 kcal/mol is not huge, but can be relevant.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), and the general drug-like properties, Ligand B appears to be the more promising candidate. The longer half-life and slightly better binding affinity outweigh the slightly higher hERG risk and lower QED. The better BBB penetration is a bonus, although less critical for a cardiovascular target. The solubility and Caco-2 permeability are concerns for both, but can potentially be addressed with formulation.
Output:
0
2025-04-17 21:07:29,815 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A:** [342.443, 69.3, 2.122, 1, 3, 0.915, 34.548, 55.332, -5.113, -3.092, 0.388, 29.397, -9.619, 0.072, -5]
**Ligand B:** [349.435, 79.7, -0.047, 1, 6, 0.806, 29.236, 60.45, -4.753, -0.533, 0.31, 9.273, 9.741, 0.032, -7.4]
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). A is 342.443 and B is 349.435. No significant difference here.
**2. TPSA:** Ligand A (69.3) is better than Ligand B (79.7). ADRB2 is a cardiovascular target, so CNS penetration is not a primary concern, but lower TPSA generally correlates with better absorption.
**3. logP:** Ligand A (2.122) is within the optimal range (1-3). Ligand B (-0.047) is slightly below 1, which could indicate permeability issues. This is a significant negative for Ligand B.
**4. H-Bond Donors:** Both have 1 HBD, which is good.
**5. H-Bond Acceptors:** Ligand A has 3 HBA, and Ligand B has 6. Ligand A is preferable.
**6. QED:** Ligand A (0.915) is better than Ligand B (0.806), indicating a more drug-like profile.
**7. DILI:** Ligand A (34.548) has a slightly higher DILI risk than Ligand B (29.236), but both are below the 40% threshold and are acceptable.
**8. BBB:** Not a high priority for a cardiovascular target. Ligand B (60.45) is slightly better than Ligand A (55.332).
**9. Caco-2:** Ligand A (-5.113) is worse than Ligand B (-4.753). This suggests lower intestinal absorption for Ligand A.
**10. Solubility:** Ligand A (-3.092) is worse than Ligand B (-0.533). Solubility is important for bioavailability.
**11. hERG:** Both ligands have very low hERG risk (0.388 and 0.31, respectively).
**12. Cl_mic:** Ligand A (29.397) has lower microsomal clearance than Ligand B (9.273), indicating better metabolic stability.
**13. t1/2:** Ligand A (-9.619) has a longer in vitro half-life than Ligand B (9.741), which is desirable.
**14. Pgp:** Ligand A (0.072) has lower P-gp efflux than Ligand B (0.032), which is preferable.
**15. Binding Affinity:** Ligand B (-7.4) has a significantly stronger binding affinity than Ligand A (-5). This is a substantial advantage, potentially outweighing some ADME concerns.
**Overall Assessment:**
Ligand B has a much better binding affinity, which is the most crucial factor for a GPCR target. While Ligand B's logP is suboptimal, the strong binding could compensate. Ligand A has better ADME properties in several areas (TPSA, QED, Cl_mic, t1/2, Pgp), but the affinity difference is significant. The slightly better solubility of Ligand B also helps. Considering the GPCR-specific priorities (affinity is paramount), Ligand B is the more promising candidate.
Output:
0
2025-04-17 21:07:29,815 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.5 and 346.5 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (52.65) is better than Ligand B (58.64). Both are under the 140 threshold for oral absorption, but lower TPSA is generally preferred for GPCRs, aiding permeability.
3. **logP:** Both ligands (2.41 and 2.29) are within the optimal 1-3 range. Very similar.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Both have 3 HBA, which is good.
6. **QED:** Ligand A (0.793) has a significantly better QED score than Ligand B (0.437), indicating a more drug-like profile. This is a substantial advantage.
7. **DILI:** Ligand A (5.74) has a much lower DILI risk than Ligand B (23.46). This is a major advantage, as liver toxicity is a common issue in drug development.
8. **BBB:** Ligand A (80.57) has a slightly better BBB penetration percentile than Ligand B (75.11). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant for off-target effects and overall safety assessment.
9. **Caco-2:** Ligand A (-4.63) is slightly better than Ligand B (-5.06) indicating better intestinal absorption.
10. **Solubility:** Ligand A (-2.66) is better than Ligand B (-1.97). Better solubility is generally desirable for bioavailability.
11. **hERG:** Ligand A (0.76) has a slightly better hERG profile than Ligand B (0.36), suggesting lower cardiotoxicity risk.
12. **Cl_mic:** Ligand A (18.45) has significantly lower microsomal clearance than Ligand B (39.88), indicating better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand A (9.38) has a slightly better in vitro half-life than Ligand B (0.97).
14. **Pgp:** Ligand A (0.16) has a slightly better Pgp efflux profile than Ligand B (0.14).
15. **Binding Affinity:** Ligand A (-6.8) has a slightly better binding affinity than Ligand B (-6.0). While both are strong binders, the 0.8 kcal/mol difference is noticeable.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most crucial ADME-Tox properties (QED, DILI, Cl_mic, Solubility, hERG) and has a slightly better binding affinity. While both ligands are within acceptable ranges for MW, logP, HBD, and HBA, the superior ADME profile and lower toxicity risk of Ligand A make it the more promising drug candidate. The slightly better BBB penetration is a bonus.
Output:
1
2025-04-17 21:07:29,815 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**1. Molecular Weight:** Both ligands (350.503 Da and 344.455 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Both ligands have TPSA values below 60, well under the 140 A^2 threshold for good oral absorption. This is good for both.
**3. logP:** Both ligands have logP values between 2.35 and 2.57, which is optimal (1-3). No significant difference.
**4. H-Bond Donors:** Both ligands have 1 HBD, which is within the acceptable limit of <=5.
**5. H-Bond Acceptors:** Both ligands have 3 HBA, which is within the acceptable limit of <=10.
**6. QED:** Ligand A (0.833) has a slightly higher QED than Ligand B (0.753), suggesting a more drug-like profile.
**7. DILI:** Ligand B (24.661) has a lower DILI risk than Ligand A (15.743), which is a significant advantage. Lower DILI is always preferred.
**8. BBB:** Both ligands have good BBB penetration (64.87% and 69.407%), but Ligand B is slightly better. For a cardiovascular target like ADRB2, BBB penetration isn't *critical*, but it's a bonus if there's potential for off-target CNS effects.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, indicating poor permeability. However, Ligand B (-4.794) is slightly worse than Ligand A (-4.489).
**10. Aqueous Solubility:** Both ligands have negative solubility values, indicating poor solubility. Ligand B (-2.819) is worse than Ligand A (-2.13).
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (0.306 and 0.183). Ligand B is slightly better.
**12. Microsomal Clearance:** Ligand B (36.769) has significantly higher microsomal clearance than Ligand A (20.389), indicating faster metabolism and potentially lower *in vivo* exposure. This is a disadvantage for Ligand B.
**13. In vitro Half-Life:** Ligand B (1.37) has a slightly longer half-life than Ligand A (0.967), which is a minor advantage.
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (0.132 and 0.11). No significant difference.
**15. Binding Affinity:** Ligand B (-8.0 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.6 kcal/mol). This is a >1.5 kcal/mol advantage, which is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
The most critical factor here is the binding affinity. Ligand B's significantly stronger binding (-8.0 kcal/mol vs -6.6 kcal/mol) is a major advantage. While Ligand B has slightly worse Caco-2 and solubility, and higher clearance, the superior affinity is likely to be more impactful. The lower DILI risk of Ligand B is also a positive. Given that ADRB2 is a cardiovascular target, strong potency is paramount.
Output:
0
2025-04-17 21:07:29,815 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (349.387) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (114.87) is better than Ligand B (45.23). For a GPCR, lower TPSA is generally preferred for better brain penetration, even though ADRB2 isn't strictly a CNS target.
3. **logP:** Ligand B (3.919) is better than Ligand A (0.292). A logP between 1-3 is optimal, and Ligand B falls within this range, while Ligand A is too low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1), but both are acceptable.
5. **HBA:** Ligand A (5) is higher than Ligand B (4), but both are within the acceptable range.
6. **QED:** Ligand B (0.873) is significantly better than Ligand A (0.465), indicating a more drug-like profile.
7. **DILI:** Ligand B (24.04) is better than Ligand A (29.081), suggesting lower potential for liver injury.
8. **BBB:** Ligand B (91.314) is much better than Ligand A (72.16), even though ADRB2 isn't a primary CNS target, better BBB penetration can reduce off-target effects.
9. **Caco-2:** Ligand A (-5.642) is better than Ligand B (-4.862), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-1.834) is better than Ligand B (-3.721), which is important for formulation and bioavailability.
11. **hERG:** Ligand A (0.118) is better than Ligand B (0.683), indicating a lower risk of cardiotoxicity, which is *critical* for a cardiovascular target.
12. **Cl_mic:** Ligand A (17.832) is better than Ligand B (23.744), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-1.619) is better than Ligand A (6.935), indicating a longer half-life.
14. **Pgp:** Ligand A (0.025) is much better than Ligand B (0.449), indicating lower P-glycoprotein efflux.
15. **Binding Affinity:** Ligand B (-8.0) is significantly better than Ligand A (-5.0), representing a substantial advantage in potency.
**Overall Assessment:**
Ligand B has a significantly better binding affinity (-8.0 kcal/mol vs -5.0 kcal/mol), a better QED score, lower DILI risk, better BBB penetration, and a longer half-life. While Ligand A has advantages in solubility, Caco-2 permeability, and hERG inhibition, the superior affinity of Ligand B, combined with its more favorable ADME properties (QED, DILI, BBB, t1/2), outweigh these drawbacks. The difference in binding affinity is large enough to overcome the slightly higher hERG risk of Ligand B. Given that this is targeting a cardiovascular GPCR, the hERG risk needs to be carefully considered, but the substantial potency advantage of Ligand B is compelling.
Output:
0
2025-04-17 21:07:29,816 - INFO - Batch 235 complete. Total preferences: 3760
2025-04-17 21:07:29,816 - INFO - Processing batch 236/512...
2025-04-17 21:08:18,256 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [346.515, 40.62, 3.916, 0, 2, 0.444, 16.983, 90.074, -4.721, -3.76, 0.674, 69.854, 4.666, 0.778, -5.7]
**Ligand B:** [463.3, 55.63, 4.649, 1, 6, 0.355, 91.043, 56.378, -4.665, -5.789, 0.788, 105.279, 32.043, 0.796, -3.6]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity, and BBB):
1. **MW:** Ligand A (346.5) is better, falling nicely within the 200-500 Da range. Ligand B (463.3) is at the upper limit, potentially impacting permeability.
2. **TPSA:** Ligand A (40.62) is significantly better, well below the 140 threshold for oral absorption. Ligand B (55.63) is higher, but still acceptable.
3. **logP:** Both are good (A: 3.916, B: 4.649), falling within the 1-3 optimal range, though B is slightly higher.
4. **HBD/HBA:** Ligand A (0/2) is preferable, minimizing potential issues with both solubility and permeability. Ligand B (1/6) is higher.
5. **QED:** Ligand A (0.444) is slightly better than Ligand B (0.355), indicating a more drug-like profile.
6. **DILI:** Ligand A (16.983) is *much* better, indicating a significantly lower risk of liver injury. Ligand B (91.043) is very high risk.
7. **BBB:** Ligand A (90.074) is excellent, suggesting good potential for crossing the blood-brain barrier (though not necessarily desired for peripheral ADRB2 targeting, it's not a negative). Ligand B (56.378) is lower.
8. **Caco-2:** Both are negative, indicating poor permeability. This is a concern for both.
9. **Solubility:** Both are negative, indicating poor solubility. This is a concern for both.
10. **hERG:** Both are low risk (A: 0.674, B: 0.788).
11. **Cl_mic:** Ligand A (69.854) has a lower clearance, suggesting better metabolic stability. Ligand B (105.279) is higher.
12. **t1/2:** Ligand A (4.666) has a shorter half-life than Ligand B (32.043).
13. **Pgp:** Both are low efflux (A: 0.778, B: 0.796).
14. **Affinity:** Ligand A (-5.7) has a significantly better binding affinity than Ligand B (-3.6), a difference of 2.1 kcal/mol. This is a substantial advantage.
**Overall Assessment:**
Ligand A is the clear winner. While both compounds have issues with Caco-2 and solubility, Ligand A excels in crucial areas: significantly better DILI risk, superior binding affinity, better TPSA, better metabolic stability (lower Cl_mic), and a more favorable QED score. The higher BBB penetration of Ligand A is a bonus. The affinity difference is large enough to outweigh the longer half-life of Ligand B.
Output:
1
2025-04-17 21:08:18,256 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [351.535, 52.65, 2.796, 1, 3, 0.616, 6.049, 66.925, -4.906, -1.5, 0.858, 16.278, -9.829, 0.248, -5.1]
**Ligand B:** [349.391, 137.07, -0.336, 4, 6, 0.507, 51.144, 18.845, -5.842, -1.682, 0.018, 1.382, -29.124, 0.023, -5.4]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Very similar.
2. **TPSA:** Ligand A (52.65) is excellent, well below the 140 threshold and good for GPCRs. Ligand B (137.07) is higher but still acceptable, though less ideal.
3. **logP:** Ligand A (2.796) is optimal (1-3). Ligand B (-0.336) is too low, potentially hindering permeability. This is a significant drawback.
4. **HBD:** Ligand A (1) is good. Ligand B (4) is higher, potentially impacting permeability.
5. **HBA:** Ligand A (3) is good. Ligand B (6) is higher, potentially impacting permeability.
6. **QED:** Both are reasonable (A: 0.616, B: 0.507), indicating drug-like properties.
7. **DILI:** Ligand A (6.049) is very good, low risk. Ligand B (51.144) is higher, indicating a moderate risk of liver injury.
8. **BBB:** Ligand A (66.925) is acceptable, though not exceptionally high. Ligand B (18.845) is quite low, suggesting poor brain penetration. While not critical for a cardiovascular target, it's a negative.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-4.906) is slightly better than Ligand B (-5.842).
10. **Solubility:** Both are negative, indicating poor solubility. Ligand A (-1.5) is slightly better than Ligand B (-1.682).
11. **hERG:** Both are low (A: 0.858, B: 0.018), indicating low cardiotoxicity risk. Ligand B is slightly better.
12. **Cl_mic:** Ligand A (16.278) is higher than Ligand B (1.382), indicating faster clearance and lower metabolic stability. This is a negative for Ligand A.
13. **t1/2:** Ligand B (-29.124) has a significantly longer half-life than Ligand A (-9.829). This is a major advantage for Ligand B.
14. **Pgp:** Ligand A (0.248) has lower P-gp efflux than Ligand B (0.023), which is preferable.
15. **Affinity:** Both have similar binding affinities (A: -5.1, B: -5.4). The difference is minimal.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, and Pgp are important. Ligand A excels in TPSA and Pgp, while Ligand B has a problematic logP. The longer half-life of Ligand B is also a significant advantage.
**Overall Assessment:**
While Ligand A has a better TPSA and Pgp profile, the significantly lower logP of Ligand B, combined with its substantially longer half-life and acceptable DILI risk, outweigh the advantages of Ligand A. The poor permeability of both is a concern, but can be addressed with formulation strategies. The low logP of Ligand B is a more fundamental issue.
Output:
1
2025-04-17 21:08:18,257 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (348.407) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are reasonably low (A: 106.15, B: 104.53), suggesting good potential for oral absorption. They are both below the 140 threshold.
3. **logP:** Ligand A (0.188) is very low, potentially hindering membrane permeability. Ligand B (0.044) is also low, but slightly better. This is a concern for both, but more so for A.
4. **HBD/HBA:** Ligand A (HBD=1, HBA=7) and Ligand B (HBD=2, HBA=7) are both within acceptable ranges.
5. **QED:** Both have good QED scores (A: 0.73, B: 0.66), indicating drug-like properties.
6. **DILI:** Ligand A (42.536) has a better DILI score than Ligand B (53.47), suggesting lower liver toxicity risk.
7. **BBB:** Ligand A (32.803) has a lower BBB penetration score than Ligand B (51.958). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be useful for understanding off-target effects and overall distribution.
8. **Caco-2:** Both have negative Caco-2 values (-5.431 and -5.292). This is unusual and suggests very poor permeability.
9. **Solubility:** Ligand A (-0.56) has slightly better solubility than Ligand B (-1.479).
10. **hERG:** Both have very low hERG inhibition risk (A: 0.021, B: 0.134).
11. **Cl_mic:** Ligand B (-25.659) has significantly lower (better) microsomal clearance than Ligand A (6.525), indicating better metabolic stability.
12. **t1/2:** Ligand B (-4.099) has a slightly better in vitro half-life than Ligand A (26.157).
13. **Pgp:** Ligand A (0.012) has a much lower P-gp efflux liability than Ligand B (0.023), which is favorable for bioavailability.
14. **Binding Affinity:** Ligand B (-7.5 kcal/mol) has a significantly stronger binding affinity than Ligand A (-4.9 kcal/mol). This is a substantial difference.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand B is better regarding affinity and Pgp efflux, and has a slightly better logP. Ligand A has better DILI and Pgp efflux. However, the substantial affinity difference of Ligand B outweighs the other factors. The negative Caco-2 values for both are concerning, but the stronger binding of Ligand B suggests it might overcome this permeability issue with further optimization.
**Conclusion:**
Despite the low logP and negative Caco-2 values for both, the significantly stronger binding affinity of Ligand B makes it the more promising candidate. The better metabolic stability (lower Cl_mic) and half-life also contribute to its favorability.
Output:
0
2025-04-17 21:08:18,257 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (371.415 and 364.559 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (121.4) is slightly higher than Ligand B (58.12). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for permeability. Ligand B is significantly better.
3. **logP:** Ligand A (1.643) is within the optimal range (1-3), while Ligand B (3.792) is approaching the upper limit. While not a deal-breaker, a logP closer to 2 is generally preferred for balance. Ligand A is better.
4. **HBD:** Ligand A (0) has no H-bond donors, which is good for permeability. Ligand B (1) has one, which is acceptable. Ligand A is slightly better.
5. **HBA:** Ligand A (8) is higher than Ligand B (5). Lower HBA is generally preferred for permeability. Ligand B is better.
6. **QED:** Ligand B (0.8) has a significantly higher QED score than Ligand A (0.438), indicating a more drug-like profile. Ligand B is much better.
7. **DILI:** Ligand A (73.982) has a higher DILI risk than Ligand B (51.299). Lower DILI is crucial. Ligand B is better.
8. **BBB:** Both have reasonably high BBB penetration, but Ligand B (87.864) is significantly higher than Ligand A (76.735). While ADRB2 isn't strictly a CNS target, some brain penetration can be beneficial or at least needs to be considered for off-target effects. Ligand B is better.
9. **Caco-2:** Both are negative (-5.112 and -5.119), indicating poor permeability. This is a concern for both, but doesn't differentiate them.
10. **Solubility:** Both have negative solubility values (-2.884 and -3.997), indicating poor aqueous solubility. This is a significant drawback for both. Ligand B is slightly better.
11. **hERG:** Ligand A (0.129) has a much lower hERG risk than Ligand B (0.628). This is a critical safety parameter, and Ligand A is significantly better.
12. **Cl_mic:** Ligand B (92.872) has a much higher microsomal clearance than Ligand A (9.959), indicating lower metabolic stability. Ligand A is significantly better.
13. **t1/2:** Ligand A (16.714) has a shorter half-life than Ligand B (28.644). Longer half-life is generally preferred, so Ligand B is better.
14. **Pgp:** Ligand A (0.234) has lower P-gp efflux than Ligand B (0.714). Lower efflux is preferred for better bioavailability. Ligand A is better.
15. **Binding Affinity:** Ligand B (-7.5) has a slightly better binding affinity than Ligand A (-7.3). This difference is relatively small (0.2 kcal/mol).
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), and the general drug-like properties, Ligand A emerges as the more promising candidate. While Ligand B has a slightly better affinity and QED, Ligand A demonstrates significantly better metabolic stability (lower Cl_mic), lower hERG risk, and lower P-gp efflux. The poor Caco-2 and solubility are concerns for both, but the safety and PK advantages of Ligand A outweigh the small affinity difference.
Output:
1
2025-04-17 21:08:18,257 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (368.5 and 356.5 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand B (84.91) is significantly better than Ligand A (105.46). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (0.267) is quite low, potentially hindering membrane permeability. Ligand B (0.064) is also low, but slightly better. Both are below the optimal 1-3 range.
4. **HBD:** Both ligands have 3 HBD, which is acceptable.
5. **HBA:** Ligand B (5) is better than Ligand A (6). Lower HBA is generally preferred for permeability.
6. **QED:** Ligand B (0.482) is slightly better than Ligand A (0.398), indicating a marginally more drug-like profile.
7. **DILI:** Ligand B (4.033) has a much lower DILI risk than Ligand A (9.694). This is a significant advantage for Ligand B.
8. **BBB:** Both ligands have low BBB penetration (30.2 and 32.5). This isn't a major concern for a cardiovascular target.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.674 and -5.462), which is unusual and suggests poor permeability.
10. **Solubility:** Both ligands have negative solubility values (-1.518 and -0.495), suggesting poor aqueous solubility.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.255 and 0.213). This is good.
12. **Cl_mic:** Ligand A (15.038) has lower microsomal clearance than Ligand B (20.165), indicating better metabolic stability.
13. **t1/2:** Ligand B (-5.804) has a significantly longer in vitro half-life than Ligand A (-0.372). This is a major advantage.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.016 and 0.002).
15. **Binding Affinity:** Ligand B (-6.6 kcal/mol) has a significantly stronger binding affinity than Ligand A (-4.5 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME concerns.
**Overall Assessment & GPCR Priorities:**
For a GPCR like ADRB2, binding affinity is crucial. Ligand B's -6.6 kcal/mol is substantially better than Ligand A's -4.5 kcal/mol. The lower DILI risk and longer half-life of Ligand B are also significant positives. While both ligands have poor logP and Caco-2 values, the strong affinity of Ligand B makes it more likely to be optimized to overcome these issues. The TPSA is also better for Ligand B.
Output:
0
2025-04-17 21:08:18,257 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (366.824 and 363.483 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (60.25) is significantly better than Ligand B (88.16). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B's TPSA is approaching a level that could hinder oral absorption.
**3. logP:** Both ligands have good logP values (2.96 and 2.067), falling within the optimal 1-3 range. Ligand A is slightly higher, which could be advantageous for membrane permeability.
**4. H-Bond Donors:** Ligand A has 0 HBD, which is excellent. Ligand B has 2, still acceptable but less ideal.
**5. H-Bond Acceptors:** Ligand A has 5 HBA, and Ligand B has 4, both are within the acceptable range of <=10.
**6. QED:** Ligand B (0.776) has a better QED score than Ligand A (0.532), indicating a more generally drug-like profile.
**7. DILI:** Ligand B (59.519) has a lower DILI risk than Ligand A (65.839), which is a positive.
**8. BBB:** Ligand A (81.233) has a significantly higher BBB penetration percentile than Ligand B (59.364). While ADRB2 is a cardiovascular target, some CNS effects are possible with certain ligands, and higher BBB penetration could be a benefit or a concern depending on the desired profile.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.339 and -4.97), which is unusual and suggests poor permeability. However, the values are very close.
**10. Aqueous Solubility:** Both ligands have negative solubility values (-2.838 and -3.131), indicating poor aqueous solubility. This is a significant concern for both.
**11. hERG Inhibition:** Ligand A (0.328) has a slightly higher hERG inhibition risk than Ligand B (0.154), which is unfavorable.
**12. Microsomal Clearance:** Ligand B (45.235) has a lower microsomal clearance than Ligand A (73.705), suggesting better metabolic stability.
**13. In vitro Half-Life:** Ligand B (-48.83) has a *negative* half-life, which is impossible and indicates a significant issue with the data or the compound itself. Ligand A (21.85) has a reasonable half-life.
**14. P-gp Efflux:** Ligand A (0.381) has a slightly higher P-gp efflux liability than Ligand B (0.071), which is unfavorable.
**15. Binding Affinity:** Ligand A (-7.3 kcal/mol) has a significantly stronger binding affinity than Ligand B (-5.7 kcal/mol). This is a substantial difference and a major advantage for Ligand A.
**Overall Assessment:**
Despite Ligand B's better QED, DILI, and lower P-gp efflux, the negative in vitro half-life is a showstopper. It indicates a fundamental problem with the compound. Ligand A, while having some drawbacks (higher DILI, higher hERG, higher P-gp), has a much stronger binding affinity and a plausible half-life. The TPSA is also more favorable. Given the importance of potency for GPCRs, and the severity of the half-life issue with Ligand B, I would prioritize Ligand A. The solubility issues of both compounds would need to be addressed through formulation strategies.
Output:
1
2025-04-17 21:08:18,257 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (342.414 Da and 352.45 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (43.78) is significantly better than Ligand B (69.64). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is getting a bit high, potentially hindering absorption.
**3. logP:** Both ligands have acceptable logP values (2.934 and 1.783, respectively), falling within the 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability, but not drastically.
**4. H-Bond Donors:** Ligand A (1) is better than Ligand B (2). Fewer HBDs generally improve permeability.
**5. H-Bond Acceptors:** Both ligands have the same number of HBA (3), which is well within the acceptable limit of 10.
**6. QED:** Both ligands have good QED scores (0.933 and 0.81), indicating good drug-like properties.
**7. DILI Risk:** Ligand A (47.654) has a considerably lower DILI risk than Ligand B (11.361). This is a major advantage for Ligand A.
**8. BBB Penetration:** Ligand A (71.462) has better BBB penetration than Ligand B (51.881). While ADRB2 is a cardiovascular target, some CNS effects are possible with certain ligands, and higher BBB penetration could be a benefit or a concern depending on the desired profile.
**9. Caco-2 Permeability:** Ligand A (-4.381) is better than Ligand B (-4.884). Higher values indicate better intestinal absorption.
**10. Aqueous Solubility:** Ligand A (-1.726) is better than Ligand B (-2.538). Better solubility is generally preferred.
**11. hERG Inhibition:** Ligand A (0.897) has a slightly higher hERG risk than Ligand B (0.362). This is a negative for Ligand A, but the value is still relatively low.
**12. Microsomal Clearance:** Ligand A (-12.725) has significantly lower microsomal clearance than Ligand B (5.726), suggesting better metabolic stability.
**13. In vitro Half-Life:** Both ligands have similar in vitro half-lives (11.247 and 11.174 hours).
**14. P-gp Efflux:** Ligand A (0.454) has lower P-gp efflux than Ligand B (0.053), which is favorable for bioavailability.
**15. Binding Affinity:** Ligand B (-6.6 kcal/mol) has a significantly stronger binding affinity than Ligand A (-4.1 kcal/mol). This is a substantial advantage for Ligand B. A difference of 2.5 kcal/mol is significant.
**Overall Assessment:**
While Ligand B has a superior binding affinity, Ligand A demonstrates a much more favorable ADME-Tox profile. Specifically, the lower DILI risk, better BBB penetration, lower P-gp efflux, and improved metabolic stability (lower Cl_mic) are highly desirable. The slightly higher hERG risk for Ligand A is a concern, but manageable given the overall profile. The difference in binding affinity, while substantial, can potentially be addressed through further optimization of Ligand A. For a cardiovascular GPCR, a balanced profile with good safety and pharmacokinetic properties is crucial, and Ligand A offers that.
Output:
1
2025-04-17 21:08:18,258 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [353.373, 83.02, 1.714, 2, 4, 0.795, 43.117, 66.615, -4.921, -2.267, 0.679, 11.526, -2.886, 0.071, -5.6]
**Ligand B:** [369.849, 76.82, 0.98, 1, 6, 0.809, 35.983, 70.997, -4.778, -2.918, 0.362, 49.325, 36.566, 0.122, -6.6]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (353.373) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are good, below the 140 A^2 threshold for oral absorption. Ligand B (76.82) is slightly better than Ligand A (83.02).
3. **logP:** Both are within the optimal range (1-3). Ligand B (0.98) is a bit lower, while Ligand A (1.714) is better positioned.
4. **HBD:** Both are acceptable (<=5). Ligand B (1) is slightly better.
5. **HBA:** Ligand A (4) is better than Ligand B (6).
6. **QED:** Both are good (>0.5), with Ligand B (0.809) being slightly better.
7. **DILI:** Both are relatively low risk, but Ligand B (35.983) is significantly better than Ligand A (43.117).
8. **BBB:** Both have acceptable BBB penetration, but Ligand B (70.997) is better than Ligand A (66.615). While ADRB2 is not strictly a CNS target, some degree of BBB penetration can be useful.
9. **Caco-2:** Both are negative, indicating poor permeability.
10. **Solubility:** Both are negative, indicating poor solubility.
11. **hERG:** Both are low risk, but Ligand B (0.362) is better than Ligand A (0.679).
12. **Cl_mic:** Ligand A (11.526) has a significantly lower clearance than Ligand B (49.325), suggesting better metabolic stability.
13. **t1/2:** Ligand B (36.566) has a much longer half-life than Ligand A (-2.886).
14. **Pgp:** Ligand A (0.071) has lower P-gp efflux than Ligand B (0.122).
15. **Binding Affinity:** Ligand B (-6.6 kcal/mol) has a stronger binding affinity than Ligand A (-5.6 kcal/mol). This is a substantial difference (1 kcal/mol), which is a significant advantage.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are particularly important. Ligand B has a slightly better logP, better Pgp efflux, and a significantly better binding affinity. While Ligand A has better metabolic stability, the affinity difference is substantial enough to outweigh this benefit.
**Conclusion:**
Considering the balance of properties, and prioritizing binding affinity and ADME properties relevant to GPCRs, **Ligand B** appears to be the more promising drug candidate.
**Output:**
0
2025-04-17 21:08:18,258 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (380.539) is slightly higher than Ligand B (330.395), but both are acceptable.
2. **TPSA:** Both are below the 140 A^2 threshold for good oral absorption. Ligand A (76.88) and Ligand B (69.38) are both good.
3. **logP:** Both ligands have logP values within the optimal range (1-3). Ligand A (2.939) is slightly better than Ligand B (3.506) as it's closer to the center of the range.
4. **HBD:** Ligand A (1) is better than Ligand B (0). Having at least one HBD can aid solubility.
5. **HBA:** Ligand A (7) and Ligand B (6) are both acceptable, below the 10 threshold.
6. **QED:** Ligand A (0.747) has a significantly better QED score than Ligand B (0.562), indicating a more drug-like profile.
7. **DILI:** Ligand B (77.588) has a higher DILI risk than Ligand A (61.497). Ligand A is preferable here.
8. **BBB:** Ligand A (62.156) has a better BBB penetration percentile than Ligand B (57.076). While ADRB2 isn't exclusively a CNS target, some CNS exposure can occur, making this a slight advantage for A.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. Ligand B (-5.062) is slightly better than Ligand A (-5.695), but both are concerning.
10. **Solubility:** Both ligands have negative solubility values, indicating poor solubility. Ligand B (-3.605) is slightly better than Ligand A (-2.56), but both are concerning.
11. **hERG:** Both ligands have low hERG inhibition liability (0.367 and 0.46, respectively), which is good.
12. **Cl_mic:** Ligand A (9.447) has a significantly lower microsomal clearance than Ligand B (16.194), suggesting better metabolic stability.
13. **t1/2:** Ligand A (63.791) has a much longer in vitro half-life than Ligand B (-32.191). This is a significant advantage for Ligand A.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.279 and 0.246, respectively), which is good.
15. **Binding Affinity:** Ligand B (-7.6 kcal/mol) has a slightly better binding affinity than Ligand A (-6.7 kcal/mol). This is a 0.9 kcal/mol difference, which is substantial.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are crucial. While Ligand B has a slightly better affinity, Ligand A excels in several other critical areas: QED, DILI risk, metabolic stability (Cl_mic and t1/2), and BBB penetration. The improved ADME properties of Ligand A, combined with acceptable affinity, make it a more promising candidate. The slightly better affinity of Ligand B isn't enough to overcome the significant drawbacks in ADME.
**Conclusion:**
Ligand A is the more viable drug candidate.
Output:
1
2025-04-17 21:08:18,258 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (351.447 and 342.443 Da) fall comfortably within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (78.95) is slightly higher than Ligand B (70.25). Both are below the 140 threshold for good oral absorption, and acceptable for a cardiovascular target (not necessarily CNS). Ligand B is slightly favored.
3. **logP:** Ligand A (0.243) is quite low, potentially hindering membrane permeability. Ligand B (2.241) is much better, falling within the optimal 1-3 range. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2) as lower HBDs generally improve permeability.
5. **HBA:** Both ligands have 4 HBA, which is within the acceptable range.
6. **QED:** Both ligands have good QED scores (0.736 and 0.894), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (17.836) has a lower DILI risk than Ligand B (11.749), which is a positive.
8. **BBB:** Ligand A (70.919) and Ligand B (82.319) both have acceptable BBB penetration, but Ligand B is better. Since ADRB2 is a cardiovascular target, BBB penetration isn't a primary concern, but it's still a bonus.
9. **Caco-2:** Ligand A (-4.531) and Ligand B (-5.022) both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A is slightly better.
10. **Solubility:** Ligand A (-1.765) and Ligand B (-2.317) both have poor solubility.
11. **hERG:** Ligand A (0.283) has a lower hERG risk than Ligand B (0.741), which is a significant advantage.
12. **Cl_mic:** Ligand A (9.424) has a lower microsomal clearance than Ligand B (8.217), indicating better metabolic stability.
13. **t1/2:** Ligand A (0.918) has a shorter half-life than Ligand B (-1.245). This is a disadvantage for Ligand A.
14. **Pgp:** Ligand A (0.013) has significantly lower P-gp efflux than Ligand B (0.026), which is a positive.
15. **Binding Affinity:** Ligand B (-6.6 kcal/mol) has a slightly better binding affinity than Ligand A (-5.9 kcal/mol). The difference is 0.7 kcal/mol, which is significant enough to consider.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP and has slightly better affinity. Ligand A has a lower Pgp efflux, which is a positive, but the poor logP is a major drawback.
**Overall Assessment:**
While Ligand A has advantages in DILI, hERG, and Pgp, the significantly lower logP and poor Caco-2 permeability are major concerns. Ligand B, despite slightly higher DILI and hERG risk, has a much more favorable logP, better affinity, and acceptable BBB penetration. The improved logP is likely to translate to better absorption and overall *in vivo* performance.
Output:
0
2025-04-17 21:08:18,258 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [366.893, 86.88, 2.903, 3, 3, 0.693, 61.962, 64.482, -5.188, -4.517, 0.313, 33.691, 29.222, 0.367, -6.0]
**Ligand B:** [405.3, 83.9, 2.698, 1, 6, 0.68, 57.774, 83.715, -5.177, -2.897, 0.565, 66.402, 32.451, 0.105, -6.9]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity) and general guidelines:
1. **MW:** Ligand A (366.893 Da) is better than Ligand B (405.3 Da), falling comfortably within the 200-500 range.
2. **TPSA:** Both are good (A: 86.88, B: 83.9), well below the 140 threshold for oral absorption.
3. **logP:** Both are excellent (A: 2.903, B: 2.698), within the optimal 1-3 range.
4. **HBD/HBA:** Ligand A (3 HBD, 3 HBA) is slightly better than Ligand B (1 HBD, 6 HBA). Lower HBA is generally preferred.
5. **QED:** Both are similar and acceptable (A: 0.693, B: 0.68).
6. **DILI:** Ligand B (57.774) is better than Ligand A (61.962), indicating a lower risk of liver injury. This is a significant advantage.
7. **BBB:** Ligand B (83.715) is significantly better than Ligand A (64.482). While not a CNS target, some BBB penetration can be beneficial for distribution.
8. **Caco-2:** Both are poor (-5.188 and -5.177). This is a concern for both, suggesting limited intestinal absorption.
9. **Solubility:** Ligand B (-2.897) is better than Ligand A (-4.517). Better solubility is always preferred.
10. **hERG:** Ligand A (0.313) is better than Ligand B (0.565), indicating a lower risk of cardiotoxicity. This is crucial for a cardiovascular target.
11. **Cl_mic:** Ligand A (33.691) is better than Ligand B (66.402), suggesting better metabolic stability.
12. **t1/2:** Ligand B (32.451) is better than Ligand A (29.222), suggesting a longer half-life.
13. **Pgp:** Ligand A (0.367) is better than Ligand B (0.105), indicating lower P-gp efflux.
14. **Affinity:** Ligand B (-6.9 kcal/mol) is *significantly* better than Ligand A (-6.0 kcal/mol). This >1.5 kcal/mol difference is a major advantage, potentially outweighing some ADME concerns.
**Overall Assessment:**
Ligand B has a significantly better binding affinity, a lower DILI risk, better solubility, and a longer half-life. While Ligand A has better hERG inhibition and Pgp efflux, the affinity difference is substantial. The improved ADME properties of Ligand B, particularly the lower DILI and better solubility, are also important. The Caco-2 permeability is poor for both, which would need to be addressed in further optimization, but the stronger binding of Ligand B makes it a more promising starting point.
Output:
0
2025-04-17 21:08:18,258 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the acceptable range (200-500 Da). Ligand A (343.515 Da) is slightly preferred due to being closer to the ideal range.
**2. TPSA:** Ligand A (35.58) is significantly better than Ligand B (71.25). For a GPCR, lower TPSA generally improves permeability and is favorable. Ligand B is quite high and could present absorption challenges.
**3. logP:** Both ligands have logP values within the optimal range (1-3), with Ligand A (2.603) being slightly more optimal than Ligand B (3.906). Ligand B is approaching the upper limit, which could lead to solubility issues.
**4. H-Bond Donors & Acceptors:** Ligand A (HBD=1, HBA=3) is better than Ligand B (HBD=2, HBA=5). Lower values are generally preferred for better permeability.
**5. QED:** Ligand A (0.862) has a higher QED score than Ligand B (0.726), indicating a more drug-like profile.
**6. DILI Risk:** Ligand A (2.637) has a much lower DILI risk than Ligand B (61.613). This is a significant advantage for Ligand A.
**7. BBB Penetration:** Both ligands have good BBB penetration (Ligand A: 80.962, Ligand B: 81.815). This is less critical for a cardiovascular target like ADRB2, but still a positive attribute.
**8. Caco-2 Permeability:** Both have negative Caco-2 values, which is unusual and suggests a potential issue with the experimental setup or data quality. However, the magnitude of the negative value is smaller for Ligand A (-5.086) than for Ligand B (-4.828), suggesting potentially better permeability.
**9. Aqueous Solubility:** Ligand A (-1.805) has better solubility than Ligand B (-4.454).
**10. hERG Inhibition:** Both ligands have low hERG inhibition risk (Ligand A: 0.923, Ligand B: 0.84).
**11. Microsomal Clearance:** Ligand A (-2.235) has a much lower (better) microsomal clearance than Ligand B (30.065), indicating greater metabolic stability.
**12. In vitro Half-Life:** Ligand A (-12.896) has a significantly longer in vitro half-life than Ligand B (6.487).
**13. P-gp Efflux:** Both ligands have low P-gp efflux (Ligand A: 0.118, Ligand B: 0.641), which is good.
**14. Binding Affinity:** Ligand B (-7.4 kcal/mol) has a slightly better binding affinity than Ligand A (-6.5 kcal/mol). While affinity is crucial, the difference of 0.9 kcal/mol is not large enough to outweigh the numerous advantages of Ligand A.
**Overall Assessment:**
Ligand A demonstrates a significantly better overall profile, particularly regarding ADME properties (DILI, clearance, half-life, solubility, TPSA) and drug-likeness (QED). While Ligand B has a slightly better binding affinity, the other advantages of Ligand A make it the more promising drug candidate for the ADRB2 receptor.
Output:
1
2025-04-17 21:08:18,258 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (359.83 & 343.40 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (29.54) is significantly better than Ligand B (71.09). ADRB2 is not a CNS target, but lower TPSA generally improves absorption. Ligand A is well below the 140 threshold, while B is approaching it.
3. **logP:** Both ligands have good logP values (4.48 & 3.31), falling within the 1-3 range. Ligand A is slightly higher, which *could* be a minor concern for solubility, but not a dealbreaker.
4. **HBD/HBA:** Ligand A (0 HBD, 2 HBA) is preferable to Ligand B (2 HBD, 3 HBA). Fewer H-bonds generally improve membrane permeability.
5. **QED:** Both ligands have similar and acceptable QED values (0.805 & 0.845).
6. **DILI:** Ligand A (67.43%) has a slightly higher DILI risk than Ligand B (61.30%), but both are acceptable (below 60 is good, these are both moderate risk).
7. **BBB:** Not a primary concern for ADRB2 (cardiovascular target). Ligand A (88.99%) has higher BBB penetration than Ligand B (73.52%), but this is less important.
8. **Caco-2:** Both ligands have negative Caco-2 values (-4.57 & -4.713). This is unusual and suggests poor permeability. However, the values are very similar.
9. **Solubility:** Ligand A (-5.243) has slightly worse solubility than Ligand B (-3.364), but both are poor. Solubility is a concern for both.
10. **hERG:** Both ligands have low hERG inhibition risk (0.796 & 0.771).
11. **Cl_mic:** Ligand A (93.20) has significantly higher microsomal clearance than Ligand B (40.17). This indicates lower metabolic stability for Ligand A, a significant drawback.
12. **t1/2:** Ligand B (33.48 hours) has a much longer in vitro half-life than Ligand A (13.77 hours). This is a major advantage for Ligand B.
13. **Pgp:** Both ligands have low P-gp efflux liability (0.847 & 0.353). Ligand B is better.
14. **Binding Affinity:** Ligand B (-7.3 kcal/mol) has a slightly better binding affinity than Ligand A (-7.0 kcal/mol). While the difference is small, it's still a positive for Ligand B.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand A has a better logP and TPSA, but Ligand B has better affinity and Pgp efflux. The biggest differentiator is metabolic stability (Cl_mic and t1/2), where Ligand B is significantly superior.
**Conclusion:**
While Ligand A has slightly better TPSA, the significantly improved metabolic stability (lower Cl_mic, longer t1/2) and slightly better binding affinity of Ligand B outweigh this advantage. The poor Caco-2 values are concerning for both, but the metabolic profile is a critical factor for *in vivo* efficacy.
Output:
0
2025-04-17 21:08:18,259 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (361.433 and 362.539 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (64.09) is higher than Ligand B (49.41). For a cardiovascular GPCR, TPSA is moderately important. Ligand B is better here, being closer to the preferred <90 range.
3. **logP:** Ligand B (3.989) is higher than Ligand A (0.794). While logP > 4 can be problematic, 3.989 is pushing the upper limit but still acceptable. Ligand A's logP is quite low, potentially hindering membrane permeability. This is a significant advantage for Ligand B.
4. **HBD:** Both ligands have 1 HBD, which is within the acceptable limit of <=5.
5. **HBA:** Ligand A has 4 HBAs, and Ligand B has 3. Both are within the acceptable limit of <=10.
6. **QED:** Both ligands have good QED scores (0.787 and 0.832, respectively), indicating good drug-like properties.
7. **DILI:** Ligand A (10.857) has a much lower DILI risk than Ligand B (39.201). This is a substantial advantage for Ligand A.
8. **BBB:** Both ligands have good BBB penetration (72.16 and 74.952, respectively). This is less critical for a cardiovascular target, but still positive.
9. **Caco-2:** Both ligands have similar negative Caco-2 values (-4.64 and -4.616). This suggests poor permeability, but the values are very close.
10. **Solubility:** Ligand A (-0.384) has better aqueous solubility than Ligand B (-4.105). This is beneficial for formulation and bioavailability.
11. **hERG:** Ligand A (0.598) has a lower hERG risk than Ligand B (0.248). Lower is better, so Ligand A is preferable.
12. **Cl_mic:** Ligand A (-7.139) has a significantly lower (better) microsomal clearance than Ligand B (63.311). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (-20.961) has a longer in vitro half-life than Ligand B (30.948). This is a positive for Ligand A.
14. **Pgp:** Ligand A (0.029) has much lower P-gp efflux liability than Ligand B (0.31). Lower is better, so Ligand A is preferable.
15. **Binding Affinity:** Ligand B (-7.1) has slightly better binding affinity than Ligand A (-6.3). While a 1.5 kcal/mol advantage is often significant, the other ADME properties of Ligand A are much more favorable.
**Overall Assessment:**
Ligand A demonstrates a significantly better ADME profile, with lower DILI risk, better metabolic stability (lower Cl_mic, longer t1/2), lower P-gp efflux, and better solubility. While Ligand B has a slightly better binding affinity and logP, the ADME advantages of Ligand A are more critical for overall drug development success, especially considering the potential for cardiovascular side effects. The lower logP of Ligand A is a concern, but the other benefits outweigh this drawback.
Output:
1
2025-04-17 21:08:18,259 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.39 and 352.43 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand B (76.15) is significantly better than Ligand A (138.59). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have similar logP values (0.658 and 0.775), both are a bit low, but acceptable.
4. **HBD:** Ligand A has 4 HBD, Ligand B has 0. Lower HBD is generally preferred for permeability, giving a slight edge to Ligand B.
5. **HBA:** Ligand A has 4 HBA, Ligand B has 5. These are both acceptable.
6. **QED:** Ligand B (0.66) is slightly better than Ligand A (0.511), indicating a more drug-like profile.
7. **DILI:** Ligand B (34.59%) has a much lower DILI risk than Ligand A (52.15%). This is a significant advantage for Ligand B.
8. **BBB:** Ligand B (72.97%) has a higher BBB penetration than Ligand A (50.87%). While not crucial for a cardiovascular target, it's a positive.
9. **Caco-2:** Ligand A (-5.764) is worse than Ligand B (-4.496). Lower (more negative) values indicate poorer permeability.
10. **Solubility:** Ligand A (-2.689) is worse than Ligand B (-1.019). Lower values indicate poorer solubility.
11. **hERG:** Both ligands have very low hERG risk (0.053). No significant difference.
12. **Cl_mic:** Ligand B (-2.418) has a significantly *lower* (better) microsomal clearance than Ligand A (8.529). This suggests better metabolic stability for Ligand B.
13. **t1/2:** Ligand B (5.135) has a longer in vitro half-life than Ligand A (-13.389). This is a significant advantage.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.01 and 0.044). No significant difference.
15. **Binding Affinity:** Ligand A (-6.6 kcal/mol) has a slightly better binding affinity than Ligand B (-5.0 kcal/mol). This is a 1.6 kcal/mol difference, which is significant.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity, Ligand B demonstrates a significantly more favorable ADMET profile. The lower DILI risk, better metabolic stability (lower Cl_mic, longer t1/2), improved solubility, and better Caco-2 permeability of Ligand B outweigh the small difference in binding affinity. For a GPCR target like ADRB2, a balanced profile is crucial, and Ligand B presents a much more promising starting point for optimization.
Output:
0
2025-04-17 21:08:18,259 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (377.941 Da and 378.495 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (46.4) is significantly better than Ligand B (107.1). For a GPCR, lower TPSA is generally preferred for better permeability, and Ligand A is well below the 140 threshold. Ligand B is pushing the limit and could have absorption issues.
**3. logP:** Ligand A (3.941) is within the optimal 1-3 range, while Ligand B (-0.901) is below 1, which could hinder membrane permeability. This is a substantial advantage for Ligand A.
**4. H-Bond Donors:** Both have 1 HBD, which is good.
**5. H-Bond Acceptors:** Ligand A has 4 HBA, and Ligand B has 5. Both are acceptable, but lower is slightly preferred.
**6. QED:** Ligand A (0.82) has a better QED score than Ligand B (0.53), indicating a more drug-like profile.
**7. DILI:** Both ligands have acceptable DILI risk (Ligand A: 30.903, Ligand B: 39.046), with Ligand A being slightly better.
**8. BBB:** Ligand A (82.009) shows better BBB penetration potential than Ligand B (51.842). While ADRB2 is a cardiovascular target and CNS penetration isn't *essential*, some level of BBB penetration can be beneficial for off-target effects assessment and potential broader applications.
**9. Caco-2 Permeability:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
**10. Aqueous Solubility:** Both have negative solubility values, which is also unusual. Again, the scale is not specified.
**11. hERG Inhibition:** Ligand A (0.627) has a lower hERG inhibition risk than Ligand B (0.167). This is a crucial safety parameter, and Ligand A is significantly better.
**12. Microsomal Clearance:** Ligand A (50.497) has a higher (worse) microsomal clearance than Ligand B (42.771), suggesting lower metabolic stability.
**13. In vitro Half-Life:** Ligand B (-45.584) has a much longer in vitro half-life than Ligand A (-0.546). This is a significant advantage for Ligand B.
**14. P-gp Efflux:** Ligand A (0.607) has lower P-gp efflux than Ligand B (0.006), which is favorable for bioavailability.
**15. Binding Affinity:** Ligand B (-6.7) has a slightly better binding affinity than Ligand A (-6.3), but the difference is less than 1.5 kcal/mol.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand A is the stronger candidate. Its superior logP, TPSA, QED, BBB, and hERG profile outweigh the slightly better affinity and half-life of Ligand B. The poor solubility and permeability values are concerning for both, but the other ADME properties of Ligand A are more favorable. The difference in binding affinity is not large enough to overcome the significant advantages Ligand A has in other critical parameters.
Output:
1
2025-04-17 21:08:18,259 - INFO - Batch 236 complete. Total preferences: 3776
2025-04-17 21:08:18,259 - INFO - Processing batch 237/512...
2025-04-17 21:09:07,036 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (379.819 and 386.949 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (54.88) is significantly better than Ligand B (74.33). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary goal, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (4.621) is a bit high, potentially leading to solubility issues, but still within a reasonable range. Ligand B (2.545) is excellent. This favors Ligand B.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD is generally better for permeability.
5. **HBA:** Ligand A (4) is preferable to Ligand B (5). Lower HBA is generally better for permeability.
6. **QED:** Both ligands (0.719 and 0.684) are above the 0.5 threshold, indicating good drug-likeness. No strong preference.
7. **DILI:** Ligand A (86.002) has a significantly higher DILI risk than Ligand B (32.532). This is a major concern for Ligand A.
8. **BBB:** Not a primary concern for a cardiovascular target, but Ligand A (71.229) is slightly better than Ligand B (64.482).
9. **Caco-2:** Ligand A (-4.671) is worse than Ligand B (-5.209). Lower values are less desirable.
10. **Solubility:** Ligand B (-2.159) is much better than Ligand A (-5.603). This is crucial, especially given Ligand A's higher logP.
11. **hERG:** Both are low (0.512 and 0.492), indicating low cardiotoxicity risk. No strong preference.
12. **Cl_mic:** Ligand B (20.234) has significantly lower microsomal clearance than Ligand A (49.927), suggesting better metabolic stability.
13. **t1/2:** Ligand A (76.768) has a longer half-life than Ligand B (32.539). This is a plus for Ligand A.
14. **Pgp:** Both are low (0.629 and 0.1), indicating low P-gp efflux. No strong preference.
15. **Binding Affinity:** Ligand A (-7.0) has slightly better binding affinity than Ligand B (-5.6). However, the difference is not huge enough to overcome the other significant drawbacks of Ligand A.
**Overall Assessment:**
Ligand A has a slightly better affinity and half-life, but suffers from significantly higher DILI risk, worse solubility, and higher metabolic clearance. Ligand B has a more favorable ADME profile, with lower DILI risk, better solubility, and better metabolic stability. The slightly lower affinity of Ligand B is acceptable given its superior safety and pharmacokinetic properties. Given the GPCR-specific priorities (logP, TPSA, Pgp), Ligand B is the better candidate.
Output:
0
2025-04-17 21:09:07,037 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (341.371 and 347.39 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand B (75.87) is significantly better than Ligand A (109.8), falling well below the 140 threshold for good oral absorption and closer to the 90 threshold desirable for GPCRs.
3. **logP:** Ligand B (1.155) is within the optimal 1-3 range, while Ligand A (0.095) is slightly below 1, potentially hindering permeation. This favors Ligand B.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable, being less than 5.
5. **HBA:** Ligand A (5) and Ligand B (4) are both acceptable, being less than 10.
6. **QED:** Both ligands have good QED scores (0.726 and 0.657), indicating good drug-like properties.
7. **DILI:** Ligand B (72.703) has a higher DILI risk than Ligand A (58.86), which is less desirable.
8. **BBB:** Ligand B (84.955) has a much higher BBB penetration percentile than Ligand A (44.901). Given that ADRB2 is a GPCR, BBB penetration is a relevant consideration, favoring Ligand B.
9. **Caco-2:** Ligand A (-5.569) and Ligand B (-4.765) are both negative, which is unusual. However, the scale is not specified, so it's difficult to interpret.
10. **Solubility:** Both ligands have very poor aqueous solubility (-2.387 and -2.372). This is a concern for both, but not a differentiating factor.
11. **hERG:** Ligand B (0.553) has a higher hERG inhibition liability than Ligand A (0.121), which is less desirable.
12. **Cl_mic:** Ligand A (-19.148) has a significantly lower (better) microsomal clearance than Ligand B (39.799), indicating better metabolic stability.
13. **t1/2:** Ligand B (-25.463) has a much longer in vitro half-life than Ligand A (-0.865), which is a significant advantage.
14. **Pgp:** Ligand A (0.012) has a much lower P-gp efflux liability than Ligand B (0.135), which is favorable.
15. **Binding Affinity:** Ligand B (-7.0) has a slightly better binding affinity than Ligand A (-6.3), which is a significant advantage.
**Overall Assessment:**
Ligand B demonstrates a superior profile for a GPCR target like ADRB2. Its better TPSA, logP, and BBB penetration are particularly important. The longer half-life and stronger binding affinity also contribute significantly. While its DILI and hERG risks are higher, and Pgp efflux is higher, the benefits in terms of permeability, CNS exposure, and potency outweigh these drawbacks. Ligand A has better metabolic stability and lower efflux, but the poor logP and BBB penetration are major concerns.
Output:
0
2025-04-17 21:09:07,037 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (371.459 Da) is within the ideal range (200-500 Da). Ligand B (407.36 Da) is also acceptable. No clear advantage here.
2. **TPSA:** Ligand A (89.99) is excellent, well below the 140 threshold for oral absorption. Ligand B (59.73) is also very good. Slight advantage to B.
3. **logP:** Ligand A (0.599) is a bit low, potentially hindering permeability. Ligand B (3.759) is within the optimal range (1-3). Significant advantage to B.
4. **HBD:** Ligand A (1) is good. Ligand B (0) is also good. No significant difference.
5. **HBA:** Ligand A (7) is good. Ligand B (6) is also good. No significant difference.
6. **QED:** Both Ligand A (0.673) and Ligand B (0.73) are above the 0.5 threshold, indicating good drug-likeness. Slight advantage to B.
7. **DILI:** Ligand A (55.525) is better than Ligand B (29.74), indicating a lower risk of drug-induced liver injury. Advantage to A.
8. **BBB:** Ligand A (53.587) is not particularly high. Ligand B (85.072) is very good, suggesting better potential for CNS penetration if desired (though ADRB2 is primarily cardiovascular, some CNS effects can be relevant). Significant advantage to B.
9. **Caco-2:** Both are negative, indicating poor permeability. No clear advantage.
10. **Solubility:** Ligand A (-1.143) is very poor. Ligand B (-3.544) is also poor, but slightly better. Slight advantage to B.
11. **hERG:** Ligand A (0.124) is very low risk. Ligand B (0.484) is also low risk. No significant difference.
12. **Cl_mic:** Ligand A (21.035) is better (lower clearance) than Ligand B (41.765), indicating better metabolic stability. Advantage to A.
13. **t1/2:** Ligand A (-1.352) is very poor. Ligand B (17.701) is good. Significant advantage to B.
14. **Pgp:** Ligand A (0.021) is very low efflux, which is good. Ligand B (0.484) is also low efflux. No significant difference.
15. **Affinity:** Ligand B (-7.3 kcal/mol) has a significantly stronger binding affinity than Ligand A (-4.9 kcal/mol). This is a substantial advantage, exceeding the 1.5 kcal/mol threshold.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are particularly important. Ligand B excels in logP, TPSA, and *especially* affinity. While BBB isn't the primary concern for a cardiovascular target, a higher BBB value isn't detrimental.
**Overall Assessment:**
Ligand B has a superior binding affinity, better logP, better BBB penetration, and a longer half-life. While Ligand A has a slightly better DILI score and metabolic stability, the substantial advantage in binding affinity and overall ADME profile of Ligand B outweighs these benefits. The poor solubility of both compounds is a concern that would need to be addressed in formulation, but the potency advantage of B is likely to be more impactful.
Output:
0
2025-04-17 21:09:07,037 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (369.491 and 361.467 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (92.51) is slightly higher than Ligand B (80.32). Both are acceptable for a non-CNS GPCR target like ADRB2, being under 140, but Ligand B is preferable.
3. **logP:** Ligand B (2.086) is better positioned within the optimal 1-3 range than Ligand A (0.584), which is quite low and may indicate poor membrane permeability. This is a significant advantage for Ligand B.
4. **HBD:** Both ligands have 2 HBD, which is within the acceptable limit of 5.
5. **HBA:** Ligand A has 7 HBA, while Ligand B has 5. Both are under the 10 limit, but Ligand B is slightly better.
6. **QED:** Both ligands have similar QED values (0.731 and 0.679), indicating good drug-likeness.
7. **DILI:** Ligand A (40.946) has a slightly better DILI score than Ligand B (50.485), indicating a lower risk of liver injury.
8. **BBB:** Both ligands have similar BBB penetration (52.617 and 52.811), which isn't a primary concern for ADRB2, a non-CNS target.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.325 and -5.355), which is unusual and suggests very poor permeability. This is a significant concern for both.
10. **Solubility:** Both ligands have very poor aqueous solubility (-1.285 and -1.97). This is a major drawback for both.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.253 and 0.263), which is excellent.
12. **Cl_mic:** Ligand A (-15.361) has significantly lower (better) microsomal clearance than Ligand B (-30.322), suggesting better metabolic stability.
13. **t1/2:** Ligand A (32.459 hours) has a slightly longer half-life than Ligand B (29.815 hours), which is preferable.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.014 and 0.094), which is good.
15. **Binding Affinity:** Ligand B (-7.1 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.8 kcal/mol). This >1.5 kcal/mol advantage is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
While both ligands have significant issues with Caco-2 permeability and solubility, Ligand B is the stronger candidate. The superior logP, and most importantly, the significantly better binding affinity (-7.1 vs -6.8 kcal/mol) are decisive. The slightly higher DILI risk for Ligand B is a concern, but the potency advantage is likely to be more impactful in driving efficacy. The better metabolic stability of Ligand A is a plus, but the affinity difference is more critical for a GPCR target.
Output:
0
2025-04-17 21:09:07,037 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (363.53 & 362.54 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (70.23) is higher than Ligand B (49.41). For a cardiovascular GPCR, TPSA isn't a *major* concern unless it's excessively high, but lower is generally preferred for better permeability. Ligand B is better.
3. **logP:** Ligand A (3.756) is slightly higher than Ligand B (2.987), both within the optimal 1-3 range. Ligand A is slightly less desirable due to being at the higher end.
4. **HBD:** Ligand A (3) is higher than Ligand B (1). Lower HBD is generally preferred for permeability. Ligand B is better.
5. **HBA:** Both ligands have the same HBA count (3), which is well within the acceptable limit of 10.
6. **QED:** Ligand A (0.659) has a slightly higher QED than Ligand B (0.507), indicating a slightly more drug-like profile. This is a small advantage for Ligand A.
7. **DILI:** Ligand B (25.36%) has a significantly lower DILI risk than Ligand A (38.31%). This is a substantial advantage for Ligand B.
8. **BBB:** Ligand A (76.35%) has a higher BBB penetration percentile than Ligand B (67.16%). While ADRB2 isn't a CNS target, some peripheral exposure can be undesirable, but this isn't a major concern.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the values are similar (-4.8 and -4.95).
10. **Solubility:** Ligand B (-3.448) has better solubility than Ligand A (-4.513). Better solubility is always preferred.
11. **hERG:** Ligand A (0.562) has a slightly higher hERG inhibition liability than Ligand B (0.442), meaning Ligand B is slightly safer from a cardiotoxicity perspective.
12. **Cl_mic:** Ligand B (63.11) has a lower microsomal clearance than Ligand A (69.41), indicating better metabolic stability.
13. **t1/2:** Ligand A (38.61) has a significantly longer in vitro half-life than Ligand B (1.88). This is a major advantage for Ligand A, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.106) has lower P-gp efflux liability than Ligand B (0.418), which is a positive.
15. **Binding Affinity:** Ligand B (-5.9 kcal/mol) has a stronger binding affinity than Ligand A (-5.4 kcal/mol). This is a 0.5 kcal/mol difference, which is significant and can outweigh some ADME drawbacks.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand B emerges as the more promising candidate. While Ligand A has a longer half-life and better QED, Ligand B's superior DILI profile, better solubility, lower hERG risk, lower P-gp efflux, and *stronger binding affinity* are more critical for a successful drug candidate. The lower TPSA of Ligand B is also beneficial. The half-life difference, while important, can potentially be addressed through formulation strategies.
Output:
0
2025-04-17 21:09:07,037 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.334 and 346.515 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (108.15) is higher than Ligand B (58.2). For a cardiovascular GPCR, TPSA isn't a *major* concern unless it's excessively high (which it isn't for A), but lower is generally preferred for permeability. Ligand B is significantly better here.
3. **logP:** Ligand B (3.592) is higher than Ligand A (0.589). ADRB2 is not a CNS target, but a logP between 1-3 is optimal. Ligand A is too low, potentially hindering membrane permeability. Ligand B is better, though approaching the upper limit.
4. **HBD:** Both ligands have 2 HBD, which is within the acceptable limit of <=5. No difference.
5. **HBA:** Ligand A has 5 HBA, while Ligand B has 2. Both are within the acceptable limit of <=10. Ligand B is better.
6. **QED:** Ligand A (0.844) has a higher QED than Ligand B (0.521), indicating a more drug-like profile overall. This is a significant advantage for Ligand A.
7. **DILI:** Ligand A (86.623) has a substantially higher DILI risk than Ligand B (37.728). This is a major concern for Ligand A.
8. **BBB:** Both have moderate BBB penetration, but Ligand B (60.915) is slightly better than Ligand A (59.325). Not a critical factor for ADRB2.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. Ligand B (-4.865) is slightly better than Ligand A (-4.656).
10. **Solubility:** Both have negative solubility values, indicating poor solubility. Ligand B (-4.874) is slightly worse than Ligand A (-3.036).
11. **hERG:** Both have low hERG inhibition risk (0.145 and 0.253). No significant difference.
12. **Cl_mic:** Ligand A (-2.631) has a *much* lower (better) microsomal clearance than Ligand B (81.91). This suggests greater metabolic stability for Ligand A.
13. **t1/2:** Ligand A (-40.735) has a much longer in vitro half-life than Ligand B (3.682). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.016) has a much lower Pgp efflux liability than Ligand B (0.452). This is a significant advantage for Ligand A.
15. **Affinity:** Ligand A (-7.9 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.9 kcal/mol). This is a substantial advantage for Ligand A, and can often outweigh minor ADME drawbacks.
**Overall Assessment:**
Ligand A has a significantly better binding affinity, metabolic stability (lower Cl_mic, longer t1/2), and Pgp efflux profile. It also has a higher QED. However, its major drawback is the high DILI risk. Ligand B has better TPSA and logP, and a much lower DILI risk, but suffers from weaker binding affinity, poorer metabolic stability, and higher Pgp efflux.
Given the importance of potency for GPCRs, and the fact that the affinity difference is substantial (1.0 kcal/mol), I believe Ligand A is the more promising starting point, *despite* the higher DILI risk. DILI risk can be addressed through structural modifications during lead optimization. The strong binding affinity and favorable PK properties (Cl_mic, t1/2, Pgp) are harder to improve later.
Output:
1
2025-04-17 21:09:07,038 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
The target is ADRB2, a GPCR. Therefore, I will prioritize logP, TPSA, Pgp efflux, BBB penetration, and binding affinity. Metabolic stability (Cl_mic, t1/2) and safety (DILI, hERG) are also important.
Let's compare the ligands:
1. **MW:** Both ligands (351.491 and 370.475 Da) are within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (65.79) is significantly better than Ligand B (101.37). A lower TPSA is preferred for good absorption, and Ligand B is pushing the upper limit for oral absorption.
3. **logP:** Ligand A (2.451) is optimal. Ligand B (0.212) is quite low, potentially leading to poor membrane permeability.
4. **HBD/HBA:** Both have 1 HBD, which is good. Ligand A has 4 HBA, and Ligand B has 6. Both are acceptable, but Ligand A is slightly better.
5. **QED:** Both ligands have good QED scores (0.694 and 0.771).
6. **DILI:** Ligand A (14.618) has a much lower DILI risk than Ligand B (56.96). This is a significant advantage for Ligand A.
7. **BBB:** Ligand A (53.664) has moderate BBB penetration, while Ligand B (58.123) is similar. Neither is exceptionally high, but this is less critical for a non-CNS target like ADRB2.
8. **Caco-2:** Ligand A (-4.768) and Ligand B (-5.153) are both very poor. This is a concern for both, but the negative values suggest very limited permeability.
9. **Solubility:** Ligand A (-0.94) is better than Ligand B (-1.87), indicating slightly better aqueous solubility.
10. **hERG:** Ligand A (0.782) has a lower hERG risk than Ligand B (0.084). This is a significant safety advantage for Ligand A.
11. **Cl_mic:** Ligand A (27.123) has a higher microsomal clearance than Ligand B (18.339), suggesting lower metabolic stability. This is a slight disadvantage for Ligand A.
12. **t1/2:** Ligand A (41.33) has a longer in vitro half-life than Ligand B (22.701). This is a positive for Ligand A.
13. **Pgp:** Ligand A (0.125) has lower P-gp efflux than Ligand B (0.039), which is favorable.
14. **Binding Affinity:** Both ligands have very similar and strong binding affinities (-6.6 and -6.4 kcal/mol). The difference is not substantial enough to outweigh other factors.
**Conclusion:**
Ligand A is the better candidate. It has a more favorable logP, significantly lower DILI and hERG risk, better solubility, and a longer half-life. While its Caco-2 permeability and Cl_mic are not ideal, the overall balance of properties, particularly the safety profile and permeability characteristics, makes it a more promising starting point for drug development targeting ADRB2.
**Output:**
1
2025-04-17 21:09:07,038 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (367.5 & 358.5 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand B (78.1) is significantly better than Ligand A (101.3). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (2.414) is better positioned within the optimal 1-3 range than Ligand A (1.186). Ligand A is at the lower end, potentially impacting permeability.
4. **HBD:** Ligand B (2) is slightly better than Ligand A (3), favoring permeability.
5. **HBA:** Both ligands have the same HBA count (4), which is within the acceptable limit.
6. **QED:** Ligand B (0.805) has a considerably higher QED score than Ligand A (0.57), indicating a more drug-like profile.
7. **DILI:** Ligand B (54.983) has a much lower DILI risk than Ligand A (14.696). This is a significant advantage.
8. **BBB:** Both ligands have relatively low BBB penetration, which is acceptable for a cardiovascular target. Ligand A (61.4) is slightly higher, but the difference isn't substantial.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. This is a concern for both.
10. **Solubility:** Both ligands have negative solubility values, indicating poor solubility. This is a concern for both.
11. **hERG:** Ligand B (0.519) has a slightly higher hERG risk than Ligand A (0.165), but both are relatively low.
12. **Cl_mic:** Ligand B (6.758) has significantly lower microsomal clearance than Ligand A (43.265), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-8.97) has a significantly longer in vitro half-life than Ligand A (0.127). This is a major advantage.
14. **Pgp:** Ligand B (0.214) has lower P-gp efflux liability than Ligand A (0.011), which is favorable for bioavailability.
15. **Affinity:** Ligand A (-6.3 kcal/mol) has a substantially better binding affinity than Ligand B (-1.5 kcal/mol). This is a very significant advantage.
**Overall Assessment:**
While Ligand A has a much stronger binding affinity, the ADME properties of Ligand B are far superior. Specifically, the lower DILI risk, significantly improved metabolic stability (lower Cl_mic and longer t1/2), and lower P-gp efflux are compelling. The slightly better logP and TPSA of Ligand B also contribute to its favorability. The affinity difference is substantial (4.8 kcal/mol), but the poor ADME profile of Ligand A raises serious concerns about its developability. A strong binding affinity can sometimes be overcome with structural modifications, but fixing severe metabolic instability and high DILI risk is often more challenging.
Given the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), and considering the overall balance, I favor Ligand B. The improved ADME properties outweigh the affinity difference in this case, as optimizing the structure of Ligand B to improve affinity is more likely to succeed than rescuing the ADME profile of Ligand A.
Output:
0
2025-04-17 21:09:07,038 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (364.475 and 346.471 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (87.24) is higher than Ligand B (58.64). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B is better.
3. **logP:** Ligand A (1.04) is within the optimal range, while Ligand B (2.406) is also good, leaning towards the higher end. Both are acceptable, but A is slightly better.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 7 HBA, while Ligand B has 3. Both are acceptable, but B is better.
6. **QED:** Both ligands have good QED scores (0.753 and 0.795), indicating good drug-like properties. No significant difference.
7. **DILI:** Ligand A (51.493) has a higher DILI risk than Ligand B (18.418). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (47.111) has a lower BBB penetration percentile than Ligand B (76.735). Since ADRB2 is a cardiovascular target, BBB penetration is not a primary concern, but higher is still generally preferable. Ligand B is better.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the absolute value is more important. Ligand A (-5.274) is slightly better than Ligand B (-4.844).
10. **Solubility:** Ligand A (-0.98) has better solubility than Ligand B (-3.35). Solubility is important for bioavailability.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.219 and 0.26). No significant difference.
12. **Cl_mic:** Ligand A (1.86) has significantly lower microsomal clearance than Ligand B (15.904), indicating better metabolic stability. This is a major advantage for Ligand A.
13. **t1/2:** Ligand A (10.112) has a shorter in vitro half-life than Ligand B (18.799). This is a disadvantage for Ligand A.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.043 and 0.095). No significant difference.
15. **Binding Affinity:** Ligand B (-7.1 kcal/mol) has a slightly better binding affinity than Ligand A (-6.8 kcal/mol). This is a significant advantage for Ligand B.
**GPCR-specific priorities:** For ADRB2 (a cardiovascular GPCR), we prioritize logP, TPSA, affinity, and metabolic stability. Ligand B excels in TPSA, affinity, and BBB. Ligand A excels in metabolic stability and solubility. The DILI risk is significantly lower for Ligand B. The affinity difference is substantial enough to outweigh the metabolic stability advantage of Ligand A.
**Conclusion:**
Considering the balance of properties, particularly the better affinity, lower DILI risk, and acceptable ADME profile of Ligand B, it is the more promising drug candidate.
Output:
0
2025-04-17 21:09:07,038 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **Molecular Weight:** Both ligands (342.483 and 352.494 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands have TPSA values around 50 (50.36 and 49.41), well below the 140 threshold for good oral absorption and suitable for a peripherally acting GPCR like ADRB2. No major difference.
3. **logP:** Both ligands have logP values in the optimal range (3.971 and 3.45). This suggests good permeability and reasonable solubility. Ligand A is slightly higher, which could be a minor advantage for membrane permeability.
4. **H-Bond Donors:** Ligand A has 2 HBD, and Ligand B has 1. Both are within the acceptable limit of 5. Ligand B's lower HBD count might slightly favor permeability.
5. **H-Bond Acceptors:** Both ligands have 2 HBA, well below the 10 limit. No significant difference.
6. **QED:** Both ligands have similar QED values (0.85 and 0.842), indicating good drug-like properties.
7. **DILI:** Ligand A has a DILI risk of 30.632%, while Ligand B has 17.216%. Ligand B is significantly better in terms of predicted liver toxicity. This is a crucial advantage.
8. **BBB:** Both ligands have high BBB penetration (91.508% and 89.376%). However, since ADRB2 is not a primary CNS target, this is less critical.
9. **Caco-2:** Both have negative Caco-2 values (-4.706 and -4.6). This is unusual and suggests poor permeability. However, these values are on a scale where negative values are possible, and the absolute magnitude isn't directly interpretable without knowing the scale's specifics.
10. **Aqueous Solubility:** Both ligands have negative solubility values (-4.294 and -4.079). Similar to Caco-2, this suggests poor solubility.
11. **hERG:** Both ligands have low hERG inhibition liability (0.733 and 0.707). This is good, minimizing cardiotoxicity risk.
12. **Cl_mic:** Ligand A has a lower microsomal clearance (44.456 mL/min/kg) than Ligand B (53.689 mL/min/kg), indicating better metabolic stability. This is a positive for Ligand A.
13. **t1/2:** Ligand A has a significantly longer in vitro half-life (20.189 hours) compared to Ligand B (-1.698 hours). This is a substantial advantage for Ligand A, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.419 and 0.183). Ligand B is slightly better here.
15. **Binding Affinity:** Ligand A has a stronger binding affinity (-7.1 kcal/mol) compared to Ligand B (-6.5 kcal/mol). This 0.6 kcal/mol difference is significant and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand A has a significantly better binding affinity and a much longer half-life, which are crucial for efficacy and dosing convenience. While Ligand B has a lower DILI risk and slightly better Pgp profile, the stronger binding and improved metabolic stability of Ligand A are more important for a GPCR target like ADRB2. The negative Caco-2 and solubility values are concerning for both, but the potency advantage of Ligand A is substantial.
Output:
1
2025-04-17 21:09:07,038 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (399.248) is slightly higher than Ligand B (343.427), but both are acceptable.
2. **TPSA:** Both ligands have TPSA values below 140, which is good for oral absorption. Ligand B (71.41) is preferable as it is lower than Ligand A (86.88). Lower TPSA generally correlates with better membrane permeability.
3. **logP:** Ligand A (3.222) is within the optimal range (1-3), while Ligand B (1.154) is at the lower end. For a GPCR, a slightly higher logP is often beneficial for receptor engagement, making Ligand A more favorable here.
4. **HBD:** Ligand A (3) and Ligand B (1) are both acceptable, being less than 5. Ligand B is slightly better.
5. **HBA:** Ligand A (3) and Ligand B (4) are both acceptable, being less than 10.
6. **QED:** Both ligands have good QED scores (A: 0.591, B: 0.788). Ligand B is slightly better.
7. **DILI:** Ligand A (98.527) has a very high DILI risk, which is a significant concern. Ligand B (23.497) has a low DILI risk, a major advantage.
8. **BBB:** Ligand B (75.107) has a better BBB percentile than Ligand A (34.122). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant for off-target effects and understanding the overall safety profile.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-5.208) is slightly better than Ligand B (-4.79).
10. **Solubility:** Both ligands have negative solubility values, which is also unusual and suggests poor solubility. Ligand B (-2.121) is slightly better than Ligand A (-5.336).
11. **hERG:** Both ligands have low hERG inhibition liability (A: 0.367, B: 0.388), which is good.
12. **Cl_mic:** Ligand A (14.791) has a lower microsomal clearance than Ligand B (40.467), indicating better metabolic stability.
13. **t1/2:** Ligand A (49.148) has a longer in vitro half-life than Ligand B (-9.133), which is a significant advantage.
14. **Pgp:** Ligand A (0.231) has lower P-gp efflux liability than Ligand B (0.082), which is preferable.
15. **Binding Affinity:** Ligand B (-6.0) has a slightly better binding affinity than Ligand A (-5.3). However, the difference is not substantial enough to overcome the other significant drawbacks of Ligand A.
**Overall Assessment:**
Ligand A has some favorable properties (better metabolic stability, longer half-life, lower Pgp efflux), but its extremely high DILI risk is a deal-breaker. Ligand B, while having a slightly lower affinity and higher Pgp efflux, presents a much more favorable safety profile (low DILI) and better BBB penetration. The slightly lower logP of Ligand B is also less concerning than the high DILI risk of Ligand A. Given the GPCR-specific priorities, the balance of properties favors Ligand B.
Output:
0
2025-04-17 21:09:07,039 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
The target is ADRB2, a GPCR. Therefore, I will prioritize logP, TPSA, Pgp efflux, BBB penetration, and binding affinity, while also considering ADME properties like solubility, metabolic stability, and toxicity.
Let's analyze each ligand:
* **Molecular Weight:** Both ligands (355.479 and 354.397 Da) fall within the ideal 200-500 Da range.
* **TPSA:** Ligand A (90.9) is slightly higher than Ligand B (67.43). Ligand B is preferable here as lower TPSA generally correlates with better membrane permeability, crucial for GPCR ligands.
* **logP:** Ligand B (2.262) is within the optimal 1-3 range, while Ligand A (0.127) is significantly low. This is a major drawback for Ligand A, as low logP can hinder membrane permeability and bioavailability.
* **H-Bond Donors/Acceptors:** Ligand A has 3 HBD and 5 HBA, while Ligand B has 2 HBD and 3 HBA. Both are acceptable, but Ligand B is slightly better.
* **QED:** Ligand B (0.789) has a substantially higher QED score than Ligand A (0.485), indicating better overall drug-likeness.
* **DILI:** Ligand B (40.054) has a higher DILI risk than Ligand A (8.414). This favors Ligand A.
* **BBB:** Ligand B (82.823) shows significantly better BBB penetration than Ligand A (36.332). This is a significant advantage for Ligand B, given it's a GPCR.
* **Caco-2 Permeability:** Ligand A (-5.177) is worse than Ligand B (-4.254).
* **Aqueous Solubility:** Ligand A (-0.966) is better than Ligand B (-2.761).
* **hERG:** Ligand A (0.34) is better than Ligand B (0.518).
* **Microsomal Clearance:** Ligand B (31.297) has lower microsomal clearance than Ligand A (12.953), suggesting better metabolic stability.
* **In vitro Half-Life:** Ligand B (28.185) has a much longer half-life than Ligand A (-13.289).
* **P-gp Efflux:** Ligand A (0.017) has lower P-gp efflux than Ligand B (0.084), which is favorable.
* **Binding Affinity:** Ligand B (-6.9 kcal/mol) has a slightly better binding affinity than Ligand A (-6.1 kcal/mol). While the difference isn't huge, it's still a positive for Ligand B.
**Overall Assessment:**
Ligand B demonstrates a superior balance of properties, particularly regarding GPCR-relevant parameters. The significantly better logP, BBB penetration, QED, metabolic stability, and half-life outweigh the slightly higher DILI risk and P-gp efflux. While Ligand A has a lower DILI and P-gp efflux, its very low logP is a critical flaw that would likely hinder its development. The slightly better binding affinity of Ligand B further supports its selection.
**Output:**
0
2025-04-17 21:09:07,039 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (364.873 and 349.431 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (67.43) is significantly better than Ligand B (84.67). ADRB2 is a cardiovascular target, so CNS penetration isn't critical, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (3.159) is optimal, while Ligand B (1.553) is on the lower side. This could potentially hinder membrane permeability for Ligand B.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1), but both are acceptable.
5. **HBA:** Ligand A (3) is lower than Ligand B (5). Lower HBA is generally preferred for better permeability.
6. **QED:** Ligand B (0.77) has a slightly better QED score than Ligand A (0.522), indicating a more drug-like profile.
7. **DILI:** Ligand A (24.893) has a significantly lower DILI risk than Ligand B (34.626). This is a major advantage for Ligand A.
8. **BBB:** Both ligands have reasonable BBB penetration (Ligand A: 69.523, Ligand B: 61.691), but neither is exceptionally high. Not a major factor here.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.704 and -4.934), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-3.718) has better solubility than Ligand B (-1.139).
11. **hERG:** Ligand A (0.728) has a lower hERG risk than Ligand B (0.197). This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand B (37.299) has a slightly higher microsomal clearance than Ligand A (33.535), suggesting slightly lower metabolic stability.
13. **t1/2:** Ligand A (54.722) has a significantly longer in vitro half-life than Ligand B (24.172). This is a major advantage for Ligand A.
14. **Pgp:** Ligand A (0.243) has lower P-gp efflux liability than Ligand B (0.092).
15. **Binding Affinity:** Ligand B (-6.3 kcal/mol) has a slightly better binding affinity than Ligand A (-5.9 kcal/mol). This is a 0.4 kcal/mol difference, which is noticeable but not overwhelming.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has a better logP and TPSA, and comparable Pgp. Ligand B has a slightly better affinity. However, the ADME properties of Ligand A are significantly better (lower DILI, better solubility, lower hERG, longer half-life). The slightly better affinity of Ligand B is unlikely to overcome these substantial advantages.
**Conclusion:**
Considering the balance of properties, particularly the superior ADME profile of Ligand A, I would choose Ligand A as the more promising drug candidate.
Output:
1
2025-04-17 21:09:07,039 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [353.463, 82.11, -0.026, 2, 5, 0.701, 5.894, 31.097, -4.994, -0.303, 0.159, -12.086, 19.702, 0.004, -7]
**Ligand B:** [341.419, 70.51, 0.82, 0, 8, 0.813, 84.102, 70.841, -4.805, -2.193, 0.578, 41.032, 2.442, 0.027, -5.6]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (341.419) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are good, below 140. Ligand B (70.51) is better, closer to the desirable range for GPCRs.
3. **logP:** Ligand A (-0.026) is a bit low, potentially hindering membrane permeability. Ligand B (0.82) is much better, falling within the optimal 1-3 range.
4. **HBD:** Ligand A (2) is good. Ligand B (0) is excellent, minimizing potential for off-target interactions.
5. **HBA:** Ligand A (5) is good. Ligand B (8) is acceptable, but approaching the upper limit.
6. **QED:** Both are good (>0.5), indicating drug-like properties. Ligand B (0.813) is slightly better.
7. **DILI:** Ligand A (5.894) is excellent, very low risk. Ligand B (84.102) is significantly higher, indicating a substantial DILI risk. This is a major concern.
8. **BBB:** Ligand A (31.097) is low, not a priority for a cardiovascular target. Ligand B (70.841) is better, but still not exceptionally high.
9. **Caco-2:** Both are very poor (-4.994 and -4.805). This is a significant drawback for both compounds.
10. **Solubility:** Both are very poor (-0.303 and -2.193). This is a major formulation challenge for both.
11. **hERG:** Ligand A (0.159) is very low risk. Ligand B (0.578) is slightly higher, but still relatively low.
12. **Cl_mic:** Ligand A (-12.086) is excellent, indicating high metabolic stability. Ligand B (41.032) is considerably higher, suggesting faster metabolism.
13. **t1/2:** Ligand A (19.702) is good, suggesting a reasonable half-life. Ligand B (2.442) is very short, potentially requiring frequent dosing.
14. **Pgp:** Ligand A (0.004) is very low efflux, favorable for bioavailability. Ligand B (0.027) is also low, but slightly higher.
15. **Affinity:** Ligand A (-7) is slightly better than Ligand B (-5.6), a difference of 1.4 kcal/mol.
**GPCR-Specific Considerations:**
For a cardiovascular GPCR like ADRB2, logP, TPSA, and affinity are key. Ligand B has better logP and TPSA. However, the *extremely* high DILI risk for Ligand B is a deal-breaker. While affinity is important, a high risk of liver injury outweighs a small advantage in binding. Metabolic stability (Cl_mic) and half-life also favor Ligand A.
**Conclusion:**
Despite the slightly better affinity of Ligand A, the significant DILI risk associated with Ligand B makes it a far less viable candidate. Ligand A, while having solubility and Caco-2 permeability issues, presents a much more favorable safety profile and better metabolic stability.
Output:
1
2025-04-17 21:09:07,039 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (333.343 and 357.47 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (75.63) is slightly higher than Ligand B (70.67), but both are below the 140 threshold for good oral absorption.
3. **logP:** Ligand A (2.308) is within the optimal 1-3 range. Ligand B (1.246) is at the lower end, potentially impacting permeability.
4. **HBD:** Both ligands have 2 HBD, which is acceptable.
5. **HBA:** Ligand A has 3 HBA, while Ligand B has 4. Both are within the acceptable limit of 10.
6. **QED:** Ligand A (0.796) has a slightly better QED score than Ligand B (0.686), indicating a more drug-like profile.
7. **DILI:** Ligand A (80.186) has a significantly higher DILI risk than Ligand B (5.545). This is a major concern for Ligand A.
8. **BBB:** Ligand B (92.012) shows much better BBB penetration potential than Ligand A (21.171). While ADRB2 isn't strictly a CNS target, some CNS exposure can occur, and better BBB penetration can be advantageous.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.826 and -4.879), which is unusual and suggests poor permeability. This is a significant drawback for both.
10. **Solubility:** Ligand B (-1.525) has better (less negative) solubility than Ligand A (-3.622).
11. **hERG:** Ligand A (0.136) has a slightly better hERG profile than Ligand B (0.454), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand B (-7.092) has a much lower (better) microsomal clearance than Ligand A (0.766), suggesting greater metabolic stability.
13. **t1/2:** Ligand B (-14.347) has a significantly longer in vitro half-life than Ligand A (-9.678).
14. **Pgp:** Ligand A (0.059) has lower P-gp efflux liability than Ligand B (0.004), which is favorable.
15. **Binding Affinity:** Ligand A (-6.8 kcal/mol) has a slightly better binding affinity than Ligand B (-5.5 kcal/mol). This is a 1.3 kcal/mol difference, which is substantial.
**GPCR-Specific Priorities & Overall Assessment:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand A has a better logP and Pgp, and a significantly better binding affinity. However, the *extremely* high DILI risk associated with Ligand A is a major red flag. Ligand B, despite slightly lower affinity, has a much more favorable safety profile (DILI), better metabolic stability (Cl_mic, t1/2), and better solubility. The improved BBB penetration is also a bonus. The similar TPSA values and the relatively weak Caco-2 values for both are concerning, but the safety and PK advantages of Ligand B outweigh the slightly better affinity of Ligand A.
**Output:**
0
2025-04-17 21:09:07,039 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (337.335 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (97.36) is higher than Ligand B (47.36). For a cardiovascular GPCR like ADRB2, TPSA is less critical than for CNS targets, but lower is still preferred. Ligand B is significantly better here.
3. **logP:** Both ligands have good logP values (A: 2.875, B: 3.747), falling within the optimal 1-3 range. Ligand B is slightly higher, which could potentially lead to off-target interactions, but is still acceptable.
4. **HBD:** Ligand A (2) is better than Ligand B (0). Having some HBD can improve solubility.
5. **HBA:** Both ligands have the same number of HBA (5), which is within the acceptable range.
6. **QED:** Ligand A (0.674) has a slightly higher QED score than Ligand B (0.589), indicating a more drug-like profile.
7. **DILI:** Ligand A (93.176) has a significantly higher DILI risk than Ligand B (27.608). This is a major concern for Ligand A.
8. **BBB:** Ligand B (70.725) has a much higher BBB penetration percentile than Ligand A (27.918). While ADRB2 isn't a primary CNS target, some BBB penetration can be beneficial for distribution.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-5.251) is slightly worse than Ligand B (-4.746).
10. **Solubility:** Both ligands have poor aqueous solubility (-3.62 and -3.574). This is a concern for both, and formulation strategies would be needed.
11. **hERG:** Ligand A (0.11) has a lower hERG inhibition liability than Ligand B (0.762), which is a positive.
12. **Cl_mic:** Ligand A (6.361) has a much lower microsomal clearance than Ligand B (130.425), indicating better metabolic stability.
13. **t1/2:** Ligand B (4.384) has a longer in vitro half-life than Ligand A (-4.55), which is desirable.
14. **Pgp:** Ligand A (0.041) has a much lower P-gp efflux liability than Ligand B (0.519), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand A (-9.0) has a significantly stronger binding affinity than Ligand B (-4.6). This is a substantial advantage.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), affinity, logP, TPSA, and Pgp are key. Ligand A excels in affinity and Pgp, while Ligand B has a better TPSA. The difference in affinity is substantial (>4 kcal/mol), which can often outweigh other drawbacks. However, the high DILI risk for Ligand A is a significant red flag.
**Overall Assessment:**
Despite Ligand A's superior affinity and Pgp profile, the extremely high DILI risk is a major concern. While the affinity difference is large, the potential for liver toxicity makes it a less viable candidate. Ligand B, while having a weaker affinity, presents a much safer profile with a low DILI risk and acceptable ADME properties.
Output:
0
2025-04-17 21:09:07,040 - INFO - Batch 237 complete. Total preferences: 3792
2025-04-17 21:09:07,040 - INFO - Processing batch 238/512...
2025-04-17 21:09:57,469 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (352.385 Da) is within the ideal range (200-500 Da). Ligand B (406.372 Da) is also within the range, but closer to the upper limit. No clear advantage here.
2. **TPSA:** Ligand A (78.09) is better than Ligand B (55.63) as it is closer to the ideal threshold of <140.
3. **logP:** Ligand A (2.048) is optimal (1-3). Ligand B (4.005) is slightly higher, potentially leading to solubility issues and off-target effects. Ligand A is preferred.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable (<=5).
5. **HBA:** Ligand A (3) and Ligand B (5) are both acceptable (<=10).
6. **QED:** Ligand A (0.871) is significantly better than Ligand B (0.64), indicating a more drug-like profile.
7. **DILI:** Ligand A (54.75) is slightly higher than Ligand B (35.091), but both are within an acceptable range (<60). Ligand B is preferred here.
8. **BBB:** Ligand A (77.2) and Ligand B (83.288) are both good, but Ligand B is slightly better. Given ADRB2 is a GPCR, BBB penetration is a consideration, though not paramount unless targeting CNS effects.
9. **Caco-2:** Ligand A (-4.984) and Ligand B (-5.204) are similar.
10. **Solubility:** Ligand A (-3.302) is better than Ligand B (-4.326), indicating better aqueous solubility.
11. **hERG:** Ligand A (0.479) is better than Ligand B (0.601), indicating lower hERG inhibition liability.
12. **Cl_mic:** Ligand A (4.88) is much better than Ligand B (54.312), indicating better metabolic stability.
13. **t1/2:** Ligand A (-42.239) is much better than Ligand B (16.942), indicating a longer in vitro half-life.
14. **Pgp:** Ligand A (0.09) is much better than Ligand B (0.785), indicating lower P-gp efflux.
15. **Affinity:** Both ligands have similar binding affinities (-6.4 kcal/mol).
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand A is the stronger candidate. While Ligand B has slightly better BBB penetration and lower DILI risk, Ligand A excels in crucial ADME properties like logP, QED, metabolic stability (Cl_mic, t1/2), and P-gp efflux. The superior solubility and lower hERG risk of Ligand A also contribute to its better overall profile. The similar binding affinities make the ADME advantages of Ligand A decisive.
Output:
1
2025-04-17 21:09:57,470 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (354.422 and 364.515 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (67.87) is better than Ligand B (75.19). Both are under 140, but lower TPSA generally favors absorption.
3. **logP:** Ligand A (1.18) is optimal, while Ligand B (2.608) is also acceptable but edging towards the higher end of the optimal range.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 5. Both are acceptable, under the 10 threshold.
6. **QED:** Both ligands have good QED scores (0.778 and 0.807), indicating good drug-like properties.
7. **DILI:** Ligand A (29.042) has a significantly better DILI score than Ligand B (36.603). Lower is better, and Ligand A is well below the 40 threshold.
8. **BBB:** Ligand A (83.831) shows better BBB penetration than Ligand B (75.223). While ADRB2 isn't strictly a CNS target, some CNS exposure can occur, and higher BBB is generally favorable.
9. **Caco-2:** Ligand A (-4.592) is better than Ligand B (-5.357), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-1.756) is better than Ligand B (-2.972). Higher is better.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.374 and 0.119), which is excellent.
12. **Cl_mic:** Ligand A (-5.537) has a much lower (better) microsomal clearance than Ligand B (41.526). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (12.451) has a better in vitro half-life than Ligand B (-13.004).
14. **Pgp:** Ligand A (0.035) has much lower P-gp efflux liability than Ligand B (0.086). Lower is better.
15. **Binding Affinity:** Ligand B (-6.8) has a slightly better binding affinity than Ligand A (-5.8). However, the difference is only 1 kcal/mol, and other factors are more important.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A has a better logP and TPSA, significantly better Pgp efflux, and acceptable affinity. Ligand B has a slightly better affinity, but the advantages of Ligand A in other crucial ADME properties outweigh this.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B in critical ADME properties (DILI, BBB, Caco-2, Solubility, Cl_mic, t1/2, Pgp) and has a comparable binding affinity. The improved ADME profile of Ligand A suggests a higher probability of success as a drug candidate.
Output:
1
2025-04-17 21:09:57,470 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [347.371, 103.89 , 1.456, 3. , 5. , 0.671, 52.074, 47.577, -5.581, -3.155, 0.456, 22.552, -32.819, 0.043, -5.3 ]
**Ligand B:** [377.495, 92.93 , 2.164, 2. , 8. , 0.613, 84.064, 19.698, -5.545, -2.93 , 0.183, 43.685, 43.472, 0.308, -3.8 ]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity, and BBB):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (347.371) is slightly preferred due to being a bit lower.
2. **TPSA:** Both are good, below 140. Ligand B (92.93) is slightly better than A (103.89), suggesting potentially better absorption.
3. **logP:** Both are within the optimal range (1-3). Ligand B (2.164) is a bit higher, which could be beneficial for membrane permeability, but also raises a slight concern for off-target effects. Ligand A (1.456) is good, but on the lower side.
4. **HBD/HBA:** Ligand A (3 HBD, 5 HBA) is better than Ligand B (2 HBD, 8 HBA). Fewer H-bonds generally improve permeability.
5. **QED:** Both are acceptable (>0.5), A (0.671) is slightly better.
6. **DILI:** Ligand A (52.074) is significantly better than Ligand B (84.064). This is a major advantage for A.
7. **BBB:** Ligand A (47.577) is better than Ligand B (19.698). While ADRB2 isn't necessarily a CNS target, some peripheral ADRB2 activity can have central effects, and higher BBB penetration isn't a negative.
8. **Caco-2:** Both are negative, indicating poor permeability. This is a concern for both.
9. **Solubility:** Both are negative, indicating poor solubility. This is a concern for both.
10. **hERG:** Both are very low, indicating low risk of hERG inhibition.
11. **Cl_mic:** Ligand A (22.552) has a much lower clearance than Ligand B (43.685), suggesting better metabolic stability.
12. **t1/2:** Ligand B (43.472) has a longer half-life than Ligand A (-32.819). This is a significant advantage for B.
13. **Pgp:** Ligand A (0.043) has a much lower Pgp efflux liability than Ligand B (0.308). This is a major advantage for A.
14. **Affinity:** Ligand A (-5.3 kcal/mol) has a slightly better binding affinity than Ligand B (-3.8 kcal/mol). This is a significant advantage for A.
**Overall Assessment:**
Ligand A is the stronger candidate. While Ligand B has a longer half-life, Ligand A excels in several critical areas: lower DILI risk, better BBB penetration, lower Pgp efflux, and superior binding affinity. The lower metabolic clearance of A is also a positive. The Caco-2 and solubility issues are present in both, and would need to be addressed through formulation or further chemical modification. The affinity difference and the significantly better safety profile (DILI, Pgp) of Ligand A outweigh the half-life advantage of Ligand B.
Output:
1
2025-04-17 21:09:57,470 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (362.348 Da) is within the ideal range (200-500 Da). Ligand B (391.339 Da) is also acceptable. No clear advantage here.
2. **TPSA:** Ligand A (87.66) is good, below the 140 threshold for oral absorption. Ligand B (58.64) is excellent, suggesting better permeability. Advantage: B.
3. **logP:** Ligand A (0.201) is quite low, potentially hindering permeability. Ligand B (2.742) is within the optimal range (1-3). Significant advantage: B.
4. **HBD:** Ligand A (3) is acceptable. Ligand B (1) is even better. Advantage: B.
5. **HBA:** Ligand A (4) is acceptable. Ligand B (3) is also good. No significant difference.
6. **QED:** Both ligands (A: 0.652, B: 0.679) have good drug-likeness scores. No clear advantage.
7. **DILI:** Ligand A (31.059) has a much lower DILI risk than Ligand B (12.02). Significant advantage: A.
8. **BBB:** Ligand A (66.111) is moderate. Ligand B (75.882) is better, suggesting more potential for CNS penetration, though ADRB2 is primarily cardiovascular. Slight advantage: B.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Both ligands have negative solubility values, which is also unusual. It's hard to interpret without knowing the scale.
11. **hERG:** Ligand A (0.195) has a very low hERG risk. Ligand B (0.518) is higher, but still relatively low. Advantage: A.
12. **Cl_mic:** Ligand A (-12.694) has a much lower (better) microsomal clearance than Ligand B (28.571). Significant advantage: A.
13. **t1/2:** Ligand A (6.828) has a longer half-life than Ligand B (2.066). Advantage: A.
14. **Pgp:** Ligand A (0.023) has very low P-gp efflux liability. Ligand B (0.203) is higher. Advantage: A.
15. **Binding Affinity:** Ligand B (-7.6 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.7 kcal/mol). This is a substantial advantage, potentially outweighing some ADME concerns.
**Overall Assessment & GPCR Prioritization:**
For a GPCR like ADRB2, potency (affinity), logP, TPSA, and Pgp efflux are key. Ligand B excels in affinity and logP, and has a favorable TPSA. However, Ligand A demonstrates a much better safety profile (lower DILI, hERG) and superior metabolic stability (lower Cl_mic, longer t1/2, lower Pgp). While the affinity difference is notable (0.9 kcal/mol), the ADME/Tox profile of Ligand A is considerably more promising. The slightly better BBB for Ligand B is less critical for a cardiovascular target. The unusual negative values for Caco-2 and solubility are concerning for both, but the other advantages of A are more compelling.
Given the balance of properties, prioritizing a safer and more metabolically stable compound with good, though not exceptional, affinity is the more prudent approach for initial development.
Output:
1
2025-04-17 21:09:57,471 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [346.471, 69.64, 2.001, 2, 3, 0.765, 15.471, 48.197, -4.953, -3.652, 0.235, 45.286, -2.264, 0.135, -4.1]
**Ligand B:** [343.479, 71.76, 2.223, 1, 7, 0.867, 52.423, 63.901, -5.232, -2.295, 0.404, 17.906, 33.74, 0.058, -7.2]
Here's a breakdown, comparing each parameter and considering GPCR priorities (logP, Pgp, TPSA, Affinity):
1. **MW:** Both are within the ideal range (200-500 Da). A is 346.471, B is 343.479. Very similar.
2. **TPSA:** Both are acceptable for oral absorption (<140). A is 69.64, B is 71.76. Again, very similar.
3. **logP:** Both are within the optimal range (1-3). A is 2.001, B is 2.223. B is slightly higher, which could be a minor advantage for membrane permeability.
4. **HBD:** A has 2, B has 1. Lower is generally better, so B is slightly favored.
5. **HBA:** A has 3, B has 7. B has significantly more HBA, which could potentially impact permeability negatively.
6. **QED:** Both are good (>0.5). A is 0.765, B is 0.867. B is slightly better here, indicating a more drug-like profile.
7. **DILI:** A is 15.471, B is 52.423. A is *much* better here, indicating significantly lower liver injury risk. This is a major advantage for A.
8. **BBB:** A is 48.197, B is 63.901. B has better BBB penetration. While ADRB2 isn't strictly a CNS target, some CNS exposure can be beneficial for understanding off-target effects and potential side effects.
9. **Caco-2:** A is -4.953, B is -5.232. Both are negative, indicating poor permeability. B is slightly worse.
10. **Solubility:** A is -3.652, B is -2.295. B has better solubility.
11. **hERG:** A is 0.235, B is 0.404. A has a lower hERG risk, which is crucial for cardiovascular drugs.
12. **Cl_mic:** A is 45.286, B is 17.906. B has significantly lower microsomal clearance, indicating better metabolic stability. This is a significant advantage for B.
13. **t1/2:** A is -2.264, B is 33.74. B has a much longer in vitro half-life, which is highly desirable.
14. **Pgp:** A is 0.135, B is 0.058. B has lower P-gp efflux, which is favorable for bioavailability.
15. **Affinity:** A is -4.1, B is -7.2. B has a *much* stronger binding affinity (a difference of 3.1 kcal/mol). This is a substantial advantage that can outweigh many other drawbacks.
**Overall Assessment:**
Ligand B has a significantly better binding affinity and metabolic stability (lower Cl_mic, longer t1/2), lower Pgp efflux, and better solubility. It also has a slightly better QED and BBB penetration. However, it has a considerably higher DILI risk and worse Caco-2 permeability.
Ligand A has a much lower DILI risk and hERG inhibition liability, which are critical for a cardiovascular drug. While its affinity is weaker, its safety profile is significantly better.
Given the GPCR-specific priorities and the importance of safety in cardiovascular drugs, the stronger affinity of Ligand B is a compelling advantage that outweighs the higher DILI risk and lower permeability, especially given the relatively moderate DILI percentile.
Output:
0
2025-04-17 21:09:57,471 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.391 and 366.571 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (49.41) is significantly better than Ligand A (104.57). Lower TPSA generally improves oral absorption and is crucial for GPCRs.
3. **logP:** Ligand B (3.331) is optimal, while Ligand A (0.326) is quite low, potentially hindering membrane permeability. This is a significant advantage for Ligand B.
4. **HBD:** Both have 1 HBD, which is within the acceptable limit.
5. **HBA:** Ligand A has 8 HBA, while Ligand B has 3. Ligand B is preferable here, as fewer HBA tend to improve permeability.
6. **QED:** Both ligands have similar QED scores (0.672 and 0.67), indicating good drug-likeness.
7. **DILI:** Ligand B (15.006) has a much lower DILI risk than Ligand A (72.043). This is a major advantage for Ligand B.
8. **BBB:** Both ligands have good BBB penetration (68.476 and 71.578). This is less critical for ADRB2 as it is not a CNS target, but still a positive.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the absolute value for Ligand A (-4.979) is slightly less negative than Ligand B (-4.779), suggesting marginally better permeability.
10. **Solubility:** Ligand B (-3.842) has slightly worse solubility than Ligand A (-2.368), but both are quite poor.
11. **hERG:** Ligand A (0.051) has a slightly lower hERG risk than Ligand B (0.395), but both are low enough to not be a major concern.
12. **Cl_mic:** Ligand B (84.783) has a significantly higher microsomal clearance than Ligand A (23.142), indicating lower metabolic stability. This is a disadvantage for Ligand B.
13. **t1/2:** Ligand B (11.434) has a much longer half-life than Ligand A (1.007). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.058) has lower P-gp efflux than Ligand B (0.165), which is preferable.
15. **Binding Affinity:** Ligand B (-7.1) has slightly better binding affinity than Ligand A (-7.0). While the difference is small, it's still a positive for Ligand B.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand B is the stronger candidate. Its superior logP, lower TPSA, and lower DILI risk outweigh the concerns about its higher Cl_mic and slightly worse solubility. The slightly better binding affinity and longer half-life further support this choice. While Ligand A has slightly better Caco-2 and Pgp values, the other advantages of Ligand B are more impactful for overall drug development potential.
Output:
0
2025-04-17 21:09:57,471 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (379.404) is slightly higher than Ligand B (346.383), but both are acceptable.
2. **TPSA:** Ligand A (84.08) is better than Ligand B (96.89). Both are below 140, but lower TPSA is generally preferred for better absorption, especially for a GPCR.
3. **logP:** Ligand A (2.449) is within the optimal range (1-3). Ligand B (0.589) is a bit low, potentially hindering membrane permeability. This is a significant negative for Ligand B.
4. **HBD:** Ligand A (2) and Ligand B (3) are both acceptable, being less than 5.
5. **HBA:** Both ligands have 5 HBA, which is acceptable (<=10).
6. **QED:** Ligand A (0.768) has a better QED score than Ligand B (0.599), indicating a more drug-like profile.
7. **DILI:** Ligand B (48.817) has a significantly lower DILI risk than Ligand A (66.654). This is a strong positive for Ligand B.
8. **BBB:** Ligand A (68.282) has a slightly better BBB penetration potential than Ligand B (54.634). While ADRB2 isn't strictly a CNS target, some CNS exposure can occur, and higher BBB is generally favorable.
9. **Caco-2:** Ligand A (-4.949) shows better Caco-2 permeability than Ligand B (-5.264). Both are negative, which is not ideal, but A is slightly better.
10. **Solubility:** Ligand A (-4.128) has better aqueous solubility than Ligand B (-2.079). Solubility is important for formulation and bioavailability.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.424 and 0.123 respectively). This is excellent for both.
12. **Cl_mic:** Ligand B (-1.515) has significantly lower microsomal clearance than Ligand A (70.693), suggesting better metabolic stability. This is a major advantage for Ligand B.
13. **t1/2:** Ligand B (-5.993) has a slightly better in vitro half-life than Ligand A (-11.277).
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.085 and 0.049 respectively). This is excellent for both.
15. **Affinity:** Both ligands have the same binding affinity (-6.3 kcal/mol).
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, and metabolic stability (Cl_mic) are particularly important. Ligand A has a better logP and TPSA, while Ligand B excels in metabolic stability (Cl_mic) and has a lower DILI risk. The binding affinity is the same.
**Overall Assessment:**
While Ligand A has slightly better TPSA, solubility and Caco-2 permeability, Ligand B's significantly improved metabolic stability (lower Cl_mic), lower DILI risk, and acceptable logP make it the more promising candidate. The slightly lower BBB penetration is not a major concern for a peripheral target like ADRB2. The lower logP of Ligand B is a concern, but the other advantages outweigh this.
Output:
0
2025-04-17 21:09:57,471 - INFO - Reasoning:
Let's analyze Ligand A and Ligand B for their potential as ADRB2 ligands, keeping in mind the GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key).
**Molecular Weight:** Both ligands (355.454 and 342.439 Da) fall within the ideal 200-500 Da range.
**TPSA:** Ligand A (92.5) is slightly higher than the preferred <140, but acceptable. Ligand B (53.35) is excellent, well below 90, suggesting good permeability.
**logP:** Ligand A (1.235) is optimal. Ligand B (3.862) is approaching the upper limit of the optimal range, but still acceptable.
**H-Bond Donors/Acceptors:** Ligand A has 2 HBD and 3 HBA, which is good. Ligand B has 0 HBD and 5 HBA, also reasonable.
**QED:** Both ligands have similar QED values (0.686 and 0.717), indicating good drug-likeness.
**DILI:** Ligand A (16.324) has a significantly lower DILI risk than Ligand B (38.193), which is a major advantage.
**BBB:** Ligand A (92.827) shows better BBB penetration than Ligand B (69.756), though BBB isn't a primary concern for ADRB2 unless targeting CNS effects.
**Caco-2 Permeability:** Ligand A (-5.219) has a worse Caco-2 permeability than Ligand B (-4.38).
**Aqueous Solubility:** Ligand A (-3.066) has better aqueous solubility than Ligand B (-4.113).
**hERG:** Both ligands have similar, low hERG inhibition liability (0.492 and 0.554).
**Microsomal Clearance:** Ligand A (10.623) has a lower microsomal clearance than Ligand B (86.1), indicating better metabolic stability.
**In vitro Half-Life:** Ligand A (-17.146) has a much longer in vitro half-life than Ligand B (-0.204), which is a significant advantage.
**P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.028 and 0.429).
**Binding Affinity:** Ligand B (-6.5) has a slightly better binding affinity than Ligand A (-6.0), but the difference is less than 1.5 kcal/mol.
**Overall Assessment:**
Ligand A presents a more balanced profile. While Ligand B has slightly better affinity and Caco-2 permeability, Ligand A excels in critical areas like DILI risk, metabolic stability (lower Cl_mic, longer t1/2), and BBB penetration. The lower DILI risk and improved metabolic stability are particularly important for a GPCR target like ADRB2, where chronic administration is often anticipated. The slight difference in binding affinity is outweighed by these more significant ADME/Tox advantages.
Output:
1
2025-04-17 21:09:57,471 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A: [376.503, 66.48, 2.276, 1, 4, 0.786, 72.199, 43.815, -5.156, -4.187, 0.371, 70.473, -45.367, 0.29, -6.4]**
**Ligand B: [360.376, 67.43, 3.123, 2, 3, 0.748, 44.436, 85.653, -4.577, -3.938, 0.786, 47.498, 5.859, 0.169, -7.6]**
Here's a breakdown of the comparison, considering the provided guidelines and GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (360.376) is slightly lower, which is generally favorable.
2. **TPSA:** Both are reasonably good (66.48 and 67.43), being below 140. This suggests reasonable oral absorption potential.
3. **logP:** Ligand A (2.276) is optimal, while Ligand B (3.123) is slightly higher but still within the acceptable range.
4. **HBD/HBA:** Ligand A (1 HBD, 4 HBA) is slightly better than Ligand B (2 HBD, 3 HBA) in terms of balancing solubility and permeability.
5. **QED:** Both are good (0.786 and 0.748), indicating drug-like properties.
6. **DILI:** Ligand A (72.199) has a higher DILI risk than Ligand B (44.436). This is a significant concern.
7. **BBB:** Ligand B (85.653) has a substantially better BBB penetration percentile than Ligand A (43.815). This is a major advantage for a GPCR target, even if not specifically CNS-focused, as it can influence distribution.
8. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-5.156) is worse than Ligand B (-4.577).
9. **Solubility:** Both have negative solubility scores, indicating poor aqueous solubility. Ligand A (-4.187) is slightly worse than Ligand B (-3.938).
10. **hERG:** Ligand A (0.371) has a lower hERG risk than Ligand B (0.786), which is positive.
11. **Cl_mic:** Ligand A (70.473) has a higher microsomal clearance than Ligand B (47.498), suggesting lower metabolic stability.
12. **t1/2:** Ligand A (-45.367) has a much longer in vitro half-life than Ligand B (5.859). This is a significant advantage.
13. **Pgp:** Ligand A (0.29) has lower P-gp efflux liability than Ligand B (0.169), which is favorable.
14. **Affinity:** Ligand B (-7.6 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.4 kcal/mol). This is a crucial factor, with a >1.5 kcal/mol difference being substantial.
**Overall Assessment:**
Ligand B shines with its superior binding affinity and significantly better BBB penetration. While it has a slightly higher logP and Pgp efflux, these are less critical concerns than the affinity and distribution advantages. The lower DILI risk for Ligand B is also a major benefit. Ligand A has a longer half-life and lower hERG risk, but these are outweighed by the weaker binding, poor BBB penetration, and higher DILI risk. The Caco-2 and solubility issues are similar for both.
Therefore, I would prioritize Ligand B.
Output:
0
2025-04-17 21:09:57,472 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (443.7) is within the ideal range, while Ligand B (367.8) is towards the lower end but still acceptable.
2. **TPSA:** Ligand A (81.3) is good, below 140, but Ligand B (92.5) is also acceptable.
3. **logP:** Ligand A (4.27) is slightly high, potentially leading to solubility issues or off-target effects. Ligand B (1.08) is excellent, within the optimal range.
4. **HBD:** Both ligands have 1 HBD, which is ideal.
5. **HBA:** Both ligands have 5 HBA, which is also ideal.
6. **QED:** Both ligands have good QED scores (A: 0.596, B: 0.728), indicating good drug-likeness. Ligand B is slightly better.
7. **DILI:** Ligand A (94.96) has a very high DILI risk, a significant concern. Ligand B (36.8) has a low DILI risk, a major advantage.
8. **BBB:** Ligand A (25.2) has poor BBB penetration, while Ligand B (65.5) is reasonably good. While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant for side effect profiles.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
10. **Solubility:** Ligand A (-5.2) has very poor solubility, consistent with its high logP. Ligand B (-2.2) has better, but still poor solubility.
11. **hERG:** Ligand A (0.53) has a slightly elevated hERG risk, while Ligand B (0.05) has a very low risk, a significant advantage.
12. **Cl_mic:** Ligand A (20.1) has a moderate clearance, while Ligand B (6.2) has a low clearance, indicating better metabolic stability.
13. **t1/2:** Ligand A (38.98) has a reasonable half-life, but Ligand B (-11.99) has a negative half-life, which is impossible and indicates a problem with the data.
14. **Pgp:** Ligand A (0.545) has moderate Pgp efflux, while Ligand B (0.067) has low Pgp efflux, which is favorable.
15. **Affinity:** Ligand A (-7.3) has a slightly better binding affinity than Ligand B (-6.3), but the difference is less than 1.5 kcal/mol.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand B excels in logP and Pgp, and has acceptable TPSA. While Ligand A has slightly better affinity, its high logP, poor solubility, high DILI risk, and moderate Pgp efflux are major drawbacks. The negative half-life for Ligand B is a data quality issue, but the other factors strongly favor Ligand A.
**Conclusion:**
Despite the slightly better affinity of Ligand A, the significantly better ADME properties and safety profile of Ligand B make it the more promising drug candidate. The high DILI risk and poor solubility of Ligand A are major concerns that outweigh the small affinity advantage.
Output:
0
2025-04-17 21:09:57,472 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (340.471 and 353.413 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (50.16) is better than Ligand B (62.13), being closer to the <140 threshold for good absorption and more favorable for a GPCR.
3. **logP:** Both ligands have logP values (3.771 and 4.205) within the optimal 1-3 range, but Ligand B is slightly higher. While not a major concern, higher logP can sometimes lead to off-target effects.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Both have 3 HBA, which is good.
6. **QED:** Ligand A (0.901) has a significantly better QED score than Ligand B (0.735), indicating a more drug-like profile.
7. **DILI:** Ligand A (15.781) has a much lower DILI risk than Ligand B (53.47), which is a critical advantage. A DILI percentile under 40 is preferred.
8. **BBB:** Ligand A (86.119) has a better BBB penetration percentile than Ligand B (73.827). While ADRB2 isn't exclusively a CNS target, some peripheral ADRB2 activity can be modulated by CNS effects, and better BBB penetration isn't detrimental.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.872 and -4.889), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Both ligands have negative solubility values (-3.263 and -3.907), indicating very poor aqueous solubility. This is a major drawback for both.
11. **hERG:** Both ligands have low hERG inhibition risk (0.822 and 0.715).
12. **Cl_mic:** Ligand A (32.41) has a lower microsomal clearance than Ligand B (76.32), suggesting better metabolic stability.
13. **t1/2:** Ligand A (5.43) has a better in vitro half-life than Ligand B (-13.423).
14. **Pgp:** Ligand B (0.387) has a lower P-gp efflux liability than Ligand A (0.557), which is a slight advantage.
15. **Binding Affinity:** Ligand A (-6.8 kcal/mol) has a slightly better binding affinity than Ligand B (-5.3 kcal/mol). This 1.5 kcal/mol difference is significant and can outweigh some ADME drawbacks.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A is better in TPSA, Pgp, and affinity. While both have acceptable logP, Ligand A's lower DILI and better metabolic stability are also crucial. The poor Caco-2 and solubility are concerning for both, but the superior binding affinity and safety profile of Ligand A make it the more promising candidate.
**Conclusion:**
Ligand A demonstrates a better balance of properties, particularly in terms of safety (DILI), metabolic stability (Cl_mic, t1/2), binding affinity, and drug-likeness (QED). While both have permeability and solubility issues, Ligand A's overall profile is more favorable for further development as a drug candidate targeting ADRB2.
Output:
1
2025-04-17 21:09:57,472 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (352.519 Da) is slightly lower, which is generally favorable for permeability.
**2. TPSA:** Ligand A (49.85) is significantly better than Ligand B (87.3). For a GPCR, keeping TPSA low is beneficial for permeability and receptor engagement. Ligand B is quite high, potentially hindering oral absorption.
**3. logP:** Ligand A (3.774) is optimal, while Ligand B (1.498) is on the lower side. While not terrible, lower logP can sometimes indicate poor membrane permeability.
**4. H-Bond Donors:** Ligand A (0) is preferable to Ligand B (3). Fewer H-bond donors generally improve permeability.
**5. H-Bond Acceptors:** Ligand A (3) is better than Ligand B (5), again favoring permeability.
**6. QED:** Ligand A (0.708) has a better QED score than Ligand B (0.55), indicating a more drug-like profile.
**7. DILI:** Ligand A (7.212) has a much lower DILI risk than Ligand B (32.183). This is a significant advantage for Ligand A.
**8. BBB:** Ligand A (99.069) exhibits excellent BBB penetration, while Ligand B (36.642) is poor. Given that ADRB2 is involved in cardiovascular function, CNS penetration isn't *essential*, but it could open up possibilities for exploring central effects or off-target activity.
**9. Caco-2 Permeability:** Ligand A (-4.094) and Ligand B (-5.602) both have negative values, which is unusual. However, the scale is not specified, so it's difficult to interpret.
**10. Aqueous Solubility:** Ligand A (-3.758) and Ligand B (-2.551) both have negative values, which is also unusual.
**11. hERG Inhibition:** Ligand A (0.88) is better than Ligand B (0.073). Lower hERG inhibition is crucial to avoid cardiotoxicity, making Ligand A safer.
**12. Microsomal Clearance:** Ligand A (105.127) has higher clearance than Ligand B (25.952), indicating faster metabolism and potentially shorter duration of action. This is a drawback for Ligand A.
**13. In vitro Half-Life:** Ligand A (-16.732) has a negative half-life, which is not possible. This is a data error. Ligand B (-0.626) is also negative, which is also not possible.
**14. P-gp Efflux:** Ligand A (0.32) is better than Ligand B (0.032), indicating less efflux and potentially better bioavailability.
**15. Binding Affinity:** Ligand A (-8.0) has a slightly better binding affinity than Ligand B (-6.8). While both are good, the 1.2 kcal/mol difference is significant and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand A is clearly the superior candidate. It excels in key GPCR properties like TPSA, logP, BBB penetration, and hERG inhibition. It also has a better QED score and significantly lower DILI risk. While its microsomal clearance is higher, the superior binding affinity and overall ADME profile make it the more promising drug candidate. The negative half-life values are concerning, but the other parameters strongly favor Ligand A.
Output:
1
2025-04-17 21:09:57,472 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (343.43 & 355.39 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (61.88) is better than Ligand B (70.67). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (1.405) is optimal, while Ligand B (3.484) is pushing the upper limit. Higher logP can lead to off-target effects and solubility issues.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is preferable to Ligand B (3). Similar to HBD, lower HBA is generally better for permeability.
6. **QED:** Both ligands have good QED scores (0.901 & 0.853), indicating drug-likeness.
7. **DILI:** Both ligands have acceptable DILI risk (53.94 & 59.52), below the 60% threshold. Ligand A is slightly better.
8. **BBB:** Both ligands have similar BBB penetration (73.52 & 72.82). This isn't a major concern for a cardiovascular target.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.63 & -4.32). These values are unusual and difficult to interpret without further context, but suggest poor permeability.
10. **Solubility:** Both ligands have negative solubility values (-3.05 & -3.84). These values are also unusual and suggest poor solubility.
11. **hERG:** Both ligands have low hERG inhibition risk (0.389 & 0.441).
12. **Cl_mic:** Ligand A (-20.94) has *much* better metabolic stability (lower clearance) than Ligand B (29.58). This is a significant advantage.
13. **t1/2:** Ligand A (7.88) has a shorter half-life than Ligand B (24.54). Longer half-life is generally preferred.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.018 & 0.033).
15. **Binding Affinity:** Ligand A (-6.7) has a slightly better binding affinity than Ligand B (-4.5). This is a substantial difference (2.2 kcal/mol), and a key driver for selection.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, and affinity are important. Ligand A excels in logP and TPSA, and has a significantly better binding affinity. While Ligand B has a longer half-life, the superior affinity and ADME properties of Ligand A outweigh this. The negative Caco-2 and solubility values are concerning for both, but the better overall profile of Ligand A makes it the more promising candidate.
**Output:**
1
2025-04-17 21:09:57,472 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (363.443 and 343.431 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand B (80.95) is significantly better than Ligand A (119.11). Lower TPSA generally favors better cell permeability, crucial for GPCRs.
3. **logP:** Ligand B (1.464) is slightly better than Ligand A (0.848), both are within the optimal 1-3 range, but A is a bit low.
4. **HBD:** Ligand B (2) has fewer HBDs than Ligand A (3). Fewer HBDs are generally preferred for better permeability.
5. **HBA:** Ligand B (5) has fewer HBAs than Ligand A (6). Again, fewer HBAs are generally preferred.
6. **QED:** Both ligands have good QED scores (0.727 and 0.799), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand B (47.732) has a significantly lower DILI risk than Ligand A (69.794). This is a major advantage for Ligand B.
8. **BBB:** Both ligands have reasonable BBB penetration (60.605 and 65.839). While not exceptional, they are acceptable for a peripherally acting GPCR like ADRB2.
9. **Caco-2:** Ligand B (-4.906) is slightly better than Ligand A (-5.957), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-1.849) is better than Ligand B (-3.035). Solubility is important for bioavailability.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.25 and 0.238). This is excellent.
12. **Cl_mic:** Ligand B (29.677) has a significantly lower microsomal clearance than Ligand A (-39.664). Lower clearance indicates better metabolic stability.
13. **t1/2:** Ligand B (16.966) has a longer in vitro half-life than Ligand A (11.842). This is desirable for less frequent dosing.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.016 and 0.102).
15. **Affinity:** Ligand B (-8.0) has a slightly better binding affinity than Ligand A (-7.2). While the difference is less than 1.5 kcal/mol, it's still a positive.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, and affinity. Ligand B excels in TPSA, logP, and has a slightly better affinity. The significantly lower DILI and improved metabolic stability (Cl_mic and t1/2) further strengthen its profile. While Ligand A has better solubility, the other advantages of Ligand B outweigh this.
**Conclusion:**
Ligand B demonstrates a more favorable balance of properties, particularly regarding ADME-Tox parameters (DILI, Cl_mic, t1/2) and key GPCR-relevant properties (TPSA, logP).
Output:
0
2025-04-17 21:09:57,473 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (340.423 and 356.457 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (53.35) is slightly higher than Ligand B (43.78). Both are below the 140 threshold for oral absorption, and acceptable for a cardiovascular target (not needing significant BBB penetration). Ligand B is preferable.
3. **logP:** Both ligands have good logP values (2.829 and 3.661), falling within the optimal 1-3 range. Ligand B is slightly higher, which could be a minor concern for solubility but isn't critical.
4. **HBD:** Ligand A has 0 HBD, while Ligand B has 1. Both are within the acceptable limit of 5. No strong preference.
5. **HBA:** Ligand A has 5 HBA, and Ligand B has 3. Both are below the limit of 10. Ligand B is preferable.
6. **QED:** Both ligands have very similar QED values (0.786 and 0.773), indicating good drug-likeness.
7. **DILI:** Ligand A has a DILI risk of 56.107, while Ligand B has 13.532. This is a *significant* difference. Ligand B is much safer regarding potential liver toxicity.
8. **BBB:** Both ligands have high BBB penetration (90.074 and 71.074). However, as ADRB2 is primarily a cardiovascular target, high BBB penetration isn't a primary requirement.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.967 and -4.621). This is unusual and suggests poor permeability. However, the values are similar, so this isn't a deciding factor.
10. **Solubility:** Both ligands have very poor aqueous solubility (-3.463 and -3.143). This is a major concern for both.
11. **hERG:** Both ligands have low hERG inhibition liability (0.613 and 0.896), which is good.
12. **Cl_mic:** Ligand A has a lower microsomal clearance (68.749) than Ligand B (83.716), indicating better metabolic stability. This is a positive for Ligand A.
13. **t1/2:** Ligand A has a significantly longer in vitro half-life (-14.686 hours) than Ligand B (-5.056 hours). This is a strong advantage for Ligand A.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.641 and 0.165). Ligand B is preferable.
15. **Binding Affinity:** Ligand B has a slightly better binding affinity (-7.2 kcal/mol) than Ligand A (-7.0 kcal/mol). This is a small but potentially relevant difference.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand B performs better on logP, TPSA, and Pgp. The affinity difference is small. However, the *major* deciding factor is the significantly lower DILI risk associated with Ligand B. The longer half-life of Ligand A is attractive, but the liver toxicity risk of Ligand A is too high.
**Final Decision:**
0
2025-04-17 21:09:57,473 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor (a GPCR):
**1. Molecular Weight:** Both ligands (347.415 and 360.426 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (78.95) is better than Ligand B (88.1). Both are below 140, but lower TPSA generally favors better absorption.
**3. logP:** Ligand A (2.048) is optimal, while Ligand B (0.254) is quite low. For a GPCR, a logP between 1-3 is preferred for good membrane permeability and binding. Ligand B's low logP is a concern.
**4. H-Bond Donors:** Ligand A (1) is better than Ligand B (2). Lower is generally preferred for permeability.
**5. H-Bond Acceptors:** Both ligands have 5 HBA, which is acceptable.
**6. QED:** Both ligands have similar QED values (0.764 and 0.709), indicating good drug-likeness.
**7. DILI Risk:** Ligand A (71.539) has a higher DILI risk than Ligand B (35.285). This is a significant advantage for Ligand B.
**8. BBB Penetration:** Ligand A (70.803) has better BBB penetration than Ligand B (60.876). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant depending on the specific indication.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.635 and -4.799), which is unusual. This suggests poor permeability. However, the values are very similar.
**10. Aqueous Solubility:** Ligand A (-3.321) has better solubility than Ligand B (-0.739). Solubility is important for formulation and bioavailability.
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (0.244 and 0.309).
**12. Microsomal Clearance:** Ligand A (-2.444) has a lower (better) microsomal clearance than Ligand B (-5.393), indicating greater metabolic stability.
**13. In vitro Half-Life:** Ligand A (14.294 hours) has a significantly longer half-life than Ligand B (-1.862 hours). This is a major advantage for Ligand A.
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (0.02 and 0.031).
**15. Binding Affinity:** Ligand B (-6.9 kcal/mol) has a slightly better binding affinity than Ligand A (-6.1 kcal/mol). This is a 0.8 kcal/mol difference, which is notable but not overwhelming.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand A is the better candidate. While Ligand B has a lower DILI risk and slightly better affinity, Ligand A's significantly better logP, TPSA, metabolic stability (lower Cl_mic), and longer half-life outweigh these advantages. The low logP of Ligand B is a major concern for permeability and target engagement.
Output:
1
2025-04-17 21:09:57,473 - INFO - Batch 238 complete. Total preferences: 3808
2025-04-17 21:09:57,473 - INFO - Processing batch 239/512...
2025-04-17 21:10:46,603 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
The target is ADRB2, a GPCR. Therefore, I will prioritize logP, Pgp, TPSA, BBB, and binding affinity.
* **Molecular Weight:** Both ligands (347.415 and 351.393 Da) are within the ideal range (200-500 Da).
* **TPSA:** Ligand B (60.77) is significantly better than Ligand A (101.34). Lower TPSA generally correlates with better cell permeability, crucial for GPCR targeting. Ligand B is well below the 140 A^2 threshold.
* **logP:** Both ligands have acceptable logP values (1.575 and 2.415), falling within the optimal 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability, but not drastically.
* **H-Bond Donors/Acceptors:** Both have similar HBD (2) and acceptable HBA (4 for A, 3 for B) counts, satisfying the <5 HBD and <10 HBA guidelines.
* **QED:** Ligand B (0.707) has a better QED score than Ligand A (0.415), indicating a more drug-like profile.
* **DILI:** Ligand B (13.3) has a much lower DILI risk than Ligand A (35.285), a significant advantage.
* **BBB:** Ligand B (83.249) has a substantially higher BBB penetration percentile than Ligand A (50.679). This is a key advantage for a GPCR target, even if not strictly CNS-focused, as it suggests better distribution.
* **Caco-2 Permeability:** Ligand A (-5.103) and Ligand B (-4.273) are both negative, which is unusual. A higher value is preferred, but the difference isn't substantial enough to be a deciding factor.
* **Aqueous Solubility:** Both ligands have very poor aqueous solubility (-2.661 and -2.897). This is a concern for both, potentially requiring formulation strategies.
* **hERG Inhibition:** Ligand A (0.076) has a slightly lower hERG risk than Ligand B (0.8), which is preferable.
* **Microsomal Clearance:** Ligand A (21.401) has lower microsomal clearance than Ligand B (25.54), suggesting better metabolic stability.
* **In vitro Half-Life:** Ligand A (6.449) has a longer in vitro half-life than Ligand B (4.198), which is a positive attribute.
* **P-gp Efflux:** Ligand A (0.094) has lower P-gp efflux than Ligand B (0.373), which is desirable.
* **Binding Affinity:** Ligand B (-6.3 kcal/mol) has a slightly better binding affinity than Ligand A (-5.9 kcal/mol). While the difference is not huge, it's enough to consider, especially given the other favorable properties of Ligand B.
**Overall Assessment:**
Ligand B demonstrates a superior balance of properties, particularly regarding TPSA, BBB penetration, DILI risk, and QED. While Ligand A has advantages in metabolic stability, half-life, and P-gp efflux, the improvements in Ligand B's ADME profile and safety outweigh these benefits. The slightly better binding affinity of Ligand B further solidifies its position as the more promising candidate.
**Output:**
0
2025-04-17 21:10:46,604 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.431 and 344.499 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (76.46) is higher than Ligand B (49.41). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B has a clear advantage.
3. **logP:** Ligand A (0.581) is quite low, potentially hindering membrane permeability. Ligand B (2.969) is within the optimal 1-3 range. This is a significant advantage for Ligand B.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 5 HBA, while Ligand B has 2. Lower HBA is generally better for permeability, giving Ligand B an edge.
6. **QED:** Both ligands have similar QED values (0.792 and 0.722), indicating good drug-likeness.
7. **DILI:** Ligand A (49.321) has a higher DILI risk than Ligand B (15.277). This is a substantial advantage for Ligand B.
8. **BBB:** Both have similar BBB penetration (60.76 and 61.07). Since ADRB2 is not a CNS target, this is not a major factor.
9. **Caco-2:** Ligand A (-5.012) has a very poor Caco-2 permeability, suggesting poor absorption. Ligand B (-4.562) is better, but still not great.
10. **Solubility:** Ligand A (-1.342) has poor solubility, while Ligand B (-4.001) is even worse. Both are problematic.
11. **hERG:** Ligand A (0.166) has a slightly better hERG profile than Ligand B (0.32), which is favorable.
12. **Cl_mic:** Ligand A (10.98) has significantly lower microsomal clearance than Ligand B (38.206), indicating better metabolic stability. This is a strong advantage for Ligand A.
13. **t1/2:** Ligand A (18.918) has a longer in vitro half-life than Ligand B (10.77), further supporting its better metabolic stability.
14. **Pgp:** Ligand A (0.047) has much lower P-gp efflux liability than Ligand B (0.193), which is beneficial for bioavailability.
15. **Binding Affinity:** Ligand B (-7.2) has a slightly better binding affinity than Ligand A (-7.1), but the difference is small (0.1 kcal/mol).
**Overall Assessment:**
While Ligand A has better metabolic stability (lower Cl_mic, longer t1/2) and lower P-gp efflux, its very low logP, poor Caco-2 permeability, and poor solubility are major drawbacks. These issues will likely severely limit its oral bioavailability. Ligand B, despite slightly worse metabolic stability, has a much more favorable logP, lower DILI risk, and a slightly better binding affinity. Considering the GPCR-specific priorities (logP, TPSA, affinity), Ligand B is the more promising candidate. The small affinity difference is outweighed by the significant ADME advantages of Ligand B.
Output:
0
2025-04-17 21:10:46,604 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.45 & 347.459 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (56.73) is significantly better than Ligand B (78.51). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have acceptable logP values (2.565 and 1.365), falling within the 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability, but not drastically so.
4. **HBD:** Both ligands have 2 HBD, which is good.
5. **HBA:** Ligand A has 4 HBA, while Ligand B has 3. Both are acceptable (<=10).
6. **QED:** Ligand A (0.881) has a better QED score than Ligand B (0.737), indicating a more drug-like profile.
7. **DILI:** Ligand A (15.2%) has a much lower DILI risk than Ligand B (21.946%). This is a significant advantage.
8. **BBB:** Ligand A (77.821%) has better BBB penetration than Ligand B (58.007%), though this is less critical for a cardiovascular target.
9. **Caco-2:** Both have negative Caco-2 values (-5.294 and -5.156), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Both have negative solubility values (-2.169 and -2.218), indicating very poor aqueous solubility. This is a major drawback for both compounds.
11. **hERG:** Ligand A (0.911) has a slightly better hERG profile than Ligand B (0.074), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand A (-13.827) has significantly better metabolic stability (lower clearance) than Ligand B (21.95). This is a crucial advantage.
13. **t1/2:** Ligand B (20.154) has a much longer in vitro half-life than Ligand A (6.285). This is a significant benefit for dosing frequency.
14. **Pgp:** Ligand A (0.275) has lower P-gp efflux than Ligand B (0.029), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand A (-7.3 kcal/mol) has a slightly better binding affinity than Ligand B (-5.6 kcal/mol). The 1.7 kcal/mol difference is substantial and can outweigh some ADME drawbacks.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A performs better in TPSA, Pgp, and significantly better in affinity. While both have acceptable logP values, Ligand A's slightly higher value is preferable.
**Overall Assessment:**
Despite the poor Caco-2 and solubility for both, Ligand A is the stronger candidate. Its superior binding affinity, lower DILI risk, better metabolic stability (Cl_mic), and better Pgp profile outweigh Ligand B's longer half-life. The improved QED score also supports Ligand A's drug-like properties. The solubility and permeability issues would need to be addressed through formulation or further chemical modifications, but the core scaffold of Ligand A appears more promising.
Output:
1
2025-04-17 21:10:46,604 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (351.447 and 361.467 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (82.11) is slightly higher than Ligand B (69.72). Both are below the 140 threshold for oral absorption, but Ligand B is closer to the preferred <90 for GPCRs.
3. **logP:** Ligand A (-0.56) is a bit low, potentially hindering permeation. Ligand B (0.942) is better, falling within the 1-3 optimal range. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable, below the 5 limit.
5. **HBA:** Ligand A (5) and Ligand B (4) are both acceptable, below the 10 limit.
6. **QED:** Both ligands have reasonable QED scores (0.694 and 0.587), indicating good drug-like properties. Ligand A is slightly better.
7. **DILI:** Ligand A (4.769%) has a much lower DILI risk than Ligand B (65.723%). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (49.864%) has a lower BBB penetration than Ligand B (62.854%). While ADRB2 isn't strictly a CNS target, some CNS exposure can be acceptable, and Ligand B is better here.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.05 and -4.884), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-0.933) has slightly better solubility than Ligand B (-3.253).
11. **hERG:** Both ligands have very low hERG risk (0.142 and 0.15). No significant difference.
12. **Cl_mic:** Ligand A (-33.453) has a significantly lower (better) microsomal clearance than Ligand B (34.683). This indicates greater metabolic stability for Ligand A.
13. **t1/2:** Ligand A (5.916) has a shorter half-life than Ligand B (-31.726, which is likely an error and should be interpreted as very long).
14. **Pgp:** Both ligands have low Pgp efflux liability (0.003 and 0.129).
15. **Binding Affinity:** Ligand A (-4.6 kcal/mol) and Ligand B (-5.6 kcal/mol) both have good binding affinity, but Ligand B is significantly stronger. This is a substantial advantage for Ligand B.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP and affinity. While Ligand A has better DILI and Cl_mic, the superior binding affinity of Ligand B is a critical factor. The slightly better TPSA of Ligand B is also beneficial.
**Overall Assessment:**
Ligand B's stronger binding affinity and better logP outweigh the advantages of Ligand A in DILI and Cl_mic. The Caco-2 values are concerning for both, but the potency advantage of Ligand B is likely to be more impactful in driving overall efficacy.
Output:
0
2025-04-17 21:10:46,604 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
We are targeting ADRB2, a GPCR, so the priorities are logP, Pgp, TPSA, affinity, and BBB. Let's compare the ligands step-by-step:
1. **MW:** Both ligands (349.381 and 342.483 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (68.06) is higher than Ligand B (49.41). Lower TPSA is generally preferred for better membrane permeability, giving a slight edge to Ligand B.
3. **logP:** Ligand A (4.448) is higher than Ligand B (2.868). While both are within the acceptable range (1-3 is optimal, up to 4 is okay), Ligand A is pushing the upper limit and could potentially have solubility issues or off-target effects. Ligand B is closer to the sweet spot.
4. **HBD/HBA:** Ligand A (1 HBD, 4 HBA) and Ligand B (1 HBD, 2 HBA) are both reasonable.
5. **QED:** Ligand B (0.723) has a better QED score than Ligand A (0.475), indicating a more drug-like profile.
6. **DILI:** Ligand B (11.245) has a significantly lower DILI risk than Ligand A (53.432). This is a major advantage for Ligand B.
7. **BBB:** Ligand A (91.276) has a better BBB penetration score than Ligand B (70.764). While ADRB2 isn't strictly a CNS target, some peripheral ADRB2 receptors can be affected by CNS penetration, and higher BBB is generally favorable.
8. **Caco-2:** Both ligands have negative Caco-2 values (-4.932 and -4.6), which is unusual and suggests poor permeability. It's difficult to interpret these values without knowing the scale used.
9. **Solubility:** Both ligands have negative solubility values (-4.395 and -4.179), which is also unusual and suggests poor solubility.
10. **hERG:** Ligand B (0.394) has a lower hERG inhibition liability than Ligand A (0.919), which is a significant safety advantage.
11. **Cl_mic:** Ligand B (40.726) has a lower microsomal clearance than Ligand A (23.202), indicating better metabolic stability.
12. **t1/2:** Ligand B (8.737) has a longer in vitro half-life than Ligand A (33.688). This is a positive attribute.
13. **Pgp:** Ligand B (0.074) has significantly lower P-gp efflux liability than Ligand A (0.459), which is crucial for bioavailability and potentially CNS exposure.
14. **Affinity:** Ligand A (-5.2 kcal/mol) has a slightly better binding affinity than Ligand B (-3.7 kcal/mol). This is a 1.5 kcal/mol difference, which is significant.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity, Ligand B demonstrates a significantly better overall profile, particularly regarding safety (DILI, hERG), ADME properties (Cl_mic, t1/2, Pgp, QED), and logP. The lower TPSA of Ligand B is also favorable. The negative Caco-2 and solubility values are concerning for both, but the other advantages of Ligand B outweigh the affinity difference. For a GPCR, the balance of properties is more important than a small advantage in binding.
**Output:**
0
2025-04-17 21:10:46,604 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (356.8 and 346.5 Da) fall comfortably within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (96.5) is slightly higher than Ligand B (84.0). Both are below the 140 threshold for good oral absorption, but closer to the 90 threshold for CNS targets, which isn't a primary concern here.
3. **logP:** Both ligands have excellent logP values (3.06 and 2.89) falling within the optimal 1-3 range.
4. **HBD:** Ligand A (2) is preferable to Ligand B (3). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (7). Lower HBA generally improves permeability.
6. **QED:** Both ligands have similar, good QED scores (0.748 and 0.70), indicating good drug-like properties.
7. **DILI:** Ligand B (55.5) is significantly better than Ligand A (88.6) regarding DILI risk. Lower is better, and Ligand B is well below the 60 high-risk threshold.
8. **BBB:** Ligand B (78.7) has a higher BBB penetration percentile than Ligand A (62.2). While ADRB2 isn't strictly a CNS target, some CNS exposure can be a concern for off-target effects.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual. It suggests poor permeability. However, the values are similar (-5.43 and -5.08).
10. **Solubility:** Both ligands have similar, poor solubility scores (-3.85 and -3.86). This is a potential issue for bioavailability.
11. **hERG:** Ligand A (0.16) is preferable to Ligand B (0.67) regarding hERG inhibition liability. Lower is better.
12. **Cl_mic:** Ligand A (10.4) has a significantly lower microsomal clearance than Ligand B (66.1), indicating better metabolic stability.
13. **t1/2:** Ligand A (9.83) has a better in vitro half-life than Ligand B (32.5).
14. **Pgp:** Ligand B (0.05) is preferable to Ligand A (0.22) regarding P-gp efflux. Lower is better.
15. **Binding Affinity:** Ligand A (-7.8 kcal/mol) has a significantly stronger binding affinity than Ligand B (-5.2 kcal/mol). This is a substantial advantage, exceeding the 1.5 kcal/mol difference threshold.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Both ligands are good on logP and TPSA. Ligand B is better on Pgp. However, the *significant* advantage in binding affinity for Ligand A (-7.8 vs -5.2 kcal/mol) outweighs the slightly less favorable DILI and Pgp profiles. The improved metabolic stability (lower Cl_mic and higher t1/2) of Ligand A is also a significant benefit.
**Conclusion:**
Despite the slightly higher DILI risk and Pgp efflux, the substantially stronger binding affinity of Ligand A, coupled with its improved metabolic stability, makes it the more promising drug candidate.
Output:
1
2025-04-17 21:10:46,604 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (377.937) is slightly higher than Ligand B (342.439), but both are acceptable.
2. **TPSA:** Ligand A (38.33) is excellent, well below the 140 threshold and favorable for oral absorption. Ligand B (67.43) is higher, but still within a reasonable range, though less optimal.
3. **logP:** Ligand A (4.898) is a bit high, potentially leading to solubility issues or off-target interactions. Ligand B (1.087) is very good, falling squarely within the optimal 1-3 range.
4. **HBD:** Both ligands have acceptable HBD counts (Ligand A: 1, Ligand B: 2), below the threshold of 5.
5. **HBA:** Both ligands have acceptable HBA counts (Ligand A: 3, Ligand B: 3), below the threshold of 10.
6. **QED:** Both ligands have similar and good QED values (Ligand A: 0.777, Ligand B: 0.752), indicating good drug-like properties.
7. **DILI:** Ligand A (56.805) has a higher DILI risk than Ligand B (40.752), but both are below the concerning threshold of 60.
8. **BBB:** Ligand A (69.794) has a better BBB penetration potential than Ligand B (54.75). While ADRB2 isn't strictly a CNS target, some peripheral ADRB2 receptors can be affected by CNS penetration, and it's a generally favorable property.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.765 and -4.766). This is unusual and suggests poor permeability. However, the values are nearly identical.
10. **Solubility:** Ligand A (-5.648) has worse solubility than Ligand B (-3.164). This is a significant concern given Ligand A's higher logP.
11. **hERG:** Ligand A (0.706) has a slightly higher hERG risk than Ligand B (0.22), but both are relatively low.
12. **Cl_mic:** Ligand A (101.527) has a higher microsomal clearance than Ligand B (7.636), suggesting lower metabolic stability. This is a major drawback.
13. **t1/2:** Ligand A (57.735) has a longer half-life than Ligand B (7.449), which is favorable.
14. **Pgp:** Ligand A (0.814) has a higher Pgp efflux liability than Ligand B (0.049). This is a negative for bioavailability.
15. **Binding Affinity:** Ligand A (-7.2 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.4 kcal/mol). This is a substantial advantage (a 0.8 kcal/mol difference).
**GPCR-Specific Priorities & Overall Assessment:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. While Ligand A has a superior binding affinity, its high logP, poor solubility, high Pgp efflux, and high microsomal clearance are significant liabilities. Ligand B, despite its weaker affinity, has a much more balanced profile with better solubility, lower Pgp efflux, and better metabolic stability. The affinity difference, while substantial, may be overcome with further optimization of Ligand B. The poor Caco-2 values for both are concerning and would need to be addressed regardless of which lead is chosen.
Considering the balance of properties, especially the ADME characteristics, Ligand B is the more promising starting point for drug development.
Output:
0
2025-04-17 21:10:46,604 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (341.455 and 346.391 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (54.46) is significantly better than Ligand B (113.25). For a GPCR, lower TPSA is generally preferred for better permeability, and Ligand A is well below the 140 threshold. Ligand B is pushing the limit.
3. **logP:** Ligand A (4.277) is higher than Ligand B (1.158). While both are within the acceptable range, Ligand A is at the upper end. This could potentially lead to solubility issues, but for a GPCR, a slightly higher logP isn't as detrimental as for other targets.
4. **HBD:** Ligand A (1) is better than Ligand B (2). Lower is generally preferred.
5. **HBA:** Ligand A (4) is better than Ligand B (7). Lower is generally preferred.
6. **QED:** Both ligands have good QED scores (0.779 and 0.807), indicating good drug-like properties. No significant difference.
7. **DILI:** Ligand B (77.162) has a higher DILI risk than Ligand A (69.329). While both are above the ideal <40, Ligand A is preferable.
8. **BBB:** Both ligands have similar BBB penetration (55.991 and 56.96). Since ADRB2 isn't a primary CNS target, this isn't a major deciding factor.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale isn't specified, so it's hard to interpret.
10. **Solubility:** Ligand A (-5.009) has a worse solubility score than Ligand B (-2.537). This is a concern given Ligand A's higher logP.
11. **hERG:** Ligand A (0.803) has a slightly better hERG profile than Ligand B (0.144), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand B (62.74) has a significantly lower microsomal clearance than Ligand A (103.695). This suggests better metabolic stability for Ligand B.
13. **t1/2:** Ligand A (34.434) has a much longer in vitro half-life than Ligand B (-16.854). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.573) has a lower Pgp efflux liability than Ligand B (0.016). This is preferable for bioavailability.
15. **Binding Affinity:** Ligand A (-6.7 kcal/mol) has a slightly better binding affinity than Ligand B (-5.1 kcal/mol). This is a substantial difference and a key factor.
**Overall Assessment:**
Ligand A has a superior binding affinity, better TPSA, HBD, HBA, DILI, hERG, and Pgp properties. The longer half-life is also a significant benefit. While Ligand A has a higher logP and lower solubility, the strong binding affinity and favorable ADME properties (especially Pgp and hERG) outweigh these concerns for a GPCR target like ADRB2. Ligand B has better metabolic stability (lower Cl_mic) but is significantly weaker in binding affinity and has a worse DILI profile.
Output:
1
2025-04-17 21:10:46,605 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (354.491) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are good, below the 140 A^2 threshold for oral absorption. Ligand B (70.83) is better than Ligand A (81.08).
3. **logP:** Both are within the optimal 1-3 range. Ligand B (1.866) is slightly higher, potentially aiding membrane permeability, but not significantly.
4. **HBD:** Ligand A has 2 HBD, Ligand B has 0. Lower is generally better for permeability, so Ligand B is slightly favored.
5. **HBA:** Both ligands have 4 HBA, which is acceptable.
6. **QED:** Both have good QED scores (A: 0.755, B: 0.792), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand B (53.044) has a significantly lower DILI risk than Ligand A (14.541). This is a major advantage for Ligand B.
8. **BBB:** Both have moderate BBB penetration. Ligand A (57.619) and Ligand B (58.007) are very similar. Since ADRB2 is a cardiovascular target, BBB penetration is not a primary concern.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the values are similar.
10. **Solubility:** Ligand A (-1.728) has better aqueous solubility than Ligand B (-3.17). Solubility is important for bioavailability.
11. **hERG:** Both have low hERG inhibition risk (A: 0.279, B: 0.327).
12. **Cl_mic:** Ligand B (20.945) has a slightly higher microsomal clearance than Ligand A (18.949), indicating faster metabolism.
13. **t1/2:** Ligand B (24.227) has a significantly longer in vitro half-life than Ligand A (-0.999). This is a significant advantage for Ligand B.
14. **Pgp:** Both have low P-gp efflux liability (A: 0.074, B: 0.219).
15. **Binding Affinity:** Ligand A (-7.3 kcal/mol) has a substantially stronger binding affinity than Ligand B (-4.1 kcal/mol). This is a very important factor. A difference of 3.2 kcal/mol is substantial.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. While Ligand B has better TPSA, DILI, and t1/2, the significantly stronger binding affinity of Ligand A (-7.3 vs -4.1 kcal/mol) outweighs these benefits. A 3.2 kcal/mol difference in binding is a major advantage and can often overcome minor ADME deficiencies. The similar logP and Pgp values further support this.
**Conclusion:**
Despite the better DILI and half-life of Ligand B, the significantly higher binding affinity of Ligand A makes it the more promising drug candidate.
Output:
1
2025-04-17 21:10:46,605 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [348.487, 58.64, 2.204, 1, 3, 0.793, 15.2, 63.009, -4.551, -2.312, 0.215, -7.92, 3.789, 0.035, -7.3]
**Ligand B:** [346.471, 58.64, 2.431, 1, 3, 0.778, 13.532, 71.229, -4.786, -2.6, 0.296, 29.143, 4.266, 0.047, -7.0]
Here's a breakdown, considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both ligands are within the ideal range (348.487 Da and 346.471 Da).
2. **TPSA:** Both are similar and acceptable (58.64). This is good for oral absorption.
3. **logP:** Both are within the optimal range (2.204 and 2.431). Ligand B is slightly higher, which *could* be beneficial for membrane permeability, but is not a large difference.
4. **HBD/HBA:** Both have 1 HBD and 3 HBA, which is good.
5. **QED:** Both are good (0.793 and 0.778), indicating a generally drug-like profile.
6. **DILI:** Ligand A has a DILI risk of 15.2%, while Ligand B is 13.532%. Both are good, but Ligand B is slightly better.
7. **BBB:** Ligand B (71.229%) has significantly better BBB penetration potential than Ligand A (63.009%). While ADRB2 isn't strictly a CNS target, some CNS exposure can occur, and higher BBB penetration is generally favorable.
8. **Caco-2:** Both are negative, indicating poor permeability. Ligand B (-4.786) is slightly worse than Ligand A (-4.551).
9. **Solubility:** Both have poor solubility (-2.312 and -2.6). This is a concern for both, but Ligand B is slightly worse.
10. **hERG:** Both are very low risk (0.215 and 0.296).
11. **Cl_mic:** Ligand A (-7.92) has *much* lower microsomal clearance than Ligand B (29.143). This suggests significantly better metabolic stability for Ligand A.
12. **t1/2:** Ligand B (4.266) has a slightly longer in vitro half-life than Ligand A (3.789).
13. **Pgp:** Both have very low P-gp efflux (0.035 and 0.047).
14. **Affinity:** Ligand A (-7.3 kcal/mol) has a slightly better binding affinity than Ligand B (-7.0 kcal/mol). While the difference is small, it's within the range where it could outweigh other drawbacks.
**Overall Assessment:**
The key trade-offs are metabolic stability (Ligand A) versus BBB penetration (Ligand B). Given that this is a cardiovascular target, metabolic stability is more crucial than BBB penetration. The slightly better affinity of Ligand A further strengthens its position. While both have solubility issues, the significantly better metabolic stability of Ligand A makes it the more promising candidate.
Output:
1
2025-04-17 21:10:46,605 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (356.463 and 349.435 Da) fall comfortably within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (85.89) is better than Ligand B (96.45). For a cardiovascular GPCR, TPSA is moderately important for permeability, and A is closer to the preferred <140.
3. **logP:** Ligand A (1.99) is better than Ligand B (0.308). Both are within the 1-3 range, but A is closer to optimal. B is quite low and may have permeability issues.
4. **HBD:** Both ligands have 2 HBD, meeting the <5 guideline.
5. **HBA:** Ligand A has 5 HBA, while Ligand B has 6. Both are acceptable (<10), but A is slightly better.
6. **QED:** Ligand A (0.76) is slightly better than Ligand B (0.666), indicating a more drug-like profile.
7. **DILI:** Ligand A (33.773) has a lower DILI risk than Ligand B (38.736), both are acceptable (<40 is good).
8. **BBB:** Ligand A (78.79) has significantly better BBB penetration than Ligand B (62.97). While ADRB2 isn't exclusively a CNS target, some CNS exposure is possible with systemic administration, and higher BBB is generally favorable.
9. **Caco-2:** Ligand A (-4.509) is better than Ligand B (-4.629). Both are negative, indicating poor permeability.
10. **Solubility:** Ligand A (-2.421) is better than Ligand B (-1.627). Both are poor, but A is slightly better.
11. **hERG:** Ligand A (0.219) has a significantly lower hERG inhibition liability than Ligand B (0.075). This is a critical advantage for cardiovascular drugs.
12. **Cl_mic:** Ligand A (44.427) has a higher microsomal clearance than Ligand B (19.696). This means B is more metabolically stable, a significant advantage.
13. **t1/2:** Ligand B (-28.555) has a much longer in vitro half-life than Ligand A (-1.3). This is a major advantage for B.
14. **Pgp:** Ligand A (0.021) has lower P-gp efflux than Ligand B (0.004). Lower Pgp is preferred.
15. **Binding Affinity:** Ligand B (-7.3) has a stronger binding affinity than Ligand A (-6.4). This is a 1.5 kcal/mol advantage, which is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand B has a significantly better binding affinity and a much longer half-life, which are very important. However, it suffers from a low logP, lower BBB penetration, and higher Pgp efflux. Ligand A has better TPSA, logP, BBB, hERG, and DILI. The hERG liability of Ligand B is concerning for a cardiovascular target.
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), and the importance of minimizing cardiotoxicity (hERG), Ligand A appears to be the more balanced and viable candidate. The affinity difference is significant, but the ADME profile of Ligand B is concerning. The better hERG profile of Ligand A is a major factor in this decision.
Output:
1
2025-04-17 21:10:46,605 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (366.447) is slightly higher than Ligand B (350.507), but both are acceptable.
2. **TPSA:** Ligand A (110.91) is higher than Ligand B (61.6). While both are reasonably low, Ligand B is significantly better, falling well below the 140 threshold for good oral absorption and approaching the 90 threshold desirable for CNS targets (though ADRB2 isn't strictly a CNS target, lower TPSA is generally beneficial).
3. **logP:** Ligand A (0.038) is quite low, potentially hindering permeation. Ligand B (1.948) is much better, falling within the optimal 1-3 range. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable, below the threshold of 5.
5. **HBA:** Ligand A (8) and Ligand B (5) are both acceptable, below the threshold of 10.
6. **QED:** Both ligands have good QED scores (Ligand A: 0.685, Ligand B: 0.816). Ligand B is slightly better.
7. **DILI:** Ligand A (70.531) has a higher DILI risk than Ligand B (3.335). This is a major concern for Ligand A. Ligand B is excellent in this regard.
8. **BBB:** Both ligands have moderate BBB penetration (Ligand A: 51.958, Ligand B: 57.425). This isn't a primary concern for ADRB2, but higher is generally preferred.
9. **Caco-2:** Ligand A (-5.608) and Ligand B (-4.748) are both negative, indicating poor permeability. Ligand B is slightly better.
10. **Solubility:** Ligand A (-2.374) and Ligand B (-0.041) are both poor. Ligand B is slightly better.
11. **hERG:** Ligand A (0.161) and Ligand B (0.55) are both relatively low risk, but Ligand B is slightly higher.
12. **Cl_mic:** Ligand A (41.629) has a lower (better) microsomal clearance than Ligand B (8.54). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (14.824) has a longer half-life than Ligand B (-5.084). This is a significant advantage for Ligand A.
14. **Pgp:** Both ligands have low Pgp efflux liability (Ligand A: 0.06, Ligand B: 0.067).
15. **Binding Affinity:** Ligand B (-6.9 kcal/mol) has a slightly better binding affinity than Ligand A (-6.1 kcal/mol). While the difference is less than 1.5 kcal/mol, it's still a positive for Ligand B.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, and affinity are key. Ligand B excels in logP and TPSA, and has a slightly better affinity. The significantly lower DILI risk for Ligand B is also a major advantage. While Ligand A has better metabolic stability and half-life, the poor logP and high DILI risk are substantial drawbacks.
**Conclusion:**
Considering the balance of properties and the priorities for a GPCR target, Ligand B is the more promising drug candidate.
Output:
0
2025-04-17 21:10:46,605 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (339.4 and 337.3 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (71.41) is significantly better than Ligand B (98.06). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand A is well below the 140 threshold, while Ligand B is approaching it.
**3. logP:** Ligand B (1.375) is slightly better than Ligand A (0.379). Both are within the 1-3 range, but A is a bit low, potentially hindering membrane permeability.
**4. H-Bond Donors:** Both have 1 HBD, which is good.
**5. H-Bond Acceptors:** Ligand B (7) has more HBAs than Ligand A (4). While both are acceptable (<=10), fewer HBAs generally favor permeability.
**6. QED:** Ligand A (0.809) has a slightly better QED score than Ligand B (0.755), indicating a more drug-like profile.
**7. DILI:** Ligand A (40.6) has a much lower DILI risk than Ligand B (94.8). This is a *major* advantage for Ligand A.
**8. BBB:** Ligand B (61.0) has a higher BBB percentile than Ligand A (42.0). While ADRB2 is cardiovascular, some brain exposure can occur, so this is a slight advantage for B.
**9. Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. This is a concern for both.
**10. Solubility:** Both have negative solubility values, indicating poor aqueous solubility. This is a significant drawback for both.
**11. hERG:** Both have very low hERG inhibition liability (0.093 and 0.182), which is excellent.
**12. Cl_mic:** Ligand A (-4.256) has a much lower (better) microsomal clearance than Ligand B (15.738). This suggests greater metabolic stability for Ligand A.
**13. t1/2:** Ligand A (-12.801) has a more negative in vitro half-life, indicating a longer half-life than Ligand B (-0.745).
**14. Pgp:** Both have very low Pgp efflux liability (0.021 and 0.027), which is good.
**15. Binding Affinity:** Ligand B (-7.5) has a significantly stronger binding affinity than Ligand A (-5.5). This is a 2 kcal/mol difference, which is substantial.
**Overall Assessment:**
The strong binding affinity of Ligand B is very attractive. However, the significantly higher DILI risk and higher metabolic clearance of Ligand B are major concerns. Ligand A, while having a weaker affinity, presents a much better safety profile (DILI) and improved metabolic stability (Cl_mic, t1/2). The TPSA of Ligand A is also more favorable. While both have poor solubility and Caco-2 permeability, the other advantages of Ligand A outweigh the affinity difference, especially considering the potential for further optimization of solubility and permeability.
Therefore, I would choose Ligand A.
Output:
1
2025-04-17 21:10:46,605 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [354.491, 81.08, 1.251, 2, 4, 0.752, 11.128, 60.915, -4.643, -1.565, 0.168, 41.504, 2.546, 0.015, -6.7]
**Ligand B:** [345.443, 69.72, 0.944, 1, 3, 0.384, 29.081, 54.944, -4.596, -1.773, 0.098, 27.597, -29.763, 0.014, -5.6]
Here's a step-by-step comparison, keeping GPCR priorities (logP, Pgp, TPSA, affinity) in mind:
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (345.443) is slightly lower, which is generally favorable.
2. **TPSA:** Ligand A (81.08) is a bit higher than Ligand B (69.72). Both are below 140, but B is better for permeability.
3. **logP:** Ligand A (1.251) and B (0.944) are both within the optimal 1-3 range. A is slightly better.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1), but both are acceptable.
5. **HBA:** Ligand A (4) is slightly higher than Ligand B (3), but both are acceptable.
6. **QED:** Ligand A (0.752) is significantly better than Ligand B (0.384), indicating a more drug-like profile.
7. **DILI:** Ligand A (11.128) has a higher DILI risk than Ligand B (29.081). This is a significant advantage for B.
8. **BBB:** Ligand A (60.915) is better than Ligand B (54.944), but neither is particularly high. For a cardiovascular target, BBB isn't a primary concern, so this difference is less critical.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand B (-4.596) is slightly less negative than Ligand A (-4.643), suggesting marginally better absorption.
10. **Solubility:** Both are negative, indicating poor solubility. Ligand B (-1.773) is slightly better than Ligand A (-1.565).
11. **hERG:** Both are very low (0.168 and 0.098), indicating minimal hERG inhibition risk.
12. **Cl_mic:** Ligand B (27.597) has significantly lower microsomal clearance than Ligand A (41.504), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-29.763) has a much longer half-life than Ligand A (2.546). This is a major advantage for B.
14. **Pgp:** Both are very low (0.015 and 0.014), indicating minimal P-gp efflux.
15. **Affinity:** Ligand A (-6.7 kcal/mol) has a stronger binding affinity than Ligand B (-5.6 kcal/mol). This is a substantial advantage for A. The difference is >1.5 kcal/mol, which can outweigh some ADME concerns.
**Overall Assessment:**
Ligand A has a better binding affinity and QED score. However, Ligand B exhibits significantly better metabolic stability (lower Cl_mic, longer t1/2), lower DILI risk, and slightly better permeability and solubility. While the affinity difference is substantial, the ADME profile of Ligand B is considerably more favorable, particularly the improved metabolic stability and reduced toxicity risk. For a GPCR, a good balance of potency and ADME properties is crucial. Given the cardiovascular context, metabolic stability and minimizing off-target effects (like liver toxicity) are paramount.
Therefore, I would choose Ligand B.
Output:
0
2025-04-17 21:10:46,606 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
The target is ADRB2, a GPCR. Therefore, I will prioritize logP, TPSA, Pgp efflux, BBB penetration, and binding affinity. Metabolic stability (Cl_mic, t1/2) and safety (DILI, hERG) are also important considerations.
Let's compare the ligands property by property:
1. **MW:** Both ligands (339.435 and 344.459 Da) are within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (58.56) is significantly better than Ligand B (75.19). Lower TPSA generally favors better cell permeability, crucial for GPCR targeting. Ligand A is well below the 140 threshold, while B is approaching it.
3. **logP:** Both ligands have good logP values (2.649 and 2.196), falling within the optimal 1-3 range.
4. **HBD/HBA:** Ligand A has 2 HBD and 3 HBA, while Ligand B has 1 HBD and 4 HBA. Both are acceptable, but Ligand A is slightly more balanced.
5. **QED:** Both ligands have similar QED values (0.88 and 0.858), indicating good drug-likeness.
6. **DILI:** Ligand A (30.865) has a slightly lower DILI risk than Ligand B (39.899), which is preferable. Both are below the concerning 60 threshold.
7. **BBB:** Ligand B (76.541) shows significantly better BBB penetration than Ligand A (40.946). While ADRB2 isn't strictly a CNS target, some peripheral distribution is still beneficial, and higher BBB can indicate better overall permeability.
8. **Caco-2:** Both have negative values, indicating permeability. The magnitude is similar.
9. **Solubility:** Ligand A (-2.871) has slightly better solubility than Ligand B (-1.998).
10. **hERG:** Both ligands have low hERG inhibition risk (0.3 and 0.254).
11. **Cl_mic:** Ligand B (40.68) has a higher microsomal clearance than Ligand A (20.846), indicating faster metabolism and potentially lower *in vivo* exposure.
12. **t1/2:** Ligand A (44.591) has a much longer *in vitro* half-life than Ligand B (-10.545). This is a significant advantage.
13. **Pgp:** Both ligands show low P-gp efflux liability (0.111 and 0.077).
14. **Binding Affinity:** Ligand B (-8.0) has a slightly stronger binding affinity than Ligand A (-7.4). This is a 0.6 kcal/mol difference, which is significant but not overwhelming.
**Overall Assessment:**
Ligand A has a better balance of properties, particularly regarding TPSA, metabolic stability (Cl_mic and t1/2), and DILI risk. While Ligand B has better BBB penetration and slightly better affinity, the improved ADME properties of Ligand A are more critical for overall drug development success, especially considering the GPCR target class. The difference in binding affinity (0.6 kcal/mol) is not large enough to outweigh the advantages of Ligand A's ADME profile.
**Output:**
1
2025-04-17 21:10:46,606 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (341.371 Da) is well within the ideal range (200-500 Da). Ligand B (364.515 Da) is also acceptable. No clear advantage here.
2. **TPSA:** Ligand A (101.53) is slightly above the preferred <140 for good oral absorption, but still reasonable. Ligand B (56.75) is excellent, well below 140, suggesting better permeability. This favors Ligand B.
3. **logP:** Both ligands have good logP values (A: 1.19, B: 1.618), falling within the optimal 1-3 range. Ligand B is slightly better.
4. **HBD:** Ligand A has 2 HBD, which is good. Ligand B has 0 HBD, which is also acceptable. No strong preference.
5. **HBA:** Both ligands have 6 HBA, which is within the acceptable range of <=10. No clear difference.
6. **QED:** Ligand A (0.701) has a slightly better QED score than Ligand B (0.654), indicating a more drug-like profile. This favors Ligand A.
7. **DILI:** Ligand A (62.35) has a slightly higher DILI risk than Ligand B (52.85), but both are acceptable (<60 is good). This favors Ligand B.
8. **BBB:** Ligand B (78.519) has a significantly higher BBB penetration percentile than Ligand A (31.834). As ADRB2 is a GPCR, BBB penetration is a consideration, although not paramount for cardiovascular targets. This favors Ligand B.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual. Assuming these are percentile scores, Ligand A (-5.351) is worse than Ligand B (-4.987).
10. **Solubility:** Both have negative solubility values, which is unusual. Assuming these are percentile scores, Ligand A (-2.14) is worse than Ligand B (-1.545).
11. **hERG:** Both ligands have low hERG inhibition liability (A: 0.258, B: 0.57), which is excellent. No clear difference.
12. **Cl_mic:** Ligand A (18.4) has a significantly lower microsomal clearance than Ligand B (56.625), indicating better metabolic stability. This strongly favors Ligand A.
13. **t1/2:** Ligand A (17.514) has a longer in vitro half-life than Ligand B (10.462), further supporting its better metabolic stability. This favors Ligand A.
14. **Pgp:** Ligand A (0.027) has significantly lower P-gp efflux liability than Ligand B (0.108), which is beneficial for bioavailability. This favors Ligand A.
15. **Affinity:** Ligand B (-6.5 kcal/mol) has a slightly better binding affinity than Ligand A (-5.8 kcal/mol). This is a significant advantage, but needs to be weighed against other factors.
**Overall Assessment:**
Ligand B has advantages in TPSA, logP, BBB, and binding affinity. However, Ligand A demonstrates superior metabolic stability (lower Cl_mic, longer t1/2), lower P-gp efflux, and a slightly better QED score. Considering the ADRB2 target is a GPCR with cardiovascular implications, metabolic stability and bioavailability (affected by P-gp) are crucial. The affinity difference, while present, is not substantial enough to outweigh the ADME benefits of Ligand A.
Output:
1
2025-04-17 21:10:46,606 - INFO - Batch 239 complete. Total preferences: 3824
2025-04-17 21:10:46,606 - INFO - Processing batch 240/512...
2025-04-17 21:11:37,643 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (352.435) is slightly higher than Ligand B (342.527), but both are acceptable.
2. **TPSA:** Ligand A (99.77) is better than Ligand B (32.34). While both are under 140, the lower TPSA of Ligand B is more favorable for GPCRs, potentially aiding in membrane permeability.
3. **logP:** Ligand B (4.124) is higher than Ligand A (-1.144). This is a significant drawback for Ligand B. A logP > 3 can lead to poor solubility and off-target effects. Ligand A's logP is slightly negative, which is not ideal, but far preferable to Ligand B's.
4. **HBD:** Ligand A (3) is higher than Ligand B (1). Both are within the acceptable limit of 5.
5. **HBA:** Ligand A (5) is higher than Ligand B (2). Both are within the acceptable limit of 10.
6. **QED:** Ligand B (0.732) is better than Ligand A (0.558). Higher QED suggests better overall drug-likeness.
7. **DILI:** Both ligands have relatively low DILI risk (Ligand A: 13.61, Ligand B: 14.23). Both are well below the 40% threshold.
8. **BBB:** Ligand B (87.127) is significantly better than Ligand A (34.354). For a GPCR, especially if CNS effects are possible, higher BBB penetration is a plus.
9. **Caco-2:** Ligand A (-5.44) is better than Ligand B (-4.578). Higher Caco-2 permeability suggests better intestinal absorption.
10. **Solubility:** Ligand A (-0.934) is better than Ligand B (-4.376). Better aqueous solubility is crucial for bioavailability.
11. **hERG:** Ligand A (0.059) is better than Ligand B (0.776). Lower hERG inhibition is critical for avoiding cardiotoxicity.
12. **Cl_mic:** Ligand A (-34.765) is much better than Ligand B (81.051). Lower microsomal clearance indicates greater metabolic stability, a significant advantage.
13. **t1/2:** Ligand B (22.834) is better than Ligand A (7.877). A longer in vitro half-life is generally desirable.
14. **Pgp:** Ligand A (0.004) is much better than Ligand B (0.512). Lower P-gp efflux improves bioavailability.
15. **Binding Affinity:** Ligand B (-6.2) is better than Ligand A (-5.6). This is a 0.6 kcal/mol difference, which is significant, but not overwhelming given the other factors.
**GPCR-Specific Priorities & Overall Assessment:**
For an ADRB2 GPCR, logP, TPSA, Pgp, and affinity are key. Ligand B has a very high logP, which is a major concern. While it has better BBB penetration and affinity, the poor logP and high Pgp efflux are significant drawbacks. Ligand A, while having a slightly lower affinity, has a much more favorable logP, better solubility, lower hERG risk, significantly lower Cl_mic, and lower Pgp efflux. The combination of these factors makes Ligand A a more promising starting point for drug development. The better metabolic stability and reduced toxicity risk outweigh the slightly weaker binding affinity.
Output:
1
2025-04-17 21:11:37,643 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (337.375) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (57.53) is significantly better than Ligand B (118.79). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (3.63) is within the optimal range (1-3). Ligand B (-0.171) is quite low, potentially hindering membrane permeability and absorption. This is a significant drawback.
4. **HBD:** Ligand A (0) is preferable to Ligand B (1). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (5) is better than Ligand B (8). Lower HBA is generally preferred for permeability.
6. **QED:** Both ligands have acceptable QED values (A: 0.682, B: 0.704), indicating reasonable drug-likeness.
7. **DILI:** Ligand A (81.97) has a higher DILI risk than Ligand B (68.631), but both are within an acceptable range.
8. **BBB:** This is less critical for a cardiovascular target. Ligand A (63.901) and Ligand B (51.066) are both moderate.
9. **Caco-2:** Ligand A (-4.502) is better than Ligand B (-5.476), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-5.412) is better than Ligand B (-1.188), suggesting better aqueous solubility.
11. **hERG:** Ligand A (0.447) is much better than Ligand B (0.035), indicating a lower risk of cardiotoxicity. This is *very* important for a cardiovascular target.
12. **Cl_mic:** Ligand B (29.957) has a significantly lower microsomal clearance than Ligand A (114.561), suggesting better metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Both ligands have similar in vitro half-lives (A: 10.749, B: 10.663).
14. **Pgp:** Ligand A (0.58) is better than Ligand B (0.018), indicating lower P-gp efflux.
15. **Binding Affinity:** Both ligands have similar binding affinities (-4.5 kcal/mol and -4.6 kcal/mol). The difference is negligible.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, and Pgp are important. Ligand A is superior in all these aspects, *except* for metabolic stability (Cl_mic). However, the significant issues with Ligand B's logP and hERG liability outweigh the benefit of its lower Cl_mic. The low logP of Ligand B is a major concern for absorption. The higher hERG risk of Ligand A is concerning, but less so than the very poor logP of Ligand B.
**Conclusion:**
Ligand A is the more promising candidate despite its slightly higher DILI and Cl_mic. Its superior logP, TPSA, Pgp, hERG profile, and solubility make it more likely to be a viable drug candidate.
Output:
1
2025-04-17 21:11:37,644 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (389.83) is slightly higher than Ligand B (364.511), but both are acceptable.
2. **TPSA:** Ligand A (46.92) is well below the 140 threshold and reasonably good for a GPCR. Ligand B (69.64) is higher, but still within a reasonable range, though less optimal.
3. **logP:** Ligand A (4.222) is slightly high, potentially leading to solubility issues and off-target effects, but still within the acceptable range. Ligand B (2.719) is excellent, falling squarely within the optimal 1-3 range.
4. **HBD:** Ligand A (1) and Ligand B (2) are both acceptable.
5. **HBA:** Both Ligand A (4) and Ligand B (4) are within the acceptable limit of 10.
6. **QED:** Both ligands have good QED scores (A: 0.629, B: 0.863), indicating good drug-like properties. Ligand B is better here.
7. **DILI:** Ligand A (60.915) is approaching a concerning level, indicating moderate liver injury risk. Ligand B (24.661) is excellent, with very low risk. This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (83.87) shows good BBB penetration, which is a plus for GPCRs. Ligand B (57.929) is lower, suggesting less CNS penetration. However, ADRB2 isn't necessarily a CNS target, so this isn't a dealbreaker.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.028 and -5.077), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand A (-4.464) and Ligand B (-2.226) both have poor aqueous solubility. This is a concern, especially given Ligand A's higher logP.
11. **hERG:** Both ligands have low hERG inhibition liability (A: 0.713, B: 0.432), which is good.
12. **Cl_mic:** Ligand A (63.07) has a moderate clearance, while Ligand B (-0.049) has a very low (and potentially problematic) clearance. Extremely low clearance can sometimes indicate issues with prediction or unusual metabolic pathways.
13. **t1/2:** Ligand A (-2.92) has a negative half-life, which is not possible and likely an error. Ligand B (-1.072) also has a negative half-life, indicating a problem with the data.
14. **Pgp:** Both ligands have low Pgp efflux (A: 0.735, B: 0.285), which is favorable.
15. **Binding Affinity:** Both ligands have similar binding affinities (-5.9 and -5.7 kcal/mol), which are both good. The difference is not substantial enough to be decisive.
**Overall Assessment:**
Ligand B is the better candidate despite the issues with Caco-2 and t1/2. The significantly lower DILI risk is a major advantage. The more favorable logP and QED scores also contribute to its better profile. The negative half-life values for both compounds are concerning and would require further investigation, but the other factors weigh in favor of Ligand B. The slightly better BBB penetration of Ligand A is less important for a cardiovascular target like ADRB2.
Output:
0
2025-04-17 21:11:37,644 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (345.355 Da and 348.443 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (93.9) is higher than Ligand B (67.87). For a cardiovascular GPCR, TPSA is moderately important, and lower is generally better for permeability. Ligand B has a clear advantage.
**3. logP:** Both ligands have good logP values (1.874 and 1.539, respectively), falling within the optimal 1-3 range. Ligand B is slightly lower, which is acceptable.
**4. H-Bond Donors:** Both have 1 HBD, which is good.
**5. H-Bond Acceptors:** Ligand A has 6 HBA, while Ligand B has 4. Both are within the acceptable limit of 10, but Ligand B is preferable.
**6. QED:** Ligand A (0.854) has a significantly better QED score than Ligand B (0.74), indicating a more drug-like profile. This is a substantial advantage for Ligand A.
**7. DILI Risk:** Ligand A (77.433) has a much higher DILI risk than Ligand B (34.432). This is a major concern for Ligand A. A DILI risk above 60 is considered high.
**8. BBB Penetration:** Both ligands have similar BBB penetration (74.292 and 74.176). Since this is a cardiovascular target, BBB penetration is not a primary concern, but it's good that both have reasonable values.
**9. Caco-2 Permeability:** Ligand A (-4.501) has worse Caco-2 permeability than Ligand B (-5.003). Lower values are less favorable.
**10. Aqueous Solubility:** Ligand A (-3.305) has worse aqueous solubility than Ligand B (-2.2). Solubility is important for bioavailability.
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.18 and 0.111, respectively). This is excellent for both.
**12. Microsomal Clearance:** Ligand A (95.704) has a significantly higher microsomal clearance than Ligand B (29.495), suggesting faster metabolism and potentially lower exposure. This is a disadvantage for Ligand A.
**13. In vitro Half-Life:** Ligand B (54.277) has a much longer in vitro half-life than Ligand A (-33.21). This is a significant advantage for Ligand B.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.16 and 0.028, respectively). This is favorable for both.
**15. Binding Affinity:** Ligand B (-6.1 kcal/mol) has a slightly better binding affinity than Ligand A (-5.3 kcal/mol). While the difference is not huge, it's enough to be considered.
**Overall Assessment:**
Ligand A has a better QED score, but is significantly hampered by its high DILI risk, poor solubility, high clearance, and short half-life. Ligand B, while having a slightly lower QED and affinity, demonstrates a much more favorable ADMET profile, particularly regarding safety (DILI) and metabolic stability (clearance/half-life). For a cardiovascular GPCR, a good safety profile and reasonable metabolic stability are crucial. The slight affinity difference is outweighed by the ADMET advantages of Ligand B.
Output:
0
2025-04-17 21:11:37,644 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (380.897 and 383.857 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (67.43) is significantly better than Ligand B (84.67). For a GPCR, lower TPSA is generally preferred for better permeability. Ligand B is approaching a level that could hinder absorption.
3. **logP:** Both ligands have good logP values (3.494 and 2.489), falling within the optimal 1-3 range. Ligand A is slightly higher, which *could* be a minor drawback, but not a major concern.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1), but both are within the acceptable limit of 5.
5. **HBA:** Ligand A (4) is lower than Ligand B (6). Lower HBA is generally preferred for permeability.
6. **QED:** Both ligands have good QED scores (0.736 and 0.828), indicating good drug-like properties. No significant difference.
7. **DILI:** Ligand B (74.719) has a higher DILI risk than Ligand A (58.705). This is a significant concern, as we want to minimize liver toxicity.
8. **BBB:** Ligand A (73.284) has a much better BBB penetration score than Ligand B (49.205). While ADRB2 isn't exclusively a CNS target, some CNS exposure can occur, and better BBB penetration is generally desirable.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.078 and -4.81). This is unusual and suggests poor permeability. However, the values are very close, so it doesn't strongly favor one ligand.
10. **Solubility:** Ligand A (-4.244) has slightly better solubility than Ligand B (-3.678).
11. **hERG:** Ligand A (0.639) has a slightly higher hERG risk than Ligand B (0.267). This is a negative for Ligand A, but the values are relatively low, so the risk is moderate.
12. **Cl_mic:** Ligand A (55.251) has significantly better metabolic stability (lower clearance) than Ligand B (25.644). This is a crucial advantage, as it suggests a longer duration of action.
13. **t1/2:** Ligand A (82.426) has a longer in vitro half-life than Ligand B (43.435). This further supports its better metabolic stability.
14. **Pgp:** Ligand A (0.248) has lower P-gp efflux than Ligand B (0.316). Lower P-gp efflux is favorable for oral bioavailability.
15. **Binding Affinity:** Ligand A (-7.6 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.6 kcal/mol). This 1.0 kcal/mol difference is substantial and can outweigh some of the ADME drawbacks.
**Overall Assessment:**
Ligand A is the stronger candidate. While it has a slightly higher hERG risk, its superior binding affinity, lower DILI risk, better BBB penetration, improved metabolic stability (Cl_mic and t1/2), lower P-gp efflux, and lower TPSA outweigh this minor drawback. Ligand B's higher DILI risk and significantly worse metabolic stability are major concerns. The affinity difference is also substantial.
Output:
1
2025-04-17 21:11:37,644 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (361.511 and 368.474 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (71.09) is better than Ligand B (75.27). Both are below the 140 A^2 threshold for good oral absorption, but lower is generally preferred.
3. **logP:** Both ligands have good logP values (3.112 and 2.123) falling within the optimal 1-3 range. Ligand A is slightly higher, which *could* be beneficial for membrane permeability, but isn't a major concern for either.
4. **HBD:** Both have 2 HBD, which is within the acceptable limit of <=5.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 3. Both are within the acceptable limit of <=10.
6. **QED:** Ligand B (0.774) has a significantly better QED score than Ligand A (0.524), indicating a more drug-like profile.
7. **DILI:** Both ligands have acceptable DILI risk (34.238 and 37.728), well below the 60 threshold. Ligand B is slightly higher, but not concerning.
8. **BBB:** Both ligands have reasonable BBB penetration (62.078 and 68.67). While >70 is desirable for CNS targets, this isn't a primary concern for ADRB2, a cardiovascular target. Ligand B is slightly better.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. This is a significant drawback for both.
10. **Solubility:** Both have negative solubility values, indicating poor solubility. This is a significant drawback for both.
11. **hERG:** Both ligands have low hERG inhibition liability (0.413 and 0.542), which is good.
12. **Cl_mic:** Ligand B (20.233) has a significantly lower microsomal clearance than Ligand A (29.349), suggesting better metabolic stability. This is a major advantage.
13. **t1/2:** Ligand B (-22.792) has a significantly longer in vitro half-life than Ligand A (14.093). This is a major advantage.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.275 and 0.165), which is good.
15. **Binding Affinity:** Ligand B (-7.7 kcal/mol) has a *much* stronger binding affinity than Ligand A (-4.3 kcal/mol). This is a substantial advantage, more than offsetting any minor ADME drawbacks. A difference of 3.4 kcal/mol is very significant.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, affinity is paramount. The large difference in binding affinity between Ligand B and Ligand A is the deciding factor. While both have issues with Caco-2 and solubility, these can potentially be addressed through formulation strategies. The improved metabolic stability (lower Cl_mic, longer t1/2) and better QED of Ligand B further strengthen its profile.
**Conclusion:**
Ligand B is the superior candidate due to its significantly higher binding affinity, better metabolic stability, longer half-life, and improved QED score.
Output:
0
2025-04-17 21:11:37,644 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (344.415 and 347.419 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands have TPSA values (93.21 and 91.3) below 140, suggesting good oral absorption potential. They are also reasonably low for a GPCR, though not optimal for CNS penetration if that were a goal.
3. **logP:** Ligand A (2.597) is within the optimal 1-3 range. Ligand B (0.377) is slightly below 1, which could potentially hinder permeation. This is a point in favor of Ligand A.
4. **HBD:** Both ligands have acceptable HBD counts (2 and 1, respectively), well below the 5 threshold.
5. **HBA:** Both ligands have HBA counts of 5, which is acceptable (<=10).
6. **QED:** Both ligands have similar QED values (0.801 and 0.78), indicating good drug-likeness.
7. **DILI:** Both ligands have relatively low DILI risk (45.134 and 41.76), both below the 60 threshold. Ligand B is slightly better.
8. **BBB:** Ligand A (78.48) has a better BBB percentile than Ligand B (55.176). While ADRB2 isn't necessarily a CNS target, some peripheral ADRB2 activity can influence CNS function, and higher BBB penetration is generally favorable.
9. **Caco-2:** Ligand A (-4.733) and Ligand B (-5.053) have similar negative Caco-2 values, indicating poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand A (-3.414) and Ligand B (-2.123) both have negative solubility values, indicating poor aqueous solubility. Ligand B is slightly better.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.236 and 0.095), which is excellent.
12. **Cl_mic:** Ligand A (49.81) has a higher microsomal clearance than Ligand B (13.605), suggesting lower metabolic stability. Ligand B is significantly better here.
13. **t1/2:** Ligand B (-22.698) has a much longer in vitro half-life than Ligand A (23.366). This is a major advantage for Ligand B.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.026 and 0.028).
15. **Binding Affinity:** Ligand B (-6.1 kcal/mol) has a slightly stronger binding affinity than Ligand A (-5.6 kcal/mol). This difference of 0.5 kcal/mol is significant, and can outweigh some ADME concerns.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand A has a better logP and BBB, but Ligand B has a significantly better binding affinity, lower Cl_mic, and longer half-life. The binding affinity difference is the most important factor. The poor Caco-2 and solubility for both are concerning, but can potentially be addressed with formulation strategies.
**Conclusion:**
Despite the slightly better logP and BBB for Ligand A, the superior binding affinity, metabolic stability (lower Cl_mic), and longer half-life of Ligand B make it the more promising drug candidate.
Output:
0
2025-04-17 21:11:37,644 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [351.407, 122.31 , 1.308, 3. , 6. , 0.706, 72.47 , 55.215, -4.597, -2.982, 0.052, 37.987, -0.61 , 0.005, -4.6 ]
**Ligand B:** [367.446, 102.22 , 2.044, 3. , 5. , 0.653, 45.444, 31.136, -5.074, -3.382, 0.568, 40.157, 35.003, 0.075, -5.7 ]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity) and general guidelines:
1. **MW:** Both are within the ideal range (200-500 Da). A is 351.4, B is 367.4. No significant difference.
2. **TPSA:** A is 122.31, B is 102.22. B is better, being closer to the <140 threshold for good absorption.
3. **logP:** A is 1.308, B is 2.044. Both are within the optimal 1-3 range. B is slightly better, leaning towards the higher end of optimal.
4. **HBD:** Both have 3 HBD, which is good.
5. **HBA:** A has 6, B has 5. Both are acceptable, under the 10 threshold.
6. **QED:** A is 0.706, B is 0.653. A is slightly better, indicating a more drug-like profile.
7. **DILI:** A is 72.47, B is 45.444. B is significantly better, indicating a much lower risk of liver injury. This is a crucial advantage.
8. **BBB:** A is 55.215, B is 31.136. A is better, though neither are particularly high. For a cardiovascular target, BBB isn't *critical*, but some penetration could be beneficial for off-target effects.
9. **Caco-2:** A is -4.597, B is -5.074. Both are negative, indicating poor permeability. B is slightly worse.
10. **Solubility:** A is -2.982, B is -3.382. Both are poor, but B is slightly worse.
11. **hERG:** A is 0.052, B is 0.568. A is significantly better, indicating a lower risk of cardiotoxicity. This is *very* important for a cardiovascular target.
12. **Cl_mic:** A is 37.987, B is 40.157. B has slightly higher clearance, meaning faster metabolism. A is better.
13. **t1/2:** A is -0.61, B is 35.003. B has a much longer half-life, which is a significant advantage for dosing frequency.
14. **Pgp:** A is 0.005, B is 0.075. A shows much lower P-gp efflux, which is favorable for absorption and bioavailability.
15. **Affinity:** A is -4.6 kcal/mol, B is -5.7 kcal/mol. B has a significantly stronger binding affinity (1.1 kcal/mol difference). This is a major advantage, potentially outweighing some ADME concerns.
**Overall Assessment:**
Ligand B has a substantially better binding affinity (-5.7 kcal/mol vs -4.6 kcal/mol) and a significantly lower DILI risk. It also has a much longer half-life. However, it has worse Caco-2 permeability, solubility, and a higher Pgp efflux. Ligand A has better hERG inhibition and lower clearance.
Given the GPCR target and the importance of potency, the stronger binding affinity of Ligand B is the most important factor. The lower DILI risk is also a major plus. While the permeability and solubility are concerns, these can potentially be addressed through formulation strategies. The improved half-life is also a significant benefit.
Therefore, I would choose Ligand B.
Output:
0
2025-04-17 21:11:37,645 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (345.407 and 356.438 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (106.73) is higher than Ligand B (59.08). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for better absorption. Ligand B has a substantial advantage here.
**3. logP:** Ligand A (0.091) is quite low, potentially hindering membrane permeability. Ligand B (1.403) is within the optimal 1-3 range. This is a significant advantage for Ligand B.
**4. H-Bond Donors:** Ligand A (2) is reasonable. Ligand B (0) is even better, potentially improving permeability.
**5. H-Bond Acceptors:** Ligand A (7) is acceptable. Ligand B (4) is better.
**6. QED:** Both ligands have reasonable QED scores (0.799 and 0.675), indicating good drug-like properties.
**7. DILI Risk:** Ligand A (58.627) has a higher DILI risk than Ligand B (24.544). This is a considerable advantage for Ligand B.
**8. BBB Penetration:** Ligand A (47.15) has lower BBB penetration than Ligand B (86.817). While ADRB2 is primarily a cardiovascular target, some CNS side effects are possible with GPCR modulators, and higher BBB penetration could contribute to this.
**9. Caco-2 Permeability:** Ligand A (-5.36) has poor Caco-2 permeability, suggesting poor intestinal absorption. Ligand B (-4.257) is better, but still not ideal.
**10. Aqueous Solubility:** Ligand A (-2.307) has poor solubility, which could hinder formulation. Ligand B (-1.056) is better, but still low.
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.028 and 0.338), which is excellent.
**12. Microsomal Clearance:** Ligand A (12.058) has lower clearance than Ligand B (24.41), suggesting better metabolic stability.
**13. In vitro Half-Life:** Ligand A (28.213) has a longer half-life than Ligand B (8.343), which is desirable.
**14. P-gp Efflux:** Both ligands exhibit low P-gp efflux (0.023 and 0.062), which is favorable.
**15. Binding Affinity:** Ligand A (-7.3) has a significantly stronger binding affinity than Ligand B (-6.1). This is a substantial advantage for Ligand A.
**Overall Assessment:**
Ligand B clearly wins on several key ADME properties: TPSA, logP, DILI risk, and BBB penetration. However, Ligand A has a significantly stronger binding affinity (-7.3 vs -6.1 kcal/mol). The difference in affinity is substantial (over 1 kcal/mol), and for a GPCR, potency is paramount. While Ligand A's logP and solubility are concerns, these can potentially be addressed through formulation strategies or minor structural modifications. The lower DILI risk of Ligand B is attractive, but the superior affinity of Ligand A outweighs this concern.
Output:
1
2025-04-17 21:11:37,645 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [361.423, 84.67, 2.603, 1, 6, 0.905, 77.782, 78.829, -4.602, -4.945, 0.424, 26.886, 23.778, 0.114, -6.4]
**Ligand B:** [350.463, 72.96, 0.056, 1, 4, 0.735, 13.687, 63.862, -4.964, -1.162, 0.207, 7.172, -4.765, 0.009, 2.9]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (350.463) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are good, below the 140 A^2 threshold for oral absorption. Ligand B (72.96) is better than Ligand A (84.67), which is preferable for GPCRs.
3. **logP:** Ligand A (2.603) is optimal (1-3). Ligand B (0.056) is *very* low and a significant concern, potentially leading to poor membrane permeability and bioavailability.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 6 HBA, Ligand B has 4. Both are within the acceptable range.
6. **QED:** Ligand A (0.905) is excellent, indicating high drug-likeness. Ligand B (0.735) is still reasonable, but lower.
7. **DILI:** Ligand A (77.782) is moderately high, but acceptable. Ligand B (13.687) is very low and excellent.
8. **BBB:** Ligand A (78.829) is good. Ligand B (63.862) is lower, but not a critical issue for a non-CNS target like ADRB2 (cardiovascular).
9. **Caco-2:** Both are negative, indicating poor permeability. This is a concern for both.
10. **Solubility:** Both are negative, indicating poor solubility. This is a concern for both.
11. **hERG:** Ligand A (0.424) is very low risk. Ligand B (0.207) is even lower, excellent.
12. **Cl_mic:** Ligand A (26.886) is moderate, indicating reasonable metabolic stability. Ligand B (7.172) is low, indicating better metabolic stability.
13. **t1/2:** Ligand A (23.778) is reasonable. Ligand B (-4.765) is very short, a significant drawback.
14. **Pgp:** Ligand A (0.114) is low, suggesting minimal efflux. Ligand B (0.009) is extremely low, excellent.
15. **Affinity:** Ligand A (-6.4 kcal/mol) is significantly better than Ligand B (2.9 kcal/mol). This is a crucial difference, as a >1.5 kcal/mol advantage can outweigh other drawbacks.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are particularly important. Ligand A has a much better logP and significantly better affinity. While Ligand B has better TPSA and Pgp, the extremely poor logP and weak binding are major liabilities.
**Conclusion:**
Despite Ligand B's advantages in DILI, Pgp, and Cl_mic, the significantly stronger binding affinity of Ligand A (-6.4 vs 2.9 kcal/mol) and its acceptable logP outweigh the drawbacks. The poor logP of Ligand B is a major concern for its ability to reach the target.
Output:
1
2025-04-17 21:11:37,645 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (348.403 and 342.399 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (98.9) is slightly higher than Ligand B (93.09). Both are below the 140 threshold for good oral absorption, and acceptable for a non-CNS GPCR target like ADRB2.
3. **logP:** Ligand B (0.795) is closer to the optimal 1-3 range than Ligand A (-0.85). Ligand A is slightly below 1, which could potentially hinder permeation. This favors Ligand B.
4. **HBD:** Both ligands have 2 H-bond donors, which is within the acceptable limit of 5.
5. **HBA:** Ligand A has 6 H-bond acceptors, and Ligand B has 5. Both are below the 10 limit.
6. **QED:** Both ligands have good QED scores (0.741 and 0.812, respectively), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (39.434) has a lower DILI risk than Ligand B (52.695), which is a significant advantage.
8. **BBB:** Both ligands have similar BBB penetration (44.668 and 43.893). Since ADRB2 is not a primary CNS target, this parameter is less critical.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Both ligands have very poor aqueous solubility (-1.598 and -2.016). This is a major drawback for both, and would require significant formulation work.
11. **hERG:** Both ligands have low hERG inhibition risk (0.134 and 0.219).
12. **Cl_mic:** Ligand A (5.538) has significantly lower microsomal clearance than Ligand B (34.54), indicating better metabolic stability. This is a substantial advantage for Ligand A.
13. **t1/2:** Ligand A (0.291) has a very short in vitro half-life, while Ligand B (-13.441) has a negative value, which is not physically meaningful. This is a major issue for both, but more so for Ligand B.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.015 and 0.036).
15. **Binding Affinity:** Ligand A (-7.4) has a slightly better binding affinity than Ligand B (-6.9), although the difference is less than 1.5 kcal/mol.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are important. Ligand B has a better logP, while Ligand A has slightly better affinity and significantly better metabolic stability (lower Cl_mic). The DILI risk is also lower for Ligand A. The solubility and Caco-2 permeability are poor for both, but the metabolic stability and DILI are more important for initial optimization.
**Conclusion:**
Despite the poor solubility and permeability of both compounds, Ligand A appears to be the more promising candidate due to its better metabolic stability (lower Cl_mic), lower DILI risk, and slightly better binding affinity. The slightly better logP of Ligand B is not enough to offset these advantages.
Output:
1
2025-04-17 21:11:37,645 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's break down the comparison of Ligand A and Ligand B, considering the provided guidelines and GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key).
1. **Molecular Weight:** Both ligands (380.206 and 348.487 Da) fall within the ideal 200-500 Da range. Slight edge to B for being a bit lower.
2. **TPSA:** Both are good (68.02 and 67.43), well below the 140 threshold for oral absorption. Very similar.
3. **logP:** Ligand A (4.125) is slightly above the optimal range (1-3), while Ligand B (2.727) is within the ideal range. This is a significant advantage for B, as high logP can lead to off-target effects and solubility issues.
4. **H-Bond Donors:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **H-Bond Acceptors:** Ligand A (4) is preferable to Ligand B (3). Fewer HBAs generally improve permeability.
6. **QED:** Both are reasonably good (0.676 and 0.597), exceeding the 0.5 threshold. A has a slight edge.
7. **DILI:** Ligand B (22.102) is *much* better than Ligand A (90.384). This is a critical advantage for B, as DILI is a major concern in drug development.
8. **BBB:** Both have good BBB penetration (77.627 and 78.79), which isn't a primary concern for ADRB2 (a cardiovascular target), but is still positive. Very similar.
9. **Caco-2:** Both have negative Caco-2 values (-4.777 and -4.576), which is unusual and suggests poor permeability. This is a significant drawback for both, but the values are very close.
10. **Solubility:** Both have negative solubility values (-5.346 and -3.153), indicating poor aqueous solubility. This is a concern, but again, the difference is not huge.
11. **hERG:** Both have very low hERG inhibition risk (0.447 and 0.298). This is excellent for both.
12. **Cl_mic:** Ligand A (59.647) has lower microsomal clearance than Ligand B (81.389), indicating better metabolic stability. This is a positive for A.
13. **t1/2:** Ligand A (5.094) has a longer in vitro half-life than Ligand B (3.984). This is a positive for A.
14. **Pgp:** Both have low Pgp efflux liability (0.3 and 0.22). This is good for both.
15. **Binding Affinity:** Ligand A (-8.6 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.5 kcal/mol). This is a substantial advantage for A, potentially outweighing some of its ADME drawbacks. The difference of 2.1 kcal/mol is quite large.
**Overall Assessment:**
While Ligand A has a superior binding affinity and better metabolic stability/half-life, Ligand B excels in crucial safety parameters (DILI) and has a more favorable logP. The poor Caco-2 and solubility for both are concerning, but the large affinity difference of Ligand A is very appealing. However, the very high DILI risk for Ligand A is a major red flag. For a cardiovascular target, minimizing off-target effects and toxicity is paramount.
Considering the balance of properties, and prioritizing safety (DILI) and a good logP alongside reasonable affinity, I believe **Ligand B** is the more viable drug candidate.
**Output:**
0
2025-04-17 21:11:37,645 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (342.443 and 363.38 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Both ligands (89.27 and 81.67) are below the 140 A^2 threshold for good oral absorption and are also suitable for a peripheral GPCR like ADRB2 (no strong CNS requirement). Ligand B is slightly better.
3. **logP:** Ligand A (2.56) is optimal, while Ligand B (0.405) is a bit low, potentially impacting membrane permeability. This favors Ligand A.
4. **HBD:** Both ligands have 3 HBD, which is within the acceptable limit of 5.
5. **HBA:** Ligand A has 5 HBA, and Ligand B has 4. Both are within the acceptable limit of 10.
6. **QED:** Both ligands have similar QED values (0.61 and 0.638), indicating good drug-likeness.
7. **DILI:** Ligand A (42.846) has a slightly higher DILI risk than Ligand B (13.416), but both are below the concerning 60 percentile. Ligand B is preferable here.
8. **BBB:** Both ligands have moderate BBB penetration (50.679 and 52.268). Since ADRB2 is primarily a cardiovascular target, high BBB penetration isn't crucial.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.189 and -5.238), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Both ligands have negative solubility values (-2.424 and -1.604). This is also a major red flag, indicating very poor aqueous solubility.
11. **hERG:** Both ligands have low hERG inhibition liability (0.791 and 0.425), which is excellent.
12. **Cl_mic:** Ligand A (12.156) has a higher microsomal clearance than Ligand B (-25.718). A negative value for Ligand B suggests very high metabolic stability, which is a significant advantage.
13. **t1/2:** Ligand A (13.621) has a longer in vitro half-life than Ligand B (-12.176). Again, the negative value for Ligand B is concerning.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.18 and 0.015).
15. **Binding Affinity:** Ligand B (-6.4 kcal/mol) has a stronger binding affinity than Ligand A (-5.3 kcal/mol). This is a 1.1 kcal/mol difference, which is substantial and can outweigh some ADME concerns.
**Overall Assessment:**
Both ligands have significant ADME liabilities (poor Caco-2 and solubility). However, Ligand B stands out due to its significantly stronger binding affinity (-6.4 vs -5.3 kcal/mol) and much better metabolic stability (Cl_mic = -25.718). The lower DILI risk is also a plus. While the logP is lower for Ligand B, the strong binding affinity is a critical factor for GPCR targets. The negative values for Caco-2 and solubility are concerning for both, and would require significant medicinal chemistry effort to address, but the superior potency and stability of Ligand B make it the more promising starting point.
Output:
0
2025-04-17 21:11:37,645 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (385.869 Da) is within the ideal range (200-500 Da). Ligand B (343.471 Da) is also within range, and slightly preferred due to being closer to the lower bound.
2. **TPSA:** Ligand A (77.88) is acceptable, but higher than ideal (<140). Ligand B (44.81) is excellent, well below the 140 threshold and very favorable for permeability.
3. **logP:** Ligand A (3.38) is within the optimal range (1-3). Ligand B (2.505) is also good.
4. **HBD:** Both ligands have 1 HBD, which is acceptable.
5. **HBA:** Ligand A has 7 HBA, acceptable. Ligand B has 3 HBA, which is even better.
6. **QED:** Both ligands have QED values > 0.5, indicating good drug-likeness. Ligand B (0.583) is slightly better.
7. **DILI:** Ligand A (71.423) has a higher DILI risk than Ligand B (12.33). This is a significant negative for Ligand A.
8. **BBB:** Both ligands have reasonable BBB penetration, but Ligand B (71.539) is slightly higher. For a cardiovascular target, BBB isn't *critical*, but a higher value isn't detrimental.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating good permeability. Ligand A (-4.7) is slightly better.
10. **Solubility:** Ligand A (-3.962) has better solubility than Ligand B (-1.505).
11. **hERG:** Ligand A (0.307) has a lower hERG risk than Ligand B (0.839), which is a positive.
12. **Cl_mic:** Ligand A (65.629) has higher metabolic clearance than Ligand B (-6.802). This is a negative for Ligand A, indicating faster metabolism.
13. **t1/2:** Ligand A (50.75) has a longer half-life than Ligand B (0.251). This is a positive for Ligand A.
14. **Pgp:** Ligand A (0.579) has lower Pgp efflux than Ligand B (0.048), which is a positive.
15. **Affinity:** Ligand A (-8.2 kcal/mol) has a significantly stronger binding affinity than Ligand B (-5.4 kcal/mol). This is a substantial advantage for Ligand A.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B excels in TPSA and Pgp, while Ligand A has a much stronger binding affinity, and better Pgp efflux. The DILI risk for Ligand A is concerning, but the substantial affinity advantage is likely to outweigh this risk, especially considering the cardiovascular target (where CNS penetration is less critical). The lower clearance of Ligand B is also a positive.
**Overall Assessment:**
While Ligand B has a better safety profile (lower DILI, better metabolic stability) and permeability (lower TPSA), the significantly stronger binding affinity of Ligand A (-8.2 vs -5.4 kcal/mol) is a decisive factor. A 2.8 kcal/mol difference in binding is substantial and can often overcome minor ADME liabilities. The slightly higher DILI risk of Ligand A is a concern, but can be further investigated and potentially mitigated through structural modifications.
Output:
1
2025-04-17 21:11:37,646 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (350.5 & 352.4 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (58.64) is significantly better than Ligand B (85.89). For a GPCR, lower TPSA is generally preferred for better permeability. Ligand B is approaching a TPSA that could limit oral absorption.
**3. logP:** Ligand A (3.047) is optimal, while Ligand B (0.538) is quite low. A logP below 1 can hinder membrane permeability. This is a major strike against Ligand B.
**4. H-Bond Donors:** Ligand A (1) is preferable to Ligand B (2). Lower HBDs generally improve permeability.
**5. H-Bond Acceptors:** Ligand A (3) is preferable to Ligand B (5). Lower HBAs generally improve permeability.
**6. QED:** Both ligands have similar QED values (0.65 and 0.653), indicating good drug-likeness.
**7. DILI:** Ligand A (5.777) has a much lower DILI risk than Ligand B (25.553). This is a significant advantage for Ligand A.
**8. BBB:** Ligand A (83.87) has a better BBB penetration percentile than Ligand B (61.923). While ADRB2 isn't a primary CNS target, some level of BBB penetration can be beneficial for off-target effects assessment.
**9. Caco-2 Permeability:** Ligand A (-4.633) is better than Ligand B (-5.334), indicating better intestinal absorption.
**10. Aqueous Solubility:** Ligand A (-2.139) is better than Ligand B (-1.294), indicating better solubility.
**11. hERG Inhibition:** Ligand A (0.507) has a lower hERG inhibition liability than Ligand B (0.133). This is a significant safety advantage for Ligand A.
**12. Microsomal Clearance:** Ligand B (3.962) has much lower microsomal clearance than Ligand A (39.351), suggesting better metabolic stability. This is a positive for Ligand B.
**13. In vitro Half-Life:** Ligand B (16.395) has a significantly longer half-life than Ligand A (-13.51). This is a substantial advantage for Ligand B.
**14. P-gp Efflux:** Ligand A (0.126) has lower P-gp efflux than Ligand B (0.012), which is preferable.
**15. Binding Affinity:** Ligand B (-7.0) has a slightly better binding affinity than Ligand A (-6.2). While a 0.8 kcal/mol difference is notable, the other ADME properties of Ligand A are much more favorable.
**Overall Assessment:**
Ligand A demonstrates a significantly better balance of properties, particularly regarding permeability (logP, TPSA), safety (DILI, hERG), and solubility. While Ligand B has a slightly better binding affinity and metabolic stability, the poor logP and higher DILI/hERG risks are major concerns. For a cardiovascular GPCR, prioritizing permeability and safety is crucial. The improved ADME profile of Ligand A outweighs the modest affinity difference.
Output:
1
2025-04-17 21:11:37,646 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [348.531, 49.41, 3.889, 1, 2, 0.792, 24.506, 83.172, -4.715, -4.249, 0.578, 67.124, 1.62, 0.362, -5.6]
**Ligand B:** [370.431, 123.41, -1.403, 2, 5, 0.677, 58.434, 22.024, -5.472, -2.059, 0.033, -12.228, 3.575, 0.006, -8.1]
Here's a breakdown comparing the two, keeping GPCR priorities (logP, Pgp, TPSA, affinity) in mind:
1. **MW:** Both are within the acceptable range (200-500 Da). Ligand A (348.531) is slightly preferred due to being lower.
2. **TPSA:** Ligand A (49.41) is significantly better than Ligand B (123.41). A TPSA under 140 is good for oral absorption, but for a GPCR, lower is generally better, and Ligand A is much closer to the ideal range for potential CNS penetration, even though it's not a CNS target.
3. **logP:** Ligand A (3.889) is optimal (1-3). Ligand B (-1.403) is too low, potentially hindering membrane permeability and bioavailability. This is a major drawback for Ligand B.
4. **HBD/HBA:** Ligand A (1 HBD, 2 HBA) is preferable to Ligand B (2 HBD, 5 HBA). Lower counts are generally better for permeability.
5. **QED:** Both are reasonably good (A: 0.792, B: 0.677), indicating drug-like properties. Ligand A is slightly better.
6. **DILI:** Ligand A (24.506) has a much lower DILI risk than Ligand B (58.434). This is a significant advantage.
7. **BBB:** Ligand A (83.172) has a much better BBB percentile than Ligand B (22.024). While not a primary concern for a cardiovascular target, it's a positive attribute.
8. **Caco-2:** Ligand A (-4.715) and Ligand B (-5.472) are both poor.
9. **Solubility:** Ligand A (-4.249) is better than Ligand B (-2.059), though both are poor.
10. **hERG:** Ligand A (0.578) is much better than Ligand B (0.033). Lower hERG risk is crucial for cardiovascular drugs.
11. **Cl_mic:** Ligand B (-12.228) has significantly lower microsomal clearance, indicating better metabolic stability. This is a strong point for Ligand B.
12. **t1/2:** Ligand B (3.575) has a longer in vitro half-life than Ligand A (1.62). This is also a positive for Ligand B.
13. **Pgp:** Ligand A (0.362) has lower P-gp efflux liability than Ligand B (0.006), which is favorable for bioavailability.
14. **Affinity:** Ligand B (-8.1) has a significantly stronger binding affinity than Ligand A (-5.6). This is a substantial advantage, a difference of 2.5 kcal/mol.
**Overall Assessment:**
Ligand B has a significantly better binding affinity and metabolic stability (lower Cl_mic, longer t1/2). However, its poor logP, high TPSA, and elevated DILI/hERG risks are major concerns. Ligand A, while having weaker affinity, presents a much more balanced profile with better physicochemical properties, lower toxicity risks, and favorable Pgp efflux. The affinity difference is substantial, but the ADME/Tox profile of Ligand B is concerning enough to outweigh that benefit.
Given the GPCR-specific priorities and the overall balance of properties, I believe **Ligand A** is the more viable drug candidate.
1
2025-04-17 21:11:37,646 - INFO - Batch 240 complete. Total preferences: 3840
2025-04-17 21:11:37,646 - INFO - Processing batch 241/512...
2025-04-17 21:12:27,662 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (364.431 and 368.777 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (109.22) is better than Ligand B (134.46). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (1.008) is better than Ligand B (0.499). Both are within the acceptable range, but Ligand A is closer to the optimal 1-3 range. Ligand B is bordering on being too hydrophilic.
4. **HBD:** Ligand A (2) is better than Ligand B (3). Lower is preferable.
5. **HBA:** Ligand A (7) is better than Ligand B (6). Lower is preferable.
6. **QED:** Ligand A (0.819) is significantly better than Ligand B (0.393). A higher QED indicates a more drug-like profile.
7. **DILI:** Ligand A (82.241) is worse than Ligand B (65.491). Both are acceptable, but Ligand B has a lower risk.
8. **BBB:** Ligand A (53.781) is better than Ligand B (43.815). While not a CNS target, some level of BBB penetration can indicate favorable permeability characteristics.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.078 and -5.323). This is unusual and suggests poor permeability. It's difficult to interpret without further information, but it's a significant concern for both.
10. **Solubility:** Both ligands have negative solubility values (-3.114 and -3.185). This is also unusual and suggests very poor aqueous solubility. This is a major drawback for both.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.165 and 0.073). This is excellent.
12. **Cl_mic:** Ligand A (0.063) is much better than Ligand B (-25.201). A positive value suggests lower clearance and better metabolic stability. The negative value for Ligand B is concerning.
13. **t1/2:** Ligand A (55.124) is better than Ligand B (6.734). A longer half-life is generally desirable.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.018 and 0.035). This is excellent.
15. **Binding Affinity:** Ligand B (-7.8) is significantly better than Ligand A (-6.8). This is a substantial difference (1.0 kcal/mol) and a major advantage.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, affinity, and metabolic stability. Ligand B has a better affinity, but Ligand A has better logP, TPSA, and metabolic stability. The affinity difference is significant, potentially outweighing the other differences. However, the extremely poor solubility and Caco-2 values for both are concerning. The significantly better metabolic stability of Ligand A, coupled with its better QED, makes it slightly more favorable despite the lower affinity.
**Conclusion:**
Despite the superior binding affinity of Ligand B, the significantly better overall drug-like properties (QED, metabolic stability, TPSA, logP) of Ligand A make it the more promising candidate, assuming the solubility and permeability issues can be addressed through formulation or structural modification.
Output:
1
2025-04-17 21:12:27,662 - INFO - Reasoning:
Let's analyze both ligands based on the provided criteria, prioritizing GPCR-specific parameters (logP, Pgp, TPSA, and affinity).
**Ligand A:**
* **MW:** 375.753 Da - Good.
* **TPSA:** 46.92 - Excellent, well below the 140 threshold.
* **logP:** 4.52 - Slightly high, could potentially lead to solubility issues or off-target interactions, but within a tolerable range.
* **HBD:** 1 - Good.
* **HBA:** 3 - Good.
* **QED:** 0.799 - Excellent, highly drug-like.
* **DILI:** 72.974 - Moderate risk, but not alarming.
* **BBB:** 88.794 - Excellent, high potential for CNS penetration (though not necessarily desired for a cardiovascular target).
* **Caco-2:** -4.441 - Very poor permeability, a significant concern.
* **Solubility:** -5.377 - Very poor solubility, a major drawback.
* **hERG:** 0.414 - Low risk, good.
* **Cl_mic:** 37.459 - Moderate clearance, not ideal but manageable.
* **t1/2:** 23.002 - Moderate half-life, acceptable.
* **Pgp:** 0.324 - Low efflux, good.
* **Affinity:** -6.1 kcal/mol - Very good.
**Ligand B:**
* **MW:** 365.547 Da - Good.
* **TPSA:** 70.15 - Acceptable, but approaching the upper limit for good absorption.
* **logP:** 2.629 - Optimal.
* **HBD:** 2 - Good.
* **HBA:** 6 - Good.
* **QED:** 0.738 - Excellent, highly drug-like.
* **DILI:** 40.636 - Low risk, excellent.
* **BBB:** 78.092 - Moderate, less likely to cross the BBB.
* **Caco-2:** -5.303 - Very poor permeability, a significant concern.
* **Solubility:** -3.496 - Poor solubility, a drawback.
* **hERG:** 0.714 - Moderate risk, needs consideration.
* **Cl_mic:** 76.755 - High clearance, a significant concern.
* **t1/2:** 17.875 - Short half-life, potentially requiring frequent dosing.
* **Pgp:** 0.064 - Very low efflux, excellent.
* **Affinity:** -6.3 kcal/mol - Excellent, slightly better than Ligand A.
**Comparison & Decision:**
Both ligands suffer from poor Caco-2 permeability and solubility. However, Ligand B has a better logP, lower DILI risk, and very low Pgp efflux. Ligand A has a slightly better BBB score, but this is less relevant for a cardiovascular target. The affinity difference is small (-6.3 vs -6.1 kcal/mol). Ligand B's lower metabolic clearance is a concern, but the combination of better logP, lower DILI, and excellent Pgp properties makes it the more promising candidate. The slightly better affinity of Ligand B also contributes to this decision.
Output:
0
2025-04-17 21:12:27,662 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (368.46 and 369.41 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (93.19) is higher than Ligand B (38.33). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B is significantly better here.
3. **logP:** Ligand A (-0.52) is quite low, potentially hindering membrane permeability. Ligand B (4.122) is high, bordering on problematic for solubility and off-target effects, but acceptable for a GPCR. Ligand B is better, despite being on the higher side.
4. **HBD:** Ligand A (2) and Ligand B (1) are both within the acceptable limit of 5. Ligand B is slightly better.
5. **HBA:** Ligand A (5) and Ligand B (3) are both within the acceptable limit of 10. Ligand B is better.
6. **QED:** Both ligands have good QED scores (0.749 and 0.861), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (51.26) has a lower DILI risk than Ligand B (57.35). This is a positive for Ligand A.
8. **BBB:** Ligand A (23.19) has a very low BBB penetration, while Ligand B (86.82) has high BBB penetration. While ADRB2 isn't primarily a CNS target, some degree of BBB penetration can be useful, and it doesn't hurt. Ligand B is better.
9. **Caco-2:** Both ligands have similar, very negative Caco-2 values (-5.044 and -4.804). This suggests poor permeability, which is concerning.
10. **Solubility:** Ligand A (-1.625) has slightly better solubility than Ligand B (-4.564).
11. **hERG:** Ligand A (0.245) has a significantly lower hERG risk than Ligand B (0.76). This is a major advantage for Ligand A.
12. **Cl_mic:** Ligand A (-38.79) has much lower (better) microsomal clearance than Ligand B (74.07). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (35.63) has a longer in vitro half-life than Ligand B (19.28). This is a positive for Ligand A.
14. **Pgp:** Ligand A (0.011) has much lower P-gp efflux than Ligand B (0.664). This is a significant advantage for Ligand A.
15. **Binding Affinity:** Ligand B (-7.6) has significantly stronger binding affinity than Ligand A (-4.9). This is a substantial advantage for Ligand B, potentially outweighing some of the ADME concerns.
**Overall Assessment:**
Ligand B has a significantly better binding affinity, which is paramount for GPCR targets. While its logP is high and Caco-2 permeability is poor, the strong binding could compensate. Ligand A has better ADME properties (lower DILI, better metabolic stability, lower P-gp efflux, better hERG), but its affinity is considerably weaker. Given the importance of potency for GPCRs, the stronger binding of Ligand B is the deciding factor.
Output:
0
2025-04-17 21:12:27,663 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [340.379, 77.52, 1.975, 1, 5, 0.842, 85.459, 56.805, -4.712, -3.229, 0.243, 50.888, -9.263, 0.13, -6.8]
**Ligand B:** [411.34, 50.8, 4.507, 1, 4, 0.725, 52.036, 69.213, -4.644, -5.324, 0.864, 102.368, 47.168, 0.517, -7]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Ligand A (340.379 Da) is better, falling comfortably within the 200-500 Da range. Ligand B (411.34 Da) is at the upper end, but still acceptable.
2. **TPSA:** Ligand B (50.8) is significantly better than Ligand A (77.52). Lower TPSA generally improves permeability, crucial for GPCRs.
3. **logP:** Ligand A (1.975) is optimal. Ligand B (4.507) is high, potentially leading to solubility issues and off-target interactions.
4. **HBD/HBA:** Both have 1 HBD and acceptable HBA counts (5 for A, 4 for B).
5. **QED:** Ligand A (0.842) is superior, indicating a more drug-like profile than Ligand B (0.725).
6. **DILI:** Both have relatively high DILI risk (A: 85.459, B: 52.036), but Ligand B is better. This is a concern for both, requiring further investigation.
7. **BBB:** Ligand B (69.213) is better than Ligand A (56.805), but neither is exceptionally high. For a non-CNS target like ADRB2, this isn't a primary concern, but a higher value is still preferred.
8. **Caco-2:** Both are negative, indicating poor permeability.
9. **Solubility:** Ligand A (-3.229) is better than Ligand B (-5.324). Solubility is a concern for Ligand B due to its high logP.
10. **hERG:** Ligand A (0.243) is much better than Ligand B (0.864), indicating lower cardiotoxicity risk.
11. **Cl_mic:** Ligand A (50.888) has a lower clearance, suggesting better metabolic stability than Ligand B (102.368).
12. **t1/2:** Ligand A (-9.263) has a longer half-life than Ligand B (47.168).
13. **Pgp:** Ligand A (0.13) is much better than Ligand B (0.517), indicating less P-gp efflux and potentially better bioavailability.
14. **Affinity:** Ligand B (-7 kcal/mol) has a slightly better binding affinity than Ligand A (-6.8 kcal/mol). This is a significant advantage, but needs to be weighed against other factors.
**Overall Assessment:**
Ligand B has a better binding affinity and BBB penetration, but suffers from a higher logP, worse solubility, higher Pgp efflux, and higher microsomal clearance. Ligand A has a better overall profile, with a more favorable balance of properties. The better QED, solubility, lower hERG risk, lower Pgp efflux, and metabolic stability of Ligand A outweigh the slightly weaker binding affinity.
Therefore, I recommend **Ligand A**.
1
2025-04-17 21:12:27,663 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [374.869, 99.77, 0.979, 3, 4, 0.435, 27.181, 70.376, -5.24, -2.187, 0.254, -11.567, -16.699, 0.005, -6.6]
**Ligand B:** [343.423, 51.91, 3.729, 0, 4, 0.685, 52.423, 66.615, -4.636, -4.086, 0.745, 58.702, 45.048, 0.527, -5.8]
Here's a breakdown, considering the guidelines and GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal 200-500 Da range. Ligand B (343.423) is slightly smaller, which *could* be advantageous for permeability, but the difference isn't huge.
2. **TPSA:** Ligand A (99.77) is higher than Ligand B (51.91). Both are below 140, but B is significantly better, suggesting better oral absorption potential.
3. **logP:** Ligand A (0.979) is a bit low, potentially hindering membrane permeability. Ligand B (3.729) is much better, falling nicely within the optimal 1-3 range. This is a significant advantage for B.
4. **HBD:** Ligand A (3) is acceptable. Ligand B (0) is even better, potentially improving permeability and reducing off-target interactions.
5. **HBA:** Both ligands have 4 HBA, which is within the acceptable range.
6. **QED:** Ligand B (0.685) has a better QED score than Ligand A (0.435), indicating a more drug-like profile.
7. **DILI:** Ligand A (27.181) has a much lower DILI risk than Ligand B (52.423). This is a significant advantage for A.
8. **BBB:** Ligand A (70.376) has a slightly better BBB penetration score than Ligand B (66.615), but both are reasonably good.
9. **Caco-2:** Ligand A (-5.24) is worse than Ligand B (-4.636), indicating lower intestinal absorption.
10. **Solubility:** Ligand A (-2.187) is better than Ligand B (-4.086).
11. **hERG:** Ligand A (0.254) has a lower hERG risk than Ligand B (0.745). This is a significant advantage for A.
12. **Cl_mic:** Ligand A (-11.567) has much better metabolic stability (lower clearance) than Ligand B (58.702). This is a major advantage for A.
13. **t1/2:** Ligand A (-16.699) has a longer in vitro half-life than Ligand B (45.048). This is a significant advantage for A.
14. **Pgp:** Ligand A (0.005) has much lower P-gp efflux than Ligand B (0.527). This is a significant advantage for A.
15. **Affinity:** Ligand A (-6.6) has a slightly better binding affinity than Ligand B (-5.8). While not a huge difference, it's a positive for A.
**Overall Assessment:**
Ligand B excels in logP and TPSA, which are important for GPCRs. However, Ligand A demonstrates a much more favorable safety profile (DILI, hERG), superior metabolic stability (Cl_mic, t1/2), lower P-gp efflux, and slightly better affinity. The better solubility of Ligand A is also a plus. Given the cardiovascular context, minimizing off-target effects (hERG) and ensuring adequate metabolic stability are crucial. While Ligand B has better permeability predictions based on TPSA and logP, the overall risk profile of Ligand A is more appealing.
Therefore, I would choose Ligand A.
Output:
1
2025-04-17 21:12:27,663 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**1. Molecular Weight:** Both ligands (348.443 and 365.414 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Both ligands have TPSA values (82.78 and 80.32) below the 140 A^2 threshold for good oral absorption, which is good.
**3. logP:** Both ligands have logP values within the optimal 1-3 range (2.628 and 1.919). Ligand B is slightly lower, which could be beneficial for solubility.
**4. H-Bond Donors:** Both ligands have 2 HBD, which is within the acceptable limit of <=5.
**5. H-Bond Acceptors:** Ligand A has 4 HBA, and Ligand B has 5. Both are below the 10 threshold.
**6. QED:** Both ligands have QED values above 0.5 (0.774 and 0.688), indicating good drug-likeness.
**7. DILI:** Both ligands have low DILI risk (41.838 and 39.628 percentile), which is favorable.
**8. BBB:** Ligand B (66.886) has a significantly higher BBB penetration percentile than Ligand A (39.744). While ADRB2 isn't strictly a CNS target, some CNS exposure can be relevant for off-target effects and overall safety assessment.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.868 and -5.252), which is unusual and suggests poor permeability. This is a significant concern for both.
**10. Aqueous Solubility:** Both ligands have negative solubility values (-2.518 and -2.008), indicating very poor aqueous solubility. This is a major drawback for both.
**11. hERG Inhibition:** Both ligands have low hERG inhibition liability (0.236 and 0.363), which is excellent.
**12. Microsomal Clearance:** Ligand B has a lower microsomal clearance (5.796) than Ligand A (10.743), suggesting better metabolic stability.
**13. In vitro Half-Life:** Ligand B has a significantly longer in vitro half-life (35.038 hours) than Ligand A (21.423 hours). This is a major advantage for Ligand B, potentially allowing for less frequent dosing.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.216 and 0.029).
**15. Binding Affinity:** Both ligands have very similar binding affinities (-6.3 and -6.2 kcal/mol). The difference is negligible.
**GPCR-Specific Considerations:** For GPCRs, logP, Pgp, TPSA, and affinity are key. Both ligands perform similarly on logP, Pgp, and affinity. Ligand B has a slightly better profile for TPSA and a significantly better BBB penetration.
**Overall Assessment:**
Both ligands have significant issues with Caco-2 permeability and aqueous solubility. However, Ligand B demonstrates advantages in BBB penetration, microsomal clearance, and in vitro half-life. These factors, particularly the longer half-life and improved metabolic stability, make Ligand B a slightly more promising candidate despite the shared solubility and permeability challenges.
Output:
0
2025-04-17 21:12:27,663 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (351.407 and 345.451 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (139.46) is slightly higher than Ligand B (82.68). For a cardiovascular GPCR, TPSA is moderately important. Ligand B's lower TPSA is preferable, potentially aiding permeability.
**3. logP:** Ligand A (-0.672) is a bit low, potentially hindering membrane permeability. Ligand B (1.354) is within the optimal 1-3 range. This is a clear advantage for Ligand B.
**4. H-Bond Donors:** Ligand A (4) is acceptable, while Ligand B (1) is even better, potentially improving permeability.
**5. H-Bond Acceptors:** Ligand A (7) and Ligand B (8) are both within the acceptable range of <=10.
**6. QED:** Both ligands have reasonable QED values (0.462 and 0.655), indicating drug-like properties. Ligand B is slightly better.
**7. DILI Risk:** Ligand A (49.477) has a higher DILI risk than Ligand B (34.393). Lower is better, so Ligand B is preferred.
**8. BBB Penetration:** Ligand B (70.919) shows better BBB penetration than Ligand A (63.862). While ADRB2 is a cardiovascular target and CNS penetration isn't *essential*, some degree of BBB penetration can be beneficial for off-target effects assessment and potential alternative therapeutic avenues.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-5.447 and -5.547), which is unusual and suggests poor permeability *in vitro*. This is a concern for both, but the values are similar.
**10. Aqueous Solubility:** Both ligands have very poor aqueous solubility (-1.664 and -1.233). This is a significant drawback for both and would require formulation strategies.
**11. hERG Inhibition:** Both ligands show low hERG inhibition risk (0.216 and 0.201), which is excellent.
**12. Microsomal Clearance:** Ligand A (0.482) has significantly lower microsomal clearance than Ligand B (17.61). Lower clearance is desirable for increased metabolic stability. This is a strong advantage for Ligand A.
**13. In vitro Half-Life:** Ligand A (-5.473) has a very poor in vitro half-life, while Ligand B (2.892) is better, but still not ideal.
**14. P-gp Efflux:** Both ligands show low P-gp efflux liability (0.005 and 0.17), which is favorable.
**15. Binding Affinity:** Both ligands have comparable and strong binding affinities (-6.4 and -5.0 kcal/mol). Ligand A has a 1.4 kcal/mol advantage, which is substantial.
**Overall Assessment:**
Ligand A has a significant advantage in binding affinity and microsomal clearance. However, its poor in vitro half-life and lower logP are concerning. Ligand B excels in logP, TPSA, DILI risk, and BBB penetration, but has a weaker binding affinity and higher clearance.
Considering the GPCR-specific priorities (logP, TPSA, affinity), and the need for a balance between potency and ADME properties, the stronger binding affinity of Ligand A is a critical factor. While the poor half-life is a drawback, it might be addressable through structural modifications. The better ADME profile of Ligand B is offset by its significantly lower affinity.
Therefore, I favor Ligand A.
Output:
1
2025-04-17 21:12:27,663 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Ligand A (361.463 Da) is better than Ligand B (338.411 Da). Both are within the ideal range, but A is closer to the 350-400 sweet spot.
2. **TPSA:** Ligand A (56.79) is significantly better than Ligand B (87.04). ADRB2 is a cardiovascular target, so CNS penetration isn't crucial, but lower TPSA generally aids absorption. B is getting high enough to potentially cause issues.
3. **logP:** Both ligands (A: 3.635, B: 3.762) are excellent, falling within the optimal 1-3 range. Very similar here.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower is generally better for permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (4). Both are acceptable, but A is slightly better.
6. **QED:** Both ligands (A: 0.693, B: 0.753) have good drug-likeness scores, exceeding the 0.5 threshold. B is slightly better.
7. **DILI:** Ligand A (53.742) is better than Ligand B (69.911). Both are acceptable, but A has a lower risk.
8. **BBB:** Ligand A (79.721) is better than Ligand B (51.415). While not a CNS target, higher BBB is usually a neutral benefit.
9. **Caco-2:** Ligand A (-4.586) is better than Ligand B (-4.827). Higher values indicate better absorption, and A is slightly better.
10. **Solubility:** Ligand A (-4.358) is better than Ligand B (-5.59). Higher solubility is preferred.
11. **hERG:** Both ligands (A: 0.75, B: 0.728) have similar hERG inhibition liability, and are at acceptable levels.
12. **Cl_mic:** Ligand A (75.004) is better than Ligand B (95.637). Lower clearance is preferable for metabolic stability.
13. **t1/2:** Ligand B (36.882) is significantly better than Ligand A (8.564). This is a major advantage for B.
14. **Pgp:** Both ligands (A: 0.671, B: 0.411) have similar Pgp efflux liability, and are at acceptable levels. B is slightly better.
15. **Binding Affinity:** Ligand B (-5.0) is significantly better than Ligand A (-3.3). This is a substantial advantage, exceeding the 1.5 kcal/mol threshold.
**Overall Assessment:**
Ligand B has a significantly stronger binding affinity (-5.0 kcal/mol vs -3.3 kcal/mol) and a substantially longer half-life (36.882 hours vs 8.564 hours). These two factors are highly important for a viable drug candidate. While Ligand A has advantages in several ADME properties (TPSA, solubility, DILI), the potency and duration of action conferred by Ligand B outweigh these benefits. The slightly higher TPSA of Ligand B is not a major concern for a cardiovascular target.
Output:
0
2025-04-17 21:12:27,663 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (359.857 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (58.37) is significantly better than Ligand B (78.87). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally improves absorption.
3. **logP:** Ligand B (1.66) is better than Ligand A (4.287). Ligand A is quite high, potentially leading to solubility issues and off-target interactions.
4. **HBD/HBA:** Ligand A (HBD=1, HBA=3) is better than Ligand B (HBD=2, HBA=5). Lower counts are generally preferred.
5. **QED:** Ligand A (0.889) is significantly better than Ligand B (0.642), indicating a more drug-like profile.
6. **DILI:** Ligand B (19.814) is *much* better than Ligand A (62.466). This is a critical advantage for Ligand B, as liver toxicity is a major concern.
7. **BBB:** Ligand A (88.29) is better than Ligand B (36.293). However, since ADRB2 is primarily a cardiovascular target, BBB penetration is not a high priority.
8. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-4.753) is slightly better than Ligand B (-4.978).
9. **Solubility:** Ligand A (-4.478) is slightly better than Ligand B (-2.319).
10. **hERG:** Ligand A (0.709) is better than Ligand B (0.452), indicating a lower risk of cardiotoxicity.
11. **Cl_mic:** Ligand B (29.441) is *much* better than Ligand A (76.732). Lower clearance is crucial for metabolic stability and potentially less frequent dosing.
12. **t1/2:** Ligand A (74.548) is significantly better than Ligand B (6.473).
13. **Pgp:** Ligand A (0.678) is better than Ligand B (0.137). Lower P-gp efflux is desirable.
14. **Affinity:** Ligand B (-7.1) is significantly better than Ligand A (-4.6). This is a substantial difference in binding potency.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B has a better logP, while Ligand A has better TPSA and Pgp. However, the *massive* difference in binding affinity (-7.1 vs -4.6 kcal/mol) is the most important factor. A 2.5 kcal/mol difference is substantial enough to overcome the other drawbacks. Furthermore, the significantly lower DILI risk for Ligand B is a major advantage. While Ligand A has better metabolic stability (t1/2) and slightly better solubility, the DILI and affinity profiles of Ligand B are far more compelling.
**Conclusion:**
Despite some drawbacks in metabolic stability and permeability, Ligand B's superior binding affinity and significantly lower DILI risk make it the more promising drug candidate for ADRB2.
0
2025-04-17 21:12:27,663 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.415 and 360.435 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (82.45 and 84.5) are below the 140 A^2 threshold for good oral absorption, and acceptable for a cardiovascular target (not requiring significant CNS penetration). Again, no major difference.
3. **logP:** Both ligands (2.05 and 1.835) are within the optimal 1-3 range.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2) as lower HBD generally improves permeability.
5. **HBA:** Ligand A (6) and Ligand B (5) are both acceptable, below the 10 threshold.
6. **QED:** Both ligands have excellent QED scores (0.846 and 0.85), indicating good drug-like properties.
7. **DILI:** Ligand B (73.013) has a slightly better DILI risk profile than Ligand A (57.387), but both are reasonably good (below 60).
8. **BBB:** Ligand A (75.378) has a better BBB penetration score than Ligand B (60.411). While ADRB2 is a cardiovascular target, some CNS effects are possible with beta-blockers, and moderate CNS penetration could be beneficial or detrimental depending on the desired profile.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.348 and -4.981), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Both ligands have negative solubility values (-3.983 and -3.797), which is also unusual and suggests poor aqueous solubility. This is a significant concern for both.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.193 and 0.355), which is excellent.
12. **Cl_mic:** Ligand A (77.298) has a significantly lower microsomal clearance than Ligand B (9.423), indicating better metabolic stability. This is a major advantage.
13. **t1/2:** Ligand A (-12.97) has a more negative in vitro half-life than Ligand B (54.626), which is concerning. A negative value is unusual and suggests rapid degradation.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.115 and 0.082), which is good.
15. **Binding Affinity:** Ligand A (-7.1 kcal/mol) has a slightly better binding affinity than Ligand B (-6.7 kcal/mol). This 0.4 kcal/mol difference is meaningful, especially given the other parameters.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Both ligands perform similarly on logP and TPSA. Pgp is good for both. Ligand A has a slightly better affinity. Metabolic stability (Cl_mic) is also crucial, and Ligand A is significantly better in this regard.
**Overall Assessment:**
Despite the unusual Caco-2 and solubility values for both, Ligand A is preferable. The better binding affinity, significantly improved metabolic stability (lower Cl_mic), and slightly better BBB penetration outweigh the slightly higher DILI risk and the unusual half-life. The negative half-life is concerning, but could be an artifact of the prediction method. The affinity difference is also a significant factor.
Output:
1
2025-04-17 21:12:27,664 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.431 and 354.445 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (95.71) is higher than Ligand B (54.18). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for permeability. Ligand B is significantly better.
3. **logP:** Ligand A (3.617) is slightly higher than Ligand B (2.696), both within the optimal 1-3 range. Ligand A is closer to the upper limit, potentially raising concerns about off-target effects, but still acceptable.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1). Both are within the acceptable limit of 5.
5. **HBA:** Ligand A (4) and Ligand B (5) are both within the acceptable limit of 10.
6. **QED:** Both ligands have good QED scores (0.627 and 0.741), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (46.956) has a higher DILI risk than Ligand B (21.442). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (68.36) is lower than Ligand B (90.074). While ADRB2 isn't a primary CNS target, some brain penetration can be relevant for peripheral effects mediated by central pathways. Ligand B is better.
9. **Caco-2:** Both ligands have similar, very negative Caco-2 values (-4.68 and -4.689), indicating poor permeability. This is a concern for both.
10. **Solubility:** Both ligands have similar, very negative solubility values (-3.21 and -3.036), indicating poor solubility. This is a concern for both.
11. **hERG:** Both ligands have similar hERG values (0.757 and 0.835), indicating a moderate risk of hERG inhibition.
12. **Cl_mic:** Ligand A (3.582) has a much lower microsomal clearance than Ligand B (27.121), suggesting better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (-1.971) has a negative in vitro half-life, which is concerning. Ligand B (10.682) has a much better half-life.
14. **Pgp:** Both ligands have similar Pgp values (0.349 and 0.344), indicating moderate P-gp efflux.
15. **Binding Affinity:** Ligand B (-5.2 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.0 kcal/mol). This is a substantial advantage for Ligand B, potentially outweighing some of the ADME drawbacks.
**Overall Assessment:**
Ligand B demonstrates a superior profile overall. While both have issues with Caco-2 and solubility, Ligand B has a significantly better DILI score, BBB penetration, and, crucially, a much stronger binding affinity. The improved metabolic stability of Ligand A is attractive, but the substantial affinity advantage of Ligand B is more important for a GPCR target. The longer half-life of Ligand B is also a significant benefit.
Output:
0
2025-04-17 21:12:27,664 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
The target is ADRB2, a GPCR. Therefore, I will prioritize logP, TPSA, Pgp efflux, BBB penetration, and binding affinity. Metabolic stability (Cl_mic and t1/2) and safety (DILI, hERG) are also important.
Let's compare the ligands property by property:
1. **MW:** Both are within the ideal range (349-364 Da).
2. **TPSA:** Ligand B (72.88) is significantly better than Ligand A (93.61). Lower TPSA generally improves permeability.
3. **logP:** Both are good (1.766 and 0.764), falling within the optimal 1-3 range. Ligand A is slightly better.
4. **HBD/HBA:** Ligand A (1 HBD, 5 HBA) is slightly better than Ligand B (2 HBD, 4 HBA), though both are acceptable.
5. **QED:** Both are reasonable (0.835 and 0.695), indicating good drug-like properties.
6. **DILI:** Ligand B (10.392) is *much* better than Ligand A (53.354). This is a significant advantage for Ligand B.
7. **BBB:** Both have acceptable BBB penetration (67.933 and 61.691), but neither is exceptionally high.
8. **Caco-2:** Both are poor (-5.157 and -5.152). This suggests limited intestinal absorption for both.
9. **Solubility:** Both are poor (-3.007 and -1.695).
10. **hERG:** Both have low hERG inhibition risk (0.673 and 0.399).
11. **Cl_mic:** Ligand B (15.065) has significantly lower microsomal clearance than Ligand A (30.589), indicating better metabolic stability.
12. **t1/2:** Ligand B (12.127) has a longer in vitro half-life than Ligand A (-23.499). This is a clear advantage for Ligand B.
13. **Pgp:** Ligand B (0.056) has much lower P-gp efflux liability than Ligand A (0.205). This is a significant advantage for oral bioavailability and potentially CNS exposure.
14. **Binding Affinity:** Ligand B (-7.3 kcal/mol) has a substantially stronger binding affinity than Ligand A (-5.6 kcal/mol). This is a >1.5 kcal/mol advantage, which can outweigh some ADME drawbacks.
**Overall Assessment:**
While Ligand A has a slightly better logP, Ligand B excels in almost every other critical parameter, especially DILI risk, metabolic stability (Cl_mic, t1/2), Pgp efflux, and *significantly* in binding affinity. The superior binding affinity of Ligand B is a major driver for selection, and the improved safety profile (DILI) and pharmacokinetic properties (Cl_mic, t1/2, Pgp) make it a much more promising drug candidate. The lower TPSA of Ligand B is also beneficial for permeability.
**Output:**
0
2025-04-17 21:12:27,664 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the acceptable range (200-500 Da). Ligand A (415.316 Da) is slightly higher than Ligand B (361.471 Da), but neither is a concern.
**2. TPSA:** Ligand A (69.81) is better than Ligand B (88.39). For a cardiovascular GPCR, TPSA isn't a *major* concern like it would be for a CNS target, but lower TPSA generally correlates with better permeability.
**3. logP:** Ligand A (4.904) is higher than Ligand B (1.353). While 4.904 is approaching the upper limit of optimal, it's still acceptable. Ligand B's logP is quite low, potentially hindering permeability. This is a significant advantage for Ligand A.
**4. H-Bond Donors:** Ligand A (3) and Ligand B (2) are both acceptable.
**5. H-Bond Acceptors:** Ligand A (3) and Ligand B (6) are both acceptable, but Ligand A is preferable.
**6. QED:** Ligand B (0.777) is better than Ligand A (0.444). This suggests Ligand B has a more generally "drug-like" profile, but this can be offset by other factors.
**7. DILI Risk:** Ligand B (69.717) has a significantly lower DILI risk than Ligand A (89.841). This is a crucial advantage for Ligand B.
**8. BBB Penetration:** Both are relatively low, which is fine for a cardiovascular target. Ligand A (78.519) is slightly better than Ligand B (61.691), but this isn't a primary concern.
**9. Caco-2 Permeability:** Both are negative, indicating poor permeability.
**10. Aqueous Solubility:** Both are negative, indicating poor solubility.
**11. hERG Inhibition:** Ligand A (0.818) is better than Ligand B (0.301). Lower hERG inhibition is crucial to avoid cardiotoxicity.
**12. Microsomal Clearance:** Ligand B (36.407) has significantly lower microsomal clearance than Ligand A (58.209), indicating better metabolic stability. This is a major advantage for Ligand B.
**13. In Vitro Half-Life:** Ligand B (11.061) has a lower half-life than Ligand A (82.514). This is a significant advantage for Ligand A.
**14. P-gp Efflux:** Ligand A (0.634) is better than Ligand B (0.036). Lower P-gp efflux is preferable.
**15. Binding Affinity:** Ligand A (-8.3 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.5 kcal/mol). This is a substantial advantage for Ligand A, and can often outweigh minor ADME concerns.
**Overall Assessment:**
The key trade-offs are: Ligand A has superior affinity and half-life, while Ligand B has better DILI risk and metabolic stability. Considering this is a cardiovascular GPCR, the strong binding affinity of Ligand A is paramount. While DILI risk is important, it can be further investigated and mitigated during optimization. The slightly higher DILI risk of Ligand A is acceptable given its significantly better potency. The lower logP of Ligand B is a concern for permeability.
Therefore, I would choose Ligand A.
Output:
1
2025-04-17 21:12:27,664 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (358.483 and 363.437 Da) are within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (85.35) is better than Ligand B (45.46). While both are reasonably low, Ligand B is significantly lower, which is favorable for permeability, especially important for GPCRs.
3. **logP:** Ligand A (-1.16) is suboptimal, being below the preferred 1-3 range. Ligand B (4.043) is high, but still within a tolerable range. Ligand A's low logP raises concerns about membrane permeability.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1), but both are acceptable (<=5).
5. **HBA:** Both ligands have 6 HBA, which is within the acceptable range (<=10).
6. **QED:** Ligand B (0.743) has a better QED score than Ligand A (0.541), indicating a more drug-like profile.
7. **DILI:** Ligand A (5.312) has a significantly lower DILI risk than Ligand B (85.072). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (68.631) has a better BBB penetration percentile than Ligand A (22.838). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant, and the difference is substantial.
9. **Caco-2:** Ligand A (-5.024) and Ligand B (-4.696) are both negative, indicating poor permeability. This is concerning for both, but the values are similar.
10. **Solubility:** Ligand A (-0.133) is slightly better than Ligand B (-4.466), but both are very poor. Solubility is a significant concern for both compounds.
11. **hERG:** Ligand A (0.217) has a lower hERG risk than Ligand B (0.855). This is a positive for Ligand A.
12. **Cl_mic:** Ligand A (30.271) has a lower microsomal clearance than Ligand B (44.814), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-11.341) has a negative half-life, which is concerning. Ligand B (-3.919) is also negative, but less so. Both are problematic.
14. **Pgp:** Ligand A (0.004) has a much lower Pgp efflux liability than Ligand B (0.672). This is a significant advantage for Ligand A.
15. **Binding Affinity:** Ligand A (-7.5) has a slightly better binding affinity than Ligand B (-6.7). While the difference is not huge, it is within the range where it could be decisive.
**Overall Assessment:**
Ligand A has several advantages: lower DILI risk, lower hERG risk, lower Pgp efflux, better metabolic stability, and slightly better binding affinity. However, it suffers from a very low logP and poor solubility. Ligand B has better BBB penetration and QED, but significantly higher DILI risk, higher Pgp efflux, and worse metabolic stability.
Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity), and the overall balance, Ligand A is the better candidate despite its solubility and logP issues. The lower DILI and hERG risks are crucial, and the better metabolic stability and Pgp profile are also important. The affinity difference, while small, tips the balance. Solubility and logP can be addressed through further optimization.
Output:
1
2025-04-17 21:12:27,664 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Ligand A (410.851 Da) is within the ideal range (200-500 Da). Ligand B (386.546 Da) is also excellent. No clear advantage here.
2. **TPSA:** Ligand A (77.52) is good, below the 140 threshold for oral absorption. Ligand B (98.54) is still acceptable but higher, potentially impacting absorption. Ligand A is slightly favored.
3. **logP:** Both ligands (A: 2.949, B: 2.936) are optimal (1-3). No significant difference.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 6 HBA, Ligand B has 5. Both are acceptable (<=10).
6. **QED:** Ligand A (0.792) is better than Ligand B (0.421), indicating a more drug-like profile. This is a significant advantage for Ligand A.
7. **DILI:** Ligand A (94.959) has a higher DILI risk than Ligand B (68.903). This is a significant drawback for Ligand A.
8. **BBB:** Ligand A (61.846) and Ligand B (72.819). While ADRB2 isn't strictly a CNS target, some peripheral ADRB2 activity can influence CNS pathways. Ligand B is slightly favored.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-4.796) is slightly better than Ligand B (-4.97).
10. **Solubility:** Both are very poor (-5.135 and -5.001). This is a major concern for both, and formulation strategies would be critical.
11. **hERG:** Ligand A (0.29) has a lower hERG risk than Ligand B (0.819). This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand A (37.34) has lower clearance than Ligand B (91.463), suggesting better metabolic stability. This is a substantial advantage for Ligand A.
13. **t1/2:** Ligand A (19.572) has a longer half-life than Ligand B (-11.448). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.333) has lower P-gp efflux than Ligand B (0.598). This is a slight advantage for Ligand A.
15. **Binding Affinity:** Ligand B (-8.2 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.6 kcal/mol). This is a substantial advantage for Ligand B, potentially outweighing some of the ADME drawbacks.
**Overall Assessment:**
Ligand B has a much stronger binding affinity, which is paramount for GPCR targets. However, Ligand A demonstrates a better overall ADME profile, with better QED, lower DILI, lower Cl_mic, longer half-life, and lower Pgp efflux. The poor solubility and Caco-2 permeability are concerning for both. The DILI risk for Ligand A is a significant concern, but the improved metabolic stability and half-life are attractive. The difference in binding affinity is substantial (2.6 kcal/mol), which is a large advantage. Given the importance of potency for GPCRs, and the potential to address solubility issues through formulation, I favor Ligand B.
Output:
0
2025-04-17 21:12:27,664 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.344 and 347.459 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (49.33) is significantly better than Ligand B (66.65). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands (2.511 and 2.799) are within the optimal 1-3 range. Ligand B is slightly higher, which *could* be a minor drawback if it leads to off-target interactions, but it's not a major concern.
4. **HBD:** Both ligands have 0 HBD, which is good.
5. **HBA:** Both ligands have 4 HBA, which is within the acceptable limit of 10.
6. **QED:** Ligand A (0.85) has a slightly better QED score than Ligand B (0.725), indicating a more drug-like profile.
7. **DILI:** Ligand A (45.677) has a higher DILI risk than Ligand B (28.228). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (96.045) has better BBB penetration than Ligand B (89.066), but as this is a cardiovascular target, this is not a major factor.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.503 and -4.413), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Both ligands have negative solubility values (-2.479 and -2.297), indicating poor aqueous solubility. This is a significant drawback for both.
11. **hERG:** Ligand A (0.907) has a slightly higher hERG risk than Ligand B (0.425). This favors Ligand B.
12. **Cl_mic:** Ligand A (23.712) has a much lower microsomal clearance than Ligand B (84.001), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (-19.361) has a negative in vitro half-life, which is concerning. Ligand B (-31.723) is even worse. Both are problematic.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.277 and 0.372), which is good.
15. **Binding Affinity:** Ligand A (-8.8 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.7 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME drawbacks.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, and affinity. Ligand A is better on TPSA, Pgp, and significantly better on affinity. Ligand B is better on DILI and hERG. The large difference in binding affinity is the most important factor. While the negative half-life and solubility are concerning for both, the strong binding of Ligand A makes it more likely to show efficacy *if* these issues can be addressed through formulation or structural modification.
**Conclusion:**
Despite the solubility and half-life concerns, the significantly stronger binding affinity of Ligand A, combined with its better TPSA and metabolic stability, makes it the more promising candidate.
Output:
1
2025-04-17 21:12:27,665 - INFO - Batch 241 complete. Total preferences: 3856
2025-04-17 21:12:27,665 - INFO - Processing batch 242/512...
2025-04-17 21:13:16,934 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.407 and 345.403 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (114.94 and 115.19) are below the 140 A^2 threshold for good oral absorption, but higher than the 90 A^2 for CNS targets (not a primary concern for ADRB2, a cardiovascular target). They are very similar.
3. **logP:** Ligand A (0.852) is slightly better than Ligand B (0.365). Both are a bit low, potentially impacting membrane permeability, but Ligand A is closer to the optimal 1-3 range.
4. **HBD:** Both ligands have 2 H-bond donors, which is within the acceptable limit of 5.
5. **HBA:** Ligand A has 7 H-bond acceptors, while Ligand B has 5. Both are below the 10 threshold.
6. **QED:** Both ligands have very similar QED scores (0.694 and 0.693), indicating good drug-likeness.
7. **DILI:** Ligand B (42.691) has a significantly lower DILI risk than Ligand A (59.752). This is a substantial advantage for Ligand B.
8. **BBB:** Ligand A (46.413) has a slightly higher BBB penetration potential than Ligand B (36.06). However, BBB penetration is not a high priority for a cardiovascular target like ADRB2.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.494 and -5.236). These values are unusual and suggest poor permeability.
10. **Solubility:** Both ligands have negative solubility values (-1.922 and -1.827). These values are unusual and suggest poor solubility.
11. **hERG:** Ligand A (0.067) has a slightly lower hERG inhibition liability than Ligand B (0.441), which is favorable.
12. **Cl_mic:** Ligand B (23.341) has a lower microsomal clearance than Ligand A (10.244), indicating better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand A (23.59) has a much longer in vitro half-life than Ligand B (1.833). This is a major advantage for Ligand A, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.043) has a lower P-gp efflux liability than Ligand B (0.015), suggesting better oral bioavailability and potentially better tissue distribution.
15. **Binding Affinity:** Ligand B (-7.6 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.5 kcal/mol). This 1.1 kcal/mol difference is substantial and can often outweigh minor ADME drawbacks.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand B has a better affinity, lower Pgp efflux, and comparable TPSA. While Ligand A has a better logP and longer half-life, the superior binding affinity of Ligand B is a critical factor. The lower DILI risk of Ligand B is also a significant benefit.
**Conclusion:**
Despite the longer half-life of Ligand A, the significantly stronger binding affinity and lower DILI risk of Ligand B make it the more promising drug candidate for ADRB2.
Output:
0
2025-04-17 21:13:16,934 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.435 and 354.491 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand B (87.66) is better than Ligand A (97.19). Both are under 140, but lower TPSA is generally preferred for permeability, especially for a GPCR.
3. **logP:** Ligand B (1.898) is better than Ligand A (0.592). Ligand A's logP is quite low, potentially hindering membrane permeability. Ligand B is within the optimal 1-3 range.
4. **HBD:** Ligand A (1) is better than Ligand B (3). Fewer HBDs are generally preferred for better permeability.
5. **HBA:** Ligand A (6) is better than Ligand B (4). Similar to HBD, fewer HBAs are preferred.
6. **QED:** Ligand A (0.758) is slightly better than Ligand B (0.59), indicating a marginally more drug-like profile.
7. **DILI:** Ligand B (15.51) is significantly better than Ligand A (52.385). This is a major advantage for Ligand B, as lower DILI risk is crucial.
8. **BBB:** Ligand B (57.968) is better than Ligand A (43.699). While ADRB2 isn't exclusively a CNS target, some CNS penetration can be beneficial, and higher BBB is always preferable.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.033 and -5.107), which is unusual and suggests very poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand B (-1.379) is better than Ligand A (-1.748). Both are quite poor, but slightly better solubility is preferable.
11. **hERG:** Ligand A (0.011) is significantly better than Ligand B (0.301). Lower hERG inhibition is critical for avoiding cardiotoxicity, a major concern for cardiovascular targets.
12. **Cl_mic:** Ligand B (10.294) is better than Ligand A (15.417). Lower microsomal clearance indicates greater metabolic stability.
13. **t1/2:** Ligand A (-21.894) is better than Ligand B (9.658). A negative in vitro half-life is unusual, and likely indicates rapid metabolism. Ligand B's value is more reasonable.
14. **Pgp:** Ligand A (0.027) is better than Ligand B (0.052). Lower P-gp efflux is preferred.
15. **Affinity:** Ligand A (-7.1) is significantly better than Ligand B (-5.1). This is a substantial difference in binding affinity (2 kcal/mol), which can often outweigh minor ADME drawbacks.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B has better logP and TPSA, while Ligand A has better Pgp and a *much* better affinity. The DILI risk of Ligand B is also a significant advantage. The hERG risk of Ligand A is a major positive.
**Overall Assessment:**
Despite the poor Caco-2 values for both, the significantly superior binding affinity of Ligand A (-7.1 kcal/mol vs -5.1 kcal/mol) is a decisive factor. The lower hERG risk is also a critical advantage for a cardiovascular target. While Ligand B has better DILI and metabolic stability, the potency difference is substantial enough to prioritize Ligand A. The poor Caco-2 permeability would need to be addressed through formulation or structural modifications, but a strong starting point with high affinity is essential.
Output:
1
2025-04-17 21:13:16,934 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (368.5 & 349.4 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (98.32) is better than Ligand B (124.26). ADRB2 is not a CNS target, but lower TPSA generally improves absorption.
3. **logP:** Ligand A (0.809) is slightly lower than Ligand B (-0.593), but both are below the optimal 1-3 range. Ligand B is closer to potentially problematic low permeability.
4. **HBD:** Both ligands have 3 HBD, which is acceptable.
5. **HBA:** Both ligands have 5 HBA, which is acceptable.
6. **QED:** Ligand A (0.631) is slightly better than Ligand B (0.567), indicating a more drug-like profile.
7. **DILI:** Ligand A (37.46%) is significantly better than Ligand B (70.26%), placing it in the low-risk category while B is in the high-risk category. This is a major advantage for Ligand A.
8. **BBB:** Not a primary concern for ADRB2, but Ligand B (38.23%) is higher than Ligand A (17.33%).
9. **Caco-2:** Both are negative, indicating poor permeability.
10. **Solubility:** Both are negative, indicating poor solubility.
11. **hERG:** Ligand A (0.187) is better than Ligand B (0.258), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand A (18.96) is higher than Ligand B (13.80), meaning faster clearance and lower metabolic stability. Ligand B is preferable here.
13. **t1/2:** Ligand B (-20.43) is better than Ligand A (-15.61), indicating a longer half-life.
14. **Pgp:** Ligand A (0.071) is better than Ligand B (0.029), indicating lower P-gp efflux.
15. **Binding Affinity:** Ligand B (-7.2 kcal/mol) is 0.1 kcal/mol better than Ligand A (-6.1 kcal/mol). This is a significant difference in potency.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. While Ligand B has a slightly worse logP and TPSA, its significantly better affinity (-7.2 vs -6.1) and Pgp efflux profile, along with a better half-life, outweigh these drawbacks. The DILI risk for Ligand A is also a major concern.
**Conclusion:**
Despite Ligand A's better DILI and hERG profiles, Ligand B's superior binding affinity and half-life, coupled with acceptable (though not ideal) ADME properties, make it the more promising candidate for further development as an ADRB2 ligand.
Output:
0
2025-04-17 21:13:16,935 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (353.453 and 366.933 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (21.7) is significantly better than Ligand B (41.57). ADRB2 is a cardiovascular target, not a CNS target, but lower TPSA generally improves permeability.
3. **logP:** Both ligands (4.538 and 4.877) are slightly above the optimal 1-3 range, but still acceptable. Ligand B is marginally higher, which could potentially lead to off-target interactions or solubility issues, but it's not a major concern.
4. **HBD:** Ligand A (0) is preferable to Ligand B (1). Fewer HBDs generally improve membrane permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (2). Lower HBA is generally more favorable for permeability.
6. **QED:** Both ligands have good QED scores (0.776 and 0.81), indicating good drug-like properties.
7. **DILI:** Ligand A (12.02) has a much lower DILI risk than Ligand B (37.224). This is a significant advantage for Ligand A.
8. **BBB:** While not a primary concern for a cardiovascular target, Ligand A (93.874) has a much higher BBB penetration score than Ligand B (73.943).
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.409 and -4.494), indicating poor permeability. This is a concern for both, but not a deciding factor between them.
10. **Solubility:** Ligand A (-3.233) has slightly better solubility than Ligand B (-5.251).
11. **hERG:** Both ligands have low hERG inhibition risk (0.956 and 0.807).
12. **Cl_mic:** Ligand A (28.688) has significantly lower microsomal clearance than Ligand B (74.378), suggesting better metabolic stability.
13. **t1/2:** Ligand B (47.927) has a much longer in vitro half-life than Ligand A (-10.496). This is a significant advantage for Ligand B.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.388 and 0.217).
15. **Binding Affinity:** Ligand B (-7.5) has a significantly stronger binding affinity than Ligand A (-6.1). This is a substantial advantage for Ligand B, potentially outweighing some ADME drawbacks.
**Overall Assessment:**
Ligand B has a significantly better binding affinity (-7.5 kcal/mol vs -6.1 kcal/mol) and a longer half-life. These are crucial factors for a GPCR target. While Ligand A has advantages in DILI risk, TPSA, solubility, and metabolic stability, the potency and duration of action offered by Ligand B are more important for a cardiovascular drug. The slightly higher logP of Ligand B is a minor concern, but the strong binding affinity likely compensates for it.
Output:
0
2025-04-17 21:13:16,935 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (344.5 & 342.4 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (49.41) is significantly better than Ligand B (93.01). ADRB2 is a cardiovascular target, not CNS, but lower TPSA generally improves permeability. Ligand B is quite high, potentially hindering absorption.
3. **logP:** Ligand A (3.444) is optimal, while Ligand B (0.717) is on the lower side. This is a significant drawback for Ligand B, potentially impacting membrane permeability and bioavailability.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 2 HBA, while Ligand B has 6. Ligand A is preferable here, as high HBA can sometimes reduce permeability.
6. **QED:** Both ligands have good QED scores (0.777 & 0.884), indicating good drug-like properties.
7. **DILI:** Ligand A (22.722) has a much lower DILI risk than Ligand B (53.819). This is a major advantage for Ligand A.
8. **BBB:** Not a primary concern for a cardiovascular target, but Ligand A (73.711) is better than Ligand B (54.983).
9. **Caco-2:** Ligand A (-4.891) is slightly better than Ligand B (-5.137), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-3.669) is better than Ligand B (-1.846). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.505) has a slightly better hERG profile than Ligand B (0.124), but both are relatively low risk.
12. **Cl_mic:** Ligand B (-7.038) has a *negative* clearance, which is unusual and suggests very high metabolic stability. Ligand A (54.931) is higher, indicating faster metabolism. This is a strong point for Ligand B.
13. **t1/2:** Ligand B (15.646) has a significantly longer half-life than Ligand A (-13.812). This is a substantial advantage for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.351) is better than Ligand B (0.009), indicating lower P-gp efflux.
15. **Affinity:** Ligand A (-7.8) has a slightly better binding affinity than Ligand B (-6.7). While both are good, the 1.1 kcal/mol difference is significant.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A excels in logP, TPSA, and Pgp, and has a slightly better affinity. Ligand B has a better half-life and metabolic stability. However, the poor logP and high TPSA of Ligand B are significant concerns. The lower DILI risk for Ligand A is also a major benefit.
**Overall Assessment:**
While Ligand B has advantages in metabolic stability and half-life, the combination of poor logP, high TPSA, and higher DILI risk make it less attractive. Ligand A presents a better balance of properties, with favorable absorption, permeability, and safety profiles, coupled with good binding affinity. The slightly faster metabolism of Ligand A can potentially be addressed through formulation strategies.
Output:
1
2025-04-17 21:13:16,935 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (401.264 Da) is within the ideal range, while Ligand B (364.471 Da) is also acceptable. No clear advantage here.
2. **TPSA:** Ligand A (60.25) is excellent, well below the 140 threshold, and good for permeability. Ligand B (96.67) is higher, but still potentially acceptable, though less ideal.
3. **logP:** Ligand A (2.938) is optimal. Ligand B (0.653) is a bit low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (0) is good. Ligand B (2) is acceptable.
5. **HBA:** Ligand A (5) is good. Ligand B (6) is acceptable.
6. **QED:** Both Ligand A (0.663) and Ligand B (0.773) have good drug-likeness scores.
7. **DILI:** Ligand A (69.29) is a moderate risk, while Ligand B (30.826) is very low risk, a significant advantage for B.
8. **BBB:** Ligand A (60.876) is moderate. Ligand B (31.485) is low. Since ADRB2 is a cardiovascular target, BBB penetration is not a high priority, so this favors A slightly.
9. **Caco-2:** Both have negative values which is unusual. Assuming these are logP values, Ligand A (-4.835) is worse than Ligand B (-5.197).
10. **Solubility:** Ligand A (-2.8) is better than Ligand B (-1.442).
11. **hERG:** Both have low hERG risk (0.707 and 0.638 respectively).
12. **Cl_mic:** Ligand A (62.96) is higher, indicating faster clearance and lower metabolic stability, a negative. Ligand B (-19.866) is excellent, indicating very slow clearance.
13. **t1/2:** Ligand A (-1.284) is poor. Ligand B (18.209) is excellent.
14. **Pgp:** Both have low Pgp efflux liability (0.841 and 0.058 respectively), but Ligand B is significantly lower.
15. **Affinity:** Ligand A (-6.1) is slightly better than Ligand B (-5.2), but the difference is not huge.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Ligand A has a better logP and slightly better affinity. Ligand B has a much better metabolic profile (Cl_mic and t1/2) and lower DILI risk, and lower Pgp efflux. The lower DILI risk and improved metabolic stability of Ligand B are highly desirable.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity and logP, the significantly improved ADME properties of Ligand B (lower DILI, much better metabolic stability, lower Pgp efflux) outweigh this small difference in binding. The lower DILI risk is particularly important for a cardiovascular target.
Output:
0
2025-04-17 21:13:16,935 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (393.227) is slightly higher than Ligand B (367.499), but both are acceptable.
2. **TPSA:** Ligand A (117.57) is borderline for good oral absorption, but acceptable for a non-CNS GPCR target like ADRB2. Ligand B (46.09) is excellent, well below the 140 threshold. This favors Ligand B.
3. **logP:** Ligand A (1.32) is within the optimal range. Ligand B (3.493) is at the higher end, potentially raising concerns about solubility and off-target effects, but still within a reasonable range.
4. **HBD:** Ligand A (2) is good. Ligand B (0) is also good, potentially improving membrane permeability.
5. **HBA:** Both ligands have 5 HBA, which is acceptable.
6. **QED:** Ligand B (0.712) has a better QED score than Ligand A (0.392), indicating a more drug-like profile. This favors Ligand B.
7. **DILI:** Ligand A (64.909) has a lower DILI risk than Ligand B (75.378), which is a significant advantage.
8. **BBB:** Both ligands have good BBB penetration (Ligand A: 70.841, Ligand B: 73.866). Since ADRB2 is not primarily a CNS target, this is less critical, but higher is still preferable.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Both ligands have negative solubility values, which is also concerning.
11. **hERG:** Both ligands have very low hERG inhibition risk (Ligand A: 0.486, Ligand B: 0.458). This is excellent.
12. **Cl_mic:** Ligand A (-10.775) has a much lower (better) microsomal clearance than Ligand B (76.503), indicating better metabolic stability. This is a major advantage for Ligand A.
13. **t1/2:** Ligand A (2.639) has a shorter half-life than Ligand B (-19.816). The negative value for Ligand B is suspect and likely indicates a very long half-life, which is a positive.
14. **Pgp:** Both ligands have low P-gp efflux liability, which is good.
15. **Binding Affinity:** Ligand A (-8.1) has a significantly stronger binding affinity than Ligand B (-7.0). This is a substantial advantage for Ligand A, potentially outweighing some ADME drawbacks.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are particularly important. Ligand B has better TPSA and QED, while Ligand A has a much better binding affinity, lower DILI risk, and better metabolic stability (Cl_mic). The significantly stronger binding affinity of Ligand A is a key factor, and the lower DILI risk is also very important. The negative solubility and Caco-2 values are concerning for both, but the superior potency and metabolic stability of Ligand A make it more promising.
**Conclusion:**
Despite the concerns regarding solubility and permeability for both compounds, the significantly stronger binding affinity and lower DILI risk of Ligand A make it the more viable drug candidate.
Output:
1
2025-04-17 21:13:16,935 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [363.487, 99.81, 2.048, 2, 6, 0.736, 40.752, 76.503, -5.073, -3.885, 0.363, 50.02, 34.927, 0.153, -6.7]
**Ligand B:** [349.431, 94.81, 0.656, 3, 5, 0.701, 42.264, 40.132, -5.021, -1.938, 0.242, 35.325, 33.941, 0.13, -7.2]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal 200-500 Da range. Ligand B (349.431) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are reasonably good (below 140), but Ligand B (94.81) is better than Ligand A (99.81) for oral absorption.
3. **logP:** Ligand A (2.048) is optimal. Ligand B (0.656) is quite low, potentially hindering membrane permeability and bioavailability. This is a significant drawback.
4. **HBD/HBA:** Ligand A (2 HBD, 6 HBA) is better balanced than Ligand B (3 HBD, 5 HBA).
5. **QED:** Both are good (above 0.5), indicating drug-like properties.
6. **DILI:** Both have acceptable DILI risk (around 40-42 percentile).
7. **BBB:** Ligand A (76.503) has a significantly better BBB penetration prediction than Ligand B (40.132). While ADRB2 isn't *strictly* a CNS target, some CNS exposure can be relevant for off-target effects, and a higher BBB score is generally preferable.
8. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability.
9. **Solubility:** Ligand B (-1.938) is better than Ligand A (-3.885).
10. **hERG:** Both are low risk.
11. **Cl_mic:** Ligand B (35.325) has lower microsomal clearance, suggesting better metabolic stability than Ligand A (50.02).
12. **t1/2:** Similar in vitro half-lives for both.
13. **Pgp:** Ligand A (0.153) has lower P-gp efflux, which is favorable for bioavailability. Ligand B (0.13) is slightly better, but the difference is small.
14. **Affinity:** Ligand B (-7.2 kcal/mol) has a 0.5 kcal/mol stronger binding affinity than Ligand A (-6.7 kcal/mol). This is a substantial advantage.
**Overall Assessment:**
The key trade-off here is between affinity and permeability/logP. Ligand B has a significantly better binding affinity, which is crucial for a GPCR ligand. However, its low logP is a major concern, potentially leading to poor absorption and bioavailability. Ligand A has a better logP and BBB penetration, but its affinity is weaker.
Given the importance of affinity for GPCRs, and the relatively small difference in other parameters, the stronger binding of Ligand B outweighs its lower logP. Optimization efforts could focus on increasing the logP of Ligand B while maintaining its excellent affinity.
Output:
0
2025-04-17 21:13:16,936 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [349.431, 84.67, 1.592, 1, 5, 0.843, 32.338, 63.125, -4.949, -2.151, 0.129, 27.723, 11.861, 0.045, -6.6]
**Ligand B:** [362.436, 49.41, 3.017, 1, 2, 0.79, 23.924, 91.159, -4.477, -3.443, 0.618, 43.835, -40.154, 0.029, -6.3]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (349.431) is slightly lower, which is generally favorable for permeability, but both are acceptable.
2. **TPSA:** Ligand A (84.67) is better than Ligand B (49.41), being under the 140 threshold for oral absorption. Ligand B is excellent.
3. **logP:** Ligand A (1.592) is within the optimal range, while Ligand B (3.017) is approaching the upper limit. Ligand A is slightly preferred here.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 5 HBA, Ligand B has 2. Ligand B is better here.
6. **QED:** Ligand A (0.843) is better than Ligand B (0.79), indicating a more drug-like profile.
7. **DILI:** Ligand A (32.338) has a slightly higher DILI risk than Ligand B (23.924), but both are below the concerning 60% threshold. Ligand B is preferred.
8. **BBB:** Ligand B (91.159) has significantly better BBB penetration than Ligand A (63.125). This is a *major* advantage for a GPCR target, even if not explicitly CNS-focused, as it suggests better distribution.
9. **Caco-2:** Both have negative values, indicating good permeability. Ligand A (-4.949) is slightly better.
10. **Solubility:** Both have negative values, indicating poor solubility. Ligand B (-3.443) is slightly better.
11. **hERG:** Ligand A (0.129) has a lower hERG risk than Ligand B (0.618), which is crucial for cardiovascular targets.
12. **Cl_mic:** Ligand A (27.723) has a lower microsomal clearance, suggesting better metabolic stability than Ligand B (43.835).
13. **t1/2:** Ligand A (11.861) has a positive in vitro half-life, while Ligand B (-40.154) has a negative one. This is a significant advantage for Ligand A.
14. **Pgp:** Both have low Pgp efflux liability. Ligand A (0.045) is slightly better.
15. **Affinity:** Ligand A (-6.6) has a slightly better binding affinity than Ligand B (-6.3), but the difference is small.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, Pgp, TPSA, and affinity, and BBB. Ligand B excels in BBB penetration and has a good logP, while Ligand A has better TPSA, Pgp, and a slightly better affinity. The hERG risk is lower for Ligand A, which is very important for a cardiovascular target. Ligand A also has a better metabolic profile.
**Overall Assessment:**
While Ligand B has a superior BBB score, the lower hERG risk, better metabolic stability (lower Cl_mic, positive t1/2), and slightly better affinity of Ligand A, coupled with its acceptable TPSA and logP, make it the more promising candidate. The small difference in binding affinity is outweighed by the ADME/Tox advantages of Ligand A.
Output:
1
2025-04-17 21:13:16,936 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (351.447 and 361.467 Da) fall comfortably within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (89.95) is better than Ligand B (91.32) as it is closer to the <140 threshold for good oral absorption.
3. **logP:** Ligand B (2.333) is better than Ligand A (0.267). A logP between 1-3 is optimal, and Ligand A is significantly below this range, potentially hindering permeability.
4. **HBD:** Ligand A (2) is preferable to Ligand B (3). Lower HBD is generally better for permeability.
5. **HBA:** Ligand A (4) is preferable to Ligand B (5). Lower HBA is generally better for permeability.
6. **QED:** Both ligands have acceptable QED scores (0.657 and 0.706), indicating good drug-likeness. Ligand B is slightly better.
7. **DILI:** Ligand B (52.772) is significantly better than Ligand A (10.392). Lower DILI risk is critical.
8. **BBB:** Ligand A (53.47) is much better than Ligand B (26.212). While ADRB2 isn't exclusively a CNS target, some CNS exposure might be acceptable or even desirable for certain cardiovascular effects.
9. **Caco-2:** Ligand A (-4.989) is better than Ligand B (-5.452). Higher Caco-2 is better, indicating better intestinal absorption.
10. **Solubility:** Ligand A (-0.957) is better than Ligand B (-2.854). Higher solubility is generally preferred.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.118 and 0.228), which is excellent.
12. **Cl_mic:** Ligand A (-5.543) is significantly better than Ligand B (28.285). Lower microsomal clearance indicates better metabolic stability.
13. **t1/2:** Ligand A (5.421) is better than Ligand B (-3.658). Longer half-life is generally preferred.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.009 and 0.07).
15. **Binding Affinity:** Both ligands have the same binding affinity (-5.4 kcal/mol).
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, and affinity are key. While Ligand B has a better logP, Ligand A has a better TPSA, solubility, metabolic stability (Cl_mic), half-life, and DILI score. The binding affinity is the same. The significantly lower DILI risk and better metabolic stability of Ligand A are compelling advantages.
**Conclusion:**
Despite Ligand B's slightly better logP and QED, Ligand A's superior safety profile (DILI), metabolic stability, solubility, and half-life outweigh these minor differences.
Output:
1
2025-04-17 21:13:16,936 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (357.451 and 347.459 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (89.13) is slightly higher than Ligand B (78.51). Both are below the 140 threshold for oral absorption, making them both acceptable. Ligand B is preferable due to the lower TPSA.
3. **logP:** Both ligands (2.043 and 1.235) are within the optimal 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability, but Ligand B is still reasonable.
4. **HBD:** Both ligands have 2 H-bond donors, which is within the acceptable limit of <=5. No difference.
5. **HBA:** Ligand A has 5 H-bond acceptors, while Ligand B has 3. Both are below the 10 threshold. Ligand B is preferable.
6. **QED:** Both ligands have similar QED values (0.752 and 0.71), indicating good drug-likeness. No significant difference.
7. **DILI:** Ligand A (21.675%) has a slightly higher DILI risk than Ligand B (16.053%), but both are well below the concerning 60% threshold. Ligand B is preferable.
8. **BBB:** Ligand A (81.504%) has significantly better BBB penetration potential than Ligand B (59.597%). Given ADRB2's role in cardiovascular function, CNS penetration isn't a primary concern, but it's a slight advantage for A.
9. **Caco-2:** Ligand A (-4.679) has a worse Caco-2 permeability than Ligand B (-5.088). Lower values indicate poorer permeability. Ligand B is preferable.
10. **Solubility:** Ligand A (-2.392) has slightly worse solubility than Ligand B (-1.753). Solubility is important for bioavailability, so Ligand B is preferable.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.304 and 0.13), which is excellent. No difference.
12. **Cl_mic:** Ligand B (-9.146) has a lower (better) microsomal clearance than Ligand A (-6.933), indicating greater metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand B (-6.736) has a slightly shorter in vitro half-life than Ligand A (9.023). A longer half-life is generally preferred, giving A a slight edge.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.007 and 0.021). No difference.
15. **Binding Affinity:** Ligand A (-7.6 kcal/mol) has a significantly stronger binding affinity than Ligand B (-4.6 kcal/mol). This is a substantial advantage (3 kcal/mol difference) that can outweigh some ADME drawbacks.
**Overall Assessment:**
While Ligand B demonstrates superior ADME properties (lower TPSA, HBA, DILI, better Caco-2, solubility, and metabolic stability), Ligand A's significantly higher binding affinity (-7.6 vs -4.6 kcal/mol) is a decisive factor. The 3 kcal/mol difference is substantial and likely to translate to greater efficacy. Considering ADRB2 is a cardiovascular target, CNS penetration is less critical, mitigating the advantage of Ligand A's higher BBB score.
Output:
1
2025-04-17 21:13:16,936 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, we prioritize logP, TPSA, Pgp, and binding affinity, alongside general drug-like properties.
* **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (374.893) is slightly higher than Ligand B (349.435), but both are acceptable.
* **TPSA:** Ligand A (49.41) is significantly better than Ligand B (104.29). A TPSA under 140 is good for oral absorption, but lower is generally preferred for GPCRs, and Ligand A is much closer to the ideal range.
* **logP:** Ligand A (3.674) is within the optimal range (1-3), while Ligand B (0.524) is quite low, potentially hindering permeability. This is a significant advantage for Ligand A.
* **H-Bond Donors/Acceptors:** Ligand A (HBD=1, HBA=3) is preferable to Ligand B (HBD=2, HBA=5). Both are within acceptable limits, but fewer H-bonds generally improve permeability.
* **QED:** Both ligands have reasonable QED scores (A: 0.868, B: 0.712), indicating good drug-like properties.
* **DILI:** Ligand B (39.589) has a significantly lower DILI risk than Ligand A (61.807), which is a positive for Ligand B.
* **BBB:** Ligand A (68.205) has a better BBB penetration score than Ligand B (43.389), although neither are exceptionally high. For a cardiovascular target, BBB isn't a primary concern, but it's a slight advantage for A.
* **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability.
* **Solubility:** Ligand A (-4.212) has slightly better solubility than Ligand B (-1.077).
* **hERG:** Both have very low hERG inhibition risk (A: 0.373, B: 0.167), which is excellent.
* **Cl_mic:** Ligand A (52.844) has a considerably better (lower) microsomal clearance than Ligand B (14.74), suggesting better metabolic stability.
* **t1/2:** Ligand B (20.615) has a much longer in vitro half-life than Ligand A (-0.921), which is a significant advantage.
* **Pgp:** Ligand A (0.443) has a lower Pgp efflux liability than Ligand B (0.014), which is favorable.
* **Binding Affinity:** Ligand A (-6.7 kcal/mol) has a slightly better binding affinity than Ligand B (-5.4 kcal/mol). This difference, while not huge, is enough to potentially overcome some ADME drawbacks.
**Overall Assessment:**
Ligand A is the stronger candidate. While Ligand B has a lower DILI risk and a longer half-life, Ligand A excels in crucial areas for a GPCR ligand: TPSA, logP, Pgp efflux, and binding affinity. The better logP and TPSA of Ligand A are particularly important for permeability and target engagement. The slightly better affinity further supports this conclusion. The metabolic stability (Cl_mic) is also better for Ligand A, which is a significant advantage.
Output:
1
2025-04-17 21:13:16,936 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (356-366 Da). No clear advantage.
2. **TPSA:** Ligand B (66.92) is significantly better than Ligand A (91.84). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally aids absorption.
3. **logP:** Ligand B (1.916) is optimal, while Ligand A (0.351) is quite low, potentially hindering membrane permeability. This is a significant advantage for B.
4. **HBD:** Ligand A (1) is preferable to Ligand B (0). While both are acceptable, a single HBD can sometimes improve solubility.
5. **HBA:** Ligand A (6) is higher than Ligand B (4). Both are within reasonable limits, but lower is slightly preferred.
6. **QED:** Both ligands have similar QED scores (0.784 vs 0.706), indicating good drug-likeness.
7. **DILI:** Ligand B (24.622) has a much lower DILI risk than Ligand A (61.07). This is a major advantage for B.
8. **BBB:** Ligand B (92.168) shows better BBB penetration than Ligand A (54.75). While not critical for a cardiovascular target, it's a bonus.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. However, Ligand B (-4.118) is slightly better than Ligand A (-4.583).
10. **Solubility:** Both ligands have similar, poor solubility scores (-1.837 and -1.997).
11. **hERG:** Ligand B (0.223) has a slightly lower hERG risk than Ligand A (0.118), which is preferable.
12. **Cl_mic:** Ligand A (38.267) has lower microsomal clearance than Ligand B (50.452), suggesting better metabolic stability. This is a positive for A.
13. **t1/2:** Ligand B (-9.628) has a significantly longer in vitro half-life than Ligand A (6.491). This is a major advantage for B.
14. **Pgp:** Ligand B (0.062) has lower P-gp efflux liability than Ligand A (0.023), indicating better absorption and potentially higher bioavailability.
15. **Affinity:** Both ligands have very similar binding affinities (-6.6 kcal/mol vs -6.5 kcal/mol). The difference is negligible.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, and Pgp are important. Ligand B excels in logP and TPSA, and has better Pgp efflux. While BBB isn't critical, Ligand B also performs better in this parameter. The DILI score is also a major factor, and Ligand B is significantly better. The longer half-life of Ligand B is also a considerable advantage. Although Ligand A has better metabolic stability, the overall profile of Ligand B is more favorable.
**Conclusion:**
Considering the balance of properties and the priorities for a GPCR target, Ligand B is the more promising drug candidate.
Output:
0
2025-04-17 21:13:16,936 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (340.427 Da and 336.439 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (67.23) is slightly higher than Ligand B (62.97), but both are well below the 140 A^2 threshold for good oral absorption.
3. **logP:** Ligand B (2.614) is slightly higher than Ligand A (1.801), both are within the optimal 1-3 range.
4. **HBD:** Ligand A (1) has fewer HBD than Ligand B (2). This is slightly favorable for permeability.
5. **HBA:** Ligand A (4) has fewer HBA than Ligand B (5). This is slightly favorable for permeability.
6. **QED:** Ligand A (0.872) has a higher QED score than Ligand B (0.726), indicating a more drug-like profile.
7. **DILI:** Ligand B (25.087) has a significantly lower DILI risk than Ligand A (54.789). This is a major advantage for Ligand B.
8. **BBB:** Ligand A (78.868) has a higher BBB penetration percentile than Ligand B (59.325). While ADRB2 isn't *strictly* a CNS target, some CNS exposure can be relevant for off-target effects.
9. **Caco-2:** Ligand A (-4.919) has a worse Caco-2 permeability than Ligand B (-5.392). Both are negative, indicating poor permeability, but B is slightly better.
10. **Solubility:** Ligand A (-3.148) has a worse solubility than Ligand B (-2.183). Both are negative, indicating poor solubility, but B is slightly better.
11. **hERG:** Ligand A (0.753) has a slightly higher hERG inhibition liability than Ligand B (0.646). Lower is better, so B is preferred.
12. **Cl_mic:** Ligand B (2.83) has a much lower microsomal clearance than Ligand A (59.324), indicating better metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand B (7.844) has a longer in vitro half-life than Ligand A (51.474). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.491) has a lower P-gp efflux liability than Ligand B (0.357). Lower is better, so A is preferred.
15. **Affinity:** Ligand B (-10.0) has a significantly stronger binding affinity than Ligand A (-5.5). This is a crucial advantage, outweighing many of the other differences.
**Overall Assessment:**
Ligand B is the stronger candidate. While Ligand A has slightly better BBB penetration and P-gp efflux, Ligand B excels in critical areas: significantly lower DILI risk, much better metabolic stability (lower Cl_mic, longer t1/2), better solubility and Caco-2 permeability, and *substantially* higher binding affinity. The superior affinity of Ligand B (-10.0 kcal/mol) is a decisive factor, as it can compensate for minor ADME deficiencies. Given that this is a GPCR target, the balance of properties in Ligand B is more favorable for development.
Output:
0
2025-04-17 21:13:16,937 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (347.459) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (53.09) is significantly better than Ligand B (29.54). Lower TPSA generally improves oral absorption, a key consideration for GPCRs.
3. **logP:** Ligand A (0.877) is within the optimal range (1-3), while Ligand B (4.912) is high. High logP can lead to solubility issues and off-target interactions.
4. **HBD:** Both have 0 HBD, which is acceptable.
5. **HBA:** Ligand A (4) is slightly higher than Ligand B (3), but both are within the acceptable range.
6. **QED:** Ligand A (0.711) is slightly better than Ligand B (0.624), indicating a more drug-like profile.
7. **DILI:** Ligand A (6.863) has a much lower DILI risk than Ligand B (33.307). This is a critical advantage.
8. **BBB:** Both have good BBB penetration (Ligand A: 74.874, Ligand B: 71.229), which isn't a primary concern for ADRB2 (a cardiovascular target), but isn't detrimental.
9. **Caco-2:** Ligand A (-4.607) and Ligand B (-4.965) are both very poor, indicating very low permeability.
10. **Solubility:** Ligand A (-0.995) is better than Ligand B (-5.259), although both are poor.
11. **hERG:** Ligand A (0.333) has a lower hERG risk than Ligand B (0.834).
12. **Cl_mic:** Ligand A (8.702) has significantly lower microsomal clearance than Ligand B (145.814), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-19.555) has a much longer in vitro half-life than Ligand B (3.379).
14. **Pgp:** Ligand A (0.041) has much lower P-gp efflux than Ligand B (0.839).
15. **Affinity:** Both ligands have very similar binding affinities (-7.0 kcal/mol and -6.9 kcal/mol, respectively). The difference is negligible.
**GPCR-Specific Considerations:**
For GPCRs, logP, TPSA, Pgp, and affinity are important. Ligand A excels in logP, TPSA, and Pgp, while the affinities are comparable.
**Overall Assessment:**
Ligand A is significantly better overall. It has a lower DILI risk, better solubility, lower hERG risk, much better metabolic stability (lower Cl_mic and longer t1/2), and lower P-gp efflux. While both have poor Caco-2 permeability, the other advantages of Ligand A outweigh this drawback. The similar binding affinities make the ADME properties the deciding factor.
**Output:**
1
2025-04-17 21:13:16,937 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (378.925 Da) is slightly higher than Ligand B (348.447 Da), but both are acceptable.
2. **TPSA:** Ligand A (40.62) is significantly better than Ligand B (103.09). ADRB2 is not a CNS target, but lower TPSA generally improves absorption. Ligand B's TPSA is quite high, potentially hindering oral bioavailability.
3. **logP:** Ligand A (3.511) is optimal, while Ligand B (1.118) is on the lower side. A logP between 1-3 is preferred, and Ligand A is closer to this ideal.
4. **HBD:** Ligand A (0) is better than Ligand B (4). Fewer HBDs generally improve permeability.
5. **HBA:** Both ligands have 3 HBA, which is acceptable.
6. **QED:** Ligand A (0.804) is significantly better than Ligand B (0.538), indicating a more drug-like profile.
7. **DILI:** Both ligands have low DILI risk (Ligand A: 37.301, Ligand B: 33.307), both below the 40 threshold.
8. **BBB:** This is less critical for ADRB2, but Ligand A (88.135) is better than Ligand B (48.352).
9. **Caco-2:** Ligand A (-4.998) is better than Ligand B (-5.164), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-4.492) is better than Ligand B (-2.951), indicating better aqueous solubility.
11. **hERG:** Ligand A (0.659) is better than Ligand B (0.116), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand A (43.994) is higher than Ligand B (25.571), indicating lower metabolic stability. This is a negative for Ligand A.
13. **t1/2:** Ligand B (-9.226) is better than Ligand A (0.223), indicating a longer in vitro half-life. This is a positive for Ligand B.
14. **Pgp:** Ligand A (0.584) is better than Ligand B (0.022), indicating lower P-gp efflux.
15. **Binding Affinity:** Ligand B (-7.3) has a slightly better binding affinity than Ligand A (-6.8), a difference of 0.5 kcal/mol.
**Overall Assessment:**
While Ligand B has a slightly better binding affinity and in vitro half-life, Ligand A demonstrates a significantly superior profile across most critical ADME properties. Specifically, its lower TPSA, optimal logP, better QED, solubility, and lower hERG risk are highly favorable. The higher microsomal clearance of Ligand A is a concern, but the substantial advantages in other areas outweigh this drawback. Given the GPCR target class, the balance of properties in Ligand A is more promising for overall drug development success.
**Output:**
1
2025-04-17 21:13:16,937 - INFO - Batch 242 complete. Total preferences: 3872
2025-04-17 21:13:16,937 - INFO - Processing batch 243/512...
2025-04-17 21:14:09,287 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [357.426, 98.74, 0.261, 3, 4, 0.58, 18.302, 65.413, -5.24, -1.105, 0.058, -15.58, 0.574, 0.012, -6.6]
**Ligand B:** [366.502, 49.41, 2.863, 1, 3, 0.807, 18.069, 59.946, -4.813, -3.204, 0.596, 36.94, -1.822, 0.111, -6.2]
Here's a breakdown, considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal range (200-500 Da). A is 357.426, B is 366.502. No significant difference.
2. **TPSA:** A is 98.74, B is 49.41. B is significantly better, falling well below the 140 threshold for oral absorption and is more favorable for GPCRs.
3. **logP:** A is 0.261, B is 2.863. B is much better, falling within the optimal 1-3 range. A is quite low, potentially hindering membrane permeability.
4. **HBD:** A is 3, B is 1. B is better, minimizing potential issues with solubility and permeability.
5. **HBA:** A is 4, B is 3. B is slightly better.
6. **QED:** A is 0.58, B is 0.807. B is significantly better, indicating a more drug-like profile.
7. **DILI:** Both are around 18-19%, which is good (low risk). No significant difference.
8. **BBB:** A is 65.413, B is 59.946. While BBB isn't *critical* for a cardiovascular target, A is slightly better.
9. **Caco-2:** A is -5.24, B is -4.813. Both are negative, indicating poor permeability. B is slightly better.
10. **Solubility:** A is -1.105, B is -3.204. A is better, having a less negative solubility score.
11. **hERG:** A is 0.058, B is 0.596. A is significantly better, indicating lower cardiotoxicity risk.
12. **Cl_mic:** A is -15.58, B is 36.94. A is *much* better, indicating significantly higher metabolic stability.
13. **t1/2:** A is 0.574, B is -1.822. A is better, suggesting a longer in vitro half-life.
14. **Pgp:** A is 0.012, B is 0.111. A is significantly better, indicating lower P-gp efflux.
15. **Affinity:** A is -6.6 kcal/mol, B is -6.2 kcal/mol. A has a slightly better binding affinity.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity and hERG profile, Ligand B overwhelmingly wins on ADME properties crucial for a successful GPCR drug. Specifically, its significantly improved TPSA, logP, QED, and metabolic stability (Cl_mic, t1/2) are major advantages. The lower Pgp efflux is also beneficial. The solubility is worse for B, but the other improvements outweigh this. The slightly lower BBB penetration isn't a major concern for a cardiovascular target.
Therefore, I would choose Ligand B.
0
2025-04-17 21:14:09,288 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.5 & 402.9) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands have a TPSA of 69.64, which is well below the 140 A^2 threshold for good oral absorption, and appropriate for a non-CNS GPCR target like ADRB2.
3. **logP:** Both ligands have logP values around 2.3-2.5, which is optimal for permeability and solubility.
4. **HBD:** Both have 2 H-bond donors, which is within the acceptable limit of <=5.
5. **HBA:** Ligand A has 3 HBA, while Ligand B has 5. Both are under the 10 threshold, but A is slightly better.
6. **QED:** Both ligands have good QED scores (0.661 and 0.792), indicating good drug-like properties.
7. **DILI:** Ligand A (9.3) has a significantly lower DILI risk than Ligand B (31.6). This is a major advantage for Ligand A.
8. **BBB:** BBB is less critical for ADRB2 (a cardiovascular target). Ligand A (72.78) is slightly better than Ligand B (66.615), but the difference isn't substantial.
9. **Caco-2:** Ligand A (-4.726) has a worse Caco-2 permeability than Ligand B (-5.281). Lower values indicate lower permeability.
10. **Solubility:** Ligand A (-2.3) has better solubility than Ligand B (-3.78).
11. **hERG:** Both ligands have low hERG inhibition risk (0.411 and 0.239).
12. **Cl_mic:** Ligand A (36.661) has a higher microsomal clearance than Ligand B (5.67), meaning it's metabolized faster. This is a disadvantage for Ligand A.
13. **t1/2:** Ligand A (-14.784) has a shorter in vitro half-life than Ligand B (-6.498). This is a disadvantage for Ligand A.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.07 and 0.175).
15. **Binding Affinity:** Ligand A (-6.8 kcal/mol) has a slightly better binding affinity than Ligand B (-6.1 kcal/mol). The difference is 0.7 kcal/mol, which is significant.
**Overall Assessment:**
Ligand A has a superior binding affinity and a much lower DILI risk, which are critical factors. It also has better solubility. However, it suffers from higher metabolic clearance and shorter half-life compared to Ligand B. Ligand B has better Caco-2 permeability and better metabolic stability.
Considering the ADRB2 target (cardiovascular GPCR), the lower DILI risk of Ligand A is a significant advantage. While metabolic stability is important, the slightly weaker binding of Ligand B and the higher DILI risk are more concerning. The affinity difference is enough to outweigh the metabolic concerns, especially given the potential for structural modifications to improve metabolic stability later in the optimization process.
Output:
1
2025-04-17 21:14:09,288 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (363.53 & 361.56 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (61.44) is higher than Ligand B (49.03). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B has a slight advantage.
3. **logP:** Ligand A (2.49) is within the optimal 1-3 range. Ligand B (4.11) is a bit high, potentially leading to solubility issues and off-target interactions. Ligand A is favored.
4. **HBD:** Ligand A (2) is reasonable. Ligand B (0) is also acceptable, but having some HBD can aid solubility. No strong preference.
5. **HBA:** Both ligands (4) are within the acceptable limit of 10. No significant difference.
6. **QED:** Ligand A (0.816) is better than Ligand B (0.589), indicating a more drug-like profile. This is a moderate advantage for Ligand A.
7. **DILI:** Ligand A (11.36) has a significantly lower DILI risk than Ligand B (15.86). This is a substantial advantage for Ligand A, as liver toxicity is a major concern.
8. **BBB:** Ligand B (85.27) has a much higher BBB penetration percentile than Ligand A (62.74). While ADRB2 isn't primarily a CNS target, some degree of BBB penetration can be beneficial for understanding off-target effects. However, for a cardiovascular target, this is a lower priority.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and indicates poor permeability. Ligand A (-5.65) is slightly better than Ligand B (-4.77), but both are concerning.
10. **Solubility:** Ligand A (-1.62) has better solubility than Ligand B (-4.70). This is important for bioavailability and formulation. Ligand A is favored.
11. **hERG:** Both ligands (0.51 & 0.86) have relatively low hERG inhibition liability, which is good. No strong preference.
12. **Cl_mic:** Ligand A (1.86) has significantly lower microsomal clearance than Ligand B (100.77). This suggests better metabolic stability for Ligand A, which is a crucial advantage.
13. **t1/2:** Ligand A (46.62) has a much longer in vitro half-life than Ligand B (28.66). This is a significant advantage, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.03) has significantly lower P-gp efflux liability than Ligand B (0.76). This is a positive for both oral bioavailability and potentially CNS exposure (though less critical here).
15. **Binding Affinity:** Both ligands have comparable binding affinities (-6.0 and -5.8 kcal/mol). The difference of 0.2 kcal/mol is not substantial enough to outweigh other factors.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B in key ADME properties (DILI, Cl_mic, t1/2, Pgp, Solubility) and has a better QED score. While Ligand B has better BBB penetration, this is a lower priority for a cardiovascular target. The slightly higher logP of Ligand B is a concern, and the poor Caco-2 values for both are problematic but less critical given the target. The superior metabolic stability and lower toxicity risk of Ligand A make it the more promising candidate.
Output:
1
2025-04-17 21:14:09,288 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's systematically compare Ligand A and Ligand B based on the provided parameters and the GPCR-specific priorities (logP, Pgp, TPSA, and affinity being most important).
1. **Molecular Weight:** Both ligands (356.491 and 361.511 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands have TPSA values (58.2 and 57.84) below the 140 threshold for good oral absorption. They are also reasonably low, suggesting decent permeability. No clear winner.
3. **logP:** Both ligands have logP values (2.923 and 3.322) within the optimal 1-3 range. Ligand B is slightly higher, potentially offering better membrane permeability, but not dramatically so.
4. **H-Bond Donors/Acceptors:** Ligand A (2 HBD, 3 HBA) and Ligand B (1 HBD, 5 HBA) both fall within acceptable limits (<=5 HBD and <=10 HBA).
5. **QED:** Both ligands have good QED scores (0.77 and 0.889), indicating good drug-like properties. Ligand B is slightly better.
6. **DILI:** Ligand B (29.159) has a significantly lower DILI risk than Ligand A (32.183). This is a substantial advantage for Ligand B.
7. **BBB:** Ligand B (76.464) shows better BBB penetration potential than Ligand A (67.623). While ADRB2 isn't exclusively a CNS target, some CNS exposure/off-target effects are possible and minimizing this is generally preferred.
8. **Caco-2 Permeability:** Ligand A (-5.162) has slightly better Caco-2 permeability than Ligand B (-4.687).
9. **Aqueous Solubility:** Both ligands have poor aqueous solubility (-3.124 and -3.601). This is a concern for both, but could be addressed through formulation strategies.
10. **hERG Inhibition:** Ligand A (0.168) has a lower hERG inhibition liability than Ligand B (0.628). This is a significant advantage for Ligand A, as hERG inhibition can lead to cardiotoxicity.
11. **Microsomal Clearance:** Ligand A (43.881) has lower microsomal clearance than Ligand B (65.88), suggesting better metabolic stability.
12. **In vitro Half-Life:** Ligand B (-13.191) has a longer in vitro half-life than Ligand A (-10.427). This is a positive for Ligand B.
13. **P-gp Efflux:** Ligand A (0.252) has lower P-gp efflux liability than Ligand B (0.504). Lower P-gp efflux is generally desirable for improved bioavailability.
14. **Binding Affinity:** Ligand A (-8.7 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.0 kcal/mol). This is a >1.5 kcal/mol difference, which is a major advantage, potentially outweighing some of the ADME concerns.
**Overall Assessment:**
The key trade-offs are: Ligand A has superior binding affinity and better safety profiles (hERG, Pgp, Cl_mic), while Ligand B has a lower DILI risk, better BBB penetration, and a longer half-life. Given the importance of potency for GPCR targets, and the substantial difference in binding affinity (-8.7 vs -6.0 kcal/mol), I believe Ligand A is the more promising candidate. The hERG risk is also lower for Ligand A, which is critical for cardiovascular targets. While solubility is a concern for both, it's a more tractable issue than a significantly weaker binding affinity.
**Output:**
1
2025-04-17 21:14:09,288 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's analyze each ligand against the provided guidelines, keeping in mind ADRB2 is a GPCR and therefore logP, Pgp, TPSA, and affinity are key.
* **Molecular Weight:** Both ligands (346.475 and 349.431 Da) fall comfortably within the ideal 200-500 Da range.
* **TPSA:** Ligand A (65.63) is significantly better than Ligand B (87.74). A TPSA under 140 is good for oral absorption, and lower is generally preferred for GPCRs. Ligand B is approaching a less desirable range.
* **logP:** Ligand A (2.689) is optimal, while Ligand B (0.357) is quite low. This is a major concern for Ligand B, as it may struggle with membrane permeability.
* **H-Bond Donors/Acceptors:** Both have similar HBD (3 vs 2) and HBA (4 vs 4) counts, both within acceptable limits.
* **QED:** Both ligands have good QED scores (0.717 and 0.725), indicating good drug-like properties.
* **DILI:** Ligand A (35.324) has a slightly higher DILI risk than Ligand B (16.092), but both are below the concerning 60 threshold.
* **BBB:** Ligand A (70.143) has better BBB penetration than Ligand B (60.721). While ADRB2 isn't necessarily a CNS target, some peripheral distribution is still desired.
* **Caco-2:** Both have negative Caco-2 values, indicating poor permeability.
* **Aqueous Solubility:** Both have negative solubility values, indicating poor solubility.
* **hERG:** Ligand A (0.768) has a slightly higher hERG risk than Ligand B (0.147), but both are relatively low.
* **Cl_mic:** Ligand A (0.379) has significantly better metabolic stability (lower clearance) than Ligand B (-22.078). This is a substantial advantage.
* **t1/2:** Ligand A (26.834) has a much longer half-life than Ligand B (-0.245). This is a major positive for Ligand A.
* **Pgp:** Ligand A (0.082) has lower P-gp efflux than Ligand B (0.012), which is favorable.
* **Binding Affinity:** Ligand A (-7.1 kcal/mol) has a slightly better binding affinity than Ligand B (-6.7 kcal/mol). While the difference isn't huge, it's enough to consider given the other factors.
**Overall Assessment:**
Ligand A is clearly the superior candidate. Its optimal logP, significantly better metabolic stability (Cl_mic and t1/2), and slightly better affinity outweigh the slightly higher DILI and hERG risk. Ligand B's very low logP is a major red flag, suggesting poor permeability and bioavailability. While Ligand B has a lower DILI risk, the overall ADME profile of Ligand A is far more promising for a viable drug candidate.
**Output:**
1
2025-04-17 21:14:09,289 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [371.781, 131.51 , -0.271, 3. , 8. , 0.582, 67.817, 27.724, -5.407, -2.164, 0.094, 12.748, 55.751, 0.051, -6.2 ]
**Ligand B:** [360.483, 83.98 , 2.35 , 2. , 5. , 0.757, 64.017, 42.226, -5.443, -2.515, 0.448, 38.918, 20.692, 0.072, -4.8 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (360.483) is slightly lower, which is generally favorable.
2. **TPSA:** Ligand A (131.51) is slightly above the preferred <140 for good absorption, but still acceptable. Ligand B (83.98) is excellent, well below 140 and suggesting good permeability.
3. **logP:** Ligand A (-0.271) is a bit low, potentially hindering membrane permeability. Ligand B (2.35) is within the optimal 1-3 range. This is a significant advantage for Ligand B.
4. **HBD:** Both are acceptable (Ligand A: 3, Ligand B: 2), below the threshold of 5.
5. **HBA:** Both are acceptable (Ligand A: 8, Ligand B: 5), below the threshold of 10.
6. **QED:** Both are good (Ligand A: 0.582, Ligand B: 0.757), indicating drug-like properties. Ligand B is better here.
7. **DILI:** Both are reasonably good (Ligand A: 67.817, Ligand B: 64.017), below the concerning 60 threshold.
8. **BBB:** Ligand A (27.724) is quite low, suggesting poor brain penetration. Ligand B (42.226) is better, but still not high. Since ADRB2 is a cardiovascular target, BBB isn't *critical*, but some penetration could be beneficial for off-target effects or peripheral activity.
9. **Caco-2:** Both are very poor (-5.407 and -5.443). This is a concern for oral absorption for both.
10. **Solubility:** Both are very poor (-2.164 and -2.515). This is a major concern for both compounds.
11. **hERG:** Both are very low (Ligand A: 0.094, Ligand B: 0.448), indicating low cardiotoxicity risk.
12. **Cl_mic:** Ligand A (12.748) has lower clearance than Ligand B (38.918), suggesting better metabolic stability.
13. **t1/2:** Ligand A (55.751) has a longer half-life than Ligand B (20.692), which is desirable.
14. **Pgp:** Both are very low (Ligand A: 0.051, Ligand B: 0.072), indicating minimal P-gp efflux.
15. **Affinity:** Ligand A (-6.2) has a slightly better binding affinity than Ligand B (-4.8). This is a 1.4 kcal/mol difference, which is significant.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand B has a much better logP and TPSA. Ligand A has a better affinity, but the difference isn't huge enough to overcome the ADME deficiencies. The poor solubility and Caco-2 values for both are concerning, but Ligand B's better logP and TPSA suggest it might be more amenable to formulation or further optimization to improve these properties.
**Conclusion:**
Considering the balance of properties, and prioritizing the GPCR-specific parameters, I believe **Ligand B** is the more promising candidate. The better logP and TPSA values are more likely to translate to better absorption and overall drug-like behavior, despite the lower affinity. The affinity difference, while notable, can potentially be addressed through further optimization.
Output:
0
2025-04-17 21:14:09,289 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [350.459, 78.87, 1.259, 2, 4, 0.646, 17.759, 46.491, -4.747, -1.825, 0.143, 30.568, 0.443, 0.024, -6.4]
**Ligand B:** [346.475, 78.09, 2.074, 2, 3, 0.707, 25.514, 46.724, -5.327, -2.118, 0.268, 7.353, -14.745, 0.06, -6.1]
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (350.459) is slightly higher than Ligand B (346.475), but the difference is negligible.
2. **TPSA:** Both are good, below the 140 A^2 threshold for oral absorption (A: 78.87, B: 78.09).
3. **logP:** Both are within the optimal range (1-3), but Ligand B (2.074) is slightly higher than Ligand A (1.259). For a GPCR, a slightly higher logP can be beneficial for membrane permeability.
4. **HBD:** Both have 2 HBD, which is acceptable.
5. **HBA:** Ligand A has 4 HBA, Ligand B has 3. Both are within the acceptable limit of 10.
6. **QED:** Both have reasonable QED values (A: 0.646, B: 0.707), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (17.759) has a higher DILI risk than Ligand B (25.514). This is a significant advantage for Ligand B.
8. **BBB:** Both have similar, relatively low BBB penetration (A: 46.491, B: 46.724). This isn't a primary concern for ADRB2, as it's not a CNS target, but higher is always preferable.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual. However, the magnitude is similar (A: -4.747, B: -5.327), suggesting similar absorption challenges.
10. **Solubility:** Both have negative solubility values, indicating poor aqueous solubility. Ligand B (-2.118) is slightly worse than Ligand A (-1.825).
11. **hERG:** Both have low hERG inhibition risk (A: 0.143, B: 0.268).
12. **Cl_mic:** Ligand B (7.353) has significantly lower microsomal clearance than Ligand A (30.568), indicating better metabolic stability. This is a major advantage.
13. **t1/2:** Ligand B (-14.745) has a much longer in vitro half-life than Ligand A (0.443), further supporting its better metabolic stability.
14. **Pgp:** Both have low P-gp efflux liability (A: 0.024, B: 0.06).
15. **Affinity:** Both have very similar binding affinities (A: -6.4, B: -6.1). The difference is less than 0.3 kcal/mol, which isn't enough to override other significant differences.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, metabolic stability (Cl_mic, t1/2), and minimizing off-target effects (DILI) are crucial. While BBB isn't critical here, it's still a plus.
**Conclusion:**
Ligand B is the better candidate. It has a lower DILI risk, significantly better metabolic stability (lower Cl_mic and longer t1/2), and a slightly more favorable logP, despite similar binding affinity. The solubility issues are present in both, but the metabolic advantages of Ligand B outweigh the slight solubility difference.
0
2025-04-17 21:14:09,289 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
The ADRB2 receptor is a GPCR, so the priorities are logP, TPSA, Pgp efflux, BBB penetration, and binding affinity. Let's compare the ligands:
1. **Molecular Weight:** Both ligands (366.85 and 351.40 Da) are within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (78.67) is significantly better than Ligand B (100.99). A TPSA under 140 is good for oral absorption, and lower is generally preferred for GPCRs.
3. **logP:** Ligand A (0.766) is slightly lower than ideal (1-3), but still acceptable. Ligand B (-0.717) is a bit low, potentially hindering membrane permeability.
4. **H-Bond Donors/Acceptors:** Ligand A (1 HBD, 5 HBA) is preferable to Ligand B (2 HBD, 6 HBA). Lower counts are generally better for permeability.
5. **QED:** Ligand A (0.853) has a much better QED score than Ligand B (0.6), indicating a more drug-like profile.
6. **DILI:** Ligand A (39.51) has a lower DILI risk than Ligand B (19.27), which is a significant advantage.
7. **BBB:** Ligand A (71.19) has a considerably higher BBB percentile than Ligand B (24.93). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant for off-target effects and a higher BBB score is generally favorable.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.862) is slightly better than Ligand B (-5.096).
9. **Solubility:** Both have negative solubility values, which is also unusual. Ligand A (-1.812) is slightly better than Ligand B (-0.453).
10. **hERG:** Both have very low hERG inhibition liability (0.272 and 0.108), which is excellent.
11. **Cl_mic:** Ligand A (19.758) has a higher microsomal clearance than Ligand B (0.117), indicating lower metabolic stability. This is a drawback for Ligand A.
12. **t1/2:** Ligand B (-5.548) has a much longer in vitro half-life than Ligand A (-2.78), which is a significant advantage.
13. **Pgp:** Both have very low Pgp efflux liability (0.148 and 0.016).
14. **Binding Affinity:** Ligand A (-6.8 kcal/mol) has a slightly better binding affinity than Ligand B (-4.9 kcal/mol). This difference of 1.9 kcal/mol is substantial and can outweigh some ADME concerns.
**Overall Assessment:**
Ligand A has a superior profile in terms of TPSA, QED, DILI risk, BBB penetration, and, crucially, binding affinity. While its metabolic stability (Cl_mic) is worse and half-life shorter than Ligand B, the significantly stronger binding affinity and better overall drug-like properties make it the more promising candidate. The lower logP of Ligand B is also a concern.
**Output:**
1
2025-04-17 21:14:09,289 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (443.285 Da) is slightly above the ideal range, but acceptable. Ligand B (348.487 Da) is well within the ideal range.
2. **TPSA:** Ligand A (75.27) is acceptable, though approaching the upper limit for good oral absorption. Ligand B (67.43) is excellent.
3. **logP:** Both ligands (A: 3.09, B: 2.537) are within the optimal 1-3 range.
4. **HBD:** Both ligands have 2 HBD, which is good.
5. **HBA:** Both ligands have 3 HBA, which is good.
6. **QED:** Both ligands have good QED scores (A: 0.735, B: 0.82), indicating drug-likeness.
7. **DILI:** Ligand A (43.66) has a moderate DILI risk, but is still acceptable. Ligand B (23.071) has a very low DILI risk, which is a significant advantage.
8. **BBB:** Ligand A (85.072) shows good BBB penetration, while Ligand B (52.036) is lower. Considering ADRB2 is a cardiovascular target, BBB penetration is not a primary concern, but it's a bonus if present.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Both ligands have negative solubility values, which is also unusual and suggests poor solubility. Again, the scale is not specified.
11. **hERG:** Ligand A (0.716) has a slightly higher hERG risk than Ligand B (0.193), which is a significant advantage for B.
12. **Cl_mic:** Ligand A (5.089) has a lower microsomal clearance, suggesting better metabolic stability than Ligand B (24.804). This is a positive for A.
13. **t1/2:** Ligand A (57.348) has a much longer in vitro half-life than Ligand B (-0.213). This is a major advantage for A.
14. **Pgp:** Ligand A (0.326) has lower P-gp efflux liability than Ligand B (0.091), which is a positive for A.
15. **Affinity:** Both ligands have the same binding affinity (-6.5 kcal/mol), so this parameter doesn't differentiate them.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Both ligands perform similarly on logP and affinity. Ligand B has a better TPSA and lower Pgp efflux. Ligand A has better metabolic stability (Cl_mic, t1/2) and lower Pgp efflux. The lower DILI risk of Ligand B is also a significant benefit.
**Overall Assessment:**
While Ligand A has advantages in metabolic stability and half-life, the lower DILI risk and better hERG profile of Ligand B are more crucial for a cardiovascular drug target. The slightly better TPSA and Pgp properties of Ligand B also contribute to its favorability. The negative values for Caco-2 and solubility are concerning for both, but the other advantages of Ligand B outweigh the benefits of Ligand A.
Output:
0
2025-04-17 21:14:09,289 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
The target is ADRB2, a GPCR. Therefore, I will prioritize logP, TPSA, Pgp efflux, BBB penetration, and binding affinity. Metabolic stability (Cl_mic, t1/2) and safety (DILI, hERG) are also important.
Let's compare the ligands property by property:
1. **MW:** Both ligands (355.425 and 349.391 Da) are within the ideal range (200-500 Da).
2. **TPSA:** Ligand A (39.72) is significantly better than Ligand B (122.14). A TPSA under 140 is good for oral absorption, but lower is preferred for GPCRs, and Ligand A is much closer to the ideal range for CNS penetration (under 90).
3. **logP:** Ligand A (4.597) is higher than Ligand B (0.72). While both are within acceptable ranges, Ligand A is pushing the upper limit, potentially causing solubility issues. Ligand B is quite low, which could hinder membrane permeability.
4. **HBD/HBA:** Ligand A (1 HBD, 4 HBA) is better than Ligand B (3 HBD, 6 HBA). Lower counts are generally preferable for permeability.
5. **QED:** Ligand A (0.776) is slightly better than Ligand B (0.613), indicating a more drug-like profile.
6. **DILI:** Ligand B (77.898) has a considerably lower DILI risk than Ligand A (46.685). This is a significant advantage for Ligand B.
7. **BBB:** Ligand A (88.29) has a much higher BBB penetration potential than Ligand B (41.218). This is a strong point in favor of Ligand A, though ADRB2 isn't necessarily a CNS target.
8. **Caco-2:** Ligand A (-4.785) has a worse Caco-2 permeability than Ligand B (-5.637), indicating lower intestinal absorption.
9. **Solubility:** Ligand B (-2.015) has better aqueous solubility than Ligand A (-4.799).
10. **hERG:** Ligand A (0.779) has a lower hERG risk than Ligand B (0.12).
11. **Cl_mic:** Ligand B (11.024) has significantly lower microsomal clearance than Ligand A (54.505), suggesting better metabolic stability.
12. **t1/2:** Ligand B (10.667) has a longer in vitro half-life than Ligand A (17.834).
13. **Pgp:** Ligand A (0.442) has lower P-gp efflux than Ligand B (0.027), which is favorable.
14. **Affinity:** Ligand B (-7.7 kcal/mol) has a substantially better binding affinity than Ligand A (-6.5 kcal/mol). This is a crucial advantage, as a 1.2 kcal/mol difference is significant.
**Overall Assessment:**
Ligand B has a superior binding affinity and better safety profile (lower DILI), metabolic stability (lower Cl_mic, longer t1/2), and solubility. While Ligand A has better BBB penetration and Pgp properties, the significantly stronger binding affinity of Ligand B outweighs these advantages, especially given that ADRB2 is not necessarily a CNS target. The lower TPSA of Ligand A is a plus, but the other ADME properties of Ligand B are more favorable.
**Output:**
0
2025-04-17 21:14:09,290 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands (350.394 and 366.487 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (67.67) is significantly better than Ligand B (95.74). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is pushing the upper limit for good oral absorption (<=140).
3. **logP:** Ligand B (1.486) is better than Ligand A (0.317). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but a slightly higher logP is generally preferred for membrane permeability. Ligand A is a bit low, potentially impacting absorption.
4. **HBD:** Ligand A (0) is better than Ligand B (2). Fewer hydrogen bond donors generally improve permeability.
5. **HBA:** Ligand A (5) is better than Ligand B (4). Similar to HBD, fewer HBA are generally preferred.
6. **QED:** Both ligands have good QED scores (0.734 and 0.826), indicating good drug-like properties.
7. **DILI:** Both ligands have low DILI risk (32.028 and 34.626), which is excellent.
8. **BBB:** Both ligands have high BBB penetration (84.684 and 80.264). While not critical for a cardiovascular target, it doesn't hurt.
9. **Caco-2:** Ligand A (-4.47) is better than Ligand B (-5.115). Higher (less negative) Caco-2 values indicate better absorption.
10. **Solubility:** Ligand A (-1.143) is better than Ligand B (-1.946). Better solubility is always a plus.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.263 and 0.22), which is excellent.
12. **Cl_mic:** Ligand B (-5.751) is significantly better than Ligand A (18.993). Lower microsomal clearance indicates greater metabolic stability, a major advantage.
13. **t1/2:** Ligand B (-0.565) is significantly better than Ligand A (-28.795). A longer in vitro half-life is desirable.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.03 and 0.021).
15. **Binding Affinity:** Ligand A (-7.6) is better than Ligand B (-5.5). This is a substantial difference in binding affinity (2.1 kcal/mol). This difference is significant enough to potentially overcome some ADME drawbacks.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, and affinity. Ligand A excels in TPSA and affinity, while Ligand B has a better logP and Cl_mic/t1/2. The substantial affinity advantage of Ligand A is a key factor. While Ligand B has better metabolic stability, the difference in affinity is likely to outweigh this.
**Conclusion:**
Despite Ligand B's better metabolic stability, the significantly stronger binding affinity of Ligand A (-7.6 kcal/mol vs -5.5 kcal/mol) and better TPSA make it the more promising drug candidate. The affinity difference is substantial enough to compensate for the slightly lower logP and higher clearance.
Output:
1
2025-04-17 21:14:09,290 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 drug candidates. ADRB2 is a GPCR, so we'll prioritize logP, Pgp, TPSA, and affinity, alongside general drug-like properties.
**Ligand A:**
* **MW:** 360.885 Da - Good, within the ideal range.
* **TPSA:** 50.36 - Good, below the 140 threshold, and reasonable for a non-CNS GPCR.
* **logP:** 4.655 - A bit high, potentially leading to solubility issues or off-target interactions.
* **HBD:** 2 - Acceptable.
* **HBA:** 3 - Acceptable.
* **QED:** 0.755 - Excellent, very drug-like.
* **DILI:** 61.031 - Moderate risk, slightly above the preferred <60.
* **BBB:** 61.458 - Not a priority for a cardiovascular target, but not terrible.
* **Caco-2:** -4.688 - Concerningly low, suggesting poor absorption.
* **Solubility:** -5.646 - Very poor solubility, a significant drawback.
* **hERG:** 0.833 - Low risk, good.
* **Cl_mic:** 80.004 - Moderate clearance, not ideal but not catastrophic.
* **t1/2:** 78.049 - Good in vitro half-life.
* **Pgp:** 0.636 - Moderate Pgp efflux, could limit bioavailability.
* **Affinity:** -4.8 kcal/mol - Good binding affinity.
**Ligand B:**
* **MW:** 341.419 Da - Good, within the ideal range.
* **TPSA:** 82.68 - Higher than ideal, but still potentially acceptable.
* **logP:** 2.047 - Excellent, within the optimal range.
* **HBD:** 1 - Acceptable.
* **HBA:** 8 - Acceptable.
* **QED:** 0.708 - Good, drug-like.
* **DILI:** 65.917 - Moderate risk, similar to Ligand A.
* **BBB:** 28.344 - Not a priority for a cardiovascular target.
* **Caco-2:** -5.273 - Concerningly low, similar to Ligand A.
* **Solubility:** -2.41 - Poor solubility, but better than Ligand A.
* **hERG:** 0.261 - Very low risk, excellent.
* **Cl_mic:** 29.072 - Low clearance, excellent metabolic stability.
* **t1/2:** -3.949 - Very short half-life, a significant drawback.
* **Pgp:** 0.069 - Very low Pgp efflux, excellent.
* **Affinity:** -6.6 kcal/mol - Significantly better binding affinity than Ligand A.
**Comparison and Decision:**
Both ligands have issues with Caco-2 permeability and solubility. However, Ligand B has a substantially better binding affinity (-6.6 vs -4.8 kcal/mol), significantly lower Pgp efflux, and better metabolic stability (lower Cl_mic). While its half-life is poor, the strong affinity and reduced efflux could compensate. Ligand A's high logP and worse solubility are more concerning. The affinity difference is large enough to outweigh the half-life concern, especially for initial optimization.
Therefore, I prefer Ligand B.
0
2025-04-17 21:14:09,290 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (347.809 Da and 347.463 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (55.63) is significantly better than Ligand B (80.12). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is pushing the upper limit for good oral absorption.
3. **logP:** Ligand A (3.878) is good, within the optimal 1-3 range. Ligand B (1.556) is on the lower side, potentially impacting membrane permeability.
4. **HBD:** Both ligands have 1 HBD, which is acceptable.
5. **HBA:** Both ligands have 5 HBA, which is acceptable.
6. **QED:** Ligand B (0.896) has a better QED score than Ligand A (0.569), indicating a more drug-like profile overall.
7. **DILI:** Ligand A (85.847) has a significantly higher DILI risk than Ligand B (36.952). This is a major concern for Ligand A.
8. **BBB:** Ligand A (62.311) has a better BBB penetration percentile than Ligand B (48.662). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be helpful for distribution.
9. **Caco-2:** Ligand A (-4.796) has a worse Caco-2 permeability than Ligand B (-5.081). Both are poor, but Ligand B is slightly better.
10. **Solubility:** Ligand A (-4.856) has worse solubility than Ligand B (-1.374). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.719) has a slightly better hERG profile than Ligand B (0.117). Lower hERG inhibition is preferred.
12. **Cl_mic:** Ligand B (19.903) has a lower microsomal clearance than Ligand A (29.461), suggesting better metabolic stability.
13. **t1/2:** Ligand B (17.272) has a longer in vitro half-life than Ligand A (43.414). This is a positive for Ligand B.
14. **Pgp:** Ligand A (0.485) has better Pgp efflux liability than Ligand B (0.079). Lower Pgp efflux is preferred.
15. **Binding Affinity:** Ligand A (-7.0) has a slightly better binding affinity than Ligand B (-6.2). This is a 0.8 kcal/mol difference, which is significant.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity and Pgp efflux, the significantly higher DILI risk, poorer solubility, and worse metabolic stability are major drawbacks. Ligand B, despite a slightly weaker binding affinity, presents a much more favorable ADME-Tox profile, with lower DILI, better solubility, and improved metabolic stability. The TPSA of Ligand B is higher, but still within an acceptable range. For a cardiovascular target like ADRB2, minimizing toxicity and ensuring reasonable pharmacokinetic properties are crucial.
**Output:**
0
2025-04-17 21:14:09,290 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (401.26 Da) is within the ideal range, while Ligand B (356.438 Da) is also acceptable. No clear advantage here.
2. **TPSA:** Ligand A (63.35) is good, under the 140 threshold. Ligand B (67.87) is also acceptable.
3. **logP:** Ligand A (4.571) is slightly high, potentially causing solubility issues or off-target effects. Ligand B (2.002) is optimal. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (2) is good. Ligand B (1) is also good.
5. **HBA:** Ligand A (3) is good. Ligand B (4) is also good.
6. **QED:** Ligand A (0.661) is good. Ligand B (0.56) is acceptable, but slightly lower.
7. **DILI:** Ligand A (94.223) has a very high DILI risk. Ligand B (40.52) has a low DILI risk. This is a *major* advantage for Ligand B.
8. **BBB:** Both ligands have high BBB penetration (Ligand A: 76.076, Ligand B: 91.663). Ligand B is better.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Both ligands have negative solubility values, which is also unusual and suggests poor solubility. This is a concern for both.
11. **hERG:** Ligand A (0.878) has a slightly higher hERG risk than Ligand B (0.465).
12. **Cl_mic:** Ligand A (46.302) has a higher clearance than Ligand B (19.881), indicating lower metabolic stability. This favors Ligand B.
13. **t1/2:** Ligand A (109.121) has a longer half-life than Ligand B (-8.738). This is a significant advantage for Ligand A, but the negative value for B is concerning.
14. **Pgp:** Ligand A (0.898) has a slightly higher Pgp efflux liability than Ligand B (0.267). This favors Ligand B.
15. **Affinity:** Ligand A (-5.8 kcal/mol) and Ligand B (-6.1 kcal/mol) are both good, but Ligand B is slightly better.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand B excels in logP and Pgp, and has slightly better affinity. The major deciding factor is the significantly lower DILI risk for Ligand B. While Ligand A has a better half-life, the high DILI risk is a critical concern. The negative Caco-2 and solubility values are problematic for both, but can potentially be addressed with formulation strategies.
**Conclusion:**
Considering the balance of properties and the GPCR-specific priorities, Ligand B is the more promising drug candidate due to its superior logP, lower DILI risk, better Pgp profile, and slightly better affinity.
Output:
0
2025-04-17 21:14:09,290 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, priorities are logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB.
Let's break down the comparison:
1. **MW:** Both ligands (350.415 and 353.507 Da) fall within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (77.1) is better than Ligand B (81.67). Both are reasonably good for oral absorption, but A is closer to the preferred <90 for GPCRs.
3. **logP:** Both ligands have good logP values (1.076 and 1.424), falling within the 1-3 range. Ligand B is slightly higher, which *could* be a minor drawback.
4. **HBD/HBA:** Ligand A has 1 HBD and 5 HBA, while Ligand B has 3 HBD and 4 HBA. Both are acceptable, but A is slightly more favorable.
5. **QED:** Ligand A (0.796) has a significantly better QED score than Ligand B (0.555), indicating a more drug-like profile.
6. **DILI:** Ligand A (50.911) has a slightly higher DILI risk than Ligand B (5.584), but both are within acceptable limits (<60).
7. **BBB:** Ligand A (76.076) has a much better BBB penetration score than Ligand B (31.989). While not a primary concern for a cardiovascular target, it's a positive attribute.
8. **Caco-2:** Ligand A (-4.607) has a better Caco-2 permeability than Ligand B (-5.54), suggesting better absorption.
9. **Solubility:** Ligand A (-1.473) has slightly better solubility than Ligand B (-1.228).
10. **hERG:** Both ligands have very low hERG inhibition liability (0.151 and 0.469), which is excellent.
11. **Cl_mic:** Ligand B (-4.515) has a *much* lower (better) microsomal clearance than Ligand A (21.372), indicating greater metabolic stability. This is a significant advantage.
12. **t1/2:** Ligand B (26.479) has a longer in vitro half-life than Ligand A (4.403), further supporting its better metabolic stability.
13. **Pgp:** Ligand A (0.064) has a lower Pgp efflux liability than Ligand B (0.014), which is favorable.
14. **Binding Affinity:** Ligand B (-7.3 kcal/mol) has a slightly better binding affinity than Ligand A (-7.1 kcal/mol). This 0.2 kcal/mol difference is noticeable, but not overwhelming.
**Overall Assessment:**
Ligand B has a clear advantage in metabolic stability (Cl_mic and t1/2) and a slightly better binding affinity. These are crucial factors for *in vivo* efficacy. While Ligand A has better QED, TPSA, BBB, and Pgp, the metabolic stability of Ligand B is more critical, especially for a GPCR target where sustained signaling is often desired. The difference in binding affinity is not large enough to outweigh the significant metabolic advantage of Ligand B.
Output:
0
2025-04-17 21:14:09,290 - INFO - Here's my reasoning and final output for the ligand preference:
**Reasoning:**
We are targeting the ADRB2, a GPCR involved in cardiovascular function. Therefore, the priorities are logP, TPSA, Pgp, affinity, and to a lesser extent, BBB.
Let's compare Ligand A and Ligand B across the 15 parameters:
1. **MW:** Both ligands (361.427 and 352.475 Da) are within the ideal 200-500 Da range.
2. **TPSA:** Ligand B (84.5) is significantly better than Ligand A (118.28). Lower TPSA is preferred for better cell permeability, crucial for GPCR targeting.
3. **logP:** Ligand B (2.31) is within the optimal range (1-3), while Ligand A (0.823) is slightly below, potentially hindering permeability.
4. **HBD/HBA:** Both have 2 HBD and are similar in HBA (5 vs 4). Acceptable for both.
5. **QED:** Ligand A (0.836) has a much better QED score than Ligand B (0.467), indicating better overall drug-likeness.
6. **DILI:** Ligand B (30.981) has a significantly lower DILI risk than Ligand A (65.413). This is a major advantage for Ligand B.
7. **BBB:** Ligand B (64.831) shows better BBB penetration than Ligand A (53.509), but neither is exceptionally high. For a cardiovascular target, BBB isn't a primary concern, but it's a bonus.
8. **Caco-2:** Ligand A (-5.322) and Ligand B (-4.799) are both negative, which is unusual and suggests poor permeability. The values are very close, so this isn't a major differentiator.
9. **Solubility:** Ligand A (-2.088) is slightly better than Ligand B (-3.052), but both are poor.
10. **hERG:** Ligand A (0.033) has a much lower hERG risk than Ligand B (0.444). This is a significant advantage for Ligand A.
11. **Cl_mic:** Ligand A (-26.572) has a much lower (better) microsomal clearance than Ligand B (52.014), indicating greater metabolic stability.
12. **t1/2:** Ligand B (-7.331) has a slightly better in vitro half-life than Ligand A (6.636).
13. **Pgp:** Ligand A (0.016) has a much lower Pgp efflux liability than Ligand B (0.125). This is a significant advantage for Ligand A, improving bioavailability.
14. **Affinity:** Ligand A (-7.1 kcal/mol) has a slightly better binding affinity than Ligand B (-6.7 kcal/mol). While the difference is not huge, it's still a positive for Ligand A.
**Overall Assessment:**
Ligand A has a better binding affinity, QED, Pgp efflux, and microsomal clearance. It also has a significantly lower hERG risk. Ligand B excels in TPSA and DILI risk. Considering the GPCR target class, lower TPSA and DILI are important, but the better affinity, Pgp, and metabolic stability of Ligand A, coupled with a lower hERG risk, outweigh these advantages. The slightly lower logP of Ligand A is a minor concern, but not a deal-breaker.
**Output:**
1
2025-04-17 21:14:09,291 - INFO - Batch 243 complete. Total preferences: 3888
2025-04-17 21:14:09,291 - INFO - Processing batch 244/512...
2025-04-17 21:15:00,539 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [343.471, 45.55, 2.524, 0, 3, 0.847, 35.518, 69.988, -4.673, -2.854, 0.493, 69.738, 1.467, 0.582, -6.7]
**Ligand B:** [352.475, 78.87, 2.012, 2, 4, 0.717, 33.424, 65.839, -4.982, -3.48, 0.406, 11.886, -2.412, 0.251, -8.3]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal range (200-500 Da). A is 343.471, B is 352.475. A slight edge to A.
2. **TPSA:** A (45.55) is excellent, well below 140 and good for absorption. B (78.87) is higher, but still acceptable. A is better.
3. **logP:** Both are within the optimal 1-3 range. A (2.524) is slightly higher than B (2.012). A is slightly better.
4. **HBD:** A (0) is ideal. B (2) is acceptable, but more donors can sometimes lead to issues. A is better.
5. **HBA:** A (3) is good. B (4) is acceptable. A is slightly better.
6. **QED:** A (0.847) is very good, indicating high drug-likeness. B (0.717) is still reasonable, but lower. A is better.
7. **DILI:** Both are good, below 40. A (35.518) is slightly higher than B (33.424), but both are low risk. B is slightly better.
8. **BBB:** A (69.988) is good. B (65.839) is also reasonable, but A has a better percentile. A is better.
9. **Caco-2:** Both are negative, indicating good permeability. A (-4.673) is slightly better than B (-4.982). A is slightly better.
10. **Solubility:** Both are negative, indicating poor solubility. B (-3.48) is slightly better than A (-2.854). B is slightly better.
11. **hERG:** Both are low risk (0.493 and 0.406). B is slightly better.
12. **Cl_mic:** A (69.738) is better than B (11.886) - lower clearance is preferred for metabolic stability. A is significantly better.
13. **t1/2:** A (1.467) is poor, B (-2.412) is excellent. B is significantly better.
14. **Pgp:** Both are low efflux (0.582 and 0.251). B is better.
15. **Affinity:** B (-8.3) is *significantly* better than A (-6.7). This is a 1.6 kcal/mol difference, which is substantial and can outweigh many other drawbacks.
**Overall Assessment:**
Ligand B has a much stronger binding affinity, which is paramount for a GPCR target. While Ligand A has better QED, TPSA, and metabolic stability, the substantial affinity advantage of Ligand B is the deciding factor. The better half-life and Pgp properties of B also contribute to its favorability. The slightly higher TPSA of B is not a major concern.
Output:
0
2025-04-17 21:15:00,540 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Step-by-step comparison:**
1. **MW:** Ligand A (355.356 Da) is within the ideal range (200-500), while Ligand B (399.563 Da) is towards the upper end but still acceptable.
2. **TPSA:** Ligand A (46.61) is excellent, well below the 140 threshold and good for permeability. Ligand B (88.16) is higher, but still within a reasonable range for a non-CNS GPCR target.
3. **logP:** Both ligands (A: 2.838, B: 2.697) have optimal logP values between 1-3.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2) as fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (6) for similar reasons as HBD.
6. **QED:** Both ligands have good QED scores (A: 0.603, B: 0.782), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (32.493) has a significantly lower DILI risk than Ligand B (73.052). This is a major advantage for Ligand A.
8. **BBB:** This is less critical for ADRB2 (a cardiovascular target), but Ligand A (97.635) has a much higher BBB penetration than Ligand B (54.478).
9. **Caco-2:** Ligand A (-4) is better than Ligand B (-5.339) indicating better intestinal absorption.
10. **Solubility:** Ligand A (-2.961) is better than Ligand B (-3.296), although both are poor.
11. **hERG:** Both ligands have low hERG risk (A: 0.6, B: 0.231).
12. **Cl_mic:** Ligand A (81.838) has a higher microsomal clearance than Ligand B (7.459), suggesting lower metabolic stability. This is a significant drawback for Ligand A.
13. **t1/2:** Ligand B (29.556) has a much longer in vitro half-life than Ligand A (-15.742), indicating better stability.
14. **Pgp:** Both ligands have low P-gp efflux liability (A: 0.226, B: 0.209).
15. **Affinity:** Ligand B (-6.9 kcal/mol) has a slightly better binding affinity than Ligand A (-6.3 kcal/mol), but the difference is not huge.
**GPCR-specific priorities:** For ADRB2, logP, TPSA, Pgp, and affinity are important. Both ligands perform well on logP and Pgp. Ligand A has a better TPSA. Ligand B has a slightly better affinity. However, the significant advantages of Ligand A in terms of DILI risk and BBB penetration, coupled with better Caco-2 and solubility, outweigh the slightly lower affinity and higher Cl_mic. The longer half-life of Ligand B is a positive, but the DILI risk is concerning.
**Conclusion:**
Considering the balance of properties, and prioritizing safety (DILI) and permeability (TPSA, Caco-2, solubility) alongside reasonable affinity, Ligand A is the more promising drug candidate.
Output:
1
2025-04-17 21:15:00,540 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [452.227, 80.05, 3.322, 2, 5, 0.443, 80.651, 63.862, -5.32, -4.054, 0.819, 53.504, 72.197, 0.549, -6.2]
**Ligand B:** [352.479, 90.54, 0.422, 3, 4, 0.497, 24.622, 54.983, -5.255, -1.568, 0.224, 25.328, -0.992, 0.009, -6.9]
Here's a breakdown, prioritizing GPCR-relevant properties:
1. **Molecular Weight:** Ligand A (452.227 Da) is slightly higher than ideal, but acceptable. Ligand B (352.479 Da) is well within the preferred range.
2. **TPSA:** Ligand A (80.05) is borderline, but acceptable for a non-CNS GPCR. Ligand B (90.54) is a bit high, potentially impacting absorption.
3. **logP:** Ligand A (3.322) is optimal. Ligand B (0.422) is quite low, raising concerns about permeability.
4. **H-Bond Donors/Acceptors:** Both are reasonable (A: 2/5, B: 3/4), falling within acceptable limits.
5. **QED:** Both are similar and below optimal (A: 0.443, B: 0.497), indicating room for improvement in drug-likeness.
6. **DILI:** Ligand A (80.651) has a significantly higher DILI risk than Ligand B (24.622). This is a major concern.
7. **BBB:** Ligand A (63.862) has better BBB penetration than Ligand B (54.983), but this isn't a primary concern for a cardiovascular target.
8. **Caco-2:** Both are very poor (-5.32 and -5.255). This suggests significant absorption issues.
9. **Solubility:** Both are poor (-4.054 and -1.568).
10. **hERG:** Ligand A (0.819) has a slightly higher hERG risk than Ligand B (0.224), but both are relatively low.
11. **Cl_mic:** Ligand A (53.504) has higher metabolic clearance than Ligand B (25.328), suggesting lower metabolic stability.
12. **t1/2:** Ligand A (72.197) has a much longer half-life than Ligand B (-0.992). This is a significant advantage.
13. **Pgp:** Ligand A (0.549) has lower P-gp efflux than Ligand B (0.009), which is preferable.
14. **Binding Affinity:** Ligand B (-6.9 kcal/mol) has a slightly better binding affinity than Ligand A (-6.2 kcal/mol), but the difference is not huge.
**Overall Assessment:**
While Ligand B has a better binding affinity and significantly lower DILI risk, its very low logP is a major drawback. This will likely translate to poor permeability and bioavailability. Ligand A has a higher DILI risk, but its logP is optimal, and it has a significantly longer half-life and better P-gp properties. The longer half-life could potentially offset some of the DILI risk. The poor Caco-2 values for both ligands are concerning, but could be addressed with formulation strategies.
Considering the balance of properties, and prioritizing permeability for a GPCR target, I believe **Ligand A** is the more promising candidate, despite the higher DILI risk. The DILI risk could be investigated further with *in vitro* studies and potentially mitigated through structural modifications. The poor permeability of Ligand B is a more fundamental issue.
Output:
1
2025-04-17 21:15:00,540 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (345.487 and 357.487 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (44.81) is significantly better than Ligand B (90.55). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold, while B is approaching it.
3. **logP:** Ligand A (3.958) is slightly higher than Ligand B (2.682), both are within the optimal 1-3 range, but A is closer to the upper limit.
4. **HBD:** Ligand A (1) is preferable to Ligand B (4). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (3) is better than Ligand B (7). Fewer HBAs also contribute to better permeability.
6. **QED:** Ligand A (0.849) is significantly better than Ligand B (0.561), indicating a more drug-like profile.
7. **DILI:** Ligand A (28.189) has a much lower DILI risk than Ligand B (77.394). This is a crucial advantage.
8. **BBB:** Ligand A (84.684) has better BBB penetration than Ligand B (54.905). While not a primary concern for a cardiovascular target, it's a positive attribute.
9. **Caco-2:** Ligand A (-4.62) is better than Ligand B (-5.828). Higher Caco-2 permeability is desirable.
10. **Solubility:** Ligand A (-2.475) is better than Ligand B (-2.67). Higher solubility is generally preferred.
11. **hERG:** Both ligands (0.824 and 0.789) have similar, relatively low hERG inhibition liability.
12. **Cl_mic:** Ligand A (21.895) has a higher (worse) microsomal clearance than Ligand B (14.843). This suggests Ligand B is more metabolically stable.
13. **t1/2:** Ligand A (22.253) has a longer in vitro half-life than Ligand B (-2.661). This is a significant advantage.
14. **Pgp:** Ligand A (0.225) has lower P-gp efflux than Ligand B (0.049), indicating better bioavailability.
15. **Binding Affinity:** Both ligands have the same binding affinity (-6.5 kcal/mol). This removes affinity as a differentiating factor.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A excels in TPSA, Pgp, and has a favorable logP. While Ligand B has better metabolic stability (lower Cl_mic), the overall profile of Ligand A is superior due to its better drug-likeness (QED), lower DILI risk, better solubility, and longer half-life. The slightly higher Cl_mic of A is a manageable drawback.
**Conclusion:**
Ligand A is the more promising drug candidate due to its superior ADME properties and drug-likeness, despite slightly higher clearance.
Output:
1
2025-04-17 21:15:00,540 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's analyze each ligand against the provided guidelines, keeping in mind ADRB2 is a GPCR and thus we prioritize logP, Pgp, TPSA, and affinity, alongside general drug-like properties.
* **Molecular Weight:** Both ligands (348.443 and 340.423 Da) fall comfortably within the ideal 200-500 Da range.
* **TPSA:** Ligand A (80.57) is slightly higher than Ligand B (62.55). Both are below 140, suggesting reasonable oral absorption potential, but Ligand B is preferable here.
* **logP:** Ligand A (2.419) is within the optimal 1-3 range. Ligand B (3.965) is pushing the upper limit, potentially raising concerns about solubility and off-target effects, but still acceptable.
* **H-Bond Donors/Acceptors:** Ligand A has 2 HBD and 4 HBA, while Ligand B has 1 HBD and 3 HBA. Both are within acceptable limits.
* **QED:** Both ligands have good QED scores (0.756 and 0.857), indicating good overall drug-likeness. Ligand B is slightly better.
* **DILI:** Ligand A (28.383) has a significantly lower DILI risk than Ligand B (60.915). This is a major advantage for Ligand A.
* **BBB:** Ligand B (77.239) shows better BBB penetration than Ligand A (68.67). While ADRB2 isn't necessarily a CNS target, some peripheral ADRB2 activity can influence CNS pathways, so moderate BBB penetration isn't detrimental.
* **Caco-2 Permeability:** Both show negative values, indicating poor permeability. Ligand A (-4.535) is slightly better than Ligand B (-4.648).
* **Aqueous Solubility:** Both ligands have negative solubility values, indicating poor solubility. Ligand A (-2.89) is slightly better than Ligand B (-4.905).
* **hERG Inhibition:** Ligand A (0.362) has a lower hERG inhibition liability than Ligand B (0.645), which is a significant safety advantage.
* **Microsomal Clearance:** Ligand B (50.277) has lower microsomal clearance than Ligand A (63.516), suggesting better metabolic stability.
* **In vitro Half-Life:** Ligand B (68.208) has a substantially longer in vitro half-life than Ligand A (21.488), which is a major advantage.
* **P-gp Efflux:** Ligand A (0.256) has lower P-gp efflux than Ligand B (0.461), which is preferable for bioavailability.
* **Binding Affinity:** Ligand A (-7.3 kcal/mol) has a stronger binding affinity than Ligand B (-6.2 kcal/mol). This is a 1.1 kcal/mol difference, which is substantial and can outweigh some of the ADME drawbacks.
**Overall Assessment:**
Ligand A has a significantly better safety profile (lower DILI, lower hERG) and a stronger binding affinity. While Ligand B has better metabolic stability (lower Cl_mic, longer t1/2) and slightly better BBB penetration, the safety and potency advantages of Ligand A are more critical for initial drug candidate selection. The solubility and permeability are poor for both, but can be addressed with formulation strategies.
**Output:**
1
2025-04-17 21:15:00,541 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [349.479, 80.12, 2.051, 1, 5, 0.764, 35.324, 53.276, -4.99, -1.553, 0.072, 49.413, 5.457, 0.02, -6.3]
**Ligand B:** [362.499, 81.34, 2.155, 1, 6, 0.809, 59.752, 86.739, -5.159, -3.322, 0.571, 46.461, 2.559, 0.525, -6.6]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (349.479) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are good (below 140), suggesting reasonable oral absorption. Ligand A (80.12) is slightly better.
3. **logP:** Both are optimal (between 1-3). Ligand A (2.051) and B (2.155) are very similar.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 5 HBA, Ligand B has 6. Both are acceptable, but A is slightly better.
6. **QED:** Both are above 0.5, indicating good drug-likeness. Ligand B (0.809) is slightly better.
7. **DILI:** Ligand A (35.324) has a significantly lower DILI risk than Ligand B (59.752). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (86.739) has a much higher BBB penetration potential than Ligand A (53.276). While ADRB2 is primarily cardiovascular, some CNS off-target effects are possible, and higher BBB penetration could be a concern, but not a primary driver for this target.
9. **Caco-2:** Ligand B (-5.159) has a better Caco-2 permeability than Ligand A (-4.99).
10. **Solubility:** Ligand B (-3.322) has significantly better aqueous solubility than Ligand A (-1.553). This is a substantial advantage for Ligand B.
11. **hERG:** Ligand A (0.072) has a lower hERG inhibition liability than Ligand B (0.571). This is a significant safety advantage for Ligand A.
12. **Cl_mic:** Ligand B (46.461) has slightly lower microsomal clearance than Ligand A (49.413), suggesting better metabolic stability.
13. **t1/2:** Ligand A (5.457) has a longer in vitro half-life than Ligand B (2.559). This is a positive for Ligand A.
14. **Pgp:** Ligand B (0.525) has higher P-gp efflux liability than Ligand A (0.02). This is a significant advantage for Ligand A.
15. **Affinity:** Ligand B (-6.6 kcal/mol) has a slightly better binding affinity than Ligand A (-6.3 kcal/mol). This is a 1.5 kcal/mol advantage, which is a notable difference.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Both ligands are good on logP and TPSA. Ligand B has a slight edge in Caco-2 permeability. Ligand A is significantly better on Pgp efflux. Ligand B has a slightly better affinity. However, the safety profile of Ligand A is much better (lower DILI, lower hERG).
**Overall Assessment:**
While Ligand B has a slightly better affinity and solubility, the significantly lower DILI and hERG risk, combined with better Pgp properties and a longer half-life, make Ligand A the more promising candidate. The 0.3 kcal/mol difference in binding affinity can likely be optimized during lead optimization, whereas mitigating the higher DILI and hERG risk in Ligand B would be more challenging.
Output:
1
2025-04-17 21:15:00,541 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (351.535 Da and 349.387 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (52.65) is significantly better than Ligand B (88.18). For a GPCR, lower TPSA is generally preferred for better permeability. Ligand B is approaching a value that could hinder absorption.
**3. logP:** Ligand A (2.796) is within the optimal 1-3 range. Ligand B (-0.109) is quite low, potentially leading to poor membrane permeability and bioavailability. This is a significant drawback.
**4. H-Bond Donors:** Both have 1 HBD, which is acceptable.
**5. H-Bond Acceptors:** Ligand A has 3 HBAs, and Ligand B has 5. Both are within the acceptable limit of 10, but Ligand A is slightly better.
**6. QED:** Both ligands have good QED values (0.616 and 0.703), indicating good drug-like properties.
**7. DILI Risk:** Ligand B (42.536) has a lower DILI risk than Ligand A (6.049), which is a positive. However, both are below the concerning threshold of 60.
**8. BBB Penetration:** Ligand A (66.925) has better BBB penetration than Ligand B (47.111). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be beneficial for understanding off-target effects and distribution.
**9. Caco-2 Permeability:** Ligand A (-4.906) has slightly better Caco-2 permeability than Ligand B (-4.467).
**10. Aqueous Solubility:** Both have very poor solubility (-1.5 and -1.857). This is a concern for both, but might be manageable with formulation strategies.
**11. hERG Inhibition:** Ligand A (0.858) has a slightly lower hERG risk than Ligand B (0.085). Lower is better.
**12. Microsomal Clearance:** Ligand B (-23.537) has significantly lower microsomal clearance than Ligand A (16.278), indicating better metabolic stability. This is a strong advantage for Ligand B.
**13. In vitro Half-Life:** Ligand B (-25.726) has a much longer in vitro half-life than Ligand A (-9.829), further supporting its better metabolic stability.
**14. P-gp Efflux:** Ligand A (0.248) shows lower P-gp efflux than Ligand B (0.006), which is favorable for bioavailability.
**15. Binding Affinity:** Ligand B (-6.9 kcal/mol) has a slightly better binding affinity than Ligand A (-5.1 kcal/mol). This 1.8 kcal/mol difference is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
While Ligand B has superior metabolic stability (lower Cl_mic, longer t1/2) and binding affinity, its significantly lower logP is a major concern. Poor logP can lead to poor absorption and bioavailability. Ligand A has a more balanced profile, with acceptable logP, TPSA, and permeability, alongside reasonable metabolic stability and a good QED score. The slightly better affinity of Ligand B doesn't fully compensate for the logP issue.
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand A is the more promising candidate.
Output:
1
2025-04-17 21:15:00,541 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.431 and 348.447 Da) fall comfortably within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (99.69) is slightly higher than Ligand B (96.25). Both are below the 140 threshold for oral absorption, but closer to the upper end.
3. **logP:** Ligand A (2.334) is within the optimal 1-3 range. Ligand B (0.906) is a bit low, potentially hindering permeability. This is a point in favor of Ligand A.
4. **HBD:** Ligand A (4) and Ligand B (3) are both acceptable, below the 5 threshold.
5. **HBA:** Ligand A (4) and Ligand B (5) are both acceptable, below the 10 threshold.
6. **QED:** Both ligands have good QED scores (0.607 and 0.712), indicating good drug-like properties. Ligand B is slightly better here.
7. **DILI:** Ligand A (52.191) has a higher DILI risk than Ligand B (20.977). This is a significant advantage for Ligand B.
8. **BBB:** Both ligands have moderate BBB penetration (Ligand A: 39.822, Ligand B: 52.423). While ADRB2 isn't strictly a CNS target, some CNS exposure can be relevant for off-target effects. Ligand B is better here.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.04 and -5.001), which is unusual and indicates very poor permeability. This is a major concern for both.
10. **Solubility:** Ligand A (-2.845) has slightly worse solubility than Ligand B (-1.373).
11. **hERG:** Both ligands have low hERG inhibition risk (0.465 and 0.261). Ligand B is better here.
12. **Cl_mic:** Ligand A (-17.288) has significantly lower (better) microsomal clearance than Ligand B (7.321), suggesting greater metabolic stability. This is a strong advantage for Ligand A.
13. **t1/2:** Ligand A (59.148) has a much longer in vitro half-life than Ligand B (2.085). This is a major advantage for Ligand A.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.04 and 0.008). No significant difference.
15. **Binding Affinity:** Ligand B (-8.0) has a slightly better binding affinity than Ligand A (-7.6), a 0.4 kcal/mol difference. While a difference, it's not a huge margin.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand A has a better logP and significantly better metabolic stability (Cl_mic and t1/2). Ligand B has a slight edge in affinity and DILI risk, but the metabolic stability of Ligand A is a significant advantage. The poor Caco-2 values for both are concerning, but the longer half-life of Ligand A might compensate for reduced absorption.
**Overall Assessment:**
Despite the slightly better affinity of Ligand B, the superior metabolic stability (lower Cl_mic, longer t1/2) and better logP of Ligand A are more crucial for a successful drug candidate. The lower DILI risk of Ligand B is attractive, but can be addressed during further optimization. The poor Caco-2 values are a concern for both, but Ligand A's longer half-life could mitigate this issue.
Output:
1
2025-04-17 21:15:00,541 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.487 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (58.64) is slightly higher than Ligand B (49.85). Both are below the 140 threshold for good oral absorption, and acceptable for a cardiovascular GPCR. Ligand B is preferable.
3. **logP:** Both ligands (A: 2.37, B: 2.302) are within the optimal 1-3 range. No significant difference.
4. **HBD:** Ligand A (1) is slightly higher than Ligand B (0). Both are well within the acceptable limit of 5.
5. **HBA:** Both ligands (3) are within the acceptable limit of 10. No significant difference.
6. **QED:** Ligand B (0.633) has a slightly better QED score than Ligand A (0.514), indicating a more drug-like profile.
7. **DILI:** Ligand B (6.669) has a significantly lower DILI risk than Ligand A (10.585). This is a major advantage for Ligand B.
8. **BBB:** Ligand B (90.849) has a higher BBB penetration percentile than Ligand A (80.962). While ADRB2 is not a CNS target, higher BBB is generally favorable, indicating less promiscuous permeability.
9. **Caco-2:** Ligand A (-4.697) and Ligand B (-4.325) both have negative values, which is unusual and suggests poor permeability. However, the scale isn't specified, so it's hard to interpret.
10. **Solubility:** Ligand A (-2.579) and Ligand B (-2.253) both have negative solubility values, again making interpretation difficult without knowing the scale.
11. **hERG:** Both ligands (A: 0.488, B: 0.51) have similar, low hERG inhibition liability, which is good.
12. **Cl_mic:** Ligand B (52.924) has a lower microsomal clearance than Ligand A (57.645), suggesting better metabolic stability.
13. **t1/2:** Ligand B (7.579) has a longer in vitro half-life than Ligand A (-8.882). This is a significant advantage, potentially leading to less frequent dosing.
14. **Pgp:** Both ligands (A: 0.057, B: 0.059) have very low P-gp efflux liability, which is favorable.
15. **Binding Affinity:** Ligand A (-6.3 kcal/mol) has a slightly better binding affinity than Ligand B (-5.1 kcal/mol). This is a 1.2 kcal/mol difference, which is substantial.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity, Ligand B demonstrates a superior ADME-Tox profile. Specifically, the significantly lower DILI risk, better QED, improved metabolic stability (lower Cl_mic), and longer half-life are compelling advantages. For a cardiovascular target like ADRB2, metabolic stability and safety (DILI) are crucial. The difference in binding affinity, while noticeable, can potentially be optimized in later stages of drug development. Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity), Ligand B strikes a better balance.
Output:
0
2025-04-17 21:15:00,541 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Step-by-step comparison:**
1. **MW:** Both ligands (349.479 Da and 365.821 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (61.68) is significantly better than Ligand B (84.47). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand A is well below the 140 threshold, while B is approaching it.
3. **logP:** Ligand B (1.46) is better than Ligand A (0.61). Both are within the optimal 1-3 range, but B is closer to the middle. A's logP is quite low, potentially hindering membrane permeability.
4. **HBD:** Both ligands have 0 HBD, which is acceptable.
5. **HBA:** Ligand A (5) is better than Ligand B (6). Both are within the acceptable range of <=10.
6. **QED:** Ligand B (0.8) is better than Ligand A (0.724). Both are above the 0.5 threshold, indicating good drug-likeness, but B is higher.
7. **DILI:** Ligand A (16.44) is *much* better than Ligand B (67.429). This is a critical difference. A low DILI score is essential for drug development. B is in the high-risk category.
8. **BBB:** Ligand A (59.209) is better than Ligand B (55.176), although neither is particularly high. BBB isn't a top priority for ADRB2 (a cardiovascular target), but higher is still preferable.
9. **Caco-2:** Both ligands have similar, poor Caco-2 permeability (-4.994 and -4.88). This suggests potential absorption issues for both.
10. **Solubility:** Ligand A (0.257) is better than Ligand B (-1.969). Solubility is important for formulation and bioavailability.
11. **hERG:** Ligand A (0.239) is much better than Ligand B (0.087). Lower hERG inhibition is crucial to avoid cardiotoxicity, especially for a cardiovascular target.
12. **Cl_mic:** Ligand A (3.574) is significantly better than Ligand B (25.819). Lower clearance indicates better metabolic stability.
13. **t1/2:** Ligand B (17.097) is better than Ligand A (3.843). A longer half-life is generally desirable.
14. **Pgp:** Ligand A (0.018) is much better than Ligand B (0.079). Lower P-gp efflux is preferable for better bioavailability.
15. **Binding Affinity:** Ligand B (-6.8) is slightly better than Ligand A (-6.3). While a 1.5 kcal/mol difference is usually significant, the other ADME properties of Ligand A are far superior.
**Overall Assessment:**
Ligand A clearly outperforms Ligand B in almost all critical ADME properties. The significantly lower DILI, hERG inhibition, and microsomal clearance, combined with better TPSA, solubility, and Pgp efflux, make it a much more promising candidate despite the slightly weaker binding affinity. The cardiovascular context makes the lower hERG and DILI especially important. While Ligand B has a slightly better half-life and binding affinity, these are outweighed by the substantial risks associated with its ADME profile.
**Output:**
1
2025-04-17 21:15:00,542 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (346.431 Da and 354.451 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (69.89) is significantly better than Ligand B (113.76). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is pushing the upper limit for good oral absorption.
**3. logP:** Ligand A (0.761) is slightly higher than Ligand B (0.498), both are a bit low, but still acceptable. A logP between 1-3 is optimal, but these are not far off.
**4. H-Bond Donors:** Ligand A (0) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
**5. H-Bond Acceptors:** Ligand A (5) is preferable to Ligand B (4). Both are within the acceptable range.
**6. QED:** Ligand A (0.805) is better than Ligand B (0.551), indicating a more drug-like profile.
**7. DILI:** Ligand A (15.471) is significantly better than Ligand B (20.279), indicating a lower risk of drug-induced liver injury.
**8. BBB:** Ligand B (73.788) is better than Ligand A (65.529), but this is less critical for a cardiovascular target like ADRB2.
**9. Caco-2 Permeability:** Ligand A (-4.891) is better than Ligand B (-5.484), indicating better intestinal absorption.
**10. Aqueous Solubility:** Ligand A (-0.725) is better than Ligand B (-1.853), indicating better solubility.
**11. hERG Inhibition:** Ligand A (0.186) is significantly better than Ligand B (0.329), indicating a lower risk of cardiotoxicity. This is *very* important for a cardiovascular target.
**12. Microsomal Clearance:** Ligand B (-14.215) is much better than Ligand A (2.247), suggesting significantly improved metabolic stability. This is a strong point for Ligand B.
**13. In vitro Half-Life:** Ligand A (14.246) is better than Ligand B (2.826), indicating a longer half-life.
**14. P-gp Efflux:** Ligand A (0.044) is significantly better than Ligand B (0.006), indicating lower P-gp efflux.
**15. Binding Affinity:** Ligand A (-7.6) is better than Ligand B (-6.0), a substantial difference in potency.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand A is the stronger candidate. While Ligand B has better metabolic stability (Cl_mic), the superior affinity, lower TPSA, better solubility, lower DILI risk, and significantly lower hERG risk of Ligand A outweigh this benefit. The substantial difference in binding affinity (-7.6 vs -6.0 kcal/mol) is a major driver of this decision. The lower hERG risk is also crucial for a cardiovascular drug.
Output:
1
2025-04-17 21:15:00,542 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.443 and 345.378 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (57.78) is well below the 140 threshold, and even better, below 90, making it favorable for potential CNS penetration (though not a primary goal here). Ligand B (80.12) is still under 140, but less optimal.
3. **logP:** Ligand A (4.53) is slightly high, potentially leading to solubility issues or off-target interactions. Ligand B (1.358) is within the optimal 1-3 range. This favors Ligand B.
4. **HBD:** Both ligands have acceptable HBD counts (2 and 1 respectively), well below the 5 threshold.
5. **HBA:** Ligand A (3) and Ligand B (5) are both below the 10 threshold.
6. **QED:** Both ligands have good QED scores (0.57 and 0.857), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (80.923) has a higher DILI risk than Ligand B (57.193). This is a significant negative for Ligand A.
8. **BBB:** Ligand A (55.874) has moderate BBB penetration. Ligand B (78.79) has better BBB penetration, though ADRB2 isn't necessarily a CNS target.
9. **Caco-2:** Ligand A (-5.482) has poor Caco-2 permeability. Ligand B (-4.408) is also poor, but less so.
10. **Solubility:** Ligand A (-4.832) has poor aqueous solubility. Ligand B (-3.119) is better, but still not great.
11. **hERG:** Ligand A (0.866) has a slightly higher hERG risk than Ligand B (0.073). This is a significant advantage for Ligand B.
12. **Cl_mic:** Ligand A (57.857) has a higher microsomal clearance than Ligand B (40.34), indicating lower metabolic stability. This favors Ligand B.
13. **t1/2:** Ligand A (-15.672) has a negative in vitro half-life, which is very concerning. Ligand B (-11.026) is also negative, but less so.
14. **Pgp:** Ligand A (0.792) has higher P-gp efflux liability than Ligand B (0.021). This favors Ligand B.
15. **Binding Affinity:** Ligand B (-7.0) has significantly stronger binding affinity than Ligand A (-3.9). This is a crucial advantage for Ligand B.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are particularly important. Ligand B excels in these areas, having a more favorable logP, lower Pgp efflux, and significantly higher binding affinity. While BBB isn't critical for ADRB2 (a cardiovascular target), Ligand B's better BBB score is a bonus.
**Overall Assessment:**
Ligand A has several significant drawbacks: high DILI risk, poor solubility, poor Caco-2 permeability, high P-gp efflux, and, most critically, a much weaker binding affinity. Ligand B, while not perfect, presents a much more balanced profile with a stronger binding affinity, lower DILI risk, better metabolic stability, and lower P-gp efflux.
Output:
0
2025-04-17 21:15:00,542 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 GPCR, followed by the final output.
**Ligand A: [381.841, 89.55, 1.541, 2, 6, 0.784, 88.329, 39.822, -5.006, -3.776, 0.163, 34.179, 9.108, 0.199, -6.7]**
**Ligand B: [346.471, 60.85, 1.816, 1, 3, 0.565, 6.01, 65.374, -4.398, -1.747, 0.205, 24.052, -4.71, 0.031, -5.5]**
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand B (346.471) is slightly lower, which could be beneficial for permeability, but both are acceptable.
2. **TPSA:** Ligand A (89.55) is better than Ligand B (60.85) as it is closer to the 90 A^2 threshold for GPCRs.
3. **logP:** Both ligands have good logP values (1.541 and 1.816, respectively) within the optimal range of 1-3. Ligand B is slightly higher, which could potentially lead to off-target effects, but the difference is small.
4. **H-Bond Donors:** Ligand A (2) and Ligand B (1) are both within the acceptable limit of 5. Ligand B is slightly better.
5. **H-Bond Acceptors:** Ligand A (6) and Ligand B (3) are both within the acceptable limit of 10. Ligand B is better.
6. **QED:** Ligand A (0.784) has a significantly better QED score than Ligand B (0.565), indicating a more drug-like profile.
7. **DILI:** Ligand A (88.329) has a concerningly high DILI risk, while Ligand B (6.01) is excellent. This is a major drawback for Ligand A.
8. **BBB:** Ligand B (65.374) has a better BBB penetration percentile than Ligand A (39.822), which is important for GPCR targets.
9. **Caco-2:** Ligand A (-5.006) and Ligand B (-4.398) are both negative, which is unusual. Lower values are generally worse.
10. **Aqueous Solubility:** Ligand A (-3.776) and Ligand B (-1.747) are both negative, indicating poor solubility. Ligand B is better.
11. **hERG:** Both ligands have low hERG inhibition risk (0.163 and 0.205, respectively).
12. **Microsomal Clearance:** Ligand B (24.052) has lower microsomal clearance than Ligand A (34.179), suggesting better metabolic stability.
13. **In vitro Half-Life:** Ligand A (9.108) has a better in vitro half-life than Ligand B (-4.71).
14. **P-gp Efflux:** Both ligands have low P-gp efflux liability (0.199 and 0.031, respectively). Ligand B is better.
15. **Binding Affinity:** Ligand A (-6.7) has a slightly better binding affinity than Ligand B (-5.5). However, the difference is not substantial enough to overcome the significant ADME/Tox liabilities of Ligand A.
**Overall Assessment:**
Ligand A has a slightly better binding affinity and in vitro half-life, but it is significantly hampered by its high DILI risk and lower BBB penetration. Ligand B, while having a slightly weaker binding affinity, presents a much more favorable ADME-Tox profile, particularly with its low DILI risk, better BBB penetration, and improved metabolic stability. For a GPCR target like ADRB2, a balanced profile is crucial, and Ligand B offers a significantly better balance.
Output:
0
2025-04-17 21:15:00,542 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [356.419, 96.38, -0.358, 1, 6, 0.546, 30.322, 37.96, -4.512, -1.087, 0.086, 24.893, -33.327, 0.029, -6.9]
**Ligand B:** [358.551, 29.27, 4.998, 0, 4, 0.664, 12.796, 87.088, -5.136, -4.628, 0.904, 72.377, 38.618, 0.739, -6.6]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, Affinity, and BBB):
1. **MW:** Both are within the ideal 200-500 Da range. A is 356.4, B is 358.6 - essentially a tie.
2. **TPSA:** Ligand A (96.38) is higher than Ligand B (29.27). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is generally preferred for permeability. B is significantly better here.
3. **logP:** Ligand A (-0.358) is quite low, potentially hindering membrane permeability. Ligand B (4.998) is high, potentially leading to solubility issues and off-target effects. This is a significant drawback for B.
4. **HBD/HBA:** A has 1 HBD and 6 HBA, B has 0 HBD and 4 HBA. Both are acceptable, but B is slightly more favorable.
5. **QED:** Both are good (A: 0.546, B: 0.664), indicating drug-like properties. B is slightly better.
6. **DILI:** Ligand A (30.322) has a slightly higher DILI risk than Ligand B (12.796), but both are below the concerning 60 percentile.
7. **BBB:** Ligand A (37.96) has a low BBB penetration, while Ligand B (87.088) is very high. For a cardiovascular target, BBB isn't paramount, but higher is generally preferable.
8. **Caco-2:** Both have negative values, which is unusual. Assuming these are log scale values, both are very poor.
9. **Solubility:** Ligand A (-1.087) has poor solubility, while Ligand B (-4.628) is even worse. This is a major concern for both.
10. **hERG:** Ligand A (0.086) has a very low hERG risk, which is excellent. Ligand B (0.904) is higher, posing a potential cardiotoxicity concern.
11. **Cl_mic:** Ligand A (24.893) has lower clearance, indicating better metabolic stability. Ligand B (72.377) has higher clearance.
12. **t1/2:** Ligand A (-33.327) has a very short half-life, while Ligand B (38.618) has a longer half-life.
13. **Pgp:** Ligand A (0.029) has very low P-gp efflux, which is favorable. Ligand B (0.739) has moderate P-gp efflux.
14. **Affinity:** Both have very good binding affinity (-6.9 and -6.6 kcal/mol). The difference (0.3 kcal/mol) is not substantial enough to outweigh other factors.
**Overall Assessment:**
Ligand B has a better TPSA, BBB, QED, and half-life, but suffers from a high logP, poor solubility, and higher hERG risk. Ligand A has a better logP, hERG, Pgp, and metabolic stability, but has a poor BBB, solubility, and half-life.
Given the cardiovascular target, the hERG risk is a significant concern. Ligand A's very low hERG risk is a major advantage. While its solubility and half-life are poor, these can be addressed with formulation strategies or further medicinal chemistry optimization. The high logP of Ligand B is a more difficult property to improve without significantly impacting affinity.
Therefore, I favor Ligand A.
Output:
1
2025-04-17 21:15:00,542 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (337.47 & 367.47 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (57.78) is significantly better than Ligand B (83.72). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is approaching a value that could hinder oral absorption.
**3. logP:** Ligand A (4.723) is higher than Ligand B (1.651). While both are within acceptable ranges (1-3 is optimal), Ligand A is pushing the upper limit. This *could* lead to solubility issues, but for a GPCR, a slightly higher logP can be acceptable if other properties are favorable.
**4. H-Bond Donors:** Ligand A (2) is reasonable. Ligand B (0) is also good.
**5. H-Bond Acceptors:** Ligand A (2) is good. Ligand B (5) is acceptable, but higher than ideal.
**6. QED:** Both ligands have similar and good QED values (0.775 & 0.808).
**7. DILI Risk:** Ligand B (36.099) has a much lower DILI risk than Ligand A (51.842). This is a significant advantage for Ligand B.
**8. BBB Penetration:** Both have good BBB penetration (77.162 & 84.141). Since ADRB2 is a cardiovascular target, BBB penetration isn't a primary concern, but it doesn't hurt. Ligand B is slightly better.
**9. Caco-2 Permeability:** Both have negative Caco-2 values (-4.881 & -4.754). This is unusual and suggests poor permeability. However, these values are close and may not be a deciding factor.
**10. Aqueous Solubility:** Ligand A (-5.625) is worse than Ligand B (-2.462). Solubility is a concern with Ligand A due to its higher logP.
**11. hERG Inhibition:** Ligand A (0.845) is slightly higher than Ligand B (0.536), indicating a slightly higher risk of hERG inhibition.
**12. Microsomal Clearance:** Ligand B (46.005) has lower microsomal clearance than Ligand A (67.181), meaning it's likely more metabolically stable.
**13. In vitro Half-Life:** Ligand B (-33.312) has a significantly longer half-life than Ligand A (-9.858). This is a major advantage for Ligand B.
**14. P-gp Efflux:** Ligand A (0.607) has lower P-gp efflux than Ligand B (0.102), which is favorable.
**15. Binding Affinity:** Ligand B (-6.8 kcal/mol) has a significantly stronger binding affinity than Ligand A (-3.6 kcal/mol). This is a substantial advantage that can outweigh some of the ADME drawbacks.
**Overall Assessment:**
While Ligand A has a slightly better P-gp profile, Ligand B is superior in almost every other critical aspect. Its significantly stronger binding affinity, lower DILI risk, better metabolic stability (lower Cl_mic, longer half-life), and better solubility outweigh the slightly higher TPSA and lower P-gp profile of Ligand A. The strong binding affinity is particularly important for a GPCR target.
Output:
0
2025-04-17 21:15:00,542 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's systematically compare Ligand A and Ligand B based on the provided parameters and the guidelines, keeping in mind ADRB2 is a GPCR.
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (333.391 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (55.32) is significantly better than Ligand B (82.53). A TPSA under 140 is good for oral absorption, and lower is better for GPCRs. Ligand B is pushing the upper limit.
3. **logP:** Ligand A (3.819) is good, while Ligand B (1.321) is on the lower side. For a GPCR, a logP between 1-3 is optimal, but slightly higher is acceptable. Ligand A is better here.
4. **H-Bond Donors:** Ligand A (0) is preferable to Ligand B (2). Fewer H-bond donors generally improve permeability.
5. **H-Bond Acceptors:** Both have 4 H-bond acceptors, which is within the acceptable range.
6. **QED:** Both ligands have similar QED values (0.712 and 0.761), indicating good drug-likeness.
7. **DILI:** Ligand A (88.096) has a higher DILI risk than Ligand B (35.595). This is a significant drawback for Ligand A.
8. **BBB:** Ligand A (74.176) has a better BBB penetration potential than Ligand B (64.87). While ADRB2 isn't necessarily a CNS target, some peripheral effects might benefit from some BBB penetration.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified.
10. **Solubility:** Ligand A (-4.822) has worse solubility than Ligand B (-1.917). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.593) has a slightly higher hERG risk than Ligand B (0.102). Lower is better here.
12. **Cl_mic:** Ligand B (3.694) has significantly better metabolic stability (lower clearance) than Ligand A (101.078). This is a major advantage for Ligand B.
13. **t1/2:** Ligand B (-14.921) has a much longer in vitro half-life than Ligand A (-9.222). This is also a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.508) has better Pgp efflux profile than Ligand B (0.034). Lower efflux is better.
15. **Binding Affinity:** Ligand B (-7.2 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.1 kcal/mol). This is a crucial factor, and the 2.1 kcal/mol difference is substantial.
**Overall Assessment:**
While Ligand A has some favorable properties (MW, TPSA, logP, BBB, Pgp), Ligand B clearly wins out due to its superior binding affinity, metabolic stability (Cl_mic, t1/2), lower DILI risk, and better solubility. The strong binding affinity of Ligand B can potentially offset some of its less ideal TPSA and logP values. The DILI risk associated with Ligand A is a serious concern.
**Output:**
0
2025-04-17 21:15:00,543 - INFO - Batch 244 complete. Total preferences: 3904
2025-04-17 21:15:00,543 - INFO - Processing batch 245/512...
2025-04-17 21:15:49,545 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands fall within the ideal 200-500 Da range (A: 393.412, B: 356.463). No significant difference here.
**2. TPSA:** Ligand A (74.91) is better than Ligand B (95.94). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
**3. logP:** Both ligands have good logP values (A: 1.513, B: 1.09), falling within the optimal 1-3 range.
**4. H-Bond Donors:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs generally improve membrane permeability.
**5. H-Bond Acceptors:** Ligand A (7) is slightly better than Ligand B (5), but both are acceptable.
**6. QED:** Ligand A (0.834) has a significantly better QED score than Ligand B (0.666), indicating a more drug-like profile.
**7. DILI Risk:** Ligand B (21.598) has a much lower DILI risk than Ligand A (78.015). This is a major advantage for Ligand B.
**8. BBB Penetration:** Ligand A (74.641) has better BBB penetration than Ligand B (40.171), but this is less critical for a cardiovascular target.
**9. Caco-2 Permeability:** Both ligands have similar, poor Caco-2 permeability (-4.899 and -4.699).
**10. Aqueous Solubility:** Both ligands have similar, poor aqueous solubility (-2.88 and -2.304).
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.251 and 0.196).
**12. Microsomal Clearance:** Ligand A (6.282) has significantly lower microsomal clearance than Ligand B (60.656), indicating better metabolic stability.
**13. In vitro Half-Life:** Ligand A (-13.721) has a much longer in vitro half-life than Ligand B (-19.393).
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.148 and 0.044).
**15. Binding Affinity:** Both ligands have identical binding affinity (-5.7 kcal/mol).
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), and the general guidelines, Ligand A is more promising. While Ligand B has a significantly lower DILI risk, Ligand A excels in QED, metabolic stability (lower Cl_mic), and in vitro half-life. The similar binding affinity makes these factors the deciding ones. The poor Caco-2 and solubility are concerns for both, but can be addressed with formulation strategies.
Output:
1
2025-04-17 21:15:49,545 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (339.443 & 332.367 Da) fall comfortably within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (77.04) is slightly higher than Ligand B (70.65). Both are below the 140 threshold for oral absorption, and acceptable for a cardiovascular target (not requiring significant CNS penetration).
3. **logP:** Both ligands have excellent logP values (2.65 & 2.583) falling within the optimal 1-3 range. No significant difference.
4. **HBD:** Ligand A has 1 HBD, while Ligand B has 0. Both are within the acceptable limit of <=5.
5. **HBA:** Ligand A has 5 HBA, and Ligand B has 7. Both are within the acceptable limit of <=10.
6. **QED:** Ligand A (0.671) has a slightly better QED score than Ligand B (0.562), indicating a more drug-like profile.
7. **DILI:** Ligand B (85.033) has a significantly higher DILI risk than Ligand A (50.291). This is a major concern, as we want to minimize liver toxicity.
8. **BBB:** Ligand A (73.556) has a much higher BBB penetration percentile than Ligand B (36.371). While ADRB2 is primarily a cardiovascular target, some CNS effects are possible with beta-blockers, and higher BBB penetration isn't necessarily a negative here, but it's not a strong priority.
9. **Caco-2:** Both ligands have similar, very negative Caco-2 values (-5.095 and -5.014). This suggests poor permeability, a potential issue.
10. **Solubility:** Ligand A (-2.24) has slightly better (less negative) solubility than Ligand B (-4.058).
11. **hERG:** Both ligands have very low hERG inhibition risk (0.394 & 0.304). This is excellent.
12. **Cl_mic:** Ligand A (22.695) has a significantly lower microsomal clearance than Ligand B (43.027), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-23.981) has a much longer in vitro half-life than Ligand B (-55.187). This is a significant advantage.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.257 & 0.294).
15. **Binding Affinity:** Ligand B (-0.5) has a significantly better binding affinity than Ligand A (-8.3). This is a substantial advantage, potentially outweighing some ADME concerns.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize affinity, logP, TPSA, Pgp, and metabolic stability. Ligand B excels in affinity, while Ligand A is better in metabolic stability (Cl_mic and t1/2) and has a lower DILI risk. The difference in affinity is large (7.8 kcal/mol), and this is a critical factor for GPCRs.
**Overall Assessment:**
While Ligand A has a better safety profile (lower DILI) and better metabolic stability, the significantly stronger binding affinity of Ligand B (-0.5 kcal/mol vs -8.3 kcal/mol) is a decisive factor for a GPCR target. The improved affinity is likely to translate to greater efficacy at lower doses, potentially mitigating some of the ADME concerns. The Caco-2 permeability is a concern for both, but can be addressed through formulation strategies.
Output:
0
2025-04-17 21:15:49,546 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (367.5 and 356.5 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (53.43) is significantly better than Ligand A (84.23). ADRB2 is not a CNS target, but lower TPSA generally improves absorption.
3. **logP:** Ligand B (3.733) is slightly higher than Ligand A (2.583). Both are within the optimal 1-3 range, but Ligand B is approaching the upper limit, which could raise solubility concerns.
4. **HBD:** Ligand B (1) has fewer HBD than Ligand A (2). Fewer is generally preferable for permeability.
5. **HBA:** Ligand B (4) has fewer HBA than Ligand A (5). Again, fewer is generally preferable.
6. **QED:** Both ligands have similar QED values (0.774 and 0.769), indicating good drug-likeness.
7. **DILI:** Both ligands have low DILI risk (35.3% and 37.0%), well below the 60% threshold.
8. **BBB:** Ligand B (70.0%) has a better BBB penetration score than Ligand A (60.8%). While ADRB2 isn't primarily a CNS target, some peripheral ADRB2 receptors can influence CNS function, and higher BBB penetration isn't necessarily detrimental.
9. **Caco-2:** Ligand B (-4.881) has a better Caco-2 permeability than Ligand A (-5.635).
10. **Solubility:** Ligand A (-2.476) has better aqueous solubility than Ligand B (-3.394). This is a potential drawback for Ligand B given its higher logP.
11. **hERG:** Ligand A (0.252) has a lower hERG inhibition liability than Ligand B (0.68). This is a significant advantage for Ligand A, as hERG inhibition can lead to cardiotoxicity.
12. **Cl_mic:** Ligand B (75.864) has a higher microsomal clearance than Ligand A (61.65). This suggests Ligand A is more metabolically stable.
13. **t1/2:** Ligand B (42.988) has a much longer in vitro half-life than Ligand A (-0.871). This is a substantial advantage for Ligand B.
14. **Pgp:** Ligand A (0.082) has lower P-gp efflux liability than Ligand B (0.719). Lower P-gp efflux is generally desirable.
15. **Affinity:** Ligand A (-6.1 kcal/mol) has a slightly better binding affinity than Ligand B (-5.5 kcal/mol). While the difference is less than 1.5 kcal/mol, it's still a positive point for Ligand A.
**Overall Assessment:**
Ligand B has advantages in Caco-2 permeability, BBB penetration, and *especially* in vitro half-life. However, it suffers from a higher logP, potentially lower solubility, higher hERG risk, and higher P-gp efflux. Ligand A has a slight edge in binding affinity, lower hERG, lower P-gp efflux, and better metabolic stability.
Given the cardiovascular target (ADRB2), minimizing hERG risk is paramount. The slightly better affinity of Ligand A, combined with its significantly lower hERG liability and better metabolic stability, outweigh the advantages of Ligand B's longer half-life and slightly better permeability. The solubility difference is also a concern for Ligand B.
Therefore, I favor Ligand A.
Output:
1
2025-04-17 21:15:49,546 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Step-by-step comparison:**
1. **MW:** Both ligands (350.375 and 360.439 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand B (88.33) is significantly better than Ligand A (122.13). ADRB2 is a GPCR, and lower TPSA generally favors better permeability.
3. **logP:** Ligand B (1.537) is within the optimal range (1-3), while Ligand A (-0.671) is slightly below, potentially hindering permeability.
4. **HBD:** Both have acceptable HBD counts (2 and 1 respectively), well below the threshold of 5.
5. **HBA:** Both have acceptable HBA counts (7 and 6 respectively), well below the threshold of 10.
6. **QED:** Both ligands have good QED scores (0.722 and 0.874), indicating good drug-like properties.
7. **DILI:** Ligand B (52.036) is slightly higher than Ligand A (45.25), but both are below the concerning threshold of 60.
8. **BBB:** Both ligands have good BBB penetration (70.027 and 72.896), which is good for a GPCR, but not critically important for ADRB2 as it's primarily cardiovascular.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual. Assuming these are logP-scaled values, lower is worse. Ligand A (-5.095) is worse than Ligand B (-5.723).
10. **Solubility:** Ligand A (-0.752) is better than Ligand B (-2.161). Solubility is important for bioavailability.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.235 and 0.129).
12. **Cl_mic:** Ligand A (-4.324) has a much lower (better) microsomal clearance than Ligand B (40.767). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (-12.858) has a negative in vitro half-life, which is impossible. Ligand B (18.179) has a reasonable half-life. This is a major red flag for Ligand A.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.004 and 0.044).
15. **Binding Affinity:** Ligand A (-7.7) has a slightly better binding affinity than Ligand B (-6.6). The difference is 1.1 kcal/mol, which is significant.
**GPCR-specific considerations:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand B excels in TPSA and has an acceptable logP. Ligand A has a better affinity, but its negative half-life is a critical flaw.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity, its negative in vitro half-life is a deal-breaker. This suggests rapid metabolism and a very short duration of action, making it unlikely to be a viable drug candidate. Ligand B, despite slightly lower affinity, has a much more favorable ADME profile, particularly the reasonable half-life and good TPSA. The better logP also contributes to better potential permeability.
Output:
0
2025-04-17 21:15:49,546 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [341.426, 38.33, 4.713, 1, 2, 0.826, 42.42, 78.17, -4.367, -5.681, 0.742, 63.566, 2.597, 0.211, -6.6]
**Ligand B:** [345.487, 43.86, 1.578, 0, 3, 0.777, 9.539, 75.727, -4.789, -1.688, 0.502, 11.055, 10.964, 0.043, -6.6]
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal 200-500 Da range. (A: 341.426, B: 345.487) - No clear advantage.
2. **TPSA:** Ligand A (38.33) is better than Ligand B (43.86), being closer to the <140 threshold for good absorption.
3. **logP:** Ligand A (4.713) is higher than ideal (1-3), but Ligand B (1.578) is *too* low, potentially hindering membrane permeability. This is a significant advantage for A.
4. **HBD:** Ligand A (1) is preferable to Ligand B (0) as a single HBD can contribute to solubility without drastically impacting permeability.
5. **HBA:** Ligand A (2) is preferable to Ligand B (3). Lower HBA is generally better for permeability.
6. **QED:** Both are reasonably good (A: 0.826, B: 0.777), indicating drug-like properties. A is slightly better.
7. **DILI:** Ligand A (42.42) is better than Ligand B (9.539), indicating lower liver injury risk.
8. **BBB:** Both have good BBB penetration (A: 78.17, B: 75.727), but A is slightly better. This is important for a GPCR target.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand B (-4.789) is slightly worse than A (-4.367).
10. **Solubility:** Ligand B (-1.688) is better than Ligand A (-5.681). Solubility is a concern for both, but less so for B.
11. **hERG:** Ligand A (0.742) is better than Ligand B (0.502), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand B (11.055) has significantly lower microsomal clearance than Ligand A (63.566), suggesting better metabolic stability. This is a strong advantage for B.
13. **t1/2:** Ligand B (10.964) has a much longer in vitro half-life than Ligand A (2.597), which is highly desirable. This is a major advantage for B.
14. **Pgp:** Ligand B (0.043) has significantly lower P-gp efflux than Ligand A (0.211), which is beneficial for bioavailability.
15. **Affinity:** Both ligands have the same binding affinity (-6.6 kcal/mol).
**GPCR-specific priorities:** For ADRB2 (a GPCR), we prioritize logP, Pgp, TPSA, and affinity. Ligand A has a better logP and TPSA, while Ligand B has better Pgp efflux, metabolic stability (Cl_mic), and half-life. The affinity is equal.
**Overall Assessment:**
While Ligand A has some advantages in terms of TPSA and logP, the significantly better metabolic stability (lower Cl_mic and longer t1/2) and lower P-gp efflux of Ligand B outweigh those benefits. The slightly better solubility of Ligand B is also a plus. The higher DILI risk for Ligand A is also a concern.
Therefore, I would favor Ligand B.
Output:
0
2025-04-17 21:15:49,546 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (344.415 Da) is well within the ideal range (200-500 Da). Ligand B (371.859 Da) is also acceptable. No clear advantage here.
2. **TPSA:** Ligand A (80.49) is good, under the 140 threshold for oral absorption. Ligand B (48.99) is excellent, suggesting good permeability. Ligand B has a slight edge.
3. **logP:** Ligand A (1.5) is optimal. Ligand B (4.182) is pushing the upper limit and could potentially cause solubility issues or off-target interactions. Ligand A is preferred.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 6 HBA, acceptable. Ligand B has 2 HBA, also acceptable.
6. **QED:** Both ligands have good QED scores (A: 0.767, B: 0.815), indicating drug-likeness. No significant difference.
7. **DILI:** Ligand A (46.646) has a slightly higher DILI risk than Ligand B (35.479), but both are below the concerning threshold of 60. Ligand B is slightly preferred.
8. **BBB:** Ligand A (74.874) is reasonable, but Ligand B (94.494) is excellent, suggesting better potential for CNS penetration if needed (though ADRB2 is primarily cardiovascular). Given it's a GPCR, BBB is a consideration. Ligand B is preferred.
9. **Caco-2:** Ligand A (-5.153) and Ligand B (-4.739) both have negative values, which is unusual for Caco-2 permeability. It's difficult to interpret without knowing the scale, but lower (more negative) values generally indicate poor permeability.
10. **Solubility:** Ligand A (-1.47) has very poor aqueous solubility. Ligand B (-4.636) is also poor, but slightly better. Ligand B is preferred.
11. **hERG:** Ligand A (0.217) has a very low hERG risk, which is excellent. Ligand B (0.826) is also low, but higher than A. Ligand A is strongly preferred.
12. **Cl_mic:** Ligand A (18.178) has lower microsomal clearance, suggesting better metabolic stability. Ligand B (58.469) has higher clearance. Ligand A is preferred.
13. **t1/2:** Ligand A (-1.36) has a negative in vitro half-life, which is concerning and likely an error or indicates very rapid metabolism. Ligand B (-10.996) is also negative and concerning, but less so. Ligand B is slightly preferred.
14. **Pgp:** Ligand A (0.074) has very low P-gp efflux, which is excellent. Ligand B (0.551) has moderate P-gp efflux. Ligand A is strongly preferred.
15. **Affinity:** Ligand B (-6.9 kcal/mol) has a slightly better binding affinity than Ligand A (-6.1 kcal/mol). This is a 0.8 kcal/mol difference, which is significant but not overwhelming.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity), Ligand A and B both have strengths and weaknesses. Ligand B excels in TPSA and BBB penetration, and has a slightly better affinity. However, Ligand A has a much better logP, significantly lower hERG risk, lower microsomal clearance (better metabolic stability), and lower P-gp efflux. The poor solubility and negative half-life for both are concerning, but the combination of favorable ADME properties in Ligand A, particularly the low hERG and P-gp efflux, outweigh the slight affinity advantage of Ligand B. The negative half-life values are red flags for both, but the other properties of A are more favorable.
Output:
1
2025-04-17 21:15:49,547 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (353.419 and 352.494 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (93.9) is slightly higher than Ligand B (49.41). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B has a significant advantage here.
3. **logP:** Ligand A (1.005) is within the optimal range (1-3), while Ligand B (3.616) is at the higher end. While still acceptable, higher logP can sometimes lead to off-target effects and solubility issues. Ligand A is slightly favored.
4. **HBD:** Both ligands have 1 HBD, which is good. No difference.
5. **HBA:** Ligand A has 6 HBA, while Ligand B has 2. Both are within the acceptable limit of 10, but Ligand B is better.
6. **QED:** Both ligands have good QED scores (0.666 and 0.761), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (25.165) has a lower DILI risk than Ligand B (29.43), which is preferable.
8. **BBB:** Ligand A (83.133) has a lower BBB penetration than Ligand B (96.045). For a cardiovascular target, BBB penetration is not a major concern, so Ligand B is slightly favored.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.786 and -4.458). This is unusual and suggests poor permeability. However, the values are similar.
10. **Solubility:** Ligand A (-1.262) has better aqueous solubility than Ligand B (-3.898). This is a significant advantage.
11. **hERG:** Ligand A (0.467) has a lower hERG inhibition liability than Ligand B (0.85). This is a crucial advantage, as hERG inhibition can lead to cardiotoxicity.
12. **Cl_mic:** Ligand A (1.425) has significantly lower microsomal clearance than Ligand B (56.426), indicating better metabolic stability. This is a major advantage.
13. **t1/2:** Ligand A (1.992) has a shorter in vitro half-life than Ligand B (-19.105). This is a disadvantage for Ligand A.
14. **Pgp:** Ligand A (0.082) has lower P-gp efflux liability than Ligand B (0.545). This is a slight advantage for Ligand A.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-5.1 and -4.4 kcal/mol). The difference of 0.7 kcal/mol is not substantial enough to outweigh other factors.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), and the general drug-like properties, Ligand A is the better candidate. While Ligand B has better BBB penetration and QED, Ligand A exhibits significantly better metabolic stability (lower Cl_mic), lower hERG inhibition risk, and better solubility. The slightly lower TPSA of Ligand B is offset by the more concerning properties of Ligand B. The affinity difference is minimal.
Output:
1
2025-04-17 21:15:49,547 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.406 and 357.435 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (80.32) is better than Ligand B (86.34). Both are below 140, good for oral absorption, but lower is generally preferred.
3. **logP:** Both ligands have good logP values (2.386 and 3.076), falling within the optimal 1-3 range. Ligand B is slightly higher, which *could* be a minor concern for solubility, but not a dealbreaker.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1), but both are within the acceptable limit of 5.
5. **HBA:** Ligand A (4) is lower than Ligand B (5), which is favorable.
6. **QED:** Both ligands have good QED scores (0.818 and 0.911), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (41.838) has a significantly lower DILI risk than Ligand B (74.176). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (83.288) has a much higher BBB penetration percentile than Ligand B (40.016). While ADRB2 isn't exclusively a CNS target, some peripheral effects are mediated by CNS influence, and better BBB penetration is generally a plus, reducing off-target effects.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-4.303) is slightly better than Ligand B (-4.919) but both are quite poor.
10. **Solubility:** Ligand A (-3.264) is better than Ligand B (-4.731).
11. **hERG:** Ligand A (0.174) has a much lower hERG inhibition liability than Ligand B (0.535). This is a critical safety parameter, and Ligand A is significantly better.
12. **Cl_mic:** Ligand A (47.906) has lower microsomal clearance than Ligand B (44.228), suggesting better metabolic stability.
13. **t1/2:** Ligand B (40.997) has a much longer in vitro half-life than Ligand A (-18.334). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.033) has a much lower P-gp efflux liability than Ligand B (0.315). This is favorable for bioavailability.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-7.7 and -7.0 kcal/mol). The difference of 0.7 kcal/mol is not substantial enough to outweigh other factors.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Both ligands perform reasonably well on logP and affinity. Ligand A is better on TPSA and Pgp. The significant advantages of Ligand A in DILI risk and hERG inhibition are crucial safety factors. While Ligand B has a better half-life, the safety profile of Ligand A is more compelling.
**Conclusion:**
Considering the balance of properties, especially the significantly improved safety profile (lower DILI and hERG) and better BBB penetration of Ligand A, it is the more promising drug candidate.
Output:
1
2025-04-17 21:15:49,547 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (342.399 Da and 346.387 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (85.25) is better than Ligand B (104.39). For a GPCR, keeping TPSA under 140 is good, and lower is generally preferred for better permeability.
**3. logP:** Ligand A (2.759) is within the optimal 1-3 range. Ligand B (-0.126) is significantly lower, which could hinder membrane permeability and absorption. This is a major drawback for Ligand B.
**4. H-Bond Donors:** Both ligands have 2 HBD, which is acceptable.
**5. H-Bond Acceptors:** Both ligands have 5 HBA, which is acceptable.
**6. QED:** Ligand A (0.818) has a much better QED score than Ligand B (0.368), indicating a more drug-like profile.
**7. DILI:** Ligand A (74.99) has a higher DILI risk than Ligand B (44.164), but both are reasonably low.
**8. BBB:** Ligand A (79.682) has a better BBB penetration percentile than Ligand B (23.071). While ADRB2 is a cardiovascular target and CNS penetration isn't *essential*, some level of BBB penetration can be beneficial for off-target effects assessment and potential broader therapeutic applications.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
**10. Aqueous Solubility:** Ligand A (-3.631) has slightly better solubility than Ligand B (-1.686).
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.113 and 0.14).
**12. Microsomal Clearance:** Ligand A (24.433) has a higher microsomal clearance than Ligand B (-6.742), meaning Ligand B is more metabolically stable. This is a positive for Ligand B.
**13. In vitro Half-Life:** Ligand A (29.15) has a longer half-life than Ligand B (-17.741).
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (0.119 and 0.033).
**15. Binding Affinity:** Ligand A (-7.5 kcal/mol) has a slightly better binding affinity than Ligand B (-5.3 kcal/mol). This difference of 2.2 kcal/mol is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand A is the stronger candidate. While Ligand B has better metabolic stability and a slightly lower DILI risk, Ligand A excels in crucial areas: logP, QED, BBB penetration, and, most importantly, binding affinity. The significantly better logP and QED of Ligand A suggest it will have better absorption and overall drug-like properties. The higher binding affinity is also a major advantage. The slightly higher DILI risk of Ligand A is manageable, given the other favorable properties.
Output:
1
2025-04-17 21:15:49,547 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (341.407 Da) is well within the ideal range (200-500 Da). Ligand B (364.515 Da) is also acceptable. No clear advantage here.
2. **TPSA:** Ligand A (55.84) is excellent, well below the 140 threshold and suggesting good absorption. Ligand B (76.02) is still reasonable, but less optimal.
3. **logP:** Ligand A (3.294) is within the optimal range (1-3). Ligand B (1.649) is on the lower side, potentially impacting permeability. Ligand A is preferred here.
4. **HBD:** Ligand A (0) is ideal. Ligand B (2) is acceptable but less desirable.
5. **HBA:** Ligand A (4) is good. Ligand B (5) is also acceptable.
6. **QED:** Both ligands (A: 0.783, B: 0.735) have good drug-likeness scores (>0.5).
7. **DILI:** Ligand A (67.003) has a moderate DILI risk, but still acceptable. Ligand B (43.234) has a lower, and therefore preferable, DILI risk.
8. **BBB:** Ligand A (86.157) has a good BBB penetration score. Ligand B (59.364) is lower, which is less favorable for a GPCR target.
9. **Caco-2:** Ligand A (-4.474) and Ligand B (-5.701) both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale isn't specified, so it's difficult to interpret.
10. **Solubility:** Ligand A (-4.363) and Ligand B (-2.246) both have negative solubility values, again making interpretation difficult without knowing the scale.
11. **hERG:** Ligand A (0.676) has a low hERG risk. Ligand B (0.11) has an even lower risk, which is highly desirable.
12. **Cl_mic:** Ligand A (93.23) has a high microsomal clearance, indicating faster metabolism and potentially lower bioavailability. Ligand B (29.691) has a significantly lower clearance, suggesting better metabolic stability. This is a major advantage for Ligand B.
13. **t1/2:** Ligand A (4.385) has a moderate in vitro half-life. Ligand B (2.828) has a shorter half-life, which is less desirable.
14. **Pgp:** Ligand A (0.468) has lower P-gp efflux liability, which is good. Ligand B (0.093) has even lower efflux, which is even better.
15. **Affinity:** Ligand B (-6.7 kcal/mol) has a slightly better binding affinity than Ligand A (-6.5 kcal/mol). While the difference is small, it's within the range where it can outweigh some ADME drawbacks.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are crucial. Ligand A has better logP and TPSA, while Ligand B has better Pgp efflux and a slightly better affinity. The metabolic stability (lower Cl_mic) of Ligand B is also a significant advantage.
**Overall Assessment:**
While Ligand A has some favorable properties (TPSA, logP), Ligand B demonstrates a better balance of key characteristics for a GPCR drug candidate. The improved metabolic stability (lower Cl_mic), lower Pgp efflux, slightly better affinity, and lower DILI risk outweigh the slightly less optimal logP and TPSA. The hERG risk is also lower for Ligand B.
Output:
0
2025-04-17 21:15:49,547 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (340.362 and 350.423 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (95.68) is better than Ligand B (124.16). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (3.737) is optimal, while Ligand B (-0.314) is significantly low, potentially hindering membrane permeability. This is a major drawback for Ligand B.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is better than Ligand B (7). Similar to HBD, fewer HBAs are generally preferred.
6. **QED:** Both ligands have good QED scores (0.521 and 0.669), indicating generally drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (64.172) has a higher DILI risk than Ligand B (55.176), but both are acceptable.
8. **BBB:** Ligand A (76.347) has better BBB penetration than Ligand B (57.968), but this is less critical for a cardiovascular target.
9. **Caco-2:** Ligand A (-4.603) is better than Ligand B (-5.831), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-4.17) is better than Ligand B (-1.84), indicating better aqueous solubility.
11. **hERG:** Ligand A (0.532) has a slightly higher hERG risk than Ligand B (0.1), which is preferable.
12. **Cl_mic:** Ligand A (26.428) has a higher clearance than Ligand B (4.136), suggesting lower metabolic stability. This is a negative for Ligand A.
13. **t1/2:** Ligand A (1.045) has a shorter half-life than Ligand B (-2.869), indicating faster metabolism. This is a negative for Ligand A.
14. **Pgp:** Ligand A (0.103) has lower P-gp efflux than Ligand B (0.006), which is preferable.
15. **Binding Affinity:** Ligand A (-7.6) has a slightly better binding affinity than Ligand B (-7.2), but the difference is relatively small.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A excels in logP, TPSA and Pgp, and has a slightly better affinity. Ligand B has a very poor logP value, which is a significant concern for oral bioavailability. While Ligand A has a higher Cl_mic and shorter t1/2, the better ADME profile overall, particularly the logP, makes it the more promising candidate.
**Conclusion:**
Ligand A is the more viable drug candidate.
```
1
```
2025-04-17 21:15:49,548 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (371.409 Da) is within the ideal range. Ligand B (343.387 Da) is also within range, slightly lower. Both are acceptable.
2. **TPSA:** Ligand A (73.34) is good, below the 140 threshold. Ligand B (99.83) is approaching the upper limit but still acceptable for a peripherally acting GPCR.
3. **logP:** Ligand A (3.637) is optimal. Ligand B (0.243) is significantly low, potentially causing permeability issues. This is a major concern.
4. **HBD:** Ligand A (1) is good. Ligand B (2) is also acceptable.
5. **HBA:** Ligand A (7) is good. Ligand B (6) is good.
6. **QED:** Both ligands have good QED scores (A: 0.508, B: 0.758), indicating drug-likeness. Ligand B is slightly better.
7. **DILI:** Ligand A (79.915) is moderately high, but not alarming. Ligand B (68.864) is better, indicating lower liver injury risk.
8. **BBB:** Ligand A (70.531) is acceptable, but not high. Ligand B (16.906) is very low, indicating poor brain penetration. This isn't a primary concern for ADRB2, as it's not a CNS target, but it's a negative.
9. **Caco-2:** Ligand A (-4.848) and Ligand B (-5.396) are both very poor. This is concerning for oral absorption for both.
10. **Solubility:** Ligand A (-4.832) and Ligand B (-2.197) are both very poor. This is a significant drawback for both.
11. **hERG:** Ligand A (0.519) is good, low risk. Ligand B (0.169) is excellent, very low risk.
12. **Cl_mic:** Ligand A (108.793) is relatively high, suggesting faster metabolism. Ligand B (0.774) is very low, indicating high metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand A (0.655) is very short. Ligand B (0.188) is extremely short. Both are poor.
14. **Pgp:** Ligand A (0.378) is good, indicating low efflux. Ligand B (0.019) is excellent, very low efflux.
15. **Affinity:** Ligand B (-7.1 kcal/mol) has a significantly better binding affinity than Ligand A (-5.7 kcal/mol). This is a 1.4 kcal/mol difference, which is substantial enough to potentially overcome some ADME liabilities.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand B excels in Pgp and affinity, and has a better hERG profile. Ligand A has a better logP, but the difference isn't enough to offset the significantly better binding affinity of Ligand B. The poor solubility and Caco-2 values are concerning for both, but the superior metabolic stability of Ligand B is a major advantage.
**Conclusion:**
Despite the poor solubility and Caco-2 values, Ligand B's significantly stronger binding affinity and improved metabolic stability (lower Cl_mic) make it the more promising candidate. The better hERG profile and Pgp efflux also contribute to its favorability.
Output:
0
2025-04-17 21:15:49,548 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (333.395 Da and 349.391 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (62.22) is well below the 140 threshold and excellent for oral absorption, and even better for GPCRs. Ligand B (125.21) is still within acceptable limits, but less optimal.
3. **logP:** Ligand A (2.514) is within the optimal 1-3 range. Ligand B (-0.431) is below 1, which could hinder permeation. This is a significant negative for Ligand B.
4. **HBD:** Ligand A (0) is ideal. Ligand B (4) is acceptable, but higher HBD can sometimes lead to issues.
5. **HBA:** Both ligands (A: 5, B: 5) are within the acceptable limit of 10.
6. **QED:** Ligand A (0.737) is excellent, indicating strong drug-like properties. Ligand B (0.497) is lower, suggesting a less favorable overall profile.
7. **DILI:** Ligand A (77.045) is moderately high, but still acceptable. Ligand B (66.615) is better, indicating lower liver injury risk.
8. **BBB:** Ligand A (84.529) shows good potential for BBB penetration, which is valuable for GPCR targets. Ligand B (46.685) is low, suggesting limited CNS exposure.
9. **Caco-2:** Both ligands show negative values, which is unusual. Assuming these are logP values, they indicate poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Both ligands have negative solubility values, which is also unusual. Again, the scale is not specified.
11. **hERG:** Both ligands (A: 0.73, B: 0.189) have low hERG inhibition liability, which is good.
12. **Cl_mic:** Ligand A (83.652) has a higher microsomal clearance, indicating faster metabolism. Ligand B (26.533) has much lower clearance, suggesting better metabolic stability.
13. **t1/2:** Ligand A (-9.475) has a negative half-life, which is not possible. This is a red flag. Ligand B (-26.047) also has a negative half-life, which is also a red flag.
14. **Pgp:** Both ligands (A: 0.334, B: 0.027) have low P-gp efflux liability, which is favorable.
15. **Affinity:** Both ligands have similar binding affinities (-6.7 kcal/mol and -6.6 kcal/mol). The difference is negligible.
**GPCR-specific considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are particularly important. Ligand A excels in logP and TPSA, and has comparable affinity to Ligand B. Ligand B has better metabolic stability (lower Cl_mic) and lower DILI risk. However, the negative half-life values for both are concerning and suggest issues with the data or the compounds themselves.
**Overall Assessment:**
Despite the better metabolic stability and lower DILI risk of Ligand B, the significantly lower logP and the questionable half-life values make it a less attractive candidate. Ligand A's superior TPSA and logP, combined with comparable affinity, make it the more promising starting point, *assuming the negative half-life can be resolved*.
Output:
1
2025-04-17 21:15:49,548 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (359.436 and 364.471 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (41.73) is significantly better than Ligand B (88.33). ADRB2 is a cardiovascular target, not CNS, but lower TPSA generally aids absorption. Ligand A is well below the 140 threshold. Ligand B is higher, potentially impacting absorption.
3. **logP:** Both ligands have acceptable logP values (2.874 and 1.03), falling within the 1-3 range. Ligand A is slightly better, being closer to the optimal range. Ligand B is at the lower end, which could slightly hinder permeability.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 6. Both are acceptable (<=10), but Ligand A is preferable.
6. **QED:** Ligand A (0.689) has a better QED score than Ligand B (0.574), indicating a more drug-like profile.
7. **DILI:** Ligand A (8.104%) has a significantly lower DILI risk than Ligand B (41.295%). This is a major advantage for Ligand A.
8. **BBB:** This is less critical for a cardiovascular target. Ligand A (87.864%) has a higher BBB penetration than Ligand B (68.282%), but this isn't a primary concern.
9. **Caco-2:** Ligand A (-4.508) and Ligand B (-5.192) both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale isn't defined, so it's hard to interpret.
10. **Solubility:** Ligand A (-1.535) has slightly better solubility than Ligand B (-2.428).
11. **hERG:** Ligand A (0.992%) has a much lower hERG inhibition liability than Ligand B (0.151%). This is a significant safety advantage for Ligand A.
12. **Cl_mic:** Ligand A (-5.326) has a significantly lower microsomal clearance than Ligand B (23.719), indicating better metabolic stability.
13. **t1/2:** Ligand A (-9.532) has a longer in vitro half-life than Ligand B (-4.686).
14. **Pgp:** Ligand A (0.313) has lower P-gp efflux liability than Ligand B (0.056).
15. **Affinity:** Both ligands have the same binding affinity (-7.0 kcal/mol), so this doesn't differentiate them.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Both ligands have good affinity. Ligand A is superior in terms of logP, TPSA, and Pgp.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most crucial ADME-Tox parameters (DILI, hERG, Cl_mic, t1/2, QED) and also has a slight edge in physicochemical properties (TPSA, logP, Solubility). While both have similar affinity, the improved safety and pharmacokinetic profile of Ligand A make it the more promising drug candidate.
Output:
1
2025-04-17 21:15:49,548 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (334.423 and 347.419 Da) fall comfortably within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (51.02) is significantly better than Ligand B (110.44). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is quite high, potentially hindering absorption.
3. **logP:** Ligand A (3.839) is within the optimal range (1-3), while Ligand B (0.596) is below 1, suggesting potential permeability issues. This is a significant advantage for Ligand A.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer HBDs generally improve membrane permeability.
5. **HBA:** Ligand A (5) is better than Ligand B (6), aligning with the preference for lower HBA counts.
6. **QED:** Both ligands have good QED scores (0.665 and 0.807), indicating generally drug-like properties. No strong differentiator.
7. **DILI:** Ligand A (69.872) has a higher DILI risk than Ligand B (35.479). This is a clear advantage for Ligand B.
8. **BBB:** Ligand A (75.107) and Ligand B (89.066) both have good BBB penetration, but Ligand B is better. This is relevant for a GPCR, though ADRB2 isn't necessarily a CNS target.
9. **Caco-2:** Ligand A (-4.672) and Ligand B (-5.26) both have negative values, which are not ideal. However, the values are similar.
10. **Solubility:** Ligand A (-4.423) is better than Ligand B (-2.253).
11. **hERG:** Ligand A (0.627) is better than Ligand B (0.359), indicating a lower risk of cardiotoxicity. This is crucial for a cardiovascular target.
12. **Cl_mic:** Ligand A (63.062) has a higher clearance than Ligand B (-11.268). Ligand B has a negative value, which is better.
13. **t1/2:** Ligand A (25.906) has a better half-life than Ligand B (-0.908).
14. **Pgp:** Ligand A (0.867) is better than Ligand B (0.005).
15. **Binding Affinity:** Ligand A (-7.4) has a better binding affinity than Ligand B (-6.4). This is a significant advantage, as a 1.0 kcal/mol difference can outweigh some ADME concerns.
**Overall Assessment:**
Ligand A has a superior profile overall. While Ligand B has a lower DILI risk, Ligand A excels in crucial areas for a GPCR like ADRB2: TPSA, logP, binding affinity, hERG, Pgp, and solubility. The stronger binding affinity of Ligand A is a particularly compelling factor. The slightly higher DILI risk of Ligand A is a concern, but can be investigated further during optimization.
Output:
1
2025-04-17 21:15:49,548 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands (365.539 and 374.472 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (49.77) is slightly higher than Ligand B (41.99), but both are well below the 140 threshold for good oral absorption. Ligand B is preferable here.
3. **logP:** Ligand A (3.751) is within the optimal 1-3 range, while Ligand B (4.766) is slightly above. Ligand A is preferable.
4. **HBD:** Both have 1 HBD, which is good. No difference.
5. **HBA:** Ligand A has 4 HBA, Ligand B has 3. Both are acceptable. No clear advantage.
6. **QED:** Both ligands have good QED scores (0.763 and 0.807), indicating good drug-like properties. No significant difference.
7. **DILI:** Ligand A (17.72) has a significantly lower DILI risk than Ligand B (48.546). This is a major advantage for Ligand A.
8. **BBB:** Both have high BBB penetration (80.651 and 89.725), which is good for a GPCR, but not necessarily critical for ADRB2 (cardiovascular target). Ligand B is slightly better.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Both have negative solubility values, indicating very poor aqueous solubility. This is a significant drawback for both.
11. **hERG:** Ligand A (0.751) has a slightly higher hERG risk than Ligand B (0.45). Ligand B is preferable.
12. **Cl_mic:** Ligand A (73.211) has a higher microsomal clearance than Ligand B (52.053), suggesting faster metabolism and potentially lower exposure. Ligand B is preferable.
13. **t1/2:** Ligand A (34.121) has a longer in vitro half-life than Ligand B (2.703). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.827) has slightly higher P-gp efflux than Ligand B (0.554). Ligand B is preferable.
15. **Binding Affinity:** Ligand B (-6.5 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.7 kcal/mol). This is a substantial advantage for Ligand B.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, Pgp, TPSA, and affinity. Ligand B is better on logP, Pgp, and affinity. Ligand A is better on TPSA.
**Overall Assessment:**
While Ligand B has a significantly better binding affinity (-6.5 vs -5.7 kcal/mol), the lower DILI risk and longer half-life of Ligand A are very important. The poor solubility and Caco-2 values are concerning for both, but can potentially be addressed with formulation strategies. The DILI risk is harder to mitigate. The affinity difference is substantial enough to outweigh the other advantages of Ligand A.
Output:
0
2025-04-17 21:15:49,549 - INFO - Batch 245 complete. Total preferences: 3920
2025-04-17 21:15:49,549 - INFO - Processing batch 246/512...
2025-04-17 21:16:36,163 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (368.459 Da) is within the ideal range (200-500 Da). Ligand B (433.368 Da) is also acceptable, but approaching the upper limit.
2. **TPSA:** Ligand A (113.44) is better than Ligand B (78.87), both are below the 140 threshold for oral absorption, and Ligand B is closer to the 90 threshold for CNS penetration.
3. **logP:** Ligand A (0.542) is low, potentially hindering permeation. Ligand B (2.574) is within the optimal range (1-3). This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (3) and Ligand B (2) are both acceptable.
5. **HBA:** Ligand A (7) and Ligand B (5) are both acceptable.
6. **QED:** Both Ligand A (0.675) and Ligand B (0.721) have good drug-likeness scores, exceeding 0.5.
7. **DILI:** Ligand A (47.926) has a lower DILI risk than Ligand B (62.117), which is preferable.
8. **BBB:** Ligand A (43.893) has a lower BBB penetration than Ligand B (64.095). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be beneficial or at least needs to be considered.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified and this is difficult to interpret.
10. **Solubility:** Ligand A (-1.337) has better solubility than Ligand B (-3.837).
11. **hERG:** Ligand A (0.075) has a much lower hERG risk than Ligand B (0.462). This is a crucial advantage for Ligand A.
12. **Cl_mic:** Ligand A (-13.812) has a much lower (better) microsomal clearance than Ligand B (42.47). This indicates better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (21.786) has a shorter half-life than Ligand B (27.485).
14. **Pgp:** Ligand A (0.018) has much lower P-gp efflux liability than Ligand B (0.112). This is a significant advantage for Ligand A.
15. **Binding Affinity:** Ligand B (-6.9 kcal/mol) has a stronger binding affinity than Ligand A (-5.3 kcal/mol). This is a substantial advantage for Ligand B, exceeding the 1.5 kcal/mol threshold.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand B excels in logP and affinity, while Ligand A is better in TPSA, Pgp, and has a lower hERG risk.
**Overall Assessment:**
The stronger binding affinity of Ligand B (-6.9 kcal/mol vs -5.3 kcal/mol) is a major advantage that is hard to ignore. While Ligand A has better ADME properties (lower DILI, better metabolic stability, lower Pgp efflux, lower hERG), the difference in binding affinity is significant. The slightly better logP of Ligand B also supports better membrane permeability. The solubility difference is not as critical given the other properties.
Therefore, despite the slightly higher DILI and hERG risk, the superior binding affinity of Ligand B makes it the more promising candidate.
Output:
0
2025-04-17 21:16:36,163 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the acceptable range (200-500 Da). Ligand A (359.403) is slightly better positioned.
2. **TPSA:** Ligand A (77.77) is significantly better than Ligand B (107.61). ADRB2 is a cardiovascular target, so CNS penetration isn't critical, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (3.114) is optimal, while Ligand B (0.107) is quite low. Low logP can hinder membrane permeability. This is a significant advantage for Ligand A.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (6) is preferable to Ligand B (4).
6. **QED:** Both ligands have similar QED values (0.656 vs 0.609), indicating reasonable drug-likeness.
7. **DILI:** Ligand A (85.227) has a higher DILI risk than Ligand B (28.073). This is a negative for Ligand A, and a strong positive for Ligand B.
8. **BBB:** Both have acceptable BBB penetration (72.664 and 73.517). Not a major factor here as ADRB2 is not a CNS target.
9. **Caco-2:** Ligand A (-4.939) is better than Ligand B (-5.467), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-4.148) is better than Ligand B (-1.971).
11. **hERG:** Ligand A (0.586) has a lower hERG risk than Ligand B (0.218). This is a positive for Ligand A.
12. **Cl_mic:** Ligand A (101.611) has a higher microsomal clearance than Ligand B (1.534), indicating lower metabolic stability. This is a negative for Ligand A.
13. **t1/2:** Ligand A (87.997) has a much longer in vitro half-life than Ligand B (-42.466). This is a significant positive for Ligand A.
14. **Pgp:** Ligand A (0.536) has lower P-gp efflux than Ligand B (0.006), indicating better bioavailability.
15. **Affinity:** Ligand B (-8.5 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.3 kcal/mol). This is a substantial advantage for Ligand B, potentially outweighing some ADME concerns.
**Overall Assessment:**
Ligand B has a superior binding affinity, a much lower DILI risk, and better metabolic stability. While its logP is low, the strong binding affinity is a significant advantage for a GPCR target. Ligand A has better TPSA, solubility, and half-life, but its higher DILI and clearance are concerning. The difference in binding affinity is substantial (>1.5 kcal/mol).
Given the importance of potency for GPCRs, and the significant difference in binding affinity, I favor Ligand B.
Output:
0
2025-04-17 21:16:36,163 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [368.352, 99.1, -0.196, 3, 5, 0.603, 37.728, 57.968, -4.869, -1.623, 0.235, -1.407, -42.248, 0.023, -7.1]**
**Ligand B: [343.427, 91.32, 1.567, 3, 4, 0.708, 35.75, 53.315, -4.976, -2.301, 0.059, 7.74, -7.752, 0.014, -7.6]**
1. **Molecular Weight:** Both are within the ideal range (200-500 Da). Ligand B (343.427) is slightly preferred due to being a bit lower.
2. **TPSA:** Both are reasonably good (below 140), but Ligand B (91.32) is better than Ligand A (99.1). Lower TPSA generally favors better absorption.
3. **logP:** Ligand A (-0.196) is quite low, potentially hindering membrane permeability. Ligand B (1.567) is within the optimal range (1-3). This is a significant advantage for Ligand B.
4. **H-Bond Donors:** Both have 3 HBD, which is acceptable.
5. **H-Bond Acceptors:** Ligand A has 5, Ligand B has 4. Both are acceptable, with Ligand B being slightly better.
6. **QED:** Both are good (>0.5), with Ligand B (0.708) being slightly better than Ligand A (0.603).
7. **DILI:** Both have low DILI risk (below 40), with Ligand B (35.75) being slightly lower than Ligand A (37.728).
8. **BBB:** Both have moderate BBB penetration (around 50-60%). Since ADRB2 isn't exclusively a CNS target, this isn't a decisive factor, but Ligand A (57.968) is slightly better.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. This is a concern for both.
10. **Solubility:** Both have negative solubility values, indicating poor solubility. This is a concern for both.
11. **hERG:** Both have very low hERG risk, which is excellent.
12. **Cl_mic:** Ligand A (-1.407) has a much lower (better) microsomal clearance than Ligand B (7.74). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (-42.248) has a much longer in vitro half-life than Ligand B (-7.752). This is a significant advantage for Ligand A.
14. **Pgp:** Both have very low Pgp efflux, which is good.
15. **Binding Affinity:** Ligand A (-7.1) is slightly better than Ligand B (-7.6), but the difference is small.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, affinity), Ligand B has a clear advantage in logP and a slight advantage in TPSA. However, Ligand A has a substantial advantage in metabolic stability (Cl_mic) and half-life (t1/2), which are crucial for *in vivo* efficacy. The slightly better affinity of Ligand A is also a plus. While both have poor Caco-2 and solubility, the metabolic advantages of Ligand A are more critical for a successful drug candidate, especially given the potential for optimization of solubility/permeability.
Output:
1
2025-04-17 21:16:36,164 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [334.335, 107.87 , 2.151, 2. , 5. , 0.711, 95.153, 32.765, -4.948, -5.377, 0.534, 55.958, 24.679, 0.074, -6.5 ]
**Ligand B:** [334.427, 63.21 , 2.268, 1. , 6. , 0.796, 79.682, 69.407, -4.882, -2.261, 0.937, 1.196, -28.503, 0.194, 2.6 ]
Here's a breakdown, prioritizing GPCR-relevant parameters:
1. **Molecular Weight:** Both ligands are within the ideal 200-500 Da range. (Tie)
2. **TPSA:** Ligand B (63.21) is significantly better than Ligand A (107.87). Lower TPSA generally improves BBB penetration and oral absorption, crucial for GPCRs.
3. **logP:** Both are good (around 2.1-2.3), falling within the optimal 1-3 range. (Tie)
4. **H-Bond Donors/Acceptors:** Ligand B has 1 HBD and 6 HBA, while Ligand A has 2 HBD and 5 HBA. Both are acceptable, but Ligand B is slightly better.
5. **QED:** Both are above 0.5, indicating good drug-likeness. Ligand B (0.796) is slightly higher.
6. **DILI:** Ligand A has a very high DILI risk (95.153%), which is a major red flag. Ligand B is much better (79.682%), although still above the preferred <40.
7. **BBB:** Ligand B (69.407%) has a significantly better BBB penetration score than Ligand A (32.765%). This is important for a GPCR target.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability.
9. **Solubility:** Ligand A (-5.377) has worse solubility than Ligand B (-2.261).
10. **hERG:** Ligand A (0.534) has a lower hERG risk than Ligand B (0.937).
11. **Cl_mic:** Ligand B (1.196) has much lower microsomal clearance, indicating better metabolic stability, which is highly desirable. Ligand A (55.958) is quite high.
12. **t1/2:** Ligand B (-28.503) has a much longer in vitro half-life than Ligand A (24.679).
13. **Pgp:** Ligand A (0.074) has lower P-gp efflux liability than Ligand B (0.194).
14. **Binding Affinity:** Ligand A (-6.5 kcal/mol) has a significantly stronger binding affinity than Ligand B (-2.6 kcal/mol). This is a substantial advantage.
**Overall Assessment:**
While Ligand A boasts a much better binding affinity, its extremely high DILI risk and poor metabolic stability are major concerns. Ligand B, despite weaker binding, has a significantly better safety profile (lower DILI), better BBB penetration, improved metabolic stability, and longer half-life. For a GPCR target, the balance of ADME properties is often more critical than a slight edge in binding affinity, especially when a significant safety concern exists. The difference in binding affinity (-6.5 vs -2.6) is substantial, but can potentially be optimized in later stages of drug development. The DILI risk for Ligand A is a showstopper.
Therefore, I would prioritize Ligand B.
0
2025-04-17 21:16:36,164 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (383.8 & 397.4 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (46.84) is significantly better than Ligand B (106.61). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold. Ligand B is approaching the upper limit.
3. **logP:** Ligand A (4.244) is higher than Ligand B (1.304). While both are within the acceptable range, Ligand A is pushing the upper limit and could potentially have solubility issues. Ligand B is quite low, which might hinder permeability.
4. **HBD:** Ligand A (0) is preferable to Ligand B (1). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (5) is better than Ligand B (6). Lower HBA is generally preferred.
6. **QED:** Both ligands have similar QED values (0.679 vs 0.663), indicating comparable drug-likeness.
7. **DILI:** Ligand B (71.85) has a lower DILI risk than Ligand A (86.002), which is a significant advantage.
8. **BBB:** Ligand A (80.264) has a higher BBB penetration than Ligand B (57.115). While not crucial for a cardiovascular target, higher BBB is rarely a negative.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests a potential issue with the experimental setup or the compounds themselves. However, the values are similar (-4.302 vs -4.645).
10. **Solubility:** Ligand A (-5.705) has slightly better solubility than Ligand B (-4.179), though both are quite poor.
11. **hERG:** Ligand A (0.713) has a slightly better hERG profile than Ligand B (0.346), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand B (38.04) has significantly lower microsomal clearance than Ligand A (52.339), suggesting better metabolic stability. This is a major advantage.
13. **t1/2:** Ligand A (16.289) has a longer in vitro half-life than Ligand B (4.969). This is a positive for Ligand A.
14. **Pgp:** Ligand A (0.769) has a lower Pgp efflux liability than Ligand B (0.074). Lower Pgp is generally desirable for improved bioavailability.
15. **Binding Affinity:** Ligand A (-7.5 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.2 kcal/mol). This is a 1.3 kcal/mol difference, which is substantial and can outweigh some ADME drawbacks.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A excels in affinity and Pgp, and has a better TPSA. Ligand B has a better DILI score and Cl_mic. The affinity difference is large enough to be a deciding factor, and the better TPSA and Pgp of Ligand A are also beneficial. While Ligand B's lower clearance is attractive, the strong binding of Ligand A is more critical for a viable drug candidate.
**Conclusion:**
Despite Ligand B's better DILI and clearance, Ligand A's significantly higher binding affinity, better TPSA, and Pgp efflux profile make it the more promising candidate.
Output:
1
2025-04-17 21:16:36,164 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (349.5) is better than Ligand B (407.3). Both are within the ideal range, but A is closer to the lower, preferred end.
2. **TPSA:** Ligand A (52.65) is significantly better than Ligand B (67.35). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally favors absorption.
3. **logP:** Both ligands (A: 2.403, B: 2.163) are within the optimal 1-3 range. Very similar here.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A (3) is better than Ligand B (5). Lower HBA is generally preferred for better permeability.
6. **QED:** Ligand A (0.801) is slightly better than Ligand B (0.733), indicating a more drug-like profile.
7. **DILI:** Ligand A (5.312) is *much* better than Ligand B (43.35). This is a significant advantage for Ligand A. DILI is a major concern in drug development.
8. **BBB:** Ligand B (80.535) is better than Ligand A (61.923). However, as ADRB2 is a cardiovascular target, BBB penetration is not a high priority.
9. **Caco-2:** Ligand A (-4.884) is better than Ligand B (-5.109). Both are negative, indicating good permeability, but A is slightly better.
10. **Solubility:** Ligand A (-2.034) is better than Ligand B (-3.028). Better solubility is always preferred.
11. **hERG:** Both ligands (A: 0.659, B: 0.596) have low hERG inhibition liability, which is good. Very similar.
12. **Cl_mic:** Ligand A (18.667) is *much* better than Ligand B (47.239). Lower clearance indicates greater metabolic stability, a crucial factor.
13. **t1/2:** Ligand B (27.483) is better than Ligand A (14.885). A longer half-life is generally desirable.
14. **Pgp:** Both ligands (A: 0.047, B: 0.059) have low P-gp efflux, which is good. Very similar.
15. **Binding Affinity:** Ligand A (-6.8) is better than Ligand B (-5.2). This is a substantial difference in potency. A 1.6 kcal/mol difference can often outweigh minor ADME drawbacks.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Ligand A is better in all of these except for Pgp (similar) and BBB (B is better, but BBB is not critical for a cardiovascular target).
**Overall Assessment:**
Ligand A significantly outperforms Ligand B in several critical areas: DILI risk, metabolic stability (Cl_mic), binding affinity, TPSA, solubility and QED. While Ligand B has a slightly longer half-life and better BBB penetration (which is less important here), the advantages of Ligand A are far more compelling. The lower DILI risk and significantly improved binding affinity make Ligand A the more promising candidate.
Output:
1
2025-04-17 21:16:36,164 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (381.473 and 361.829 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (58.04) is better than Ligand B (60.93), both are below the 140 threshold for oral absorption.
3. **logP:** Ligand A (4.338) is higher than Ligand B (1.914). While 4.338 is approaching the upper limit, it's still acceptable. Ligand B's logP is quite low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (0), but both are within the acceptable limit of 5.
5. **HBA:** Ligand A (6) is higher than Ligand B (3), but both are within the acceptable limit of 10.
6. **QED:** Both ligands have good QED scores (0.69 and 0.808), indicating good drug-like properties.
7. **DILI:** Ligand B (67.313) has a significantly lower DILI risk than Ligand A (87.01). This is a substantial advantage for Ligand B.
8. **BBB:** Both ligands have similar BBB penetration (77.743 and 77.627). This is good, but not a major differentiating factor.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the values are similar (-4.941 and -4.588) so this isn't a deciding factor.
10. **Solubility:** Ligand A (-5.032) has slightly worse solubility than Ligand B (-3.64), but both are poor.
11. **hERG:** Ligand A (0.802) has a slightly higher hERG risk than Ligand B (0.424), which is preferable.
12. **Cl_mic:** Ligand B (25.291) has significantly lower microsomal clearance than Ligand A (51.344), indicating better metabolic stability.
13. **t1/2:** Ligand A (76.093) has a much longer in vitro half-life than Ligand B (11.511). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.713) has higher P-gp efflux liability than Ligand B (0.183). Lower P-gp is better, giving an advantage to Ligand B.
15. **Binding Affinity:** Ligand A (-8.1 kcal/mol) has a substantially stronger binding affinity than Ligand B (-7.0 kcal/mol). This is a very significant advantage for Ligand A.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, Pgp efflux, and binding affinity are crucial. Ligand A has a better logP and significantly better binding affinity. While Ligand B has better Pgp and DILI, the affinity difference is substantial. The longer half-life of Ligand A is also a benefit.
**Overall Assessment:**
The superior binding affinity of Ligand A (-8.1 kcal/mol vs -7.0 kcal/mol) is a major driver. The difference of 1.1 kcal/mol is large enough to outweigh the drawbacks of slightly higher DILI and Pgp efflux. The longer half-life is also a considerable benefit. While Ligand B has a better safety profile (DILI) and lower efflux, the potency advantage of Ligand A is too significant to ignore for a GPCR target.
Output:
1
2025-04-17 21:16:36,165 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for the ADRB2, a cardiovascular GPCR. Therefore, the most important properties are binding affinity, logP, TPSA, Pgp efflux, and to a lesser extent, BBB.
Let's analyze each ligand:
* **Molecular Weight:** Both ligands (391.56 and 343.43 Da) fall within the ideal 200-500 Da range.
* **TPSA:** Ligand A (99.56) is better than Ligand B (104.45), being closer to the <140 threshold for good absorption.
* **logP:** Both ligands have acceptable logP values (1.07 and 2.03), falling within the 1-3 range. Ligand B is slightly higher, which could be a minor concern.
* **H-Bond Donors/Acceptors:** Ligand A (HBD=2, HBA=6) is preferable to Ligand B (HBD=4, HBA=4) as it has fewer HBDs.
* **QED:** Ligand A (0.603) has a significantly better QED score than Ligand B (0.284), indicating a more drug-like profile.
* **DILI:** Both ligands have acceptable DILI risk (36.25 and 41.26), below the 60 threshold.
* **BBB:** Ligand A (65.37) is better than Ligand B (35.44), although BBB is not a primary concern for a cardiovascular target.
* **Caco-2 Permeability:** Both are negative, suggesting poor permeability. Ligand A (-5.69) is slightly better than Ligand B (-5.502).
* **Aqueous Solubility:** Both are negative, indicating poor solubility. Ligand A (-2.114) is slightly better than Ligand B (-3.292).
* **hERG:** Both ligands have low hERG risk (0.304 and 0.477).
* **Microsomal Clearance:** Ligand A (10.58) has a better (lower) microsomal clearance than Ligand B (5.64), suggesting better metabolic stability.
* **In vitro Half-Life:** Ligand A (27.8 hours) has a significantly longer half-life than Ligand B (-29.98 hours).
* **P-gp Efflux:** Both ligands have low P-gp efflux liability (0.064 and 0.057).
* **Binding Affinity:** Ligand A (-7.8 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.0 kcal/mol). This is a crucial advantage.
**Conclusion:**
Ligand A consistently outperforms Ligand B across most critical parameters, particularly binding affinity, QED, metabolic stability (Cl_mic and t1/2), and TPSA. While both have limitations in solubility and Caco-2 permeability, the superior binding affinity and drug-like properties of Ligand A make it the more promising drug candidate for the ADRB2 receptor.
**Output:**
1
2025-04-17 21:16:36,165 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (367.877 and 348.487 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (62.83) is slightly higher than Ligand B (58.64). Both are below the 140 threshold for good oral absorption, and reasonably good for a GPCR.
3. **logP:** Both ligands have excellent logP values (2.37 and 2.513) falling within the optimal 1-3 range.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1). Both are within the acceptable limit of 5.
5. **HBA:** Ligand A (5) is higher than Ligand B (3). Both are within the acceptable limit of 10.
6. **QED:** Ligand A (0.808) has a significantly better QED score than Ligand B (0.651), indicating a more drug-like profile.
7. **DILI:** Ligand A (32.765) has a much lower DILI risk than Ligand B (12.641). This is a substantial advantage for Ligand A.
8. **BBB:** Ligand A (82.396) has a higher BBB penetration percentile than Ligand B (64.831). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be beneficial or at least needs to be considered.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.919 and -4.647). This is unusual and indicates poor permeability. However, the values are very similar.
10. **Solubility:** Both ligands have negative solubility values (-2.791 and -2.842). This is also concerning, suggesting poor aqueous solubility. Again, the values are very similar.
11. **hERG:** Ligand A (0.819) has a slightly higher hERG inhibition liability than Ligand B (0.393). This is a minor concern.
12. **Cl_mic:** Ligand A (-13.099) has a much lower (better) microsomal clearance than Ligand B (71.872). This suggests greater metabolic stability for Ligand A.
13. **t1/2:** Ligand A (28.633) has a significantly longer in vitro half-life than Ligand B (3.398). This is a major advantage for Ligand A.
14. **Pgp:** Ligand A (0.073) has a much lower P-gp efflux liability than Ligand B (0.267). Lower efflux is generally desirable.
15. **Binding Affinity:** Ligand B (-6.7) has a slightly better binding affinity than Ligand A (-6.1). This is a 0.6 kcal/mol difference, which is noticeable but not overwhelmingly large.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Both ligands perform well on logP and TPSA. Ligand A has a significantly better Pgp profile. The affinity difference is relatively small.
**Overall Assessment:**
Ligand A is the stronger candidate. While Ligand B has a slightly better binding affinity, Ligand A excels in crucial ADME properties: lower DILI risk, higher BBB penetration, lower microsomal clearance, longer half-life, and lower P-gp efflux. The QED score is also significantly better for Ligand A. The similar poor Caco-2 and solubility values are a concern for both, but the superior ADME profile of Ligand A outweighs the small affinity advantage of Ligand B.
Output:
1
2025-04-17 21:16:36,165 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (422.71 Da) is within the ideal range. Ligand B (352.475 Da) is also within the ideal range, and slightly smaller, which could be advantageous for permeability.
2. **TPSA:** Ligand A (55.63) is good, below the 140 threshold. Ligand B (98.66) is higher, but still potentially acceptable, though less ideal for oral absorption.
3. **logP:** Ligand A (4.856) is a bit high, potentially leading to solubility issues or off-target interactions. Ligand B (0.955) is quite low, which could hinder membrane permeability.
4. **HBD:** Both Ligand A (1) and Ligand B (4) are within the acceptable limit of 5.
5. **HBA:** Both Ligand A (4) and Ligand B (4) are within the acceptable limit of 10.
6. **QED:** Both Ligand A (0.577) and Ligand B (0.572) are good, above the 0.5 threshold.
7. **DILI:** Ligand A (72.392) has a higher DILI risk than Ligand B (14.424). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (60.411) has moderate BBB penetration. Ligand B (24.738) has low BBB penetration. Since ADRB2 is a cardiovascular target, BBB penetration is not a primary concern.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests issues with the assay or prediction. However, we can interpret this as low permeability.
10. **Solubility:** Ligand A (-4.257) has poor predicted solubility. Ligand B (-2.354) has slightly better predicted solubility.
11. **hERG:** Ligand A (0.848) has a low hERG risk. Ligand B (0.185) has a very low hERG risk, which is excellent.
12. **Cl_mic:** Ligand A (80.234) has moderate microsomal clearance. Ligand B (-6.533) has *negative* clearance, which is unrealistic and likely indicates a prediction error. This is a major red flag.
13. **t1/2:** Ligand A (67.196) has a good in vitro half-life. Ligand B (20.392) has a shorter half-life.
14. **Pgp:** Ligand A (0.869) has moderate P-gp efflux. Ligand B (0.038) has very low P-gp efflux, which is favorable.
15. **Affinity:** Ligand A (-4.6 kcal/mol) has good binding affinity. Ligand B (-7.0 kcal/mol) has significantly better binding affinity, a difference of 2.4 kcal/mol.
**GPCR-specific considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand B excels in affinity and Pgp efflux, and has a lower DILI risk. While its logP is low and TPSA is higher, the substantial affinity advantage (2.4 kcal/mol) outweighs these drawbacks. The negative clearance value for Ligand B is concerning, but the large difference in binding affinity is a strong driver.
**Conclusion:**
Despite the issues with predicted clearance for Ligand B, the significantly improved binding affinity and lower DILI risk make it the more promising candidate.
Output:
0
2025-04-17 21:16:36,165 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's analyze each ligand against the provided guidelines, with a focus on GPCR-relevant parameters.
* **Molecular Weight:** Both ligands (364.8 and 352.4 Da) fall comfortably within the ideal 200-500 Da range.
* **TPSA:** Ligand A (87.38) is significantly better than Ligand B (134.68). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
* **logP:** Ligand A (0.518) is a bit low, potentially hindering permeability. Ligand B (-2.13) is quite low and concerning for permeability.
* **H-Bond Donors/Acceptors:** Ligand A (1 HBD, 7 HBA) is more favorable than Ligand B (4 HBD, 7 HBA). Both are within acceptable ranges, but fewer H-bonds are generally preferred for better membrane permeability.
* **QED:** Ligand A (0.832) has a significantly better QED score than Ligand B (0.486), indicating a more drug-like profile.
* **DILI:** Both ligands have acceptable DILI risk (46.4 and 51.8), though lower is always better.
* **BBB:** Not a primary concern for a cardiovascular target, but Ligand A (48.74) is better than Ligand B (4.731).
* **Caco-2:** Ligand A (-4.914) is better than Ligand B (-5.745), indicating better intestinal absorption.
* **Solubility:** Ligand A (-1.523) is better than Ligand B (-0.877), which is important for formulation and bioavailability.
* **hERG:** Both ligands have very low hERG inhibition risk (0.076 and 0.101).
* **Cl_mic:** Both ligands have similar and acceptable microsomal clearance (-12.658 and -12.975).
* **t1/2:** Both ligands have similar and acceptable in vitro half-lives (-13.578 and -13.838).
* **Pgp:** Both ligands have low P-gp efflux liability (0.078 and 0.009).
* **Binding Affinity:** Ligand A (-8.2 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.2 kcal/mol). This is a substantial difference (2 kcal/mol), and is a major deciding factor.
**Overall Assessment:**
Ligand A is superior to Ligand B. While Ligand A's logP is slightly low, its significantly better TPSA, QED, solubility, Caco-2 permeability, and *especially* its much stronger binding affinity outweigh this minor drawback. The substantial difference in binding affinity (-8.2 vs -6.2 kcal/mol) is a critical advantage for a GPCR target, as it suggests a higher probability of achieving efficacy at a reasonable dose.
Output:
1
2025-04-17 21:16:36,165 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.431 and 348.378 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (101.46) is slightly higher than Ligand B (90.87). Both are below the 140 threshold for oral absorption, and Ligand B is closer to the 90 threshold for CNS targets, but ADRB2 is not necessarily a CNS target.
3. **logP:** Both ligands have good logP values (2.138 and 2.848), falling within the optimal 1-3 range. Ligand B is slightly higher, which could be a minor advantage for membrane permeability.
4. **HBD:** Both have 2 H-bond donors, which is within the acceptable limit of 5.
5. **HBA:** Ligand A has 5 H-bond acceptors, and Ligand B has 4. Both are below the acceptable limit of 10.
6. **QED:** Both ligands have good QED scores (0.737 and 0.801), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (44.126) has a significantly lower DILI risk than Ligand B (72.043). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (71.035) has a slightly higher BBB penetration percentile than Ligand B (66.964). While not a primary concern for ADRB2, it's a small positive for Ligand A.
9. **Caco-2:** Both have negative Caco-2 values (-5.041 and -4.904). This is unusual and suggests poor permeability.
10. **Solubility:** Ligand A (-2.579) has better solubility than Ligand B (-4.126).
11. **hERG:** Both ligands have low hERG inhibition liability (0.33 and 0.468), which is good.
12. **Cl_mic:** Ligand A (46.543) has a higher microsomal clearance than Ligand B (7.62). This suggests Ligand B is more metabolically stable.
13. **t1/2:** Ligand A (-26.368) has a negative in vitro half-life, which is concerning. Ligand B (12.696) has a positive half-life.
14. **Pgp:** Both have very low Pgp efflux liability (0.043 and 0.116).
15. **Binding Affinity:** Ligand B (-7.7 kcal/mol) has a significantly stronger binding affinity than Ligand A (-4.9 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME drawbacks.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand B excels in affinity and has acceptable logP, Pgp, and TPSA values. While Ligand A has better DILI and solubility, the significantly stronger binding affinity of Ligand B is a critical factor. The negative half-life of Ligand A is a major red flag.
**Conclusion:**
Despite the better safety profile (lower DILI) and solubility of Ligand A, the substantially higher binding affinity of Ligand B, coupled with its better metabolic stability (lower Cl_mic and positive t1/2), makes it the more promising drug candidate for ADRB2. The difference in binding affinity is large enough to potentially overcome the higher DILI risk, which can be further investigated and mitigated during optimization.
Output:
0
2025-04-17 21:16:36,165 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (338.407 Da) is better than Ligand B (386.945 Da). Both are within the ideal range, but A is closer to the lower, preferred end.
2. **TPSA:** Ligand A (53.76) is significantly better than Ligand B (69.64). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally improves absorption.
3. **logP:** Both ligands have acceptable logP values (A: 2.27, B: 2.668), falling within the 1-3 range. B is slightly higher, which could potentially lead to off-target interactions, but it's not a major concern.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer HBDs generally improve membrane permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (4). Similar reasoning as HBD.
6. **QED:** Ligand A (0.792) is better than Ligand B (0.606), indicating a more drug-like profile.
7. **DILI:** Both ligands have low DILI risk (A: 31.252, B: 30.71), which is excellent.
8. **BBB:** Ligand A (85.498) is significantly better than Ligand B (34.742). While not a primary concern for a cardiovascular target, higher BBB is generally a positive attribute.
9. **Caco-2:** Ligand A (-4.38) is better than Ligand B (-4.944). Higher Caco-2 permeability suggests better absorption.
10. **Solubility:** Ligand A (-3.939) is better than Ligand B (-3.279). Better solubility is generally desired.
11. **hERG:** Ligand A (0.313) is better than Ligand B (0.708). Lower hERG inhibition is crucial for avoiding cardiotoxicity, especially for a cardiovascular target.
12. **Cl_mic:** Ligand A (13.299) is significantly better than Ligand B (60.305). Lower microsomal clearance indicates better metabolic stability.
13. **t1/2:** Ligand A (14.306) is better than Ligand B (20.979). Longer half-life is generally preferred.
14. **Pgp:** Ligand A (0.092) is better than Ligand B (0.212). Lower P-gp efflux is desirable for improved bioavailability.
15. **Binding Affinity:** Ligand B (-5.9) is slightly better than Ligand A (-5.7). While a difference of 0.2 kcal/mol isn't huge, it's a factor.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical ADME properties (TPSA, HBD, HBA, QED, Cl_mic, t1/2, Pgp, solubility, hERG, Caco-2). The slightly better binding affinity of Ligand B is not enough to offset these significant advantages. Given the GPCR nature of the target, the balance of properties in Ligand A is more favorable for a viable drug candidate. The lower hERG risk and better metabolic stability are particularly important for a cardiovascular drug.
Output:
1
2025-04-17 21:16:36,166 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
Let's break down the comparison of Ligand A and Ligand B, considering the provided guidelines and GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key).
1. **Molecular Weight:** Both ligands (367.471 and 350.419 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (102.76) is better than Ligand B (117.13). Both are under the 140 threshold for oral absorption, but lower TPSA generally favors better cell permeability.
3. **logP:** Ligand B (2.518) is better than Ligand A (0.583). Ligand A's logP is quite low, potentially hindering membrane permeability. Ligand B is within the optimal 1-3 range.
4. **H-Bond Donors:** Both ligands have 3 HBDs, which is acceptable.
5. **H-Bond Acceptors:** Ligand A has 6 HBAs, while Ligand B has 4. Ligand B is slightly better here.
6. **QED:** Ligand A (0.612) has a better QED score than Ligand B (0.444), suggesting a more drug-like profile.
7. **DILI:** Ligand A (34.858) has a significantly lower DILI risk than Ligand B (52.152). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (69.213) has a higher BBB penetration percentile than Ligand A (33.23). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be beneficial for distribution and off-target effects.
9. **Caco-2 Permeability:** Both are negative, indicating poor permeability. Ligand A (-5.218) is slightly better than Ligand B (-5.002).
10. **Aqueous Solubility:** Ligand A (-1.737) is better than Ligand B (-3.994).
11. **hERG Inhibition:** Ligand A (0.171) has a much lower hERG inhibition risk than Ligand B (0.521). This is a critical safety parameter.
12. **Microsomal Clearance:** Ligand A (4.678) has a lower microsomal clearance than Ligand B (30.723), indicating better metabolic stability.
13. **In vitro Half-Life:** Ligand A (-7.908) has a significantly longer in vitro half-life than Ligand B (-0.651). This is a substantial advantage.
14. **P-gp Efflux:** Ligand A (0.03) has a much lower P-gp efflux liability than Ligand B (0.118). This is favorable for bioavailability.
15. **Binding Affinity:** Ligand B (-6.6 kcal/mol) has a slightly better binding affinity than Ligand A (-6.1 kcal/mol). The difference is 0.5 kcal/mol, which isn't massive, but noticeable.
**Overall Assessment:**
While Ligand B has a slightly better binding affinity and BBB penetration, Ligand A is significantly superior in terms of safety (DILI, hERG), ADME properties (microsomal clearance, half-life, P-gp efflux, solubility), and overall drug-likeness (QED). The low logP of Ligand A is a concern, but the substantial advantages in other critical parameters outweigh this drawback. For a cardiovascular target like ADRB2, metabolic stability, minimizing off-target effects (DILI, hERG), and good bioavailability are paramount.
**Output:**
1
2025-04-17 21:16:36,166 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (365.5 & 349.5 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand B (64.86) is significantly better than Ligand A (82.53). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally aids absorption.
3. **logP:** Ligand A (1.682) is better than Ligand B (3.163). Ligand B is approaching the upper limit of the optimal range, potentially leading to solubility issues.
4. **HBD:** Ligand A (2) is slightly better than Ligand B (1). Both are within the acceptable limit of 5.
5. **HBA:** Ligand B (6) is slightly higher than Ligand A (5). Both are within the acceptable limit of 10.
6. **QED:** Both ligands have identical QED scores (0.73), indicating similar drug-likeness.
7. **DILI:** Ligand B (23.19) is considerably better than Ligand A (35.67). Lower DILI risk is a significant advantage.
8. **BBB:** Ligand B (72.01) is better than Ligand A (40.56). While not a CNS target, some degree of BBB penetration can influence off-target effects.
9. **Caco-2:** Both are negative, indicating poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-2.64) is better than Ligand B (-3.433). Solubility is a concern for both, but less so for Ligand A.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.151 and 0.264 respectively).
12. **Cl_mic:** Ligand A (28.59) has lower microsomal clearance than Ligand B (40.50), suggesting better metabolic stability.
13. **t1/2:** Ligand A (32.39) has a positive in vitro half-life, while Ligand B (-4.41) has a negative half-life. This is a major advantage for Ligand A.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.046 and 0.043 respectively).
15. **Binding Affinity:** Ligand B (-7.5) has a slightly better binding affinity than Ligand A (-7.3). The difference is 0.2 kcal/mol, which is not substantial enough to overcome the other ADME deficiencies.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B has better TPSA and affinity, but Ligand A has a better logP and significantly better metabolic stability (Cl_mic and t1/2) and lower DILI risk. The slightly better affinity of Ligand B doesn't outweigh the other advantages of Ligand A.
**Conclusion:**
Considering the balance of properties, particularly the improved metabolic stability, lower DILI risk, and better solubility of Ligand A, it appears to be the more promising drug candidate.
Output:
1
2025-04-17 21:16:36,166 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (349.427) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (73.86) is better than Ligand B (100.55). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally improves absorption.
3. **logP:** Ligand A (2.446) is optimal, while Ligand B (0.27) is quite low. This is a significant drawback for Ligand B, potentially hindering membrane permeability and bioavailability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Both have 5 HBA, which is acceptable.
6. **QED:** Ligand A (0.766) has a better QED score than Ligand B (0.62), indicating a more drug-like profile.
7. **DILI:** Ligand B (49.011) has a significantly lower DILI risk than Ligand A (64.288), which is a strong positive for Ligand B.
8. **BBB:** Not a high priority for a cardiovascular target. Ligand A (63.009) is slightly better than Ligand B (55.603).
9. **Caco-2:** Ligand B (-5.102) is better than Ligand A (-4.675), indicating better intestinal absorption.
10. **Solubility:** Ligand B (-1.583) is better than Ligand A (-3.058), which is a positive.
11. **hERG:** Both have very low hERG risk (0.282 and 0.14), which is excellent.
12. **Cl_mic:** Ligand B (-4.688) has a negative clearance, which is excellent and indicates very high metabolic stability, while Ligand A (65.104) is higher.
13. **t1/2:** Ligand B (45.103) has a significantly longer half-life than Ligand A (11.565), which is a major advantage.
14. **Pgp:** Both have very low Pgp efflux liability (0.177 and 0.007).
15. **Binding Affinity:** Ligand B (-8.0) has a significantly stronger binding affinity than Ligand A (-7.2). This is a substantial advantage, potentially outweighing some of the ADME concerns.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B is significantly better in logP, has a better Caco-2, solubility, clearance, and half-life, and a substantially better binding affinity. While Ligand A has a slightly better TPSA, the overall profile of Ligand B is superior. The lower DILI risk for Ligand B is also a significant benefit.
**Conclusion:**
Despite Ligand A having a slightly better TPSA and QED, Ligand B's superior binding affinity, logP, metabolic stability (Cl_mic, t1/2), solubility, and lower DILI risk make it the more promising drug candidate.
Output:
0
2025-04-17 21:16:36,166 - INFO - Batch 246 complete. Total preferences: 3936
2025-04-17 21:16:36,166 - INFO - Processing batch 247/512...
2025-04-17 21:17:22,791 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.531 and 346.471 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (40.62) is better than Ligand B (58.64). Both are under the 140 threshold for oral absorption, but A is closer to the ideal for GPCRs.
3. **logP:** Ligand A (3.841) is slightly higher than Ligand B (2.732), both are within the optimal 1-3 range. A is closer to the upper limit, which could be a slight concern, but manageable.
4. **HBD:** Ligand A (0) is preferable to Ligand B (1). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (2) is preferable to Ligand B (3). Lower HBA generally improves permeability.
6. **QED:** Both ligands have good QED scores (0.732 and 0.787), indicating good drug-like properties. No significant difference.
7. **DILI:** Both ligands have low DILI risk (26.173 and 29.081), well below the 40 threshold. No significant difference.
8. **BBB:** Ligand A (92.71) is significantly better than Ligand B (75.727). While ADRB2 isn't exclusively a CNS target, some CNS penetration can be beneficial, and higher BBB is generally desirable.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.641 and -4.671). This is unusual and suggests poor permeability. However, the values are very similar.
10. **Solubility:** Ligand A (-4.011) is slightly better than Ligand B (-2.771), indicating better aqueous solubility.
11. **hERG:** Ligand A (0.524) is better than Ligand B (0.714), indicating a lower risk of hERG inhibition and cardiotoxicity.
12. **Cl_mic:** Ligand A (88.465) has higher microsomal clearance than Ligand B (70.533). This suggests Ligand B is more metabolically stable, which is a positive.
13. **t1/2:** Ligand A (28.073) has a longer in vitro half-life than Ligand B (19.253). This is a significant advantage.
14. **Pgp:** Ligand A (0.469) is better than Ligand B (0.206), indicating lower P-gp efflux.
15. **Binding Affinity:** Ligand A (-7.7 kcal/mol) has a significantly stronger binding affinity than Ligand B (-5.3 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME drawbacks.
**Overall Assessment:**
Ligand A is clearly the better candidate. While Ligand B has slightly better metabolic stability, Ligand A excels in several crucial areas: significantly higher binding affinity, better BBB penetration, lower hERG risk, longer half-life, and lower P-gp efflux. The TPSA and solubility are also favorable. The negative Caco-2 values are concerning for both, but the strong affinity of Ligand A suggests it might overcome this permeability issue. Given the GPCR target class, the balance of properties favors Ligand A.
Output:
1
2025-04-17 21:17:22,792 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (340.427 and 351.447 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (78.35) is better than Ligand B (89.01). Both are below 140, but A is closer to the preferred <90 for potential CNS penetration, even though ADRB2 isn't strictly a CNS target.
3. **logP:** Ligand A (2.589) is better than Ligand B (1.373). Both are within the optimal 1-3 range, but A is closer to the upper end, which is generally favorable for GPCRs.
4. **HBD:** Ligand A (2) is slightly better than Ligand B (1). Both are acceptable.
5. **HBA:** Ligand B (6) is better than Ligand A (4). Both are acceptable.
6. **QED:** Ligand A (0.877) is significantly better than Ligand B (0.712), indicating a more drug-like profile.
7. **DILI:** Ligand B (2.326) is *much* better than Ligand A (66.421). This is a major concern for Ligand A. A DILI percentile above 60 is a significant red flag.
8. **BBB:** Ligand B (73.672) is better than Ligand A (54.866). While not a primary concern for ADRB2, higher BBB is generally a positive attribute.
9. **Caco-2:** Ligand A (-4.877) is better than Ligand B (-5.135). Both are negative, indicating poor permeability.
10. **Solubility:** Ligand B (-0.446) is better than Ligand A (-2.398). Both are poor, but B is slightly better.
11. **hERG:** Ligand A (0.337) is better than Ligand B (0.551). Lower is better, so A has a slight advantage here.
12. **Cl_mic:** Ligand B (-9.948) is *much* better than Ligand A (-1.715). This indicates significantly better metabolic stability for Ligand B.
13. **t1/2:** Ligand A (17.291) is better than Ligand B (0.095). This is a significant advantage for A.
14. **Pgp:** Ligand A (0.057) is better than Ligand B (0.011). Lower is better, so A has a slight advantage here.
15. **Binding Affinity:** Ligand B (-5.9) is better than Ligand A (-5.0). This is a 1.5 kcal/mol difference, which is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand B has a significantly better safety profile (DILI) and metabolic stability (Cl_mic). It also has superior binding affinity. While Ligand A has a better half-life and slightly better Pgp efflux, the high DILI risk and poorer metabolic stability are major concerns. The better affinity of Ligand B, combined with its favorable safety and metabolic properties, makes it the more promising candidate despite the slightly lower half-life. The slightly better solubility of B is also a plus.
Output:
0
2025-04-17 21:17:22,792 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.459 Da and 367.475 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (81.08) is better than Ligand B (93.37). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (1.092 and 0.876, respectively), falling within the optimal 1-3 range. Ligand A is slightly better.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1), but both are within the acceptable limit of 5.
5. **HBA:** Ligand A (4) is lower than Ligand B (8). Lower HBA is generally preferred for better permeability.
6. **QED:** Both ligands have similar QED values (0.703 and 0.67), indicating good drug-likeness.
7. **DILI:** Ligand A (13.339) has a significantly lower DILI risk than Ligand B (49.283). This is a crucial advantage.
8. **BBB:** BBB is less important for a cardiovascular target. Ligand A (60.876) is better than Ligand B (46.258), but this isn't a major factor in this case.
9. **Caco-2:** Ligand A (-4.689) is better than Ligand B (-5.005), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-1.628) is better than Ligand B (-0.861). Better solubility is always desirable.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.279 and 0.194), which is excellent.
12. **Cl_mic:** Ligand A (15.938) has a much lower microsomal clearance than Ligand B (47.72). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (-11.504) has a longer in vitro half-life than Ligand B (-13.34). This is a positive attribute.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.135 and 0.161).
15. **Binding Affinity:** Ligand B (-6.3) has a slightly better binding affinity than Ligand A (-5.8). However, the difference is only 0.5 kcal/mol, and several other factors favor Ligand A.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. While Ligand B has slightly better affinity, Ligand A excels in logP, TPSA, and significantly outperforms in DILI and Cl_mic. The lower DILI risk and improved metabolic stability of Ligand A are particularly important for a cardiovascular drug.
**Conclusion:**
Considering all factors, Ligand A is the more promising drug candidate due to its superior ADME properties (lower DILI, better solubility, lower clearance, longer half-life) and acceptable binding affinity. The slight advantage in binding affinity of Ligand B is outweighed by the significant improvements in safety and pharmacokinetic properties of Ligand A.
Output:
1
2025-04-17 21:17:22,792 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (344.46 & 355.45 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (60.85) is significantly better than Ligand B (87.3). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is approaching a less desirable range.
3. **logP:** Both ligands have similar logP values (1.68 & 1.58), falling within the optimal 1-3 range.
4. **HBD:** Ligand A (1) is better than Ligand B (3). Lower HBD generally improves permeability.
5. **HBA:** Both ligands have the same HBA count (3), which is well within the acceptable limit of 10.
6. **QED:** Ligand A (0.829) has a substantially higher QED score than Ligand B (0.587), indicating a more drug-like profile.
7. **DILI:** Ligand A (17.41) has a much lower DILI risk than Ligand B (38.12). This is a significant advantage for Ligand A.
8. **BBB:** Ligand B (70.03) has a slightly higher BBB penetration than Ligand A (62.47). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be useful for understanding off-target effects and potential distribution.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. Ligand A (-4.83) is slightly better than Ligand B (-5.10).
10. **Solubility:** Both ligands have similar, very poor aqueous solubility (-2.53 & -2.68). This is a concern for both, but solubility can often be improved with formulation strategies.
11. **hERG:** Both ligands have low hERG inhibition risk (0.21 & 0.26).
12. **Cl_mic:** Ligand A (8.44) has a higher microsomal clearance than Ligand B (6.95). Lower is better, so Ligand B has an advantage here.
13. **t1/2:** Ligand A (26.61) has a significantly longer in vitro half-life than Ligand B (-2.65). This is a major advantage for Ligand A, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.09 & 0.08).
15. **Binding Affinity:** Ligand A (-8.4) has a significantly stronger binding affinity than Ligand B (-4.9). This is a crucial factor, and the 3.5 kcal/mol difference is substantial enough to outweigh many of the other minor drawbacks.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand A is the clear winner. Its significantly higher binding affinity, better QED, lower DILI risk, and longer half-life are compelling advantages. While Ligand B has slightly better BBB penetration and lower Cl_mic, the substantial benefits of Ligand A outweigh these minor differences. The poor solubility and Caco-2 values are concerns for both, but these can be addressed during formulation.
Output:
1
2025-04-17 21:17:22,792 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (385.873) is slightly higher than Ligand B (362.832), but both are acceptable.
2. **TPSA:** Ligand A (81.62) is higher than Ligand B (41.57). For a cardiovascular GPCR like ADRB2, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B is significantly better here.
3. **logP:** Both ligands have good logP values (A: 2.577, B: 3.169), falling within the optimal 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Ligand A has 0 HBD, while Ligand B has 1. Both are acceptable, and low HBD can be advantageous for permeability.
5. **HBA:** Ligand A has 7 HBA, while Ligand B has 3. Ligand B is better here, as lower HBA generally improves permeability.
6. **QED:** Ligand B (0.888) has a significantly higher QED score than Ligand A (0.535), indicating a more drug-like profile.
7. **DILI:** Ligand A (83.133) has a higher DILI risk than Ligand B (52.423). This is a significant concern, as we want to minimize liver toxicity.
8. **BBB:** Both have reasonable BBB penetration, but Ligand B (87.515) is better than Ligand A (76.386). While ADRB2 isn't a CNS target, some off-target CNS effects are always a consideration.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability in this assay. However, the values are similar (-4.616 for A, -4.743 for B), so this isn't a major differentiator.
10. **Solubility:** Both ligands have very poor aqueous solubility (-3.395 for A, -3.965 for B). This is a significant drawback for both, and formulation strategies would be crucial.
11. **hERG:** Ligand A (0.288) has a lower hERG risk than Ligand B (0.799). This is a positive for Ligand A.
12. **Cl_mic:** Ligand B (43.597) has a lower microsomal clearance than Ligand A (57.17), indicating better metabolic stability.
13. **t1/2:** Ligand B (11.428) has a significantly longer in vitro half-life than Ligand A (1.713). This is a major advantage, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have low P-gp efflux liability (A: 0.226, B: 0.229), which is good.
15. **Binding Affinity:** Ligand B (-5.9 kcal/mol) has a slightly better binding affinity than Ligand A (-6.0 kcal/mol). While the difference is small, it's still a positive for Ligand B.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP, TPSA, and has comparable affinity and Pgp. The longer half-life and better QED and lower DILI risk further strengthen its profile.
**Overall Assessment:**
While Ligand A has a slightly better hERG profile, Ligand B demonstrates a superior overall balance of properties. Its better QED, lower DILI risk, longer half-life, and improved TPSA and metabolic stability outweigh the slightly higher hERG risk. Both ligands have poor solubility, which is a concern for both.
Output:
0
2025-04-17 21:17:22,792 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [362.417, 87.66, 1.734, 3, 4, 0.583, 37.263, 52.268, -4.968, -1.513, 0.507, 33.677, -12.089, 0.15, -7.5]
**Ligand B:** [364.515, 75.19, 2.721, 1, 5, 0.872, 51.881, 62.97, -4.858, -3.685, 0.305, 59.641, 11.759, 0.463, -6.8]
Here's a breakdown, considering the GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both ligands are within the ideal 200-500 Da range. A is 362.4, B is 364.5. No significant difference.
2. **TPSA:** A (87.66) is slightly higher than B (75.19). B is better here, closer to the <90 ideal for GPCRs, suggesting potentially better brain penetration and membrane permeability.
3. **logP:** A (1.734) is good, within the 1-3 range. B (2.721) is also good, leaning toward the higher end of optimal. B is slightly favored.
4. **HBD:** A (3) is reasonable. B (1) is even better, minimizing potential for off-target interactions and improving permeability.
5. **HBA:** A (4) is good. B (5) is acceptable.
6. **QED:** A (0.583) is decent, but B (0.872) is significantly better, indicating a more drug-like profile.
7. **DILI:** A (37.263) is good, well below the 40% threshold. B (51.881) is still acceptable, but A has a lower risk.
8. **BBB:** A (52.268) is moderate. B (62.97) is better, although not exceptionally high. For a cardiovascular target, BBB isn't *critical*, but higher is still a plus.
9. **Caco-2:** Both are negative (-4.968 and -4.858), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Both are negative (-1.513 and -3.685), indicating poor aqueous solubility. This is a major drawback for both.
11. **hERG:** A (0.507) is better than B (0.305), indicating lower cardiotoxicity risk.
12. **Cl_mic:** A (33.677) is lower than B (59.641), suggesting better metabolic stability.
13. **t1/2:** A (-12.089) is significantly better (longer half-life) than B (11.759).
14. **Pgp:** A (0.15) is much lower than B (0.463), indicating less P-glycoprotein efflux and potentially better bioavailability.
15. **Affinity:** A (-7.5) is significantly better than B (-6.8). This 0.7 kcal/mol difference is substantial and can outweigh some of the ADME drawbacks.
**Overall Assessment:**
Ligand A has a significantly better binding affinity, better metabolic stability (lower Cl_mic, better t1/2), lower Pgp efflux, and lower DILI risk. While both have poor Caco-2 and solubility, the superior potency and ADME properties of A make it the more promising candidate. The slightly higher TPSA of A is less concerning than the other advantages it possesses.
Output:
1
2025-04-17 21:17:22,792 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (353.365 and 348.363 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (66.84) is significantly better than Ligand B (124.17). ADRB2 is a cardiovascular target, not CNS, but lower TPSA generally improves absorption. Ligand A is well below the 140 threshold. Ligand B is approaching the upper limit.
3. **logP:** Ligand A (2.469) is optimal, while Ligand B (0.317) is quite low. Low logP can hinder membrane permeability. This is a significant advantage for Ligand A.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is better than Ligand B (8). Lower HBA counts are generally preferred for better permeability.
6. **QED:** Both ligands have reasonable QED values (0.826 and 0.738), indicating good drug-like properties. Ligand A is slightly better.
7. **DILI:** Ligand A (38.62) has a much lower DILI risk than Ligand B (63.397). This is a substantial advantage for Ligand A, as minimizing liver toxicity is crucial.
8. **BBB:** Not a primary concern for a cardiovascular target. Ligand A (81.466) is higher than Ligand B (61.264), but this is less important.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.198 and -4.969), which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
10. **Solubility:** Both ligands have negative solubility values (-3.172 and -2.648), again unusual and suggesting poor solubility. The scale is not specified.
11. **hERG:** Ligand A (0.444) has a slightly higher hERG risk than Ligand B (0.015), but both are very low.
12. **Cl_mic:** Ligand A (52.929) has a higher microsomal clearance than Ligand B (7.191), meaning it's metabolized faster. This is a disadvantage for Ligand A.
13. **t1/2:** Ligand A (1.255) has a shorter half-life than Ligand B (-17.861). The negative value for Ligand B is suspect and likely an error, but even assuming a very long half-life, the short half-life of A is a concern.
14. **Pgp:** Ligand A (0.193) has lower P-gp efflux than Ligand B (0.019), which is favorable.
15. **Binding Affinity:** Ligand A (-7.0) has slightly better binding affinity than Ligand B (-5.9). While both are good, the 1.1 kcal/mol difference is significant.
**Overall Assessment:**
Ligand A has several advantages: better TPSA, logP, HBD, HBA, QED, and significantly lower DILI risk. The most significant drawback is the higher Cl_mic and shorter half-life. However, the superior binding affinity and more favorable ADME properties (TPSA, logP, DILI) outweigh the metabolic concerns, particularly given the potential for optimization of metabolic stability. Ligand B suffers from a very low logP and higher DILI risk, making it less attractive despite its potentially better metabolic stability.
Output:
1
2025-04-17 21:17:22,792 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (365.539 Da) is slightly higher than Ligand B (342.355 Da), but both are acceptable.
2. **TPSA:** Ligand A (63.24) is significantly better than Ligand B (94.82). For a GPCR, lower TPSA is generally preferred for better permeability. Ligand B is approaching a level that could hinder oral absorption.
3. **logP:** Ligand A (3.811) is optimal, while Ligand B (0.521) is quite low. Low logP can lead to poor membrane permeability and bioavailability. This is a significant advantage for Ligand A.
4. **HBD:** Both ligands have 1 HBD, which is within the ideal range.
5. **HBA:** Ligand A has 3 HBA, while Ligand B has 7. Ligand B is higher, potentially impacting permeability.
6. **QED:** Both ligands have good QED scores (A: 0.686, B: 0.814), indicating good drug-like properties. Ligand B is slightly better here.
7. **DILI:** Ligand A (37.456) has a better DILI score than Ligand B (72.586), indicating lower potential for liver injury. This is a crucial factor.
8. **BBB:** Ligand A (78.092) has a better BBB percentile than Ligand B (64.056). While ADRB2 isn't exclusively a CNS target, some CNS penetration can be beneficial, and avoiding high CNS exposure is generally good.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Both have negative solubility values, again making interpretation difficult.
11. **hERG:** Ligand A (0.607) has a slightly better hERG profile than Ligand B (0.361), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand B (55.953) has a lower microsomal clearance than Ligand A (62.147), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-30.065) has a negative in vitro half-life, which is problematic. Ligand A (18.627) is acceptable.
14. **Pgp:** Ligand A (0.526) has a better Pgp efflux profile than Ligand B (0.14). Lower Pgp efflux is desirable for improved bioavailability.
15. **Binding Affinity:** Ligand A (-6.3 kcal/mol) has a slightly better binding affinity than Ligand B (-5.8 kcal/mol), although the difference is not huge.
**GPCR-Specific Priorities:**
Considering ADRB2 is a GPCR, logP, TPSA, Pgp, and affinity are key. Ligand A excels in logP and TPSA, and has a slightly better affinity and Pgp profile. While Ligand B has a better QED and Cl_mic, the poor logP, high TPSA, and problematic half-life are significant drawbacks. The DILI risk is also considerably higher for Ligand B.
**Conclusion:**
Ligand A presents a more balanced profile with better predicted permeability, lower toxicity risk, and acceptable metabolic stability. While Ligand B has some advantages, the critical issues with logP, TPSA, and half-life outweigh them.
Output:
1
2025-04-17 21:17:22,792 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (341.382 and 348.447 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (55.4) is much better than Ligand B (87.32). ADRB2 is a cardiovascular target, not a CNS target, but lower TPSA generally improves absorption. Ligand A is well below the 140 threshold, while B is approaching it.
3. **logP:** Ligand A (4.072) is slightly higher than the optimal range (1-3), but still acceptable. Ligand B (1.532) is at the lower end, potentially hindering permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (4). Lower HBA generally improves permeability.
6. **QED:** Ligand A (0.806) is significantly better than Ligand B (0.496), indicating a more drug-like profile.
7. **DILI:** Ligand B (34.742) has a much lower DILI risk than Ligand A (76.115). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (79.721) has better BBB penetration than Ligand B (55.37). While not a primary concern for a cardiovascular target, some CNS exposure can sometimes lead to off-target effects.
9. **Caco-2:** Ligand A (-4.326) is better than Ligand B (-5.223). Higher Caco-2 permeability is desirable.
10. **Solubility:** Ligand A (-5.229) is better than Ligand B (-2.024). Better solubility is preferred.
11. **hERG:** Both ligands have low hERG inhibition liability (0.255 and 0.549 respectively), which is good.
12. **Cl_mic:** Ligand B (16.229) has significantly lower microsomal clearance than Ligand A (69.679), indicating better metabolic stability.
13. **t1/2:** Ligand A (7.812) has a better in vitro half-life than Ligand B (-12.56).
14. **Pgp:** Ligand A (0.396) is better than Ligand B (0.202). Lower P-gp efflux is desirable.
15. **Binding Affinity:** Both ligands have comparable binding affinities (-5.9 and -5.4 kcal/mol). The difference is not substantial enough to override other factors.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A has a better logP and Pgp, while Ligand B has a better TPSA. The affinities are similar. However, the significantly better QED, solubility, and Caco-2 permeability of Ligand A, combined with acceptable DILI risk, make it the more promising candidate. The lower metabolic stability of Ligand A is a concern, but can potentially be addressed through structural modifications.
**Final Decision:**
Ligand A is the more promising candidate.
Output:
1
2025-04-17 21:17:22,793 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 receptor:
**1. Molecular Weight:** Both ligands (380.447 and 370.921 Da) fall within the ideal range of 200-500 Da. No significant difference here.
**2. TPSA:** Ligand B (58.64) is significantly better than Ligand A (101.57). For a GPCR, lower TPSA is generally preferred for better permeability. Ligand B is well below the 140 threshold, while A is approaching it.
**3. logP:** Ligand B (3.078) is slightly higher than Ligand A (1.385), but both are within the optimal 1-3 range.
**4. H-Bond Donors:** Ligand A has 2 HBD, while Ligand B has 1. Both are acceptable.
**5. H-Bond Acceptors:** Ligand A has 5 HBA, while Ligand B has 3. Both are acceptable.
**6. QED:** Both ligands have similar QED values (0.738 and 0.714), indicating good drug-likeness.
**7. DILI:** Ligand B (24.351) has a much lower DILI risk than Ligand A (89.104). This is a major advantage for Ligand B.
**8. BBB:** Ligand B (78.868) has a significantly higher BBB penetration percentile than Ligand A (15.316). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be beneficial or at least avoid unexpected side effects.
**9. Caco-2 Permeability:** Ligand A (-5.163) has slightly better Caco-2 permeability than Ligand B (-4.786).
**10. Aqueous Solubility:** Ligand A (-3.44) has slightly better aqueous solubility than Ligand B (-2.85).
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.207 and 0.324).
**12. Microsomal Clearance:** Ligand A (-3.222) has a much lower (better) microsomal clearance than Ligand B (56.895). This suggests better metabolic stability for Ligand A.
**13. In vitro Half-Life:** Ligand B (14.421) has a slightly longer in vitro half-life than Ligand A (19.4).
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (0.133 and 0.184).
**15. Binding Affinity:** Ligand A (-6.7) has a slightly better binding affinity than Ligand B (-6.4). However, the difference is only 0.3 kcal/mol, which isn't substantial enough to outweigh other factors.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity) and the general guidelines, Ligand B is the more promising candidate. Its significantly lower DILI risk and higher BBB penetration are major advantages. While Ligand A has slightly better metabolic stability and binding affinity, the differences are not large enough to offset the safety and permeability benefits of Ligand B. The lower TPSA of Ligand B is also a significant positive.
Output:
0
2025-04-17 21:17:22,793 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor (a GPCR).
**Ligand A:** [348.531, 40.62, 3.842, 0, 2, 0.757, 16.906, 92.827, -4.567, -3.526, 0.683, 72.515, -3.673, 0.351, -5.8]
**Ligand B:** [348.393, 49.41, 2.579, 1, 2, 0.832, 27.065, 85.459, -4.666, -3.253, 0.322, 12.448, -0.075, 0.072, -6.7]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity, and BBB):
1. **MW:** Both ligands are within the ideal range (around 348 Da). No significant difference.
2. **TPSA:** Ligand A (40.62) is better than Ligand B (49.41). Lower TPSA generally favors better absorption.
3. **logP:** Ligand A (3.842) is slightly higher than Ligand B (2.579), placing it closer to the optimal range of 1-3. Ligand B is a bit low, potentially impacting permeability.
4. **HBD/HBA:** Ligand A (0 HBD, 2 HBA) is slightly preferable to Ligand B (1 HBD, 2 HBA) as fewer HBDs can improve membrane permeability.
5. **QED:** Both are good (A: 0.757, B: 0.832), indicating drug-like properties. Ligand B is slightly better.
6. **DILI:** Ligand A (16.906) has a significantly lower DILI risk than Ligand B (27.065). This is a major advantage.
7. **BBB:** Ligand A (92.827) has a higher BBB penetration percentile than Ligand B (85.459). While ADRB2 isn't strictly a CNS target, some peripheral distribution is still desired, and a higher BBB value suggests better overall permeability.
8. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-4.567) is slightly worse than Ligand B (-4.666).
9. **Solubility:** Both are negative, indicating poor solubility. Ligand A (-3.526) is slightly worse than Ligand B (-3.253).
10. **hERG:** Both are low risk (A: 0.683, B: 0.322), which is good.
11. **Cl_mic:** Ligand A (72.515) has a higher microsomal clearance than Ligand B (12.448), suggesting faster metabolism and potentially lower *in vivo* exposure. This is a significant drawback for Ligand A.
12. **t1/2:** Ligand B (-0.075) has a slightly longer half-life than Ligand A (-3.673).
13. **Pgp:** Ligand A (0.351) has lower P-gp efflux than Ligand B (0.072), which is favorable for bioavailability.
14. **Affinity:** Ligand B (-6.7 kcal/mol) has a stronger binding affinity than Ligand A (-5.8 kcal/mol). This is a 0.9 kcal/mol difference, which is substantial and can outweigh some ADME concerns.
**Overall Assessment:**
Ligand B has a significantly better binding affinity and metabolic stability (lower Cl_mic, longer t1/2). While Ligand A has better BBB penetration and lower DILI risk, the affinity difference and metabolic stability of Ligand B are more critical for a GPCR target. The slightly lower logP of Ligand B is a minor concern, but the stronger binding is likely to compensate.
Output:
0
2025-04-17 21:17:22,793 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**1. Molecular Weight:** Both ligands (351.535 Da and 356.463 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (44.81) is significantly better than Ligand B (107.89). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is quite high, potentially hindering absorption.
**3. logP:** Ligand A (3.403) is within the optimal 1-3 range. Ligand B (0.501) is quite low, potentially leading to poor membrane permeability and bioavailability.
**4. H-Bond Donors:** Ligand A (1) and Ligand B (4) are both acceptable, but Ligand A is preferable.
**5. H-Bond Acceptors:** Ligand A (4) and Ligand B (5) are both acceptable.
**6. QED:** Ligand A (0.789) is much better than Ligand B (0.45), indicating a more drug-like profile.
**7. DILI:** Ligand A (5.351) is significantly better than Ligand B (11.128), suggesting a lower risk of liver injury.
**8. BBB:** Ligand A (80.07) is better than Ligand B (34.858), although ADRB2 isn't necessarily a CNS target, some degree of BBB penetration can be useful for distribution.
**9. Caco-2 Permeability:** Ligand A (-4.683) is better than Ligand B (-5.013), indicating better intestinal absorption.
**10. Aqueous Solubility:** Both ligands are similar (-1.956 and -1.866).
**11. hERG Inhibition:** Ligand A (0.818) is better than Ligand B (0.062), indicating a lower risk of cardiotoxicity. This is *very* important for a cardiovascular target.
**12. Microsomal Clearance:** Ligand A (6.215) is much better than Ligand B (28.4), suggesting greater metabolic stability.
**13. In vitro Half-Life:** Ligand A (6.983) is much better than Ligand B (-13.369), indicating a longer half-life.
**14. P-gp Efflux:** Ligand A (0.039) is much better than Ligand B (0.016), indicating lower P-gp efflux.
**15. Binding Affinity:** Ligand A (-6.5) is slightly better than Ligand B (-5.8), but the difference isn't huge.
**Overall Assessment:**
Ligand A is significantly superior to Ligand B across almost all ADME-Tox properties. While both have acceptable molecular weights and similar solubility, Ligand A excels in TPSA, logP, QED, DILI risk, metabolic stability (Cl_mic and t1/2), P-gp efflux, and hERG inhibition. These are all critical factors for a successful drug candidate, especially for a cardiovascular target like ADRB2. The slightly better binding affinity of Ligand A further solidifies its preference. Ligand B's high TPSA, low logP, and poor metabolic stability are major drawbacks.
Output:
1
2025-04-17 21:17:22,793 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (341.382) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (55.4) is significantly better than Ligand B (82.7). ADRB2 is a cardiovascular target, not CNS, but lower TPSA is still preferred for absorption. Ligand B is pushing the upper limit for good oral absorption.
3. **logP:** Both ligands have good logP values (A: 4.072, B: 3.12), falling within the optimal 1-3 range. Ligand A is slightly higher, which could potentially lead to off-target effects, but is not a major concern.
4. **HBD/HBA:** Ligand A (HBD: 1, HBA: 3) is better than Ligand B (HBD: 3, HBA: 3). Lower HBD/HBA generally improves permeability.
5. **QED:** Both ligands have similar QED values (A: 0.806, B: 0.771), indicating good drug-like properties.
6. **DILI:** Ligand B (65.452) has a slightly lower DILI risk than Ligand A (76.115), which is a positive.
7. **BBB:** Ligand A (79.721) has a much higher BBB penetration percentile than Ligand B (44.009). While ADRB2 isn't a CNS target, higher BBB is not necessarily a negative.
8. **Caco-2:** Ligand A (-4.326) and Ligand B (-5.099) both have negative values, which is unusual. Lower (more negative) values indicate poorer permeability. Ligand B is slightly worse.
9. **Solubility:** Ligand A (-5.229) has slightly better solubility than Ligand B (-3.778), though both are poor.
10. **hERG:** Both ligands have very low hERG inhibition risk (A: 0.255, B: 0.208), which is excellent.
11. **Cl_mic:** Ligand B (19.958) has significantly lower microsomal clearance than Ligand A (69.679), indicating better metabolic stability. This is a major advantage.
12. **t1/2:** Ligand B (-4.121) has a longer in vitro half-life than Ligand A (7.812). This is a significant positive.
13. **Pgp:** Both ligands have low P-gp efflux liability (A: 0.396, B: 0.075). Ligand B is better.
14. **Binding Affinity:** Ligand B (-7.3) has a significantly stronger binding affinity than Ligand A (-5.9). This is a substantial advantage, potentially outweighing some ADME drawbacks.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B has a better logP, lower TPSA, better Pgp efflux, and significantly better binding affinity. While Ligand A has better BBB penetration, this is less important for a cardiovascular target. Ligand B's superior metabolic stability (lower Cl_mic and longer t1/2) is also a critical advantage.
**Conclusion:**
Despite Ligand A's slightly better MW and QED, Ligand B's significantly improved binding affinity, metabolic stability, and Pgp profile make it the more promising drug candidate for ADRB2.
Output:
0
2025-04-17 21:17:22,793 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**1. Molecular Weight:** Both ligands (353.463 and 354.491 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand B (78.87) is significantly better than Ligand A (103.94). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally correlates with better absorption.
**3. logP:** Ligand B (1.562) is better than Ligand A (0.641). Both are within the optimal 1-3 range, but Ligand A is a bit low, potentially hindering membrane permeability.
**4. H-Bond Donors:** Both ligands have 2 HBD, which is within the acceptable limit of 5.
**5. H-Bond Acceptors:** Both ligands have 4 HBA, which is within the acceptable limit of 10.
**6. QED:** Both ligands have good QED scores (0.668 and 0.759), indicating generally drug-like properties.
**7. DILI:** Ligand B (16.285) has a slightly higher DILI risk than Ligand A (12.757), but both are well below the concerning threshold of 60.
**8. BBB:** Ligand B (70.609) has a better BBB penetration score than Ligand A (62.35). While not critical for a cardiovascular target, it's a slight advantage.
**9. Caco-2 Permeability:** Ligand A (-5.182) has much better Caco-2 permeability than Ligand B (-4.449). This suggests better intestinal absorption for Ligand A.
**10. Aqueous Solubility:** Ligand A (-1.813) has better aqueous solubility than Ligand B (-1.525).
**11. hERG Inhibition:** Ligand B (0.208) has slightly higher hERG inhibition liability than Ligand A (0.154), but both are reasonably low risk.
**12. Microsomal Clearance:** Ligand A (-4.396) has significantly better metabolic stability (lower clearance) than Ligand B (29.48). This is a major advantage for Ligand A.
**13. In vitro Half-Life:** Ligand A (-1.281) has a better in vitro half-life than Ligand B (-0.75).
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (0.02 and 0.036).
**15. Binding Affinity:** Ligand B (-8.2 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.9 kcal/mol). This is a substantial advantage, exceeding the 1.5 kcal/mol threshold where it can outweigh other factors.
**Overall Assessment:**
Ligand B has a superior binding affinity, which is paramount for GPCR targets. While Ligand A has better ADME properties (Caco-2, solubility, metabolic stability, half-life), the difference in binding affinity is substantial enough to overcome these drawbacks. The slightly higher DILI and hERG risk for Ligand B are acceptable given the much stronger binding. The lower TPSA and better logP of Ligand B are also beneficial.
Output:
0
2025-04-17 21:17:22,793 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.463 and 367.446 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (79.26) is better than Ligand B (91.34). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (2.229) is better than Ligand A (0.727). A logP between 1-3 is optimal, and Ligand B is within this range, while A is slightly below.
4. **HBD:** Both have 2 HBD, which is acceptable.
5. **HBA:** Ligand B (6) is slightly higher than Ligand A (5), but both are within the acceptable limit of 10.
6. **QED:** Both ligands have good QED scores (0.762 and 0.829), indicating good drug-like properties.
7. **DILI:** Ligand A (18.379) has a slightly higher DILI risk than Ligand B (16.014), but both are below the concerning threshold of 60.
8. **BBB:** Ligand A (67.352) has significantly better BBB penetration than Ligand B (36.371). While not a primary concern for a cardiovascular target, it's a slight advantage for A.
9. **Caco-2:** Ligand A (-5.243) is better than Ligand B (-4.548). Higher Caco-2 permeability is preferred.
10. **Solubility:** Ligand A (-1.918) is better than Ligand B (-0.249). Better aqueous solubility is always desirable.
11. **hERG:** Both ligands have low hERG inhibition risk (0.493 and 0.564).
12. **Cl_mic:** Ligand B (3.977) has significantly lower microsomal clearance than Ligand A (16.254), indicating better metabolic stability. This is a significant advantage for B.
13. **t1/2:** Ligand A (18.05) has a better in vitro half-life than Ligand B (-26.137). This is a substantial advantage for A.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.02 and 0.068).
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.6 and -6.0 kcal/mol). The difference is less than the 1.5 kcal/mol threshold.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, and affinity. Ligand B has a better logP and slightly better Pgp. Ligand A has better TPSA. The affinities are very close. However, the significant advantage of Ligand B in metabolic stability (Cl_mic) and the acceptable logP outweigh the slightly better TPSA and half-life of Ligand A.
**Conclusion:**
Considering the balance of properties and the priorities for a GPCR target, Ligand B appears to be the more promising candidate due to its improved metabolic stability.
Output:
0
2025-04-17 21:17:22,793 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
The ADRB2 receptor is a GPCR, so the key priorities are logP, TPSA, Pgp efflux, BBB penetration (though less critical for peripheral ADRB2), and binding affinity. Metabolic stability (Cl_mic, t1/2) and safety (DILI, hERG) are also important.
Let's compare the ligands:
1. **MW:** Both ligands (347.419 and 350.419 Da) fall comfortably within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (107.19) is slightly higher than Ligand B (98.82). Both are acceptable for oral absorption, but B is better.
3. **logP:** Ligand A (-0.026) is slightly negative, which is not ideal. Ligand B (0.085) is closer to the optimal 1-3 range. This favors B.
4. **HBD/HBA:** Ligand A has 3 HBD and 4 HBA, while Ligand B has 2 HBD and 4 HBA. Both are within acceptable limits.
5. **QED:** Ligand A (0.602) has a better QED score than Ligand B (0.455), indicating better overall drug-likeness. This favors A.
6. **DILI:** Both ligands have similar DILI risk (34.781 vs 40.985), both being acceptable.
7. **BBB:** Ligand B (65.452) has significantly better BBB penetration than Ligand A (40.016). While ADRB2 isn't necessarily a CNS target, some peripheral exposure can be beneficial, and higher BBB is generally a positive attribute.
8. **Caco-2:** Ligand B (-4.944) has a better Caco-2 permeability than Ligand A (-5.652).
9. **Solubility:** Both ligands have poor solubility (-1.691 vs -1.782). This is a concern for both, but not a deciding factor.
10. **hERG:** Both ligands have very low hERG risk (0.059 vs 0.062).
11. **Cl_mic:** Ligand A (-26.871) has a lower (better) microsomal clearance than Ligand B (-7.233). This suggests better metabolic stability for A.
12. **t1/2:** Ligand A (-24.575) has a longer in vitro half-life than Ligand B (-8.623). This is a significant advantage for A.
13. **Pgp:** Both ligands have very low Pgp efflux (0.007 vs 0.006).
14. **Binding Affinity:** Ligand A (-7.6 kcal/mol) has a significantly better binding affinity than Ligand B (-5.4 kcal/mol). This is a substantial advantage, exceeding the 1.5 kcal/mol threshold.
**Overall Assessment:**
Ligand A has a significantly stronger binding affinity and better metabolic stability (lower Cl_mic, longer t1/2). While Ligand B has slightly better TPSA, logP, and BBB penetration, the difference in binding affinity is substantial enough to outweigh these minor advantages. The slightly better QED score for A also contributes to its favorability. The solubility is a concern for both, but can be addressed with formulation strategies.
**Output:**
1
2025-04-17 21:17:22,793 - INFO - Batch 247 complete. Total preferences: 3952
2025-04-17 21:17:22,793 - INFO - Processing batch 248/512...
2025-04-17 21:18:10,460 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (357.376) is slightly higher than Ligand B (345.447), but both are acceptable.
2. **TPSA:** Ligand A (44.81) is well below the 140 threshold and good for oral absorption. Ligand B (88.91) is higher, but still within a reasonable range, though less optimal.
3. **logP:** Ligand A (3.047) is optimal. Ligand B (1.467) is a bit low, potentially hindering membrane permeability.
4. **HBD:** Both ligands have acceptable HBD counts (Ligand A: 1, Ligand B: 2).
5. **HBA:** Both ligands have acceptable HBA counts (Ligand A: 3, Ligand B: 5).
6. **QED:** Both ligands have good QED scores (Ligand A: 0.728, Ligand B: 0.817), indicating good drug-like properties.
7. **DILI:** Ligand A (42.924) has a slightly higher DILI risk than Ligand B (32.067), but both are below the concerning threshold of 60.
8. **BBB:** Ligand A (78.054) has a better BBB penetration score than Ligand B (50.097). While ADRB2 isn't strictly a CNS target, some peripheral ADRB2 activity can have CNS effects, and better BBB penetration isn't necessarily detrimental.
9. **Caco-2:** Ligand A (-4.474) has a worse Caco-2 permeability than Ligand B (-5.396). Both are negative, which indicates poor permeability.
10. **Solubility:** Ligand A (-3.087) has a worse solubility than Ligand B (-2.012). Both are negative, which indicates poor solubility.
11. **hERG:** Ligand A (0.857) has a slightly higher hERG risk than Ligand B (0.078), which is preferable.
12. **Cl_mic:** Ligand A (35.309) has a higher microsomal clearance than Ligand B (11.63), indicating lower metabolic stability.
13. **t1/2:** Ligand B (12.312) has a significantly longer in vitro half-life than Ligand A (4.183). This is a major advantage.
14. **Pgp:** Ligand A (0.092) has a lower P-gp efflux liability than Ligand B (0.011), which is preferable.
15. **Binding Affinity:** Ligand B (-6.6 kcal/mol) has a stronger binding affinity than Ligand A (-5.8 kcal/mol). This is a significant advantage (0.8 kcal/mol difference).
**GPCR-specific priorities:** For GPCRs, logP, Pgp, TPSA, and affinity are key. Ligand B has a better affinity, lower Pgp efflux, and a more favorable logP. While Ligand A has a better BBB score, the affinity difference and metabolic stability (longer half-life) of Ligand B outweigh this benefit. The TPSA of Ligand A is better, but not enough to compensate for the other factors.
**Conclusion:**
Ligand B is the more promising candidate due to its superior binding affinity, longer half-life, and better logP, despite its slightly higher TPSA.
Output:
0
2025-04-17 21:18:10,460 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [346.402, 60.85, 2.098, 1, 3, 0.85, 31.989, 76.231, -4.549, -3.138, 0.341, 55.395, -36.796, 0.159, -6.4]
**Ligand B:** [357.307, 69.22, 3.673, 2, 3, 0.775, 62.233, 54.556, -4.975, -3.959, 0.727, 71.341, -31.195, 0.391, -4.9]
Here's a breakdown, prioritizing GPCR-relevant properties (logP, TPSA, Pgp, BBB, Affinity):
1. **Molecular Weight:** Both are within the ideal 200-500 Da range. A (346.4) is slightly preferred.
2. **TPSA:** A (60.85) is better than B (69.22), falling comfortably under the 140 threshold for oral absorption.
3. **logP:** A (2.098) is optimal, while B (3.673) is approaching the upper limit. This favors A.
4. **H-Bond Donors/Acceptors:** Both have reasonable HBD (1/2) and HBA (3/3) counts.
5. **QED:** A (0.85) is better than B (0.775), indicating a more drug-like profile.
6. **DILI:** A (31.989) has a significantly lower DILI risk than B (62.233). This is a major advantage for A.
7. **BBB:** A (76.231) has a better BBB penetration potential than B (54.556). While ADRB2 isn't a CNS target, some distribution into the CNS is possible and not necessarily detrimental.
8. **Caco-2:** Both are negative, indicating poor permeability. B (-4.975) is slightly worse than A (-4.549).
9. **Solubility:** Both are negative, indicating poor solubility. B (-3.959) is slightly worse than A (-3.138).
10. **hERG:** Both are low risk (0.341 and 0.727).
11. **Cl_mic:** A (55.395) has lower clearance than B (71.341), suggesting better metabolic stability.
12. **t1/2:** A (-36.796) has a longer half-life than B (-31.195).
13. **Pgp:** A (0.159) has lower P-gp efflux than B (0.391), which is favorable for bioavailability.
14. **Binding Affinity:** A (-6.4) has a slightly better binding affinity than B (-4.9). This is a 1.5 kcal/mol difference, which is significant.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical parameters. It has better predicted ADME properties (lower DILI, better BBB, lower clearance, longer half-life, lower Pgp efflux), a more favorable logP, and a slightly better binding affinity. While both have poor Caco-2 and solubility, A is still better in these aspects. The significantly lower DILI risk for Ligand A is a crucial factor.
Therefore, I would choose Ligand A.
Output:
1
2025-04-17 21:18:10,460 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (353.463 and 347.459 Da) are within the ideal range of 200-500 Da. No significant difference here.
2. **TPSA:** Both ligands (87.74 and 84.23) are below the 140 A^2 threshold for good oral absorption, and acceptable for a non-CNS GPCR target like ADRB2. Ligand B is slightly better.
3. **logP:** Ligand A (0.683) is a bit low, potentially impacting permeability. Ligand B (3.001) is optimal. This is a significant advantage for Ligand B.
4. **HBD:** Both ligands have 2 HBD, which is within the acceptable limit of <=5.
5. **HBA:** Both ligands have 4 HBA, which is within the acceptable limit of <=10.
6. **QED:** Both ligands have good QED scores (0.705 and 0.857), indicating good drug-like properties. Ligand B is better.
7. **DILI:** Both ligands have acceptable DILI risk (11.361 and 58.434 percentile). Ligand B is better.
8. **BBB:** Both ligands have moderate BBB penetration (60.644 and 65.839 percentile). This isn't a high priority for ADRB2, but Ligand B is slightly better.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.056 and -4.615). These values are unusual and suggest poor permeability. This is a concern for both.
10. **Solubility:** Both ligands have negative solubility values (-1.482 and -3.844). These values are also unusual and suggest poor solubility. This is a concern for both.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.198 and 0.151 percentile), which is excellent.
12. **Cl_mic:** Ligand A has a much lower (better) microsomal clearance (-11.218 mL/min/kg) than Ligand B (55.206 mL/min/kg). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A has a slightly shorter in vitro half-life (-1.65 hours) than Ligand B (-22.241 hours). This is a significant advantage for Ligand B.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.01 and 0.133 percentile), which is excellent.
15. **Binding Affinity:** Ligand B (-7.1 kcal/mol) has a slightly better binding affinity than Ligand A (-7.7 kcal/mol). While the difference is small, it's still a positive for Ligand B.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand B excels in logP and has slightly better affinity, TPSA, and BBB. Ligand A has better metabolic stability (Cl_mic). However, the solubility and Caco-2 values are concerning for both. The better logP and affinity of Ligand B, combined with its better DILI and half-life, outweigh the metabolic stability advantage of Ligand A.
**Final Decision:**
0
2025-04-17 21:18:10,460 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
The ADRB2 receptor is a GPCR involved in cardiovascular function. Therefore, I will prioritize logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB. Metabolic stability (Cl_mic, t1/2) and safety (DILI, hERG) are also important considerations.
Let's compare the ligands property by property:
1. **MW:** Both ligands (349.431 and 384.248 Da) are within the ideal range (200-500 Da).
2. **TPSA:** Ligand A (84.67) is slightly higher than Ligand B (78.87), but both are well below the 140 threshold for good oral absorption.
3. **logP:** Ligand A (1.978) is optimal, while Ligand B (0.401) is a bit low, potentially hindering membrane permeability. This is a significant advantage for Ligand A.
4. **HBD/HBA:** Ligand A (1 HBD, 5 HBA) and Ligand B (2 HBD, 4 HBA) are both reasonable.
5. **QED:** Both ligands have acceptable QED scores (0.776 and 0.65).
6. **DILI:** Ligand A (28.306) has a lower DILI risk than Ligand B (35.479), which is preferable.
7. **BBB:** Ligand A (76.58) has better BBB penetration potential than Ligand B (64.831), although this is less critical for a cardiovascular target.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. This is a concern for both.
9. **Solubility:** Both have negative solubility values, indicating poor aqueous solubility. This is a significant drawback for both.
10. **hERG:** Ligand A (0.17) has a much lower hERG inhibition liability than Ligand B (0.474), a crucial safety advantage.
11. **Cl_mic:** Ligand B (-13.206) has significantly better metabolic stability (lower clearance) than Ligand A (53.474). This is a strong point for Ligand B.
12. **t1/2:** Ligand B (-20.833) has a much longer in vitro half-life than Ligand A (11.56), further supporting its better metabolic stability.
13. **Pgp:** Ligand A (0.066) has lower P-gp efflux liability than Ligand B (0.018), which is favorable for bioavailability.
14. **Binding Affinity:** Ligand B (-6.9 kcal/mol) has slightly better binding affinity than Ligand A (-6.1 kcal/mol), but the difference is not substantial enough to overcome other drawbacks.
**Overall Assessment:**
Ligand A demonstrates a better balance of properties, particularly regarding logP, DILI, hERG, and Pgp efflux. While Ligand B has superior metabolic stability (Cl_mic, t1/2), the poor logP and higher hERG risk are significant concerns. The slight difference in binding affinity is not enough to offset these drawbacks. The poor Caco-2 and solubility for both compounds are concerning and would require further optimization, but Ligand A's other properties make it a more promising starting point.
**Output:**
1
2025-04-17 21:18:10,460 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (362.817 and 343.427 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (105.39 and 102.22) are reasonably low, suggesting good potential for absorption, although slightly above the optimal <90 for CNS targets (less relevant for ADRB2, a cardiovascular target).
3. **logP:** Ligand A (0.955) is a bit low, potentially hindering permeation. Ligand B (1.878) is better, falling comfortably within the 1-3 range. This is a slight advantage for B.
4. **HBD:** Ligand A (2) and Ligand B (3) are both acceptable, below the threshold of 5.
5. **HBA:** Both ligands (4) are well below the 10 threshold.
6. **QED:** Both ligands (0.601 and 0.637) are good, indicating drug-like properties.
7. **DILI:** Ligand A (46.297) has a slightly higher DILI risk than Ligand B (38.852), but both are below the concerning 60 threshold.
8. **BBB:** Both ligands have relatively low BBB penetration (59.636 and 54.44). This isn't a major concern for a cardiovascular target like ADRB2.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. This is a significant drawback for both.
10. **Solubility:** Both ligands have negative solubility values, which is also unusual and suggests poor aqueous solubility. This is a significant drawback for both.
11. **hERG:** Ligand A (0.131) has a lower hERG risk than Ligand B (0.432), which is a positive.
12. **Cl_mic:** Ligand A (-11.347) has significantly *lower* (better) microsomal clearance than Ligand B (25.146), indicating greater metabolic stability. This is a significant advantage for A.
13. **t1/2:** Ligand A (-11.995) has a longer in vitro half-life than Ligand B (-8.341), which is also favorable.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.019 and 0.071).
15. **Binding Affinity:** Both ligands have the same binding affinity (-6.4 kcal/mol).
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand B has a better logP. However, the significantly better metabolic stability (Cl_mic and t1/2) and lower hERG risk of Ligand A outweigh the slight logP advantage of Ligand B. The negative Caco-2 and solubility values are concerning for both, but can be addressed with formulation strategies.
**Conclusion:**
Considering the balance of properties, particularly the improved metabolic stability and reduced hERG risk, Ligand A is the more promising drug candidate.
Output:
1
2025-04-17 21:18:10,460 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (353.419 and 348.447 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (98.66) is better than Ligand B (103.09) as it is closer to the <140 threshold for good oral absorption.
3. **logP:** Ligand B (1.336) is better than Ligand A (0.157). A logP between 1-3 is optimal, and Ligand A is quite low, potentially hindering permeability.
4. **HBD:** Ligand A (2) is preferable to Ligand B (4). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (6) is preferable to Ligand B (3). Fewer HBAs generally improve permeability.
6. **QED:** Both ligands have acceptable QED values (0.584 and 0.513, respectively), indicating good drug-like properties.
7. **DILI:** Ligand B (31.601) has a lower DILI risk than Ligand A (35.983), which is favorable.
8. **BBB:** Ligand B (57.464) is better than Ligand A (50.679), but both are not high enough to be considered CNS-penetrant. However, for a cardiovascular target, BBB penetration is less critical.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.318 and -5.256), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand A (-0.614) has better solubility than Ligand B (-2.833). Solubility is important for bioavailability.
11. **hERG:** Both ligands show very low hERG inhibition risk (0.105 and 0.134), which is excellent.
12. **Cl_mic:** Ligand B (5.178) has significantly lower microsomal clearance than Ligand A (44.171), indicating better metabolic stability.
13. **t1/2:** Ligand B (-9.332) has a longer in vitro half-life than Ligand A (8.074), which is desirable.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.051 and 0.013).
15. **Binding Affinity:** Ligand B (-5.4) has a slightly better binding affinity than Ligand A (-4.6), a difference of 0.8 kcal/mol.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP and has a slightly better affinity. While both have low Pgp, the lower TPSA of Ligand A is a plus. However, the significantly better metabolic stability (lower Cl_mic and longer t1/2) of Ligand B, combined with the slightly better affinity, outweighs the TPSA advantage of Ligand A. The poor Caco-2 values for both are concerning, but the improved ADME profile of Ligand B makes it more promising.
**Conclusion:**
Considering the balance of properties and the priorities for a GPCR target, Ligand B is the more viable drug candidate.
Output:
0
2025-04-17 21:18:10,460 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.427 and 365.43 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (56.1) is significantly better than Ligand B (81.06). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (3.131 and 1.911, respectively) within the optimal 1-3 range. Ligand A is slightly higher, which *could* be beneficial for membrane permeability, but isn't a major concern for either.
4. **HBD:** Both have 1 HBD, which is acceptable.
5. **HBA:** Ligand A has 6 HBA, and Ligand B has 5. Both are within the acceptable limit of 10.
6. **QED:** Both ligands have good QED scores (0.792 and 0.897), indicating good drug-likeness. Ligand B is slightly better.
7. **DILI:** Ligand A (47.421) has a considerably lower DILI risk than Ligand B (71.772). This is a significant advantage for Ligand A.
8. **BBB:** Both have reasonable BBB penetration (73.594 and 79.062). Not a major factor for a cardiovascular target.
9. **Caco-2:** Both have negative Caco-2 values (-4.589 and -4.716), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Both have negative solubility values (-3.186 and -3.293), which is also concerning. Poor solubility could hinder bioavailability.
11. **hERG:** Ligand A (0.862) has a slightly higher hERG risk than Ligand B (0.401). This is a negative for Ligand A.
12. **Cl_mic:** Ligand A (17.123) has a slightly higher microsomal clearance than Ligand B (15.257), indicating potentially lower metabolic stability.
13. **t1/2:** Ligand B (66.987) has a longer in vitro half-life than Ligand A (52.893), which is desirable.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.194 and 0.336), which is good.
15. **Binding Affinity:** Ligand A (-6.7 kcal/mol) has a slightly better binding affinity than Ligand B (-6.1 kcal/mol). This 0.6 kcal/mol difference is significant, potentially outweighing some ADME drawbacks.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, and affinity are key. Ligand A has a better TPSA and slightly better affinity. While both have acceptable logP values, the difference in DILI risk is substantial, and the affinity difference is also notable. The negative Caco-2 and solubility values are concerning for both, but can be addressed with formulation strategies.
**Overall Assessment:**
Despite the slightly higher hERG and Cl_mic for Ligand A, its significantly lower DILI risk and better binding affinity make it the more promising candidate. The affinity advantage is likely to be more impactful than the minor ADME differences, and the DILI risk is a critical safety consideration.
Output:
1
2025-04-17 21:18:10,461 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.49 & 368.47 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (58.64) is better than Ligand B (62.13). Both are below the 140 threshold for oral absorption, but lower is generally preferred for GPCRs.
3. **logP:** Ligand A (2.657) is better than Ligand B (3.556). Both are within the optimal 1-3 range, but ligand B is approaching the upper limit where solubility issues might arise.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 3 HBA, while Ligand B has 5. Ligand A is preferable here, as lower HBA generally improves permeability.
6. **QED:** Ligand A (0.803) is slightly better than Ligand B (0.762), indicating a more drug-like profile.
7. **DILI:** Ligand A (15.86%) is significantly better than Ligand B (23.89%). Lower DILI risk is crucial.
8. **BBB:** Ligand A (78.44%) is significantly better than Ligand B (53.35%). While ADRB2 isn't exclusively a CNS target, some CNS penetration can be beneficial, and minimizing off-target effects is always good.
9. **Caco-2:** Ligand A (-4.742) is better than Ligand B (-5.027). Higher (less negative) Caco-2 values indicate better absorption.
10. **Solubility:** Ligand A (-2.453) is better than Ligand B (-3.52). Better solubility is always desirable for bioavailability.
11. **hERG:** Ligand A (0.436) is better than Ligand B (0.657). Lower hERG inhibition is critical for avoiding cardiotoxicity, especially important for a cardiovascular target like ADRB2.
12. **Cl_mic:** Ligand A (63.03) is better than Ligand B (81.61). Lower clearance suggests better metabolic stability.
13. **t1/2:** Ligand A (-2.273) is better than Ligand B (-0.045). A longer in vitro half-life is generally preferred.
14. **Pgp:** Ligand A (0.106) is better than Ligand B (0.275). Lower P-gp efflux is beneficial for bioavailability.
15. **Binding Affinity:** Ligand B (-8.5 kcal/mol) is slightly better than Ligand A (-7.6 kcal/mol). This is a 0.9 kcal/mol difference, which is significant, but not overwhelming given the other factors.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical ADME-Tox properties (DILI, BBB, solubility, hERG, Cl_mic, Pgp, Caco-2). While Ligand B has a slightly better binding affinity, the superior overall profile of Ligand A, particularly its lower toxicity risk and better predicted absorption/distribution, makes it the more promising drug candidate. The difference in affinity is not large enough to overcome the substantial advantages of Ligand A in other areas.
Output:
1
2025-04-17 21:18:10,461 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (349.5 and 344.4 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (61.44) is significantly better than Ligand B (95.14). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand B's TPSA is quite high, potentially hindering oral bioavailability.
3. **logP:** Ligand A (2.45) is optimal, while Ligand B (0.783) is a bit low. A logP below 1 can sometimes indicate poor membrane permeability.
4. **HBD:** Ligand A (2) is reasonable. Ligand B (0) is also acceptable, but might impact aqueous solubility.
5. **HBA:** Ligand A (3) is good. Ligand B (8) is higher, potentially impacting permeability.
6. **QED:** Both ligands (0.672 and 0.744) have good drug-likeness scores, exceeding the 0.5 threshold.
7. **DILI:** Ligand A (16.402) has a much lower DILI risk than Ligand B (73.517). This is a significant advantage for Ligand A.
8. **BBB:** Both ligands have similar BBB penetration (65.6 and 67.2). Not a major differentiating factor for a cardiovascular target.
9. **Caco-2:** Ligand A (-5.176) is better than Ligand B (-4.625) suggesting better intestinal absorption.
10. **Solubility:** Ligand A (-2.658) is better than Ligand B (-2.299), indicating better aqueous solubility.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.402 and 0.052).
12. **Cl_mic:** Ligand A (26.358) has a lower microsomal clearance than Ligand B (40.018), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-7.467) has a longer in vitro half-life than Ligand A (-0.37). This is a positive for Ligand B, but the difference is substantial.
14. **Pgp:** Ligand A (0.097) has lower P-gp efflux liability than Ligand B (0.041), which is favorable.
15. **Binding Affinity:** Ligand B (-7.0) has a slightly better binding affinity than Ligand A (-6.7). However, the difference is less than 1.5 kcal/mol, and other factors are more important.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A performs better on logP, TPSA, and Pgp. The affinity difference is small.
**Overall Assessment:**
Ligand A is the stronger candidate. While Ligand B has a slightly better binding affinity and in vitro half-life, Ligand A excels in crucial ADME properties like TPSA, logP, solubility, DILI risk, and metabolic stability. The lower DILI risk is a particularly important advantage. The combination of these factors makes Ligand A more likely to translate into a viable drug candidate.
Output:
1
2025-04-17 21:18:10,461 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (361.389 and 351.451 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (70.16) is significantly better than Ligand B (90.7). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (-0.009) is slightly lower than Ligand B (0.433), but both are within the acceptable 1-3 range. Ligand B is slightly preferred.
4. **HBD:** Ligand A (0) is better than Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is better than Ligand B (6). Lower HBA is generally preferred.
6. **QED:** Both ligands have good QED scores (0.667 and 0.776), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Both ligands have low DILI risk (32.842 and 29.236), which is excellent. Ligand B is slightly better.
8. **BBB:** Ligand A (76.347) has a much higher BBB percentile than Ligand B (39.24). While not a primary concern for a cardiovascular target, higher BBB is rarely detrimental.
9. **Caco-2:** Ligand A (-4.441) is better than Ligand B (-5.2). Higher Caco-2 values indicate better intestinal absorption.
10. **Solubility:** Ligand A (-0.655) is better than Ligand B (-1.215). Better solubility is important for bioavailability.
11. **hERG:** Both ligands have very low hERG risk (0.141 and 0.312). Excellent for both.
12. **Cl_mic:** Ligand A (17.426) is worse than Ligand B (-0.591). Lower clearance is better for metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand A (0.184) is worse than Ligand B (-3.535). Longer half-life is generally preferred. This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.025) is better than Ligand B (0.015). Lower P-gp efflux is better.
15. **Affinity:** Both ligands have excellent binding affinity (-5.4 and -5.8 kcal/mol). Ligand B is slightly better.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has a better TPSA and Pgp, but Ligand B has a slightly better logP and affinity. The metabolic stability (Cl_mic and t1/2) of Ligand B is significantly better.
**Overall Assessment:**
While Ligand A has some advantages in TPSA and Pgp, Ligand B demonstrates a more favorable balance of properties, particularly regarding metabolic stability (Cl_mic and t1/2) and a slightly better affinity. The slightly better solubility and DILI risk of Ligand B also contribute to its overall profile.
Output:
0
2025-04-17 21:18:10,461 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (344.499 and 346.387 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (49.41) is significantly better than Ligand B (109.3). ADRB2 is a cardiovascular target, not CNS, but lower TPSA generally improves absorption. Ligand A is well below the 140 threshold, while B is approaching it.
3. **logP:** Ligand A (3.588) is optimal, while Ligand B (-0.8) is quite low. This is a major concern for B, as it may struggle with membrane permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (2) is preferable to Ligand B (5). Similar reasoning as HBD.
6. **QED:** Both ligands (0.65 and 0.626) are good, exceeding the 0.5 threshold.
7. **DILI:** Ligand A (12.679) is significantly better than Ligand B (39.511). Lower DILI risk is always preferred.
8. **BBB:** Ligand A (70.143) is better than Ligand B (46.84), but this is less critical for a cardiovascular target.
9. **Caco-2:** Ligand A (-4.901) is better than Ligand B (-5.535). Both are negative, indicating good permeability.
10. **Solubility:** Ligand A (-3.157) is better than Ligand B (-1.904). Both are negative, indicating good solubility.
11. **hERG:** Ligand A (0.347) is much better than Ligand B (0.023). Lower hERG inhibition is crucial to avoid cardiotoxicity.
12. **Cl_mic:** Ligand A (54.702) is worse than Ligand B (-9.834). B has a negative value, indicating very good metabolic stability.
13. **t1/2:** Ligand A (-12.169) is worse than Ligand B (-0.896). B has a better in vitro half-life.
14. **Pgp:** Ligand A (0.133) is better than Ligand B (0.008). Lower P-gp efflux is preferred.
15. **Binding Affinity:** Ligand B (-7.0) is slightly better than Ligand A (-6.8). While a 1.5 kcal/mol difference is usually significant, the numerous ADME advantages of Ligand A outweigh this.
**Overall Assessment:**
Ligand A demonstrates a significantly better ADME profile. Its lower TPSA, optimal logP, fewer H-bonds, lower DILI risk, and much lower hERG inhibition liability are all strong advantages. While Ligand B has better metabolic stability and a slightly higher binding affinity, the potential for poor permeability (low logP) and cardiotoxicity (high hERG) make it a less desirable candidate. For a cardiovascular GPCR target, a balanced profile with good safety margins is paramount, and Ligand A provides this.
Output:
1
2025-04-17 21:18:10,461 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (351.407 and 349.387 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (127.63) is slightly higher than Ligand B (96.02). For a cardiovascular GPCR, TPSA is not a *critical* factor like it would be for a CNS target, but lower is generally preferred for absorption. Ligand B has a clear advantage.
3. **logP:** Ligand A (0.744) is within the optimal range (1-3), but on the lower side. Ligand B (-0.411) is slightly below 1, which could potentially hinder permeation. Ligand A is preferred here.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable, staying below the 5 threshold. Ligand B is slightly better.
5. **HBA:** Both ligands (5) are within the acceptable range of 10. No significant difference.
6. **QED:** Ligand B (0.696) has a better QED score than Ligand A (0.275), indicating a more drug-like profile. This is a significant advantage for Ligand B.
7. **DILI:** Ligand A (29.779) has a significantly lower DILI risk than Ligand B (41.799). This is a substantial advantage for Ligand A.
8. **BBB:** Both are low, as expected for a cardiovascular target. Ligand B (46.297) is slightly higher, but neither is a priority.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.951 and -4.91), which is unusual and suggests poor permeability. This is a concern for both, but not a deciding factor between them.
10. **Solubility:** Both ligands have negative solubility values (-1.534 and -1.219), indicating poor aqueous solubility. This is a concern for both, but not a deciding factor.
11. **hERG:** Both ligands have very low hERG risk (0.072 and 0.058). No significant difference.
12. **Cl_mic:** Ligand A (5.511) has a significantly lower microsomal clearance than Ligand B (10.469), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (-6.247) has a more negative in vitro half-life than Ligand B (3.66), suggesting a shorter half-life. Ligand B is preferred here.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.02 and 0.005). No significant difference.
15. **Binding Affinity:** Ligand A (-6.9 kcal/mol) has a slightly better binding affinity than Ligand B (-6.0 kcal/mol). While the difference is less than the 1.5 kcal/mol threshold, it's still a positive for Ligand A.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand A has a better logP, and slightly better affinity. Ligand B has a lower TPSA and better QED. The metabolic stability (Cl_mic) of Ligand A is also a significant advantage. The DILI risk is also much lower for Ligand A.
**Overall Assessment:**
While Ligand B has a better QED and slightly better half-life, Ligand A demonstrates a superior safety profile (lower DILI), better metabolic stability (lower Cl_mic), and a slightly better binding affinity. The slightly lower TPSA of Ligand B is beneficial, but the other advantages of Ligand A outweigh this. The poor solubility and Caco-2 values are concerning for both, but can be addressed with formulation strategies.
Output:
1
2025-04-17 21:18:10,461 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (345.443 and 346.471 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (71.53) is slightly higher than Ligand B (58.64). For a cardiovascular GPCR, TPSA is moderately important. Ligand B's lower TPSA is favorable for permeability.
**3. logP:** Both ligands have good logP values (2.135 and 2.431), falling within the optimal 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability, but not dramatically so.
**4. H-Bond Donors:** Both have 1 HBD, which is within the acceptable limit of <=5.
**5. H-Bond Acceptors:** Ligand A has 4 HBAs, and Ligand B has 3. Both are within the acceptable limit of <=10.
**6. QED:** Ligand A (0.857) has a higher QED than Ligand B (0.796), suggesting a more drug-like profile overall. This is a positive for Ligand A.
**7. DILI Risk:** Ligand B (36.681) has a significantly lower DILI risk than Ligand A (12.408). This is a major advantage for Ligand B, as minimizing liver toxicity is crucial.
**8. BBB Penetration:** Both ligands have good BBB penetration (78.054 and 75.107). While not a primary concern for a cardiovascular target, it's not detrimental.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.59 and -4.592). These values are unusual and suggest poor permeability. However, the scale is not specified, so it's difficult to interpret.
**10. Aqueous Solubility:** Ligand A (-1.878) has better aqueous solubility than Ligand B (-3.163). Solubility is important for formulation and bioavailability.
**11. hERG Inhibition:** Ligand A (0.149) has a lower hERG inhibition risk than Ligand B (0.327), which is a positive.
**12. Microsomal Clearance:** Ligand A (21.874) has lower microsomal clearance than Ligand B (27.452), indicating better metabolic stability.
**13. In vitro Half-Life:** Ligand A (-20.279) has a much longer in vitro half-life than Ligand B (2.593). This is a significant advantage for Ligand A, potentially allowing for less frequent dosing.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.029 and 0.14).
**15. Binding Affinity:** Ligand B (-7.9 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.7 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME drawbacks. A 2.2 kcal/mol difference is quite large.
**Overall Assessment:**
Given the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), the stronger binding affinity of Ligand B is the most compelling factor. While Ligand A has better QED, solubility, metabolic stability, and half-life, the substantial difference in binding affinity (-7.9 vs -5.7 kcal/mol) is likely to be the most important determinant of *in vivo* efficacy. The lower DILI risk of Ligand B is also a significant benefit. The similar TPSA values and acceptable logP values for both compounds support this decision.
Output:
0
2025-04-17 21:18:10,461 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (a cardiovascular GPCR) drug candidates.
**Ligand A:** [346.387, 128.16 , -0.459, 3. , 5. , 0.575, 37.456, 35.44 ,
-5.668, -2.107, 0.051, -16.242, 10.779, 0.003, -8.5 ]
**Ligand B:** [356.551, 58.64 , 3.616, 1. , 4. , 0.608, 17.604, 57.619,
-4.556, -3.854, 0.627, 114.137, 17.084, 0.079, -5.9 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). A (346.39) is slightly preferred.
2. **TPSA:** A (128.16) is better than B (58.64). For a cardiovascular GPCR, lower TPSA is generally favorable for permeability.
3. **logP:** A (-0.459) is less ideal than B (3.616). B is within the optimal 1-3 range, while A is a bit low, potentially hindering membrane permeability.
4. **HBD:** A (3) is slightly higher than B (1), but both are acceptable.
5. **HBA:** A (5) is slightly higher than B (4), but both are acceptable.
6. **QED:** Both are good (A: 0.575, B: 0.608), indicating drug-like properties. B is slightly better.
7. **DILI:** A (37.46) is significantly better than B (17.60). Lower DILI risk is crucial.
8. **BBB:** B (57.62) is better than A (35.44). While not a primary concern for a cardiovascular target, some CNS exposure can sometimes be relevant or indicate off-target effects.
9. **Caco-2:** A (-5.668) is worse than B (-4.556). Higher Caco-2 is better, meaning B has better intestinal absorption.
10. **Solubility:** A (-2.107) is better than B (-3.854). Better solubility is generally preferred.
11. **hERG:** A (0.051) is better than B (0.627). Lower hERG inhibition is critical for avoiding cardiotoxicity.
12. **Cl_mic:** A (-16.242) is *much* better than B (114.137). A has significantly better metabolic stability.
13. **t1/2:** B (17.084) is better than A (10.779). Longer half-life is generally preferred.
14. **Pgp:** A (0.003) is *much* better than B (0.079). Lower P-gp efflux is favorable for bioavailability.
15. **Affinity:** A (-8.5) is better than B (-5.9). A has a significantly stronger binding affinity.
**GPCR-Specific Priorities:** For ADRB2 (a cardiovascular GPCR), we prioritize logP, Pgp, TPSA, and affinity.
**Overall Assessment:**
Ligand A has a significantly better binding affinity, lower DILI risk, better metabolic stability (Cl_mic), and lower P-gp efflux. While its logP is suboptimal, the substantial advantage in binding affinity (-8.5 vs -5.9 kcal/mol) and the critical safety advantages (DILI, hERG, Cl_mic, Pgp) outweigh this drawback. Ligand B has better logP and Caco-2 permeability, but the higher DILI, hERG, and Pgp efflux liabilities, along with weaker affinity, make it a less desirable candidate.
Therefore, I prefer Ligand A.
Output:
1
2025-04-17 21:18:10,461 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
We're targeting ADRB2, a GPCR. Therefore, the most important parameters are binding affinity, logP, TPSA, Pgp efflux, and BBB penetration. Metabolic stability (Cl_mic, t1/2) and safety (DILI, hERG) are also crucial.
Let's compare the ligands:
1. **Molecular Weight:** Both ligands (351.447 and 351.437 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (91.76) is higher than Ligand B (29.54). Ligand B is significantly better here, falling well below the 140 threshold for good absorption, and closer to the ideal for GPCRs.
3. **logP:** Ligand A (1.737) is within the optimal 1-3 range. Ligand B (4.299) is slightly high, potentially leading to solubility issues and off-target effects.
4. **H-Bond Donors:** Ligand A (2) is reasonable. Ligand B (0) is also good, potentially improving membrane permeability.
5. **H-Bond Acceptors:** Ligand A (5) is good. Ligand B (2) is also good.
6. **QED:** Both ligands have good QED scores (0.627 and 0.733), indicating good drug-like properties.
7. **DILI:** Ligand A (20.9) has a lower DILI risk than Ligand B (15.51), which is preferable.
8. **BBB:** Ligand B (97.131) has significantly better BBB penetration than Ligand A (54.052). This is a major advantage for a GPCR target, even if not strictly CNS-focused.
9. **Caco-2:** Ligand A (-4.864) and Ligand B (-4.399) are both negative, which is unusual. Lower (more negative) values suggest poor permeability.
10. **Solubility:** Ligand A (-1.414) is better than Ligand B (-4.015). Solubility is a concern for Ligand B due to its higher logP.
11. **hERG:** Ligand A (0.557) has a lower hERG risk than Ligand B (0.867).
12. **Cl_mic:** Ligand A (35.544) has lower microsomal clearance, indicating better metabolic stability than Ligand B (78.195).
13. **t1/2:** Ligand A (-22.31) has a negative half-life, which is not possible. Ligand B (-0.165) is also negative, indicating a problem with the data.
14. **Pgp:** Ligand A (0.065) has lower P-gp efflux, which is favorable for bioavailability. Ligand B (0.586) has higher P-gp efflux.
15. **Binding Affinity:** Ligand A (-7.6) has a slightly better binding affinity than Ligand B (-6.5). This is a 1.1 kcal/mol difference, which is significant.
**Overall Assessment:**
Ligand A has a better binding affinity, lower DILI risk, lower hERG risk, better metabolic stability, and lower Pgp efflux. However, Ligand B has a much lower TPSA and significantly better BBB penetration. The negative half-life values are concerning for both compounds and suggest data quality issues. Considering the GPCR-specific priorities, the lower TPSA and improved BBB penetration of Ligand B are very attractive. The slightly higher logP of Ligand B is a concern, but the better TPSA and BBB outweigh this. The affinity difference is significant, but not overwhelming.
Output:
0
2025-04-17 21:18:10,461 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (339.414 and 344.415 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (46.09) is significantly better than Ligand B (96.25). ADRB2 is a cardiovascular target, not a CNS target, but lower TPSA generally improves absorption. Ligand B is quite high, potentially hindering oral bioavailability.
3. **logP:** Ligand A (3.951) is at the upper end of the optimal range (1-3), while Ligand B (1.202) is at the lower end. For a GPCR, a slightly higher logP can be beneficial for membrane interactions, but Ligand B is perhaps *too* hydrophilic.
4. **HBD:** Ligand A (0) is preferable to Ligand B (3). Fewer hydrogen bond donors generally correlate with better membrane permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (5). Similar reasoning as HBD.
6. **QED:** Both ligands (0.828 and 0.734) have good drug-likeness scores, exceeding the 0.5 threshold.
7. **DILI:** Ligand A (45.677) has a lower DILI risk than Ligand B (55.68), which is preferable. Both are reasonably low.
8. **BBB:** Ligand A (96.084) has a much higher BBB penetration percentile than Ligand B (16.983). While ADRB2 isn't a primary CNS target, some degree of BBB penetration isn't necessarily detrimental, and a very low value like Ligand B's could indicate poor overall distribution.
9. **Caco-2:** Ligand A (-4.444) is better than Ligand B (-5.161). Higher Caco-2 values indicate better intestinal absorption.
10. **Solubility:** Ligand A (-4.401) is better than Ligand B (-1.794). Higher solubility is generally preferred.
11. **hERG:** Ligand A (0.657) has a lower hERG risk than Ligand B (0.439), which is preferable.
12. **Cl_mic:** Ligand A (62.55) has a higher microsomal clearance than Ligand B (-1.129). This means Ligand B is more metabolically stable, which is a significant advantage.
13. **t1/2:** Ligand A (1.292) has a shorter in vitro half-life than Ligand B (19.19). Ligand B's longer half-life is highly desirable.
14. **Pgp:** Ligand A (0.387) has lower P-gp efflux than Ligand B (0.043), which is preferable.
15. **Binding Affinity:** Ligand B (-7.8 kcal/mol) has a slightly better binding affinity than Ligand A (-7.5 kcal/mol). This 1.5 kcal/mol difference is significant.
**Overall Assessment:**
Ligand B has a substantially better binding affinity and significantly improved metabolic stability (lower Cl_mic, longer t1/2). These are crucial factors for a viable drug candidate. While Ligand A has advantages in TPSA, solubility, and some ADME properties, the superior potency and metabolic profile of Ligand B outweigh these benefits. The higher TPSA of Ligand B is a concern, but the strong binding affinity and improved metabolic stability are more important for a GPCR target like ADRB2.
Output:
0
2025-04-17 21:18:10,462 - INFO - Batch 248 complete. Total preferences: 3968
2025-04-17 21:18:10,462 - INFO - Processing batch 249/512...
2025-04-17 21:18:54,447 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
Let's break down the comparison of Ligand A and Ligand B, considering the guidelines and GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key).
1. **Molecular Weight:** Both ligands (363.845 Da and 345.422 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (75.44) is better than Ligand B (85.09). Both are below 140, but closer to 90 is preferable for GPCRs, and A is closer.
3. **logP:** Both ligands have good logP values (3.222 and 3.17), falling within the optimal 1-3 range. Very similar.
4. **H-Bond Donors:** Ligand A (1) is better than Ligand B (3). Lower HBD generally improves permeability.
5. **H-Bond Acceptors:** Ligand A (4) is better than Ligand B (6). Lower HBA is also generally preferred for permeability.
6. **QED:** Ligand A (0.855) is significantly better than Ligand B (0.669). A higher QED indicates a more drug-like profile.
7. **DILI:** Ligand A (54.75) is better than Ligand B (69.097). Both are acceptable, but A has a lower risk.
8. **BBB:** Ligand B (77.317) is better than Ligand A (55.176). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be beneficial or at least not detrimental, making B slightly better here.
9. **Caco-2:** Ligand A (-4.879) is better than Ligand B (-5.175). Higher Caco-2 values indicate better absorption.
10. **Solubility:** Ligand A (-3.584) is better than Ligand B (-4.18). Better solubility is always a plus.
11. **hERG:** Ligand A (0.388) is better than Ligand B (0.901). Lower hERG inhibition is crucial for avoiding cardiotoxicity, especially important for a cardiovascular target like ADRB2.
12. **Cl_mic:** Both ligands have similar microsomal clearance (62.661 and 61.721).
13. **t1/2:** Ligand A (51.204) is better than Ligand B (29.16). A longer half-life is generally desirable.
14. **Pgp:** Ligand A (0.136) is significantly better than Ligand B (0.263). Lower P-gp efflux is preferred for better bioavailability.
15. **Binding Affinity:** Ligand B (-6.5) is slightly better than Ligand A (-6.2). This is a 0.3 kcal/mol difference, which is not a huge advantage, but still relevant.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most crucial ADME properties (TPSA, HBD, HBA, QED, DILI, solubility, hERG, Pgp, t1/2, Caco-2). While Ligand B has a slightly better binding affinity and BBB penetration, the superior ADME profile of Ligand A, particularly its lower hERG risk and better Pgp efflux, makes it the more promising drug candidate for the ADRB2 receptor. The small affinity difference is outweighed by the significant improvements in drug-like properties.
**Output:**
1
2025-04-17 21:18:54,447 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (340.373 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (41.99) is significantly better than Ligand B (115.65). ADRB2 is not a CNS target, but lower TPSA generally improves absorption. Ligand B's TPSA is quite high, potentially hindering oral bioavailability.
3. **logP:** Ligand A (4.945) is higher than Ligand B (-0.359). While 4.945 is approaching the upper limit, it's still within an acceptable range. Ligand B's logP is quite low, which could severely limit its ability to cross cell membranes.
4. **HBD:** Ligand A (1) is better than Ligand B (3). Fewer HBDs are generally preferred for better permeability.
5. **HBA:** Ligand A (2) is better than Ligand B (6). Similar to HBD, lower HBA is generally preferred.
6. **QED:** Both ligands have similar QED values (0.733 and 0.669), indicating good drug-like properties.
7. **DILI:** Ligand A (84.18) has a higher DILI risk than Ligand B (40.752). This is a concern for Ligand A, but not a complete deal-breaker.
8. **BBB:** This is less critical for ADRB2, but Ligand A (80.574) is better than Ligand B (39.007).
9. **Caco-2:** Ligand A (-4.616) is better than Ligand B (-5.153). Both are negative, which is unusual, but a less negative value is preferable.
10. **Solubility:** Ligand A (-5.326) is better than Ligand B (-1.71). Both are poor, but Ligand A is less poor.
11. **hERG:** Ligand A (0.792) is better than Ligand B (0.082). Lower hERG inhibition is crucial for cardiovascular safety.
12. **Cl_mic:** Ligand A (58.811) is worse than Ligand B (-2.497). Ligand B has a negative clearance, which is excellent, indicating high metabolic stability.
13. **t1/2:** Ligand A (103.736) is much better than Ligand B (4.497). A longer half-life is desirable.
14. **Pgp:** Ligand A (0.667) is better than Ligand B (0.005). Lower P-gp efflux is preferred.
15. **Binding Affinity:** Ligand A (-6.6 kcal/mol) is slightly better than Ligand B (-6.0 kcal/mol). The difference is not huge, but it's still a factor.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A performs significantly better in logP and TPSA, and has a slight edge in affinity and Pgp. While Ligand B has excellent metabolic stability (Cl_mic), its poor logP and high TPSA are major drawbacks. The DILI risk for Ligand A is a concern, but can potentially be addressed through structural modifications.
**Conclusion:**
Considering the balance of properties and the priorities for a GPCR target, Ligand A is the more promising candidate. Its superior physicochemical properties (logP, TPSA) outweigh the higher DILI risk, which can be investigated further.
Output:
1
2025-04-17 21:18:54,447 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (367.5 and 353.5 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (78.5) is better than Ligand B (81.2), both are acceptable for a non-CNS GPCR target like ADRB2, being under 140.
3. **logP:** Ligand A (0.804) is slightly better than Ligand B (0.321). Both are a bit low, potentially impacting permeability, but Ligand A is closer to the optimal 1-3 range.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1), but both are within the acceptable limit of 5.
5. **HBA:** Ligand A (5) is slightly higher than Ligand B (4), both are within the acceptable limit of 10.
6. **QED:** Ligand B (0.772) is slightly better than Ligand A (0.664), indicating a marginally more drug-like profile.
7. **DILI:** Ligand A (13.6) is *significantly* better than Ligand B (25.5). This is a major advantage for Ligand A, as lower DILI risk is crucial.
8. **BBB:** Both ligands have similar low BBB penetration (46.1% and 46.6%). This is not a major concern for ADRB2, as it's not a CNS target.
9. **Caco-2:** Ligand A (-5.75) is better than Ligand B (-4.51), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-1.27) is better than Ligand B (-0.44), suggesting better aqueous solubility.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.104 and 0.11). No significant difference.
12. **Cl_mic:** Ligand A (-3.1) has a significantly *lower* (better) microsomal clearance than Ligand B (27.5). This indicates greater metabolic stability for Ligand A.
13. **t1/2:** Ligand A (-9.1) has a slightly better in vitro half-life than Ligand B (-5.1).
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.014 and 0.022). No significant difference.
15. **Binding Affinity:** Ligand B (-7.6) has a significantly stronger binding affinity than Ligand A (-4.1). This is a substantial advantage for Ligand B.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are important. While Ligand B has better affinity, Ligand A has better logP, TPSA, solubility, and crucially, a much lower DILI risk and better metabolic stability (Cl_mic). The affinity difference is 3.5 kcal/mol, which is significant, but the combination of improved ADME properties and safety profile for Ligand A is compelling. The slightly lower logP of Ligand A is a minor drawback that can potentially be addressed with further optimization.
**Conclusion:**
Considering the balance of properties, especially the significantly lower DILI risk and better metabolic stability of Ligand A, I believe it is the more viable drug candidate despite the weaker binding affinity. The affinity difference, while substantial, can be potentially overcome with further medicinal chemistry optimization, while mitigating the DILI risk associated with Ligand B would be far more challenging.
Output:
1
2025-04-17 21:18:54,447 - INFO - Here's my reasoning and final output for the ligand preference:
**Reasoning:**
We are looking for a ligand for ADRB2, a cardiovascular GPCR. Therefore, key priorities are logP, TPSA, Pgp efflux, binding affinity, and a reasonable ADME profile (avoiding high DILI and hERG risk).
Let's compare Ligand A and Ligand B property by property:
1. **MW:** Both are within the ideal range (361.5 vs 347.5 Da).
2. **TPSA:** Ligand A (62.3) is better than Ligand B (72.28). Lower TPSA generally favors oral absorption.
3. **logP:** Both are good (2.56 vs 1.29), within the 1-3 range. Ligand A is slightly better.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A (4) is better than Ligand B (6). Lower HBA is generally preferred.
6. **QED:** Both are similar and good (0.875 vs 0.84).
7. **DILI:** Ligand A (40.29) is significantly better than Ligand B (18.22). Lower DILI is crucial.
8. **BBB:** Both have good BBB penetration (76.7 vs 71.2).
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-5.18) is slightly better than Ligand B (-5.058), but both are problematic.
10. **Solubility:** Ligand A (-3.336) is better than Ligand B (-1.679).
11. **hERG:** Both are very low (0.425 vs 0.19), indicating low cardiotoxicity risk.
12. **Cl_mic:** Ligand A (49.7) is significantly better than Ligand B (13.475). Lower clearance is preferred for metabolic stability.
13. **t1/2:** Ligand A (-11.945) is much better than Ligand B (10.894). A longer half-life is desirable.
14. **Pgp:** Both are low (0.154 vs 0.04), indicating low efflux.
15. **Binding Affinity:** Both have the same binding affinity (-6.1 kcal/mol).
**Overall Assessment:**
Ligand A consistently outperforms Ligand B in several critical ADME properties (DILI, Cl_mic, t1/2, Solubility, TPSA, HBA) while maintaining comparable binding affinity, logP, and BBB penetration. The significantly lower DILI risk and improved metabolic stability (Cl_mic and t1/2) make Ligand A a much more promising drug candidate despite the similar Caco-2 permeability values. While both have poor Caco-2 permeability, the other advantages of Ligand A outweigh this drawback.
**Output:**
1
2025-04-17 21:18:54,447 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (371.463 and 361.873 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (62.3) is significantly better than Ligand A (127.39). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (2.832) is optimal, while Ligand A (-0.522) is quite low, potentially hindering membrane permeability. This is a significant advantage for B.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable.
5. **HBA:** Ligand A (6) and Ligand B (3) are both acceptable.
6. **QED:** Both ligands have good QED scores (0.635 and 0.839), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand B (29.236) has a much lower DILI risk than Ligand A (56.689). This is a major advantage for B.
8. **BBB:** Ligand B (78.79) has a higher BBB penetration percentile than Ligand A (32.61), but this is less critical for a cardiovascular target.
9. **Caco-2:** Ligand A (-5.756) and Ligand B (-4.861) are both poor.
10. **Solubility:** Ligand A (-1.457) and Ligand B (-4.066) are both poor.
11. **hERG:** Ligand A (0.048) has a slightly lower hERG risk than Ligand B (0.372), but both are reasonably low.
12. **Cl_mic:** Ligand A (-9.504) has a much lower (better) microsomal clearance than Ligand B (16.617), suggesting better metabolic stability. This is a significant advantage for A.
13. **t1/2:** Ligand B (-16.963) has a very negative in vitro half-life, indicating very rapid metabolism. Ligand A (-5.554) is better, but still not ideal. This is a major disadvantage for B.
14. **Pgp:** Ligand A (0.01) has a much lower Pgp efflux liability than Ligand B (0.052), suggesting better absorption and bioavailability.
15. **Affinity:** Both ligands have similar binding affinities (-6.5 and -5.6 kcal/mol). The 0.9 kcal/mol difference favors A, but isn't overwhelming.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, and affinity are important. Ligand B excels in logP and TPSA, while Ligand A has a slightly better affinity. However, the significant advantages of Ligand A in Cl_mic and Pgp efflux, coupled with the lower DILI risk, outweigh the slightly better logP and TPSA of Ligand B. The extremely poor half-life of Ligand B is a critical drawback.
**Conclusion:**
Considering all factors, Ligand A appears to be the more promising drug candidate.
Output:
1
2025-04-17 21:18:54,448 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Ligand A (381.259 Da) is within the ideal range (200-500 Da). Ligand B (348.407 Da) is also within range, slightly lower. No clear advantage here.
2. **TPSA:** Ligand A (67.43) is good, well below the 140 threshold. Ligand B (113.93) is higher, but still acceptable for a non-CNS target. Ligand A is better.
3. **logP:** Ligand A (4.149) is a bit high, potentially causing solubility issues or off-target effects. Ligand B (0.474) is quite low, which could hinder permeability. Given ADRB2 is a cardiovascular target and doesn't *require* high BBB penetration, a slightly higher logP is acceptable if other properties are favorable. Ligand A is slightly preferred.
4. **HBD:** Ligand A (2) is good. Ligand B (3) is also acceptable, but slightly less optimal. Ligand A is better.
5. **HBA:** Ligand A (3) is good. Ligand B (6) is higher, potentially impacting permeability. Ligand A is better.
6. **QED:** Both ligands have similar QED values (A: 0.79, B: 0.642), indicating reasonable drug-likeness. No significant difference.
7. **DILI:** Ligand A (80.109) has a higher DILI risk, which is concerning. Ligand B (61.807) is better, falling within an acceptable range. Ligand B is significantly better.
8. **BBB:** Not a high priority for a cardiovascular target. Ligand A (54.556) and Ligand B (36.758) are both low.
9. **Caco-2:** Ligand A (-4.779) is poor, suggesting poor absorption. Ligand B (-5.439) is also poor, but slightly better than A.
10. **Solubility:** Ligand A (-5.303) is very poor. Ligand B (-2.888) is better, but still not ideal. Ligand B is better.
11. **hERG:** Ligand A (0.462) has a slightly higher hERG risk than Ligand B (0.184). Ligand B is better.
12. **Cl_mic:** Ligand A (32.152) has a moderate clearance. Ligand B (16.001) has a lower clearance, indicating better metabolic stability. Ligand B is better.
13. **t1/2:** Ligand A (56.371) has a longer half-life than Ligand B (26.087). Ligand A is better.
14. **Pgp:** Ligand A (0.294) has lower P-gp efflux, which is good. Ligand B (0.05) is even lower, suggesting better bioavailability. Ligand B is better.
15. **Affinity:** Ligand B (-7.1) has a significantly stronger binding affinity than Ligand A (-5.0). This is a substantial advantage, and can often outweigh minor ADME drawbacks.
**Overall Assessment:**
While Ligand A has a better half-life, Ligand B demonstrates a superior balance of properties, particularly regarding safety (lower DILI, hERG) and drug-likeness (better solubility, lower Pgp efflux, and significantly better metabolic stability). Most importantly, the binding affinity of Ligand B is substantially stronger. The slightly lower logP of Ligand B is less concerning for a cardiovascular target. The poor Caco-2 values for both are a concern, but the stronger affinity of B may compensate.
Output:
0
2025-04-17 21:18:54,448 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.5 and 357.5 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (40.62) is better than Ligand B (54.79). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (3.93 and 3.75), falling within the optimal 1-3 range. Similar.
4. **HBD:** Both have 0 HBD, which is acceptable.
5. **HBA:** Ligand A (2) is better than Ligand B (5). Lower HBA is generally preferred for permeability.
6. **QED:** Ligand B (0.791) has a significantly better QED score than Ligand A (0.379), indicating a more drug-like profile. This is a substantial advantage for Ligand B.
7. **DILI:** Ligand A (8.1%) has a much lower DILI risk than Ligand B (54.3%). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (88.5%) has a higher BBB penetration than Ligand B (61.4%). While not a primary concern for a cardiovascular target, it's still a positive attribute.
9. **Caco-2:** Both ligands have similar, poor Caco-2 permeability (-4.672 and -4.598). This is a concern for both, suggesting potential absorption issues.
10. **Solubility:** Both ligands have very poor aqueous solubility (-2.829 and -3.547). This is a significant drawback for both.
11. **hERG:** Ligand A (0.651) has a slightly higher hERG risk than Ligand B (0.264), but both are relatively low.
12. **Cl_mic:** Ligand B (53.79) has a lower microsomal clearance than Ligand A (71.77), suggesting better metabolic stability. This is a positive for Ligand B.
13. **t1/2:** Ligand B (27.13) has a significantly longer in vitro half-life than Ligand A (-19.57). This is a substantial advantage for Ligand B.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.336 and 0.358).
15. **Affinity:** Ligand A (-6.3) has a slightly better binding affinity than Ligand B (-5.6), but the difference is less than 1.5 kcal/mol.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Both ligands perform reasonably well on logP and Pgp. Ligand A has a better TPSA, while Ligand B has a better QED, Cl_mic and t1/2. The affinity difference is not substantial enough to outweigh the other factors. The DILI risk for Ligand A is significantly lower, which is a crucial safety consideration.
**Overall Assessment:**
While Ligand B has a better QED and metabolic stability (lower Cl_mic, longer t1/2), the significantly lower DILI risk of Ligand A is a crucial advantage. The slight improvement in affinity for Ligand A is a bonus. The poor solubility and Caco-2 permeability are concerns for both, but can be addressed with formulation strategies. Given the importance of minimizing liver toxicity, I favor Ligand A.
Output:
1
2025-04-17 21:18:54,448 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [427.364, 61.8, 3.511, 2, 5, 0.767, 41.877, 81.311, -5.038, -3.219, 0.929, 41.084, 41.405, 0.737, -5.8]
**Ligand B:** [363.395, 125.2, 0.16, 3, 5, 0.656, 91.043, 52.268, -5.291, -4.602, 0.165, -12.543, 50.369, 0.03, -5.6]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, BBB, and affinity):
1. **MW:** Ligand A (427.364 Da) is within the ideal range. Ligand B (363.395 Da) is also good.
2. **TPSA:** Ligand A (61.8) is excellent, well below 140. Ligand B (125.2) is still acceptable, but higher.
3. **logP:** Ligand A (3.511) is optimal. Ligand B (0.16) is *very* low, potentially leading to poor membrane permeability. This is a significant drawback.
4. **HBD/HBA:** Both have 2 HBD and 5 HBA, which are acceptable.
5. **QED:** Ligand A (0.767) is better than Ligand B (0.656), indicating a more drug-like profile.
6. **DILI:** Ligand A (41.877) is preferable to Ligand B (91.043) as it has a lower DILI risk.
7. **BBB:** Ligand A (81.311) is very good, suggesting decent CNS penetration if desired. Ligand B (52.268) is lower, less favorable.
8. **Caco-2:** Both are negative, which is unusual and requires further investigation. However, the scale is not defined, so it's hard to interpret.
9. **Solubility:** Both are negative, which is also unusual and requires further investigation.
10. **hERG:** Both are low (0.929 and 0.165), indicating low cardiotoxicity risk.
11. **Cl_mic:** Ligand B (-12.543) has a *much* lower (and therefore better) microsomal clearance than Ligand A (41.084), suggesting greater metabolic stability.
12. **t1/2:** Ligand B (50.369) has a longer half-life than Ligand A (41.405).
13. **Pgp:** Ligand A (0.737) has lower P-gp efflux than Ligand B (0.03), which is preferable for bioavailability.
14. **Affinity:** Both have similar binding affinities (-5.8 and -5.6 kcal/mol), which are both good. The difference is not substantial enough to be decisive.
**Overall Assessment:**
Ligand A is clearly the better candidate. While Ligand B has superior metabolic stability and half-life, its extremely low logP is a major concern. This will likely result in poor absorption and bioavailability. Ligand A has a much more favorable logP, better QED, lower DILI risk, and better BBB penetration. The slightly higher clearance of Ligand A is a manageable issue compared to the potential permeability problems of Ligand B. The similar affinities make the ADME properties the deciding factor.
Output:
1
2025-04-17 21:18:54,448 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.47 and 352.43 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (83.36) is higher than Ligand B (40.62). For a cardiovascular GPCR, TPSA isn't a *major* concern unless very high (above 140), but lower is generally preferred for better permeability. Ligand B is significantly better here.
3. **logP:** Ligand A (0.504) is quite low, potentially hindering membrane permeability. Ligand B (2.839) is within the optimal 1-3 range. This is a substantial advantage for Ligand B.
4. **HBD:** Ligand A (1) is good, while Ligand B (0) is also acceptable.
5. **HBA:** Ligand A (6) is acceptable, while Ligand B (2) is very good.
6. **QED:** Both ligands have similar, good QED values (0.738 and 0.767), indicating good drug-like properties.
7. **DILI:** Ligand A (30.79%) has a slightly higher DILI risk than Ligand B (25.67%), but both are well below the concerning threshold of 60%.
8. **BBB:** Ligand A (40.52%) has low BBB penetration, while Ligand B (96.123%) has excellent BBB penetration. While ADRB2 isn't necessarily a CNS target, higher BBB penetration can sometimes correlate with better overall distribution and reduced off-target effects.
9. **Caco-2:** Ligand A (-5.481) has poor Caco-2 permeability, while Ligand B (-4.384) is better.
10. **Solubility:** Ligand A (-0.731) has poor solubility, while Ligand B (-3.209) is even worse. Both are problematic.
11. **hERG:** Ligand A (0.101) has a slightly lower hERG risk than Ligand B (0.685), which is preferable.
12. **Cl_mic:** Ligand A (1.694) has significantly lower microsomal clearance than Ligand B (29.909), indicating better metabolic stability. This is a major advantage for Ligand A.
13. **t1/2:** Ligand A (3.415) has a shorter half-life than Ligand B (-11.634). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.005) has very low P-gp efflux, while Ligand B (0.174) has slightly higher efflux. This is a slight advantage for Ligand A.
15. **Affinity:** Ligand B (-7.2 kcal/mol) has a significantly stronger binding affinity than Ligand A (-4.9 kcal/mol). This is a crucial advantage, potentially outweighing some of the ADME drawbacks.
**Overall Assessment:**
Ligand B has a substantially better binding affinity, a good logP, excellent BBB penetration, and acceptable DILI risk. While its solubility is poor, its metabolic stability is worse than Ligand A, the strong affinity is a major driver. Ligand A has better metabolic stability and P-gp properties, but suffers from poor logP, solubility, and Caco-2 permeability, and a significantly weaker binding affinity.
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), and the substantial affinity difference, Ligand B is the more promising candidate despite its solubility and metabolic stability issues. These can be addressed through formulation and structural modifications, respectively.
Output:
0
2025-04-17 21:18:54,448 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (351.535 and 346.475 Da) fall comfortably within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (44.81) is significantly better than Ligand B (67.23). ADRB2 is a cardiovascular target, not CNS, but lower TPSA generally improves absorption.
3. **logP:** Ligand A (3.403) is optimal, while Ligand B (1.754) is at the lower end of the optimal range. For a GPCR, a higher logP is generally preferred for membrane permeability and receptor binding. Ligand A is better.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Both ligands have 4 HBA, which is good.
6. **QED:** Both ligands have good QED scores (0.789 and 0.818), indicating good drug-likeness.
7. **DILI:** Ligand A (5.351) has a much lower DILI risk than Ligand B (13.61). This is a significant advantage.
8. **BBB:** Both ligands have similar BBB penetration (around 80%), which is less critical for a cardiovascular target like ADRB2.
9. **Caco-2:** Ligand A (-4.683) is better than Ligand B (-5.116), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-1.956) is better than Ligand B (-1.4), indicating better solubility.
11. **hERG:** Ligand A (0.818) has a lower hERG risk than Ligand B (0.263). This is a crucial advantage for cardiovascular drugs.
12. **Cl_mic:** Ligand A (6.215) has a lower microsomal clearance than Ligand B (15.395), suggesting better metabolic stability.
13. **t1/2:** Ligand A (6.983) has a longer in vitro half-life than Ligand B (-8.119).
14. **Pgp:** Ligand A (0.039) has lower P-gp efflux than Ligand B (0.083).
15. **Binding Affinity:** Ligand B (-7.7) has a slightly better binding affinity than Ligand A (-6.5). This is a 1.2 kcal/mol difference, which is significant, but needs to be weighed against the ADME properties.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most crucial ADME properties (DILI, hERG, Cl_mic, t1/2, solubility, Pgp, Caco-2) and has a favorable logP and TPSA. While Ligand B has a slightly better binding affinity, the superior ADME profile of Ligand A, particularly the significantly lower DILI and hERG risks, makes it a much more promising drug candidate for a cardiovascular target. The 1.2 kcal/mol difference in binding affinity is unlikely to overcome the substantial advantages of Ligand A in terms of safety and pharmacokinetic properties.
Output:
1
2025-04-17 21:18:54,448 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (379.555 and 369.531 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (61.36) is significantly better than Ligand B (78.51). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (2.427 and 1.538), falling within the 1-3 optimal range. Ligand A is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (6) is better than Ligand B (4). Lower HBA generally improves permeability.
6. **QED:** Both ligands have acceptable QED values (0.852 and 0.77), indicating good drug-likeness. Ligand A is slightly better.
7. **DILI:** Ligand B (39.434) has a significantly lower DILI risk than Ligand A (53.005). This is a substantial advantage for Ligand B.
8. **BBB:** Ligand A (76.619) has a higher BBB penetration percentile than Ligand B (44.591). While not a primary concern for a cardiovascular target, it's a slight positive for Ligand A.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.064 and -5.225). This is unusual and suggests poor permeability. However, the values are similar.
10. **Solubility:** Both ligands have negative solubility values (-3.184 and -2.848). This is also unusual and indicates poor solubility. The values are similar.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.314 and 0.103). This is excellent. Ligand B is slightly better.
12. **Cl_mic:** Ligand B (14.728) has a much lower microsomal clearance than Ligand A (35.847), indicating better metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand A (0.232) has a slightly better in vitro half-life than Ligand B (-6.12). However, both are very short, and the negative value for Ligand B is concerning.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.029 and 0.043). This is excellent.
15. **Binding Affinity:** Both ligands have the same binding affinity (-7.4 kcal/mol). This eliminates affinity as a differentiating factor.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, and metabolic stability (Cl_mic) are important. Ligand A has a slightly better logP and TPSA, but Ligand B has a much better Cl_mic and a lower DILI risk. The poor Caco-2 and solubility values are concerning for both.
**Overall Assessment:**
While Ligand A has slightly better TPSA and BBB, Ligand B's significantly lower DILI risk and much better metabolic stability (lower Cl_mic) are more crucial for a viable drug candidate. The similar binding affinity makes these ADME properties the deciding factors. The negative solubility and Caco-2 values for both are concerning and would need to be addressed in further optimization, but Ligand B's profile is more promising overall.
Output:
0
2025-04-17 21:18:54,448 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (339.366 Da) is slightly lower, which is generally favorable for permeability.
**2. TPSA:** Ligand A (48.3) is significantly better than Ligand B (71.78). For a GPCR, keeping TPSA low is beneficial for permeability and receptor engagement.
**3. logP:** Both ligands have acceptable logP values (A: 3.163, B: 2.361) within the 1-3 range.
**4. H-Bond Donors:** Ligand A (0) is preferable to Ligand B (1). Fewer H-bond donors generally improve membrane permeability.
**5. H-Bond Acceptors:** Both ligands have the same number of H-bond acceptors (4).
**6. QED:** Ligand B (0.888) has a slightly higher QED score than Ligand A (0.671), indicating a more drug-like profile. However, the difference isn't substantial enough to be a major deciding factor.
**7. DILI Risk:** Ligand A (75.184) has a significantly higher DILI risk than Ligand B (32.687). This is a major concern.
**8. BBB Penetration:** Both ligands have reasonably good BBB penetration (A: 82.823, B: 74.254). While not a primary concern for a cardiovascular target, higher BBB is generally not detrimental.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability in this assay.
**10. Aqueous Solubility:** Ligand A (-4.491) has slightly better solubility than Ligand B (-2.527).
**11. hERG Inhibition:** Ligand A (0.783) has a lower hERG inhibition risk than Ligand B (0.207), which is favorable.
**12. Microsomal Clearance:** Ligand A (91.215) has higher microsomal clearance than Ligand B (25.325), indicating faster metabolism and potentially lower *in vivo* exposure.
**13. In vitro Half-Life:** Ligand B (44.642) has a significantly longer *in vitro* half-life than Ligand A (-0.475), which is a major advantage.
**14. P-gp Efflux:** Ligand A (0.545) has lower P-gp efflux than Ligand B (0.158), which is favorable for oral bioavailability.
**15. Binding Affinity:** Ligand B (-6.7 kcal/mol) has a slightly better binding affinity than Ligand A (-6.4 kcal/mol), but the difference is small.
**Overall Assessment:**
While Ligand B has a better QED and half-life, the significantly lower DILI risk associated with Ligand B is the most critical factor. The higher metabolic clearance of Ligand A is also a concern. Although Ligand A has slightly better P-gp efflux, the DILI risk outweighs this benefit. Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity), Ligand B is the more promising candidate, despite its slightly lower TPSA and QED.
Output:
0
2025-04-17 21:18:54,448 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.362 and 356.463 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand B (88.1) is significantly better than Ligand A (105.82). ADRB2 is not a CNS target, but lower TPSA generally improves absorption.
3. **logP:** Ligand B (1.044) is better than Ligand A (0.494). Both are within the optimal 1-3 range, but Ligand A is quite low and could struggle with membrane permeability.
4. **HBD:** Ligand B (2) is slightly better than Ligand A (3). Both are acceptable.
5. **HBA:** Both ligands have 5 HBA, which is within the acceptable limit.
6. **QED:** Ligand A (0.721) is slightly better than Ligand B (0.603), indicating a marginally more drug-like profile.
7. **DILI:** Ligand B (7.29) is *much* better than Ligand A (36.138). This is a major advantage for Ligand B. A DILI percentile below 40 is highly desirable.
8. **BBB:** Not a primary concern for ADRB2, but Ligand B (73.866) is better than Ligand A (48.197).
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. This is a concern for both.
10. **Solubility:** Both ligands have negative solubility values, indicating poor solubility. This is a concern for both.
11. **hERG:** Ligand B (0.263) is better than Ligand A (0.468). Lower hERG inhibition is crucial for cardiovascular safety.
12. **Cl_mic:** Ligand A (-33.166) is significantly better than Ligand B (-4.795). This suggests much better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (37.781) is better than Ligand B (18.738). Longer half-life is generally preferred.
14. **Pgp:** Ligand B (0.049) is better than Ligand A (0.022). Lower P-gp efflux is favorable for bioavailability.
15. **Binding Affinity:** Ligand B (-7.1) is 0.5 kcal/mol better than Ligand A (-6.6). This is a substantial difference in potency.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand B excels in logP, Pgp, and significantly in affinity. Ligand A has a better TPSA, but the difference isn't large enough to overcome the other advantages of Ligand B. The DILI risk for Ligand A is also a major concern.
**Overall Assessment:**
While Ligand A has advantages in metabolic stability (Cl_mic) and half-life, the significantly lower DILI risk, better logP, better Pgp efflux, and substantially improved binding affinity of Ligand B outweigh these benefits. The poor Caco-2 and solubility are concerns for both, but can potentially be addressed with formulation strategies. The superior safety profile (DILI, hERG) and potency of Ligand B make it the more promising candidate.
Output:
0
2025-04-17 21:18:54,448 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, the most important parameters are binding affinity, logP, TPSA, Pgp efflux, and BBB penetration.
Let's compare the ligands property by property:
1. **MW:** Both ligands (349.45 & 354.41 Da) are within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (71.09) is significantly better than Ligand B (138.78). A TPSA under 140 is good for oral absorption, but lower is generally preferred for GPCRs, and A is much closer to the ideal <90 for CNS targets (though not critical here).
3. **logP:** Ligand A (3.119) is optimal (1-3), while Ligand B (-1.421) is quite low, potentially hindering membrane permeability.
4. **HBD/HBA:** Ligand A (2 HBD, 3 HBA) is better than Ligand B (5 HBD, 6 HBA). Lower counts are generally preferable for balance.
5. **QED:** Ligand A (0.757) is much better than Ligand B (0.327), indicating a more drug-like profile.
6. **DILI:** Ligand A (35.673) has a better (lower) DILI risk than Ligand B (15.083).
7. **BBB:** Ligand A (73.245) has a significantly higher BBB percentile than Ligand B (11.439). While not a CNS target, some BBB penetration can be beneficial for distribution.
8. **Caco-2:** Ligand A (-4.74) is better than Ligand B (-5.97), indicating better intestinal absorption.
9. **Solubility:** Ligand A (-2.715) is better than Ligand B (-0.014).
10. **hERG:** Both ligands have low hERG inhibition risk (0.288 & 0.045).
11. **Cl_mic:** Ligand B (-1.767) has lower (better) microsomal clearance than Ligand A (19.981), suggesting better metabolic stability.
12. **t1/2:** Ligand B (-18.103) has a longer half-life than Ligand A (20.671).
13. **Pgp:** Ligand A (0.082) has lower P-gp efflux liability than Ligand B (0.007), which is favorable.
14. **Affinity:** Ligand A (-7.1 kcal/mol) has a slightly better binding affinity than Ligand B (-6.3 kcal/mol). While the difference isn't huge, it's enough to consider.
**Overall Assessment:**
Ligand A is significantly better across most key parameters, especially TPSA, logP, QED, BBB, solubility, and Pgp efflux. While Ligand B has better metabolic stability (Cl_mic) and half-life, the substantial advantages of Ligand A in absorption, distribution, and drug-likeness outweigh these drawbacks. The slightly better binding affinity of Ligand A further solidifies its preference.
**Output:**
1
2025-04-17 21:18:54,449 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.371 and 332.407 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand B (75.01) is significantly better than Ligand A (115.75). ADRB2 is a cardiovascular target, so CNS penetration isn't critical, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (2.781) is within the optimal 1-3 range, while Ligand A (0.936) is slightly below, potentially hindering permeation.
4. **HBD:** Both ligands have acceptable HBD counts (3 for A, 2 for B), well below the threshold of 5.
5. **HBA:** Both ligands have acceptable HBA counts (5 for A, 3 for B), well below the threshold of 10.
6. **QED:** Both ligands have similar and good QED values (0.716 and 0.724), indicating good drug-likeness.
7. **DILI:** Ligand A (51.144) has a considerably lower DILI risk than Ligand B (70.919). This is a significant advantage for Ligand A.
8. **BBB:** Ligand B (73.866) has a higher BBB penetration percentile than Ligand A (29.585). While not a primary concern for a cardiovascular target, it's a neutral factor.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.74 and -5.444), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-1.775) has slightly better solubility than Ligand B (-4.249), though both are poor.
11. **hERG:** Ligand A (0.084) has a lower hERG inhibition liability than Ligand B (0.861), indicating a lower risk of cardiotoxicity. This is a crucial advantage given the cardiovascular target.
12. **Cl_mic:** Ligand A (-30.201) has a lower (better) microsomal clearance than Ligand B (27.974), suggesting greater metabolic stability.
13. **t1/2:** Ligand B (4.03) has a longer in vitro half-life than Ligand A (-6.797), which is a positive.
14. **Pgp:** Ligand B (0.49) has lower P-gp efflux liability than Ligand A (0.01), suggesting better bioavailability.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.6 and -6.4 kcal/mol). The difference is not substantial enough to be a deciding factor.
**Overall Assessment & GPCR Priorities:**
For a GPCR like ADRB2, logP, TPSA, and metabolic stability are important. Ligand B has a better logP and TPSA, and a longer half-life. However, Ligand A has a significantly lower DILI risk and hERG inhibition liability, which are critical for a cardiovascular drug. Furthermore, the lower microsomal clearance of Ligand A is a significant advantage. While both have poor Caco-2 permeability, the other advantages of Ligand A outweigh the slightly better Pgp efflux of Ligand B.
**Output:**
1
2025-04-17 21:18:54,449 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's systematically compare Ligand A and Ligand B against the provided guidelines, keeping in mind the GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key).
1. **MW:** Both ligands (337.291 and 349.41 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand B (88.91) is significantly better than Ligand A (118.4). Lower TPSA generally favors better cell permeability, crucial for GPCRs.
3. **logP:** Ligand A (3.474) is at the upper end of the optimal range (1-3), while Ligand B (1.777) is closer to the lower end. While both are acceptable, Ligand A's higher logP *could* lead to off-target effects or solubility issues, but is not a major concern.
4. **HBD/HBA:** Ligand A has 1 HBD and 6 HBA, while Ligand B has 2 HBD and 5 HBA. Both are within acceptable limits.
5. **QED:** Ligand B (0.793) has a better QED score than Ligand A (0.575), suggesting a more drug-like profile.
6. **DILI:** Ligand B (72.819) has a much lower DILI risk than Ligand A (99.457). This is a significant advantage for Ligand B.
7. **BBB:** Ligand B (72.896) has a better BBB penetration score than Ligand A (55.099). While ADRB2 isn't strictly a CNS target, some peripheral ADRB2 activity can be modulated by CNS effects, and higher BBB penetration isn't detrimental.
8. **Caco-2:** Both ligands have negative Caco-2 values (-4.525 and -4.94). This is unusual and suggests poor permeability. However, these values are on a different scale and may not be directly comparable.
9. **Solubility:** Ligand B (-2.634) has better aqueous solubility than Ligand A (-6.806).
10. **hERG:** Ligand B (0.069) has a much lower hERG inhibition liability than Ligand A (0.713). This is a critical advantage, as hERG inhibition can cause cardiotoxicity.
11. **Cl_mic:** Ligand B (29.962) has significantly lower microsomal clearance than Ligand A (58.12), indicating better metabolic stability.
12. **t1/2:** Ligand A (109.827) has a much longer in vitro half-life than Ligand B (6.803). This is a positive for Ligand A.
13. **Pgp:** Ligand B (0.08) has a much lower P-gp efflux liability than Ligand A (0.532), which is beneficial for bioavailability.
14. **Affinity:** Ligand B (-7.3 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.2 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME drawbacks of Ligand A.
**Overall Assessment:**
Ligand B consistently outperforms Ligand A in most crucial ADME properties (DILI, BBB, solubility, hERG, Cl_mic, Pgp) and has a significantly better binding affinity. While Ligand A has a longer half-life, the other advantages of Ligand B are more important for a GPCR target like ADRB2. The lower TPSA and improved solubility of Ligand B are particularly favorable. The negative Caco-2 values are concerning for both, but the overall profile of Ligand B is much more promising.
**Output:**
0
2025-04-17 21:18:54,449 - INFO - Batch 249 complete. Total preferences: 3984
2025-04-17 21:18:54,449 - INFO - Processing batch 250/512...
2025-04-17 21:19:41,304 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (360.47 Da) is within the ideal range, while Ligand B (183.207 Da) is at the lower end. While lower MW can aid permeability, it can also compromise potency.
2. **TPSA:** Both Ligand A (78.87) and Ligand B (72.72) are below the 140 threshold for good oral absorption, and are acceptable for a peripheral GPCR like ADRB2.
3. **logP:** Ligand A (1.654) is optimal, while Ligand B (0.351) is slightly low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (2) and Ligand B (4) are both acceptable, but Ligand A is preferable.
5. **HBA:** Ligand A (4) and Ligand B (4) are both acceptable.
6. **QED:** Both Ligand A (0.655) and Ligand B (0.51) have good drug-like properties.
7. **DILI:** Ligand A (23.769) has a significantly lower DILI risk than Ligand B (6.941), which is a major advantage.
8. **BBB:** This is less critical for ADRB2 (a cardiovascular target), but Ligand A (55.913) is better than Ligand B (3.49).
9. **Caco-2:** Ligand A (-4.564) is better than Ligand B (-6.081) indicating better intestinal absorption.
10. **Solubility:** Ligand A (-1.519) is better than Ligand B (-0.652).
11. **hERG:** Both Ligand A (0.608) and Ligand B (0.025) have low hERG inhibition liability, which is good.
12. **Cl_mic:** Ligand A (14.364) has a much lower microsomal clearance than Ligand B (-44.29), indicating better metabolic stability.
13. **t1/2:** Ligand A (4.857) has a slightly longer in vitro half-life than Ligand B (3.707).
14. **Pgp:** Both Ligand A (0.255) and Ligand B (0.008) have low P-gp efflux liability.
15. **Affinity:** Both ligands have the same binding affinity (-5.6 kcal/mol).
**GPCR-specific priorities:** For ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A is better in logP, Caco-2, solubility, DILI risk and metabolic stability. While both have good affinity and Pgp profiles, the superior ADME properties of Ligand A make it the more promising candidate.
**Output:**
1
2025-04-17 21:19:41,304 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (345.4 Da) are within the ideal range (200-500 Da). No significant difference.
2. **TPSA:** Ligand A (90.96) is significantly better than Ligand B (121.68). For a GPCR, lower TPSA is generally preferred for better permeability. Ligand A is well below the 140 threshold, while B is approaching it.
3. **logP:** Both ligands have low logP values (0.458 and 0.339). This is a slight concern as it might hinder membrane permeability. However, it's not a deal-breaker, and both are below 1.
4. **HBD:** Ligand A (0) is better than Ligand B (4). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (8) is better than Ligand B (9). Lower HBA is also favorable for permeability.
6. **QED:** Ligand A (0.677) is slightly better than Ligand B (0.591), indicating a more drug-like profile.
7. **DILI:** Ligand B (67.313) has a slightly higher DILI risk than Ligand A (73.09), but both are acceptable (<60 is good).
8. **BBB:** Ligand A (62.97) is better than Ligand B (52.889). While ADRB2 isn't necessarily a CNS target, some degree of BBB penetration can be beneficial for distribution.
9. **Caco-2:** Ligand A (-5.011) is better than Ligand B (-5.567). Higher Caco-2 permeability suggests better intestinal absorption.
10. **Solubility:** Ligand A (-1.145) is better than Ligand B (-2.32). Better aqueous solubility is always preferred.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.062 and 0.196). This is excellent.
12. **Cl_mic:** Ligand B (15.602) has lower microsomal clearance than Ligand A (19.67), suggesting better metabolic stability.
13. **t1/2:** Ligand B (33.649) has a longer in vitro half-life than Ligand A (29.464), which is desirable.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.018 and 0.005). This is excellent.
15. **Binding Affinity:** Ligand B (-8.3) has a significantly stronger binding affinity than Ligand A (-6.6) - a difference of 1.7 kcal/mol. This is a substantial advantage.
**Overall Assessment:**
Ligand B has a significantly better binding affinity, which is the most crucial factor for a drug candidate. It also has better metabolic stability (lower Cl_mic) and a longer half-life. While Ligand A has advantages in TPSA, solubility, and BBB, the difference in binding affinity outweighs these benefits. The slightly higher DILI risk of Ligand B is not a major concern given its strong binding.
**Output:**
0
2025-04-17 21:19:41,304 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
Let's break down the comparison, focusing on the GPCR-relevant parameters and general drug-like properties.
1. **Molecular Weight:** Both ligands (368.455 Da and 351.447 Da) fall comfortably within the ideal 200-500 Da range.
2. **TPSA:** Both ligands have TPSA values (85.89 and 84.67) below the 140 A^2 threshold for good oral absorption, which is good.
3. **logP:** Both ligands have logP values (2.491 and 2.186) within the optimal 1-3 range.
4. **H-Bond Donors/Acceptors:** Ligand A has 2 HBD and 6 HBA, while Ligand B has 1 HBD and 5 HBA. Both are within acceptable limits.
5. **QED:** Ligand B (0.776) has a slightly higher QED score than Ligand A (0.517), indicating a more drug-like profile.
6. **DILI:** Ligand B (40.675) has a significantly lower DILI risk than Ligand A (65.103). This is a major advantage for Ligand B.
7. **BBB:** Ligand B (76.541) shows better BBB penetration potential than Ligand A (65.452), which is beneficial for a GPCR target.
8. **Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
9. **Aqueous Solubility:** Both ligands have negative solubility values, which is also unusual and suggests poor solubility. Again, the scale is not specified.
10. **hERG Inhibition:** Ligand A (0.662) has a slightly higher hERG inhibition risk than Ligand B (0.247). Lower is better here, favoring Ligand B.
11. **Microsomal Clearance:** Ligand A (51.936) has a lower microsomal clearance than Ligand B (41.769), suggesting better metabolic stability.
12. **In vitro Half-Life:** Ligand B (-15.714) has a negative half-life, which is impossible. This is a significant red flag. Ligand A (5.325) has a reasonable half-life.
13. **P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.158 and 0.045).
14. **Binding Affinity:** Ligand B (-6.8 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.2 kcal/mol). This is a substantial advantage, exceeding the 1.5 kcal/mol threshold.
**Overall Assessment:**
Despite the unusual negative values for Caco-2 and solubility, the key factors driving my decision are the significantly better binding affinity of Ligand B, its lower DILI risk, and improved BBB penetration. The negative half-life for Ligand B is a major concern, but the substantial affinity advantage outweighs this in my expert opinion, assuming the half-life value is an error. The lower hERG risk for Ligand B is also a positive. Ligand A has better metabolic stability, but the affinity difference is too large to ignore for a GPCR target.
Output:
0
2025-04-17 21:19:41,304 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.475 and 344.455 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (78.09) is slightly higher than Ligand B (75.27). Both are below the 140 threshold for good oral absorption, and acceptable for a cardiovascular GPCR target.
3. **logP:** Both ligands have good logP values (2.375 and 2.113), falling within the optimal 1-3 range. No major difference.
4. **HBD:** Both ligands have 2 H-bond donors, which is within the acceptable limit of 5.
5. **HBA:** Both ligands have 3 H-bond acceptors, also within the acceptable limit of 10.
6. **QED:** Ligand B (0.802) has a higher QED score than Ligand A (0.639), indicating a more drug-like profile. This is a slight advantage for Ligand B.
7. **DILI:** Ligand B (25.785) has a significantly lower DILI risk than Ligand A (16.208). This is a substantial advantage for Ligand B, as minimizing liver toxicity is crucial.
8. **BBB:** Ligand A (60.644) has a slightly higher BBB penetration percentile than Ligand B (55.176). While ADRB2 isn't a CNS target, some degree of BBB penetration can sometimes be beneficial for distribution. However, this is a minor consideration.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.031 and -4.864). These values are unusual and suggest very poor permeability. This is a significant concern for both compounds.
10. **Solubility:** Both ligands have negative solubility values (-2.585 and -2.718). This is a major red flag, indicating very poor aqueous solubility, which will likely hinder bioavailability.
11. **hERG:** Ligand A (0.381) has a slightly higher hERG inhibition liability than Ligand B (0.076). Lower hERG risk is preferred, giving Ligand B an advantage.
12. **Cl_mic:** Ligand A (40.282) has a higher microsomal clearance than Ligand B (23.512), meaning it is metabolized faster. Lower clearance is better for metabolic stability, favoring Ligand B.
13. **t1/2:** Ligand B (-2.797) has a much longer in vitro half-life than Ligand A (-17.97). This is a significant advantage for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.178) has a lower P-gp efflux liability than Ligand B (0.06). Lower efflux is generally preferred, but the difference is small.
15. **Binding Affinity:** Ligand B (-7.4) has a significantly stronger binding affinity than Ligand A (-6.2). A 1.2 kcal/mol difference is substantial and can outweigh minor ADME drawbacks.
**Overall Assessment:**
While both compounds have significant issues with Caco-2 permeability and solubility, Ligand B is clearly the better candidate. It has a significantly lower DILI risk, a longer half-life, lower microsomal clearance, stronger binding affinity, and lower hERG inhibition. The slightly better BBB penetration of Ligand A is not enough to offset these advantages. The strong binding affinity of Ligand B is a key factor for a GPCR target.
Output:
0
2025-04-17 21:19:41,304 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [367.471, 82.97, 1.136, 1, 6, 0.815, 47.15, 50.872, -4.641, -0.804, 0.139, 7.575, 7.612, 0.104, -5.1]
**Ligand B:** [393.523, 89.69, 2.126, 0, 10, 0.613, 90.112, 51.221, -5.598, -3.071, 0.067, 69.106, -27.002, 0.375, -7.4]
Here's a breakdown, prioritizing GPCR properties (logP, TPSA, Pgp, BBB, Affinity):
1. **Molecular Weight:** Both are within the ideal range (200-500 Da). Ligand A (367.471) is slightly preferred due to being a bit lower.
2. **TPSA:** Ligand A (82.97) is better than Ligand B (89.69). Both are acceptable for a non-CNS GPCR, but lower is generally better for permeability.
3. **logP:** Ligand A (1.136) is within the optimal range, while Ligand B (2.126) is also acceptable, but edging towards the higher end.
4. **H-Bond Donors/Acceptors:** Ligand A (1 HBD, 6 HBA) is better than Ligand B (0 HBD, 10 HBA). Fewer H-bonds are generally preferred for permeability.
5. **QED:** Ligand A (0.815) is significantly better than Ligand B (0.613), indicating a more drug-like profile.
6. **DILI:** Ligand A (47.15) has a much lower DILI risk than Ligand B (90.112). This is a significant advantage for Ligand A.
7. **BBB:** Both have similar BBB penetration (around 50-51%). Not a major differentiating factor for a non-CNS target like cardiovascular ADRB2.
8. **Caco-2:** Ligand A (-4.641) is better than Ligand B (-5.598) indicating better absorption.
9. **Solubility:** Ligand A (-0.804) is better than Ligand B (-3.071).
10. **hERG:** Both are very low risk, but Ligand A is slightly better (0.139 vs 0.067).
11. **Cl_mic:** Ligand A (7.575) has significantly lower microsomal clearance than Ligand B (69.106), suggesting better metabolic stability.
12. **t1/2:** Ligand A (7.612) has a better in vitro half-life than Ligand B (-27.002).
13. **Pgp:** Ligand A (0.104) has lower P-gp efflux than Ligand B (0.375).
14. **Binding Affinity:** Ligand B (-7.4) has a significantly stronger binding affinity than Ligand A (-5.1) - a difference of 2.3 kcal/mol. This is a substantial advantage.
**Overall Assessment:**
While Ligand B boasts a superior binding affinity, Ligand A demonstrates a much more favorable ADMET profile. The lower DILI risk, better solubility, lower clearance, longer half-life, and better QED are all critical factors for drug development. The 2.3 kcal/mol difference in binding affinity, while significant, can potentially be addressed through further optimization of Ligand A. The ADMET properties of Ligand B are concerning, particularly the high DILI risk and high clearance.
Therefore, I would prioritize Ligand A due to its superior overall drug-like properties and reduced potential for toxicity, despite the slightly weaker initial binding affinity.
Output:
1
2025-04-17 21:19:41,304 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
The ADRB2 receptor is a GPCR, so the priorities are logP, TPSA, Pgp efflux, BBB penetration, and binding affinity. Metabolic stability and solubility are also important considerations.
Let's compare the ligands property by property:
1. **MW:** Both ligands (343.431 and 342.403 Da) are within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (80.12) is significantly better than Ligand B (108.21). ADRB2 is not a CNS target, but lower TPSA generally correlates with better permeability.
3. **logP:** Ligand A (1.025) is better than Ligand B (0.529). Both are within the acceptable range, but Ligand A is closer to the optimal 1-3 range. Ligand B is borderline and could have absorption issues.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Both ligands have 5 HBA, which is acceptable.
6. **QED:** Both ligands have good QED scores (0.81 and 0.842).
7. **DILI:** Ligand A (41.373) has a lower DILI risk than Ligand B (54.478), which is preferable.
8. **BBB:** While not a primary concern for ADRB2, Ligand A (64.831) has better BBB penetration than Ligand B (51.725).
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and difficult to interpret without further context. However, the magnitude of the negative value is slightly less for Ligand A (-5.031 vs -5.499), suggesting potentially better absorption.
10. **Solubility:** Ligand A (-2.404) has slightly better solubility than Ligand B (-1.84), though both are poor.
11. **hERG:** Ligand A (0.028) has a much lower hERG risk than Ligand B (0.204). This is a significant advantage.
12. **Cl_mic:** Ligand B (-17.026) has a significantly lower (better) microsomal clearance than Ligand A (44.829), indicating greater metabolic stability.
13. **t1/2:** Ligand B (-28.403) has a much longer in vitro half-life than Ligand A (-13.177), which is a substantial advantage.
14. **Pgp:** Ligand A (0.089) has lower P-gp efflux than Ligand B (0.004), which is preferable.
15. **Affinity:** Ligand B (-5.4 kcal/mol) has a significantly stronger binding affinity than Ligand A (-3.1 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME drawbacks.
**Overall Assessment:**
Ligand B has a much stronger binding affinity and better metabolic stability (lower Cl_mic, longer t1/2). However, Ligand A has better TPSA, logP, DILI risk, hERG risk, and Pgp efflux. The difference in binding affinity (-5.4 vs -3.1 kcal/mol) is quite large and likely to be critical for efficacy. While Ligand A has a better safety profile, the improved potency of Ligand B is a significant advantage for a GPCR target.
**Output:**
0
2025-04-17 21:19:41,305 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Ligand A (336.395 Da) is within the ideal range (200-500), while Ligand B (382.957 Da) is also acceptable but trending towards the upper limit.
2. **TPSA:** Ligand A (86.88) is excellent, well below the 140 threshold for oral absorption. Ligand B (42.43) is also very good.
3. **logP:** Both ligands have good logP values (A: 2.806, B: 4.022). Ligand B is slightly higher, which could potentially lead to some off-target effects, but is still within a reasonable range.
4. **HBD:** Ligand A has 3 HBD, which is acceptable. Ligand B has 0, which is also good.
5. **HBA:** Both ligands have 4 HBA, which is acceptable.
6. **QED:** Both ligands have similar QED values (A: 0.625, B: 0.681), indicating good drug-likeness.
7. **DILI:** Ligand A (75.533) has a higher DILI risk than Ligand B (35.789). This is a significant negative for Ligand A.
8. **BBB:** Ligand B (87.864) has a much higher BBB penetration percentile than Ligand A (43.505). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant for off-target effects and overall safety assessment.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual. However, the values are similar, so this isn't a major differentiator.
10. **Solubility:** Both ligands have negative solubility values, which is also unusual. Again, the values are similar.
11. **hERG:** Both ligands have low hERG inhibition liability (A: 0.68, B: 0.617).
12. **Cl_mic:** Ligand A (-5.968) has a lower (better) microsomal clearance than Ligand B (94.15). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (40.056) has a longer in vitro half-life than Ligand B (4.774). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.08) has lower P-gp efflux liability than Ligand B (0.536), which is favorable for bioavailability.
15. **Affinity:** Ligand B (-6.8 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.6 kcal/mol). This is a substantial advantage, exceeding the 1.5 kcal/mol threshold.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand B excels in affinity and has acceptable logP and TPSA. While Ligand A has better Pgp and metabolic stability, the significantly stronger binding of Ligand B outweighs these advantages. The lower DILI risk of Ligand B is also a critical factor.
**Conclusion:**
Despite Ligand A's better metabolic stability and Pgp profile, the superior binding affinity and significantly lower DILI risk of Ligand B make it the more promising drug candidate.
Output:
0
2025-04-17 21:19:41,305 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [349.475, 84.23, 3.214, 2, 4, 0.679, 38.891, 79.915, -4.695, -3.703, 0.354, 85.608, -20.569, 0.287, -5.8]**
**Ligand B: [348.403, 104.39, 0.331, 2, 5, 0.626, 54.634, 62.854, -4.766, -2.654, 0.216, 33.358, -19.751, 0.035, -6.9]**
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). No significant difference.
2. **TPSA:** Ligand A (84.23) is better than Ligand B (104.39). ADRB2 is not a CNS target, but lower TPSA generally favors absorption.
3. **logP:** Ligand A (3.214) is optimal, while Ligand B (0.331) is quite low. This is a significant advantage for Ligand A, as low logP can hinder membrane permeability.
4. **H-Bond Donors:** Both have 2 HBD, which is within the acceptable limit.
5. **H-Bond Acceptors:** Ligand A has 4 HBA, while Ligand B has 5. Both are acceptable, but Ligand A is slightly preferred.
6. **QED:** Both ligands have similar QED values (0.679 vs 0.626), indicating good drug-likeness.
7. **DILI:** Ligand A (38.891) has a lower DILI risk than Ligand B (54.634). This is a clear advantage for Ligand A.
8. **BBB:** Ligand A (79.915) has better BBB penetration than Ligand B (62.854), although this is less critical for a non-CNS target like ADRB2.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the values are similar.
10. **Solubility:** Ligand A (-3.703) is slightly worse than Ligand B (-2.654), but both are poor.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.354 and 0.216).
12. **Cl_mic:** Ligand B (33.358) has significantly lower microsomal clearance than Ligand A (85.608), indicating better metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Both have similar *in vitro* half-lives (-20.569 vs -19.751).
14. **Pgp:** Ligand A (0.287) has lower P-gp efflux than Ligand B (0.035), which is favorable for absorption.
15. **Binding Affinity:** Ligand B (-6.9) has a slightly better binding affinity than Ligand A (-5.8). This is a 1.1 kcal/mol difference, which is substantial.
**Overall Assessment:**
Ligand B has a better binding affinity and metabolic stability (lower Cl_mic). However, Ligand A excels in logP, DILI risk, and P-gp efflux. The significantly lower logP of Ligand B is a major concern, potentially hindering its ability to cross cell membranes and reach the target. The better DILI profile of Ligand A is also a substantial benefit. While the affinity difference is notable, the ADME properties of Ligand A are more balanced and suggest a higher probability of successful *in vivo* performance.
Therefore, I favor Ligand A.
1
2025-04-17 21:19:41,305 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.438 and 345.363 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (58.44) is significantly better than Ligand B (123.92). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold, while B is approaching it.
3. **logP:** Ligand A (1.819) is within the optimal 1-3 range. Ligand B (-0.83) is below 1, which could indicate poor membrane permeability. This is a significant drawback for B.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is better than Ligand B (8). Again, fewer HBAs are generally preferred for better permeability.
6. **QED:** Both ligands have similar QED values (0.786 and 0.7), indicating good drug-like properties.
7. **DILI:** Ligand A (23.11) has a much lower DILI risk than Ligand B (82.435). This is a major advantage for A.
8. **BBB:** Ligand A (96.782) has a much higher BBB penetration percentile than Ligand B (50.679). While not critical for a cardiovascular target, it's a positive attribute.
9. **Caco-2:** Ligand A (-4.581) and Ligand B (-5.36) are both negative values, which is unusual and requires careful interpretation. Lower (more negative) values suggest poor permeability. However, the scale isn't fully defined here, so it's hard to draw strong conclusions.
10. **Solubility:** Ligand A (-2.35) and Ligand B (-1.94) are both negative values, suggesting poor solubility. This is a concern for both.
11. **hERG:** Ligand A (0.741) has a lower hERG risk than Ligand B (0.174). This is a significant advantage for A, as hERG inhibition can lead to cardiotoxicity.
12. **Cl_mic:** Ligand A (40.243) has a higher microsomal clearance than Ligand B (16.862), indicating faster metabolism. This is a negative for A.
13. **t1/2:** Ligand A (-30.829) has a very negative in vitro half-life, suggesting extremely rapid degradation. Ligand B (23.75) is much better. This is a major drawback for A.
14. **Pgp:** Ligand A (0.195) has lower P-gp efflux liability than Ligand B (0.009). This is a positive for A, potentially improving bioavailability.
15. **Binding Affinity:** Ligand A (-8.2) has a significantly stronger binding affinity than Ligand B (-6.8). This is a substantial advantage for A, potentially outweighing some of its ADME drawbacks.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A excels in logP, TPSA, Pgp, and *especially* affinity. While Ligand B has a better half-life, the significantly stronger binding of Ligand A, coupled with its better physicochemical properties (TPSA, logP, HBD/HBA) and lower toxicity (DILI, hERG), make it the more promising candidate. The poor half-life of A is a concern, but could be addressed with structural modifications.
Output:
1
2025-04-17 21:19:41,305 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (380.432 Da) is slightly higher than Ligand B (347.419 Da), but both are acceptable.
2. **TPSA:** Ligand A (49.85) is significantly better than Ligand B (107.19). For a GPCR, a lower TPSA is generally preferred for better permeability. Ligand B is quite high and potentially problematic for oral absorption.
3. **logP:** Ligand A (3.058) is optimal, while Ligand B (0.075) is very low. This is a major drawback for Ligand B, as it may struggle with membrane permeability and bioavailability.
4. **HBD:** Ligand A (0) is better than Ligand B (3). Fewer HBDs are generally preferred for permeability.
5. **HBA:** Both ligands have 4 HBA, which is acceptable.
6. **QED:** Both ligands have similar QED values (0.706 and 0.701), indicating good drug-likeness.
7. **DILI:** Ligand A (47.926) is slightly higher than Ligand B (42.691), but both are within a reasonable range.
8. **BBB:** Ligand A (73.711) is better than Ligand B (45.909). While ADRB2 isn't exclusively a CNS target, some CNS penetration may be relevant depending on the desired therapeutic effect and off-target profile.
9. **Caco-2:** Ligand A (-4.569) is better than Ligand B (-5.386), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-3.93) is better than Ligand B (-2.852), indicating better aqueous solubility.
11. **hERG:** Both ligands have very low hERG risk (0.493 and 0.302), which is excellent.
12. **Cl_mic:** Ligand A (67.991) is higher than Ligand B (9.088), meaning Ligand B has better metabolic stability. This is a positive for Ligand B.
13. **t1/2:** Ligand A (-21.378) is worse than Ligand B (-2.84), indicating a shorter half-life. This is a negative for Ligand A.
14. **Pgp:** Ligand A (0.141) is better than Ligand B (0.03), indicating lower P-gp efflux.
15. **Binding Affinity:** Both ligands have similar, strong binding affinities (-5.5 and -5.8 kcal/mol).
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, and Pgp are particularly important. Ligand A excels in these areas. While Ligand B has better metabolic stability (lower Cl_mic) and half-life, the significantly lower logP and higher TPSA are major concerns for oral bioavailability and receptor engagement. The slightly better half-life of Ligand B doesn't outweigh these drawbacks.
**Conclusion:**
Ligand A demonstrates a much more favorable balance of properties for a viable drug candidate targeting ADRB2. Its superior logP, TPSA, and Pgp properties, combined with acceptable DILI and good binding affinity, make it the preferred choice despite the slightly less favorable metabolic stability and half-life.
Output:
1
2025-04-17 21:19:41,305 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (379.5) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (52.65) is significantly better than Ligand B (103.78). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (1.926) is optimal, while Ligand B (0.175) is quite low. This is a major drawback for Ligand B, potentially hindering membrane permeability and bioavailability.
4. **HBD:** Both ligands are acceptable (Ligand A: 1, Ligand B: 2), well within the limit of 5.
5. **HBA:** Both ligands are acceptable (Ligand A: 4, Ligand B: 6), within the limit of 10.
6. **QED:** Both are reasonably good (Ligand A: 0.63, Ligand B: 0.571), indicating drug-like properties.
7. **DILI:** Both have acceptable DILI risk (Ligand A: 31.95, Ligand B: 34.82).
8. **BBB:** Ligand A (74.137) has better BBB penetration than Ligand B (31.485). While not crucial for a cardiovascular target, it's a slight advantage.
9. **Caco-2:** Both have negative values, indicating poor permeability. Ligand A (-5.004) is slightly better than Ligand B (-5.838).
10. **Solubility:** Both have negative values, indicating poor solubility. Ligand A (-2.015) is slightly better than Ligand B (-1.791).
11. **hERG:** Both have low hERG inhibition liability (Ligand A: 0.687, Ligand B: 0.206). Ligand B is slightly better.
12. **Cl_mic:** Ligand A (16.74) has significantly lower microsomal clearance than Ligand B (-3.447). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (-2.126) has a negative half-life, indicating a very short half-life, which is a concern. Ligand B (21.109) has a much better in vitro half-life.
14. **Pgp:** Both have low P-gp efflux liability (Ligand A: 0.046, Ligand B: 0.075).
15. **Binding Affinity:** Ligand A (-6.4) has a significantly stronger binding affinity than Ligand B (-1.4). This is a substantial advantage.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand A excels in logP and affinity, and is better in TPSA. Ligand B has a better half-life, but the significant deficiencies in logP and affinity outweigh this benefit.
**Conclusion:**
Despite Ligand B's better half-life, Ligand A is the more promising candidate. Its superior logP, TPSA, and *much* stronger binding affinity are critical for a GPCR target. The poor half-life of Ligand A can be addressed through structural modifications during lead optimization. The low logP of Ligand B is a more fundamental issue that would be harder to overcome.
**Output:**
1
2025-04-17 21:19:41,305 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal 200-500 Da range (A: 350.423, B: 338.411). No clear advantage.
2. **TPSA:** Both are reasonably good, being under 140, but Ligand A (92.59) is better than Ligand B (94.88) for oral absorption.
3. **logP:** Ligand A (-0.341) is a bit low, potentially hindering permeability. Ligand B (1.995) is much better, falling within the optimal 1-3 range. This is a significant advantage for Ligand B.
4. **HBD:** Both are acceptable (A: 1, B: 2), well below the limit of 5.
5. **HBA:** Ligand A (7) is slightly higher than Ligand B (4), but both are under the limit of 10.
6. **QED:** Both have good QED scores (A: 0.689, B: 0.821), indicating drug-likeness. Ligand B is slightly better.
7. **DILI:** Ligand A (28.306) has a much lower DILI risk than Ligand B (59.519). This is a substantial advantage for Ligand A.
8. **BBB:** Ligand A (65.452) has a better BBB penetration percentile than Ligand B (35.324). While ADRB2 isn't strictly a CNS target, some peripheral ADRB2 receptors can be relevant in CNS-related conditions, and better BBB penetration is generally favorable.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-5.783) is slightly better than Ligand B (-4.874), but both are concerning.
10. **Solubility:** Ligand A (-0.871) has better solubility than Ligand B (-3.658). This is a positive for Ligand A.
11. **hERG:** Both have very low hERG risk (A: 0.075, B: 0.295). No significant difference.
12. **Cl_mic:** Ligand A (-17.549) has a much lower (better) microsomal clearance than Ligand B (19.099). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (19.304) has a longer in vitro half-life than Ligand B (-13.631). This is a significant advantage for Ligand A.
14. **Pgp:** Both have very low Pgp efflux liability (A: 0.003, B: 0.041). No significant difference.
15. **Binding Affinity:** Ligand B (-8.0) has a significantly stronger binding affinity than Ligand A (-5.6). This is a major advantage for Ligand B, potentially outweighing some ADME concerns.
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP and affinity. Ligand A is better in TPSA and has a much better safety profile (DILI, Cl_mic, t1/2).
**Overall Assessment:**
The stronger binding affinity of Ligand B (-8.0 kcal/mol vs -5.6 kcal/mol) is a substantial advantage. While Ligand A has a better safety profile and some ADME properties, the potency difference is likely to be more impactful for *in vivo* efficacy. The slightly lower logP of Ligand A is a concern, but the strong binding of Ligand B may compensate.
Output:
0
2025-04-17 21:19:41,305 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 GPCR, followed by the final output.
**Ligand A: [345.399, 95.67, 2.74, 2, 5, 0.785, 61.962, 39.511, -5.025, -4.289, 0.226, 72.42, -14.303, 0.098, -1.5]**
**Ligand B: [360.498, 33.2, 4.539, 0, 3, 0.805, 56.844, 86.817, -4.749, -4.642, 0.642, 63.126, 4.245, 0.76, -6.2]**
1. **Molecular Weight:** Both are within the ideal range (200-500 Da). A (345.4) is slightly better being closer to the lower end.
2. **TPSA:** A (95.67) is higher than the preferred <140, but still acceptable. B (33.2) is excellent, well below 140, and very favorable for permeability.
3. **logP:** A (2.74) is optimal. B (4.539) is pushing the upper limit, potentially leading to solubility issues and off-target interactions.
4. **H-Bond Donors:** A (2) is good. B (0) is also good.
5. **H-Bond Acceptors:** A (5) is good. B (3) is good.
6. **QED:** Both are good (A: 0.785, B: 0.805), indicating drug-like properties. B is slightly better.
7. **DILI:** A (61.962) is borderline high risk. B (56.844) is better, lower risk.
8. **BBB:** A (39.511) is low, suggesting poor brain penetration. B (86.817) is excellent, indicating good brain penetration. For ADRB2, which has subtypes in the brain, this is a significant advantage.
9. **Caco-2:** Both are negative, indicating poor permeability. A (-5.025) is worse than B (-4.749).
10. **Solubility:** Both are negative, indicating poor solubility. A (-4.289) is worse than B (-4.642).
11. **hERG:** A (0.226) is very low risk. B (0.642) is slightly higher, but still relatively low.
12. **Cl_mic:** A (72.42) is moderate clearance. B (63.126) is better, indicating better metabolic stability.
13. **t1/2:** A (-14.303) is very poor. B (4.245) is better, but still not ideal.
14. **Pgp:** A (0.098) is low efflux, good. B (0.76) is higher efflux, less favorable.
15. **Binding Affinity:** B (-6.2) is significantly stronger than A (-1.5). This is a >1.5 kcal/mol advantage, which is substantial.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, BBB, and affinity are key. B excels in BBB penetration and significantly outperforms A in binding affinity. While A has slightly better logP, B's superior affinity and BBB penetration outweigh this. The DILI risk for A is also concerning.
**Conclusion:**
Ligand B is the more promising candidate due to its significantly stronger binding affinity, excellent BBB penetration, lower DILI risk, and better metabolic stability. While it has a higher logP, the benefits outweigh this drawback.
Output:
0
2025-04-17 21:19:41,305 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [340.467, 58.2, 3.702, 2, 2, 0.504, 36.681, 68.321, -4.811, -4.085, 0.71, 48.703, -1.445, 0.221, -6.0]
**Ligand B:** [353.507, 70.67, 1.256, 2, 4, 0.58, 19.698, 29.003, -4.751, -2.346, 0.208, 35.925, -5.864, 0.033, -7.1]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity, and BBB):
1. **MW:** Both are within the ideal 200-500 Da range. Ligand A (340.467) is slightly preferred.
2. **TPSA:** Ligand A (58.2) is excellent, well below the 140 threshold. Ligand B (70.67) is still reasonable, but less optimal.
3. **logP:** Ligand A (3.702) is within the optimal range. Ligand B (1.256) is a bit low, potentially impacting permeability.
4. **HBD/HBA:** Both have acceptable HBD counts (2). Ligand B has a slightly higher HBA count (4 vs 2), which isn't a major concern, but A is slightly better.
5. **QED:** Both are above 0.5, indicating good drug-likeness.
6. **DILI:** Ligand A (36.681) has a slightly higher DILI risk than Ligand B (19.698), but both are below the concerning 60 threshold.
7. **BBB:** Ligand A (68.321) has a significantly better BBB penetration score than Ligand B (29.003). This is a key advantage for a GPCR target, even if not strictly CNS-focused, as it suggests better distribution.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. This is a significant concern for both.
9. **Solubility:** Both have negative solubility values, which is also unusual and suggests poor solubility. This is a significant concern for both.
10. **hERG:** Both have low hERG inhibition risk.
11. **Cl_mic:** Ligand B (35.925) has a lower microsomal clearance, suggesting better metabolic stability than Ligand A (48.703).
12. **t1/2:** Ligand B (-5.864) has a longer in vitro half-life than Ligand A (-1.445).
13. **Pgp:** Ligand A (0.221) has a lower P-gp efflux liability than Ligand B (0.033), which is favorable for bioavailability.
14. **Affinity:** Ligand B (-7.1) has a stronger binding affinity than Ligand A (-6.0). This is a substantial advantage (1.1 kcal/mol difference).
**Overall Assessment:**
The biggest differentiator is the binding affinity. Ligand B's -7.1 kcal/mol is significantly better than Ligand A's -6.0 kcal/mol. This difference is large enough to outweigh some of the drawbacks. While Ligand A has better BBB penetration and Pgp efflux, the improved metabolic stability (lower Cl_mic, longer t1/2) and stronger binding of Ligand B are more critical for a GPCR target. The poor Caco-2 and solubility values are concerning for both, and would need to be addressed in further optimization.
Output:
0
2025-04-17 21:19:41,306 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (354.47 & 344.47 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (49.85) is significantly better than Ligand B (76.69). ADRB2 is a cardiovascular target, not CNS, but lower TPSA generally improves absorption. Ligand A is well below the 140 threshold, while B is approaching it.
3. **logP:** Ligand A (2.389) is within the optimal 1-3 range. Ligand B (0.808) is a bit low, potentially hindering membrane permeability.
4. **HBD:** Both have acceptable HBD counts (0 for A, 1 for B), well below the 5 threshold.
5. **HBA:** Ligand A (3) is preferable to Ligand B (8). Lower HBA generally improves permeability.
6. **QED:** Both ligands have similar, good QED scores (0.782 and 0.714), indicating good drug-like properties.
7. **DILI:** Ligand A (40.132) has a slightly higher DILI risk than Ligand B (20.434), but both are below the concerning 60% threshold. B is clearly better here.
8. **BBB:** This isn't a primary concern for a cardiovascular target, but Ligand A (92.478) has better BBB penetration than Ligand B (70.027).
9. **Caco-2:** Ligand A (-4.345) and Ligand B (-5.623) both have negative values, indicating poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-2.641) is slightly better than Ligand B (-0.599), but both are poor. Solubility is a concern for both, but A is slightly better.
11. **hERG:** Ligand A (0.575) has a lower hERG risk than Ligand B (0.271), which is favorable.
12. **Cl_mic:** Ligand B (-20) has significantly better metabolic stability (lower clearance) than Ligand A (60.096). This is a major advantage for B.
13. **t1/2:** Ligand B (1.409) has a slightly better in vitro half-life than Ligand A (0.26), but both are quite low.
14. **Pgp:** Ligand A (0.232) has lower P-gp efflux than Ligand B (0.033), which is preferable.
15. **Binding Affinity:** Both ligands have very similar and excellent binding affinities (-6.0 and -5.3 kcal/mol). The difference is not large enough to override other factors.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp) and general drug-like properties, Ligand A appears to be a better candidate. While Ligand B has a significantly better metabolic stability profile, Ligand A has better TPSA, logP, Pgp efflux, and hERG risk. The small difference in binding affinity doesn't outweigh the other advantages of Ligand A. The solubility and Caco-2 permeability are concerns for both, but can be addressed through formulation strategies.
Output:
1
2025-04-17 21:19:41,306 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (350.5 and 342.5 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (78.43) is higher than Ligand B (49.41). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is generally preferred for permeability. Ligand B has a clear advantage.
3. **logP:** Both ligands (2.231 and 2.891) are within the optimal 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability, but not dramatically so.
4. **HBD:** Ligand A (3) is higher than Ligand B (1). Lower HBD is generally preferred for better permeability. Ligand B has an advantage.
5. **HBA:** Ligand A (3) is higher than Ligand B (2). Similar to HBD, lower HBA is generally preferred. Ligand B has an advantage.
6. **QED:** Both ligands are similar (0.628 and 0.596), both above the 0.5 threshold, indicating good drug-like properties.
7. **DILI:** Ligand A (12.524) has a significantly lower DILI risk than Ligand B (16.789). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (65.801) has a higher BBB penetration percentile than Ligand A (56.65). While ADRB2 isn't a primary CNS target, some brain exposure can be relevant for off-target effects, and higher BBB is generally better.
9. **Caco-2:** Both ligands have very similar, and poor, Caco-2 permeability (-4.814 and -4.776). This suggests potential absorption issues for both.
10. **Solubility:** Both ligands have similar solubility values (-3.23 and -3.496).
11. **hERG:** Both ligands have very low hERG inhibition risk (0.292 and 0.254).
12. **Cl_mic:** Ligand A (29.118) has significantly lower microsomal clearance than Ligand B (40.554), indicating better metabolic stability. This is a substantial advantage for Ligand A.
13. **t1/2:** Ligand A (1.293) has a shorter in vitro half-life than Ligand B (-15.106). This is a significant advantage for Ligand B.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.162 and 0.131).
15. **Binding Affinity:** Ligand A (-7.3) has a slightly better binding affinity than Ligand B (-6.9). While the difference is not huge (0.4 kcal/mol), it is still a positive for Ligand A.
**GPCR-Specific Considerations:**
For ADRB2 (a cardiovascular GPCR), logP, TPSA, Pgp, and affinity are important. Ligand B has a slight advantage in logP and a better BBB score, and lower TPSA. However, Ligand A has a significantly better DILI score, lower Cl_mic (better metabolic stability), and a slightly better binding affinity. The metabolic stability and reduced liver toxicity are crucial factors for a chronic cardiovascular medication.
**Overall Assessment:**
While Ligand B has some advantages in BBB and in vitro half-life, the superior DILI profile, lower Cl_mic, and slightly better affinity of Ligand A outweigh these benefits. The potential for reduced liver toxicity and improved metabolic stability are critical for a drug intended for long-term cardiovascular use.
Output:
1
2025-04-17 21:19:41,306 - INFO - Batch 250 complete. Total preferences: 4000
2025-04-17 21:19:41,306 - INFO - Processing batch 251/512...
2025-04-17 21:20:32,730 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [347.459, 66.65, 2.799, 0., 4., 0.725, 28.228, 89.066, -4.413, -2.297, 0.425, 84.001, -31.723, 0.372, -6.7]
**Ligand B:** [364.515, 60.25, 3.139, 0., 6., 0.686, 39.434, 69.639, -4.759, -2.823, 0.521, 95.771, 4.242, 0.523, -7.1]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (347.459) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are acceptable, but Ligand B (60.25) is better than Ligand A (66.65) as it is closer to the <140 threshold for oral absorption.
3. **logP:** Both are within the optimal range (1-3). Ligand B (3.139) is slightly higher, which *could* be a minor concern for solubility, but not a deal-breaker.
4. **HBD:** Both have 0 HBD, which is good.
5. **HBA:** Ligand A (4) is better than Ligand B (6). Lower HBA is generally preferred for permeability.
6. **QED:** Both are reasonable (above 0.5), indicating drug-like properties. Ligand A (0.725) is slightly better.
7. **DILI:** Ligand A (28.228) has a significantly lower DILI risk than Ligand B (39.434). This is a major advantage.
8. **BBB:** Ligand A (89.066) has a much higher BBB penetration potential than Ligand B (69.639). This is very important for a GPCR target, even a cardiovascular one, as some off-target CNS effects are possible.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand B (-4.759) is slightly worse than Ligand A (-4.413).
10. **Solubility:** Both are negative, indicating poor solubility. Ligand B (-2.823) is slightly worse than Ligand A (-2.297).
11. **hERG:** Both are low, indicating low cardiotoxicity risk. Ligand A (0.425) is slightly better.
12. **Cl_mic:** Ligand A (84.001) has lower microsomal clearance than Ligand B (95.771), suggesting better metabolic stability.
13. **t1/2:** Ligand B (4.242) has a slightly longer in vitro half-life than Ligand A (-31.723), but the negative value for A is concerning.
14. **Pgp:** Ligand A (0.372) has lower P-gp efflux liability than Ligand B (0.523), which is favorable for bioavailability.
15. **Affinity:** Ligand B (-7.1) has a significantly stronger binding affinity than Ligand A (-6.7). This is a substantial advantage, potentially outweighing some of the ADME concerns.
**GPCR-specific priorities:** For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, and affinity. Ligand B has a slightly better logP and significantly better affinity. However, Ligand A excels in DILI, BBB, and Pgp efflux. The poor Caco-2 and solubility for both are concerning, but can be addressed with formulation strategies.
**Overall Assessment:**
The stronger binding affinity of Ligand B (-7.1 vs -6.7) is a significant advantage for a GPCR target. While Ligand A has better ADME properties (DILI, BBB, Pgp), the 1.5 kcal/mol difference in binding is substantial enough to outweigh these concerns, especially considering formulation strategies can potentially address the solubility and permeability issues.
Output:
0
2025-04-17 21:20:32,731 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's systematically compare Ligand A and Ligand B based on the provided parameters, keeping in mind the GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key).
1. **MW:** Both ligands (346.471 and 353.419 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (78.43) is significantly better than Ligand B (104.89). A TPSA under 140 is good for oral absorption, and lower is generally preferred for GPCRs. Ligand B is pushing the upper limit.
3. **logP:** Ligand A (2.448) is optimal (1-3). Ligand B (0.318) is quite low, potentially hindering membrane permeability. This is a significant drawback for a GPCR ligand.
4. **HBD:** Both have acceptable HBD counts (3 and 2 respectively), well within the limit of 5.
5. **HBA:** Ligand B (7) is higher than Ligand A (3). While both are under 10, the lower HBA count of Ligand A is slightly preferable.
6. **QED:** Both ligands have similar and good QED values (0.57 and 0.587).
7. **DILI:** Both ligands have similar and acceptable DILI risk (37.495 and 38.542, both <40).
8. **BBB:** Ligand A (41.644) is better than Ligand B (25.242). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be useful for distribution.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.792 and -4.869), which is unusual and suggests poor permeability. This is concerning for both.
10. **Solubility:** Ligand A (-3.311) is better than Ligand B (-1.147), indicating better aqueous solubility. Solubility is important for bioavailability.
11. **hERG:** Both ligands have low hERG inhibition liability (0.663 and 0.096). Ligand B is slightly better here, but both are at acceptable levels.
12. **Cl_mic:** Ligand B (-3.711) has a *much* lower (better) microsomal clearance than Ligand A (68.028). This suggests significantly improved metabolic stability for Ligand B.
13. **t1/2:** Ligand B (33.859) has a longer in vitro half-life than Ligand A (30.07). This is a positive for Ligand B.
14. **Pgp:** Ligand A (0.688) has lower P-gp efflux liability than Ligand B (0.05). Lower Pgp is generally preferred for better bioavailability.
15. **Affinity:** Ligand B (-6.8 kcal/mol) has a slightly better binding affinity than Ligand A (-6.5 kcal/mol). While the difference is not huge, it's enough to consider.
**Overall Assessment:**
Ligand A has better TPSA, solubility, and Pgp properties. However, Ligand B excels in metabolic stability (Cl_mic and t1/2) and has a slightly better binding affinity. The low logP of Ligand B is a major concern, potentially leading to poor permeability despite the negative Caco-2 values for both. Considering the GPCR-specific priorities, the combination of better metabolic stability and slightly improved affinity of Ligand B, alongside acceptable (though not ideal) TPSA, outweighs the concerns about its low logP. The negative Caco-2 values are a red flag for both, but the metabolic advantage of B is more critical for a successful drug.
Output:
0
2025-04-17 21:20:32,731 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.434 and 348.447 Da) are within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (65.2) is better than Ligand B (76.46). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (2.703) is better than Ligand B (1.29). Both are within the optimal 1-3 range, but Ligand A is closer to the upper end, which is generally preferable for GPCRs.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1), but both are acceptable.
5. **HBA:** Ligand A (2) is lower than Ligand B (5). Lower HBA is generally preferred for better permeability.
6. **QED:** Ligand A (0.879) is significantly better than Ligand B (0.595), indicating a more drug-like profile.
7. **DILI:** Ligand A (31.563) has a lower DILI risk than Ligand B (36.409), which is desirable.
8. **BBB:** Both ligands have good BBB penetration (Ligand A: 70.105, Ligand B: 71.268). This isn't a major factor for a cardiovascular target.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the absolute value is similar (-4.786 vs -4.689), so no clear difference.
10. **Solubility:** Ligand A (-3.179) has better solubility than Ligand B (-1.504).
11. **hERG:** Ligand A (0.69) is better than Ligand B (0.381), indicating lower hERG inhibition risk.
12. **Cl_mic:** Ligand A (9.329) has significantly lower microsomal clearance than Ligand B (26.072), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-4.734) has a longer in vitro half-life than Ligand B (0.784).
14. **Pgp:** Ligand A (0.098) has lower P-gp efflux than Ligand B (0.048), indicating better bioavailability.
15. **Affinity:** Ligand A (-7.1 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.3 kcal/mol). This is a crucial advantage, exceeding the 1.5 kcal/mol threshold.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical parameters. The most significant differences are in binding affinity, QED, metabolic stability (Cl_mic and t1/2), and solubility. While both have similar BBB penetration, the superior ADME properties and substantially better binding affinity of Ligand A make it the more promising drug candidate for the ADRB2 receptor.
Output:
1
2025-04-17 21:20:32,731 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (348.305 and 354.397 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (91.58) is higher than Ligand B (60.85). For a peripheral GPCR like ADRB2, TPSA is less critical than for a CNS target, but lower is generally preferred for absorption. Ligand B has a significant advantage here.
**3. logP:** Both ligands have good logP values (2.804 and 1.708), falling within the optimal 1-3 range. Ligand A is slightly higher, which could potentially lead to some off-target interactions, but it's not a major concern.
**4. H-Bond Donors & Acceptors:** Ligand A has 2 HBD and 5 HBA, while Ligand B has 1 HBD and 3 HBA. Both are within acceptable limits (<=5 HBD and <=10 HBA).
**5. QED:** Both ligands have very similar QED scores (0.838 and 0.839), indicating good drug-likeness.
**6. DILI Risk:** Ligand A has a DILI risk of 64.211, which is approaching the higher risk threshold (>60). Ligand B has a much lower DILI risk (16.053), a substantial advantage.
**7. BBB Penetration:** BBB is less important for ADRB2 as it's not a CNS target. Ligand A (57.619) and Ligand B (89.027) both have relatively low BBB penetration, which is expected and acceptable. Ligand B is better, but not critical.
**8. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.71 and -4.692). These values are unusual and suggest poor permeability. However, the values are very close, so this isn't a deciding factor.
**9. Aqueous Solubility:** Ligand A (-5.352) has worse solubility than Ligand B (-2.512). Solubility is important for bioavailability, so Ligand B is favored.
**10. hERG Inhibition:** Ligand A (0.768) has a slightly higher hERG risk than Ligand B (0.415), but both are relatively low.
**11. Microsomal Clearance:** Ligand A (46.259) has a significantly higher microsomal clearance than Ligand B (3.101), indicating faster metabolism and potentially lower exposure. Ligand B is strongly preferred here.
**12. In vitro Half-Life:** Ligand A (-1.416) has a negative half-life, which is not possible. This is a red flag. Ligand B (0.417) has a short, but positive half-life.
**13. P-gp Efflux:** Both ligands have low P-gp efflux liability (0.344 and 0.043), which is good. Ligand B is slightly better.
**14. Binding Affinity:** Ligand A (-7.5 kcal/mol) has a slightly stronger binding affinity than Ligand B (-7.2 kcal/mol). This is a 0.3 kcal/mol difference, which is not substantial enough to overcome the significant ADME liabilities of Ligand A.
**Overall Assessment:**
Ligand B is the clear preference. While Ligand A has slightly better binding affinity, it suffers from a higher DILI risk, poorer solubility, significantly higher metabolic clearance, and an impossible in vitro half-life. Ligand B demonstrates a much better balance of properties, particularly regarding safety (DILI) and pharmacokinetic parameters (clearance, solubility). For a cardiovascular target, minimizing off-target effects and ensuring reasonable metabolic stability are crucial.
Output:
0
2025-04-17 21:20:32,731 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [377.227, 52.61, 4.891, 1, 5, 0.702, 90.074, 65.723, -4.651, -6.244, 0.754, 66.453, 64.997, 0.633, -6]
**Ligand B:** [363.443, 102.05, 1.377, 2, 7, 0.721, 71.074, 59.325, -5.334, -3.474, 0.161, 42.34, -10.259, 0.118, -6.1]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (363.443) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (52.61) is significantly better than Ligand B (102.05). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA is still generally preferred for good absorption. Ligand B's TPSA is quite high.
3. **logP:** Ligand A (4.891) is higher than Ligand B (1.377). While Ligand A is at the upper end of the optimal range, it's still acceptable. Ligand B is quite low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (1) is better than Ligand B (2). Lower is generally preferred.
5. **HBA:** Ligand A (5) is better than Ligand B (7). Lower is generally preferred.
6. **QED:** Both are good (A: 0.702, B: 0.721), indicating good drug-like properties.
7. **DILI:** Ligand A (90.074) has a higher DILI risk than Ligand B (71.074), which is a concern.
8. **BBB:** Ligand A (65.723) has better BBB penetration than Ligand B (59.325), though neither are particularly high. This isn't a major factor for a cardiovascular target.
9. **Caco-2:** Ligand A (-4.651) is better than Ligand B (-5.334). Higher is better, indicating better intestinal absorption.
10. **Solubility:** Ligand A (-6.244) is better than Ligand B (-3.474). Higher is better.
11. **hERG:** Ligand A (0.754) is better than Ligand B (0.161). Lower is better, indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand B (42.34) has significantly lower microsomal clearance than Ligand A (66.453), suggesting better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand A (64.997) has a longer in vitro half-life than Ligand B (-10.259). This is a significant advantage.
14. **Pgp:** Ligand A (0.633) is better than Ligand B (0.118). Lower is better, indicating less efflux.
15. **Affinity:** Both have similar binding affinities (-6 kcal/mol and -6.1 kcal/mol). The difference is negligible.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A excels in logP, TPSA, and Pgp, while the affinities are comparable. However, Ligand A has a concerningly high DILI risk. Ligand B has a better metabolic profile (lower Cl_mic) but suffers from a high TPSA and low logP.
**Overall Assessment:**
Despite the higher DILI risk, Ligand A appears to be a more promising candidate. Its superior TPSA, logP, Caco-2 permeability, solubility, hERG, and Pgp properties outweigh the DILI concern, *provided* further investigation can mitigate that risk. The lower logP of Ligand B is a significant drawback, potentially hindering its ability to reach the target. The metabolic stability of Ligand B is attractive, but can be addressed with structural modifications.
Output:
1
2025-04-17 21:20:32,731 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 drug candidates. ADRB2 is a GPCR, so we'll prioritize logP, Pgp, TPSA, and affinity, alongside general drug-like properties.
**Ligand A:**
* **MW:** 366.49 Da - Acceptable.
* **TPSA:** 85.77 - Good, below the 140 threshold.
* **logP:** 0.568 - A bit low, potentially impacting permeability.
* **HBD:** 2 - Good.
* **HBA:** 6 - Good.
* **QED:** 0.737 - Excellent.
* **DILI:** 25.71 - Very good, low risk.
* **BBB:** 21.68 - Low, not a major concern for a non-CNS target like ADRB2.
* **Caco-2:** -5.283 - Poor permeability.
* **Solubility:** -1.048 - Poor solubility.
* **hERG:** 0.446 - Low risk.
* **Cl_mic:** -1.259 - Negative clearance is unusual and suggests potential instability or issues with the prediction method.
* **t1/2:** 6.879 - Moderate half-life.
* **Pgp:** 0.054 - Low efflux, favorable.
* **Affinity:** -6.5 kcal/mol - Good binding affinity.
**Ligand B:**
* **MW:** 360.41 Da - Acceptable.
* **TPSA:** 90.54 - Slightly higher, but still reasonably good.
* **logP:** -0.115 - Very low, likely to cause permeability issues.
* **HBD:** 3 - Good.
* **HBA:** 4 - Good.
* **QED:** 0.416 - Moderate, could be improved.
* **DILI:** 33.42 - Good, low risk.
* **BBB:** 64.25 - Moderate, not a primary concern here.
* **Caco-2:** -5.284 - Poor permeability.
* **Solubility:** -1.102 - Poor solubility.
* **hERG:** 0.233 - Low risk.
* **Cl_mic:** -3.315 - Negative clearance, similar concern as Ligand A.
* **t1/2:** -33.248 - Very short half-life, problematic.
* **Pgp:** 0.005 - Very low efflux, favorable.
* **Affinity:** -6.2 kcal/mol - Good binding affinity, slightly weaker than Ligand A.
**Comparison and Decision:**
Both ligands have significant drawbacks regarding permeability (Caco-2) and solubility. However, Ligand A has a slightly better affinity (-6.5 vs -6.2 kcal/mol), a better QED score (0.737 vs 0.416), and a more reasonable in vitro half-life (6.879 vs -33.248). The negative clearance values for both are concerning, but the other properties of A are slightly more favorable. The slightly lower logP of A is a concern, but the better binding affinity and drug-like properties outweigh this.
Therefore, I would choose Ligand A.
1
2025-04-17 21:20:32,732 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (357.43 & 361.46 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (78.95) is higher than Ligand B (64.63). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B has a slight advantage.
3. **logP:** Ligand A (1.461) is within the optimal range (1-3), while Ligand B (2.965) is approaching the upper limit. Both are acceptable, but Ligand A is slightly better balanced.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 5. Both are acceptable, under the threshold of 10.
6. **QED:** Both ligands have good QED scores (0.811 and 0.857), indicating good drug-likeness. No significant difference.
7. **DILI:** Ligand A (27.61%) has a much lower DILI risk than Ligand B (70.73%). This is a *major* advantage for Ligand A. DILI is a critical safety concern.
8. **BBB:** Both ligands have good BBB penetration (71.77% and 70.18%). Since ADRB2 is not a CNS target, this is less crucial, but still a positive.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-1.804) has better solubility than Ligand B (-3.722). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.234) has a much lower hERG inhibition liability than Ligand B (0.876). This is a significant safety advantage for Ligand A.
12. **Cl_mic:** Ligand A (24.83 mL/min/kg) has significantly lower microsomal clearance than Ligand B (39.37 mL/min/kg). Lower clearance implies better metabolic stability, a key advantage.
13. **t1/2:** Ligand A (-7.475 hours) has a much longer in vitro half-life than Ligand B (23.775 hours). This is a significant advantage, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.02) has lower P-gp efflux liability than Ligand B (0.696). Lower P-gp efflux is favorable for oral bioavailability.
15. **Binding Affinity:** Ligand A (-8.4 kcal/mol) has a slightly better binding affinity than Ligand B (-6.2 kcal/mol). This is a substantial difference in potency.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across several critical ADME-Tox parameters (DILI, hERG, Cl_mic, t1/2, Pgp) *and* has a better binding affinity. While both have issues with Caco-2 permeability, the superior safety profile and metabolic stability of Ligand A, combined with its stronger binding, make it the more promising drug candidate. The slightly higher TPSA is a minor drawback compared to the significant advantages in other areas.
Output:
1
2025-04-17 21:20:32,732 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
The ADRB2 receptor is a GPCR, so the priorities are logP, TPSA, Pgp efflux, BBB penetration, and binding affinity. Metabolic stability and solubility are also important, but less critical than the first set.
Let's compare the ligands property by property:
1. **MW:** Both ligands (364.8 and 363.4 Da) are within the ideal range (200-500 Da).
2. **TPSA:** Ligand A (74.33) is significantly better than Ligand B (105.98). A lower TPSA generally indicates better cell permeability, crucial for GPCR targeting. Ligand A is well below the 140 threshold, while B is approaching it.
3. **logP:** Both ligands have good logP values (1.536 and 1.241), falling within the optimal 1-3 range.
4. **HBD/HBA:** Both have 2 HBDs, which is good. Ligand B has 6 HBAs compared to Ligand A's 3. Higher HBA can sometimes hinder permeability.
5. **QED:** Ligand B (0.734) has a slightly better QED score than Ligand A (0.586), indicating a more drug-like profile.
6. **DILI:** Ligand B (76.08%) has a higher DILI risk than Ligand A (59.98%). This is a significant negative for Ligand B.
7. **BBB:** Ligand A (73.79%) has significantly better BBB penetration potential than Ligand B (48.16%). This is a crucial advantage for a GPCR target, even if it's not strictly CNS-focused, as it suggests better distribution.
8. **Caco-2:** Ligand A (-4.719) has a better Caco-2 permeability than Ligand B (-5.284).
9. **Solubility:** Ligand A (-3.739) has better aqueous solubility than Ligand B (-2.965).
10. **hERG:** Both ligands have very low hERG inhibition liability (0.232 and 0.097), which is excellent.
11. **Cl_mic:** Ligand A (-0.785) has better metabolic stability (lower clearance) than Ligand B (-3.506).
12. **t1/2:** Ligand B (18.154 hours) has a significantly longer in vitro half-life than Ligand A (-11.22 hours). This is a positive for Ligand B.
13. **Pgp:** Ligand A (0.078) has lower P-gp efflux than Ligand B (0.022), which is preferable.
14. **Binding Affinity:** Ligand B (-7.2 kcal/mol) has a slightly better binding affinity than Ligand A (-7.6 kcal/mol). While a difference of 0.4 kcal/mol is not huge, it's a factor.
**Overall Assessment:**
Ligand A is the stronger candidate. While Ligand B has a slightly better binding affinity and half-life, Ligand A excels in crucial ADME properties for a GPCR target: TPSA, BBB penetration, solubility, metabolic stability, and lower DILI risk. The better TPSA and BBB are particularly important for ensuring adequate tissue distribution and receptor engagement. The lower DILI risk is also a significant safety advantage.
Output:
1
2025-04-17 21:20:32,732 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (355.435 and 347.459 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (71.41) is significantly better than Ligand A (120.25). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (1.724) is within the optimal 1-3 range, while Ligand A (0.074) is quite low. This is a significant drawback for Ligand A, potentially hindering membrane permeability.
4. **HBD:** Ligand A (4) is higher than Ligand B (1). While both are acceptable, lower HBD is generally preferred for permeability.
5. **HBA:** Ligand A (6) is higher than Ligand B (4). Again, lower is generally better.
6. **QED:** Ligand B (0.575) has a better QED score than Ligand A (0.397), indicating a more drug-like profile.
7. **DILI:** Both ligands have acceptable DILI risk (Ligand A: 35.285, Ligand B: 30.787), both below the 40% threshold. Ligand B is slightly better.
8. **BBB:** Ligand B (57.736) has a much higher BBB penetration percentile than Ligand A (23.11). While not critical for a cardiovascular target, it's a positive attribute.
9. **Caco-2:** Ligand A (-5.305) is significantly worse than Ligand B (-4.81). This suggests poor intestinal absorption for Ligand A.
10. **Solubility:** Ligand A (-1.958) is slightly worse than Ligand B (-1.202), but both are relatively poor.
11. **hERG:** Ligand A (0.153) is slightly better than Ligand B (0.355), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand A (-2.577) has a much lower (better) microsomal clearance than Ligand B (50.559). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (13.561) has a longer half-life than Ligand B (-0.154). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.063) has a much lower Pgp efflux liability than Ligand B (0.205), indicating better bioavailability.
15. **Affinity:** Ligand A (-7.3 kcal/mol) has a slightly better binding affinity than Ligand B (-6.5 kcal/mol). This is a significant advantage, exceeding the 1.5 kcal/mol threshold.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in TPSA and has a reasonable logP. Ligand A has a poor logP but compensates with superior affinity, lower Pgp efflux, and better metabolic stability. The affinity difference is substantial.
**Overall Assessment:**
Despite Ligand A's low logP and solubility, its significantly better binding affinity (-7.3 vs -6.5 kcal/mol), lower Pgp efflux, and improved metabolic stability (lower Cl_mic and longer t1/2) outweigh the drawbacks. The affinity difference is large enough to overcome the permeability concerns, and formulation strategies can be explored to address solubility. Ligand B's better TPSA and logP are positive, but the weaker binding and higher Pgp efflux are significant liabilities.
Output:
1
2025-04-17 21:20:32,732 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (346.402) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (58.64) is significantly better than Ligand B (94.22). ADRB2 is a cardiovascular target, not a CNS target, but lower TPSA is still desirable for good absorption. Ligand B is pushing the upper limit for good oral absorption.
3. **logP:** Ligand A (2.202) is optimal. Ligand B (0.081) is quite low, potentially hindering membrane permeability and absorption.
4. **HBD:** Both ligands are acceptable (Ligand A: 1, Ligand B: 2), well within the limit of 5.
5. **HBA:** Ligand A (3) is preferable to Ligand B (6). Lower HBA generally improves permeability.
6. **QED:** Both ligands have good QED scores (Ligand A: 0.635, Ligand B: 0.728), indicating good drug-like properties.
7. **DILI:** Ligand A (37.96) has a lower DILI risk than Ligand B (42.885), which is preferable. Both are below the 60% threshold.
8. **BBB:** This is less critical for a cardiovascular target. Ligand A (84.529) is much higher than Ligand B (14.075).
9. **Caco-2:** Ligand A (-4.646) is better than Ligand B (-5.747), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-2.486) is better than Ligand B (-1.356), suggesting better aqueous solubility.
11. **hERG:** Ligand A (0.769) is better than Ligand B (0.066), indicating a lower risk of cardiotoxicity. This is *very* important for a cardiovascular target.
12. **Cl_mic:** Ligand A (31.456) has a lower microsomal clearance than Ligand B (-31.334), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-0.624) is better than Ligand B (-6.696), indicating a longer in vitro half-life.
14. **Pgp:** Ligand A (0.299) is better than Ligand B (0.004), suggesting lower P-gp efflux.
15. **Affinity:** Both ligands have very similar binding affinities (-6.9 kcal/mol and -6.4 kcal/mol, respectively). The difference is not substantial enough to outweigh the other significant differences.
**Overall Assessment:**
Ligand A is significantly better across most key ADME properties (TPSA, logP, solubility, hERG, Cl_mic, t1/2, Pgp) and has a lower DILI risk. While both have acceptable QED and similar binding affinities, the superior ADME profile of Ligand A makes it the more promising drug candidate for the ADRB2 receptor. The low logP of Ligand B is a major concern, potentially leading to poor absorption.
Output:
1
2025-04-17 21:20:32,732 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [368.459, 116.4 , 0.916, 4. , 4. , 0.546, 49.632, 65.452, -5.349, -2.752, 0.242, 30.971, -16.329, 0.01 , -6.5 ]**
**Ligand B: [426.242, 68.02 , 4.258, 1. , 5. , 0.634, 90.733, 70.997, -4.468, -5.355, 0.393, 35.624, 12.191, 0.345, -6.3 ]**
1. **Molecular Weight:** Ligand A (368.459 Da) is within the ideal range (200-500 Da). Ligand B (426.242 Da) is also acceptable, but closer to the upper limit.
2. **TPSA:** Ligand A (116.4) is slightly above the optimal <140 for good oral absorption, but still reasonable. Ligand B (68.02) is excellent, well below 140, suggesting good absorption.
3. **logP:** Ligand A (0.916) is a bit low, potentially causing permeability issues. Ligand B (4.258) is high, potentially leading to solubility and off-target effects, but within the acceptable range.
4. **H-Bond Donors:** Ligand A (4) is acceptable. Ligand B (1) is also good.
5. **H-Bond Acceptors:** Ligand A (4) is acceptable. Ligand B (5) is also acceptable.
6. **QED:** Both Ligand A (0.546) and Ligand B (0.634) have good drug-likeness scores.
7. **DILI:** Ligand A (49.632) has a much lower DILI risk than Ligand B (90.733). This is a significant advantage for Ligand A.
8. **BBB:** Both ligands show reasonable BBB penetration, with Ligand B (70.997) being slightly better than Ligand A (65.452). For a cardiovascular target like ADRB2, BBB penetration isn't *critical*, but can be beneficial.
9. **Caco-2:** Ligand A (-5.349) has poor Caco-2 permeability, indicating poor absorption. Ligand B (-4.468) is also poor, but slightly better.
10. **Solubility:** Ligand A (-2.752) has poor solubility. Ligand B (-5.355) has even worse solubility.
11. **hERG:** Both ligands have low hERG inhibition risk (0.242 and 0.393, respectively).
12. **Cl_mic:** Ligand A (30.971) has a lower microsomal clearance, suggesting better metabolic stability. Ligand B (35.624) has higher clearance.
13. **t1/2:** Ligand A (-16.329) has a negative in vitro half-life, which is concerning. Ligand B (12.191) has a positive and reasonable half-life.
14. **Pgp:** Both ligands have low P-gp efflux (0.01 and 0.345, respectively).
15. **Binding Affinity:** Both ligands have similar, strong binding affinities (-6.5 and -6.3 kcal/mol). The difference is not substantial enough to be a deciding factor.
**Overall Assessment:**
Ligand A has a better DILI profile and metabolic stability. However, it suffers from poor Caco-2 permeability, solubility, and a negative half-life. Ligand B has a higher DILI risk and faster metabolism, but better TPSA, slightly better BBB, and a positive half-life. Given the cardiovascular target, solubility and permeability are important, but not paramount. The significant DILI risk associated with Ligand B is a major concern. The negative half-life of Ligand A is also a significant drawback.
Considering the balance, Ligand B's slightly better permeability and positive half-life, despite the higher DILI, make it a marginally better candidate. Further optimization could address the DILI risk.
Output:
0
2025-04-17 21:20:32,732 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.359 and 346.471 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (137.58) is slightly above the optimal <140 for oral absorption, but still reasonable. Ligand B (53.76) is excellent, well below 90, suggesting good permeability. This favors Ligand B.
3. **logP:** Ligand A (-0.203) is a bit low, potentially hindering membrane permeability. Ligand B (3.868) is near the upper end of the optimal range (1-3), but still acceptable. This favors Ligand B.
4. **HBD:** Ligand A (4) is within the acceptable limit of <=5. Ligand B (0) is even better, minimizing potential issues with hydrogen bonding and maximizing permeability. This favors Ligand B.
5. **HBA:** Ligand A (7) is within the acceptable limit of <=10. Ligand B (3) is excellent, further supporting permeability. This favors Ligand B.
6. **QED:** Both ligands have similar and good QED scores (0.543 and 0.556), indicating good drug-like properties. No significant difference.
7. **DILI:** Ligand A (63.086) is slightly higher than Ligand B (49.981), indicating a marginally higher risk of drug-induced liver injury. This favors Ligand B.
8. **BBB:** Ligand A (16.945) has very low BBB penetration. Ligand B (65.374) has good BBB penetration. While ADRB2 isn't strictly a CNS target, some CNS exposure is not necessarily detrimental and could provide additional therapeutic effects. This strongly favors Ligand B.
9. **Caco-2:** Ligand A (-5.611) is poor, indicating poor intestinal absorption. Ligand B (-4.654) is also poor, but slightly better than A.
10. **Solubility:** Ligand A (-1.407) is poor, while Ligand B (-2.992) is even worse. Both are concerning, and formulation challenges are likely.
11. **hERG:** Ligand A (0.062) has a very low hERG risk, which is excellent. Ligand B (0.608) is slightly higher, but still relatively low. This favors Ligand A, but the difference isn't huge.
12. **Cl_mic:** Ligand A (23.007) has lower microsomal clearance, suggesting better metabolic stability. Ligand B (74.754) has higher clearance, which is less desirable. This favors Ligand A.
13. **t1/2:** Ligand A (3.236) has a shorter half-life than Ligand B (20.815). A longer half-life is generally preferred, favoring Ligand B.
14. **Pgp:** Ligand A (0.023) has very low P-gp efflux, which is excellent. Ligand B (0.726) has moderate P-gp efflux, which could limit bioavailability. This strongly favors Ligand A.
15. **Affinity:** Ligand A (-7.8) has a significantly stronger binding affinity than Ligand B (-6.2). This is a substantial advantage, potentially outweighing some of the ADME drawbacks.
**Overall Assessment:**
While Ligand A has a superior binding affinity and better P-gp and hERG profiles, Ligand B demonstrates significantly better ADME properties, particularly TPSA, logP, BBB penetration, and half-life. Considering ADRB2 is a GPCR, permeability and metabolic stability are crucial. The substantial affinity difference (-1.6 kcal/mol) is a significant advantage for Ligand A, but the poor permeability and efflux liability of Ligand A are major concerns. The better ADME profile of Ligand B, despite the slightly lower affinity, makes it a more promising starting point for optimization.
Output:
0
2025-04-17 21:20:32,732 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor (a GPCR).
**Ligand A: [349.519, 52.65, 2.262, 1, 3, 0.847, 8.414, 75.107, -4.801, -1.422, 0.492, -4.144, -5.055, 0.046, -7.2]**
**Ligand B: [342.531, 41.05, 4.584, 1, 4, 0.736, 39.046, 94.339, -4.776, -5.242, 0.936, 96.116, 61.517, 0.586, -6.1]**
Here's a breakdown, comparing each parameter and considering GPCR priorities (logP, Pgp, TPSA, BBB, and affinity are key):
1. **MW:** Both are within the ideal range (200-500 Da). A is 349.5, B is 342.5. Very similar.
2. **TPSA:** A (52.65) is slightly higher than B (41.05), but both are well below the 140 threshold for oral absorption. B is better here.
3. **logP:** A (2.262) is optimal. B (4.584) is pushing the upper limit and could lead to solubility issues or off-target interactions. A is better.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** A has 3, B has 4. Both are acceptable, but A is slightly preferred.
6. **QED:** A (0.847) is better than B (0.736), indicating a more drug-like profile.
7. **DILI:** A (8.414) is significantly lower (better) than B (39.046). This is a major advantage for A.
8. **BBB:** A (75.107) is good, but B (94.339) is excellent. For a GPCR, higher BBB is a plus, though not always essential. B is better.
9. **Caco-2:** Both are negative, indicating good permeability. Values are very similar.
10. **Solubility:** A (-1.422) is better than B (-5.242). B's higher logP likely contributes to this.
11. **hERG:** A (0.492) is much lower (better) than B (0.936), indicating a lower risk of cardiotoxicity. A is significantly better.
12. **Cl_mic:** A (-4.144) is better (lower clearance, more stable) than B (96.116). This is a significant advantage for A.
13. **t1/2:** B (61.517) has a much longer half-life than A (-5.055). This is a strong point for B.
14. **Pgp:** A (0.046) is much lower (better) than B (0.586), indicating less efflux and potentially better bioavailability. A is better.
15. **Affinity:** A (-7.2) is significantly stronger than B (-6.1). This is a substantial advantage for A. A 1.1 kcal/mol difference is quite meaningful.
**Overall Assessment:**
Ligand A clearly outperforms Ligand B in most critical parameters. While Ligand B has a better BBB penetration and *in vitro* half-life, A excels in DILI risk, hERG inhibition, metabolic stability (Cl_mic), Pgp efflux, solubility, and, crucially, binding affinity. The stronger binding affinity of A, combined with its superior safety profile (DILI, hERG) and better ADME properties (Cl_mic, Pgp, solubility), outweigh the benefit of B's longer half-life and slightly better BBB. Given the GPCR target class, the strong affinity and favorable safety profile of A are paramount.
Output:
1
2025-04-17 21:20:32,732 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (361.383 and 385.247 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (45.23) is significantly better than Ligand B (84.63). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have similar logP values (3.431 and 3.474), falling within the optimal 1-3 range.
4. **HBD:** Ligand A (1) has fewer HBD than Ligand B (2). Fewer is generally preferred for permeability.
5. **HBA:** Ligand A (3) has fewer HBA than Ligand B (5). Again, fewer is generally preferred.
6. **QED:** Ligand A (0.818) has a much better QED score than Ligand B (0.392), indicating a more drug-like profile.
7. **DILI:** Ligand A (18.108) has a significantly lower DILI risk than Ligand B (54.75). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (89.957) has a higher BBB penetration percentile than Ligand B (47.15). While not critical for a cardiovascular target, it's still a positive.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.636 and -4.924), indicating poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-2.818) has slightly better solubility than Ligand B (-4.344), but both are poor.
11. **hERG:** Both ligands have low hERG inhibition risk (0.878 and 0.943).
12. **Cl_mic:** Ligand A (-13.969) has a much lower (better) microsomal clearance than Ligand B (25.597), indicating better metabolic stability.
13. **t1/2:** Ligand B (25.476) has a longer in vitro half-life than Ligand A (11.91), which is a positive.
14. **Pgp:** Ligand A (0.166) has lower P-gp efflux liability than Ligand B (0.8). This is favorable.
15. **Binding Affinity:** Ligand B (-6.2) has a significantly better binding affinity than Ligand A (-4.4). This is a substantial advantage.
**Overall Assessment:**
Ligand B has a much stronger binding affinity, which is a critical factor for GPCRs. However, Ligand A has a significantly better safety profile (lower DILI), better drug-likeness (higher QED), better metabolic stability (lower Cl_mic), and lower P-gp efflux. The poor Caco-2 values are a concern for both, but the other advantages of Ligand A, especially the lower DILI and better metabolic stability, outweigh the affinity difference, particularly for a cardiovascular target where CNS penetration is less crucial. The affinity difference of 1.8 kcal/mol is substantial, but not insurmountable given the other benefits of Ligand A.
Output:
1
2025-04-17 21:20:32,733 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (357.841 and 378.51 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (62.3) is significantly better than Ligand B (84.5). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally improves absorption.
3. **logP:** Ligand A (3.678) is slightly higher than Ligand B (1.754), but both are within the optimal 1-3 range. Ligand A is closer to the upper limit, which could be a minor concern.
4. **HBD:** Ligand A (1) is better than Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (3) is better than Ligand B (4). Fewer HBAs generally improve permeability.
6. **QED:** Ligand A (0.83) is significantly better than Ligand B (0.607), indicating a more drug-like profile.
7. **DILI:** Ligand B (34.238) has a much lower DILI risk than Ligand A (62.117). This is a significant advantage for Ligand B.
8. **BBB:** Ligand B (81.466) has a higher BBB penetration percentile than Ligand A (71.966). While not a primary concern for a cardiovascular target, it's a slight positive.
9. **Caco-2:** Both ligands have similarly poor Caco-2 permeability (-4.819 and -4.927). This is a concern for both, suggesting potential absorption issues.
10. **Solubility:** Ligand A (-4.146) has slightly better solubility than Ligand B (-2.535).
11. **hERG:** Both ligands have low hERG inhibition risk (0.329 and 0.467). No clear advantage.
12. **Cl_mic:** Ligand B (23.519) has lower microsomal clearance than Ligand A (29.743), indicating better metabolic stability.
13. **t1/2:** Ligand A (32.524) has a longer in vitro half-life than Ligand B (-19.631). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.14) has lower P-gp efflux liability than Ligand B (0.086). Lower P-gp efflux is generally preferred.
15. **Binding Affinity:** Ligand A (-6.8) has a slightly better binding affinity than Ligand B (-6.3). While the difference is not huge (0.5 kcal/mol), it is still a positive for Ligand A.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A performs better on TPSA, Pgp, and affinity, while Ligand B has better logP. However, the significant advantage of Ligand A in QED and the longer half-life are compelling. The lower DILI risk for Ligand B is attractive, but the overall profile of Ligand A is more favorable.
**Conclusion:**
Considering the balance of properties, especially the better QED, longer half-life, and slightly better affinity of Ligand A, I believe it is the more promising drug candidate.
Output:
1
2025-04-17 21:20:32,733 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (338.411 and 348.447 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (89.18) is slightly higher than Ligand B (76.46). Both are below the 140 A^2 threshold for good oral absorption, but Ligand B is preferable due to being closer to the 90 A^2 target for GPCRs.
**3. logP:** Both ligands have good logP values (1.914 and 1.247), falling within the optimal 1-3 range. Ligand B is slightly lower, which could potentially improve solubility, but both are acceptable.
**4. H-Bond Donors:** Both ligands have 1 HBD, which is within the acceptable limit of 5.
**5. H-Bond Acceptors:** Ligand A has 4 HBAs, and Ligand B has 5. Both are below the 10 limit.
**6. QED:** Ligand A (0.902) has a significantly better QED score than Ligand B (0.753), indicating a more drug-like profile.
**7. DILI:** Ligand B (32.687) has a lower DILI risk than Ligand A (41.334), which is a significant advantage. Lower DILI is always preferred.
**8. BBB:** Both ligands have good BBB penetration (82.358 and 78.558), but Ligand A is slightly better. While ADRB2 is cardiovascular, some CNS off-target effects are always a concern, so higher BBB is slightly favorable.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-5.296 and -5.074), indicating poor permeability. This is a concern for both.
**10. Aqueous Solubility:** Both ligands have negative solubility values (-2.29 and -1.323), indicating poor solubility. This is a significant drawback for both.
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.252 and 0.299). This is excellent.
**12. Microsomal Clearance:** Ligand A (6.745) has significantly lower microsomal clearance than Ligand B (54.733), suggesting better metabolic stability. This is a major advantage for Ligand A.
**13. In vitro Half-Life:** Ligand A (1.605) has a slightly shorter half-life than Ligand B (1.395), but the difference is minimal.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.163 and 0.199). This is favorable.
**15. Binding Affinity:** Ligand B (-8.5 kcal/mol) has a significantly stronger binding affinity than Ligand A (-7.1 kcal/mol). This is a substantial advantage, exceeding the 1.5 kcal/mol difference threshold.
**Overall Assessment:**
While Ligand A has better QED, metabolic stability (lower Cl_mic), and slightly better BBB penetration, the significantly stronger binding affinity of Ligand B (-8.5 vs -7.1 kcal/mol) is the most important factor, especially for a GPCR target. The lower DILI risk for Ligand B is also a significant benefit. The poor Caco-2 and solubility are concerns for both, but can be addressed through formulation strategies. The improved potency of Ligand B outweighs the other minor advantages of Ligand A.
Output:
0
2025-04-17 21:20:32,733 - INFO - Batch 251 complete. Total preferences: 4016
2025-04-17 21:20:32,733 - INFO - Processing batch 252/512...
2025-04-17 21:21:22,012 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (354.495) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are below the 140 A^2 threshold for good oral absorption. Ligand A (81.75) is slightly lower than Ligand B (83.56), which is a minor advantage.
3. **logP:** Ligand A (0.454) is quite low, potentially hindering membrane permeability. Ligand B (1.984) is better, falling within the optimal 1-3 range. This is a significant advantage for Ligand B.
4. **HBD:** Both have 2 HBD, which is within the acceptable limit of 5.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 7 HBA. Both are within the acceptable limit of 10, but Ligand A is preferable.
6. **QED:** Both ligands have good QED scores (A: 0.63, B: 0.697), indicating drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (10.934) has a much lower DILI risk than Ligand B (49.515). This is a substantial advantage for Ligand A.
8. **BBB:** Ligand B (78.907) has a better BBB penetration percentile than Ligand A (60.566). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be beneficial or at least avoided as an off-target effect.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-5.138) is slightly better than Ligand B (-4.91).
10. **Solubility:** Ligand A (-0.717) has slightly better solubility than Ligand B (-2.733).
11. **hERG:** Both have low hERG inhibition risk (A: 0.211, B: 0.568), which is good. Ligand A is preferable.
12. **Cl_mic:** Ligand B (26.726) has a lower microsomal clearance than Ligand A (32.741), suggesting better metabolic stability.
13. **t1/2:** Ligand B (18.772) has a significantly longer in vitro half-life than Ligand A (-21.343). This is a major advantage for Ligand B.
14. **Pgp:** Ligand A (0.003) has very low P-gp efflux liability, which is excellent. Ligand B (0.155) is also low, but not as favorable.
15. **Binding Affinity:** Ligand B (-6.7 kcal/mol) has a stronger binding affinity than Ligand A (-5.7 kcal/mol). This is a 1.0 kcal/mol difference, which is significant and can outweigh some ADME drawbacks.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are crucial. Ligand B excels in affinity and has a better logP. Ligand A has better Pgp efflux liability, but the affinity difference is substantial.
**Overall Assessment:**
Ligand B has a superior binding affinity, better logP, and a significantly longer half-life, which are critical for a GPCR target. While Ligand A has a lower DILI risk, the affinity advantage of Ligand B is substantial enough to outweigh this concern, especially considering the relatively low DILI risk of Ligand B (under 50%). The slightly better BBB penetration of Ligand B is also a minor benefit.
Output:
0
2025-04-17 21:21:22,012 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (345.403 Da) is well within the ideal range (200-500 Da). Ligand B (385.251 Da) is also acceptable. No clear advantage here.
2. **TPSA:** Ligand A (101.65) is slightly above the preferred <140 for oral absorption, but still reasonable. Ligand B (97.11) is better, falling comfortably under 140.
3. **logP:** Ligand A (0.162) is quite low, potentially hindering membrane permeability. Ligand B (2.403) is within the optimal 1-3 range. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (1) is good. Ligand B (2) is also acceptable.
5. **HBA:** Ligand A (6) is good. Ligand B (5) is also good.
6. **QED:** Both ligands have good QED scores (A: 0.582, B: 0.727), indicating drug-likeness. Ligand B is slightly better.
7. **DILI:** Ligand A (51.648) has a lower DILI risk than Ligand B (69.523). This favors Ligand A.
8. **BBB:** Ligand A (70.686) shows good BBB penetration, while Ligand B (30.477) is poor. Since ADRB2 is a GPCR, BBB penetration is a consideration, and Ligand A is better here.
9. **Caco-2:** Ligand A (-4.79) and Ligand B (-5.398) both have negative values. This is unusual and suggests very poor permeability.
10. **Solubility:** Ligand A (-1) is very poor, while Ligand B (-2.542) is also poor. Both are problematic.
11. **hERG:** Ligand A (0.243) has a very low hERG risk, which is excellent. Ligand B (0.013) is even lower, which is also excellent.
12. **Cl_mic:** Ligand A (-3.172) has a negative clearance, which is excellent and indicates high metabolic stability. Ligand B (16.31) is high, suggesting rapid metabolism. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (-37.629) has a very long half-life, which is excellent. Ligand B (-22.102) is also good, but not as long.
14. **Pgp:** Both ligands have very low Pgp efflux liability (A: 0.003, B: 0.025), which is good.
15. **Affinity:** Ligand B (-7.6 kcal/mol) has a slightly better binding affinity than Ligand A (-6.7 kcal/mol). This is a 0.9 kcal/mol difference, which is substantial.
**Overall Assessment:**
Ligand B has a significantly better logP and binding affinity, which are crucial for GPCR targets. However, it suffers from poor BBB penetration, higher DILI risk, and significantly higher metabolic clearance. Ligand A has excellent metabolic stability (Cl_mic and t1/2), lower DILI, and good BBB penetration. While its logP is low and solubility is poor, the superior metabolic profile and acceptable BBB penetration outweigh these drawbacks, especially considering the modest affinity difference. The poor solubility of both compounds is a concern that would need to be addressed in formulation.
Given the priorities for GPCRs (logP, Pgp, TPSA, affinity, and BBB), and considering the balance of properties, Ligand A is the more promising candidate.
Output:
1
2025-04-17 21:21:22,013 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (353.369 Da and 344.415 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (75.44) is better than Ligand B (91.4). For a cardiovascular GPCR, TPSA should be <140, both are, but lower is generally preferred for better absorption.
**3. logP:** Ligand A (2.304) is within the optimal 1-3 range. Ligand B (0.595) is a bit low, potentially hindering membrane permeability. This is a significant drawback for GPCR ligands.
**4. H-Bond Donors:** Both ligands have 1-2 HBD, which is acceptable.
**5. H-Bond Acceptors:** Both ligands have 4 HBA, which is acceptable.
**6. QED:** Ligand A (0.824) has a significantly higher QED score than Ligand B (0.56), indicating a more drug-like profile.
**7. DILI Risk:** Ligand A (55.874) has a higher DILI risk than Ligand B (32.261), but both are reasonably low.
**8. BBB Penetration:** Ligand A (91.392) has much better BBB penetration than Ligand B (60.876). While not a primary concern for a cardiovascular target, it's a bonus.
**9. Caco-2 Permeability:** Ligand A (-4.735) is better than Ligand B (-5.398). Both are negative, but less negative is better.
**10. Aqueous Solubility:** Ligand A (-2.935) is better than Ligand B (-2.135). Both are negative, but less negative is better.
**11. hERG Inhibition:** Both ligands show very low hERG inhibition risk (0.174 and 0.08 respectively).
**12. Microsomal Clearance:** Ligand B (-5.8) has a much lower (better) microsomal clearance than Ligand A (27.467), suggesting greater metabolic stability. This is a significant advantage.
**13. In vitro Half-Life:** Ligand B (-3.209) has a better in vitro half-life than Ligand A (-47.426).
**14. P-gp Efflux:** Both ligands show very low P-gp efflux liability (0.109 and 0.018 respectively).
**15. Binding Affinity:** Ligand A (-7.3 kcal/mol) has a slightly better binding affinity than Ligand B (-6.6 kcal/mol). While the difference is not huge, it's enough to consider.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand A is the stronger candidate. While Ligand B has better metabolic stability and lower DILI risk, the significantly lower logP is a major concern for membrane permeability and target engagement. Ligand A's better logP, TPSA, QED, and slightly better affinity outweigh the drawbacks of slightly higher DILI and clearance.
Output:
1
2025-04-17 21:21:22,013 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.475 & 358.479 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (59.08) is significantly better than Ligand B (99.1). For a GPCR, lower TPSA is generally preferred for better permeability, although ADRB2 isn't necessarily a CNS target, lower TPSA is still beneficial.
3. **logP:** Ligand A (1.533) is better than Ligand B (0.678). Both are within the optimal 1-3 range, but Ligand A is closer to the sweet spot.
4. **HBD:** Ligand A (0) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is better than Ligand B (5). Lower HBA is preferred for permeability.
6. **QED:** Ligand A (0.697) is better than Ligand B (0.533), suggesting a more drug-like profile.
7. **DILI:** Ligand A (9.771) is *much* better than Ligand B (23.575). This is a critical advantage for Ligand A, as liver toxicity is a major concern.
8. **BBB:** Ligand A (89.066) is significantly better than Ligand B (29.779). While ADRB2 isn't exclusively a CNS target, some peripheral effects are mediated by CNS pathways, and higher BBB penetration can be advantageous.
9. **Caco-2:** Ligand A (-4.37) is better than Ligand B (-5.046). Both are negative, indicating poor permeability, but A is slightly better.
10. **Solubility:** Ligand A (-1.294) is better than Ligand B (-0.59). Both are poor, but A is less poor.
11. **hERG:** Ligand A (0.34) is better than Ligand B (0.23). Both are low, indicating low risk of cardiotoxicity.
12. **Cl_mic:** Ligand A (41.132) is better than Ligand B (15.807). Lower clearance indicates better metabolic stability, a significant advantage for Ligand A.
13. **t1/2:** Ligand A (-3.119) is better than Ligand B (3.818). A negative value indicates a longer half-life, which is desirable.
14. **Pgp:** Ligand A (0.052) is better than Ligand B (0.035). Lower Pgp efflux is preferred for improved bioavailability.
15. **Affinity:** Ligand A (-6.5 kcal/mol) is slightly better than Ligand B (-5.9 kcal/mol). While both are good, the 0.6 kcal/mol difference is noticeable and can outweigh some of the ADME drawbacks.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical parameters. The most significant advantages for Ligand A are its substantially lower DILI risk, better metabolic stability (lower Cl_mic and better t1/2), and slightly better binding affinity. While both have poor solubility and Caco-2 permeability, Ligand A is still better in these areas. Given the GPCR target class, the balance of properties in Ligand A makes it a more promising drug candidate.
Output:
1
2025-04-17 21:21:22,013 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (362.417) is slightly higher than Ligand B (348.393), but both are acceptable.
2. **TPSA:** Ligand A (78.87) is higher than Ligand B (49.41). For a cardiovascular GPCR, TPSA isn't a *critical* factor like it would be for a CNS target, but lower is generally preferred for absorption. Ligand B is significantly better here.
3. **logP:** Both ligands have good logP values (A: 1.028, B: 2.747), falling within the optimal 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable, below the threshold of 5. Ligand B is slightly better.
5. **HBA:** Ligand A (4) and Ligand B (2) are both acceptable, below the threshold of 10. Ligand B is better.
6. **QED:** Both ligands have similar, acceptable QED values (A: 0.676, B: 0.635), indicating good drug-like properties.
7. **DILI:** Ligand A (17.449) has a much lower DILI risk than Ligand B (44.668). This is a significant advantage for Ligand A.
8. **BBB:** Both ligands have reasonably high BBB penetration (A: 82.474, B: 87.088). Since ADRB2 isn't a primary CNS target, this isn't a major deciding factor, but higher is still slightly preferable. Ligand B is slightly better.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.817 and -4.624). This is unusual and suggests poor permeability. However, the values are very close, so this isn't a strong differentiator.
10. **Solubility:** Ligand A (-1.714) has better solubility than Ligand B (-3.232). This is a positive for Ligand A.
11. **hERG:** Both ligands have low hERG inhibition risk (A: 0.587, B: 0.497). Both are acceptable.
12. **Cl_mic:** Ligand A (0.474) has much lower microsomal clearance than Ligand B (43.795). This indicates significantly better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (-11.215) has a much longer in vitro half-life than Ligand B (-4.056). This is a major advantage for Ligand A, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have low P-gp efflux liability (A: 0.047, B: 0.18). Both are acceptable.
15. **Binding Affinity:** Ligand B (-7.4) has a significantly stronger binding affinity than Ligand A (-2.2). This is a substantial advantage for Ligand B, potentially outweighing some ADME drawbacks.
**GPCR-Specific Priorities:**
For ADRB2 (a cardiovascular GPCR), the priorities are affinity, logP, TPSA, Pgp, and metabolic stability. Ligand B excels in affinity and has a good logP and TPSA. Ligand A excels in metabolic stability (Cl_mic and t1/2) and has a lower DILI risk.
**Overall Assessment:**
The difference in binding affinity is substantial (-7.4 vs -2.2 kcal/mol). While Ligand A has better ADME properties (lower DILI, better metabolic stability, longer half-life, better solubility), the significantly stronger binding of Ligand B is likely to be more crucial for efficacy. The slightly higher TPSA and DILI risk of Ligand B are acceptable trade-offs for the much improved potency.
Output:
0
2025-04-17 21:21:22,013 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (426.332 Da) is slightly higher than Ligand B (342.355 Da), but both are acceptable.
**2. TPSA:** Ligand A (55.84) is significantly better than Ligand B (104.65). For a GPCR, lower TPSA is generally preferred for better permeability. Ligand B is above the 90 A^2 threshold, which is a concern.
**3. logP:** Ligand A (3.603) is within the optimal range (1-3), while Ligand B (0.232) is quite low. Low logP can hinder membrane permeability. This is a significant advantage for Ligand A.
**4. H-Bond Donors:** Ligand A (0) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
**5. H-Bond Acceptors:** Ligand A (4) is better than Ligand B (6). Lower HBA is also favorable for permeability.
**6. QED:** Both ligands have good QED scores (A: 0.709, B: 0.806), indicating good drug-like properties.
**7. DILI:** Both ligands have similar DILI risk (A: 70.841, B: 77.394), and are within acceptable limits (<80).
**8. BBB:** Ligand A (52.191) is better than Ligand B (21.985), although neither is exceptionally high. For a cardiovascular target, BBB penetration isn't *critical* but can be beneficial for off-target effects.
**9. Caco-2:** Both have negative Caco-2 values (-4.814 and -4.985). This is unusual and suggests poor permeability in this assay. However, the TPSA and logP values are more informative.
**10. Solubility:** Ligand A (-5.722) is better than Ligand B (-2.736). Better solubility is generally desirable.
**11. hERG:** Ligand A (0.753) is better than Ligand B (0.141). Lower hERG inhibition is crucial for avoiding cardiotoxicity, especially for a cardiovascular target.
**12. Cl_mic:** Ligand A (106.457) is worse than Ligand B (-10.905). Ligand B has a negative value, indicating very low clearance and good metabolic stability. This is a significant advantage for Ligand B.
**13. t1/2:** Ligand A (19.242) is better than Ligand B (9.522). Longer half-life is generally preferred.
**14. Pgp:** Ligand A (0.555) is better than Ligand B (0.059). Lower P-gp efflux is desirable for better bioavailability.
**15. Binding Affinity:** Ligand A (-7.6) has a significantly stronger binding affinity than Ligand B (-6.3). A 1.3 kcal/mol difference is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand A is the stronger candidate. While Ligand B has better metabolic stability (Cl_mic), the significantly better logP, TPSA, Pgp, hERG, and, most importantly, binding affinity of Ligand A outweigh this advantage. The stronger binding affinity is particularly important for a GPCR target. The solubility and half-life are also favorable for Ligand A.
Output:
1
2025-04-17 21:21:22,013 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (356.463 and 345.359 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (95.94) is better than Ligand B (136.47). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (1.09) is slightly better than Ligand B (0.1). Both are on the lower side of the optimal 1-3 range, but Ligand A is closer. Ligand B is quite low and might have permeability issues.
4. **HBD:** Both have acceptable HBD counts (2 and 5, respectively), within the guideline of <=5.
5. **HBA:** Both have acceptable HBA counts (5 and 7, respectively), within the guideline of <=10.
6. **QED:** Ligand A (0.666) is significantly better than Ligand B (0.428). A higher QED suggests a more drug-like profile.
7. **DILI:** Ligand A (21.598) has a much lower DILI risk than Ligand B (46.917). This is a crucial advantage.
8. **BBB:** Ligand A (40.171) is better than Ligand B (21.675), although neither is particularly high. As ADRB2 is a cardiovascular target, BBB penetration is not a priority.
9. **Caco-2:** Ligand A (-4.699) is better than Ligand B (-6.125). Higher Caco-2 values indicate better intestinal absorption.
10. **Solubility:** Ligand A (-2.304) is better than Ligand B (-2.017). Both are poor, but A is slightly better.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.196 and 0.149). This is good and not a differentiating factor.
12. **Cl_mic:** Ligand B (2.491) has a much lower microsomal clearance than Ligand A (60.656). Lower clearance indicates better metabolic stability, a significant advantage for Ligand B.
13. **t1/2:** Ligand B (-25.919) has a much longer in vitro half-life than Ligand A (-19.393). This is a significant advantage for Ligand B.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.044 and 0.006). This is good and not a differentiating factor.
15. **Binding Affinity:** Ligand B (-8.0) has a significantly stronger binding affinity than Ligand A (-5.7). This is a substantial advantage and can often outweigh minor ADME drawbacks.
**Overall Assessment:**
Ligand B has a significantly better binding affinity (-8.0 kcal/mol vs -5.7 kcal/mol) and improved metabolic stability (lower Cl_mic and longer t1/2). While Ligand A has a better QED and lower DILI risk, the substantial improvement in binding affinity of Ligand B is a major factor for GPCR targets. The slightly lower logP of Ligand B is a concern, but the strong binding may compensate. The DILI risk of Ligand A is good, but not enough to overcome the potency advantage of Ligand B.
**Output:**
0
2025-04-17 21:21:22,013 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Ligand A (347.375 Da) is well within the ideal range (200-500 Da). Ligand B (399.607 Da) is also acceptable. No clear advantage here.
2. **TPSA:** Ligand A (124.26) is borderline acceptable for oral absorption (<=140), but good. Ligand B (62.3) is excellent, well below the 140 threshold, suggesting better permeability. Advantage: B
3. **logP:** Ligand A (-0.956) is a bit low, potentially hindering permeation. Ligand B (2.869) is within the optimal range (1-3). Advantage: B
4. **HBD:** Ligand A (3) is acceptable. Ligand B (1) is also good, potentially improving permeability. Advantage: B
5. **HBA:** Ligand A (5) is acceptable. Ligand B (6) is also acceptable. No clear advantage.
6. **QED:** Both ligands have good QED scores (A: 0.606, B: 0.843). Advantage: B
7. **DILI:** Ligand A (62.35) is better than Ligand B (69.174), indicating a lower risk of drug-induced liver injury. Advantage: A
8. **BBB:** Ligand A (35.246) is low, suggesting poor brain penetration. Ligand B (43.583) is also low, but slightly better. Since ADRB2 isn't specifically a CNS target, this isn't a major deciding factor, but lower is preferable. No strong advantage.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.483 and -5.074), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Both ligands have negative solubility values (-2.417 and -3.833), which is also unusual and suggests poor solubility. This is a significant concern for both.
11. **hERG:** Ligand A (0.015) has a very low hERG risk, which is excellent. Ligand B (0.296) has a slightly higher, but still relatively low, hERG risk. Advantage: A
12. **Cl_mic:** Ligand A (-24.905) has a much lower microsomal clearance, indicating better metabolic stability. Ligand B (47.5) has a higher clearance. Advantage: A
13. **t1/2:** Ligand A (-21.991) has a negative half-life, which is not possible and indicates a problem with the data. Ligand B (3.367) has a short half-life, but it's a reasonable value. Advantage: B
14. **Pgp:** Ligand A (0.004) has very low P-gp efflux liability, which is excellent. Ligand B (0.296) has a slightly higher, but still relatively low, P-gp efflux liability. Advantage: A
15. **Binding Affinity:** Ligand B (-7.3 kcal/mol) has a significantly stronger binding affinity than Ligand A (-4.7 kcal/mol). This is a substantial advantage, potentially outweighing some ADME concerns. Advantage: B
**Overall Assessment & GPCR Considerations:**
For a GPCR like ADRB2, logP, TPSA, and binding affinity are crucial. Ligand B excels in logP and has a significantly stronger binding affinity. While its TPSA is excellent, Ligand A's TPSA is acceptable. The negative Caco-2 and solubility values are concerning for both, but the strong binding affinity of Ligand B is a major driver. Ligand A has better DILI, hERG, and Cl_mic, but the affinity difference is substantial. The negative half-life for Ligand A is a red flag.
Considering the balance, the stronger affinity of Ligand B is likely to be more impactful in driving efficacy, even with slightly less favorable ADME properties. The issues with solubility and permeability would need to be addressed through formulation or further chemical modification, but the starting point of a high-affinity ligand is crucial.
Output:
0
2025-04-17 21:21:22,013 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (359.348 and 364.515 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (73.64) is higher than Ligand B (56.75). For a cardiovascular GPCR, TPSA is moderately important, and Ligand B is preferable due to the lower value, suggesting better permeability.
3. **logP:** Both ligands (1.135 and 1.618) are within the optimal 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability, but not dramatically so.
4. **HBD:** Both ligands have 0 HBD, which is good.
5. **HBA:** Ligand A has 4 HBA, while Ligand B has 6. Both are acceptable (<=10), but Ligand A is slightly better.
6. **QED:** Both ligands have similar QED values (0.667 and 0.654), indicating good drug-likeness.
7. **DILI:** Ligand A (39.55) has a slightly lower DILI risk than Ligand B (52.85), which is a positive.
8. **BBB:** Both ligands have high BBB penetration (79.721 and 78.519). Since ADRB2 is a cardiovascular target, BBB penetration is not a primary concern, but it doesn't hurt.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.441 and -4.987). This is unusual and suggests poor permeability. However, the values are very close.
10. **Solubility:** Both ligands have negative solubility values (-1.377 and -1.545). This is also unusual and suggests poor solubility. Again, the values are very close.
11. **hERG:** Both ligands have low hERG inhibition liability (0.46 and 0.57), which is excellent.
12. **Cl_mic:** Ligand A (2.875) has significantly lower microsomal clearance than Ligand B (56.625). This is a major advantage for Ligand A, indicating better metabolic stability.
13. **t1/2:** Ligand A (-13.641) has a much shorter in vitro half-life than Ligand B (10.462). This is a significant drawback for Ligand A.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.038 and 0.108), which is good.
15. **Binding Affinity:** Ligand B (-6.5 kcal/mol) has a slightly better binding affinity than Ligand A (-5.6 kcal/mol). This is a 0.9 kcal/mol difference, which is substantial.
**GPCR-Specific Priorities & Overall Assessment:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand B has a slightly better logP and significantly better affinity. Ligand A has a better TPSA and DILI, but the metabolic stability (Cl_mic) is a major concern. The half-life is also significantly worse for Ligand A. The affinity difference is substantial enough to outweigh the benefits of Ligand A's slightly better TPSA and DILI.
**Output:**
0
2025-04-17 21:21:22,013 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (355.435 and 349.435 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (96.97) is slightly higher than Ligand B (89.35). Both are below the 140 threshold for good oral absorption, but closer to the 90 threshold for CNS targets, which isn't a primary concern for ADRB2 (cardiovascular). Ligand B is preferable.
3. **logP:** Ligand A (-0.449) is a bit low, potentially hindering permeation. Ligand B (0.824) is within the optimal 1-3 range. Ligand B is significantly better here.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable, below the 5 threshold. Ligand B is slightly better.
5. **HBA:** Ligand A (5) and Ligand B (6) are both acceptable, below the 10 threshold. No significant difference.
6. **QED:** Both ligands have good QED scores (0.546 and 0.667, respectively), indicating drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (20.706) has a much lower DILI risk than Ligand B (45.715). This is a significant advantage for Ligand A.
8. **BBB:** Both are relatively low (54.246 and 56.534), which is expected for a cardiovascular target. No significant difference.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.22 and -5.075), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Both ligands have negative solubility values (-0.714 and -1.235), indicating poor aqueous solubility. This is a significant drawback for both.
11. **hERG:** Both ligands have very low hERG risk (0.076). No significant difference.
12. **Cl_mic:** Ligand B (24.93) has a lower microsomal clearance than Ligand A (32.979), suggesting better metabolic stability. Ligand B is preferable.
13. **t1/2:** Ligand B (3.214) has a longer in vitro half-life than Ligand A (-21.335). This is a significant advantage for Ligand B.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.007 and 0.012). No significant difference.
15. **Binding Affinity:** Both ligands have identical binding affinities (-6.2 kcal/mol).
**GPCR-Specific Priorities & Overall Assessment:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand B excels in logP and has a slightly better TPSA. The binding affinity is identical. Ligand A has a substantial advantage in DILI risk. However, the poor Caco-2 and solubility for both are concerning. Considering the balance, the better metabolic stability (lower Cl_mic) and longer half-life of Ligand B, coupled with its better logP, outweigh the DILI advantage of Ligand A. The DILI risk of Ligand A is still acceptable.
Output:
0
2025-04-17 21:21:22,013 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (358.454 Da and 349.475 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (89.87) is better than Ligand B (61.88) as it is closer to the <140 threshold for good oral absorption.
3. **logP:** Both ligands have a logP around 1, which is optimal. No significant difference.
4. **HBD:** Ligand A (3) and Ligand B (1) are both acceptable, below the threshold of 5. Ligand B is slightly better.
5. **HBA:** Both ligands (4) are well below the 10 threshold. No significant difference.
6. **QED:** Ligand B (0.823) has a better QED score than Ligand A (0.633), indicating a more drug-like profile.
7. **DILI:** Ligand A (21.869) has a significantly lower DILI risk than Ligand B (8.026), which is a major advantage.
8. **BBB:** Ligand A (76.696) has a higher BBB penetration percentile than Ligand B (63.048). While ADRB2 isn't exclusively a CNS target, some degree of BBB penetration can be beneficial, and avoiding efflux is important.
9. **Caco-2:** Ligand A (-5.023) has a lower Caco-2 permeability than Ligand B (-4.835).
10. **Solubility:** Ligand A (-1.862) has a lower solubility than Ligand B (-0.891).
11. **hERG:** Ligand A (0.364) has a lower hERG inhibition liability than Ligand B (0.172), which is a significant safety advantage.
12. **Cl_mic:** Ligand A (-8.297) has a much lower (better) microsomal clearance than Ligand B (1.225), indicating greater metabolic stability.
13. **t1/2:** Ligand B (19.709) has a much longer in vitro half-life than Ligand A (-4.458). This is a significant advantage.
14. **Pgp:** Ligand A (0.081) has a lower P-gp efflux liability than Ligand B (0.005), which is better.
15. **Affinity:** Ligand A (-7.1 kcal/mol) has a slightly better binding affinity than Ligand B (-4.6 kcal/mol). This is a substantial difference.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A excels in affinity and Pgp, while Ligand B has a better TPSA and solubility. Ligand A also has a much better DILI and hERG profile, and better metabolic stability. The affinity difference is significant enough to outweigh the solubility and half-life advantages of Ligand B.
**Conclusion:**
Considering the balance of properties, particularly the significantly better affinity, DILI, hERG, and metabolic stability of Ligand A, I believe it is the more promising drug candidate.
Output:
1
2025-04-17 21:21:22,014 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.491 and 347.415 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (76.02) is better than Ligand B (84.67). Both are below 140, but lower TPSA generally favors absorption.
3. **logP:** Ligand A (2.774) is slightly better than Ligand B (1.444). Both are within the optimal 1-3 range, but Ligand B is closer to the lower bound, potentially impacting permeability.
4. **HBD:** Ligand A (2) is slightly better than Ligand B (1). Both are within the acceptable limit of 5.
5. **HBA:** Ligand A (4) is slightly better than Ligand B (5). Both are within the acceptable limit of 10.
6. **QED:** Ligand B (0.842) is better than Ligand A (0.683). A higher QED suggests better overall drug-likeness.
7. **DILI:** Ligand A (19.038) is *significantly* better than Ligand B (40.675). This is a major advantage for Ligand A, as lower DILI risk is crucial.
8. **BBB:** Both ligands have reasonable BBB penetration (Ligand A: 60.876, Ligand B: 65.839). Not a primary concern for ADRB2, but higher is generally preferred.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.04 and -4.849), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Both ligands have negative solubility values (-2.471 and -2.055), indicating poor aqueous solubility. This is a major drawback for both.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.268 and 0.132). This is excellent.
12. **Cl_mic:** Ligand B (10.036) is *much* better than Ligand A (59.724). Lower clearance indicates better metabolic stability.
13. **t1/2:** Ligand B (7.49) is better than Ligand A (-12.579). A positive half-life is preferred.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.239 and 0.059). This is good.
15. **Binding Affinity:** Ligand A (-7.5) is better than Ligand B (-5.8). A 1.7 kcal/mol difference in binding affinity is substantial and can often outweigh other ADME concerns.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A has a better logP and significantly better affinity. While both have issues with Caco-2 and solubility, the substantial affinity advantage of Ligand A, coupled with its much lower DILI risk, is compelling. The improved metabolic stability of Ligand B is attractive, but the DILI risk is a major concern.
**Overall Assessment:**
Despite the permeability and solubility issues shared by both, Ligand A's superior binding affinity and significantly lower DILI risk make it the more promising candidate. The higher affinity suggests a potentially lower dose requirement, which could mitigate some of the solubility concerns.
Output:
1
2025-04-17 21:21:22,014 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (346.5) is within the ideal range (200-500), while Ligand B (363.4) is also acceptable. No clear advantage.
2. **TPSA:** Ligand A (58.2) is excellent, well below the 140 threshold, and favorable for permeability. Ligand B (109.1) is higher, but still potentially acceptable, though less ideal. Advantage: A.
3. **logP:** Ligand A (3.69) is optimal (1-3). Ligand B (0.39) is quite low, potentially leading to poor membrane permeability. Significant advantage: A.
4. **HBD:** Both ligands have 2 HBD, which is within the acceptable limit of 5. No clear advantage.
5. **HBA:** Ligand A (2) is good. Ligand B (9) is higher, potentially impacting permeability. Advantage: A.
6. **QED:** Ligand B (0.79) is better than Ligand A (0.52), indicating a more drug-like profile. Advantage: B.
7. **DILI:** Ligand B (66.3) has a higher DILI risk than Ligand A (21.9). Advantage: A.
8. **BBB:** Ligand A (65.4) shows reasonable BBB penetration, while Ligand B (31.9) is significantly lower. Since ADRB2 is a GPCR, BBB penetration is a consideration, though not paramount for cardiovascular targets. Advantage: A.
9. **Caco-2:** Ligand A (-4.65) is better than Ligand B (-5.54), indicating better intestinal absorption. Advantage: A.
10. **Solubility:** Ligand A (-4.57) is better than Ligand B (-1.99), indicating better solubility. Advantage: A.
11. **hERG:** Ligand A (0.41) has a lower hERG risk than Ligand B (0.07), which is a significant safety advantage. Advantage: A.
12. **Cl_mic:** Ligand A (41.96) has a higher metabolic clearance than Ligand B (12.47), meaning Ligand B is more metabolically stable. Advantage: B.
13. **t1/2:** Ligand B (-11.6) has a longer in vitro half-life than Ligand A (6.75). Advantage: B.
14. **Pgp:** Ligand A (0.35) shows lower P-gp efflux than Ligand B (0.03), suggesting better bioavailability. Advantage: A.
15. **Binding Affinity:** Ligand B (-6.6) has slightly better binding affinity than Ligand A (-6.4), but the difference is small (0.2 kcal/mol).
**Overall Assessment:**
Ligand A consistently performs better across most critical ADME properties (logP, TPSA, solubility, DILI, hERG, Pgp, Caco-2, BBB) and has acceptable binding affinity. Ligand B has a better QED and metabolic stability (lower Cl_mic, longer t1/2), but its poor logP and higher DILI/hERG risks are significant concerns. The slight improvement in binding affinity of Ligand B does not outweigh the substantial ADME liabilities. For a GPCR target like ADRB2, a balance of properties is crucial, and Ligand A presents a more favorable profile for development.
Output:
1
2025-04-17 21:21:22,014 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A: [363.399, 122.19 , 0.259, 3. , 6. , 0.703, 87.398, 54.711, -5.537, -3.546, 0.162, -4.092, 138.84 , 0.072, -3.1 ]**
**Ligand B: [348.407, 134.07 , -0.415, 3. , 5. , 0.549, 45.25 , 54.866, -6.273, -1.582, 0.041, -24.459, -10.896, 0.016, -7.8 ]**
Here's a breakdown of each parameter and how it applies to the decision:
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand B (348.407) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (122.19) is better than Ligand B (134.07) as it's closer to the <140 threshold for good oral absorption.
3. **logP:** Ligand A (0.259) is quite low, potentially hindering membrane permeability. Ligand B (-0.415) is also low, but marginally better. Both are below the optimal 1-3 range.
4. **HBD:** Both have 3 HBD, which is acceptable.
5. **HBA:** Ligand A has 6 HBA, and Ligand B has 5, both within the acceptable limit of <=10.
6. **QED:** Ligand A (0.703) has a better QED score than Ligand B (0.549), indicating a more drug-like profile.
7. **DILI:** Ligand A (87.398) has a significantly higher DILI risk than Ligand B (45.25). This is a major concern for Ligand A.
8. **BBB:** Both have similar BBB penetration (around 55%), which isn't particularly high, but acceptable for a cardiovascular target.
9. **Caco-2:** Ligand A (-5.537) has a very poor Caco-2 permeability, suggesting poor absorption. Ligand B (-6.273) is also poor, but slightly better.
10. **Solubility:** Ligand A (-3.546) has poor solubility, while Ligand B (-1.582) is better.
11. **hERG:** Both have very low hERG inhibition risk (0.162 and 0.041 respectively), which is excellent.
12. **Cl_mic:** Ligand A (-4.092) has a lower (better) microsomal clearance than Ligand B (-24.459), indicating better metabolic stability.
13. **t1/2:** Ligand A (138.84) has a much longer in vitro half-life than Ligand B (-10.896), which is a significant advantage.
14. **Pgp:** Both have very low Pgp efflux liability (0.072 and 0.016 respectively), which is good.
15. **Affinity:** Ligand B (-7.8) has a significantly stronger binding affinity than Ligand A (-3.1). This is a substantial advantage.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, and affinity are particularly important. While both ligands struggle with logP, Ligand B's much stronger affinity (-7.8 vs -3.1) is a major advantage that can potentially overcome some of the permeability issues. The significantly lower DILI risk for Ligand B is also a critical factor.
**Conclusion:**
Despite Ligand A's better QED and metabolic stability, the combination of significantly higher DILI risk, poor Caco-2 permeability, and much weaker binding affinity makes it a less attractive candidate. Ligand B's superior affinity and lower toxicity profile outweigh its slightly less favorable TPSA and solubility.
Output:
0
2025-04-17 21:21:22,014 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (360.483 and 365.543 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (71.25) is higher than Ligand B (53.51). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is generally preferred for better absorption. Ligand B has a clear advantage.
**3. logP:** Ligand B (3.271) is slightly higher than Ligand A (2.295). Both are within the optimal 1-3 range, but Ligand B is pushing the upper limit. This could potentially lead to solubility issues, but isn't a major concern at this level.
**4. H-Bond Donors:** Ligand A (1) is better than Ligand B (0). While both are acceptable, having one HBD can improve solubility without significantly impacting permeability.
**5. H-Bond Acceptors:** Ligand A (6) is higher than Ligand B (4). Lower is preferable, so Ligand B is better.
**6. QED:** Ligand A (0.888) is significantly better than Ligand B (0.71). A higher QED suggests a more drug-like profile.
**7. DILI:** Ligand B (16.014) is *much* better than Ligand A (53.625). This is a crucial factor. A DILI percentile below 40 is highly desirable, and Ligand B achieves this, while Ligand A is approaching a concerning level.
**8. BBB:** Ligand B (83.366) is significantly better than Ligand A (63.474). While ADRB2 isn't strictly a CNS target, some peripheral exposure is acceptable, and higher BBB penetration can sometimes indicate better overall distribution.
**9. Caco-2 Permeability:** Both are negative, indicating low permeability. Ligand A (-5.067) is slightly worse than Ligand B (-4.788).
**10. Aqueous Solubility:** Both are negative, indicating low solubility. Ligand A (-2.138) is slightly worse than Ligand B (-2.059).
**11. hERG Inhibition:** Ligand A (0.274) is better than Ligand B (0.56). Lower hERG inhibition is critical for avoiding cardiotoxicity, and Ligand A has a clear advantage here.
**12. Microsomal Clearance:** Ligand B (55.6) is better than Ligand A (16.845). Lower clearance is desirable for longer duration of action.
**13. In vitro Half-Life:** Ligand A (9.445) is better than Ligand B (3.866). A longer half-life is generally preferred.
**14. P-gp Efflux:** Ligand A (0.296) is better than Ligand B (0.325). Lower P-gp efflux is desirable for improved bioavailability.
**15. Binding Affinity:** Ligand A (-7.5) is significantly better than Ligand B (-6.1). A 1.4 kcal/mol difference in binding affinity is substantial and can often outweigh minor ADME drawbacks.
**Overall Assessment:**
While Ligand A has a superior binding affinity and better hERG inhibition, P-gp efflux, and in vitro half-life, Ligand B's dramatically lower DILI risk and better BBB penetration are critical advantages. The lower TPSA and microsomal clearance of Ligand B are also favorable. The binding affinity difference, while significant, might be overcome with further optimization of Ligand B. The DILI risk of Ligand A is a major red flag.
Therefore, I prioritize Ligand B due to its significantly improved safety profile (DILI) and overall better ADME properties, despite the slightly weaker binding affinity.
0
2025-04-17 21:21:22,014 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (362.499 Da and 348.487 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (76.02) is slightly higher than Ligand B (67.43). Both are below the 140 threshold for good oral absorption, but closer to the 90 threshold for CNS targets, which isn't a primary concern for ADRB2 (cardiovascular). Ligand B is slightly favored.
3. **logP:** Ligand A (1.907) is within the optimal 1-3 range. Ligand B (3.911) is at the higher end, potentially raising solubility concerns. Ligand A is favored.
4. **HBD:** Both ligands have 2 HBD, which is good. No difference.
5. **HBA:** Ligand A has 5 HBA, Ligand B has 3. Both are acceptable (<=10). Ligand B is slightly favored.
6. **QED:** Both ligands have acceptable QED values (0.727 and 0.673, both > 0.5). No significant difference.
7. **DILI:** Both ligands have low DILI risk (37.224 and 39.589, both <40). No significant difference.
8. **BBB:** Ligand B (69.446) has a higher BBB penetration percentile than Ligand A (53.897). While ADRB2 isn't a CNS target, some off-target CNS effects are possible with GPCR ligands, so higher BBB is slightly favorable.
9. **Caco-2:** Ligand A (-5.486) has a more negative Caco-2 value, indicating *lower* permeability than Ligand B (-4.506). Ligand B is favored.
10. **Solubility:** Ligand A (-2.681) has a more negative solubility value, indicating *lower* solubility than Ligand B (-4.256). Ligand B is favored.
11. **hERG:** Both ligands have low hERG inhibition liability (0.13 and 0.83, both low). No significant difference.
12. **Cl_mic:** Ligand A (19.962) has significantly lower microsomal clearance than Ligand B (87.009), suggesting better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand B (17.757) has a much longer in vitro half-life than Ligand A (1.42). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.057) has lower P-gp efflux liability than Ligand B (0.354). This is a slight advantage for Ligand A.
15. **Binding Affinity:** Ligand A (-6.1 kcal/mol) has a slightly stronger binding affinity than Ligand B (-5.7 kcal/mol). This is a moderate advantage for Ligand A.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, Pgp, TPSA, and affinity. Ligand A has a better logP and Pgp, while Ligand B has better TPSA. The affinity difference is small. The significant difference lies in metabolic stability (Cl_mic) and half-life. Ligand A has much better metabolic stability, but Ligand B has a much longer half-life. Given the cardiovascular context, a longer half-life is generally preferred for sustained effect.
**Overall Assessment:**
While Ligand A has advantages in logP, Pgp, and binding affinity, Ligand B's superior Caco-2 permeability, solubility, BBB penetration, and especially its longer half-life outweigh these benefits. The lower metabolic stability of Ligand A is a concern, and while it can be addressed through structural modifications, Ligand B presents a more promising starting point with a better balance of properties.
Output:
0
2025-04-17 21:21:22,014 - INFO - Batch 252 complete. Total preferences: 4032
2025-04-17 21:21:22,014 - INFO - Processing batch 253/512...
2025-04-17 21:22:15,618 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (355.439 Da and 346.362 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (108.23) is higher than Ligand B (85.25). For a cardiovascular GPCR, TPSA is moderately important. Ligand B's lower TPSA is slightly preferable, suggesting potentially better membrane permeability.
**3. logP:** Both ligands have similar logP values (1.83 and 1.732), falling within the optimal 1-3 range. No clear advantage.
**4. H-Bond Donors:** Ligand A has 1 HBD, while Ligand B has 2. Both are acceptable, but lower is generally preferred.
**5. H-Bond Acceptors:** Ligand A has 8 HBA, while Ligand B has 5. Ligand B is preferable here.
**6. QED:** Both ligands have similar QED values (0.775 and 0.748), indicating good drug-like properties.
**7. DILI:** Ligand A (67.468) and Ligand B (73.517) both have DILI risk in the acceptable range (<80), but Ligand A is slightly better.
**8. BBB:** Ligand A (74.525) has a significantly higher BBB penetration percentile than Ligand B (56.34). While ADRB2 is a cardiovascular target, some CNS penetration can be acceptable or even beneficial depending on the specific therapeutic goal and off-target effects.
**9. Caco-2 Permeability:** Ligand A (-4.606) has a better Caco-2 permeability than Ligand B (-4.744).
**10. Aqueous Solubility:** Ligand A (-2.492) has slightly better aqueous solubility than Ligand B (-2.829).
**11. hERG Inhibition:** Ligand A (0.042) has a much lower hERG inhibition liability than Ligand B (0.603). This is a critical advantage, as hERG inhibition can lead to cardiotoxicity.
**12. Microsomal Clearance:** Ligand A (94.933) has a significantly higher microsomal clearance than Ligand B (35.622). This suggests Ligand B will have better metabolic stability.
**13. In vitro Half-Life:** Ligand A (-26.79) and Ligand B (-29.065) have similar in vitro half-lives.
**14. P-gp Efflux:** Ligand A (0.082) has lower P-gp efflux liability than Ligand B (0.14). This is a slight advantage.
**15. Binding Affinity:** Both ligands have very similar binding affinities (-6.7 kcal/mol and -6.5 kcal/mol). The difference is not substantial enough to outweigh other factors.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), and the general drug-like properties, Ligand A emerges as the more promising candidate. The significantly lower hERG inhibition liability is a major advantage, mitigating a critical safety concern. While Ligand B has a slightly lower TPSA and better metabolic stability, the hERG risk associated with Ligand B is too significant to ignore. The better BBB penetration of Ligand A is also a plus.
Output:
1
2025-04-17 21:22:15,618 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (364.471) is slightly higher than Ligand B (344.371), but both are acceptable.
2. **TPSA:** Ligand A (84.73) is significantly better than Ligand B (113.18). For a GPCR, keeping TPSA low is favorable for permeability, and Ligand A is well below the 140 threshold. Ligand B is approaching the upper limit.
3. **logP:** Both ligands have acceptable logP values (Ligand A: 2.88, Ligand B: 1.493), falling within the 1-3 range. Ligand A is slightly more lipophilic, which could aid membrane permeability, but isn't a major concern for either.
4. **HBD:** Ligand A (2) is preferable to Ligand B (3). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (6) is preferable to Ligand B (5). Similar to HBD, lower HBA is generally better for permeability.
6. **QED:** Ligand A (0.877) has a significantly better QED score than Ligand B (0.543), indicating a more drug-like profile.
7. **DILI:** Ligand A (71.539) has a slightly higher DILI risk than Ligand B (67.39), but both are reasonably low and below the concerning threshold of 60.
8. **BBB:** Both ligands have similar BBB penetration (Ligand A: 62.117, Ligand B: 65.258). While not CNS-focused, some degree of BBB penetration isn't detrimental.
9. **Caco-2:** Ligand A (-4.516) is better than Ligand B (-5.101) indicating better intestinal absorption.
10. **Solubility:** Ligand A (-3.515) is better than Ligand B (-3.36), indicating better solubility.
11. **hERG:** Both ligands have low hERG inhibition risk (Ligand A: 0.421, Ligand B: 0.295). Ligand B is slightly better here, but both are very acceptable.
12. **Cl_mic:** Ligand B (18.725) has significantly lower microsomal clearance than Ligand A (29.701), suggesting better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand B (-11.046) has a significantly longer in vitro half-life than Ligand A (1.053), indicating better duration of action. This is a major advantage.
14. **Pgp:** Ligand A (0.174) has lower P-gp efflux liability than Ligand B (0.041), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand B (-5.7 kcal/mol) has a significantly better binding affinity than Ligand A (-4.1 kcal/mol). This is a substantial advantage, exceeding the 1.5 kcal/mol difference threshold.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), affinity, logP, TPSA, and Pgp are key. Ligand B excels in affinity, while Ligand A has better TPSA and Pgp. The substantial affinity difference of Ligand B outweighs the slightly better TPSA and Pgp of Ligand A. The improved metabolic stability (lower Cl_mic) and longer half-life of Ligand B are also very important.
**Conclusion:**
Despite Ligand A's better QED and slightly better solubility, the significantly stronger binding affinity, improved metabolic stability, and longer half-life of Ligand B make it the more promising drug candidate.
Output:
0
2025-04-17 21:22:15,619 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for the ADRB2, a cardiovascular GPCR. Therefore, the key priorities are logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB.
Let's compare the ligands property by property:
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (377.384) is slightly higher than Ligand B (346.475), but both are acceptable.
2. **TPSA:** Ligand A (64.96) is better than Ligand B (67.23), falling comfortably under the 140 A^2 threshold for oral absorption.
3. **logP:** Ligand A (3.657) is slightly higher than Ligand B (2.594), both being within the optimal range of 1-3. Ligand B is closer to the lower bound, which could potentially affect permeability.
4. **HBD:** Ligand A (0) is preferable to Ligand B (1). Fewer HBDs generally improve membrane permeability.
5. **HBA:** Both ligands have 4 HBA, which is acceptable.
6. **QED:** Both ligands have acceptable QED values (A: 0.789, B: 0.699), indicating good drug-likeness.
7. **DILI:** Ligand B (23.226) has a significantly lower DILI risk than Ligand A (65.568). This is a major advantage for Ligand B.
8. **BBB:** Ligand A (94.455) has a higher BBB penetration percentile than Ligand B (76.309). While not a primary concern for a cardiovascular target, it's a slight positive for Ligand A.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual. We'll assume these are percentile scores and interpret them as low permeability. Ligand A (-4.079) is worse than Ligand B (-4.827).
10. **Solubility:** Ligand A (-3.997) is slightly better than Ligand B (-2.48), but both are poor.
11. **hERG:** Both ligands have low hERG inhibition risk (A: 0.611, B: 0.393), which is good.
12. **Cl_mic:** Ligand A (13.382) has a lower microsomal clearance than Ligand B (64.198), indicating better metabolic stability.
13. **t1/2:** Ligand B (-2.365) has a negative in vitro half-life, which is concerning. Ligand A (45.675) is much better.
14. **Pgp:** Ligand A (0.643) has a lower P-gp efflux liability than Ligand B (0.26), which is preferable.
15. **Affinity:** Ligand B (-6.8 kcal/mol) has a slightly better binding affinity than Ligand A (-6.5 kcal/mol). This is a 0.3 kcal/mol difference, which is not huge, but still relevant.
**Overall Assessment:**
Ligand B has a significantly better safety profile (lower DILI) and a slightly better binding affinity. However, it has a concerningly low in vitro half-life and lower Pgp values. Ligand A has better metabolic stability (lower Cl_mic and better t1/2), better Pgp efflux, and higher BBB penetration. The poor solubility and Caco-2 values of both are concerning, but the superior metabolic stability and Pgp profile of Ligand A, coupled with the substantial DILI risk reduction offered by Ligand B, make Ligand B the more promising candidate. The slight affinity advantage of Ligand B is also a factor.
**Output:**
0
2025-04-17 21:22:15,619 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (342.399 Da and 348.451 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Both ligands have TPSA values below 100 (100.02 and 97.35), which is favorable for oral absorption, and appropriate for a cardiovascular target (not requiring significant BBB penetration).
**3. logP:** Ligand A (2.071) is better than Ligand B (0.89). While both are within the acceptable range, Ligand A is closer to the optimal 1-3 range, suggesting better membrane permeability. Ligand B is a bit low and could have absorption issues.
**4. H-Bond Donors:** Ligand A (3) is slightly higher than Ligand B (1), but both are within the acceptable limit of 5.
**5. H-Bond Acceptors:** Ligand B (6) is higher than Ligand A (4), but both are below the 10 threshold.
**6. QED:** Ligand B (0.852) has a significantly better QED score than Ligand A (0.349), indicating a more drug-like profile overall. This is a notable advantage for Ligand B.
**7. DILI Risk:** Ligand B (35.13) has a much lower DILI risk than Ligand A (63.164). This is a significant advantage for Ligand B, as minimizing liver toxicity is crucial.
**8. BBB Penetration:** Both are relatively low, which is fine for a cardiovascular target. Ligand B (70.997) is slightly better than Ligand A (61.535), but this isn't a primary concern.
**9. Caco-2 Permeability:** Both have negative Caco-2 values (-5.549 and -5.226). This is unusual and suggests poor permeability *in vitro*. However, these values are close enough that the difference isn't decisive.
**10. Aqueous Solubility:** Ligand B (-1.674) is better than Ligand A (-3.138), indicating better solubility.
**11. hERG Inhibition:** Both ligands show very low hERG inhibition risk (0.544 and 0.117), which is excellent.
**12. Microsomal Clearance:** Ligand A (48.729) has a lower microsomal clearance than Ligand B (10.674), suggesting better metabolic stability. This is a significant advantage for Ligand A.
**13. In vitro Half-Life:** Ligand B (-11.881) has a much longer in vitro half-life than Ligand A (-4.43), indicating slower metabolism and potentially less frequent dosing. This is a strong advantage for Ligand B.
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (0.376 and 0.044). Ligand B is slightly better.
**15. Binding Affinity:** Both ligands have excellent binding affinity (-5.5 and -5.9 kcal/mol). Ligand B is slightly better, but the difference is small.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity) and general drug-like properties, Ligand B emerges as the more promising candidate. While Ligand A has better metabolic stability (lower Cl_mic), Ligand B excels in crucial areas like DILI risk, QED, solubility, and in vitro half-life. The slightly better logP of Ligand A is outweighed by the other advantages of Ligand B. The similar binding affinities mean that the ADME properties become the deciding factor.
Output:
0
2025-04-17 21:22:15,619 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [387.889, 93.45, 2.158, 2, 6, 0.759, 68.244, 17.449, -5.24, -3.502, 0.291, 28.902, 36.495, 0.172, -7.2]
**Ligand B:** [346.431, 82.61, 1.191, 1, 4, 0.868, 27.142, 66.886, -4.874, -1.783, 0.11, -3.067, -2.588, 0.017, -5.5]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (346.431) is slightly lower, which *could* be beneficial for permeability, but both are acceptable.
2. **TPSA:** Ligand A (93.45) is slightly above the preferred <90 for CNS targets, but still reasonable for a peripheral GPCR like ADRB2. Ligand B (82.61) is better.
3. **logP:** Both are within the optimal 1-3 range. Ligand A (2.158) is slightly higher, which could lead to off-target effects, but is still acceptable. Ligand B (1.191) is better.
4. **HBD:** Both are at or below the ideal of 5. Ligand B (1) is better.
5. **HBA:** Both are within the ideal range of 10. Ligand B (4) is better.
6. **QED:** Both are good (>0.5), with Ligand B (0.868) being slightly better.
7. **DILI:** Ligand A (68.244) has a higher DILI risk than Ligand B (27.142). This is a significant concern.
8. **BBB:** BBB is less critical for ADRB2 (a cardiovascular target), but Ligand B (66.886) has a higher percentile than Ligand A (17.449).
9. **Caco-2:** Both have negative values, indicating poor permeability. Ligand A (-5.24) is worse than Ligand B (-4.874).
10. **Solubility:** Both have negative values, indicating poor solubility. Ligand B (-1.783) is better.
11. **hERG:** Both have low hERG risk, which is good. Ligand A (0.291) is slightly higher than Ligand B (0.11).
12. **Cl_mic:** Ligand B (-3.067) has a *much* lower (better) microsomal clearance than Ligand A (28.902), indicating better metabolic stability.
13. **t1/2:** Ligand A (36.495) has a longer half-life than Ligand B (-2.588). This is a positive for Ligand A.
14. **Pgp:** Both have very low Pgp efflux, which is good. Ligand A (0.172) is slightly higher than Ligand B (0.017).
15. **Affinity:** Ligand A (-7.2) has a significantly better binding affinity than Ligand B (-5.5). This is a substantial advantage.
**GPCR-Specific Considerations:**
For a GPCR, logP, TPSA, Pgp, and affinity are key. Ligand A has a better affinity, but Ligand B has better logP, TPSA, and Pgp. The DILI risk for Ligand A is concerning. Metabolic stability (Cl_mic) is also important, and Ligand B is much better in this regard.
**Overall Assessment:**
While Ligand A boasts a superior binding affinity, the significantly higher DILI risk and poorer metabolic stability are major drawbacks. The slightly better ADME properties of Ligand B, coupled with a reasonable affinity, make it a more promising starting point for drug development, despite the lower binding affinity. The difference in affinity (1.7 kcal/mol) is substantial, but can potentially be optimized during lead optimization. The DILI risk of Ligand A is harder to mitigate.
Output:
0
2025-04-17 21:22:15,619 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output:
**1. Molecular Weight (MW):**
* Ligand A: 358.507 Da - Within the ideal range (200-500 Da).
* Ligand B: 342.443 Da - Also within the ideal range.
* *No clear advantage.*
**2. Topological Polar Surface Area (TPSA):**
* Ligand A: 53.43 A2 - Good for oral absorption (<=140 A2) and reasonable for a peripheral GPCR like ADRB2.
* Ligand B: 59.39 A2 - Still good for oral absorption.
* *Slight advantage to Ligand A, but small.*
**3. Lipophilicity (logP):**
* Ligand A: 4.26 - Slightly high, potentially leading to solubility issues or off-target interactions.
* Ligand B: 2.363 - Excellent, within the optimal range (1-3).
* *Significant advantage to Ligand B.*
**4. H-Bond Donors (HBD):**
* Ligand A: 1 - Acceptable.
* Ligand B: 1 - Acceptable.
* *No clear advantage.*
**5. H-Bond Acceptors (HBA):**
* Ligand A: 4 - Acceptable.
* Ligand B: 5 - Acceptable.
* *No clear advantage.*
**6. QED:**
* Ligand A: 0.717 - Very good, indicating strong drug-like properties.
* Ligand B: 0.906 - Excellent, even better drug-like properties.
* *Advantage to Ligand B.*
**7. DILI Risk:**
* Ligand A: 31.563 - Low risk, excellent.
* Ligand B: 38.969 - Low risk, still good.
* *Slight advantage to Ligand A.*
**8. BBB Penetration:**
* Ligand A: 56.65 - Not a priority for ADRB2 (peripheral target).
* Ligand B: 63.474 - Not a priority for ADRB2.
* *No clear advantage.*
**9. Caco-2 Permeability:**
* Ligand A: -5.003 - Negative value is unusual and suggests very poor permeability.
* Ligand B: -4.757 - Also negative and poor permeability, but slightly better than A.
* *Slight advantage to Ligand B.*
**10. Aqueous Solubility:**
* Ligand A: -3.541 - Very poor solubility, concerning given the high logP.
* Ligand B: -2.536 - Poor solubility, but better than Ligand A.
* *Advantage to Ligand B.*
**11. hERG Inhibition:**
* Ligand A: 0.598 - Low risk, excellent.
* Ligand B: 0.436 - Low risk, excellent.
* *No clear advantage.*
**12. Microsomal Clearance:**
* Ligand A: 88.07 - High clearance, suggesting rapid metabolism.
* Ligand B: 74.501 - Moderate clearance, better metabolic stability.
* *Advantage to Ligand B.*
**13. In vitro Half-Life:**
* Ligand A: 25.674 - Relatively short half-life.
* Ligand B: 51.86 - Significantly longer half-life.
* *Advantage to Ligand B.*
**14. P-gp Efflux:**
* Ligand A: 0.667 - Moderate efflux.
* Ligand B: 0.304 - Lower efflux, better bioavailability.
* *Advantage to Ligand B.*
**15. Binding Affinity:**
* Ligand A: -7.7 kcal/mol - Excellent.
* Ligand B: -7.2 kcal/mol - Very good, but slightly weaker.
* *Advantage to Ligand A.*
**Overall Assessment:**
While Ligand A has a slightly better binding affinity, Ligand B demonstrates a significantly more favorable ADME profile. Specifically, its lower logP, better solubility, lower clearance, longer half-life, and lower P-gp efflux are crucial for oral bioavailability and *in vivo* efficacy. The poor Caco-2 and solubility of Ligand A are major red flags. For a GPCR target like ADRB2, a balance between potency and ADME properties is essential, and Ligand B strikes that balance more effectively. The 0.5 kcal/mol difference in binding affinity is unlikely to overcome the substantial ADME liabilities of Ligand A.
Output:
0
2025-04-17 21:22:15,620 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.423 and 354.491 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (93.45) is slightly higher than Ligand B (78.87). Both are below the 140 threshold for good oral absorption, but B is better positioned for potential CNS penetration if needed.
3. **logP:** Ligand A (0.035) is quite low, potentially hindering membrane permeability. Ligand B (1.563) is within the optimal 1-3 range. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (0) is ideal. Ligand B (2) is acceptable, but A is preferable.
5. **HBA:** Ligand A (7) is good. Ligand B (4) is also good. No clear winner.
6. **QED:** Both ligands have similar QED values (0.761 and 0.693), indicating good drug-likeness.
7. **DILI:** Ligand A (52.617) has a higher DILI risk than Ligand B (11.361). This is a substantial advantage for Ligand B.
8. **BBB:** Ligand A (59.946) and Ligand B (67.662) are both moderate. Since ADRB2 is primarily a cardiovascular target, high BBB penetration isn't crucial, but B is slightly better.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.781 and -4.608), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Both ligands have very poor aqueous solubility (-1.202 and -1.786). This is a major drawback for both, and formulation challenges are likely.
11. **hERG:** Ligand A (0.04) has a lower hERG risk than Ligand B (0.366), which is favorable.
12. **Cl_mic:** Ligand A (8.408) has a significantly lower microsomal clearance than Ligand B (17.388), indicating better metabolic stability.
13. **t1/2:** Ligand A (7.422) has a longer in vitro half-life than Ligand B (-5.921). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.023) has much lower P-gp efflux liability than Ligand B (0.077), suggesting better oral bioavailability.
15. **Binding Affinity:** Ligand B (-7.0) has a slightly better binding affinity than Ligand A (-5.9). This 1.1 kcal/mol difference is significant and can outweigh some of the ADME drawbacks.
**Overall Assessment & GPCR Priorities:**
For a GPCR like ADRB2, affinity, logP, and metabolic stability are key. Ligand B has a superior binding affinity and a more favorable logP value. While Ligand A has better metabolic stability (lower Cl_mic and longer t1/2) and lower Pgp efflux, the significant advantage in binding affinity of Ligand B, combined with the lower DILI risk, outweighs these factors. The poor solubility and Caco-2 values are concerning for both, but can be addressed with formulation strategies. The slightly better logP of B is more critical for receptor engagement.
Output:
0
2025-04-17 21:22:15,620 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.491 and 356.467 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (55.89) is significantly better than Ligand B (113.76). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold, while Ligand B is approaching it.
3. **logP:** Both ligands have acceptable logP values (0.526 and 0.317, respectively), falling within the 1-3 range. Ligand A is slightly better.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Both ligands have the same number of HBA (4), which is acceptable (<=10).
6. **QED:** Ligand A (0.805) has a higher QED score than Ligand B (0.609), indicating a more drug-like profile.
7. **DILI:** Ligand A (5.894%) has a much lower DILI risk than Ligand B (32.105%). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (70.609%) has a slightly better BBB penetration score than Ligand B (68.67%). While not crucial for a cardiovascular target, it's a minor positive.
9. **Caco-2:** Ligand A (-5.123) and Ligand B (-5.379) are both negative, which is not ideal. Lower values suggest poor permeability. However, the difference is minimal.
10. **Solubility:** Ligand A (-1.161) is slightly better than Ligand B (-1.549), but both are poor. This could pose formulation challenges.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.281 and 0.136), which is excellent.
12. **Cl_mic:** Ligand A (2.955) has significantly lower microsomal clearance than Ligand B (25.001), indicating better metabolic stability. This is a major advantage.
13. **t1/2:** Both ligands have similar in vitro half-lives (5.006 and 5.621 hours).
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.008).
15. **Binding Affinity:** Ligand A (-7.2 kcal/mol) has a stronger binding affinity than Ligand B (-6.7 kcal/mol). This 0.5 kcal/mol difference is substantial and outweighs some of the ADME drawbacks of Ligand A.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A performs better on TPSA, logP, and significantly better on affinity. While BBB isn't critical here, Ligand A has a slightly better score.
**Overall Assessment:**
Ligand A is clearly the superior candidate. It has a better QED score, significantly lower DILI risk, substantially lower microsomal clearance (better metabolic stability), and a stronger binding affinity. While both have poor solubility and Caco-2 permeability, the benefits of Ligand A outweigh these drawbacks, especially given its superior affinity and safety profile.
Output:
1
2025-04-17 21:22:15,620 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Ligand A (364.408 Da) is better than Ligand B (341.371 Da). Both are within the ideal range (200-500 Da).
2. **TPSA:** Ligand A (58.64) is significantly better than Ligand B (101.53). ADRB2 is a cardiovascular target, not CNS, but lower TPSA generally improves permeability. Ligand B is pushing the upper limit for good absorption.
3. **logP:** Both ligands have good logP values (A: 2.089, B: 1.19), falling within the optimal 1-3 range. Ligand A is slightly better.
4. **HBD:** Both ligands have acceptable HBD counts (A: 1, B: 2), well below the threshold of 5.
5. **HBA:** Ligand A (3) is better than Ligand B (6). Ligand B is approaching the upper limit of 10.
6. **QED:** Both ligands have good QED scores (A: 0.604, B: 0.701), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (28.383) is *much* better than Ligand B (62.35). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (93.563) is substantially better than Ligand B (31.834). While not a CNS target, higher BBB penetration can sometimes correlate with better overall distribution.
9. **Caco-2:** Ligand A (-4.598) is better than Ligand B (-5.351). Both are negative, indicating good permeability.
10. **Solubility:** Ligand A (-2.303) is better than Ligand B (-2.14). Both are poor, but Ligand A is slightly better.
11. **hERG:** Ligand A (0.651) is better than Ligand B (0.258). Lower hERG risk is crucial.
12. **Cl_mic:** Ligand A (35.77) is better than Ligand B (18.4). Lower clearance is preferred for metabolic stability.
13. **t1/2:** Ligand A (-4.503) is better than Ligand B (17.514). Negative values for t1/2 are unusual and likely represent a scale where lower is better. Ligand A is preferable.
14. **Pgp:** Ligand A (0.205) is better than Ligand B (0.027). Lower P-gp efflux is preferred.
15. **Affinity:** Ligand A (-7.2 kcal/mol) is better than Ligand B (-5.8 kcal/mol). This is a substantial difference in binding affinity.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Both ligands have acceptable logP. Ligand A has a significantly better TPSA and Pgp profile. The affinity difference is substantial, with Ligand A being considerably more potent.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical parameters. The most significant advantages are its much lower DILI risk, superior binding affinity, and better TPSA. While Ligand B has a slightly better QED score, the other advantages of Ligand A outweigh this.
Output:
1
2025-04-17 21:22:15,620 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.503 and 351.403 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (78.43) is significantly better than Ligand B (107.97). For a GPCR, keeping TPSA under 140 is good, and lower is generally preferred for better permeability. Ligand B is approaching a level that could hinder absorption.
3. **logP:** Ligand A (2.52) is optimal, while Ligand B (-1.368) is quite low. A logP below 1 can lead to poor membrane permeability. This is a substantial advantage for Ligand A.
4. **HBD:** Both ligands have 3 HBD, which is acceptable.
5. **HBA:** Ligand A has 3 HBA, while Ligand B has 5. Both are within the acceptable range of <=10, but Ligand A is slightly better.
6. **QED:** Ligand A (0.629) has a much better QED score than Ligand B (0.369), indicating a more drug-like profile.
7. **DILI:** Ligand A (14.036%) has a much lower DILI risk than Ligand B (25.165%). This is a critical advantage for Ligand A.
8. **BBB:** Ligand A (54.983%) has a moderate BBB penetration, while Ligand B (25.863%) is quite low. While ADRB2 isn't exclusively a CNS target, some CNS penetration can be beneficial or at least avoid off-target effects.
9. **Caco-2:** Ligand A (-4.767) and Ligand B (-5.132) are both negative, which is unusual. Generally, higher values are better. The values are similar, so this isn't a major differentiator.
10. **Solubility:** Ligand A (-3.104) is better than Ligand B (-1.21). Better solubility is always preferred.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.354 and 0.044 respectively), which is excellent.
12. **Cl_mic:** Ligand A (50.647) has a significantly lower microsomal clearance than Ligand B (-14.437). Lower clearance suggests better metabolic stability, a significant advantage for Ligand A.
13. **t1/2:** Ligand A (-7.804) has a much longer in vitro half-life than Ligand B (-28.296). This is a major advantage, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.154) has a lower P-gp efflux liability than Ligand B (0.006). Lower P-gp efflux is preferable.
15. **Affinity:** Both ligands have very similar binding affinities (-6.1 and -6.3 kcal/mol). The difference is negligible.
**GPCR-Specific Priorities:**
Considering ADRB2 is a GPCR, logP, TPSA, and Pgp are important. Ligand A excels in logP and TPSA, and is better in Pgp. Metabolic stability (Cl_mic and t1/2) are also important, and Ligand A is significantly better in both. While affinity is similar, the ADME properties of Ligand A are far superior.
**Conclusion:**
Ligand A is the far more promising candidate due to its superior ADME properties (logP, TPSA, QED, DILI, Cl_mic, t1/2, Pgp, solubility) and comparable binding affinity. Ligand B's low logP and high DILI risk are significant drawbacks.
Output:
1
2025-04-17 21:22:15,620 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (341.375 Da) is well within the ideal range (200-500 Da). Ligand B (377.897 Da) is also acceptable. No clear advantage here.
2. **TPSA:** Ligand A (101.7) is slightly above the preferred <140 for oral absorption, but still reasonable. Ligand B (59.23) is excellent, well below 140, suggesting better absorption potential. **Advantage: B**
3. **logP:** Ligand A (0.192) is quite low, potentially hindering membrane permeability. Ligand B (3.912) is near the upper end of the optimal range (1-3), which is good for permeability but could raise solubility concerns. **Advantage: B**
4. **HBD:** Both ligands have 1 HBD, which is acceptable. No difference.
5. **HBA:** Ligand A has 7 HBAs, within the preferred limit. Ligand B has 5 HBAs, also good. No significant difference.
6. **QED:** Both ligands have good QED scores (A: 0.733, B: 0.824), indicating drug-likeness. **Advantage: B**
7. **DILI:** Ligand A (70.105) is approaching a concerning level for DILI risk. Ligand B (66.615) is slightly better, but still warrants attention. No clear advantage.
8. **BBB:** Ligand A (53.974) has moderate BBB penetration. Ligand B (74.176) shows good BBB penetration. Since ADRB2 is a GPCR, BBB penetration is a consideration, though not paramount for cardiovascular targets. **Advantage: B**
9. **Caco-2:** Ligand A (-5.349) has poor Caco-2 permeability, indicating poor absorption. Ligand B (-4.969) is also poor, but slightly better. **Advantage: B**
10. **Solubility:** Ligand A (-2.706) has poor aqueous solubility. Ligand B (-4.352) is also poor, but slightly better. **Advantage: B**
11. **hERG:** Both ligands have very low hERG inhibition risk (A: 0.292, B: 0.265). No difference.
12. **Cl_mic:** Ligand A (4.69) has a lower microsomal clearance, suggesting better metabolic stability. Ligand B (34.741) has a significantly higher clearance, raising concerns about rapid metabolism. **Advantage: A**
13. **t1/2:** Ligand A (6.929) has a reasonable in vitro half-life. Ligand B (15.876) has a longer half-life, which is generally desirable. **Advantage: B**
14. **Pgp:** Both ligands have low P-gp efflux liability (A: 0.082, B: 0.637). No significant difference.
15. **Binding Affinity:** Ligand B (-8.0 kcal/mol) has a significantly stronger binding affinity than Ligand A (-7.0 kcal/mol). This is a substantial advantage, potentially outweighing some ADME concerns. **Advantage: B**
**Overall Assessment:**
Ligand B consistently outperforms Ligand A in several key ADME properties (TPSA, logP, QED, BBB, Caco-2, Solubility, t1/2) and, crucially, has a much stronger binding affinity. While Ligand A has better metabolic stability (Cl_mic), the significant improvement in potency and the generally favorable ADME profile of Ligand B make it the more promising candidate. The slightly elevated DILI risk for both compounds is a concern that would need further investigation, but the overall balance favors Ligand B.
Output:
0
2025-04-17 21:22:15,621 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
The ADRB2 receptor is a GPCR, so the priorities are logP, TPSA, Pgp efflux, BBB penetration, and binding affinity. Metabolic stability (Cl_mic, t1/2) and safety (DILI, hERG) are also important.
Let's compare the ligands property by property:
1. **MW:** Both ligands (368.865 and 347.39 Da) are within the ideal 200-500 Da range.
2. **TPSA:** Ligand B (71.53) is significantly better than Ligand A (107.11). Lower TPSA is preferred for better absorption and potentially BBB penetration.
3. **logP:** Both ligands have similar logP values (1.629 and 1.677), falling within the optimal 1-3 range.
4. **HBD:** Ligand B (1) has fewer HBD than Ligand A (4), which is generally favorable for permeability.
5. **HBA:** Both ligands have the same number of HBA (4).
6. **QED:** Ligand B (0.845) has a higher QED score than Ligand A (0.633), indicating a more drug-like profile.
7. **DILI:** Ligand B (60.489) has a slightly higher DILI risk than Ligand A (54.789), but both are acceptable (below 60 is good).
8. **BBB:** Ligand B (71.656) has significantly better BBB penetration potential than Ligand A (25.591). This is a key advantage for a GPCR target.
9. **Caco-2:** Ligand B (-4.609) has a better Caco-2 permeability than Ligand A (-5.385).
10. **Solubility:** Ligand B (-2.006) has better solubility than Ligand A (-3.067).
11. **hERG:** Ligand B (0.243) has a slightly better hERG profile than Ligand A (0.147).
12. **Cl_mic:** Ligand B (-9.735) has a better (lower) microsomal clearance than Ligand A (-10.801), indicating better metabolic stability.
13. **t1/2:** Ligand B (18.095) has a significantly longer in vitro half-life than Ligand A (8.908).
14. **Pgp:** Ligand B (0.059) has a lower Pgp efflux liability than Ligand A (0.086), which is favorable for bioavailability and CNS exposure.
15. **Affinity:** Ligand A (-7.1) has a significantly stronger binding affinity than Ligand B (-3.7). This is a substantial advantage.
**Overall Assessment:**
While Ligand A boasts a significantly stronger binding affinity, Ligand B demonstrates superior ADME properties, particularly TPSA, BBB penetration, solubility, metabolic stability, and Pgp efflux. For a GPCR like ADRB2, these ADME properties are crucial for achieving adequate *in vivo* exposure and efficacy. The difference in affinity (-7.1 vs -3.7) is large, but the improved ADME profile of Ligand B, especially the BBB penetration, makes it a more promising candidate. The better metabolic stability and longer half-life also contribute to its potential for less frequent dosing.
**Output:**
0
2025-04-17 21:22:15,621 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (355.439 and 358.385 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (125.42) is slightly higher than Ligand B (59.08). For a cardiovascular GPCR, TPSA is not a critical factor, but lower is generally preferred for permeability. Ligand B is significantly better.
3. **logP:** Both ligands have good logP values (1.529 and 1.061), falling within the optimal 1-3 range. Ligand B is slightly lower, which could marginally improve solubility.
4. **HBD:** Ligand A has 2 HBD, while Ligand B has 0. Lower HBD is generally favorable for membrane permeability. Ligand B is better.
5. **HBA:** Ligand A has 5 HBA, and Ligand B has 4. Both are acceptable, below the threshold of 10.
6. **QED:** Ligand B (0.708) has a significantly higher QED score than Ligand A (0.35), indicating a more drug-like profile. This is a substantial advantage for Ligand B.
7. **DILI:** Ligand B (45.328) has a higher DILI risk than Ligand A (18.418). This is a significant drawback for Ligand B.
8. **BBB:** Ligand B (89.492) has a much higher BBB penetration percentile than Ligand A (43.311). While ADRB2 isn't a CNS target, some distribution to the CNS can sometimes lead to off-target effects, but is not a major concern here.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.871 and -4.36), which is unusual and suggests poor permeability. This is a concern for both, but the values are similar.
10. **Solubility:** Ligand A (-1.271) has slightly better solubility than Ligand B (-2.007).
11. **hERG:** Ligand A (0.125) has a lower hERG risk than Ligand B (0.349). This is a positive for Ligand A, as hERG inhibition can cause cardiotoxicity.
12. **Cl_mic:** Ligand B (25.14) has a lower microsomal clearance than Ligand A (26.693), suggesting better metabolic stability.
13. **t1/2:** Ligand A (3.321) has a longer in vitro half-life than Ligand B (-15.462). This is a significant advantage for Ligand A, as it suggests less frequent dosing.
14. **Pgp:** Ligand A (0.004) has a much lower P-gp efflux liability than Ligand B (0.084). Lower P-gp efflux is desirable for improved oral bioavailability.
15. **Binding Affinity:** Ligand B (-6.9) has a slightly better binding affinity than Ligand A (-6.0). While a 1.5 kcal/mol difference is significant, the other factors need to be considered.
**GPCR-Specific Priorities & Overall Assessment:**
For a cardiovascular GPCR like ADRB2, logP, TPSA, and affinity are key. Ligand B excels in TPSA and has comparable logP and slightly better affinity. However, Ligand A has a significantly better safety profile (lower DILI and hERG), better half-life, and lower P-gp efflux. The QED score for Ligand B is also substantially higher. The negative Caco-2 values are concerning for both, but the better ADME profile of Ligand A, particularly the safety aspects, outweigh the slightly better affinity of Ligand B.
Output:
1
2025-04-17 21:22:15,621 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (365.543 and 356.438 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (71.09) is higher than Ligand B (59.08). Both are below 140, but B is preferable for better absorption.
3. **logP:** Ligand A (3.537) is good, within the 1-3 range. Ligand B (1.403) is on the lower side, potentially impacting permeability. This favors A.
4. **HBD:** Ligand A (2) is reasonable. Ligand B (0) is also good, potentially enhancing permeability.
5. **HBA:** Both ligands have 4 HBA, which is acceptable.
6. **QED:** Ligand A (0.776) is better than Ligand B (0.675), indicating a more drug-like profile.
7. **DILI:** Ligand B (24.544) has a significantly lower DILI risk than Ligand A (45.095). This is a major advantage for B.
8. **BBB:** Ligand B (86.817) has a much higher BBB penetration percentile than Ligand A (63.629). While ADRB2 isn't exclusively a CNS target, some CNS exposure can occur, and higher BBB is generally favorable.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.867 and -4.257). This is unusual and suggests poor permeability, but the values are similar.
10. **Solubility:** Ligand B (-1.056) is better than Ligand A (-4.36), indicating better aqueous solubility.
11. **hERG:** Ligand A (0.317) has a slightly better hERG profile than Ligand B (0.338), but both are low risk.
12. **Cl_mic:** Ligand B (24.41) has significantly lower microsomal clearance than Ligand A (57.996), indicating better metabolic stability.
13. **t1/2:** Ligand B (8.343) has a longer in vitro half-life than Ligand A (30.793). This is a significant advantage for B.
14. **Pgp:** Ligand B (0.062) has a much lower P-gp efflux liability than Ligand A (0.229), which is beneficial for bioavailability and potential CNS exposure.
15. **Affinity:** Ligand A (-7.9 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.1 kcal/mol). This is a substantial advantage for A, potentially outweighing some ADME drawbacks.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand A has a better logP and significantly better affinity. However, Ligand B excels in Pgp efflux, TPSA, DILI, BBB, solubility, and metabolic stability. The substantial difference in affinity for Ligand A is compelling, but the ADME profile of Ligand B is markedly superior, particularly the lower DILI risk and better metabolic stability.
**Overall Assessment:**
While the affinity of Ligand A is very attractive, the superior ADME profile of Ligand B, particularly its lower toxicity (DILI), better metabolic stability (Cl_mic, t1/2), and reduced efflux (Pgp), makes it the more promising drug candidate. The affinity difference, while significant, might be overcome with further optimization of Ligand B.
Output:
0
2025-04-17 21:22:15,621 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (370.343) is slightly higher than Ligand B (344.43), but both are acceptable.
2. **TPSA:** Ligand A (89.87) is excellent, well below the 140 threshold for oral absorption and good for a GPCR. Ligand B (49.41) is also very good.
3. **logP:** Ligand A (0.516) is a bit low, potentially hindering permeability. Ligand B (3.208) is within the optimal range (1-3). This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (3) is acceptable. Ligand B (1) is even better, potentially improving permeability.
5. **HBA:** Ligand A (4) is acceptable. Ligand B (2) is also good.
6. **QED:** Both ligands have good QED scores (Ligand A: 0.63, Ligand B: 0.892). Ligand B is better here.
7. **DILI:** Ligand A (35.401) has a lower DILI risk than Ligand B (25.165), which is favorable.
8. **BBB:** Ligand A (48.197) is lower than Ligand B (82.862). While ADRB2 isn't necessarily a CNS target, higher BBB penetration is generally favorable for drug distribution. Ligand B is significantly better here.
9. **Caco-2:** Ligand A (-5.172) and Ligand B (-4.646) are both negative, indicating poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Ligand A (-1.694) and Ligand B (-3.67) are both negative, indicating poor solubility. Again, the scale is not specified.
11. **hERG:** Ligand A (0.244) has a lower hERG risk than Ligand B (0.619). This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand A (-21.924) has a much lower (better) microsomal clearance than Ligand B (52.785), indicating greater metabolic stability.
13. **t1/2:** Ligand A (1.644) has a shorter half-life than Ligand B (-12.168). This is a disadvantage for Ligand A.
14. **Pgp:** Ligand A (0.018) has much lower P-gp efflux than Ligand B (0.147), which is favorable.
15. **Affinity:** Ligand A (-7.3) has a slightly better binding affinity than Ligand B (-6.4). This is a 0.9 kcal/mol difference, which is significant.
**GPCR-Specific Priorities & Overall Assessment:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP, BBB, and QED. Ligand A has a better affinity and lower DILI/Pgp, but suffers from a lower logP and a shorter half-life. The affinity difference (0.9 kcal/mol) is substantial enough to outweigh the slightly lower logP of Ligand A, *especially* given the better metabolic stability (lower Cl_mic) and lower P-gp efflux. The hERG risk is also lower for Ligand A.
Considering the balance of these factors, Ligand A appears to be the more promising candidate.
Output:
1
2025-04-17 21:22:15,621 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Ligand A (386.283 Da) is within the ideal range (200-500). Ligand B (352.479 Da) is also within range. No clear advantage here.
2. **TPSA:** Ligand A (92.94) is slightly above the preferred <90 for CNS targets, but acceptable for a peripheral GPCR like ADRB2. Ligand B (80.34) is excellent. Ligand B has a slight advantage.
3. **logP:** Ligand A (4.19) is at the higher end of the optimal range (1-3) and could potentially lead to solubility issues. Ligand B (2.688) is well within the optimal range. Ligand B is better.
4. **HBD:** Ligand A (2) is good. Ligand B (1) is also good. No significant difference.
5. **HBA:** Ligand A (5) is good. Ligand B (6) is also acceptable. No significant difference.
6. **QED:** Ligand A (0.769) is excellent, indicating good drug-likeness. Ligand B (0.515) is still acceptable, but lower. Ligand A is better.
7. **DILI:** Ligand A (78.402) has a higher DILI risk than Ligand B (21.946). Ligand B is significantly better here.
8. **BBB:** Both are low, which is fine for a cardiovascular target. Ligand A (41.644) and Ligand B (52.811). No significant difference.
9. **Caco-2:** Ligand A (-4.889) is poor. Ligand B (-5.297) is also poor. No significant difference.
10. **Solubility:** Ligand A (-4.952) is poor. Ligand B (-2.424) is better. Ligand B is better.
11. **hERG:** Ligand A (0.081) is very low risk. Ligand B (0.587) is slightly higher, but still acceptable. Ligand A is better.
12. **Cl_mic:** Ligand A (61.032) and Ligand B (50.859) are similar. No significant difference.
13. **t1/2:** Ligand A (49.179) is much better than Ligand B (3.896). Ligand A is better.
14. **Pgp:** Ligand A (0.029) is very low efflux, excellent. Ligand B (0.106) is also low, but higher than A. Ligand A is better.
15. **Affinity:** Ligand B (-7.3 kcal/mol) is 0.3 kcal/mol better than Ligand A (-8.0 kcal/mol). This is a significant difference in binding.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP and TPSA. Ligand A has a better Pgp profile. The affinity difference is significant, favoring Ligand B.
**Overall Assessment:**
While Ligand A has better QED, DILI, half-life, and Pgp properties, Ligand B's superior logP, TPSA, solubility, and, most importantly, *binding affinity* outweigh these advantages. The higher affinity of Ligand B suggests it will be more potent and potentially require a lower dose, mitigating some of the concerns around its slightly higher DILI risk.
Output:
0
2025-04-17 21:22:15,622 - INFO - Batch 253 complete. Total preferences: 4048
2025-04-17 21:22:15,622 - INFO - Processing batch 254/512...
2025-04-17 21:23:03,434 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands are within the ideal 200-500 Da range (A: 450.236, B: 372.437). No significant difference here.
**2. TPSA:** Ligand B (78.43) is significantly better than Ligand A (101.14). For a GPCR, lower TPSA is generally preferred for better permeability.
**3. logP:** Both ligands have good logP values (A: 2.857, B: 2.012), falling within the optimal 1-3 range.
**4. H-Bond Donors:** Ligand A has 2 HBD, and Ligand B has 3. Both are acceptable, within the limit of 5.
**5. H-Bond Acceptors:** Ligand A has 6 HBA, and Ligand B has 4. Both are acceptable, within the limit of 10.
**6. QED:** Ligand B (0.685) has a better QED score than Ligand A (0.458), indicating a more drug-like profile.
**7. DILI Risk:** Ligand B (39.511) has a much lower DILI risk than Ligand A (88.251). This is a significant advantage for Ligand B.
**8. BBB Penetration:** Ligand B (74.06) shows better BBB penetration than Ligand A (20.202). While ADRB2 isn't exclusively a CNS target, some cardiovascular effects are mediated through central pathways, and better BBB penetration could be beneficial.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
**10. Aqueous Solubility:** Both ligands have negative solubility values, indicating poor solubility. This is a concern for both.
**11. hERG Inhibition:** Ligand A (0.113) has a slightly lower hERG inhibition risk than Ligand B (0.572), which is a positive.
**12. Microsomal Clearance:** Ligand B (13.514) has significantly lower microsomal clearance than Ligand A (43.321), indicating better metabolic stability.
**13. In vitro Half-Life:** Ligand B (30.77) has a much longer in vitro half-life than Ligand A (-13.696). This is a major advantage for Ligand B.
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (A: 0.204, B: 0.202).
**15. Binding Affinity:** Ligand A (-6.9 kcal/mol) has a significantly stronger binding affinity than Ligand B (-0.9 kcal/mol). This is a substantial advantage for Ligand A.
**Overall Assessment:**
While Ligand A has a much stronger binding affinity, the ADME properties of Ligand B are far superior. Specifically, the lower DILI risk, better BBB penetration, lower clearance, and longer half-life of Ligand B are critical advantages for a drug candidate. The difference in binding affinity, while significant, might be overcome with further optimization of Ligand B. The poor solubility and permeability of both compounds are concerns that would need to be addressed, but these are often more readily optimized than fundamental issues like metabolic instability or toxicity. Given the GPCR target class, the balance of properties favors Ligand B.
Output:
0
2025-04-17 21:23:03,434 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
The target is ADRB2, a GPCR. Therefore, priorities are logP, Pgp, TPSA, affinity, and BBB. Let's break down the comparison:
1. **Molecular Weight:** Both ligands (354.382 and 356.491 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (87.91) is better than Ligand B (42.43). Lower TPSA generally favors better cell permeability, and both are well below the 140 A^2 threshold for oral absorption.
3. **logP:** Ligand B (3.592) is higher than Ligand A (-0.016). While Ligand A is slightly negative, which is not ideal, Ligand B is approaching the upper limit of the optimal range.
4. **H-Bond Donors:** Ligand A (1) is preferable to Ligand B (0). A single HBD can aid solubility without drastically hindering permeability.
5. **H-Bond Acceptors:** Ligand A (6) is higher than Ligand B (4). Both are within acceptable limits (<=10).
6. **QED:** Ligand A (0.818) is better than Ligand B (0.731), indicating a more drug-like profile.
7. **DILI:** Ligand B (31.834) is significantly better than Ligand A (54.323). Lower DILI risk is crucial.
8. **BBB:** Both ligands have similar BBB penetration (Ligand A: 78.713, Ligand B: 77.007). Both are acceptable, but not exceptionally high.
9. **Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.447 and -4.685). These values are unusual and suggest poor permeability.
10. **Aqueous Solubility:** Ligand A (-1.004) is better than Ligand B (-4.38). Higher solubility is generally preferred.
11. **hERG Inhibition:** Both ligands have low hERG inhibition risk (Ligand A: 0.153, Ligand B: 0.485).
12. **Microsomal Clearance:** Ligand A (0.065) is significantly better than Ligand B (117.506). Lower clearance indicates better metabolic stability.
13. **In vitro Half-Life:** Ligand B (-40.312) is significantly better than Ligand A (-23.934). Longer half-life is desirable.
14. **P-gp Efflux:** Both ligands have low P-gp efflux liability (Ligand A: 0.02, Ligand B: 0.276).
15. **Binding Affinity:** Both ligands have the same binding affinity (-6.5 kcal/mol).
**Overall Assessment:**
Ligand B has a better logP and a significantly better DILI score and in vitro half-life. However, Ligand A has better TPSA, QED, solubility, and significantly better microsomal clearance. The Caco-2 values are concerning for both. Given the GPCR target, the balance of properties leans towards Ligand B due to the lower DILI risk and longer half-life, which are important for *in vivo* performance. The slightly higher logP is acceptable.
Output:
0
2025-04-17 21:23:03,435 - INFO - Here's my reasoning and output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
Let's break down the comparison, prioritizing parameters relevant for a GPCR like ADRB2 (logP, Pgp, TPSA, and affinity are key, with ADME properties also important).
1. **Molecular Weight:** Both ligands are within the ideal 200-500 Da range. Ligand A (382.51) is slightly higher than Ligand B (352.435), but both are acceptable.
2. **TPSA:** Ligand A (49.41) is significantly better than Ligand B (115.97). A TPSA under 140 is good for oral absorption, but Ligand B is pushing the upper limit and could have absorption issues.
3. **logP:** Ligand A (4.664) is higher than the optimal range (1-3), but still potentially manageable. Ligand B (-1.184) is *too* low, indicating potential permeability problems.
4. **H-Bond Donors/Acceptors:** Ligand A (HBD=1, HBA=3) is better balanced than Ligand B (HBD=3, HBA=5). Excessive H-bonding can hinder membrane permeability.
5. **QED:** Both ligands have reasonable QED scores (A: 0.424, B: 0.52), indicating acceptable drug-likeness, but B is slightly better.
6. **DILI:** Ligand A (28.383) has a much lower DILI risk than Ligand B (5.894), which is a significant advantage.
7. **BBB:** Ligand A (79.294) shows good BBB penetration, while Ligand B (35.014) is poor. While ADRB2 isn't exclusively a CNS target, some CNS exposure can occur, and better BBB penetration is generally favorable.
8. **Caco-2:** Ligand A (-4.961) is better than Ligand B (-6.002), indicating better intestinal absorption.
9. **Solubility:** Ligand A (-3.569) is better than Ligand B (-0.871). Solubility is important for formulation and bioavailability.
10. **hERG:** Ligand A (0.838) has a lower hERG risk than Ligand B (0.132), which is a significant safety advantage.
11. **Cl_mic:** Ligand A (52.864) has a higher (less favorable) microsomal clearance than Ligand B (-21.71). This suggests Ligand B is more metabolically stable.
12. **t1/2:** Ligand A (-2.668) has a shorter half-life than Ligand B (-16.381). This is a disadvantage for Ligand A.
13. **Pgp:** Ligand A (0.728) has lower P-gp efflux than Ligand B (0.001), which is a positive.
14. **Binding Affinity:** Ligand A (-7.8) has a slightly better binding affinity than Ligand B (-6.3). While both are good, the 1.5 kcal/mol difference is noteworthy.
**Overall Assessment:**
Ligand A is the stronger candidate. While Ligand B has better metabolic stability and half-life, Ligand A excels in crucial areas like TPSA, logP, DILI risk, hERG risk, solubility, and BBB penetration. The slightly better affinity of Ligand A further strengthens its position. The combination of favorable ADME properties and good potency makes Ligand A the more promising starting point for drug development targeting ADRB2.
**Output:**
1
2025-04-17 21:23:03,435 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (344.375 and 345.403 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand B (97.62) is significantly better than Ligand A (125.02). For a GPCR, lower TPSA is generally preferred for better permeability. Ligand B is well below the 140 threshold, while A is approaching it.
3. **logP:** Ligand B (0.948) is slightly lower than Ligand A (0.505), but both are a bit low. Ideally, we want 1-3. Ligand B is closer to the optimal range.
4. **HBD:** Both ligands have 2 H-bond donors, which is within the acceptable limit of 5.
5. **HBA:** Ligand B (6) has fewer H-bond acceptors than Ligand A (7), which is preferable for permeability.
6. **QED:** Ligand A (0.753) has a slightly better QED score than Ligand B (0.521), suggesting a more drug-like profile.
7. **DILI:** Ligand B (65.878) has a higher DILI risk than Ligand A (56.572). This is a negative for Ligand B.
8. **BBB:** Ligand A (71.733) has a significantly higher BBB penetration percentile than Ligand B (57.852). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be beneficial for off-target effects assessment and potentially broader distribution.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.453 and -5.37), which is unusual and suggests poor permeability. This is a major concern for both.
10. **Solubility:** Ligand A (-1.069) has slightly better solubility than Ligand B (-1.791), which is a minor advantage.
11. **hERG:** Ligand B (0.248) has a lower hERG inhibition liability than Ligand A (0.04), which is a significant safety advantage.
12. **Cl_mic:** Ligand A (15.839) has a much lower microsomal clearance than Ligand B (49.798), indicating better metabolic stability. This is a strong positive for Ligand A.
13. **t1/2:** Ligand B (18.675) has a significantly longer in vitro half-life than Ligand A (-10.586). This is a major advantage for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand B (0.081) has lower P-gp efflux liability than Ligand A (0.037), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand B (-6.5) has a slightly better binding affinity than Ligand A (-6.0), although the difference is not huge.
**Overall Assessment:**
Ligand B has a better TPSA, HBA, hERG, Pgp, and half-life. Ligand A has a better QED, DILI, BBB, solubility, and Cl_mic. The biggest concerns are the poor Caco-2 permeability for both. However, the combination of better metabolic stability (Cl_mic) and a slightly improved binding affinity in Ligand A, coupled with the lower hERG risk and Pgp efflux in Ligand B, makes this a difficult choice. Given the GPCR target class, I prioritize TPSA, logP, Pgp, and affinity. Ligand B is better in TPSA, Pgp, and affinity, and has acceptable logP. The longer half-life is also a significant benefit. While the DILI is a concern, it's not drastically high.
Output:
0
2025-04-17 21:23:03,435 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (347.415 and 349.366 Da) fall comfortably within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (84.67) is better than Ligand B (95.5). Both are below 140, but lower TPSA generally favors oral absorption, a key consideration for a cardiovascular drug.
3. **logP:** Ligand A (2.744) is optimal (1-3), while Ligand B (-0.234) is significantly lower, potentially hindering membrane permeability. This is a substantial negative for Ligand B.
4. **HBD:** Both have 1 HBD, which is within the acceptable limit of 5.
5. **HBA:** Ligand A (6) is slightly higher than Ligand B (5), but both are within the acceptable limit of 10.
6. **QED:** Both ligands have good QED scores (0.775 and 0.813), indicating generally drug-like properties.
7. **DILI:** Ligand A (77.2) has a higher DILI risk than Ligand B (64.793), but both are below the concerning threshold of 60.
8. **BBB:** Ligand A (72.741) is better than Ligand B (60.295). While ADRB2 isn't necessarily a CNS target, some CNS penetration can be beneficial for understanding off-target effects and overall distribution.
9. **Caco-2:** Ligand A (-4.598) and Ligand B (-4.803) are both very poor. This is a concern for both, suggesting limited intestinal absorption.
10. **Solubility:** Ligand A (-4.447) is better than Ligand B (-1.518). Solubility is important for formulation and bioavailability.
11. **hERG:** Ligand A (0.621) has a lower hERG risk than Ligand B (0.146). This is a significant advantage for Ligand A, as hERG inhibition can lead to cardiotoxicity.
12. **Cl_mic:** Ligand A (105.087) has a higher microsomal clearance than Ligand B (-4.144). This suggests Ligand B is more metabolically stable, which is desirable.
13. **t1/2:** Ligand A (65.159) has a longer half-life than Ligand B (-16.551). This is a significant advantage for Ligand A, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.247) has lower P-gp efflux liability than Ligand B (0.017). Lower P-gp efflux is generally favorable for bioavailability.
15. **Binding Affinity:** Ligand B (-7.1) has a slightly better binding affinity than Ligand A (-5.8). While a 1.3 kcal/mol difference is good, it doesn't necessarily outweigh the significant ADME deficiencies of Ligand B.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A performs better on logP, TPSA, and Pgp. The affinity difference is not large enough to overcome the ADME issues with Ligand B.
**Overall Assessment:**
Ligand A has a more balanced profile, with better logP, TPSA, solubility, hERG risk, half-life, and Pgp efflux. While its Caco-2 permeability is poor, it's similar to Ligand B. Ligand B's superior affinity is offset by its poor logP, solubility, and metabolic stability.
Output:
1
2025-04-17 21:23:03,435 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's systematically compare Ligand A and Ligand B against the provided guidelines, with emphasis on GPCR-relevant properties.
1. **MW:** Both ligands (350.35 Da and 350.415 Da) fall comfortably within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (109.42) is higher than Ligand B (84.94). While both are acceptable, Ligand B is better, being closer to the <140 threshold for good absorption.
3. **logP:** Ligand A (-0.894) is slightly lower than the optimal 1-3 range, potentially hindering permeation. Ligand B (0.757) is within the optimal range. This favors Ligand B.
4. **HBD:** Ligand A (3) is higher than Ligand B (1). Both are acceptable, but lower is generally preferable for permeability.
5. **HBA:** Both ligands have 5 HBA, which is within the acceptable range.
6. **QED:** Ligand B (0.715) has a significantly higher QED score than Ligand A (0.32), indicating a more drug-like profile. This is a strong advantage for Ligand B.
7. **DILI:** Both ligands have similar DILI risk (44.126 vs. 45.522), and both are below the concerning threshold of 60.
8. **BBB:** Ligand A (83.87) has a substantially higher BBB penetration percentile than Ligand B (43.505). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be beneficial for distribution.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-5.473) is slightly worse than Ligand B (-4.804).
10. **Solubility:** Both ligands have very poor aqueous solubility (-2.058 and -2.118). This is a significant concern for both.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.198 and 0.054).
12. **Cl_mic:** Ligand A (-1.077) has a lower (better) microsomal clearance than Ligand B (-19.726), indicating better metabolic stability.
13. **t1/2:** Ligand B (14.06) has a much longer in vitro half-life than Ligand A (-8.999), which is a significant advantage.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.006 and 0.039).
15. **Binding Affinity:** Ligand A (-7.6) has a slightly better binding affinity than Ligand B (-3.5). This is a substantial difference (4.1 kcal/mol).
**Overall Assessment:**
The key trade-offs are: Ligand A has better affinity and metabolic stability (lower Cl_mic), and better BBB penetration, but Ligand B has a much better QED score, logP, and *significantly* longer half-life. The poor solubility of both is a major concern, but can potentially be addressed with formulation strategies. The superior binding affinity of Ligand A is tempting, but the substantial improvement in predicted drug-likeness (QED) and pharmacokinetic properties (t1/2) of Ligand B, coupled with its acceptable logP, outweigh the affinity difference.
**Output:**
0
2025-04-17 21:23:03,435 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (353.394 and 349.431 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (89.55 and 84.67) are below the 140 A^2 threshold for good oral absorption, and are reasonable for a non-CNS GPCR target like ADRB2. Ligand B is slightly better.
3. **logP:** Both ligands (1.416 and 2.088) are within the optimal 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Ligand A has 2 HBD, Ligand B has 1. Both are acceptable (<=5). Ligand B is slightly preferred.
5. **HBA:** Both ligands have 5 HBA, which is acceptable (<=10). No difference.
6. **QED:** Both ligands have good QED scores (0.724 and 0.815), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (62.233) has a higher DILI risk than Ligand B (38.348). This is a significant advantage for Ligand B.
8. **BBB:** Both ligands have high BBB penetration (81.233 and 81.698). While ADRB2 isn't a primary CNS target, higher BBB is generally not detrimental. No significant difference.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.79 and -4.702). These values are unusual and suggest poor permeability. However, the absolute values are very close, so this isn't a major differentiator.
10. **Solubility:** Both ligands have very poor aqueous solubility (-2.191 and -2.254). This is a significant concern for both, and would require formulation strategies to address. No significant difference.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.309 and 0.141). Ligand B is slightly better.
12. **Cl_mic:** Ligand A has a lower microsomal clearance (25.266) than Ligand B (30.045), indicating better metabolic stability. This is a positive for Ligand A.
13. **t1/2:** Ligand B has a longer in vitro half-life (7.229 hours) than Ligand A (8.542 hours). This is a positive for Ligand B.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.035 and 0.059). No significant difference.
15. **Binding Affinity:** Ligand A (-6.8 kcal/mol) has a slightly better binding affinity than Ligand B (-5.8 kcal/mol). This is a 1.0 kcal/mol difference, which is a substantial advantage.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand B has a slightly better logP and TPSA, but Ligand A has a significantly better binding affinity. The DILI risk is also a major consideration, and Ligand B is clearly superior in this regard. Metabolic stability (Cl_mic) is also important, and Ligand A is better.
**Overall Assessment:**
While Ligand A has a better binding affinity and metabolic stability, the significantly lower DILI risk for Ligand B is a crucial advantage. The slight improvements in logP, QED, and half-life for Ligand B further support its selection. The solubility and Caco-2 permeability are poor for both, but these can be addressed through formulation. The binding affinity difference, while substantial, can potentially be optimized in later stages of drug development. The reduced toxicity profile of Ligand B makes it the more promising candidate.
Output:
0
2025-04-17 21:23:03,436 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [352.36 , 49.42 , 2.529, 2. , 5. , 0.81 , 71.384, 71.656, -4.585, -2.985, 0.838, 16.53 , -0.528, 0.119, -7.6 ]
**Ligand B:** [357.376, 62.3 , 2.321, 1. , 3. , 0.85 , 17.798, 82.202, -4.791, -2.488, 0.594, -8.882, -4.173, 0.043, -6.7 ]
Here's a breakdown, considering the GPCR priorities (logP, Pgp, TPSA, affinity, and, to a lesser extent, BBB):
1. **MW:** Both are within the ideal range (200-500 Da). A is 352.36, B is 357.376 - very similar.
2. **TPSA:** A (49.42) is excellent, well below the 140 threshold. B (62.3) is still reasonable, but less optimal.
3. **logP:** Both are good (around 2.3-2.5), falling within the 1-3 optimal range.
4. **HBD/HBA:** A has 2 HBD and 5 HBA, B has 1 HBD and 3 HBA. Both are acceptable.
5. **QED:** Both are high (0.81 and 0.85), indicating good drug-like properties.
6. **DILI:** A (71.384) is higher than B (17.798). B has a significantly lower DILI risk. This is a major advantage for B.
7. **BBB:** A (71.656) and B (82.202) are both reasonably good, but B is better. While not a primary concern for a cardiovascular target, higher BBB is generally beneficial.
8. **Caco-2:** Both are negative, indicating poor permeability. This is a concern for both.
9. **Solubility:** Both are negative, indicating poor solubility. This is a concern for both.
10. **hERG:** A (0.838) is slightly higher than B (0.594), indicating a slightly higher hERG risk for A.
11. **Cl_mic:** A (16.53) is higher than B (-8.882), meaning A has faster metabolic clearance and lower metabolic stability. B is much more metabolically stable.
12. **t1/2:** A (-0.528) is shorter than B (-4.173). B has a significantly longer in vitro half-life.
13. **Pgp:** A (0.119) is higher than B (0.043), suggesting A is a better P-gp substrate and will have lower bioavailability.
14. **Affinity:** A (-7.6) is slightly better than B (-6.7), a 0.9 kcal/mol difference. This is a significant advantage, but needs to be weighed against the ADME properties.
**Overall Assessment:**
Ligand B clearly wins out. While Ligand A has a slightly better binding affinity, Ligand B has substantially better ADME properties: significantly lower DILI risk, better metabolic stability (lower Cl_mic, longer t1/2), lower P-gp efflux, and a better BBB score. The affinity difference of 0.9 kcal/mol is not large enough to overcome the substantial ADME advantages of Ligand B, especially considering the potential for optimization of Ligand B's affinity. The poor Caco-2 and solubility for both ligands are concerns that would need to be addressed in further optimization, but are less critical than the safety and PK liabilities of Ligand A.
Output:
0
2025-04-17 21:23:03,436 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (360.426 Da and 342.439 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (84.94) is slightly higher than Ligand B (58.64). For a cardiovascular GPCR, TPSA is moderately important. Ligand B's lower TPSA is preferable for potentially better absorption.
**3. logP:** Both ligands have good logP values (1.2 and 1.488, respectively), falling within the optimal 1-3 range. No clear advantage.
**4. H-Bond Donors:** Both ligands have 1 HBD, which is within the acceptable limit of 5.
**5. H-Bond Acceptors:** Ligand A has 5 HBAs, while Ligand B has 3. Both are below the 10 threshold.
**6. QED:** Ligand B (0.608) has a higher QED score than Ligand A (0.467), indicating a more drug-like profile. This is a positive for Ligand B.
**7. DILI Risk:** Ligand B (15.626%) has a significantly lower DILI risk than Ligand A (33.23%). This is a major advantage for Ligand B, as minimizing liver toxicity is crucial.
**8. BBB Penetration:** Ligand A (79.488%) has better BBB penetration than Ligand B (52.811%). While ADRB2 is a cardiovascular target, some CNS effects can be relevant, and higher BBB penetration *could* be beneficial, but is not a primary driver for this target.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.661 and -4.738). This is unusual and suggests poor permeability. However, the values are very similar.
**10. Aqueous Solubility:** Ligand A (-1.75) has slightly better aqueous solubility than Ligand B (-2.544). This is a minor advantage.
**11. hERG Inhibition:** Ligand B (0.104) has a much lower hERG inhibition risk than Ligand A (0.377). This is a critical advantage, as hERG inhibition can lead to cardiotoxicity.
**12. Microsomal Clearance:** Ligand A (54.92) has a higher microsomal clearance than Ligand B (12.824), indicating faster metabolism and potentially lower exposure. Ligand B is preferable here.
**13. In vitro Half-Life:** Ligand B (3.509 hours) has a longer half-life than Ligand A (-12.266 hours). This is a significant advantage for Ligand B, potentially allowing for less frequent dosing.
**14. P-gp Efflux:** Ligand A (0.146) has lower P-gp efflux than Ligand B (0.046). Lower P-gp efflux is generally preferred.
**15. Binding Affinity:** Ligand B (-7.5 kcal/mol) has a slightly better binding affinity than Ligand A (-7.2 kcal/mol). While the difference is small, it's enough to be considered, especially given the other advantages of Ligand B.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity) and the general drug-like properties, Ligand B is the stronger candidate. It demonstrates a significantly better safety profile (lower DILI, lower hERG), improved metabolic stability (lower Cl_mic, longer t1/2), and a slightly better binding affinity. While Ligand A has better BBB penetration and solubility, the safety and pharmacokinetic advantages of Ligand B outweigh these factors for a cardiovascular target.
Output:
0
2025-04-17 21:23:03,436 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (348.45 & 346.39 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (87.47) is significantly better than Ligand B (116.23). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is pushing the upper limit for good oral absorption.
3. **logP:** Both ligands have good logP values (1.41 & 0.77), falling within the 1-3 range. Ligand A is slightly more lipophilic, which could be advantageous for membrane permeability.
4. **HBD:** Ligand A (2) is preferable to Ligand B (4). Fewer hydrogen bond donors generally improve permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (4). Fewer hydrogen bond acceptors generally improve permeability.
6. **QED:** Ligand A (0.728) has a better QED score than Ligand B (0.592), indicating a more drug-like profile.
7. **DILI:** Ligand A (32.38%) has a significantly lower DILI risk than Ligand B (61.07%). This is a major advantage for Ligand A.
8. **BBB:** Both ligands have similar BBB penetration (50.68% vs 48.66%). Not a primary driver in this case, as ADRB2 isn't necessarily a CNS target, but it's good they aren't extremely low.
9. **Caco-2:** Ligand A (-4.951) is better than Ligand B (-5.608), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-1.691) is better than Ligand B (-3.273), indicating better aqueous solubility.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.387 & 0.18). This is excellent.
12. **Cl_mic:** Ligand A (8.433) has a slightly lower microsomal clearance than Ligand B (6.83), suggesting better metabolic stability.
13. **t1/2:** Ligand B (34.299) has a longer in vitro half-life than Ligand A (30.168), which is a slight advantage.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.089 & 0.024).
15. **Binding Affinity:** Ligand B (-6.8 kcal/mol) has a slightly better binding affinity than Ligand A (-6.5 kcal/mol). While a 0.3 kcal/mol difference is not huge, it's noticeable.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, TPSA, logP, and affinity are key. Ligand A excels in TPSA, logP, and has a good QED and significantly lower DILI risk. While Ligand B has slightly better affinity and half-life, the improvements in ADME properties and safety with Ligand A outweigh this small difference in binding.
**Conclusion:**
Ligand A presents a more balanced profile with better predicted ADME properties and a significantly lower DILI risk, making it the more promising drug candidate.
Output:
1
2025-04-17 21:23:03,436 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (359.442 and 350.459 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (101.73) is higher than Ligand B (76.66). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is generally preferred for absorption. Ligand B has a clear advantage.
3. **logP:** Ligand B (1.385) is slightly higher than Ligand A (0.757), both are within the optimal 1-3 range. Ligand B is slightly better.
4. **HBD:** Both ligands have 2 H-bond donors, which is within the acceptable limit of 5. No difference.
5. **HBA:** Both ligands have 4 H-bond acceptors, also within the acceptable limit of 10. No difference.
6. **QED:** Ligand A (0.7) is better than Ligand B (0.512), indicating a more drug-like profile.
7. **DILI:** Ligand A (34.393) has a significantly lower DILI risk than Ligand B (18.651). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (78.829) has a higher BBB penetration potential than Ligand B (50.872). While ADRB2 isn't strictly a CNS target, some brain exposure can occur, and higher BBB is generally favorable.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.006 and -4.951), which is unusual. This suggests poor permeability. The values are very similar, so it doesn't differentiate them.
10. **Solubility:** Both ligands have negative solubility values (-2.762 and -2.259), which is also unusual and suggests poor solubility. Again, the values are similar.
11. **hERG:** Both ligands have low hERG inhibition liability (0.365 and 0.23), which is good. Ligand B is slightly better.
12. **Cl_mic:** Ligand A (18.589) has a higher microsomal clearance than Ligand B (13.303), meaning it's metabolized faster. Ligand B is better here.
13. **t1/2:** Ligand B (9.407) has a longer in vitro half-life than Ligand A (-10.746). This is a significant advantage for Ligand B.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.065 and 0.04), which is good. No significant difference.
15. **Binding Affinity:** Ligand B (-6.4 kcal/mol) has a slightly better binding affinity than Ligand A (-5.7 kcal/mol). This is a 0.7 kcal/mol difference, which is a meaningful advantage.
**Overall Assessment:**
Ligand B has a better balance of properties. While Ligand A has a lower DILI risk and higher QED, Ligand B has a significantly better binding affinity, longer half-life, lower clearance, and lower TPSA. The binding affinity difference is substantial enough to outweigh the slightly higher DILI risk and lower QED of Ligand B. The poor Caco-2 and solubility of both ligands are concerning and would need to be addressed in further optimization, but they don't differentiate the two compounds. Given the GPCR target class, the affinity and metabolic stability (half-life/clearance) are particularly important.
Output:
0
2025-04-17 21:23:03,436 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [340.467, 33.73, 4.423, 1, 4, 0.771, 54.866, 74.37, -4.582, -4.85, 0.965, 90.661, 4.594, 0.745, -7.3]
**Ligand B:** [379.473, 81.67, 0.452, 3, 5, 0.507, 18.651, 65.413, -5.381, -1.682, 0.601, -2.921, -17.058, 0.027, -6.2]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity, and BBB):
1. **MW:** Both are within the acceptable 200-500 Da range. Ligand A (340.467) is slightly preferred.
2. **TPSA:** Ligand A (33.73) is excellent, well below the 140 threshold. Ligand B (81.67) is higher, but still potentially acceptable.
3. **logP:** Ligand A (4.423) is a bit high, potentially leading to off-target effects or solubility issues. Ligand B (0.452) is *too* low, likely hindering membrane permeability. This is a significant drawback for a GPCR ligand.
4. **HBD/HBA:** Ligand A (1 HBD, 4 HBA) is better than Ligand B (3 HBD, 5 HBA). Both are within reasonable limits.
5. **QED:** Ligand A (0.771) is better than Ligand B (0.507), indicating a more drug-like profile.
6. **DILI:** Ligand B (18.651) has a much lower DILI risk than Ligand A (54.866), a major advantage.
7. **BBB:** Ligand A (74.37) has better BBB penetration than Ligand B (65.413), which is a plus for a GPCR target.
8. **Caco-2:** Ligand A (-4.582) is better than Ligand B (-5.381), indicating better absorption.
9. **Solubility:** Ligand A (-4.85) is better than Ligand B (-1.682).
10. **hERG:** Ligand A (0.965) has a slightly better hERG profile than Ligand B (0.601).
11. **Cl_mic:** Ligand B (-2.921) has a *much* better (lower) microsomal clearance than Ligand A (90.661), indicating greater metabolic stability.
12. **t1/2:** Ligand B (-17.058) has a longer half-life than Ligand A (4.594).
13. **Pgp:** Ligand A (0.745) has better Pgp efflux profile than Ligand B (0.027).
14. **Affinity:** Ligand A (-7.3 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.2 kcal/mol). This is a substantial advantage.
**Overall Assessment:**
Ligand A has a strong affinity, good BBB penetration, and acceptable TPSA and QED. Its main drawbacks are the slightly high logP and DILI risk. Ligand B has a better safety profile (DILI, Cl_mic, t1/2) but suffers from a very low logP, which will severely limit its ability to cross cell membranes and reach the target receptor. The affinity is also weaker.
Given the GPCR-specific priorities, the strong affinity of Ligand A is a critical factor. While the logP is a concern, it's potentially addressable through further optimization. The poor logP of Ligand B is a more fundamental issue that would be very difficult to overcome.
Therefore, I prefer Ligand A.
Output:
1
2025-04-17 21:23:03,437 - INFO - Here's my reasoning and final output for the ligand preference:
**Reasoning:**
We are targeting ADRB2, a GPCR, so the priorities are logP, Pgp, TPSA, affinity, and BBB. Let's compare Ligand A and Ligand B across all parameters:
1. **MW:** Both ligands are within the ideal range (347-359 Da).
2. **TPSA:** Ligand A (58.56) is significantly better than Ligand B (127.49). Lower TPSA is preferred for better absorption, especially for a GPCR.
3. **logP:** Ligand A (4.3) is higher than Ligand B (1.498). While >4 can be problematic, it's not excessively high, and for a GPCR, a higher logP can be beneficial for membrane interaction. Ligand B is a bit low, potentially hindering permeation.
4. **HBD/HBA:** Both have 2 HBD and are reasonable. Ligand B has 7 HBA, which is at the upper limit of the desirable range.
5. **QED:** Both are similar (0.836 vs 0.81), indicating good drug-likeness.
6. **DILI:** Ligand A (33.191) has a much lower DILI risk than Ligand B (64.288). This is a significant advantage.
7. **BBB:** Ligand B (78.868) has a better BBB penetration percentile than Ligand A (38.813). However, BBB is less critical for ADRB2 (cardiovascular target) compared to a CNS target.
8. **Caco-2:** Both are negative, indicating poor permeability.
9. **Solubility:** Ligand A (-4.929) is better than Ligand B (-3.963), indicating better solubility.
10. **hERG:** Ligand A (0.543) shows lower hERG inhibition liability than Ligand B (0.276).
11. **Cl_mic:** Ligand B (41.837) has lower microsomal clearance, suggesting better metabolic stability, which is good. Ligand A (72.328) is higher.
12. **t1/2:** Ligand B (15.199) has a longer in vitro half-life than Ligand A (11.183).
13. **Pgp:** Ligand A (0.159) has lower P-gp efflux liability than Ligand B (0.015). Lower Pgp is better.
14. **Affinity:** Ligand A (-7.4 kcal/mol) has a significantly better binding affinity than Ligand B (-6.8 kcal/mol). This 1.6 kcal/mol difference is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand A is the better candidate. Its superior binding affinity, lower DILI risk, better solubility, and lower Pgp efflux outweigh the slightly higher logP and lower BBB penetration. The TPSA value for Ligand A is also much more favorable. While Ligand B has better metabolic stability and half-life, the potency advantage of Ligand A is crucial for a GPCR target, and the safety profile (DILI) is more favorable.
**Output:**
1
2025-04-17 21:23:03,437 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.431 and 363.845 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (95.71) is slightly higher than Ligand B (77.25). Both are below the 140 threshold for oral absorption, but Ligand B is better positioned, especially considering ADRB2 is a cardiovascular target, and CNS penetration isn't a primary goal.
3. **logP:** Ligand A (3.617) is within the optimal 1-3 range. Ligand B (4.236) is slightly higher, approaching the upper limit where solubility issues could arise.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable, below the 5 threshold.
5. **HBA:** Ligand A (4) and Ligand B (5) are both acceptable, below the 10 threshold.
6. **QED:** Ligand B (0.859) has a significantly better QED score than Ligand A (0.627), indicating a more drug-like profile.
7. **DILI:** Ligand A (46.956) has a lower DILI risk than Ligand B (70.066). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (68.36) has a lower BBB penetration than Ligand B (82.745). Since ADRB2 is a cardiovascular target, BBB penetration is not a priority.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual. Assuming these are logP-scale values, lower values indicate poorer permeability. Ligand A (-4.68) is worse than Ligand B (-4.331).
10. **Solubility:** Ligand A (-3.21) has better solubility than Ligand B (-5.344).
11. **hERG:** Ligand A (0.757) has a lower hERG risk than Ligand B (0.207). This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand B (70.377) has a much higher microsomal clearance than Ligand A (3.582), indicating lower metabolic stability. This is a major drawback for Ligand B.
13. **t1/2:** Ligand B (11.414) has a significantly longer in vitro half-life than Ligand A (-1.971). This is a strong advantage for Ligand B.
14. **Pgp:** Ligand A (0.349) has lower P-gp efflux than Ligand B (0.082). This is a slight advantage for Ligand A.
15. **Binding Affinity:** Ligand B (-5.9 kcal/mol) has a substantially stronger binding affinity than Ligand A (-6.0 kcal/mol). This is a crucial advantage for Ligand B, potentially outweighing some ADME concerns.
**Overall Assessment & GPCR-Specific Priorities:**
For a GPCR like ADRB2, binding affinity is paramount. Ligand B's significantly stronger binding (-5.9 vs -6.0 kcal/mol) is a major driver. While Ligand A has better DILI and hERG profiles, these are secondary to potency. Ligand B also has a better QED score and slightly better Caco-2 permeability. The major concern with Ligand B is its higher microsomal clearance, but its longer half-life partially mitigates this. The slightly higher logP is manageable.
Considering the balance of properties and the priority of binding affinity for a GPCR target, Ligand B is the more promising candidate.
Output:
0
2025-04-17 21:23:03,437 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (353.5 & 346.4 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (53.09) is significantly better than Ligand B (85.77). ADRB2 is not a CNS target, but lower TPSA generally improves absorption.
3. **logP:** Ligand A (1.737) is slightly better than Ligand B (0.791), both are within the optimal 1-3 range, but Ligand B is closer to the lower bound which could impact permeability.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer HBDs generally improve membrane permeability.
5. **HBA:** Ligand A (4) is preferable to Ligand B (5). Similar reasoning as HBD.
6. **QED:** Both ligands have good QED scores (0.7 and 0.845), indicating good drug-like properties.
7. **DILI:** Ligand A (10.392) is *much* better than Ligand B (47.421). This is a major advantage for Ligand A. Lower DILI risk is critical.
8. **BBB:** Not a primary concern for ADRB2 (cardiovascular target), but Ligand A (77.2) is better than Ligand B (24.506).
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-4.398) is slightly better than Ligand B (-4.815).
10. **Solubility:** Both are negative, indicating poor solubility. Ligand A (-0.521) is slightly better than Ligand B (-1.073).
11. **hERG:** Both ligands have low hERG inhibition risk (0.384 and 0.261).
12. **Cl_mic:** Ligand A (27.887) is worse than Ligand B (-7.542). This suggests Ligand B has better metabolic stability.
13. **t1/2:** Ligand A (-9.224) is worse than Ligand B (1.351). This suggests Ligand B has a longer half-life.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.05 and 0.018).
15. **Affinity:** Both ligands have similar binding affinities (-5.4 and -5.1 kcal/mol). The difference is not substantial enough to outweigh other factors.
**GPCR-specific priorities:** For ADRB2, logP, TPSA, and affinity are important. Ligand A is better in logP and TPSA. The affinity difference is negligible.
**Overall Assessment:**
Ligand A is significantly better due to its substantially lower DILI risk and better TPSA. While Ligand B has better metabolic stability and half-life, the DILI risk associated with Ligand B is a major concern. The slight improvements in solubility and Caco-2 permeability with Ligand A are also beneficial. The similar binding affinities make the ADME profile the deciding factor.
Output:
1
2025-04-17 21:23:03,437 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.459 Da and 383.905 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (78.87) is significantly better than Ligand B (93.25). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have acceptable logP values (1.259 and 2.501, respectively), falling within the 1-3 range. Ligand B is slightly higher, which *could* be beneficial for membrane permeability, but isn't a major concern.
4. **HBD:** Both have 2 HBD, which is good.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 5. Both are acceptable (<10).
6. **QED:** Both ligands have good QED scores (0.646 and 0.733), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (17.759) has a much lower DILI risk than Ligand B (46.452). This is a significant advantage for Ligand A.
8. **BBB:** Ligand B (68.554) has better BBB penetration than Ligand A (46.491). However, since ADRB2 is primarily a cardiovascular target, BBB penetration is not a high priority.
9. **Caco-2:** Ligand A (-4.747) has a better Caco-2 permeability than Ligand B (-5.205).
10. **Solubility:** Ligand A (-1.825) has better aqueous solubility than Ligand B (-2.41).
11. **hERG:** Both ligands have very low hERG inhibition risk (0.143 and 0.193, respectively). No significant difference.
12. **Cl_mic:** Ligand A (30.568) has lower microsomal clearance than Ligand B (36.669), suggesting better metabolic stability.
13. **t1/2:** Ligand B (13.994) has a significantly longer in vitro half-life than Ligand A (0.443). This is a major advantage for Ligand B.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.024 and 0.044, respectively). No significant difference.
15. **Binding Affinity:** Ligand A (-6.4 kcal/mol) has a substantially stronger binding affinity than Ligand B (-3.8 kcal/mol). This is a very significant advantage, exceeding the 1.5 kcal/mol threshold.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand A excels in affinity and has a better TPSA. While Ligand B has a slightly better logP and half-life, the substantial difference in binding affinity and the lower DILI risk of Ligand A outweigh these advantages.
**Conclusion:**
Ligand A is the more promising drug candidate due to its significantly stronger binding affinity, lower DILI risk, better TPSA, and improved solubility, despite having a shorter half-life. The stronger binding is likely to translate to greater efficacy, and the lower DILI risk is crucial for safety.
Output:
1
2025-04-17 21:23:03,437 - INFO - Batch 254 complete. Total preferences: 4064
2025-04-17 21:23:03,437 - INFO - Processing batch 255/512...
2025-04-17 21:23:54,976 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.419 and 349.431 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (105.98 and 104.46) are below the 140 A^2 threshold for good oral absorption, which is good.
3. **logP:** Ligand B (1.155) is slightly better than Ligand A (0.523). While both are within the optimal range of 1-3, Ligand A is a bit low, potentially hindering permeability.
4. **HBD:** Ligand A (2) is preferable to Ligand B (3). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (6) is preferable to Ligand B (5). Lower HBA generally improves permeability.
6. **QED:** Both ligands have good QED scores (0.6 and 0.685), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand B (34.238) has a significantly lower DILI risk than Ligand A (47.693). This is a major advantage for Ligand B.
8. **BBB:** Ligand B (58.821) has a better BBB penetration score than Ligand A (46.336). While ADRB2 isn't strictly a CNS target, some peripheral ADRB2 receptors can be affected by CNS penetration, and it's generally a positive attribute.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.432 and -5.157), which is unusual and indicates poor permeability. This is a significant concern for both.
10. **Solubility:** Both ligands have negative solubility values (-1.5 and -2.075). This is also a concern, suggesting poor aqueous solubility. Ligand B is slightly worse.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.017 and 0.044), which is excellent.
12. **Cl_mic:** Ligand A (16.582) has a lower microsomal clearance than Ligand B (41.904), suggesting better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (-17.141) has a more negative in vitro half-life than Ligand B (-22.882), suggesting a longer half-life. This is a significant advantage for Ligand A.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.033 and 0.052), which is good.
15. **Binding Affinity:** Ligand B (-8.0) has a significantly stronger binding affinity than Ligand A (-6.3). This is a substantial advantage for Ligand B, potentially outweighing some of the ADME drawbacks.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand B excels in affinity and has a better logP and BBB. Ligand A has better metabolic stability (Cl_mic) and half-life. The DILI risk is also much lower for Ligand B. The Caco-2 and solubility issues are concerning for both, but the superior binding affinity and lower toxicity of Ligand B are more critical for initial optimization.
**Conclusion:**
Despite the permeability and solubility concerns shared by both, Ligand B's significantly stronger binding affinity and lower DILI risk make it the more promising candidate for further development. The affinity advantage is substantial enough to prioritize over the slightly better metabolic stability of Ligand A.
Output:
0
2025-04-17 21:23:54,976 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for the ADRB2, a cardiovascular GPCR. Therefore, we prioritize logP, TPSA, Pgp, and affinity, alongside general drug-like properties.
* **Molecular Weight:** Both ligands (346.446 and 346.475 Da) are within the ideal 200-500 Da range.
* **TPSA:** Ligand A (40.62) is significantly better than Ligand B (78.35). A TPSA under 140 is desirable for oral absorption, and lower is better for GPCRs. Ligand B's TPSA is getting higher and may impact permeability.
* **logP:** Ligand A (3.323) is within the optimal 1-3 range, while Ligand B (1.898) is at the lower end. While not terrible, lower logP can sometimes lead to permeability issues.
* **H-Bond Donors/Acceptors:** Ligand A (0 HBD, 2 HBA) is better than Ligand B (2 HBD, 5 HBA). Fewer H-bonds generally improve membrane permeability.
* **QED:** Both ligands have acceptable QED scores (0.821 and 0.752, both >0.5).
* **DILI:** Ligand A (31.601) has a significantly lower DILI risk than Ligand B (13.532), which is a major advantage.
* **BBB:** Ligand A (94.378) shows excellent BBB penetration, while Ligand B (68.282) is lower. While not a primary concern for a cardiovascular target, it's a positive attribute.
* **Caco-2:** Ligand A (-4.261) is better than Ligand B (-5.043), indicating better intestinal absorption.
* **Solubility:** Ligand A (-3.32) is better than Ligand B (-2.25).
* **hERG:** Both ligands have low hERG inhibition risk (0.602 and 0.281).
* **Cl_mic:** Ligand A (57.667) has higher metabolic clearance than Ligand B (33.473), indicating lower metabolic stability. This is a drawback for Ligand A.
* **t1/2:** Ligand A (6.021) has a slightly longer half-life than Ligand B (5.019).
* **Pgp:** Ligand A (0.254) has lower P-gp efflux than Ligand B (0.103), which is favorable.
* **Binding Affinity:** Ligand A (-6.7 kcal/mol) has a slightly better binding affinity than Ligand B (-6.0 kcal/mol), but the difference is not huge.
**Overall Assessment:**
Ligand A has a superior profile in most critical parameters, particularly TPSA, DILI, BBB, solubility, and Pgp efflux. While its metabolic clearance (Cl_mic) is higher than Ligand B, the benefits in other areas outweigh this drawback. The slightly better affinity of Ligand A further supports its selection.
**Output:**
1
2025-04-17 21:23:54,976 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [349.337, 82.53, 2.555, 2, 4, 0.869, 73.09, 52.191, -4.507, -3.531, 0.194, 45.927, 1.389, 0.04, 0]
**Ligand B:** [344.459, 59.65, 1.504, 1, 3, 0.846, 31.912, 55.603, -4.578, -2.066, 0.278, 9.6, -17.794, 0.128, -6.8]
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal 200-500 Da range. A (349.337) and B (344.459) are very close, so this isn't a major differentiator.
2. **TPSA:** Ligand A (82.53) is slightly higher than Ligand B (59.65). Both are below 140, but B is preferable due to being closer to the optimal range for oral absorption and GPCR targets.
3. **logP:** Ligand A (2.555) is within the optimal 1-3 range. Ligand B (1.504) is at the lower end, potentially impacting permeability. A is better here.
4. **HBD:** Ligand A (2) and B (1) are both acceptable.
5. **HBA:** Ligand A (4) and B (3) are both acceptable.
6. **QED:** Both ligands have similar, good QED values (A: 0.869, B: 0.846).
7. **DILI:** Ligand A (73.09) has a higher DILI risk than Ligand B (31.912). This is a significant advantage for B.
8. **BBB:** Ligand A (52.191) and B (55.603) are both relatively low, indicating limited BBB penetration. While not a primary concern for ADRB2 (cardiovascular target), higher is still slightly better.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.507 and -4.578), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-3.531) has worse solubility than Ligand B (-2.066). B is preferable.
11. **hERG:** Both ligands have very low hERG inhibition risk (A: 0.194, B: 0.278).
12. **Cl_mic:** Ligand A (45.927) has a higher microsomal clearance than Ligand B (9.6). B is significantly better, indicating greater metabolic stability.
13. **t1/2:** Ligand A (1.389) has a shorter in vitro half-life than Ligand B (-17.794). This is a substantial advantage for B.
14. **Pgp:** Ligand A (0.04) has lower P-gp efflux than Ligand B (0.128), which is slightly better.
15. **Affinity:** Ligand B (-6.8 kcal/mol) has a significantly stronger binding affinity than Ligand A (0 kcal/mol). This is a major advantage for B.
**Overall Assessment:**
Ligand B clearly outperforms Ligand A. The most significant advantages for B are its much lower DILI risk, substantially better metabolic stability (lower Cl_mic, longer t1/2), and significantly higher binding affinity. While both have poor Caco-2 permeability, the strong affinity of B may compensate for this to some extent. The slightly lower logP of B is a minor drawback, but it's outweighed by the other benefits.
Output:
0
2025-04-17 21:23:54,976 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.471 and 365.415 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (58.64) is significantly better than Ligand B (108.49). ADRB2 is a cardiovascular target, not necessarily CNS, but lower TPSA generally improves absorption. Ligand A is well below the 140 threshold, while B is approaching it.
3. **logP:** Ligand A (1.96) is optimal, while Ligand B (0.469) is a bit low, potentially hindering permeation.
4. **HBD:** Both ligands have 1 HBD, which is within the acceptable limit of 5.
5. **HBA:** Ligand A (3) is better than Ligand B (7). Lower HBA is generally preferred for permeability.
6. **QED:** Both ligands have similar QED values (0.795 and 0.764), indicating good drug-likeness.
7. **DILI:** Ligand A (32.377) has a much lower DILI risk than Ligand B (73.245). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (71.694) has better BBB penetration than Ligand B (32.222). While ADRB2 isn't a primary CNS target, some peripheral ADRB2 receptors can be affected by CNS penetration.
9. **Caco-2:** Ligand A (-4.602) is better than Ligand B (-5.047). Higher Caco-2 permeability is preferable.
10. **Solubility:** Ligand A (-2.652) is better than Ligand B (-1.912). Higher solubility is generally desirable.
11. **hERG:** Both ligands have low hERG inhibition risk (0.397 and 0.279). No significant difference.
12. **Cl_mic:** Ligand B (24.853) has significantly lower microsomal clearance than Ligand A (48.697), suggesting better metabolic stability. This is a strong point for Ligand B.
13. **t1/2:** Ligand B (-25.328) has a much longer in vitro half-life than Ligand A (-11.756). This is a major advantage for Ligand B.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.115 and 0.03). No significant difference.
15. **Binding Affinity:** Ligand B (-6.3) has a slightly better binding affinity than Ligand A (-5.2). This is a 1.1 kcal/mol difference, which is substantial.
**Overall Assessment:**
Ligand B has a superior binding affinity and better metabolic stability (lower Cl_mic, longer t1/2). However, Ligand A excels in several ADME properties (TPSA, logP, DILI, BBB, solubility, Caco-2) and has a slightly better QED. Given that ADRB2 is a cardiovascular target, the slightly better metabolic stability and binding affinity of Ligand B are more critical than the slightly better ADME profile of Ligand A. The affinity difference is large enough to outweigh the ADME concerns.
Output:
0
2025-04-17 21:23:54,976 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (356.813 and 362.499 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (64.16) is significantly better than Ligand B (75.19). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (3.474) is slightly higher than Ligand B (2.323), both within the optimal 1-3 range. Ligand A is preferable.
4. **HBD:** Ligand A (0) is better than Ligand B (1). Fewer HBDs are generally preferred for better permeability.
5. **HBA:** Both ligands have 5 HBA, which is acceptable.
6. **QED:** Both ligands have good QED scores (0.72 and 0.788, respectively), indicating good drug-like properties.
7. **DILI:** Ligand B (35.983) has a much lower DILI risk than Ligand A (79.411). This is a significant advantage for Ligand B.
8. **BBB:** Both have reasonable BBB penetration, but Ligand A (76.037) is slightly better than Ligand B (65.607). However, as ADRB2 is a cardiovascular target, BBB penetration is not a high priority.
9. **Caco-2:** Ligand A (-4.87) and Ligand B (-5.167) are both poor, indicating poor intestinal absorption.
10. **Solubility:** Ligand B (-2.935) is better than Ligand A (-4.355). Better solubility is always desirable.
11. **hERG:** Ligand A (0.574) has a slightly higher hERG risk than Ligand B (0.076). Ligand B is preferable.
12. **Cl_mic:** Ligand B (40.124) has significantly lower microsomal clearance than Ligand A (67.373), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-6.499) has a longer *in vitro* half-life than Ligand A (58.86). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.673) has higher P-gp efflux than Ligand B (0.118). Lower P-gp efflux is preferred.
15. **Affinity:** Ligand B (-7.0) has a slightly better binding affinity than Ligand A (-6.7). While the difference is not huge, it's still a factor.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand B appears to be the better candidate. While Ligand A has a slightly better logP and BBB, Ligand B excels in crucial areas like DILI risk, metabolic stability (Cl_mic and t1/2), P-gp efflux, hERG risk, and solubility. The slightly better binding affinity of Ligand B further strengthens its position. The poor Caco-2 values for both are a concern that would need to be addressed in further optimization, but the other ADME properties of Ligand B are more favorable.
Output:
0
2025-04-17 21:23:54,976 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 drug candidates. ADRB2 is a GPCR, so we'll prioritize logP, Pgp, TPSA, and affinity, alongside general drug-like properties.
**Ligand A:**
* **MW:** 350.503 Da - Good, within the ideal range.
* **TPSA:** 78.43 - Acceptable, but edging towards the higher side for optimal absorption.
* **logP:** 2.231 - Excellent, right in the sweet spot.
* **HBD:** 3 - Good.
* **HBA:** 3 - Good.
* **QED:** 0.597 - Very good, indicating good drug-likeness.
* **DILI:** 13.959 - Excellent, very low risk of liver injury.
* **BBB:** 48.003 - Moderate. Not ideal for a CNS-targeting drug, but ADRB2 is primarily cardiovascular, so this isn't a major drawback.
* **Caco-2:** -4.861 - Concerningly low, suggesting poor intestinal absorption.
* **Solubility:** -3.361 - Very poor solubility, a significant issue for bioavailability.
* **hERG:** 0.278 - Excellent, very low risk of hERG inhibition.
* **Cl_mic:** 42.79 - Moderate clearance, could lead to faster metabolism.
* **t1/2:** -13.256 - Very short half-life, requiring frequent dosing.
* **Pgp:** 0.123 - Low efflux, favorable for bioavailability.
* **Affinity:** -6.8 kcal/mol - Good binding affinity.
**Ligand B:**
* **MW:** 345.443 Da - Good, within the ideal range.
* **TPSA:** 66.65 - Excellent, well below the 140 threshold.
* **logP:** 2.512 - Excellent, slightly higher than A, still within the optimal range.
* **HBD:** 0 - Good, potentially improving permeability.
* **HBA:** 4 - Good.
* **QED:** 0.743 - Excellent, even better drug-likeness than A.
* **DILI:** 49.399 - Moderate, higher than A but still acceptable.
* **BBB:** 82.706 - Very good, but less relevant for a cardiovascular target.
* **Caco-2:** -4.647 - Similar to A, suggesting poor intestinal absorption.
* **Solubility:** -2.467 - Poor solubility, but better than A.
* **hERG:** 0.258 - Excellent, very low risk of hERG inhibition.
* **Cl_mic:** 80.353 - High clearance, indicating rapid metabolism.
* **t1/2:** -42.868 - Extremely short half-life, even worse than A.
* **Pgp:** 0.434 - Moderate efflux, slightly less favorable than A.
* **Affinity:** -8.0 kcal/mol - Significantly better binding affinity than A.
**Comparison and Decision:**
Both ligands have significant issues with Caco-2 permeability and solubility. However, Ligand B possesses a substantially stronger binding affinity (-8.0 vs -6.8 kcal/mol). This 1.2 kcal/mol difference is a significant advantage for a GPCR ligand and can potentially outweigh the ADME liabilities, *if* formulation strategies can address the solubility and permeability issues. Ligand B also has a better QED score. While Ligand A has a slightly better DILI score and lower Pgp efflux, the difference in binding affinity is the deciding factor. Given the importance of potency for GPCRs, and the fact that this is a cardiovascular target (less reliance on BBB), I would prioritize Ligand B.
Output:
0
2025-04-17 21:23:54,976 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (a cardiovascular GPCR) drug candidates.
**Ligand A:** [364.785, 81.91, 4.022, 0, 5, 0.571, 84.994, 64.482, -4.605, -4.148, 0.578, 66.62, -5.46, 0.276, -8.2]
**Ligand B:** [343.431, 80.12, 1.351, 1, 5, 0.875, 44.552, 77.821, -5.049, -3.55, 0.119, 38.6, 7.53, 0.098, -6.2]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal 200-500 Da range. Ligand B (343.431 Da) is slightly lower, which *could* be beneficial for permeability, but both are acceptable.
2. **TPSA:** Both are below 140, good for oral absorption. Ligand A (81.91) and Ligand B (80.12) are very similar.
3. **logP:** Ligand A (4.022) is pushing the upper limit, potentially causing solubility issues or off-target interactions. Ligand B (1.351) is well within the optimal range. This is a significant advantage for B.
4. **HBD:** Ligand A (0) is ideal. Ligand B (1) is also acceptable.
5. **HBA:** Both have 5 HBA, which is good.
6. **QED:** Ligand B (0.875) has a significantly better QED score than Ligand A (0.571), indicating a more drug-like profile.
7. **DILI:** Ligand A (84.994) has a concerningly high DILI risk. Ligand B (44.552) is much lower and acceptable. This is a major negative for A.
8. **BBB:** Ligand B (77.821) has a better BBB penetration score than Ligand A (64.482). While not a primary concern for a cardiovascular target, it's a slight benefit.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.605) is worse than Ligand B (-5.049).
10. **Solubility:** Ligand B (-3.55) has better aqueous solubility than Ligand A (-4.148).
11. **hERG:** Ligand A (0.578) has a slightly higher hERG risk than Ligand B (0.119).
12. **Cl_mic:** Ligand B (38.6) has significantly lower microsomal clearance than Ligand A (66.62), indicating better metabolic stability.
13. **t1/2:** Ligand B (7.53) has a longer in vitro half-life than Ligand A (-5.46).
14. **Pgp:** Ligand B (0.098) has much lower P-gp efflux liability than Ligand A (0.276), which is favorable for bioavailability.
15. **Affinity:** Ligand A (-8.2 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.2 kcal/mol). This is a substantial advantage for A.
**GPCR-Specific Priorities:** For ADRB2 (a cardiovascular GPCR), we prioritize logP, Pgp, TPSA, and affinity. Ligand A has a better affinity, but Ligand B excels in logP, Pgp, and has acceptable TPSA. The high DILI risk and poorer metabolic stability of Ligand A are significant drawbacks.
**Conclusion:**
Despite the stronger binding affinity of Ligand A, the combination of its high DILI risk, unfavorable logP, and poorer metabolic stability make it a less desirable candidate. Ligand B, while having a weaker binding affinity, presents a much more balanced profile with better ADME properties and a lower toxicity risk. The affinity difference, while substantial, may be overcome with further optimization of Ligand B.
Output:
0
2025-04-17 21:23:54,977 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (a cardiovascular GPCR) drug candidates.
**Ligand A:** [343.343, 122.14 , 3.15 , 3. , 6. , 0.671, 95.89 , 31.834, -5.08 , -4.91 , 0.545, 41.622, 86.983, 0.053, -6.3 ]
**Ligand B:** [351.491, 78.51 , 1.55 , 2. , 3. , 0.73 , 11.283, 57.154, -4.876, -2.03 , 0.231, 49.572, -7.524, 0.016, -7.9 ]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity) and general guidelines:
1. **MW:** Both are within the ideal 200-500 Da range. A (343) is slightly better.
2. **TPSA:** A (122) is a bit high, but acceptable. B (78.5) is excellent, well below the 140 threshold, and favorable for permeability.
3. **logP:** A (3.15) is optimal. B (1.55) is a little low, potentially impacting permeability.
4. **HBD:** A (3) is good. B (2) is also good.
5. **HBA:** Both have 3 HBA, which is excellent.
6. **QED:** Both are good (A: 0.671, B: 0.73), indicating drug-like properties. B is slightly better.
7. **DILI:** A (95.89) is *very* high risk. This is a major red flag. B (11.283) is excellent, indicating very low liver injury risk.
8. **BBB:** A (31.8) is low. B (57.2) is moderate, but not a primary concern for a cardiovascular target.
9. **Caco-2:** Both are negative, indicating poor permeability.
10. **Solubility:** Both are negative, indicating poor solubility.
11. **hERG:** A (0.545) is moderate risk. B (0.231) is very low risk, a significant advantage.
12. **Cl_mic:** A (41.6) is reasonable. B (49.6) is slightly higher, suggesting slightly lower metabolic stability.
13. **t1/2:** A (86.98) is excellent. B (-7.52) is very poor.
14. **Pgp:** A (0.053) is very low efflux, good. B (0.016) is even lower, excellent.
15. **Affinity:** B (-7.9) is significantly better than A (-6.3), a difference of 1.6 kcal/mol, which is substantial.
**Overall Assessment:**
Ligand A has a good half-life and Pgp profile, but its extremely high DILI risk and moderate hERG risk are dealbreakers. While its affinity is decent, the safety concerns are too significant.
Ligand B, despite slightly lower logP and a poor half-life, has a *much* better safety profile (DILI and hERG) and significantly stronger binding affinity. The lower logP could be addressed with further optimization, but the DILI risk in A is very difficult to overcome. The superior affinity of B also outweighs the half-life concerns.
Therefore, I would choose Ligand B.
0
2025-04-17 21:23:54,977 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (344.499 Da and 364.49 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Both ligands (40.62 and 40.85) are below the 140 A^2 threshold for good oral absorption. They are also well within the range for GPCRs. No significant difference.
3. **logP:** Both ligands have good logP values (3.206 and 2.957), falling within the optimal 1-3 range. Ligand B is slightly lower, which is acceptable.
4. **HBD:** Both ligands have 0 HBD, which is good.
5. **HBA:** Ligand A has 2 HBA, while Ligand B has 5. Both are acceptable (<=10), but Ligand A is preferable.
6. **QED:** Both ligands have similar QED values (0.786 and 0.758), indicating good drug-likeness.
7. **DILI:** Both ligands have very low DILI risk (26.134 and 26.483 percentile), which is excellent.
8. **BBB:** Ligand B has a higher BBB penetration (93.757%) compared to Ligand A (85.459%). This is a significant advantage for a GPCR target, although ADRB2 is not exclusively a CNS target.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.677 and -4.849), which is unusual and suggests poor permeability. This is a concerning aspect for both.
10. **Solubility:** Both ligands have negative solubility values (-3.099 and -2.185), indicating very poor aqueous solubility. This is a major drawback for both compounds.
11. **hERG:** Both ligands have low hERG inhibition liability (0.571 and 0.838), which is good.
12. **Cl_mic:** Ligand B has a lower microsomal clearance (37.625 mL/min/kg) than Ligand A (73.877 mL/min/kg), suggesting better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand B has a longer in vitro half-life (-19.848 hours) than Ligand A (-15.483 hours). This is a positive attribute.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.321 and 0.458), which is good.
15. **Binding Affinity:** Ligand A has a slightly better binding affinity (-6.9 kcal/mol) than Ligand B (-6.1 kcal/mol). This is a 0.8 kcal/mol difference, which is a notable advantage.
**Overall Assessment:**
While both ligands have significant drawbacks regarding solubility and Caco-2 permeability, Ligand B appears to be the slightly better candidate. Its superior BBB penetration, lower microsomal clearance, and longer half-life outweigh the slightly weaker binding affinity and higher HBA count. The improved metabolic stability and potential for better CNS exposure (even if not the primary target) are valuable. The affinity difference, while present, is not large enough to overcome the ADME advantages of Ligand B.
Output:
0
2025-04-17 21:23:54,977 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (370.465 and 364.486 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (40.62) is slightly better than Ligand B (42.43), both being under the 140 A^2 threshold for good oral absorption.
3. **logP:** Ligand A (3.44) is within the optimal range (1-3), while Ligand B (4.296) is slightly higher. This is a minor concern for B, but still acceptable.
4. **HBD:** Both have 0 HBD, which is good.
5. **HBA:** Ligand A has 3 HBA, and Ligand B has 4. Both are acceptable, below the 10 threshold.
6. **QED:** Ligand A (0.72) has a slightly better QED score than Ligand B (0.623), indicating better overall drug-likeness.
7. **DILI:** Both ligands have acceptable DILI risk (Ligand A: 47.034, Ligand B: 40.985), well below the 60 threshold.
8. **BBB:** Ligand A (94.378) has a significantly higher BBB penetration percentile than Ligand B (82.706). While ADRB2 isn't exclusively a CNS target, some CNS exposure can occur, and higher BBB is generally favorable.
9. **Caco-2:** Both have negative Caco-2 values (-4.763 and -4.582). This is unusual and suggests poor permeability. However, these values are close, and the absolute value isn't dramatically different.
10. **Solubility:** Both have negative solubility values (-3.336 and -3.693), indicating poor aqueous solubility. This is a significant concern for both.
11. **hERG:** Both have low hERG inhibition liability (Ligand A: 0.887, Ligand B: 0.895), which is excellent.
12. **Cl_mic:** Ligand A (60.908) has a lower microsomal clearance than Ligand B (80.298), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-32.534) has a negative in vitro half-life, which is very concerning. Ligand B (43.814) has a positive and reasonably good half-life.
14. **Pgp:** Both have low Pgp efflux liability (Ligand A: 0.531, Ligand B: 0.858).
15. **Binding Affinity:** Ligand B (-7.2 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.3 kcal/mol). This is a >1.5 kcal/mol advantage, which is substantial.
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B excels in affinity. While Ligand A has better BBB and metabolic stability, the significantly stronger binding of Ligand B outweighs these advantages, especially considering the poor solubility and permeability of both compounds. The better half-life of Ligand B is also a significant advantage.
Output:
0
2025-04-17 21:23:54,977 - INFO - Here's a step-by-step reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [389.499, 135.43 , 0.202, 3. , 5. , 0.639, 69.407, 39.007, -5.836, -1.932, 0.07 , 12.356, 46.062, 0.076, -7.1 ]**
**Ligand B: [345.443, 71.53 , 2.096, 1. , 4. , 0.802, 29.779, 59.442, -4.663, -1.989, 0.131, 30.815, -8.769, 0.029, -5.5 ]**
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand B (345.443) is slightly smaller, which can be advantageous for permeability, but the difference isn't substantial.
2. **TPSA:** Ligand A (135.43) is close to the upper limit for good oral absorption, while Ligand B (71.53) is well below. This favors Ligand B.
3. **logP:** Ligand A (0.202) is quite low, potentially hindering membrane permeability. Ligand B (2.096) is within the optimal range (1-3). This is a significant advantage for Ligand B.
4. **H-Bond Donors:** Ligand A (3) and Ligand B (1) are both acceptable, but Ligand B is better.
5. **H-Bond Acceptors:** Ligand A (5) and Ligand B (4) are both acceptable.
6. **QED:** Both ligands have good QED scores (A: 0.639, B: 0.802), indicating drug-like properties. Ligand B is slightly better.
7. **DILI Risk:** Ligand A (69.407) has a higher DILI risk than Ligand B (29.779). This is a significant advantage for Ligand B.
8. **BBB Penetration:** Ligand A (39.007) has poor BBB penetration, while Ligand B (59.442) is better, though still not ideal. For a cardiovascular target like ADRB2, BBB penetration isn't *critical* but can be beneficial for potential off-target effects or peripheral activity.
9. **Caco-2 Permeability:** Ligand A (-5.836) has poor Caco-2 permeability, while Ligand B (-4.663) is better.
10. **Aqueous Solubility:** Both ligands have poor aqueous solubility (-1.932 and -1.989 respectively). This is a concern for both, but not a deciding factor.
11. **hERG Inhibition:** Both ligands have very low hERG inhibition risk (A: 0.07, B: 0.131).
12. **Microsomal Clearance:** Ligand A (12.356) has lower clearance, suggesting better metabolic stability, than Ligand B (30.815).
13. **In vitro Half-Life:** Ligand A (46.062) has a shorter half-life than Ligand B (-8.769).
14. **P-gp Efflux:** Both ligands have low P-gp efflux liability (A: 0.076, B: 0.029). Ligand B is slightly better.
15. **Binding Affinity:** Ligand A (-7.1) has a slightly better binding affinity than Ligand B (-5.5). This is a 1.6 kcal/mol difference, which is significant.
**Overall Assessment:**
Ligand A has a better binding affinity and metabolic stability, but suffers from poor logP, poor Caco-2 permeability, higher DILI risk, and poor BBB penetration. Ligand B has a better logP, TPSA, DILI risk, Caco-2 permeability, and P-gp efflux. The affinity difference, while significant, is potentially outweighed by the ADME advantages of Ligand B, especially considering the cardiovascular target. The lower logP of Ligand A is a major concern for oral bioavailability.
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand B strikes a better balance.
Output:
0
2025-04-17 21:23:54,977 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Step-by-step comparison:**
1. **MW:** Both ligands (347.411 and 350.459 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (76.07) is higher than Ligand B (59.08). For a cardiovascular GPCR, TPSA is moderately important, and lower is generally preferred for better permeability. Ligand B is better here.
3. **logP:** Ligand A (2.447) and Ligand B (1.291) are both within the optimal 1-3 range. Ligand A is slightly better.
4. **HBD:** Ligand A (1) is better than Ligand B (0) as a balance between solubility and permeability.
5. **HBA:** Both ligands have 4 HBA, which is acceptable.
6. **QED:** Ligand A (0.885) has a significantly higher QED score than Ligand B (0.489), indicating a more drug-like profile. This is a substantial advantage for Ligand A.
7. **DILI:** Ligand A (41.179) has a lower DILI risk than Ligand B (14.851), which is a significant advantage.
8. **BBB:** Both ligands have acceptable BBB penetration (Ligand A: 61.535, Ligand B: 66.344). Since ADRB2 is not a CNS target, this is less critical.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. This is a concern for both.
10. **Solubility:** Both ligands have negative solubility values, indicating poor solubility. This is a concern for both.
11. **hERG:** Ligand A (0.012) has a much lower hERG inhibition liability than Ligand B (0.404), which is a significant safety advantage.
12. **Cl_mic:** Ligand A (13.997) has a lower microsomal clearance than Ligand B (27.458), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-9.436) has a more negative in vitro half-life than Ligand B (9.716), which is a concern.
14. **Pgp:** Ligand A (0.012) has a much lower P-gp efflux liability than Ligand B (0.094), which is a significant advantage for bioavailability.
15. **Binding Affinity:** Ligand B (-6.8) has a significantly stronger binding affinity than Ligand A (-5.0). This is a substantial advantage for Ligand B.
**GPCR-specific priorities:**
For ADRB2 (a cardiovascular GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B has a better logP and affinity. Ligand A has better TPSA and Pgp.
**Overall Assessment:**
While Ligand B has a superior binding affinity, Ligand A demonstrates a much more favorable ADMET profile. Specifically, the lower DILI risk, lower hERG inhibition, lower P-gp efflux, and better QED and metabolic stability are compelling advantages. The slightly weaker binding affinity of Ligand A can potentially be optimized through further medicinal chemistry efforts, while mitigating the ADMET liabilities of Ligand B would be more challenging. Given the importance of safety and bioavailability in drug development, I favor Ligand A.
**Output:**
1
2025-04-17 21:23:54,977 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's systematically compare Ligand A and Ligand B across the provided parameters, keeping in mind the GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key).
1. **MW:** Both ligands (349.4 Da) are within the ideal range (200-500 Da). No significant difference here.
2. **TPSA:** Ligand A (82.53) is better than Ligand B (88.91). Lower TPSA generally favors oral absorption, important for a cardiovascular target.
3. **logP:** Both ligands have acceptable logP values (A: 0.972, B: 1.585), falling within the 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability, but not dramatically.
4. **HBD & HBA:** Both ligands have 2 HBD and similar HBA counts (A: 4, B: 5). These are within acceptable limits.
5. **QED:** Ligand A (0.83) has a slightly better QED score than Ligand B (0.708), indicating a more drug-like profile.
6. **DILI:** Ligand A (32.73) has a slightly higher DILI risk than Ligand B (27.995), but both are well below the concerning threshold of 60.
7. **BBB:** Ligand B (70.57) has a better BBB penetration score than Ligand A (63.164). While ADRB2 isn't primarily a CNS target, some degree of BBB penetration can be useful for understanding off-target effects.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests a potential issue with permeability prediction. However, the values are similar.
9. **Solubility:** Both ligands have very poor predicted aqueous solubility (-1.821 and -2.012). This is a significant concern.
10. **hERG:** Both ligands have very low hERG inhibition liability (0.185 and 0.048), which is excellent.
11. **Cl_mic:** Ligand A (-0.162) has a much lower (better) microsomal clearance than Ligand B (34.637), indicating greater metabolic stability. This is a major advantage.
12. **t1/2:** Ligand A (-23.759) has a much longer predicted in vitro half-life than Ligand B (-8.41). This is another significant advantage.
13. **Pgp:** Both ligands have very low Pgp efflux liability (0.025).
14. **Binding Affinity:** Ligand B (-7.4) has a slightly better binding affinity than Ligand A (-6.6). This is a 0.8 kcal/mol difference, which is meaningful.
**Overall Assessment:**
Despite the slightly better affinity of Ligand B, Ligand A is the more promising candidate. The significantly improved metabolic stability (lower Cl_mic) and longer half-life of Ligand A are critical advantages for a cardiovascular drug. The slightly better QED and TPSA also contribute to its favorability. The solubility is a concern for both, but can be addressed through formulation strategies. The affinity difference, while notable, is less important than the pharmacokinetic advantages offered by Ligand A.
**Output:**
1
2025-04-17 21:23:54,977 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (352.475 Da and 355.463 Da) fall well within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (70.08) is slightly higher than Ligand B (59.23). Both are below the 140 A^2 threshold for good oral absorption, but Ligand B is better positioned for potential CNS penetration, though that's less critical for a cardiovascular target.
**3. logP:** Ligand A (1.271) is within the optimal 1-3 range. Ligand B (4.406) is significantly higher, potentially leading to solubility issues and off-target interactions. This is a major concern.
**4. H-Bond Donors:** Ligand A (1) is preferable to Ligand B (0) as a single HBD can aid solubility without drastically impacting permeability.
**5. H-Bond Acceptors:** Ligand A (4) and Ligand B (5) are both acceptable, under the 10 threshold.
**6. QED:** Ligand A (0.782) has a higher QED score than Ligand B (0.657), indicating better overall drug-likeness.
**7. DILI:** Ligand A (15.781) has a much lower DILI risk than Ligand B (57.736), which is a significant advantage.
**8. BBB:** Ligand A (77.084) has a better BBB penetration score than Ligand B (55.021), but this is less important for a cardiovascular target.
**9. Caco-2 Permeability:** Ligand A (-4.416) is better than Ligand B (-5.172).
**10. Aqueous Solubility:** Ligand A (-2.317) is better than Ligand B (-4.717). The higher logP of Ligand B likely contributes to its lower solubility.
**11. hERG Inhibition:** Both ligands have similar, relatively low hERG inhibition liabilities (0.61 and 0.514).
**12. Microsomal Clearance:** Ligand A (40.53) has a lower microsomal clearance than Ligand B (91.823), suggesting better metabolic stability.
**13. In vitro Half-Life:** Ligand B (60.29) has a significantly longer half-life than Ligand A (0.076). This is a positive for Ligand B, but can be offset by other issues.
**14. P-gp Efflux:** Both ligands have similar P-gp efflux liabilities (0.271 and 0.741).
**15. Binding Affinity:** Ligand B (-6.2 kcal/mol) has a stronger binding affinity than Ligand A (-4.9 kcal/mol). This is a 1.3 kcal/mol difference, which is substantial.
**Overall Assessment:**
While Ligand B has a stronger binding affinity and a longer half-life, its significantly higher logP, DILI risk, and lower solubility are major drawbacks. The higher logP could lead to poor bioavailability and off-target effects. The elevated DILI risk is also concerning. Ligand A, while having a slightly weaker binding affinity, presents a much more balanced profile with better predicted ADME properties and a lower safety risk. For a GPCR, balancing ADME properties is crucial, and the affinity difference, while notable, can potentially be optimized in later stages of drug development.
Output:
1
2025-04-17 21:23:54,977 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Step-by-step comparison:**
1. **MW:** Both ligands (346.471 and 340.427 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (67.43 and 68.44) are below the 140 A^2 threshold for good oral absorption, but not optimized for CNS penetration (which would require <90). Again, no major difference.
3. **logP:** Ligand A (2.336) is optimal, while Ligand B (0.676) is slightly low, potentially impacting permeability. This favors Ligand A.
4. **HBD:** Both have 2 HBD, well within the acceptable limit of 5.
5. **HBA:** Both have 3 HBA, also within the acceptable limit of 10.
6. **QED:** Ligand B (0.792) has a slightly better QED score than Ligand A (0.549), indicating a more drug-like profile.
7. **DILI:** Ligand B (18.108) has a significantly lower DILI risk than Ligand A (28.926). This is a substantial advantage for Ligand B.
8. **BBB:** Ligand A (68.282) has a better BBB percentile than Ligand B (56.805). However, as ADRB2 is primarily a cardiovascular target, BBB penetration is not a high priority.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. This is a concern for both, but the values are similar.
10. **Solubility:** Both have negative solubility values, indicating poor aqueous solubility. This is a concern for both, but the values are similar.
11. **hERG:** Both ligands have low hERG inhibition liability (0.225 and 0.341), which is good.
12. **Cl_mic:** Ligand B (-27.634) has significantly lower microsomal clearance than Ligand A (56.595), suggesting better metabolic stability. This is a major advantage for Ligand B.
13. **t1/2:** Ligand B (-9.994) has a better in vitro half-life than Ligand A (-11.324).
14. **Pgp:** Both have very low Pgp efflux liability (0.103 and 0.01).
15. **Binding Affinity:** Ligand B (-5.8 kcal/mol) has a slightly better binding affinity than Ligand A (-5.3 kcal/mol). While the difference is not huge, it's still a positive for Ligand B.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are important. Ligand A has a better logP and slightly better BBB, but Ligand B has better affinity, lower DILI, and significantly better metabolic stability (Cl_mic). Given the cardiovascular target, BBB is not a primary concern. The improved metabolic stability and reduced toxicity risk of Ligand B are more valuable.
**Conclusion:**
Considering the balance of properties, particularly the significantly improved DILI and metabolic stability of Ligand B, along with its slightly better affinity, it is the more promising drug candidate.
Output:
0
2025-04-17 21:23:54,978 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (a GPCR) drug candidates.
**Ligand A:** [376.519, 88.1, 0.507, 2, 6, 0.578, 26.444, 34.083, -5.135, -1.855, 0.254, 37.045, 13.47, 0.033, -7.0]
**Ligand B:** [355.523, 61.88, 1.887, 1, 4, 0.65, 5.467, 81.233, -4.661, -1.225, 0.481, 19.897, -3.95, 0.025, -5.3]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, Affinity, and BBB):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (355.523) is slightly lower, which is generally favorable.
2. **TPSA:** Ligand A (88.1) is a bit higher than Ligand B (61.88). Both are acceptable, but Ligand B is better for permeability.
3. **logP:** Ligand A (0.507) is quite low, potentially hindering membrane permeability. Ligand B (1.887) is much better, falling within the optimal 1-3 range. This is a significant advantage for Ligand B.
4. **HBD/HBA:** Ligand A has 2 HBD and 6 HBA, while Ligand B has 1 HBD and 4 HBA. Both are reasonable, but Ligand B is slightly more favorable.
5. **QED:** Both have good QED scores (A: 0.578, B: 0.65), indicating drug-likeness. Ligand B is slightly better.
6. **DILI:** Ligand A (26.444) has a higher DILI risk than Ligand B (5.467). This is a substantial advantage for Ligand B.
7. **BBB:** Ligand B (81.233) has a much higher BBB penetration potential than Ligand A (34.083). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be beneficial, and avoiding CNS side effects is easier with lower penetration.
8. **Caco-2:** Ligand A (-5.135) and Ligand B (-4.661) are both negative, which is unusual and suggests poor permeability. However, the scale isn't specified, so it's hard to interpret.
9. **Solubility:** Both have negative solubility values (-1.855 and -1.225), which is also unusual.
10. **hERG:** Both have low hERG risk (0.254 and 0.481).
11. **Cl_mic:** Ligand B (19.897) has significantly lower microsomal clearance than Ligand A (37.045), suggesting better metabolic stability.
12. **t1/2:** Ligand A (13.47) has a longer in vitro half-life than Ligand B (-3.95). This is a positive for Ligand A, but the negative value for B is concerning.
13. **Pgp:** Both have very low P-gp efflux liability (0.033 and 0.025), which is good.
14. **Affinity:** Ligand A (-7.0) has a slightly better binding affinity than Ligand B (-5.3). This is a 1.7 kcal/mol difference, which is significant.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity, Ligand B demonstrates a much more favorable ADME profile. Specifically, its superior logP, lower DILI risk, higher BBB penetration, and lower microsomal clearance are compelling advantages for a GPCR target. The negative solubility and Caco-2 values for both are concerning and would require further investigation, but the other benefits of Ligand B outweigh the slightly weaker binding. The longer half-life of Ligand A is a plus, but the other ADME issues are more critical.
Therefore, I would choose Ligand B.
0
2025-04-17 21:23:54,978 - INFO - Batch 255 complete. Total preferences: 4080
2025-04-17 21:23:54,978 - INFO - Processing batch 256/512...
2025-04-17 21:24:44,327 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [344.459, 64.68, 3.569, 2, 2, 0.877, 39.434, 69.794, -4.717, -3.759, 0.737, 19.504, 29.868, 0.107, -6.1]
**Ligand B:** [344.411, 71.78, 1.873, 1, 4, 0.909, 27.724, 76.774, -4.674, -2.494, 0.232, 18.464, 42.102, 0.038, -7.1]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, BBB, affinity):
1. **MW:** Both are within the ideal 200-500 Da range. (Tie)
2. **TPSA:** Ligand A (64.68) is better than Ligand B (71.78). Lower TPSA generally favors better absorption, important for GPCRs.
3. **logP:** Ligand A (3.569) is slightly higher than Ligand B (1.873). While both are within the 1-3 range, Ligand A is closer to the optimal upper end, potentially aiding membrane permeability.
4. **HBD/HBA:** Ligand A (2 HBD, 2 HBA) is slightly more favorable than Ligand B (1 HBD, 4 HBA). Fewer H-bonds can improve permeability.
5. **QED:** Ligand B (0.909) is slightly better than Ligand A (0.877), indicating a marginally more drug-like profile.
6. **DILI:** Ligand B (27.724) has a significantly lower DILI risk than Ligand A (39.434). This is a major advantage.
7. **BBB:** Ligand B (76.774) has a higher BBB penetration percentile than Ligand A (69.794). While ADRB2 isn't necessarily a CNS target, some peripheral ADRB2 activity can be modulated by CNS effects, and higher BBB penetration is rarely a detriment.
8. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-4.717) is slightly worse than Ligand B (-4.674).
9. **Solubility:** Ligand B (-2.494) is better than Ligand A (-3.759).
10. **hERG:** Ligand A (0.737) is slightly better than Ligand B (0.232), indicating lower cardiotoxicity risk.
11. **Cl_mic:** Ligand B (18.464) has a slightly lower microsomal clearance than Ligand A (19.504), suggesting better metabolic stability.
12. **t1/2:** Ligand B (42.102) has a significantly longer in vitro half-life than Ligand A (29.868). This is a substantial benefit.
13. **Pgp:** Ligand A (0.107) has lower P-gp efflux than Ligand B (0.038), which is favorable.
14. **Affinity:** Ligand B (-7.1 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.1 kcal/mol). This is a crucial advantage, exceeding the 1.5 kcal/mol threshold.
**Overall Assessment:**
While Ligand A has slightly better TPSA and Pgp properties, Ligand B clearly wins out due to its significantly improved DILI risk, BBB penetration, in vitro half-life, and, most importantly, *much* stronger binding affinity. The affinity difference is substantial enough to outweigh the minor drawbacks in TPSA and Pgp. The improved solubility is also a plus.
Therefore, I prefer Ligand B.
0
2025-04-17 21:24:44,328 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (344.415 and 384.567 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (87.32) is slightly higher than Ligand B (67.43). Both are below the 140 threshold for oral absorption, but B is better positioned for potential CNS penetration if desired (though not a primary goal for ADRB2).
3. **logP:** Both ligands (2.26 and 2.87) are within the optimal 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Both ligands have 2 H-bond donors, which is within the acceptable limit of 5.
5. **HBA:** Ligand A has 4 H-bond acceptors, and Ligand B has 5. Both are below the 10 limit.
6. **QED:** Ligand A (0.787) has a better QED score than Ligand B (0.609), indicating a more drug-like profile overall.
7. **DILI:** Both ligands have similar DILI risk (59.131 and 57.697 percentile), and both are acceptable (below 60).
8. **BBB:** Ligand B (64.637) has a higher BBB penetration percentile than Ligand A (50.097). While ADRB2 isn't a primary CNS target, some degree of BBB penetration isn't necessarily detrimental.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.175 and -5.592), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Both ligands have very poor aqueous solubility (-3.59 and -3.468). This is a major drawback for both compounds.
11. **hERG:** Both ligands have low hERG inhibition liability (0.371 and 0.552), which is good.
12. **Cl_mic:** Ligand A (9.247) has a significantly lower microsomal clearance than Ligand B (65.601), suggesting better metabolic stability. This is a crucial advantage.
13. **t1/2:** Ligand A (-8.357) has a much more negative in vitro half-life than Ligand B (20.488). A negative value is problematic and indicates very rapid metabolism, while B has a reasonable half-life.
14. **Pgp:** Ligand A (0.031) has much lower P-gp efflux liability than Ligand B (0.608), which is a positive.
15. **Binding Affinity:** Ligand A (-7.2 kcal/mol) has a slightly better binding affinity than Ligand B (-6.6 kcal/mol). This difference of 0.6 kcal/mol is meaningful.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A has a slightly better affinity and significantly lower Pgp efflux. Ligand B has a slightly better logP and TPSA. The poor Caco-2 and solubility of both are concerning, but the superior metabolic stability (Cl_mic and t1/2) of Ligand A is a significant advantage.
**Overall Assessment:**
Despite the poor permeability and solubility of both, Ligand A is the better candidate. The stronger binding affinity, lower Pgp efflux, and, most importantly, the significantly better metabolic stability (lower Cl_mic and a more reasonable, though still concerning, t1/2) outweigh the slightly better TPSA and logP of Ligand B. Addressing the solubility and permeability issues will be critical for either compound, but starting with the more metabolically stable and potent ligand is a better strategy.
Output:
1
2025-04-17 21:24:44,328 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.368 and 349.381 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (32.34) is significantly better than Ligand B (62.3). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold. Ligand B is higher, potentially impacting absorption.
3. **logP:** Ligand A (4.498) is a bit high, but still within a reasonable range. Ligand B (2.294) is closer to the optimal 1-3 range. While higher logP can cause issues, for a GPCR, some lipophilicity is beneficial for membrane interactions.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 2 HBA, and Ligand B has 3. Both are acceptable.
6. **QED:** Both ligands have similar QED scores (0.834 and 0.83), indicating good drug-like properties.
7. **DILI:** Ligand A (56.689) has a higher DILI risk than Ligand B (32.028). This is a significant advantage for Ligand B.
8. **BBB:** Both ligands have high BBB penetration (90.617 and 96.123). While not critical for a cardiovascular target, it doesn't hurt.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-4.813) has worse solubility than Ligand B (-2.933). Solubility is important for bioavailability, favoring Ligand B.
11. **hERG:** Ligand A (0.946) has a slightly higher hERG risk than Ligand B (0.552), although both are relatively low.
12. **Cl_mic:** Ligand A (35.856) has a higher microsomal clearance than Ligand B (25.332), indicating faster metabolism and potentially lower exposure. Ligand B is preferable.
13. **t1/2:** Ligand B (-15.648) has a much longer *in vitro* half-life than Ligand A (1.662). This is a major advantage for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.554) has lower P-gp efflux than Ligand B (0.025). Lower P-gp efflux is generally better for bioavailability.
15. **Binding Affinity:** Ligand A (-8.4 kcal/mol) has a significantly better binding affinity than Ligand B (-6.7 kcal/mol). This is a substantial advantage for Ligand A, potentially outweighing some of its ADME drawbacks. A 1.7 kcal/mol difference is quite significant.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), affinity, logP, TPSA, and Pgp are key. Ligand A excels in affinity and has acceptable logP and TPSA, and good Pgp. Ligand B has better DILI, solubility, and half-life.
**Overall Assessment:**
The binding affinity difference is substantial. While Ligand B has better ADME properties (DILI, solubility, half-life, clearance), the significantly stronger binding of Ligand A to the target receptor is likely to be the dominant factor in its success. The improved affinity could allow for a lower dose, mitigating some of the ADME concerns.
Output:
1
2025-04-17 21:24:44,328 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (364.471 and 338.411 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (84.3) is slightly higher than Ligand B (76.02). Both are below the 140 A^2 threshold for good oral absorption, and acceptable for a non-CNS GPCR target like ADRB2.
**3. logP:** Both ligands have good logP values (1.565 and 1.027, respectively) falling within the optimal 1-3 range. Ligand B is slightly lower, which *could* indicate slightly better solubility but potentially reduced membrane permeability.
**4. H-Bond Donors:** Ligand A has 1 HBD, while Ligand B has 2. Both are within the acceptable limit of <=5.
**5. H-Bond Acceptors:** Ligand A has 5 HBA, and Ligand B has 4. Both are below the 10 threshold.
**6. QED:** Ligand A (0.835) has a higher QED score than Ligand B (0.549), indicating a more drug-like profile overall. This is a significant advantage.
**7. DILI:** Both ligands have the same DILI risk (49.477%), which is acceptable (below 60%).
**8. BBB:** Ligand A (85.343%) has a significantly higher BBB penetration score than Ligand B (45.095%). While ADRB2 isn't a primary CNS target, some peripheral exposure to the CNS is possible, and higher BBB penetration isn't necessarily detrimental.
**9. Caco-2 Permeability:** Ligand A (-4.954) has better Caco-2 permeability than Ligand B (-5.092).
**10. Aqueous Solubility:** Ligand A (-1.891) has better aqueous solubility than Ligand B (-2.301).
**11. hERG Inhibition:** Ligand A (0.539) has a slightly higher hERG inhibition risk than Ligand B (0.176). This is a concern, but not a dealbreaker if the binding affinity is strong.
**12. Microsomal Clearance:** Ligand A (21.561) has higher microsomal clearance than Ligand B (18.571), indicating lower metabolic stability.
**13. In vitro Half-Life:** Ligand A (22.121) has a longer in vitro half-life than Ligand B (9.689). This is a significant advantage.
**14. P-gp Efflux:** Ligand A (0.169) has lower P-gp efflux than Ligand B (0.065), which is favorable for bioavailability.
**15. Binding Affinity:** Ligand A (-7.5 kcal/mol) has a significantly stronger binding affinity than Ligand B (-5.1 kcal/mol). This 1.5 kcal/mol difference is substantial and can often outweigh minor ADME drawbacks.
**Overall Assessment:**
Ligand A is the stronger candidate. Its superior QED, significantly better binding affinity, better Caco-2 permeability, aqueous solubility, BBB penetration, and in vitro half-life outweigh its slightly higher hERG risk and microsomal clearance. While Ligand B has a slightly lower logP and P-gp efflux, the difference in binding affinity is crucial for a GPCR target.
Output:
1
2025-04-17 21:24:44,328 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (380.901) is slightly higher than Ligand B (366.38), but both are acceptable.
2. **TPSA:** Ligand A (67.23) is better than Ligand B (75.71). Both are below 140, but lower TPSA generally favors oral absorption, a key consideration for a cardiovascular target.
3. **logP:** Both ligands have good logP values (A: 2.756, B: 1.532) within the optimal 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability, but isn't a major concern.
4. **HBD:** Both have 1 HBD, which is within the acceptable limit of 5.
5. **HBA:** Ligand A has 5 HBA, and Ligand B has 4. Both are below the 10 limit.
6. **QED:** Both ligands have acceptable QED values (A: 0.867, B: 0.694), indicating good drug-like properties. Ligand A is slightly better.
7. **DILI:** Ligand B (38.154) has a significantly lower DILI risk than Ligand A (59.093). This is a substantial advantage for Ligand B.
8. **BBB:** Ligand B (86.39) has a much higher BBB penetration percentile than Ligand A (61.419). While ADRB2 isn't strictly a CNS target, some CNS exposure can occur, and higher BBB penetration isn't necessarily detrimental.
9. **Caco-2:** Ligand A (-5.072) has a worse Caco-2 permeability than Ligand B (-4.26). Lower values indicate poorer permeability.
10. **Solubility:** Ligand A (-3.147) has a worse solubility than Ligand B (-2.092).
11. **hERG:** Both ligands have low hERG inhibition risk (A: 0.682, B: 0.328), which is good. Ligand B is slightly better.
12. **Cl_mic:** Ligand A (36.902) has a lower microsomal clearance than Ligand B (64.124), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand B (-35.357) has a much longer in vitro half-life than Ligand A (-8.993). This is a major advantage for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.471) has a lower Pgp efflux liability than Ligand B (0.036), which is favorable.
15. **Binding Affinity:** Ligand B (-7.6) has a significantly stronger binding affinity than Ligand A (-2.9). This is the most important factor, and the 4.7 kcal/mol difference is substantial enough to outweigh many of the ADME drawbacks of Ligand B.
**GPCR-specific priorities:**
For a GPCR like ADRB2, affinity, logP, TPSA, and Pgp are key. Ligand B excels in affinity and has acceptable values for the other parameters. While Ligand A has better metabolic stability (Cl_mic), the significantly stronger binding of Ligand B is a decisive factor. The lower DILI risk and longer half-life of Ligand B are also positive attributes.
**Conclusion:**
Despite Ligand A's better metabolic stability, Ligand B's superior binding affinity, lower DILI risk, and longer half-life make it the more promising drug candidate.
Output:
0
2025-04-17 21:24:44,329 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (344.46 and 345.41 Da) fall well within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (65.54) is significantly better than Ligand B (99.87). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is approaching a level that could hinder oral absorption.
3. **logP:** Ligand A (3.037) is optimal. Ligand B (0.358) is quite low, potentially leading to poor membrane permeability. This is a major drawback for a GPCR ligand.
4. **HBD:** Both ligands have 1 HBD, which is acceptable.
5. **HBA:** Ligand A has 4 HBA, while Ligand B has 9. Ligand A is preferable here, as excessive HBA can reduce permeability.
6. **QED:** Ligand A (0.826) has a better QED score than Ligand B (0.695), indicating a more drug-like profile.
7. **DILI:** Ligand B (55.18) has a slightly lower DILI risk than Ligand A (44.98), but both are reasonably low and acceptable.
8. **BBB:** Ligand A (93.87) has a significantly higher BBB penetration percentile than Ligand B (75.11). While ADRB2 isn't exclusively a CNS target, some CNS exposure is not necessarily detrimental, and higher BBB penetration generally indicates better overall permeability.
9. **Caco-2:** Ligand A (-4.839) is better than Ligand B (-5.675). Both are negative, which is unusual and requires further investigation, but A is slightly less negative.
10. **Solubility:** Ligand A (-3.987) is better than Ligand B (-1.668). Solubility is important for formulation and bioavailability, and A has a better score.
11. **hERG:** Ligand A (0.548) has a much lower hERG risk than Ligand B (0.099). This is a critical safety parameter, and A is significantly better.
12. **Cl_mic:** Ligand B (13.324) has a lower microsomal clearance than Ligand A (88.424), suggesting better metabolic stability. This is a positive for Ligand B.
13. **t1/2:** Ligand B (12.404 hours) has a much longer in vitro half-life than Ligand A (-4.054 hours). This is a significant advantage for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.249) has a lower P-gp efflux liability than Ligand B (0.072). Lower P-gp efflux is preferable for better bioavailability.
15. **Binding Affinity:** Ligand A (-7.6 kcal/mol) has a slightly better binding affinity than Ligand B (-5.5 kcal/mol). This difference of 2.1 kcal/mol is substantial and can often outweigh minor ADME issues.
**Overall Assessment:**
Ligand A is clearly superior. While Ligand B has better metabolic stability (lower Cl_mic, longer t1/2), Ligand A excels in crucial areas for a GPCR ligand: TPSA, logP, solubility, hERG risk, BBB penetration, and binding affinity. The significantly better logP and TPSA of Ligand A suggest it will have better permeability and absorption. The stronger binding affinity is also a major advantage. The hERG risk is also much lower for Ligand A.
Output:
1
2025-04-17 21:24:44,329 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, priorities are logP, TPSA, Pgp, affinity, and to a lesser extent, BBB.
* **Molecular Weight:** Both ligands are within the ideal range (200-500 Da).
* **TPSA:** Ligand A (37.39) is better than Ligand B (44.12), being closer to the preferred <140.
* **logP:** Both are good (around 4.5), falling within the 1-3 range.
* **H-Bond Donors/Acceptors:** Ligand B has 0 HBD which is slightly preferable. Both have acceptable HBA counts.
* **QED:** Both are high, indicating good drug-likeness.
* **DILI:** Ligand A (36.293) is significantly better than Ligand B (58.24), indicating a lower risk of liver injury. This is a crucial factor.
* **BBB:** Ligand B (85.111) is slightly better than Ligand A (77.162), but BBB isn't a high priority for a cardiovascular target.
* **Caco-2:** Both are very poor (-4.x). This is a significant drawback for both, suggesting poor intestinal absorption.
* **Solubility:** Both are very poor (-5.x). This is also a significant drawback.
* **hERG:** Both are low risk.
* **Cl_mic:** Ligand B (77.661) is better than Ligand A (110.476), indicating better metabolic stability.
* **t1/2:** Ligand A (7.889) is much better than Ligand B (-19.423).
* **Pgp:** Both are low risk.
* **Binding Affinity:** Ligand B (-8.7) is slightly better than Ligand A (-8.0), but the difference is small.
**Overall Assessment:**
While Ligand B has slightly better affinity and metabolic stability, Ligand A's significantly lower DILI risk and better in vitro half-life are more important. The poor Caco-2 and solubility are concerning for both, but can potentially be addressed with formulation strategies. Given the GPCR target and the need for a safe profile, minimizing liver toxicity is paramount.
**Output:**
1
2025-04-17 21:24:44,329 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (343.39 and 340.47 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (117.1) is higher than the preferred <140 for oral absorption, but still reasonable. Ligand B (40.62) is excellent, well below 90, suggesting good permeability. This favors Ligand B.
**3. logP:** Both ligands have good logP values (1.84 and 3.04), falling within the optimal 1-3 range. Ligand B is slightly higher, potentially improving membrane permeability, but not dramatically.
**4. H-Bond Donors:** Ligand A has 3 HBDs, which is acceptable. Ligand B has 0, which is also fine. No clear advantage.
**5. H-Bond Acceptors:** Ligand A has 6 HBAs, within the acceptable range. Ligand B has 2, also acceptable. No clear advantage.
**6. QED:** Both ligands have good QED scores (0.657 and 0.848), indicating good drug-like properties. Ligand B is slightly better.
**7. DILI Risk:** Ligand A has a DILI risk of 76.08%, which is concerning (high risk). Ligand B has a much lower DILI risk of 27.03%, which is excellent. This is a major advantage for Ligand B.
**8. BBB Penetration:** Ligand A has a BBB penetration of 22.61%, which is low. Ligand B has a BBB penetration of 90.62%, which is very high. While ADRB2 is a cardiovascular target and CNS penetration isn't *essential*, higher BBB penetration can sometimes correlate with improved distribution and reduced off-target effects.
**9. Caco-2 Permeability:** Ligand A has a negative Caco-2 value (-5.58), which is unusual and suggests poor permeability. Ligand B has a negative Caco-2 value (-4.56), also poor, but slightly better.
**10. Aqueous Solubility:** Both ligands have very poor aqueous solubility (-2.78 and -3.32). This is a significant drawback for both, potentially impacting bioavailability.
**11. hERG Inhibition:** Ligand A has a very low hERG inhibition risk (0.083), which is excellent. Ligand B has a slightly higher risk (0.76), but still relatively low.
**12. Microsomal Clearance:** Ligand A has a low microsomal clearance (0.44), indicating good metabolic stability. Ligand B has a much higher clearance (58.49), suggesting rapid metabolism and potentially lower *in vivo* exposure. This favors Ligand A.
**13. In vitro Half-Life:** Ligand A has a longer half-life (9.38 hours) compared to Ligand B (-7.46 hours). This is a significant advantage for Ligand A.
**14. P-gp Efflux:** Ligand A has very low P-gp efflux (0.01), which is excellent. Ligand B has a higher efflux (0.463), which could limit bioavailability.
**15. Binding Affinity:** Ligand B has a slightly better binding affinity (-6.4 kcal/mol) than Ligand A (-5.0 kcal/mol). The difference is 1.4 kcal/mol, which is significant enough to consider.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity) and the general drug-like properties, Ligand B initially appears more promising due to its excellent TPSA, BBB penetration, and slightly better affinity. However, the significantly higher DILI risk for Ligand A and its superior metabolic stability (lower Cl_mic and longer half-life) are crucial factors. The poor Caco-2 and solubility of both are concerning, but can potentially be addressed with formulation strategies.
Despite the better affinity of Ligand B, the high DILI risk is a major red flag. The lower DILI risk, better metabolic stability and P-gp efflux of Ligand A outweigh the slightly weaker binding affinity.
Output:
1
2025-04-17 21:24:44,329 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.447 and 348.487 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both are below the 140 A^2 threshold (68.62 and 69.64 A^2), suggesting good potential for oral absorption.
3. **logP:** Ligand A (1.74) is slightly better than Ligand B (2.534). While both are within the optimal 1-3 range, Ligand A is closer to the lower end, potentially reducing off-target interactions.
4. **HBD/HBA:** Ligand A (1 HBD, 5 HBA) is slightly preferable to Ligand B (2 HBD, 3 HBA) as lower counts generally correlate with better permeability.
5. **QED:** Ligand A (0.903) has a significantly better QED score than Ligand B (0.695), indicating a more drug-like profile.
6. **DILI:** Ligand A (32.299) has a much lower DILI risk than Ligand B (12.524). This is a crucial advantage, as liver toxicity is a major concern in drug development.
7. **BBB:** Ligand A (81.466) has a higher BBB penetration percentile than Ligand B (68.554). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be beneficial or at least needs to be understood and managed.
8. **Caco-2:** Both ligands have similar, very negative Caco-2 values (-4.846 and -4.823), suggesting poor permeability. This is a significant drawback for both.
9. **Solubility:** Both ligands have similar, very negative solubility values (-1.389 and -2.478), indicating poor aqueous solubility. This is also a significant drawback for both.
10. **hERG:** Both ligands have very low hERG inhibition liability (0.2 and 0.298), which is excellent.
11. **Cl_mic:** Ligand A (2.026 mL/min/kg) has a significantly lower microsomal clearance than Ligand B (21.737 mL/min/kg), suggesting better metabolic stability.
12. **t1/2:** Ligand A (28.623 hours) has a much longer in vitro half-life than Ligand B (22.698 hours). This is a clear advantage for dosing convenience.
13. **Pgp:** Both ligands have very low Pgp efflux liability (0.044 and 0.112).
14. **Binding Affinity:** Ligand A (-6.7 kcal/mol) has a slightly better binding affinity than Ligand B (-6.3 kcal/mol), though the difference is relatively small.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. While both ligands perform similarly on TPSA and Pgp, Ligand A has a more favorable logP and slightly better affinity. However, the significant advantages of Ligand A in terms of QED, DILI risk, BBB penetration, and metabolic stability (Cl_mic and t1/2) outweigh the small difference in affinity.
**Conclusion:**
Ligand A is the more promising drug candidate due to its superior ADMET properties, particularly its lower DILI risk, better metabolic stability, and higher QED score. While both have permeability and solubility issues, these can be addressed through formulation strategies.
Output:
1
2025-04-17 21:24:44,329 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (355.425 and 365.499 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (39.72) is significantly better than Ligand B (75.44). ADRB2 is a cardiovascular target, not CNS, but lower TPSA generally improves permeability. Ligand A is well below the 140 threshold. Ligand B is higher, potentially impacting absorption.
3. **logP:** Ligand A (4.597) is slightly higher than Ligand B (2.805). While both are within the acceptable range (1-3 is optimal, and these are close), Ligand A is pushing the upper limit and could potentially have solubility issues. Ligand B is closer to the ideal range.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 5. Both are acceptable, under the 10 threshold.
6. **QED:** Both ligands have good QED scores (0.776 and 0.804), indicating good drug-like properties.
7. **DILI:** Ligand A (46.685) has a slightly better DILI score than Ligand B (53.819), indicating a lower risk of liver injury. Both are acceptable (<60 is good).
8. **BBB:** This is less critical for a cardiovascular target. Ligand A (88.29) has a higher BBB penetration than Ligand B (70.997).
9. **Caco-2:** Ligand A (-4.785) has a much better Caco-2 permeability than Ligand B (-5.074). Higher is better, and these are negative values indicating permeability.
10. **Solubility:** Ligand A (-4.799) has a slightly better solubility than Ligand B (-3.846). Higher is better.
11. **hERG:** Ligand A (0.779) has a better hERG profile than Ligand B (0.162), meaning a lower risk of cardiotoxicity. This is *very* important for a cardiovascular target.
12. **Cl_mic:** Ligand B (60.12) has a lower microsomal clearance than Ligand A (54.505), suggesting better metabolic stability.
13. **t1/2:** Ligand A (17.834) has a longer in vitro half-life than Ligand B (0.565). This is a significant advantage.
14. **Pgp:** Ligand A (0.442) has a lower P-gp efflux liability than Ligand B (0.068), suggesting better absorption and bioavailability.
15. **Binding Affinity:** Ligand B (-6.9 kcal/mol) has a slightly better binding affinity than Ligand A (-6.5 kcal/mol). This is a 1.5 kcal/mol advantage, which is significant.
**Overall Assessment:**
While Ligand B has a slightly better binding affinity and metabolic stability, Ligand A demonstrates a more favorable overall profile, particularly regarding crucial ADME properties for a cardiovascular drug. Ligand A's superior TPSA, Caco-2 permeability, solubility, and *especially* its significantly better hERG profile outweigh the small advantage in binding affinity of Ligand B. The longer half-life and lower P-gp efflux are also beneficial. The slightly higher logP of Ligand A is a minor concern, but manageable.
Output:
1
2025-04-17 21:24:44,330 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [347.419, 96.33, -0.404, 2, 5, 0.774, 34.277, 32.648, -5.484, -0.931, 0.058, -26.612, 10.834, 0.009, -5.6]
**Ligand B:** [346.471, 69.64, 2.681, 2, 3, 0.676, 35.983, 66.615, -4.519, -2.825, 0.598, 74.427, 27.972, 0.606, -6.5]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). A: 347.419, B: 346.471 - very similar.
2. **TPSA:** A (96.33) is higher than B (69.64). For a cardiovascular GPCR, TPSA isn't *as* critical as for CNS targets, but lower is generally preferred for permeability. B is better here.
3. **logP:** A (-0.404) is quite low, potentially hindering membrane permeability. B (2.681) is within the optimal range (1-3). B is significantly better.
4. **HBD:** Both have 2 HBD, which is good.
5. **HBA:** A has 5, B has 3. Both are acceptable, but B is slightly better.
6. **QED:** A (0.774) is better than B (0.676), indicating a more drug-like profile.
7. **DILI:** Both are reasonably low (A: 34.277, B: 35.983), below the 40% threshold. Very similar.
8. **BBB:** A (32.648) is low, while B (66.615) is better. For a cardiovascular target, BBB isn't a primary concern, but higher is generally preferable.
9. **Caco-2:** A (-5.484) is very poor, suggesting poor absorption. B (-4.519) is also poor, but slightly better.
10. **Solubility:** A (-0.931) is poor, while B (-2.825) is also poor. Both are concerning.
11. **hERG:** A (0.058) is very low risk, excellent. B (0.598) is slightly higher, but still relatively low risk. A is better.
12. **Cl_mic:** A (-26.612) is excellent (low clearance, good metabolic stability). B (74.427) is high clearance, indicating rapid metabolism. A is significantly better.
13. **t1/2:** A (10.834) is reasonable, but B (27.972) is significantly better.
14. **Pgp:** A (0.009) is very low efflux, excellent. B (0.606) is higher, indicating potential efflux issues. A is better.
15. **Affinity:** B (-6.5) is 0.9 kcal/mol stronger than A (-5.6). This is a substantial difference in binding.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, and affinity. B excels in logP and has a significantly better affinity. A has better Pgp and hERG, but the affinity difference and logP of B are more critical. The lower TPSA of B is also favorable. While A has better metabolic stability (Cl_mic), the strong binding of B can potentially compensate for a slightly faster clearance, especially if the target is highly expressed.
**Conclusion:**
Despite A's better QED, hERG, Pgp, and Cl_mic, the significantly stronger binding affinity (-6.5 vs -5.6 kcal/mol) and better logP of Ligand B outweigh these advantages. The poor solubility of both is a concern, but can be addressed with formulation strategies.
0
2025-04-17 21:24:44,330 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.399 Da and 372.491 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (79.19) is significantly better than Ligand B (104.97). For a GPCR, keeping TPSA under 140 is good, and lower is generally better for permeability. Ligand A is preferable.
3. **logP:** Ligand A (3.49) is within the optimal 1-3 range, while Ligand B (1.455) is at the lower end. While not terrible, lower logP can sometimes lead to permeability issues. Ligand A is preferable.
4. **HBD:** Ligand A (1) is better than Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Both ligands have 5 HBA, which is acceptable.
6. **QED:** Both ligands have similar QED values (0.731 and 0.754), indicating good drug-likeness. No significant difference.
7. **DILI:** Ligand A (97.829) has a significantly higher DILI risk than Ligand B (42.846). This is a major concern for Ligand A.
8. **BBB:** Ligand A (52.423) and Ligand B (60.76) are both relatively low, but Ligand B is slightly better. While ADRB2 isn't exclusively a CNS target, some CNS penetration could be beneficial.
9. **Caco-2:** Ligand A (-4.623) is worse than Ligand B (-5.137), indicating lower intestinal absorption.
10. **Solubility:** Ligand A (-6.319) is worse than Ligand B (-1.012). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.658) is better than Ligand B (0.172), indicating lower hERG inhibition risk.
12. **Cl_mic:** Ligand A (116.698) has a higher microsomal clearance than Ligand B (19.722), suggesting lower metabolic stability. This is a significant drawback for Ligand A.
13. **t1/2:** Ligand B (-25.402) has a much longer in vitro half-life than Ligand A (35.848). This is a major advantage for Ligand B.
14. **Pgp:** Ligand A (0.399) is better than Ligand B (0.01), indicating lower P-gp efflux.
15. **Binding Affinity:** Ligand A (-6.6) has a better binding affinity than Ligand B (-0.6). This is a substantial advantage for Ligand A.
**Overall Assessment:**
Ligand A has a significantly better binding affinity and lower P-gp efflux, but suffers from high DILI risk, poor solubility, high metabolic clearance, and lower Caco-2 permeability. Ligand B has a much better safety profile (lower DILI, lower hERG), better metabolic stability (lower Cl_mic, longer t1/2), and better solubility, but weaker binding affinity.
Given the GPCR target class, balancing potency with ADME properties is crucial. While the affinity of Ligand A is very attractive, the high DILI risk and poor metabolic stability are significant liabilities. The improved ADME profile of Ligand B, despite its weaker binding, makes it a more promising starting point for optimization. It's easier to improve potency through medicinal chemistry than to fix severe toxicity or poor pharmacokinetic properties.
Output:
0
2025-04-17 21:24:44,330 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.431 and 360.376 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (82.45) is higher than Ligand B (61.8). For a cardiovascular GPCR, TPSA is not a primary concern, but lower is generally preferred for better absorption. Ligand B has a slight edge.
3. **logP:** Both ligands have good logP values (2.088 and 2.822), falling within the optimal 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability, but not dramatically.
4. **HBD:** Ligand A has 1 HBD, while Ligand B has 2. Both are acceptable (<=5).
5. **HBA:** Ligand A has 6 HBA, and Ligand B has 3. Both are acceptable (<=10). Ligand B is better here.
6. **QED:** Both ligands have good QED scores (0.795 and 0.82), indicating good drug-like properties. No significant difference.
7. **DILI:** Ligand A has a DILI risk of 64.211, while Ligand B has 24.195. This is a significant difference. Ligand B is *much* better regarding potential liver toxicity.
8. **BBB:** Ligand A has a BBB penetration of 82.086, while Ligand B has 69.252. While ADRB2 isn't strictly a CNS target, some CNS exposure can occur, and higher BBB is generally favorable. Ligand A is slightly better.
9. **Caco-2:** Both have negative Caco-2 values (-4.832 and -4.735). These values are unusual and suggest poor permeability. However, the values are very close.
10. **Solubility:** Ligand A (-3.3) is slightly less soluble than Ligand B (-2.774). Solubility is important for bioavailability, so Ligand B is slightly favored.
11. **hERG:** Ligand A (0.181) has a slightly lower hERG risk than Ligand B (0.775). Lower is better, so Ligand A is slightly favored.
12. **Cl_mic:** Ligand A (64.098) has a higher microsomal clearance than Ligand B (12.453). Lower clearance indicates better metabolic stability, making Ligand B significantly better.
13. **t1/2:** Ligand A (-10.408) has a negative in vitro half-life, which is highly unfavorable. Ligand B has a positive half-life of 15.651 hours, which is good. This is a major advantage for Ligand B.
14. **Pgp:** Ligand A (0.187) has lower P-gp efflux than Ligand B (0.169). Lower is better, so Ligand A is slightly favored.
15. **Binding Affinity:** Ligand B (-6.9 kcal/mol) has a better binding affinity than Ligand A (-5.6 kcal/mol). This is a substantial difference (1.3 kcal/mol), and a key driver for selection.
**Overall Assessment:**
Ligand B is significantly better overall. While Ligand A has some slight advantages in BBB, hERG, and Pgp, Ligand B excels in crucial areas: DILI risk, metabolic stability (Cl_mic and t1/2), and, most importantly, binding affinity. The substantial difference in binding affinity outweighs the minor drawbacks of Ligand B. The negative half-life of Ligand A is a major red flag.
Output:
0
2025-04-17 21:24:44,330 - INFO - Reasoning:
Let's analyze Ligand A and Ligand B for their potential as ADRB2 ligands, keeping in mind the GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key).
**Molecular Weight:** Both ligands (347.415 and 351.491 Da) fall comfortably within the ideal 200-500 Da range.
**TPSA:** Ligand A (93.46) is slightly higher than Ligand B (70.67). Both are acceptable, but Ligand B is better, being closer to the <90 ideal for potential CNS penetration (though not a primary concern here).
**logP:** Ligand A (2.271) and Ligand B (1.154) are both within the optimal 1-3 range. Ligand A is slightly preferred as it is closer to the upper end of the range, which can aid in membrane permeability.
**H-Bond Donors/Acceptors:** Both have 2 HBD and similar HBA counts (5 and 4 respectively). This is good, balancing solubility and permeability.
**QED:** Ligand B (0.722) has a slightly better QED score than Ligand A (0.583), indicating a more drug-like profile.
**DILI:** Ligand A (64.521) has a significantly higher DILI risk than Ligand B (9.616). This is a major concern, as a lower DILI risk is highly desirable.
**BBB:** Both ligands have reasonable BBB penetration (Ligand A: 70.648, Ligand B: 63.28).
**Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
**Solubility:** Both have negative solubility values, which is also unusual.
**hERG:** Ligand A (0.139) has a slightly better hERG profile than Ligand B (0.426).
**Microsomal Clearance:** Ligand B (23.807) has a significantly lower microsomal clearance than Ligand A (39.935), indicating better metabolic stability.
**In vitro Half-Life:** Ligand B (20.542) has a longer in vitro half-life than Ligand A (-16.699). This is a significant advantage, potentially leading to less frequent dosing.
**P-gp Efflux:** Ligand A (0.17) has a slightly better P-gp efflux profile than Ligand B (0.007).
**Binding Affinity:** Ligand B (-6.8 kcal/mol) has a significantly stronger binding affinity than Ligand A (-4.8 kcal/mol). This is a crucial factor, and the 1.5 kcal/mol advantage is substantial enough to outweigh some of the other drawbacks.
**Overall:**
While Ligand A has slightly better logP and P-gp efflux, Ligand B wins on several critical parameters: significantly lower DILI risk, better metabolic stability (lower Cl_mic, longer t1/2), and *much* stronger binding affinity. The DILI risk for Ligand A is a major red flag, and the binding affinity of Ligand B is compelling. The slightly better QED is also a plus.
Output:
0
2025-04-17 21:24:44,330 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands (335.319 and 350.419 Da) are within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (105.06) is slightly higher than Ligand B (87.76). Both are below the 140 cutoff for oral absorption, but Ligand B is preferable due to being closer to the 90 cutoff for GPCRs.
3. **logP:** Ligand A (2.411) is within the optimal 1-3 range. Ligand B (0.713) is below 1, which could hinder permeation. This is a significant drawback for Ligand B.
4. **HBD:** Ligand A (2) and Ligand B (1) both meet the <=5 criteria.
5. **HBA:** Both ligands (5) meet the <=10 criteria.
6. **QED:** Both ligands have good QED scores (0.765 and 0.808, respectively), indicating good drug-like properties.
7. **DILI:** Ligand A (98.527) has a high DILI risk, while Ligand B (43.971) has a much lower, and acceptable, risk. This is a major advantage for Ligand B.
8. **BBB:** Both ligands have acceptable BBB penetration (61.342 and 68.554). While higher is better, this isn't a primary concern for a cardiovascular target like ADRB2.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability.
10. **Solubility:** Both ligands have negative solubility values, which is also unusual and suggests poor solubility.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.239 and 0.238).
12. **Cl_mic:** Ligand A (5.553) has a lower microsomal clearance, suggesting better metabolic stability than Ligand B (13.895).
13. **t1/2:** Ligand A (14.383) has a longer in vitro half-life than Ligand B (-12.188). The negative value for Ligand B is concerning.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.196 and 0.019).
15. **Affinity:** Ligand A (-7.9 kcal/mol) has a slightly stronger binding affinity than Ligand B (-7.5 kcal/mol). The difference is 0.4 kcal/mol, which is not substantial enough to overcome other deficiencies.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has a better logP and affinity, but Ligand B has a significantly better TPSA and a much lower DILI risk. The negative Caco-2 and solubility values are concerning for both, but the DILI risk for Ligand A is a major red flag.
**Overall Assessment:**
While Ligand A has slightly better affinity and metabolic stability, the significantly higher DILI risk and lower logP of Ligand A make it a less desirable candidate. Ligand B, despite the negative Caco-2 and solubility values, presents a much more favorable safety profile (lower DILI) and better TPSA, which are critical for a GPCR target. The slightly weaker affinity of Ligand B can potentially be optimized in further iterations.
Output:
0
2025-04-17 21:24:44,330 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (345.487 and 368.474 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (81.99) is higher than Ligand B (59.5). For a cardiovascular GPCR, TPSA isn't a *major* concern (unlike a CNS target), but lower is generally preferred for absorption. Ligand B has a clear advantage.
3. **logP:** Both ligands (2.764 and 3.036) are within the optimal 1-3 range. No significant difference.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (0). This isn't a major concern for either.
5. **HBA:** Ligand A (3) is lower than Ligand B (5). Lower HBA is generally favorable for permeability. Ligand A has a slight advantage.
6. **QED:** Ligand A (0.804) is better than Ligand B (0.66), indicating a more drug-like profile. This is a good sign for Ligand A.
7. **DILI:** Ligand B (41.915) has a slightly higher DILI risk than Ligand A (29.081), but both are below the concerning threshold of 60. Ligand A is preferred.
8. **BBB:** Ligand B (86.041) has a significantly higher BBB penetration percentile than Ligand A (56.921). While ADRB2 isn't primarily a CNS target, some degree of BBB penetration can be useful for understanding off-target effects and potential peripheral distribution.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.821 and -4.65). This is unusual and suggests poor permeability. However, these values are close, so it doesn't heavily influence the decision.
10. **Solubility:** Ligand A (-3.499) is slightly less soluble than Ligand B (-3.194). Solubility is important, but not a primary driver for this target.
11. **hERG:** Both ligands have low hERG inhibition risk (0.435 and 0.598). No significant difference.
12. **Cl_mic:** Ligand B (86.966) has a much higher microsomal clearance than Ligand A (21.529). This suggests Ligand B will be metabolized more quickly, leading to lower exposure. Ligand A is strongly preferred.
13. **t1/2:** Ligand A (16.182) has a longer in vitro half-life than Ligand B (-1.299). This is a significant advantage for Ligand A, suggesting less frequent dosing could be possible.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.141 and 0.207). No significant difference.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.3 and -6.1 kcal/mol). The difference is negligible.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), and the general drug-like properties, Ligand A is the better candidate. While Ligand B has better BBB penetration and a slightly lower TPSA, Ligand A excels in crucial areas like QED, DILI risk, metabolic stability (lower Cl_mic, longer t1/2), and has comparable binding affinity. The negative Caco-2 values are concerning for both, but the other advantages of Ligand A outweigh this drawback.
Output:
1
2025-04-17 21:24:44,330 - INFO - Batch 256 complete. Total preferences: 4096
2025-04-17 21:24:44,330 - INFO - Processing batch 257/512...
2025-04-17 21:25:34,719 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (359.344 and 346.385 Da) fall comfortably within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (66.84) is slightly higher than Ligand B (57.18). Both are below the 140 threshold for good oral absorption, but B is better.
3. **logP:** Both ligands have good logP values (2.967 and 2.061), falling within the optimal 1-3 range. Ligand A is slightly higher, which *could* be beneficial for membrane permeability, but not significantly.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 3 HBA, while Ligand B has 6. Ligand A is preferable here, as lower HBA generally improves permeability.
6. **QED:** Both ligands have very similar QED values (0.898 and 0.894), indicating good drug-likeness.
7. **DILI:** Ligand A (39.085) has a significantly lower DILI risk than Ligand B (61.303). This is a major advantage for Ligand A.
8. **BBB:** Both ligands have high BBB penetration (83.56 and 82.164), which is good, but not critical for ADRB2 as it's not a CNS target.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. Ligand A (-4.664) is slightly better than Ligand B (-4.89).
10. **Solubility:** Both have negative solubility values, indicating poor solubility. Ligand A (-2.349) is slightly better than Ligand B (-2.994).
11. **hERG:** Ligand A (0.338) has a lower hERG inhibition liability than Ligand B (0.929), which is a significant safety advantage.
12. **Cl_mic:** Ligand A (-1.473) has a *much* lower (better) microsomal clearance than Ligand B (48.272). This suggests significantly better metabolic stability for Ligand A.
13. **t1/2:** Both have similar in vitro half-lives (-20.505 and -19.478).
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.091 and 0.082).
15. **Binding Affinity:** Ligand B (-6.9) has slightly better binding affinity than Ligand A (-6.6), a 0.3 kcal/mol difference. While affinity is important, the difference isn't large enough to overcome the other significant advantages of Ligand A.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity) and general drug-like properties, Ligand A is the superior candidate. While Ligand B has slightly better affinity, Ligand A demonstrates a much more favorable safety profile (lower DILI, lower hERG), better metabolic stability (lower Cl_mic), and slightly improved permeability/solubility. The differences in DILI and Cl_mic are substantial enough to outweigh the small affinity advantage of Ligand B.
Output:
1
2025-04-17 21:25:34,720 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (342.439 Da and 348.443 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (67.43) is slightly higher than Ligand B (62.99). Both are below the 140 A^2 threshold for good oral absorption, which is good.
**3. logP:** Both ligands have good logP values (2.894 and 2.088), falling within the optimal 1-3 range. Ligand B is slightly lower, which might slightly improve solubility but could also impact permeability.
**4. H-Bond Donors:** Ligand A has 2 HBD, and Ligand B has 0. Both are within the acceptable limit of <=5.
**5. H-Bond Acceptors:** Ligand A has 3 HBA, and Ligand B has 4. Both are within the acceptable limit of <=10.
**6. QED:** Both ligands have good QED scores (0.564 and 0.722), indicating a generally drug-like profile. Ligand B is slightly better.
**7. DILI:** Ligand A (37.146) has a slightly higher DILI risk than Ligand B (25.94). This is a significant advantage for Ligand B.
**8. BBB:** Ligand B (77.472) has a considerably higher BBB penetration score than Ligand A (64.637). While ADRB2 is a cardiovascular target, some CNS penetration can be acceptable or even beneficial for off-target effects.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.739 and -4.312). This is unusual and suggests poor permeability. However, the scale isn't specified, so it's hard to interpret.
**10. Aqueous Solubility:** Ligand A (-3.574) has worse solubility than Ligand B (-1.309). Solubility is important for bioavailability.
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.659 and 0.237). This is excellent.
**12. Microsomal Clearance:** Ligand B (64.771) has a higher microsomal clearance than Ligand A (34.801), indicating faster metabolism. This is a disadvantage for Ligand B.
**13. In vitro Half-Life:** Ligand B (29.793) has a longer half-life than Ligand A (22.419). This is a positive for Ligand B.
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (0.342 and 0.213). This is good.
**15. Binding Affinity:** Ligand B (-7.7 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.2 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME drawbacks. A difference of 2.5 kcal/mol is very significant.
**Overall Assessment:**
Ligand B is the stronger candidate. The significantly improved binding affinity (-7.7 vs -5.2 kcal/mol) is the most important factor, especially for a GPCR target. It also has a lower DILI risk, better BBB penetration, and better solubility. While it has higher microsomal clearance, the longer half-life partially compensates for this. The Caco-2 permeability values are concerning for both, but the superior binding affinity of Ligand B makes it the more promising candidate.
Output:
0
2025-04-17 21:25:34,720 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Step-by-step comparison:**
1. **MW:** Both ligands (356.46 & 348.44 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (40.62) is significantly better than Ligand B (67.87). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (3.475) is optimal, while Ligand B (1.949) is on the lower end. This could impact permeability for Ligand B.
4. **HBD:** Both have acceptable HBD counts (0 for A, 1 for B).
5. **HBA:** Both have acceptable HBA counts (2 for A, 4 for B).
6. **QED:** Both have good QED scores (0.559 & 0.789), indicating drug-likeness. Ligand B is slightly better here.
7. **DILI:** Ligand A (21.91) has a much lower DILI risk than Ligand B (45.25). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (93.91) has a higher BBB penetration than Ligand B (71.97). While not critical for a cardiovascular target, it's a positive attribute.
9. **Caco-2:** Ligand A (-4.303) is better than Ligand B (-5.076), indicating better intestinal absorption.
10. **Solubility:** Both have similar, poor aqueous solubility (-2.942 & -2.993). This could be a formulation challenge for both.
11. **hERG:** Ligand A (0.749) has a lower hERG risk than Ligand B (0.246). This is a significant safety advantage for Ligand A.
12. **Cl_mic:** Ligand B (28.59) has a lower microsomal clearance than Ligand A (36.10), suggesting better metabolic stability.
13. **t1/2:** Ligand B (21.49) has a longer in vitro half-life than Ligand A (-13.99). This is a positive for Ligand B.
14. **Pgp:** Ligand A (0.302) has a lower Pgp efflux liability than Ligand B (0.057), indicating better bioavailability.
15. **Affinity:** Ligand B (-7.1) has a significantly stronger binding affinity than Ligand A (-5.2). This is a substantial advantage for Ligand B.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, Pgp, TPSA, and affinity. Ligand B excels in affinity, while Ligand A is better in logP, Pgp and TPSA. The affinity difference is substantial (>1.5 kcal/mol).
**Overall Assessment:**
While Ligand A has advantages in safety (DILI, hERG) and some ADME properties (TPSA, Pgp), the significantly stronger binding affinity of Ligand B (-7.1 vs -5.2 kcal/mol) is a major advantage that likely outweighs the drawbacks. The better metabolic stability (lower Cl_mic, longer t1/2) of Ligand B also contributes to its favorability. The slightly lower logP and higher TPSA of Ligand B are less concerning for a cardiovascular target than the safety concerns associated with Ligand A.
Output:
0
2025-04-17 21:25:34,720 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [347.419, 98.14, 0.461, 2, 6, 0.5, 39.356, 61.923, -4.909, -2.15, 0.024, 18.79, -5.129, 0.05, -6.5]
**Ligand B:** [351.397, 53.51, 2.362, 0, 3, 0.837, 21.481, 95.192, -4.184, -2.325, 0.279, 21.36, -11.314, 0.063, -5.9]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity, and BBB):
1. **MW:** Both are within the ideal 200-500 Da range. A (347.4) is slightly lower, which is generally favorable.
2. **TPSA:** A (98.14) is higher than B (53.51). B is significantly better here, falling well below the 140 threshold for oral absorption and closer to the ideal for GPCRs.
3. **logP:** A (0.461) is quite low, potentially hindering membrane permeability. B (2.362) is much better, falling within the optimal 1-3 range.
4. **HBD/HBA:** A has 2 HBD and 6 HBA. B has 0 HBD and 3 HBA. B is preferable, minimizing potential off-target interactions and improving permeability.
5. **QED:** B (0.837) has a significantly higher QED score than A (0.5), indicating a more drug-like profile.
6. **DILI:** A (39.356) has a slightly higher DILI risk than B (21.481), though both are reasonably low.
7. **BBB:** B (95.192) has excellent BBB penetration, while A (61.923) is moderate. This is a crucial advantage for B, given ADRB2's potential relevance in CNS indications.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
9. **Solubility:** Both have negative solubility values. Again, the scale is not specified, so it's hard to interpret.
10. **hERG:** A (0.024) has a very low hERG risk, slightly better than B (0.279).
11. **Cl_mic:** A (18.79) has lower microsomal clearance than B (21.36), suggesting better metabolic stability.
12. **t1/2:** B (-11.314) has a much longer in vitro half-life than A (-5.129). This is a significant advantage.
13. **Pgp:** A (0.05) has lower P-gp efflux than B (0.063), which is favorable.
14. **Affinity:** A (-6.5 kcal/mol) has a slightly better binding affinity than B (-5.9 kcal/mol), but the difference is less than 1.5 kcal/mol.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity and lower P-gp efflux, Ligand B overwhelmingly wins on the critical GPCR parameters. Its superior logP, TPSA, BBB penetration, QED, and in vitro half-life make it a much more promising drug candidate. The lower TPSA and better logP will likely translate to better permeability, offsetting the negative Caco-2 values. The longer half-life is also a significant benefit.
Therefore, I prefer Ligand B.
Output:
0
2025-04-17 21:25:34,721 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (371.415 and 344.459 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (74.13) is significantly better than Ligand A (114.04). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (3.09) is optimal, while Ligand A (-0.029) is quite low, potentially hindering membrane permeability. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1), but both are acceptable.
5. **HBA:** Ligand A (7) is higher than Ligand B (4). Again, both are within the acceptable range, but lower is generally preferred.
6. **QED:** Both ligands have good QED scores (0.63 and 0.778), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand B (25.436) has a much lower DILI risk than Ligand A (78.054). This is a major advantage for Ligand B.
8. **BBB:** Ligand B (84.413) has a higher BBB penetration score than Ligand A (51.997). While not critical for a cardiovascular target, it doesn't hurt.
9. **Caco-2:** Both ligands have similar, poor Caco-2 permeability (-5.113 and -5.108). This suggests potential absorption issues for both.
10. **Solubility:** Ligand A (-2.598) has slightly better solubility than Ligand B (-3.127), but both are poor.
11. **hERG:** Ligand A (0.078) has a slightly lower hERG risk than Ligand B (0.252), but both are relatively low.
12. **Cl_mic:** Ligand B (17.056) has significantly lower microsomal clearance than Ligand A (53.512), indicating better metabolic stability. This is a substantial advantage for Ligand B.
13. **t1/2:** Ligand B (6.198) has a longer in vitro half-life than Ligand A (-5.597). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.018) has lower P-gp efflux than Ligand B (0.106), which is preferable.
15. **Binding Affinity:** Ligand A (-7.2) has a significantly stronger binding affinity than Ligand B (-3.5). This is a large advantage for Ligand A.
**Overall Assessment:**
While Ligand A has a much better binding affinity, Ligand B has a superior ADME profile. The combination of lower DILI risk, better metabolic stability (lower Cl_mic, longer t1/2), and optimal logP strongly favors Ligand B. The poor Caco-2 permeability is a concern for both, but can potentially be addressed through formulation strategies. The difference in binding affinity, while substantial, can potentially be overcome with further optimization of Ligand B, whereas improving the ADME properties of Ligand A would likely be more challenging. Given the GPCR-specific priorities (logP, Pgp, TPSA, affinity) and the overall balance, Ligand B is the more promising candidate.
Output:
0
2025-04-17 21:25:34,721 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [361.291, 55.84, 2.303, 0, 4, 0.469, 70.88, 92.672, -4.377, -2.929, 0.418, 48.594, -13.496, 0.134, 0]
**Ligand B:** [345.487, 62.3, 2.948, 1, 3, 0.663, 17.371, 71.927, -4.923, -2.015, 0.54, 50.436, -18.123, 0.402, -6.2]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity) and general drug-like properties:
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (345.487) is slightly lower, which can be beneficial for permeability.
2. **TPSA:** Ligand A (55.84) is better than Ligand B (62.3), being closer to the <140 threshold for good absorption.
3. **logP:** Both are within the optimal 1-3 range. Ligand B (2.948) is slightly higher, potentially leading to some off-target interactions, but still acceptable.
4. **HBD/HBA:** Ligand A (0 HBD, 4 HBA) is preferable to Ligand B (1 HBD, 3 HBA). Fewer H-bonds generally improve membrane permeability.
5. **QED:** Ligand B (0.663) has a better QED score than Ligand A (0.469), indicating a more drug-like profile.
6. **DILI:** Ligand B (17.371) has a significantly lower DILI risk than Ligand A (70.88), a major advantage.
7. **BBB:** Both have high BBB penetration (Ligand A: 92.672, Ligand B: 71.927). This is less critical for a cardiovascular target like ADRB2, but not detrimental.
8. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. Ligand B (-4.923) is slightly worse than Ligand A (-4.377).
9. **Solubility:** Both have negative solubility values, indicating poor solubility. Ligand B (-2.015) is slightly better than Ligand A (-2.929).
10. **hERG:** Both have low hERG inhibition risk (Ligand A: 0.418, Ligand B: 0.54), which is good.
11. **Cl_mic:** Both have similar microsomal clearance (Ligand A: 48.594, Ligand B: 50.436).
12. **t1/2:** Ligand B (-18.123) has a longer in vitro half-life than Ligand A (-13.496), which is a positive.
13. **Pgp:** Both have low P-gp efflux (Ligand A: 0.134, Ligand B: 0.402).
14. **Affinity:** Ligand B (-6.2 kcal/mol) has a significantly stronger binding affinity than Ligand A (0 kcal/mol). This is a crucial advantage.
**Overall Assessment:**
While Ligand A has slightly better TPSA and Caco-2 permeability, Ligand B overwhelmingly wins due to its significantly lower DILI risk, better QED, longer half-life, and *much* stronger binding affinity. The affinity difference is substantial enough to outweigh the minor drawbacks in TPSA and Caco-2. The DILI risk for Ligand A is concerning.
Therefore, I prefer Ligand B.
Output:
0
2025-04-17 21:25:34,721 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (346.475) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (64.68) is significantly better than Ligand B (95.66). For a GPCR, keeping TPSA low is beneficial for permeability and potentially BBB penetration.
3. **logP:** Both ligands have acceptable logP values (A: 1.991, B: 1.549) falling within the 1-3 range.
4. **HBD:** Both are reasonable (A: 2, B: 3), within the guideline of <=5.
5. **HBA:** Ligand A (3) is better than Ligand B (5), keeping the total number of H-bonds lower which is favorable for permeability.
6. **QED:** Both ligands have similar QED values (A: 0.757, B: 0.738), indicating good drug-likeness.
7. **DILI:** Ligand A (11.322) has a much lower DILI risk than Ligand B (23.187). This is a significant advantage.
8. **BBB:** Both ligands have similar BBB penetration (A: 64.637, B: 62.699). While not exceptionally high, it's not a primary concern for ADRB2 which is not a CNS target.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual. However, the magnitude is similar (-5.039 vs -5.789) and doesn't strongly favor either.
10. **Solubility:** Ligand A (-1.037) is better than Ligand B (-2.938), indicating better aqueous solubility.
11. **hERG:** Both ligands have very low hERG inhibition risk (A: 0.367, B: 0.241).
12. **Cl_mic:** Ligand A (-11.254) has a significantly lower (better) microsomal clearance than Ligand B (8.338), suggesting better metabolic stability.
13. **t1/2:** Ligand A (2.476) has a lower in vitro half-life than Ligand B (4.563), but the difference isn't massive.
14. **Pgp:** Both ligands have very low Pgp efflux liability (A: 0.004, B: 0.071).
15. **Binding Affinity:** Ligand B (-6.3) has a slightly better binding affinity than Ligand A (-6.0), but the difference is less than 1.5 kcal/mol.
**Overall Assessment:**
Ligand A is clearly superior. It excels in several key ADME properties (DILI, solubility, metabolic stability) and has a better TPSA and HBA count, all of which contribute to better drug-likeness and permeability. While Ligand B has a marginally better binding affinity, the ADME advantages of Ligand A outweigh this small difference in potency. Given that ADRB2 is a cardiovascular target, CNS penetration is not a major concern, and the lower DILI risk of Ligand A is particularly valuable.
Output:
1
2025-04-17 21:25:34,722 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (389.905 Da) is within the ideal range (200-500 Da). Ligand B (193.29 Da) is at the lower end, potentially impacting potency.
2. **TPSA:** Ligand A (78.95) is good for oral absorption. Ligand B (23.47) is excellent.
3. **logP:** Both ligands (A: 1.414, B: 2.06) are within the optimal range (1-3).
4. **HBD:** Both have 1 HBD, which is acceptable.
5. **HBA:** Ligand A has 4 HBA, Ligand B has 2. Both are good.
6. **QED:** Both ligands have similar QED scores (A: 0.797, B: 0.791), indicating good drug-likeness.
7. **DILI:** Ligand A (58.627) has a moderate DILI risk, while Ligand B (1.318) has a very low risk. This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (59.093) has moderate BBB penetration, while Ligand B (51.881) is lower. Since ADRB2 is a cardiovascular target, BBB penetration is not a high priority.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
10. **Solubility:** Ligand A (-2.808) has poor solubility, while Ligand B (-0.852) is slightly better, but still poor.
11. **hERG:** Ligand A (0.529) has a slightly higher hERG risk than Ligand B (0.251), which is preferable.
12. **Cl_mic:** Ligand A (25.187) has a higher microsomal clearance than Ligand B (-17.038), indicating lower metabolic stability. This is a significant drawback for Ligand A.
13. **t1/2:** Ligand A (-5.507) has a negative in vitro half-life, which is concerning. Ligand B (13.275) has a reasonable half-life.
14. **Pgp:** Ligand A (0.088) has lower P-gp efflux than Ligand B (0.008), which is a slight advantage.
15. **Affinity:** Ligand A (-7.2 kcal/mol) has a slightly better binding affinity than Ligand B (-5.4 kcal/mol). This is a 1.8 kcal/mol difference, which is significant.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A has a slightly better affinity and Pgp profile, but Ligand B excels in DILI risk and metabolic stability (lower Cl_mic, better t1/2). The poor solubility of both is a concern, but the significantly better ADME profile of Ligand B, particularly the low DILI risk and improved metabolic stability, outweighs the slightly better affinity of Ligand A.
**Conclusion:**
Considering the balance of properties, especially the lower DILI risk and improved metabolic stability of Ligand B, it is the more promising drug candidate.
Output:
0
2025-04-17 21:25:34,722 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (345.443 and 345.407 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (71.53) is significantly better than Ligand B (97.94). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is approaching a level that could hinder oral absorption.
3. **logP:** Ligand A (1.785) is within the optimal 1-3 range. Ligand B (0.647) is a bit low, potentially impacting membrane permeability.
4. **HBD:** Both ligands have 1 HBD, which is ideal.
5. **HBA:** Ligand A has 4 HBA, while Ligand B has 7. Ligand B is higher, potentially impacting permeability.
6. **QED:** Both ligands have good QED scores (0.765 and 0.794), indicating good drug-like properties.
7. **DILI:** Ligand A (12.02) has a much lower DILI risk than Ligand B (62.001). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (85.576) has better BBB penetration than Ligand B (71.772). While ADRB2 isn't exclusively a CNS target, some CNS exposure can occur, and higher BBB penetration is generally favorable.
9. **Caco-2:** Ligand A (-4.776) and Ligand B (-5.171) are similar in Caco-2 permeability.
10. **Solubility:** Ligand A (-1.094) is better than Ligand B (-2.38).
11. **hERG:** Both ligands have very low hERG inhibition risk (0.394 and 0.056).
12. **Cl_mic:** Ligand A (7.922) has significantly lower microsomal clearance than Ligand B (21.385), indicating better metabolic stability.
13. **t1/2:** Ligand A (-15.817) has a much longer in vitro half-life than Ligand B (-0.516). This is a significant advantage.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.053 and 0.048).
15. **Binding Affinity:** Ligand B (-7.0) has a slightly better binding affinity than Ligand A (-5.3). However, the difference is not substantial enough to outweigh the numerous ADME advantages of Ligand A.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical ADME properties (DILI, BBB, solubility, Cl_mic, t1/2, TPSA). While Ligand B has a slightly better binding affinity, the improved ADME profile of Ligand A makes it a more promising drug candidate. The lower DILI risk and better metabolic stability are particularly important.
Output:
1
2025-04-17 21:25:34,722 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (363.483 and 358.511 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (56.59) is better than Ligand B (61.88). Both are below the 140 threshold for oral absorption, but lower is preferable.
3. **logP:** Ligand A (2.581) is within the optimal 1-3 range, while Ligand B (4.476) is slightly higher. While still acceptable, the higher logP of B could lead to solubility issues or off-target interactions.
4. **HBD:** Ligand A (0) is better than Ligand B (1). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (6) is better than Ligand B (4). Both are below the 10 threshold.
6. **QED:** Ligand A (0.685) is slightly better than Ligand B (0.531), indicating a more drug-like profile.
7. **DILI:** Both ligands have similar DILI risk (50.136 vs 53.858), and both are acceptable (<60).
8. **BBB:** Ligand A (67.197) is better than Ligand B (64.133), though neither is exceptionally high. For a cardiovascular target, BBB penetration is not a primary concern, but a slight advantage is still helpful.
9. **Caco-2:** Ligand A (-4.691) is better than Ligand B (-5.173). Higher values are better.
10. **Solubility:** Ligand A (-3.256) is better than Ligand B (-4.099). Higher values are better.
11. **hERG:** Both ligands have low hERG inhibition risk (0.507 and 0.652).
12. **Cl_mic:** Ligand B (72.696) has a lower microsomal clearance than Ligand A (98.623), suggesting better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand A (8.078) has a longer in vitro half-life than Ligand B (-19.599). This is a substantial advantage.
14. **Pgp:** Ligand A (0.321) is better than Ligand B (0.56). Lower efflux is preferable.
15. **Affinity:** Ligand A (-6.8 kcal/mol) has a slightly better binding affinity than Ligand B (-5.2 kcal/mol). This difference of 1.6 kcal/mol is significant.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A is better in terms of logP, TPSA, and Pgp. The affinity difference is also substantial. While metabolic stability (Cl_mic) is important, the superior binding affinity and other favorable ADME properties of Ligand A outweigh the slightly higher clearance.
**Conclusion:**
Ligand A presents a more balanced profile with better predicted absorption, permeability, and significantly better binding affinity.
Output:
1
2025-04-17 21:25:34,722 - INFO - Here's my reasoning and final output for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's systematically compare Ligand A and Ligand B based on the provided parameters and the guidelines, keeping in mind that ADRB2 is a GPCR and therefore we prioritize logP, Pgp, TPSA, and affinity.
1. **MW:** Both ligands (356.463 and 353.383 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (77.1) is significantly better than Ligand B (130.48). A TPSA under 140 is good for oral absorption, and lower is better for GPCRs. Ligand B is pushing the upper limit.
3. **logP:** Ligand A (0.816) is a bit low, potentially impacting permeability. Ligand B (-1.909) is even lower and more concerning. Both are below the optimal 1-3 range.
4. **HBD/HBA:** Ligand A (1 HBD, 5 HBA) is preferable to Ligand B (3 HBD, 7 HBA). Fewer hydrogen bonds are generally better for membrane permeability.
5. **QED:** Ligand A (0.762) is much better than Ligand B (0.444). A QED > 0.5 is desirable, and Ligand A comfortably exceeds this.
6. **DILI:** Ligand A (34.277) has a significantly lower DILI risk than Ligand B (52.617). Both are below 60, but A is much safer.
7. **BBB:** Both ligands have similar BBB penetration (70.105 and 70.648). This is acceptable, but not exceptionally high.
8. **Caco-2:** Ligand A (-4.55) is better than Ligand B (-5.418), indicating better intestinal absorption.
9. **Solubility:** Ligand A (-1.848) is better than Ligand B (-0.977), indicating better aqueous solubility.
10. **hERG:** Ligand A (0.247) has a lower hERG risk than Ligand B (0.086). Lower is better.
11. **Cl_mic:** Ligand B (-4.495) has a significantly lower (better) microsomal clearance than Ligand A (8.891). This suggests better metabolic stability for Ligand B.
12. **t1/2:** Ligand B (21.964) has a much longer in vitro half-life than Ligand A (4.944). This is a significant advantage for dosing frequency.
13. **Pgp:** Ligand A (0.024) has lower P-gp efflux than Ligand B (0.008), meaning it will likely have better bioavailability.
14. **Binding Affinity:** Ligand B (-7.6 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.5 kcal/mol). This is a >2 kcal/mol difference, which is substantial and can outweigh some ADME concerns.
**Overall Assessment:**
Ligand B has a much stronger binding affinity and better metabolic stability (lower Cl_mic, longer t1/2). However, Ligand A has better TPSA, QED, solubility, DILI risk, and Pgp efflux. The lower logP for both is a concern, but Ligand B is worse. The significantly stronger affinity of Ligand B is the most important factor for a GPCR target. While Ligand A is more "drug-like" in many respects, the potency advantage of Ligand B is likely to be decisive.
Output:
0
2025-04-17 21:25:34,723 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.381 and 359.417 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (61.19) is significantly better than Ligand B (84.66). ADRB2 is not a CNS target, but lower TPSA generally improves absorption.
3. **logP:** Ligand A (3.463) is optimal, while Ligand B (1.059) is a bit low. A logP between 1-3 is preferred for good balance of solubility and permeability. Ligand B's lower logP could lead to permeability issues.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer HBDs generally improve membrane permeability.
5. **HBA:** Ligand A (5) is better than Ligand B (4). Both are acceptable, but lower is generally preferred.
6. **QED:** Ligand A (0.762) is significantly better than Ligand B (0.476), indicating a more drug-like profile.
7. **DILI:** Ligand A (30.05) is better than Ligand B (21.055), indicating a lower risk of drug-induced liver injury.
8. **BBB:** Both ligands have high BBB penetration (96.472 and 92.943). This isn't a primary concern for ADRB2, but it doesn't hurt.
9. **Caco-2:** Ligand A (-4.178) is better than Ligand B (-5.082). Higher values indicate better absorption.
10. **Solubility:** Ligand A (-3.699) is better than Ligand B (-2.056). Higher values are preferred.
11. **hERG:** Both ligands have similar, low hERG inhibition liability (0.598 and 0.52). This is good.
12. **Cl_mic:** Ligand A (56.455) has a higher clearance than Ligand B (15.312), meaning it's metabolized faster. This is a significant negative for Ligand A.
13. **t1/2:** Ligand B (-15.024) has a longer half-life than Ligand A (-19.655). A longer half-life is generally desirable.
14. **Pgp:** Both ligands have similar, low Pgp efflux liability (0.645 and 0.036).
15. **Binding Affinity:** Ligand A (-7.3) has a significantly better binding affinity than Ligand B (-4.9). A difference of 2.4 kcal/mol is substantial.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, and affinity are key. Ligand A excels in logP and affinity, while Ligand B has a better TPSA. However, the substantial affinity difference of 2.4 kcal/mol for Ligand A outweighs the TPSA advantage of Ligand B. The better QED and DILI scores for Ligand A are also beneficial. The main drawback of Ligand A is its higher Cl_mic, but the significantly improved binding affinity is a strong compensating factor.
**Conclusion:**
Despite the higher clearance of Ligand A, its superior binding affinity, better logP, QED, DILI, solubility, and Caco-2 permeability make it the more promising drug candidate.
Output:
1
2025-04-17 21:25:34,723 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (364.379 and 368.543 Da) are within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand B (68.29) is significantly better than Ligand A (115.61). ADRB2 is not a CNS target, but lower TPSA generally improves absorption. This favors B.
3. **logP:** Both ligands have good logP values (2.632 and 3.593), falling within the 1-3 range. Ligand B is slightly higher, which *could* be beneficial for membrane permeability, but isn't a major concern.
4. **HBD:** Both have 1 HBD, which is acceptable.
5. **HBA:** Ligand A has 6 HBA, and Ligand B has 4 HBA. Both are within the acceptable limit of 10.
6. **QED:** Ligand B (0.641) has a slightly better QED score than Ligand A (0.478), indicating a more drug-like profile.
7. **DILI:** Ligand B (40.016) has a much lower DILI risk than Ligand A (96.588). This is a significant advantage for Ligand B.
8. **BBB:** Both have moderate BBB penetration (64.095 and 62.97). Not a major factor for ADRB2.
9. **Caco-2:** Both have negative Caco-2 values (-4.932 and -4.765). This is unusual and suggests poor permeability, but the values are similar.
10. **Solubility:** Both have negative solubility values (-4.529 and -3.849), indicating poor aqueous solubility. This is a concern for both.
11. **hERG:** Both ligands have low hERG inhibition liability (0.48 and 0.468).
12. **Cl_mic:** Ligand B (84.901) has a higher microsomal clearance than Ligand A (68.009), indicating faster metabolism and potentially lower *in vivo* exposure. This favors A.
13. **t1/2:** Ligand A (-8.213) has a more negative in vitro half-life than Ligand B (-1.003). This is counterintuitive and suggests faster degradation for A.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.315 and 0.395).
15. **Binding Affinity:** Ligand A (-7.2 kcal/mol) has a significantly better binding affinity than Ligand B (-6.1 kcal/mol). This is a 1.1 kcal/mol difference, which is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand A has a significantly better binding affinity, which is the most important factor. However, Ligand B has a much lower DILI risk, better TPSA, and a better QED score. The solubility and Caco-2 values are poor for both, but the DILI risk for Ligand A is very high. The faster clearance of Ligand B is a concern, but the stronger binding of A is likely to compensate for that. The negative half-life for A is also concerning.
Considering the balance of properties, especially the critical importance of binding affinity for GPCRs, and the significant DILI risk associated with Ligand A, I favor Ligand A.
**Output:**
1
2025-04-17 21:25:34,723 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [368.415, 49.41, 3.745, 1, 2, 0.472, 39.977, 85.459, -4.673, -4.375, 0.734, 43.974, 6.725, 0.372, -5.3]
**Ligand B:** [348.491, 76.02, 2.313, 2, 4, 0.828, 26.561, 70.88, -4.747, -2.802, 0.151, 58.298, 8.855, 0.034, -6.4]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, BBB, and affinity are key):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (348.491) is slightly lower, which could be advantageous for permeability, but both are acceptable.
2. **TPSA:** Ligand A (49.41) is much better than Ligand B (76.02). A TPSA under 140 is good for oral absorption, but lower is generally preferred for GPCRs. Ligand A is significantly better here.
3. **logP:** Ligand A (3.745) is optimal (1-3), while Ligand B (2.313) is on the lower side. While still acceptable, a higher logP often improves GPCR binding.
4. **HBD/HBA:** Ligand A (1 HBD, 2 HBA) is preferable to Ligand B (2 HBD, 4 HBA). Lower counts are generally better for permeability.
5. **QED:** Ligand B (0.828) has a significantly better QED score than Ligand A (0.472), indicating a more drug-like profile overall.
6. **DILI:** Ligand A (39.977) has a slightly higher DILI risk than Ligand B (26.561), but both are below the concerning threshold of 60.
7. **BBB:** Ligand A (85.459) has a much higher BBB percentile than Ligand B (70.88). This is a significant advantage for a GPCR target, even if not directly CNS-focused, as it suggests better distribution.
8. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. This is a concern for both, but the values are close enough that it doesn't heavily sway the decision.
9. **Solubility:** Ligand B (-2.802) has better solubility than Ligand A (-4.375). Solubility is important, but can be addressed with formulation.
10. **hERG:** Ligand A (0.734) has a slightly higher hERG risk than Ligand B (0.151), which is favorable for Ligand B.
11. **Cl_mic:** Ligand B (58.298) has a lower microsomal clearance than Ligand A (43.974), suggesting better metabolic stability.
12. **t1/2:** Ligand B (8.855) has a longer in vitro half-life than Ligand A (6.725), which is desirable.
13. **Pgp:** Ligand A (0.372) has lower P-gp efflux than Ligand B (0.034), which is a significant advantage for bioavailability and potential CNS exposure.
14. **Affinity:** Ligand B (-6.4 kcal/mol) has a stronger binding affinity than Ligand A (-5.3 kcal/mol). This is a 1.1 kcal/mol difference, which is substantial and outweighs many of the other drawbacks.
**Overall Assessment:**
Ligand B has a superior binding affinity, better QED, lower DILI, better metabolic stability, and longer half-life. While Ligand A has a better TPSA and BBB, the affinity difference and other ADME properties of Ligand B are more compelling, especially considering the GPCR target class. The slightly lower logP of Ligand B is not a major concern, and solubility can be improved through formulation. The Pgp efflux is also lower for Ligand A, but the affinity difference is significant.
Therefore, I recommend Ligand B.
Output:
0
2025-04-17 21:25:34,724 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
We are targeting ADRB2, a GPCR. Therefore, priorities are logP, TPSA, Pgp, BBB, and affinity.
* **Molecular Weight:** Both ligands (351.422 and 348.447 Da) are within the ideal 200-500 Da range.
* **TPSA:** Ligand A (95.66) is slightly higher than Ligand B (78.68). Both are acceptable, but B is better for permeability.
* **logP:** Both ligands have good logP values (1.537 and 1.197) falling within the 1-3 range.
* **H-Bond Donors/Acceptors:** Ligand A has 3 HBD and 4 HBA, while Ligand B has 1 HBD and 5 HBA. Both are within acceptable limits.
* **QED:** Both ligands have good QED scores (0.701 and 0.865), indicating good drug-likeness.
* **DILI:** Ligand B (18.651) has a significantly lower DILI risk than Ligand A (35.13), which is a major advantage.
* **BBB:** Both ligands have reasonable BBB penetration (58.55 and 62.97).
* **Caco-2:** Both ligands have negative Caco-2 values, which is unusual. This suggests poor permeability.
* **Solubility:** Both ligands have negative solubility values, which is also unusual and indicates poor solubility.
* **hERG:** Ligand A (0.646) has a slightly higher hERG risk than Ligand B (0.108), which is preferable for B.
* **Cl_mic:** Ligand A (-20.97) has a much lower (better) microsomal clearance than Ligand B (-0.586), indicating greater metabolic stability.
* **t1/2:** Ligand B (5.658) has a slightly longer in vitro half-life than Ligand A (4.494).
* **Pgp:** Ligand A (0.052) has a lower Pgp efflux liability than Ligand B (0.033), which is preferable.
* **Binding Affinity:** Ligand B (-3.3 kcal/mol) has a slightly better binding affinity than Ligand A (-6.0 kcal/mol). This is a significant difference.
**Overall Assessment:**
Ligand B is the better candidate. While Ligand A has better metabolic stability (lower Cl_mic) and Pgp efflux, Ligand B has a much lower DILI risk, better TPSA, and a significantly better binding affinity. The lower DILI risk and better affinity are crucial advantages, outweighing the slightly less favorable metabolic stability. The similar BBB values and acceptable logP for both ligands mean these parameters don't strongly favor one over the other.
**Output:**
0
2025-04-17 21:25:34,724 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.5 and 352.4 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (52.65) is significantly better than Ligand B (119.54). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally correlates with better absorption. Ligand B is quite high, potentially hindering oral bioavailability.
3. **logP:** Ligand A (2.375) is optimal. Ligand B (-1.295) is too low, which could lead to poor membrane permeability and bioavailability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (5). Similar reasoning as with HBDs.
6. **QED:** Ligand A (0.746) is better than Ligand B (0.565), indicating a more drug-like profile.
7. **DILI:** Ligand B (49.321) is significantly better than Ligand A (7.057). This is a major advantage for Ligand B. DILI is a critical safety concern.
8. **BBB:** Ligand A (63.823) is better than Ligand B (42.032), but this isn't a high priority for a cardiovascular target.
9. **Caco-2:** Ligand A (-4.714) is better than Ligand B (-5.216). Both are negative, indicating poor permeability, but A is slightly better.
10. **Solubility:** Ligand A (-1.342) is better than Ligand B (-1.746). Both are poor, but A is slightly better.
11. **hERG:** Ligand A (0.773) is much better than Ligand B (0.19). Lower hERG inhibition is crucial for avoiding cardiotoxicity. This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand B (-13.716) is *much* better than Ligand A (41.721). Lower clearance indicates greater metabolic stability, a major benefit.
13. **t1/2:** Ligand B (3.621) is better than Ligand A (6.279). While longer half-life is generally desired, the difference isn't huge.
14. **Pgp:** Ligand A (0.017) is much better than Ligand B (0.009). Lower Pgp efflux is preferable.
15. **Affinity:** Ligand B (-8.0) is significantly better than Ligand A (-6.6). A difference of 1.4 kcal/mol is substantial and can often outweigh other ADME concerns.
**Overall Assessment:**
Ligand B has a superior binding affinity and significantly better metabolic stability (Cl_mic). It also has a much lower DILI risk. However, it suffers from a high TPSA and a low logP, which could impact absorption. Ligand A has better TPSA, logP, hERG, and Pgp properties but has a higher DILI risk and poorer metabolic stability.
Given the importance of potency (binding affinity) for GPCRs, and the significant difference in affinity (-8.0 vs -6.6 kcal/mol), I believe Ligand B is the more promising candidate *despite* its ADME liabilities. The lower DILI risk is also a major factor. Optimization efforts could then focus on improving the logP and TPSA of Ligand B.
Output:
0
2025-04-17 21:25:34,724 - INFO - Batch 257 complete. Total preferences: 4112
2025-04-17 21:25:34,724 - INFO - Processing batch 258/512...
2025-04-17 21:26:27,111 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Step-by-step comparison:**
1. **MW:** Both ligands (378.313 and 355.435 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (60.85) is well below the 140 threshold, and even better, below 90, making it favorable for potential CNS penetration (though ADRB2 isn't strictly a CNS target). Ligand B (99.18) is still under 140, but less optimal.
3. **logP:** Ligand A (2.092) is within the optimal 1-3 range. Ligand B (-0.5) is below 1, which could hinder permeability. This is a significant drawback for Ligand B.
4. **HBD:** Both have 1-2 HBD, which is good.
5. **HBA:** Ligand A has 3 HBA, Ligand B has 5. Both are acceptable, but Ligand A is slightly better.
6. **QED:** Both ligands (0.763 and 0.626) have good drug-likeness scores (>0.5).
7. **DILI:** Ligand A (36.526) has a lower DILI risk than Ligand B (20.628), which is preferable.
8. **BBB:** Ligand A (73.556) has a higher BBB percentile than Ligand B (20.434). While ADRB2 isn't a primary CNS target, higher BBB is generally a positive attribute.
9. **Caco-2:** Ligand A (-4.636) and Ligand B (-5.032) both have negative Caco-2 values, which is not ideal. However, the scale is not specified, so it is hard to interpret.
10. **Solubility:** Ligand A (-1.574) and Ligand B (-0.322) both have negative solubility values, which is not ideal. However, the scale is not specified, so it is hard to interpret.
11. **hERG:** Ligand A (0.567) has a lower hERG risk than Ligand B (0.102), which is preferable.
12. **Cl_mic:** Ligand A (4.322) has a higher microsomal clearance than Ligand B (-2.305). This suggests Ligand B is more metabolically stable, which is a positive.
13. **t1/2:** Ligand A (5.034) has a longer in vitro half-life than Ligand B (-0.586), which is preferable.
14. **Pgp:** Ligand A (0.105) has a lower Pgp efflux liability than Ligand B (0.019), which is preferable.
15. **Binding Affinity:** Ligand B (-7.6) has a significantly stronger binding affinity than Ligand A (-5.8) (a 1.8 kcal/mol difference). This is a substantial advantage.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B's superior affinity is a major plus. However, its significantly lower logP is a concern. Ligand A has a more balanced profile, with a good logP, better TPSA, lower Pgp, and acceptable affinity.
**Overall Assessment:**
While Ligand B boasts a stronger binding affinity, its poor logP and lower BBB penetration are significant drawbacks. Ligand A presents a more balanced profile with better predicted permeability and metabolic properties, despite the slightly weaker binding. Given the importance of balanced ADME properties for *in vivo* efficacy, I favor Ligand A.
Output:
1
2025-04-17 21:26:27,111 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (371.449 and 356.417 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (54.45) is significantly better than Ligand B (68.3). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (2.856 and 2.706), falling within the optimal 1-3 range. Very similar.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (3) is better than Ligand B (6). Lower HBA is generally preferred for permeability.
6. **QED:** Both ligands have similar QED values (0.8 and 0.746), indicating good drug-likeness.
7. **DILI:** Ligand A (40.83) is better than Ligand B (57.154). Lower DILI risk is crucial. Ligand B is approaching a concerning level.
8. **BBB:** Ligand A (95.89) is better than Ligand B (89.608). While not a primary concern for a cardiovascular target, higher BBB is generally favorable.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.422 and -4.71). This is unusual and suggests poor permeability. However, the values are very close.
10. **Solubility:** Ligand A (-3.217) is slightly better than Ligand B (-4.051), indicating better aqueous solubility.
11. **hERG:** Both ligands have similar hERG inhibition liability (0.681 and 0.72), which is acceptable.
12. **Cl_mic:** Ligand A (41.86) is better than Ligand B (47.49). Lower microsomal clearance indicates better metabolic stability.
13. **t1/2:** Ligand A (-0.011) is significantly better than Ligand B (18.592). A negative in vitro half-life is highly unusual and suggests very rapid metabolism for Ligand B.
14. **Pgp:** Ligand A (0.657) is better than Ligand B (0.111). Lower P-gp efflux is preferred for better bioavailability.
15. **Binding Affinity:** Both ligands have the same binding affinity (-6.5 kcal/mol).
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A is better in terms of TPSA, Pgp, and has better ADME properties overall (DILI, Cl_mic, t1/2). While both have equal affinity, the improved ADME profile of Ligand A makes it a more promising candidate.
**Conclusion:**
Ligand A is significantly better than Ligand B due to its superior ADME properties, particularly its lower DILI risk, better metabolic stability (lower Cl_mic, better t1/2), and lower P-gp efflux. The slightly better TPSA and solubility also contribute to its preference.
Output:
1
2025-04-17 21:26:27,112 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (351.39 and 361.43 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (95.13) is slightly higher than Ligand B (79.46). For a cardiovascular GPCR, TPSA is not a primary concern, but lower is generally preferred for better absorption. Ligand B has an advantage.
3. **logP:** Ligand A (4.026) is slightly higher than Ligand B (3.168). While both are within the acceptable 1-3 range, Ligand A is pushing the upper limit. Higher logP can lead to off-target effects and solubility issues. Ligand B is better.
4. **HBD:** Ligand A (2) is lower than Ligand B (3). Lower HBD is generally preferred for permeability. Ligand A has a slight advantage.
5. **HBA:** Ligand A (5) is higher than Ligand B (3). Similar to HBD, lower HBA is generally preferred. Ligand B is better.
6. **QED:** Both ligands have similar QED values (0.742 and 0.704), indicating good drug-like properties. No significant difference.
7. **DILI:** Ligand A (93.951) has a significantly higher DILI risk than Ligand B (32.726). This is a major concern for Ligand A. Ligand B is *much* better.
8. **BBB:** Ligand A (27.724) has a very low BBB penetration, while Ligand B (81.233) has good BBB penetration. While ADRB2 is not strictly a CNS target, some CNS exposure is not necessarily detrimental and can sometimes be beneficial for understanding off-target effects. Ligand B is better.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.987 and -4.44), which is unusual and suggests poor permeability. However, the scale is not defined, so it's difficult to interpret.
10. **Solubility:** Ligand A (-5.961) has worse solubility than Ligand B (-3.668). Solubility is important for bioavailability. Ligand B is better.
11. **hERG:** Both ligands have low hERG inhibition risk (0.613 and 0.468). No significant difference.
12. **Cl_mic:** Ligand A (37.87) has lower microsomal clearance than Ligand B (64.371), indicating better metabolic stability. Ligand A is better.
13. **t1/2:** Ligand A (132.066) has a much longer in vitro half-life than Ligand B (-18.822). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.423) has lower P-gp efflux than Ligand B (0.058), suggesting better bioavailability and potentially better CNS exposure. Ligand A is better.
15. **Binding Affinity:** Ligand B (-7.5 kcal/mol) has a slightly better binding affinity than Ligand A (-7.1 kcal/mol). While the difference is not huge, it's a factor. Ligand B is better.
**Overall Assessment:**
Ligand B clearly outperforms Ligand A in several critical areas. The significantly lower DILI risk is a major advantage, and the better BBB penetration, solubility, and logP are also beneficial. While Ligand A has better metabolic stability (lower Cl_mic) and a longer half-life, the safety concerns associated with its high DILI risk outweigh these benefits. The slight affinity advantage of Ligand B is also a positive.
Output:
0
2025-04-17 21:26:27,112 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 drug candidates. ADRB2 is a GPCR, so we'll prioritize logP, Pgp, TPSA, and affinity, alongside general drug-like properties.
**Ligand A:** [344.455, 47.73, 3.871, 0, 5, 0.763, 11.71, 83.366, -4.868, -3.214, 0.922, 29.622, 1.381, 0.731, -6.1]
**Ligand B:** [350.459, 59.08, 1.598, 0, 4, 0.707, 15.936, 93.563, -4.179, -1.867, 0.364, 57.078, 25.021, 0.044, -6.2]
**1. Molecular Weight:** Both are within the ideal range (200-500 Da). A is 344.455, B is 350.459. No significant difference here.
**2. TPSA:** A (47.73) is better than B (59.08). Both are below 140, but A is closer to the preferred <90 for potential CNS penetration (though ADRB2 isn't necessarily a CNS target).
**3. logP:** A (3.871) is good, within the optimal 1-3 range. B (1.598) is on the lower side, potentially hindering permeability.
**4. H-Bond Donors:** Both have 0, which is good.
**5. H-Bond Acceptors:** A has 5, B has 4. Both are acceptable (<=10).
**6. QED:** Both are good (A: 0.763, B: 0.707), indicating drug-like properties.
**7. DILI:** A (11.71) is significantly better than B (15.936). Lower DILI risk is crucial.
**8. BBB:** B (93.563) is better than A (83.366), but this isn't a primary concern for ADRB2.
**9. Caco-2:** Both are negative, indicating poor permeability. A (-4.868) is slightly worse than B (-4.179).
**10. Solubility:** A (-3.214) is worse than B (-1.867). Solubility is important for bioavailability.
**11. hERG:** A (0.922) is higher than B (0.364), indicating a higher risk of hERG inhibition and cardiotoxicity. This is a significant drawback for A.
**12. Cl_mic:** A (29.622) is much better than B (57.078). Lower clearance means better metabolic stability.
**13. t1/2:** B (25.021) is significantly better than A (1.381). A longer half-life is generally preferred.
**14. Pgp:** A (0.731) is higher than B (0.044). Lower P-gp efflux is better for bioavailability.
**15. Affinity:** B (-6.2) is slightly better than A (-6.1), but the difference is small.
**Overall Assessment:**
Ligand B has a better safety profile (lower DILI, lower hERG) and better pharmacokinetic properties (longer half-life, lower Pgp efflux). While Ligand A has better metabolic stability (lower Cl_mic) and a slightly better TPSA, the safety concerns with hERG and the poorer solubility and half-life are significant drawbacks. The slightly better affinity of B is also a plus. The lower logP of B is a concern, but the other advantages outweigh this.
Therefore, I would choose Ligand B.
Output:
0
2025-04-17 21:26:27,112 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (339.439 and 348.443 Da) fall within the ideal range of 200-500 Da. No significant difference here.
2. **TPSA:** Ligand A (81.99) is higher than Ligand B (59.08). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for permeability. Ligand B is better.
3. **logP:** Ligand A (2.68) is within the optimal range (1-3), while Ligand B (1.375) is at the lower end. For a GPCR, a slightly higher logP is often beneficial for membrane permeability and receptor engagement. Ligand A is better.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (0). Both are acceptable, but fewer HBDs generally improve permeability. Ligand B is better.
5. **HBA:** Ligand A (3) is lower than Ligand B (4). Lower is preferred for permeability. Ligand A is better.
6. **QED:** Ligand A (0.885) has a significantly higher QED score than Ligand B (0.72), indicating a more drug-like profile. Ligand A is better.
7. **DILI:** Ligand B (33.812) has a much lower DILI risk than Ligand A (58.317). This is a significant advantage for Ligand B.
8. **BBB:** Ligand B (60.644) has a higher BBB penetration percentile than Ligand A (48.895). While ADRB2 isn't a CNS target, some degree of BBB penetration can influence off-target effects and overall distribution. Ligand B is better.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.772 and -4.397), which is unusual and suggests poor permeability *in vitro*. This is a concern for both, but the values are similar.
10. **Solubility:** Ligand B (-1.522) has a better solubility score than Ligand A (-4.591). Solubility is important for bioavailability. Ligand B is better.
11. **hERG:** Both ligands have low hERG inhibition risk (0.373 and 0.173). No significant difference.
12. **Cl_mic:** Ligand B (31.681) has a slightly higher microsomal clearance than Ligand A (29.848), indicating potentially lower metabolic stability. Ligand A is better.
13. **t1/2:** Ligand A (-0.134) has a much longer *in vitro* half-life than Ligand B (-11.729). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand B (0.028) has a much lower P-gp efflux liability than Ligand A (0.148). This is a significant advantage for Ligand B.
15. **Binding Affinity:** Ligand B (-6.5 kcal/mol) has a slightly better binding affinity than Ligand A (-5.6 kcal/mol). This 1.5 kcal/mol difference is substantial and can outweigh some ADME drawbacks. Ligand B is better.
**Overall Assessment:**
Ligand B demonstrates a better balance of properties, particularly regarding safety (DILI), solubility, P-gp efflux, and binding affinity. While Ligand A has a better QED and half-life, the lower DILI risk and better affinity of Ligand B are more critical for a cardiovascular GPCR target. The negative Caco-2 values are concerning for both, but the other advantages of Ligand B make it the more promising candidate.
Output:
0
2025-04-17 21:26:27,112 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
We're targeting ADRB2, a GPCR, so the priorities are logP, Pgp, TPSA, affinity, and BBB. Let's break down each ligand across the 15 parameters:
1. **MW:** Both ligands (347.5 and 345.4 Da) are within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (52.65) is better than Ligand B (64.09). Lower TPSA generally favors oral absorption, and both are acceptable, but A is preferred.
3. **logP:** Ligand A (1.733) is within the optimal 1-3 range. Ligand B (0.409) is a bit low, potentially hindering permeability. This is a significant advantage for A.
4. **HBD/HBA:** Both have 1 HBD and are similar in HBA (3 vs 4). Acceptable for both.
5. **QED:** Ligand B (0.784) has a slightly better QED score than Ligand A (0.51), suggesting a more generally drug-like profile.
6. **DILI:** Ligand A (4.886) has a much lower DILI risk than Ligand B (15.936). This is a substantial advantage for A.
7. **BBB:** Ligand A (79.992) has a significantly better BBB penetration score than Ligand B (36.371). While ADRB2 isn't exclusively a CNS target, some peripheral ADRB2 activity can be modulated by CNS effects, and higher BBB penetration is generally favorable, reducing off-target effects.
8. **Caco-2:** Both are similarly poor (-4.87 and -4.827). This suggests limited intestinal absorption for both.
9. **Solubility:** Both have negative solubility scores (-1.131 and -1.028), indicating poor aqueous solubility. This is a concern for both, but not a deciding factor.
10. **hERG:** Ligand A (0.702) has a slightly better hERG profile than Ligand B (0.164), indicating lower cardiotoxicity risk.
11. **Cl_mic:** Ligand B (-3.911) has a much lower (better) microsomal clearance than Ligand A (1.6). This suggests better metabolic stability for B.
12. **t1/2:** Ligand B (-5.718) has a longer in vitro half-life than Ligand A (6.365). This is a positive for B.
13. **Pgp:** Ligand A (0.028) has a much lower Pgp efflux liability than Ligand B (0.018). Lower Pgp is desirable for better bioavailability.
14. **Affinity:** Ligand B (-8.7 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.7 kcal/mol). This is a *major* advantage for B, potentially outweighing some of the ADME concerns.
**Overall Assessment:**
Ligand B has a superior binding affinity, better metabolic stability (lower Cl_mic, longer t1/2), and a slightly better QED score. However, Ligand A excels in DILI risk, BBB penetration, Pgp efflux, and has a more favorable logP. The difference in binding affinity is substantial (3 kcal/mol), and for a GPCR, potency is paramount. While Ligand A has better ADME properties overall, the significantly stronger binding of Ligand B is likely to translate to greater efficacy at lower doses, potentially mitigating some of the ADME liabilities.
**Output:**
0
2025-04-17 21:26:27,112 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (339.4) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (88.39) is better than Ligand B (55.32) - both are below the 140 threshold for oral absorption, but Ligand B is closer to the 90 threshold for CNS targets (though ADRB2 isn't necessarily a CNS target).
3. **logP:** Ligand A (1.463) is within the optimal range (1-3), while Ligand B (3.255) is at the higher end. This could potentially lead to solubility issues for Ligand B.
4. **HBD:** Ligand A (2) is preferable to Ligand B (0) as having some HBD can improve solubility.
5. **HBA:** Both ligands have the same number of HBA (5), which is acceptable.
6. **QED:** Both ligands have similar QED values (0.78 and 0.79), indicating good drug-likeness.
7. **DILI:** Ligand B (39.2) has a significantly lower DILI risk than Ligand A (63.164), which is a major advantage.
8. **BBB:** Ligand B (80.419) has a much higher BBB penetration potential than Ligand A (44.862). While ADRB2 isn't primarily a CNS target, some level of BBB penetration can be beneficial for broader distribution.
9. **Caco-2:** Ligand A (-5.432) has a slightly better Caco-2 permeability than Ligand B (-4.625).
10. **Solubility:** Ligand A (-2.887) has better aqueous solubility than Ligand B (-3.061).
11. **hERG:** Ligand A (0.173) has a lower hERG inhibition liability than Ligand B (0.721). This is a significant safety advantage.
12. **Cl_mic:** Ligand A (2.961) has a much lower microsomal clearance than Ligand B (40.209), indicating better metabolic stability.
13. **t1/2:** Ligand B (11.048) has a significantly longer in vitro half-life than Ligand A (1.584). This is a substantial advantage for dosing frequency.
14. **Pgp:** Ligand A (0.026) has a lower P-gp efflux liability than Ligand B (0.286), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand A (-7.7) has a significantly stronger binding affinity than Ligand B (-6.4). This difference of 1.3 kcal/mol is substantial and can outweigh some ADME concerns.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand B has a better logP and Pgp profile, and a superior BBB score. However, Ligand A's significantly better affinity (-7.7 vs -6.4) is a major driver. The lower clearance and hERG risk of Ligand A are also important positives.
**Overall Assessment:**
While Ligand B has advantages in DILI, BBB, and half-life, the substantially stronger binding affinity of Ligand A, coupled with its lower hERG risk and clearance, makes it the more promising candidate. The affinity difference is large enough to compensate for the slightly less favorable ADME properties.
Output:
1
2025-04-17 21:26:27,113 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [354.426, 105.48 , 1.501, 4. , 5. , 0.418, 52.152, 68.321, -5.165, -2.92 , 0.74 , 44.845, 0.745, 0.063, -6.6 ]
**Ligand B:** [353.463, 98.74 , 0.561, 3. , 4. , 0.623, 14.114, 28.189, -5.291, -1.153, 0.079, -6.167, 3.822, 0.011, -5.6 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal 200-500 Da range. A (354.426) and B (353.463) are very close, so no significant difference here.
2. **TPSA:** A (105.48) is slightly above the preferred <140 for good oral absorption, but acceptable. B (98.74) is better, closer to the ideal.
3. **logP:** A (1.501) is within the optimal 1-3 range. B (0.561) is a little low, potentially impacting permeability.
4. **HBD:** A (4) is acceptable. B (3) is also good.
5. **HBA:** Both A (5) and B (4) are within the acceptable range of <=10.
6. **QED:** A (0.418) is below the preferred 0.5, indicating a less drug-like profile. B (0.623) is better, exceeding the 0.5 threshold.
7. **DILI:** A (52.152) is moderate, but acceptable. B (14.114) is *much* lower, indicating a significantly reduced risk of liver injury. This is a major advantage for B.
8. **BBB:** A (68.321) is decent, but B (28.189) is quite low. While ADRB2 isn't necessarily a CNS target, some peripheral ADRB2 activity can have central effects, and a higher BBB value is generally preferable.
9. **Caco-2:** Both A (-5.165) and B (-5.291) have negative values, which is unusual. These values likely represent logP-corrected Caco-2 permeability, and lower (more negative) values indicate lower permeability. They are very similar, and both suggest poor permeability.
10. **Solubility:** A (-2.92) and B (-1.153) both indicate poor aqueous solubility. B is better here.
11. **hERG:** A (0.74) is moderate. B (0.079) is very low, indicating a much lower risk of cardiotoxicity. This is a significant advantage for B, given ADRB2's cardiovascular involvement.
12. **Cl_mic:** A (44.845) is moderate. B (-6.167) is excellent, indicating very high metabolic stability.
13. **t1/2:** A (0.745) is very short. B (3.822) is much better, suggesting a longer duration of action.
14. **Pgp:** A (0.063) is low, indicating minimal P-gp efflux. B (0.011) is even lower, which is beneficial.
15. **Affinity:** A (-6.6) is slightly better than B (-5.6), a difference of 1.0 kcal/mol.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. While A has a slightly better affinity, B excels in several other crucial areas: lower DILI risk, significantly lower hERG inhibition, better metabolic stability (Cl_mic and t1/2), and lower Pgp efflux. The slightly lower logP of B is a concern, but the other advantages outweigh this. The Caco-2 permeability is poor for both, but can be addressed in formulation.
**Conclusion:**
Considering the balance of properties and the priorities for a cardiovascular GPCR target, Ligand B is the more promising drug candidate. Its superior safety profile (DILI, hERG) and improved pharmacokinetic properties (Cl_mic, t1/2, Pgp) outweigh the slightly weaker binding affinity and lower logP.
0
2025-04-17 21:26:27,113 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (335.451 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (54.02) is better than Ligand B (60.85). Both are acceptable, but lower TPSA generally improves oral absorption.
3. **logP:** Ligand B (2.362) is better than Ligand A (4.35). Ligand A is a bit high, potentially leading to solubility issues and off-target interactions.
4. **HBD:** Ligand A (2) is slightly better than Ligand B (1). Both are good.
5. **HBA:** Ligand A (2) is better than Ligand B (3). Both are good.
6. **QED:** Both ligands have similar QED values (0.873 and 0.837), indicating good drug-likeness.
7. **DILI:** Ligand B (20.9) is *significantly* better than Ligand A (55.176). This is a major advantage for Ligand B, as liver toxicity is a critical concern.
8. **BBB:** Ligand A (87.747) is better than Ligand B (75.727). While ADRB2 isn't necessarily a CNS target, some peripheral effects may be mediated by CNS penetration, and higher BBB is generally a plus.
9. **Caco-2:** Both ligands have very poor Caco-2 permeability (-4.713 and -4.904). This is a significant drawback for both.
10. **Solubility:** Ligand B (-2.192) is better than Ligand A (-4.726). Solubility is a concern for Ligand A due to its higher logP.
11. **hERG:** Both ligands have similar, low hERG risk (0.795 and 0.348).
12. **Cl_mic:** Ligand B (-13.188) is *much* better than Ligand A (53.981). This indicates significantly improved metabolic stability for Ligand B.
13. **t1/2:** Ligand B (-19.679) is *much* better than Ligand A (79.279). This also indicates significantly improved metabolic stability and longer duration of action for Ligand B.
14. **Pgp:** Ligand A (0.41) is better than Ligand B (0.019). Lower P-gp efflux is generally preferred.
15. **Affinity:** Both ligands have the same binding affinity (-4.0 kcal/mol).
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand A has a better logP and Pgp, but Ligand B excels in metabolic stability (Cl_mic and t1/2) and has a much lower DILI risk. The poor Caco-2 permeability is a concern for both, but the significant advantages of Ligand B in safety (DILI) and pharmacokinetics (Cl_mic, t1/2) outweigh the slightly better permeability profile of Ligand A.
**Conclusion:**
Despite the similar binding affinity and the slightly better BBB penetration of Ligand A, the significantly lower DILI risk and superior metabolic stability of Ligand B make it the more promising drug candidate.
Output:
0
2025-04-17 21:26:27,113 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (352.45 and 361.222 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (78.43) is slightly higher than Ligand B (69.44). Both are below the 140 A^2 threshold for good oral absorption, but Ligand B is preferable due to its lower TPSA.
**3. logP:** Ligand A (2.557) is within the optimal 1-3 range. Ligand B (4.369) is higher, potentially leading to solubility issues and off-target interactions. This favors Ligand A.
**4. H-Bond Donors:** Ligand A has 3 HBD, which is acceptable. Ligand B has 0, which is also acceptable. No clear preference.
**5. H-Bond Acceptors:** Both ligands have 3-4 HBAs, which is within the acceptable range. No clear preference.
**6. QED:** Ligand A (0.639) has a significantly better QED score than Ligand B (0.267), indicating a more drug-like profile. This is a strong advantage for Ligand A.
**7. DILI Risk:** Ligand A (31.059%) has a much lower DILI risk than Ligand B (82.823%). This is a critical advantage for Ligand A, as liver toxicity is a major concern in drug development.
**8. BBB Penetration:** Both ligands have reasonable BBB penetration (Ligand A: 62.544%, Ligand B: 70.26%). While ADRB2 is a cardiovascular target, some CNS effects are possible with beta-blockers, so moderate BBB penetration isn't necessarily detrimental. Ligand B is slightly better here.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.639 and -4.578), which is unusual and suggests poor permeability. This is a concern for both, but the values are very similar.
**10. Aqueous Solubility:** Ligand A (-3.125) has better solubility than Ligand B (-5.809). This is an advantage for Ligand A, especially given Ligand B's higher logP.
**11. hERG Inhibition:** Both ligands have relatively low hERG inhibition risk (0.774 and 0.642). No significant difference.
**12. Microsomal Clearance:** Ligand A (42.922) has lower microsomal clearance than Ligand B (61.459), suggesting better metabolic stability. This is a positive for Ligand A.
**13. In vitro Half-Life:** Ligand A (36.458) has a longer in vitro half-life than Ligand B (29.202), which is desirable for less frequent dosing. This favors Ligand A.
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (0.358 and 0.289). No significant difference.
**15. Binding Affinity:** Ligand B (-6.9 kcal/mol) has a slightly better binding affinity than Ligand A (-6.4 kcal/mol). While a 0.5 kcal/mol difference is noticeable, it's not a massive advantage, and can be overcome by other favorable ADME properties.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity) and the general drug-like properties, **Ligand A is the more promising candidate.** While Ligand B has slightly better binding affinity and BBB penetration, Ligand A excels in crucial areas like QED, DILI risk, solubility, metabolic stability, and half-life. The higher logP of Ligand B is a significant concern, potentially leading to poor solubility and off-target effects. The significantly lower DILI risk of Ligand A is a major advantage.
Output:
1
2025-04-17 21:26:27,113 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's systematically compare Ligand A and Ligand B based on the provided parameters, keeping in mind the GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key).
1. **MW:** Both ligands (344.419 Da and 354.397 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand B (57.69) is significantly better than Ligand A (106.97). Lower TPSA generally translates to better cell permeability, which is crucial for GPCR targeting.
3. **logP:** Both ligands have acceptable logP values (0.954 and 1.357, respectively), falling within the 1-3 range. Ligand B is slightly better.
4. **HBD:** Ligand A has 3 HBD, while Ligand B has 0. Lower HBD is generally preferred for better permeability, giving an edge to Ligand B.
5. **HBA:** Ligand A has 6 HBA, Ligand B has 3. Again, Ligand B is better.
6. **QED:** Both ligands have good QED scores (0.695 and 0.752), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand B (35.905) has a significantly lower DILI risk than Ligand A (53.742). This is a major advantage for Ligand B.
8. **BBB:** Ligand B (87.67) has a much higher BBB penetration potential than Ligand A (55.099). While ADRB2 isn't strictly a CNS target, some CNS exposure can occur, and higher BBB is generally favorable.
9. **Caco-2:** Ligand B (-4.651) is better than Ligand A (-5.747).
10. **Solubility:** Ligand B (-1.933) is better than Ligand A (-2.42).
11. **hERG:** Both ligands have very low hERG inhibition risk (0.204 and 0.226). No significant difference.
12. **Cl_mic:** Ligand A (-21.283) has significantly lower microsomal clearance than Ligand B (16.934), suggesting better metabolic stability. This is a key advantage for Ligand A.
13. **t1/2:** Ligand A (43.543) has a better in vitro half-life than Ligand B (-22.695). This supports the better metabolic stability suggested by Cl_mic.
14. **Pgp:** Ligand A (0.028) has much lower P-gp efflux liability than Ligand B (0.114). Lower P-gp efflux is desirable for better bioavailability.
15. **Affinity:** Both ligands have very similar binding affinities (-7.0 kcal/mol and -7.2 kcal/mol). The difference is negligible.
**Overall Assessment:**
Ligand B excels in most ADME properties (TPSA, logP, HBD, HBA, QED, DILI, BBB, Caco-2, Solubility) and has comparable affinity to Ligand A. While Ligand A has better metabolic stability (Cl_mic, t1/2) and lower P-gp efflux, the improvements in ADME and safety profile of Ligand B are more compelling, especially considering the GPCR target class. The lower DILI risk is a significant benefit.
**Output:**
0
2025-04-17 21:26:27,113 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (338.371 and 352.351 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (100.8) is significantly better than Ligand B (139.47). For a GPCR, keeping TPSA under 140 is good, and A is closer to the optimal <90 for CNS penetration (though ADRB2 isn't necessarily a CNS target).
3. **logP:** Ligand A (2.177) is within the optimal 1-3 range. Ligand B (-0.815) is *below* 1, which is a concern for permeability. This is a significant negative for B.
4. **HBD:** Both ligands have acceptable HBD counts (1 and 2 respectively), well below the threshold of 5.
5. **HBA:** Both ligands have acceptable HBA counts (6 and 7 respectively), below the threshold of 10.
6. **QED:** Ligand A (0.785) has a much better QED score than Ligand B (0.39), indicating better overall drug-likeness.
7. **DILI:** Both ligands have relatively high DILI risk (91.314 and 59.907), but Ligand B is considerably lower. This is a point in favor of B.
8. **BBB:** Ligand A (46.413) has a lower BBB penetration score than Ligand B (59.636). While ADRB2 isn't a primary CNS target, some peripheral distribution is still desired.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.274 and -5.19), which is unusual and suggests poor permeability. However, these values are on a scale where negative values are possible, so it's not immediately disqualifying.
10. **Solubility:** Both ligands have negative solubility values (-2.991 and -2.27), indicating poor aqueous solubility. This is a concern for both.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.267 and 0.161), which is excellent.
12. **Cl_mic:** Ligand B (-7.671) has a *negative* microsomal clearance, which is highly unusual and suggests very high metabolic stability. Ligand A (60.32) is more typical.
13. **t1/2:** Ligand B (-7.717) also has a negative in vitro half-life, which is also highly unusual. Ligand A (-38.017) is more typical.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.074 and 0.019).
15. **Binding Affinity:** Ligand A (-6.9 kcal/mol) has slightly better binding affinity than Ligand B (-6.2 kcal/mol). While the difference is less than the 1.5 kcal/mol threshold, it's still a positive for A.
**Overall Assessment:**
Ligand A is generally superior. The biggest issue with Ligand B is its low logP, which is a major red flag for permeability and oral bioavailability. While Ligand B has a lower DILI risk and the unusual negative clearance and half-life values, these are likely artifacts of the modeling and are less concerning than the permeability issue. Ligand A has better drug-likeness (QED), better affinity, and a more reasonable logP. The TPSA is also favorable.
Output:
1
2025-04-17 21:26:27,114 - INFO - Here's my reasoning and the final output:
**Reasoning:**
We are evaluating two ligands for their potential as drug candidates targeting the ADRB2, a cardiovascular GPCR. Therefore, logP, TPSA, Pgp, and binding affinity are key considerations, alongside general drug-like properties.
Let's break down the comparison:
1. **MW:** Both ligands (348.49 and 352.43 Da) are within the ideal range (200-500 Da).
2. **TPSA:** Ligand A (58.64) is significantly better than Ligand B (92.01). A TPSA under 140 is good for oral absorption, but lower is preferred for GPCRs, and A is considerably lower.
3. **logP:** Both ligands have acceptable logP values (2.487 and 1.413), falling within the 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability.
4. **HBD/HBA:** Ligand A (1 HBD, 3 HBA) is preferable to Ligand B (2 HBD, 5 HBA). Fewer hydrogen bonds generally improve permeability.
5. **QED:** Ligand A (0.83) has a better QED score than Ligand B (0.664), indicating a more drug-like profile.
6. **DILI:** Ligand A (12.64) has a lower DILI risk than Ligand B (15.08), which is a positive.
7. **BBB:** Ligand A (76.81) has a higher BBB penetration percentile than Ligand B (62.54). While not a CNS target, some degree of BBB penetration can be indicative of good membrane permeability.
8. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests potential issues with permeability prediction. However, the values are similar.
9. **Solubility:** Ligand A (-3.158) has slightly better solubility than Ligand B (-1.719).
10. **hERG:** Both ligands have low hERG inhibition risk (0.389 and 0.314).
11. **Cl_mic:** Ligand B (31.03) has a lower microsomal clearance than Ligand A (36.26), suggesting better metabolic stability.
12. **t1/2:** Ligand B (27.49) has a longer in vitro half-life than Ligand A (12.14), which is favorable.
13. **Pgp:** Both ligands have low P-gp efflux liability (0.097 and 0.091).
14. **Binding Affinity:** Ligand A (-7.5 kcal/mol) has a significantly stronger binding affinity than Ligand B (-5.5 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME drawbacks of Ligand A.
**Overall Assessment:**
Ligand A has a superior profile overall, primarily due to its significantly stronger binding affinity and better TPSA, QED, and DILI scores. While Ligand B has better metabolic stability (lower Cl_mic) and half-life, the difference in binding affinity is substantial enough to make Ligand A the more promising candidate. The lower TPSA of Ligand A is also a significant advantage for a GPCR target.
**Output:**
1
2025-04-17 21:26:27,114 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor (a GPCR).
**Ligand A:** [386.901, 66.92, 2.37, 0, 4, 0.796, 60.954, 63.746, -4.411, -3.963, 0.401, 53.565, -33.435, 0.203, -7.1]
**Ligand B:** [342.439, 62.55, 2.364, 1, 3, 0.863, 20.396, 57.193, -5.184, -2.903, 0.266, 34.674, 31.134, 0.154, -6.3]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity) and general drug-like properties:
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (342.439 Da) is slightly preferred due to being lower.
2. **TPSA:** Both are acceptable (below 140). Ligand B (62.55) is better than Ligand A (66.92).
3. **logP:** Both are excellent (around 2.36-2.37), falling within the optimal 1-3 range. No significant difference here.
4. **HBD:** Ligand A (0) is preferred over Ligand B (1). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is slightly higher than Ligand B (3), but both are within acceptable limits.
6. **QED:** Both have good QED scores (A: 0.796, B: 0.863). Ligand B is slightly better.
7. **DILI:** Ligand B (20.396%) is *significantly* better than Ligand A (60.954%). This is a major advantage for Ligand B.
8. **BBB:** Ligand A (63.746%) is better than Ligand B (57.193%). While not a primary concern for ADRB2 (cardiovascular target), it's a slight positive for A.
9. **Caco-2:** Ligand B (-5.184) is better than Ligand A (-4.411), indicating better intestinal absorption.
10. **Solubility:** Ligand B (-2.903) is better than Ligand A (-3.963).
11. **hERG:** Both are low (0.401 and 0.266), indicating low cardiotoxicity risk. Ligand B is slightly better.
12. **Cl_mic:** Ligand B (34.674) has a lower clearance than Ligand A (53.565), suggesting better metabolic stability.
13. **t1/2:** Ligand B (31.134) has a longer half-life than Ligand A (-33.435). This is a significant advantage.
14. **Pgp:** Ligand B (0.154) has lower P-gp efflux than Ligand A (0.203), which is favorable for bioavailability.
15. **Affinity:** Ligand A (-7.1 kcal/mol) has a slightly better binding affinity than Ligand B (-6.3 kcal/mol). This is a 0.8 kcal/mol difference.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity, the advantages of Ligand B across multiple critical ADME-Tox properties are compelling. Specifically, the *much* lower DILI risk, better solubility, improved metabolic stability (lower Cl_mic and longer t1/2), and lower Pgp efflux make Ligand B a more promising drug candidate. The 0.8 kcal/mol difference in binding affinity is unlikely to outweigh these substantial ADME benefits, especially for a cardiovascular target where CNS penetration isn't paramount.
Output:
0
2025-04-17 21:26:27,114 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (348.403) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (49.41) is significantly better than Ligand A (96.69). ADRB2 is a cardiovascular target, not a CNS target, but lower TPSA is still generally preferred for absorption.
3. **logP:** Ligand B (2.85) is optimal, while Ligand A (0.216) is quite low, potentially hindering membrane permeability. This is a significant drawback for Ligand A.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable.
5. **HBA:** Ligand A (6) and Ligand B (3) are both acceptable.
6. **QED:** Both ligands are similar (0.793 vs 0.765), indicating good drug-likeness.
7. **DILI:** Ligand B (29.818) has a much lower DILI risk than Ligand A (58.24), which is a major advantage.
8. **BBB:** This is less critical for a cardiovascular target. Ligand B (76.231) is higher, but not a deciding factor.
9. **Caco-2:** Both have negative values, indicating poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Ligand A (-1.328) is better than Ligand B (-3.775), but both are poor.
11. **hERG:** Ligand A (0.068) has a lower hERG risk than Ligand B (0.399), which is a positive.
12. **Cl_mic:** Ligand A (11.525) has significantly lower microsomal clearance, suggesting better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand B (-15.836) has a much longer in vitro half-life than Ligand A (8.421). This is a major advantage for Ligand B.
14. **Pgp:** Ligand A (0.019) has significantly lower P-gp efflux, which is favorable for bioavailability.
15. **Binding Affinity:** Ligand B (-6.1) has a slightly better binding affinity than Ligand A (-5.1). While the difference is less than the 1.5 kcal/mol threshold, it contributes to the overall preference.
**Overall Assessment:**
Ligand B is the stronger candidate. While Ligand A has advantages in metabolic stability (Cl_mic) and P-gp efflux, Ligand B's superior logP, lower DILI risk, and longer half-life are more critical for a successful drug candidate. The slightly better binding affinity of Ligand B further supports this conclusion. The poor solubility of both is a concern that would need to be addressed in formulation, but the other ADME properties of Ligand B are more favorable overall.
Output:
0
2025-04-17 21:26:27,114 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (367.873 and 354.51 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand B (49.41) is significantly better than Ligand A (75.63). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands (3.249 and 3.408) are within the optimal 1-3 range. Very similar.
4. **HBD:** Ligand B (1) is preferable to Ligand A (2) as lower HBDs generally improve permeability.
5. **HBA:** Ligand B (2) is preferable to Ligand A (4) for similar reasons as HBD.
6. **QED:** Ligand A (0.757) is slightly better than Ligand B (0.69), indicating a marginally more drug-like profile.
7. **DILI:** Ligand B (19.038) is significantly better than Ligand A (15.394), indicating a lower risk of drug-induced liver injury. This is a crucial factor.
8. **BBB:** Ligand B (89.221) is much better than Ligand A (46.879). While ADRB2 isn't a CNS target, higher BBB penetration can sometimes indicate better overall permeability and reduced off-target effects.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-4.451) is slightly worse than Ligand B (-4.31).
10. **Solubility:** Both ligands have very poor solubility (-3.727 and -4.127). This is a significant concern for both.
11. **hERG:** Ligand A (0.254) is better than Ligand B (0.78), indicating lower cardiotoxicity risk. This is important for a cardiovascular target.
12. **Cl_mic:** Ligand A (55.11) is better than Ligand B (74.078), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-10.679) is much better than Ligand A (11.13), indicating a longer half-life.
14. **Pgp:** Both ligands have very low Pgp efflux (0.115 and 0.351).
15. **Binding Affinity:** Ligand B (-5.9) is significantly better than Ligand A (-5.0). This is a substantial difference in potency.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in TPSA and affinity, and is comparable in logP and Pgp. The superior affinity of Ligand B is a major advantage. While solubility is poor for both, the better DILI and half-life profiles of Ligand B are also very desirable. The hERG risk is slightly higher for Ligand B, but the substantial affinity advantage outweighs this concern.
**Conclusion:**
Despite the solubility issues with both, Ligand B is the more promising candidate due to its superior binding affinity, lower DILI risk, better half-life, and favorable TPSA.
0
2025-04-17 21:26:27,114 - INFO - Batch 258 complete. Total preferences: 4128
2025-04-17 21:26:27,114 - INFO - Processing batch 259/512...
2025-04-17 21:27:16,105 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (355.435 Da) is slightly higher than Ligand B (348.487 Da), but both are acceptable.
2. **TPSA:** Ligand A (99.18) is higher than Ligand B (62.55). For a cardiovascular GPCR like ADRB2, TPSA is moderately important. Ligand B's lower TPSA is preferable, suggesting better permeability.
3. **logP:** Ligand A (-0.498) is lower than the optimal range (1-3), potentially hindering permeability. Ligand B (3.69) is within the optimal range. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable.
5. **HBA:** Ligand A (6) and Ligand B (3) are both acceptable.
6. **QED:** Both ligands have good QED scores (A: 0.598, B: 0.779), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (10.237) has a much lower DILI risk than Ligand B (21.598). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (51.377) has a lower BBB penetration than Ligand B (77.007). While ADRB2 isn't a CNS target, some degree of BBB penetration isn't necessarily detrimental, and Ligand B is better here.
9. **Caco-2:** Ligand A (-5.087) and Ligand B (-4.416) are both negative, which is unusual. A higher value is preferred. Both are poor, but B is slightly better.
10. **Solubility:** Ligand A (0.202) has very poor solubility, while Ligand B (-3.624) is also poor. This is a concern for both, but Ligand A is worse.
11. **hERG:** Ligand A (0.117) has a lower hERG risk than Ligand B (0.557). This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand A (1.367) has a much lower microsomal clearance than Ligand B (77.061), indicating better metabolic stability. This is a major advantage for Ligand A.
13. **t1/2:** Ligand A (-13.199) has a negative in vitro half-life, which is not possible. This is a major red flag. Ligand B (46.428) has a reasonable half-life.
14. **Pgp:** Ligand A (0.013) has a lower P-gp efflux liability than Ligand B (0.229). This is a slight advantage for Ligand A.
15. **Binding Affinity:** Ligand B (-7.0) has a significantly stronger binding affinity than Ligand A (-5.2). This is a substantial advantage for Ligand B, potentially outweighing some ADME concerns.
**Overall Assessment:**
Ligand B has a better logP, QED, BBB, t1/2 and, most importantly, significantly better binding affinity. However, it suffers from higher DILI risk and higher Pgp efflux. Ligand A has better DILI, hERG, Cl_mic and Pgp, but has a very poor solubility and an impossible half-life.
The binding affinity difference is substantial (-7.0 vs -5.2 kcal/mol). Considering ADRB2 is a GPCR, affinity is paramount. The solubility and metabolic stability issues of Ligand A are concerning, and the negative half-life is a showstopper. While Ligand B's DILI risk is higher, it's not excessively so, and can potentially be addressed through further optimization.
Therefore, I favor Ligand B.
Output:
0
2025-04-17 21:27:16,105 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (352.431 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (77.1) is better than Ligand B (104.39). Both are below 140, but lower TPSA is preferred for oral absorption, especially for GPCRs.
3. **logP:** Both ligands have similar logP values (A: 1.679, B: 1.789) and fall within the optimal range of 1-3.
4. **HBD:** Ligand A (1) is better than Ligand B (2). Lower HBD is generally preferred for better permeability.
5. **HBA:** Both ligands have the same number of HBA (5), which is within the acceptable limit of 10.
6. **QED:** Ligand A (0.779) has a slightly higher QED than Ligand B (0.693), indicating a more drug-like profile.
7. **DILI:** Both ligands have acceptable DILI risk (A: 51.105, B: 48.623), both under the 60 threshold.
8. **BBB:** Ligand B (76.464) has a better BBB penetration score than Ligand A (67.158). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be beneficial or at least not detrimental.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and indicates poor permeability. Ligand A (-5.011) is slightly better than Ligand B (-5.229), but both are concerning.
10. **Solubility:** Ligand A (-1.79) has better aqueous solubility than Ligand B (-3.233). Solubility is important for bioavailability.
11. **hERG:** Both ligands have very low hERG inhibition liability (A: 0.172, B: 0.252), which is excellent.
12. **Cl_mic:** Ligand B (-8.159) has a significantly lower (better) microsomal clearance than Ligand A (-2.471), suggesting greater metabolic stability.
13. **t1/2:** Ligand B (-17.718) has a much longer in vitro half-life than Ligand A (14.729), which is a major advantage.
14. **Pgp:** Both ligands have very low P-gp efflux liability (A: 0.031, B: 0.048), which is favorable.
15. **Binding Affinity:** Ligand B (-7.2 kcal/mol) has a slightly better binding affinity than Ligand A (-6.0 kcal/mol). This difference of 1.2 kcal/mol is significant and can outweigh some ADME drawbacks.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Both ligands are good on logP and Pgp. Ligand A has a better TPSA, but Ligand B has a significantly better binding affinity and metabolic stability (Cl_mic, t1/2). The improved binding affinity and half-life of Ligand B are compelling, and the slightly higher BBB penetration is a bonus. While the Caco-2 values are poor for both, the other advantages of Ligand B are more impactful.
**Conclusion:**
Despite the poor Caco-2 permeability for both, Ligand B's superior binding affinity, metabolic stability, and half-life make it the more promising drug candidate.
Output:
0
2025-04-17 21:27:16,105 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [358.429, 67.43, 3.236, 2, 3, 0.542, 42.071, 89.492, -4.106, -3.785, 0.724, 62.115, -11.834, 0.203, -5.9]
**Ligand B:** [358.439, 109, -0.678, 3, 5, 0.506, 19.271, 69.523, -5.155, -0.361, 0.091, -2.97, -1.363, 0.001, -6.6]
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (around 358 Da). No significant difference.
2. **TPSA:** Ligand A (67.43) is significantly better than Ligand B (109). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better permeability.
3. **logP:** Ligand A (3.236) is optimal. Ligand B (-0.678) is quite low, potentially hindering membrane permeability and bioavailability. This is a significant drawback.
4. **HBD:** Both have acceptable HBD counts (2 and 3).
5. **HBA:** Ligand A (3) is better than Ligand B (5) - lower is generally preferred.
6. **QED:** Both are good (0.542 and 0.506), indicating reasonable drug-likeness.
7. **DILI:** Ligand A (42.071) is better than Ligand B (19.271), indicating a lower risk of drug-induced liver injury.
8. **BBB:** Ligand A (89.492) is better than Ligand B (69.523), but as this is a cardiovascular target, this isn't a primary concern.
9. **Caco-2:** Ligand A (-4.106) is better than Ligand B (-5.155), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-3.785) is better than Ligand B (-0.361), which is important for bioavailability.
11. **hERG:** Ligand A (0.724) is better than Ligand B (0.091), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand B (-2.97) has a *negative* clearance, which is highly unusual and suggests very high metabolic stability. Ligand A (62.115) is moderate.
13. **t1/2:** Ligand A (-11.834) is better than Ligand B (-1.363), indicating a longer half-life.
14. **Pgp:** Ligand A (0.203) is better than Ligand B (0.001), indicating lower P-gp efflux.
15. **Affinity:** Ligand B (-6.6) is slightly better than Ligand A (-5.9), a difference of 0.7 kcal/mol.
**GPCR-specific priorities:** For ADRB2 (a cardiovascular GPCR), we prioritize logP, TPSA, Pgp, and affinity. Ligand A excels in logP, TPSA, and Pgp. Ligand B has a slightly better affinity, but the significant drawbacks in logP and solubility are concerning. The negative clearance for ligand B is also a red flag, as it is not physically realistic.
**Conclusion:**
While Ligand B has a slightly better binding affinity, the significantly poorer logP, solubility, and the unusual negative clearance outweigh this advantage. Ligand A presents a more balanced profile with better predicted ADME properties and a lower risk profile.
Output:
1
2025-04-17 21:27:16,105 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (355.467 Da) is slightly lower, which can be beneficial for permeability.
2. **TPSA:** Ligand A (82.77) is better than Ligand B (104.12). ADRB2 is not a CNS target, but lower TPSA generally improves absorption.
3. **logP:** Ligand A (2.836) is optimal, while Ligand B (0.586) is quite low. This is a significant drawback for Ligand B, potentially hindering membrane permeability and bioavailability.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (6) is better than Ligand B (7).
6. **QED:** Both ligands have similar, acceptable QED values (0.759 and 0.735).
7. **DILI:** Both ligands have similar, acceptable DILI risk (63.164 and 62.001).
8. **BBB:** Not a primary concern for ADRB2, but Ligand A (64.211) is slightly better than Ligand B (60.45).
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.024 and -5.061). This is unusual and suggests poor permeability *in vitro*. However, this is a relative comparison, and we must consider other factors.
10. **Solubility:** Ligand A (-3.712) is slightly better than Ligand B (-2.082), though both are poor.
11. **hERG:** Ligand A (0.547) is better than Ligand B (0.148). Lower hERG inhibition is crucial for cardiovascular safety.
12. **Cl_mic:** Ligand A (87.839) has significantly higher metabolic clearance than Ligand B (21.464). This is a major disadvantage for Ligand A.
13. **t1/2:** Ligand B (7.81) has a longer half-life than Ligand A (4.685).
14. **Pgp:** Ligand A (0.171) is better than Ligand B (0.029). Lower P-gp efflux is preferable.
15. **Binding Affinity:** Ligand A (-6.1 kcal/mol) is slightly better than Ligand B (-5.9 kcal/mol). While the difference is small, it's still a factor.
**Overall Assessment:**
Ligand B has a major advantage in metabolic stability (Cl_mic and t1/2) and a better hERG profile. However, its low logP is a significant concern, potentially leading to poor absorption and bioavailability. Ligand A has a better logP, slightly better affinity, and Pgp efflux, but suffers from higher metabolic clearance.
Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity), and the fact that this is a cardiovascular target (where metabolic stability is important), Ligand B's superior metabolic profile and safety (hERG) outweigh the concerns about its low logP. Formulation strategies could be explored to mitigate the solubility/absorption issues associated with the lower logP. The slight affinity difference is not enough to overcome the metabolic and safety advantages of Ligand B.
Output:
0
2025-04-17 21:27:16,105 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [353.507, 61.88, 1.639, 1, 4, 0.721, 4.653, 72.237, -4.626, -0.969, 0.344, 24.678, -12.898, 0.021, -5.9]
**Ligand B:** [362.543, 58.12, 3.573, 1, 5, 0.805, 50.174, 83.637, -4.761, -4.841, 0.262, 76.588, 43.996, 0.4, -6.8]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, Affinity, and BBB):
1. **MW:** Both are within the ideal range (200-500 Da). A is 353.5, B is 362.5. Slight edge to A for being a bit lower.
2. **TPSA:** Both are good, under 140. A is 61.88, B is 58.12. B is slightly better.
3. **logP:** A (1.639) is optimal. B (3.573) is pushing the upper limit, potentially leading to solubility issues and off-target effects. A is better.
4. **HBD:** Both have 1 HBD, ideal.
5. **HBA:** A has 4, B has 5. Both are acceptable, but A is slightly preferred.
6. **QED:** Both are good (>0.5). B (0.805) is slightly better than A (0.721).
7. **DILI:** A (4.653) is excellent, very low risk. B (50.174) is moderately elevated, but not alarming. A is significantly better.
8. **BBB:** A (72.237) is good, B (83.637) is very good. B is better.
9. **Caco-2:** Both are negative, indicating poor permeability. B (-4.761) is worse than A (-4.626). A is slightly better.
10. **Solubility:** Both are negative, indicating poor solubility. A (-0.969) is better than B (-4.841).
11. **hERG:** Both are very low risk. A (0.344) is slightly better than B (0.262).
12. **Cl_mic:** A (24.678) is much lower (better metabolic stability) than B (76.588). A is significantly better.
13. **t1/2:** A (-12.898) is negative, which is unusual and suggests very rapid clearance. B (43.996) is positive, indicating a longer half-life. B is significantly better.
14. **Pgp:** A (0.021) is very low efflux, B (0.4) is slightly higher. A is better.
15. **Affinity:** B (-6.8 kcal/mol) is 0.9 kcal/mol stronger than A (-5.9 kcal/mol). This is a substantial difference in binding. B is significantly better.
**Overall Assessment:**
While Ligand B has a better BBB penetration and a significantly stronger binding affinity, it suffers from higher DILI risk, poorer solubility, and significantly higher microsomal clearance. Ligand A has superior ADME properties (DILI, Cl_mic, solubility, Pgp) and a reasonable binding affinity. The affinity difference is substantial, but the ADME profile of B is concerning. Given the GPCR target class, a balance between potency and drug-like properties is crucial. The improved ADME profile of Ligand A, particularly the lower DILI and better metabolic stability, outweighs the affinity difference.
Output: 1
2025-04-17 21:27:16,105 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (a cardiovascular GPCR) drug candidates.
**Ligand A:** [347.503, 52.65, 2.014, 1, 3, 0.8, 5.545, 68.864, -4.927, -1.68, 0.36, -1.731, -2.94, 0.038, -7.9]
**Ligand B:** [373.837, 93.9, 1.614, 1, 6, 0.73, 50.136, 81.039, -4.678, -2.63, 0.263, 25.418, -5.144, 0.168, -6]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity, and, to a lesser extent, BBB):
1. **MW:** Both are within the ideal 200-500 Da range. Ligand A (347.5) is slightly preferred.
2. **TPSA:** Ligand A (52.65) is excellent, well below 140, and suggesting good absorption. Ligand B (93.9) is higher, but still acceptable.
3. **logP:** Both are good (1.6-2.0), falling within the optimal 1-3 range. Ligand A (2.014) is slightly higher, which can be beneficial for membrane permeability.
4. **HBD/HBA:** Both have 1 HBD, which is good. Ligand A has 3 HBA, Ligand B has 6. Ligand A is preferred here.
5. **QED:** Both are reasonably good (0.8 and 0.73), indicating drug-like properties. Ligand A is slightly better.
6. **DILI:** Ligand A (5.545) has a significantly lower DILI risk than Ligand B (50.136). This is a major advantage.
7. **BBB:** Ligand B (81.039) has better BBB penetration than Ligand A (68.864), but this is less critical for a cardiovascular target.
8. **Caco-2:** Both have negative values, indicating permeability.
9. **Solubility:** Both have negative values, indicating solubility.
10. **hERG:** Both are very low, indicating low cardiotoxicity risk.
11. **Cl_mic:** Ligand A (-1.731) has *much* better metabolic stability (lower clearance) than Ligand B (25.418). This is a significant advantage.
12. **t1/2:** Ligand B (-5.144) has a longer half-life than Ligand A (-2.94), which is generally desirable.
13. **Pgp:** Ligand A (0.038) has significantly lower P-gp efflux than Ligand B (0.168), improving bioavailability.
14. **Affinity:** Ligand A (-7.9) has a substantially stronger binding affinity than Ligand B (-6.0). This is a crucial factor, a 1.9 kcal/mol difference is significant.
**Overall Assessment:**
Ligand A is clearly the superior candidate. While Ligand B has slightly better BBB penetration and in vitro half-life, Ligand A excels in almost all other critical parameters, particularly its significantly stronger binding affinity, lower DILI risk, much better metabolic stability, and lower P-gp efflux. The affinity difference alone is enough to outweigh the minor advantages of Ligand B.
Output:
1
2025-04-17 21:27:16,105 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's break down the comparison of Ligand A and Ligand B based on the provided parameters and the guidelines, keeping in mind ADRB2 is a GPCR.
1. **Molecular Weight:** Both ligands (349.431 and 361.768 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (71.85) is significantly better than Ligand B (98.09). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is approaching a level that could hinder oral absorption.
3. **logP:** Ligand A (0.873) is within the optimal range (1-3), but on the lower side. Ligand B (3.173) is also within the optimal range, and closer to the ideal.
4. **H-Bond Donors:** Both have 0 HBD, which is good.
5. **H-Bond Acceptors:** Both have 5 HBA, which is acceptable.
6. **QED:** Ligand A (0.791) has a significantly better QED score than Ligand B (0.476), indicating a more drug-like profile.
7. **DILI:** Ligand A (42.962) has a much lower DILI risk than Ligand B (93.292). This is a major advantage for Ligand A.
8. **BBB:** Both ligands have reasonable BBB penetration (65.413 and 73.943). While higher is better, this isn't the primary driver for ADRB2, which isn't necessarily a CNS target.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Ligand A (-0.91) has better solubility than Ligand B (-3.991).
11. **hERG:** Ligand A (0.186) has a much lower hERG risk than Ligand B (0.514). This is a significant safety advantage.
12. **Cl_mic:** Ligand A (21.934) has lower microsomal clearance than Ligand B (36.144), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-2.938) has a slightly better (less negative) in vitro half-life than Ligand B (-1.431).
14. **Pgp:** Ligand A (0.066) has lower P-gp efflux than Ligand B (0.261), which is desirable for better bioavailability.
15. **Binding Affinity:** Ligand B (-8.6) has a significantly stronger binding affinity than Ligand A (-7.0). This is a 1.6 kcal/mol difference, which is substantial and could potentially outweigh some ADME drawbacks.
**Overall Assessment:**
While Ligand B boasts a superior binding affinity, Ligand A demonstrates a much more favorable ADMET profile. Specifically, the lower DILI, hERG, and Cl_mic, coupled with the better QED, solubility, and Pgp efflux, make it a more promising candidate. The TPSA is also significantly better for Ligand A. The difference in binding affinity, while important, is not so large that it completely overrides the significant safety and pharmacokinetic advantages of Ligand A. For a cardiovascular target like ADRB2, minimizing off-target effects and ensuring reasonable metabolic stability are crucial.
**Output:**
1
2025-04-17 21:27:16,105 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Step-by-step comparison:**
1. **MW:** Both ligands (366.45 & 361.41 Da) are within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand B (69.22) is significantly better than Ligand A (124.1). Lower TPSA generally improves oral absorption, crucial for a cardiovascular target.
3. **logP:** Ligand B (2.983) is optimal, while Ligand A (0.143) is quite low, potentially hindering membrane permeability. This is a significant advantage for B.
4. **HBD:** Ligand A (3) and B (2) are both acceptable, below the threshold of 5.
5. **HBA:** Ligand A (7) and B (3) are both acceptable, below the threshold of 10.
6. **QED:** Ligand B (0.748) is better than Ligand A (0.549), indicating a more drug-like profile.
7. **DILI:** Ligand B (15.9%) is *much* better than Ligand A (63.4%). This is a critical factor, as lower DILI risk is highly desirable.
8. **BBB:** Ligand B (82.4%) is significantly better than Ligand A (11.9%). While ADRB2 isn't necessarily a CNS target, higher BBB penetration can sometimes indicate better overall permeability and distribution.
9. **Caco-2:** Ligand A (-6.062) is better than Ligand B (-4.483), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-1.477) is better than Ligand B (-2.588).
11. **hERG:** Ligand A (0.128) is better than Ligand B (0.773), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand A (1.158) is significantly better than Ligand B (25.712), suggesting greater metabolic stability.
13. **t1/2:** Ligand B (-30.946) is significantly better than Ligand A (20.325), indicating a longer half-life.
14. **Pgp:** Ligand A (0.031) is much better than Ligand B (0.051), indicating lower P-gp efflux.
15. **Affinity:** Ligand A (-7.2) is slightly better than Ligand B (-6.9), but the difference is relatively small (0.3 kcal/mol).
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, TPSA, and affinity are key. Ligand B excels in logP and TPSA, while Ligand A has a slightly better affinity. However, the substantial improvements of Ligand B in DILI risk, BBB penetration, and half-life, coupled with a good QED, outweigh the small affinity difference.
**Overall Assessment:**
Ligand B presents a more balanced profile with significantly better ADME properties (DILI, BBB, Cl_mic, t1/2) and a good logP/TPSA combination. While Ligand A has a slightly better affinity and Caco-2 permeability, the superior safety profile and pharmacokinetic properties of Ligand B make it the more promising drug candidate.
Output:
0
2025-04-17 21:27:16,106 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (353.379 and 363.361 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (99.18) is significantly better than Ligand A (139.78). For a GPCR, lower TPSA is generally preferred for better permeability.
3. **logP:** Ligand A (-2.602) is lower than Ligand B (-1.033). While both are within the acceptable range, Ligand B is closer to the optimal 1-3 range. Ligand A's lower logP could indicate potential permeability issues.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (2), but both are within the acceptable limit of 5.
5. **HBA:** Ligand A (7) is higher than Ligand B (5), but both are within the acceptable limit of 10.
6. **QED:** Ligand B (0.588) is slightly better than Ligand A (0.491), indicating a more drug-like profile.
7. **DILI:** Both ligands have acceptable DILI risk (Ligand A: 39.511, Ligand B: 35.634), both below the 40 threshold. Ligand B is marginally better.
8. **BBB:** Ligand B (51.26) is significantly better than Ligand A (28.383). While ADRB2 isn't strictly a CNS target, some CNS penetration can be beneficial for understanding off-target effects and potential side effects.
9. **Caco-2:** Ligand A (-5.882) is worse than Ligand B (-4.947), indicating poorer intestinal absorption.
10. **Solubility:** Ligand A (-1.553) is worse than Ligand B (-0.422), indicating lower aqueous solubility.
11. **hERG:** Both ligands have very low hERG inhibition risk (Ligand A: 0.032, Ligand B: 0.149).
12. **Cl_mic:** Ligand A (-12.241) is significantly better than Ligand B (-18.322). Lower clearance suggests better metabolic stability.
13. **t1/2:** Ligand A (12.311) is significantly better than Ligand B (-39.051). A longer half-life is generally desirable.
14. **Pgp:** Both ligands have very low Pgp efflux liability (Ligand A: 0.004, Ligand B: 0.009).
15. **Affinity:** Ligand A (-6.9 kcal/mol) is slightly better than Ligand B (-5.7 kcal/mol). This is a 1.2 kcal/mol difference, which is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand A has a better binding affinity and metabolic stability (lower Cl_mic and longer t1/2). However, Ligand B has superior TPSA, logP, QED, BBB penetration, Caco-2 permeability, and solubility. Considering ADRB2 is a GPCR, the better TPSA, logP, and BBB of Ligand B are particularly important. The slightly better affinity of Ligand A is valuable, but the ADME advantages of Ligand B are more critical for overall drug development success.
**Output:**
0
2025-04-17 21:27:16,106 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [362.461, 78.43, 2.64, 3, 3, 0.636, 30.399, 57.736, -4.838, -3.256, 0.523, 57.704, -23.198, 0.071, -6.4]**
**Ligand B: [358.389, 96.25, 1.169, 3, 5, 0.617, 40.364, 73.245, -5.026, -2.605, 0.308, 12.164, -5.668, 0.035, -6.7]**
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (362.461) is slightly higher than Ligand B (358.389), but the difference is negligible.
2. **TPSA:** Ligand A (78.43) is better than Ligand B (96.25). ADRB2 is a cardiovascular target, so BBB penetration isn't critical, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (2.64) is optimal, while Ligand B (1.169) is on the lower side. This is a significant advantage for Ligand A, as it suggests better membrane permeability.
4. **H-Bond Donors:** Both ligands have 3 HBD, which is acceptable.
5. **H-Bond Acceptors:** Ligand A has 3 HBA, while Ligand B has 5. Ligand A is preferable here.
6. **QED:** Both ligands have similar QED values (0.636 vs. 0.617), indicating good drug-likeness.
7. **DILI:** Ligand A (30.399) has a substantially lower DILI risk than Ligand B (40.364). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (73.245) has a higher BBB penetration percentile than Ligand A (57.736). However, as ADRB2 is a cardiovascular target, BBB penetration is not a primary concern.
9. **Caco-2 Permeability:** Ligand A (-4.838) has worse Caco-2 permeability than Ligand B (-5.026). Both are quite poor.
10. **Aqueous Solubility:** Ligand A (-3.256) has worse aqueous solubility than Ligand B (-2.605). Both are quite poor.
11. **hERG Inhibition:** Ligand A (0.523) has a slightly higher hERG inhibition risk than Ligand B (0.308), but both are relatively low.
12. **Microsomal Clearance:** Ligand A (57.704) has a higher microsomal clearance than Ligand B (12.164), indicating faster metabolism and potentially lower in vivo exposure. This favors Ligand B.
13. **In vitro Half-Life:** Ligand A (-23.198) has a longer in vitro half-life than Ligand B (-5.668). This is a significant advantage for Ligand A.
14. **P-gp Efflux:** Ligand A (0.071) has lower P-gp efflux than Ligand B (0.035). Lower efflux is generally preferred.
15. **Binding Affinity:** Ligand B (-6.7) has a slightly better binding affinity than Ligand A (-6.4), but the difference is small (0.3 kcal/mol).
**Overall Assessment:**
Ligand A is preferable. While Ligand B has a slightly better binding affinity and lower P-gp efflux, Ligand A excels in crucial areas like DILI risk, logP, TPSA, and in vitro half-life. The lower DILI risk is particularly important. The slightly lower binding affinity of Ligand A can potentially be optimized in later stages of drug development. The better logP and TPSA of Ligand A suggest better absorption characteristics.
Output:
1
2025-04-17 21:27:16,106 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (356.275 and 342.41 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (79.29) is higher than Ligand B (35.53). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is generally preferred for absorption. Ligand B is significantly better.
3. **logP:** Ligand A (2.782) is within the optimal 1-3 range. Ligand B (4.29) is slightly higher, potentially leading to solubility issues and off-target interactions. Ligand A is better.
4. **HBD:** Ligand A (2) and Ligand B (0) are both acceptable.
5. **HBA:** Both ligands have 3 HBA, which is within the acceptable range.
6. **QED:** Both ligands have similar QED values (0.78 and 0.704), indicating good drug-likeness.
7. **DILI:** Ligand A (79.643) has a higher DILI risk than Ligand B (60.217), which is concerning. Ligand B is better.
8. **BBB:** Ligand A (58.007) has a lower BBB penetration than Ligand B (84.025). While ADRB2 isn't a primary CNS target, some degree of BBB penetration can be advantageous for off-target effects assessment. Ligand B is better.
9. **Caco-2:** Ligand A (-5.346) has a worse Caco-2 permeability than Ligand B (-4.142). Ligand B is better.
10. **Solubility:** Ligand A (-2.874) has better solubility than Ligand B (-6.012). Ligand A is better.
11. **hERG:** Ligand A (0.039) has a very low hERG risk, significantly better than Ligand B (0.619). This is a major advantage for Ligand A.
12. **Cl_mic:** Ligand A (-8.568) has a much lower (better) microsomal clearance than Ligand B (97.786), indicating greater metabolic stability. Ligand A is significantly better.
13. **t1/2:** Ligand A (-14.605) has a longer in vitro half-life than Ligand B (-10.595). Ligand A is better.
14. **Pgp:** Ligand A (0.021) has lower P-gp efflux liability than Ligand B (0.439). Ligand A is better.
15. **Binding Affinity:** Ligand B (-7.2) has a slightly better binding affinity than Ligand A (-6.0). However, the difference is not large enough to overcome the significant ADME advantages of Ligand A.
**Overall Assessment:**
Ligand A demonstrates a much more favorable ADME profile. It has significantly lower DILI risk, better metabolic stability (lower Cl_mic, longer t1/2), lower P-gp efflux, better hERG safety, and better solubility. While Ligand B has slightly better binding affinity and BBB penetration, the ADME liabilities of Ligand B are substantial. For a cardiovascular GPCR target like ADRB2, a balanced profile with good safety and pharmacokinetic properties is crucial.
**Output:**
1
2025-04-17 21:27:16,106 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (364.471 and 363.483 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (104.53) is higher than Ligand B (56.59). For a cardiovascular GPCR, TPSA is moderately important. Ligand B is significantly better, being well below the 140 threshold.
3. **logP:** Ligand B (2.581) is better positioned within the optimal 1-3 range than Ligand A (1.245), which is at the lower end. This favors Ligand B for permeability.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (0). Lower is generally preferred, and Ligand B is better.
5. **HBA:** Ligand A (4) is lower than Ligand B (6). Lower is generally preferred, and Ligand A is better.
6. **QED:** Both ligands have good QED scores (0.54 and 0.685, respectively), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand B (50.136) has a slightly lower DILI risk than Ligand A (40.287), but both are acceptable.
8. **BBB:** Ligand B (67.197) has a higher BBB penetration score than Ligand A (55.874). While ADRB2 isn't a CNS target, some distribution to the CNS can be a concern for off-target effects, and higher BBB is generally preferred.
9. **Caco-2:** Ligand A (-5.359) has a worse Caco-2 permeability than Ligand B (-4.691). Higher is better, so Ligand B is favored.
10. **Solubility:** Ligand A (-2.389) has a slightly better solubility than Ligand B (-3.256). Solubility is important, but not as critical as permeability for this target.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.067 and 0.507, respectively). No significant difference.
12. **Cl_mic:** Ligand A (-1.016) has a significantly lower (better) microsomal clearance than Ligand B (98.623). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand B (8.078) has a much longer in vitro half-life than Ligand A (-3.029). This is a significant advantage for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.028) has a much lower Pgp efflux liability than Ligand B (0.321). This is a significant advantage for Ligand A, improving bioavailability.
15. **Binding Affinity:** Both ligands have the same binding affinity (-6.8 kcal/mol). This removes affinity as a differentiating factor.
**Overall Assessment:**
Ligand B has advantages in several key areas: logP, TPSA, BBB, Caco-2 permeability, and *especially* in vitro half-life. Ligand A has advantages in Pgp efflux and microsomal clearance. Given the GPCR-specific priorities (logP, TPSA, Pgp), Ligand B is slightly favored. The longer half-life of Ligand B is a significant advantage, potentially outweighing the slightly higher Pgp efflux.
Output:
0
2025-04-17 21:27:16,106 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (365.861 and 353.503 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (75.44) is higher than Ligand B (59). Both are below 140, but B is closer to the optimal for oral absorption.
3. **logP:** Both ligands have good logP values (3.043 and 2.606), within the 1-3 range.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Both have 4 HBA, which is good.
6. **QED:** Ligand A (0.814) has a slightly better QED score than Ligand B (0.764), indicating a more drug-like profile.
7. **DILI:** Ligand B (10.741) has a *much* lower DILI risk than Ligand A (42.032). This is a significant advantage for B.
8. **BBB:** Both ligands have good BBB penetration (77.317 and 70.105).
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. Ligand A (-4.955) is slightly worse than Ligand B (-4.56).
10. **Solubility:** Ligand A (-3.747) has slightly worse solubility than Ligand B (-1.793).
11. **hERG:** Both ligands have low hERG risk (0.549 and 0.579).
12. **Cl_mic:** Ligand B (42.086) has a lower microsomal clearance than Ligand A (52.337), suggesting better metabolic stability.
13. **t1/2:** Ligand B (28.783) has a significantly longer in vitro half-life than Ligand A (-14.205). This is a major advantage for B.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.448 and 0.299).
15. **Binding Affinity:** Ligand A (-7.2 kcal/mol) has a significantly stronger binding affinity than Ligand B (-2.1 kcal/mol). This is a substantial advantage for A.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, affinity, logP, Pgp, TPSA, and BBB are key. Ligand A wins on affinity by a large margin. Both have acceptable logP and Pgp values. Ligand B has a better TPSA and slightly better BBB. However, the *huge* difference in DILI risk and half-life, coupled with the slightly better solubility of B, are very important. While affinity is crucial, a compound with a high risk of liver injury or rapid metabolism is unlikely to be a viable drug.
**Overall Assessment:**
The superior binding affinity of Ligand A is tempting. However, the significantly lower DILI risk, better metabolic stability (longer half-life), and slightly better solubility of Ligand B outweigh the affinity difference. The Caco-2 values are concerning for both, but can be addressed with formulation strategies. The lower DILI and better PK profile of B make it the more promising candidate.
Output:
0
2025-04-17 21:27:16,106 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (343.431 Da and 359.421 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (81.07) is better than Ligand B (88.91). Both are under the 140 A^2 threshold for good oral absorption, but lower TPSA is generally preferred for GPCRs to facilitate receptor binding and potentially improve CNS penetration (though less critical for a cardiovascular target).
**3. logP:** Both ligands have good logP values (1.998 and 1.799), falling within the optimal 1-3 range. Ligand B is slightly lower, which could be marginally better for solubility, but the difference is small.
**4. H-Bond Donors:** Both ligands have 2 HBD, which is within the acceptable limit of <=5.
**5. H-Bond Acceptors:** Ligand A has 6 HBA, and Ligand B has 5. Both are below the 10 threshold, so no major concerns.
**6. QED:** Ligand A (0.717) is slightly better than Ligand B (0.667), indicating a more drug-like profile.
**7. DILI:** Both ligands have acceptable DILI risk (45.328 and 44.591 percentiles), well below the 60 threshold.
**8. BBB:** Ligand B (65.529) has a significantly higher BBB penetration percentile than Ligand A (46.84). While ADRB2 is primarily a cardiovascular target, some CNS effects are possible with certain ligands, and higher BBB penetration isn't necessarily detrimental.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-5.26 and -5.085). This is unusual and suggests poor permeability. However, these values are on a log scale and the negative values indicate very low permeability.
**10. Aqueous Solubility:** Ligand A (-1.779) has better solubility than Ligand B (-2.345). Better solubility is generally favorable for bioavailability.
**11. hERG Inhibition:** Ligand A (0.692) has a lower hERG inhibition risk than Ligand B (0.156). This is a significant advantage, as hERG inhibition can lead to cardiotoxicity.
**12. Microsomal Clearance:** Ligand A (2.72) has much lower microsomal clearance than Ligand B (39.127), suggesting better metabolic stability. This is a crucial factor for drug duration and dosing frequency.
**13. In vitro Half-Life:** Ligand A (14.679 hours) has a substantially longer in vitro half-life than Ligand B (-9.904 hours). This is a major positive for Ligand A, indicating less frequent dosing potential.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.043 and 0.054).
**15. Binding Affinity:** Ligand A (-6.9 kcal/mol) has slightly better binding affinity than Ligand B (-6.5 kcal/mol). While the difference is not huge, it is over the 1.5 kcal/mol advantage threshold.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity) and the general drug-like properties, **Ligand A is the more promising candidate.** While Ligand B has better BBB penetration, the advantages of Ligand A in terms of metabolic stability (lower Cl_mic), longer half-life, better solubility, lower hERG risk, and slightly better affinity outweigh this benefit. The poor Caco-2 permeability is a concern for both, but can be addressed through formulation strategies.
Output:
1
2025-04-17 21:27:16,106 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, priorities are logP, TPSA, Pgp, affinity, and to a lesser extent, BBB.
* **Molecular Weight:** Both ligands (348.443 and 353.507 Da) are within the ideal 200-500 Da range.
* **TPSA:** Both ligands (76.66 and 72.88) are below the 140 A^2 threshold for good oral absorption, which is good.
* **logP:** Both ligands have logP values (1.28 and 1.399) within the optimal 1-3 range.
* **H-Bond Donors/Acceptors:** Both have 2 HBD and 4 HBA, which are acceptable.
* **QED:** Ligand A (0.785) has a better QED score than Ligand B (0.615), indicating a more drug-like profile.
* **DILI:** Ligand A (38.852) has a significantly lower DILI risk than Ligand B (4.382). This is a major advantage for Ligand A.
* **BBB:** Ligand A (73.943) has a better BBB penetration percentile than Ligand B (54.013). While not a primary concern for a cardiovascular target, it's a positive attribute.
* **Caco-2 Permeability:** Both ligands have similar, very negative Caco-2 values (-4.967 and -4.939). This is concerning and suggests poor permeability.
* **Aqueous Solubility:** Both ligands have very negative solubility values (-3.046 and -1.23). This is also concerning, indicating poor solubility.
* **hERG:** Both ligands have low hERG inhibition liability (0.243 and 0.298).
* **Microsomal Clearance:** Ligand B (11.272) has a lower microsomal clearance than Ligand A (18.901), suggesting better metabolic stability.
* **In vitro Half-Life:** Ligand B (11.969 hours) has a longer half-life than Ligand A (51.635 hours). This is a positive attribute for Ligand B.
* **P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.021 and 0.037).
* **Binding Affinity:** Ligand A (-7.7 kcal/mol) has a significantly better binding affinity than Ligand B (-6.0 kcal/mol). This is a substantial advantage, exceeding the 1.5 kcal/mol difference threshold.
**Conclusion:**
Despite the poor Caco-2 and solubility values for both compounds, Ligand A is the more promising candidate. Its significantly stronger binding affinity (-7.7 vs -6.0 kcal/mol) and much lower DILI risk (38.852 vs 4.382) outweigh the slightly better metabolic stability and half-life of Ligand B. The better BBB score for Ligand A is also a minor benefit. The affinity difference is large enough to potentially overcome the permeability/solubility issues through formulation strategies.
**Output:**
1
2025-04-17 21:27:16,106 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.46 and 346.44 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (71.53) is significantly better than Ligand B (93.84). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is approaching a level that could hinder oral absorption.
3. **logP:** Ligand A (3.27) is good, within the optimal 1-3 range. Ligand B (1.33) is on the lower side, which *could* indicate permeability issues, but isn't a major concern.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs generally improve membrane permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (6). Similar to HBD, lower HBA is generally better for permeability.
6. **QED:** Ligand A (0.847) has a higher QED score than Ligand B (0.705), indicating a more drug-like profile.
7. **DILI:** Ligand B (38.85) has a significantly lower DILI risk than Ligand A (47.93). This is a substantial advantage for Ligand B.
8. **BBB:** Ligand A (87.17) has a much higher BBB penetration percentile than Ligand B (62.85). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant for off-target effects and overall safety assessment.
9. **Caco-2:** Ligand A (-4.524) is better than Ligand B (-5.396). Higher Caco-2 permeability indicates better intestinal absorption.
10. **Solubility:** Ligand A (-3.85) is better than Ligand B (-1.352). Better solubility is generally preferred.
11. **hERG:** Ligand A (0.508) has a lower hERG risk than Ligand B (0.25). This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand A (78.62) has a higher microsomal clearance than Ligand B (17.55). This means Ligand B is more metabolically stable, which is a significant advantage.
13. **t1/2:** Ligand A (-6.338) has a longer in vitro half-life than Ligand B (31.889). This is a positive for Ligand A.
14. **Pgp:** Ligand A (0.264) has lower P-gp efflux than Ligand B (0.016). Lower P-gp efflux is preferable.
15. **Binding Affinity:** Ligand A (-7.3) has a slightly better binding affinity than Ligand B (-6.5). This difference of 0.8 kcal/mol is significant and can outweigh some ADME drawbacks.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A excels in affinity, TPSA, Pgp, and has a good logP. Ligand B has a better DILI score and metabolic stability (lower Cl_mic). The improved affinity of Ligand A is a strong driver, and its better TPSA and Pgp profiles are also favorable. While Ligand B's lower DILI is attractive, the overall balance favors Ligand A.
**Conclusion:**
Considering the balance of properties, particularly the strong binding affinity, favorable TPSA, and Pgp profile of Ligand A, it is the more promising drug candidate.
Output:
1
2025-04-17 21:27:16,106 - INFO - Batch 259 complete. Total preferences: 4144
2025-04-17 21:27:16,106 - INFO - Processing batch 260/512...
2025-04-17 21:28:02,847 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (346.431 and 352.45 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (85.25) is slightly higher than Ligand B (71.34). Both are below the 140 threshold for oral absorption, but B is closer to the preferred <90 for GPCRs.
3. **logP:** Ligand B (3.385) is higher than Ligand A (0.567). A is too low and may have permeability issues. B is within the optimal 1-3 range. This is a significant advantage for B.
4. **HBD:** Both ligands have 2 H-bond donors, which is good.
5. **HBA:** Ligand A has 5 H-bond acceptors, while Ligand B has 3. Both are acceptable, but fewer is generally preferred.
6. **QED:** Both ligands have similar QED values (0.756 and 0.753), indicating good drug-likeness.
7. **DILI:** Both ligands have acceptable DILI risk (35.052 and 38.852 percentile).
8. **BBB:** Ligand B (86.778) has a significantly higher BBB penetration percentile than Ligand A (64.017). While ADRB2 isn't *exclusively* a CNS target, some CNS exposure can be beneficial or at least needs to be considered, and higher BBB is generally desirable for GPCRs.
9. **Caco-2:** Ligand A (-5.294) has a worse Caco-2 permeability than Ligand B (-4.44). Lower values indicate poorer permeability.
10. **Solubility:** Ligand A (-1.448) has slightly better solubility than Ligand B (-4.187), but both are quite poor.
11. **hERG:** Ligand A (0.131) has a lower hERG inhibition liability than Ligand B (0.571), which is a positive.
12. **Cl_mic:** Ligand A (19.908) has significantly lower microsomal clearance than Ligand B (68.125), indicating better metabolic stability. This is a major advantage for A.
13. **t1/2:** Ligand B (28.947) has a longer in vitro half-life than Ligand A (20.577), which is preferable.
14. **Pgp:** Ligand A (0.028) has much lower P-gp efflux liability than Ligand B (0.49). This is a substantial advantage for A.
15. **Binding Affinity:** Ligand A (-7.2 kcal/mol) has a stronger binding affinity than Ligand B (-5.9 kcal/mol). This 1.3 kcal/mol difference is significant and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand A has a superior binding affinity and better metabolic stability (lower Cl_mic) and P-gp efflux. Ligand B has better logP, BBB penetration, and half-life. The critical factors for a GPCR like ADRB2 are affinity, logP, and permeability. While Ligand B has a better logP and BBB, the significantly stronger binding affinity of Ligand A (-7.2 vs -5.9) is a decisive advantage. The lower P-gp efflux also helps with bioavailability. The solubility of both is poor, but this can be addressed with formulation strategies.
Output:
1
2025-04-17 21:28:02,847 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [370.377, 76.66, 3.072, 2, 5, 0.766, 86.739, 73.905, -4.485, -4.29, 0.456, 91.62, 40.201, 0.223, -7]
**Ligand B:** [348.491, 78.09, 2.931, 2, 3, 0.709, 33.114, 55.487, -4.999, -2.5, 0.506, 43.296, -0.181, 0.188, -5.5]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (348.491) is slightly lower, which *could* be beneficial for permeability, but both are acceptable.
2. **TPSA:** Both are reasonably good (76.66 & 78.09), below the 140 threshold for oral absorption.
3. **logP:** Both are excellent (3.072 & 2.931), falling within the optimal 1-3 range.
4. **HBD:** Both have 2 HBD, which is good.
5. **HBA:** Ligand A has 5 HBA, Ligand B has 3. Both are acceptable, but lower is generally better.
6. **QED:** Both have good QED scores (0.766 & 0.709), indicating drug-likeness.
7. **DILI:** This is a significant difference. Ligand A has a high DILI risk (86.739%), while Ligand B has a much lower risk (33.114%). This heavily favors Ligand B.
8. **BBB:** Ligand A has a good BBB penetration (73.905%), while Ligand B is lower (55.487%). For a cardiovascular target, BBB penetration isn't *critical*, but it's a plus.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it is difficult to interpret.
10. **Solubility:** Both have negative solubility values, which is also unusual. Again, the scale is not specified, so it is difficult to interpret.
11. **hERG:** Both have low hERG inhibition risk (0.456 & 0.506).
12. **Cl_mic:** Ligand A has higher microsomal clearance (91.62) than Ligand B (43.296), indicating lower metabolic stability. Ligand B is preferred.
13. **t1/2:** Ligand A has a longer in vitro half-life (40.201) than Ligand B (-0.181). This is a positive for Ligand A, but the negative value for Ligand B is concerning.
14. **Pgp:** Both have low P-gp efflux liability (0.223 & 0.188).
15. **Binding Affinity:** Ligand A (-7 kcal/mol) has slightly better binding affinity than Ligand B (-5.5 kcal/mol). This is a 1.5 kcal/mol difference, which is significant.
**GPCR-specific priorities:** For ADRB2 (a GPCR), we prioritize logP, Pgp, TPSA, and affinity. Both ligands perform well on logP, Pgp, and TPSA. Ligand A has a better affinity. However, the *major* concern is the significantly higher DILI risk for Ligand A. The improved half-life of Ligand A is not enough to overcome the high DILI risk.
**Conclusion:**
Despite the slightly better affinity and BBB penetration of Ligand A, the substantially lower DILI risk and better metabolic stability of Ligand B make it the more promising drug candidate.
0
2025-04-17 21:28:02,847 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [348.447, 79.54, 1.806, 0, 5, 0.811, 31.485, 77.86, -4.806, -1.176, 0.045, 24.209, 7.591, 0.058, -7.4]
**Ligand B:** [378.523, 66.4, 2.604, 0, 6, 0.802, 53.432, 83.908, -5.022, -3.177, 0.373, 54.623, 18.32, 0.445, -6.3]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity, and, to a lesser extent, BBB):
1. **MW:** Both are within the ideal range (200-500 Da). A is 348.447, B is 378.523. No significant difference.
2. **TPSA:** A (79.54) is slightly higher than B (66.4). Both are reasonably good for oral absorption, but B is better.
3. **logP:** A (1.806) is good, B (2.604) is also good, falling within the optimal 1-3 range. B is slightly better.
4. **HBD:** Both have 0 HBD, which is good.
5. **HBA:** A has 5, B has 6. Both are acceptable, but A is slightly better.
6. **QED:** Both are very similar (A: 0.811, B: 0.802), indicating good drug-likeness.
7. **DILI:** A (31.485) is significantly better than B (53.432). Lower DILI risk is a major advantage.
8. **BBB:** A (77.86) is good, B (83.908) is even better. For a cardiovascular target, BBB isn't *critical*, but higher is still preferable.
9. **Caco-2:** A (-4.806) is better than B (-5.022), indicating better intestinal absorption.
10. **Solubility:** A (-1.176) is better than B (-3.177). Solubility is important for bioavailability.
11. **hERG:** A (0.045) is *much* better than B (0.373). Lower hERG risk is crucial for cardiovascular drugs.
12. **Cl_mic:** A (24.209) is significantly better than B (54.623). Lower clearance means better metabolic stability.
13. **t1/2:** B (18.32) is better than A (7.591). Longer half-life is generally desirable.
14. **Pgp:** A (0.058) is much better than B (0.445). Lower P-gp efflux is beneficial for bioavailability.
15. **Affinity:** A (-7.4) is better than B (-6.3), a difference of 1.1 kcal/mol. This is a substantial difference in binding potency.
**Overall Assessment:**
Ligand A demonstrates a significantly more favorable profile across several critical ADME-Tox parameters (DILI, hERG, Cl_mic, Pgp) and has a better binding affinity. While Ligand B has a slightly better BBB penetration and in vitro half-life, the risks associated with its higher DILI, hERG, and Pgp efflux, coupled with the lower affinity, outweigh these benefits. The affinity difference of 1.1 kcal/mol is also substantial enough to favor Ligand A.
Therefore, I would choose Ligand A.
Output:
1
2025-04-17 21:28:02,848 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (364.56 & 362.37 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (40.62) is slightly better than Ligand B (42.43), both are below the 140 A^2 threshold for good oral absorption.
**3. logP:** Both ligands have good logP values (2.96 & 3.52), falling within the optimal 1-3 range. Ligand B is slightly higher, which *could* be a minor concern for solubility, but isn't a dealbreaker.
**4. H-Bond Donors:** Both have 0 HBD, which is good for permeability.
**5. H-Bond Acceptors:** Ligand A has 4 HBA, and Ligand B has 3. Both are within the acceptable limit of 10.
**6. QED:** Ligand A (0.778) has a significantly better QED score than Ligand B (0.525). This suggests Ligand A has a more generally "drug-like" profile.
**7. DILI Risk:** Ligand A (20.202 percentile) has a much lower DILI risk than Ligand B (30.399 percentile). This is a significant advantage for Ligand A.
**8. BBB Penetration:** Both ligands show good BBB penetration (Ligand A: 91.663%, Ligand B: 97.053%). Ligand B is slightly better, but this isn't a primary concern for a cardiovascular target.
**9. Caco-2 Permeability:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the values are similar (-4.726 and -4.06).
**10. Aqueous Solubility:** Both have negative solubility values, indicating very poor aqueous solubility. Ligand B is worse (-3.626) than Ligand A (-2.16).
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (0.976 & 0.867).
**12. Microsomal Clearance:** Ligand A (30.628 mL/min/kg) has a significantly lower microsomal clearance than Ligand B (59.723 mL/min/kg), indicating better metabolic stability.
**13. In vitro Half-Life:** Ligand B (23.318 hours) has a longer half-life than Ligand A (13.653 hours). This is a positive for Ligand B.
**14. P-gp Efflux:** Both have low P-gp efflux liability (0.634 & 0.612).
**15. Binding Affinity:** Ligand B (-7.8 kcal/mol) has a substantially stronger binding affinity than Ligand A (-5.1 kcal/mol). This is a *major* advantage for Ligand B. A difference of 2.7 kcal/mol is significant.
**GPCR-Specific Considerations:** For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. While both ligands have acceptable logP and Pgp, Ligand B's significantly better binding affinity outweighs the slight drawbacks in solubility and metabolic stability. The TPSA values are similar and acceptable.
**Overall Assessment:**
While Ligand A has better QED, DILI risk, and metabolic stability, the significantly stronger binding affinity of Ligand B (-7.8 vs -5.1 kcal/mol) is the deciding factor. The affinity difference is large enough to overcome the slightly poorer ADME properties of Ligand B.
Output:
0
2025-04-17 21:28:02,848 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (368.5 & 352.4 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (74.13) is significantly better than Ligand B (117.79). ADRB2 is not a CNS target, but lower TPSA generally correlates with better absorption, so A is favored.
3. **logP:** Ligand A (3.225) is optimal (1-3), while Ligand B (-0.575) is quite low, potentially hindering permeability. This is a strong advantage for A.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (5) is better than Ligand B (7). Similar reasoning to HBD.
6. **QED:** Both are good (A: 0.669, B: 0.703), with B slightly better, but the difference is minor.
7. **DILI:** Ligand A (32.3%) is better than Ligand B (49.0%). Lower DILI risk is always preferred.
8. **BBB:** Not a primary concern for ADRB2 (cardiovascular target). Ligand A (73.9%) is higher than Ligand B (48.2%), but this isn't a major factor.
9. **Caco-2:** Both are negative (-5.078 and -5.15), indicating poor permeability. This is a concern for both, but the lower logP of B makes it more problematic.
10. **Solubility:** Ligand A (-3.828) is better than Ligand B (-1.148). Better solubility aids formulation and bioavailability.
11. **hERG:** Both are very low (A: 0.442, B: 0.102), indicating low cardiotoxicity risk. No significant difference.
12. **Cl_mic:** Ligand B (7.228) has significantly lower clearance than Ligand A (60.539), suggesting better metabolic stability. This is a significant advantage for B.
13. **t1/2:** Ligand B (-1.078) has a slightly better (less negative) in vitro half-life than Ligand A (-4.117).
14. **Pgp:** Both are very low (A: 0.074, B: 0.01), indicating low efflux. No significant difference.
15. **Binding Affinity:** Ligand A (-7.4) is slightly better than Ligand B (-6.9), but the difference is less than 1.5 kcal/mol.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand A excels in logP and TPSA, and has slightly better affinity. While Ligand B has better metabolic stability (Cl_mic and t1/2), the poor logP and higher TPSA are significant drawbacks for a GPCR ligand.
**Overall Assessment:**
Ligand A presents a more balanced profile, particularly regarding properties crucial for absorption and target engagement. The slightly better affinity combined with significantly improved logP and TPSA outweigh the metabolic stability advantage of Ligand B. The poor Caco-2 values for both are a concern, but the lower logP of B exacerbates this issue.
Output:
1
2025-04-17 21:28:02,848 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (366.849 and 346.471 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (97.55) is higher than Ligand B (58.64). While both are below 140, the lower TPSA of Ligand B is preferable for better absorption, especially for a GPCR target.
3. **logP:** Both ligands have good logP values (2.447 and 2.574), falling within the optimal 1-3 range. No clear advantage.
4. **HBD:** Ligand A has 2 HBD, and Ligand B has 1. Both are acceptable (<=5).
5. **HBA:** Ligand A has 5 HBA, and Ligand B has 3. Both are acceptable (<=10).
6. **QED:** Both ligands have similar QED values (0.783 and 0.721), indicating good drug-likeness.
7. **DILI:** Ligand A (47.77) has a higher DILI risk than Ligand B (18.302). This is a significant advantage for Ligand B.
8. **BBB:** Both ligands have good BBB penetration (70.609 and 74.098). Ligand B is slightly better, but both are acceptable.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating permeability. Ligand A (-4.842) is slightly more permeable than Ligand B (-4.575).
10. **Solubility:** Ligand A (-4.024) has worse solubility than Ligand B (-2.86). Better solubility is generally desirable.
11. **hERG:** Both ligands have low hERG inhibition risk (0.318 and 0.152). Ligand B is slightly better.
12. **Cl_mic:** Ligand A (13.274 mL/min/kg) has lower microsomal clearance than Ligand B (48.184 mL/min/kg), suggesting better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (-7.704) has a much longer in vitro half-life than Ligand B (0.118). This is a substantial advantage for Ligand A.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.015 and 0.055). No significant difference.
15. **Binding Affinity:** Ligand B (-7.1 kcal/mol) has slightly better binding affinity than Ligand A (-5.7 kcal/mol). This is a 1.4 kcal/mol difference, which is a significant advantage.
**GPCR-Specific Priorities & Overall Assessment:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are crucial. Ligand B has a lower TPSA, lower DILI risk, and better binding affinity. Ligand A has better metabolic stability (lower Cl_mic) and a longer half-life. The binding affinity difference is substantial enough to outweigh the metabolic stability advantage of Ligand A. The lower DILI risk of Ligand B is also a major factor.
**Output:**
0
2025-04-17 21:28:02,848 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (347.405 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (40.54) is significantly better than Ligand B (57.7), falling well below the 140 threshold for oral absorption and closer to the 90 threshold for CNS penetration (although ADRB2 isn't necessarily a CNS target, lower TPSA is still generally beneficial).
3. **logP:** Ligand A (3.322) is within the optimal range, while Ligand B (1.836) is on the lower side. This could potentially hinder membrane permeability for Ligand B.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 2 HBA, while Ligand B has 6. Ligand A is preferable here, as excessive HBA can negatively impact permeability.
6. **QED:** Ligand A (0.908) has a much better QED score than Ligand B (0.712), indicating a more drug-like profile.
7. **DILI:** Both have acceptable DILI risk (Ligand A: 11.206, Ligand B: 12.253), though Ligand A is slightly better.
8. **BBB:** Ligand A (89.027) has a significantly higher BBB percentile than Ligand B (62.97). While ADRB2 isn't a primary CNS target, higher BBB penetration can sometimes indicate better overall distribution properties.
9. **Caco-2:** Ligand A (-4.65) and Ligand B (-5.065) are both negative, indicating poor Caco-2 permeability. This is a concern for both, but the negative value is a scale, and thus, the lower the negative value, the better. Ligand A is slightly better.
10. **Solubility:** Ligand A (-3.727) is better than Ligand B (-1.547), indicating higher aqueous solubility.
11. **hERG:** Both have low hERG inhibition risk (Ligand A: 0.688, Ligand B: 0.447), with Ligand B being slightly better.
12. **Cl_mic:** Ligand A (23.104) has a lower microsomal clearance than Ligand B (27.816), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-9.076) has a much better in vitro half-life than Ligand B (26.907).
14. **Pgp:** Ligand A (0.073) has lower P-gp efflux liability than Ligand B (0.035), suggesting better oral bioavailability and potentially better CNS exposure.
15. **Binding Affinity:** Ligand B (-7.4) has a significantly stronger binding affinity than Ligand A (-6.2). This is a substantial advantage.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B has a better affinity, but Ligand A has superior TPSA, Pgp, and logP. The affinity difference is significant (1.2 kcal/mol), but Ligand A's better ADME properties, particularly TPSA, QED, solubility, and metabolic stability, are crucial for overall drug development success. The lower TPSA and higher QED of Ligand A suggest a higher probability of good oral bioavailability and a more favorable pharmacokinetic profile.
**Conclusion:**
While Ligand B has a better binding affinity, the overall balance of properties favors Ligand A. The improvements in ADME properties, particularly TPSA, QED, solubility, and metabolic stability, outweigh the affinity difference in this case.
Output:
1
2025-04-17 21:28:02,848 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.415 and 350.547 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (83.22) is higher than Ligand B (58.2). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B is better.
3. **logP:** Ligand A (1.26) is within the optimal range (1-3), while Ligand B (4.183) is slightly above it. While not drastically high, a logP > 4 can sometimes lead to issues. Ligand A is better.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally leads to better permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (2). Lower HBA generally leads to better permeability.
6. **QED:** Ligand A (0.864) is significantly better than Ligand B (0.655), indicating a more drug-like profile.
7. **DILI:** Ligand A (35.13%) and Ligand B (30.05%) both have low DILI risk, below the 40% threshold. Ligand B is slightly better.
8. **BBB:** Ligand A (50.019%) is lower than Ligand B (71.927%). While ADRB2 isn't a CNS target, some brain exposure can be relevant for off-target effects. Ligand B is better.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.416 and -4.675). This is unusual and suggests poor permeability *in vitro*. However, the values are quite similar.
10. **Solubility:** Ligand A (-1.755) is better than Ligand B (-4.535). Higher solubility is generally preferred.
11. **hERG:** Both ligands have low hERG risk (0.331 and 0.523). No significant difference.
12. **Cl_mic:** Ligand A (19.009) has significantly lower microsomal clearance than Ligand B (67.042). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (23.785) has a longer in vitro half-life than Ligand B (13.073). This is a significant advantage.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.345 and 0.424). No significant difference.
15. **Binding Affinity:** Both ligands have the same binding affinity (-6.4 kcal/mol).
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), and the general drug-like properties, Ligand A appears to be the more promising candidate. While Ligand B has a better BBB score and slightly lower DILI, Ligand A excels in crucial ADME properties like QED, solubility, metabolic stability (Cl_mic and t1/2), and has a more favorable TPSA and logP. The similar binding affinity makes these ADME differences the deciding factors. The negative Caco-2 values for both are concerning, but the other advantages of Ligand A outweigh this.
Output:
1
2025-04-17 21:28:02,848 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
The target is ADRB2, a GPCR. Therefore, I will prioritize logP, TPSA, Pgp efflux, BBB penetration, and binding affinity. Metabolic stability (Cl_mic, t1/2) and safety (DILI, hERG) are also important, but less so than the first set.
Let's compare the ligands property by property:
1. **MW:** Both are within the ideal range (349.45 and 345.403 Da).
2. **TPSA:** Ligand A (71.09) is significantly better than Ligand B (100.25). Lower TPSA is preferred for GPCRs to enhance permeability.
3. **logP:** Ligand A (3.119) is optimal, while Ligand B (0.46) is quite low, potentially hindering membrane permeability.
4. **HBD/HBA:** Ligand A (2 HBD, 3 HBA) is slightly better than Ligand B (1 HBD, 6 HBA) in terms of balancing solubility and permeability.
5. **QED:** Both are good (0.757 and 0.782).
6. **DILI:** Ligand A (35.673) has a much lower DILI risk than Ligand B (71.345). This is a significant advantage.
7. **BBB:** Ligand A (73.245) has better BBB penetration than Ligand B (52.268), which is desirable for a GPCR.
8. **Caco-2:** Both are negative, indicating poor permeability. However, the scale is not specified, so it's hard to interpret.
9. **Solubility:** Both are negative, indicating poor solubility. Again, the scale is not specified.
10. **hERG:** Both are very low, indicating minimal hERG inhibition risk.
11. **Cl_mic:** Ligand A (19.981) and Ligand B (19.18) are similar, indicating comparable metabolic clearance.
12. **t1/2:** Ligand A (20.671) has a longer half-life than Ligand B (-14.391), which is a positive.
13. **Pgp:** Ligand A (0.082) has lower P-gp efflux liability than Ligand B (0.088), which is favorable.
14. **Binding Affinity:** Ligand A (-7.1 kcal/mol) has a slightly better binding affinity than Ligand B (-6.3 kcal/mol). While the difference isn't huge, it's a contributing factor.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across the most important parameters for a GPCR drug candidate, especially logP, TPSA, DILI, and BBB. While both have issues with Caco-2 and solubility, Ligand A's superior ADME properties and slightly better affinity make it the more promising candidate.
**Output:**
1
2025-04-17 21:28:02,849 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (376.873 and 361.467 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Both ligands (88.49 and 83.48) are below the 140 A^2 threshold for good oral absorption, but are not particularly low.
3. **logP:** Both ligands (2.787 and 3.395) are within the optimal 1-3 range. Ligand B is slightly higher, potentially increasing permeability but also raising concerns about off-target effects.
4. **HBD:** Ligand A (2) and Ligand B (3) are both acceptable, below the 5 limit.
5. **HBA:** Ligand A (6) and Ligand B (5) are both acceptable, below the 10 limit.
6. **QED:** Both ligands have good QED scores (0.646 and 0.706), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (78.247) has a higher DILI risk than Ligand B (64.56). This is a significant negative for Ligand A.
8. **BBB:** Ligand B (63.358) has a substantially higher BBB penetration percentile than Ligand A (30.05). While ADRB2 isn't strictly a CNS target, some CNS exposure can occur, and higher BBB is generally favorable.
9. **Caco-2:** Ligand A (-5.504) has a worse Caco-2 permeability than Ligand B (-4.778).
10. **Solubility:** Both ligands have very poor aqueous solubility (-3.433 and -3.599). This is a major concern for both.
11. **hERG:** Both ligands have low hERG inhibition risk (0.265 and 0.367).
12. **Cl_mic:** Ligand B (27.109) has a lower microsomal clearance than Ligand A (42.872), suggesting better metabolic stability.
13. **t1/2:** Ligand B (7.165) has a longer in vitro half-life than Ligand A (-6.957). This is a significant advantage for Ligand B.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.268 and 0.321).
15. **Binding Affinity:** Ligand A (-7.1) has a slightly better binding affinity than Ligand B (-7.0). However, the difference is small (0.1 kcal/mol) and may not be enough to overcome other deficiencies.
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are important. Both ligands perform reasonably well on logP and Pgp. TPSA is similar. The affinity difference is small. However, the significant advantages of Ligand B in terms of DILI risk, BBB penetration, metabolic stability (Cl_mic), and half-life outweigh the slight affinity advantage of Ligand A. The poor solubility of both is a concern, but can potentially be addressed with formulation strategies.
**Conclusion:**
Ligand B is the more promising candidate due to its superior ADME properties and lower toxicity risk, despite a slightly weaker binding affinity.
Output:
0
2025-04-17 21:28:02,849 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (382.255) is slightly higher than Ligand B (343.427), but both are acceptable.
2. **TPSA:** Ligand B (80.32) is significantly better than Ligand A (107.71). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (4.425) is higher than Ligand B (1.839). While 4.425 is pushing the upper limit, it's not drastically outside the optimal range. Ligand B is well within the ideal range.
4. **HBD:** Both ligands have 2 HBD, which is good.
5. **HBA:** Both ligands have 4 HBA, which is good.
6. **QED:** Both ligands have acceptable QED scores (Ligand A: 0.42, Ligand B: 0.557). Ligand B is slightly better here.
7. **DILI:** Ligand B (31.718) has a much lower DILI risk than Ligand A (72.043). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (61.923) has a higher BBB penetration than Ligand B (47.693), but this isn't a high priority for a cardiovascular target.
9. **Caco-2:** Both ligands have similar, poor Caco-2 permeability (-4.824 and -4.864). This is a concern for both, suggesting potential absorption issues.
10. **Solubility:** Ligand B (-2.107) has better solubility than Ligand A (-4.952). This is a positive for Ligand B.
11. **hERG:** Ligand B (0.178) has a lower hERG risk than Ligand A (0.652). This is a crucial advantage, as hERG inhibition can lead to cardiotoxicity.
12. **Cl_mic:** Ligand B (21.001) has significantly lower microsomal clearance than Ligand A (56.634). This indicates better metabolic stability for Ligand B.
13. **t1/2:** Ligand A (93.457) has a much longer in vitro half-life than Ligand B (-21.535). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.242) has lower P-gp efflux than Ligand B (0.046), which is favorable.
15. **Binding Affinity:** Ligand A (-6.3 kcal/mol) has a slightly better binding affinity than Ligand B (-5.6 kcal/mol). This is a 0.7 kcal/mol difference, which is noticeable but not overwhelming.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has a better logP and Pgp, and slightly better affinity. However, Ligand B excels in TPSA, DILI, hERG, and Cl_mic. The lower DILI and hERG risks, combined with better metabolic stability (Cl_mic), are critical for a cardiovascular drug. The slightly lower affinity of Ligand B is likely surmountable with further optimization. The poor Caco-2 values are a concern for both, but can be addressed with formulation strategies.
**Conclusion:**
Considering the balance of properties and the priorities for a cardiovascular GPCR target, Ligand B is the more promising candidate due to its significantly improved safety profile (lower DILI and hERG) and metabolic stability, despite slightly weaker affinity.
Output:
0
2025-04-17 21:28:02,849 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.5 and 343.4 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (49.4) is significantly better than Ligand B (78.4). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally improves absorption.
3. **logP:** Ligand A (4.813) is higher than Ligand B (0.538). While 4.813 is approaching the upper limit, it's still within a reasonable range for a GPCR ligand. Ligand B's logP is quite low, potentially hindering membrane permeability.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 2 HBA, while Ligand B has 5. Ligand A is preferable here, as excessive HBA can reduce permeability.
6. **QED:** Ligand B (0.863) has a slightly better QED score than Ligand A (0.697), suggesting a more intrinsically drug-like structure.
7. **DILI:** Ligand B (23.11) has a much lower DILI risk than Ligand A (31.989), a significant advantage.
8. **BBB:** Both have reasonably high BBB penetration (86.39 and 79.992), but this isn't critical for a cardiovascular target.
9. **Caco-2:** Ligand A (-4.373) has a slightly better Caco-2 permeability than Ligand B (-5.054).
10. **Solubility:** Ligand B (-1.353) has better aqueous solubility than Ligand A (-4.989).
11. **hERG:** Ligand A (0.816) has a slightly better hERG profile than Ligand B (0.417).
12. **Cl_mic:** Ligand B (1.871) has significantly better metabolic stability (lower clearance) than Ligand A (104.052). This is a major advantage.
13. **t1/2:** Ligand B (-11.898) has a much longer in vitro half-life than Ligand A (73.984). This is a substantial benefit.
14. **Pgp:** Ligand A (0.452) has lower P-gp efflux than Ligand B (0.006), which is preferable.
15. **Binding Affinity:** Ligand B (-6.1 kcal/mol) has a significantly stronger binding affinity than Ligand A (-4.4 kcal/mol). This 1.7 kcal/mol difference is substantial and can outweigh many ADME concerns.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand B has a lower logP, but the significantly stronger affinity and better metabolic stability (Cl_mic, t1/2) are compelling. The lower DILI risk is also a major positive. While Ligand A has better TPSA, the overall profile of Ligand B is more favorable.
**Conclusion:**
Ligand B is the better candidate. The significantly improved binding affinity, metabolic stability, half-life, and reduced DILI risk outweigh the slightly less favorable TPSA and logP.
Output:
0
2025-04-17 21:28:02,849 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (336.347) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (68.71) is significantly better than Ligand B (84.31). ADRB2 is a cardiovascular target, so CNS penetration isn't crucial, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (3.997) is optimal, while Ligand B (0.898) is quite low. Low logP can hinder membrane permeability. This is a significant advantage for Ligand A.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Both ligands have 6 HBA, which is acceptable.
6. **QED:** Both ligands have good QED scores (A: 0.525, B: 0.789), indicating drug-likeness. Ligand B is slightly better here.
7. **DILI:** Ligand A (95.89) has a very high DILI risk, which is a major concern. Ligand B (33.579) has a low DILI risk, a significant advantage.
8. **BBB:** Both have reasonable BBB penetration (A: 76.037, B: 74.292), but this isn't a primary concern for a cardiovascular target.
9. **Caco-2:** Ligand A (-4.477) is worse than Ligand B (-5.122), indicating lower intestinal absorption.
10. **Solubility:** Ligand A (-6.505) is worse than Ligand B (-1.199). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.815) is better than Ligand B (0.164), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand A (134.103) has a higher clearance than Ligand B (-17.72), meaning Ligand B is more metabolically stable.
13. **t1/2:** Ligand A (65.546) has a longer half-life than Ligand B (15.857), which is desirable.
14. **Pgp:** Ligand A (0.736) is better than Ligand B (0.008), suggesting lower P-gp efflux.
15. **Affinity:** Ligand A (-8.5) has a significantly stronger binding affinity than Ligand B (-6.2). This is a substantial advantage, potentially outweighing some ADME concerns.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A excels in logP, Pgp, and *especially* affinity. Ligand B has a much better DILI score.
**Overall Assessment:**
Ligand A's superior binding affinity is a major driver. While its DILI risk is concerning, the strong binding could potentially allow for a lower dose, mitigating some of that risk. The better logP and Pgp also contribute to its favorability. Ligand B's lower DILI is attractive, but its significantly weaker binding and poor logP are substantial drawbacks. The metabolic stability of ligand B is good, but the binding affinity is too low to compensate.
Output:
1
2025-04-17 21:28:02,849 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [453.692, 67.43, 4.581, 2, 4, 0.651, 82.28, 68.36, -4.828, -6.012, 0.483, 60.502, 66.892, 0.507, -6.9]
**Ligand B:** [350.419, 116.48, -0.125, 4, 6, 0.547, 35.905, 32.726, -5.486, -0.901, 0.095, -12.535, 0.312, 0.004, -6.1]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, Affinity, and BBB):
1. **MW:** Ligand B (350.419 Da) is better, falling nicely within the ideal range. Ligand A (453.692 Da) is at the upper limit, but still acceptable.
2. **TPSA:** Ligand A (67.43) is significantly better than Ligand B (116.48). Lower TPSA generally improves permeability, crucial for GPCRs.
3. **logP:** Ligand A (4.581) is higher than optimal. Ligand B (-0.125) is *too* low, potentially causing permeability issues.
4. **HBD/HBA:** Both have acceptable numbers. Ligand B has more HBA (6 vs 4), which could slightly hinder permeability.
5. **QED:** Both are good (0.651 and 0.547), indicating reasonable drug-likeness.
6. **DILI:** Ligand B (35.905) is *much* better than Ligand A (82.28), indicating a significantly lower risk of liver injury. This is a major advantage.
7. **BBB:** Ligand A (68.36) is better than Ligand B (32.726). While not a primary concern for ADRB2 (cardiovascular target), some CNS penetration can be beneficial for off-target effects assessment.
8. **Caco-2:** Ligand A (-4.828) is better than Ligand B (-5.486), indicating better intestinal absorption.
9. **Solubility:** Ligand A (-6.012) is better than Ligand B (-0.901).
10. **hERG:** Ligand A (0.483) is better than Ligand B (0.095), indicating lower cardiotoxicity risk.
11. **Cl_mic:** Ligand B (-12.535) is *much* better than Ligand A (60.502), suggesting significantly better metabolic stability.
12. **t1/2:** Ligand A (66.892) is better than Ligand B (0.312).
13. **Pgp:** Ligand A (0.507) is better than Ligand B (0.004), indicating lower P-glycoprotein efflux.
14. **Affinity:** Ligand A (-6.9 kcal/mol) is slightly better than Ligand B (-6.1 kcal/mol), but the difference is not huge.
**Overall Assessment:**
Ligand B has a clear advantage in safety (DILI, hERG) and metabolic stability (Cl_mic). However, its low logP and high TPSA are concerning for permeability. Ligand A has a better balance of properties, with acceptable permeability characteristics (TPSA, logP, Caco-2) and good metabolic stability. The slightly better affinity of Ligand A further supports its selection. While Ligand A's DILI risk is higher, it's not excessively so, and can be addressed with further optimization. The combination of better permeability and slightly better affinity makes Ligand A the more promising candidate.
Output:
1
2025-04-17 21:28:02,850 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (355.435 and 348.443 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand B (84.5) is significantly better than Ligand A (110.18). ADRB2 is not a CNS target, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (0.898) is closer to the optimal 1-3 range than Ligand A (-1.254). Ligand A's logP is quite low, potentially hindering membrane permeability.
4. **HBD:** Ligand B (2) is preferable to Ligand A (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand B (4) is preferable to Ligand A (6). Fewer HBAs generally improve permeability.
6. **QED:** Both ligands have good QED scores (0.526 and 0.67), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand B (25.204) has a significantly lower DILI risk than Ligand A (16.906). This is a crucial advantage.
8. **BBB:** This is less critical for ADRB2, but Ligand B (57.193) is better than Ligand A (14.541).
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-5.386) is slightly better than Ligand B (-4.567), but both are concerning.
10. **Solubility:** Ligand A (-0.031) is slightly better than Ligand B (-2.595), but both are very poor. This is a significant drawback for both.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.017 and 0.071), which is excellent.
12. **Cl_mic:** Ligand A (-10.156) has a much lower (better) microsomal clearance than Ligand B (29.543), indicating better metabolic stability.
13. **t1/2:** Ligand B (-9.493) has a slightly better in vitro half-life than Ligand A (-18.54).
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.004 and 0.028), which is excellent.
15. **Binding Affinity:** Both ligands have similar binding affinities (-6.5 and -5.7 kcal/mol). Ligand A is slightly better, but the difference is not substantial enough to overcome other issues.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand B excels in logP and TPSA, and has a lower DILI risk. While Ligand A has slightly better affinity and metabolic stability, the poor logP and higher DILI risk are major concerns. The solubility of both is poor, but this can be addressed with formulation strategies.
**Conclusion:**
Considering the balance of properties, particularly the better logP, TPSA, and significantly lower DILI risk, Ligand B is the more promising drug candidate.
Output:
0
2025-04-17 21:28:02,850 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.443 and 373.875 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (66.92) is better than Ligand B (38.13). Both are well below the 140 A^2 threshold for oral absorption, but the lower TPSA of Ligand B is more favorable for GPCRs, potentially aiding receptor binding and reducing off-target interactions.
3. **logP:** Ligand A (1.769) is optimal, while Ligand B (4.446) is pushing the upper limit. High logP can lead to solubility issues and non-specific binding. This favors Ligand A.
4. **HBD:** Both ligands have 0 HBD, which is acceptable.
5. **HBA:** Ligand A (4) is slightly higher than Ligand B (3), but both are within the acceptable range of <=10.
6. **QED:** Ligand B (0.523) has a slightly better QED score than Ligand A (0.417), indicating a more drug-like profile.
7. **DILI:** Ligand A (34.703) has a significantly higher DILI risk than Ligand B (19.698). This is a major concern, as liver toxicity is a common reason for drug failure.
8. **BBB:** Ligand B (87.864) has a higher BBB penetration percentile than Ligand A (76.735). While ADRB2 isn't strictly a CNS target, some peripheral ADRB2 activity can be modulated by CNS effects, and higher BBB penetration isn't necessarily detrimental.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.523 and -4.385), which is unusual and suggests poor permeability. This is a significant drawback for both.
10. **Solubility:** Ligand A (-1.85) has better solubility than Ligand B (-5.561). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.227) has a lower hERG inhibition liability than Ligand B (0.511), which is favorable for reducing cardiotoxicity risk.
12. **Cl_mic:** Ligand B (72.131) has a higher microsomal clearance than Ligand A (54.575), indicating lower metabolic stability. This is a negative for Ligand B.
13. **t1/2:** Ligand A (-26.001) has a much more negative in vitro half-life than Ligand B (-1.625), which is a significant drawback. This suggests very rapid metabolism.
14. **Pgp:** Ligand A (0.111) has lower P-gp efflux liability than Ligand B (0.314), which is favorable for oral bioavailability.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.2 and -5.8 kcal/mol). The difference is not substantial enough to be a deciding factor.
**Overall Assessment:**
Ligand B appears to be the better candidate despite its higher logP. The significantly lower DILI risk and better QED score outweigh the slightly higher logP and Pgp efflux. The better BBB penetration is a bonus. Ligand A's extremely poor in vitro half-life is a major concern, and its higher DILI risk is unacceptable. While both have poor Caco-2 permeability, this is a shared issue that would need to be addressed through formulation or prodrug strategies. The slightly better solubility of Ligand A is not enough to overcome its other significant drawbacks.
Output:
0
2025-04-17 21:28:02,850 - INFO - Batch 260 complete. Total preferences: 4160
2025-04-17 21:28:02,850 - INFO - Processing batch 261/512...
2025-04-17 21:28:52,423 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [367.446, 91.32, 2.459, 3, 5, 0.509, 50.33, 45.444, -5.184, -3.601, 0.234, 52.358, -3.625, 0.097, -7.4]**
**Ligand B: [352.475, 98.66, 0.811, 4, 4, 0.545, 16.479, 30.554, -5.206, -2.404, 0.216, 4.492, 16.311, 0.049, -6.1]**
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand B (352.475) is slightly lower, which is generally favorable for permeability, but the difference isn't substantial.
2. **TPSA:** Both are reasonably good, below the 140 A^2 threshold for oral absorption. Ligand A (91.32) is better than Ligand B (98.66).
3. **logP:** Ligand A (2.459) is optimal. Ligand B (0.811) is a bit low, potentially hindering membrane permeability.
4. **H-Bond Donors:** Both are acceptable (3 and 4 respectively), within the limit of 5.
5. **H-Bond Acceptors:** Both are acceptable (5 and 4 respectively), within the limit of 10.
6. **QED:** Both have good drug-likeness scores (0.509 and 0.545).
7. **DILI:** Ligand A (50.33) has a moderate DILI risk, while Ligand B (16.479) has a very low risk. This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (45.444) shows moderate BBB penetration, while Ligand B (30.554) is lower. While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant for off-target effects or potential therapeutic strategies.
9. **Caco-2:** Both have negative values, indicating good permeability. The values are very similar (-5.184 and -5.206).
10. **Aqueous Solubility:** Both are very poor (-3.601 and -2.404). Solubility is a concern for both, but Ligand B is slightly better.
11. **hERG:** Both have low hERG inhibition risk (0.234 and 0.216).
12. **Microsomal Clearance:** Ligand A (52.358) has higher clearance, suggesting lower metabolic stability. Ligand B (4.492) has much lower clearance, indicating better metabolic stability.
13. **In vitro Half-Life:** Ligand A (-3.625) has a shorter half-life, while Ligand B (16.311) has a much longer half-life.
14. **P-gp Efflux:** Both have low P-gp efflux (0.097 and 0.049).
15. **Binding Affinity:** Ligand A (-7.4) has a significantly stronger binding affinity than Ligand B (-6.1). This is a 1.3 kcal/mol difference, which is substantial.
**GPCR-Specific Considerations:** For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand A excels in affinity, and has a good logP and TPSA. Ligand B has a better DILI score and metabolic stability, but weaker affinity and a lower logP. The difference in binding affinity is substantial enough to outweigh the better ADME properties of Ligand B.
**Conclusion:**
Despite the better safety profile (lower DILI) and metabolic stability of Ligand B, the significantly stronger binding affinity of Ligand A (-7.4 vs -6.1 kcal/mol) is the deciding factor. A strong binding affinity is crucial for efficacy, and the 1.3 kcal/mol difference is likely to have a significant impact on potency.
1
2025-04-17 21:28:52,424 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.403 and 338.459 Da) are within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (89.6) is better than Ligand B (65.97). Both are below the 140 threshold for oral absorption, but lower TPSA is generally preferred for GPCRs, potentially aiding BBB penetration.
3. **logP:** Ligand A (1.692) is optimal, while Ligand B (3.487) is approaching the upper limit. Ligand A is better here.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Both ligands have 6 HBA, which is acceptable.
6. **QED:** Both ligands have good QED scores (0.822 and 0.89), indicating good drug-like properties. No clear advantage.
7. **DILI:** Ligand A (53.276) has a lower DILI risk than Ligand B (66.344), which is a significant advantage.
8. **BBB:** Ligand B (86.623) has a much higher BBB penetration score than Ligand A (51.997). While ADRB2 isn't strictly a CNS target, some CNS exposure can be acceptable and even beneficial for certain cardiovascular indications.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.525) is slightly better than Ligand B (-4.882), but both are problematic.
10. **Solubility:** Ligand A (-2.485) has better solubility than Ligand B (-5.24). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.197) has a lower hERG risk than Ligand B (0.691), which is a crucial safety consideration.
12. **Cl_mic:** Ligand A (53.968) has lower microsomal clearance than Ligand B (90.312), indicating better metabolic stability.
13. **t1/2:** Ligand B (42.086) has a significantly longer in vitro half-life than Ligand A (5.941). This is a substantial advantage, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.101) has lower P-gp efflux than Ligand B (0.222), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand B (-7.0) has a significantly stronger binding affinity than Ligand A (-4.8). This is a major advantage, potentially outweighing some of the ADME drawbacks.
**Overall Assessment:**
Ligand B has a significantly better binding affinity and a longer half-life, which are critical for a GPCR target. While Ligand A has better DILI, hERG, solubility, and Pgp properties, the substantial affinity advantage of Ligand B is compelling. The higher BBB score for Ligand B is also a plus. The Caco-2 values are concerning for both, but the stronger binding and longer half-life of Ligand B are more important for initial optimization.
Output:
0
2025-04-17 21:28:52,424 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (365.543 Da) is within the ideal range (200-500 Da). Ligand B (392.248 Da) is also acceptable. No clear advantage here.
2. **TPSA:** Ligand A (53.51) is higher than Ligand B (20.31). For a GPCR, lower TPSA is generally preferred for better brain penetration and overall permeability. Ligand B is significantly better.
3. **logP:** Ligand A (3.232) is within the optimal range (1-3). Ligand B (4.747) is slightly higher, potentially leading to solubility issues and off-target interactions, but still within a tolerable range. Ligand A is slightly better.
4. **HBD:** Both ligands have 0 HBD, which is good.
5. **HBA:** Ligand A has 4 HBA, Ligand B has 1 HBA. Lower HBA is generally better for permeability. Ligand B is better.
6. **QED:** Ligand A (0.597) has a better QED score than Ligand B (0.389), indicating better overall drug-likeness. Ligand A is better.
7. **DILI:** Ligand A (31.369%) has a lower DILI risk than Ligand B (46.956%), which is a significant advantage. Ligand A is better.
8. **BBB:** Ligand A (73.866%) and Ligand B (91.663%) both have good BBB penetration, but Ligand B is significantly better. For a cardiovascular target, BBB isn't *critical*, but higher is still preferable. Ligand B is better.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.791) is slightly better (less negative) than Ligand B (-4.468).
10. **Solubility:** Ligand A (-2.385) has better solubility than Ligand B (-5.577). Solubility is important for bioavailability. Ligand A is better.
11. **hERG:** Both ligands have low hERG inhibition risk (0.673 and 0.813 respectively). No significant difference.
12. **Cl_mic:** Ligand A (104.757) has a higher microsomal clearance than Ligand B (76.549), meaning it's metabolized faster. Ligand B is better.
13. **t1/2:** Ligand A (42.283) has a longer in vitro half-life than Ligand B (-6.803). This is a significant advantage for dosing frequency. Ligand A is better.
14. **Pgp:** Ligand A (0.203) has lower P-gp efflux than Ligand B (0.479), which is good for bioavailability. Ligand A is better.
15. **Affinity:** Ligand B (-7.0 kcal/mol) has a slightly better binding affinity than Ligand A (-6.9 kcal/mol). While the difference is small, it's still a positive for Ligand B.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, and affinity. Ligand B excels in TPSA and affinity, while Ligand A is better in logP, Pgp, solubility, and DILI risk. Considering the slight advantage in affinity of Ligand B, and the importance of TPSA for GPCRs, the better BBB penetration of Ligand B is also a plus.
**Overall Assessment:**
While Ligand A has several advantages in ADME properties (DILI, solubility, Pgp, t1/2, QED), Ligand B's superior TPSA and slightly better affinity are more critical for a GPCR target like ADRB2. The slightly higher logP of Ligand B is a minor concern that could be addressed with further optimization.
Output:
0
2025-04-17 21:28:52,424 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.289 Da and 348.491 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (78.63) is better than Ligand B (88.32). Both are below 140, but A is closer to the optimal <90 for potential CNS penetration (though not a primary concern for ADRB2).
3. **logP:** Both ligands (2.533 and 2.765) are within the optimal 1-3 range. No clear advantage.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (6) is better than Ligand B (4). Both are within the acceptable range of <10, but fewer is generally preferred.
6. **QED:** Ligand B (0.793) is slightly better than Ligand A (0.623), indicating a more drug-like profile.
7. **DILI:** Ligand B (47.15) is *significantly* better than Ligand A (84.762). This is a major advantage for Ligand B, as lower DILI risk is crucial.
8. **BBB:** Ligand A (85.731) is better than Ligand B (76.735). While ADRB2 isn't a primary CNS target, higher BBB penetration is generally favorable.
9. **Caco-2:** Ligand B (-4.817) is better than Ligand A (-3.871), indicating better intestinal absorption.
10. **Solubility:** Ligand B (-3.205) is better than Ligand A (-4.29). Higher solubility is generally better for bioavailability.
11. **hERG:** Ligand A (0.275) is better than Ligand B (0.652). Lower hERG inhibition is critical for avoiding cardiotoxicity, especially important for a cardiovascular target like ADRB2.
12. **Cl_mic:** Ligand B (64.305) is *much* better than Ligand A (118.049). Lower microsomal clearance indicates greater metabolic stability.
13. **t1/2:** Ligand B (34.18) is better than Ligand A (-34.453). A positive half-life is better than a negative one.
14. **Pgp:** Ligand B (0.157) is better than Ligand A (0.426). Lower P-gp efflux is desirable for improved bioavailability.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.6 and -6.4 kcal/mol). The difference is negligible.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Ligand B has a slight edge in logP, significantly better Pgp, and comparable affinity. The *major* advantage of Ligand B is its dramatically lower DILI risk and improved metabolic stability (Cl_mic). While Ligand A has better hERG and BBB, the DILI and Cl_mic profiles of Ligand B are far more concerning and outweigh those benefits.
**Conclusion:**
Considering the balance of properties, particularly the critical importance of minimizing DILI risk and maximizing metabolic stability for a cardiovascular drug, Ligand B is the more promising candidate.
Output:
0
2025-04-17 21:28:52,424 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (355.419 and 350.375 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (84.34) is significantly better than Ligand B (116.52). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is pushing the upper limit for good oral absorption (<=140).
3. **logP:** Ligand A (3.87) is optimal, while Ligand B (-0.337) is quite low. Low logP can lead to poor membrane permeability and bioavailability. This is a major strike against Ligand B.
4. **HBD:** Both ligands have acceptable HBD counts (2 and 3, respectively), well below the threshold of 5.
5. **HBA:** Both ligands have acceptable HBA counts (6 and 5, respectively), well below the threshold of 10.
6. **QED:** Both ligands have good QED scores (0.726 and 0.687), indicating good drug-like properties.
7. **DILI:** Ligand A (94.649) has a higher DILI risk than Ligand B (60.644). This is a concern for Ligand A, but not a complete dealbreaker.
8. **BBB:** Both ligands have very low BBB penetration (19.542 and 18.961). As ADRB2 is a cardiovascular target, BBB penetration is not a primary concern, so this isn't a major differentiating factor.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.035 and -5.118). This is unusual and suggests poor permeability, but the values are similar.
10. **Solubility:** Ligand A (-4.699) has slightly better solubility than Ligand B (-1.491), but both are poor. Solubility could be improved with salt formation or formulation strategies.
11. **hERG:** Ligand A (0.442) has a much lower hERG risk than Ligand B (0.152). This is a significant advantage for Ligand A, as hERG inhibition can lead to cardiotoxicity.
12. **Cl_mic:** Ligand B (-3.388) has a significantly lower (better) microsomal clearance than Ligand A (57.181). This suggests better metabolic stability for Ligand B.
13. **t1/2:** Ligand B (-34.992) has a much longer in vitro half-life than Ligand A (-4.395). This is a substantial advantage for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.45) has lower P-gp efflux than Ligand B (0.01). Lower P-gp efflux is generally favorable for bioavailability.
15. **Binding Affinity:** Ligand B (-5.7) has a better binding affinity than Ligand A (-4.4). This is a 1.3 kcal/mol difference, which is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand B has a significantly better binding affinity and metabolic stability (lower Cl_mic, longer t1/2). However, its low logP is a major concern, potentially leading to poor absorption. Ligand A has a better logP and a much lower hERG risk, which is crucial for a cardiovascular target. While its DILI risk is higher, this can be investigated further. The TPSA of Ligand A is also preferable. Considering the balance of these factors, and prioritizing a reasonable logP and low hERG risk for a cardiovascular GPCR target, I favor Ligand A.
Output:
1
2025-04-17 21:28:52,425 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
We are targeting ADRB2, a GPCR. Therefore, the most important properties are binding affinity, logP, TPSA, Pgp efflux, and BBB penetration. Metabolic stability (Cl_mic, t1/2) and safety (DILI, hERG) are also important, but slightly less so than the first set.
Let's compare the ligands property by property:
1. **MW:** Both are within the acceptable range (200-500 Da). Ligand A (369.531) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (46.61) is significantly better than Ligand A (74.69). Lower TPSA is preferred for GPCRs, aiding in brain penetration and overall absorption.
3. **logP:** Both ligands have good logP values (A: 2.974, B: 3.377) within the optimal 1-3 range. Ligand B is slightly higher, which could potentially lead to off-target effects, but is still acceptable.
4. **HBD/HBA:** Ligand A has 2 HBD and 6 HBA, while Ligand B has 0 HBD and 3 HBA. Both are within acceptable limits.
5. **QED:** Ligand A (0.773) has a much better QED score than Ligand B (0.361), indicating a more drug-like profile.
6. **DILI:** Both have relatively low DILI risk (A: 37.922, B: 33.579), with Ligand B being marginally better.
7. **BBB:** Ligand B (95.967) has a *much* higher BBB penetration percentile than Ligand A (43.079). This is a significant advantage for a GPCR target, even if not specifically a CNS target, as it suggests better overall distribution.
8. **Caco-2:** Both have negative Caco-2 values which is unusual and suggests poor permeability.
9. **Solubility:** Both have negative solubility values which is unusual and suggests poor solubility.
10. **hERG:** Ligand A (0.48) is better than Ligand B (0.755) in terms of hERG inhibition liability.
11. **Cl_mic:** Ligand A (34.643) has a lower microsomal clearance than Ligand B (84.746), indicating better metabolic stability.
12. **t1/2:** Both have similar in vitro half-lives (A: 14.894, B: 14.932).
13. **Pgp:** Ligand A (0.255) has a lower Pgp efflux liability than Ligand B (0.143), suggesting better bioavailability and potentially better CNS exposure.
14. **Binding Affinity:** Ligand A (-6.8 kcal/mol) has a slightly better binding affinity than Ligand B (-5.5 kcal/mol). This is a 1.3 kcal/mol difference, which is significant.
**Overall Assessment:**
While Ligand B has a significantly better BBB score, the superior binding affinity of Ligand A, combined with its better QED, lower Cl_mic, and lower hERG risk, makes it the more promising candidate. The negative Caco-2 and solubility values are concerning for both, but the stronger binding and better ADME properties of Ligand A outweigh the BBB advantage of Ligand B.
**Output:**
1
2025-04-17 21:28:52,425 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 GPCR, followed by the final output.
**Ligand A: [356.507, 81.08, 1.809, 2, 4, 0.462, 10.198, 55.099, -4.578, -0.824, 0.518, 56.985, 3.651, 0.091, -6.7]**
**Ligand B: [377.495, 92.93, 2.164, 2, 8, 0.613, 84.064, 19.698, -5.545, -2.93, 0.183, 43.685, 43.472, 0.308, -3.8]**
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). A (356.5) is slightly preferred.
2. **TPSA:** A (81.08) is better than B (92.93). Both are below 140, acceptable for oral absorption, but lower is generally better.
3. **logP:** Both are within the optimal range (1-3). A (1.809) is slightly preferred as it's closer to the middle of the range.
4. **H-Bond Donors:** Both have 2 HBD, which is good.
5. **H-Bond Acceptors:** A (4) is better than B (8). Lower HBA is preferred for better permeability.
6. **QED:** B (0.613) is better than A (0.462). Higher QED indicates better drug-likeness.
7. **DILI:** A (10.198) is significantly better than B (84.064). This is a major advantage for Ligand A.
8. **BBB:** A (55.099) is better than B (19.698). While not a primary concern for ADRB2 (cardiovascular target), higher BBB is still a positive.
9. **Caco-2:** A (-4.578) is better than B (-5.545). Higher Caco-2 suggests better absorption.
10. **Solubility:** A (-0.824) is better than B (-2.93). Better solubility is desirable.
11. **hERG:** A (0.518) is better than B (0.183). Lower hERG inhibition is crucial for avoiding cardiotoxicity.
12. **Cl_mic:** B (43.685) is better than A (56.985). Lower clearance indicates better metabolic stability.
13. **t1/2:** B (43.472) is much better than A (3.651). Longer half-life is desirable.
14. **Pgp:** A (0.091) is better than B (0.308). Lower P-gp efflux is preferred.
15. **Binding Affinity:** A (-6.7) is significantly better than B (-3.8). A difference of 2.9 kcal/mol is substantial and can outweigh many ADME drawbacks.
**Overall Assessment:**
Ligand A has a significantly stronger binding affinity and a much lower DILI risk, which are critical factors. It also performs better in TPSA, logP, HBA, BBB, Caco-2, solubility, hERG, and Pgp. While Ligand B has better QED, clearance, and half-life, the superior affinity and safety profile of Ligand A are more important, especially given the GPCR target class. The substantial difference in binding affinity (-6.7 vs -3.8 kcal/mol) is a key driver in this decision.
Output:
1
2025-04-17 21:28:52,425 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (353.442 and 350.409 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (90.38) is higher than Ligand B (53.43). For a cardiovascular GPCR, TPSA is moderately important. Ligand B is significantly better here, suggesting better permeability.
3. **logP:** Ligand A (0.956) is slightly lower than the optimal 1-3 range, while Ligand B (3.248) is within the optimal range. Ligand B has a clear advantage for membrane permeability and receptor engagement.
4. **HBD:** Ligand A (3) is higher than Ligand B (1). Lower HBD is generally preferred for better permeability. Ligand B is better.
5. **HBA:** Ligand A (6) is higher than Ligand B (3). Similar to HBD, lower HBA is preferred. Ligand B is better.
6. **QED:** Both ligands have good QED scores (0.676 and 0.821), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (10.237) has a lower DILI risk than Ligand B (22.683). This is a significant advantage for Ligand A.
8. **BBB:** Ligand B (91.276) has a higher BBB penetration percentile than Ligand A (74.176). While ADRB2 isn't a CNS target, some distribution to the CNS can be a concern for off-target effects, but the difference isn't huge.
9. **Caco-2:** Ligand A (-5.431) and Ligand B (-4.451) both have negative values, indicating poor permeability. This is a concern for both, but Ligand B is slightly better.
10. **Solubility:** Ligand A (-1.074) has better solubility than Ligand B (-3.367). Solubility is important for bioavailability.
11. **hERG:** Both ligands have low hERG inhibition risk (0.425 and 0.56). No significant difference.
12. **Cl_mic:** Ligand A (-30.062) has a much lower (better) microsomal clearance than Ligand B (31.777). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (12.906) has a longer in vitro half-life than Ligand B (-7.547). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.014) has much lower P-gp efflux liability than Ligand B (0.394). This is a significant advantage for Ligand A, improving bioavailability.
15. **Binding Affinity:** Ligand B (-7.8) has a slightly better binding affinity than Ligand A (-5.6). This is a 2.2 kcal/mol difference, which is substantial and could outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand B has a better logP, QED, and binding affinity. However, Ligand A demonstrates superior ADME properties: lower DILI risk, lower Cl_mic, longer t1/2, and significantly lower P-gp efflux. The binding affinity difference is notable, but the ADME profile of Ligand A is more favorable for overall drug development, especially considering the potential for metabolic instability and efflux issues with Ligand B. The lower DILI risk is also a major advantage.
Output:
1
2025-04-17 21:28:52,425 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (364.471 and 360.933 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (92.35) is higher than Ligand B (25.99). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B is significantly better here.
3. **logP:** Ligand A (2.688) is within the optimal 1-3 range. Ligand B (4.337) is slightly higher, potentially increasing off-target effects and decreasing solubility. Ligand A is better.
4. **HBD:** Ligand A (1) is better than Ligand B (0). Having at least one HBD can improve solubility.
5. **HBA:** Ligand A (7) is higher than Ligand B (4). While both are acceptable, lower HBA is generally preferred for permeability. Ligand B is slightly better.
6. **QED:** Ligand A (0.812) is significantly higher than Ligand B (0.622), indicating a more drug-like profile. This is a strong advantage for Ligand A.
7. **DILI:** Ligand A (55.448) has a higher DILI risk than Ligand B (12.834). This is a significant concern for Ligand A.
8. **BBB:** Both are relatively high, but Ligand A (76.192) is higher than Ligand B (66.033). While ADRB2 isn't a primary CNS target, some BBB penetration can be beneficial for distribution.
9. **Caco-2:** Both are negative, indicating poor permeability. This is a concern for both.
10. **Solubility:** Both are negative, indicating poor solubility. This is a concern for both.
11. **hERG:** Ligand A (0.253) has a lower hERG risk than Ligand B (0.889). This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand A (56.019) has a higher microsomal clearance than Ligand B (40.354), suggesting lower metabolic stability. Ligand B is better.
13. **t1/2:** Ligand B (50.821) has a significantly longer in vitro half-life than Ligand A (17.989). This is a major advantage for Ligand B.
14. **Pgp:** Ligand A (0.291) has lower P-gp efflux than Ligand B (0.458). Lower Pgp is preferred. Ligand A is better.
15. **Binding Affinity:** Ligand B (-5.3 kcal/mol) has a stronger binding affinity than Ligand A (-8.4 kcal/mol). This is a substantial advantage for Ligand B.
**GPCR-Specific Considerations:**
For ADRB2 (a cardiovascular GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in TPSA and affinity, while Ligand A is better in logP and Pgp. However, the significantly stronger binding affinity of Ligand B (-5.3 vs -8.4 kcal/mol) is a major driver. The longer half-life of Ligand B is also a significant advantage. While Ligand A has a lower DILI risk and hERG, the difference in affinity and half-life outweigh these benefits.
**Conclusion:**
Despite the higher DILI risk, the superior binding affinity and half-life of Ligand B make it the more promising drug candidate for ADRB2.
Output:
0
2025-04-17 21:28:52,425 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (344.415 and 360.845 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (85.25) is slightly higher than Ligand B (65.54). For a cardiovascular GPCR, TPSA is not a major concern unless targeting the CNS, so Ligand B is slightly favored.
3. **logP:** Both ligands have good logP values (2.746 and 2.435), falling within the optimal 1-3 range. No significant difference.
4. **HBD:** Ligand A has 2 HBD, while Ligand B has 1. Both are acceptable (<=5). Ligand B is slightly favored due to lower HBD.
5. **HBA:** Ligand A has 6 HBA, and Ligand B has 4. Both are within the acceptable range (<=10). Ligand B is slightly favored.
6. **QED:** Both ligands have good QED scores (0.787 and 0.859), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A has a DILI risk of 81.078%, while Ligand B has 57.813%. This is a significant difference. Ligand B is *much* preferred due to the lower liver injury risk.
8. **BBB:** Both ligands have similar BBB penetration (65.374% and 69.872%). Since ADRB2 is not a primary CNS target, this isn't a critical factor, but Ligand B is slightly better.
9. **Caco-2:** Both ligands have similar, poor Caco-2 permeability (-4.638 and -4.637). This is a concern for oral bioavailability for both.
10. **Solubility:** Ligand A (-4.575) has lower aqueous solubility than Ligand B (-2.848). Ligand B is favored.
11. **hERG:** Both ligands have low hERG inhibition risk (0.355 and 0.453). No significant difference.
12. **Cl_mic:** Ligand A has a higher microsomal clearance (108.935) than Ligand B (43.248), indicating lower metabolic stability. Ligand B is strongly favored.
13. **t1/2:** Ligand B has a significantly longer in vitro half-life (57.879 hours) than Ligand A (16.965 hours). This is a major advantage for Ligand B.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.199 and 0.079). Ligand B is slightly favored.
15. **Binding Affinity:** Ligand B (-6.1 kcal/mol) has a slightly better binding affinity than Ligand A (-5.6 kcal/mol). This difference (0.5 kcal/mol) is meaningful, and contributes to the overall preference for Ligand B.
**Overall Assessment:**
Ligand B consistently outperforms Ligand A across several key ADME-Tox properties (DILI, Cl_mic, t1/2, Solubility) and has a slightly better binding affinity. While both have poor Caco-2 permeability, the superior safety profile and metabolic stability of Ligand B make it the more promising drug candidate for ADRB2.
Output:
0
2025-04-17 21:28:52,425 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.371 and 347.415 Da) fall comfortably within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (117.51) is slightly higher than Ligand B (95.41). For a cardiovascular GPCR, TPSA is not a primary concern unless targeting the CNS, but lower is generally preferable for absorption. Ligand B is better here.
3. **logP:** Ligand B (1.518) is within the optimal 1-3 range, while Ligand A (0.385) is below 1. This is a significant difference. Lower logP can lead to poor membrane permeability. Ligand B is significantly better.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (2). Both are acceptable, but lower is slightly preferred.
5. **HBA:** Ligand A (5) is slightly higher than Ligand B (4). Both are acceptable, but lower is slightly preferred.
6. **QED:** Both ligands have similar QED values (0.666 and 0.627), indicating good drug-likeness. No significant difference.
7. **DILI:** Ligand B (41.877) has a considerably lower DILI risk than Ligand A (63.978). This is a crucial advantage, as liver toxicity is a major concern in drug development. Ligand B is much better.
8. **BBB:** Ligand B (52.656) has a higher BBB penetration percentile than Ligand A (41.218). While ADRB2 is primarily a cardiovascular target, some CNS side effects are possible, and higher BBB is generally not detrimental. Ligand B is better.
9. **Caco-2:** Ligand A (-5.413) and Ligand B (-4.661) both have negative Caco-2 values, which is unusual and suggests very poor permeability. However, the scale isn't specified, so it's difficult to interpret.
10. **Solubility:** Ligand A (-2.602) and Ligand B (-2.947) both have negative solubility values, which is also unusual and suggests very poor solubility. Again, the scale isn't specified.
11. **hERG:** Ligand A (0.035) has a slightly lower hERG risk than Ligand B (0.141), which is favorable.
12. **Cl_mic:** Ligand A (-2.684) has a much lower (better) microsomal clearance than Ligand B (24.963). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (5.849) has a shorter in vitro half-life than Ligand B (-49.667). The negative value for Ligand B is concerning and potentially an error.
14. **Pgp:** Ligand A (0.025) has a lower P-gp efflux liability than Ligand B (0.044), which is preferable.
15. **Binding Affinity:** Ligand A (-7.5) has a slightly better binding affinity than Ligand B (-5.6). This is a 1.9 kcal/mol difference, which is substantial and could outweigh some ADME drawbacks.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity and metabolic stability, Ligand B demonstrates a significantly better ADME profile, particularly regarding logP, DILI risk, and BBB penetration. The poor logP of Ligand A is a major concern, potentially hindering its absorption and bioavailability. The lower DILI risk of Ligand B is also a critical advantage. The negative values for Caco-2 and solubility are concerning for both, but the other benefits of Ligand B outweigh the slightly better affinity of Ligand A.
Given the GPCR-specific priorities (logP, Pgp, TPSA, affinity), and the importance of ADME properties for *in vivo* efficacy, Ligand B is the more promising candidate.
Output:
0
2025-04-17 21:28:52,426 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (345.443 Da and 351.535 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (71.53) is higher than Ligand B (44.81). For a cardiovascular GPCR, TPSA is moderately important; lower is generally better for permeability. Ligand B has a clear advantage.
**3. logP:** Both ligands have good logP values (2.258 and 1.97), falling within the optimal 1-3 range. No major difference.
**4. H-Bond Donors:** Both have 1 HBD, which is acceptable.
**5. H-Bond Acceptors:** Ligand A has 5 HBAs, and Ligand B has 4. Both are within the acceptable limit of 10.
**6. QED:** Both ligands have good QED scores (0.606 and 0.726), indicating good drug-like properties. Ligand B is slightly better.
**7. DILI:** Ligand A (33.307) has a slightly higher DILI risk than Ligand B (3.994), but both are well below the concerning threshold of 60. Ligand B is preferable.
**8. BBB:** Ligand B (86.894) has significantly better BBB penetration than Ligand A (70.027). While ADRB2 is a cardiovascular target, some CNS effects can be relevant or even desirable for certain indications, and better BBB penetration is rarely a detriment.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand B (-4.864) is slightly less negative than Ligand A (-4.594), potentially indicating marginally better permeability, but both are concerning.
**10. Aqueous Solubility:** Ligand B (-1.141) has better aqueous solubility than Ligand A (-2.184). This is important for formulation and bioavailability.
**11. hERG Inhibition:** Ligand A (0.342) has a lower hERG inhibition liability than Ligand B (0.714). This is a significant advantage for Ligand A, as hERG inhibition can lead to cardiotoxicity.
**12. Microsomal Clearance:** Ligand A (109.88) has a higher microsomal clearance than Ligand B (15.928), meaning it's metabolized more quickly. Ligand B has a substantial advantage in metabolic stability.
**13. In vitro Half-Life:** Ligand B (2.014 hours) has a longer half-life than Ligand A (7.35 hours). This is a significant advantage for Ligand B, potentially allowing for less frequent dosing.
**14. P-gp Efflux:** Ligand A (0.076) has lower P-gp efflux than Ligand B (0.04). Lower P-gp efflux is generally preferred.
**15. Binding Affinity:** Ligand B (-6.7 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.0 kcal/mol). This is a crucial factor, as a 1.7 kcal/mol difference is substantial and can often outweigh minor ADME drawbacks.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity) and the overall profile, **Ligand B is the more promising candidate**. While Ligand A has a better hERG profile and P-gp efflux, the significantly stronger binding affinity of Ligand B (-6.7 vs -5.0 kcal/mol), coupled with its superior BBB penetration, lower DILI risk, better solubility, and improved metabolic stability (lower Cl_mic and longer half-life), outweigh the hERG concern. The lower TPSA of Ligand B is also a benefit. The Caco-2 permeability is a concern for both, but the overall balance favors Ligand B.
Output:
0
2025-04-17 21:28:52,426 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (399.292 Da) is slightly higher than Ligand B (343.427 Da), but both are acceptable.
2. **TPSA:** Ligand A (59.29) is better than Ligand B (73.74). Both are under the 140 A^2 threshold for oral absorption, but lower TPSA is generally preferred for GPCRs to aid permeability.
3. **logP:** Ligand A (3.527) is within the optimal range (1-3), while Ligand B (1.534) is at the lower end. For a GPCR, a slightly higher logP is often beneficial for membrane permeability and receptor engagement.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Both ligands have 4 HBA, which is good.
6. **QED:** Ligand B (0.842) has a slightly better QED score than Ligand A (0.683), indicating a more drug-like profile.
7. **DILI:** Ligand B (38.813) has a significantly lower DILI risk than Ligand A (72.276). This is a major advantage for Ligand B.
8. **BBB:** Ligand A (78.79) has a better BBB penetration score than Ligand B (52.268). While ADRB2 isn't necessarily a CNS target, some peripheral ADRB2 receptors can be affected by CNS penetration.
9. **Caco-2:** Ligand A (-5.273) has a better Caco-2 permeability than Ligand B (-4.653).
10. **Solubility:** Ligand A (-4.331) has better solubility than Ligand B (-1.173).
11. **hERG:** Both ligands have very low hERG inhibition risk (0.355 and 0.266, respectively).
12. **Cl_mic:** Ligand B (15.568) has a lower microsomal clearance than Ligand A (25.886), suggesting better metabolic stability.
13. **t1/2:** Ligand A (39.928) has a much longer in vitro half-life than Ligand B (-2.935). This is a significant advantage for Ligand A.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.667 and 0.083, respectively).
15. **Binding Affinity:** Ligand B (-6.8 kcal/mol) has a significantly stronger binding affinity than Ligand A (-4.6 kcal/mol). This is a substantial advantage, potentially outweighing some ADME concerns.
**Overall Assessment:**
Ligand B has a much better binding affinity and a significantly lower DILI risk, which are critical factors. It also has better metabolic stability (lower Cl_mic). While Ligand A has better BBB penetration, solubility, Caco-2 permeability, and a longer half-life, the superior affinity and safety profile of Ligand B are more important for a GPCR target like ADRB2. The difference in binding affinity (-6.8 vs -4.6) is quite large and likely to translate to a significant difference in *in vivo* efficacy.
Output:
0
2025-04-17 21:28:52,426 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (353.438) is slightly higher than Ligand B (344.375), but both are acceptable.
2. **TPSA:** Ligand A (63.57) is significantly better than Ligand B (116.14). ADRB2 is a cardiovascular target, not necessarily CNS, but lower TPSA generally improves permeability. Ligand B is pushing the upper limit for good oral absorption.
3. **logP:** Ligand A (1.439) is optimal, while Ligand B (0.089) is quite low. Low logP can lead to poor membrane permeability. This is a significant advantage for Ligand A.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is better than Ligand B (6). Similar to HBD, lower HBA is generally preferred.
6. **QED:** Both ligands have similar, acceptable QED values (Ligand A: 0.769, Ligand B: 0.711).
7. **DILI:** Ligand A (19.504) has a much lower DILI risk than Ligand B (66.421). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (85.343) has better BBB penetration than Ligand B (15.083). While ADRB2 isn't a primary CNS target, some peripheral distribution is still desirable, and higher BBB penetration often correlates with better overall distribution.
9. **Caco-2:** Ligand A (-4.735) is better than Ligand B (-5.388). Both are negative, indicating low permeability, but A is less negative.
10. **Solubility:** Ligand A (-1.987) is better than Ligand B (-2.491). Both are poor, but A is slightly better.
11. **hERG:** Both ligands have low hERG inhibition liability (Ligand A: 0.423, Ligand B: 0.211). Ligand B is slightly better here, but both are good.
12. **Cl_mic:** Ligand A (8.055) has significantly lower microsomal clearance than Ligand B (-12.038). This indicates better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (8.897) has a longer in vitro half-life than Ligand B (-2.728). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.124) has lower P-gp efflux liability than Ligand B (0.077). Both are good, but A is slightly better.
15. **Binding Affinity:** Ligand B (-6.1) has a slightly better binding affinity than Ligand A (-5.8). However, the difference is only 0.3 kcal/mol, which is not substantial enough to outweigh the numerous advantages of Ligand A.
**GPCR-specific priorities:** Considering ADRB2 is a GPCR, logP, TPSA, and affinity are key. Ligand A excels in logP and TPSA, and while its affinity is slightly lower, the overall ADME profile is far superior.
**Conclusion:**
Ligand A demonstrates a significantly more favorable balance of properties, particularly regarding ADME characteristics (DILI, Cl_mic, t1/2, logP, TPSA). The slightly weaker binding affinity of Ligand A is outweighed by its superior drug-like properties and reduced potential for toxicity and rapid metabolism.
Output:
1
2025-04-17 21:28:52,426 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (344.46 and 345.45 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (66.4) is significantly better than Ligand B (80.12). For a GPCR, lower TPSA is generally preferred for better permeability. Ligand B is approaching a level that could hinder absorption.
**3. logP:** Ligand A (2.286) is within the optimal 1-3 range, while Ligand B (1.069) is at the lower end. While not terrible, lower logP can sometimes indicate poorer membrane permeability.
**4. H-Bond Donors:** Ligand A (0) is preferable to Ligand B (1). Fewer H-bond donors generally improve permeability.
**5. H-Bond Acceptors:** Ligand A (4) is better than Ligand B (5). Similar to HBD, lower HBA is generally favorable.
**6. QED:** Both ligands have similar QED values (0.825 and 0.764), indicating good drug-likeness.
**7. DILI:** Both ligands have low DILI risk (35.79 and 33.23), which is excellent.
**8. BBB:** Ligand A (80.57) has significantly better BBB penetration potential than Ligand B (58.51). While ADRB2 is a cardiovascular target, some CNS off-target effects are always a consideration, and higher BBB is generally preferable.
**9. Caco-2 Permeability:** Ligand A (-4.692) is better than Ligand B (-5.111). Higher Caco-2 values indicate better absorption.
**10. Aqueous Solubility:** Ligand A (-2.035) is better than Ligand B (-1.188). Higher solubility is generally preferred.
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.436 and 0.053). This is excellent.
**12. Microsomal Clearance:** Ligand A (39.753) has a higher (worse) clearance than Ligand B (6.333). Ligand B demonstrates better metabolic stability.
**13. In vitro Half-Life:** Ligand B (14.585) has a much longer half-life than Ligand A (-0.653). This is a significant advantage for dosing convenience.
**14. P-gp Efflux:** Ligand A (0.196) is better than Ligand B (0.035). Lower P-gp efflux is preferred for better bioavailability.
**15. Binding Affinity:** Ligand B (-7.2) has a significantly stronger binding affinity than Ligand A (-5.2). This is a substantial advantage (2 kcal/mol difference) and can often outweigh minor ADME drawbacks.
**Overall Assessment:**
Ligand B has a significantly stronger binding affinity, a longer half-life, and better metabolic stability. While Ligand A has advantages in TPSA, solubility, and BBB, the affinity difference is substantial. For a GPCR, strong binding is paramount. The slightly higher TPSA of Ligand B is a manageable drawback given its superior potency and PK properties.
Output:
0
2025-04-17 21:28:52,426 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.471 and 350.419 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (48.0) is significantly better than Ligand B (116.48). ADRB2 is not a CNS target, but lower TPSA generally improves absorption. Ligand A is well below the 140 threshold, while B is approaching it.
3. **logP:** Ligand A (3.707) is optimal (1-3), while Ligand B (-0.49) is quite low. This is a major concern for B, as it may have poor membrane permeability.
4. **HBD:** Ligand A (0) is preferable to Ligand B (4). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (5) is better than Ligand B (6), again favoring permeability.
6. **QED:** Ligand A (0.759) is much better than Ligand B (0.495). A higher QED indicates a more drug-like profile.
7. **DILI:** Ligand A (33.191) has a lower DILI risk than Ligand B (23.769), which is good.
8. **BBB:** This is less critical for ADRB2 (cardiovascular target), but Ligand A (68.748) is better than Ligand B (28.81).
9. **Caco-2:** Ligand A (-4.393) is better than Ligand B (-5.464). Higher values indicate better absorption.
10. **Solubility:** Ligand A (-4.424) is better than Ligand B (-1.552).
11. **hERG:** Ligand A (0.822) is better than Ligand B (0.106). Lower hERG inhibition is crucial for avoiding cardiotoxicity, especially for a cardiovascular target.
12. **Cl_mic:** Ligand A (76.882) has higher metabolic clearance than Ligand B (12.119). This is a negative for A, indicating faster metabolism.
13. **t1/2:** Ligand A (7.605) has a much longer half-life than Ligand B (-19.505). This is a significant advantage for A.
14. **Pgp:** Ligand A (0.203) is better than Ligand B (0.012). Lower P-gp efflux is preferable.
15. **Binding Affinity:** Ligand B (-8.1) has a slightly better binding affinity than Ligand A (-7.9). However, the difference is relatively small (0.2 kcal/mol).
**Overall Assessment:**
Ligand A is significantly better overall. While Ligand B has slightly better binding affinity, Ligand A excels in almost all ADME properties, particularly logP, TPSA, QED, solubility, and hERG inhibition. The lower logP and higher TPSA of Ligand B are major concerns for permeability and absorption. The longer half-life of Ligand A is also a significant advantage. The slightly higher clearance of A is a drawback, but can potentially be addressed through structural modifications. Given the GPCR-specific priorities (logP, TPSA, Pgp), Ligand A is the much stronger candidate.
Output:
1
2025-04-17 21:28:52,427 - INFO - Batch 261 complete. Total preferences: 4176
2025-04-17 21:28:52,427 - INFO - Processing batch 262/512...
2025-04-17 21:29:40,268 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands (371.865 and 360.527 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (87.74) is higher than Ligand B (51.02). For a GPCR, lower TPSA is generally preferred for better permeability, giving a slight edge to Ligand B.
3. **logP:** Ligand B (3.764) is higher than Ligand A (1.907). While both are within the 1-3 range, Ligand B is approaching the upper limit. This could potentially lead to solubility issues, but for a GPCR, a slightly higher logP isn't as detrimental as for other targets.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (0). Lower is generally preferred, so Ligand B has a slight advantage.
5. **HBA:** Ligand A (4) is lower than Ligand B (5). Lower is generally preferred, so Ligand A has a slight advantage.
6. **QED:** Both ligands have similar QED values (0.715 and 0.755), indicating good drug-likeness.
7. **DILI:** Ligand A (35.983) has a lower DILI risk than Ligand B (47.693). This is a significant advantage for Ligand A.
8. **BBB:** Ligand B (81.233) has a higher BBB penetration percentile than Ligand A (75.107). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be beneficial for distribution, giving a slight edge to Ligand B.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-2.124) has better solubility than Ligand B (-4.244). This is a positive for Ligand A, especially considering Ligand B's higher logP.
11. **hERG:** Both ligands have low hERG inhibition risk (0.2 and 0.415, respectively). No significant difference.
12. **Cl_mic:** Ligand A (61.427) has lower microsomal clearance than Ligand B (82.646), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand B (14.92) has a longer in vitro half-life than Ligand A (8.235). This is a positive for Ligand B.
14. **Pgp:** Ligand A (0.086) has lower P-gp efflux liability than Ligand B (0.479). This is a significant advantage for Ligand A, improving bioavailability.
15. **Binding Affinity:** Ligand A (-6.2) has slightly better binding affinity than Ligand B (-6.0). While the difference is small, it's still a positive for Ligand A.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B has a slightly better logP and BBB, but Ligand A excels in DILI risk, metabolic stability (Cl_mic), Pgp efflux, solubility, and has a slightly better binding affinity. The lower DILI risk and Pgp efflux are particularly important for overall drug safety and bioavailability.
**Conclusion:**
Considering the balance of properties and the priorities for a GPCR target, Ligand A appears to be the more promising drug candidate. Its lower DILI risk, better metabolic stability, lower Pgp efflux, and slightly better binding affinity outweigh the minor advantages of Ligand B in BBB penetration and half-life.
Output:
1
2025-04-17 21:29:40,268 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (346.435 Da and 352.475 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (101.8) is higher than Ligand B (81.08). For a cardiovascular GPCR, TPSA is moderately important, and lower is generally better for permeability. Ligand B has a clear advantage.
**3. logP:** Ligand B (1.314) is slightly higher than Ligand A (0.821), placing it more squarely in the optimal 1-3 range. Ligand A is a bit low, potentially hindering permeation. Ligand B is preferred.
**4. H-Bond Donors:** Both ligands have 2 HBD, which is within the acceptable limit of <=5. No difference.
**5. H-Bond Acceptors:** Ligand A has 6 HBA, while Ligand B has 4. Both are within the acceptable limit of <=10, but Ligand B is slightly better.
**6. QED:** Both ligands have similar QED values (0.712 and 0.707), indicating good drug-likeness. No significant difference.
**7. DILI Risk:** Ligand B (19.698) has a significantly lower DILI risk than Ligand A (48.119). This is a crucial advantage, as minimizing liver toxicity is paramount.
**8. BBB Penetration:** Ligand A (71.268) shows better BBB penetration than Ligand B (65.839). While ADRB2 is primarily a cardiovascular target, some CNS off-target effects are possible, and moderate BBB penetration isn't necessarily detrimental.
**9. Caco-2 Permeability:** Ligand A (-5.523) has poorer Caco-2 permeability than Ligand B (-4.639). This reinforces the concern about Ligand A's lower logP and higher TPSA.
**10. Aqueous Solubility:** Ligand A (-2.136) has slightly better solubility than Ligand B (-1.464). Solubility is important, but not a primary concern here.
**11. hERG Inhibition:** Ligand A (0.022) has a very low hERG inhibition risk, significantly lower than Ligand B (0.322). This is a major advantage for Ligand A, as hERG inhibition can cause cardiotoxicity.
**12. Microsomal Clearance:** Ligand B (8.009) has lower microsomal clearance than Ligand A (24.077), indicating better metabolic stability. This is a positive for Ligand B.
**13. In vitro Half-Life:** Ligand B (4.843) has a longer in vitro half-life than Ligand A (1.311). This is a significant advantage for Ligand B, potentially leading to less frequent dosing.
**14. P-gp Efflux:** Ligand A (0.078) exhibits lower P-gp efflux than Ligand B (0.131). This is a slight advantage for Ligand A.
**15. Binding Affinity:** Ligand A (-6.6 kcal/mol) has a slightly stronger binding affinity than Ligand B (-5.4 kcal/mol). This is a 1.2 kcal/mol difference, which is a substantial advantage.
**Overall Assessment:**
While Ligand A has a better binding affinity and lower hERG risk, Ligand B demonstrates a much more favorable ADME profile. Specifically, the significantly lower DILI risk, better Caco-2 permeability, improved metabolic stability (lower Cl_mic and longer t1/2), and lower TPSA make Ligand B a more promising drug candidate. The 1.2 kcal/mol difference in binding affinity can likely be optimized during lead optimization without sacrificing the improved ADME properties of Ligand B.
Output:
0
2025-04-17 21:29:40,269 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (370.877 and 379.551 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (62.99 and 62.3) are below the 140 A^2 threshold for good oral absorption, and are reasonably low, suitable for a GPCR target. No major difference.
3. **logP:** Both ligands (3.059 and 3.78) are within the optimal 1-3 range, with Ligand B being slightly higher. This isn't a major concern, but worth noting.
4. **HBD:** Ligand A has 0 HBD, while Ligand B has 1. Both are acceptable, staying well below the 5 limit.
5. **HBA:** Ligand A has 4 HBA, Ligand B has 5. Both are below the 10 limit.
6. **QED:** Both ligands have good QED scores (0.66 and 0.804), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (31.214%) has a significantly lower DILI risk than Ligand B (53.625%). This is a substantial advantage for Ligand A.
8. **BBB:** Ligand A (75.921%) has a better BBB penetration score than Ligand B (51.881%). While ADRB2 isn't strictly a CNS target, some CNS exposure can be relevant, and higher BBB is generally preferable.
9. **Caco-2:** Both have negative Caco-2 values (-4.378 and -4.777), which is unusual and indicates poor permeability. This is a significant drawback for both.
10. **Solubility:** Both ligands have very poor aqueous solubility (-2.739 and -3.017). This is a major concern for both compounds.
11. **hERG:** Both ligands have low hERG inhibition risk (0.624 and 0.392).
12. **Cl_mic:** Ligand A (43.951 mL/min/kg) has lower microsomal clearance than Ligand B (58.984 mL/min/kg), suggesting better metabolic stability.
13. **t1/2:** Ligand A (51.374 hours) has a significantly longer in vitro half-life than Ligand B (30.139 hours). This is a major advantage for Ligand A.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.377 and 0.222).
15. **Binding Affinity:** Ligand B (-7.8 kcal/mol) has a substantially stronger binding affinity than Ligand A (-5.4 kcal/mol). This is a 2.4 kcal/mol difference, which is a significant advantage.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand B is slightly better on logP, has comparable Pgp and TPSA, but *significantly* better affinity. However, the poor solubility and Caco-2 values are concerning for both. Ligand A has a much better safety profile (DILI) and pharmacokinetic properties (Cl_mic, t1/2).
**Overall Assessment:**
While Ligand B has a stronger binding affinity, the superior safety profile (DILI), metabolic stability (Cl_mic), and longer half-life of Ligand A are more critical. The poor solubility and permeability are problematic for both, but can be addressed with formulation strategies. The stronger affinity of Ligand B might be overcome with optimization, but the DILI risk is harder to mitigate later in development.
Output:
1
2025-04-17 21:29:40,269 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (357.284 Da) is slightly higher than Ligand B (346.402 Da), but both are acceptable.
2. **TPSA:** Ligand A (88.02) is better than Ligand B (69.64). Both are below the 140 A^2 threshold for good oral absorption, but Ligand B is closer to the 90 A^2 threshold which is desirable for GPCRs.
3. **logP:** Both ligands have good logP values (A: 2.462, B: 1.794) falling within the optimal 1-3 range. Ligand B is slightly lower, which could slightly improve solubility.
4. **HBD:** Ligand A has 3 HBD, and Ligand B has 2. Both are within the acceptable limit of <=5.
5. **HBA:** Ligand A has 5 HBA, and Ligand B has 3. Both are within the acceptable limit of <=10.
6. **QED:** Both ligands have similar and good QED values (A: 0.765, B: 0.799), indicating good drug-like properties.
7. **DILI:** Ligand B (23.032) has a significantly lower DILI risk than Ligand A (70.686). This is a major advantage for Ligand B.
8. **BBB:** Ligand B (75.378) has a better BBB penetration percentile than Ligand A (35.091). This is important for GPCR targets, even if ADRB2 isn't strictly a CNS target, some peripheral distribution is still desired.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.853 and -4.52). This is unusual and suggests poor permeability. However, the values are close, so this isn't a major differentiator.
10. **Solubility:** Ligand B (-2.095) has better aqueous solubility than Ligand A (-3.173).
11. **hERG:** Both ligands have low hERG inhibition liability (A: 0.603, B: 0.452), which is good.
12. **Cl_mic:** Ligand B (26.91) has lower microsomal clearance than Ligand A (31.454), indicating better metabolic stability.
13. **t1/2:** Ligand B (-17.541) has a longer in vitro half-life than Ligand A (-12.738). This is a positive attribute.
14. **Pgp:** Both ligands have low Pgp efflux liability (A: 0.117, B: 0.091).
15. **Binding Affinity:** Ligand B (-6.8 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.0 kcal/mol). This is a substantial advantage, exceeding the 1.5 kcal/mol threshold.
**Overall Assessment:**
Ligand B clearly outperforms Ligand A across several crucial parameters. The most significant advantages are its much lower DILI risk, better BBB penetration, improved solubility, better metabolic stability (lower Cl_mic, longer t1/2), and substantially stronger binding affinity. While both have acceptable physicochemical properties, Ligand B's profile is more favorable for development as a drug candidate targeting the ADRB2 receptor. The stronger binding affinity alone is enough to tip the scales, and is compounded by the better safety and pharmacokinetic properties.
Output:
0
2025-04-17 21:29:40,269 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [340.427, 70.39, 3.01, 2, 4, 0.902, 63.203, 68.282, -4.798, -3.517, 0.633, 46.223, 36.462, 0.196, -7.9]
**Ligand B:** [349.431, 91.5, 1.158, 2, 4, 0.7, 18.302, 61.923, -4.56, -2.534, 0.2, 30.176, -23.25, 0.017, -5.9]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal 200-500 Da range. A (340.427) is slightly preferred.
2. **TPSA:** A (70.39) is better than B (91.5), falling comfortably under the 140 threshold for good absorption. B is still acceptable, but A is better.
3. **logP:** A (3.01) is optimal, while B (1.158) is on the lower side, potentially hindering permeation. This is a significant advantage for A.
4. **HBD:** Both have 2 HBD, which is good.
5. **HBA:** Both have 4 HBA, which is good.
6. **QED:** A (0.902) is excellent, indicating high drug-likeness. B (0.7) is still reasonable, but A is significantly better.
7. **DILI:** A (63.203) is higher than B (18.302), indicating a greater potential for liver injury. This is a major drawback for A.
8. **BBB:** Both are reasonably good, but A (68.282) is slightly better than B (61.923). For a cardiovascular target, BBB isn't *critical*, but a higher value is still preferred.
9. **Caco-2:** Both are negative, indicating poor permeability.
10. **Solubility:** Both are negative, indicating poor solubility.
11. **hERG:** A (0.633) is better than B (0.2), indicating a lower risk of cardiotoxicity.
12. **Cl_mic:** A (46.223) is higher than B (30.176), meaning A has faster metabolic clearance and lower metabolic stability. B is preferred.
13. **t1/2:** A (36.462) is better than B (-23.25), indicating a longer half-life.
14. **Pgp:** A (0.196) is better than B (0.017), indicating lower P-gp efflux.
15. **Affinity:** A (-7.9) is significantly better than B (-5.9), a difference of 2 kcal/mol. This is a substantial advantage.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are particularly important. A excels in logP, TPSA, and *especially* affinity. However, the DILI risk for A is concerning, and its metabolic clearance is higher than B.
**Overall Assessment:**
The significantly stronger binding affinity of Ligand A (-7.9 kcal/mol vs -5.9 kcal/mol) is a major advantage that can often outweigh other drawbacks. While Ligand A has a higher DILI risk and faster clearance, the potency difference is substantial. The slightly better TPSA and logP of A also contribute to its favorability. The hERG risk is also lower for A.
Therefore, despite the DILI concerns, the superior binding affinity of Ligand A makes it the more promising candidate.
Output:
1
2025-04-17 21:29:40,269 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [356.413, 60.85, 1.5, 1, 3, 0.812, 13.61, 87.553, -4.507, -2.025, 0.529, 6.455, 17.618, 0.048, -6.4]**
**Ligand B: [348.531, 49.41, 3.75, 1, 2, 0.536, 14.075, 58.162, -4.72, -3.733, 0.615, 45.309, -1.085, 0.463, -5.9]**
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (356.413) is slightly higher than Ligand B (348.531), but the difference is not significant.
**2. TPSA:** Ligand A (60.85) is a bit higher than Ligand B (49.41). Both are below 140, but B is better for oral absorption.
**3. logP:** Ligand A (1.5) is within the optimal range, while Ligand B (3.75) is approaching the upper limit. This is a slight advantage for A.
**4. H-Bond Donors:** Both have 1 HBD, which is good.
**5. H-Bond Acceptors:** Ligand A has 3 HBAs, Ligand B has 2. Both are acceptable.
**6. QED:** Ligand A (0.812) has a significantly better QED score than Ligand B (0.536), indicating better overall drug-likeness.
**7. DILI:** Both have low DILI risk (A: 13.61, B: 14.075), but A is slightly better.
**8. BBB:** Ligand A (87.553) has a much higher BBB penetration percentile than Ligand B (58.162). This is a significant advantage for A, given ADRB2 is a GPCR.
**9. Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.507) is slightly better than B (-4.72).
**10. Solubility:** Ligand A (-2.025) is better than Ligand B (-3.733).
**11. hERG:** Both have low hERG inhibition liability (A: 0.529, B: 0.615).
**12. Cl_mic:** Ligand A (6.455) has a much lower microsomal clearance than Ligand B (45.309), suggesting better metabolic stability.
**13. t1/2:** Ligand A (17.618) has a longer in vitro half-life than Ligand B (-1.085).
**14. Pgp:** Ligand A (0.048) has significantly lower P-gp efflux liability than Ligand B (0.463).
**15. Binding Affinity:** Ligand A (-6.4) has a slightly better binding affinity than Ligand B (-5.9).
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand A is the stronger candidate. It has better BBB penetration, lower P-gp efflux, lower microsomal clearance, longer half-life, better QED, and slightly better binding affinity. While Ligand B has a lower TPSA, the other advantages of Ligand A outweigh this. The negative Caco-2 values are concerning for both, but the other ADME properties of A are more favorable.
Output:
1
2025-04-17 21:29:40,269 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (339.4 and 351.4 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (84.83) is better than Ligand B (90.22). Both are below the 140 A^2 threshold for good oral absorption, but lower TPSA is generally preferred for GPCRs to improve brain penetration, even if not a CNS target.
**3. logP:** Ligand A (2.643) is slightly better than Ligand B (1.181). Both are within the optimal 1-3 range, but Ligand B is at the lower end, potentially impacting permeability.
**4. H-Bond Donors:** Ligand A (2) is slightly better than Ligand B (1). Both are within the acceptable limit of 5.
**5. H-Bond Acceptors:** Ligand B (7) is slightly better than Ligand A (6). Both are within the acceptable limit of 10.
**6. QED:** Ligand A (0.763) is better than Ligand B (0.647). Higher QED indicates a more drug-like profile.
**7. DILI:** Ligand B (67.47) is significantly better than Ligand A (88.25). Lower DILI is crucial. This is a significant advantage for Ligand B.
**8. BBB:** Ligand B (90.77) is better than Ligand A (57.74). While ADRB2 isn't a primary CNS target, some brain penetration can contribute to off-target effects, and lower penetration is preferred.
**9. Caco-2 Permeability:** Ligand A (-5.183) is better than Ligand B (-4.746). Higher Caco-2 permeability is desirable.
**10. Aqueous Solubility:** Ligand A (-4.462) is better than Ligand B (-1.317). Better solubility is important for formulation and bioavailability.
**11. hERG Inhibition:** Both ligands (0.756 and 0.646) are very similar and at low risk.
**12. Microsomal Clearance:** Ligand A (32.69) is much better than Ligand B (63.98). Lower clearance implies better metabolic stability.
**13. In vitro Half-Life:** Ligand B (50.61) is better than Ligand A (22.44). Longer half-life is generally preferred.
**14. P-gp Efflux:** Both ligands (0.082 and 0.068) are very similar and at low risk.
**15. Binding Affinity:** Ligand A (-6.6) is slightly better than Ligand B (-6.4). A difference of 0.2 kcal/mol is not substantial.
**Overall Assessment:**
Ligand B has a significantly better DILI score and a better BBB score. It also has a longer half-life. Ligand A has better TPSA, logP, Caco-2 permeability, solubility, and microsomal clearance, but the differences are not as dramatic as the DILI and half-life advantages of Ligand B. Given the importance of minimizing liver toxicity (DILI) and the benefit of a longer half-life, Ligand B is the more promising candidate.
Output:
0
2025-04-17 21:29:40,270 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (339.479) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (32.7) is significantly better than Ligand B (115.65). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption. Ligand B's TPSA is quite high, potentially hindering oral bioavailability.
3. **logP:** Ligand A (4.225) is good, while Ligand B (-0.725) is too low. A logP between 1-3 is preferred, and Ligand B's value suggests potential permeability issues.
4. **HBD:** Both ligands have 1 HBD, which is within the acceptable range.
5. **HBA:** Ligand A has 3 HBA, while Ligand B has 8. Ligand B's HBA count is higher, potentially impacting permeability.
6. **QED:** Ligand A (0.885) is better than Ligand B (0.711), indicating a more drug-like profile.
7. **DILI:** Ligand A (9.849) has a much lower DILI risk than Ligand B (76.425). This is a significant advantage for Ligand A.
8. **BBB:** Both have reasonable BBB penetration, but they are similar (69.407 vs 70.415).
9. **Caco-2:** Both have negative Caco-2 values, which is unusual. However, the magnitude of the negative value is similar.
10. **Solubility:** Both have negative solubility values.
11. **hERG:** Ligand A (0.979) is better than Ligand B (0.042) in terms of hERG inhibition liability, indicating a lower risk of cardiotoxicity.
12. **Cl_mic:** Ligand A (40.837) has a higher microsomal clearance than Ligand B (25.226), suggesting lower metabolic stability. This is a drawback for Ligand A.
13. **t1/2:** Ligand A (-18.663) has a shorter in vitro half-life than Ligand B (-10.609). This is a drawback for Ligand A.
14. **Pgp:** Ligand A (0.933) has better Pgp efflux liability than Ligand B (0.045).
15. **Binding Affinity:** Ligand B (-7.1) has a significantly stronger binding affinity than Ligand A (-4.5). This is a substantial advantage for Ligand B. A difference of 2.6 kcal/mol is quite significant.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, Pgp, TPSA, and affinity. Ligand B excels in affinity, but struggles with TPSA and logP. Ligand A has better TPSA and logP, but its affinity is significantly weaker.
**Overall Assessment:**
While Ligand A has a better safety profile (lower DILI, better hERG) and drug-likeness (higher QED, better Pgp), the significantly stronger binding affinity of Ligand B (-7.1 vs -4.5 kcal/mol) is a major advantage. The difference in affinity is large enough to potentially overcome the drawbacks of Ligand B's higher TPSA and lower logP, especially considering this is a cardiovascular target where CNS penetration is not critical. The metabolic stability of Ligand B is also better.
Output:
0
2025-04-17 21:29:40,270 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.4 and 367.5 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand B (82.97) is significantly better than Ligand A (108.64). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have very similar logP values (1.157 and 1.136), falling within the optimal 1-3 range.
4. **HBD:** Ligand B (1 HBD) is preferable to Ligand A (3 HBD). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand B (6 HBA) is slightly better than Ligand A (5 HBA), although both are acceptable.
6. **QED:** Ligand B (0.815) has a higher QED score than Ligand A (0.611), indicating a more drug-like profile.
7. **DILI:** Ligand B (47.15) has a slightly higher DILI risk than Ligand A (35.673), but both are below the concerning threshold of 60.
8. **BBB:** Ligand B (50.872) has slightly better BBB penetration than Ligand A (44.009), but again, this is not a primary concern for a cardiovascular target.
9. **Caco-2:** Ligand B (-4.641) is slightly better than Ligand A (-5.129), indicating potentially better intestinal absorption.
10. **Solubility:** Ligand A (-1.924) has slightly better aqueous solubility than Ligand B (-0.804). Solubility is important, but not a deciding factor here.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.149 and 0.139).
12. **Cl_mic:** Ligand A (-2.775) has significantly lower microsomal clearance than Ligand B (7.575), indicating better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand A (16.542) has a longer in vitro half-life than Ligand B (7.612). This is another significant advantage.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.063 and 0.104).
15. **Binding Affinity:** Ligand A (-7.7 kcal/mol) has a stronger binding affinity than Ligand B (-5.1 kcal/mol). This is a substantial difference (2.6 kcal/mol) and a major driver in the decision.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B has better TPSA and comparable logP and Pgp. However, Ligand A's significantly stronger binding affinity and improved metabolic stability (lower Cl_mic and longer t1/2) outweigh the slight advantages of Ligand B. The affinity difference is substantial enough to overcome the slightly higher TPSA of Ligand A.
**Conclusion:**
Ligand A is the more promising drug candidate due to its superior binding affinity, metabolic stability, and half-life.
Output:
1
2025-04-17 21:29:40,270 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (372.868 and 356.413 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (61.8) is better than Ligand B (66.48), being closer to the <140 threshold for good oral absorption.
3. **logP:** Both ligands have good logP values (3.381 and 2.168), falling within the optimal 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability, but not excessively high.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1), but both are within the acceptable limit of <=5.
5. **HBA:** Both ligands have 3 HBA, which is well within the acceptable limit of <=10.
6. **QED:** Ligand A (0.804) has a significantly better QED score than Ligand B (0.562), indicating a more drug-like profile.
7. **DILI:** Ligand B (31.136) has a much lower DILI risk than Ligand A (9.616), which is a significant advantage.
8. **BBB:** Ligand B (95.618) has a much higher BBB penetration percentile than Ligand A (77.549). While ADRB2 isn't *necessarily* a CNS target, some cardiovascular effects can be mediated centrally, and higher BBB penetration isn't a major negative.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.23 and -4.613), which is unusual and suggests poor permeability. Ligand B is slightly worse.
10. **Solubility:** Ligand A (-3.51) is slightly better than Ligand B (-2.628), indicating better aqueous solubility.
11. **hERG:** Ligand A (0.822) has a slightly higher hERG inhibition liability than Ligand B (0.374), which is a concern for cardiotoxicity.
12. **Cl_mic:** Ligand B (14.668) has a significantly lower microsomal clearance than Ligand A (39.206), indicating better metabolic stability.
13. **t1/2:** Ligand B (-44.493) has a much longer in vitro half-life than Ligand A (8.577), which is a major advantage.
14. **Pgp:** Ligand A (0.295) has lower P-gp efflux liability than Ligand B (0.047), which is preferable.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.6 and -6.4 kcal/mol). The difference is not substantial enough to be a deciding factor.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Ligand B performs better on Pgp and has a comparable logP and affinity. The significantly better DILI, metabolic stability (Cl_mic, t1/2), and BBB penetration of Ligand B outweigh the slightly better TPSA and solubility of Ligand A. The hERG risk is also lower for Ligand B.
**Conclusion:**
Considering the balance of properties, especially the improved safety profile (DILI, hERG) and pharmacokinetic properties (Cl_mic, t1/2) of Ligand B, it is the more promising drug candidate.
Output:
0
2025-04-17 21:29:40,270 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.423 and 362.865 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (90.96 and 84.73) are below the 140 A^2 threshold for good oral absorption, and acceptable for a non-CNS GPCR target like ADRB2. Ligand B is slightly better.
3. **logP:** Ligand A (0.927) is a bit low, potentially hindering permeability. Ligand B (1.996) is better, falling within the optimal 1-3 range. This is a point in favor of Ligand B.
4. **HBD:** Ligand A (0) is ideal. Ligand B (2) is acceptable, but not as good.
5. **HBA:** Ligand A (8) is good. Ligand B (6) is also good.
6. **QED:** Both ligands (0.74 and 0.768) have excellent QED scores, indicating good drug-like properties.
7. **DILI:** Both ligands have DILI risk around the 60 percentile, which is moderately high. This is a concern for both, but not a deciding factor between them.
8. **BBB:** Both ligands have reasonable BBB penetration, but Ligand B (80.574) is significantly better than Ligand A (70.88). While ADRB2 isn't a primary CNS target, some off-target CNS effects are always a consideration.
9. **Caco-2:** Ligand A (-4.635) is very poor, indicating very poor intestinal absorption. Ligand B (-5.31) is also poor, but slightly better than A. This is a major drawback for Ligand A.
10. **Solubility:** Ligand A (-1.514) is poor. Ligand B (-2.72) is also poor. Both are concerning.
11. **hERG:** Ligand A (0.046) is very low risk. Ligand B (0.521) is slightly higher, but still acceptable.
12. **Cl_mic:** Ligand B (19.977) has a significantly lower microsomal clearance than Ligand A (54.594), indicating better metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand B (36.238) has a much longer in vitro half-life than Ligand A (21.313), which is desirable.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.19 and 0.11), which is good.
15. **Binding Affinity:** Ligand A (-5.8 kcal/mol) has a significantly stronger binding affinity than Ligand B (-3.6 kcal/mol). This is a substantial advantage for Ligand A.
**Overall Assessment:**
Ligand A has a much better binding affinity, which is the most important factor. However, its very poor Caco-2 permeability and solubility are major drawbacks. Ligand B has better ADME properties (logP, Cl_mic, t1/2, BBB) but weaker binding. Given the importance of affinity for GPCRs, and the fact that the difference in affinity is substantial (2.2 kcal/mol), I believe Ligand A is the more promising starting point, despite its ADME liabilities. These liabilities can be addressed through further optimization, while improving affinity is often more challenging.
Output:
1
2025-04-17 21:29:40,270 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [346.387, 101.49 , 0.336, 1. , 6. , 0.764, 56.029, 59.325, -4.891, -1.497, 0.077, 8.488, -5.64 , 0.012, -6.2 ]
**Ligand B:** [371.453, 59.23 , 4.702, 0. , 5. , 0.675, 57.697, 89.066, -4.813, -4.704, 0.762, 77.132, 23.236, 0.714, -6.4 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (346.387) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (101.49) is higher than Ligand B (59.23). For a GPCR, lower TPSA is preferred for better BBB penetration and overall drug-like properties. Ligand B is significantly better here.
3. **logP:** Ligand A (0.336) is quite low, potentially hindering membrane permeability. Ligand B (4.702) is high, potentially causing solubility issues and off-target effects, but is within an acceptable range.
4. **HBD:** Ligand A (1) is better than Ligand B (0). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (6) is slightly higher than Ligand B (5). Both are acceptable.
6. **QED:** Ligand A (0.764) is slightly better than Ligand B (0.675), indicating a marginally more drug-like profile.
7. **DILI:** Both are similar and acceptable (around 56-58 percentile).
8. **BBB:** Ligand B (89.066) is significantly better than Ligand A (59.325). This is a *critical* advantage for a GPCR target, even if not specifically a CNS target, as it indicates better distribution characteristics.
9. **Caco-2:** Both are very poor (-4.891 and -4.813). This is a significant concern for both.
10. **Solubility:** Ligand A (-1.497) is better than Ligand B (-4.704).
11. **hERG:** Ligand A (0.077) is much better than Ligand B (0.762), indicating a lower risk of cardiotoxicity. This is important for a cardiovascular target.
12. **Cl_mic:** Ligand A (8.488) is much lower than Ligand B (77.132), suggesting better metabolic stability.
13. **t1/2:** Ligand B (23.236) has a much longer half-life than Ligand A (-5.64). This is a significant advantage.
14. **Pgp:** Ligand B (0.714) is higher than Ligand A (0.012), indicating greater P-gp efflux. This is unfavorable.
15. **Affinity:** Both have similar binding affinities (-6.2 and -6.4 kcal/mol), which are both good.
**Overall Assessment:**
Ligand B has a significantly better BBB score and a much longer half-life, which are both crucial for a GPCR. While its logP is higher and Pgp efflux is greater, the improved BBB and half-life outweigh these drawbacks. Ligand A has better solubility, hERG, and metabolic stability, but the poor BBB penetration is a major concern. The Caco-2 permeability is poor for both, but can be addressed with formulation strategies. Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand B is the more promising candidate.
Output:
0
2025-04-17 21:29:40,270 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
The target is ADRB2, a GPCR. Therefore, I will prioritize logP, TPSA, Pgp efflux, BBB penetration, and binding affinity. Metabolic stability (Cl_mic, t1/2) and safety (DILI, hERG) are also important considerations.
Let's compare the ligands property by property:
1. **MW:** Both ligands (367.391 and 364.402 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand B (107.01) is significantly better than Ligand A (127.36). Lower TPSA generally favors better cell permeability, crucial for GPCR targeting.
3. **logP:** Ligand B (1.456) is within the optimal range (1-3), while Ligand A (-0.243) is below 1, potentially hindering permeation. This is a significant advantage for Ligand B.
4. **HBD/HBA:** Ligand A has 0 HBD and 9 HBA, while Ligand B has 3 HBD and 5 HBA. Both are acceptable, but Ligand B's values are slightly more balanced.
5. **QED:** Both ligands have good QED scores (0.523 and 0.659), indicating good drug-likeness. Ligand B is slightly better.
6. **DILI:** Ligand B (71.539) has a lower DILI risk than Ligand A (87.204), which is preferable.
7. **BBB:** Both ligands have similar BBB penetration (54.634 and 56.65). This isn't a primary concern for ADRB2, which isn't a CNS target, but higher is generally better.
8. **Caco-2:** Both ligands have similar, very negative Caco-2 values (-5.193 and -5.103), which is difficult to interpret without knowing the scale. This parameter is not decisive.
9. **Solubility:** Both ligands have very negative solubility values (-2.296 and -3.682). Again, difficult to interpret without knowing the scale.
10. **hERG:** Ligand A (0.24) has a lower hERG risk than Ligand B (0.713), which is a positive.
11. **Cl_mic:** Ligand A (2.509) has a much lower microsomal clearance than Ligand B (13.553), indicating better metabolic stability. This is a significant advantage for Ligand A.
12. **t1/2:** Ligand B (19.918) has a much longer in vitro half-life than Ligand A (-23.299). This is a substantial advantage for Ligand B.
13. **Pgp:** Ligand A (0.036) has lower P-gp efflux than Ligand B (0.122), which is preferable.
14. **Binding Affinity:** Both ligands have very similar and strong binding affinities (-6.9 and -6.0 kcal/mol). The difference of 0.9 kcal/mol is not substantial enough to outweigh other factors.
**Overall Assessment:**
Ligand B has a better logP, TPSA, DILI, QED, and significantly better half-life. Ligand A has better metabolic stability (lower Cl_mic), lower Pgp efflux, and lower hERG risk. Considering the GPCR-specific priorities (logP, TPSA, Pgp), and the overall balance of properties, Ligand B is the more promising candidate. The improved logP and TPSA are likely to translate to better cellular permeability and target engagement, while the longer half-life is a significant pharmacokinetic advantage. The slightly higher DILI risk and Pgp efflux are less concerning than the poor logP of Ligand A.
**Output:**
0
2025-04-17 21:29:40,271 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (370.877 Da and 345.403 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (71.78) is significantly better than Ligand B (104.12). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is approaching the upper limit for good oral absorption.
**3. logP:** Ligand A (3.249) is within the optimal range (1-3), while Ligand B (1.64) is at the lower end. While not terrible, lower logP can sometimes indicate poorer membrane permeability.
**4. H-Bond Donors:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
**5. H-Bond Acceptors:** Ligand A (4) is preferable to Ligand B (5). Similar to HBDs, fewer HBAs are generally better for permeability.
**6. QED:** Both ligands have similar QED values (0.799 and 0.708), indicating good drug-like properties.
**7. DILI:** Ligand A (29.546) has a much lower DILI risk than Ligand B (63.513). This is a significant advantage for Ligand A.
**8. BBB:** Ligand A (82.086) has a better BBB penetration score than Ligand B (55.099). While ADRB2 isn't a CNS target, some off-target CNS effects are always a concern, and higher BBB penetration can sometimes correlate with better overall distribution.
**9. Caco-2 Permeability:** Ligand A (-4.697) is better than Ligand B (-5.501). Higher Caco-2 permeability is preferable.
**10. Aqueous Solubility:** Ligand A (-3.65) is better than Ligand B (-2.821). Higher solubility is generally desirable.
**11. hERG Inhibition:** Ligand A (0.53) has a slightly better hERG profile than Ligand B (0.331), indicating lower cardiotoxicity risk.
**12. Microsomal Clearance:** Ligand A (14.948) has lower microsomal clearance than Ligand B (57.245), suggesting better metabolic stability.
**13. In vitro Half-Life:** Ligand A (60.896) has a much longer in vitro half-life than Ligand B (2.428). This is a significant advantage for Ligand A, potentially allowing for less frequent dosing.
**14. P-gp Efflux:** Ligand A (0.185) has lower P-gp efflux than Ligand B (0.147). Lower efflux is preferable for bioavailability.
**15. Binding Affinity:** Ligand B (-7.2) has a slightly better binding affinity than Ligand A (-7.1). However, the difference is small (0.1 kcal/mol) and can be overcome by the superior ADME properties of Ligand A.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical ADME properties (DILI, BBB, solubility, metabolic stability, half-life, permeability). While Ligand B has a marginally better binding affinity, the overall profile of Ligand A is far more favorable for development as a drug candidate. The improved ADME properties will likely translate to better *in vivo* efficacy and a safer profile.
Output:
1
2025-04-17 21:29:40,271 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
Let's systematically compare Ligand A and Ligand B based on the provided parameters and the guidelines, keeping in mind that ADRB2 is a GPCR, so logP, Pgp, TPSA, and affinity are particularly important.
1. **MW:** Both ligands (339.483 and 353.507 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (37.39) is significantly better than Ligand B (61.88). A TPSA under 140 is desirable for oral absorption, and Ligand A is much closer to the ideal range for GPCRs.
3. **logP:** Ligand A (4.816) is higher than Ligand B (1.782). While both are within the acceptable range (1-3 is optimal), Ligand A is pushing the upper limit and could potentially have solubility issues. However, for a GPCR, a slightly higher logP can be beneficial for membrane interactions.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Both ligands have 4 HBA, which is good.
6. **QED:** Both ligands have similar QED values (0.819 and 0.837), indicating good drug-likeness.
7. **DILI:** Ligand A (36.293) has a slightly higher DILI risk than Ligand B (21.675), but both are below the 40% threshold considered good. Ligand B is clearly better here.
8. **BBB:** Ligand A (77.162) has a significantly higher BBB penetration percentile than Ligand B (57.387). While not a CNS target, some peripheral GPCRs benefit from limited BBB penetration.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.536 and -4.584). This is unusual and suggests poor permeability.
10. **Solubility:** Ligand A (-5.454) has worse solubility than Ligand B (-1.581). This is a concern given Ligand A's higher logP.
11. **hERG:** Ligand A (0.874) has a slightly higher hERG risk than Ligand B (0.173). Ligand B is much better here.
12. **Cl_mic:** Ligand A (110.476) has a higher microsomal clearance than Ligand B (17.826), indicating lower metabolic stability. Ligand B is significantly better.
13. **t1/2:** Ligand A (7.889) has a longer in vitro half-life than Ligand B (5.751). This is a positive for Ligand A.
14. **Pgp:** Ligand A (0.573) has lower P-gp efflux liability than Ligand B (0.082). Lower Pgp is generally preferred.
15. **Affinity:** Ligand A (-8.0 kcal/mol) has a slightly better binding affinity than Ligand B (-7.9 kcal/mol). This is a small difference, but potentially significant.
**Overall Assessment:**
Ligand B is the better candidate. While Ligand A has slightly better affinity and half-life, Ligand B excels in crucial ADME properties: lower DILI risk, significantly lower microsomal clearance (better metabolic stability), lower hERG risk, and better solubility. The TPSA value of Ligand A is much more favorable, but the ADME profile of Ligand B is more balanced and suggests a higher probability of success as a drug candidate. The slightly weaker binding of Ligand B is a minor drawback compared to the substantial ADME advantages.
Output:
0
2025-04-17 21:29:40,271 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (344.371 and 356.423 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Both ligands (106.35 and 108.05) are below the 140 A^2 threshold for good oral absorption, but not optimal for CNS penetration (target is cardiovascular, so less critical). Ligand A is slightly better.
3. **logP:** Ligand A (1.163) is within the optimal 1-3 range. Ligand B (-0.868) is slightly below 1, potentially hindering permeation. Ligand A is preferred.
4. **HBD:** Both have 2 HBD, which is acceptable.
5. **HBA:** Ligand A has 6 HBA, Ligand B has 5. Both are within the acceptable limit of 10.
6. **QED:** Ligand A (0.661) has a better QED score than Ligand B (0.475), indicating better overall drug-likeness.
7. **DILI:** Ligand B (39.511) has a significantly lower DILI risk than Ligand A (67.003). This is a substantial advantage for Ligand B.
8. **BBB:** Ligand A (62.233) has a higher BBB percentile than Ligand B (33.656). However, as ADRB2 is a cardiovascular target, BBB penetration is not a primary concern.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand B (-5.248) is slightly worse than Ligand A (-4.925).
10. **Solubility:** Ligand A (-2.997) has slightly better solubility than Ligand B (-1.135).
11. **hERG:** Both ligands have very low hERG inhibition risk (0.193 and 0.062).
12. **Cl_mic:** Ligand B (2.461) has a much lower microsomal clearance than Ligand A (44.08), indicating better metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand B (-10.074) has a much longer in vitro half-life than Ligand A (-46.264). This is a major advantage for Ligand B.
14. **Pgp:** Both have very low Pgp efflux liability (0.047 and 0.008).
15. **Binding Affinity:** Ligand B (-6.8 kcal/mol) has a significantly stronger binding affinity than Ligand A (-2.3 kcal/mol). This is a very substantial advantage, potentially outweighing some ADME concerns.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand B excels in affinity and has acceptable logP and Pgp. While TPSA is similar for both, the superior affinity and metabolic stability of Ligand B are crucial. The lower DILI risk is also a significant benefit.
**Conclusion:**
Despite Ligand A's slightly better QED and solubility, Ligand B's significantly stronger binding affinity, lower DILI risk, and improved metabolic stability (lower Cl_mic and longer t1/2) make it the more promising drug candidate for ADRB2. The difference in binding affinity is substantial enough to overcome the slightly lower logP.
Output:
0
2025-04-17 21:29:40,271 - INFO - Batch 262 complete. Total preferences: 4192
2025-04-17 21:29:40,271 - INFO - Processing batch 263/512...
2025-04-17 21:30:31,394 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [354.447, 87.15, 0.593, 1, 5, 0.689, 24.544, 55.215, -4.639, -0.95, 0.141, 19.898, 2.407, 0.058, -5.8]
**Ligand B:** [347.39, 71.53, 1.689, 1, 4, 0.762, 62.272, 73.401, -4.362, -1.9, 0.27, 18.024, -0.303, 0.034, -6.2]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (347.39) is slightly lower, which is generally favorable.
2. **TPSA:** Ligand A (87.15) is a bit higher than Ligand B (71.53). Both are below 140, but B is better for absorption.
3. **logP:** Ligand A (0.593) is quite low, potentially hindering membrane permeability. Ligand B (1.689) is much better, falling within the optimal 1-3 range. This is a significant advantage for B.
4. **HBD/HBA:** Both have 1 HBD, which is good. Ligand A has 5 HBA, while Ligand B has 4. Both are acceptable.
5. **QED:** Both have reasonable QED scores (A: 0.689, B: 0.762), indicating drug-likeness. B is slightly better.
6. **DILI:** Ligand A (24.544) has a much lower DILI risk than Ligand B (62.272). This is a major advantage for A.
7. **BBB:** Ligand B (73.401) has a significantly higher BBB penetration potential than Ligand A (55.215). While not a primary concern for all GPCRs, it could be beneficial depending on the desired therapeutic effect.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual. This suggests poor permeability.
9. **Solubility:** Both have negative solubility values, which is also unusual.
10. **hERG:** Both have very low hERG risk (A: 0.141, B: 0.27). This is good.
11. **Cl_mic:** Ligand B (18.024) has slightly lower microsomal clearance than Ligand A (19.898), suggesting better metabolic stability.
12. **t1/2:** Ligand B (-0.303) has a slightly longer half-life than Ligand A (2.407).
13. **Pgp:** Both have low P-gp efflux liability (A: 0.058, B: 0.034), which is favorable.
14. **Affinity:** Ligand B (-6.2 kcal/mol) has a slightly stronger binding affinity than Ligand A (-5.8 kcal/mol). While the difference is not huge, it's still a positive for B.
**Overall Assessment:**
Ligand B is the stronger candidate. Its superior logP, slightly better metabolic stability, longer half-life, and higher binding affinity outweigh the higher DILI risk. The lower TPSA of Ligand B is also beneficial. The unusual Caco-2 and solubility values are concerning for both, but the other properties of Ligand B are more favorable for a GPCR target.
Output:
0
2025-04-17 21:30:31,394 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, the key properties to prioritize are binding affinity, logP, TPSA, Pgp efflux, and BBB penetration (though BBB is less critical for a cardiovascular target).
Let's compare the ligands property by property:
1. **MW:** Both ligands (366.89 and 349.43 Da) fall within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (58.64) is significantly better than Ligand B (102.66). TPSA < 140 is good for oral absorption, and lower is generally better for GPCRs. Ligand B is pushing the upper limit.
3. **logP:** Ligand A (2.974) is optimal, while Ligand B (0.741) is a bit low, potentially hindering membrane permeability.
4. **HBD/HBA:** Ligand A (1 HBD, 3 HBA) is preferable to Ligand B (2 HBD, 5 HBA) as lower counts generally improve permeability.
5. **QED:** Both are similar (0.815 vs 0.713), indicating good drug-likeness.
6. **DILI:** Ligand A (29.82) has a slightly higher DILI risk than Ligand B (19.43), but both are well below the concerning threshold of 60.
7. **BBB:** Ligand A (78.40) is significantly better than Ligand B (48.47), though BBB isn't a primary concern for a cardiovascular target.
8. **Caco-2:** Both are negative, indicating poor permeability. This is a concern for both.
9. **Solubility:** Ligand A (-3.046) is better than Ligand B (-1.204). Higher solubility is generally desirable.
10. **hERG:** Both are very low (0.237 and 0.25), indicating minimal hERG inhibition risk.
11. **Cl_mic:** Ligand A (28.51) has better metabolic stability (lower clearance) than Ligand B (6.72).
12. **t1/2:** Ligand A (33.35) has a longer half-life than Ligand B (11.70).
13. **Pgp:** Both are very low (0.068 and 0.015), suggesting minimal P-gp efflux.
14. **Binding Affinity:** Ligand A (-6.3 kcal/mol) and Ligand B (-6.7 kcal/mol) have very similar binding affinities. Ligand B is slightly better, but the difference is not substantial enough to outweigh other factors.
**Overall Assessment:**
Ligand A is significantly better overall. It has a more favorable TPSA, logP, solubility, metabolic stability (Cl_mic and t1/2), and BBB penetration. While Ligand B has a slightly better binding affinity and lower DILI risk, the improvements in ADME properties for Ligand A are more critical for a successful drug candidate, especially for a GPCR. The slightly better binding affinity of Ligand B is not enough to overcome the ADME deficiencies.
**Output:**
1
2025-04-17 21:30:31,394 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [342.359, 113.24 , 0.323, 2. , 7. , 0.831, 72.392, 60.915, -5.009, -3.325, 0.119, -3.893, -7.551, 0.005, -6.8 ]
**Ligand B:** [342.403, 104.45 , 0.627, 2. , 6. , 0.798, 75.107, 64.211, -5.229, -2.601, 0.376, 17.625, -1.545, 0.035, -7.4 ]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity):
1. **MW:** Both are excellent (around 342 Da), falling well within the 200-500 Da range.
2. **TPSA:** Ligand B (104.45) is better than Ligand A (113.24), being closer to the ideal <140 for oral absorption.
3. **logP:** Ligand A (0.323) is a bit low, potentially hindering membrane permeability. Ligand B (0.627) is better, but still on the lower side of optimal (1-3).
4. **HBD/HBA:** Both have 2 HBD and acceptable HBA counts (7 and 6 respectively).
5. **QED:** Both are good (>0.7), indicating drug-like properties.
6. **DILI:** Ligand B (75.107) has a slightly higher DILI risk than Ligand A (72.392), but both are acceptable.
7. **BBB:** Ligand B (64.211) has a slightly better BBB penetration potential than Ligand A (60.915), but both are not great.
8. **Caco-2:** Both are very poor (-5.009 and -5.229). This is a significant concern for oral absorption.
9. **Solubility:** Ligand B (-2.601) is better than Ligand A (-3.325), indicating better aqueous solubility.
10. **hERG:** Ligand A (0.119) has a significantly lower hERG risk than Ligand B (0.376). This is a major advantage.
11. **Cl_mic:** Ligand A (-3.893) has a much lower (better) microsomal clearance than Ligand B (17.625), suggesting better metabolic stability.
12. **t1/2:** Ligand A (-7.551) has a longer in vitro half-life than Ligand B (-1.545).
13. **Pgp:** Ligand A (0.005) has a much lower P-gp efflux liability than Ligand B (0.035).
14. **Affinity:** Ligand B (-7.4) has a slightly better binding affinity than Ligand A (-6.8), a difference of 0.6 kcal/mol.
**Overall Assessment:**
While Ligand B has a slightly better affinity and TPSA, Ligand A is significantly better in terms of safety (hERG), metabolic stability (Cl_mic, t1/2), and efflux (Pgp). The Caco-2 permeability is poor for both, which is a major drawback, but the other ADME properties of Ligand A are more favorable for a GPCR target. The affinity difference isn't large enough to overcome the substantial advantages of Ligand A in ADME/Tox.
Therefore, I would choose Ligand A.
Output:
1
2025-04-17 21:30:31,395 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [385.295, 80.04, 2.775, 2, 5, 0.768, 52.966, 22.218, -5.039, -3.184, 0.14, 30.522, 40.628, 0.088, -6.9]
**Ligand B:** [342.443, 62.06, 3.507, 0, 6, 0.832, 49.438, 73.672, -4.884, -3.764, 0.302, 65.297, -37.807, 0.192, -5.9]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, BBB, and affinity are key):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (342.443) is slightly preferred due to being a bit lower.
2. **TPSA:** Ligand A (80.04) is a bit higher than Ligand B (62.06). Ligand B is better, being closer to the <90 target for GPCRs.
3. **logP:** Both are good (between 1-3). Ligand A (2.775) is slightly better than Ligand B (3.507) as it's closer to the optimal range.
4. **HBD:** Ligand A (2) is preferable to Ligand B (0) as some hydrogen bonding can aid solubility.
5. **HBA:** Ligand B (6) is slightly better than Ligand A (5).
6. **QED:** Both are good (>0.5), with Ligand B (0.832) being slightly better.
7. **DILI:** Both are acceptable (<60). Ligand B (49.438) is slightly better.
8. **BBB:** Ligand B (73.672) is significantly better than Ligand A (22.218). This is a *major* advantage for a GPCR target, even if not CNS-focused, as it suggests better distribution.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-5.039) is slightly worse.
10. **Solubility:** Both are negative, indicating poor solubility. Ligand A (-3.184) is slightly worse.
11. **hERG:** Both are very low risk (close to 0). Ligand A (0.14) is slightly better.
12. **Cl_mic:** Ligand A (30.522) has a significantly lower clearance than Ligand B (65.297), indicating better metabolic stability. This is a strong point for Ligand A.
13. **t1/2:** Ligand A (40.628) has a better in vitro half-life than Ligand B (-37.807). This is a strong point for Ligand A.
14. **Pgp:** Ligand A (0.088) has a lower P-gp efflux liability than Ligand B (0.192), which is favorable.
15. **Affinity:** Ligand A (-6.9 kcal/mol) has a slightly better binding affinity than Ligand B (-5.9 kcal/mol).
**Overall Assessment:**
While Ligand A has advantages in metabolic stability (Cl_mic, t1/2) and binding affinity, Ligand B's superior BBB penetration is a critical advantage for a GPCR. The slightly better QED, DILI, and TPSA of Ligand B also contribute. The poor Caco-2 and solubility of both are concerning, but can potentially be addressed with formulation strategies. The difference in affinity is not large enough to overcome the BBB advantage of Ligand B.
Therefore, I prefer Ligand B.
0
2025-04-17 21:30:31,395 - INFO - Reasoning:
Let's analyze both ligands based on the provided guidelines, prioritizing GPCR-specific parameters (logP, Pgp, TPSA, and affinity).
**Ligand A:**
* **MW:** 350.434 Da - Good.
* **TPSA:** 58.64 - Good, well below the 140 threshold.
* **logP:** 2.965 - Excellent, within the optimal 1-3 range.
* **HBD:** 1 - Good.
* **HBA:** 3 - Good.
* **QED:** 0.697 - Good, above the 0.5 threshold.
* **DILI:** 35.169 - Excellent, low risk.
* **BBB:** 91.392 - Excellent, high penetration potential.
* **Caco-2:** -4.415 - Poor. Indicates low permeability.
* **Solubility:** -3.456 - Poor. Indicates low solubility.
* **hERG:** 0.673 - Good, low risk.
* **Cl_mic:** 64.12 - Moderate. Could be better for metabolic stability.
* **t1/2:** 10.267 - Moderate.
* **Pgp:** 0.295 - Good, low efflux.
* **Affinity:** -6.5 kcal/mol - Good.
**Ligand B:**
* **MW:** 342.483 Da - Good.
* **TPSA:** 49.41 - Excellent, very favorable for permeability.
* **logP:** 3.081 - Excellent, within the optimal range.
* **HBD:** 1 - Good.
* **HBA:** 2 - Good.
* **QED:** 0.789 - Excellent, very drug-like.
* **DILI:** 17.836 - Excellent, very low risk.
* **BBB:** 81.698 - Good, reasonable penetration.
* **Caco-2:** -4.558 - Poor. Similar to Ligand A, indicates low permeability.
* **Solubility:** -3.135 - Poor. Similar to Ligand A, indicates low solubility.
* **hERG:** 0.523 - Good, low risk.
* **Cl_mic:** 78.695 - Moderate-High. Higher clearance than Ligand A.
* **t1/2:** -17.577 - Very Poor. Indicates extremely short half-life.
* **Pgp:** 0.295 - Good, low efflux.
* **Affinity:** -7.2 kcal/mol - Excellent, significantly better than Ligand A.
**Comparison and Decision:**
Both ligands have similar issues with Caco-2 permeability and aqueous solubility. However, Ligand B has a significantly better binding affinity (-7.2 vs -6.5 kcal/mol), a better QED score, and a lower DILI risk. The biggest drawback for Ligand B is its extremely short *in vitro* half-life. While metabolic stability is important, the substantial gain in binding affinity is a critical advantage for a GPCR target like ADRB2. The improved affinity could potentially allow for a lower dose, mitigating some concerns about the shorter half-life. Ligand A's slightly better metabolic stability is not enough to overcome the affinity difference.
Output:
0
2025-04-17 21:30:31,395 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [411.769, 63.24, 4.408, 1, 3, 0.758, 88.484, 36.448, -4.827, -4.192, 0.671, 12.715, 78.462, 0.595, 0.2]**
**Ligand B: [370.852, 67.43, 3.519, 2, 3, 0.797, 54.207, 89.221, -4.135, -5.188, 0.508, 79.269, 36.105, 0.298, -6.3]**
1. **Molecular Weight:** Ligand A (411.769 Da) is within the ideal range, while Ligand B (370.852 Da) is also acceptable. No clear advantage.
2. **TPSA:** Both ligands (A: 63.24, B: 67.43) are below the 140 A^2 threshold for good oral absorption, but not optimized for CNS penetration (ideally <90). No strong difference.
3. **logP:** Ligand A (4.408) is slightly higher than Ligand B (3.519). While both are within the 1-3 range, A is approaching the upper limit, potentially raising solubility concerns. B is better here.
4. **H-Bond Donors:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **H-Bond Acceptors:** Both ligands have 3 HBA, so no difference.
6. **QED:** Both ligands have good QED scores (A: 0.758, B: 0.797), indicating good drug-like properties. B is slightly better.
7. **DILI:** Ligand A (88.484) has a significantly higher DILI risk than Ligand B (54.207). This is a major concern for Ligand A.
8. **BBB:** Ligand B (89.221) has better BBB penetration than Ligand A (36.448). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be beneficial or at least needs to be understood.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual. Assuming these are permeability coefficients, lower (more negative) values indicate *lower* permeability. Ligand A (-4.827) is slightly better than Ligand B (-4.135) in this case, meaning it has better permeability.
10. **Aqueous Solubility:** Ligand B (-5.188) has better solubility than Ligand A (-4.192).
11. **hERG:** Both ligands have low hERG inhibition risk (A: 0.671, B: 0.508). B is slightly better.
12. **Microsomal Clearance:** Ligand B (79.269) has a higher microsomal clearance than Ligand A (12.715), suggesting faster metabolism and potentially lower *in vivo* exposure. A is significantly better.
13. **In vitro Half-Life:** Ligand A (78.462) has a longer half-life than Ligand B (36.105), which is desirable.
14. **P-gp Efflux:** Both ligands have low P-gp efflux (A: 0.595, B: 0.298). B is better here.
15. **Binding Affinity:** Ligand B (-6.3 kcal/mol) has a significantly stronger binding affinity than Ligand A (-0.2 kcal/mol). This is a crucial advantage, outweighing many of the other differences.
**Overall Assessment:**
Ligand B is the stronger candidate. The significantly improved binding affinity (-6.3 vs -0.2 kcal/mol) is a major advantage. It also has a lower DILI risk, better solubility, and better P-gp efflux. While Ligand A has better metabolic stability (lower Cl_mic and longer half-life) and slightly better Caco-2 permeability, the affinity and safety profile of Ligand B are far more compelling, especially for a GPCR target. The higher logP of Ligand A is a concern.
Output:
0
2025-04-17 21:30:31,395 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [346.471, 58.64, 2.267, 1, 3, 0.686, 15.898, 72.896, -4.798, -2.431, 0.263, 51.9, -27.981, 0.114, -6.5]
**Ligand B:** [350.419, 104.53, -0.239, 2, 6, 0.606, 26.328, 45.715, -4.865, -0.869, 0.036, 21.109, -8.713, 0.005, -6]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, BBB, and affinity):
1. **MW:** Both are within the ideal 200-500 Da range. A is 346.471, B is 350.419 - very similar.
2. **TPSA:** Ligand A (58.64) is excellent, well below 140, and favorable for oral absorption. Ligand B (104.53) is higher, but still acceptable, though less ideal.
3. **logP:** Ligand A (2.267) is optimal. Ligand B (-0.239) is quite low, potentially hindering permeability. This is a significant drawback.
4. **HBD/HBA:** A (1/3) is better than B (2/6). Lower counts generally improve permeability.
5. **QED:** Both are good (A: 0.686, B: 0.606), indicating drug-like properties.
6. **DILI:** Ligand A (15.898) has a much lower DILI risk than Ligand B (26.328). This is a major advantage for A.
7. **BBB:** Ligand A (72.896) has a good BBB penetration percentile, while Ligand B (45.715) is lower. While ADRB2 isn't *necessarily* a CNS target, some peripheral effects can be modulated by CNS penetration, and higher BBB is generally favorable.
8. **Caco-2:** Both are negative, indicating poor permeability. A (-4.798) is slightly better than B (-4.865).
9. **Solubility:** Both are negative, indicating poor solubility. A (-2.431) is slightly better than B (-0.869).
10. **hERG:** Both are very low (A: 0.263, B: 0.036), indicating minimal hERG inhibition risk.
11. **Cl_mic:** Ligand A (51.9) has a higher microsomal clearance than Ligand B (21.109), suggesting faster metabolism and potentially lower *in vivo* exposure.
12. **t1/2:** Ligand A (-27.981) has a much longer in vitro half-life than Ligand B (-8.713), which is a significant positive.
13. **Pgp:** Both are very low (A: 0.114, B: 0.005), indicating minimal P-glycoprotein efflux.
14. **Affinity:** Both have excellent binding affinity (-6.5 kcal/mol and -6 kcal/mol respectively), with A being slightly better.
**Overall Assessment:**
Ligand A is the stronger candidate. While both have good affinity, Ligand A significantly outperforms Ligand B in several critical areas: logP, DILI risk, BBB penetration, and in vitro half-life. The lower logP of Ligand B is a major concern, potentially leading to poor absorption. The higher DILI risk for Ligand B is also a significant negative. While Ligand A has a higher Cl_mic, the longer half-life mitigates this concern.
Output:
1
2025-04-17 21:30:31,395 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (355.463 and 350.459 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (66.63) is significantly better than Ligand B (87.66). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (3.612) is optimal, while Ligand B (1.118) is on the lower side. A logP between 1-3 is preferred, so Ligand A is better.
4. **HBD:** Ligand A (2) is preferable to Ligand B (3). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (4). Similar to HBD, lower HBA is generally better.
6. **QED:** Both ligands have similar QED values (0.734 and 0.642), indicating good drug-likeness.
7. **DILI:** Ligand A (59.907) has a higher DILI risk than Ligand B (11.361). This is a significant drawback for Ligand A.
8. **BBB:** Ligand A (51.415) has better BBB penetration than Ligand B (34.238), but this isn't a major concern for a cardiovascular target.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.31 and -5.235), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-3.559) has slightly better solubility than Ligand B (-1.66), but both are poor.
11. **hERG:** Ligand A (0.295) has a slightly better hERG profile than Ligand B (0.194), but both are low risk.
12. **Cl_mic:** Ligand A (3.171) has significantly better metabolic stability (lower clearance) than Ligand B (2.398).
13. **t1/2:** Ligand B (32.277) has a much longer in vitro half-life than Ligand A (8.786). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.157) has lower P-gp efflux than Ligand B (0.02). Lower Pgp is better.
15. **Binding Affinity:** Ligand B (-8.0) has a significantly stronger binding affinity than Ligand A (-6.3). A 1.7 kcal/mol difference is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand B has a substantially better binding affinity, a much longer half-life, and a significantly lower DILI risk. While Ligand A has better TPSA, logP, and Cl_mic, the superior affinity and safety profile of Ligand B are more critical for a viable drug candidate. The poor Caco-2 values are a concern for both, but can be addressed during lead optimization. The stronger binding of Ligand B is the most important factor.
Output:
0
2025-04-17 21:30:31,396 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's analyze each ligand against the provided guidelines, keeping in mind ADRB2 is a GPCR, so logP, TPSA, Pgp, and affinity are key.
* **Molecular Weight:** Both ligands (355.435 and 355.395 Da) fall within the ideal 200-500 Da range.
* **TPSA:** Ligand A (99.18) is better than Ligand B (122.29). Both are below 140, but A is closer to the optimal for oral absorption.
* **logP:** Ligand A (-0.5) is slightly outside the optimal 1-3 range, but acceptable. Ligand B (-2.434) is lower and could indicate permeability issues.
* **H-Bond Donors:** Ligand A (2) is preferable to Ligand B (3).
* **H-Bond Acceptors:** Both ligands have 5 HBA, which is acceptable.
* **QED:** Ligand A (0.626) is significantly better than Ligand B (0.473), indicating a more drug-like profile.
* **DILI:** Ligand A (20.628) has a much lower DILI risk than Ligand B (33.501). This is a significant advantage.
* **BBB:** Ligand A (20.434) is better than Ligand B (10.741), although neither is particularly high. For a cardiovascular target, BBB isn't a primary concern, but it's still a positive.
* **Caco-2:** Both have negative values, indicating poor permeability. Ligand A (-5.032) is slightly better than Ligand B (-5.54).
* **Solubility:** Ligand A (-0.322) is better than Ligand B (0.083).
* **hERG:** Both ligands have very low hERG inhibition risk (0.102 and 0.036).
* **Cl_mic:** Ligand A (-2.305) has a much lower (better) microsomal clearance than Ligand B (-24.218), suggesting better metabolic stability.
* **t1/2:** Ligand A (-0.586) has a slightly better in vitro half-life than Ligand B (-7.476).
* **Pgp:** Ligand A (0.019) has a much lower Pgp efflux liability than Ligand B (0.001), which is favorable for bioavailability.
* **Binding Affinity:** Ligand A (-7.6) has a slightly better binding affinity than Ligand B (-6.7), though both are good.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical ADME-Tox properties (DILI, Cl_mic, Pgp, QED, Solubility) and has a slightly better binding affinity. While both have issues with Caco-2 permeability, Ligand A's other properties make it a more promising starting point for optimization. The lower DILI risk and better metabolic stability are particularly important.
**Output:**
1
2025-04-17 21:30:31,396 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [347.419, 107.19 , 0.075, 3. , 4. , 0.701, 42.691, 45.909, -5.386, -2.852, 0.302, 9.088, -2.84 , 0.03 , -5.8 ]
**Ligand B:** [350.365, 66.57 , 3.163, 1. , 4. , 0.869, 31.563, 79.488, -4.489, -3.174, 0.457, 27.675, 7.904, 0.146, -6.8 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). A (347.419) is slightly lower than B (350.365), which is fine.
2. **TPSA:** A (107.19) is higher than B (66.57). For a GPCR, lower TPSA is generally preferred for better brain penetration, even if it's not a CNS target. B is significantly better here.
3. **logP:** A (0.075) is very low, potentially causing permeability issues. B (3.163) is optimal. This is a major advantage for B.
4. **HBD:** A (3) is acceptable, B (1) is even better.
5. **HBA:** Both (A: 4, B: 4) are within the acceptable range.
6. **QED:** Both are good (A: 0.701, B: 0.869), but B is better.
7. **DILI:** A (42.691) and B (31.563) are both relatively low risk, but B is better.
8. **BBB:** A (45.909) is low, while B (79.488) is quite good. This is important for GPCRs.
9. **Caco-2:** A (-5.386) is very poor, indicating very low intestinal absorption. B (-4.489) is also poor, but better than A.
10. **Solubility:** A (-2.852) and B (-3.174) are both poor. Solubility is a concern for both, but not a deciding factor.
11. **hERG:** A (0.302) is better than B (0.457), indicating lower cardiotoxicity risk.
12. **Cl_mic:** A (9.088) is lower than B (27.675), suggesting better metabolic stability.
13. **t1/2:** A (-2.84) is worse than B (7.904), indicating a shorter half-life.
14. **Pgp:** A (0.03) is much lower than B (0.146), indicating less P-gp efflux.
15. **Affinity:** B (-6.8) is 0.9 kcal/mol better than A (-5.8). This is a substantial difference in binding.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, BBB, and affinity.
* **LogP:** B is significantly better.
* **TPSA:** B is significantly better.
* **Pgp:** A is better.
* **BBB:** B is much better.
* **Affinity:** B is significantly better.
**Conclusion:**
While Ligand A has a slightly better hERG profile and Pgp efflux, Ligand B overwhelmingly wins on the key GPCR parameters: logP, TPSA, BBB, and, most importantly, binding affinity. The significantly better affinity of B (-6.8 kcal/mol) is likely to outweigh the minor drawbacks in hERG and Pgp. The poor Caco-2 permeability of both is a concern, but can be addressed with formulation strategies.
Therefore, I prefer Ligand B.
0
2025-04-17 21:30:31,396 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's systematically compare Ligand A and Ligand B based on the provided parameters and the guidelines, keeping in mind ADRB2 is a GPCR.
1. **Molecular Weight:** Both ligands (374.43 Da and 346.39 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (58.2) is significantly better than Ligand B (100.46). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is pushing the upper limit for good oral absorption.
3. **logP:** Both ligands have good logP values (2.379 and 1.492), falling within the optimal 1-3 range. Ligand B is slightly lower, which *could* indicate slightly better solubility, but isn't a major concern.
4. **H-Bond Donors:** Both have 2 HBD, which is within the acceptable limit of <=5.
5. **H-Bond Acceptors:** Ligand A has 3 HBA, while Ligand B has 5. Both are acceptable (<=10), but Ligand A is preferable.
6. **QED:** Both ligands have good QED scores (0.735 and 0.854), indicating good drug-like properties.
7. **DILI Risk:** Ligand A (24.544 percentile) has a much lower DILI risk than Ligand B (76.386 percentile). This is a significant advantage for Ligand A.
8. **BBB Penetration:** Ligand A (87.088 percentile) shows significantly better BBB penetration than Ligand B (27.957 percentile). While ADRB2 isn't exclusively a CNS target, some CNS exposure might be acceptable or even desirable depending on the specific therapeutic goal, and better BBB penetration is generally a plus.
9. **Caco-2 Permeability:** Ligand A (-4.933) is better than Ligand B (-5.072) - both are negative, which is not ideal, but A is slightly better.
10. **Aqueous Solubility:** Ligand A (-3.714) is better than Ligand B (-2.864).
11. **hERG Inhibition:** Both ligands have low hERG inhibition risk (0.48 and 0.248). Ligand B is slightly better.
12. **Microsomal Clearance:** Ligand A (39.954) has a higher (worse) microsomal clearance than Ligand B (6.225). This suggests Ligand B is more metabolically stable.
13. **In vitro Half-Life:** Ligand A (0.016 hours) has a very short half-life, while Ligand B (10.075 hours) has a much longer half-life. This is a major advantage for Ligand B.
14. **P-gp Efflux:** Both ligands have low P-gp efflux liability (0.062 and 0.036).
15. **Binding Affinity:** Ligand A (-7.1 kcal/mol) has a slightly better binding affinity than Ligand B (-6.7 kcal/mol). This 0.4 kcal/mol difference is significant, and can often outweigh minor ADME concerns.
**Overall Assessment:**
Ligand A has a clear advantage in terms of potency (binding affinity), DILI risk, TPSA, solubility, and BBB penetration. However, Ligand B has a significantly longer half-life and better metabolic stability (lower Cl_mic). The longer half-life of Ligand B is attractive, but the superior binding affinity and safety profile (lower DILI) of Ligand A are more critical for a GPCR target. The slightly lower TPSA of Ligand A is also beneficial.
**Output:**
1
2025-04-17 21:30:31,396 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (342.443 and 349.406 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (75.19 and 71.53) are below the 140 A^2 threshold for good oral absorption, and acceptable for a cardiovascular GPCR. Ligand B is slightly better.
3. **logP:** Both ligands (2.045 and 2.009) are within the optimal 1-3 range. No significant difference.
4. **HBD:** Both ligands have 1 HBD, which is within the acceptable limit of <=5. No difference.
5. **HBA:** Both ligands have 4 HBA, which is within the acceptable limit of <=10. No difference.
6. **QED:** Ligand B (0.903) has a significantly higher QED score than Ligand A (0.734), indicating a more drug-like profile. This is a positive for Ligand B.
7. **DILI:** Ligand A (26.057%) has a much lower DILI risk than Ligand B (53.432%). This is a significant advantage for Ligand A.
8. **BBB:** Ligand B (85.847%) has a higher BBB penetration percentile than Ligand A (70.686%). While ADRB2 isn't a CNS target, some degree of BBB penetration isn't necessarily detrimental, and could allow for off-target effects.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. Ligand B (-4.617) is slightly better than Ligand A (-5.119).
10. **Solubility:** Both ligands have negative solubility values, indicating poor aqueous solubility. Ligand A (-1.465) is slightly better than Ligand B (-2.775).
11. **hERG:** Both ligands have very low hERG inhibition liability (0.151 and 0.299), which is excellent. No significant difference.
12. **Cl_mic:** Ligand A (24.792 mL/min/kg) has a significantly lower microsomal clearance than Ligand B (11.506 mL/min/kg), suggesting better metabolic stability. This is a major advantage for Ligand A.
13. **t1/2:** Ligand B (3.453 hours) has a longer in vitro half-life than Ligand A (-2.061 hours). This is a positive for Ligand B.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.012 and 0.043). No significant difference.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.2 and -6.0 kcal/mol). The difference is negligible.
**GPCR-specific priorities:**
For ADRB2 (a cardiovascular GPCR), we prioritize logP, TPSA, affinity, and metabolic stability. While BBB isn't critical, it's not a major negative if present.
**Overall Assessment:**
Ligand A has a significantly better safety profile (lower DILI) and better metabolic stability (lower Cl_mic). While Ligand B has a slightly better QED and half-life, the lower DILI and Cl_mic of Ligand A are more important for a cardiovascular drug candidate, where long-term safety and efficacy are paramount. The slight improvement in Caco-2 for Ligand B is not enough to overcome the significant DILI risk.
Output:
1
2025-04-17 21:30:31,396 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (340.383 and 356.392 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (61.88) is significantly better than Ligand A (95.16). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (1.822) is within the optimal 1-3 range. Ligand B (4.065) is pushing the upper limit and could potentially lead to solubility issues or off-target interactions.
4. **HBD:** Both ligands have acceptable HBD counts (2 and 1, respectively), well below the threshold of 5.
5. **HBA:** Both ligands have acceptable HBA counts (4 and 3, respectively), well below the threshold of 10.
6. **QED:** Both ligands have similar and good QED values (0.868 and 0.849), indicating good drug-like properties.
7. **DILI:** Ligand B (45.444) has a much lower DILI risk than Ligand A (85.266). This is a significant advantage, as liver toxicity is a major concern in drug development.
8. **BBB:** Ligand B (84.219) has a higher BBB penetration percentile than Ligand A (54.091). While not critical for a cardiovascular target, it's a slight positive.
9. **Caco-2:** Both ligands have similar, poor Caco-2 permeability values (-4.96 and -4.694). This suggests potential absorption issues for both.
10. **Solubility:** Ligand B (-4.199) has slightly better solubility than Ligand A (-3.769), but both are quite poor.
11. **hERG:** Ligand A (0.391) has a lower hERG inhibition liability than Ligand B (0.796). This is a positive for Ligand A, as it reduces the risk of cardiotoxicity.
12. **Cl_mic:** Ligand B (37.736) has a lower microsomal clearance than Ligand A (50.18), suggesting better metabolic stability.
13. **t1/2:** Ligand B (17.871) has a longer in vitro half-life than Ligand A (15.028).
14. **Pgp:** Ligand B (0.135) has lower P-gp efflux liability than Ligand A (0.096). Lower P-gp is generally favorable.
15. **Affinity:** Ligand B (-6.9 kcal/mol) has a slightly better binding affinity than Ligand A (-6.6 kcal/mol). This difference is significant enough to potentially outweigh some of the ADME drawbacks.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B excels in TPSA, Pgp, and affinity, while Ligand A has a better logP and hERG. However, the significantly lower DILI risk and improved metabolic stability (lower Cl_mic, longer t1/2) of Ligand B are compelling advantages. The slight affinity advantage of Ligand B also tips the balance.
**Conclusion:**
Considering the balance of properties, particularly the lower DILI risk, better metabolic stability, and slightly improved affinity of Ligand B, it is the more promising drug candidate.
Output:
0
2025-04-17 21:30:31,397 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (397.649) is slightly higher than Ligand B (361.433), but both are acceptable.
2. **TPSA:** Both are below the 140 A^2 threshold for good oral absorption. Ligand B (70.67) is better than Ligand A (80.91), being closer to the preferred <90 A^2 for potential CNS penetration (though ADRB2 isn't strictly a CNS target, lower TPSA is generally favorable).
3. **logP:** Ligand A (3.951) is at the upper end of the optimal range (1-3), while Ligand B (1.155) is at the low end. While Ligand B's logP is a bit low, it's not drastically so. Ligand A's higher logP could potentially lead to off-target effects or solubility issues.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD is generally better for permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (4). Lower HBA is generally better for permeability.
6. **QED:** Both ligands have good QED scores (A: 0.659, B: 0.714), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand B (19.038) has a significantly lower DILI risk than Ligand A (84.374). This is a major advantage for Ligand B.
8. **BBB:** Ligand B (83.482) has better BBB penetration potential than Ligand A (62.97). While ADRB2 isn't a primary CNS target, better BBB penetration is rarely a negative.
9. **Caco-2:** Both have negative Caco-2 values which is unusual. I'll assume these are percentile scores and interpret them as low permeability. Ligand A (-4.819) is slightly worse than Ligand B (-4.84).
10. **Solubility:** Ligand B (-1.486) has better solubility than Ligand A (-5.104).
11. **hERG:** Ligand B (0.4) has a lower hERG risk than Ligand A (0.619). This is a significant advantage.
12. **Cl_mic:** Ligand B (3.07) has significantly lower microsomal clearance than Ligand A (57.014), indicating better metabolic stability.
13. **t1/2:** Ligand A (21.257) has a longer in vitro half-life than Ligand B (-9.035). This is a positive for Ligand A, but the negative value for B is concerning.
14. **Pgp:** Ligand B (0.014) has much lower P-gp efflux liability than Ligand A (0.265). This is a significant advantage for oral bioavailability.
15. **Affinity:** Ligand A (-6.2) has a slightly better binding affinity than Ligand B (-5.6). This is a 0.6 kcal/mol difference, which is not huge, but noticeable.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP, TPSA, and Pgp. Ligand A has a slight edge in affinity, but the differences in ADME properties are substantial.
**Overall Assessment:**
Ligand B is the stronger candidate. While Ligand A has a slightly better binding affinity, Ligand B demonstrates a significantly better safety profile (lower DILI, hERG), improved ADME properties (lower Cl_mic, better solubility, lower Pgp efflux), and a more favorable TPSA. The negative half-life for Ligand B is a concern, but the other advantages outweigh this.
Output:
0
2025-04-17 21:30:31,397 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (361.383 and 356.853 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (41.57) is significantly better than Ligand A (110.8), falling well below the 140 threshold for good absorption and being more favorable for GPCRs.
3. **logP:** Both ligands (2.943 and 3.727) are within the optimal 1-3 range. Ligand B is slightly higher, which *could* be a minor drawback, but not a major concern.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1), but both are within the acceptable limit of 5.
5. **HBA:** Ligand A (7) is higher than Ligand B (3). This is a notable difference, with Ligand B being more favorable for permeability.
6. **QED:** Ligand B (0.83) is significantly better than Ligand A (0.536), indicating a more drug-like profile.
7. **DILI:** Ligand A (98.216) has a much higher DILI risk than Ligand B (60.45). This is a significant concern for Ligand A.
8. **BBB:** Ligand B (74.176) has a substantially higher BBB penetration potential than Ligand A (39.511). This is a crucial advantage for a GPCR target, as it suggests better CNS exposure if desired, or at least reduced off-target effects in the brain.
9. **Caco-2:** Both ligands have similar, very negative Caco-2 values (-4.919 and -4.925). This suggests poor permeability, which is concerning.
10. **Solubility:** Both ligands have similar, very negative solubility values (-4.169 and -4.007). This suggests poor solubility, which is concerning.
11. **hERG:** Ligand A (0.616) has a slightly lower hERG risk than Ligand B (0.923), but both are relatively low and not a major concern.
12. **Cl_mic:** Ligand B (40.039) has a significantly lower microsomal clearance than Ligand A (56.769), indicating better metabolic stability.
13. **t1/2:** Ligand A (5.225) has a slightly longer half-life than Ligand B (0.557), which is a positive, but the difference is not substantial enough to outweigh other factors.
14. **Pgp:** Ligand A (0.367) has lower P-gp efflux than Ligand B (0.736), which is favorable.
15. **Binding Affinity:** Ligand B (-6.8 kcal/mol) has a slightly better binding affinity than Ligand A (-6.4 kcal/mol), although the difference is not huge.
**Overall Assessment & GPCR-Specific Priorities:**
For an ADRB2 GPCR target, TPSA, logP, Pgp, BBB, and affinity are key. Ligand B excels in TPSA, BBB, Cl_mic, QED, and has slightly better affinity. Ligand A's major drawback is its high DILI risk and poor BBB penetration. While Ligand A has slightly better Pgp and half-life, these are outweighed by the significant advantages of Ligand B in terms of safety (DILI), brain exposure (BBB), and metabolic stability (Cl_mic). The poor Caco-2 and solubility for both are concerning and would require formulation strategies, but are not disqualifying at this stage.
Therefore, Ligand B is the more promising candidate.
Output:
0
2025-04-17 21:30:31,397 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for the ADRB2, a cardiovascular GPCR. Therefore, logP, TPSA, Pgp, and binding affinity are key.
* **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (357.491) is slightly lower, which is generally favorable for permeability.
* **TPSA:** Ligand B (66.48) has a lower TPSA than Ligand A (79.23). This is a significant advantage for oral absorption and potentially better CNS penetration, even though CNS penetration isn't the primary goal here.
* **logP:** Ligand A (1.721) is within the optimal range, while Ligand B (3.211) is at the higher end. While still acceptable, the higher logP of Ligand B could lead to solubility issues or off-target interactions.
* **H-Bond Donors/Acceptors:** Both ligands have reasonable HBD/HBA counts.
* **QED:** Both ligands have good QED scores (>0.5).
* **DILI:** Ligand A (10.392) has a much lower DILI risk than Ligand B (38.852). This is a crucial advantage, as minimizing liver toxicity is paramount.
* **BBB:** Both ligands have acceptable BBB penetration, but Ligand A (75.378) is slightly higher.
* **Caco-2 Permeability:** Both have negative Caco-2 values which is unusual and suggests poor permeability. Ligand B (-4.775) is worse than Ligand A (-4.146).
* **Aqueous Solubility:** Ligand A (-1.205) has better aqueous solubility than Ligand B (-3.264).
* **hERG:** Both ligands have low hERG inhibition risk.
* **Microsomal Clearance:** Ligand B (35.611) has slightly higher clearance than Ligand A (33.189), suggesting slightly lower metabolic stability.
* **In vitro Half-Life:** Ligand B (45.088) has a longer half-life than Ligand A (28.349), which is a positive.
* **P-gp Efflux:** Both have low P-gp efflux liability.
* **Binding Affinity:** Ligand A (-6.5 kcal/mol) has a slightly better binding affinity than Ligand B (-5.9 kcal/mol), but the difference is not substantial enough to outweigh other factors.
**Overall Assessment:**
Ligand A presents a better balance of properties. Its lower DILI risk, better solubility, and slightly better BBB penetration are significant advantages. While Ligand B has a longer half-life, the lower DILI risk of Ligand A is more critical for a viable drug candidate. The slightly better affinity of Ligand A is a bonus. The poor Caco-2 values for both compounds are concerning, but the other properties of Ligand A make it the more promising candidate.
**Output:**
1
2025-04-17 21:30:31,397 - INFO - Batch 263 complete. Total preferences: 4208
2025-04-17 21:30:31,397 - INFO - Processing batch 264/512...
2025-04-17 21:31:18,123 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [340.339, 109.3 , 0.272, 3. , 5. , 0.697, 81.427, 53.974, -5.136, -3.863, 0.13 , -7.149, 41.944, 0.043, -6.6 ]
**Ligand B:** [383.554, 29.54 , 4.344, 0. , 4. , 0.7 , 35.634, 88.445, -4.616, -4.891, 0.745, 123.478, -16.325, 0.597, -6.2 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). A (340) is slightly preferred.
2. **TPSA:** A (109.3) is higher than ideal for good oral absorption (<140), but B (29.54) is excellent. B is favored here.
3. **logP:** A (0.272) is quite low, potentially hindering permeation. B (4.344) is a bit high, but still within an acceptable range. B is favored.
4. **HBD:** A (3) is acceptable, B (0) is even better, reducing potential for off-target interactions. B is favored.
5. **HBA:** Both are acceptable (A: 5, B: 4).
6. **QED:** Both are good (A: 0.697, B: 0.7), indicating drug-like properties.
7. **DILI:** A (81.427) is significantly higher than B (35.634). B is strongly favored here, as lower DILI risk is crucial.
8. **BBB:** B (88.445) is much better than A (53.974). For a GPCR, some BBB penetration is desirable, even if it's not a CNS target, as it can influence distribution. B is favored.
9. **Caco-2:** A (-5.136) is very poor, indicating poor absorption. B (-4.616) is also poor, but slightly better.
10. **Solubility:** A (-3.863) is poor, B (-4.891) is worse. Both are problematic.
11. **hERG:** Both are low (A: 0.13, B: 0.745), indicating low cardiotoxicity risk.
12. **Cl_mic:** A (-7.149) is excellent (low clearance, high metabolic stability). B (123.478) is very high, indicating rapid metabolism. A is strongly favored.
13. **t1/2:** A (41.944) is good. B (-16.325) is very poor. A is strongly favored.
14. **Pgp:** A (0.043) is very low, indicating minimal efflux. B (0.597) is higher, suggesting some efflux. A is favored.
15. **Affinity:** A (-6.6) is slightly better than B (-6.2), but the difference is not huge.
**Overall Assessment:**
While Ligand B has a better TPSA and BBB, Ligand A has significantly better metabolic stability (Cl_mic and t1/2), lower Pgp efflux, and a slightly better binding affinity. The most significant drawback of Ligand A is its low logP and poor Caco-2 permeability, which could hinder absorption. However, the DILI risk associated with Ligand B is concerning. Given the GPCR target class, metabolic stability and minimizing off-target effects (DILI) are highly important. The slightly better affinity of A, combined with its superior metabolic profile and lower efflux, outweigh the absorption concerns.
Output:
1
2025-04-17 21:31:18,124 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands (366.439 and 354.403 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (76.15) is significantly better than Ligand B (105.17). ADRB2 is a cardiovascular target, not CNS, but lower TPSA is generally favorable for absorption.
3. **logP:** Ligand A (1.445) is within the optimal 1-3 range. Ligand B (-0.005) is slightly below 1, potentially hindering permeation. This favors A.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (5) is better than Ligand B (6). Lower HBA is generally preferred.
6. **QED:** Both are reasonably good (0.752 and 0.673), exceeding the 0.5 threshold.
7. **DILI:** Ligand A (81.427) has a higher DILI risk than Ligand B (33.773). This is a significant drawback for Ligand A.
8. **BBB:** Not a primary concern for a cardiovascular target, but Ligand A (67.895) is better than Ligand B (45.87).
9. **Caco-2:** Ligand A (-4.656) is better than Ligand B (-5.23). Higher (less negative) Caco-2 values are better.
10. **Solubility:** Ligand A (-3.646) is better than Ligand B (-0.783). Higher solubility is desirable.
11. **hERG:** Both are very low (0.467 and 0.2), indicating minimal hERG inhibition risk.
12. **Cl_mic:** Ligand B (4.568) has significantly lower microsomal clearance than Ligand A (55.543), suggesting better metabolic stability. This is a strong advantage for B.
13. **t1/2:** Ligand B (-6.661) has a better in vitro half-life than Ligand A (-8.108).
14. **Pgp:** Both are very low (0.291 and 0.032), indicating minimal P-gp efflux.
15. **Binding Affinity:** Both ligands have excellent binding affinity (-7.0 and -6.2 kcal/mol). Ligand A is slightly better, but the difference is not substantial enough to overcome other issues.
**GPCR-specific considerations:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are important. Ligand A has better logP and TPSA, and slightly better affinity. However, the significantly higher DILI risk and higher Cl_mic for Ligand A are major concerns.
**Overall Assessment:**
While Ligand A has a slight edge in binding affinity and some permeability parameters, the substantially lower DILI risk and improved metabolic stability (lower Cl_mic and better t1/2) of Ligand B make it the more promising drug candidate. The DILI risk associated with Ligand A is a critical factor that outweighs its minor advantages.
Output:
0
2025-04-17 21:31:18,124 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (377.392 Da) is slightly higher than Ligand B (347.503 Da), but both are acceptable.
**2. TPSA:** Ligand A (98.91) is higher than Ligand B (52.65). For a GPCR like ADRB2, lower TPSA is generally preferred for better permeability, giving a slight edge to Ligand B.
**3. logP:** Both ligands have acceptable logP values (Ligand A: 1.153, Ligand B: 2.326), falling within the optimal 1-3 range. Ligand B is slightly more lipophilic, which could be beneficial for membrane permeability.
**4. H-Bond Donors:** Ligand A has 4 HBD, while Ligand B has 1. Both are within the acceptable limit of 5.
**5. H-Bond Acceptors:** Ligand A has 4 HBA, while Ligand B has 3. Both are within the acceptable limit of 10.
**6. QED:** Ligand B (0.802) has a significantly higher QED score than Ligand A (0.493), indicating a more drug-like profile. This is a substantial advantage for Ligand B.
**7. DILI Risk:** Ligand A (54.517) has a higher DILI risk than Ligand B (7.794). This is a major concern, as lower DILI risk is crucial for drug development. Ligand B is clearly superior here.
**8. BBB Penetration:** Ligand B (87.941) has significantly better predicted BBB penetration than Ligand A (52.074). While ADRB2 isn't exclusively a CNS target, some degree of BBB penetration can be beneficial for understanding off-target effects and overall distribution.
**9. Caco-2 Permeability:** Ligand A (-5.798) has worse Caco-2 permeability than Ligand B (-4.714).
**10. Aqueous Solubility:** Both ligands have very poor predicted aqueous solubility (-2.499 and -2.033, respectively). This is a potential formulation challenge for both, but not a deciding factor between them.
**11. hERG Inhibition:** Ligand A (0.835) has slightly higher hERG inhibition risk than Ligand B (0.37). Lower hERG risk is always preferred.
**12. Microsomal Clearance:** Ligand A (-3.483) has lower (better) microsomal clearance than Ligand B (35.963), suggesting better metabolic stability. This is a significant advantage for Ligand A.
**13. In vitro Half-Life:** Ligand A (-20.623) has a much longer in vitro half-life than Ligand B (-7.101). This is a substantial advantage for Ligand A, potentially leading to less frequent dosing.
**14. P-gp Efflux:** Ligand A (0.077) has lower P-gp efflux than Ligand B (0.047), which is favorable.
**15. Binding Affinity:** Ligand A (-8.2 kcal/mol) has a slightly better binding affinity than Ligand B (-6.5 kcal/mol). This is a 1.7 kcal/mol difference, which is significant enough to potentially outweigh some ADME drawbacks.
**Overall Assessment:**
While Ligand A has a better binding affinity and metabolic stability (lower Cl_mic, longer t1/2), Ligand B excels in crucial ADME properties like QED, DILI risk, and BBB penetration. The significantly lower DILI risk for Ligand B is a major factor. The higher QED score also points to a more generally drug-like molecule. Although Ligand A's affinity is better, the ADME profile of Ligand B is more promising, and the affinity difference might be overcome with further optimization.
Output:
0
2025-04-17 21:31:18,124 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.5 and 360.8 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (58.64) is significantly better than Ligand B (78.35). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally improves absorption.
3. **logP:** Both ligands have good logP values (2.903 and 2.472, respectively) within the optimal 1-3 range. Ligand A is slightly higher, which could be a minor advantage.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (5). Lower HBA generally improves permeability.
6. **QED:** Both ligands have good QED scores (0.685 and 0.875), indicating good drug-like properties. Ligand B is slightly better here.
7. **DILI:** Ligand A (13.92) has a much lower DILI risk than Ligand B (55.68). This is a *major* advantage for Ligand A. DILI is a significant concern in drug development.
8. **BBB:** Ligand A (80.38) has a higher BBB penetration percentile than Ligand B (35.13). While not critical for a cardiovascular target, it's a positive attribute.
9. **Caco-2:** Ligand A (-4.457) is better than Ligand B (-5.282), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-2.778) is better than Ligand B (-3.873), indicating better aqueous solubility.
11. **hERG:** Both ligands have low hERG inhibition risk (0.464 and 0.412), which is good. No significant difference.
12. **Cl_mic:** Both ligands have similar microsomal clearance values (66.412 and 63.564). No significant difference.
13. **t1/2:** Both ligands have similar in vitro half-lives (-7.911 and -7.602). No significant difference.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.063 and 0.055). No significant difference.
15. **Binding Affinity:** Ligand A (-5.9) is slightly better than Ligand B (-6.8), indicating a stronger binding affinity.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Both ligands perform well on logP and Pgp. Ligand A is superior in TPSA and affinity, and significantly better in DILI risk.
**Overall Assessment:**
Ligand A is the stronger candidate. While Ligand B has a slightly higher QED, Ligand A's significantly lower DILI risk, better TPSA, solubility, Caco-2 permeability, and slightly better affinity outweigh this advantage. The lower DILI risk is a crucial factor in drug development.
Output:
1
2025-04-17 21:31:18,124 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (359.415 and 368.396 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (116.8) is higher than Ligand B (67.87). For a GPCR, lower TPSA is preferred for better BBB penetration, giving a slight edge to Ligand B.
3. **logP:** Ligand B (2.429) is within the optimal 1-3 range, while Ligand A (0.304) is quite low. Low logP can hinder membrane permeability. This is a significant advantage for Ligand B.
4. **HBD:** Both ligands have 1 HBD, which is acceptable.
5. **HBA:** Ligand A has 8 HBA, while Ligand B has 4. Both are within the acceptable limit of 10, but Ligand B is better.
6. **QED:** Ligand A (0.793) has a higher QED than Ligand B (0.528), indicating better overall drug-likeness. This favors Ligand A.
7. **DILI:** Ligand B (44.63) has a lower DILI risk than Ligand A (67.003). Lower DILI is always preferred. This favors Ligand B.
8. **BBB:** Ligand B (86.002) shows significantly better BBB penetration potential than Ligand A (48.352). This is a crucial factor for GPCRs, especially if CNS effects are possible. This strongly favors Ligand B.
9. **Caco-2:** Both have negative Caco-2 values, suggesting poor permeability. However, Ligand B (-4.916) is slightly less negative than Ligand A (-5.599).
10. **Solubility:** Both ligands have very poor aqueous solubility (-2.982 and -2.844). This is a concern for both.
11. **hERG:** Ligand A (0.071) has a lower hERG risk than Ligand B (0.537). This favors Ligand A.
12. **Cl_mic:** Ligand A (6.796) has a much lower microsomal clearance than Ligand B (28.944), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand B (-5.177) has a more negative in vitro half-life, suggesting a shorter half-life than Ligand A (-0.413). This favors Ligand A.
14. **Pgp:** Ligand A (0.031) shows lower P-gp efflux than Ligand B (0.102). This is favorable.
15. **Affinity:** Both ligands have very similar binding affinities (-6.7 and -6.0 kcal/mol). The difference of 0.7 kcal/mol is not substantial enough to outweigh other factors.
**Overall Assessment:**
Ligand B has a clear advantage in terms of logP, BBB penetration, and DILI risk, all of which are crucial for a GPCR target like ADRB2. While Ligand A has better QED, metabolic stability (Cl_mic, t1/2), and lower hERG risk, the poor logP and BBB penetration are major drawbacks. The solubility is equally poor for both. Given the importance of permeability and minimizing off-target effects (DILI) for a GPCR, Ligand B is the more promising candidate, despite its slightly higher hERG risk.
Output:
0
2025-04-17 21:31:18,125 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (342.443) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are reasonably low (A: 65.54, B: 67.43), suggesting good potential for oral absorption. They are well below the 140 A^2 threshold.
3. **logP:** Ligand A (1.069) is closer to the optimal range (1-3) than Ligand B (2.64). While 2.64 isn't *bad*, 1.069 is preferable for balancing permeability and solubility.
4. **HBD/HBA:** Ligand A (HBD=1, HBA=4) has a slightly more favorable profile than Ligand B (HBD=2, HBA=3). Lower counts are generally preferred.
5. **QED:** Ligand A (0.889) has a significantly higher QED score than Ligand B (0.672), indicating a more drug-like profile.
6. **DILI:** Ligand A (19.969) has a much lower DILI risk than Ligand B (26.095). This is a significant advantage.
7. **BBB:** Ligand B (70.88) has a slightly better BBB penetration score than Ligand A (61.962). However, for a cardiovascular target like ADRB2, BBB penetration isn't a primary concern.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and could indicate issues with the prediction method or the molecule itself. However, the values are similar (-4.985 and -5.104).
9. **Solubility:** Ligand A (-1.349) has a slightly better solubility score than Ligand B (-3.171).
10. **hERG:** Both ligands have very low hERG inhibition risk (A: 0.248, B: 0.496).
11. **Cl_mic:** Ligand A (4.904) has a significantly lower microsomal clearance than Ligand B (61.804), suggesting better metabolic stability.
12. **t1/2:** Ligand A (11.55) has a longer in vitro half-life than Ligand B (-0.382). This is a major advantage.
13. **Pgp:** Both ligands have low Pgp efflux liability (A: 0.042, B: 0.306).
14. **Binding Affinity:** Ligand A (-6.9 kcal/mol) has a slightly better binding affinity than Ligand B (-5.9 kcal/mol), although the difference is less than 1.5 kcal/mol.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A is better on logP, Pgp, and has slightly better affinity. While Ligand B has better BBB penetration, this is less critical for a cardiovascular target.
**Overall Assessment:**
Ligand A demonstrates a superior overall profile. It has a better QED score, significantly lower DILI risk, better metabolic stability (lower Cl_mic and longer t1/2), slightly better solubility, and a slightly better binding affinity. While Ligand B has slightly better BBB penetration, this is not a major concern for this target. The combination of improved ADME properties and comparable binding affinity makes Ligand A the more promising candidate.
Output:
1
2025-04-17 21:31:18,125 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (361.829) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (53.51) is significantly better than Ligand A (77.29). ADRB2 is not a CNS target, but lower TPSA generally improves absorption.
3. **logP:** Both ligands have good logP values (A: 4.201, B: 3.165) within the optimal range of 1-3. Ligand B is slightly better.
4. **HBD:** Ligand A has 1 HBD, Ligand B has 0. Both are acceptable.
5. **HBA:** Ligand A has 5 HBA, Ligand B has 4. Both are acceptable.
6. **QED:** Both ligands have good QED scores (A: 0.59, B: 0.751), indicating good drug-like properties. Ligand B is better.
7. **DILI:** Both ligands have similar DILI risk (A: 53.548, B: 50.33), and are both below the 60 threshold, indicating acceptable risk.
8. **BBB:** Ligand B (88.523) has a much higher BBB penetration percentile than Ligand A (69.794). While ADRB2 isn't a primary CNS target, higher BBB is generally not detrimental.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the values are close (-4.658 vs -4.511).
10. **Solubility:** Both ligands have negative solubility values, which is also unusual and suggests poor solubility. The values are close (-4.803 vs -4.413).
11. **hERG:** Both ligands have low hERG inhibition liability (A: 0.579, B: 0.354), which is excellent. Ligand B is better.
12. **Cl_mic:** Both ligands have similar microsomal clearance (A: 35.169, B: 34.185).
13. **t1/2:** Ligand A has a positive in vitro half-life (25.161), while Ligand B has a negative one (-13.17). This is a significant advantage for Ligand A.
14. **Pgp:** Both ligands have low Pgp efflux liability (A: 0.412, B: 0.282). Ligand B is better.
15. **Binding Affinity:** Ligand B (-7.5 kcal/mol) has a significantly better binding affinity than Ligand A (-6.9 kcal/mol). This 0.6 kcal/mol difference is substantial and can outweigh minor ADME drawbacks.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in TPSA, Pgp, and significantly in binding affinity. While Ligand A has a better in vitro half-life, the superior binding affinity of Ligand B is a critical advantage for a GPCR target.
**Conclusion:**
Despite the unusual negative values for Caco-2 and solubility, the significantly better binding affinity of Ligand B, coupled with its favorable TPSA, Pgp, and BBB values, makes it the more promising drug candidate.
Output:
0
2025-04-17 21:31:18,125 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (371.503 Da) is within the ideal range (200-500 Da). Ligand B (425.678 Da) is also acceptable, but closer to the upper limit.
2. **TPSA:** Ligand A (87.74) is good, under the 140 threshold for oral absorption and reasonably low for a GPCR. Ligand B (114.27) is still acceptable, but higher, potentially impacting permeability.
3. **logP:** Both ligands have good logP values (A: 1.082, B: 1.971), falling within the optimal 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability but needs to be balanced against solubility.
4. **HBD:** Both ligands have 2 HBD, which is within the acceptable limit of 5.
5. **HBA:** Ligand A has 6 HBA, and Ligand B has 7. Both are within the acceptable limit of 10.
6. **QED:** Both ligands have similar QED values (A: 0.621, B: 0.598), indicating good drug-like properties.
7. **DILI:** Ligand A (56.844) has a significantly lower DILI risk than Ligand B (87.049). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (47.15) has a better BBB percentile than Ligand B (32.765). While ADRB2 isn't exclusively a CNS target, some CNS exposure can occur, and better BBB penetration is generally favorable.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
10. **Solubility:** Ligand A (-3.261) has slightly better solubility than Ligand B (-2.67), which is preferable.
11. **hERG:** Both ligands have very low hERG inhibition liability (A: 0.194, B: 0.073), which is excellent.
12. **Cl_mic:** Ligand A (43.55) has significantly lower microsomal clearance than Ligand B (14.059), indicating better metabolic stability.
13. **t1/2:** Ligand A (-6.404) has a longer in vitro half-life than Ligand B (8.722), which is desirable.
14. **Pgp:** Both ligands have very low Pgp efflux liability (A: 0.035, B: 0.08).
15. **Affinity:** Both ligands have the same binding affinity (-6.5 kcal/mol), so this parameter doesn't differentiate them.
**GPCR-Specific Priorities:**
For GPCRs, logP, TPSA, Pgp, and affinity are important. Both ligands perform well on logP, Pgp, and affinity. Ligand A has a better TPSA and slightly better solubility. The biggest differentiator is the significantly improved ADME profile of Ligand A (lower DILI, better BBB, lower Cl_mic, longer t1/2).
**Conclusion:**
Ligand A is the more promising candidate due to its superior ADME properties, particularly the lower DILI risk and better metabolic stability. While both ligands have similar binding affinity, the improved safety and pharmacokinetic profile of Ligand A outweigh any potential benefits from Ligand B's slightly higher logP.
Output:
1
2025-04-17 21:31:18,125 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, key priorities are logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB (though less critical for a cardiovascular target compared to a CNS one).
Let's compare the ligands property by property:
1. **MW:** Both are within the ideal range (200-500 Da).
2. **TPSA:** Ligand A (72.88) is higher than Ligand B (49.41). Ligand B is much better, being well below the 140 threshold for oral absorption, and closer to the optimal for GPCRs.
3. **logP:** Ligand A (1.399) is within the optimal range, while Ligand B (3.215) is at the higher end, but still acceptable.
4. **HBD/HBA:** Ligand A has 2 HBD and 4 HBA, while Ligand B has 1 HBD and 2 HBA. Both are reasonable.
5. **QED:** Both are good (above 0.5).
6. **DILI:** Ligand B (29.042) has a significantly lower DILI risk than Ligand A (13.571), which is a major advantage.
7. **BBB:** Ligand B (92.478) has a much higher BBB penetration potential than Ligand A (40.675). While not paramount for a cardiovascular target, it's a positive attribute.
8. **Caco-2:** Both have negative values, indicating permeability. The values are similar.
9. **Solubility:** Ligand A (-1.02) has better aqueous solubility than Ligand B (-3.539).
10. **hERG:** Ligand A (0.279) has a lower hERG risk than Ligand B (0.661). This is a positive for Ligand A.
11. **Cl_mic:** Ligand A (38.208) has lower microsomal clearance, indicating better metabolic stability, than Ligand B (50.512).
12. **t1/2:** Ligand B (-33.382) has a much longer in vitro half-life than Ligand A (2.942). This is a significant advantage.
13. **Pgp:** Ligand A (0.032) has lower P-gp efflux liability than Ligand B (0.071), which is a positive.
14. **Binding Affinity:** Ligand A (-6.4 kcal/mol) has a slightly better binding affinity than Ligand B (-5.1 kcal/mol), a difference of 1.3 kcal/mol.
**Overall Assessment:**
Ligand B is the more promising candidate. While Ligand A has slightly better affinity and lower Pgp efflux, Ligand B excels in several critical areas: significantly lower DILI risk, much better TPSA, higher BBB penetration, and a substantially longer half-life. The lower solubility and slightly higher hERG risk for Ligand B are less concerning than the DILI risk associated with Ligand A. The affinity difference is not large enough to overcome the ADME advantages of Ligand B, especially considering the GPCR target class.
**Output:**
0
2025-04-17 21:31:18,125 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.45 and 348.49 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (54.34) is significantly better than Ligand B (67.43). For a GPCR, keeping TPSA lower is beneficial for permeability. Ligand A is well under the 140 threshold.
3. **logP:** Both ligands have good logP values (2.78 and 2.96), falling within the optimal 1-3 range. Ligand B is slightly higher, but not concerning.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Both ligands have the same number of HBA (3), which is acceptable.
6. **QED:** Ligand A (0.734) has a slightly higher QED than Ligand B (0.683), indicating a more drug-like profile.
7. **DILI:** Ligand A (38.12) has a substantially better DILI score than Ligand B (13.34). This is a crucial advantage, as lower DILI risk is highly desirable.
8. **BBB:** Ligand A (86.74) has a better BBB percentile than Ligand B (70.42). While ADRB2 isn't exclusively a CNS target, some CNS exposure can occur, and higher BBB penetration is generally favorable.
9. **Caco-2:** Both ligands have very poor Caco-2 permeability (-4.472 and -4.532). This is a significant concern for both.
10. **Solubility:** Both ligands have poor solubility (-2.879 and -3.091). This is a concern for both.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.525 and 0.573). This is good.
12. **Cl_mic:** Ligand A (55.75) has a lower microsomal clearance than Ligand B (76.09), suggesting better metabolic stability.
13. **t1/2:** Ligand A (34.52) has a significantly longer in vitro half-life than Ligand B (13.03). This is a major advantage.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.299 and 0.119).
15. **Binding Affinity:** Ligand A (-8.3 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.9 kcal/mol). This is a substantial advantage that can outweigh some of the ADME drawbacks.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A excels in affinity and has better TPSA and Pgp. The improved metabolic stability (lower Cl_mic, longer t1/2) and significantly lower DILI risk are also very important. While both have poor Caco-2 and solubility, the superior binding affinity and safety profile of Ligand A make it the more promising candidate.
**Output:**
1
2025-04-17 21:31:18,126 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (357.523 and 350.503 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (54.02) is significantly better than Ligand B (69.64). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand A is well below the 140 threshold, while Ligand B is approaching it.
3. **logP:** Ligand A (4.697) is higher than Ligand B (2.328). While both are within the acceptable range (1-3 is optimal), Ligand A is pushing the upper limit. This could potentially lead to solubility issues, but is not a dealbreaker.
4. **HBD:** Both ligands have 2 HBD, which is within the acceptable limit of 5.
5. **HBA:** Both ligands have 3 HBA, which is within the acceptable limit of 10.
6. **QED:** Both ligands have the same QED score of 0.67, indicating good drug-likeness.
7. **DILI:** Ligand A (38.813) has a significantly lower DILI risk than Ligand B (6.941). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (79.488) has a better BBB penetration percentile than Ligand B (64.017). While ADRB2 isn't exclusively a CNS target, some peripheral effects are mediated through sympathetic nervous system interactions, so some BBB penetration isn't necessarily detrimental.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.951 and -4.88), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-4.195) has slightly worse solubility than Ligand B (-2.038), but both are poor.
11. **hERG:** Ligand A (0.67) has a slightly higher hERG risk than Ligand B (0.461), but both are relatively low.
12. **Cl_mic:** Ligand A (64.022) has a higher microsomal clearance than Ligand B (27.923), indicating faster metabolism and potentially lower *in vivo* exposure. This is a disadvantage for Ligand A.
13. **t1/2:** Ligand A (24.199) has a significantly longer half-life than Ligand B (0.46). This is a major advantage for Ligand A.
14. **Pgp:** Ligand A (0.64) has higher P-gp efflux liability than Ligand B (0.115). This is a disadvantage for Ligand A.
15. **Binding Affinity:** Ligand A (-7.3 kcal/mol) has a significantly stronger binding affinity than Ligand B (-5.6 kcal/mol). This is a substantial advantage for Ligand A, and can often outweigh minor ADME drawbacks.
**Overall Assessment:**
Ligand A has a significantly stronger binding affinity and a longer half-life, which are crucial for efficacy. It also has a lower DILI risk and better BBB penetration. While it has some drawbacks (higher logP, higher Cl_mic, higher Pgp efflux, and worse solubility), the strong affinity and lower toxicity profile outweigh these concerns. Ligand B has better metabolic stability and Pgp efflux, but its significantly weaker binding affinity is a major disadvantage. The poor Caco-2 values for both are concerning, but can potentially be addressed with formulation strategies.
Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity), and the overall balance of properties, Ligand A is the more promising candidate.
Output:
1
2025-04-17 21:31:18,126 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
The target is ADRB2, a GPCR. Therefore, I will prioritize logP, TPSA, Pgp efflux, BBB penetration, and binding affinity, alongside general drug-like properties.
* **Molecular Weight:** Both ligands (348.4 and 346.4 Da) fall within the ideal 200-500 Da range.
* **TPSA:** Ligand A (98.91) is better than Ligand B (105.82). Both are acceptable, but lower TPSA generally favors better absorption.
* **logP:** Ligand A (-0.753) is slightly lower than optimal (1-3), but still reasonable. Ligand B (1.484) is within the ideal range.
* **H-Bond Donors/Acceptors:** Both have 2 HBD and 6 HBA, which are within acceptable limits.
* **QED:** Both ligands have good QED scores (0.726 and 0.812), indicating good overall drug-likeness.
* **DILI:** Ligand A (18.845) has a significantly lower DILI risk than Ligand B (50.136). This is a major advantage for Ligand A.
* **BBB:** Ligand A (26.638) has a lower BBB penetration than Ligand B (49.787). While ADRB2 isn't necessarily a CNS target, some peripheral ADRB2 receptors can be affected by CNS penetration.
* **Caco-2 Permeability:** Both ligands have similar, very negative Caco-2 values (-5.526 and -5.144), suggesting poor permeability. This is a concern for both.
* **Aqueous Solubility:** Ligand A (-0.551) is slightly better than Ligand B (-2.436), but both are poor.
* **hERG:** Both ligands have very low hERG inhibition risk (0.121 and 0.062).
* **Microsomal Clearance:** Ligand A (-5.275) has a much lower (better) microsomal clearance than Ligand B (-14.384), indicating better metabolic stability.
* **In vitro Half-Life:** Ligand B (25.431) has a significantly longer half-life than Ligand A (7.03). This is a positive for Ligand B.
* **P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.011 and 0.029).
* **Binding Affinity:** Ligand B (-7.2) has a slightly better binding affinity than Ligand A (-7.6). However, the difference is small (0.4 kcal/mol) and may not be enough to overcome other issues.
**Overall Assessment:**
Ligand A is the better candidate. While Ligand B has slightly better affinity and half-life, Ligand A has a significantly lower DILI risk and better metabolic stability (lower Cl_mic). The poor Caco-2 permeability is a concern for both, but the lower DILI risk is a critical factor for clinical development. The slightly better BBB penetration of Ligand B is less important for a primarily peripheral target like ADRB2.
**Output:**
1
2025-04-17 21:31:18,126 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [348.443, 91.57, 2.327, 3, 4, 0.629, 25.204, 18.069, -5.22, -2.529, 0.104, 30.267, 33.701, 0.045, -6.3]
**Ligand B:** [346.471, 62.55, 3.616, 1, 3, 0.767, 27.142, 76.541, -4.372, -3.894, 0.32, 67.261, 27.441, 0.17, -6.2]
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). A is 348.443, B is 346.471 - very similar.
2. **TPSA:** Ligand A (91.57) is slightly above the preferred <90 for CNS targets, but still reasonable for a peripheral GPCR like ADRB2. Ligand B (62.55) is excellent, well below 90.
3. **logP:** Both are good (between 1-3). A is 2.327, B is 3.616. B is a bit higher, potentially increasing off-target interactions, but still acceptable.
4. **HBD:** A has 3, B has 1. Lower is generally better for permeability, so B is favored.
5. **HBA:** A has 4, B has 3. Again, B is slightly better for permeability.
6. **QED:** Both are decent, but B (0.767) is better than A (0.629), indicating a more drug-like profile.
7. **DILI:** Both are low risk (A: 25.204, B: 27.142). B is slightly higher but still good.
8. **BBB:** A (18.069) is low, as expected for a non-CNS target. B (76.541) is high, which isn't necessarily *bad* for ADRB2, but doesn't provide a significant advantage.
9. **Caco-2:** A (-5.22) is poor, suggesting low intestinal absorption. B (-4.372) is also poor, but slightly better than A.
10. **Solubility:** Both are very poor (-2.529 and -3.894). This is a significant concern for both.
11. **hERG:** Both are very low risk (A: 0.104, B: 0.32).
12. **Cl_mic:** A (30.267) is better than B (67.261), indicating better metabolic stability.
13. **t1/2:** A (33.701) is better than B (27.441), suggesting a longer half-life.
14. **Pgp:** Both are very low efflux (A: 0.045, B: 0.17).
15. **Affinity:** Both have excellent binding affinity (-6.3 and -6.2 kcal/mol). The difference is negligible.
**GPCR-Specific Priorities:** For ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B excels in TPSA and has a slightly higher logP. However, A has better metabolic stability (Cl_mic) and half-life, and a slightly better Caco-2 value. The poor solubility of both is a major drawback. Given the similar affinities, the better metabolic stability and half-life of ligand A, coupled with a slightly better Caco-2 value, outweigh the benefits of ligand B's lower TPSA.
**Conclusion:**
I prefer Ligand A.
1
2025-04-17 21:31:18,126 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (337.379) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are good, below the 140 A^2 threshold. Ligand B (69.64) is better, being significantly lower, which is favorable for permeability.
3. **logP:** Both are within the optimal range (1-3). Ligand B (1.573) is slightly lower, which could be a minor concern for permeability, but not a dealbreaker.
4. **HBD:** Both have 2 HBD, which is acceptable.
5. **HBA:** Both have 4 HBA, which is acceptable.
6. **QED:** Both are above 0.5, indicating good drug-likeness, but Ligand A (0.901) is better.
7. **DILI:** Ligand B (50.446) has a lower DILI risk than Ligand A (67.429), which is a significant advantage.
8. **BBB:** Both have similar BBB penetration (around 67-68%), which is reasonable for a non-CNS target like ADRB2.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. Ligand A (-4.827) is slightly worse than Ligand B (-5.001).
10. **Solubility:** Ligand B (-2.627) has better solubility than Ligand A (-5.145).
11. **hERG:** Both have low hERG inhibition risk, but Ligand B (0.355) is better.
12. **Cl_mic:** Ligand B (-0.775) has significantly lower microsomal clearance than Ligand A (14.576), indicating better metabolic stability.
13. **t1/2:** Ligand A (40.147) has a longer in vitro half-life than Ligand B (-13.975), which is a positive.
14. **Pgp:** Both have low Pgp efflux liability, but Ligand B (0.055) is better.
15. **Binding Affinity:** Ligand B (-8.3 kcal/mol) has a slightly better binding affinity than Ligand A (-7.6 kcal/mol), a difference of 0.7 kcal/mol.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand B has a better TPSA, Pgp, and affinity. Ligand A has a better QED and half-life. However, the better DILI score and metabolic stability of Ligand B are crucial.
**Overall Assessment:**
While Ligand A has a slightly better QED and half-life, Ligand B demonstrates a more favorable balance of properties, particularly regarding safety (DILI, hERG) and metabolic stability (Cl_mic). The slightly improved binding affinity of Ligand B further strengthens its profile. The poor Caco-2 values for both are a concern, but can be addressed with formulation strategies. Given the importance of minimizing off-target effects and maximizing drug exposure for a cardiovascular target, Ligand B is the more promising candidate.
Output:
0
2025-04-17 21:31:18,126 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (338.371 and 344.455 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (93.96) is slightly higher than Ligand B (69.64). For a cardiovascular GPCR like ADRB2, TPSA is less critical than for CNS targets, but lower is generally preferable for absorption. Ligand B has a clear advantage.
3. **logP:** Both ligands have good logP values (2.549 and 1.801), falling within the optimal 1-3 range. Ligand B is slightly lower, which could be beneficial for solubility.
4. **HBD:** Both ligands have 2 H-bond donors, which is within the acceptable limit of 5.
5. **HBA:** Ligand A has 7 H-bond acceptors, while Ligand B has 3. Both are below the 10 threshold. Ligand B is better here.
6. **QED:** Ligand A (0.687) has a better QED score than Ligand B (0.454), indicating a more drug-like profile. This is a significant advantage for Ligand A.
7. **DILI:** Ligand A (84.606) has a considerably higher DILI risk than Ligand B (14.696). This is a major concern for Ligand A.
8. **BBB:** Both ligands have reasonable BBB penetration, but Ligand A (72.237) is higher than Ligand B (58.86). While ADRB2 isn't a primary CNS target, some brain exposure can occur, so this is a slight advantage for Ligand A.
9. **Caco-2:** Both ligands have negative Caco-2 values, suggesting poor permeability. This is a significant drawback for both.
10. **Solubility:** Ligand A (-3.815) has worse solubility than Ligand B (-2.257). Solubility is important for bioavailability. Ligand B is better.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.198 and 0.166). No significant difference.
12. **Cl_mic:** Ligand A (35.897) has a lower microsomal clearance than Ligand B (39.77), suggesting better metabolic stability. This is a positive for Ligand A.
13. **t1/2:** Ligand A (9.603) has a longer in vitro half-life than Ligand B (-31.12). This is a significant advantage for Ligand A.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.368 and 0.091). No significant difference.
15. **Binding Affinity:** Ligand B (-6.3 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.7 kcal/mol). This is a substantial advantage for Ligand B, potentially outweighing some ADME concerns.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in TPSA and affinity, while Ligand A has a slight edge in BBB and metabolic stability. However, the *extremely* high DILI risk associated with Ligand A is a deal-breaker.
**Overall Assessment:**
Despite the slightly better QED, BBB, and metabolic stability of Ligand A, the significantly higher DILI risk and lower binding affinity make it a less desirable candidate. Ligand B's superior affinity and much lower DILI risk, coupled with acceptable logP and TPSA, make it the more promising drug candidate. The negative Caco-2 values for both are concerning and would require further investigation, but the other factors strongly favor Ligand B.
Output:
0
2025-04-17 21:31:18,127 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, the key priorities are logP, TPSA, Pgp efflux, binding affinity, and, to a lesser extent, BBB.
Let's compare the ligands property by property:
1. **MW:** Both ligands (372.853 & 342.418 Da) are within the ideal 200-500 Da range.
2. **TPSA:** Ligand B (61.02) is significantly better than Ligand A (96.55). Lower TPSA generally favors oral absorption and GPCR penetration.
3. **logP:** Both ligands have acceptable logP values (1.227 & 2.666), falling within the 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability.
4. **HBD/HBA:** Both have 2 HBD and acceptable HBA counts (5 & 3 respectively), posing no major concerns.
5. **QED:** Both ligands have good QED scores (0.715 & 0.878), indicating good drug-like properties.
6. **DILI:** Ligand B (32.261) has a much lower DILI risk than Ligand A (65.917), a significant advantage.
7. **BBB:** Ligand B (81.698) has a higher BBB penetration percentile than Ligand A (44.901). While ADRB2 isn't a CNS target, some peripheral exposure can be mitigated by lower BBB penetration.
8. **Caco-2:** Both have negative Caco-2 values which is unusual, but we can assume they both have low permeability.
9. **Solubility:** Both have negative solubility values which is unusual, but we can assume they both have low solubility.
10. **hERG:** Ligand A (0.144) has a slightly lower hERG risk than Ligand B (0.681), but both are relatively low.
11. **Cl_mic:** Ligand A (3.04) has a much lower microsomal clearance than Ligand B (19.316), indicating better metabolic stability.
12. **t1/2:** Ligand B (-26.211) has a negative half-life, which is impossible. Ligand A (41.228) has a reasonable in vitro half-life.
13. **Pgp:** Ligand A (0.037) has a significantly lower Pgp efflux liability than Ligand B (0.171), which is favorable for bioavailability.
14. **Binding Affinity:** Ligand B (-7.6 kcal/mol) has a slightly better binding affinity than Ligand A (-7.2 kcal/mol), a 0.4 kcal/mol difference.
**Overall Assessment:**
Ligand B has a superior profile in terms of TPSA, DILI risk, and BBB penetration. The slightly better binding affinity of Ligand B is also a plus. However, Ligand A has better metabolic stability (lower Cl_mic) and Pgp efflux liability. The negative half-life for Ligand B is a major red flag. Considering the GPCR-specific priorities and the overall balance of properties, Ligand B is the more promising candidate despite the issues with its half-life.
**Output:**
0
2025-04-17 21:31:18,127 - INFO - Batch 264 complete. Total preferences: 4224
2025-04-17 21:31:18,127 - INFO - Processing batch 265/512...
2025-04-17 21:32:07,073 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.475 and 342.439 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (87.66) is slightly higher than Ligand B (49.85). For a cardiovascular GPCR, TPSA is not a primary concern, but lower is generally preferred for better absorption. Ligand B is better here.
3. **logP:** Both ligands have good logP values (1.245 and 1.132), falling within the optimal 1-3 range. No clear advantage.
4. **HBD:** Ligand A has 3 HBD, while Ligand B has 0. Lower HBD can improve membrane permeability. Ligand B is better.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 3. Similar to HBD, lower is slightly preferred. Ligand B is better.
6. **QED:** Ligand B (0.723) has a slightly higher QED score than Ligand A (0.574), indicating a more drug-like profile. Ligand B is better.
7. **DILI:** Ligand A (8.957%) has a significantly lower DILI risk than Ligand B (31.989%). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (78.868%) has a much higher BBB penetration potential than Ligand A (32.416%). While ADRB2 isn't a CNS target, some distribution to the CNS can occur, and higher BBB is generally favorable. Ligand B is better.
9. **Caco-2:** Ligand A (-5.123) has a more negative Caco-2 value, which is unusual and suggests *poor* permeability. Ligand B (-4.41) is better, though still not ideal.
10. **Solubility:** Ligand A (-1.527) has slightly better solubility than Ligand B (-2.821). Solubility is important for bioavailability, so Ligand A is better.
11. **hERG:** Both ligands have low hERG inhibition liability (0.238 and 0.398), which is good. No significant difference.
12. **Cl_mic:** Ligand B (32.737) has a slightly higher microsomal clearance than Ligand A (19.465), suggesting faster metabolism. Ligand A is better.
13. **t1/2:** Ligand A (-4.053) has a more negative in vitro half-life, which is unusual and suggests a *shorter* half-life. Ligand B (-2.448) is better.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.023 and 0.089). No significant difference.
15. **Binding Affinity:** Ligand A (-6.9 kcal/mol) has a slightly better binding affinity than Ligand B (-6.4 kcal/mol). This is a 0.5 kcal/mol difference, which is significant.
**Overall Assessment:**
Ligand A has a better binding affinity, lower DILI risk, better solubility, and lower microsomal clearance. However, Ligand B has a significantly better BBB score, lower TPSA and HBD/HBA, and a better QED score. Ligand A has a concerningly poor Caco-2 permeability and a shorter half-life.
Given the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), and the fact that this is a cardiovascular target (so BBB is less critical), the stronger binding affinity of Ligand A, combined with the lower DILI risk, outweigh the slightly less favorable ADME properties. The poor Caco-2 value for Ligand A is a concern, but could potentially be addressed through formulation strategies.
Output:
1
2025-04-17 21:32:07,074 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (349.391 and 351.447 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (115.21) is slightly higher than Ligand B (110.52). Both are below the 140 A^2 threshold for good oral absorption, but closer to the upper end.
**3. logP:** Ligand B (1.021) is better positioned within the optimal 1-3 range than Ligand A (-0.081), which is slightly below 1. This is a point in favor of Ligand B for permeability.
**4. H-Bond Donors:** Ligand A (2) is preferable to Ligand B (3). Lower HBD generally improves permeability.
**5. H-Bond Acceptors:** Ligand A (7) is higher than Ligand B (4). Lower HBA is generally preferred.
**6. QED:** Ligand A (0.694) has a better QED score than Ligand B (0.539), indicating a more drug-like profile.
**7. DILI:** Ligand B (37.456) has a significantly lower DILI risk than Ligand A (78.868). This is a major advantage for Ligand B.
**8. BBB:** Ligand B (61.497) shows better BBB penetration than Ligand A (42.536), although neither is exceptionally high. For a cardiovascular target, BBB penetration is less critical than for CNS targets, but still a consideration.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-5.398 and -5.706), which is unusual and suggests poor permeability. This is a significant concern for both.
**10. Aqueous Solubility:** Ligand A (-1.83) is better than Ligand B (-3.454). Solubility is important for formulation.
**11. hERG Inhibition:** Ligand A (0.013) has a slightly lower hERG risk than Ligand B (0.182).
**12. Microsomal Clearance:** Ligand A (-20.126) has a much lower (better) microsomal clearance than Ligand B (19.738), suggesting greater metabolic stability.
**13. In vitro Half-Life:** Ligand A (20.88 hours) has a significantly longer half-life than Ligand B (-15.473 hours). This is a major advantage for Ligand A.
**14. P-gp Efflux:** Ligand A (0.02) has a lower P-gp efflux liability than Ligand B (0.102), which is favorable for bioavailability.
**15. Binding Affinity:** Ligand A (-7.1 kcal/mol) has a slightly better binding affinity than Ligand B (-5.3 kcal/mol). This 1.8 kcal/mol difference is substantial and can outweigh some ADME drawbacks.
**GPCR-Specific Considerations:** For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand B has a better logP, and better BBB penetration, while Ligand A has better affinity, lower Pgp efflux, and lower microsomal clearance.
**Overall Assessment:**
While Ligand B has a significantly lower DILI risk, the superior binding affinity, metabolic stability (lower Cl_mic), longer half-life, and lower P-gp efflux of Ligand A are more compelling, especially given the relatively modest importance of BBB penetration for a cardiovascular target. The affinity difference is substantial. The Caco-2 permeability is poor for both, but can be addressed with formulation strategies. The better QED score for Ligand A also supports its selection.
Output:
1
2025-04-17 21:32:07,074 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.5 and 345.4 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (69.64) is significantly better than Ligand B (106.73). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally correlates with better absorption. Ligand B is pushing the upper limit for good oral absorption.
3. **logP:** Ligand A (2.471) is optimal, while Ligand B (0.862) is a bit low. A logP below 1 can sometimes hinder permeability.
4. **HBD:** Both ligands have 2 HBD, which is within the acceptable limit of 5.
5. **HBA:** Ligand A has 3 HBA, while Ligand B has 7. Ligand A is preferable here, as higher HBA can sometimes reduce permeability.
6. **QED:** Both ligands have very similar QED scores (0.773 and 0.774), indicating good drug-likeness.
7. **DILI:** Ligand A (13.494) has a much lower DILI risk than Ligand B (64.521). This is a substantial advantage for Ligand A.
8. **BBB:** Ligand A (62.078) has slightly better BBB penetration than Ligand B (49.748), but neither are particularly high. Not a major factor for a cardiovascular target.
9. **Caco-2:** Ligand A (-4.816) is better than Ligand B (-5.196), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-3.508) is better than Ligand B (-2.763), indicating better aqueous solubility.
11. **hERG:** Ligand A (0.375) has a lower hERG risk than Ligand B (0.068). This is a significant safety advantage for Ligand A.
12. **Cl_mic:** Ligand A (65.045) has a higher microsomal clearance than Ligand B (8.461), meaning it's metabolized faster. Ligand B is preferable here.
13. **t1/2:** Ligand A (-1.455) has a shorter in vitro half-life than Ligand B (-0.82). Ligand B is preferable here.
14. **Pgp:** Ligand A (0.25) has lower P-gp efflux than Ligand B (0.055), which is preferable.
15. **Binding Affinity:** Ligand B (-6.9 kcal/mol) has a slightly better binding affinity than Ligand A (-6.1 kcal/mol). This is a 0.8 kcal/mol difference, which is a meaningful advantage.
**GPCR-Specific Priorities & Overall Assessment:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B has a better affinity and lower Pgp efflux, but Ligand A wins on almost all other parameters, especially safety (DILI and hERG) and absorption/solubility (TPSA, logP, solubility, Caco-2). The affinity difference, while present, is not large enough to overcome the substantial advantages of Ligand A in terms of safety and ADME properties. The faster clearance and shorter half-life of Ligand A could be addressed with further optimization, but the safety profile of Ligand B is concerning.
Output:
1
2025-04-17 21:32:07,074 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.45 & 352.37 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (84.42) is significantly better than Ligand B (104.97). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand A is well below the 140 threshold, while B is approaching it.
3. **logP:** Ligand A (1.711) is optimal, while Ligand B (0.147) is quite low. A logP below 1 can hinder membrane permeability. This is a significant advantage for Ligand A.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Both ligands have 5 HBA, which is acceptable.
6. **QED:** Ligand A (0.876) is much better than Ligand B (0.448). A higher QED indicates a more drug-like profile.
7. **DILI:** Ligand B (68.98) has a slightly higher DILI risk than Ligand A (33.35), but both are acceptable (<60 is good).
8. **BBB:** Ligand A (70.03) is better than Ligand B (49.79). While ADRB2 isn't exclusively a CNS target, some CNS penetration might be beneficial, and lower Pgp efflux (see below) can be aided by some BBB penetration.
9. **Caco-2:** Ligand A (-4.637) and Ligand B (-5.044) are both negative, indicating poor permeability. This is a concern for both, but the negative value is a scale, and the difference is small.
10. **Solubility:** Ligand A (-1.917) is better than Ligand B (-2.366), indicating slightly better solubility.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.17 and 0.353 respectively). This is excellent.
12. **Cl_mic:** Ligand B (-5.673) has a *much* lower (better) microsomal clearance than Ligand A (15.448). This suggests significantly improved metabolic stability for Ligand B.
13. **t1/2:** Ligand B (-28.149) has a much longer in vitro half-life than Ligand A (-11.316). This is a major advantage for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.031) has significantly lower P-gp efflux liability than Ligand B (0.012), which is desirable.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-5.8 and -5.0 kcal/mol). The difference of 0.8 kcal/mol is not enough to overcome the other ADME differences.
**Overall Assessment:**
Ligand A has advantages in TPSA, logP, QED, BBB, Solubility and Pgp efflux. Ligand B excels in metabolic stability (Cl_mic) and half-life. Given that ADRB2 is a GPCR, logP and TPSA are important. The significantly better logP and TPSA of Ligand A, coupled with its better QED and Pgp profile, outweigh the advantages of Ligand B's improved metabolic stability and half-life. While metabolic stability is important, it can often be improved through structural modifications later in the optimization process. The permeability issues indicated by Caco-2 are a concern for both, but Ligand A's better logP suggests it might be easier to address.
Output:
1
2025-04-17 21:32:07,074 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (352.5 and 370.6 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands have a TPSA of 58.64, well below the 140 A^2 threshold for good oral absorption, and appropriate for a non-CNS GPCR target like ADRB2.
3. **logP:** Ligand A (3.125) is slightly higher than Ligand B (2.544). Both are within the optimal 1-3 range, but A is closer to the upper limit.
4. **HBD:** Both ligands have 1 H-bond donor, which is good.
5. **HBA:** Ligand A has 3 H-bond acceptors, while Ligand B has 4. Both are acceptable, below the 10 threshold.
6. **QED:** Ligand A (0.73) has a slightly better QED score than Ligand B (0.678), indicating a more drug-like profile.
7. **DILI:** Ligand A (19.7%) has a lower DILI risk than Ligand B (21.7%). Both are good (below 40%), but A is preferable.
8. **BBB:** Both ligands have good BBB penetration (A: 71.8%, B: 76.0%). This isn't a primary concern for ADRB2, but B is slightly better.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests potential issues with permeability prediction. However, the magnitude is similar.
10. **Solubility:** Both ligands have very poor predicted aqueous solubility (-2.967 and -2.851). This is a significant concern for both.
11. **hERG:** Both ligands have low hERG inhibition risk (0.403 and 0.496).
12. **Cl_mic:** Ligand B (60.5 mL/min/kg) has a significantly lower microsomal clearance than Ligand A (83.2 mL/min/kg), suggesting better metabolic stability. This is a key advantage.
13. **t1/2:** Ligand B (8.23 hours) has a much longer in vitro half-life than Ligand A (2.6 hours). This is a major advantage, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.209 and 0.161).
15. **Binding Affinity:** Ligand B (-7.6 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.1 kcal/mol). This 1.5 kcal/mol difference is substantial and can outweigh some ADME drawbacks.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are important. Ligand B excels in affinity and has acceptable values for the other parameters. While solubility is a concern for both, the superior binding affinity and metabolic stability of Ligand B are more critical for initial optimization.
**Conclusion:**
Despite the solubility concerns shared by both, Ligand B's significantly stronger binding affinity, lower clearance, and longer half-life make it the more promising candidate. The difference in binding affinity is substantial enough to outweigh the slightly higher DILI risk and the slightly lower QED.
Output:
0
2025-04-17 21:32:07,074 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [351.491, 87.3, 1.738, 3, 3, 0.622, 27.608, 67.623, -5.126, -2.35, 0.114, 34.367, -3.211, 0.021, -5.7]
**Ligand B:** [366.483, 84.5, 1.561, 2, 4, 0.616, 44.668, 52.966, -4.873, -2.992, 0.464, 55.89, -50.957, 0.074, -4.8]
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (351.491) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are below 140, good for oral absorption. Ligand B (84.5) is slightly better than Ligand A (87.3).
3. **logP:** Both are within the optimal range (1-3). Ligand B (1.561) is slightly lower, which could potentially impact permeability, but is still acceptable.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (2), but both are within the acceptable limit of 5.
5. **HBA:** Ligand A (3) is lower than Ligand B (4), both are within the acceptable limit of 10.
6. **QED:** Both are similar (0.622 and 0.616), indicating good drug-like properties.
7. **DILI:** Ligand A (27.608) has a significantly lower DILI risk than Ligand B (44.668). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (67.623) has a better BBB penetration percentile than Ligand B (52.966). While not a primary concern for a cardiovascular target, it's a positive attribute.
9. **Caco-2:** Ligand A (-5.126) has a slightly better Caco-2 permeability than Ligand B (-4.873).
10. **Solubility:** Ligand B (-2.992) has slightly better solubility than Ligand A (-2.35), but both are poor.
11. **hERG:** Ligand A (0.114) has a much lower hERG inhibition liability than Ligand B (0.464). This is a critical advantage, as hERG inhibition can lead to cardiotoxicity.
12. **Cl_mic:** Ligand A (34.367) has a lower microsomal clearance than Ligand B (55.89), indicating better metabolic stability.
13. **t1/2:** Ligand A (-3.211) has a better in vitro half-life than Ligand B (-50.957).
14. **Pgp:** Ligand A (0.021) has a lower P-gp efflux liability than Ligand B (0.074), which is favorable for bioavailability.
15. **Affinity:** Both ligands have very similar binding affinities (-5.7 and -4.8 kcal/mol). The difference is 0.9 kcal/mol, which is not substantial enough to outweigh the significant ADME advantages of Ligand A.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Both ligands are reasonable in these aspects. However, the superior ADME profile of Ligand A (lower DILI, better BBB, lower hERG, better metabolic stability, lower Pgp efflux) makes it a more promising candidate.
**Conclusion:**
Ligand A clearly demonstrates a more favorable balance of properties, particularly regarding safety (DILI, hERG) and pharmacokinetic parameters (Cl_mic, t1/2, Pgp). While Ligand B has slightly better solubility, the other advantages of Ligand A are more critical for overall drug development success.
**Output:**
1
2025-04-17 21:32:07,074 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (358.31) is slightly higher than Ligand B (347.459), but both are acceptable.
2. **TPSA:** Ligand A (41.99) is significantly better than Ligand B (84.23). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally improves absorption. Ligand B's TPSA is quite high, potentially hindering oral bioavailability.
3. **logP:** Ligand A (4.599) is higher than Ligand B (2.444). While Ligand A is approaching the upper limit, both are within the acceptable range.
4. **HBD:** Both ligands have a reasonable number of HBDs (1 and 2, respectively).
5. **HBA:** Ligand B (4) has more HBAs than Ligand A (2). This contributes to the higher TPSA of Ligand B.
6. **QED:** Both ligands have good QED scores (0.627 and 0.756), indicating good drug-like properties.
7. **DILI:** Ligand A (65.491) has a significantly higher DILI risk than Ligand B (24.118). This is a major concern for Ligand A.
8. **BBB:** Both have reasonable BBB penetration, but this is less critical for a cardiovascular target.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it is hard to interpret.
10. **Solubility:** Ligand A (-5.276) has worse solubility than Ligand B (-1.724).
11. **hERG:** Ligand A (0.761) has a slightly higher hERG risk than Ligand B (0.185).
12. **Cl_mic:** Ligand A (67.028) has a higher microsomal clearance than Ligand B (48.238), indicating lower metabolic stability.
13. **t1/2:** Ligand B (-15.461) has a much longer in vitro half-life than Ligand A (-5.468).
14. **Pgp:** Both ligands have very low Pgp efflux liability.
15. **Binding Affinity:** Ligand B (-6.9 kcal/mol) has a significantly better binding affinity than Ligand A (-4.9 kcal/mol). This is a substantial difference (2 kcal/mol), and given that we are targeting a GPCR, this is a critical factor.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), affinity, logP, TPSA, and Pgp are key. Ligand B excels in affinity and has a better TPSA. While Ligand A has a better logP, the significant advantages of Ligand B in affinity and TPSA, coupled with its much lower DILI risk and better metabolic stability (longer t1/2), outweigh this.
**Conclusion:**
Ligand B is the more promising candidate due to its superior binding affinity, lower DILI risk, better metabolic stability, and more favorable TPSA. The higher logP of Ligand A is not enough to compensate for its significant drawbacks.
Output:
0
2025-04-17 21:32:07,074 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for the ADRB2 receptor, a cardiovascular GPCR. Therefore, priorities are logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB.
Let's compare the ligands property by property:
1. **MW:** Both ligands (361.47 and 349.39 Da) fall within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (82.53) is better than Ligand B (87.23), both are acceptable for a non-CNS GPCR.
3. **logP:** Ligand A (2.884) is optimal (1-3). Ligand B (-0.482) is significantly lower, potentially hindering permeability. This is a major drawback for Ligand B.
4. **HBD:** Ligand A (2) is good. Ligand B (0) is also acceptable.
5. **HBA:** Both ligands (5) are within the acceptable range (<=10).
6. **QED:** Ligand A (0.829) is excellent, indicating high drug-likeness. Ligand B (0.626) is still reasonable, but lower.
7. **DILI:** Ligand B (32.07) has a much lower DILI risk than Ligand A (54.52), which is a significant advantage.
8. **BBB:** Ligand B (79.22) has a higher BBB penetration than Ligand A (34.55), but BBB is less critical for a cardiovascular target.
9. **Caco-2:** Both have negative values, indicating poor permeability.
10. **Solubility:** Both have negative values, indicating poor solubility.
11. **hERG:** Both ligands have very low hERG inhibition risk.
12. **Cl_mic:** Ligand B (11.31) has significantly lower microsomal clearance than Ligand A (62.37), indicating better metabolic stability.
13. **t1/2:** Ligand B (4.62) has a longer half-life than Ligand A (2.75).
14. **Pgp:** Ligand A (0.046) has lower P-gp efflux than Ligand B (0.011), which is favorable.
15. **Affinity:** Ligand A (-6.8 kcal/mol) has a slightly better binding affinity than Ligand B (-5.6 kcal/mol), a difference of 1.2 kcal/mol.
**Overall Assessment:**
While Ligand B has a better safety profile (lower DILI) and metabolic stability (lower Cl_mic, longer t1/2), the significantly lower logP is a major concern. Poor logP will likely translate to poor permeability and bioavailability. Ligand A, despite the slightly higher DILI risk, has a much more favorable logP and slightly better affinity, making it more likely to be a viable drug candidate. The difference in affinity, while not huge, combined with the logP advantage, outweighs the DILI concern.
**Output:**
1
2025-04-17 21:32:07,074 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (356.5 & 357.8 Da) fall comfortably within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (81.08) is higher than Ligand B (58.22). For a cardiovascular GPCR, TPSA isn't *as* critical as for a CNS target, but lower is generally preferred for permeability. Ligand B has an advantage here.
3. **logP:** Ligand A (1.809) is within the optimal range (1-3), while Ligand B (4.034) is slightly higher. While not drastically outside the range, higher logP can sometimes lead to off-target effects and solubility issues. Ligand A is better.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable. No strong preference.
5. **HBA:** Ligand A (4) and Ligand B (3) are both acceptable. No strong preference.
6. **QED:** Both ligands (0.462 & 0.464) are similar and marginally below the ideal 0.5, but not concerning.
7. **DILI:** Ligand A (10.198) has a significantly lower DILI risk than Ligand B (69.717). This is a major advantage for Ligand A.
8. **BBB:** Both are relatively low, which is fine for a cardiovascular target. Ligand B (60.76) is slightly higher than Ligand A (55.099), but neither is a priority.
9. **Caco-2:** Ligand A (-4.578) is significantly better than Ligand B (-5.344), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-0.824) is better than Ligand B (-4.281). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.518) has a lower hERG risk than Ligand B (0.809). This is a significant safety advantage for Ligand A.
12. **Cl_mic:** Ligand B (86.205) has a higher microsomal clearance than Ligand A (56.985), meaning it's metabolized faster. Ligand A is preferred for metabolic stability.
13. **t1/2:** Ligand B (44.911) has a longer half-life than Ligand A (3.651). This is a positive for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.091) has lower P-gp efflux than Ligand B (0.843), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand B (-7.6 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.7 kcal/mol). This is a substantial advantage for Ligand B, and could potentially outweigh some of the ADME drawbacks.
**Overall Assessment:**
Ligand B has a significantly better binding affinity, and a longer half-life. However, Ligand A demonstrates a much better safety profile (lower DILI, lower hERG), better solubility, better Caco-2 permeability, and lower P-gp efflux. The higher logP of Ligand B is a slight concern. Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity), the substantial affinity difference of Ligand B is a strong pull. However, the safety concerns with Ligand B are significant. The improved ADME properties of Ligand A, particularly the lower DILI and hERG risks, make it a more viable candidate overall.
Output:
1
2025-04-17 21:32:07,075 - INFO - Here's my reasoning and final output for the ligand preference:
**Reasoning:**
Both ligands have identical binding affinities (-6.9 kcal/mol), which is excellent and removes that as a differentiating factor. Given the target is ADRB2, a cardiovascular GPCR, the priorities are logP, TPSA, Pgp, and metabolic stability.
Let's break down the comparison:
1. **Molecular Weight:** Both are within the ideal range (200-500 Da). Ligand A (380.5) is slightly higher than Ligand B (347.4).
2. **TPSA:** Ligand A (105.2) is better than Ligand B (112.9). Both are below the 140 threshold for oral absorption, but closer to the ideal for GPCRs.
3. **logP:** Ligand B (1.85) is better than Ligand A (0.52). Ligand A is a bit low, potentially hindering permeability.
4. **H-Bond Donors/Acceptors:** Ligand B has 3 HBD and 5 HBA, while Ligand A has 2 HBD and 6 HBA. Both are acceptable.
5. **QED:** Both are similar (0.674 vs 0.641), indicating good drug-likeness.
6. **DILI:** Ligand B (73.1) has a significantly higher DILI risk than Ligand A (38.8). This is a major concern.
7. **BBB:** Ligand A (53.97) has better BBB penetration than Ligand B (36.37). While not a primary concern for a cardiovascular target, it's a slight advantage.
8. **Caco-2:** Ligand B (-5.664) has better Caco-2 permeability than Ligand A (-4.805).
9. **Solubility:** Ligand A (-2.393) has better solubility than Ligand B (-3.194).
10. **hERG:** Ligand A (0.471) has a lower hERG risk than Ligand B (0.275).
11. **Cl_mic:** Ligand B (54.6) has lower microsomal clearance than Ligand A (71.8), suggesting better metabolic stability.
12. **t1/2:** Ligand A (-40.35) has a longer in vitro half-life than Ligand B (0.18).
13. **Pgp:** Ligand A (0.03) has lower P-gp efflux than Ligand B (0.262), which is favorable.
**Overall Assessment:**
Ligand A is preferable despite the slightly lower logP. The significantly lower DILI risk, better solubility, lower hERG risk, better Pgp profile, and longer half-life outweigh the slightly better Caco-2 permeability and metabolic stability of Ligand B. The DILI risk associated with Ligand B is a major red flag, and the other advantages of Ligand A are more critical for a cardiovascular GPCR target.
**Output:**
1
2025-04-17 21:32:07,075 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.515 and 350.375 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (49.41) is significantly better than Ligand B (121.08). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold, while Ligand B is approaching it.
3. **logP:** Ligand A (3.358) is optimal, while Ligand B (1.171) is on the lower side. For a GPCR, a logP between 1-3 is preferred, and A is closer to this ideal.
4. **HBD:** Both have acceptable HBD counts (1 and 2, respectively), well below the 5 threshold.
5. **HBA:** Ligand A (2) is better than Ligand B (6). Lower HBA is generally preferable for permeability.
6. **QED:** Ligand A (0.768) is significantly better than Ligand B (0.562), indicating a more drug-like profile.
7. **DILI:** Ligand A (11.206%) has a much lower DILI risk than Ligand B (67.197%). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (87.941%) shows good BBB penetration, while Ligand B (33.075%) is low. While not crucial for ADRB2, it doesn't hurt.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests potential issues with permeability prediction. However, the magnitude of the negative value is greater for Ligand A (-4.824 vs -5.196), suggesting slightly better potential permeability.
10. **Solubility:** Ligand A (-3.673) is better than Ligand B (-2.206) indicating better solubility.
11. **hERG:** Ligand A (0.729) is better than Ligand B (0.132), indicating a lower risk of hERG inhibition.
12. **Cl_mic:** Ligand A (69.209) has a higher microsomal clearance than Ligand B (15.111), meaning it's metabolized faster. This is a disadvantage for Ligand A.
13. **t1/2:** Ligand A (3.823) has a longer half-life than Ligand B (2.579), which is preferable.
14. **Pgp:** Ligand A (0.139) has lower P-gp efflux than Ligand B (0.081), indicating better bioavailability.
15. **Binding Affinity:** Ligand A (-5.8 kcal/mol) has a slightly better binding affinity than Ligand B (-3.8 kcal/mol). This is a substantial difference and a major driver in the decision.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A excels in logP, TPSA, Pgp, and significantly in affinity. While Ligand B has better metabolic stability (lower Cl_mic), the superior binding affinity and overall ADME profile of Ligand A outweigh this drawback. The large difference in binding affinity (-5.8 vs -3.8) is a compelling factor. The lower DILI risk and better solubility of Ligand A are also important positives.
**Conclusion:**
Ligand A is the more promising drug candidate due to its superior binding affinity, better ADME properties (TPSA, logP, QED, DILI, hERG, solubility, Pgp, t1/2), despite slightly higher Cl_mic.
Output:
1
2025-04-17 21:32:07,075 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's analyze each ligand against the provided guidelines, with a focus on GPCR-relevant parameters (logP, TPSA, Pgp, BBB, and affinity).
* **Molecular Weight:** Both ligands (355.419 and 350.463 Da) fall comfortably within the ideal 200-500 Da range.
* **TPSA:** Ligand A (77.25) is better than Ligand B (84.3). Both are acceptable, but lower TPSA generally favors better absorption.
* **logP:** Ligand A (3.668) is slightly higher than Ligand B (1.76). While both are within the optimal 1-3 range, Ligand B is closer to the lower bound, which could potentially impact permeability.
* **H-Bond Donors/Acceptors:** Both have 1 HBD and similar HBA counts (6 vs 5). This is acceptable.
* **QED:** Both ligands have similar QED values (0.769 and 0.688), indicating good drug-likeness.
* **DILI:** Ligand A (99.341) has a significantly higher DILI risk than Ligand B (42.652). This is a major concern for Ligand A.
* **BBB:** Ligand A (58.007) has a slightly better BBB penetration potential than Ligand B (50.679), but neither is particularly high. Since ADRB2 is a cardiovascular target, BBB penetration is not a primary concern, but it's still a positive attribute.
* **Caco-2 Permeability:** Ligand A (-5.103) has worse Caco-2 permeability than Ligand B (-4.773).
* **Aqueous Solubility:** Ligand B (-1.521) has better aqueous solubility than Ligand A (-5.482).
* **hERG Inhibition:** Ligand A (0.606) has a higher hERG risk than Ligand B (0.076). This is another significant safety concern for Ligand A.
* **Microsomal Clearance:** Ligand A (93.893) has higher microsomal clearance than Ligand B (55.202), indicating lower metabolic stability.
* **In vitro Half-Life:** Ligand B (-1.238) has a significantly longer in vitro half-life than Ligand A (54.099).
* **P-gp Efflux:** Ligand A (0.149) has slightly higher P-gp efflux liability than Ligand B (0.043).
* **Binding Affinity:** Ligand A (-6.9 kcal/mol) has a slightly better binding affinity than Ligand B (-6.6 kcal/mol). This 0.3 kcal/mol difference is not substantial enough to outweigh the significant ADME/Tox liabilities of Ligand A.
**Overall Assessment:**
Ligand A has a slightly better binding affinity, but it is severely hampered by its high DILI risk, hERG inhibition liability, poor solubility, and faster metabolic clearance. Ligand B, while having slightly lower affinity, presents a much more favorable ADME-Tox profile, with lower DILI risk, better solubility, and improved metabolic stability. For a cardiovascular target like ADRB2, minimizing toxicity and ensuring reasonable pharmacokinetic properties are paramount.
**Output:**
0
2025-04-17 21:32:07,075 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [371.409, 91.22, 2.609, 2, 5, 0.487, 68.98, 54.246, -5.208, -4.144, 0.794, 46.579, -7.609, 0.222, -5.9]
**Ligand B:** [348.451, 85.17, 0.547, 1, 7, 0.724, 25.553, 84.257, -5.379, -1.184, 0.116, 18.102, -0.468, 0.071, -7.9]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (348.451) is slightly lower, which could be beneficial for permeability, but both are acceptable.
2. **TPSA:** Both are reasonably low (A: 91.22, B: 85.17), below the 140 threshold for oral absorption. Ligand B is slightly better.
3. **logP:** Ligand A (2.609) is optimal. Ligand B (0.547) is quite low, potentially hindering membrane permeability. This is a significant drawback.
4. **HBD:** Both are acceptable (A: 2, B: 1).
5. **HBA:** Both are acceptable (A: 5, B: 7).
6. **QED:** Both are reasonable (A: 0.487, B: 0.724). Ligand B is better here, indicating a more drug-like profile.
7. **DILI:** Ligand A (68.98) is higher risk than Ligand B (25.553). This is a significant advantage for Ligand B.
8. **BBB:** Ligand B (84.257) has a much higher BBB penetration score than Ligand A (54.246). While not strictly *required* for ADRB2 (a cardiovascular target), higher BBB is rarely a detriment.
9. **Caco-2:** Both are negative, indicating poor permeability. This is concerning for both.
10. **Solubility:** Both are negative, indicating poor solubility. This is concerning for both.
11. **hERG:** Both are low risk (A: 0.794, B: 0.116). Ligand B is better.
12. **Cl_mic:** Ligand B (18.102) has significantly lower microsomal clearance than Ligand A (46.579), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-7.609) has a longer in vitro half-life than Ligand B (-0.468). This is a positive for Ligand A.
14. **Pgp:** Ligand A (0.222) has lower P-gp efflux than Ligand B (0.071). This is a positive for Ligand A.
15. **Affinity:** Ligand B (-7.9) has a slightly better binding affinity than Ligand A (-5.9). The difference is 2 kcal/mol, which is substantial.
**GPCR-Specific Priorities:** For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand B excels in affinity and has a better BBB score. However, its low logP is a major concern. Ligand A has a better logP, better Pgp, and a reasonable half-life, but suffers from higher DILI risk and lower affinity. The affinity difference is significant enough to consider, but the logP of B is a major liability.
**Conclusion:**
Despite the slightly better affinity of Ligand B, the significantly lower logP and higher DILI risk are major drawbacks. Ligand A, while not perfect, presents a more balanced profile with a more favorable logP and acceptable DILI.
Output:
1
2025-04-17 21:32:07,075 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (349.519) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (52.65) is better than Ligand B (64.86). Both are below 140, but lower TPSA is preferred for oral absorption, a key consideration for cardiovascular drugs.
3. **logP:** Both ligands have acceptable logP values (A: 2.428, B: 3.256), falling within the 1-3 range. Ligand B is slightly higher, potentially leading to some solubility issues.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A (3) is better than Ligand B (6). Lower HBA is generally preferred for permeability.
6. **QED:** Both ligands have good QED scores (A: 0.776, B: 0.896), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (6.049) is significantly better than Ligand B (74.99). This is a major advantage for Ligand A, as DILI is a critical safety concern.
8. **BBB:** Both have high BBB penetration (A: 83.637, B: 88.833). Since ADRB2 isn't exclusively a CNS target, this isn't a deciding factor, but higher is still a slight benefit to B.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-2.27) is better than Ligand B (-5.362), though both are poor. Solubility is a concern for both, but less so for A.
11. **hERG:** Ligand A (0.687) is better than Ligand B (0.143). Lower hERG inhibition is crucial for avoiding cardiotoxicity, a particularly important consideration for a cardiovascular target.
12. **Cl_mic:** Ligand A (26.521) is much better than Ligand B (44.892). Lower clearance indicates better metabolic stability, which is desirable.
13. **t1/2:** Ligand A (-5.189) is better than Ligand B (0.861). A negative value suggests a longer half-life.
14. **Pgp:** Ligand A (0.065) is much better than Ligand B (0.185). Lower P-gp efflux is beneficial for bioavailability.
15. **Binding Affinity:** Ligand B (-6.9) is slightly better than Ligand A (-7.1), but the difference is small.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. While both ligands perform reasonably well on logP and affinity, Ligand A has a significantly better TPSA, Pgp, and crucially, a much lower DILI and hERG risk, and better metabolic stability (Cl_mic and t1/2). The slight affinity difference is outweighed by these ADMET advantages.
**Conclusion:**
Ligand A demonstrates a superior balance of properties, particularly regarding safety (DILI, hERG) and ADME characteristics (Cl_mic, t1/2, Pgp). While Ligand B has slightly better affinity and BBB penetration, the significant advantages of Ligand A in crucial areas make it the more promising drug candidate.
Output:
1
2025-04-17 21:32:07,076 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's break down the comparison of Ligand A and Ligand B across the 15 parameters, keeping in mind the GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key).
1. **MW:** Both ligands (356.419 and 352.385 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (88.54) is slightly higher than Ligand B (78.09). Both are below the 140 A^2 threshold for good oral absorption, and reasonably close to the 90 A^2 for CNS targets (though ADRB2 isn't necessarily a CNS target). Ligand B is preferable here.
3. **logP:** Ligand A (-0.609) is quite low, potentially hindering permeability. Ligand B (1.584) is within the optimal 1-3 range. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (1) is better than Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (6) is higher than Ligand B (3). Lower HBA is preferable for permeability. Ligand B is preferable here.
6. **QED:** Both ligands have good QED scores (0.683 and 0.763), indicating generally drug-like properties. No strong preference.
7. **DILI:** Ligand A (20.706%) has a much lower DILI risk than Ligand B (56.727%). This is a substantial advantage for Ligand A.
8. **BBB:** Ligand A (28.383%) has a lower BBB penetration than Ligand B (80.729%). While ADRB2 isn't a primary CNS target, higher BBB penetration isn't necessarily detrimental, and could allow for off-target effects. Ligand B is preferable.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual. Assuming these are percentile scores, and higher is better, Ligand A (-4.795) is slightly better than Ligand B (-5.08).
10. **Solubility:** Ligand A (-0.337) is slightly better than Ligand B (-2.893). Higher solubility is generally preferred.
11. **hERG:** Both ligands have low hERG inhibition risk (0.098 and 0.247). No significant difference.
12. **Cl_mic:** Ligand A (11.257) has lower microsomal clearance than Ligand B (21.538), suggesting better metabolic stability. This favors Ligand A.
13. **t1/2:** Ligand A (26.599) has a longer in vitro half-life than Ligand B (-25.087). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.025) has much lower P-gp efflux liability than Ligand B (0.066). This is a significant advantage for Ligand A.
15. **Affinity:** Ligand B (-7.4 kcal/mol) has a slightly better binding affinity than Ligand A (-6.7 kcal/mol). This is a 0.7 kcal/mol difference, which is a moderate advantage, but not overwhelming.
**Overall Assessment:**
Ligand B has advantages in logP, BBB, and binding affinity. However, Ligand A excels in DILI risk, metabolic stability (Cl_mic, t1/2), P-gp efflux, solubility, and has a slightly better Caco-2 value. The lower logP of Ligand A is a concern, but the significantly improved safety profile (DILI, Pgp) and metabolic stability are crucial for a viable drug candidate. The affinity difference is not large enough to overcome these advantages.
**Output:**
1
2025-04-17 21:32:07,076 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's break down the comparison based on the provided guidelines and GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key).
1. **Molecular Weight:** Both ligands (364.471 and 354.407 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (84.73) is significantly better than Ligand B (114.2). ADRB2 is not a CNS target, but lower TPSA generally correlates with better permeability.
3. **logP:** Ligand A (2.88) is optimal, while Ligand B (-0.948) is quite low. This is a major drawback for Ligand B, potentially hindering membrane permeability and bioavailability.
4. **H-Bond Donors:** Both have 2 HBD, which is acceptable.
5. **H-Bond Acceptors:** Ligand A has 6, and Ligand B has 5. Both are within the acceptable range.
6. **QED:** Ligand A (0.877) is superior to Ligand B (0.638), indicating a more drug-like profile.
7. **DILI:** Ligand A (71.539) has a higher DILI risk than Ligand B (32.842). This favors Ligand B.
8. **BBB:** Not a primary concern for ADRB2, but Ligand B (75.184) is better than Ligand A (62.117).
9. **Caco-2:** Ligand B (-5.404) is better than Ligand A (-4.516), suggesting better intestinal absorption.
10. **Solubility:** Ligand B (-1.051) is better than Ligand A (-3.515).
11. **hERG:** Ligand A (0.421) is better than Ligand B (0.093), indicating a lower risk of cardiotoxicity. This is crucial for a cardiovascular target.
12. **Cl_mic:** Ligand B (-18.087) has significantly lower (better) microsomal clearance than Ligand A (29.701), suggesting greater metabolic stability.
13. **t1/2:** Ligand B (6.005) has a longer half-life than Ligand A (1.053), which is desirable.
14. **Pgp:** Ligand A (0.174) has lower P-gp efflux than Ligand B (0.004), which is favorable for oral bioavailability.
15. **Binding Affinity:** Ligand B (-6.3 kcal/mol) has a significantly stronger binding affinity than Ligand A (-4.1 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME drawbacks.
**Overall Assessment:**
Ligand B has a significantly better binding affinity and metabolic stability (lower Cl_mic, longer t1/2). It also has better solubility and lower DILI risk. However, its low logP is a concern. Ligand A has a better logP, QED, and hERG profile, but weaker affinity and poorer metabolic stability.
The strong binding affinity of Ligand B is a critical advantage for a GPCR target like ADRB2. While the low logP is a concern, it might be addressable through formulation strategies. The improved metabolic stability also increases the chances of achieving therapeutic concentrations *in vivo*. The lower DILI risk is also a positive.
Therefore, despite the lower logP, the superior affinity and metabolic properties of Ligand B make it the more promising candidate.
**Output:**
0
2025-04-17 21:32:07,076 - INFO - Batch 265 complete. Total preferences: 4240
2025-04-17 21:32:07,076 - INFO - Processing batch 266/512...
2025-04-17 21:32:55,342 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 drug candidates. ADRB2 is a GPCR, so we'll prioritize logP, Pgp, TPSA, and affinity, alongside general drug-like properties.
**Ligand A:** [344.459, 58.44, 1.688, 0, 4, 0.764, 17.332, 70.997, -4.789, -1.606, 0.162, 33.785, -6.981, 0.031, -6.7]
**Ligand B:** [348.487, 58.64, 2.062, 1, 3, 0.748, 31.563, 78.907, -4.302, -2.98, 0.59, 39.585, -7.748, 0.154, -6.7]
1. **MW:** Both are within the ideal range (200-500 Da). A is 344.459, B is 348.487 - very similar.
2. **TPSA:** Both are good (58.44 & 58.64), well below the 140 threshold for oral absorption.
3. **logP:** Both are within the optimal range (1-3). A is 1.688, B is 2.062. B is slightly higher, potentially better for membrane permeability, but still acceptable for A.
4. **HBD:** A has 0, B has 1. Lower is generally preferred, so A is slightly better here.
5. **HBA:** A has 4, B has 3. Both are good, below the 10 threshold.
6. **QED:** Both are good (0.764 and 0.748), indicating good drug-like properties.
7. **DILI:** A is 17.332, B is 31.563. A is significantly better, indicating lower liver injury risk. This is a substantial advantage.
8. **BBB:** Both are good, but B is better (78.907 vs 70.997). For a cardiovascular target, BBB isn't *critical*, but higher is still preferable.
9. **Caco-2:** Both are negative, indicating poor permeability. A (-4.789) is slightly worse than B (-4.302).
10. **Solubility:** Both are negative, indicating poor solubility. B (-2.98) is slightly worse than A (-1.606).
11. **hERG:** Both are very low (0.162 and 0.59), indicating low cardiotoxicity risk.
12. **Cl_mic:** A is 33.785, B is 39.585. A has lower clearance, suggesting better metabolic stability.
13. **t1/2:** B is better (-7.748 vs -6.981), indicating a longer half-life.
14. **Pgp:** Both are very low (0.031 and 0.154), indicating low P-gp efflux.
15. **Affinity:** Both are identical (-6.7 kcal/mol).
**Overall Assessment:**
Ligand A has a significant advantage in DILI risk and metabolic stability (Cl_mic), and slightly better solubility. Ligand B has a slightly better BBB penetration and *in vitro* half-life. The Caco-2 permeability is poor for both, which is a concern. However, the lower DILI risk of Ligand A is a major factor, especially early in development. While the slightly longer half-life of B is attractive, the DILI risk is a more critical concern. Since both have the same affinity, the ADME properties become the deciding factor.
Therefore, I would choose Ligand A.
1
2025-04-17 21:32:55,342 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (345.447 and 343.471 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Both ligands have TPSA values (70.47 and 71.09) that are acceptable for a non-CNS GPCR target, being below 140.
**3. logP:** Ligand A (0.939) is slightly lower than Ligand B (2.985). While both are within the optimal 1-3 range, Ligand B is closer to the upper limit. For a cardiovascular GPCR, a slightly higher logP can be tolerated, but we need to consider other factors.
**4. H-Bond Donors & Acceptors:** Ligand A has 1 HBD and 5 HBA, while Ligand B has 2 HBD and 3 HBA. Both are within acceptable limits (<=5 HBD and <=10 HBA).
**5. QED:** Ligand A (0.833) has a slightly higher QED score than Ligand B (0.799), indicating a more drug-like profile.
**6. DILI Risk:** Ligand A (16.285 percentile) has a significantly lower DILI risk than Ligand B (25.94 percentile). This is a crucial advantage.
**7. BBB Penetration:** While not a primary concern for a cardiovascular target, Ligand A (91.043) has better BBB penetration than Ligand B (76.154).
**8. Caco-2 Permeability:** Ligand A (-5.15) has better Caco-2 permeability than Ligand B (-4.704).
**9. Aqueous Solubility:** Ligand A (-1.586) has better aqueous solubility than Ligand B (-3.184).
**10. hERG Inhibition:** Both ligands have low hERG inhibition risk (0.549 and 0.404 respectively).
**11. Microsomal Clearance:** Ligand A (22.882 mL/min/kg) has significantly lower microsomal clearance than Ligand B (42.216 mL/min/kg), suggesting better metabolic stability.
**12. In Vitro Half-Life:** Ligand A (17.193 hours) has a much longer in vitro half-life than Ligand B (3.86 hours). This is a substantial advantage, potentially allowing for less frequent dosing.
**13. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.08 and 0.081).
**14. Binding Affinity:** Both ligands have very similar binding affinities (-7.3 and -7.2 kcal/mol). The difference is minimal and doesn't outweigh other factors.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B in several critical ADME-Tox properties: DILI risk, metabolic stability (lower Cl_mic, longer t1/2), solubility, and Caco-2 permeability. While Ligand B has a slightly higher logP, the benefits of Ligand A's superior safety and pharmacokinetic profile are more important for a cardiovascular drug candidate. The binding affinity difference is negligible.
Output:
1
2025-04-17 21:32:55,343 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (358.429 Da) is slightly higher than Ligand B (347.463 Da), but both are acceptable.
2. **TPSA:** Ligand A (58.64) is well below the 140 threshold and good for oral absorption. Ligand B (77.57) is still acceptable, but less optimal.
3. **logP:** Ligand A (2.656) is within the optimal range (1-3). Ligand B (0.724) is a little low, potentially hindering membrane permeability.
4. **HBD:** Both ligands have acceptable HBD counts (Ligand A: 1, Ligand B: 2), well below the 5 threshold.
5. **HBA:** Both ligands have acceptable HBA counts (Ligand A: 3, Ligand B: 5), below the 10 threshold.
6. **QED:** Both ligands have similar and acceptable QED values (Ligand A: 0.743, Ligand B: 0.688), indicating good drug-like properties.
7. **DILI:** Both ligands have low DILI risk (Ligand A: 41.334, Ligand B: 43.932), both below the 60 threshold.
8. **BBB:** Ligand A (90.151) has a significantly higher BBB penetration percentile than Ligand B (73.129). While ADRB2 isn't exclusively a CNS target, some cardiovascular effects are mediated through CNS pathways, and higher BBB penetration can be beneficial.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the values are similar (-4.548 for A, -4.996 for B).
10. **Solubility:** Both ligands have negative solubility values, which is also unusual. Ligand B (-1.127) is slightly better than Ligand A (-2.803).
11. **hERG:** Both ligands have low hERG inhibition liability (Ligand A: 0.425, Ligand B: 0.494), which is good.
12. **Cl_mic:** Ligand A (39.915) has a higher microsomal clearance than Ligand B (23.248), indicating lower metabolic stability.
13. **t1/2:** Ligand B (29.749) has a much longer in vitro half-life than Ligand A (-2.742), which is a significant advantage.
14. **Pgp:** Both ligands have low P-gp efflux liability (Ligand A: 0.15, Ligand B: 0.01), which is favorable.
15. **Binding Affinity:** Ligand B (-7.1 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.8 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME drawbacks.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B has a better affinity and lower Pgp efflux. Ligand A has a better TPSA and BBB, but the affinity difference is substantial.
**Overall Assessment:**
While Ligand A has a better TPSA and BBB, the significantly stronger binding affinity of Ligand B (-7.1 vs -5.8 kcal/mol) and its longer half-life are more critical for a GPCR target. The slightly lower logP of Ligand B is a concern, but the affinity advantage is likely to be more impactful. The similar Caco-2 and solubility values are not decisive.
Output:
0
2025-04-17 21:32:55,343 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's systematically compare Ligand A and Ligand B across the provided parameters, keeping in mind the GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key).
1. **MW:** Both ligands (370.559 Da and 357.491 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (58.64) is significantly better than Ligand B (76.07). A lower TPSA generally favors better cell permeability, which is crucial for GPCR targeting.
3. **logP:** Both ligands have good logP values (2.686 and 2.523), falling within the optimal 1-3 range. Very similar.
4. **HBD:** Both have 1 HBD, which is acceptable.
5. **HBA:** Ligand A has 4 HBA, while Ligand B has 5. Both are within the acceptable limit of 10, but A is slightly preferred.
6. **QED:** Both ligands have similar QED values (0.678 and 0.608), indicating good drug-like properties.
7. **DILI:** Ligand A (31.291) has a considerably lower DILI risk than Ligand B (16.053). This is a significant advantage for A.
8. **BBB:** Both ligands have reasonably good BBB penetration (68.205 and 66.848). While not exceptionally high, it's not a major differentiating factor for ADRB2, which isn't necessarily a CNS target.
9. **Caco-2:** Ligand A (-5.007) has a better Caco-2 permeability than Ligand B (-4.26).
10. **Solubility:** Ligand A (-3.169) has better aqueous solubility than Ligand B (-2.321).
11. **hERG:** Both ligands have low hERG inhibition risk (0.458 and 0.502). No significant difference.
12. **Cl_mic:** Ligand A (48.851) has a lower microsomal clearance than Ligand B (52.398), indicating better metabolic stability.
13. **t1/2:** Ligand B (17.634) has a significantly longer in vitro half-life than Ligand A (3.295). This is a notable advantage for B.
14. **Pgp:** Both have low Pgp efflux liability (0.286 and 0.172). B is slightly better.
15. **Binding Affinity:** Ligand B (-8.1) has a substantially stronger binding affinity than Ligand A (-6.2). This is a difference of 1.9 kcal/mol, which is a significant advantage, and often outweighs minor ADME concerns.
**Overall Assessment:**
Ligand B has a significantly stronger binding affinity, and a longer half-life. However, Ligand A has a much better safety profile (lower DILI risk), better TPSA, solubility, Caco-2 permeability, and metabolic stability. Considering the balance, the stronger binding affinity of Ligand B is a compelling factor for a GPCR target. The slight advantage in Pgp efflux is also beneficial. While the DILI risk is higher, it's not excessively so, and could be further mitigated through structural modifications if needed.
**Output:**
0
2025-04-17 21:32:55,343 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [418.257, 56.92, 3.295, 3, 2, 0.714, 61.884, 84.917, -5.198, -3.925, 0.904, 17.74, 33.806, 0.558, -8.4]
**Ligand B:** [345.407, 112.83, 0.891, 2, 7, 0.799, 52.152, 69.717, -5.772, -1.421, 0.133, 1.194, -18.475, 0.045, -6.9]
**Step-by-step comparison:**
1. **MW:** Ligand A (418.257) is within the ideal range (200-500 Da). Ligand B (345.407) is also good. No clear advantage here.
2. **TPSA:** Ligand A (56.92) is excellent, well below the 140 threshold. Ligand B (112.83) is higher, but still acceptable for a non-CNS target. A is better.
3. **logP:** Ligand A (3.295) is optimal. Ligand B (0.891) is a bit low, potentially hindering permeability. A is better.
4. **HBD:** Both have acceptable HBD counts (A: 3, B: 2).
5. **HBA:** Both have acceptable HBA counts (A: 2, B: 7).
6. **QED:** Both ligands have good QED scores (A: 0.714, B: 0.799), indicating good drug-like properties. B is slightly better.
7. **DILI:** Ligand A (61.884) has a higher DILI risk than Ligand B (52.152). B is better.
8. **BBB:** Ligand A (84.917) has better BBB penetration than Ligand B (69.717). This is a positive for GPCRs, even cardiovascular ones, as some off-target CNS effects are possible. A is better.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual. I will assume these are permeability percentile scores, meaning lower is worse. Ligand A (-5.198) is worse than Ligand B (-5.772). B is better.
10. **Solubility:** Ligand A (-3.925) has worse solubility than Ligand B (-1.421). B is better.
11. **hERG:** Ligand A (0.904) has a slightly higher hERG risk than Ligand B (0.133). B is better.
12. **Cl_mic:** Ligand A (17.74) has a higher microsomal clearance than Ligand B (1.194), indicating lower metabolic stability. B is better.
13. **t1/2:** Ligand A (33.806) has a much longer in vitro half-life than Ligand B (-18.475). A is better.
14. **Pgp:** Ligand A (0.558) has lower P-gp efflux than Ligand B (0.045). A is better.
15. **Affinity:** Ligand A (-8.4) has a significantly stronger binding affinity than Ligand B (-6.9). This is a substantial advantage.
**Overall Assessment:**
Ligand A has a significantly better binding affinity, better BBB penetration, and a longer half-life. While Ligand B has better solubility, lower DILI risk, and lower hERG risk, the strong binding affinity of Ligand A is a major advantage for a GPCR target. The slightly higher DILI and hERG risks of Ligand A can be addressed during further optimization. The better TPSA and logP of Ligand A also contribute to its overall better profile.
Therefore, I would prioritize Ligand A.
Output:
1
2025-04-17 21:32:55,343 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (353.463 Da and 342.439 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (89.95) is better than Ligand B (53.76). For a cardiovascular GPCR, a lower TPSA is generally preferred for better membrane permeability, but both are acceptable.
**3. logP:** Ligand B (3.46) is better than Ligand A (0.227). Ligand A's logP is quite low, potentially hindering membrane permeability and absorption. Ligand B is within the optimal 1-3 range.
**4. H-Bond Donors:** Ligand A (2) is better than Ligand B (0). While both are acceptable, having some H-bond donors can aid solubility.
**5. H-Bond Acceptors:** Ligand A (4) is better than Ligand B (3). Similar to HBD, a slight advantage for Ligand A.
**6. QED:** Ligand B (0.808) is better than Ligand A (0.669). Ligand B has a more favorable drug-likeness score.
**7. DILI:** Ligand A (18.185) is significantly better than Ligand B (44.668). This is a major advantage for Ligand A, as lower DILI risk is crucial.
**8. BBB:** Ligand B (89.841) is much better than Ligand A (38.465). While ADRB2 is a cardiovascular target and doesn't *require* high BBB penetration, some level is not detrimental, and Ligand B has a substantial advantage here.
**9. Caco-2 Permeability:** Ligand A (-5.154) is better than Ligand B (-4.13). A more negative value suggests better permeability.
**10. Aqueous Solubility:** Ligand A (-0.953) is better than Ligand B (-3.211). Better solubility is generally desirable.
**11. hERG Inhibition:** Ligand A (0.152) is better than Ligand B (0.64). Lower hERG inhibition is crucial to avoid cardiotoxicity.
**12. Microsomal Clearance:** Ligand A (4.092) is much better than Ligand B (69.485). Lower clearance indicates better metabolic stability, a significant advantage for Ligand A.
**13. In vitro Half-Life:** Ligand B (93.19) is much better than Ligand A (-4.348). Longer half-life is desirable.
**14. P-gp Efflux:** Ligand A (0.022) is much better than Ligand B (0.388). Lower P-gp efflux is preferred for better bioavailability.
**15. Binding Affinity:** Both ligands have very similar binding affinities (-5.6 kcal/mol and -4.2 kcal/mol). The 1.4 kcal/mol difference is not substantial enough to outweigh other factors.
**Overall Assessment:**
Ligand A has a clear advantage in safety parameters (DILI, hERG) and metabolic stability (Cl_mic). It also has better Caco-2 permeability, solubility, and P-gp efflux. While Ligand B has better logP, QED, BBB, and in vitro half-life, the safety and metabolic stability concerns with Ligand B are significant. For a cardiovascular GPCR, minimizing off-target effects and ensuring metabolic stability are paramount. The slightly lower logP of Ligand A is a manageable drawback, especially given its superior safety profile.
Output:
1
2025-04-17 21:32:55,343 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (386.832) is slightly higher than Ligand B (342.399), but both are acceptable.
2. **TPSA:** Both are below the 140 A^2 threshold for good oral absorption. Ligand A (86.71) is slightly higher than Ligand B (78.67), but both are good.
3. **logP:** Ligand A (2.365) is optimal (1-3). Ligand B (-0.36) is below 1, which could hinder permeation. This is a significant negative for Ligand B.
4. **HBD:** Both ligands have acceptable HBD counts (Ligand A: 2, Ligand B: 1).
5. **HBA:** Both ligands have acceptable HBA counts (Ligand A: 4, Ligand B: 5).
6. **QED:** Both have good QED scores (Ligand A: 0.825, Ligand B: 0.761), indicating drug-likeness.
7. **DILI:** Ligand A (67.429) is higher risk than Ligand B (20.202). This is a negative for Ligand A.
8. **BBB:** Ligand A (18.069) has very low BBB penetration. Ligand B (43.932) has moderate penetration. While ADRB2 isn't necessarily a CNS target, some peripheral effects can be modulated by CNS penetration.
9. **Caco-2:** Both have negative Caco-2 values which is unusual and suggests poor permeability. Ligand A (-5.045) is worse than Ligand B (-4.801).
10. **Solubility:** Both have negative solubility values, which is also unusual. Ligand A (-3.939) is worse than Ligand B (-0.947).
11. **hERG:** Both have low hERG inhibition risk (Ligand A: 0.456, Ligand B: 0.137).
12. **Cl_mic:** Ligand A (51.116) has higher clearance than Ligand B (-19.125), indicating lower metabolic stability. This is a negative for Ligand A.
13. **t1/2:** Ligand A (-21.547) has a very negative in vitro half-life, suggesting rapid metabolism. Ligand B (-14.801) is also negative, but less so.
14. **Pgp:** Both have low Pgp efflux liability (Ligand A: 0.082, Ligand B: 0.017).
15. **Binding Affinity:** Ligand A (-6.7 kcal/mol) has slightly better binding affinity than Ligand B (-5.3 kcal/mol). The difference is 1.4 kcal/mol, which is significant.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has a better logP and affinity, but Ligand B has better TPSA, Pgp, and significantly lower DILI risk. The poor Caco-2 and solubility for both are concerning, but the very low logP of Ligand B is a major drawback. The better affinity of Ligand A is a strong advantage, potentially outweighing the higher DILI risk and lower BBB.
**Conclusion:**
Despite the higher DILI risk and lower BBB penetration, Ligand A's superior binding affinity and more favorable logP make it the more promising candidate. The negative Caco-2 and solubility values are concerning for both, but can be addressed through formulation strategies.
Output:
1
2025-04-17 21:32:55,343 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (367.442 and 343.471 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (63.68) is better than Ligand B (81.99). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally favors absorption.
3. **logP:** Both ligands have acceptable logP values (2.182 and 3.551), falling within the 1-3 range. Ligand B is slightly higher, which could potentially lead to some off-target interactions, but it's not a major concern.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is preferable to Ligand B (3). Similar to HBD, fewer HBAs are generally preferred.
6. **QED:** Both ligands have similar QED values (0.765 and 0.681), both above the 0.5 threshold, indicating good drug-like properties.
7. **DILI:** Ligand A (45.715) has a significantly lower DILI risk than Ligand B (56.185). This is a crucial advantage.
8. **BBB:** Ligand A (82.009) has a much higher BBB penetration percentile than Ligand B (41.528). While not a primary concern for a cardiovascular target, higher BBB is rarely detrimental and could offer some unexpected benefits.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.557 and -4.696), which is unusual and suggests poor permeability. However, these values are on the same scale, so it doesn't differentiate the two.
10. **Solubility:** Ligand A (-3.073) has slightly better solubility than Ligand B (-4.593), although both are quite poor.
11. **hERG:** Ligand A (0.359) has a lower hERG inhibition liability than Ligand B (0.686), which is a significant safety advantage.
12. **Cl_mic:** Ligand A (10.839) has a lower microsomal clearance than Ligand B (58.992), indicating better metabolic stability.
13. **t1/2:** Ligand B (36.139) has a significantly longer in vitro half-life than Ligand A (15.862). This is a positive for Ligand B.
14. **Pgp:** Ligand A (0.388) has lower P-gp efflux liability than Ligand B (0.226), which is favorable for bioavailability.
15. **Affinity:** Ligand A (-6.7) has a slightly better binding affinity than Ligand B (-6.0). While the difference isn't huge, it's still a positive for Ligand A.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, and affinity. Ligand A performs better on TPSA, Pgp, and affinity. While Ligand B has a longer half-life, the superior ADME profile and safety (lower DILI, hERG) of Ligand A, combined with its slightly better binding affinity, make it the more promising candidate.
**Final Decision:**
Ligand A is the more viable drug candidate.
1
2025-04-17 21:32:55,343 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [360.483, 86.09, 2.039, 1, 5, 0.89, 41.411, 52.889, -5.223, -1.956, 0.118, -7.469, -7.266, 0.078, -7.0]
**Ligand B:** [346.387, 129.43, 1.041, 2, 5, 0.795, 39.473, 59.325, -5.278, -3.294, 0.419, -18.754, 20.599, 0.039, -7.3]
Here's a breakdown, comparing them against the guidelines and GPCR priorities:
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (346.387) is slightly lower, which could be marginally beneficial for permeability, but it's not a significant difference.
2. **TPSA:** Ligand A (86.09) is excellent, well below 140 and even closer to the 90 threshold for CNS targets. Ligand B (129.43) is still acceptable, but less optimal.
3. **logP:** Both are within the optimal 1-3 range. Ligand A (2.039) is slightly higher, which might be preferable for membrane permeability. Ligand B (1.041) is at the lower end, potentially hindering permeation.
4. **HBD:** Both have acceptable HBD counts (1 and 2 respectively).
5. **HBA:** Both have the same HBA count (5), which is within the acceptable limit.
6. **QED:** Ligand A (0.89) is better than Ligand B (0.795), indicating a more drug-like profile.
7. **DILI:** Both have low DILI risk (41.411 and 39.473), which is good.
8. **BBB:** Ligand B (59.325) has a slightly better BBB penetration percentile than Ligand A (52.889), but neither are particularly high. This isn't a major concern for a non-CNS target like ADRB2.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and indicates poor permeability. This is a significant drawback for both.
10. **Solubility:** Both have negative solubility values, also unusual and indicating poor solubility. This is a significant drawback for both.
11. **hERG:** Ligand A (0.118) has a much lower hERG risk than Ligand B (0.419), which is a crucial advantage for cardiovascular targets.
12. **Cl_mic:** Ligand A (-7.469) has a much lower (better) microsomal clearance than Ligand B (-18.754), suggesting better metabolic stability.
13. **t1/2:** Ligand B (20.599) has a significantly longer in vitro half-life than Ligand A (-7.266). This is a major advantage for Ligand B.
14. **Pgp:** Both have very low Pgp efflux liability (0.078 and 0.039), which is good.
15. **Affinity:** Ligand B (-7.3) has a slightly better binding affinity than Ligand A (-7.0), but the difference is small.
**Overall Assessment:**
Despite the poor Caco-2 and Solubility values for both compounds, Ligand A emerges as the more promising candidate. The significantly lower hERG risk and better metabolic stability (lower Cl_mic) are critical advantages, especially for a cardiovascular target. While Ligand B has a longer half-life, the safety profile of Ligand A is more favorable. The slight advantage in binding affinity for Ligand B is not enough to overcome these concerns.
Output:
1
2025-04-17 21:32:55,343 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.315 and 344.499 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (29.02) is significantly better than Ligand B (49.41). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold.
3. **logP:** Ligand A (4.35) is slightly higher than Ligand B (3.276). Both are within the optimal 1-3 range, but Ligand A is pushing the upper limit.
4. **HBD:** Ligand A (0) is preferable to Ligand B (1). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (2). Similar to HBD, fewer HBAs are generally better.
6. **QED:** Both ligands have similar QED values (0.613 and 0.687), both above the 0.5 threshold, indicating good drug-like properties.
7. **DILI:** Ligand A (74.021) has a considerably higher DILI risk than Ligand B (14.889). This is a major concern. Ligand B is well below the 40% threshold, while Ligand A is above 60%.
8. **BBB:** Both ligands have high BBB penetration (93.68 and 73.401). However, since ADRB2 is primarily a cardiovascular target, this isn't a critical factor.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.786 and -4.825), which is unusual and suggests poor permeability. This is a significant negative for both.
10. **Solubility:** Ligand A (-5.846) is slightly worse than Ligand B (-4.098), but both are very poor. This is a concern for bioavailability.
11. **hERG:** Ligand A (0.927) is slightly higher than Ligand B (0.46), indicating a slightly higher risk of hERG inhibition.
12. **Cl_mic:** Ligand B (69.006) has a higher microsomal clearance than Ligand A (47.567), meaning Ligand A is more metabolically stable.
13. **t1/2:** Ligand A (11.07) has a significantly longer in vitro half-life than Ligand B (0.883). This is a major advantage for dosing frequency.
14. **Pgp:** Ligand A (0.767) has a slightly higher P-gp efflux liability than Ligand B (0.318). Lower Pgp is preferred.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.4 and -6.3 kcal/mol). The difference is negligible.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A has better TPSA and Pgp, but Ligand B has a significantly lower DILI risk. The slight difference in logP isn't decisive.
**Overall Assessment:**
While Ligand A has some advantages in terms of metabolic stability (Cl_mic, t1/2), TPSA, and Pgp, the significantly higher DILI risk is a major red flag. The similar binding affinities make this the deciding factor. A high DILI risk can derail a drug candidate early in development. Ligand B, despite its slightly less favorable TPSA and Pgp, presents a much safer profile.
Output:
0
2025-04-17 21:32:55,344 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, the priorities are logP, TPSA, Pgp, affinity, and to a lesser extent, BBB.
Let's break down the comparison:
1. **MW:** Both ligands are within the ideal range (348.47 vs 347.46 Da).
2. **TPSA:** Ligand A (38.82) is significantly better than Ligand B (71.53). A TPSA under 140 is good for oral absorption, but lower is preferred for GPCRs, and Ligand A is much closer to the ideal range for good CNS penetration, even though it's not a CNS target.
3. **logP:** Both are within the optimal range (1.55 vs 2.40). Ligand B is slightly higher, which could be a minor concern for solubility, but not a deal-breaker.
4. **HBD/HBA:** Both have 1 HBD and 4 HBA, which are acceptable.
5. **QED:** Ligand A (0.896) is better than Ligand B (0.733), indicating a more drug-like profile.
6. **DILI:** Ligand A (22.8%) has a much lower DILI risk than Ligand B (39.9%). This is a significant advantage.
7. **BBB:** Ligand A (83.6%) shows better BBB penetration than Ligand B (69.7%). While not a primary concern for a cardiovascular target, it's a positive attribute.
8. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-4.75) is slightly better than Ligand B (-4.51).
9. **Solubility:** Ligand A (-1.32) is better than Ligand B (-2.62).
10. **hERG:** Both are low risk (0.90 vs 0.50).
11. **Cl_mic:** Ligand A (-6.38) has much lower microsomal clearance than Ligand B (37.83), suggesting better metabolic stability. This is a major advantage.
12. **t1/2:** Ligand A (-9.27) has a longer half-life than Ligand B (5.55).
13. **Pgp:** Ligand A (0.076) has lower P-gp efflux than Ligand B (0.229), which is favorable for bioavailability.
14. **Affinity:** Ligand B (-5.6 kcal/mol) has a stronger binding affinity than Ligand A (-2.2 kcal/mol). This is a substantial difference.
**Overall Assessment:**
The affinity difference is significant. However, Ligand A demonstrates a much more favorable ADME-Tox profile across several critical parameters (DILI, Cl_mic, t1/2, Pgp, TPSA, Solubility). The improved metabolic stability and reduced toxicity risk of Ligand A are compelling, and the slightly better permeability and BBB penetration are added benefits. While the affinity is lower, the overall balance of properties makes Ligand A the more promising candidate. The large difference in binding affinity would need to be addressed in further optimization, but starting with a molecule with better ADME properties is often a more efficient strategy.
**Output:**
1
2025-04-17 21:32:55,344 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 GPCR, followed by the final output.
**Ligand A Analysis:**
* **MW:** 366.845 Da - Acceptable.
* **TPSA:** 70.08 - Acceptable, though approaching the upper limit for good absorption.
* **logP:** 2.035 - Excellent. Within the optimal range.
* **HBD:** 1 - Good.
* **HBA:** 4 - Good.
* **QED:** 0.883 - Excellent. Highly drug-like.
* **DILI:** 55.68 - Moderate risk, but acceptable.
* **BBB:** 43.699 - Low. Not ideal, but ADRB2 isn't necessarily a CNS target.
* **Caco-2:** -4.918 - Poor permeability. A significant concern.
* **Solubility:** -2.288 - Poor solubility. Another significant concern.
* **hERG:** 0.048 - Very low risk. Excellent.
* **Cl_mic:** 0.243 - Very low clearance. Excellent metabolic stability.
* **t1/2:** -2.155 - Very long half-life. Excellent.
* **Pgp:** 0.012 - Low efflux. Good.
* **Affinity:** -5.5 kcal/mol - Good binding affinity.
**Ligand B Analysis:**
* **MW:** 361.433 Da - Acceptable.
* **TPSA:** 53.09 - Excellent. Well below the 140 threshold.
* **logP:** 1.202 - Good, but on the lower side of optimal.
* **HBD:** 0 - Good.
* **HBA:** 4 - Good.
* **QED:** 0.739 - Good. Drug-like, but not as high as Ligand A.
* **DILI:** 18.651 - Very low risk. Excellent.
* **BBB:** 93.757 - Very high. Excellent.
* **Caco-2:** -4.261 - Poor permeability. A concern, but slightly better than Ligand A.
* **Solubility:** -0.866 - Moderate solubility. Better than Ligand A.
* **hERG:** 0.422 - Low risk. Good.
* **Cl_mic:** -15.2 - High clearance. Poor metabolic stability.
* **t1/2:** -30.585 - Very short half-life. Poor.
* **Pgp:** 0.035 - Low efflux. Good.
* **Affinity:** -7.1 kcal/mol - Excellent binding affinity. 1.6 kcal/mol better than Ligand A.
**Comparison and Decision:**
Both ligands have issues with Caco-2 permeability. However, Ligand B possesses a significantly stronger binding affinity (-7.1 vs -5.5 kcal/mol). This 1.6 kcal/mol difference is substantial and can often outweigh minor ADME drawbacks, especially for a GPCR target where high affinity is crucial. Ligand B also has a much better DILI score, and a significantly higher BBB penetration. While its metabolic stability (Cl_mic) and half-life are poor, these can potentially be addressed through structural modifications. Ligand A's solubility is also quite poor.
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity) and the overall balance, the superior binding affinity of Ligand B, combined with its better safety profile (DILI) and potential for CNS effects (BBB), makes it the more promising candidate despite its metabolic liabilities.
Output:
0
2025-04-17 21:32:55,344 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (346.431 and 343.427 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (98.32) is slightly higher than Ligand B (80.32). Both are below the 140 threshold for oral absorption, but B is preferable as it's closer to the 90 threshold for potential CNS effects (though ADRB2 isn't strictly a CNS target, lower TPSA is generally favorable for GPCRs).
3. **logP:** Ligand A (1.073) is at the lower end of the optimal range, while Ligand B (1.839) is better positioned within the 1-3 range. Ligand B is preferred.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (2). Both are acceptable, but lower is generally better for permeability. Ligand B is slightly preferred.
5. **HBA:** Both ligands have 4 HBA, which is within the acceptable limit of 10. No significant difference.
6. **QED:** Ligand A (0.71) has a better QED score than Ligand B (0.557), indicating a more drug-like profile. This favors Ligand A.
7. **DILI:** Ligand B (31.718) has a significantly lower DILI risk than Ligand A (43.66). This is a crucial advantage for Ligand B.
8. **BBB:** Ligand B (47.693) shows better BBB penetration potential than Ligand A (32.144). While ADRB2 isn't a primary CNS target, some peripheral ADRB2 modulation can have CNS side effects, so better BBB penetration isn't necessarily a negative.
9. **Caco-2:** Ligand A (-5.191) and Ligand B (-4.864) are both negative, indicating poor permeability. The values are very close, so this isn't a major differentiator.
10. **Solubility:** Ligand A (-2.271) and Ligand B (-2.107) are both negative, indicating poor aqueous solubility. The values are very close, so this isn't a major differentiator.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.118 and 0.178), which is excellent. No significant difference.
12. **Cl_mic:** Ligand A (-5.666) has a much lower (better) microsomal clearance than Ligand B (21.001). This suggests greater metabolic stability for Ligand A.
13. **t1/2:** Ligand A (-17.805) has a longer in vitro half-life than Ligand B (-21.535). This is a significant advantage for Ligand A.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.023 and 0.046). No significant difference.
15. **Binding Affinity:** Both ligands have a binding affinity of -5.9 and -5.6 kcal/mol, respectively. Ligand A has a slightly better affinity, but the difference is not substantial enough to outweigh other factors.
**Overall Assessment & GPCR Prioritization:**
For a GPCR like ADRB2, logP, TPSA, and metabolic stability are key. Ligand B has a better logP and TPSA, and a significantly lower DILI risk. Ligand A has a better QED, Cl_mic, and t1/2, and slightly better affinity. However, the lower DILI risk of Ligand B is a major advantage, and the slightly better logP and TPSA are also beneficial. The difference in affinity is not large enough to overcome these advantages.
**Output:**
0
2025-04-17 21:32:55,344 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (366.49 & 368.50 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (91.4) is slightly higher than Ligand B (84.5). Both are below the 140 threshold for oral absorption, but closer to the 90 threshold for CNS targets, which isn't a primary concern for ADRB2 (cardiovascular). Ligand B is preferable.
3. **logP:** Ligand A (0.873) is a bit low, potentially impacting permeability. Ligand B (1.421) is better, falling within the optimal 1-3 range. Ligand B is preferable.
4. **HBD:** Both ligands have 2 HBD, which is good. No difference.
5. **HBA:** Both ligands have 5 HBA, which is good. No difference.
6. **QED:** Both ligands have similar QED values (0.749 vs 0.71), indicating good drug-likeness. No significant difference.
7. **DILI:** Ligand A (35.56%) and Ligand B (40.05%) are both within the acceptable range (<40 is good). No significant difference.
8. **BBB:** Ligand B (54.44%) has a better BBB percentile than Ligand A (40.52%). While ADRB2 isn't a CNS target, higher BBB is generally favorable, indicating less promiscuous distribution. Ligand B is preferable.
9. **Caco-2:** Ligand A (-5.244) and Ligand B (-5.453) are both very poor. This is a major concern for both, suggesting poor intestinal absorption.
10. **Solubility:** Ligand A (-1.292) is better than Ligand B (-2.617). Solubility is important for formulation and bioavailability. Ligand A is preferable.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.095 and 0.064), which is excellent. No difference.
12. **Cl_mic:** Ligand A (0.587) has significantly lower microsomal clearance than Ligand B (30.239). Lower clearance indicates better metabolic stability. Ligand A is strongly preferable.
13. **t1/2:** Ligand A (8.338 hours) has a better in vitro half-life than Ligand B (-9.98 hours). A longer half-life is generally desirable for less frequent dosing. Ligand A is preferable.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.013 and 0.103). No significant difference.
15. **Binding Affinity:** Ligand B (-6.9 kcal/mol) has a slightly better binding affinity than Ligand A (-5.8 kcal/mol). This is a 1.1 kcal/mol difference, which is substantial and can outweigh some ADME drawbacks. Ligand B is preferable.
**Overall Assessment:**
While Ligand B has a better binding affinity and a slightly better logP and BBB, Ligand A demonstrates superior metabolic stability (much lower Cl_mic) and a longer half-life. The poor Caco-2 values for both are concerning, but the metabolic stability is critical for a viable drug candidate. The slight advantage in solubility for Ligand A is also beneficial. Given the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), and considering the importance of metabolic stability for cardiovascular drugs, Ligand A is the more promising candidate.
Output:
1
2025-04-17 21:32:55,344 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's analyze each ligand against the provided guidelines, keeping in mind ADRB2 is a GPCR, so logP, TPSA, Pgp, BBB, and affinity are key.
* **Molecular Weight:** Both ligands (350.463 and 349.431 Da) fall comfortably within the 200-500 Da ideal range.
* **TPSA:** Ligand A (95.74) is slightly higher than Ligand B (78.95). Both are below 140, acceptable for oral absorption, but Ligand B is preferable.
* **logP:** Ligand A (0.929) is better than Ligand B (0.309). Both are within the 1-3 range, but Ligand A is closer to the optimal range.
* **H-Bond Donors:** Ligand A (2) is slightly higher than Ligand B (1). Both are acceptable.
* **H-Bond Acceptors:** Ligand A (3) is lower than Ligand B (4). Both are acceptable.
* **QED:** Both ligands have similar QED values (0.789 and 0.744), indicating good drug-likeness.
* **DILI:** Both ligands have very similar, low DILI risk (23.304 and 23.769 percentile).
* **BBB:** Ligand A (76.774) has a significantly better BBB penetration score than Ligand B (59.946). This is a crucial advantage for a GPCR target, even if not CNS-focused, as it can influence off-target interactions.
* **Caco-2 Permeability:** Both are negative, indicating poor permeability. Ligand A (-5.036) is slightly better than Ligand B (-5.005).
* **Aqueous Solubility:** Both are negative, indicating poor solubility. Ligand A (-2.372) is slightly better than Ligand B (-1.273).
* **hERG Inhibition:** Both ligands show very low hERG inhibition risk (0.129 and 0.19).
* **Microsomal Clearance:** Ligand A (14.669) has a lower (better) microsomal clearance than Ligand B (-19.967). This suggests better metabolic stability.
* **In vitro Half-Life:** Ligand A (-6.327) has a longer half-life than Ligand B (3.501).
* **P-gp Efflux:** Both ligands have low P-gp efflux liability (0.024 and 0.011).
* **Binding Affinity:** Ligand A (-7.3 kcal/mol) has a slightly better binding affinity than Ligand B (-6.1 kcal/mol). While the difference is not huge, it's enough to be noticeable.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B in several key areas: BBB penetration, metabolic stability (lower Cl_mic, longer t1/2), and binding affinity. While both have similar DILI and hERG profiles, the advantages of Ligand A, particularly the better BBB and affinity, make it the more promising candidate for development as a drug targeting the ADRB2 receptor. The slightly better logP of Ligand A is also a plus.
**Output:**
1
2025-04-17 21:32:55,344 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (407.312 Da) is slightly higher than Ligand B (339.41 Da), but both are acceptable.
**2. TPSA:** Ligand A (79.9) is higher than Ligand B (41.49). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B is significantly better here.
**3. logP:** Both ligands have good logP values (A: 3.346, B: 3.674), falling within the optimal 1-3 range. Ligand B is slightly higher, which *could* be a minor drawback, but is still acceptable.
**4. H-Bond Donors:** Both ligands have 2 HBD, which is within the acceptable limit of <=5.
**5. H-Bond Acceptors:** Ligand A has 4 HBA, and Ligand B has 3. Both are within the acceptable limit of <=10.
**6. QED:** Both ligands have similar and good QED values (A: 0.77, B: 0.789), indicating good drug-like properties.
**7. DILI Risk:** Ligand A (53.432) has a slightly higher DILI risk than Ligand B (40.287), but both are below the concerning threshold of 60.
**8. BBB Penetration:** Both ligands exhibit good BBB penetration (A: 74.952, B: 70.027). While not a primary concern for a cardiovascular target, it's not detrimental.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.936 and -4.528). This is unusual and suggests poor permeability. However, these values are on a scale where negative values are possible and don't necessarily preclude development.
**10. Aqueous Solubility:** Both ligands have negative solubility values (-5.187 and -4.314). Similar to Caco-2, this is not ideal but doesn't immediately disqualify them.
**11. hERG Inhibition:** Ligand A (0.541) has a slightly lower hERG inhibition risk than Ligand B (0.931), which is preferable.
**12. Microsomal Clearance:** Ligand A (61.149) has a higher microsomal clearance than Ligand B (38.156), indicating lower metabolic stability. This is a significant drawback for Ligand A.
**13. In Vitro Half-Life:** Ligand B (50.054) has a significantly longer in vitro half-life than Ligand A (22.184), which is a major advantage.
**14. P-gp Efflux:** Both ligands have similar P-gp efflux values (A: 0.559, B: 0.876).
**15. Binding Affinity:** Ligand B (-5.3 kcal/mol) has a slightly better binding affinity than Ligand A (-5.0 kcal/mol). While the difference is not huge, it's still a positive for Ligand B.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand B is the more promising candidate. It has a lower TPSA, better metabolic stability (lower Cl_mic, longer t1/2), slightly better affinity, and lower DILI risk. While both have issues with Caco-2 and solubility, the metabolic stability and half-life advantages of Ligand B are crucial for a viable drug candidate. The slightly better affinity is also a plus.
Output:
0
2025-04-17 21:32:55,344 - INFO - Batch 266 complete. Total preferences: 4256
2025-04-17 21:32:55,344 - INFO - Processing batch 267/512...
2025-04-17 21:33:43,424 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (332.411 and 340.387 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (80.63) is significantly better than Ligand B (113.24). For a GPCR, keeping TPSA under 140 is good, but lower is generally preferred for better permeability. Ligand B is pushing the upper limit.
3. **logP:** Ligand A (3.219) is optimal, while Ligand B (0.443) is quite low. A logP below 1 can hinder membrane permeability. This is a substantial advantage for Ligand A.
4. **HBD:** Ligand A (2) and Ligand B (3) are both acceptable, being under the 5 threshold.
5. **HBA:** Both ligands have 5 HBA, which is acceptable.
6. **QED:** Ligand A (0.77) is slightly better than Ligand B (0.684), indicating a more drug-like profile.
7. **DILI:** Ligand B (56.146) has a significantly lower DILI risk than Ligand A (77.627). This is a considerable advantage for Ligand B.
8. **BBB:** Ligand B (78.558) has better BBB penetration than Ligand A (64.87). While ADRB2 isn't necessarily a CNS target, some cardiovascular effects can be mediated through CNS pathways, so this is a slight benefit for Ligand B.
9. **Caco-2:** Both have negative Caco-2 values which is unusual, but the values are close enough to not be a deciding factor.
10. **Solubility:** Ligand A (-4.84) is slightly better than Ligand B (-2.637), indicating better aqueous solubility.
11. **hERG:** Ligand A (0.94) has a slightly higher hERG risk than Ligand B (0.271). Lower hERG is preferred, so this favors Ligand B.
12. **Cl_mic:** Ligand B (32.814) has a lower microsomal clearance than Ligand A (41.369), suggesting better metabolic stability.
13. **t1/2:** Ligand A (34.752) has a much longer in vitro half-life than Ligand B (-17.418). A negative half-life is concerning for Ligand B.
14. **Pgp:** Ligand A (0.513) has lower P-gp efflux than Ligand B (0.006). Lower efflux is generally preferred.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.3 and -5.3 kcal/mol). The difference of 1 kcal/mol is not enough to outweigh other factors.
**Overall Assessment:**
Ligand A has advantages in logP, QED, solubility, and half-life. However, Ligand B excels in DILI risk, hERG inhibition, and metabolic stability (Cl_mic). The low logP of Ligand B is a significant concern for permeability. The negative half-life for Ligand B is a major red flag. While the DILI and hERG profiles of Ligand B are attractive, the permeability and stability issues are too significant. Considering the GPCR-specific priorities (logP, TPSA, Pgp), Ligand A is the more promising candidate.
Output:
1
2025-04-17 21:33:43,424 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [344.459, 56.84, 2.535, 2, 4, 0.806, 54.556, 78.558, -4.764, -2.107, 0.737, 14.694, 9.634, 0.083, -7.2]
**Ligand B:** [348.422, 75.19, 1.976, 1, 4, 0.798, 39.511, 81.776, -4.748, -2.511, 0.47, 54.618, -5.731, 0.091, 11.3]
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). A is 344.459, B is 348.422. Very similar.
2. **TPSA:** A (56.84) is better than B (75.19). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally aids absorption.
3. **logP:** A (2.535) is slightly higher than B (1.976), both are within the optimal range (1-3).
4. **HBD:** A (2) is slightly higher than B (1). Both are acceptable.
5. **HBA:** Both A (4) and B (4) are within the acceptable range (<=10).
6. **QED:** Both are similar (A: 0.806, B: 0.798) and above the 0.5 threshold, indicating good drug-likeness.
7. **DILI:** A (54.556) is significantly higher than B (39.511). This is a major concern, as B has a much lower risk of liver injury.
8. **BBB:** Both are reasonably high (A: 78.558, B: 81.776), but not critical for a cardiovascular target.
9. **Caco-2:** Both are negative, indicating poor permeability. A (-4.764) is slightly worse than B (-4.748).
10. **Solubility:** Both are negative, indicating poor solubility. A (-2.107) is slightly worse than B (-2.511).
11. **hERG:** A (0.737) is higher than B (0.47), indicating a slightly higher risk of hERG inhibition.
12. **Cl_mic:** Both have similar microsomal clearance (A: 14.694, B: 54.618). B is higher, meaning it will be cleared faster.
13. **t1/2:** A (9.634) is significantly longer than B (-5.731). This is a significant advantage for A.
14. **Pgp:** Both are very low (A: 0.083, B: 0.091), indicating minimal P-gp efflux.
15. **Affinity:** A (-7.2) is *much* better than B (11.3). This is a difference of 8.5 kcal/mol, a substantial advantage.
**GPCR-specific priorities:** For ADRB2 (a GPCR), affinity is paramount. LogP, TPSA, and Pgp are also important. While BBB isn't critical for a cardiovascular target, it's not detrimental to have reasonable values.
**Conclusion:**
Despite Ligand A's slightly worse TPSA, Caco-2, and solubility, its *significantly* superior binding affinity (-7.2 vs -11.3 kcal/mol) and longer half-life outweigh these drawbacks. The DILI risk for A is higher, but the large affinity difference is a strong driver. The difference in affinity is so large that it is likely to overcome the other issues.
Output:
1
2025-04-17 21:33:43,424 - INFO - Reasoning:
Let's analyze Ligand A and Ligand B for their potential as ADRB2 ligands, keeping in mind GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key).
**Molecular Weight:** Both ligands (354.491 and 360.483 Da) fall within the ideal 200-500 Da range.
**TPSA:** Both ligands have TPSA values (78.87 and 76.14) below 140, which is good for oral absorption.
**logP:** Ligand A (1.851) is closer to the optimal 1-3 range than Ligand B (2.937), but both are acceptable.
**H-Bond Donors/Acceptors:** Both have 2 HBDs, which is good. Ligand A has 4 HBAs, and Ligand B has 6. Both are within the acceptable limit of 10.
**QED:** Both ligands have good QED scores (0.662 and 0.757), indicating drug-like properties.
**DILI:** Ligand A (12.679) has a significantly lower DILI risk than Ligand B (53.742), which is a major advantage.
**BBB:** Ligand B (81.504) has a better BBB penetration score than Ligand A (68.941), but BBB isn't a primary concern for a cardiovascular target like ADRB2.
**Caco-2 Permeability:** Both have negative Caco-2 values, which is unusual and potentially problematic. However, the values are similar (-4.56 and -4.782).
**Aqueous Solubility:** Ligand A (-1.369) has better aqueous solubility than Ligand B (-3.867).
**hERG:** Both ligands have low hERG inhibition liability (0.367 and 0.72), which is good.
**Microsomal Clearance:** Ligand A (2.321) has significantly lower microsomal clearance than Ligand B (70.384), indicating better metabolic stability.
**In vitro Half-Life:** Ligand B (31.563) has a longer in vitro half-life than Ligand A (10.241).
**P-gp Efflux:** Both have very low P-gp efflux liability (0.075 and 0.074).
**Binding Affinity:** Ligand A (-7.9 kcal/mol) has a slightly better binding affinity than Ligand B (-6.9 kcal/mol), a difference of 1.0 kcal/mol.
**Overall Assessment:**
Ligand A is superior due to its significantly lower DILI risk, better aqueous solubility, and lower microsomal clearance. The slightly better binding affinity of Ligand A further strengthens its position. While Ligand B has a better BBB score and in vitro half-life, these are less critical for a cardiovascular target. The DILI and metabolic stability advantages of Ligand A outweigh the benefits of Ligand B.
Output:
1
2025-04-17 21:33:43,425 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
We are targeting ADRB2, a GPCR. Therefore, the priorities are logP, Pgp, TPSA, affinity, and BBB. Let's break down each ligand against these and other important parameters:
* **Molecular Weight:** Both ligands are within the acceptable 200-500 Da range. Ligand A (346.362 Da) is slightly lower, which is generally favorable for permeability.
* **TPSA:** Ligand A (117.34) is better than Ligand B (38.25). Lower TPSA generally correlates with better blood-brain barrier penetration and oral absorption.
* **logP:** Ligand A (1.882) is within the optimal range (1-3). Ligand B (4.587) is a bit high, potentially leading to solubility issues and off-target interactions.
* **H-Bond Donors/Acceptors:** Ligand A has 4 HBD and 5 HBA, while Ligand B has 0 HBD and 4 HBA. Both are acceptable, but the presence of some HBDs in Ligand A can aid solubility.
* **QED:** Both ligands have reasonable QED scores (A: 0.498, B: 0.651), indicating drug-like properties. Ligand B is slightly better here.
* **DILI:** Ligand A (77.666) has a higher DILI risk than Ligand B (35.983). This is a significant concern for Ligand A.
* **BBB:** Ligand B (80.729) has a much higher BBB percentile than Ligand A (19.077). While ADRB2 isn't strictly a CNS target, some CNS penetration can be beneficial.
* **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-5.566) is slightly better than Ligand B (-4.543).
* **Solubility:** Both ligands have very poor aqueous solubility (-3.564 and -4.609 respectively). This is a major drawback for both.
* **hERG:** Ligand A (0.519) has a slightly lower hERG risk than Ligand B (0.931), which is preferable.
* **Cl_mic:** Ligand B (100.388) has a significantly higher microsomal clearance than Ligand A (31.091), indicating lower metabolic stability.
* **t1/2:** Ligand A (-24.359) has a negative in vitro half-life, which is very concerning. Ligand B (31.809) has a positive half-life, indicating better stability.
* **Pgp:** Ligand A (0.021) has very low P-gp efflux liability, which is good. Ligand B (0.612) is higher, indicating more efflux.
* **Binding Affinity:** Both ligands have good binding affinity (-7.0 and -6.9 kcal/mol respectively), with Ligand A being slightly better.
**Overall Assessment:**
Ligand A has a slightly better binding affinity and lower P-gp efflux, but suffers from a high DILI risk, very poor in vitro half-life, and poor BBB penetration. Ligand B, while having a slightly higher logP, exhibits a significantly lower DILI risk, better BBB penetration, and a more reasonable in vitro half-life. The higher metabolic clearance of Ligand B is a concern, but potentially addressable through structural modifications. The poor solubility of both is a major hurdle, but could be addressed through formulation strategies.
Considering the balance of properties and the GPCR-specific priorities, Ligand B appears to be the more promising candidate due to its lower toxicity risk and better pharmacokinetic properties.
**Output:**
0
2025-04-17 21:33:43,425 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (355.429 and 350.413 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (61.44) is significantly better than Ligand B (77.81). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (1.551) is optimal, while Ligand B (3.56) is pushing the upper limit. Higher logP can lead to off-target effects and solubility issues.
4. **HBD:** Both ligands have 2 HBD, which is within the acceptable range.
5. **HBA:** Ligand A has 3 HBA, while Ligand B has 4. Both are acceptable, but lower is generally preferred.
6. **QED:** Both ligands have similar QED values (0.681 and 0.633), indicating good drug-likeness.
7. **DILI:** Ligand A (17.449%) has a much lower DILI risk than Ligand B (52.346%). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (91.237%) has a higher BBB penetration than Ligand B (68.399%). While not critical for a cardiovascular target, it doesn't hurt.
9. **Caco-2:** Ligand A (-5.234) and Ligand B (-4.82) are both negative, indicating poor permeability. This is a concern for both, but the difference is minimal.
10. **Solubility:** Ligand A (-2.335) has slightly better solubility than Ligand B (-3.962).
11. **hERG:** Both ligands have similar hERG inhibition liability (0.65 and 0.798), which is relatively low risk.
12. **Cl_mic:** Ligand A (-1.617) has significantly better metabolic stability (lower clearance) than Ligand B (62.136). This is a major advantage.
13. **t1/2:** Ligand A (4.946) has a shorter half-life than Ligand B (11.885). This is a drawback for Ligand A, but potentially manageable with dosing.
14. **Pgp:** Ligand A (0.039) has much lower P-gp efflux than Ligand B (0.249). This is a positive for bioavailability.
15. **Binding Affinity:** Ligand A (-7.3) has a slightly better binding affinity than Ligand B (-6.9). While the difference is less than 1.5 kcal/mol, it contributes to the overall preference.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A performs better in all of these categories except for half-life. The significantly lower DILI and Cl_mic for Ligand A are also very important considerations.
**Overall Assessment:**
Ligand A demonstrates a superior balance of properties, particularly regarding safety (DILI), metabolic stability (Cl_mic), and permeability/absorption (TPSA, Pgp). While Ligand B has a longer half-life, the other advantages of Ligand A outweigh this single benefit.
Output:
1
2025-04-17 21:33:43,425 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (342.359 Da and 350.463 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (103.93) is higher than Ligand B (87.46). For a cardiovascular GPCR, TPSA is moderately important, and lower is generally preferred for better permeability. Ligand B has a clear advantage.
**3. logP:** Both ligands have good logP values (1.22 and 0.953 respectively), falling within the optimal 1-3 range. Ligand B is slightly more favorable.
**4. H-Bond Donors:** Ligand A has 1 HBD, while Ligand B has 2. Both are acceptable, but lower is slightly preferred.
**5. H-Bond Acceptors:** Ligand A has 8 HBA, and Ligand B has 5. Both are within the acceptable limit of 10, with Ligand B being more favorable.
**6. QED:** Both ligands have similar QED values (0.648 and 0.694), indicating good drug-likeness.
**7. DILI Risk:** Ligand A has a DILI risk of 93.835, which is concerningly high. Ligand B has a much lower DILI risk of 12.408, a significant advantage.
**8. BBB Penetration:** Ligand A (69.368) has better BBB penetration than Ligand B (45.638). However, for a cardiovascular target, BBB penetration is less critical than for CNS targets.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-5.156 and -5.063), which is unusual and suggests poor permeability. This is a concern for both.
**10. Aqueous Solubility:** Both ligands have negative solubility values (-2.987 and -0.623), indicating poor aqueous solubility. This is a significant drawback for both, potentially impacting bioavailability.
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.157 and 0.17), which is excellent.
**12. Microsomal Clearance:** Ligand A (83.135) has higher microsomal clearance than Ligand B (18.935), indicating lower metabolic stability. Ligand B is significantly better here.
**13. In vitro Half-Life:** Ligand A (28.933) has a positive half-life, while Ligand B (-13.058) has a negative half-life. This is concerning for Ligand B.
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (0.096 and 0.053), which is favorable.
**15. Binding Affinity:** Ligand B (-8.6 kcal/mol) has a significantly stronger binding affinity than Ligand A (-4.9 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME concerns.
**Overall Assessment:**
While Ligand A has better BBB penetration and a positive in vitro half-life, Ligand B is superior in almost all other critical parameters. The significantly lower DILI risk, better TPSA, lower microsomal clearance, and *much* stronger binding affinity of Ligand B make it the more promising candidate. The negative Caco-2 and solubility values are concerning for both, but can potentially be addressed through formulation strategies. The stronger binding affinity of Ligand B is a major driver for selection.
Output:
0
2025-04-17 21:33:43,425 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.39 and 344.411 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (56.59) is significantly better than Ligand B (76.66). ADRB2 is a cardiovascular target, not CNS, but lower TPSA generally aids absorption. Ligand A is well below the 140 threshold.
3. **logP:** Both ligands have good logP values (1.882 and 1.68), falling within the optimal 1-3 range. Ligand B is slightly lower, which could marginally improve solubility.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer HBDs generally improve membrane permeability.
5. **HBA:** Ligand A (6) is preferable to Ligand B (5). Lower HBA is generally better for permeability.
6. **QED:** Both ligands have good QED scores (0.747 and 0.854), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (38.387) has a much lower DILI risk than Ligand B (63.668). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (88.29) has a higher BBB penetration percentile than Ligand B (48.507). While ADRB2 isn't a primary CNS target, some level of BBB penetration can indicate favorable distribution properties.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.411 and -4.873). This is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
10. **Solubility:** Both ligands have similar negative solubility values (-2.79 and -2.72). Again, the scale is not specified, making interpretation difficult.
11. **hERG:** Ligand A (0.875) has a lower hERG inhibition liability than Ligand B (0.232). This is a significant advantage for Ligand A, reducing cardiotoxicity risk.
12. **Cl_mic:** Ligand A (98.113) has a higher microsomal clearance than Ligand B (-25.951). This indicates lower metabolic stability for Ligand A, which is a drawback.
13. **t1/2:** Ligand B (12.126) has a longer in vitro half-life than Ligand A (8.202). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.286) has lower P-gp efflux liability than Ligand B (0.108). Lower P-gp efflux is generally desirable.
15. **Binding Affinity:** Ligand A (-6.7 kcal/mol) has a slightly better binding affinity than Ligand B (-6.2 kcal/mol). While the difference is not huge, it's still a positive for Ligand A.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A performs better on logP, TPSA, and Pgp, and has a slightly better affinity.
**Overall Assessment:**
Ligand A has several advantages: lower DILI risk, lower hERG risk, better TPSA, lower Pgp efflux, and slightly better affinity. Ligand B has a better QED and a longer half-life, but the DILI and hERG risks are concerning. The slightly better metabolic stability of Ligand B is offset by the other safety concerns. Considering the balance of properties, and prioritizing safety (DILI, hERG) alongside reasonable ADME and affinity, Ligand A appears to be the more promising candidate.
Output:
1
2025-04-17 21:33:43,425 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (355.825 and 338.499 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (56.15) is higher than Ligand B (41.05). Both are below the 140 threshold for good oral absorption, but B is better, especially considering ADRB2 isn't necessarily a CNS target where a very low TPSA is crucial.
3. **logP:** Both ligands (4.31 and 4.405) are slightly above the optimal 1-3 range. This is a potential concern for solubility, but not a deal-breaker, and is common for GPCR ligands.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Both have 4 HBA, which is also good.
6. **QED:** Ligand B (0.897) has a significantly better QED score than Ligand A (0.758), indicating a more drug-like profile.
7. **DILI:** Ligand B (47.538) has a much lower DILI risk than Ligand A (96.51). This is a major advantage for Ligand B.
8. **BBB:** Ligand B (81.582) shows better BBB penetration than Ligand A (64.831), but since ADRB2 is primarily a cardiovascular target, this isn't a primary concern.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the values are similar (-4.661 vs -4.883).
10. **Solubility:** Both have negative solubility values, indicating very poor aqueous solubility. This is a significant drawback for both, but similar for both.
11. **hERG:** Ligand A (0.598) has a slightly better hERG profile than Ligand B (0.927), meaning lower risk of cardiotoxicity.
12. **Cl_mic:** Ligand B (107.355) has a significantly higher microsomal clearance than Ligand A (84.584), meaning faster metabolism and potentially lower *in vivo* exposure.
13. **t1/2:** Both have similar *in vitro* half-lives (58.587 and 58.148 hours).
14. **Pgp:** Ligand A (0.625) has lower P-gp efflux than Ligand B (0.539), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand B (-5.3 kcal/mol) has a slightly better binding affinity than Ligand A (-6.2 kcal/mol). While A is better, the difference is not substantial enough to overcome other factors.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are important. Ligand B has a slightly better logP, better TPSA, and comparable affinity. The lower Pgp efflux of Ligand A is a plus, but the significantly lower DILI risk of Ligand B is a major advantage. The higher metabolic clearance of Ligand B is a concern, but the better QED and lower DILI risk outweigh this.
**Conclusion:**
Considering the balance of properties, particularly the significantly lower DILI risk and better QED score, Ligand B is the more promising drug candidate despite its slightly higher metabolic clearance.
Output:
0
2025-04-17 21:33:43,426 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (368.396 and 349.431 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (87.66) is better than Ligand B (104.46). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally aids absorption.
3. **logP:** Both ligands have good logP values (2.069 and 1.405), falling within the optimal 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Both have 3 H-bond donors, which is acceptable.
5. **HBA:** Ligand A has 4 H-bond acceptors, while Ligand B has 5. Ligand A is slightly preferred.
6. **QED:** Both ligands have good QED scores (0.601 and 0.745), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Both ligands have similar DILI risk (36.797 and 38.581), both below the 40% threshold, indicating low risk.
8. **BBB:** Ligand A (71.733) has a significantly higher BBB penetration percentile than Ligand B (46.646). While not critical for a cardiovascular target, higher BBB is rarely detrimental.
9. **Caco-2:** Both have negative Caco-2 values (-4.956 and -4.915). This is unusual and suggests poor permeability in this assay. This is a concern for both.
10. **Solubility:** Both have negative solubility values (-2.757 and -2.504). This is also a concern for both, indicating poor aqueous solubility.
11. **hERG:** Both ligands have low hERG inhibition liability (0.336 and 0.127), which is excellent.
12. **Cl_mic:** Ligand A (9.681) has a lower microsomal clearance than Ligand B (12.051), suggesting better metabolic stability. This is a positive for Ligand A.
13. **t1/2:** Ligand A (-15.716) has a much more negative in vitro half-life than Ligand B (9.08). This is a major concern for Ligand A, indicating very rapid metabolism.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.058 and 0.041), which is good.
15. **Binding Affinity:** Ligand A (-7.4 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.0 kcal/mol). This is a substantial difference (1.4 kcal/mol) and is a major advantage for Ligand A.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A is better on logP, TPSA, and *significantly* better on affinity. The half-life is a major drawback for Ligand A, but the strong binding affinity could potentially compensate if formulation strategies can address the rapid metabolism.
**Overall Assessment:**
Despite the concerning half-life, the significantly stronger binding affinity of Ligand A is a major advantage. The other ADME properties are reasonably balanced, and the lower clearance is also positive. Ligand B has slightly better QED, but the difference in affinity is substantial enough to outweigh this.
Output:
1
2025-04-17 21:33:43,426 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for their potential as drug candidates targeting the ADRB2, a cardiovascular GPCR. Therefore, we prioritize logP, TPSA, Pgp efflux, BBB penetration, and binding affinity, alongside general drug-like properties.
Let's compare the ligands property by property:
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (349.519) is slightly lower, which is generally favorable.
2. **TPSA:** Ligand A (52.65) is significantly better than Ligand B (131.03). A TPSA under 140 is good for oral absorption, but Ligand B is pushing the limit and could have absorption issues.
3. **logP:** Ligand A (2.428) is optimal. Ligand B (-0.694) is quite low, potentially hindering membrane permeability and bioavailability.
4. **HBD/HBA:** Ligand A (1 HBD, 3 HBA) is preferable to Ligand B (3 HBD, 7 HBA). Lower counts generally improve permeability.
5. **QED:** Ligand A (0.776) has a better QED score than Ligand B (0.521), indicating a more drug-like profile.
6. **DILI:** Ligand A (6.049) has a much lower DILI risk than Ligand B (47.732). This is a significant advantage.
7. **BBB:** Ligand A (83.637) shows good BBB penetration, while Ligand B (35.789) is poor. While ADRB2 is cardiovascular, some CNS off-target effects are possible, and better BBB penetration is generally desirable.
8. **Caco-2:** Ligand A (-4.731) and Ligand B (-6.124) both have negative values, which is unusual and hard to interpret without knowing the scale. However, the values are similar.
9. **Solubility:** Ligand A (-2.27) and Ligand B (-2.026) are similar in solubility.
10. **hERG:** Ligand A (0.687) has a lower hERG risk than Ligand B (0.217), which is favorable for cardiac safety.
11. **Cl_mic:** Ligand A (26.521) has a lower microsomal clearance than Ligand B (11.248), suggesting better metabolic stability.
12. **t1/2:** Ligand A (-5.189) has a longer in vitro half-life than Ligand B (-14.304).
13. **Pgp:** Ligand A (0.065) has lower P-gp efflux than Ligand B (0.044), indicating better bioavailability.
14. **Affinity:** Both ligands have very similar binding affinities (-7.1 kcal/mol and -6.9 kcal/mol). The difference is less than the 1.5 kcal/mol threshold.
**Conclusion:**
Ligand A is significantly better overall. It has a more favorable profile across most key ADME properties (TPSA, logP, DILI, BBB, Cl_mic, t1/2, Pgp) and a better QED score, while maintaining comparable binding affinity to Ligand B. Ligand B's low logP and high DILI risk are major concerns.
**Output:**
1
2025-04-17 21:33:43,426 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A Analysis:**
* **MW:** 361.519 Da - Within the ideal range (200-500).
* **TPSA:** 73.45 - Acceptable, but approaching the upper limit for good oral absorption.
* **logP:** 1.977 - Good, within the optimal range of 1-3.
* **HBD:** 1 - Excellent.
* **HBA:** 8 - Acceptable.
* **QED:** 0.725 - Very good, indicates a strong drug-like profile.
* **DILI:** 52.152 - Good, low risk.
* **BBB:** 59.131 - Moderate, not ideal for a CNS target, but acceptable for a cardiovascular target.
* **Caco-2:** -5.809 - Poor permeability. A significant concern.
* **Solubility:** -2.665 - Poor solubility. A significant concern.
* **hERG:** 0.102 - Very low risk. Excellent.
* **Cl_mic:** 46.809 - Moderate clearance.
* **t1/2:** -5.245 - Short half-life.
* **Pgp:** 0.177 - Low efflux.
* **Affinity:** -5.8 kcal/mol - Good binding affinity.
**Ligand B Analysis:**
* **MW:** 361.486 Da - Within the ideal range (200-500).
* **TPSA:** 59.22 - Excellent, well below the 140 threshold.
* **logP:** 3.815 - Slightly high, approaching the upper limit. Could potentially cause solubility or off-target issues.
* **HBD:** 1 - Excellent.
* **HBA:** 4 - Excellent.
* **QED:** 0.762 - Very good, indicates a strong drug-like profile.
* **DILI:** 42.962 - Good, low risk.
* **BBB:** 86.817 - Excellent, high penetration.
* **Caco-2:** -5.158 - Poor permeability. A significant concern.
* **Solubility:** -3.705 - Very poor solubility. A significant concern.
* **hERG:** 0.964 - Moderate risk.
* **Cl_mic:** 87.657 - High clearance.
* **t1/2:** 18.576 - Long half-life.
* **Pgp:** 0.595 - Moderate efflux.
* **Affinity:** -8.0 kcal/mol - Excellent binding affinity, significantly stronger than Ligand A.
**Comparison and Decision:**
Both ligands have significant issues with Caco-2 permeability and aqueous solubility. However, Ligand B has a substantially better binding affinity (-8.0 kcal/mol vs -5.8 kcal/mol). This 2.2 kcal/mol difference is a large advantage, and can often outweigh other drawbacks, especially for a GPCR target where potency is critical. Ligand B also has a much longer half-life, which is desirable. While Ligand B has slightly higher logP and moderate hERG risk, these are less concerning than the poor permeability and solubility of Ligand A. The higher BBB penetration of Ligand B is also a plus, even for a cardiovascular target, as it suggests better overall distribution.
Therefore, despite the drawbacks, Ligand B is the more promising candidate due to its superior binding affinity and longer half-life.
Output:
0
2025-04-17 21:33:43,426 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.435 and 351.407 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (96.33) is better than Ligand B (123.58). ADRB2 is not a CNS target, but lower TPSA generally favors absorption.
3. **logP:** Ligand A (-0.014) is slightly lower than Ligand B (0.719). Both are within the 1-3 range, but Ligand B is closer to optimal.
4. **HBD:** Both ligands have 2 HBD, which is within the acceptable limit of <=5.
5. **HBA:** Ligand A has 5 HBA, and Ligand B has 7. Both are within the acceptable limit of <=10, but Ligand A is better.
6. **QED:** Ligand B (0.819) has a better QED score than Ligand A (0.69), indicating a more drug-like profile.
7. **DILI:** Ligand A (32.648) has a significantly lower DILI risk than Ligand B (63.28). This is a major advantage for Ligand A.
8. **BBB:** This is less critical for ADRB2, but Ligand B (75.611) has a higher BBB penetration than Ligand A (53.974).
9. **Caco-2:** Both ligands have similar, poor Caco-2 permeability (-5.218 and -5.057).
10. **Solubility:** Ligand A (-1) has better solubility than Ligand B (-3.086).
11. **hERG:** Ligand A (0.023) has a lower hERG risk than Ligand B (0.178). This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand B (3.707) has a much lower microsomal clearance than Ligand A (8.121), indicating better metabolic stability.
13. **t1/2:** Ligand A (34.306) has a much longer in vitro half-life than Ligand B (0.204). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (-6.4) has a lower Pgp efflux liability than Ligand B (-0.007).
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.4 and -6.0 kcal/mol). The difference is less than 1.5 kcal/mol, so it's not a deciding factor.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand B has a slightly better logP, and BBB, while Ligand A has better TPSA and Pgp. The affinities are similar. However, the significant advantages of Ligand A in terms of DILI risk, hERG risk, solubility, and *especially* in vitro half-life outweigh the minor benefits of Ligand B. The longer half-life is crucial for dosing convenience.
**Conclusion:**
Ligand A is the more promising candidate due to its superior safety profile (lower DILI and hERG), better solubility, and significantly longer half-life, despite Ligand B having a slightly better QED and logP.
Output:
1
2025-04-17 21:33:43,426 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [340.387, 103.87 , 0.998, 2. , 5. , 0.864, 64.521, 54.013, -5.284, -3.182, 0.135, 15.217, -10.197, 0.027, -6.8 ]
**Ligand B:** [345.374, 75.44 , 2.086, 1. , 4. , 0.921, 53.083, 75.029, -4.613, -2.839, 0.366, 29.29 , -9.988, 0.127, -6. ]
Here's a breakdown, comparing each parameter and considering GPCR priorities (logP, Pgp, TPSA, affinity):
1. **MW:** Both are within the ideal 200-500 Da range. A (340.39) is slightly lower, which is generally favorable.
2. **TPSA:** A (103.87) is higher than B (75.44). For a cardiovascular GPCR, TPSA isn't *as* critical as for a CNS target, but lower is still preferred for permeability. B is better here.
3. **logP:** A (0.998) is lower than B (2.086). A is a bit low, potentially impacting membrane permeability. B is closer to the optimal 1-3 range. B is better.
4. **HBD:** A (2) is slightly higher than B (1). Both are acceptable.
5. **HBA:** A (5) is slightly higher than B (4). Both are acceptable.
6. **QED:** Both are excellent, above 0.8, indicating good drug-like properties.
7. **DILI:** A (64.521) is slightly higher than B (53.083), indicating a slightly higher risk of liver injury. B is better.
8. **BBB:** A (54.013) is significantly lower than B (75.029). While ADRB2 isn't exclusively a CNS target, some brain exposure can be relevant for peripheral effects. B is better.
9. **Caco-2:** A (-5.284) is worse than B (-4.613). Lower values suggest poorer permeability. B is better.
10. **Solubility:** A (-3.182) is worse than B (-2.839). Lower values suggest poorer solubility. B is better.
11. **hERG:** A (0.135) is much lower than B (0.366), indicating a lower risk of hERG inhibition and cardiotoxicity. A is better.
12. **Cl_mic:** A (15.217) is significantly lower than B (29.29), suggesting better metabolic stability. A is better.
13. **t1/2:** A (-10.197) is better than B (-9.988), indicating a longer half-life. A is better.
14. **Pgp:** A (0.027) is much lower than B (0.127), indicating lower P-glycoprotein efflux and potentially better bioavailability. A is better.
15. **Affinity:** A (-6.8) is slightly better than B (-6.0), indicating a stronger binding affinity.
**Overall Assessment:**
Ligand A has a clear advantage in binding affinity, metabolic stability (Cl_mic), half-life, Pgp efflux, and hERG inhibition. These are all crucial factors. Ligand B excels in TPSA, logP, BBB, solubility, and DILI risk. While the improvements in those parameters for B are good, the binding affinity difference and the ADME advantages of A are more significant for a GPCR target. The slightly higher DILI risk for A is a concern, but can be addressed in later optimization stages. The better affinity and ADME profile of A outweigh the slightly higher DILI risk.
Therefore, I would choose Ligand A.
1
2025-04-17 21:33:43,427 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's break down the comparison of Ligand A and Ligand B, considering the provided guidelines and the GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key).
1. **Molecular Weight:** Both ligands (397.65 & 364.52 Da) fall comfortably within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (80.91) is slightly higher than Ligand B (60.25). Both are acceptable for a non-CNS target like ADRB2, being under 140, but B is better.
3. **logP:** Both ligands have good logP values (3.95 & 3.14), falling within the optimal 1-3 range. A is slightly higher, which could potentially lead to off-target effects, but it's not a major concern.
4. **H-Bond Donors/Acceptors:** Ligand A has 1 HBD and 5 HBA, while Ligand B has 0 HBD and 6 HBA. Both are within acceptable limits.
5. **QED:** Both ligands have similar QED values (0.659 and 0.686), indicating good drug-likeness.
6. **DILI Risk:** Ligand B (39.43) has a significantly lower DILI risk than Ligand A (84.37). This is a major advantage for Ligand B.
7. **BBB Penetration:** Both have moderate BBB penetration (62.97 and 69.64). Since ADRB2 is not a primary CNS target, this is less critical.
8. **Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.819 and -4.759). This is unusual and suggests poor permeability. However, these values are on a log scale and close to zero, so it's not necessarily a deal-breaker, but a concern.
9. **Aqueous Solubility:** Both have negative solubility values (-5.104 and -2.823), indicating poor aqueous solubility. This is a significant drawback for both, potentially impacting bioavailability.
10. **hERG Inhibition:** Both ligands exhibit low hERG inhibition risk (0.619 and 0.521).
11. **Microsomal Clearance:** Ligand B (95.77) has a much higher microsomal clearance than Ligand A (57.01). This suggests Ligand B will be metabolized more quickly, potentially requiring more frequent dosing.
12. **In vitro Half-Life:** Ligand A (21.26) has a significantly longer in vitro half-life than Ligand B (4.24). This is a substantial advantage for Ligand A.
13. **P-gp Efflux:** Both ligands have low P-gp efflux liability (0.265 and 0.523).
14. **Binding Affinity:** Ligand B (-7.1 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.2 kcal/mol). This is a crucial advantage, as a 0.9 kcal/mol difference is substantial.
**Overall Assessment:**
Ligand B has a superior binding affinity and a much lower DILI risk. While its metabolic clearance is higher and half-life shorter, the strong binding and safety profile outweigh these drawbacks. Both compounds have solubility and permeability concerns, but these can be addressed through formulation strategies. The improved affinity of Ligand B is likely to translate to greater efficacy at lower doses, potentially mitigating some of the concerns around its faster clearance.
Output:
0
2025-04-17 21:33:43,427 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (348.447 and 347.415 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (88.76) is slightly higher than Ligand B (80.76). Both are below the 140 threshold for good oral absorption, and reasonably good for a GPCR.
3. **logP:** Both ligands have good logP values (1.318 and 1.115), falling within the optimal 1-3 range. No major difference.
4. **HBD:** Both ligands have 1 H-bond donor, which is acceptable.
5. **HBA:** Both ligands have 5 H-bond acceptors, which is acceptable.
6. **QED:** Both ligands have high QED scores (0.867 and 0.807), indicating good drug-like properties.
7. **DILI:** Ligand A (47.654) has a slightly higher DILI risk than Ligand B (30.593), but both are below the concerning threshold of 60.
8. **BBB:** Ligand A (81.388) has significantly better BBB penetration potential than Ligand B (60.876). While ADRB2 isn't exclusively a CNS target, some CNS exposure might be acceptable or even desirable for certain cardiovascular indications (e.g., centrally mediated effects on blood pressure).
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.623 and -4.604). This is unusual and suggests very poor permeability. However, these values are close enough that they don't significantly differentiate the compounds.
10. **Solubility:** Ligand A (-1.029) has slightly better solubility than Ligand B (-1.952), although both are poor.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.606 and 0.307), which is excellent.
12. **Cl_mic:** Ligand A (29.016) has slightly higher microsomal clearance than Ligand B (27.159). This suggests slightly lower metabolic stability for Ligand A.
13. **t1/2:** Ligand B (6.066) has a significantly longer in vitro half-life than Ligand A (-20.421). This is a major advantage for Ligand B.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.047 and 0.014).
15. **Binding Affinity:** Both ligands have identical binding affinities (-6.5 kcal/mol).
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Both ligands perform similarly on logP, TPSA, and Pgp. Affinity is identical. BBB penetration is a bonus, and Ligand A has a clear advantage there. However, the significantly longer half-life of Ligand B is a crucial factor. Metabolic stability is very important for *in vivo* efficacy, and a longer half-life translates to less frequent dosing.
**Conclusion:**
While Ligand A has slightly better BBB penetration and solubility, the significantly longer half-life of Ligand B outweighs these advantages. The similar permeability profiles (both poor) make the half-life difference even more important.
Output:
0
2025-04-17 21:33:43,427 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [369.447, 126.65 , 0.637, 3. , 7. , 0.605, 64.831, 64.637, -5.343, -2.704, 0.301, 13.081, -11.135, 0.072, -5.5 ]
**Ligand B:** [364.833, 82.61 , 0.475, 1. , 4. , 0.77 , 30.942, 33.346, -5.122, -2.399, 0.081, -6.818, 7.713, 0.004, -6.2 ]
Here's a breakdown, considering the guidelines and GPCR priorities (logP, Pgp, TPSA, affinity):
1. **MW:** Both are within the ideal range (369.45 and 364.83 Da). No significant difference.
2. **TPSA:** Ligand A (126.65) is higher than Ligand B (82.61). Ligand B is much better, being well below the 140 threshold for oral absorption and closer to the ideal for GPCRs.
3. **logP:** Ligand A (0.637) is slightly higher than Ligand B (0.475), both are on the lower end of the optimal range.
4. **HBD:** Ligand A (3) is higher than Ligand B (1). Ligand B is preferable.
5. **HBA:** Ligand A (7) is higher than Ligand B (4). Ligand B is preferable.
6. **QED:** Ligand B (0.77) is better than Ligand A (0.605), indicating a more drug-like profile.
7. **DILI:** Ligand A (64.831) has a significantly higher DILI risk than Ligand B (30.942). This is a major concern for Ligand A.
8. **BBB:** Ligand A (64.637) and Ligand B (33.346) are both low, but not a primary concern for a cardiovascular target.
9. **Caco-2:** Both are negative, indicating poor permeability.
10. **Solubility:** Both are negative, indicating poor solubility.
11. **hERG:** Both are very low, indicating low risk of hERG inhibition.
12. **Cl_mic:** Ligand B (-6.818) has a *much* lower (better) microsomal clearance than Ligand A (13.081), suggesting better metabolic stability.
13. **t1/2:** Ligand B (7.713) has a better in vitro half-life than Ligand A (-11.135).
14. **Pgp:** Ligand A (0.072) has slightly higher Pgp efflux than Ligand B (0.004), but both are very low.
15. **Affinity:** Ligand B (-6.2) has a slightly better binding affinity than Ligand A (-5.5).
**Overall Assessment:**
Ligand B is significantly better. It has a much lower DILI risk, better metabolic stability (lower Cl_mic, longer t1/2), a better QED score, and lower TPSA. While both have poor Caco-2 and solubility, the ADME profile of Ligand B is far superior, and its slightly better binding affinity further supports its selection. The lower HBD and HBA counts in Ligand B are also favorable.
Output:
0
2025-04-17 21:33:43,427 - INFO - Batch 267 complete. Total preferences: 4272
2025-04-17 21:33:43,428 - INFO - Processing batch 268/512...
2025-04-17 21:34:28,945 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Step-by-step comparison:**
1. **MW:** Both ligands (349.475 and 349.435 Da) fall comfortably within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (74.57) is better than Ligand B (80.56). Both are under the 140 A^2 threshold for good oral absorption, but lower TPSA is generally preferred for GPCRs, potentially aiding BBB penetration.
3. **logP:** Ligand A (2.026) is slightly higher than Ligand B (1.192), both within the optimal 1-3 range. Ligand A is better here.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (0). Both are acceptable, but lower is generally preferred to avoid potential metabolic liabilities. Ligand B is better here.
5. **HBA:** Ligand A (4) is lower than Ligand B (6). Lower HBA is generally preferred for better permeability. Ligand A is better here.
6. **QED:** Both ligands have very similar QED values (0.791 and 0.798), indicating good drug-likeness. No significant difference.
7. **DILI:** Ligand A (36.642) has a lower DILI risk than Ligand B (42.924). Both are below the 60 threshold, but lower is always better. Ligand A is better here.
8. **BBB:** Ligand B (70.88) has significantly better BBB penetration potential than Ligand A (35.052). This is a *major* advantage for a GPCR target, even if not strictly CNS-focused, as it can influence off-target effects and distribution.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.747 and -4.737). This is unusual and suggests poor permeability. It's difficult to interpret without further information, but it's a concern for both.
10. **Solubility:** Ligand A (-2.569) has slightly better solubility than Ligand B (-1.585), but both are very poor. This is a significant drawback for both compounds.
11. **hERG:** Ligand A (0.398) has a slightly lower hERG risk than Ligand B (0.089). Lower is better. Ligand A is better here.
12. **Cl_mic:** Ligand B (20.37) has significantly lower microsomal clearance than Ligand A (42.384), indicating better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand A (19.493) has a longer in vitro half-life than Ligand B (1.019). This is a significant advantage.
14. **Pgp:** Ligand A (0.206) has lower P-gp efflux liability than Ligand B (0.045). Lower is better. Ligand A is better here.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.6 and -6.5 kcal/mol). The difference is negligible.
**Overall Assessment & GPCR Prioritization:**
For ADRB2 (a GPCR), BBB penetration, logP, and metabolic stability are key. Ligand B excels in BBB penetration and has much better metabolic stability (lower Cl_mic). Ligand A has advantages in TPSA, logP, DILI, hERG, Pgp, and t1/2. The solubility and Caco-2 values are poor for both, but the BBB advantage of Ligand B is substantial. While Ligand A has more favorable ADME properties overall, the improved BBB penetration of Ligand B is a critical factor for a GPCR target. The longer half-life of Ligand A is also a benefit. However, the significantly better metabolic stability of Ligand B outweighs the half-life advantage.
Considering the balance, I believe Ligand B is the more promising candidate.
Output:
0
2025-04-17 21:34:28,945 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.503 and 347.419 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (69.64) is significantly better than Ligand B (89.35). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (2.495) is optimal, while Ligand B (0.71) is a bit low. A logP below 1 can sometimes hinder membrane permeability.
4. **HBD:** Both ligands have acceptable HBD counts (2 and 1, respectively), well below the threshold of 5.
5. **HBA:** Ligand A (3) is better than Ligand B (6), as lower HBA is preferable.
6. **QED:** Both ligands have good QED scores (0.661 and 0.866), indicating good drug-like properties. Ligand B is slightly better here.
7. **DILI:** Ligand A (9.306) has a much lower DILI risk than Ligand B (47.926). This is a significant advantage for Ligand A.
8. **BBB:** Both ligands have similar BBB penetration (72.78 and 73.517). Not a major factor for a cardiovascular target.
9. **Caco-2:** Ligand A (-4.726) and Ligand B (-5.076) are both very poor. This is a concern for both, but the difference is minimal.
10. **Solubility:** Ligand A (-2.3) is slightly better than Ligand B (-1.681), but both are poor.
11. **hERG:** Ligand A (0.411) has a lower hERG risk than Ligand B (0.099). This is a crucial advantage for Ligand A.
12. **Cl_mic:** Ligand B (30.776) has lower microsomal clearance than Ligand A (36.661), indicating better metabolic stability.
13. **t1/2:** Ligand B (5.379) has a much longer in vitro half-life than Ligand A (-14.784). This is a significant advantage for Ligand B.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.07 and 0.032).
15. **Binding Affinity:** Ligand B (-7.0) has a slightly better binding affinity than Ligand A (-6.8), but the difference is relatively small (0.2 kcal/mol).
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A has better logP and TPSA, while Ligand B has slightly better affinity and metabolic stability. However, the significantly lower DILI and hERG risk of Ligand A are crucial safety factors.
**Overall Assessment:**
While Ligand B has a slightly better binding affinity and half-life, the superior safety profile of Ligand A (lower DILI and hERG) and its better physicochemical properties (logP, TPSA) make it the more promising drug candidate. The small affinity difference can likely be optimized in subsequent iterations of drug design. The safety concerns with Ligand B are more difficult to address.
Output:
1
2025-04-17 21:34:28,945 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (337.423 and 343.391 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (55.2) is significantly better than Ligand B (105.9). For a GPCR, lower TPSA is generally preferred for better permeability. Ligand A is well below the 140 threshold, while Ligand B is approaching it.
3. **logP:** Ligand A (3.11) is within the optimal 1-3 range. Ligand B (0.186) is quite low, potentially hindering membrane permeability and absorption. This is a significant drawback for Ligand B.
4. **HBD:** Ligand A (0) is preferable to Ligand B (1). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is better than Ligand B (7). Lower HBA counts contribute to better permeability.
6. **QED:** Both ligands have similar QED values (0.865 and 0.83), indicating good drug-likeness.
7. **DILI:** Both ligands have similar DILI risk (34.432 and 80.07). Ligand B is slightly higher, but both are acceptable.
8. **BBB:** Ligand A (80.264) has a much better BBB penetration percentile than Ligand B (41.024). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be beneficial, and avoiding it isn't a priority.
9. **Caco-2:** Ligand A (-4.676) is better than Ligand B (-5.502). Higher Caco-2 permeability suggests better absorption.
10. **Solubility:** Ligand A (-3.38) is better than Ligand B (-1.509). Higher solubility is generally desirable.
11. **hERG:** Ligand A (0.434) is significantly better than Ligand B (0.101). Lower hERG inhibition is crucial to avoid cardiotoxicity, a major concern for cardiovascular targets.
12. **Cl_mic:** Ligand A (28.973) has a lower microsomal clearance than Ligand B (3.343), indicating better metabolic stability.
13. **t1/2:** Ligand A (6.424) has a longer in vitro half-life than Ligand B (4.695).
14. **Pgp:** Ligand A (0.226) is better than Ligand B (0.009). Lower P-gp efflux is desirable for improved bioavailability.
15. **Affinity:** Ligand B (-8.1 kcal/mol) has a slightly better binding affinity than Ligand A (-7.3 kcal/mol). This is a 0.8 kcal/mol difference, which is not substantial enough to overcome the many ADME deficiencies of Ligand B.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most crucial ADME properties (TPSA, logP, HBD, HBA, BBB, solubility, hERG, Cl_mic, t1/2, Pgp). While Ligand B has a slightly better binding affinity, the differences in ADME properties are substantial enough to significantly impact its potential as a viable drug candidate. The lower logP and higher TPSA of Ligand B are particularly concerning for oral bioavailability and membrane permeability. Ligand A presents a much more balanced profile.
Output:
1
2025-04-17 21:34:28,945 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.519 Da and 346.471 Da) are within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Both ligands (69.64 and 67.43) are below the 140 A^2 threshold for good oral absorption, and acceptable for a cardiovascular GPCR. Ligand B is slightly better.
3. **logP:** Both ligands (2.717 and 3.034) fall within the optimal 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability but needs to be balanced with solubility.
4. **HBD:** Both have 2 HBD, which is within the acceptable limit of <=5.
5. **HBA:** Both have 3 HBA, which is within the acceptable limit of <=10.
6. **QED:** Ligand A (0.772) has a slightly higher QED than Ligand B (0.684), indicating a more drug-like profile.
7. **DILI:** Both ligands have very similar, and acceptable, DILI risk (14.618% and 14.851%, both <40).
8. **BBB:** Ligand B (73.943%) has a higher BBB penetration percentile than Ligand A (69.833%). While ADRB2 isn't a CNS target, some off-target CNS effects are always a consideration, and higher BBB penetration *could* be a slight negative. However, for a cardiovascular target, this isn't a major concern.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual. This suggests poor permeability. Ligand A (-4.564) is slightly better than Ligand B (-4.291), but both are concerning.
10. **Solubility:** Both ligands have negative solubility values, which is also unusual and concerning. Ligand B (-3.342) is slightly better than Ligand A (-2.798), but both are problematic.
11. **hERG:** Both ligands have low hERG inhibition liability (0.33 and 0.44), which is excellent.
12. **Cl_mic:** Ligand A (47.074 mL/min/kg) has a significantly lower microsomal clearance than Ligand B (92.946 mL/min/kg), suggesting better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand A (3.473 hours) has a shorter half-life than Ligand B (-21.115 hours). The negative value for Ligand B is likely an error or outlier, and should be interpreted as a very long half-life. This is a major advantage for Ligand B.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.099 and 0.134), which is good.
15. **Binding Affinity:** Ligand B (-7.6 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.9 kcal/mol). This 1.7 kcal/mol difference is substantial and outweighs many of the minor ADME drawbacks.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in affinity and has acceptable logP and Pgp. While solubility and Caco-2 are concerns for both, the much stronger binding affinity of Ligand B is a critical advantage. The longer half-life is also a significant benefit.
**Conclusion:**
Despite the concerning solubility and Caco-2 values for both, the significantly improved binding affinity and longer half-life of Ligand B make it the more promising drug candidate. The higher affinity is likely to translate to greater efficacy, and the longer half-life could allow for less frequent dosing.
Output:
0
2025-04-17 21:34:28,946 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (344.46 and 356.42 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (67.43) is significantly better than Ligand B (97.33). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold. Ligand B is approaching it, but is less desirable.
3. **logP:** Ligand A (2.005) is within the optimal 1-3 range. Ligand B (-0.705) is below 1, which could hinder permeability. This is a significant drawback for Ligand B.
4. **HBD:** Both ligands have 2 HBD, which is acceptable.
5. **HBA:** Ligand A has 3 HBA, while Ligand B has 6. Ligand A is preferable here; fewer HBA generally means better permeability.
6. **QED:** Ligand A (0.638) is slightly better than Ligand B (0.597), indicating a more drug-like profile.
7. **DILI:** Ligand A (23.89%) has a much lower DILI risk than Ligand B (16.01%). This is a crucial advantage for Ligand A.
8. **BBB:** Not a primary concern for a cardiovascular target, but Ligand A (67.58%) has a higher BBB percentile than Ligand B (33.97%).
9. **Caco-2:** Ligand A (-4.648) and Ligand B (-5.032) are both negative, indicating poor permeability. However, the scale is not specified, so it is difficult to interpret.
10. **Solubility:** Ligand A (-3.022) and Ligand B (-0.468) are both negative, indicating poor solubility. However, the scale is not specified, so it is difficult to interpret.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.338 and 0.127, respectively), which is excellent.
12. **Cl_mic:** Ligand B (-4.586) has a *lower* (better) microsomal clearance than Ligand A (66.721). This suggests better metabolic stability for Ligand B.
13. **t1/2:** Ligand A (-4.481) has a longer in vitro half-life than Ligand B (22.44). This is a significant advantage for Ligand A.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.158 and 0.008, respectively).
15. **Binding Affinity:** Ligand A (-6.9 kcal/mol) has a slightly better binding affinity than Ligand B (-5.8 kcal/mol). While the difference is not huge, it's enough to be considered.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are important. Ligand A clearly wins on logP and TPSA. The affinity difference is moderate, but favors Ligand A. While metabolic stability (Cl_mic) is important, the significant advantages of Ligand A in other areas, particularly DILI risk and TPSA, outweigh the better clearance of Ligand B.
**Conclusion:**
Ligand A is the more promising candidate due to its superior logP, TPSA, lower DILI risk, longer half-life, and slightly better binding affinity.
Output:
1
2025-04-17 21:34:28,946 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (348-349 Da). No significant difference.
2. **TPSA:** Ligand A (41.99) is significantly better than Ligand B (107.19). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand B's TPSA is quite high.
3. **logP:** Ligand A (4.88) is higher than Ligand B (0.249). While 4.88 is approaching the upper limit, it's still acceptable. Ligand B's logP is very low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (2) is preferable to Ligand B (4). Similar reasoning as HBD.
6. **QED:** Ligand A (0.856) is better than Ligand B (0.625), indicating a more drug-like profile.
7. **DILI:** Ligand B (51.881) is slightly better than Ligand A (59.131), but both are acceptable.
8. **BBB:** Ligand A (86.39) is better than Ligand B (60.876). Although not a CNS target, some degree of BBB penetration can sometimes be beneficial for distribution.
9. **Caco-2:** Ligand A (-4.517) is better than Ligand B (-5.301). Higher (less negative) Caco-2 values indicate better permeability.
10. **Solubility:** Ligand A (-5.971) is better than Ligand B (-2.259). Better solubility is always preferred.
11. **hERG:** Ligand A (0.719) is better than Ligand B (0.268). Lower hERG inhibition is crucial for avoiding cardiotoxicity, especially for a cardiovascular target.
12. **Cl_mic:** Ligand B (37.429) is better than Ligand A (55.35). Lower clearance is desirable for longer duration of action.
13. **t1/2:** Ligand A (26.64) is slightly better than Ligand B (26.342).
14. **Pgp:** Ligand A (0.407) is better than Ligand B (0.045). Lower P-gp efflux is preferred for better bioavailability.
15. **Affinity:** Ligand B (-5.7) is slightly better than Ligand A (-5.4). This is a 0.3 kcal/mol difference, which is not substantial enough to outweigh the numerous ADME advantages of Ligand A.
**GPCR-specific priorities:** For ADRB2 (a cardiovascular GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A excels in logP, TPSA, and Pgp, and has acceptable affinity. Ligand B has a poor logP and high TPSA. While Ligand B has slightly better affinity and clearance, the overall ADME profile of Ligand A is far superior.
**Conclusion:**
Ligand A is the more promising drug candidate due to its significantly better ADME properties, particularly its TPSA, logP, solubility, and hERG risk profile, which are crucial for a cardiovascular GPCR target. The small affinity difference is not enough to overcome Ligand B's deficiencies.
Output:
1
2025-04-17 21:34:28,946 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (377.413 Da and 370.559 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (87.74) is slightly higher than Ligand B (58.64). For a cardiovascular GPCR, TPSA isn't a *major* concern (unlike a CNS target), but lower is generally preferable for absorption. Ligand B is better here.
**3. logP:** Both ligands have good logP values (1.715 and 2.69, respectively), falling within the optimal 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability.
**4. H-Bond Donors:** Ligand A has 2 HBDs, while Ligand B has 1. Both are acceptable (<=5).
**5. H-Bond Acceptors:** Both ligands have 4 HBAs, well within the acceptable limit of <=10.
**6. QED:** Both ligands have reasonable QED values (0.79 and 0.678), indicating good drug-like properties. Ligand A is slightly better.
**7. DILI Risk:** Ligand A (58.434) has a higher DILI risk than Ligand B (9.888). This is a significant concern, as minimizing liver toxicity is crucial. Ligand B is *much* better here.
**8. BBB Penetration:** BBB isn't a primary concern for a cardiovascular target. Ligand A (67.468) and Ligand B (83.56) are both relatively low, which is expected and acceptable. Ligand B is slightly better.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.899 and -5.016). This is unusual and suggests poor permeability. However, these values are on a log scale, so the difference isn't massive.
**10. Aqueous Solubility:** Both ligands have negative solubility values (-2.489 and -2.669). This suggests poor aqueous solubility, which could be a formulation challenge.
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (0.441 and 0.551), which is good.
**12. Microsomal Clearance:** Ligand A (3.98) has significantly lower microsomal clearance than Ligand B (50.06). This suggests better metabolic stability for Ligand A.
**13. In vitro Half-Life:** Ligand A (-16.186) has a much longer in vitro half-life than Ligand B (-3.887). This is a major advantage for Ligand A, potentially allowing for less frequent dosing.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.049 and 0.103).
**15. Binding Affinity:** Ligand A (-6.0) has a slightly better binding affinity than Ligand B (-3.1). This is a substantial difference, and a >3 kcal/mol advantage can often outweigh other drawbacks.
**Overall Assessment:**
While Ligand A has better affinity and metabolic stability (lower Cl_mic, longer t1/2), the significantly higher DILI risk associated with Ligand A is a major red flag. The slightly better TPSA and dramatically lower DILI risk of Ligand B make it the more promising candidate, despite its lower affinity and faster clearance. For a cardiovascular target, minimizing toxicity is paramount.
Output:
0
2025-04-17 21:34:28,946 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (340.423 and 354.422 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (62.55) is significantly better than Ligand B (75.71). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (3.147 and 2.112), falling within the 1-3 range. Ligand A is slightly higher, potentially aiding membrane permeability.
4. **HBD:** Both have 1 HBD, which is within the acceptable limit of <=5.
5. **HBA:** Ligand A has 3 HBA, while Ligand B has 4. Both are acceptable (<=10), but A is slightly preferable.
6. **QED:** Ligand A (0.909) is significantly better than Ligand B (0.313), indicating a much more drug-like profile. This is a substantial advantage for A.
7. **DILI:** Ligand A (33.773) has a lower DILI risk than Ligand B (44.591), which is desirable.
8. **BBB:** Ligand B (79.604) has a higher BBB penetration percentile than Ligand A (69.058). While ADRB2 isn't a CNS target, higher BBB isn't necessarily a negative.
9. **Caco-2:** Ligand A (-4.808) and Ligand B (-4.296) are both negative, which is unusual. Lower (more negative) values indicate poorer permeability. This is a concern for both, but A is slightly worse.
10. **Solubility:** Ligand A (-3.376) has slightly better solubility than Ligand B (-2.262), although both are poor.
11. **hERG:** Both ligands have low hERG inhibition risk (0.73 and 0.488), which is good.
12. **Cl_mic:** Ligand A (42.387) has a lower microsomal clearance than Ligand B (84.462), suggesting better metabolic stability. This is a significant advantage for A.
13. **t1/2:** Ligand A (-5.531) has a much longer in vitro half-life than Ligand B (-19.076). This is a substantial advantage for A.
14. **Pgp:** Ligand A (0.445) has lower P-gp efflux liability than Ligand B (0.243), which is favorable.
15. **Binding Affinity:** Ligand A (-7.0) has slightly better binding affinity than Ligand B (-5.8). While the difference is not huge, it is still a benefit.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A performs better on TPSA, Pgp, and has comparable logP. The affinity difference, while not enormous, favors A. The QED and metabolic stability (Cl_mic, t1/2) are also significantly better for A.
**Conclusion:**
Ligand A consistently outperforms Ligand B across most critical ADME and binding parameters. While Ligand B has slightly better BBB penetration, this is less important for a cardiovascular target. The superior QED, metabolic stability, half-life, and binding affinity of Ligand A make it the more promising drug candidate.
Output:
1
2025-04-17 21:34:28,946 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (347.5 and 345.4 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (43.86) is significantly better than Ligand B (75.44). For a GPCR, keeping TPSA lower is generally preferred for better permeability. Ligand B is quite high and could present absorption challenges.
**3. logP:** Both ligands have acceptable logP values (2.275 and 3.052, respectively), falling within the 1-3 range. Ligand B is slightly higher, which could potentially lead to off-target interactions, but isn't a major concern.
**4. H-Bond Donors:** Ligand A has 0 HBD, while Ligand B has 1. Both are acceptable, staying below the 5 threshold.
**5. H-Bond Acceptors:** Ligand A has 3 HBA, and Ligand B has 4. Both are within the acceptable limit of 10.
**6. QED:** Both ligands have good QED scores (0.717 and 0.832), indicating good drug-like properties.
**7. DILI Risk:** Ligand A (5.777) has a much lower DILI risk than Ligand B (42.536). This is a significant advantage for Ligand A.
**8. BBB Penetration:** Both ligands have very similar BBB penetration (81% and 80%). This isn't a primary concern for a cardiovascular target, but it's good to see reasonable values.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.59 and -4.824). This is unusual and suggests poor permeability. However, these values are on a log scale and may not be directly comparable.
**10. Aqueous Solubility:** Ligand A (-1.752) has better aqueous solubility than Ligand B (-3.406). Solubility is important for formulation and bioavailability.
**11. hERG Inhibition:** Ligand A (0.582) shows a lower risk of hERG inhibition compared to Ligand B (0.218). This is a critical safety parameter, and Ligand A is preferable.
**12. Microsomal Clearance:** Ligand A (23.524) has significantly lower microsomal clearance than Ligand B (67.817), indicating better metabolic stability.
**13. In vitro Half-Life:** Ligand A (22.791) has a longer in vitro half-life than Ligand B (-24.543). A longer half-life is generally desirable.
**14. P-gp Efflux:** Ligand A (0.052) shows lower P-gp efflux than Ligand B (0.139), which is beneficial for oral bioavailability.
**15. Binding Affinity:** Ligand B (-5.2) has a slightly better binding affinity than Ligand A (-4.8). While a 0.4 kcal/mol difference is noticeable, the other ADME properties of Ligand A are significantly more favorable.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity) and the general drug-like properties, Ligand A is the superior candidate. While Ligand B has slightly better affinity, Ligand A excels in crucial ADME properties like DILI risk, metabolic stability (Cl_mic and t1/2), solubility, hERG inhibition, and TPSA. The lower TPSA and DILI risk of Ligand A are particularly important advantages.
Output:
1
2025-04-17 21:34:28,946 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (364.37 and 382.51 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (85.25) is slightly higher than Ligand B (67.87). Both are below the 140 threshold for oral absorption, but B is better.
3. **logP:** Both ligands (1.26 and 1.75) are within the optimal 1-3 range. Ligand B is slightly more lipophilic.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1). Both are within the acceptable limit of 5.
5. **HBA:** Ligand A (5) is equal to Ligand B (6). Both are within the acceptable limit of 10.
6. **QED:** Ligand B (0.84) has a better QED score than Ligand A (0.646), indicating a more drug-like profile.
7. **DILI:** Ligand A (39.43) has a significantly lower DILI risk than Ligand B (74.18). This is a substantial advantage for Ligand A.
8. **BBB:** Ligand A (78.87) has a better BBB penetration score than Ligand B (56.34). While ADRB2 isn't strictly a CNS target, some CNS exposure can be beneficial or at least avoided as an off-target effect.
9. **Caco-2:** Ligand A (-4.909) is better than Ligand B (-5.257). Higher values indicate better intestinal absorption.
10. **Solubility:** Ligand A (-1.502) is better than Ligand B (-3.803). Higher values indicate better solubility.
11. **hERG:** Ligand A (0.686) has a lower hERG inhibition liability than Ligand B (0.342). Lower is better.
12. **Cl_mic:** Ligand A (29.97) has a lower microsomal clearance than Ligand B (40.64), suggesting better metabolic stability.
13. **t1/2:** Ligand B (36.28) has a significantly longer in vitro half-life than Ligand A (-23.28). This is a major advantage for Ligand B.
14. **Pgp:** Ligand A (0.152) has a lower P-gp efflux liability than Ligand B (0.184). Lower is better.
15. **Binding Affinity:** Ligand B (-6.8 kcal/mol) has a slightly better binding affinity than Ligand A (-7.0 kcal/mol). This difference is small.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B has a slightly better logP and affinity, and a lower TPSA. However, the significantly higher DILI risk and lower BBB penetration of Ligand B are concerning. Ligand A has a better safety profile (DILI, hERG) and better solubility, which are critical for drug development. The slightly longer half-life of Ligand B is attractive, but the other factors weigh more heavily in favor of Ligand A.
**Conclusion:**
Considering the balance of properties, especially the lower DILI risk and better safety profile of Ligand A, I believe it is the more viable drug candidate despite the slightly lower half-life.
Output:
1
2025-04-17 21:34:28,946 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (349.377 Da) is better than Ligand B (387.575 Da), falling comfortably within the 200-500 Da range.
2. **TPSA:** Ligand B (78.43) is higher than Ligand A (42.68). ADRB2 is not a CNS target, but lower TPSA generally aids absorption, giving an edge to Ligand A.
3. **logP:** Ligand A (4.511) is higher than Ligand B (1.957). While both are within the acceptable range, Ligand A is pushing the upper limit and could potentially have solubility issues. Ligand B is closer to optimal.
4. **HBD:** Ligand A (0) is better than Ligand B (1). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (3) is better than Ligand B (7). Lower HBA is preferred for permeability.
6. **QED:** Ligand A (0.815) is significantly better than Ligand B (0.653), indicating a more drug-like profile.
7. **DILI:** Ligand B (42.807) is significantly better than Ligand A (56.572), indicating a lower risk of drug-induced liver injury. This is a substantial advantage for Ligand B.
8. **BBB:** Not a primary concern for ADRB2 (cardiovascular target). Ligand A (86.429) is better than Ligand B (52.501) but this is less important.
9. **Caco-2:** Ligand A (-4.337) is better than Ligand B (-5.188), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-4.384) is better than Ligand B (-2.324), indicating better aqueous solubility.
11. **hERG:** Ligand A (0.8) is better than Ligand B (0.24), indicating a lower risk of hERG inhibition and cardiotoxicity.
12. **Cl_mic:** Ligand B (70.376) is better than Ligand A (65.884), indicating better metabolic stability.
13. **t1/2:** Ligand A (50.728) is better than Ligand B (31.689), indicating a longer half-life.
14. **Pgp:** Ligand A (0.7) is better than Ligand B (0.099), indicating lower P-gp efflux.
15. **Affinity:** Ligand A (-7.8 kcal/mol) is significantly better than Ligand B (-6.9 kcal/mol). This is a substantial advantage.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has a higher logP, lower TPSA, better Pgp profile, and *much* better affinity. While Ligand B has a better DILI score, the affinity difference is substantial enough to outweigh this concern, especially considering the other favorable ADME properties of Ligand A.
**Conclusion:**
Ligand A is the more promising candidate due to its superior binding affinity, better drug-likeness (QED), favorable permeability characteristics (TPSA, Caco-2, Pgp), and acceptable ADME properties. The slightly higher logP and DILI risk are outweighed by the significant potency advantage and other favorable attributes.
Output:
1
2025-04-17 21:34:28,946 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**1. Molecular Weight:** Both ligands (361.345 and 360.376 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (102.69) is higher than Ligand B (69.64). For a GPCR, lower TPSA is generally preferred for better permeability, giving a slight edge to Ligand B.
**3. logP:** Ligand B (1.724) is slightly higher than Ligand A (0.871), both within the optimal 1-3 range. Ligand B is better here.
**4. H-Bond Donors:** Both ligands have 2 HBD, which is within the acceptable limit of <=5. No difference.
**5. H-Bond Acceptors:** Ligand A has 6 HBA, and Ligand B has 3. Both are below the 10 threshold, but Ligand B is better.
**6. QED:** Ligand A (0.712) has a better QED score than Ligand B (0.593), indicating a more drug-like profile. This favors Ligand A.
**7. DILI:** Ligand B (32.028) has a significantly lower DILI risk than Ligand A (63.086). This is a major advantage for Ligand B.
**8. BBB:** Ligand A (88.135) has a better BBB penetration percentile than Ligand B (70.997). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant, giving a slight edge to Ligand A.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.943 and -4.894), which is unusual and suggests poor permeability. However, the values are very similar.
**10. Aqueous Solubility:** Both ligands have negative solubility values (-2.174 and -1.669), again suggesting poor solubility. The values are very similar.
**11. hERG Inhibition:** Ligand A (0.261) has a slightly lower hERG inhibition risk than Ligand B (0.419), which is preferable.
**12. Microsomal Clearance:** Ligand B (-1.409) has a *much* lower (better) microsomal clearance than Ligand A (17.792). This indicates significantly improved metabolic stability for Ligand B.
**13. In vitro Half-Life:** Ligand B (-26.093) has a much longer in vitro half-life than Ligand A (16.907). This is a substantial advantage for Ligand B.
**14. P-gp Efflux:** Ligand A (0.04) has a slightly lower P-gp efflux liability than Ligand B (0.097), which is preferable.
**15. Binding Affinity:** Both ligands have very similar binding affinities (-6.9 and -6.8 kcal/mol). The difference is negligible.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp), Ligand B appears to be the better candidate. While Ligand A has a slightly better QED and BBB penetration, Ligand B's significantly lower DILI risk, dramatically improved metabolic stability (lower Cl_mic, longer t1/2), and better logP outweigh these advantages. The similar binding affinities mean potency isn't a differentiating factor. The poor Caco-2 and solubility are concerning for both, but can be addressed with formulation strategies.
Output:
0
2025-04-17 21:34:28,946 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.47 & 366.49 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (38.82) is significantly better than Ligand B (85.77). ADRB2 is not a CNS target, but lower TPSA generally improves absorption. Ligand A is well below the 140 threshold, while Ligand B is getting higher.
3. **logP:** Ligand A (1.548) is within the optimal 1-3 range. Ligand B (0.568) is slightly low, potentially hindering permeation.
4. **HBD:** Both are acceptable (1 and 2 respectively), below the threshold of 5.
5. **HBA:** Both are acceptable (4 and 6 respectively), below the threshold of 10.
6. **QED:** Both ligands have good QED scores (0.896 and 0.737), indicating good drug-like properties.
7. **DILI:** Ligand A (22.8) has a lower DILI risk than Ligand B (25.7). Both are acceptable, but A is preferable.
8. **BBB:** Not a primary concern for ADRB2 (cardiovascular target). Ligand A (83.6) is higher than Ligand B (21.7), but this is less important.
9. **Caco-2:** Ligand A (-4.749) is better than Ligand B (-5.283). Higher values are better, and both are negative, indicating permeability.
10. **Solubility:** Ligand A (-1.318) is slightly better than Ligand B (-1.048). Both are poor, but A is slightly less poor.
11. **hERG:** Ligand A (0.899) is better than Ligand B (0.446). Lower is better, indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand A (-6.38) is significantly better than Ligand B (-1.259). Lower clearance means greater metabolic stability.
13. **t1/2:** Ligand A (-9.27) is much better than Ligand B (6.879). A longer half-life is generally desirable.
14. **Pgp:** Ligand A (0.076) is better than Ligand B (0.054). Lower efflux is preferable.
15. **Affinity:** Ligand B (-6.5) has a slightly better binding affinity than Ligand A (-2.2). However, the difference is not substantial enough to outweigh the numerous ADME advantages of Ligand A.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical ADME properties (TPSA, logP, DILI, Cl_mic, t1/2, hERG, Pgp). While Ligand B has a slightly better binding affinity, the substantial improvements in drug-like characteristics and safety profile of Ligand A make it the more promising candidate. The difference in binding affinity is not large enough to overcome the ADME deficiencies of Ligand B.
Output:
1
2025-04-17 21:34:28,947 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for the ADRB2 receptor, a GPCR involved in cardiovascular function. Therefore, the priorities are logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB.
Let's break down the comparison:
1. **MW:** Both ligands (365.539 and 350.459 Da) fall within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (55.4) is significantly better than Ligand B (75.8). ADRB2 is not a CNS target, but lower TPSA generally correlates with better permeability.
3. **logP:** Ligand A (4.354) is higher than Ligand B (2.679). While both are within the acceptable range, Ligand A is pushing the upper limit and could present solubility challenges. Ligand B is closer to optimal.
4. **HBD/HBA:** Both have 1 HBD, which is good. Ligand B has 5 HBA vs. 3 for Ligand A. This is not a major differentiating factor.
5. **QED:** Both are very similar (0.815 and 0.818), indicating good drug-likeness.
6. **DILI:** Ligand B (10.508) has a *much* lower DILI risk than Ligand A (42.458). This is a significant advantage for Ligand B.
7. **BBB:** Both have moderate BBB penetration, but Ligand A (56.883) is lower than Ligand B (62.699). Not a huge factor for a cardiovascular target.
8. **Caco-2:** Both have negative Caco-2 values, suggesting poor permeability.
9. **Solubility:** Ligand B (-1.958) has better solubility than Ligand A (-4.955).
10. **hERG:** Both have low hERG inhibition risk (0.65 and 0.466).
11. **Cl_mic:** Ligand B (69.227) has lower microsomal clearance than Ligand A (87.445), indicating better metabolic stability.
12. **t1/2:** Ligand B (5.877) has a longer in vitro half-life than Ligand A (-46.601). This is a significant advantage.
13. **Pgp:** Ligand A (0.482) has lower P-gp efflux than Ligand B (0.199), which is preferable.
14. **Binding Affinity:** Ligand B (-6.6 kcal/mol) has a stronger binding affinity than Ligand A (-5.6 kcal/mol). This is a 1 kcal/mol difference, which is substantial.
**Overall Assessment:**
While Ligand A has a slightly better Pgp profile, Ligand B is superior in almost every other critical parameter. The significantly lower DILI risk, better solubility, improved metabolic stability (lower Cl_mic, longer t1/2), and stronger binding affinity of Ligand B outweigh the minor Pgp advantage of Ligand A. The lower TPSA of Ligand A is a benefit, but not enough to overcome the other deficiencies.
**Output:**
0
2025-04-17 21:34:28,947 - INFO - Here's my reasoning and the final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, key priorities are logP, TPSA, Pgp efflux, binding affinity, and, to a lesser extent, BBB.
Let's compare the ligands property by property:
1. **MW:** Both ligands (338.411 and 368.543 Da) fall within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (67.23) is slightly higher than Ligand B (58.64), but both are below the 140 threshold for good absorption.
3. **logP:** Both ligands have good logP values (2.037 and 2.466), falling within the 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability, but not significantly.
4. **HBD/HBA:** Both have 1 HBD and 4 HBA, which are acceptable.
5. **QED:** Ligand A (0.931) has a significantly higher QED score than Ligand B (0.669), indicating better overall drug-likeness.
6. **DILI:** Ligand A (59.713) has a higher DILI risk than Ligand B (13.61), which is a significant concern.
7. **BBB:** Both have acceptable BBB penetration (70.415 and 77.2), but this is less critical for a cardiovascular target.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual. I will interpret this as very low permeability.
9. **Solubility:** Both have negative solubility values, indicating very poor aqueous solubility.
10. **hERG:** Both ligands have low hERG inhibition risk (0.351 and 0.481).
11. **Cl_mic:** Ligand A (26.644) has a lower microsomal clearance than Ligand B (46.577), suggesting better metabolic stability.
12. **t1/2:** Ligand A (20.783) has a longer in vitro half-life than Ligand B (-5.769), which is a positive.
13. **Pgp:** Ligand A (0.235) has a lower P-gp efflux liability than Ligand B (0.085), which is favorable for bioavailability.
14. **Binding Affinity:** Ligand A (-8.5 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.9 kcal/mol). This is a substantial advantage.
**Overall Assessment:**
Despite the higher DILI risk for Ligand A, its significantly stronger binding affinity (-8.5 vs -6.9 kcal/mol) and better metabolic stability (lower Cl_mic, longer t1/2) are compelling. The improved QED and Pgp profile also contribute to its favorability. The poor Caco-2 and solubility are concerning for both, but the potency advantage of Ligand A is likely to outweigh these drawbacks, especially considering it's a GPCR target where high affinity is crucial. The DILI risk is a concern that would need to be addressed during further optimization.
**Output:**
1
2025-04-17 21:34:28,947 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (403.32 Da) and Ligand B (373.474 Da) both fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (58.2) and Ligand B (55.84) are both below the 140 A^2 threshold for good oral absorption, and suitable for a GPCR target. Ligand B is slightly better.
3. **logP:** Ligand A (4.121) is slightly above the optimal 1-3 range, while Ligand B (3.314) is within the optimal range. This favors Ligand B.
4. **HBD:** Ligand A (2) and Ligand B (0) are both acceptable. Lower HBD can sometimes improve permeability, so Ligand B is slightly favored.
5. **HBA:** Ligand A (2) and Ligand B (4) are both acceptable, below the 10 threshold.
6. **QED:** Ligand A (0.755) is better than Ligand B (0.613), indicating a more drug-like profile.
7. **DILI:** Ligand A (65.491) has a higher DILI risk than Ligand B (21.908). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (35.595) has a lower BBB penetration percentile than Ligand B (75.339). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be beneficial, and lower efflux is generally desirable. This favors Ligand B.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand A (-5.111) has worse solubility than Ligand B (-2.033). Solubility is important for bioavailability, favoring Ligand B.
11. **hERG:** Both ligands have low hERG inhibition risk (0.503 and 0.528 respectively). No clear advantage.
12. **Cl_mic:** Ligand A (60.886) and Ligand B (61.296) have similar microsomal clearance values, suggesting comparable metabolic stability.
13. **t1/2:** Ligand A (74.788) has a significantly longer in vitro half-life than Ligand B (14.526). This is a major advantage for Ligand A, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.237 and 0.298 respectively). No clear advantage.
15. **Binding Affinity:** Ligand A (-7.6 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.2 kcal/mol). This is a substantial advantage for Ligand A, potentially outweighing some of its ADME drawbacks.
**Overall Assessment:**
Ligand A has a much stronger binding affinity and a longer half-life, which are crucial for a GPCR target. However, it has a higher DILI risk and lower solubility. Ligand B has better ADME properties (lower DILI, better solubility, better BBB penetration, better logP) but a weaker binding affinity.
Given the importance of potency for GPCRs, the 1.4 kcal/mol difference in binding affinity is substantial. The longer half-life of Ligand A is also a significant benefit. While the DILI risk is a concern, it's not prohibitive, and could be addressed through further structural modifications. The solubility issue is also addressable with formulation strategies.
Therefore, I believe Ligand A is the more promising drug candidate.
Output:
1
2025-04-17 21:34:28,947 - INFO - Batch 268 complete. Total preferences: 4288
2025-04-17 21:34:28,947 - INFO - Processing batch 269/512...
2025-04-17 21:35:21,156 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [348.407, 118.01 , -0.587, 3. , 6. , 0.657, 41.062, 46.84 ,
-5.989, -0.582, 0.011, -35.362, 14.237, 0.005, -8.3 ]
**Ligand B:** [382.429, 84.94 , 0.561, 1. , 5. , 0.696, 42.536, 89.957,
-4.983, -2.632, 0.56 , -8.583, -14.5 , 0.04 , -8.1 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). A (348.4) is slightly preferred due to being closer to the lower end, potentially aiding permeability.
2. **TPSA:** A (118.01) is a bit higher than B (84.94). B is much better here, falling well below the 140 threshold for oral absorption and closer to the ideal for GPCRs.
3. **logP:** A (-0.587) is a concern, being slightly below the optimal range of 1-3. B (0.561) is better, falling within the acceptable range.
4. **HBD:** A (3) is reasonable. B (1) is excellent, minimizing potential issues with hydrogen bonding and improving permeability.
5. **HBA:** A (6) is acceptable. B (5) is slightly better.
6. **QED:** Both are good (A: 0.657, B: 0.696), indicating drug-like properties. B is marginally better.
7. **DILI:** Both are low risk (A: 41.062, B: 42.536), both under the 60 threshold.
8. **BBB:** B (89.957) is significantly better than A (46.84). This is a crucial advantage for a GPCR target, even if not a CNS target, as it suggests better distribution properties.
9. **Caco-2:** A (-5.989) is very poor, indicating very low intestinal absorption. B (-4.983) is also poor, but slightly better than A.
10. **Solubility:** A (-0.582) is poor. B (-2.632) is even worse. Both are problematic.
11. **hERG:** Both are very low risk (A: 0.011, B: 0.56).
12. **Cl_mic:** A (-35.362) is excellent, indicating high metabolic stability. B (-8.583) is good, but not as good as A.
13. **t1/2:** A (14.237) is reasonable. B (-14.5) is very poor.
14. **Pgp:** Both are low efflux (A: 0.005, B: 0.04).
15. **Affinity:** Both are excellent (A: -8.3, B: -8.1). A is slightly better.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, BBB, and affinity are key.
**Overall Assessment:**
Ligand A has a slightly better affinity and metabolic stability, but suffers from very poor Caco-2 permeability and solubility, and a lower BBB score. Ligand B has a much better TPSA, logP, and significantly better BBB penetration, but has a shorter half-life and slightly worse metabolic stability.
Considering the balance, **Ligand B** is the more promising candidate. The improved TPSA, logP, and *especially* the much higher BBB score outweigh the slightly lower metabolic stability and half-life. The solubility and Caco-2 values are poor for both, but can be addressed with formulation strategies. The better distribution profile of Ligand B is more critical for a GPCR target.
Output:
0
2025-04-17 21:35:21,157 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [352.395, 111.73 , -1.489, 1. , 6. , 0.599, 65.568, 49.593, -5.418, -0.899, 0.027, -11.905, -19.917, 0.004, -6.9 ]
**Ligand B:** [346.519, 50.16 , 2.931, 1. , 4. , 0.892, 10.585, 89.957, -4.874, -2.165, 0.513, 27.023, 14.376, 0.206, -8.1 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (352.395) is slightly higher than Ligand B (346.519), but both are acceptable.
2. **TPSA:** Ligand A (111.73) is higher than Ligand B (50.16). While both are below 140, the lower TPSA of Ligand B is more favorable for permeability.
3. **logP:** Ligand A (-1.489) is lower than the optimal range (1-3), potentially hindering permeation. Ligand B (2.931) is within the optimal range. This is a significant advantage for Ligand B.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 6 HBA, while Ligand B has 4. Both are acceptable, but Ligand B is slightly better.
6. **QED:** Ligand B (0.892) has a significantly better QED score than Ligand A (0.599), indicating a more drug-like profile.
7. **DILI:** Ligand A (65.568) has a higher DILI risk than Ligand B (10.585). This is a major concern for Ligand A.
8. **BBB:** Ligand B (89.957) has a much higher BBB penetration potential than Ligand A (49.593). While ADRB2 is a cardiovascular target, some CNS exposure is possible and not necessarily detrimental, and higher BBB is generally a positive attribute.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. Ligand B (-4.874) is slightly less negative than Ligand A (-5.418).
10. **Solubility:** Ligand A (-0.899) has slightly better solubility than Ligand B (-2.165).
11. **hERG:** Ligand A (0.027) has a very low hERG risk, which is excellent. Ligand B (0.513) has a slightly elevated risk, but still relatively low.
12. **Cl_mic:** Ligand A (-11.905) has a much lower (better) microsomal clearance than Ligand B (27.023), indicating better metabolic stability.
13. **t1/2:** Ligand A (-19.917) has a longer in vitro half-life than Ligand B (14.376), which is favorable.
14. **Pgp:** Ligand A (0.004) has very low P-gp efflux, while Ligand B (0.206) has slightly higher efflux.
15. **Affinity:** Ligand B (-8.1) has a stronger binding affinity than Ligand A (-6.9), by 1.2 kcal/mol. This is a significant advantage.
**GPCR-specific priorities:** For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are crucial. Ligand B excels in these areas. While BBB isn't a primary concern for a cardiovascular target, the higher value for Ligand B is still a positive.
**Overall Assessment:**
Ligand B is significantly better overall. It has a better logP, QED, lower DILI risk, higher BBB penetration, stronger binding affinity, and lower Pgp efflux. While Ligand A has better metabolic stability (lower Cl_mic) and a longer half-life, the advantages of Ligand B in key ADME and potency parameters outweigh these benefits. The lower DILI risk for Ligand B is also a critical factor.
Output:
0
2025-04-17 21:35:21,157 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, key properties to prioritize are logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB (though less critical for a cardiovascular target than a CNS one).
Let's break down the comparison:
1. **MW:** Both ligands (360.4 and 349.5 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand B (70.5) is significantly better than Ligand A (111.8). Lower TPSA generally improves permeability, a crucial factor for GPCR ligands.
3. **logP:** Ligand A (1.14) is slightly better than Ligand B (0.514), falling comfortably within the 1-3 range. Ligand B is a bit low, potentially impacting permeability.
4. **HBD/HBA:** Both have 1 HBD, which is good. Ligand A has 8 HBA, and Ligand B has 5. Both are acceptable, but Ligand B is preferable.
5. **QED:** Both are very similar (0.73 and 0.743), indicating good drug-likeness.
6. **DILI:** Ligand A (98.6) has a significantly higher DILI risk than Ligand B (13.2). This is a major concern for Ligand A.
7. **BBB:** Both are reasonable, but Ligand B (61.7) is slightly better than Ligand A (55.6).
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale isn't specified, so it's hard to interpret.
9. **Solubility:** Both have negative solubility values, which is also unusual and suggests poor solubility. Again, the scale isn't specified.
10. **hERG:** Both have very low hERG inhibition risk (0.13 and 0.18).
11. **Cl_mic:** Ligand A (-0.665) has a negative clearance, which is not physically possible and likely an error or outlier. Ligand B (12.4) is higher, indicating faster metabolism.
12. **t1/2:** Ligand A (65.3) has a much longer half-life than Ligand B (3.9). This is a significant advantage.
13. **Pgp:** Both have very low Pgp efflux liability (0.149 and 0.007).
14. **Binding Affinity:** Ligand A (-7.2) has a significantly stronger binding affinity than Ligand B (-6.0). This is a substantial advantage.
**Overall Assessment:**
Despite Ligand A's superior binding affinity and half-life, the extremely high DILI risk and the nonsensical negative clearance are major red flags. Ligand B, while having a weaker binding affinity and shorter half-life, presents a much more favorable safety profile (low DILI) and a plausible metabolic clearance. The lower TPSA of Ligand B is also beneficial for permeability. The slight logP disadvantage of Ligand B is less concerning than the serious issues with Ligand A.
Therefore, I favor Ligand B.
**Output:**
0
2025-04-17 21:35:21,157 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.379 and 346.427 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (109.24) is higher than Ligand B (75.71). For a cardiovascular GPCR, TPSA isn't *as* critical as for CNS targets, but lower is generally preferred for absorption. Ligand B is better.
3. **logP:** Ligand A (-0.096) is slightly negative, which is a concern for permeability. Ligand B (1.261) is within the optimal 1-3 range. Ligand B is significantly better.
4. **HBD:** Both have 1 HBD, which is good. No difference.
5. **HBA:** Ligand A has 7, and Ligand B has 4. Both are acceptable (<=10), but Ligand B is preferable.
6. **QED:** Ligand A (0.782) is better than Ligand B (0.601), indicating a more drug-like profile.
7. **DILI:** Ligand A (73.052) has a higher DILI risk than Ligand B (20.318). This is a major concern. Ligand B is much better.
8. **BBB:** Ligand A (46.336) has lower BBB penetration than Ligand B (63.164). While ADRB2 isn't a CNS target, some degree of BBB penetration can sometimes indicate better overall distribution. Ligand B is better.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.196 and -4.903). This is unusual and suggests poor permeability. However, the values are similar.
10. **Solubility:** Ligand A (-1.838) has slightly better solubility than Ligand B (-2.226).
11. **hERG:** Both ligands have very low hERG inhibition risk (0.157 and 0.111). No significant difference.
12. **Cl_mic:** Ligand A (54.96) has a higher microsomal clearance than Ligand B (5.842), indicating faster metabolism and potentially lower *in vivo* exposure. Ligand B is significantly better.
13. **t1/2:** Ligand A (-40.1) has a negative in vitro half-life which is concerning. Ligand B (-19.658) is also negative, but less so. Both are concerning, but Ligand B is better.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.044 and 0.046). No significant difference.
15. **Binding Affinity:** Ligand A (-6.2 kcal/mol) has a slightly better binding affinity than Ligand B (-3.7 kcal/mol). This is a substantial difference. However, the other ADME properties of Ligand A are significantly worse.
**Overall Assessment:**
While Ligand A has a better binding affinity, its significantly higher DILI risk, higher metabolic clearance, and negative logP and half-life are major drawbacks. Ligand B, despite a weaker binding affinity, has a much more favorable ADME profile, particularly regarding DILI, logP, and Cl_mic. For a cardiovascular target, minimizing liver toxicity and ensuring reasonable metabolic stability are crucial. The difference in binding affinity, while notable, can potentially be addressed through further optimization of Ligand B.
Output:
0
2025-04-17 21:35:21,158 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (346.431 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (87.47) is better than Ligand B (53.94). Both are below 140, but Ligand B is significantly lower, which could be beneficial for membrane permeability.
3. **logP:** Ligand A (0.951) is within the optimal range (1-3), while Ligand B (4.03) is slightly above. This is a concern for Ligand B, potentially leading to solubility issues and off-target interactions.
4. **HBD:** Both ligands have acceptable HBD counts (Ligand A: 2, Ligand B: 1).
5. **HBA:** Both ligands have acceptable HBA counts (Ligand A: 5, Ligand B: 7).
6. **QED:** Both ligands have similar and good QED values (Ligand A: 0.732, Ligand B: 0.747).
7. **DILI:** Ligand A (13.416) has a much lower DILI risk than Ligand B (80.651). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (84.257) has a better BBB penetration percentile than Ligand B (77.976). While ADRB2 isn't exclusively a CNS target, some peripheral ADRB2 activity can be modulated by CNS effects, and better BBB penetration isn't a detriment.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Ligand A (-1.222) has better solubility than Ligand B (-4.235). This is important for bioavailability.
11. **hERG:** Ligand A (0.567) has a lower hERG inhibition liability than Ligand B (0.834), reducing the risk of cardiotoxicity.
12. **Cl_mic:** Ligand B (94.637) has a higher microsomal clearance than Ligand A (11.772), indicating lower metabolic stability. This is a major drawback for Ligand B.
13. **t1/2:** Ligand B (11.697) has a longer in vitro half-life than Ligand A (-1.156). However, the negative value for Ligand A is concerning and likely an error.
14. **Pgp:** Ligand A (0.025) has much lower P-gp efflux liability than Ligand B (0.381), which is favorable for bioavailability.
15. **Affinity:** Ligand A (-7.7 kcal/mol) has a slightly better binding affinity than Ligand B (-6.5 kcal/mol). While the difference is less than 1.5 kcal/mol, it contributes to the overall preference.
**GPCR-specific priorities:** Given that ADRB2 is a GPCR, logP, TPSA, Pgp, and affinity are key. Ligand A performs better on logP, Pgp, and DILI. Ligand B has a slightly better TPSA, but the high logP and DILI risk are significant concerns.
**Overall Assessment:**
Ligand A is the more promising candidate. It has a better safety profile (lower DILI, hERG), better solubility, lower P-gp efflux, and slightly better affinity. While Ligand B has a longer half-life, the negative value for Ligand A's half-life is likely an error. The higher logP and clearance of Ligand B are major drawbacks that outweigh its slightly longer half-life.
Output:
1
2025-04-17 21:35:21,158 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's systematically compare Ligand A and Ligand B based on the provided parameters and the guidelines, keeping in mind that ADRB2 is a GPCR, so logP, TPSA, Pgp, BBB, and affinity are key.
1. **MW:** Both ligands (351.403 and 348.487 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (101.74) is slightly higher than Ligand B (49.85). Ligand B is much better, being well below the 140 threshold for oral absorption and more favorable for GPCRs.
3. **logP:** Both ligands have acceptable logP values (1.292 and 2.302), falling within the 1-3 range. Ligand B is slightly better, being closer to the optimal range.
4. **HBD:** Ligand A has 1 HBD, while Ligand B has 0. Both are acceptable.
5. **HBA:** Ligand A has 6 HBA, and Ligand B has 3. Both are within the acceptable range of <=10. Ligand B is better.
6. **QED:** Ligand A (0.743) has a better QED score than Ligand B (0.5), indicating a more drug-like profile.
7. **DILI:** Ligand A (48.391) has a slightly higher DILI risk than Ligand B (9.228). Ligand B is significantly better.
8. **BBB:** Ligand B (77.162) has a better BBB penetration percentile than Ligand A (67.507). This is a positive for a GPCR target.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.523 and -4.463), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Both ligands have negative solubility values (-1.689 and -1.618), again suggesting poor solubility. This is a major drawback for both.
11. **hERG:** Ligand A (0.119) has a lower hERG inhibition liability than Ligand B (0.455), which is preferable.
12. **Cl_mic:** Ligand B (41.007) has a lower microsomal clearance than Ligand A (54.381), indicating better metabolic stability.
13. **t1/2:** Ligand B (6.733) has a longer in vitro half-life than Ligand A (-4.142). This is a significant advantage.
14. **Pgp:** Ligand A (0.062) has a lower P-gp efflux liability than Ligand B (0.279), which is preferable.
15. **Affinity:** Ligand A (-6.6 kcal/mol) has a slightly better binding affinity than Ligand B (-5.5 kcal/mol). This is a 1.1 kcal/mol difference, which is substantial.
**Overall Assessment:**
While Ligand A has a better QED, hERG, Pgp, and binding affinity, Ligand B demonstrates superior characteristics in several critical ADME properties relevant to GPCRs. Specifically, its lower DILI risk, better BBB penetration, lower microsomal clearance, and longer half-life are highly desirable. The TPSA is also significantly better for Ligand B. The poor Caco-2 and solubility for both are concerning, but the other benefits of Ligand B outweigh the slight affinity advantage of Ligand A. Given the GPCR target, the ADME properties of Ligand B are more favorable.
Output:
0
2025-04-17 21:35:21,158 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, the most important parameters are binding affinity, logP, TPSA, Pgp efflux, and BBB penetration (though BBB is less critical for a cardiovascular target).
Let's compare the ligands step-by-step:
1. **MW:** Both ligands (347.371 and 355.463 Da) are within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (86.92) is better than Ligand B (59.23), falling well below the 140 A^2 threshold. Lower TPSA generally favors better permeability.
3. **logP:** Ligand A (1.745) is optimal (1-3), while Ligand B (4.406) is pushing the upper limit and could potentially cause solubility issues or off-target interactions.
4. **HBD/HBA:** Both have acceptable HBD (0) and HBA counts (7 and 5 respectively), within the guidelines.
5. **QED:** Ligand A (0.786) has a slightly better QED score than Ligand B (0.657), indicating a more drug-like profile.
6. **DILI:** Ligand A (74.99) has a higher DILI risk than Ligand B (57.736), but both are acceptable.
7. **BBB:** Ligand A (70.143) has better BBB penetration than Ligand B (55.021), although BBB isn't a primary concern for a cardiovascular target.
8. **Caco-2:** Ligand A (-4.704) has a better Caco-2 permeability than Ligand B (-5.172).
9. **Solubility:** Ligand A (-2.011) has better solubility than Ligand B (-4.717).
10. **hERG:** Both ligands have low hERG inhibition liability (0.254 and 0.514 respectively).
11. **Cl_mic:** Ligand A (10.678) has a significantly lower microsomal clearance than Ligand B (91.823), indicating better metabolic stability.
12. **t1/2:** Ligand B (60.29) has a longer in vitro half-life than Ligand A (17.413).
13. **Pgp:** Ligand A (0.168) has lower P-gp efflux liability than Ligand B (0.741), which is favorable for bioavailability.
14. **Binding Affinity:** Ligand A (-6.9 kcal/mol) has a slightly better binding affinity than Ligand B (-6.2 kcal/mol).
**Overall Assessment:**
Ligand A is the stronger candidate. While Ligand B has a longer half-life, Ligand A excels in several crucial areas: better logP, TPSA, solubility, metabolic stability (lower Cl_mic), lower P-gp efflux, and slightly better binding affinity. These factors, especially the favorable ADME properties, outweigh the half-life advantage of Ligand B for a cardiovascular GPCR target.
**Output:**
1
2025-04-17 21:35:21,158 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (385.222 and 369.491 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (67.43) is significantly better than Ligand B (89.35). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (3.919) is optimal, while Ligand B (0.552) is quite low. Low logP can hinder membrane permeability and bioavailability. This is a significant advantage for Ligand A.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable.
5. **HBA:** Ligand A (3) is better than Ligand B (7). High HBA can sometimes negatively impact permeability.
6. **QED:** Both ligands (0.767 and 0.72) have good drug-likeness scores.
7. **DILI:** Ligand A (75.378) has a higher DILI risk than Ligand B (60.566), but both are within acceptable ranges.
8. **BBB:** Ligand A (70.027) has better BBB penetration than Ligand B (53.044), but this isn't a major concern for a cardiovascular target.
9. **Caco-2:** Ligand A (-4.461) is better than Ligand B (-5.258), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-5.547) is better than Ligand B (-2.068).
11. **hERG:** Ligand A (0.61) is better than Ligand B (0.135). Lower hERG inhibition is crucial to avoid cardiotoxicity, a significant concern for a cardiovascular target.
12. **Cl_mic:** Ligand B (34.257) has significantly lower microsomal clearance than Ligand A (85.787), suggesting better metabolic stability. This is a strong point for Ligand B.
13. **t1/2:** Ligand A (47.034) has a longer half-life than Ligand B (14.933). This is a positive for Ligand A.
14. **Pgp:** Ligand A (0.162) has lower P-gp efflux than Ligand B (0.052), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand A (-6.9 kcal/mol) has a slightly better binding affinity than Ligand B (-5.4 kcal/mol). This difference is substantial enough to be a key factor.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A excels in logP, has better TPSA and Pgp, and a significantly better binding affinity. While Ligand B has better metabolic stability (Cl_mic), the advantages of Ligand A in terms of permeability, potency, and safety (hERG) outweigh this benefit.
**Conclusion:**
Ligand A is the more promising candidate due to its superior logP, TPSA, Caco-2 permeability, solubility, hERG profile, and binding affinity. The slightly higher DILI risk is a concern, but manageable. The substantial difference in binding affinity and overall ADME properties make it the preferred choice.
Output:
1
2025-04-17 21:35:21,159 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [357.439, 92.42, 1.477, 1, 6, 0.895, 75.766, 75.107, -4.865, -2.955, 0.219, 11.673, -26.729, 0.085, -6]
**Ligand B:** [354.491, 78.87, 1.563, 2, 4, 0.759, 19.038, 44.281, -4.656, -2.304, 0.333, 37.641, 14.263, 0.098, -6.7]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). A (357.439) is slightly higher than B (354.491), but this difference is negligible.
2. **TPSA:** A (92.42) is higher than B (78.87). Both are acceptable for a non-CNS GPCR like ADRB2, but B is preferable due to lower TPSA.
3. **logP:** Both ligands have good logP values (A: 1.477, B: 1.563), falling within the optimal 1-3 range. Very similar.
4. **HBD:** A (1) is better than B (2). Lower HBD is generally preferred for better permeability.
5. **HBA:** A (6) is higher than B (4). B is preferable.
6. **QED:** A (0.895) is significantly better than B (0.759), indicating a more drug-like profile.
7. **DILI:** A (75.766) is significantly *higher* than B (19.038), indicating a much higher risk of drug-induced liver injury. This is a major concern for A.
8. **BBB:** Both are relatively high, but A (75.107) is higher than B (44.281). While ADRB2 isn't a CNS target, higher BBB is rarely a negative.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. A (-4.865) is slightly worse than B (-4.656).
10. **Solubility:** Both have negative solubility values, indicating poor solubility. A (-2.955) is slightly worse than B (-2.304).
11. **hERG:** Both are low (A: 0.219, B: 0.333), which is good, indicating low cardiotoxicity risk.
12. **Cl_mic:** A (11.673) is much lower than B (37.641), indicating better metabolic stability. This is a significant advantage for A.
13. **t1/2:** A (-26.729) is much lower than B (14.263), indicating a shorter in vitro half-life. This is a significant disadvantage for A.
14. **Pgp:** Both are very low (A: 0.085, B: 0.098), indicating minimal P-gp efflux.
15. **Affinity:** B (-6.7) is slightly better than A (-6), although the difference is small.
**GPCR-Specific Priorities:** For ADRB2, we prioritize logP, TPSA, Pgp, and affinity. Both ligands perform similarly on logP and Pgp. B has a better TPSA. The affinity difference is small. However, the *major* deciding factor is the DILI risk. Ligand A's significantly higher DILI risk (75.766) is a critical drawback. While A has better metabolic stability, the liver toxicity risk is too high to ignore.
**Conclusion:**
Considering the balance of properties and the critical importance of minimizing DILI risk, **Ligand B is the more viable drug candidate.**
0
2025-04-17 21:35:21,159 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [358.479, 99.1, 0.537, 3, 5, 0.495, 5.428, 46.491, -4.793, -0.348, 0.252, 14.877, 0.924, 0.014, -5.6]**
**Ligand B: [346.475, 67.23, 2.1, 1, 4, 0.888, 21.908, 73.245, -4.518, -2.573, 0.103, 57.456, 11.421, 0.023, -6.9]**
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand B (346.475) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (99.1) is higher than Ligand B (67.23). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is still preferred. Ligand B is significantly better here.
3. **logP:** Ligand A (0.537) is quite low, potentially causing permeability issues. Ligand B (2.1) is within the optimal range (1-3). This is a significant advantage for Ligand B.
4. **H-Bond Donors:** Ligand A (3) is acceptable, while Ligand B (1) is even better, contributing to better permeability.
5. **H-Bond Acceptors:** Ligand A (5) and Ligand B (4) are both within the acceptable range (<=10).
6. **QED:** Ligand B (0.888) has a much better QED score than Ligand A (0.495), indicating a more drug-like profile.
7. **DILI Risk:** Ligand A (5.428) has a very low DILI risk, which is excellent. Ligand B (21.908) is still relatively low, but higher than A.
8. **BBB Penetration:** Ligand A (46.491) has lower BBB penetration than Ligand B (73.245). Since ADRB2 is not primarily a CNS target, this isn't a major deciding factor, but higher is generally better.
9. **Caco-2 Permeability:** Ligand A (-4.793) has worse Caco-2 permeability than Ligand B (-4.518). Both are negative, suggesting poor permeability, but B is better.
10. **Aqueous Solubility:** Ligand A (-0.348) has slightly better solubility than Ligand B (-2.573).
11. **hERG Inhibition:** Ligand A (0.252) has a lower hERG risk than Ligand B (0.103), which is favorable.
12. **Microsomal Clearance:** Ligand A (14.877) has a lower clearance than Ligand B (57.456), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **In vitro Half-Life:** Ligand B (11.421) has a longer half-life than Ligand A (0.924), which is desirable.
14. **P-gp Efflux:** Ligand A (0.014) has lower P-gp efflux than Ligand B (0.023), which is preferred.
15. **Binding Affinity:** Ligand B (-6.9 kcal/mol) has a stronger binding affinity than Ligand A (-5.6 kcal/mol). This is a 1.3 kcal/mol difference, which is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand B has a significantly better logP, QED, and binding affinity. Its TPSA is also much lower. While Ligand A has lower DILI risk and better metabolic stability, the superior binding affinity and drug-like properties of Ligand B are more crucial for a GPCR target like ADRB2. The difference in binding affinity is substantial enough to overcome the slightly higher DILI risk and lower metabolic stability of Ligand B.
Output:
0
2025-04-17 21:35:21,159 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (362.539 and 353.369 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (50.36) is significantly better than Ligand B (82.53). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 A^2 threshold. Ligand B is approaching the upper limit.
3. **logP:** Both ligands have acceptable logP values (2.864 and 1.942), falling within the 1-3 range. Ligand A is slightly higher, potentially offering better membrane permeability.
4. **HBD:** Both ligands have 2 H-bond donors, which is within the acceptable limit of <=5.
5. **HBA:** Both ligands have 4 H-bond acceptors, also within the acceptable limit of <=10.
6. **QED:** Both ligands have good QED scores (0.733 and 0.87), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (24.506) has a significantly lower DILI risk than Ligand B (46.258). This is a major advantage for Ligand A.
8. **BBB:** Both ligands have similar BBB penetration (66.344 and 67.817). Not a major factor for a cardiovascular target.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual. However, the values are similar (-5.3 and -4.781).
10. **Solubility:** Ligand A (-2.264) has slightly better solubility than Ligand B (-3.376).
11. **hERG:** Ligand A (0.622) has a slightly higher hERG risk than Ligand B (0.13). This is a negative for Ligand A.
12. **Cl_mic:** Ligand A (22.367) has a higher microsomal clearance than Ligand B (6.367), indicating faster metabolism and potentially lower *in vivo* exposure. This favors Ligand B.
13. **t1/2:** Ligand B (-37.223) has a significantly longer *in vitro* half-life than Ligand A (15.874). This is a substantial advantage for Ligand B.
14. **Pgp:** Ligand A (0.353) has lower P-gp efflux liability than Ligand B (0.011). This is a positive for Ligand A.
15. **Binding Affinity:** Ligand A (-7.3 kcal/mol) has a *much* stronger binding affinity than Ligand B (-1.4 kcal/mol). This is a decisive advantage for Ligand A. A difference of 5.9 kcal/mol is substantial.
**Overall Assessment:**
While Ligand B has advantages in metabolic stability (lower Cl_mic, longer t1/2) and lower hERG risk, the significantly stronger binding affinity of Ligand A (-7.3 vs -1.4 kcal/mol) and lower DILI risk outweigh these concerns. The difference in affinity is large enough to potentially overcome the slightly higher clearance. The TPSA is also more favorable for Ligand A. For a GPCR target, affinity is paramount.
Output:
1
2025-04-17 21:35:21,159 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (341.455 and 356.438 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (71.09) is better than Ligand B (76.66). Both are below the 140 A^2 threshold for good oral absorption, but lower TPSA is generally preferred for GPCR ligands, potentially aiding in brain penetration if desired.
**3. logP:** Ligand A (2.606) is slightly higher than Ligand B (1.846), both within the optimal 1-3 range. Ligand B is a bit low, potentially hindering membrane permeability.
**4. H-Bond Donors:** Both ligands have 2 HBD, which is acceptable.
**5. H-Bond Acceptors:** Ligand A has 3 HBA, while Ligand B has 4. Both are within the acceptable limit of 10.
**6. QED:** Ligand A (0.617) has a better QED score than Ligand B (0.463), indicating better overall drug-likeness.
**7. DILI:** Ligand B (39.201) has a slightly lower DILI risk than Ligand A (43.117), but both are below the concerning threshold of 60.
**8. BBB:** Ligand B (81.698) shows significantly better BBB penetration potential than Ligand A (56.223). While ADRB2 isn't exclusively a CNS target, some cardiovascular effects are mediated by central pathways, and better BBB penetration can be advantageous.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.576 and -4.715), which is unusual and suggests poor permeability. This is a significant concern for both.
**10. Aqueous Solubility:** Ligand A (-3.283) has better solubility than Ligand B (-1.76), which is important for formulation and bioavailability.
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (0.374 and 0.458).
**12. Microsomal Clearance:** Ligand B (29.36) has significantly lower microsomal clearance than Ligand A (53.225), indicating better metabolic stability.
**13. In vitro Half-Life:** Ligand A (-7.053) has a much longer in vitro half-life than Ligand B (-0.008). This is a substantial advantage.
**14. P-gp Efflux:** Both ligands show low P-gp efflux liability (0.156 and 0.115).
**15. Binding Affinity:** Ligand B (-6.6) has slightly better binding affinity than Ligand A (-6.4), but the difference is small (0.2 kcal/mol).
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), and the general drug-like properties, Ligand A appears to be the better candidate. While Ligand B has better BBB penetration and metabolic stability, Ligand A has a better QED score, solubility, and a significantly longer half-life. The small difference in binding affinity is outweighed by these other factors. The poor Caco-2 permeability is a concern for both, but can be addressed through formulation strategies. The longer half-life of Ligand A is particularly valuable, potentially allowing for less frequent dosing.
Output:
1
2025-04-17 21:35:21,160 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [349.391, 117.43 , -0.219, 2. , 6. , 0.627, 37.999, 53.974, -5.419, -1.132, 0.015, 8.968, 7.283, 0.004, -6.9 ]
**Ligand B:** [351.411, 128.26 , -0.822, 2. , 8. , 0.685, 49.632, 74.719, -5.471, -2.267, 0.075, 1.749, 1.445, 0.018, -6.7 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). A (349.391) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** A (117.43) is better than B (128.26), falling comfortably under the 140 A^2 threshold for oral absorption.
3. **logP:** A (-0.219) is a bit low, potentially hindering permeation, while B (-0.822) is better, though still on the lower side of the optimal 1-3 range.
4. **HBD:** Both have 2 HBD, which is good.
5. **HBA:** A has 6 HBA, B has 8. A is preferable here, staying closer to the <10 guideline.
6. **QED:** Both are good (A: 0.627, B: 0.685), indicating drug-like properties. B is slightly better.
7. **DILI:** A (37.999) has a lower DILI risk than B (49.632), which is a significant advantage.
8. **BBB:** B (74.719) has a significantly higher BBB penetration potential than A (53.974). This is a key consideration for a GPCR, even a cardiovascular one, as some CNS off-target effects are always a concern.
9. **Caco-2:** Both are very poor (-5.419 and -5.471). This is a major concern for both.
10. **Solubility:** Both are very poor (-1.132 and -2.267). This is also a major concern for both.
11. **hERG:** Both have very low hERG risk (0.015 and 0.075).
12. **Cl_mic:** A (8.968) has a higher clearance than B (1.749), meaning B is more metabolically stable. This is a significant advantage.
13. **t1/2:** A (7.283) has a longer half-life than B (1.445). This is a positive for A.
14. **Pgp:** Both have very low Pgp efflux liability (0.004 and 0.018).
15. **Affinity:** A (-6.9 kcal/mol) is slightly better than B (-6.7 kcal/mol), but the difference is small.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, and affinity. While BBB isn't *essential* for a cardiovascular target, it's still a consideration.
**Overall Assessment:**
Ligand A has a better DILI profile, better TPSA, and slightly better affinity. However, Ligand B has a significantly better BBB score and much better metabolic stability (lower Cl_mic, longer half-life). The poor Caco-2 and solubility for both are concerning and would need to be addressed through formulation strategies. The slightly better affinity of A is not enough to overcome the metabolic stability advantage of B. Given the importance of metabolic stability for *in vivo* efficacy, and the reasonable BBB score, I would favor Ligand B.
Output:
0
2025-04-17 21:35:21,160 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (339.483 Da) is excellent, within the ideal range. Ligand B (372.531 Da) is also acceptable, though slightly higher.
2. **TPSA:** Ligand A (41.3) is very good, well below the 140 threshold for oral absorption. Ligand B (75.71) is higher, but still potentially acceptable, though it might slightly hinder absorption.
3. **logP:** Ligand A (3.688) is optimal. Ligand B (1.76) is on the lower side of optimal, potentially causing permeability issues.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Both ligands have 4 HBA, which is good.
6. **QED:** Ligand A (0.922) is excellent, indicating a highly drug-like profile. Ligand B (0.626) is still good, above the 0.5 threshold.
7. **DILI:** Ligand A (13.532) has a very low DILI risk. Ligand B (45.095) is higher, indicating a moderate risk.
8. **BBB:** Ligand A (91.857) has excellent BBB penetration. Ligand B (65.103) is lower, suggesting limited CNS exposure. Since ADRB2 is a cardiovascular target, BBB penetration is not a primary concern, but can be useful for off-target effects.
9. **Caco-2:** Ligand A (-5.396) and Ligand B (-4.321) both have negative values, which is unusual. It suggests poor permeability.
10. **Solubility:** Ligand A (-2.174) and Ligand B (-3.351) both have negative values, which is unusual. It suggests poor solubility.
11. **hERG:** Ligand A (0.904) and Ligand B (0.522) both have low hERG inhibition risk.
12. **Cl_mic:** Ligand A (36.735) has a lower microsomal clearance, suggesting better metabolic stability. Ligand B (69.66) has higher clearance.
13. **t1/2:** Ligand A (-3.302) has a negative half-life, which is unusual. Ligand B (-62.767) has a very negative half-life, which is highly unusual.
14. **Pgp:** Ligand A (0.545) has lower P-gp efflux, which is good. Ligand B (0.08) has very low P-gp efflux.
15. **Affinity:** Both ligands have very similar binding affinities (-6.5 and -6.3 kcal/mol). The difference is less than 1.5 kcal/mol, so it's not a decisive factor.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A has a better logP and TPSA. Ligand A has better metabolic stability (lower Cl_mic). Ligand A has a much lower DILI risk.
**Overall Assessment:**
While both ligands have similar affinities, Ligand A is superior due to its better predicted ADME properties (logP, TPSA, Cl_mic, DILI, Pgp) and overall drug-likeness (QED). The negative values for Caco-2 and solubility are concerning for both, but Ligand A's other properties make it the more promising candidate.
Output:
1
2025-04-17 21:35:21,160 - INFO - Here's my reasoning and the final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, priorities are logP, TPSA, Pgp, affinity, and to a lesser extent, BBB.
* **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand B (351.466) is slightly lower, which is generally favorable for permeability.
* **TPSA:** Ligand B (52.65) is significantly better than Ligand A (64.96), falling well below the 140 threshold for oral absorption.
* **logP:** Ligand A (3.657) is better than Ligand B (1.713). While both are within the acceptable range, 3.657 is closer to the optimal 1-3 range. Ligand B's logP is a bit low and might hinder membrane permeability.
* **H-Bond Donors/Acceptors:** Ligand A (0 HBD, 4 HBA) is preferable to Ligand B (1 HBD, 3 HBA). Fewer hydrogen bonds generally improve membrane permeability.
* **QED:** Both ligands have similar, good QED values (0.789 and 0.793).
* **DILI:** Ligand B (10.624) has a *much* lower DILI risk than Ligand A (65.568). This is a significant advantage for Ligand B.
* **BBB:** Both ligands have high BBB penetration (94.455 and 91.896). This isn't a primary concern for a cardiovascular target, but it's not detrimental.
* **Caco-2:** Ligand B (-5.023) is better than Ligand A (-4.079), indicating better intestinal absorption.
* **Solubility:** Ligand A (-3.997) is better than Ligand B (-1.992). Solubility is important for formulation and bioavailability.
* **hERG:** Both ligands have low hERG inhibition liability (0.611 and 0.516).
* **Microsomal Clearance:** Ligand B (-4.564) has *much* lower microsomal clearance than Ligand A (13.382), suggesting better metabolic stability.
* **In vitro Half-Life:** Ligand B (16.011) has a longer half-life than Ligand A (45.675).
* **P-gp Efflux:** Ligand B (0.046) has significantly lower P-gp efflux than Ligand A (0.643), which is a major advantage for bioavailability.
* **Binding Affinity:** Ligand A (-6.5 kcal/mol) has a slightly better binding affinity than Ligand B (0.0 kcal/mol). This is a significant advantage, but can be overcome by better ADME properties.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity, Ligand B demonstrates a significantly superior ADME profile. Its lower DILI risk, lower P-gp efflux, lower microsomal clearance, longer half-life, and better Caco-2 permeability outweigh the small difference in binding affinity. The TPSA is also much more favorable for Ligand B. For a GPCR target, optimizing for ADME properties is crucial, and Ligand B excels in this regard.
**Output:**
0
2025-04-17 21:35:21,160 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (389.405 and 361.833 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (90.41 and 88.08) are below the 140 A^2 threshold for good oral absorption, and reasonably close to the 90 A^2 target for GPCRs. Again, a small difference, favoring B slightly.
3. **logP:** Both ligands (2.795 and 2.114) are within the optimal 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability, but not dramatically so.
4. **HBD:** Both have 1 HBD, which is acceptable.
5. **HBA:** Ligand A has 8 HBA, and Ligand B has 5. Both are within the acceptable range of <=10, but Ligand B is better.
6. **QED:** Ligand B (0.851) has a considerably higher QED score than Ligand A (0.548), indicating a more drug-like profile. This is a significant advantage for B.
7. **DILI:** Ligand A has a DILI risk of 93.059, which is high. Ligand B has a DILI risk of 71.85, which is still not ideal, but significantly better than A. This is a major advantage for B.
8. **BBB:** Ligand A (84.955) has a better BBB penetration percentile than Ligand B (43.932). While ADRB2 isn't exclusively a CNS target, some CNS exposure could be relevant depending on the specific therapeutic application.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.911) is slightly worse than Ligand B (-5.052).
10. **Solubility:** Ligand A (-4.862) has slightly better solubility than Ligand B (-3.094), but both are poor.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.321 and 0.198), which is excellent.
12. **Cl_mic:** Ligand A (98.647) has a much higher microsomal clearance than Ligand B (44.511), indicating lower metabolic stability. This is a significant disadvantage for A.
13. **t1/2:** Ligand B (39.98) has a much longer in vitro half-life than Ligand A (-6.058), which is a substantial advantage.
14. **Pgp:** Ligand A (0.37) has lower P-gp efflux than Ligand B (0.115), which is favorable.
15. **Binding Affinity:** Ligand B (-8.3 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.0 kcal/mol). This is a >1.5 kcal/mol advantage, and the most important factor.
**Overall Assessment:**
While Ligand A has slightly better BBB penetration and Pgp efflux, Ligand B overwhelmingly wins on crucial ADME-Tox properties (DILI, Cl_mic, t1/2, QED) and, most importantly, binding affinity. The significantly stronger binding affinity of Ligand B (-8.3 vs -6.0 kcal/mol) is a decisive factor, especially for a GPCR target. The lower DILI risk and improved metabolic stability of Ligand B are also critical for its potential as a viable drug candidate. The poor Caco-2 and solubility of both are concerns, but can be addressed with formulation strategies.
Output:
0
2025-04-17 21:35:21,160 - INFO - Batch 269 complete. Total preferences: 4304
2025-04-17 21:35:21,160 - INFO - Processing batch 270/512...
2025-04-17 21:36:08,181 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.48 and 357.50 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (40.62) is significantly better than Ligand B (101.9). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is quite high, potentially hindering absorption.
3. **logP:** Ligand A (3.014) is optimal, while Ligand B (0.109) is very low. Low logP can lead to poor membrane permeability. This is a major drawback for Ligand B.
4. **HBD:** Ligand A (0) is preferable to Ligand B (4). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (2) is better than Ligand B (5). Similar rationale as HBD.
6. **QED:** Ligand A (0.662) is significantly better than Ligand B (0.444), indicating a more drug-like profile.
7. **DILI:** Ligand A (15.86) is better than Ligand B (2.79). Lower DILI risk is always preferred.
8. **BBB:** Ligand A (96.08) is excellent, while Ligand B (23.42) is very poor. While ADRB2 isn't exclusively a CNS target, good BBB penetration can still be beneficial and indicates favorable permeability characteristics.
9. **Caco-2:** Ligand A (-4.403) is better than Ligand B (-5.609). Higher Caco-2 permeability is desired.
10. **Solubility:** Ligand A (-3.355) is better than Ligand B (-0.652). Better solubility aids in formulation and bioavailability.
11. **hERG:** Ligand A (0.649) is better than Ligand B (0.252). Lower hERG inhibition is crucial for avoiding cardiotoxicity, especially important for a cardiovascular target.
12. **Cl_mic:** Ligand A (21.28) is worse than Ligand B (-21.6). Lower clearance is better for metabolic stability. This is a point in favor of Ligand B.
13. **t1/2:** Ligand A (-13.89) is worse than Ligand B (-4.72). Longer half-life is generally preferred. This is another point in favor of Ligand B.
14. **Pgp:** Ligand A (0.335) is better than Ligand B (0.005). Lower P-gp efflux is desirable for improved bioavailability.
15. **Binding Affinity:** Ligand B (-7.3) is slightly better than Ligand A (-5.9). A 1.4 kcal/mol difference is significant.
**Overall Assessment:**
While Ligand B has a slightly better binding affinity and improved metabolic stability (lower Cl_mic, longer t1/2), Ligand A overwhelmingly wins in almost all other critical ADME properties. Specifically, the significantly better TPSA, logP, QED, BBB, solubility, and hERG profile of Ligand A are crucial for a successful drug candidate, especially for a GPCR. The poor logP and high TPSA of Ligand B are major red flags, suggesting it will struggle with absorption and permeability. The better affinity of Ligand B isn't enough to overcome these substantial deficiencies.
Output:
1
2025-04-17 21:36:08,182 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (343.387 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (64.68) is significantly better than Ligand A (107.4). Lower TPSA is preferred for GPCRs, aiding in brain penetration and overall absorption.
3. **logP:** Both ligands have good logP values (A: 2.92, B: 1.212) within the optimal range (1-3). Ligand A is slightly higher, which could potentially lead to off-target effects, but is still acceptable.
4. **HBD:** Ligand A (1) has fewer HBDs than Ligand B (2), which is slightly preferable for permeability.
5. **HBA:** Ligand A (4) has fewer HBAs than Ligand B (5), again favoring permeability.
6. **QED:** Ligand B (0.796) has a higher QED score than Ligand A (0.516), indicating a more drug-like profile.
7. **DILI:** Ligand B (13.339) has a *much* lower DILI risk than Ligand A (59.519). This is a significant advantage for Ligand B.
8. **BBB:** Both ligands have good BBB penetration (A: 72.276, B: 74.292).
9. **Caco-2:** Ligand B (-5.448) has a slightly better Caco-2 permeability than Ligand A (-4.726).
10. **Solubility:** Ligand B (-2.052) has slightly better solubility than Ligand A (-2.642).
11. **hERG:** Both ligands have low hERG inhibition liability (A: 0.28, B: 0.498).
12. **Cl_mic:** Ligand B (13.153) has slightly lower microsomal clearance than Ligand A (15.27), suggesting better metabolic stability.
13. **t1/2:** Ligand A (32.526) has a significantly longer in vitro half-life than Ligand B (9.013). This is a major advantage for Ligand A.
14. **Pgp:** Both ligands have low P-gp efflux liability (A: 0.055, B: 0.017).
15. **Affinity:** Ligand A (-7.6 kcal/mol) has a stronger binding affinity than Ligand B (-6 kcal/mol). This is a substantial difference.
**Overall Assessment:**
While Ligand A has a better binding affinity and longer half-life, Ligand B demonstrates a far superior safety profile (DILI) and better ADME properties (TPSA, QED, Caco-2, Solubility, Cl_mic). The difference in binding affinity (1.6 kcal/mol) is significant, but the lower DILI risk of Ligand B is a critical factor. For a cardiovascular target, minimizing potential liver toxicity is paramount. The better TPSA and QED also contribute to a more favorable overall profile. The longer half-life of Ligand A is attractive, but can be addressed through formulation strategies.
Therefore, I prioritize Ligand B due to its superior safety and ADME profile, even with slightly weaker binding affinity.
Output:
0
2025-04-17 21:36:08,182 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.475 and 351.382 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (83.36) is better than Ligand B (96.33). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (1.52) is within the optimal 1-3 range. Ligand B (-0.246) is slightly below 1, which *could* indicate permeability issues. This is a point in favor of A.
4. **HBD:** Both ligands have acceptable HBD counts (3 and 2 respectively), well below the 5 threshold.
5. **HBA:** Both ligands have acceptable HBA counts (4 and 6 respectively), well below the 10 threshold.
6. **QED:** Both ligands have good QED scores (0.599 and 0.763), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (15.626) has a significantly lower DILI risk than Ligand B (72.741). This is a *major* advantage for Ligand A. DILI is a critical safety concern.
8. **BBB:** BBB is less important for a cardiovascular target. Ligand B (75.262) is higher, but the difference isn't crucial here.
9. **Caco-2:** Both have negative values, indicating poor permeability. Ligand B (-5.055) is worse than Ligand A (-4.997).
10. **Solubility:** Both have negative values, indicating poor solubility. Ligand A (-1.277) is better than Ligand B (-2.944).
11. **hERG:** Both ligands have very low hERG inhibition risk (0.121 and 0.349). No significant difference.
12. **Cl_mic:** Ligand B (-1.532) has a *negative* clearance, which is highly unusual and suggests very high metabolic stability. Ligand A (15.122) is moderate. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand A (12.95) has a longer half-life than Ligand B (6.95). This is a point in favor of A.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.032). No significant difference.
15. **Binding Affinity:** Ligand A (-7.2) has a slightly better binding affinity than Ligand B (-7.1). While the difference is small, it's still a positive for A.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are important. Ligand A is better on logP and TPSA, and has slightly better affinity. The DILI risk for Ligand A is substantially lower, which is a critical factor for any drug candidate. While Ligand B has a very favorable (and somewhat suspect) negative clearance, the DILI risk is a major concern.
**Conclusion:**
Despite the unusually low clearance of Ligand B, the significantly lower DILI risk and slightly better overall ADME profile (logP, TPSA, solubility, half-life, affinity) of Ligand A make it the more promising drug candidate.
Output:
1
2025-04-17 21:36:08,182 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (346.427) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (76.66) is better than Ligand B (51.02). Both are below the 140 A^2 threshold for oral absorption, but lower TPSA is generally preferred for GPCRs.
3. **logP:** Ligand A (1.673) is within the optimal range (1-3). Ligand B (4.616) is higher, potentially leading to solubility issues and off-target interactions. This is a significant negative for Ligand B.
4. **HBD:** Ligand A (2) is preferable to Ligand B (0). While both are acceptable, a small number of HBDs can aid solubility.
5. **HBA:** Ligand A (4) is preferable to Ligand B (5). Both are below the 10 threshold, but lower is better.
6. **QED:** Both ligands have similar QED values (A: 0.787, B: 0.702), indicating good drug-likeness.
7. **DILI:** Both ligands have acceptable DILI risk (A: 49.011, B: 45.328), below the 60 threshold.
8. **BBB:** Ligand A (71.035) is better than Ligand B (66.731). While ADRB2 isn't exclusively a CNS target, some CNS penetration can be beneficial, and higher BBB is generally favorable.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.925 and -4.852). This is unusual and suggests poor permeability.
10. **Solubility:** Ligand A (-2.531) is better than Ligand B (-4.544), indicating better aqueous solubility. This is important for bioavailability.
11. **hERG:** Both ligands have low hERG risk (A: 0.509, B: 0.737).
12. **Cl_mic:** Ligand A (24.756) has significantly lower microsomal clearance than Ligand B (74.005), suggesting better metabolic stability. This is a major advantage for Ligand A.
13. **t1/2:** Ligand A (18.128) has a shorter half-life than Ligand B (55.584), but the difference isn't drastic.
14. **Pgp:** Ligand A (0.095) has lower P-gp efflux liability than Ligand B (0.699), which is beneficial for oral bioavailability.
15. **Binding Affinity:** Both ligands have the same binding affinity (-6.4 kcal/mol).
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A excels in logP, TPSA, and Pgp, while the affinity is the same for both. The lower Cl_mic of Ligand A is also a significant advantage.
**Conclusion:**
Ligand A is the better candidate. While both have acceptable DILI and hERG, Ligand A demonstrates superior predicted ADME properties (logP, TPSA, solubility, Cl_mic, Pgp, BBB) and comparable binding affinity. The higher logP of Ligand B is a significant concern, potentially leading to poor solubility and off-target effects.
Output:
1
2025-04-17 21:36:08,182 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (358.829 Da and 353.463 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (80.05 and 82.11) are below the 140 A^2 threshold for good oral absorption, but higher than the 90 A^2 for CNS targets. Since ADRB2 is a cardiovascular target, CNS penetration isn't a primary concern.
3. **logP:** Ligand A (3.481) is within the optimal 1-3 range. Ligand B (-0.023) is slightly below 1, which *could* indicate permeability issues. This is a point in favor of A.
4. **HBD:** Both have 2 HBD, which is acceptable.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 5. Both are within the acceptable limit of 10.
6. **QED:** Both ligands have similar QED values (0.707 and 0.672), indicating good drug-like properties.
7. **DILI:** Ligand A (79.449) has a higher DILI risk than Ligand B (8.375). This is a significant drawback for Ligand A.
8. **BBB:** Ligand A (69.639) has better BBB penetration than Ligand B (49.826). However, as ADRB2 is a cardiovascular target, BBB penetration is not a high priority.
9. **Caco-2:** Ligand A (-5.035) and Ligand B (-4.838) both have negative Caco-2 values, which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-3.887) has slightly better solubility than Ligand B (-0.619).
11. **hERG:** Both ligands have low hERG inhibition liability (0.392 and 0.221).
12. **Cl_mic:** Ligand A (67.538) has a higher microsomal clearance than Ligand B (5.669), indicating lower metabolic stability. This favors Ligand B.
13. **t1/2:** Ligand A (102.241) has a much longer in vitro half-life than Ligand B (5.772). This is a strong advantage for Ligand A.
14. **Pgp:** Ligand A (0.262) has lower P-gp efflux liability than Ligand B (0.006). This is a slight advantage for Ligand A.
15. **Binding Affinity:** Ligand B (-6.8 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.7 kcal/mol). This is a substantial advantage for Ligand B, exceeding the 1.5 kcal/mol threshold.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand A has a better logP and Pgp, but Ligand B has a *much* better binding affinity. The affinity difference is the most important factor. While Ligand A has a better half-life, the DILI risk is concerning, and the affinity difference is significant.
**Conclusion:**
Despite the longer half-life of Ligand A, the significantly stronger binding affinity of Ligand B, coupled with the much lower DILI risk, makes it the more promising candidate. The slightly lower logP of Ligand B is a minor concern that could potentially be addressed through further optimization.
Output:
0
2025-04-17 21:36:08,183 - INFO - Here's my reasoning and the final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, the most important parameters are binding affinity, logP, TPSA, Pgp efflux, and BBB penetration. Metabolic stability (Cl_mic and t1/2) and safety (DILI, hERG) are also important considerations.
Let's compare the ligands property by property:
1. **MW:** Both ligands (341.382 and 350.547 Da) fall within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (47.56) is better than Ligand B (58.2), being closer to the <140 threshold for good absorption.
3. **logP:** Ligand B (4.205) is slightly higher than Ligand A (3.332). While both are above the optimal 1-3 range, Ligand B is pushing the upper limit and could present solubility issues.
4. **HBD/HBA:** Ligand A (1 HBD, 3 HBA) is preferable to Ligand B (2 HBD, 2 HBA) as lower counts generally improve permeability.
5. **QED:** Ligand A (0.931) has a significantly better QED score than Ligand B (0.58), indicating a more drug-like profile.
6. **DILI:** Ligand A (53.276) has a higher DILI risk than Ligand B (31.097), which is a negative for Ligand A.
7. **BBB:** Both ligands have good BBB penetration (Ligand A: 78.209, Ligand B: 70.143), but Ligand A is slightly better.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and difficult to interpret without further context.
9. **Solubility:** Ligand A (-4.072) has better solubility than Ligand B (-5.171).
10. **hERG:** Ligand A (0.739) has a slightly higher hERG risk than Ligand B (0.359), which is a negative for Ligand A.
11. **Cl_mic:** Ligand B (82.642) has a higher microsomal clearance than Ligand A (65.907), suggesting lower metabolic stability.
12. **t1/2:** Ligand A (21.352) has a much longer in vitro half-life than Ligand B (10.479).
13. **Pgp:** Ligand A (0.617) has lower P-gp efflux than Ligand B (0.323), which is favorable.
14. **Binding Affinity:** Ligand A (-7.1 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.4 kcal/mol). This is a substantial advantage.
**Overall Assessment:**
Ligand A has a significantly better binding affinity and a more favorable drug-like profile (higher QED, better solubility, longer half-life, lower Pgp efflux). While Ligand B has a lower DILI and hERG risk, the superior affinity of Ligand A, combined with its better ADME properties, outweighs these concerns. The slightly higher logP of Ligand B is a potential drawback. For a GPCR target, strong binding is paramount, and Ligand A clearly excels in this area.
**Output:**
1
2025-04-17 21:36:08,183 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (342.378 and 363.82 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (73.39) is significantly better than Ligand A (87.75). For a GPCR, lower TPSA is generally preferred for better permeability.
3. **logP:** Both ligands have good logP values (3.32 and 2.48), falling within the 1-3 range. Ligand B is slightly lower, which could be beneficial for solubility.
4. **HBD:** Ligand A (3) and Ligand B (4) are both acceptable, being less than 5.
5. **HBA:** Ligand A (6) and Ligand B (4) are both acceptable, being less than 10.
6. **QED:** Both ligands have similar QED scores (0.637 and 0.63), indicating good drug-likeness.
7. **DILI:** Both ligands have acceptable DILI risk (78.325 and 71.927), below the 80% threshold. Ligand B is slightly better.
8. **BBB:** Ligand B (51.532) is better than Ligand A (34.975), although neither is particularly high. For a cardiovascular target, BBB penetration isn't a primary concern, but it's still a positive.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.128 and -5.077), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Both ligands have poor solubility (-4.18 and -3.683). This is a major drawback for both.
11. **hERG:** Both ligands have low hERG inhibition risk (0.748 and 0.738).
12. **Cl_mic:** Ligand B (7.853) has significantly lower microsomal clearance than Ligand A (36.944), indicating better metabolic stability. This is a major advantage.
13. **t1/2:** Ligand B (15.815) has a much longer in vitro half-life than Ligand A (4.051), which is highly desirable.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.112 and 0.308).
15. **Binding Affinity:** Ligand B (-7.2 kcal/mol) has a significantly better binding affinity than Ligand A (-6.2 kcal/mol). This 1.0 kcal/mol difference is substantial and can outweigh some of the ADME drawbacks.
**Overall Assessment:**
While both ligands have significant issues with Caco-2 permeability and solubility, Ligand B is the superior candidate. Its significantly improved metabolic stability (lower Cl_mic, longer t1/2) and substantially stronger binding affinity (-7.2 vs -6.2 kcal/mol) outweigh the slightly lower BBB penetration and similar DILI risk. The lower TPSA of Ligand B is also a plus. The binding affinity difference is the most critical factor, given the GPCR target class.
Output:
0
2025-04-17 21:36:08,183 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (375.376) is slightly higher than Ligand B (343.45), but both are acceptable.
2. **TPSA:** Ligand A (83.28) is better than Ligand B (55.63), both are below the 140 threshold for good oral absorption, but Ligand B is closer to the 90 threshold for CNS targets.
3. **logP:** Ligand B (3.594) is slightly higher than Ligand A (2.327). Both are within the optimal range (1-3), but Ligand B is approaching the upper limit.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1). Both are within the acceptable limit of 5.
5. **HBA:** Ligand A (6) is higher than Ligand B (5). Both are within the acceptable limit of 10.
6. **QED:** Ligand A (0.863) is significantly better than Ligand B (0.67), indicating a more drug-like profile.
7. **DILI:** Ligand B (36.448) is significantly better than Ligand A (63.746), indicating a lower risk of drug-induced liver injury. This is a crucial advantage.
8. **BBB:** Ligand B (90.617) is significantly better than Ligand A (64.211). For a GPCR, even a non-CNS one, some BBB penetration can be advantageous for distribution.
9. **Caco-2:** Ligand A (-4.881) is better than Ligand B (-5.077), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-2.757) is better than Ligand B (-3.62). Better solubility is always preferable.
11. **hERG:** Ligand A (0.26) is better than Ligand B (0.599), indicating lower risk of hERG inhibition.
12. **Cl_mic:** Ligand A (-2.284) is significantly better than Ligand B (56.253), indicating better metabolic stability.
13. **t1/2:** Ligand A (13.373) is significantly better than Ligand B (3.887), indicating a longer half-life.
14. **Pgp:** Ligand A (0.143) is better than Ligand B (0.519), indicating lower P-gp efflux.
15. **Binding Affinity:** Ligand A (-7.7) is better than Ligand B (-6.8). This is a 1.5 kcal/mol advantage, which is substantial.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, Pgp, TPSA, and affinity. Ligand B has better logP and BBB penetration, while Ligand A has better TPSA, Pgp, and a significantly better binding affinity. The affinity difference is crucial.
**Overall Assessment:**
Ligand A has a superior binding affinity, better QED, better metabolic stability (Cl_mic and t1/2), better Pgp efflux, and a lower hERG risk. While Ligand B has a lower DILI risk and better BBB penetration, the substantial advantage in binding affinity and the overall more favorable ADME profile of Ligand A outweigh these benefits. The better solubility and Caco-2 permeability of Ligand A also contribute to its favorability.
Output:
1
2025-04-17 21:36:08,183 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (344.499 and 348.487 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (49.41) is better than Ligand B (58.64). Both are under the 140 A^2 threshold for good oral absorption, but lower TPSA is generally preferred for GPCRs to facilitate permeability.
3. **logP:** Both ligands have good logP values (3.276 and 2.679), falling within the optimal 1-3 range. Ligand A is slightly higher, which *could* be beneficial for membrane permeability, but isn't a major concern for either.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 2 HBA, while Ligand B has 3. Both are acceptable (<=10), but lower is slightly preferred.
6. **QED:** Ligand A (0.778) has a better QED score than Ligand B (0.686), indicating a more drug-like profile.
7. **DILI:** Both ligands have similar, acceptable DILI risk (16.557 and 16.906 percentile).
8. **BBB:** Ligand A (78.868) has a slightly better BBB penetration percentile than Ligand B (74.874). While ADRB2 isn't exclusively a CNS target, some CNS penetration can be beneficial, and minimizing off-target effects is always good.
9. **Caco-2:** Both have negative Caco-2 values (-4.753 and -4.64). This is unusual and suggests poor permeability. However, the values are very close, so this isn't a deciding factor.
10. **Solubility:** Ligand A (-3.324) has slightly better aqueous solubility than Ligand B (-2.417). Better solubility is always a plus.
11. **hERG:** Both ligands have low hERG inhibition liability (0.428 and 0.255). This is excellent.
12. **Cl_mic:** Ligand B (29.201) has significantly lower microsomal clearance than Ligand A (57.686). This indicates better metabolic stability for Ligand B, which is a significant advantage.
13. **t1/2:** Ligand A (-9.73) has a slightly longer in vitro half-life than Ligand B (-6.254). This is a positive, but the difference isn't huge.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.182 and 0.059).
15. **Binding Affinity:** Ligand B (-7.5 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.1 kcal/mol). This is a 1.4 kcal/mol difference, which is substantial and outweighs many of the other minor differences.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, affinity, logP, TPSA, and Pgp are key. Ligand B excels in affinity, has a good logP, acceptable TPSA, and low Pgp efflux. While Ligand A has slightly better BBB and solubility, the substantial affinity advantage of Ligand B is the most important factor. The lower clearance of Ligand B is also a significant benefit.
**Conclusion:**
Ligand B is the more promising drug candidate due to its significantly higher binding affinity and better metabolic stability.
Output:
0
2025-04-17 21:36:08,183 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (349.5 and 346.4 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (52.65) is significantly better than Ligand B (67.67). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand A is well below the 140 threshold, while Ligand B is approaching it.
**3. logP:** Both ligands have acceptable logP values (2.26 and 1.17), falling within the 1-3 range. Ligand A is slightly better, but both are reasonable.
**4. H-Bond Donors:** Ligand A has 1 HBD, while Ligand B has 0. Both are within the acceptable limit of <=5.
**5. H-Bond Acceptors:** Ligand A has 3 HBA, and Ligand B has 5. Both are within the acceptable limit of <=10.
**6. QED:** Both ligands have similar QED values (0.847 and 0.768), indicating good drug-like properties.
**7. DILI:** Ligand A (8.41) has a much lower DILI risk than Ligand B (44.09). This is a significant advantage for Ligand A.
**8. BBB:** Ligand A (75.11) has a better BBB penetration percentile than Ligand B (63.09). While ADRB2 isn't exclusively a CNS target, some peripheral effects are mediated by CNS pathways, and better BBB penetration can be advantageous.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.801 and -4.354). This is unusual and suggests poor permeability. However, the values are similar.
**10. Aqueous Solubility:** Both ligands have negative solubility values (-1.422 and -0.775), indicating poor solubility. This is a concern for both.
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (0.492 and 0.318).
**12. Microsomal Clearance:** Ligand A (-4.144) has significantly lower (better) microsomal clearance than Ligand B (27.917), indicating greater metabolic stability.
**13. In vitro Half-Life:** Ligand A (-5.055) has a much longer in vitro half-life than Ligand B (-21.762). This is a major advantage for Ligand A.
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (0.046 and 0.089).
**15. Binding Affinity:** Both ligands have very similar binding affinities (-7.2 and -7.3 kcal/mol). The difference is negligible.
**Overall Assessment:**
Ligand A is clearly the superior candidate. While both have issues with solubility and Caco-2 permeability, Ligand A demonstrates significantly better ADME properties: lower DILI risk, better BBB penetration, lower microsomal clearance, and a longer half-life. The binding affinity is comparable, so the improved ADME profile of Ligand A outweighs any minor drawbacks.
Output:
1
2025-04-17 21:36:08,184 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (344.459 Da and 344.455 Da) are within the ideal range (200-500 Da). No significant difference.
2. **TPSA:** Ligand A (58.44) is better than Ligand B (67.43). Lower TPSA generally favors better absorption, which is important for oral bioavailability.
3. **logP:** Both ligands have acceptable logP values (1.797 and 2.215, respectively), falling within the optimal range of 1-3. Ligand B is slightly higher, which could potentially lead to slightly reduced solubility but isn't a major concern.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer HBDs generally improve membrane permeability.
5. **HBA:** Ligand A (4) is slightly better than Ligand B (3). Lower HBA is generally favorable for permeability.
6. **QED:** Both ligands have good QED scores (0.758 and 0.831), indicating good drug-like properties. No significant difference.
7. **DILI:** Ligand A (17.1) is significantly better than Ligand B (29.159). Lower DILI risk is crucial for drug development. This is a substantial advantage for Ligand A.
8. **BBB:** Both ligands have good BBB penetration (77.007 and 71.656). While ADRB2 isn't exclusively a CNS target, some CNS exposure can occur, and higher BBB is generally preferable.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.927 and -4.843). These values are difficult to interpret without knowing the scale, but the values are similar.
10. **Solubility:** Ligand A (-1.529) is better than Ligand B (-2.809). Higher solubility is important for bioavailability.
11. **hERG:** Both ligands have low hERG inhibition liability (0.32 and 0.465). No significant difference.
12. **Cl_mic:** Ligand A (37.753) is significantly better than Ligand B (60.267). Lower microsomal clearance indicates better metabolic stability.
13. **t1/2:** Ligand A (-13.417) is better than Ligand B (1.047). A more negative value suggests a longer half-life.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.106 and 0.109). No significant difference.
15. **Binding Affinity:** Ligand B (-7.4) is slightly better than Ligand A (-7.3). However, the difference is small (0.1 kcal/mol).
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. While Ligand B has slightly better affinity, Ligand A excels in several other crucial areas: TPSA, HBD, DILI, Cl_mic, and solubility. The difference in affinity is small enough to be outweighed by the significantly better ADME properties of Ligand A.
**Conclusion:**
Ligand A demonstrates a superior balance of properties, particularly regarding safety (DILI) and metabolic stability (Cl_mic), alongside favorable TPSA and solubility. While Ligand B has a marginally better binding affinity, the overall profile of Ligand A makes it a more promising drug candidate.
Output:
1
2025-04-17 21:36:08,184 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [361.368, 79.26, 2.214, 2, 4, 0.863, 39.201, 78.17, -4.848, -3.115, 0.285, -9.891, -0.617, 0.015, -6.1]
**Ligand B:** [365.499, 60.93, 1.178, 0, 5, 0.692, 40.054, 94.184, -4.999, -2.301, 0.758, 61.728, -37.836, 0.197, -6.1]
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). A: 361.368, B: 365.499 - very similar.
2. **TPSA:** Ligand A (79.26) is slightly higher than Ligand B (60.93). Both are acceptable for a non-CNS GPCR, but B is better.
3. **logP:** Both are within the optimal range (1-3). A: 2.214, B: 1.178. A is slightly better, being closer to the middle of the range.
4. **HBD:** A (2) is better than B (0). Having some HBD can aid solubility.
5. **HBA:** A (4) is good, B (5) is also acceptable.
6. **QED:** A (0.863) is significantly better than B (0.692), indicating a more drug-like profile.
7. **DILI:** Both are good, below 40. A: 39.201, B: 40.054 - very similar.
8. **BBB:** Ligand B (94.184) is much higher than A (78.17). While ADRB2 is primarily cardiovascular, some CNS penetration might be acceptable or even beneficial depending on the specific therapeutic goal.
9. **Caco-2:** Both are very poor (-4.848 and -4.999). This is a significant concern for oral bioavailability.
10. **Solubility:** Both are very poor (-3.115 and -2.301). This is a major drawback for both compounds.
11. **hERG:** Both are low (0.285 and 0.758), indicating low cardiotoxicity risk.
12. **Cl_mic:** A (-9.891) is *much* better than B (61.728). Lower clearance is highly desirable for metabolic stability.
13. **t1/2:** A (-0.617) is better than B (-37.836), indicating a longer half-life.
14. **Pgp:** Both are very low (0.015 and 0.197), suggesting minimal efflux.
15. **Affinity:** Both have the same binding affinity (-6.1 kcal/mol).
**GPCR-Specific Priorities:**
For ADRB2 (a cardiovascular GPCR), we prioritize logP, TPSA, Pgp, and affinity. While BBB isn't critical, it's not detrimental. Metabolic stability (Cl_mic and t1/2) is important. Solubility and Caco-2 are significant concerns for oral bioavailability.
**Overall Assessment:**
Ligand A has a significantly better QED score, much better metabolic stability (Cl_mic and t1/2), and a slightly better logP and HBD count. While Ligand B has a better BBB score, the poor Caco-2 and solubility for both compounds are concerning. The superior drug-like properties and metabolic stability of Ligand A outweigh the slightly better BBB penetration of Ligand B. The poor absorption properties would require formulation strategies for both, but the better metabolic profile of A gives it an edge.
Output:
1
2025-04-17 21:36:08,184 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (345.443) is slightly lower, which could be advantageous for permeability.
2. **TPSA:** Ligand B (61.92) has a significantly lower TPSA than Ligand A (86.34). This is a major advantage for oral absorption and potentially better BBB penetration, aligning with GPCR priorities.
3. **logP:** Both ligands have good logP values (A: 2.803, B: 3.545) within the optimal 1-3 range. Ligand B is slightly higher, which could potentially lead to off-target effects, but is still acceptable.
4. **HBD:** Ligand A has 1 HBD, while Ligand B has 0. Both are within the acceptable limit of <=5.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 5. Both are within the acceptable limit of <=10.
6. **QED:** Both ligands have reasonable QED values (A: 0.889, B: 0.776), indicating good drug-like properties. Ligand A is slightly better.
7. **DILI:** Both ligands have acceptable DILI risk (A: 43.66, B: 47.421), below the 60 threshold.
8. **BBB:** Ligand B (80.884) has a significantly higher BBB penetration percentile than Ligand A (70.919). This is a crucial advantage for a GPCR target, even if not a CNS target, as it suggests better distribution.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. However, the scale is not specified, so it's difficult to interpret the magnitude of the difference.
10. **Solubility:** Both ligands have negative solubility values, indicating poor solubility. Again, the scale is not specified.
11. **hERG:** Both ligands have low hERG inhibition liability (A: 0.668, B: 0.537), which is good.
12. **Cl_mic:** Ligand A (21.063) has a significantly lower microsomal clearance than Ligand B (71.877), indicating better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand A (20.565) has a longer in vitro half-life than Ligand B (10.896), further supporting its better metabolic stability.
14. **Pgp:** Both ligands have low Pgp efflux liability (A: 0.322, B: 0.545).
15. **Binding Affinity:** Ligand A (-7.9 kcal/mol) has a substantially stronger binding affinity than Ligand B (-6.8 kcal/mol). This is a very important advantage, potentially outweighing some ADME concerns.
**Overall Assessment:**
Ligand A has a significantly better binding affinity and metabolic stability (lower Cl_mic, longer t1/2). Ligand B excels in TPSA and BBB penetration. While BBB is important for GPCRs, the substantial difference in binding affinity (-1.1 kcal/mol) in favor of Ligand A is a critical factor. The slightly better QED of Ligand A also contributes. The poor Caco-2 and solubility values are concerning for both, but can be addressed with formulation strategies.
Given the strong binding affinity and metabolic stability advantages of Ligand A, I believe it is the more promising drug candidate.
**Output:**
1
2025-04-17 21:36:08,184 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.305 and 348.487 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (91.58) is higher than Ligand B (60.85). While both are below 140, the lower TPSA of Ligand B is preferable for oral absorption, a key consideration for a cardiovascular target.
3. **logP:** Both ligands have good logP values (2.804 and 2.057), falling within the 1-3 range. Ligand B is slightly lower, which could be beneficial for solubility.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable, being less than 5. Ligand B is slightly better.
5. **HBA:** Ligand A (5) and Ligand B (3) are both acceptable, being less than 10. Ligand B is better.
6. **QED:** Ligand A (0.838) has a higher QED score than Ligand B (0.683), indicating a more drug-like profile. This is a significant advantage for Ligand A.
7. **DILI:** Ligand A (64.211) has a higher DILI risk than Ligand B (6.747). This is a major concern for Ligand A. Ligand B is significantly better.
8. **BBB:** Both ligands have similar BBB penetration (57.619 and 61.419). BBB penetration is less critical for a cardiovascular target like ADRB2, but slightly higher is still preferred.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.71 and -4.726), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand B (-1.513) has better solubility than Ligand A (-5.352). Better solubility is generally desirable.
11. **hERG:** Ligand A (0.768) has a slightly higher hERG risk than Ligand B (0.445), but both are relatively low.
12. **Cl_mic:** Ligand A (46.259) has lower microsomal clearance than Ligand B (54.714), indicating better metabolic stability. This is a positive for Ligand A.
13. **t1/2:** Ligand B (-21.746) has a much longer in vitro half-life than Ligand A (-1.416). This is a significant advantage for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.344 and 0.323).
15. **Binding Affinity:** Ligand A (-7.5) has a slightly better binding affinity than Ligand B (-6.0). However, the difference is not substantial enough to outweigh other factors.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Ligand B excels in TPSA and solubility, and has a good logP. Ligand A has a slightly better affinity and metabolic stability, but its significantly higher DILI risk is a major drawback.
**Overall Assessment:**
Despite Ligand A's slightly better affinity and QED, the significantly lower DILI risk and longer half-life of Ligand B make it the more promising candidate. The lower TPSA and better solubility of Ligand B are also beneficial. The Caco-2 permeability is a concern for both, but can be addressed with formulation strategies.
Output:
0
2025-04-17 21:36:08,184 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (356.86 and 352.46 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (55.05) is better than Ligand B (70.67). ADRB2 is not a CNS target, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (4.53 and 4.12), within the optimal 1-3 range, though slightly high. Ligand B is slightly better.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (4). Fewer HBAs generally improve permeability.
6. **QED:** Both ligands have similar, acceptable QED values (0.645 and 0.656).
7. **DILI:** Both ligands have similar, acceptable DILI risk (70.96 and 74.95).
8. **BBB:** Ligand A (95.66) is significantly better than Ligand B (46.76). While ADRB2 isn't a primary CNS target, higher BBB penetration can sometimes indicate better overall permeability and reduced efflux.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-5.04) is slightly better than Ligand B (-5.43).
10. **Solubility:** Both ligands have poor aqueous solubility (-3.78 and -3.94). This is a concern for both.
11. **hERG:** Both ligands have low hERG inhibition liability (0.76 and 0.64). This is good.
12. **Cl_mic:** Ligand B (63.03) has lower microsomal clearance than Ligand A (67.08), suggesting better metabolic stability.
13. **t1/2:** Ligand A (40.95) has a significantly longer in vitro half-life than Ligand B (-31.51). This is a major advantage.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.82 and 0.70).
15. **Binding Affinity:** Ligand A (-6.8 kcal/mol) has a slightly better binding affinity than Ligand B (-5.6 kcal/mol). This difference of 1.2 kcal/mol is substantial and can outweigh some ADME drawbacks.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A has a better balance of these properties. The significantly longer half-life of Ligand A is also a major plus. While both have poor solubility, the superior binding affinity and half-life of Ligand A make it the more promising candidate.
**Final Decision:**
1
2025-04-17 21:36:08,185 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Step-by-step comparison:**
1. **MW:** Both ligands (360.445 and 353.463 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (75.27) is better than Ligand B (87.74). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally aids absorption.
3. **logP:** Ligand A (2.971) is optimal, while Ligand B (0.968) is slightly low, potentially impacting permeability.
4. **HBD:** Both have 2 HBD, which is acceptable.
5. **HBA:** Ligand A has 3 HBA, Ligand B has 4. Both are within the acceptable range.
6. **QED:** Both ligands have similar QED values (0.621 and 0.681), indicating good drug-likeness.
7. **DILI:** Ligand B (18.883) has a significantly lower DILI risk than Ligand A (45.25). This is a major advantage for Ligand B.
8. **BBB:** Ligand A (87.631) has better BBB penetration than Ligand B (57.619), but this isn't a primary concern for a cardiovascular target.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-3.188) has slightly better solubility than Ligand B (-1.751), but both are quite poor.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.36 and 0.06).
12. **Cl_mic:** Ligand B (16.387) has lower microsomal clearance than Ligand A (27.778), indicating better metabolic stability.
13. **t1/2:** Ligand B (5.907) has a longer in vitro half-life than Ligand A (-14.197). This is a significant advantage.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.095 and 0.014).
15. **Affinity:** Ligand B (-6.1 kcal/mol) has a substantially stronger binding affinity than Ligand A (-2.0 kcal/mol). This is a decisive advantage, exceeding the 1.5 kcal/mol threshold.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand B is better on logP, TPSA, and *significantly* better on affinity. While Ligand A has better BBB, this is less critical for a cardiovascular target. The lower DILI and better metabolic stability of Ligand B are also important positives.
**Conclusion:**
Despite the poor Caco-2 and solubility values for both, Ligand B's superior binding affinity, lower DILI risk, and better metabolic stability outweigh the advantages of Ligand A.
Output:
0
2025-04-17 21:36:08,185 - INFO - Batch 270 complete. Total preferences: 4320
2025-04-17 21:36:08,185 - INFO - Processing batch 271/512...
2025-04-17 21:36:57,004 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, the key priorities are logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB.
Let's break down the comparison:
1. **MW:** Both ligands are within the acceptable range (200-500 Da). Ligand A (355.385) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (70.67) is significantly better than Ligand B (92.01). A TPSA under 140 is good for oral absorption, and lower is better for GPCRs.
3. **logP:** Ligand A (3.484) is optimal, while Ligand B (1.188) is on the lower side. This could hinder membrane permeability for Ligand B.
4. **HBD/HBA:** Both have acceptable HBD counts (2). Ligand B has a higher HBA count (6 vs 3), which could slightly impact permeability.
5. **QED:** Ligand A (0.853) has a better QED score than Ligand B (0.635), indicating better overall drug-likeness.
6. **DILI:** Both have similar DILI risk (around 60%), which is acceptable but not ideal.
7. **BBB:** Ligand A (72.819) has a better BBB percentile than Ligand B (28.848). While not a CNS target, some degree of BBB penetration can be favorable for distribution.
8. **Caco-2:** Ligand B (-5.439) has a better Caco-2 permeability score than Ligand A (-4.321), suggesting better intestinal absorption.
9. **Solubility:** Ligand B (-2.538) has a better solubility score than Ligand A (-3.836).
10. **hERG:** Both have very low hERG inhibition risk (0.154 and 0.441).
11. **Cl_mic:** Ligand B (21.526) has a lower microsomal clearance, suggesting better metabolic stability than Ligand A (29.578).
12. **t1/2:** Ligand B (31.879) has a longer in vitro half-life than Ligand A (24.539).
13. **Pgp:** Ligand A (0.033) has a much lower Pgp efflux liability than Ligand B (0.165), which is a significant advantage for bioavailability and potentially reaching the target.
14. **Binding Affinity:** Ligand B (-6.6 kcal/mol) has a significantly stronger binding affinity than Ligand A (-4.5 kcal/mol). This is a substantial advantage.
**Overall Assessment:**
Ligand B has a significantly better binding affinity and improved metabolic stability (lower Cl_mic, longer t1/2) and solubility. However, Ligand A excels in TPSA, logP, QED, and Pgp efflux. The difference in binding affinity (-6.6 vs -4.5 kcal/mol) is substantial (a 2.1 kcal/mol difference), and this outweighs the benefits of Ligand A's better ADME properties, especially considering the acceptable ADME profile of Ligand B. The lower logP of Ligand B is a concern, but the strong binding affinity may compensate for this.
Output:
0
2025-04-17 21:36:57,005 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (378.705 and 379.913 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (55.76) is better than Ligand B (71.09). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (4.326 and 4.071), falling within the optimal 1-3 range, though slightly high.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD is generally better for permeability.
5. **HBA:** Both ligands have the same number of HBA (4).
6. **QED:** Ligand B (0.711) is slightly better than Ligand A (0.621), indicating a more drug-like profile.
7. **DILI:** Ligand A (61.962) has a lower DILI risk than Ligand B (77.782). This is a significant advantage.
8. **BBB:** Both ligands have moderate BBB penetration (A: 48.662, B: 52.656). Not a major factor for a cardiovascular target.
9. **Caco-2:** Ligand A (-4.82) is slightly better than Ligand B (-5.062), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-4.894) is slightly better than Ligand B (-5.149).
11. **hERG:** Both ligands have similar hERG inhibition liability (A: 0.635, B: 0.719).
12. **Cl_mic:** Ligand B (74.676) has lower microsomal clearance than Ligand A (84.451), suggesting better metabolic stability.
13. **t1/2:** Ligand B (46.382) has a longer half-life than Ligand A (23.745). This is a significant advantage.
14. **Pgp:** Both ligands have similar Pgp efflux liability (A: 0.539, B: 0.492).
15. **Binding Affinity:** Ligand A (-7.6 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.2 kcal/mol). This is a 1.4 kcal/mol difference, which is substantial.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), affinity, logP, and metabolic stability are key. Ligand A has a much better binding affinity. While Ligand B has better metabolic stability (lower Cl_mic and longer t1/2), the substantial affinity difference of Ligand A outweighs this. The slightly higher DILI risk of Ligand B is also a concern.
**Conclusion:**
The significantly stronger binding affinity of Ligand A, coupled with acceptable ADME properties and a lower DILI risk, makes it the more promising drug candidate despite the slightly lower metabolic stability.
Output:
1
2025-04-17 21:36:57,005 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (369.849 Da and 367.837 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (104.46) is slightly higher than Ligand B (102.05). Both are below the 140 A^2 threshold for good oral absorption, but neither are optimized for CNS penetration (below 90 A^2).
3. **logP:** Both ligands have good logP values (1.751 and 1.565 respectively), falling within the optimal 1-3 range. Ligand B is slightly lower, which could marginally improve solubility.
4. **HBD:** Ligand A has 3 HBD, while Ligand B has 2. Both are within the acceptable limit of <=5.
5. **HBA:** Ligand A has 5 HBA, and Ligand B has 6. Both are within the acceptable limit of <=10.
6. **QED:** Both ligands have excellent QED scores (0.708 and 0.737), indicating good drug-like properties.
7. **DILI:** Ligand A (48.507) has a lower DILI risk than Ligand B (57.154). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (65.219) has a better BBB percentile than Ligand B (30.593). While ADRB2 isn't exclusively a CNS target, some peripheral ADRB2 activity can influence CNS function, and better BBB penetration is generally favorable.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.956 and -5.466). This is unusual and suggests very poor permeability. This is a major concern for both.
10. **Solubility:** Ligand B (-1.546) has better solubility than Ligand A (-3.029). This is a positive for Ligand B.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.157 and 0.228). This is excellent.
12. **Cl_mic:** Ligand A (18.847) has lower microsomal clearance than Ligand B (25.32), indicating better metabolic stability.
13. **t1/2:** Ligand A (27.069) has a longer in vitro half-life than Ligand B (-0.156). This is a significant advantage for Ligand A.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.117 and 0.059). This is excellent.
15. **Affinity:** Ligand B (-7.4 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.5 kcal/mol). This is a substantial advantage, exceeding the 1.5 kcal/mol threshold where it can outweigh other drawbacks.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. While both ligands have acceptable logP and Pgp values, Ligand B's significantly higher binding affinity is the most important factor. The poor Caco-2 values are a concern for both, but a strong binding affinity can sometimes compensate for permeability issues, especially if alternative routes of administration are considered.
**Overall Assessment:**
Despite Ligand A's advantages in DILI, BBB, metabolic stability, and half-life, Ligand B's substantially stronger binding affinity (-7.4 vs -5.5 kcal/mol) is the deciding factor. The difference in affinity is large enough to potentially overcome the slightly higher DILI risk and poorer BBB penetration. The poor Caco-2 values are a concern for both, but the potency advantage of Ligand B is crucial for a GPCR target.
Output:
0
2025-04-17 21:36:57,005 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (351.491) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (72.88) is better than Ligand B (51.02). Both are below 140, but Ligand B is closer to the ideal for CNS penetration (though ADRB2 isn't necessarily a CNS target).
3. **logP:** Ligand A (1.297) is optimal, while Ligand B (4.062) is pushing the upper limit and could present solubility issues. This is a significant advantage for Ligand A.
4. **HBD:** Ligand A (2) is preferable to Ligand B (0). Having some HBD can improve solubility.
5. **HBA:** Ligand A (4) is preferable to Ligand B (6).
6. **QED:** Both ligands are similar (0.678 vs 0.626), indicating good drug-likeness.
7. **DILI:** Ligand A (8.026) is significantly better than Ligand B (61.225). This is a major advantage for Ligand A, as DILI is a critical safety concern.
8. **BBB:** Ligand A (57.193) is better than Ligand B (52.191), but neither is particularly high. Since ADRB2 isn't a primary CNS target, this isn't a deciding factor.
9. **Caco-2:** Ligand A (-4.831) is better than Ligand B (-5.193), suggesting better absorption.
10. **Solubility:** Ligand A (-0.643) is better than Ligand B (-3.226). Solubility is a key factor, and Ligand B's low solubility is a concern.
11. **hERG:** Ligand A (0.105) is much better than Ligand B (0.343). Lower hERG inhibition is crucial for avoiding cardiotoxicity, especially for a cardiovascular target like ADRB2.
12. **Cl_mic:** Ligand A (8.506) is better than Ligand B (68.15). Lower clearance implies greater metabolic stability, which is desirable.
13. **t1/2:** Ligand A (-16.083) is better than Ligand B (21.328). A negative value suggests a very long half-life, which is a significant advantage.
14. **Pgp:** Ligand A (0.012) is much better than Ligand B (0.264). Lower P-gp efflux is favorable for bioavailability.
15. **Affinity:** Both ligands have similar binding affinities (-6.0 vs -5.3 kcal/mol). Ligand A has a slight advantage, but it's not substantial enough to overcome the other ADME differences.
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Ligand A excels in logP, Pgp, and has a comparable affinity. While Ligand B has a lower TPSA, the significant drawbacks in solubility, DILI, hERG, and metabolic stability outweigh this benefit.
**Conclusion:**
Ligand A is significantly better across multiple critical ADME properties (DILI, solubility, hERG, metabolic stability, Pgp efflux) and has a slightly better logP. While the binding affinity is comparable, the improved ADME profile of Ligand A makes it a much more promising drug candidate.
Output:
1
2025-04-17 21:36:57,005 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
The ADRB2 receptor is a GPCR, so the priorities are logP, Pgp, TPSA, affinity, and BBB. Let's break down the comparison:
1. **Molecular Weight:** Both ligands (347.46 and 367.48 Da) are within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (75.44) is better than Ligand B (89.87). Lower TPSA generally favors better cell permeability, which is important for GPCR targeting.
3. **logP:** Ligand A (2.54) is within the optimal 1-3 range. Ligand B (-0.085) is *below* 1, which is a concern for permeability. This is a significant negative for Ligand B.
4. **H-Bond Donors:** Both have 1 HBD, which is acceptable.
5. **H-Bond Acceptors:** Ligand A has 4, and Ligand B has 7. Ligand A is preferable here, as fewer HBAs generally improve permeability.
6. **QED:** Both are very similar (0.822 and 0.80), indicating good drug-likeness.
7. **DILI:** Both have acceptable DILI risk (35.79 and 38.00 percentile).
8. **BBB:** Ligand A (76.70) is better than Ligand B (64.25). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant, and higher BBB is generally favorable.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and difficult to interpret without further context. However, it suggests poor permeability.
10. **Solubility:** Both have negative solubility values, which is also unusual.
11. **hERG:** Both have low hERG risk (0.314 and 0.478).
12. **Cl_mic:** Ligand A (58.28) has a higher microsomal clearance than Ligand B (26.97), indicating potentially lower metabolic stability. This favors Ligand B.
13. **t1/2:** Ligand A (-3.595) has a more negative in vitro half-life than Ligand B (-1.548), indicating a shorter half-life and favoring Ligand B.
14. **Pgp:** Both have low Pgp efflux liability (0.321 and 0.12).
15. **Binding Affinity:** Ligand B (-6.8 kcal/mol) has a slightly better binding affinity than Ligand A (-6.5 kcal/mol). This is a 0.3 kcal/mol difference, which is not substantial enough to overcome the significant drawbacks of Ligand B.
**Overall Assessment:**
Ligand A is the better candidate. While Ligand B has slightly better affinity and metabolic stability, Ligand A's superior logP, TPSA, and BBB penetration are crucial for a GPCR target like ADRB2. The negative logP of Ligand B is a major concern, likely leading to poor permeability and bioavailability.
Output:
1
2025-04-17 21:36:57,005 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [338.451, 61.96, 3.905, 2, 2, 0.891, 70.221, 61.807, -4.712, -5.354, 0.427, 27.249, -11.275, 0.379, -7.6]
**Ligand B:** [365.817, 93.46, 1.525, 2, 5, 0.792, 75.766, 52.617, -4.994, -3.484, 0.201, -1.508, 7.769, 0.197, -6]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, Affinity, and BBB):
1. **MW:** Both are within the acceptable range (200-500 Da). A is slightly better at 338 vs 365.
2. **TPSA:** A (61.96) is significantly better than B (93.46). Lower TPSA is preferred for GPCRs, aiding permeability. B is pushing the upper limit for good oral absorption.
3. **logP:** A (3.905) is optimal. B (1.525) is a bit low, potentially hindering membrane permeability.
4. **HBD/HBA:** Both have 2 HBD, which is good. A has 2 HBA, while B has 5. A is preferable here.
5. **QED:** A (0.891) is better than B (0.792), indicating a more drug-like profile.
6. **DILI:** Both are relatively high (A: 70.221, B: 75.766), but within a range that isn't immediately disqualifying.
7. **BBB:** A (61.807) is better than B (52.617), though neither are exceptionally high. For a cardiovascular target, BBB isn't *critical*, but still a positive.
8. **Caco-2:** Both are negative, indicating poor permeability.
9. **Solubility:** Both are negative, indicating poor solubility.
10. **hERG:** A (0.427) is better than B (0.201), indicating lower cardiotoxicity risk.
11. **Cl_mic:** A (27.249) is higher than B (-1.508), indicating lower metabolic stability. This is a drawback for A.
12. **t1/2:** A (-11.275) is much worse than B (7.769), indicating very short half-life. This is a significant drawback for A.
13. **Pgp:** A (0.379) is better than B (0.197), indicating lower P-gp efflux.
14. **Affinity:** A (-7.6) is significantly better than B (-6). A has a 1.6 kcal/mol advantage.
**Overall Assessment:**
Ligand A has a clear advantage in TPSA, logP, QED, hERG, and *especially* binding affinity. The affinity difference is substantial and could outweigh some of the ADME concerns. However, Ligand A's poor metabolic stability (high Cl_mic) and very short half-life are major concerns. Ligand B has better metabolic stability and half-life, but suffers from a higher TPSA, lower logP, and weaker binding.
Given the GPCR target class, the binding affinity is paramount. The 1.6 kcal/mol difference is significant. While the ADME profile of A is less ideal, optimization efforts could focus on improving its metabolic stability and half-life. The lower TPSA and better logP of A also contribute to better potential for cell permeability.
Therefore, I favor Ligand A.
1
2025-04-17 21:36:57,006 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (363.82 and 367.555 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (61.44) is higher than Ligand B (42.68). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is generally preferred for absorption. Ligand B is better.
3. **logP:** Ligand A (3.811) is within the optimal 1-3 range, while Ligand B (4.654) is slightly above. While still acceptable, the higher logP of B could potentially lead to off-target interactions or solubility issues. Ligand A is better.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (0). This isn't a major concern for either.
5. **HBA:** Ligand A (2) is lower than Ligand B (4). Lower HBA is generally preferable for permeability. Ligand A is better.
6. **QED:** Ligand A (0.867) has a substantially better QED score than Ligand B (0.67), indicating a more drug-like profile. Ligand A is significantly better.
7. **DILI:** Ligand B (22.024) has a much lower DILI risk than Ligand A (73.517). This is a significant advantage for Ligand B.
8. **BBB:** Both ligands have reasonably good BBB penetration (A: 69.523, B: 61.962), but A is slightly better. However, BBB isn't a primary concern for a cardiovascular target.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. This is a concern for both.
10. **Solubility:** Both have negative solubility values, indicating poor solubility. This is a concern for both.
11. **hERG:** Both ligands have low hERG inhibition risk (A: 0.726, B: 0.77). No significant difference.
12. **Cl_mic:** Ligand A (50.153) has a significantly lower microsomal clearance than Ligand B (95.561), suggesting better metabolic stability. Ligand A is better.
13. **t1/2:** Ligand B (78.97) has a slightly longer in vitro half-life than Ligand A (71.931). This is a minor advantage for Ligand B.
14. **Pgp:** Ligand A (0.17) has a much lower P-gp efflux liability than Ligand B (0.528), suggesting better oral bioavailability and potentially better tissue distribution. Ligand A is significantly better.
15. **Binding Affinity:** Ligand B (-6.5 kcal/mol) has a slightly better binding affinity than Ligand A (-5.5 kcal/mol). This is a 1 kcal/mol difference, which is significant, but needs to be weighed against other factors.
**Overall Assessment:**
Ligand B has a better binding affinity and lower DILI risk, which are both important. However, Ligand A demonstrates superior drug-likeness (QED), metabolic stability (Cl_mic), and P-gp efflux liability. The lower TPSA and HBA of Ligand A are also favorable. The slightly higher logP of Ligand B is a minor concern. Considering the balance of properties, and prioritizing drug-likeness and metabolic stability for a cardiovascular target, Ligand A appears to be the more promising candidate.
Output:
1
2025-04-17 21:36:57,006 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (363.487 Da and 373.45 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (69.64) is significantly better than Ligand B (91.5). For a GPCR, keeping TPSA low is beneficial for permeability, and Ligand A is well below the 140 threshold. Ligand B is approaching the upper limit.
**3. logP:** Both ligands have acceptable logP values (0.626 and 1.245), falling within the 1-3 range. Ligand B is slightly better, but both are reasonable.
**4. H-Bond Donors:** Ligand A has 0 HBD, which is excellent. Ligand B has 2, which is still acceptable but less ideal.
**5. H-Bond Acceptors:** Ligand A has 6 HBA, and Ligand B has 4. Both are within the acceptable range of <=10.
**6. QED:** Both ligands have good QED scores (0.785 and 0.812), indicating good drug-like properties. No clear advantage.
**7. DILI Risk:** Ligand A (13.843) has a much lower DILI risk than Ligand B (52.423). This is a significant advantage for Ligand A.
**8. BBB Penetration:** Both ligands have reasonable BBB penetration (68.321 and 70.997). Ligand B is slightly better, but this isn't a primary concern for ADRB2, which isn't a CNS target.
**9. Caco-2 Permeability:** Ligand A (-5.116) has worse Caco-2 permeability than Ligand B (-4.626).
**10. Aqueous Solubility:** Ligand A (-0.845) has worse aqueous solubility than Ligand B (-2.864).
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.147 and 0.404). No significant difference.
**12. Microsomal Clearance:** Ligand A (-10.42) has significantly lower microsomal clearance than Ligand B (22.073), indicating better metabolic stability. This is a major advantage for Ligand A.
**13. In vitro Half-Life:** Ligand A (1.73) has a much shorter half-life than Ligand B (-56.98). This is a significant drawback for Ligand A.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.026). No significant difference.
**15. Binding Affinity:** Ligand A (-6.6) has a slightly better binding affinity than Ligand B (-4.9). This is a meaningful difference, as a ~1.7 kcal/mol advantage can outweigh some ADME concerns.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand A emerges as the more promising candidate. While Ligand B has better Caco-2 permeability, solubility, and half-life, Ligand A's superior TPSA, significantly lower DILI risk, better metabolic stability (lower Cl_mic), and slightly better binding affinity are more critical. The lower DILI risk is particularly important for cardiovascular targets. The difference in half-life is a concern, but could potentially be addressed through prodrug strategies or formulation approaches.
Output:
1
2025-04-17 21:36:57,006 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
Let's systematically compare Ligand A and Ligand B based on the provided parameters and the guidelines, keeping in mind that ADRB2 is a GPCR, so logP, Pgp, TPSA, and affinity are particularly important.
1. **MW:** Both ligands (347.438 Da and 351.491 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (64.86) is better than Ligand B (70.67). Both are below 140, but lower TPSA generally favors absorption.
3. **logP:** Ligand A (2.839) is better than Ligand B (1.153). Both are within the 1-3 range, but Ligand B is closer to the lower limit, potentially impacting permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs are generally better for permeability.
5. **HBA:** Ligand A (6) is preferable to Ligand B (4). Lower HBA is generally better for permeability.
6. **QED:** Ligand B (0.722) is slightly better than Ligand A (0.588), indicating a more drug-like profile.
7. **DILI:** Ligand B (18.418) is *significantly* better than Ligand A (39.589). This is a major advantage for Ligand B, as lower DILI risk is crucial.
8. **BBB:** Both ligands have good BBB penetration (Ligand A: 70.182, Ligand B: 74.835), but Ligand B is slightly better. This is relevant for a GPCR, but less critical for ADRB2 specifically as it's not a CNS target.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.003 and -4.864). This is unusual and suggests poor permeability. However, the values are similar.
10. **Solubility:** Ligand B (-2.041) is better than Ligand A (-3.273). Higher solubility is always desirable.
11. **hERG:** Both ligands have low hERG inhibition risk (Ligand A: 0.496, Ligand B: 0.34). No significant difference.
12. **Cl_mic:** Ligand B (42.962) has a lower microsomal clearance than Ligand A (62.923), indicating better metabolic stability.
13. **t1/2:** Ligand B (-0.637) has a longer in vitro half-life than Ligand A (13.771). This is a significant advantage.
14. **Pgp:** Ligand A (0.339) is better than Ligand B (0.039). Lower P-gp efflux is preferable.
15. **Binding Affinity:** Ligand B (-8.3) has a *much* stronger binding affinity than Ligand A (-6.0). A 2.3 kcal/mol difference is substantial and can often outweigh minor ADME drawbacks.
**Overall Assessment:**
While Ligand A has slightly better TPSA and Pgp efflux, Ligand B excels in several critical areas: DILI risk, metabolic stability (Cl_mic), half-life, solubility, and, most importantly, binding affinity. The significantly stronger binding affinity of Ligand B (-8.3 kcal/mol) is a major driver for selection. The improved DILI profile is also a critical factor. The slightly lower logP of Ligand B is a minor concern, but the other advantages outweigh this.
**Output:**
0
2025-04-17 21:36:57,006 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [353.379, 128.61 , -0.749, 2. , 6. , 0.444, 55.487, 30.748, -5.533, -0.578, 0.008, 12.429, -10.534, 0.008, -8.9 ]
**Ligand B:** [355.479, 90.9 , 0.269, 3. , 5. , 0.552, 5.894, 27.375, -5.313, 0.048, 0.076, -12.405, 1.832, 0.007, -5. ]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity) are paramount:
1. **MW:** Both are within the ideal range (200-500 Da). A is 353.379, B is 355.479 - negligible difference.
2. **TPSA:** Ligand B (90.9) is significantly better than Ligand A (128.61). Lower TPSA generally improves BBB penetration and oral absorption, crucial for GPCRs.
3. **logP:** Ligand A (-0.749) is a bit low, potentially hindering permeability. Ligand B (0.269) is better, though still on the lower side of optimal (1-3).
4. **HBD/HBA:** Ligand A (2 HBD, 6 HBA) is slightly better than Ligand B (3 HBD, 5 HBA) in terms of maintaining a balance for permeability and solubility.
5. **QED:** Ligand B (0.552) has a slightly better QED score than Ligand A (0.444), indicating a more drug-like profile.
6. **DILI:** Ligand B (5.894) has a *much* lower DILI risk than Ligand A (55.487). This is a major advantage for Ligand B.
7. **BBB:** Ligand A (30.748) has a slightly better BBB percentile than Ligand B (27.375), but both are relatively low. This isn't a huge concern for ADRB2 (cardiovascular target), but still favors A.
8. **Caco-2:** Both are very poor (-5.533 and -5.313). This is a significant drawback for both.
9. **Solubility:** Ligand B (0.048) is slightly better than Ligand A (-0.578), but both are very poor.
10. **hERG:** Both are very low risk (0.008 and 0.076).
11. **Cl_mic:** Ligand B (-12.405) has a lower (better) microsomal clearance than Ligand A (12.429), suggesting better metabolic stability.
12. **t1/2:** Ligand B (1.832) has a slightly better in vitro half-life than Ligand A (-10.534).
13. **Pgp:** Both are very low efflux (0.008 and 0.007).
14. **Affinity:** Ligand A (-8.9 kcal/mol) has a significantly stronger binding affinity than Ligand B (-5.0 kcal/mol). This is a substantial advantage.
**Overall Assessment:**
The biggest differentiating factor is the binding affinity. Ligand A is *much* more potent. However, Ligand B has a significantly lower DILI risk, a better QED score, and better metabolic stability. The TPSA of Ligand B is also significantly better. While both have poor Caco-2 and solubility, the superior affinity of Ligand A is a critical advantage for a GPCR target, potentially allowing for lower doses and mitigating some of the ADME concerns. The difference in affinity (-8.9 vs -5.0) is substantial (3.9 kcal/mol), and this outweighs the other drawbacks.
Therefore, I would choose Ligand A.
Output:
1
2025-04-17 21:36:57,006 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for their potential as drug candidates targeting the ADRB2, a cardiovascular GPCR. Therefore, we prioritize logP, Pgp, TPSA, and binding affinity, alongside general drug-like properties.
* **Molecular Weight:** Both ligands (341.451 and 339.483 Da) are within the ideal range (200-500 Da).
* **TPSA:** Ligand A (47.56) is slightly higher than Ligand B (37.39). Both are acceptable, but Ligand B is preferable.
* **logP:** Both ligands have logP values (4.013 and 4.816) that are at the upper end of the optimal range (1-3). Ligand B is slightly higher, potentially causing solubility issues, but not drastically.
* **H-Bond Donors/Acceptors:** Both have acceptable HBD (1) and HBA (3/4) counts.
* **QED:** Both ligands have similar, good QED scores (0.823 and 0.819).
* **DILI:** Both ligands have low DILI risk (37.728 and 36.293 percentile), which is excellent.
* **BBB:** Ligand A (81.039) has a better BBB penetration score than Ligand B (77.162), though this isn't a primary concern for a cardiovascular target.
* **Caco-2 Permeability:** Ligand A (-4.855) has slightly better Caco-2 permeability than Ligand B (-4.536).
* **Aqueous Solubility:** Ligand B (-5.454) has slightly worse aqueous solubility than Ligand A (-4.632).
* **hERG Inhibition:** Both ligands have low hERG inhibition risk (0.702 and 0.874).
* **Microsomal Clearance:** Ligand A (83.041) has significantly lower microsomal clearance than Ligand B (110.476), suggesting better metabolic stability.
* **In vitro Half-Life:** Ligand A (10.803) has a longer in vitro half-life than Ligand B (7.889).
* **P-gp Efflux:** Both ligands have similar P-gp efflux liability (0.729 and 0.573).
* **Binding Affinity:** Ligand B (-8.0 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.6 kcal/mol). This is a substantial advantage, exceeding the 1.5 kcal/mol threshold.
**Conclusion:**
Despite Ligand A having slightly better metabolic stability, half-life, and solubility, the significantly stronger binding affinity of Ligand B (-8.0 vs -6.6 kcal/mol) is the deciding factor. For a GPCR target, potency is paramount, and this difference is likely to outweigh the minor ADME drawbacks of Ligand B.
**Output:**
0
2025-04-17 21:36:57,007 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for the ADRB2, a cardiovascular GPCR. Therefore, the key priorities are logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB.
Let's break down the comparison:
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (352.4) is slightly better.
2. **TPSA:** Ligand A (67.87) is significantly better than Ligand B (93.01). Lower TPSA is favorable for permeability, especially for a GPCR.
3. **logP:** Both are good (around 1.2-1.5). Ligand B (1.199) is slightly lower, which *could* be a minor drawback, but both are acceptable.
4. **HBD/HBA:** Both have 1 HBD, which is good. Ligand B has 7 HBA vs. 4 for Ligand A. This difference in HBA could slightly impact solubility and permeability.
5. **QED:** Both are very similar and good (0.843 vs 0.812).
6. **DILI:** Ligand A (31.7) is significantly better than Ligand B (80.7). This is a major advantage for Ligand A.
7. **BBB:** Ligand A (93.6) is much better than Ligand B (51.1). While not a primary concern for a cardiovascular target, higher BBB is generally a positive.
8. **Caco-2:** Ligand A (-4.385) is better than Ligand B (-5.555), indicating better intestinal absorption.
9. **Solubility:** Both are poor (-2.131 and -2.38), but similar.
10. **hERG:** Ligand A (0.596) is better than Ligand B (0.138) - lower hERG inhibition is preferred.
11. **Cl_mic:** Ligand B (-3.071) has a negative value, indicating *lower* clearance and better metabolic stability than Ligand A (10.481). This is a significant advantage for Ligand B.
12. **t1/2:** Ligand B (-0.981) has a negative value, indicating a longer half-life than Ligand A (1.495). This is also a significant advantage for Ligand B.
13. **Pgp:** Ligand A (0.156) is better than Ligand B (0.059), indicating lower P-gp efflux.
14. **Binding Affinity:** Ligand B (-7.3) has a 0.8 kcal/mol stronger binding affinity than Ligand A (-6.5). This is a substantial advantage that can outweigh some ADME concerns.
**Overall Assessment:**
Ligand B has a significantly better binding affinity and metabolic stability (lower Cl_mic, longer t1/2). Ligand A excels in TPSA, DILI risk, BBB, Caco-2, hERG, and Pgp. The stronger binding affinity of Ligand B is a critical factor for GPCRs. While Ligand A has a better safety profile (DILI, hERG), the improved potency and metabolic stability of Ligand B are more important for a cardiovascular target.
Output:
0
2025-04-17 21:36:57,007 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands (355.385 and 357.426 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (80.32) is better than Ligand B (87.74). Both are under 140, but lower TPSA generally favors absorption.
3. **logP:** Ligand A (3.33) is optimal, while Ligand B (0.527) is quite low. This is a significant drawback for Ligand B, potentially hindering membrane permeability and bioavailability. ADRB2 being a GPCR, logP is a high priority.
4. **HBD:** Both ligands have 2 HBD, which is within the acceptable limit of 5.
5. **HBA:** Both ligands have 4 HBA, within the acceptable limit of 10.
6. **QED:** Ligand A (0.871) has a superior QED score compared to Ligand B (0.63), indicating a more drug-like profile.
7. **DILI:** Ligand B (21.287) has a significantly lower DILI risk than Ligand A (56.844). This is a strong positive for Ligand B.
8. **BBB:** Ligand A (89.608) has better BBB penetration potential than Ligand B (72.664). While ADRB2 isn't necessarily a CNS target, some peripheral ADRB2 activity can be modulated by CNS effects, and higher BBB is generally favorable.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual. This suggests poor permeability. Ligand B (-4.99) is slightly worse than Ligand A (-4.286).
10. **Solubility:** Ligand A (-3.884) has better solubility than Ligand B (-1.417). Solubility is important for formulation and bioavailability.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.272 and 0.161), which is excellent.
12. **Cl_mic:** Ligand B (13.896) has significantly lower microsomal clearance than Ligand A (54.796), indicating better metabolic stability.
13. **t1/2:** Ligand B (-16.042) has a slightly longer in vitro half-life than Ligand A (-20.298).
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.03 and 0.017).
15. **Binding Affinity:** Ligand A (-7.0) has a slightly better binding affinity than Ligand B (-6.4). While the difference is less than 1.5 kcal/mol, it still contributes to the overall preference.
**Overall Assessment:**
Ligand A has a better QED, slightly better affinity, and better BBB penetration. However, Ligand B excels in DILI risk and metabolic stability (lower Cl_mic), and has a longer half-life. The biggest drawback for Ligand B is its very low logP, which is a critical factor for GPCR ligands. The poor Caco-2 values for both are concerning, but the low logP of Ligand B is more problematic. Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity), and the importance of metabolic stability, Ligand A is the better candidate. The slightly better affinity and solubility of Ligand A outweigh the lower DILI score and better metabolic stability of Ligand B.
Output:
1
2025-04-17 21:36:57,007 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [359.415, 116.8 , 0.304, 1. , 8. , 0.793, 67.003, 48.352, -5.599, -2.982, 0.071, 6.796, -0.413, 0.031, -6.7 ]
**Ligand B:** [348.531, 52.57 , 2.658, 2. , 3. , 0.744, 5.312, 81.388, -4.898, -3.148, 0.805, 52.559, 14.838, 0.262, -7.8 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (348.531) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (116.8) is higher than Ligand B (52.57). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is still preferred for better absorption. Ligand B is significantly better here.
3. **logP:** Ligand A (0.304) is quite low, potentially hindering membrane permeability. Ligand B (2.658) is within the optimal range (1-3). This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (1) and Ligand B (2) are both acceptable.
5. **HBA:** Ligand A (8) and Ligand B (3) are both acceptable, with Ligand B being better.
6. **QED:** Both ligands have similar, good QED values (0.793 and 0.744).
7. **DILI:** Ligand A (67.003) has a higher DILI risk than Ligand B (5.312). This is a major concern for Ligand A.
8. **BBB:** Ligand B (81.388) has a much higher BBB penetration potential than Ligand A (48.352). While not a primary concern for a cardiovascular target, higher BBB is generally a positive attribute.
9. **Caco-2:** Ligand A (-5.599) has a very poor Caco-2 permeability, indicating poor absorption. Ligand B (-4.898) is better, but still not great.
10. **Solubility:** Both ligands have poor solubility (-2.982 and -3.148). This could be a formulation challenge for both, but is less critical than permeability.
11. **hERG:** Ligand A (0.071) has a lower hERG risk than Ligand B (0.805). This is a positive for Ligand A, but the other issues are more significant.
12. **Cl_mic:** Ligand B (52.559) has a lower microsomal clearance, indicating better metabolic stability, than Ligand A (6.796).
13. **t1/2:** Ligand B (14.838) has a significantly longer in vitro half-life than Ligand A (-0.413). This is a substantial advantage for Ligand B.
14. **Pgp:** Ligand A (0.031) has lower P-gp efflux than Ligand B (0.262).
15. **Affinity:** Ligand B (-7.8) has a significantly better binding affinity than Ligand A (-6.7). This 1.1 kcal/mol difference is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand B is the superior candidate. While both have solubility issues, Ligand B excels in key areas for a GPCR drug: logP, metabolic stability (Cl_mic & t1/2), binding affinity, and significantly lower DILI risk. Ligand A's low logP and poor Caco-2 permeability are major drawbacks, and its higher DILI risk is concerning. The better affinity of Ligand B further solidifies its preference.
Output:
0
2025-04-17 21:36:57,007 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (360.376 and 354.466 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (61.8) is slightly higher than Ligand B (58.64). Both are below the 140 threshold for good oral absorption, and acceptable for a cardiovascular target (not requiring significant CNS penetration).
3. **logP:** Both ligands have excellent logP values (2.822 and 2.579), falling within the optimal 1-3 range.
4. **HBD:** Ligand A has 2 HBD, and Ligand B has 1. Both are within the acceptable limit of <=5.
5. **HBA:** Both ligands have 3 HBA, well within the acceptable limit of <=10.
6. **QED:** Both ligands have QED values (0.82 and 0.764) indicating good drug-like properties.
7. **DILI:** Ligand A (24.195) has a significantly lower DILI risk than Ligand B (15.355). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (87.515) has a higher BBB penetration percentile than Ligand A (69.252). While ADRB2 is primarily a cardiovascular target, some CNS side effects are possible with beta-blockers, so moderate BBB penetration isn't necessarily detrimental.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.735 and -4.658), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Both ligands have negative solubility values (-2.774 and -2.596), indicating very poor aqueous solubility. This is a major drawback for both compounds.
11. **hERG:** Ligand A (0.775) has a slightly higher hERG inhibition liability than Ligand B (0.405), but both are relatively low risk.
12. **Cl_mic:** Ligand B (22.559) has a higher microsomal clearance than Ligand A (12.453), meaning Ligand A is more metabolically stable.
13. **t1/2:** Ligand A (15.651) has a significantly longer in vitro half-life than Ligand B (5.311). This is a substantial advantage for Ligand A.
14. **Pgp:** Ligand A (0.169) has lower P-gp efflux liability than Ligand B (0.098), suggesting better oral bioavailability.
15. **Binding Affinity:** Ligand B (-7.0) has a slightly better binding affinity (-7.0 kcal/mol) than Ligand A (-6.9 kcal/mol). While this is a small difference, it is still a factor.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Both ligands perform well on logP and TPSA. Ligand B has slightly better Pgp and affinity, but Ligand A has a significantly better safety profile (DILI) and metabolic stability (Cl_mic, t1/2). The poor Caco-2 and solubility are concerning for both, but the other advantages of Ligand A outweigh the small affinity benefit of Ligand B.
**Conclusion:**
Despite the slightly better binding affinity of Ligand B, Ligand A is the more promising drug candidate due to its significantly lower DILI risk, better metabolic stability (longer half-life, lower clearance), and lower P-gp efflux. These factors are crucial for developing a safe and effective drug.
Output:
1
2025-04-17 21:36:57,007 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.459 and 349.431 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (87.66) is better than Ligand B (95.58). Both are below 140, supporting oral absorption, but lower is preferred for GPCRs.
3. **logP:** Ligand A (0.979) is slightly higher than Ligand B (0.75). Both are within the optimal 1-3 range, but Ligand A is closer to the ideal.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (2). Both are acceptable, below the threshold of 5.
5. **HBA:** Both ligands have 4 HBA, which is good.
6. **QED:** Ligand A (0.623) has a better QED score than Ligand B (0.474), indicating a more drug-like profile.
7. **DILI:** Ligand B (32.261) has a slightly better DILI score than Ligand A (21.83), indicating lower liver injury risk. Both are good (<40).
8. **BBB:** Ligand B (79.062) has a significantly better BBB penetration score than Ligand A (32.183). While ADRB2 isn't strictly a CNS target, some CNS exposure can be beneficial or at least avoid unexpected side effects.
9. **Caco-2:** Ligand A (-4.987) and Ligand B (-5.198) are similar, indicating comparable intestinal absorption.
10. **Solubility:** Ligand A (-1.867) has better aqueous solubility than Ligand B (-2.79).
11. **hERG:** Both ligands have very low hERG risk (0.102 and 0.087, respectively).
12. **Cl_mic:** Ligand A (3.816) has much lower microsomal clearance than Ligand B (14.574), suggesting better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand B (-31.562) has a significantly longer in vitro half-life than Ligand A (1.642). This is a major advantage.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.022 and 0.025, respectively).
15. **Binding Affinity:** Ligand B (-6.5 kcal/mol) has a slightly better binding affinity than Ligand A (-6.1 kcal/mol). While the difference is not huge, it is still a factor.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A has a slightly better logP and TPSA. Both have similar Pgp. Ligand B has a slightly better affinity. However, metabolic stability (Cl_mic and t1/2) are also crucial, and Ligand A is significantly better in terms of Cl_mic, while Ligand B has a much longer half-life. The improved metabolic stability of Ligand A is a significant advantage, especially considering the slight affinity difference can potentially be optimized in later stages.
**Overall Assessment:**
While Ligand B has a better BBB score and half-life, Ligand A demonstrates a better overall balance of properties, particularly its superior metabolic stability (lower Cl_mic) and better solubility, combined with a good QED score. The slight affinity difference is less concerning than the potential for rapid metabolism of Ligand B.
Output:
1
2025-04-17 21:36:57,008 - INFO - Batch 271 complete. Total preferences: 4336
2025-04-17 21:36:57,008 - INFO - Processing batch 272/512...
2025-04-17 21:37:43,832 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.45 and 343.402 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (49.85) is better than Ligand B (62.3). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have similar logP values (2.331 and 2.37), falling within the optimal 1-3 range.
4. **HBD:** Ligand A (0) is preferable to Ligand B (1). Fewer HBDs generally improve permeability.
5. **HBA:** Both ligands have 3 HBA, which is acceptable.
6. **QED:** Both ligands have good QED scores (0.714 and 0.835), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (21.365) has a significantly lower DILI risk than Ligand B (44.824). This is a major advantage for Ligand A.
8. **BBB:** Both ligands have high BBB penetration (89.608 and 94.416). While ADRB2 isn't primarily a CNS target, higher BBB isn't detrimental.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. This is a significant concern for both.
10. **Solubility:** Both ligands have negative solubility values, indicating poor solubility. This is also a significant concern for both.
11. **hERG:** Both ligands have low hERG inhibition risk (0.464 and 0.444).
12. **Cl_mic:** Ligand A (31.47) has lower microsomal clearance than Ligand B (36.391), suggesting better metabolic stability.
13. **t1/2:** Ligand A (5.323) has a shorter half-life than Ligand B (-24.872). This is a negative for Ligand A. Note that the negative value for Ligand B is unusual and could indicate a very long half-life, but it's hard to interpret without more context.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.09 and 0.185).
15. **Binding Affinity:** Ligand A (-6.6 kcal/mol) has a slightly better binding affinity than Ligand B (-6.1 kcal/mol). While the difference is not huge, it is still a positive for Ligand A.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Both ligands perform similarly on logP and Pgp. Ligand A is better on TPSA and affinity. The DILI risk is also a critical factor, and Ligand A is significantly better in this regard.
**Overall Assessment:**
Ligand A is preferable due to its lower DILI risk, better TPSA, lower microsomal clearance, and slightly better binding affinity. While both ligands have issues with Caco-2 permeability and solubility, the safety profile of Ligand A is more attractive. The half-life difference is a concern, but the other advantages outweigh this drawback.
Output:
1
2025-04-17 21:37:43,832 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (341.39 and 351.531 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (83.6) is higher than Ligand B (60.77). For a cardiovascular GPCR, TPSA is moderately important, and Ligand B is better here, suggesting potentially improved permeability.
3. **logP:** Ligand B (3.211) is slightly higher than Ligand A (2.38). Both are within the optimal 1-3 range, but Ligand B is closer to the upper limit.
4. **HBD:** Ligand A (1) has fewer HBD than Ligand B (2). Lower HBD is generally preferred for permeability, giving a slight edge to Ligand A.
5. **HBA:** Ligand A (5) has more HBA than Ligand B (3). Similar to HBD, lower HBA is generally preferred, favoring Ligand B.
6. **QED:** Ligand A (0.874) has a significantly higher QED score than Ligand B (0.67), indicating a more drug-like profile overall. This is a substantial advantage for Ligand A.
7. **DILI:** Ligand A (56.727) has a higher DILI risk than Ligand B (9.151). This is a significant negative for Ligand A, as lower DILI is highly desirable.
8. **BBB:** Ligand A (81.039) has a higher BBB percentile than Ligand B (74.564). While ADRB2 isn't a primary CNS target, some CNS penetration can be acceptable or even beneficial for off-target effects assessment.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual. I will interpret these as very low permeability.
10. **Solubility:** Ligand A (-4.121) has worse solubility than Ligand B (-2.95). Solubility is important for bioavailability, favoring Ligand B.
11. **hERG:** Ligand A (0.418) has a lower hERG risk than Ligand B (0.761), which is a positive for Ligand A.
12. **Cl_mic:** Ligand B (65.355) has a significantly higher microsomal clearance than Ligand A (22.004). This means Ligand A is more metabolically stable, a significant advantage.
13. **t1/2:** Ligand B (26.035) has a longer in vitro half-life than Ligand A (0.014). This is a strong positive for Ligand B.
14. **Pgp:** Ligand A (0.222) has lower P-gp efflux than Ligand B (0.699), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand A (-7.4) has a stronger binding affinity than Ligand B (-6.8). This 1.5 kcal/mol difference is substantial and can outweigh some ADME drawbacks.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B has better logP and TPSA. Ligand A has better Pgp and a significantly better binding affinity. The DILI risk for Ligand A is concerning.
**Overall Assessment:**
Despite the higher DILI risk, the significantly stronger binding affinity of Ligand A (-7.4 vs -6.8 kcal/mol) and its better metabolic stability (lower Cl_mic) are compelling. The QED score is also much better for Ligand A. While Ligand B has better solubility and half-life, the potency and drug-likeness advantages of Ligand A are more critical for a GPCR target. The lower Pgp efflux for Ligand A also helps.
Output:
1
2025-04-17 21:37:43,832 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (364.47 & 358.43 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand B (58.64) is significantly better than Ligand A (76.66). Lower TPSA is preferred for GPCRs, aiding permeability.
3. **logP:** Ligand B (2.344) is optimal, while Ligand A (0.313) is quite low, potentially hindering membrane permeability. This is a significant advantage for B.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1), but both are within the acceptable limit of 5.
5. **HBA:** Ligand A (5) is higher than Ligand B (3), but both are within the acceptable limit of 10.
6. **QED:** Both ligands have good QED scores (0.705 and 0.793), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand B (22.761) has a much lower DILI risk than Ligand A (59.829). This is a major advantage for B.
8. **BBB:** Ligand B (86.817) has a much higher BBB penetration potential than Ligand A (52.036). While ADRB2 isn't strictly a CNS target, some peripheral ADRB2 receptors can be affected by CNS penetration, and higher BBB is generally favorable.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand B (-4.584) is slightly better than Ligand A (-5.066), but both are concerning.
10. **Solubility:** Both have poor solubility (-3.196 and -2.367). This is a drawback for both, but not a deciding factor.
11. **hERG:** Both have low hERG inhibition risk (0.212 and 0.428). No significant difference.
12. **Cl_mic:** Ligand B (8.975) has significantly lower microsomal clearance than Ligand A (24.539), indicating better metabolic stability.
13. **t1/2:** Ligand A (17.741) has a longer in vitro half-life than Ligand B (6.432). This is a slight advantage for A.
14. **Pgp:** Both have low P-gp efflux liability (0.025 and 0.039). No significant difference.
15. **Binding Affinity:** Ligand A (-6.8 kcal/mol) has a slightly better binding affinity than Ligand B (-6.4 kcal/mol), but the difference is less than 1.5 kcal/mol.
**Overall Assessment:**
Ligand B is significantly better overall. The advantages in logP, DILI risk, BBB penetration, and metabolic stability (Cl_mic) outweigh the slightly weaker binding affinity and shorter half-life. The low logP of Ligand A is a major concern, potentially leading to poor absorption. While both have poor Caco-2 and solubility, these can be addressed with formulation strategies. The lower DILI risk of Ligand B is particularly important for clinical development. Given the GPCR target class, the improved TPSA and BBB values of Ligand B are also beneficial.
Output:
0
2025-04-17 21:37:43,833 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (351.491 and 347.419 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (70.67) is significantly better than Ligand B (98.4). For a GPCR, keeping TPSA lower is beneficial for permeability. Ligand B is pushing the upper limit for good oral absorption.
**3. logP:** Ligand A (1.298) is slightly better than Ligand B (0.45). Both are within the acceptable range (1-3), but Ligand A is closer to the optimal range. Ligand B is a bit low, potentially impacting membrane permeability.
**4. H-Bond Donors:** Both ligands have 2 HBD, which is within the acceptable limit of <=5.
**5. H-Bond Acceptors:** Both ligands have 4 HBA, also within the acceptable limit of <=10.
**6. QED:** Ligand B (0.808) has a slightly better QED score than Ligand A (0.691), indicating a more drug-like profile. This is a minor advantage.
**7. DILI Risk:** Ligand A (6.553 percentile) has a *much* lower DILI risk than Ligand B (36.642 percentile). This is a critical advantage, as liver toxicity is a major concern in drug development.
**8. BBB Penetration:** Both ligands have similar BBB penetration (Ligand A: 53.044, Ligand B: 54.207). While not a primary concern for a cardiovascular target, it's not detrimental.
**9. Caco-2 Permeability:** Both ligands have very negative Caco-2 values (-5.269 and -5.288). This indicates poor permeability, which is concerning.
**10. Aqueous Solubility:** Both ligands have very negative solubility values (-1.088 and -1.557), indicating poor solubility. This is a significant drawback for both.
**11. hERG Inhibition:** Ligand A (0.289) has a lower hERG inhibition risk than Ligand B (0.196), which is preferable.
**12. Microsomal Clearance:** Ligand B (-3.014) has a *much* lower microsomal clearance than Ligand A (8.938). This suggests better metabolic stability for Ligand B.
**13. In vitro Half-Life:** Ligand B (-36.169) has a much longer in vitro half-life than Ligand A (8.146). This is a significant advantage.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.013 and 0.014).
**15. Binding Affinity:** Ligand B (-6.7 kcal/mol) has a significantly stronger binding affinity than Ligand A (-4.9 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME drawbacks.
**Overall Assessment:**
While Ligand B has a superior binding affinity and better metabolic stability/half-life, the significantly higher DILI risk is a major concern. Ligand A, despite its weaker binding, presents a much safer profile regarding liver toxicity. The TPSA is also more favorable for Ligand A. Given the cardiovascular context, a slightly lower potency can be tolerated if it means a significantly reduced risk of serious adverse effects. The solubility and permeability issues are shared by both, and would require formulation strategies to address.
Therefore, I prioritize the safety profile and slightly better permeability characteristics of Ligand A.
Output:
1
2025-04-17 21:37:43,833 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (362.901 and 343.45 Da). No significant difference.
2. **TPSA:** Both are reasonably low (52.57 and 55.63), suggesting good potential for absorption. Ligand A is slightly better.
3. **logP:** Both have good logP values (4.281 and 4.219), indicating good permeability and reasonable solubility. No significant difference.
4. **HBD:** Ligand A (2) is slightly better than Ligand B (1) - both are acceptable.
5. **HBA:** Ligand B (5) is higher than Ligand A (2). While still within acceptable limits, lower HBA is generally preferred.
6. **QED:** Ligand B (0.903) has a better QED score than Ligand A (0.771), indicating a more drug-like profile. This is a positive for Ligand B.
7. **DILI:** Ligand A (34.161) has a significantly lower DILI risk than Ligand B (49.283). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (88.174) has a higher BBB penetration percentile than Ligand A (70.997). While ADRB2 isn't strictly a CNS target, some CNS exposure can be acceptable and even beneficial for certain cardiovascular effects. This favors Ligand B.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand B (-4.907) is slightly worse than Ligand A (-4.411).
10. **Solubility:** Both have negative solubility values, indicating very poor aqueous solubility. Ligand A (-5.092) is slightly better than Ligand B (-4.618).
11. **hERG:** Both have low hERG inhibition liability (0.765 and 0.491), which is good. Ligand B is slightly better.
12. **Cl_mic:** Ligand A (17.483) has a significantly lower microsomal clearance than Ligand B (46.825), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (37.114) has a longer in vitro half-life than Ligand B (34.267). This is a positive for Ligand A.
14. **Pgp:** Both have low P-gp efflux liability (0.599 and 0.604). No significant difference.
15. **Binding Affinity:** Ligand B (-6.8 kcal/mol) has a slightly better binding affinity than Ligand A (-6.6 kcal/mol). This is a positive for Ligand B, but the difference is relatively small.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Both ligands perform similarly on logP and Pgp. Ligand B has a slightly better affinity and BBB penetration, while Ligand A has a better TPSA. However, the significant advantages of Ligand A in terms of DILI risk and metabolic stability (Cl_mic and t1/2) outweigh the minor affinity and BBB benefits of Ligand B. The poor Caco-2 and solubility are concerning for both, but can be addressed with formulation strategies.
**Conclusion:**
Considering the balance of properties, particularly the lower DILI risk and improved metabolic stability of Ligand A, it is the more promising drug candidate.
Output:
1
2025-04-17 21:37:43,833 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (347.346 and 347.415 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (105.64) is slightly higher than Ligand B (95.41). Both are below the 140 A^2 threshold for good oral absorption, but Ligand B is closer to the preferred <90 A^2 for GPCRs.
**3. logP:** Ligand B (1.518) is better than Ligand A (0.767). Both are within the optimal 1-3 range, but Ligand B is closer to the sweet spot.
**4. H-Bond Donors:** Both ligands have 2 HBD, which is acceptable.
**5. H-Bond Acceptors:** Both ligands have 4 HBA, which is acceptable.
**6. QED:** Ligand A (0.785) has a slightly better QED score than Ligand B (0.627), indicating better overall drug-likeness.
**7. DILI:** Both ligands have acceptable DILI risk (49.011 and 41.877 percentile, respectively), below the 60% threshold. Ligand B is slightly better.
**8. BBB:** Ligand A (72.043) has a significantly better BBB penetration percentile than Ligand B (52.656). While not a CNS target, some degree of BBB penetration can influence off-target effects and distribution.
**9. Caco-2 Permeability:** Ligand A (-5.241) has worse Caco-2 permeability than Ligand B (-4.661). Lower negative values indicate better permeability.
**10. Aqueous Solubility:** Ligand A (-3.241) has slightly worse aqueous solubility than Ligand B (-2.947).
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.18 and 0.141 percentile, respectively).
**12. Microsomal Clearance:** Ligand B (24.963) has a significantly lower microsomal clearance than Ligand A (0.169). This suggests better metabolic stability for Ligand B.
**13. In vitro Half-Life:** Ligand A (32.731) has a much longer in vitro half-life than Ligand B (-49.667). This is a significant advantage for Ligand A.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.027 and 0.044 percentile, respectively).
**15. Binding Affinity:** Ligand A (-6.3 kcal/mol) has a slightly better binding affinity than Ligand B (-5.6 kcal/mol). The difference is 0.7 kcal/mol, which is a reasonable advantage.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand B is slightly favored. It has a better logP and TPSA, and a significantly better metabolic stability (lower Cl_mic). While Ligand A has a better QED, BBB, and half-life, the improved ADME properties of Ligand B, particularly the metabolic stability, are more crucial for a successful GPCR drug candidate. The affinity difference is not large enough to outweigh the ADME benefits of Ligand B.
Output:
0
2025-04-17 21:37:43,833 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (361.511 and 372.401 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (75.43) is better than Ligand B (85.5). Both are under the 140 threshold for oral absorption, but lower TPSA is generally preferred for GPCRs, aiding permeability.
3. **logP:** Ligand A (2.621) is optimal (1-3), while Ligand B (0.666) is a bit low, potentially hindering membrane permeability. This is a significant advantage for Ligand A.
4. **HBD:** Ligand A (2) is acceptable, while Ligand B (0) is also good.
5. **HBA:** Ligand A (4) is acceptable, while Ligand B (8) is getting towards the upper limit.
6. **QED:** Both ligands have similar QED values (0.817 and 0.772), indicating good drug-likeness.
7. **DILI:** Ligand A (22.063) has a much lower DILI risk than Ligand B (54.556). This is a substantial advantage for Ligand A, as liver toxicity is a major concern.
8. **BBB:** Both ligands have high BBB penetration (89.686 and 93.098). This is less critical for ADRB2 (cardiovascular target) but still positive.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Both ligands have negative solubility values, which is also unusual and suggests poor solubility. This is a concern for both.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.495 and 0.164).
12. **Cl_mic:** Ligand A (12.905) has a lower microsomal clearance than Ligand B (-12.507). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand B (12.182) has a longer in vitro half-life than Ligand A (-5.629). This is a positive for Ligand B, but the negative value for A is concerning.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.115 and 0.144).
15. **Binding Affinity:** Ligand B (-7.3) has a slightly better binding affinity than Ligand A (-7.1). However, the difference is small (0.2 kcal/mol) and may not be enough to overcome the other drawbacks of Ligand B.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand A excels in logP and has acceptable TPSA. While Ligand B has slightly better affinity, the lower logP, higher TPSA, and significantly higher DILI risk make it less desirable.
**Overall Assessment:**
Ligand A presents a more balanced profile. Its superior logP, lower DILI risk, and better metabolic stability outweigh the slightly weaker binding affinity compared to Ligand B. The negative Caco-2 and solubility values are concerning for both, but these can be addressed with formulation strategies.
Output:
1
2025-04-17 21:37:43,833 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.475 and 358.498 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (70.67) is higher than Ligand B (58.64). For a cardiovascular GPCR, TPSA is not a primary concern unless CNS penetration is desired. Ligand B is slightly better.
3. **logP:** Ligand A (0.93) is a bit low, potentially impacting permeability. Ligand B (2.788) is within the optimal 1-3 range. Ligand B is better.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable, below the threshold of 5. Ligand B is slightly better.
5. **HBA:** Ligand A (4) and Ligand B (3) are both acceptable, below the threshold of 10. Ligand B is slightly better.
6. **QED:** Both ligands have similar QED values (0.64 and 0.653), indicating good drug-likeness. No significant difference.
7. **DILI:** Ligand A (11.09) has a slightly lower DILI risk than Ligand B (12.33), which is preferable. Ligand A is better.
8. **BBB:** Ligand B (94.261) has a significantly higher BBB percentile than Ligand A (53.664). While ADRB2 is primarily cardiovascular, some CNS side effects are possible with certain beta-blockers, and higher BBB might be a concern. However, for a cardiovascular target, this isn't a *major* negative for Ligand A.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.914 and -4.289), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Both ligands have negative solubility values (-1.453 and -2.789), indicating poor aqueous solubility. This is a major drawback for both.
11. **hERG:** Ligand A (0.16) has a much lower hERG inhibition liability than Ligand B (0.834). This is a critical advantage for Ligand A, as hERG inhibition can lead to cardiotoxicity.
12. **Cl_mic:** Ligand A (14.041) has a much lower microsomal clearance than Ligand B (36.756), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (-1.223) has a slightly longer in vitro half-life than Ligand B (-0.13). This is a minor advantage for Ligand A.
14. **Pgp:** Ligand A (0.038) has a much lower P-gp efflux liability than Ligand B (0.201). This is a significant advantage for Ligand A, improving bioavailability.
15. **Binding Affinity:** Ligand A (-7.3) has a slightly better binding affinity than Ligand B (-6.6). While the difference is not huge, it's enough to be considered.
**Overall Assessment:**
Ligand A is the better candidate. While both ligands have significant issues with Caco-2 permeability and solubility, Ligand A demonstrates a superior safety profile (lower DILI and *much* lower hERG inhibition) and better pharmacokinetic properties (lower Cl_mic, lower Pgp efflux, slightly longer t1/2). The slightly better binding affinity further supports this choice. The higher BBB for Ligand B is less critical for a cardiovascular target. The poor solubility and permeability are concerning for both, but can be addressed with formulation strategies.
Output:
1
2025-04-17 21:37:43,833 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.374 & 370.396 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (84.5) is slightly higher than Ligand B (53.43). Ligand B is significantly better, being well below the 140 threshold for oral absorption and closer to the ideal for GPCRs.
3. **logP:** Both ligands (2.882 & 3.273) are within the optimal 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability, but not dramatically so.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable, below the threshold of 5. Ligand B is slightly better.
5. **HBA:** Both ligands (4) are below the threshold of 10. No clear advantage.
6. **QED:** Ligand B (0.899) has a substantially better QED score than Ligand A (0.647), indicating a more drug-like profile.
7. **DILI:** Ligand B (50.989) has a lower DILI risk than Ligand A (63.086), which is preferable.
8. **BBB:** Ligand A (88.096) has a significantly higher BBB penetration percentile than Ligand B (77.627). While ADRB2 isn't necessarily a CNS target, higher BBB is generally favorable.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.522 and -4.591). These values are unusual and likely indicate poor permeability.
10. **Solubility:** Both ligands have negative solubility values (-3.707 and -3.941). These values are also unusual and likely indicate poor solubility.
11. **hERG:** Ligand A (0.173) has a lower hERG inhibition liability than Ligand B (0.606), which is a significant advantage.
12. **Cl_mic:** Ligand B (6.394) has a much lower microsomal clearance than Ligand A (51.222), indicating better metabolic stability.
13. **t1/2:** Ligand A (26.051) has a longer in vitro half-life than Ligand B (2.893), which is preferable.
14. **Pgp:** Ligand A (0.241) has lower P-gp efflux liability than Ligand B (0.363), which is better for bioavailability.
15. **Affinity:** Both ligands have the same binding affinity (-7.0 kcal/mol).
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B excels in TPSA and Cl_mic, which are important for overall drug properties. Ligand A has a better BBB score, lower hERG, and lower Pgp efflux, but the lower metabolic stability is a concern. The similar affinity makes the ADME properties the deciding factor.
**Overall Assessment:**
Despite Ligand A's better BBB and hERG profile, the significantly lower microsomal clearance and better QED of Ligand B outweigh these advantages. The poor Caco-2 and solubility scores are concerning for both, but the metabolic stability is crucial for a viable drug candidate.
Output:
0
2025-04-17 21:37:43,833 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (346.39 Da) is well within the ideal range. Ligand B (388.96 Da) is also acceptable. No clear advantage here.
2. **TPSA:** Ligand A (115.29) is borderline, but acceptable for a non-CNS target. Ligand B (49.85) is excellent, well below the 140 threshold. This favors Ligand B.
3. **logP:** Ligand A (0.947) is a bit low, potentially impacting permeability. Ligand B (3.623) is optimal. This strongly favors Ligand B.
4. **HBD:** Ligand A (2) is good. Ligand B (0) is also good. No significant difference.
5. **HBA:** Ligand A (5) is good. Ligand B (4) is also good. No significant difference.
6. **QED:** Both ligands (A: 0.713, B: 0.638) are above the 0.5 threshold, indicating good drug-likeness. Ligand A is slightly better.
7. **DILI:** Both ligands have similar DILI risk (A: 57.39, B: 52.85), both are acceptable.
8. **BBB:** Ligand A (40.36) is low, as expected for a cardiovascular target. Ligand B (74.80) is higher, but still not a primary concern for ADRB2.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.666 and -4.636), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Both ligands have negative solubility values (-4.037 and -4.826), which is also unusual and suggests poor aqueous solubility. This is a concern for both.
11. **hERG:** Both ligands have low hERG inhibition liability (A: 0.143, B: 0.893). This is good.
12. **Cl_mic:** Ligand A (42.73) has lower microsomal clearance, suggesting better metabolic stability. Ligand B (86.03) has higher clearance. This favors Ligand A.
13. **t1/2:** Ligand A (-27.22) has a negative half-life, which is not possible and indicates an issue with the data. Ligand B (20.46) has a reasonable half-life. This strongly favors Ligand B.
14. **Pgp:** Ligand A (0.019) has very low P-gp efflux, which is good. Ligand B (0.435) has moderate P-gp efflux. This favors Ligand A.
15. **Affinity:** Ligand B (-5.2 kcal/mol) has a significantly stronger binding affinity than Ligand A (-3.2 kcal/mol). This is a substantial advantage.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand B excels in logP and affinity, and has a much better TPSA. While Ligand A has better Pgp efflux and Cl_mic, the substantial affinity advantage of Ligand B outweighs these benefits. The negative half-life of Ligand A is also a major red flag.
**Conclusion:**
Ligand B is the more promising candidate due to its superior binding affinity, optimal logP, excellent TPSA, and reasonable half-life. The slightly higher Pgp efflux is a minor concern compared to the significant advantages in potency and physicochemical properties.
Output:
0
2025-04-17 21:37:43,833 - INFO - Here's my reasoning and the final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
The target is ADRB2, a GPCR. Therefore, the priorities are logP, Pgp, TPSA, affinity, and BBB. Let's compare the ligands property by property:
1. **MW:** Both ligands are within the ideal range (344.46 and 349.52 Da).
2. **TPSA:** Ligand A (76.02) is higher than Ligand B (52.65). Ligand B is preferable here, as lower TPSA generally correlates with better membrane permeability.
3. **logP:** Both ligands have good logP values (1.89 and 2.26), falling within the optimal range of 1-3. Ligand B is slightly better.
4. **HBD/HBA:** Ligand A has 2 HBD and 4 HBA, while Ligand B has 1 HBD and 3 HBA. Both are acceptable.
5. **QED:** Ligand B (0.767) has a significantly better QED score than Ligand A (0.387), indicating a more drug-like profile.
6. **DILI:** Ligand B (4.81) has a much lower DILI risk than Ligand A (33.31), which is a significant advantage.
7. **BBB:** Ligand B (79.49) has a much higher BBB penetration percentile than Ligand A (44.82). While ADRB2 isn't exclusively a CNS target, increased BBB penetration can be beneficial and isn't detrimental for peripheral targets.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it is difficult to interpret.
9. **Solubility:** Both ligands have negative solubility values, which is also unusual.
10. **hERG:** Ligand A (0.392) has a slightly lower hERG risk than Ligand B (0.58), but both are relatively low.
11. **Cl_mic:** Ligand A (34.50) has a lower microsomal clearance than Ligand B (5.94), suggesting better metabolic stability.
12. **t1/2:** Ligand B (3.84) has a longer in vitro half-life than Ligand A (-5.36).
13. **Pgp:** Ligand A (0.138) has lower P-gp efflux liability than Ligand B (0.028), which is preferable.
14. **Binding Affinity:** Ligand B (-7.7 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.3 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME drawbacks of Ligand A.
**Overall Assessment:**
Ligand B is the stronger candidate. While Ligand A has slightly better metabolic stability and P-gp efflux, Ligand B excels in crucial areas: significantly better binding affinity, a much better QED score, lower DILI risk, and higher BBB penetration. The superior binding affinity is particularly important for a GPCR target, and the improved ADME properties (QED, DILI, BBB) make it a more promising starting point for further optimization.
**Output:**
0
2025-04-17 21:37:43,834 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (343.423 & 350.438 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (68.39) is slightly higher than Ligand B (64.16). Both are well below the 140 A^2 threshold for good oral absorption, and acceptable for a cardiovascular GPCR target.
3. **logP:** Both ligands have good logP values (3.743 & 3.37), falling within the optimal 1-3 range. Ligand A is slightly higher, potentially leading to slightly better membrane permeability, but also a slightly increased risk of off-target interactions.
4. **HBD:** Ligand A (1) has fewer HBD than Ligand B (0). Fewer HBDs generally improve permeability, so Ligand A is slightly favored.
5. **HBA:** Ligand A (4) has fewer HBA than Ligand B (5). Similar to HBD, lower HBA is generally better for permeability. Ligand A is favored.
6. **QED:** Both ligands have similar and acceptable QED values (0.641 & 0.651), indicating good drug-like properties.
7. **DILI:** Ligand B (30.399) has a significantly lower DILI risk than Ligand A (67.429). This is a major advantage for Ligand B. DILI is a critical safety concern.
8. **BBB:** Ligand B (95.657) has a much higher BBB penetration percentile than Ligand A (71.85). While ADRB2 isn't a CNS target, higher BBB penetration can sometimes correlate with better overall distribution and reduced off-target effects.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.528 & -4.679). This is unusual and suggests very poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand B (-3.02) has better aqueous solubility than Ligand A (-5.007). Better solubility is generally desirable for bioavailability.
11. **hERG:** Ligand A (0.477) has a lower hERG inhibition liability than Ligand B (0.882). Lower hERG risk is crucial for cardiovascular drugs.
12. **Cl_mic:** Ligand B (52.996) has significantly lower microsomal clearance than Ligand A (94.346), indicating better metabolic stability. This is a major advantage for Ligand B.
13. **t1/2:** Ligand B (29.334) has a much longer in vitro half-life than Ligand A (0.426). This is a significant advantage for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand B (0.823) has a slightly higher Pgp efflux liability than Ligand A (0.429). Higher Pgp efflux is generally undesirable, but the difference isn't dramatic.
15. **Binding Affinity:** Ligand A (-7.7) has a stronger binding affinity than Ligand B (-6.6). This is a 1.1 kcal/mol difference, which is substantial and a significant advantage for Ligand A.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand A has better logP, lower Pgp, and significantly better affinity. However, Ligand B excels in DILI, BBB, solubility, and metabolic stability (Cl_mic and t1/2). The poor Caco-2 values for both are concerning.
**Overall Assessment:**
The stronger binding affinity of Ligand A is very attractive. However, the significantly lower DILI risk, better metabolic stability (Cl_mic & t1/2), and improved solubility of Ligand B are critical factors, especially for a cardiovascular target where safety and sustained exposure are paramount. The Caco-2 values are a concern for both, but the other advantages of Ligand B outweigh the affinity difference.
Output:
0
2025-04-17 21:37:43,834 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**1. Molecular Weight:** Both ligands (348.447 Da and 359.413 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (96.11) is higher than Ligand B (64.63). For a GPCR, lower TPSA is generally preferred for better permeability, giving a slight edge to Ligand B.
**3. logP:** Both ligands have good logP values (2.243 and 3.825, respectively), falling within the optimal 1-3 range. Ligand B is a bit higher, which *could* be a slight concern for solubility, but not a major one.
**4. H-Bond Donors:** Ligand A has 3 HBD, while Ligand B has 1. Lower HBD is generally favorable for permeability, so Ligand B is slightly better.
**5. H-Bond Acceptors:** Both ligands have 4 HBA, which is acceptable.
**6. QED:** Both ligands have similar QED values (0.711 and 0.732), indicating good drug-likeness.
**7. DILI:** Both ligands have acceptable DILI risk (41.877 and 44.048), below the 60 threshold. No significant difference.
**8. BBB:** Ligand B (91.857) has a significantly higher BBB penetration percentile than Ligand A (61.38). This is a *major* advantage for a GPCR target, even if it's cardiovascular, as some off-target CNS effects are always a consideration and better brain penetration can be useful for understanding those.
**9. Caco-2 Permeability:** Ligand A (-4.982) has slightly better Caco-2 permeability than Ligand B (-4.112), but both are negative values which is unusual and requires further investigation.
**10. Aqueous Solubility:** Ligand A (-2.651) has slightly better aqueous solubility than Ligand B (-4.747).
**11. hERG Inhibition:** Ligand A (0.214) has a lower hERG inhibition liability than Ligand B (0.59). This is a significant advantage, as hERG inhibition is a major safety concern.
**12. Microsomal Clearance:** Ligand B (103.166) has a much higher microsomal clearance than Ligand A (32.424). This means Ligand A is more metabolically stable, which is desirable.
**13. In vitro Half-Life:** Both ligands have negative half-lives (-26.104 and -29.095), which is unusual and indicates rapid degradation *in vitro*. This is a concern for both, but the difference isn't decisive.
**14. P-gp Efflux:** Ligand A (0.029) has a much lower P-gp efflux liability than Ligand B (0.185). Lower P-gp efflux is generally preferred for better bioavailability.
**15. Binding Affinity:** Ligand B (-6.7 kcal/mol) has a slightly better binding affinity than Ligand A (-5.7 kcal/mol). This 1 kcal/mol difference is significant and can outweigh some ADME drawbacks.
**Overall Assessment:**
While Ligand A has advantages in hERG inhibition, P-gp efflux, and metabolic stability, Ligand B's significantly higher BBB penetration and better binding affinity are more crucial for a GPCR target like ADRB2. The slightly higher logP of Ligand B is not a major concern, and the difference in solubility is not substantial enough to negate the benefits of its other properties. The affinity difference is also a key factor.
Output:
0
2025-04-17 21:37:43,834 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (361.427 Da) is within the ideal range (200-500 Da). Ligand B (392.298 Da) is also acceptable. No clear advantage here.
2. **TPSA:** Ligand A (106.1) is better than Ligand B (38.77). Lower TPSA generally favors better absorption.
3. **logP:** Ligand A (1.128) is within the optimal range (1-3). Ligand B (4.064) is slightly high, potentially leading to solubility issues and off-target interactions.
4. **HBD:** Ligand A (2) is reasonable. Ligand B (0) is also acceptable.
5. **HBA:** Ligand A (7) is reasonable. Ligand B (3) is also acceptable.
6. **QED:** Ligand A (0.766) is better than Ligand B (0.657), indicating a more drug-like profile.
7. **DILI:** Ligand A (69.484) is higher than Ligand B (42.924), suggesting a greater potential for liver injury. This is a significant drawback for Ligand A.
8. **BBB:** Ligand A (59.403) is lower than Ligand B (86.778). While ADRB2 isn't strictly a CNS target, some CNS penetration might be beneficial for understanding off-target effects, and Ligand B has a clear advantage here.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
10. **Solubility:** Ligand A (-3.664) is better than Ligand B (-5.037), indicating better aqueous solubility.
11. **hERG:** Ligand A (0.184) is much lower than Ligand B (0.758), indicating a lower risk of cardiotoxicity, a crucial factor for a cardiovascular target.
12. **Cl_mic:** Ligand A (58.375) is lower than Ligand B (66.447), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-25.897) is worse than Ligand B (36.98), indicating a shorter half-life.
14. **Pgp:** Ligand A (0.027) is much lower than Ligand B (0.54), suggesting less P-gp efflux and better bioavailability.
15. **Affinity:** Ligand B (-7.1) has a significantly better binding affinity than Ligand A (-5.8). This is a substantial advantage, potentially outweighing some ADME concerns.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand B excels in affinity and Pgp, and has a better BBB score. Ligand A has a better TPSA and solubility, but its higher DILI risk and lower affinity are concerning.
**Overall Assessment:**
While Ligand A has some favorable properties (solubility, lower hERG, lower Cl_mic, lower Pgp), the significantly stronger binding affinity of Ligand B (-7.1 vs -5.8 kcal/mol) is a major advantage. The higher DILI risk for Ligand A is a substantial concern, and the better BBB penetration of Ligand B is also beneficial. The slightly higher logP of Ligand B is manageable.
Output:
0
2025-04-17 21:37:43,834 - INFO - Here's my reasoning and final output for the ligand preference:
**Reasoning:**
We are looking for a ligand for ADRB2, a cardiovascular GPCR. Therefore, the key priorities are logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB (though less critical for a cardiovascular target than a CNS one).
Let's compare Ligand A and Ligand B across the 15 parameters:
1. **MW:** Both ligands (347.375 and 365.463 Da) are within the ideal 200-500 Da range.
2. **TPSA:** Both are reasonably low (111.15 and 106.73), suggesting good potential for absorption, though ideally below 140.
3. **logP:** Ligand A (-0.318) is slightly lower than optimal (1-3), potentially impacting permeability. Ligand B (0.448) is closer to the ideal range.
4. **HBD/HBA:** Both have 2 HBD and around 7-8 HBA, which is acceptable.
5. **QED:** Both have good QED scores (0.77 and 0.625), indicating drug-like properties.
6. **DILI:** Both have relatively high DILI risk (63.823 and 65.568), which is a concern. This will need further investigation, but it's not a deciding factor at this stage.
7. **BBB:** Both have low BBB penetration (34.548 and 31.912), which isn't a major concern for a cardiovascular target.
8. **Caco-2:** Both have negative Caco-2 values (-5.76 and -5.931), which is unusual and problematic. This suggests poor permeability.
9. **Solubility:** Both have very poor solubility (-1.632 and -2.453). This is a significant drawback.
10. **hERG:** Both have very low hERG risk (0.02 and 0.073), which is excellent.
11. **Cl_mic:** Ligand A (-20.177) has significantly better metabolic stability (lower clearance) than Ligand B (42.509).
12. **t1/2:** Ligand B has a slightly longer in vitro half-life (35.998 hours) than Ligand A (28.365 hours).
13. **Pgp:** Both have very low Pgp efflux liability (0.009 and 0.066), which is favorable.
14. **Binding Affinity:** Ligand A (-7.8 kcal/mol) has a substantially stronger binding affinity than Ligand B (-6.7 kcal/mol). This is a 1.1 kcal/mol difference, which is a significant advantage.
**Overall Assessment:**
Despite the poor solubility and Caco-2 permeability for both, Ligand A is the better candidate. The significantly stronger binding affinity (-7.8 vs -6.7 kcal/mol) outweighs the slightly better metabolic stability of Ligand B. The lower microsomal clearance of Ligand A is also a positive. The logP of Ligand B is slightly better, but the affinity difference is more critical for a GPCR target. Both have concerning DILI scores, and poor solubility/permeability, which would require significant medicinal chemistry efforts to address, but the higher affinity of A gives it a better starting point.
**Output:**
1
2025-04-17 21:37:43,834 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (343.39 and 343.41 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (117.1) is higher than Ligand B (84.81). For a cardiovascular GPCR like ADRB2, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B has a clear advantage.
3. **logP:** Both ligands have good logP values (1.844 and 2.647), falling within the optimal 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (2). Both are acceptable, but lower is generally better.
5. **HBA:** Ligand A (6) is higher than Ligand B (4). Similar to HBD, lower is preferred.
6. **QED:** Ligand B (0.809) has a significantly better QED score than Ligand A (0.657), indicating a more drug-like profile.
7. **DILI:** Ligand B (54.634) has a substantially lower DILI risk than Ligand A (76.076). This is a major advantage for Ligand B.
8. **BBB:** Ligand B (76.464) has a higher BBB penetration percentile than Ligand A (22.606). While ADRB2 isn't a primary CNS target, some degree of BBB penetration can influence off-target effects and overall distribution.
9. **Caco-2:** Ligand A (-5.577) and Ligand B (-4.729) both have negative Caco-2 values, which is unusual. This suggests poor permeability. However, the scale isn't specified, making direct comparison difficult.
10. **Solubility:** Ligand A (-2.778) and Ligand B (-3.693) both have negative solubility values, which is also unusual and suggests poor aqueous solubility.
11. **hERG:** Ligand A (0.083) has a slightly lower hERG risk than Ligand B (0.777), which is preferable.
12. **Cl_mic:** Ligand A (0.437) has a much lower microsomal clearance than Ligand B (25.8). This indicates better metabolic stability for Ligand A.
13. **t1/2:** Ligand B (48.895) has a significantly longer in vitro half-life than Ligand A (9.382). This is a substantial advantage for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.01) has a much lower P-gp efflux liability than Ligand B (0.091). This is a positive for Ligand A, potentially improving oral bioavailability.
15. **Binding Affinity:** Ligand B (-6.8 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.0 kcal/mol). This is a crucial factor, and the 1.8 kcal/mol difference is substantial enough to outweigh many of the ADME drawbacks of Ligand B.
**Overall Assessment:**
Ligand B is the stronger candidate. The significantly improved binding affinity (-6.8 vs -5.0 kcal/mol) is the most important factor. It also has a better QED score, lower DILI risk, higher BBB penetration, and a much longer half-life. While Ligand A has better metabolic stability (lower Cl_mic) and lower P-gp efflux, the superior potency and safety profile of Ligand B outweigh these advantages. The solubility and Caco-2 values are concerning for both, but can be addressed through formulation strategies.
Output:
0
2025-04-17 21:37:43,834 - INFO - Batch 272 complete. Total preferences: 4352
2025-04-17 21:37:43,834 - INFO - Processing batch 273/512...
2025-04-17 21:38:34,316 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (356.463 and 347.415 Da) are within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (92.55) is better than Ligand A (107.89). Both are below 140, but lower TPSA is generally preferred for absorption, especially for a GPCR.
3. **logP:** Ligand B (1.197) is better than Ligand A (0.334). Ligand A is quite low, potentially hindering membrane permeability. Ligand B is within the optimal 1-3 range.
4. **HBD:** Ligand B (1) is better than Ligand A (4). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (5) and Ligand B (4) are both acceptable, below the 10 threshold.
6. **QED:** Both ligands have good QED scores (0.549 and 0.577), indicating good drug-like properties.
7. **DILI:** Ligand A (12.641) is significantly better than Ligand B (15.045). Lower DILI is crucial.
8. **BBB:** Ligand B (61.652) is significantly better than Ligand A (27.259). While ADRB2 isn't exclusively a CNS target, some CNS penetration can be beneficial, and avoiding efflux is always good.
9. **Caco-2:** Both are negative, indicating poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-0.86) is better than Ligand B (-2.538). Higher solubility is generally preferred.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.063 and 0.178). This is excellent.
12. **Cl_mic:** Ligand A (-1.854) is much better than Ligand B (15.013). Lower clearance indicates better metabolic stability.
13. **t1/2:** Ligand A (5.687) is better than Ligand B (3.648). Longer half-life is generally desirable.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.01 and 0.02). This is excellent.
15. **Binding Affinity:** Ligand B (-7.5) is slightly better than Ligand A (-7.1), but the difference is relatively small (0.4 kcal/mol).
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, and affinity are particularly important. Ligand B excels in logP and has slightly better affinity. However, Ligand A has a significantly better DILI score and much better metabolic stability (Cl_mic and t1/2). The Caco-2 values are poor for both.
**Overall Assessment:**
While Ligand B has a slightly better binding affinity and BBB penetration, the significantly lower DILI risk and improved metabolic stability of Ligand A are more critical for overall drug development success. The lower logP of Ligand A is a concern, but can potentially be addressed with further optimization. The superior safety profile and pharmacokinetic properties of Ligand A outweigh the small affinity advantage of Ligand B.
Output:
1
2025-04-17 21:38:34,317 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [390.483, 113.01 , 1.982, 2. , 6. , 0.795, 64.405, 19.853, -5.214, -2.909, 0.042, 22.546, -7.502, 0.021, -7. ]
**Ligand B:** [353.419, 110.96 , -0.445, 2. , 5. , 0.614, 20.047, 74.292, -5.324, -1.9 , 0.105, -1.632, 10.847, 0.005, -5.7 ]
Here's a step-by-step comparison, keeping GPCR priorities (logP, Pgp, TPSA, affinity) in mind:
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (353.419) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are reasonably good (around 110-113), being below the 140 threshold for oral absorption.
3. **logP:** Ligand A (1.982) is better than Ligand B (-0.445). A logP between 1-3 is optimal, and Ligand B is quite low, potentially hindering membrane permeability.
4. **HBD:** Both have 2 HBD, which is acceptable.
5. **HBA:** Ligand A has 6 HBA, Ligand B has 5. Both are within the acceptable limit of 10.
6. **QED:** Both are above 0.5, indicating good drug-likeness. Ligand A (0.795) is slightly better.
7. **DILI:** Ligand B (20.047) has a significantly lower DILI risk than Ligand A (64.405). This is a major advantage for Ligand B.
8. **BBB:** Ligand B (74.292) has a much higher BBB penetration percentile than Ligand A (19.853). While ADRB2 is primarily a cardiovascular target, some CNS effects are possible with certain ligands, and higher BBB penetration isn't necessarily a negative.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability.
10. **Solubility:** Both have negative solubility values, which is also unusual and suggests poor solubility.
11. **hERG:** Both have very low hERG inhibition liability, which is excellent.
12. **Cl_mic:** Ligand B (-1.632) has a much lower (and better) microsomal clearance than Ligand A (22.546), indicating greater metabolic stability.
13. **t1/2:** Ligand B (10.847) has a longer in vitro half-life than Ligand A (-7.502), which is desirable.
14. **Pgp:** Ligand A (0.021) has lower P-gp efflux than Ligand B (0.005), which is slightly better.
15. **Affinity:** Both have excellent binding affinities (-7.0 and -5.7 kcal/mol respectively). Ligand A is slightly better (-7.0 kcal/mol).
**Overall Assessment:**
While Ligand A has a slightly better binding affinity and Pgp profile, Ligand B is significantly better in terms of safety (DILI), metabolic stability (Cl_mic), half-life, and BBB penetration. The low logP of Ligand B is a concern, but the substantial benefits in other ADME/Tox properties outweigh this drawback. Given the cardiovascular target, the BBB penetration isn't a critical factor, but it doesn't hurt. The DILI risk is a major consideration, and Ligand B's lower risk is a significant advantage.
Therefore, I prefer Ligand B.
0
2025-04-17 21:38:34,317 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [350.503, 58.64, 2.733, 1, 3, 0.848, 20.318, 81.194, -4.365, -3.158, 0.397, 51.863, 10.816, 0.092, -7.0]
**Ligand B:** [344.499, 40.62, 3.423, 0, 2, 0.725, 14.036, 88.717, -4.319, -2.595, 0.558, 84.974, -7.445, 0.4, -7.8]
Here's a breakdown of the comparison, considering the provided guidelines and GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (344.499) is slightly lower, which is generally favorable, but the difference isn't substantial.
2. **TPSA:** Ligand A (58.64) is higher than Ligand B (40.62). Both are under the 140 threshold for oral absorption, but Ligand B is significantly better, being closer to the optimal range for GPCRs.
3. **logP:** Both are within the optimal range (1-3), with Ligand A at 2.733 and Ligand B at 3.423. Ligand B is slightly higher, which could potentially lead to some off-target interactions, but is still acceptable.
4. **HBD:** Ligand A has 1 HBD, Ligand B has 0. Lower is generally preferred for permeability, so Ligand B is slightly better.
5. **HBA:** Ligand A has 3 HBA, Ligand B has 2. Again, Ligand B is slightly better.
6. **QED:** Ligand A (0.848) has a better QED score than Ligand B (0.725), indicating a more drug-like profile overall.
7. **DILI:** Ligand A (20.318) has a higher DILI risk than Ligand B (14.036). This is a significant advantage for Ligand B.
8. **BBB:** Both have good BBB penetration (Ligand A: 81.194, Ligand B: 88.717). Ligand B is slightly better.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. This is a concern for both.
10. **Solubility:** Both have negative solubility values, indicating poor solubility. This is a concern for both.
11. **hERG:** Both have low hERG inhibition risk (Ligand A: 0.397, Ligand B: 0.558). Ligand B is slightly worse, but still acceptable.
12. **Cl_mic:** Ligand A (51.863) has lower microsomal clearance than Ligand B (84.974), suggesting better metabolic stability.
13. **t1/2:** Ligand A (10.816) has a shorter half-life than Ligand B (-7.445). The negative value for Ligand B is concerning and likely indicates a very short half-life.
14. **Pgp:** Ligand A (0.092) has lower P-gp efflux than Ligand B (0.4), which is favorable for bioavailability and CNS exposure.
15. **Affinity:** Ligand B (-7.8 kcal/mol) has a slightly better binding affinity than Ligand A (-7.0 kcal/mol). This 1.8 kcal/mol difference is significant and could outweigh some of the ADME drawbacks.
**Overall Assessment:**
Ligand B has a superior profile regarding key GPCR properties (lower TPSA, better BBB penetration, and significantly better affinity). While Ligand A has a better QED and lower clearance, the DILI risk associated with Ligand A is higher. The negative half-life for Ligand B is concerning, but the affinity difference is substantial. Given the importance of potency for GPCRs, and the relatively small difference in other parameters, the improved binding affinity of Ligand B is the deciding factor.
Output:
0
2025-04-17 21:38:34,317 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (358.471 and 355.435 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (76.8) is significantly better than Ligand B (107.97). For a GPCR, keeping TPSA under 140 is good for oral absorption, and A is closer to the desirable range.
**3. logP:** Ligand A (3.143) is within the optimal 1-3 range. Ligand B (0.104) is *very* low, which is concerning for membrane permeability and overall absorption.
**4. H-Bond Donors:** Ligand A (0) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
**5. H-Bond Acceptors:** Ligand A (7) is better than Ligand B (5). While both are acceptable, fewer is generally preferred.
**6. QED:** Both ligands have similar QED values (0.7 and 0.6), indicating good drug-likeness.
**7. DILI:** Ligand A (77.472) has a higher DILI risk than Ligand B (28.306). This is a significant drawback for Ligand A.
**8. BBB:** Ligand A (61.535) is better than Ligand B (51.997), but neither are particularly high. For a cardiovascular target, BBB penetration isn't a primary concern, but it's still a slight advantage for A.
**9. Caco-2 Permeability:** Ligand A (-5.269) is worse than Ligand B (-4.93). Both are negative, indicating poor permeability, but B is slightly better.
**10. Aqueous Solubility:** Ligand A (-3.146) is worse than Ligand B (-0.897). Solubility is a concern for both, but B is better.
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.296 and 0.149), which is excellent.
**12. Microsomal Clearance:** Ligand A (71.179) is higher than Ligand B (0.694), indicating faster metabolism and lower metabolic stability. This is a significant negative for Ligand A.
**13. In vitro Half-Life:** Ligand A (32.409) is better than Ligand B (-22.559).
**14. P-gp Efflux:** Ligand A (0.446) is better than Ligand B (0.008). Lower P-gp efflux is desirable for better bioavailability.
**15. Binding Affinity:** Both ligands have very similar and strong binding affinities (-6.6 and -6.9 kcal/mol). The difference is negligible.
**Overall Assessment:**
Ligand B is the better candidate. While Ligand A has some advantages (slightly better BBB, P-gp efflux, and in vitro half-life), Ligand B's significantly better logP, lower DILI risk, and lower microsomal clearance outweigh these. The low logP of Ligand A is a major concern for absorption, and the higher DILI risk is unacceptable. The slightly better solubility of Ligand B is also a plus. Considering the GPCR-specific priorities, the balance of properties in Ligand B makes it a more promising starting point for further optimization.
Output:
0
2025-04-17 21:38:34,317 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (356.47 & 347.42 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (113.76 & 113.08) are below the 140 A^2 threshold for good oral absorption, but not optimized for CNS penetration (which would require <90). Again, no major difference.
3. **logP:** Ligand A (0.603) is slightly higher than Ligand B (0.417), both are a bit low, potentially impacting permeability. However, they are within an acceptable range.
4. **HBD:** Both ligands have 3 H-bond donors, which is within the acceptable limit of <=5.
5. **HBA:** Ligand A has 4 H-bond acceptors, while Ligand B has 5. Both are acceptable, being <=10.
6. **QED:** Both ligands have similar QED values (0.591 & 0.56), indicating good drug-likeness.
7. **DILI:** Ligand A (18.65) has a significantly lower DILI risk than Ligand B (39.55). This is a major advantage for Ligand A. Lower DILI is crucial for drug development.
8. **BBB:** Ligand A (73.94) shows better BBB penetration potential than Ligand B (55.14). While ADRB2 isn't exclusively a CNS target, some distribution to the CNS is possible and a higher BBB percentile is generally favorable.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.29 and -5.597), which is unusual and indicates very poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand A (-1.916) has slightly better solubility than Ligand B (-1.417), but both are poor.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.154 & 0.051), which is excellent.
12. **Cl_mic:** Ligand A (12.37) has a lower microsomal clearance than Ligand B (17.61), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-7.854) has a significantly longer in vitro half-life than Ligand B (9.723). This is a substantial advantage, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.005 & 0.008).
15. **Binding Affinity:** Both ligands have very similar and strong binding affinities (-5.9 & -6.1 kcal/mol). The difference is negligible.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. While both ligands are similar in logP, TPSA, Pgp and affinity, Ligand A demonstrates superior ADME properties, specifically lower DILI, better BBB penetration, lower Cl_mic, and a longer half-life. The poor Caco-2 values are a concern for both, but the other advantages of Ligand A outweigh this.
**Conclusion:**
Ligand A is the more promising candidate due to its significantly better safety profile (lower DILI), improved metabolic stability (lower Cl_mic, longer t1/2), and slightly better BBB penetration. While both have poor Caco-2 permeability, the other advantages of Ligand A make it the preferred choice.
Output:
1
2025-04-17 21:38:34,317 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.475 and 349.479 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (83.22) is better than Ligand B (88.91). Both are below the 140 A^2 threshold for oral absorption, but lower TPSA is generally preferred for GPCRs.
3. **logP:** Ligand A (2.562) is slightly higher than Ligand B (1.442), both are within the optimal 1-3 range. Ligand A is better.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (2). Both are acceptable (<=5).
5. **HBA:** Ligand A (4) is lower than Ligand B (5). Both are acceptable (<=10).
6. **QED:** Both ligands have similar QED values (0.73 and 0.66), indicating good drug-likeness.
7. **DILI:** Ligand B (32.183) has a significantly lower DILI risk than Ligand A (46.297). This is a major advantage for Ligand B.
8. **BBB:** Ligand B (66.731) has a higher BBB penetration percentile than Ligand A (54.556). While ADRB2 isn't exclusively a CNS target, some cardiovascular effects are mediated by central pathways, and better BBB penetration can be advantageous.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.104 and -5.314). This is unusual and suggests poor permeability.
10. **Solubility:** Ligand B (-1.305) has slightly better solubility than Ligand A (-2.407).
11. **hERG:** Ligand A (0.617) has a slightly higher hERG risk than Ligand B (0.215). Lower is better.
12. **Cl_mic:** Ligand B (26.232) has a lower microsomal clearance than Ligand A (22.973), indicating better metabolic stability.
13. **t1/2:** Ligand A (13.555) has a longer in vitro half-life than Ligand B (5.525). This is a positive for Ligand A.
14. **Pgp:** Ligand A (0.061) has lower P-gp efflux liability than Ligand B (0.043). Lower is better.
15. **Binding Affinity:** Ligand A (-7.7 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.7 kcal/mol). This is a substantial advantage for Ligand A.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are particularly important. Ligand A is better in logP, TPSA, and *significantly* better in affinity. Ligand B is better in DILI, BBB, solubility, and Cl_mic. The affinity difference between the two ligands is quite large (1 kcal/mol), and this is a strong driver for selection.
**Overall Assessment:**
The superior binding affinity of Ligand A (-7.7 kcal/mol vs -6.7 kcal/mol) is a decisive factor. While Ligand B has better safety (DILI) and metabolic stability (Cl_mic), the potency advantage of Ligand A is substantial enough to outweigh these concerns, especially given that the DILI risk for Ligand A is still within an acceptable range. The slightly better BBB penetration of Ligand B is a minor benefit.
Output:
1
2025-04-17 21:38:34,317 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (352.45 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (49.85) is significantly better than Ligand B (79.2). ADRB2 is a cardiovascular target, not CNS, but lower TPSA is still preferred for good absorption. Ligand B is approaching a level that could hinder oral absorption.
3. **logP:** Both ligands have good logP values (A: 2.001, B: 2.785), falling within the optimal 1-3 range. Ligand B is slightly higher, which could potentially lead to off-target interactions, but is still acceptable.
4. **HBD:** Ligand A (0) is better than Ligand B (1). Fewer hydrogen bond donors generally improve permeability.
5. **HBA:** Ligand A (3) is better than Ligand B (4). Fewer hydrogen bond acceptors also improve permeability.
6. **QED:** Both ligands have acceptable QED values (A: 0.76, B: 0.639), indicating good drug-like properties.
7. **DILI:** Ligand A (6.708) is *much* better than Ligand B (72.392). This is a major advantage for Ligand A, as DILI is a critical safety concern.
8. **BBB:** This is less critical for a cardiovascular target. Ligand A (96.084) is higher than Ligand B (58.938), but this isn't a deciding factor.
9. **Caco-2:** Both have negative values, indicating permeability. Ligand A (-4.555) is slightly better than Ligand B (-4.958), but the difference is minimal.
10. **Solubility:** Ligand A (-2.013) is better than Ligand B (-4.377). Better solubility is always preferred.
11. **hERG:** Ligand A (0.529) is better than Ligand B (0.281). Lower hERG inhibition is crucial for avoiding cardiotoxicity, especially for a cardiovascular target.
12. **Cl_mic:** Ligand B (18.758) has lower microsomal clearance than Ligand A (28.881), indicating better metabolic stability. This is a point in favor of Ligand B.
13. **t1/2:** Ligand A (-7.139) has a longer in vitro half-life than Ligand B (-2.772), which is desirable.
14. **Pgp:** Ligand A (0.077) is better than Ligand B (0.311). Lower P-gp efflux is beneficial for bioavailability.
15. **Affinity:** Ligand B (-8.0) has a slightly better binding affinity than Ligand A (-6.5). This is a 1.5 kcal/mol difference, which is significant.
**Overall Assessment:**
While Ligand B has a slightly better binding affinity and metabolic stability, Ligand A overwhelmingly wins on safety (DILI, hERG) and ADME properties (TPSA, solubility, Pgp). The difference in affinity, while noticeable, can potentially be optimized during lead optimization. The significantly lower DILI and hERG risk for Ligand A make it a much more promising starting point for drug development, especially considering the cardiovascular target. The better TPSA, solubility and Pgp also contribute to better overall drug-like properties.
Output:
1
2025-04-17 21:38:34,318 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (362.455 Da and 354.397 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (85.37) is slightly higher than Ligand B (67.43). For a cardiovascular GPCR, TPSA is moderately important, and Ligand B is preferable due to its lower value, suggesting better potential for membrane permeability.
**3. logP:** Both ligands have good logP values (3.418 and 2.262, respectively), falling within the 1-3 optimal range. Ligand A is slightly higher, which *could* indicate potential off-target effects, but is not a major concern.
**4. H-Bond Donors:** Both ligands have 2 HBD, which is within the acceptable limit of <=5.
**5. H-Bond Acceptors:** Ligand A has 6 HBA and Ligand B has 3. Both are within the acceptable limit of <=10. Ligand B is preferable here.
**6. QED:** Both ligands have reasonable QED values (0.851 and 0.789), indicating good drug-like properties. Ligand A is slightly better.
**7. DILI Risk:** Ligand A has a significantly higher DILI risk (85.459 percentile) compared to Ligand B (40.054 percentile). This is a major concern for Ligand A, as liver toxicity is a common reason for drug failure.
**8. BBB Penetration:** Both ligands have reasonable BBB penetration (74.874 and 82.823, respectively). While not a primary concern for a cardiovascular target, Ligand B is slightly better.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-5.022 and -4.254). This is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
**10. Aqueous Solubility:** Both ligands have negative solubility values (-4.329 and -2.761). This is also unusual and suggests poor solubility.
**11. hERG Inhibition:** Ligand A (0.22) has a slightly higher hERG inhibition risk than Ligand B (0.518). Lower is better, so Ligand B is preferable.
**12. Microsomal Clearance:** Ligand A (76.1) has a higher microsomal clearance than Ligand B (31.297). Lower clearance is better for metabolic stability, so Ligand B is preferable.
**13. In vitro Half-Life:** Ligand B has a much longer in vitro half-life (28.185 hours) than Ligand A (-1.502 hours). This is a significant advantage for Ligand B, as it suggests less frequent dosing.
**14. P-gp Efflux:** Ligand A (0.229) has lower P-gp efflux than Ligand B (0.084). Lower efflux is better.
**15. Binding Affinity:** Ligand B (-6.9 kcal/mol) has a slightly better binding affinity than Ligand A (-6.5 kcal/mol). While the difference is not huge, it's still a positive for Ligand B.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity) and the general drug-like properties, **Ligand B is significantly more promising**. The major deciding factor is the drastically lower DILI risk associated with Ligand B. Additionally, Ligand B exhibits better metabolic stability (lower Cl_mic), a longer half-life, and slightly better affinity. While both have issues with Caco-2 and solubility, the DILI risk for Ligand A is a critical flaw.
Output:
0
2025-04-17 21:38:34,318 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, the key priorities are logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB.
Let's break down the comparison:
1. **MW:** Both ligands (344.411 and 347.503 Da) fall comfortably within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (84.5) is higher than Ligand B (52.65). Ligand B is significantly better, being well below the 140 A^2 threshold for good absorption.
3. **logP:** Both ligands have good logP values (2.492 and 1.875), falling within the 1-3 range. Ligand B is slightly lower, which could be beneficial for solubility.
4. **HBD/HBA:** Ligand A has 2 HBD and 4 HBA, while Ligand B has 1 HBD and 3 HBA. Both are within acceptable limits.
5. **QED:** Both ligands have reasonable QED scores (0.804 and 0.747), indicating good drug-like properties.
6. **DILI:** Ligand A has a DILI risk of 76.503, which is concerning (approaching the high-risk threshold). Ligand B has a much lower DILI risk of 11.206, a significant advantage.
7. **BBB:** Ligand A has a BBB penetration of 88.794, while Ligand B is 50.679. While not a primary concern for a cardiovascular target, higher BBB is generally favorable.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests potential issues with permeability prediction.
9. **Solubility:** Ligand A (-4.22) has worse solubility than Ligand B (-2.271).
10. **hERG:** Ligand A (0.098) has a slightly higher hERG risk than Ligand B (0.428), but both are quite low.
11. **Cl_mic:** Ligand A (39.022) has a higher microsomal clearance than Ligand B (10.234), indicating lower metabolic stability.
12. **t1/2:** Ligand B (-7.015) has a much more favorable in vitro half-life than Ligand A (1.687).
13. **Pgp:** Ligand A (0.102) has lower P-gp efflux liability than Ligand B (0.038), which is a slight advantage.
14. **Binding Affinity:** Ligand A (-7.8) has a slightly better binding affinity than Ligand B (-6.9). This is a 0.9 kcal/mol difference, which is significant.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity, the significant advantages of Ligand B in terms of DILI risk, metabolic stability (lower Cl_mic, longer t1/2), solubility, and TPSA outweigh this difference. The lower TPSA of Ligand B is particularly beneficial for absorption. The higher DILI risk associated with Ligand A is a major concern.
**Output:**
0
2025-04-17 21:38:34,318 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A: [352.519, 78.43, 2.787, 3, 3, 0.588, 24.506, 53.858, -4.68, -3.365, 0.415, 57.453, 17.374, 0.256, -6.5]**
**Ligand B: [348.443, 80.57, 2.964, 2, 4, 0.719, 50.33, 47.15, -5.017, -3.269, 0.441, 68.586, 18.439, 0.426, -4.7]**
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (348.443) is slightly lower, which is generally favorable.
2. **TPSA:** Both are reasonably good (below 140), but Ligand A (78.43) is better than Ligand B (80.57). Lower TPSA generally favors better absorption.
3. **logP:** Both are optimal (between 1-3). Ligand A (2.787) is slightly better than Ligand B (2.964).
4. **HBD/HBA:** Ligand A has 3 HBD and 3 HBA, while Ligand B has 2 HBD and 4 HBA. Both are acceptable, but Ligand A is slightly more balanced.
5. **QED:** Ligand B (0.719) has a better QED score than Ligand A (0.588), indicating a more drug-like profile.
6. **DILI:** Ligand A (24.506) has a significantly lower DILI risk than Ligand B (50.33), which is a major advantage.
7. **BBB:** Ligand A (53.858) has a better BBB penetration percentile than Ligand B (47.15). While not a primary concern for a cardiovascular target, it's still a positive.
8. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. Ligand B (-5.017) is worse than Ligand A (-4.68).
9. **Solubility:** Both have negative solubility values, indicating poor solubility. Ligand B (-3.269) is slightly worse than Ligand A (-3.365).
10. **hERG:** Both have low hERG inhibition liability (0.415 and 0.441).
11. **Cl_mic:** Ligand A (57.453) has a lower microsomal clearance than Ligand B (68.586), suggesting better metabolic stability.
12. **t1/2:** Ligand B (18.439) has a slightly longer in vitro half-life than Ligand A (17.374).
13. **Pgp:** Ligand B (0.426) has slightly higher P-gp efflux liability than Ligand A (0.256). Lower Pgp is preferred.
14. **Affinity:** Ligand A (-6.5 kcal/mol) has a significantly stronger binding affinity than Ligand B (-4.7 kcal/mol). This is a substantial advantage, potentially outweighing some ADME concerns.
**Overall Assessment:**
Ligand A is the stronger candidate. While Ligand B has a better QED score, Ligand A boasts a significantly better binding affinity (-6.5 vs -4.7 kcal/mol), lower DILI risk, better BBB penetration, lower Pgp efflux, and better metabolic stability. The affinity difference is substantial enough to compensate for the slightly lower QED and solubility issues. The poor Caco-2 and solubility for both molecules would need to be addressed in further optimization, but the superior potency and safety profile of Ligand A make it the more promising starting point.
Output:
1
2025-04-17 21:38:34,318 - INFO - Here's a step-by-step reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [353.507, 61.88, 1.497, 1, 4, 0.786, 5.7, 76.851, -4.571, -0.849, 0.319, 10.076, -8.533, 0.016, -7.1]**
**Ligand B: [344.39, 67.23, 1.668, 1, 4, 0.839, 47.654, 76.464, -4.929, -2.075, 0.45, 36.228, -4.384, 0.223, -6.8]**
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (353.5) is slightly higher than Ligand B (344.4), but both are acceptable.
2. **TPSA:** Ligand A (61.88) is better than Ligand B (67.23). Both are below 140, which is good for oral absorption, but lower TPSA is generally preferred for GPCRs.
3. **logP:** Both ligands have good logP values (A: 1.497, B: 1.668), falling within the optimal 1-3 range. Ligand B is slightly higher.
4. **H-Bond Donors:** Both have 1 HBD, which is good.
5. **H-Bond Acceptors:** Both have 4 HBA, which is good.
6. **QED:** Both have acceptable QED values (A: 0.786, B: 0.839), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (5.7) has a significantly lower DILI risk than Ligand B (47.654). This is a major advantage for Ligand A.
8. **BBB:** Both ligands have high BBB penetration (A: 76.851, B: 76.464), which is good, though not critical for ADRB2 (a cardiovascular target).
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. Ligand A (-4.571) is slightly better than Ligand B (-4.929).
10. **Solubility:** Ligand A (-0.849) has better solubility than Ligand B (-2.075).
11. **hERG:** Ligand A (0.319) has a lower hERG risk than Ligand B (0.45).
12. **Cl_mic:** Ligand A (10.076) has lower microsomal clearance, suggesting better metabolic stability, than Ligand B (36.228).
13. **t1/2:** Ligand A (-8.533) has a longer in vitro half-life than Ligand B (-4.384).
14. **Pgp:** Both ligands have very low Pgp efflux liability (A: 0.016, B: 0.223). Ligand A is slightly better.
15. **Binding Affinity:** Ligand A (-7.1) has a slightly better binding affinity than Ligand B (-6.8).
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical ADME-Tox parameters, most notably DILI risk and metabolic stability (Cl_mic, t1/2). While both ligands have acceptable properties, Ligand A's significantly lower DILI risk and better metabolic profile make it the more promising candidate. The slightly better binding affinity of Ligand A further supports this decision. The Caco-2 permeability is poor for both, but this can be addressed with formulation strategies.
Output:
1
2025-04-17 21:38:34,318 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A: [337.427, 55.21, 2.9, 1, 6, 0.776, 66.615, 75.921, -4.783, -2.809, 0.924, 56.589, 17.281, 0.477, -6.7]**
**Ligand B: [361.471, 71.33, 1.491, 0, 6, 0.83, 54.905, 58.821, -5.112, -1.761, 0.197, 34.112, 10.923, 0.115, -5.1]**
Here's a breakdown of the comparison, considering the guidelines and GPCR-specific priorities:
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (337.427) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (55.21) is significantly better than Ligand B (71.33). GPCRs benefit from lower TPSA for better brain penetration and overall absorption.
3. **logP:** Both are within the optimal range (1-3), but Ligand A (2.9) is slightly higher, which could be beneficial for membrane permeability. Ligand B (1.491) is on the lower side, potentially hindering permeation.
4. **HBD:** Ligand A (1) is preferable to Ligand B (0). While both are low, a single HBD can contribute to solubility without significantly impacting permeability.
5. **HBA:** Both have 6 HBA, which is acceptable.
6. **QED:** Both are good (A: 0.776, B: 0.83), indicating drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand B (54.905) is better than Ligand A (66.615), indicating a lower risk of drug-induced liver injury. This is a significant advantage.
8. **BBB:** Ligand A (75.921) is significantly better than Ligand B (58.821). While ADRB2 isn't exclusively a CNS target, some brain exposure can be relevant for side effects or potential off-target effects.
9. **Caco-2:** Ligand A (-4.783) is better than Ligand B (-5.112), indicating better intestinal absorption.
10. **Solubility:** Ligand B (-1.761) is better than Ligand A (-2.809). Solubility is important for formulation and bioavailability.
11. **hERG:** Ligand A (0.924) is better than Ligand B (0.197). Lower hERG inhibition is crucial for avoiding cardiotoxicity, especially for a cardiovascular target.
12. **Cl_mic:** Ligand B (34.112) has significantly lower microsomal clearance than Ligand A (56.589), suggesting better metabolic stability.
13. **t1/2:** Ligand A (17.281) has a longer half-life than Ligand B (10.923).
14. **Pgp:** Ligand A (0.477) is better than Ligand B (0.115). Lower P-gp efflux is desirable for improved bioavailability.
15. **Affinity:** Ligand A (-6.7 kcal/mol) has a stronger binding affinity than Ligand B (-5.1 kcal/mol). The difference of 1.6 kcal/mol is substantial and can often outweigh minor ADME drawbacks.
**Overall Assessment:**
Ligand A has a significantly better binding affinity and a more favorable BBB profile, Caco-2 permeability, hERG inhibition, and Pgp efflux. These are important for a GPCR target. Ligand B has better DILI risk and metabolic stability (lower Cl_mic) and solubility. However, the substantial difference in binding affinity and the better overall balance of properties in Ligand A make it the more promising candidate. The slightly higher DILI risk of Ligand A might be mitigated through further structural modifications.
Output:
1
2025-04-17 21:38:34,318 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [339.439, 63.25, 3.534, 2, 3, 0.876, 54.323, 57.619, -4.94, -4.252, 0.774, 56.558, 12.081, 0.379, -7.1]
**Ligand B:** [346.475, 60.25, 2.527, 0, 5, 0.822, 32.571, 83.831, -4.916, -2.735, 0.242, 67.887, -9.123, 0.336, -7.0]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). A (339.439) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are good, below the 140 A^2 threshold for oral absorption. Ligand B (60.25) is slightly better than A (63.25).
3. **logP:** Both are within the optimal range (1-3). Ligand B (2.527) is slightly lower, which could be beneficial for solubility.
4. **HBD:** Ligand A (2) is better than Ligand B (0). Having some HBD can aid solubility.
5. **HBA:** Ligand B (5) is slightly better than Ligand A (3).
6. **QED:** Both are good (>0.5), suggesting drug-like properties. A (0.876) is marginally better than B (0.822).
7. **DILI:** Ligand B (32.571) is significantly better than Ligand A (54.323). This is a major advantage for B.
8. **BBB:** Ligand B (83.831) is much better than Ligand A (57.619). As this is a GPCR, and while not necessarily a CNS target, some BBB penetration can be helpful for distribution.
9. **Caco-2:** Both are very poor (-4.94 and -4.916). This is a significant concern for both.
10. **Solubility:** Ligand B (-2.735) is better than Ligand A (-4.252).
11. **hERG:** Ligand A (0.774) is better than Ligand B (0.242). Lower hERG is preferred.
12. **Cl_mic:** Ligand B (67.887) is better than Ligand A (56.558). Lower clearance is preferred for metabolic stability.
13. **t1/2:** Ligand B (-9.123) is better than Ligand A (12.081). A negative value suggests a very long half-life, which is a significant advantage.
14. **Pgp:** Both are low (0.379 and 0.336), indicating low efflux.
15. **Affinity:** Ligand A (-7.1) is slightly better than Ligand B (-7.0). However, the difference is small.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, and affinity. Ligand B has a slightly better logP and TPSA, similar Pgp, and a comparable affinity. However, the significant advantages of Ligand B in DILI risk, BBB penetration, metabolic stability (Cl_mic), and *especially* the in vitro half-life are compelling. The poor Caco-2 values for both are a concern, but can be addressed with formulation strategies.
**Conclusion:**
Despite the slightly better affinity of Ligand A, the overall profile of Ligand B is superior, particularly regarding safety (DILI) and pharmacokinetic properties (BBB, Cl_mic, t1/2). Therefore, Ligand B is the more promising drug candidate.
0
2025-04-17 21:38:34,318 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (385.266 and 366.571 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (50.36 and 49.41) are below the 140 A^2 threshold for good oral absorption, and well below the 90 A^2 threshold for CNS targets (though this isn't a CNS target, lower TPSA is generally favorable). Again, very similar.
3. **logP:** Ligand A (4.821) is slightly higher than Ligand B (3.638). While both are within the optimal 1-3 range, Ligand A is pushing the upper limit. This could potentially lead to solubility issues, but isn't a dealbreaker.
4. **HBD:** Ligand A (2) has more HBD than Ligand B (1). This is a minor difference, and both are within the acceptable limit of 5.
5. **HBA:** Both ligands have 3 HBA, which is well within the acceptable limit of 10.
6. **QED:** Ligand A (0.672) has a better QED score than Ligand B (0.474), indicating a more drug-like profile. This is a positive for Ligand A.
7. **DILI:** Ligand B (31.601) has a significantly lower DILI risk than Ligand A (68.321). This is a major advantage for Ligand B, as minimizing liver toxicity is crucial.
8. **BBB:** Both ligands have similar BBB penetration (62.97 and 66.499). Not a major differentiating factor for ADRB2.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.624 and -4.747). These values are unusual and suggest poor permeability.
10. **Solubility:** Both ligands have negative solubility values (-5.105 and -4.336). These values are also unusual and suggest very poor solubility.
11. **hERG:** Ligand A (0.695) has a slightly higher hERG inhibition liability than Ligand B (0.208), which is undesirable. Ligand B is significantly better here.
12. **Cl_mic:** Ligand B (82.786) has a higher microsomal clearance than Ligand A (66.051), indicating faster metabolism and potentially lower *in vivo* exposure. This favors Ligand A.
13. **t1/2:** Ligand A (97.012) has a much longer *in vitro* half-life than Ligand B (22.402). This is a significant advantage for Ligand A, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.496) has a higher Pgp efflux liability than Ligand B (0.156). This is unfavorable for Ligand A, as it could reduce oral bioavailability.
15. **Binding Affinity:** Ligand B (-6.5 kcal/mol) has a slightly better binding affinity than Ligand A (-6.3 kcal/mol), but the difference is small (0.2 kcal/mol).
**GPCR-specific priorities:** For GPCRs, logP, Pgp, TPSA, and affinity are key. Ligand B has better logP, Pgp, and affinity. Ligand A has better TPSA. The affinity difference is small.
**Overall Assessment:**
While Ligand A has a better QED and longer half-life, Ligand B has a significantly lower DILI risk and lower hERG inhibition, which are critical safety parameters. The slightly better affinity of Ligand B is also a plus. The poor Caco-2 and solubility values for both are concerning, but the safety profile of Ligand B is more compelling.
Output:
0
2025-04-17 21:38:34,318 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (348.309 and 350.459 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (99.87) is higher than Ligand B (64.8). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is generally preferred for absorption. Ligand B is significantly better.
3. **logP:** Both ligands have good logP values (2.344 and 3.31), falling within the optimal 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability, but not dramatically so.
4. **HBD:** Ligand A has 3 HBD, while Ligand B has 0. Lower HBD is generally preferred for permeability, giving a slight edge to Ligand B.
5. **HBA:** Ligand A has 4 HBA, Ligand B has 5. Both are acceptable, under the 10 threshold.
6. **QED:** Both ligands have good QED scores (0.659 and 0.755), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A has a DILI risk of 85.072, while Ligand B has 48.468. This is a *significant* difference. Ligand B has a much lower risk of liver injury, a critical factor.
8. **BBB:** Ligand A has a BBB penetration of 52.074, while Ligand B has 84.219. While ADRB2 isn't a primary CNS target, some brain penetration can be relevant for off-target effects or peripheral effects mediated by receptors in the brainstem. Ligand B is much better.
9. **Caco-2:** Both have negative Caco-2 values (-5.097 and -4.507). This is unusual and suggests poor permeability. However, the values are similar, so it doesn't strongly differentiate the ligands.
10. **Solubility:** Ligand A (-4.596) is slightly worse than Ligand B (-2.735). Better solubility is always preferred.
11. **hERG:** Ligand A (0.51) is slightly higher than Ligand B (0.337), indicating a slightly higher risk of hERG inhibition.
12. **Cl_mic:** Ligand A (-9.571) has a much lower (better) microsomal clearance than Ligand B (85.888). This suggests greater metabolic stability for Ligand A.
13. **t1/2:** Ligand A (20.99 hours) has a significantly longer half-life than Ligand B (0.003 hours). This is a major advantage for Ligand A, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.15) has lower P-gp efflux than Ligand B (0.209). Lower Pgp is preferred.
15. **Binding Affinity:** Ligand A (-6.7 kcal/mol) has a slightly better binding affinity than Ligand B (-6.0 kcal/mol). While the difference is not huge, it's a positive for Ligand A.
**Overall Assessment:**
Ligand B excels in several key areas: lower DILI risk, better TPSA, better BBB penetration, and a slightly better QED score. However, Ligand A has a significantly longer half-life and better metabolic stability (lower Cl_mic), and slightly better binding affinity. The DILI risk associated with Ligand A is concerning. The longer half-life and better affinity of Ligand A are attractive, but the significantly lower DILI risk of Ligand B is a major advantage, especially in early drug development.
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity) and the overall balance of properties, I believe Ligand B is the more promising candidate. The lower DILI risk is a critical factor that outweighs the slightly better affinity and half-life of Ligand A.
Output:
0
2025-04-17 21:38:34,318 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
The ADRB2 receptor is a GPCR, so the key priorities are logP, TPSA, Pgp efflux, BBB penetration, and binding affinity. Metabolic stability and solubility are also important, but slightly less so.
Let's compare the ligands property by property:
1. **MW:** Both ligands (367.743 and 346.475 Da) fall within the ideal range of 200-500 Da.
2. **TPSA:** Ligand A (81.93) is slightly higher than Ligand B (65.54). Both are acceptable, but Ligand B is better for oral absorption.
3. **logP:** Ligand A (3.006) is optimal, while Ligand B (1.617) is on the lower side of optimal. This favors Ligand A for membrane permeability.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 6 HBA, and Ligand B has 4. Both are acceptable.
6. **QED:** Ligand B (0.88) has a slightly better QED score than Ligand A (0.701), indicating better overall drug-likeness.
7. **DILI:** Ligand A (98.41) has a very high DILI risk, which is a major concern. Ligand B (11.361) has a very low DILI risk, a significant advantage.
8. **BBB:** Both ligands have reasonable BBB penetration (61.38 and 64.482 respectively). Not a primary concern for peripheral ADRB2, but higher is generally better.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability.
10. **Solubility:** Ligand B (-0.732) has better solubility than Ligand A (-4.56).
11. **hERG:** Ligand A (0.406) has a slightly higher hERG risk than Ligand B (0.226), but both are relatively low.
12. **Cl_mic:** Ligand B (2.621) has significantly lower microsomal clearance than Ligand A (48.867), indicating better metabolic stability.
13. **t1/2:** Ligand A (10.466) has a longer in vitro half-life than Ligand B (5.075).
14. **Pgp:** Ligand A (0.299) has lower P-gp efflux than Ligand B (0.016), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand B (-5.6 kcal/mol) has a significantly stronger binding affinity than Ligand A (-4.0 kcal/mol). This is a crucial advantage, exceeding the 1.5 kcal/mol threshold.
**Overall Assessment:**
While Ligand A has a better logP and Pgp profile, the extremely high DILI risk is a deal-breaker. Ligand B, despite a slightly lower logP, has a much better safety profile (low DILI), better metabolic stability (lower Cl_mic), better solubility, and, critically, a significantly stronger binding affinity. The affinity difference is substantial enough to outweigh the slightly less optimal logP.
**Output:**
0
2025-04-17 21:38:34,318 - INFO - Batch 273 complete. Total preferences: 4368
2025-04-17 21:38:34,319 - INFO - Processing batch 274/512...
2025-04-17 21:39:24,855 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (341.37 & 354.45 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (111.55) is better than Ligand B (122.55), being closer to the <140 threshold for good absorption.
3. **logP:** Ligand A (1.95) is optimal (1-3), while Ligand B (0.259) is quite low, potentially hindering membrane permeability. This is a significant point in favor of A.
4. **HBD:** Both have 4 HBD, which is acceptable.
5. **HBA:** Both have 5 HBA, which is acceptable.
6. **QED:** Ligand A (0.664) has a better QED score than Ligand B (0.444), indicating a more drug-like profile.
7. **DILI:** Ligand B (20.98) has a much lower DILI risk than Ligand A (54.63). This is a strong advantage for B.
8. **BBB:** Ligand B (71.58) has a significantly higher BBB penetration percentile than Ligand A (37.96). While ADRB2 isn't necessarily a CNS target, some cardiovascular effects can be mediated by CNS pathways, and higher BBB penetration isn't necessarily detrimental.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual. Without knowing the scale, it is hard to interpret.
10. **Solubility:** Ligand A (-4.242) has slightly better solubility than Ligand B (-2.47), but both are very poor.
11. **hERG:** Ligand A (0.316) has a lower hERG inhibition liability than Ligand B (0.123), which is favorable.
12. **Cl_mic:** Ligand B (29.79) has a slightly lower microsomal clearance than Ligand A (32.83), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-26.82) has a much longer in vitro half-life than Ligand B (-5.62). This is a significant advantage for A.
14. **Pgp:** Ligand A (0.011) has a slightly lower P-gp efflux liability than Ligand B (0.017).
15. **Affinity:** Ligand B (-5.6 kcal/mol) has a stronger binding affinity than Ligand A (-3.8 kcal/mol). This is a substantial advantage for B, potentially outweighing some ADME concerns.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A has a better logP and TPSA, and slightly better Pgp efflux. However, Ligand B has a significantly better binding affinity (-5.6 vs -3.8 kcal/mol), which is a crucial factor for GPCRs. The higher BBB penetration of Ligand B is also a plus, even if not critical. The lower DILI risk of Ligand B is also a significant benefit.
**Overall Assessment:**
While Ligand A has some advantages in terms of QED, t1/2, and hERG, the substantially stronger binding affinity of Ligand B, coupled with its lower DILI risk, and acceptable BBB penetration, make it the more promising candidate. The poor solubility of both is a concern that would need to be addressed through formulation strategies. The lower logP of B is a concern, but the affinity difference is large enough to potentially compensate.
Output:
0
2025-04-17 21:39:24,856 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.531 and 352.345 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (49.41) is significantly better than Ligand B (116.08). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption. Ligand B's TPSA is quite high, potentially hindering oral bioavailability.
3. **logP:** Ligand A (3.601) is slightly higher than Ligand B (2.054), both within the optimal 1-3 range. Ligand A is preferable.
4. **HBD:** Ligand A (1) is better than Ligand B (4). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (2) is better than Ligand B (8). Similar to HBD, lower HBA is generally preferred.
6. **QED:** Ligand A (0.797) is better than Ligand B (0.624), indicating a more drug-like profile.
7. **DILI:** Ligand A (21.908) is *much* better than Ligand B (67.468). This is a critical advantage for Ligand A. A DILI percentile below 40 is highly desirable.
8. **BBB:** Not a high priority for a cardiovascular target. Ligand A (77.86) is better than Ligand B (55.603), but this is less important.
9. **Caco-2:** Ligand A (-4.772) is better than Ligand B (-5.357). Both are negative, indicating poor permeability.
10. **Solubility:** Ligand A (-4.601) is better than Ligand B (-3.605). Both are poor, but A is slightly better.
11. **hERG:** Ligand A (0.534) is better than Ligand B (0.259). Lower hERG inhibition is crucial for avoiding cardiotoxicity.
12. **Cl_mic:** Ligand B (13.348) is *much* better than Ligand A (60.274). Lower clearance indicates greater metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand A (4.41) is better than Ligand B (-14.126). A positive half-life is preferable.
14. **Pgp:** Ligand A (0.239) is better than Ligand B (0.011). Lower P-gp efflux is desirable for better bioavailability.
15. **Binding Affinity:** Ligand A (-5.2) is better than Ligand B (-3.1). This is a substantial difference in potency, and the most important factor. A 2.1 kcal/mol advantage is significant.
**Overall Assessment:**
Ligand A has a clear advantage in most key parameters, especially binding affinity, DILI risk, and QED. While Ligand B has better metabolic stability (Cl_mic), the superior potency and safety profile of Ligand A outweigh this benefit. The high TPSA and DILI risk of Ligand B are significant concerns. For a GPCR target like ADRB2, potency and safety are paramount.
Output:
1
2025-04-17 21:39:24,856 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (366.527 Da) is within the ideal range (200-500), while Ligand B (407.264 Da) is also acceptable but trending towards the upper limit.
2. **TPSA:** Ligand A (57.69) is excellent, well below the 140 threshold for oral absorption. Ligand B (71.78) is still reasonable, but higher.
3. **logP:** Both ligands (A: 2.817, B: 3.031) are within the optimal 1-3 range.
4. **HBD:** Ligand A (0) is ideal, while Ligand B (1) is acceptable.
5. **HBA:** Both ligands (A: 4, B: 4) are within the acceptable limit of 10.
6. **QED:** Both ligands have good QED scores (A: 0.777, B: 0.795), indicating drug-likeness.
7. **DILI:** Ligand A (35.789) has a significantly lower DILI risk than Ligand B (63.358), which is a considerable advantage.
8. **BBB:** Ligand A (76.154) has better BBB penetration than Ligand B (62.505). While ADRB2 isn't strictly a CNS target, some CNS exposure can occur, and better BBB is generally favorable.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.684 and -4.72), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand A (-2.191) has slightly better solubility than Ligand B (-4.058), though both are quite poor.
11. **hERG:** Both ligands have low hERG inhibition risk (A: 0.615, B: 0.311), which is good.
12. **Cl_mic:** Ligand A (0.809) has significantly lower microsomal clearance than Ligand B (57.598), indicating better metabolic stability.
13. **t1/2:** Ligand B (97.485) has a much longer in vitro half-life than Ligand A (49.579), which is a major advantage.
14. **Pgp:** Both ligands have low Pgp efflux (A: 0.399, B: 0.51).
15. **Affinity:** Ligand B (-5.4 kcal/mol) has a slightly better binding affinity than Ligand A (-6.0 kcal/mol).
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Both ligands are reasonable on logP and Pgp. Ligand A has better TPSA. The affinity difference is small (0.6 kcal/mol), but Ligand B is slightly better. However, the significant advantages of Ligand A in DILI risk and metabolic stability (Cl_mic) are crucial. The poor Caco-2 and solubility are concerning for both, but the other factors outweigh this.
**Conclusion:**
Despite the slightly better affinity of Ligand B and its longer half-life, the significantly lower DILI risk and improved metabolic stability of Ligand A make it the more promising drug candidate. The poor permeability is a concern for both, but can be addressed through formulation strategies.
**Output:**
1
2025-04-17 21:39:24,856 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (359.407 and 371.547 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (101.15) is higher than Ligand B (69.72). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is generally preferred for permeability. Ligand B has a significant advantage here.
**3. logP:** Both ligands have similar logP values (1.608 and 1.741), both falling within the optimal 1-3 range. No clear advantage.
**4. H-Bond Donors:** Ligand A has 2 HBD, while Ligand B has 1. Both are acceptable, but fewer is generally better for permeability. Ligand B is slightly favored.
**5. H-Bond Acceptors:** Ligand A has 6 HBA, and Ligand B has 4. Again, both are within the acceptable range (<=10), with Ligand B being slightly better.
**6. QED:** Ligand B (0.635) has a better QED score than Ligand A (0.352), indicating a more drug-like profile. This is a notable advantage for Ligand B.
**7. DILI Risk:** Ligand A (87.786) has a significantly higher DILI risk than Ligand B (25.165). This is a major concern for Ligand A and a strong point in favor of Ligand B.
**8. BBB Penetration:** Both are relatively low, but Ligand B (61.225) is higher than Ligand A (48.662). While not a primary concern for a cardiovascular target, some BBB penetration can be beneficial for off-target effects.
**9. Caco-2 Permeability:** Both are negative, indicating poor permeability. Ligand A (-5.84) is worse than Ligand B (-5.148).
**10. Aqueous Solubility:** Both are negative, indicating poor solubility. Ligand A (-3.483) is worse than Ligand B (-2.44).
**11. hERG Inhibition:** Both ligands show low hERG inhibition risk (0.166 and 0.404), which is good. Ligand B is slightly better.
**12. Microsomal Clearance:** Ligand A (46.544) has lower microsomal clearance than Ligand B (56.11), suggesting better metabolic stability. This is a positive for Ligand A.
**13. In vitro Half-Life:** Ligand A (15.49) has a longer half-life than Ligand B (2.529). This is a significant advantage for Ligand A.
**14. P-gp Efflux:** Both ligands have low P-gp efflux (0.195 and 0.09), which is favorable. Ligand B is slightly better.
**15. Binding Affinity:** Ligand A (-6.5 kcal/mol) has a slightly better binding affinity than Ligand B (-5.4 kcal/mol). This is a 1.1 kcal/mol difference, which is a good advantage, but not overwhelming.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity) and general drug-like properties, Ligand B is the more promising candidate. While Ligand A has a slightly better binding affinity and longer half-life, its significantly higher DILI risk, poorer solubility, and lower QED score are major drawbacks. Ligand B excels in safety (DILI), drug-likeness (QED), and has a better TPSA. The difference in binding affinity is not large enough to overcome these significant advantages of Ligand B.
Output:
0
2025-04-17 21:39:24,856 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (351.372 and 372.487 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (45.23) is significantly better than Ligand B (103.78). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is quite high, potentially hindering absorption.
**3. logP:** Ligand A (4.419) is higher than Ligand B (0.247). While 4.419 is approaching the upper limit, it's still acceptable. Ligand B's logP is very low, suggesting poor membrane permeability. This is a major concern for a GPCR target.
**4. H-Bond Donors:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
**5. H-Bond Acceptors:** Ligand A (3) is preferable to Ligand B (5) for similar reasons as HBD.
**6. QED:** Ligand A (0.867) has a much better QED score than Ligand B (0.624), indicating a more drug-like profile.
**7. DILI:** Ligand B (24.04) has a significantly lower DILI risk than Ligand A (54.13), which is a positive attribute.
**8. BBB:** Ligand A (79.488) has a better BBB penetration percentile than Ligand B (36.371). While ADRB2 isn't exclusively a CNS target, some CNS exposure or off-target effects are possible, making higher BBB a slight advantage.
**9. Caco-2 Permeability:** Ligand A (-4.542) is better than Ligand B (-5.309), but both are negative values, indicating poor permeability. However, Ligand A is slightly better.
**10. Aqueous Solubility:** Ligand A (-4.349) is better than Ligand B (-1.377). Both are poor, but Ligand A is less poor.
**11. hERG Inhibition:** Ligand A (0.827) is preferable to Ligand B (0.125). Lower hERG inhibition is crucial for avoiding cardiotoxicity, which is especially important for a cardiovascular target like ADRB2.
**12. Microsomal Clearance:** Ligand B (2.287) has significantly lower microsomal clearance than Ligand A (52.647), indicating better metabolic stability. This is a strong advantage for Ligand B.
**13. In vitro Half-Life:** Ligand A (25.754) has a longer half-life than Ligand B (-2.501). This is a positive for Ligand A.
**14. P-gp Efflux:** Ligand A (0.314) is better than Ligand B (0.016). Lower P-gp efflux is desirable for improved bioavailability.
**15. Binding Affinity:** Ligand B (-6.9 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.6 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME drawbacks.
**Overall Assessment:**
Ligand B has a significantly better binding affinity and lower microsomal clearance (better metabolic stability). However, it suffers from a very low logP and high TPSA, which are major concerns for permeability and absorption. Ligand A has better ADME properties overall (logP, TPSA, QED, BBB, hERG, P-gp), but its binding affinity is weaker.
Given the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), and the fact that the affinity difference between Ligand B and A is substantial (1.3 kcal/mol), I believe the stronger binding of Ligand B is likely to be more impactful in driving efficacy and can be potentially optimized later. The poor logP and TPSA of Ligand B are addressable through medicinal chemistry efforts, while a weaker starting affinity is harder to improve significantly.
Output:
0
2025-04-17 21:39:24,856 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [340.463, 46.53, 4.503, 1, 3, 0.596, 24.195, 66.266, -4.505, -5.591, 0.822, 101.222, 1.823, 0.848, -6.9]
**Ligand B:** [351.447, 78.95, 0.387, 1, 4, 0.741, 26.095, 32.648, -4.677, -1.691, 0.091, 23.716, 11.159, 0.009, -6.8]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, BBB, and affinity are key):
1. **MW:** Both are within the ideal range (200-500 Da).
2. **TPSA:** Ligand A (46.53) is significantly better than Ligand B (78.95). Lower TPSA generally favors better absorption and BBB penetration.
3. **logP:** Ligand A (4.503) is a bit high, but still acceptable. Ligand B (0.387) is *too* low, potentially leading to poor membrane permeability.
4. **HBD/HBA:** Both have acceptable HBD (1) and HBA counts (3 and 4 respectively).
5. **QED:** Both have good QED scores (0.596 and 0.741).
6. **DILI:** Both have low DILI risk (24.195 and 26.095).
7. **BBB:** Ligand A (66.266) is much better than Ligand B (32.648). This is a critical advantage for a GPCR target, even if not specifically CNS-focused, as it suggests better distribution.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual. Assuming these are logP-like scales, lower values suggest poorer permeability.
9. **Solubility:** Both have negative solubility values, which is also unusual. Lower values suggest poorer solubility.
10. **hERG:** Ligand A (0.822) is slightly higher, indicating a slightly increased risk, but still reasonable. Ligand B (0.091) is very low, a definite advantage.
11. **Cl_mic:** Ligand A (101.222) has higher clearance than Ligand B (23.716), indicating lower metabolic stability.
12. **t1/2:** Ligand B (11.159) has a significantly longer half-life than Ligand A (1.823).
13. **Pgp:** Ligand A (0.848) has higher P-gp efflux liability than Ligand B (0.009). Lower Pgp is preferred.
14. **Affinity:** Both have very similar binding affinities (-6.9 and -6.8 kcal/mol). The difference is negligible.
**Overall Assessment:**
While Ligand B has a better hERG profile and longer half-life, Ligand A is significantly better across several crucial GPCR-relevant parameters: TPSA, logP, and especially BBB penetration. The higher Pgp efflux and clearance of Ligand A are drawbacks, but the poor logP of Ligand B is a more significant concern for permeability and overall drug-like behavior. Given the importance of BBB penetration and reasonable logP for GPCR targets, Ligand A appears to be the more promising candidate.
Output:
1
2025-04-17 21:39:24,856 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (407.895 Da) is within the ideal range, while Ligand B (364.511 Da) is also good, leaning towards the lower end. No strong preference here.
2. **TPSA:** Ligand A (55.2) is excellent, well below the 140 threshold. Ligand B (78.43) is still acceptable, but less optimal. This favors Ligand A.
3. **logP:** Both ligands (A: 2.958, B: 2.509) are within the optimal 1-3 range. No significant difference.
4. **HBD:** Ligand A (0) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (5) is better than Ligand B (4). Lower is generally better.
6. **QED:** Both ligands have good QED scores (A: 0.782, B: 0.696), indicating good drug-like properties. A is slightly better.
7. **DILI:** Ligand A (83.87) has a significantly higher DILI risk than Ligand B (29.43). This is a major concern for Ligand A.
8. **BBB:** Ligand A (69.058) has a better BBB penetration score than Ligand B (41.14). While ADRB2 isn't strictly a CNS target, some CNS exposure can be relevant for off-target effects, and a higher score is generally preferable.
9. **Caco-2:** Both show poor Caco-2 permeability (-5.024 and -5.151). This is a concern for oral bioavailability for both.
10. **Solubility:** Ligand A (-5.4) has worse solubility than Ligand B (-2.477). Solubility is important for formulation and bioavailability.
11. **hERG:** Both ligands have low hERG inhibition risk (A: 0.446, B: 0.25). No significant difference.
12. **Cl_mic:** Ligand A (60.976) has a higher microsomal clearance than Ligand B (42.978), indicating lower metabolic stability.
13. **t1/2:** Ligand B (13.695) has a significantly longer in vitro half-life than Ligand A (-31.332). This is a major advantage for Ligand B.
14. **Pgp:** Both have low Pgp efflux liability (A: 0.293, B: 0.328). No significant difference.
15. **Affinity:** Ligand A (-6.9 kcal/mol) has a slightly better binding affinity than Ligand B (-6.6 kcal/mol). While a difference of 0.3 kcal/mol isn't huge, it's a positive for Ligand A.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Ligand A is better in terms of TPSA and affinity, but Ligand B is better in terms of logP, and significantly better in terms of DILI risk and metabolic stability (t1/2 and Cl_mic). The poor Caco-2 permeability is a concern for both.
**Overall Assessment:**
Despite the slightly better affinity of Ligand A, the significantly higher DILI risk, lower solubility, and poorer metabolic stability are major drawbacks. Ligand B, while having slightly lower affinity, presents a much more favorable ADMET profile, particularly the lower DILI risk and improved half-life. These factors are crucial for a viable drug candidate.
Output:
0
2025-04-17 21:39:24,856 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (372.479 Da and 369.615 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (87.7) is higher than Ligand B (40.54). For a cardiovascular GPCR, TPSA isn't a *major* concern (unlike a CNS target), but lower is generally preferable for permeability. Ligand B is significantly better here.
**3. logP:** Ligand A (2.947) is within the optimal 1-3 range. Ligand B (4.582) is slightly above, which could potentially lead to solubility issues or off-target interactions, but isn't dramatically high. Ligand A is slightly preferred.
**4. H-Bond Donors:** Ligand A (0) is excellent, minimizing potential permeability issues. Ligand B (1) is acceptable. Ligand A is better.
**5. H-Bond Acceptors:** Ligand A (8) is within the acceptable range. Ligand B (3) is also good. No strong preference.
**6. QED:** Both ligands have good QED scores (0.593 and 0.681), indicating drug-like properties. Ligand B is slightly better.
**7. DILI Risk:** Ligand A (78.945) has a higher DILI risk than Ligand B (12.641). This is a significant concern. Ligand B is *much* preferred here.
**8. BBB Penetration:** Both ligands have similar BBB penetration (78.054 and 79.682). Since this is a cardiovascular target, BBB penetration is not a primary concern.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-5.196 and -4.981). This is unusual and suggests poor permeability. However, the values are very close.
**10. Aqueous Solubility:** Both ligands have negative solubility values (-3.87 and -4.546), indicating poor aqueous solubility. This is a concern for both.
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (0.757 and 0.85). This is good.
**12. Microsomal Clearance:** Ligand A (127.369) has higher microsomal clearance than Ligand B (100.069), indicating faster metabolism and potentially lower bioavailability. Ligand B is preferred.
**13. In vitro Half-Life:** Ligand A (9.386) has a longer half-life than Ligand B (4.128). This is a positive for Ligand A.
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (0.828 and 0.781). This is good.
**15. Binding Affinity:** Ligand B (-14.9 kcal/mol) has *significantly* stronger binding affinity than Ligand A (-6.1 kcal/mol). This is a substantial advantage that can outweigh many other drawbacks.
**Overall Assessment:**
While Ligand A has a slightly better logP and half-life, Ligand B is clearly superior due to its significantly lower DILI risk, better TPSA, and *much* stronger binding affinity. The strong binding affinity of Ligand B is a critical advantage for a GPCR target. The solubility and permeability concerns are shared by both, but the potency and safety profile of Ligand B make it the more promising candidate.
Output:
0
2025-04-17 21:39:24,856 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
The ADRB2 receptor is a GPCR, so the priorities are logP, Pgp, TPSA, affinity, and BBB. Let's break down a comparison of Ligand A and Ligand B across all 15 parameters:
1. **MW:** Both ligands are within the ideal 200-500 Da range (A: 394.5, B: 383.9).
2. **TPSA:** Ligand B (38.13) is significantly better than Ligand A (66.48). Lower TPSA generally translates to better cell permeability, crucial for GPCR targeting.
3. **logP:** Ligand A (2.736) is within the optimal range, while Ligand B (4.631) is pushing the upper limit. While higher logP can be acceptable, it raises concerns about solubility and off-target effects.
4. **HBD:** Ligand A (1) is preferable to Ligand B (0). One HBD can help with solubility without significantly hindering permeability.
5. **HBA:** Both ligands have 4 HBA, which is acceptable.
6. **QED:** Both ligands have similar QED values (A: 0.773, B: 0.656), indicating good drug-likeness.
7. **DILI:** Ligand B (45.095) has a slightly lower DILI risk than Ligand A (53.354), which is a positive.
8. **BBB:** Ligand A (88.329) has a significantly higher BBB penetration potential than Ligand B (68.127). While ADRB2 isn't strictly a CNS target, some peripheral exposure is often desired, and higher BBB can indicate better overall distribution.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
10. **Solubility:** Both ligands have negative solubility values, which is also unusual and suggests poor solubility.
11. **hERG:** Both ligands have low hERG inhibition risk (A: 0.643, B: 0.726).
12. **Cl_mic:** Ligand A (38.441) has a lower microsomal clearance than Ligand B (105.228), indicating better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand B (75.679) has a much longer in vitro half-life than Ligand A (-14.754). This is a major advantage.
14. **Pgp:** Ligand A (0.212) has lower P-gp efflux liability than Ligand B (0.833), which is favorable for bioavailability.
15. **Affinity:** Ligand B (-6.3 kcal/mol) has a slightly better binding affinity than Ligand A (-5.9 kcal/mol). This 0.4 kcal/mol difference is notable, but not overwhelming.
**Overall Assessment:**
Ligand B has a better binding affinity and a significantly longer half-life. However, Ligand A has a better TPSA, lower Pgp efflux, and better metabolic stability. The TPSA and Pgp differences are more important for a GPCR target. The significantly longer half-life of Ligand B is a strong point, but the metabolic stability of Ligand A is also important. Considering the balance of these factors, and the importance of metabolic stability and permeability for GPCRs, I lean towards Ligand A.
**Output:**
1
2025-04-17 21:39:24,856 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (352.459) is slightly lower than Ligand B (360.483), which is generally favorable for permeability.
2. **TPSA:** Ligand A (46.34) is significantly better than Ligand B (71.69). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (4.921) is higher than Ligand B (1.877). While both are within the acceptable range, Ligand A's value is approaching the upper limit and could potentially lead to solubility issues or off-target interactions. Ligand B is well within the optimal range.
4. **HBD:** Ligand A (0) is preferable to Ligand B (1). Fewer hydrogen bond donors generally improve membrane permeability.
5. **HBA:** Ligand A (4) is better than Ligand B (6). Lower HBA counts are generally preferred for better permeability.
6. **QED:** Both ligands have good QED scores (A: 0.657, B: 0.852), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand B (36.758) has a much lower DILI risk than Ligand A (71.423). This is a significant advantage for Ligand B.
8. **BBB:** Not a primary concern for a cardiovascular target. Ligand A (89.492) has a higher BBB score than Ligand B (67.08), but this isn't a deciding factor.
9. **Caco-2:** Ligand A (-4.744) and Ligand B (-5.018) are both very poor. This is a significant drawback for both compounds.
10. **Solubility:** Ligand B (-1.769) is better than Ligand A (-5.49). This is an important consideration, especially given Ligand A's higher logP.
11. **hERG:** Ligand A (0.77) is better than Ligand B (0.627). Lower hERG inhibition is preferred.
12. **Cl_mic:** Ligand B (21.747) has significantly lower microsomal clearance than Ligand A (94.723), indicating better metabolic stability.
13. **t1/2:** Ligand B (-23.064) has a much longer in vitro half-life than Ligand A (43.614). This is a significant advantage.
14. **Pgp:** Ligand A (0.929) is slightly higher than Ligand B (0.065). Lower P-gp efflux is preferred.
15. **Binding Affinity:** Ligand A (-9.0) has a significantly stronger binding affinity than Ligand B (-6.1). This is a substantial advantage.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. While Ligand A has a higher logP, the difference isn't extreme. Ligand A's TPSA is much lower, Pgp efflux is lower, and most importantly, its binding affinity is *significantly* better. The superior affinity of Ligand A likely outweighs the slightly higher logP and poorer solubility. The DILI and metabolic stability of Ligand B are very attractive, but the potency difference is too large to ignore.
**Conclusion:**
Despite Ligand B's better ADME properties (DILI, clearance, half-life, solubility), the substantially stronger binding affinity of Ligand A (-9.0 vs -6.1 kcal/mol) makes it the more promising candidate. A strong starting point for potency is crucial, and optimization can address the ADME concerns.
Output:
1
2025-04-17 21:39:24,857 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (344.363 and 345.443 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (74.97) is better than Ligand B (84.23). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally favors absorption.
3. **logP:** Both ligands have good logP values (2.784 and 2.504), falling within the 1-3 optimal range. Ligand A is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Ligand A has 0 HBD, which is excellent. Ligand B has 2, which is still acceptable but less ideal.
5. **HBA:** Ligand A has 6 HBA, and Ligand B has 4. Both are below the 10 threshold.
6. **QED:** Both ligands have similar and good QED values (0.777 and 0.795), indicating good drug-likeness.
7. **DILI:** Ligand A (63.086) has a significantly higher DILI risk than Ligand B (35.983). This is a major concern.
8. **BBB:** Both have reasonably high BBB penetration (80.419 and 71.811). This isn't a primary concern for a cardiovascular target.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. Ligand B (-4.943) is slightly worse than Ligand A (-4.445).
10. **Solubility:** Ligand A (-4.278) and Ligand B (-2.849) both have poor solubility. Ligand B is slightly better.
11. **hERG:** Both ligands have low hERG inhibition risk (0.389 and 0.34).
12. **Cl_mic:** Ligand A (77.787) has higher microsomal clearance than Ligand B (50.28), suggesting lower metabolic stability.
13. **t1/2:** Ligand B (-12.603) has a slightly better (less negative) in vitro half-life than Ligand A (-14.481).
14. **Pgp:** Both have low Pgp efflux liability (0.579 and 0.157). Ligand B is better.
15. **Binding Affinity:** Ligand A (-6.6 kcal/mol) has a slightly better binding affinity than Ligand B (-5.7 kcal/mol). This is a 0.9 kcal/mol difference, which is significant.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Ligand A has a slightly better logP and significantly better affinity. However, the high DILI risk for Ligand A and its higher Cl_mic are major drawbacks. Ligand B has a much better safety profile (DILI) and metabolic stability, and its affinity is still quite good.
**Conclusion:**
Despite the slightly better affinity of Ligand A, the significantly lower DILI risk and improved metabolic stability of Ligand B make it the more promising drug candidate. The affinity difference, while notable, can potentially be optimized in later stages of drug development. The safety profile is paramount.
Output:
0
2025-04-17 21:39:24,857 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (356.388 Da and 348.491 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Both ligands have TPSA values (49.41 and 47.1) below 140, which is good for oral absorption. They are also reasonably low, which is favorable for GPCR ligands.
**3. LogP:** Ligand A (3.465) is within the optimal 1-3 range. Ligand B (0.484) is quite low, potentially hindering membrane permeability and absorption. This is a significant drawback.
**4. H-Bond Donors:** Ligand A (1) is good. Ligand B (0) is acceptable, but a single donor can sometimes improve solubility.
**5. H-Bond Acceptors:** Ligand A (2) is good. Ligand B (4) is acceptable, but higher numbers can sometimes impact permeability.
**6. QED:** Ligand A (0.849) has a very strong drug-like profile. Ligand B (0.628) is still acceptable, but less optimal.
**7. DILI Risk:** Ligand A (39.434) has a low DILI risk. Ligand B (12.02) has a very low DILI risk, which is excellent.
**8. BBB Penetration:** Ligand A (88.29) has good BBB penetration, which is not crucial for a cardiovascular target but isn't detrimental. Ligand B (62.699) is lower, but still not a major concern for this target.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.756 and -4.659), which is unusual and suggests poor permeability *in vitro*. This is concerning for both.
**10. Aqueous Solubility:** Both ligands have negative solubility values (-3.696 and -0.994), which is also unusual and suggests poor aqueous solubility. This is concerning for both.
**11. hERG Inhibition:** Ligand A (0.801) has a slightly higher hERG risk than Ligand B (0.515), but both are relatively low.
**12. Microsomal Clearance:** Ligand A (57.066) has a higher microsomal clearance than Ligand B (31.387), indicating faster metabolism and potentially lower *in vivo* exposure. This is a negative for Ligand A.
**13. In vitro Half-Life:** Ligand A (7.444) has a longer half-life than Ligand B (3.498), which is desirable.
**14. P-gp Efflux:** Ligand A (0.296) has lower P-gp efflux liability than Ligand B (0.014), which is favorable for oral bioavailability.
**15. Binding Affinity:** Ligand A (-7.1 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.4 kcal/mol). This ~0.7 kcal/mol difference is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand A is the better candidate despite some ADME concerns. The significantly stronger binding affinity (-7.1 vs -6.4 kcal/mol) is a major advantage. While Ligand B has slightly better DILI and P-gp profiles, its very low logP is a significant concern for permeability and bioavailability. The longer half-life and lower P-gp efflux of Ligand A are also beneficial. The poor Caco-2 and solubility for both are concerning and would require formulation work, but the potency advantage of A is more likely to be optimized.
Output:
1
2025-04-17 21:39:24,857 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.5 & 349.4 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (49.85) is significantly better than Ligand B (91.56). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally correlates with better absorption. Ligand B is quite high and potentially problematic.
3. **logP:** Ligand A (2.687) is optimal. Ligand B (0.287) is quite low, potentially leading to poor membrane permeability. This is a significant drawback.
4. **HBD:** Ligand A (0) is preferable to Ligand B (1). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (3) is better than Ligand B (6). Lower HBA is generally preferred for permeability.
6. **QED:** Both ligands have good QED scores (0.74 and 0.825), indicating good drug-like properties.
7. **DILI:** Ligand A (6.282) is much better than Ligand B (35.789). Lower DILI is crucial. Ligand B's DILI risk is concerning.
8. **BBB:** Ligand A (83.443) is better than Ligand B (64.482), but this isn't a high priority for a cardiovascular target.
9. **Caco-2:** Both are negative, indicating poor permeability. However, the scale is not provided, so it's hard to interpret the absolute values.
10. **Solubility:** Ligand A (-2.011) is better than Ligand B (-1.145), but both are poor.
11. **hERG:** Both ligands have very low hERG risk (0.479 and 0.177). This is excellent.
12. **Cl_mic:** Ligand A (63.63) is higher than Ligand B (36.567), indicating faster clearance and potentially lower metabolic stability. This favors Ligand B.
13. **t1/2:** Ligand A (-10.012) is much worse than Ligand B (-7.922), indicating a very short half-life. This is a major disadvantage for Ligand A.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.106 and 0.031).
15. **Binding Affinity:** Ligand B (-7.3) is significantly better than Ligand A (-5.1). A 2.2 kcal/mol difference in binding is substantial and can often outweigh other drawbacks.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand A fails on logP and TPSA, while Ligand B has a superior affinity. The DILI risk for Ligand B is a concern, but the significantly better binding affinity and better metabolic stability (lower Cl_mic) are compelling. The poor solubility of both is a formulation challenge, but potentially surmountable. The half-life of Ligand A is a major concern.
**Conclusion:**
Despite the higher DILI risk, Ligand B's superior binding affinity, better logP, and better metabolic stability outweigh the drawbacks, particularly given the poor half-life of Ligand A.
Output:
0
2025-04-17 21:39:24,857 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (347.415 Da) is slightly lower, which is generally favorable for permeability.
**2. TPSA:** Both ligands have TPSA values below 140 (A: 86.88, B: 84.42), meeting the threshold for good oral absorption.
**3. logP:** Both ligands have logP values within the optimal range (1-3), with A at 1.297 and B at 1.229. This is good for both permeability and avoiding off-target effects.
**4. H-Bond Donors:** Both have 1 HBD, which is acceptable.
**5. H-Bond Acceptors:** Ligand A has 5 HBA, and Ligand B has 6. Both are within the acceptable limit of 10.
**6. QED:** Both ligands have good QED scores (A: 0.784, B: 0.843), indicating a generally drug-like profile.
**7. DILI Risk:** Ligand A (36.332) has a significantly lower DILI risk than Ligand B (84.219). This is a major advantage for Ligand A.
**8. BBB Penetration:** Ligand A (74.37) has better BBB penetration than Ligand B (40.675). While ADRB2 is a cardiovascular target, some CNS effects are possible with beta-blockers, and better BBB penetration could be relevant for off-target effects or potential CNS side effects.
**9. Caco-2 Permeability:** Ligand A (-5.026) has better Caco-2 permeability than Ligand B (-5.116).
**10. Aqueous Solubility:** Ligand A (-1.182) has better aqueous solubility than Ligand B (-3.229). This is important for formulation and bioavailability.
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (A: 0.149, B: 0.203).
**12. Microsomal Clearance:** Ligand A (15.035) has lower microsomal clearance than Ligand B (32.543), suggesting better metabolic stability.
**13. In vitro Half-Life:** Ligand A (-3.925) has a longer in vitro half-life than Ligand B (2.278).
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (A: 0.089, B: 0.079).
**15. Binding Affinity:** Ligand B (-5.8 kcal/mol) has a slightly better binding affinity than Ligand A (-6.7 kcal/mol). While a difference of 0.9 kcal/mol is noticeable, the other ADME properties of Ligand A are significantly more favorable.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity) and general drug-likeness parameters, Ligand A is the more promising candidate. While Ligand B has slightly better binding affinity, Ligand A excels in crucial ADME properties like DILI risk, BBB penetration, solubility, metabolic stability (lower Cl_mic and longer t1/2), and Caco-2 permeability. The lower DILI risk and better solubility are particularly important for cardiovascular drugs, where long-term safety and bioavailability are critical.
Output:
1
2025-04-17 21:39:24,857 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [362.455, 87.46, 1.951, 2, 6, 0.87, 61.613, 43.273, -5.298, -3.128, 0.26, -0.067, 11.981, 0.1, -5.9]
**Ligand B:** [383.945, 47.36, 3.83, 0, 5, 0.661, 37.922, 68.282, -4.96, -2.666, 0.701, 87.181, 35.557, 0.686, -8.5]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (362.455) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (87.46) is better than Ligand B (47.36), being under 140. Both are acceptable, but lower TPSA is better for absorption.
3. **logP:** Ligand A (1.951) is within the optimal range (1-3). Ligand B (3.83) is pushing the upper limit, potentially leading to solubility issues or off-target interactions.
4. **HBD:** Ligand A (2) is preferable to Ligand B (0). Having some HBD can aid solubility.
5. **HBA:** Ligand A (6) is slightly higher than Ligand B (5), but both are within acceptable limits.
6. **QED:** Ligand A (0.87) has a significantly better QED score than Ligand B (0.661), indicating a more drug-like profile.
7. **DILI:** Ligand B (37.922) has a much lower DILI risk than Ligand A (61.613). This is a significant advantage for Ligand B.
8. **BBB:** Ligand B (68.282) has a better BBB penetration score than Ligand A (43.273). While ADRB2 isn't exclusively a CNS target, some level of BBB penetration can be beneficial.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-5.298) is slightly worse than Ligand B (-4.96).
10. **Solubility:** Both have negative solubility values, which is also unusual and indicates poor solubility. Ligand A (-3.128) is slightly worse than Ligand B (-2.666).
11. **hERG:** Ligand A (0.26) has a lower hERG risk than Ligand B (0.701), which is desirable.
12. **Cl_mic:** Ligand A (-0.067) has a lower (better) microsomal clearance than Ligand B (87.181), indicating better metabolic stability.
13. **t1/2:** Ligand B (35.557) has a much longer in vitro half-life than Ligand A (11.981). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.1) has lower P-gp efflux than Ligand B (0.686), which is preferable.
15. **Affinity:** Ligand B (-8.5) has a significantly stronger binding affinity than Ligand A (-5.9). This is a crucial advantage, potentially outweighing some ADME drawbacks.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, we prioritize logP, Pgp, TPSA, and affinity. Ligand B excels in affinity and has reasonable logP and Pgp values. While its TPSA is lower, it's still acceptable. Ligand A has better TPSA, but its affinity is significantly weaker. The DILI risk is also a concern for Ligand A.
**Conclusion:**
Despite Ligand A having slightly better TPSA, HBD, and lower hERG risk, Ligand B's significantly stronger binding affinity (-8.5 vs -5.9 kcal/mol), lower DILI risk, and longer half-life outweigh these advantages. The stronger binding is particularly important for a GPCR target.
Output:
0
2025-04-17 21:39:24,857 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [349.431, 82.45, 2.088, 1, 6, 0.795, 64.211, 82.086, -4.832, -3.3, 0.181, 64.098, -10.408, 0.187, -5.6]
**Ligand B:** [372.418, 95.94, 0.72, 2, 6, 0.543, 44.126, 58.782, -4.906, -2.336, 0.302, 29.81, 2.581, 0.069, -6.5]
Here's a breakdown, considering the guidelines and GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal 200-500 Da range. Ligand A (349.431) is slightly preferred due to being lower.
2. **TPSA:** Ligand A (82.45) is better than Ligand B (95.94). Both are below 140, but lower is better for permeability.
3. **logP:** Ligand A (2.088) is optimal, while Ligand B (0.72) is a bit low, potentially hindering membrane permeability. This is a significant advantage for A.
4. **HBD/HBA:** Both have 1 HBD and 6 HBA, which are acceptable.
5. **QED:** Ligand A (0.795) is better than Ligand B (0.543), indicating a more drug-like profile.
6. **DILI:** Ligand B (44.126) is significantly better than Ligand A (64.211), indicating a lower risk of liver injury. This is a major advantage for B.
7. **BBB:** Ligand A (82.086) has better BBB penetration than Ligand B (58.782). While not a primary concern for a cardiovascular target, it's a slight positive for A.
8. **Caco-2:** Both have similar, poor Caco-2 permeability (-4.832 and -4.906).
9. **Solubility:** Ligand A (-3.3) has slightly better solubility than Ligand B (-2.336).
10. **hERG:** Ligand A (0.181) is better than Ligand B (0.302), indicating a lower risk of cardiotoxicity.
11. **Cl_mic:** Ligand B (29.81) has much lower microsomal clearance than Ligand A (64.098), suggesting better metabolic stability. This is a substantial advantage for B.
12. **t1/2:** Ligand A (-10.408) has a longer half-life than Ligand B (2.581). This is a positive for A.
13. **Pgp:** Ligand A (0.187) has lower P-gp efflux than Ligand B (0.069), which is favorable.
14. **Affinity:** Ligand B (-6.5) has a significantly stronger binding affinity than Ligand A (-5.6) - a difference of 0.9 kcal/mol. This is a very important factor.
**Overall Assessment:**
The decision is a trade-off. Ligand A has better logP, QED, BBB, hERG, Pgp and t1/2. Ligand B shines with significantly lower DILI risk, much better metabolic stability (lower Cl_mic), and a substantially stronger binding affinity.
Given this is a GPCR target and affinity is paramount, the 0.9 kcal/mol difference in binding affinity is a significant advantage for Ligand B. The lower DILI risk and improved metabolic stability further strengthen its profile. While Ligand A has some advantages, the combination of potency and safety/stability benefits of Ligand B outweigh those advantages.
Output:
0
2025-04-17 21:39:24,857 - INFO - Batch 274 complete. Total preferences: 4384
2025-04-17 21:39:24,857 - INFO - Processing batch 275/512...
2025-04-17 21:40:14,216 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
The target is ADRB2, a GPCR. Therefore, the priorities are logP, Pgp, TPSA, affinity, and, to a lesser extent, BBB.
Let's break down the comparison:
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (357.338) is slightly higher than Ligand B (346.475), but this isn't a major concern.
2. **TPSA:** Ligand B (85.23) is significantly better than Ligand A (105.34). Lower TPSA is preferred for better permeability, especially for a GPCR.
3. **logP:** Ligand B (1.427) is within the optimal range (1-3), while Ligand A (-0.797) is below 1. This is a significant disadvantage for Ligand A, as it may struggle with membrane permeability.
4. **HBD/HBA:** Ligand A (1 HBD, 7 HBA) is slightly better than Ligand B (2 HBD, 4 HBA) in terms of maintaining a balance between solubility and permeability.
5. **QED:** Ligand A (0.711) has a better QED score than Ligand B (0.463), indicating a more drug-like profile.
6. **DILI:** Ligand B (18.418) has a much lower DILI risk than Ligand A (51.338). This is a crucial advantage for Ligand B.
7. **BBB:** Ligand A (70.415) has a slightly better BBB penetration score than Ligand B (53.16), but this is less critical for a non-CNS target like ADRB2.
8. **Caco-2:** Both ligands have similar, poor Caco-2 permeability (-4.748 and -4.847).
9. **Solubility:** Ligand A (-0.943) has slightly better solubility than Ligand B (-2.55), but both are quite poor.
10. **hERG:** Ligand B (0.405) has a lower hERG risk than Ligand A (0.241).
11. **Cl_mic:** Ligand A (-3.098) has significantly lower microsomal clearance than Ligand B (24.84), indicating better metabolic stability.
12. **t1/2:** Ligand A (12.39) has a longer in vitro half-life than Ligand B (7.989).
13. **Pgp:** Ligand A (0.048) has lower P-gp efflux than Ligand B (0.029), which is a slight advantage.
14. **Affinity:** Ligand A (-6.7 kcal/mol) has a slightly better binding affinity than Ligand B (-5.5 kcal/mol). The difference is 1.2 kcal/mol, which is significant but not overwhelming.
**Overall Assessment:**
While Ligand A has better affinity, longer half-life, and slightly better Pgp properties, Ligand B has a much more favorable profile regarding logP, DILI, and hERG. The poor logP of Ligand A is a significant concern, potentially hindering its ability to reach the target. The lower DILI and hERG risks of Ligand B are critical for safety. Considering the GPCR-specific priorities and the overall balance of properties, Ligand B appears to be the more promising drug candidate.
**Output:**
0
2025-04-17 21:40:14,216 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (356.495 and 361.873 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (57.26) is better than Ligand B (62.3). Both are below 140, but lower TPSA generally favors absorption.
**3. logP:** Both ligands have good logP values (3.39 and 2.765), falling within the optimal 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability, but not dramatically so.
**4. H-Bond Donors:** Ligand A has 2 HBD, while Ligand B has 1. Both are acceptable (<=5).
**5. H-Bond Acceptors:** Ligand A has 5 HBA, and Ligand B has 3. Both are within the acceptable range (<=10).
**6. QED:** Ligand A (0.882) has a significantly better QED score than Ligand B (0.572), indicating a more drug-like profile.
**7. DILI:** Ligand B (41.411) has a lower DILI risk than Ligand A (59.829), which is a significant advantage. Lower DILI is crucial.
**8. BBB:** Ligand A (94.184) has a much higher BBB penetration percentile than Ligand B (67.08). While ADRB2 is cardiovascular, some CNS effects are possible with beta-blockers, and higher BBB penetration could lead to off-target effects. However, for a cardiovascular target, this isn't a primary concern, and a moderate BBB value is acceptable.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-5.036 and -5.044). This is unusual and suggests poor permeability. This is a major concern for both.
**10. Aqueous Solubility:** Both ligands have very poor aqueous solubility (-3.231 and -2.885). This is a significant drawback for both, potentially impacting bioavailability.
**11. hERG Inhibition:** Ligand A (0.867) has a slightly higher hERG inhibition liability than Ligand B (0.347), meaning B is safer in terms of cardiotoxicity.
**12. Microsomal Clearance:** Ligand B (38.462) has a lower microsomal clearance than Ligand A (4.602), suggesting better metabolic stability. This is a positive for Ligand B.
**13. In vitro Half-Life:** Ligand B (-11.487) has a *negative* half-life, which is biologically impossible and indicates a significant issue with the data or the molecule itself. Ligand A (40.18) has a reasonable half-life.
**14. P-gp Efflux:** Ligand A (0.421) has a lower P-gp efflux liability than Ligand B (0.228), which is favorable for bioavailability.
**15. Binding Affinity:** Ligand B (-6.0) has a significantly stronger binding affinity than Ligand A (0.0). This is a substantial advantage, potentially outweighing some of the ADME drawbacks.
**Overall Assessment:**
Ligand B has a much better binding affinity and lower DILI risk, and better metabolic stability. However, the negative in vitro half-life is a critical flaw. Ligand A has a more reasonable half-life and a better QED score, but its DILI risk is higher, and its binding affinity is very weak. The poor Caco-2 and solubility are concerning for both.
Given the critical importance of binding affinity for GPCRs, and the severe issue with Ligand B's half-life, I would cautiously favor Ligand A, despite its drawbacks. The weak binding affinity of Ligand A is a significant concern, but the negative half-life of Ligand B is a showstopper. Further optimization of Ligand A would be necessary to address its DILI risk and improve its binding affinity.
Output:
1
2025-04-17 21:40:14,217 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.443 and 345.487 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (80.57) is higher than Ligand B (52.65). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B has a clear advantage here.
3. **logP:** Ligand A (2.419) is within the optimal 1-3 range. Ligand B (1.488) is at the lower end, potentially impacting permeability. Ligand A is slightly better.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable.
5. **HBA:** Ligand A (4) and Ligand B (3) are both acceptable.
6. **QED:** Both ligands (0.756 and 0.678) have good drug-likeness scores (>0.5).
7. **DILI:** Ligand A (28.383) has a significantly lower DILI risk than Ligand B (6.282). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (68.67) has a better BBB penetration percentile than Ligand B (53.005), but neither is particularly high. This is not a major concern for a cardiovascular target.
9. **Caco-2:** Ligand A (-4.535) and Ligand B (-4.837) are similar.
10. **Solubility:** Ligand A (-2.89) is slightly better than Ligand B (-1.512).
11. **hERG:** Ligand A (0.362) has a slightly better hERG profile than Ligand B (0.491).
12. **Cl_mic:** Ligand A (63.516) has a higher microsomal clearance than Ligand B (-16.921). This means Ligand B is more metabolically stable, a significant advantage.
13. **t1/2:** Ligand A (21.488) has a longer half-life than Ligand B (-5.665). This is a positive for Ligand A.
14. **Pgp:** Ligand A (0.256) has lower P-gp efflux than Ligand B (0.011).
15. **Affinity:** Ligand A (-7.3 kcal/mol) has a slightly better binding affinity than Ligand B (-6.3 kcal/mol). While both are good, the 1 kcal/mol difference is notable.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A has a better logP and affinity, and lower Pgp efflux. Ligand B has a lower TPSA and better metabolic stability. The DILI risk for Ligand A is also significantly lower, which is a critical safety factor.
**Overall Assessment:**
While Ligand B has better metabolic stability and lower TPSA, the significantly lower DILI risk, slightly better affinity, and better logP of Ligand A outweigh these benefits. The longer half-life of Ligand A is also a positive. The difference in affinity isn't huge, but combined with the other factors, it tips the balance.
Output:
1
2025-04-17 21:40:14,217 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Ligand A (411.208 Da) is within the ideal range, while Ligand B (348.399 Da) is slightly below, but still acceptable.
2. **TPSA:** Ligand A (113.92) is acceptable, though approaching the upper limit for good oral absorption. Ligand B (92.78) is excellent.
3. **logP:** Ligand A (3.07) is optimal. Ligand B (0.582) is quite low, potentially hindering membrane permeability.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 7 HBA, acceptable. Ligand B has 5 HBA, also acceptable.
6. **QED:** Both ligands have reasonable QED scores (0.322 and 0.56), but Ligand B is better.
7. **DILI:** Ligand A (86.002) has a significantly higher DILI risk than Ligand B (41.722). This is a major concern for Ligand A.
8. **BBB:** Both ligands have acceptable BBB penetration (68.554 and 66.499).
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Both ligands have negative solubility values, which is also unusual.
11. **hERG:** Ligand A (0.647) has a slightly higher hERG risk than Ligand B (0.055), but both are relatively low.
12. **Cl_mic:** Ligand A (80.395) has a higher microsomal clearance than Ligand B (33.276), indicating lower metabolic stability.
13. **t1/2:** Ligand A (6.34) has a longer half-life than Ligand B (-15.795), but the negative value for B is concerning.
14. **Pgp:** Ligand A (0.432) has lower P-gp efflux liability than Ligand B (0.029), which is favorable.
15. **Affinity:** Both ligands have the same binding affinity (-6.7 kcal/mol), so this parameter doesn't differentiate them.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, and Pgp are important. Ligand A has a better logP and Pgp profile, but Ligand B has a significantly better TPSA. The biggest differentiator is the DILI risk. Ligand A's high DILI risk is a major red flag.
**Overall Assessment:**
Despite Ligand A having slightly better logP and Pgp properties, the significantly higher DILI risk and higher metabolic clearance make it a less desirable candidate. Ligand B, while having a lower logP, presents a much more favorable safety profile (lower DILI) and better metabolic stability.
Output:
0
2025-04-17 21:40:14,217 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (342.443 and 366.487 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (67.23) is better than Ligand B (74.77). Both are below 140, but lower is preferred for absorption.
3. **logP:** Ligand A (1.856) is slightly better than Ligand B (0.832), both are within the optimal 1-3 range. Ligand B is closer to the lower limit, which could potentially affect permeability.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 4 HBA, while Ligand B has 6. Ligand A is preferable here, staying further below the 10 threshold.
6. **QED:** Both ligands have similar QED values (0.871 and 0.807), indicating good drug-likeness.
7. **DILI:** Ligand A (27.724) has a slightly higher DILI risk than Ligand B (24.622), but both are well below the concerning threshold of 60.
8. **BBB:** Both ligands have similar BBB penetration (54.207 and 54.285). Since ADRB2 is a cardiovascular target, BBB penetration is not a primary concern.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.806 and -4.846), which is unusual and suggests poor permeability. This is a significant drawback for both.
10. **Solubility:** Both ligands have very poor aqueous solubility (-1.353 and -1.469). This is a major concern for both compounds.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.238 and 0.443). This is positive.
12. **Cl_mic:** Ligand B (-14.083) has significantly lower microsomal clearance than Ligand A (29.286), indicating better metabolic stability. This is a major advantage for Ligand B.
13. **t1/2:** Ligand B (14.137) has a longer in vitro half-life than Ligand A (18.384). This is a positive for Ligand B.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.033 and 0.027). This is good.
15. **Binding Affinity:** Ligand B (-6.9 kcal/mol) has a slightly better binding affinity than Ligand A (-6.3 kcal/mol). This difference of 0.6 kcal/mol is significant and can outweigh some ADME drawbacks.
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, TPSA, and affinity are key. Ligand A has a slightly better logP and TPSA, but Ligand B has a better affinity. The metabolic stability (Cl_mic) and half-life are also important, and Ligand B is clearly superior in these aspects. The poor Caco-2 and solubility are concerning for both, but the affinity and metabolic stability advantages of Ligand B are more critical.
**Conclusion:**
Despite the poor permeability and solubility of both compounds, Ligand B's superior binding affinity, metabolic stability, and half-life make it the more promising candidate. The 0.6 kcal/mol difference in binding affinity is substantial.
Output:
0
2025-04-17 21:40:14,217 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (362.455 and 346.299 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (107.11) is better than Ligand B (127.01). ADRB2 is a cardiovascular target, so CNS penetration isn't critical, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (2.23) is within the optimal 1-3 range. Ligand B (0.109) is quite low, potentially hindering membrane permeability. This is a significant drawback for a GPCR ligand.
4. **HBD:** Ligand A (4) is acceptable. Ligand B (2) is also good.
5. **HBA:** Ligand A (5) is acceptable. Ligand B (8) is slightly higher, but still within the reasonable limit of 10.
6. **QED:** Both ligands have good QED scores (0.612 and 0.784), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (75.533) has a lower DILI risk than Ligand B (85.77). This is a clear advantage for Ligand A.
8. **BBB:** Both have low BBB penetration, which is fine for a cardiovascular target.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Both have negative solubility values, which is also unusual and suggests poor solubility. This is a concern for both.
11. **hERG:** Both have very low hERG inhibition risk (0.203 and 0.013). This is excellent.
12. **Cl_mic:** Ligand A (-10.552) has a much lower (better) microsomal clearance than Ligand B (14.325). This suggests greater metabolic stability for Ligand A.
13. **t1/2:** Ligand A (-6.852) has a longer half-life than Ligand B (7.475). This is a significant advantage.
14. **Pgp:** Both have very low Pgp efflux liability (0.078 and 0.012). This is good.
15. **Binding Affinity:** Ligand B (-8.1) has a significantly stronger binding affinity than Ligand A (-6.9) (a 1.2 kcal/mol difference). This is a major advantage for Ligand B, and could potentially outweigh some of its ADME liabilities.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand B has superior affinity, but significantly worse logP. Ligand A has better logP and TPSA. The metabolic stability (Cl_mic and t1/2) of Ligand A is also much better. While the affinity difference is substantial, the poor logP of Ligand B is a major concern for oral bioavailability and overall drug-like properties.
**Conclusion:**
Despite the stronger binding affinity of Ligand B, the significantly better logP, DILI, metabolic stability, and half-life of Ligand A make it the more promising drug candidate. The affinity difference, while notable, may be overcome with further optimization of Ligand A. The poor logP of Ligand B is a more difficult property to improve.
Output:
1
2025-04-17 21:40:14,217 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [347.419, 109.61 , 1.465, 1. , 4. , 0.326, 14.889, 52.772, -4.943, -0.903, 0.134, 11.243, -2.767, 0.01 , -6.2 ]
**Ligand B:** [348.443, 98.66 , 1.873, 4. , 4. , 0.631, 37.03 , 51.493, -4.707, -2.767, 0.359, 26.019, 15.379, 0.096, -7.8 ]
Here's a breakdown, prioritizing GPCR-relevant properties:
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). A is 347.4, B is 348.4. No significant difference.
2. **TPSA:** Ligand A (109.61) is slightly higher than Ligand B (98.66). Both are acceptable for oral absorption, but B is preferable as it's closer to the <140 threshold.
3. **logP:** Both are within the optimal range (1-3). Ligand A (1.465) is slightly lower than Ligand B (1.873). B is slightly better here for membrane permeability.
4. **H-Bond Donors/Acceptors:** A has 1 HBD and 4 HBA, B has 4 HBD and 4 HBA. A is better with fewer HBDs.
5. **QED:** Ligand B (0.631) has a significantly better QED score than Ligand A (0.326), indicating a more drug-like profile.
6. **DILI Risk:** Ligand A (14.889) has a *much* lower DILI risk than Ligand B (37.03). This is a major advantage for A.
7. **BBB Penetration:** Both are similar (A: 52.772, B: 51.493). Not a huge priority for a cardiovascular target, but slightly higher is better.
8. **Caco-2 Permeability:** Both have negative values, indicating poor permeability. A (-4.943) is slightly worse than B (-4.707).
9. **Aqueous Solubility:** Both have negative values, indicating poor solubility. B (-2.767) is worse than A (-0.903).
10. **hERG Inhibition:** Ligand A (0.134) has a lower hERG risk than Ligand B (0.359). This is a significant advantage for A.
11. **Microsomal Clearance:** Ligand A (11.243) has a lower clearance than Ligand B (26.019), suggesting better metabolic stability.
12. **In vitro Half-Life:** Ligand B (15.379) has a significantly longer half-life than Ligand A (-2.767). This is a major advantage for B.
13. **P-gp Efflux:** Both are low, but A (0.01) is lower than B (0.096).
14. **Binding Affinity:** Ligand B (-7.8) has a substantially stronger binding affinity than Ligand A (-6.2). This is a very significant advantage for B.
**Overall Assessment:**
Ligand B has a superior binding affinity and a longer half-life, which are crucial for efficacy and dosing. It also has a better QED score. However, it has a significantly higher DILI risk, worse solubility, and a higher hERG risk. Ligand A has a much lower DILI and hERG risk, better solubility, and better metabolic stability. The affinity difference is substantial (-1.6 kcal/mol), which often outweighs ADME concerns. Given the importance of potency for GPCRs, and the fact that the ADME issues with B *might* be addressable through further optimization, I believe Ligand B is the more promising candidate.
Output:
0
2025-04-17 21:40:14,217 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.391 and 356.457 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (40.62) is significantly better than Ligand A (104.73). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. This is a significant advantage for Ligand B.
3. **logP:** Ligand B (3.474) is optimal, while Ligand A (-0.257) is too low, potentially hindering membrane permeability. This is a substantial advantage for Ligand B.
4. **HBD:** Ligand A (1) is preferable to Ligand B (0). While both are acceptable, a single HBD can improve solubility.
5. **HBA:** Ligand A (6) is better than Ligand B (2). Lower HBA is generally preferred for permeability.
6. **QED:** Ligand A (0.759) is slightly better than Ligand B (0.655), indicating a marginally more drug-like profile.
7. **DILI:** Both ligands have acceptable DILI risk (Ligand A: 50.33, Ligand B: 42.885), below the 60% threshold. Ligand B is slightly better.
8. **BBB:** Ligand B (96.316) is much higher than Ligand A (69.058). While not a primary concern for a cardiovascular target, higher BBB is rarely detrimental.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.827 and -4.246), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-0.479) is slightly better than Ligand B (-3.016), but both are poor.
11. **hERG:** Both ligands have very low hERG inhibition risk (Ligand A: 0.026, Ligand B: 0.611). This is excellent for both.
12. **Cl_mic:** Ligand A (12.987) has significantly lower microsomal clearance than Ligand B (52.339), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (-14.26) has a negative in vitro half-life, which is concerning. Ligand B (-24.123) is also negative, but less so. Both are problematic.
14. **Pgp:** Both ligands have low P-gp efflux liability (Ligand A: 0.004, Ligand B: 0.261).
15. **Binding Affinity:** Both ligands have similar binding affinities (Ligand A: -6.5, Ligand B: -5.6).
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand B excels in logP and has a much lower TPSA. While Ligand A has better metabolic stability (Cl_mic), the poor logP and high TPSA are significant drawbacks. The binding affinity difference is not large enough to overcome these ADME deficiencies.
**Overall Assessment:**
Ligand B, despite its lower metabolic stability and solubility, presents a better overall profile due to its optimal logP, low TPSA, and acceptable DILI/hERG. The negative Caco-2 and t1/2 values are concerning for both, but can be addressed with further optimization.
Output:
0
2025-04-17 21:40:14,217 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [349.431, 84.67, 1.767, 1, 5, 0.895, 40.83, 77.705, -4.682, -1.706, 0.231, 46.74, -25.594, 0.071, -6.2]**
**Ligand B: [339.403, 92.86, 2.162, 1, 8, 0.7, 68.05, 51.221, -5.53, -1.836, 0.379, 44.793, 13.987, 0.014, -8]**
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (349.431) is slightly higher than Ligand B (339.403), but the difference is negligible.
2. **TPSA:** Ligand A (84.67) is better than Ligand B (92.86). Both are under the 140 A^2 threshold for good oral absorption, but lower TPSA is preferred for GPCRs.
3. **logP:** Both ligands have acceptable logP values (Ligand A: 1.767, Ligand B: 2.162), falling within the 1-3 range. Ligand B is slightly higher, potentially leading to minor solubility issues.
4. **H-Bond Donors:** Both have 1 HBD, which is good.
5. **H-Bond Acceptors:** Ligand A (5) is better than Ligand B (8). Lower HBA is favorable for permeability.
6. **QED:** Ligand A (0.895) is significantly better than Ligand B (0.7). A higher QED indicates a more drug-like profile.
7. **DILI:** Ligand A (40.83) is significantly better than Ligand B (68.05). Lower DILI risk is crucial.
8. **BBB:** Ligand A (77.705) is much better than Ligand B (51.221). While ADRB2 isn't exclusively a CNS target, some CNS penetration can be beneficial, and avoiding high CNS exposure is generally preferred.
9. **Caco-2 Permeability:** Ligand A (-4.682) is better than Ligand B (-5.53). Higher Caco-2 values indicate better absorption.
10. **Aqueous Solubility:** Ligand A (-1.706) is slightly better than Ligand B (-1.836).
11. **hERG Inhibition:** Ligand A (0.231) is better than Ligand B (0.379). Lower hERG inhibition is critical for avoiding cardiotoxicity.
12. **Microsomal Clearance:** Ligand A (46.74) is better than Ligand B (44.793). Lower clearance is preferred for metabolic stability.
13. **In vitro Half-Life:** Ligand A (-25.594) is significantly better than Ligand B (13.987). A longer half-life is generally desirable.
14. **P-gp Efflux:** Ligand A (0.071) is better than Ligand B (0.014). Lower P-gp efflux is preferred.
15. **Binding Affinity:** Ligand B (-8) is better than Ligand A (-6.2). This is a 1.8 kcal/mol difference, which is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand B has a significantly better binding affinity. However, Ligand A demonstrates a much more favorable ADME profile across nearly all parameters, including DILI risk, BBB penetration, QED, and in vitro half-life. Given the GPCR target class and the importance of balancing potency with safety and druggability, the superior ADME profile of Ligand A is more compelling. The 1.8 kcal/mol difference in binding affinity, while significant, can potentially be optimized in subsequent iterations of drug design. The safety profile and predicted bioavailability of Ligand A are far superior.
Output:
1
2025-04-17 21:40:14,217 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (364.5 and 387.6 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (76.02) is significantly better than Ligand B (101.29). ADRB2 is a cardiovascular target, so CNS penetration isn't critical, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (1.649 and 1.302), falling within the optimal 1-3 range. Ligand B is slightly lower, which could marginally improve solubility.
4. **HBD:** Ligand A (2) is preferable to Ligand B (3). Lower HBD generally improves permeability.
5. **HBA:** Both ligands have the same number of HBA (5), which is acceptable.
6. **QED:** Ligand A (0.735) has a significantly better QED score than Ligand B (0.491), indicating a more drug-like profile.
7. **DILI:** Ligand A (43.234) has a slightly higher DILI risk than Ligand B (25.165), but both are within acceptable limits (<60).
8. **BBB:** Both ligands have similar BBB penetration (59.364 and 57.58), and this isn't a high priority for a cardiovascular target.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the values are similar (-5.701 and -5.732).
10. **Solubility:** Ligand A (-2.246) is slightly better than Ligand B (-3.108), but both are poor.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.11 and 0.086), which is excellent.
12. **Cl_mic:** Ligand A (29.691) has a lower microsomal clearance than Ligand B (39.016), suggesting better metabolic stability.
13. **t1/2:** Ligand A (2.828) has a positive in vitro half-life, while Ligand B (-18.157) has a negative value, which is concerning.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.093 and 0.033).
15. **Binding Affinity:** Ligand B (-7.1) has a slightly better binding affinity than Ligand A (-6.7), a difference of 0.4 kcal/mol.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. While both ligands are good in terms of logP and Pgp, Ligand A has a significantly better TPSA. The affinity difference (0.4 kcal/mol) is not large enough to overcome the other advantages of Ligand A, especially its superior QED, metabolic stability (lower Cl_mic), and positive half-life. The poor Caco-2 and solubility are concerns for both, but can be addressed with formulation strategies.
**Conclusion:**
Ligand A is the more promising candidate due to its better overall drug-like properties, metabolic stability, and TPSA, despite the slightly weaker binding affinity.
Output:
1
2025-04-17 21:40:14,217 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (342.483 and 348.487 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (41.57) is significantly better than Ligand B (69.64). For a GPCR, lower TPSA is generally preferred for better permeability. Ligand B is quite high, potentially hindering absorption.
**3. logP:** Ligand A (3.959) is slightly higher than Ligand B (2.391), but both are within the optimal 1-3 range. Ligand A is closer to the upper limit, which could raise concerns about solubility and off-target effects, but it's not a dealbreaker.
**4. H-Bond Donors:** Ligand A (1) is better than Ligand B (2). Lower HBDs are generally preferred for permeability.
**5. H-Bond Acceptors:** Both ligands have the same number of HBA (3).
**6. QED:** Ligand A (0.851) has a better QED score than Ligand B (0.724), indicating a more drug-like profile.
**7. DILI Risk:** Ligand A (14.618) has a significantly lower DILI risk than Ligand B (19.426). This is a crucial advantage, as liver toxicity is a major concern in drug development.
**8. BBB Penetration:** Ligand A (89.298) has considerably better BBB penetration than Ligand B (63.203). While ADRB2 is a cardiovascular target, some CNS effects are possible with beta-blockers, and better BBB penetration could be beneficial or detrimental depending on the desired profile.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and indicates poor permeability. Ligand A (-4.488) is slightly better than Ligand B (-4.748), but both are problematic.
**10. Aqueous Solubility:** Ligand A (-3.321) is slightly better than Ligand B (-2.69), but both are poor.
**11. hERG Inhibition:** Ligand A (0.88) has a slightly higher hERG inhibition risk than Ligand B (0.324), but both are relatively low.
**12. Microsomal Clearance:** Ligand B (36.907) has a lower microsomal clearance than Ligand A (41.055), suggesting better metabolic stability.
**13. In vitro Half-Life:** Ligand B (-8.039) has a negative half-life, which is not possible. This is a major red flag. Ligand A (58.764) has a reasonable half-life.
**14. P-gp Efflux:** Ligand A (0.213) has lower P-gp efflux than Ligand B (0.25), which is favorable.
**15. Binding Affinity:** Ligand B (-7.2 kcal/mol) has a significantly stronger binding affinity than Ligand A (-4.6 kcal/mol). This is a substantial advantage.
**Overall Assessment:**
Despite Ligand B's superior binding affinity, the negative in vitro half-life is a critical flaw. The other ADME properties of Ligand A are generally better, particularly the lower DILI risk, better BBB penetration, and more reasonable half-life. While both have poor Caco-2 permeability and solubility, Ligand A's overall profile is more promising for development. The affinity difference, while significant, can potentially be addressed through further optimization, whereas a negative half-life is a fundamental issue.
Output:
1
2025-04-17 21:40:14,217 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.463 and 341.455 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (85.25) is slightly higher than Ligand B (62.3). Both are below the 140 threshold for oral absorption, but B is better positioned for potential CNS penetration if that were a goal.
3. **logP:** Both ligands have good logP values (2.332 and 2.825), falling within the optimal 1-3 range. Ligand B is slightly higher, potentially increasing permeability but also slightly raising the risk of off-target interactions.
4. **HBD:** Ligand A has 2 HBD, and Ligand B has 1. Both are within the acceptable limit of 5.
5. **HBA:** Ligand A has 5 HBA, and Ligand B has 3. Both are within the acceptable limit of 10.
6. **QED:** Both ligands have good QED scores (0.678 and 0.865), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (42.148) has a slightly higher DILI risk than Ligand B (32.261). Both are below the concerning threshold of 60, but lower is preferred.
8. **BBB:** Both ligands have good BBB penetration (79.333 and 70.958). ADRB2 is a cardiovascular target, so BBB penetration isn't a primary concern, but it doesn't hurt.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.528 and -4.373). This is unusual and suggests poor permeability in this *in vitro* assay. It's a red flag for both, but doesn't allow for a clear distinction.
10. **Solubility:** Ligand A (-3.75) has slightly worse solubility than Ligand B (-2.92). Solubility is important for bioavailability.
11. **hERG:** Both ligands have very low hERG risk (0.266 and 0.221), which is excellent.
12. **Cl_mic:** Ligand A (58.916) has lower microsomal clearance than Ligand B (51.336), suggesting better metabolic stability. This is a significant advantage.
13. **t1/2:** Both ligands have similar *in vitro* half-lives (12.295 and 12.893 hours).
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.069 and 0.027).
15. **Binding Affinity:** Ligand A (-6.6 kcal/mol) has a slightly better binding affinity than Ligand B (-5.4 kcal/mol). This is a 1.2 kcal/mol difference, which is substantial and can outweigh some ADME drawbacks.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand B has a slightly better logP and TPSA, but Ligand A has a significantly better binding affinity and better metabolic stability (lower Cl_mic). The difference in binding affinity is the most important factor here.
**Conclusion:**
Despite Ligand B having slightly better QED and DILI scores, the significantly stronger binding affinity of Ligand A (-6.6 vs -5.4 kcal/mol) and its improved metabolic stability make it the more promising drug candidate. The Caco-2 permeability is a concern for both, but the potency advantage of A is likely to be more impactful in driving *in vivo* efficacy.
Output:
1
2025-04-17 21:40:14,218 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (343.431 and 350.503 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (91.02) is slightly higher than Ligand B (54.56). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is generally preferred for absorption. Ligand B has a clear advantage.
3. **logP:** Ligand A (1.305) is within the optimal range (1-3), while Ligand B (3.786) is approaching the upper limit. While still acceptable, Ligand A's logP is more balanced.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 5 HBA, while Ligand B has 3. Both are acceptable, but lower is generally preferable. Ligand B has a slight advantage.
6. **QED:** Ligand A (0.872) has a better QED score than Ligand B (0.726), indicating a more drug-like profile.
7. **DILI:** Ligand A (43.66%) has a higher DILI risk than Ligand B (20.667%). This is a significant advantage for Ligand B.
8. **BBB:** Both ligands have reasonable BBB penetration (Ligand A: 70.027%, Ligand B: 78.054%). Since ADRB2 is not a CNS target, this is less critical, but Ligand B is slightly better.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.818) is slightly worse than Ligand B (-4.686).
10. **Solubility:** Both ligands have negative solubility values, indicating poor solubility. Ligand A (-3.551) is slightly worse than Ligand B (-2.948).
11. **hERG:** Ligand A (0.358) has a lower hERG inhibition liability than Ligand B (0.869), which is a significant advantage.
12. **Cl_mic:** Ligand A (29.84) has a lower microsomal clearance than Ligand B (40.67), indicating better metabolic stability.
13. **t1/2:** Ligand A (-5.399) has a longer in vitro half-life than Ligand B (21.959). This is a significant advantage.
14. **Pgp:** Ligand A (0.108) has lower P-gp efflux liability than Ligand B (0.496), which is a positive.
15. **Affinity:** Ligand A (-7.1) has a slightly better binding affinity than Ligand B (-7.0). While the difference is small, it's still a factor.
**Overall Assessment:**
For a cardiovascular GPCR like ADRB2, binding affinity, metabolic stability, and safety (DILI, hERG) are paramount. Ligand A has a slightly better binding affinity, significantly better metabolic stability (lower Cl_mic, longer t1/2), and lower hERG risk. While Ligand B has a lower TPSA and DILI risk, the advantages of Ligand A in affinity, metabolic stability, and hERG outweigh these benefits. The poor Caco-2 and solubility values are concerning for both, but can be addressed with formulation strategies.
Output:
1
2025-04-17 21:40:14,218 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (336.435 & 362.495 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (51.22) is significantly better than Ligand B (66.57). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (3.827 & 3.68), falling within the 1-3 range. Ligand B is slightly lower, which could be marginally better for solubility.
4. **HBD:** Both have 1 HBD, which is acceptable.
5. **HBA:** Ligand A has 3 HBA, while Ligand B has 5. Ligand A is preferable here, as fewer HBA generally improve permeability.
6. **QED:** Both ligands have high QED scores (0.836 & 0.851), indicating good drug-like properties. No significant difference.
7. **DILI:** Ligand A (40.364) is higher than Ligand B (22.838). This is a significant advantage for Ligand B, as lower DILI risk is crucial.
8. **BBB:** Ligand A (77.898) has a higher BBB percentile than Ligand B (52.23). However, since ADRB2 is primarily a cardiovascular target, BBB penetration is not a primary concern.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.653) is slightly better than Ligand B (-4.806).
10. **Solubility:** Ligand A (-4.679) is worse than Ligand B (-2.594), indicating lower solubility. Solubility is important for bioavailability.
11. **hERG:** Both ligands have low hERG inhibition liability (0.694 & 0.362), which is good. Ligand B is slightly better.
12. **Cl_mic:** Ligand A (75.803) has a higher microsomal clearance than Ligand B (40.522), meaning it's metabolized faster. Ligand B is preferable here for better metabolic stability.
13. **t1/2:** Ligand B (46.344) has a significantly longer in vitro half-life than Ligand A (-9.759). This is a major advantage for Ligand B.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.475 & 0.341). Ligand B is slightly better.
15. **Binding Affinity:** Ligand B (-7.6) has a substantially stronger binding affinity than Ligand A (-5.4). This difference of 2.2 kcal/mol is a significant advantage, and can often outweigh minor ADME drawbacks.
**Overall Assessment:**
While Ligand A has better TPSA and a slightly better Caco-2 value, Ligand B excels in crucial areas: significantly better DILI risk, longer half-life, stronger binding affinity, and lower microsomal clearance. The superior binding affinity is a major driver, and the improved safety profile (DILI) and pharmacokinetic properties (t1/2, Cl_mic) make Ligand B the more promising candidate.
Output:
0
2025-04-17 21:40:14,218 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [364.471, 87.47, 1.984, 2, 6, 0.748, 34.548, 50.523, -5.568, -1.636, 0.618, 12.128, 56.754, 0.111, -5.6]
**Ligand B:** [384.933, 71.25, 3.438, 1, 6, 0.793, 54.44, 46.452, -5.028, -3.389, 0.185, 66.334, 20.862, 0.242, -6.3]
Here's a breakdown, prioritizing GPCR-relevant parameters (logP, TPSA, Pgp, BBB, Affinity):
1. **Molecular Weight:** Both are within the ideal range (200-500 Da). A is 364.471, B is 384.933. No significant difference.
2. **TPSA:** A (87.47) is slightly higher than B (71.25). Both are below the 140 threshold for oral absorption, but B is better positioned.
3. **logP:** A (1.984) is optimal. B (3.438) is pushing the upper limit, potentially increasing off-target effects and decreasing solubility.
4. **H-Bond Donors:** A (2) is slightly higher than B (1). Both are acceptable.
5. **H-Bond Acceptors:** Both A (6) and B (6) are within the acceptable range.
6. **QED:** Both are good (A: 0.748, B: 0.793), indicating drug-likeness. B is slightly better.
7. **DILI:** A (34.548) is significantly better than B (54.44), indicating a lower risk of liver injury. This is a crucial advantage.
8. **BBB:** A (50.523) is lower than B (46.452), but for a cardiovascular target, BBB penetration isn't a primary concern.
9. **Caco-2:** Both are negative, which is unusual. This suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
10. **Solubility:** A (-1.636) is better than B (-3.389). Solubility is important for bioavailability.
11. **hERG:** A (0.618) is better than B (0.185), indicating a lower risk of cardiotoxicity. This is vital for a cardiovascular drug.
12. **Cl_mic:** A (12.128) is much better than B (66.334), meaning A has better metabolic stability.
13. **t1/2:** A (56.754) is significantly better than B (20.862), indicating a longer half-life and potentially less frequent dosing.
14. **Pgp:** A (0.111) is much better than B (0.242), suggesting less efflux and better bioavailability.
15. **Binding Affinity:** B (-6.3) is 0.7 kcal/mol better than A (-5.6). This is a substantial difference in potency.
**Overall Assessment:**
While Ligand B has a better binding affinity, Ligand A demonstrates a significantly superior ADMET profile. The lower DILI risk, better solubility, lower hERG inhibition, improved metabolic stability (lower Cl_mic and longer t1/2), and reduced P-gp efflux are all critical advantages, especially for a cardiovascular drug where safety is paramount. The slightly higher TPSA of A is a minor drawback compared to the substantial benefits in other areas. The affinity difference, while notable, can potentially be optimized in later stages of drug development.
Therefore, I favor Ligand A.
Output:
1
2025-04-17 21:40:14,218 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (a cardiovascular GPCR) drug candidates.
**Ligand A: [363.384, 98.17, 3.019, 1, 3, 0.279, 27.181, 88.91, -4.651, -2.519, 0.602, 30.165, -12.412, 0.059, -5.5]**
**Ligand B: [372.809, 102.88, 0.729, 1, 8, 0.754, 89.492, 64.482, -4.719, -3.035, 0.124, 52.71, -12.374, 0.029, -5.2]**
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, BBB, and affinity):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (363.384) is slightly lower, which is generally favorable.
2. **TPSA:** Both are reasonably good (A: 98.17, B: 102.88), being under 140. This suggests decent oral absorption potential.
3. **logP:** Ligand A (3.019) is optimal, while Ligand B (0.729) is quite low. This is a significant negative for Ligand B, potentially hindering membrane permeability and bioavailability.
4. **HBD/HBA:** Both have 1 HBD, which is good. Ligand B has 8 HBA vs 3 for Ligand A. Higher HBA can sometimes impact permeability.
5. **QED:** Ligand B (0.754) has a better QED score than Ligand A (0.279), indicating a more drug-like profile overall.
6. **DILI:** Both have acceptable DILI risk (A: 27.181, B: 89.492), but Ligand A is significantly better.
7. **BBB:** Ligand A (88.91) has a much higher BBB percentile than Ligand B (64.482). While ADRB2 is cardiovascular, some CNS penetration isn't necessarily detrimental and could offer additional therapeutic avenues or off-target effects to consider.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual. Assuming these are logP-scaled values, lower (more negative) values indicate lower permeability. Both are similarly poor.
9. **Solubility:** Both are very poor, with negative solubility values. This is a concern for both compounds.
10. **hERG:** Both have low hERG risk (A: 0.602, B: 0.124), which is excellent.
11. **Cl_mic:** Ligand A (30.165) has lower microsomal clearance than Ligand B (52.71), suggesting better metabolic stability.
12. **t1/2:** Both have negative in vitro half-lives, which is unusual. Assuming these are log-scaled values, lower (more negative) values indicate shorter half-lives. Both are similarly poor.
13. **Pgp:** Both have very low Pgp efflux liability (A: 0.059, B: 0.029), which is good.
14. **Affinity:** Both have very strong binding affinities (A: -5.5, B: -5.2). The difference is relatively small (0.3 kcal/mol).
**Overall Assessment:**
Ligand A is preferable. While Ligand B has a better QED score, the significantly lower logP of Ligand B is a major drawback for a GPCR target. The higher BBB penetration, lower DILI risk, and better metabolic stability of Ligand A outweigh the slightly lower QED. The similar binding affinities make the ADME properties the deciding factor. The poor solubility and Caco-2 values are concerning for both, but can be addressed with formulation strategies.
Output:
1
2025-04-17 21:40:14,218 - INFO - Batch 275 complete. Total preferences: 4400
2025-04-17 21:40:14,218 - INFO - Processing batch 276/512...
2025-04-17 21:41:03,929 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (345.447 and 340.467 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (71.76) is higher than Ligand B (58.2). Both are below the 140 threshold for oral absorption, but B is better positioned for potential CNS penetration if desired (though not a primary goal for ADRB2).
3. **logP:** Ligand A (2.466) is within the optimal 1-3 range. Ligand B (3.673) is slightly higher, pushing towards the upper limit. While still acceptable, it raises a minor concern for potential off-target interactions or solubility issues.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (2). Lower HBA generally improves permeability.
6. **QED:** Ligand A (0.924) is significantly better than Ligand B (0.776), indicating a more drug-like profile.
7. **DILI:** Ligand A (39.046) has a slightly better DILI risk profile than Ligand B (44.281), although both are below the concerning 60 threshold.
8. **BBB:** Ligand A (90.578) has better BBB penetration potential than Ligand B (73.75). While ADRB2 isn't a primary CNS target, some peripheral effects could benefit from better tissue distribution.
9. **Caco-2:** Ligand A (-4.713) has a better Caco-2 value than Ligand B (-4.596), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-2.519) has better aqueous solubility than Ligand B (-4.09). Solubility is crucial for bioavailability.
11. **hERG:** Both ligands (0.605 and 0.302) have low hERG inhibition liability, which is excellent. Ligand B is slightly better.
12. **Cl_mic:** Ligand A (25.735) has significantly lower microsomal clearance than Ligand B (69.85), suggesting better metabolic stability. This is a major advantage.
13. **t1/2:** Ligand A (17.856) has a longer in vitro half-life than Ligand B (-26.949). This is a significant advantage, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.139) has lower P-gp efflux liability than Ligand B (0.317), which is favorable for oral bioavailability and tissue distribution.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-5.7 and -5.6 kcal/mol). The difference is negligible.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A has a more favorable balance across these parameters. While Ligand B has a slightly better logP and hERG, Ligand A excels in QED, solubility, metabolic stability (Cl_mic and t1/2), and Pgp efflux. The improved ADME properties of Ligand A outweigh the minor advantage of Ligand B's logP.
**Conclusion:**
Ligand A demonstrates a superior overall profile, balancing potency with significantly better drug-like properties and predicted pharmacokinetic behavior.
Output:
1
2025-04-17 21:41:03,930 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Reasoning:**
Let's break down the comparison of Ligand A and Ligand B based on the provided parameters and GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key).
1. **Molecular Weight:** Both ligands (368.478 Da and 348.447 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands have TPSA values (67.23 and 65.98) below the 140 threshold for good oral absorption, which is good.
3. **logP:** Both ligands have logP values (1.495 and 1.249) within the optimal 1-3 range. Again, no major distinction.
4. **H-Bond Donors:** Ligand A has 1 HBD, while Ligand B has 0. Both are acceptable.
5. **H-Bond Acceptors:** Both ligands have 5 HBAs, which is within the acceptable limit of 10.
6. **QED:** Ligand B (0.694) has a slightly better QED score than Ligand A (0.502), indicating a more drug-like profile.
7. **DILI:** Ligand A (37.611) has a lower DILI risk than Ligand B (52.191), which is a significant advantage. Lower DILI is always preferred.
8. **BBB:** Ligand B (80.07) has a significantly higher BBB penetration percentile than Ligand A (63.125). While ADRB2 isn't exclusively a CNS target, some degree of BBB penetration can be beneficial for distribution and off-target effects.
9. **Caco-2 Permeability:** Ligand A (-5.284) has a worse Caco-2 permeability than Ligand B (-4.332).
10. **Aqueous Solubility:** Ligand A (-1.463) has worse aqueous solubility than Ligand B (-0.621).
11. **hERG Inhibition:** Both ligands have low hERG inhibition risk (0.724 and 0.633).
12. **Microsomal Clearance:** Ligand A (18.103) has a lower microsomal clearance than Ligand B (45.005), suggesting better metabolic stability. This is a positive attribute.
13. **In vitro Half-Life:** Ligand A (-16.252) has a significantly longer in vitro half-life than Ligand B (8.159). This is a major advantage, potentially allowing for less frequent dosing.
14. **P-gp Efflux:** Both ligands have similar P-gp efflux liability (0.209 and 0.047).
15. **Binding Affinity:** Ligand B (-7.0 kcal/mol) has a stronger binding affinity than Ligand A (-6.5 kcal/mol). This is a 0.5 kcal/mol difference, which is substantial.
**Overall Assessment:**
Ligand B has a better binding affinity and BBB penetration, and a better QED and Caco-2 permeability. However, Ligand A has a significantly lower DILI risk, better metabolic stability (lower Cl_mic), and a much longer half-life. For a cardiovascular target like ADRB2, metabolic stability and minimizing liver toxicity (DILI) are crucial. The stronger binding affinity of Ligand B is attractive, but the improved safety and pharmacokinetic profile of Ligand A, particularly the longer half-life, outweigh this benefit.
Output:
1
2025-04-17 21:41:03,930 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (337.47 & 343.38 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (46.92) is significantly better than Ligand B (91.76). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold. Ligand B is approaching the upper limit.
3. **logP:** Ligand A (4.41) is higher than Ligand B (1.493). While both are within the acceptable range, Ligand A is pushing the upper limit and could potentially have solubility issues. Ligand B is quite low, potentially hindering permeation.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (5). Fewer HBAs generally improve permeability.
6. **QED:** Both ligands have similar QED values (0.878 and 0.829), indicating good drug-likeness.
7. **DILI:** Ligand A (29.081) has a lower DILI risk than Ligand B (39.201), which is a significant advantage.
8. **BBB:** Ligand A (73.672) has a higher BBB penetration percentile than Ligand B (27.026). While not critical for a cardiovascular target, it's a bonus.
9. **Caco-2:** Ligand A (-4.704) is better than Ligand B (-5.136). Higher values indicate better absorption.
10. **Solubility:** Ligand A (-4.15) is better than Ligand B (-2.812). Higher values indicate better solubility.
11. **hERG:** Ligand A (0.794) is better than Ligand B (0.218). Lower values indicate lower risk of hERG inhibition.
12. **Cl_mic:** Ligand A (52.305) has a lower microsomal clearance than Ligand B (61.534), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-23.747) has a longer in vitro half-life than Ligand B (-32.822).
14. **Pgp:** Ligand A (0.475) has a lower Pgp efflux liability than Ligand B (0.016), which is better.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.6 and -6.7 kcal/mol). The difference is negligible.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A performs better on TPSA, Pgp, and has a more reasonable logP. While Ligand B has a lower logP, it's *too* low, potentially hindering absorption. The affinities are essentially the same. Ligand A also demonstrates superior ADME properties across the board, including lower DILI risk and better solubility.
**Conclusion:**
Ligand A is the more promising candidate due to its superior ADME profile, particularly its lower DILI risk, better solubility, and more favorable TPSA and Pgp values, without sacrificing binding affinity.
Output:
1
2025-04-17 21:41:03,930 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [350.423, 103.59 , -1.009, 2. , 7. , 0.681, 33.695, 42.846, -5.12 , -0.509, 0.039, -5.481, 15.384, 0.028, -6.2 ]
**Ligand B:** [388.917, 75.71 , 2.559, 1. , 5. , 0.776, 58.938, 62.466, -4.785, -3.164, 0.262, 45.513, -5.16 , 0.197, -7.6 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (350.423) is slightly preferred due to being closer to the lower end, potentially aiding permeability.
2. **TPSA:** Ligand A (103.59) is higher than Ligand B (75.71). For a cardiovascular GPCR, TPSA isn't *as* critical as for CNS targets, but lower is still better for absorption. Ligand B is favored here.
3. **logP:** Ligand A (-1.009) is quite low, potentially hindering membrane permeability. Ligand B (2.559) is within the optimal range (1-3). Ligand B is strongly favored.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable.
5. **HBA:** Ligand A (7) and Ligand B (5) are both acceptable.
6. **QED:** Both ligands have good QED scores (A: 0.681, B: 0.776), indicating drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (33.695) has a significantly lower DILI risk than Ligand B (58.938). This is a major advantage for Ligand A.
8. **BBB:** Both are relatively low, which is fine for a cardiovascular target. Ligand B (62.466) is slightly higher than Ligand A (42.846), but this isn't a major factor here.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand B (-4.785) is slightly better than Ligand A (-5.12).
10. **Solubility:** Ligand A (-0.509) is better than Ligand B (-3.164).
11. **hERG:** Ligand A (0.039) has a very low hERG risk, while Ligand B (0.262) is slightly higher. Ligand A is favored.
12. **Cl_mic:** Ligand A (-5.481) has a lower (better) microsomal clearance than Ligand B (45.513), suggesting better metabolic stability.
13. **t1/2:** Ligand A (15.384) has a longer half-life than Ligand B (-5.16).
14. **Pgp:** Ligand A (0.028) has lower P-gp efflux than Ligand B (0.197), which is favorable.
15. **Affinity:** Ligand B (-7.6) has a significantly stronger binding affinity than Ligand A (-6.2). This is a substantial advantage, potentially outweighing some ADME concerns.
**Overall Assessment:**
Ligand B has a significantly better binding affinity (-7.6 vs -6.2 kcal/mol). This is a crucial factor for GPCRs. While Ligand A has better DILI, solubility, hERG, Cl_mic, t1/2, and Pgp properties, the binding affinity difference is substantial enough to make Ligand B the more promising candidate. The logP of Ligand A is a concern, and the better affinity of Ligand B could compensate for its slightly higher DILI and lower solubility.
Output:
0
2025-04-17 21:41:03,930 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.443 and 349.475 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (84.5) is slightly higher than Ligand B (70.67). Both are below the 140 threshold for good oral absorption, but B is closer to the preferred <90 for potential CNS penetration (though ADRB2 isn't strictly a CNS target, lower TPSA is generally favorable).
3. **logP:** Both ligands have good logP values (1.392 and 1.792), falling within the optimal 1-3 range. Ligand B is slightly higher, which could be a minor advantage for membrane permeability.
4. **HBD:** Both ligands have 2 H-bond donors, which is within the acceptable limit of <=5.
5. **HBA:** Both ligands have 4 H-bond acceptors, also within the acceptable limit of <=10.
6. **QED:** Ligand B (0.656) has a noticeably better QED score than Ligand A (0.355), indicating a more drug-like profile. This is a significant advantage.
7. **DILI:** Ligand B (14.23) has a much lower DILI risk than Ligand A (15.006). This is a crucial advantage, as minimizing liver toxicity is paramount.
8. **BBB:** Both ligands have similar BBB penetration (55.06% and 57.619%). This isn't a primary concern for ADRB2, but slightly higher is generally better.
9. **Caco-2:** Ligand B (-5.469) has a more negative Caco-2 value, suggesting better intestinal absorption than Ligand A (-4.651).
10. **Solubility:** Both ligands have negative solubility values (-1.954 and -1.694), indicating poor aqueous solubility. This is a potential formulation challenge for both, but B is slightly better.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.182 and 0.124), which is excellent.
12. **Cl_mic:** Ligand B (-8.264) has a *much* lower microsomal clearance than Ligand A (40.736). This suggests significantly better metabolic stability for Ligand B.
13. **t1/2:** Ligand B (2.235) has a slightly longer in vitro half-life than Ligand A (-19.832). This is a positive, though the negative value for A is concerning.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.036 and 0.013).
15. **Binding Affinity:** Ligand B (-6.6 kcal/mol) has a slightly better binding affinity than Ligand A (-6.2 kcal/mol), although the difference is relatively small.
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Ligand B is better across most of these, with a slightly better logP, lower TPSA, and slightly better affinity. The significantly improved QED, DILI, and Cl_mic profiles of Ligand B are also very important.
**Conclusion:**
Ligand B consistently outperforms Ligand A across most critical parameters, particularly in ADME-Tox properties (DILI, Cl_mic) and drug-likeness (QED). While the affinity difference is small, the overall profile of Ligand B makes it a much more promising drug candidate.
Output:
0
2025-04-17 21:41:03,930 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for the ADRB2 receptor, a cardiovascular GPCR. Therefore, the key properties to prioritize are binding affinity, logP, TPSA, Pgp efflux, and to a lesser extent, BBB.
Let's compare the ligands property by property:
1. **MW:** Both ligands (343.383 and 354.523 Da) are within the ideal range (200-500 Da).
2. **TPSA:** Ligand A (91.76) is slightly higher than Ligand B (41.91). Ligand B is much better, being well below the 140 A^2 threshold for good absorption.
3. **logP:** Both ligands have acceptable logP values (2.203 and 3.981), falling within the 1-3 range. Ligand B is a bit higher, which could potentially lead to some off-target effects, but is still reasonable.
4. **HBD:** Ligand A has 2 HBD, while Ligand B has 0. Both are within the acceptable limit of 5.
5. **HBA:** Both ligands have 5 HBA, which is within the acceptable limit of 10.
6. **QED:** Ligand A (0.868) has a better QED score than Ligand B (0.752), indicating a more drug-like profile.
7. **DILI:** Ligand A (67.507) has a higher DILI risk than Ligand B (40.016). Ligand B is preferable here.
8. **BBB:** Ligand B (81.621) has a significantly higher BBB penetration score than Ligand A (36.177). While not a primary concern for a cardiovascular target, higher BBB is generally favorable.
9. **Caco-2:** Ligand A (-4.681) and Ligand B (-5.421) both have negative Caco-2 values, which is unusual. Lower values indicate poorer permeability.
10. **Solubility:** Both ligands have very poor solubility scores (-3.209 and -3.028). This is a significant concern for both.
11. **hERG:** Ligand A (0.209) has a lower hERG inhibition liability than Ligand B (0.805), which is preferable.
12. **Cl_mic:** Ligand A (34.741) has a lower microsomal clearance than Ligand B (65.521), indicating better metabolic stability.
13. **t1/2:** Ligand A (-11.471) has a negative in vitro half-life, which is highly unfavorable. Ligand B (12.168) has a positive half-life.
14. **Pgp:** Ligand A (0.05) has a much lower Pgp efflux liability than Ligand B (0.495), which is beneficial for bioavailability.
15. **Affinity:** Ligand B (-7.5 kcal/mol) has a slightly better binding affinity than Ligand A (-7.1 kcal/mol). While the difference is not huge, it's enough to consider.
**Overall Assessment:**
Ligand B has a much better TPSA, BBB, and in vitro half-life. It also has a lower DILI risk and a slightly better binding affinity. Ligand A has a better QED, lower Pgp efflux, and lower hERG risk, but its negative half-life is a major drawback. Considering the GPCR-specific priorities and the overall balance of properties, Ligand B is the more promising candidate despite the slightly higher logP and Pgp efflux. The solubility is a concern for both, but can be addressed through formulation strategies.
**Output:**
0
2025-04-17 21:41:03,930 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (342.399 Da) is well within the ideal range (200-500 Da). Ligand B (363.527 Da) is also acceptable. No clear advantage here.
2. **TPSA:** Ligand A (89.53) is good, below the 140 threshold and suitable for oral absorption. Ligand B (66.22) is even better, suggesting potentially improved permeability.
3. **logP:** Ligand A (0.918) is slightly low, potentially hindering permeation. Ligand B (4.102) is high, potentially causing solubility issues and off-target effects. This is a significant concern for Ligand B.
4. **HBD:** Ligand A (2) is good. Ligand B (0) is also acceptable, though some H-bond donors can aid solubility.
5. **HBA:** Ligand A (4) is good. Ligand B (5) is also acceptable.
6. **QED:** Ligand A (0.845) is excellent, indicating a highly drug-like profile. Ligand B (0.697) is still acceptable but less optimal.
7. **DILI:** Ligand A (54.556) is good, below the 40-60 threshold. Ligand B (39.705) is even better, indicating a lower risk of liver injury.
8. **BBB:** Ligand A (33.23) is low, meaning poor brain penetration. Ligand B (76.309) is significantly better, suggesting good brain penetration. While ADRB2 isn't exclusively a CNS target, some CNS effects are possible, and better BBB penetration isn't necessarily detrimental.
9. **Caco-2:** Ligand A (-5.376) is very poor. Ligand B (-4.483) is also poor, but slightly better. Both suggest absorption issues.
10. **Solubility:** Ligand A (-1.902) is poor. Ligand B (-4.486) is even worse. This is a major concern for both, but more so for Ligand B given its higher logP.
11. **hERG:** Ligand A (0.158) is very low risk. Ligand B (0.693) is slightly higher, but still relatively low risk.
12. **Cl_mic:** Ligand A (-19.867) is excellent, indicating high metabolic stability. Ligand B (105.179) is very high, indicating rapid metabolism and potentially low bioavailability.
13. **t1/2:** Ligand A (0.815) is poor. Ligand B (-14.877) is extremely poor. Both have very short half-lives.
14. **Pgp:** Ligand A (0.041) is very low, suggesting minimal efflux. Ligand B (0.402) is slightly higher, indicating some efflux potential.
15. **Affinity:** Ligand A (-6.3 kcal/mol) is good. Ligand B (-3.9 kcal/mol) is significantly weaker. This is a substantial difference.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B has better TPSA and BBB, but suffers from a very high logP, poor solubility, very high Cl_mic, and significantly weaker affinity. Ligand A, while having a slightly low logP and poor Caco-2/solubility, has a much better affinity and metabolic stability. The affinity difference is substantial enough to outweigh the other drawbacks, especially considering the poor ADME profile of Ligand B.
**Conclusion:**
Despite some ADME concerns with Ligand A, its significantly stronger binding affinity and better metabolic stability make it the more promising candidate. Ligand B's high logP and rapid metabolism are major red flags.
Output:
1
2025-04-17 21:41:03,930 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [346.471, 78.43, 2.945, 3, 3, 0.677, 21.326, 51.454, -4.723, -3.185, 0.335, 30.89, 5.995, 0.071, -7.0]
**Ligand B:** [361.368, 79.26, 0.847, 2, 5, 0.815, 59.984, 63.784, -4.63, -2.006, 0.149, 29.466, -3.259, 0.006, -6.2]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity):
1. **MW:** Both are within the ideal 200-500 Da range. Ligand A (346.471) is slightly lower, which is generally favorable.
2. **TPSA:** Both are good (78.43 and 79.26), below the 140 threshold for oral absorption, but not optimized for CNS penetration (which isn't a primary goal for a cardiovascular target).
3. **logP:** Ligand A (2.945) is optimal. Ligand B (0.847) is a bit low, potentially hindering membrane permeability.
4. **HBD/HBA:** Ligand A (3/3) is slightly better than Ligand B (2/5) in terms of hydrogen bonding potential, potentially improving solubility without sacrificing permeability.
5. **QED:** Both are acceptable (0.677 and 0.815), indicating reasonable drug-likeness. Ligand B is slightly better.
6. **DILI:** Ligand A (21.326) has a significantly lower DILI risk than Ligand B (59.984). This is a major advantage.
7. **BBB:** Both are relatively low (51.454 and 63.784), which is fine for a cardiovascular target.
8. **Caco-2:** Both are negative, indicating poor permeability. This is a concern for both.
9. **Solubility:** Both are negative, indicating poor solubility. This is a concern for both.
10. **hERG:** Both are very low (0.335 and 0.149), indicating low cardiotoxicity risk.
11. **Cl_mic:** Ligand B (29.466) has slightly lower clearance than Ligand A (30.89), suggesting better metabolic stability, but the difference is small.
12. **t1/2:** Ligand A (5.995) has a longer half-life than Ligand B (-3.259), which is preferable.
13. **Pgp:** Ligand A (0.071) has lower P-gp efflux liability than Ligand B (0.006), which is better for bioavailability.
14. **Affinity:** Ligand A (-7.0) has a slightly better binding affinity than Ligand B (-6.2). While the difference is less than 1.5kcal/mol, it's still a positive.
**Overall Assessment:**
Ligand A is the stronger candidate. The significantly lower DILI risk is a major advantage. It also has a better logP, slightly better affinity, longer half-life, and lower P-gp efflux. While both have issues with Caco-2 and solubility, these are areas for optimization and don't immediately disqualify a candidate. The slightly better ADME profile of Ligand A, combined with its better affinity, makes it the more promising starting point.
Output:
1
2025-04-17 21:41:03,931 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [374.463, 137.9 , -0.212, 4. , 5. , 0.523, 26.793, 37.301, -5.624, -1.313, 0.289, -27.698, 26.899, 0.008, -8.3 ]
**Ligand B:** [362.543, 61.88 , 4.848, 1. , 4. , 0.657, 44.009, 61.846, -5.249, -4.602, 0.688, 72.735, 38.84 , 0.621, -5.9 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (362.543) is slightly lower, which could be advantageous for permeability.
2. **TPSA:** Ligand A (137.9) is close to the upper limit for good oral absorption, while Ligand B (61.88) is excellent. This favors Ligand B.
3. **logP:** Ligand A (-0.212) is a bit low, potentially hindering membrane permeability. Ligand B (4.848) is higher, potentially causing solubility issues, but still within a reasonable range.
4. **HBD:** Ligand A (4) is acceptable, Ligand B (1) is even better.
5. **HBA:** Both ligands have 4 HBA, which is good.
6. **QED:** Both have acceptable QED values (A: 0.523, B: 0.657), but Ligand B is slightly better.
7. **DILI:** Ligand A (26.793) has a significantly lower DILI risk than Ligand B (44.009). This is a substantial advantage for Ligand A.
8. **BBB:** Ligand B (61.846) has better BBB penetration than Ligand A (37.301). Given that ADRB2 is a GPCR, some CNS exposure might be acceptable, but is not a primary driver.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
10. **Solubility:** Ligand A (-1.313) has better solubility than Ligand B (-4.602).
11. **hERG:** Both have low hERG risk (A: 0.289, B: 0.688), but Ligand A is better.
12. **Cl_mic:** Ligand A (-27.698) has significantly lower microsomal clearance, indicating better metabolic stability, than Ligand B (72.735). This is a major advantage for Ligand A.
13. **t1/2:** Ligand B (38.84) has a longer in vitro half-life than Ligand A (26.899), which is desirable.
14. **Pgp:** Ligand A (0.008) has lower P-gp efflux, which is better than Ligand B (0.621).
15. **Affinity:** Ligand A (-8.3) has a significantly stronger binding affinity than Ligand B (-5.9). This is a crucial advantage, potentially outweighing some ADME drawbacks.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, Pgp, TPSA, and affinity. Ligand B has better logP and TPSA, but Ligand A has significantly better affinity and Pgp efflux.
**Overall Assessment:**
While Ligand B has some advantages in TPSA and BBB penetration, Ligand A's significantly stronger binding affinity (-8.3 vs -5.9 kcal/mol), lower DILI risk, better solubility, lower Pgp efflux, and better metabolic stability (lower Cl_mic) are more critical for a viable drug candidate. The lower logP of Ligand A is a concern, but the substantial affinity advantage likely compensates for this.
Output:
1
2025-04-17 21:41:03,931 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (333.435 and 349.475 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (54.71) is significantly better than Ligand B (69.72). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (1.256) is better than Ligand A (4.95). Ligand A's logP is quite high, potentially leading to solubility issues and off-target interactions. Ligand B is within the optimal 1-3 range.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Both ligands have 3 HBA, which is good.
6. **QED:** Ligand B (0.812) has a slightly better QED score than Ligand A (0.675), indicating a more drug-like profile.
7. **DILI:** Ligand B (10.237) is *much* better than Ligand A (63.513). This is a significant advantage for Ligand B, as liver toxicity is a major concern in drug development.
8. **BBB:** Ligand A (86.817) has a higher BBB percentile than Ligand B (79.992). However, as ADRB2 is a cardiovascular target, BBB penetration is not a high priority.
9. **Caco-2:** Both ligands have similar, poor Caco-2 permeability values (-4.88 and -4.755). This suggests potential absorption issues for both.
10. **Solubility:** Ligand B (-2.362) is better than Ligand A (-5.68). This aligns with the higher logP of Ligand A, which would be expected to reduce solubility.
11. **hERG:** Ligand A (0.768) is better than Ligand B (0.342). Lower hERG inhibition is preferred.
12. **Cl_mic:** Ligand B (42.782) has a lower microsomal clearance than Ligand A (33.459), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-5.807) has a longer in vitro half-life than Ligand A (-1.361). This is a significant advantage.
14. **Pgp:** Ligand A (0.767) has a lower Pgp efflux liability than Ligand B (0.028), which is better.
15. **Binding Affinity:** Ligand A (-6.3 kcal/mol) has a slightly better binding affinity than Ligand B (-5.4 kcal/mol). This is a 1.5 kcal/mol difference, which is significant.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity and Pgp efflux profile, Ligand B is significantly better in several critical ADME-Tox parameters. The lower DILI risk, better solubility, and improved metabolic stability (lower Cl_mic and longer t1/2) of Ligand B outweigh the small advantage in binding affinity. The high logP of Ligand A is a significant concern. For a cardiovascular target, the BBB value is less important. Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity), Ligand B strikes a better balance.
Output:
0
2025-04-17 21:41:03,931 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.5 & 344.4 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (61.44) is better than Ligand B (66.9). Both are below the 140 threshold for oral absorption, which is good.
3. **logP:** Both ligands (2.474 & 2.816) are within the optimal 1-3 range. Ligand B is slightly higher, which *could* be a minor drawback if it leads to off-target effects, but it's not a major concern.
4. **HBD:** Ligand A (2) is slightly better than Ligand B (0). Having some HBD can improve solubility.
5. **HBA:** Ligand A (3) is lower than Ligand B (4). Lower is generally preferred for permeability.
6. **QED:** Ligand B (0.808) has a significantly better QED score than Ligand A (0.596), indicating a more drug-like profile. This is a positive for Ligand B.
7. **DILI:** Ligand A (10.585) has a much lower DILI risk than Ligand B (24.157). This is a significant advantage for Ligand A. DILI is a critical safety concern.
8. **BBB:** Ligand B (77.976) has a higher BBB penetration score than Ligand A (65.801). While ADRB2 isn't strictly a CNS target, some CNS penetration can be acceptable and may even offer some off-target benefits.
9. **Caco-2:** Ligand A (-5.083) has a better Caco-2 permeability than Ligand B (-4.656). Better intestinal absorption is preferred.
10. **Solubility:** Ligand A (-1.95) has slightly better solubility than Ligand B (-2.149).
11. **hERG:** Ligand A (0.399) has a lower hERG inhibition liability than Ligand B (0.614). Lower is better, reducing cardiotoxicity risk.
12. **Cl_mic:** Ligand A (17.085) has a lower microsomal clearance than Ligand B (21.641), suggesting better metabolic stability.
13. **t1/2:** Ligand A (7.551) has a longer in vitro half-life than Ligand B (3.836). This is a positive for Ligand A, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.029) has much lower P-gp efflux liability than Ligand B (0.286). This is a significant advantage for Ligand A, improving bioavailability.
15. **Binding Affinity:** Ligand A (-6.5) has a slightly better binding affinity than Ligand B (-6.1). While the difference is not huge, it's still a positive for Ligand A.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Both ligands are good on logP and TPSA. Ligand A is significantly better on Pgp efflux and has a slightly better affinity.
**Overall Assessment:**
While Ligand B has a better QED and BBB score, Ligand A demonstrates a much more favorable safety profile (lower DILI, hERG) and better ADME properties (lower Cl_mic, longer t1/2, lower Pgp efflux). The slightly better binding affinity of Ligand A further strengthens its position. The safety and ADME advantages of Ligand A outweigh the slightly better QED and BBB of Ligand B.
Output:
1
2025-04-17 21:41:03,931 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (a cardiovascular GPCR) drug candidates.
**Ligand A:** [349.391, 139.34 , -1.315, 4. , 6. , 0.431, 36.681, 25.475, -6.273, -0.951, 0.092, -13.392, -6.072, 0.008, -7.1 ]
**Ligand B:** [353.388, 36.86 , 2.6 , 1. , 4. , 0.908, 8.298, 83.288, -4.748, -3.919, 0.841, 19.561, -27.977, 0.239, -5.3 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). A is 349.391, B is 353.388. Very similar.
2. **TPSA:** A (139.34) is excellent, just under the 140 threshold for good absorption. B (36.86) is also good.
3. **logP:** A (-1.315) is a bit low, potentially hindering permeation. B (2.6) is within the optimal 1-3 range. This is a significant advantage for B.
4. **HBD:** A (4) is acceptable. B (1) is better, reducing potential for off-target interactions.
5. **HBA:** Both A (6) and B (4) are within the acceptable limit of 10.
6. **QED:** A (0.431) is below the desirable 0.5 threshold, indicating a less drug-like profile. B (0.908) is excellent.
7. **DILI:** A (36.681) is good, low risk. B (8.298) is even better, indicating a very low risk of liver injury.
8. **BBB:** A (25.475) is low, suggesting poor brain penetration. B (83.288) is very high, indicating good BBB penetration. While ADRB2 is primarily cardiovascular, some CNS off-target effects are possible, and lower CNS exposure is generally preferred.
9. **Caco-2:** A (-6.273) is very poor permeability. B (-4.748) is also poor, but slightly better than A.
10. **Solubility:** A (-0.951) is poor. B (-3.919) is also poor. Both ligands present solubility challenges.
11. **hERG:** A (0.092) is very low risk. B (0.841) is a moderate risk. This is a concern for B.
12. **Cl_mic:** A (-13.392) is excellent, indicating high metabolic stability. B (19.561) is high clearance, suggesting poor metabolic stability.
13. **t1/2:** A (-6.072) is poor. B (-27.977) is very poor. Both have short half-lives.
14. **Pgp:** A (0.008) is very low efflux, good. B (0.239) is moderate efflux.
15. **Affinity:** A (-7.1) is slightly better than B (-5.3). However, the difference is not huge.
**GPCR-Specific Considerations:**
For a cardiovascular GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. While BBB isn't *essential* for a cardiovascular target, minimizing CNS exposure can be beneficial to avoid off-target effects.
**Overall Assessment:**
Ligand B has a much better logP, QED, DILI, and BBB penetration. While it has a higher hERG risk and poorer metabolic stability, the benefits outweigh the drawbacks. Ligand A has better affinity, but its poor logP, QED, Caco-2 permeability, and solubility are significant liabilities. The improved metabolic stability of Ligand A is not enough to overcome its other deficiencies.
Therefore, I prefer Ligand B.
Output:
0
2025-04-17 21:41:03,931 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (339.359 and 348.443 Da) are within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (101.88) is higher than Ligand B (76.66). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B is better here.
3. **logP:** Ligand A (1.027) is within the optimal range (1-3), while Ligand B (3.253) is at the higher end. While still acceptable, higher logP can sometimes lead to off-target effects and solubility issues. Ligand A is slightly better.
4. **HBD:** Ligand A (1) and Ligand B (2) are both acceptable, being less than 5. No significant difference.
5. **HBA:** Ligand A (8) and Ligand B (4) are both acceptable, being less than 10. Ligand B is better.
6. **QED:** Both ligands have good QED scores (0.744 and 0.856), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (96.704) has a significantly higher DILI risk than Ligand B (59.984). This is a major concern for Ligand A.
8. **BBB:** Both ligands have similar BBB penetration (75.727 and 74.796). Not a primary concern for a cardiovascular target.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual. This suggests poor permeability. However, the values are similar (-4.859 and -4.615).
10. **Solubility:** Both ligands have negative solubility values, which is also unusual. Again, the values are similar (-3.854 and -4.158).
11. **hERG:** Ligand A (0.536) has a slightly higher hERG risk than Ligand B (0.384), but both are relatively low.
12. **Cl_mic:** Ligand A (50.33) has significantly lower microsomal clearance than Ligand B (64.759), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (-32.073) has a much more negative in vitro half-life than Ligand B (6.505). This is a major drawback for Ligand A.
14. **Pgp:** Ligand A (0.141) has lower P-gp efflux than Ligand B (0.087), which is favorable.
15. **Binding Affinity:** Ligand A (-6.8) has a slightly better binding affinity than Ligand B (-5.3). This is a 1.5kcal/mol difference, which is significant.
**Overall Assessment:**
Ligand A has a better binding affinity and lower P-gp efflux, and better metabolic stability. However, it has a significantly higher DILI risk and a very poor in vitro half-life. Ligand B has a lower DILI risk, better TPSA and QED, but weaker binding affinity and higher P-gp efflux.
Considering the ADRB2 target (a cardiovascular GPCR), the DILI risk is a critical factor. A high DILI risk is a major red flag. While the affinity difference is notable, the safety concerns associated with Ligand A outweigh this benefit. The slightly better metabolic stability is not enough to compensate for the DILI risk and poor half-life.
Therefore, I prefer Ligand B.
Output:
0
2025-04-17 21:41:03,931 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (370.503) is slightly higher than Ligand B (349.431), but both are acceptable.
2. **TPSA:** Ligand A (66.91) is significantly better than Ligand B (86.88). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (4.44) is higher than Ligand B (1.158). While 4.44 is approaching the upper limit, it's still within a reasonable range. Ligand B's logP is quite low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1), but both are well within the acceptable limit of 5.
5. **HBA:** Ligand A (6) is higher than Ligand B (5), but both are below the limit of 10.
6. **QED:** Both ligands have good QED scores (Ligand A: 0.644, Ligand B: 0.779). Ligand B is slightly better here.
7. **DILI:** Ligand A (86.894) has a significantly higher DILI risk than Ligand B (21.908). This is a major concern for Ligand A.
8. **BBB:** Ligand A (70.415) is better than Ligand B (43.815), but BBB isn't a high priority for a cardiovascular target.
9. **Caco-2:** Ligand A (-5.489) is worse than Ligand B (-4.863), indicating poorer intestinal absorption.
10. **Solubility:** Ligand A (-5.376) is worse than Ligand B (-0.702). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.606) is better than Ligand B (0.064), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand A (80.217) is higher than Ligand B (19.811), meaning faster metabolic clearance and potentially lower exposure.
13. **t1/2:** Ligand A (72.594) is much better than Ligand B (-18.263). A longer half-life is generally preferred.
14. **Pgp:** Ligand A (0.739) is better than Ligand B (0.113), indicating lower P-gp efflux.
15. **Affinity:** Ligand A (-6.7 kcal/mol) is slightly better than Ligand B (-5.9 kcal/mol), but the difference is not huge.
**GPCR-specific priorities:** For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, and affinity. Ligand A has a better logP and Pgp, and slightly better affinity. However, Ligand A's significantly higher DILI risk, poorer solubility, and worse Caco-2 permeability are major drawbacks. Ligand B, while having a lower logP, has a much more favorable safety profile (DILI) and better absorption characteristics (Caco-2, solubility). The small difference in binding affinity is outweighed by these ADME/Tox concerns.
**Conclusion:**
Despite Ligand A's slightly better affinity and Pgp properties, the significantly higher DILI risk and poorer absorption characteristics make it a less desirable candidate. Ligand B, with its lower toxicity and better absorption, is the more promising starting point for further optimization.
Output:
0
2025-04-17 21:41:03,931 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (374.413) is slightly higher than Ligand B (344.371), but both are acceptable.
2. **TPSA:** Ligand A (93.21) is better than Ligand B (127.17). For a GPCR, keeping TPSA low is good, and Ligand A is closer to the <140 threshold.
3. **logP:** Both ligands have similar logP values (A: 1.08, B: 1.141), falling within the optimal 1-3 range.
4. **HBD:** Ligand A (2) is preferable to Ligand B (3). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (6) is preferable to Ligand B (5). Similar to HBD, lower HBA is generally better.
6. **QED:** Ligand A (0.664) is better than Ligand B (0.554), indicating a more drug-like profile.
7. **DILI:** Ligand B (75.378) has a higher DILI risk than Ligand A (55.448). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (83.443) has significantly better BBB penetration potential than Ligand B (46.219). This is a *critical* factor for a GPCR, even a cardiovascular one, as off-target CNS effects are always a concern.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual. Assuming these are logP-like scales, lower values suggest poorer permeability. The values are very similar (-5.041 vs -5.154) and don't strongly differentiate the two.
10. **Solubility:** Ligand A (-2.853) has slightly better solubility than Ligand B (-4.124).
11. **hERG:** Ligand A (0.418) has a slightly better hERG profile than Ligand B (0.185). Lower is better.
12. **Cl_mic:** Ligand B (42.222) has significantly lower microsomal clearance than Ligand A (6.575), indicating better metabolic stability. This is a strong point for Ligand B.
13. **t1/2:** Ligand B (-31.561) has a much longer in vitro half-life than Ligand A (8.848). This is a substantial advantage for Ligand B.
14. **Pgp:** Ligand A (0.109) has lower P-gp efflux liability than Ligand B (0.045). Lower is better.
15. **Binding Affinity:** Ligand B (-6.7) has a significantly stronger binding affinity than Ligand A (-1.4). This is a *major* advantage for Ligand B, potentially outweighing some ADME concerns.
**Overall Assessment:**
Ligand B has a much stronger binding affinity and better metabolic stability (lower Cl_mic, longer t1/2). However, Ligand A excels in drug-likeness (QED), DILI risk, BBB penetration, and Pgp efflux. The superior binding affinity of Ligand B is a significant advantage for a GPCR target. While Ligand A's better BBB penetration is valuable, the substantial difference in binding affinity (-6.7 vs -1.4 kcal/mol) is likely to be decisive. The slightly higher DILI risk and Pgp efflux for Ligand B can potentially be addressed through further optimization.
Output:
0
2025-04-17 21:41:03,931 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (347.419 Da) is better, falling comfortably within the 200-500 Da range. Ligand B (388.45 Da) is still acceptable but closer to the upper limit.
2. **TPSA:** Ligand A (98.4) is significantly better. It's below the 140 threshold for good absorption. Ligand B (139.96) is nearing the upper limit and could present absorption challenges.
3. **logP:** Both ligands have similar logP values (A: 0.45, B: 0.389), both are a little low, but acceptable.
4. **HBD:** Ligand A (2) is preferable to Ligand B (3). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (4) is better than Ligand B (8). Lower HBA is preferred for permeability.
6. **QED:** Ligand A (0.808) is superior to Ligand B (0.594), indicating a more drug-like profile.
7. **DILI:** Ligand A (36.642) is *much* better than Ligand B (86.39). Ligand B's DILI risk is quite high.
8. **BBB:** Both are similar (A: 54.207, B: 50.679). Not a major factor here as ADRB2 isn't necessarily a CNS target, but slightly better for A.
9. **Caco-2:** Both are negative (-5.288 and -5.662), indicating poor permeability. This is a concern for both.
10. **Solubility:** Both are very poor (-1.557 and -2.643). This is a significant drawback for both, but B is worse.
11. **hERG:** Ligand A (0.196) is significantly better than Ligand B (0.362), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand A (-3.014) is much better than Ligand B (8.095). A negative value for A suggests very slow clearance and high metabolic stability, which is highly desirable.
13. **t1/2:** Ligand A (-36.169) is much better than Ligand B (10.647). A negative value for A suggests a very long half-life.
14. **Pgp:** Both are very low (A: 0.014, B: 0.129), suggesting minimal P-gp efflux.
15. **Binding Affinity:** Ligand A (-6.7 kcal/mol) is slightly better than Ligand B (-5.1 kcal/mol), though the difference isn't huge.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A performs better on TPSA, Pgp, and has a slightly better affinity. While both have low logP, the other advantages of A outweigh this.
**Overall Assessment:**
Ligand A is significantly better across most critical ADME-Tox parameters. Its superior QED, dramatically lower DILI risk, excellent metabolic stability (Cl_mic and t1/2), and lower hERG risk make it a much more promising drug candidate despite the poor Caco-2 and solubility. The slightly better binding affinity further supports this conclusion. Ligand B's high DILI risk is a major red flag.
Output:
1
2025-04-17 21:41:03,931 - INFO - Batch 276 complete. Total preferences: 4416
2025-04-17 21:41:03,931 - INFO - Processing batch 277/512...
2025-04-17 21:41:54,811 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's systematically compare Ligand A and Ligand B based on the provided parameters and the guidelines, keeping in mind this is a GPCR target (ADRB2, cardiovascular). This means logP, TPSA, Pgp, and affinity are particularly important.
1. **MW:** Both ligands (355.236 and 351.455 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand B (95.39) is significantly better than Ligand A (120.25). Lower TPSA generally improves permeability, and is very important for GPCRs.
3. **logP:** Ligand A (1.642) is within the optimal 1-3 range. Ligand B (-0.567) is slightly below 1, which *could* indicate permeability issues, but is not a dealbreaker.
4. **HBD/HBA:** Ligand A (1 HBD, 8 HBA) and Ligand B (2 HBD, 7 HBA) are both acceptable.
5. **QED:** Both ligands have good QED scores (0.563 and 0.651), indicating drug-likeness. Ligand B is slightly better.
6. **DILI:** Ligand A (98.216) has a very high DILI risk, which is a major concern. Ligand B (23.226) has a low DILI risk, a significant advantage.
7. **BBB:** Ligand A (73.866) has a reasonable BBB penetration, while Ligand B (47.266) is lower. While ADRB2 isn't necessarily a CNS target, some peripheral exposure is still desirable.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests a potential issue with the data or the compounds themselves. We'll proceed cautiously.
9. **Solubility:** Both have negative solubility values, also unusual. This is a concern for both, but the value for Ligand B is worse.
10. **hERG:** Ligand A (0.368) has a slightly better hERG profile than Ligand B (0.049), indicating lower cardiotoxicity risk.
11. **Cl_mic:** Ligand B (-27.555) has a *much* lower (better) microsomal clearance than Ligand A (22.159), indicating greater metabolic stability.
12. **t1/2:** Ligand B (-2.418) has a very short in vitro half-life, which is a significant drawback. Ligand A (60.692) has a much longer half-life.
13. **Pgp:** Ligand A (0.24) has lower P-gp efflux than Ligand B (0.002), which is preferable.
14. **Binding Affinity:** Ligand A (-7.9 kcal/mol) has a slightly better binding affinity than Ligand B (-7.0 kcal/mol). This is a 0.9 kcal/mol difference, which is substantial.
**Overall Assessment:**
Ligand A has a better binding affinity and half-life, and acceptable Pgp efflux. However, its extremely high DILI risk is a major red flag. Ligand B has a much better safety profile (DILI) and metabolic stability (Cl_mic), and a lower TPSA. The lower affinity and shorter half-life of Ligand B are concerning, but the DILI risk associated with Ligand A is a dealbreaker. While the solubility and Caco-2 values are concerning for both, the DILI risk is the most critical factor in this case.
**Output:**
0
2025-04-17 21:41:54,812 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (361.829 Da and 352.475 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (60.93) is significantly better than Ligand B (87.66). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (1.914 and 1.221), falling within the optimal 1-3 range. Ligand A is slightly higher, which might be beneficial for membrane permeability.
4. **HBD:** Ligand A (0) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (4). Fewer HBAs generally improve permeability.
6. **QED:** Ligand A (0.808) is better than Ligand B (0.643), indicating a more drug-like profile.
7. **DILI:** Ligand A (67.313) has a higher DILI risk than Ligand B (11.283). This is a significant drawback for Ligand A.
8. **BBB:** Ligand A (77.627) has better BBB penetration than Ligand B (51.183), but this is less critical for a cardiovascular target.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.588 and -4.643), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-3.64) is slightly better than Ligand B (-2.002), indicating better aqueous solubility.
11. **hERG:** Ligand A (0.424) has a lower hERG risk than Ligand B (0.192), which is a positive.
12. **Cl_mic:** Ligand A (25.291) has a lower microsomal clearance than Ligand B (29.065), suggesting better metabolic stability.
13. **t1/2:** Ligand B (14.695) has a longer in vitro half-life than Ligand A (11.511). This is a positive for Ligand B.
14. **Pgp:** Ligand A (0.183) has lower P-gp efflux liability than Ligand B (0.026), which is favorable.
15. **Affinity:** Ligand A (-7.0) has a slightly better binding affinity than Ligand B (-6.7). While the difference is relatively small, it's still a positive for Ligand A.
**Overall Assessment:**
Ligand A has a better overall profile regarding drug-likeness (QED), permeability-related properties (TPSA, HBD, HBA, Pgp), metabolic stability (Cl_mic), and binding affinity. However, the significantly higher DILI risk for Ligand A is a major concern. Ligand B has a much lower DILI risk and a slightly longer half-life. The Caco-2 values are concerning for both, but the other properties of Ligand B are more balanced. Given the cardiovascular target, minimizing toxicity (DILI) is crucial.
Output:
0
2025-04-17 21:41:54,812 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [342.443, 76.44, 1.539, 1, 4, 0.904, 41.179, 43.815, -4.932, -1.455, 0.564, -4.566, 29.583, 0.049, -6.7]
**Ligand B:** [365.547, 63.05, 2.475, 1, 6, 0.69, 29.779, 61.342, -5.628, -1.98, 0.303, 45.046, 24.646, 0.168, -7.8]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, Affinity):
1. **MW:** Both are within the acceptable 200-500 Da range. Ligand A (342.443) is slightly preferred.
2. **TPSA:** Ligand A (76.44) is better than Ligand B (63.05), both are good for oral absorption.
3. **logP:** Ligand A (1.539) is good, while Ligand B (2.475) is also acceptable, but approaching the upper limit.
4. **HBD/HBA:** Both have 1 HBD, which is good. Ligand A has 4 HBA, Ligand B has 6. Both are acceptable, but lower is generally better.
5. **QED:** Ligand A (0.904) is significantly better than Ligand B (0.69), indicating a more drug-like profile.
6. **DILI:** Ligand A (41.179) is better than Ligand B (29.779), both are good.
7. **BBB:** Ligand B (61.342) shows better BBB penetration than Ligand A (43.815). This is a plus for a GPCR, but ADRB2 is not a CNS target, so it's less critical.
8. **Caco-2:** Ligand B (-5.628) is better than Ligand A (-4.932), suggesting better absorption.
9. **Solubility:** Ligand B (-1.98) is better than Ligand A (-1.455).
10. **hERG:** Ligand A (0.564) is better than Ligand B (0.303), indicating lower cardiotoxicity risk.
11. **Cl_mic:** Ligand A (-4.566) is much better than Ligand B (45.046), indicating significantly better metabolic stability.
12. **t1/2:** Ligand A (29.583) is better than Ligand B (24.646).
13. **Pgp:** Ligand A (0.049) is much better than Ligand B (0.168), suggesting less efflux and better bioavailability.
14. **Affinity:** Ligand B (-7.8) has a significantly stronger binding affinity than Ligand A (-6.7), a difference of 1.1 kcal/mol. This is a substantial advantage.
**Overall Assessment:**
Ligand B has a clear advantage in binding affinity, which is the most important factor. It also has better Caco-2 permeability and solubility. However, Ligand A has a much better QED score, lower DILI risk, significantly better metabolic stability (Cl_mic and t1/2), and lower P-gp efflux. The difference in affinity is significant, but the ADME profile of Ligand A is substantially better. Given the balance, the superior affinity of Ligand B outweighs the ADME concerns.
Output:
0
2025-04-17 21:41:54,812 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (344.46 & 346.47 Da) fall comfortably within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Both ligands (59.39 & 58.64) are below the 140 A^2 threshold for good oral absorption, and acceptable for a cardiovascular GPCR. Again, no clear advantage.
3. **logP:** Ligand A (3.768) is slightly higher than Ligand B (2.747). Both are within the optimal 1-3 range, but A is closer to the upper limit.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Both have 4 HBA, which is good.
6. **QED:** Ligand A (0.898) has a slightly better QED score than Ligand B (0.833), indicating a more drug-like profile.
7. **DILI:** Ligand B (11.09) has a *much* lower DILI risk than Ligand A (48.042). This is a significant advantage for B.
8. **BBB:** Ligand B (88.096) has a higher BBB penetration percentile than Ligand A (78.79). While ADRB2 isn't strictly a CNS target, some CNS exposure can occur, and higher BBB is generally favorable.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand B (-4.723) is slightly worse than Ligand A (-4.399).
10. **Solubility:** Ligand B (-2.131) is slightly better than Ligand A (-2.894).
11. **hERG:** Ligand B (0.854) has a slightly higher hERG risk than Ligand A (0.621), but both are relatively low.
12. **Cl_mic:** Ligand A (36.437) has a lower microsomal clearance than Ligand B (45.104), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-15.588) has a *much* longer in vitro half-life than Ligand A (40.916). This is a major advantage for B.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.098 and 0.088).
15. **Affinity:** Ligand B (-6.4 kcal/mol) has a significantly stronger binding affinity than Ligand A (-4.3 kcal/mol). This is a >1.5 kcal/mol difference, which is substantial.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, Pgp, TPSA, and affinity. Ligand B excels in affinity and has acceptable logP, TPSA, and Pgp values. Ligand A has a slightly better logP, but the difference is not significant enough to outweigh the other factors.
**Overall Assessment:**
Ligand B is the stronger candidate. The significantly improved binding affinity and substantially longer half-life, coupled with a much lower DILI risk, outweigh the slightly worse Caco-2 permeability and slightly higher hERG risk. The better BBB penetration is also a bonus.
Output:
0
2025-04-17 21:41:54,812 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [364.471, 84.3, 1.565, 1, 5, 0.835, 49.477, 85.343, -4.954, -1.891, 0.539, 21.561, 22.121, 0.169, -7.5]
**Ligand B:** [341.499, 53.16, 3.262, 3, 3, 0.791, 23.614, 80.574, -5.307, -2.192, 0.785, -28.973, 28.833, 0.232, -7]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, Affinity, BBB):
1. **MW:** Both are within the ideal 200-500 Da range. Ligand B (341.499) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (84.3) is slightly higher than Ligand B (53.16). Ligand B is significantly better here, being well below the 140 threshold for oral absorption and closer to the ideal for GPCRs.
3. **logP:** Ligand A (1.565) is within the optimal 1-3 range. Ligand B (3.262) is at the higher end, but still acceptable.
4. **HBD/HBA:** Ligand A has 1 HBD and 5 HBA, while Ligand B has 3 HBD and 3 HBA. Both are reasonable.
5. **QED:** Both ligands have acceptable QED scores (A: 0.835, B: 0.791), indicating good drug-like properties.
6. **DILI:** Ligand A (49.477) has a higher DILI risk than Ligand B (23.614). This is a significant advantage for Ligand B.
7. **BBB:** Ligand A (85.343) has a slightly better BBB penetration score than Ligand B (80.574). While ADRB2 isn't necessarily a CNS target, some peripheral distribution is still desired.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. This is a concern for both.
9. **Solubility:** Both have negative solubility values, which is also unusual and indicates poor solubility. This is a concern for both.
10. **hERG:** Ligand A (0.539) has a lower hERG risk than Ligand B (0.785), which is a positive.
11. **Cl_mic:** Ligand A (21.561) has a much lower (better) microsomal clearance than Ligand B (-28.973). This suggests better metabolic stability for Ligand A.
12. **t1/2:** Ligand B (28.833) has a longer in vitro half-life than Ligand A (22.121), which is desirable.
13. **Pgp:** Ligand A (0.169) has lower P-gp efflux liability than Ligand B (0.232), which is favorable for bioavailability.
14. **Affinity:** Ligand A (-7.5 kcal/mol) has a slightly better binding affinity than Ligand B (-7 kcal/mol). While the difference is small, it is still a factor.
**Overall Assessment:**
Ligand B has several key advantages: significantly lower DILI risk, better TPSA, and a longer half-life. Ligand A has better metabolic stability (lower Cl_mic) and slightly better affinity and Pgp efflux. The negative Caco-2 and solubility values are concerning for both, but the lower DILI risk of Ligand B is a major advantage for a cardiovascular target. Given the GPCR-specific priorities, the lower TPSA and DILI risk of Ligand B outweigh the slightly better affinity and metabolic stability of Ligand A.
Output:
0
2025-04-17 21:41:54,812 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (337.375 and 362.539 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (60.7) is slightly higher than Ligand B (49.41). Both are below the 140 threshold for oral absorption, but B is better positioned for potential CNS penetration if desired.
3. **logP:** Both ligands have good logP values (3.588 and 3.178), falling within the 1-3 optimal range. Ligand B is slightly lower, which could be beneficial for solubility.
4. **HBD:** Both ligands have 1 HBD, which is within the acceptable limit of 5.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 3. Both are below the 10 limit.
6. **QED:** Both ligands have high QED scores (0.79 and 0.845), indicating good drug-like properties.
7. **DILI:** Ligand A (68.941) has a higher DILI risk than Ligand B (35.479). This is a significant concern, as lower DILI is highly desirable.
8. **BBB:** Both ligands have reasonably good BBB penetration (72.625 and 70.027). This isn't a primary concern for ADRB2, but it's a positive attribute.
9. **Caco-2:** Both ligands show negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.956) is slightly worse than Ligand B (-5.007).
10. **Solubility:** Both ligands have negative solubility values, which is also unusual and suggests poor solubility. Ligand A (-4.373) is slightly worse than Ligand B (-3.742).
11. **hERG:** Ligand A (0.876) has a slightly higher hERG risk than Ligand B (0.59). Lower hERG is preferred.
12. **Cl_mic:** Ligand A (65.034) has lower microsomal clearance than Ligand B (84.904), indicating better metabolic stability. This is a positive for Ligand A.
13. **t1/2:** Ligand A (94.48) has a significantly longer in vitro half-life than Ligand B (-3.068). This is a major advantage for Ligand A, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.873) has slightly higher P-gp efflux than Ligand B (0.462). Lower P-gp efflux is generally preferred.
15. **Binding Affinity:** Ligand A (-7.1) has a stronger binding affinity than Ligand B (-6.3). This is a substantial difference (1.8 kcal/mol), and potency is a key driver in GPCR drug discovery.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), affinity, logP, TPSA, and Pgp are important. Ligand A excels in affinity and has acceptable logP and TPSA. Ligand B has slightly better TPSA and Pgp, but the affinity difference is substantial. The DILI risk for Ligand B is a significant advantage.
**Overall Assessment:**
While Ligand B has a lower DILI risk and slightly better Pgp efflux, the significantly stronger binding affinity (-7.1 vs -6.3 kcal/mol) and longer half-life of Ligand A outweigh these benefits. The higher DILI risk of Ligand A is a concern, but can be addressed through further structural modifications. The substantial affinity difference is more difficult to achieve through modification. The poor Caco-2 and solubility of both compounds are concerning and would need to be addressed regardless of which lead is chosen.
Output:
1
2025-04-17 21:41:54,812 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (425.352 Da) is within the ideal range, while Ligand B (350.463 Da) is also good, but slightly lower. This is a minor advantage to A.
2. **TPSA:** Both ligands (A: 88.32, B: 87.46) are below the 140 threshold for good oral absorption and reasonably close to the 90 threshold for CNS targets (though ADRB2 isn't necessarily a CNS target). Very similar.
3. **logP:** Ligand A (2.881) is optimal, while Ligand B (0.643) is quite low. This is a significant advantage for A, as low logP can hinder membrane permeability.
4. **HBD:** Both ligands have 2 HBD, which is within the acceptable limit.
5. **HBA:** Both ligands have 5 HBA, also within the acceptable limit.
6. **QED:** Both ligands have similar QED values (A: 0.787, B: 0.674), indicating good drug-likeness.
7. **DILI:** Ligand A (76.968) has a higher DILI risk than Ligand B (18.224). This is a significant drawback for A.
8. **BBB:** Both have moderate BBB penetration (A: 52.889, B: 49.826). Not a major factor for ADRB2.
9. **Caco-2:** Both have negative Caco-2 values (-5.419 and -5.02), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-2.956) has worse solubility than Ligand B (-0.978).
11. **hERG:** Ligand A (0.611) has a slightly higher hERG risk than Ligand B (0.167).
12. **Cl_mic:** Ligand A (27.121) has a higher microsomal clearance than Ligand B (21.582), suggesting lower metabolic stability.
13. **t1/2:** Ligand A (24.642) has a longer half-life than Ligand B (5.169). This is a positive for A.
14. **Pgp:** Ligand A (0.207) has lower P-gp efflux than Ligand B (0.029), which is favorable.
15. **Affinity:** Ligand B (-5.8 kcal/mol) has a significantly stronger binding affinity than Ligand A (-1.5 kcal/mol). This is a *major* advantage for B, easily outweighing most other differences.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand A has better logP and Pgp, but Ligand B *far* surpasses it in binding affinity. The Caco-2 values are concerning for both, but the much stronger affinity of B is likely to be more impactful. The DILI risk for A is also a significant concern.
**Conclusion:**
Despite the higher DILI risk, the substantially stronger binding affinity of Ligand B makes it the more promising candidate. The difference in affinity (4.3 kcal/mol) is substantial and likely to overcome the other drawbacks.
Output:
0
2025-04-17 21:41:54,812 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (349.431 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are well below the 140 A^2 threshold for good oral absorption (A: 80.76, B: 78.24).
3. **logP:** Both ligands have optimal logP values (A: 2.146, B: 2.422), falling within the 1-3 range.
4. **HBD:** Ligand A has 1 HBD, and Ligand B has 0. Both are acceptable, with lower being slightly preferred.
5. **HBA:** Ligand A has 5 HBA, and Ligand B has 4. Both are within the acceptable range of <=10.
6. **QED:** Both ligands have good QED scores (A: 0.824, B: 0.765), indicating drug-like properties.
7. **DILI:** Ligand A (35.712) has a lower DILI risk than Ligand B (45.832), which is a significant advantage. Both are below the 60 threshold, but A is preferable.
8. **BBB:** Both ligands have high BBB penetration (A: 80.07, B: 81.233). This is good, but less critical for a cardiovascular target like ADRB2.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the values are similar (-4.378 for A, -4.671 for B).
10. **Solubility:** Both ligands have negative solubility values, indicating poor aqueous solubility. Ligand B is slightly worse (-4.304 vs -1.794).
11. **hERG:** Both ligands have low hERG inhibition risk (A: 0.407, B: 0.671), which is good.
12. **Cl_mic:** Ligand A has a higher microsomal clearance (31.636) than Ligand B (7.964), indicating lower metabolic stability. This is a significant drawback for Ligand A.
13. **t1/2:** Ligand B has a longer in vitro half-life (11.511 hours) than Ligand A (-12.253 hours). This is a major advantage for Ligand B.
14. **Pgp:** Both ligands have low P-gp efflux liability (A: 0.034, B: 0.151).
15. **Binding Affinity:** Ligand B has a significantly better binding affinity (-7.0 kcal/mol) than Ligand A (-5.7 kcal/mol). This is a substantial advantage that can outweigh some of the ADME drawbacks.
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are important. Both ligands perform well on logP, Pgp, and TPSA. However, Ligand B has a much stronger binding affinity. While BBB is important for CNS GPCRs, it's less crucial for a cardiovascular target.
**Overall Assessment:**
Ligand B is the more promising candidate. While both have issues with Caco-2 and solubility, Ligand B's significantly improved binding affinity (-7.0 vs -5.7 kcal/mol), better metabolic stability (lower Cl_mic, longer t1/2), and lower DILI risk outweigh the slightly worse solubility. The stronger binding affinity is particularly important for a GPCR target.
Output:
0
2025-04-17 21:41:54,812 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [347.379, 137.87 , 2.145, 4. , 6. , 0.483, 86.39 , 48.236, -5.27 , -4.172, 0.18 , 17.951, 22.957, 0.032, -4.8 ]
**Ligand B:** [350.463, 85.25 , 2.332, 2. , 5. , 0.678, 42.148, 79.333, -4.528, -3.75 , 0.266, 58.916, 12.295, 0.069, -6.6 ]
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). A (347.379) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (137.87) is close to the upper limit for good oral absorption, while Ligand B (85.25) is well below. This favors Ligand B.
3. **logP:** Both are within the optimal range (1-3). Ligand B (2.332) is slightly higher, which could potentially lead to some off-target interactions but isn't a major concern.
4. **HBD:** Ligand A (4) is higher than Ligand B (2). Lower HBD is generally preferred for better permeability. Ligand B is better here.
5. **HBA:** Ligand A (6) is higher than Ligand B (5). Similar to HBD, lower HBA is preferred. Ligand B is better.
6. **QED:** Ligand B (0.678) has a significantly better QED score than Ligand A (0.483), indicating a more drug-like profile.
7. **DILI:** Ligand A (86.39) has a much higher DILI risk than Ligand B (42.148). This is a significant negative for Ligand A.
8. **BBB:** Ligand B (79.333) has a higher BBB penetration score than Ligand A (48.236). While ADRB2 isn't a CNS target, some distribution to the CNS can sometimes lead to off-target effects and is generally undesirable for cardiovascular drugs.
9. **Caco-2:** Ligand A (-5.27) has a much lower Caco-2 permeability than Ligand B (-4.528). This suggests Ligand A will have poorer intestinal absorption.
10. **Solubility:** Ligand A (-4.172) has a lower solubility than Ligand B (-3.75).
11. **hERG:** Both ligands have low hERG inhibition liability (0.18 and 0.266, respectively), which is good.
12. **Cl_mic:** Ligand A (17.951) has a significantly lower microsomal clearance than Ligand B (58.916), suggesting better metabolic stability. This is a positive for Ligand A.
13. **t1/2:** Ligand A (22.957) has a longer in vitro half-life than Ligand B (12.295). This is a positive for Ligand A.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.032 and 0.069, respectively).
15. **Affinity:** Ligand B (-6.6 kcal/mol) has a significantly stronger binding affinity than Ligand A (-4.8 kcal/mol). This is a crucial advantage, exceeding the 1.5 kcal/mol threshold.
**GPCR-specific priorities:** For GPCRs, we prioritize logP, Pgp, TPSA, and affinity. Ligand B excels in affinity and TPSA. While Ligand A has better metabolic stability and half-life, the substantial improvement in binding affinity and the better overall ADME profile (lower DILI, better Caco-2, better solubility, better QED) of Ligand B outweigh these advantages.
**Conclusion:**
Ligand B is the more promising drug candidate. The stronger binding affinity, coupled with a better overall ADME profile, makes it a superior choice despite the slightly higher logP and lower metabolic stability.
```
0
```
2025-04-17 21:41:54,813 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (347.415 and 352.406 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (96.53) is slightly higher than Ligand B (78.87). For a cardiovascular GPCR, TPSA is not a major concern, but lower is generally preferred for better permeability. Ligand B has a clear advantage.
**3. logP:** Ligand A (0.736) is a bit low, potentially hindering permeability. Ligand B (1.916) is within the optimal 1-3 range. Ligand B is better.
**4. H-Bond Donors:** Ligand A (3) is slightly higher than Ligand B (2), but both are acceptable (<=5).
**5. H-Bond Acceptors:** Both ligands have 4 H-bond acceptors, which is good.
**6. QED:** Both ligands have similar QED values (0.604 and 0.666), indicating good drug-likeness.
**7. DILI Risk:** Ligand A (52.113) has a higher DILI risk than Ligand B (36.254). Lower is better, so Ligand B is preferred.
**8. BBB Penetration:** Ligand B (75.029) shows better BBB penetration than Ligand A (68.205). While not a primary concern for a cardiovascular target, it's a slight advantage for Ligand B.
**9. Caco-2 Permeability:** Both ligands have similar, very negative Caco-2 values (-4.739 and -4.71). These values are unusual and suggest poor permeability.
**10. Aqueous Solubility:** Both ligands have very negative solubility values (-2.606 and -2.305), indicating very poor aqueous solubility. This is a significant drawback for both.
**11. hERG Inhibition:** Ligand A (0.083) has a lower hERG inhibition risk than Ligand B (0.322). This is a significant advantage for Ligand A.
**12. Microsomal Clearance:** Ligand A (17.73) has higher microsomal clearance than Ligand B (13.286), meaning it's less metabolically stable. Ligand B is better.
**13. In vitro Half-Life:** Ligand B (-15.321) has a significantly longer in vitro half-life than Ligand A (5.912). This is a major advantage for Ligand B.
**14. P-gp Efflux:** Ligand A (0.025) has much lower P-gp efflux than Ligand B (0.052), which is favorable for bioavailability.
**15. Binding Affinity:** Both ligands have very similar and strong binding affinities (-6.2 and -6.0 kcal/mol). The difference is negligible.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand B is the more promising candidate. It has a better logP, lower DILI risk, better BBB penetration, a longer half-life, and lower microsomal clearance. While Ligand A has a lower hERG risk and P-gp efflux, the benefits of Ligand B's improved ADME profile and metabolic stability outweigh this. The poor solubility and permeability are concerning for both, but can be addressed with formulation strategies.
Output:
0
2025-04-17 21:41:54,813 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [383.543, 92.93, 1.785, 2, 8, 0.608, 65.491, 16.014, -5.733, -2.093, 0.154, 31.946, -0.845, 0.067, -6.7]
**Ligand B:** [359.417, 56.59, 1.944, 0, 5, 0.633, 23.691, 96.084, -4.415, -1.472, 0.732, 44.619, 11.004, 0.259, -5.3]
Here's a breakdown, prioritizing GPCR properties (logP, Pgp, TPSA, BBB, and affinity):
1. **Molecular Weight:** Both are within the ideal range (200-500 Da). Ligand B (359.417) is slightly preferred due to being a bit lower.
2. **TPSA:** Ligand B (56.59) is significantly better than Ligand A (92.93). Below 140 is good for oral absorption, but lower is better for GPCRs, and B is much closer to optimal.
3. **logP:** Both are good (around 1.8-1.9), falling within the 1-3 range. No strong preference here.
4. **H-Bond Donors/Acceptors:** Ligand B (0 HBD, 5 HBA) is better than Ligand A (2 HBD, 8 HBA). Fewer H-bonds generally improve permeability.
5. **QED:** Both are acceptable (0.608 and 0.633), indicating good drug-like properties.
6. **DILI:** Ligand B (23.691) is *much* better than Ligand A (65.491). This is a significant advantage for B.
7. **BBB:** Ligand B (96.084) is excellent, while Ligand A (16.014) is poor. This is a critical advantage for B, as BBB penetration is important for GPCR targets.
8. **Caco-2:** Ligand A (-5.733) is better than Ligand B (-4.415), indicating better intestinal absorption.
9. **Solubility:** Ligand A (-2.093) is better than Ligand B (-1.472), but both are poor.
10. **hERG:** Ligand B (0.732) is better than Ligand A (0.154), indicating lower cardiotoxicity risk.
11. **Cl_mic:** Ligand A (31.946) is better than Ligand B (44.619), suggesting better metabolic stability.
12. **t1/2:** Ligand B (11.004) is better than Ligand A (-0.845), suggesting a longer half-life.
13. **Pgp:** Ligand A (0.067) is better than Ligand B (0.259), indicating lower P-gp efflux.
14. **Binding Affinity:** Ligand A (-6.7 kcal/mol) is slightly better than Ligand B (-5.3 kcal/mol). This is a 1.4 kcal/mol difference, which is significant.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity and Pgp profile, Ligand B overwhelmingly wins on critical ADME properties for a GPCR target, particularly BBB penetration and DILI risk. The lower TPSA and favorable H-bonding characteristics of Ligand B also contribute to its better profile. The difference in affinity, while notable, can potentially be addressed through further optimization, whereas fixing poor BBB or high DILI risk is much more challenging.
Therefore, I favor Ligand B.
0
2025-04-17 21:41:54,813 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (378.351 and 348.487 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (90.34) is slightly higher than Ligand B (58.64). For a cardiovascular GPCR, TPSA is moderately important, and lower is generally better for permeability. Ligand B has a substantial advantage here.
**3. logP:** Ligand A (1.932) is within the optimal range (1-3), while Ligand B (3.352) is at the higher end. While still acceptable, Ligand B's higher logP could potentially lead to off-target interactions or solubility issues.
**4. H-Bond Donors:** Both ligands have 1 HBD, which is good.
**5. H-Bond Acceptors:** Ligand A has 5 HBAs, and Ligand B has 3. Both are within the acceptable limit of 10.
**6. QED:** Ligand A (0.824) has a significantly better QED score than Ligand B (0.567), indicating a more drug-like profile overall.
**7. DILI Risk:** Ligand A (55.448) has a higher DILI risk than Ligand B (21.093). This is a significant concern, as minimizing liver toxicity is crucial. Ligand B is much better here.
**8. BBB Penetration:** Both ligands have good BBB penetration (Ligand A: 79.217, Ligand B: 70.609). While not a primary concern for a cardiovascular target, it's not detrimental.
**9. Caco-2 Permeability:** Ligand A (-4.635) and Ligand B (-5.121) both have negative values, indicating poor permeability. Ligand B is slightly worse.
**10. Aqueous Solubility:** Both ligands have poor aqueous solubility (-2.884 and -3.141 respectively).
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.279 and 0.309). Excellent for both.
**12. Microsomal Clearance:** Ligand A (3.701) has a lower microsomal clearance than Ligand B (40.718), suggesting better metabolic stability. This is a positive for Ligand A.
**13. In vitro Half-Life:** Ligand A (39.851) has a significantly longer in vitro half-life than Ligand B (-15.79). This is a major advantage for Ligand A.
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (0.135 and 0.131).
**15. Binding Affinity:** Ligand B (-6.1) has a slightly better binding affinity than Ligand A (-5.8), but the difference is relatively small (0.3 kcal/mol).
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), and the general drug-like properties, Ligand B emerges as the more promising candidate. While Ligand A has advantages in QED, metabolic stability, and half-life, Ligand B's significantly lower DILI risk and lower TPSA are critical advantages. The slight improvement in binding affinity for Ligand B also contributes. The solubility and permeability issues are concerning for both, but can be addressed through formulation strategies. The DILI risk for Ligand A is too high to ignore.
Output:
0
2025-04-17 21:41:54,813 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (364.8 & 342.4 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (68.29) is significantly better than Ligand B (103.87). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (3.227) is optimal, while Ligand B (0.951) is a bit low, potentially hindering membrane permeability.
4. **HBD:** Both ligands have acceptable HBD counts (1 & 2, respectively).
5. **HBA:** Both ligands have acceptable HBA counts (4 & 5, respectively).
6. **QED:** Both ligands have good QED scores (0.605 & 0.861), indicating good drug-like properties.
7. **DILI:** Ligand A (72.043) has a slightly higher DILI risk than Ligand B (64.676), but both are still within an acceptable range (<80).
8. **BBB:** Ligand A (70.531) has better BBB penetration than Ligand B (27.918), but this is less critical for a cardiovascular target.
9. **Caco-2:** Ligand A (-4.612) and Ligand B (-5.476) have similar Caco-2 permeability, both indicating good absorption.
10. **Solubility:** Ligand A (-3.71) has slightly better solubility than Ligand B (-2.094).
11. **hERG:** Both ligands have very low hERG inhibition risk (0.281 & 0.246).
12. **Cl_mic:** Ligand B (-7.498) has significantly lower microsomal clearance than Ligand A (92.061), suggesting better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand B (-11.076) has a much longer in vitro half-life than Ligand A (8.081), indicating slower metabolism and potentially less frequent dosing. This is another significant advantage.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.103 & 0.012).
15. **Affinity:** Both ligands have the same binding affinity (-6.9 kcal/mol).
**GPCR-Specific Priorities:** For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand A excels in logP and TPSA. However, Ligand B has a much better metabolic profile (Cl_mic and t1/2). While affinity is the same, the improved PK properties of Ligand B are likely to translate to better *in vivo* efficacy.
**Conclusion:**
Despite Ligand A's slightly better TPSA and solubility, the significantly improved metabolic stability (lower Cl_mic, longer t1/2) of Ligand B makes it the more promising drug candidate. These PK advantages are crucial for maintaining therapeutic concentrations *in vivo*.
Output:
0
2025-04-17 21:41:54,814 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (344.371 and 345.403 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (99.51) is slightly higher than Ligand B (93.26). Both are below the 140 threshold for good oral absorption, and acceptable for a peripherally acting GPCR like ADRB2.
3. **logP:** Ligand B (1.487) is better than Ligand A (0.507). A logP between 1-3 is optimal, and Ligand B is within this range, while Ligand A is slightly low, potentially impacting permeability.
4. **HBD:** Both ligands have 1 HBD, which is within the acceptable limit of 5.
5. **HBA:** Ligand A has 5 HBA, while Ligand B has 6. Both are below the 10 threshold.
6. **QED:** Both ligands have similar QED values (0.874 and 0.856), indicating good drug-likeness.
7. **DILI:** Ligand B (54.634) has a lower DILI risk than Ligand A (63.164). Lower is better, and both are below the concerning 60 threshold, but Ligand B is preferable.
8. **BBB:** Ligand B (68.282) has a higher BBB penetration than Ligand A (51.415). While ADRB2 isn't a CNS target, some degree of BBB penetration can sometimes be beneficial for distribution.
9. **Caco-2:** Both ligands have very negative Caco-2 values (-5.043 and -5.055). This is unusual and suggests poor permeability, or an issue with the assay.
10. **Solubility:** Both ligands have very negative solubility values (-1.552 and -1.788). This is also concerning and suggests poor aqueous solubility.
11. **hERG:** Both ligands have low hERG inhibition liability (0.152 and 0.084), which is excellent.
12. **Cl_mic:** Ligand A (5.585) has significantly lower microsomal clearance than Ligand B (48.946). Lower clearance indicates better metabolic stability, a significant advantage.
13. **t1/2:** Ligand B (-23.603) has a much longer in vitro half-life than Ligand A (-5.813). This is a substantial benefit, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.031 and 0.057).
15. **Binding Affinity:** Ligand B (-7.1) has a slightly better binding affinity than Ligand A (-6.7). While the difference is not huge (0.4 kcal/mol), it's enough to consider, especially given the other factors.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand B is superior in logP and affinity. Both are good on Pgp and TPSA. The biggest differentiator is the metabolic stability (Cl_mic) and half-life, where Ligand B is significantly better.
**Overall Assessment:**
Despite both ligands having issues with Caco-2 and solubility, Ligand B emerges as the more promising candidate. Its superior logP, binding affinity, lower DILI risk, better BBB penetration, and significantly improved metabolic stability (longer half-life) outweigh the slightly higher TPSA. The better affinity, while not a massive difference, further supports this conclusion.
Output:
0
2025-04-17 21:41:54,814 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (342.439 Da) is well within the ideal range (200-500 Da). Ligand B (478.181 Da) is at the upper limit, but still acceptable.
2. **TPSA:** Ligand A (60.45) is excellent, well below the 140 threshold for oral absorption. Ligand B (76.66) is still reasonable, but less favorable.
3. **logP:** Both ligands have good logP values (A: 3.63, B: 3.022), falling within the 1-3 optimal range.
4. **HBD:** Ligand A (1) is preferred, as lower HBD generally improves permeability. Ligand B (2) is acceptable.
5. **HBA:** Both ligands have the same HBA count (4), which is well within the acceptable limit of 10.
6. **QED:** Ligand A (0.835) has a higher QED score than Ligand B (0.592), indicating a more drug-like profile.
7. **DILI:** Ligand B (39.201) has a significantly lower DILI risk than Ligand A (58.705), which is a substantial advantage.
8. **BBB:** Ligand B (86.894) has a much higher BBB penetration percentile than Ligand A (51.415). While ADRB2 isn't strictly a CNS target, some CNS exposure can be beneficial or at least less detrimental than complete exclusion.
9. **Caco-2:** Both ligands have similar, very negative Caco-2 values (-4.584 and -4.696). This suggests poor permeability, which is a concern.
10. **Solubility:** Ligand B (-3.875) has slightly better solubility than Ligand A (-4.733), though both are quite poor.
11. **hERG:** Both ligands have similar, low hERG inhibition liability (A: 0.496, B: 0.606), which is good.
12. **Cl_mic:** Ligand B (78.59) has lower microsomal clearance than Ligand A (100.086), suggesting better metabolic stability.
13. **t1/2:** Ligand B (16.663 hours) has a significantly longer in vitro half-life than Ligand A (6.501 hours). This is a major advantage.
14. **Pgp:** Both ligands have very low Pgp efflux liability (A: 0.154, B: 0.177).
15. **Binding Affinity:** Both ligands have very similar binding affinities (A: -5.8 kcal/mol, B: -5.6 kcal/mol). The difference is not substantial enough to be a deciding factor.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Both ligands perform well on logP and Pgp. Ligand A has a better TPSA, but Ligand B has a significantly better BBB score, longer half-life, lower DILI risk, and better metabolic stability.
**Overall Assessment:**
While Ligand A has a slightly better QED and TPSA, Ligand B's superior DILI profile, BBB penetration, metabolic stability (lower Cl_mic, longer t1/2), and comparable binding affinity make it the more promising candidate. The poor Caco-2 values for both are a concern that would need to be addressed through formulation or structural modification, but the other advantages of Ligand B outweigh the slightly better TPSA of Ligand A.
Output:
0
2025-04-17 21:41:54,814 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**1. Molecular Weight:** Both ligands (366.53 and 368.50 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (62.55) is better than Ligand B (67.87). Both are below the 140 threshold for oral absorption, but lower TPSA is generally preferred for GPCRs.
**3. logP:** Ligand A (3.45) is slightly higher than Ligand B (2.29), placing it more optimally within the 1-3 range. Ligand B is still acceptable, but slightly lower could pose permeability challenges.
**4. H-Bond Donors:** Both ligands have 1 HBD, which is within the acceptable limit of 5.
**5. H-Bond Acceptors:** Ligand A has 4 HBAs, while Ligand B has 5. Both are below the 10 limit, but lower is generally better.
**6. QED:** Ligand B (0.802) has a slightly better QED score than Ligand A (0.68), indicating a more drug-like profile.
**7. DILI Risk:** Ligand B (39.05) has a significantly lower DILI risk than Ligand A (20.74). This is a major advantage for Ligand B.
**8. BBB Penetration:** Both ligands have similar BBB penetration (Ligand A: 62.54, Ligand B: 69.83). While not exceptionally high, they are acceptable for a peripherally-acting GPCR like ADRB2.
**9. Caco-2 Permeability:** Ligand A (-5.31) has slightly better Caco-2 permeability than Ligand B (-4.64), indicating better intestinal absorption.
**10. Aqueous Solubility:** Both ligands have poor aqueous solubility (-3.27 and -2.96 respectively). This is a potential issue for both, requiring formulation strategies.
**11. hERG Inhibition:** Ligand A (0.63) shows a slightly higher hERG inhibition risk than Ligand B (0.46), although both are relatively low.
**12. Microsomal Clearance:** Ligand A (55.82) has higher microsomal clearance than Ligand B (37.34), meaning it's likely to be metabolized faster. Lower clearance is preferred.
**13. In vitro Half-Life:** Ligand B (34.20) has a slightly longer in vitro half-life than Ligand A (40.16).
**14. P-gp Efflux:** Both ligands have low P-gp efflux (0.18 and 0.17 respectively), which is good.
**15. Binding Affinity:** Ligand A (-7.7 kcal/mol) has a significantly stronger binding affinity than Ligand B (-4.0 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME drawbacks.
**Overall Assessment:**
The biggest differentiator is the binding affinity. Ligand A binds almost 4 kcal/mol stronger. For a GPCR, this is a very significant difference. While Ligand B has a better DILI profile and QED, the potency advantage of Ligand A is substantial. The slightly higher clearance of Ligand A can be addressed through structural modifications. The solubility issues are present in both and would require formulation work.
Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity), the superior affinity of Ligand A is the deciding factor.
Output:
1
2025-04-17 21:41:54,814 - INFO - Batch 277 complete. Total preferences: 4432
2025-04-17 21:41:54,814 - INFO - Processing batch 278/512...
2025-04-17 21:42:43,488 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.463 and 366.443 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (85.77) is better than Ligand B (104.12). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have similar logP values (0.533 and 0.586), which are a little low. While not ideal, they aren't drastically outside the 1-3 range.
4. **HBD:** Both have 2 HBD, which is within the acceptable limit of 5.
5. **HBA:** Ligand A has 5 HBA, while Ligand B has 7. Ligand A is preferable here, staying closer to the ideal of 10 or less.
6. **QED:** Both ligands have good QED scores (0.679 and 0.735), indicating good drug-like properties.
7. **DILI:** Ligand A (19.659) has a significantly better DILI score than Ligand B (62.001). This is a major advantage for Ligand A. A DILI percentile above 60 is concerning.
8. **BBB:** Ligand A (33.501) has a lower BBB penetration than Ligand B (60.45). Since ADRB2 is a cardiovascular target, BBB penetration is not a priority.
9. **Caco-2:** Ligand A (-4.906) and Ligand B (-5.061) are similar.
10. **Solubility:** Ligand A (-1.09) is better than Ligand B (-2.082).
11. **hERG:** Both ligands have very low hERG inhibition liability (0.264 and 0.148), which is excellent.
12. **Cl_mic:** Ligand B (21.464) has a lower microsomal clearance than Ligand A (40.879), suggesting better metabolic stability.
13. **t1/2:** Ligand A (24.858) has a longer in vitro half-life than Ligand B (7.81).
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.032 and 0.029).
15. **Binding Affinity:** Ligand A (-6.2) has a slightly better binding affinity than Ligand B (-5.9). While the difference is not huge, it's a positive for Ligand A.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Both ligands are similar in logP and Pgp. Ligand A is better in TPSA and has a slightly better affinity. The biggest differentiator is the DILI score, where Ligand A is significantly better. Metabolic stability (Cl_mic) is better for Ligand B, but the longer half-life of Ligand A partially compensates for this.
**Overall Assessment:**
Ligand A presents a more favorable overall profile. The significantly lower DILI risk is a major advantage, and it's balanced by acceptable metabolic stability, better TPSA, solubility and slightly better affinity.
Output:
1
2025-04-17 21:42:43,489 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (386.5 and 340.5 Da) fall within the ideal 200-500 Da range. Ligand B is slightly smaller, which could be a minor advantage for permeability.
2. **TPSA:** Ligand A (100.62) is higher than Ligand B (54.12). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred. Ligand B is significantly better here.
3. **logP:** Ligand A (0.667) is lower than Ligand B (3.919). Ligand B is approaching the upper limit of the optimal range, but still acceptable. Ligand A is quite low, potentially hindering membrane permeability. This is a significant drawback for Ligand A.
4. **HBD:** Ligand A (1) is lower than Ligand B (2). Both are within the acceptable limit of 5.
5. **HBA:** Ligand A (5) is higher than Ligand B (3). Both are within the acceptable limit of 10.
6. **QED:** Both ligands (0.742 and 0.716) have good drug-likeness scores, exceeding the 0.5 threshold.
7. **DILI:** Ligand A (54.56) has a higher DILI risk than Ligand B (21.95). Ligand B is considerably better in terms of predicted liver toxicity.
8. **BBB:** Both ligands have good BBB penetration (82.09 and 77.2). Since ADRB2 is not a CNS target, this is less critical.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual. Assuming these are logP-scaled permeability values, lower values indicate lower permeability.
10. **Solubility:** Both ligands have negative solubility values, which is also unusual. Assuming these are logS values, lower values indicate lower solubility.
11. **hERG:** Ligand A (0.271) has a lower hERG risk than Ligand B (0.836). This is a positive for Ligand A.
12. **Cl_mic:** Ligand A (49.94) has lower microsomal clearance than Ligand B (70.48), suggesting better metabolic stability. This is a positive for Ligand A.
13. **t1/2:** Ligand A (-21.3) has a negative in vitro half-life, which is unusual. Ligand B (-11.6) is also negative, but less so.
14. **Pgp:** Ligand A (0.121) has lower P-gp efflux than Ligand B (0.412), which is favorable for bioavailability.
15. **Affinity:** Ligand A (-7.9) has a slightly better binding affinity than Ligand B (-7.5). This is a 1.5 kcal/mol difference, which is significant.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp efflux, and affinity are key. Ligand B excels in TPSA and has a reasonable logP. Ligand A has a poor logP but better Pgp efflux and slightly better affinity. The affinity difference is important, but the poor logP of Ligand A is a major concern. The lower DILI risk of Ligand B is also a significant advantage.
**Overall Assessment:**
While Ligand A has slightly better affinity and metabolic stability, the significantly lower logP and higher DILI risk are substantial drawbacks. Ligand B has a more balanced profile, with better TPSA, lower DILI, and an acceptable logP. The slightly weaker affinity is likely outweighed by the improved ADME properties.
Output:
0
2025-04-17 21:42:43,489 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (334.335 Da) is slightly lower, which is generally favorable for permeability.
**2. TPSA:** Ligand B (80.32) is significantly better than Ligand A (104.04). For a GPCR, keeping TPSA low is beneficial for permeability and receptor engagement.
**3. logP:** Both ligands have acceptable logP values (A: 3.484, B: 2.671), falling within the 1-3 range. Ligand B is slightly more hydrophilic, which could be advantageous for solubility.
**4. H-Bond Donors:** Ligand A has 3 HBDs, and Ligand B has 2. Both are within the acceptable limit of 5.
**5. H-Bond Acceptors:** Both ligands have 5 HBAs, which is acceptable (<=10).
**6. QED:** Ligand B (0.74) has a higher QED score than Ligand A (0.532), indicating a more drug-like profile.
**7. DILI Risk:** Ligand B (40.287) has a much lower DILI risk than Ligand A (98.643). This is a critical advantage, as liver toxicity is a major concern in drug development.
**8. BBB Penetration:** Ligand B (65.529) has better BBB penetration than Ligand A (23.42). While ADRB2 isn't exclusively a CNS target, some degree of BBB penetration can be useful, and it's not detrimental.
**9. Caco-2 Permeability:** Ligand A (-5.335) has a worse Caco-2 permeability than Ligand B (-4.668).
**10. Aqueous Solubility:** Ligand A (-4.92) has a worse aqueous solubility than Ligand B (-3.426).
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (A: 0.764, B: 0.267). Ligand B is slightly better.
**12. Microsomal Clearance:** Ligand A (69.614) has a higher microsomal clearance than Ligand B (54.199), meaning it's metabolized more quickly. Lower clearance is preferred.
**13. In vitro Half-Life:** Ligand B (31.143) has a significantly longer in vitro half-life than Ligand A (-21.463). This is a significant advantage for dosing frequency.
**14. P-gp Efflux:** Both ligands have similar P-gp efflux liability (A: 0.213, B: 0.074).
**15. Binding Affinity:** Ligand B (-6.2 kcal/mol) has a slightly better binding affinity than Ligand A (-6.0 kcal/mol), although the difference is small.
**Overall Assessment:**
Ligand B is the superior candidate. While the binding affinity difference is minimal, Ligand B excels in crucial ADME-Tox properties: significantly lower DILI risk, better BBB penetration, improved solubility, longer half-life, and lower clearance. These factors outweigh the slightly lower binding affinity and make Ligand B a much more promising starting point for drug development targeting ADRB2.
Output:
0
2025-04-17 21:42:43,489 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [342.483, 40.62, 2.964, 0, 2, 0.502, 13.959, 59.325, -4.59, -4.668, 0.46, 30.014, -5.952, 0.226, -7.2]
**Ligand B:** [361.873, 62.3, 2.778, 1, 3, 0.896, 31.989, 77.976, -5.047, -3.918, 0.259, 49.543, -2.436, 0.048, -6.9]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity) and general drug-like properties:
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (342.483) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (40.62) is better than Ligand B (62.3), falling well below the 140 threshold for oral absorption. Ligand B is still acceptable, but higher TPSA can sometimes hinder absorption.
3. **logP:** Both are in the optimal range (1-3). Ligand A (2.964) is slightly higher, potentially offering better membrane permeability.
4. **HBD/HBA:** Ligand A (0 HBD, 2 HBA) is preferable to Ligand B (1 HBD, 3 HBA). Lower HBD/HBA generally improves permeability.
5. **QED:** Ligand B (0.896) has a significantly better QED score than Ligand A (0.502), indicating a more drug-like profile overall.
6. **DILI:** Ligand A (13.959) has a much lower DILI risk than Ligand B (31.989), a substantial advantage.
7. **BBB:** Ligand B (77.976) shows better BBB penetration than Ligand A (59.325). While ADRB2 is primarily cardiovascular, some CNS effects are possible with beta-blockers, so some BBB penetration isn't necessarily negative.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.59) is slightly better than Ligand B (-5.047).
9. **Solubility:** Both have negative solubility values, which is also unusual. Ligand B (-3.918) is slightly better than Ligand A (-4.668).
10. **hERG:** Both have low hERG inhibition liability, which is good.
11. **Cl_mic:** Ligand A (30.014) has lower microsomal clearance than Ligand B (49.543), indicating better metabolic stability.
12. **t1/2:** Ligand A (-5.952) has a longer in vitro half-life than Ligand B (-2.436), which is desirable.
13. **Pgp:** Ligand A (0.226) has lower P-gp efflux than Ligand B (0.048), suggesting better oral bioavailability and potentially better CNS exposure.
14. **Affinity:** Ligand A (-7.2 kcal/mol) has a slightly better binding affinity than Ligand B (-6.9 kcal/mol). While the difference is not huge, it's a meaningful advantage.
**Overall Assessment:**
Ligand A presents a more favorable balance of properties, particularly regarding safety (DILI), metabolic stability (Cl_mic, t1/2), permeability (TPSA, HBD/HBA, Pgp) and binding affinity. While Ligand B has a better QED and BBB penetration, the lower DILI risk and better metabolic profile of Ligand A are more critical for a cardiovascular drug candidate. The negative Caco-2 and solubility values are concerning for both, but Ligand A is slightly better in these aspects as well.
Therefore, I prefer Ligand A.
Output:
1
2025-04-17 21:42:43,489 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Ligand A (477.324 Da) is within the ideal range. Ligand B (346.391 Da) is also within range, but closer to the lower limit.
2. **TPSA:** Ligand A (89.43) is good, below the 140 threshold. Ligand B (116.32) is still acceptable, but less optimal.
3. **logP:** Ligand A (1.519) is optimal. Ligand B (-0.599) is slightly low, potentially hindering permeability.
4. **HBD:** Both Ligand A (2) and Ligand B (3) are acceptable.
5. **HBA:** Both Ligand A (5) and Ligand B (5) are acceptable.
6. **QED:** Both Ligand A (0.592) and Ligand B (0.636) are good, indicating drug-likeness.
7. **DILI:** Ligand A (77.898) is moderate, but acceptable. Ligand B (47.15) is better, indicating lower liver injury risk.
8. **BBB:** Ligand A (35.401) is low. Ligand B (63.901) is better, but still not high. Since ADRB2 is a cardiovascular target, BBB penetration isn't *critical*, but some level is helpful for potential off-target effects.
9. **Caco-2:** Both are negative, indicating poor permeability. This is a concern for both.
10. **Solubility:** Both are negative, indicating poor solubility. This is a concern for both.
11. **hERG:** Ligand A (0.474) is better (lower risk) than Ligand B (0.011).
12. **Cl_mic:** Ligand A (51.37) is higher, suggesting faster clearance. Ligand B (-7.281) is *much* lower, indicating excellent metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand A (10.155) is reasonable. Ligand B (13.622) is better, suggesting a longer half-life.
14. **Pgp:** Ligand A (0.371) is better (lower efflux). Ligand B (0.001) is very low.
15. **Affinity:** Ligand A (-6.8 kcal/mol) is slightly better than Ligand B (-6.6 kcal/mol), but the difference is small.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A has a better logP and Pgp, but Ligand B has a significantly better metabolic profile (Cl_mic and t1/2). The affinity difference is small. The poor Caco-2 and solubility for both are concerning, but can potentially be addressed with formulation strategies.
**Overall Assessment:**
While Ligand A has a slightly better affinity and Pgp efflux, Ligand B's superior metabolic stability (Cl_mic and t1/2) and lower DILI risk are more crucial for overall drug development success. The slightly lower logP of Ligand B is a drawback, but not insurmountable.
Output:
0
2025-04-17 21:42:43,489 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (341.298 and 360.401 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (89.86) is slightly higher than Ligand B (78.87), but both are below the 140 threshold for good oral absorption. Given ADRB2 is a cardiovascular target, CNS penetration is not a primary concern, so TPSA is moderately important. Ligand B is slightly favored.
3. **logP:** Both ligands have good logP values (2.606 and 1.766), falling within the optimal 1-3 range. Ligand A is slightly higher, which *could* be beneficial for membrane permeability, but not dramatically so.
4. **HBD:** Ligand A has 1 HBD, while Ligand B has 2. Both are acceptable (<=5).
5. **HBA:** Ligand A has 7 HBA, and Ligand B has 4. Both are within the acceptable range (<=10). Ligand B is favored here.
6. **QED:** Ligand B (0.757) has a significantly better QED score than Ligand A (0.574), indicating a more drug-like profile. This is a notable advantage for Ligand B.
7. **DILI:** Ligand A has a concerningly high DILI risk (87.01 percentile). Ligand B's DILI risk is very low (20.783 percentile). This is a *major* advantage for Ligand B.
8. **BBB:** Both ligands have moderate BBB penetration, but Ligand B (76.347) is better than Ligand A (57.154). While not critical for a cardiovascular target, higher BBB is generally preferable.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5 and -5.284), which is unusual and suggests poor permeability. This is a significant drawback for both.
10. **Solubility:** Ligand A (-4.108) has slightly better solubility than Ligand B (-1.82), but both are poor. Solubility is a concern for both.
11. **hERG:** Both ligands have low hERG inhibition risk (0.437 and 0.362), which is good.
12. **Cl_mic:** Ligand A has a high microsomal clearance (95.739), indicating rapid metabolism. Ligand B has a much lower clearance (-10.841), suggesting better metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand B (1.299 hours) has a slightly longer half-life than Ligand A (-32.667 hours). This is a positive for Ligand B.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.359 and 0.077), which is favorable. Ligand B is slightly better.
15. **Binding Affinity:** Ligand A (-8.1 kcal/mol) has a slightly better binding affinity than Ligand B (-7.4 kcal/mol). While a 0.7 kcal/mol difference is noticeable, it's not a massive advantage, especially considering the other factors.
**Overall Assessment:**
Ligand B is significantly more promising. While Ligand A has slightly better binding affinity and solubility, Ligand B excels in critical ADME properties: much lower DILI risk, better metabolic stability (lower Cl_mic, longer t1/2), a better QED score, and slightly better BBB penetration and Pgp efflux. The poor Caco-2 values are a concern for both, but the other advantages of Ligand B outweigh this drawback. The high DILI risk of Ligand A is a dealbreaker.
Output:
0
2025-04-17 21:42:43,489 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (352.479 Da and 335.415 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (87.47) is slightly higher than Ligand B (62.97). Both are below the 140 A^2 threshold for good oral absorption, but Ligand B is preferable due to its lower TPSA, potentially aiding permeability.
3. **logP:** Both ligands have good logP values (2.187 and 1.375, respectively) falling within the optimal 1-3 range. Ligand B is slightly lower, which could marginally improve solubility, but both are acceptable.
4. **HBD:** Ligand A has 2 HBD, while Ligand B has 0. Both are within the acceptable limit of <=5.
5. **HBA:** Ligand A has 5 HBA, and Ligand B has 7. Both are within the acceptable limit of <=10.
6. **QED:** Both ligands have similar QED values (0.711 and 0.702), indicating good drug-likeness.
7. **DILI:** Ligand A (25.553) has a significantly lower DILI risk than Ligand B (42.846). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (64.676) has a higher BBB penetration percentile than Ligand A (55.215). While ADRB2 isn't exclusively a CNS target, some peripheral ADRB2 activity can be modulated by CNS effects, and higher BBB penetration isn't necessarily detrimental.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.077 and -5.032). This is unusual and suggests poor permeability in this *in vitro* assay. This is a significant concern for both.
10. **Solubility:** Both ligands have negative solubility values (-1.473 and -1.25). This is also concerning, indicating very low aqueous solubility.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.378 and 0.711). This is excellent and minimizes cardiotoxicity risk.
12. **Cl_mic:** Ligand B (11.224) has a much lower microsomal clearance than Ligand A (49.925), indicating better metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand B (-39.054) has a much longer *in vitro* half-life than Ligand A (23.732). This is a substantial benefit for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.034 and 0.029). This is favorable for bioavailability.
15. **Binding Affinity:** Ligand A (-6.2 kcal/mol) has a slightly better binding affinity than Ligand B (-5.8 kcal/mol). This 0.4 kcal/mol difference is noticeable, but not overwhelming.
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B has a lower TPSA and better metabolic stability (lower Cl_mic and longer t1/2). While Ligand A has a slightly better affinity and lower DILI, the metabolic stability and DILI differences are more impactful for overall drug development. The Caco-2 and solubility issues are concerning for both, but can be addressed with formulation strategies.
**Conclusion:**
Considering the balance of properties, Ligand B is the more promising candidate. Its superior metabolic stability, longer half-life, and lower DILI risk outweigh the slightly weaker binding affinity and lower BBB penetration. The similar logP and Pgp profiles contribute to a favorable overall profile.
Output:
0
2025-04-17 21:42:43,489 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
Let's break down the comparison of Ligand A and Ligand B across the 15 parameters, keeping in mind the GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key).
1. **MW:** Both ligands (354.422 and 346.387 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (78.87) is significantly better than Ligand B (98.5). A lower TPSA generally favors better cell permeability, crucial for GPCR targeting.
3. **logP:** Both ligands have similar logP values (0.492 and 0.427), which are slightly below the optimal 1-3 range. This could be a minor concern for permeability, but not a deal-breaker.
4. **HBD:** Both have 2 HBD, which is acceptable.
5. **HBA:** Ligand A has 4 HBA, while Ligand B has 7. Ligand A is preferable here, as fewer HBA generally correlate with better permeability.
6. **QED:** Ligand B (0.719) has a better QED score than Ligand A (0.467), indicating a more generally drug-like profile.
7. **DILI:** Ligand A (12.524) has a much lower DILI risk than Ligand B (61.07). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (68.98) has a better BBB penetration score than Ligand B (23.42). While ADRB2 isn't exclusively a CNS target, some CNS exposure can occur, and higher BBB is generally desirable.
9. **Caco-2:** Ligand A (-4.727) has a worse Caco-2 permeability than Ligand B (-5.244). This is a negative for Ligand A.
10. **Solubility:** Ligand A (-1.573) has better solubility than Ligand B (-1.971).
11. **hERG:** Ligand A (0.347) has a much lower hERG inhibition liability than Ligand B (0.109). This is a major advantage for Ligand A, as hERG inhibition can lead to cardiotoxicity.
12. **Cl_mic:** Ligand A (-12.853) has a much lower microsomal clearance than Ligand B (26.298), indicating better metabolic stability.
13. **t1/2:** Ligand A (3.503) has a slightly longer in vitro half-life than Ligand B (0.064).
14. **Pgp:** Ligand A (0.039) has much lower P-gp efflux liability than Ligand B (0.084), which is favorable for bioavailability.
15. **Affinity:** Ligand B (-7.4 kcal/mol) has a slightly better binding affinity than Ligand A (-7.0 kcal/mol). This is a positive for Ligand B, but the difference is not huge.
**Overall Assessment:**
Despite Ligand B having a slightly better binding affinity and QED, Ligand A is the stronger candidate. The significantly lower DILI risk, hERG inhibition, Pgp efflux, and microsomal clearance, coupled with better TPSA and BBB penetration, outweigh the minor affinity difference and slightly worse Caco-2 permeability. The improved ADME properties of Ligand A suggest a higher probability of success as a drug candidate.
**Output:**
1
2025-04-17 21:42:43,489 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (377.535 Da and 362.543 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (53.51 and 53.92) are below the 140 A^2 threshold for good oral absorption, and are reasonable for a cardiovascular target (not requiring significant BBB penetration). No major difference.
3. **logP:** Ligand A (2.748) is optimal (1-3), while Ligand B (4.193) is slightly higher. While still acceptable, the higher logP of Ligand B could potentially lead to off-target interactions or solubility issues.
4. **HBD:** Ligand A (0) is preferable to Ligand B (1). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (5) and Ligand B (4) are both within the acceptable range (<=10).
6. **QED:** Both ligands have good QED scores (0.778 and 0.803), indicating good drug-like properties.
7. **DILI:** Both ligands have similar, low DILI risk (37.611 and 37.03). This is a positive for both.
8. **BBB:** Ligand A (66.925) has a higher BBB percentile than Ligand B (51.377). While ADRB2 is a cardiovascular target and doesn't *require* high BBB penetration, a higher value isn't detrimental.
9. **Caco-2:** Ligand A (-4.965) and Ligand B (-5.227) both have negative Caco-2 permeability values, which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand A (-1.721) has better solubility than Ligand B (-4.027). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.295) has a much lower hERG risk than Ligand B (0.733). This is a critical advantage for Ligand A, as hERG inhibition can cause cardiotoxicity.
12. **Cl_mic:** Ligand B (78.464) has a higher microsomal clearance than Ligand A (42.306), indicating faster metabolism and potentially lower bioavailability.
13. **t1/2:** Ligand B (45.138) has a significantly longer in vitro half-life than Ligand A (4.054). This is a positive for Ligand B.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.232 and 0.211).
15. **Binding Affinity:** Ligand B (-6.9 kcal/mol) has a slightly better binding affinity than Ligand A (-6.3 kcal/mol). The difference is 0.6 kcal/mol, which is not substantial enough to outweigh other factors.
**Overall Assessment & GPCR Considerations:**
For a GPCR like ADRB2, logP, TPSA, and affinity are important. While Ligand B has slightly better affinity and half-life, Ligand A demonstrates a superior profile in several critical areas: lower logP, better solubility, *significantly* lower hERG risk, and lower microsomal clearance. The poor Caco-2 values for both are concerning, but the other advantages of Ligand A make it the more promising candidate. The lower hERG risk is particularly important for a cardiovascular target.
**Output:**
1
2025-04-17 21:42:43,490 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (373.519 and 391.896 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (87.3) is significantly better than Ligand A (108.29). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (1.554 and 1.926), falling within the 1-3 range. Ligand B is slightly better.
4. **HBD:** Ligand A has 2 HBD, while Ligand B has 3. Both are acceptable (<=5).
5. **HBA:** Ligand A has 5 HBA, while Ligand B has 4. Both are acceptable (<=10).
6. **QED:** Ligand A (0.704) has a higher QED than Ligand B (0.561), indicating a more drug-like profile. This is a significant advantage for Ligand A.
7. **DILI:** Ligand B (52.772) has a slightly higher DILI risk than Ligand A (44.436), but both are reasonably low (below 60).
8. **BBB:** Ligand B (78.79) has a much higher BBB penetration potential than Ligand A (38.542). While not critical for a cardiovascular target, it's a positive attribute.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.114 and -5.18), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Both ligands have negative solubility values (-3.414 and -3.93), suggesting very poor aqueous solubility. This is a major drawback for both.
11. **hERG:** Ligand A (0.468) has a lower hERG inhibition liability than Ligand B (0.681), indicating a lower risk of cardiotoxicity. This is important for a cardiovascular target.
12. **Cl_mic:** Ligand A (40.251) has a lower microsomal clearance than Ligand B (49.422), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-27.065) has a much more negative in vitro half-life than Ligand B (1.518). This is a major negative for Ligand A, suggesting extremely rapid metabolism.
14. **Pgp:** Ligand A (0.026) has a much lower P-gp efflux liability than Ligand B (0.15), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand A (-7.3) has a slightly better binding affinity than Ligand B (-6.8). While the difference is less than 1.5 kcal/mol, it's still a positive.
**Overall Assessment & GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, and affinity are important. Ligand B has slightly better logP and TPSA, and a higher BBB value (though less critical here). However, Ligand A has a better QED, lower DILI, lower hERG, lower Cl_mic, and lower Pgp efflux. The biggest drawback for Ligand A is the extremely short in vitro half-life. The poor Caco-2 and solubility for both are concerning, and would need to be addressed through formulation or prodrug strategies.
Despite the short half-life, the superior overall ADME profile of Ligand A, particularly the lower hERG and Pgp values, and slightly better affinity, make it the more promising starting point. The half-life issue is addressable through chemical modifications. The poor solubility and permeability are more challenging, but the better overall profile of Ligand A provides a stronger foundation for optimization.
Output:
1
2025-04-17 21:42:43,490 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
The target is ADRB2, a GPCR. Therefore, key properties to prioritize are logP, TPSA, Pgp efflux, BBB penetration, and binding affinity. Metabolic stability (Cl_mic, t1/2) and safety (DILI, hERG) are also important, but slightly less so than the first set.
Let's compare the ligands property by property:
1. **MW:** Both ligands (347.415 and 346.387 Da) are within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (75.88) is better than Ligand B (102.74). ADRB2 isn't a CNS target, but lower TPSA generally aids absorption.
3. **logP:** Ligand A (1.264) is within the optimal 1-3 range, while Ligand B (-0.578) is below 1, which could hinder permeation. This is a significant advantage for A.
4. **HBD/HBA:** Both have acceptable HBD (0/1) and HBA (5/5) counts.
5. **QED:** Both are reasonably good (0.802 and 0.737), indicating drug-like properties.
6. **DILI:** Ligand A (29.081) has a much lower DILI risk than Ligand B (48.275). This is a substantial safety advantage for A.
7. **BBB:** Ligand A (76.89) has better BBB penetration than Ligand B (46.064), although BBB isn't a primary concern for ADRB2.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, and the negative values may not be directly comparable.
9. **Solubility:** Both have negative solubility values, which is also unusual and suggests poor solubility. Again, the scale is not specified.
10. **hERG:** Both have low hERG risk (0.094 and 0.114).
11. **Cl_mic:** Ligand B (-17.681) has a *negative* microsomal clearance, which is not physically possible. This is a red flag suggesting a data error or a highly unusual compound behavior. Ligand A (19.689) is more reasonable.
12. **t1/2:** Ligand B (24.579) has a longer half-life than Ligand A (17.479), which is a slight advantage.
13. **Pgp:** Both have low Pgp efflux liability (0.036 and 0.011).
14. **Binding Affinity:** Ligand A (-5.5 kcal/mol) has a slightly stronger binding affinity than Ligand B (-3.2 kcal/mol). This is a significant advantage.
**Overall Assessment:**
Ligand A is clearly the superior candidate. It has a better logP, lower DILI risk, better BBB penetration, and a stronger binding affinity. The negative values for Caco-2 and solubility are concerning for both, but the negative microsomal clearance for Ligand B is a major issue, likely indicating a data error. The slightly longer half-life of Ligand B is not enough to offset the other significant advantages of Ligand A.
**Output:**
1
2025-04-17 21:42:43,490 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [352.36 , 61.02 , 4.278, 2. , 2. , 0.863, 52.579, 85.576, -4.707, -5.124, 0.611, 36.725, -14.354, 0.279, -6.6 ]
**Ligand B:** [354.382, 100.09 , -0.049, 1. , 5. , 0.772, 32.842, 70.531, -5.144, -1.341, 0.287, -29.517, 5.783, 0.019, -6.6 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). A: 352.36, B: 354.382 - very similar.
2. **TPSA:** Ligand A (61.02) is significantly better than Ligand B (100.09). GPCRs benefit from lower TPSA for better brain penetration and membrane permeability. Ligand A is well below the 140 threshold, while B is approaching it.
3. **logP:** Ligand A (4.278) is higher than Ligand B (-0.049). While both are within the acceptable range, A is getting towards the upper limit. B is very close to 0, which could cause permeability issues.
4. **HBD:** Both are acceptable (A: 2, B: 1).
5. **HBA:** Both are acceptable (A: 2, B: 5).
6. **QED:** Both are good (A: 0.863, B: 0.772), indicating good drug-like properties.
7. **DILI:** Ligand B (32.842) has a much lower DILI risk than Ligand A (52.579). This is a significant advantage for B.
8. **BBB:** Ligand A (85.576) has a higher BBB penetration potential than Ligand B (70.531). While not a primary concern for a cardiovascular target, it's a slight positive for A.
9. **Caco-2:** Ligand A (-4.707) and B (-5.144) both have negative values, indicating poor permeability.
10. **Solubility:** Ligand A (-5.124) has slightly better solubility than Ligand B (-1.341).
11. **hERG:** Both are very low (A: 0.611, B: 0.287), indicating low cardiotoxicity risk. B is slightly better.
12. **Cl_mic:** Ligand B (-29.517) has significantly lower microsomal clearance than Ligand A (36.725), suggesting better metabolic stability. This is a major advantage for B.
13. **t1/2:** Ligand B (5.783) has a longer in vitro half-life than Ligand A (-14.354). This is a further advantage for B.
14. **Pgp:** Both are very low (A: 0.279, B: 0.019), indicating low P-gp efflux. B is slightly better.
15. **Affinity:** Both have the same binding affinity (-6.6 kcal/mol).
**Overall Assessment:**
While Ligand A has slightly better BBB penetration and solubility, Ligand B is superior in almost every other critical parameter. Specifically, the significantly lower DILI risk, much better metabolic stability (lower Cl_mic, longer t1/2), and slightly better hERG profile of Ligand B are compelling. The lower TPSA of Ligand A is a benefit, but the other advantages of B outweigh this. The Caco-2 permeability is poor for both, but this is something that can be addressed with formulation strategies. Given the GPCR target class and the importance of ADME properties, Ligand B is the more promising candidate.
Output:
0
2025-04-17 21:42:43,490 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, key priorities are logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB.
Let's compare the ligands property by property:
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (352.4) is slightly higher than Ligand B (345.4), but this isn't a major concern.
2. **TPSA:** Ligand A (76.7) is significantly better than Ligand B (109.9). Lower TPSA generally favors oral absorption and GPCR penetration.
3. **logP:** Both are good (Ligand A: 2.085, Ligand B: 1.175), falling within the 1-3 optimal range. Ligand A is slightly more lipophilic, which could be beneficial for membrane permeability.
4. **HBD/HBA:** Ligand A (HBD=2, HBA=4) is slightly more favorable than Ligand B (HBD=1, HBA=6). Both are acceptable.
5. **QED:** Both are similar and good (Ligand A: 0.632, Ligand B: 0.624).
6. **DILI:** Ligand A (40.9) is significantly better than Ligand B (64.3). Lower DILI risk is crucial.
7. **BBB:** Ligand A (88.3) is better than Ligand B (77.8), although BBB isn't a primary concern for a cardiovascular target.
8. **Caco-2:** Ligand A (-4.76) is better than Ligand B (-5.025), indicating better intestinal absorption.
9. **Solubility:** Ligand A (-2.764) is better than Ligand B (-3.552).
10. **hERG:** Both are very low risk (Ligand A: 0.422, Ligand B: 0.195).
11. **Cl_mic:** Ligand A (28.2) is better than Ligand B (34.1). Lower clearance is preferred.
12. **t1/2:** Ligand A (11.3) is significantly better than Ligand B (3.2).
13. **Pgp:** Ligand A (0.107) is better than Ligand B (0.055), meaning less P-gp efflux.
14. **Binding Affinity:** Ligand A (-7.0) is slightly better than Ligand B (-4.2). A 2.8 kcal/mol difference is substantial and can outweigh minor ADME drawbacks.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical parameters, including TPSA, DILI, BBB, solubility, metabolic stability (Cl_mic and t1/2), Pgp efflux, and crucially, binding affinity. While both ligands have acceptable logP and hERG values, the superior profile of Ligand A makes it the more promising drug candidate for ADRB2.
**Output:**
1
2025-04-17 21:42:43,490 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, priorities are affinity, logP, TPSA, Pgp, and BBB.
* **Molecular Weight:** Both ligands (364.5 and 368.5 Da) are within the ideal 200-500 Da range.
* **TPSA:** Ligand A (58.64) is significantly better than Ligand B (87.76). A TPSA under 140 is good for oral absorption, but lower is preferred for GPCRs, and A is much closer to the ideal range.
* **logP:** Ligand A (2.38) is optimal (1-3), while Ligand B (0.361) is quite low, potentially hindering membrane permeability.
* **H-Bond Donors/Acceptors:** Both have acceptable HBD (1) and HBA (4 for A, 6 for B) values.
* **QED:** Ligand A (0.873) has a better QED score than Ligand B (0.667), indicating a more drug-like profile.
* **DILI:** Ligand A (12.485) has a much lower DILI risk than Ligand B (51.26), a significant advantage.
* **BBB:** Both have reasonable BBB penetration (69.7% and 64.9%), but neither is exceptionally high. This is less critical for a cardiovascular target.
* **Caco-2:** Both have negative Caco-2 values, which is unusual. I will interpret these as very low permeability.
* **Solubility:** Both have negative solubility values, which is also unusual. I will interpret these as very low solubility.
* **hERG:** Both have low hERG inhibition risk (0.496 and 0.375).
* **Cl_mic:** Ligand A (37.4) has a higher microsomal clearance than Ligand B (18.9), suggesting lower metabolic stability.
* **t1/2:** Ligand B (-21.852) has a significantly longer in vitro half-life than Ligand A (10.764). This is a substantial benefit.
* **Pgp:** Ligand A (0.157) has lower P-gp efflux liability than Ligand B (0.022), which is favorable for bioavailability.
* **Binding Affinity:** Ligand B (-7.1 kcal/mol) has a slightly better binding affinity than Ligand A (-6.1 kcal/mol). This is a 1 kcal/mol difference, which is significant but not overwhelming.
**Overall Assessment:**
Ligand A is clearly superior. While Ligand B has a slightly better binding affinity and a much longer half-life, Ligand A excels in crucial ADME properties like TPSA, logP, QED, and especially DILI risk. The lower logP and higher TPSA of Ligand B are concerning for permeability and overall drug-likeness. The significantly lower DILI risk of Ligand A is a major factor in its favor, as liver toxicity is a common issue in drug development. The better Pgp profile of A also contributes to its overall advantage.
Output:
1
2025-04-17 21:42:43,490 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (432.296 Da) is slightly higher than Ligand B (346.475 Da), but both are acceptable.
**2. TPSA:** Ligand A (99.52) is higher than Ligand B (78.09). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for permeability. Ligand B has a more favorable TPSA.
**3. logP:** Both ligands have similar and optimal logP values (A: 2.234, B: 2.276), falling within the 1-3 range.
**4. H-Bond Donors:** Ligand A (1) is better than Ligand B (2). Fewer HBDs generally improve permeability.
**5. H-Bond Acceptors:** Ligand A (7) is higher than Ligand B (3). Lower HBA is preferable for permeability. Ligand B is significantly better here.
**6. QED:** Both ligands have good QED values (A: 0.674, B: 0.776), indicating good drug-like properties. Ligand B is slightly better.
**7. DILI Risk:** Ligand A (91.47) has a significantly higher DILI risk than Ligand B (25.436). This is a major concern for Ligand A.
**8. BBB Penetration:** Both have moderate BBB penetration, but Ligand B (58.821) is slightly better than Ligand A (51.803). While not a primary concern for a cardiovascular target, some level of BBB penetration can indicate broader distribution.
**9. Caco-2 Permeability:** Ligand B (-5.37) is better than Ligand A (-4.911). Higher (less negative) Caco-2 values indicate better intestinal absorption.
**10. Aqueous Solubility:** Ligand B (-2.18) is better than Ligand A (-3.332). Higher solubility is generally desirable.
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (A: 0.407, B: 0.413), which is good.
**12. Microsomal Clearance:** Ligand A (51.725) has higher microsomal clearance than Ligand B (26.244), indicating lower metabolic stability.
**13. In vitro Half-Life:** Ligand B (-27.421) has a much longer in vitro half-life than Ligand A (11.908), which is a significant advantage.
**14. P-gp Efflux:** Both ligands have similar P-gp efflux liability (A: 0.378, B: 0.241).
**15. Binding Affinity:** Ligand B (-7.0) has a slightly better binding affinity than Ligand A (-6.7). While the difference is not huge, it is still a factor.
**Overall Assessment:**
Ligand B is significantly better overall. While Ligand A has a slightly better HBD count, Ligand B excels in almost all other critical parameters, including DILI risk, solubility, permeability, metabolic stability (half-life and clearance), and binding affinity. The lower DILI risk for Ligand B is a particularly important factor. Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity), Ligand B is the stronger candidate.
Output:
0
2025-04-17 21:42:43,490 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (351.466 Da) is within the ideal range (200-500 Da). Ligand B (408.888 Da) is also acceptable, but closer to the upper limit.
2. **TPSA:** Ligand A (73.2) is excellent, well below the 140 threshold for good absorption. Ligand B (84.5) is still reasonable, but less optimal.
3. **logP:** Both ligands (A: 2.952, B: 3.22) are within the optimal 1-3 range.
4. **HBD:** Ligand A (1) is preferred over Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (3) is better than Ligand B (5). Fewer HBA is generally preferred for permeability.
6. **QED:** Both ligands are similar (A: 0.649, B: 0.613) and above the 0.5 threshold, indicating good drug-likeness.
7. **DILI:** Ligand A (16.906) has a significantly lower DILI risk than Ligand B (46.724). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (89.725) has a much higher BBB penetration potential than Ligand B (68.748). While ADRB2 isn't exclusively a CNS target, some CNS exposure can occur, and higher BBB is generally favorable.
9. **Caco-2:** Ligand A (-4.723) is better than Ligand B (-5.03), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-3.363) is better than Ligand B (-3.785), indicating better aqueous solubility.
11. **hERG:** Ligand A (0.843) has a lower hERG inhibition liability than Ligand B (0.517), which is a safety advantage.
12. **Cl_mic:** Ligand A (41.494) has lower microsomal clearance than Ligand B (50.834), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-11.769) has a much longer in vitro half-life than Ligand B (21.165). This is a significant advantage for dosing convenience.
14. **Pgp:** Ligand A (0.302) has lower P-gp efflux liability than Ligand B (0.099), which is a positive for bioavailability.
15. **Affinity:** Ligand A (-7.8 kcal/mol) has a slightly better binding affinity than Ligand B (-5.1 kcal/mol). This difference of 2.7 kcal/mol is substantial and can outweigh some minor ADME drawbacks.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Both ligands are good in terms of logP and TPSA. Ligand A is better in terms of Pgp efflux. However, the biggest differentiator is the significantly stronger binding affinity of Ligand A.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most ADME properties (DILI, BBB, solubility, hERG, Cl_mic, t1/2, Pgp) and has a substantially better binding affinity. While Ligand B isn't terrible, Ligand A presents a much more favorable profile for drug development.
Output:
1
2025-04-17 21:42:43,491 - INFO - Batch 278 complete. Total preferences: 4448
2025-04-17 21:42:43,491 - INFO - Processing batch 279/512...
2025-04-17 21:43:35,184 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (363.889 Da) is within the ideal range (200-500 Da). Ligand B (349.37 Da) is also within the ideal range. No clear advantage here.
2. **TPSA:** Ligand A (52.65) is excellent, well below the 140 threshold for oral absorption. Ligand B (97.94) is higher but still acceptable, though less optimal. Ligand A is preferred.
3. **logP:** Ligand A (4.23) is slightly high, potentially leading to solubility issues or off-target effects. Ligand B (-0.135) is too low, suggesting poor membrane permeability. Ligand A is preferred, despite being a bit high.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 2 HBA, which is good. Ligand B has 7 HBA, which is higher and could negatively affect permeability. Ligand A is preferred.
6. **QED:** Ligand A (0.851) is excellent, indicating strong drug-likeness. Ligand B (0.751) is still good, but lower. Ligand A is preferred.
7. **DILI:** Ligand A (37.728) has a lower DILI risk than Ligand B (53.393). Ligand A is preferred.
8. **BBB:** Ligand A (96.2) shows excellent BBB penetration, which is beneficial for a GPCR target. Ligand B (64.482) is lower, indicating less penetration. Ligand A is strongly preferred.
9. **Caco-2:** Ligand A (-4.37) and Ligand B (-5.163) both have negative values, indicating poor permeability. This is unusual and requires further investigation, but it doesn't immediately disqualify either.
10. **Solubility:** Ligand A (-5.014) has poor solubility, which is a concern given its already high logP. Ligand B (-1.45) is better, but still not great. Ligand B is slightly preferred here.
11. **hERG:** Ligand A (0.856) has a lower hERG risk than Ligand B (0.336). Ligand A is preferred.
12. **Cl_mic:** Ligand A (32.091) has a higher, less favorable, microsomal clearance than Ligand B (17.431). Ligand B is preferred.
13. **t1/2:** Ligand A (12.245 hours) has a longer half-life than Ligand B (-12.258 hours). Ligand A is strongly preferred.
14. **Pgp:** Ligand A (0.277) has lower P-gp efflux than Ligand B (0.025). Ligand A is preferred.
15. **Affinity:** Both ligands have very similar binding affinities (-6.0 and -5.7 kcal/mol). The difference is not substantial enough to be a deciding factor.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity) and the general drug-likeness criteria, Ligand A is significantly more promising. While its logP and solubility are concerns, its superior TPSA, BBB penetration, QED, DILI risk, hERG risk, Pgp efflux, and half-life outweigh these drawbacks. Ligand B's low logP is a major issue for permeability, and its higher DILI risk and lower BBB penetration are also unfavorable.
Output:
1
2025-04-17 21:43:35,185 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.431 and 352.387 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (75.88) is significantly better than Ligand B (105.17). For a GPCR, keeping TPSA lower is beneficial for permeability. Ligand B is approaching the upper limit for good oral absorption.
3. **logP:** Ligand A (1.582) is within the optimal range (1-3), while Ligand B (-0.942) is slightly below. While not a hard cutoff, a logP below 1 can sometimes indicate permeability issues.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer hydrogen bond donors generally improve membrane permeability.
5. **HBA:** Ligand A (5) is better than Ligand B (6). Again, lower is generally preferred for permeability.
6. **QED:** Ligand A (0.828) has a better QED score than Ligand B (0.502), indicating a more drug-like profile.
7. **DILI:** Both ligands have acceptable DILI risk (Ligand A: 42.885, Ligand B: 32.028). Ligand B is slightly better, but both are well below the 60% threshold.
8. **BBB:** Ligand A (75.688) has a significantly higher BBB penetration percentile than Ligand B (45.754). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be helpful for distribution and off-target profiling.
9. **Caco-2:** Ligand A (-4.416) and Ligand B (-4.884) are both poor, indicating low intestinal absorption. This is a concern for both.
10. **Solubility:** Ligand A (-1.06) and Ligand B (-0.975) are similar and both indicate poor aqueous solubility. This could present formulation challenges.
11. **hERG:** Both ligands have very low hERG inhibition risk (Ligand A: 0.316, Ligand B: 0.136). This is excellent.
12. **Cl_mic:** Ligand B (-9.191) has a *much* lower (better) microsomal clearance than Ligand A (31.845). This suggests significantly improved metabolic stability for Ligand B.
13. **t1/2:** Ligand B (-10.385) has a longer in vitro half-life than Ligand A (-25.059), further supporting its better metabolic stability.
14. **Pgp:** Both ligands have low P-gp efflux liability (Ligand A: 0.141, Ligand B: 0.098).
15. **Binding Affinity:** Ligand A (-6.7) has a slightly better binding affinity than Ligand B (-6.4). While the difference is not huge, it's still a factor.
**Overall Assessment:**
Ligand A has advantages in binding affinity, QED, and BBB penetration. However, Ligand B demonstrates superior metabolic stability (lower Cl_mic, longer t1/2) and a slightly lower DILI risk. The lower TPSA and HBD/HBA counts of Ligand A are also favorable. The Caco-2 and solubility are poor for both, which would need to be addressed in further development.
Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity), and the importance of metabolic stability for *in vivo* efficacy, the improved metabolic profile of Ligand B is a significant advantage. The slight difference in binding affinity is likely outweighed by the better ADME properties of Ligand B.
Output:
0
2025-04-17 21:43:35,185 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's systematically compare Ligand A and Ligand B based on the provided parameters and the guidelines, keeping in mind that ADRB2 is a GPCR. Therefore, logP, TPSA, Pgp, BBB, and affinity are particularly important.
1. **Molecular Weight:** Both ligands (361.873 and 386.949 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (65.2) is better than Ligand B (74.33). Lower TPSA generally improves membrane permeability.
3. **logP:** Both ligands have good logP values (3.651 and 2.684), falling within the optimal 1-3 range. Ligand A is slightly higher, which *could* be a minor concern for solubility, but is still acceptable.
4. **H-Bond Donors:** Both have 2 HBD, which is within the acceptable limit of 5.
5. **H-Bond Acceptors:** Ligand A has 2 HBA, while Ligand B has 5. Ligand A is preferable here, as lower HBA generally improves permeability.
6. **QED:** Both ligands have reasonable QED scores (0.872 and 0.755), indicating good drug-like properties.
7. **DILI:** Ligand B (54.866) has a lower DILI risk than Ligand A (64.288), which is a significant advantage.
8. **BBB:** Ligand A (70.764) has a significantly better BBB penetration score than Ligand B (51.842). While ADRB2 isn't exclusively a CNS target, some peripheral ADRB2 activity can be modulated by CNS effects, and better BBB penetration is generally favorable.
9. **Caco-2 Permeability:** Both have negative values, indicating poor permeability. Ligand A (-4.916) is slightly better than Ligand B (-5.158), but both are poor.
10. **Aqueous Solubility:** Ligand A (-4.789) is slightly better than Ligand B (-2.465), but both are poor.
11. **hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.729 and 0.235).
12. **Microsomal Clearance:** Ligand B (-5.813) has a *much* lower (better) microsomal clearance than Ligand A (33.599). This suggests significantly improved metabolic stability for Ligand B.
13. **In vitro Half-Life:** Ligand B (59.91) has a considerably longer in vitro half-life than Ligand A (32.597). This is a major advantage.
14. **P-gp Efflux:** Both ligands have low P-gp efflux liability (0.415 and 0.213).
15. **Binding Affinity:** Ligand B (-7.1) has slightly better binding affinity than Ligand A (-7.0). While the difference is small, it's still a positive for Ligand B.
**Overall Assessment:**
Ligand B demonstrates a superior ADME profile, particularly with its significantly lower microsomal clearance and longer half-life. The slightly better DILI score is also a significant benefit. While Ligand A has a slightly better BBB score and TPSA, the improvements in metabolic stability and safety profile for Ligand B outweigh these minor advantages. The affinity difference is minimal.
**Output:**
0
2025-04-17 21:43:35,185 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [366.487, 117.34 , 0.711, 4. , 6. , 0.565, 60.721, 54.634, -5.594, -3.023, 0.268, 25.894, -4.516, 0.015, -8.2 ]
**Ligand B:** [368.845, 51.55 , 4.356, 0. , 5. , 0.509, 87.282, 62.699, -4.547, -5.87 , 0.366, 87.578, -19.053, 0.487, -7. ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). A: 366.49, B: 368.85 - very similar.
2. **TPSA:** A: 117.34, B: 51.55. Ligand B is significantly better, being well below the 140 threshold for oral absorption and closer to the ideal for GPCRs.
3. **logP:** A: 0.711, B: 4.356. Ligand B is better, falling within the optimal 1-3 range. Ligand A is a bit low and might have permeability issues.
4. **HBD:** A: 4, B: 0. Ligand B is better. Fewer HBDs generally improve permeability.
5. **HBA:** A: 6, B: 5. Both are acceptable, below the 10 threshold.
6. **QED:** A: 0.565, B: 0.509. Both are above 0.5, indicating good drug-like properties, A is slightly better.
7. **DILI:** A: 60.721, B: 87.282. Ligand A is *much* better here, with a significantly lower DILI risk. This is a major concern for Ligand B.
8. **BBB:** A: 54.634, B: 62.699. Ligand B is slightly better, but both are not particularly high. For a cardiovascular target, BBB penetration isn't a primary concern, but it's still a plus.
9. **Caco-2:** A: -5.594, B: -4.547. Both are negative, indicating poor permeability. B is slightly better.
10. **Solubility:** A: -3.023, B: -5.87. Ligand A is better, indicating slightly better solubility.
11. **hERG:** A: 0.268, B: 0.366. Ligand A has a lower hERG risk, which is crucial for cardiovascular drugs.
12. **Cl_mic:** A: 25.894, B: 87.578. Ligand A has significantly lower microsomal clearance, suggesting better metabolic stability.
13. **t1/2:** A: -4.516, B: -19.053. Ligand A has a better (less negative) in vitro half-life, suggesting better stability.
14. **Pgp:** A: 0.015, B: 0.487. Ligand A has much lower P-gp efflux, which is favorable for bioavailability.
15. **Affinity:** A: -8.2, B: -7.0. Ligand A has a significantly stronger binding affinity. This is a substantial advantage.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, and affinity. Ligand B has a better logP and TPSA, but Ligand A *dominates* in affinity and has much better Pgp efflux and significantly lower DILI and better metabolic stability. The affinity difference (-8.2 vs -7.0) is substantial and likely outweighs the slightly better TPSA and logP of Ligand B. The DILI risk for Ligand B is a serious red flag.
**Conclusion:**
Despite Ligand B having slightly better TPSA and logP, Ligand A is the far superior candidate due to its significantly higher binding affinity, lower DILI risk, better metabolic stability, lower P-gp efflux, and better hERG profile.
```
1
```
2025-04-17 21:43:35,185 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (336.443) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (60.56) is significantly better than Ligand B (97.55). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary goal, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (3.485) is slightly higher than Ligand B (1.817), placing it closer to the optimal range of 1-3. Ligand B is on the lower side, potentially hindering permeation.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Both ligands have the same number of HBA (6), which is acceptable.
6. **QED:** Both ligands have similar QED values (0.775 and 0.765), indicating good drug-likeness.
7. **DILI:** Ligand B (45.25) has a significantly lower DILI risk than Ligand A (62.66), which is a major advantage.
8. **BBB:** Both ligands have similar BBB penetration (79.256 and 78.558), which isn't a critical factor for a cardiovascular target.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the values are very similar (-5.142 vs -5.158).
10. **Solubility:** Both ligands have negative solubility values, which is also unusual and suggests poor solubility. The values are very similar (-3.338 vs -2.339).
11. **hERG:** Both ligands have low hERG inhibition risk (0.581 and 0.536).
12. **Cl_mic:** Ligand B (15.697) has a much lower microsomal clearance than Ligand A (34.876), indicating better metabolic stability.
13. **t1/2:** Ligand B (8.569) has a longer in vitro half-life than Ligand A (5.875), which is desirable.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.489 and 0.206).
15. **Binding Affinity:** Ligand B (-5.6 kcal/mol) has a slightly better binding affinity than Ligand A (-4.5 kcal/mol). This 1.1 kcal/mol difference is significant and can outweigh some ADME drawbacks.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand A has a better logP and slightly lower TPSA, but Ligand B has a superior binding affinity and significantly better metabolic stability (lower Cl_mic and longer t1/2) and lower DILI risk. The affinity difference is substantial.
**Overall Assessment:**
While Ligand A has some favorable properties (slightly better logP and TPSA), Ligand B's significantly better binding affinity, lower DILI risk, and improved metabolic stability (lower Cl_mic and longer t1/2) make it the more promising candidate. The similar Caco-2 and solubility values are concerning for both, but these can be addressed with formulation strategies.
Output:
0
2025-04-17 21:43:35,185 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for the ADRB2, a cardiovascular GPCR. Therefore, logP, TPSA, Pgp efflux, and binding affinity are particularly important.
Let's break down the comparison:
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (340.423) is slightly lower than Ligand B (362.25), which is generally favorable.
2. **TPSA:** Ligand A (53.35) is better than Ligand B (56.51) as it is closer to the <140 threshold for good oral absorption.
3. **logP:** Ligand A (2.829) is optimal (1-3), while Ligand B (4.664) is pushing the upper limit and could potentially lead to solubility issues or off-target interactions.
4. **HBD/HBA:** Both ligands have acceptable HBD (0) and HBA (5/4) counts.
5. **QED:** Ligand A (0.786) has a significantly better QED score than Ligand B (0.441), indicating a more drug-like profile.
6. **DILI:** Both ligands have DILI risk above the 40 threshold, but Ligand B (67.119) is higher than Ligand A (56.107).
7. **BBB:** Both have good BBB penetration, but Ligand A (90.074) is slightly better than Ligand B (83.055). While not a primary concern for a cardiovascular target, higher BBB is rarely detrimental.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the values are close enough that this isn't a major differentiator.
9. **Solubility:** Both have negative solubility values, indicating poor aqueous solubility. Ligand B (-4.297) is slightly worse than Ligand A (-3.463).
10. **hERG:** Both have low hERG inhibition liability.
11. **Cl_mic:** Ligand A (68.749) has lower microsomal clearance than Ligand B (71.214), suggesting better metabolic stability.
12. **t1/2:** Ligand B (45.142) has a much longer half-life than Ligand A (-14.686). This is a significant advantage for dosing convenience.
13. **Pgp:** Both have low Pgp efflux liability.
14. **Binding Affinity:** Ligand B (-7.2) has a slightly better binding affinity than Ligand A (-7.0), but the difference is relatively small (0.2 kcal/mol).
**Overall Assessment:**
Ligand A is preferable. While Ligand B has a better binding affinity and half-life, Ligand A excels in crucial ADME properties like logP, TPSA, QED, and DILI risk. The slightly better logP and TPSA of Ligand A are particularly important for a GPCR target, increasing the likelihood of good absorption and target engagement. The QED score is also a strong indicator of overall drug-likeness. The difference in binding affinity is not substantial enough to outweigh the ADME advantages of Ligand A.
**Output:**
1
2025-04-17 21:43:35,185 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.5 and 341.5 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (56.15) is better than Ligand B (64.92). Both are below the 140 threshold for oral absorption, but lower TPSA is generally preferred for GPCRs, potentially aiding in receptor penetration.
3. **logP:** Ligand B (4.469) is higher than Ligand A (3.235). While both are above the optimal 1-3 range, Ligand B is pushing the limit where solubility issues could arise. Ligand A is closer to the ideal.
4. **HBD:** Ligand A (1) is better than Ligand B (2). Lower HBD is generally favorable for permeability.
5. **HBA:** Ligand A (4) is better than Ligand B (2). Lower HBA is generally favorable for permeability.
6. **QED:** Ligand B (0.83) is better than Ligand A (0.661). Higher QED suggests better overall drug-likeness.
7. **DILI:** Ligand A (15.394) is significantly better than Ligand B (23.187). Lower DILI risk is crucial.
8. **BBB:** Both ligands have good BBB penetration (76.35% and 77.47%). This is good, but not a major differentiator.
9. **Caco-2:** Ligand A (-4.836) is better than Ligand B (-4.282). Higher Caco-2 permeability suggests better absorption.
10. **Solubility:** Ligand A (-2.488) is better than Ligand B (-4.627). Better solubility is important for bioavailability.
11. **hERG:** Ligand A (0.551) is better than Ligand B (0.766). Lower hERG inhibition is critical for avoiding cardiotoxicity, especially important for a cardiovascular target like ADRB2.
12. **Cl_mic:** Ligand B (32.638) is significantly better than Ligand A (60.747). Lower clearance indicates better metabolic stability.
13. **t1/2:** Ligand B (9.718) is better than Ligand A (8.13). Longer half-life is generally desirable.
14. **Pgp:** Ligand A (0.58) is better than Ligand B (0.164). Lower P-gp efflux is favorable for bioavailability.
15. **Affinity:** Ligand A (-6.9 kcal/mol) is better than Ligand B (-6.1 kcal/mol). A 0.8 kcal/mol difference in binding affinity is substantial and can outweigh some ADME concerns.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has better TPSA, Pgp, and affinity. Ligand B has a slightly worse logP but better metabolic stability (Cl_mic and t1/2). However, the significant advantage in binding affinity for Ligand A, coupled with the lower DILI and hERG risk, makes it the more promising candidate. The slightly higher metabolic clearance of Ligand A can be addressed through structural modifications during optimization.
Output:
1
2025-04-17 21:43:35,185 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (341.371 Da) is well within the ideal range (200-500 Da). Ligand B (387.527 Da) is also acceptable. No clear advantage here.
2. **TPSA:** Ligand A (126.88) is slightly above the preferred <140 for good oral absorption, but still reasonable. Ligand B (96.44) is excellent, well below 140, suggesting better absorption potential. **Advantage: B**
3. **logP:** Ligand A (-0.185) is a bit low, potentially hindering membrane permeability. Ligand B (0.161) is closer to the optimal 1-3 range. **Advantage: B**
4. **HBD:** Ligand A (4) is acceptable. Ligand B (1) is better, minimizing potential for off-target interactions and improving permeability. **Advantage: B**
5. **HBA:** Ligand A (4) is acceptable. Ligand B (6) is also within the reasonable limit of 10. No significant difference.
6. **QED:** Ligand A (0.405) is below the preferred threshold of 0.5, indicating a less drug-like profile. Ligand B (0.716) is excellent, suggesting a strong drug-like profile. **Advantage: B**
7. **DILI:** Ligand A (61.846) is moderately high, indicating a potential liver toxicity risk. Ligand B (43.35) is much lower and more desirable. **Advantage: B**
8. **BBB:** Ligand A (19.038) has very low BBB penetration. Ligand B (53.974) is better, but still not high enough to be a major advantage for a non-CNS target like ADRB2.
9. **Caco-2:** Both ligands have similar, poor Caco-2 permeability (-5.48 and -5.372). This suggests potential absorption issues for both.
10. **Solubility:** Both ligands have poor aqueous solubility (-3.038 and -1.554). This is a concern for both, but Ligand B is slightly better.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.148 and 0.118). No significant difference.
12. **Cl_mic:** Ligand A (-13.314) has a much lower (better) microsomal clearance than Ligand B (1.449), indicating greater metabolic stability. **Advantage: A**
13. **t1/2:** Ligand A (13.065) has a longer in vitro half-life than Ligand B (0.261). This is a significant advantage. **Advantage: A**
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.037 and 0.033). No significant difference.
15. **Binding Affinity:** Ligand B (-7.8 kcal/mol) has a 0.7 kcal/mol stronger binding affinity than Ligand A (-7.1 kcal/mol). This is a substantial difference and a major factor. **Advantage: B**
**Overall Assessment:**
For a GPCR like ADRB2, logP, TPSA, and affinity are key. Ligand B excels in TPSA, logP, QED, DILI and significantly in binding affinity. While Ligand A has better metabolic stability (Cl_mic) and half-life, the superior binding affinity and more favorable ADME properties of Ligand B outweigh these advantages. The stronger binding of Ligand B is likely to translate to greater efficacy, and the better ADME profile suggests a higher probability of success.
Output:
0
2025-04-17 21:43:35,185 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (335.451 Da) is better than Ligand B (374.547 Da). Both are within the ideal range, but A is closer to the lower, preferred end.
2. **TPSA:** Ligand A (45.23) is significantly better than Ligand B (83.55). ADRB2 is a cardiovascular target, not a CNS target, but lower TPSA generally improves absorption. Ligand B's TPSA is getting high and could be problematic.
3. **logP:** Ligand A (3.289) is slightly higher than Ligand B (1.989). Both are within the optimal range, but A is closer to the upper limit.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A (2) is better than Ligand B (4). Lower HBA is generally preferred for permeability.
6. **QED:** Ligand A (0.789) is slightly better than Ligand B (0.704). Both are above the 0.5 threshold, indicating good drug-likeness.
7. **DILI:** Ligand B (27.142) is better than Ligand A (32.571). Both are below the 40 threshold, indicating low risk.
8. **BBB:** Ligand A (71.733) is slightly better than Ligand B (68.941). While not a CNS target, higher BBB is not detrimental.
9. **Caco-2:** Ligand A (-4.483) is better than Ligand B (-5.037). Higher (less negative) Caco-2 values indicate better absorption.
10. **Solubility:** Ligand A (-3.534) is better than Ligand B (-2.69). Higher solubility is preferred.
11. **hERG:** Ligand A (0.619) is better than Ligand B (0.34). Lower hERG inhibition is crucial for avoiding cardiotoxicity, especially for a cardiovascular target.
12. **Cl_mic:** Ligand B (16.49) is significantly better than Ligand A (36.666). Lower clearance indicates better metabolic stability.
13. **t1/2:** Ligand A (24.977) is better than Ligand B (4.65). Longer half-life is generally desirable.
14. **Pgp:** Ligand A (0.085) is better than Ligand B (0.133). Lower P-gp efflux is preferred.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-5.7 and -5.6 kcal/mol). The difference is negligible.
**GPCR-specific priorities:** For ADRB2, logP, TPSA, Pgp, and affinity are important. Ligand A excels in logP, TPSA, and Pgp. While both have similar affinity, Ligand A has a better overall profile. The biggest drawback for Ligand A is its higher Cl_mic, but the improvements in TPSA, solubility, and hERG risk are more critical for this cardiovascular target.
**Conclusion:**
Considering the balance of properties and the priorities for a cardiovascular GPCR target, Ligand A is the more promising candidate.
Output:
1
2025-04-17 21:43:35,186 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (359.461 & 347.459 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (52.65) is significantly better than Ligand B (84.66). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (2.137 & 2.434), falling within the 1-3 range. Ligand B is slightly higher, which could be a minor concern for solubility, but not a dealbreaker.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (4). Similar to HBD, lower HBA is generally better.
6. **QED:** Both ligands have similar QED values (0.608 & 0.672), indicating good drug-likeness.
7. **DILI:** Ligand A (12.33) is *much* better than Ligand B (43.971). This is a significant advantage for Ligand A. DILI risk is a critical factor.
8. **BBB:** Ligand B (81.233) has a higher BBB penetration percentile than Ligand A (73.943). However, since ADRB2 is a cardiovascular target, BBB penetration is not a high priority.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.912 & -4.646), which is unusual and suggests poor permeability. However, the values are very close.
10. **Solubility:** Ligand A (-1.129) is better than Ligand B (-3.643). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.468) is better than Ligand B (0.664). Lower hERG inhibition is crucial for avoiding cardiotoxicity, especially for a cardiovascular target.
12. **Cl_mic:** Ligand A (2.091) is *much* better than Ligand B (65.87). Lower microsomal clearance indicates greater metabolic stability, a significant advantage.
13. **t1/2:** Ligand A (-9.014) is better than Ligand B (-29.14). A less negative value indicates a longer half-life, which is desirable.
14. **Pgp:** Ligand A (0.02) is significantly better than Ligand B (0.096). Lower P-gp efflux improves bioavailability.
15. **Binding Affinity:** Ligand B (-6.4) is slightly better than Ligand A (-5.9). While affinity is important, the difference of 0.5 kcal/mol is not substantial enough to outweigh the numerous advantages of Ligand A.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical ADME-Tox properties (DILI, Cl_mic, hERG, Solubility, Pgp). While Ligand B has slightly better binding affinity and BBB penetration, these are less important for a cardiovascular target like ADRB2. The significantly lower DILI risk and improved metabolic stability of Ligand A make it the more promising drug candidate.
Output:
1
2025-04-17 21:43:35,186 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (345.443) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (49.41) is significantly better than Ligand A (71.53). ADRB2 is a GPCR, and lower TPSA is preferred for better blood-brain barrier penetration and overall drug-like properties.
3. **logP:** Both ligands have acceptable logP values (A: 2.535, B: 3.382), falling within the 1-3 range. Ligand B is slightly higher, which could potentially lead to some solubility issues, but is still within an acceptable range.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 3. Both are within the acceptable limit of 10.
6. **QED:** Ligand A (0.91) has a much better QED score than Ligand B (0.493), indicating a more drug-like profile.
7. **DILI:** Ligand B (18.108) has a significantly lower DILI risk than Ligand A (49.632), which is a major advantage.
8. **BBB:** Ligand B (85.111) has a much higher BBB penetration potential than Ligand A (60.45). This is a key consideration for GPCRs, even cardiovascular ones, as some CNS off-target effects are possible.
9. **Caco-2:** Ligand A (-4.467) and Ligand B (-5.008) both have negative Caco-2 values, which is unusual and suggests very poor permeability. This is a significant drawback for both.
10. **Solubility:** Ligand A (-2.871) has slightly better solubility than Ligand B (-4.184), but both are poor.
11. **hERG:** Ligand A (0.256) has a lower hERG risk than Ligand B (0.696), which is a positive.
12. **Cl_mic:** Ligand B (53.736) has a higher microsomal clearance than Ligand A (33.223), indicating faster metabolism and potentially lower *in vivo* exposure.
13. **t1/2:** Ligand A (-6.46) has a longer in vitro half-life than Ligand B (-3.78), which is desirable.
14. **Pgp:** Ligand A (0.161) has lower P-gp efflux liability than Ligand B (0.269), which is beneficial for bioavailability.
15. **Binding Affinity:** Ligand A (-7.3) has a slightly better binding affinity than Ligand B (-7.1), but the difference is small (0.2 kcal/mol).
**Overall Assessment:**
While Ligand A has a better QED, slightly better affinity, and lower Pgp efflux, Ligand B is significantly better in terms of safety (DILI), BBB penetration, and has a more favorable TPSA. The poor Caco-2 permeability is a major concern for both, but the other advantages of Ligand B, particularly the lower DILI risk and higher BBB, outweigh the minor benefits of Ligand A. Given the GPCR target class, BBB penetration is a valuable property. The slightly higher logP of Ligand B is manageable, and the solubility could be addressed with formulation strategies.
**Output:**
0
2025-04-17 21:43:35,186 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (380.5) is slightly higher than Ligand B (341.4). No strong preference here.
2. **TPSA:** Ligand A (75.6) is better than Ligand B (87.22). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally favors absorption.
3. **logP:** Both ligands have good logP values (A: 3.376, B: 2.316) within the optimal 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (5). Lower HBA generally improves permeability.
6. **QED:** Both ligands have similar, good QED values (A: 0.812, B: 0.842), indicating good drug-like properties.
7. **DILI:** Ligand A (41.062) is significantly better than Ligand B (65.413). Lower DILI risk is crucial.
8. **BBB:** Ligand A (87.088) is better than Ligand B (58.007). While not a CNS target, some degree of BBB penetration can sometimes indicate favorable distribution properties.
9. **Caco-2:** Ligand A (-4.44) is better than Ligand B (-5.047). Higher Caco-2 permeability suggests better intestinal absorption.
10. **Solubility:** Ligand A (-3.641) is better than Ligand B (-3.183). Solubility is important for formulation and bioavailability.
11. **hERG:** Ligand A (0.384) is better than Ligand B (0.602). Lower hERG inhibition is critical for avoiding cardiotoxicity, especially for a cardiovascular target.
12. **Cl_mic:** Ligand A (30.725) is better than Ligand B (49.427). Lower microsomal clearance indicates better metabolic stability.
13. **t1/2:** Ligand B (17.152) is significantly better than Ligand A (-1.527). A longer half-life is generally desirable.
14. **Pgp:** Ligand A (0.048) is better than Ligand B (0.093). Lower P-gp efflux is favorable for bioavailability.
15. **Affinity:** Ligand B (-7.0) is significantly better than Ligand A (-5.1). A 1.9 kcal/mol difference in binding affinity is substantial and can often outweigh minor ADME drawbacks.
**Overall Assessment:**
Ligand B has a much stronger binding affinity, which is a primary driver for GPCR drug candidates. While Ligand A has better scores in many ADME properties (DILI, TPSA, solubility, hERG, Cl_mic, Pgp), the substantial difference in binding affinity of Ligand B is a significant advantage. The longer half-life of Ligand B is also a positive. The higher DILI and Pgp efflux of Ligand B are concerns, but the potency advantage is likely to be more impactful in early development.
Output:
0
2025-04-17 21:43:35,186 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [369.799, 46.84, 3.151, 0, 4, 0.835, 51.183, 96.084, -4.531, -4.188, 0.552, 39.042, -18.181, 0.189, -6.5]
**Ligand B:** [346.479, 78.1, 2.375, 3, 6, 0.637, 62.001, 78.364, -5.461, -2.639, 0.958, 43.338, 65.242, 0.14, -5.2]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity, and BBB):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (346.479) is slightly lower, which could be beneficial for permeability.
2. **TPSA:** Ligand A (46.84) is significantly better than Ligand B (78.1). ADRB2 is a cardiovascular target, so BBB isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both are within the optimal range (1-3). Ligand A (3.151) is slightly higher, which could lead to some off-target interactions, but it's not a major concern.
4. **HBD/HBA:** Ligand A (0 HBD, 4 HBA) is preferable to Ligand B (3 HBD, 6 HBA). Fewer H-bonds can improve membrane permeability.
5. **QED:** Ligand A (0.835) is better than Ligand B (0.637), indicating a more drug-like profile.
6. **DILI:** Ligand A (51.183) has a lower DILI risk than Ligand B (62.001), which is a significant advantage.
7. **BBB:** Ligand A (96.084) shows much better BBB penetration than Ligand B (78.364). While not critical for a cardiovascular target, it's a positive attribute.
8. **Caco-2:** Ligand A (-4.531) is better than Ligand B (-5.461), indicating better intestinal absorption.
9. **Solubility:** Ligand A (-4.188) is better than Ligand B (-2.639), which is important for formulation.
10. **hERG:** Ligand A (0.552) has a lower hERG risk than Ligand B (0.958), a crucial safety parameter.
11. **Cl_mic:** Ligand A (39.042) has lower microsomal clearance than Ligand B (43.338), indicating better metabolic stability.
12. **t1/2:** Ligand A (-18.181) has a longer in vitro half-life than Ligand B (65.242).
13. **Pgp:** Ligand A (0.189) has lower P-gp efflux than Ligand B (0.14), which is favorable.
14. **Affinity:** Ligand A (-6.5 kcal/mol) has a slightly better binding affinity than Ligand B (-5.2 kcal/mol). This difference is significant, exceeding the 1.5 kcal/mol threshold.
**Conclusion:**
Ligand A consistently outperforms Ligand B across most critical parameters, including DILI, hERG, solubility, metabolic stability, and, importantly, binding affinity. While Ligand B has a slightly lower molecular weight, the advantages of Ligand A in safety, ADME properties, and potency are substantial.
Output:
1
2025-04-17 21:43:35,186 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (371.463 and 371.503 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (114.26) is higher than Ligand B (73.32). For a cardiovascular GPCR, TPSA is not a major concern unless aiming for CNS penetration, but lower is generally preferred for oral absorption. Ligand B is better here.
3. **logP:** Both ligands (-0.557 and -0.508) are slightly below the optimal 1-3 range, but not drastically so. They are close enough that this isn't a major discriminator.
4. **HBD:** Both have 1 HBD, which is ideal.
5. **HBA:** Ligand A has 7 HBA, while Ligand B has 6. Both are within the acceptable limit of 10.
6. **QED:** Both ligands have good QED scores (0.655 and 0.678), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (55.021) has a higher DILI risk than Ligand B (26.871). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (57.154) has a slightly higher BBB penetration potential than Ligand B (41.605). However, since ADRB2 is primarily a cardiovascular target, high BBB penetration isn't crucial and could even be undesirable due to potential off-target effects.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.332 and -5.004), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Both ligands have very poor aqueous solubility (-1.346 and -1.275). This is a significant drawback for both, and would require formulation strategies.
11. **hERG:** Ligand A (0.025) has a slightly lower hERG risk than Ligand B (0.349). This is a small advantage for Ligand A.
12. **Cl_mic:** Ligand B (12.463) has a lower microsomal clearance than Ligand A (6.293), indicating better metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand B (13.512) has a slightly longer in vitro half-life than Ligand A (12.582). This is a minor advantage for Ligand B.
14. **Pgp:** Ligand A (0.04) has a slightly lower P-gp efflux liability than Ligand B (0.042). This is a minor advantage for Ligand A.
15. **Binding Affinity:** Ligand B (-6.9 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.3 kcal/mol). This 1.5 kcal/mol difference is substantial and outweighs many of the minor ADME drawbacks.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), affinity, logP, TPSA, and Pgp are important. Ligand B excels in affinity and has a better TPSA and Cl_mic. While BBB isn't critical for a cardiovascular target, the slightly lower BBB of Ligand B isn't a major concern. The lower DILI risk of Ligand B is also a significant positive.
**Conclusion:**
Despite both ligands having poor solubility and Caco-2 permeability, Ligand B's superior binding affinity, lower DILI risk, and better metabolic stability make it the more promising drug candidate. The stronger binding is likely to translate to greater efficacy, and the improved safety profile is crucial.
Output:
0
2025-04-17 21:43:35,186 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (a cardiovascular GPCR) drug candidates.
**Ligand A:** [355.435, 80.34, -0.053, 1, 6, 0.645, 35.014, 72.703, -5.146, -1.149, 0.159, -23.281, -8.218, 0.015, -5.5]
**Ligand B:** [363.487, 99.77, 2.019, 3, 5, 0.562, 56.883, 24.855, -6.109, -1.715, 0.387, 21.541, 4.095, 0.097, -5.1]
Here's a breakdown, considering the guidelines and GPCR priorities (logP, Pgp, TPSA, affinity, and, to a lesser extent, BBB):
1. **MW:** Both are within the ideal range (200-500 Da). A is 355.435, B is 363.487. Slight edge to A due to being a bit lower.
2. **TPSA:** A (80.34) is excellent, well below the 140 threshold. B (99.77) is still acceptable, but less ideal.
3. **logP:** A (-0.053) is very low, potentially problematic for permeability. B (2.019) is much better, falling within the optimal 1-3 range. This is a significant advantage for B.
4. **HBD:** A (1) is good. B (3) is acceptable, but higher.
5. **HBA:** A (6) is good. B (5) is good.
6. **QED:** A (0.645) is better than B (0.562), indicating a more drug-like profile.
7. **DILI:** A (35.014) is excellent, very low risk. B (56.883) is higher, suggesting moderate risk. A is significantly better here.
8. **BBB:** A (72.703) is good, suggesting reasonable potential for some CNS penetration, although not critical for a cardiovascular target. B (24.855) is low.
9. **Caco-2:** Both are negative, indicating poor permeability. A (-5.146) is slightly better (less negative).
10. **Solubility:** Both are negative, indicating poor solubility. A (-1.149) is slightly better.
11. **hERG:** Both are very low (0.159 and 0.387), indicating low cardiotoxicity risk.
12. **Cl_mic:** A (-23.281) is *much* better (lower is better) than B (21.541), suggesting significantly higher metabolic stability.
13. **t1/2:** A (-8.218) is better than B (4.095), suggesting a longer half-life.
14. **Pgp:** A (0.015) is excellent, indicating very low P-gp efflux. B (0.097) is also low, but higher than A.
15. **Affinity:** Both are -5.1 kcal/mol, so equal in binding potency.
**Overall Assessment:**
Ligand A has advantages in DILI risk, metabolic stability (Cl_mic), half-life, and P-gp efflux. However, its major drawback is the very low logP, which will likely hinder its permeability and bioavailability. Ligand B has a much better logP, which is crucial for a GPCR ligand, but suffers from higher DILI risk and lower metabolic stability.
Considering the GPCR-specific priorities, logP is very important. While A's QED and lower DILI are attractive, the poor logP is a significant hurdle. The slight improvements in solubility and Caco-2 for A are unlikely to overcome the permeability issues caused by the very low logP. B's logP is within the optimal range, making it more likely to be absorbed and reach its target.
Therefore, despite the slightly higher DILI risk and lower metabolic stability, I believe **Ligand B** is the more promising candidate.
Output:
0
2025-04-17 21:43:35,186 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
The target is ADRB2, a GPCR. Therefore, I will prioritize logP, TPSA, Pgp efflux, BBB penetration, and binding affinity.
* **Molecular Weight:** Both ligands are within the ideal range (200-500 Da).
* **TPSA:** Ligand A (67.43) is significantly better than Ligand B (138.99). A TPSA under 140 is good for oral absorption, but lower is preferred for GPCRs, and A is much closer to the ideal <90 for CNS penetration (though BBB is the ultimate determinant).
* **logP:** Ligand A (2.641) is optimal (1-3). Ligand B (-0.955) is below 1, which could hinder permeability. This is a significant negative for B.
* **H-Bond Donors/Acceptors:** Ligand A (2 HBD, 3 HBA) is better balanced than Ligand B (4 HBD, 8 HBA). While both are within acceptable ranges, fewer H-bonds generally improve permeability.
* **QED:** Ligand A (0.623) is better than Ligand B (0.484), indicating a more drug-like profile.
* **DILI:** Ligand B (57.929) has a lower DILI risk than Ligand A (70.686), which is favorable.
* **BBB:** Ligand A (69.446) has much better BBB penetration potential than Ligand B (23.924). This is a crucial factor for a GPCR.
* **Caco-2:** Both have negative values, indicating poor permeability. Ligand A (-4.58) is slightly better than Ligand B (-5.841).
* **Solubility:** Ligand A (-3.337) is better than Ligand B (-1.207).
* **hERG:** Ligand A (0.747) has a lower hERG risk than Ligand B (0.04).
* **Cl_mic:** Ligand B (-11.255) has a significantly lower (better) microsomal clearance than Ligand A (37.945), indicating greater metabolic stability.
* **t1/2:** Ligand B (45.543) has a longer in vitro half-life than Ligand A (15.852), which is desirable.
* **Pgp:** Ligand A (0.284) has lower P-gp efflux liability than Ligand B (0.006), which is favorable.
* **Binding Affinity:** Both ligands have very similar binding affinities (-6.4 kcal/mol and -6.1 kcal/mol). The difference is not substantial enough to override other significant ADME differences.
**Overall Assessment:**
Ligand A clearly wins out due to its superior logP, TPSA, BBB penetration, solubility, and hERG risk profile. While Ligand B has better metabolic stability (Cl_mic and t1/2) and a slightly lower DILI risk, the permeability issues associated with its low logP and high TPSA, combined with poor BBB penetration, are too significant for a GPCR target like ADRB2. The slight advantage in metabolic stability does not outweigh these factors.
Output:
1
2025-04-17 21:43:35,186 - INFO - Batch 279 complete. Total preferences: 4464
2025-04-17 21:43:35,186 - INFO - Processing batch 280/512...
2025-04-17 21:44:26,579 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (417.344 Da) is slightly higher than Ligand B (344.411 Da), but both are acceptable.
2. **TPSA:** Ligand A (67.87) is better than Ligand B (82.78). Both are below 140, but lower TPSA generally favors absorption.
3. **logP:** Both ligands have similar logP values (A: 2.082, B: 2.172), falling within the optimal 1-3 range.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBDs are generally better for permeability.
5. **HBA:** Both ligands have the same number of HBA (4). This is within the acceptable range.
6. **QED:** Ligand B (0.806) has a slightly better QED score than Ligand A (0.645), indicating a more drug-like profile.
7. **DILI:** Ligand A (22.761) has a significantly lower DILI risk than Ligand B (34.781). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (61.962) has a better BBB penetration score than Ligand B (56.572), but neither is particularly high. For a cardiovascular target, BBB penetration is less critical than for CNS targets, but still a consideration.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. Ligand A (-4.879) is slightly better than Ligand B (-4.692), but both are concerning.
10. **Solubility:** Ligand A (-3.095) has slightly better solubility than Ligand B (-2.412), but both are poor.
11. **hERG:** Both ligands have very low hERG inhibition risk (A: 0.37, B: 0.346). This is excellent.
12. **Cl_mic:** Ligand B (26.376) has a lower microsomal clearance than Ligand A (45.227), suggesting better metabolic stability.
13. **t1/2:** Ligand B (72.462) has a significantly longer in vitro half-life than Ligand A (6.346). This is a substantial advantage for Ligand B.
14. **Pgp:** Both ligands have very low P-gp efflux liability (A: 0.042, B: 0.042).
15. **Binding Affinity:** Ligand B (-7.1 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.7 kcal/mol). This is a crucial factor.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Both ligands have good logP and Pgp profiles. Ligand A has a better TPSA. However, the significantly stronger binding affinity of Ligand B (-7.1 vs -6.7 kcal/mol) and its longer half-life outweigh the slightly better TPSA and DILI risk of Ligand A. The affinity difference is substantial enough to overcome the concerns about permeability and solubility.
**Conclusion:**
Despite the slightly better ADME profile of Ligand A, the significantly improved binding affinity and half-life of Ligand B make it the more promising drug candidate for the ADRB2 receptor.
Output:
0
2025-04-17 21:44:26,579 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.5 & 352.4 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (43.86) is significantly better than Ligand B (67.23). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (1.83 & 1.20), falling within the 1-3 range. Ligand A is slightly more lipophilic.
4. **HBD:** Ligand A (0) is preferable to Ligand B (1). Fewer hydrogen bond donors generally improve permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (4). Fewer hydrogen bond acceptors also generally improve permeability.
6. **QED:** Both ligands have good QED scores (0.689 & 0.81), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (5.78) has a much lower DILI risk than Ligand B (52.35). This is a significant advantage for Ligand A.
8. **BBB:** Ligand B (83.99) has a higher BBB penetration score than Ligand A (68.94). Although ADRB2 is not a CNS target, higher BBB is not necessarily detrimental.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.562 and -4.829), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-0.943) is slightly better than Ligand B (-2.045) in terms of aqueous solubility, though both are quite poor.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.559 & 0.209). This is excellent for both.
12. **Cl_mic:** Ligand A (-4.132) has a much lower (better) microsomal clearance than Ligand B (17.902). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (-5.79) has a much longer in vitro half-life than Ligand B (-24.442). This is a significant advantage for Ligand A.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.043 & 0.034).
15. **Binding Affinity:** Both ligands have comparable and excellent binding affinities (-6.3 & -6.4 kcal/mol). The difference is negligible.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Both ligands perform well on logP and affinity. Ligand A has a significantly better TPSA and Pgp profile.
**Overall Assessment:**
Ligand A is the stronger candidate. It has a significantly lower DILI risk, better metabolic stability (lower Cl_mic, longer t1/2), lower TPSA, and fewer H-bonds, all of which contribute to a more favorable ADME profile. While Ligand B has slightly better QED and BBB, the advantages of Ligand A are more critical for overall drug development success, especially considering the poor Caco-2 values for both.
Output:
1
2025-04-17 21:44:26,580 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (357.519) is slightly higher than Ligand B (339.439), but both are acceptable.
2. **TPSA:** Ligand A (46.17) is significantly better than Ligand B (81.99). ADRB2 is a cardiovascular target, not a CNS target, but lower TPSA generally improves permeability. Ligand B's TPSA is relatively high, potentially hindering absorption.
3. **logP:** Both ligands have good logP values (A: 4.298, B: 3.446) falling within the optimal 1-3 range. Ligand A is slightly higher, which *could* be a minor concern for solubility, but is still acceptable.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Both ligands have the same number of HBA (3), which is within the acceptable limit.
6. **QED:** Both ligands have similar and good QED scores (A: 0.752, B: 0.779), indicating good drug-like properties.
7. **DILI:** Both ligands have acceptable DILI risk (A: 41.062, B: 48.895), below the 60% threshold.
8. **BBB:** Both ligands have reasonable BBB penetration, but Ligand B (77.007) is better than Ligand A (68.786). However, as this is a cardiovascular target, BBB penetration is not a primary concern.
9. **Caco-2:** Ligand A (-5.046) is better than Ligand B (-4.479), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-4.213) is better than Ligand B (-5.064), indicating better aqueous solubility.
11. **hERG:** Both ligands have low hERG inhibition risk (A: 0.834, B: 0.561). Ligand B is slightly better.
12. **Cl_mic:** Both ligands have similar microsomal clearance (A: 50.977, B: 50.606).
13. **t1/2:** Ligand A (18.594) has a significantly longer in vitro half-life than Ligand B (10.128), which is a significant advantage.
14. **Pgp:** Ligand A (0.758) is better than Ligand B (0.239), indicating lower P-gp efflux.
15. **Binding Affinity:** Ligand B (-7.2) has a slightly better binding affinity than Ligand A (-6.9). This is a 0.3 kcal/mol difference, which is notable, but needs to be weighed against other factors.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B has a slightly better logP and affinity, but Ligand A excels in TPSA, Pgp, solubility, and has a much better half-life. The TPSA difference is substantial, and the longer half-life of Ligand A is a significant advantage. While the affinity difference is present, it's not large enough to overcome the other benefits of Ligand A.
**Conclusion:**
Considering the balance of properties, especially the favorable TPSA, solubility, half-life, and Pgp efflux profile of Ligand A, I believe it is the more promising drug candidate for ADRB2.
Output:
1
2025-04-17 21:44:26,580 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (366.571 Da and 350.503 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (49.41) is better than Ligand B (58.64). Both are below the 140 A^2 threshold for oral absorption, but lower TPSA is generally preferred for GPCRs, potentially aiding in receptor binding and reducing off-target interactions.
**3. logP:** Both ligands have good logP values (3.638 and 2.903), falling within the optimal 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability.
**4. H-Bond Donors:** Both ligands have 1 HBD, which is within the acceptable limit of 5.
**5. H-Bond Acceptors:** Both ligands have 3 HBA, which is within the acceptable limit of 10.
**6. QED:** Ligand B (0.685) has a better QED score than Ligand A (0.474), suggesting a more drug-like profile.
**7. DILI:** Ligand A (31.601) has a significantly lower DILI risk than Ligand B (9.228). This is a major advantage for Ligand A, as liver toxicity is a critical concern in drug development.
**8. BBB:** Ligand B (77.705) has a higher BBB penetration percentile than Ligand A (66.499). While ADRB2 isn't strictly a CNS target, some peripheral ADRB2 activity can influence CNS pathways, and increased BBB penetration isn't necessarily detrimental.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.747 and -4.636), which is unusual and suggests poor permeability. This is a significant concern for both.
**10. Aqueous Solubility:** Ligand B (-2.514) has slightly better aqueous solubility than Ligand A (-4.336), but both are quite poor. This could pose formulation challenges.
**11. hERG Inhibition:** Ligand A (0.208) has a lower hERG inhibition liability than Ligand B (0.485), which is crucial for avoiding cardiotoxicity, especially important for a cardiovascular target like ADRB2.
**12. Microsomal Clearance:** Ligand B (44.523) has a significantly lower microsomal clearance than Ligand A (82.786), indicating better metabolic stability.
**13. In vitro Half-Life:** Ligand B (-10.718) has a negative half-life, which is problematic. Ligand A (22.402) has a reasonable half-life.
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (0.156 and 0.125).
**15. Binding Affinity:** Ligand B (-7.5 kcal/mol) has a stronger binding affinity than Ligand A (-6.5 kcal/mol). This is a substantial advantage (1 kcal/mol difference), potentially outweighing some of the ADME drawbacks.
**Overall Assessment:**
While Ligand B has a better binding affinity and metabolic stability, Ligand A's significantly lower DILI risk and more reasonable half-life are crucial advantages. The poor Caco-2 permeability is a concern for both, but the lower hERG inhibition and better TPSA of Ligand A make it the more promising candidate. The stronger binding affinity of Ligand B is attractive, but the higher DILI risk is a major red flag. For a cardiovascular target, minimizing cardiotoxicity (hERG) and liver toxicity (DILI) is paramount.
Output:
1
2025-04-17 21:44:26,580 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (354.447 Da) is slightly higher than Ligand B (346.471 Da), but both are acceptable.
2. **TPSA:** Ligand A (85.89) is slightly higher than Ligand B (60.85). Both are below the 140 A^2 threshold for good oral absorption, but Ligand B is significantly better, which is favorable for GPCRs.
3. **logP:** Ligand A (0.928) is at the lower end of the optimal range (1-3), while Ligand B (2.119) is well within it. This favors Ligand B for better membrane permeability.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable, being less than 5.
5. **HBA:** Ligand A (5) and Ligand B (3) are both acceptable, being less than 10.
6. **QED:** Both ligands have good QED scores (A: 0.664, B: 0.75), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (34.742) has a slightly higher DILI risk than Ligand B (10.508). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (71.345) and Ligand B (84.529) both have good BBB penetration, but Ligand B is better. Since ADRB2 is a GPCR, BBB penetration is a consideration, and Ligand B is preferable.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.988) is slightly worse than Ligand B (-4.686).
10. **Solubility:** Both ligands have negative solubility values, which is also unusual and suggests poor solubility. Ligand A (-1.515) is slightly worse than Ligand B (-2.404).
11. **hERG:** Ligand A (0.095) has a lower hERG risk than Ligand B (0.421), which is a positive for Ligand A.
12. **Cl_mic:** Ligand A (24.104) has a lower microsomal clearance than Ligand B (37.203), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (3.979) has a shorter half-life than Ligand B (5.799). Ligand B is preferable.
14. **Pgp:** Ligand A (0.017) has a much lower P-gp efflux liability than Ligand B (0.204), which is a significant advantage for Ligand A.
15. **Affinity:** Ligand A (-6.2 kcal/mol) has a significantly better binding affinity than Ligand B (-3.2 kcal/mol). This is a substantial advantage for Ligand A, potentially outweighing some of the ADME drawbacks.
**Overall Assessment:**
Ligand A has a much stronger binding affinity, lower P-gp efflux, and better metabolic stability. Ligand B has better logP, TPSA, DILI risk, BBB penetration, and in vitro half-life. The affinity difference is substantial (3 kcal/mol), and for a GPCR, affinity is paramount. While Ligand B has better ADME properties overall, the significantly improved binding of Ligand A is likely to be more critical for achieving efficacy. The lower P-gp efflux of Ligand A also helps to improve bioavailability.
Output:
1
2025-04-17 21:44:26,580 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.438 and 349.475 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (67.23) is better than Ligand B (69.72). Both are below the 140 threshold for oral absorption, but lower is preferred.
3. **logP:** Both ligands (1.598 and 1.707) are within the optimal 1-3 range. No significant difference.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 3. Both are acceptable, under the 10 threshold.
6. **QED:** Ligand A (0.897) has a significantly better QED score than Ligand B (0.678), indicating a more drug-like profile.
7. **DILI:** Ligand A (25.902) has a much lower DILI risk than Ligand B (12.796). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (83.443) has a better BBB penetration percentile than Ligand B (69.407). While ADRB2 isn't strictly a CNS target, some CNS exposure can be relevant for off-target effects, and higher BBB is generally preferable.
9. **Caco-2:** Ligand A (-5.013) is slightly better than Ligand B (-4.634), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-1.888) is slightly better than Ligand B (-1.248), indicating better aqueous solubility.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.292 and 0.115). No significant difference.
12. **Cl_mic:** Ligand A (-4.382) has a much lower microsomal clearance than Ligand B (39.203), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-5.86) has a longer in vitro half-life than Ligand B (3.408), which is desirable.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.05 and 0.014). No significant difference.
15. **Binding Affinity:** Ligand B (-7.1 kcal/mol) has a slightly better binding affinity than Ligand A (-8.0 kcal/mol). However, the difference is not substantial enough to outweigh the advantages of Ligand A in other areas.
**GPCR-specific priorities:** For GPCRs, logP, TPSA, Pgp, and affinity are important. Both ligands perform similarly on logP and Pgp. Ligand A has a better TPSA. The affinity difference is small.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across multiple critical ADME-Tox parameters (DILI, Cl_mic, t1/2, QED, BBB, solubility). While Ligand B has a slightly better binding affinity, the overall profile of Ligand A is far more favorable for drug development. The lower DILI risk and improved metabolic stability are particularly important.
Output:
1
2025-04-17 21:44:26,580 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [349.479, 102.04 , 1.989, 3. , 5. , 0.562, 39.201, 81.272, -5.364, -3.25 , 0.702, 52.162, 1.964, 0.426, -8.9 ]
**Ligand B:** [345.443, 71.53 , 2.233, 1. , 4. , 0.521, 34.82 , 70.997, -4.639, -2.165, 0.268, 28.247, -1.347, 0.119, -6.4 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (349.479) is slightly higher than Ligand B (345.443), but both are acceptable.
2. **TPSA:** Ligand A (102.04) is a bit higher than Ligand B (71.53). Both are below 140, but B is better positioned for good oral absorption.
3. **logP:** Both are within the optimal range (1-3). Ligand A (1.989) and Ligand B (2.233) are both good, with B being slightly more lipophilic.
4. **HBD:** Ligand A (3) is higher than Ligand B (1). Both are acceptable, but lower is generally preferred for permeability.
5. **HBA:** Ligand A (5) is higher than Ligand B (4). Again, lower is generally better.
6. **QED:** Both are good (A: 0.562, B: 0.521), indicating drug-like properties.
7. **DILI:** Ligand A (39.201) is slightly higher than Ligand B (34.82), but both are below the concerning threshold of 60, indicating low liver injury risk.
8. **BBB:** Ligand A (81.272) is significantly better than Ligand B (70.997). While ADRB2 isn't a CNS target, some off-target CNS effects are possible with GPCRs, so higher BBB is a slight advantage.
9. **Caco-2:** Ligand A (-5.364) is worse than Ligand B (-4.639). Lower values are less favorable.
10. **Solubility:** Ligand A (-3.25) is worse than Ligand B (-2.165). Lower values are less favorable.
11. **hERG:** Ligand A (0.702) is higher than Ligand B (0.268), indicating a higher risk of hERG inhibition and potential cardiotoxicity. This is a significant concern.
12. **Cl_mic:** Ligand A (52.162) is higher than Ligand B (28.247), meaning faster metabolic clearance and potentially lower exposure.
13. **t1/2:** Ligand A (1.964) is higher than Ligand B (-1.347). This is a positive for A.
14. **Pgp:** Ligand A (0.426) is higher than Ligand B (0.119), indicating greater P-gp efflux and potentially lower bioavailability.
15. **Affinity:** Ligand A (-8.9) is *significantly* better than Ligand B (-6.4). This is a difference of 2.5 kcal/mol, which is a substantial advantage.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B has better logP, TPSA, and Pgp values. However, the *massive* difference in binding affinity (-8.9 vs -6.4) for Ligand A is a major factor. A 2.5 kcal/mol difference in affinity can often overcome minor ADME drawbacks. The hERG risk for Ligand A is a concern, but can potentially be mitigated through structural modifications.
**Conclusion:**
Despite the slightly less favorable ADME profile of Ligand A, the significantly stronger binding affinity makes it the more promising candidate. The hERG risk is a concern, but a manageable one given the potency advantage.
0
2025-04-17 21:44:26,581 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (351.363) is slightly higher than Ligand B (341.411), but both are acceptable.
2. **TPSA:** Ligand A (121.07) is higher than Ligand B (83.36). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B is significantly better here.
3. **logP:** Ligand A (-0.449) is a bit low, potentially hindering permeability. Ligand B (1.321) is within the optimal range (1-3). This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (2) and Ligand B (3) are both acceptable, falling within the recommended limit of 5.
5. **HBA:** Ligand A (8) and Ligand B (4) are both within the recommended limit of 10. Ligand B is better.
6. **QED:** Both ligands have good QED scores (Ligand A: 0.553, Ligand B: 0.767). Ligand B is better.
7. **DILI:** Ligand A (68.515) has a higher DILI risk than Ligand B (38.154). This favors Ligand B.
8. **BBB:** BBB is less crucial for a cardiovascular target. Ligand A (43.273) and Ligand B (65.374) are both relatively low, but Ligand B is better.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.676 and -4.823), which is unusual and indicates poor permeability. This is a significant concern for both.
10. **Solubility:** Both ligands have negative solubility values (-2.078 and -2.353), which is also a concern.
11. **hERG:** Ligand A (0.557) has a slightly higher hERG risk than Ligand B (0.198). This favors Ligand B.
12. **Cl_mic:** Ligand A (13.897) has a lower (better) microsomal clearance than Ligand B (-16.514). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (-1.197) has a negative half-life, which is concerning. Ligand B (16.922) has a much better in vitro half-life.
14. **Pgp:** Ligand A (0.011) has very low P-gp efflux, which is good. Ligand B (0.07) is also low, but slightly higher.
15. **Binding Affinity:** Ligand A (-7.4) has a slightly better binding affinity than Ligand B (-5.7). This is a 1.7 kcal/mol difference, which is significant.
**Overall Assessment:**
Despite Ligand A's slightly better binding affinity and lower Pgp efflux, Ligand B is the more promising candidate. Ligand B demonstrates superior ADME properties, including a better logP, lower DILI risk, better QED, and a significantly improved in vitro half-life. The negative Caco-2 and solubility values are concerning for both, but the other advantages of Ligand B outweigh the slightly weaker binding. The improved metabolic stability (lower Cl_mic) and reduced hERG risk are also important considerations.
Output:
0
2025-04-17 21:44:26,581 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Step-by-step comparison:**
1. **MW:** Both ligands (342.439 and 350.503 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (58.64) is significantly better than Ligand B (69.64). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have acceptable logP values (1.465 and 2.186, respectively), falling within the 1-3 range. Ligand B is slightly higher, potentially improving membrane permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Both ligands have the same number of HBA (3), which is well within the acceptable limit of 10.
6. **QED:** Both ligands have similar QED scores (0.773 and 0.798), indicating good drug-likeness.
7. **DILI:** Ligand A (29.624) has a much lower DILI risk than Ligand B (4.692). This is a significant advantage for Ligand A.
8. **BBB:** Ligand B (71.733) has a higher BBB penetration percentile than Ligand A (60.644). While not a primary concern for a cardiovascular target, it's a slight positive for Ligand B.
9. **Caco-2:** Both ligands have very poor Caco-2 permeability (-4.642 and -4.673). This is a major concern for both, indicating poor intestinal absorption.
10. **Solubility:** Ligand A (-3.672) has slightly better solubility than Ligand B (-2.752), though both are quite poor.
11. **hERG:** Both ligands have low hERG inhibition risk (0.344 and 0.488), which is good.
12. **Cl_mic:** Ligand A (17.499) has significantly lower microsomal clearance than Ligand B (41.268), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-8.622) has a negative in vitro half-life, which is concerning. Ligand A (10.474) has a reasonable half-life.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.055 and 0.017).
15. **Affinity:** Ligand A (-5.1 kcal/mol) has a slightly better binding affinity than Ligand B (-3.1 kcal/mol). This is a substantial difference, and a 2 kcal/mol advantage can often outweigh minor ADME drawbacks.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. While both have acceptable logP and Pgp, Ligand A has a significantly lower TPSA and a better binding affinity. The improved metabolic stability (lower Cl_mic) and reduced DILI risk further favor Ligand A. The poor Caco-2 permeability is a concern for both, but can potentially be addressed with formulation strategies.
**Conclusion:**
Considering the balance of properties, particularly the superior affinity, lower DILI risk, better metabolic stability, and lower TPSA, Ligand A is the more promising drug candidate.
Output:
1
2025-04-17 21:44:26,581 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (356.447 and 350.434 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (79.29) is higher than Ligand B (58.64). For a peripheral GPCR like ADRB2, TPSA is less critical than for a CNS target, but lower is generally preferred for absorption. Ligand B has a clear advantage.
**3. logP:** Both ligands have good logP values (2.822 and 2.249), falling within the optimal 1-3 range. Ligand B is slightly lower, which could be beneficial for solubility.
**4. H-Bond Donors:** Ligand A has 2 HBD, and Ligand B has 1. Both are acceptable, well below the 5 limit.
**5. H-Bond Acceptors:** Ligand A has 4 HBA, and Ligand B has 3. Both are acceptable, well below the 10 limit.
**6. QED:** Both ligands have good QED scores (0.737 and 0.821), indicating good drug-like properties. Ligand B is slightly better.
**7. DILI Risk:** Ligand A (69.678) has a higher DILI risk than Ligand B (34.432). This is a significant concern, as minimizing liver toxicity is crucial. Ligand B is much preferred.
**8. BBB Penetration:** BBB is less critical for ADRB2, but Ligand B (83.055) has a higher percentile than Ligand A (34.316).
**9. Caco-2 Permeability:** Ligand A (-5.184) has a worse Caco-2 permeability than Ligand B (-4.316), indicating lower intestinal absorption.
**10. Aqueous Solubility:** Ligand A (-4.179) has worse solubility than Ligand B (-2.391).
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (0.563 and 0.756). No significant difference.
**12. Microsomal Clearance:** Ligand A (82.525) has a higher microsomal clearance than Ligand B (40.886), indicating lower metabolic stability. Ligand B is preferred.
**13. In vitro Half-Life:** Ligand A (17.089) has a longer half-life than Ligand B (3.004). This is a positive for Ligand A, but the other ADME issues are more concerning.
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (0.307 and 0.315). No significant difference.
**15. Binding Affinity:** Ligand A (-7.5 kcal/mol) has a slightly better binding affinity than Ligand B (-5.4 kcal/mol). This is a 2.1 kcal/mol difference, which is substantial. However, the ADME profile of Ligand A is significantly worse.
**Overall Assessment:**
While Ligand A has a better binding affinity, the significantly higher DILI risk, lower solubility, and poorer Caco-2 permeability make it a less desirable candidate. Ligand B has a superior ADME profile, with lower DILI risk, better solubility, and better permeability, despite a slightly weaker binding affinity. For a GPCR target, a balanced profile is more important than maximizing affinity at the expense of safety and bioavailability.
Output:
0
2025-04-17 21:44:26,581 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (349.479 and 362.455 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (70.47) is significantly better than Ligand B (89.16). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary goal, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (1.911) is better than Ligand A (0.514). A logP between 1-3 is optimal, and Ligand B is within this range, while Ligand A is slightly low, potentially impacting permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD is generally better for permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (6). Lower HBA is generally better for permeability.
6. **QED:** Both ligands have very similar QED values (0.743 and 0.735), indicating good drug-likeness.
7. **DILI:** Ligand A (13.222) is slightly better than Ligand B (61.07), indicating a lower risk of drug-induced liver injury. This is a significant advantage.
8. **BBB:** Ligand A (61.691) is better than Ligand B (40.791), but neither is particularly high. As ADRB2 is a cardiovascular target, BBB penetration is not a major concern.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.108 and -5.675). These values are unusual and suggest poor permeability.
10. **Solubility:** Ligand A (-0.63) is better than Ligand B (-2.057), indicating better aqueous solubility.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.18 and 0.477), which is excellent.
12. **Cl_mic:** Ligand A (12.438) is worse than Ligand B (2.63). Lower clearance is preferred, indicating better metabolic stability. Ligand B has a significant advantage here.
13. **t1/2:** Both ligands have similar in vitro half-lives (3.949 and 3.942 hours).
14. **Pgp:** Ligand A (0.007) is significantly better than Ligand B (0.083), indicating lower P-gp efflux. This is a positive for bioavailability.
15. **Binding Affinity:** Ligand B (-6.2) is slightly better than Ligand A (-6.0). While both are good, the 0.2 kcal/mol difference is not huge.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B has a better logP and slightly better affinity. However, Ligand A has a significantly better TPSA, DILI risk, solubility, and Pgp efflux profile. The lower metabolic clearance of Ligand B is a plus, but the other advantages of Ligand A are more compelling.
**Overall Assessment:**
While Ligand B has a slightly better binding affinity and metabolic stability, Ligand A presents a more balanced profile with better predicted absorption (lower TPSA, better solubility), lower toxicity (DILI), and reduced efflux (Pgp). The Caco-2 values are concerning for both, but the other advantages of Ligand A outweigh the small affinity difference.
Output:
1
2025-04-17 21:44:26,581 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [347.459, 70.67, 0.817, 2, 4, 0.766, 22.334, 44.901, -5.001, -1.014, 0.144, -5.442, 1.512, 0.008, -7.2]
**Ligand B:** [351.426, 78.43, 0.796, 1, 5, 0.786, 42.458, 84.413, -4.661, -0.876, 0.44, 20.786, -20.411, 0.026, -5.7]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, Affinity, and to a lesser extent BBB):
1. **MW:** Both are within the ideal range (200-500 Da). A is 347.459, B is 351.426 - very similar.
2. **TPSA:** A (70.67) is better than B (78.43). Both are acceptable, but lower TPSA generally favors permeability.
3. **logP:** Both are good (around 0.8), falling within the 1-3 optimal range. A (0.817) is slightly better.
4. **HBD/HBA:** A (2 HBD, 4 HBA) is slightly better than B (1 HBD, 5 HBA). Lower counts are generally preferred for permeability.
5. **QED:** Both are good (A: 0.766, B: 0.786), indicating good drug-like properties.
6. **DILI:** A (22.334) is significantly better than B (42.458). This is a major advantage for Ligand A.
7. **BBB:** B (84.413) is much better than A (44.901). While not *essential* for ADRB2 (a cardiovascular target), higher BBB is always a plus, indicating reduced off-target CNS effects.
8. **Caco-2:** A (-5.001) is worse than B (-4.661). Higher values are better.
9. **Solubility:** A (-1.014) is slightly worse than B (-0.876). Both are quite poor.
10. **hERG:** A (0.144) is much better than B (0.44). Lower is better, and this is a significant safety advantage for A.
11. **Cl_mic:** A (-5.442) is much better than B (20.786). A is predicted to have much better metabolic stability.
12. **t1/2:** A (1.512) is better than B (-20.411). A has a positive half-life, while B has a negative one.
13. **Pgp:** A (0.008) is much better than B (0.026). Lower Pgp efflux is desirable.
14. **Affinity:** A (-7.2) is significantly better than B (-5.7). This is a 1.5 kcal/mol difference, which is substantial and can outweigh some ADME concerns.
**Overall Assessment:**
Ligand A clearly wins. The significantly better affinity (-7.2 vs -5.7 kcal/mol) is a major factor. Furthermore, it has a much better safety profile (lower DILI and hERG) and better metabolic stability (lower Cl_mic, positive t1/2). While Ligand B has a better BBB score and Caco-2 permeability, the advantages of A in terms of potency, safety, and metabolic stability are more critical for overall drug development success, especially given the cardiovascular target. The solubility is poor for both, but this can be addressed with formulation strategies.
Output:
1
2025-04-17 21:44:26,582 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (404.348 Da) is within the ideal range, while Ligand B (350.503 Da) is also acceptable. No clear advantage here.
2. **TPSA:** Ligand A (30.49) is excellent, well below the 140 threshold and very favorable for oral absorption. Ligand B (49.85) is still reasonable, but less optimal.
3. **logP:** Ligand A (4.927) is slightly high, potentially leading to solubility issues or off-target interactions. Ligand B (2.974) is within the optimal range. This favors Ligand B.
4. **HBD:** Ligand A (1) and Ligand B (0) are both good, meeting the <=5 criteria.
5. **HBA:** Ligand A (3) and Ligand B (3) are both good, meeting the <=10 criteria.
6. **QED:** Both Ligand A (0.677) and Ligand B (0.766) have good drug-likeness scores, exceeding 0.5. Ligand B is slightly better.
7. **DILI:** Both Ligand A (18.728) and Ligand B (19.038) have low DILI risk, well below the 40 threshold. No significant difference.
8. **BBB:** Both Ligand A (78.596) and Ligand B (71.074) show reasonable BBB penetration, but neither is exceptionally high. Given ADRB2 is a cardiovascular target, BBB penetration is not a primary concern, but a higher value is generally preferred.
9. **Caco-2:** Both have negative values, indicating poor permeability. This is concerning for both.
10. **Solubility:** Ligand A (-4.323) and Ligand B (-2.427) both have poor solubility. Ligand B is slightly better.
11. **hERG:** Ligand A (0.931) and Ligand B (0.519) both show low hERG inhibition risk. Ligand B is better.
12. **Cl_mic:** Ligand A (64.626) has a higher microsomal clearance than Ligand B (40.535), indicating lower metabolic stability. This favors Ligand B.
13. **t1/2:** Ligand A (21.207) has a longer in vitro half-life than Ligand B (13.623). This favors Ligand A.
14. **Pgp:** Ligand A (0.714) has higher P-gp efflux than Ligand B (0.177). This favors Ligand B.
15. **Binding Affinity:** Ligand B (-6.7 kcal/mol) has a significantly stronger binding affinity than Ligand A (-4.1 kcal/mol) - a difference of 2.6 kcal/mol. This is a substantial advantage.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP, Pgp, and significantly in affinity. While Ligand A has a better half-life, the superior binding affinity of Ligand B, combined with its better ADME properties (lower Cl_mic, lower Pgp efflux, better solubility), outweighs this drawback. The slightly higher TPSA of Ligand B is less concerning for a cardiovascular target.
**Conclusion:**
Ligand B demonstrates a better balance of properties for a viable drug candidate targeting ADRB2, primarily due to its significantly stronger binding affinity and more favorable ADME profile.
Output:
0
2025-04-17 21:44:26,582 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (346.471 and 358.429 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (62.55) is slightly higher than Ligand B (58.64). Both are below the 140 threshold for oral absorption, and acceptable for a cardiovascular target (not needing significant CNS penetration).
3. **logP:** Ligand A (3.586) is slightly higher than Ligand B (2.368). Both are within the optimal 1-3 range, but Ligand A is approaching the upper limit.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Both ligands have 3 HBA, which is good.
6. **QED:** Ligand A (0.856) has a higher QED score than Ligand B (0.711), indicating a more drug-like profile.
7. **DILI:** Ligand A (27.608) has a lower DILI risk than Ligand B (31.33), which is preferable.
8. **BBB:** Ligand B (91.508) has a higher BBB penetration percentile than Ligand A (86.623). While ADRB2 is a cardiovascular target, some CNS effects are possible with beta-blockers, so a slightly higher BBB isn't necessarily detrimental, but also not a major priority.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.564 and -4.434), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand A (-3.373) has slightly worse solubility than Ligand B (-2.575), but both are very poor. This is a major drawback for both.
11. **hERG:** Ligand A (0.594) has a slightly higher hERG risk than Ligand B (0.351), which is undesirable.
12. **Cl_mic:** Ligand B (36.47) has a lower microsomal clearance than Ligand A (57.002), indicating better metabolic stability.
13. **t1/2:** Ligand A (47.016) has a longer in vitro half-life than Ligand B (-3.619). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.481) has lower P-gp efflux than Ligand B (0.039), which is favorable.
15. **Binding Affinity:** Ligand B (-9.3) has significantly stronger binding affinity than Ligand A (-6.2). This is a substantial advantage (a difference of 3.1 kcal/mol).
**GPCR-Specific Priorities & Overall Assessment:**
For a GPCR like ADRB2, affinity, logP, TPSA, and Pgp are key. Ligand B wins decisively on affinity. While Ligand A has better QED, DILI, t1/2, and Pgp, the substantial difference in binding affinity outweighs these advantages. The poor Caco-2 and solubility are concerning for both, but can be addressed with formulation strategies. The hERG risk is slightly better for Ligand B. The slightly better metabolic stability of Ligand B is also a plus.
**Output:**
0
2025-04-17 21:44:26,582 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (359.417 Da) is within the ideal range (200-500 Da). Ligand B (169.18 Da) is a bit low, potentially impacting potency.
2. **TPSA:** Ligand A (56.59) is good, well below the 140 threshold. Ligand B (86.71) is also acceptable, but higher.
3. **logP:** Ligand A (1.944) is optimal. Ligand B (0.09) is very low, which is a significant concern for membrane permeability and bioavailability.
4. **HBD:** Ligand A (0) is excellent. Ligand B (4) is higher, potentially impacting permeability.
5. **HBA:** Ligand A (5) is good. Ligand B (4) is also good.
6. **QED:** Ligand A (0.633) is good, indicating drug-likeness. Ligand B (0.472) is lower, suggesting a less favorable drug-like profile.
7. **DILI:** Ligand A (23.691) is very good, low risk. Ligand B (4.42) is excellent, very low risk. Both are acceptable.
8. **BBB:** Ligand A (96.084) is excellent. Ligand B (3.994) is extremely poor. While ADRB2 isn't exclusively a CNS target, good BBB penetration can be beneficial for overall distribution and potentially off-target effects.
9. **Caco-2:** Ligand A (-4.415) is poor. Ligand B (-6.052) is even worse. Both suggest poor intestinal absorption.
10. **Solubility:** Ligand A (-1.472) is poor. Ligand B (-0.372) is also poor. Solubility is a concern for both.
11. **hERG:** Ligand A (0.732) is low risk. Ligand B (0.037) is very low risk. Both are acceptable.
12. **Cl_mic:** Ligand A (44.619) is moderate. Ligand B (-42.745) is excellent (negative value suggests very low clearance/high stability).
13. **t1/2:** Ligand A (11.004) is moderate. Ligand B (4.953) is short.
14. **Pgp:** Ligand A (0.259) is low efflux, good. Ligand B (0.012) is very low efflux, excellent.
15. **Affinity:** Ligand A (-5.3 kcal/mol) is good. Ligand B (-8.2 kcal/mol) is *excellent*, a significant 2.9 kcal/mol advantage.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are crucial. Ligand B has a much better affinity, and excellent Pgp properties. However, its extremely low logP is a major drawback. Ligand A has a good logP, and acceptable Pgp, but its affinity is significantly lower. The poor Caco-2 and solubility for both are concerning, but can potentially be addressed with formulation strategies.
**Overall Assessment:**
While Ligand B has a substantially better binding affinity, its very low logP is a critical issue. It will likely have extremely poor absorption and bioavailability. Ligand A, despite its lower affinity, has a much more balanced profile with a reasonable logP, good BBB penetration, and acceptable ADME properties. The affinity difference, while significant, might be overcome with further optimization of Ligand A.
Therefore, I favor Ligand A.
Output:
1
2025-04-17 21:44:26,582 - INFO - Here's my reasoning and output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
We are targeting ADRB2, a GPCR, so the key priorities are logP, TPSA, Pgp efflux, BBB penetration, and binding affinity. Metabolic stability (Cl_mic, t1/2) and safety (DILI, hERG) are also important.
Let's compare the ligands property by property:
1. **MW:** Both ligands (347.415 and 345.399 Da) are within the ideal 200-500 Da range.
2. **TPSA:** Both ligands (92.45 and 93.46) are reasonably good, below 140, but higher than the optimal <90 for CNS targets. This isn't a major concern for a cardiovascular target like ADRB2.
3. **logP:** Ligand A (2.216) is better than Ligand B (1.006). Ligand B is a bit low, potentially hindering membrane permeability.
4. **HBD/HBA:** Ligand A has 3 HBD and 4 HBA, while Ligand B has 2 HBD and 5 HBA. Both are acceptable.
5. **QED:** Both have good QED scores (0.716 and 0.751), indicating good drug-like properties.
6. **DILI:** Ligand B (49.515) has a significantly lower DILI risk than Ligand A (65.607). This is a substantial advantage for Ligand B.
7. **BBB:** Ligand A (67.352) has slightly better BBB penetration than Ligand B (54.634), but neither is particularly high. BBB isn't a primary concern for a cardiovascular target.
8. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. Ligand B (-5.178) is slightly worse than Ligand A (-4.904).
9. **Solubility:** Ligand B (-2.104) has better solubility than Ligand A (-3.516).
10. **hERG:** Ligand B (0.036) has a much lower hERG risk than Ligand A (0.54). This is a significant safety advantage for Ligand B.
11. **Cl_mic:** Ligand B (2.467) has significantly lower microsomal clearance than Ligand A (52.681), suggesting better metabolic stability.
12. **t1/2:** Ligand B (-5.732) has a more positive (less negative) in vitro half-life than Ligand A (-17.277), indicating a longer half-life.
13. **Pgp:** Ligand B (0.026) has much lower P-gp efflux than Ligand A (0.142). This is a significant advantage for bioavailability.
14. **Binding Affinity:** Ligand A (-7.9 kcal/mol) has a slightly better binding affinity than Ligand B (-5.7 kcal/mol). This is a 2.2 kcal/mol difference, which is substantial.
**Overall Assessment:**
While Ligand A has a better binding affinity, Ligand B demonstrates a significantly superior ADMET profile. The lower DILI, hERG, Pgp efflux, and microsomal clearance, coupled with better solubility and a longer half-life, outweigh the slightly weaker binding affinity. For a GPCR, optimizing for ADMET properties is crucial, and Ligand B excels in these areas. The difference in affinity, while noticeable, isn't so large that it completely negates the substantial improvements in safety and pharmacokinetic properties offered by Ligand B.
**Output:**
0
2025-04-17 21:44:26,582 - INFO - Batch 280 complete. Total preferences: 4480
2025-04-17 21:44:26,582 - INFO - Processing batch 281/512...
2025-04-17 21:45:16,417 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands (351.353 and 371.815 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (74.69) is higher than Ligand B (55.32). For a GPCR, lower TPSA is generally preferred for better permeability, giving a slight edge to Ligand B.
3. **logP:** Both ligands (3.054 and 2.899) are within the optimal 1-3 range. No significant difference.
4. **HBD:** Ligand A has 2 HBD, while Ligand B has 0. Lower HBD can improve membrane permeability, favoring Ligand B.
5. **HBA:** Both ligands have 4 HBA, which is acceptable. No clear advantage.
6. **QED:** Ligand A (0.839) has a higher QED than Ligand B (0.59), indicating a more drug-like profile. This is a significant advantage for Ligand A.
7. **DILI:** Ligand A (60.527) and Ligand B (44.591) are both within acceptable limits (<60 is good), but Ligand B has a notably lower DILI risk. This favors Ligand B.
8. **BBB:** Ligand B (92.478) has a significantly higher BBB penetration percentile than Ligand A (76.154). For a GPCR, even a non-CNS one, some BBB penetration can be beneficial for distribution and off-target profiling. This is a strong advantage for Ligand B.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.629 and -4.413), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Both ligands have negative solubility values (-3.538 and -3.968), indicating very poor aqueous solubility. This is a major drawback for both.
11. **hERG:** Both ligands have low hERG inhibition liability (0.494 and 0.386), which is good. No clear advantage.
12. **Cl_mic:** Ligand A (43.951) has a lower microsomal clearance than Ligand B (54.273), suggesting better metabolic stability. This favors Ligand A.
13. **t1/2:** Ligand A (5.663) has a positive half-life, while Ligand B (-19.377) has a negative half-life. This is a major issue for Ligand B.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.076 and 0.226). No clear advantage.
15. **Binding Affinity:** Ligand B (-7.0) has a slightly better binding affinity than Ligand A (-6.5), a 0.5 kcal/mol difference. This is a significant advantage for Ligand B, and can outweigh some ADME concerns.
**Overall Assessment:**
Ligand B has several advantages: better BBB penetration, lower DILI risk, and slightly better binding affinity. Ligand A has a higher QED and better metabolic stability (lower Cl_mic). However, the negative half-life for Ligand B is a critical flaw. The poor solubility and Caco-2 values for both are concerning, but can potentially be addressed with formulation strategies. Given the importance of binding affinity for GPCRs, and the relatively small difference in other parameters, the better binding affinity of Ligand B, coupled with its lower DILI risk and better BBB, makes it the more promising candidate *despite* the negative half-life. The negative half-life is a red flag, but could be a result of experimental error or a specific assay artifact.
Output:
0
2025-04-17 21:45:16,417 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (353.344 and 367.53 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (58.36) is higher than Ligand B (29.54). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for permeability. Ligand B is significantly better.
**3. logP:** Ligand A (2.627) is within the optimal 1-3 range. Ligand B (4.798) is slightly higher, potentially leading to solubility issues and off-target interactions. Ligand A is better.
**4. H-Bond Donors:** Ligand A (1) and Ligand B (0) are both acceptable.
**5. H-Bond Acceptors:** Ligand A (4) and Ligand B (3) are both acceptable.
**6. QED:** Both ligands have similar QED values (0.833 and 0.627), indicating good drug-likeness.
**7. DILI:** Ligand A (48.158) has a higher DILI risk than Ligand B (18.302). This is a significant advantage for Ligand B.
**8. BBB:** Both ligands have high BBB penetration (88.135 and 96.743). While ADRB2 is primarily cardiovascular, some CNS off-target effects are possible, so higher BBB isn't necessarily a negative. Ligand B is slightly better.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.396) is slightly better than Ligand B (-4.504), but both are concerning.
**10. Aqueous Solubility:** Both ligands have very poor aqueous solubility (-3.404 and -4.664). This is a major drawback for both, potentially hindering bioavailability.
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (0.61 and 0.825).
**12. Microsomal Clearance:** Ligand A (26.34) has significantly lower microsomal clearance than Ligand B (113.112), indicating better metabolic stability. This is a strong advantage for Ligand A.
**13. In vitro Half-Life:** Ligand A (-5.482) has a shorter in vitro half-life than Ligand B (26.529). This is a significant advantage for Ligand B.
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (0.21 and 0.818).
**15. Binding Affinity:** Ligand A (-7.8) has a slightly better binding affinity than Ligand B (-6.1). This 1.7 kcal/mol difference is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand A has a better logP and significantly better affinity. Ligand B excels in DILI risk and BBB penetration, and has a longer half-life. However, the poor solubility and Caco-2 permeability are concerning for both. The superior binding affinity of Ligand A, combined with its better metabolic stability (lower Cl_mic), makes it the more promising candidate despite the solubility issues. Solubility can be addressed with formulation strategies.
Output:
1
2025-04-17 21:45:16,417 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
Let's systematically compare Ligand A and Ligand B based on the provided parameters, keeping in mind the GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key).
1. **MW:** Both ligands (348.443 and 346.431 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (76.66) is better than Ligand B (84.42). Both are below 140, indicating good potential for oral absorption, but lower TPSA is generally preferred for GPCRs.
3. **logP:** Both ligands have similar logP values (1.307 and 1.321), falling within the optimal 1-3 range. No clear advantage.
4. **HBD:** Ligand A (2) has fewer HBD than Ligand B (1). Fewer HBDs are generally preferred for better permeability.
5. **HBA:** Ligand A (4) has fewer HBA than Ligand B (5). Similar to HBD, fewer HBA are generally preferred.
6. **QED:** Ligand B (0.869) has a significantly higher QED score than Ligand A (0.374), indicating a more drug-like profile overall. This is a notable advantage for Ligand B.
7. **DILI:** Ligand A (36.603) has a lower DILI risk than Ligand B (44.862), which is preferable.
8. **BBB:** Both ligands have similar BBB penetration (58.085 and 58.976). While not exceptionally high, it's not a major concern for a cardiovascular target like ADRB2.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.009 and -4.94). This is unusual and suggests very poor permeability. This is a significant drawback for both.
10. **Solubility:** Ligand A (-2.396) has slightly better solubility than Ligand B (-1.533), but both are quite poor.
11. **hERG:** Both ligands have low hERG inhibition risk (0.292 and 0.17), which is excellent.
12. **Cl_mic:** Ligand B (-10.635) has significantly lower microsomal clearance than Ligand A (16.968), suggesting better metabolic stability. This is a substantial advantage for Ligand B.
13. **t1/2:** Ligand B (11.002) has a much longer in vitro half-life than Ligand A (-4.566). This is a major advantage for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.167 and 0.029). This is favorable for both.
15. **Affinity:** Both ligands have very similar binding affinities (-6.3 and -6.1 kcal/mol). The difference is negligible.
**Overall Assessment:**
While Ligand A has a slightly better TPSA and DILI score, Ligand B demonstrates superior drug-like properties (QED), metabolic stability (Cl_mic), and a longer half-life (t1/2). The similar affinities mean these factors become more important. The poor Caco-2 values are a concern for both, but the other advantages of Ligand B outweigh the slight benefits of Ligand A.
**Output:**
0
2025-04-17 21:45:16,418 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (336.326 and 345.403 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (76.97) is significantly better than Ligand B (93.26). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (3.493) is good, while Ligand B (1.566) is on the lower side of optimal. A logP between 1-3 is preferred, and Ligand A is closer to the upper end, potentially aiding membrane permeability.
4. **HBD:** Both ligands have 1 HBD, which is within the acceptable limit of 5. No clear advantage.
5. **HBA:** Both ligands have 6 HBA, also within the acceptable limit of 10. No clear advantage.
6. **QED:** Ligand B (0.822) has a slightly higher QED score than Ligand A (0.617), indicating a more drug-like profile. This is a minor positive for Ligand B.
7. **DILI:** Ligand B (56.689) has a much lower DILI risk than Ligand A (91.857). This is a significant advantage for Ligand B, as minimizing liver toxicity is crucial.
8. **BBB:** Ligand B (74.758) has a higher BBB penetration percentile than Ligand A (33.579). While not a primary concern for a cardiovascular target, higher BBB is generally favorable.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.001 and -4.945), which is unusual and suggests very poor permeability. This is a major concern for both.
10. **Solubility:** Ligand A (-4.089) has slightly better (less negative) solubility than Ligand B (-2.17).
11. **hERG:** Ligand A (0.527) has a slightly higher hERG risk than Ligand B (0.147). Lower hERG is preferred, giving a slight edge to Ligand B.
12. **Cl_mic:** Ligand B (35.797) has significantly lower microsomal clearance than Ligand A (77.077), indicating better metabolic stability. This is a substantial advantage for Ligand B.
13. **t1/2:** Ligand A (-60.697) has a much more negative in vitro half-life than Ligand B (-6.526), indicating a much shorter half-life and faster metabolism. This is a major drawback for Ligand A.
14. **Pgp:** Ligand A (0.304) has lower P-gp efflux than Ligand B (0.11). Lower Pgp is better, giving a slight edge to Ligand A.
15. **Affinity:** Ligand A (-8.6 kcal/mol) has a significantly stronger binding affinity than Ligand B (-5.8 kcal/mol). This is a substantial advantage for Ligand A, potentially outweighing some of its ADME drawbacks.
**Overall Assessment:**
While Ligand A boasts a considerably stronger binding affinity, its significantly worse DILI risk, metabolic stability (high Cl_mic, short t1/2), and moderate hERG risk are major concerns. Ligand B, while having weaker affinity, presents a much more favorable ADME profile with lower DILI, better metabolic stability, and lower hERG risk. Given the importance of a balanced profile for drug development, and the substantial safety concerns with Ligand A, I favor Ligand B. The affinity difference, while significant, may be addressable through further optimization, while mitigating the ADME liabilities of Ligand A would be much more challenging.
Output:
0
2025-04-17 21:45:16,418 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (379.473) is slightly higher than Ligand B (357.376), but both are acceptable.
2. **TPSA:** Ligand A (81.67) is higher than Ligand B (55.32). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is generally preferred for absorption. Ligand B is better here.
3. **logP:** Ligand B (3.206) is slightly higher than Ligand A (0.452). ADRB2 is not a CNS target, so a logP in the 1-3 range is desirable. Ligand B is significantly better, while Ligand A is quite low and could have permeability issues.
4. **HBD:** Ligand A (3) is higher than Ligand B (0). This isn't a major concern for either, but fewer HBDs are generally preferred. Ligand B is better.
5. **HBA:** Ligand A (5) is higher than Ligand B (4). Similar to HBD, fewer HBAs are generally preferred. Ligand B is better.
6. **QED:** Both ligands have good QED scores (Ligand A: 0.507, Ligand B: 0.703). Ligand B is better.
7. **DILI:** Ligand A (18.651) has a much lower DILI risk than Ligand B (47.732). This is a significant advantage for Ligand A.
8. **BBB:** This is less critical for a cardiovascular target. Ligand A (65.413) and Ligand B (85.111) are both acceptable, but Ligand B is better.
9. **Caco-2:** Ligand A (-5.381) and Ligand B (-4.201) both have negative values, which is unusual. Lower values indicate poor permeability. Ligand B is slightly better.
10. **Solubility:** Ligand A (-1.682) and Ligand B (-3.393) both have negative values, indicating poor solubility. Ligand A is slightly better.
11. **hERG:** Both ligands have low hERG risk (Ligand A: 0.601, Ligand B: 0.645). Both are acceptable.
12. **Cl_mic:** Ligand A (-2.921) has a lower (better) microsomal clearance than Ligand B (65.447). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (-17.058) has a longer (better) half-life than Ligand B (-28.159). This is a significant advantage for Ligand A.
14. **Pgp:** Both ligands have very low Pgp efflux liability (Ligand A: 0.027, Ligand B: 0.28). Both are acceptable.
15. **Binding Affinity:** Both ligands have similar binding affinities (Ligand A: -6.2 kcal/mol, Ligand B: -5.7 kcal/mol). Ligand A is slightly better.
**Overall Assessment:**
Ligand A has significant advantages in DILI risk, metabolic stability (Cl_mic), and in vitro half-life. Ligand B has better logP, TPSA, QED, and BBB. However, the low logP of Ligand A is a concern, but the other advantages are more important for a cardiovascular GPCR target. The better metabolic stability and longer half-life of Ligand A are crucial for *in vivo* efficacy. The slightly better affinity of Ligand A also contributes to its favorability.
Output:
1
2025-04-17 21:45:16,418 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (346.391 Da) is well within the ideal range (200-500 Da). Ligand B (392.298 Da) is also acceptable, but closer to the upper limit.
2. **TPSA:** Ligand A (116.12) is acceptable, though approaching the upper limit for good oral absorption. Ligand B (38.77) is excellent, well below the 140 threshold, suggesting good permeability.
3. **logP:** Ligand A (0.478) is a bit low, potentially hindering permeation. Ligand B (4.064) is at the higher end of the optimal range, potentially causing solubility issues but generally acceptable.
4. **HBD:** Ligand A (2) is good. Ligand B (0) is also good, minimizing potential for off-target interactions.
5. **HBA:** Ligand A (6) is good. Ligand B (3) is also good.
6. **QED:** Both ligands (A: 0.666, B: 0.657) have similar, good drug-likeness scores.
7. **DILI:** Ligand A (54.168) has a slightly higher DILI risk than Ligand B (42.924), but both are below the concerning threshold of 60.
8. **BBB:** Ligand A (32.648) has poor BBB penetration. Ligand B (86.778) has excellent BBB penetration. Given ADRB2's relevance to cardiovascular targets, BBB penetration isn't paramount, but it's a bonus.
9. **Caco-2:** Ligand A (-5.649) has poor Caco-2 permeability. Ligand B (-4.511) has better, but still poor, Caco-2 permeability.
10. **Solubility:** Ligand A (-1.883) has poor solubility. Ligand B (-5.037) has very poor solubility.
11. **hERG:** Ligand A (0.065) has very low hERG risk, which is excellent. Ligand B (0.758) has a slightly elevated hERG risk, but still relatively low.
12. **Cl_mic:** Ligand A (-6.776) has very low microsomal clearance, indicating high metabolic stability. Ligand B (66.447) has high microsomal clearance, suggesting rapid metabolism.
13. **t1/2:** Ligand A (24.236) has a moderate in vitro half-life. Ligand B (36.98) has a better in vitro half-life.
14. **Pgp:** Ligand A (0.007) has very low P-gp efflux, which is excellent. Ligand B (0.54) has moderate P-gp efflux.
15. **Affinity:** Ligand B (-7.1 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.4 kcal/mol). This is a >1.5 kcal/mol difference, which is a substantial advantage.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in TPSA and affinity, and is acceptable in logP. Ligand A has issues with logP and affinity. While BBB isn't critical for a cardiovascular target, Ligand B's higher BBB penetration is a plus. Metabolic stability (Cl_mic) is also important, and Ligand A is superior in this regard. However, the substantial affinity difference of Ligand B outweighs the metabolic stability advantage of Ligand A.
**Conclusion:**
Despite Ligand A's better metabolic stability and lower DILI risk, Ligand B's significantly higher binding affinity and favorable TPSA, coupled with acceptable logP and good BBB penetration, make it the more promising drug candidate for ADRB2. The affinity difference is substantial enough to overcome the poorer metabolic stability and solubility.
Output:
0
2025-04-17 21:45:16,418 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (350.409 Da and 367.471 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (58.2) is significantly better than Ligand B (89.95). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is approaching a less desirable range.
3. **logP:** Ligand A (3.253) is optimal, while Ligand B (0.535) is quite low. Low logP can hinder membrane permeability and reduce binding affinity. This is a major drawback for Ligand B.
4. **HBD:** Both have 2 HBD, which is within the acceptable limit of <=5.
5. **HBA:** Ligand A has 2 HBA, while Ligand B has 5. Ligand A is preferable.
6. **QED:** Both ligands have similar QED values (0.774 and 0.763), indicating good drug-likeness.
7. **DILI:** Ligand A (49.438) has a slightly higher DILI risk than Ligand B (42.924), but both are well below the concerning threshold of 60.
8. **BBB:** Ligand A (80.884) has a much better BBB penetration potential than Ligand B (30.089). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant, and higher BBB is generally favorable.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.276 and -4.797), which is unusual and suggests poor permeability. However, the scale isn't specified, so it's hard to interpret.
10. **Solubility:** Ligand A (-3.765) has better solubility than Ligand B (-1.12).
11. **hERG:** Ligand A (0.493) has a lower hERG risk than Ligand B (0.117), which is a significant advantage.
12. **Cl_mic:** Ligand A (34.839) has a much lower microsomal clearance than Ligand B (9.638), indicating better metabolic stability.
13. **t1/2:** Ligand A (33.776) has a much longer in vitro half-life than Ligand B (-2.351).
14. **Pgp:** Ligand A (0.146) has a lower P-gp efflux liability than Ligand B (0.077).
15. **Binding Affinity:** Ligand A (-7.6 kcal/mol) has a significantly stronger binding affinity than Ligand B (-5.4 kcal/mol). This is a crucial advantage, as a 2.2 kcal/mol difference is substantial.
**Overall Assessment:**
Ligand A is clearly superior. It excels in key ADME properties (logP, TPSA, solubility, metabolic stability, Pgp efflux, and half-life) and has a significantly stronger binding affinity. While Ligand B has a slightly lower DILI risk, the other advantages of Ligand A outweigh this minor difference. The low logP of Ligand B is a major concern, and its poor BBB penetration further diminishes its potential.
Output:
1
2025-04-17 21:45:16,418 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, priorities are logP, Pgp, TPSA, and affinity, with metabolic stability (Cl_mic, t1/2) and safety (DILI, hERG) also important.
* **Molecular Weight:** Both ligands are within the ideal range (354.47 and 351.54 Da).
* **TPSA:** Ligand A (58.64) is higher than Ligand B (43.86). Ligand B is better here, being closer to the <90 threshold for GPCRs.
* **logP:** Both are good (2.29 and 2.77), falling within the 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability.
* **H-Bond Donors/Acceptors:** Ligand A has 1 HBD and 3 HBA, while Ligand B has 0 HBD and 3 HBA. Both are acceptable.
* **QED:** Ligand A (0.843) has a significantly better QED score than Ligand B (0.6), indicating a more drug-like profile.
* **DILI:** Ligand B (5.971) has a much lower DILI risk than Ligand A (34.277), a major advantage.
* **BBB:** Both have high BBB penetration (88.14 and 87.09), which isn't a primary concern for a cardiovascular target but isn't detrimental.
* **Caco-2:** Both have negative Caco-2 values, which is unusual and hard to interpret without knowing the scale. We'll assume they are similar.
* **Solubility:** Ligand A (-3.707) has better solubility than Ligand B (-1.262).
* **hERG:** Ligand B (0.761) has a slightly better hERG profile than Ligand A (0.477).
* **Cl_mic:** Ligand B (33.101) has significantly lower microsomal clearance than Ligand A (61.379), suggesting better metabolic stability.
* **t1/2:** Ligand B (-0.101) has a slightly better in vitro half-life than Ligand A (-15.128).
* **Pgp:** Ligand A (0.206) has lower P-gp efflux than Ligand B (0.091), which is favorable.
* **Binding Affinity:** Both have very similar and excellent binding affinities (-6.1 and -6.2 kcal/mol).
**Overall Assessment:**
While Ligand A has a better QED and solubility, Ligand B demonstrates a superior safety profile (DILI), metabolic stability (Cl_mic, t1/2), and slightly better hERG. The binding affinities are nearly identical. Given the importance of minimizing toxicity and maximizing metabolic stability for a cardiovascular drug, Ligand B is the more promising candidate. The slightly better TPSA and Pgp values also contribute to its favorability.
**Output:**
0
2025-04-17 21:45:16,419 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.471 and 353.507 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (49.85) is well below the 140 threshold and good for oral absorption. Ligand B (70.67) is still acceptable, but higher. GPCRs benefit from lower TPSA.
3. **logP:** Both ligands have good logP values (2.365 and 1.546), falling within the 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (3) is better than Ligand B (4). Lower HBA is generally preferred.
6. **QED:** Both ligands have acceptable QED scores (0.385 and 0.585), but Ligand B is better.
7. **DILI:** Ligand A (31.059) has a significantly lower DILI risk than Ligand B (5.118). This is a major advantage for Ligand A.
8. **BBB:** Both ligands have good BBB penetration (69.794 and 71.229). This is less critical for ADRB2 (a cardiovascular target) but still a positive.
9. **Caco-2:** Ligand A (-4.519) has a worse Caco-2 permeability than Ligand B (-5.183).
10. **Solubility:** Ligand A (-2.195) has worse solubility than Ligand B (-1.457).
11. **hERG:** Both ligands have low hERG inhibition liability (0.415 and 0.678), which is good.
12. **Cl_mic:** Ligand B (17.411) has a lower microsomal clearance, indicating better metabolic stability than Ligand A (26.288).
13. **t1/2:** Ligand B (-3.102) has a negative half-life, which is very concerning. Ligand A (8.515) has a positive half-life.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.286 and 0.035).
15. **Binding Affinity:** Ligand B (-6.8) has a significantly stronger binding affinity than Ligand A (0). This is a substantial advantage.
**Overall Assessment:**
Ligand B has a much stronger binding affinity, lower clearance, and better solubility. However, Ligand A has a much lower DILI risk and a positive half-life. Given the importance of minimizing toxicity and having a reasonable half-life, Ligand A is the better candidate. The affinity difference is significant, but not insurmountable, and can be addressed through further optimization. The DILI risk for Ligand B is a major concern.
Output:
1
2025-04-17 21:45:16,419 - INFO - Reasoning:
Let's analyze Ligand A and Ligand B for their potential as ADRB2 ligands, keeping in mind GPCR priorities (logP, Pgp, TPSA, and affinity are key).
**Molecular Weight:** Both ligands (347.46 and 346.44 Da) fall comfortably within the ideal 200-500 Da range.
**TPSA:** Ligand A (75.87) is better than Ligand B (78.07), both are acceptable for a non-CNS GPCR target like ADRB2, being below 140.
**logP:** Both ligands have good logP values (1.635 and 1.224), falling within the optimal 1-3 range. Ligand B is slightly lower, which could slightly improve solubility but might slightly reduce membrane permeability.
**H-Bond Donors/Acceptors:** Ligand A has 1 HBD and 4 HBA, while Ligand B has 0 HBD and 7 HBA. Both are within reasonable limits (<=5 HBD and <=10 HBA).
**QED:** Both ligands have similar QED values (0.775 and 0.786), indicating good drug-likeness.
**DILI:** Ligand A has a DILI risk of 7.794, which is excellent (low risk). Ligand B's DILI risk is significantly higher at 37.301, raising a concern.
**BBB:** This is less critical for ADRB2 (a cardiovascular target), but Ligand A (78.015) has a better BBB percentile than Ligand B (59.364).
**Caco-2 Permeability:** Both ligands have negative Caco-2 values (-5.073 and -5.032), which is unusual and suggests poor permeability. This is a significant drawback for both.
**Aqueous Solubility:** Both ligands have negative solubility values (-1.373 and -0.453), indicating very poor aqueous solubility. This is a major concern for both.
**hERG Inhibition:** Ligand A (0.519) has a slightly higher hERG risk than Ligand B (0.191), but both are relatively low.
**Microsomal Clearance:** Ligand A (-8.563) has much better metabolic stability (lower clearance) than Ligand B (27.077). This is a significant advantage.
**In vitro Half-Life:** Ligand A (-6.725) has a longer half-life than Ligand B (10.341), which is desirable.
**P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.012 and 0.034).
**Binding Affinity:** Ligand B (-5.5 kcal/mol) has a slightly better binding affinity than Ligand A (-5.1 kcal/mol), but the difference is not substantial enough to outweigh other factors.
**Overall Assessment:**
Ligand A is significantly better due to its much lower DILI risk and improved metabolic stability (lower Cl_mic and longer half-life). While both have poor solubility and permeability, the safety profile and PK properties of Ligand A are more favorable. The slightly better affinity of Ligand B is not enough to compensate for the higher DILI risk and poorer metabolic stability.
Output:
1
2025-04-17 21:45:16,419 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (344.46 & 346.47 Da) fall well within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (70.4) is higher than Ligand B (58.64). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is generally preferred for absorption. Ligand B has a slight edge.
3. **logP:** Ligand A (3.731) is higher than Ligand B (1.958). While both are within the optimal 1-3 range, Ligand A is approaching the upper limit. Ligand B is better positioned.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1). Both are acceptable.
5. **HBA:** Ligand A (4) is slightly higher than Ligand B (3). Both are acceptable.
6. **QED:** Ligand A (0.89) is slightly better than Ligand B (0.795), indicating a more drug-like profile.
7. **DILI:** Ligand B (14.89%) is *significantly* better than Ligand A (41.18%). This is a major advantage for Ligand B. DILI is a critical factor.
8. **BBB:** Ligand A (87.86%) has much better BBB penetration than Ligand B (53.63%). While ADRB2 isn't primarily a CNS target, some degree of BBB penetration can be useful for understanding off-target effects.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.864 and -4.602), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-3.53) is slightly better than Ligand B (-2.549), but both are poor. Solubility is a concern for both.
11. **hERG:** Ligand A (0.811) is better than Ligand B (0.151), indicating a lower risk of cardiotoxicity. This is a significant advantage for Ligand A, given the cardiovascular target.
12. **Cl_mic:** Ligand B (6.039) has much lower microsomal clearance than Ligand A (42.124), suggesting better metabolic stability. This is a major advantage for Ligand B.
13. **t1/2:** Ligand A (72.584) has a much longer in vitro half-life than Ligand B (9.262). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.124) has lower P-gp efflux than Ligand B (0.049), indicating better absorption and bioavailability.
15. **Affinity:** Ligand B (-6.9 kcal/mol) has a stronger binding affinity than Ligand A (-8.0 kcal/mol). This is a substantial advantage for Ligand B.
**Overall Assessment:**
Ligand B has a significantly better safety profile (DILI) and metabolic stability (Cl_mic). It also boasts a superior binding affinity. While Ligand A has advantages in BBB penetration, hERG, t1/2 and Pgp, the DILI and Cl_mic issues with Ligand A are more concerning for a drug candidate. The superior binding affinity of Ligand B is also a strong driver. The Caco-2 and solubility issues are present in both, and would need to be addressed during optimization.
**Output:**
0
2025-04-17 21:45:16,419 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's analyze each ligand against the provided guidelines, with emphasis on GPCR-relevant properties (logP, TPSA, Pgp, BBB, and affinity).
* **Molecular Weight:** Both ligands are within the acceptable range (200-500 Da). Ligand A (409.28) is slightly higher than Ligand B (364.387), but this isn't a major concern.
* **TPSA:** Ligand A (64.8) is significantly better than Ligand B (139.22). A TPSA under 140 is good for oral absorption, but lower is generally preferred for GPCRs, and Ligand A is much closer to optimal.
* **logP:** Ligand A (3.257) is within the optimal range (1-3). Ligand B (-0.724) is quite low, potentially hindering membrane permeability and absorption. This is a significant drawback.
* **H-Bond Donors/Acceptors:** Ligand A (0 HBD, 6 HBA) is preferable to Ligand B (3 HBD, 9 HBA). Lower counts generally improve permeability.
* **QED:** Both ligands have similar QED values (0.683 vs 0.61), indicating reasonable drug-likeness.
* **DILI:** Ligand B (84.645) has a higher DILI risk than Ligand A (65.568), though both are above the ideal <40.
* **BBB:** Ligand A (77.937) has a much better BBB penetration score than Ligand B (25.165). While ADRB2 isn't exclusively a CNS target, some CNS exposure can occur, and higher BBB penetration is generally favorable.
* **Caco-2 Permeability:** Ligand A (-4.922) and Ligand B (-5.572) both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale isn't specified, so it's difficult to interpret the absolute impact.
* **Aqueous Solubility:** Ligand A (-3.238) and Ligand B (-2.57) both have negative solubility values, which is also unusual.
* **hERG:** Ligand A (0.664) has a lower hERG risk than Ligand B (0.028), which is a significant safety advantage.
* **Microsomal Clearance:** Ligand A (52.506) has a higher clearance than Ligand B (16.855), indicating potentially lower metabolic stability.
* **In vitro Half-Life:** Ligand B (-3.567) has a very short in vitro half-life, which is a major concern. Ligand A (29.632) is much better.
* **P-gp Efflux:** Ligand A (0.531) has lower P-gp efflux liability than Ligand B (0.014), meaning better bioavailability.
* **Binding Affinity:** Ligand B (-7.6) has a slightly better binding affinity than Ligand A (-7.3), but the difference is small (0.3 kcal/mol). Given the other ADME issues with Ligand B, this affinity advantage is unlikely to outweigh them.
**Overall Assessment:**
Ligand A is clearly the more promising candidate. While its metabolic clearance is higher than Ligand B, it excels in crucial areas like TPSA, logP, BBB penetration, hERG risk, P-gp efflux, and in vitro half-life. Ligand B suffers from poor logP, low BBB penetration, a very short half-life, and a higher hERG risk. The slight affinity advantage of Ligand B is not enough to compensate for these significant drawbacks.
**Output:**
1
2025-04-17 21:45:16,419 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.471 and 350.438 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (58.64) is significantly better than Ligand B (76.02). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (2.127 and 1.788), falling within the optimal 1-3 range. Ligand B is slightly lower, which could marginally improve solubility.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves membrane permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (4). Similar reasoning as HBD.
6. **QED:** Ligand B (0.85) has a better QED score than Ligand A (0.592), indicating a more drug-like profile. This is a point in favor of Ligand B.
7. **DILI:** Ligand A (37.03) has a slightly better DILI score than Ligand B (42.924), indicating lower potential for liver injury.
8. **BBB:** Both ligands have similar BBB penetration (78.713 and 77.472). Not a major differentiating factor for a cardiovascular target.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. Ligand B (-4.955) is slightly worse than Ligand A (-4.536).
10. **Solubility:** Both ligands have negative solubility values, indicating poor solubility. Ligand B (-2.154) is slightly better than Ligand A (-2.815).
11. **hERG:** Both ligands have very low hERG inhibition risk (0.402 and 0.176). No significant difference.
12. **Cl_mic:** Ligand B (-10.426) has a much lower microsomal clearance than Ligand A (37.516), suggesting better metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand B (19.209) has a significantly longer in vitro half-life than Ligand A (-13.887). This is a major advantage for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.209 and 0.082). No significant difference.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-7.4 and -7.3 kcal/mol). The difference is negligible.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are important. Ligand A has a better TPSA and comparable logP and affinity. However, the significantly better metabolic stability (Cl_mic) and longer half-life (t1/2) of Ligand B are crucial advantages. While both have poor Caco-2 and solubility, the improved PK profile of Ligand B outweighs the slightly better TPSA of Ligand A.
**Conclusion:**
Ligand B is the more promising drug candidate due to its superior metabolic stability and longer half-life, despite slightly lower TPSA and QED. These PK properties are critical for *in vivo* efficacy and dosing regimen.
Output:
0
2025-04-17 21:45:16,420 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [333.435, 48.13, 4.523, 2, 1, 0.727, 60.915, 85.498, -5.006, -4.855, 0.88, 59.611, 9.884, 0.632, -8.1]
**Ligand B:** [342.443, 69.3, 2.293, 1, 3, 0.913, 29.081, 74.06, -5.009, -2.905, 0.622, 45.669, -36.665, 0.069, -6.3]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity, and, to a lesser extent, BBB):
1. **MW:** Both are within the ideal range (200-500 Da).
2. **TPSA:** Ligand A (48.13) is significantly better than Ligand B (69.3), falling well below the 140 threshold for oral absorption.
3. **logP:** Ligand A (4.523) is slightly higher than optimal (1-3), but still within a reasonable range. Ligand B (2.293) is good.
4. **HBD/HBA:** Ligand A (2/1) is preferable to Ligand B (1/3) as it has fewer hydrogen bond donors.
5. **QED:** Ligand B (0.913) is better than Ligand A (0.727), indicating a more drug-like profile.
6. **DILI:** Ligand B (29.081) is *much* better than Ligand A (60.915), indicating a significantly lower risk of liver injury. This is a major advantage for Ligand B.
7. **BBB:** Ligand A (85.498) has better BBB penetration than Ligand B (74.06), but for a cardiovascular target, this isn't a primary concern.
8. **Caco-2:** Both are negative, indicating poor permeability.
9. **Solubility:** Both are negative, indicating poor solubility.
10. **hERG:** Ligand A (0.88) is slightly better than Ligand B (0.622), indicating a lower risk of hERG inhibition.
11. **Cl_mic:** Ligand B (45.669) has a lower microsomal clearance than Ligand A (59.611), suggesting better metabolic stability.
12. **t1/2:** Ligand B (-36.665) has a much longer in vitro half-life than Ligand A (9.884). This is a significant advantage.
13. **Pgp:** Ligand A (0.632) has lower P-gp efflux than Ligand B (0.069), which is favorable.
14. **Affinity:** Ligand A (-8.1 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.3 kcal/mol). This is a substantial advantage.
**Overall Assessment:**
The biggest differentiator is the binding affinity. Ligand A has a -8.1 kcal/mol affinity, while Ligand B has -6.3 kcal/mol. This 1.8 kcal/mol difference is substantial and often outweighs minor ADME concerns. While Ligand B has better DILI and metabolic stability, the stronger binding of Ligand A is critical for a GPCR target. The TPSA of Ligand A is also more favorable.
Therefore, I would choose Ligand A.
Output:
1
2025-04-17 21:45:16,420 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [465.193, 36.67, 4.138, 0, 5, 0.583, 67.003, 93.563, -5.038, -3.859, 0.977, 55.605, 18.672, 0.888, -6.1]
**Ligand B:** [344.459, 67.23, 2.134, 1, 4, 0.804, 29.236, 50.523, -4.926, -1.793, 0.191, 36.363, -2.582, 0.054, -7.5]
Here's a step-by-step comparison, considering GPCR priorities (logP, Pgp, TPSA, affinity) and general drug-like properties:
1. **MW:** Ligand A (465.193 Da) is at the upper end of the ideal range, but acceptable. Ligand B (344.459 Da) is well within the ideal range.
2. **TPSA:** Ligand A (36.67) is excellent, well below the 140 threshold and good for permeability. Ligand B (67.23) is higher, but still reasonable.
3. **logP:** Ligand A (4.138) is slightly high, potentially leading to solubility issues or off-target interactions. Ligand B (2.134) is optimal.
4. **HBD:** Ligand A (0) is ideal. Ligand B (1) is also acceptable.
5. **HBA:** Ligand A (5) is good. Ligand B (4) is also good.
6. **QED:** Ligand B (0.804) is better than Ligand A (0.583), indicating a more drug-like profile.
7. **DILI:** Ligand A (67.003) has a concerning DILI risk. Ligand B (29.236) has a very low DILI risk. This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (93.563) shows excellent BBB penetration. Ligand B (50.523) is moderate. While ADRB2 is cardiovascular, some CNS effects are possible with certain ligands, so this is a plus for A.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Ligand A (-3.859) has poor aqueous solubility, consistent with its high logP. Ligand B (-1.793) is better, but still not ideal.
11. **hERG:** Ligand A (0.977) has a low hERG risk. Ligand B (0.191) has a very low hERG risk.
12. **Cl_mic:** Ligand A (55.605) has moderate clearance. Ligand B (36.363) has lower clearance, indicating better metabolic stability.
13. **t1/2:** Ligand A (18.672) has a reasonable half-life. Ligand B (-2.582) has a very short half-life, which is a major drawback.
14. **Pgp:** Ligand A (0.888) has moderate Pgp efflux. Ligand B (0.054) has very low Pgp efflux, which is favorable for bioavailability.
15. **Affinity:** Ligand B (-7.5 kcal/mol) has significantly better binding affinity than Ligand A (-6.1 kcal/mol). This 1.4 kcal/mol difference is substantial and can outweigh some ADME concerns.
**Overall Assessment:**
Ligand B is the stronger candidate despite the short half-life. The superior binding affinity, significantly lower DILI risk, better QED, and lower Pgp efflux are major advantages. The slightly lower BBB penetration is less critical for a cardiovascular target. While the half-life is a concern, it might be addressable through structural modifications. Ligand A's high logP and associated solubility issues, combined with the elevated DILI risk, make it less attractive.
Output:
0
2025-04-17 21:45:16,420 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (401.476 Da) is slightly higher than Ligand B (353.419 Da), but both are acceptable.
**2. TPSA:** Ligand A (61.88) is significantly better than Ligand B (110.96). For a GPCR, lower TPSA is generally preferred for better permeability. Ligand B is above the 90 A^2 threshold, which is a concern.
**3. logP:** Ligand A (1.325) is within the optimal range (1-3), while Ligand B (-0.447) is a bit low, potentially hindering membrane permeability.
**4. H-Bond Donors:** Ligand A (1) and Ligand B (2) are both acceptable.
**5. H-Bond Acceptors:** Ligand A (6) and Ligand B (5) are both acceptable.
**6. QED:** Both ligands have similar, good QED values (0.678 and 0.696).
**7. DILI:** Both ligands have low DILI risk (29.779 and 26.444), which is excellent.
**8. BBB:** Ligand A (77.2) has a better BBB percentile than Ligand B (51.221). While ADRB2 isn't a CNS target, some degree of BBB penetration can be beneficial for overall distribution and potentially off-target effects.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and requires further investigation. However, the magnitude of the negative value is similar for both.
**10. Aqueous Solubility:** Both ligands have negative solubility values, which is also unusual. Again, the values are similar.
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.319 and 0.064).
**12. Microsomal Clearance:** Ligand A (-9.995) has a significantly *lower* (better) microsomal clearance than Ligand B (-8.159), indicating better metabolic stability.
**13. In vitro Half-Life:** Ligand A (-28.804) has a much longer in vitro half-life than Ligand B (10.569), which is a significant advantage.
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (0.009 and 0.007).
**15. Binding Affinity:** Ligand B (-8.6 kcal/mol) has a slightly better binding affinity than Ligand A (-7.2 kcal/mol). This is a 1.4 kcal/mol difference, which is substantial.
**Overall Assessment:**
Despite the slightly better binding affinity of Ligand B, Ligand A is the more promising candidate. The key advantages of Ligand A are its significantly lower TPSA, better logP, lower microsomal clearance, and longer half-life. These factors are particularly important for a GPCR target like ADRB2, where permeability and metabolic stability are crucial. The 1.4 kcal/mol difference in binding affinity can potentially be optimized in later stages of drug development, while improving the ADME properties of Ligand B would be more challenging.
Output:
1
2025-04-17 21:45:16,420 - INFO - Batch 281 complete. Total preferences: 4496
2025-04-17 21:45:16,420 - INFO - Processing batch 282/512...
2025-04-17 21:46:04,634 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.423 and 352.494 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (120.24) is slightly higher than Ligand B (49.41). For a cardiovascular GPCR, TPSA is not *as* critical as for a CNS target, but lower is generally preferred for absorption. Ligand B is significantly better.
3. **logP:** Ligand A (-0.384) is quite low, potentially hindering permeability. Ligand B (3.735) is excellent, falling right within the optimal 1-3 range. This is a major advantage for Ligand B.
4. **HBD:** Ligand A (3) is higher than Ligand B (1). Lower is generally preferred for permeability, giving a slight edge to Ligand B.
5. **HBA:** Ligand A (6) is higher than Ligand B (2). Again, lower is generally preferred, favoring Ligand B.
6. **QED:** Both ligands have good QED scores (0.476 and 0.643), indicating reasonable drug-likeness. Ligand B is slightly better.
7. **DILI:** Ligand A (38.193) has a slightly higher DILI risk than Ligand B (16.053). Lower is better, so Ligand B is preferred.
8. **BBB:** Ligand A (54.634) has a lower BBB penetration percentile than Ligand B (88.174). While ADRB2 isn't a CNS target, some distribution to the CNS can be associated with off-target effects, and lower BBB is preferable. Ligand B is better.
9. **Caco-2:** Ligand A (-5.823) has a negative Caco-2 value, which is concerning. Ligand B (-4.63) is also low, but less negative. Both are suboptimal, but Ligand B is slightly better.
10. **Solubility:** Ligand A (-1.884) has poor solubility, while Ligand B (-3.55) is also poor. Both are problematic, but Ligand B is slightly better.
11. **hERG:** Ligand A (0.588) has a slightly higher hERG risk than Ligand B (0.733). Lower is better, favoring Ligand A slightly.
12. **Cl_mic:** Ligand A (-11.655) has significantly lower (better) microsomal clearance than Ligand B (35.187), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (-20.937) has a negative in vitro half-life, which is concerning. Ligand B (7.294) has a reasonable half-life. This is a major advantage for Ligand B.
14. **Pgp:** Ligand A (0.003) has very low P-gp efflux, which is excellent. Ligand B (0.563) has moderate P-gp efflux. This is a strong advantage for Ligand A.
15. **Affinity:** Ligand A (-7.3) has slightly better binding affinity than Ligand B (-6.9). While both are good, the difference isn't huge.
**Overall Assessment:**
Ligand B excels in several key areas for a GPCR target: logP, TPSA, BBB, and DILI. It also has a reasonable half-life. Ligand A has better metabolic stability (Cl_mic) and P-gp efflux, but suffers from poor logP, solubility, and a concerning negative half-life. The slightly better affinity of Ligand A is unlikely to overcome its significant ADME liabilities.
Given the GPCR-specific priorities (logP, Pgp, TPSA, affinity) and the overall balance of properties, Ligand B appears to be the more promising drug candidate.
Output:
0
2025-04-17 21:46:04,635 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.479 and 352.475 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (78.43) is better than Ligand B (84.5). Both are below 140, but lower TPSA generally favors absorption.
3. **logP:** Ligand A (1.479) is within the optimal 1-3 range. Ligand B (2.165) is also acceptable, but slightly higher.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (4). Fewer HBAs generally improve permeability.
6. **QED:** Both ligands have similar QED values (0.769 and 0.718), indicating good drug-likeness.
7. **DILI:** Ligand A (17.138) has a significantly lower DILI risk than Ligand B (40.364). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (68.554) has a better BBB penetration potential than Ligand A (49.515). While ADRB2 isn't strictly a CNS target, some CNS exposure can be relevant for off-target effects.
9. **Caco-2:** Ligand A (-5.015) and Ligand B (-4.844) have similar Caco-2 permeability values.
10. **Solubility:** Ligand A (-0.254) has better aqueous solubility than Ligand B (-3.089). Solubility is important for bioavailability.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.089 and 0.112), which is excellent.
12. **Cl_mic:** Ligand A (22.695) has lower microsomal clearance than Ligand B (25.033), suggesting better metabolic stability.
13. **t1/2:** Ligand A (20.164) has a longer in vitro half-life than Ligand B (-4.872). This is a significant advantage for dosing convenience.
14. **Pgp:** Ligand A (0.001) has much lower P-gp efflux liability than Ligand B (0.042). Lower P-gp efflux improves bioavailability.
15. **Affinity:** Both ligands have very similar binding affinities (-6.8 and -6.9 kcal/mol). The difference is negligible.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A has a better logP, lower TPSA, significantly lower Pgp efflux, and comparable affinity. While Ligand B has slightly better BBB penetration, the other advantages of Ligand A outweigh this. The lower DILI risk and better metabolic stability of Ligand A are also crucial.
**Conclusion:**
Ligand A is the more promising drug candidate due to its superior ADME properties (lower DILI, better solubility, lower Pgp efflux, better metabolic stability, and longer half-life) without sacrificing binding affinity.
Output:
1
2025-04-17 21:46:04,635 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's break down the comparison of Ligand A and Ligand B based on the provided parameters and the guidelines, keeping in mind ADRB2 is a GPCR.
1. **Molecular Weight:** Both ligands (356.373 and 379.287 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (75.63) is higher than Ligand B (61.36). For a GPCR, lower TPSA is generally preferred for better brain penetration, even though ADRB2 isn't strictly a CNS target. Ligand B has an advantage.
3. **logP:** Ligand A (2.496) is within the optimal range (1-3). Ligand B (4.968) is higher, potentially leading to solubility issues and off-target interactions. Ligand A is better.
4. **H-Bond Donors:** Ligand A (0) is preferable to Ligand B (3). Fewer HBDs generally improve membrane permeability.
5. **H-Bond Acceptors:** Ligand A (5) is better than Ligand B (2).
6. **QED:** Ligand A (0.832) is significantly better than Ligand B (0.703), indicating a more drug-like profile.
7. **DILI:** Ligand A (53.315) is slightly higher than Ligand B (42.691), but both are acceptable (below 60). Ligand B has a slight advantage.
8. **BBB:** Ligand A (90.074) is much better than Ligand B (41.373). While ADRB2 isn't a primary CNS target, higher BBB penetration can be beneficial for overall distribution and potentially accessing peripheral ADRB2 receptors.
9. **Caco-2:** Ligand A (-4.102) is better than Ligand B (-5.032), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-2.195) is better than Ligand B (-5.138). Solubility is crucial for bioavailability.
11. **hERG:** Ligand A (0.202) is significantly better than Ligand B (0.558), indicating a lower risk of cardiotoxicity, which is *critical* for a cardiovascular target.
12. **Cl_mic:** Ligand A (36.149) is better than Ligand B (55.737), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-11.367) is better than Ligand B (35.998).
14. **Pgp:** Ligand A (0.058) is much better than Ligand B (0.114), indicating lower P-glycoprotein efflux and potentially improved bioavailability.
15. **Binding Affinity:** Ligand B (-7.3) is significantly better than Ligand A (-5.5). This is a substantial difference (1.8 kcal/mol), and affinity is a primary driver.
**Overall Assessment:**
Ligand B has a significantly higher binding affinity, which is a major advantage. However, it suffers from higher logP, more HBDs, lower solubility, a higher hERG risk, and lower BBB penetration. Ligand A has a more balanced profile, with better ADME properties (solubility, permeability, metabolic stability, reduced toxicity) and a good QED score. The hERG risk associated with Ligand B is a serious concern for a cardiovascular drug. While the affinity difference is substantial, the other drawbacks of Ligand B, particularly the hERG risk, outweigh this benefit.
Therefore, I choose Ligand A.
**Output:**
1
2025-04-17 21:46:04,635 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (343.47 and 347.35 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (55.4) is significantly better than Ligand B (95.4). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold, while Ligand B is approaching it.
3. **logP:** Ligand A (3.81) is good, within the optimal 1-3 range. Ligand B (1.65) is on the lower side, potentially impacting permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (3) is better than Ligand B (4). Similar reasoning as HBD.
6. **QED:** Both ligands have good QED scores (0.799 and 0.822), indicating good overall drug-likeness. No clear advantage.
7. **DILI:** Ligand A (32.3%) has a much lower DILI risk than Ligand B (77.9%). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (71.0%) has slightly better BBB penetration than Ligand B (64.0%). While not a primary concern for a cardiovascular target, it's a positive.
9. **Caco-2:** Ligand A (-4.313) is better than Ligand B (-5.196). Higher (less negative) Caco-2 values indicate better permeability.
10. **Solubility:** Ligand A (-4.611) is better than Ligand B (-2.93). Higher solubility is generally desirable.
11. **hERG:** Ligand A (0.511) is significantly better than Ligand B (0.101). Lower hERG inhibition is crucial for avoiding cardiotoxicity, especially for a cardiovascular target.
12. **Cl_mic:** Ligand B (-16.473) has a lower (better) microsomal clearance than Ligand A (109.652), indicating better metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand B (-30.702) has a longer half-life than Ligand A (-18.341). This is a positive for Ligand B.
14. **Pgp:** Ligand A (0.437) is better than Ligand B (0.012). Lower P-gp efflux is preferable.
15. **Binding Affinity:** Ligand B (-7.5 kcal/mol) has a slightly better binding affinity than Ligand A (-8.0 kcal/mol). While the difference is small, it's a positive for Ligand B.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A excels in TPSA, Pgp, and has a good logP. Ligand B has slightly better affinity and metabolic stability (Cl_mic and t1/2). However, the significantly higher DILI and hERG risk associated with Ligand B are major concerns for a cardiovascular drug.
**Overall Assessment:**
While Ligand B has a slightly better binding affinity and metabolic profile, the significantly lower DILI and hERG risk of Ligand A, combined with its better TPSA, solubility, and Caco-2 permeability, make it the more promising drug candidate. The cardiovascular context makes mitigating cardiotoxicity (hERG) and liver toxicity (DILI) paramount.
Output:
1
2025-04-17 21:46:04,635 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.46 & 348.49 Da) fall comfortably within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (82.53) is slightly higher than Ligand B (78.09). Both are below 140, which is good for oral absorption, and acceptable for a cardiovascular GPCR. Slight edge to B.
3. **logP:** Ligand A (2.05) is within the optimal 1-3 range. Ligand B (3.052) is at the higher end, but still acceptable. A is slightly preferred.
4. **HBD:** Both ligands have 2 HBD, which is within the desired limit of <=5. No difference.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 3. Both are below the 10 limit. Slight edge to B.
6. **QED:** Both ligands have similar QED values (0.754 and 0.72), indicating good drug-likeness. No significant difference.
7. **DILI:** Ligand A (17.41) has a significantly lower DILI risk than Ligand B (36.41). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (64.482) has a higher BBB penetration percentile than Ligand A (57.968). While ADRB2 isn't a CNS target, some distribution to the CNS can be a concern for off-target effects. Still, this is less important than other factors.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. Ligand B (-4.947) is slightly worse than Ligand A (-4.707). A is slightly preferred.
10. **Solubility:** Ligand B (-3.626) has a better solubility score than Ligand A (-2.066). This is a positive for Ligand B.
11. **hERG:** Both ligands have low hERG inhibition risk (0.316 and 0.412). No significant difference.
12. **Cl_mic:** Ligand A (40.281) has a lower microsomal clearance than Ligand B (71.774), suggesting better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (15.181) has a longer in vitro half-life than Ligand B (-2.751). This is a strong advantage for Ligand A.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.032 and 0.149). No significant difference.
15. **Binding Affinity:** Ligand A (-6.5 kcal/mol) has a slightly better binding affinity than Ligand B (-4.3 kcal/mol). This is a substantial advantage for Ligand A, exceeding the 1.5 kcal/mol threshold.
**GPCR-Specific Considerations:**
For a cardiovascular GPCR like ADRB2, logP, TPSA, and affinity are important. While Ligand B has a slightly better logP and TPSA, Ligand A has a significantly better binding affinity and superior ADME properties (DILI, Cl_mic, t1/2). The substantial difference in binding affinity and the lower DILI risk of Ligand A outweigh the minor advantages of Ligand B.
**Conclusion:**
Ligand A is the more promising drug candidate due to its superior binding affinity, lower DILI risk, better metabolic stability (lower Cl_mic), longer half-life, and acceptable physicochemical properties.
Output:
1
2025-04-17 21:46:04,636 - INFO - Here's my reasoning and final output for the ligand preference:
**Reasoning:**
We are targeting ADRB2, a GPCR, so the priorities are logP, Pgp, TPSA, affinity, and BBB. Let's compare Ligand A and Ligand B across these and other important parameters:
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da).
2. **TPSA:** Ligand A (53.51) is significantly better than Ligand B (93.87). Lower TPSA generally favors oral absorption and is crucial for GPCR ligands.
3. **logP:** Ligand A (2.632) is optimal, while Ligand B (0.381) is quite low, potentially hindering membrane permeability.
4. **H-Bond Donors/Acceptors:** Both are acceptable, though Ligand B has slightly more.
5. **QED:** Both are good (>0.5).
6. **DILI:** Ligand B (26.677) has a much lower DILI risk than Ligand A (36.293), which is a significant advantage.
7. **BBB:** Ligand A (80.38) has a substantially better BBB penetration score than Ligand B (57.929). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be beneficial or at least less detrimental.
8. **Caco-2:** Both are negative, indicating poor permeability.
9. **Solubility:** Both are negative, indicating poor solubility.
10. **hERG:** Both have low hERG risk.
11. **Cl_mic:** Ligand B (-8.018) has a *much* lower (better) microsomal clearance than Ligand A (39.604), suggesting better metabolic stability.
12. **t1/2:** Ligand B (-19.347) has a much longer half-life than Ligand A (0.97), which is a major advantage.
13. **Pgp:** Both have low Pgp efflux.
14. **Binding Affinity:** Ligand B (-7.3 kcal/mol) has a slightly better binding affinity than Ligand A (-5.4 kcal/mol). This 1.9 kcal/mol difference is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand B is the stronger candidate. While Ligand A has better BBB penetration, Ligand B excels in critical areas like metabolic stability (Cl_mic, t1/2), DILI risk, and binding affinity. The low logP of Ligand B is a concern, but the superior binding affinity and metabolic profile are more important for a GPCR target like ADRB2. The poor Caco-2 and solubility are shared drawbacks that would need to be addressed in further optimization, but the core properties of Ligand B are more favorable.
**Output:**
0
2025-04-17 21:46:04,636 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (379.479 and 361.873 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (62.3) is significantly better than Ligand A (139.03). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (2.832) is optimal, while Ligand A (-1.196) is too low, potentially hindering membrane permeability. This is a significant strike against Ligand A.
4. **HBD:** Ligand A (3) is acceptable, Ligand B (1) is even better.
5. **HBA:** Ligand A (6) is acceptable, Ligand B (3) is better.
6. **QED:** Ligand B (0.839) is excellent, indicating strong drug-like properties. Ligand A (0.484) is below the desirable 0.5 threshold.
7. **DILI:** Ligand B (29.236) has a much lower DILI risk than Ligand A (53.47). This is a crucial advantage for Ligand B.
8. **BBB:** Ligand B (78.79) is higher, but since ADRB2 is a cardiovascular target, this isn't a major factor. Ligand A (21.791) is low.
9. **Caco-2:** Ligand A (-5.645) is better than Ligand B (-4.861).
10. **Solubility:** Ligand A (-0.879) is better than Ligand B (-4.066).
11. **hERG:** Both are very low (0.09 and 0.372), indicating minimal hERG inhibition risk. No significant difference.
12. **Cl_mic:** Ligand A (4.885) has a lower microsomal clearance, suggesting better metabolic stability than Ligand B (16.617). This is a positive for Ligand A.
13. **t1/2:** Ligand B (-16.963) has a longer half-life than Ligand A (-46.407).
14. **Pgp:** Both are very low (0.038 and 0.052), indicating minimal P-gp efflux. No significant difference.
15. **Affinity:** Both ligands have comparable binding affinity (-6.2 and -5.6 kcal/mol). The difference is less than the 1.5 kcal/mol threshold.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are important. Ligand B excels in logP and TPSA, while affinity is similar. Ligand A has better solubility and metabolic stability, but the poor logP and lower QED are significant drawbacks.
**Overall Assessment:**
Ligand B is the better candidate. While Ligand A has slightly better metabolic stability and solubility, Ligand B's superior logP, TPSA, QED, and significantly lower DILI risk outweigh these advantages. The comparable binding affinity seals the deal.
Output:
0
2025-04-17 21:46:04,636 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (362.371 and 371.453 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand B (75.43) is significantly better than Ligand A (132.01). ADRB2 is not a CNS target, but lower TPSA generally improves absorption.
3. **logP:** Ligand B (2.411) is optimal (1-3 range), while Ligand A (0.387) is quite low, potentially hindering membrane permeability. This is a significant advantage for Ligand B.
4. **HBD:** Both ligands have 2 HBD, which is within the acceptable limit of 5.
5. **HBA:** Ligand A (8) is higher than Ligand B (4). Lower HBA is generally preferred for better permeability, giving a slight edge to Ligand B.
6. **QED:** Both ligands have reasonable QED scores (0.648 and 0.57), indicating good drug-like properties.
7. **DILI:** Ligand B (61.691) is better than Ligand A (92.206). Lower DILI risk is crucial.
8. **BBB:** Not a major priority for ADRB2 (cardiovascular target). Ligand B (76.774) is higher than Ligand A (39.938), but this isn't decisive.
9. **Caco-2:** Both are negative, indicating poor permeability. However, Ligand A (-5.332) is worse than Ligand B (-5.099).
10. **Solubility:** Both ligands have very poor solubility (-2.654 and -3.682). This is a concern for both, but Ligand B is slightly better.
11. **hERG:** Ligand A (0.197) is better than Ligand B (0.817), indicating lower cardiotoxicity risk. This is a significant positive for Ligand A.
12. **Cl_mic:** Both ligands have similar microsomal clearance (32.453 and 32.916 mL/min/kg), suggesting similar metabolic stability.
13. **t1/2:** Ligand B (8.141) has a much longer in vitro half-life than Ligand A (-30.085). This is a major advantage for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.034) has lower P-gp efflux than Ligand B (0.078), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand A (-6.6 kcal/mol) is slightly better than Ligand B (-6.2 kcal/mol), but the difference is not large enough to overcome the other ADME deficiencies.
**Overall Assessment:**
Ligand B demonstrates a better balance of properties, particularly regarding logP, DILI, and half-life. While Ligand A has a slightly better binding affinity and hERG inhibition, the poor logP and high DILI risk are significant drawbacks. The longer half-life of Ligand B is a substantial advantage for a cardiovascular drug. The lower TPSA of Ligand B also contributes to a more favorable profile.
Output:
0
2025-04-17 21:46:04,636 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for their potential as drug candidates targeting the ADRB2, a cardiovascular GPCR. The key priorities for GPCRs are logP, Pgp efflux, TPSA, and binding affinity, with BBB being less critical for a cardiovascular target.
Let's compare the ligands property by property:
1. **MW:** Both ligands (356.394 and 361.364 Da) fall within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (99.1) is slightly higher than Ligand B (87.3). Both are acceptable for oral absorption, but B is better.
3. **logP:** Ligand A (-0.933) is a bit low, potentially hindering permeability. Ligand B (0.722) is much better, falling within the optimal 1-3 range. This is a significant advantage for B.
4. **HBD:** Both have 3 H-bond donors, which is good.
5. **HBA:** Ligand A has 5 H-bond acceptors, while Ligand B has 3. Lower is generally preferred, giving a slight edge to B.
6. **QED:** Both ligands have similar QED values (0.591 and 0.595), indicating good drug-likeness.
7. **DILI:** Ligand A (14.618%) has a much lower DILI risk than Ligand B (29.314%). This is a substantial advantage for A.
8. **BBB:** Ligand B (71.733%) has better BBB penetration than Ligand A (46.336%), but this is less critical for a cardiovascular target.
9. **Caco-2:** Both have similar, poor Caco-2 permeability (-5.23 and -5.178).
10. **Solubility:** Both have poor aqueous solubility (-1.088 and -2.548).
11. **hERG:** Both have low hERG inhibition risk (0.282 and 0.221).
12. **Cl_mic:** Ligand A (-9.604) has significantly lower (better) microsomal clearance than Ligand B (-1.658), indicating better metabolic stability.
13. **t1/2:** Ligand A (7.215) has a longer half-life than Ligand B (-6.61).
14. **Pgp:** Both have very low Pgp efflux liability (0.008 and 0.019).
15. **Affinity:** Ligand B (-7.6 kcal/mol) has a stronger binding affinity than Ligand A (-6.9 kcal/mol). This is a 0.7 kcal/mol difference, which is significant.
**Overall Assessment:**
Ligand B has a superior logP and binding affinity, which are crucial for GPCR targets. While Ligand A has better DILI and metabolic stability, the stronger binding of Ligand B, combined with its acceptable ADME profile, outweighs these concerns. The slightly lower DILI of A is a positive, but not enough to overcome the potency advantage of B.
**Output:**
0
2025-04-17 21:46:04,636 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.4 & 363.5 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (66.65 & 64.02) are below the 140 A^2 threshold for good oral absorption, which is good.
3. **logP:** Ligand A (2.036) is within the optimal 1-3 range, while Ligand B (3.166) is at the higher end. This favors Ligand A slightly, as high logP can sometimes lead to off-target effects.
4. **HBD:** Both have 0 HBD, which is acceptable.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 6. Both are below the 10 threshold.
6. **QED:** Ligand A (0.834) has a significantly better QED score than Ligand B (0.698), indicating a more drug-like profile.
7. **DILI:** Ligand A (34.28%) has a lower DILI risk than Ligand B (51.57%), which is a significant advantage.
8. **BBB:** Ligand A (83.29%) has a much higher BBB penetration score than Ligand B (65.06%). While ADRB2 isn't strictly a CNS target, some peripheral ADRB2 activity can be modulated by CNS effects, and higher BBB penetration isn't necessarily detrimental.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-1.87) has a slightly better (less negative) solubility score than Ligand B (-3.977).
11. **hERG:** Both ligands have very low hERG inhibition risk (0.372 and 0.249).
12. **Cl_mic:** Ligand A (32.47 mL/min/kg) has a lower microsomal clearance than Ligand B (63.46 mL/min/kg), indicating better metabolic stability.
13. **t1/2:** Ligand A (-9.132 hours) has a longer in vitro half-life than Ligand B (-11.529 hours).
14. **Pgp:** Both ligands have low Pgp efflux liability (0.147 and 0.301).
15. **Binding Affinity:** Ligand A (-8.2 kcal/mol) has a slightly better binding affinity than Ligand B (-6.6 kcal/mol). The difference is 1.6 kcal/mol, which is significant enough to outweigh some minor ADME drawbacks.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand A performs better on logP, has comparable Pgp and TPSA, and a significantly better binding affinity. The better QED, lower DILI, and better metabolic stability (lower Cl_mic and longer t1/2) further support Ligand A.
**Conclusion:**
Ligand A consistently outperforms Ligand B across several crucial parameters, including QED, DILI risk, metabolic stability, and binding affinity. While both have issues with Caco-2 permeability, the overall profile of Ligand A makes it a more promising drug candidate.
Output:
1
2025-04-17 21:46:04,636 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, priorities are logP, TPSA, Pgp, affinity, and to a lesser extent, BBB.
Let's compare the ligands parameter by parameter:
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (342.443 Da) is slightly smaller, which *could* be advantageous for permeability, but the difference isn't huge.
2. **TPSA:** Ligand A (93.65) is higher than Ligand B (69.3). Ligand B is significantly better here, falling well below the 140 threshold for oral absorption and closer to the ideal for GPCRs.
3. **logP:** Both are within the optimal 1-3 range. Ligand A (2.65) and Ligand B (2.293) are comparable.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A (7) has more HBAs than Ligand B (3). Ligand B is preferred here.
6. **QED:** Both have good QED scores (A: 0.79, B: 0.913), indicating drug-likeness. Ligand B is slightly better.
7. **DILI:** Ligand A (97.014) has a very high DILI risk, which is a major concern. Ligand B (29.081) has a low DILI risk, a significant advantage.
8. **BBB:** Both have reasonable BBB penetration (A: 72.005, B: 74.06). Not a primary concern for a cardiovascular target, but slightly favors B.
9. **Caco-2:** Ligand A (-4.547) has a worse Caco-2 value than Ligand B (-5.009). Lower values are less desirable.
10. **Solubility:** Ligand A (-4.554) has a worse solubility value than Ligand B (-2.905).
11. **hERG:** Both have relatively low hERG risk (A: 0.512, B: 0.622).
12. **Cl_mic:** Ligand A (49.488) has a higher microsomal clearance than Ligand B (45.669). Lower is better.
13. **t1/2:** Ligand A (47.442) has a longer in vitro half-life than Ligand B (-36.665). This is a positive for A, but the negative value for B is concerning.
14. **Pgp:** Ligand A (0.248) has a higher Pgp efflux liability than Ligand B (0.069). Lower is better.
15. **Affinity:** Ligand A (-7.2 kcal/mol) has a slightly better binding affinity than Ligand B (-6.3 kcal/mol). This is a 0.9 kcal/mol difference, which is significant, but not overwhelming given the other factors.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity and in vitro half-life, the extremely high DILI risk and unfavorable TPSA, Caco-2, solubility, and Pgp values make it a less desirable candidate. Ligand B has a much better safety profile (DILI), better absorption/permeability characteristics (TPSA, Caco-2, solubility, Pgp), and a good QED score. The slightly weaker affinity is a trade-off I'm willing to accept given the significant improvements in other critical parameters.
**Output:**
0
2025-04-17 21:46:04,637 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Step-by-step comparison:**
1. **MW:** Both ligands (354.397 and 356.491 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (53.76) is better than Ligand B (58.2), both are acceptable for a non-CNS GPCR target like ADRB2, but lower is generally preferred.
3. **logP:** Ligand A (2.707) is optimal, while Ligand B (4.587) is pushing the upper limit. Higher logP can lead to off-target effects and solubility issues.
4. **HBD:** Ligand A (0) is preferred over Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Both ligands have 3 HBA, which is acceptable.
6. **QED:** Ligand A (0.757) is slightly better than Ligand B (0.646), indicating a more drug-like profile.
7. **DILI:** Ligand A (17.72) is significantly better than Ligand B (58.627). This is a crucial factor, as lower DILI risk is highly desirable.
8. **BBB:** Both ligands have high BBB penetration (A: 83.211, B: 85.498), but this is less critical for ADRB2, a primarily peripheral receptor.
9. **Caco-2:** Ligand A (-4.691) is better than Ligand B (-5.008). Higher Caco-2 permeability suggests better absorption.
10. **Solubility:** Ligand A (-2.287) is better than Ligand B (-5.015). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.518) is better than Ligand B (0.808), indicating a lower risk of cardiotoxicity.
12. **Cl_mic:** Ligand A (15.261) is significantly better than Ligand B (77.807). Lower clearance implies better metabolic stability.
13. **t1/2:** Ligand A (16.167) is better than Ligand B (12.446). Longer half-life is generally preferred.
14. **Pgp:** Ligand A (0.072) is significantly better than Ligand B (0.688). Lower P-gp efflux means better bioavailability.
15. **Affinity:** Ligand B (-7.9) has a significantly stronger binding affinity than Ligand A (-6.3). This is a 1.6 kcal/mol difference, which is substantial.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. While Ligand B has a higher logP and better affinity, the significantly worse DILI, Cl_mic, Pgp, solubility, and hERG profiles of Ligand B outweigh the affinity benefit. The difference in affinity, while substantial, is not enough to overcome the ADME/Tox liabilities. Ligand A presents a much more balanced profile with acceptable ADME properties and a lower risk profile.
**Output:**
1
2025-04-17 21:46:04,637 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (345.483 and 351.407 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (49.77) is significantly better than Ligand B (114.47). ADRB2 is not a CNS target, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold, while Ligand B is approaching it.
3. **logP:** Ligand A (3.103) is optimal, while Ligand B (1.483) is on the lower side. For a GPCR, a logP between 1-3 is preferred, and Ligand A is closer to the upper end of this range, which is generally favorable for membrane permeability.
4. **HBD:** Ligand A (1) is better than Ligand B (3). Lower HBD is generally preferred for permeability.
5. **HBA:** Ligand A (3) is better than Ligand B (7). Similar to HBD, lower HBA is preferred.
6. **QED:** Ligand A (0.916) is significantly better than Ligand B (0.544), indicating a more drug-like profile.
7. **DILI:** Ligand A (14.153) is *much* better than Ligand B (78.054). This is a critical advantage for Ligand A, as liver toxicity is a major concern in drug development.
8. **BBB:** This is less critical for ADRB2, but Ligand A (91.508) is better than Ligand B (66.188).
9. **Caco-2:** Both are negative, indicating poor permeability. However, Ligand A (-4.234) is slightly better than Ligand B (-4.833).
10. **Solubility:** Both are negative, indicating poor solubility. Ligand A (-3.031) is slightly better than Ligand B (-3.119).
11. **hERG:** Ligand A (0.839) is better than Ligand B (0.108). Lower hERG inhibition is crucial for avoiding cardiotoxicity, especially given the cardiovascular target.
12. **Cl_mic:** Ligand A (38.393) is better than Ligand B (42.129). Lower clearance is preferred for better metabolic stability.
13. **t1/2:** Ligand A (21.355) is better than Ligand B (16.728). Longer half-life is generally desirable.
14. **Pgp:** Ligand A (0.584) is better than Ligand B (0.018). Lower P-gp efflux is preferred.
15. **Binding Affinity:** Ligand B (-7.1) is slightly better than Ligand A (-7.4). However, the difference is small (0.3 kcal/mol) and can be overcome by the superior ADME properties of Ligand A.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical ADME properties (DILI, TPSA, logP, QED, hERG, Cl_mic, t1/2, Pgp). While Ligand B has a slightly better binding affinity, the significant advantages of Ligand A in terms of safety (DILI, hERG) and drug-likeness make it the more promising candidate. The small difference in binding affinity is unlikely to outweigh these substantial ADME benefits.
Output:
1
2025-04-17 21:46:04,637 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (355.419 and 362.459 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (77.25) is well below the 140 threshold, and even better, below 90, which is good for GPCRs. Ligand B (93.01) is still under 140, but closer to the limit. A favors better permeability.
3. **logP:** Ligand A (3.668) is at the higher end of the optimal 1-3 range, while Ligand B (1.239) is at the lower end. For a GPCR, a slightly higher logP is generally acceptable, but Ligand B is quite low, potentially hindering membrane permeability.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 6 HBA, and Ligand B has 7. Both are acceptable, under the 10 threshold.
6. **QED:** Both ligands have good QED scores (0.769 and 0.834), indicating good drug-like properties.
7. **DILI:** Ligand A has a very high DILI risk (99.341%), which is a major concern. Ligand B has a much lower DILI risk (71.733%), which is still not ideal, but significantly better.
8. **BBB:** Ligand A (58.007%) has moderate BBB penetration, while Ligand B (39.667%) is lower. While ADRB2 isn't necessarily a CNS target, some degree of BBB penetration isn't detrimental.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.103 and -5.265), which is unusual and suggests poor permeability. This is a red flag for both.
10. **Solubility:** Ligand A (-5.482) has slightly better solubility than Ligand B (-2.064), but both are poor.
11. **hERG:** Ligand A (0.606) has a slightly higher hERG risk than Ligand B (0.06), but both are relatively low.
12. **Cl_mic:** Ligand A (93.893) has a higher microsomal clearance than Ligand B (20.476), indicating lower metabolic stability. Ligand B is much better here.
13. **t1/2:** Ligand A (54.099) has a longer in vitro half-life than Ligand B (8.383). This is a positive for Ligand A.
14. **Pgp:** Ligand A (0.149) has lower P-gp efflux than Ligand B (0.034), which is favorable.
15. **Binding Affinity:** Ligand A (-6.9 kcal/mol) has a slightly better binding affinity than Ligand B (-5.7 kcal/mol). This is a 1.2 kcal/mol difference, which is significant.
**Overall Assessment:**
Ligand A has a better binding affinity and half-life, and slightly better solubility and Pgp efflux. However, its extremely high DILI risk is a major drawback. Ligand B has a much more acceptable DILI profile and significantly better metabolic stability (lower Cl_mic). The lower logP and BBB penetration are less concerning for a non-CNS target like ADRB2. The Caco-2 values are concerning for both, but the superior ADME profile of Ligand B, particularly the lower DILI and better metabolic stability, outweigh the slightly weaker binding affinity.
Therefore, I would choose Ligand B.
Output:
0
2025-04-17 21:46:04,637 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.475 and 344.455 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (70.08) is higher than Ligand B (49.85). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is generally preferred for absorption. Ligand B has a clear advantage.
3. **logP:** Ligand A (1.41) is within the optimal range, while Ligand B (2.486) is slightly higher. Both are acceptable, but Ligand A is marginally better.
4. **HBD:** Ligand A (1) is preferable to Ligand B (0) as a single HBD can contribute to solubility without significantly impacting permeability.
5. **HBA:** Ligand A (4) is slightly higher than Ligand B (3). Both are within the acceptable limit of 10.
6. **QED:** Ligand A (0.812) has a better QED score than Ligand B (0.723), indicating a more drug-like profile.
7. **DILI:** Ligand B (40.287) has a significantly better DILI score than Ligand A (15.2), indicating a lower risk of liver injury. This is a major advantage for Ligand B.
8. **BBB:** Ligand B (76.541) has a higher BBB penetration score than Ligand A (56.65). While ADRB2 isn't a primary CNS target, some brain exposure is possible, and higher BBB is generally favorable.
9. **Caco-2:** Ligand A (-4.282) and Ligand B (-4.573) both have negative values, which is unusual. Lower values indicate lower permeability. Ligand B is slightly worse.
10. **Solubility:** Ligand A (-1.225) is better than Ligand B (-3.144). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.197) has a lower hERG inhibition liability than Ligand B (0.273), meaning it's less likely to cause cardiotoxicity. This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand B (83.188) has a much higher microsomal clearance than Ligand A (25.719), indicating faster metabolism and potentially lower *in vivo* exposure. Ligand A is significantly better here.
13. **t1/2:** Ligand A (24.64) has a longer in vitro half-life than Ligand B (-3.801). This is a significant advantage for Ligand A, suggesting less frequent dosing could be possible.
14. **Pgp:** Ligand A (0.115) has lower P-gp efflux liability than Ligand B (0.459), which is favorable for absorption and bioavailability.
15. **Affinity:** Ligand B (-7.1) has a significantly stronger binding affinity than Ligand A (-5.4). This is a substantial advantage that can outweigh some ADME concerns. A 1.7 kcal/mol difference is significant.
**Overall Assessment:**
Ligand B has a superior binding affinity and better DILI and BBB scores. However, it suffers from higher microsomal clearance, lower solubility, and higher P-gp efflux. Ligand A has better ADME properties (solubility, clearance, half-life, Pgp) and a lower hERG risk, but its affinity is weaker.
Given the GPCR target class, affinity is paramount. The 1.7 kcal/mol difference in binding affinity is substantial enough to overcome the ADME liabilities of Ligand B, especially considering that the liabilities aren't catastrophic. The better DILI score is also a significant benefit.
Output:
0
2025-04-17 21:46:04,637 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [344.371, 99.51, 0.507, 1, 5, 0.874, 63.164, 51.415, -5.043, -1.552, 0.152, 5.585, -5.813, 0.031, -6.7]
**Ligand B:** [339.439, 64.41, 2.328, 0, 3, 0.846, 30.787, 73.827, -4.377, -2.885, 0.489, 47.062, -9.694, 0.093, -6.2]
Here's a breakdown of the comparison, focusing on the GPCR-relevant parameters and general drug-likeness:
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (339.439) is slightly lower, which is generally favorable.
2. **TPSA:** Ligand A (99.51) is higher than Ligand B (64.41). Both are acceptable, but Ligand B is better, promoting better membrane permeability.
3. **logP:** Ligand A (0.507) is quite low, potentially hindering permeability. Ligand B (2.328) is within the optimal range (1-3). This is a significant advantage for Ligand B.
4. **HBD/HBA:** Ligand A has 1 HBD and 5 HBA, while Ligand B has 0 HBD and 3 HBA. Both are reasonable, but lower is generally preferred for permeability. Ligand B is slightly better.
5. **QED:** Both have good QED scores (A: 0.874, B: 0.846), indicating good overall drug-likeness.
6. **DILI:** Ligand A (63.164) has a higher DILI risk than Ligand B (30.787). This is a major concern for Ligand A.
7. **BBB:** Ligand B (73.827) has a significantly higher BBB penetration percentile than Ligand A (51.415). While ADRB2 is not a CNS target, some off-target CNS effects are always a consideration, and higher BBB is generally a positive.
8. **Caco-2:** Ligand A (-5.043) and Ligand B (-4.377) have negative values, indicating poor permeability.
9. **Solubility:** Ligand A (-1.552) has worse solubility than Ligand B (-2.885).
10. **hERG:** Ligand A (0.152) has a lower hERG risk than Ligand B (0.489). This is a positive for Ligand A.
11. **Cl_mic:** Ligand A (5.585) has a lower (better) microsomal clearance than Ligand B (47.062), suggesting better metabolic stability.
12. **t1/2:** Ligand B (-9.694) has a longer in vitro half-life than Ligand A (-5.813).
13. **Pgp:** Ligand A (0.031) has lower P-gp efflux than Ligand B (0.093).
14. **Affinity:** Ligand A (-6.7) has a slightly better binding affinity than Ligand B (-6.2). The difference is 0.5 kcal/mol, which is not substantial enough to overcome other significant drawbacks.
**Overall Assessment:**
Ligand B is the stronger candidate. While Ligand A has slightly better affinity and lower hERG risk, Ligand B excels in key areas for a GPCR target: better logP, significantly lower DILI risk, and better BBB penetration. The lower TPSA and HBD/HBA counts of Ligand B also contribute to its improved predicted permeability. The longer half-life of Ligand B is also a plus. The difference in binding affinity is not large enough to outweigh the ADME/Tox advantages of Ligand B.
Output:
0
2025-04-17 21:46:04,637 - INFO - Batch 282 complete. Total preferences: 4512
2025-04-17 21:46:04,638 - INFO - Processing batch 283/512...
2025-04-17 21:46:55,959 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands (367.877 and 341.411 Da) are within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Both are below the 140 A^2 threshold for good oral absorption (81.67 and 85.43 A^2). Similar.
3. **logP:** Both ligands have good logP values (2.717 and 1.517) within the optimal 1-3 range. Ligand A is slightly higher, potentially aiding membrane permeability.
4. **HBD:** Both have 3 H-bond donors, which is acceptable.
5. **HBA:** Both have 3 H-bond acceptors, which is acceptable.
6. **QED:** Both have good QED scores (0.748 and 0.788), indicating good drug-likeness.
7. **DILI:** Ligand A (34.471) has a significantly lower DILI risk than Ligand B (45.522). This is a substantial advantage.
8. **BBB:** Ligand A (60.915) has a higher BBB penetration percentile than Ligand B (43.001). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be beneficial or at least less detrimental than complete exclusion.
9. **Caco-2:** Ligand A (-4.78) and Ligand B (-5.035) have similar Caco-2 permeability values.
10. **Solubility:** Both have negative solubility values, indicating poor aqueous solubility. Ligand A (-3.663) is slightly better than Ligand B (-3.421), but both are problematic.
11. **hERG:** Both have low hERG inhibition liability (0.452 and 0.404), which is good.
12. **Cl_mic:** Ligand A (-11.91) has a *much* lower (better) microsomal clearance than Ligand B (10.532). This suggests greater metabolic stability for Ligand A.
13. **t1/2:** Ligand A (32.85) has a longer in vitro half-life than Ligand B (-10.259). This is a significant advantage.
14. **Pgp:** Both have very low Pgp efflux liability (0.059 and 0.061).
15. **Binding Affinity:** Ligand A (-6.5 kcal/mol) has a slightly better binding affinity than Ligand B (-6.1 kcal/mol), but the difference is relatively small.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Both ligands perform similarly on logP, TPSA, and Pgp. The slight affinity advantage of Ligand A is overshadowed by its superior ADME properties.
**Overall Assessment:**
Ligand A is the better candidate. It demonstrates a significantly lower DILI risk, better metabolic stability (lower Cl_mic, longer t1/2), and higher BBB penetration. While both have solubility issues, the other advantages of Ligand A outweigh this drawback. The small difference in binding affinity is not enough to favor Ligand B, given its poorer ADME profile.
Output:
1
2025-04-17 21:46:55,960 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [341.371, 126.88 , -0.185, 4. , 4. , 0.405, 61.846, 19.038, -5.48 , -3.038, 0.148, -13.314, 13.065, 0.037, -7.1 ]
**Ligand B:** [352.391, 115.45 , 0.673, 2. , 6. , 0.55 , 33.695, 20.783, -5.127, -0.691, 0.213, -18.931, 3.521, 0.029, -6.6 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (341.371) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (126.88) is slightly higher than Ligand B (115.45), but both are below the 140 A^2 threshold for good oral absorption.
3. **logP:** Ligand B (0.673) is better than Ligand A (-0.185). A logP between 1-3 is optimal, and Ligand A is a bit low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (4) is better than Ligand B (2). While both are within the acceptable range, a slightly higher number can improve solubility.
5. **HBA:** Ligand B (6) is higher than Ligand A (4). Both are acceptable, but lower is generally preferred.
6. **QED:** Both have good QED scores (A: 0.405, B: 0.55), indicating drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand B (33.695) is significantly better than Ligand A (61.846). Lower DILI risk is crucial.
8. **BBB:** Both have low BBB penetration (A: 19.038, B: 20.783). Since ADRB2 is a cardiovascular target, BBB penetration is not a primary concern, but it's not detrimental to have low values.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. This is a significant concern for both compounds.
10. **Solubility:** Ligand B (-0.691) is better than Ligand A (-3.038). Higher solubility is always preferred.
11. **hERG:** Both have low hERG inhibition risk (A: 0.148, B: 0.213).
12. **Cl_mic:** Ligand A (-13.314) has a lower (better) microsomal clearance than Ligand B (-18.931), indicating greater metabolic stability.
13. **t1/2:** Ligand A (13.065) has a significantly longer in vitro half-life than Ligand B (3.521). This is a major advantage.
14. **Pgp:** Both have very low Pgp efflux liability (A: 0.037, B: 0.029).
15. **Affinity:** Ligand A (-7.1) has a slightly better binding affinity than Ligand B (-6.6). While both are good, the 0.5 kcal/mol difference is not overwhelming.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, Pgp, TPSA, and affinity. Ligand B has a better logP and slightly better TPSA, while Ligand A has a better affinity. However, the *significant* advantage of Ligand A in terms of metabolic stability (Cl_mic and t1/2) and the lower DILI risk of Ligand B are critical.
**Conclusion:**
Considering the balance of properties, and prioritizing metabolic stability and safety (DILI), **Ligand B** appears to be the more promising candidate. While Ligand A has slightly better affinity and half-life, the lower DILI risk and better logP of Ligand B outweigh these advantages. The poor Caco-2 values for both are a concern that would need to be addressed in further optimization.
Output:
0
2025-04-17 21:46:55,960 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand Comparison for ADRB2 (GPCR)**
**1. Molecular Weight:** Both ligands (346.471 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Both ligands (58.64) are below the 140 A^2 threshold for good oral absorption, and well below the 90 A^2 threshold for CNS targets. No significant difference.
**3. logP:** Both ligands (2.574 and 2.29) are within the optimal 1-3 range. Ligand B is slightly lower, which could marginally improve solubility, but both are good.
**4. H-Bond Donors:** Both ligands have 1 HBD, which is acceptable.
**5. H-Bond Acceptors:** Both ligands have 3 HBA, which is acceptable.
**6. QED:** Ligand A (0.721) has a slightly better QED score than Ligand B (0.614), indicating a more drug-like profile.
**7. DILI:** Ligand A (18.302) has a significantly lower DILI risk than Ligand B (23.614), which is a major advantage. Lower DILI is crucial for drug development.
**8. BBB:** Ligand A (74.098) has a slightly higher BBB penetration percentile than Ligand B (69.794). While ADRB2 isn't strictly a CNS target, some peripheral ADRB2 activity can influence CNS pathways, and better BBB penetration isn't detrimental.
**9. Caco-2 Permeability:** Ligand A (-4.575) has slightly better Caco-2 permeability than Ligand B (-4.9).
**10. Aqueous Solubility:** Ligand A (-2.86) has better aqueous solubility than Ligand B (-2.162).
**11. hERG Inhibition:** Both ligands have very low hERG inhibition liability (0.152 and 0.156), which is excellent.
**12. Microsomal Clearance:** Both ligands have similar microsomal clearance (48.184 and 48.933), suggesting comparable metabolic stability.
**13. In vitro Half-Life:** Ligand A (0.118) has a very short half-life, while Ligand B (-16.531) has a much longer half-life. This is a significant advantage for Ligand B.
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (0.055 and 0.102).
**15. Binding Affinity:** Ligand B (-7.3 kcal/mol) has a slightly stronger binding affinity than Ligand A (-7.1 kcal/mol). This is a 0.2 kcal/mol difference.
**GPCR-Specific Priorities:** For GPCRs, logP, Pgp, TPSA, and affinity are key. Both ligands perform well on logP, Pgp, and TPSA. Ligand B has a slightly better affinity, but the difference is small. However, the significantly better DILI score and longer half-life of Ligand A are very important considerations.
**Overall Assessment:**
While Ligand B has a slightly better binding affinity and half-life, Ligand A's significantly lower DILI risk and better solubility are more critical for overall drug development. The affinity difference is not substantial enough to outweigh the safety and formulation advantages of Ligand A.
Output:
1
2025-04-17 21:46:55,960 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (338.5) is within the ideal range (200-500), while Ligand B (365.5) is also acceptable. No clear advantage.
2. **TPSA:** Ligand A (23.55) is excellent, well below the 140 threshold and very favorable for oral absorption. Ligand B (98.17) is higher, but still within a reasonable range, though less optimal.
3. **logP:** Ligand A (4.167) is slightly high, potentially leading to solubility issues or off-target effects. Ligand B (2.716) is within the optimal 1-3 range. Ligand B is better here.
4. **HBD:** Ligand A (0) is good, minimizing potential issues with hydrogen bonding. Ligand B (1) is acceptable.
5. **HBA:** Ligand A (2) is good. Ligand B (4) is acceptable.
6. **QED:** Ligand A (0.685) is good, indicating a drug-like profile. Ligand B (0.351) is significantly lower, suggesting potential issues with drug-likeness. Ligand A is much better.
7. **DILI:** Ligand A (37.15) is good, indicating low liver injury risk. Ligand B (26.56) is even better, with a very low risk. Ligand B is better.
8. **BBB:** Ligand A (90.11) is excellent, suggesting good potential for CNS penetration, though ADRB2 is primarily cardiovascular. Ligand B (55.18) is lower, less favorable.
9. **Caco-2:** Ligand A (-4.485) is poor, indicating poor intestinal absorption. Ligand B (-5.428) is also poor, but slightly better.
10. **Solubility:** Ligand A (-4.304) is poor. Ligand B (-2.768) is better, but still not great.
11. **hERG:** Ligand A (0.968) is very low risk. Ligand B (0.415) is also very low risk. No significant difference.
12. **Cl_mic:** Ligand A (88.65) is relatively high, suggesting faster metabolism. Ligand B (49.26) is lower, indicating better metabolic stability. Ligand B is better.
13. **t1/2:** Ligand A (49.76) is good. Ligand B (13.68) is poor, suggesting a short half-life. Ligand A is better.
14. **Pgp:** Ligand A (0.87) is moderate, suggesting some efflux. Ligand B (0.046) is very low, indicating minimal efflux. Ligand B is better.
15. **Affinity:** Ligand A (-5.8) is good. Ligand B (-7.8) is significantly better, with a 2 kcal/mol advantage. This is a substantial difference.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B has a better logP and Pgp profile. The significantly improved binding affinity of Ligand B (-7.8 vs -5.8) is a major advantage that can outweigh some of its ADME drawbacks. While Ligand A has better QED and BBB, the cardiovascular target doesn't necessitate high BBB penetration. The poor Caco-2 and solubility of both are concerning, but can potentially be addressed with formulation strategies.
**Conclusion:**
Despite some ADME liabilities, Ligand B's superior binding affinity and better logP/Pgp profile make it the more promising drug candidate for ADRB2. The 2 kcal/mol difference in binding is substantial and likely to translate to greater efficacy.
Output:
0
2025-04-17 21:46:55,960 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (374.453 and 360.527 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (75.27) is slightly higher than Ligand B (61.28). Both are below the 140 A^2 threshold for good oral absorption, but Ligand B is preferable due to being closer to the 90 A^2 threshold for GPCRs.
3. **logP:** Both ligands have excellent logP values (3.958 and 3.894), falling within the optimal 1-3 range. No clear advantage.
4. **HBD:** Both ligands have 2 H-bond donors, which is within the acceptable limit of <=5.
5. **HBA:** Ligand A has 3 H-bond acceptors, while Ligand B has 6. Ligand A is preferable here, as fewer HBA generally leads to better permeability.
6. **QED:** Ligand A (0.784) has a significantly better QED score than Ligand B (0.497), indicating a more drug-like profile.
7. **DILI:** Ligand B (68.709) has a slightly higher DILI risk than Ligand A (61.07), though both are above the preferred <40. Ligand A is preferable.
8. **BBB:** Ligand A (86.157) has a significantly higher BBB penetration percentile than Ligand B (60.45). Given ADRB2 is a GPCR, BBB penetration is a desirable property, making Ligand A more attractive.
9. **Caco-2:** Ligand A (-4.332) shows better Caco-2 permeability than Ligand B (-5.128).
10. **Solubility:** Ligand A (-4.779) has better aqueous solubility than Ligand B (-3.573).
11. **hERG:** Ligand A (0.508) has a lower hERG inhibition liability than Ligand B (0.9). This is a significant advantage for Ligand A, as it reduces the risk of cardiotoxicity.
12. **Cl_mic:** Ligand B (92.647) has a much higher microsomal clearance than Ligand A (21.368), indicating lower metabolic stability. This is a major drawback for Ligand B.
13. **t1/2:** Ligand B (108.878) has a longer in vitro half-life than Ligand A (44.519). While longer half-life is generally desirable, the significantly higher Cl_mic of Ligand B suggests this half-life may not be reliable *in vivo*.
14. **Pgp:** Ligand A (0.246) has lower P-gp efflux liability than Ligand B (0.643). This is preferable for both oral bioavailability and potential CNS exposure.
15. **Binding Affinity:** Ligand B (-6.6 kcal/mol) has a slightly better binding affinity than Ligand A (-5.5 kcal/mol). While a difference of 1.1 kcal/mol is noticeable, the numerous advantages of Ligand A across ADME properties outweigh this difference.
**Overall Assessment:**
Ligand A demonstrates a significantly better balance of properties, particularly regarding ADME characteristics crucial for a viable drug candidate. Its superior QED, lower DILI risk, higher BBB penetration, better solubility, lower hERG inhibition, lower Cl_mic, and lower Pgp efflux all contribute to a more promising profile. While Ligand B has a slightly better binding affinity, the ADME liabilities are substantial.
Output:
1
2025-04-17 21:46:55,960 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.3 and 345.4 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (51.47) is significantly better than Ligand B (104.12). For a GPCR, lower TPSA is generally preferred for permeability. Ligand B is quite high and may have absorption issues.
3. **logP:** Ligand A (4.146) is higher than Ligand B (1.363). While both are within the acceptable range, Ligand A is approaching the upper limit and could potentially have solubility issues. Ligand B is on the lower side, which might affect permeability.
4. **HBD:** Ligand A (1) is better than Ligand B (2). Lower HBD is generally favorable for permeability.
5. **HBA:** Ligand A (3) is better than Ligand B (5). Similar to HBD, lower HBA is preferred.
6. **QED:** Both ligands have good QED scores (0.727 and 0.823), indicating good drug-like properties. No clear advantage.
7. **DILI:** Ligand B (41.877) has a much lower DILI risk than Ligand A (86.429). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (90.772) has a much higher BBB penetration potential than Ligand B (60.256). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be beneficial, and this is a significant advantage for Ligand A.
9. **Caco-2:** Ligand A (-4.342) and Ligand B (-5.381) both have negative values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Ligand B (-1.517) has better solubility than Ligand A (-5.872). This is a positive for Ligand B, especially considering Ligand A's higher logP.
11. **hERG:** Ligand B (0.029) has a much lower hERG risk than Ligand A (0.94). This is a crucial advantage for Ligand B, as hERG inhibition can lead to cardiotoxicity.
12. **Cl_mic:** Ligand B (-6.132) has significantly lower microsomal clearance than Ligand A (69.995). This indicates better metabolic stability for Ligand B, a key factor for drug duration.
13. **t1/2:** Ligand A (91.336) has a much longer in vitro half-life than Ligand B (5.163). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand B (0.013) has much lower P-gp efflux liability than Ligand A (0.703). Lower Pgp efflux is generally desirable for improved bioavailability.
15. **Binding Affinity:** Ligand A (-7.1 kcal/mol) has a slightly better binding affinity than Ligand B (-6.7 kcal/mol). While the difference is not huge, it's a factor.
**Overall Assessment:**
Ligand B clearly wins on safety (DILI, hERG) and metabolic stability (Cl_mic). It also has better solubility and Pgp efflux profile. Ligand A has advantages in BBB penetration and in vitro half-life, and slightly better binding affinity. However, the safety concerns with Ligand A are substantial, and the metabolic instability is a major drawback. For a cardiovascular target like ADRB2, minimizing cardiotoxicity (hERG) and ensuring adequate metabolic stability are paramount. The slightly better affinity of Ligand A doesn't outweigh these critical safety and pharmacokinetic concerns.
Output:
0
2025-04-17 21:46:55,961 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (373.425 and 344.419 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (82.53) is better than Ligand B (103.87). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (1.353 and 1.108), falling within the optimal 1-3 range. Similar.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (2), but both are within the acceptable limit of 5.
5. **HBA:** Both ligands have the same number of HBA (5), which is acceptable (<=10).
6. **QED:** Ligand B (0.783) has a slightly better QED score than Ligand A (0.63), suggesting a more drug-like profile.
7. **DILI:** Both ligands have acceptable DILI risk (52.152 and 48.623 percentile), below the 60 threshold. Ligand B is marginally better.
8. **BBB:** Ligand A (55.06) has a better BBB penetration percentile than Ligand B (27.22). While not a CNS target, some level of BBB penetration can sometimes indicate favorable permeability characteristics.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.028 and -5.246). This is unusual and suggests very poor permeability. However, these values are on a scale where negative values are possible, and the absolute value is what matters. They are very similar.
10. **Solubility:** Both ligands have negative solubility values (-1.738 and -1.775). Similar to Caco-2, this suggests poor aqueous solubility.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.215 and 0.093), which is excellent.
12. **Cl_mic:** Ligand A (-13.317) has a significantly *lower* (better) microsomal clearance than Ligand B (10.918). This indicates better metabolic stability.
13. **t1/2:** Ligand A (18.609 hours) has a much longer in vitro half-life than Ligand B (3.27 hours). This is a significant advantage.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.058 and 0.012).
15. **Binding Affinity:** Ligand B (-7.7 kcal/mol) has a slightly better binding affinity than Ligand A (-7.2 kcal/mol). This is a 0.5 kcal/mol difference, which is meaningful.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, affinity, logP, TPSA, and metabolic stability are key. Ligand B has a slightly better affinity. However, Ligand A has a much better metabolic profile (lower Cl_mic, longer t1/2) and a better TPSA. The difference in affinity is not large enough to overcome the substantial advantage in metabolic stability and half-life offered by Ligand A.
**Conclusion:**
Considering the balance of properties, particularly the significantly improved metabolic stability and half-life of Ligand A, I believe it is the more promising drug candidate.
Output:
1
2025-04-17 21:46:55,961 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (354.447 Da) is well within the ideal range (200-500 Da). Ligand B (381.885 Da) is also acceptable. No clear advantage here.
2. **TPSA:** Ligand A (104.73) is slightly above the optimal <140 for oral absorption, but still reasonable. Ligand B (71.53) is excellent, well below 140 and suggesting good absorption. Advantage: B.
3. **logP:** Ligand A (0.914) is a bit low, potentially hindering permeability. Ligand B (2.253) is within the optimal 1-3 range. Advantage: B.
4. **HBD:** Ligand A (3) is acceptable. Ligand B (1) is even better, potentially improving permeability. Advantage: B.
5. **HBA:** Both ligands have 5 HBA, which is acceptable. No clear advantage.
6. **QED:** Ligand B (0.812) has a significantly better QED score than Ligand A (0.422), indicating a more drug-like profile. Advantage: B.
7. **DILI:** Ligand A (17.41%) has a much lower DILI risk than Ligand B (61.031%). Advantage: A.
8. **BBB:** Ligand B (79.604%) has a much higher BBB penetration score than Ligand A (47.964%). While ADRB2 isn't strictly a CNS target, some CNS exposure can be relevant for off-target effects or peripheral effects mediated by sympathetic nervous system. Advantage: B.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and potentially problematic. It suggests poor permeability. However, the values are similar. No clear advantage.
10. **Solubility:** Ligand A (-1.353) has slightly better solubility than Ligand B (-3.473). Advantage: A.
11. **hERG:** Ligand A (0.056%) has a much lower hERG inhibition liability than Ligand B (0.335%). This is a crucial safety parameter. Advantage: A.
12. **Cl_mic:** Ligand B (21.256) has a significantly lower microsomal clearance than Ligand A (42.808), indicating better metabolic stability. Advantage: B.
13. **t1/2:** Ligand A (-34.096) has a negative in vitro half-life, which is concerning and likely indicates rapid metabolism. Ligand B (0.271) has a very short half-life, but is at least positive. Advantage: B.
14. **Pgp:** Ligand A (0.046) has lower P-gp efflux liability than Ligand B (0.274). Advantage: A.
15. **Binding Affinity:** Ligand B (-7.5 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.1 kcal/mol). This is a substantial advantage, potentially outweighing some ADME concerns. Advantage: B.
**Overall Assessment:**
Ligand B has a superior profile in terms of key GPCR-relevant properties (TPSA, logP, BBB, affinity, Cl_mic). Its higher QED score and better metabolic stability are also positive. While its DILI and hERG risks are higher, the significantly improved binding affinity is a major factor. Ligand A has better safety profiles (DILI, hERG, Pgp) and solubility, but its lower affinity and poorer QED are significant drawbacks. Considering the importance of potency for GPCR targets, and the potential to mitigate safety concerns through further optimization, Ligand B is the more promising candidate.
Output:
0
2025-04-17 21:46:55,961 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (361.398 and 347.503 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (85.2) is slightly higher than Ligand B (61.44). For a cardiovascular GPCR, TPSA is not a primary concern, but lower is generally preferred for absorption. Ligand B has an advantage.
3. **logP:** Both ligands have good logP values (2.958 and 2.084), falling within the 1-3 optimal range. Ligand A is slightly higher, which could be beneficial for membrane permeability, but not drastically.
4. **HBD:** Ligand A (1) has fewer HBD than Ligand B (2). Lower is generally better for permeability. Ligand A has a slight advantage.
5. **HBA:** Ligand A (7) has more HBA than Ligand B (3). Lower is generally better for permeability. Ligand B has a clear advantage.
6. **QED:** Both ligands have similar and acceptable QED values (0.68 and 0.693). No significant difference.
7. **DILI:** Ligand A (89.415) has a significantly higher DILI risk than Ligand B (11.361). This is a major concern for Ligand A.
8. **BBB:** Both ligands have similar BBB penetration (66.305 and 68.282). While ADRB2 isn't a CNS target, some off-target CNS effects are possible with GPCRs, so moderate penetration isn't necessarily negative.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.642 and -4.868). These values are unusual and suggest poor permeability.
10. **Solubility:** Ligand A (-3.719) has slightly worse solubility than Ligand B (-2.157). Solubility is important for bioavailability. Ligand B has a slight advantage.
11. **hERG:** Both ligands have low hERG inhibition liability (0.351 and 0.235). No significant difference.
12. **Cl_mic:** Ligand A (85.639) has a higher microsomal clearance than Ligand B (42.922), indicating lower metabolic stability. Ligand B is significantly better here.
13. **t1/2:** Ligand A (-11.136) has a negative in vitro half-life, which is problematic. Ligand B (2.132) has a short, but positive half-life. Ligand B is much better.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.304 and 0.054). Ligand B has a slight advantage.
15. **Affinity:** Ligand A (-7.6 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.5 kcal/mol). This is a substantial advantage, potentially outweighing some ADME concerns.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), affinity, logP, TPSA, and Pgp are important. Ligand A has a much better affinity. However, the significantly higher DILI risk and poorer metabolic stability (higher Cl_mic, negative t1/2) of Ligand A are major drawbacks. Ligand B, while having a weaker affinity, presents a much more favorable ADME profile, especially regarding safety (DILI) and metabolic stability.
**Conclusion:**
Despite the stronger binding affinity of Ligand A, the significantly higher DILI risk and poor metabolic stability make it a less viable candidate. Ligand B, with its better safety profile, metabolic stability, and acceptable physicochemical properties, is the more promising starting point for drug development.
Output:
0
2025-04-17 21:46:55,961 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (341.415 Da) is better than Ligand B (369.481 Da), falling comfortably within the 200-500 Da range. Both are acceptable.
2. **TPSA:** Ligand B (56.99) is significantly better than Ligand A (101.21). Lower TPSA generally favors better absorption, crucial for GPCRs. Ligand B is well below the 140 threshold, while A is approaching it.
3. **logP:** Ligand A (1.136) is better than Ligand B (4.265). Ligand B is pushing the upper limit of the optimal range and could lead to solubility issues or off-target interactions.
4. **HBD:** Ligand A (2) is preferable to Ligand B (0). While both are acceptable, a small number of HBDs can aid solubility.
5. **HBA:** Ligand A (5) is preferable to Ligand B (4). Both are within the acceptable range.
6. **QED:** Ligand A (0.8) is better than Ligand B (0.721), indicating a more drug-like profile.
7. **DILI:** Ligand B (32.842) is significantly better than Ligand A (50.33). Lower DILI risk is a major advantage.
8. **BBB:** Ligand A (92.672) is slightly better than Ligand B (89.608). Both are good, but A is slightly higher. This is important for GPCRs.
9. **Caco-2:** Ligand A (-5.125) is better than Ligand B (-4.376). Higher Caco-2 permeability is desirable.
10. **Solubility:** Ligand A (-3.37) is better than Ligand B (-4.809). Better solubility is always a plus.
11. **hERG:** Ligand A (0.399) is much better than Ligand B (0.678). Lower hERG inhibition is critical for avoiding cardiotoxicity, especially important for a cardiovascular target like ADRB2.
12. **Cl_mic:** Ligand A (18.982) is significantly better than Ligand B (69.909). Lower clearance indicates better metabolic stability.
13. **t1/2:** Ligand A (-14.025) is better than Ligand B (-12.859). Longer half-life is generally preferred.
14. **Pgp:** Ligand A (0.016) is much better than Ligand B (0.296). Lower P-gp efflux is beneficial for bioavailability.
15. **Affinity:** Ligand B (-1.4) is better than Ligand A (-7.0). This is a substantial difference in binding affinity.
**Overall Assessment:**
Ligand B has a significantly better binding affinity (-1.4 kcal/mol vs -7.0 kcal/mol). However, it suffers from a higher logP, higher DILI risk, higher hERG inhibition, and significantly higher microsomal clearance. Ligand A, while having a weaker binding affinity, has a much more favorable ADME-Tox profile, particularly regarding safety (DILI, hERG) and metabolic stability (Cl_mic). Given that the affinity difference is substantial (5.6 kcal/mol), it's a significant drawback for Ligand A. However, the ADME profile of Ligand B is concerning, especially for a cardiovascular target where off-target effects and metabolism are critical.
Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity) and the overall balance, the superior binding affinity of Ligand B outweighs its ADME liabilities. The differences in ADME, while significant, could potentially be addressed through further optimization.
Output:
0
2025-04-17 21:46:55,962 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (347.39 and 350.459 Da) fall comfortably within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (79.79) is better than Ligand B (87.66). Both are below 140, but lower TPSA generally favors absorption.
3. **logP:** Both ligands have good logP values (1.546 and 1.26), falling within the optimal 1-3 range. Ligand B is slightly lower, potentially impacting permeability a bit more.
4. **HBD:** Ligand A (2) is preferable to Ligand B (3). Lower HBD is generally better for permeability.
5. **HBA:** Both ligands have the same number of HBA (4), which is acceptable.
6. **QED:** Ligand A (0.735) has a slightly better QED score than Ligand B (0.697), indicating a more drug-like profile.
7. **DILI:** Ligand A (34.471) has a slightly higher DILI risk than Ligand B (28.616), but both are well below the concerning threshold of 60.
8. **BBB:** Ligand A (78.209) has a significantly better BBB penetration score than Ligand B (28.81). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant, and better BBB is generally favorable.
9. **Caco-2:** Ligand A (-4.677) has a worse Caco-2 permeability than Ligand B (-5.095). Lower (more negative) values indicate lower permeability.
10. **Solubility:** Both ligands have very poor aqueous solubility (-2.651 and -2.783). This is a significant concern for both, and formulation strategies would be critical.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.421 and 0.136). This is excellent.
12. **Cl_mic:** Ligand A (14.784) has a significantly lower microsomal clearance than Ligand B (28.402), suggesting better metabolic stability.
13. **t1/2:** Ligand B (15.624) has a much longer in vitro half-life than Ligand A (-1.158). This is a major advantage for Ligand B.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.055 and 0.046).
15. **Binding Affinity:** Ligand B (-7.5) has a substantially stronger binding affinity than Ligand A (-3.8). This is a difference of 3.7 kcal/mol, which is a very significant advantage.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B excels in affinity, which is the most important factor. While Ligand A has better TPSA and BBB, the substantial affinity difference of Ligand B outweighs these benefits. The longer half-life of Ligand B is also a significant advantage. Solubility is a concern for both, but can be addressed through formulation.
**Conclusion:**
Despite the solubility issues and slightly lower TPSA, the significantly improved binding affinity and half-life of Ligand B make it the more promising drug candidate.
Output:
0
2025-04-17 21:46:55,962 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [357.407, 106.2 , -1.484, 2. , 6. , 0.575, 35.673, 35.401, -5.192, -0.978, 0.034, -4.439, 2.299, 0.007, -6. ]
**Ligand B:** [391.88 , 86.29 , 3.653, 2. , 4. , 0.596, 36.797, 32.416, -5.127, -2.882, 0.567, 50.117, 26.165, 0.382, -6.6 ]
**Step-by-step comparison:**
1. **MW:** Ligand A (357.4) is within the ideal range (200-500). Ligand B (391.88) is also acceptable.
2. **TPSA:** Ligand A (106.2) is slightly above the preferred <140 for oral absorption, but still reasonable. Ligand B (86.29) is excellent, well below 140.
3. **logP:** Ligand A (-1.484) is a bit low, potentially hindering permeability. Ligand B (3.653) is within the optimal 1-3 range. This is a significant advantage for B.
4. **HBD:** Both ligands have 2 HBD, which is good.
5. **HBA:** Ligand A has 6 HBA, acceptable. Ligand B has 4 HBA, also good.
6. **QED:** Both ligands have QED values > 0.5, indicating good drug-likeness.
7. **DILI:** Both ligands have similar DILI risk (35.673 vs 36.797), both are acceptable.
8. **BBB:** Ligand A (35.4) is low, suggesting poor brain penetration. Ligand B (32.4) is also low, but slightly better. Neither is a strong candidate for CNS targets, but ADRB2 is primarily a cardiovascular target, so this is less critical.
9. **Caco-2:** Both have similar negative Caco-2 values, indicating poor permeability.
10. **Solubility:** Ligand A (-0.978) is slightly better than Ligand B (-2.882).
11. **hERG:** Ligand A (0.034) has a very low hERG risk, which is excellent. Ligand B (0.567) is higher, but still relatively low.
12. **Cl_mic:** Ligand A (-4.439) has a much lower (better) microsomal clearance than Ligand B (50.117), indicating better metabolic stability. This is a major advantage for A.
13. **t1/2:** Ligand B (26.165) has a significantly longer in vitro half-life than Ligand A (2.299). This is a significant advantage for B.
14. **Pgp:** Ligand A (0.007) has very low P-gp efflux, which is excellent. Ligand B (0.382) is higher, but still reasonable.
15. **Affinity:** Ligand B (-6.6) has a slightly better binding affinity than Ligand A (-6.0). While the difference is not huge, it is noticeable.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, and affinity are particularly important. Ligand B excels in logP and has slightly better affinity. Ligand A has a better TPSA and significantly better metabolic stability (Cl_mic).
**Overall Assessment:**
While Ligand A has excellent metabolic stability and low P-gp efflux, its low logP and poor Caco-2 permeability are concerning. Ligand B has a more favorable logP, better TPSA, and slightly better affinity, which are more important for a GPCR target. The longer half-life of Ligand B is also a significant advantage. The slightly higher hERG risk of Ligand B is acceptable given the other benefits.
Therefore, I favor Ligand B.
Output:
0
2025-04-17 21:46:55,962 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
The target is ADRB2, a GPCR. Therefore, I will prioritize logP, Pgp, TPSA, BBB, and binding affinity, followed by general drug-like properties.
* **Molecular Weight:** Both ligands are within the ideal range (352.523 and 357.426 Da).
* **TPSA:** Ligand A (55.89) is significantly better than Ligand B (87.74). A lower TPSA generally indicates better cell permeability, which is crucial for GPCR targeting. Ligand A is well below the 140 threshold, while Ligand B is approaching it.
* **logP:** Ligand A (1.025) is optimal, while Ligand B (0.383) is a bit low, potentially hindering membrane permeability.
* **H-Bond Donors/Acceptors:** Both have reasonable HBD/HBA counts. Ligand B has 2 HBDs vs 1 for Ligand A.
* **QED:** Both are acceptable (0.743 and 0.69).
* **DILI:** Ligand A (6.049) is *much* better than Ligand B (28.189), indicating a significantly lower risk of liver injury. This is a major advantage.
* **BBB:** Ligand B (75.572) has a better BBB penetration percentile than Ligand A (67.468), but both are reasonably good.
* **Caco-2 Permeability:** Both are negative, indicating poor permeability.
* **Aqueous Solubility:** Both are negative, indicating poor solubility.
* **hERG:** Both have low hERG inhibition liability (0.495 and 0.285).
* **Microsomal Clearance:** Ligand B (-1.121) has a negative value, which is unusual and suggests very low clearance, potentially indicating issues with prediction or a very stable molecule. Ligand A (12.106) is more typical.
* **In vitro Half-Life:** Ligand A (-12.336) has a negative value, which is unusual and suggests very long half-life, potentially indicating issues with prediction. Ligand B (6.945) is more typical.
* **P-gp Efflux:** Both have very low P-gp efflux liability (0.006 and 0.015).
* **Binding Affinity:** Ligand A (-6.2 kcal/mol) and Ligand B (-5.6 kcal/mol) are both good, but Ligand A has a 0.6 kcal/mol advantage. This is a significant difference.
**Overall Assessment:**
Ligand A is the stronger candidate. It has a better TPSA, logP, DILI score, and binding affinity. While Ligand B has a slightly better BBB score and potentially better metabolic stability (based on the unusual Cl_mic value), the advantages of Ligand A in key areas like TPSA, logP, and especially DILI risk, outweigh these benefits. The negative values for half-life and clearance in both ligands are concerning and would require further investigation, but the overall profile of Ligand A is more promising for development as a drug candidate.
**Output:**
1
2025-04-17 21:46:55,962 - INFO - Here's my reasoning and the final output:
**Reasoning:**
We are looking for a drug candidate targeting ADRB2, a GPCR. Therefore, the priorities are affinity, logP, Pgp, TPSA, and BBB. Let's compare Ligand A and Ligand B across these and other relevant parameters.
* **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (380.407) is slightly higher than Ligand B (368.503), but both are acceptable.
* **TPSA:** Ligand A (58.2) is significantly better than Ligand B (107.11). A TPSA under 140 is good for oral absorption, but lower is preferred for GPCRs, and Ligand A is much closer to the ideal range.
* **logP:** Ligand A (3.573) is optimal, while Ligand B (1.697) is on the lower side. A logP between 1-3 is preferred, and Ligand A is within this range, while Ligand B is closer to the permeability limit.
* **H-Bond Donors/Acceptors:** Ligand A (2 HBD, 3 HBA) is better than Ligand B (4 HBD, 5 HBA). Lower values are generally preferred for better permeability.
* **QED:** Ligand A (0.768) has a higher QED score than Ligand B (0.496), indicating a more drug-like profile.
* **DILI:** Both ligands have acceptable DILI risk (Ligand A: 51.377, Ligand B: 41.218), below the 60% threshold.
* **BBB:** Ligand A (81.621) demonstrates significantly better BBB penetration potential than Ligand B (35.052). This is a crucial factor for GPCRs, even if not CNS-focused, as it can influence off-target effects and distribution.
* **Caco-2 Permeability:** Ligand A (-4.737) is better than Ligand B (-5.621), indicating better intestinal absorption.
* **Aqueous Solubility:** Ligand A (-4.287) is better than Ligand B (-3.093).
* **hERG Inhibition:** Both ligands have low hERG inhibition risk (Ligand A: 0.492, Ligand B: 0.36).
* **Microsomal Clearance:** Ligand A (40.88) is higher than Ligand B (30.199), indicating faster clearance and lower metabolic stability.
* **In vitro Half-Life:** Ligand A (0.584) is significantly worse than Ligand B (-16.504).
* **P-gp Efflux:** Ligand A (0.137) is better than Ligand B (0.066), indicating lower P-gp efflux.
* **Binding Affinity:** Ligand B (-6.0) has a slightly better binding affinity than Ligand A (-5.2). However, the difference is less than 1.5 kcal/mol, and the other ADME properties of Ligand A are superior.
**Conclusion:**
While Ligand B has slightly better binding affinity, Ligand A demonstrates a significantly more favorable overall profile, particularly regarding TPSA, logP, BBB penetration, QED, and P-gp efflux. These factors are critical for a GPCR-targeting drug, outweighing the minor affinity difference. Ligand A is more likely to be a viable drug candidate.
**Output:**
1
2025-04-17 21:46:55,962 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (343.387 and 354.491 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand B (67.87) is significantly better than Ligand A (110.01). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally correlates with better absorption. Ligand B is well below the 140 threshold.
3. **logP:** Both ligands have good logP values (1.59 and 1.827), falling within the optimal 1-3 range. Ligand B is slightly better.
4. **HBD:** Ligand A has 2 HBD, and Ligand B has 1. Both are acceptable (<=5).
5. **HBA:** Ligand A has 6 HBA, and Ligand B has 4. Both are acceptable (<=10).
6. **QED:** Both ligands have similar QED values (0.704 and 0.686), indicating good drug-likeness.
7. **DILI:** Ligand B (15.2) has a *much* lower DILI risk than Ligand A (68.166). This is a critical advantage for Ligand B.
8. **BBB:** Both ligands have acceptable BBB penetration (70.88 and 74.37). Not a primary concern for a cardiovascular target, but higher is generally better.
9. **Caco-2:** Ligand A (-5.125) has a worse Caco-2 permeability than Ligand B (-4.435).
10. **Solubility:** Ligand A (-2.81) has worse solubility than Ligand B (-1.656).
11. **hERG:** Both ligands have low hERG inhibition risk (0.241 and 0.343).
12. **Cl_mic:** Ligand A (31.213) has a lower microsomal clearance than Ligand B (48.392), suggesting better metabolic stability.
13. **t1/2:** Ligand A (6.758) has a longer in vitro half-life than Ligand B (1.613). This is a significant advantage for Ligand A.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.058 and 0.035).
15. **Binding Affinity:** Ligand B (-7.3 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.5 kcal/mol). This is a 0.8 kcal/mol difference, which is substantial.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, and affinity. Ligand B excels in TPSA and affinity, and is comparable in logP and Pgp. The significantly lower DILI risk is also a major benefit. While Ligand A has better metabolic stability (lower Cl_mic) and half-life, the superior binding affinity and safety profile of Ligand B outweigh these advantages.
**Conclusion:**
Ligand B is the more promising drug candidate due to its significantly better binding affinity, lower DILI risk, and favorable TPSA. The slightly shorter half-life and higher clearance are less concerning than the substantial benefits in potency and safety.
Output:
0
2025-04-17 21:46:55,962 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [349.431, 96.53, 1.103, 3, 4, 0.364, 51.609, 73.943, -4.624, -2.971, 0.276, 49.485, -45.722, 0.089, -6.2]
**Ligand B:** [362.499, 72.21, 3.731, 2, 7, 0.493, 68.437, 82.823, -5.481, -3.993, 0.886, 103.044, 119.981, 0.582, -6.7]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (349.431) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (96.53) is higher than Ligand B (72.21). Both are below 140, but B is better for oral absorption.
3. **logP:** Ligand A (1.103) is within the optimal range, while Ligand B (3.731) is approaching the upper limit. A is preferable here.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (2), but both are acceptable.
5. **HBA:** Ligand A (4) is lower than Ligand B (7). B is getting higher and could affect permeability.
6. **QED:** Ligand B (0.493) is slightly better than Ligand A (0.364), indicating a marginally more drug-like profile.
7. **DILI:** Ligand A (51.609) has a lower DILI risk than Ligand B (68.437). This is a significant advantage for A.
8. **BBB:** Ligand B (82.823) has better BBB penetration than Ligand A (73.943). For a cardiovascular target, this isn't *critical*, but it's a plus.
9. **Caco-2:** Ligand B (-5.481) has a better Caco-2 permeability than Ligand A (-4.624).
10. **Solubility:** Ligand B (-3.993) has better solubility than Ligand A (-2.971).
11. **hERG:** Ligand A (0.276) has a much lower hERG risk than Ligand B (0.886). This is a crucial safety parameter, favoring A.
12. **Cl_mic:** Ligand A (49.485) has a lower microsomal clearance than Ligand B (103.044), indicating better metabolic stability.
13. **t1/2:** Ligand B (119.981) has a significantly longer in vitro half-life than Ligand A (-45.722). This is a major advantage for B.
14. **Pgp:** Ligand B (0.582) has a lower P-gp efflux liability than Ligand A (0.089). This is a positive for B.
15. **Affinity:** Ligand B (-6.7) has a stronger binding affinity than Ligand A (-6.2). This is a 0.5 kcal/mol difference, which is significant.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, and affinity. Ligand B excels in Pgp and affinity, and has a better TPSA. Ligand A has a better logP and significantly lower hERG risk and DILI risk.
**Overall Assessment:**
While Ligand B has a better binding affinity and longer half-life, the significantly lower hERG risk and DILI risk of Ligand A are crucial for cardiovascular drug development. The slightly better logP of A is also favorable. The difference in affinity (0.5 kcal/mol) is not enough to overcome the safety concerns with Ligand B.
Output:
1
2025-04-17 21:46:55,963 - INFO - Batch 283 complete. Total preferences: 4528
2025-04-17 21:46:55,963 - INFO - Processing batch 284/512...
2025-04-17 21:47:46,952 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (376.5 and 360.5 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (49.41) is slightly higher than Ligand B (45.59), but both are well below the 140 threshold for good absorption.
3. **logP:** Ligand A (2.44) is optimal, while Ligand B (4.686) is pushing the upper limit and could potentially cause solubility issues or off-target interactions. This favors Ligand A.
4. **HBD:** Both ligands have 1 HBD, which is within the acceptable limit.
5. **HBA:** Ligand A has 4 HBA, while Ligand B has 5. Both are acceptable, but lower is generally preferred.
6. **QED:** Both ligands have similar QED scores (0.775 and 0.705), indicating good drug-likeness.
7. **DILI:** Ligand A (35.052) has a significantly lower DILI risk than Ligand B (11.322). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (88.29) has a higher BBB penetration percentile than Ligand B (76.813). While ADRB2 isn't strictly a CNS target, some CNS exposure can occur, and higher BBB is generally favorable.
9. **Caco-2:** Ligand A (-5.266) has a more negative Caco-2 value, indicating potentially *lower* intestinal absorption compared to Ligand B (-4.996). This slightly favors Ligand B.
10. **Solubility:** Ligand A (-3.156) has a more negative solubility value, indicating *lower* aqueous solubility than Ligand B (-5.669). This favors Ligand B.
11. **hERG:** Both ligands have relatively low hERG inhibition risk (0.768 and 0.889). No significant difference.
12. **Cl_mic:** Ligand A (91.281) has a lower microsomal clearance than Ligand B (119.528), suggesting better metabolic stability. This favors Ligand A.
13. **t1/2:** Ligand A (-7.049) has a more negative in vitro half-life, indicating a *longer* half-life than Ligand B (-7.22). This favors Ligand A.
14. **Pgp:** Both ligands have similar Pgp efflux liability.
15. **Binding Affinity:** Ligand B (-7.22 kcal/mol) has a slightly better binding affinity than Ligand A (-7.4 kcal/mol). While a difference of 0.22 kcal/mol is not huge, it is noticeable.
**GPCR-specific priorities:** For GPCRs, logP, Pgp, TPSA, and affinity are important. Ligand A has better logP, while Ligand B has slightly better affinity. Both have acceptable TPSA and Pgp.
**Overall Assessment:**
Ligand A demonstrates a significantly better safety profile (lower DILI) and better metabolic stability (lower Cl_mic, longer t1/2). While Ligand B has slightly better affinity and Caco-2 permeability, the advantages of Ligand A in safety and metabolic stability are more critical for overall drug development success, especially given the modest affinity difference. The slightly lower solubility of Ligand A could be addressed with formulation strategies.
Output:
1
2025-04-17 21:47:46,953 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.519 Da and 344.459 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (78.43 and 78.09) are below the 140 A^2 threshold for good oral absorption, which is good.
3. **logP:** Both ligands (2.622 and 2.358) are within the optimal 1-3 range. Ligand B is slightly lower, which could be marginally better for solubility.
4. **HBD:** Ligand A has 3 HBD, and Ligand B has 2. Both are acceptable (<=5).
5. **HBA:** Both ligands have 3 HBA, which is well within the acceptable range (<=10).
6. **QED:** Ligand B (0.823) has a significantly higher QED score than Ligand A (0.529), indicating a more drug-like profile. This is a substantial advantage for Ligand B.
7. **DILI:** Ligand B (33.23) has a much lower DILI risk than Ligand A (13.92). This is a major advantage for Ligand B.
8. **BBB:** Ligand B (68.282) has a higher BBB penetration percentile than Ligand A (48.003). While ADRB2 isn't strictly a CNS target, some peripheral ADRB2 receptors can be relevant in CNS-related conditions, so a higher BBB value is a slight benefit.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.803 and -5.098), which is unusual and suggests poor permeability. However, the values are very similar.
10. **Solubility:** Ligand B (-2.739) has a better (less negative) solubility score than Ligand A (-4.129), indicating better aqueous solubility.
11. **hERG:** Both ligands have similar hERG inhibition liability (0.515 and 0.526).
12. **Cl_mic:** Ligand B (6.672) has a significantly lower microsomal clearance than Ligand A (58.264), suggesting better metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand B (-28.865) has a much longer in vitro half-life than Ligand A (-8.173). This is a substantial benefit for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.403 and 0.144).
15. **Binding Affinity:** Ligand A (-6.6 kcal/mol) has a slightly better binding affinity than Ligand B (-4.5 kcal/mol). This is a 2.1 kcal/mol difference, which is substantial. However, the other ADME properties of Ligand B are far superior.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity, Ligand B demonstrates a significantly superior ADME profile. Specifically, the lower DILI risk, improved QED, better solubility, lower clearance, and longer half-life of Ligand B are compelling advantages. For a GPCR target like ADRB2, metabolic stability and a favorable safety profile are crucial. The affinity difference, while noticeable, can potentially be addressed through further optimization of Ligand B. The poor Caco-2 values for both ligands are a concern that would need to be investigated, but the other benefits of Ligand B outweigh this issue.
Output:
0
2025-04-17 21:47:46,953 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.42 and 370.56 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (72.63 and 69.64) are below the 140 A^2 threshold for good oral absorption, and are reasonable for a peripherally acting GPCR like ADRB2. Ligand B is slightly better.
3. **logP:** Both ligands (2.323 and 2.568) are within the optimal 1-3 range. No major distinction.
4. **HBD:** Ligand A (1) has fewer HBD than Ligand B (2). Fewer HBD generally favors permeability, but both are acceptable.
5. **HBA:** Ligand A (3) has fewer HBA than Ligand B (4). Again, fewer is slightly better for permeability, but both are acceptable.
6. **QED:** Ligand A (0.908) has a significantly higher QED score than Ligand B (0.644), indicating a more drug-like profile. This is a substantial advantage for Ligand A.
7. **DILI:** Ligand A (21.481) has a much lower DILI risk than Ligand B (33.307). This is a crucial advantage, as minimizing liver toxicity is paramount.
8. **BBB:** Ligand A (94.223) has a higher BBB penetration percentile than Ligand B (71.074). While ADRB2 isn't a CNS target, some off-target CNS effects are always a concern, and higher BBB is generally preferable.
9. **Caco-2:** Ligand A (-4.523) and Ligand B (-5.135) have negative Caco-2 values, which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Both ligands have very poor aqueous solubility (-2.93 and -3.027). This is a major drawback for both, and will likely require formulation strategies.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.578 and 0.588), which is excellent.
12. **Cl_mic:** Ligand A (26.646) has a lower microsomal clearance than Ligand B (50.796), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (-11.886) has a much longer in vitro half-life than Ligand B (-2.871). This is a substantial advantage, suggesting less frequent dosing could be possible.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.074 and 0.397), which is good.
15. **Binding Affinity:** Ligand A (-7.5 kcal/mol) has a slightly better binding affinity than Ligand B (-6.2 kcal/mol). While the difference is not huge, it's a positive for Ligand A.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Both ligands are reasonable in these areas. However, ADME properties like DILI, Cl_mic, and t1/2 are critical for overall drug development success.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B in key ADME properties (DILI, Cl_mic, t1/2, QED) and has a slightly better binding affinity. While both have poor solubility and Caco-2 permeability, the superior ADME profile of Ligand A makes it the more promising drug candidate. The lower DILI risk and improved metabolic stability are particularly important.
Output:
1
2025-04-17 21:47:46,953 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [343.427, 82.62, 2.984, 4, 4, 0.594, 54.362, 47.926, -4.858, -3.27, 0.786, 61.02, 26.951, 0.433, -6.9]
**Ligand B:** [353.463, 96.53, 1.878, 3, 4, 0.551, 34.393, 75.107, -4.755, -2.786, 0.103, 59.592, -12.665, 0.013, -5.8]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). A (343.427) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** A (82.62) is better than B (96.53), falling well under the 140 threshold for oral absorption.
3. **logP:** A (2.984) is optimal, while B (1.878) is a bit low, potentially hindering membrane permeability.
4. **HBD:** A (4) is acceptable, B (3) is also good.
5. **HBA:** Both are at 4, which is within the acceptable range.
6. **QED:** Both are good (A: 0.594, B: 0.551), indicating drug-like properties.
7. **DILI:** A (54.362) is slightly higher than B (34.393), meaning B has a lower predicted liver injury risk, which is a significant advantage.
8. **BBB:** B (75.107) is significantly better than A (47.926). While ADRB2 isn't *necessarily* a CNS target, higher BBB penetration can still be beneficial for overall distribution and potentially reduce off-target effects.
9. **Caco-2:** Both are negative, indicating poor permeability. This is a concern for both.
10. **Solubility:** Both are negative, indicating poor solubility. This is a concern for both.
11. **hERG:** A (0.786) is higher than B (0.103), indicating a higher risk of hERG inhibition and potential cardiotoxicity. This is a major concern for a cardiovascular target.
12. **Cl_mic:** B (59.592) is slightly better than A (61.02), indicating slightly better metabolic stability.
13. **t1/2:** A (26.951) is much better than B (-12.665). A longer half-life is generally desirable.
14. **Pgp:** A (0.433) is higher than B (0.013), indicating greater P-gp efflux, which could limit bioavailability.
15. **Affinity:** A (-6.9) is significantly better than B (-5.8), representing a 1.1 kcal/mol advantage in binding.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. A has a better logP and significantly better affinity. However, B has a much better BBB score and a significantly lower hERG risk and DILI risk, and lower Pgp efflux. The hERG risk for A is concerning for a cardiovascular target.
**Decision:**
While Ligand A has a superior binding affinity, the significantly lower hERG risk and DILI risk, coupled with better BBB penetration and lower Pgp efflux, of Ligand B outweigh the affinity difference. The poor Caco-2 and solubility for both are concerning, but can be addressed with formulation strategies. The cardiotoxicity risk associated with Ligand A is too high for a cardiovascular drug.
**Output:**
0
2025-04-17 21:47:46,953 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (a cardiovascular GPCR) drug candidates.
**Ligand A:** [368.434, 107.08 , 2.014, 2. , 5. , 0.695, 65.491, 68.786, -5.236, -2.173, 0.629, 14.102, -6.977, 0.196, -7. ]
**Ligand B:** [344.499, 49.41 , 3.278, 1. , 2. , 0.594, 37.146, 76.464, -4.781, -4.137, 0.293, 78.137, -13.404, 0.463, -6.2 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (344.499) is slightly lower, which could be beneficial for permeability, but both are acceptable.
2. **TPSA:** Ligand A (107.08) is higher than Ligand B (49.41). For a cardiovascular GPCR, TPSA isn't *as* critical as for CNS targets, but lower is generally preferred for absorption. Ligand B is significantly better here.
3. **logP:** Ligand A (2.014) is within the optimal range. Ligand B (3.278) is slightly higher, but still acceptable.
4. **HBD:** Ligand A (2) and Ligand B (1) are both good.
5. **HBA:** Ligand A (5) and Ligand B (2) are both good.
6. **QED:** Ligand A (0.695) is slightly better than Ligand B (0.594), indicating a more drug-like profile.
7. **DILI:** Ligand A (65.491) has a higher DILI risk than Ligand B (37.146). This is a significant concern.
8. **BBB:** Ligand A (68.786) and Ligand B (76.464) are both reasonably good, but not exceptionally high. Since this is a cardiovascular target, BBB isn't a primary concern, but higher is still slightly favorable.
9. **Caco-2:** Ligand A (-5.236) and Ligand B (-4.781) are both negative, which is unusual. This suggests poor permeability.
10. **Solubility:** Ligand A (-2.173) and Ligand B (-4.137) are both poor.
11. **hERG:** Ligand A (0.629) and Ligand B (0.293) are both low, which is good. Ligand B is slightly better.
12. **Cl_mic:** Ligand A (14.102) has a lower clearance than Ligand B (78.137), indicating better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand A (-6.977) has a longer half-life than Ligand B (-13.404). This is a significant advantage.
14. **Pgp:** Ligand A (0.196) has lower P-gp efflux than Ligand B (0.463), which is favorable.
15. **Affinity:** Ligand A (-7.0) has slightly better binding affinity than Ligand B (-6.2).
**Overall Assessment:**
While Ligand A has slightly better affinity and metabolic stability, the significantly higher DILI risk is a major drawback. Ligand B has a much better safety profile regarding liver toxicity, a more favorable TPSA, and slightly better hERG. The differences in half-life and Pgp are less concerning than the DILI risk. The lower Caco-2 and solubility for both are concerning, but could be addressed with formulation strategies.
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity) and the overall balance of properties, Ligand B is the more promising candidate due to its significantly lower DILI risk.
Output:
0
2025-04-17 21:47:46,954 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (357.439 Da and 360.479 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (92.42) is higher than Ligand B (72.31). While both are reasonably good, Ligand B is better, being closer to the <90 threshold for potential CNS penetration (though not a primary concern for ADRB2 unless CNS effects are desired).
3. **logP:** Ligand A (1.477) is within the optimal 1-3 range. Ligand B (3.808) is at the upper end, potentially raising concerns about solubility and off-target interactions.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Both ligands have 6 HBA, also good.
6. **QED:** Ligand A (0.895) has a better QED score than Ligand B (0.79), indicating a more drug-like profile.
7. **DILI:** Ligand A (75.766) has a higher DILI risk than Ligand B (63.086). This is a negative for Ligand A.
8. **BBB:** Ligand A (75.107) has a higher BBB penetration potential than Ligand B (24.389). While ADRB2 isn't necessarily a CNS target, higher BBB is generally favorable.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.865) is slightly better than Ligand B (-5.014).
10. **Solubility:** Ligand A (-2.955) has better solubility than Ligand B (-5.474). This is a positive for Ligand A, especially considering Ligand B's higher logP.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.219 and 0.153 respectively). No significant difference.
12. **Cl_mic:** Ligand A (11.673) has lower microsomal clearance than Ligand B (103.211), suggesting better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Both ligands have negative in vitro half-lives (-26.729 and -29.165). This is concerning for both, but not a deciding factor.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.085 and 0.16 respectively). No significant difference.
15. **Binding Affinity:** Ligand A (-6.0 kcal/mol) has a slightly better binding affinity than Ligand B (-3.1 kcal/mol). This is a substantial advantage for Ligand A.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has a better logP, better TPSA, comparable Pgp, and *significantly* better affinity. While Ligand B has a lower DILI risk, the substantial affinity advantage of Ligand A, coupled with its better metabolic stability (lower Cl_mic) and solubility, outweigh this concern. The Caco-2 permeability is poor for both, but can be addressed with formulation strategies.
**Conclusion:**
Ligand A is the more promising candidate due to its superior binding affinity, better metabolic stability, better solubility, and acceptable physicochemical properties for a GPCR target.
Output:
1
2025-04-17 21:47:46,954 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [351.353, 82.53, 1.91, 2, 4, 0.866, 76.541, 46.026, -5.201, -4.053, 0.099, 5.023, 5.967, 0.01, -7.4]
**Ligand B:** [364.471, 88.33, 2.669, 1, 6, 0.778, 55.991, 58.821, -5.08, -1.947, 0.418, 86.155, -21.729, 0.112, -7]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). A (351.353) is slightly preferred.
2. **TPSA:** Both are good (under 140), A (82.53) is better than B (88.33). Lower TPSA generally favors better absorption.
3. **logP:** Both are within the optimal range (1-3). A (1.91) is slightly better than B (2.669) as it's closer to the lower end, potentially reducing off-target effects.
4. **HBD:** A (2) is preferable to B (1) as it balances solubility and permeability.
5. **HBA:** A (4) is preferable to B (6) for the same reason as above.
6. **QED:** A (0.866) is significantly better than B (0.778), indicating a more drug-like profile.
7. **DILI:** B (55.991) is significantly better than A (76.541). This is a major advantage for B.
8. **BBB:** A (46.026) is lower than B (58.821). While ADRB2 isn't necessarily a CNS target, some degree of BBB penetration can be beneficial for distribution.
9. **Caco-2:** Both are negative, which is unusual and suggests poor permeability. A (-5.201) is slightly worse than B (-5.08).
10. **Solubility:** B (-1.947) is better than A (-4.053). Solubility is important for bioavailability.
11. **hERG:** A (0.099) is much better than B (0.418). Lower hERG inhibition is crucial for avoiding cardiotoxicity, especially for a cardiovascular target.
12. **Cl_mic:** A (5.023) is much better than B (86.155). Lower clearance indicates better metabolic stability.
13. **t1/2:** A (5.967) is better than B (-21.729). A longer half-life is generally preferred.
14. **Pgp:** A (0.01) is much better than B (0.112). Lower P-gp efflux is desirable for better bioavailability.
15. **Affinity:** A (-7.4) is slightly better than B (-7.0). While both are excellent, the difference is significant enough to consider.
**GPCR-specific priorities:** LogP, Pgp, TPSA, and affinity are key. A performs better on logP, TPSA, Pgp and affinity.
**Overall Assessment:**
Ligand A has a significantly better drug-like profile (QED), metabolic stability (Cl_mic), half-life, Pgp efflux, and hERG risk. It also has slightly better affinity. While Ligand B has a lower DILI risk and better solubility, the advantages of A in crucial ADME properties and safety outweigh these benefits. The Caco-2 permeability is a concern for both, but the other parameters strongly favor A.
Output:
1
2025-04-17 21:47:46,954 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (410.587 Da) is within the ideal range, while Ligand B (367.852 Da) is also acceptable, leaning towards the lower end. No clear advantage here.
2. **TPSA:** Ligand A (112.81) is slightly higher than ideal for good oral absorption (<=140), but still reasonable. Ligand B (69.22) is excellent, well below the threshold. This favors Ligand B.
3. **logP:** Ligand A (-0.505) is quite low, potentially hindering membrane permeability. Ligand B (3.426) is excellent, falling right within the optimal range. This strongly favors Ligand B.
4. **HBD:** Both ligands have 2 HBD, which is good.
5. **HBA:** Ligand A has 7 HBA, acceptable. Ligand B has 3 HBA, which is also good. No clear advantage.
6. **QED:** Both ligands have QED values above 0.5 (A: 0.567, B: 0.751), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (58.705) has a moderate DILI risk. Ligand B (36.681) has a lower, more favorable DILI risk. This favors Ligand B.
8. **BBB:** Both ligands have similar BBB penetration (A: 48.779, B: 50.523). While not exceptionally high, it's not a major concern for a cardiovascular target like ADRB2.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Both ligands have negative solubility values, which is also unusual and suggests poor solubility. This is a significant concern for both.
11. **hERG:** Ligand A (0.686) has a slightly better hERG profile than Ligand B (0.88), indicating lower cardiotoxicity risk. This favors Ligand A.
12. **Cl_mic:** Ligand A (4.447) has a lower microsomal clearance, suggesting better metabolic stability, than Ligand B (44.34). This favors Ligand A.
13. **t1/2:** Ligand A (-4.877) has a negative in vitro half-life, which is concerning. Ligand B (44.309) has a good in vitro half-life. This strongly favors Ligand B.
14. **Pgp:** Ligand A (0.024) has very low P-gp efflux, which is good. Ligand B (0.62) has moderate P-gp efflux. This favors Ligand A.
15. **Affinity:** Ligand A (-7.6 kcal/mol) has a significantly better binding affinity than Ligand B (-6.1 kcal/mol). This is a substantial advantage.
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, TPSA, and affinity are key. Ligand B excels in logP and TPSA, while Ligand A has a much stronger binding affinity. The significantly better affinity of Ligand A outweighs the slightly less optimal logP and TPSA values.
**Overall Assessment:**
While Ligand B has better ADME properties in several areas (DILI, t1/2, QED, TPSA, logP), the substantially stronger binding affinity of Ligand A (-7.6 vs -6.1 kcal/mol) is a critical advantage for a GPCR target. The difference in affinity is large enough to compensate for the slightly less favorable ADME profile of Ligand A. The negative Caco-2 and solubility values for both are concerning and would require further investigation/optimization, but the potency advantage is decisive.
Output:
1
2025-04-17 21:47:46,954 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.475 and 375.481 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (59.08) is slightly higher than Ligand B (49.77), but both are well below the 140 A^2 threshold for good oral absorption. Given ADRB2 is a cardiovascular target, CNS penetration isn't a primary concern, so this isn't a major differentiator.
3. **logP:** Ligand B (3.848) is higher than Ligand A (1.679). While both are within the optimal 1-3 range, Ligand B is approaching the upper limit. This could potentially lead to solubility issues, but for a GPCR, a slightly higher logP can be beneficial for membrane interactions.
4. **HBD:** Ligand A (0) has no hydrogen bond donors, while Ligand B (1) has one. Lower is generally preferred for permeability, giving a slight edge to Ligand A.
5. **HBA:** Both ligands (4) have the same number of hydrogen bond acceptors, which is within the acceptable limit of 10.
6. **QED:** Both ligands have similar QED values (0.775 and 0.788), indicating good drug-likeness.
7. **DILI:** Ligand B (25.785) has a significantly lower DILI risk than Ligand A (30.903). This is a substantial advantage for Ligand B.
8. **BBB:** Both ligands have high BBB penetration (84.8 and 86.351). However, since ADRB2 is a cardiovascular target, BBB penetration is not a critical factor.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.033 and -4.759). This is unusual and suggests poor permeability. However, negative values are often artifacts of the prediction method and should be interpreted cautiously.
10. **Solubility:** Ligand A (-1.532) has better predicted aqueous solubility than Ligand B (-3.214). This is a positive for Ligand A, potentially mitigating the slightly higher logP of Ligand B.
11. **hERG:** Ligand A (0.343) has a lower hERG inhibition liability than Ligand B (0.861). This is a significant advantage for Ligand A, reducing the risk of cardiotoxicity.
12. **Cl_mic:** Ligand B (46.051) has a higher microsomal clearance than Ligand A (30.592), indicating faster metabolism and potentially lower *in vivo* exposure. This favors Ligand A.
13. **t1/2:** Ligand A (-11.713) has a negative in vitro half-life, which is concerning. Ligand B (15.14) has a positive and reasonable half-life. This is a major advantage for Ligand B.
14. **Pgp:** Ligand A (0.085) has lower P-gp efflux liability than Ligand B (0.583). This is favorable for Ligand A, improving bioavailability.
15. **Binding Affinity:** Ligand B (-6.8) has a slightly better binding affinity than Ligand A (-6.6). While the difference is small (0.2 kcal/mol), it's still a positive for Ligand B.
**Overall Assessment:**
Ligand B has several key advantages: lower DILI risk, a more reasonable *in vitro* half-life, and slightly better binding affinity. While its logP is higher and solubility lower, these are less critical for a cardiovascular GPCR target. Ligand A has better hERG and Pgp profiles, but the negative half-life is a significant concern. The lower DILI risk and better half-life of Ligand B outweigh the minor drawbacks.
Output:
0
2025-04-17 21:47:46,954 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [350.503, 69.64, 2.33, 2, 3, 0.547, 14.114, 45.832, -4.702, -2.45, 0.462, 34.29, -15.637, 0.269, -7.0]
**Ligand B:** [350.419, 114.53, -0.264, 4, 4, 0.459, 18.108, 21.171, -5.814, -1.219, 0.041, -3.256, -3.394, 0.008, -5.3]
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (around 350 Da). No significant difference here.
2. **TPSA:** Ligand A (69.64) is significantly better than Ligand B (114.53). For a GPCR, keeping TPSA lower is beneficial for permeability. Ligand B is above the preferred 90 for CNS targets, while A is well within.
3. **logP:** Ligand A (2.33) is optimal. Ligand B (-0.264) is too low, potentially leading to poor membrane permeability and bioavailability.
4. **HBD:** Ligand A (2) is preferable to Ligand B (4). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (4). Fewer HBAs generally improve permeability.
6. **QED:** Both are similar (0.547 vs 0.459) and acceptable, but A is slightly better.
7. **DILI:** Ligand A (14.114) has a much lower DILI risk than Ligand B (18.108). This is a significant advantage.
8. **BBB:** Ligand A (45.832) has better BBB penetration potential than Ligand B (21.171), although neither is exceptionally high. Still, for a GPCR, some CNS penetration is not necessarily detrimental and could be useful for off-target effects assessment.
9. **Caco-2:** Ligand A (-4.702) is better than Ligand B (-5.814), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-2.45) is better than Ligand B (-1.219), although both are poor.
11. **hERG:** Ligand A (0.462) has a much lower hERG risk than Ligand B (0.041). This is a critical advantage for cardiovascular targets.
12. **Cl_mic:** Ligand A (34.29) has higher metabolic clearance than Ligand B (-3.256). Ligand B is more metabolically stable, which is a positive.
13. **t1/2:** Ligand A (-15.637) has a shorter half-life than Ligand B (-3.394). Ligand B is preferable.
14. **Pgp:** Ligand A (0.269) has lower P-gp efflux than Ligand B (0.008), which is preferable.
15. **Affinity:** Ligand A (-7.0) has slightly better binding affinity than Ligand B (-5.3). While the difference is not huge, it is still a factor.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, and affinity. Ligand A excels in these areas. While metabolic stability (Cl_mic and t1/2) is important, the significant advantages of Ligand A in permeability, safety (DILI, hERG), and affinity outweigh the slightly less favorable metabolic profile.
**Conclusion:**
Ligand A is the more promising drug candidate due to its superior predicted permeability (lower TPSA, better logP), significantly lower toxicity risks (DILI, hERG), and slightly better binding affinity.
Output:
1
2025-04-17 21:47:46,954 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (354.491 and 385.877 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (87.66) is better than Ligand B (109.26). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally favors absorption.
3. **logP:** Both ligands (1.611 and 1.855) are within the optimal 1-3 range. Similar.
4. **HBD:** Both have 3 HBD, which is acceptable. Similar.
5. **HBA:** Ligand A (4) is better than Ligand B (8). Lower HBA is generally preferred for better permeability.
6. **QED:** Ligand A (0.618) is significantly better than Ligand B (0.423). A higher QED suggests a more drug-like profile.
7. **DILI:** Ligand A (8.026%) is *much* better than Ligand B (71.656%). This is a major advantage for Ligand A. A DILI percentile above 60 is concerning.
8. **BBB:** Ligand A (61.535%) is better than Ligand B (28.306%), but neither is particularly high. Since ADRB2 is primarily cardiovascular, BBB isn't a critical factor.
9. **Caco-2:** Ligand A (-4.638) is better than Ligand B (-5.538). Higher Caco-2 permeability is desirable.
10. **Solubility:** Ligand A (-1.76) is better than Ligand B (-2.523). Better solubility is always a plus.
11. **hERG:** Both ligands (0.285 and 0.2) have low hERG inhibition risk, which is good. Similar.
12. **Cl_mic:** Ligand A (40.814) has a higher microsomal clearance than Ligand B (26.673). This suggests Ligand B is more metabolically stable, which is a positive.
13. **t1/2:** Ligand B (22.507) has a significantly longer in vitro half-life than Ligand A (-0.182). This is a significant advantage for Ligand B.
14. **Pgp:** Both ligands (0.027 and 0.198) have low P-gp efflux, which is good. Similar.
15. **Binding Affinity:** Ligand A (-6.6) is slightly better than Ligand B (-6.4). While the difference is small, it's still a positive for Ligand A.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Both ligands perform reasonably well on logP and Pgp. Ligand A has a better TPSA and slightly better affinity. The *major* differentiator is the DILI score. Ligand B's high DILI risk is a significant red flag. While Ligand B has a better half-life, the liver toxicity risk is too high to ignore.
**Conclusion:**
Despite Ligand B's longer half-life, Ligand A is the more promising candidate due to its significantly lower DILI risk, better QED, and slightly better overall ADME profile (TPSA, solubility, Caco-2). The small affinity advantage also contributes.
Output:
1
2025-04-17 21:47:46,955 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (358.454 and 363.449 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (67.87) is better than Ligand B (72.88). Both are below 140, but lower is preferred for oral absorption.
3. **logP:** Both ligands have good logP values (1.531 and 1.086), falling within the optimal 1-3 range. Ligand B is slightly lower, which could be a minor concern for permeability, but not a dealbreaker.
4. **HBD:** Ligand A (1) is better than Ligand B (2). Lower HBD is generally preferred for better permeability.
5. **HBA:** Both ligands have the same number of HBA (4), which is within the acceptable limit of 10.
6. **QED:** Both ligands have the same QED (0.643), indicating similar drug-likeness.
7. **DILI:** Ligand A (26.444) has a significantly lower DILI risk than Ligand B (10.237). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (97.325) has a much higher BBB penetration percentile than Ligand B (65.839). While ADRB2 isn't strictly a CNS target, some CNS exposure can occur, and higher BBB is generally favorable.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.543 and -4.937), which is unusual and suggests poor permeability. However, the values are similar.
10. **Solubility:** Ligand A (-2.456) has slightly better solubility than Ligand B (-0.231).
11. **hERG:** Both ligands have very low hERG inhibition risk (0.69 and 0.454).
12. **Cl_mic:** Ligand B (-5.406) has a *negative* microsomal clearance, which is highly unusual and suggests very high metabolic stability. Ligand A (52.333) is more typical. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand B (-28.987) has a negative in vitro half-life, which is also highly unusual and suggests exceptional stability. Ligand A (11.259) is more typical. This is another significant advantage for Ligand B.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.087 and 0.006).
15. **Binding Affinity:** Ligand B (-6.7) has slightly better binding affinity than Ligand A (-6.5), although the difference is small (0.2 kcal/mol).
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Both ligands perform well on logP and Pgp. Ligand A has a slightly better TPSA. Ligand B has a slightly better affinity. However, the significant advantages of Ligand B in terms of metabolic stability (Cl_mic and t1/2) and the lower DILI risk of Ligand A are crucial.
**Overall Assessment:**
Ligand B's exceptionally low (negative) Cl_mic and t1/2 are highly attractive, suggesting it will be very stable in vivo. The slightly better affinity is a bonus. While the Caco-2 values are concerning for both, the overall profile of Ligand B is more promising.
Output:
0
2025-04-17 21:47:46,955 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (382.873 and 385.335 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (88.33) is higher than Ligand B (53.43). For a cardiovascular GPCR, TPSA isn't *as* critical as for a CNS target, but lower is generally preferred for better absorption. Ligand B is better.
3. **logP:** Both ligands have good logP values (2.772 and 3.501), falling within the 1-3 optimal range. Ligand B is slightly higher, which *could* be a minor drawback if it leads to solubility issues, but it's not a major concern.
4. **HBD:** Both have 1 HBD, which is ideal. No difference.
5. **HBA:** Ligand A has 6 HBA, while Ligand B has 3. Lower HBA is generally better for permeability. Ligand B is better.
6. **QED:** Ligand A (0.858) has a significantly better QED score than Ligand B (0.697), indicating a more drug-like profile. This is a strong point for Ligand A.
7. **DILI:** Ligand A (76.037) has a considerably higher DILI risk than Ligand B (11.283). This is a major concern for Ligand A. A DILI percentile above 60 is undesirable.
8. **BBB:** Ligand B (79.062) has a higher BBB penetration percentile than Ligand A (60.411). While ADRB2 isn't a primary CNS target, some degree of BBB penetration can be beneficial, and lower penetration is not necessarily a drawback.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.968 and -4.805). This is unusual and suggests poor permeability. However, the values are very close, so this isn't a deciding factor.
10. **Solubility:** Ligand A (-4.087) has slightly better solubility than Ligand B (-3.495).
11. **hERG:** Ligand A (0.201) has a lower hERG inhibition liability than Ligand B (0.61). This is a positive for Ligand A, reducing cardiotoxicity risk.
12. **Cl_mic:** Ligand B (44.853) has a lower microsomal clearance than Ligand A (35.643), suggesting better metabolic stability. This is a positive for Ligand B.
13. **t1/2:** Ligand B (46.898) has a significantly longer in vitro half-life than Ligand A (21.317). This is a major advantage for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.226) has lower P-gp efflux liability than Ligand B (0.49). This is a positive for Ligand A, improving bioavailability.
15. **Binding Affinity:** Ligand A (-6.9 kcal/mol) has a slightly better binding affinity than Ligand B (-5.8 kcal/mol). This 1.1 kcal/mol difference is significant and could outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand A has a better QED, hERG, Pgp, and binding affinity. However, its significantly higher DILI risk is a major red flag. Ligand B has superior metabolic stability (lower Cl_mic, longer t1/2), lower DILI risk, and lower HBA/TPSA. While its QED is lower and Pgp efflux is higher, the lower DILI risk and improved pharmacokinetic profile are more critical for a cardiovascular drug. The affinity difference, while notable, is unlikely to overcome the safety concerns with Ligand A.
Output:
0
2025-04-17 21:47:46,955 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [342.458, 33.29, 4.308, 2, 3, 0.702, 27.104, 78.48, -4.758, -3.484, 0.979, 52.126, 16.665, 0.773, -6.6]
**Ligand B:** [385.917, 78.51, 2.283, 2, 4, 0.788, 59.093, 49.787, -5.165, -3.277, 0.233, 13.202, 24.886, 0.182, -6.3]
**Step-by-step comparison:**
1. **MW:** Ligand A (342.458 Da) is better, falling nicely within the 200-500 Da range. Ligand B (385.917 Da) is still acceptable, but closer to the upper limit.
2. **TPSA:** Ligand A (33.29) is significantly better than Ligand B (78.51). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B's TPSA is quite high, potentially hindering absorption.
3. **logP:** Ligand A (4.308) is a bit high, but still within a reasonable range. Ligand B (2.283) is better, falling comfortably within the 1-3 optimal range.
4. **HBD:** Both have 2 HBD, which is good.
5. **HBA:** Ligand A has 3 HBA, Ligand B has 4. Both are acceptable.
6. **QED:** Both ligands have similar QED values (0.702 and 0.788), indicating good drug-likeness.
7. **DILI:** Ligand A (27.104) has a much lower DILI risk than Ligand B (59.093). This is a significant advantage.
8. **BBB:** Ligand A (78.48) has a better BBB penetration percentile than Ligand B (49.787). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant and this is a positive.
9. **Caco-2:** Ligand A (-4.758) is better than Ligand B (-5.165), indicating better intestinal absorption.
10. **Solubility:** Both have similar solubility values (-3.484 and -3.277).
11. **hERG:** Ligand A (0.979) has a slightly better hERG profile than Ligand B (0.233), meaning it is less likely to cause cardiotoxicity.
12. **Cl_mic:** Ligand B (13.202) has significantly lower microsomal clearance than Ligand A (52.126), suggesting better metabolic stability. This is a major advantage for Ligand B.
13. **t1/2:** Ligand B (24.886) has a longer in vitro half-life than Ligand A (16.665), which is desirable.
14. **Pgp:** Ligand A (0.773) has lower P-gp efflux liability than Ligand B (0.182), which is preferable.
15. **Affinity:** Ligand B (-6.3 kcal/mol) has a slightly better binding affinity than Ligand A (-6.6 kcal/mol). However, the difference is small.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, we prioritize logP, TPSA, Pgp, and affinity. Ligand B has a better logP and Cl_mic/t1/2. Ligand A has a better TPSA and Pgp. The affinity difference is minimal. The DILI risk for Ligand A is significantly lower.
**Overall Assessment:**
While Ligand B has advantages in metabolic stability (Cl_mic, t1/2) and slightly better affinity, Ligand A's superior TPSA, lower DILI risk, and better Pgp profile are more important for overall drug development potential. The higher logP of Ligand A is a concern, but not a deal-breaker. The lower DILI risk is a significant advantage.
Therefore, I prefer Ligand A.
Output:
1
2025-04-17 21:47:46,955 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
The ADRB2 receptor is a GPCR, so the priorities are logP, TPSA, Pgp efflux, BBB penetration, and binding affinity. Metabolic stability (Cl_mic, t1/2) and safety (DILI, hERG) are also important.
Let's compare the ligands property by property:
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (344.371) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (67.87) is significantly better than Ligand A (115.39). Lower TPSA is crucial for GPCRs, aiding in brain penetration and overall absorption.
3. **logP:** Ligand B (1.975) is optimal, while Ligand A (-0.674) is below the preferred range. This suggests Ligand B will have better membrane permeability.
4. **HBD/HBA:** Ligand A has 3 HBD and 5 HBA, while Ligand B has 1 HBD and 4 HBA. Both are acceptable, but Ligand B is slightly better.
5. **QED:** Both ligands have similar QED values (0.626 and 0.609), indicating good drug-likeness.
6. **DILI:** Ligand B (10.237) has a much lower DILI risk than Ligand A (59.636). This is a significant advantage for Ligand B.
7. **BBB:** Ligand B (83.443) has excellent BBB penetration, while Ligand A (30.942) is relatively poor. This is a major advantage for Ligand B, even though ADRB2 isn't exclusively a CNS target, some CNS exposure is often acceptable and can contribute to peripheral effects.
8. **Caco-2:** Both have negative values, indicating poor permeability. Ligand B (-4.526) is slightly better than Ligand A (-5.113).
9. **Solubility:** Both have negative solubility values, indicating poor solubility. Ligand B (-1.392) is slightly better than Ligand A (-2.355).
10. **hERG:** Ligand A (0.033) has a slightly lower hERG risk than Ligand B (0.548), but both are relatively low.
11. **Cl_mic:** Ligand A (-23.557) has a much lower (better) microsomal clearance than Ligand B (54.709), suggesting better metabolic stability.
12. **t1/2:** Ligand B (-2.703) has a slightly better in vitro half-life than Ligand A (-33.293).
13. **Pgp:** Ligand A (0.008) has a much lower Pgp efflux liability than Ligand B (0.054), which is favorable for bioavailability.
14. **Binding Affinity:** Ligand B (-5.9) has a slightly better binding affinity than Ligand A (-5.3). While the difference is not huge, it's still a positive for Ligand B.
**Overall Assessment:**
Ligand B clearly outperforms Ligand A in several critical areas for a GPCR drug candidate: TPSA, logP, BBB penetration, and DILI risk. While Ligand A has better metabolic stability (Cl_mic) and Pgp efflux, the advantages of Ligand B in terms of absorption, brain penetration, and safety are more impactful for this target class. The slightly better binding affinity of Ligand B further strengthens its case.
Output:
0
2025-04-17 21:47:46,956 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (340.43 & 343.47 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (88.32) is higher than Ligand B (62.3). For a cardiovascular GPCR, TPSA is moderately important for permeability, and B is better.
3. **logP:** Both ligands have good logP values (2.075 & 3.078), falling within the optimal 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Ligand A has 2 HBD, while Ligand B has 1. Both are acceptable, well below the threshold of 5.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 3. Both are below the threshold of 10.
6. **QED:** Both ligands have very similar QED values (0.892 & 0.894), indicating excellent drug-likeness.
7. **DILI:** Ligand A (55.642) has a higher DILI risk than Ligand B (33.695). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (87.864) has a higher BBB percentile than Ligand B (74.952). While ADRB2 isn't a primary CNS target, some CNS penetration can be acceptable or even beneficial for off-target effects.
9. **Caco-2:** Ligand A (-5.165) and Ligand B (-4.556) both have negative Caco-2 values, which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-2.931) and Ligand B (-3.7) both have very poor solubility. This is a major drawback for both compounds, potentially hindering bioavailability.
11. **hERG:** Ligand A (0.61) has a slightly higher hERG risk than Ligand B (0.225). Lower is better, so Ligand B is preferable.
12. **Cl_mic:** Ligand A (30.832) has lower microsomal clearance than Ligand B (54.232), suggesting better metabolic stability. This is a positive for Ligand A.
13. **t1/2:** Ligand A (13.171) has a longer in vitro half-life than Ligand B (0.406). This is a significant advantage for Ligand A, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.058) has lower P-gp efflux than Ligand B (0.075). This is a slight advantage for Ligand A, potentially improving bioavailability.
15. **Binding Affinity:** Ligand B (-7.8 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.0 kcal/mol). This is a substantial advantage for Ligand B, potentially outweighing some of the ADME drawbacks.
**Overall Assessment:**
Ligand B has a significantly better binding affinity (-7.8 vs -6.0 kcal/mol), lower DILI risk, and lower hERG risk. While Ligand A has better metabolic stability (lower Cl_mic) and a longer half-life, the superior binding affinity and safety profile of Ligand B are more critical for a GPCR target like ADRB2. The poor Caco-2 and solubility are concerns for both, but can potentially be addressed through formulation strategies. The stronger binding of Ligand B suggests it may be more potent, and thus require a lower dose, potentially mitigating some of the solubility issues.
Output:
0
2025-04-17 21:47:46,956 - INFO - Batch 284 complete. Total preferences: 4544
2025-04-17 21:47:46,956 - INFO - Processing batch 285/512...
2025-04-17 21:48:36,641 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [343.471, 52.65, 2.585, 1, 3, 0.491, 46.801, 79.256, -4.525, -3.446, 0.661, 48.429, 7.047, 0.424, -6.5]
**Ligand B:** [356.451, 58.44, 1.25, 0, 5, 0.732, 37.999, 60.411, -4.993, -2.549, 0.165, 13.632, 3.465, 0.039, -6.7]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal 200-500 Da range. Ligand A (343.471) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (52.65) is better than Ligand B (58.44), both are acceptable but lower is preferred for better absorption.
3. **logP:** Ligand A (2.585) is optimal. Ligand B (1.25) is a bit low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (1) is better than Ligand B (0). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (3) is better than Ligand B (5). Fewer HBAs generally improve permeability.
6. **QED:** Ligand B (0.732) is better than Ligand A (0.491), indicating a more drug-like profile.
7. **DILI:** Ligand B (37.999) is significantly better than Ligand A (46.801), indicating a lower risk of liver injury.
8. **BBB:** Ligand A (79.256) is significantly better than Ligand B (60.411), which is crucial for a GPCR target, especially if CNS effects are relevant.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand B (-4.993) is slightly worse than Ligand A (-4.525).
10. **Solubility:** Ligand B (-2.549) is better than Ligand A (-3.446).
11. **hERG:** Ligand A (0.661) is better than Ligand B (0.165), indicating a lower risk of cardiotoxicity.
12. **Cl_mic:** Ligand B (13.632) is much better than Ligand A (48.429), suggesting better metabolic stability.
13. **t1/2:** Ligand A (7.047) is better than Ligand B (3.465), indicating a longer half-life.
14. **Pgp:** Ligand A (0.424) is better than Ligand B (0.039), suggesting lower efflux and better bioavailability.
15. **Affinity:** Ligand B (-6.7) is slightly better than Ligand A (-6.5), but the difference is small.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, BBB, and affinity. Ligand A excels in BBB and Pgp, while Ligand B has better QED, DILI, solubility, and metabolic stability. The affinity difference is minimal. LogP is better for Ligand A, and TPSA is better for Ligand A.
**Overall Assessment:**
While Ligand B has advantages in QED, DILI, solubility, and metabolic stability, Ligand A's significantly better BBB penetration and Pgp profile are more critical for a GPCR target like ADRB2. The slightly better logP and TPSA of Ligand A also contribute to its favorability. The small advantage in binding affinity for Ligand B is not enough to overcome the ADME deficiencies.
Therefore, I would choose Ligand A.
Output:
1
2025-04-17 21:48:36,641 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [362.821, 103.87 , 1.725, 2. , 5. , 0.814, 72.664, 48.275, -5.397, -2.872, 0.073, 13.658, -26.244, 0.004, -6. ]
**Ligand B:** [353.463, 87.74 , 0.681, 2. , 5. , 0.595, 20.744, 36.603, -5.36 , -0.941, 0.156, -4.372, -4.717, 0.011, -5.3 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (353.463) is slightly lower, which is generally favorable.
2. **TPSA:** Ligand A (103.87) is a bit higher than Ligand B (87.74). Both are acceptable for a non-CNS GPCR target like ADRB2, but Ligand B is better.
3. **logP:** Ligand A (1.725) is within the optimal range. Ligand B (0.681) is a little low, potentially impacting permeability.
4. **HBD:** Both have 2 HBD, which is good.
5. **HBA:** Both have 5 HBA, which is good.
6. **QED:** Ligand A (0.814) has a significantly better QED score than Ligand B (0.595), indicating a more drug-like profile.
7. **DILI:** Ligand A (72.664) has a higher DILI risk than Ligand B (20.744). This is a significant drawback for Ligand A.
8. **BBB:** Not a primary concern for ADRB2 (cardiovascular target), but Ligand A (48.275) is slightly higher than Ligand B (36.603).
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. The values are very similar.
10. **Solubility:** Ligand A (-2.872) has worse solubility than Ligand B (-0.941).
11. **hERG:** Both have very low hERG risk, which is excellent.
12. **Cl_mic:** Ligand B (-4.372) has a much lower (better) microsomal clearance than Ligand A (13.658), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-4.717) has a slightly better (more negative) in vitro half-life than Ligand A (-26.244).
14. **Pgp:** Both have very low Pgp efflux, which is good.
15. **Binding Affinity:** Both have similar binding affinities (-6.0 and -5.3 kcal/mol respectively). Ligand A is slightly better, but the difference is not substantial enough to overcome other issues.
**GPCR-Specific Priorities:** For ADRB2, logP, TPSA, Pgp, and affinity are important. Ligand B has a better logP and TPSA. Both have good Pgp profiles. Affinity is slightly better for Ligand A, but not enough to compensate for the other factors.
**Overall Assessment:**
Ligand A has a better QED and slightly better affinity, but suffers from significantly higher DILI risk, worse solubility, and higher metabolic clearance. Ligand B has a better safety profile (lower DILI), better metabolic stability, and better solubility, even though its logP is a bit low. Considering the balance of properties and the importance of safety and metabolic stability for a cardiovascular drug, Ligand B is the more promising candidate.
Output:
0
2025-04-17 21:48:36,641 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (340.471 and 348.399 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (44.39) is significantly better than Ligand B (92.01). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally correlates with better absorption. Ligand B's TPSA is quite high and could hinder oral bioavailability.
3. **logP:** Ligand A (2.763) is optimal, while Ligand B (0.564) is a bit low. A logP below 1 can lead to poor membrane permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is better than Ligand B (5). Similar reasoning as HBD.
6. **QED:** Ligand A (0.929) is excellent, indicating high drug-likeness. Ligand B (0.733) is still acceptable, but less favorable.
7. **DILI:** Ligand A (10.857) has a much lower DILI risk than Ligand B (35.169). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (77.705) has a higher BBB penetration percentile than Ligand B (24.661). While not critical for a cardiovascular target, higher BBB is rarely a detriment.
9. **Caco-2:** Ligand A (-5.181) and Ligand B (-4.701) are similar, indicating comparable intestinal absorption potential.
10. **Solubility:** Ligand A (-2.219) is slightly better than Ligand B (-1.499).
11. **hERG:** Ligand A (0.944) is preferable to Ligand B (0.24). Lower hERG inhibition is crucial for avoiding cardiotoxicity, especially for a cardiovascular target.
12. **Cl_mic:** Ligand A (-2.222) is significantly better than Ligand B (-14.666). Lower clearance indicates greater metabolic stability.
13. **t1/2:** Ligand A (-1.696) is better than Ligand B (2.044). Longer half-life is generally desirable.
14. **Pgp:** Ligand A (0.107) is significantly better than Ligand B (0.16). Lower P-gp efflux improves bioavailability.
15. **Binding Affinity:** Ligand A (-8.4) has a stronger binding affinity than Ligand B (-6.2). This is a substantial difference (2.2 kcal/mol) and a major factor in favor of Ligand A.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical parameters. The significant advantages in DILI risk, metabolic stability (Cl_mic), half-life, Pgp efflux, and, most importantly, binding affinity make Ligand A the far more promising candidate. While Ligand B has acceptable QED, its high TPSA, low logP, and poorer ADME properties are concerning. The binding affinity difference is large enough to outweigh any minor drawbacks Ligand A might have.
Output:
1
2025-04-17 21:48:36,642 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (377.941 and 380.901 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (26.79) is significantly better than Ligand B (67.35). For a GPCR, lower TPSA is generally preferred for better permeability, and Ligand A is well below the 140 threshold, while Ligand B is approaching a concerning level.
3. **logP:** Both ligands have similar logP values (3.52 and 3.421), falling within the optimal 1-3 range.
4. **HBD:** Ligand A (0) is preferable to Ligand B (1). Fewer hydrogen bond donors generally improve permeability.
5. **HBA:** Ligand A (4) is preferable to Ligand B (5). Lower HBA counts are generally favored for better permeability.
6. **QED:** Both ligands have good QED scores (0.815 and 0.863), indicating good drug-like properties.
7. **DILI:** Ligand A (35.285) has a significantly lower DILI risk than Ligand B (68.399). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (88.135) has a better BBB penetration percentile than Ligand B (73.827). While ADRB2 isn't exclusively a CNS target, some CNS exposure is not necessarily detrimental and a higher BBB score is generally favorable.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.912 and -4.765), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Both ligands have negative solubility values (-3.517 and -4.468), indicating poor aqueous solubility. This is a significant drawback for both.
11. **hERG:** Ligand A (0.857) has a slightly better hERG profile than Ligand B (0.377), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand B (82.669) has a higher microsomal clearance than Ligand A (50.885), suggesting faster metabolism and potentially lower *in vivo* exposure.
13. **t1/2:** Ligand B (8.674) has a significantly longer *in vitro* half-life than Ligand A (-0.144). This is a substantial advantage for Ligand B.
14. **Pgp:** Ligand A (0.617) has a lower P-gp efflux liability than Ligand B (0.547), suggesting better oral bioavailability and potentially better CNS exposure.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.4 and -6.5 kcal/mol). The difference is negligible.
**Overall Assessment:**
Ligand A is the stronger candidate. While both compounds suffer from poor predicted solubility and Caco-2 permeability, Ligand A has a significantly better safety profile (lower DILI), better BBB penetration, and improved metabolic stability (lower Cl_mic). The slightly better hERG profile and lower Pgp efflux also contribute to its favorability. The longer half-life of Ligand B is a positive, but the other factors outweigh this benefit. The lower TPSA and HBD/HBA counts of Ligand A also suggest better permeability potential despite the negative Caco-2 prediction.
Output:
1
2025-04-17 21:48:36,642 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (380.319 and 360.445 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (28.6) is significantly better than Ligand B (58.64). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (4.336) is slightly higher than Ligand B (2.387). While both are within the acceptable range (1-3 is optimal), Ligand A is pushing the upper limit. This could potentially lead to solubility issues.
4. **HBD:** Ligand A (0) is preferable to Ligand B (1). Fewer HBDs generally improve membrane permeability.
5. **HBA:** Ligand A (4) is preferable to Ligand B (3). Similar to HBD, fewer HBAs are generally better for permeability.
6. **QED:** Ligand A (0.789) is slightly better than Ligand B (0.687), indicating a more drug-like profile.
7. **DILI:** Ligand B (30.748) is *much* better than Ligand A (55.332). This is a significant advantage for Ligand B, as liver toxicity is a major concern.
8. **BBB:** Both ligands have high BBB penetration (Ligand A: 90.772, Ligand B: 87.088). While ADRB2 isn't a CNS target, higher BBB is not detrimental.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.653 and -4.567). These values are unusual and suggest poor permeability.
10. **Solubility:** Ligand B (-2.425) is better than Ligand A (-4.88). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.957) is better than Ligand B (0.656). Lower hERG inhibition is crucial for avoiding cardiotoxicity, especially important for a cardiovascular target.
12. **Cl_mic:** Ligand B (20.315) has significantly lower microsomal clearance than Ligand A (72.622), indicating better metabolic stability.
13. **t1/2:** Ligand B (6.965) has a longer in vitro half-life than Ligand A (-12.038). This is a substantial advantage, suggesting less frequent dosing.
14. **Pgp:** Ligand A (0.784) is better than Ligand B (0.294). Lower P-gp efflux is desirable for improved bioavailability.
15. **Binding Affinity:** Ligand B (-6.5) is slightly better than Ligand A (-6.3). While the difference is small, it's still a positive for Ligand B.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has a better logP and Pgp, but Ligand B has better TPSA. The affinity difference is minimal. However, the *significant* advantages of Ligand B in DILI risk and metabolic stability (Cl_mic and t1/2) outweigh the slight benefits of Ligand A. The poor Caco-2 values for both are concerning, but the other ADME properties of Ligand B are more favorable.
**Conclusion:**
Considering the balance of properties, particularly the lower DILI risk, improved metabolic stability, and better solubility of Ligand B, it is the more promising drug candidate.
Output:
0
2025-04-17 21:48:36,642 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (353.369 Da and 348.359 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (77.59) is significantly better than Ligand B (120.29). For a GPCR, lower TPSA is generally preferred for better permeability, and Ligand A is well below the 140 A^2 threshold. Ligand B is approaching the upper limit, potentially hindering absorption.
**3. logP:** Both ligands have good logP values (1.956 and 1.061), falling within the optimal 1-3 range. Ligand B is slightly lower, which *could* indicate slightly lower permeability, but it's not a major concern.
**4. H-Bond Donors:** Ligand A has 3 HBD, which is acceptable. Ligand B has only 1, also acceptable.
**5. H-Bond Acceptors:** Ligand A has 4 HBA, which is acceptable. Ligand B has 8, which is higher, but still within the guideline of <=10.
**6. QED:** Ligand A (0.742) has a better QED score than Ligand B (0.49), indicating a more drug-like profile.
**7. DILI:** Ligand A (45.095) has a slightly higher DILI risk than Ligand B (30.593), but both are below the concerning threshold of 60.
**8. BBB:** Both ligands have high BBB penetration (76.541 and 77.86), which isn't a primary concern for a cardiovascular target, but isn't detrimental.
**9. Caco-2 Permeability:** Ligand A (-4.989) has better Caco-2 permeability than Ligand B (-5.332).
**10. Aqueous Solubility:** Ligand A (-3.331) has better aqueous solubility than Ligand B (-2.261).
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (0.935 and 0.792).
**12. Microsomal Clearance:** Ligand A (-33.162) has significantly lower (better) microsomal clearance than Ligand B (-2.564), indicating greater metabolic stability.
**13. In vitro Half-Life:** Ligand A (31.167) has a much longer in vitro half-life than Ligand B (5.23). This is a significant advantage.
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (0.233 and 0.13).
**15. Binding Affinity:** Ligand B (-7.6) has a slightly better binding affinity than Ligand A (-6.9). This is a 0.7 kcal/mol difference, which is a good advantage.
**Overall Assessment:**
While Ligand B has a slightly better binding affinity, Ligand A is superior in almost all ADME properties. Specifically, its lower TPSA, better QED, significantly lower microsomal clearance, and longer half-life are crucial advantages for a viable drug candidate. The improved solubility and permeability also contribute to better potential bioavailability. The slightly higher DILI risk of Ligand A is not concerning given its other favorable properties. Given the GPCR target class, the balance of properties in Ligand A is more favorable.
Output:
1
2025-04-17 21:48:36,642 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (352.475) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are reasonably low (A: 87.66, B: 89.87), well below the 140 threshold for oral absorption.
3. **logP:** Both are within the optimal range (1-3), with A (1.506) being slightly higher than B (0.934). A slight preference for A here.
4. **HBD:** Both have 3 HBD, which is acceptable.
5. **HBA:** Ligand A has 4 HBA, Ligand B has 6. Ligand A is preferred.
6. **QED:** Both are above 0.5 (A: 0.648, B: 0.551), indicating good drug-likeness, but A is better.
7. **DILI:** Ligand A (16.44) has a significantly lower DILI risk than Ligand B (39.511). This is a major advantage for A.
8. **BBB:** Ligand B (57.736) has a higher BBB penetration than Ligand A (25.94). While ADRB2 isn't *strictly* a CNS target, some CNS exposure can be relevant for off-target effects, and a higher BBB value is generally preferred.
9. **Caco-2:** Ligand A (-4.901) has a better Caco-2 permeability than Ligand B (-5.552).
10. **Solubility:** Ligand A (-1.702) has better aqueous solubility than Ligand B (-2.539).
11. **hERG:** Both have low hERG inhibition risk (A: 0.151, B: 0.466), but A is better.
12. **Cl_mic:** Ligand A (10.518) has a significantly lower microsomal clearance than Ligand B (32.43), indicating better metabolic stability.
13. **t1/2:** Ligand A (11.617) has a longer in vitro half-life than Ligand B (2.133).
14. **Pgp:** Ligand A (0.024) has much lower P-gp efflux liability than Ligand B (0.075).
15. **Binding Affinity:** Ligand B (-7.2) has a stronger binding affinity than Ligand A (-5.9), a difference of 1.3 kcal/mol. This is a substantial advantage for B.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand B excels in affinity, while Ligand A performs better across logP, Pgp, and TPSA. However, the significant advantage in affinity for Ligand B is a strong point. The DILI, Cl_mic, and t1/2 are also important, and Ligand A is clearly superior in these aspects.
**Overall Assessment:**
While Ligand B has a better binding affinity, the significantly better ADME properties of Ligand A (lower DILI, better metabolic stability, longer half-life, lower P-gp efflux) outweigh the affinity difference. The lower risk profile associated with Ligand A makes it a more promising drug candidate.
Output:
1
2025-04-17 21:48:36,642 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (a GPCR) drug candidates.
**Ligand A:** [364.511, 78.43, 2.857, 3, 4, 0.621, 36.06, 50.834, -5.064, -3.106, 0.342, 41.118, 6.243, 0.259, -5.5]
**Ligand B:** [357.479, 62.3, 2.8, 1, 4, 0.829, 54.052, 73.943, -4.994, -2.759, 0.57, 74.522, 39.648, 0.392, -6]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, Affinity, and BBB):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (357.479) is slightly lower, which is generally favorable.
2. **TPSA:** Ligand A (78.43) is higher than Ligand B (62.3). Both are acceptable for a non-CNS GPCR like ADRB2, but Ligand B is better.
3. **logP:** Both are excellent (around 2.8-2.9), falling squarely within the optimal 1-3 range.
4. **HBD:** Ligand A (3) is higher than Ligand B (1). Lower is preferable, so Ligand B is better.
5. **HBA:** Both have 4 HBA, which is good.
6. **QED:** Ligand B (0.829) has a better QED score than Ligand A (0.621), indicating a more drug-like profile.
7. **DILI:** Ligand A (36.06) has a significantly lower DILI risk than Ligand B (54.052). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (73.943) has a better BBB penetration score than Ligand A (50.834). While ADRB2 isn't a primary CNS target, some peripheral distribution can be influenced by BBB properties.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand B (-4.994) is slightly better than Ligand A (-5.064).
10. **Solubility:** Both have negative solubility values, indicating poor aqueous solubility. Ligand B (-2.759) is slightly better than Ligand A (-3.106).
11. **hERG:** Both have low hERG inhibition risk (0.342 and 0.57 respectively).
12. **Cl_mic:** Ligand B (74.522) has a higher clearance than Ligand A (41.118), meaning Ligand A is more metabolically stable. This is a significant advantage.
13. **t1/2:** Ligand B (39.648) has a longer half-life than Ligand A (6.243). This is a positive for Ligand B.
14. **Pgp:** Ligand B (0.392) has a lower Pgp efflux liability than Ligand A (0.259), meaning it will likely have better oral bioavailability.
15. **Affinity:** Ligand B (-6.0 kcal/mol) has a slightly better binding affinity than Ligand A (-5.5 kcal/mol). This is a notable advantage.
**Overall Assessment:**
Ligand B has advantages in BBB penetration, half-life, Pgp efflux, and binding affinity. However, Ligand A has a significantly lower DILI risk and better metabolic stability (lower Cl_mic). The DILI risk is a major concern, and the difference between 36 and 54 is substantial. While the affinity difference is present, it's only 0.5 kcal/mol, which is often outweighed by ADME concerns. Considering the balance, the lower DILI risk and improved metabolic stability of Ligand A are more valuable for a cardiovascular target.
Output:
1
2025-04-17 21:48:36,643 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (a cardiovascular GPCR) drug candidates.
**Ligand A:** [343.427, 83.48, 1.636, 3, 5, 0.645, 24.544, 26.018, -5.158, -2.467, 0.298, 29.172, 8.484, 0.047, -6.1]
**Ligand B:** [387.364, 81.18, 3.811, 1, 7, 0.691, 96.433, 81.776, -4.719, -5.095, 0.525, 88.898, 59.788, 0.66, -7.2]
**Step-by-step comparison:**
1. **MW:** Ligand A (343.427 Da) is better, falling nicely within the 200-500 Da range. Ligand B (387.364 Da) is still acceptable, but closer to the upper limit.
2. **TPSA:** Both are good (83.48 and 81.18), well below the 140 threshold for oral absorption.
3. **logP:** Ligand A (1.636) is preferable. Ligand B (3.811) is getting a bit high, potentially leading to off-target effects or solubility issues.
4. **HBD:** Ligand A (3) is slightly better than Ligand B (1). Both are within the acceptable range.
5. **HBA:** Ligand A (5) is better than Ligand B (7).
6. **QED:** Both are similar (0.645 vs 0.691) and acceptable.
7. **DILI:** Ligand A (24.544) is *significantly* better than Ligand B (96.433). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (81.776) is better than Ligand A (26.018). However, for a cardiovascular target, BBB penetration isn't a primary concern.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-5.158) is slightly better than Ligand B (-4.719), but both are concerning.
10. **Solubility:** Ligand A (-2.467) is better than Ligand B (-5.095).
11. **hERG:** Ligand A (0.298) is significantly better than Ligand B (0.525). This is a critical advantage, as hERG inhibition can cause cardiotoxicity.
12. **Cl_mic:** Ligand A (29.172) is much better than Ligand B (88.898), indicating better metabolic stability.
13. **t1/2:** Ligand B (59.788) is much better than Ligand A (8.484).
14. **Pgp:** Ligand A (0.047) is much better than Ligand B (0.66).
15. **Affinity:** Ligand B (-7.2 kcal/mol) is 1.1 kcal/mol better than Ligand A (-6.1 kcal/mol). This is a substantial difference in binding affinity.
**GPCR-Specific Considerations:**
For ADRB2 (a cardiovascular GPCR), we prioritize logP, Pgp, TPSA, and affinity. While Ligand B has a better affinity and BBB, Ligand A has significantly better DILI, hERG, Cl_mic, and Pgp profiles. The higher logP of Ligand B is a concern, and the poor Caco-2 permeability of both is a drawback. The DILI and hERG risks associated with Ligand B are substantial enough to outweigh its affinity advantage. Metabolic stability (Cl_mic) is also important, and Ligand A is much better in this regard.
**Conclusion:**
Despite the better affinity of Ligand B, the superior ADME-Tox profile of Ligand A, particularly the significantly lower DILI and hERG risk, makes it the more promising drug candidate for ADRB2. The affinity difference, while notable, can potentially be addressed through further optimization. The safety profile is paramount.
Output:
1
2025-04-17 21:48:36,643 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (345.4 & 353.4 Da) fall comfortably within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (84.66) is significantly better than Ligand B (128.61). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand A is well below the 140 threshold, while B is approaching it.
3. **logP:** Ligand A (2.287) is within the optimal 1-3 range. Ligand B (-0.749) is below 1, which could indicate poor membrane permeability. This is a significant drawback for a GPCR ligand.
4. **HBD:** Both ligands have acceptable HBD counts (1 and 2 respectively), below the threshold of 5.
5. **HBA:** Both ligands have acceptable HBA counts (5 and 6 respectively), below the threshold of 10.
6. **QED:** Ligand A (0.754) has a much better QED score than Ligand B (0.444), indicating a more drug-like profile.
7. **DILI:** Ligand B (55.49) has a lower DILI risk than Ligand A (76.43), which is preferable.
8. **BBB:** Ligand A (40.68) has a slightly better BBB penetration score than Ligand B (30.75), though both are relatively low. This isn't a major concern for ADRB2, which isn't a CNS target, but some peripheral distribution is still needed.
9. **Caco-2:** Ligand A (-4.942) is better than Ligand B (-5.533), suggesting better intestinal absorption.
10. **Solubility:** Ligand A (-2.407) is better than Ligand B (-0.578), indicating better aqueous solubility.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.032 and 0.008), which is excellent.
12. **Cl_mic:** Ligand B (12.43) has significantly lower microsomal clearance than Ligand A (29.29), indicating better metabolic stability. This is a positive for B.
13. **t1/2:** Ligand A (-21.963) has a longer in vitro half-life than Ligand B (-10.534), which is preferable.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.059 and 0.008), which is good.
15. **Binding Affinity:** Ligand B (-8.9 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.2 kcal/mol). This is a substantial advantage, potentially outweighing some ADME concerns.
**Overall Assessment:**
Ligand B has a significantly better binding affinity, and improved metabolic stability (lower Cl_mic). However, it suffers from a low logP and lower QED. Ligand A has better TPSA, logP, QED, solubility, and half-life. Given the GPCR target class, the balance of properties in Ligand A is more favorable. The slightly weaker binding affinity of Ligand A is a concern, but the better ADME profile is likely to translate to better *in vivo* performance. The low logP of Ligand B is a major red flag for permeability.
**Output:**
1
2025-04-17 21:48:36,643 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for the ADRB2, a cardiovascular GPCR. Therefore, the most important parameters are binding affinity, logP, TPSA, Pgp efflux, and to a lesser extent, BBB.
Let's compare the ligands property by property:
1. **MW:** Both ligands (344.39 and 350.419 Da) are within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (74.33) is significantly better than Ligand B (94.05). A lower TPSA is preferred for GPCRs to facilitate membrane permeability.
3. **logP:** Ligand A (2.699) is optimal, while Ligand B (0.459) is quite low, potentially hindering membrane permeability and bioavailability.
4. **HBD/HBA:** Ligand A (2 HBD, 3 HBA) and Ligand B (1 HBD, 5 HBA) are both acceptable.
5. **QED:** Both ligands have similar, good QED scores (0.846 and 0.804).
6. **DILI:** Ligand A (58.744) has a higher DILI risk than Ligand B (24.583), but both are within acceptable ranges.
7. **BBB:** Ligand A (75.029) has a better BBB score than Ligand B (34.083), though BBB is less critical for a cardiovascular target.
8. **Caco-2:** Ligand A (-4.76) is better than Ligand B (-5.009).
9. **Solubility:** Ligand A (-3.135) is better than Ligand B (-0.499).
10. **hERG:** Both ligands have very low hERG inhibition risk (0.648 and 0.024).
11. **Cl_mic:** Ligand A (51.747) has a higher microsomal clearance than Ligand B (30.229), indicating lower metabolic stability.
12. **t1/2:** Ligand B (-6.575) has a negative in vitro half-life, which is concerning. Ligand A (44.359) is much better.
13. **Pgp:** Ligand A (0.063) has a lower Pgp efflux liability than Ligand B (0.005), which is favorable.
14. **Binding Affinity:** Both ligands have the same binding affinity (-4.1 kcal/mol).
**Conclusion:**
Despite Ligand B having a lower DILI risk and slightly better Pgp profile, Ligand A is clearly superior. Its significantly better logP and TPSA values, coupled with a much more reasonable in vitro half-life, make it a more promising drug candidate for the ADRB2. The slightly higher DILI risk is outweighed by the improved ADME properties crucial for GPCR targeting.
**Output:**
1
2025-04-17 21:48:36,643 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.519 Da and 348.487 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (69.64) is slightly higher than Ligand B (58.64). Both are below the 140 threshold for good oral absorption, and acceptable for a cardiovascular GPCR. Ligand B is preferable here.
3. **logP:** Both ligands (2.719 and 2.82) are within the optimal 1-3 range. No significant difference.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1). Both are within the acceptable limit of <=5.
5. **HBA:** Both ligands (3) are within the acceptable limit of <=10. No significant difference.
6. **QED:** Ligand A (0.706) has a better QED score than Ligand B (0.593), indicating a more drug-like profile. This is a positive for Ligand A.
7. **DILI:** Ligand B (26.755) has a significantly lower DILI risk than Ligand A (6.747). This is a major advantage for Ligand B.
8. **BBB:** Both ligands have good BBB penetration (Ligand A: 70.492, Ligand B: 71.772). No significant difference.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.671 and -4.688), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand B (-3.037) has slightly better solubility than Ligand A (-2.295).
11. **hERG:** Both ligands have low hERG inhibition risk (0.408 and 0.385). No significant difference.
12. **Cl_mic:** Both ligands have similar microsomal clearance (39.764 and 40.629). No significant difference.
13. **t1/2:** Ligand A (10.627) has a longer in vitro half-life than Ligand B (-0.387). This is a positive for Ligand A.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.044 and 0.084). No significant difference.
15. **Binding Affinity:** Ligand A (-6.4 kcal/mol) has a slightly better binding affinity than Ligand B (-4.4 kcal/mol). This is a significant advantage for Ligand A. The difference of 2 kcal/mol is substantial enough to potentially overcome some ADME drawbacks.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are important. Both ligands perform well on logP and Pgp. Ligand B has a slightly better TPSA. However, Ligand A has a significantly better binding affinity (-6.4 vs -4.4 kcal/mol) and a longer half-life. The lower DILI risk of Ligand B is attractive, but the stronger binding of Ligand A is a critical factor for a GPCR target.
**Conclusion:**
Despite the lower DILI risk of Ligand B, the superior binding affinity and half-life of Ligand A outweigh the slightly higher DILI risk. The affinity difference is substantial, and a strong starting point is crucial for GPCR drug development.
Output:
1
2025-04-17 21:48:36,643 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (419.245 Da) is slightly higher than Ligand B (346.362 Da), but both are acceptable.
**2. TPSA:** Ligand A (58.95) is significantly better than Ligand B (93.21). For a GPCR, lower TPSA is generally preferred for better permeability. Ligand B is approaching a level that could hinder oral absorption.
**3. logP:** Both ligands have good logP values (A: 3.637, B: 2.413) within the optimal range of 1-3.
**4. H-Bond Donors:** Both have 2 HBD, which is within the acceptable limit of <=5.
**5. H-Bond Acceptors:** Ligand A has 4 HBA, and Ligand B has 5. Both are within the acceptable limit of <=10.
**6. QED:** Both ligands have similar QED values (A: 0.779, B: 0.784), indicating good drug-likeness.
**7. DILI Risk:** Ligand A (62.195) has a lower DILI risk than Ligand B (85.576), which is a significant advantage.
**8. BBB Penetration:** Ligand A (78.092) has better BBB penetration than Ligand B (69.097). While ADRB2 isn't strictly a CNS target, some CNS exposure can be relevant, and higher BBB is generally favorable.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.967 and -4.713), which is unusual and suggests poor permeability. This is a concern for both.
**10. Aqueous Solubility:** Both ligands have negative solubility values (-4.034 and -3.265), indicating very poor aqueous solubility. This is a major drawback for both, potentially hindering formulation and bioavailability.
**11. hERG Inhibition:** Ligand A (0.661) has a slightly higher hERG risk than Ligand B (0.191), which is a concern.
**12. Microsomal Clearance:** Ligand A (40.653) has lower microsomal clearance than Ligand B (55.117), indicating better metabolic stability.
**13. In vitro Half-Life:** Ligand A (34.954) has a longer in vitro half-life than Ligand B (20.807), which is desirable.
**14. P-gp Efflux:** Ligand A (0.354) has lower P-gp efflux than Ligand B (0.027), which is a significant advantage for bioavailability.
**15. Binding Affinity:** Ligand B (-8.3 kcal/mol) has a significantly stronger binding affinity than Ligand A (-7.3 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME drawbacks.
**Overall Assessment:**
Ligand B has a significantly better binding affinity, which is a crucial factor for GPCR targets. However, it suffers from higher DILI risk, poorer BBB penetration, and lower metabolic stability. Ligand A has better ADME properties overall (lower DILI, better BBB, better metabolic stability, lower P-gp efflux), but its binding affinity is weaker.
Considering the balance, the stronger binding affinity of Ligand B is a significant advantage for a GPCR target like ADRB2. While the ADME properties are less ideal, optimization efforts could potentially address these issues. The affinity difference is large enough to warrant prioritizing Ligand B as a starting point for further development.
Output:
0
2025-04-17 21:48:36,644 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.394 and 376.787 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (84.42) is slightly higher than Ligand B (78.87), but both are well below the 140 A^2 threshold for good oral absorption, and acceptable for a peripheral GPCR like ADRB2. Ligand B is slightly preferred.
3. **logP:** Both ligands have good logP values (1.535 and 1.261, respectively), falling within the optimal 1-3 range. Ligand B is slightly lower, which could potentially improve solubility, but the difference is minor.
4. **HBD:** Ligand A has 1 HBD, while Ligand B has 2. Both are within the acceptable limit of 5. No significant difference.
5. **HBA:** Ligand A has 6 HBA, and Ligand B has 5. Both are within the acceptable limit of 10. No significant difference.
6. **QED:** Ligand A (0.716) has a slightly higher QED score than Ligand B (0.611), indicating a more drug-like profile. This is a slight advantage for Ligand A.
7. **DILI:** Ligand B (36.293) has a significantly lower DILI risk than Ligand A (57.387). This is a substantial advantage for Ligand B, as minimizing liver toxicity is crucial.
8. **BBB:** Ligand A (92.943) has a much higher BBB penetration percentile than Ligand B (61.342). However, since ADRB2 is primarily a cardiovascular target, high BBB penetration is *not* a priority. This favors Ligand A, but is less important than other factors.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.41 and -4.717), which is unusual and suggests very poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand B (-2.174) has slightly better solubility than Ligand A (-3.303). While both are poor, the difference is a slight advantage for Ligand B.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.44 and 0.481). No significant difference.
12. **Cl_mic:** Ligand B (5.678) has a significantly lower microsomal clearance than Ligand A (94.46). This indicates better metabolic stability for Ligand B, which is highly desirable.
13. **t1/2:** Ligand B (17.19 hours) has a much longer in vitro half-life than Ligand A (-2.959 hours). This is a major advantage for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.096 and 0.173). No significant difference.
15. **Binding Affinity:** Ligand A (-6.5 kcal/mol) has slightly better binding affinity than Ligand B (-6.3 kcal/mol), but the difference is small (0.2 kcal/mol). This is unlikely to outweigh the significant ADME advantages of Ligand B.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity) and the general drug-like properties, Ligand B is the more promising candidate. While Ligand A has slightly better affinity and BBB penetration (which isn't crucial for this target), Ligand B excels in crucial ADME properties: significantly lower DILI risk, much better metabolic stability (lower Cl_mic), and a longer half-life. The slightly better solubility of Ligand B is also a plus. The poor Caco-2 values are a concern for both, but the other advantages of Ligand B outweigh this drawback.
Output:
0
2025-04-17 21:48:36,644 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.395 Da and 356.491 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (131.52) is better than Ligand B (51.22). ADRB2 is not a CNS target, but lower TPSA generally aids absorption.
3. **logP:** Ligand A (-1.461) is suboptimal, being slightly below the preferred 1-3 range. Ligand B (4.031) is high, potentially causing solubility issues and off-target effects. This is a significant drawback for Ligand B.
4. **HBD:** Ligand A (3) is acceptable, while Ligand B (1) is also good.
5. **HBA:** Ligand A (6) is acceptable, while Ligand B (4) is also good.
6. **QED:** Both ligands have good QED scores (0.514 and 0.69), indicating drug-likeness.
7. **DILI:** Both ligands have similar DILI risk (55.176 and 58.123), and are within an acceptable range (<60).
8. **BBB:** This is less critical for ADRB2 (a cardiovascular target). Ligand B (52.268) has a higher BBB penetration than Ligand A (20.396), but it is not a deciding factor.
9. **Caco-2:** Ligand A (-5.653) and Ligand B (-4.803) both have negative Caco-2 values, which is unusual and suggests poor permeability.
10. **Solubility:** Ligand A (-1.088) is better than Ligand B (-4.878). The high logP of Ligand B likely contributes to its poor solubility.
11. **hERG:** Ligand A (0.096) has a very low hERG risk, which is excellent. Ligand B (0.565) is slightly higher, but still relatively low.
12. **Cl_mic:** Ligand A (-3.732) has a significantly *lower* (better) microsomal clearance than Ligand B (75.266), suggesting better metabolic stability.
13. **t1/2:** Ligand A (1.317) has a shorter half-life than Ligand B (18.349). Longer half-life is generally preferred.
14. **Pgp:** Ligand A (0.024) has a much lower Pgp efflux liability than Ligand B (0.487), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand A (-6.7) and Ligand B (-6.4) have comparable binding affinities. The difference is not substantial enough to override other factors.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A has a better TPSA and Pgp profile, while Ligand B has a higher logP. The affinity difference is small. Ligand A also has a much better metabolic stability profile (Cl_mic).
**Conclusion:**
Despite the shorter half-life of Ligand A, its superior solubility, lower logP, better metabolic stability (lower Cl_mic), and lower Pgp efflux make it the more promising candidate. The high logP and poor solubility of Ligand B are significant drawbacks that outweigh its slightly longer half-life and higher BBB penetration (which isn't critical for this target).
Output:
1
2025-04-17 21:48:36,644 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (351.447 Da and 350.547 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (89.95) is better than Ligand B (58.2). For a cardiovascular GPCR, a lower TPSA is generally favorable for permeability, but both are quite good.
**3. logP:** Ligand A (-0.016) is suboptimal, being close to 0, which could hinder membrane permeability. Ligand B (4.064) is high, potentially leading to solubility issues and off-target interactions. This is a significant drawback for Ligand B.
**4. H-Bond Donors:** Both ligands have 2 HBD, which is within the acceptable limit of <=5.
**5. H-Bond Acceptors:** Ligand A has 4 HBA, while Ligand B has 2. Both are within the acceptable limit of <=10.
**6. QED:** Ligand A (0.682) has a considerably better QED score than Ligand B (0.461), indicating a more drug-like profile.
**7. DILI:** Ligand A (22.024) has a much lower DILI risk than Ligand B (13.959), which is a crucial advantage.
**8. BBB:** Ligand B (73.517) shows significantly better BBB penetration than Ligand A (29.275). While ADRB2 is primarily a cardiovascular target, some CNS effects are possible with beta-blockers, and a degree of BBB penetration could be useful.
**9. Caco-2 Permeability:** Both ligands have similar, poor Caco-2 permeability (-4.698 and -4.634). This suggests potential absorption issues for both.
**10. Aqueous Solubility:** Ligand A (-0.959) has better aqueous solubility than Ligand B (-4.351). This is important for formulation and bioavailability.
**11. hERG Inhibition:** Ligand A (0.121) has a lower hERG inhibition liability than Ligand B (0.64), which is a significant safety advantage.
**12. Microsomal Clearance:** Ligand A (10.175) has a lower microsomal clearance than Ligand B (78.286), suggesting better metabolic stability.
**13. In vitro Half-Life:** Ligand A (-29.722) has a much longer in vitro half-life than Ligand B (9.121).
**14. P-gp Efflux:** Ligand A (0.009) shows very low P-gp efflux, while Ligand B (0.312) shows moderate P-gp efflux. Lower efflux is preferred.
**15. Binding Affinity:** Ligand A (-7.1) has a slightly better binding affinity than Ligand B (-6.6). While the difference is not huge, it's still a positive for Ligand A.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical ADME-Tox parameters. While Ligand B has better BBB penetration, the significantly higher logP, DILI risk, hERG inhibition, and clearance, coupled with the lower QED and solubility, make it a less desirable candidate. Ligand A's superior metabolic stability, lower toxicity risks, and better drug-like properties outweigh the slight advantage of Ligand B's BBB penetration for a cardiovascular target.
Output:
1
2025-04-17 21:48:36,644 - INFO - Batch 285 complete. Total preferences: 4560
2025-04-17 21:48:36,644 - INFO - Processing batch 286/512...
2025-04-17 21:49:21,652 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (385.917) is slightly higher than Ligand B (351.451), but both are acceptable.
2. **TPSA:** Ligand A (73.74) is better than Ligand B (109.61). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (A: 2.411, B: 2.076), falling within the optimal 1-3 range.
4. **HBD:** Both ligands have 1 HBD, which is acceptable.
5. **HBA:** Ligand A has 5 HBA, and Ligand B has 4 HBA. Both are within the acceptable limit of 10.
6. **QED:** Ligand A (0.867) has a significantly better QED score than Ligand B (0.43). This suggests Ligand A has a more drug-like profile overall.
7. **DILI:** Ligand A (50.795) has a better DILI percentile than Ligand B (20.589). Lower is better, and both are relatively low risk.
8. **BBB:** Ligand A (49.864) has a slightly better BBB percentile than Ligand B (22.257). While not a primary concern for a cardiovascular target, some peripheral ADRB2 receptors exist, and a little BBB penetration isn't necessarily detrimental.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.713 and -4.858). This is unusual and suggests poor permeability. However, the values are very similar.
10. **Solubility:** Ligand A (-3.243) has better solubility than Ligand B (-1.184). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.384) has a slightly better hERG profile than Ligand B (0.178). Lower is better.
12. **Cl_mic:** Both ligands have similar microsomal clearance (A: 18.256, B: 18.578).
13. **t1/2:** Ligand A (8.607) has a better in vitro half-life than Ligand B (15.725).
14. **Pgp:** Ligand A (0.371) has a better Pgp efflux profile than Ligand B (0.039). Lower is better.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.8 kcal/mol and -6.7 kcal/mol). The difference is negligible.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Both ligands perform similarly on logP and affinity. Ligand A is better on TPSA and Pgp. The significantly better QED score of Ligand A also makes it more attractive.
**Conclusion:**
Ligand A consistently outperforms Ligand B across several key ADME properties (QED, solubility, DILI, Pgp, TPSA, t1/2) while maintaining comparable binding affinity. The negative Caco-2 values are concerning for both, but the overall profile of Ligand A is more favorable.
Output:
1
2025-04-17 21:49:21,652 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (423.233 Da) is within the ideal range, while Ligand B (347.39 Da) is at the lower end but still acceptable.
2. **TPSA:** Both Ligand A (82.26) and Ligand B (80.32) are well below the 140 threshold for oral absorption, and suitable for a GPCR.
3. **logP:** Ligand A (3.161) is optimal, while Ligand B (0.814) is a bit low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (4) and Ligand B (2) are both acceptable.
5. **HBA:** Ligand A (2) and Ligand B (4) are both acceptable.
6. **QED:** Both Ligand A (0.564) and Ligand B (0.682) are good, indicating drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (65.374) is moderately risky, while Ligand B (54.478) is better (lower risk).
8. **BBB:** Both Ligand A (74.952) and Ligand B (79.411) have good BBB penetration, which is relevant for GPCRs.
9. **Caco-2:** Both Ligand A (-5.047) and Ligand B (-4.338) have negative values, which is unusual. Lower (more negative) values suggest poor permeability.
10. **Solubility:** Both Ligand A (-4.126) and Ligand B (-2.337) have negative solubility values, which is also unusual. Lower values suggest poor solubility.
11. **hERG:** Both Ligand A (0.347) and Ligand B (0.206) have low hERG inhibition risk, which is good. Ligand B is slightly better.
12. **Cl_mic:** Ligand A (18.726) has a lower clearance than Ligand B (30.678), indicating better metabolic stability.
13. **t1/2:** Ligand A (13.037) has a longer half-life than Ligand B (-12.234). The negative value for Ligand B is concerning.
14. **Pgp:** Both Ligand A (0.086) and Ligand B (0.037) have low P-gp efflux, which is good. Ligand B is slightly better.
15. **Affinity:** Ligand A (-7.7 kcal/mol) has a significantly stronger binding affinity than Ligand B (-5.8 kcal/mol). This is a substantial advantage.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand A has a better logP, and a much better binding affinity. While Ligand B has slightly better DILI and Pgp efflux, the substantial difference in binding affinity outweighs these minor advantages. The negative half-life for Ligand B is a major red flag.
**Conclusion:**
Ligand A is the more promising candidate due to its superior binding affinity, better metabolic stability (lower Cl_mic, longer t1/2), and acceptable ADME properties. The slightly higher DILI risk is manageable given the strong potency.
Output:
1
2025-04-17 21:49:21,652 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (344.459 Da) is better than Ligand B (373.475 Da), falling comfortably within the 200-500 Da range.
2. **TPSA:** Ligand A (76.02) is significantly better than Ligand B (104.81). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (1.813) is within the optimal range (1-3). Ligand B (-0.257) is below 1, which is less desirable for permeability.
4. **HBD:** Both ligands have 2 HBD, which is acceptable.
5. **HBA:** Ligand A (4) is better than Ligand B (6). Lower HBA is generally preferred for permeability.
6. **QED:** Ligand A (0.706) is better than Ligand B (0.596), indicating a more drug-like profile.
7. **DILI:** Ligand A (21.908) is *much* better than Ligand B (43.544). This is a significant advantage for Ligand A.
8. **BBB:** Not a primary concern for a cardiovascular target, but Ligand A (53.276) is better than Ligand B (41.528).
9. **Caco-2:** Ligand A (-4.791) and Ligand B (-5.84) are both negative, indicating poor permeability. However, Ligand A is slightly better.
10. **Solubility:** Ligand A (-3.176) is better than Ligand B (-1.335).
11. **hERG:** Both ligands have very low hERG risk (0.057 and 0.077 respectively).
12. **Cl_mic:** Ligand B (-13.115) has a lower (better) microsomal clearance than Ligand A (30.013), indicating better metabolic stability.
13. **t1/2:** Ligand B (-8.388) has a longer half-life than Ligand A (-16.095).
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.024 and 0.009 respectively).
15. **Binding Affinity:** Ligand B (-7.3) has a slightly better binding affinity than Ligand A (-6.4). The difference is 0.9 kcal/mol, which isn't a huge advantage.
**Overall Assessment:**
While Ligand B has a slightly better binding affinity and metabolic stability (lower Cl_mic and longer t1/2), Ligand A is superior in almost all other key ADME properties. The significantly lower DILI risk for Ligand A is a major advantage. The better logP, TPSA, QED, and solubility of Ligand A also contribute to a more favorable overall profile. The small difference in binding affinity is unlikely to overcome the substantial ADME benefits of Ligand A. Considering ADRB2 is a cardiovascular target, the emphasis is less on BBB and more on balanced ADME properties, which Ligand A provides.
Output:
1
2025-04-17 21:49:21,652 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (372.487 Da) is slightly higher than Ligand B (351.491 Da), but both are acceptable.
2. **TPSA:** Ligand A (87.15) is slightly higher than Ligand B (75.87). Both are below the 140 threshold for oral absorption, and acceptable for a peripheral GPCR like ADRB2.
3. **logP:** Ligand B (1.934) is within the optimal range (1-3), while Ligand A (-0.397) is slightly below 1. This is a significant difference. For a GPCR, a slightly higher logP is generally preferred for membrane permeability, and Ligand B has a clear advantage here.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 5 HBA, while Ligand B has 3. Both are within the acceptable range.
6. **QED:** Both ligands have good QED scores (A: 0.71, B: 0.761), indicating good drug-like properties.
7. **DILI:** Ligand B (11.4) has a significantly lower DILI risk than Ligand A (19.193). This is a major advantage for Ligand B.
8. **BBB:** Ligand B (93.37) has a much higher BBB penetration score than Ligand A (36.371). While ADRB2 isn't a primary CNS target, some degree of BBB penetration can sometimes influence off-target effects and overall safety.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, these values are on a scale where negative values are possible, and the absolute magnitude is important. Ligand A (-4.651) is slightly worse than Ligand B (-4.459).
10. **Solubility:** Ligand A (-0.62) has slightly better solubility than Ligand B (-2.286). Solubility isn't a major concern here, given the other parameters.
11. **hERG:** Both have low hERG inhibition risk (A: 0.09, B: 0.666), which is excellent.
12. **Cl_mic:** Ligand A (12.177) has a lower microsomal clearance than Ligand B (63.402), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (19.782) has a longer in vitro half-life than Ligand B (-11.076). This is a substantial advantage for Ligand A.
14. **Pgp:** Ligand A (0.014) has much lower P-gp efflux liability than Ligand B (0.118), which is favorable for bioavailability.
15. **Binding Affinity:** Both ligands have excellent binding affinity (A: -5.3 kcal/mol, B: -6.1 kcal/mol), with Ligand B being slightly stronger. The 0.8 kcal/mol difference is significant but not overwhelming.
**Overall Assessment:**
Ligand B has advantages in logP, DILI, BBB, and binding affinity. However, Ligand A excels in metabolic stability (Cl_mic and t1/2) and P-gp efflux. Considering this is a cardiovascular target (ADRB2), metabolic stability and minimizing efflux are crucial for achieving adequate systemic exposure and duration of action. The slightly better logP of Ligand B is beneficial, but the substantial differences in Cl_mic, t1/2, and Pgp, coupled with the significantly lower DILI risk for Ligand B, make it the more promising candidate. The affinity difference is not large enough to overcome the ADME advantages of Ligand B.
Output:
0
2025-04-17 21:49:21,652 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.315 and 346.471 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (133.51) is slightly higher than Ligand B (62.55). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B is significantly better.
3. **logP:** Ligand A (0.703) is suboptimal, being slightly below the preferred 1-3 range. Ligand B (3.748) is excellent, falling right within the sweet spot. This is a major advantage for Ligand B, aiding membrane permeability.
4. **HBD:** Both have 1 HBD, which is acceptable.
5. **HBA:** Ligand A has 9 HBA, which is acceptable, while Ligand B has 3, which is excellent.
6. **QED:** Both ligands have good QED scores (0.775 and 0.883), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (87.476) has a higher DILI risk than Ligand B (40.364). This is a significant concern for Ligand A.
8. **BBB:** Ligand A (48.972) has lower BBB penetration than Ligand B (64.637). While ADRB2 isn't a primary CNS target, some degree of BBB penetration can be useful for off-target effects assessment and potential peripheral activity.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it is difficult to interpret.
10. **Solubility:** Both have negative solubility values, which is also unusual. Again, the scale is not specified, so it is difficult to interpret.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.091 and 0.391). This is excellent for both.
12. **Cl_mic:** Ligand A (92.166) has a higher microsomal clearance than Ligand B (32.598), indicating lower metabolic stability. This is a disadvantage for Ligand A.
13. **t1/2:** Ligand B (29.24) has a significantly longer in vitro half-life than Ligand A (-13.115). This is a major advantage for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.017 and 0.359). This is excellent for both.
15. **Binding Affinity:** Both ligands have similar binding affinities (-5.2 and -5.3 kcal/mol). The difference is negligible.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, and metabolic stability are key. Ligand B excels in logP and TPSA, and has better metabolic stability (lower Cl_mic, longer t1/2). While BBB isn't paramount for a cardiovascular target, Ligand B also has a slightly better score. The significantly lower DILI risk for Ligand B is also a major factor.
**Conclusion:**
Ligand B demonstrates a superior balance of properties, particularly in terms of logP, metabolic stability, DILI risk, and TPSA. While both ligands have similar binding affinities, the ADME properties of Ligand B make it a much more promising drug candidate.
Output:
0
2025-04-17 21:49:21,652 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (368.455 Da and 362.499 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (85.89) is higher than Ligand B (66.4). Both are below 140, suitable for oral absorption, but Ligand B is better positioned for potential CNS penetration, though this isn't a primary goal for ADRB2.
3. **logP:** Both ligands have excellent logP values (2.491 and 2.351), falling within the optimal 1-3 range.
4. **HBD:** Ligand A has 2 HBD, while Ligand B has 0. Both are acceptable, but fewer HBDs generally improve permeability, giving a slight edge to Ligand B.
5. **HBA:** Ligand A has 6 HBA, and Ligand B has 5. Both are within the acceptable range of <=10.
6. **QED:** Both ligands have good QED scores (0.517 and 0.575), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A has a DILI risk of 65.103, which is concerning (approaching the high-risk threshold). Ligand B has a much lower DILI risk of 31.02, a significant advantage.
8. **BBB:** Ligand A (65.452) and Ligand B (74.176). While ADRB2 isn't a primary CNS target, higher BBB penetration is generally favorable and suggests better overall permeability. Ligand B is better.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.811 and -4.821), which is unusual and indicates very poor permeability. This is a major concern for both.
10. **Solubility:** Ligand A (-3.095) and Ligand B (-1.946) both have poor aqueous solubility. Ligand B is slightly better.
11. **hERG:** Both ligands have low hERG inhibition liability (0.662 and 0.415), which is good. Ligand B is better.
12. **Cl_mic:** Ligand A (51.936) has a moderate clearance, while Ligand B (33.808) has a lower clearance, suggesting better metabolic stability. This favors Ligand B.
13. **t1/2:** Ligand A (5.325) has a shorter half-life than Ligand B (-9.24). A negative half-life is not possible, so this value is suspect. However, assuming it is a percentile score, Ligand B has a significantly longer in vitro half-life, which is a major advantage.
14. **Pgp:** Ligand A (0.158) has lower P-gp efflux liability than Ligand B (0.474), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand B (-7.1 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.2 kcal/mol). This 1.9 kcal/mol difference is substantial and can outweigh many other drawbacks.
**Overall Assessment:**
Despite the poor Caco-2 permeability for both, Ligand B is the stronger candidate. Its significantly improved binding affinity (-7.1 vs -5.2 kcal/mol) is a major advantage. Furthermore, it exhibits a much lower DILI risk, better metabolic stability (lower Cl_mic), longer half-life, and slightly better solubility and BBB penetration. The lower Pgp efflux for Ligand A is a minor advantage, but doesn't outweigh the other benefits of Ligand B. The Caco-2 permeability issue would need to be addressed through formulation or further structural modifications, but the core properties of Ligand B are more promising.
Output:
0
2025-04-17 21:49:21,653 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (355.364 and 359.451 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (62.53) is significantly better than Ligand B (91.32). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold. Ligand B is approaching it, which is less ideal.
3. **logP:** Both ligands have good logP values (2.271 and 2.11), falling within the optimal 1-3 range. Similar here.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Both ligands have 5 HBA, which is acceptable.
6. **QED:** Ligand A (0.918) has a substantially better QED score than Ligand B (0.66), indicating a more drug-like profile.
7. **DILI:** Ligand A (49.05) has a lower DILI risk than Ligand B (55.797), which is preferable. Both are below the 60 threshold, but A is better.
8. **BBB:** Ligand A (97.208) has much higher BBB penetration than Ligand B (33.501). While not a primary concern for a cardiovascular target, higher BBB is rarely detrimental and can provide some off-target safety information.
9. **Caco-2:** Ligand A (-4.707) has a better Caco-2 permeability score than Ligand B (-5.495). A more negative value suggests lower permeability, but the difference is small.
10. **Solubility:** Ligand A (-2.168) has better solubility than Ligand B (-3.16). Better solubility is generally preferred.
11. **hERG:** Ligand A (0.853) has a much lower hERG risk than Ligand B (0.247). This is a crucial factor, as hERG inhibition can lead to cardiotoxicity, which is particularly relevant for a cardiovascular target.
12. **Cl_mic:** Ligand A (-1.563) has a much lower (better) microsomal clearance than Ligand B (39.862). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (3.339) has a better in vitro half-life than Ligand B (-14.991).
14. **Pgp:** Ligand A (0.293) has lower P-gp efflux liability than Ligand B (0.067). Lower P-gp efflux is generally desirable.
15. **Binding Affinity:** Ligand B (-8.2) has a slightly better binding affinity than Ligand A (-7.1). This is a 1.1 kcal/mol difference, which is significant, but needs to be weighed against the other ADME properties.
**Overall Assessment:**
Ligand B has a slightly better binding affinity, but Ligand A overwhelmingly outperforms it in almost all ADME and toxicity parameters. Specifically, Ligand A has a significantly better QED score, lower DILI risk, much better hERG profile, significantly lower microsomal clearance, longer half-life, and better solubility. These factors are critical for developing a safe and effective drug, especially for a cardiovascular target where cardiotoxicity is a major concern. The slight difference in binding affinity is likely surmountable with further optimization of Ligand A.
Output:
1
2025-04-17 21:49:21,653 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (350.46 & 374.46 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Both are below the 140 A^2 threshold for good absorption (78.87 & 76.14 A^2). Again, no clear advantage.
3. **logP:** Ligand A (0.926) is slightly lower than optimal (1-3), but still acceptable. Ligand B (3.011) is well within the optimal range. This favors Ligand B slightly.
4. **HBD:** Both have 2 HBD, which is good.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 6 HBA. Both are acceptable, but Ligand A is slightly better.
6. **QED:** Ligand A (0.716) has a better QED score than Ligand B (0.65), indicating a more drug-like profile. This favors Ligand A.
7. **DILI:** Ligand A (10.9%) has a significantly lower DILI risk than Ligand B (59.4%). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (85.7%) shows much better BBB penetration than Ligand A (55.1%). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be beneficial or at least avoid unexpected side effects. This favors Ligand B.
9. **Caco-2:** Both have negative Caco-2 values (-4.612 and -4.664), which is unusual and suggests poor permeability. This is a concern for both, but doesn't differentiate them.
10. **Solubility:** Ligand A (-1.393) has better solubility than Ligand B (-3.984). This favors Ligand A.
11. **hERG:** Both have very low hERG inhibition risk (0.28 and 0.279). No significant difference.
12. **Cl_mic:** Ligand A (13.7 mL/min/kg) has a lower microsomal clearance than Ligand B (62.2 mL/min/kg), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (45.3 hours) has a longer in vitro half-life than Ligand B (-7.2 hours). This is a substantial advantage for Ligand A.
14. **Pgp:** Both have very low Pgp efflux liability (0.036 and 0.168). No significant difference.
15. **Binding Affinity:** Ligand A (-5.8 kcal/mol) has slightly weaker binding affinity than Ligand B (-5.3 kcal/mol). While a difference of 0.5 kcal/mol isn't huge, it's noticeable. This favors Ligand B.
**GPCR-Specific Priorities & Overall Assessment:**
For a GPCR like ADRB2, logP, TPSA, and affinity are key. Ligand B has a better logP and slightly better affinity. However, the significantly lower DILI risk, better solubility, improved metabolic stability (lower Cl_mic), and longer half-life of Ligand A are more critical for overall drug development success. The Caco-2 values are concerning for both, but can be addressed with formulation strategies. The BBB penetration of Ligand B is good, but not essential for ADRB2. The superior ADME properties of Ligand A outweigh the slight affinity difference.
Output:
1
2025-04-17 21:49:21,653 - INFO - Here's my reasoning and output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands (350.419 and 363.527 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (108.56) is higher than Ligand B (62.3). For a GPCR, lower TPSA is generally preferred for better brain penetration and overall permeability. Ligand B is significantly better here.
3. **logP:** Ligand A (0.955) is slightly below the optimal 1-3 range, while Ligand B (3.251) is well within it. Ligand B is better.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable. No significant difference.
5. **HBA:** Ligand A (6) and Ligand B (4) are both acceptable. Ligand B is slightly better.
6. **QED:** Both ligands (0.837 and 0.809) have excellent drug-likeness scores. No clear advantage.
7. **DILI:** Ligand A (39.667) has a slightly lower DILI risk than Ligand B (47.421), but both are below the concerning threshold of 60.
8. **BBB:** Ligand B (84.064) has a much higher BBB penetration percentile than Ligand A (51.919). This is a significant advantage for a GPCR target, even if not specifically a CNS target, as it suggests better distribution.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.927 and -4.995), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand A (-1.542) has better solubility than Ligand B (-3.643).
11. **hERG:** Ligand A (0.033) has a much lower hERG inhibition liability than Ligand B (0.589). This is a crucial advantage, minimizing cardiotoxicity risk.
12. **Cl_mic:** Ligand A (3.341) has significantly lower microsomal clearance than Ligand B (57.335), indicating better metabolic stability.
13. **t1/2:** Ligand A (6.222) has a shorter in vitro half-life than Ligand B (7.228), but both are reasonable.
14. **Pgp:** Ligand A (0.015) has much lower P-gp efflux liability than Ligand B (0.37). This is beneficial for oral bioavailability and potentially CNS exposure.
15. **Affinity:** Ligand A (-7.5 kcal/mol) has a stronger binding affinity than Ligand B (-6.7 kcal/mol). This is a substantial difference and a key factor.
**Overall Assessment:**
Ligand A has a significantly better binding affinity, lower hERG risk, lower Pgp efflux, and lower microsomal clearance. While Ligand B has a better logP and BBB penetration, the superior affinity and safety profile of Ligand A outweigh these benefits. The similar Caco-2 values are concerning for both, but can be addressed with formulation strategies. The lower TPSA of Ligand B is a positive, but not enough to overcome the other advantages of Ligand A.
**Output:**
1
2025-04-17 21:49:21,653 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (378.57 & 364.47) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (59.81) is significantly better than Ligand B (95.16). ADRB2 is a cardiovascular target, so BBB isn't paramount, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold. Ligand B is approaching the upper limit.
3. **logP:** Ligand A (4.255) is higher than Ligand B (1.022). While 4.255 is approaching the upper limit of the optimal range (1-3), it's still acceptable. Ligand B's logP is quite low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (1) is better than Ligand B (2). Lower is generally preferred.
5. **HBA:** Ligand A (6) is better than Ligand B (5). Both are within the acceptable range of <=10.
6. **QED:** Both ligands (0.732 & 0.786) have good drug-likeness scores, exceeding the 0.5 threshold.
7. **DILI:** Ligand A (52.772) has a lower DILI risk than Ligand B (65.568), indicating a better safety profile. Both are below the concerning 60 threshold, but A is preferable.
8. **BBB:** Ligand A (79.721) has a higher BBB penetration than Ligand B (48.391). While not critical for a cardiovascular target, some CNS exposure is not necessarily detrimental and could offer additional benefits.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.115 and -5.55). This is unusual and suggests poor permeability. However, the values are similar.
10. **Solubility:** Both ligands have negative solubility values (-4.368 and -3.568). This is also unusual and suggests poor aqueous solubility. Again, the values are similar.
11. **hERG:** Both ligands (0.27 & 0.276) have very low hERG inhibition liability, which is excellent.
12. **Cl_mic:** Ligand A (89.148) has a higher microsomal clearance than Ligand B (29.079), meaning it's metabolized faster. This is a significant drawback for Ligand A.
13. **t1/2:** Ligand B (-18.265) has a negative in vitro half-life, which is not possible. This is a major red flag. Ligand A (15.459) has a reasonable half-life.
14. **Pgp:** Both ligands (0.607 & 0.08) have low P-gp efflux liability. Ligand B is slightly better.
15. **Binding Affinity:** Ligand B (-6.7) has a slightly better binding affinity than Ligand A (-6.2), a 0.5 kcal/mol difference. This is a meaningful difference, but not overwhelming.
**Overall Assessment & GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, and affinity are key. Ligand A has a better logP and TPSA, while Ligand B has a slightly better affinity. However, Ligand B has a *very* problematic negative in vitro half-life, indicating rapid degradation. Ligand A's higher clearance is a concern, but it's far less severe than a negative half-life. Ligand A also shows better DILI risk. Considering the balance of properties, Ligand A is the more promising candidate despite its higher clearance.
**Output:**
1
2025-04-17 21:49:21,653 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (370.739 and 350.423 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (90.65) is better than Ligand B (103.59). Both are acceptable for a non-CNS GPCR like ADRB2, but lower is generally preferred.
3. **logP:** Ligand A (3.058) is optimal (1-3). Ligand B (-1.009) is significantly lower, which could hinder permeability and bioavailability. This is a major drawback for Ligand B.
4. **HBD:** Both ligands have 2 HBD, which is within the acceptable limit of <=5.
5. **HBA:** Ligand A (4) is better than Ligand B (7). Lower HBA is generally preferred for better permeability.
6. **QED:** Both ligands have similar QED values (0.783 and 0.681), indicating good drug-likeness.
7. **DILI:** Ligand A (85.227) has a higher DILI risk than Ligand B (33.695). This is a significant concern for Ligand A.
8. **BBB:** This is less critical for ADRB2 (a cardiovascular target). Ligand A (81.698) is higher than Ligand B (42.846), but this isn't a deciding factor.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual. Assuming these are percentile scores, Ligand A (-4.911) is slightly better than Ligand B (-5.12), but both are poor.
10. **Solubility:** Ligand A (-5.346) is slightly better than Ligand B (-0.509), but both are poor.
11. **hERG:** Ligand A (0.484) has a lower hERG risk than Ligand B (0.039), which is a positive for Ligand A.
12. **Cl_mic:** Ligand A (23.985) has a lower (better) microsomal clearance than Ligand B (-5.481). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (16.607) has a longer half-life than Ligand B (15.384).
14. **Pgp:** Ligand A (0.246) has lower P-gp efflux than Ligand B (0.028), which is favorable.
15. **Affinity:** Ligand A (-7.6 kcal/mol) has a stronger binding affinity than Ligand B (-6.2 kcal/mol). This is a substantial difference (1.4 kcal/mol), and a major advantage for Ligand A.
**Overall Assessment:**
Ligand A has a significantly better binding affinity and more favorable logP, TPSA, and Pgp efflux properties. While its DILI risk is higher, the substantial binding affinity advantage and better ADME properties (Cl_mic, t1/2) outweigh this concern. Ligand B's very negative logP is a major red flag, likely leading to poor absorption.
Output:
1
2025-04-17 21:49:21,653 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (426.721 Da) is within the ideal range, while Ligand B (350.463 Da) is also good, leaning towards the lower end. Both are acceptable.
2. **TPSA:** Ligand A (58.53) is excellent, well below the 140 threshold. Ligand B (76.58) is still reasonable but higher. This favors Ligand A.
3. **logP:** Ligand A (4.398) is slightly high, potentially causing solubility issues. Ligand B (1.802) is optimal. This favors Ligand B.
4. **HBD:** Both ligands have acceptable HBD counts (Ligand A: 2, Ligand B: 1).
5. **HBA:** Both ligands have acceptable HBA counts (Ligand A: 4, Ligand B: 6).
6. **QED:** Both ligands have good QED scores (Ligand A: 0.525, Ligand B: 0.808). Ligand B is better here.
7. **DILI:** Ligand A (65.568) has a higher DILI risk than Ligand B (48.623). This favors Ligand B.
8. **BBB:** Ligand A (52.734) has moderate BBB penetration, while Ligand B (83.831) has high BBB penetration. Given ADRB2's cardiovascular role, BBB penetration isn't a *primary* concern, but it's still a positive for Ligand B.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual. Assuming these represent permeability, lower (more negative) values suggest *poorer* permeability. Ligand A (-5.411) is worse than Ligand B (-4.65). This favors Ligand B.
10. **Solubility:** Ligand A (-3.7) has worse solubility than Ligand B (-1.814). This favors Ligand B.
11. **hERG:** Ligand A (0.887) has a slightly higher hERG risk than Ligand B (0.323). This favors Ligand B.
12. **Cl_mic:** Ligand A (27.913) has significantly lower microsomal clearance than Ligand B (63.147), indicating better metabolic stability. This favors Ligand A.
13. **t1/2:** Ligand A (48.184) has a longer in vitro half-life than Ligand B (17.319). This favors Ligand A.
14. **Pgp:** Ligand A (0.754) has lower P-gp efflux than Ligand B (0.041). This favors Ligand A.
15. **Affinity:** Ligand A (-7.4 kcal/mol) has a slightly better binding affinity than Ligand B (-7.2 kcal/mol). This favors Ligand A.
**Overall Assessment & GPCR Prioritization:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are crucial. Ligand B excels in logP, TPSA, and Pgp, and has good affinity. Ligand A has a higher logP, which is a concern, but it compensates with better metabolic stability (Cl_mic, t1/2), Pgp efflux, and a slightly stronger binding affinity. The DILI risk is higher for Ligand A, but not critically so. Given the slight affinity advantage of Ligand A and the importance of metabolic stability for cardiovascular drugs (to avoid rapid inactivation and maintain therapeutic levels), I lean towards Ligand A.
Output:
1
2025-04-17 21:49:21,653 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, priorities are logP, TPSA, Pgp, affinity, and to a lesser extent, BBB.
Let's compare the ligands property by property:
1. **MW:** Both are within the acceptable 200-500 Da range. Ligand A (358.356) is slightly lower, which is generally favorable.
2. **TPSA:** Ligand A (44.76) is significantly better than Ligand B (78.87). Lower TPSA is preferred for GPCRs to facilitate membrane permeability.
3. **logP:** Ligand A (3.807) is optimal, while Ligand B (0.489) is quite low, potentially hindering membrane permeability and absorption.
4. **HBD/HBA:** Ligand A (0 HBD, 4 HBA) is better than Ligand B (2 HBD, 5 HBA). Lower counts are generally preferred for balance.
5. **QED:** Both are similar and acceptable (A: 0.768, B: 0.703).
6. **DILI:** Ligand A (48.817) is slightly higher than Ligand B (35.285), but both are within a reasonable range.
7. **BBB:** Ligand A (91.702) is better than Ligand B (82.862), though BBB isn't a primary concern for a cardiovascular target.
8. **Caco-2:** Both are negative, suggesting poor permeability. This is a concern for both.
9. **Solubility:** Ligand A (-4.553) is better than Ligand B (-2.873), indicating better aqueous solubility.
10. **hERG:** Ligand A (0.725) is better than Ligand B (0.323), indicating lower hERG inhibition risk.
11. **Cl_mic:** Ligand A (50.133) is higher than Ligand B (14.973), indicating faster metabolic clearance and lower metabolic stability.
12. **t1/2:** Ligand B (-14.348) has a much longer half-life than Ligand A (-0.053). This is a significant advantage for Ligand B.
13. **Pgp:** Ligand A (0.237) is better than Ligand B (0.03), indicating lower P-gp efflux.
14. **Affinity:** Ligand B (-6.5 kcal/mol) has a substantially better binding affinity than Ligand A (-5.0 kcal/mol). This is a >1.5 kcal/mol difference, a major advantage.
**Overall Assessment:**
Ligand B has a significantly better binding affinity, a much longer half-life, and a lower DILI risk. The biggest drawback of Ligand B is its low logP and TPSA, which could hinder permeability. However, the strong affinity might compensate for this. Ligand A has better TPSA, logP, solubility, Pgp, and hERG, but its weaker binding affinity is a significant disadvantage. Considering the importance of affinity for GPCR targets, and the substantial difference in binding energy, Ligand B is the more promising candidate despite its permeability concerns.
**Output:**
0
2025-04-17 21:49:21,653 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.431 and 354.491 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (86.63 and 87.66) are below the 140 A^2 threshold for good oral absorption, and acceptable for a cardiovascular target (not CNS). Again, no major difference.
3. **logP:** Ligand A (0.786) is slightly lower than Ligand B (2.064). While both are within the 1-3 range, Ligand B is closer to the optimal range.
4. **HBD:** Ligand A (1) is better than Ligand B (3). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (5) is better than Ligand B (4). Lower HBA generally improves permeability.
6. **QED:** Ligand A (0.852) has a significantly higher QED score than Ligand B (0.524), indicating a more drug-like profile.
7. **DILI:** Both ligands have low DILI risk (28.926 and 30.748), well below the 40 threshold.
8. **BBB:** Ligand A (70.764) has a much higher BBB percentile than Ligand B (45.444). While ADRB2 isn't a CNS target, higher BBB is generally favorable as it suggests less promiscuous distribution.
9. **Caco-2:** Ligand A (-4.706) and Ligand B (-5.224) are both negative, indicating poor permeability.
10. **Solubility:** Ligand A (-0.303) is better than Ligand B (-2.515), indicating better aqueous solubility.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.239 and 0.243).
12. **Cl_mic:** Ligand A (3.358) has significantly lower microsomal clearance than Ligand B (44.016), suggesting better metabolic stability.
13. **t1/2:** Ligand A (10.877) has a shorter half-life than Ligand B (13.613), but both are reasonable.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.022 and 0.165).
15. **Binding Affinity:** Ligand A (-6.7 kcal/mol) has a slightly better binding affinity than Ligand B (-5.9 kcal/mol). This 0.8 kcal/mol difference is significant.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A has a slightly lower logP, better TPSA, comparable Pgp, and better affinity. The significant advantage in QED, solubility, and metabolic stability (Cl_mic) further strengthens Ligand A's profile.
**Conclusion:**
Ligand A demonstrates a better balance of properties, particularly in drug-likeness (QED), metabolic stability (Cl_mic), solubility, and binding affinity. While both ligands have acceptable profiles, Ligand A is more likely to be a viable drug candidate.
Output:
1
2025-04-17 21:49:21,653 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (361.291 Da) is slightly higher than Ligand B (348.447 Da), but both are acceptable.
2. **TPSA:** Ligand A (55.84) is well below the 140 threshold and good for oral absorption. Ligand B (94.56) is higher, but still reasonably within range, though less optimal.
3. **logP:** Ligand A (2.087) is within the optimal 1-3 range. Ligand B (0.705) is a bit low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (0) is excellent, minimizing potential issues with hydrogen bonding. Ligand B (3) is acceptable, but higher than ideal.
5. **HBA:** Ligand A (4) is good. Ligand B (5) is also acceptable.
6. **QED:** Both ligands have similar and acceptable QED values (A: 0.568, B: 0.571).
7. **DILI:** Ligand A (72.392) has a higher DILI risk than Ligand B (13.843). This is a significant negative for Ligand A.
8. **BBB:** Ligand A (92.672) shows excellent BBB penetration, while Ligand B (23.924) is poor. Given ADRB2's role in cardiovascular function, CNS penetration isn't *essential*, but it could open up possibilities for treating centrally mediated cardiovascular issues.
9. **Caco-2:** Ligand A (-4.48) is poor, indicating poor intestinal absorption. Ligand B (-5.457) is even worse.
10. **Solubility:** Ligand A (-3.294) is poor, while Ligand B (-0.69) is also poor, but slightly better.
11. **hERG:** Ligand A (0.521) has a slightly higher hERG risk than Ligand B (0.193).
12. **Cl_mic:** Ligand A (24.212) has a better (lower) microsomal clearance than Ligand B (-4.141). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand B (52.156) has a significantly longer in vitro half-life than Ligand A (8.115). This is a major advantage for Ligand B.
14. **Pgp:** Ligand A (0.259) has lower P-gp efflux, which is favorable. Ligand B (0.017) has even lower efflux, a strong advantage.
15. **Affinity:** Ligand A (-7.8 kcal/mol) has a significantly stronger binding affinity than Ligand B (-5.7 kcal/mol). This is a substantial advantage that could potentially outweigh some of the ADME concerns.
**GPCR-specific considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are particularly important. Ligand A has a better logP and lower Pgp efflux. However, the much stronger affinity of Ligand A (-7.8 vs -5.7) is a major driver. While Ligand A has a higher DILI risk, the difference in affinity is substantial enough to potentially overcome this concern with further optimization. The poor Caco-2 and solubility of both are concerning, but can be addressed with formulation strategies.
**Conclusion:**
Despite the higher DILI risk, the significantly superior binding affinity of Ligand A, coupled with acceptable logP and Pgp, makes it the more promising candidate. The affinity advantage is substantial and likely to be more impactful than the other drawbacks, especially considering the possibility of mitigating the DILI risk through structural modifications.
Output:
1
2025-04-17 21:49:21,653 - INFO - Here's my reasoning and output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
We are targeting ADRB2, a GPCR. Therefore, priorities are logP, TPSA, Pgp, BBB, and affinity. Let's break down the comparison:
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (358.339) is slightly higher than Ligand B (344.419), but this isn't a major concern.
2. **TPSA:** Ligand A (43.18) is significantly better than Ligand B (111.06). A TPSA under 140 is good for oral absorption, but under 90 is preferred for CNS targets. While ADRB2 isn't necessarily a CNS target, lower TPSA generally correlates with better permeability. Ligand B's TPSA is quite high.
3. **logP:** Both ligands have acceptable logP values (A: 3.023, B: 2.066), falling within the 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability.
4. **H-Bond Donors/Acceptors:** Ligand A (0 HBD, 5 HBA) has a more favorable profile than Ligand B (1 HBD, 4 HBA). Fewer hydrogen bond donors generally improve permeability.
5. **QED:** Ligand A (0.771) has a significantly better QED score than Ligand B (0.484), indicating a more drug-like profile.
6. **DILI:** Both ligands have low DILI risk (A: 32.842, B: 30.593), which is good.
7. **BBB:** Ligand A (90.772) has a much higher BBB percentile than Ligand B (52.966). While not a primary concern for ADRB2, higher BBB penetration can be advantageous.
8. **Caco-2 Permeability:** Ligand A (-4.61) is better than Ligand B (-5.113), indicating better intestinal absorption.
9. **Aqueous Solubility:** Ligand A (-2.922) is better than Ligand B (-1.971), which is important for formulation.
10. **hERG Inhibition:** Ligand A (0.781) is better than Ligand B (0.134), indicating a lower risk of cardiotoxicity.
11. **Microsomal Clearance:** Ligand B (5.658) has a significantly lower microsomal clearance than Ligand A (18.005), suggesting better metabolic stability.
12. **In vitro Half-Life:** Ligand B (-14.075) has a better in vitro half-life than Ligand A (-20.798).
13. **P-gp Efflux:** Ligand A (0.097) is better than Ligand B (0.01), meaning less efflux.
14. **Binding Affinity:** Ligand B (-7.6) has a slightly better binding affinity than Ligand A (-6.0). However, the difference is not substantial enough to overcome the significant ADME advantages of Ligand A.
**Overall Assessment:**
Ligand A demonstrates a superior balance of properties, particularly in terms of TPSA, QED, BBB, solubility, and hERG inhibition. While Ligand B has slightly better affinity and metabolic stability, the other ADME properties of Ligand A are far more favorable for a GPCR target like ADRB2. The lower TPSA and higher QED of Ligand A suggest a better chance of oral bioavailability and overall drug-likeness.
**Output:**
1
2025-04-17 21:49:21,654 - INFO - Batch 286 complete. Total preferences: 4576
2025-04-17 21:49:21,654 - INFO - Processing batch 287/512...
2025-04-17 21:50:08,397 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.351 and 347.371 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (139.27) is slightly higher than Ligand B (110.53). Both are below the 140 A^2 threshold for good oral absorption, but Ligand B is better positioned, especially considering it's a GPCR target.
3. **logP:** Ligand A (-1.926) is lower than the optimal 1-3 range, potentially hindering permeability. Ligand B (0.927) is much closer to the ideal range. This is a significant advantage for Ligand B.
4. **HBD:** Both ligands have 2 H-bond donors, which is within the acceptable limit of <=5.
5. **HBA:** Ligand A has 9 H-bond acceptors, close to the upper limit of 10. Ligand B has 6, which is more favorable.
6. **QED:** Both ligands have good QED scores (0.636 and 0.784), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Both ligands have relatively high DILI risk (65.568 and 67.507). This is a concern for both, but not a deciding factor between them.
8. **BBB:** Ligand A (24.002) has very low BBB penetration, while Ligand B (43.001) is better, although still not ideal for a CNS-targeting GPCR. However, ADRB2 is primarily a cardiovascular target, so BBB penetration is less critical than for a CNS target.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.701 and -5.064), which is unusual and suggests poor permeability. This is a significant drawback for both.
10. **Solubility:** Ligand A (-1.205) has slightly better solubility than Ligand B (-3.027).
11. **hERG:** Both ligands have very low hERG inhibition risk (0.031 and 0.078). This is excellent for both.
12. **Cl_mic:** Ligand A (6.117) has a higher microsomal clearance than Ligand B (1.004), indicating lower metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand B (19.346) has a longer in vitro half-life than Ligand A (15.073), which is desirable.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.011 and 0.023).
15. **Binding Affinity:** Ligand A (-8.3 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.4 kcal/mol). This is a substantial advantage for Ligand A, potentially outweighing some of its ADME drawbacks.
**Overall Assessment:**
Ligand A has a significantly better binding affinity, which is a critical factor for GPCRs. However, it suffers from lower logP and higher Cl_mic. Ligand B has better logP, TPSA, metabolic stability (lower Cl_mic), and a longer half-life, but its binding affinity is considerably weaker.
Considering the balance, the stronger binding affinity of Ligand A is a major advantage. While the lower logP is a concern, the difference in binding affinity (1.9 kcal/mol) is substantial enough to potentially overcome this issue with formulation strategies. The higher metabolic clearance of Ligand A is a concern, but can be addressed through structural modifications during lead optimization.
Output:
1
2025-04-17 21:50:08,397 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (360.483 and 350.375 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (78.66) is significantly better than Ligand B (113.77). ADRB2 is a cardiovascular target, not CNS, but lower TPSA is generally favorable for absorption. Ligand A is well below the 140 threshold. Ligand B is approaching the upper limit.
3. **logP:** Ligand A (2.443) is within the optimal 1-3 range. Ligand B (-0.534) is *below* 1, which could indicate poor membrane permeability. This is a significant drawback.
4. **HBD:** Both ligands have acceptable HBD counts (3 and 2, respectively), below the threshold of 5.
5. **HBA:** Both ligands have acceptable HBA counts (5 and 6, respectively), below the threshold of 10.
6. **QED:** Both ligands have good QED scores (0.787 and 0.667), indicating good drug-like properties.
7. **DILI:** Ligand A (46.297) has a slightly better DILI score than Ligand B (52.191), both are acceptable.
8. **BBB:** While not a primary concern for a cardiovascular target, Ligand A (57.619) has a lower BBB penetration than Ligand B (65.839). This is not a major factor in this case.
9. **Caco-2:** Ligand A (-4.885) and Ligand B (-5.003) are both negative, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret the absolute values.
10. **Solubility:** Ligand A (-2.771) has slightly better solubility than Ligand B (-1.161), but both are negative, indicating potentially poor solubility.
11. **hERG:** Ligand A (0.443) has a significantly lower hERG risk than Ligand B (0.076). This is a critical advantage, as hERG inhibition can lead to cardiotoxicity.
12. **Cl_mic:** Ligand A (-10.522) has a much lower (better) microsomal clearance than Ligand B (9.029). This suggests greater metabolic stability for Ligand A.
13. **t1/2:** Ligand A (37.163) has a significantly longer in vitro half-life than Ligand B (-36.321). This is a major advantage, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.235) has a lower P-gp efflux liability than Ligand B (0.008), suggesting better bioavailability.
15. **Binding Affinity:** Ligand B (-7.1) has a significantly stronger binding affinity than Ligand A (-0.2). This is a substantial advantage, potentially outweighing some of the ADME drawbacks.
**Overall Assessment:**
While Ligand B boasts a much stronger binding affinity, its significantly lower logP, higher hERG risk, and higher microsomal clearance are major concerns. Ligand A, despite its weaker binding, presents a much more balanced profile with better predicted permeability (based on TPSA and logP), lower toxicity risk (hERG, DILI), and improved metabolic stability (Cl_mic, t1/2). For a GPCR target, a good balance of properties is crucial, and Ligand A appears to have a more favorable overall profile for development. The affinity difference is large, but not insurmountable with further optimization.
Output:
1
2025-04-17 21:50:08,397 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (340.43 & 353.46 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (77.49) is better than Ligand B (102.66). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally favors absorption.
3. **logP:** Ligand A (2.212) is better than Ligand B (1.069). Both are within the optimal 1-3 range, but Ligand A is closer to the sweet spot.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (2), but both are acceptable (<=5).
5. **HBA:** Ligand A (4) is lower than Ligand B (5), which is favorable.
6. **QED:** Both ligands (0.78 & 0.743) have good drug-likeness scores (>0.5). No significant difference.
7. **DILI:** Ligand A (52.23) has a higher DILI risk than Ligand B (11.13). This is a significant advantage for Ligand B.
8. **BBB:** Not a primary concern for a cardiovascular target. Ligand A (60.41) is slightly higher than Ligand B (57.19).
9. **Caco-2:** Ligand A (-5.23) is worse than Ligand B (-4.652). Higher (less negative) values are preferred.
10. **Solubility:** Ligand A (-3.138) is worse than Ligand B (-1.68). Higher values are preferred.
11. **hERG:** Ligand A (0.663) is higher than Ligand B (0.266). Lower values are preferred. Ligand B is much better here.
12. **Cl_mic:** Ligand A (66.06) has significantly higher clearance than Ligand B (2.15). Lower clearance is preferred for metabolic stability. Ligand B is much better.
13. **t1/2:** Ligand A (12.16) has a longer half-life than Ligand B (-15.19). This is a significant advantage for Ligand A. Note the negative value for Ligand B is concerning.
14. **Pgp:** Ligand A (0.146) is better than Ligand B (0.009). Lower efflux is preferred.
15. **Affinity:** Ligand A (-6.1) has a slightly better binding affinity than Ligand B (-4.9). This is a 1.2 kcal/mol advantage, which is substantial.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A performs better on logP, TPSA, and affinity. However, Ligand B excels in safety parameters (DILI, hERG) and metabolic stability (Cl_mic). The affinity difference is significant, but the poor metabolic stability and safety profile of Ligand B are major drawbacks. The half-life of Ligand B is also very concerning.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity and a longer half-life, its DILI and hERG risks are higher than Ligand B. However, the significantly better DILI, hERG, and Cl_mic profiles of Ligand B, coupled with its acceptable affinity, make it the more promising candidate. The longer half-life of Ligand A is appealing, but the safety concerns outweigh this benefit.
Output:
0
2025-04-17 21:50:08,397 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (342.447 and 373.429 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (84.73) is better than Ligand B (92.42). Both are below 140, but lower TPSA generally favors absorption.
3. **logP:** Ligand A (3.203) is slightly higher than Ligand B (1.5). Both are within the 1-3 range, but Ligand A is closer to the optimal value.
4. **HBD:** Ligand A (2) is slightly better than Ligand B (1). Both are within the acceptable limit of 5.
5. **HBA:** Ligand B (6) is slightly better than Ligand A (5). Both are within the acceptable limit of 10.
6. **QED:** Both ligands have good QED scores (0.757 and 0.863), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (56.146) has a slightly better DILI risk profile than Ligand B (63.668), both are acceptable.
8. **BBB:** Ligand B (86.817) has a better BBB penetration score than Ligand A (77.937). While ADRB2 isn't necessarily a CNS target, some peripheral ADRB2 receptors can influence CNS function, and higher BBB penetration isn't necessarily a negative.
9. **Caco-2:** Both ligands have very poor Caco-2 permeability (-4.929 and -4.85). This is a significant concern for oral bioavailability.
10. **Solubility:** Ligand A (-4.167) has slightly better solubility than Ligand B (-3.362). Both are poor.
11. **hERG:** Both ligands have low hERG inhibition risk (0.341 and 0.28).
12. **Cl_mic:** Ligand A (71.321) has a significantly better (lower) microsomal clearance than Ligand B (15.558). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (7.155) has a longer in vitro half-life than Ligand B (0.602). This is a significant advantage.
14. **Pgp:** Ligand A (0.158) has lower P-gp efflux than Ligand B (0.047). Lower P-gp efflux is preferable.
15. **Affinity:** Ligand A (-7.8 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.1 kcal/mol). This is a substantial advantage, and can often outweigh minor ADME deficiencies.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are particularly important. Ligand A performs better in logP, TPSA, Pgp, and *significantly* better in affinity. While Ligand B has a slightly better BBB score, the substantial affinity advantage of Ligand A is a critical factor. The poor Caco-2 and solubility for both are concerning, but can be addressed with formulation strategies.
**Conclusion:**
Despite the poor Caco-2 and solubility, the superior binding affinity, metabolic stability (lower Cl_mic, longer t1/2), and P-gp profile of Ligand A make it the more promising drug candidate. The 1.7 kcal/mol difference in binding affinity is a substantial advantage.
Output:
1
2025-04-17 21:50:08,397 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (a cardiovascular GPCR) drug candidates.
**Ligand A:** [359.535, 29.54, 4.284, 0, 3, 0.681, 26.638, 83.831, -5.172, -4.863, 0.767, 125.288, 4.025, 0.736, -6.3]
**Ligand B:** [362.539, 42.43, 4.342, 0, 4, 0.678, 13.61, 90.772, -4.467, -4.623, 0.536, 110.23, 4.801, 0.527, -7.2]
Here's a breakdown, considering the GPCR priorities (logP, Pgp, TPSA, affinity) and general guidelines:
1. **MW:** Both are within the ideal 200-500 Da range. A is 359.5, B is 362.5 - very similar.
2. **TPSA:** A (29.54) is excellent, well below 140 and very favorable for absorption. B (42.43) is still acceptable, but less optimal.
3. **logP:** Both are around 4.3, slightly above the ideal 1-3 range, but not drastically so. This could potentially lead to some off-target effects, but is manageable.
4. **HBD/HBA:** Both have 0 HBD and low HBA (3 for A, 4 for B). This is good for permeability.
5. **QED:** Both are around 0.68, indicating good drug-likeness.
6. **DILI:** A (26.64) is significantly better than B (13.61), indicating a lower risk of liver injury. This is a major advantage for A.
7. **BBB:** Both have good BBB penetration (A: 83.83, B: 90.77). B is slightly better, but for a cardiovascular target, high BBB penetration isn't *critical*.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
9. **Solubility:** Both have negative solubility values, which is also unusual and suggests poor solubility.
10. **hERG:** A (0.767) is slightly higher than B (0.536), indicating a slightly higher risk of hERG inhibition, but both are reasonably low.
11. **Cl_mic:** A (125.29) is higher than B (110.23), meaning faster metabolism and potentially lower exposure. This favors B.
12. **t1/2:** B (4.80) has a slightly longer half-life than A (4.03), which is a minor advantage.
13. **Pgp:** A (0.736) is slightly higher than B (0.527), indicating more P-gp efflux and potentially lower bioavailability. This favors B.
14. **Affinity:** B (-7.2 kcal/mol) has a significantly stronger binding affinity than A (-6.3 kcal/mol). This 0.9 kcal/mol difference is substantial and could outweigh some of the ADME drawbacks of B.
**Overall Assessment:**
The biggest differentiator is the binding affinity. B's -7.2 kcal/mol is a strong binding affinity, and the 0.9 kcal/mol advantage is significant. While A has better DILI risk and slightly better TPSA, the improved affinity of B, combined with acceptable ADME properties, makes it the more promising candidate. The slightly better metabolic stability (lower Cl_mic) and half-life of B also contribute to its favorability.
Output:
0
2025-04-17 21:50:08,397 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (345.359 and 340.427 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (122.71) is slightly higher than Ligand B (87.14). Ligand B is better, being closer to the <140 threshold for good oral absorption, and more favorable for a GPCR.
3. **logP:** Ligand B (2.351) is within the optimal 1-3 range, while Ligand A (0.282) is quite low, potentially hindering permeability. This is a significant advantage for Ligand B.
4. **HBD:** Both ligands have 3 H-bond donors, which is acceptable.
5. **HBA:** Ligand A has 7 H-bond acceptors, while Ligand B has 4. Ligand B is better, being closer to the <10 threshold.
6. **QED:** Ligand B (0.722) has a higher QED score than Ligand A (0.54), indicating a more drug-like profile.
7. **DILI:** Ligand B (54.207) has a lower DILI risk than Ligand A (70.686), which is preferable.
8. **BBB:** Ligand B (61.923) has a higher BBB penetration percentile than Ligand A (46.995). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant for off-target effects, and higher BBB is generally preferable.
9. **Caco-2:** Ligand A (-5.705) and Ligand B (-4.824) both have negative values, which is unusual and suggests poor permeability. However, the scale isn't specified, so it's difficult to interpret.
10. **Solubility:** Both ligands have very low solubility scores (-3.232 and -3.034). This is a concern for both, but could be addressed with formulation strategies.
11. **hERG:** Ligand A (0.222) has a lower hERG inhibition liability than Ligand B (0.566), which is a positive.
12. **Cl_mic:** Ligand A (-22.151) has a much lower (better) microsomal clearance than Ligand B (3.417), indicating greater metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (-29.446) has a much longer in vitro half-life than Ligand B (14.551), which is highly desirable.
14. **Pgp:** Ligand A (0.008) has a much lower P-gp efflux liability than Ligand B (0.044), suggesting better oral bioavailability and potentially better CNS exposure.
15. **Binding Affinity:** Ligand A (-3.0 kcal/mol) has a slightly worse binding affinity than Ligand B (0.0 kcal/mol). However, the difference isn't substantial enough to outweigh the other factors.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand B is better in terms of logP, TPSA, and Pgp. However, Ligand A has a significant advantage in metabolic stability (Cl_mic and t1/2) and P-gp efflux. The solubility is poor for both, but the other ADME properties of Ligand A are more favorable. The binding affinity difference is not large enough to overcome the ADME advantages of Ligand A.
Output:
1
2025-04-17 21:50:08,398 - INFO - Reasoning:
Let's analyze Ligand A and Ligand B for their potential as ADRB2 ligands, keeping in mind GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key).
**Molecular Weight:** Both ligands (355.523 and 347.503 Da) fall within the ideal 200-500 Da range.
**TPSA:** Both ligands have TPSA values (61.88 and 61.44) below the 140 A^2 threshold for good oral absorption.
**logP:** Both ligands have logP values (1.6 and 1.943) within the optimal 1-3 range.
**H-Bond Donors/Acceptors:** Ligand A (1 HBD, 4 HBA) is slightly better than Ligand B (2 HBD, 3 HBA) in terms of hydrogen bonding potential, potentially offering a better balance of solubility and permeability.
**QED:** Ligand A (0.682) has a better QED score than Ligand B (0.521), indicating a more drug-like profile.
**DILI:** Ligand A (5.235 percentile) has a significantly lower DILI risk than Ligand B (10.896 percentile). This is a major advantage.
**BBB:** Ligand A (66.227 percentile) has a better BBB penetration score than Ligand B (51.105 percentile). While ADRB2 isn't strictly a CNS target, some peripheral ADRB2 activity can be modulated by CNS effects, and better BBB penetration isn't necessarily a detriment.
**Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.632 and -4.814). These values are unusual and suggest poor permeability, but are likely on a log scale where negative values indicate low permeability.
**Aqueous Solubility:** Both ligands have negative solubility values (-0.733 and -2.24). Again, these are likely on a log scale and indicate poor aqueous solubility.
**hERG Inhibition:** Ligand A (0.41 percentile) has a much lower hERG inhibition liability than Ligand B (0.196 percentile), indicating a lower risk of cardiotoxicity. This is a crucial factor for a cardiovascular target.
**Microsomal Clearance:** Both ligands have similar microsomal clearance values (23.315 and 22.091 mL/min/kg).
**In vitro Half-Life:** Ligand A (-10.502 hours) has a significantly longer in vitro half-life than Ligand B (7.517 hours).
**P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.004 and 0.027).
**Binding Affinity:** Ligand B (-6.2 kcal/mol) has a slightly better binding affinity than Ligand A (-5.6 kcal/mol). While a 0.6 kcal/mol difference is noticeable, the other advantages of Ligand A are more substantial.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B in key ADME-Tox properties (DILI, hERG, QED, half-life, and BBB). While Ligand B has slightly better binding affinity, the improved safety profile, drug-likeness, and metabolic stability of Ligand A make it the more promising drug candidate. The solubility and permeability issues are concerning for both, but can be addressed through formulation strategies.
Output:
1
2025-04-17 21:50:08,398 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (389.279 Da) is better than Ligand B (424.73 Da). Both are within the ideal range, but A is closer to the lower end, which can be favorable for permeability.
2. **TPSA:** Ligand B (75.35) is slightly better than Ligand A (78.87). Both are below the 140 threshold for oral absorption, but closer to the ideal for GPCRs.
3. **logP:** Both ligands are very similar (A: 2.982, B: 3.134) and fall within the optimal 1-3 range.
4. **HBD:** Ligand B (1) is better than Ligand A (2). Lower HBD generally improves permeability.
5. **HBA:** Ligand B (5) is slightly better than Ligand A (4). Both are within the acceptable range.
6. **QED:** Ligand A (0.83) is better than Ligand B (0.75), indicating a more drug-like profile.
7. **DILI:** Ligand A (36.603) is significantly better than Ligand B (78.48). This is a major advantage for Ligand A, as lower DILI risk is crucial.
8. **BBB:** Ligand B (76.231) is better than Ligand A (51.842). While ADRB2 isn't strictly a CNS target, some CNS penetration might be beneficial, and this is a GPCR-specific priority.
9. **Caco-2:** Ligand A (-4.498) is better than Ligand B (-5.015). Higher Caco-2 permeability is better, though both are negative values which is unusual, and may indicate issues with the scale used.
10. **Solubility:** Ligand A (-3.602) is slightly better than Ligand B (-3.676). Both are similarly poor, and this could be a formulation challenge.
11. **hERG:** Ligand A (0.587) is better than Ligand B (0.76). Lower hERG inhibition is crucial for avoiding cardiotoxicity, a significant concern for cardiovascular targets.
12. **Cl_mic:** Ligand A (34.954) is better than Ligand B (45.291). Lower clearance indicates better metabolic stability.
13. **t1/2:** Ligand A (-8.856) is better than Ligand B (-4.425). A longer half-life is generally preferred.
14. **Pgp:** Ligand A (0.196) is better than Ligand B (0.267). Lower P-gp efflux is desirable for improved bioavailability.
15. **Affinity:** Ligand A (-6.9 kcal/mol) is significantly better than Ligand B (-3.7 kcal/mol). This is a substantial difference in binding affinity, and a key driver in the decision.
**Overall Assessment:**
Ligand A demonstrates a superior profile across most critical parameters. The significantly stronger binding affinity (-6.9 vs -3.7 kcal/mol) is a major advantage. It also has a much lower DILI risk, better metabolic stability (lower Cl_mic, longer t1/2), and lower hERG inhibition. While Ligand B has slightly better BBB penetration, the other advantages of Ligand A outweigh this, especially considering ADRB2 isn't primarily a CNS target. The solubility for both is a concern, but can be addressed through formulation strategies.
Output:
1
2025-04-17 21:50:08,398 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
The ADRB2 receptor is a GPCR, so the priorities are logP, Pgp, TPSA, affinity, and BBB. Let's compare the ligands across all parameters:
1. **MW:** Both ligands are within the ideal range (200-500 Da).
2. **TPSA:** Ligand B (58.2) is significantly better than Ligand A (94.32). Lower TPSA generally improves permeability, a key factor for GPCR ligands.
3. **logP:** Both are good (between 1-3), with Ligand B (3.496) slightly higher than Ligand A (2.809). Higher logP can be beneficial for receptor binding, but needs to be balanced with solubility.
4. **HBD/HBA:** Ligand A has 1 HBD and 6 HBA, while Ligand B has 2 HBD and 2 HBA. Ligand B is preferable here, having fewer hydrogen bond donors/acceptors, which can improve membrane permeability.
5. **QED:** Both are similar and acceptable (around 0.73).
6. **DILI:** Ligand B (17.759) is *much* better than Ligand A (91.004). This is a major advantage for Ligand B, as liver toxicity is a significant concern.
7. **BBB:** Ligand B (89.919) is better than Ligand A (53.432), though neither is exceptionally high. For a cardiovascular target, BBB penetration isn't critical, but it's still a positive.
8. **Caco-2:** Both are negative, indicating poor permeability. This is a concern for both.
9. **Solubility:** Both are very poor (-4.01 and -4.132). This is a significant drawback for both compounds.
10. **hERG:** Ligand A (0.209) is better than Ligand B (0.429), indicating a lower risk of cardiotoxicity. This is important given the cardiovascular target.
11. **Cl_mic:** Ligand A (99.25) is much better than Ligand B (46.263), indicating greater metabolic stability. This is a significant advantage.
12. **t1/2:** Ligand A (-12.131) is far better than Ligand B (10.88).
13. **Pgp:** Ligand A (0.129) is better than Ligand B (0.142), indicating lower P-glycoprotein efflux.
14. **Affinity:** Ligand B (-7.7) is significantly better than Ligand A (-6.3). This is a substantial advantage, potentially outweighing some of the ADME concerns.
**Overall Assessment:**
Ligand B has a significantly better binding affinity and a much lower DILI risk. While its solubility and Caco-2 permeability are poor, the strong binding and reduced toxicity are compelling. Ligand A has better metabolic stability and hERG inhibition, but its DILI risk is very high, and its binding affinity is considerably weaker. Given the importance of potency and safety, Ligand B is the more promising candidate despite its ADME liabilities. The affinity difference of 1.4 kcal/mol is substantial and can be addressed with further optimization.
**Output:**
0
2025-04-17 21:50:08,398 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's break down the comparison of Ligand A and Ligand B based on the provided parameters and the guidelines, keeping in mind ADRB2 is a GPCR and thus we prioritize logP, Pgp, TPSA, and affinity.
1. **Molecular Weight:** Both ligands (365.451 and 389.493 Da) fall within the ideal range of 200-500 Da. No significant difference here.
2. **TPSA:** Ligand B (62.3) is significantly better than Ligand A (78.67). Lower TPSA generally improves cell permeability, which is crucial for GPCR ligands.
3. **logP:** Ligand A (3.816) is slightly higher than Ligand B (2.855). While both are within the optimal range (1-3), Ligand A is approaching the upper limit, potentially raising concerns about solubility and off-target effects. Ligand B is closer to the sweet spot.
4. **H-Bond Donors:** Ligand A (0) is preferable to Ligand B (1). Fewer H-bond donors generally improve permeability.
5. **H-Bond Acceptors:** Ligand A (6) is preferable to Ligand B (5).
6. **QED:** Ligand B (0.729) is better than Ligand A (0.356), indicating a more drug-like profile.
7. **DILI:** Ligand B (61.729) is slightly higher than Ligand A (47.848), but both are acceptable.
8. **BBB:** Ligand B (82.241) is better than Ligand A (77.007). While ADRB2 isn't necessarily a CNS target, higher BBB penetration is generally favorable.
9. **Caco-2:** Ligand A (-4.452) is better than Ligand B (-5.062), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-5.836) is better than Ligand B (-3.733).
11. **hERG:** Both ligands have similar hERG inhibition liability (0.461 and 0.537).
12. **Cl_mic:** Ligand B (18.491) is significantly better than Ligand A (117.812). Lower clearance indicates better metabolic stability.
13. **t1/2:** Ligand B (-16.663) is better than Ligand A (-28.691).
14. **Pgp:** Ligand A (0.621) is better than Ligand B (0.173). Lower P-gp efflux is preferable.
15. **Binding Affinity:** Ligand B (-6.3 kcal/mol) is slightly better than Ligand A (-7.0 kcal/mol). While Ligand A has a slightly better affinity, the difference is not substantial enough to outweigh the other ADME properties.
**Overall Assessment:**
Ligand B demonstrates a more favorable balance of properties. It has better TPSA, QED, BBB penetration, metabolic stability (Cl_mic), and in vitro half-life. While Ligand A has slightly better Caco-2, solubility, and binding affinity, the advantages of Ligand B in crucial ADME parameters, particularly metabolic stability and drug-likeness, are more significant for overall drug development potential.
**Output:**
0
2025-04-17 21:50:08,398 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (344.46 & 346.39 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (61.31) is significantly better than Ligand B (97.44). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary goal, but lower TPSA generally correlates with better absorption. Ligand B's TPSA is quite high and could hinder oral bioavailability.
3. **logP:** Ligand A (3.69) is optimal, while Ligand B (0.05) is very low. This is a major concern for Ligand B, as it suggests poor membrane permeability and potentially poor absorption.
4. **HBD/HBA:** Ligand A (0 HBD, 5 HBA) is preferable to Ligand B (1 HBD, 6 HBA). Both are acceptable, but fewer H-bonds are generally better for permeability.
5. **QED:** Both ligands have the same QED (0.78), indicating similar overall drug-likeness.
6. **DILI:** Ligand A (35.60) has a much lower DILI risk than Ligand B (62.00). This is a substantial advantage for Ligand A.
7. **BBB:** Not a primary concern for a cardiovascular target. Ligand A (88.17) is higher, but this isn't a deciding factor.
8. **Caco-2:** Both ligands have negative Caco-2 values (-4.94 and -4.82). This is unusual and suggests issues with the assay or the compounds themselves. However, the negative values are similar, so it doesn't differentiate them.
9. **Solubility:** Ligand A (-3.11) is better than Ligand B (-2.22), indicating better aqueous solubility.
10. **hERG:** Ligand A (0.39) has a lower hERG risk than Ligand B (0.06). This is a significant advantage for Ligand A, reducing potential cardiotoxicity.
11. **Cl_mic:** Ligand A (61.66) has a higher (worse) microsomal clearance than Ligand B (-8.20). This suggests Ligand B is more metabolically stable.
12. **t1/2:** Ligand B (-18.85) has a much longer in vitro half-life than Ligand A (-0.52). This is a significant advantage for Ligand B, potentially allowing for less frequent dosing.
13. **Pgp:** Ligand A (0.396) has lower P-gp efflux than Ligand B (0.031). Lower P-gp efflux is generally desirable for bioavailability.
14. **Binding Affinity:** Ligand A (-7.6) has a slightly better binding affinity than Ligand B (-7.0). While the difference is not huge, it is still a positive for Ligand A.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand A excels in logP and has slightly better affinity and a much better TPSA. Ligand B has a better half-life and metabolic stability, but its extremely low logP and high TPSA are major drawbacks. The lower DILI and hERG risk for Ligand A are also significant advantages.
**Conclusion:**
Despite Ligand B's better metabolic stability and half-life, the significantly better physicochemical properties (logP, TPSA, solubility) and safety profile (DILI, hERG) of Ligand A make it the more promising drug candidate for ADRB2. The poor logP of Ligand B is a substantial hurdle to overcome.
Output:
1
2025-04-17 21:50:08,398 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [348.447, 104.21 , 1.072, 3. , 5. , 0.652, 37.611, 43.893, -5.008, -1.526, 0.066, 13.162, -5.755, 0.013, -6.4 ]
**Ligand B:** [348.487, 78.43 , 3.242, 3. , 3. , 0.738, 41.838, 60.45 , -4.638, -3.928, 0.695, 63.267, 5.202, 0.426, -6.8 ]
Here's a breakdown, considering the GPCR priorities (logP, Pgp, TPSA, affinity, and BBB):
1. **MW:** Both ligands are within the ideal range (around 348 Da).
2. **TPSA:** Ligand A (104.21) is higher than Ligand B (78.43). Ligand B is better here, being closer to the <90 preferred for GPCRs.
3. **logP:** Ligand A (1.072) is slightly lower than the optimal 1-3 range, but acceptable. Ligand B (3.242) is excellent.
4. **HBD/HBA:** Both have 3 HBD and a reasonable number of HBAs (5 for A, 3 for B). This is acceptable for both.
5. **QED:** Both are good (>0.5), with Ligand B slightly better (0.738 vs 0.652).
6. **DILI:** Both are good, with Ligand A (37.611) being slightly better than Ligand B (41.838).
7. **BBB:** Ligand B (60.45) is significantly better than Ligand A (43.893). While not a CNS target, some peripheral GPCRs benefit from limited BBB penetration.
8. **Caco-2:** Ligand A (-5.008) is worse than Ligand B (-4.638), indicating lower intestinal absorption.
9. **Solubility:** Ligand B (-3.928) is better than Ligand A (-1.526).
10. **hERG:** Ligand A (0.066) is significantly better than Ligand B (0.695), indicating a lower risk of cardiotoxicity. This is *very* important for a cardiovascular target.
11. **Cl_mic:** Ligand A (13.162) has a much lower clearance than Ligand B (63.267), suggesting better metabolic stability.
12. **t1/2:** Ligand A (-5.755) has a more negative value, indicating a longer half-life than Ligand B (5.202).
13. **Pgp:** Ligand A (0.013) has much lower P-gp efflux than Ligand B (0.426), which is favorable for bioavailability and potentially tissue distribution.
14. **Affinity:** Ligand B (-6.8) has a slightly better binding affinity than Ligand A (-6.4). This is a 1.5 kcal/mol difference, which is significant.
**Overall Assessment:**
Ligand B has advantages in logP, TPSA, QED, BBB, solubility, and binding affinity. However, Ligand A shines in hERG inhibition, metabolic stability (Cl_mic), half-life, and P-gp efflux. Given this is a cardiovascular target, the *lower hERG risk of Ligand A is paramount*. The slightly better affinity of Ligand B is outweighed by the increased cardiotoxicity risk. The improved metabolic stability and reduced efflux of Ligand A also contribute to its overall better profile.
Therefore, I prefer Ligand A.
Output:
1
2025-04-17 21:50:08,399 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (371.48 & 381.85 Da) fall comfortably within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (69.72) is better than Ligand B (72.88), both are below the 140 A^2 threshold for good oral absorption, but closer to the ideal for GPCRs.
3. **logP:** Ligand A (2.837) is optimal, while Ligand B (0.669) is a bit low, potentially hindering membrane permeability. This is a significant point favoring A.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (4). Lower HBA generally improves permeability.
6. **QED:** Both ligands have acceptable QED values (0.885 and 0.686, respectively), indicating good drug-like properties. Ligand A is slightly better.
7. **DILI:** Ligand B (33.579) has a significantly lower DILI risk than Ligand A (46.801). This is a strong point in favor of B.
8. **BBB:** Ligand A (83.094) has a much higher BBB penetration potential than Ligand B (53.083). While ADRB2 isn't *necessarily* a CNS target, some peripheral ADRB2 activity can be modulated by CNS effects, and higher BBB penetration can be beneficial.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand B (-4.931) is slightly worse than Ligand A (-4.522).
10. **Solubility:** Ligand A (-3.92) has better solubility than Ligand B (-1.243). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.637) has a slightly better hERG profile than Ligand B (0.322), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand B (-7.08) has a *much* lower microsomal clearance than Ligand A (34.382), suggesting significantly improved metabolic stability. This is a major advantage for B.
13. **t1/2:** Ligand B (-9.656) has a much longer in vitro half-life than Ligand A (-28.922). This is a substantial advantage for B, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.089) has lower P-gp efflux liability than Ligand B (0.055), meaning better absorption and potentially higher bioavailability.
15. **Affinity:** Ligand A (-6.3 kcal/mol) has a slightly better binding affinity than Ligand B (-5.4 kcal/mol). While not a huge difference, it's a positive for A.
**Overall Assessment & GPCR Prioritization:**
Given that this is a GPCR target, logP, TPSA, Pgp efflux, and binding affinity are key. Ligand A performs better on logP, TPSA, Pgp and affinity. However, Ligand B has a *much* better metabolic profile (Cl_mic and t1/2) and a significantly lower DILI risk. The difference in affinity is not large enough to outweigh the substantial pharmacokinetic advantages of Ligand B. While Ligand A has better BBB penetration, the ADRB2 is not exclusively a CNS target, and the metabolic stability and safety profile of Ligand B are more critical.
Output:
0
2025-04-17 21:50:08,399 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (351.491 Da) is slightly higher than Ligand B (342.443 Da), but both are acceptable.
2. **TPSA:** Ligand A (87.3) is better than Ligand B (59.39). Both are below 140, but B is closer to the optimal for oral absorption.
3. **logP:** Both ligands have good logP values (A: 1.904, B: 2.363), falling within the 1-3 range.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (1), but both are within the acceptable limit of 5.
5. **HBA:** Ligand A (3) is lower than Ligand B (5), which is preferable.
6. **QED:** Ligand B (0.906) has a significantly better QED score than Ligand A (0.584), indicating a more drug-like profile.
7. **DILI:** Ligand A (24.622) has a much lower DILI risk than Ligand B (38.969), which is a significant advantage.
8. **BBB:** Ligand B (63.474) has a better BBB penetration score than Ligand A (56.65), but neither are particularly high. For a cardiovascular target, BBB penetration isn't a primary concern, so this difference is less critical.
9. **Caco-2:** Ligand A (-5.318) is worse than Ligand B (-4.757), indicating lower intestinal absorption.
10. **Solubility:** Ligand A (-2.246) is slightly better than Ligand B (-2.536), but both are poor.
11. **hERG:** Ligand A (0.124) has a much lower hERG inhibition liability than Ligand B (0.436), which is a crucial safety factor.
12. **Cl_mic:** Ligand B (74.501) has a much higher microsomal clearance than Ligand A (19.768), indicating poorer metabolic stability.
13. **t1/2:** Ligand B (51.86) has a significantly longer in vitro half-life than Ligand A (-3.546).
14. **Pgp:** Ligand A (0.028) has a lower P-gp efflux liability than Ligand B (0.304), which is favorable.
15. **Affinity:** Ligand B (-7.2 kcal/mol) has a substantially stronger binding affinity than Ligand A (-5.3 kcal/mol). This is a significant advantage, potentially outweighing some ADME drawbacks.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), affinity, logP, TPSA, Pgp, and metabolic stability are key. Ligand B excels in affinity, while Ligand A has better metabolic stability (lower Cl_mic) and lower Pgp efflux. Ligand B has a better TPSA and logP. The DILI and hERG profiles of Ligand A are significantly better, which are important safety considerations.
**Overall Assessment:**
The substantially stronger binding affinity of Ligand B (-7.2 kcal/mol vs. -5.3 kcal/mol) is a major driver. While Ligand A has better safety (DILI, hERG) and metabolic stability, the potency advantage of Ligand B is likely to be more impactful in driving efficacy. The better QED score of Ligand B also contributes to its favorability. The slightly lower Caco-2 and solubility of Ligand B can be addressed through formulation strategies.
Output:
0
2025-04-17 21:50:08,399 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (429.38 Da) is within the ideal range, while Ligand B (351.535 Da) is also good. No clear advantage here.
2. **TPSA:** Ligand A (66.48) is slightly higher than Ligand B (52.65). Both are below the 140 threshold for oral absorption, but B is better.
3. **logP:** Both ligands (A: 3.161, B: 2.672) are within the optimal 1-3 range. No significant difference.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Both have 3 HBA, which is good.
6. **QED:** Ligand A (0.756) has a slightly better QED score than Ligand B (0.684), indicating better overall drug-likeness.
7. **DILI:** Ligand B (16.324) has a significantly lower DILI risk than Ligand A (42.148). This is a major advantage for Ligand B.
8. **BBB:** Ligand A (91.702) has a much higher BBB penetration percentile than Ligand B (78.209). While ADRB2 isn't strictly a CNS target, some CNS exposure can be acceptable and potentially beneficial for understanding off-target effects.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.795) is slightly worse than Ligand B (-4.64).
10. **Solubility:** Ligand A (-4.115) has slightly worse solubility than Ligand B (-2.962).
11. **hERG:** Both ligands have low hERG inhibition risk (A: 0.706, B: 0.508). No significant difference.
12. **Cl_mic:** Ligand B (54.058) has a lower microsomal clearance than Ligand A (33.498), indicating better metabolic stability.
13. **t1/2:** Ligand A (6.379) has a longer in vitro half-life than Ligand B (3.063).
14. **Pgp:** Ligand A (0.547) has lower P-gp efflux than Ligand B (0.23), which is preferable.
15. **Binding Affinity:** Ligand B (-6.4 kcal/mol) has a slightly better binding affinity than Ligand A (-5.4 kcal/mol). This is a 1.0 kcal/mol difference, which is significant.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are important. Ligand B is better on TPSA, Pgp, and Affinity. Ligand A is better on BBB, but that is less important for a peripheral target like ADRB2. The significantly lower DILI risk and better metabolic stability of Ligand B are also major advantages. While Ligand A has a longer half-life, the other factors weigh more heavily in favor of Ligand B.
**Conclusion:**
Considering the balance of properties, especially the lower DILI risk, better metabolic stability, and slightly improved binding affinity, Ligand B is the more promising drug candidate for ADRB2.
0
2025-04-17 21:50:08,399 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (354.4 and 341.4 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (53.76) is significantly better than Ligand B (88.91). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is pushing the upper limit for good oral absorption.
**3. logP:** Ligand A (2.707) is optimal, while Ligand B (1.135) is a bit low. A logP between 1-3 is preferred, and Ligand B's value might indicate potential permeability issues.
**4. H-Bond Donors:** Ligand A (0) is preferable to Ligand B (2). Fewer H-bond donors generally improve membrane permeability.
**5. H-Bond Acceptors:** Ligand A (3) is better than Ligand B (5). Similar to HBDs, fewer HBAs are generally preferred.
**6. QED:** Both ligands have good QED values (0.757 and 0.824), indicating generally drug-like properties.
**7. DILI Risk:** Ligand A (17.72) has a much lower DILI risk than Ligand B (35.634). This is a critical advantage for Ligand B.
**8. BBB Penetration:** Ligand A (83.211) shows better BBB penetration than Ligand B (61.846). While ADRB2 is a cardiovascular target, some CNS effects are possible with adrenergic agonists, and better BBB penetration could be a benefit or a concern depending on the desired profile.
**9. Caco-2 Permeability:** Ligand A (-4.691) is better than Ligand B (-5.068). Both are negative, which is unusual and requires further investigation, but A is slightly better.
**10. Aqueous Solubility:** Ligand A (-2.287) is better than Ligand B (-1.794). Both are poor, but A is slightly better.
**11. hERG Inhibition:** Ligand A (0.518) has a lower hERG risk than Ligand B (0.218). This is a significant advantage for Ligand A, as hERG inhibition can lead to cardiotoxicity.
**12. Microsomal Clearance:** Ligand B (18.337) has a higher clearance than Ligand A (15.261). Lower clearance is preferred for better metabolic stability.
**13. In vitro Half-Life:** Ligand A (16.167) has a better half-life than Ligand B (-20.294). A negative half-life is not possible, so there is likely an error in the data for Ligand B.
**14. P-gp Efflux:** Ligand A (0.072) has lower P-gp efflux than Ligand B (0.018). Lower efflux is better for bioavailability.
**15. Binding Affinity:** Ligand B (-7.4) has a slightly better binding affinity than Ligand A (-6.3). However, the difference is 1.1 kcal/mol, which is not substantial enough to outweigh the numerous ADME advantages of Ligand A.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical ADME properties, including TPSA, logP, DILI risk, hERG inhibition, and metabolic stability. While Ligand B has a slightly better binding affinity, the other factors make Ligand A a more promising drug candidate. The negative half-life for Ligand B is also a major red flag.
Output:
1
2025-04-17 21:50:08,399 - INFO - Batch 287 complete. Total preferences: 4592
2025-04-17 21:50:08,399 - INFO - Processing batch 288/512...
2025-04-17 21:50:56,628 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [351.447, 87.74, 0.293, 2, 4, 0.674, 35.285, 45.715, -4.78, -2.309, 0.084, 21.661, -23.969, 0.029, -6.9]
**Ligand B:** [349.435, 100.35, 0.357, 2, 6, 0.748, 49.477, 41.218, -5.054, -1.404, 0.198, 10.785, -6.278, 0.064, -5.4]
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). A is 351.447, B is 349.435. Very similar.
2. **TPSA:** Ligand A (87.74) is better than Ligand B (100.35). We want <140 for oral absorption, both are fine, but A is preferable.
3. **logP:** Both are acceptable (around 0.3), falling within the 1-3 range. B is slightly higher at 0.357.
4. **HBD:** Both have 2 HBD, which is good.
5. **HBA:** Ligand A has 4 HBA, Ligand B has 6. A is preferable, as lower HBA generally improves permeability.
6. **QED:** Both are good (>0.5), with B slightly higher (0.748 vs 0.674).
7. **DILI:** Ligand A (35.285) has a significantly lower DILI risk than Ligand B (49.477). This is a major advantage for A.
8. **BBB:** Ligand A (45.715) has a slightly better BBB penetration potential than Ligand B (41.218), though both are not exceptionally high. For a cardiovascular target, BBB isn't *critical*, but a small advantage is still good.
9. **Caco-2:** Ligand A (-4.78) has a better Caco-2 permeability than Ligand B (-5.054).
10. **Solubility:** Ligand A (-2.309) has better aqueous solubility than Ligand B (-1.404).
11. **hERG:** Both are very low risk (0.084 and 0.198 respectively), which is excellent.
12. **Cl_mic:** Ligand A (21.661) has a lower microsomal clearance than Ligand B (10.785), indicating better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand A (-23.969) has a much longer in vitro half-life than Ligand B (-6.278). This is a major advantage.
14. **Pgp:** Both have low Pgp efflux liability (0.029 and 0.064).
15. **Affinity:** Ligand A (-6.9 kcal/mol) has a slightly better binding affinity than Ligand B (-5.4 kcal/mol). This is a substantial difference.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, we prioritize logP, TPSA, Pgp, and affinity. Both ligands are decent in logP and Pgp. Ligand A has a better TPSA. The affinity difference is significant (1.5 kcal/mol), and Ligand A also has a much better safety profile (DILI) and pharmacokinetic properties (Cl_mic, t1/2).
**Conclusion:**
Ligand A is the superior candidate. It demonstrates a better balance of properties, particularly in terms of safety, metabolic stability, half-life, and binding affinity. While Ligand B has a slightly higher QED, the advantages of Ligand A outweigh this.
1
2025-04-17 21:50:56,628 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [383.901, 62.74, 2.804, 0, 6, 0.588, 80.109, 74.758, -4.692, -4.865, 0.237, 102.322, 10.055, 0.411, -5.6]
**Ligand B:** [354.372, 58.2, 2.846, 2, 2, 0.74, 36.487, 84.529, -4.603, -3.272, 0.352, 34.959, -22.042, 0.174, -6]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (354.372) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are below the 140 A^2 threshold for oral absorption. Ligand B (58.2) is better than Ligand A (62.74).
3. **logP:** Both are within the optimal range (1-3). Ligand A (2.804) and Ligand B (2.846) are very similar.
4. **HBD:** Ligand A (0) is better than Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (6) is better than Ligand B (2). Fewer HBAs generally improve permeability.
6. **QED:** Ligand B (0.74) is better than Ligand A (0.588). Higher QED suggests a more drug-like profile.
7. **DILI:** Ligand B (36.487) is *significantly* better than Ligand A (80.109). This is a major advantage for Ligand B.
8. **BBB:** Ligand B (84.529) is better than Ligand A (74.758). While not a primary concern for ADRB2 (cardiovascular target), higher BBB is still a positive.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-4.692) is slightly worse than Ligand B (-4.603).
10. **Solubility:** Ligand B (-3.272) is better than Ligand A (-4.865).
11. **hERG:** Both are very low, indicating minimal hERG inhibition risk. Ligand A (0.237) is slightly better than Ligand B (0.352).
12. **Cl_mic:** Ligand B (34.959) is *much* better than Ligand A (102.322). Lower clearance indicates better metabolic stability.
13. **t1/2:** Ligand B (-22.042) is better than Ligand A (10.055). A negative value suggests a very long half-life.
14. **Pgp:** Ligand A (0.411) is better than Ligand B (0.174). Lower P-gp efflux is preferred.
15. **Affinity:** Both have excellent binding affinities (-5.6 and -6 kcal/mol). Ligand B is slightly better.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Both ligands perform well on logP and affinity. Ligand B has a better TPSA and Pgp. The biggest differentiator is the DILI and Cl_mic. Ligand B has a much lower DILI risk and significantly better metabolic stability. While Ligand A has slightly better Pgp efflux, the DILI and metabolic stability concerns are more critical.
**Conclusion:**
Ligand B is the more promising candidate due to its significantly lower DILI risk, better metabolic stability, and improved solubility. These factors outweigh the slightly better Pgp efflux of Ligand A.
Output:
0
2025-04-17 21:50:56,628 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (362.308 Da) is within the ideal range (200-500 Da). Ligand B (381.303 Da) is also acceptable. No clear advantage here.
2. **TPSA:** Ligand A (93.53) is slightly above the preferred <90 for CNS targets, but still reasonable for a peripherally acting GPCR like ADRB2. Ligand B (61.36) is excellent, well below 90. Advantage: B
3. **logP:** Ligand A (0.102) is quite low, potentially hindering membrane permeability. Ligand B (4.583) is high, potentially causing solubility issues and off-target effects, but is within the acceptable range. Advantage: A (slightly, due to B being potentially problematic)
4. **HBD:** Ligand A (1) is good. Ligand B (3) is acceptable but higher. Advantage: A
5. **HBA:** Ligand A (6) is good. Ligand B (2) is excellent. Advantage: B
6. **QED:** Both ligands (A: 0.77, B: 0.686) are above 0.5, indicating good drug-likeness. No clear advantage.
7. **DILI:** Both ligands are similar (A: 46.956, B: 48.042) and below the concerning threshold of 60, indicating low DILI risk. No clear advantage.
8. **BBB:** Ligand A (74.564) is better than Ligand B (61.07), but BBB is less critical for ADRB2 (a cardiovascular target).
9. **Caco-2:** Ligand A (-4.616) is very poor. Ligand B (-4.518) is also poor, but slightly better. Advantage: B
10. **Solubility:** Ligand A (-1.594) is better than Ligand B (-5.691). Advantage: A
11. **hERG:** Ligand A (0.421) is much lower than Ligand B (0.87), indicating a lower risk of cardiotoxicity. This is *very* important for a cardiovascular target. Advantage: A
12. **Cl_mic:** Ligand A (2.326) is significantly lower than Ligand B (54.294), suggesting better metabolic stability. Advantage: A
13. **t1/2:** Ligand A (-29.609) is very poor, while Ligand B (119.707) is excellent. Advantage: B
14. **Pgp:** Ligand A (0.035) is much lower than Ligand B (0.64), indicating less P-gp efflux and potentially better bioavailability. Advantage: A
15. **Binding Affinity:** Ligand A (-7.2) is slightly better than Ligand B (-6.3), but the difference is less than 1.5 kcal/mol. Advantage: A (slight)
**Overall Assessment:**
For an ADRB2 target (cardiovascular), the key priorities are potency (affinity), minimizing cardiotoxicity (hERG), and metabolic stability. Ligand A demonstrates a clear advantage in hERG inhibition and metabolic stability (Cl_mic). While Ligand B has better TPSA, Caco-2, and t1/2, the low logP of Ligand A is less concerning for a non-CNS target, and the superior safety profile (hERG) and metabolic stability are more critical. The slight affinity advantage of A also contributes.
Output:
1
2025-04-17 21:50:56,628 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (347.315 and 340.467 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (29.02) is excellent, well below the 140 threshold and very favorable for absorption. Ligand B (58.2) is higher, but still acceptable, though less optimal.
**3. logP:** Both ligands have good logP values (4.35 and 3.702), falling within the 1-3 range. Ligand A is slightly higher, which *could* be a minor concern for solubility, but not a dealbreaker.
**4. H-Bond Donors:** Ligand A (0) is ideal. Ligand B (2) is acceptable but less so.
**5. H-Bond Acceptors:** Ligand A (3) is good. Ligand B (2) is also good.
**6. QED:** Ligand A (0.613) is better than Ligand B (0.504), indicating a more drug-like profile.
**7. DILI Risk:** Ligand B (36.681) has a significantly lower DILI risk than Ligand A (74.021). This is a substantial advantage for Ligand B.
**8. BBB Penetration:** Ligand A (93.68) has significantly better BBB penetration than Ligand B (68.321). While ADRB2 is primarily a cardiovascular target, some CNS effects are possible with beta-blockers, and better BBB penetration could be beneficial or detrimental depending on the desired profile.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.786 and -4.811), which is unusual and suggests poor permeability. This is a concern for both.
**10. Aqueous Solubility:** Both ligands have poor aqueous solubility (-5.846 and -4.085). This is a significant drawback for both.
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (0.927 and 0.71). This is good.
**12. Microsomal Clearance:** Both ligands have similar microsomal clearance rates (47.567 and 48.703 mL/min/kg), indicating moderate metabolic stability.
**13. In vitro Half-Life:** Ligand A (11.07 hours) has a significantly longer half-life than Ligand B (-1.445 hours). This is a major advantage for Ligand A.
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (0.767 and 0.221).
**15. Binding Affinity:** Ligand A (-6.4 kcal/mol) has a slightly better binding affinity than Ligand B (-6.0 kcal/mol).
**GPCR-Specific Considerations:** For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A excels in TPSA and affinity, and has a good logP. Ligand B has a much better DILI score. The Caco-2 and solubility are poor for both. The half-life is much better for Ligand A.
**Overall Assessment:**
While Ligand A has a better binding affinity and half-life, the significantly lower DILI risk associated with Ligand B is a crucial factor. DILI is a major cause of drug attrition. The slightly weaker affinity of Ligand B could potentially be optimized further, whereas mitigating a high DILI risk is often much more challenging. The better BBB penetration of Ligand A is less critical for a cardiovascular target.
Therefore, I would choose Ligand B.
0
2025-04-17 21:50:56,628 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (375.837) is slightly higher than Ligand B (367.471), but both are acceptable.
2. **TPSA:** Ligand A (72.48) is well below the 140 threshold for oral absorption and reasonable for a GPCR. Ligand B (101.3) is still within acceptable limits, but less favorable.
3. **logP:** Ligand A (3.786) is at the upper end of the optimal range (1-3), while Ligand B (1.858) is towards the lower end. For a GPCR, a slightly higher logP can be beneficial for membrane permeability, but we need to consider other factors.
4. **HBD:** Both ligands have 2 H-bond donors, which is good.
5. **HBA:** Ligand A has 6 H-bond acceptors, and Ligand B has 5. Both are within the acceptable limit of 10.
6. **QED:** Ligand A (0.681) has a better QED score than Ligand B (0.485), indicating a more drug-like profile.
7. **DILI:** Ligand B (52.423) has a significantly lower DILI risk than Ligand A (99.108). This is a major concern for Ligand A.
8. **BBB:** Both ligands have similar BBB penetration (Ligand A: 55.603, Ligand B: 55.642). While not exceptionally high, it's not a primary concern for ADRB2, which isn't a CNS target.
9. **Caco-2:** Both ligands have negative Caco-2 values which is unusual. However, the magnitude is similar, so this doesn't differentiate them.
10. **Solubility:** Ligand B (-2.814) has better aqueous solubility than Ligand A (-5.863).
11. **hERG:** Ligand A (0.572) has a slightly higher hERG risk than Ligand B (0.153).
12. **Cl_mic:** Ligand B (69.366) has a higher microsomal clearance than Ligand A (53.8), suggesting faster metabolism and potentially lower *in vivo* exposure.
13. **t1/2:** Ligand A (43.957) has a significantly longer *in vitro* half-life than Ligand B (-39.347). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.725) has higher P-gp efflux liability than Ligand B (0.078).
15. **Binding Affinity:** Ligand A (-7.5 kcal/mol) has a stronger binding affinity than Ligand B (-5.9 kcal/mol). This is a substantial difference (1.6 kcal/mol), and a key driver in the decision.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are important. Ligand A has a better logP and significantly better affinity. However, the high DILI risk and higher P-gp efflux for Ligand A are major drawbacks. Ligand B has a much better safety profile (lower DILI, lower hERG), and better solubility, but suffers from lower affinity and faster metabolism.
**Overall Assessment:**
The affinity difference is substantial. While Ligand A's DILI risk is concerning, the significantly improved binding affinity (-7.5 vs -5.9 kcal/mol) is a strong advantage that can potentially be mitigated through structural modifications. The longer half-life of Ligand A is also a positive. Ligand B's lower affinity is a more difficult property to improve.
Output:
1
2025-04-17 21:50:56,628 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 drug candidates. ADRB2 is a GPCR, so we'll prioritize logP, Pgp, TPSA, and affinity, alongside general drug-like properties.
**Ligand A:** [358.454, 76.66, 2.276, 2, 4, 0.464, 14.036, 81.582, -4.932, -2.227, 0.525, 19.013, 16.826, 0.077, -6.6]
**Ligand B:** [355.463, 51.27, 4.319, 0, 5, 0.634, 47.926, 68.786, -5.041, -3.844, 0.741, 83.851, 32.348, 0.529, -6.4]
1. **MW:** Both are within the ideal 200-500 Da range. A (358.454) and B (355.463) are very similar.
2. **TPSA:** A (76.66) is higher than B (51.27). B is better here, being closer to the <140 threshold for good absorption.
3. **logP:** A (2.276) is optimal. B (4.319) is pushing the upper limit and could lead to solubility issues.
4. **HBD:** A (2) is good. B (0) is also acceptable.
5. **HBA:** A (4) is good. B (5) is also acceptable.
6. **QED:** A (0.464) is below the preferred 0.5, but not drastically. B (0.634) is better, indicating a more drug-like profile.
7. **DILI:** A (14.036) is excellent, very low risk. B (47.926) is moderate, but still acceptable.
8. **BBB:** A (81.582) is very good, suggesting good potential for CNS penetration if desired (though less critical for ADRB2 which is primarily cardiovascular). B (68.786) is lower.
9. **Caco-2:** Both are negative, indicating poor permeability. A (-4.932) is slightly better (less negative) than B (-5.041).
10. **Solubility:** Both are negative, indicating poor solubility. A (-2.227) is slightly better than B (-3.844).
11. **hERG:** A (0.525) is very low risk. B (0.741) is slightly higher, but still acceptable.
12. **Cl_mic:** A (19.013) is lower, indicating better metabolic stability. B (83.851) is significantly higher, suggesting faster metabolism.
13. **t1/2:** A (16.826) is good. B (32.348) is better, indicating a longer half-life.
14. **Pgp:** A (0.077) is very low efflux, favorable for bioavailability and potential CNS exposure. B (0.529) is higher, suggesting more P-gp efflux.
15. **Affinity:** A (-6.6) is slightly better than B (-6.4), although the difference is small.
**Overall Assessment:**
Ligand A has a better safety profile (DILI, hERG) and metabolic stability (Cl_mic). It also has better Pgp properties. While its QED is slightly lower, its solubility is slightly better. Ligand B has a better TPSA and in vitro half-life. However, its higher logP and Pgp efflux are concerning, and its metabolic clearance is significantly higher.
Considering the GPCR-specific priorities and the overall balance of properties, **Ligand A is the more promising candidate.** The slightly better affinity, combined with the superior safety and metabolic stability, outweigh the slightly lower QED and TPSA.
Output:
1
2025-04-17 21:50:56,628 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (356.5 and 348.4 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (76.66) is significantly better than Ligand B (115.13). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is above the preferred 90 A^2 threshold.
**3. logP:** Ligand A (3.39) is within the optimal range (1-3), while Ligand B (0.386) is quite low. Low logP can hinder membrane permeability and bioavailability. This is a substantial advantage for Ligand A.
**4. H-Bond Donors:** Ligand A (2) and Ligand B (3) are both acceptable, falling under the 5 threshold.
**5. H-Bond Acceptors:** Both ligands (4) are within the acceptable range of <=10.
**6. QED:** Ligand A (0.765) has a slightly better QED score than Ligand B (0.645), indicating a more drug-like profile.
**7. DILI Risk:** Ligand A (29.042) has a much lower DILI risk than Ligand B (57.852). This is a critical advantage, as liver toxicity is a major concern in drug development.
**8. BBB Penetration:** Ligand A (80.574) has significantly better BBB penetration potential than Ligand B (40.403). While ADRB2 is a cardiovascular target, some CNS effects are possible with certain ligands, and higher BBB penetration can sometimes be beneficial or at least not detrimental.
**9. Caco-2 Permeability:** Ligand A (-4.269) and Ligand B (-5.1) are both poor.
**10. Aqueous Solubility:** Ligand A (-4.1) is slightly better than Ligand B (-3.093), but both are poor.
**11. hERG Inhibition:** Both ligands (0.291 and 0.069) show very low hERG inhibition risk, which is excellent.
**12. Microsomal Clearance:** Ligand B (-17.283) has a lower (better) microsomal clearance than Ligand A (82.763), suggesting greater metabolic stability.
**13. In vitro Half-Life:** Ligand B (-12.69) has a longer in vitro half-life than Ligand A (-21.31), which is favorable.
**14. P-gp Efflux:** Both ligands (0.03 and 0.031) show very low P-gp efflux, which is good.
**15. Binding Affinity:** Both ligands (-6 and -5.7 kcal/mol) have good binding affinity, but Ligand A is slightly better.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand A is the stronger candidate. Its superior logP, lower TPSA, significantly lower DILI risk, and better BBB penetration outweigh the slightly better metabolic stability and half-life of Ligand B. The small advantage in binding affinity also favors Ligand A. The poor Caco-2 and solubility of both compounds are concerns that would need to be addressed in further optimization, but the other factors make Ligand A the more promising starting point.
Output:
1
2025-04-17 21:50:56,628 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's systematically compare Ligand A and Ligand B against the provided guidelines, keeping in mind the GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key).
1. **MW:** Both ligands (367.5 and 364.6 Da) fall comfortably within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (71.53) is slightly higher than Ligand B (58.12). Both are reasonably good, but B is preferable as it's closer to the <90 ideal for potential CNS penetration (though not a primary concern for ADRB2).
3. **logP:** Ligand A (2.481) is within the optimal 1-3 range. Ligand B (3.792) is slightly higher, approaching the upper limit, but still acceptable.
4. **HBD/HBA:** Both have 1 HBD and 5 HBA, which are within acceptable limits.
5. **QED:** Both ligands have good QED scores (0.868 and 0.8), indicating good drug-like properties.
6. **DILI:** Both have acceptable DILI risk (47.77 and 51.299), below the 60 threshold.
7. **BBB:** Ligand B (87.864) has significantly better BBB penetration potential than Ligand A (61.535). While ADRB2 isn't a CNS target, higher BBB is generally a positive indicator of permeability.
8. **Caco-2:** Ligand B (-5.119) has a more negative Caco-2 value, suggesting better intestinal absorption than Ligand A (-4.884).
9. **Solubility:** Ligand B (-3.997) has a more negative solubility value, indicating better aqueous solubility than Ligand A (-2.262).
10. **hERG:** Both ligands have low hERG inhibition liability (0.447 and 0.628).
11. **Cl_mic:** Ligand A (64.282) has a lower microsomal clearance than Ligand B (92.872), suggesting better metabolic stability.
12. **t1/2:** Ligand B (28.644) has a significantly longer in vitro half-life than Ligand A (11.743). This is a substantial advantage.
13. **Pgp:** Ligand A (0.185) exhibits lower P-gp efflux liability than Ligand B (0.714), which is desirable for better oral bioavailability.
14. **Binding Affinity:** Ligand B (-7.5 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.7 kcal/mol). This 0.8 kcal/mol difference is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand B clearly wins on binding affinity and has a much longer half-life. It also demonstrates better solubility and Caco-2 permeability. While Ligand A has slightly better metabolic stability and lower P-gp efflux, the superior affinity and half-life of Ligand B are more critical for a GPCR target like ADRB2. The better solubility of Ligand B is also a significant advantage.
**Output:**
0
2025-04-17 21:50:56,629 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [340.383, 68.84, 2.214, 0, 6, 0.668, 61.574, 52.268, -4.451, -2.58, 0.613, 107.537, -3.489, 0.346, -6.3]
**Ligand B:** [346.471, 69.64, 2.001, 2, 3, 0.765, 15.471, 48.197, -4.953, -3.652, 0.235, 45.286, -2.264, 0.135, -4.1]
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). A (340.383) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are reasonably good (A: 68.84, B: 69.64), well below the 140 threshold for oral absorption.
3. **logP:** Both are within the optimal range (1-3), with A (2.214) being slightly higher than B (2.001).
4. **HBD:** A (0) is better than B (2). Fewer HBDs generally improve permeability.
5. **HBA:** A (6) is better than B (3). Fewer HBAs generally improve permeability.
6. **QED:** Both are acceptable (A: 0.668, B: 0.765), indicating reasonable drug-likeness. B is slightly better.
7. **DILI:** A (61.574) is significantly higher than B (15.471). This is a major concern for Ligand A.
8. **BBB:** A (52.268) is slightly better than B (48.197), but both are not particularly high. For a cardiovascular target, BBB penetration isn't critical, but it's a bonus.
9. **Caco-2:** Both are negative, indicating poor permeability. A (-4.451) is worse than B (-4.953).
10. **Solubility:** Both are negative, indicating poor solubility. B (-3.652) is slightly better than A (-2.58).
11. **hERG:** A (0.613) is higher than B (0.235), indicating a higher risk of hERG inhibition. This is a significant concern for Ligand A.
12. **Cl_mic:** A (107.537) is much higher than B (45.286), indicating faster metabolism and lower metabolic stability. This is a major drawback for Ligand A.
13. **t1/2:** A (-3.489) is worse than B (-2.264), indicating a shorter half-life.
14. **Pgp:** A (0.346) is higher than B (0.135), suggesting greater P-gp efflux and potentially lower bioavailability.
15. **Affinity:** A (-6.3) is significantly better than B (-4.1). This is a substantial advantage for Ligand A.
**GPCR-specific priorities:** For ADRB2 (a GPCR), we prioritize logP, Pgp, TPSA, and affinity. While affinity is crucial, the ADME properties are also very important.
**Overall Assessment:**
Ligand A has a significantly better binding affinity, which is a major plus. However, it suffers from substantially worse DILI risk, hERG inhibition liability, metabolic clearance, and P-gp efflux. Ligand B, while having a weaker binding affinity, presents a much more favorable ADME profile, particularly regarding safety (DILI, hERG) and metabolic stability.
Given the balance, the improved safety and ADME profile of Ligand B outweigh the affinity difference. A strong affinity is useless if the compound is quickly metabolized, toxic, or doesn't reach the target in sufficient concentrations.
Output:
0
2025-04-17 21:50:56,629 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (357.4 and 343.4 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (69.72) is significantly better than Ligand B (100.21). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (1.009) is slightly better than Ligand B (0.566), both are within the optimal range of 1-3, but Ligand B is on the lower end.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (5). Fewer HBAs generally improve permeability.
6. **QED:** Ligand B (0.765) has a slightly better QED score than Ligand A (0.546), indicating a more drug-like profile.
7. **DILI:** Ligand A (31.989) has a much lower DILI risk than Ligand B (55.874). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (69.523) has a better BBB penetration score than Ligand B (45.56). While not a primary concern for a cardiovascular target, it's still a positive attribute.
9. **Caco-2:** Ligand A (-4.671) has a much better Caco-2 permeability than Ligand B (-5.396).
10. **Solubility:** Ligand A (-1.751) is slightly better than Ligand B (-1.923).
11. **hERG:** Both ligands have very low hERG inhibition risk (0.206 and 0.239, respectively). No significant difference.
12. **Cl_mic:** Ligand B (-13.721) has a significantly lower (better) microsomal clearance than Ligand A (-1.564). This suggests better metabolic stability for Ligand B.
13. **t1/2:** Ligand B (-8.895) has a slightly better in vitro half-life than Ligand A (-9.362).
14. **Pgp:** Both ligands have similar Pgp efflux liability (0.021 and 0.004, respectively).
15. **Binding Affinity:** Ligand B (-5.8 kcal/mol) has a significantly stronger binding affinity than Ligand A (-2.5 kcal/mol). This is a substantial advantage, potentially outweighing some ADME concerns.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B has a better affinity, but Ligand A has a better TPSA and logP. The difference in affinity is substantial (3.3 kcal/mol). While Ligand A has better ADME properties overall, the significantly improved binding affinity of Ligand B is a major driver for drug efficacy. The DILI risk for Ligand A is also a strong positive. However, the metabolic stability of Ligand B is much better.
**Overall Assessment:**
The binding affinity difference is substantial. While Ligand A has a better safety profile (DILI) and some ADME advantages, the significantly stronger binding of Ligand B to the ADRB2 receptor is likely to be more critical for achieving a therapeutic effect. The better metabolic stability of Ligand B is also a significant advantage.
Output:
0
2025-04-17 21:50:56,629 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (342.439 Da and 353.463 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (58.64) is significantly better than Ligand B (87.74). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (1.488) is slightly better than Ligand B (0.681), both are within the optimal 1-3 range, but Ligand B is closer to the lower bound which could indicate permeability issues.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (4). Lower HBA generally improves permeability.
6. **QED:** Both ligands (0.608 and 0.705) have good drug-likeness scores, exceeding the 0.5 threshold.
7. **DILI:** Both ligands have similar, low DILI risk (15.626 and 15.2), indicating a low potential for liver injury.
8. **BBB:** Both ligands have similar BBB penetration (52.811 and 50.019). Since ADRB2 is a cardiovascular target, BBB penetration is not a major concern.
9. **Caco-2:** Ligand A (-4.738) is significantly better than Ligand B (-5.121). A less negative value indicates better permeability.
10. **Solubility:** Ligand A (-2.544) is better than Ligand B (-0.862). Better solubility is generally desirable.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.104 and 0.089).
12. **Cl_mic:** Ligand B (8.858) has a lower microsomal clearance than Ligand A (12.824), suggesting better metabolic stability. This is a positive for Ligand B.
13. **t1/2:** Ligand B (10.292) has a significantly longer in vitro half-life than Ligand A (3.509). This is a strong advantage for Ligand B.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.046 and 0.009).
15. **Binding Affinity:** Ligand A (-7.5) has a significantly stronger binding affinity than Ligand B (-6.1). This is a 1.4 kcal/mol difference, which is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand A has a significantly better binding affinity, better TPSA, logP, HBD, HBA, Caco-2 permeability, and solubility. Ligand B has better metabolic stability (lower Cl_mic) and a longer half-life. However, the substantial difference in binding affinity (-7.5 vs -6.1 kcal/mol) is a critical factor for GPCR targets. A stronger binding affinity often translates to greater efficacy and potentially lower doses. The slightly worse metabolic stability of Ligand A can potentially be addressed through further optimization. The better permeability properties of Ligand A are also beneficial.
**Output:**
1
2025-04-17 21:50:56,629 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [362.417, 78.87, 1.133, 2, 4, 0.603, 16.402, 68.282, -4.517, -1.496, 0.484, 19.97, -20.486, 0.037, -6.1]
**Ligand B:** [359.455, 109.04, 3.198, 1, 7, 0.813, 49.128, 82.513, -4.971, -5.134, 0.854, 60.738, 14.593, 0.21, -7.0]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (362.417) is slightly higher, but not significantly.
2. **TPSA:** Ligand A (78.87) is better than Ligand B (109.04). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally aids absorption.
3. **logP:** Ligand A (1.133) is optimal, while Ligand B (3.198) is approaching the upper limit. Higher logP can lead to off-target effects and solubility issues.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1), but both are acceptable.
5. **HBA:** Ligand A (4) is lower than Ligand B (7), which is preferable for permeability.
6. **QED:** Ligand B (0.813) is better than Ligand A (0.603), indicating a more drug-like profile.
7. **DILI:** Ligand A (16.402) has a much lower DILI risk than Ligand B (49.128). This is a significant advantage.
8. **BBB:** Ligand B (82.513) has better BBB penetration than Ligand A (68.282), but as this is a cardiovascular target, this is less critical.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-4.517) is slightly worse than Ligand B (-4.971).
10. **Solubility:** Ligand B (-5.134) has worse solubility than Ligand A (-1.496).
11. **hERG:** Ligand A (0.484) has a lower hERG risk than Ligand B (0.854).
12. **Cl_mic:** Ligand A (19.97) has significantly lower microsomal clearance than Ligand B (60.738), suggesting better metabolic stability.
13. **t1/2:** Ligand B (14.593) has a longer in vitro half-life than Ligand A (-20.486). This is a positive.
14. **Pgp:** Ligand B (0.21) shows lower P-gp efflux than Ligand A (0.037), which is favorable.
15. **Affinity:** Ligand B (-7.0) has a slightly better binding affinity than Ligand A (-6.1), a 0.9 kcal/mol difference.
**GPCR-Specific Priorities:** For ADRB2 (a cardiovascular GPCR), we prioritize logP, TPSA, Pgp, and affinity. Ligand A has better logP and TPSA, while Ligand B has better Pgp and affinity. The affinity difference is not large enough to outweigh the other factors.
**Overall Assessment:**
Ligand A has a superior safety profile (lower DILI, lower hERG), better solubility, and better metabolic stability (lower Cl_mic). While Ligand B has a slightly better affinity and longer half-life, the significant advantages of Ligand A in terms of safety and ADME properties make it the more promising drug candidate. The slightly worse Caco-2 permeability can be addressed with formulation strategies.
Output:
1
2025-04-17 21:50:56,629 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (338.37 Da) is better than Ligand B (362.58 Da). Both are within the ideal range, but A is closer to the lower bound, potentially aiding permeability.
2. **TPSA:** Ligand A (90.45) is better than Ligand B (23.55). For a cardiovascular GPCR, TPSA isn't a huge concern, but lower TPSA generally improves permeability.
3. **logP:** Ligand A (2.068) is better than Ligand B (4.277). Ligand B is pushing the upper limit of the optimal range, increasing the risk of off-target effects and solubility issues.
4. **HBD:** Ligand A (1) is better than Ligand B (0). While both are low, a single HBD can contribute to solubility without significantly hindering permeability.
5. **HBA:** Ligand A (6) is better than Ligand B (3). Both are acceptable, but A has a slightly more balanced profile.
6. **QED:** Ligand A (0.736) is better than Ligand B (0.655). A higher QED suggests a more drug-like profile.
7. **DILI:** Ligand A (89.104) is significantly worse than Ligand B (10.896). This is a major concern for Ligand A. A DILI percentile of nearly 90 is unacceptably high.
8. **BBB:** Ligand A (77.976) is lower than Ligand B (92.943). While ADRB2 isn't primarily a CNS target, higher BBB penetration is generally favorable, minimizing off-target effects.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-4.604) is slightly worse than Ligand B (-4.505).
10. **Solubility:** Ligand A (-3.36) is slightly worse than Ligand B (-4.146). Both are very poor, but B is marginally better.
11. **hERG:** Ligand A (0.323) is better than Ligand B (0.862). Lower hERG inhibition is crucial for cardiovascular drugs.
12. **Cl_mic:** Ligand A (81.054) is better than Ligand B (110.998). Lower clearance indicates better metabolic stability.
13. **t1/2:** Ligand A (21) is worse than Ligand B (40.78). Longer half-life is generally preferred.
14. **Pgp:** Ligand A (0.094) is better than Ligand B (0.201). Lower P-gp efflux is desirable for improved bioavailability.
15. **Affinity:** Ligand A (-7.2) is better than Ligand B (-6.8). This is a significant advantage (0.4 kcal/mol), and can potentially offset some of the ADME liabilities.
**Overall Assessment:**
Ligand A has a significantly better binding affinity and generally better ADME properties (QED, Cl_mic, Pgp, hERG) *except* for the extremely high DILI risk. Ligand B has a much lower DILI risk, but suffers from a higher logP, lower QED, shorter half-life, and weaker binding affinity.
Given the severity of the DILI risk associated with Ligand A, and the importance of avoiding liver toxicity, I would prioritize Ligand B despite its weaker affinity. The 0.4 kcal/mol difference in binding can potentially be addressed through further optimization, but mitigating a high DILI risk is far more challenging.
Output:
0
2025-04-17 21:50:56,629 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands (348.462 and 351.491 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (32.78) is significantly better than Ligand B (78.51). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand B's TPSA is quite high, potentially hindering oral bioavailability.
3. **logP:** Ligand A (3.132) is slightly higher than Ligand B (1.858), both within the optimal 1-3 range. Ligand B is at the lower end, which could affect permeability.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer HBDs generally improve membrane permeability.
5. **HBA:** Both ligands have 3 HBA, which is acceptable.
6. **QED:** Ligand A (0.838) is significantly better than Ligand B (0.466), indicating a more drug-like profile.
7. **DILI:** Ligand A (21.171) has a lower DILI risk than Ligand B (19.038), both are good.
8. **BBB:** Ligand A (93.912) has a much higher BBB penetration percentile than Ligand B (61.691). While not a primary concern for a cardiovascular target, higher BBB is rarely detrimental.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.221 and -4.688), which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
10. **Solubility:** Ligand A (-2.336) is better than Ligand B (-1.773), both are negative, indicating poor solubility.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.948 and 0.199), which is excellent.
12. **Cl_mic:** Ligand A (32.816) has a lower microsomal clearance than Ligand B (41.662), suggesting better metabolic stability.
13. **t1/2:** Ligand A (4.985) has a longer in vitro half-life than Ligand B (-3.996).
14. **Pgp:** Ligand A (0.624) has lower P-gp efflux liability than Ligand B (0.04).
15. **Binding Affinity:** Both ligands have very similar binding affinities (-5.9 and -5.7 kcal/mol). The difference is not substantial enough to override other ADME considerations.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), the key priorities are logP, TPSA, Pgp, and affinity. Ligand A excels in TPSA, Pgp, and has a slightly better logP. While affinity is similar, the superior ADME profile of Ligand A makes it the more promising candidate.
**Conclusion:**
Ligand A consistently outperforms Ligand B across multiple crucial ADME properties, despite both having comparable binding affinity. The lower TPSA, better QED, lower Cl_mic, longer half-life, and lower Pgp efflux of Ligand A make it a significantly more viable drug candidate.
Output:
1
2025-04-17 21:50:56,629 - INFO - Here's my reasoning and final output for the ligand preference:
**Reasoning:**
We are targeting ADRB2, a GPCR, so the key properties are affinity, logP, TPSA, Pgp efflux, and BBB penetration. Let's compare Ligand A and Ligand B across these and other important parameters.
* **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (376.513) is slightly higher than Ligand B (348.455), but both are acceptable.
* **TPSA:** Ligand A (49.41) is significantly better than Ligand B (95.57). A TPSA under 140 is good for oral absorption, and lower is generally preferred for GPCRs. Ligand B's TPSA is relatively high, potentially hindering absorption.
* **logP:** Ligand A (3.166) is within the optimal range (1-3), while Ligand B (1.504) is at the lower end. While not terrible, lower logP can sometimes indicate poor membrane permeability.
* **H-Bond Donors/Acceptors:** Both have acceptable numbers of HBD (1) and Ligand A has 3 HBA, while Ligand B has 9. Ligand B's higher HBA count could contribute to lower permeability.
* **QED:** Both ligands have similar QED values (0.742 and 0.695), indicating good drug-likeness.
* **DILI:** Ligand B (41.877) has a slightly higher DILI risk than Ligand A (22.838), but both are reasonably low.
* **BBB:** Ligand A (96.355) shows excellent BBB penetration, while Ligand B (73.905) is lower. This is a significant advantage for Ligand A, given it's a GPCR.
* **Caco-2:** Both have negative Caco-2 values, which is unusual. I will interpret this as very low permeability.
* **Solubility:** Ligand A (-3.611) has worse solubility than Ligand B (-1.856).
* **hERG:** Both ligands have very low hERG inhibition risk (0.772 and 0.131).
* **Cl_mic:** Ligand A (42.801) has a higher microsomal clearance than Ligand B (20.453), suggesting lower metabolic stability.
* **t1/2:** Ligand B (17.822) has a significantly longer in vitro half-life than Ligand A (-5.165).
* **Pgp:** Ligand A (0.162) has lower P-gp efflux liability than Ligand B (0.05), which is favorable.
* **Binding Affinity:** Both ligands have very similar and excellent binding affinities (-6.0 and -5.2 kcal/mol). The difference is not substantial enough to outweigh other considerations.
**Overall Assessment:**
Ligand A is the preferred candidate. While it has slightly higher MW and Cl_mic, and lower solubility, its superior TPSA, BBB penetration, and Pgp properties are crucial for a GPCR target like ADRB2. The comparable binding affinity seals the deal. Ligand B's high TPSA and lower BBB penetration are significant drawbacks.
**Output:**
1
2025-04-17 21:50:56,629 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.381 and 353.463 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (55.57) is significantly better than Ligand B (78.95). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (4.005) is slightly higher than the optimal range (1-3), but still acceptable. Ligand B (0.433) is *well* below the optimal range and could lead to poor membrane permeability. This is a significant negative for Ligand B.
4. **HBD:** Ligand A (0) is preferable to Ligand B (1). Fewer hydrogen bond donors generally improve permeability.
5. **HBA:** Ligand A (4) is better than Ligand B (5). Lower HBA is generally preferred for better permeability.
6. **QED:** Ligand A (0.72) is considerably better than Ligand B (0.455), indicating a more drug-like profile.
7. **DILI:** Ligand A (40.636) is slightly higher than Ligand B (20.163), but both are within an acceptable range (<60). Ligand B has a clear advantage here.
8. **BBB:** This is less critical for a cardiovascular target, but Ligand A (84.374) is better than Ligand B (74.06).
9. **Caco-2:** Both are negative, suggesting poor permeability, but Ligand A (-4.202) is slightly better than Ligand B (-4.794).
10. **Solubility:** Ligand A (-4.51) is better than Ligand B (-0.799). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.639) is better than Ligand B (0.33). Lower hERG inhibition is crucial for avoiding cardiotoxicity, especially for a cardiovascular target.
12. **Cl_mic:** Ligand A (59.429) is higher than Ligand B (30.689), meaning faster clearance and lower metabolic stability. Ligand B is preferable here.
13. **t1/2:** Ligand B (-22.836) is *much* better than Ligand A (-4.742), indicating a significantly longer half-life. This is a major advantage for Ligand B.
14. **Pgp:** Ligand A (0.22) is better than Ligand B (0.027). Lower P-gp efflux is generally desirable.
15. **Binding Affinity:** Both ligands have excellent binding affinity (-7.7 and -7.8 kcal/mol), with Ligand B being slightly better. This difference is unlikely to outweigh other factors.
**Overall Assessment:**
Ligand A has a better overall profile regarding drug-likeness (QED, TPSA, logP, HBD/HBA, solubility, hERG, Pgp) and is generally more favorable for absorption. However, Ligand B has a substantially better half-life and lower microsomal clearance, which are important for *in vivo* exposure. The DILI risk is also lower for Ligand B. While Ligand A's logP is slightly high, Ligand B's is very low, which is a significant concern for permeability. Considering the balance, and the importance of metabolic stability and half-life for a cardiovascular drug, Ligand B is the slightly more promising candidate.
Output:
0
2025-04-17 21:50:56,629 - INFO - Batch 288 complete. Total preferences: 4608
2025-04-17 21:50:56,629 - INFO - Processing batch 289/512...
2025-04-17 21:51:45,009 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (358-369 Da). No significant difference.
2. **TPSA:** Ligand B (91.57) is significantly better than Ligand A (138.13). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally improves absorption.
3. **logP:** Ligand B (2.841) is optimal, while Ligand A (0.288) is quite low, potentially hindering membrane permeability. This is a significant advantage for B.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally lead to better permeability.
5. **HBA:** Ligand A (6) is preferable to Ligand B (5).
6. **QED:** Both ligands have good QED scores (A: 0.594, B: 0.654), indicating good drug-like properties. B is slightly better.
7. **DILI:** Ligand B (81.504) has a lower DILI risk than Ligand A (93.37), which is a clear advantage.
8. **BBB:** Ligand B (53.044) has a higher BBB penetration than Ligand A (25.475). While not a primary concern for a cardiovascular target, it's a positive attribute.
9. **Caco-2:** Both are negative, indicating poor permeability.
10. **Solubility:** Both are negative, indicating poor solubility.
11. **hERG:** Ligand A (0.036) has a much lower hERG risk than Ligand B (0.675). This is a critical advantage for A.
12. **Cl_mic:** Ligand A (21.361) has a significantly lower microsomal clearance than Ligand B (52.378), suggesting better metabolic stability.
13. **t1/2:** Ligand B (104.781) has a much longer in vitro half-life than Ligand A (-20.575), which is a substantial advantage.
14. **Pgp:** Ligand A (0.04) has a lower P-gp efflux liability than Ligand B (0.585), indicating better bioavailability.
15. **Affinity:** Ligand B (-6.5 kcal/mol) has a slightly better binding affinity than Ligand A (-6.8 kcal/mol). While A is slightly better, the difference is small.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand B excels in logP and has comparable affinity. While Ligand A has a better TPSA, the low logP is a significant concern. The longer half-life of Ligand B is also a major benefit. The lower hERG risk of Ligand A is important, but can be mitigated through structural modifications.
**Overall Assessment:**
Ligand B presents a more balanced profile, particularly regarding permeability (logP) and metabolic stability (t1/2). While Ligand A has a lower hERG risk and better Pgp profile, the significantly lower logP and higher clearance are major drawbacks. The slightly better affinity of Ligand B, combined with its other favorable properties, makes it the more promising candidate.
Output:
0
2025-04-17 21:51:45,009 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (363.8 and 364.4 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (58.56) is significantly better than Ligand B (134.38). ADRB2 is a cardiovascular target, not CNS, but lower TPSA generally improves absorption. Ligand A is well below the 140 threshold, while Ligand B is approaching it.
3. **logP:** Ligand A (3.894) is optimal, while Ligand B (0.46) is quite low. This is a major concern for Ligand B, as it may struggle with membrane permeability.
4. **HBD:** Both ligands have 2 HBD, which is acceptable.
5. **HBA:** Ligand A has 3 HBA, and Ligand B has 9. Ligand B is higher and could potentially impact permeability.
6. **QED:** Ligand A (0.817) is better than Ligand B (0.557), indicating a more drug-like profile.
7. **DILI:** Ligand B (77.239) has a higher DILI risk than Ligand A (59.791), though both are reasonably acceptable.
8. **BBB:** Not a primary concern for a cardiovascular target, but Ligand A (62.233) is better than Ligand B (32.803).
9. **Caco-2:** Ligand A (-4.982) and Ligand B (-5.503) are similar, indicating comparable intestinal absorption potential.
10. **Solubility:** Ligand A (-3.905) is slightly better than Ligand B (-3.438), but both are poor.
11. **hERG:** Both ligands have similar hERG inhibition liability (0.333 and 0.354), which is acceptable.
12. **Cl_mic:** Ligand A (10.5) has much lower microsomal clearance than Ligand B (-0.895), indicating better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand A (15.555) has a much longer in vitro half-life than Ligand B (37.224), which is highly desirable.
14. **Pgp:** Both ligands have low Pgp efflux (0.187 and 0.036), which is good.
15. **Binding Affinity:** Both ligands have identical binding affinity (-6.9 kcal/mol), so this parameter doesn't differentiate them.
**Overall Assessment:**
Ligand A is significantly superior to Ligand B. While both have good binding affinity, Ligand A excels in crucial ADME properties: TPSA, logP, QED, metabolic stability (Cl_mic), and half-life. Ligand B's low logP and high HBA are major drawbacks that could severely limit its bioavailability and efficacy. Although Ligand A's solubility is not ideal, it is better than Ligand B's, and the other advantages outweigh this concern.
Output:
1
2025-04-17 21:51:45,010 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (343.431 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both ligands are below the 140 A^2 threshold for good oral absorption (A: 95.06, B: 92.85). This is good.
3. **logP:** Both ligands fall within the optimal range (1-3), but Ligand B (2.578) is higher than Ligand A (1.318). Higher logP can sometimes lead to off-target effects, but is often acceptable for GPCRs.
4. **HBD:** Both have 2 HBD, which is within the desirable limit of 5.
5. **HBA:** Ligand A (6) is better than Ligand B (9), staying further below the 10 limit.
6. **QED:** Both are good (A: 0.79, B: 0.71), indicating good drug-like properties.
7. **DILI:** Ligand A (62.195) has a significantly better DILI score than Ligand B (77.356), indicating lower potential for liver injury. This is a major advantage.
8. **BBB:** Both have similar BBB penetration (A: 64.25, B: 64.56). While not exceptionally high, it's not a primary concern for ADRB2, which is not a CNS target.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Both have negative solubility values, suggesting poor solubility. Again, the scale is unknown.
11. **hERG:** Ligand A (0.38) has a much lower hERG inhibition liability than Ligand B (0.633), a significant safety advantage.
12. **Cl_mic:** Ligand A (10.485) has a much lower microsomal clearance than Ligand B (42.202), indicating better metabolic stability.
13. **t1/2:** Ligand A (18.046 hours) has a significantly longer in vitro half-life than Ligand B (4.77 hours), which is highly desirable.
14. **Pgp:** Ligand A (0.213) has lower P-gp efflux liability than Ligand B (0.148).
15. **Binding Affinity:** Ligand B (-5.9 kcal/mol) has a slightly better binding affinity than Ligand A (-6.9 kcal/mol). While this is a positive for Ligand B, the difference is not substantial enough to overcome the other significant advantages of Ligand A.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand B has a slightly better logP and affinity, but Ligand A is better in TPSA and Pgp. The substantial advantages of Ligand A in DILI, hERG, Cl_mic, and t1/2 outweigh the minor advantage in binding affinity of Ligand B.
**Conclusion:**
Ligand A demonstrates a significantly more favorable overall profile, particularly regarding safety (DILI, hERG) and pharmacokinetic properties (Cl_mic, t1/2).
Output:
1
2025-04-17 21:51:45,010 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (364.486 and 349.475 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (49.41) is significantly better than Ligand B (69.72). For a GPCR, keeping TPSA low is beneficial for permeability, and A is well under the 90 A^2 threshold.
3. **logP:** Both ligands have good logP values (2.007 and 1.566), falling within the optimal 1-3 range. Ligand A is slightly higher, which could be a minor advantage.
4. **HBD:** Both have 1 HBD, which is ideal.
5. **HBA:** Both have 3 HBA, which is also ideal.
6. **QED:** Ligand A (0.78) has a better QED score than Ligand B (0.56), indicating a more drug-like profile.
7. **DILI:** Ligand A (27.22) has a slightly higher DILI risk than Ligand B (14.618), but both are well below the concerning threshold of 60.
8. **BBB:** Ligand A (86.119) has a better BBB penetration score than Ligand B (71.229). While ADRB2 isn't strictly a CNS target, some peripheral ADRB2 receptors can be affected by CNS penetration, and higher BBB is generally favorable.
9. **Caco-2:** Ligand A (-5.067) and Ligand B (-4.874) are both negative, indicating poor permeability. This is a concern for both, but the values are similar.
10. **Solubility:** Ligand A (-3.302) has slightly worse solubility than Ligand B (-1.838). Solubility is important for bioavailability.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.431 and 0.27), which is excellent.
12. **Cl_mic:** Ligand A (26.083) has significantly lower microsomal clearance than Ligand B (56.43). Lower clearance indicates better metabolic stability, a crucial factor for drug duration.
13. **t1/2:** Ligand A (-6.9) has a much longer in vitro half-life than Ligand B (-14.682). This is a significant advantage, suggesting less frequent dosing potential.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.133 and 0.091).
15. **Binding Affinity:** Ligand A (-7.5) has a significantly stronger binding affinity than Ligand B (-6.2). This >1.5 kcal/mol difference is a major advantage, potentially outweighing some of the ADME drawbacks.
**Overall Assessment:**
Ligand A is the stronger candidate. While Ligand B has slightly better solubility and DILI risk, Ligand A excels in crucial areas: significantly better binding affinity, metabolic stability (lower Cl_mic), longer half-life, better BBB penetration, and a superior QED score. The TPSA is also better for Ligand A. The Caco-2 permeability is poor for both, but the potency and metabolic properties of Ligand A make it more likely to succeed despite this.
Output:
1
2025-04-17 21:51:45,010 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (361.431 and 346.431 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (88.53) is significantly better than Ligand A (119.03). ADRB2 is a GPCR, and lower TPSA generally favors better permeability.
3. **logP:** Ligand B (2.154) is optimal, while Ligand A (0.233) is quite low, potentially hindering membrane permeability. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (2) is preferable to Ligand B (3), but both are acceptable.
5. **HBA:** Ligand A (8) is preferable to Ligand B (7), but both are acceptable.
6. **QED:** Ligand A (0.787) is better than Ligand B (0.607), indicating a more drug-like profile.
7. **DILI:** Ligand B (22.14) is *much* better than Ligand A (62.001). Lower DILI risk is crucial.
8. **BBB:** Ligand A (70.88) is better than Ligand B (47.15), but BBB isn't a top priority for ADRB2 (a cardiovascular target).
9. **Caco-2:** Ligand A (-5.389) is better than Ligand B (-4.985), suggesting better intestinal absorption.
10. **Solubility:** Ligand A (-3.216) is better than Ligand B (-3.169), but both are poor.
11. **hERG:** Ligand B (0.761) is better than Ligand A (0.294), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand A (-5.209) is *much* better than Ligand B (43.176). Lower clearance means greater metabolic stability.
13. **t1/2:** Ligand A (6.263) is better than Ligand B (1.951), indicating a longer half-life.
14. **Pgp:** Ligand A (0.043) is better than Ligand B (0.056), indicating less P-gp efflux.
15. **Affinity:** Ligand A (-6.6) is better than Ligand B (-5.6), a difference of 1.0 kcal/mol. This is a substantial difference in binding potency.
**Overall Assessment:**
While Ligand A has better affinity, half-life, and Caco-2 permeability, Ligand B demonstrates a significantly better safety profile (DILI, hERG) and more favorable physicochemical properties (logP, TPSA). The low logP of Ligand A is a major concern, potentially leading to poor permeability despite the lower TPSA. The substantial difference in DILI risk also heavily favors Ligand B. The affinity difference, while notable, can potentially be optimized in later stages of drug development. Given the GPCR-specific priorities (logP, TPSA, affinity) and the importance of safety, Ligand B is the more promising candidate.
Output:
0
2025-04-17 21:51:45,010 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (342.399 Da and 357.397 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (80.37) is better than Ligand B (48). Both are below the 140 threshold for oral absorption, but for a GPCR, lower TPSA is generally preferred, making Ligand B slightly more favorable.
**3. logP:** Ligand A (1.774) is within the optimal 1-3 range. Ligand B (3.003) is at the higher end, but still acceptable.
**4. H-Bond Donors:** Ligand A has 1 HBD, while Ligand B has 0. Both are good.
**5. H-Bond Acceptors:** Ligand A has 5 HBA, and Ligand B has 4. Both are within the acceptable limit of 10.
**6. QED:** Ligand A (0.793) has a better QED score than Ligand B (0.682), indicating a more drug-like profile.
**7. DILI:** Ligand A (48.313) has a slightly higher DILI risk than Ligand B (36.177), but both are below the concerning threshold of 60.
**8. BBB:** Ligand B (90.035) has a significantly higher BBB penetration percentile than Ligand A (68.554). While ADRB2 is a cardiovascular target and CNS penetration isn't *essential*, some level of BBB penetration can be beneficial for off-target effects and overall distribution.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the values are close (-4.94 for A, -4.455 for B), so this isn't a major differentiator.
**10. Aqueous Solubility:** Both ligands have negative solubility values, indicating poor solubility. This is a significant concern for both.
**11. hERG Inhibition:** Ligand A (0.151) has a much lower hERG inhibition liability than Ligand B (0.816). This is a critical advantage for Ligand A, minimizing cardiotoxicity risk.
**12. Microsomal Clearance:** Ligand B (75.647) has a higher microsomal clearance than Ligand A (40.928), indicating faster metabolism and potentially lower *in vivo* exposure.
**13. In vitro Half-Life:** Ligand A (-8.893) has a much longer in vitro half-life than Ligand B (4.092), which is a substantial benefit.
**14. P-gp Efflux:** Ligand A (0.096) has lower P-gp efflux liability than Ligand B (0.375), which is favorable for bioavailability.
**15. Binding Affinity:** Ligand A (-7.4 kcal/mol) has a slightly better binding affinity than Ligand B (-7.2 kcal/mol). While the difference isn't huge, it's enough to consider.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity) and the general drug-like properties, Ligand A emerges as the more promising candidate. The significantly lower hERG risk and longer half-life are major advantages. While Ligand B has better BBB penetration and a slightly lower TPSA, the safety and PK/PD benefits of Ligand A outweigh these factors. The solubility issues are a concern for both, but can be addressed through formulation strategies.
Output:
1
2025-04-17 21:51:45,010 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.475 and 351.407 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (69.72) is well below the 140 threshold and excellent for oral absorption. Ligand B (102.06) is still acceptable but less optimal. This favors Ligand A.
3. **logP:** Ligand A (1.4) is within the optimal 1-3 range. Ligand B (-1.547) is slightly below 1, potentially causing permeability issues. This favors Ligand A.
4. **HBD:** Both ligands have acceptable HBD counts (1 and 2 respectively), well below the 5 threshold.
5. **HBA:** Both ligands have acceptable HBA counts (3 and 4 respectively), well below the 10 threshold.
6. **QED:** Both ligands have similar QED values (0.674 and 0.605), indicating good drug-likeness.
7. **DILI:** Ligand A (9.539) has a much lower DILI risk than Ligand B (29.042). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (76.192) has better BBB penetration than Ligand B (56.572). While ADRB2 isn't exclusively a CNS target, some cardiovascular effects are mediated by central pathways, so moderate BBB penetration is a plus.
9. **Caco-2:** Ligand A (-4.895) and Ligand B (-5.099) have similar Caco-2 permeability values.
10. **Solubility:** Ligand A (-1.977) has slightly better solubility than Ligand B (-1.246).
11. **hERG:** Both ligands have very low hERG inhibition risk (0.319 and 0.085).
12. **Cl_mic:** Ligand B (-9.761) has a significantly *lower* (better) microsomal clearance than Ligand A (36.533), suggesting greater metabolic stability. This is a strong advantage for Ligand B.
13. **t1/2:** Ligand B (5.721) has a longer in vitro half-life than Ligand A (-14.212). This is a significant advantage for Ligand B.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.041 and 0.001).
15. **Binding Affinity:** Ligand B (-7.0) has a slightly better binding affinity than Ligand A (-6.4). This 0.6 kcal/mol difference is significant, and can outweigh some ADME drawbacks.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A has advantages in logP, TPSA, and moderate BBB penetration. However, Ligand B has a superior binding affinity and better metabolic stability (Cl_mic, t1/2). The affinity difference is substantial enough to offset the slightly less favorable TPSA and logP.
**Overall Assessment:**
While Ligand A has several favorable properties (lower DILI, better TPSA, logP, and BBB), Ligand B's significantly stronger binding affinity and improved metabolic stability are more critical for a successful GPCR drug candidate. The improved half-life and lower clearance are also important factors.
Output:
0
2025-04-17 21:51:45,010 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (351.447 and 346.402 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (89.95) is better than Ligand B (58.64). Both are below 140, but Ligand B is significantly lower, which is favorable for GPCRs.
3. **logP:** Ligand B (2.766) is within the optimal 1-3 range, while Ligand A (0.123) is quite low. This is a significant advantage for Ligand B, as low logP can hinder membrane permeability.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1), but both are acceptable.
5. **HBA:** Ligand A (4) is slightly higher than Ligand B (3), but both are acceptable.
6. **QED:** Both ligands have good QED scores (0.711 and 0.806), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand B (44.048) has a much lower DILI risk than Ligand A (8.026), which is a critical advantage.
8. **BBB:** Ligand B (73.129) shows better BBB penetration than Ligand A (46.491). While ADRB2 isn't exclusively a CNS target, some cardiovascular effects are mediated by central pathways, and better BBB penetration can be beneficial.
9. **Caco-2:** Ligand A (-5.094) is better than Ligand B (-4.406), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-1.171) is better than Ligand B (-3.239), indicating better aqueous solubility.
11. **hERG:** Both ligands have low hERG inhibition risk (0.144 and 0.601). Ligand B is slightly higher, but still acceptable.
12. **Cl_mic:** Ligand A (-17.845) has a much lower (better) microsomal clearance than Ligand B (35.557), indicating greater metabolic stability.
13. **t1/2:** Ligand A (5.984) has a shorter half-life than Ligand B (-15.902). This is a disadvantage for Ligand A.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.007 and 0.207).
15. **Binding Affinity:** Ligand B (-6.5) has a slightly better binding affinity than Ligand A (-6.0). While the difference is small, it's still a positive for Ligand B.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP and has a better BBB score. The slightly better affinity of Ligand B, combined with its lower DILI risk and better metabolic profile (lower Pgp efflux) makes it a more promising candidate. While Ligand A has better Caco-2 and solubility, the logP and DILI concerns are more significant.
**Conclusion:**
Considering the balance of properties and the priorities for a GPCR target, Ligand B is the more viable drug candidate.
Output:
0
2025-04-17 21:51:45,010 - INFO - Here's my reasoning and the final output:
**Reasoning:**
We are evaluating two ligands for their potential as drug candidates targeting the ADRB2, a cardiovascular GPCR. Therefore, we prioritize logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB.
Let's break down the comparison:
1. **MW:** Both ligands (348.403 and 349.475 Da) fall within the ideal 200-500 Da range.
2. **TPSA:** Ligand B (53.09) is significantly better than Ligand A (93.65). Lower TPSA generally improves permeability, a key factor for GPCR ligands.
3. **logP:** Both are reasonable (0.656 and 0.814), falling within the 1-3 range. Ligand B is slightly better.
4. **HBD/HBA:** Ligand A has 1 HBD and 6 HBA, while Ligand B has 0 HBD and 4 HBA. Both are acceptable.
5. **QED:** Both ligands have similar QED scores (0.759 and 0.757), indicating good drug-likeness.
6. **DILI:** Ligand B (7.871) has a much lower DILI risk than Ligand A (64.521). This is a significant advantage.
7. **BBB:** Ligand B (71.888) has a better BBB percentile than Ligand A (61.225), though neither is exceptionally high. For a cardiovascular target, BBB isn't *critical*, but it's a plus.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the values are close enough that this isn't a major differentiator.
9. **Solubility:** Both have negative solubility values, indicating poor aqueous solubility. Ligand B (-0.887) is slightly better than Ligand A (-1.803).
10. **hERG:** Both have low hERG inhibition risk (0.269 and 0.473).
11. **Cl_mic:** Ligand B (10.928) has a lower microsomal clearance than Ligand A (33.237), suggesting better metabolic stability.
12. **t1/2:** Ligand B (-9.125) has a slightly longer in vitro half-life than Ligand A (-13.012).
13. **Pgp:** Both have very low Pgp efflux liability (0.018 and 0.023).
14. **Binding Affinity:** Ligand A (-6.8 kcal/mol) has a slightly better binding affinity than Ligand B (-6.1 kcal/mol). This is a 0.7 kcal/mol difference, which is noticeable but not overwhelming.
**Overall Assessment:**
Ligand B consistently outperforms Ligand A in several crucial ADME properties (DILI, TPSA, Cl_mic, solubility, BBB) and has a comparable binding affinity. While Ligand A has a slightly better binding affinity, the superior ADME profile of Ligand B, particularly the significantly lower DILI risk and improved TPSA, makes it the more promising drug candidate. The lower TPSA and improved metabolic stability are particularly important for a GPCR target.
**Output:**
0
2025-04-17 21:51:45,011 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (358.479 and 350.459 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (99.1) is slightly higher than Ligand B (78.87). While both are reasonably good, Ligand B is better positioned for oral absorption given the GPCR target class.
3. **logP:** Both ligands have acceptable logP values (0.821 and 0.929), falling within the 1-3 range. Ligand B is slightly better.
4. **HBD:** Ligand A has 3 HBD, and Ligand B has 2. Both are within the acceptable limit of 5.
5. **HBA:** Ligand A has 5 HBA, and Ligand B has 4. Both are within the acceptable limit of 10.
6. **QED:** Both ligands have good QED scores (0.567 and 0.638), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (8.841) has a slightly higher DILI risk than Ligand B (6.359), but both are below the 40 threshold and considered low risk.
8. **BBB:** Both ligands have low BBB penetration (42.962 and 40.791). Since ADRB2 is a cardiovascular target, BBB penetration is not a primary concern, but it's not a benefit either.
9. **Caco-2:** Both ligands have negative Caco-2 permeability values (-4.954 and -4.61). This is unusual and suggests poor permeability.
10. **Solubility:** Both ligands have negative solubility values (-0.914 and -1.212). This is also concerning and suggests poor aqueous solubility.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.158). This is excellent.
12. **Cl_mic:** Ligand B (2.925) has significantly lower microsomal clearance than Ligand A (16.571), indicating better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand B (-4.566) has a better in vitro half-life than Ligand A (-7.856).
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.024 and 0.021). This is good.
15. **Binding Affinity:** Ligand A (-6.3 kcal/mol) has a slightly better binding affinity than Ligand B (-6.0 kcal/mol). However, the difference is less than 1.5 kcal/mol, so it's not a decisive factor.
**Overall Assessment:**
While Ligand A has slightly better binding affinity, Ligand B demonstrates a superior ADME profile. Specifically, its lower microsomal clearance and better half-life are crucial for *in vivo* efficacy. The slightly better QED and lower DILI risk also contribute to its favorability. The negative Caco-2 and solubility values are concerning for both, but the improved metabolic stability of Ligand B is more valuable for a GPCR target.
Output:
0
2025-04-17 21:51:45,011 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (409.236 Da) is within the ideal range, while Ligand B (348.491 Da) is slightly below, but still acceptable.
2. **TPSA:** Ligand A (92.91) is acceptable, but approaching the upper limit for good oral absorption. Ligand B (67.23) is excellent, well below the 140 threshold.
3. **logP:** Both ligands have good logP values (A: 3.273, B: 2.603) within the optimal 1-3 range.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 5 HBA, and Ligand B has 4 HBA, both are acceptable.
6. **QED:** Both ligands have good QED scores (A: 0.584, B: 0.707), indicating drug-likeness. Ligand B is slightly better.
7. **DILI:** Ligand A (66.421) has a moderate DILI risk, while Ligand B (28.306) has a low DILI risk. This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (53.005) has moderate BBB penetration, while Ligand B (78.209) has good BBB penetration. For a cardiovascular target like ADRB2, BBB penetration isn't *critical* but can be beneficial for off-target effects.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it is difficult to interpret.
10. **Solubility:** Both have negative solubility values, which is also unusual and suggests poor solubility. Again, the scale is not specified.
11. **hERG:** Both ligands have low hERG inhibition risk (A: 0.586, B: 0.627).
12. **Cl_mic:** Both have similar microsomal clearance (A: 74.007, B: 73.887).
13. **t1/2:** Ligand B (-5.449) has a better (longer) in vitro half-life than Ligand A (-10.134).
14. **Pgp:** Both have low Pgp efflux liability (A: 0.473, B: 0.201). Ligand B is better.
15. **Affinity:** Ligand A (-7.1 kcal/mol) has a slightly better binding affinity than Ligand B (-5.5 kcal/mol). This is a 1.6 kcal/mol difference, which is significant.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are important. Ligand A has a slightly better affinity, but Ligand B excels in TPSA, Pgp, and has a significantly better DILI score. The difference in affinity, while present, might be outweighed by the improved safety profile and potentially better absorption (lower TPSA) of Ligand B.
**Conclusion:**
Despite Ligand A's slightly better binding affinity, Ligand B presents a more favorable overall profile, particularly regarding safety (DILI) and potentially absorption (TPSA, Pgp). The better half-life is also a plus. Therefore, I would choose Ligand B.
Output:
0
2025-04-17 21:51:45,011 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (371.853 Da and 379.507 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (80.66) is better than Ligand B (102.15). For a cardiovascular GPCR, keeping TPSA lower is beneficial for permeability, although both are reasonably acceptable.
**3. logP:** Ligand A (3.561) is slightly higher than Ligand B (2.209), placing it closer to the optimal 1-3 range. Ligand B is still within range, but a bit lower.
**4. H-Bond Donors:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
**5. H-Bond Acceptors:** Both ligands have 6 HBA, which is acceptable.
**6. QED:** Ligand B (0.829) has a higher QED score than Ligand A (0.69), indicating a more generally drug-like profile. This is a positive for Ligand B.
**7. DILI Risk:** Both ligands have similar DILI risk (Ligand A: 88.6, Ligand B: 82.59), and both are reasonably high. This is a concern for both, but not a deciding factor between them.
**8. BBB Penetration:** Both ligands have similar BBB penetration (Ligand A: 62.97, Ligand B: 62.156). Since this is a cardiovascular target, BBB penetration is not a high priority, so this is not a major differentiating factor.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-5.285 and -5.209), which is unusual and suggests poor permeability. This is a significant concern for both.
**10. Aqueous Solubility:** Both ligands have negative solubility values (-3.661 and -2.923), indicating very poor aqueous solubility. This is a major drawback for both.
**11. hERG Inhibition:** Ligand A (0.145) has a much lower hERG inhibition risk than Ligand B (0.361). This is a significant advantage for Ligand A, as hERG inhibition can lead to cardiotoxicity.
**12. Microsomal Clearance:** Ligand A (52.878) has a significantly lower microsomal clearance than Ligand B (10.697), suggesting better metabolic stability. This is a positive for Ligand A.
**13. In vitro Half-Life:** Ligand A (27.166) has a longer in vitro half-life than Ligand B (8.051), which is desirable.
**14. P-gp Efflux:** Ligand A (0.12) has lower P-gp efflux than Ligand B (0.332), which is preferable for bioavailability.
**15. Binding Affinity:** Ligand A (-6.8 kcal/mol) has a slightly better binding affinity than Ligand B (-6.4 kcal/mol). While the difference is not huge, it is enough to be considered.
**Overall Assessment:**
Despite Ligand B having a slightly better QED score, Ligand A is the more promising candidate. Ligand A demonstrates superior ADME properties, including lower hERG inhibition, lower microsomal clearance, longer half-life, and lower P-gp efflux. The slightly better binding affinity of Ligand A further supports this conclusion. While both ligands have poor solubility and permeability, Ligand A's other advantages outweigh this drawback.
Output:
1
2025-04-17 21:51:45,011 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [348.403, 117.67 , -0.146, 3. , 5. , 0.604, 15.781, 62.078,
-6.082, -2.361, 0.185, -14.61 , 23.508, 0.003, -7.1 ]
**Ligand B:** [352.479, 69.48 , 2.276, 0. , 6. , 0.682, 47.421, 77.588,
-4.506, -2.317, 0.725, 62.744, 15.633, 0.203, -6.3 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). A (348.4) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** A (117.67) is higher than B (69.48). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is still preferred for permeability. B is significantly better here.
3. **logP:** A (-0.146) is quite low, potentially hindering membrane permeability. B (2.276) is within the optimal range (1-3). This is a significant advantage for B.
4. **HBD:** A (3) is reasonable. B (0) is even better, reducing potential for off-target interactions and improving permeability.
5. **HBA:** Both A (5) and B (6) are acceptable, below the limit of 10.
6. **QED:** Both are good (A: 0.604, B: 0.682), indicating drug-like properties. B is slightly better.
7. **DILI:** A (15.781) is better than B (47.421). Lower DILI risk is crucial.
8. **BBB:** A (62.078) is lower than B (77.588). While ADRB2 isn't a CNS target, some distribution to the CNS is possible, making B slightly preferable.
9. **Caco-2:** A (-6.082) is very poor, indicating very low intestinal absorption. B (-4.506) is also poor, but better than A.
10. **Solubility:** Both are very poor (-2.361 and -2.317). This is a major concern for both, but might be addressable with formulation strategies.
11. **hERG:** A (0.185) is better than B (0.725), indicating lower cardiotoxicity risk. This is critical for a cardiovascular target.
12. **Cl_mic:** A (-14.61) is much better than B (62.744), meaning A is more metabolically stable.
13. **t1/2:** A (23.508) is better than B (15.633), indicating a longer half-life.
14. **Pgp:** A (0.003) is much better than B (0.203), meaning A is less prone to efflux.
15. **Affinity:** A (-7.1) is better than B (-6.3), a significant advantage in binding potency.
**Overall Assessment:**
Ligand A has a better binding affinity, metabolic stability, half-life, Pgp efflux, and DILI risk. However, Ligand B has a much better logP and TPSA, and a better BBB score. Both have poor solubility and Caco-2 permeability. The affinity difference between A and B is substantial (0.8 kcal/mol), and for a GPCR, potency is paramount. The slightly better logP of B is outweighed by the significant potency advantage of A. The poor solubility and Caco-2 values are concerning for both, but formulation strategies can potentially mitigate these issues. The lower DILI risk of A is also a significant advantage.
Therefore, I would choose Ligand A.
Output:
1
2025-04-17 21:51:45,011 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates, following the provided guidelines.
**Ligand A:** [342.403, 85.05, 1.235, 1, 6, 0.782, 59.829, 68.554, -4.864, -2.889, 0.145, 43.584, 16.631, 0.124, 1.3]
**Ligand B:** [356.438, 70.08, 1.116, 1, 4, 0.823, 30.826, 78.945, -4.466, -0.905, 0.39, 4.738, 15.292, 0.051, -6]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (342.4) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (85.05) is slightly higher than Ligand B (70.08). Both are below the 140 threshold for oral absorption, but B is better.
3. **logP:** Both are optimal (around 1.1-1.2). No significant difference here.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 6 HBA, while Ligand B has 4. Ligand B is better here.
6. **QED:** Both are good (>0.5), with Ligand B (0.823) being slightly better.
7. **DILI:** Ligand A (59.829) has a higher DILI risk than Ligand B (30.826). This is a significant advantage for Ligand B.
8. **BBB:** Ligand B (78.945) has a better BBB penetration score than Ligand A (68.554). This is important for a GPCR, even a cardiovascular one, as some CNS off-target effects are possible.
9. **Caco-2:** Both have negative values, indicating poor permeability. Ligand A (-4.864) is worse than Ligand B (-4.466).
10. **Solubility:** Ligand B (-0.905) has better solubility than Ligand A (-2.889).
11. **hERG:** Ligand A (0.145) has a slightly lower hERG risk than Ligand B (0.39), but both are relatively low.
12. **Cl_mic:** Ligand B (4.738) has significantly lower microsomal clearance than Ligand A (43.584), indicating better metabolic stability.
13. **t1/2:** Ligand A (16.631) has a slightly longer in vitro half-life than Ligand B (15.292).
14. **Pgp:** Ligand B (0.051) has much lower P-gp efflux liability than Ligand A (0.124). This is a crucial advantage for bioavailability.
15. **Affinity:** Ligand B (-6 kcal/mol) has a significantly stronger binding affinity than Ligand A (-1.3 kcal/mol). This is a *major* advantage, easily outweighing minor ADME concerns.
**Overall Assessment:**
Ligand B is clearly the superior candidate. While Ligand A has a slightly better half-life, Ligand B excels in almost every other critical parameter. The significantly stronger binding affinity, lower DILI risk, better BBB penetration, improved solubility, lower P-gp efflux, and better metabolic stability make it a much more promising drug candidate for the ADRB2 receptor. The Caco-2 values are concerning for both, but the superior binding affinity of Ligand B suggests it might still be effective at lower concentrations, potentially mitigating the permeability issue.
Output:
0
2025-04-17 21:51:45,012 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (354.495 Da and 364.515 Da) fall within the ideal range of 200-500 Da. No significant difference here.
**2. TPSA:** Both ligands have TPSA values (76.12 and 74.33) below 140, which is good for oral absorption.
**3. logP:** Ligand A (-0.254) is a bit low, potentially hindering permeation. Ligand B (1.633) is within the optimal range of 1-3. This favors Ligand B.
**4. H-Bond Donors:** Both have 2 HBD, which is acceptable.
**5. H-Bond Acceptors:** Both have 5 HBA, which is acceptable.
**6. QED:** Both ligands have good QED scores (0.688 and 0.735), indicating good drug-likeness.
**7. DILI:** Ligand A (5.079) has a significantly lower DILI risk than Ligand B (22.722). This is a major advantage for Ligand A.
**8. BBB:** Ligand A (18.147) has a very low BBB penetration, while Ligand B (41.644) is higher. Since ADRB2 is a cardiovascular target (not CNS), BBB penetration is less critical, but some level is still useful for distribution.
**9. Caco-2 Permeability:** Both have negative values (-5.079 and -5.56). This is unusual and suggests poor permeability. However, the scale is not clearly defined, so it's hard to interpret.
**10. Aqueous Solubility:** Both have negative values (-0.009 and -0.799), indicating poor solubility. This is a concern for both.
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.177 and 0.207).
**12. Microsomal Clearance:** Ligand A (2.652) has a lower microsomal clearance than Ligand B (-17.009), suggesting better metabolic stability. This is a significant advantage for Ligand A.
**13. In vitro Half-Life:** Ligand A (1.122) has a shorter half-life than Ligand B (6.069). This is a disadvantage for Ligand A.
**14. P-gp Efflux:** Both have very low P-gp efflux liability (0.008 and 0.024).
**15. Binding Affinity:** Ligand B (-6.9 kcal/mol) has a slightly better binding affinity than Ligand A (-5.8 kcal/mol). This is a 1.1 kcal/mol difference, which is notable but not overwhelming.
**GPCR-Specific Priorities:** For GPCRs, logP, Pgp, TPSA, and affinity are important. Ligand B has a better logP and slightly better affinity. However, the DILI and metabolic stability (Cl_mic) are critical factors. Ligand A has a much lower DILI risk and better metabolic stability.
**Overall Assessment:**
While Ligand B has slightly better affinity and logP, Ligand A's significantly lower DILI risk and better metabolic stability are more important considerations for a cardiovascular drug candidate. The poor solubility and permeability are concerns for both, but can be addressed with formulation strategies. The lower DILI risk is a major safety advantage.
Output:
1
2025-04-17 21:51:45,012 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (361.873 and 355.869 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (54.46 and 54.02) are below the 140 A^2 threshold for good oral absorption, which is good.
3. **logP:** Ligand A (3.174) is optimal, while Ligand B (4.062) is approaching the upper limit where solubility issues could arise.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2) as lower HBD generally improves permeability.
5. **HBA:** Ligand A (4) is preferable to Ligand B (2) as lower HBA generally improves permeability.
6. **QED:** Both ligands have good QED scores (0.745 and 0.868), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Both ligands have low DILI risk (29.934 and 36.293), which is excellent.
8. **BBB:** Both ligands have good BBB penetration (70.415 and 78.907). Ligand B is slightly better.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.801 and -4.726), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand A (-2.728) is better than Ligand B (-4.071) in terms of solubility.
11. **hERG:** Both ligands have low hERG inhibition liability (0.686 and 0.475), which is good. Ligand B is slightly better.
12. **Cl_mic:** Both ligands have similar microsomal clearance (33.501 and 36.953).
13. **t1/2:** Ligand A has a longer in vitro half-life (105.882 hours) than Ligand B (68.504 hours), which is a significant advantage.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.154 and 0.178).
15. **Binding Affinity:** Ligand B (-7.5 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.8 kcal/mol) - a difference of 1.7 kcal/mol. This is a substantial advantage.
**GPCR-specific priorities:** For ADRB2 (a GPCR), we prioritize logP, Pgp, TPSA, and affinity. Ligand B is better in logP, Pgp, and significantly better in affinity. The Caco-2 values are concerning for both, but the strong affinity of Ligand B outweighs this concern. The longer half-life of Ligand A is a positive, but the affinity difference is more critical.
**Conclusion:**
Despite the similar ADME profiles and concerning Caco-2 values, Ligand B's substantially stronger binding affinity (-7.5 kcal/mol vs -5.8 kcal/mol) makes it the more promising candidate. A strong binding affinity can often compensate for minor ADME drawbacks, especially in early-stage drug discovery.
Output:
0
2025-04-17 21:51:45,012 - INFO - Batch 289 complete. Total preferences: 4624
2025-04-17 21:51:45,012 - INFO - Processing batch 290/512...
2025-04-17 21:52:35,519 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (a GPCR) drug candidates.
**Ligand A:** [368.543, 49.85, 2.392, 0, 4, 0.767, 21.869, 77.007, -4.436, -2.813, 0.269, 53.017, -9.013, 0.066, -7.0]
**Ligand B:** [349.431, 104.46, 1.155, 3, 5, 0.685, 34.238, 58.821, -5.157, -2.075, 0.044, 41.904, -22.882, 0.052, -8.0]
Here's a breakdown, prioritizing GPCR-relevant properties (logP, TPSA, Pgp, BBB, Affinity) and considering the general guidelines:
1. **Molecular Weight:** Both are within the ideal range (200-500 Da). A is 368.543, B is 349.431. No strong preference here.
2. **TPSA:** Ligand A (49.85) is excellent, well below the 140 threshold and good for oral absorption. Ligand B (104.46) is higher but still acceptable, though less ideal. A wins here.
3. **logP:** Ligand A (2.392) is optimal. Ligand B (1.155) is a bit low, potentially impacting permeability. A wins.
4. **H-Bond Donors:** Ligand A (0) is preferred. Ligand B (3) is acceptable but higher.
5. **H-Bond Acceptors:** Ligand A (4) is good. Ligand B (5) is acceptable.
6. **QED:** Both are reasonable (A: 0.767, B: 0.685), indicating good drug-like properties. A is slightly better.
7. **DILI:** Ligand A (21.869) has a significantly lower DILI risk than Ligand B (34.238). This is a major advantage for A.
8. **BBB:** Ligand A (77.007) has a much better BBB penetration potential than Ligand B (58.821). This is important for a GPCR target, even if not strictly CNS-focused, as it can influence distribution. A wins.
9. **Caco-2:** Ligand A (-4.436) and Ligand B (-5.157) are both negative values, which is unusual and suggests very poor permeability. However, the scale is not specified, so it's difficult to interpret.
10. **Solubility:** Both are very poor (-2.813 and -2.075). This is a concern for both, but could be addressed with formulation strategies.
11. **hERG:** Both are very low (A: 0.269, B: 0.044), indicating low cardiotoxicity risk. B is slightly better here.
12. **Cl_mic:** Ligand A (53.017) has a higher clearance than Ligand B (41.904), suggesting lower metabolic stability. B wins.
13. **t1/2:** Ligand A (-9.013) has a longer half-life than Ligand B (-22.882). A wins.
14. **Pgp:** Both are very low (A: 0.066, B: 0.052), suggesting minimal P-gp efflux. B is slightly better.
15. **Affinity:** Ligand B (-8.0) has a slightly better binding affinity than Ligand A (-7.0). This is a 1 kcal/mol difference, which is significant.
**Overall Assessment:**
While Ligand B has a slightly better binding affinity and slightly better metabolic stability, Ligand A is significantly better in several crucial areas: TPSA, logP, DILI risk, and BBB penetration. The lower DILI risk and better BBB are particularly important for a GPCR target like ADRB2. The solubility issues are a concern for both, but can potentially be mitigated. The slightly better half-life of A is also a positive.
Therefore, considering the balance of properties and the priorities for a GPCR target, I favor Ligand A.
1
2025-04-17 21:52:35,519 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (353.463 and 354.447 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (96.53) is better than Ligand B (99.1). Both are under the 140 threshold for oral absorption, but lower TPSA is generally preferred for GPCRs, aiding permeability.
3. **logP:** Ligand A (1.57) is within the optimal 1-3 range. Ligand B (-0.097) is slightly below 1, which *could* indicate permeability issues. This is a point in favor of A.
4. **HBD:** Both ligands have 3 HBD, which is acceptable.
5. **HBA:** Ligand A has 4 HBA, Ligand B has 5. Both are acceptable, but lower is slightly preferred.
6. **QED:** Both ligands have similar QED scores (0.519 and 0.502), indicating good drug-likeness.
7. **DILI:** Ligand A (24.544) has a lower DILI risk than Ligand B (27.336), which is favorable.
8. **BBB:** Ligand A (80.419) has significantly better BBB penetration potential than Ligand B (29.779). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant, and higher BBB is generally desirable for GPCRs.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.733 and -4.852), indicating poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-2.41) has slightly better solubility than Ligand B (-1.241).
11. **hERG:** Both ligands have very low hERG risk (0.342 and 0.209).
12. **Cl_mic:** Ligand A (52.188) has higher microsomal clearance than Ligand B (21.483), indicating lower metabolic stability. This favors Ligand B.
13. **t1/2:** Ligand B (-14.512) has a longer in vitro half-life than Ligand A (-28.96), indicating better stability. This is a significant advantage for Ligand B.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.066 and 0.017).
15. **Binding Affinity:** Ligand A (-6.5 kcal/mol) has a slightly better binding affinity than Ligand B (-5.6 kcal/mol). This 0.9 kcal/mol difference is significant and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand A has a better logP, TPSA, DILI risk, BBB penetration, and binding affinity. Ligand B has better metabolic stability (lower Cl_mic and longer t1/2). The Caco-2 permeability is poor for both, a significant drawback. However, the stronger binding affinity of Ligand A, combined with its better predicted BBB penetration and lower DILI risk, makes it the more promising candidate, especially considering the GPCR target class. The slightly worse metabolic stability of A is a concern, but can be addressed through structural modifications.
Output:
1
2025-04-17 21:52:35,519 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (345.487 and 361.515 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (54.34) is significantly better than Ligand B (81.91). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary goal, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (2.647 and 2.463), falling within the optimal 1-3 range. Again, no significant difference.
4. **HBD:** Both ligands have 1 HBD, which is within the acceptable limit of <=5.
5. **HBA:** Ligand A has 3 HBAs, while Ligand B has 6. Ligand A is preferable here, as fewer HBAs generally improve permeability.
6. **QED:** Ligand A (0.912) has a much better QED score than Ligand B (0.716), indicating a more drug-like profile.
7. **DILI:** Ligand A (18.728) has a significantly lower DILI risk than Ligand B (38.154). This is a crucial advantage.
8. **BBB:** Both ligands have reasonable BBB penetration (78.868 and 88.794). Since ADRB2 is a cardiovascular target, this isn't a major deciding factor.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and potentially problematic. However, the magnitude is similar (-4.939 vs -5.284).
10. **Solubility:** Both ligands have negative solubility values, which is also concerning. Ligand A (-2.08) is slightly better than Ligand B (-2.529), but both need improvement.
11. **hERG:** Both ligands have low hERG inhibition liability (0.412 and 0.864), which is good.
12. **Cl_mic:** Ligand A (14.576) has a much lower microsomal clearance than Ligand B (69.526), suggesting better metabolic stability.
13. **t1/2:** Ligand A (1.593) has a slightly longer in vitro half-life than Ligand B (-0.195).
14. **Pgp:** Both ligands have low Pgp efflux liability (0.242 and 0.296).
15. **Binding Affinity:** Both ligands have excellent binding affinity (-5.0 and -4.5 kcal/mol). The difference of 0.5 kcal/mol is not enough to outweigh the other advantages of Ligand A.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, and affinity are important. Ligand A is better in TPSA and has a better overall profile.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B in key ADME properties (QED, DILI, Cl_mic, t1/2, TPSA, HBA) while maintaining comparable potency and logP. The lower DILI risk and better metabolic stability are particularly important for a cardiovascular drug. While both have issues with Caco-2 and solubility, Ligand A is slightly better in these areas as well.
Output:
1
2025-04-17 21:52:35,519 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [351.363, 114.79 , -1.127, 2. , 7. , 0.71 , 79.837, 54.052, -5.036, -1.93 , 0.06 , -14.665, -10.098, 0.008, -4.8 ]
**Ligand B:** [346.406, 65.54 , 1.74 , 1. , 4. , 0.844, 60.915, 80.031, -4.578, -2.835, 0.431, 34.223, 12.196, 0.027, -6.3 ]
Here's a breakdown of each parameter and how the ligands compare, with emphasis on GPCR-relevant properties:
1. **MW:** Both are within the ideal 200-500 Da range. A (351.363) and B (346.406) are very close, so no significant difference here.
2. **TPSA:** A (114.79) is slightly higher than B (65.54). B is much better, being well below the 140 A^2 threshold for oral absorption and more favorable for GPCRs.
3. **logP:** A (-1.127) is quite low, potentially hindering permeability. B (1.74) is much better, falling within the optimal 1-3 range.
4. **HBD:** A (2) and B (1) are both acceptable, below the 5 limit.
5. **HBA:** A (7) and B (4) are both acceptable, below the 10 limit.
6. **QED:** Both are good (A: 0.71, B: 0.844), indicating drug-like properties. B is slightly better.
7. **DILI:** A (79.837) is higher than B (60.915), indicating a higher risk of liver injury. B is preferable.
8. **BBB:** B (80.031) has significantly better BBB penetration potential than A (54.052). This is a key consideration for GPCRs, even cardiovascular ones, as off-target CNS effects are always a concern.
9. **Caco-2:** A (-5.036) and B (-4.578) are both negative, which is unusual and suggests poor permeability. However, the values are close.
10. **Solubility:** A (-1.93) and B (-2.835) are both poor, but B is slightly worse.
11. **hERG:** A (0.06) is slightly better than B (0.431), indicating lower risk of cardiotoxicity.
12. **Cl_mic:** A (-14.665) is much lower (better) than B (34.223), suggesting greater metabolic stability.
13. **t1/2:** A (-10.098) is worse than B (12.196), indicating a shorter half-life.
14. **Pgp:** A (0.008) is much lower (better) than B (0.027), indicating less P-gp efflux.
15. **Affinity:** B (-6.3) has a significantly stronger binding affinity than A (-4.8). This is a substantial advantage (>1.5 kcal/mol difference).
**Overall Assessment:**
Ligand B clearly emerges as the more promising candidate. While Ligand A has slightly better hERG inhibition and Pgp efflux, Ligand B excels in critical areas for a GPCR drug: significantly better logP, TPSA, BBB penetration, and, most importantly, a much stronger binding affinity. The improved metabolic stability (lower Cl_mic) and longer half-life are also beneficial. The slightly higher DILI risk is a concern, but potentially manageable with further optimization, especially given the strong affinity. The lower solubility is a drawback for both, but can be addressed through formulation strategies.
Therefore, I recommend prioritizing Ligand B for further development.
Output:
0
2025-04-17 21:52:35,519 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A: [356.373, 96.11, 0.942, 3, 4, 0.574, 54.246, 84.374, -5.158, -2.533, 0.095, 11.283, -20.297, 0.025, -7.1]**
**Ligand B: [365.405, 56.67, 3.313, 1, 5, 0.903, 68.903, 71.85, -4.683, -4.659, 0.361, 54.518, -9.204, 0.239, -7.1]**
Here's a breakdown, considering the guidelines and GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal 200-500 Da range. A (356.373) is slightly better.
2. **TPSA:** A (96.11) is higher than B (56.67). B is significantly better, being well under the 140 threshold for oral absorption and closer to the ideal for GPCRs.
3. **logP:** A (0.942) is lower than B (3.313). B is better, falling within the optimal 1-3 range. A is borderline and could have absorption issues.
4. **HBD:** A (3) is higher than B (1). B is preferable.
5. **HBA:** A (4) is lower than B (5). B is acceptable, but A is slightly better.
6. **QED:** B (0.903) is significantly better than A (0.574), indicating a more drug-like profile.
7. **DILI:** A (54.246) is better than B (68.903), indicating a lower risk of liver injury.
8. **BBB:** A (84.374) is better than B (71.85). While not a primary concern for a cardiovascular target, higher BBB is generally favorable.
9. **Caco-2:** A (-5.158) is worse than B (-4.683). Lower (more negative) values suggest poorer permeability.
10. **Solubility:** A (-2.533) is better than B (-4.659).
11. **hERG:** A (0.095) is better than B (0.361), indicating lower cardiotoxicity risk.
12. **Cl_mic:** A (11.283) is better than B (54.518), suggesting better metabolic stability.
13. **t1/2:** A (-20.297) is better than B (-9.204), indicating a longer half-life.
14. **Pgp:** A (0.025) is much better than B (0.239), suggesting lower efflux and better bioavailability.
15. **Affinity:** Both are identical at -7.1 kcal/mol.
**Overall Assessment:**
Ligand B has a much better TPSA and logP, which are crucial for GPCRs. It also has a significantly better QED score. However, Ligand A excels in DILI, BBB, solubility, hERG, Cl_mic, t1/2, and Pgp. The metabolic stability (Cl_mic and t1/2) and reduced efflux (Pgp) of Ligand A are very attractive. While Ligand B's logP is better, Ligand A's solubility is better, which could offset some of the logP concerns. The similar binding affinity means that the ADME properties become the deciding factor. Given the importance of metabolic stability and reduced efflux for a cardiovascular drug (to ensure adequate systemic exposure), and the acceptable solubility of Ligand A, I favor Ligand A.
Output:
1
2025-04-17 21:52:35,519 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (342.45 & 344.46 Da) fall comfortably within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (75.94) is slightly higher than Ligand B (67.43). Both are below the 140 threshold for oral absorption, but closer to the 90 threshold for CNS targets, which isn't a primary concern for ADRB2 (cardiovascular). Ligand B is preferable here.
3. **logP:** Both ligands (2.518 & 2.497) are within the optimal 1-3 range. No significant difference.
4. **HBD:** Ligand A (1) has fewer HBDs than Ligand B (2). Fewer HBDs generally improve permeability, so Ligand A is slightly favored.
5. **HBA:** Ligand A (6) has more HBAs than Ligand B (3). Fewer HBAs are generally preferable for permeability. Ligand B is favored.
6. **QED:** Ligand A (0.903) has a significantly higher QED score than Ligand B (0.641), indicating a more drug-like profile. This is a strong advantage for Ligand A.
7. **DILI:** Ligand A (66.382) has a higher DILI risk than Ligand B (29.314). This is a significant drawback for Ligand A. Ligand B is strongly favored.
8. **BBB:** Ligand A (73.788) has a higher BBB penetration percentile than Ligand B (55.603). While not a primary concern for ADRB2, higher BBB is generally a plus.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.115 and -5.164). These values are unusual and suggest poor permeability. This is a concern for both, but the difference is negligible.
10. **Solubility:** Both ligands have negative solubility values (-2.769 and -2.472). These values are also unusual and suggest poor solubility. This is a concern for both, but the difference is negligible.
11. **hERG:** Ligand A (0.089) has a lower hERG inhibition liability than Ligand B (0.364), indicating a lower risk of cardiotoxicity. This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand A (41.41) has a higher microsomal clearance than Ligand B (26.765), indicating lower metabolic stability. Ligand B is favored.
13. **t1/2:** Ligand A (17.61) and Ligand B (18.151) have similar in vitro half-lives. No significant difference.
14. **Pgp:** Ligand A (0.14) has lower P-gp efflux liability than Ligand B (0.079), suggesting better oral bioavailability. Ligand A is favored.
15. **Binding Affinity:** Ligand A (-8.4 kcal/mol) has a significantly stronger binding affinity than Ligand B (-7.3 kcal/mol) - a difference of 1.1 kcal/mol. This is a substantial advantage for Ligand A and can outweigh some of the ADME drawbacks.
**Overall Assessment & GPCR Considerations:**
For a GPCR like ADRB2, affinity, logP, TPSA, and Pgp efflux are important. Ligand A has a substantially better binding affinity (-8.4 vs -7.3). While Ligand B has better DILI and Cl_mic profiles, the significantly better affinity of Ligand A, coupled with a reasonable QED and lower hERG risk, makes it the more promising candidate. The negative Caco-2 and solubility values are concerning for both, and would require further investigation, but the potency advantage of Ligand A is likely to be more impactful in early optimization.
Output:
1
2025-04-17 21:52:35,519 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
We are targeting ADRB2, a GPCR. Therefore, key priorities are logP, TPSA, Pgp efflux, BBB penetration, and binding affinity. Let's break down the comparison:
1. **Molecular Weight:** Both ligands (363.5 and 375.8 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (70.23) is significantly better than Ligand B (102.05). A TPSA under 140 is good for oral absorption, and lower is generally preferred for GPCRs. Ligand B is pushing the upper limit.
3. **logP:** Ligand A (3.756) is optimal, while Ligand B (1.692) is a bit low, potentially hindering membrane permeability.
4. **H-Bond Donors/Acceptors:** Ligand A has 3 HBD and 3 HBA, while Ligand B has 2 HBD and 6 HBA. Both are acceptable, but Ligand B's higher HBA count could slightly impact permeability.
5. **QED:** Both ligands have good QED scores (0.659 and 0.766), indicating reasonable drug-likeness.
6. **DILI:** Both have relatively high DILI risk (38.3 and 70.5), but Ligand B is considerably higher. This is a concern.
7. **BBB:** Ligand A (76.3%) shows significantly better BBB penetration than Ligand B (52.9%). While ADRB2 isn't exclusively a CNS target, some CNS exposure can occur, and higher BBB is generally favorable.
8. **Caco-2:** Ligand A (-4.8) is better than Ligand B (-5.312), indicating better intestinal absorption.
9. **Solubility:** Ligand A (-4.513) is better than Ligand B (-2.536), indicating better aqueous solubility.
10. **hERG:** Both ligands have low hERG inhibition risk (0.562 and 0.159).
11. **Cl_mic:** Ligand A (69.414) has a higher microsomal clearance than Ligand B (20.009), suggesting faster metabolism and potentially lower *in vivo* exposure. This is a negative for Ligand A.
12. **t1/2:** Ligand A (38.605) has a longer half-life than Ligand B (24.034), which is favorable.
13. **Pgp:** Ligand A (0.106) has lower P-gp efflux than Ligand B (0.06), meaning it is less likely to be pumped out of cells, improving bioavailability.
14. **Binding Affinity:** Ligand B (-6.1 kcal/mol) has a slightly stronger binding affinity than Ligand A (-5.4 kcal/mol). This is a 0.7 kcal/mol difference, which is significant.
**Overall Assessment:**
Ligand B has a better binding affinity and lower clearance, but suffers from a higher DILI risk, lower logP, and significantly worse TPSA and BBB penetration. Ligand A has better ADME properties (TPSA, logP, BBB, solubility, Pgp, half-life) and a lower DILI risk, but its binding affinity is slightly weaker and it has a higher clearance.
Given the GPCR-specific priorities and the importance of good ADME properties for *in vivo* efficacy, I believe Ligand A represents a more promising starting point for drug development, despite the slightly weaker affinity. The better ADME profile will likely translate to better bioavailability and reduced off-target effects. The affinity can be optimized in later stages of lead optimization.
**Output:**
1
2025-04-17 21:52:35,520 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (361.829 Da and 346.431 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (72.48) is well below the 140 threshold and good for oral absorption. Ligand B (84.42) is still acceptable but higher. This favors Ligand A slightly.
**3. logP:** Ligand A (3.723) is at the upper end of the optimal range (1-3), while Ligand B (1.207) is at the lower end. For a GPCR, a slightly higher logP can be beneficial for membrane permeability and receptor engagement, but we need to consider other factors.
**4. H-Bond Donors:** Ligand A (2) and Ligand B (1) are both within the acceptable limit of 5.
**5. H-Bond Acceptors:** Ligand A (4) and Ligand B (5) are both within the acceptable limit of 10.
**6. QED:** Both ligands have good QED scores (0.822 and 0.866), indicating good drug-like properties. No significant difference.
**7. DILI Risk:** Ligand B (34.432) has a significantly lower DILI risk than Ligand A (69.135). This is a major advantage for Ligand B.
**8. BBB Penetration:** Ligand A (77.898) has better BBB penetration than Ligand B (66.964). While ADRB2 isn't a CNS target, some level of BBB penetration can be useful for understanding off-target effects and overall distribution.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.408) is slightly better than Ligand B (-5.109), but both are concerning.
**10. Aqueous Solubility:** Ligand A (-5.111) has very poor solubility, while Ligand B (-1.009) is better, though still not ideal. Solubility is a significant concern for bioavailability.
**11. hERG Inhibition:** Ligand A (0.253) has a slightly higher hERG risk than Ligand B (0.076). Lower is better here, favoring Ligand B.
**12. Microsomal Clearance:** Ligand B (-1.218) has significantly better metabolic stability (lower clearance) than Ligand A (74.403). This is a major advantage for Ligand B, potentially leading to a longer duration of action.
**13. In vitro Half-Life:** Ligand B (7.906) has a longer half-life than Ligand A (6.44). This supports the better metabolic stability observed in the Cl_mic data.
**14. P-gp Efflux:** Ligand A (0.101) has lower P-gp efflux than Ligand B (0.008), indicating potentially better bioavailability.
**15. Binding Affinity:** Ligand B (-6.7 kcal/mol) has a slightly better binding affinity than Ligand A (-6.3 kcal/mol). While the difference is not huge, it's still a positive for Ligand B.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity) and the general drug-like properties, Ligand B is the more promising candidate. While Ligand A has slightly better TPSA and P-gp efflux, Ligand B excels in crucial areas like DILI risk, metabolic stability (Cl_mic and t1/2), solubility, and hERG inhibition. The better binding affinity of Ligand B further solidifies its advantage. The poor Caco-2 permeability is a concern for both, but the other benefits of Ligand B outweigh this drawback.
0
2025-04-17 21:52:35,520 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (361.511 and 351.491 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (62.3) is better than Ligand B (72.88). Lower TPSA generally favors oral absorption, which is important for a cardiovascular target.
3. **logP:** Both ligands have acceptable logP values (2.773 and 1.129), falling within the 1-3 range. Ligand A is slightly better, but both are reasonable.
4. **HBD:** Ligand A (1) is better than Ligand B (2). Lower HBD is generally preferred for better permeability.
5. **HBA:** Both ligands have the same HBA count (4), which is well within the acceptable limit of 10.
6. **QED:** Ligand A (0.839) has a higher QED score than Ligand B (0.752), indicating a more drug-like profile.
7. **DILI:** Ligand A (45.25) has a slightly higher DILI risk than Ligand B (6.902). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (78.054) has a better BBB penetration percentile than Ligand B (48.352). While ADRB2 isn't strictly a CNS target, some brain exposure can be relevant for off-target effects or peripheral effects mediated by sympathetic nervous system.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.818 and -4.93). These values are difficult to interpret without knowing the scale, but negative values suggest poor permeability.
10. **Solubility:** Ligand A (-2.952) has slightly better solubility than Ligand B (-1.129).
11. **hERG:** Both ligands have low hERG inhibition liability (0.299 and 0.306), which is good.
12. **Cl_mic:** Ligand A (63.201) has a higher microsomal clearance than Ligand B (4.968), indicating lower metabolic stability. This is a significant disadvantage for Ligand A.
13. **t1/2:** Ligand B (21.408) has a much longer in vitro half-life than Ligand A (-14.428). This is a major advantage for Ligand B, suggesting less frequent dosing.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.173 and 0.018).
15. **Binding Affinity:** Both ligands have similar binding affinities (-6.2 and -6.4 kcal/mol). The difference is minimal.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. While both ligands are acceptable in terms of logP and affinity, Ligand A has a better TPSA. However, the significantly better DILI, metabolic stability (lower Cl_mic), and longer half-life of Ligand B outweigh the slight TPSA advantage of Ligand A.
**Conclusion:**
Ligand B is the more promising drug candidate due to its significantly improved safety profile (lower DILI), better metabolic stability (lower Cl_mic), and longer half-life.
Output:
0
2025-04-17 21:52:35,520 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (361.368 Da and 374.472 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (79.26) is higher than Ligand B (41.99). For a GPCR, lower TPSA is generally preferred for better brain penetration and overall permeability. Ligand B is significantly better here.
3. **logP:** Ligand A (0.847) is lower than Ligand B (4.766). Ligand B is considerably higher, potentially leading to solubility issues and off-target interactions. Ligand A is better.
4. **HBD:** Ligand A (2) is higher than Ligand B (1). Both are acceptable, but lower is generally preferred.
5. **HBA:** Ligand A (5) is higher than Ligand B (3). Similar to HBD, lower is better, and Ligand B is preferable.
6. **QED:** Both ligands have similar QED values (0.815 and 0.807), indicating good drug-likeness.
7. **DILI:** Ligand A (59.984) has a slightly higher DILI risk than Ligand B (48.546), but both are within an acceptable range (<60 is good).
8. **BBB:** Ligand B (89.725) has a significantly higher BBB penetration percentile than Ligand A (63.784). This is a key advantage for a GPCR, even if it's not a CNS target, as it can indicate better overall permeability.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.63 and -4.585), which is unusual and suggests very poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand A (-2.006) has better solubility than Ligand B (-4.889). This is important given Ligand B's high logP.
11. **hERG:** Ligand A (0.149) has a lower hERG risk than Ligand B (0.45). This is a crucial safety parameter, and Ligand A is better.
12. **Cl_mic:** Ligand B (52.053) has higher microsomal clearance than Ligand A (29.466), indicating faster metabolism and potentially lower bioavailability. Ligand A is preferable.
13. **t1/2:** Ligand A (-3.259) has a more negative in vitro half-life than Ligand B (2.703), which is not ideal. However, the scale is unclear and the values are both quite low.
14. **Pgp:** Ligand A (0.006) has a much lower Pgp efflux liability than Ligand B (0.554). Lower Pgp is desirable for better oral bioavailability and potential CNS exposure.
15. **Binding Affinity:** Ligand B (-6.5) has a slightly better binding affinity than Ligand A (-6.2). While a 1.5 kcal/mol advantage is usually significant, the other ADME properties of Ligand B are concerning.
**Overall Assessment:**
While Ligand B has slightly better binding affinity and BBB penetration, its high logP, higher Pgp efflux, and higher microsomal clearance are major drawbacks. Ligand A has a better balance of properties, with better solubility, lower hERG risk, lower Pgp efflux, and lower microsomal clearance. The negative Caco-2 values are concerning for both, but the other properties of Ligand A make it a more promising starting point for optimization.
Output:
1
2025-04-17 21:52:35,520 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [349.337, 82.53, 2.555, 2, 4, 0.869, 64.909, 49.128, -4.837, -3.457, 0.378, 64.873, -26.617, 0.035, -5.1]
**Ligand B:** [379.295, 62.63, 3.278, 1, 5, 0.668, 36.758, 70.997, -5.428, -2.678, 0.714, 11.37, 7.819, 0.231, -6.6]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity) and general drug-like properties:
1. **MW:** Both are within the ideal 200-500 Da range. A (349.337) is slightly preferred.
2. **TPSA:** A (82.53) is higher than B (62.63). B is better here, falling well below the 140 threshold.
3. **logP:** Both are good (1-3). B (3.278) is a bit higher, which could be slightly concerning for solubility, but still acceptable. A (2.555) is excellent.
4. **HBD:** A (2) and B (1) are both good. B is slightly better.
5. **HBA:** A (4) and B (5) are both acceptable, but B is slightly higher.
6. **QED:** A (0.869) is significantly better than B (0.668), indicating a more drug-like profile.
7. **DILI:** A (64.909) is higher risk than B (36.758). B is significantly better here.
8. **BBB:** B (70.997) is better than A (49.128). While not a primary concern for a cardiovascular target, higher BBB is generally favorable.
9. **Caco-2:** A (-4.837) is worse than B (-5.428). Both are negative, indicating poor permeability.
10. **Solubility:** A (-3.457) is worse than B (-2.678). Both are poor, but B is slightly better.
11. **hERG:** A (0.378) is better than B (0.714). Lower hERG is preferred.
12. **Cl_mic:** A (64.873) is higher than B (11.37). B is *much* better, indicating greater metabolic stability.
13. **t1/2:** A (-26.617) is worse than B (7.819). B is significantly better, indicating a longer half-life.
14. **Pgp:** A (0.035) is better than B (0.231). Lower P-gp efflux is preferred.
15. **Affinity:** B (-6.6) is significantly better than A (-5.1). This is a 1.5 kcal/mol difference, which is substantial and can outweigh some ADME concerns.
**Overall Assessment:**
Ligand B has a significantly better binding affinity, much better metabolic stability (lower Cl_mic, longer t1/2), lower DILI risk, and better BBB penetration. While its solubility and Caco-2 permeability are also slightly better, they are both still poor. Ligand A has a better QED and lower Pgp efflux, but the affinity difference is too large to ignore. The improved ADME properties of B, particularly the metabolic stability and reduced toxicity risk, make it the more promising candidate despite the slightly higher logP.
Output:
0
2025-04-17 21:52:35,521 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [385.917, 82.53, 2.79, 2, 5, 0.761, 67.313, 52.268, -5.141, -4.6, 0.442, 33.38, 0.686, 0.21, -6.5]
**Ligand B:** [330.395, 69.38, 3.506, 0, 6, 0.562, 77.588, 57.076, -5.062, -3.605, 0.46, 16.194, -32.191, 0.246, -7.6]
Here's a breakdown, considering the guidelines and GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal 200-500 Da range. Ligand B (330.395) is slightly preferred due to being a bit lower.
2. **TPSA:** Both are good, below the 140 threshold. Ligand B (69.38) is better than Ligand A (82.53), favoring better absorption.
3. **logP:** Both are within the optimal 1-3 range, but Ligand B (3.506) is pushing the upper limit, while Ligand A (2.79) is more ideal.
4. **HBD:** Ligand A (2) is better than Ligand B (0). Having some HBD can improve solubility.
5. **HBA:** Ligand B (6) is slightly better than Ligand A (5).
6. **QED:** Ligand A (0.761) is significantly better than Ligand B (0.562), indicating a more drug-like profile.
7. **DILI:** Ligand A (67.313) is better than Ligand B (77.588), indicating lower liver injury risk.
8. **BBB:** Both are moderate, around 50-60%. Not a primary concern for a cardiovascular target. Ligand B is slightly better.
9. **Caco-2:** Both are negative, indicating poor permeability. This is a concern for both.
10. **Solubility:** Both are negative, indicating poor solubility. This is a concern for both.
11. **hERG:** Both are low, which is good. Ligand B (0.46) is slightly better.
12. **Cl_mic:** Ligand B (16.194) has significantly lower clearance than Ligand A (33.38), indicating better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand B (-32.191) has a much longer half-life than Ligand A (0.686). This is a major advantage.
14. **Pgp:** Both are low, indicating low efflux. Ligand B (0.246) is slightly better.
15. **Affinity:** Ligand B (-7.6) has a significantly stronger binding affinity than Ligand A (-6.5) - a difference of 1.1 kcal/mol. This is a substantial advantage that can outweigh some ADME concerns.
**Overall Assessment:**
Ligand B has a significantly better binding affinity and metabolic stability (lower Cl_mic, longer t1/2). While Ligand A has better QED and DILI scores, the potency and PK advantages of Ligand B are more crucial for a GPCR target. The slightly higher logP of Ligand B is a minor concern, but the strong binding affinity likely compensates for it. The poor Caco-2 and solubility are concerns for both, but can be addressed with formulation strategies.
Therefore, I prefer Ligand B.
Output:
0
2025-04-17 21:52:35,521 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (361.398 and 351.422 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (85.2) is slightly higher than Ligand B (75.44). Both are below the 140 threshold for oral absorption, but closer to the 90 threshold for CNS targets. Ligand B is preferable.
3. **logP:** Both ligands have good logP values (2.958 and 2.409), falling within the 1-3 optimal range. Ligand B is slightly lower, which could be advantageous for solubility.
4. **HBD:** Both ligands have 1 HBD, which is within the acceptable limit of 5. No difference.
5. **HBA:** Ligand A has 7 HBAs, while Ligand B has 4. Ligand B is preferable, as fewer HBAs generally correlate with better membrane permeability.
6. **QED:** Ligand A (0.68) has a slightly better QED score than Ligand B (0.519), suggesting a more drug-like profile.
7. **DILI:** Ligand B (39.744) has a significantly lower DILI risk than Ligand A (89.415). This is a major advantage for Ligand B.
8. **BBB:** Ligand B (76.735) has a higher BBB penetration percentile than Ligand A (66.305). While ADRB2 isn't exclusively a CNS target, some CNS exposure is not necessarily detrimental and higher BBB is generally favorable.
9. **Caco-2:** Both ligands show negative Caco-2 values, indicating poor permeability. Ligand B (-4.956) is slightly worse than Ligand A (-3.719).
10. **Solubility:** Ligand B (-2.158) has better solubility than Ligand A (-3.719).
11. **hERG:** Both ligands show low hERG inhibition risk (0.351 and 0.411). No significant difference.
12. **Cl_mic:** Ligand B (53.024) has a lower microsomal clearance than Ligand A (85.639), indicating better metabolic stability.
13. **t1/2:** Ligand B (-20.261) has a significantly longer in vitro half-life than Ligand A (-11.136). This is a strong advantage for Ligand B.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.304 and 0.436). No significant difference.
15. **Binding Affinity:** Ligand A (-7.6 kcal/mol) has a significantly stronger binding affinity than Ligand B (-4.3 kcal/mol). This is a substantial advantage for Ligand A.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A has a better affinity. Ligand B has better TPSA, Pgp, and solubility. The DILI and metabolic stability (Cl_mic and t1/2) of Ligand B are also significantly better. The affinity difference is substantial (3.3 kcal/mol), which is a large advantage.
**Overall Assessment:**
While Ligand B has several advantages in terms of safety (DILI), metabolic stability, and solubility, the significantly stronger binding affinity of Ligand A (-7.6 vs -4.3 kcal/mol) is a critical factor for a GPCR target. A difference of this magnitude can often overcome minor ADME drawbacks.
Output:
1
2025-04-17 21:52:35,521 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**1. Molecular Weight:** Both ligands (347.459 Da and 349.475 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Both ligands have similar TPSA values (82.43 and 82.53), which are acceptable for a non-CNS GPCR target like ADRB2, being under the 140 A^2 threshold.
**3. logP:** Both ligands have good logP values (2.016 and 2.224), falling within the optimal 1-3 range.
**4. H-Bond Donors/Acceptors:** Ligand A has 1 HBD and 4 HBA, while Ligand B has 2 HBD and 4 HBA. Both are within acceptable limits (<=5 HBD and <=10 HBA).
**5. QED:** Ligand B (0.754) has a significantly better QED score than Ligand A (0.484), indicating a more drug-like profile.
**6. DILI:** Ligand B (32.377) has a much lower DILI risk than Ligand A (12.718), which is a significant advantage. Lower DILI is always preferred.
**7. BBB:** While not a primary concern for ADRB2 (a cardiovascular target), Ligand A (65.801) has a better BBB penetration score than Ligand B (50.679). This is a minor advantage.
**8. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.455 and -4.622). These values are unusual and suggest poor permeability. However, the difference between them is minimal.
**9. Aqueous Solubility:** Ligand A (-1.524) has slightly better aqueous solubility than Ligand B (-2.56), which is a minor advantage.
**10. hERG Inhibition:** Ligand A (0.421) has a lower hERG inhibition liability than Ligand B (0.663), which is a positive.
**11. Microsomal Clearance:** Ligand B (79.297) has a significantly higher microsomal clearance than Ligand A (38.036), indicating faster metabolism and potentially lower *in vivo* exposure. This is a major drawback for Ligand B.
**12. In vitro Half-Life:** Ligand B (17.666) has a much longer half-life than Ligand A (2.61), which is a significant advantage.
**13. P-gp Efflux:** Both ligands have low P-gp efflux liability (0.135 and 0.097), which is good.
**14. Binding Affinity:** Ligand A (-7.0 kcal/mol) has a slightly better binding affinity than Ligand B (-6.3 kcal/mol). While the difference is less than the 1.5 kcal/mol threshold, it's still a positive for Ligand A.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity) and general drug-like properties, Ligand A appears to be the better candidate. Although Ligand B has a better QED score and longer half-life, its significantly higher DILI risk and faster microsomal clearance are major concerns. Ligand A's slightly better affinity, lower DILI, lower hERG, and better metabolic stability outweigh the advantages of Ligand B.
Output:
1
2025-04-17 21:52:35,521 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [352.385, 75.19, 1.879, 1, 4, 0.878, 51.028, 88.135, -4.711, -2.991, 0.348, 11.848, -10.897, 0.026, -5.6]
**Ligand B:** [347.419, 120.04, 0.121, 3, 6, 0.675, 29.236, 15.083, -5.601, -1.274, 0.197, 6.256, 9.12, 0.013, -6.9]
Here's a breakdown, considering the guidelines and GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal range (200-500 Da). A is 352.385, B is 347.419. Very similar.
2. **TPSA:** A (75.19) is excellent, well below 140 and suggesting good absorption. B (120.04) is still acceptable, but less ideal.
3. **logP:** A (1.879) is optimal. B (0.121) is quite low, potentially hindering membrane permeability. This is a significant drawback for a GPCR ligand.
4. **HBD:** A (1) is good. B (3) is acceptable, but higher.
5. **HBA:** A (4) is good. B (6) is acceptable, but higher.
6. **QED:** A (0.878) is excellent, indicating strong drug-likeness. B (0.675) is still reasonable, but lower.
7. **DILI:** A (51.028) is good (low risk). B (29.236) is also very good. Similar.
8. **BBB:** A (88.135) is excellent, suggesting good potential for distribution. B (15.083) is very low, indicating poor BBB penetration. While not crucial for a cardiovascular target, it doesn't hurt to have good BBB penetration.
9. **Caco-2:** Both are negative, indicating poor permeability. A (-4.711) is worse than B (-5.601).
10. **Solubility:** Both are negative, indicating poor solubility. A (-2.991) is better than B (-1.274).
11. **hERG:** Both are very low, indicating low risk of cardiotoxicity. A (0.348) is better than B (0.197).
12. **Cl_mic:** A (11.848) is better (lower clearance, more stable). B (6.256) is acceptable.
13. **t1/2:** A (-10.897) is better (longer half-life). B (9.12) is acceptable.
14. **Pgp:** Both are very low, indicating low efflux. A (0.026) is better than B (0.013).
15. **Affinity:** B (-6.9) is significantly better than A (-5.6), a difference of 1.3 kcal/mol.
**Overall Assessment:**
Ligand B has a substantially better binding affinity. However, its low logP and BBB penetration are concerning. The poor logP could severely limit its ability to reach the receptor *in vivo*. Ligand A, while having a weaker affinity, has a much better logP, TPSA, QED, and BBB penetration. The better ADME properties of Ligand A, combined with acceptable affinity, make it a more promising starting point for optimization. The affinity difference, while notable, might be overcome with further medicinal chemistry efforts on Ligand A.
Therefore, I would choose Ligand A.
1
2025-04-17 21:52:35,521 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (383.857 Da) is within the ideal range (200-500 Da). Ligand B (345.407 Da) is also within range, and slightly lower, which could be beneficial for permeability.
2. **TPSA:** Ligand A (90.41) is good, below the 140 threshold and reasonably good for a GPCR. Ligand B (119.66) is higher, potentially impacting absorption, but still within a reasonable range.
3. **logP:** Ligand A (1.891) is optimal. Ligand B (0.518) is a bit low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (1) is good. Ligand B (3) is acceptable but higher.
5. **HBA:** Ligand A (7) is good. Ligand B (5) is also good.
6. **QED:** Both Ligand A (0.7) and Ligand B (0.73) are excellent, indicating good drug-like properties.
7. **DILI:** Ligand A (78.402) is higher risk, but still under the 60 threshold. Ligand B (50.136) is better, indicating lower liver injury risk.
8. **BBB:** Ligand A (52.772) is moderate. Ligand B (36.487) is lower, suggesting less BBB penetration. For ADRB2, which isn't necessarily a CNS target, this isn't a major drawback, but it's a consideration.
9. **Caco-2:** Ligand A (-4.738) is very poor. Ligand B (-5.668) is also poor, but slightly better.
10. **Solubility:** Ligand A (-3.713) is poor. Ligand B (-2.013) is also poor, but slightly better.
11. **hERG:** Both Ligand A (0.103) and Ligand B (0.105) have very low hERG risk.
12. **Cl_mic:** Ligand A (72.17) is moderate. Ligand B (-26.809) is excellent, indicating high metabolic stability.
13. **t1/2:** Ligand A (-12.392) is very long, which is good. Ligand B (6.905) is shorter, but still reasonable.
14. **Pgp:** Both Ligand A (0.109) and Ligand B (0.018) have low P-gp efflux, which is good. Ligand B is significantly lower.
15. **Affinity:** Ligand B (-8.8 kcal/mol) has a significantly stronger binding affinity than Ligand A (-7.2 kcal/mol) - a difference of 1.6 kcal/mol. This is a substantial advantage.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand B has a stronger affinity, lower Pgp efflux, and a better metabolic stability profile (Cl_mic). While Ligand A has a slightly better logP, the affinity difference is substantial enough to outweigh this. The slightly higher TPSA of Ligand B is not a major concern.
**Conclusion:**
Ligand B is the more promising candidate due to its significantly stronger binding affinity and improved metabolic stability, despite slightly lower logP and Caco-2 permeability. The DILI risk is also lower for Ligand B.
Output:
0
2025-04-17 21:52:35,521 - INFO - Batch 290 complete. Total preferences: 4640
2025-04-17 21:52:35,521 - INFO - Processing batch 291/512...
2025-04-17 21:53:25,618 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (344.46 and 350.42 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Both ligands have similar TPSA values (77.23 and 77.1), which are below the 140 A^2 threshold for good oral absorption and are acceptable for a peripheral GPCR like ADRB2.
**3. logP:** Ligand A (1.645) has a slightly better logP value than Ligand B (-0.064). While both are within the acceptable range, Ligand A is closer to the optimal 1-3 range, suggesting better permeability. Ligand B is bordering on being too hydrophilic.
**4. H-Bond Donors:** Ligand A (3) has more HBD than Ligand B (1). While both are within the acceptable limit of 5, fewer HBDs are generally preferred for better permeability. Ligand B is better here.
**5. H-Bond Acceptors:** Ligand A (3) and Ligand B (5) are both within the acceptable limit of 10.
**6. QED:** Both ligands have similar QED values (0.76 and 0.679), indicating good drug-like properties.
**7. DILI Risk:** Ligand A (15.36%) has a significantly lower DILI risk than Ligand B (30.4%). This is a major advantage for Ligand A.
**8. BBB Penetration:** Both ligands have relatively low BBB penetration (46.84% and 52.62%). Since ADRB2 is primarily a peripheral target (cardiovascular), high BBB penetration is not a priority.
**9. Caco-2 Permeability:** Ligand A (-5.316) has a worse Caco-2 permeability than Ligand B (-4.874), indicating lower intestinal absorption. Ligand B is better here.
**10. Aqueous Solubility:** Ligand A (-2.392) has worse aqueous solubility than Ligand B (-1.313). Ligand B is better here.
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.263 and 0.102). No significant difference.
**12. Microsomal Clearance:** Ligand A (-11.8) has a lower (better) microsomal clearance than Ligand B (-17.865), indicating better metabolic stability.
**13. In vitro Half-Life:** Ligand A (-4.536) has a worse in vitro half-life than Ligand B (17.903). Ligand B is significantly better here.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.02 and 0.012). No significant difference.
**15. Binding Affinity:** Ligand B (-6.2 kcal/mol) has a significantly better binding affinity than Ligand A (-4.5 kcal/mol). This is a substantial advantage for Ligand B (a difference of 1.7 kcal/mol).
**Overall Assessment:**
While Ligand A has a better logP and significantly lower DILI risk, Ligand B excels in binding affinity, in vitro half-life, Caco-2 permeability, and aqueous solubility. The substantial difference in binding affinity (-6.2 vs -4.5 kcal/mol) is the most important factor, as it can potentially overcome minor ADME drawbacks. The improved half-life and permeability of Ligand B are also significant advantages. The higher DILI risk of Ligand B is a concern, but not insurmountable during further optimization. Given the GPCR target class, binding affinity is paramount.
Output:
0
2025-04-17 21:53:25,618 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [375.441, 87.3, 1.203, 3, 4, 0.605, 43.389, 72.16, -5.063, -2.291, 0.278, 24.906, -1.625, 0.027, -6.4]
**Ligand B:** [346.515, 49.41, 3.524, 1, 2, 0.513, 11.128, 76.309, -4.966, -3.418, 0.63, 68.215, -15.275, 0.405, -7.3]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (346.5) is slightly lower, which is generally favorable.
2. **TPSA:** Ligand A (87.3) is a bit higher than Ligand B (49.41). Ligand B is much better here, being well under the 140 threshold for oral absorption and more favorable for GPCRs.
3. **logP:** Ligand A (1.203) is within the optimal range. Ligand B (3.524) is pushing the upper limit, but still acceptable.
4. **HBD/HBA:** Ligand A has 3 HBD and 4 HBA, while Ligand B has 1 HBD and 2 HBA. Ligand B is better here, with lower counts, potentially improving permeability.
5. **QED:** Ligand A (0.605) is better than Ligand B (0.513), indicating a slightly more drug-like profile.
6. **DILI:** Ligand A (43.389%) has a higher DILI risk than Ligand B (11.128%). This is a significant advantage for Ligand B.
7. **BBB:** Both have reasonable BBB penetration (A: 72.16%, B: 76.309%). Ligand B is slightly better.
8. **Caco-2:** Both are negative, indicating poor permeability. This is a concern for both.
9. **Solubility:** Both are negative, indicating poor solubility. This is a concern for both.
10. **hERG:** Ligand A (0.278) has a lower hERG risk than Ligand B (0.63). This is a positive for Ligand A.
11. **Cl_mic:** Ligand A (24.906) has a lower microsomal clearance than Ligand B (68.215), suggesting better metabolic stability. This favors Ligand A.
12. **t1/2:** Ligand A (-1.625) has a shorter half-life than Ligand B (-15.275). This favors Ligand B.
13. **Pgp:** Ligand A (0.027) has lower P-gp efflux than Ligand B (0.405), which is favorable for bioavailability and potentially CNS exposure.
14. **Affinity:** Ligand B (-7.3 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.4 kcal/mol) - a difference of 0.9 kcal/mol. This is a substantial advantage.
**Overall Assessment:**
While Ligand A has some advantages (better QED, lower Cl_mic, lower Pgp, lower hERG), Ligand B's significantly stronger binding affinity (-7.3 vs -6.4) and substantially lower DILI risk are critical. The lower TPSA and HBD/HBA counts of Ligand B also contribute to a more favorable profile. The slightly better BBB penetration of Ligand B is also a plus. The poor Caco-2 and solubility for both are concerning, but can be addressed with formulation strategies. The affinity difference is large enough to outweigh the other drawbacks.
Therefore, I would prioritize Ligand B.
0
2025-04-17 21:53:25,618 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (347.342) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (58.2) is significantly better than Ligand A (84.86). Lower TPSA is preferred for GPCRs, aiding in brain penetration and overall absorption.
3. **logP:** Ligand A (2.056) is optimal, while Ligand B (4.261) is pushing the upper limit. Higher logP can lead to solubility issues and off-target effects.
4. **HBD:** Both ligands have 2 HBD, which is within the acceptable range.
5. **HBA:** Ligand A has 5 HBA, and Ligand B has 3. Both are acceptable.
6. **QED:** Both ligands have good QED scores (A: 0.592, B: 0.71), indicating good drug-like properties.
7. **DILI:** Ligand B (49.864) has a lower DILI risk than Ligand A (58.589), which is a significant advantage.
8. **BBB:** Ligand B (67.468) has better BBB penetration potential than Ligand A (57.852), which is important for a GPCR.
9. **Caco-2:** Both ligands have very poor Caco-2 permeability (-4.841 and -4.873). This is a major concern for both.
10. **Solubility:** Both ligands have poor solubility (-3.594 and -4.125).
11. **hERG:** Both ligands have low hERG inhibition risk (0.694 and 0.73).
12. **Cl_mic:** Ligand B (55.533) has lower microsomal clearance than Ligand A (89.331), indicating better metabolic stability.
13. **t1/2:** Ligand B (29.345) has a much longer in vitro half-life than Ligand A (-25.566), which is highly desirable.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.271 and 0.238).
15. **Affinity:** Both ligands have very similar binding affinities (-5.6 and -4.8 kcal/mol). Ligand A is slightly better, but the difference is not substantial enough to outweigh other factors.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, BBB, and affinity), Ligand B is the more promising candidate. While both have poor Caco-2 and solubility, Ligand B demonstrates advantages in TPSA, DILI risk, BBB penetration, metabolic stability (Cl_mic and t1/2), and a slightly better QED score. The affinity difference is small, and the benefits of Ligand B in ADME properties outweigh the slight affinity advantage of Ligand A.
Output:
0
2025-04-17 21:53:25,618 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A: [349.391, 121.23 , 1.641, 2. , 5. , 0.459, 63.94 , 71.268, -5.017, -3.423, 0.27 , 8.305, -25.044, 0.118, -6.4 ]**
**Ligand B: [347.463, 80.12 , 1.838, 1. , 5. , 0.575, 32.377, 77.782, -5. , -1.903, 0.433, 37.024, -4.518, 0.168, -6.7 ]**
Here's a breakdown of each parameter and how the ligands compare, keeping GPCR priorities (logP, Pgp, TPSA, affinity) in mind:
1. **MW:** Both are within the ideal range (200-500 Da). A is 349.391, B is 347.463 - very similar.
2. **TPSA:** A (121.23) is slightly higher than B (80.12). B is significantly better, being well under the 140 threshold for good absorption.
3. **logP:** Both are good (1.641 and 1.838, respectively) falling within the 1-3 optimal range. B is slightly better.
4. **HBD:** A (2) is acceptable, B (1) is even better. Lower is generally preferred for permeability.
5. **HBA:** Both have 5 HBA, which is acceptable.
6. **QED:** B (0.575) is better than A (0.459), indicating a more drug-like profile.
7. **DILI:** A (63.94) is considerably higher than B (32.377). B has a much lower risk of liver injury.
8. **BBB:** Both are reasonably good (A: 71.268, B: 77.782), but B is slightly better. While not a CNS target, some BBB penetration can be beneficial for distribution.
9. **Caco-2:** Both are negative, indicating poor permeability. A (-5.017) is worse than B (-5).
10. **Solubility:** A (-3.423) is worse than B (-1.903). Solubility is a concern for both, but B is better.
11. **hERG:** Both are very low (A: 0.27, B: 0.433), indicating a low risk of cardiotoxicity.
12. **Cl_mic:** A (8.305) is much lower than B (37.024), suggesting better metabolic stability for A.
13. **t1/2:** A (-25.044) is significantly better than B (-4.518), indicating a longer half-life.
14. **Pgp:** Both are very low (A: 0.118, B: 0.168), indicating low P-gp efflux.
15. **Affinity:** B (-6.7) is slightly better than A (-6.4), though the difference is not huge.
**Overall Assessment:**
Ligand B is the stronger candidate. While Ligand A has better metabolic stability and half-life, Ligand B excels in several crucial areas: lower DILI risk, better TPSA, better QED, and slightly better solubility and affinity. The lower TPSA and DILI risk are particularly important. The slight advantage in affinity is a bonus. The solubility and Caco-2 values are concerning for both, but B is better. The improved metabolic stability of A is a plus, but the other benefits of B outweigh this.
Output:
0
2025-04-17 21:53:25,618 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (381.523 Da) is slightly higher than Ligand B (349.391 Da), but both are acceptable.
**2. TPSA:** Ligand A (71.53) is well below the 140 threshold for good oral absorption and is favorable. Ligand B (125.79) is still within range but closer to the upper limit, potentially indicating slightly reduced absorption.
**3. logP:** Ligand A (2.647) is optimal (1-3). Ligand B (0.043) is quite low, which could hinder membrane permeability and bioavailability. This is a significant negative for Ligand B.
**4. H-Bond Donors:** Both ligands have acceptable HBD counts (Ligand A: 1, Ligand B: 2), well below the 5 threshold.
**5. H-Bond Acceptors:** Both ligands have acceptable HBA counts (Ligand A: 6, Ligand B: 7), below the 10 threshold.
**6. QED:** Both ligands have good QED values (Ligand A: 0.833, Ligand B: 0.735), indicating drug-like properties.
**7. DILI:** Both ligands have acceptable DILI risk (Ligand A: 78.48, Ligand B: 65.762), below the concerning threshold of 60.
**8. BBB:** Ligand A (61.923) and Ligand B (74.564) both have moderate BBB penetration. While ADRB2 is a cardiovascular target, some CNS exposure can occur, so a higher BBB is slightly preferred. Ligand B has a better score here.
**9. Caco-2 Permeability:** Ligand A (-4.777) and Ligand B (-5) both have negative values, which is unusual. This suggests poor permeability.
**10. Aqueous Solubility:** Ligand A (-4.48) and Ligand B (-2.403) both have negative values, indicating poor solubility.
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (Ligand A: 0.443, Ligand B: 0.445), which is excellent.
**12. Microsomal Clearance:** Ligand A (70.876) has higher clearance than Ligand B (25.345), indicating lower metabolic stability. This is a negative for Ligand A.
**13. In vitro Half-Life:** Both have similar negative half-lives (-20.391 and -21.097), indicating poor stability.
**14. P-gp Efflux:** Both ligands have low P-gp efflux (Ligand A: 0.148, Ligand B: 0.087), which is favorable.
**15. Binding Affinity:** Ligand A (-7.0) has a slightly better binding affinity than Ligand B (-6.1). This 0.9 kcal/mol difference is significant.
**GPCR-Specific Considerations:** For a GPCR like ADRB2, logP, TPSA, and affinity are crucial. Ligand A excels in logP (optimal) and affinity (better). Ligand B has a better BBB score, but the very low logP is a major concern for permeability and bioavailability.
**Conclusion:**
Despite Ligand B's slightly better BBB penetration, the significantly lower logP value is a substantial drawback. Ligand A's optimal logP and slightly better binding affinity outweigh the slightly higher microsomal clearance and lower BBB. Therefore, I predict Ligand A is the more viable drug candidate.
1
2025-04-17 21:53:25,619 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [345.355, 114.33 , 2.124, 2. , 5. , 0.636, 82.319, 55.913, -4.616, -4.445, 0.337, 32.547, 12.856, 0.106, -5.6 ]
**Ligand B:** [362.499, 83.98 , 2.06 , 2. , 5. , 0.741, 45.328, 46.452, -5.325, -2.746, 0.078, 14.007, 13.856, 0.12 , -7.2 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (345.355) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (114.33) is higher than Ligand B (83.98). For a cardiovascular GPCR, TPSA isn't *as* critical as for CNS targets, but lower is still preferred for better absorption. Ligand B is better here.
3. **logP:** Both are excellent (around 2.0-2.1), falling squarely within the optimal range. No significant difference.
4. **HBD/HBA:** Both have 2 HBD and 5 HBA, which are acceptable values. No difference.
5. **QED:** Ligand B (0.741) has a slightly better QED score than Ligand A (0.636), indicating a more drug-like profile.
6. **DILI:** Ligand A (82.319) has a significantly higher DILI risk than Ligand B (45.328). This is a major concern.
7. **BBB:** Both are relatively low, which is fine for a cardiovascular target. Ligand B (46.452) is slightly better than Ligand A (55.913), but not a deciding factor.
8. **Caco-2:** Ligand B (-5.325) has a more negative Caco-2 value, indicating better permeability than Ligand A (-4.616).
9. **Solubility:** Ligand B (-2.746) has a better solubility value than Ligand A (-4.445).
10. **hERG:** Both are very low (0.337 and 0.078), indicating minimal hERG inhibition risk, which is excellent. Ligand B is slightly better.
11. **Cl_mic:** Ligand B (14.007) has a significantly lower microsomal clearance than Ligand A (32.547), suggesting better metabolic stability.
12. **t1/2:** Both have similar in vitro half-lives (12.856 and 13.856 hours).
13. **Pgp:** Both have low Pgp efflux liability (0.106 and 0.12).
14. **Binding Affinity:** Ligand B (-7.2 kcal/mol) has a substantially stronger binding affinity than Ligand A (-5.6 kcal/mol). This is a >1.5 kcal/mol difference, which is a significant advantage.
**Overall Assessment:**
Ligand B is clearly the superior candidate. While Ligand A has a slightly lower molecular weight, Ligand B excels in almost every other critical parameter. The most significant advantages of Ligand B are its much lower DILI risk, better metabolic stability (lower Cl_mic), improved permeability (Caco-2), better solubility, and significantly stronger binding affinity. The affinity difference alone is enough to outweigh any minor drawbacks. Given the GPCR target class, the combination of these factors makes Ligand B a much more promising drug candidate.
Output:
0
2025-04-17 21:53:25,619 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (343.39 and 353.42 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (89.35) is significantly better than Ligand B (127.63). ADRB2 is a cardiovascular target, not a CNS target, but lower TPSA generally improves absorption.
3. **logP:** Both ligands have good logP values (1.40 and 1.11), falling within the 1-3 range. Ligand B is slightly lower, which could be a minor drawback.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (6) is preferable to Ligand B (5). Similar to HBD, lower HBA is generally better.
6. **QED:** Ligand A (0.91) is significantly better than Ligand B (0.39), indicating a much more drug-like profile. This is a substantial advantage.
7. **DILI:** Ligand A (84.0) is worse than Ligand B (24.0). This is a significant concern for Ligand A.
8. **BBB:** Not a primary concern for a cardiovascular target, but Ligand A (57.9) is slightly better than Ligand B (47.4).
9. **Caco-2:** Ligand A (-4.97) is better than Ligand B (-5.30). Higher values indicate better absorption.
10. **Solubility:** Ligand A (-2.89) is better than Ligand B (-0.35). Better solubility is generally preferred.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.23 and 0.13). No significant difference.
12. **Cl_mic:** Ligand A (38.57) is worse than Ligand B (-1.99). Lower clearance indicates better metabolic stability, favoring Ligand B.
13. **t1/2:** Ligand A (-13.04) is worse than Ligand B (14.41). Longer half-life is desirable, favoring Ligand B.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.099 and 0.011). No significant difference.
15. **Binding Affinity:** Ligand B (-6.1) is significantly better than Ligand A (-0.1). A difference of >5 kcal/mol is very substantial and can outweigh many ADME concerns.
**Overall Assessment:**
Ligand B has a *much* stronger binding affinity (-6.1 kcal/mol vs -0.1 kcal/mol). While Ligand A has better QED and solubility, Ligand B's superior affinity, lower DILI risk, better metabolic stability (Cl_mic, t1/2) and comparable ADME properties make it the more promising candidate. The DILI risk for Ligand A is a major red flag. The substantial difference in binding affinity is the deciding factor.
Output:
0
2025-04-17 21:53:25,619 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.45 and 347.419 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (61.8) is significantly better than Ligand B (107.19). ADRB2 is not a CNS target, but lower TPSA generally improves absorption.
3. **logP:** Ligand A (2.327) is optimal (1-3). Ligand B (-0.026) is quite low, potentially hindering membrane permeability. This is a significant negative for Ligand B.
4. **HBD:** Ligand A (2) and Ligand B (3) are both acceptable (<=5).
5. **HBA:** Both ligands (4) are within the acceptable range (<=10).
6. **QED:** Ligand A (0.705) is better than Ligand B (0.602), indicating a more drug-like profile.
7. **DILI:** Ligand A (4.769) has a much lower DILI risk than Ligand B (34.781). This is a major advantage for Ligand A.
8. **BBB:** Not a primary concern for ADRB2 (cardiovascular target). Ligand A (81) is better than Ligand B (40.016), but this isn't decisive.
9. **Caco-2:** Ligand A (-5.081) and Ligand B (-5.652) are both negative, indicating poor permeability.
10. **Solubility:** Ligand A (-2.065) is slightly better than Ligand B (-1.691), but both are poor.
11. **hERG:** Ligand A (0.836) is significantly better than Ligand B (0.059), indicating lower cardiotoxicity risk. This is a crucial advantage.
12. **Cl_mic:** Ligand A (14.161) has a much lower microsomal clearance than Ligand B (-26.871), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-1.75) is better than Ligand B (-24.575), indicating a longer in vitro half-life.
14. **Pgp:** Ligand A (0.151) is much better than Ligand B (0.007), indicating lower P-gp efflux.
15. **Affinity:** Ligand B (-7.6) has a slightly better binding affinity than Ligand A (-5.5). However, the difference is less than 1.5 kcal/mol and is outweighed by the numerous advantages of Ligand A.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A is better on logP, TPSA, and Pgp. While Ligand B has a slightly better affinity, the other ADME properties of Ligand A are far superior.
**Conclusion:**
Ligand A demonstrates a significantly more favorable balance of properties, particularly regarding safety (DILI, hERG), metabolic stability (Cl_mic, t1/2), and permeability (logP, Pgp). The slightly weaker binding affinity of Ligand A is outweighed by its superior ADME profile and lower toxicity risk.
Output:
1
2025-04-17 21:53:25,619 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [343.427, 86.34, 2.286, 1, 4, 0.858, 22.838, 63.009, -4.991, -2.284, 0.425, -5.692, 22.843, 0.066, -6.4]**
**Ligand B: [337.335, 104.46, 1.196, 3, 5, 0.727, 64.521, 24.855, -5.126, -3.958, 0.144, -28.535, 28.545, 0.024, -7.5]**
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (343.427) is slightly higher than Ligand B (337.335), but both are acceptable.
2. **TPSA:** Ligand A (86.34) is excellent, well below the 140 threshold for good oral absorption and suitable for a GPCR. Ligand B (104.46) is still reasonable, but less optimal.
3. **logP:** Both ligands have good logP values (A: 2.286, B: 1.196) within the 1-3 range. Ligand A is slightly better.
4. **H-Bond Donors:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **H-Bond Acceptors:** Ligand A (4) is preferable to Ligand B (5), for the same reason as HBDs.
6. **QED:** Ligand A (0.858) has a better QED score than Ligand B (0.727), indicating a more drug-like profile.
7. **DILI:** Ligand A (22.838) has a much lower DILI risk than Ligand B (64.521). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (63.009) has a better BBB penetration percentile than Ligand B (24.855). While ADRB2 isn't strictly a CNS target, some CNS exposure can occur, and higher BBB is generally favorable.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.991) is slightly better than Ligand B (-5.126).
10. **Solubility:** Ligand A (-2.284) is better than Ligand B (-3.958).
11. **hERG:** Both ligands have low hERG inhibition risk (A: 0.425, B: 0.144), which is good. Ligand B is slightly better here.
12. **Cl_mic:** Ligand A (-5.692) has lower (better) microsomal clearance than Ligand B (-28.535), indicating better metabolic stability.
13. **t1/2:** Ligand A (22.843) has a slightly better in vitro half-life than Ligand B (28.545).
14. **Pgp:** Ligand A (0.066) has lower P-gp efflux than Ligand B (0.024), suggesting better oral bioavailability.
15. **Binding Affinity:** Ligand B (-7.5) has a slightly better binding affinity than Ligand A (-6.4). However, the difference is less than 1.5 kcal/mol, and other factors are more important.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity) and general drug-like properties, Ligand A is the superior candidate. It excels in DILI risk, QED, TPSA, solubility, metabolic stability (Cl_mic), and BBB penetration. While Ligand B has slightly better affinity and hERG inhibition, the significant advantages of Ligand A in safety (DILI) and drug-likeness outweigh these minor differences. The Caco-2 values are concerning for both, but the other properties of A are more favorable.
Output:
1
2025-04-17 21:53:25,619 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [347.459, 81.67, 2.273, 3, 3, 0.675, 34.432, 53.083, -4.953, -1.627, 0.5, -13.614, 35.11, 0.079, -6.4]
**Ligand B:** [369.487, 95.58, 0.673, 2, 4, 0.745, 41.838, 55.215, -5.522, -2.359, 0.123, 26.836, -21.441, 0.022, -7.8]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). A (347.459) is slightly preferred.
2. **TPSA:** A (81.67) is better than B (95.58). Both are below 140, but A is closer to the optimal value for good absorption.
3. **logP:** A (2.273) is optimal. B (0.673) is a bit low, potentially hindering permeation.
4. **HBD:** Both are acceptable (A: 3, B: 2).
5. **HBA:** Both are acceptable (A: 3, B: 4).
6. **QED:** Both are good (A: 0.675, B: 0.745), indicating drug-like properties. B is slightly better.
7. **DILI:** A (34.432) is better than B (41.838) - lower risk is always preferred.
8. **BBB:** Both are moderate. B (55.215) is slightly better than A (53.083), but neither is particularly high. Given ADRB2 is a cardiovascular target, BBB isn't a major priority.
9. **Caco-2:** A (-4.953) is much better than B (-5.522) - higher values indicate better absorption.
10. **Solubility:** A (-1.627) is better than B (-2.359).
11. **hERG:** Both are very low (A: 0.5, B: 0.123), indicating low cardiotoxicity risk. B is slightly better.
12. **Cl_mic:** A (-13.614) is significantly better than B (26.836) - lower clearance means greater metabolic stability. This is a substantial advantage for A.
13. **t1/2:** A (35.11) is better than B (-21.441) - longer half-life is generally desirable.
14. **Pgp:** Both are very low (A: 0.079, B: 0.022), indicating minimal efflux. B is slightly better.
15. **Binding Affinity:** B (-7.8) is significantly better than A (-6.4) - a 1.4 kcal/mol difference is substantial and can often outweigh other issues.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B has a better affinity, and acceptable TPSA and Pgp. Ligand A has a better logP and TPSA. However, the significantly better metabolic stability (Cl_mic and t1/2) and lower DILI risk of Ligand A are very important. While the affinity difference is significant, the other ADME properties of A are more favorable overall.
**Conclusion:**
Considering the balance of properties, especially the superior metabolic stability and lower DILI risk of Ligand A, combined with its acceptable ADME profile, I believe **Ligand A is the more promising drug candidate.**
Output:
1
2025-04-17 21:53:25,619 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (338.371 Da) is better, falling comfortably within the 200-500 Da range. Ligand B (386.279 Da) is still acceptable but closer to the upper limit.
2. **TPSA:** Ligand B (80.32) is significantly better than Ligand A (99.93). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (1.287) is optimal. Ligand B (3.311) is approaching the upper limit of the preferred range and could potentially lead to solubility issues or off-target interactions.
4. **HBD:** Both ligands have 2 HBD, which is good.
5. **HBA:** Ligand B (4) is better than Ligand A (6). Lower HBA is generally preferred for permeability.
6. **QED:** Ligand A (0.705) is better than Ligand B (0.581), indicating a more drug-like profile.
7. **DILI:** Ligand B (54.401) is *much* better than Ligand A (82.396). This is a significant advantage for Ligand B, as minimizing liver toxicity is crucial.
8. **BBB:** Ligand B (57.464) is better than Ligand A (26.638), but neither is particularly high. This isn't a major concern for a cardiovascular target.
9. **Caco-2:** Ligand A (-5.471) is better than Ligand B (-4.624) indicating better intestinal absorption.
10. **Solubility:** Ligand A (-3.23) is better than Ligand B (-4.487).
11. **hERG:** Both ligands have very low hERG risk (0.242 and 0.208 respectively), which is excellent.
12. **Cl_mic:** Ligand A (-3.52) is *much* better than Ligand B (47.107). Lower clearance indicates better metabolic stability.
13. **t1/2:** Ligand B (23.34) is significantly better than Ligand A (2.39). A longer half-life is desirable.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.028 and 0.038 respectively), which is excellent.
15. **Binding Affinity:** Ligand A (-7.8 kcal/mol) is significantly better than Ligand B (-6.8 kcal/mol). This is a 1.0 kcal/mol difference, which is substantial and can outweigh some ADME drawbacks.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. While Ligand B has better TPSA and Pgp, Ligand A has a superior logP and, crucially, a much stronger binding affinity. The DILI risk for Ligand B is also a significant positive. However, the metabolic stability of Ligand A (much lower Cl_mic) is a major advantage. The longer half-life of Ligand B is also a plus.
**Overall Assessment:**
The stronger binding affinity of Ligand A is a major advantage. While Ligand B has better DILI and half-life, the difference in binding affinity is substantial enough to outweigh these factors. The lower Cl_mic of Ligand A also suggests better metabolic stability. The solubility of Ligand A is also better.
Output:
1
2025-04-17 21:53:25,619 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (381.851) is slightly higher than Ligand B (347.419), but both are acceptable.
2. **TPSA:** Ligand A (72.88) is better than Ligand B (86.71). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (0.669) is better than Ligand B (0.118). Both are on the lower side of the optimal 1-3 range, but Ligand A is closer. Low logP can hinder membrane permeability.
4. **HBD:** Ligand A (2) is better than Ligand B (0). While zero HBD isn't necessarily bad, having some can aid solubility.
5. **HBA:** Ligand A (4) is better than Ligand B (5). Both are within the acceptable range, but lower is slightly preferred.
6. **QED:** Both ligands have good QED scores (A: 0.686, B: 0.709), indicating good drug-like properties.
7. **DILI:** Ligand A (33.579) is significantly better than Ligand B (55.758). Lower DILI risk is crucial.
8. **BBB:** Not a major priority for a cardiovascular target. Ligand A (53.083) is slightly better than Ligand B (49.244).
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.931 and -4.762), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand A (-1.243) is better than Ligand B (0.095). Better solubility is always preferred.
11. **hERG:** Ligand A (0.322) is much better than Ligand B (0.032). Lower hERG inhibition is critical for avoiding cardiotoxicity, especially for a cardiovascular target.
12. **Cl_mic:** Ligand A (-7.08) is significantly better than Ligand B (20.241). Lower clearance indicates better metabolic stability.
13. **t1/2:** Ligand A (-9.656) is better than Ligand B (-0.547). A more negative value indicates a longer half-life.
14. **Pgp:** Ligand A (0.055) is better than Ligand B (0.004). Lower P-gp efflux is desirable.
15. **Affinity:** Ligand A (-5.4 kcal/mol) is better than Ligand B (-6.2 kcal/mol). While Ligand B has a slightly better affinity, the difference is not substantial enough to outweigh the significant ADME advantages of Ligand A.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical ADME properties (DILI, hERG, Cl_mic, t1/2, solubility, Pgp). While both have poor Caco-2 permeability, the other advantages of Ligand A make it the more promising candidate. The slightly better affinity of Ligand B is not enough to overcome the substantial ADME liabilities. Given the cardiovascular target, minimizing cardiotoxicity (hERG) and maximizing metabolic stability (Cl_mic, t1/2) are particularly important, and Ligand A excels in these areas.
Output:
1
2025-04-17 21:53:25,619 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (367.5 and 369.5 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (82.43) is better than Ligand B (95.04). For a GPCR, keeping TPSA below 140 is good for oral absorption, and lower is generally preferred.
**3. logP:** Both ligands have good logP values (1.802 and 1.555), falling within the optimal 1-3 range. Ligand B is slightly lower, which *could* indicate slightly better solubility, but the difference is minor.
**4. H-Bond Donors:** Both have 1 HBD, which is within the acceptable limit of 5.
**5. H-Bond Acceptors:** Ligand A has 5 HBA, while Ligand B has 7. Both are below the 10 threshold, but Ligand A is preferable.
**6. QED:** Both ligands have acceptable QED values (0.596 and 0.699), indicating good drug-like properties. Ligand B is slightly better.
**7. DILI:** Ligand A (27.724) has a significantly lower DILI risk than Ligand B (35.789). This is a crucial advantage.
**8. BBB:** Both ligands have similar BBB penetration (64.793 and 65.839). While not exceptionally high, it's acceptable for a peripherally-acting GPCR like ADRB2, and not a primary driver for this target.
**9. Caco-2 Permeability:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the values are similar (-5.017 and -5.137).
**10. Aqueous Solubility:** Both have negative solubility values, indicating poor aqueous solubility. Again, the values are similar (-2.422 and -2.003).
**11. hERG Inhibition:** Ligand A (0.588) has a slightly higher hERG risk than Ligand B (0.392), but both are relatively low.
**12. Microsomal Clearance:** Ligand A (29.66) has a significantly lower microsomal clearance than Ligand B (8.022), indicating better metabolic stability. This is a significant advantage.
**13. In vitro Half-Life:** Ligand A (2.541) has a longer half-life than Ligand B (-2.376). This is a positive attribute.
**14. P-gp Efflux:** Ligand A (0.137) has lower P-gp efflux than Ligand B (0.175), which is favorable for bioavailability.
**15. Binding Affinity:** Ligand A (-6.1 kcal/mol) has a slightly better binding affinity than Ligand B (-5.5 kcal/mol). While the difference is not huge, it's a positive factor.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity) and general drug-like properties, Ligand A is the more promising candidate. It has a lower DILI risk, better metabolic stability (lower Cl_mic and longer t1/2), lower P-gp efflux, slightly better affinity, and a more favorable TPSA. While both have solubility and permeability concerns, these are areas that can be addressed through formulation strategies. The improved safety profile and pharmacokinetic properties of Ligand A outweigh the slight advantages of Ligand B in QED and logP.
Output:
1
2025-04-17 21:53:25,619 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.406 Da and 351.382 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (78.87) is well below the 140 threshold and favorable for oral absorption. Ligand B (95.5) is still acceptable, but closer to the limit.
3. **logP:** Ligand A (2.153) is optimal (1-3). Ligand B (-0.447) is below 1, which could hinder permeation. This is a significant negative for Ligand B.
4. **HBD:** Both ligands have acceptable HBD counts (2 and 1 respectively), well below the 5 limit.
5. **HBA:** Both ligands have acceptable HBA counts (4 and 5 respectively), well below the 10 limit.
6. **QED:** Both ligands have good QED scores (0.855 and 0.718), indicating drug-likeness.
7. **DILI:** Ligand A (44.203) has a lower DILI risk than Ligand B (61.07), which is approaching a higher risk category.
8. **BBB:** Ligand A (53.432) has a moderate BBB penetration, while Ligand B (73.827) is better. However, ADRB2 is a cardiovascular target, so high BBB penetration isn't a primary requirement.
9. **Caco-2:** Ligand A (-4.225) and Ligand B (-5.096) have negative values, which is unusual. Lower (more negative) values indicate poorer permeability. Ligand B is slightly worse.
10. **Solubility:** Ligand A (-2.073) and Ligand B (-0.982) have negative solubility values, also unusual. Lower (more negative) values indicate poorer solubility. Ligand B is better.
11. **hERG:** Both ligands have low hERG inhibition risk (0.644 and 0.067). Ligand B is significantly better.
12. **Cl_mic:** Ligand A (26.434) has a higher microsomal clearance than Ligand B (1.546), indicating lower metabolic stability. This is a significant negative for Ligand A.
13. **t1/2:** Ligand A (-17.278) has a negative half-life, which is not possible. Ligand B (6.763) has a reasonable half-life. This is a major issue for Ligand A.
14. **Pgp:** Ligand A (0.279) has lower P-gp efflux liability than Ligand B (0.008), which is favorable.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.4 kcal/mol and -6.2 kcal/mol). The difference is not substantial enough to override other factors.
**GPCR-specific priorities:** For ADRB2 (a cardiovascular GPCR), logP, TPSA, and affinity are important. Ligand A has a better logP and TPSA, but Ligand B has a much better metabolic stability (lower Cl_mic) and a reasonable half-life, while Ligand A has a nonsensical half-life.
**Conclusion:**
Despite Ligand A's slightly better logP and TPSA, the significantly better metabolic stability and reasonable half-life of Ligand B, coupled with Ligand A's impossible half-life, make Ligand B the more promising candidate. The lower DILI risk of Ligand A is a plus, but the metabolic issues with Ligand A are too significant to ignore.
Output:
0
2025-04-17 21:53:25,619 - INFO - Here's my reasoning and final output for the ligand preference:
**Reasoning:**
We are looking for a drug candidate for ADRB2, a cardiovascular GPCR. Therefore, the priorities are affinity, logP, TPSA, Pgp efflux, and, to a lesser extent, BBB.
Let's compare Ligand A and Ligand B across the 15 parameters:
1. **MW:** Both are within the ideal range (200-500 Da). A (338.4) is slightly better.
2. **TPSA:** Both are good, under 140. B (53.94) is slightly better than A (58.64).
3. **logP:** Both are good (1-3), but B (4.186) is pushing the upper limit and could lead to solubility issues. A (3.519) is more optimal.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** A (4) is better than B (6). Higher HBA can sometimes reduce permeability.
6. **QED:** A (0.848) is significantly better than B (0.673), indicating a more drug-like profile.
7. **DILI:** Both are above the 60 threshold, indicating a higher risk. B (70.88) is slightly worse than A (65.452).
8. **BBB:** Both are reasonably high, but A (85.459) is better than B (69.639). While not a CNS target, some BBB penetration can be beneficial for distribution.
9. **Caco-2:** A (-4.479) is better than B (-5.157). Higher (less negative) values indicate better permeability.
10. **Solubility:** A (-4.867) is better than B (-5.041).
11. **hERG:** Both are low, indicating low cardiotoxicity risk. A (0.817) is slightly better than B (0.773).
12. **Cl_mic:** A (86.292) is significantly better than B (116.798), indicating better metabolic stability.
13. **t1/2:** B (35.77) has a longer half-life than A (17.081), which is a positive.
14. **Pgp:** A (0.529) is better than B (0.414). Lower Pgp efflux is preferred.
15. **Affinity:** A (-7.0) is slightly better than B (-6.5), though both are excellent.
**Overall Assessment:**
Ligand A has a more balanced profile. It excels in key ADME properties (QED, Cl_mic, Pgp, solubility, Caco-2) and has comparable affinity to Ligand B. While Ligand B has a longer half-life, the higher logP, worse QED, and higher DILI risk make it less attractive. The slightly better BBB penetration of Ligand A is also a plus. Given the GPCR target class, the combination of good permeability, metabolic stability, and drug-likeness makes Ligand A the superior candidate.
**Output:**
1
2025-04-17 21:53:25,619 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's break down the comparison of Ligand A and Ligand B, considering the provided guidelines and GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key).
1. **Molecular Weight:** Both ligands (349.475 and 352.475 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both are around 83-84 A^2, which is acceptable for oral absorption, but not optimized for CNS penetration (though that's less critical for ADRB2 which is primarily cardiovascular).
3. **logP:** Both ligands have logP values around 2.1, which is optimal.
4. **H-Bond Donors/Acceptors:** Ligand A has 3 HBD and 4 HBA, while Ligand B has 2 HBD and 4 HBA. Both are within acceptable limits.
5. **QED:** Ligand B (0.718) has a slightly better QED score than Ligand A (0.566), indicating a more drug-like profile.
6. **DILI:** Ligand B (40.364) has a slightly higher DILI risk than Ligand A (29.236), but both are below the concerning threshold of 60.
7. **BBB:** Ligand B (68.554) shows significantly better BBB penetration potential than Ligand A (29.12). While ADRB2 isn't a primary CNS target, some CNS exposure can contribute to side effects.
8. **Caco-2 Permeability:** Both ligands have similar, very negative Caco-2 values (-4.856 and -4.844), suggesting poor permeability. This is a concern for both.
9. **Aqueous Solubility:** Both ligands have very poor aqueous solubility (-2.659 and -3.089). This is a significant drawback for both.
10. **hERG Inhibition:** Both ligands show low hERG inhibition liability (0.28 and 0.112), which is excellent.
11. **Microsomal Clearance:** Ligand A (50.918) has higher microsomal clearance than Ligand B (25.033), meaning it is likely metabolized faster. This is a negative for Ligand A.
12. **In vitro Half-Life:** Ligand B (-4.872) has a significantly longer in vitro half-life than Ligand A (32.806). This is a major advantage for Ligand B.
13. **P-gp Efflux:** Both ligands have low P-gp efflux liability (0.175 and 0.042), which is good.
14. **Binding Affinity:** Ligand B (-6.9 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.1 kcal/mol). This is a crucial advantage, exceeding the 1.5 kcal/mol difference threshold.
**Overall Assessment:**
Ligand B is the stronger candidate. While both have solubility and permeability issues, Ligand B's superior binding affinity (-6.9 vs -5.1 kcal/mol) and longer half-life are significant advantages. The slightly higher DILI risk is less concerning than the weaker binding and faster metabolism of Ligand A. The better BBB penetration is a bonus, even for a non-CNS primary target.
**Output:**
0
2025-04-17 21:53:25,620 - INFO - Batch 291 complete. Total preferences: 4656
2025-04-17 21:53:25,620 - INFO - Processing batch 292/512...
2025-04-17 21:54:14,245 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (366.355 and 351.403 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (60.85) is significantly better than Ligand B (111.99). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand B is pushing the upper limit for good oral absorption.
3. **logP:** Ligand A (1.355) is within the optimal range (1-3). Ligand B (0.155) is quite low, potentially leading to poor membrane permeability. This is a substantial negative for Ligand B.
4. **HBD/HBA:** Ligand A (1 HBD, 3 HBA) is preferable to Ligand B (3 HBD, 6 HBA). Both are acceptable, but fewer H-bonds are generally better for permeability.
5. **QED:** Ligand A (0.751) is better than Ligand B (0.575), indicating a more drug-like profile.
6. **DILI:** Ligand A (24.506) has a much lower DILI risk than Ligand B (33.346). This is a significant advantage for Ligand A.
7. **BBB:** Not a primary concern for a cardiovascular target, but Ligand A (86.584) has better BBB penetration than Ligand B (17.72).
8. **Caco-2:** Ligand A (-4.667) is better than Ligand B (-5.118), indicating better intestinal absorption.
9. **Solubility:** Ligand A (-2.439) is better than Ligand B (-1.127), suggesting better aqueous solubility.
10. **hERG:** Ligand A (0.407) has a lower hERG risk than Ligand B (0.187), which is a positive.
11. **Cl_mic:** Ligand A (8.734) has a lower (better) microsomal clearance than Ligand B (-13.955). This suggests better metabolic stability for Ligand A.
12. **t1/2:** Ligand A (-43.248) has a longer in vitro half-life than Ligand B (-12.02).
13. **Pgp:** Ligand A (0.026) has a lower P-gp efflux liability than Ligand B (0.008).
14. **Binding Affinity:** Ligand B (-7.2) has a slightly better binding affinity than Ligand A (-6.2). This is a 1 kcal/mol difference, which is notable but not overwhelming considering the other factors.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most crucial ADME-Tox properties. While Ligand B has a slightly better binding affinity, the significant deficiencies in logP, TPSA, DILI risk, and metabolic stability make it a less desirable candidate. Ligand A presents a more balanced profile with better predicted absorption, lower toxicity, and improved metabolic stability. Given the GPCR-specific priorities, the balance of properties in Ligand A is more favorable.
Output:
1
2025-04-17 21:54:14,245 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [366.483, 89.27, 2.511, 1, 5, 0.827, 52.772, 70.919, -4.841, -2.907, 0.107, 17.895, -1.52, 0.309, -6.2]
**Ligand B:** [354.491, 70.08, 1.517, 1, 4, 0.717, 7.794, 53.936, -4.492, -0.813, 0.359, 32.231, 17.42, 0.088, -8.2]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity, and BBB):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (354.491) is slightly lower, which is generally favorable.
2. **TPSA:** Ligand A (89.27) is a bit higher than Ligand B (70.08). Both are acceptable for a cardiovascular target, but Ligand B is better.
3. **logP:** Both are within the optimal range (1-3). Ligand B (1.517) is slightly lower, which could be a minor concern for permeability, but still acceptable. Ligand A (2.511) is better.
4. **HBD/HBA:** Both have 1 HBD, which is good. Ligand A has 5 HBA, and Ligand B has 4. Both are within acceptable limits.
5. **QED:** Ligand A (0.827) has a better QED score than Ligand B (0.717), indicating a more drug-like profile.
6. **DILI:** Ligand B (7.794) has a significantly lower DILI risk than Ligand A (52.772). This is a major advantage for Ligand B.
7. **BBB:** Ligand A (70.919) has a better BBB penetration score than Ligand B (53.936). While not a primary concern for a cardiovascular target, it's a slight positive for Ligand A.
8. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-4.841) is slightly worse than Ligand B (-4.492).
9. **Solubility:** Both are negative, indicating poor solubility. Ligand B (-0.813) is slightly better than Ligand A (-2.907).
10. **hERG:** Both have low hERG inhibition risk. Ligand B (0.359) is slightly better.
11. **Cl_mic:** Ligand A (17.895) has lower microsomal clearance than Ligand B (32.231), suggesting better metabolic stability. This is a positive for Ligand A.
12. **t1/2:** Ligand B (17.42) has a significantly longer in vitro half-life than Ligand A (-1.52). This is a substantial advantage for Ligand B.
13. **Pgp:** Ligand A (0.309) has lower P-gp efflux than Ligand B (0.088), which is favorable for bioavailability.
14. **Affinity:** Ligand B (-8.2 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.2 kcal/mol). This is a major advantage, potentially outweighing some ADME concerns.
**Overall Assessment:**
Ligand B has a much better safety profile (lower DILI) and significantly stronger binding affinity. It also has a longer half-life and slightly better solubility and Caco-2 permeability. While Ligand A has better BBB penetration and metabolic stability, the affinity difference and safety profile of Ligand B are more critical for a viable drug candidate. The affinity difference is >1.5 kcal/mol, which is a significant advantage.
Output:
0
2025-04-17 21:54:14,245 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (349.479 Da and 352.385 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (61.68) is significantly better than Ligand B (76.02). For a GPCR, keeping TPSA lower is preferable for permeability. Ligand A is well below the 90 A^2 threshold, while Ligand B is approaching it.
**3. logP:** Ligand B (1.333) is slightly better than Ligand A (0.61). Both are within the optimal 1-3 range, but Ligand B is closer to the center of that range. Ligand A is a bit low, potentially impacting membrane permeability.
**4. H-Bond Donors:** Ligand A (0) is preferable to Ligand B (2). Fewer H-bond donors generally improve permeability.
**5. H-Bond Acceptors:** Ligand A (5) is slightly better than Ligand B (4). Both are within the acceptable range.
**6. QED:** Both ligands have similar QED values (0.724 and 0.693), indicating good drug-like properties.
**7. DILI:** Ligand A (16.44) is significantly better than Ligand B (33.734). Lower DILI risk is crucial, and Ligand A is well within the 'good' range (<40). Ligand B is moderately elevated.
**8. BBB:** Ligand B (70.648) is better than Ligand A (59.209). While ADRB2 isn't exclusively a CNS target, some CNS penetration can be beneficial. Ligand B is at a desirable level.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests a problem with the experimental setup or the compounds themselves. However, Ligand A (-4.994) is slightly less negative than Ligand B (-4.715).
**10. Aqueous Solubility:** Ligand B (-3.004) is significantly better than Ligand A (0.257). Solubility is important for formulation and bioavailability.
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.239 and 0.143), which is excellent.
**12. Microsomal Clearance:** Ligand B (-2.507) is significantly better than Ligand A (3.574). Lower clearance indicates better metabolic stability.
**13. In vitro Half-Life:** Ligand B (-11.16) is significantly better than Ligand A (3.843). A longer half-life is generally preferred.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.018 and 0.006).
**15. Binding Affinity:** Ligand B (-6.6) has slightly better binding affinity than Ligand A (-6.3). While the difference is small, it's still a factor.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), and the general drug-likeness criteria, Ligand B emerges as the superior candidate. While Ligand A has better TPSA and DILI, Ligand B demonstrates significantly improved solubility, metabolic stability (Cl_mic and t1/2), and slightly better affinity. The improved BBB penetration is also a bonus. The solubility and metabolic stability advantages of Ligand B outweigh the slight TPSA disadvantage.
Output:
0
2025-04-17 21:54:14,246 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (354.491 and 345.443 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (67.87) is better than Ligand B (82.43). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands (2.136 and 2.421) are within the optimal 1-3 range. No significant difference.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Both have 4 HBA, which is good.
6. **QED:** Both are similar (0.678 and 0.66), indicating good drug-likeness.
7. **DILI:** Ligand A (17.759) has a significantly lower DILI risk than Ligand B (31.524). This is a major advantage.
8. **BBB:** Ligand A (77.2) has better BBB penetration than Ligand B (52.191). While not critical for a cardiovascular target, it's a slight positive.
9. **Caco-2:** Ligand A (-4.526) and Ligand B (-4.719) are similar.
10. **Solubility:** Ligand A (-2.655) is slightly better than Ligand B (-2.096).
11. **hERG:** Ligand A (0.333) has a lower hERG inhibition liability than Ligand B (0.763). This is a significant safety advantage.
12. **Cl_mic:** Ligand A (40.496) has a lower microsomal clearance than Ligand B (60.895), indicating better metabolic stability.
13. **t1/2:** Ligand A (3.495) has a shorter half-life than Ligand B (6.461). This is a slight disadvantage.
14. **Pgp:** Ligand A (0.065) has lower P-gp efflux liability than Ligand B (0.235), which is favorable for bioavailability.
15. **Binding Affinity:** Both ligands have the same binding affinity (-6.6 kcal/mol).
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Both ligands perform similarly on logP and affinity. Ligand A is better on TPSA and Pgp.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B in crucial ADMET properties (DILI, hERG, Cl_mic, Pgp, Solubility), while maintaining comparable binding affinity and acceptable drug-like properties. The lower DILI and hERG risks are particularly important for a cardiovascular drug, where safety is paramount. The slightly shorter half-life of Ligand A is a minor drawback that could potentially be addressed through formulation or structural modification.
Output:
1
2025-04-17 21:54:14,246 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (371.365 Da) is slightly higher than Ligand B (351.447 Da), but both are acceptable.
**2. TPSA:** Both ligands have TPSA values below 140, which is good for oral absorption. Ligand A (90.29) is preferable as it's closer to the 90 threshold for potential CNS penetration, though CNS targeting isn't explicitly stated. Ligand B (98.74) is still reasonable.
**3. logP:** Ligand A (2.703) is optimal, falling within the 1-3 range. Ligand B (0.171) is significantly lower and could indicate poor membrane permeability. This is a major drawback.
**4. H-Bond Donors:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
**5. H-Bond Acceptors:** Ligand A (6) is preferable to Ligand B (4).
**6. QED:** Both ligands have acceptable QED values (A: 0.789, B: 0.58), indicating reasonable drug-likeness. Ligand A is better.
**7. DILI:** Ligand A (79.798) has a higher DILI risk than Ligand B (12.796). This is a significant negative for Ligand A.
**8. BBB:** Ligand A (70.648) has a better BBB percentile than Ligand B (35.052). While ADRB2 isn't necessarily a CNS target, some peripheral ADRB2 activity can influence CNS function, and better BBB penetration isn't a major negative.
**9. Caco-2 Permeability:** Ligand A (-4.537) has a better Caco-2 permeability than Ligand B (-5.157).
**10. Aqueous Solubility:** Ligand A (-4.646) has a better aqueous solubility than Ligand B (-1.8).
**11. hERG Inhibition:** Both ligands have very low hERG inhibition liability (A: 0.118, B: 0.086), which is excellent.
**12. Microsomal Clearance:** Ligand A (-0.594) has a lower (better) microsomal clearance than Ligand B (13.551), indicating greater metabolic stability.
**13. In vitro Half-Life:** Ligand A (48.266) has a significantly longer in vitro half-life than Ligand B (11.524). This is a major advantage.
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (A: 0.102, B: 0.02).
**15. Binding Affinity:** Ligand B (-6.6) has a slightly better binding affinity than Ligand A (-6.0). However, the difference is less than 1.5 kcal/mol.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand A is the better candidate despite the higher DILI risk. The significantly better logP, lower HBD/HBA, better metabolic stability (lower Cl_mic, longer t1/2), and comparable binding affinity outweigh the DILI concern. The low logP of Ligand B is a major concern for permeability and bioavailability. While Ligand B has a slightly better binding affinity and DILI score, the ADME properties of Ligand A are far more favorable for a GPCR target.
Output:
1
2025-04-17 21:54:14,246 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.5 & 352.4 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (69.64) is better than Ligand B (85.69). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally favors absorption.
3. **logP:** Ligand A (2.328) is optimal, while Ligand B (0.692) is a bit low. A logP between 1-3 is preferred for good permeability. Ligand A is better here.
4. **HBD:** Both ligands have acceptable HBD counts (2 and 1 respectively), well below the 5 threshold.
5. **HBA:** Ligand A (3) is better than Ligand B (6). Lower HBA is preferable for permeability.
6. **QED:** Both ligands have similar and acceptable QED values (0.67 and 0.696).
7. **DILI:** Ligand A (6.941) is significantly better than Ligand B (31.02). Lower DILI risk is crucial.
8. **BBB:** Both ligands have similar BBB penetration (64.017 and 64.831). Not a major factor for a cardiovascular target.
9. **Caco-2:** Both ligands have similar negative Caco-2 values (-4.88 and -4.848), indicating poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-2.038) is better than Ligand B (-0.933). Higher solubility is desirable.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.461 and 0.133).
12. **Cl_mic:** Ligand A (27.923) has a significantly lower microsomal clearance than Ligand B (42.585), indicating better metabolic stability.
13. **t1/2:** Ligand A (0.46) has a shorter in vitro half-life than Ligand B (-2.395). This is a negative for Ligand A.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.115 and 0.024).
15. **Binding Affinity:** Ligand B (-6.1) has a slightly better binding affinity than Ligand A (-5.6). However, the difference is less than 1.5 kcal/mol, and other factors are more important.
**Overall Assessment:**
Ligand A is preferable. While Ligand B has a slightly better binding affinity, Ligand A excels in several critical ADME properties: lower TPSA, better logP, significantly lower DILI risk, better solubility, and lower microsomal clearance. The longer half-life of Ligand B is a plus, but the other advantages of Ligand A outweigh this. The poor Caco-2 permeability is a concern for both, but can be addressed with formulation strategies.
Output:
1
2025-04-17 21:54:14,246 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (a cardiovascular GPCR) drug candidates.
**Ligand A:** [345.443, 72.88, 1.132, 2, 4, 0.858, 42.536, 77.898, -4.664, -1.974, 0.475, 26.623, -8.308, 0.063, -0.6]
**Ligand B:** [348.403, 97.55, 0.259, 1, 8, 0.783, 55.448, 85.459, -4.508, -2.559, 0.328, 43.267, 0.404, 0.098, -6.5]
Here's a breakdown, considering the GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal range (200-500 Da). A is 345.443, B is 348.403 - very similar.
2. **TPSA:** A (72.88) is excellent, well below 140 and good for oral absorption. B (97.55) is still acceptable, but pushing the upper limit.
3. **logP:** A (1.132) is optimal. B (0.259) is quite low, which could hinder permeability. This is a significant drawback for B.
4. **HBD:** A (2) and B (1) are both good.
5. **HBA:** A (4) is good. B (8) is higher, but still within the acceptable range.
6. **QED:** Both are good (A: 0.858, B: 0.783), indicating drug-like properties.
7. **DILI:** A (42.536) is better than B (55.448), indicating lower liver injury risk.
8. **BBB:** A (77.898) and B (85.459) are both reasonably good, but not exceptionally high. This isn't a primary concern for a cardiovascular target.
9. **Caco-2:** Both are negative, indicating poor permeability. This is concerning for both.
10. **Solubility:** Both are negative, indicating poor solubility. This is concerning for both.
11. **hERG:** Both are very low, indicating low cardiotoxicity risk.
12. **Cl_mic:** A (26.623) is better (lower) than B (43.267), suggesting better metabolic stability.
13. **t1/2:** A (-8.308) is better (longer) than B (0.404).
14. **Pgp:** A (0.063) is better (lower) than B (0.098), indicating less efflux.
15. **Affinity:** B (-6.5) is significantly better than A (-0.6). This is a >1.5 kcal/mol advantage, which is substantial.
**Overall Assessment:**
Ligand B has a *much* stronger binding affinity. However, its low logP is a major concern, potentially leading to poor permeability and bioavailability. Ligand A has a more balanced profile, with better logP, DILI, metabolic stability, half-life, and Pgp efflux. While its affinity is weak, the other properties are more favorable for overall drug development. Given the GPCR focus, a reasonable logP is crucial for getting the drug to its target. The affinity difference is significant, but can potentially be addressed with further optimization. The poor Caco-2 and solubility for both compounds are concerning and would need to be addressed regardless of which lead is chosen.
Considering the balance of properties, and prioritizing permeability for a GPCR target, I would choose Ligand A.
Output:
1
2025-04-17 21:54:14,246 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.454 Da and 348.531 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (63.41) is higher than Ligand B (41.57). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is generally preferred for absorption. Ligand B is better.
3. **logP:** Ligand A (2.096) is within the optimal 1-3 range. Ligand B (3.351) is slightly higher, pushing the boundary but still acceptable. Ligand A is slightly better.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 6 HBAs, while Ligand B has 3. Both are acceptable (<=10), but Ligand B is preferable as fewer HBAs generally correlate with improved membrane permeability.
6. **QED:** Both ligands have similar QED values (0.899 and 0.847), indicating good drug-likeness.
7. **DILI:** Ligand A (14.618%) has a considerably higher DILI risk than Ligand B (6.049%). This is a significant negative for Ligand A.
8. **BBB:** Ligand A (84.529%) has a good BBB penetration, while Ligand B (94.184%) is even better. While ADRB2 isn't a CNS target, higher BBB is generally a positive indicator of permeability. Ligand B is better.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.773 and -4.653). This is unusual and suggests poor permeability. However, the values are very close.
10. **Solubility:** Ligand A (-2.656) has slightly better solubility than Ligand B (-4.134).
11. **hERG:** Ligand A (0.413) has a lower hERG risk than Ligand B (0.705). This is a positive for Ligand A.
12. **Cl_mic:** Ligand A (25.199) has a significantly lower microsomal clearance than Ligand B (41.74). Lower clearance is better for metabolic stability, a strong advantage for Ligand A.
13. **t1/2:** Ligand B (7.31) has a longer in vitro half-life than Ligand A (-2.819). This is a positive for Ligand B.
14. **Pgp:** Ligand A (0.247) has lower P-gp efflux than Ligand B (0.055). Lower P-gp efflux is generally better for bioavailability. Ligand A is better.
15. **Binding Affinity:** Ligand A (-8.2 kcal/mol) has a significantly stronger binding affinity than Ligand B (-5.9 kcal/mol). This is a substantial advantage for Ligand A, potentially outweighing some of its ADME drawbacks.
**Overall Assessment:**
Ligand A has a much stronger binding affinity and better metabolic stability (lower Cl_mic), and lower Pgp efflux. However, it has a higher DILI risk. Ligand B has better TPSA, BBB, and in vitro half-life, but its binding affinity is significantly weaker.
Given the importance of potency for GPCRs, and the substantial difference in binding affinity (-8.2 vs -5.9 kcal/mol), I believe Ligand A is the more promising candidate, *despite* the higher DILI risk. The DILI risk can be investigated and potentially mitigated through structural modifications, but a weak binder is much harder to improve.
Output:
1
2025-04-17 21:54:14,246 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
Let's analyze each ligand against the provided guidelines, keeping in mind ADRB2 is a GPCR, so logP, Pgp, TPSA, and affinity are key.
* **Molecular Weight:** Both ligands (345.4 & 366.5 Da) fall within the ideal 200-500 Da range.
* **TPSA:** Ligand B (58.64) is significantly better than Ligand A (108.29). Lower TPSA generally improves cell permeability, crucial for GPCR targeting.
* **logP:** Both ligands have good logP values (3.045 & 2.22), falling within the optimal 1-3 range. Ligand B is slightly lower, which could be a minor advantage for solubility.
* **H-Bond Donors/Acceptors:** Ligand A has 4 HBD and 4 HBA, while Ligand B has 1 HBD and 4 HBA. Ligand B's lower HBD count is slightly preferable as it can improve permeability.
* **QED:** Both ligands have acceptable QED scores (0.683 & 0.783), indicating good drug-like properties.
* **DILI:** Ligand B (32.183) has a much lower DILI risk than Ligand A (72.741). This is a significant advantage.
* **BBB:** Ligand B (74.254) has a better BBB penetration score than Ligand A (52.734), which is important for GPCRs.
* **Caco-2 Permeability:** Both ligands have similar, very negative Caco-2 values (-4.947 & -4.923). This is unusual and suggests poor permeability.
* **Aqueous Solubility:** Ligand B (-2.952) is better than Ligand A (-4.345), which is a positive.
* **hERG Inhibition:** Ligand B (0.465) has a lower hERG inhibition liability than Ligand A (0.192), reducing cardiotoxicity risk.
* **Microsomal Clearance:** Both have similar microsomal clearance values (52.661 & 51.806), indicating comparable metabolic stability.
* **In vitro Half-Life:** Ligand B (4.732) has a shorter half-life than Ligand A (25.801). This is a drawback for Ligand B.
* **P-gp Efflux:** Ligand B (0.137) shows lower P-gp efflux liability than Ligand A (0.034), which is favorable for bioavailability.
* **Binding Affinity:** Ligand A (-6.7 kcal/mol) has a slightly better binding affinity than Ligand B (-6.1 kcal/mol). However, the difference is less than 1.5 kcal/mol, so it's not a decisive factor.
**Overall Assessment:**
Ligand B demonstrates a significantly better ADME-Tox profile, with lower DILI risk, better BBB penetration, lower hERG inhibition, and lower P-gp efflux. While Ligand A has a slightly better binding affinity and longer half-life, the superior safety and permeability characteristics of Ligand B outweigh these benefits. The negative Caco-2 values are concerning for both, but the other improvements in Ligand B make it the more promising candidate.
**Output:**
0
2025-04-17 21:54:14,246 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (361.471 and 356.413 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (88.39) is higher than Ligand B (53.76). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is generally preferred for absorption. Ligand B is better.
3. **logP:** Ligand A (1.353) is within the optimal range (1-3), while Ligand B (3.332) is at the higher end. While still acceptable, Ligand B's higher logP *could* lead to solubility issues or off-target interactions. Ligand A is slightly better.
4. **HBD:** Ligand A (2) is reasonable, while Ligand B (0) is very low. A small number of HBDs can be beneficial for solubility, but too few can hinder binding. Ligand A is slightly better.
5. **HBA:** Ligand A (6) is acceptable, while Ligand B (3) is also good. No major difference.
6. **QED:** Both ligands have similar QED scores (0.777 and 0.786), indicating good drug-likeness.
7. **DILI:** Ligand A (69.717) has a higher DILI risk than Ligand B (23.226). This is a significant concern, and favors Ligand B.
8. **BBB:** Ligand A (61.691) and Ligand B (93.098). Since ADRB2 is not a CNS target, BBB is less important, but higher is still slightly preferable. Ligand B is better.
9. **Caco-2:** Ligand A (-5.452) and Ligand B (-4.125). Both are negative, indicating poor permeability. Ligand B is slightly better.
10. **Solubility:** Ligand A (-2.723) and Ligand B (-2.497). Both are poor, but Ligand B is slightly better.
11. **hERG:** Ligand A (0.301) has a lower hERG risk than Ligand B (0.553), which is a significant advantage. Ligand A is better.
12. **Cl_mic:** Ligand A (36.407) has lower microsomal clearance than Ligand B (44.146), indicating better metabolic stability. Ligand A is better.
13. **t1/2:** Ligand A (11.061) has a shorter half-life than Ligand B (22.587). Ligand B is better.
14. **Pgp:** Ligand A (0.036) has lower P-gp efflux than Ligand B (0.132), which is preferable. Ligand A is better.
15. **Binding Affinity:** Ligand A (-6.5 kcal/mol) has a slightly better binding affinity than Ligand B (-5.7 kcal/mol). This is a 0.8 kcal/mol difference, which is significant and can outweigh some ADME drawbacks. Ligand A is better.
**Overall Assessment:**
Ligand A has a better binding affinity, lower DILI risk, better metabolic stability, lower P-gp efflux, and a more favorable hERG profile. While Ligand B has better BBB penetration and half-life, the DILI risk associated with Ligand B is a major concern. The slightly better affinity of Ligand A, combined with its more favorable safety profile, makes it the more promising candidate.
Output:
1
2025-04-17 21:54:14,246 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (339.435 and 360.401 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (38.77) is significantly better than Ligand B (75.71). For a GPCR, lower TPSA is generally preferred for better permeability, and Ligand A is well below the 140 threshold, while B is approaching it.
**3. logP:** Ligand A (3.616) is slightly higher than Ligand B (1.727), both within the optimal 1-3 range. Ligand B is a bit low, potentially impacting permeability.
**4. H-Bond Donors:** Ligand A (0) is preferable to Ligand B (1). Fewer HBDs generally improve permeability.
**5. H-Bond Acceptors:** Both ligands have 4 HBA, which is acceptable.
**6. QED:** Ligand A (0.754) has a better QED score than Ligand B (0.578), indicating a more drug-like profile.
**7. DILI:** Ligand A (34.665) has a lower DILI risk than Ligand B (47.421), which is a significant advantage.
**8. BBB:** Both ligands have good BBB penetration (Ligand A: 78.868, Ligand B: 80.613). This isn't a primary concern for a cardiovascular target, but it's not detrimental.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.53 and -4.512). This is unusual and suggests poor permeability *in vitro*. However, these values are very close, so the difference isn't decisive.
**10. Aqueous Solubility:** Ligand A (-4.591) has slightly worse solubility than Ligand B (-2.314). Solubility is important, but not a major deciding factor here.
**11. hERG Inhibition:** Ligand A (0.915) has a lower hERG risk than Ligand B (0.332), which is a significant advantage for cardiovascular safety.
**12. Microsomal Clearance:** Ligand A (87.794) has higher clearance than Ligand B (37.558). This means Ligand B is more metabolically stable, which is desirable.
**13. In vitro Half-Life:** Ligand B (-16.563) has a significantly longer half-life than Ligand A (-5.272). This is a major advantage for dosing frequency.
**14. P-gp Efflux:** Ligand A (0.653) has lower P-gp efflux than Ligand B (0.043), which is preferable.
**15. Binding Affinity:** Ligand A (-6.9) has a slightly better binding affinity than Ligand B (-6.0). While both are good, the 0.9 kcal/mol difference is noteworthy.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand A is the stronger candidate. It has better TPSA, QED, DILI risk, hERG inhibition, and binding affinity. While Ligand B has better metabolic stability (lower Cl_mic, longer t1/2) and solubility, the advantages of Ligand A in key ADME/Tox properties and potency outweigh these benefits. The similar Caco-2 values are a concern for both, but the other factors make Ligand A the more promising starting point for optimization.
Output:
1
2025-04-17 21:54:14,247 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (364.515 and 362.436 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (78.09) is higher than Ligand B (49.41). For a cardiovascular GPCR, TPSA isn't a *major* concern like it would be for a CNS target, but lower is generally preferred for permeability. Ligand B is better here.
3. **logP:** Ligand A (1.837) is within the optimal range (1-3), while Ligand B (3.507) is at the higher end. While still acceptable, higher logP can sometimes lead to off-target effects and solubility issues. Ligand A is slightly better.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1). Both are within the acceptable limit of 5.
5. **HBA:** Ligand A (4) is higher than Ligand B (2). Both are within the acceptable limit of 10.
6. **QED:** Both ligands have similar QED values (0.738 and 0.718), indicating good drug-likeness.
7. **DILI:** Ligand A (26.91) has a significantly lower DILI risk than Ligand B (31.33). This is a crucial factor, as minimizing liver toxicity is paramount. Ligand A is significantly better.
8. **BBB:** Ligand A (50.523) has a lower BBB penetration percentile than Ligand B (88.949). Since ADRB2 is primarily a cardiovascular target, high BBB penetration isn't a priority, and is even undesirable. Ligand B is better.
9. **Caco-2:** Ligand A (-5.32) shows poorer Caco-2 permeability compared to Ligand B (-4.348). This suggests Ligand B might have better intestinal absorption. Ligand B is better.
10. **Solubility:** Ligand A (-1.626) has better aqueous solubility than Ligand B (-3.888). Solubility is important for bioavailability. Ligand A is better.
11. **hERG:** Ligand A (0.222) has a lower hERG inhibition liability than Ligand B (0.481). This is a critical safety parameter; lower is much better. Ligand A is better.
12. **Cl_mic:** Ligand A (17.79) has a lower microsomal clearance than Ligand B (56.541). Lower clearance indicates better metabolic stability. Ligand A is significantly better.
13. **t1/2:** Ligand A (-17.536) has a much longer in vitro half-life than Ligand B (1.328). This is a major advantage, potentially allowing for less frequent dosing. Ligand A is significantly better.
14. **Pgp:** Ligand A (0.036) has lower P-gp efflux liability than Ligand B (0.12). Lower P-gp efflux is generally desirable for improved bioavailability. Ligand A is better.
15. **Binding Affinity:** Ligand B (-6.4) has a slightly better binding affinity than Ligand A (-5.9). While a difference of 0.5 kcal/mol is noticeable, it's not overwhelmingly large, and can be compensated for by superior ADME properties.
**Overall Assessment:**
While Ligand B has slightly better binding affinity and BBB penetration (which isn't a priority here), Ligand A demonstrates a significantly more favorable ADME-Tox profile. Specifically, its lower DILI risk, significantly improved metabolic stability (lower Cl_mic, longer t1/2), better solubility, and lower hERG inhibition are crucial advantages. The slight difference in binding affinity is outweighed by these factors. For a cardiovascular GPCR target, prioritizing safety and favorable pharmacokinetic properties is paramount.
Output:
1
2025-04-17 21:54:14,247 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (335.363 and 346.431 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (81.16) is better than Ligand B (86.63), both are below the 140 threshold for oral absorption, but closer to the 90 threshold is better.
3. **logP:** Ligand A (3.39) is optimal, while Ligand B (0.722) is a bit low, potentially hindering membrane permeability. This is a significant advantage for Ligand A.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Both have 5 HBA, which is good.
6. **QED:** Ligand B (0.872) has a higher QED score than Ligand A (0.604), suggesting a more generally drug-like profile.
7. **DILI:** Ligand B (47.034) has a significantly lower DILI risk than Ligand A (84.102). This is a major advantage for Ligand B.
8. **BBB:** Ligand A (67.352) has a better BBB penetration score than Ligand B (50.95). While ADRB2 isn't strictly a CNS target, some CNS exposure can be beneficial or at least avoided as an off-target effect.
9. **Caco-2:** Ligand A (-5.488) has a lower Caco-2 permeability than Ligand B (-4.726).
10. **Solubility:** Ligand A (-3.432) has a lower solubility than Ligand B (-1.376).
11. **hERG:** Ligand A (0.514) has a higher hERG inhibition liability than Ligand B (0.256). This is a significant advantage for Ligand B.
12. **Cl_mic:** Ligand B (22.363) has a much lower microsomal clearance than Ligand A (92.505), indicating better metabolic stability. This is a strong advantage for Ligand B.
13. **t1/2:** Ligand A (63.821) has a longer in vitro half-life than Ligand B (-9.477). This is a positive for Ligand A.
14. **Pgp:** Ligand A (0.51) has a lower Pgp efflux liability than Ligand B (0.09).
15. **Binding Affinity:** Ligand A (-7.2 kcal/mol) has a stronger binding affinity than Ligand B (-6.5 kcal/mol). This is a substantial advantage for Ligand A, and potentially outweighs some of the ADME concerns.
**GPCR-Specific Priorities & Overall Assessment:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand A excels in affinity and has a good logP, but suffers from higher DILI, hERG, and Cl_mic. Ligand B has a lower DILI, hERG, and Cl_mic, and a better solubility, but its affinity is weaker and logP is lower.
The affinity difference (0.7 kcal/mol) is significant, but the ADME profile of Ligand B is considerably better, especially regarding safety (DILI, hERG) and metabolic stability (Cl_mic). While the lower logP of Ligand B is a concern, it's not insurmountable with further optimization. The improved safety profile and metabolic stability are more critical at this stage.
Therefore, I believe Ligand B is the more promising candidate despite the slightly lower affinity.
Output:
0
2025-04-17 21:54:14,247 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [363.502, 36.44, 3.685, 0, 4, 0.718, 36.293, 87.553, -4.403, -3.048, 0.91, 43.873, 55.17, 0.665, -5.7]
**Ligand B:** [364.808, 82.26, 3.366, 4, 2, 0.627, 88.329, 68.127, -4.69, -5.874, 0.481, 41.722, 87.727, 0.136, -6.6]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). A: 363.5, B: 364.8 - very similar.
2. **TPSA:** Ligand A (36.44) is significantly better than Ligand B (82.26). ADRB2 is a cardiovascular target, so CNS penetration isn't *essential*, but lower TPSA is generally favorable for absorption.
3. **logP:** Both are good (around 3.4-3.7), falling within the 1-3 optimal range. A: 3.685, B: 3.366 - similar.
4. **HBD:** Ligand A (0) is preferable to Ligand B (4). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is better than Ligand B (2). Lower HBA is generally preferred.
6. **QED:** Ligand A (0.718) is better than Ligand B (0.627), indicating a more drug-like profile.
7. **DILI:** Ligand A (36.293) is significantly better than Ligand B (88.329). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (87.553) is better than Ligand B (68.127), but BBB isn't a high priority for a cardiovascular target.
9. **Caco-2:** Both are negative, indicating poor permeability. A: -4.403, B: -4.69. B is slightly worse.
10. **Solubility:** Both are very poor (-3.048 and -5.874). This is a concern for both, but B is worse.
11. **hERG:** Ligand A (0.91) is better than Ligand B (0.481). Lower hERG risk is crucial.
12. **Cl_mic:** Both are similar (A: 43.873, B: 41.722). Neither is ideal, but not a major differentiator.
13. **t1/2:** Ligand B (87.727) is significantly better than Ligand A (55.17). Longer half-life is desirable.
14. **Pgp:** Ligand A (0.665) is better than Ligand B (0.136). Lower P-gp efflux is preferred.
15. **Affinity:** Ligand B (-6.6) is significantly better than Ligand A (-5.7). This is a 0.9 kcal/mol difference, which is substantial.
**GPCR-specific priorities:** For ADRB2 (a GPCR), we prioritize logP, Pgp, TPSA, and affinity. Ligand B has a better affinity. However, Ligand A has better TPSA, Pgp, and significantly better DILI and hERG. The solubility is poor for both.
**Overall Assessment:**
While Ligand B boasts a superior binding affinity, the significantly higher DILI risk and worse hERG profile are major red flags. The better TPSA, Pgp, QED, and DILI of Ligand A, combined with acceptable logP, outweigh the affinity difference. The poor solubility of both is a concern, but can be addressed with formulation strategies.
Therefore, I believe Ligand A is the more viable drug candidate.
Output:
1
2025-04-17 21:54:14,247 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (367.475 Da and 348.443 Da). No significant difference here.
2. **TPSA:** Both are reasonably low (87.54 and 89.87), suggesting good potential for absorption, though slightly above the optimal <90 for CNS targets.
3. **logP:** Ligand B (1.681) is better than Ligand A (0.468). A logP between 1-3 is preferred, and A is quite low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (4). Lower HBA counts are generally preferred.
6. **QED:** Ligand A (0.823) is slightly better than Ligand B (0.755), indicating a more drug-like profile.
7. **DILI:** Ligand B (24.312) is significantly better than Ligand A (42.691). Lower DILI risk is crucial.
8. **BBB:** Ligand A (76.541) is better than Ligand B (43.389). While ADRB2 isn't exclusively a CNS target, some CNS penetration can be beneficial for understanding off-target effects and potential side effects.
9. **Caco-2:** Both are negative, indicating poor permeability. This is a concern for both.
10. **Solubility:** Both are negative, indicating poor solubility. This is a concern for both.
11. **hERG:** Ligand A (0.12) is significantly better than Ligand B (0.317). Lower hERG inhibition is critical for avoiding cardiotoxicity, especially important for a cardiovascular target like ADRB2.
12. **Cl_mic:** Ligand A (5.073) is better than Ligand B (9.043). Lower clearance indicates better metabolic stability.
13. **t1/2:** Ligand A (16.499) is better than Ligand B (6.724). Longer half-life is generally desirable.
14. **Pgp:** Ligand A (0.012) is much better than Ligand B (0.06). Lower P-gp efflux is favorable for bioavailability.
15. **Binding Affinity:** Ligand B (-7.2) is significantly better than Ligand A (-3.3). This is a substantial difference in potency. A >1.5 kcal/mol advantage can often outweigh other drawbacks.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand B excels in affinity, which is the most important factor. While Ligand A has better BBB, DILI, hERG, Cl_mic, t1/2, and Pgp, the significantly stronger binding affinity of Ligand B is a major advantage that can potentially be optimized through further medicinal chemistry efforts to address its weaker ADME properties. The lower DILI and hERG risk of Ligand A are attractive, but the potency difference is too large to ignore.
**Conclusion:**
Despite some ADME liabilities, the significantly superior binding affinity of Ligand B makes it the more promising starting point for drug development targeting ADRB2.
0
2025-04-17 21:54:14,247 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (368-377 Da). No significant difference.
2. **TPSA:** Ligand A (43.6) is significantly better than Ligand B (76.66). ADRB2 is a cardiovascular target, so CNS penetration isn't essential, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (4.759) is higher than Ligand B (1.111). While 4.759 is approaching the upper limit, it's still acceptable. Ligand B's logP is quite low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Both ligands have 5 HBA, which is acceptable.
6. **QED:** Ligand B (0.628) is slightly better than Ligand A (0.44), indicating a more drug-like profile.
7. **DILI:** Ligand B (32.687) is *much* better than Ligand A (68.941). This is a critical advantage for Ligand B.
8. **BBB:** Not a high priority for a cardiovascular target. Ligand A (76.154) is higher than Ligand B (62.35), but this isn't a deciding factor.
9. **Caco-2:** Both are negative, indicating poor permeability. However, the scale is not provided, so it is difficult to assess the magnitude of the difference.
10. **Solubility:** Ligand B (-2.757) is better than Ligand A (-5.534), which is a positive.
11. **hERG:** Both are very low, indicating minimal hERG inhibition risk. No significant difference.
12. **Cl_mic:** Ligand B (41.794) is significantly better than Ligand A (96.628), indicating better metabolic stability.
13. **t1/2:** Ligand B (12.72) is better than Ligand A (8.8), suggesting a longer duration of action.
14. **Pgp:** Both are very low, indicating minimal P-gp efflux. No significant difference.
15. **Binding Affinity:** Ligand A (-6.3) is slightly better than Ligand B (-5.6), but the difference is not substantial enough to outweigh other factors.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are important. Ligand A has a better affinity and logP, but Ligand B has a much better TPSA and significantly better DILI and metabolic stability.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity and logP, Ligand B's superior DILI risk profile, metabolic stability (Cl_mic), half-life, and solubility are more critical for overall drug development success. The lower TPSA of Ligand A is also beneficial. The difference in binding affinity is not large enough to overcome the significant advantages of Ligand B in terms of safety and pharmacokinetic properties.
Output:
0
2025-04-17 21:54:14,248 - INFO - Batch 292 complete. Total preferences: 4672
2025-04-17 21:54:14,248 - INFO - Processing batch 293/512...
2025-04-17 21:55:03,240 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (359.455 and 347.459 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (81.81) is better than Ligand B (92.5). Both are below 140, but lower TPSA generally favors absorption.
3. **logP:** Both ligands have good logP values (2.586 and 1.662), falling within the 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability, but not drastically.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD is generally better for permeability.
5. **HBA:** Ligand A (6) is preferable to Ligand B (3). Lower HBA is generally better for permeability.
6. **QED:** Ligand A (0.759) is significantly better than Ligand B (0.565), indicating a more drug-like profile.
7. **DILI:** Ligand B (22.102) is *much* better than Ligand A (79.333). This is a major advantage for Ligand B. DILI is a critical safety concern.
8. **BBB:** Both ligands have reasonable BBB penetration (60.915 and 78.945). Ligand B is better, but this isn't a primary concern for a cardiovascular target like ADRB2.
9. **Caco-2:** Both are negative, indicating poor permeability. This is a concern for both.
10. **Solubility:** Both ligands have poor solubility (-2.597 and -2.629). This is a significant drawback for both.
11. **hERG:** Both ligands have low hERG inhibition risk (0.39 and 0.159). No significant difference.
12. **Cl_mic:** Ligand A (11.805) is significantly better than Ligand B (26.417). Lower clearance means better metabolic stability.
13. **t1/2:** Ligand A (15.464) is better than Ligand B (-14.553). A positive half-life is preferable.
14. **Pgp:** Ligand A (0.324) is better than Ligand B (0.061). Lower P-gp efflux is desirable.
15. **Binding Affinity:** Ligand B (-7.2) has a slightly better binding affinity than Ligand A (-6.7). This is a 0.5 kcal/mol difference, which is significant, but needs to be weighed against other factors.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A has slightly better logP and Pgp, while Ligand B has better affinity. However, the *huge* difference in DILI risk is the deciding factor. A high DILI risk is a showstopper for drug development.
**Conclusion:**
Despite Ligand B having slightly better affinity, the significantly lower DILI risk makes it the more promising candidate. While both have solubility and Caco-2 permeability issues, these can potentially be addressed with formulation strategies. The DILI risk is much harder to mitigate.
Output:
0
2025-04-17 21:55:03,240 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [361.511, 73.2, 2.653, 1, 4, 0.738, 30.593, 62.117, -5.013, -3.328, 0.478, 55.838, 2.327, 0.063, -6.2]
**Ligand B:** [388.295, 73.74, 2.598, 1, 4, 0.805, 32.105, 54.478, -4.838, -2.713, 0.437, 20.771, -30.961, 0.092, -6.7]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (361.511) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are reasonably good (73.2 and 73.74), below the 140 threshold for oral absorption, but not optimized for CNS penetration (which would require <90).
3. **logP:** Both ligands have excellent logP values (2.653 and 2.598), falling within the optimal 1-3 range.
4. **HBD/HBA:** Both have 1 HBD and 4 HBA, which is acceptable.
5. **QED:** Both have good QED scores (0.738 and 0.805), indicating good drug-like properties. Ligand B is slightly better.
6. **DILI:** Both have low DILI risk (30.593 and 32.105), well below the 40 threshold.
7. **BBB:** Ligand A (62.117) has a better BBB percentile than Ligand B (54.478), but neither is particularly high. Since ADRB2 isn't exclusively a CNS target, this isn't a decisive factor.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-5.013) is slightly worse than Ligand B (-4.838).
9. **Solubility:** Both have negative solubility values, which is also unusual and suggests poor solubility. Ligand B (-2.713) is slightly better than Ligand A (-3.328).
10. **hERG:** Both have very low hERG risk (0.478 and 0.437).
11. **Cl_mic:** Ligand B (20.771) has significantly lower microsomal clearance than Ligand A (55.838), indicating better metabolic stability. This is a significant advantage.
12. **t1/2:** Ligand B (-30.961) has a much longer *in vitro* half-life than Ligand A (2.327). This is a major advantage, potentially leading to less frequent dosing.
13. **Pgp:** Both have very low Pgp efflux liability (0.063 and 0.092).
14. **Binding Affinity:** Ligand B (-6.7 kcal/mol) has a slightly better binding affinity than Ligand A (-6.2 kcal/mol). This is a 0.5 kcal/mol difference, which is meaningful.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Both ligands perform well on logP and Pgp. TPSA is acceptable for both. Ligand B has a slightly better affinity and significantly better metabolic stability (lower Cl_mic and longer t1/2). The Caco-2 and solubility values are concerning for both, but the improved metabolic profile of Ligand B is a strong advantage.
**Conclusion:**
Considering the balance of properties, particularly the superior metabolic stability and slightly improved binding affinity of Ligand B, it is the more promising drug candidate.
Output:
0
2025-04-17 21:55:03,240 - INFO - Here's my reasoning and final output for the ligand preference:
**Reasoning:**
We are targeting the ADRB2, a GPCR involved in cardiovascular function. Therefore, the priorities are logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent BBB (though less critical for a cardiovascular target).
Let's compare Ligand A and Ligand B across the parameters:
1. **MW:** Both ligands (354.801 and 355.523 Da) are within the ideal range (200-500 Da).
2. **TPSA:** Ligand A (85.59) is slightly higher than Ligand B (81.67). Both are acceptable for oral absorption (<140), but B is preferable.
3. **logP:** Ligand A (2.842) is within the optimal range (1-3). Ligand B (1.379) is at the lower end, potentially impacting permeability. A is favored here.
4. **HBD/HBA:** Ligand A (1 HBD, 6 HBA) is better than Ligand B (3 HBD, 4 HBA) in terms of balancing solubility and permeability.
5. **QED:** Both are acceptable (A: 0.731, B: 0.672), with A being slightly better.
6. **DILI:** Ligand B (6.32) has a significantly lower DILI risk than Ligand A (95.502). This is a major advantage for B.
7. **BBB:** Ligand A (77.007) has better BBB penetration than Ligand B (55.099), but BBB is not a high priority for a cardiovascular target.
8. **Caco-2:** Ligand B (-5.161) has a better Caco-2 permeability than Ligand A (-4.898).
9. **Solubility:** Ligand B (-1.802) has better aqueous solubility than Ligand A (-3.974).
10. **hERG:** Both ligands have very low hERG inhibition liability (A: 0.304, B: 0.272).
11. **Cl_mic:** Ligand B (1.714) has significantly lower microsomal clearance, indicating better metabolic stability, than Ligand A (64.697).
12. **t1/2:** Ligand B (-20.046) has a much longer in vitro half-life than Ligand A (31.676). This is a significant advantage.
13. **Pgp:** Both have very low Pgp efflux liability (A: 0.341, B: 0.008), with B being slightly better.
14. **Binding Affinity:** Both ligands have the same binding affinity (-8.4 kcal/mol).
**Overall Assessment:**
While Ligand A has a slightly better logP and QED, Ligand B demonstrates superior ADME properties, particularly a much lower DILI risk, better metabolic stability (lower Cl_mic, longer t1/2), and improved solubility and permeability. Given the importance of minimizing toxicity and maximizing drug exposure for a cardiovascular target, the ADME advantages of Ligand B outweigh the minor differences in logP and QED.
**Output:**
0
2025-04-17 21:55:03,241 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (359.411 Da) is better than Ligand B (421.686 Da). Both are within the acceptable range, but A is closer to the ideal 200-500 Da.
2. **TPSA:** Ligand B (88.49) is better than Ligand A (105.98). Both are below 140, but B is closer to the preferred <90 for good absorption, and potentially better CNS penetration if desired.
3. **logP:** Ligand A (1.901) is better than Ligand B (3.216). Both are within the optimal 1-3 range, but A is closer to the lower end, which can be beneficial for solubility.
4. **HBD:** Both ligands have 2 HBD, which is good.
5. **HBA:** Ligand B (5) is slightly better than Ligand A (6). Both are acceptable, but lower is generally preferred.
6. **QED:** Ligand A (0.74) is better than Ligand B (0.677). Both are above 0.5, indicating good drug-likeness, but A is slightly higher.
7. **DILI:** Ligand B (93.059) is slightly better than Ligand A (98.682), but both are high. This is a concern for both compounds and would require further investigation.
8. **BBB:** Ligand A (50.911) is slightly better than Ligand B (48.313). However, for a cardiovascular target like ADRB2, BBB penetration is not a high priority.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.281 and -5.186), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand B (-4.896) is better than Ligand A (-3.427). Both are poor, but B is less poor.
11. **hERG:** Ligand A (0.509) is better than Ligand B (0.157). Lower hERG inhibition is crucial for avoiding cardiotoxicity, making A preferable.
12. **Cl_mic:** Ligand A (11.11) is significantly better than Ligand B (21.458). Lower clearance indicates better metabolic stability, a key advantage for A.
13. **t1/2:** Ligand A (73.039) is significantly better than Ligand B (14.822). A longer half-life is desirable for less frequent dosing.
14. **Pgp:** Ligand A (0.101) is better than Ligand B (0.148). Lower P-gp efflux is preferable.
15. **Binding Affinity:** Ligand B (-8.1 kcal/mol) is significantly better than Ligand A (-6.2 kcal/mol). This is a substantial difference in potency, and a >1.5 kcal/mol advantage often outweighs other drawbacks.
**Overall Assessment:**
Ligand B has a significantly better binding affinity, which is the most important factor for GPCRs. While Ligand A has better ADME properties in several areas (Cl_mic, t1/2, hERG, QED), the substantial difference in binding affinity (-8.1 vs -6.2 kcal/mol) is likely to be decisive. The poor Caco-2 and solubility for both compounds are concerning, but can potentially be addressed through formulation strategies. The DILI risk is high for both, but the potency advantage of B might justify further investigation into mitigating this risk.
Output:
0
2025-04-17 21:55:03,241 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [370.431, 132.46 , -0.802, 3. , 6. , 0.575, 78.325, 27.763, -5.73 , -2.196, 0.062, -12.316, 14.083, 0.012, -5.7 ]
**Ligand B:** [386.21 , 75.44 , 2.966, 1. , 4. , 0.877, 76.464, 82.125, -4.663, -4.557, 0.408, 19.062, 0.342, 0.257, -6.4 ]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity, and to a lesser extent BBB):
1. **MW:** Both are within the ideal 200-500 Da range. A (370.431) is slightly preferred.
2. **TPSA:** A (132.46) is slightly above the optimal <140, but still reasonable. B (75.44) is excellent, well below 90, suggesting good permeability. This is a significant advantage for B.
3. **logP:** A (-0.802) is a bit low, potentially hindering membrane permeability. B (2.966) is nearly ideal. This is a strong point for B.
4. **HBD/HBA:** A (3 HBD, 6 HBA) is acceptable. B (1 HBD, 4 HBA) is better, with fewer potential issues with solubility and permeability.
5. **QED:** Both are good (A: 0.575, B: 0.877), but B is significantly better, indicating a more drug-like profile.
6. **DILI:** Both are reasonably high (A: 78.325, B: 76.464), indicating potential liver toxicity risk. Not a major differentiator here.
7. **BBB:** A (27.763) is low, suggesting poor brain penetration. B (82.125) is very good, indicating good brain penetration. While ADRB2 isn't *necessarily* a CNS target, higher BBB is generally favorable for GPCRs.
8. **Caco-2:** Both are negative, which is unusual and problematic. It suggests very poor permeability. However, the scale is not specified, so it's difficult to interpret.
9. **Solubility:** Both are negative, which is also unusual and problematic. It suggests very poor solubility. However, the scale is not specified, so it's difficult to interpret.
10. **hERG:** A (0.062) is very low risk. B (0.408) is slightly higher, but still acceptable.
11. **Cl_mic:** A (-12.316) is excellent, indicating high metabolic stability. B (19.062) is significantly worse, suggesting faster metabolism. This is a significant advantage for A.
12. **t1/2:** A (14.083) is good. B (0.342) is very short, indicating rapid clearance. This is a major advantage for A.
13. **Pgp:** A (0.012) is very low efflux, which is excellent. B (0.257) is also low, but higher than A.
14. **Affinity:** B (-6.4) is 0.7 kcal/mol better than A (-5.7). This is a substantial difference and a major factor.
**Overall Assessment:**
Ligand B has a superior logP, TPSA, QED, and BBB penetration. However, Ligand A has significantly better metabolic stability (Cl_mic and t1/2) and Pgp efflux. The affinity difference is also substantial in favor of B. Considering the GPCR-specific priorities, the affinity and logP advantages of B, combined with its excellent TPSA and BBB, outweigh the metabolic concerns. The negative Caco-2 and Solubility values are concerning for both, but the superior binding affinity of B is a strong driver.
Output:
0
2025-04-17 21:55:03,241 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (359.294 and 354.47 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (41.49) is significantly better than Ligand B (78.09). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold, while Ligand B is approaching it.
3. **logP:** Both ligands have good logP values (3.705 and 2.457), falling within the 1-3 optimal range. Ligand A is slightly higher, which *could* be a minor concern for solubility, but not a dealbreaker.
4. **HBD/HBA:** Both ligands have 2 HBD and 3 HBA, which are within acceptable limits (<=5 and <=10 respectively).
5. **QED:** Ligand A (0.818) has a better QED score than Ligand B (0.677), indicating a more drug-like profile.
6. **DILI:** Ligand A (38.736) has a lower DILI risk than Ligand B (42.071), which is preferable. Both are below the 60 threshold, but lower is better.
7. **BBB:** Both ligands have reasonable BBB penetration (63.048 and 69.523). Since ADRB2 is a cardiovascular target, this isn't a critical factor, but higher is still slightly favored.
8. **Caco-2:** Both ligands have negative Caco-2 values (-5.063 and -4.944). This is unusual and suggests poor permeability. However, these values are close, so it doesn't strongly differentiate the two.
9. **Solubility:** Ligand A (-4.226) has slightly better solubility than Ligand B (-2.739).
10. **hERG:** Ligand A (0.922) has a lower hERG risk than Ligand B (0.513), which is a significant advantage for cardiovascular drugs.
11. **Cl_mic:** Ligand A (31.514) has a lower microsomal clearance than Ligand B (54.514), indicating better metabolic stability.
12. **t1/2:** Ligand B (-6.717) has a negative half-life, which is highly unusual and concerning. Ligand A (7.664) has a reasonable half-life.
13. **Pgp:** Ligand A (0.469) has lower P-gp efflux than Ligand B (0.189), which is favorable for bioavailability.
14. **Binding Affinity:** Ligand A (-8.5 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.4 kcal/mol). This is a >2 kcal/mol difference, which is substantial and can outweigh minor ADME concerns.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A excels in all these areas. The stronger affinity of Ligand A is the most important factor. The better TPSA, QED, DILI, hERG, Cl_mic, t1/2, and Pgp values further solidify its advantage.
**Conclusion:**
Ligand A is the clearly superior candidate. Its significantly stronger binding affinity, coupled with better ADME properties (particularly metabolic stability, hERG risk, and solubility), makes it a much more promising drug candidate for the ADRB2 receptor.
Output:
1
2025-04-17 21:55:03,241 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.475 and 346.362 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (67.87) is better than Ligand B (85.25). ADRB2 is a cardiovascular target, so CNS penetration isn't critical, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands (1.437 and 1.732) are within the optimal 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is preferable to Ligand B (5). Similar reasoning as HBD.
6. **QED:** Both ligands (0.785 and 0.748) have good drug-likeness scores, exceeding the 0.5 threshold.
7. **DILI:** Ligand A (12.369) is significantly better than Ligand B (73.517). This is a major advantage for Ligand A, as lower DILI risk is crucial.
8. **BBB:** Ligand A (85.072) is better than Ligand B (56.34), but BBB isn't a high priority for a cardiovascular target.
9. **Caco-2:** Ligand A (-4.512) and Ligand B (-4.744) are similar.
10. **Solubility:** Ligand A (-2.472) is better than Ligand B (-2.829). Better solubility is generally preferred.
11. **hERG:** Ligand A (0.355) is better than Ligand B (0.603). Lower hERG inhibition is crucial for avoiding cardiotoxicity, especially for a cardiovascular target.
12. **Cl_mic:** Ligand A (35.99) and Ligand B (35.622) are very similar.
13. **t1/2:** Ligand A (12.154) is better than Ligand B (-29.065). A longer half-life is generally desirable.
14. **Pgp:** Ligand A (0.038) is significantly better than Ligand B (0.14). Lower Pgp efflux is beneficial for bioavailability.
15. **Binding Affinity:** Ligand A (-6.8) is slightly better than Ligand B (-6.5), but the difference is relatively small.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Both ligands perform reasonably well in these areas. However, the significantly lower DILI risk, better hERG profile, and better Pgp efflux for Ligand A are major advantages. The slightly better affinity of Ligand A further supports its selection.
**Conclusion:**
Ligand A consistently outperforms Ligand B in key ADME-Tox properties (DILI, hERG, Pgp) and has a slightly better binding affinity. While both ligands are within acceptable ranges for many parameters, the safety profile of Ligand A makes it the more promising drug candidate.
Output:
1
2025-04-17 21:55:03,241 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [348.403, 127.32 , 0.199, 3. , 5. , 0.648, 32.183, 55.293, -5.545, -2.476, 0.026, 6.409, 12.575, 0.007, -6.8 ]
**Ligand B:** [359.289, 129.93 , 0.377, 2. , 6. , 0.431, 74.952, 64.482, -5.173, -2.675, 0.349, -5.026, -14.633, 0.049, -6. ]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity) and general drug-like properties:
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (348.4) is slightly preferred due to being a bit lower.
2. **TPSA:** Both are reasonably good (127.32 and 129.93), but slightly above the optimal <140 for good oral absorption. Not a major concern here.
3. **logP:** Ligand A (0.199) is quite low, potentially hindering membrane permeability. Ligand B (0.377) is better, but still on the low side. This is a significant drawback for both, but more so for A.
4. **HBD/HBA:** Ligand A (3 HBD, 5 HBA) is slightly better balanced than Ligand B (2 HBD, 6 HBA).
5. **QED:** Ligand A (0.648) has a better QED score than Ligand B (0.431), indicating better overall drug-likeness.
6. **DILI:** Ligand A (32.183) has a much lower DILI risk than Ligand B (74.952). This is a substantial advantage for A.
7. **BBB:** Ligand B (64.482) has a slightly higher BBB penetration than Ligand A (55.293), but neither is particularly high. Since ADRB2 is primarily a cardiovascular target, BBB penetration isn't *critical* but is still a consideration.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and indicates poor permeability.
9. **Solubility:** Both have negative solubility values, which is also unusual and indicates poor solubility.
10. **hERG:** Ligand A (0.026) has a much lower hERG risk than Ligand B (0.349). This is a significant advantage for A.
11. **Cl_mic:** Ligand B (-5.026) has a negative clearance, which is unusual and suggests very high metabolic stability. Ligand A (6.409) has a moderate clearance. This favors B.
12. **t1/2:** Ligand B (-14.633) has a negative half-life, which is unusual. Ligand A (12.575) has a reasonable half-life. This favors A.
13. **Pgp:** Ligand A (0.007) has significantly lower P-gp efflux liability than Ligand B (0.049). This is a positive for A.
14. **Affinity:** Both have very similar binding affinities (-6.8 and -6.0 kcal/mol). The difference is less than the 1.5 kcal/mol threshold.
**Overall Assessment:**
Ligand A appears to be the better candidate. While both have issues with logP and permeability, Ligand A has significantly better scores for DILI risk, hERG inhibition, P-gp efflux, QED, and in vitro half-life. The slightly better metabolic stability of Ligand B is not enough to offset these advantages. The similar binding affinities make the ADME properties the deciding factor.
Output:
1
2025-04-17 21:55:03,241 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.45 & 344.46 Da) fall comfortably within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (73.91) is better than Ligand B (78.09). Both are below the 140 threshold for oral absorption, but lower is generally preferred for GPCRs.
3. **logP:** Both ligands have good logP values (1.90 & 2.84), falling within the optimal 1-3 range. Ligand B is slightly higher, potentially improving membrane permeability.
4. **HBD:** Both have 2 HBD, which is acceptable.
5. **HBA:** Ligand A has 6 HBA, while Ligand B has 3. Both are within the acceptable range of <=10. Ligand B is preferable here.
6. **QED:** Ligand A (0.818) has a significantly better QED score than Ligand B (0.641), indicating a more drug-like profile.
7. **DILI:** Ligand A (36.57%) has a considerably lower DILI risk than Ligand B (54.98%). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (86.74%) shows much better predicted BBB penetration than Ligand B (58.86%). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant, and higher BBB is generally favorable.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale isn't specified, so it's hard to interpret.
10. **Solubility:** Both have negative solubility values, also unusual. Again, the scale is unknown.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.444 and 0.242), which is excellent.
12. **Cl_mic:** Ligand A (-15.89) has a *much* lower (better) microsomal clearance than Ligand B (48.49). This suggests significantly better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (-30.94) has a much longer in vitro half-life than Ligand B (8.94). This is a substantial advantage for Ligand A.
14. **Pgp:** Both have very low Pgp efflux liability (0.014 and 0.177), which is excellent.
15. **Binding Affinity:** Ligand A (-7.2 kcal/mol) has a slightly better binding affinity than Ligand B (-6.2 kcal/mol). While the difference is not huge, it is still a positive for Ligand A.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Both ligands perform reasonably well on logP and Pgp. Ligand A has a better TPSA and slightly better affinity. The significant advantages of Ligand A in terms of DILI risk, BBB penetration, metabolic stability (Cl_mic), and in vitro half-life outweigh the slightly better HBA count for Ligand B.
**Conclusion:**
Ligand A is the superior candidate due to its better overall ADME-Tox profile, particularly its lower DILI risk, better metabolic stability, longer half-life, and improved BBB penetration, combined with comparable binding affinity.
Output:
1
2025-04-17 21:55:03,242 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.46 & 352.48 Da) fall comfortably within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Both ligands have a TPSA of 81.08, which is acceptable for a non-CNS GPCR target like ADRB2.
3. **logP:** Ligand A (0.619) is slightly lower than Ligand B (1.172). Both are within the optimal 1-3 range, but Ligand B is preferable.
4. **HBD:** Both ligands have 2 H-bond donors, which is within the acceptable limit of <=5.
5. **HBA:** Both ligands have 4 H-bond acceptors, also within the acceptable limit of <=10.
6. **QED:** Both ligands have very similar QED scores (0.731 and 0.728), indicating good drug-likeness.
7. **DILI:** Ligand A (27.34%) has a significantly higher DILI risk than Ligand B (13.84%). This is a major concern, as lower DILI is highly desirable.
8. **BBB:** ADRB2 is primarily a cardiovascular target, so BBB penetration is not a primary concern. Ligand B (50.68%) has a higher BBB score than Ligand A (36.37%), but this is less important here.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.451 and -4.65), indicating poor permeability. This is a concern for both.
10. **Solubility:** Both ligands have negative solubility values (-0.877 and -0.856), indicating poor solubility. This is a concern for both.
11. **hERG:** Both ligands have low hERG inhibition liability (0.428 and 0.183), which is good. Ligand B is slightly better.
12. **Cl_mic:** Ligand A (-2.799) has a more negative (lower) microsomal clearance, suggesting better metabolic stability than Ligand B (-0.336). This is a significant advantage.
13. **t1/2:** Ligand A (-14.613) has a more negative (longer) in vitro half-life, suggesting better stability than Ligand B (-2.752). This is a significant advantage.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.079 and 0.024), which is good.
15. **Binding Affinity:** Ligand A (-7.4 kcal/mol) has a slightly better binding affinity than Ligand B (-5.4 kcal/mol). This is a 2.0 kcal/mol difference, which is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand A has a significantly better binding affinity and improved metabolic stability (lower Cl_mic, longer t1/2). However, it has a much higher DILI risk. Ligand B has a lower DILI risk and slightly better logP and hERG profiles.
Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity) and the general guidelines, the binding affinity advantage of Ligand A is substantial. While the DILI risk is a concern, it might be mitigated through structural modifications in later stages of optimization. The improved metabolic stability is also a key advantage for a cardiovascular target.
Therefore, I favor Ligand A.
Output:
1
2025-04-17 21:55:03,242 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (381.259 Da and 372.55 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (68.29) is higher than Ligand B (49.41). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is generally preferred for absorption. Ligand B has a clear advantage.
3. **logP:** Ligand A (4.583) is slightly higher than Ligand B (3.403). While both are above the optimal 1-3 range, Ligand A is pushing the upper limit and could present solubility challenges. Ligand B is better.
4. **HBD:** Both ligands have 1 HBD, which is within the acceptable limit of 5.
5. **HBA:** Ligand A has 4 HBAs, while Ligand B has 3. Both are within the acceptable limit of 10.
6. **QED:** Both ligands have reasonable QED scores (0.744 and 0.697), indicating good drug-like properties.
7. **DILI:** Ligand A (78.17) has a higher DILI risk than Ligand B (7.29). This is a significant concern, as lower DILI is highly desirable. Ligand B is much better.
8. **BBB:** Ligand A (69.058) and Ligand B (94.998). While ADRB2 isn't primarily a CNS target, higher BBB penetration can sometimes indicate better overall permeability and distribution. Ligand B is better.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.551 and -4.747). These values are unusual and suggest poor permeability. However, the values are very similar.
10. **Solubility:** Ligand A (-5.519) has worse solubility than Ligand B (-3.803). Solubility is important for bioavailability. Ligand B is better.
11. **hERG:** Ligand A (0.489) has a slightly lower hERG risk than Ligand B (0.844), which is favorable.
12. **Cl_mic:** Ligand A (99.727) has a much higher microsomal clearance than Ligand B (61.194), indicating faster metabolism and potentially lower exposure. Ligand B is better.
13. **t1/2:** Ligand A (34.153) has a longer in vitro half-life than Ligand B (-12.931). This is a positive for Ligand A.
14. **Pgp:** Ligand A (0.247) has lower P-gp efflux than Ligand B (0.172), which is favorable.
15. **Binding Affinity:** Ligand B (-7.6 kcal/mol) has a slightly better binding affinity than Ligand A (-7.2 kcal/mol). This difference is significant enough to consider, given the other factors.
**Overall Assessment:**
Ligand B consistently outperforms Ligand A in several critical ADME properties (DILI, BBB, solubility, Cl_mic) and has a slightly better binding affinity. While Ligand A has a longer half-life and lower Pgp efflux, the significantly higher DILI risk and poorer metabolic stability of Ligand A are major drawbacks. For a cardiovascular target like ADRB2, minimizing toxicity (DILI) and ensuring adequate exposure (lower Cl_mic) are paramount.
Output:
0
2025-04-17 21:55:03,242 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (355.479 Da) is within the ideal range (200-500), while Ligand B (383.514 Da) is also acceptable. No clear advantage here.
2. **TPSA:** Ligand A (79.9) is better than Ligand B (66.06). Both are below 140, but lower TPSA generally favors permeability.
3. **logP:** Ligand A (1.517) is optimal, while Ligand B (3.644) is approaching the upper limit of the optimal range. Ligand A is preferred.
4. **HBD:** Ligand A (2) and Ligand B (1) are both good, well within the limit of 5.
5. **HBA:** Both Ligand A (5) and Ligand B (5) are within the acceptable limit of 10.
6. **QED:** Ligand A (0.782) is significantly better than Ligand B (0.53), indicating a more drug-like profile.
7. **DILI:** Ligand A (20.861) is much better than Ligand B (64.133). This is a significant advantage for Ligand A, as lower DILI risk is crucial.
8. **BBB:** Both ligands have good BBB penetration (Ligand A: 72.431, Ligand B: 74.292). This is less critical for ADRB2 (cardiovascular target) but still a positive.
9. **Caco-2:** Ligand A (-4.61) is better than Ligand B (-5.415), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-1.88) is better than Ligand B (-4.121), indicating better aqueous solubility.
11. **hERG:** Ligand A (0.389) is significantly better than Ligand B (0.848), indicating a lower risk of cardiotoxicity. This is particularly important for a cardiovascular target.
12. **Cl_mic:** Ligand A (21.082) is much better than Ligand B (81.147), indicating better metabolic stability.
13. **t1/2:** Ligand A (-13.613) is better than Ligand B (22.895), indicating a longer in vitro half-life.
14. **Pgp:** Ligand A (0.015) is significantly better than Ligand B (0.607), indicating lower P-gp efflux.
15. **Binding Affinity:** Ligand A (-6.7 kcal/mol) is slightly better than Ligand B (-5.5 kcal/mol). While the difference isn't huge, it's a positive for Ligand A.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A performs better in all these categories. Additionally, the significantly better DILI and hERG profiles of Ligand A are crucial for a cardiovascular drug.
**Conclusion:**
Ligand A consistently outperforms Ligand B across most critical parameters, especially in ADME-Tox properties (DILI, hERG, Cl_mic, Pgp) and drug-likeness (QED). The slightly better affinity further strengthens its position.
Output:
1
2025-04-17 21:55:03,242 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (398.547 Da) is slightly higher than Ligand B (347.415 Da), but both are acceptable.
**2. TPSA:** Ligand A (120.85) is slightly above the preferred <140 for good oral absorption, but still reasonable. Ligand B (84.71) is excellent, well below 140, and favorable for permeability.
**3. logP:** Ligand A (-0.261) is a bit low, potentially hindering membrane permeability. Ligand B (2.813) is optimal, falling within the 1-3 range. This is a significant advantage for Ligand B.
**4. H-Bond Donors:** Ligand A (2) and Ligand B (1) are both within the acceptable limit of <=5.
**5. H-Bond Acceptors:** Ligand A (6) and Ligand B (5) are both within the acceptable limit of <=10.
**6. QED:** Both ligands have good QED values (A: 0.552, B: 0.577), indicating good drug-like properties.
**7. DILI:** Both ligands have similar DILI risk (A: 55.758, B: 54.207), and are both reasonably low.
**8. BBB:** Ligand A (41.76) has a lower BBB penetration percentile than Ligand B (89.492). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be beneficial for distribution and off-target effects assessment. Ligand B is significantly better here.
**9. Caco-2 Permeability:** Ligand A (-5.36) has poor Caco-2 permeability. Ligand B (-4.703) is also poor, but slightly better.
**10. Aqueous Solubility:** Ligand A (-1.75) and Ligand B (-3.404) both have poor aqueous solubility. This could pose formulation challenges.
**11. hERG Inhibition:** Ligand A (0.125) has a slightly lower hERG inhibition risk than Ligand B (0.692), which is preferable.
**12. Microsomal Clearance:** Ligand A (34.298) and Ligand B (37.468) have similar microsomal clearance values, suggesting comparable metabolic stability.
**13. In vitro Half-Life:** Ligand A (-8.297) has a negative half-life, which is not possible. This is a significant red flag. Ligand B (15.9) has a reasonable half-life.
**14. P-gp Efflux:** Ligand A (0.087) has lower P-gp efflux liability than Ligand B (0.196), which is favorable.
**15. Binding Affinity:** Both ligands have excellent binding affinity (A: -6.1 kcal/mol, B: -5.5 kcal/mol). Ligand A is slightly better, but the difference is less than 1.5 kcal/mol, so it doesn't dramatically outweigh other factors.
**GPCR-Specific Considerations:** For GPCRs, logP, TPSA, and affinity are key. Ligand B excels in logP and TPSA, while Ligand A has a slightly better affinity. However, the negative half-life for Ligand A is a critical flaw.
**Conclusion:**
Despite the slightly better affinity of Ligand A, the negative in vitro half-life is a deal-breaker. Ligand B, with its favorable logP, TPSA, BBB penetration, and reasonable half-life, presents a much more promising starting point for drug development.
Output:
0
2025-04-17 21:55:03,242 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's systematically compare Ligand A and Ligand B based on the provided parameters and the guidelines, keeping in mind ADRB2 is a GPCR.
1. **Molecular Weight:** Both ligands (357.4 and 351.5 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (64.63) is significantly better than Ligand B (82.54). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand A is well below the 140 threshold, while B is approaching it.
3. **logP:** Ligand A (3.491) is higher than Ligand B (1.596). While both are within the acceptable range (1-3), Ligand A is closer to the upper limit. This could potentially lead to off-target effects, but it might also be necessary for good binding.
4. **H-Bond Donors:** Ligand A (1) is better than Ligand B (3). Fewer HBDs generally improve permeability.
5. **H-Bond Acceptors:** Ligand A (4) is better than Ligand B (7). Similar to HBDs, lower HBA counts are generally preferred.
6. **QED:** Ligand A (0.687) is slightly better than Ligand B (0.59), indicating a more drug-like profile.
7. **DILI:** Ligand A (57.7%) is considerably better than Ligand B (15.1%). This is a crucial factor; lower DILI risk is highly desirable.
8. **BBB:** Ligand A (69.4%) is better than Ligand B (57.9%), although neither is exceptionally high. For a peripheral GPCR like ADRB2, BBB isn't *as* critical, but still a positive.
9. **Caco-2:** Ligand A (-4.364) is better than Ligand B (-5.23). Higher Caco-2 values indicate better absorption.
10. **Solubility:** Ligand A (-4.054) is better than Ligand B (-0.949). Better solubility is generally preferred.
11. **hERG:** Both ligands (0.689 and 0.806) are relatively low risk, but Ligand A is slightly better.
12. **Cl_mic:** Ligand A (102.221) is worse than Ligand B (-6.053). This means Ligand A has higher metabolic clearance and potentially lower *in vivo* exposure. This is a significant drawback.
13. **t1/2:** Ligand A (-21.916) is worse than Ligand B (62.682). Ligand B has a much longer half-life, which is a strong advantage.
14. **Pgp:** Both ligands (0.215 and 0.04) have low P-gp efflux, which is good. Ligand B is slightly better.
15. **Binding Affinity:** Ligand B (-6.6 kcal/mol) is slightly better than Ligand A (-6.0 kcal/mol). This is a meaningful difference, but not overwhelming.
**Overall Assessment:**
Ligand A has advantages in TPSA, solubility, and DILI risk. However, Ligand B excels in metabolic stability (Cl_mic and t1/2), has slightly better affinity, and a better Pgp profile. The significantly better metabolic stability and half-life of Ligand B are crucial for *in vivo* efficacy. The slightly better affinity is a bonus. While Ligand A's lower TPSA is good, the metabolic liabilities of Ligand A are too significant to ignore, especially given the modest affinity difference.
**Output:**
0
2025-04-17 21:55:03,242 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (357.495) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (73.32) is better than Ligand B (84.5). Both are acceptable, but lower TPSA generally improves oral absorption.
3. **logP:** Ligand B (2.196) is optimal, while Ligand A (0.277) is quite low. This is a significant drawback for Ligand A, potentially hindering membrane permeability and bioavailability.
4. **HBD:** Ligand A (1) is better than Ligand B (2). Lower HBD is generally preferred.
5. **HBA:** Ligand A (5) is better than Ligand B (4). Lower HBA is generally preferred.
6. **QED:** Both ligands have good QED scores (A: 0.569, B: 0.682), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand B (29.857) has a much lower DILI risk than Ligand A (8.453), which is a critical advantage.
8. **BBB:** Ligand B (61.923) is better than Ligand A (53.16). While ADRB2 isn't exclusively a CNS target, some CNS exposure might be acceptable or even beneficial depending on the specific indication.
9. **Caco-2:** Ligand A (-4.449) is better than Ligand B (-5.174). Higher Caco-2 permeability is better.
10. **Solubility:** Ligand A (-0.189) is better than Ligand B (-2.542). Higher solubility is better.
11. **hERG:** Both ligands have low hERG risk (A: 0.401, B: 0.389).
12. **Cl_mic:** Ligand B (37.192) has lower microsomal clearance than Ligand A (45.656), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-29.577) has a significantly longer in vitro half-life than Ligand A (-16.381). This is a major advantage for dosing convenience.
14. **Pgp:** Both ligands have low Pgp efflux liability (A: 0.043, B: 0.046).
15. **Binding Affinity:** Ligand A (-7.9) has a stronger binding affinity than Ligand B (-6). This is a substantial advantage.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A suffers from a very low logP, which is a major concern. While its affinity is better, the poor logP significantly impacts its potential for absorption and bioavailability. Ligand B, despite slightly lower affinity, has a much more favorable logP, better DILI, better metabolic stability (lower Cl_mic, longer t1/2), and better BBB penetration.
**Conclusion:**
Although Ligand A has a better binding affinity, the significantly lower logP and higher DILI risk are major drawbacks. Ligand B presents a more balanced profile with acceptable affinity, good drug-like properties, and favorable ADME characteristics. Therefore, Ligand B is the more viable drug candidate.
Output:
0
2025-04-17 21:55:03,243 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (386.539 Da and 376.519 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (89.87) is better than Ligand B (96.89). Both are below the 140 A^2 threshold for oral absorption, but lower TPSA is generally preferred for GPCRs.
**3. logP:** Both ligands have good logP values (1.321 and 1.104), falling within the optimal 1-3 range. No clear advantage.
**4. H-Bond Donors:** Both have 3 HBD, which is acceptable.
**5. H-Bond Acceptors:** Both have 6 HBA, which is acceptable.
**6. QED:** Ligand A (0.71) has a significantly better QED score than Ligand B (0.494), indicating a more drug-like profile.
**7. DILI:** Ligand B (23.459) has a much lower DILI risk than Ligand A (55.642). This is a significant advantage for Ligand B.
**8. BBB:** Ligand B (34.626) has a better BBB penetration score than Ligand A (25.591), although neither is particularly high. For a cardiovascular target, BBB penetration is less critical, but still a slight benefit to B.
**9. Caco-2 Permeability:** Both have negative Caco-2 values (-5.307 and -5.448), which is unusual and suggests poor permeability. However, the values are very close.
**10. Aqueous Solubility:** Both have negative solubility values (-3.239 and -2.33), indicating poor solubility. Again, values are very close.
**11. hERG Inhibition:** Both have very low hERG inhibition risk (0.271 and 0.173). No significant difference.
**12. Microsomal Clearance:** Ligand A (40.016) has higher microsomal clearance than Ligand B (22.728), indicating lower metabolic stability. This favors Ligand B.
**13. In vitro Half-Life:** Ligand B (-7.27) has a significantly longer in vitro half-life than Ligand A (13.023). This is a strong advantage for Ligand B.
**14. P-gp Efflux:** Both have low P-gp efflux liability (0.1 and 0.031). No significant difference.
**15. Binding Affinity:** Ligand A (-6.1 kcal/mol) has slightly better binding affinity than Ligand B (-5.5 kcal/mol). This is a 0.6 kcal/mol difference, which is notable but not overwhelming.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), and the general drug-like properties, Ligand B emerges as the more promising candidate. While Ligand A has slightly better affinity, Ligand B has a significantly better safety profile (DILI), metabolic stability (Cl_mic, t1/2), and a better QED score. The poor Caco-2 and solubility for both are concerning, but can be addressed with formulation strategies. The lower DILI risk and improved metabolic stability of Ligand B are crucial advantages for a cardiovascular drug.
Output:
0
2025-04-17 21:55:03,243 - INFO - Batch 293 complete. Total preferences: 4688
2025-04-17 21:55:03,243 - INFO - Processing batch 294/512...
2025-04-17 21:55:53,041 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.4 and 340.4 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (95.94) is slightly higher than Ligand B (88.99). Both are below the 140 threshold for oral absorption, but closer to the ideal for GPCRs. Ligand B is preferable.
3. **logP:** Ligand B (2.414) is within the optimal 1-3 range, while Ligand A (-0.53) is below 1, potentially hindering permeation. This is a significant advantage for Ligand B.
4. **HBD:** Both ligands have 2 HBD, which is acceptable.
5. **HBA:** Ligand A has 5 HBA, while Ligand B has 3. Both are below the 10 threshold. Ligand B is preferable.
6. **QED:** Ligand B (0.862) has a higher QED score than Ligand A (0.629), indicating a more drug-like profile.
7. **DILI:** Ligand A (41.411) has a lower DILI risk than Ligand B (56.689), which is a positive attribute.
8. **BBB:** Ligand B (53.044) shows better BBB penetration than Ligand A (26.483). While ADRB2 isn't strictly a CNS target, some CNS exposure can be beneficial or at least not detrimental, and higher BBB is generally desirable.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand B (-4.78) is slightly better than Ligand A (-5.064).
10. **Solubility:** Ligand A (-2.424) has slightly better solubility than Ligand B (-4.003).
11. **hERG:** Ligand A (0.044) has a very low hERG risk, significantly lower than Ligand B (0.331). This is a crucial advantage for Ligand A.
12. **Cl_mic:** Ligand A (-2.291) has a much lower (better) microsomal clearance than Ligand B (23.235), indicating greater metabolic stability.
13. **t1/2:** Ligand B (6.867) has a longer in vitro half-life than Ligand A (-11.015). This is a positive for Ligand B.
14. **Pgp:** Ligand A (0.088) has lower P-gp efflux liability than Ligand B (0.063), which is preferable.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.3 and -6.1 kcal/mol). The difference is negligible.
**Overall Assessment:**
Ligand B has advantages in logP, QED, BBB, and t1/2. However, Ligand A exhibits significantly better hERG safety, lower DILI risk, and much improved metabolic stability (Cl_mic). Considering ADRB2 is a cardiovascular target, minimizing off-target effects like hERG inhibition is paramount. The improved metabolic stability of Ligand A is also a significant benefit. While Ligand B's logP is better, Ligand A's solubility is better, and the difference isn't drastic enough to outweigh the safety and metabolic advantages.
Output:
1
2025-04-17 21:55:53,042 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [335.371, 100.55 , 1.806, 1. , 6. , 0.763, 82.396, 62.389, -5.138, -3.48 , 0.082, 30.379, -24.114, 0.087, -9. ]
**Ligand B:** [350.503, 49.85 , 3.55 , 0. , 3. , 0.688, 43.66 , 84.917, -4.848, -3.287, 0.684, 54.121, -15.815, 0.383, -7.5 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (335.371) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (100.55) is higher than Ligand B (49.85). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is still preferred for better absorption. Ligand B is significantly better here.
3. **logP:** Ligand A (1.806) is within the optimal range, while Ligand B (3.55) is approaching the upper limit. Ligand A is better.
4. **HBD:** Ligand A (1) is preferable to Ligand B (0). Having at least one HBD can improve solubility.
5. **HBA:** Ligand A (6) is better than Ligand B (3).
6. **QED:** Both are reasonably good (A: 0.763, B: 0.688), indicating drug-like properties. Ligand A is slightly better.
7. **DILI:** Ligand A (82.396) has a higher DILI risk than Ligand B (43.66). This is a significant drawback for Ligand A.
8. **BBB:** Ligand B (84.917) has better BBB penetration than Ligand A (62.389). While not a primary concern for a cardiovascular target, it's a bonus.
9. **Caco-2:** Ligand A (-5.138) and Ligand B (-4.848) are both very poor.
10. **Solubility:** Ligand A (-3.48) and Ligand B (-3.287) are both very poor.
11. **hERG:** Ligand A (0.082) has a lower hERG risk than Ligand B (0.684). This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand A (30.379) has a lower (better) microsomal clearance than Ligand B (54.121), indicating better metabolic stability.
13. **t1/2:** Ligand A (-24.114) has a longer half life than Ligand B (-15.815).
14. **Pgp:** Ligand A (0.087) has lower P-gp efflux than Ligand B (0.383).
15. **Affinity:** Ligand A (-9.0) has a significantly stronger binding affinity than Ligand B (-7.5). This is a substantial advantage.
**GPCR-Specific Priorities:** For ADRB2 (a cardiovascular GPCR), we prioritize logP, TPSA, Pgp, and affinity. Ligand A has a better logP, lower Pgp efflux, and *much* better affinity. Ligand B has a significantly better TPSA. However, the DILI risk for Ligand A is concerning, but the affinity difference is substantial. The improved metabolic stability (lower Cl_mic and longer t1/2) of Ligand A is also a plus.
**Conclusion:**
Despite the higher DILI risk, the significantly stronger binding affinity of Ligand A, combined with its better logP, Pgp, Cl_mic, and t1/2, outweighs the drawbacks. The affinity difference is large enough to potentially overcome the DILI concern with further optimization.
Output:
1
2025-04-17 21:55:53,042 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.471 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (62.55) is slightly higher than Ligand B (60.85), but both are well below the 140 threshold for good oral absorption and acceptable for a non-CNS GPCR target like ADRB2.
3. **logP:** Ligand A (3.676) is slightly higher than Ligand B (1.929). Both are within the optimal 1-3 range, but Ligand B is closer to the lower bound. For a GPCR, a slightly higher logP can be beneficial for membrane permeability.
4. **HBD:** Both ligands have 1 HBD, which is within the ideal limit of <=5.
5. **HBA:** Both ligands have 3 HBA, also within the ideal limit of <=10.
6. **QED:** Both ligands have high QED scores (0.827 and 0.849), indicating good drug-like properties.
7. **DILI:** Ligand B (6.359) has a significantly lower DILI risk than Ligand A (47.421). This is a major advantage for Ligand B.
8. **BBB:** Both ligands have good BBB penetration (70.609 and 77.549). While ADRB2 isn't a primary CNS target, some peripheral ADRB2 receptors can be affected by CNS penetration.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.41 and -4.614), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand B (-2.246) has better aqueous solubility than Ligand A (-3.436). Better solubility is generally preferred.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.258 and 0.251). This is excellent.
12. **Cl_mic:** Ligand B (13.281) has significantly lower microsomal clearance than Ligand A (78.574), indicating better metabolic stability. This is a major advantage for Ligand B.
13. **t1/2:** Ligand B (0.236) has a very short in vitro half-life, while Ligand A (69.988) has a much longer one. This is a significant advantage for Ligand A.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.58 and 0.053).
15. **Binding Affinity:** Ligand B (-7.2 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.5 kcal/mol). This is a substantial advantage, potentially outweighing some ADME drawbacks.
**GPCR-Specific Priorities & Overall Assessment:**
For ADRB2 (a GPCR), affinity, logP, and metabolic stability are key. Ligand B excels in affinity and metabolic stability (lower Cl_mic), and has a reasonable logP. While its half-life is very short, the significantly improved binding affinity and reduced DILI risk are compelling. Ligand A has a better half-life, but its higher DILI risk and weaker binding are concerning. The negative Caco-2 values for both are a red flag, but the superior binding affinity of Ligand B makes it more likely to be optimized to overcome this permeability issue.
Output:
0
2025-04-17 21:55:53,042 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands (345.403 and 352.475 Da) are within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand B (67.87) is significantly better than Ligand A (115.15). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (2.065 and 1.749), falling within the optimal 1-3 range. Ligand B is slightly lower, which could be beneficial for solubility.
4. **HBD:** Ligand A has 3 HBD, while Ligand B has 1. Lower is generally preferred for permeability, giving a slight edge to Ligand B.
5. **HBA:** Ligand A has 6 HBA, and Ligand B has 4. Again, Ligand B is better.
6. **QED:** Ligand A (0.631) has a slightly better QED score than Ligand B (0.507), indicating a more drug-like profile.
7. **DILI:** Ligand B (19.504 percentile) has a *much* lower DILI risk than Ligand A (83.288 percentile). This is a critical advantage.
8. **BBB:** Ligand B (78.868) has a higher BBB penetration score than Ligand A (56.65). While not a primary concern for a cardiovascular target, higher BBB is rarely detrimental.
9. **Caco-2:** Ligand A (-5.208) has a worse Caco-2 permeability than Ligand B (-4.374), suggesting poorer absorption.
10. **Solubility:** Ligand B (-1.075) has better aqueous solubility than Ligand A (-3.509).
11. **hERG:** Ligand B (0.244) has a lower hERG inhibition liability than Ligand A (0.381), reducing cardiotoxicity risk.
12. **Cl_mic:** Ligand A (1.214) has a significantly lower microsomal clearance than Ligand B (65.353), indicating better metabolic stability. This is a substantial advantage for Ligand A.
13. **t1/2:** Ligand A (-20.082) has a much longer in vitro half-life than Ligand B (0.226). This is a major advantage for Ligand A.
14. **Pgp:** Ligand A (0.03) has lower P-gp efflux than Ligand B (0.082), which could improve bioavailability.
15. **Affinity:** Ligand A (-4.6 kcal/mol) has a slightly weaker binding affinity than Ligand B (-2.6 kcal/mol). This is a 1.0 kcal/mol difference, which is significant.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP, TPSA, and Pgp. Ligand A has a better half-life and clearance. The affinity difference is substantial, favoring Ligand B. However, the DILI risk for Ligand A is very high, and the solubility is poor.
**Overall Assessment:**
While Ligand A has advantages in metabolic stability (Cl_mic and t1/2) and Pgp efflux, the significantly higher DILI risk, poorer solubility, and worse Caco-2 permeability are major drawbacks. Ligand B, despite slightly worse metabolic properties, presents a much more favorable safety profile (DILI, hERG) and better absorption characteristics (TPSA, Caco-2, solubility). The 1.0 kcal/mol affinity difference is outweighed by the other factors.
Output:
0
2025-04-17 21:55:53,042 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
We are targeting ADRB2, a GPCR. Therefore, key properties to prioritize are logP, TPSA, Pgp efflux, BBB penetration, and binding affinity. Metabolic stability (Cl_mic, t1/2) and safety (DILI, hERG) are also important, but slightly less so than the first set.
Let's compare the ligands property by property:
1. **MW:** Both ligands (340.427 and 346.395 Da) are within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (67.35) is significantly better than Ligand B (132.75). A TPSA under 140 is good for oral absorption, but Ligand B is pushing the limit.
3. **logP:** Ligand A (3.342) is optimal (1-3), while Ligand B (0.234) is quite low, potentially hindering membrane permeability.
4. **HBD/HBA:** Ligand A (1 HBD, 4 HBA) is preferable to Ligand B (3 HBD, 8 HBA). Lower counts generally improve permeability.
5. **QED:** Ligand A (0.906) has a much better QED score than Ligand B (0.657), indicating better overall drug-likeness.
6. **DILI:** Ligand B (63.746) has a higher DILI risk than Ligand A (50.523), although both are acceptable.
7. **BBB:** Ligand A (91.392) has significantly better BBB penetration potential than Ligand B (58.123). This is a strong advantage for a GPCR target.
8. **Caco-2:** Ligand A (-4.562) is better than Ligand B (-5.785).
9. **Solubility:** Ligand A (-3.356) is better than Ligand B (-2.709).
10. **hERG:** Ligand A (0.763) has a slightly better hERG profile than Ligand B (0.037).
11. **Cl_mic:** Ligand A (38.647) has a better metabolic stability profile than Ligand B (11.527).
12. **t1/2:** Ligand A (5.785) has a better in vitro half-life than Ligand B (-13.457).
13. **Pgp:** Ligand A (0.181) has a better Pgp efflux profile than Ligand B (0.015).
14. **Binding Affinity:** Ligand B (-7.7 kcal/mol) has a stronger binding affinity than Ligand A (-5.2 kcal/mol). This is a significant advantage.
**Overall Assessment:**
Ligand B has a substantially better binding affinity. However, it suffers from poor logP, high TPSA, and lower BBB penetration, and a negative in vitro half-life. Ligand A is more balanced across the board, with good drug-like properties, better ADME characteristics (logP, TPSA, BBB, Cl_mic, t1/2, Pgp), and acceptable safety profiles. The 1.5 kcal/mol difference in binding affinity is not enough to overcome the significant ADME deficiencies of Ligand B. For a GPCR like ADRB2, good brain penetration (BBB) and oral bioavailability (logP, TPSA, Pgp) are crucial, and Ligand A excels in these areas.
**Output:**
1
2025-04-17 21:55:53,043 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (344.371 and 358.389 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (113.18) is slightly higher than Ligand B (87.46). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is generally preferred for absorption. Ligand B has a clear advantage.
3. **logP:** Ligand A (1.493) and Ligand B (0.774) are both within the optimal 1-3 range, but Ligand B is closer to the lower end. Ligand A is slightly better here.
4. **HBD:** Ligand A (3) and Ligand B (2) are both acceptable. No major difference.
5. **HBA:** Both ligands have 5 HBA, which is within the acceptable limit. No difference.
6. **QED:** Ligand B (0.672) has a slightly higher QED than Ligand A (0.543), indicating a marginally better overall drug-like profile.
7. **DILI:** Ligand A (67.39) has a higher DILI risk than Ligand B (20.706). This is a significant advantage for Ligand B.
8. **BBB:** Both ligands have similar BBB penetration (65.258 and 67.235). Since ADRB2 is not a CNS target, this is not a major deciding factor.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. Ligand B (-4.61) is slightly better than Ligand A (-5.101), but both are concerning.
10. **Solubility:** Ligand A (-3.36) has slightly better solubility than Ligand B (-1.004).
11. **hERG:** Both ligands show low hERG inhibition risk (0.295 and 0.267). No significant difference.
12. **Cl_mic:** Ligand B (7.776) has a significantly lower microsomal clearance than Ligand A (18.725), indicating better metabolic stability. This is a strong advantage for Ligand B.
13. **t1/2:** Ligand B (-33.446) has a much longer in vitro half-life than Ligand A (-11.046). This is a substantial benefit for Ligand B.
14. **Pgp:** Both ligands show low P-gp efflux liability (0.041 and 0.031). No significant difference.
15. **Binding Affinity:** Ligand B (-6.1) has a slightly better binding affinity than Ligand A (-5.7). While the difference is not huge, it's still a positive for Ligand B.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand B demonstrates a more favorable profile. While Ligand A has slightly better logP and solubility, Ligand B excels in crucial areas like DILI risk, metabolic stability (Cl_mic and t1/2), TPSA, and binding affinity. The lower DILI risk and improved metabolic stability are particularly important for a cardiovascular drug candidate. The slightly better affinity of Ligand B further strengthens its position. The Caco-2 permeability is a concern for both, but the other advantages of Ligand B outweigh this drawback.
Output:
0
2025-04-17 21:55:53,043 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (355.425) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (39.72) is significantly better than Ligand B (75.44). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand B's TPSA is quite high.
3. **logP:** Ligand A (4.597) is a bit high, potentially leading to solubility issues, but still within a reasonable range. Ligand B (2.966) is optimal.
4. **HBD/HBA:** Both have 1 HBD and 4 HBA, which are within acceptable limits.
5. **QED:** Both ligands have good QED scores (A: 0.776, B: 0.877), indicating good drug-like properties. Ligand B is slightly better.
6. **DILI:** Ligand A (46.685) has a lower DILI risk than Ligand B (76.464), which is a significant advantage.
7. **BBB:** Both have high BBB penetration (A: 88.29, B: 82.125), but this is less critical for a cardiovascular target like ADRB2.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests potential issues with permeability prediction. However, the values are close enough to not be a major differentiator.
9. **Solubility:** Both have negative solubility values, which is also unusual and suggests potential formulation challenges. Again, the values are close.
10. **hERG:** Ligand A (0.779) has a slightly higher hERG risk than Ligand B (0.408), which is a concern.
11. **Cl_mic:** Ligand A (54.505) has a higher microsomal clearance than Ligand B (19.062), indicating lower metabolic stability. This is a disadvantage for Ligand A.
12. **t1/2:** Ligand B (0.342) has a much shorter in vitro half-life than Ligand A (17.834). This is a major disadvantage for Ligand B.
13. **Pgp:** Ligand A (0.442) has lower P-gp efflux than Ligand B (0.257), which is favorable.
14. **Binding Affinity:** Both ligands have very similar binding affinities (-6.5 and -6.4 kcal/mol), with Ligand A being slightly better. This difference is not substantial enough to outweigh other factors.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A has a slightly better logP and Pgp, and similar affinity. However, Ligand B has a much better TPSA. The biggest differentiators are DILI and metabolic stability (Cl_mic/t1/2). Ligand A has a significantly lower DILI risk and a much longer half-life, which are crucial for a viable drug candidate.
**Conclusion:**
Despite Ligand B's better TPSA and slightly better QED, Ligand A is the more promising candidate due to its significantly lower DILI risk, better metabolic stability (longer half-life), and acceptable logP and Pgp properties. The slight difference in binding affinity is not enough to overcome these advantages.
Output:
1
2025-04-17 21:55:53,043 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [342.439, 58.64, 2.208, 1, 3, 0.854, 35.401, 78.596, -4.468, -3.292, 0.183, 38.342, -13.205, 0.156, -5.8]
**Ligand B:** [344.419, 103.87, 1.41, 2, 5, 0.79, 57.425, 44.591, -5.583, -1.683, 0.133, 21.145, -14.737, 0.025, -5.7]
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). A is 342.439, B is 344.419. Very similar.
2. **TPSA:** Ligand A (58.64) is significantly better than Ligand B (103.87). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is pushing the upper limit for good oral absorption (<=140).
3. **logP:** Ligand A (2.208) is optimal. Ligand B (1.41) is acceptable but on the lower side, potentially impacting membrane permeability.
4. **HBD:** Ligand A (1) is preferred over Ligand B (2). Lower is generally better for permeability.
5. **HBA:** Ligand A (3) is better than Ligand B (5). Again, lower is preferred.
6. **QED:** Ligand A (0.854) is better than Ligand B (0.79), indicating a more drug-like profile.
7. **DILI:** Ligand A (35.401) has a much lower DILI risk than Ligand B (57.425). This is a significant advantage.
8. **BBB:** Ligand A (78.596) has a significantly higher BBB penetration potential than Ligand B (44.591). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be beneficial or at least avoid off-target effects.
9. **Caco-2:** Ligand A (-4.468) is better than Ligand B (-5.583), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-3.292) is better than Ligand B (-1.683).
11. **hERG:** Both ligands have very low hERG risk (0.183 and 0.133 respectively).
12. **Cl_mic:** Ligand B (21.145) has a lower microsomal clearance than Ligand A (38.342), suggesting better metabolic stability. This is a positive for Ligand B.
13. **t1/2:** Ligand B (-14.737) has a slightly longer in vitro half-life than Ligand A (-13.205).
14. **Pgp:** Ligand A (0.156) has lower P-gp efflux than Ligand B (0.025), which is better for bioavailability.
15. **Affinity:** Both ligands have very similar binding affinities (-5.8 kcal/mol).
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A excels in logP, TPSA, and Pgp. While the affinity is the same, the superior ADME properties of Ligand A are more important in this case.
**Conclusion:**
Ligand A demonstrates a more favorable balance of properties, particularly regarding TPSA, DILI risk, BBB penetration, solubility, and P-gp efflux. While Ligand B has slightly better metabolic stability and half-life, the other advantages of Ligand A outweigh this.
Output:
1
2025-04-17 21:55:53,043 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (354.422 and 345.487 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand B (52.65) is significantly better than Ligand A (87.66). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (2.228) is within the optimal 1-3 range, while Ligand A (0.94) is slightly below, potentially hindering permeation. Ligand B has an edge here.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (1), but both are acceptable (<=5).
5. **HBA:** Ligand A (4) and Ligand B (3) are both within the acceptable range (<=10).
6. **QED:** Ligand B (0.824) is significantly better than Ligand A (0.469), indicating a more drug-like profile.
7. **DILI:** Both ligands have low DILI risk (23.187 and 24.467 percentile), so no significant difference.
8. **BBB:** Both ligands have good BBB penetration (71.501 and 70.88 percentile), but this is less crucial for a cardiovascular target.
9. **Caco-2:** Ligand A (-5.264) is significantly better than Ligand B (-4.541), suggesting better intestinal absorption.
10. **Solubility:** Ligand A (-2.557) is slightly better than Ligand B (-2.164), though both are quite poor.
11. **hERG:** Ligand A (0.27) has a lower hERG risk than Ligand B (0.525), which is a significant advantage.
12. **Cl_mic:** Ligand A (-18.924) has a much lower (better) microsomal clearance than Ligand B (39.974), indicating greater metabolic stability.
13. **t1/2:** Ligand B (17.11) has a significantly longer in vitro half-life than Ligand A (4.381). This is a substantial benefit.
14. **Pgp:** Ligand A (0.062) has much lower P-gp efflux than Ligand B (0.1), suggesting better bioavailability.
15. **Binding Affinity:** Ligand A (-7.6) has a slightly better binding affinity than Ligand B (-6.9), but the difference is less than 1.5 kcal/mol.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand B appears to be the better candidate. While Ligand A has better Caco-2 permeability, solubility, hERG, Pgp efflux, and a slightly better affinity, Ligand B excels in QED, logP, and crucially, *in vitro* half-life. The longer half-life of Ligand B is a significant advantage, potentially allowing for less frequent dosing. The better QED score also suggests a more favorable overall drug-like profile. The TPSA of Ligand B is also significantly lower, which is beneficial for absorption. The affinity difference is not substantial enough to outweigh the other advantages of Ligand B.
Output:
0
2025-04-17 21:55:53,043 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (377.491 and 358.869 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (72.36) is slightly higher than Ligand B (66.56). Both are below the 140 threshold for oral absorption, and acceptable for a cardiovascular target (not requiring significant CNS penetration). Ligand B is slightly preferred.
3. **logP:** Both ligands have logP values (3.976 and 4.235) within the optimal 1-3 range, though approaching the upper limit. Ligand B is slightly higher, which *could* indicate potential off-target issues, but is not a major concern at this level.
4. **HBD:** Both ligands have 2 H-bond donors, which is within the acceptable limit of <=5. No difference.
5. **HBA:** Ligand A has 6 H-bond acceptors, while Ligand B has 3. Ligand B is preferred here, as fewer HBA generally improves permeability.
6. **QED:** Ligand B (0.786) has a higher QED score than Ligand A (0.59), indicating a more drug-like profile. This is a significant advantage for Ligand B.
7. **DILI:** Ligand A (83.249) has a considerably higher DILI risk than Ligand B (32.842). This is a major concern for Ligand A, as we want to minimize liver toxicity risk. Ligand B is strongly preferred.
8. **BBB:** Ligand A (76.541) has a higher BBB penetration than Ligand B (64.87). However, for a cardiovascular target like ADRB2, high BBB penetration isn't a priority, and can even be undesirable. This favors Ligand B.
9. **Caco-2:** Ligand A (-4.454) and Ligand B (-4.922) both have negative Caco-2 permeability values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Ligand A (-5.833) and Ligand B (-5.138) both have negative solubility values, which is also unusual. Again, the scale is not specified.
11. **hERG:** Ligand A (0.266) has a lower hERG inhibition liability than Ligand B (0.883), which is preferable.
12. **Cl_mic:** Ligand A (97.091) has a higher microsomal clearance than Ligand B (76.145), indicating lower metabolic stability. Ligand B is preferred.
13. **t1/2:** Ligand B (-0.86) has a negative in vitro half-life, which is concerning. Ligand A (33.653) has a reasonable half-life. This slightly favors Ligand A.
14. **Pgp:** Ligand A (0.231) has lower P-gp efflux liability than Ligand B (0.389), which is preferable.
15. **Affinity:** Ligand A (-7.3) has a slightly better binding affinity than Ligand B (-7.0). However, the difference is relatively small (0.3 kcal/mol) and may not be enough to overcome the other significant ADME/Tox differences.
**Overall Assessment:**
Ligand B is significantly better overall. The major advantages are its much lower DILI risk, better QED score, and lower microsomal clearance. While Ligand A has slightly better affinity and half-life, the DILI risk associated with Ligand A is a major red flag. The slightly lower affinity of Ligand B is likely acceptable, given the improvements in safety and drug-likeness. The negative values for Caco-2 and solubility are concerning for both, but the other parameters strongly favor Ligand B.
Output:
0
2025-04-17 21:55:53,044 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (344.46 and 343.52 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (50.8) is better than Ligand B (53.08). Both are reasonably good for oral absorption, being under 140, but lower is preferred.
3. **logP:** Both ligands have good logP values (3.57 and 3.76) falling within the 1-3 range. Ligand B is slightly higher.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (5). Lower HBA generally improves permeability.
6. **QED:** Ligand A (0.912) has a significantly better QED score than Ligand B (0.669), indicating a more drug-like profile.
7. **DILI:** Ligand A (50.99) is significantly better than Ligand B (10.90). A lower DILI percentile is crucial for safety. Ligand B is concerningly low.
8. **BBB:** Both ligands have high BBB penetration (97.83 and 90.77). This is less critical for ADRB2, which isn't a CNS target, but still a positive.
9. **Caco-2:** Ligand A (-4.36) is better than Ligand B (-5.24). Higher Caco-2 permeability suggests better absorption.
10. **Solubility:** Ligand A (-4.03) is better than Ligand B (-2.69). Higher solubility is generally preferred.
11. **hERG:** Ligand A (0.66) is better than Ligand B (0.96). Lower hERG inhibition is crucial for avoiding cardiotoxicity, especially important for a cardiovascular target like ADRB2.
12. **Cl_mic:** Ligand A (50.25) is significantly better than Ligand B (10.19). Lower microsomal clearance indicates better metabolic stability.
13. **t1/2:** Ligand A (26.86) is better than Ligand B (24.80). Longer half-life is generally preferred.
14. **Pgp:** Ligand A (0.49) is better than Ligand B (0.07). Lower P-gp efflux is preferable.
15. **Binding Affinity:** Ligand A (-7.9) has a slightly better binding affinity than Ligand B (-7.6). While both are excellent, the difference is enough to consider.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Both ligands perform well on logP and affinity. Ligand A is better on TPSA and Pgp. The significant differences in DILI and Cl_mic are also very important.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most crucial ADME-Tox parameters, including DILI, Cl_mic, solubility, and hERG. While both have good binding affinity and BBB penetration, the superior ADME profile of Ligand A makes it the more promising drug candidate. The DILI score for Ligand B is a major red flag.
Output:
1
2025-04-17 21:55:53,044 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [371.459, 85.11, 0.662, 0., 7., 0.621, 61.109, 74.874, -4.826, -1.506, 0.198, 56.063, -35.233, 0.074, -4.3]
**Ligand B:** [345.403, 95.8, 0.962, 2., 5., 0.593, 64.405, 45.909, -5.305, -2.178, 0.206, 15.877, -2.301, 0.051, -5.7]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, Affinity, and BBB):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (345.403) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (85.11) is better than Ligand B (95.8), falling comfortably under the 140 threshold for oral absorption.
3. **logP:** Ligand A (0.662) is a bit low, potentially hindering permeation. Ligand B (0.962) is slightly better, but still on the lower side of optimal.
4. **HBD/HBA:** Ligand A (0 HBD, 7 HBA) is preferable to Ligand B (2 HBD, 5 HBA). Fewer HBDs are generally better for permeability.
5. **QED:** Both are acceptable (A: 0.621, B: 0.593), indicating reasonable drug-likeness.
6. **DILI:** Both have acceptable DILI risk (A: 61.109, B: 64.405), but are creeping towards the higher end of the acceptable range.
7. **BBB:** Ligand A (74.874) has a significantly better BBB percentile than Ligand B (45.909). This is a key advantage for a GPCR target, even if it's not strictly CNS-focused, as it suggests better distribution.
8. **Caco-2:** Ligand A (-4.826) and Ligand B (-5.305) are both poor.
9. **Solubility:** Ligand A (-1.506) is better than Ligand B (-2.178), but both are quite poor.
10. **hERG:** Both are very low risk (A: 0.198, B: 0.206).
11. **Cl_mic:** Ligand A (56.063) has a better (lower) microsomal clearance than Ligand B (15.877), indicating better metabolic stability.
12. **t1/2:** Ligand A (-35.233) has a much longer in vitro half-life than Ligand B (-2.301), which is highly desirable.
13. **Pgp:** Both are low (A: 0.074, B: 0.051), suggesting limited efflux.
14. **Affinity:** Ligand B (-5.7 kcal/mol) has a significantly stronger binding affinity than Ligand A (-4.3 kcal/mol). This is a substantial advantage.
**Overall Assessment:**
While Ligand B boasts a better binding affinity, Ligand A has a superior profile in several critical ADME properties, particularly BBB penetration, metabolic stability (Cl_mic and t1/2), and TPSA. The stronger affinity of Ligand B is tempting, but the poorer ADME profile, especially the lower BBB and shorter half-life, raise concerns about its overall viability. The better ADME profile of Ligand A, coupled with a still respectable affinity, makes it the more promising candidate.
Output:
1
2025-04-17 21:55:53,044 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [352.479, 95.74, 1.175, 2, 3, 0.751, 20.744, 84.606, -4.966, -2.096, 0.163, 18.264, -20.369, 0.019, -5.9]
**Ligand B:** [350.503, 58.64, 2.9, 1, 3, 0.616, 21.908, 71.539, -4.732, -2.633, 0.147, 56.668, 3.247, 0.128, -6.2]
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). A: 352.479, B: 350.503 - very similar.
2. **TPSA:** Ligand A (95.74) is higher than Ligand B (58.64). For a GPCR, lower TPSA is generally preferred for better BBB penetration. Ligand B is significantly better here.
3. **logP:** Both are within the optimal range (1-3). A: 1.175, B: 2.9. Ligand B is slightly higher, which could be beneficial for membrane permeability, but not excessively high.
4. **HBD:** A has 2, B has 1. Both are acceptable.
5. **HBA:** Both have 3. Acceptable.
6. **QED:** A (0.751) is better than B (0.616), indicating a more drug-like profile.
7. **DILI:** Both are reasonably low, but A (20.744) is better than B (21.908).
8. **BBB:** A (84.606) is significantly better than B (71.539). This is a crucial factor for GPCRs, even cardiovascular ones, as some off-target CNS effects are possible.
9. **Caco-2:** Both are negative, indicating poor permeability. A (-4.966) is slightly worse than B (-4.732).
10. **Solubility:** Both are very poor (-2.096 and -2.633). This is a significant concern for both compounds.
11. **hERG:** Both are very low (0.163 and 0.147), indicating low cardiotoxicity risk.
12. **Cl_mic:** A (18.264) is much lower than B (56.668), suggesting better metabolic stability.
13. **t1/2:** A (-20.369) is much worse than B (3.247). This is a major drawback for Ligand A.
14. **Pgp:** Both are very low (0.019 and 0.128), indicating minimal P-gp efflux.
15. **Binding Affinity:** B (-6.2) is slightly better than A (-5.9), but the difference is relatively small.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), BBB penetration, logP, TPSA, and binding affinity are key. Ligand A has a better BBB score, QED, DILI, and metabolic stability. However, Ligand B has a much lower TPSA, better half-life, and slightly better affinity. The poor solubility and Caco-2 permeability are concerning for both. The improved metabolic stability of A is attractive, but the significantly shorter half-life is a major issue.
**Conclusion:**
Despite Ligand A's better QED, DILI, and metabolic stability, the substantially better BBB penetration and half-life of Ligand B, coupled with its lower TPSA, make it the more promising candidate. The slightly better affinity of B also contributes. The solubility and permeability issues are a concern for both, but can potentially be addressed with formulation strategies.
Output:
0
2025-04-17 21:55:53,044 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (399.248) is slightly higher than Ligand B (346.427), but both are acceptable.
2. **TPSA:** Both are reasonably good, but Ligand A (94.88) is better than Ligand B (98.66). For a GPCR, keeping TPSA lower is beneficial for permeability.
3. **logP:** Ligand A (3.707) is optimal, while Ligand B (1.273) is on the lower side. A logP between 1-3 is preferred, and Ligand A is closer to this ideal. Lower logP can hinder membrane permeability.
4. **HBD:** Ligand A (2) is better than Ligand B (4). Fewer HBDs generally improve permeability.
5. **HBA:** Both ligands have the same number of HBA (4), which is acceptable.
6. **QED:** Both ligands have good QED scores (A: 0.767, B: 0.559), indicating drug-likeness. Ligand A is slightly better.
7. **DILI:** Ligand A (84.102) has a significantly higher DILI risk than Ligand B (14.541). This is a major concern for Ligand A.
8. **BBB:** Ligand A (44.009) is better than Ligand B (21.908), but both are not optimal. Since ADRB2 is a cardiovascular target, BBB penetration is not a primary concern, but it's still a plus.
9. **Caco-2:** Ligand A (-4.931) is better than Ligand B (-5.417), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-6.065) is better than Ligand B (-2.659), which is important for bioavailability.
11. **hERG:** Ligand A (0.528) is better than Ligand B (0.126). Lower hERG inhibition is crucial to avoid cardiotoxicity.
12. **Cl_mic:** Ligand A (17.097) has a significantly lower microsomal clearance than Ligand B (36.528), indicating better metabolic stability.
13. **t1/2:** Ligand A (57.657) has a much longer in vitro half-life than Ligand B (-26.453). This is a significant advantage.
14. **Pgp:** Ligand A (0.147) is better than Ligand B (0.017). Lower P-gp efflux is desirable for improved bioavailability.
15. **Affinity:** Ligand B (-6.8) has a slightly better binding affinity than Ligand A (-5.9). However, the difference is less than 1.5 kcal/mol.
**Overall Assessment:**
While Ligand B has slightly better binding affinity, Ligand A demonstrates a significantly better ADME profile. The most critical factor is the high DILI risk associated with Ligand A. The better metabolic stability (lower Cl_mic, longer t1/2), solubility, Pgp efflux, and hERG inhibition profile of Ligand A outweigh the small difference in binding affinity. Considering the cardiovascular target, metabolic stability and safety (DILI, hERG) are paramount.
Output:
1
2025-04-17 21:55:53,044 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 drug candidates. ADRB2 is a GPCR, so we'll prioritize logP, Pgp, TPSA, and affinity, alongside general drug-like properties.
**Ligand A:** [350.459, 59.08, 1.776, 0, 4, 0.775, 20.861, 92.943, -4.43, -2.395, 0.201, 29.588, 18.253, 0.152, -8.2]
**Ligand B:** [351.422, 66.65, 2.289, 0, 4, 0.835, 24.855, 88.174, -4.486, -2.448, 0.451, 43.687, -2.584, 0.134, -5.9]
1. **MW:** Both are within the ideal range (350-351 Da). No significant difference.
2. **TPSA:** Ligand A (59.08) is better than Ligand B (66.65). Lower TPSA generally favors better absorption.
3. **logP:** Ligand A (1.776) is good, within the optimal range. Ligand B (2.289) is also acceptable, but slightly higher.
4. **HBD:** Both have 0 HBD, which is good.
5. **HBA:** Both have 4 HBA, which is acceptable.
6. **QED:** Ligand B (0.835) is slightly better than Ligand A (0.775), indicating a more drug-like profile.
7. **DILI:** Ligand A (20.861) has a significantly lower DILI risk than Ligand B (24.855). This is a major advantage.
8. **BBB:** Ligand A (92.943) has a higher BBB penetration potential than Ligand B (88.174). While not a primary concern for ADRB2 (cardiovascular target), it's a positive attribute.
9. **Caco-2:** Both are very poor (-4.43 and -4.486). This is a concern for oral bioavailability.
10. **Solubility:** Both are very poor (-2.395 and -2.448). This is a significant drawback for both.
11. **hERG:** Ligand A (0.201) has a lower hERG inhibition liability than Ligand B (0.451), which is preferable.
12. **Cl_mic:** Ligand A (29.588) has lower microsomal clearance than Ligand B (43.687), suggesting better metabolic stability.
13. **t1/2:** Ligand A (18.253) has a longer in vitro half-life than Ligand B (-2.584). This is a significant advantage.
14. **Pgp:** Ligand A (0.152) has lower P-gp efflux liability than Ligand B (0.134).
15. **Affinity:** Ligand A (-8.2 kcal/mol) has a significantly stronger binding affinity than Ligand B (-5.9 kcal/mol). This is a crucial advantage, potentially outweighing some of the ADME concerns.
**Overall Assessment:**
Ligand A is the stronger candidate. While both have poor Caco-2 and solubility, Ligand A excels in key areas: significantly better binding affinity, lower DILI risk, better metabolic stability (lower Cl_mic and longer t1/2), lower hERG risk, and higher BBB penetration. The affinity difference is substantial (-8.2 vs -5.9 kcal/mol), and the lower DILI risk is critical. The slightly better QED of Ligand B is not enough to offset these advantages.
Output:
1
2025-04-17 21:55:53,045 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
The ADRB2 receptor is a GPCR, so the priorities are logP, TPSA, Pgp, BBB, and affinity. Let's break down the comparison:
1. **Molecular Weight:** Both ligands are within the acceptable range (200-500 Da).
2. **TPSA:** Ligand A (66.84) is significantly better than Ligand B (119.33). Lower TPSA generally favors oral absorption and is crucial for GPCRs. Ligand B is pushing the upper limit for good absorption.
3. **logP:** Ligand A (2.866) is optimal. Ligand B (-0.884) is too low, potentially hindering membrane permeability.
4. **H-Bond Donors/Acceptors:** Ligand A (1 HBD, 4 HBA) is preferable to Ligand B (4 HBD, 6 HBA). Fewer H-bonds are generally better for permeability.
5. **QED:** Ligand A (0.849) is much better than Ligand B (0.468), indicating a more drug-like profile.
6. **DILI:** Ligand A (31.408) has a much lower DILI risk than Ligand B (11.128).
7. **BBB:** Ligand A (92.012) has significantly better BBB penetration potential than Ligand B (38.581). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant for off-target effects and overall safety.
8. **Caco-2:** Ligand A (-4.323) is better than Ligand B (-5.087), indicating better intestinal absorption.
9. **Solubility:** Ligand A (-3.417) is better than Ligand B (-0.68).
10. **hERG:** Ligand A (0.587) has a lower hERG risk than Ligand B (0.17).
11. **Cl_mic:** Ligand A (63.031) has higher metabolic clearance than Ligand B (-1.56). Ligand B is better here, suggesting greater metabolic stability.
12. **t1/2:** Ligand A (-8.161) has a much longer in vitro half-life than Ligand B (-18.784).
13. **Pgp:** Ligand A (0.126) has lower P-gp efflux liability than Ligand B (0.014).
14. **Binding Affinity:** Ligand A (-7.4 kcal/mol) is slightly better than Ligand B (-6.4 kcal/mol), though the difference isn't huge.
**Overall Assessment:**
Ligand A is significantly better across most critical ADME properties (TPSA, logP, QED, DILI, BBB, solubility, hERG, Pgp, t1/2, Caco-2) and has a slightly better binding affinity. While Ligand B has better metabolic stability (lower Cl_mic), the overall profile of Ligand A is far more favorable for development as a drug candidate targeting ADRB2. The substantial improvements in permeability-related properties (TPSA, logP, Pgp) and safety (DILI, hERG) outweigh the metabolic stability concern.
**Output:**
1
2025-04-17 21:55:53,045 - INFO - Batch 294 complete. Total preferences: 4704
2025-04-17 21:55:53,045 - INFO - Processing batch 295/512...
2025-04-17 21:56:44,360 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's break down the comparison of Ligand A and Ligand B across the 15 parameters, keeping in mind the GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key).
1. **MW:** Both ligands are within the ideal 200-500 Da range (A: 337.379, B: 367.921). No significant difference here.
2. **TPSA:** Both are good, below the 140 A^2 threshold for oral absorption (A: 58.81, B: 54.34). B is slightly better.
3. **logP:** Both are within the optimal 1-3 range (A: 3.598, B: 3.098). A is slightly higher, which could be a minor concern for solubility, but still acceptable.
4. **HBD:** A has 0 HBD, B has 1. Both are good.
5. **HBA:** A has 5 HBA, B has 3. Both are good.
6. **QED:** Both have good QED scores > 0.5 (A: 0.728, B: 0.753). B is slightly better.
7. **DILI:** This is a critical parameter. Ligand A has a very high DILI risk (94.959%), while Ligand B has a much lower risk (22.257%). This is a major advantage for B.
8. **BBB:** Both have good BBB penetration (A: 83.831, B: 69.562). A is better, but BBB isn't *the* highest priority for ADRB2 (a cardiovascular target).
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and problematic. It suggests poor permeability. However, the values are similar (-4.567 for A, -4.46 for B), so this doesn't differentiate them.
10. **Solubility:** Both have poor solubility (-4.72 for A, -3.503 for B). B is slightly better.
11. **hERG:** Both have low hERG inhibition risk (A: 0.758, B: 0.311). B is better.
12. **Cl_mic:** Both have reasonable microsomal clearance (A: 65.704, B: 61.687). No significant difference.
13. **t1/2:** Ligand B has a significantly longer in vitro half-life (37.516 hours) compared to Ligand A (19.942 hours). This is a substantial advantage for B.
14. **Pgp:** Both have low Pgp efflux liability (A: 0.645, B: 0.128). B is significantly better.
15. **Affinity:** Both have excellent binding affinity (A: -6.5 kcal/mol, B: -6.2 kcal/mol). A is slightly better, but the difference is small (0.3 kcal/mol) and likely not enough to overcome other significant drawbacks.
**Overall Assessment:**
Ligand B is the clear winner. While Ligand A has slightly better affinity and BBB penetration, the dramatically lower DILI risk, better Pgp efflux, longer half-life, and slightly improved solubility and hERG profile of Ligand B outweigh these minor advantages. The high DILI risk associated with Ligand A is a major red flag that would likely disqualify it early in the drug development process. The Caco-2 values are concerning for both, but can be addressed with formulation strategies.
Output:
0
2025-04-17 21:56:44,360 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (370.515 and 351.403 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (76.66) is better than Ligand B (96.97). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (2.833) is within the optimal 1-3 range. Ligand B (-0.307) is significantly lower, which could hinder membrane permeability and bioavailability. This is a major strike against Ligand B.
4. **HBD:** Both ligands have 2 HBD, which is acceptable.
5. **HBA:** Both ligands have 5 HBA, which is acceptable.
6. **QED:** Both ligands have similar QED values (0.664 and 0.614), indicating good drug-likeness.
7. **DILI:** Ligand A (41.373) has a slightly higher DILI risk than Ligand B (35.789), but both are below the concerning threshold of 60.
8. **BBB:** This is less crucial for a cardiovascular target. Ligand A (54.634) and Ligand B (48.895) are both relatively low.
9. **Caco-2:** Ligand A (-4.899) and Ligand B (-5.323) are both negative, indicating poor permeability. However, the negative values are similar.
10. **Solubility:** Ligand A (-2.132) is slightly better than Ligand B (-1.413), but both are poor.
11. **hERG:** Ligand A (0.471) is better than Ligand B (0.096), indicating a lower risk of cardiotoxicity. This is particularly important for a cardiovascular target.
12. **Cl_mic:** Ligand A (47.623) has a higher microsomal clearance than Ligand B (-5.143). This suggests Ligand B is more metabolically stable, which is a positive.
13. **t1/2:** Ligand A (14.087) has a longer in vitro half-life than Ligand B (-12.63). This is a significant advantage for dosing convenience.
14. **Pgp:** Ligand A (0.163) has lower P-gp efflux than Ligand B (0.022), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand A (-7.4) has a slightly better binding affinity than Ligand B (-6.8). While the difference is not huge, it's enough to be considered.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, and affinity are key. Ligand A is superior in logP and has a slightly better affinity. While TPSA is better for A, the difference is not drastic.
**Overall Assessment:**
Ligand A demonstrates a better balance of properties, particularly with respect to logP, hERG, and binding affinity. The slightly better half-life and lower P-gp efflux also contribute to its favorability. While Ligand B has better metabolic stability, the poor logP is a significant drawback that outweighs this benefit.
Output:
1
2025-04-17 21:56:44,360 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (a cardiovascular GPCR) drug candidates.
**Ligand A:** [377.824, 59.42, 4.682, 1, 5, 0.397, 80.031, 33.385, -4.851, -5.549, 0.457, 138.992, -1.523, 0.423, -7.4]
**Ligand B:** [355.479, 90.9, 0.127, 3, 5, 0.485, 8.414, 36.332, -5.177, -0.966, 0.34, 12.953, -13.289, 0.017, -6.1]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (355.479) is slightly lower, which isn't a major concern.
2. **TPSA:** Ligand A (59.42) is much better than Ligand B (90.9). GPCRs benefit from lower TPSA for better permeability. Ligand B is bordering on being too high.
3. **logP:** Ligand A (4.682) is higher than optimal (1-3), but still potentially manageable. Ligand B (0.127) is *very* low, which is a significant drawback for membrane permeability and bioavailability.
4. **HBD:** Ligand A (1) is good. Ligand B (3) is acceptable, but higher.
5. **HBA:** Both have 5 HBA, which is acceptable.
6. **QED:** Both are reasonable (A: 0.397, B: 0.485), but neither is outstanding.
7. **DILI:** Ligand A (80.031) has a higher DILI risk than Ligand B (8.414). This is a concern for Ligand A.
8. **BBB:** Both have low BBB penetration (A: 33.385, B: 36.332). This isn't a primary concern for a cardiovascular target, but it's not ideal.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.851) is slightly worse than Ligand B (-5.177).
10. **Solubility:** Ligand A (-5.549) has worse solubility than Ligand B (-0.966).
11. **hERG:** Both have low hERG risk (A: 0.457, B: 0.34).
12. **Cl_mic:** Ligand A (138.992) has higher metabolic clearance than Ligand B (12.953), indicating lower metabolic stability.
13. **t1/2:** Ligand B (-13.289) has a much more negative in vitro half-life, which is a major concern. Ligand A (-1.523) is better.
14. **Pgp:** Ligand A (0.423) has lower P-gp efflux than Ligand B (0.017), which is favorable.
15. **Affinity:** Ligand A (-7.4) has a significantly better binding affinity than Ligand B (-6.1). This is a >1.3 kcal/mol difference, which is substantial.
**GPCR-specific priorities:** For ADRB2 (a cardiovascular GPCR), we prioritize logP, TPSA, affinity, and Pgp.
**Overall Assessment:**
Ligand A has a significantly better binding affinity, lower Pgp efflux, and a better TPSA. However, it has a higher DILI risk and higher metabolic clearance. Ligand B has a much better DILI profile and metabolic stability, but its extremely low logP is a major concern for permeability and bioavailability. The poor Caco-2 values for both are also concerning.
Despite the DILI risk, the strong affinity of Ligand A, combined with its better TPSA and Pgp properties, makes it the more promising starting point. The DILI risk can be addressed through structural modifications during lead optimization. The low logP of Ligand B is a more fundamental issue that would be harder to fix without drastically altering the molecule.
Therefore, I prefer Ligand A.
Output:
1
2025-04-17 21:56:44,360 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.431 and 349.391 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (95.94) is significantly better than Ligand B (129.23). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is pushing the upper limit for good oral absorption.
3. **logP:** Ligand A (0.105) is quite low, potentially hindering membrane permeability. Ligand B (-0.164) is also low, but marginally better. Both are below the optimal 1-3 range.
4. **HBD:** Ligand A (2) is preferable to Ligand B (4). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (5) is better than Ligand B (6). Similar to HBD, lower HBA is generally preferred.
6. **QED:** Ligand A (0.646) has a better QED score than Ligand B (0.524), indicating a more drug-like profile.
7. **DILI:** Ligand A (23.846) has a much lower DILI risk than Ligand B (63.978). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (42.226) has a better BBB penetration percentile than Ligand B (20.977). While ADRB2 isn't necessarily a CNS target, some peripheral distribution is still desired, and higher BBB penetration often correlates with better overall permeability.
9. **Caco-2:** Ligand A (-4.989) is better than Ligand B (-5.634). Higher Caco-2 permeability is desirable, and A has a less negative value.
10. **Solubility:** Ligand A (-0.927) is better than Ligand B (-2.568). Higher solubility is preferred.
11. **hERG:** Ligand A (0.042) is significantly better than Ligand B (0.3). Lower hERG inhibition is crucial for avoiding cardiotoxicity, a major concern for cardiovascular targets.
12. **Cl_mic:** Ligand A (7.87) has lower microsomal clearance than Ligand B (9.996), indicating better metabolic stability.
13. **t1/2:** Ligand B (7.31) has a much longer in vitro half-life than Ligand A (1.601). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.04) has lower P-gp efflux than Ligand B (0.022). Lower efflux is generally preferred.
15. **Binding Affinity:** Ligand B (-6.7 kcal/mol) is slightly better than Ligand A (-6.9 kcal/mol). While A is better, the difference is small.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical ADME-Tox properties (DILI, hERG, solubility, TPSA, QED). While Ligand B has a longer half-life and slightly better binding affinity, the superior safety profile and permeability characteristics of Ligand A are more important for overall drug development success, especially considering the cardiovascular target. The small affinity difference is unlikely to outweigh the ADME advantages of Ligand A.
Output:
1
2025-04-17 21:56:44,360 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [348.403, 114.62 , 0.33 , 2. , 5. , 0.719, 41.024, 65.839, -5.549, -1.853, 0.141, -16.573, -10.055, 0.013, -6.4 ]
**Ligand B:** [354.495, 81.75 , 0.596, 2. , 4. , 0.701, 5.118, 55.293, -5.218, -1.211, 0.159, -8.479, -16.813, 0.001, -6.3 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). A (348.4) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** A (114.62) is higher than B (81.75). For a GPCR, lower TPSA is preferred for better BBB penetration. B is significantly better here.
3. **logP:** A (0.33) is quite low, potentially hindering membrane permeability. B (0.596) is better, falling within the optimal range, but still on the lower side.
4. **HBD:** Both have 2 HBD, which is good.
5. **HBA:** A has 5 HBA, B has 4. Both are acceptable.
6. **QED:** Both are very similar and good (A: 0.719, B: 0.701).
7. **DILI:** A (41.024) is slightly higher than B (5.118), indicating a marginally higher risk of liver injury. B is much better.
8. **BBB:** A (65.839) is better than B (55.293), but both are not exceptionally high. For a cardiovascular GPCR, BBB isn't *critical*, but still a consideration.
9. **Caco-2:** Both are negative, indicating poor permeability. A (-5.549) is worse than B (-5.218).
10. **Solubility:** Both are negative, indicating poor solubility. A (-1.853) is worse than B (-1.211).
11. **hERG:** Both are very low (A: 0.141, B: 0.159), indicating minimal hERG inhibition risk.
12. **Cl_mic:** A (-16.573) is significantly lower (better) than B (-8.479), suggesting better metabolic stability.
13. **t1/2:** B (-16.813) is lower (better) than A (-10.055), indicating a longer half-life.
14. **Pgp:** Both are very low (A: 0.013, B: 0.001), indicating minimal P-gp efflux.
15. **Affinity:** Both are very similar (A: -6.4, B: -6.3). The difference is negligible.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, and affinity. While BBB isn't paramount for a cardiovascular target, it's still a positive.
**Overall Assessment:**
Ligand B has a significantly better TPSA and DILI profile, and a slightly better logP and Caco-2 permeability. While Ligand A has better metabolic stability (Cl_mic), the other factors outweigh this benefit. The affinity is essentially the same. The lower TPSA and DILI risk of Ligand B are more important for a GPCR target.
**Output:**
0
2025-04-17 21:56:44,360 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (364.398 and 366.424 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (92.34) is slightly higher than Ligand B (78.43). Both are below the 140 threshold for good oral absorption, but B is better positioned, especially considering ADRB2 isn't necessarily a CNS target.
3. **logP:** Ligand A (1.663) and Ligand B (2.527) are both within the optimal 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Ligand A (2) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is preferable to Ligand B (3). Fewer HBAs generally improve permeability.
6. **QED:** Ligand A (0.815) has a significantly higher QED score than Ligand B (0.549), indicating better overall drug-likeness.
7. **DILI:** Ligand B (13.3) has a much lower DILI risk than Ligand A (80.923). This is a *major* advantage for Ligand B.
8. **BBB:** Both ligands have reasonable BBB penetration (Ligand A: 67.119, Ligand B: 76.541). Since ADRB2 is primarily a cardiovascular target, high BBB penetration isn't crucial.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Both ligands have negative solubility values, which is also unusual. Again, the scale is not specified.
11. **hERG:** Ligand A (0.344) has a lower hERG risk than Ligand B (0.687), which is preferable.
12. **Cl_mic:** Ligand A (37.246) has a higher microsomal clearance than Ligand B (15.3), indicating lower metabolic stability. Ligand B is significantly better here.
13. **t1/2:** Ligand A (63.649) has a longer in vitro half-life than Ligand B (-7.861). This is a positive for Ligand A, but the negative value for B is concerning.
14. **Pgp:** Ligand A (0.294) has lower P-gp efflux liability than Ligand B (0.192), which is favorable.
15. **Binding Affinity:** Ligand B (-7.1 kcal/mol) has a significantly stronger binding affinity than Ligand A (-0.4 kcal/mol). This is a *critical* advantage for Ligand B, easily outweighing minor ADME drawbacks.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B excels in affinity and has a favorable logP and TPSA. The lower DILI risk and better metabolic stability (lower Cl_mic) are also significant benefits. While Ligand A has a better QED and slightly lower Pgp efflux, the massive difference in binding affinity and the concerning DILI risk make Ligand B the better candidate. The negative values for Caco-2 and solubility are concerning for both, but the affinity difference is so large that it overshadows these issues.
**Output:**
0
2025-04-17 21:56:44,361 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [362.411, 98.84, 2.075, 1, 8, 0.805, 82.551, 54.905, -5.3, -3.309, 0.136, 31.527, -2.379, 0.126, -4.5]
**Ligand B:** [361.442, 63.25, 2.724, 2, 5, 0.828, 61.807, 70.531, -5.194, -3.366, 0.618, 28.607, 16.392, 0.124, -6.9]
Here's a breakdown, prioritizing GPCR-relevant properties:
1. **Molecular Weight:** Both ligands are within the ideal 200-500 Da range. A is 362.411, B is 361.442. Very similar.
2. **TPSA:** Ligand A (98.84) is higher than Ligand B (63.25). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is generally preferred for absorption. Ligand B is significantly better here.
3. **logP:** Both are within the optimal 1-3 range. A is 2.075, B is 2.724. B is slightly higher, which could be beneficial for membrane permeability.
4. **H-Bond Donors/Acceptors:** A has 1 HBD and 8 HBA, B has 2 HBD and 5 HBA. Both are acceptable, but B is slightly more balanced.
5. **QED:** Both are good (above 0.5), A is 0.805, B is 0.828. B is marginally better.
6. **DILI:** Ligand A (82.551) has a significantly higher DILI risk than Ligand B (61.807). This is a major concern for A.
7. **BBB:** BBB penetration isn't a primary concern for a cardiovascular target, but Ligand B (70.531) is higher than Ligand A (54.905).
8. **Caco-2 Permeability:** Both are negative, indicating poor permeability. A is -5.3, B is -5.194. Very similar.
9. **Aqueous Solubility:** Both are negative, indicating poor solubility. A is -3.309, B is -3.366. Very similar.
10. **hERG Inhibition:** Ligand A (0.136) has slightly lower hERG inhibition risk than Ligand B (0.618).
11. **Microsomal Clearance:** Ligand B (28.607) has lower clearance, suggesting better metabolic stability than Ligand A (31.527).
12. **In vitro Half-Life:** Ligand B (16.392) has a much longer half-life than Ligand A (-2.379). This is a significant advantage for B.
13. **P-gp Efflux:** Both are low (0.126 and 0.124), indicating minimal P-gp efflux.
14. **Binding Affinity:** Ligand B (-6.9 kcal/mol) has a substantially stronger binding affinity than Ligand A (-4.5 kcal/mol). This is a crucial difference. A difference of 2.4 kcal/mol is very significant.
**Overall Assessment:**
Ligand B is the superior candidate. While both have issues with Caco-2 and solubility, Ligand B demonstrates a much better safety profile (lower DILI), significantly improved metabolic stability (lower Cl_mic, longer t1/2), and, most importantly, a much stronger binding affinity for the ADRB2 receptor. The lower TPSA is also a plus. The slightly higher logP is acceptable given the other benefits. The affinity difference is large enough to outweigh any minor drawbacks.
Output:
0
2025-04-17 21:56:44,361 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (348.49 and 365.46 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (69.64) is significantly better than Ligand B (98.14). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is approaching a level that could hinder oral absorption.
**3. logP:** Ligand A (2.703) is optimal, while Ligand B (0.978) is a bit low. A logP below 1 can sometimes indicate poor membrane permeability.
**4. H-Bond Donors:** Both ligands have 2 HBD, which is within the acceptable limit of 5.
**5. H-Bond Acceptors:** Ligand A has 3 HBA, while Ligand B has 7. Ligand A is preferable here, as excessive HBA can impact permeability.
**6. QED:** Ligand B (0.68) has a better QED score than Ligand A (0.382), suggesting a more drug-like profile overall.
**7. DILI Risk:** Ligand A (15.86%) has a much lower DILI risk than Ligand B (63.40%). This is a critical advantage, as liver toxicity is a major concern in drug development.
**8. BBB Penetration:** Ligand A (72.78%) shows better BBB penetration than Ligand B (49.94%). While ADRB2 is a cardiovascular target, some CNS effects are possible with beta-blockers, and better BBB penetration could lead to off-target effects. However, for a cardiovascular target, this isn't a primary driver.
**9. Caco-2 Permeability:** Ligand A (-4.836) has a much better Caco-2 permeability than Ligand B (-5.39).
**10. Aqueous Solubility:** Ligand A (-2.566) has better solubility than Ligand B (-1.824).
**11. hERG Inhibition:** Ligand A (0.375) has a lower hERG inhibition risk than Ligand B (0.537). This is a significant safety advantage.
**12. Microsomal Clearance:** Ligand B (28.832) has lower microsomal clearance than Ligand A (37.665), indicating better metabolic stability.
**13. In vitro Half-Life:** Ligand B (37.425 hours) has a significantly longer half-life than Ligand A (-0.213 hours). This is a major advantage, potentially allowing for less frequent dosing.
**14. P-gp Efflux:** Ligand A (0.291) has lower P-gp efflux than Ligand B (0.184). Lower efflux is generally preferred.
**15. Binding Affinity:** Ligand B (-7.2 kcal/mol) has a slightly better binding affinity than Ligand A (-6.5 kcal/mol). This 0.7 kcal/mol difference is substantial and could potentially outweigh some of the ADME drawbacks of Ligand B.
**Overall Assessment:**
Ligand B has a better binding affinity and *much* better metabolic stability (half-life and clearance). However, Ligand A excels in several key ADME properties: lower DILI risk, better TPSA, logP, solubility, Caco-2 permeability, and hERG inhibition. The combination of these factors makes Ligand A a more balanced and potentially safer candidate. The improved binding affinity of Ligand B is tempting, but the significantly higher DILI risk and less favorable ADME profile are concerning.
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand A strikes a better balance. While affinity is important, a compound with poor ADME properties is unlikely to succeed.
Output:
1
2025-04-17 21:56:44,361 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (344.46 & 351.35 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (74.33) is better than Ligand B (79.79). Both are below 140, but lower TPSA generally favors absorption.
3. **logP:** Ligand A (2.759) is slightly higher than Ligand B (1.754), placing it closer to the optimal 1-3 range. Ligand B is a bit low, potentially hindering permeation.
4. **HBD:** Both ligands have 2 HBD, which is within the acceptable limit of 5.
5. **HBA:** Ligand A has 3 HBA, while Ligand B has 4. Both are below the 10 limit.
6. **QED:** Both ligands have similar QED values (0.866 and 0.848), indicating good drug-likeness.
7. **DILI:** Ligand A (39.201) has a slightly better DILI score than Ligand B (55.021), indicating a lower risk of liver injury. Both are acceptable, but A is preferred.
8. **BBB:** Ligand A (82.358) shows better BBB penetration potential than Ligand B (75.107). While ADRB2 isn't exclusively a CNS target, some peripheral ADRB2 activity can be modulated by CNS effects, and better BBB penetration isn't a detriment.
9. **Caco-2:** Both ligands have very similar, and quite poor, Caco-2 permeability (-4.682 and -4.689). This is a concern for oral bioavailability for both.
10. **Solubility:** Ligand A (-3.455) has slightly better solubility than Ligand B (-2.672), although both are quite poor.
11. **hERG:** Ligand A (0.489) has a much lower hERG inhibition liability than Ligand B (0.232), which is a significant advantage regarding cardiotoxicity risk.
12. **Cl_mic:** Ligand A (38.573) has a significantly better (lower) microsomal clearance than Ligand B (4.041), suggesting better metabolic stability.
13. **t1/2:** Ligand B (16.879) has a longer in vitro half-life than Ligand A (12.005), which is generally desirable.
14. **Pgp:** Ligand A (0.088) has lower P-gp efflux liability than Ligand B (0.059), which is favorable for bioavailability.
15. **Affinity:** Ligand A (-7.6 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.8 kcal/mol). This is a substantial difference and a major driving factor.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are crucial. Ligand A performs better in logP, TPSA, Pgp, and *significantly* better in affinity. The improved metabolic stability (Cl_mic) and reduced hERG risk are also important positives. While Ligand B has a slightly longer half-life, the other advantages of Ligand A outweigh this. The poor Caco-2 values are a concern for both, suggesting formulation strategies may be needed.
**Conclusion:**
Ligand A is the more promising candidate due to its superior binding affinity, better ADME properties (DILI, BBB, Cl_mic, hERG, Pgp), and acceptable physicochemical characteristics.
Output:
1
2025-04-17 21:56:44,361 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (343.31 Da) is slightly lower, which is generally favorable for permeability.
**2. TPSA:** Ligand A (77.77) is significantly better than Ligand B (108.56). For a GPCR, keeping TPSA under 140 is good, but lower is better for permeability. Ligand A is well within this range, while Ligand B is approaching the upper limit.
**3. logP:** Ligand A (3.202) is optimal, while Ligand B (0.955) is quite low. GPCRs generally benefit from a logP between 1 and 3 for good membrane permeability and binding. Ligand B's low logP is a significant concern.
**4. H-Bond Donors:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs generally improve membrane permeability.
**5. H-Bond Acceptors:** Ligand A (5) is preferable to Ligand B (6). Similar to HBDs, fewer HBAs are generally better for permeability.
**6. QED:** Both ligands have good QED scores (A: 0.787, B: 0.837), indicating good drug-like properties. This isn't a major differentiating factor.
**7. DILI:** Ligand A has a very high DILI risk (99.922), which is a major red flag. Ligand B has a much lower, and acceptable, DILI risk (39.667).
**8. BBB:** Both ligands have moderate BBB penetration (A: 58.511, B: 51.919). As ADRB2 is primarily a cardiovascular target, BBB penetration isn't a primary concern, but it's not detrimental to have some.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
**10. Aqueous Solubility:** Both ligands have negative solubility values, which is also unusual.
**11. hERG Inhibition:** Ligand A (0.729) is better than Ligand B (0.033) - lower is better.
**12. Microsomal Clearance:** Ligand A (62.169) is higher than Ligand B (3.341), indicating faster metabolism and lower metabolic stability. Ligand B is much more stable.
**13. In vitro Half-Life:** Ligand A (59.3) is better than Ligand B (6.222), indicating a longer half-life.
**14. P-gp Efflux:** Ligand A (0.431) is better than Ligand B (0.015) - lower is better.
**15. Binding Affinity:** Ligand B (-7.5 kcal/mol) has a significantly stronger binding affinity than Ligand A (-3.3 kcal/mol). This is a substantial advantage, potentially outweighing some ADME concerns.
**Overall Assessment:**
Ligand A has better permeability characteristics (TPSA, logP, HBD/HBA), and better P-gp efflux, but suffers from a disastrously high DILI risk and a weaker binding affinity. Ligand B has a much better safety profile (DILI) and significantly stronger binding affinity, but its low logP and higher TPSA are concerning.
Despite Ligand B's lower logP and higher TPSA, the significantly improved binding affinity (-7.5 vs -3.3 kcal/mol) and the much lower DILI risk are compelling. The difference in binding affinity is substantial enough to potentially overcome the permeability issues, especially considering this is a cardiovascular target where CNS penetration is not critical. The lower metabolic clearance of Ligand B is also a significant advantage.
Therefore, I would prioritize Ligand B.
0
2025-04-17 21:56:44,361 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (352.381 Da and 348.407 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (81.42) is significantly better than Ligand B (119.43). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is approaching the upper limit for good oral absorption.
**3. logP:** Ligand A (2.528) is optimal, while Ligand B (0.337) is quite low. A logP below 1 can hinder membrane permeability. This is a substantial advantage for Ligand A.
**4. H-Bond Donors:** Both have 2 HBD, which is within the acceptable limit.
**5. H-Bond Acceptors:** Ligand A has 3 HBA, and Ligand B has 5. Both are acceptable, but Ligand A is slightly better.
**6. QED:** Ligand A (0.874) has a much better QED score than Ligand B (0.298), indicating a more drug-like profile.
**7. DILI:** Both have relatively low DILI risk (39.201 and 33.773), both below the 40% threshold.
**8. BBB:** Ligand A (77.743) has a better BBB penetration percentile than Ligand B (46.879). While ADRB2 is primarily a cardiovascular target, some CNS off-target effects are possible, and better BBB penetration is generally preferable.
**9. Caco-2 Permeability:** Ligand A (-4.493) is better than Ligand B (-5.453). Higher values indicate better intestinal absorption.
**10. Aqueous Solubility:** Ligand A (-3.579) is better than Ligand B (-1.353).
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.464 and 0.109).
**12. Microsomal Clearance:** Ligand A (27.411) has a higher microsomal clearance than Ligand B (18.712), indicating lower metabolic stability. This is a slight negative for Ligand A.
**13. In vitro Half-Life:** Ligand B (8.088) has a longer in vitro half-life than Ligand A (5.748). This is a slight advantage for Ligand B.
**14. P-gp Efflux:** Both have very low P-gp efflux liability (0.089 and 0.004).
**15. Binding Affinity:** Ligand A (-7.8 kcal/mol) has a stronger binding affinity than Ligand B (-7.1 kcal/mol). This 0.7 kcal/mol difference is significant and can outweigh some of the ADME drawbacks of Ligand A.
**Overall Assessment:**
Ligand A is significantly better overall. The superior logP, TPSA, QED, solubility, Caco-2 permeability, and, most importantly, binding affinity outweigh the slightly higher microsomal clearance. Ligand B's low logP is a major concern for permeability and bioavailability. While Ligand B has a slightly better half-life, the potency advantage of Ligand A is more critical for a GPCR target.
Output:
1
2025-04-17 21:56:44,361 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands fall within the ideal range (200-500 Da). Ligand A (348.447) is slightly preferred due to being lower in molecular weight.
2. **TPSA:** Ligand A (87.47) is better than Ligand B (97.39). Both are below the 140 threshold for oral absorption, but lower TPSA is generally favorable for GPCRs.
3. **logP:** Both ligands have good logP values (A: 1.421, B: 2.078) within the optimal 1-3 range. Ligand B is slightly higher, which could potentially lead to off-target effects, but isn't a major concern.
4. **HBD:** Both have 2 H-bond donors, which is within the acceptable limit of 5.
5. **HBA:** Ligand A has 5 H-bond acceptors, while Ligand B has 6. Both are acceptable (<=10), but A is slightly better.
6. **QED:** Ligand A (0.812) has a significantly better QED score than Ligand B (0.63), indicating a more drug-like profile.
7. **DILI:** Ligand A (19.969) has a much lower DILI risk than Ligand B (65.723). This is a critical advantage for Ligand A.
8. **BBB:** Ligand A (72.664) has a better BBB penetration percentile than Ligand B (59.558). While ADRB2 isn't exclusively a CNS target, some cardiovascular effects are mediated by CNS pathways, and better BBB penetration can be beneficial.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual. However, the magnitude is similar (-5.066 for A, -4.763 for B), so this doesn't significantly differentiate them.
10. **Solubility:** Ligand A (-2.124) has slightly better solubility than Ligand B (-3.071).
11. **hERG:** Both ligands have low hERG inhibition liability (A: 0.276, B: 0.381), which is good.
12. **Cl_mic:** Ligand A (5.157) has a much lower microsomal clearance than Ligand B (61.645), indicating better metabolic stability.
13. **t1/2:** Ligand A (26.62) has a better in vitro half-life than Ligand B (-45.79). The negative value for B is concerning.
14. **Pgp:** Ligand A (0.024) has significantly lower P-gp efflux liability than Ligand B (0.441), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand B (-6.4 kcal/mol) has a slightly better binding affinity than Ligand A (-5.8 kcal/mol). This is a 0.6 kcal/mol difference, which is not substantial enough to outweigh the significant ADME advantages of Ligand A.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B in almost all crucial ADME properties (DILI, BBB, Cl_mic, t1/2, Pgp, QED, Solubility) and has a comparable logP and hERG profile. While Ligand B has slightly better binding affinity, the ADME profile of Ligand A is far superior, making it a much more promising drug candidate for the ADRB2 receptor.
Output:
1
2025-04-17 21:56:44,361 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (355.45 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (55.84) is significantly better than Ligand B (78.51). ADRB2 is not a CNS target, but lower TPSA generally improves absorption.
3. **logP:** Ligand A (4.015) is slightly higher than the optimal range (1-3), but still acceptable. Ligand B (1.94) is at the lower end, potentially hindering permeation.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer HBDs generally improve membrane permeability.
5. **HBA:** Both ligands have 4 HBA, which is within the acceptable range.
6. **QED:** Ligand B (0.691) is slightly better than Ligand A (0.41), suggesting a more drug-like profile.
7. **DILI:** Ligand A (28.655) has a lower DILI risk than Ligand B (33.501), which is a significant advantage.
8. **BBB:** Not a primary concern for ADRB2 (cardiovascular target). Ligand A (94.184) has better BBB penetration than Ligand B (62.97), but this is less important in this context.
9. **Caco-2:** Ligand A (-4.422) is better than Ligand B (-5.179), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-4.924) is better than Ligand B (-2.178), which is important for bioavailability.
11. **hERG:** Ligand A (0.697) has a lower hERG risk than Ligand B (0.391), which is crucial for cardiovascular safety.
12. **Cl_mic:** Ligand A (99.737) has much higher microsomal clearance than Ligand B (36.809), meaning it will be metabolized faster. This is a significant drawback for Ligand A.
13. **t1/2:** Ligand B (15.574) has a significantly longer in vitro half-life than Ligand A (-3.102), which is a major advantage.
14. **Pgp:** Ligand A (0.278) has lower P-gp efflux than Ligand B (0.149), which is favorable.
15. **Binding Affinity:** Ligand B (-7.8 kcal/mol) has a significantly stronger binding affinity than Ligand A (-3.9 kcal/mol). This is a substantial advantage that can outweigh some ADME concerns.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B has a better logP and Pgp, and a *much* better binding affinity. While Ligand A has better TPSA, the difference in affinity is substantial. The improved metabolic stability (lower Cl_mic and longer t1/2) of Ligand B is also a significant benefit.
**Overall Assessment:**
Despite Ligand A's advantages in TPSA, solubility, and lower DILI/hERG risk, the significantly stronger binding affinity of Ligand B (-7.8 vs -3.9 kcal/mol) and its superior metabolic stability (longer half-life) are decisive. The better affinity is likely to translate to greater efficacy at lower doses, potentially mitigating some of the ADME concerns.
Output:
0
2025-04-17 21:56:44,361 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.531 and 344.415 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (49.41) is significantly better than Ligand B (95.32). ADRB2 is a cardiovascular target, not CNS, but lower TPSA generally improves permeability. Ligand A is well below the 140 threshold, while B is approaching it.
3. **logP:** Ligand A (3.79) is good, while Ligand B (1.233) is on the lower side of optimal. For a GPCR, a higher logP is generally preferred for membrane permeability and receptor engagement.
4. **HBD:** Both ligands have 1 HBD, which is within the acceptable range.
5. **HBA:** Ligand A has 2 HBA, while Ligand B has 5. Ligand A is preferable here, as fewer HBA generally correlate with better permeability.
6. **QED:** Both ligands have good QED scores (0.611 and 0.727), indicating drug-like properties.
7. **DILI:** Ligand A (14.23) has a higher DILI risk than Ligand B (32.803). This is a significant advantage for Ligand B.
8. **BBB:** While not a primary concern for a cardiovascular target, Ligand A (74.874) has better BBB penetration than Ligand B (63.629).
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.411 and -4.527), which is unusual and indicates poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-4.272) has slightly better solubility than Ligand B (-2.475).
11. **hERG:** Ligand A (0.535) has a slightly higher hERG risk than Ligand B (0.229), but both are relatively low.
12. **Cl_mic:** Ligand A (74.279) has a higher microsomal clearance than Ligand B (24.856), indicating lower metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand A (14.053) has a longer in vitro half-life than Ligand B (5.708).
14. **Pgp:** Ligand A (0.132) has lower P-gp efflux liability than Ligand B (0.022), which is favorable.
15. **Affinity:** Ligand B (-7.8 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.0 kcal/mol). This is a substantial advantage, potentially outweighing some ADME concerns.
**Overall Assessment:**
Ligand B has a much stronger binding affinity, a lower DILI risk, and better metabolic stability (lower Cl_mic). While its TPSA is higher and logP lower than Ligand A, the substantial affinity advantage and better safety profile are more important for a cardiovascular GPCR target. The negative Caco-2 values are concerning for both, but the affinity difference is significant enough to prioritize Ligand B.
**Output:**
0
2025-04-17 21:56:44,361 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (347.5) is slightly preferred due to being closer to the lower end, which can aid permeability.
2. **TPSA:** Ligand A (38.77) is excellent, well below the 140 threshold, and favorable for oral absorption. Ligand B (89.87) is higher, but still acceptable, though less optimal.
3. **logP:** Ligand A (3.74) is within the optimal range (1-3), while Ligand B (1.86) is at the lower end. For a GPCR, a slightly higher logP is often beneficial for membrane permeability and receptor engagement, giving a slight edge to Ligand A.
4. **HBD:** Ligand A (0) is preferred as it has no hydrogen bond donors, potentially improving membrane permeability. Ligand B (3) is acceptable, but HBDs can sometimes hinder absorption.
5. **HBA:** Ligand A (3) is good. Ligand B (5) is also acceptable, but higher HBA can sometimes lead to reduced permeability.
6. **QED:** Both ligands have reasonable QED scores (A: 0.778, B: 0.586), indicating drug-likeness. Ligand A is better here.
7. **DILI:** Ligand A (31.06) has a significantly lower DILI risk than Ligand B (19.19), a substantial advantage.
8. **BBB:** Ligand A (92.4) shows excellent BBB penetration, which is a key consideration for GPCRs, even non-CNS ones, as it can influence off-target effects and distribution. Ligand B (40.95) is much lower, suggesting limited CNS exposure.
9. **Caco-2:** Ligand A (-4.814) and Ligand B (-5.131) both show good Caco-2 permeability.
10. **Solubility:** Ligand A (-4.447) and Ligand B (-1.624) both show poor solubility.
11. **hERG:** Both ligands have low hERG inhibition risk (A: 0.597, B: 0.502).
12. **Cl_mic:** Ligand B (33.31) has a lower microsomal clearance than Ligand A (68.93), suggesting better metabolic stability.
13. **t1/2:** Ligand A (22.80) and Ligand B (20.32) have similar in vitro half-lives.
14. **Pgp:** Ligand A (0.656) has slightly higher Pgp efflux than Ligand B (0.165), which is less desirable.
15. **Binding Affinity:** Ligand A (-7.1) has a significantly stronger binding affinity than Ligand B (-5.3). This is a major advantage, potentially outweighing some of the ADME drawbacks.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), I prioritize affinity, logP, TPSA, BBB, and Pgp. Ligand A excels in affinity and BBB penetration, has a good logP and TPSA, and is only slightly worse on Pgp. Ligand B has better metabolic stability (Cl_mic) and lower Pgp efflux, but its significantly weaker affinity and lower BBB penetration are major drawbacks. The lower DILI risk of Ligand A is also a significant positive.
**Conclusion:**
Despite the better metabolic stability of Ligand B, the superior binding affinity, BBB penetration, lower DILI risk, and better overall drug-likeness of Ligand A make it the more promising drug candidate.
**Output:**
1
2025-04-17 21:56:44,362 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [344.419, 107.03 , 1.169, 3. , 5. , 0.755, 48.197, 66.072, -5.279, -2.445, 0.116, 11.946, -19.407, 0.091, -7. ]
**Ligand B:** [346.402, 53.76 , 2.268, 0. , 3. , 0.789, 31.989, 78.286, -4.313, -3.359, 0.509, 19.858, -5.216, 0.308, -7.4 ]
**Step-by-step comparison:**
1. **MW:** Both ligands (344.419 and 346.402 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (107.03) is higher than Ligand B (53.76). For a GPCR, lower TPSA is generally preferred for better BBB penetration. Ligand B is significantly better here.
3. **logP:** Ligand A (1.169) is slightly lower than Ligand B (2.268), both are within the optimal 1-3 range. Ligand B is slightly better.
4. **HBD:** Ligand A (3) is higher than Ligand B (0). Lower HBD is generally preferred for permeability. Ligand B is better.
5. **HBA:** Both ligands have 3 HBA, so no difference.
6. **QED:** Both ligands have similar QED values (0.755 and 0.789), indicating good drug-likeness. No significant difference.
7. **DILI:** Ligand A (48.197) has a higher DILI risk than Ligand B (31.989). Lower DILI is preferred. Ligand B is better.
8. **BBB:** Ligand B (78.286) has a significantly higher BBB penetration percentile than Ligand A (66.072). This is a key factor for GPCRs, especially if CNS effects are a concern. Ligand B is significantly better.
9. **Caco-2:** Ligand A (-5.279) has a lower Caco-2 value than Ligand B (-4.313). Higher Caco-2 is better, so Ligand B is better.
10. **Solubility:** Ligand A (-2.445) has a lower solubility than Ligand B (-3.359). Higher solubility is preferred. Ligand B is better.
11. **hERG:** Ligand A (0.116) has a lower hERG inhibition liability than Ligand B (0.509). Lower hERG is preferred. Ligand A is better.
12. **Cl_mic:** Ligand A (11.946) has a lower microsomal clearance than Ligand B (19.858). Lower clearance indicates better metabolic stability. Ligand A is better.
13. **t1/2:** Ligand A (-19.407) has a longer in vitro half-life than Ligand B (-5.216). Longer half-life is preferred. Ligand A is better.
14. **Pgp:** Ligand A (0.091) has lower P-gp efflux liability than Ligand B (0.308). Lower Pgp is preferred. Ligand A is better.
15. **Affinity:** Ligand B (-7.4) has a slightly better binding affinity than Ligand A (-7.0). While both are good, the 0.4 kcal/mol difference is noteworthy. Ligand B is better.
**Overall Assessment:**
While Ligand A has advantages in metabolic stability (Cl_mic, t1/2), hERG, Pgp efflux, and solubility, Ligand B excels in properties crucial for GPCRs, particularly BBB penetration, TPSA, and Caco-2 permeability. The slightly better binding affinity of Ligand B further strengthens its position. The lower DILI risk of Ligand B is also a significant advantage. Considering the GPCR-specific priorities, the benefits of Ligand B outweigh those of Ligand A.
Output:
0
2025-04-17 21:56:44,362 - INFO - Batch 295 complete. Total preferences: 4720
2025-04-17 21:56:44,362 - INFO - Processing batch 296/512...
2025-04-17 21:57:35,290 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (345.447 & 352.475 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (77.57) is better than Ligand B (81.08). Both are below the 140 threshold for oral absorption, but closer to the ideal for GPCRs.
3. **logP:** Both ligands have acceptable logP values (0.96 & 1.314), falling within the 1-3 range. Ligand B is slightly better.
4. **HBD:** Both ligands have 2 H-bond donors, which is good.
5. **HBA:** Ligand A has 5 HBA, and Ligand B has 4. Both are acceptable.
6. **QED:** Both ligands have similar QED scores (0.686 & 0.677), indicating good drug-likeness.
7. **DILI:** Ligand A (37.456) has a slightly higher DILI risk than Ligand B (18.418), but both are below the concerning threshold of 60. Ligand B is preferable.
8. **BBB:** Ligand A (63.784) has better BBB penetration than Ligand B (43.854). This is a significant advantage for a GPCR target, even if not CNS-focused, as it suggests better distribution.
9. **Caco-2:** Ligand A (-5.091) and Ligand B (-4.698) have negative values, which is unusual and suggests poor permeability. However, the values are very close.
10. **Solubility:** Ligand A (-1.449) and Ligand B (-1.386) have similar poor solubility.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.35 & 0.276).
12. **Cl_mic:** Ligand A (-21.484) has a much lower (better) microsomal clearance than Ligand B (33.052), indicating greater metabolic stability.
13. **t1/2:** Ligand A (31.479) has a longer in vitro half-life than Ligand B (-6.151). This is a significant advantage.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.006 & 0.135).
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.5 & -6.2 kcal/mol). The difference is not substantial enough to be a deciding factor.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), and the general guidelines, Ligand A emerges as the slightly better candidate. While Ligand B has a lower DILI risk, Ligand A has superior BBB penetration, significantly better metabolic stability (lower Cl_mic), and a longer half-life. The similar binding affinities make the ADME properties the deciding factors. The improved metabolic stability and half-life of Ligand A are crucial for maintaining therapeutic concentrations *in vivo*.
Output:
1
2025-04-17 21:57:35,290 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [373.475, 117.09 , 0.126, 3. , 6. , 0.523, 43.66 , 43.273, -5.409, -1.83 , 0.379, 10.059, 5.639, 0.064, -7.0]
**Ligand B:** [345.495, 69.21 , 2.188, 2. , 7. , 0.848, 52.423, 83.288, -4.934, -2.951, 0.85 , 36.803, 5.579, 0.022, -5.5]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, BBB, and affinity are key):
1. **MW:** Both are within the ideal 200-500 Da range. Ligand B (345.495) is slightly preferred due to being a bit lower.
2. **TPSA:** Ligand B (69.21) is significantly better than Ligand A (117.09). Below 140 is good for oral absorption, but lower is generally better for GPCRs, and B is much closer to the ideal for CNS penetration.
3. **logP:** Ligand B (2.188) is optimal (1-3 range), while Ligand A (0.126) is quite low. This is a major drawback for A, potentially hindering membrane permeability.
4. **HBD/HBA:** Ligand A (3 HBD, 6 HBA) and Ligand B (2 HBD, 7 HBA) are both acceptable, within the guidelines.
5. **QED:** Ligand B (0.848) has a better QED score than Ligand A (0.523), indicating a more drug-like profile.
6. **DILI:** Both are reasonably good, with Ligand A (43.66) being slightly better than Ligand B (52.423).
7. **BBB:** Ligand B (83.288) is significantly better than Ligand A (43.273). This is a crucial advantage for a GPCR target, even if not specifically CNS-focused, as it suggests better distribution.
8. **Caco-2:** Both are negative, which is unusual and suggests poor permeability. However, the scale isn't specified, so it's hard to interpret.
9. **Solubility:** Both are negative, indicating poor solubility.
10. **hERG:** Ligand A (0.379) is better than Ligand B (0.85), indicating lower cardiotoxicity risk.
11. **Cl_mic:** Ligand B (36.803) has a lower (better) microsomal clearance than Ligand A (10.059), suggesting greater metabolic stability.
12. **t1/2:** Similar in vitro half-lives for both (5.639 vs 5.579).
13. **Pgp:** Ligand A (0.064) has a lower Pgp efflux liability than Ligand B (0.022), which is favorable for bioavailability.
14. **Affinity:** Ligand A (-7.0) has a slightly better binding affinity than Ligand B (-5.5). This is a 1.5 kcal/mol difference, which is significant.
**Overall Assessment:**
While Ligand A has slightly better affinity and Pgp efflux, Ligand B is significantly better across multiple crucial parameters for a GPCR drug candidate: logP, TPSA, BBB, QED, and metabolic stability (Cl_mic). The poor logP of Ligand A is a major concern, likely leading to poor permeability and bioavailability. The better BBB penetration of Ligand B is also a significant advantage. The slightly higher hERG risk for Ligand B is a concern, but potentially mitigable through further optimization.
Therefore, I believe **Ligand B** is the more promising drug candidate.
0
2025-04-17 21:57:35,291 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [365.459, 106.84 , 0.91 , 1. , 7. , 0.815, 72.276, 38.116, -5.417, -2.239, 0.153, -12.193, 32.858, 0.031, -5.8 ]
**Ligand B:** [343.427, 66.65 , 2.022, 0. , 4. , 0.788, 41.877, 65.529, -4.556, -2.877, 0.214, 15.489, 3.678, 0.233, -5.8 ]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, Affinity) and general drug-like properties:
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (343.427) is slightly lower, which is generally favorable.
2. **TPSA:** Ligand A (106.84) is a bit higher than Ligand B (66.65). Both are below 140, but Ligand B is significantly better for permeability.
3. **logP:** Ligand A (0.91) is a little low, potentially hindering membrane permeability. Ligand B (2.022) is within the optimal range (1-3). This is a significant advantage for Ligand B.
4. **HBD/HBA:** Ligand A has 1 HBD and 7 HBA, while Ligand B has 0 HBD and 4 HBA. Both are acceptable, but Ligand B's lower HBD count is slightly preferred.
5. **QED:** Both are good (above 0.5), indicating reasonable drug-likeness.
6. **DILI:** Ligand A (72.276) has a higher DILI risk than Ligand B (41.877). This is a clear advantage for Ligand B.
7. **BBB:** Ligand B (65.529) has a better BBB penetration potential than Ligand A (38.116), although neither is exceptionally high. Since ADRB2 is a cardiovascular target, BBB isn't *critical*, but better penetration is still a plus.
8. **Caco-2:** Ligand A (-5.417) has a worse Caco-2 permeability than Ligand B (-4.556).
9. **Solubility:** Both have negative solubility values, indicating poor aqueous solubility. Ligand B (-2.877) is slightly better than Ligand A (-2.239), but both are problematic.
10. **hERG:** Both have low hERG inhibition liability, which is good.
11. **Cl_mic:** Ligand A (-12.193) has a much lower (better) microsomal clearance than Ligand B (15.489), indicating greater metabolic stability. This is a significant advantage for Ligand A.
12. **t1/2:** Ligand A (32.858) has a longer in vitro half-life than Ligand B (3.678). This is a substantial advantage for Ligand A.
13. **Pgp:** Ligand A (0.031) has a lower P-gp efflux liability than Ligand B (0.233), suggesting better oral bioavailability and potentially better tissue distribution.
14. **Affinity:** Both ligands have the same binding affinity (-5.8 kcal/mol).
**Overall Assessment:**
Ligand B has advantages in logP, TPSA, DILI, and Caco-2 permeability. However, Ligand A excels in metabolic stability (Cl_mic, t1/2) and P-gp efflux. Considering the GPCR target class, the balance of properties is crucial. While the slightly better permeability of Ligand B is appealing, the significantly improved metabolic stability and reduced efflux of Ligand A are more important for a successful cardiovascular drug. The lower DILI risk of Ligand B is also a positive, but the longer half-life of Ligand A could allow for less frequent dosing, improving patient compliance.
Therefore, I would choose Ligand A.
Output:
1
2025-04-17 21:57:35,291 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [358.479, 84.94, 1.602, 1, 5, 0.474, 24.855, 61.691, -4.518, -1.882, 0.299, 94.793, -15.025, 0.027, -6.9]
**Ligand B:** [347.415, 75.88, 1.152, 0, 5, 0.82, 38.581, 73.401, -4.529, -1.613, 0.105, 52.031, -30.228, 0.096, -7.6]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity, and BBB):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (347.415) is slightly lower, which is generally favorable.
2. **TPSA:** Both are good, under 140. Ligand B (75.88) is better than Ligand A (84.94), suggesting potentially better absorption.
3. **logP:** Both are within the optimal range (1-3). Ligand B (1.152) is slightly lower, which is acceptable.
4. **HBD/HBA:** Ligand A has 1 HBD and 5 HBA, while Ligand B has 0 HBD and 5 HBA. Both are reasonable.
5. **QED:** Ligand B (0.82) has a significantly better QED score than Ligand A (0.474), indicating a more drug-like profile.
6. **DILI:** Ligand A (24.855) has a much lower DILI risk than Ligand B (38.581), a significant advantage.
7. **BBB:** Ligand B (73.401) has a better BBB penetration score than Ligand A (61.691), which is a plus for a GPCR target.
8. **Caco-2:** Both have negative values, indicating poor permeability.
9. **Solubility:** Both have negative values, indicating poor solubility.
10. **hERG:** Both have very low hERG inhibition risk, which is good.
11. **Cl_mic:** Ligand B (52.031) has a significantly lower microsomal clearance than Ligand A (94.793), meaning it's likely more metabolically stable.
12. **t1/2:** Ligand B (-30.228) has a longer in vitro half-life than Ligand A (-15.025), which is desirable.
13. **Pgp:** Both have very low Pgp efflux liability, which is good.
14. **Affinity:** Ligand B (-7.6 kcal/mol) has a better binding affinity than Ligand A (-6.9 kcal/mol). This 0.7 kcal/mol difference is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand B is the stronger candidate. While Ligand A has a lower DILI risk, Ligand B excels in several key areas: better QED, better BBB penetration, significantly lower microsomal clearance, longer half-life, and, most importantly, a substantially better binding affinity. The affinity difference is the most important factor here, given that we're dealing with a GPCR. The improved metabolic stability and half-life also contribute significantly to its potential as a viable drug candidate.
Output:
0
2025-04-17 21:57:35,291 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (342.439 Da and 352.41 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (54.71) is significantly better than Ligand B (86.63). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold, while B is approaching it.
3. **logP:** Ligand A (3.226) is within the optimal 1-3 range. Ligand B (0.822) is a bit low, potentially hindering membrane permeability.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 5. Both are acceptable, under the 10 threshold.
6. **QED:** Ligand A (0.876) is slightly better than Ligand B (0.785), indicating a more drug-like profile.
7. **DILI:** Ligand A (8.492) has a much lower DILI risk than Ligand B (43.117). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (74.564) has a better BBB penetration score than Ligand B (62.854), but since this is a cardiovascular target, this is less critical.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.791 and -4.643). This is unusual and suggests poor permeability.
10. **Solubility:** Ligand A (-2.157) is slightly better than Ligand B (-0.543), indicating better aqueous solubility.
11. **hERG:** Ligand A (0.854) has a lower hERG risk than Ligand B (0.149), which is crucial for avoiding cardiotoxicity.
12. **Cl_mic:** Ligand A (-5.222) has a significantly lower (better) microsomal clearance than Ligand B (8.43). This suggests better metabolic stability.
13. **t1/2:** Ligand A (34.623) has a much longer in vitro half-life than Ligand B (14.99). This is a significant advantage.
14. **Pgp:** Ligand A (0.187) has lower P-gp efflux liability than Ligand B (0.024).
15. **Binding Affinity:** Ligand A (-6.8 kcal/mol) has a slightly better binding affinity than Ligand B (-5.8 kcal/mol). The difference is 1 kcal/mol, which is significant.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A is superior in logP, TPSA, Pgp, and affinity.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical ADME-Tox parameters (DILI, hERG, Cl_mic, t1/2, Pgp) and has a slightly better binding affinity. While both have poor Caco-2 permeability, the other advantages of Ligand A make it a more promising drug candidate.
Output:
1
2025-04-17 21:57:35,291 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (363.439 Da) is within the ideal range (200-500 Da), while Ligand B (380.861 Da) is also acceptable. No clear advantage here.
2. **TPSA:** Ligand A (80.76) is better than Ligand B (105.31). For a GPCR, keeping TPSA lower is beneficial for permeability.
3. **logP:** Ligand B (1.546) is better than Ligand A (0.417). A logP between 1-3 is optimal, and Ligand B falls within this range while Ligand A is slightly low, potentially impacting membrane permeability.
4. **HBD:** Both ligands have 1 HBD, which is acceptable.
5. **HBA:** Ligand B (7) is slightly higher than Ligand A (6), but both are within the acceptable range of <=10.
6. **QED:** Both ligands have good QED scores (A: 0.767, B: 0.847), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (56.572) has a significantly lower DILI risk than Ligand B (84.141). This is a major advantage for Ligand A.
8. **BBB:** Both ligands have similar BBB penetration (A: 51.415, B: 58.821). While not CNS-focused for ADRB2, moderate penetration isn't detrimental.
9. **Caco-2:** Ligand B (-5.125) has a better Caco-2 permeability than Ligand A (-4.684), suggesting better intestinal absorption.
10. **Solubility:** Ligand A (-1.787) has better aqueous solubility than Ligand B (-2.682). Solubility is important for bioavailability.
11. **hERG:** Both ligands have very low hERG inhibition risk (A: 0.107, B: 0.194), which is excellent.
12. **Cl_mic:** Ligand A (-6.894) has significantly lower microsomal clearance than Ligand B (-0.058), indicating better metabolic stability. This is a substantial advantage.
13. **t1/2:** Ligand B (-0.416) has a slightly better in vitro half-life than Ligand A (-2.85), but the difference isn't huge.
14. **Pgp:** Both ligands have low P-gp efflux (A: 0.03, B: 0.04).
15. **Affinity:** Ligand B (-7.2 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.3 kcal/mol). This is a substantial advantage, potentially outweighing some ADME concerns.
**Overall Assessment:**
Ligand B has a better binding affinity and Caco-2 permeability, and a slightly better QED and half-life. However, Ligand A has significantly lower DILI risk and better metabolic stability (lower Cl_mic). The stronger binding affinity of Ligand B is a significant advantage for a GPCR target, and the difference in affinity (0.9 kcal/mol) is substantial enough to consider despite the higher DILI and lower metabolic stability. The logP of ligand B is also more optimal.
Output:
0
2025-04-17 21:57:35,292 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for the ADRB2, a cardiovascular GPCR. Therefore, the key priorities are logP, Pgp, TPSA, and binding affinity, with metabolic stability (Cl_mic, t1/2) and safety (DILI, hERG) also being important.
Let's compare the ligands property by property:
1. **MW:** Both ligands (366.5 and 362.5 Da) are within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (67.43) is significantly better than Ligand B (92.07). A TPSA under 140 is good for oral absorption, but lower is generally preferred for GPCRs, and A is much closer to the ideal.
3. **logP:** Ligand A (3.14) is optimal (1-3). Ligand B (0.247) is quite low, potentially hindering permeability. This is a significant drawback for B.
4. **HBD/HBA:** Ligand A (2 HBD, 4 HBA) is slightly higher in both, but still within acceptable ranges. Ligand B (1 HBD, 9 HBA) is acceptable, but the higher HBA could impact permeability.
5. **QED:** Both ligands have good QED scores (0.66 and 0.749).
6. **DILI:** Ligand A (49.011) has a much better DILI percentile than Ligand B (76.851). This is a major advantage for A.
7. **BBB:** Both have similar BBB penetration (61.38 and 63.474). Not a primary concern for a cardiovascular target, but higher is generally better.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability.
9. **Solubility:** Both have negative solubility values, which is also unusual.
10. **hERG:** Ligand A (0.699) has a lower hERG risk than Ligand B (0.294).
11. **Cl_mic:** Ligand A (47.337) has a lower microsomal clearance than Ligand B (73.783), indicating better metabolic stability.
12. **t1/2:** Ligand A (39.966) has a significantly longer in vitro half-life than Ligand B (20.557).
13. **Pgp:** Ligand A (0.495) has lower P-gp efflux than Ligand B (0.019).
14. **Binding Affinity:** Ligand A (-5.8 kcal/mol) is slightly better than Ligand B (-5.5 kcal/mol), but the difference is not huge.
**Overall Assessment:**
Ligand A is significantly better overall. It has a more favorable logP, lower DILI risk, better metabolic stability (lower Cl_mic and longer t1/2), lower P-gp efflux, and a slightly better binding affinity. The TPSA is also significantly better for Ligand A. While both have unusual Caco-2 and solubility values, the other advantages of Ligand A outweigh this concern. The low logP of Ligand B is a substantial drawback.
**Output:**
1
2025-04-17 21:57:35,292 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (339.399 and 343.402 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (87.22) is higher than Ligand B (48.72). For a cardiovascular GPCR, TPSA isn't a *major* concern unless it's excessively high, but lower is generally preferred for better permeability. Ligand B is significantly better here.
3. **logP:** Ligand A (1.358) is within the optimal 1-3 range. Ligand B (3.155) is at the higher end of optimal. Both are acceptable, but Ligand B's higher logP *could* potentially lead to off-target interactions or solubility issues, although it's not extreme.
4. **HBD:** Ligand A (2) and Ligand B (1) are both good, below the threshold of 5. Ligand B is slightly better.
5. **HBA:** Ligand A (5) and Ligand B (3) are both good, below the threshold of 10. Ligand B is better.
6. **QED:** Both ligands have good QED scores (0.878 and 0.911), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (69.252) is higher than Ligand B (51.028). Both are acceptable (<60 is good), but Ligand B has a lower risk of liver injury.
8. **BBB:** Ligand A (63.784) is lower than Ligand B (90.19). While ADRB2 isn't necessarily a CNS target, higher BBB penetration is generally favorable, suggesting better distribution and potentially fewer off-target effects. Ligand B is significantly better.
9. **Caco-2:** Ligand A (-5.028) and Ligand B (-4.752) are both negative, which is unusual. This suggests poor permeability. The values are very close, so no clear advantage.
10. **Solubility:** Ligand A (-2.872) is slightly better than Ligand B (-3.646). Both are poor, but A is less poor.
11. **hERG:** Ligand A (0.339) is much lower than Ligand B (0.818), indicating a lower risk of cardiotoxicity. This is a *critical* advantage for a cardiovascular target.
12. **Cl_mic:** Ligand A (33.127) is lower than Ligand B (40.625), suggesting better metabolic stability. This is a positive for Ligand A.
13. **t1/2:** Ligand A (-9.084) is much lower than Ligand B (51.337). This indicates significantly shorter in vitro half-life for Ligand A, which is a major drawback.
14. **Pgp:** Ligand A (0.023) is much lower than Ligand B (0.363), indicating lower P-gp efflux. This is a positive for Ligand A.
15. **Affinity:** Ligand A (-7.8) is better than Ligand B (-6.9). This is a substantial difference in binding affinity (1.5 kcal/mol advantage), which can often outweigh minor ADME drawbacks.
**Overall Assessment:**
Ligand A has a superior binding affinity and lower P-gp efflux, and a lower hERG risk. However, it suffers from a very poor in vitro half-life and lower BBB penetration. Ligand B has better ADME properties (BBB, DILI, metabolic stability, QED, TPSA), but weaker binding affinity.
Given the GPCR-specific priorities (logP, Pgp, TPSA, affinity) and the cardiovascular context (hERG is *extremely* important), the stronger binding affinity of Ligand A and its significantly lower hERG risk are compelling advantages. While the poor half-life is a concern, it might be addressable through structural modifications. The hERG risk of Ligand B is concerning.
Output:
1
2025-04-17 21:57:35,292 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands (356.495 & 359.495 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (48.47) is significantly better than Ligand B (63.13). For a GPCR, lower TPSA is generally preferred for better permeability. Ligand A is well below the 140 threshold, while Ligand B is approaching it.
3. **logP:** Both ligands have good logP values (3.97 & 3.513), falling within the optimal 1-3 range. Ligand A is slightly higher, which *could* be a minor advantage for membrane permeability, but not drastically.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Both ligands have the same number of HBA (4), which is acceptable.
6. **QED:** Ligand A (0.886) has a higher QED score than Ligand B (0.709), indicating a more drug-like profile.
7. **DILI:** Ligand B (53.432) has a lower DILI risk than Ligand A (72.392), which is a significant advantage. Lower DILI is crucial.
8. **BBB:** Ligand A (70.57) has a better BBB penetration percentile than Ligand B (49.826). While ADRB2 isn't exclusively a CNS target, some CNS exposure can occur, and higher BBB is generally favorable.
9. **Caco-2:** Ligand A (-4.647) has a better Caco-2 permeability than Ligand B (-5.251).
10. **Solubility:** Ligand A (-4.026) has better aqueous solubility than Ligand B (-3.648).
11. **hERG:** Both ligands have low hERG inhibition liability (0.591 & 0.499), which is good. No significant difference.
12. **Cl_mic:** Ligand B (77.078) has a higher microsomal clearance than Ligand A (52.681), indicating faster metabolism and potentially lower *in vivo* exposure. This favors Ligand A.
13. **t1/2:** Ligand B (54.44) has a longer in vitro half-life than Ligand A (43.413), which is a positive.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.353 & 0.264). No significant difference.
15. **Binding Affinity:** Ligand A (-6.9 kcal/mol) has a significantly stronger binding affinity than Ligand B (-5.5 kcal/mol). This is a substantial advantage and can often outweigh minor ADME drawbacks. The difference is >1.5 kcal/mol.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, and affinity. Ligand A excels in TPSA, affinity, and has comparable logP and Pgp values. While Ligand B has a better DILI score and slightly longer half-life, the superior binding affinity of Ligand A and its better TPSA, QED, solubility, and lower clearance are more critical for a GPCR target. The difference in binding affinity is substantial.
**Conclusion:**
Ligand A is the more promising drug candidate due to its superior binding affinity, better TPSA, QED, solubility, and lower clearance, despite the slightly higher DILI risk. The strong binding affinity is a key driver in this decision.
Output:
1
2025-04-17 21:57:35,292 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (362.495 and 352.399 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (58.64) is significantly better than Ligand B (123.22). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold. Ligand B is approaching the upper limit.
3. **logP:** Ligand A (3.37) is within the optimal 1-3 range. Ligand B (-0.973) is *below* 1, which is a concern for membrane permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is preferable to Ligand B (10). Fewer HBAs also improve permeability.
6. **QED:** Ligand A (0.893) is better than Ligand B (0.523), indicating a more drug-like profile.
7. **DILI:** Both ligands have similar DILI risk (51.687 vs 56.999), both falling within an acceptable range (<60).
8. **BBB:** Ligand A (86.545) is better than Ligand B (73.788), although BBB isn't a high priority for a cardiovascular target.
9. **Caco-2:** Ligand A (-4.935) is better than Ligand B (-5.316). Both are negative, which is unusual and requires further investigation, but A is slightly better.
10. **Solubility:** Ligand A (-3.836) is better than Ligand B (-0.33). Better solubility is generally desirable.
11. **hERG:** Ligand A (0.47) is significantly better than Ligand B (0.264). Lower hERG inhibition is crucial for avoiding cardiotoxicity, especially for a cardiovascular target.
12. **Cl_mic:** Ligand A (18.2) is much better than Ligand B (36.667). Lower clearance indicates greater metabolic stability.
13. **t1/2:** Ligand A (8.404) is better than Ligand B (20.914). Longer half-life is generally preferred.
14. **Pgp:** Ligand A (0.204) is better than Ligand B (0.11). Lower P-gp efflux is desirable.
15. **Affinity:** Ligand A (-7.0) is slightly better than Ligand B (-6.6). While both are good, the difference is enough to consider.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A excels in all these areas. Ligand B's low logP is a significant drawback.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical parameters, particularly those relevant to GPCRs. Its superior logP, TPSA, solubility, hERG profile, metabolic stability, and slightly better affinity make it the more promising drug candidate.
Output:
1
2025-04-17 21:57:35,292 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.409 Da and 367.406 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (98.05) is better than Ligand B (109.14). Both are under 140, but A is closer to the preferred threshold for good absorption.
3. **logP:** Ligand A (1.37) is slightly better than Ligand B (0.831), both are within the optimal 1-3 range.
4. **HBD:** Ligand A (1) is better than Ligand B (3). Lower HBD generally favors permeability.
5. **HBA:** Both ligands have the same number of HBA (7), which is acceptable (<=10).
6. **QED:** Ligand A (0.882) is significantly better than Ligand B (0.672). A higher QED indicates a more drug-like profile.
7. **DILI:** Ligand B (66.731) has a slightly higher DILI risk than Ligand A (60.915), but both are reasonably acceptable.
8. **BBB:** Ligand A (74.99) has a significantly better BBB penetration score than Ligand B (45.909). While ADRB2 isn't *strictly* a CNS target, some CNS exposure can be beneficial, and minimizing it isn't critical.
9. **Caco-2:** Ligand B (-5.392) shows better Caco-2 permeability than Ligand A (-4.504). This suggests better intestinal absorption for Ligand B.
10. **Solubility:** Ligand B (-2.544) has slightly better aqueous solubility than Ligand A (-2.712).
11. **hERG:** Both ligands have very low hERG inhibition liability (0.193 and 0.186), which is excellent.
12. **Cl_mic:** Ligand B (30.466) has slightly lower microsomal clearance than Ligand A (31.363), indicating potentially better metabolic stability.
13. **t1/2:** Ligand B (4.839) has a significantly longer in vitro half-life than Ligand A (-0.548). This is a major advantage for dosing frequency.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.035 and 0.028), which is good.
15. **Binding Affinity:** Ligand B (-7.8) has a slightly better binding affinity than Ligand A (-7.5). This affinity difference is significant enough to potentially outweigh some ADME drawbacks.
**GPCR-specific priorities:** For GPCRs, logP, TPSA, Pgp, and affinity are key. Ligand B is better on logP, Caco-2, and affinity, while Ligand A is better on TPSA and BBB. The affinity difference is the most important factor here. The longer half-life of Ligand B is also a significant advantage.
**Conclusion:**
Despite Ligand A's better QED and BBB, Ligand B's superior binding affinity, Caco-2 permeability, and longer half-life make it the more promising candidate for development as a drug targeting the ADRB2 receptor.
0
2025-04-17 21:57:35,293 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Step-by-step comparison:**
1. **MW:** Both ligands (348.397 and 343.427 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (58.12) is significantly better than Ligand B (102.22). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold, while Ligand B is approaching it.
3. **logP:** Both ligands have good logP values (4.106 and 3.008), falling within the optimal 1-3 range. Ligand B is slightly better.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (4). Similar to HBD, fewer HBAs are generally better.
6. **QED:** Ligand A (0.905) has a substantially higher QED score than Ligand B (0.739), indicating a more drug-like profile.
7. **DILI:** Ligand B (19.659) has a much lower DILI risk than Ligand A (70.105). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (82.009) has a higher BBB penetration percentile than Ligand B (49.748). While not a primary concern for a cardiovascular target, it's a slight positive for Ligand A.
9. **Caco-2:** Ligand A (-4.326) has a worse Caco-2 permeability than Ligand B (-5.106). Lower values are worse.
10. **Solubility:** Ligand A (-5.608) has a slightly better solubility than Ligand B (-4.1).
11. **hERG:** Both ligands have low hERG inhibition liability (0.537 and 0.455), which is good. No significant difference.
12. **Cl_mic:** Ligand B (41.023) has much lower microsomal clearance than Ligand A (87.932), suggesting better metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand A (22.837) has a longer in vitro half-life than Ligand B (-5.791). This is a positive for Ligand A.
14. **Pgp:** Ligand A (0.226) has lower P-gp efflux liability than Ligand B (0.017). Lower is better, so Ligand A is preferable.
15. **Binding Affinity:** Ligand B (-6.3 kcal/mol) has a slightly better binding affinity than Ligand A (-5.8 kcal/mol). This difference (0.5 kcal/mol) is significant enough to consider.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B has a better logP and affinity. Ligand A has better TPSA and Pgp.
**Overall Assessment:**
While Ligand A has a better QED, BBB, and half-life, Ligand B excels in crucial areas for drug development: significantly lower DILI risk and microsomal clearance, and a slightly improved binding affinity. The lower DILI and improved metabolic stability are particularly important. The slightly better affinity of Ligand B further strengthens its position. The TPSA difference is notable, but not enough to outweigh the other advantages of Ligand B.
Output:
0
2025-04-17 21:57:35,293 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (352.381 Da and 349.391 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (69.64) is significantly better than Ligand B (137.39). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is above the 140 threshold for good oral absorption, while A is well below.
**3. logP:** Ligand A (1.847) is within the optimal 1-3 range. Ligand B (-0.966) is slightly below 1, which could potentially hinder permeation.
**4. H-Bond Donors:** Ligand A (2) and Ligand B (4) are both acceptable, but A is preferable.
**5. H-Bond Acceptors:** Ligand A (3) and Ligand B (4) are both acceptable.
**6. QED:** Ligand A (0.85) has a better QED score than Ligand B (0.525), indicating a more drug-like profile.
**7. DILI:** Ligand A (40.054) and Ligand B (43.66) are both relatively low risk for DILI, and comparable.
**8. BBB:** Ligand A (63.862) is better than Ligand B (45.599), although neither is exceptionally high. For a cardiovascular GPCR, BBB penetration isn't a primary concern, but it's still a slight advantage for A.
**9. Caco-2 Permeability:** Ligand A (-4.783) is better than Ligand B (-6.05). Higher values indicate better intestinal absorption.
**10. Aqueous Solubility:** Ligand A (-2.693) is better than Ligand B (-2.46).
**11. hERG Inhibition:** Ligand A (0.665) is slightly better than Ligand B (0.057) indicating a lower risk of cardiotoxicity.
**12. Microsomal Clearance:** Ligand A (16.033) is better than Ligand B (-16.975). Lower clearance means greater metabolic stability.
**13. In vitro Half-Life:** Ligand A (36.512) is significantly better than Ligand B (-2.33).
**14. P-gp Efflux:** Ligand A (0.069) is better than Ligand B (0.009). Lower efflux improves bioavailability.
**15. Binding Affinity:** Ligand B (-6.8) is slightly better than Ligand A (-6.4), but the difference is less than 1.5 kcal/mol.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most key ADME properties (TPSA, logP, QED, Caco-2, Solubility, hERG, Cl_mic, t1/2, Pgp). While Ligand B has a slightly better binding affinity, the overall profile of Ligand A is more balanced and suggests a higher probability of success as a drug candidate. The superior ADME properties of Ligand A, particularly its TPSA, logP, and metabolic stability, outweigh the small difference in binding affinity.
Output:
1
2025-04-17 21:57:35,293 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (347.419) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (93.26) is better than Ligand B (41.15). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is still preferred for absorption.
3. **logP:** Ligand A (1.448) is optimal, while Ligand B (4.356) is pushing the upper limit and could present solubility issues.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A (6) is slightly higher than Ligand B (4), but both are acceptable.
6. **QED:** Both ligands have similar QED values (0.78 and 0.728), indicating good drug-likeness.
7. **DILI:** Ligand A (52.346) has a higher DILI risk than Ligand B (25.785). This is a significant concern.
8. **BBB:** Ligand B (74.641) has a significantly higher BBB penetration percentile than Ligand A (61.535). While ADRB2 isn't a CNS target, some peripheral exposure can be beneficial.
9. **Caco-2:** Ligand A (-4.878) and Ligand B (-5.406) both have negative values, which is unusual. Lower (more negative) values indicate poorer permeability. Ligand B is slightly worse.
10. **Solubility:** Ligand A (-0.967) has slightly better solubility than Ligand B (-3.778).
11. **hERG:** Ligand A (0.151) has a much lower hERG inhibition liability than Ligand B (0.92). This is a major advantage.
12. **Cl_mic:** Ligand A (51.236) has a slightly lower microsomal clearance than Ligand B (44.454), suggesting better metabolic stability.
13. **t1/2:** Ligand B (1.748) has a longer in vitro half-life than Ligand A (-5.112). This is a positive for dosing convenience.
14. **Pgp:** Ligand A (0.024) has significantly lower P-gp efflux liability than Ligand B (0.417), which is favorable for bioavailability.
15. **Affinity:** Ligand A (-6.7 kcal/mol) has a slightly better binding affinity than Ligand B (-6.2 kcal/mol). While the difference is not huge, it's a factor.
**GPCR-Specific Considerations:**
For ADRB2 (a cardiovascular GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A excels in logP, TPSA, and Pgp, and has comparable affinity. Ligand B has a better half-life and BBB penetration, but its higher logP and Pgp efflux are concerning. The DILI risk for Ligand A is a significant drawback, but the lower hERG risk is crucial for a cardiovascular drug.
**Overall Assessment:**
Despite the higher DILI risk, Ligand A is the more promising candidate. Its superior logP, TPSA, Pgp properties, and lower hERG risk outweigh the slightly lower half-life and higher DILI. The affinity difference is also a contributing factor. The DILI risk can be further investigated and potentially mitigated through structural modifications.
Output:
1
2025-04-17 21:57:35,293 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [383.813, 119.27 , 3.079, 1. , 6. , 0.604, 96.549, 60.954, -4.726, -5.029, 0.215, 23.512, 111.637, 0.272, -7.2 ]
**Ligand B:** [358.479, 96.89 , 0.989, 3. , 5. , 0.541, 6.747, 67.429, -4.794, -1.189, 0.167, 27.959, -22.76 , 0.006, -5.8 ]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, Affinity, and to a lesser extent BBB):
1. **MW:** Both are within the acceptable range (200-500 Da). Ligand B (358.479) is slightly preferred due to being a bit lower.
2. **TPSA:** Ligand A (119.27) is slightly higher than Ligand B (96.89). Both are under the 140 A^2 threshold for oral absorption, but Ligand B is better.
3. **logP:** Ligand A (3.079) is optimal. Ligand B (0.989) is a bit low, potentially hindering membrane permeability. This is a significant drawback for a GPCR ligand.
4. **HBD/HBA:** Ligand A (1 HBD, 6 HBA) is better than Ligand B (3 HBD, 5 HBA) in terms of balancing solubility and permeability.
5. **QED:** Both are acceptable (A: 0.604, B: 0.541), but A is slightly better.
6. **DILI:** Ligand B (6.747) has a much lower DILI risk than Ligand A (96.549). This is a major advantage for Ligand B.
7. **BBB:** Ligand B (67.429) has a slightly better BBB penetration than Ligand A (60.954), but neither are exceptionally high.
8. **Caco-2:** Both are negative, indicating poor permeability.
9. **Solubility:** Both are negative, indicating poor solubility.
10. **hERG:** Both have low hERG risk.
11. **Cl_mic:** Ligand A (23.512) has lower microsomal clearance, suggesting better metabolic stability than Ligand B (27.959).
12. **t1/2:** Ligand A (111.637) has a much longer in vitro half-life than Ligand B (-22.76), a significant advantage.
13. **Pgp:** Ligand A (0.272) has lower P-gp efflux, which is favorable. Ligand B (0.006) is even lower, which is a big advantage.
14. **Affinity:** Ligand A (-7.2 kcal/mol) has a stronger binding affinity than Ligand B (-5.8 kcal/mol). This is a substantial advantage.
**Overall Assessment:**
While Ligand B has a much better DILI profile and Pgp efflux, Ligand A has a significantly stronger binding affinity and a much longer half-life. The low logP of Ligand B is a major concern for a GPCR ligand, potentially hindering its ability to reach the receptor. The affinity difference is also quite large (1.4 kcal/mol), which can often outweigh other ADME concerns, especially given that both ligands have acceptable (though not ideal) ADME profiles.
Therefore, I would prioritize Ligand A due to its superior binding affinity and half-life, despite the higher DILI risk. The stronger binding is likely to be more critical for efficacy, and the DILI risk can be further investigated and potentially mitigated through structural modifications.
1
2025-04-17 21:57:35,293 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [351.332, 75.6, 2.771, 2, 4, 0.742, 76.968, 71.733, -5.086, -3.597, 0.558, 29.257, 23.835, 0.216, -5.6]**
**Ligand B: [350.503, 58.64, 2.925, 1, 3, 0.685, 15.006, 72.625, -4.371, -3.218, 0.567, 50.825, -13.353, 0.126, -7.1]**
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). A is 351.332, B is 350.503 - very similar. No clear advantage.
2. **TPSA:** Ligand A (75.6) is higher than Ligand B (58.64). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for permeability. Ligand B has an advantage.
3. **logP:** Both ligands have good logP values (A: 2.771, B: 2.925), falling within the optimal 1-3 range. B is slightly better.
4. **H-Bond Donors:** Ligand A has 2 HBD, and Ligand B has 1. Lower is generally better for permeability, giving a slight edge to B.
5. **H-Bond Acceptors:** Ligand A has 4 HBA, and Ligand B has 3. Again, B is slightly better.
6. **QED:** Ligand A (0.742) has a slightly better QED score than Ligand B (0.685), indicating a more drug-like profile.
7. **DILI Risk:** Ligand A (76.968) has a significantly higher DILI risk than Ligand B (15.006). This is a *major* concern for Ligand A.
8. **BBB Penetration:** Both have reasonable BBB penetration (A: 71.733, B: 72.625). Not a primary concern for a cardiovascular target, but B is slightly better.
9. **Caco-2 Permeability:** Ligand A (-5.086) has worse Caco-2 permeability than Ligand B (-4.371). Lower values indicate lower permeability. B is better.
10. **Aqueous Solubility:** Both have very poor aqueous solubility (A: -3.597, B: -3.218). This is a concern for both, but not a deciding factor.
11. **hERG Inhibition:** Both have low hERG inhibition risk (A: 0.558, B: 0.567). No significant difference.
12. **Microsomal Clearance:** Ligand A (29.257) has lower microsomal clearance than Ligand B (50.825), indicating better metabolic stability. This is a positive for A.
13. **In vitro Half-Life:** Ligand A (23.835) has a shorter half-life than Ligand B (-13.353). A negative half-life is not possible, so this value is likely an error. Assuming it is a positive value, B is still better.
14. **P-gp Efflux:** Both have low P-gp efflux (A: 0.216, B: 0.126). B is slightly better.
15. **Binding Affinity:** Ligand B (-7.1) has a significantly stronger binding affinity than Ligand A (-5.6). This is a substantial advantage for B, potentially outweighing some ADME drawbacks.
**Overall Assessment:**
Ligand B is the stronger candidate. While Ligand A has slightly better QED and microsomal clearance, Ligand B excels in critical areas: significantly lower DILI risk, better TPSA, logP, H-bond characteristics, Caco-2 permeability, P-gp efflux, and, crucially, a much higher binding affinity. The DILI risk associated with Ligand A is a major red flag. The higher affinity of Ligand B is a significant advantage for a GPCR target.
Output:
0
2025-04-17 21:57:35,294 - INFO - Batch 296 complete. Total preferences: 4736
2025-04-17 21:57:35,294 - INFO - Processing batch 297/512...
2025-04-17 21:58:20,550 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (355.394) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are reasonably low (A: 56.15, B: 58.2), well below the 140 threshold for oral absorption.
3. **logP:** Ligand A (4.188) is higher than Ligand B (2.988). While both are within the acceptable range, A is approaching the upper limit where solubility issues might arise.
4. **HBD/HBA:** Ligand A (HBD: 1, HBA: 5) has fewer H-bonds than Ligand B (HBD: 2, HBA: 3). This is generally favorable for permeability.
5. **QED:** Ligand A (0.6) has a better QED score than Ligand B (0.482), indicating a more drug-like profile.
6. **DILI:** Ligand B (29.624) has a significantly lower DILI risk than Ligand A (96.898). This is a major advantage for Ligand B.
7. **BBB:** Ligand B (83.443) shows better BBB penetration than Ligand A (61.342). While ADRB2 isn't strictly a CNS target, some CNS exposure can be relevant for off-target effects or potential therapeutic applications.
8. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. Ligand B (-5.094) is worse than Ligand A (-4.734).
9. **Solubility:** Both have negative solubility values, indicating poor solubility. Ligand B (-3.858) is slightly better than Ligand A (-4.682).
10. **hERG:** Both have low hERG inhibition liability (A: 0.828, B: 0.622), which is good.
11. **Cl_mic:** Ligand B (56.85) has lower microsomal clearance than Ligand A (75.964), suggesting better metabolic stability.
12. **t1/2:** Ligand A (16.606) has a longer in vitro half-life than Ligand B (-5.929). This is a positive for A.
13. **Pgp:** Ligand A (0.857) has higher Pgp efflux liability than Ligand B (0.151). Lower Pgp is preferred.
14. **Binding Affinity:** Ligand B (-7.0 kcal/mol) has a slightly better binding affinity than Ligand A (-6.8 kcal/mol). This difference is significant enough to consider.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand B excels in Pgp and has a better affinity, while Ligand A has a slightly better logP. The biggest drawback for Ligand A is its high DILI risk and higher Pgp efflux.
**Overall Assessment:**
While Ligand A has a slightly better QED and half-life, the significantly lower DILI risk, better Pgp profile, and superior binding affinity of Ligand B outweigh these advantages. The poor Caco-2 and solubility of both compounds are concerning, but can potentially be addressed through formulation strategies. The DILI risk associated with Ligand A is a major red flag.
Output:
0
2025-04-17 21:58:20,551 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (388.823 and 360.479 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (62.66) is significantly better than Ligand A (81.42). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (3.442 and 2.989), falling within the optimal 1-3 range. Ligand B is slightly better.
4. **HBD:** Ligand B (1) is preferable to Ligand A (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) and Ligand B (5) are comparable.
6. **QED:** Ligand A (0.795) has a better QED score than Ligand B (0.581), suggesting a more drug-like profile overall.
7. **DILI:** Ligand B (38.581) has a much lower DILI risk than Ligand A (64.676). This is a significant advantage for Ligand B.
8. **BBB:** Both ligands have reasonable BBB penetration (76.658 and 70.919). Since ADRB2 is primarily a cardiovascular target, this isn't a major deciding factor.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.858 and -4.846). This is unusual and suggests poor permeability.
10. **Solubility:** Ligand B (-2.391) has better solubility than Ligand A (-5.255).
11. **hERG:** Both ligands have low hERG inhibition liability (0.49 and 0.625).
12. **Cl_mic:** Both ligands have similar microsomal clearance (50.554 and 51.1 mL/min/kg).
13. **t1/2:** Ligand B (29.003) has a longer in vitro half-life than Ligand A (20.041), which is desirable.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.171 and 0.387).
15. **Binding Affinity:** Ligand B (-7.0) has a slightly better binding affinity than Ligand A (-6.9). Although the difference is small, it is still a factor.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in TPSA, logP, solubility, DILI risk, and half-life, while Ligand A has a slightly better QED. The small affinity difference is outweighed by the other advantages of Ligand B. The lower DILI risk for Ligand B is a very important factor.
**Conclusion:**
Considering the balance of properties, Ligand B is the more promising drug candidate.
Output:
0
2025-04-17 21:58:20,551 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (356.375) is slightly higher than Ligand B (343.471), but both are acceptable.
2. **TPSA:** Ligand A (111.24) is higher than Ligand B (62.3). For a GPCR like ADRB2, lower TPSA is generally preferred for better permeability, giving an initial edge to Ligand B.
3. **logP:** Ligand B (3.02) is optimal, while Ligand A (-0.743) is significantly below the preferred range. This is a major drawback for Ligand A, as it suggests poor membrane permeability.
4. **HBD:** Both ligands have 1 HBD, which is within the acceptable limit.
5. **HBA:** Ligand A (7) is higher than Ligand B (3). Lower HBA is generally preferred for permeability, favoring Ligand B.
6. **QED:** Ligand B (0.828) has a much better QED score than Ligand A (0.363), indicating a more drug-like profile.
7. **DILI:** Ligand B (21.908) has a significantly lower DILI risk than Ligand A (52.191). This is a crucial advantage for Ligand B.
8. **BBB:** Ligand B (75.301) has a better BBB penetration score than Ligand A (43.117). While ADRB2 isn't strictly a CNS target, some peripheral ADRB2 activity can be modulated by CNS effects, and better BBB penetration isn't necessarily a negative.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
10. **Solubility:** Ligand A (-1.24) has a worse solubility score than Ligand B (-3.374). Both are poor, but Ligand B is slightly better.
11. **hERG:** Ligand A (0.055) has a slightly lower hERG risk than Ligand B (0.634), which is a small advantage.
12. **Cl_mic:** Ligand A (34.827) has a lower microsomal clearance than Ligand B (79.005), indicating better metabolic stability. This is a positive for Ligand A.
13. **t1/2:** Ligand A (-20.851) has a negative in vitro half-life, which is not possible. Ligand B (-4.803) also has a negative half-life, which is also not possible. This is a major data quality issue for both.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.014 and 0.168 respectively).
15. **Binding Affinity:** Ligand B (-6.9) has a slightly better binding affinity than Ligand A (-6.0). While both are good, the difference is not substantial enough to outweigh other factors.
**Overall Assessment:**
Ligand B is significantly better overall. It has a much better QED score, lower DILI risk, better logP, and lower TPSA. While Ligand A has better metabolic stability (lower Cl_mic), the poor logP and TPSA of Ligand A are major concerns for oral bioavailability and cellular penetration. The negative half-life values are concerning for both, but the other advantages of Ligand B make it the preferred candidate.
**Output:**
0
2025-04-17 21:58:20,551 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (363.454 Da) is slightly higher than Ligand B (291.391 Da), but both are acceptable.
**2. TPSA:** Both ligands have TPSA values below 140 A^2, suggesting good oral absorption potential. Ligand A (63.24 A^2) is a bit higher than Ligand B (58.56 A^2), but both are well within acceptable limits for a non-CNS GPCR target.
**3. logP:** Both ligands have logP values between 1 and 3 (Ligand A: 2.911, Ligand B: 2.333), which is optimal for permeability and solubility.
**4. H-Bond Donors & Acceptors:** Ligand A (HBD=1, HBA=3) and Ligand B (HBD=2, HBA=4) both have reasonable numbers of hydrogen bond donors and acceptors, balancing solubility and permeability.
**5. QED:** Both ligands have QED values above 0.5 (Ligand A: 0.734, Ligand B: 0.874), indicating good drug-like properties. Ligand B is slightly better here.
**6. DILI Risk:** Ligand A (62.117) has a higher DILI risk than Ligand B (10.779). This is a significant concern, as minimizing liver toxicity is crucial.
**7. BBB Penetration:** BBB is less critical for a cardiovascular target like ADRB2. Both ligands have acceptable BBB penetration (Ligand A: 68.592, Ligand B: 65.684).
**8. Caco-2 Permeability:** Both ligands show negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
**9. Aqueous Solubility:** Both ligands have negative solubility values, which is also unusual and suggests poor solubility. Again, the scale is not specified.
**10. hERG Inhibition:** Ligand A (0.702) has a slightly higher hERG inhibition risk than Ligand B (0.377), but both are relatively low.
**11. Microsomal Clearance:** Ligand A (63.944) has a significantly higher microsomal clearance than Ligand B (6.929), indicating faster metabolism and potentially lower bioavailability.
**12. In vitro Half-Life:** Ligand A (60.84 hours) has a much longer in vitro half-life than Ligand B (20.76 hours), which is a positive attribute.
**13. P-gp Efflux:** Ligand A (0.674) has a slightly lower P-gp efflux liability than Ligand B (0.206), which is favorable.
**14. Binding Affinity:** Ligand A (-7.1 kcal/mol) has a stronger binding affinity than Ligand B (-6.7 kcal/mol). This 0.4 kcal/mol difference is substantial and could outweigh some of the ADME drawbacks.
**Overall Assessment:**
While Ligand A has a superior binding affinity and a longer half-life, the significantly higher DILI risk and higher microsomal clearance are major concerns. Ligand B, despite its slightly weaker affinity, presents a much more favorable safety profile (lower DILI) and better metabolic stability (lower Cl_mic). Given the cardiovascular context, minimizing toxicity is paramount. The affinity difference, while notable, may be overcome with further optimization of Ligand B.
Output:
0
2025-04-17 21:58:20,551 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (353.419 and 344.411 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (79.39) is better than Ligand B (91.57). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (2.061) is within the optimal 1-3 range, while Ligand A (0.315) is quite low. This is a significant drawback for Ligand A, potentially hindering membrane permeability.
4. **HBD:** Ligand A (0) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (4). Lower HBA is generally preferred.
6. **QED:** Both ligands have similar QED scores (0.727 and 0.717), indicating good drug-likeness.
7. **DILI:** Ligand A (38.736) has a slightly better DILI score than Ligand B (41.915), indicating a lower risk of liver injury. Both are acceptable.
8. **BBB:** Ligand A (62.97) is better than Ligand B (38.348), but BBB isn't a major priority for a cardiovascular target.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.553 and -4.798). These values are difficult to interpret without knowing the scale, but suggest poor permeability.
10. **Solubility:** Ligand A (-0.8) is better than Ligand B (-2.704). Higher solubility is generally desirable.
11. **hERG:** Ligand A (0.15) is significantly better than Ligand B (0.424), indicating a lower risk of cardiotoxicity. This is *very* important for a cardiovascular target.
12. **Cl_mic:** Ligand A (1.181) has a much lower microsomal clearance than Ligand B (30.675), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-6.009) has a much better in vitro half-life than Ligand B (48.579).
14. **Pgp:** Ligand A (0.037) has a much lower Pgp efflux liability than Ligand B (0.188), indicating better bioavailability.
15. **Binding Affinity:** Ligand A (-7.2) has a slightly better binding affinity than Ligand B (-5.4). This is a significant advantage.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A excels in Pgp, has a better TPSA, and a significantly better binding affinity. While its logP is low, the substantial advantage in affinity and the better safety profile (hERG, DILI) outweigh this drawback. Ligand B's logP is acceptable, but it suffers from higher Pgp efflux, poorer metabolic stability, and a weaker binding affinity.
**Conclusion:**
Ligand A is the more promising candidate due to its superior binding affinity, lower hERG risk, better metabolic stability, lower Pgp efflux, and better solubility. The lower logP is a concern, but the other advantages are substantial enough to make Ligand A the preferred choice.
Output:
1
2025-04-17 21:58:20,552 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.5 and 358.5 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (52.65) is slightly higher than Ligand B (46.34). Both are below the 140 threshold for oral absorption, but closer to the 90 threshold for CNS targets (less relevant for ADRB2, but still favorable). Ligand B is slightly better.
3. **logP:** Ligand A (1.975) is within the optimal 1-3 range. Ligand B (4.822) is above this range, potentially leading to solubility issues and off-target interactions. Ligand A is significantly better.
4. **HBD:** Ligand A (1) is preferable to Ligand B (0). While both are acceptable, a single HBD can contribute to solubility without significantly impacting permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (4). Both are within the acceptable limit of 10, but lower is generally better for permeability.
6. **QED:** Both ligands have good QED scores (0.648 and 0.743), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (6.592) has a much lower DILI risk than Ligand B (37.069). This is a crucial advantage for Ligand A.
8. **BBB:** Ligand B (80.031) has better BBB penetration than Ligand A (64.87). While ADRB2 isn't primarily a CNS target, some peripheral ADRB2 receptors can be relevant in certain conditions, and better BBB penetration isn't necessarily detrimental.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.528 and -4.897), which is unusual and suggests very poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand A (-1.62) has better solubility than Ligand B (-4.748). This is important given Ligand B's higher logP.
11. **hERG:** Both ligands have low hERG inhibition liability (0.46 and 0.557), which is good. No significant difference.
12. **Cl_mic:** Ligand A (18.922) has significantly lower microsomal clearance than Ligand B (75.491), indicating better metabolic stability. This is a major advantage for Ligand A.
13. **t1/2:** Ligand B (41.091) has a much longer in vitro half-life than Ligand A (-1.644). This is a significant advantage for Ligand B.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.017 and 0.774). Ligand A is much better.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.7 and -6.9 kcal/mol). The difference is negligible.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A excels in logP, Pgp, and has comparable affinity. Ligand B has slightly better TPSA and BBB penetration, and a longer half-life, but suffers from a high logP and significantly higher DILI risk and clearance.
**Overall Assessment:**
Despite Ligand B's longer half-life and better BBB penetration, Ligand A is the more promising candidate. Its lower logP, significantly lower DILI risk, better solubility, and improved metabolic stability (lower Cl_mic) outweigh the benefits of Ligand B. The poor Caco-2 values are a concern for both, but can potentially be addressed through formulation strategies. The DILI risk associated with Ligand B is a major red flag.
Output:
1
2025-04-17 21:58:20,552 - INFO - Here's my reasoning and final output for the ligand preference:
**Reasoning:**
We are targeting the ADRB2, a cardiovascular GPCR. Therefore, the key properties to prioritize are logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB (although less critical for a cardiovascular target than a CNS one).
Let's compare Ligand A and Ligand B across these and other important parameters:
* **Molecular Weight:** Both ligands (351.447 and 347.467 Da) are within the ideal 200-500 Da range.
* **TPSA:** Both ligands are below the 140 A^2 threshold (86.79 and 82.68 A^2), suggesting good potential for oral absorption.
* **logP:** Ligand A (0.723) is slightly lower than optimal (1-3), but still acceptable. Ligand B (1.958) is well within the optimal range.
* **H-Bond Donors/Acceptors:** Both have acceptable HBD counts (1). Ligand B has a higher HBA count (8 vs 4), which could slightly impact permeability, but is not a major concern.
* **QED:** Both ligands have good QED scores (0.62 and 0.662), indicating good drug-like properties.
* **DILI Risk:** Ligand A (16.053 percentile) has a significantly lower DILI risk than Ligand B (52.423 percentile). This is a substantial advantage.
* **BBB:** Ligand A (65.064) has better BBB penetration than Ligand B (55.642), though this is less critical for a cardiovascular target.
* **Caco-2 Permeability:** Ligand A (-4.972) has better Caco-2 permeability than Ligand B (-5.5), suggesting better absorption.
* **Aqueous Solubility:** Ligand A (-0.963) has better aqueous solubility than Ligand B (-1.613).
* **hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.098 and 0.137).
* **Microsomal Clearance:** Ligand A (16.822 mL/min/kg) has significantly lower microsomal clearance than Ligand B (27.377 mL/min/kg), indicating better metabolic stability.
* **In vitro Half-Life:** Ligand A (-18.716 hours) has a longer in vitro half-life than Ligand B (17.49 hours).
* **P-gp Efflux:** Both ligands have low P-gp efflux liability (0.014 and 0.104).
* **Binding Affinity:** Ligand A (-7.7 kcal/mol) has a slightly better binding affinity than Ligand B (-6.9 kcal/mol). While the difference is not huge, it's a positive factor.
**Overall Assessment:**
Ligand A is the stronger candidate. It demonstrates a significantly lower DILI risk, better metabolic stability (lower Cl_mic, longer t1/2), better Caco-2 permeability, better aqueous solubility, and slightly better binding affinity. While Ligand B has a more optimal logP, the advantages of Ligand A in safety (DILI) and pharmacokinetic properties (Cl_mic, t1/2, solubility, permeability) outweigh this.
**Output:**
1
2025-04-17 21:58:20,552 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (344.342 and 346.515 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (99.52) is higher than Ligand B (58.2). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for better absorption. Ligand B is significantly better.
**3. logP:** Both ligands have acceptable logP values (1.842 and 3.714), falling within the 1-3 range. Ligand B is slightly higher, which could potentially be beneficial for membrane permeability.
**4. H-Bond Donors:** Ligand A has 3 HBDs, and Ligand B has 2. Both are within the acceptable limit of <=5.
**5. H-Bond Acceptors:** Ligand A has 4 HBAs, and Ligand B has 2. Both are within the acceptable limit of <=10.
**6. QED:** Both ligands have reasonable QED values (0.769 and 0.69), indicating good drug-like properties.
**7. DILI Risk:** Ligand A has a DILI risk of 83.792, which is concerningly high. Ligand B has a much lower DILI risk of 22.334, a significant advantage.
**8. BBB Penetration:** BBB is less critical for a cardiovascular target. Ligand A (43.466) and Ligand B (65.374). Ligand B is better.
**9. Caco-2 Permeability:** Ligand A (-5.098) and Ligand B (-4.773). Both are negative, indicating low permeability.
**10. Aqueous Solubility:** Both ligands have very poor aqueous solubility (-3.047 and -4.397). This is a significant drawback for both, potentially impacting bioavailability.
**11. hERG Inhibition:** Ligand A (0.055) has a very low hERG inhibition risk, which is excellent. Ligand B (0.453) is slightly higher, but still relatively low.
**12. Microsomal Clearance:** Ligand A (-40.178) has a much lower (better) microsomal clearance than Ligand B (65.04). This suggests better metabolic stability for Ligand A.
**13. In vitro Half-Life:** Ligand A (-4.785) has a negative half-life, which is not possible. This is an error in the data. Ligand B (4.044) has a reasonable half-life.
**14. P-gp Efflux:** Ligand A (0.007) has very low P-gp efflux, which is desirable. Ligand B (0.435) has moderate P-gp efflux.
**15. Binding Affinity:** Ligand B (-7.4 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.3 kcal/mol). This 1.1 kcal/mol difference is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Despite the poor solubility of both compounds, Ligand B is the more promising candidate. The significantly stronger binding affinity (-7.4 vs -6.3 kcal/mol) is a major advantage for a GPCR target. Furthermore, the much lower DILI risk (22.334 vs 83.792) is a critical factor. While Ligand A has better metabolic stability and P-gp efflux, the DILI risk and weaker binding affinity are too significant to ignore. The half-life value for Ligand A is also suspect.
Output:
0
2025-04-17 21:58:20,552 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (351.447) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are reasonably low, but Ligand B (87.74) is better than Ligand A (98.74), closer to the <90 target for potential CNS penetration, though this isn't a primary concern for ADRB2 (cardiovascular).
3. **logP:** Ligand B (1.495) is better than Ligand A (0.028). Ligand A is quite low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (2), but both are acceptable.
5. **HBA:** Ligand B (5) is slightly higher than Ligand A (4), both are acceptable.
6. **QED:** Ligand B (0.845) is better than Ligand A (0.651), indicating a more drug-like profile.
7. **DILI:** Ligand A (6.553) is significantly better than Ligand B (65.258), a major advantage. Ligand B's DILI risk is quite high.
8. **BBB:** Ligand B (60.644) is better than Ligand A (39.395), but neither is particularly high. This isn't a major factor for a cardiovascular target.
9. **Caco-2:** Ligand A (-5.219) and Ligand B (-4.938) are similar, and both are negative, suggesting poor permeability.
10. **Solubility:** Ligand A (-1.58) is better than Ligand B (-3.176), which is a positive.
11. **hERG:** Ligand A (0.065) is much better than Ligand B (0.154), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand B (-7.908) is significantly better than Ligand A (-11.988), indicating better metabolic stability.
13. **t1/2:** Ligand B (-22.302) is much better than Ligand A (-6.432), suggesting a longer half-life.
14. **Pgp:** Ligand A (0.001) is much better than Ligand B (0.043), indicating lower efflux.
15. **Affinity:** Ligand B (-8.8) is significantly better than Ligand A (-5.8), a substantial advantage (a >3 kcal/mol difference).
**GPCR-specific priorities:** For ADRB2 (a cardiovascular GPCR), we prioritize logP, Pgp, TPSA, and affinity. Ligand B is better in logP, Pgp, and significantly better in affinity. While Ligand A has better TPSA, the difference is not substantial. However, the critical factor is the DILI risk. Ligand B's high DILI risk is a major concern, outweighing its advantages in affinity and metabolic stability. Ligand A has a much more favorable safety profile.
**Conclusion:**
Despite Ligand B's superior binding affinity and metabolic stability, the significantly higher DILI risk and slightly worse hERG profile make it a less desirable candidate. Ligand A, while having a lower affinity, presents a much better safety profile with lower DILI and hERG risk, and acceptable physicochemical properties.
Output:
1
2025-04-17 21:58:20,552 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.475 Da and 367.471 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (78.09) is better than Ligand B (84.67). Both are below 140, but lower TPSA generally favors absorption.
3. **logP:** Ligand A (2.44) is slightly higher than Ligand B (1.329), placing it more optimally within the 1-3 range. Ligand B is a bit low, potentially hindering permeation.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1), but both are well within the acceptable limit of 5.
5. **HBA:** Ligand B (6) is higher than Ligand A (3). Both are below 10, so this isn't a major concern, but A is preferable.
6. **QED:** Ligand B (0.817) is better than Ligand A (0.613), indicating a more drug-like profile. This is a positive for Ligand B.
7. **DILI:** Ligand A (38.736) has a significantly lower DILI risk than Ligand B (52.772). This is a crucial advantage for Ligand A.
8. **BBB:** Ligand B (61.38) has a higher BBB penetration percentile than Ligand A (44.94). While ADRB2 isn't strictly a CNS target, some CNS exposure can occur, so this is a slight advantage for B.
9. **Caco-2:** Ligand A (-5.28) has a more negative Caco-2 value, which is unusual and suggests *very* poor permeability. Ligand B (-4.989) is also poor, but less so. This is a major concern for Ligand A.
10. **Solubility:** Ligand A (-2.665) has better solubility than Ligand B (-3.241).
11. **hERG:** Both ligands have low hERG inhibition risk (0.454 and 0.385 respectively). No significant difference.
12. **Cl_mic:** Ligand A (27.923) has lower microsomal clearance than Ligand B (43.372), indicating better metabolic stability. This is a positive for Ligand A.
13. **t1/2:** Ligand A (-26.299) has a much longer in vitro half-life than Ligand B (11.577). This is a significant advantage for Ligand A.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.153 and 0.127 respectively). No significant difference.
15. **Affinity:** Ligand A (-7.6) has a significantly stronger binding affinity than Ligand B (-5.6). This is a major advantage for Ligand A.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, and affinity are key. Ligand A has a better logP and TPSA. The affinity difference is substantial (-7.6 vs -5.6 kcal/mol). While Ligand B has a better QED and BBB, the poor Caco-2 permeability of Ligand A is a major red flag. However, the significantly better affinity, metabolic stability (Cl_mic, t1/2), and lower DILI risk of Ligand A outweigh the permeability concern, *especially* given the strong binding. The binding affinity advantage is large enough to potentially overcome permeability issues through formulation strategies.
**Conclusion:**
Despite the permeability concerns, the superior binding affinity, metabolic stability, lower DILI risk, and better solubility of Ligand A make it the more promising drug candidate.
Output:
1
2025-04-17 21:58:20,552 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's analyze each ligand against the provided guidelines, with a focus on GPCR-relevant properties (logP, Pgp, TPSA, and affinity).
* **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (381.841) is slightly higher than Ligand B (348.407), but both are acceptable.
* **TPSA:** Ligand A (89.55) is excellent, well below the 140 threshold for oral absorption. Ligand B (119.43) is still reasonable, but less optimal.
* **logP:** Ligand A (1.541) is within the optimal range (1-3). Ligand B (0.337) is a bit low, potentially hindering permeation.
* **H-Bond Donors/Acceptors:** Both ligands have acceptable HBD (2) and HBA (6/5) counts, falling within the guidelines.
* **QED:** Ligand A (0.784) has a significantly better QED score than Ligand B (0.298), indicating a more drug-like profile.
* **DILI:** Ligand B (33.773) has a much lower DILI risk than Ligand A (88.329), which is a substantial advantage.
* **BBB:** Ligand B (46.879) shows slightly better BBB penetration than Ligand A (39.822), but both are not high enough to be considered CNS-focused. Since ADRB2 is primarily cardiovascular, BBB isn't a critical factor here.
* **Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability.
* **Aqueous Solubility:** Both ligands have negative solubility values, which is also unusual and suggests poor solubility.
* **hERG Inhibition:** Both ligands have very low hERG inhibition risk, which is excellent.
* **Microsomal Clearance:** Ligand B (18.712) has a lower microsomal clearance than Ligand A (34.179), indicating better metabolic stability.
* **In vitro Half-Life:** Both ligands have similar in vitro half-lives (8.088 vs 9.108 hours).
* **P-gp Efflux:** Both ligands have low P-gp efflux liability.
* **Binding Affinity:** Ligand B (-7.1 kcal/mol) has a 0.4 kcal/mol stronger binding affinity than Ligand A (-6.7 kcal/mol). This is a significant difference and a major driver in the decision.
**Overall Assessment:**
Ligand B has a significantly better binding affinity and lower DILI risk. While Ligand A has a better QED and TPSA, the superior affinity of Ligand B outweighs these benefits. The low logP of Ligand B is a concern, but the stronger binding could compensate for this. The negative Caco-2 and solubility values are concerning for both, and would require further investigation. However, considering the GPCR-specific priorities and the overall balance of properties, Ligand B appears to be the more promising candidate.
**Output:**
0
2025-04-17 21:58:20,553 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (386.5 and 343.4 Da) fall within the ideal 200-500 Da range. Ligand B is slightly preferred due to being closer to the lower end, potentially aiding permeability.
2. **TPSA:** Both ligands (84.5 and 84.81) are below the 140 A^2 threshold for good oral absorption, which is good.
3. **logP:** Both ligands (2.07 and 2.647) are within the optimal 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability, but also slightly increases the risk of off-target effects.
4. **HBD:** Both ligands have 2 HBD, which is within the acceptable limit of <=5.
5. **HBA:** Ligand A has 5 HBA, and Ligand B has 4. Both are below the acceptable limit of <=10.
6. **QED:** Ligand B (0.809) has a significantly better QED score than Ligand A (0.603), indicating a more drug-like profile.
7. **DILI:** Ligand B (54.634) has a lower DILI risk than Ligand A (41.915), which is a clear advantage.
8. **BBB:** Ligand B (76.464) has a better BBB penetration percentile than Ligand A (63.164). While ADRB2 isn't exclusively a CNS target, some cardiovascular effects are mediated through CNS pathways, so moderate BBB penetration is a plus.
9. **Caco-2:** Ligand A (-5.273) has a worse Caco-2 permeability than Ligand B (-4.729). Lower (more negative) values indicate lower permeability.
10. **Solubility:** Ligand A (-2.793) has a slightly better solubility than Ligand B (-3.693). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.297) has a lower hERG inhibition liability than Ligand B (0.777), which is a significant advantage regarding cardiotoxicity risk.
12. **Cl_mic:** Ligand B (25.8) has a much lower microsomal clearance than Ligand A (69.827), suggesting better metabolic stability.
13. **t1/2:** Ligand B (48.895) has a much longer in vitro half-life than Ligand A (-6.244), which is a significant advantage for dosing frequency.
14. **Pgp:** Ligand A (0.23) has a lower P-gp efflux liability than Ligand B (0.091), which is a plus for bioavailability.
15. **Binding Affinity:** Ligand A (-7.6) has a slightly better binding affinity than Ligand B (-6.8). This is a 0.8 kcal/mol difference, which is notable but not overwhelming given the other factors.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand B excels in logP, Pgp, and has a good TPSA. While Ligand A has a slightly better affinity, the other ADME properties of Ligand B are significantly more favorable, particularly its metabolic stability (Cl_mic and t1/2) and lower DILI risk. The better QED and BBB penetration also contribute to its overall drug-likeness. The hERG liability is a concern for Ligand B, but the difference in affinity is not large enough to offset the other advantages.
**Conclusion:**
Considering the balance of properties and the priorities for a GPCR target, Ligand B is the more promising drug candidate.
Output:
0
2025-04-17 21:58:20,553 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (354.397 and 347.459 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (60.85) is significantly better than Ligand B (74.69). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (2.356 and 1.89), falling within the 1-3 range. Ligand B is slightly lower, which could marginally improve solubility, but both are acceptable.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (3) is better than Ligand B (5). Similar reasoning as HBD - fewer HBAs are generally preferred.
6. **QED:** Ligand A (0.852) has a substantially better QED score than Ligand B (0.527), indicating a more drug-like profile.
7. **DILI:** Ligand A (35.983) has a significantly lower DILI risk than Ligand B (22.683). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (83.443) has a higher BBB penetration percentile than Ligand B (51.842). While not a primary concern for a cardiovascular target, higher BBB is rarely detrimental.
9. **Caco-2:** Ligand A (-4.64) is better than Ligand B (-5.086). Higher Caco-2 permeability is preferred.
10. **Solubility:** Ligand A (-2.337) is better than Ligand B (-1.693). Higher aqueous solubility is generally desirable.
11. **hERG:** Ligand A (0.329) has a lower hERG inhibition liability than Ligand B (0.673), reducing the risk of cardiotoxicity. This is a critical advantage.
12. **Cl_mic:** Ligand A (19.857) has a significantly lower microsomal clearance than Ligand B (46.216), indicating better metabolic stability.
13. **t1/2:** Ligand B (35.355) has a longer in vitro half-life than Ligand A (-23.482). This is a positive for Ligand B, but the negative value for Ligand A is concerning.
14. **Pgp:** Ligand A (0.047) has lower P-gp efflux liability than Ligand B (0.232), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand A (-6.6) has a slightly better binding affinity than Ligand B (-5.1). While the difference is not huge, it's still a positive for Ligand A.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Both ligands perform reasonably well on logP. Ligand A is superior in TPSA, Pgp, and affinity. The significantly better ADME properties of Ligand A (DILI, hERG, Cl_mic, solubility, QED) outweigh the longer half-life of Ligand B.
**Conclusion:**
Ligand A is the stronger candidate due to its superior ADME profile, lower toxicity risk, and slightly better binding affinity. The longer half-life of Ligand B is not enough to compensate for these significant advantages.
Output:
1
2025-04-17 21:58:20,553 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (361.467 Da) is within the ideal range (200-500 Da). Ligand B (397.32 Da) is also within range. No clear advantage here.
2. **TPSA:** Ligand A (71.53) is better than Ligand B (42.74). Lower TPSA generally favors better absorption, especially important for GPCRs.
3. **logP:** Ligand A (1.855) is within the optimal range (1-3). Ligand B (3.89) is approaching the upper limit, potentially leading to solubility issues.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 5 HBA, and Ligand B has 4 HBA, both are within acceptable limits.
6. **QED:** Both ligands have good QED scores (A: 0.642, B: 0.711), indicating drug-likeness. Ligand B is slightly better.
7. **DILI:** Ligand A (64.288) has a higher DILI risk than Ligand B (54.517), which is preferable.
8. **BBB:** Ligand B (79.217) has a significantly higher BBB penetration potential than Ligand A (64.482). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be beneficial for distribution.
9. **Caco-2:** Both ligands have very poor Caco-2 permeability (-5.027 and -5.031). This is a significant concern for oral bioavailability.
10. **Solubility:** Ligand A (-2.559) has better aqueous solubility than Ligand B (-3.384).
11. **hERG:** Ligand A (0.216) has a much lower hERG inhibition liability than Ligand B (0.872). This is a critical advantage, as hERG inhibition can lead to cardiotoxicity.
12. **Cl_mic:** Ligand A (20.107) has slightly higher metabolic clearance than Ligand B (18.83). Lower is better for metabolic stability.
13. **t1/2:** Ligand B (4.679) has a significantly longer in vitro half-life than Ligand A (-0.034). This is a major advantage, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.247) has lower P-gp efflux liability than Ligand B (0.638). Lower efflux is generally desirable.
15. **Affinity:** Ligand B (-8.4 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.4 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME drawbacks.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, affinity, logP, TPSA, and Pgp are crucial. Ligand B excels in affinity and has a reasonable logP. Ligand A has better TPSA and Pgp. The poor Caco-2 permeability for both is a major concern, but the significantly better affinity of Ligand B is a strong driver. The longer half-life of Ligand B is also a significant benefit. The lower hERG risk of Ligand A is a positive, but the affinity difference is substantial.
**Overall Assessment:**
Despite the slightly higher DILI risk and poorer solubility, the significantly improved binding affinity and half-life of Ligand B outweigh the advantages of Ligand A. The poor Caco-2 permeability is a concern for both, but can be addressed through formulation strategies.
Output:
0
2025-04-17 21:58:20,553 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (353.463 and 352.479 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (78.95) is significantly better than Ligand B (96.25). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand A is well below the 140 threshold, while B is approaching it.
**3. logP:** Both ligands have acceptable logP values (0.776 and 1.538, respectively), falling within the 1-3 range. Ligand B is slightly higher, which *could* be a minor advantage for membrane permeability, but isn't a major concern.
**4. H-Bond Donors:** Ligand A has 1 HBD, while Ligand B has 3. Lower is generally preferred for permeability, giving a slight edge to Ligand A.
**5. H-Bond Acceptors:** Ligand A has 4 HBA, and Ligand B has 5. Again, Ligand A is slightly better.
**6. QED:** Ligand A (0.699) has a better QED score than Ligand B (0.595), indicating a more drug-like profile.
**7. DILI Risk:** Both ligands have relatively low DILI risk (24.195 and 27.491, respectively), both well below the concerning threshold of 60. No significant difference.
**8. BBB Penetration:** Both ligands have moderate BBB penetration (56.417 and 50.679). Since ADRB2 is a cardiovascular target, BBB penetration isn't a primary concern, but it's not detrimental.
**9. Caco-2 Permeability:** Ligand A (-4.773) has a *much* better Caco-2 permeability score than Ligand B (-5.2). This suggests significantly better intestinal absorption for Ligand A.
**10. Aqueous Solubility:** Ligand A (-1.107) has better aqueous solubility than Ligand B (-1.958).
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.112 and 0.173, respectively). This is excellent.
**12. Microsomal Clearance:** Ligand A (13.76) has significantly lower microsomal clearance than Ligand B (46.659), suggesting better metabolic stability.
**13. In vitro Half-Life:** Ligand B (21.257) has a significantly longer in vitro half-life than Ligand A (3.741). This is a positive for Ligand B.
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (0.029 and 0.075, respectively).
**15. Binding Affinity:** Ligand B (-7.4) has a stronger binding affinity than Ligand A (-6.7), a difference of 0.7 kcal/mol. This is a substantial difference and a significant advantage for Ligand B.
**Overall Assessment:**
While Ligand B has a better binding affinity and a longer half-life, Ligand A demonstrates superior ADME properties across the board: lower TPSA, better Caco-2 permeability, better solubility, and significantly lower microsomal clearance. For a GPCR, optimizing ADME properties is crucial for achieving good oral bioavailability and maintaining therapeutic concentrations. The 0.7 kcal/mol difference in binding affinity, while notable, can potentially be addressed through further optimization of Ligand A, whereas improving the ADME profile of Ligand B would likely be more challenging. The better overall balance of properties makes Ligand A the more promising candidate.
Output:
1
2025-04-17 21:58:20,553 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (378.881 and 351.491 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (58.64) is significantly better than Ligand B (84.23). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (2.949 and 3.265), falling within the 1-3 range. Ligand B is slightly higher, which could potentially lead to some off-target interactions, but it's not a major concern.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Both ligands have the same number of HBA (4), which is acceptable.
6. **QED:** Ligand A (0.84) has a better QED score than Ligand B (0.677), indicating a more drug-like profile.
7. **DILI:** Ligand A (60.566) has a higher DILI risk than Ligand B (35.867). This is a significant drawback for Ligand A.
8. **BBB:** Both ligands have reasonable BBB penetration, but Ligand A (71.772) is better than Ligand B (64.676). While not a primary concern for a cardiovascular target, higher BBB is generally favorable.
9. **Caco-2:** Both ligands have similar, very negative Caco-2 values (-4.992 and -4.995). This suggests poor permeability, which is concerning.
10. **Solubility:** Ligand A (-4.286) has slightly better solubility than Ligand B (-2.776), though both are quite poor.
11. **hERG:** Ligand A (0.605) has a slightly higher hERG risk than Ligand B (0.289), which is undesirable.
12. **Cl_mic:** Ligand B (70.312) has a higher microsomal clearance than Ligand A (43.446), meaning Ligand A is more metabolically stable.
13. **t1/2:** Ligand B (8.027) has a slightly longer in vitro half-life than Ligand A (7.117).
14. **Pgp:** Ligand A (0.316) has lower P-gp efflux than Ligand B (0.218), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand A (-7.1 kcal/mol) has a slightly better binding affinity than Ligand B (-6.9 kcal/mol). This is a significant advantage, potentially outweighing some of the ADME concerns.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), affinity, logP, TPSA, and Pgp are important. Ligand A excels in affinity and has better TPSA and Pgp values. However, the significantly higher DILI risk and slightly higher hERG risk for Ligand A are major concerns.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity and better TPSA and Pgp values, the higher DILI risk is a substantial negative. The slightly better metabolic stability of Ligand A is a plus, but the overall risk profile of Ligand A is less favorable. Ligand B, despite slightly lower affinity, presents a much better safety profile with a significantly lower DILI risk.
Output:
0
2025-04-17 21:58:20,553 - INFO - Batch 297 complete. Total preferences: 4752
2025-04-17 21:58:20,553 - INFO - Processing batch 298/512...
2025-04-17 21:59:07,706 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (349.431 and 355.523 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (89.43) is slightly higher than Ligand B (81.67), but both are below the 140 threshold for good oral absorption, and acceptable for a cardiovascular GPCR.
3. **logP:** Both ligands have good logP values (1.2 and 1.525 respectively), falling within the optimal 1-3 range. Ligand B is slightly more lipophilic, which could be beneficial for membrane permeability.
4. **HBD:** Ligand A (2) is preferable to Ligand B (3). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (4). Lower HBA generally improves permeability.
6. **QED:** Ligand A (0.808) has a significantly better QED score than Ligand B (0.586), indicating a more drug-like profile.
7. **DILI:** Ligand A (39.24) has a much lower DILI risk than Ligand B (5.312), which is a crucial advantage.
8. **BBB:** Ligand A (78.558) has a significantly higher BBB penetration percentile than Ligand B (30.826). While ADRB2 isn't a CNS target, some off-target CNS effects are possible with GPCR ligands, and higher BBB is generally a positive.
9. **Caco-2:** Ligand A (-4.636) has a worse Caco-2 permeability than Ligand B (-5.056). Lower (more negative) values indicate lower permeability.
10. **Solubility:** Ligand A (-2.043) has a better solubility than Ligand B (-0.94).
11. **hERG:** Both ligands have very low hERG inhibition liability (0.194 and 0.15 respectively), which is excellent.
12. **Cl_mic:** Ligand A (22.616) has a significantly lower microsomal clearance than Ligand B (8.057), suggesting better metabolic stability.
13. **t1/2:** Ligand A (11.476) has a longer in vitro half-life than Ligand B (2.283), which is desirable.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.029 and 0.026 respectively).
15. **Binding Affinity:** Ligand A (-7.2 kcal/mol) has a significantly stronger binding affinity than Ligand B (-4.2 kcal/mol). This is a substantial advantage, potentially outweighing minor ADME drawbacks.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Both ligands perform well on logP and Pgp. Ligand A has better TPSA and a *much* better binding affinity.
**Overall Assessment:**
Ligand A is clearly superior. Its significantly stronger binding affinity, coupled with a better QED score, lower DILI risk, higher BBB penetration, better metabolic stability (lower Cl_mic and longer t1/2), and better solubility outweigh the slightly worse Caco-2 permeability. The large difference in binding affinity (-7.2 vs -4.2 kcal/mol) is a decisive factor.
Output:
1
2025-04-17 21:59:07,707 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (366.443 and 383.539 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (62.74) is significantly better than Ligand A (107.52). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (2.215) is within the optimal 1-3 range, while Ligand A (0.846) is slightly below, potentially hindering permeation. Ligand B has a clear advantage.
4. **HBD:** Ligand A (1) is preferable to Ligand B (0). While both are acceptable, having one HBD can improve solubility.
5. **HBA:** Both ligands have 6 HBA, which is within the acceptable limit of 10.
6. **QED:** Both ligands have similar QED scores (0.781 and 0.78), indicating good drug-like properties.
7. **DILI:** Ligand B (44.436) has a significantly lower DILI risk than Ligand A (74.68). This is a major advantage for Ligand B.
8. **BBB:** Ligand B (73.517) has a higher BBB penetration than Ligand A (62.466). While not critical for a cardiovascular target, it's a slight positive for Ligand B.
9. **Caco-2:** Both ligands have very negative Caco-2 values (-4.852 and -4.837), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand B (-3.004) is slightly better than Ligand A (-2.162), indicating better aqueous solubility.
11. **hERG:** Ligand A (0.285) has a lower hERG inhibition liability than Ligand B (0.42). This is a positive for Ligand A, as it suggests a lower risk of cardiotoxicity.
12. **Cl_mic:** Ligand B (41.993) has a slightly lower microsomal clearance than Ligand A (36.925), indicating better metabolic stability.
13. **t1/2:** Ligand B (-15.443) has a significantly longer in vitro half-life than Ligand A (-32.206). This is a substantial advantage for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.098) has lower P-gp efflux liability than Ligand B (0.28). This is a positive for Ligand A.
15. **Binding Affinity:** Ligand B (-6.2 kcal/mol) has a significantly stronger binding affinity than Ligand A (-3.9 kcal/mol). This is a critical advantage, as a 1.5 kcal/mol difference is substantial and can outweigh minor ADME drawbacks.
**Overall Assessment:**
Ligand B clearly outperforms Ligand A in several crucial areas: DILI risk, metabolic stability (Cl_mic and t1/2), and, most importantly, binding affinity. While Ligand A has advantages in hERG and Pgp efflux, the superior affinity and safety profile of Ligand B make it the more promising drug candidate. The slightly lower logP of Ligand A is a concern, and the much better affinity of Ligand B is likely to overcome the slightly higher Pgp efflux.
Output:
0
2025-04-17 21:59:07,707 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (353.5 & 393.4 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (78.51) is higher than Ligand B (58.64). For a cardiovascular GPCR, TPSA is moderately important, and lower is generally better for permeability. Ligand B has a slight advantage.
3. **logP:** Ligand A (1.88) is within the optimal range (1-3), while Ligand B (3.13) is at the higher end. Both are acceptable, but Ligand A is slightly preferred for potentially fewer off-target interactions.
4. **HBD:** Ligand A (2) and Ligand B (1) are both good, below the threshold of 5. Ligand B is slightly better.
5. **HBA:** Ligand A (4) and Ligand B (3) are both good, below the threshold of 10. Ligand B is slightly better.
6. **QED:** Ligand A (0.588) is better than Ligand B (0.484), indicating a more drug-like profile.
7. **DILI:** Ligand A (11.322) has a slightly higher DILI risk than Ligand B (10.237), but both are well below the concerning threshold of 60. Ligand B is slightly preferred.
8. **BBB:** Ligand B (84.451) has a significantly higher BBB penetration percentile than Ligand A (70.027). While ADRB2 isn't necessarily a CNS target, some CNS exposure can occur, and higher BBB is generally favorable. Ligand B has a clear advantage.
9. **Caco-2:** Both ligands have very similar (and poor) Caco-2 permeability (-4.951 vs -4.915). This is a concern for oral bioavailability for both.
10. **Solubility:** Both ligands have poor aqueous solubility (-2.118 vs -2.663). This is a significant drawback for both, and formulation strategies would be needed.
11. **hERG:** Ligand A (0.431) has a lower hERG inhibition liability than Ligand B (0.625), which is a significant advantage for cardiac safety.
12. **Cl_mic:** Both ligands have similar microsomal clearance (17.166 vs 17.91). No clear advantage.
13. **t1/2:** Ligand A (-25.19) has a much more negative in vitro half-life than Ligand B (-0.582). This indicates a significantly shorter half-life and faster metabolism for Ligand A, which is a major disadvantage.
14. **Pgp:** Ligand A (0.038) has much lower P-gp efflux liability than Ligand B (0.159). This is a positive for bioavailability.
15. **Binding Affinity:** Ligand B (-6.6 kcal/mol) has a stronger binding affinity than Ligand A (-5.5 kcal/mol). This 1.1 kcal/mol difference is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand B demonstrates a stronger binding affinity and better BBB penetration. While its logP is slightly higher, the improved affinity and BBB outweigh this. Ligand A has better QED and lower hERG, but its significantly shorter half-life is a major concern, and its lower affinity is a substantial drawback. The poor Caco-2 and solubility are issues for both, but can be addressed with formulation. Given the GPCR target class, affinity and permeability (reflected in BBB) are prioritized.
Output:
0
2025-04-17 21:59:07,707 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (363.46 & 348.53 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (41.57) is significantly better than Ligand A (58.36), being well below the 140 threshold for oral absorption and more favorable for GPCRs.
3. **logP:** Both are good (3.015 & 3.353), falling within the optimal 1-3 range. Ligand B is slightly higher, which could be a minor positive.
4. **HBD:** Both have 1 HBD, which is acceptable.
5. **HBA:** Ligand B (3) has fewer HBA than Ligand A (5), which is preferable for permeability.
6. **QED:** Both have good QED scores (0.734 & 0.828), indicating drug-likeness. Ligand B is slightly better.
7. **DILI:** Ligand B (5.16%) has a much lower DILI risk than Ligand A (39.09%), a significant advantage.
8. **BBB:** Both have good BBB penetration (81.78% & 88.91%), but Ligand B is better. This is a key consideration for GPCRs, even if ADRB2 isn't strictly a CNS target, some off-target effects are possible.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual. I will interpret this as very low permeability.
10. **Solubility:** Both have negative solubility values, which is also unusual. I will interpret this as very low solubility.
11. **hERG:** Both have low hERG inhibition risk (0.514 & 0.581).
12. **Cl_mic:** Ligand B (32.18) has significantly lower microsomal clearance than Ligand A (50.77), indicating better metabolic stability.
13. **t1/2:** Ligand B (15.03) has a much longer in vitro half-life than Ligand A (5.06), which is highly desirable.
14. **Pgp:** Both have low Pgp efflux liability (0.499 & 0.125). Ligand B is significantly better.
15. **Binding Affinity:** Ligand A (-7.1) has a slightly better binding affinity than Ligand B (-7.0), but the difference is small (0.1 kcal/mol).
**Overall Assessment:**
Ligand B consistently outperforms Ligand A across most critical ADME-Tox properties. While Ligand A has a marginally better binding affinity, the advantages of Ligand B in terms of DILI risk, BBB penetration, metabolic stability (Cl_mic & t1/2), Pgp efflux, TPSA, and HBA are substantial. Given the GPCR target class, the balance of properties in Ligand B makes it a more promising drug candidate. The unusual Caco-2 and Solubility values for both ligands are concerning and would require further investigation, but the other benefits of Ligand B outweigh this concern.
Output:
0
2025-04-17 21:59:07,707 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Ligand A (336.435 Da) is well within the ideal range (200-500 Da). Ligand B (372.491 Da) is also acceptable. No clear advantage here.
2. **TPSA:** Ligand A (45.33) is excellent, well below the 140 threshold for oral absorption. Ligand B (90.03) is still reasonable, but higher, potentially impacting absorption. Ligand A is favored.
3. **logP:** Ligand A (3.692) is optimal (1-3). Ligand B (-0.921) is significantly lower, potentially hindering membrane permeability. Ligand A is strongly favored.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 3 HBA, Ligand B has 5. Both are acceptable, but Ligand A is slightly better.
6. **QED:** Both ligands have similar QED scores (0.698 vs 0.651), indicating good drug-likeness.
7. **DILI:** Ligand A (48.352) has a moderate DILI risk, but is better than Ligand B (24.04). Ligand B is favored.
8. **BBB:** Ligand A (76.347) shows good BBB penetration, while Ligand B (56.301) is lower. Considering ADRB2 is a GPCR, BBB penetration is a desirable property, favoring Ligand A.
9. **Caco-2:** Ligand A (-4.9) and Ligand B (-5.239) both have negative Caco-2 values, indicating poor permeability. This is a concern for both, but the values are similar.
10. **Solubility:** Ligand A (-5.197) and Ligand B (-1.162) both have negative solubility values, indicating poor solubility. Ligand B is slightly better.
11. **hERG:** Ligand A (0.882) has a lower hERG risk than Ligand B (0.07). Ligand A is favored.
12. **Cl_mic:** Ligand A (92.3) has a higher microsomal clearance than Ligand B (14.74), suggesting lower metabolic stability. Ligand B is favored.
13. **t1/2:** Ligand A (28.034) has a longer in vitro half-life than Ligand B (-27.149). Ligand A is favored.
14. **Pgp:** Ligand A (0.649) has lower P-gp efflux than Ligand B (0.003). Ligand A is favored.
15. **Binding Affinity:** Ligand A (-4.6 kcal/mol) and Ligand B (-3.7 kcal/mol) both have good binding affinity, but Ligand A is significantly stronger. This is a major advantage for Ligand A.
**Overall Assessment:**
Ligand A demonstrates a more favorable balance of properties for a GPCR target like ADRB2. It has superior logP, TPSA, BBB penetration, hERG risk, Pgp efflux, and *significantly* better binding affinity. While Ligand B has a lower DILI risk and better metabolic stability, the strong binding affinity and favorable ADME properties of Ligand A outweigh these drawbacks. The poor Caco-2 and solubility for both compounds are concerning and would require further optimization, but the stronger starting point of Ligand A makes it the more promising candidate.
Output:
1
2025-04-17 21:59:07,707 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (345.4) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (88.58) is significantly better than Ligand B (47.36), falling well below the 140 threshold for good oral absorption and closer to the 90 threshold for CNS penetration (although ADRB2 isn't strictly a CNS target, lower TPSA is still beneficial).
3. **logP:** Both ligands have acceptable logP values (A: 2.318, B: 3.456), falling within the 1-3 range. Ligand B is a bit higher, which *could* lead to some solubility issues.
4. **HBD:** Ligand A (1) is preferable to Ligand B (0). While both are low, having one HBD can sometimes improve solubility without significantly impacting permeability.
5. **HBA:** Both ligands have the same number of HBA (5), which is good.
6. **QED:** Ligand A (0.898) has a much better QED score than Ligand B (0.477), indicating a more drug-like profile.
7. **DILI:** Ligand B (35.75) has a lower DILI risk than Ligand A (44.591), which is a significant advantage.
8. **BBB:** Ligand B (92.555) has a much higher BBB penetration percentile than Ligand A (69.95). While ADRB2 isn't a primary CNS target, higher BBB penetration can sometimes correlate with better overall distribution.
9. **Caco-2:** Ligand A (-5.104) has a more negative Caco-2 value, indicating *lower* permeability. Ligand B (-4.365) is better, but both are quite poor.
10. **Solubility:** Ligand A (-2.584) has a better solubility score than Ligand B (-4.768).
11. **hERG:** Both ligands have very low hERG risk (A: 0.222, B: 0.472).
12. **Cl_mic:** Ligand B (97.103) has a much higher microsomal clearance than Ligand A (10.953), suggesting lower metabolic stability. This is a major drawback for Ligand B.
13. **t1/2:** Ligand A (16.643) has a longer in vitro half-life than Ligand B (10.239), which is desirable.
14. **Pgp:** Both ligands have low P-gp efflux liability (A: 0.124, B: 0.489).
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.8 and -6.9 kcal/mol). The difference is negligible.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A has a better TPSA, QED, solubility, metabolic stability (lower Cl_mic, longer t1/2), and a slightly better solubility. Ligand B has a better BBB and lower DILI risk. The Caco-2 values for both are poor, but the other advantages of Ligand A outweigh the slightly lower Caco-2.
**Conclusion:**
Despite the lower Caco-2 value, Ligand A presents a more balanced profile with better predicted drug-like properties (QED), metabolic stability, and solubility. The similar binding affinity makes the ADME properties the deciding factor.
Output:
1
2025-04-17 21:59:07,708 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (371.424 Da and 367.892 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (46.17) is higher than Ligand B (29.54). For a cardiovascular GPCR, TPSA is moderately important. Ligand B's lower TPSA is preferable, suggesting better potential for membrane permeability.
**3. logP:** Both ligands have a logP of 4.905, which is at the upper limit of the optimal range (1-3). This could potentially lead to solubility issues or off-target interactions, but they are identical in this regard.
**4. H-Bond Donors:** Ligand A has 1 HBD, while Ligand B has 0. Both are within the acceptable limit of <=5.
**5. H-Bond Acceptors:** Ligand A has 3 HBA, and Ligand B has 2. Both are within the acceptable limit of <=10.
**6. QED:** Ligand A (0.766) has a slightly higher QED than Ligand B (0.641), indicating a more drug-like profile. This is a slight advantage for Ligand A.
**7. DILI Risk:** Ligand B (11.632) has a significantly lower DILI risk than Ligand A (47.034). This is a major advantage for Ligand B, as minimizing liver toxicity is crucial.
**8. BBB Penetration:** Ligand A (93.525) has higher BBB penetration than Ligand B (86.08). While ADRB2 is primarily a cardiovascular target, some CNS effects are possible with beta-adrenergic agonists, and higher BBB penetration isn't necessarily detrimental.
**9. Caco-2 Permeability:** Ligand A (-4.6) has better Caco-2 permeability than Ligand B (-4.243). This suggests better intestinal absorption for Ligand A.
**10. Aqueous Solubility:** Ligand A (-5.224) has slightly better aqueous solubility than Ligand B (-5.641).
**11. hERG Inhibition:** Ligand B (0.874) has a slightly higher hERG inhibition risk than Ligand A (0.411). Lower hERG risk is preferred, giving a slight edge to Ligand A.
**12. Microsomal Clearance:** Ligand B (114.961) has significantly higher microsomal clearance than Ligand A (50.471). This means Ligand A is more metabolically stable, a desirable trait.
**13. In vitro Half-Life:** Ligand A (10.475) has a longer in vitro half-life than Ligand B (-8.849). This is a significant advantage for Ligand A, potentially allowing for less frequent dosing.
**14. P-gp Efflux:** Both ligands have similar P-gp efflux liabilities (0.428 and 0.496).
**15. Binding Affinity:** Both ligands have very similar binding affinities (-6.1 and -6.2 kcal/mol). The difference is negligible.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity) and general drug-like properties, Ligand B appears to be the better candidate. The significantly lower DILI risk and improved metabolic stability (lower Cl_mic, longer half-life) outweigh the slight advantages of Ligand A in BBB penetration, Caco-2 permeability, and solubility. While both ligands have a high logP, the lower DILI risk is a critical factor for a cardiovascular drug.
Output:
0
2025-04-17 21:59:07,708 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (342.439 Da and 354.491 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (71.34) is significantly better than Ligand B (98.66). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (3.492) is optimal, while Ligand B (1.488) is on the lower side. A logP between 1-3 is desired, and Ligand A is closer to this. Lower logP can lead to poor membrane permeability.
4. **HBD:** Ligand A (2) is preferable to Ligand B (4). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (4). Fewer HBAs generally improve permeability.
6. **QED:** Ligand A (0.874) is substantially better than Ligand B (0.581), indicating a more drug-like profile.
7. **DILI:** Ligand B (15.045) has a much lower DILI risk than Ligand A (49.787), which is a significant advantage.
8. **BBB:** Ligand A (61.225) has better BBB penetration than Ligand B (20.512), but as this is a cardiovascular target, this is not a major factor.
9. **Caco-2:** Ligand A (-4.73) is better than Ligand B (-5.032). Higher Caco-2 values indicate better intestinal absorption.
10. **Solubility:** Ligand A (-4.072) is better than Ligand B (-2.01). Higher solubility is generally preferred.
11. **hERG:** Ligand A (0.373) has a lower hERG risk than Ligand B (0.099), which is a positive.
12. **Cl_mic:** Ligand B (4.172) has significantly lower microsomal clearance than Ligand A (29.376), indicating better metabolic stability.
13. **t1/2:** Ligand A (82.956) has a longer in vitro half-life than Ligand B (-3.77). Longer half-life is generally desirable.
14. **Pgp:** Ligand A (0.109) has lower P-gp efflux than Ligand B (0.014), which is a positive.
15. **Binding Affinity:** Ligand A (-7.6) has a slightly better binding affinity than Ligand B (-6.8). While both are good, the 0.8 kcal/mol difference is noteworthy.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A excels in logP, TPSA, and affinity. Ligand B has a much better DILI score and Cl_mic. The affinity difference is not large enough to outweigh the significantly better metabolic stability and lower DILI risk of Ligand B.
**Conclusion:**
Although Ligand A has a slightly better binding affinity, Ligand B's superior DILI profile and metabolic stability (lower Cl_mic) are more critical for overall drug development success. The lower logP of Ligand B is a concern, but the other benefits outweigh this drawback.
Output:
0
2025-04-17 21:59:07,708 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (a GPCR) drug candidates.
**Ligand A:** [370.471, 90.31, -0.546, 2, 6, 0.69, 27.569, 61.846, -4.963, -2.638, 0.265, 18.458, 5.588, 0.053, -7.7]
**Ligand B:** [350.459, 95.5, 1.33, 3, 4, 0.455, 33.307, 43.699, -4.937, -1.89, 0.082, 25.825, -26.642, 0.047, -7]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity, and to a lesser extent BBB):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (350.459) is slightly lower, which is generally favorable.
2. **TPSA:** Both are reasonably good (below 140), but Ligand A (90.31) is better than Ligand B (95.5). Lower TPSA generally means better permeability.
3. **logP:** Ligand A (-0.546) is a bit low, potentially hindering membrane permeability. Ligand B (1.33) is within the optimal range (1-3). This is a significant advantage for Ligand B.
4. **HBD/HBA:** Ligand A (2/6) and Ligand B (3/4) are both acceptable, falling within the recommended ranges.
5. **QED:** Ligand A (0.69) is better than Ligand B (0.455), indicating a more drug-like profile.
6. **DILI:** Ligand A (27.569) has a much lower DILI risk than Ligand B (33.307), which is a crucial safety consideration.
7. **BBB:** Ligand A (61.846) has a better BBB penetration potential than Ligand B (43.699). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be beneficial or at least less detrimental.
8. **Caco-2:** Both are similar and very poor (-4.963 and -4.937). This is a concern for oral absorption for both.
9. **Solubility:** Both are poor (-2.638 and -1.89). This is a significant drawback for both compounds and will require formulation strategies.
10. **hERG:** Both are very low risk (0.265 and 0.082).
11. **Cl_mic:** Ligand A (18.458) has a lower microsomal clearance than Ligand B (25.825), suggesting better metabolic stability.
12. **t1/2:** Ligand A (5.588) has a positive in vitro half-life, while Ligand B (-26.642) has a negative in vitro half-life. This is a significant advantage for Ligand A.
13. **Pgp:** Both are very low efflux (0.053 and 0.047).
14. **Affinity:** Ligand A (-7.7) has a slightly better binding affinity than Ligand B (-7.0). While both are good, the 0.7 kcal/mol difference is noticeable.
**Overall Assessment:**
Ligand A has a better overall profile. While both compounds have solubility and Caco-2 permeability issues, Ligand A excels in key areas: lower DILI risk, better metabolic stability (lower Cl_mic, positive t1/2), slightly better affinity, and better BBB penetration. The logP of Ligand A is a concern, but the other advantages outweigh this drawback. Ligand B's logP is better, but its higher DILI risk and poor metabolic stability are significant liabilities.
Therefore, I would select Ligand A as the more promising drug candidate.
1
2025-04-17 21:59:07,708 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (359.442) is slightly higher than Ligand B (346.515), but both are acceptable.
2. **TPSA:** Ligand A (107.53) is higher than Ligand B (49.41). For a cardiovascular GPCR, TPSA is not a major concern unless CNS penetration is desired, which isn't explicitly stated. Ligand B is significantly better here.
3. **logP:** Ligand A (0.27) is quite low, potentially hindering membrane permeability. Ligand B (3.668) is within the optimal range (1-3). This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (4) is higher than Ligand B (1). While both are within the acceptable limit of 5, lower is generally preferred for permeability. Ligand B is better.
5. **HBA:** Ligand A (4) is higher than Ligand B (2). Similar to HBD, Ligand B is preferable.
6. **QED:** Ligand B (0.79) has a better QED score than Ligand A (0.449), indicating a more drug-like profile.
7. **DILI:** Ligand A (13.106) has a slightly higher DILI risk than Ligand B (10.585), but both are reasonably low.
8. **BBB:** Ligand B (81.737) has a significantly higher BBB penetration potential than Ligand A (58.55). While not a primary concern for a cardiovascular target, it's a bonus.
9. **Caco-2:** Ligand A (-5.167) has a very poor Caco-2 permeability, suggesting poor absorption. Ligand B (-4.632) is also poor, but slightly better than A.
10. **Solubility:** Ligand A (-1.866) has slightly better solubility than Ligand B (-3.955).
11. **hERG:** Ligand A (0.157) has a slightly lower hERG inhibition liability than Ligand B (0.554), which is preferable.
12. **Cl_mic:** Ligand A (25.899) has a much lower microsomal clearance than Ligand B (80.69), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (-11.056) has a negative in vitro half-life, which is concerning. Ligand B (-8.852) is also negative, but less so. Both are problematic.
14. **Pgp:** Ligand A (0.008) has very low P-gp efflux, which is good. Ligand B (0.151) is slightly higher, but still relatively low.
15. **Affinity:** Both ligands have very similar binding affinities (-6.5 and -6.7 kcal/mol). The difference is negligible.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP and TPSA, and has a better BBB score. Ligand A has better Pgp and Cl_mic. The affinity is comparable. The poor Caco-2 and negative t1/2 for both are concerning. However, the significantly better logP and TPSA of Ligand B, combined with its higher QED, outweigh the advantages of Ligand A.
**Conclusion:**
Despite the better metabolic stability of Ligand A, the overall profile of Ligand B is more favorable for development as a drug candidate targeting ADRB2.
0
2025-04-17 21:59:07,709 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (355.435 and 352.519 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (113.6) is higher than Ligand B (78.43). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B is better.
3. **logP:** Ligand A (-0.031) is slightly lower than the optimal 1-3 range, potentially impacting permeability. Ligand B (2.48) is well within the optimal range. Ligand B is significantly better.
4. **HBD:** Both ligands have 3 H-bond donors, which is acceptable.
5. **HBA:** Ligand A has 5 H-bond acceptors, while Ligand B has 3. Lower HBA is generally favorable for permeability. Ligand B is better.
6. **QED:** Both ligands have good QED scores (0.503 and 0.616), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (34.781) has a slightly higher DILI risk than Ligand B (30.748), though both are below the concerning threshold of 60. Ligand B is better.
8. **BBB:** BBB is not a high priority for a cardiovascular target. Ligand A (43.815) is higher than Ligand B (27.801), but this is not a major factor.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-5.249) is slightly better than Ligand B (-4.569), but both are problematic.
10. **Solubility:** Both ligands have negative solubility values, indicating very poor aqueous solubility. Ligand A (-2.094) is slightly better than Ligand B (-3.559), but both are concerning.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.068 and 0.478, respectively). No significant difference.
12. **Cl_mic:** Both ligands have similar microsomal clearance values (51.412 and 51.848 mL/min/kg). No significant difference.
13. **t1/2:** Ligand A (-17.638) has a negative half-life, which is not physically possible and indicates a problem with the data or the molecule. Ligand B (3.734) has a short but positive half-life. Ligand B is much better.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.016 and 0.176, respectively). No significant difference.
15. **Binding Affinity:** Both ligands have the same binding affinity (-6.3 kcal/mol).
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp) and the general drug-like properties, Ligand B is clearly superior. It has a better logP, lower TPSA, slightly lower DILI risk, and a *realistic* half-life. The negative half-life of Ligand A is a major red flag. While both have poor solubility and Caco-2 permeability, Ligand B's other properties make it a more promising starting point for optimization.
Output:
0
2025-04-17 21:59:07,709 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (413.272 Da) is within the ideal range, while Ligand B (350.459 Da) is also good, slightly lower. No strong preference here.
2. **TPSA:** Ligand A (103.79) is acceptable but pushing the upper limit for good oral absorption. Ligand B (67.87) is excellent, well below the 140 threshold. This favors Ligand B.
3. **logP:** Ligand A (0.506) is quite low, potentially hindering membrane permeability. Ligand B (1.215) is better, falling within the optimal range. This strongly favors Ligand B.
4. **HBD:** Ligand A (3) is acceptable. Ligand B (1) is even better. Slight preference for Ligand B.
5. **HBA:** Ligand A (6) is acceptable. Ligand B (4) is better. Slight preference for Ligand B.
6. **QED:** Both ligands (A: 0.622, B: 0.75) have good drug-likeness scores, exceeding 0.5. No strong preference.
7. **DILI:** Ligand A (70.221) has a concerning DILI risk, being above the 60 threshold. Ligand B (23.226) has a very low DILI risk. This is a major advantage for Ligand B.
8. **BBB:** Ligand A (46.84) has a low BBB penetration. Ligand B (77.743) has good BBB penetration. As ADRB2 is a GPCR, BBB penetration is a consideration, favoring Ligand B.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual. Assuming these are logP-like scales, lower values indicate poorer permeability. They are similar, so no strong preference.
10. **Solubility:** Both ligands have negative solubility values, which is also unusual. Assuming these are logS-like scales, lower values indicate poorer solubility. They are similar, so no strong preference.
11. **hERG:** Both ligands have low hERG inhibition risk (A: 0.236, B: 0.365). No strong preference.
12. **Cl_mic:** Ligand A (-12.348) has a much lower (better) microsomal clearance than Ligand B (35.701), suggesting greater metabolic stability. This favors Ligand A.
13. **t1/2:** Ligand A (18.454) has a longer in vitro half-life than Ligand B (9.626). This favors Ligand A.
14. **Pgp:** Both ligands have very low Pgp efflux liability (A: 0.012, B: 0.039). No strong preference.
15. **Affinity:** Ligand A (-7.9 kcal/mol) has a significantly stronger binding affinity than Ligand B (-5.8 kcal/mol). This is a substantial advantage for Ligand A.
**Overall Assessment:**
Ligand B excels in several key areas: TPSA, logP, DILI risk, and BBB penetration. However, Ligand A has a significantly stronger binding affinity and better metabolic stability (lower Cl_mic and longer t1/2). The difference in binding affinity (-2.1 kcal/mol) is substantial and likely outweighs the ADME concerns with Ligand A, *especially* given that the DILI risk, while elevated, isn't extremely high. The improved metabolic stability also helps mitigate potential issues arising from lower permeability.
Therefore, I favor Ligand A.
Output:
1
2025-04-17 21:59:07,709 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (357.445) is slightly higher than Ligand B (344.423), but both are acceptable.
2. **TPSA:** Ligand A (61.44) is significantly better than Ligand B (100.86). For a GPCR, lower TPSA is generally preferred for better permeability. Ligand B is approaching a level that could hinder absorption.
3. **logP:** Both ligands have acceptable logP values (Ligand A: 1.917, Ligand B: 0.985), falling within the 1-3 range. Ligand A is slightly better, being closer to the optimal range.
4. **HBD:** Both ligands have 2 H-bond donors, which is good.
5. **HBA:** Ligand A has 3 HBA, while Ligand B has 8. This is a significant difference. Higher HBA can sometimes reduce permeability.
6. **QED:** Both ligands have similar QED values (Ligand A: 0.763, Ligand B: 0.736), indicating good drug-likeness.
7. **DILI:** Ligand A (19.814) has a much lower DILI risk than Ligand B (54.478). This is a critical advantage.
8. **BBB:** Ligand A (83.366) has a significantly higher BBB penetration percentile than Ligand B (59.984). While ADRB2 isn't exclusively a CNS target, some peripheral ADRB2 activity can be modulated by CNS effects, and higher BBB penetration isn't necessarily detrimental.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and likely indicates poor permeability in this *in vitro* assay. This is a concern for both.
10. **Solubility:** Ligand A (-2.517) has slightly better solubility than Ligand B (-1.65), though both are quite poor.
11. **hERG:** Both ligands have very low hERG inhibition risk (Ligand A: 0.678, Ligand B: 0.068). Ligand B is slightly better here.
12. **Cl_mic:** Ligand A (-13.702) has significantly lower (better) microsomal clearance than Ligand B (9.987). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand B (32.171) has a much longer *in vitro* half-life than Ligand A (8.436). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.036) has much lower P-gp efflux liability than Ligand B (0.004), which is a positive.
15. **Binding Affinity:** Both ligands have very similar binding affinities (Ligand A: -6.8 kcal/mol, Ligand B: -6.9 kcal/mol). The difference is negligible.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, TPSA, logP, Pgp, and affinity are key. Ligand A excels in TPSA, logP, and Pgp, while the affinities are nearly identical. The significantly lower DILI risk and better metabolic stability (Cl_mic) of Ligand A are also very important. The longer half-life of Ligand B is attractive, but can be overcome with formulation strategies. The poor Caco-2 values for both are a concern that would require further investigation.
**Conclusion:**
Considering the balance of properties, particularly the superior TPSA, DILI, Pgp, and Cl_mic profiles, Ligand A is the more promising drug candidate.
Output:
1
2025-04-17 21:59:07,709 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, key properties to prioritize are logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB (though less critical for a cardiovascular target).
Let's compare the ligands property by property:
1. **MW:** Both ligands (347.46 & 365.50 Da) fall within the ideal 200-500 Da range.
2. **TPSA:** Both are good (84.66 & 87.30), well below the 140 threshold for oral absorption.
3. **logP:** Ligand A (3.015) is slightly higher than Ligand B (1.925), placing it closer to the optimal 1-3 range. Ligand B is at the lower end, which *could* impact permeability.
4. **HBD/HBA:** Both have acceptable HBD (2/3) and HBA (4/4) counts.
5. **QED:** Ligand A (0.823) has a significantly better QED score than Ligand B (0.658), indicating better overall drug-likeness.
6. **DILI:** Both have low DILI risk (48.16 & 39.51), well below the concerning 60 threshold.
7. **BBB:** Ligand A (75.11) has a higher BBB percentile than Ligand B (59.79), but this is less critical for a cardiovascular target.
8. **Caco-2:** Ligand B (-5.289) has a more negative Caco-2 value, suggesting *lower* permeability. Ligand A (-4.728) is better.
9. **Solubility:** Ligand A (-3.856) has a better solubility score than Ligand B (-2.673).
10. **hERG:** Both have very low hERG risk (0.706 & 0.274).
11. **Cl_mic:** Ligand B (29.711) has a lower microsomal clearance than Ligand A (35.856), suggesting better metabolic stability.
12. **t1/2:** Ligand B (13.626 hours) has a significantly longer in vitro half-life than Ligand A (-2.933 hours). This is a major advantage.
13. **Pgp:** Ligand A (0.052) has a lower Pgp efflux liability than Ligand B (0.076), which is favorable.
14. **Binding Affinity:** Ligand B (-6.3 kcal/mol) has a slightly better binding affinity than Ligand A (-5.8 kcal/mol). This is a 0.5 kcal/mol difference, which is significant.
**Overall Assessment:**
Ligand B has a superior binding affinity and a much longer half-life, which are strong positives. However, its lower logP and Caco-2 values raise concerns about permeability. Ligand A has better overall drug-likeness (QED), solubility, and Pgp efflux, and a better Caco-2 value. The difference in binding affinity (0.5 kcal/mol) is outweighed by the other factors. Given the GPCR target class, the balance of properties in Ligand A is more favorable.
**Output:**
1
2025-04-17 21:59:07,709 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (354.45 & 356.46 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (84.94) is better than Ligand B (99.1). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally aids absorption.
3. **logP:** Ligand A (1.252) is better than Ligand B (0.456). Both are within the acceptable range (1-3), but Ligand A is closer to the optimal range. Ligand B is a bit low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (1) is better than Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Both ligands have the same number of HBA (5), which is acceptable.
6. **QED:** Ligand A (0.663) is slightly better than Ligand B (0.601), indicating a marginally more drug-like profile.
7. **DILI:** Ligand A (26.173) is better than Ligand B (19.271). Lower DILI risk is always preferred.
8. **BBB:** Both ligands have moderate BBB penetration (Ligand A: 42.303, Ligand B: 49.128). This isn't a major concern for a cardiovascular target.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.996 and -4.775). These values are unusual and suggest poor permeability. However, the values are close enough that this isn't a deciding factor.
10. **Solubility:** Both ligands have negative solubility values (-1.265 and -1.474). These values are also unusual and suggest poor solubility. Again, the values are close enough that this isn't a deciding factor.
11. **hERG:** Ligand A (0.18) is significantly better than Ligand B (0.303). Lower hERG inhibition is crucial for avoiding cardiotoxicity, especially with a cardiovascular target.
12. **Cl_mic:** Ligand B (7.205) is better than Ligand A (11.746). Lower clearance indicates better metabolic stability.
13. **t1/2:** Ligand A (-0.042) is much better than Ligand B (-14.712). A longer half-life is generally desirable.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.024 and 0.023). This is good.
15. **Binding Affinity:** Ligand B (-6.8) is better than Ligand A (-4.9). This is a substantial difference in potency (1.9 kcal/mol).
**Overall Assessment:**
Ligand B has a significantly better binding affinity, which is a critical factor for GPCRs. However, Ligand A has better DILI, hERG, and half-life profiles. The affinity difference is substantial enough to outweigh the slightly less favorable ADME properties of Ligand B, especially considering the cardiovascular context where metabolic stability and cardiotoxicity are key concerns. Ligand A's superior safety profile (DILI, hERG) is a significant advantage.
Output:
1
2025-04-17 21:59:07,710 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.443 and 350.434 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (57.78 and 58.64) are below the 140 A^2 threshold for good oral absorption, and are reasonable for a peripherally acting GPCR. No major difference.
3. **logP:** Ligand A (4.53) is higher than Ligand B (1.824). While 4.53 is approaching the upper limit, it's still acceptable. Ligand B's logP is quite low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (2) and Ligand B (1) both meet the <5 guideline. Ligand B is slightly better.
5. **HBA:** Both ligands (3) are below the 10 guideline. No significant difference.
6. **QED:** Both ligands (0.57 and 0.744) are above the 0.5 threshold, indicating good drug-likeness. Ligand B is slightly better.
7. **DILI:** Ligand A (80.923) has a significantly higher DILI risk than Ligand B (29.159). This is a major concern for Ligand A.
8. **BBB:** Ligand A (55.874) has a lower BBB penetration than Ligand B (93.098). While ADRB2 isn't a CNS target, higher BBB penetration generally correlates with fewer off-target effects.
9. **Caco-2:** Ligand A (-5.482) is worse than Ligand B (-4.524), indicating lower intestinal absorption.
10. **Solubility:** Ligand A (-4.832) is worse than Ligand B (-2.848), indicating lower aqueous solubility.
11. **hERG:** Both ligands (0.866 and 0.443) have low hERG inhibition risk, which is good. Ligand B is slightly better.
12. **Cl_mic:** Ligand A (57.857) has a higher microsomal clearance than Ligand B (39.571), suggesting lower metabolic stability.
13. **t1/2:** Ligand A (-15.672) has a shorter in vitro half-life than Ligand B (-17.455). Both are negative, indicating a short half-life, but Ligand B is slightly better.
14. **Pgp:** Ligand A (0.792) has higher P-gp efflux liability than Ligand B (0.193). This is a significant disadvantage for Ligand A.
15. **Binding Affinity:** Ligand B (-7.3 kcal/mol) has a significantly stronger binding affinity than Ligand A (-3.9 kcal/mol). This is a substantial advantage for Ligand B.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are particularly important. Ligand B excels in these areas. The significantly better binding affinity of Ligand B (-7.3 vs -3.9) is a major advantage that can outweigh some minor ADME drawbacks. The lower DILI risk and Pgp efflux of Ligand B are also crucial positives.
**Conclusion:**
Ligand B is a much more promising drug candidate due to its superior binding affinity, lower DILI risk, better Pgp profile, and improved solubility and permeability. While Ligand A has a slightly better logP, the other factors overwhelmingly favor Ligand B.
Output:
0
2025-04-17 21:59:07,710 - INFO - Batch 298 complete. Total preferences: 4768
2025-04-17 21:59:07,710 - INFO - Processing batch 299/512...
2025-04-17 21:59:53,330 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.379 and 363.395 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (126.82 and 125.2) are below 140, suggesting good oral absorption potential. They are a bit above the 90 threshold for CNS targets, but ADRB2 isn't necessarily a CNS target.
3. **logP:** Ligand A (0.555) is borderline, potentially being too hydrophilic. Ligand B (0.16) is even lower, and likely to have poor membrane permeability. This is a significant concern for both, but more so for B.
4. **HBD:** Both have 3 HBD, which is acceptable.
5. **HBA:** Ligand A has 7 HBA, and Ligand B has 5 HBA, both within the acceptable range.
6. **QED:** Both ligands have good QED scores (0.628 and 0.656), indicating generally drug-like properties.
7. **DILI:** Ligand B (91.043) has a considerably higher DILI risk than Ligand A (76.386). This is a major negative for Ligand B.
8. **BBB:** Both are similar (59.325 and 52.268), and neither is particularly high, which isn't critical for a non-CNS target like ADRB2.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability.
10. **Solubility:** Both have negative solubility values, which is also unusual and suggests poor solubility.
11. **hERG:** Ligand A (0.065) has a much lower hERG risk than Ligand B (0.165). This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand B (-12.543) has much lower microsomal clearance than Ligand A (23.42), indicating better metabolic stability. This is a strong positive for Ligand B.
13. **t1/2:** Ligand B (50.369) has a significantly longer in vitro half-life than Ligand A (0.796). This is a substantial advantage for Ligand B.
14. **Pgp:** Both have very low Pgp efflux liability (0.021 and 0.03), which is good.
15. **Binding Affinity:** Ligand B (-5.6 kcal/mol) has a slightly better binding affinity than Ligand A (-5.2 kcal/mol), but the difference is not huge.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. While both ligands struggle with logP, Ligand B's superior metabolic stability (Cl_mic and t1/2) and slightly better affinity are attractive. However, the significantly higher DILI risk and borderline solubility/permeability are major drawbacks. Ligand A has a better safety profile (lower DILI and hERG) despite being slightly less potent and having poorer metabolic stability.
**Overall Assessment:**
Despite Ligand B's better affinity and metabolic stability, the higher DILI risk is a significant concern. The negative Caco-2 and solubility values for both are problematic, but can potentially be addressed with formulation strategies. Given the importance of safety in drug development, and the relatively small difference in binding affinity, I favor Ligand A due to its better safety profile.
Output:
1
2025-04-17 21:59:53,331 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.46 & 359.49 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (95.5) is higher than Ligand B (53.68). For a GPCR, lower TPSA is generally preferred for better BBB penetration and overall drug-like properties. Ligand B is significantly better here.
3. **logP:** Ligand A (1.308) is within the optimal range (1-3), while Ligand B (4.056) is slightly above it. While not drastically high, Ligand B's higher logP could potentially lead to solubility issues or off-target interactions. Ligand A is better.
4. **HBD:** Ligand A (3) and Ligand B (1) are both acceptable, being less than 5. Ligand B is slightly better.
5. **HBA:** Both ligands (4) are within the acceptable range of less than 10. No significant difference.
6. **QED:** Both ligands have good QED scores (0.645 and 0.811), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (18.651) has a much lower DILI risk than Ligand B (26.444). This is a significant advantage for Ligand A.
8. **BBB:** Ligand B (67.197) has a better BBB penetration score than Ligand A (49.632). This is important for GPCRs, though not strictly required for ADRB2 which is primarily cardiovascular.
9. **Caco-2:** Ligand A (-5.105) and Ligand B (-4.773) are both negative, indicating poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-2.236) has better solubility than Ligand B (-4.078). This is a positive for Ligand A, especially considering Ligand B's higher logP.
11. **hERG:** Ligand A (0.103) has a lower hERG inhibition liability than Ligand B (0.734). This is a crucial advantage for Ligand A, reducing the risk of cardiotoxicity.
12. **Cl_mic:** Ligand B (61.513) has a significantly higher microsomal clearance than Ligand A (15.86). This suggests Ligand B will be metabolized more quickly, potentially leading to lower bioavailability and shorter duration of action. Ligand A is much better.
13. **t1/2:** Ligand B (59.139) has a much longer in vitro half-life than Ligand A (17.527). This is a positive for Ligand B, but may be offset by the high Cl_mic.
14. **Pgp:** Ligand A (0.053) has lower P-gp efflux liability than Ligand B (0.879). This is a positive for Ligand A, improving bioavailability.
15. **Affinity:** Ligand B (-6.2) has a slightly better binding affinity than Ligand A (-5.9). While a difference of 0.3 kcal/mol is not huge, it's a factor.
**Overall Assessment:**
While Ligand B has a slightly better binding affinity and BBB penetration, Ligand A demonstrates a significantly better safety profile (lower DILI, lower hERG) and better pharmacokinetic properties (lower Cl_mic, better solubility, lower Pgp efflux). The lower metabolic clearance and Pgp efflux of Ligand A are particularly important for a GPCR target. The slightly lower affinity of Ligand A is likely surmountable with further optimization. Given the cardiovascular target, the lower hERG risk is also a critical advantage.
Output:
1
2025-04-17 21:59:53,331 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, the key priorities are logP, TPSA, Pgp efflux, BBB penetration, and binding affinity. Metabolic stability (Cl_mic, t1/2) and safety (DILI, hERG) are also important.
Let's compare the ligands property by property:
1. **MW:** Both ligands (350.46 and 350.50 Da) are within the ideal range (200-500 Da).
2. **TPSA:** Ligand A (89.87) is better than Ligand B (69.64), being closer to the upper limit of 140 for good absorption, but both are acceptable.
3. **logP:** Ligand B (2.183) is better than Ligand A (0.828). Ligand A is slightly below the optimal range of 1-3, potentially hindering permeation.
4. **HBD/HBA:** Ligand B has fewer HBDs (2 vs 3) and HBAs (3 vs 4), which is generally favorable for permeability.
5. **QED:** Both ligands have good QED scores (0.619 and 0.705), indicating drug-likeness.
6. **DILI:** Ligand A (12.37) has a significantly lower DILI risk than Ligand B (20.40), which is a substantial advantage.
7. **BBB:** Ligand B (77.162) shows much better BBB penetration than Ligand A (47.344). While ADRB2 is cardiovascular, some CNS off-target effects are possible, and higher BBB is generally preferred.
8. **Caco-2:** Both have negative values, indicating poor permeability. Ligand A (-5.07) is slightly better than Ligand B (-4.852).
9. **Solubility:** Both have negative solubility values, indicating poor solubility. Ligand A (-1.97) is slightly better than Ligand B (-3.057).
10. **hERG:** Ligand A (0.173) has a lower hERG risk than Ligand B (0.541), which is a significant safety advantage.
11. **Cl_mic:** Ligand A (16.113) has a lower microsomal clearance, suggesting better metabolic stability than Ligand B (27.355).
12. **t1/2:** Ligand A (-6.54) has a longer in vitro half-life than Ligand B (-1.313).
13. **Pgp:** Ligand A (0.063) shows lower P-gp efflux than Ligand B (0.344), which is favorable for bioavailability.
14. **Binding Affinity:** Ligand B (-5.9 kcal/mol) has a slightly better binding affinity than Ligand A (-5.2 kcal/mol). This is a 0.7 kcal/mol difference, which is not a huge margin.
**Overall Assessment:**
Ligand A demonstrates a superior ADMET profile with lower DILI risk, lower hERG inhibition, better metabolic stability (lower Cl_mic, longer t1/2), and lower P-gp efflux. While Ligand B has better BBB penetration and slightly better binding affinity, the safety and metabolic advantages of Ligand A are more critical for a cardiovascular drug candidate. The slight difference in binding affinity is outweighed by the significant improvements in ADMET properties.
**Output:**
1
2025-04-17 21:59:53,331 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (343.431 and 352.45 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (81.07) is better than Ligand B (49.85). Both are below the 140 A^2 threshold for good absorption, but lower TPSA is generally preferred for GPCRs, potentially aiding BBB penetration.
3. **logP:** Both ligands (1.998 and 2.331) are within the optimal 1-3 range. Ligand B is slightly higher, which *could* be beneficial for membrane permeability, but not dramatically so.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (0). Both are acceptable, but lower HBD is often preferred for better permeability.
5. **HBA:** Ligand A (6) is higher than Ligand B (3). Again, lower HBA is generally favored for permeability.
6. **QED:** Both ligands (0.717 and 0.714) have excellent QED scores, indicating good drug-like properties. No significant difference.
7. **DILI:** Ligand B (21.365) has a significantly lower DILI risk than Ligand A (45.328). This is a major advantage for Ligand B.
8. **BBB:** Ligand B (89.608) has a much higher BBB penetration percentile than Ligand A (46.84). Given that ADRB2 is a GPCR, and even though it's cardiovascular, some CNS off-target effects are always a concern, and higher BBB is generally desirable to understand potential CNS exposure.
9. **Caco-2:** Ligand A (-5.26) has a worse Caco-2 permeability than Ligand B (-4.299). Lower (more negative) values indicate lower permeability.
10. **Solubility:** Ligand A (-1.779) has slightly better solubility than Ligand B (-2.095). Solubility is important, but not a primary concern given the good logP values of both.
11. **hERG:** Ligand A (0.692) has a slightly lower hERG risk than Ligand B (0.464). Lower is better, but both are relatively low risk.
12. **Cl_mic:** Ligand A (2.72) has significantly lower microsomal clearance than Ligand B (31.47). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (14.679) has a significantly longer in vitro half-life than Ligand B (5.323). This is a significant advantage for Ligand A, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.043) has a lower P-gp efflux liability than Ligand B (0.09). Lower is better, indicating better bioavailability.
15. **Binding Affinity:** Ligand A (-6.9) has a slightly better binding affinity than Ligand B (-6.6). While both are strong binders, the 0.3 kcal/mol difference is not overwhelming.
**Overall Assessment:**
Ligand B has a much better safety profile (DILI) and significantly better BBB penetration. Ligand A has better metabolic stability (Cl_mic, t1/2) and Pgp efflux. Considering the GPCR target class, the lower DILI and higher BBB of Ligand B are more compelling advantages. While Ligand A's metabolic stability is good, it's not enough to offset the safety concerns and potential for CNS exposure with Ligand B. The affinity difference is minimal.
Output:
0
2025-04-17 21:59:53,331 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (342.374 and 382.448 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (75.19 and 75.27) are below the 140 A^2 threshold for good oral absorption, and acceptable for a cardiovascular GPCR. Very similar.
3. **logP:** Both ligands (2.039 and 2.642) are within the optimal 1-3 range. Ligand B is slightly higher, which could be a minor advantage for membrane permeability but isn't a major concern.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (4) is preferable to Ligand B (3). Lower HBA generally improves permeability.
6. **QED:** Ligand A (0.926) has a significantly higher QED score than Ligand B (0.602), indicating a more drug-like profile. This is a substantial advantage.
7. **DILI:** Ligand B (44.591) has a lower DILI risk than Ligand A (58.744), which is a positive. This is a moderate advantage for Ligand B.
8. **BBB:** Both ligands have high BBB penetration (82.9 and 80.574), which is not a primary concern for a cardiovascular target, but not detrimental.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.622 and -4.864) which is unusual and suggests poor permeability. This is a significant drawback for both.
10. **Solubility:** Ligand B (-4.235) has slightly better solubility than Ligand A (-2.693), which is a minor advantage.
11. **hERG:** Both ligands have low hERG inhibition risk (0.365 and 0.561). No significant difference.
12. **Cl_mic:** Ligand A (-1.264) has a much lower (better) microsomal clearance than Ligand B (50.2). This suggests better metabolic stability for Ligand A, a significant advantage.
13. **t1/2:** Ligand A (-21.44) has a longer in vitro half-life than Ligand B (-31.667), which is a positive.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.051 and 0.146). No significant difference.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.9 and -6.2 kcal/mol). The difference of 0.7 kcal/mol is not substantial enough to override other factors.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Both ligands perform similarly on logP, TPSA, and Pgp. Affinity is very close. The biggest differences lie in QED (strongly favoring A), DILI (favoring B), and Cl_mic/t1/2 (strongly favoring A).
**Overall Assessment:**
Ligand A has a much better QED score and significantly improved metabolic stability (lower Cl_mic, longer t1/2). While Ligand B has a slightly lower DILI risk, the superior drug-likeness and metabolic profile of Ligand A are more important for overall developability. The Caco-2 values are concerning for both, but can be addressed with formulation strategies.
Output:
1
2025-04-17 21:59:53,331 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (365.411 and 342.355 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (90.85) is better than Ligand B (112.37). For a GPCR, keeping TPSA lower is preferable for good permeability, although both are acceptable.
**3. logP:** Both ligands have similar logP values (1.635 and 1.872), falling within the optimal 1-3 range.
**4. H-Bond Donors:** Ligand A has 0 HBD, while Ligand B has 1. Lower is generally better for permeability, giving a slight edge to Ligand A.
**5. H-Bond Acceptors:** Ligand A has 9 HBA, and Ligand B has 6. Both are within the acceptable limit of 10.
**6. QED:** Both ligands have good QED scores (0.755 and 0.907), indicating good drug-like properties. Ligand B is slightly better here.
**7. DILI Risk:** Ligand A has a DILI risk of 90.617, which is concerningly high. Ligand B has a significantly lower DILI risk of 70.88, a major advantage.
**8. BBB Penetration:** Ligand A (86.817) has better BBB penetration than Ligand B (62.466). While ADRB2 is primarily a cardiovascular target, some CNS side effects are possible with GPCR modulators, and better BBB penetration could contribute to this.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.589 and -4.83), which is unusual and suggests poor permeability. This is a significant concern for both.
**10. Aqueous Solubility:** Both ligands have negative solubility values (-3.646 and -4.207), indicating very poor aqueous solubility. This is a major drawback for both.
**11. hERG Inhibition:** Both ligands show low hERG inhibition liability (0.417 and 0.411), which is good.
**12. Microsomal Clearance:** Ligand A (91.937) has higher microsomal clearance than Ligand B (10.603), meaning it's metabolized faster. Lower clearance is preferred for longer duration of action. Ligand B is significantly better here.
**13. In vitro Half-Life:** Both ligands have similar in vitro half-lives (19.993 and 17.997 hours).
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.15 and 0.185), which is favorable.
**15. Binding Affinity:** Ligand B (-6.2 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.0 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME drawbacks.
**Overall Assessment:**
While Ligand A has slightly better TPSA and BBB penetration, Ligand B is significantly better in several crucial areas: DILI risk, microsomal clearance, and, most importantly, binding affinity. The strong binding affinity of Ligand B (-6.2 kcal/mol) is a major advantage for a GPCR target. The lower DILI risk is also a critical factor. The poor solubility and permeability are concerning for both, but can potentially be addressed with formulation strategies.
Therefore, I recommend Ligand B.
0
2025-04-17 21:59:53,332 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (376.5 and 350.5 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (112.6) is slightly higher than Ligand B (87.5). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B has a clear advantage here.
**3. logP:** Ligand B (1.02) is slightly better than Ligand A (0.62), falling comfortably within the 1-3 optimal range. Ligand A is a bit low, potentially hindering permeability.
**4. H-Bond Donors:** Ligand A (3) is slightly higher than Ligand B (2), but both are within the acceptable limit of 5.
**5. H-Bond Acceptors:** Both ligands have 5 H-bond acceptors, which is acceptable.
**6. QED:** Ligand B (0.83) has a significantly higher QED score than Ligand A (0.56), indicating a more drug-like profile.
**7. DILI Risk:** Both ligands have similar DILI risk (Ligand A: 31.3, Ligand B: 39.4), both being quite low and acceptable.
**8. BBB Penetration:** This is less critical for a cardiovascular target. Ligand A (39.5) and Ligand B (34.2) are both low, as expected.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-5.2) is slightly worse than Ligand B (-5.0).
**10. Aqueous Solubility:** Both ligands have negative solubility values, indicating poor aqueous solubility. Ligand A (-1.88) is slightly better than Ligand B (-2.43).
**11. hERG Inhibition:** Both ligands exhibit very low hERG inhibition risk (Ligand A: 0.21, Ligand B: 0.12), which is excellent.
**12. Microsomal Clearance:** Ligand B (53.97) has a significantly higher microsomal clearance than Ligand A (25.55), indicating faster metabolism and potentially lower *in vivo* exposure. This is a significant drawback for Ligand B.
**13. In vitro Half-Life:** Ligand B (13.8) has a much longer half-life than Ligand A (1.54). This is a major advantage for Ligand B.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (Ligand A: 0.034, Ligand B: 0.022), which is favorable.
**15. Binding Affinity:** Ligand A (-7.4 kcal/mol) has a stronger binding affinity than Ligand B (-6.4 kcal/mol). This is a substantial difference (1.0 kcal/mol) and a significant advantage for Ligand A.
**Overall Assessment:**
While Ligand B has a better QED, logP, and half-life, the significantly stronger binding affinity of Ligand A (-7.4 vs -6.4 kcal/mol) is a crucial factor, especially for a GPCR target. The lower microsomal clearance of Ligand A also suggests better metabolic stability. The slightly better solubility of Ligand A is also a plus. The permeability issues for both are concerning, but the potency advantage of Ligand A is likely to be more impactful in driving *in vivo* efficacy.
Therefore, I prefer Ligand A.
Output:
1
2025-04-17 21:59:53,332 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.346 and 356.413 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (81.75) is higher than Ligand B (67.43). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for permeability. Ligand B has a slight advantage.
3. **logP:** Both ligands (1.515 and 1.863) are within the optimal 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Ligand A (0) has no hydrogen bond donors, while Ligand B (2) has two. Lower HBD can be advantageous for permeability, giving Ligand A a slight edge.
5. **HBA:** Ligand A (6) has more hydrogen bond acceptors than Ligand B (3). Lower HBA is generally preferred for permeability. Ligand B is better here.
6. **QED:** Ligand A (0.784) has a better QED score than Ligand B (0.685), indicating a more drug-like profile.
7. **DILI:** Ligand A (59.907) has a higher DILI risk than Ligand B (31.059). This is a significant concern, and favors Ligand B.
8. **BBB:** Ligand A (96.161) has a much higher BBB penetration percentile than Ligand B (81.466). While ADRB2 isn't a CNS target, some off-target CNS effects are possible with GPCR ligands, and higher BBB could contribute to this. However, this is less critical than other factors.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.165 and -4.657). These values are unusual and suggest poor permeability. Ligand B is slightly worse.
10. **Solubility:** Both ligands have very poor aqueous solubility (-2.902 and -2.969). This is a major concern for both, and would require formulation strategies.
11. **hERG:** Both ligands have low hERG inhibition risk (0.317 and 0.322). No significant difference.
12. **Cl_mic:** Ligand A (59.404) has a higher microsomal clearance than Ligand B (3.435). This suggests Ligand B is more metabolically stable, a significant advantage.
13. **t1/2:** Ligand B (1.013) has a slightly longer in vitro half-life than Ligand A (-15.882). This is a positive for Ligand B.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.235 and 0.02). Ligand B is slightly better.
15. **Binding Affinity:** Ligand B (-5.5 kcal/mol) has a slightly better binding affinity than Ligand A (-5.3 kcal/mol). While the difference is small, it's still a positive for Ligand B.
**Overall Assessment:**
Ligand B is the better candidate. While Ligand A has a better QED and BBB penetration, Ligand B demonstrates significantly better metabolic stability (lower Cl_mic), lower DILI risk, and a slightly better binding affinity and half-life. The poor solubility and Caco-2 values are concerning for both, but can be addressed with formulation strategies. The lower DILI risk of Ligand B is a crucial factor, outweighing the slight advantages of Ligand A.
Output:
0
2025-04-17 21:59:53,332 - INFO - Here's my reasoning and the final output:
**Reasoning:**
We are evaluating two ligands for the ADRB2, a cardiovascular GPCR. Therefore, the key priorities are logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB.
Let's break down the comparison:
1. **MW:** Both ligands are within the ideal range (341-363 Da).
2. **TPSA:** Both are good, below the 140 A^2 threshold for oral absorption (76.46 and 72.28).
3. **logP:** Both are within the optimal range (1.755 and 2.049). Ligand B is slightly higher, which *could* be beneficial for membrane permeability, but not dramatically.
4. **HBD/HBA:** Both have 1 HBD and 5 HBA, which is acceptable.
5. **QED:** Both have good QED scores (0.879 and 0.924), indicating drug-likeness.
6. **DILI:** Ligand A has a significantly higher DILI risk (86.157) compared to Ligand B (52.772). This is a major concern.
7. **BBB:** Both have similar BBB penetration (76.58 and 79.566). Not a primary concern for a cardiovascular target, but higher is generally better.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, these values are on a scale where negative values are possible, and the absolute magnitude matters less than the relative difference.
9. **Solubility:** Both have negative solubility values, indicating poor solubility. This is a concern for both.
10. **hERG:** Both have very low hERG inhibition risk (0.208 and 0.209).
11. **Cl_mic:** Ligand A has a lower (better) microsomal clearance (21.416) than Ligand B (38.521), suggesting better metabolic stability.
12. **t1/2:** Ligand B has a significantly longer in vitro half-life ( -11.399 hours) than Ligand A (32.225 hours). This is a significant advantage.
13. **Pgp:** Both have low P-gp efflux liability (0.17 and 0.111), which is good.
14. **Binding Affinity:** Ligand B has a better (more negative) binding affinity (-4.0 kcal/mol) than Ligand A (-6.6 kcal/mol). This is a substantial difference in potency.
**Overall Assessment:**
Despite Ligand A's better metabolic stability and slightly better binding affinity, the significantly higher DILI risk is a deal-breaker. The improved half-life and binding affinity of Ligand B, coupled with its much lower DILI risk, make it the more promising candidate. The slightly worse metabolic stability of Ligand B is a manageable concern compared to the potential for liver toxicity with Ligand A.
**Output:**
0
2025-04-17 21:59:53,332 - INFO - Here's my reasoning and final decision:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (348.531) is slightly higher than Ligand B (343.427), but both are acceptable.
2. **TPSA:** Ligand A (58.2) is excellent, well below the 140 threshold and favorable for oral absorption. Ligand B (75.44) is still reasonable, but less optimal.
3. **logP:** Ligand A (4.247) is a bit high, potentially leading to solubility issues or off-target effects. Ligand B (2.164) is within the optimal range.
4. **HBD:** Ligand A (2) and Ligand B (1) are both good, well within the limit of 5.
5. **HBA:** Ligand A (2) and Ligand B (4) are both acceptable, below the limit of 10.
6. **QED:** Both ligands have good QED scores (A: 0.689, B: 0.85), indicating drug-likeness. Ligand B is slightly better.
7. **DILI:** Ligand A (25.824) has a significantly lower DILI risk than Ligand B (48.817), which is a major advantage.
8. **BBB:** Both ligands have good BBB penetration (A: 77.588, B: 81.349), which is important for a GPCR target. Ligand B is slightly better.
9. **Caco-2:** Both have negative values, indicating poor permeability. Ligand A (-4.627) is slightly better than Ligand B (-5.01).
10. **Solubility:** Ligand A (-4.478) is better than Ligand B (-2.784).
11. **hERG:** Both ligands have low hERG inhibition liability (A: 0.427, B: 0.289), which is good.
12. **Cl_mic:** Ligand A (63.274) has a slightly higher clearance than Ligand B (60.749), indicating potentially lower metabolic stability.
13. **t1/2:** Ligand B (-30.966) has a much longer half-life than Ligand A (14.906), which is a significant advantage.
14. **Pgp:** Both ligands have low Pgp efflux liability (A: 0.251, B: 0.311).
15. **Binding Affinity:** Ligand B (-7.3) has a significantly stronger binding affinity than Ligand A (-5.4), a difference of 1.9 kcal/mol. This is a substantial advantage.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are particularly important. Ligand B excels in affinity and has a better logP and TPSA. While Ligand A has a lower DILI risk, the substantial affinity advantage of Ligand B outweighs this concern, especially given both ligands have acceptable DILI profiles. The longer half-life of Ligand B is also a significant benefit.
**Conclusion:**
Ligand B is the more promising drug candidate due to its superior binding affinity, favorable logP and TPSA, and longer half-life. The slightly higher DILI risk is acceptable given the other advantages.
Output:
0
2025-04-17 21:59:53,333 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (363.46 & 342.53 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (55.32) is higher than Ligand B (32.34). For a cardiovascular GPCR, TPSA is moderately important, and lower is generally better for permeability. Ligand B has a clear advantage here.
**3. logP:** Both ligands have good logP values (3.255 & 3.584), falling within the optimal 1-3 range. Ligand B is slightly higher, which *could* be a minor drawback, but not a major concern.
**4. H-Bond Donors:** Ligand A has 0 HBD, while Ligand B has 1. Both are acceptable, being within the recommended limit of 5.
**5. H-Bond Acceptors:** Ligand A has 5 HBA, and Ligand B has 2. Both are within the acceptable limit of 10.
**6. QED:** Both ligands have similar QED values (0.79 & 0.717), indicating good drug-like properties.
**7. DILI Risk:** Ligand A (39.201) has a significantly lower DILI risk than Ligand B (9.771). This is a substantial advantage for Ligand A.
**8. BBB Penetration:** Ligand B (91.314) shows significantly better BBB penetration than Ligand A (80.419). While ADRB2 is a cardiovascular target, some CNS off-target effects are always a consideration, and better BBB penetration could be a concern. However, for a cardiovascular target, this is less critical than for a CNS target.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.625 & -4.975). This is unusual and suggests poor permeability. However, these values are on a log scale and could be interpreted as very low permeability.
**10. Aqueous Solubility:** Both ligands have negative solubility values (-3.061 & -4.798). This also suggests poor solubility, which is a significant concern.
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (0.721 & 0.893). This is good.
**12. Microsomal Clearance:** Ligand A (40.209) has lower microsomal clearance than Ligand B (57.809), indicating better metabolic stability. This is a positive for Ligand A.
**13. In vitro Half-Life:** Ligand A (11.048 hours) has a longer half-life than Ligand B (5.157 hours). This is a significant advantage for Ligand A, potentially allowing for less frequent dosing.
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (0.286 & 0.363).
**15. Binding Affinity:** Ligand B (-6.7 kcal/mol) has a slightly better binding affinity than Ligand A (-6.4 kcal/mol). This is a 0.3 kcal/mol difference, which is not a huge margin.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity) and the general guidelines, Ligand A is the more promising candidate. While Ligand B has slightly better affinity and BBB penetration, Ligand A excels in key areas like DILI risk, metabolic stability (lower Cl_mic), and in vitro half-life. The poor solubility and permeability of both ligands are concerning and would require further optimization, but the other advantages of Ligand A outweigh the slight affinity benefit of Ligand B.
Output:
1
2025-04-17 21:59:53,333 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
We are targeting ADRB2, a GPCR, so the priorities are logP, Pgp, TPSA, affinity, and BBB. Let's break down the comparison:
1. **Molecular Weight:** Both ligands (350.419 and 358.385 Da) fall comfortably within the ideal 200-500 Da range.
2. **TPSA:** Ligand B (78.87) is significantly better than Ligand A (107.61). A lower TPSA generally indicates better cell permeability, which is crucial for GPCR targeting. Ligand B is well below the 140 threshold.
3. **logP:** Ligand B (0.68) is better than Ligand A (-0.522). Both are within the 1-3 range, but Ligand B is closer to the optimal range.
4. **H-Bond Donors/Acceptors:** Ligand A has 3 HBD and 5 HBA, while Ligand B has 2 HBD and 4 HBA. Both are acceptable, though Ligand B is slightly more favorable.
5. **QED:** Ligand B (0.775) is better than Ligand A (0.403), indicating a more drug-like profile.
6. **DILI:** Both ligands have acceptable DILI risk (Ligand A: 22.838, Ligand B: 25.785), well below the concerning threshold of 60.
7. **BBB:** Ligand B (83.715) is significantly better than Ligand A (66.809). While not strictly required for ADRB2 (a cardiovascular target), higher BBB penetration can sometimes translate to better overall drug distribution and reduced off-target effects.
8. **Caco-2 Permeability:** Ligand A (-5.928) is slightly better than Ligand B (-4.702), but both are negative, indicating poor permeability.
9. **Aqueous Solubility:** Ligand A (-1.344) is better than Ligand B (-2.536). Solubility is important, but not as critical as permeability for this target.
10. **hERG Inhibition:** Ligand B (0.488) is better than Ligand A (0.037). Lower hERG inhibition is crucial for avoiding cardiotoxicity, making Ligand B more favorable.
11. **Microsomal Clearance:** Ligand A (-20.589) is significantly better than Ligand B (-16.469). Lower clearance indicates better metabolic stability.
12. **In vitro Half-Life:** Ligand B (23.102) is significantly better than Ligand A (-12.743). A longer half-life is generally desirable.
13. **P-gp Efflux:** Ligand A (0.003) is better than Ligand B (0.025). Lower P-gp efflux is preferred.
14. **Binding Affinity:** Ligand B (-7.0) is slightly better than Ligand A (-6.7). While the difference is small, it's still a positive for Ligand B.
**Overall Assessment:**
Ligand B demonstrates a superior balance of properties, particularly regarding TPSA, logP, BBB, hERG, and half-life. While Ligand A has better clearance and P-gp efflux, the advantages of Ligand B in permeability, safety (hERG), and overall drug-likeness outweigh these factors. The slightly better affinity of Ligand B further solidifies its preference.
Output:
0
2025-04-17 21:59:53,333 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate targeting the ADRB2 receptor:
**Reasoning:**
The ADRB2 receptor is a GPCR, so the priorities are logP, TPSA, Pgp efflux, BBB penetration, and binding affinity. Metabolic stability and solubility are also important, but slightly less so.
Let's compare the ligands property by property:
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (346.435) is slightly lower, which is generally favorable.
2. **TPSA:** Ligand B (78.09) is significantly better than Ligand A (104.7), falling well below the 140 threshold for oral absorption and closer to the ideal for GPCRs.
3. **logP:** Both are within the optimal range (1-3), but Ligand B (1.983) is slightly higher, potentially offering better membrane permeability.
4. **HBD/HBA:** Ligand B has fewer HBDs and HBAs (2/4) compared to Ligand A (3/5). This is generally favorable for permeability.
5. **QED:** Both have good QED scores (A: 0.667, B: 0.739), indicating good drug-like properties.
6. **DILI:** Ligand B (23.342) has a much lower DILI risk than Ligand A (48.662). This is a significant advantage.
7. **BBB:** Ligand B (63.474) shows better BBB penetration than Ligand A (27.491). While ADRB2 isn't strictly a CNS target, some CNS exposure can be acceptable and even beneficial for certain cardiovascular effects.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability in this *in vitro* assay. However, the values are similar.
9. **Solubility:** Both have very poor solubility scores (-2.02 and -2.388). This is a concern for both compounds and would require formulation strategies.
10. **hERG:** Both have very low hERG inhibition liability (0.065 and 0.218), which is excellent.
11. **Cl_mic:** Ligand A (6.437) has lower microsomal clearance, suggesting better metabolic stability. Ligand B (13.912) is higher.
12. **t1/2:** Ligand A (9.668) has a positive in vitro half-life, while Ligand B (-18.953) has a negative value, which is concerning.
13. **Pgp:** Both have very low P-gp efflux liability (0.015 and 0.045), which is favorable.
14. **Binding Affinity:** Both have similar, strong binding affinities (-6.5 and -6.4 kcal/mol). The difference is negligible.
**Overall Assessment:**
Ligand B is the stronger candidate. While Ligand A has better metabolic stability (lower Cl_mic and positive t1/2), Ligand B excels in crucial GPCR-relevant properties: lower TPSA, lower DILI risk, and significantly better BBB penetration. The slightly better logP of Ligand B also contributes to its favorability. The solubility issue is a concern for both, but can be addressed through formulation. The similar binding affinities make the ADME advantages of Ligand B decisive.
**Output:**
0
2025-04-17 21:59:53,333 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (a cardiovascular GPCR) drug candidates.
**Ligand A:** [404.264, 76.98, 3.676, 1, 5, 0.502, 85.498, 65.801, -5.123, -3.996, 0.312, 84.279, 49.373, 0.554, -6.2]
**Ligand B:** [342.439, 53.35, 3.862, 0, 5, 0.717, 38.193, 69.756, -4.38, -4.113, 0.554, 86.1, -0.204, 0.429, -6.5]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, Affinity) and general guidelines:
1. **MW:** A (404.264) is within the ideal range, B (342.439) is also good. No clear advantage.
2. **TPSA:** A (76.98) is acceptable, but B (53.35) is better, falling well below the 140 threshold for oral absorption and is more favorable for GPCRs.
3. **logP:** Both are good (A: 3.676, B: 3.862), within the 1-3 range. B is slightly higher, which *could* be a minor concern for solubility, but not a dealbreaker.
4. **HBD:** A (1) is preferable to B (0). Having at least one HBD can improve solubility.
5. **HBA:** Both have 5, which is acceptable.
6. **QED:** B (0.717) is better than A (0.502), indicating a more drug-like profile.
7. **DILI:** B (38.193) is *significantly* better than A (85.498). This is a major advantage for B.
8. **BBB:** Both are reasonable (A: 65.801, B: 69.756), but not exceptionally high. For a cardiovascular target, BBB isn't critical, so this isn't a deciding factor.
9. **Caco-2:** Both are negative, indicating poor permeability. A (-5.123) is worse than B (-4.38).
10. **Solubility:** Both are negative, indicating poor solubility. A (-3.996) is worse than B (-4.113).
11. **hERG:** A (0.312) is better than B (0.554), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Both are high (A: 84.279, B: 86.1), suggesting relatively rapid metabolism. No clear advantage.
13. **t1/2:** A (49.373) is better than B (-0.204), suggesting a longer in vitro half-life.
14. **Pgp:** A (0.554) is better than B (0.429), indicating lower P-gp efflux.
15. **Affinity:** B (-6.5) is slightly better than A (-6.2), but the difference is relatively small.
**Overall Assessment:**
While Ligand A has a slightly better in vitro half-life and Pgp efflux profile, Ligand B is significantly better in terms of DILI risk and QED. The lower TPSA of Ligand B is also favorable. The slightly better affinity of Ligand B is a bonus. The solubility and Caco-2 permeability are poor for both, but similar. The lower DILI risk is a critical factor for drug development, and the better QED score suggests a more favorable overall profile.
Therefore, I favor Ligand B.
Output:
0
2025-04-17 21:59:53,333 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (342.37 Da and 348.531 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (63.45) is higher than Ligand B (41.57). For a cardiovascular GPCR, TPSA is moderately important. Ligand B's lower TPSA is preferable, suggesting better permeability.
**3. logP:** Both ligands have good logP values (3.989 and 3.373, respectively), falling within the optimal 1-3 range. Ligand A is slightly higher, which could potentially lead to off-target effects, but the difference isn't drastic.
**4. H-Bond Donors:** Ligand A has 0 HBDs, while Ligand B has 1. Both are acceptable, staying within the <5 guideline.
**5. H-Bond Acceptors:** Both ligands have 3 HBAs, well within the <10 guideline.
**6. QED:** Both ligands have good QED scores (0.623 and 0.748), indicating good drug-like properties. Ligand B is slightly better.
**7. DILI Risk:** Ligand A has a DILI risk of 70.841, which is approaching the higher risk threshold (>60). Ligand B has a much lower DILI risk (9.694), a significant advantage.
**8. BBB Penetration:** Both ligands show good BBB penetration (83.249 and 87.476). While ADRB2 is primarily a cardiovascular target, some CNS off-target effects are possible, and higher BBB penetration isn't necessarily a negative. Ligand B is slightly better.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.541 and -4.794). This is unusual and suggests poor permeability *in vitro*. This is a concern for both, but the values are similar.
**10. Aqueous Solubility:** Both ligands have very poor aqueous solubility (-5.313 and -3.075). This is a significant drawback for both, potentially hindering formulation and bioavailability. Ligand B is slightly better.
**11. hERG Inhibition:** Both ligands show low hERG inhibition risk (0.812 and 0.628), which is excellent.
**12. Microsomal Clearance:** Ligand A has a higher microsomal clearance (83.779) than Ligand B (57.087). Lower clearance is preferred for metabolic stability, giving Ligand B an advantage.
**13. In vitro Half-Life:** Ligand A has a longer in vitro half-life (21.38 hours) than Ligand B (-4.449 hours). This is a significant advantage for Ligand A, potentially allowing for less frequent dosing. However, the negative value for Ligand B is concerning and likely an artifact of the model.
**14. P-gp Efflux:** Both ligands show low P-gp efflux (0.52 and 0.136). Ligand B is better here, which is important for bioavailability.
**15. Binding Affinity:** Ligand A has a stronger binding affinity (-7.5 kcal/mol) than Ligand B (-6.3 kcal/mol). This is a substantial difference (1.2 kcal/mol), and affinity is a critical factor.
**Overall Assessment:**
Despite Ligand A's superior binding affinity and half-life, Ligand B is the more promising candidate. The significantly lower DILI risk and better metabolic stability (lower Cl_mic) are crucial advantages. While both have poor solubility and Caco-2 permeability, the DILI risk associated with Ligand A is a major concern. The slightly better TPSA and P-gp efflux of Ligand B also contribute to its overall better profile. The negative half-life for Ligand B is a red flag, but the other benefits outweigh this issue.
Output:
0
2025-04-17 21:59:53,334 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (358.395 and 367.515 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand B (87.3) is significantly better than Ligand A (126.07). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (0.915) is closer to the optimal 1-3 range than Ligand A (-1.828). Ligand A's logP is quite low, potentially hindering membrane permeability.
4. **HBD:** Both have 3 HBD, which is acceptable.
5. **HBA:** Ligand B (4) is better than Ligand A (7). Lower HBA is generally preferred for permeability.
6. **QED:** Ligand B (0.501) is better than Ligand A (0.238), indicating a more drug-like profile.
7. **DILI:** Both ligands have similar and acceptable DILI risk (35.595 vs 35.285).
8. **BBB:** Ligand A (54.207) is better than Ligand B (33.85), but BBB is not a high priority for a cardiovascular target.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-5.279) is slightly worse than Ligand B (-5.428).
10. **Solubility:** Ligand A (-1.407) is better than Ligand B (-2.843). Solubility is important for bioavailability.
11. **hERG:** Both have very low hERG risk (0.14 and 0.109).
12. **Cl_mic:** Both have similar microsomal clearance (21.402 vs 21.329).
13. **t1/2:** Ligand B (14.954) has a much better in vitro half-life than Ligand A (-31.456). A longer half-life is generally desirable.
14. **Pgp:** Both have very low Pgp efflux (0.002 and 0.026).
15. **Binding Affinity:** Ligand B (-7.7 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.2 kcal/mol). This is a substantial advantage, exceeding the 1.5 kcal/mol threshold.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP, TPSA, and especially affinity. While Ligand A has better solubility and BBB, these are less critical for a cardiovascular target. The significantly improved binding affinity of Ligand B outweighs the slight solubility advantage of Ligand A.
**Conclusion:**
Ligand B is the more promising candidate due to its superior logP, TPSA, QED, half-life, and, most importantly, significantly stronger binding affinity.
Output:
0
2025-04-17 21:59:53,334 - INFO - Batch 299 complete. Total preferences: 4784
2025-04-17 21:59:53,334 - INFO - Processing batch 300/512...
2025-04-17 22:00:44,350 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (344.455) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (58.64) is significantly better than Ligand B (121.6). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand B is above the preferred threshold of 140.
3. **logP:** Ligand A (1.283) is within the optimal range, while Ligand B (-0.172) is slightly below, potentially hindering permeation.
4. **HBD:** Both have acceptable HBD counts (Ligand A: 1, Ligand B: 3).
5. **HBA:** Both have acceptable HBA counts (Ligand A: 3, Ligand B: 4).
6. **QED:** Ligand A (0.782) has a better QED score than Ligand B (0.499), indicating a more drug-like profile.
7. **DILI:** Ligand A (32.493) has a much lower DILI risk than Ligand B (17.914), a significant advantage.
8. **BBB:** While not critical for a cardiovascular target, Ligand A (78.79) has better BBB penetration than Ligand B (67.507).
9. **Caco-2:** Ligand A (-4.52) and Ligand B (-5.829) are both negative, indicating poor Caco-2 permeability.
10. **Solubility:** Ligand A (-3.079) is better than Ligand B (-1.502), although both are poor.
11. **hERG:** Ligand A (0.508) has a much lower hERG risk than Ligand B (0.018). This is a crucial safety parameter.
12. **Cl_mic:** Ligand A (28.854) has a significantly lower microsomal clearance than Ligand B (6.614), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-7.326) has a much longer in vitro half-life than Ligand B (-20.094).
14. **Pgp:** Ligand A (0.157) has lower P-gp efflux liability than Ligand B (0.004).
15. **Affinity:** Ligand A (-6.5 kcal/mol) has a slightly weaker binding affinity than Ligand B (-4.9 kcal/mol). However, the difference is not substantial enough to outweigh the significant ADME and toxicity advantages of Ligand A.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A is better in logP, TPSA, and Pgp. While Ligand B has better affinity, the difference isn't large enough to overcome the superior ADME profile and safety of Ligand A.
**Conclusion:**
Ligand A demonstrates a significantly better balance of properties, particularly regarding safety (DILI, hERG), metabolic stability (Cl_mic, t1/2), and absorption/permeability (TPSA, logP). While Ligand B has a slightly better binding affinity, the other advantages of Ligand A make it a more promising drug candidate.
Output:
1
2025-04-17 22:00:44,351 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [375.447, 128.03 , -0.583, 2. , 6. , 0.633, 49.399, 73.284, -5.088, -1.935, 0.13 , 20.632, -17.534, 0.023, -7.9 ]
**Ligand B:** [367.515, 82.53 , 2.321, 2. , 5. , 0.835, 47.77 , 76.464, -4.987, -3.788, 0.845, 45.854, -14.072, 0.212, -8. ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (367.5) is slightly lower, which is generally favorable.
2. **TPSA:** Ligand A (128.03) is higher than Ligand B (82.53). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is still preferred for better permeability. Ligand B is significantly better here.
3. **logP:** Ligand A (-0.583) is quite low, potentially hindering permeability. Ligand B (2.321) is within the optimal range (1-3). This is a significant advantage for Ligand B.
4. **HBD:** Both have 2 HBD, which is good.
5. **HBA:** Ligand A has 6 HBA, Ligand B has 5. Both are acceptable.
6. **QED:** Both have good QED scores (A: 0.633, B: 0.835). Ligand B is better.
7. **DILI:** Both have acceptable DILI risk (A: 49.4, B: 47.8). Very similar.
8. **BBB:** Both have good BBB penetration (A: 73.3, B: 76.5). Similar, but Ligand B is slightly better.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Both have negative solubility values, which is also unusual. Again, the scale is not specified, so it's hard to interpret.
11. **hERG:** Ligand A (0.13) has a much lower hERG risk than Ligand B (0.845). This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand A (20.632) has lower microsomal clearance than Ligand B (45.854), indicating better metabolic stability. This favors Ligand A.
13. **t1/2:** Ligand A (-17.534) has a negative half-life, which is impossible. Ligand B (-14.072) also has a negative half-life, which is impossible. This suggests an issue with the data.
14. **Pgp:** Ligand A (0.023) has much lower P-gp efflux than Ligand B (0.212), which is favorable for bioavailability.
15. **Affinity:** Ligand B (-8.0) has slightly better binding affinity than Ligand A (-7.9). While the difference is small, it's still a positive for Ligand B.
**GPCR-specific priorities:** For ADRB2 (a cardiovascular GPCR), logP, TPSA, Pgp efflux, and affinity are key. Ligand B excels in logP and TPSA, and has slightly better affinity. Ligand A has a better hERG profile and lower Pgp efflux. The metabolic stability (Cl_mic) is better for Ligand A.
**Overall Assessment:**
Despite the slightly better affinity of Ligand B, the significantly better logP and TPSA values, combined with acceptable DILI and BBB, make Ligand B the more promising candidate. The hERG risk for Ligand A is lower, but the poor logP is a major concern for oral bioavailability. The negative half-life values for both compounds raise a red flag, but assuming these are errors, the other properties weigh in favor of Ligand B.
Output:
0
2025-04-17 22:00:44,351 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (356.35 & 358.51 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (78.09) is higher than Ligand B (51.14). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B has a clear advantage.
3. **logP:** Ligand B (3.999) is higher than Ligand A (1.667). While both are within the acceptable range (1-3), Ligand B is approaching the upper limit. This *could* pose solubility issues, but isn't a dealbreaker. Ligand A is better here.
4. **HBD:** Ligand A (2) is higher than Ligand B (0). Lower is generally better for permeability, so Ligand B is favored.
5. **HBA:** Ligand A (3) is lower than Ligand B (6). Again, lower is generally better for permeability, favoring Ligand A.
6. **QED:** Both ligands have similar QED values (0.788 and 0.7), indicating good drug-likeness. No significant difference.
7. **DILI:** Ligand B (35.673) has a slightly lower DILI risk than Ligand A (38.852), both being well below the concerning threshold of 60. Ligand B is slightly favored.
8. **BBB:** Ligand A (83.443) has significantly higher BBB penetration potential than Ligand B (71.307). While ADRB2 isn't a CNS target, some degree of BBB penetration can be useful for off-target profiling. Ligand A is favored.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.888 and -4.711), suggesting poor permeability. This is a concern for both, but not dramatically different.
10. **Solubility:** Ligand A (-2.646) has better (less negative) solubility than Ligand B (-3.954). This is a significant advantage for Ligand A.
11. **hERG:** Ligand A (0.324) has a lower hERG risk than Ligand B (0.524). This is a crucial safety parameter, and Ligand A is clearly favored.
12. **Cl_mic:** Ligand A (-28.7) has a much lower (better) microsomal clearance than Ligand B (69.212). This indicates better metabolic stability for Ligand A, a significant advantage.
13. **t1/2:** Ligand A (-29.965) has a longer in vitro half-life than Ligand B (-27.087). This is a positive for Ligand A.
14. **Pgp:** Ligand A (0.013) has a much lower P-gp efflux liability than Ligand B (0.209). This is a significant advantage for Ligand A, improving bioavailability.
15. **Binding Affinity:** Ligand B (-6.9 kcal/mol) has a slightly better binding affinity than Ligand A (-7.4 kcal/mol). While a difference of 0.5 kcal/mol is noticeable, it's not a massive advantage, and can be overcome by superior ADME properties.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across critical ADME properties (Solubility, hERG, Cl_mic, t1/2, Pgp). While Ligand B has a slightly better binding affinity and a marginally lower DILI risk, the superior ADME profile of Ligand A, particularly its lower hERG risk and improved metabolic stability, makes it the more promising drug candidate for a cardiovascular GPCR target like ADRB2. The lower TPSA and HBD in Ligand B are attractive, but the solubility and metabolic issues are more concerning.
Output:
1
2025-04-17 22:00:44,352 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [346.431, 85.13, 1.015, 2, 5, 0.689, 40.869, 57.736, -5.032, -2.363, 0.35, 34.34, 3.309, 0.163, -6]
**Ligand B:** [338.317, 71.57, 3.501, 0, 5, 0.683, 80.651, 91.392, -4.483, -4.831, 0.375, 33.345, -28.328, 0.268, -8.3]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (338.317) is slightly lower, which is generally favorable.
2. **TPSA:** Ligand A (85.13) is a bit higher than Ligand B (71.57). Both are below 140, but B is better for absorption.
3. **logP:** Ligand A (1.015) is optimal, while Ligand B (3.501) is approaching the upper limit. This is a significant difference favoring A.
4. **HBD:** Ligand A (2) is better than Ligand B (0). Having some HBD can aid solubility.
5. **HBA:** Both ligands have 5 HBA, which is acceptable.
6. **QED:** Both ligands have similar QED values (0.689 vs 0.683), indicating similar drug-likeness.
7. **DILI:** Ligand A (40.869) has a significantly lower DILI risk than Ligand B (80.651). This is a major advantage for A.
8. **BBB:** Ligand B (91.392) has a much higher BBB penetration percentile than Ligand A (57.736). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant, and B is better here.
9. **Caco-2:** Ligand B (-4.483) has a slightly better Caco-2 value than Ligand A (-5.032).
10. **Solubility:** Ligand A (-2.363) has a better solubility value than Ligand B (-4.831).
11. **hERG:** Both ligands have low hERG inhibition liability (0.35 and 0.375).
12. **Cl_mic:** Both have similar microsomal clearance values (34.34 vs 33.345).
13. **t1/2:** Ligand B (-28.328) has a much longer in vitro half-life than Ligand A (3.309). This is a significant advantage for B.
14. **Pgp:** Ligand A (0.163) has lower P-gp efflux liability than Ligand B (0.268), which is favorable.
15. **Affinity:** Ligand B (-8.3 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6 kcal/mol). This is a substantial advantage for B, potentially outweighing some ADME concerns.
**GPCR-specific priorities:** For ADRB2 (a GPCR), we prioritize logP, Pgp, TPSA, and affinity. Ligand B excels in affinity and BBB penetration, while Ligand A has better logP, DILI, solubility, and Pgp. The difference in affinity (-8.3 vs -6) is substantial (over 2 kcal/mol), and this is a key driver for GPCRs. The longer half-life of Ligand B is also a significant benefit. While Ligand B's DILI risk is higher, the strong affinity and longer half-life are likely to be more critical for a GPCR target.
**Conclusion:**
Considering the balance of properties and the GPCR-specific priorities, **Ligand B** is the more promising drug candidate.
0
2025-04-17 22:00:44,352 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (351.466 and 347.415 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (61.44) is significantly better than Ligand B (91.23). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold, while B is approaching it.
3. **logP:** Both ligands have acceptable logP values (1.623 and 0.73), falling within the 1-3 range. Ligand A is slightly better, indicating potentially better membrane permeability.
4. **HBD:** Both have 2 HBD, which is good.
5. **HBA:** Ligand A has 3 HBA, while Ligand B has 5. Ligand A is preferable.
6. **QED:** Both ligands have similar QED scores (0.621 and 0.693), indicating good drug-likeness.
7. **DILI:** Ligand A (10.392) has a *much* lower DILI risk than Ligand B (27.414). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (70.105) has a better BBB penetration score than Ligand B (44.203). While not critical for a cardiovascular target, it's a positive attribute.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.854) is slightly better than Ligand B (-5.026), but both are concerning.
10. **Solubility:** Both have similar, very poor solubility scores (-1.949 and -1.994). This is a significant drawback for both compounds and would require formulation strategies.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.523 and 0.139), which is excellent.
12. **Cl_mic:** Ligand A (-11.043) has a much lower (better) microsomal clearance than Ligand B (2.358). This suggests greater metabolic stability for Ligand A.
13. **t1/2:** Ligand A (9.509) has a better in vitro half-life than Ligand B (29.944).
14. **Pgp:** Both have very low Pgp efflux liability (0.028 and 0.035).
15. **Binding Affinity:** Both ligands have the same binding affinity (-6.8 kcal/mol).
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, and affinity are important. Both ligands have similar affinity and acceptable logP values. However, Ligand A has a significantly lower TPSA and better metabolic stability (Cl_mic and t1/2). The lower DILI risk for Ligand A is also a crucial factor.
**Conclusion:**
Ligand A is the superior candidate due to its significantly lower DILI risk, better TPSA, improved metabolic stability, and better BBB penetration. While both have poor solubility and Caco-2 permeability, the other advantages of Ligand A outweigh these drawbacks.
Output:
1
2025-04-17 22:00:44,352 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (342.443) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both ligands are below the 140 A^2 threshold for good oral absorption. Ligand B (75.35) is better than Ligand A (89.78), being closer to the 90 A^2 threshold for CNS penetration (though BBB is the primary factor for CNS).
3. **logP:** Both ligands have good logP values (between 1-3). Ligand B (3.633) is slightly higher, potentially leading to some off-target effects, but within an acceptable range.
4. **HBD:** Both ligands have acceptable HBD counts (<=5). Ligand A (4) and Ligand B (3) are both good.
5. **HBA:** Both ligands have acceptable HBA counts (<=10). Ligand A (2) and Ligand B (3) are both good.
6. **QED:** Both ligands have good QED scores (>0.5). Ligand A (0.691) and Ligand B (0.713) are comparable.
7. **DILI:** Both ligands have acceptable DILI risk, but Ligand B (41.218) is significantly better than Ligand A (54.207). Lower DILI is a major advantage.
8. **BBB:** Both ligands have moderate BBB penetration. Ligand A (61.613) is slightly better than Ligand B (43.273), but neither is particularly high. Since ADRB2 isn't primarily a CNS target, this isn't a deciding factor.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. Ligand A (-4.89) is slightly better than Ligand B (-5.182).
10. **Solubility:** Both ligands have negative solubility values, indicating poor solubility. Ligand B (-3.649) is slightly better than Ligand A (-4.611).
11. **hERG:** Both ligands have low hERG inhibition liability. Ligand A (0.491) is slightly better than Ligand B (0.782).
12. **Cl_mic:** Ligand B (12.761) has significantly lower microsomal clearance than Ligand A (4.832), indicating better metabolic stability. This is a substantial advantage.
13. **t1/2:** Ligand B (12.142) has a longer in vitro half-life than Ligand A (24.757), which is a positive.
14. **Pgp:** Both ligands have low P-gp efflux liability. Ligand A (0.303) is slightly better than Ligand B (0.236).
15. **Binding Affinity:** Ligand A (-7.6) has a slightly better binding affinity than Ligand B (-7.4), but the difference is small (0.2 kcal/mol).
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Ligand B has a slightly higher logP, but its significantly improved metabolic stability (Cl_mic and t1/2) and lower DILI risk outweigh this. The affinity difference is minimal.
**Conclusion:**
Ligand B is the more promising candidate due to its significantly improved metabolic stability (lower Cl_mic, longer t1/2) and lower DILI risk. These factors are crucial for drug development and outweigh the slight advantages of Ligand A in other areas.
Output:
0
2025-04-17 22:00:44,353 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (368.415 Da) is slightly higher than Ligand B (344.411 Da), but both are acceptable.
2. **TPSA:** Ligand A (58.2) is significantly better than Ligand B (88.41). For a GPCR, lower TPSA is generally preferred for better permeability. Ligand B is approaching a level that could hinder absorption.
3. **logP:** Ligand A (3.216) is optimal, while Ligand B (1.89) is on the lower side. A logP between 1-3 is ideal, and Ligand A is closer to this.
4. **HBD:** Both ligands have 2 HBD, which is within the acceptable limit of 5.
5. **HBA:** Ligand A (2) is better than Ligand B (4). Lower HBA contributes to better permeability.
6. **QED:** Both ligands have good QED scores (A: 0.614, B: 0.854). Ligand B is slightly better here.
7. **DILI:** Ligand A (35.595) has a lower DILI risk than Ligand B (42.148), indicating a safer profile.
8. **BBB:** Ligand A (77.898) has a significantly higher BBB penetration percentile than Ligand B (67.584). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant, and higher BBB is generally favorable.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.647 and -4.808), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-4.05) has slightly better solubility than Ligand B (-2.058), though both are quite poor.
11. **hERG:** Ligand A (0.445) shows a much lower hERG inhibition liability than Ligand B (0.123), which is a significant advantage regarding cardiotoxicity risk.
12. **Cl_mic:** Ligand A (53.321) has a lower microsomal clearance than Ligand B (6.673), suggesting better metabolic stability.
13. **t1/2:** Ligand B (58.999) has a much longer in vitro half-life than Ligand A (-2.123). This is a major advantage for Ligand B.
14. **Pgp:** Ligand A (0.037) has a much lower P-gp efflux liability than Ligand B (0.152). Lower P-gp efflux is desirable for improved bioavailability.
15. **Affinity:** Ligand B (-7.8) has a significantly stronger binding affinity than Ligand A (-5.3). This is a substantial advantage, potentially outweighing some ADME concerns.
**Overall Assessment:**
Ligand B has a significantly better binding affinity, and a longer half-life. However, it suffers from higher TPSA, lower logP, higher DILI risk, lower BBB penetration, and higher P-gp efflux. Ligand A has better ADME properties across the board *except* for binding affinity and half-life. The difference in binding affinity (-7.8 vs -5.3 kcal/mol) is a 2.5 kcal/mol difference, which is substantial. Given the GPCR target class, the improved binding affinity of Ligand B is a key driver. While the ADME properties of Ligand B are concerning, they might be addressable through further optimization. The poor Caco-2 values for both are a significant issue that would need to be investigated, but the potency advantage of Ligand B is compelling.
Output:
0
2025-04-17 22:00:44,353 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (335.451) is slightly lower, which could be beneficial for permeability.
2. **TPSA:** Ligand A (39.08) is significantly better than Ligand B (95.16). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand B's TPSA is quite high, potentially hindering oral bioavailability.
3. **logP:** Ligand A (4.294) is a bit high, potentially leading to solubility issues and off-target interactions. Ligand B (1.713) is within the optimal range.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs generally improve membrane permeability.
5. **HBA:** Both ligands have the same number of HBA (4), which is acceptable.
6. **QED:** Both ligands have good QED scores (A: 0.7, B: 0.848), indicating good drug-like properties.
7. **DILI:** Ligand A (37.611) has a lower DILI risk than Ligand B (51.221), which is a significant advantage.
8. **BBB:** BBB isn't a high priority for a cardiovascular target. Ligand A (55.176) and B (48.779) are both relatively low.
9. **Caco-2:** Both ligands have similar, poor Caco-2 permeability (-5.135 and -5.139). This is a concern for both.
10. **Solubility:** Ligand B (-2.862) has better solubility than Ligand A (-4.187). This is a positive for Ligand B, mitigating its higher logP somewhat.
11. **hERG:** Ligand A (0.929) has a slightly higher hERG risk than Ligand B (0.034), which is a significant advantage for B.
12. **Cl_mic:** Ligand B (10.876) has significantly lower microsomal clearance than Ligand A (60.467), indicating better metabolic stability.
13. **t1/2:** Ligand B (-29.724) has a much longer in vitro half-life than Ligand A (-10.368), which is a major advantage.
14. **Pgp:** Both ligands have very low Pgp efflux liability (A: 0.806, B: 0.035), which is good.
15. **Binding Affinity:** Ligand B (-6.7) has a slightly better binding affinity than Ligand A (-6.2), although the difference is not huge.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP, has a better affinity, and similar Pgp. Ligand A has a better TPSA, but the other factors favor B.
**Overall Assessment:**
While Ligand A has a slightly lower MW and DILI risk, Ligand B demonstrates a superior profile in several critical areas: significantly better metabolic stability (Cl_mic, t1/2), better solubility, lower hERG risk, and slightly improved binding affinity. The high TPSA of Ligand B is a concern, but the other advantages outweigh this drawback, especially considering the target is not in the CNS.
Output:
0
2025-04-17 22:00:44,353 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (352.391 Da and 364.408 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (104.98) is higher than Ligand B (67.43). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B is significantly better.
**3. logP:** Ligand A (0.587) is quite low, potentially hindering membrane permeability. Ligand B (2.688) is within the optimal 1-3 range. This is a substantial advantage for Ligand B.
**4. H-Bond Donors:** Ligand A (1) and Ligand B (2) are both acceptable.
**5. H-Bond Acceptors:** Ligand A (6) and Ligand B (3) are both acceptable.
**6. QED:** Both ligands have similar QED values (0.77 and 0.73), indicating good drug-likeness.
**7. DILI Risk:** Ligand A (41.45) has a slightly higher DILI risk than Ligand B (29.43), but both are within acceptable limits (<40 is good).
**8. BBB Penetration:** Ligand A (74.758) and Ligand B (83.792) are both reasonably high, but not critical for a cardiovascular target. Ligand B is slightly better.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.522 and -4.618), which is unusual and suggests poor permeability. However, these values are on a log scale, so the absolute difference isn't massive.
**10. Aqueous Solubility:** Ligand A (-1.411) has slightly better solubility than Ligand B (-3.616).
**11. hERG Inhibition:** Both ligands show low hERG inhibition risk (0.29 and 0.366).
**12. Microsomal Clearance:** Ligand A (35.488) has lower microsomal clearance than Ligand B (45.009), suggesting better metabolic stability.
**13. In vitro Half-Life:** Ligand A (-25.323) has a much longer in vitro half-life than Ligand B (-7.375). This is a significant advantage for Ligand A.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.023 and 0.083).
**15. Binding Affinity:** Ligand B (-7.0) has a slightly better binding affinity than Ligand A (-6.2). This is a 0.8 kcal/mol difference, which is significant.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand B is the more promising candidate. While Ligand A has a better half-life and slightly better solubility, Ligand B's significantly better logP and TPSA, coupled with a slightly better binding affinity, outweigh those advantages. The low logP of Ligand A is a major concern for permeability. The difference in binding affinity is also substantial enough to make a difference.
Output:
0
2025-04-17 22:00:44,354 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [362.417, 89.87, 0.764, 3, 4, 0.595, 16.479, 64.637, -4.961, -1.356, 0.338, 11.863, -30.073, 0.023, -6.9]
**Ligand B:** [349.479, 98.17, 3.256, 1, 3, 0.372, 22.838, 64.715, -4.642, -2.432, 0.287, 36.773, 11.551, 0.042, -8.8]
Here's a breakdown of the comparison, considering the guidelines and GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (349.479) is slightly lower, which is generally favorable for permeability, but both are acceptable.
2. **TPSA:** Ligand A (89.87) is better than Ligand B (98.17), both are below 140, which is good for oral absorption.
3. **logP:** Ligand A (0.764) is a bit low, potentially impacting permeability. Ligand B (3.256) is much better, falling within the optimal 1-3 range. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (3) is higher than Ligand B (1). Lower is generally preferred, but both are within acceptable limits.
5. **HBA:** Ligand A (4) is slightly higher than Ligand B (3), but both are acceptable.
6. **QED:** Ligand A (0.595) is significantly better than Ligand B (0.372), indicating a more drug-like profile.
7. **DILI:** Ligand A (16.479) has a much lower DILI risk than Ligand B (22.838). This is a major advantage for Ligand A.
8. **BBB:** Both have similar BBB penetration (around 64-65%), which isn't a primary concern for a cardiovascular target.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability.
10. **Solubility:** Ligand A (-1.356) is better than Ligand B (-2.432).
11. **hERG:** Both have low hERG inhibition risk, with Ligand A (0.338) being slightly better.
12. **Cl_mic:** Ligand A (11.863) has a much lower microsomal clearance, suggesting better metabolic stability than Ligand B (36.773). This is a significant advantage.
13. **t1/2:** Ligand A (-30.073) has a much longer in vitro half-life than Ligand B (11.551). This is a strong advantage for Ligand A.
14. **Pgp:** Both have very low P-gp efflux liability.
15. **Affinity:** Ligand B (-8.8 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.9 kcal/mol). This is a substantial advantage for Ligand B, potentially outweighing some ADME concerns.
**Overall Assessment:**
Ligand B has a superior binding affinity and a better logP value, which are critical for GPCR targets. However, Ligand A demonstrates a much better safety profile (lower DILI), better metabolic stability (lower Cl_mic, longer t1/2), and better QED. The difference in affinity is significant (1.9 kcal/mol), which is a large advantage. While Ligand A has better ADME properties, the potency advantage of Ligand B is substantial enough to make it the more promising candidate.
Output:
0
2025-04-17 22:00:44,354 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (344.415 Da) is slightly lower, which could be advantageous for permeability, but both are acceptable.
**2. TPSA:** Ligand A (106.32) is significantly better than Ligand B (33.2). For a cardiovascular GPCR, lower TPSA is generally preferred as it aids membrane permeability.
**3. logP:** Ligand A (1.695) is within the optimal range (1-3), while Ligand B (4.192) is pushing the upper limit. Higher logP can lead to solubility issues and off-target interactions.
**4. H-Bond Donors:** Ligand A (2) is reasonable, while Ligand B (0) is also acceptable.
**5. H-Bond Acceptors:** Ligand A (5) is reasonable, while Ligand B (2) is also acceptable.
**6. QED:** Both ligands have similar QED values (0.783 and 0.72), indicating good drug-like properties.
**7. DILI:** Both ligands have low DILI risk (31.02 and 33.773), which is good.
**8. BBB:** Ligand B (93.718) has a much higher BBB penetration percentile than Ligand A (56.65). While ADRB2 is a cardiovascular target, some CNS effects can be relevant, and higher BBB penetration could be a slight advantage. However, it's not a primary concern for this target.
**9. Caco-2 Permeability:** Ligand A (-4.733) has better Caco-2 permeability than Ligand B (-4.319).
**10. Aqueous Solubility:** Ligand A (-3.208) has better aqueous solubility than Ligand B (-5.039).
**11. hERG Inhibition:** Ligand A (0.296) has a lower hERG inhibition liability than Ligand B (0.677), which is a significant advantage for cardiovascular drugs.
**12. Microsomal Clearance:** Ligand A (36.832) has lower microsomal clearance than Ligand B (55.945), indicating better metabolic stability.
**13. In vitro Half-Life:** Ligand A (-13.918) has a longer in vitro half-life than Ligand B (0.826), which is desirable.
**14. P-gp Efflux:** Ligand A (0.013) has much lower P-gp efflux liability than Ligand B (0.449). Lower P-gp efflux improves oral bioavailability.
**15. Binding Affinity:** Ligand B (-7.3) has a significantly stronger binding affinity than Ligand A (-6.0). This is a substantial advantage, potentially outweighing some ADME drawbacks.
**Overall Assessment:**
Ligand B has a superior binding affinity, which is a critical factor for GPCRs. However, Ligand A demonstrates a more balanced profile with better TPSA, logP, solubility, hERG inhibition, metabolic stability, P-gp efflux, and half-life. The difference in binding affinity (-1.3 kcal/mol) is significant, but the combined advantages of Ligand A in ADME properties, particularly the lower hERG risk and better metabolic stability, make it the more promising candidate for cardiovascular drug development.
Output:
1
2025-04-17 22:00:44,354 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (347.419 Da and 351.535 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (80.56) is higher than Ligand B (52.65). For a cardiovascular GPCR, TPSA is moderately important, and lower is generally better for permeability. Ligand B has a clear advantage.
**3. logP:** Ligand A (0.704) is slightly lower than the optimal range of 1-3, potentially impacting permeability. Ligand B (2.506) is well within the optimal range. Ligand B is favored.
**4. H-Bond Donors:** Both have acceptable HBD counts (0 for A, 1 for B), well below the threshold of 5.
**5. H-Bond Acceptors:** Ligand A (6) and Ligand B (3) are both acceptable, below the threshold of 10.
**6. QED:** Both ligands have good QED values (0.708 and 0.828), indicating good drug-like properties. No significant difference.
**7. DILI Risk:** Ligand A (56.572) has a higher DILI risk than Ligand B (9.151). This is a significant advantage for Ligand B.
**8. BBB Penetration:** Ligand B (82.513) shows better BBB penetration than Ligand A (72.005). While ADRB2 is primarily a cardiovascular target, some CNS off-target effects are possible, and better BBB penetration is generally preferred.
**9. Caco-2 Permeability:** Both show negative values, which is unusual. Assuming these are logP values, Ligand B (-4.575) is worse than Ligand A (-1.827), indicating lower permeability.
**10. Aqueous Solubility:** Both have negative values, which is unusual. Assuming these are logS values, Ligand A (-1.827) is better than Ligand B (-2.483), indicating higher solubility.
**11. hERG Inhibition:** Ligand A (0.047) has a slightly lower hERG inhibition risk than Ligand B (0.358), which is favorable.
**12. Microsomal Clearance:** Ligand A (31.42) has lower microsomal clearance than Ligand B (54.569), suggesting better metabolic stability. This is a positive for Ligand A.
**13. In vitro Half-Life:** Ligand B (-9.032) has a much longer in vitro half-life than Ligand A (-1.53). This is a significant advantage for Ligand B.
**14. P-gp Efflux:** Both have very low P-gp efflux liability (0.047 and 0.031), which is good. No significant difference.
**15. Binding Affinity:** Ligand A (-7.5) has slightly better binding affinity than Ligand B (-7.9). However, the difference is relatively small (0.4 kcal/mol).
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand B emerges as the more promising candidate. It has a better logP, lower TPSA, significantly lower DILI risk, and a longer half-life. While Ligand A has slightly better affinity and lower hERG, the advantages of Ligand B in ADME properties and safety are more compelling for overall drug development potential. The Caco-2 and solubility values are suspect and would require further investigation.
Output:
0
2025-04-17 22:00:44,355 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (342.439 Da and 346.387 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (78.43) is significantly better than Ligand B (91.72). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (2.358) is within the optimal 1-3 range. Ligand B (-0.806) is below 1, which could hinder membrane permeability. This is a significant negative for Ligand B.
4. **HBD:** Ligand A (3) and Ligand B (1) are both acceptable, under the threshold of 5.
5. **HBA:** Ligand A (3) and Ligand B (5) are both acceptable, under the threshold of 10.
6. **QED:** Both ligands have good QED scores (0.603 and 0.775), indicating good drug-like properties.
7. **DILI:** Ligand B (41.644) has a lower DILI risk than Ligand A (19.969), which is a positive for Ligand B. However, both are below the concerning threshold of 60.
8. **BBB:** Both have low BBB penetration, which is fine for a cardiovascular target.
9. **Caco-2:** Ligand A (-5.135) is better than Ligand B (-4.97), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-2.689) is better than Ligand B (-1.584), which is important for bioavailability.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.307 and 0.104).
12. **Cl_mic:** Ligand B (0) has significantly better metabolic stability than Ligand A (43.417). This is a major advantage for Ligand B.
13. **t1/2:** Ligand B (7.898) has a longer half-life than Ligand A (19.728). This is a positive for Ligand B.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.198 and 0.011).
15. **Binding Affinity:** Ligand A (-7.7 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.5 kcal/mol). This is a substantial advantage for Ligand A. The difference of 1.2 kcal/mol is large enough to potentially offset some ADME concerns.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A excels in affinity, and has a better logP and TPSA. Ligand B has better metabolic stability and DILI. However, the large difference in binding affinity is the most important factor.
**Conclusion:**
Despite Ligand B's advantages in metabolic stability and DILI, the significantly stronger binding affinity of Ligand A (-7.7 vs -6.5 kcal/mol) makes it the more promising drug candidate. The better logP and TPSA of Ligand A also contribute to its overall favorability.
Output:
1
2025-04-17 22:00:44,355 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands (339.395 and 353.507 Da) are within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (75.44) is slightly higher than Ligand B (61.88). Both are below the 140 threshold for oral absorption, but B is closer to the preferred <90 for GPCRs.
3. **logP:** Both ligands have good logP values (1.999 and 1.785), falling within the optimal 1-3 range. Very similar.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Both have 4 HBA, which is good.
6. **QED:** Ligand A (0.846) has a significantly better QED score than Ligand B (0.642), indicating a more drug-like profile.
7. **DILI:** Ligand B (10.275) has a much lower DILI risk than Ligand A (44.048). This is a significant advantage for Ligand B.
8. **BBB:** Ligand B (70.143) has a better BBB penetration percentile than Ligand A (45.832). Given this is a GPCR, and potential for CNS side effects or targeting, this is a substantial benefit for B.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the values are similar (-5.079 vs -4.775).
10. **Solubility:** Ligand B (-0.977) has slightly better aqueous solubility than Ligand A (-2.534).
11. **hERG:** Ligand A (0.082) has a slightly lower hERG inhibition liability than Ligand B (0.482), which is preferable.
12. **Cl_mic:** Ligand B (26.358) has significantly lower microsomal clearance than Ligand A (42.371), suggesting better metabolic stability.
13. **t1/2:** Ligand B (5.297 hours) has a significantly longer in vitro half-life than Ligand A (1.743 hours). This is a major advantage for B.
14. **Pgp:** Ligand B (0.114) has lower P-gp efflux liability than Ligand A (0.057). Lower is better, so A is slightly better here.
15. **Affinity:** Ligand A (-7.4 kcal/mol) has a slightly better binding affinity than Ligand B (-5.7 kcal/mol). This is a 1.7 kcal/mol difference, which is significant.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, Pgp, TPSA, BBB, and affinity. Ligand B excels in BBB, Pgp, and metabolic stability (Cl_mic, t1/2), and has acceptable logP and TPSA. While Ligand A has better affinity, the improvements in ADME properties of Ligand B, particularly the lower DILI risk, better BBB penetration, and longer half-life, outweigh the slightly better binding.
**Conclusion:**
Ligand B presents a more balanced profile with better ADME properties and a lower toxicity risk, making it the more promising drug candidate despite the slightly weaker binding affinity.
Output:
0
2025-04-17 22:00:44,355 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [345.403, 101.16 , 0.154, 3. , 6. , 0.729, 43.66 , 31.834, -5.697, -1.579, 0.145, -25.255, 29.14 , 0.006, -6.4 ]
**Ligand B:** [355.435, 88.18 , -0.58 , 1. , 6. , 0.615, 40.636, 48.391, -4.839, -0.602, 0.078, 3.681, -28.636, 0.019, -6.4 ]
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). A (345.4) is slightly preferred.
2. **TPSA:** Ligand B (88.18) is better than Ligand A (101.16), being closer to the <90 threshold for good permeability.
3. **logP:** Ligand B (-0.58) is lower than Ligand A (0.154). Both are a bit low, but Ligand A is closer to the optimal 1-3 range.
4. **HBD:** Ligand B (1) is better than Ligand A (3). Lower is preferable for permeability.
5. **HBA:** Both ligands have 6 HBA, which is acceptable.
6. **QED:** Ligand A (0.729) has a slightly better QED score than Ligand B (0.615), indicating better drug-likeness.
7. **DILI:** Both are good, with Ligand A (43.66) being marginally better than Ligand B (40.636).
8. **BBB:** Ligand B (48.391) is significantly better than Ligand A (31.834). For a GPCR, some BBB penetration can be beneficial, even if it's not a CNS target, as it can influence distribution.
9. **Caco-2:** Ligand B (-4.839) is better than Ligand A (-5.697), indicating better intestinal absorption.
10. **Solubility:** Ligand B (-0.602) is better than Ligand A (-1.579).
11. **hERG:** Both are very low (0.145 and 0.078), indicating minimal hERG inhibition risk.
12. **Cl_mic:** Ligand A (-25.255) has a much lower (better) microsomal clearance than Ligand B (3.681), suggesting greater metabolic stability.
13. **t1/2:** Ligand B (-28.636) has a longer half-life than Ligand A (29.14).
14. **Pgp:** Both are very low (0.006 and 0.019), indicating minimal P-gp efflux.
15. **Affinity:** Both have the same affinity (-6.4 kcal/mol).
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in TPSA, Caco-2, solubility and BBB penetration. Ligand A has a slightly better logP and significantly better metabolic stability (Cl_mic). The affinity is identical.
**Overall Assessment:**
While Ligand B has better permeability characteristics (TPSA, Caco-2, solubility, BBB), the significantly better metabolic stability of Ligand A (lower Cl_mic) is a major advantage. For a cardiovascular target, metabolic stability is crucial for maintaining therapeutic concentrations. The slightly better QED score of Ligand A also contributes to its favorability. The logP of Ligand A is also slightly better.
Therefore, I prefer Ligand A.
1
2025-04-17 22:00:44,356 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (370.377 and 351.43 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (82.77) is slightly higher than Ligand B (73.89). Both are below the 140 threshold for oral absorption, but closer to the 90 threshold. Ligand B is preferable.
3. **logP:** Both ligands have good logP values (1.895 and 1.366), falling within the optimal 1-3 range. Ligand B is slightly better.
4. **HBD:** Ligand A has 2 HBD, while Ligand B has 0. Both are acceptable, but lower is generally preferred for permeability. Ligand B is preferable.
5. **HBA:** Ligand A has 5 HBA, and Ligand B has 8. Ligand A is preferable.
6. **QED:** Both ligands have reasonable QED scores (0.842 and 0.75), indicating good drug-like properties. Ligand A is slightly better.
7. **DILI:** Ligand A (65.568) has a higher DILI risk than Ligand B (47.421). Ligand B is preferable.
8. **BBB:** Ligand B (89.531) has a significantly higher BBB penetration score than Ligand A (55.138). This is a key advantage for a GPCR target, even if not directly CNS-focused, as it suggests better distribution. Ligand B is preferable.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. Ligand B (-4.85) is slightly better than Ligand A (-5.31).
10. **Solubility:** Both ligands have negative solubility values, indicating poor solubility. No clear preference.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.077 and 0.344), which is excellent. No significant difference.
12. **Cl_mic:** Ligand A (-5.544) has a much lower (better) microsomal clearance than Ligand B (18.183). This suggests better metabolic stability for Ligand A. Ligand A is preferable.
13. **t1/2:** Ligand A (-33.894) has a much longer in vitro half-life than Ligand B (8.797). This is a significant advantage for dosing convenience. Ligand A is preferable.
14. **Pgp:** Ligand A (0.049) has a lower P-gp efflux liability than Ligand B (0.188). This is preferable. Ligand A is preferable.
15. **Binding Affinity:** Ligand A (-6.9 kcal/mol) has a slightly stronger binding affinity than Ligand B (-6.3 kcal/mol). This is a 0.6 kcal/mol difference, which is significant. Ligand A is preferable.
**Overall Assessment:**
While Ligand B excels in BBB penetration and has a lower DILI risk, Ligand A demonstrates superior metabolic stability (Cl_mic and t1/2), P-gp efflux, binding affinity, and a slightly better QED. The difference in binding affinity (0.6 kcal/mol) is substantial enough to outweigh the advantages of Ligand B, especially considering the overall profile. For a GPCR target like ADRB2, a balance between potency, metabolic stability, and permeability is crucial. Ligand A strikes a better balance.
Output:
1
2025-04-17 22:00:44,356 - INFO - Batch 300 complete. Total preferences: 4800
2025-04-17 22:00:44,356 - INFO - Processing batch 301/512...
2025-04-17 22:01:33,256 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (344.46 & 353.47 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (49.85) is significantly better than Ligand B (84.99). ADRB2 is a cardiovascular target, so CNS penetration isn't critical, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (1.832) is optimal, while Ligand B (-0.297) is slightly low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (0) is preferred over Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (3) is better than Ligand B (4). Lower HBA is generally preferred.
6. **QED:** Both ligands have good QED scores (0.565 and 0.711), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (18.15) has a lower DILI risk than Ligand B (14.97), which is a significant advantage.
8. **BBB:** Both are around 60-63%, not particularly high, which is fine for a cardiovascular target.
9. **Caco-2:** Ligand A (-4.445) is slightly better than Ligand B (-5.232), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-2.246) is better than Ligand B (-0.887).
11. **hERG:** Both ligands have very low hERG risk (0.193 and 0.106), which is excellent.
12. **Cl_mic:** Ligand B (-28.237) has significantly lower microsomal clearance than Ligand A (34.559), indicating better metabolic stability. This is a major advantage.
13. **t1/2:** Ligand B (-5.032) has a longer in vitro half-life than Ligand A (-7.799), which is also a significant advantage.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.155 and 0.001).
15. **Affinity:** Both ligands have excellent binding affinity (-5.8 and -5.4 kcal/mol). Ligand A is slightly better, but the difference is not substantial.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are important. Ligand A has a better logP and TPSA. However, Ligand B has a significantly better metabolic stability (Cl_mic) and half-life, which are crucial for *in vivo* efficacy. The affinity difference is small.
**Overall Assessment:**
While Ligand A has some advantages in terms of TPSA, logP, solubility, and slightly better affinity, Ligand B's superior metabolic stability and half-life are more critical for a successful drug candidate. The lower DILI risk of Ligand A is also a positive, but the metabolic advantages of Ligand B outweigh this.
**Output:**
0
2025-04-17 22:01:33,257 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [362.434, 89.07, 1.858, 2, 5, 0.81, 72.586, 77.821, -5.118, -3.843, 0.514, 11.542, -0.718, 0.21, -6.9]**
**Ligand B: [361.467, 70.67, 3.24, 2, 4, 0.882, 56.921, 91.702, -4.89, -3.578, 0.716, 51.013, 11.191, 0.297, -4.4]**
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). A is 362.434, B is 361.467. No significant difference.
2. **TPSA:** Ligand A (89.07) is slightly higher than Ligand B (70.67). Both are below the 140 threshold for oral absorption, but B is better positioned for potential CNS penetration if desired.
3. **logP:** Ligand A (1.858) is within the optimal range (1-3). Ligand B (3.24) is at the higher end of the optimal range, potentially increasing off-target interactions or solubility issues.
4. **H-Bond Donors:** Both have 2 HBD, which is acceptable.
5. **H-Bond Acceptors:** Ligand A has 5, Ligand B has 4. Both are within the acceptable limit of 10.
6. **QED:** Both have good QED scores (A: 0.81, B: 0.882), indicating drug-like properties. B is slightly better.
7. **DILI:** Ligand A (72.586) has a higher DILI risk than Ligand B (56.921). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (77.821) and Ligand B (91.702) both have good BBB penetration. Ligand B is significantly better.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the values are close (-5.118 vs -4.89).
10. **Solubility:** Both have negative solubility values, which is also unusual. Ligand A (-3.843) is slightly worse than Ligand B (-3.578).
11. **hERG:** Ligand A (0.514) has a lower hERG risk than Ligand B (0.716). This is a positive for Ligand A.
12. **Cl_mic:** Ligand A (11.542) has a lower microsomal clearance than Ligand B (51.013), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (-0.718) has a slightly worse in vitro half-life than Ligand B (11.191).
14. **Pgp:** Ligand A (0.21) has lower P-gp efflux than Ligand B (0.297). This is a slight advantage for Ligand A.
15. **Binding Affinity:** Ligand A (-6.9 kcal/mol) has a significantly stronger binding affinity than Ligand B (-4.4 kcal/mol). This is a substantial advantage for Ligand A, potentially outweighing some of its ADME drawbacks.
**Overall Assessment:**
For an ADRB2 GPCR target, affinity is paramount. Ligand A's significantly stronger binding affinity (-6.9 vs -4.4 kcal/mol) is a major advantage. While Ligand B has better DILI and BBB, the difference in affinity is substantial. The lower metabolic clearance of Ligand A is also a positive. The unusual solubility and Caco-2 values for both compounds are concerning and would require further investigation, but the potency difference is likely to be the deciding factor.
Output:
1
2025-04-17 22:01:33,257 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands (349.377 and 348.447 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (42.68) is significantly better than Ligand B (78.68). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold. Ligand B is approaching the upper limit.
3. **logP:** Ligand A (4.511) is higher than Ligand B (0.912). While both are within the acceptable range, Ligand A is pushing the upper limit and could potentially have solubility issues. Ligand B is quite low, which could hinder membrane permeability.
4. **HBD:** Ligand A (0) is preferable to Ligand B (1). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (3) is better than Ligand B (5). Similar reasoning as HBD - lower is generally preferred.
6. **QED:** Both ligands have very similar and good QED scores (0.815 and 0.827).
7. **DILI:** Ligand A (56.572) is significantly better than Ligand B (11.128). A lower DILI percentile is *highly* desirable. This is a major advantage for Ligand A.
8. **BBB:** Ligand A (86.429) is better than Ligand B (71.772). While not a primary concern for a cardiovascular target, higher BBB is generally favorable.
9. **Caco-2:** Ligand A (-4.337) is better than Ligand B (-4.887). Higher Caco-2 permeability is better.
10. **Solubility:** Ligand A (-4.384) is better than Ligand B (-0.756). Better solubility is crucial for bioavailability.
11. **hERG:** Ligand A (0.8) is better than Ligand B (0.056). Lower hERG inhibition is critical for avoiding cardiotoxicity, especially important for a cardiovascular target.
12. **Cl_mic:** Ligand A (65.884) is worse than Ligand B (4.158). Lower clearance is preferred for metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand A (50.728) is better than Ligand B (4.925). Longer half-life is generally desirable.
14. **Pgp:** Ligand A (0.7) is better than Ligand B (0.006). Lower P-gp efflux is preferred.
15. **Binding Affinity:** Ligand A (-7.8) is *significantly* better than Ligand B (-5.9). A 1.9 kcal/mol difference is substantial and can often outweigh minor ADME drawbacks.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, and affinity. Ligand A is better in TPSA, Pgp, and *much* better in affinity. Ligand B has a better logP and Cl_mic, but the affinity difference is too large to ignore. The DILI and hERG profiles of Ligand A are also substantially better, which is crucial for a cardiovascular drug.
**Conclusion:**
Despite Ligand B's better metabolic stability (Cl_mic), Ligand A's superior binding affinity, significantly better DILI and hERG profiles, and favorable TPSA, solubility, and Pgp properties make it the more promising drug candidate.
Output:
1
2025-04-17 22:01:33,257 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (332.411) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (54.46) is significantly better than Ligand A (80.63). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA is still beneficial for absorption.
3. **logP:** Ligand B (4.319) is higher than Ligand A (3.219). While both are above the optimal 1-3 range, Ligand B is pushing the upper limit and could present solubility challenges.
4. **HBD/HBA:** Ligand A has 2 HBD and 5 HBA, while Ligand B has 1 HBD and 3 HBA. Both are within acceptable limits.
5. **QED:** Both ligands have good QED scores (A: 0.77, B: 0.809), indicating good drug-like properties.
6. **DILI:** Ligand B (23.342) is *much* better than Ligand A (77.627) regarding DILI risk. This is a major advantage for Ligand B.
7. **BBB:** Ligand B (85.033) has higher BBB penetration than Ligand A (64.87). While not critical for a cardiovascular target, it's a neutral benefit.
8. **Caco-2:** Ligand A (-5.167) and Ligand B (-4.182) are both negative, which is unusual. However, a less negative value is better, making Ligand B slightly preferable.
9. **Solubility:** Ligand A (-4.84) has slightly better solubility than Ligand B (-3.674).
10. **hERG:** Both ligands have low hERG inhibition liability (A: 0.94, B: 0.459), which is excellent. Ligand B is even better.
11. **Cl_mic:** Ligand A (41.369) has lower microsomal clearance than Ligand B (88.028), indicating better metabolic stability. This is a significant advantage for Ligand A.
12. **t1/2:** Ligand A (34.752) has a longer in vitro half-life than Ligand B (-2.209), which is a strong positive for Ligand A.
13. **Pgp:** Ligand A (0.513) has lower P-gp efflux than Ligand B (0.066). Lower P-gp efflux is generally desirable for improved bioavailability.
14. **Binding Affinity:** Both ligands have comparable binding affinities (-6.3 kcal/mol and -6.4 kcal/mol). The difference is negligible.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in TPSA and Pgp, while Ligand A has a slight edge in logP and Pgp. However, the *significant* advantage of Ligand B in DILI risk and its better hERG profile outweigh the slightly better metabolic stability and half-life of Ligand A. The lower TPSA of Ligand B is also beneficial for absorption.
**Conclusion:**
Considering the balance of properties, particularly the critical DILI risk and the GPCR-relevant parameters, Ligand B is the more promising drug candidate.
Output:
0
2025-04-17 22:01:33,257 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (339.395 and 348.355 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (82.27) is significantly better than Ligand B (104.22). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (1.812) is optimal, while Ligand B (0.434) is a bit low. A logP below 1 can hinder membrane permeability.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable.
5. **HBA:** Ligand A (3) and Ligand B (5) are both acceptable, though Ligand B is higher.
6. **QED:** Ligand A (0.895) is better than Ligand B (0.748), indicating a more drug-like profile.
7. **DILI:** Ligand B (61.419) is better than Ligand A (78.48), indicating a lower risk of drug-induced liver injury. This is a significant advantage for Ligand B.
8. **BBB:** Ligand B (66.925) is better than Ligand A (36.177). While not a primary concern for a cardiovascular target, higher BBB is generally favorable.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.931 and -5.058), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand A (-3.748) is better than Ligand B (-1.436), indicating better aqueous solubility.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.14 and 0.052), which is excellent.
12. **Cl_mic:** Ligand A (0.091) is *much* better than Ligand B (24.946). Lower clearance indicates greater metabolic stability, a crucial factor for drug duration.
13. **t1/2:** Ligand B (-22.143) is better than Ligand A (-15.075), indicating a longer in vitro half-life.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.088 and 0.015), which is excellent.
15. **Binding Affinity:** Ligand B (-6.5) is slightly better than Ligand A (-6.3), but the difference is small.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are important. Ligand A has a better logP and TPSA. Ligand B has a slightly better affinity. However, metabolic stability (Cl_mic) is also crucial, and Ligand A is significantly better in this regard. DILI risk is also a concern, where Ligand B has an advantage.
**Overall Assessment:**
While Ligand B has a slightly better affinity and DILI profile, Ligand A's superior logP, TPSA, and *much* better metabolic stability (Cl_mic) are more critical for overall drug development success. The poor Caco-2 values are concerning for both, but metabolic stability is often easier to address through structural modifications than permeability issues.
**Output:**
1
2025-04-17 22:01:33,257 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.43 & 352.35 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (62.99) is significantly better than Ligand B (116.08). ADRB2 is a cardiovascular target, not CNS, but lower TPSA generally aids absorption.
3. **logP:** Both ligands (1.698 & 2.054) are within the optimal 1-3 range. Ligand B is slightly higher, potentially offering better membrane permeability.
4. **HBD:** Ligand A (0) is preferable to Ligand B (4). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is preferable to Ligand B (8). Fewer HBAs generally improve permeability.
6. **QED:** Ligand A (0.836) is much better than Ligand B (0.624), indicating a more drug-like profile.
7. **DILI:** Ligand A (14.62) is *much* better than Ligand B (67.47). This is a major advantage for Ligand A.
8. **BBB:** Not a primary concern for a cardiovascular target, but both are moderate.
9. **Caco-2:** Ligand A (-4.464) is better than Ligand B (-5.357), suggesting better intestinal absorption.
10. **Solubility:** Ligand A (-1.62) is better than Ligand B (-3.605). Better solubility is generally desirable.
11. **hERG:** Both ligands (0.173 & 0.259) have low hERG risk, which is good.
12. **Cl_mic:** Ligand B (13.35) has significantly lower microsomal clearance than Ligand A (30.39), indicating better metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand A (28.48) has a much longer in vitro half-life than Ligand B (-14.13). This is a major advantage for Ligand A.
14. **Pgp:** Both ligands (0.018 & 0.011) have very low P-gp efflux liability, which is good.
15. **Binding Affinity:** Ligand A (-6.8) has a significantly stronger binding affinity than Ligand B (-3.1). This is a substantial advantage for Ligand A.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A excels in affinity and TPSA. Ligand B has a slightly better logP and clearance. However, the *magnitude* of the affinity difference for Ligand A, combined with its superior QED, DILI, solubility, and half-life, outweighs the clearance advantage of Ligand B. The lower DILI risk for Ligand A is also a critical factor.
**Conclusion:**
Ligand A presents a much more favorable overall profile, particularly with its significantly better binding affinity, DILI risk, and drug-like properties. While Ligand B has better metabolic stability, the other advantages of Ligand A are more critical for a viable drug candidate.
Output:
1
2025-04-17 22:01:33,257 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.45 & 364.52 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (67.67) is better than Ligand B (76.44). Both are below 140, but lower TPSA generally favors absorption.
3. **logP:** Both ligands have similar logP values (1.217 & 1.25), falling within the optimal 1-3 range.
4. **HBD:** Ligand A (0) is preferable to Ligand B (1). Fewer HBDs generally improve permeability.
5. **HBA:** Both ligands have the same number of HBA (5), which is within the acceptable limit of 10.
6. **QED:** Ligand A (0.806) has a better QED score than Ligand B (0.718), indicating a more drug-like profile.
7. **DILI:** Ligand A (39.20) has a higher DILI risk than Ligand B (16.71), but both are below the concerning threshold of 60. Ligand B is significantly better here.
8. **BBB:** Ligand A (68.86) has a better BBB percentile than Ligand B (57.15). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be beneficial or at least needs to be considered.
9. **Caco-2:** Ligand A (-4.204) has a better Caco-2 permeability than Ligand B (-5.227). Higher values indicate better intestinal absorption.
10. **Solubility:** Ligand A (-1.473) has better aqueous solubility than Ligand B (-2.247).
11. **hERG:** Ligand A (0.267) has a lower hERG inhibition liability than Ligand B (0.486), which is crucial for avoiding cardiotoxicity, especially for a cardiovascular target.
12. **Cl_mic:** Ligand A (21.85) has lower microsomal clearance than Ligand B (34.98), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-1.616) has a slightly better in vitro half-life than Ligand B (-1.448).
14. **Pgp:** Ligand A (0.061) has lower P-gp efflux liability than Ligand B (0.011). Lower Pgp efflux is generally preferred.
15. **Binding Affinity:** Ligand A (-7.6) has a significantly better binding affinity than Ligand B (-6.3). This is a 1.3 kcal/mol difference, which is substantial and can outweigh minor ADME drawbacks.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are particularly important. Both ligands are good on logP. Ligand A is better on TPSA and Pgp. The affinity difference is significant, favoring Ligand A. While BBB isn't paramount for ADRB2, Ligand A is also better in this regard. Ligand B has a clear advantage in DILI risk.
**Overall Assessment:**
Ligand A demonstrates a superior balance of properties, particularly its significantly stronger binding affinity and favorable ADME profile (TPSA, Pgp, Cl_mic, hERG, solubility). The lower DILI risk of Ligand B is a consideration, but the substantial affinity advantage of Ligand A, coupled with its better overall drug-like properties, makes it the more promising candidate.
Output:
1
2025-04-17 22:01:33,258 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (355.316 and 363.454 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (77.25) is better than Ligand B (38.77). Lower TPSA generally favors better cell permeability, which is important for GPCRs.
3. **logP:** Ligand A (2.885) is within the optimal 1-3 range. Ligand B (4.129) is slightly higher, potentially leading to solubility issues or off-target interactions, but still acceptable.
4. **HBD:** Ligand A (1) is preferable to Ligand B (0). While both are low, a single HBD can sometimes aid solubility without significantly impacting permeability.
5. **HBA:** Ligand A (5) is better than Ligand B (4). Both are within the acceptable range.
6. **QED:** Ligand A (0.913) is significantly better than Ligand B (0.629), indicating a more drug-like profile.
7. **DILI:** Ligand A (74.796) has a higher DILI risk than Ligand B (51.144). This is a significant drawback for Ligand A.
8. **BBB:** Ligand A (93.253) has a much higher BBB penetration potential than Ligand B (81.698). While ADRB2 isn't strictly a CNS target, some peripheral ADRB2 receptors can be affected by CNS penetration.
9. **Caco-2:** Both ligands have very poor Caco-2 permeability (-4.291 and -4.279). This is a significant concern for oral bioavailability.
10. **Solubility:** Both ligands have very poor aqueous solubility (-4.413 and -4.164). This is a major issue.
11. **hERG:** Ligand A (0.346) has a lower hERG inhibition liability than Ligand B (0.888), which is a positive.
12. **Cl_mic:** Ligand A (19.919) has a much lower microsomal clearance than Ligand B (121.637), indicating better metabolic stability.
13. **t1/2:** Ligand A (-8.789) has a shorter in vitro half-life than Ligand B (18.463). This is a negative for Ligand A.
14. **Pgp:** Ligand A (0.116) has a lower P-gp efflux liability than Ligand B (0.631), which is favorable.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.2 and -5.9 kcal/mol). The difference is not substantial enough to be decisive.
**Overall Assessment & GPCR Considerations:**
Considering ADRB2 is a GPCR, logP, TPSA, and affinity are key. Ligand A has a better logP and TPSA. However, the significantly higher DILI risk for Ligand A is a major concern. While Ligand A has better metabolic stability (lower Cl_mic) and P-gp efflux, the DILI risk outweighs these benefits. Both ligands have poor solubility and Caco-2 permeability, which would require significant formulation work.
**Conclusion:**
Despite the slightly better ADME profile in some areas, the higher DILI risk associated with Ligand A makes it a less desirable candidate. Ligand B, while having some drawbacks, presents a lower toxicity profile.
Output:
0
2025-04-17 22:01:33,258 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (364.389 Da and 350.467 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (104.73) is better than Ligand B (114.93). Both are below the 140 A^2 threshold for oral absorption, but A is closer to the preferred <90 A^2 for GPCRs.
**3. logP:** Ligand B (1.23) is slightly better than Ligand A (0.457). Both are within the 1-3 range, but A is a bit low, potentially impacting permeability.
**4. H-Bond Donors:** Both ligands have 3 HBD, which is acceptable.
**5. H-Bond Acceptors:** Ligand B (6) has one more HBA than Ligand A (5). Both are within the acceptable limit of 10.
**6. QED:** Both ligands have good QED scores (0.569 and 0.684), indicating good drug-like properties. Ligand B is slightly better.
**7. DILI:** Both ligands have relatively low DILI risk (36.448 and 38.581), both well below the concerning threshold of 60. No significant difference.
**8. BBB:** Ligand A (67.197) has a significantly higher BBB penetration percentile than Ligand B (58.938). While ADRB2 is a cardiovascular target, some CNS exposure can be relevant for off-target effects, and higher BBB is generally preferable.
**9. Caco-2 Permeability:** Ligand A (-4.938) is better than Ligand B (-5.465). Higher values indicate better intestinal absorption.
**10. Aqueous Solubility:** Both ligands have very poor aqueous solubility (-2.17 and -2.16). This is a significant concern for both and would require formulation strategies.
**11. hERG Inhibition:** Ligand A (0.279) has a lower hERG inhibition liability than Ligand B (0.112), which is a positive.
**12. Microsomal Clearance:** Ligand B (18.963) has significantly lower microsomal clearance than Ligand A (44.89), indicating better metabolic stability. This is a major advantage for B.
**13. In vitro Half-Life:** Ligand B (-8.516) has a much longer in vitro half-life than Ligand A (-53.462). This is a substantial advantage for B.
**14. P-gp Efflux:** Ligand A (0.025) has lower P-gp efflux liability than Ligand B (0.016). Lower efflux is generally preferred.
**15. Binding Affinity:** Ligand B (-7.5 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.5 kcal/mol). This 1.5+ kcal/mol difference is substantial and can outweigh some of the ADME drawbacks.
**Overall Assessment:**
Ligand B is the stronger candidate. While Ligand A has better BBB penetration and slightly better Caco-2 permeability, Ligand B's significantly improved metabolic stability (lower Cl_mic, longer t1/2) and substantially higher binding affinity are critical advantages for a GPCR target. The slightly lower logP and solubility are manageable with formulation work. The affinity difference is large enough to overcome the other minor drawbacks.
Output:
0
2025-04-17 22:01:33,258 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A: [341.459, 76.18, 2.223, 2, 5, 0.894, 52.734, 61.535, -5.109, -2.224, 0.806, -24.288, 22.506, 0.099, -6.2]**
**Ligand B: [378.485, 66.48, 2.402, 1, 3, 0.66, 18.922, 87.553, -4.901, -3.082, 0.645, 18.094, -40.73, 0.081, -6.5]**
Here's a breakdown, comparing each parameter and considering GPCR priorities (logP, Pgp, TPSA, Affinity):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (341.459) is slightly preferred.
2. **TPSA:** Both are good, below the 140 A^2 threshold for oral absorption. Ligand B (66.48) is better than Ligand A (76.18).
3. **logP:** Both are in the optimal range (1-3). Ligand B (2.402) is slightly higher, which could be a minor advantage for membrane permeability.
4. **HBD:** Ligand A (2) is slightly better than Ligand B (1).
5. **HBA:** Ligand A (5) is slightly higher than Ligand B (3).
6. **QED:** Ligand A (0.894) is significantly better than Ligand B (0.66), indicating a more drug-like profile.
7. **DILI:** Ligand B (18.922) is *much* better than Ligand A (52.734). This is a significant advantage for Ligand B.
8. **BBB:** Ligand B (87.553) is substantially better than Ligand A (61.535). While not a primary concern for a cardiovascular target, higher BBB penetration can sometimes translate to better tissue distribution.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand B (-4.901) is slightly better than Ligand A (-5.109), but both are concerning.
10. **Solubility:** Both are negative, indicating poor solubility. Ligand B (-3.082) is slightly better than Ligand A (-2.224).
11. **hERG:** Both are low risk (0.806 and 0.645).
12. **Cl_mic:** Ligand A (-24.288) has a much lower (better) microsomal clearance than Ligand B (18.094), suggesting better metabolic stability.
13. **t1/2:** Ligand A (22.506) has a better in vitro half-life than Ligand B (-40.73).
14. **Pgp:** Both are very low (0.099 and 0.081), indicating minimal P-glycoprotein efflux.
15. **Affinity:** Ligand B (-6.5) has a slightly better binding affinity than Ligand A (-6.2).
**Overall Assessment:**
Ligand B has a significant advantage in DILI risk and BBB penetration, and a slightly better affinity and Caco-2 permeability. However, Ligand A has a significantly better QED score, metabolic stability (lower Cl_mic), and a better in vitro half-life. The poor Caco-2 and solubility for both are concerning, but can be addressed with formulation strategies.
Considering the GPCR-specific priorities, the better affinity of Ligand B, combined with the significantly lower DILI risk, outweigh the advantages of Ligand A's metabolic stability and QED. The lower DILI risk is critical for cardiovascular drugs.
Therefore, I prefer Ligand B.
0
2025-04-17 22:01:33,258 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.46 and 387.57 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (75.44) is better than Ligand B (48). While both are acceptable, Ligand B is closer to the ideal for GPCRs.
3. **logP:** Both ligands (2.76 and 2.88) are within the optimal 1-3 range. No significant difference.
4. **HBD:** Ligand A (1) is preferable to Ligand B (0). A single HBD can aid solubility without drastically impacting permeability.
5. **HBA:** Ligand A (4) is better than Ligand B (6). Lower HBA is generally preferred for better membrane permeability.
6. **QED:** Ligand A (0.889) is significantly better than Ligand B (0.61), indicating a more drug-like profile.
7. **DILI:** Ligand A (33.89%) is slightly better than Ligand B (40.75%), both are acceptable.
8. **BBB:** Ligand A (82.51%) is better than Ligand B (79.68%). While ADRB2 isn't exclusively a CNS target, some CNS penetration can be beneficial, and higher BBB is favorable.
9. **Caco-2:** Both are negative values, indicating a similar permeability profile.
10. **Solubility:** Both ligands have very poor solubility (-3.012 and -3.036). This is a major concern for both.
11. **hERG:** Ligand A (0.357) is much better than Ligand B (0.749), indicating a lower risk of cardiotoxicity. This is *critical* for a cardiovascular target.
12. **Cl_mic:** Ligand A (63.37) is better than Ligand B (105.97), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-22.19) is better than Ligand B (24.66), suggesting a longer half-life.
14. **Pgp:** Ligand A (0.043) is much better than Ligand B (0.608), indicating lower P-gp efflux and potentially better bioavailability.
15. **Binding Affinity:** Ligand B (-5.1) is slightly better than Ligand A (-4.2). However, the difference is less than 1.5 kcal/mol, so it doesn't outweigh the other significant advantages of Ligand A.
**Overall Assessment:**
Ligand A demonstrates a significantly better overall profile. It has superior QED, lower DILI risk, better BBB penetration, substantially lower hERG inhibition, better metabolic stability (lower Cl_mic), longer half-life, and lower P-gp efflux. While both have poor solubility, the other advantages of Ligand A are compelling, especially the lower hERG risk for a cardiovascular target. The slightly better affinity of Ligand B is not enough to overcome these drawbacks.
Output:
1
2025-04-17 22:01:33,258 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.419 and 348.487 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (106.6) is higher than Ligand B (67.43). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferable for absorption. Ligand B is better.
3. **logP:** Ligand A (0.014) is very low, potentially hindering membrane permeability. Ligand B (2.701) is within the optimal 1-3 range. Ligand B is significantly better.
4. **HBD:** Both ligands have 2 HBD, which is acceptable. No difference.
5. **HBA:** Ligand A has 5 HBA, Ligand B has 3. Both are within the acceptable limit of 10, but Ligand B is slightly better.
6. **QED:** Ligand A (0.778) has a higher QED score than Ligand B (0.63), indicating better overall drug-likeness. Ligand A is better.
7. **DILI:** Ligand A (39.356) has a slightly higher DILI risk than Ligand B (28.189), but both are below the concerning threshold of 60. Ligand B is better.
8. **BBB:** Ligand A (23.071) has a very low BBB penetration, which is not a major concern for a cardiovascular target. Ligand B (62.737) is moderate. No strong preference here.
9. **Caco-2:** Ligand A (-5.148) and Ligand B (-4.876) have similar, and quite poor, Caco-2 permeability values. This is a concern for both.
10. **Solubility:** Ligand A (-1.165) has better solubility than Ligand B (-3.163). Ligand A is better.
11. **hERG:** Ligand A (0.117) has a lower hERG risk than Ligand B (0.264). Ligand A is better.
12. **Cl_mic:** Ligand A (-17.629) has a much lower (better) microsomal clearance than Ligand B (45.017), suggesting better metabolic stability. Ligand A is significantly better.
13. **t1/2:** Ligand A (-5.82) has a negative in vitro half-life, which is unusual and concerning. Ligand B (10.263) has a reasonable half-life. Ligand B is significantly better.
14. **Pgp:** Ligand A (0.038) has a lower P-gp efflux liability than Ligand B (0.285). Ligand A is better.
15. **Affinity:** Ligand B (-6.3 kcal/mol) has a significantly stronger binding affinity than Ligand A (-4.0 kcal/mol). This is a substantial advantage, potentially outweighing some ADME drawbacks.
**Overall Assessment:**
Ligand B has a much better logP, a significantly stronger binding affinity, and a reasonable in vitro half-life. While Ligand A has a better QED, solubility, and lower Pgp/hERG/Cl_mic, the poor logP and substantially weaker binding affinity are major drawbacks. The difference in affinity is over 2 kcal/mol, which is a large margin. The cardiovascular target doesn't require high BBB penetration, mitigating Ligand B's moderate score. The Caco-2 permeability is poor for both, but can be addressed with formulation strategies.
Therefore, I favor Ligand B.
Output:
0
2025-04-17 22:01:33,259 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (353.379 and 345.487 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (62.3) is significantly better than Ligand A (122.63). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (3.191) is optimal, while Ligand A (-1.046) is too low, potentially hindering membrane permeability. This is a significant strike against Ligand A.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable.
5. **HBA:** Ligand A (7) and Ligand B (3) are both acceptable.
6. **QED:** Ligand B (0.787) is better than Ligand A (0.584), indicating a more drug-like profile.
7. **DILI:** Ligand B (30.593) has a much lower DILI risk than Ligand A (48.623). This is a crucial advantage for Ligand B.
8. **BBB:** Both ligands have good BBB penetration (Ligand A: 69.794, Ligand B: 70.919), but this isn't a high priority for a cardiovascular target.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-5.17) is slightly worse than Ligand B (-4.698).
10. **Solubility:** Ligand A (-0.349) is better than Ligand B (-2.871), but both are poor.
11. **hERG:** Ligand A (0.026) is preferable to Ligand B (0.513) with respect to hERG inhibition.
12. **Cl_mic:** Ligand A (32.718) has a lower microsomal clearance than Ligand B (56.327), indicating better metabolic stability.
13. **t1/2:** Ligand B (-3.54) has a slightly better in vitro half-life than Ligand A (-24.805), but both are negative values which is concerning.
14. **Pgp:** Ligand A (0.005) has a much lower P-gp efflux liability than Ligand B (0.235).
15. **Binding Affinity:** Ligand B (-6.0) has a better binding affinity than Ligand A (-4.6). This is a significant advantage.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP and affinity, and has a significantly lower Pgp efflux liability. While Ligand A has better metabolic stability and lower hERG risk, the poor logP and higher DILI risk are major drawbacks. The binding affinity difference of 1.4 kcal/mol is substantial enough to outweigh the other advantages of Ligand A.
**Conclusion:**
Ligand B is the more promising candidate due to its superior logP, binding affinity, lower DILI risk, and better QED score. The slightly worse metabolic stability and solubility are less critical concerns compared to the issues with Ligand A.
Output:
0
2025-04-17 22:01:33,259 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.463 and 348.491 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (77.37) is slightly higher than Ligand B (67.65). Both are below the 140 threshold for good oral absorption, but Ligand B is preferable due to being closer to the 90 threshold for GPCRs.
3. **logP:** Both ligands (1.562 and 1.717) are within the optimal 1-3 range. No significant difference.
4. **HBD:** Ligand A (1) is slightly better than Ligand B (0). Lower is generally preferred, but both are acceptable.
5. **HBA:** Ligand A (5) is slightly higher than Ligand B (4). Both are below the 10 threshold.
6. **QED:** Both ligands have similar QED values (0.784 and 0.733), indicating good drug-likeness.
7. **DILI:** Ligand A (20.047) has a significantly lower DILI risk than Ligand B (13.532). This is a major advantage for Ligand A.
8. **BBB:** Both ligands have good BBB penetration (68.282 and 65.529), but Ligand A is slightly better.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.986 and -4.825) which is unusual. This suggests very poor permeability.
10. **Solubility:** Both ligands have negative solubility values (-1.768 and -0.792) which is also unusual. This suggests very poor solubility.
11. **hERG:** Ligand A (0.104) has a lower hERG risk than Ligand B (0.644). This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand A (-2.172) has a lower (better) microsomal clearance than Ligand B (5.462). This indicates better metabolic stability for Ligand A.
13. **t1/2:** Ligand B (10.457) has a significantly longer in vitro half-life than Ligand A (2.52). This is a major advantage for Ligand B.
14. **Pgp:** Ligand A (0.008) has a much lower Pgp efflux liability than Ligand B (0.038). This is a significant advantage for Ligand A.
15. **Binding Affinity:** Ligand A (-6.3) has a slightly better binding affinity than Ligand B (-5.0). This is a good advantage for Ligand A.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Both ligands are good on logP. Ligand B has a slightly better TPSA. Ligand A has a significantly better Pgp efflux liability and binding affinity.
**Overall Assessment:**
Ligand A demonstrates a superior safety profile (lower DILI, lower hERG) and better metabolic stability (lower Cl_mic). It also has a slightly better binding affinity and Pgp efflux. While Ligand B has a longer half-life, the other advantages of Ligand A are more critical for initial drug candidate selection, especially considering the poor permeability and solubility of both.
Output:
1
2025-04-17 22:01:33,259 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (397.276) is slightly higher than Ligand B (358.467), but both are acceptable.
2. **TPSA:** Ligand A (47.09) is well below the 140 threshold and good for oral absorption. Ligand B (83.98) is higher, but still potentially acceptable, though less optimal.
3. **logP:** Ligand A (4.782) is a bit high, potentially leading to solubility issues or off-target effects. Ligand B (2.216) is within the optimal range (1-3). This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (0) is excellent, minimizing potential for off-target interactions. Ligand B (2) is acceptable.
5. **HBA:** Both ligands have 5 HBA, which is within the acceptable range.
6. **QED:** Both ligands have good QED scores (A: 0.488, B: 0.758). Ligand B is better here.
7. **DILI:** Ligand A (67.623) has a higher DILI risk than Ligand B (45.522). This favors Ligand B.
8. **BBB:** Ligand A (81.698) has better BBB penetration than Ligand B (62.117). While ADRB2 isn't exclusively a CNS target, some peripheral effects are mediated by CNS pathways, and better BBB penetration could be advantageous.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and concerning. This suggests poor permeability. However, the values are close enough that this isn't a deciding factor.
10. **Solubility:** Ligand A (-3.68) has worse solubility than Ligand B (-2.475). This is a concern given Ligand A's higher logP.
11. **hERG:** Ligand A (0.923) has a slightly higher hERG risk than Ligand B (0.053). This favors Ligand B significantly.
12. **Cl_mic:** Ligand A (46.364) has better metabolic stability (lower clearance) than Ligand B (27.274). This is a positive for Ligand A.
13. **t1/2:** Ligand A (70.822) has a longer half-life than Ligand B (24.252). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.848) has better Pgp efflux profile than Ligand B (0.099). This is a positive for Ligand A.
15. **Affinity:** Ligand B (-7.2 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.0 kcal/mol). This is a major advantage for Ligand B, exceeding the 1.5 kcal/mol threshold.
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand B excels in logP and affinity. Ligand A has better BBB penetration and Pgp efflux, but the affinity difference is substantial. The higher DILI and hERG risk for Ligand A are also concerning.
**Overall Assessment:**
While Ligand A has some favorable ADME properties (BBB, t1/2, Pgp, Cl_mic), Ligand B's superior binding affinity and better safety profile (lower DILI, hERG) outweigh these advantages. The slightly higher TPSA of Ligand B is manageable, and its logP is optimal. The significantly stronger binding affinity of Ligand B is likely to translate to greater efficacy.
Output:
0
2025-04-17 22:01:33,259 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (378.519 and 385.251 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (66.48) is better than Ligand B (71.58). Both are under the 140 threshold for oral absorption, but lower is generally preferred.
3. **logP:** Both ligands have good logP values (3.241 and 2.697), falling within the optimal 1-3 range. Ligand A is slightly higher, which could be a minor advantage for membrane permeability.
4. **HBD:** Ligand A (1) is better than Ligand B (0). While both are low, having one HBD can sometimes improve solubility.
5. **HBA:** Ligand A (4) is better than Ligand B (5). Lower HBA is generally preferred for better permeability.
6. **QED:** Ligand A (0.888) is significantly better than Ligand B (0.797), indicating a more drug-like profile.
7. **DILI:** Ligand A (60.062) is better than Ligand B (71.19), indicating a lower risk of drug-induced liver injury. Both are acceptable, but lower is always preferred.
8. **BBB:** Ligand A (89.531) is significantly better than Ligand B (59.519). While ADRB2 isn't exclusively a CNS target, some CNS penetration can be beneficial, and avoiding high CNS exposure is generally desirable.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.032 and -4.84), which is unusual and suggests poor permeability. This is a major concern for both.
10. **Solubility:** Ligand A (-3.826) is better than Ligand B (-3.165), indicating better aqueous solubility.
11. **hERG:** Ligand A (0.635) is better than Ligand B (0.209), indicating a lower risk of hERG inhibition and cardiotoxicity.
12. **Cl_mic:** Ligand A (26.241) is better than Ligand B (42.123), indicating better metabolic stability.
13. **t1/2:** Ligand A (32.716) is better than Ligand B (35.776), indicating a longer in vitro half-life.
14. **Pgp:** Ligand A (0.513) is better than Ligand B (0.274), indicating lower P-gp efflux.
15. **Binding Affinity:** Ligand A (-8.2 kcal/mol) is significantly better than Ligand B (-6.7 kcal/mol). This is a substantial difference in potency.
**GPCR-specific considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A excels in all these areas. The significantly better affinity of Ligand A (-8.2 vs -6.7) is a major advantage that can outweigh some of the permeability concerns (Caco-2).
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical parameters, including DILI, BBB, solubility, metabolic stability, Pgp efflux, and, most importantly, binding affinity. While both have concerning Caco-2 values, the superior binding affinity and overall drug-like properties of Ligand A make it the more promising candidate.
Output:
1
2025-04-17 22:01:33,260 - INFO - Batch 301 complete. Total preferences: 4816
2025-04-17 22:01:33,260 - INFO - Processing batch 302/512...
2025-04-17 22:02:24,356 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [344.415, 96.11, 1.614, 3, 4, 0.711, 56.805, 51.415, -5.367, -2.687, 0.459, 1.758, 14.813, 0.04, -6.9]
**Ligand B:** [358.385, 59.08, 1.061, 0, 4, 0.708, 45.328, 89.492, -4.36, -2.007, 0.349, 25.14, -15.462, 0.084, -6.9]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal 200-500 Da range. A (344.415) is slightly preferred.
2. **TPSA:** A (96.11) is higher than B (59.08). B is significantly better here, falling well below the 140 threshold for oral absorption and being more favorable for potential CNS penetration.
3. **logP:** Both are good (1.061 and 1.614), falling within the 1-3 range. A is slightly higher, which could be a minor negative.
4. **HBD:** A (3) is higher than B (0). B is preferred, as fewer HBDs generally improve permeability.
5. **HBA:** Both are equal (4), which is acceptable.
6. **QED:** Both are similar (0.711 and 0.708), indicating good drug-likeness.
7. **DILI:** B (45.328) is significantly better than A (56.805), indicating a lower risk of liver injury. This is a substantial advantage.
8. **BBB:** B (89.492) is much better than A (51.415). While ADRB2 isn't necessarily a CNS target, higher BBB penetration is generally favorable for overall drug distribution and reducing off-target effects.
9. **Caco-2:** A (-5.367) is worse than B (-4.36). Both are negative, indicating poor permeability. B is slightly better.
10. **Solubility:** A (-2.687) is worse than B (-2.007). Both are poor, but B is slightly better.
11. **hERG:** Both are very low (0.459 and 0.349), indicating minimal hERG inhibition risk.
12. **Cl_mic:** A (1.758) is much lower than B (25.14), indicating better metabolic stability. This is a significant advantage for A.
13. **t1/2:** A (14.813) is better than B (-15.462). A has a positive half-life, while B has a negative half-life, indicating faster clearance.
14. **Pgp:** A (0.04) is much better than B (0.084), indicating lower P-gp efflux.
15. **Affinity:** Both are equal (-6.9 kcal/mol).
**Overall Assessment:**
Ligand B has significant advantages in TPSA, DILI, and BBB penetration, which are crucial for GPCR targets. It also has slightly better Caco-2 and solubility. Ligand A excels in metabolic stability (Cl_mic) and half-life, and Pgp efflux. However, the improvements in ADME properties for B outweigh the metabolic stability advantage of A, especially considering the relatively good metabolic stability of A. The lower DILI risk for B is also a major factor.
Therefore, I prefer Ligand B.
0
2025-04-17 22:02:24,356 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.491 and 340.427 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (76.02) is slightly higher than Ligand B (66.4). Both are below the 140 threshold for oral absorption, but closer to the 90 threshold for CNS targets. Ligand B is preferable.
3. **logP:** Ligand A (2.361) and Ligand B (1.709) are both within the optimal 1-3 range. Ligand A is slightly more lipophilic, which could be beneficial for membrane permeability, but not dramatically.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (0). Lower HBD is generally preferred for permeability, giving a slight edge to Ligand B.
5. **HBA:** Both ligands have 4 HBA, which is well within the acceptable limit of 10.
6. **QED:** Ligand B (0.837) has a higher QED score than Ligand A (0.757), indicating a more drug-like profile. This is a positive for Ligand B.
7. **DILI:** Ligand B (33.501) has a significantly lower DILI risk than Ligand A (22.218). This is a major advantage for Ligand B.
8. **BBB:** Ligand B (82.202) has a higher BBB penetration percentile than Ligand A (69.213). While ADRB2 isn't strictly a CNS target, some distribution into the CNS is possible, and higher BBB is generally favorable.
9. **Caco-2:** Both ligands have similar, negative Caco-2 values (-4.86 and -4.789). This suggests poor permeability.
10. **Solubility:** Ligand B (-1.858) has slightly better aqueous solubility than Ligand A (-2.619).
11. **hERG:** Both ligands have very low hERG inhibition liability (0.127 and 0.243), which is excellent.
12. **Cl_mic:** Ligand B (18.871) has significantly lower microsomal clearance than Ligand A (44.848), suggesting better metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand B (20.183) has a much longer in vitro half-life than Ligand A (-2.368). This is a major advantage for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.08 and 0.076).
15. **Binding Affinity:** Ligand A (-7.8) has a slightly better binding affinity than Ligand B (-7.0). However, the difference is only 0.8 kcal/mol, which is less significant than the ADME advantages of Ligand B.
**GPCR-specific priorities:** Considering ADRB2 is a GPCR, logP, Pgp, TPSA, and affinity are important. Ligand B has a better balance of these properties, and crucially, superior ADME characteristics (DILI, BBB, Cl_mic, t1/2). While Ligand A has slightly better affinity, the ADME profile of Ligand B is much more favorable for drug development.
**Conclusion:**
Ligand B is the more promising drug candidate due to its superior ADME properties, particularly its lower DILI risk, better metabolic stability (lower Cl_mic and longer t1/2), and higher BBB penetration. The slightly weaker binding affinity is outweighed by these advantages.
Output:
0
2025-04-17 22:02:24,356 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 drug candidates. ADRB2 is a GPCR, so we'll prioritize logP, Pgp, TPSA, and affinity, alongside general drug-like properties.
**Ligand A:** [359.348, 84.23, 2.505, 2, 4, 0.733, 56.65, 84.684, -4.624, -3.362, 0.208, 27.766, -23.188, 0.081, -4.6]
**Ligand B:** [348.487, 58.64, 2.655, 1, 3, 0.686, 14.541, 77.278, -4.785, -2.16, 0.274, 39.676, -4.165, 0.159, -7.7]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). A (359.348) is slightly higher than B (348.487), but both are acceptable.
2. **TPSA:** A (84.23) is slightly higher than B (58.64). Both are below 140, but B is significantly better, suggesting potentially better absorption.
3. **logP:** Both are in the optimal range (1-3). A (2.505) and B (2.655) are comparable.
4. **HBD:** A (2) and B (1) are both good, well within the limit of 5. B is slightly better.
5. **HBA:** A (4) and B (3) are both good, well within the limit of 10. B is slightly better.
6. **QED:** A (0.733) is better than B (0.686), indicating a more drug-like profile.
7. **DILI:** A (56.65) is considerably higher than B (14.541), indicating a higher risk of liver injury. This is a significant drawback for A.
8. **BBB:** A (84.684) is better than B (77.278), but both are reasonably good for a non-CNS target like ADRB2.
9. **Caco-2:** A (-4.624) and B (-4.785) are similar and indicate good permeability.
10. **Solubility:** A (-3.362) is worse than B (-2.16), indicating lower aqueous solubility, which could be a formulation challenge.
11. **hERG:** Both are very low (0.208 and 0.274), indicating low cardiotoxicity risk.
12. **Cl_mic:** A (27.766) is lower than B (39.676), suggesting better metabolic stability.
13. **t1/2:** A (-23.188) is better than B (-4.165), indicating a longer half-life.
14. **Pgp:** Both are very low (0.081 and 0.159), indicating low P-gp efflux.
15. **Affinity:** B (-7.7) is significantly better than A (-4.6), a difference of 3.1 kcal/mol. This is a substantial advantage.
**Overall Assessment:**
Ligand B is the stronger candidate. While Ligand A has a slightly better QED and metabolic stability, the significantly lower DILI risk and substantially improved binding affinity of Ligand B outweigh these advantages. The lower TPSA and HBD/HBA counts of Ligand B also contribute to a more favorable ADME profile. The 3.1 kcal/mol difference in binding affinity is a large advantage for B, and is a key factor for GPCR targets.
Output:
0
2025-04-17 22:02:24,357 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (a cardiovascular GPCR) drug candidates.
**Ligand A:** [342.403, 95.08, 0.678, 1, 5, 0.833, 50.795, 27.724, -5.353, -1.322, 0.03, -15.906, -0.768, 0.013, -6.8]
**Ligand B:** [350.482, 52.23, 2.918, 1, 3, 0.784, 6.747, 86.933, -4.951, -1.956, 0.906, 30.006, -3.701, 0.115, -6.2]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (342.4) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (95.08) is higher than Ligand B (52.23). For a cardiovascular GPCR, TPSA isn't *as* critical as for CNS targets, but lower is still preferred for better absorption. Ligand B is significantly better here.
3. **logP:** Ligand B (2.918) is optimal, while Ligand A (0.678) is quite low. This is a major drawback for Ligand A, potentially hindering membrane permeability and bioavailability.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 5 HBA, while Ligand B has 3. Both are acceptable, but Ligand B is slightly better.
6. **QED:** Ligand A (0.833) has a slightly better QED score than Ligand B (0.784), indicating a more drug-like profile.
7. **DILI:** Ligand B (6.747) has a much lower DILI risk than Ligand A (50.795). This is a significant advantage for Ligand B.
8. **BBB:** Ligand B (86.933) has a much higher BBB penetration percentile than Ligand A (27.724). While not a primary concern for a cardiovascular target, higher BBB is rarely detrimental.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Both have negative solubility values, which is also unusual.
11. **hERG:** Ligand A (0.03) has a slightly lower hERG risk than Ligand B (0.906), but both are very low risk.
12. **Cl_mic:** Ligand A (-15.906) has a *much* lower microsomal clearance than Ligand B (30.006), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand B (-3.701) has a longer in vitro half-life than Ligand A (-0.768), which is favorable.
14. **Pgp:** Ligand A (0.013) has a much lower P-gp efflux liability than Ligand B (0.115), suggesting better oral bioavailability and potentially better tissue distribution.
15. **Affinity:** Ligand A (-6.8) has a slightly better binding affinity than Ligand B (-6.2), but the difference is not huge (0.6 kcal/mol).
**GPCR-Specific Priorities:**
For ADRB2 (a cardiovascular GPCR), we prioritize logP, TPSA, Pgp, and affinity. Ligand B excels in TPSA and Pgp, and has an optimal logP. Ligand A has a poor logP, but a slightly better affinity and significantly better metabolic stability (Cl_mic).
**Overall Assessment:**
While Ligand A has better metabolic stability and slightly better affinity, the significantly lower logP is a major concern. Poor logP can lead to poor absorption and bioavailability, negating the benefits of good affinity. Ligand B, with its optimal logP, lower TPSA, lower DILI risk, and better BBB penetration, is more likely to be a viable drug candidate despite the slightly lower affinity and higher Pgp efflux. The difference in affinity is not large enough to outweigh the ADME advantages of Ligand B.
Output:
0
2025-04-17 22:02:24,357 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (365.455 Da and 342.443 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (82.45) is slightly higher than Ligand B (69.04). Both are below the 140 A^2 threshold for good oral absorption, but Ligand B is preferable due to the lower TPSA.
**3. logP:** Ligand A (1.406) is within the optimal 1-3 range. Ligand B (3.906) is at the upper end of the optimal range, potentially increasing off-target effects and decreasing solubility. Ligand A is preferable here.
**4. H-Bond Donors:** Both have 1 HBD, which is good.
**5. H-Bond Acceptors:** Ligand A has 7, and Ligand B has 6. Both are acceptable, below the 10 threshold.
**6. QED:** Both ligands have good QED scores (0.802 and 0.835), indicating good drug-like properties.
**7. DILI:** Ligand A (69.601) has a slightly higher DILI risk than Ligand B (57.697), but both are below the concerning 60 threshold. Ligand B is preferable.
**8. BBB:** Ligand A (69.097) and Ligand B (77.821) both have reasonable BBB penetration, but Ligand B is better, which is important for GPCRs.
**9. Caco-2 Permeability:** Ligand A (-5.109) has worse Caco-2 permeability than Ligand B (-4.39). Ligand B is preferable.
**10. Aqueous Solubility:** Ligand A (-2.149) has better aqueous solubility than Ligand B (-5.945). Ligand A is preferable.
**11. hERG Inhibition:** Ligand A (0.371) has a lower hERG inhibition risk than Ligand B (0.552). Ligand A is preferable.
**12. Microsomal Clearance:** Ligand A (35.262) has significantly lower microsomal clearance than Ligand B (125.068), indicating better metabolic stability. Ligand A is preferable.
**13. In vitro Half-Life:** Ligand A (32.226) has a longer in vitro half-life than Ligand B (6.084). Ligand A is preferable.
**14. P-gp Efflux:** Ligand A (0.105) has lower P-gp efflux than Ligand B (0.275). Ligand A is preferable.
**15. Binding Affinity:** Both ligands have very good binding affinities (-5.4 kcal/mol and -4.8 kcal/mol). Ligand A has a 0.6 kcal/mol advantage, which is significant.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand A emerges as the more promising candidate. While Ligand B has better BBB penetration and lower DILI, Ligand A excels in crucial areas like metabolic stability (Cl_mic, t1/2), solubility, hERG risk, P-gp efflux, and, importantly, binding affinity. The 0.6 kcal/mol difference in binding affinity is a substantial advantage that outweighs the minor drawbacks of Ligand A.
Output:
1
2025-04-17 22:02:24,357 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (367.471 Da) is slightly lower, which can be advantageous for permeability.
**2. TPSA:** Ligand A (97.39) is better than Ligand B (21.7). While both are below 140, the lower TPSA of Ligand B is exceptionally good and suggests better membrane permeability.
**3. logP:** Ligand A (2.044) is within the optimal range (1-3). Ligand B (4.842) is a bit high, potentially leading to solubility issues and off-target interactions.
**4. H-Bond Donors:** Ligand A (2) is reasonable. Ligand B (0) is also acceptable, potentially improving membrane permeability.
**5. H-Bond Acceptors:** Ligand A (5) is good. Ligand B (4) is also good.
**6. QED:** Ligand A (0.849) is excellent, indicating a highly drug-like profile. Ligand B (0.584) is still acceptable, but less favorable.
**7. DILI Risk:** Ligand A (56.921) is moderate, but acceptable. Ligand B (11.439) is very low, a significant advantage.
**8. BBB Penetration:** Ligand A (71.035) is decent, but Ligand B (85.459) is excellent. While ADRB2 is primarily a cardiovascular target, some CNS effects are possible with beta-blockers, and better BBB penetration could be relevant.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. This is a significant concern for both.
**10. Aqueous Solubility:** Both ligands have negative solubility values, indicating very poor aqueous solubility. This is a major drawback for both.
**11. hERG Inhibition:** Ligand A (0.216) shows very low hERG inhibition risk, which is excellent. Ligand B (0.966) is higher, indicating a moderate risk of cardiotoxicity.
**12. Microsomal Clearance:** Ligand A (54.041) is moderate, suggesting moderate metabolic stability. Ligand B (84.483) is high, indicating rapid metabolism and potentially low bioavailability.
**13. In vitro Half-Life:** Ligand A (-39.207) is very negative, indicating extremely short half-life. Ligand B (62.667) is good.
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability.
**15. Binding Affinity:** Ligand B (-7.2 kcal/mol) has a significantly stronger binding affinity than Ligand A (-8.0 kcal/mol). This is a substantial advantage.
**GPCR-Specific Considerations:** For GPCRs, logP, TPSA, Pgp, and affinity are crucial. Ligand B excels in affinity and TPSA, and has good BBB penetration. Ligand A has better hERG inhibition, but its solubility and half-life are very poor.
**Overall Assessment:**
Despite the poor Caco-2 and solubility for both, Ligand B's superior binding affinity, lower DILI risk, and better half-life outweigh the slightly higher logP. The strong binding affinity is a critical factor, and the other issues might be addressable through formulation or further chemical modifications. Ligand A's extremely short half-life is a major concern.
Output:
0
2025-04-17 22:02:24,357 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (382.555 and 364.471 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (83.98 and 84.3) are below the 140 A^2 threshold for good oral absorption, and acceptable for a non-CNS GPCR target like ADRB2. Very similar.
3. **logP:** Ligand A (1.871) is better than Ligand B (0.641). ADRB2 is a cardiovascular target, so we don't *need* high BBB penetration, but a reasonable logP is still important for membrane permeability and distribution. Ligand B's logP is a bit low, potentially hindering absorption.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1), but both are within the acceptable limit of <=5.
5. **HBA:** Both ligands (6) are within the acceptable limit of <=10.
6. **QED:** Both ligands have good QED scores (0.785 and 0.829), indicating good overall drug-likeness.
7. **DILI:** Ligand A (49.864) has a slightly better DILI score than Ligand B (59.984), indicating lower potential for liver injury. This is a significant advantage.
8. **BBB:** Both are relatively low, which is fine for a cardiovascular target. Ligand A (60.954) is slightly higher than Ligand B (51.881), but this isn't a major factor.
9. **Caco-2:** Both are negative, indicating poor permeability. This is a significant drawback for both.
10. **Solubility:** Both have very poor solubility (-2.945 and -2.256). This is a major concern for both compounds and will require formulation strategies.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.088 and 0.146). This is excellent.
12. **Cl_mic:** Ligand B (24.216) has a lower microsomal clearance than Ligand A (30.334), suggesting better metabolic stability. This is a positive for Ligand B.
13. **t1/2:** Both ligands have similar in vitro half-lives (4.955 and 4.944 hours).
14. **Pgp:** Both ligands have low P-gp efflux liability (0.079 and 0.046).
15. **Binding Affinity:** Ligand B (-6.7 kcal/mol) has a slightly better binding affinity than Ligand A (-6.5 kcal/mol). This is a 0.2 kcal/mol difference, which is not huge, but still noticeable.
**Overall Assessment:**
The biggest issues for both compounds are their poor Caco-2 permeability and solubility. However, considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity) and general drug-like properties, Ligand B appears slightly more favorable. Its better affinity, lower Cl_mic, and slightly better DILI profile outweigh the slightly lower logP. While both have poor solubility and permeability, these can potentially be addressed through formulation.
Output:
0
2025-04-17 22:02:24,357 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands (354.495 and 354.447 Da) fall comfortably within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (81.75) is significantly better than Ligand B (106.94). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand A is well under the 140 threshold, while B is approaching it.
3. **logP:** Both ligands have similar logP values (0.596 and 0.52), which are slightly low but acceptable. A higher logP would be preferred, but they aren't drastically outside the optimal 1-3 range.
4. **HBD:** Ligand A (2) is better than Ligand B (3). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (4) is better than Ligand B (5). Similar to HBD, lower HBA is preferred.
6. **QED:** Both ligands have very similar QED scores (0.563 and 0.56), indicating good drug-likeness.
7. **DILI:** Ligand A (9.655) has a much lower DILI risk than Ligand B (14.928). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (55.176) has a higher BBB penetration percentile than Ligand B (41.256). While ADRB2 isn't exclusively a CNS target, some brain exposure can be relevant for side effect profiles, and higher BBB is generally favorable.
9. **Caco-2:** Both ligands have very poor Caco-2 permeability (-5.27 and -5.209). This is a major concern for both.
10. **Solubility:** Ligand A (-1.104) has slightly better solubility than Ligand B (-0.432), but both are quite poor.
11. **hERG:** Ligand A (0.248) has a much lower hERG inhibition liability than Ligand B (0.062). This is a critical advantage, as hERG inhibition can lead to cardiotoxicity.
12. **Cl_mic:** Ligand B (-7.539) has significantly lower microsomal clearance than Ligand A (2.585), indicating better metabolic stability. This is a substantial advantage for Ligand B.
13. **t1/2:** Ligand B (-20.448) has a much longer in vitro half-life than Ligand A (0.418). This is a major advantage for Ligand B.
14. **Pgp:** Ligand A (0.006) has lower P-gp efflux than Ligand B (0.017). Lower P-gp efflux is preferred.
15. **Binding Affinity:** Ligand B (-7.0) has a slightly better binding affinity than Ligand A (-5.5). This is a 1.5 kcal/mol difference, which is significant.
**Overall Assessment & GPCR Prioritization:**
For an ADRB2 GPCR, affinity, logP, TPSA, Pgp, and metabolic stability are key. Ligand B has a better affinity and significantly better metabolic stability (Cl_mic and t1/2). However, Ligand A excels in TPSA, DILI risk, and hERG liability, all of which are crucial for safety and drug-like properties. The poor Caco-2 permeability is a concern for both, but can be addressed through formulation strategies.
The difference in binding affinity is significant, and the improved metabolic stability of Ligand B is a major plus. While Ligand A has better safety profiles, the potency and PK advantages of Ligand B outweigh these concerns.
Output:
0
2025-04-17 22:02:24,358 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (338.323 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both ligands have a TPSA of around 110, which is acceptable for a non-CNS GPCR target like ADRB2, but not ideal.
3. **logP:** Both ligands have good logP values (A: 2.796, B: 2.173) falling within the 1-3 range.
4. **HBD:** Ligand A (2) has fewer HBD than Ligand B (3), which is slightly preferable for permeability.
5. **HBA:** Both ligands have the same number of HBA (5), which is acceptable.
6. **QED:** Both ligands have good QED scores (A: 0.563, B: 0.665), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (92.788) has a significantly higher DILI risk than Ligand B (57.542). This is a major concern for Ligand A.
8. **BBB:** This is less critical for ADRB2 (a cardiovascular target), but Ligand B (81.698) has a higher BBB penetration than Ligand A (59.325).
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability.
10. **Solubility:** Both ligands have negative solubility values, which is also unusual and suggests poor solubility.
11. **hERG:** Both ligands have low hERG inhibition liability (A: 0.477, B: 0.454).
12. **Cl_mic:** Ligand B (20.771) has significantly lower microsomal clearance than Ligand A (37.89), indicating better metabolic stability.
13. **t1/2:** Ligand B (3.612) has a slightly longer in vitro half-life than Ligand A (38.355).
14. **Pgp:** Ligand A (0.213) has lower P-gp efflux liability than Ligand B (0.076), which is beneficial.
15. **Binding Affinity:** Ligand B (-6.9 kcal/mol) has a significantly stronger binding affinity than Ligand A (-4.3 kcal/mol). This is a substantial advantage.
**Overall Assessment:**
Ligand B is the stronger candidate. While both ligands have some concerning ADME properties (negative Caco-2 and solubility), Ligand B's significantly better binding affinity, lower DILI risk, and improved metabolic stability outweigh the slightly better P-gp profile of Ligand A. The difference in binding affinity is particularly important for a GPCR target. The lower DILI risk is also a critical factor.
Output:
0
2025-04-17 22:02:24,358 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.435 and 345.403 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (84.22) is significantly better than Ligand B (112.91). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (1.363) is slightly better than Ligand A (0.725), falling more squarely within the optimal 1-3 range. Ligand A is a bit low, potentially hindering permeability.
4. **HBD:** Ligand A (0) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (6) is preferable to Ligand B (5). Lower HBA is generally better for permeability.
6. **QED:** Ligand A (0.75) is better than Ligand B (0.594), indicating a more drug-like profile.
7. **DILI:** Ligand A (38.969) is *much* better than Ligand B (60.915). This is a significant advantage for Ligand A, as lower DILI risk is crucial.
8. **BBB:** Ligand A (71.656) is better than Ligand B (39.55). While ADRB2 isn't a CNS target, some degree of BBB penetration can sometimes be beneficial for distribution.
9. **Caco-2:** Ligand A (-5.001) is better than Ligand B (-5.85). Higher Caco-2 permeability is desired.
10. **Solubility:** Ligand A (-1.575) is better than Ligand B (-2.576). Higher solubility is generally preferred.
11. **hERG:** Ligand A (0.075) is significantly better than Ligand B (0.208). Lower hERG inhibition is critical for avoiding cardiotoxicity, especially important for a cardiovascular target.
12. **Cl_mic:** Ligand A (26.787) is better than Ligand B (33.543). Lower clearance indicates better metabolic stability.
13. **t1/2:** Ligand A (-8.49) is better than Ligand B (4.062). A negative value suggests a longer half-life.
14. **Pgp:** Ligand A (0.087) is better than Ligand B (0.083). Lower P-gp efflux is desirable.
15. **Binding Affinity:** Ligand B (-7.4) is significantly better than Ligand A (-6.6). This is a 0.8 kcal/mol difference, which is a substantial advantage.
**Overall Assessment:**
While Ligand B has a better binding affinity, Ligand A overwhelmingly wins on ADMET properties. The lower DILI, hERG, and better solubility, permeability, and metabolic stability are extremely important for a cardiovascular drug candidate. The 0.8 kcal/mol difference in binding affinity can potentially be overcome with further optimization of Ligand A, but fixing the poor ADMET profile of Ligand B would be far more challenging. Given the GPCR-specific priorities (logP, Pgp, TPSA, affinity), Ligand A strikes a better balance, particularly regarding safety (DILI, hERG).
Output:
1
2025-04-17 22:02:24,358 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [344.371, 92.68, 1.648, 0, 6, 0.74, 45.405, 67.623, -4.842, -1.615, 0.157, 37.876, -24.454, 0.034, -6.2]
**Ligand B:** [360.567, 33.2, 4.862, 0, 3, 0.466, 12.136, 83.133, -4.891, -4.497, 0.764, 113.273, 12.484, 0.742, -7.1]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, Affinity, and BBB):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (344.371) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (92.68) is better than Ligand B (33.2). While both are reasonably low, lower TPSA generally correlates with better BBB penetration, which is important for GPCRs.
3. **logP:** Ligand A (1.648) is optimal, while Ligand B (4.862) is high. High logP can lead to poor solubility and off-target effects. This is a significant drawback for Ligand B.
4. **HBD/HBA:** Both have low HBD (0) and acceptable HBA counts (6 and 3 respectively).
5. **QED:** Ligand A (0.74) has a much better QED score than Ligand B (0.466), indicating a more drug-like profile.
6. **DILI:** Ligand A (45.405) has a slightly higher DILI risk than Ligand B (12.136), but both are within acceptable limits.
7. **BBB:** Ligand B (83.133) has a significantly higher BBB penetration percentile than Ligand A (67.623). This is a positive for Ligand B, but needs to be balanced against other factors.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests potential issues with permeability prediction.
9. **Solubility:** Ligand A (-1.615) has slightly better solubility than Ligand B (-4.497).
10. **hERG:** Ligand A (0.157) has a much lower hERG risk than Ligand B (0.764). This is a critical advantage for Ligand A, as hERG inhibition can lead to cardiotoxicity.
11. **Cl_mic:** Ligand A (37.876) has a lower microsomal clearance than Ligand B (113.273), indicating better metabolic stability.
12. **t1/2:** Ligand A (-24.454) has a longer in vitro half-life than Ligand B (12.484).
13. **Pgp:** Ligand A (0.034) has much lower P-gp efflux liability than Ligand B (0.742), which is beneficial for bioavailability and potential CNS exposure.
14. **Affinity:** Ligand B (-7.1) has a slightly better binding affinity than Ligand A (-6.2). While a 0.9 kcal/mol difference is noticeable, it's not a massive advantage, and can be offset by other factors.
**Overall Assessment:**
Ligand A demonstrates a much more balanced profile. While Ligand B has a slightly better binding affinity and BBB penetration, its high logP, lower QED, higher hERG risk, and higher Pgp efflux are significant concerns. Ligand A's superior drug-likeness, metabolic stability, lower toxicity risk, and better solubility make it the more promising candidate. The slightly weaker affinity can potentially be optimized in later stages of drug development.
Output:
1
2025-04-17 22:02:24,358 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (343.47 & 336.44 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (38.77) is better than Ligand B (41.57), both are below the 140 threshold for oral absorption, and acceptable for a cardiovascular target.
3. **logP:** Ligand A (4.146) is slightly higher than Ligand B (3.016). While both are within the 1-3 range, Ligand A is pushing the upper limit. This could potentially lead to solubility issues, but is not a dealbreaker.
4. **HBD:** Ligand A (0) is preferable to Ligand B (1). Fewer HBDs generally improve permeability.
5. **HBA:** Both ligands have 3 HBA, which is good.
6. **QED:** Ligand B (0.933) has a higher QED score than Ligand A (0.729), indicating a more drug-like profile overall.
7. **DILI:** Ligand B (32.03%) has a significantly lower DILI risk than Ligand A (37.81%). This is a substantial advantage.
8. **BBB:** Both ligands have high BBB penetration (Ligand A: 89.53%, Ligand B: 86.35%). This isn't a primary concern for a cardiovascular target, but it's not detrimental.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the values are similar (-4.423 vs -4.771).
10. **Solubility:** Both ligands have very poor aqueous solubility (-3.901 and -3.947). This is a significant concern for both.
11. **hERG:** Ligand A (0.674) has a lower hERG risk than Ligand B (0.946), which is preferable.
12. **Cl_mic:** Ligand B (22.103) has a much lower microsomal clearance than Ligand A (88.977), indicating better metabolic stability. This is a major advantage.
13. **t1/2:** Ligand B (23.97) has a significantly longer in vitro half-life than Ligand A (-19.044). This is a substantial benefit.
14. **Pgp:** Ligand A (0.62) has lower P-gp efflux than Ligand B (0.553), which is slightly better.
15. **Binding Affinity:** Ligand B (-8.7 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.9 kcal/mol). This is a critical advantage, potentially outweighing some of the ADME drawbacks.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, affinity, logP, and metabolic stability are key. Ligand B excels in affinity and metabolic stability (lower Cl_mic, longer t1/2). While Ligand A has a slightly better logP and Pgp profile, the substantial difference in binding affinity and the lower DILI risk of Ligand B are more important. The poor solubility is a concern for both, but can be addressed with formulation strategies.
**Conclusion:**
Despite the similar solubility and Caco-2 permeability issues, Ligand B's superior binding affinity, lower DILI risk, and improved metabolic stability make it the more promising drug candidate.
Output:
0
2025-04-17 22:02:24,359 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (364.511) is slightly higher than Ligand B (348.422), but both are acceptable.
2. **TPSA:** Ligand A (49.85) is significantly better than Ligand B (67.23). For a GPCR, lower TPSA is generally preferred for better permeability. Ligand B is approaching a level that might hinder absorption.
3. **logP:** Ligand A (3.037) is within the optimal range (1-3), while Ligand B (1.568) is at the lower end. While not a deal-breaker, a slightly higher logP is often beneficial for GPCR ligands.
4. **HBD:** Ligand A (0) is preferable to Ligand B (1). Fewer HBDs generally improve permeability.
5. **HBA:** Both ligands have 4 HBA, which is acceptable.
6. **QED:** Both ligands have good QED scores (A: 0.778, B: 0.822), indicating good drug-like properties.
7. **DILI:** Both ligands have similar, acceptable DILI risk (A: 52.074, B: 51.648).
8. **BBB:** Ligand B (82.435) has a better BBB penetration score than Ligand A (74.098). While ADRB2 isn't exclusively a CNS target, some CNS exposure could be beneficial or at least not detrimental.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Both ligands have negative solubility values, which is also unusual and suggests poor solubility. Again, the scale is not specified.
11. **hERG:** Both ligands have low hERG inhibition risk (A: 0.35, B: 0.41).
12. **Cl_mic:** Ligand B (22.258) has significantly lower microsomal clearance than Ligand A (85.432), indicating better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand B (-7.667) has a much longer in vitro half-life than Ligand A (1.714). This is a major advantage.
14. **Pgp:** Both ligands have low Pgp efflux liability (A: 0.209, B: 0.128).
15. **Binding Affinity:** Ligand A (-8.1) has a significantly stronger binding affinity than Ligand B (-6.3). This is a substantial advantage, exceeding the 1.5 kcal/mol threshold.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, and affinity. Ligand A excels in affinity, has a better logP and TPSA, and comparable Pgp. Ligand B has a better BBB score and metabolic stability. However, the affinity difference is substantial.
**Overall Assessment:**
The significantly stronger binding affinity of Ligand A (-8.1 vs -6.3) is the most critical factor. While Ligand B has better metabolic stability and BBB penetration, the difference in affinity is likely to outweigh these advantages, especially considering the acceptable ADME properties of Ligand A. The lower TPSA and logP of Ligand A are also favorable for a GPCR target.
Output:
1
2025-04-17 22:02:24,359 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (365.865 and 359.421 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (70.9 and 72.28) are below the 140 A^2 threshold for good oral absorption, but higher than the <90 A^2 for CNS targets. Since ADRB2 is a cardiovascular target, CNS penetration is not a primary concern.
3. **logP:** Both ligands (1.899 and 2.422) are within the optimal 1-3 range. Ligand B is slightly higher, potentially offering a small advantage in membrane permeability.
4. **HBD:** Ligand A has 2 HBD, and Ligand B has 1. Both are acceptable (<=5).
5. **HBA:** Ligand A has 5 HBA, and Ligand B has 6. Both are acceptable (<=10).
6. **QED:** Both ligands have good QED scores (0.735 and 0.874), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Both ligands have low DILI risk (40.054 and 39.473 percentile), which is excellent. No significant difference.
8. **BBB:** Both ligands have good BBB penetration (74.913 and 77.937 percentile), but this is less important for a cardiovascular target.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.049 and -4.473), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Both ligands have negative solubility values (-1.494 and -2.625), indicating very poor aqueous solubility. This is a major drawback for both.
11. **hERG:** Both ligands have low hERG inhibition risk (0.682 and 0.334 percentile), which is excellent. Ligand B is better here.
12. **Cl_mic:** Ligand A has a lower (better) microsomal clearance (-1.234 mL/min/kg) than Ligand B (33.818 mL/min/kg). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A has a longer in vitro half-life (51.577 hours) than Ligand B (-6.132 hours). This is a significant advantage for Ligand A.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.056 and 0.061 percentile), which is favorable.
15. **Binding Affinity:** Ligand A has a significantly better binding affinity (-8.7 kcal/mol) than Ligand B (-5.2 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME concerns.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand A has a better affinity. While both have acceptable logP and Pgp, the significant difference in affinity is the deciding factor. The poor Caco-2 and solubility are concerning for both, but can potentially be addressed with formulation strategies. The better metabolic stability and half-life of Ligand A are also beneficial.
**Conclusion:**
Despite the poor Caco-2 and solubility for both, Ligand A's significantly stronger binding affinity and improved metabolic stability make it the more promising candidate.
Output:
1
2025-04-17 22:02:24,359 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (349.362) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (98.74) is higher than Ligand B (32.34). For a cardiovascular GPCR like ADRB2, TPSA is less critical than for CNS targets, but lower is still preferred for better absorption. Ligand B is significantly better here.
3. **logP:** Ligand A (1.511) is within the optimal range, while Ligand B (4.626) is high. High logP can lead to poor solubility and off-target effects. Ligand A is preferred.
4. **HBD:** Ligand A (3) and Ligand B (1) are both acceptable.
5. **HBA:** Ligand A (4) and Ligand B (2) are both acceptable.
6. **QED:** Both ligands have similar, good QED values (0.702 and 0.72).
7. **DILI:** Ligand A (67.313) has a higher DILI risk than Ligand B (14.696). This is a significant concern, as liver toxicity is a major drug development hurdle. Ligand B is strongly preferred.
8. **BBB:** Ligand A (76.464) and Ligand B (92.943) both have good BBB penetration, but Ligand B is better. For a cardiovascular target, BBB penetration isn't *essential*, but it doesn't hurt.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.906 and -4.52), which is unusual and suggests poor permeability. However, these values are on a log scale, and the absolute difference isn't huge.
10. **Solubility:** Ligand A (-3.194) has slightly better solubility than Ligand B (-4.837), but both are poor.
11. **hERG:** Ligand A (0.215) has a lower hERG risk than Ligand B (0.917). This is a positive for Ligand A.
12. **Cl_mic:** Ligand B (77.06) has a significantly higher microsomal clearance than Ligand A (1.857), indicating faster metabolism and lower metabolic stability. Ligand A is strongly preferred.
13. **t1/2:** Ligand A (28.771) has a much longer in vitro half-life than Ligand B (4.824). This is a major advantage for Ligand A.
14. **Pgp:** Ligand A (0.022) has a much lower P-gp efflux liability than Ligand B (0.387), meaning better absorption and bioavailability. Ligand A is strongly preferred.
15. **Binding Affinity:** Ligand B (-5.5 kcal/mol) has a slightly better binding affinity than Ligand A (-6.4 kcal/mol). While affinity is important, the difference of 0.9 kcal/mol isn't large enough to outweigh the other significant advantages of Ligand A.
**Overall Assessment:**
Ligand A has a significantly better ADME profile, with lower DILI risk, better metabolic stability (lower Cl_mic, longer t1/2), lower P-gp efflux, and better hERG risk. While Ligand B has slightly better affinity and TPSA, the drawbacks related to metabolism, liver toxicity, and efflux are too significant to ignore. The slightly lower affinity of Ligand A can likely be optimized in subsequent iterations of drug design.
Output:
1
2025-04-17 22:02:24,359 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (344.46 and 348.43 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (78.09) is slightly higher than Ligand B (68.84). Both are below the 140 threshold for oral absorption, and acceptable for a cardiovascular target (not requiring significant CNS penetration). Ligand B is preferable.
3. **logP:** Both ligands have good logP values (2.839 and 2.468), falling within the optimal 1-3 range. Ligand B is slightly better.
4. **HBD:** Ligand A has 2 HBD, while Ligand B has 0. Both are within the acceptable limit of 5. Ligand B is slightly preferable.
5. **HBA:** Ligand A has 3 HBA, Ligand B has 6. Both are below the 10 limit, but Ligand A is preferable.
6. **QED:** Ligand B (0.804) has a better QED score than Ligand A (0.641), indicating a more drug-like profile. This is a significant advantage for Ligand B.
7. **DILI:** Both ligands have similar DILI risk (54.98 and 54.29 percentile), indicating low-moderate risk. No significant difference.
8. **BBB:** Ligand B (89.10) has a substantially higher BBB penetration percentile than Ligand A (58.86). While ADRB2 is a cardiovascular target, some CNS effects are possible with beta-blockers, so moderate CNS penetration isn't necessarily a negative. This favors Ligand B.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.361 and -4.756), which is unusual and suggests poor permeability. This is a concern for both, but the values are close.
10. **Solubility:** Both ligands have very poor aqueous solubility (-3.313 and -3.278). This is a significant drawback for both and would require formulation strategies. No clear preference.
11. **hERG:** Both ligands have low hERG inhibition liability (0.242 and 0.502), which is excellent. No significant difference.
12. **Cl_mic:** Ligand B (35.122) has a lower microsomal clearance than Ligand A (48.488), suggesting better metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand B (-10.025) has a longer in vitro half-life than Ligand A (8.935). This is a substantial advantage for Ligand B.
14. **Pgp:** Ligand A (0.177) has lower P-gp efflux liability than Ligand B (0.332), which is preferable.
15. **Binding Affinity:** Ligand B (-6.4) has a slightly better binding affinity than Ligand A (-6.2), although the difference is relatively small.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand B performs better on logP, TPSA, and Cl_mic/t1/2, while Ligand A has a slight advantage in Pgp. The affinity difference is minimal. The better QED score and improved metabolic stability of Ligand B are also important considerations.
**Overall Assessment:**
Ligand B demonstrates a more favorable balance of properties, particularly regarding drug-likeness (QED), metabolic stability (Cl_mic, t1/2), and BBB penetration. While both have solubility and Caco-2 permeability issues, these can potentially be addressed through formulation. The small advantage in binding affinity further supports choosing Ligand B.
Output:
0
2025-04-17 22:02:24,359 - INFO - Batch 302 complete. Total preferences: 4832
2025-04-17 22:02:24,359 - INFO - Processing batch 303/512...
2025-04-17 22:03:12,408 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [373.772, 105.56 , -0.148, 2. , 6. , 0.766, 76.037, 51.609, -5.079, -2.814, 0.054, -13.68 , -19.826, 0.011, -7.6 ]
**Ligand B:** [380.417, 114.18 , 0.469, 2. , 7. , 0.644, 57.58 , 61.535, -4.988, -2.074, 0.072, -6.287, -8.055, 0.057, -6.2 ]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity):
1. **MW:** Both are within the ideal 200-500 Da range. A (373.772) is slightly preferred.
2. **TPSA:** Both are reasonable, but A (105.56) is better than B (114.18), being closer to the <140 threshold for oral absorption.
3. **logP:** A (-0.148) is a bit low, potentially hindering permeation. B (0.469) is better, falling within the 1-3 range. This is a significant advantage for B.
4. **HBD/HBA:** Both have 2 HBD and 6-7 HBA, which are acceptable.
5. **QED:** Both are above 0.5, indicating good drug-likeness, but A (0.766) is better than B (0.644).
6. **DILI:** A (76.037) has a higher DILI risk than B (57.58), which is concerning.
7. **BBB:** A (51.609) and B (61.535) are both relatively low, indicating limited CNS penetration. This isn't a major concern for ADRB2, which is primarily a cardiovascular target.
8. **Caco-2:** Both are very poor (-5.079 and -4.988). This is a significant drawback for both.
9. **Solubility:** Both are very poor (-2.814 and -2.074). This is a significant drawback for both.
10. **hERG:** Both are very low risk (0.054 and 0.072).
11. **Cl_mic:** A (-13.68) has a lower (better) microsomal clearance than B (-6.287), indicating better metabolic stability.
12. **t1/2:** A (-19.826) has a longer (better) in vitro half-life than B (-8.055).
13. **Pgp:** Both are very low (0.011 and 0.057), suggesting minimal P-gp efflux.
14. **Affinity:** A (-7.6) has a slightly better binding affinity than B (-6.2). This is a 1.4 kcal/mol difference, which is substantial.
**Overall Assessment:**
Ligand A has a better binding affinity, QED, metabolic stability, and half-life. However, it has a significantly higher DILI risk and a lower logP, which could impact absorption. Ligand B has a better logP and lower DILI risk, but its affinity is weaker, and its metabolic stability is poorer.
Given the importance of potency for GPCRs, the 1.4 kcal/mol advantage of Ligand A is significant. While the DILI risk is a concern, it might be mitigated through structural modifications. The lower logP of A is a concern, but not insurmountable. The poor Caco-2 and solubility for both are concerning, but could be addressed through formulation strategies.
Therefore, I lean towards Ligand A as the more promising starting point for optimization.
1
2025-04-17 22:03:12,409 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (339.414) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (41.15) is significantly better than Ligand B (93.19). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand B's TPSA is quite high.
3. **logP:** Ligand A (4.123) is higher than the optimal range (1-3), but still potentially manageable. Ligand B (-0.951) is *below* the optimal range, which could lead to poor membrane permeability. This is a significant drawback.
4. **HBD/HBA:** Ligand A (HBD=1, HBA=3) is better than Ligand B (HBD=2, HBA=5). Both are within acceptable limits, but Ligand A has a more favorable balance.
5. **QED:** Ligand A (0.704) is better than Ligand B (0.575), indicating a more drug-like profile.
6. **DILI:** Ligand A (35.479) has a much lower DILI risk than Ligand B (8.414), which is a major advantage.
7. **BBB:** Ligand A (85.459) has better BBB penetration than Ligand B (17.216). While not critical for a cardiovascular target, it's a neutral benefit.
8. **Caco-2:** Ligand A (-4.556) is better than Ligand B (-5.623), indicating better intestinal absorption.
9. **Solubility:** Ligand A (-4.705) is better than Ligand B (0.365). Solubility is important for bioavailability.
10. **hERG:** Ligand A (0.978) has a lower hERG risk than Ligand B (0.026), which is crucial for avoiding cardiotoxicity.
11. **Cl_mic:** Ligand A (58.634) has a higher microsomal clearance than Ligand B (2). Higher clearance means faster metabolism and potentially lower exposure. Ligand B is much better here.
12. **t1/2:** Ligand B (-14.617) has a much longer in vitro half-life than Ligand A (-6.452). This is a significant advantage for dosing frequency.
13. **Pgp:** Ligand A (0.759) has better Pgp efflux profile than Ligand B (0.003). Lower efflux is better.
14. **Binding Affinity:** Ligand B (-6.7) has a better binding affinity than Ligand A (-5.1). This is a 1.6 kcal/mol difference, which is substantial and can outweigh some ADME concerns.
**Overall Assessment:**
Ligand B has a significantly better binding affinity and a longer half-life. However, it suffers from a high TPSA, poor logP, and a higher DILI risk. Ligand A has a more balanced profile with better ADME properties (TPSA, logP, solubility, DILI, hERG, Pgp) and acceptable affinity. Considering the GPCR-specific priorities (logP, TPSA, affinity), the substantial affinity difference of Ligand B is tempting. However, the poor logP and high TPSA of Ligand B raise serious concerns about its developability. The better ADME profile of Ligand A, coupled with a reasonable binding affinity, makes it the more promising candidate.
**Output:**
1
2025-04-17 22:03:12,409 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (368.455 & 373.856 Da) are within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand B (67.59) is significantly better than Ligand A (95.94). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (1.817) is within the optimal 1-3 range, while Ligand A (0.223) is quite low, potentially hindering membrane permeability. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1), but both are acceptable.
5. **HBA:** Ligand A (6) is slightly higher than Ligand B (5), but both are acceptable.
6. **QED:** Both ligands have good QED scores (0.674 & 0.74), indicating good drug-like properties.
7. **DILI:** Ligand B (39.201) has a lower DILI risk than Ligand A (53.625), which is preferable.
8. **BBB:** Ligand B (82.009) has a higher BBB penetration than Ligand A (54.478). While not critical for a cardiovascular target, it's a slight positive.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. Ligand B (-4.623) is slightly better than Ligand A (-5.207).
10. **Solubility:** Both ligands have negative solubility values, indicating poor solubility. Ligand B (-2.084) is slightly better than Ligand A (-2.793).
11. **hERG:** Ligand A (0.103) has a lower hERG risk than Ligand B (0.389), which is preferable.
12. **Cl_mic:** Ligand B (27.363) has significantly lower microsomal clearance than Ligand A (46.964), indicating better metabolic stability. This is a major advantage.
13. **t1/2:** Ligand B (-3.658) has a better in vitro half-life than Ligand A (-12.976).
14. **Pgp:** Ligand A (0.078) has lower P-gp efflux than Ligand B (0.157), which is preferable.
15. **Binding Affinity:** Ligand B (-8.0) has a significantly stronger binding affinity than Ligand A (-4.7). This is the most important factor. A 3.3 kcal/mol difference is substantial and can outweigh many ADME concerns.
**Overall Assessment:**
Ligand B is the stronger candidate. While Ligand A has a slightly better hERG profile and Pgp efflux, Ligand B excels in crucial areas: significantly better binding affinity, lower DILI risk, improved metabolic stability (lower Cl_mic, better t1/2), and a more favorable logP. The lower TPSA of Ligand B is also a plus. The affinity difference is large enough to compensate for the slightly higher hERG and Pgp values.
Output:
0
2025-04-17 22:03:12,409 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (353.463 and 356.373 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (96.53) is better than Ligand B (107.11). Both are below 140, but closer to 90 is preferable for GPCRs. Ligand A has a slight edge.
3. **logP:** Ligand B (1.106) is slightly better than Ligand A (0.729), both are within the optimal 1-3 range.
4. **HBD:** Both ligands have 3-4 HBD, which is acceptable. No difference.
5. **HBA:** Both ligands have 4 HBA, which is acceptable. No difference.
6. **QED:** Ligand B (0.612) is slightly better than Ligand A (0.539), indicating a marginally more drug-like profile.
7. **DILI:** Ligand A (23.885) is *significantly* better than Ligand B (55.68). This is a major advantage for Ligand A. A DILI percentile under 40 is highly desirable.
8. **BBB:** Both ligands have reasonable BBB penetration (66.227 and 61.962). While higher is better, this isn't a primary concern for ADRB2, which isn't a CNS target.
9. **Caco-2:** Ligand A (-4.884) is better than Ligand B (-5.262), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-1.644) is better than Ligand B (-3.141), which is important for bioavailability.
11. **hERG:** Ligand A (0.093) is better than Ligand B (0.327), indicating a lower risk of cardiotoxicity. This is crucial for a cardiovascular target.
12. **Cl_mic:** Ligand A (29.336) is better than Ligand B (0.568), suggesting better metabolic stability.
13. **t1/2:** Ligand A (12.584) is better than Ligand B (-11.078), indicating a longer half-life.
14. **Pgp:** Ligand A (0.007) is *significantly* better than Ligand B (0.042), indicating lower P-gp efflux.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-7.2 and -7.1 kcal/mol). The difference is negligible.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most key ADME-Tox properties. The most significant advantages for Ligand A are its much lower DILI risk, better metabolic stability (Cl_mic and t1/2), lower P-gp efflux, and better solubility. While Ligand B has a slightly better QED and logP, these are outweighed by the substantial improvements in safety and pharmacokinetic properties offered by Ligand A. Considering ADRB2 is a cardiovascular target, minimizing cardiotoxicity (hERG) and maximizing metabolic stability are particularly important, both of which favor Ligand A.
Output:
1
2025-04-17 22:03:12,409 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (375.39 and 364.471 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (85.09 and 84.42) are below the 140 A^2 threshold for good oral absorption, and acceptable for a cardiovascular target (not CNS). Very similar.
3. **logP:** Ligand A (3.285) is optimal, while Ligand B (1.109) is on the lower side, potentially hindering permeation. This is a point in favor of A.
4. **HBD:** Both have 1 HBD, well within the acceptable limit of 5.
5. **HBA:** Both have 6 HBA, also within the acceptable limit of 10.
6. **QED:** Ligand A (0.692) has a slightly better QED score than Ligand B (0.576), indicating better overall drug-likeness.
7. **DILI:** Ligand A (80.225) has a higher DILI risk than Ligand B (57.193). This is a significant drawback for Ligand A.
8. **BBB:** Not a primary concern for a cardiovascular target. Ligand A (32.183) and B (57.231) are both low, which is fine.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.266 and -5.2), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-3.07) has worse solubility than Ligand B (-1.689). Solubility is a concern for both, but less so for B.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.111 and 0.057). This is excellent for both.
12. **Cl_mic:** Ligand A (19.11) has a lower microsomal clearance than Ligand B (32.825), indicating better metabolic stability. This favors A.
13. **t1/2:** Ligand A (46.427) has a significantly longer half-life than Ligand B (-26.374). This is a major advantage for A.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.372 and 0.014). This is good for both.
15. **Binding Affinity:** Ligand A (-6.9 kcal/mol) has a slightly better binding affinity than Ligand B (-5.6 kcal/mol). While the difference is less than 1.5 kcal/mol, it's still a positive for A.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity), Ligand A initially looks more promising due to its better logP, metabolic stability (lower Cl_mic), longer half-life, and slightly better affinity. However, the significantly higher DILI risk for Ligand A is a major concern. Ligand B, while having a lower logP and shorter half-life, presents a much more favorable safety profile regarding liver toxicity. The Caco-2 permeability is poor for both, but this can be addressed through formulation strategies.
Given the balance of properties, and prioritizing safety (DILI) for a cardiovascular drug, I believe Ligand B is the more viable candidate.
Output:
0
2025-04-17 22:03:12,410 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
Let's break down the comparison of Ligand A and Ligand B based on the provided parameters and the guidelines, keeping in mind that ADRB2 is a GPCR, so logP, Pgp, TPSA, and affinity are key.
1. **Molecular Weight:** Both ligands (368.5 and 362.8 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (87.47) is slightly higher than Ligand B (82.61). Both are below the 140 threshold for good oral absorption, but closer to the 90 threshold for CNS targets.
3. **logP:** Ligand A (1.3) is within the optimal range (1-3), while Ligand B (0.225) is quite low. This is a significant drawback for Ligand B, as low logP can hinder membrane permeability.
4. **H-Bond Donors:** Ligand A (2) and Ligand B (1) are both acceptable.
5. **H-Bond Acceptors:** Ligand A (6) and Ligand B (4) are both acceptable.
6. **QED:** Both ligands have similar QED values (0.683 and 0.616), indicating good drug-likeness.
7. **DILI:** Ligand A (28.81) has a significantly lower DILI risk than Ligand B (50.136). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (50.795) and Ligand B (47.383) are similar, and both are below the 70% threshold that would be desirable for a CNS target. However, since ADRB2 is primarily a cardiovascular target, BBB penetration isn't a primary concern.
9. **Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the absolute value is more important, and Ligand A (-5.572) is slightly better than Ligand B (-5.347).
10. **Aqueous Solubility:** Both ligands have negative solubility values, indicating poor solubility.
11. **hERG Inhibition:** Ligand A (0.331) has a lower hERG inhibition liability than Ligand B (0.082), which is preferable.
12. **Microsomal Clearance:** Ligand A (25.769) has a higher (worse) microsomal clearance than Ligand B (-2.069). This suggests Ligand B is more metabolically stable.
13. **In vitro Half-Life:** Ligand A (37.683) has a longer half-life than Ligand B (-13.561). This is a significant advantage for Ligand A.
14. **P-gp Efflux:** Ligand A (0.05) has lower P-gp efflux liability than Ligand B (0.018).
15. **Binding Affinity:** Ligand B (-7.0) has a slightly better binding affinity than Ligand A (-5.9). The difference is 1.1 kcal/mol, which is substantial.
**Overall Assessment:**
While Ligand B has a slightly better binding affinity and metabolic stability, Ligand A is the stronger candidate. The lower logP of Ligand B is a major concern for permeability and bioavailability. Ligand A has a significantly lower DILI risk, better hERG profile, longer half-life, and lower P-gp efflux. The affinity difference, while noticeable, is likely surmountable with further optimization, while addressing the permeability issues of Ligand B would be more challenging.
Output:
1
2025-04-17 22:03:12,410 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [364.873, 67.43, 3.387, 2, 3, 0.6, 60.644, 53.974, -4.593, -4.635, 0.322, 68.326, 28.664, 0.174, -6.8]
**Ligand B:** [344.415, 78.53, 0.756, 1, 4, 0.773, 40.287, 43.117, -5.064, -1.502, 0.225, -8.207, -4.961, 0.027, -6]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (344.415) is slightly smaller, which is generally favorable.
2. **TPSA:** Ligand A (67.43) is better than Ligand B (78.53). We want TPSA < 140 for oral absorption, both are well within this limit.
3. **logP:** Ligand A (3.387) is optimal (1-3), while Ligand B (0.756) is a bit low, potentially hindering membrane permeability. This is a significant advantage for A.
4. **HBD/HBA:** Ligand A (2 HBD, 3 HBA) is slightly better than Ligand B (1 HBD, 4 HBA). Both are acceptable.
5. **QED:** Both have good QED scores (A: 0.6, B: 0.773), indicating drug-likeness. B is slightly better.
6. **DILI:** Ligand B (40.287) has a significantly lower DILI risk than Ligand A (60.644). This is a major advantage for B.
7. **BBB:** Ligand A (53.974) has a slightly better BBB penetration potential than Ligand B (43.117), but both are not particularly high. For a non-CNS target, this isn't critical.
8. **Caco-2:** Ligand B (-5.064) has a better Caco-2 permeability than Ligand A (-4.593).
9. **Solubility:** Ligand B (-1.502) has better aqueous solubility than Ligand A (-4.635).
10. **hERG:** Both are low, indicating low cardiotoxicity risk. Ligand B (0.225) is slightly better.
11. **Cl_mic:** Ligand B (-8.207) has a significantly lower (better) microsomal clearance than Ligand A (68.326), suggesting greater metabolic stability.
12. **t1/2:** Ligand B (-4.961) has a longer in vitro half-life than Ligand A (28.664).
13. **Pgp:** Ligand A (0.174) has lower P-gp efflux liability than Ligand B (0.027), which is favorable for bioavailability.
14. **Affinity:** Ligand A (-6.8 kcal/mol) has a slightly better binding affinity than Ligand B (-6 kcal/mol). While the difference is small, it's still a positive for A.
**Overall Assessment:**
Ligand B has a clear advantage in terms of safety (DILI), metabolic stability (Cl_mic, t1/2), solubility, and Caco-2 permeability. Ligand A has a slight edge in affinity and Pgp efflux. The logP of Ligand A is much more favorable. Considering the GPCR-specific priorities, the improved logP and affinity of Ligand A, combined with acceptable ADME properties, make it the more promising candidate. The DILI risk of Ligand A is a concern, but the slightly better binding affinity and logP outweigh this.
Output:
1
2025-04-17 22:03:12,410 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.491 and 354.441 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (70.4) is higher than Ligand B (49.41). For a cardiovascular GPCR like ADRB2, TPSA is moderately important, and lower is generally better for permeability. Ligand B has a clear advantage.
3. **logP:** Both ligands have very similar logP values (2.991 and 2.989), falling within the optimal 1-3 range. No significant difference.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1). This is not a major concern as both are within the acceptable limit of 5.
5. **HBA:** Ligand A (4) is higher than Ligand B (2). Again, both are within the acceptable limit of 10, but lower is preferred. Ligand B has a slight advantage.
6. **QED:** Ligand A (0.829) has a slightly higher QED score than Ligand B (0.746), indicating better overall drug-likeness. This is a positive for Ligand A.
7. **DILI:** Ligand B (19.504) has a significantly higher DILI risk than Ligand A (12.33). This is a crucial factor; lower DILI is highly desirable. Ligand A is clearly preferred.
8. **BBB:** Ligand B (90.461) has a higher BBB penetration percentile than Ligand A (86.002). While ADRB2 is not a CNS target, some degree of BBB penetration can sometimes be beneficial for peripheral targets, but it's not a primary concern here.
9. **Caco-2:** Ligand A (-5.065) has a lower Caco-2 permeability than Ligand B (-4.773). Lower values indicate poorer permeability, so Ligand B is slightly better.
10. **Solubility:** Ligand A (-1.967) has a better solubility score than Ligand B (-3.054). Solubility is important for bioavailability, giving Ligand A an advantage.
11. **hERG:** Both ligands have similar hERG inhibition liability (0.574 and 0.609), and are within an acceptable range. No significant difference.
12. **Cl_mic:** Ligand A (19.439) has a lower microsomal clearance than Ligand B (26.928), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (-8.212) has a much longer in vitro half-life than Ligand B (-15.807). This is a substantial advantage for Ligand A, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.055) has a lower Pgp efflux liability than Ligand B (0.178), indicating better absorption and bioavailability. Ligand A is preferred.
15. **Binding Affinity:** Both ligands have the same binding affinity (-8.2 kcal/mol). This eliminates affinity as a differentiating factor.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity) and the general guidelines, Ligand A emerges as the more promising candidate. While Ligand B has slightly better Caco-2 permeability and BBB penetration, Ligand A demonstrates superior drug-likeness (QED), significantly lower DILI risk, better metabolic stability (lower Cl_mic, longer t1/2), and lower Pgp efflux. The lower TPSA of Ligand B is a plus, but the other advantages of Ligand A outweigh this. The DILI risk is a major concern for Ligand B, making Ligand A the safer and more viable option.
Output:
1
2025-04-17 22:03:12,410 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (372.447 and 348.378 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (119.39) is slightly higher than Ligand B (104.53). Both are below the 140 A^2 threshold for good oral absorption, but Ligand B is preferable due to being closer to the 90 A^2 target for GPCRs.
3. **logP:** Ligand A (-0.833) is a bit low, potentially hindering membrane permeability. Ligand B (0.706) is within the optimal 1-3 range. This is a clear advantage for Ligand B.
4. **HBD:** Ligand A (2) is good. Ligand B (3) is acceptable, but slightly higher.
5. **HBA:** Ligand A (7) is good. Ligand B (3) is excellent. Lower HBA generally improves permeability.
6. **QED:** Both ligands have good QED scores (0.644 and 0.73), indicating drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (62.233) has a higher DILI risk than Ligand B (38.348). Lower DILI is crucial, making Ligand B preferable.
8. **BBB:** Ligand B (87.67) has significantly better BBB penetration potential than Ligand A (48.895). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be beneficial and isn't necessarily detrimental.
9. **Caco-2:** Both ligands have similar, poor Caco-2 permeability (-5.342 and -5.316). This suggests potential absorption issues for both, but isn't a deciding factor.
10. **Solubility:** Both ligands have poor aqueous solubility (-1.765 and -2.956). This is a concern for both, but Ligand B is slightly worse.
11. **hERG:** Both ligands have low hERG inhibition risk (0.117 and 0.17). No significant difference.
12. **Cl_mic:** Ligand A (6.787) has slightly lower microsomal clearance than Ligand B (7.167), suggesting better metabolic stability.
13. **t1/2:** Ligand B (6.596) has a much shorter in vitro half-life than Ligand A (45.599). This is a significant advantage for Ligand A.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.014 and 0.016). No significant difference.
15. **Binding Affinity:** Ligand B (-6.5 kcal/mol) has a slightly better binding affinity than Ligand A (-6.3 kcal/mol). While the difference is small, it's still a positive for Ligand B.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand B is the more promising candidate. It has a better logP, lower TPSA, lower DILI risk, and better BBB penetration. While Ligand A has a longer half-life, the other advantages of Ligand B outweigh this benefit. The affinity difference is small enough to be considered secondary to the ADME improvements.
Output:
0
2025-04-17 22:03:12,410 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (346.431 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (58.64) is significantly better than Ligand A (83.56). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both are within the optimal range (1-3), but Ligand B (1.808) is closer to the ideal. Ligand A (0.85) is a bit low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1), but both are acceptable.
5. **HBA:** Ligand A (5) is higher than Ligand B (3), but both are acceptable.
6. **QED:** Both are very similar and good (Ligand A: 0.773, Ligand B: 0.755).
7. **DILI:** Ligand B (32.997) has a much lower DILI risk than Ligand A (49.632), a significant advantage.
8. **BBB:** Ligand B (90.694) has much better BBB penetration than Ligand A (60.682). While not a primary concern for a cardiovascular target, it's a positive attribute.
9. **Caco-2:** Ligand B (-4.651) is better than Ligand A (-5.018), indicating better intestinal absorption.
10. **Solubility:** Both are similar and poor (-2.386 for both). This is a potential issue for both compounds, but not a deciding factor.
11. **hERG:** Ligand B (0.419) has a slightly better hERG profile than Ligand A (0.256), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand B (11.611) has a lower microsomal clearance than Ligand A (22.76), suggesting better metabolic stability.
13. **t1/2:** Ligand A (32.791) has a longer in vitro half-life than Ligand B (-12.91). This is a positive for Ligand A.
14. **Pgp:** Ligand A (0.016) has a lower Pgp efflux liability than Ligand B (0.047), suggesting better bioavailability.
15. **Affinity:** Ligand B (-6.6 kcal/mol) has a slightly better binding affinity than Ligand A (-6.4 kcal/mol), but the difference is small.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand B excels in logP, TPSA, and Pgp. The affinity difference is minor. Ligand A has a slight edge in half-life and Pgp efflux. However, Ligand B's significantly lower DILI risk and better metabolic stability (lower Cl_mic) are crucial advantages.
**Overall Assessment:**
While Ligand A has a slightly longer half-life and lower Pgp efflux, Ligand B demonstrates a superior balance of properties, particularly regarding safety (DILI, hERG) and ADME characteristics (TPSA, logP, Cl_mic, Caco-2). The small affinity difference is outweighed by these benefits.
Output:
0
2025-04-17 22:03:12,411 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.447 and 345.447 Da) fall comfortably within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (58.12) is significantly better than Ligand B (87.22). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (3.84) is optimal, while Ligand B (0.75) is a bit low. A logP below 1 can hinder membrane permeability. Ligand A is favored.
4. **HBD:** Ligand A (1) and Ligand B (2) are both acceptable, being less than 5.
5. **HBA:** Both ligands (5) are within the acceptable range of less than 10.
6. **QED:** Both ligands (0.78 and 0.794) have high QED scores, indicating good drug-likeness.
7. **DILI:** Ligand A (90.733) has a concerningly high DILI risk, while Ligand B (31.95) is very good. This is a major drawback for Ligand A.
8. **BBB:** Not a primary concern for a cardiovascular target. Ligand A (73.827) is slightly better than Ligand B (67.041), but the difference isn't significant.
9. **Caco-2:** Ligand A (-4.895) is better than Ligand B (-5.297), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-4.901) is better than Ligand B (-1.604), indicating better aqueous solubility.
11. **hERG:** Ligand A (0.758) is better than Ligand B (0.245), indicating lower hERG inhibition liability.
12. **Cl_mic:** Ligand A (93.79) is significantly worse than Ligand B (17.633). Higher Cl_mic means faster metabolism and lower bioavailability. Ligand B is strongly favored.
13. **t1/2:** Ligand A (75.587) is much better than Ligand B (23.184). A longer half-life is generally desirable.
14. **Pgp:** Ligand A (0.9) is better than Ligand B (0.013), indicating lower P-gp efflux.
15. **Binding Affinity:** Ligand A (-6.8 kcal/mol) is slightly better than Ligand B (-6.5 kcal/mol). While a 0.3 kcal/mol difference is not huge, it is a positive for Ligand A.
**Overall Assessment:**
Ligand A has a better binding affinity and some advantages in permeability and half-life. However, its extremely high DILI risk and poor metabolic stability (high Cl_mic) are major red flags. Ligand B, while having a slightly weaker affinity, presents a much more favorable ADMET profile, particularly its low DILI risk and good metabolic stability. For a cardiovascular target, minimizing toxicity and ensuring reasonable bioavailability are crucial. The slight affinity difference can potentially be optimized in later stages of drug development.
**Output:**
0
2025-04-17 22:03:12,411 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (a cardiovascular GPCR) drug candidates.
**Ligand A:** [357.479, 71.09, 3.177, 2, 4, 0.834, 70.182, 55.603, -5.049, -4.175, 0.333, 38.868, 32.729, 0.321, -4.5]
**Ligand B:** [337.383, 85.69, 2.472, 1, 6, 0.739, 77.549, 59.403, -5.125, -3.361, 0.465, 59.192, -33.534, 0.321, 0]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (337.383) is slightly lower, which *could* be beneficial for permeability, but both are acceptable.
2. **TPSA:** Ligand A (71.09) is better than Ligand B (85.69). We want TPSA <= 140 for oral absorption, and both meet this, but lower is preferred.
3. **logP:** Both are within the optimal range (1-3). Ligand A (3.177) is slightly higher, which could lead to off-target effects, but is still reasonable. Ligand B (2.472) is a bit more conservative.
4. **HBD:** Ligand A (2) is better than Ligand B (1). Both are good, being <= 5.
5. **HBA:** Ligand A (4) is better than Ligand B (6). Both are acceptable, but lower is better.
6. **QED:** Ligand A (0.834) is significantly better than Ligand B (0.739). Higher QED indicates a more drug-like profile.
7. **DILI:** Ligand A (70.182) is better than Ligand B (77.549). Both are acceptable (<80), but lower is always better.
8. **BBB:** Ligand A (55.603) is lower than Ligand B (59.403). While not a primary concern for a cardiovascular target, slightly higher BBB is preferable.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand B (-5.125) is slightly worse than Ligand A (-5.049).
10. **Solubility:** Both are negative, indicating poor solubility. Ligand A (-4.175) is slightly better than Ligand B (-3.361).
11. **hERG:** Ligand A (0.333) is better than Ligand B (0.465). Lower hERG inhibition is crucial for avoiding cardiotoxicity.
12. **Cl_mic:** Ligand A (38.868) is significantly better than Ligand B (59.192). Lower clearance means better metabolic stability.
13. **t1/2:** Ligand A (32.729) is significantly better than Ligand B (-33.534). A longer half-life is generally desirable.
14. **Pgp:** Both are very low (0.321). This is good, indicating minimal P-glycoprotein efflux.
15. **Affinity:** Ligand A (-4.5) is significantly better than Ligand B (0). A stronger binding affinity is a major advantage.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A performs better in most of these categories. While BBB isn't critical for a cardiovascular target, the difference isn't substantial enough to sway the decision. The significantly better affinity, QED, metabolic stability (Cl_mic, t1/2), and lower DILI/hERG risk of Ligand A make it a much more promising candidate.
**Conclusion:**
Ligand A is the more viable drug candidate.
1
2025-04-17 22:03:12,411 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (341.415 Da) is slightly lower, which is generally favorable for permeability, but both are acceptable.
**2. TPSA:** Both ligands have TPSA values below 140, indicating good potential for oral absorption. Ligand B (83.63) is slightly lower than Ligand A (90.98), which is a small advantage.
**3. logP:** Both ligands have logP values within the optimal range (1-3). Ligand A (1.733) is slightly lower, while Ligand B (2.961) is closer to the upper end. This isn't a major concern for either.
**4. H-Bond Donors:** Both ligands have 2 HBD, which is well within the acceptable limit of 5.
**5. H-Bond Acceptors:** Ligand A has 4 HBA, and Ligand B has 5. Both are below the limit of 10.
**6. QED:** Ligand A (0.866) has a significantly better QED score than Ligand B (0.706), suggesting a more drug-like profile.
**7. DILI Risk:** Ligand B (36.681) has a lower DILI risk than Ligand A (52.656), which is a significant advantage. Lower DILI risk is crucial for cardiovascular drugs.
**8. BBB Penetration:** Ligand B (61.923) shows better BBB penetration than Ligand A (46.336). While ADRB2 is primarily a cardiovascular target, some CNS effects can be relevant, and better BBB penetration isn't necessarily a drawback.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. This is a significant concern for both.
**10. Aqueous Solubility:** Both ligands have negative solubility values, indicating poor aqueous solubility. This is a major drawback for both compounds and would require formulation strategies to address.
**11. hERG Inhibition:** Ligand A (0.087) has a much lower hERG inhibition liability than Ligand B (0.57), which is a critical advantage. Avoiding hERG inhibition is paramount in cardiovascular drug development.
**12. Microsomal Clearance:** Ligand B (50.614) has a higher microsomal clearance than Ligand A (12.833), indicating faster metabolism and potentially lower bioavailability.
**13. In vitro Half-Life:** Ligand B (-8.222) has a longer in vitro half-life than Ligand A (-5.702), which is a positive.
**14. P-gp Efflux:** Ligand A (0.011) has significantly lower P-gp efflux liability than Ligand B (0.393), which is favorable for bioavailability.
**15. Binding Affinity:** Ligand A (-7.1 kcal/mol) has a slightly better binding affinity than Ligand B (-6.9 kcal/mol), although the difference is small.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity) and the general drug-like properties, Ligand A is the slightly better candidate. While Ligand B has lower DILI risk and better BBB penetration, Ligand A has a significantly better QED score, lower hERG inhibition, and lower P-gp efflux. The small difference in binding affinity is outweighed by these factors. The poor Caco-2 and solubility are major concerns for both, but can be addressed with formulation.
Output:
1
2025-04-17 22:03:12,411 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [365.463, 123.95 , 2.231, 1. , 6. , 0.431, 60.45 , 57.619, -5.268, -2.741, 0.453, 30.859, 11.165, 0.11 , -5.3 ]
**Ligand B:** [363.527, 62.3 , 3.441, 1. , 4. , 0.769, 43.505, 67.701, -4.849, -2.756, 0.359, 71.019, 16.121, 0.287, -5.3 ]
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (365.463 and 363.527 Da). No significant difference.
2. **TPSA:** Ligand A (123.95) is slightly higher than Ligand B (62.3). Ligand B is much better here, falling well below the 140 threshold for oral absorption and being more favorable for GPCRs.
3. **logP:** Ligand A (2.231) is within the optimal range, while Ligand B (3.441) is at the higher end. Both are acceptable, but A is slightly preferred.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 6 HBA, and Ligand B has 4. Both are within the acceptable range.
6. **QED:** Ligand B (0.769) has a better QED score than Ligand A (0.431), indicating a more drug-like profile.
7. **DILI:** Ligand B (43.505) has a significantly lower DILI risk than Ligand A (60.45). This is a major advantage for Ligand B.
8. **BBB:** Ligand B (67.701) has a better BBB penetration score than Ligand A (57.619). While ADRB2 is primarily cardiovascular, some CNS effects are possible with certain ligands, and higher BBB penetration is generally favorable.
9. **Caco-2:** Ligand A (-5.268) and Ligand B (-4.849) are both negative, indicating poor permeability. This is a concern for both, but the values are similar.
10. **Solubility:** Both have similar, very poor aqueous solubility (-2.741 and -2.756). This is a significant drawback for both, potentially hindering bioavailability.
11. **hERG:** Both have low hERG inhibition risk (0.453 and 0.359).
12. **Cl_mic:** Ligand A (30.859) has a lower microsomal clearance than Ligand B (71.019), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand B (16.121) has a longer in vitro half-life than Ligand A (11.165). This is a positive for Ligand B.
14. **Pgp:** Both have low P-gp efflux liability (0.11 and 0.287).
15. **Affinity:** Both have the same binding affinity (-5.3 kcal/mol), so this parameter doesn't differentiate them.
**Overall Assessment:**
Ligand B is the more promising candidate. While both have poor solubility and Caco-2 permeability, Ligand B excels in key areas for a GPCR target: lower DILI risk, better BBB penetration, a higher QED score, and a longer half-life. Ligand A has better metabolic stability (lower Cl_mic), but the benefits of Ligand B's improved safety and pharmacokinetic properties outweigh this advantage. The TPSA value for Ligand B is also significantly better.
Output:
0
2025-04-17 22:03:12,412 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.475 and 353.419 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (83.22) is significantly better than Ligand B (115.9). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (2.348) is optimal, while Ligand B (0.248) is quite low. A logP below 1 can hinder membrane permeability. This is a significant advantage for Ligand A.
4. **HBD:** Both ligands have 3 HBD, which is acceptable.
5. **HBA:** Ligand A has 3 HBA, while Ligand B has 6. Ligand A is preferable here, as higher HBA can sometimes reduce permeability.
6. **QED:** Both ligands have good QED scores (0.567 and 0.675), indicating drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (25.436) has a much lower DILI risk than Ligand B (39.201). This is a crucial factor, as liver toxicity is a major concern.
8. **BBB:** Ligand A (59.519) has a higher BBB percentile than Ligand B (25.785). While not critical for a cardiovascular target, it's a slight positive for Ligand A.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.051 and -5.107), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-2.4) is better than Ligand B (-0.798). Solubility is important for bioavailability.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.321 and 0.254), which is excellent.
12. **Cl_mic:** Ligand A (32.544) has a higher microsomal clearance than Ligand B (13.315), suggesting faster metabolism and potentially lower *in vivo* exposure. This favors Ligand B.
13. **t1/2:** Ligand B (-20.617) has a negative in vitro half-life, which is highly unusual and problematic. Ligand A (0.634) is much better.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.097 and 0.089).
15. **Binding Affinity:** Both ligands have the same binding affinity (-6.1 kcal/mol).
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand A excels in logP and TPSA, while affinity is equal. The significantly lower DILI risk for Ligand A is also a major advantage. The negative half-life for Ligand B is a dealbreaker.
**Conclusion:**
Despite the negative Caco-2 values for both, Ligand A is the superior candidate due to its better logP, TPSA, solubility, DILI risk, and in vitro half-life. The lower metabolic clearance is a minor drawback compared to the advantages.
Output:
1
2025-04-17 22:03:12,412 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.385 and 342.403 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (101.13) is slightly higher than Ligand B (93.01). Both are below the 140 threshold for good oral absorption, but closer to the 90 threshold for CNS targets (less relevant for ADRB2, a cardiovascular target). Ligand B is slightly preferred.
3. **logP:** Both ligands have good logP values (1.995 and 1.247) within the optimal 1-3 range. Ligand B is slightly lower, which could potentially impact permeability, but it's still acceptable.
4. **HBD:** Ligand A has 3 HBD, while Ligand B has 1. Lower HBD is generally preferred for permeability, giving a slight edge to Ligand B.
5. **HBA:** Ligand A has 5 HBA, Ligand B has 6. Both are within the acceptable limit of 10.
6. **QED:** Both ligands have good QED scores (0.772 and 0.853), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (61.962) and Ligand B (58.627) both have acceptable DILI risk, below the 60 threshold. Ligand B is slightly preferred.
8. **BBB:** Both ligands have reasonable BBB penetration (74.641 and 60.838). While not a primary concern for ADRB2, higher is better. Ligand A is preferred.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.067 and -5.033). This is unusual and suggests poor permeability. It's difficult to interpret without more context, but it's a negative for both.
10. **Solubility:** Both ligands have very poor aqueous solubility (-3.24 and -2.689). This is a significant concern for bioavailability.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.416 and 0.078). This is excellent. Ligand B is significantly better.
12. **Cl_mic:** Ligand A (-4.812) has a much lower (better) microsomal clearance than Ligand B (33.401). This indicates better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (10.88 hours) has a significantly longer half-life than Ligand B (1.624 hours). This is a major advantage for Ligand A.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.03 and 0.047). This is excellent.
15. **Binding Affinity:** Ligand A (-7.8 kcal/mol) has a stronger binding affinity than Ligand B (-6.9 kcal/mol). This is a 0.9 kcal/mol difference, which is substantial and can outweigh some ADME drawbacks.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. While both ligands perform well on logP and Pgp, Ligand A has a significantly better affinity and a longer half-life, and acceptable TPSA. The solubility and Caco-2 values are poor for both, but the stronger binding and improved metabolic stability of Ligand A are more critical for a GPCR target.
**Conclusion:**
Despite the poor solubility and Caco-2 values, Ligand A's superior binding affinity, metabolic stability (lower Cl_mic), and longer half-life make it the more promising candidate. The 0.9 kcal/mol difference in binding is significant.
Output:
1
2025-04-17 22:03:12,412 - INFO - Batch 303 complete. Total preferences: 4848
2025-04-17 22:03:12,412 - INFO - Processing batch 304/512...
2025-04-17 22:04:01,067 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (346.471) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (53.51) has a significantly lower TPSA than Ligand A (70.59). This is a major advantage for oral absorption and potentially better CNS penetration, aligning with GPCR priorities.
3. **logP:** Both ligands have good logP values (A: 3.028, B: 3.331), falling within the optimal 1-3 range. Ligand B is slightly higher, which could potentially lead to some off-target interactions, but is still acceptable.
4. **HBD:** Ligand A has 3 HBD, while Ligand B has 0. Lower HBD is generally preferred for permeability, giving an edge to Ligand B.
5. **HBA:** Ligand A has 3 HBA, and Ligand B has 5. Both are within the acceptable limit of 10, but lower is generally better.
6. **QED:** Both ligands have similar QED values (A: 0.785, B: 0.776), indicating good drug-likeness.
7. **DILI:** Ligand B (48.081) has a much lower DILI risk than Ligand A (19.736), which is a significant advantage for safety.
8. **BBB:** Both ligands have good BBB penetration (A: 79.527, B: 77.084). This is less critical for ADRB2 (a cardiovascular target) but still a positive.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and requires further investigation. However, the values are similar (-4.417 for A, -4.539 for B), so this doesn't differentiate them.
10. **Solubility:** Both ligands have negative solubility values, which is also unusual. Again, the values are comparable (-3.012 for A, -2.609 for B).
11. **hERG:** Both ligands have low hERG inhibition liability (A: 0.381, B: 0.274), which is good.
12. **Cl_mic:** Ligand A (31.173) has a significantly lower microsomal clearance than Ligand B (60.298), indicating better metabolic stability.
13. **t1/2:** Ligand A (28.49) has a longer in vitro half-life than Ligand B (20.366), further supporting its better metabolic stability.
14. **Pgp:** Both ligands have low P-gp efflux liability (A: 0.263, B: 0.209).
15. **Affinity:** Ligand A (-8.6 kcal/mol) has a stronger binding affinity than Ligand B (-7.5 kcal/mol). This is a substantial difference (>1.5 kcal/mol) and a major factor in its favor.
**Overall Assessment:**
Ligand A has a significantly better binding affinity and metabolic stability (lower Cl_mic, longer t1/2). However, Ligand B excels in TPSA, DILI risk, and HBD. The stronger binding affinity of Ligand A is a critical advantage for a GPCR target like ADRB2, and the difference in affinity is large enough to outweigh the slightly less favorable TPSA and DILI scores. The comparable BBB and Pgp values are also positive for both.
Output:
1
2025-04-17 22:04:01,068 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [343.427, 65.9, 1.772, 1, 5, 0.917, 39.473, 48.468, -4.575, -1.227, 0.83, 19.407, 34.928, 0.26, -5.9]
**Ligand B:** [343.431, 80.12, 1.12, 1, 5, 0.656, 43.66, 75.998, -4.889, -1.858, 0.146, 28.156, -19.42, 0.159, -6.3]
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (around 343 Da). No significant difference.
2. **TPSA:** Ligand A (65.9) is better than Ligand B (80.12). Lower TPSA generally favors better absorption, especially for GPCRs.
3. **logP:** Both are good (1.772 and 1.12, respectively), falling within the optimal 1-3 range. Ligand A is slightly more lipophilic, which could be beneficial for membrane permeability.
4. **HBD/HBA:** Both have 1 HBD and 5 HBA, which is acceptable.
5. **QED:** Ligand A (0.917) has a significantly better QED score than Ligand B (0.656), indicating a more drug-like profile.
6. **DILI:** Both are reasonably low (39.473 and 43.66), suggesting acceptable liver safety profiles. Ligand A is slightly better.
7. **BBB:** Ligand B (75.998) has a substantially higher BBB penetration percentile than Ligand A (48.468). While ADRB2 isn't a CNS target, some off-target CNS effects are always a consideration, and higher BBB penetration could be a slight advantage.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand B (-4.889) is slightly worse than Ligand A (-4.575).
9. **Solubility:** Both have negative solubility values, which is also unusual and suggests poor aqueous solubility. Ligand B (-1.858) is worse than Ligand A (-1.227).
10. **hERG:** Both are very low (0.83 and 0.146), indicating a very low risk of hERG inhibition and cardiotoxicity. Ligand B is better.
11. **Cl_mic:** Ligand A (19.407) has lower microsomal clearance than Ligand B (28.156), suggesting better metabolic stability.
12. **t1/2:** Ligand A (34.928) has a positive in vitro half-life, while Ligand B (-19.42) has a negative value, which is concerning. This suggests Ligand A is more stable in vitro.
13. **Pgp:** Both are very low (0.26 and 0.159), indicating minimal P-gp efflux. Ligand B is slightly better.
14. **Affinity:** Ligand B (-6.3) has a slightly better binding affinity than Ligand A (-5.9). This is a 0.4 kcal/mol difference, which is not huge but potentially significant.
**GPCR-Specific Priorities:**
For ADRB2 (a cardiovascular GPCR), we prioritize logP, TPSA, affinity, and metabolic stability. While BBB isn't critical, it's a consideration.
**Overall Assessment:**
Ligand A has a better overall profile. Its superior QED, lower clearance, and positive in vitro half-life are strong advantages. While Ligand B has slightly better affinity and BBB penetration, the poor solubility and half-life are significant drawbacks. The TPSA is also better for Ligand A. The affinity difference isn't large enough to overcome the other ADME deficiencies of Ligand B.
Output:
1
2025-04-17 22:04:01,068 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.471 and 367.471 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (60.85) is significantly better than Ligand B (82.97). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (2.231 and 1.136), falling within the 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability, but both are acceptable.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 3 HBA, while Ligand B has 6. Ligand A is preferable here, as excessive HBA can sometimes hinder permeability.
6. **QED:** Both ligands have very similar QED values (0.824 and 0.815), indicating good drug-likeness.
7. **DILI:** Ligand A (36.022) has a lower DILI risk than Ligand B (47.15), which is a significant advantage.
8. **BBB:** BBB is less critical for a cardiovascular target. Ligand A (63.358) is higher than Ligand B (50.872), but this isn't a major deciding factor.
9. **Caco-2:** Both have negative Caco-2 values (-4.376 and -4.641), which is unusual and suggests poor permeability. However, these values are on a scale where negative values are possible, and the difference is small.
10. **Solubility:** Ligand A (-1.501) is slightly better than Ligand B (-0.804), indicating better aqueous solubility.
11. **hERG:** Ligand A (0.724) has a lower hERG risk than Ligand B (0.139), which is a critical safety parameter.
12. **Cl_mic:** Ligand A (54.594) has a significantly lower microsomal clearance than Ligand B (7.575), suggesting better metabolic stability.
13. **t1/2:** Ligand B (7.612) has a longer in vitro half-life than Ligand A (-0.439). This is a positive for Ligand B.
14. **Pgp:** Ligand A (0.484) has lower P-gp efflux liability than Ligand B (0.104), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand A (-6.3 kcal/mol) has a slightly better binding affinity than Ligand B (-5.1 kcal/mol). This difference of 1.2 kcal/mol is substantial enough to be a key consideration.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A performs better on TPSA, Pgp, and affinity. While both have acceptable logP values, Ligand A is slightly better.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B in most critical ADME-Tox parameters (DILI, hERG, Cl_mic, Pgp) and has a slightly better binding affinity. The longer half-life of Ligand B is a positive, but the superior overall profile of Ligand A, particularly its safety parameters and binding, makes it the more promising drug candidate.
Output:
1
2025-04-17 22:04:01,068 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (336.443 and 346.435 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (49.56) is significantly better than Ligand B (97.88). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B's TPSA is quite high, potentially hindering absorption.
**3. logP:** Ligand A (2.923) is optimal, while Ligand B (1.14) is on the lower side. While not terrible, lower logP can sometimes indicate poor membrane permeability.
**4. H-Bond Donors:** Ligand A (0) is preferable to Ligand B (1). Fewer H-bond donors generally improve permeability.
**5. H-Bond Acceptors:** Ligand A (6) is better than Ligand B (8). Similar to HBDs, fewer HBAs are generally preferred.
**6. QED:** Both ligands have similar QED values (0.717 and 0.705), indicating good drug-likeness.
**7. DILI Risk:** Ligand A (71.694) has a higher DILI risk than Ligand B (37.922). This is a significant drawback for Ligand A.
**8. BBB Penetration:** Ligand A (81.466) has better BBB penetration than Ligand B (70.919). While ADRB2 isn't exclusively a CNS target, some peripheral effects are desirable, and better BBB penetration suggests better overall distribution.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-5.073 and -5.465). This is unusual and suggests poor permeability based on this metric. However, the negative values are similar, so it doesn't differentiate them significantly.
**10. Aqueous Solubility:** Ligand A (-3.457) has slightly better solubility than Ligand B (-1.96), but both are poor.
**11. hERG Inhibition:** Ligand A (0.607) has a slightly higher hERG risk than Ligand B (0.256). Lower is better here, so Ligand B is preferable.
**12. Microsomal Clearance:** Ligand A (58.104) has a higher microsomal clearance than Ligand B (2.802), meaning it's metabolized faster. Ligand B is significantly more metabolically stable.
**13. In vitro Half-Life:** Ligand A (24.592) has a longer half-life than Ligand B (-5.729). This is a positive for Ligand A.
**14. P-gp Efflux:** Ligand A (0.758) has slightly higher P-gp efflux than Ligand B (0.086). Lower efflux is better, so Ligand B is preferable.
**15. Binding Affinity:** Ligand A (-6.5 kcal/mol) has a slightly better binding affinity than Ligand B (-5.8 kcal/mol). This is a 0.7 kcal/mol difference, which is not huge but is noticeable.
**Overall Assessment:**
Ligand B is the more promising candidate. While Ligand A has a slightly better binding affinity and half-life, Ligand B excels in crucial ADME properties. Specifically, its significantly lower DILI risk, better metabolic stability (lower Cl_mic), lower P-gp efflux, and lower hERG inhibition are major advantages. The lower logP and higher TPSA of Ligand B are concerns, but the benefits in safety and PK outweigh these drawbacks. The GPCR-specific priorities of logP, TPSA, and Pgp all favor Ligand B.
Output:
0
2025-04-17 22:04:01,068 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.475 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (67.87) is significantly better than Ligand B (87.66). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand A is well under the 140 A^2 threshold, while Ligand B is approaching it.
3. **logP:** Both ligands (1.746 and 1.674) are within the optimal 1-3 range. Very similar.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Lower HBD generally improves permeability.
5. **HBA:** Both ligands (4) are acceptable, falling below the 10 threshold.
6. **QED:** Ligand A (0.74) is better than Ligand B (0.58), indicating a more drug-like profile.
7. **DILI:** Ligand A (36.177) has a slightly higher DILI risk than Ligand B (19.969), but both are below the concerning 60 percentile. Ligand B is clearly better here.
8. **BBB:** Both ligands have similar BBB penetration (57.464 and 60.605). Since ADRB2 is a cardiovascular target, BBB penetration is not a primary concern, but a moderate value is acceptable.
9. **Caco-2:** Ligand A (-4.587) is worse than Ligand B (-5.048). Lower values here indicate poorer permeability.
10. **Solubility:** Ligand A (-2.526) is better than Ligand B (-1.644). Higher solubility is generally preferred.
11. **hERG:** Both ligands (0.234 and 0.118) have very low hERG inhibition risk. This is excellent.
12. **Cl_mic:** Ligand A (30.038) has a higher microsomal clearance than Ligand B (20.566), suggesting lower metabolic stability. Ligand B is preferable.
13. **t1/2:** Ligand A (9.784) has a longer in vitro half-life than Ligand B (-2.978). This is a significant advantage for Ligand A.
14. **Pgp:** Both ligands (0.06 and 0.042) have low P-gp efflux liability, which is good.
15. **Binding Affinity:** Ligand A (-5.7) has a significantly stronger binding affinity than Ligand B (0.0). This is a crucial advantage. A difference of >1.5 kcal/mol is substantial.
**Overall Assessment:**
Ligand A has a significantly better binding affinity and a longer half-life, which are critical for a GPCR target. It also has a better TPSA, HBD, QED, and solubility. While Ligand B has a lower DILI risk and better metabolic stability, the superior binding affinity and half-life of Ligand A outweigh these advantages. The slightly higher DILI risk of Ligand A is acceptable given its strong potency.
Output:
1
2025-04-17 22:04:01,068 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.419 and 361.467 Da) fall comfortably within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (103.71) is higher than Ligand B (75.43). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B has a clear advantage.
3. **logP:** Ligand B (1.954) is within the optimal range (1-3), while Ligand A (0.82) is slightly below, potentially impacting permeability. Ligand B is favored.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 7 HBA, while Ligand B has 6. Both are acceptable, under the limit of 10.
6. **QED:** Both ligands have similar QED values (0.857 and 0.853), indicating good drug-likeness.
7. **DILI:** Ligand A (15.82%) has a significantly lower DILI risk than Ligand B (41.218%). This is a substantial advantage for Ligand A.
8. **BBB:** Ligand A (74.758%) has a higher BBB penetration potential than Ligand B (63.086%). While ADRB2 isn't strictly a CNS target, some brain exposure can occur, and higher BBB is generally favorable.
9. **Caco-2:** Ligand A (-5.252) has a lower Caco-2 permeability than Ligand B (-4.781). Both are negative, which is unusual, but B is slightly better.
10. **Solubility:** Ligand A (-1.305) has slightly better aqueous solubility than Ligand B (-2.796).
11. **hERG:** Ligand A (0.171) has a lower hERG inhibition liability than Ligand B (0.307), indicating a lower risk of cardiotoxicity. This is a significant advantage for Ligand A, given the cardiovascular target.
12. **Cl_mic:** Ligand A (-9.016) has a much lower microsomal clearance than Ligand B (22.269), indicating better metabolic stability. This is a substantial advantage for Ligand A.
13. **t1/2:** Ligand A (9.385) has a longer in vitro half-life than Ligand B (4.204). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.011) has a much lower P-gp efflux liability than Ligand B (0.276), suggesting better oral bioavailability and potentially better tissue distribution. This is a significant advantage for Ligand A.
15. **Binding Affinity:** Ligand A (-6.8 kcal/mol) has a slightly better binding affinity than Ligand B (-4.0 kcal/mol). This is a substantial advantage for Ligand A.
**Overall Assessment:**
While Ligand B has a slightly better logP and Caco-2 permeability, Ligand A overwhelmingly outperforms it in critical ADME-Tox properties (DILI, hERG, Cl_mic, t1/2, Pgp) and has a significantly better binding affinity. The lower DILI and hERG risks are particularly important for a cardiovascular target. The improved metabolic stability (lower Cl_mic and longer t1/2) and reduced efflux (Pgp) also contribute to a more favorable pharmacokinetic profile.
Output:
1
2025-04-17 22:04:01,069 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (346.435 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both ligands are below the 140 A^2 threshold for good oral absorption. Ligand B (92.34 A^2) is significantly lower than Ligand A (113.24 A^2), which is a positive for both permeability and potentially BBB penetration.
3. **logP:** Both ligands have acceptable logP values (between 1 and 3). Ligand B (1.471) is slightly higher, which could be beneficial for membrane permeability, but not drastically.
4. **HBD:** Both are acceptable. Ligand A has 3 HBD, and Ligand B has 2.
5. **HBA:** Both are acceptable. Ligand A has 5 HBA, and Ligand B has 4.
6. **QED:** Both ligands have good QED scores (>0.5), indicating drug-likeness. Ligand B (0.742) is slightly better.
7. **DILI:** Ligand A (36.797) has a significantly lower DILI risk than Ligand B (65.491). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (85.537) has a much higher BBB penetration percentile than Ligand B (43.001). While ADRB2 isn't strictly a CNS target, some peripheral effects can be modulated by CNS penetration, and higher BBB is generally favorable.
9. **Caco-2:** Both ligands have negative Caco-2 values which is unusual and likely indicates poor permeability.
10. **Solubility:** Both ligands have negative solubility values which is unusual and likely indicates poor solubility.
11. **hERG:** Both ligands have very low hERG inhibition liability, which is excellent.
12. **Cl_mic:** Ligand B (-9.323) has a *negative* microsomal clearance, which is impossible. This is a red flag and suggests an issue with the data or the molecule's stability. Ligand A (16.115) has a reasonable clearance.
13. **t1/2:** Ligand B (40.177) has a significantly longer in vitro half-life than Ligand A (14.664). This is a positive for Ligand B.
14. **Pgp:** Both ligands have very low P-gp efflux liability.
15. **Binding Affinity:** Both ligands have the same binding affinity (-7.2 kcal/mol), so this parameter doesn't differentiate them.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand B has a slightly better logP and TPSA, but the negative Cl_mic is a critical flaw. While BBB isn't paramount for ADRB2, Ligand A's higher BBB percentile is a bonus. The significantly lower DILI risk for Ligand A is also a major factor.
**Conclusion:**
Despite Ligand B having a slightly longer half-life and better TPSA, the negative microsomal clearance value is a showstopper. It indicates either a data error or a fundamentally unstable molecule. Ligand A, while not perfect, presents a more balanced profile with a lower DILI risk, better predicted metabolic stability, and acceptable ADME properties.
Output:
1
2025-04-17 22:04:01,069 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, priorities are logP, TPSA, Pgp, affinity, and to a lesser extent, BBB.
Let's break down the comparison:
1. **MW:** Both ligands are within the ideal range (362-371 Da).
2. **TPSA:** Ligand A (49.85) is significantly better than Ligand B (69.64). Lower TPSA generally favors oral absorption, crucial for a cardiovascular drug.
3. **logP:** Both ligands have good logP values (2.64 and 2.58), falling within the optimal 1-3 range.
4. **HBD/HBA:** Ligand A (0 HBD, 4 HBA) is slightly preferable to Ligand B (2 HBD, 4 HBA).
5. **QED:** Ligand B (0.865) has a slightly better QED score than Ligand A (0.616), indicating a more drug-like profile.
6. **DILI:** Ligand A (20.744) has a much lower DILI risk than Ligand B (37.456), a significant advantage.
7. **BBB:** Both have reasonable BBB penetration (83.831 and 77.007), but this is less critical for a cardiovascular target.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual. I will assume these are percentile values, and thus higher is better. Ligand A (-4.639) is slightly better than Ligand B (-4.913).
9. **Solubility:** Both have negative solubility values, which is unusual. I will assume these are percentile values, and thus higher is better. Ligand A (-3.39) is slightly better than Ligand B (-2.965).
10. **hERG:** Both ligands have low hERG inhibition risk (0.837 and 0.434).
11. **Cl_mic:** Ligand B (23.529) has a significantly lower microsomal clearance than Ligand A (75.499), indicating better metabolic stability. This is a substantial advantage.
12. **t1/2:** Ligand B (-22.403) has a much longer in vitro half-life than Ligand A (-3.495), further supporting its better metabolic stability.
13. **Pgp:** Both ligands have low Pgp efflux liability (0.257 and 0.217).
14. **Affinity:** Ligand B (-6.8 kcal/mol) has a slightly better binding affinity than Ligand A (-6.4 kcal/mol). While the difference is less than the 1.5kcal/mol threshold, it is still a positive.
**Overall Assessment:**
Ligand B demonstrates superior metabolic stability (lower Cl_mic, longer t1/2) and slightly better binding affinity. However, Ligand A has a much lower DILI risk and a better TPSA. Considering the GPCR target class, the lower TPSA of Ligand A is advantageous for absorption. The lower DILI risk is also a significant factor. While metabolic stability is important, the difference in affinity is small, and the other advantages of Ligand A outweigh this.
**Output:**
1
2025-04-17 22:04:01,069 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, priorities are logP, TPSA, Pgp, affinity, and to a lesser extent, BBB.
* **Molecular Weight:** Both ligands are within the acceptable range (200-500 Da). Ligand B (336.351 Da) is slightly smaller than Ligand A (373.454 Da), which is generally favorable for permeability.
* **TPSA:** Ligand A (89.35) is significantly better than Ligand B (111.78). A TPSA under 140 is good for oral absorption, and under 90 is preferable for CNS targets (less relevant here, but still a positive). Ligand A is closer to the ideal range.
* **logP:** Ligand B (2.461) is better than Ligand A (0.345). A logP between 1-3 is optimal. Ligand A's logP is quite low, potentially hindering membrane permeability.
* **H-Bond Donors/Acceptors:** Ligand A has 1 HBD and 7 HBA, while Ligand B has 2 HBD and 5 HBA. Both are within acceptable limits.
* **QED:** Both ligands have similar QED values (0.742 and 0.718), indicating good drug-likeness.
* **DILI:** Ligand B (76.464) has a slightly higher DILI risk than Ligand A (64.676), but both are moderately high.
* **BBB:** Ligand A (76.813) has a much better BBB penetration score than Ligand B (30.206). While not the primary focus for a cardiovascular target, some CNS exposure is not necessarily detrimental and could offer off-target effects.
* **Caco-2 Permeability:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
* **Aqueous Solubility:** Both have negative solubility values, again unusual.
* **hERG:** Ligand A (0.204) has a lower hERG risk than Ligand B (0.476), which is a significant advantage.
* **Microsomal Clearance:** Ligand B (30.435) has lower microsomal clearance than Ligand A (17.034), indicating better metabolic stability.
* **In vitro Half-Life:** Ligand B (33.87) has a significantly longer half-life than Ligand A (-9.638). This is a major advantage.
* **P-gp Efflux:** Ligand A (0.044) has much lower P-gp efflux than Ligand B (0.462), which is favorable for bioavailability.
* **Binding Affinity:** Ligand B (-6.8 kcal/mol) has a slightly better binding affinity than Ligand A (-5.9 kcal/mol). This difference is significant enough to consider.
**Overall Assessment:**
Ligand B has a better logP, metabolic stability (lower Cl_mic, longer t1/2), and binding affinity. However, Ligand A has a much better TPSA, lower hERG risk, lower P-gp efflux, and better BBB penetration. The low logP of Ligand A is a concern, but the better TPSA and lower hERG risk are important. The affinity difference is not large enough to outweigh the other factors. Considering the GPCR-specific priorities, the balance of properties favors Ligand A.
**Output:**
1
2025-04-17 22:04:01,069 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (358.47 and 350.35 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (76.02) is significantly better than Ligand B (133.15). For a GPCR, keeping TPSA low is beneficial for permeability, and Ligand A is well below the 140 threshold. Ligand B is approaching a level that could hinder absorption.
3. **logP:** Ligand A (2.383) is within the optimal 1-3 range. Ligand B (0.981) is a bit low, potentially impacting membrane permeability.
4. **HBD:** Ligand A (2) is good. Ligand B (4) is acceptable, but higher HBD can sometimes lead to issues with permeability and metabolic instability.
5. **HBA:** Ligand A (5) is good. Ligand B (8) is higher, potentially impacting permeability.
6. **QED:** Ligand A (0.746) is better than Ligand B (0.581), indicating a more drug-like profile.
7. **DILI:** Ligand B (77.394) has a higher DILI risk than Ligand A (62.156), though both are above the preferred <40. Ligand A is preferable here.
8. **BBB:** Ligand A (67.158) has better BBB penetration potential than Ligand B (47.15). While ADRB2 isn't strictly a CNS target, some CNS exposure can occur, and higher BBB is generally favorable.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability in this assay. This is a concern for both.
10. **Solubility:** Both ligands have negative solubility values, indicating very poor aqueous solubility. This is a significant drawback for both.
11. **hERG:** Ligand A (0.25) has a much lower hERG risk than Ligand B (0.372). This is a critical advantage, as hERG inhibition can lead to cardiotoxicity.
12. **Cl_mic:** Ligand B (31.381) has lower microsomal clearance than Ligand A (37.41), suggesting better metabolic stability. This is a positive for Ligand B.
13. **t1/2:** Ligand A (37.547) has a significantly longer in vitro half-life than Ligand B (-15.588). This is a major advantage for Ligand A, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.215) has lower P-gp efflux liability than Ligand B (0.031), which is favorable for oral bioavailability and potentially CNS exposure.
15. **Binding Affinity:** Ligand A (-7.8 kcal/mol) has a substantially stronger binding affinity than Ligand B (-6.7 kcal/mol). This 1.1 kcal/mol difference is significant and can outweigh some of the ADME drawbacks.
**Overall Assessment:**
Ligand A is the stronger candidate. While both ligands have solubility and Caco-2 permeability issues, Ligand A excels in critical areas: significantly better binding affinity, lower hERG risk, longer half-life, better BBB penetration, and a more favorable QED score. The lower TPSA and logP of Ligand A also contribute to its improved profile. Although Ligand B has slightly better metabolic stability, the other advantages of Ligand A are more impactful for a GPCR target like ADRB2.
Output:
1
2025-04-17 22:04:01,069 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [355.391, 125.04 , -0.761, 3. , 6. , 0.299, 33.579, 46.336, -5.888, -1.394, 0.042, -29.024, 4.274, 0.004, -5.7 ]
**Ligand B:** [354.466, 69.64 , 2.173, 2. , 3. , 0.795, 18.573, 83.172, -4.769, -1.841, 0.513, -17.389, -0.98 , 0.128, -6.2 ]
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (355 & 354 Da). No significant difference.
2. **TPSA:** Ligand A (125) is higher than Ligand B (69.64). Ligand B is much better, being well below the 140 threshold for oral absorption and closer to the ideal for GPCRs.
3. **logP:** Ligand A (-0.761) is lower than the optimal 1-3 range, potentially hindering membrane permeability. Ligand B (2.173) is within the optimal range. This is a significant advantage for B.
4. **HBD:** Ligand A (3) is acceptable. Ligand B (2) is also good.
5. **HBA:** Ligand A (6) is acceptable. Ligand B (3) is also good.
6. **QED:** Ligand B (0.795) is much better than Ligand A (0.299), indicating a more drug-like profile.
7. **DILI:** Ligand A (33.579) has a slightly higher DILI risk than Ligand B (18.573), but both are below the concerning 60% threshold.
8. **BBB:** Ligand B (83.172) has significantly better BBB penetration potential than Ligand A (46.336). This is a key advantage for a GPCR target.
9. **Caco-2:** Ligand A (-5.888) and Ligand B (-4.769) are both negative, which is unusual. Higher values are better, and the negative values suggest poor permeability. Ligand B is slightly better.
10. **Solubility:** Ligand A (-1.394) and Ligand B (-1.841) are both negative, indicating poor solubility.
11. **hERG:** Ligand A (0.042) has a slightly lower hERG risk than Ligand B (0.513), but both are very low.
12. **Cl_mic:** Ligand A (-29.024) has a much lower (better) microsomal clearance, indicating greater metabolic stability, than Ligand B (-17.389).
13. **t1/2:** Ligand A (4.274) has a longer in vitro half-life than Ligand B (-0.98). This is a positive for A.
14. **Pgp:** Ligand A (0.004) has a much lower P-gp efflux liability than Ligand B (0.128), suggesting better oral bioavailability and potentially better CNS exposure.
15. **Affinity:** Both ligands have comparable binding affinity (-5.7 and -6.2 kcal/mol). The difference is not substantial enough to override other factors.
**Overall Assessment:**
Ligand B clearly outperforms Ligand A in several crucial areas for a GPCR drug candidate: logP, TPSA, QED, and BBB penetration. While Ligand A has better metabolic stability (lower Cl_mic) and half-life, and lower Pgp efflux, the improvements in permeability, drug-likeness, and CNS exposure potential with Ligand B are more impactful for this target class. The affinity difference is minimal.
Output:
0
2025-04-17 22:04:01,070 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (346.471 and 358.467 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Both ligands (69.64 and 68.09) are below the 140 A^2 threshold for good oral absorption, and are reasonable for a peripherally acting GPCR target like ADRB2. Very similar.
**3. logP:** Both ligands have good logP values (2.313 and 2.022), falling within the optimal 1-3 range. Again, no major difference.
**4. H-Bond Donors:** Ligand A (2) is preferable to Ligand B (0). While both are acceptable, having some H-bond donors can aid solubility.
**5. H-Bond Acceptors:** Ligand B (6) is slightly higher than Ligand A (3). This isn't a major concern, as both are below the 10 threshold, but fewer is generally better for permeability.
**6. QED:** Ligand B (0.818) has a significantly better QED score than Ligand A (0.593), indicating a more drug-like profile. This is a substantial advantage for Ligand B.
**7. DILI Risk:** Ligand A (26.095) has a much lower DILI risk than Ligand B (55.758). This is a critical advantage for Ligand A, as liver toxicity is a major concern in drug development.
**8. BBB Penetration:** This is less critical for ADRB2 (a cardiovascular target) but Ligand B (63.358) has a higher BBB penetration than Ligand A (52.268).
**9. Caco-2 Permeability:** Ligand B (-5.307) has better Caco-2 permeability than Ligand A (-4.918).
**10. Aqueous Solubility:** Ligand B (-1.982) has better aqueous solubility than Ligand A (-2.614).
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.263 and 0.256), which is excellent.
**12. Microsomal Clearance:** Ligand B (41.918) has lower microsomal clearance than Ligand A (47.722), suggesting better metabolic stability.
**13. In vitro Half-Life:** Ligand B (-10.359) has a significantly longer in vitro half-life than Ligand A (-4.376). This is a major advantage for Ligand B.
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (0.346 and 0.047).
**15. Binding Affinity:** Ligand B (-7.8 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.6 kcal/mol). This 1.2 kcal/mol difference is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand B is clearly superior. The stronger binding affinity (-7.8 vs -6.6 kcal/mol) is a major driver. The better QED, solubility, Caco-2 permeability, metabolic stability (lower Cl_mic and longer t1/2) and BBB penetration further solidify its advantage. While Ligand A has a lower DILI risk, the overall profile of Ligand B is more promising, and the DILI risk for Ligand A is still within acceptable limits.
Output:
0
2025-04-17 22:04:01,070 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (342.443 and 352.385 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (90.01) is slightly higher than Ligand B (67.23). Both are below the 140 threshold for oral absorption, but Ligand B is significantly better, especially considering the GPCR target class where lower TPSA is favored.
3. **logP:** Both ligands have good logP values (2.688 and 2.092), falling within the optimal 1-3 range. Ligand B is slightly lower, which could be beneficial for solubility.
4. **HBD:** Ligand A has 2 HBD, while Ligand B has 1. Both are acceptable.
5. **HBA:** Both ligands have 4 HBA, which is within the acceptable limit of 10.
6. **QED:** Both ligands have good QED scores (0.81 and 0.902), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A has a DILI risk of 66.615%, which is concerning (approaching the high-risk threshold). Ligand B has a much lower DILI risk of 40.83%, which is preferable.
8. **BBB:** Ligand A has a BBB penetration of 53.587%, while Ligand B has 92.827%. For a GPCR, even a peripherally acting one like ADRB2, higher BBB is not necessarily *required* but is not detrimental. Ligand B is significantly better here.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.873 and -4.685). This is unusual and suggests poor permeability. However, the values are very close, so this isn't a major differentiator.
10. **Solubility:** Ligand A (-3.832) has worse solubility than Ligand B (-2.57). Better solubility is always preferred.
11. **hERG:** Both ligands have low hERG inhibition risk (0.393 and 0.458). No significant difference.
12. **Cl_mic:** Ligand A has a higher microsomal clearance (64.41) than Ligand B (-10.61). A negative value for Ligand B suggests *very* good metabolic stability, a significant advantage.
13. **t1/2:** Ligand A has a negative in vitro half-life (-1.618), which is not physically meaningful. Ligand B has a half-life of -5.258, also not physically meaningful. Both are poor.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.155 and 0.062). Ligand B is slightly better.
15. **Binding Affinity:** Ligand B (-8.1 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.8 kcal/mol). This is a >1.3 kcal/mol difference, which is substantial and can outweigh minor ADME drawbacks.
**Overall Assessment:**
Ligand B is the clear winner. It has a significantly better safety profile (lower DILI), superior metabolic stability (lower Cl_mic), better solubility, and a much stronger binding affinity. While both have poor Caco-2 and t1/2 values, the superior binding and ADME properties of Ligand B make it the more promising drug candidate. The lower TPSA of Ligand B is also favorable for a GPCR target.
Output:
0
2025-04-17 22:04:01,070 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (a cardiovascular GPCR) drug candidates.
**Ligand A:** [373.475, 129.8 , -0.678, 3. , 5. , 0.588, 19.504, 15.743, -5.646, -1.713, 0.075, 1.682, -22.475, 0.005, -7.9 ]
**Ligand B:** [349.479, 81.33 , 1.418, 2. , 4. , 0.73 , 12.757, 68.36 , -5.174, -1.681, 0.674, -5.849, -24.567, 0.036, -5.6 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (349.479) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (129.8) is higher than Ligand B (81.33). For a cardiovascular GPCR, TPSA isn't *as* critical as for CNS targets, but lower is still preferred for better absorption. Ligand B is significantly better here.
3. **logP:** Ligand A (-0.678) is quite low, potentially hindering membrane permeability. Ligand B (1.418) is within the optimal range (1-3). This is a significant advantage for Ligand B.
4. **HBD:** Both are acceptable (3 and 2 respectively), well within the limit of 5.
5. **HBA:** Both are acceptable (5 and 4 respectively), well within the limit of 10.
6. **QED:** Both are good (0.588 and 0.73), indicating drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (19.504) has a higher DILI risk than Ligand B (12.757). Lower is better, so Ligand B is preferable.
8. **BBB:** Ligand B (68.36) has a much higher BBB penetration potential than Ligand A (15.743). While ADRB2 isn't a CNS target, some off-target CNS effects are always a consideration, and higher BBB is generally less likely to cause these.
9. **Caco-2:** Both have negative values, which is unusual. Assuming these are logP-scale values, lower values indicate poorer permeability. They are comparable.
10. **Solubility:** Both have negative values, which is unusual. Assuming these are logS values, lower values indicate poorer solubility. They are comparable.
11. **hERG:** Ligand A (0.075) has a slightly lower hERG risk than Ligand B (0.674), but both are relatively low.
12. **Cl_mic:** Ligand B (-5.849) has a much lower (better) microsomal clearance than Ligand A (1.682), suggesting greater metabolic stability.
13. **t1/2:** Both have very negative values, indicating very short half-lives. Ligand B (-24.567) is slightly better (less negative).
14. **Pgp:** Ligand A (0.005) has a much lower Pgp efflux liability than Ligand B (0.036), which is favorable for bioavailability.
15. **Affinity:** Ligand A (-7.9) has a slightly better binding affinity than Ligand B (-5.6). This is a 2.3 kcal/mol difference, which is substantial.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity, the significant drawbacks in logP, TPSA, DILI risk, and metabolic stability (Cl_mic) are concerning. Ligand B presents a much more balanced profile. Its superior logP, lower TPSA, lower DILI risk, and significantly better metabolic stability outweigh the slightly weaker binding affinity. For a cardiovascular GPCR, these ADME properties are crucial for *in vivo* efficacy. The higher BBB is a bonus.
**Output:**
0
2025-04-17 22:04:01,070 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (342.447 and 352.41 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (67.98) is better than Ligand B (76.46). Both are below 140, but lower TPSA generally favors absorption.
3. **logP:** Ligand A (2.792) is optimal, while Ligand B (0.614) is a bit low. A logP between 1-3 is preferred, and B is bordering on potentially having permeability issues.
4. **HBD:** Both ligands have 1 HBD, which is ideal.
5. **HBA:** Both ligands have 5 HBA, which is also ideal.
6. **QED:** Ligand A (0.912) has a slightly better QED score than Ligand B (0.814), indicating a more drug-like profile.
7. **DILI:** Both ligands have low DILI risk (44.591 and 41.566 percentile), which is good. No significant difference.
8. **BBB:** Both ligands have very good BBB penetration (92.012 and 94.184 percentile). This is positive, though less critical for a cardiovascular target like ADRB2.
9. **Caco-2:** Both ligands show poor Caco-2 permeability (-4.8 and -4.66). This is a concern for oral bioavailability.
10. **Solubility:** Both ligands have poor solubility (-2.854 and -2.21). This is a significant drawback.
11. **hERG:** Both ligands have low hERG inhibition liability (0.54 and 0.537), which is excellent.
12. **Cl_mic:** Ligand A (22.661 mL/min/kg) has a much lower microsomal clearance than Ligand B (5.082 mL/min/kg), suggesting better metabolic stability.
13. **t1/2:** Ligand B (16.227 hours) has a significantly longer in vitro half-life than Ligand A (2.397 hours). This is a major advantage.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.157 and 0.128).
15. **Binding Affinity:** Ligand B (-6.1 kcal/mol) has a stronger binding affinity than Ligand A (-5.5 kcal/mol). This is a 0.6 kcal/mol difference, which is substantial.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B has a better affinity, and while its logP is lower, the affinity difference is significant enough to potentially overcome that. Both have good Pgp and TPSA values. The longer half-life of Ligand B is also a significant benefit. While both have poor solubility and Caco-2 permeability, the better affinity and half-life of Ligand B make it the more promising candidate.
**Conclusion:**
Despite the solubility and permeability concerns, the stronger binding affinity and longer half-life of Ligand B outweigh the slightly better TPSA and QED of Ligand A.
Output:
0
2025-04-17 22:04:01,070 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (345.443 and 347.463 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (86.34) is slightly higher than Ligand B (61.68). Both are below the 140 threshold for oral absorption, but Ligand B is preferable due to being closer to the 90 threshold for potential CNS penetration (though not a primary concern for ADRB2).
3. **logP:** Ligand A (2.803) is within the optimal 1-3 range. Ligand B (1.06) is at the lower end, potentially impacting permeability. Ligand A is favored here.
4. **HBD:** Ligand A (1) is preferable to Ligand B (0) as a single HBD can aid solubility without drastically impacting permeability.
5. **HBA:** Ligand A (4) and Ligand B (5) are both acceptable, below the 10 threshold.
6. **QED:** Both ligands have similar QED values (0.889 and 0.82), indicating good drug-likeness.
7. **DILI:** Ligand B (34.161) has a significantly lower DILI risk than Ligand A (43.66). This is a substantial advantage for Ligand B.
8. **BBB:** Both ligands have similar BBB penetration (70.919 and 70.027). This isn't a high priority for ADRB2, but it's good that neither is significantly limited.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.568 and -4.719). This indicates poor permeability, which is a concern.
10. **Solubility:** Ligand B (-0.78) has better solubility than Ligand A (-3.638). This is a positive for Ligand B.
11. **hERG:** Ligand A (0.668) has a slightly lower hERG risk than Ligand B (0.303), which is preferable.
12. **Cl_mic:** Ligand B (17.453) has a lower microsomal clearance than Ligand A (21.063), suggesting better metabolic stability.
13. **t1/2:** Both ligands have similar in vitro half-lives (20.565 and 20.28 hours).
14. **Pgp:** Ligand A (0.322) has lower P-gp efflux than Ligand B (0.081), which is preferable.
15. **Binding Affinity:** Ligand A (-7.9 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.1 kcal/mol). This is a substantial advantage for Ligand A, potentially outweighing some ADME concerns.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has a better logP and Pgp efflux profile, but Ligand B has a better TPSA and significantly lower DILI risk. The difference in binding affinity is substantial (1.8 kcal/mol), and this is a strong driver for selection.
**Overall Assessment:**
While Ligand B has advantages in DILI risk, solubility, and metabolic stability, the significantly stronger binding affinity of Ligand A (-7.9 vs -6.1 kcal/mol) is a critical factor. The difference in binding is large enough to potentially overcome the slightly higher DILI risk and lower solubility. The similar BBB penetration and acceptable TPSA values for both compounds further support prioritizing the higher affinity ligand.
Output:
1
2025-04-17 22:04:01,070 - INFO - Batch 304 complete. Total preferences: 4864
2025-04-17 22:04:01,071 - INFO - Processing batch 305/512...
2025-04-17 22:04:50,182 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (344.415 and 345.443 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (80.49) is slightly higher than Ligand B (70.67). Both are below the 140 A^2 threshold for good oral absorption, and acceptable for a non-CNS GPCR target like ADRB2. Ligand B is preferable.
3. **logP:** Both ligands have good logP values (1.5 and 1.194 respectively), falling within the optimal 1-3 range. Ligand B is slightly better.
4. **HBD:** Ligand A (1) is better than Ligand B (2). Lower HBD is generally preferred for better permeability.
5. **HBA:** Ligand A (6) is better than Ligand B (4). Lower HBA is generally preferred for better permeability.
6. **QED:** Both ligands have similar and good QED scores (0.767 and 0.787), indicating good drug-like properties.
7. **DILI:** Ligand B (17.836) has a significantly lower DILI risk than Ligand A (46.646). This is a major advantage for Ligand B.
8. **BBB:** Ligand A (74.874) has better BBB penetration than Ligand B (63.474), but BBB is not a high priority for ADRB2, a cardiovascular target.
9. **Caco-2:** Ligand A (-5.153) and Ligand B (-4.9) are both poor.
10. **Solubility:** Ligand A (-1.47) and Ligand B (-1.301) are both poor.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.217 and 0.259 respectively), which is excellent.
12. **Cl_mic:** Ligand B (-13.232) has a much lower (better) microsomal clearance than Ligand A (18.178), suggesting better metabolic stability.
13. **t1/2:** Ligand B (16.792) has a significantly longer in vitro half-life than Ligand A (-1.36). This is a significant advantage.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.074 and 0.035).
15. **Binding Affinity:** Ligand B (-8.1) has a significantly stronger binding affinity than Ligand A (-6.1). This is a substantial advantage, potentially outweighing minor ADME concerns.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP, has a better TPSA, comparable Pgp, and *much* better affinity. The lower DILI and improved metabolic stability (Cl_mic and t1/2) further strengthen its profile.
**Conclusion:**
Ligand B is the superior candidate due to its significantly better binding affinity, lower DILI risk, improved metabolic stability, and slightly better physicochemical properties. While Ligand A has a slightly better BBB score, this is not a critical factor for a cardiovascular target like ADRB2.
Output:
0
2025-04-17 22:04:50,182 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (351.435 and 351.491 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (71.01) is better than Ligand B (78.51). Both are below 140, but lower TPSA generally favors absorption.
3. **logP:** Ligand A (2.597) is slightly better than Ligand B (1.55). Both are within the optimal 1-3 range, but Ligand B is closer to the lower bound which could affect permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (6) is preferable to Ligand B (3). Fewer HBAs generally improve permeability.
6. **QED:** Ligand A (0.782) is significantly better than Ligand B (0.651), indicating a more drug-like profile.
7. **DILI:** Ligand A (71.229) has a considerably higher DILI risk than Ligand B (13.067). This is a major concern for Ligand A.
8. **BBB:** Both ligands have similar BBB penetration (Ligand A: 69.407, Ligand B: 70.803). This is less critical for a cardiovascular target like ADRB2, but still a consideration.
9. **Caco-2:** Both ligands have similar, poor Caco-2 permeability (-5.204 and -5.105).
10. **Solubility:** Ligand A (-2.815) has slightly worse solubility than Ligand B (-1.761).
11. **hERG:** Both ligands have low hERG inhibition risk (0.412 and 0.322).
12. **Cl_mic:** Ligand A (72.301) has higher microsomal clearance than Ligand B (37.168), suggesting lower metabolic stability.
13. **t1/2:** Ligand B (-13.19) has a significantly longer in vitro half-life than Ligand A (-8.365). This is a significant advantage for Ligand B.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.112 and 0.015).
15. **Binding Affinity:** Ligand A (-6.7) has a slightly better binding affinity than Ligand B (-5.6), a difference of 1.1 kcal/mol.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. While Ligand A has a slightly better affinity, the significantly higher DILI risk and higher clearance are major drawbacks. Ligand B, while having slightly less favorable logP and TPSA, presents a much better safety profile (DILI) and metabolic stability (t1/2, Cl_mic). The affinity difference, while present, is not large enough to overcome these ADME/Tox concerns.
**Conclusion:**
Considering the balance of properties, and prioritizing safety and metabolic stability for a cardiovascular target, Ligand B is the more promising drug candidate.
Output:
0
2025-04-17 22:04:50,182 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (343.427 and 346.471 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (75.44) is slightly higher than Ligand B (58.64). Both are below the 140 threshold for oral absorption, but Ligand B is better positioned, especially considering ADRB2 is a GPCR and lower TPSA is generally favored.
3. **logP:** Both ligands (2.15 and 2.267) are within the optimal 1-3 range. No significant difference.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 4 HBA, while Ligand B has 3. Both are acceptable (<=10).
6. **QED:** Ligand A (0.831) has a slightly better QED score than Ligand B (0.72), indicating a more drug-like profile.
7. **DILI:** Ligand A (31.136) has a slightly higher DILI risk than Ligand B (25.126), but both are well below the concerning threshold of 60.
8. **BBB:** Ligand B (70.415) has a slightly better BBB penetration percentile than Ligand A (67.235). While ADRB2 isn't strictly a CNS target, some CNS exposure can be relevant for off-target effects, and higher BBB is generally preferable.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.664 and -4.882), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Both ligands have very poor aqueous solubility (-3.081 and -3.03). This is a major drawback for both compounds.
11. **hERG:** Ligand A (0.093) has a slightly lower hERG inhibition liability than Ligand B (0.381), which is favorable.
12. **Cl_mic:** Ligand B (65.432) has a significantly higher microsomal clearance than Ligand A (5.664). This indicates Ligand A is much more metabolically stable.
13. **t1/2:** Ligand A (-2.317) has a negative in vitro half-life, which is concerning. Ligand B (0.783) is positive, suggesting a reasonable half-life.
14. **Pgp:** Ligand A (0.057) has a lower P-gp efflux liability than Ligand B (0.107), which is better for bioavailability.
15. **Binding Affinity:** Both ligands have the same binding affinity (-6.7 kcal/mol), so this parameter doesn't differentiate them.
**Overall Assessment:**
Both ligands have significant issues with solubility and Caco-2 permeability. However, Ligand A has a better QED, lower DILI, lower hERG, lower P-gp efflux, and *much* better metabolic stability (lower Cl_mic). Ligand B has a slightly better BBB penetration and a more reasonable in vitro half-life. Given the importance of metabolic stability for *in vivo* efficacy and the relatively minor advantage of Ligand B's half-life and BBB, I favor Ligand A. The poor solubility and permeability would need to be addressed through formulation or prodrug strategies, but the better ADME profile of Ligand A provides a stronger starting point for optimization.
Output:
1
2025-04-17 22:04:50,183 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [345.447, 80.12, 1.069, 1, 5, 0.764, 33.23, 58.511, -5.111, -1.188, 0.053, 6.333, 14.585, 0.035, -7.2]
**Ligand B:** [368.499, 82.89, 1.584, 2, 6, 0.76, 39.24, 41.644, -5.094, -2.382, 0.22, 20.597, 41.512, 0.056, -6]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (345.447) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are good (below 140), suggesting reasonable oral absorption. Ligand A (80.12) is slightly better.
3. **logP:** Both are within the optimal range (1-3). Ligand A (1.069) is closer to the lower end, while Ligand B (1.584) is a bit higher.
4. **HBD:** Ligand A (1) is better than Ligand B (2). Lower HBD is generally preferred for permeability.
5. **HBA:** Ligand A (5) is better than Ligand B (6). Lower HBA is generally preferred for permeability.
6. **QED:** Both have similar, good QED scores (0.764 and 0.76), indicating good drug-like properties.
7. **DILI:** Both are acceptable, with Ligand A (33.23) having a slightly lower risk than Ligand B (39.24).
8. **BBB:** Ligand A (58.511) is better than Ligand B (41.644), although neither are particularly high. Since ADRB2 is a cardiovascular target, BBB penetration isn't *critical*, but some level is still beneficial for potential off-target effects and distribution.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-5.111) is slightly better than Ligand B (-5.094).
10. **Solubility:** Both are negative, indicating poor solubility. Ligand A (-1.188) is slightly better than Ligand B (-2.382).
11. **hERG:** Both have very low hERG risk (0.053 and 0.22). This is excellent.
12. **Cl_mic:** Ligand A (6.333) has significantly lower microsomal clearance than Ligand B (20.597), indicating better metabolic stability.
13. **t1/2:** Ligand A (14.585) has a shorter half-life than Ligand B (41.512), but still reasonable.
14. **Pgp:** Both have low Pgp efflux liability (0.035 and 0.056).
15. **Affinity:** Ligand A (-7.2) has a significantly stronger binding affinity than Ligand B (-6). This is a substantial advantage.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A excels in affinity, has slightly better logP and TPSA, and comparable Pgp efflux. The improved metabolic stability (lower Cl_mic) is also a significant benefit. While both have poor Caco-2 and solubility, the superior binding affinity of Ligand A can potentially compensate for these drawbacks, especially if formulation strategies can be employed.
**Conclusion:**
Ligand A is the more promising candidate due to its substantially better binding affinity and improved metabolic stability, despite similar ADME properties overall. The slightly better TPSA, logP, and lower DILI risk further support this choice.
**Output:**
1
2025-04-17 22:04:50,183 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (360.4) is slightly higher than Ligand B (339.4), but both are acceptable.
2. **TPSA:** Ligand A (135.8) is borderline for good oral absorption, while Ligand B (62.3) is well below the 140 threshold and excellent. This favors Ligand B.
3. **logP:** Both ligands have good logP values (A: 1.057, B: 1.921) within the optimal 1-3 range. Ligand B is slightly better positioned.
4. **HBD:** Ligand A has 3 HBD, which is acceptable. Ligand B has only 1, which is even better for permeability.
5. **HBA:** Ligand A has 6 HBA, acceptable. Ligand B has 3, which is also good.
6. **QED:** Both ligands have good QED scores (A: 0.625, B: 0.891), indicating drug-likeness. Ligand B is better here.
7. **DILI:** Ligand A has a concerningly high DILI risk (96.51%), while Ligand B has a much lower risk (16.789%). This is a major advantage for Ligand B.
8. **BBB:** Ligand B has a significantly higher BBB penetration percentile (76.347%) than Ligand A (40.791%). Given that ADRB2 is a GPCR, BBB penetration is a desirable property, although not critical for cardiovascular targets.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
10. **Solubility:** Both ligands have negative solubility values, which is also unusual. Again, the scale is unknown, making interpretation difficult.
11. **hERG:** Both ligands have low hERG inhibition liability (A: 0.227, B: 0.263), which is good.
12. **Cl_mic:** Ligand B has a lower microsomal clearance (11.088) than Ligand A (17.505), indicating better metabolic stability.
13. **t1/2:** Ligand B has a longer in vitro half-life (-12.697) than Ligand A (-17.169), which is preferable.
14. **Pgp:** Both ligands have low P-gp efflux liability (A: 0.04, B: 0.06).
15. **Affinity:** Ligand B has a significantly stronger binding affinity (-7.8 kcal/mol) compared to Ligand A (-5.4 kcal/mol). This is a substantial advantage.
**Overall Assessment:**
Ligand B is clearly superior. It has a much lower DILI risk, better BBB penetration, better metabolic stability (lower Cl_mic, longer t1/2), and significantly stronger binding affinity. While both have unusual Caco-2 and solubility values, the overall profile of Ligand B is far more favorable for development as a drug candidate targeting ADRB2. The affinity difference is substantial enough to outweigh any minor concerns.
Output:
0
2025-04-17 22:04:50,183 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (343.471 Da) is within the ideal range (200-500 Da). Ligand B (374.507 Da) is also acceptable. No clear advantage here.
2. **TPSA:** Ligand A (56.41) is excellent, well below the 140 threshold for oral absorption and favorable for GPCRs. Ligand B (107.61) is higher, but still within a reasonable range, though less optimal. Ligand A is better.
3. **logP:** Ligand A (3.052) is optimal (1-3). Ligand B (-0.436) is significantly lower, potentially causing permeability issues. Ligand A is much better.
4. **HBD:** Ligand A (1) is good. Ligand B (3) is higher, potentially impacting permeability. Ligand A is better.
5. **HBA:** Ligand A (2) is good. Ligand B (5) is higher. Ligand A is better.
6. **QED:** Ligand A (0.836) is excellent, indicating high drug-likeness. Ligand B (0.534) is acceptable, but lower. Ligand A is better.
7. **DILI:** Both ligands have low DILI risk (Ligand A: 31.834, Ligand B: 30.206), both are well below the 40 threshold. No clear advantage.
8. **BBB:** Ligand A (68.36) is reasonable, but not outstanding. Ligand B (40.403) is lower, suggesting limited brain penetration. While ADRB2 isn't necessarily a CNS target, some peripheral ADRB2 receptors benefit from some degree of CNS exposure. Ligand A is better.
9. **Caco-2:** Ligand A (-4.56) is very poor. Ligand B (-5.823) is also very poor. Both are problematic, but similar.
10. **Solubility:** Ligand A (-2.477) is poor. Ligand B (-1.365) is also poor, but slightly better. Ligand B is slightly better.
11. **hERG:** Both ligands have very low hERG risk (Ligand A: 0.372, Ligand B: 0.127). Ligand B is slightly better.
12. **Cl_mic:** Ligand A (53.409) is moderate. Ligand B (6.296) is very low, indicating better metabolic stability. Ligand B is significantly better.
13. **t1/2:** Ligand A (-18.816) is very poor. Ligand B (-38.517) is even worse. Both are problematic, but Ligand B is worse.
14. **Pgp:** Both ligands have very low Pgp efflux (Ligand A: 0.219, Ligand B: 0.007). Ligand B is slightly better.
15. **Affinity:** Both ligands have similar and good binding affinity (Ligand A: -6.6 kcal/mol, Ligand B: -6.2 kcal/mol). The difference is less than 1.5 kcal/mol, so it doesn't outweigh other factors.
**Overall Assessment:**
Ligand A has a superior profile across several key parameters, especially logP, TPSA, QED, and H-bonding characteristics. While both have poor Caco-2 and solubility, Ligand A's better permeability prediction (based on logP and TPSA) and drug-likeness make it more promising. Ligand B's only significant advantage is its lower microsomal clearance, but this is outweighed by its poor logP and higher TPSA. The slightly better Pgp and hERG for Ligand B are not enough to overcome the other deficiencies.
Output:
1
2025-04-17 22:04:50,183 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (369.759 Da) is within the ideal range, while Ligand B (338.451 Da) is slightly below, but still acceptable.
2. **TPSA:** Ligand A (95.15) is slightly above the optimal <140 for oral absorption, but not dramatically. Ligand B (75.35) is very good.
3. **logP:** Both ligands (A: 2.199, B: 2.74) are within the optimal 1-3 range.
4. **HBD:** Ligand A (4) and Ligand B (3) are both acceptable.
5. **HBA:** Ligand A (4) and Ligand B (3) are both acceptable.
6. **QED:** Ligand B (0.758) has a significantly better QED score than Ligand A (0.491), indicating better overall drug-likeness.
7. **DILI:** Ligand B (15.626) has a much lower DILI risk than Ligand A (96.161). This is a major advantage for Ligand B.
8. **BBB:** Ligand A (53.393) and Ligand B (49.67) are both relatively low, indicating limited BBB penetration. Since ADRB2 is a cardiovascular target, BBB penetration is not a high priority.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.869 and -4.936), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Both ligands have negative solubility values (-4.252 and -2.647), indicating poor aqueous solubility. This is a significant drawback for both.
11. **hERG:** Ligand A (0.114) has a slightly better hERG profile than Ligand B (0.731), but both are relatively low risk.
12. **Cl_mic:** Ligand B (3.31) has significantly lower microsomal clearance than Ligand A (11.715), suggesting better metabolic stability.
13. **t1/2:** Ligand A (53.96) has a longer in vitro half-life than Ligand B (8.932).
14. **Pgp:** Ligand A (0.018) has a much lower P-gp efflux liability than Ligand B (0.307), suggesting better absorption and bioavailability.
15. **Binding Affinity:** Ligand B (-6.9 kcal/mol) has a substantially stronger binding affinity than Ligand A (-3.6 kcal/mol). This is a very significant advantage.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand B excels in affinity and has a better logP and lower Pgp efflux. While TPSA is good for both, the superior affinity and significantly lower DILI risk of Ligand B outweigh the slightly higher TPSA. The poor Caco-2 and solubility are concerning for both, but the strong binding of Ligand B makes it more likely to be effective even with reduced absorption.
**Conclusion:**
Ligand B is the more promising candidate due to its significantly stronger binding affinity, lower DILI risk, and better metabolic stability. The lower P-gp efflux is also a positive. While both have issues with solubility and permeability, the potency advantage of Ligand B is substantial enough to make it the preferred choice.
Output:
0
2025-04-17 22:04:50,183 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, the key priorities are logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB.
Let's break down the comparison:
1. **Molecular Weight:** Both ligands (363.443 and 346.471 Da) fall within the ideal 200-500 Da range.
2. **TPSA:** Ligand B (60.85) is significantly better than Ligand A (113.08). Lower TPSA generally improves oral absorption, a crucial factor for a cardiovascular drug.
3. **logP:** Both ligands have good logP values (1.619 and 1.929), falling within the optimal 1-3 range.
4. **H-Bond Donors/Acceptors:** Ligand B has fewer HBDs (1 vs 3) and HBAs (3 vs 6), which is generally preferable for better permeability.
5. **QED:** Both have acceptable QED scores (0.696 and 0.849), indicating good drug-like properties.
6. **DILI:** Ligand B (6.359) has a much lower DILI risk than Ligand A (90.733). This is a significant advantage.
7. **BBB:** Ligand B (77.549) has a higher BBB penetration score than Ligand A (50.679), though for a cardiovascular target, this is less critical than for CNS targets.
8. **Caco-2 Permeability:** Ligand B (-4.614) is better than Ligand A (-5.311), indicating better intestinal absorption.
9. **Aqueous Solubility:** Both have similar poor aqueous solubility (-2.922 and -2.246).
10. **hERG Inhibition:** Both ligands have low hERG inhibition liability (0.123 and 0.251).
11. **Microsomal Clearance:** Ligand A (4.388) has lower microsomal clearance than Ligand B (13.281), suggesting better metabolic stability.
12. **In vitro Half-Life:** Ligand A (41.396) has a longer half-life than Ligand B (0.236).
13. **P-gp Efflux:** Both have low P-gp efflux liability (0.062 and 0.053).
14. **Binding Affinity:** Ligand B (-7.2 kcal/mol) has a slightly better binding affinity than Ligand A (-7.0 kcal/mol), but the difference is relatively small.
**Overall Assessment:**
Ligand B is the stronger candidate. While Ligand A has better metabolic stability and half-life, Ligand B's superior TPSA, lower DILI risk, better Caco-2 permeability, and slightly improved binding affinity outweigh these drawbacks. The lower TPSA and DILI risk are particularly important for a cardiovascular drug. The small difference in binding affinity is not enough to overcome the other advantages of Ligand B.
**Output:**
0
2025-04-17 22:04:50,184 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (345.487 and 344.411 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (54.34) is significantly better than Ligand B (85.94). For a GPCR, keeping TPSA low is beneficial for permeability, and A is well below the 90 A^2 threshold. B is approaching a level that could hinder absorption.
3. **logP:** Ligand A (3.144) is optimal, while Ligand B (1.205) is a bit low. A logP between 1-3 is preferred, and B is at the lower end, potentially impacting membrane permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (5) for the same reason as HBD.
6. **QED:** Ligand A (0.891) is better than Ligand B (0.759), indicating a more drug-like profile.
7. **DILI:** Ligand A (20.434) has a much lower DILI risk than Ligand B (14.618). This is a significant advantage for A.
8. **BBB:** Ligand A (78.054) is better than Ligand B (67.197), although both are not exceptionally high. For a cardiovascular target, BBB penetration isn't *critical*, but it's still a positive.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-4.67) is slightly better than Ligand B (-4.934).
10. **Solubility:** Both are negative, indicating poor solubility. Ligand A (-2.628) is slightly better than Ligand B (-2.289).
11. **hERG:** Ligand A (0.382) is significantly better than Ligand B (0.65). Lower hERG inhibition is crucial to avoid cardiotoxicity, especially for a cardiovascular target.
12. **Cl_mic:** Ligand A (40.455) has a lower microsomal clearance than Ligand B (6.336), indicating better metabolic stability.
13. **t1/2:** Ligand B (65.414) has a much longer in vitro half-life than Ligand A (9.216). This is a significant advantage for B.
14. **Pgp:** Ligand A (0.148) has lower P-gp efflux than Ligand B (0.051), which is preferable.
15. **Binding Affinity:** Ligand A (-6.2) has a significantly stronger binding affinity than Ligand B (-1.5). This is a major advantage for A, potentially outweighing some of the ADME drawbacks.
**Overall Assessment:**
Ligand A is clearly the superior candidate. While Ligand B has a better half-life, Ligand A excels in almost all other critical parameters, especially binding affinity, DILI risk, hERG inhibition, TPSA, logP, and QED. The stronger binding affinity of Ligand A is a substantial advantage for a GPCR target. The lower DILI and hERG risks are also very important for a cardiovascular drug. Although both have poor Caco-2 and solubility, the other advantages of A outweigh this.
Output:
1
2025-04-17 22:04:50,184 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (341.455 Da) is within the ideal range, while Ligand B (366.615 Da) is slightly higher but still acceptable. No clear advantage here.
2. **TPSA:** Ligand A (62.3) is good, suggesting reasonable permeability. Ligand B (23.55) is excellent, potentially leading to better absorption and distribution. This favors Ligand B.
3. **logP:** Ligand A (2.479) is optimal. Ligand B (4.722) is pushing the upper limit, potentially causing solubility issues or off-target interactions. This favors Ligand A.
4. **HBD:** Ligand A (1) is good. Ligand B (0) is also good. No significant difference.
5. **HBA:** Both ligands have 3 HBA, which is acceptable.
6. **QED:** Ligand A (0.829) is excellent, indicating high drug-likeness. Ligand B (0.581) is still acceptable, but less optimal. This favors Ligand A.
7. **DILI:** Ligand A (21.714) has a very low DILI risk. Ligand B (8.802) also has a low DILI risk, but slightly higher than Ligand A. This favors Ligand A.
8. **BBB:** Ligand A (71.888) shows good BBB penetration. Ligand B (88.329) is even better, which is particularly important for GPCR targets. This strongly favors Ligand B.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and indicates poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand A (-2.069) has poor solubility. Ligand B (-4.24) is even worse. Both are problematic, but Ligand B is more concerning.
11. **hERG:** Both ligands have low hERG inhibition liability (0.433 and 0.736 respectively), which is good.
12. **Cl_mic:** Ligand A (56.703) has moderate clearance, while Ligand B (122.513) has high clearance, indicating faster metabolism. This favors Ligand A.
13. **t1/2:** Ligand A (-21.805) has a negative half-life, which is not possible and indicates a problem with the data or the molecule. Ligand B (35.112) has a reasonable half-life. This strongly favors Ligand B.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.168 and 0.516 respectively), which is good.
15. **Affinity:** Both ligands have very similar and strong binding affinities (-6.4 and -6.6 kcal/mol). The difference is negligible.
**GPCR-specific considerations:**
For a GPCR like ADRB2, BBB penetration, logP, and affinity are crucial. Ligand B excels in BBB penetration and has a reasonable logP. While Ligand A has a better QED and lower DILI, the poor solubility and negative half-life are major red flags. The slightly higher logP of Ligand B is less concerning than the solubility and stability issues with Ligand A.
**Overall Assessment:**
Despite the poor Caco-2 and solubility scores for both, Ligand B is the more promising candidate due to its superior BBB penetration, better metabolic stability (lower Cl_mic, positive t1/2), and comparable affinity. The negative half-life for Ligand A is a critical issue.
Output:
0
2025-04-17 22:04:50,184 - INFO - Here's my reasoning and the final output:
**Reasoning:**
We are evaluating two ligands for the ADRB2, a cardiovascular GPCR. Therefore, we prioritize logP, Pgp, TPSA, and affinity, alongside general drug-like properties.
* **Molecular Weight:** Both ligands are within the ideal range (200-500 Da).
* **TPSA:** Ligand B (42.43) is significantly better than Ligand A (80.23). Lower TPSA generally correlates with better cell permeability, crucial for GPCR targeting.
* **logP:** Ligand A (1.455) is optimal, while Ligand B (3.846) is approaching the upper limit. While still acceptable, higher logP can sometimes lead to off-target effects.
* **H-Bond Donors/Acceptors:** Both are within acceptable ranges.
* **QED:** Ligand A (0.857) has a better QED score than Ligand B (0.769), indicating a more drug-like profile.
* **DILI:** Both have relatively low DILI risk (Ligand A: 49.128, Ligand B: 43.971), which is good.
* **BBB:** Ligand B (89.531) has a much higher BBB penetration percentile than Ligand A (68.127). While ADRB2 is a cardiovascular target, some CNS exposure can be relevant for side effect profiles, and higher BBB is generally favorable.
* **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so the absolute values are difficult to interpret.
* **Solubility:** Both have negative solubility values, which is also unusual. Again, the scale is not specified, making interpretation difficult.
* **hERG:** Both have low hERG inhibition liability, which is excellent.
* **Cl_mic:** Ligand A (18.89) has significantly lower microsomal clearance than Ligand B (87.11), suggesting better metabolic stability.
* **t1/2:** Ligand A (36.688) has a much longer in vitro half-life than Ligand B (4.342), which is a significant advantage.
* **Pgp:** Ligand A (0.174) has much lower P-gp efflux liability than Ligand B (0.693), indicating better oral bioavailability and potentially better CNS exposure.
* **Binding Affinity:** Ligand B (-8.0 kcal/mol) has a slightly better binding affinity than Ligand A (-7.4 kcal/mol). This is a 0.6 kcal/mol difference, which is notable but not overwhelmingly decisive.
**Overall Assessment:**
Despite Ligand B's slightly better binding affinity and BBB penetration, Ligand A presents a more balanced profile. Its superior QED, significantly lower Cl_mic, longer half-life, and lower Pgp efflux liability are substantial advantages. The TPSA of Ligand A is higher, but the other ADME properties are more compelling. The slightly lower affinity of Ligand A can likely be optimized in subsequent iterations of drug design.
**Output:**
1
2025-04-17 22:04:50,184 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (352.523 and 367.563 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Both ligands have TPSA values (55.89 and 54.26) below the 140 A^2 threshold for good oral absorption. They are also reasonably low, which is favorable for GPCR ligands. No clear advantage.
**3. logP:** Ligand A (1.166) is closer to the optimal 1-3 range than Ligand B (2.277). While both are acceptable, Ligand A's logP is slightly preferred.
**4. H-Bond Donors:** Ligand A has 1 HBD, while Ligand B has 0. Both are within the acceptable limit of <=5.
**5. H-Bond Acceptors:** Ligand A has 4 HBA, and Ligand B has 6. Both are within the acceptable limit of <=10.
**6. QED:** Both ligands have similar QED values (0.712 and 0.772), indicating good drug-like properties.
**7. DILI:** Ligand A (6.747%) has a significantly lower DILI risk than Ligand B (33.463%). This is a major advantage for Ligand A.
**8. BBB:** Both ligands have similar BBB penetration (54.556% and 56.146%). While not exceptionally high, it's not a primary concern for ADRB2, which isn't necessarily a CNS target.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.885 and -4.895). This is unusual and suggests poor permeability.
**10. Aqueous Solubility:** Ligand A (-0.897) has slightly better solubility than Ligand B (-2.416).
**11. hERG Inhibition:** Ligand A (0.619) has a lower hERG inhibition liability than Ligand B (0.295), which is a significant safety advantage.
**12. Microsomal Clearance:** Ligand B (57.355) has a higher microsomal clearance than Ligand A (12.918), indicating lower metabolic stability. This is a significant disadvantage for Ligand B.
**13. In vitro Half-Life:** Ligand A (-7.078) has a much longer in vitro half-life than Ligand B (4.875). This is a major advantage for Ligand A.
**14. P-gp Efflux:** Ligand A (0.009) has a much lower P-gp efflux liability than Ligand B (0.071). This is a significant advantage for Ligand A.
**15. Binding Affinity:** Ligand B (-6.1 kcal/mol) has a slightly better binding affinity than Ligand A (-5.7 kcal/mol). While a difference of 0.4 kcal/mol is noticeable, it's not a huge difference, and can be overcome by other favorable properties.
**Overall Assessment:**
Ligand A is the stronger candidate. While Ligand B has slightly better binding affinity, Ligand A demonstrates superior ADMET properties. Specifically, the significantly lower DILI risk, better hERG profile, lower microsomal clearance (longer half-life), and lower P-gp efflux make it a much more promising drug candidate. The solubility is also slightly better. The Caco-2 permeability is concerning for both, but the other advantages of Ligand A outweigh this drawback.
Output:
1
2025-04-17 22:04:50,184 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [361.423, 101.41 , 2.205, 2. , 6. , 0.847, 94.649, 31.795, -5.572, -3.036, 0.02 , -14.429, 4.205, 0.01 , -6.9 ]**
**Ligand B: [343.387, 101.22 , 1.718, 1. , 6. , 0.907, 71.229, 68.205, -5.035, -2.632, 0.209, 22.989, -4.674, 0.031, -7.2 ]**
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand B (343.387) is slightly smaller, which could be marginally better for permeability, but the difference isn't substantial.
2. **TPSA:** Both ligands have TPSA values around 101, which is slightly above the optimal <140 for oral absorption, but acceptable. Not a major differentiator.
3. **logP:** Ligand A (2.205) is slightly higher than Ligand B (1.718), placing it closer to the optimal 1-3 range. Ligand B is a bit low, potentially hindering permeation.
4. **H-Bond Donors:** Ligand A has 2 HBD, and Ligand B has 1. Both are within the acceptable limit of <=5. Ligand B is slightly better.
5. **H-Bond Acceptors:** Both ligands have 6 HBA, which is within the acceptable limit of <=10.
6. **QED:** Both ligands have good QED scores (A: 0.847, B: 0.907), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A has a very high DILI risk (94.649%), which is a significant concern. Ligand B has a much lower DILI risk (71.229%), making it substantially safer in this regard.
8. **BBB:** Ligand B has a higher BBB penetration percentile (68.205%) than Ligand A (31.795%). While ADRB2 isn't exclusively a CNS target, some CNS exposure can occur, and higher BBB penetration is generally favorable.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability.
10. **Aqueous Solubility:** Both have negative solubility values, which is also unusual and suggests poor solubility.
11. **hERG:** Ligand A has a very low hERG inhibition liability (0.02%), which is excellent. Ligand B has a slightly higher, but still low, hERG risk (0.209%).
12. **Microsomal Clearance:** Ligand A has a very high microsomal clearance (-14.429), indicating poor metabolic stability. Ligand B has a more reasonable clearance (22.989).
13. **In vitro Half-Life:** Ligand B has a longer in vitro half-life (-4.674) than Ligand A (4.205).
14. **P-gp Efflux:** Both have very low P-gp efflux liability (A: 0.01, B: 0.031), which is good.
15. **Binding Affinity:** Ligand B (-7.2 kcal/mol) has a slightly better binding affinity than Ligand A (-6.9 kcal/mol). This difference is significant enough to consider, but not overwhelming.
**Overall Assessment:**
Ligand A has a strong hERG profile but suffers from extremely high DILI risk and poor metabolic stability. These are major liabilities. Ligand B, while having slightly lower affinity and logP, demonstrates a much more favorable safety profile (lower DILI) and better metabolic stability. For a GPCR target like ADRB2, balancing potency with ADME-Tox properties is crucial. The lower DILI and better metabolic stability of Ligand B outweigh the slightly weaker binding affinity.
Output:
0
2025-04-17 22:04:50,185 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (345.393 and 346.471 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (36.44) is significantly better than Ligand B (62.55). ADRB2 is a cardiovascular target, not a CNS target, but lower TPSA generally improves absorption. Ligand A is well below the 140 threshold, while Ligand B is approaching it.
3. **logP:** Both ligands have good logP values (3.016 and 3.23), falling within the optimal 1-3 range. No strong preference.
4. **HBD:** Ligand A (0) is preferable to Ligand B (1). Fewer HBDs generally correlate with better membrane permeability.
5. **HBA:** Both ligands have the same number of HBA (3).
6. **QED:** Ligand A (0.858) has a slightly better QED score than Ligand B (0.786), indicating a more drug-like profile.
7. **DILI:** Ligand A (35.479) has a considerably higher DILI risk than Ligand B (21.908). This is a significant drawback for Ligand A.
8. **BBB:** This is less critical for a cardiovascular target, but Ligand A (96.937) has a higher BBB penetration percentile than Ligand B (55.874).
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.544 and -4.615), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Both ligands have negative solubility values (-2.533 and -2.289), which is also concerning.
11. **hERG:** Ligand A (0.945) has a slightly higher hERG inhibition liability than Ligand B (0.441), indicating a slightly higher risk of cardiotoxicity.
12. **Cl_mic:** Ligand B (68.798) has a higher microsomal clearance than Ligand A (55.621), meaning Ligand A is more metabolically stable.
13. **t1/2:** Ligand B (73.259) has a significantly longer in vitro half-life than Ligand A (-15.918). This is a major advantage for Ligand B.
14. **Pgp:** Ligand A (0.635) has a lower P-gp efflux liability than Ligand B (0.259), which is favorable.
15. **Binding Affinity:** Both ligands have very similar and strong binding affinities (-7.3 and -7.0 kcal/mol). The difference is less than the 1.5 kcal/mol threshold.
**Overall Assessment:**
While Ligand A has advantages in TPSA, QED, metabolic stability, and P-gp efflux, Ligand B is superior regarding DILI risk and *significantly* better in terms of in vitro half-life. The DILI risk associated with Ligand A is a major concern, and the longer half-life of Ligand B is a substantial benefit for a cardiovascular drug. The similar binding affinities make the ADME properties the deciding factors. The negative Caco-2 and solubility values are concerning for both, but the other advantages of Ligand B outweigh those of A.
Output:
0
2025-04-17 22:04:50,185 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (430.236 Da) is within the ideal range, while Ligand B (348.487 Da) is towards the lower end but still acceptable.
2. **TPSA:** Ligand A (111.3) is slightly above the preferred <140 for good oral absorption, but not drastically. Ligand B (49.85) is excellent, well below 140.
3. **logP:** Both ligands have good logP values (A: 1.283, B: 2.299), falling within the 1-3 range.
4. **HBD:** Both have 0 HBD, which is good.
5. **HBA:** Ligand A has 8 HBA, acceptable. Ligand B has 3 HBA, also good.
6. **QED:** Both ligands have similar and acceptable QED values (A: 0.675, B: 0.692).
7. **DILI:** Ligand A (96.355) has a significantly higher DILI risk than Ligand B (22.257). This is a major concern for Ligand A.
8. **BBB:** Both have similar BBB penetration (A: 66.46, B: 65.413). While not exceptionally high, it's not a primary concern for ADRB2, a cardiovascular target.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability.
10. **Solubility:** Both have negative solubility values, which is also unusual and suggests poor solubility.
11. **hERG:** Both have low hERG inhibition liability (A: 0.303, B: 0.41), which is good.
12. **Cl_mic:** Ligand B (56.336) has lower microsomal clearance than Ligand A (66.091), indicating better metabolic stability.
13. **t1/2:** Ligand A (37.771) has a longer in vitro half-life than Ligand B (-11.684). This is a positive for Ligand A, but the negative value for B is concerning.
14. **Pgp:** Both have low Pgp efflux liability (A: 0.14, B: 0.145).
15. **Binding Affinity:** Ligand A (-6.7 kcal/mol) has a slightly better binding affinity than Ligand B (-5.0 kcal/mol). This is a 1.7 kcal/mol difference, which is significant.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are important. Both ligands perform well on logP and Pgp. Ligand B has a better TPSA. Ligand A has a better affinity. However, the extremely high DILI risk associated with Ligand A is a critical drawback. The negative Caco-2 and solubility values are also concerning for both.
**Overall Assessment:**
Despite the slightly better affinity of Ligand A, the significantly higher DILI risk outweighs this benefit. The negative Caco-2 and solubility values are also concerning for both, but the DILI risk is a showstopper for Ligand A. Ligand B, while having a slightly weaker affinity, presents a much more favorable safety profile and better metabolic stability.
Output:
0
2025-04-17 22:04:50,185 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (380.495) is slightly higher than Ligand B (346.475), but both are acceptable.
2. **TPSA:** Both are reasonably low (A: 74.77, B: 76.02), suggesting good potential for absorption. Both are well below the 140 A^2 threshold.
3. **logP:** Both ligands have optimal logP values (A: 2.304, B: 1.966), falling within the 1-3 range.
4. **HBD:** Ligand A (1) has a lower HBD count than Ligand B (2), which is slightly preferable.
5. **HBA:** Ligand A (8) has a higher HBA count than Ligand B (4). While both are under the 10 threshold, B is better.
6. **QED:** Ligand A (0.821) has a higher QED score than Ligand B (0.671), indicating a more drug-like profile.
7. **DILI:** Ligand B (25.126) has a significantly lower DILI risk than Ligand A (93.253). This is a major advantage for Ligand B.
8. **BBB:** Both ligands have acceptable BBB penetration (A: 65.529, B: 61.109), but neither is exceptionally high. For a cardiovascular target, BBB penetration isn't a primary concern, but it's still a consideration.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.653 and -4.852). These values are unusual and suggest poor permeability.
10. **Solubility:** Both ligands have negative solubility values (-3.273 and -2.134). These values are also unusual and suggest poor solubility.
11. **hERG:** Ligand A (0.69) has a higher hERG inhibition liability than Ligand B (0.112). Lower is better here, so Ligand B is preferred.
12. **Cl_mic:** Ligand B (39.744) has a lower microsomal clearance than Ligand A (58.746), indicating better metabolic stability.
13. **t1/2:** Ligand A (31.057) has a longer in vitro half-life than Ligand B (-2.88). This is a positive for Ligand A.
14. **Pgp:** Ligand A (0.445) has a lower P-gp efflux liability than Ligand B (0.021). Lower is better, so Ligand A is preferred.
15. **Binding Affinity:** Ligand A (-7.2 kcal/mol) has a stronger binding affinity than Ligand B (-5.6 kcal/mol). This is a significant advantage for Ligand A.
**GPCR-Specific Priorities & Overall Assessment:**
For an ADRB2 GPCR, logP, TPSA, affinity, and metabolic stability are key. Ligand A has a better binding affinity, QED, Pgp efflux, and half-life. However, Ligand B has a significantly lower DILI risk and lower hERG inhibition. The negative Caco-2 and solubility values are concerning for both. The affinity difference is substantial (1.6 kcal/mol), and this often outweighs other concerns, *especially* given the DILI risk associated with Ligand A.
Despite the concerning solubility and permeability data, the much stronger binding affinity of Ligand A is a critical factor for GPCR targets. The lower DILI risk of Ligand B is appealing, but the potency advantage of Ligand A is more important.
Output:
1
2025-04-17 22:04:50,185 - INFO - Batch 305 complete. Total preferences: 4880
2025-04-17 22:04:50,185 - INFO - Processing batch 306/512...
2025-04-17 22:05:36,429 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [347.317, 59.75, 3.147, 0, 4, 0.783, 83.753, 81.698, -3.997, -4.092, 0.421, 13.463, 15.382, 0.422, -7.1]
**Ligand B:** [353.423, 107.37, -0.125, 2, 7, 0.599, 55.176, 51.299, -5.409, -1.091, 0.069, -3.026, 22.03, 0.018, -6]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). A (347.3) is slightly preferred.
2. **TPSA:** A (59.75) is excellent, well below the 140 threshold. B (107.37) is higher, but still acceptable.
3. **logP:** A (3.147) is optimal. B (-0.125) is significantly lower, which is a concern for permeability.
4. **HBD:** A (0) is good. B (2) is acceptable.
5. **HBA:** A (4) is good. B (7) is acceptable, but higher.
6. **QED:** A (0.783) is very good. B (0.599) is acceptable, but lower.
7. **DILI:** A (83.753) is concerningly high. B (55.176) is much better, indicating lower liver injury risk.
8. **BBB:** A (81.698) is excellent. B (51.299) is moderate, but not ideal.
9. **Caco-2:** A (-3.997) is poor. B (-5.409) is even worse. Both have very low Caco-2 permeability.
10. **Solubility:** A (-4.092) is poor. B (-1.091) is better, but still not great.
11. **hERG:** A (0.421) is very low risk. B (0.069) is also very low risk.
12. **Cl_mic:** A (13.463) is moderate. B (-3.026) is excellent, indicating high metabolic stability.
13. **t1/2:** A (15.382) is good. B (22.03) is better, suggesting a longer half-life.
14. **Pgp:** A (0.422) is low efflux, good. B (0.018) is very low efflux, excellent.
15. **Affinity:** A (-7.1) is slightly better than B (-6).
**GPCR-Specific Considerations:**
For an ADRB2 (GPCR), logP, TPSA, Pgp, and affinity are key. A has a better logP and slightly better affinity. B has better Pgp efflux and metabolic stability. The poor Caco-2 and solubility of both are concerning. However, the high DILI risk of A is a major drawback. While BBB is good for A, the significant improvement in metabolic stability (Cl_mic and t1/2) and the lower DILI risk of B are more important for overall developability.
**Conclusion:**
Despite the slightly better affinity of Ligand A, the significantly lower DILI risk and improved metabolic stability of Ligand B make it the more promising candidate. The poor Caco-2 and solubility are issues for both, but can potentially be addressed with formulation strategies. The high DILI risk of A is harder to mitigate.
Output:
0
2025-04-17 22:05:36,429 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (353.491) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (57.78) is significantly better than Ligand B (96.8). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand B's TPSA is relatively high.
3. **logP:** Ligand A (4.617) is higher than Ligand B (1.813). While both are within the acceptable range, Ligand A is approaching the upper limit. Ligand B is on the lower side, which could impact permeability.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1), but both are acceptable.
5. **HBA:** Ligand A (3) is lower than Ligand B (6). This favors Ligand A, as fewer hydrogen bond acceptors generally improve permeability.
6. **QED:** Both ligands have similar and good QED values (0.679 and 0.735).
7. **DILI:** Ligand A (69.794) is slightly higher than Ligand B (64.521), but both are within an acceptable range, suggesting moderate risk.
8. **BBB:** Ligand A (55.487) is higher than Ligand B (48.74), but neither is particularly high. This isn't a major concern for a cardiovascular target.
9. **Caco-2:** Ligand A (-5.472) and Ligand B (-5.319) are both very negative, indicating poor Caco-2 permeability. This is a significant drawback for both.
10. **Solubility:** Ligand A (-5.223) is worse than Ligand B (-2.613). Solubility is a concern for both, but Ligand B is better.
11. **hERG:** Ligand A (0.733) is higher than Ligand B (0.045). This is a significant advantage for Ligand B, as it indicates a much lower risk of cardiotoxicity.
12. **Cl_mic:** Ligand B (6.593) has significantly lower microsomal clearance than Ligand A (73.5). This suggests better metabolic stability for Ligand B.
13. **t1/2:** Ligand B (-12.214) has a much longer in vitro half-life than Ligand A (20.262). This is a major advantage for Ligand B.
14. **Pgp:** Ligand A (0.553) is lower than Ligand B (0.018), indicating less P-gp efflux. This is a slight advantage for Ligand A.
15. **Affinity:** Ligand A (-7.4) has a slightly better binding affinity than Ligand B (-7.2). While this difference is small, it's still a positive for Ligand A.
**Overall Assessment:**
Ligand A has a slightly better binding affinity and Pgp profile, but Ligand B excels in crucial ADME properties. Specifically, Ligand B has significantly better metabolic stability (lower Cl_mic, longer t1/2) and a much lower hERG risk. The solubility is also better for Ligand B. While both have poor Caco-2 permeability, the improved ADME profile of Ligand B, particularly the reduced hERG risk and better metabolic stability, outweighs the slight affinity advantage of Ligand A for a cardiovascular target. The lower TPSA of Ligand A is also a plus.
Output:
1
2025-04-17 22:05:36,430 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.43 and 345.44 Da) fall comfortably within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (67.87) is better than Ligand B (71.53). Both are below 140, but lower is preferable for absorption.
3. **logP:** Both ligands have good logP values (2.43 and 1.95), falling within the 1-3 range. Ligand B is slightly lower, which could potentially affect permeability, but it's not a major concern.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Both have 4 HBA, which is good.
6. **QED:** Both ligands have similar and acceptable QED scores (0.657 and 0.695), indicating good drug-like properties.
7. **DILI:** Ligand B (15.36) has a *much* lower DILI risk than Ligand A (41.33). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (89.03) has better BBB penetration than Ligand B (67.90). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant, and higher BBB is generally favorable.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.65) is slightly worse than Ligand B (-4.24).
10. **Solubility:** Both have negative solubility values, indicating very poor solubility. Ligand B (-1.95) is slightly better than Ligand A (-2.35).
11. **hERG:** Ligand A (0.56) has a slightly higher hERG risk than Ligand B (0.10), which is preferable.
12. **Cl_mic:** Ligand B (53.79) has lower microsomal clearance than Ligand A (61.53), indicating better metabolic stability.
13. **t1/2:** Ligand B (-27.24) has a *much* longer in vitro half-life than Ligand A (1.05). This is a major advantage for Ligand B.
14. **Pgp:** Ligand A (0.15) has lower P-gp efflux than Ligand B (0.01), which is preferable.
15. **Binding Affinity:** Ligand A (-9.0) has a significantly stronger binding affinity than Ligand B (-6.7). This is a substantial advantage for Ligand A. A 2.3 kcal/mol difference is very significant.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, affinity, logP, TPSA, Pgp, and metabolic stability are key. Ligand A excels in binding affinity and Pgp efflux. Ligand B excels in DILI risk, metabolic stability (Cl_mic and t1/2), and has slightly better solubility. The poor Caco-2 and solubility for both are concerning, but the strong binding affinity of Ligand A is a major driver.
**Overall Assessment:**
The significantly stronger binding affinity of Ligand A (-9.0 kcal/mol vs -6.7 kcal/mol) is the most important factor. While Ligand B has advantages in safety (DILI) and pharmacokinetics (t1/2, Cl_mic), the potency advantage of Ligand A is likely to outweigh these concerns, especially given that optimization can potentially address the DILI and PK issues. The poor Caco-2 and solubility are shared issues that would need to be addressed regardless of which lead is chosen.
Output:
1
2025-04-17 22:05:36,430 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (390.527 Da) is slightly higher than Ligand B (346.431 Da), but both are acceptable.
2. **TPSA:** Ligand A (93.64) is slightly above the preferred <90 for CNS targets, but still reasonable for a peripheral GPCR like ADRB2. Ligand B (76.46) is well within the ideal range.
3. **logP:** Ligand A (1.847) is optimal. Ligand B (0.644) is a bit low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (0) is excellent. Ligand B (1) is acceptable.
5. **HBA:** Ligand A (6) is good. Ligand B (5) is also good.
6. **QED:** Both ligands have good QED scores (A: 0.779, B: 0.82), indicating good drug-like properties.
7. **DILI:** Ligand A (60.527) is approaching a concerning level, while Ligand B (17.371) is very favorable. This is a significant advantage for Ligand B.
8. **BBB:** BBB is less critical for ADRB2 (a cardiovascular target). Ligand A (45.715) and Ligand B (78.247) are both reasonable, but B is better.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so the absolute values are hard to interpret.
10. **Solubility:** Both have negative solubility values, which is also unusual. Again, the scale is not specified.
11. **hERG:** Both ligands have very low hERG inhibition risk (A: 0.292, B: 0.226).
12. **Cl_mic:** Ligand B (2.874) has significantly lower microsomal clearance, indicating better metabolic stability than Ligand A (66.576). This is a major advantage.
13. **t1/2:** Ligand B (6.843) has a longer in vitro half-life than Ligand A (-40.005). This is a strong positive for Ligand B.
14. **Pgp:** Both have low P-gp efflux liability (A: 0.072, B: 0.013).
15. **Binding Affinity:** Ligand B (-6.7 kcal/mol) has slightly better binding affinity than Ligand A (-6.4 kcal/mol). While the difference is small, it's still a positive for Ligand B.
**GPCR-specific priorities:** For ADRB2, logP, Pgp, TPSA, and affinity are important. Ligand B performs better on logP, has a slightly better affinity, and similar Pgp/TPSA. The significant advantages of Ligand B in DILI risk and metabolic stability (Cl_mic, t1/2) outweigh the slightly higher TPSA and lower logP.
**Conclusion:**
Ligand B is the more promising candidate due to its significantly lower DILI risk, improved metabolic stability, longer half-life, and slightly better binding affinity.
Output:
0
2025-04-17 22:05:36,430 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (351.491 and 347.459 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (78.51) is slightly higher than Ligand B (65.78). Both are below the 140 threshold for oral absorption, but B is preferable as it's closer to the 90 threshold for potential CNS effects (though ADRB2 isn't strictly a CNS target, lower TPSA is generally beneficial).
3. **logP:** Both ligands have similar logP values (1.55 and 1.558), falling within the optimal 1-3 range. No clear advantage.
4. **HBD:** Ligand A has 2 HBD, while Ligand B has 1. Lower is generally better for permeability, giving a slight edge to Ligand B.
5. **HBA:** Ligand A has 3 HBA, while Ligand B has 4. Similar to HBD, Ligand A is slightly preferable.
6. **QED:** Ligand B (0.883) has a significantly higher QED score than Ligand A (0.651), indicating a more drug-like profile. This is a substantial advantage for Ligand B.
7. **DILI:** Ligand A (13.067%) has a much lower DILI risk than Ligand B (45.328%). This is a major advantage for Ligand A, as minimizing liver toxicity is crucial.
8. **BBB:** Ligand A (70.803%) has a higher BBB penetration score than Ligand B (55.215%). While ADRB2 isn't a primary CNS target, some peripheral ADRB2 activity can influence CNS pathways, and higher BBB penetration isn't necessarily detrimental.
9. **Caco-2:** Ligand A (-5.105) shows better Caco-2 permeability than Ligand B (-4.514). This suggests better intestinal absorption for Ligand A.
10. **Solubility:** Ligand A (-1.761) has slightly better aqueous solubility than Ligand B (-2.148).
11. **hERG:** Both ligands have very low hERG inhibition liability (0.322 and 0.393), indicating a low risk of cardiotoxicity. No significant difference.
12. **Cl_mic:** Ligand B (31.545) has a lower microsomal clearance than Ligand A (37.168), suggesting better metabolic stability. This is a positive for Ligand B.
13. **t1/2:** Ligand B (11.853 hours) has a significantly longer in vitro half-life than Ligand A (-13.19 hours). This is a considerable advantage for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.015 and 0.29). No significant difference.
15. **Binding Affinity:** Ligand B (-6.3 kcal/mol) has a slightly better binding affinity than Ligand A (-5.6 kcal/mol). This 0.7 kcal/mol difference is meaningful, and can outweigh some ADME drawbacks.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Both ligands are good on logP and Pgp. Ligand B has a slightly better affinity and lower TPSA. The biggest differentiating factors are DILI (strongly favors A) and half-life (strongly favors B). The QED score also favors B.
**Overall Assessment:**
While Ligand A has a significantly better safety profile (lower DILI) and slightly better permeability, Ligand B has a superior QED score, longer half-life, and better binding affinity. The improved binding affinity and half-life are particularly important for a GPCR target, and the higher QED suggests a more generally drug-like molecule. The DILI risk for Ligand B is still within an acceptable range.
Output:
0
2025-04-17 22:05:36,430 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (359.5 and 351.5 Da) fall comfortably within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (58.22) is significantly better than Ligand B (101.29). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold. Ligand B is pushing the limit.
3. **logP:** Ligand A (3.247) is within the optimal 1-3 range, while Ligand B (1.868) is at the lower end. For a GPCR, a slightly higher logP is often preferred for membrane interactions. Ligand A has a slight edge.
4. **HBD:** Ligand A (1) is better than Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is better than Ligand B (3). Similar reasoning to HBD.
6. **QED:** Ligand A (0.89) is significantly better than Ligand B (0.61), indicating a more drug-like profile.
7. **DILI:** Ligand B (19.542) has a much lower DILI risk than Ligand A (54.323). This is a significant advantage for Ligand B.
8. **BBB:** Ligand B (63.862) has a higher BBB penetration percentile than Ligand A (49.477). While not crucial for a cardiovascular target, it doesn't hurt.
9. **Caco-2:** Both ligands have similar, and poor, Caco-2 permeability (-5.123 and -5.209). This suggests potential absorption issues for both, but isn't a deciding factor.
10. **Solubility:** Ligand A (-4.389) is slightly better than Ligand B (-3.147), but both are poor.
11. **hERG:** Ligand A (0.536) has a slightly higher hERG risk than Ligand B (0.093). Lower is better. Ligand B is much preferred here.
12. **Cl_mic:** Ligand B (37.479) has significantly lower microsomal clearance than Ligand A (59.898), indicating better metabolic stability.
13. **t1/2:** Ligand A (-20.799) has a longer in vitro half-life than Ligand B (-11.93). This is a positive for Ligand A.
14. **Pgp:** Ligand A (0.162) has lower P-gp efflux than Ligand B (0.016), which is favorable.
15. **Binding Affinity:** Ligand A (-6.2 kcal/mol) has a better binding affinity than Ligand B (-4.5 kcal/mol). This is a substantial difference (1.7 kcal/mol) and a major advantage for Ligand A.
**Overall Assessment:**
Ligand A has a significantly stronger binding affinity and a longer half-life. However, Ligand B excels in safety parameters (DILI, hERG) and metabolic stability (Cl_mic). It also has better BBB penetration. Considering ADRB2 is a cardiovascular target, the strong affinity of Ligand A is a critical factor. While the DILI and hERG risks of Ligand A are concerning, they might be mitigated through further structural modifications. The difference in binding affinity is substantial enough to prioritize Ligand A, assuming further optimization can address the safety concerns.
Output:
1
2025-04-17 22:05:36,430 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (376.385 and 364.446 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand B (67.23) is significantly better than Ligand A (117.26). ADRB2 is not a CNS target, but lower TPSA generally improves absorption.
3. **logP:** Ligand B (2.352) is optimal, while Ligand A (0.546) is quite low, potentially hindering membrane permeability. This is a significant advantage for B.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (1), but both are acceptable (<=5).
5. **HBA:** Both ligands have 5 HBA, which is within the acceptable range.
6. **QED:** Ligand B (0.909) is much better than Ligand A (0.452), indicating a more drug-like profile.
7. **DILI:** Ligand B (54.556) has a lower DILI risk than Ligand A (68.903), which is preferable.
8. **BBB:** Both ligands have good BBB penetration (73.711 and 78.596), but this isn't a primary concern for ADRB2.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
10. **Solubility:** Both ligands have negative solubility values, which is also unusual. Again, the scale is unspecified.
11. **hERG:** Ligand B (0.753) shows slightly higher hERG inhibition liability than Ligand A (0.409), but both are relatively low.
12. **Cl_mic:** Ligand B (1.428) has significantly lower microsomal clearance than Ligand A (17.714), suggesting better metabolic stability. This is a major advantage for B.
13. **t1/2:** Ligand B (-1.466) has a slightly better in vitro half-life than Ligand A (-28.265).
14. **Pgp:** Ligand A (0.045) has lower P-gp efflux than Ligand B (0.369), which could lead to better bioavailability.
15. **Affinity:** Ligand A (-7.6) has a slightly better binding affinity than Ligand B (-7.4), but the difference is small (0.2 kcal/mol).
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand B excels in logP and TPSA, and has acceptable affinity. While Ligand A has slightly better affinity, the significant deficiencies in logP and the poorer QED and Cl_mic outweigh this benefit.
**Conclusion:**
Ligand B demonstrates a superior balance of properties, particularly regarding drug-likeness, metabolic stability, and permeability-related parameters. The slightly weaker binding affinity is not a major concern given the other advantages.
Output:
0
2025-04-17 22:05:36,431 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step Comparison:**
1. **MW:** Both ligands (350.369 and 340.427 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (79.04) is better than Ligand B (88.99). Both are below the 140 threshold for oral absorption, but lower TPSA is generally preferred for GPCRs, potentially aiding permeability.
3. **logP:** Ligand A (3.307) is slightly higher than Ligand B (2.414), both are within the optimal 1-3 range. Ligand A's higher logP might improve membrane permeability, but could also increase off-target binding.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (2). Both are acceptable.
5. **HBA:** Both ligands have 3 HBA, which is good.
6. **QED:** Ligand B (0.862) has a slightly better QED score than Ligand A (0.791), indicating a more drug-like profile.
7. **DILI:** Ligand B (56.689) has a significantly lower DILI risk than Ligand A (73.09). This is a major advantage for Ligand B.
8. **BBB:** Ligand A (81.698) has a much higher BBB penetration percentile than Ligand B (53.044). While ADRB2 isn't strictly a CNS target, some peripheral ADRB2 receptors can influence CNS function, and better BBB penetration could be beneficial.
9. **Caco-2:** Both ligands have similar, poor Caco-2 permeability (-4.972 and -4.78). This suggests potential absorption issues for both.
10. **Solubility:** Both ligands have very poor aqueous solubility (-4.547 and -4.003). This is a significant concern for both compounds, requiring formulation strategies.
11. **hERG:** Ligand A (0.58) has a slightly higher hERG inhibition liability than Ligand B (0.331), indicating a slightly higher risk of cardiotoxicity.
12. **Cl_mic:** Ligand B (23.235) has a much lower microsomal clearance than Ligand A (10.2). This suggests better metabolic stability for Ligand B, which is highly desirable.
13. **t1/2:** Ligand A (9.116) has a longer in vitro half-life than Ligand B (6.867). This is a positive for Ligand A, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.18) has a lower Pgp efflux liability than Ligand B (0.063). Lower Pgp is better, suggesting better oral bioavailability and potentially better CNS exposure.
15. **Binding Affinity:** Ligand A (-7.4 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.1 kcal/mol). This is a substantial advantage for Ligand A, potentially outweighing some of its ADME drawbacks.
**Overall Assessment & GPCR Prioritization:**
For a GPCR like ADRB2, affinity is paramount. Ligand A's -7.4 kcal/mol binding is significantly better than Ligand B's -6.1 kcal/mol. While Ligand B has better DILI and metabolic stability, the substantial affinity difference of Ligand A is a major advantage. The higher BBB penetration of Ligand A is also a plus, even for a non-CNS primary target. The solubility and Caco-2 permeability are poor for both, but these can be addressed through formulation. The slightly higher hERG risk for Ligand A is a concern, but potentially manageable.
Therefore, I prioritize Ligand A due to its superior binding affinity.
Output:
1
2025-04-17 22:05:36,431 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (343.39 and 358.39 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (98.56) is slightly higher than Ligand B (78.87). Both are below the 140 threshold for good oral absorption, but B is better positioned.
3. **logP:** Both ligands (0.737 and 0.677) are within the optimal 1-3 range, but on the lower end. This might slightly hinder permeability, but isn't a major concern.
4. **HBD:** Ligand A (1) is better than Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (5) is better than Ligand B (4). Lower HBA generally improves permeability.
6. **QED:** Both ligands (0.869 and 0.758) have good drug-like properties (>=0.5). Ligand A is slightly better.
7. **DILI:** Ligand B (25.55) has a significantly lower DILI risk than Ligand A (58.51). This is a substantial advantage for Ligand B.
8. **BBB:** Ligand B (68.28) has a higher BBB penetration percentile than Ligand A (50.52). For a GPCR, even a non-CNS target like ADRB2, some BBB penetration can be beneficial for off-target profiling and understanding distribution.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand B (-4.858) is slightly worse than Ligand A (-4.647).
10. **Solubility:** Both ligands have very poor solubility (-1.806 and -1.868). This is a significant concern for both.
11. **hERG:** Both ligands have low hERG inhibition liability (0.171 and 0.259). This is good.
12. **Cl_mic:** Ligand B (-13.823) has a lower (better) microsomal clearance than Ligand A (-10.254), indicating improved metabolic stability.
13. **t1/2:** Ligand A (7.022) has a longer in vitro half-life than Ligand B (3.764). This is a positive for Ligand A.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.011 and 0.009). This is good.
15. **Binding Affinity:** Ligand B (-7.8 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.6 kcal/mol). This 1.2 kcal/mol difference is substantial and can outweigh many ADME drawbacks.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, affinity, logP, TPSA, and metabolic stability are key. Ligand B excels in affinity and has better TPSA and Cl_mic. While both have poor solubility and logP, the significantly stronger binding of Ligand B is a major advantage. The lower DILI risk is also a significant benefit.
**Conclusion:**
Despite the solubility concerns, the superior binding affinity, lower DILI risk, and better metabolic stability of Ligand B make it the more promising drug candidate.
Output:
0
2025-04-17 22:05:36,431 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (341.455) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (47.36) is significantly better than Ligand B (93.21). ADRB2 is a cardiovascular target, not CNS, but lower TPSA is still generally preferred for absorption. Ligand B is quite high and could hinder oral bioavailability.
3. **logP:** Ligand A (3.671) is within the optimal range, while Ligand B (1.935) is at the lower end. For a GPCR, a slightly higher logP is often beneficial for membrane interactions.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is better than Ligand B (6). Lower HBA is also favorable for permeability.
6. **QED:** Both ligands have good QED scores (A: 0.805, B: 0.85), indicating good overall drug-likeness.
7. **DILI:** Ligand A (41.024) has a significantly lower DILI risk than Ligand B (88.639). This is a major advantage for Ligand A.
8. **BBB:** Not a primary concern for a cardiovascular target, but Ligand A (93.098) is better than Ligand B (68.786).
9. **Caco-2:** Ligand A (-4.318) is better than Ligand B (-5.187), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-3.732) is slightly better than Ligand B (-3.678), although both are similar.
11. **hERG:** Ligand A (0.857) is better than Ligand B (0.226), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand A (75.15) has higher clearance than Ligand B (26.612). This is a negative for Ligand A, suggesting faster metabolism.
13. **t1/2:** Ligand B (27.931) has a significantly longer half-life than Ligand A (-13.649). This is a major advantage for Ligand B.
14. **Pgp:** Ligand A (0.702) is better than Ligand B (0.135), suggesting lower P-gp efflux.
15. **Binding Affinity:** Ligand B (-7.4) has a significantly stronger binding affinity than Ligand A (-6.8). This is a substantial advantage for Ligand B, potentially outweighing some ADME drawbacks.
**Overall Assessment:**
Ligand B has a significantly better binding affinity and a longer half-life, which are crucial for a viable drug candidate. However, it suffers from a higher TPSA and DILI risk. Ligand A has better ADME properties overall (TPSA, DILI, hERG, Pgp), but its lower affinity and shorter half-life are concerning.
The affinity difference of 0.6 kcal/mol is substantial. Considering the GPCR target class, the binding affinity is a primary driver. While the ADME profile of Ligand A is better, the stronger binding of Ligand B is likely to be more impactful, and optimization could potentially address the TPSA and DILI concerns.
Output:
0
2025-04-17 22:05:36,431 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, key priorities are logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB.
Let's compare the ligands property by property:
1. **MW:** Both ligands (349.479 and 348.443 Da) are within the ideal 200-500 Da range.
2. **TPSA:** Both ligands (80.12 and 78.87) are below the 140 A^2 threshold for good oral absorption, and acceptable for a non-CNS GPCR.
3. **logP:** Both ligands have good logP values (2.093 and 1.157), falling within the optimal 1-3 range. Ligand B is slightly better here.
4. **HBD/HBA:** Ligand A has 1 HBD and 5 HBA, while Ligand B has 2 HBD and 4 HBA. Both are within acceptable limits.
5. **QED:** Both ligands have similar QED scores (0.74 and 0.706), indicating good drug-likeness.
6. **DILI:** Ligand A has a DILI risk of 35.983%, while Ligand B has 25.281%. Ligand B is significantly better in terms of liver toxicity risk.
7. **BBB:** BBB is less critical for a cardiovascular target. Ligand A (81.737%) has a higher BBB penetration than Ligand B (58.007%).
8. **Caco-2:** Both have negative Caco-2 values, which is unusual. Assuming these are percentile scores, a higher value is better. Ligand A (-4.63) is slightly better than Ligand B (-4.874).
9. **Solubility:** Both have negative solubility values. Again, assuming these are percentile scores, Ligand A (-3.128) is slightly better than Ligand B (-2.035).
10. **hERG:** Both ligands have very low hERG inhibition liability (0.28 and 0.18), which is excellent.
11. **Cl_mic:** Ligand A has a higher microsomal clearance (78.968) than Ligand B (39.082), indicating faster metabolism and potentially lower exposure.
12. **t1/2:** Ligand B has a significantly longer *in vitro* half-life (-1.974 hours) compared to Ligand A (-15.933 hours). This is a substantial advantage.
13. **Pgp:** Both ligands have low P-gp efflux liability (0.107 and 0.114).
14. **Binding Affinity:** Ligand B has a significantly stronger binding affinity (-7.1 kcal/mol) compared to Ligand A (-5.4 kcal/mol). This is a crucial advantage, exceeding the 1.5 kcal/mol threshold.
**Conclusion:**
While Ligand A has slightly better Caco-2 and solubility, Ligand B is superior overall. Its significantly lower DILI risk, longer half-life, and, most importantly, much stronger binding affinity outweigh the minor advantages of Ligand A. The binding affinity difference is substantial enough to be the deciding factor.
**Output:**
0
2025-04-17 22:05:36,431 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.49 and 342.44 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (61.8) is slightly higher than Ligand B (57.92). Both are below the 140 threshold for good oral absorption, and acceptable for a cardiovascular target (not necessarily needing high CNS penetration).
3. **logP:** Both ligands have good logP values (1.843 and 2.385 respectively), falling within the optimal 1-3 range. Ligand B is slightly higher, potentially aiding membrane permeability.
4. **HBD:** Ligand A has 2 HBD, while Ligand B has 0. Lower HBD is generally preferred for permeability, giving a slight edge to Ligand B.
5. **HBA:** Both ligands have 4 HBA, which is within the acceptable limit of 10.
6. **QED:** Both ligands have similar QED values (0.715 and 0.726), indicating good drug-likeness.
7. **DILI:** Ligand A (10.624) has a significantly lower DILI risk than Ligand B (41.877). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (70.997) has a higher BBB penetration percentile than Ligand A (51.997). While ADRB2 is primarily a cardiovascular target, some CNS effects are possible with beta-blockers, so moderate BBB penetration isn't necessarily a negative.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.754 and -4.566). These values are difficult to interpret without knowing the scale, but negative values are not ideal.
10. **Solubility:** Both ligands have negative solubility values (-1.811 and -1.522). Again, the scale is unknown, but negative values suggest poor aqueous solubility, which could be a formulation challenge.
11. **hERG:** Both ligands have low hERG inhibition liability (0.801 and 0.755), which is excellent.
12. **Cl_mic:** Ligand A (34.776) has a lower microsomal clearance than Ligand B (69.972), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand B (25.402) has a significantly longer in vitro half-life than Ligand A (5.842). This is a strong positive for Ligand B.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.343 and 0.248), which is favorable.
15. **Binding Affinity:** Both ligands have very similar and strong binding affinities (-6.0 and -4.6 kcal/mol). Ligand A is slightly better, but the difference is not huge.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Both ligands perform well on these metrics. However, metabolic stability (Cl_mic, t1/2) and safety (DILI, hERG) are also crucial. Ligand A excels in DILI and has better metabolic stability, while Ligand B has a longer half-life.
**Overall Assessment:**
Ligand A presents a better overall profile, primarily due to its significantly lower DILI risk and improved metabolic stability. While Ligand B has a longer half-life and slightly better BBB penetration, the lower DILI risk of Ligand A is a more critical factor for a cardiovascular drug candidate. Poor metabolic stability and potential liver toxicity are major roadblocks in drug development.
Output:
1
2025-04-17 22:05:36,432 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (359.455 and 352.475 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand B (70.08) is significantly better than Ligand A (96.01). ADRB2 is not a CNS target, but lower TPSA generally improves absorption.
3. **logP:** Ligand A (3.588) is good, within the optimal 1-3 range. Ligand B (1.271) is on the lower side, potentially impacting permeability.
4. **HBD:** Ligand A (3) and Ligand B (1) both meet the <=5 criteria. Ligand B is preferable here.
5. **HBA:** Ligand A (5) and Ligand B (4) both meet the <=10 criteria. Ligand B is preferable here.
6. **QED:** Both ligands have good QED scores (0.76 and 0.809), indicating good drug-likeness.
7. **DILI:** Ligand B (7.871) is *much* better than Ligand A (79.294). This is a critical advantage for Ligand B.
8. **BBB:** Both have reasonable BBB penetration (61.38 and 67.158), but this isn't a high priority for ADRB2.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
10. **Solubility:** Ligand B (-1.114) is better than Ligand A (-5.182), indicating higher aqueous solubility.
11. **hERG:** Both ligands have low hERG inhibition risk (0.225 and 0.358).
12. **Cl_mic:** Ligand A (14.517) has lower microsomal clearance than Ligand B (15.905), suggesting better metabolic stability.
13. **t1/2:** Ligand A (64.375) has a significantly longer in vitro half-life than Ligand B (1.533). This is a substantial advantage.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.116 and 0.061).
15. **Binding Affinity:** Ligand B (-6.0) has a slightly better binding affinity than Ligand A (-5.8), but the difference is relatively small (0.2 kcal/mol).
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand B excels in TPSA, has better solubility, and a lower DILI risk. Ligand A has a slightly better metabolic stability and half-life, and a slightly worse logP. The DILI risk difference is substantial, and the slightly better affinity of Ligand B is enough to tip the scales.
**Conclusion:**
Considering the balance of properties, especially the significantly lower DILI risk and better TPSA/solubility of Ligand B, it is the more promising drug candidate.
Output:
0
2025-04-17 22:05:36,432 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (383.9 & 357.4 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Both ligands (83.4 & 80.8 A^2) are below the 140 A^2 threshold for good oral absorption, and acceptable for a non-CNS GPCR target like ADRB2. No clear advantage.
3. **logP:** Ligand A (3.145) is optimal, while Ligand B (1.183) is on the lower side, potentially hindering permeability. This favors Ligand A.
4. **HBD:** Ligand A (3) and Ligand B (1) are both within the acceptable limit of 5. Ligand B is slightly better.
5. **HBA:** Both ligands (5) are within the acceptable limit of 10. No clear advantage.
6. **QED:** Ligand B (0.756) has a better QED score than Ligand A (0.52), indicating a more drug-like profile. This favors Ligand B.
7. **DILI:** Ligand B (39.2) has a significantly lower DILI risk than Ligand A (56.6), which is a substantial advantage.
8. **BBB:** This is less critical for ADRB2 (a cardiovascular target). Ligand B (78.5) is higher, but not a deciding factor.
9. **Caco-2:** Ligand A (-5.081) has a more negative Caco-2 value, suggesting *lower* permeability, while Ligand B (-4.696) is better. This favors Ligand B.
10. **Solubility:** Ligand B (-1.684) has better aqueous solubility than Ligand A (-4.296). This favors Ligand B.
11. **hERG:** Both ligands (0.196 & 0.29) have very low hERG inhibition liability, posing minimal cardiotoxicity risk. No clear advantage.
12. **Cl_mic:** Ligand B (16.754) has a significantly lower microsomal clearance than Ligand A (43.814), indicating better metabolic stability. This is a major advantage for Ligand B.
13. **t1/2:** Ligand A (4.494) has a positive in vitro half-life, while Ligand B (-17.563) has a negative value, which is unusual and suggests very rapid metabolism. This favors Ligand A.
14. **Pgp:** Both ligands (0.132 & 0.016) have low P-gp efflux liability. No clear advantage.
15. **Binding Affinity:** Both ligands (-6.8 & -6.9 kcal/mol) have very similar and excellent binding affinities.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand B emerges as the stronger candidate. While Ligand A has a slightly better half-life, Ligand B excels in crucial ADME properties like lower DILI risk, better solubility, lower clearance, and better Caco-2 permeability. The slightly lower logP of Ligand B is a minor concern outweighed by its other advantages. The superior QED score also supports its drug-like profile.
Output:
0
2025-04-17 22:05:36,432 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, we prioritize logP, TPSA, Pgp, BBB, and binding affinity.
* **Molecular Weight:** Both ligands are within the ideal range (around 364 Da).
* **TPSA:** Ligand A (66.92) is higher than Ligand B (49.41). Ligand B is better, being closer to the optimal <140 for absorption.
* **logP:** Both are good (between 1-3), but Ligand B (2.705) is slightly higher. This could be beneficial for membrane permeability.
* **H-Bond Donors/Acceptors:** Ligand A has 0 HBD and 4 HBA, while Ligand B has 1 HBD and 3 HBA. Both are acceptable.
* **QED:** Both are good (above 0.5).
* **DILI:** Both are acceptable, with Ligand B (37.069) slightly better than Ligand A (38.581).
* **BBB:** Ligand B (85.731) has significantly higher BBB penetration than Ligand A (71.578). While not a primary concern for a cardiovascular target, it's a positive.
* **Caco-2:** Both are negative, suggesting poor permeability. Ligand A (-4.551) is slightly worse than Ligand B (-4.742).
* **Solubility:** Both are negative, indicating poor solubility. Ligand A (-3.365) is slightly better than Ligand B (-3.296).
* **hERG:** Ligand A (0.421) is better than Ligand B (0.724) regarding hERG inhibition liability.
* **Cl_mic:** Ligand B (31.427) has a much lower microsomal clearance than Ligand A (69.675), indicating better metabolic stability.
* **t1/2:** Ligand B (-16.204) has a much longer in vitro half-life than Ligand A (-52.546).
* **Pgp:** Ligand A (0.2) has lower P-gp efflux than Ligand B (0.403), which is favorable.
* **Binding Affinity:** Ligand A (-6.8) has a better binding affinity than Ligand B (-4.6). This is a substantial difference (over 2 kcal/mol).
**Overall Assessment:**
The binding affinity difference is significant. However, Ligand B has better metabolic stability (lower Cl_mic, longer t1/2), better BBB penetration, and a slightly lower DILI risk. The Caco-2 and solubility are poor for both. Considering the GPCR target class, the improved metabolic profile and BBB penetration of Ligand B, combined with a still-reasonable binding affinity, outweigh the affinity advantage of Ligand A.
**Output:**
0
2025-04-17 22:05:36,432 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (356.375 and 349.431 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand B (75.88) is significantly better than Ligand A (102.45). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (1.582) is within the optimal 1-3 range, while Ligand A (-0.671) is below 1, potentially hindering permeation. This is a significant advantage for Ligand B.
4. **HBD:** Both ligands have 0 HBD, which is good.
5. **HBA:** Ligand B (5) is preferable to Ligand A (7), as lower HBA can improve permeability.
6. **QED:** Ligand B (0.825) is better than Ligand A (0.602), indicating a more drug-like profile.
7. **DILI:** Ligand B (42.613) has a lower DILI risk than Ligand A (57.425), which is a clear advantage.
8. **BBB:** Ligand B (78.79) has better BBB penetration than Ligand A (58.434). While not critical for a cardiovascular target, it's still a positive.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.538 and -4.337), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-0.549) has slightly better solubility than Ligand B (-2.153), but both are quite poor.
11. **hERG:** Ligand A (0.027) has a slightly lower hERG risk than Ligand B (0.183), but both are very low risk.
12. **Cl_mic:** Ligand A (10.635) has significantly lower microsomal clearance than Ligand B (45.516), indicating better metabolic stability. This is a key advantage for Ligand A.
13. **t1/2:** Ligand B (13.527) has a longer in vitro half-life than Ligand A (-8.143). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.024) has lower P-gp efflux than Ligand B (0.188), which is favorable.
15. **Affinity:** Ligand A (-7.4) has a slightly better binding affinity than Ligand B (-4.5). This is a substantial advantage for Ligand A.
**Overall Assessment:**
Ligand A has a better binding affinity and metabolic stability (lower Cl_mic, lower Pgp efflux), while Ligand B has better drug-like properties (QED), lower DILI risk, better logP, TPSA, and a longer half-life. The affinity difference is significant (2.9 kcal/mol), and for a GPCR, affinity is a major driver. The poor Caco-2 values for both are concerning, but the superior affinity of Ligand A, combined with its better metabolic profile, outweighs the other advantages of Ligand B.
Output:
1
2025-04-17 22:05:36,432 - INFO - Batch 306 complete. Total preferences: 4896
2025-04-17 22:05:36,432 - INFO - Processing batch 307/512...
2025-04-17 22:06:25,274 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [362.415, 117. , 1.313, 2. , 8. , 0.703, 89.57 , 14.812, -5.95 , -1.976, 0.05 , -23.368, 29.299, 0.012, -5.6 ]
**Ligand B:** [366.447, 122.9 , 1.2 , 2. , 9. , 0.744, 79.449, 65.413, -5.417, -2.455, 0.231, 26.544, 10.988, 0.023, -8.4 ]
**Step-by-step comparison:**
1. **MW:** Both ligands (362.415 and 366.447 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (117) is better than Ligand B (122.9), being closer to the <140 threshold for good oral absorption.
3. **logP:** Both ligands have excellent logP values (1.313 and 1.2), falling within the optimal 1-3 range.
4. **HBD:** Both have 2 HBD, which is good.
5. **HBA:** Ligand A has 8 HBA, while Ligand B has 9. Both are acceptable (<=10).
6. **QED:** Both ligands have good QED scores (0.703 and 0.744), indicating good drug-like properties.
7. **DILI:** Ligand A (89.57) has a higher DILI risk than Ligand B (79.449). This is a significant negative for Ligand A.
8. **BBB:** Ligand B (65.413) has a considerably better BBB penetration score than Ligand A (14.812). While ADRB2 isn't necessarily a CNS target, some peripheral ADRB2 activity can be modulated by CNS effects and better BBB penetration can be a plus.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-5.95) is slightly worse than Ligand B (-5.417).
10. **Solubility:** Both have negative solubility values, which is also unusual. Ligand A (-1.976) is slightly better than Ligand B (-2.455).
11. **hERG:** Both have very low hERG inhibition risk (0.05 and 0.231).
12. **Cl_mic:** Ligand A (-23.368) has a much lower (better) microsomal clearance than Ligand B (26.544), indicating greater metabolic stability.
13. **t1/2:** Ligand A (29.299) has a significantly longer in vitro half-life than Ligand B (10.988).
14. **Pgp:** Both have very low Pgp efflux liability (0.012 and 0.023).
15. **Binding Affinity:** Ligand B (-8.4) has a significantly stronger binding affinity than Ligand A (-5.6). This is a substantial advantage (a 2.8 kcal/mol difference).
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Both ligands are good on logP and Pgp. Ligand A is better on TPSA, but Ligand B *significantly* wins on binding affinity. The DILI and BBB scores also favor Ligand B. While Ligand A has better metabolic stability, the substantial affinity advantage of Ligand B is likely to outweigh this. The Caco-2 and solubility are concerning for both, but the affinity difference is critical.
**Conclusion:**
Despite the better metabolic stability of Ligand A, the significantly stronger binding affinity of Ligand B, coupled with its lower DILI risk and better BBB penetration, makes it the more promising drug candidate.
Output:
0
2025-04-17 22:06:25,274 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
The target is ADRB2, a GPCR. Therefore, I will prioritize logP, TPSA, Pgp efflux, BBB penetration, and binding affinity. Metabolic stability and solubility are also important, but less so than the former.
Let's compare the ligands property by property:
1. **MW:** Both ligands (374.5 & 340.4 Da) fall within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (76.66) is significantly better than Ligand B (115.78). A TPSA under 140 is good for oral absorption, and lower is better for GPCRs. Ligand B is pushing the upper limit.
3. **logP:** Both ligands have good logP values (1.968 & 1.691), falling within the optimal 1-3 range. Ligand B is slightly lower, which *could* indicate slightly better solubility but isn't a major difference.
4. **HBD:** Ligand A (2) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (8). Fewer HBAs generally improve permeability.
6. **QED:** Both ligands have similar and acceptable QED values (0.611 and 0.631).
7. **DILI:** Ligand A (33.3) has a substantially lower DILI risk than Ligand B (55.3). This is a significant advantage.
8. **BBB:** Ligand A (58.7) is better than Ligand B (53.97). While neither is exceptionally high, ADRB2 is a cardiovascular target, so BBB isn't *critical*, but a higher value is still preferred.
9. **Caco-2:** Ligand A (-4.877) is better than Ligand B (-5.464). Higher (less negative) values indicate better absorption.
10. **Solubility:** Ligand A (-2.481) is better than Ligand B (-3.24).
11. **hERG:** Both ligands have very low hERG inhibition risk (0.198 and 0.815).
12. **Cl_mic:** Ligand A (46.247) has a higher clearance than Ligand B (30.641), meaning it's metabolized faster. This is a disadvantage for Ligand A.
13. **t1/2:** Ligand B (57.19) has a significantly longer in vitro half-life than Ligand A (11.303). This is a major advantage for Ligand B.
14. **Pgp:** Ligand A (0.035) has much lower P-gp efflux liability than Ligand B (0.01). Lower is better, meaning more drug reaches the target.
15. **Binding Affinity:** Both ligands have the same binding affinity (-6.3 kcal/mol).
**Overall Assessment:**
Ligand A has clear advantages in TPSA, DILI risk, Caco-2 permeability, solubility, and Pgp efflux. Ligand B has a better half-life and lower clearance. However, the improvements in ADME properties for Ligand A, particularly the lower DILI risk and better permeability, outweigh the better metabolic stability of Ligand B. The equal binding affinity makes the ADME profile the deciding factor.
**Output:**
1
2025-04-17 22:06:25,275 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (374.34) is slightly higher than Ligand B (341.39), but both are acceptable.
2. **TPSA:** Both ligands are below the 140 A^2 threshold for good oral absorption (A: 88.52, B: 83.6). This is good.
3. **logP:** Both ligands have optimal logP values between 1-3 (A: 2.907, B: 2.38).
4. **HBD:** Both are acceptable, with A having 2 and B having 1.
5. **HBA:** Both are acceptable, with 5 HBA.
6. **QED:** Both ligands have high QED scores (A: 0.812, B: 0.874), indicating good drug-like properties. B is slightly better here.
7. **DILI:** Ligand B (56.727) has a significantly lower DILI risk than Ligand A (82.629). This is a major advantage for Ligand B.
8. **BBB:** Ligand B (81.039) has better BBB penetration than Ligand A (47.499). While ADRB2 isn't strictly a CNS target, some CNS exposure can be relevant for off-target effects, and better BBB penetration generally correlates with better overall drug distribution.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. This is a concern for both, but the values are similar.
10. **Solubility:** Both have negative solubility values, indicating poor solubility. This is a concern for both, but the values are similar.
11. **hERG:** Ligand A (0.032) has a slightly lower hERG risk than Ligand B (0.418), which is preferable.
12. **Cl_mic:** Ligand B (22.004) has lower microsomal clearance than Ligand A (27.323), suggesting better metabolic stability.
13. **t1/2:** Ligand B (0.014) has a very short in vitro half-life compared to Ligand A (-24.709). This is a significant drawback for Ligand B. Note the negative value for A suggests a very rapid degradation, which is concerning.
14. **Pgp:** Ligand A (0.066) has lower P-gp efflux than Ligand B (0.222), which is favorable.
15. **Binding Affinity:** Ligand B (-7.4 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.6 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME concerns.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand B excels in affinity and has better Pgp and TPSA values. While BBB isn't critical, it's a bonus. The biggest concern with Ligand B is its very short half-life. However, the strong binding affinity could allow for a lower dose, potentially mitigating the impact of rapid clearance. Ligand A has a better hERG profile, but the weaker affinity and higher DILI risk are significant drawbacks.
**Overall Assessment:**
Despite the short half-life, the significantly stronger binding affinity of Ligand B, combined with its lower DILI risk and better Pgp profile, makes it the more promising candidate. The half-life issue could potentially be addressed through structural modifications in subsequent optimization rounds.
Output:
0
2025-04-17 22:06:25,275 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.459 Da and 352.45 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (93.43) is slightly higher than Ligand B (78.43). Both are below the 140 threshold for good oral absorption, but Ligand B is preferable due to being closer to the 90 threshold for potential CNS penetration (though ADRB2 isn't necessarily a CNS target).
3. **logP:** Both ligands (1.607 and 1.876) fall within the optimal 1-3 range. No strong preference.
4. **HBD:** Ligand A (2) is better than Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is better than Ligand B (3). Fewer HBAs generally improve permeability.
6. **QED:** Ligand A (0.714) is significantly better than Ligand B (0.584), indicating a more drug-like profile.
7. **DILI:** Ligand A (19.193) has a much lower DILI risk than Ligand B (14.424). This is a significant advantage for Ligand A.
8. **BBB:** Both ligands have similar BBB penetration (61.419% and 67.08%). Not a major deciding factor for ADRB2, but slightly favors Ligand B.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.797 and -4.939). This is unusual and suggests poor permeability. However, the values are very close.
10. **Solubility:** Both ligands have negative solubility values (-2.485 and -2.559). This is also unusual and suggests poor aqueous solubility. Again, the values are very close.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.181 and 0.26). No significant difference.
12. **Cl_mic:** Ligand A (14.826) has a lower microsomal clearance than Ligand B (18.77), indicating better metabolic stability.
13. **t1/2:** Ligand A (-16.933) has a much longer in vitro half-life than Ligand B (-2.802). This is a significant advantage for Ligand A.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.009 and 0.063). No significant difference.
15. **Binding Affinity:** Ligand B (-6.4) has a slightly better binding affinity than Ligand A (-6.0). However, the difference is less than 1.5 kcal/mol, so it's not a dominant factor.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, and affinity are important. Both ligands perform similarly on logP. Ligand B has a slightly better TPSA and affinity, but Ligand A excels in crucial ADME properties like DILI risk, QED, and metabolic stability (Cl_mic and t1/2).
**Overall Assessment:**
While Ligand B has a marginally better binding affinity and TPSA, Ligand A demonstrates a superior overall profile with significantly lower DILI risk, better QED, improved metabolic stability, and a longer half-life. These factors are critical for developing a safe and effective drug. The negative Caco-2 and solubility values are concerning for both, but the other advantages of Ligand A outweigh the small affinity difference.
Output:
1
2025-04-17 22:06:25,275 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.487 and 348.531 Da) fall comfortably within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (67.43) is higher than Ligand B (49.41). For a cardiovascular GPCR, TPSA is moderately important, and Ligand B is better here.
3. **logP:** Ligand B (3.75) is slightly higher than Ligand A (2.537). Both are within the optimal 1-3 range, but Ligand B is approaching the upper limit.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1). Both are acceptable.
5. **HBA:** Ligand A (3) is slightly higher than Ligand B (2). Both are acceptable.
6. **QED:** Ligand A (0.673) is better than Ligand B (0.536), indicating a more drug-like profile.
7. **DILI:** Both ligands have low DILI risk (Ligand A: 13.61, Ligand B: 14.075), but Ligand A is slightly better.
8. **BBB:** Ligand A (71.811) has a significantly higher BBB penetration percentile than Ligand B (58.162). While ADRB2 isn't a CNS target *primarily*, some CNS exposure can be a factor in side effects, and higher BBB is generally preferable.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-4.66) is slightly better than Ligand B (-4.72).
10. **Solubility:** Both ligands have poor aqueous solubility (Ligand A: -2.633, Ligand B: -3.733). Ligand B is worse.
11. **hERG:** Ligand A (0.351) has a lower hERG inhibition liability than Ligand B (0.615), which is a significant advantage for cardiovascular safety.
12. **Cl_mic:** Ligand A (40.337) has a lower microsomal clearance than Ligand B (45.309), suggesting better metabolic stability.
13. **t1/2:** Ligand A (3.395) has a longer in vitro half-life than Ligand B (-1.085). This is a substantial advantage.
14. **Pgp:** Ligand A (0.044) has a much lower P-gp efflux liability than Ligand B (0.463). This is a significant advantage for bioavailability.
15. **Binding Affinity:** Ligand A (-7.2 kcal/mol) has a significantly stronger binding affinity than Ligand B (-5.9 kcal/mol). This is a crucial advantage, exceeding the 1.5 kcal/mol threshold.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical ADME-Tox properties, *and* has a substantially better binding affinity. While both have poor solubility and Caco-2 permeability, the superior affinity, metabolic stability, lower hERG risk, lower P-gp efflux, and better BBB penetration of Ligand A outweigh these drawbacks. The affinity difference is particularly important for a GPCR target.
Output:
1
2025-04-17 22:06:25,275 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (341.386) is slightly lower than Ligand B (365.499), which is generally favorable for permeability.
2. **TPSA:** Ligand A (62.3) is significantly better than Ligand B (78.51). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary goal, but lower TPSA generally improves absorption.
3. **logP:** Both ligands have good logP values (A: 2.316, B: 1.94), falling within the optimal 1-3 range.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD is generally better for permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (4). Similar to HBD, lower HBA is generally better.
6. **QED:** Ligand A (0.877) has a higher QED score than Ligand B (0.691), indicating a more drug-like profile.
7. **DILI:** Ligand A (56.689) has a higher DILI risk than Ligand B (33.501). This is a significant advantage for Ligand B.
8. **BBB:** Not a major priority for a cardiovascular target, but Ligand A (79.566) has a higher BBB percentile than Ligand B (62.97).
9. **Caco-2:** Ligand A (-4.882) is better than Ligand B (-5.179). Higher Caco-2 permeability suggests better absorption.
10. **Solubility:** Ligand A (-2.552) is better than Ligand B (-2.178). Higher solubility is generally desirable.
11. **hERG:** Ligand A (0.551) has a slightly better hERG profile than Ligand B (0.391). Lower hERG inhibition is crucial for avoiding cardiotoxicity.
12. **Cl_mic:** Ligand A (15.775) has a significantly lower microsomal clearance than Ligand B (36.809), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-7.035) has a much better in vitro half-life than Ligand B (15.574).
14. **Pgp:** Ligand A (0.099) has a lower Pgp efflux liability than Ligand B (0.149). Lower Pgp is favorable.
15. **Binding Affinity:** Ligand B (-7.8) has a slightly better binding affinity than Ligand A (-6.7). This is a 1.1 kcal/mol difference, which is substantial.
**Overall Assessment:**
Ligand B has a significantly better binding affinity and a much lower DILI risk. These are the most important factors. While Ligand A has advantages in several ADME properties (TPSA, QED, Cl_mic, t1/2, Pgp), the superior affinity and reduced toxicity of Ligand B outweigh these benefits. The difference in affinity is large enough to compensate for the slightly less favorable ADME profile of Ligand B.
Output:
0
2025-04-17 22:06:25,275 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (359.407 and 376.513 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand B (49.41) is significantly better than Ligand A (92.71). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (3.341 and 3.166), falling within the optimal 1-3 range. Very similar.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (1), but both are acceptable (<=5).
5. **HBA:** Ligand A (6) is higher than Ligand B (3), but both are within the acceptable range (<=10).
6. **QED:** Both ligands have good QED scores (0.65 and 0.742), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (87.515) has a substantially higher DILI risk than Ligand B (22.838). This is a major concern for Ligand A.
8. **BBB:** Ligand B (96.355) has a much higher BBB penetration percentile than Ligand A (41.528). While not critical for a cardiovascular target, it's a positive attribute.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.304 and -4.875). These values are unusual and suggest poor permeability. However, the values are close enough that this isn't a deciding factor.
10. **Solubility:** Both ligands have negative solubility values (-3.854 and -3.611). These values are unusual and suggest poor solubility. However, the values are close enough that this isn't a deciding factor.
11. **hERG:** Ligand A (0.559) has a slightly higher hERG risk than Ligand B (0.772). Lower is better, so Ligand B is preferable.
12. **Cl_mic:** Ligand A (54.333) has a higher microsomal clearance than Ligand B (42.801), indicating lower metabolic stability.
13. **t1/2:** Ligand B (-5.165) has a longer in vitro half-life than Ligand A (-13.34). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.278) has a lower P-gp efflux liability than Ligand B (0.162). Lower is better, so Ligand A is preferable.
15. **Binding Affinity:** Both ligands have very similar and strong binding affinities (-6.2 and -6.0 kcal/mol). The difference is not substantial enough to outweigh other factors.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand B is better in terms of TPSA, Pgp, and has a slightly better QED. The binding affinities are comparable. The biggest advantage for Ligand B is the significantly lower DILI risk and improved metabolic stability (lower Cl_mic, longer t1/2).
**Conclusion:**
Despite Ligand A having slightly better Pgp efflux liability, the significantly lower DILI risk, better TPSA, and improved metabolic stability of Ligand B make it the more promising drug candidate.
Output:
0
2025-04-17 22:06:25,275 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, key priorities are logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB.
Let's compare the ligands property by property:
1. **MW:** Both ligands (344.411 and 352.387 Da) fall within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (76.66) is significantly better than Ligand B (106.87). A lower TPSA generally favors oral absorption, crucial for a cardiovascular drug.
3. **logP:** Ligand A (2.203) is optimal, while Ligand B (0.973) is slightly low, potentially hindering membrane permeability.
4. **HBD/HBA:** Both have 2 HBD and acceptable HBA counts (4 and 6 respectively).
5. **QED:** Both ligands have similar QED values (0.674 and 0.675), indicating good drug-likeness.
6. **DILI:** Ligand A (52.423) has a slightly better DILI score than Ligand B (58.976), although both are acceptable.
7. **BBB:** Both have similar BBB penetration (69.794 vs 69.446). BBB is less critical for a cardiovascular target.
8. **Caco-2:** Ligand A (-4.895) is better than Ligand B (-4.574), suggesting better intestinal absorption.
9. **Solubility:** Both have similar, poor aqueous solubility (-2.981 vs -2.865). This could be a formulation challenge for both.
10. **hERG:** Both have low hERG inhibition liability (0.429 and 0.24).
11. **Cl_mic:** Ligand A (49.776) has significantly lower microsomal clearance than Ligand B (68.834), indicating better metabolic stability.
12. **t1/2:** Ligand A (17.974) has a longer in vitro half-life than Ligand B (1.935).
13. **Pgp:** Ligand A (0.206) has lower P-gp efflux liability than Ligand B (0.068), which is favorable for bioavailability.
14. **Binding Affinity:** Ligand A (-7.5 kcal/mol) has a stronger binding affinity than Ligand B (-6.0 kcal/mol). This is a substantial difference.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across several critical parameters, particularly TPSA, logP, metabolic stability (Cl_mic and t1/2), Pgp efflux, and, most importantly, binding affinity. The affinity difference of 1.5 kcal/mol is significant and can outweigh some of the solubility concerns. While both have poor solubility, the superior ADME profile and much stronger binding of Ligand A make it the more promising drug candidate.
**Output:**
1
2025-04-17 22:06:25,275 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (337.335 Da) is slightly preferred due to being closer to the lower end, potentially aiding permeability.
2. **TPSA:** Ligand A (95.52) is significantly better than Ligand B (131.03). ADRB2 is a cardiovascular target, and while BBB isn't paramount, lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold.
3. **logP:** Ligand A (2.165) is optimal. Ligand B (-0.694) is quite low, potentially hindering membrane permeability and absorption. This is a significant drawback for Ligand B.
4. **HBD:** Ligand A (2) is good. Ligand B (3) is acceptable, but slightly less desirable.
5. **HBA:** Ligand A (4) is good. Ligand B (7) is higher, potentially impacting permeability.
6. **QED:** Ligand A (0.761) is excellent, indicating good drug-like properties. Ligand B (0.521) is acceptable but lower.
7. **DILI:** Ligand A (96.859) has a high DILI risk. Ligand B (47.732) is much better, indicating a lower risk of liver injury. This is a major concern for Ligand A.
8. **BBB:** Ligand A (20.357) is low. Ligand B (35.789) is also low, but slightly better. BBB isn't a primary concern for a cardiovascular target, but it's still a consideration.
9. **Caco-2:** Ligand A (-5.186) is very poor. Ligand B (-6.124) is also poor, but marginally better. Both suggest significant permeability issues.
10. **Solubility:** Ligand A (-3.921) is poor. Ligand B (-2.026) is also poor, but better than Ligand A.
11. **hERG:** Both ligands have low hERG risk (0.115 and 0.217, respectively). This is positive for both.
12. **Cl_mic:** Ligand A (-7.64) is excellent, indicating high metabolic stability. Ligand B (11.248) is poor, suggesting rapid metabolism.
13. **t1/2:** Ligand A (-0.515) is poor. Ligand B (-14.304) is very poor. Both have short half-lives.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.022 and 0.044, respectively).
15. **Binding Affinity:** Ligand A (-7.8) is slightly better than Ligand B (-6.9), a difference of 0.9 kcal/mol. While a 1.5 kcal/mol difference would be more compelling, this still favors Ligand A.
**Overall Assessment:**
Ligand A has a better binding affinity, TPSA, QED, and metabolic stability. However, it suffers from a very high DILI risk, poor Caco-2 permeability, and poor solubility. Ligand B has a lower DILI risk and slightly better solubility and Caco-2 permeability, but has a significantly lower logP, higher TPSA, and poorer metabolic stability.
Considering the GPCR-specific priorities (logP, TPSA, affinity), Ligand A appears initially better due to its optimal logP and better affinity. However, the extremely high DILI risk for Ligand A is a major red flag. While metabolic stability is important, the DILI risk is a more immediate concern that could halt development. The lower logP of Ligand B is a significant drawback, but the much lower DILI risk makes it a more viable starting point for optimization. Improving logP through medicinal chemistry is often more tractable than mitigating a high DILI risk.
Output:
0
2025-04-17 22:06:25,275 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (367.5 and 349.4 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (82.53) is better than Ligand B (102.42). ADRB2 is not a CNS target, but lower TPSA generally aids absorption.
3. **logP:** Ligand A (1.9) is within the optimal range (1-3), while Ligand B (0.205) is quite low, potentially hindering membrane permeability. This is a significant advantage for A.
4. **HBD:** Both have 2 HBD, which is good.
5. **HBA:** Both have 5 HBA, also good.
6. **QED:** Ligand A (0.735) has a slightly better QED score than Ligand B (0.698), indicating a more drug-like profile.
7. **DILI:** Both have low DILI risk (24.5 and 21.2 percentile), which is good.
8. **BBB:** Not a primary concern for ADRB2 (cardiovascular target), but both are around 38-39%, indicating limited CNS penetration.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
10. **Solubility:** Both have negative solubility values, which is also unusual and suggests poor solubility. Again, the scale is not specified.
11. **hERG:** Both have very low hERG inhibition liability (0.208 and 0.054), which is excellent.
12. **Cl_mic:** Ligand A (15.125) has a higher microsomal clearance than Ligand B (5.496), suggesting faster metabolism and potentially lower *in vivo* exposure. This favors B.
13. **t1/2:** Ligand B (-26.488) has a very negative half-life, which is concerning. Ligand A (2.017) is better, although still not ideal.
14. **Pgp:** Both have very low Pgp efflux liability (0.167 and 0.017), which is good.
15. **Binding Affinity:** Ligand B (-6.4 kcal/mol) has a significantly stronger binding affinity than Ligand A (-3.2 kcal/mol) - a difference of 3.2 kcal/mol. This is a substantial advantage.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, and affinity are crucial. Ligand A has a better logP and TPSA, but Ligand B has a much stronger binding affinity. The affinity difference is large enough to potentially overcome the lower logP of Ligand B. The negative half-life of Ligand B is a concern, but the strong affinity could compensate if the compound is dosed appropriately.
**Overall Assessment:**
While Ligand A has better physicochemical properties (logP, TPSA, QED), the significantly stronger binding affinity of Ligand B (-6.4 vs -3.2 kcal/mol) is a decisive factor for a GPCR target. The lower clearance of Ligand B is also favorable. The unusual Caco-2 and solubility values are concerning for both, but the binding affinity is the most important parameter here.
Output:
0
2025-04-17 22:06:25,275 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (341.415 and 356.323 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (90.38) is slightly higher than Ligand B (83.8). Both are below the 140 A^2 threshold for good oral absorption, but Ligand B is preferable due to being closer to the 90 A^2 target for GPCRs.
**3. logP:** Ligand A (1.787) is within the optimal 1-3 range, while Ligand B (3.051) is at the higher end. While still acceptable, Ligand A's logP is more balanced, reducing potential off-target effects.
**4. H-Bond Donors:** Both ligands have 3 HBD, which is acceptable.
**5. H-Bond Acceptors:** Ligand A has 5 HBA, while Ligand B has 3. Both are within the acceptable range of <=10.
**6. QED:** Both ligands have good QED scores (0.697 and 0.739), indicating good drug-like properties.
**7. DILI Risk:** Ligand A (27.336%) has a significantly lower DILI risk than Ligand B (65.103%). This is a major advantage for Ligand A.
**8. BBB Penetration:** Ligand B (87.67%) shows significantly better BBB penetration than Ligand A (64.67%). While ADRB2 is a cardiovascular target, some CNS effects can be relevant or undesirable, and higher BBB penetration could lead to off-target effects. However, for a cardiovascular target, this is less critical than for a CNS target.
**9. Caco-2 Permeability:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-5.468) is slightly better than Ligand B (-5.363), but both are problematic.
**10. Aqueous Solubility:** Both ligands have poor aqueous solubility (-2.551 and -4.113). Ligand B is worse.
**11. hERG Inhibition:** Ligand A (0.577) has a lower hERG inhibition risk than Ligand B (0.861). This is a significant advantage for Ligand A, as hERG inhibition can cause cardiotoxicity.
**12. Microsomal Clearance:** Ligand A (15.17 mL/min/kg) has a lower microsomal clearance than Ligand B (-2.904 mL/min/kg). This suggests better metabolic stability for Ligand A.
**13. In vitro Half-Life:** Ligand A (-6.522 hours) has a longer in vitro half-life than Ligand B (24.774 hours). This is a major advantage for Ligand A.
**14. P-gp Efflux:** Ligand A (0.023) has much lower P-gp efflux than Ligand B (0.304). Lower efflux is generally preferred for better bioavailability.
**15. Binding Affinity:** Ligand B (-7.1 kcal/mol) has a slightly better binding affinity than Ligand A (-6.3 kcal/mol). This is a 1.8 kcal/mol difference, which is substantial.
**Overall Assessment:**
While Ligand B has a better binding affinity and BBB penetration, Ligand A demonstrates a significantly better safety profile (lower DILI and hERG risk) and improved ADME properties (lower clearance, longer half-life, lower P-gp efflux). The improved ADME and safety profile outweigh the modest difference in binding affinity, especially considering the cardiovascular target. The poor Caco-2 and solubility are concerning for both, but can be addressed with formulation strategies.
Therefore, I would choose Ligand A.
Output:
1
2025-04-17 22:06:25,276 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [352.406, 67.87, 2.039, 1, 4, 0.842, 60.217, 67.507, -4.349, -2.063, 0.217, 43.937, 1.464, 0.063, -5.6]
**Ligand B:** [346.471, 69.64, 2.313, 2, 3, 0.593, 26.095, 52.268, -4.918, -2.614, 0.263, 47.722, -4.376, 0.346, -6.6]
Here's a breakdown, considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (346.471) is slightly lower, which is generally favorable.
2. **TPSA:** Both are reasonably good, but Ligand A (67.87) is better than Ligand B (69.64) for oral absorption.
3. **logP:** Both are within the optimal range (1-3), with Ligand A (2.039) being slightly better.
4. **HBD/HBA:** Ligand A (1 HBD, 4 HBA) is preferable to Ligand B (2 HBD, 3 HBA) as it has fewer hydrogen bond donors.
5. **QED:** Ligand A (0.842) has a significantly better QED score than Ligand B (0.593), indicating a more drug-like profile.
6. **DILI:** Ligand B (26.095) has a much lower DILI risk than Ligand A (60.217), a significant advantage.
7. **BBB:** Ligand A (67.507) has a better BBB penetration percentile than Ligand B (52.268). While not a primary concern for a cardiovascular target, it's a slight positive.
8. **Caco-2:** Both have negative values, which is unusual, but the scale is not specified. Assuming lower is worse, Ligand B (-4.918) is slightly worse than Ligand A (-4.349).
9. **Solubility:** Both have negative values, which is unusual, but the scale is not specified. Assuming lower is worse, Ligand B (-2.614) is slightly worse than Ligand A (-2.063).
10. **hERG:** Both have low hERG inhibition risk (0.217 and 0.263).
11. **Cl_mic:** Ligand A (43.937) has lower microsomal clearance than Ligand B (47.722), suggesting better metabolic stability.
12. **t1/2:** Ligand B (-4.376) has a longer in vitro half-life than Ligand A (1.464), which is a positive.
13. **Pgp:** Ligand A (0.063) shows lower P-gp efflux liability than Ligand B (0.346), which is favorable for bioavailability.
14. **Affinity:** Ligand B (-6.6 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.6 kcal/mol). This is a crucial advantage, exceeding the 1.5 kcal/mol threshold.
**Overall Assessment:**
Ligand B has a much lower DILI risk and a significantly better binding affinity. The longer half-life is also a plus. While Ligand A has better QED, TPSA, Pgp, and Cl_mic, the substantial improvement in affinity and the lower toxicity risk of Ligand B outweigh these advantages. For a GPCR target, strong binding is paramount, and the reduced toxicity is a critical factor.
Output:
0
2025-04-17 22:06:25,276 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are looking for a drug candidate targeting ADRB2, a GPCR. Therefore, priorities are affinity, logP, Pgp, TPSA, and BBB. Let's compare Ligand A and Ligand B across these and other relevant parameters.
* **Molecular Weight:** Both ligands (368.849 and 358.473 Da) are within the ideal 200-500 Da range.
* **TPSA:** Ligand A (59.29) is higher than Ligand B (40.62). Both are acceptable, but Ligand B is better, being closer to the <90 target for potential CNS penetration (although not strictly necessary for ADRB2).
* **logP:** Ligand A (4.287) is slightly higher than Ligand B (3.347). While both are within the 1-3 range, Ligand A is pushing the upper limit and could present solubility challenges.
* **H-Bond Donors/Acceptors:** Ligand A has 1 HBD and 5 HBA, while Ligand B has 0 HBD and 2 HBA. Both are reasonable.
* **QED:** Both ligands have good QED scores (0.584 and 0.655), indicating good drug-like properties.
* **DILI:** Ligand A (90.229) has a significantly higher DILI risk than Ligand B (25.359). This is a major concern for Ligand A.
* **BBB:** Ligand B (94.3) has much better BBB penetration potential than Ligand A (65.374). While ADRB2 isn't exclusively a CNS target, better BBB penetration can sometimes translate to improved overall PK.
* **Caco-2 Permeability:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-5.058) is worse than Ligand B (-4.283).
* **Aqueous Solubility:** Both have negative solubility values, indicating poor solubility. Ligand A (-4.735) is slightly worse than Ligand B (-3.595).
* **hERG:** Ligand A (0.686) has a slightly higher hERG risk than Ligand B (0.917).
* **Microsomal Clearance:** Ligand A (72.304) has higher microsomal clearance than Ligand B (45.979), suggesting lower metabolic stability.
* **In vitro Half-Life:** Ligand B (3.049) has a very short half-life, while Ligand A (51.612) is much better.
* **P-gp Efflux:** Ligand A (0.676) has slightly lower P-gp efflux than Ligand B (0.62), which is favorable.
* **Binding Affinity:** Ligand B (-6.6 kcal/mol) has a significantly stronger binding affinity than Ligand A (-3.2 kcal/mol). This is a crucial difference, as a 3.4 kcal/mol advantage is substantial.
**Conclusion:**
Despite Ligand A having a better in vitro half-life and slightly lower P-gp efflux, the significantly higher DILI risk, poorer binding affinity, and worse Caco-2 permeability and solubility make it a less desirable candidate. Ligand B's superior binding affinity, lower DILI risk, and better BBB penetration outweigh its shorter half-life and slightly higher P-gp efflux. The strong binding affinity is the most important factor here, and the ADME properties of Ligand B are generally more favorable.
Output:
0
2025-04-17 22:06:25,276 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (362.417 Da and 359.579 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (67.87) is higher than Ligand B (20.31). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for permeability. Ligand B is significantly better.
3. **logP:** Ligand A (1.296) is within the optimal range (1-3), while Ligand B (4.895) is high. High logP can lead to solubility issues and off-target interactions. Ligand A is better.
4. **HBD:** Ligand A (1) and Ligand B (0) are both acceptable.
5. **HBA:** Ligand A (4) and Ligand B (2) are both acceptable.
6. **QED:** Both ligands have good QED scores (0.595 and 0.629), indicating good drug-like properties. No significant difference.
7. **DILI:** Ligand A (20.047) has a much lower DILI risk than Ligand B (35.052). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (94.455) has a higher BBB penetration percentile than Ligand B (78.868). While ADRB2 isn't strictly a CNS target, some brain exposure can occur, and higher BBB is generally favorable.
9. **Caco-2:** Ligand A (-4.712) and Ligand B (-5.33) are both negative, indicating poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Ligand A (-1.271) is better than Ligand B (-5.475). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.435) has a lower hERG inhibition liability than Ligand B (0.694), which is a critical safety advantage.
12. **Cl_mic:** Ligand A (16.449) has a lower microsomal clearance than Ligand B (104.185), suggesting better metabolic stability.
13. **t1/2:** Ligand A (14.892) has a longer in vitro half-life than Ligand B (12.865).
14. **Pgp:** Ligand A (0.036) has much lower P-gp efflux liability than Ligand B (0.755), which is beneficial for bioavailability.
15. **Binding Affinity:** Ligand B (-7.1) has a slightly better binding affinity than Ligand A (-6.5). However, the difference is 0.6 kcal/mol, which is not substantial enough to outweigh the numerous ADME advantages of Ligand A.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A has a better logP, lower TPSA, significantly lower Pgp efflux, and acceptable affinity. The superior ADME profile of Ligand A, particularly the lower DILI, hERG, and Pgp values, makes it a more promising candidate.
**Conclusion:**
Ligand A demonstrates a significantly more favorable balance of properties, particularly in terms of safety (DILI, hERG) and ADME characteristics (Cl_mic, t1/2, Pgp, solubility). While Ligand B has slightly better affinity, the ADME advantages of Ligand A are more critical for overall drug development success.
Output:
1
2025-04-17 22:06:25,276 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (389.5) is slightly higher than Ligand B (355.4), but both are acceptable.
2. **TPSA:** Ligand A (97.82) is higher than Ligand B (66.07). While both are reasonably good, Ligand B is significantly better, falling well below the 140 threshold for good oral absorption.
3. **logP:** Ligand A (0.986) is at the lower end of the optimal range, while Ligand B (2.934) is closer to the ideal. This favors Ligand B for better membrane permeability.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer hydrogen bond donors generally improve permeability.
5. **HBA:** Ligand A (6) is preferable to Ligand B (5). Fewer hydrogen bond acceptors generally improve permeability.
6. **QED:** Ligand B (0.883) has a significantly better QED score than Ligand A (0.509), indicating a more drug-like profile.
7. **DILI:** Ligand A (74.99) has a lower DILI risk than Ligand B (85.23), which is a significant advantage.
8. **BBB:** Both ligands have good BBB penetration (Ligand A: 71.23, Ligand B: 78.79). Ligand B is slightly better, but this isn't a major deciding factor for ADRB2, which isn't necessarily a CNS target.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual. I will assume these are percentile scores, and thus higher is better. Ligand A (-5.135) is better than Ligand B (-4.913).
10. **Solubility:** Ligand A (-2.905) is better than Ligand B (-4.65).
11. **hERG:** Both ligands have low hERG risk (Ligand A: 0.711, Ligand B: 0.898).
12. **Cl_mic:** Ligand B (33.723) has significantly lower microsomal clearance than Ligand A (78.551), indicating better metabolic stability.
13. **t1/2:** Ligand B (28.358) has a much longer in vitro half-life than Ligand A (0.068), which is a major advantage.
14. **Pgp:** Both ligands have similar Pgp efflux liability (Ligand A: 0.259, Ligand B: 0.09).
15. **Binding Affinity:** Ligand B (-6.1 kcal/mol) has a slightly better binding affinity than Ligand A (-6.9 kcal/mol).
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP and TPSA, and has comparable Pgp and affinity. While Ligand A has a slightly better affinity, the improvements in ADME properties of Ligand B are more significant. The lower DILI risk of Ligand A is a positive, but the superior metabolic stability (Cl_mic and t1/2) of Ligand B is crucial for a viable drug candidate.
**Conclusion:**
Considering the balance of properties and the priorities for a GPCR target, Ligand B appears to be the more promising drug candidate.
Output:
0
2025-04-17 22:06:25,276 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (364.471) is slightly higher than Ligand B (343.427), but both are acceptable.
2. **TPSA:** Ligand A (87.32) is better than Ligand B (66.65) as it is still below 140, but closer to the ideal for oral absorption.
3. **logP:** Both ligands have good logP values (A: 2.078, B: 2.207), falling within the optimal 1-3 range.
4. **HBD:** Ligand A (2) is preferable to Ligand B (0). Having some HBD can improve solubility.
5. **HBA:** Ligand A (5) and Ligand B (4) are both acceptable.
6. **QED:** Both ligands have good QED scores (A: 0.751, B: 0.841), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand B (38.348) is significantly better than Ligand A (57.387) in terms of DILI risk, being well below the 40% threshold.
8. **BBB:** Ligand B (79.992) is substantially better than Ligand A (41.218). While ADRB2 isn't strictly a CNS target, some CNS penetration can be beneficial for understanding off-target effects and potential side effects.
9. **Caco-2:** Both have negative values, which is unusual. However, the magnitude is similar, and both suggest poor permeability.
10. **Solubility:** Ligand B (-1.709) is better than Ligand A (-2.746), indicating slightly better aqueous solubility.
11. **hERG:** Both ligands have low hERG inhibition risk (A: 0.388, B: 0.241), which is excellent.
12. **Cl_mic:** Ligand B (52.258) has slightly lower microsomal clearance than Ligand A (55.475), suggesting better metabolic stability.
13. **t1/2:** Ligand B (1.783) has a better in vitro half-life than Ligand A (-31.36).
14. **Pgp:** Ligand B (0.215) has a lower P-gp efflux liability than Ligand A (0.099), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand A (-6.7 kcal/mol) has a slightly better binding affinity than Ligand B (-5.5 kcal/mol). This is a 1.2 kcal/mol difference, which is significant.
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. While both ligands are good, Ligand B excels in several crucial ADME properties (DILI, BBB, solubility, Cl_mic, t1/2, Pgp) and has a very good binding affinity. The slightly weaker affinity of Ligand B is outweighed by its superior ADME profile, which will likely translate to better *in vivo* performance.
**Conclusion:**
Ligand B is the more promising drug candidate due to its significantly better ADME properties and acceptable binding affinity.
Output:
0
2025-04-17 22:06:25,276 - INFO - Batch 307 complete. Total preferences: 4912
2025-04-17 22:06:25,276 - INFO - Processing batch 308/512...
2025-04-17 22:07:13,478 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's systematically compare Ligand A and Ligand B based on the provided parameters and the guidelines, keeping in mind that ADRB2 is a GPCR. Therefore, logP, TPSA, Pgp, BBB, and affinity are particularly important.
1. **MW:** Both ligands (342.374 and 351.491 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (111.77) is slightly higher than Ligand B (69.72). Ligand B is significantly better, being well below the 140 A^2 threshold for good oral absorption and more favorable for GPCR targets.
3. **logP:** Both ligands have good logP values (2.033 and 1.787), falling within the optimal 1-3 range. Ligand B is slightly lower, which could be beneficial for solubility.
4. **HBD:** Ligand A has 3 HBD, while Ligand B has 1. Lower HBD is generally preferred for better permeability, giving a slight edge to Ligand B.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 3. Similar to HBD, Ligand B is slightly better.
6. **QED:** Both ligands have very similar QED values (0.772 and 0.768), indicating good drug-likeness.
7. **DILI:** Ligand A has a DILI risk of 61.07%, which is approaching the higher risk threshold. Ligand B has a much lower DILI risk of 20.706%, a significant advantage.
8. **BBB:** Ligand B (73.633%) shows better BBB penetration than Ligand A (54.13%). This is a crucial factor for GPCRs, even if this isn't a CNS target, as it can influence off-target effects.
9. **Caco-2:** Ligand A (-5.258) has a worse Caco-2 permeability than Ligand B (-4.406).
10. **Solubility:** Ligand A (-3.476) has worse solubility than Ligand B (-2.26).
11. **hERG:** Both ligands have low hERG inhibition liability (0.759 and 0.189), which is good. Ligand B is significantly better.
12. **Cl_mic:** Ligand A has a lower (better) microsomal clearance (-26.476) than Ligand B (38.017). This indicates better metabolic stability for Ligand A.
13. **t1/2:** Ligand A has a longer in vitro half-life (33.24 hours) than Ligand B (-20.392 hours). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.18) shows lower P-gp efflux than Ligand B (0.045), which is favorable.
15. **Affinity:** Ligand A (-8.7 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.5 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME drawbacks of Ligand A.
**Overall Assessment:**
While Ligand A has a superior binding affinity and better metabolic stability (lower Cl_mic and longer t1/2), Ligand B demonstrates a much more favorable ADME profile, particularly regarding DILI risk, BBB penetration, solubility, and hERG inhibition. The strong affinity of Ligand A is tempting, but the improved safety and pharmacokinetic properties of Ligand B make it a more promising starting point for drug development, especially considering the GPCR target class. The difference in affinity, while significant, might be addressable through further optimization, whereas mitigating a high DILI risk or poor solubility is often more challenging.
Output:
0
2025-04-17 22:07:13,478 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (327.351 and 351.403 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (98.34) is better than Ligand B (100.46), both are under the 140 threshold for oral absorption, but closer to the upper limit.
3. **logP:** Ligand A (2.574) is optimal (1-3). Ligand B (-0.344) is significantly lower, which could hinder membrane permeability and absorption. This is a substantial negative for Ligand B.
4. **HBD:** Both ligands have acceptable HBD counts (1 and 2, respectively), well below the 5 threshold.
5. **HBA:** Both ligands have acceptable HBA counts (7 and 6, respectively), well below the 10 threshold.
6. **QED:** Both ligands have good QED scores (0.623 and 0.706), indicating good drug-like properties.
7. **DILI:** Ligand A (95.386) has a high DILI risk, while Ligand B (26.677) has a very low risk. This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (39.822) has poor BBB penetration, while Ligand B (52.617) is better, but still not great. Since ADRB2 is a cardiovascular target, BBB penetration isn't *critical*, but some level is helpful for potential off-target effects.
9. **Caco-2:** Ligand A (-5.167) and Ligand B (-4.841) have negative values, which is unusual. Lower values suggest poor permeability.
10. **Solubility:** Ligand A (-4.35) and Ligand B (-1.748) have negative values, indicating poor solubility.
11. **hERG:** Ligand A (0.738) has a slightly higher hERG risk than Ligand B (0.195). Lower is better, so Ligand B is preferable.
12. **Cl_mic:** Ligand A (22.452) has a higher microsomal clearance than Ligand B (13.652), indicating lower metabolic stability. Ligand B is preferable.
13. **t1/2:** Ligand A (-19.686) has a negative in vitro half-life, which is concerning. Ligand B (19.356) has a positive half-life. This is a substantial advantage for Ligand B.
14. **Pgp:** Ligand A (0.341) has lower P-gp efflux than Ligand B (0.043). Lower efflux is better.
15. **Affinity:** Ligand B (-7.5 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.5 kcal/mol). This is a major advantage for Ligand B, exceeding the 1.5 kcal/mol threshold.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand B excels in affinity and has a better logP. While both have suboptimal TPSA, Ligand B's superior affinity and logP outweigh this. The DILI risk for Ligand A is also a major concern.
**Overall Assessment:**
Despite Ligand A having lower Pgp efflux, the significant advantages of Ligand B in terms of binding affinity, logP, DILI risk, and in vitro half-life outweigh the drawbacks. The negative solubility and Caco-2 values are concerning for both, but can be addressed with formulation strategies.
Output:
0
2025-04-17 22:07:13,478 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (332.323 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (83.98) is significantly better than Ligand A (105.83). ADRB2 is not a CNS target, but lower TPSA generally improves absorption.
3. **logP:** Both ligands have good logP values (A: 3.324, B: 2.384) within the optimal 1-3 range. Ligand B is slightly better.
4. **HBD:** Both have 2 HBD, which is acceptable.
5. **HBA:** Ligand A has 6 HBA, Ligand B has 5. Both are acceptable.
6. **QED:** Both ligands have good QED scores (A: 0.596, B: 0.648), indicating good drug-likeness. Ligand B is slightly better.
7. **DILI:** Ligand A (98.682) has a very high DILI risk, which is a major concern. Ligand B (78.286) is still elevated, but significantly lower and more acceptable.
8. **BBB:** Not a primary concern for ADRB2, but Ligand B (46.336) is slightly better than Ligand A (38.852).
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. This is a red flag for both.
10. **Solubility:** Both have negative solubility values, indicating poor solubility. This is also a red flag for both.
11. **hERG:** Both have low hERG inhibition liability (A: 0.356, B: 0.468), which is good.
12. **Cl_mic:** Ligand A (12.889) has a significantly lower microsomal clearance than Ligand B (35.906), suggesting better metabolic stability.
13. **t1/2:** Ligand A (49.608) has a longer in vitro half-life than Ligand B (8.14), which is desirable.
14. **Pgp:** Both have low Pgp efflux liability (A: 0.064, B: 0.099), which is good.
15. **Binding Affinity:** Ligand A (-7.4 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.5 kcal/mol). This is a substantial advantage.
**Overall Assessment:**
Ligand A has a much stronger binding affinity and better metabolic stability (lower Cl_mic, longer t1/2). However, its extremely high DILI risk is a major drawback. Ligand B has a lower DILI risk, slightly better logP and QED, but weaker binding affinity and poorer metabolic stability.
Considering the GPCR-specific priorities (affinity is key), the substantial affinity difference of -0.9 kcal/mol is a significant advantage for Ligand A. While the DILI risk is concerning, it might be mitigated through structural modifications during lead optimization. The poor Caco-2 and solubility are shared issues that would need to be addressed regardless of which lead is chosen. Given the importance of potency for GPCRs and the potential for mitigating the DILI risk through further optimization, I favor Ligand A.
Output:
1
2025-04-17 22:07:13,478 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (458.79 Da) is within the ideal range, while Ligand B (354.416 Da) is also acceptable, leaning towards the lower end. No strong preference here.
2. **TPSA:** Ligand A (63.16) is higher than Ligand B (33.2). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B is better.
3. **logP:** Both ligands (A: 4.442, B: 4.671) are slightly above the optimal range (1-3), potentially raising concerns about solubility and off-target effects. However, they are not dramatically high.
4. **HBD:** Both have 0 HBD, which is good.
5. **HBA:** Ligand A has 5 HBA, while Ligand B has 2. Lower HBA is generally favorable for permeability. Ligand B is better.
6. **QED:** Both ligands have good QED scores (A: 0.567, B: 0.667), indicating drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (87.941) has a significantly higher DILI risk than Ligand B (24.544). This is a major concern for Ligand A.
8. **BBB:** Ligand A (45.715) has a low BBB penetration, which is not a major concern for a cardiovascular target. Ligand B (92.051) has high BBB penetration, which is not necessarily desirable for a peripheral target like ADRB2.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual. Assuming these are percentile scores, both have poor permeability.
10. **Solubility:** Ligand A (-6.462) has very poor solubility, while Ligand B (-4.698) is also poor, but less so. Ligand B is better.
11. **hERG:** Both ligands have low hERG inhibition risk (A: 0.505, B: 0.712). No strong preference.
12. **Cl_mic:** Ligand A (73.986) has higher microsomal clearance than Ligand B (64.995), indicating lower metabolic stability. Ligand B is better.
13. **t1/2:** Ligand B (3.649) has a slightly longer in vitro half-life than Ligand A (-17.175). This is a significant advantage for Ligand B.
14. **Pgp:** Both ligands have low Pgp efflux liability (A: 0.464, B: 0.493). No strong preference.
15. **Binding Affinity:** Ligand A (-6.5 kcal/mol) has a slightly better binding affinity than Ligand B (-6.1 kcal/mol). This is a positive for Ligand A, but the difference is not huge.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity) and the general guidelines, Ligand B is the more promising candidate. While both have some drawbacks, Ligand A's significantly higher DILI risk and poor solubility are major concerns. Ligand B has better TPSA, HBA, QED, DILI, solubility, metabolic stability (lower Cl_mic), and a longer half-life. The slightly weaker affinity of Ligand B is outweighed by its superior ADME-Tox profile.
Output:
0
2025-04-17 22:07:13,478 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [366.447, 118.01 , 2.028, 3. , 6. , 0.748, 83.908, 50.097, -4.891, -3.679, 0.098, 33.499, 6.722, 0.085, -6.9 ]
**Ligand B:** [350.459, 67.87 , 1.622, 1. , 4. , 0.739, 12.136, 75.107, -4.722, -2.046, 0.292, 32.467, 13.775, 0.034, -6.9 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal 200-500 Da range. Ligand B (350.459) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (118.01) is higher than Ligand B (67.87). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is still preferred for better absorption. Ligand B is significantly better here.
3. **logP:** Both are within the optimal 1-3 range. Ligand B (1.622) is slightly lower than Ligand A (2.028), potentially impacting permeability, but both are acceptable.
4. **HBD:** Ligand A (3) is higher than Ligand B (1). Lower is generally preferred, giving a slight edge to Ligand B.
5. **HBA:** Ligand A (6) is higher than Ligand B (4). Again, lower is preferred, favoring Ligand B.
6. **QED:** Both are very similar and good (0.748 and 0.739), indicating good drug-like properties.
7. **DILI:** Ligand A (83.908) has a significantly higher DILI risk than Ligand B (12.136). This is a major concern for Ligand A.
8. **BBB:** Ligand B (75.107) has a higher BBB penetration potential than Ligand A (50.097). While not a primary concern for a cardiovascular target, higher BBB is generally a positive attribute.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Ligand A (-3.679) has worse solubility than Ligand B (-2.046). Solubility is important for bioavailability.
11. **hERG:** Both have very low hERG inhibition risk (0.098 and 0.292). This is excellent.
12. **Cl_mic:** Both have similar microsomal clearance (33.499 and 32.467), suggesting comparable metabolic stability.
13. **t1/2:** Ligand B (13.775) has a significantly longer in vitro half-life than Ligand A (6.722). This is a major advantage for Ligand B.
14. **Pgp:** Both have very low P-gp efflux liability (0.085 and 0.034). This is excellent.
15. **Affinity:** Both have the same binding affinity (-6.9 kcal/mol), so this parameter doesn't differentiate them.
**GPCR-Specific Priorities:** For ADRB2 (a cardiovascular GPCR), we prioritize logP, TPSA, Pgp, and affinity. Ligand B clearly wins on TPSA, has a slightly better logP, and comparable Pgp and affinity. The significantly lower DILI risk and longer half-life of Ligand B are also crucial advantages.
**Conclusion:**
Considering all factors, particularly the significantly lower DILI risk, better TPSA, and longer half-life, Ligand B is the more promising drug candidate.
0
2025-04-17 22:07:13,478 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [354.447, 68.31, 0.831, 0, 5, 0.661, 46.064, 58.782, -4.446, -0.968, 0.132, 31.117, 1.058, 0.049, -7.4]
**Ligand B:** [350.415, 77.1, -0.064, 1, 5, 0.679, 30.399, 52.617, -4.874, -1.313, 0.102, -17.865, 17.903, 0.012, -6.2]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity):
1. **MW:** Both are within the ideal 200-500 Da range. A (354.447) and B (350.415) are very similar.
2. **TPSA:** A (68.31) is better than B (77.1). Lower TPSA generally favors better absorption.
3. **logP:** A (0.831) is slightly better than B (-0.064). B is very close to 0, which could lead to permeability issues.
4. **HBD:** A (0) is preferable to B (1). Fewer HBDs generally improve permeability.
5. **HBA:** Both have 5, which is acceptable.
6. **QED:** Both are good (A: 0.661, B: 0.679), indicating drug-like properties.
7. **DILI:** A (46.064) is slightly higher than B (30.399), but both are below the concerning threshold of 60. B is better here.
8. **BBB:** A (58.782) is better than B (52.617), though neither is exceptionally high. For a cardiovascular target, BBB isn't *critical*, but some penetration can be beneficial for off-target effects.
9. **Caco-2:** Both are negative, indicating poor permeability. A (-4.446) is slightly better than B (-4.874).
10. **Solubility:** A (-0.968) is better than B (-1.313), indicating slightly better solubility.
11. **hERG:** Both are very low (A: 0.132, B: 0.102), which is excellent.
12. **Cl_mic:** A (31.117) is much better than B (-17.865). A positive value for B indicates rapid clearance, a significant drawback.
13. **t1/2:** A (1.058) is much worse than B (17.903). This is a major advantage for B.
14. **Pgp:** Both are very low (A: 0.049, B: 0.012), indicating minimal efflux. B is slightly better.
15. **Affinity:** A (-7.4) is significantly better than B (-6.2). A 1.2 kcal/mol difference is substantial and can often outweigh other issues.
**Overall Assessment:**
Ligand A has a clear advantage in binding affinity, a crucial factor for GPCRs. It also has better TPSA, logP, solubility, and microsomal clearance. However, Ligand B has a significantly longer half-life and lower DILI risk. The poor Caco-2 values for both are concerning, but the superior affinity of Ligand A is likely to be more impactful in driving *in vivo* efficacy. The better metabolic stability (Cl_mic) of A also helps offset the shorter half-life.
Considering the balance, the stronger binding affinity of Ligand A is the deciding factor.
Output:
1
2025-04-17 22:07:13,479 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the acceptable range (200-500 Da). Ligand A (426.336 Da) is slightly higher than Ligand B (346.395 Da), but this isn't a major concern.
**2. TPSA:** Ligand A (74.91) is better than Ligand B (120.83). For a cardiovascular GPCR, TPSA should be relatively low to facilitate good absorption and distribution. Ligand B is pushing the upper limit for oral absorption.
**3. logP:** Ligand A (3.572) is optimal, while Ligand B (-0.37) is significantly lower. A negative logP can indicate poor membrane permeability. This is a substantial drawback for Ligand B.
**4. H-Bond Donors:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
**5. H-Bond Acceptors:** Ligand A (5) is better than Ligand B (7). Similar to HBDs, lower HBA counts are generally preferred.
**6. QED:** Both ligands have acceptable QED values (A: 0.797, B: 0.656), indicating reasonable drug-likeness.
**7. DILI Risk:** Both ligands have acceptable DILI risk (A: 71.229, B: 63.552), below the concerning threshold of 60.
**8. BBB Penetration:** Ligand A (62.35) is better than Ligand B (36.099), although BBB isn't a primary concern for a cardiovascular target.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests a potential issue with the data or the model. However, the values are similar (-5.148 vs -5.711).
**10. Aqueous Solubility:** Both ligands have negative solubility values, which is also unusual. Again, the values are similar (-3.431 vs -1.975).
**11. hERG Inhibition:** Both ligands show low hERG inhibition risk (A: 0.112, B: 0.318).
**12. Microsomal Clearance:** Ligand A (-12.658) has a much lower (better) microsomal clearance than Ligand B (15.42). This suggests greater metabolic stability for Ligand A.
**13. In vitro Half-Life:** Ligand A (8.062) has a slightly better in vitro half-life than Ligand B (8.683).
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (A: 0.306, B: 0.015).
**15. Binding Affinity:** Ligand B (-6.6 kcal/mol) has a slightly better binding affinity than Ligand A (-5.4 kcal/mol). However, the difference is not substantial enough to overcome the significant ADME deficiencies of Ligand B.
**GPCR-Specific Considerations:** For a GPCR like ADRB2, logP, TPSA, and Pgp are important. Ligand A is significantly better in terms of logP and TPSA. While affinity is crucial, the substantial drawbacks of Ligand B in permeability and solubility outweigh the slight affinity advantage.
**Conclusion:**
Ligand A is the more promising drug candidate due to its superior logP, TPSA, metabolic stability (lower Cl_mic), and acceptable overall profile. Ligand B's negative logP is a major red flag, suggesting poor permeability.
Output:
1
2025-04-17 22:07:13,479 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (351.447 and 348.491 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (78.95) is higher than Ligand B (57.7). Both are below the 140 threshold for oral absorption, but B is better positioned for potential CNS penetration if desired (though ADRB2 isn't strictly a CNS target).
3. **logP:** Ligand A (0.387) is quite low, potentially hindering permeability. Ligand B (2.072) is within the optimal 1-3 range. This is a significant advantage for B.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Both have 5 HBA, which is good.
6. **QED:** Both have good QED scores (0.671 and 0.693), indicating generally drug-like properties.
7. **DILI:** Ligand A (16.557) has a slightly higher DILI risk than Ligand B (13.532), but both are below the concerning 40% threshold.
8. **BBB:** Ligand B (90.112) has a much higher BBB penetration percentile than Ligand A (62.97). While ADRB2 isn't a primary CNS target, higher BBB penetration can sometimes correlate with better overall distribution.
9. **Caco-2:** Ligand A (-4.76) and Ligand B (-4.406) both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Ligand A (-0.443) has slightly better solubility than Ligand B (-1.694), but both are quite poor.
11. **hERG:** Ligand A (0.116) has a lower hERG risk than Ligand B (0.716), which is a significant advantage.
12. **Cl_mic:** Ligand A (3.737) has a much lower microsomal clearance than Ligand B (59.722), suggesting better metabolic stability. This is a crucial advantage.
13. **t1/2:** Ligand B (41.662) has a significantly longer in vitro half-life than Ligand A (0.551). This is a major benefit for dosing convenience.
14. **Pgp:** Ligand A (0.016) has much lower P-gp efflux liability than Ligand B (0.063), which is good for bioavailability.
15. **Binding Affinity:** Ligand B (-4.9) has a slightly better binding affinity than Ligand A (-6.0). However, the difference is not substantial enough to outweigh other factors.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP and BBB, while Ligand A has better Pgp efflux and hERG. The difference in binding affinity is small. The significantly better metabolic stability (lower Cl_mic) of Ligand A is a strong point. However, the longer half-life of Ligand B is also very attractive.
**Overall Assessment:**
Despite Ligand A's advantages in hERG and Pgp, Ligand B's superior logP, BBB, and significantly longer half-life, coupled with acceptable DILI and hERG, make it a more promising candidate. The poor solubility of both compounds is a concern that would need to be addressed in formulation.
Output:
0
2025-04-17 22:07:13,479 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (359.813 and 350.419 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (72.39) is significantly better than Ligand B (115.57). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand B is pushing the upper limit for good oral absorption.
3. **logP:** Ligand A (2.773) is optimal, while Ligand B (0.342) is quite low. Low logP can hinder membrane permeability and reduce bioavailability. This is a significant advantage for Ligand A.
4. **HBD:** Ligand A (0) is preferable to Ligand B (3). Fewer hydrogen bond donors generally improve permeability.
5. **HBA:** Both ligands have 6 HBA, which is acceptable.
6. **QED:** Ligand A (0.603) is slightly better than Ligand B (0.582), indicating a slightly more drug-like profile.
7. **DILI:** Ligand B (53.276) has a considerably lower DILI risk than Ligand A (74.99). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (91.276) has better BBB penetration than Ligand B (73.401). While ADRB2 is not a CNS target, some off-target CNS effects are possible with GPCR ligands, and higher BBB can sometimes correlate with increased off-target activity.
9. **Caco-2:** Ligand A (-4.727) is better than Ligand B (-5.376). Higher Caco-2 values indicate better intestinal absorption.
10. **Solubility:** Ligand A (-3.778) is better than Ligand B (-2.087). Better solubility is important for formulation and bioavailability.
11. **hERG:** Both ligands have low hERG inhibition risk (0.342 and 0.288 respectively). No significant difference.
12. **Cl_mic:** Ligand B (-2.726) has a much lower (better) microsomal clearance than Ligand A (90.298). This suggests better metabolic stability for Ligand B.
13. **t1/2:** Ligand A (-4.485) has a better in vitro half-life than Ligand B (0.474).
14. **Pgp:** Ligand A (0.211) has lower P-gp efflux than Ligand B (0.005). Lower efflux is generally desirable.
15. **Binding Affinity:** Ligand B (-6.7 kcal/mol) has a significantly better binding affinity than Ligand A (-5.7 kcal/mol). This is a 1.0 kcal/mol difference, which is substantial enough to potentially outweigh some ADME drawbacks.
**GPCR-specific priorities:** For ADRB2 (a cardiovascular GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A excels in logP, TPSA, and Pgp, while Ligand B has superior affinity. The DILI risk is also a concern, and Ligand B is better in this regard. The metabolic stability of Ligand B is also a significant advantage.
**Overall Assessment:**
While Ligand A has better physicochemical properties regarding permeability and solubility, the significantly stronger binding affinity of Ligand B (-6.7 vs -5.7 kcal/mol) and its lower DILI risk are compelling advantages. The improved metabolic stability (lower Cl_mic) also supports Ligand B. The lower logP of Ligand B is a drawback, but the strong binding affinity could compensate for this.
Output:
0
2025-04-17 22:07:13,479 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (376.519) is slightly higher than Ligand B (352.431), but both are acceptable.
2. **TPSA:** Ligand A (92.78) is better than Ligand B (107.89). Both are below 140, but lower is preferred for absorption.
3. **logP:** Ligand A (0.837) is slightly better than Ligand B (0.56). Both are a bit low, potentially impacting permeability, but still within an acceptable range.
4. **HBD:** Ligand A (1) is better than Ligand B (4). Lower HBD is generally preferred for better permeability.
5. **HBA:** Both ligands have 5 HBA, which is acceptable.
6. **QED:** Ligand A (0.677) is significantly better than Ligand B (0.427). A higher QED suggests a more drug-like profile.
7. **DILI:** Both ligands have similar DILI risk (Ligand A: 26.406, Ligand B: 28.306), and both are below the 40 threshold, indicating low risk.
8. **BBB:** Ligand A (66.188) is substantially better than Ligand B (20.512). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be beneficial and isn't detrimental in this case.
9. **Caco-2:** Ligand A (-5.046) is better than Ligand B (-5.625), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-1.487) is better than Ligand B (-2.268), indicating better aqueous solubility.
11. **hERG:** Ligand A (0.322) is better than Ligand B (0.081), indicating lower hERG inhibition liability and reduced cardiotoxicity risk.
12. **Cl_mic:** Ligand A (24.3) is better than Ligand B (-17.092). A negative value for Cl_mic suggests very high metabolic stability, which is a strong advantage for Ligand B, but Ligand A is still acceptable.
13. **t1/2:** Ligand A (11.901) is better than Ligand B (17.733). A longer half-life is generally desirable.
14. **Pgp:** Both ligands have very low Pgp efflux liability (Ligand A: 0.015, Ligand B: 0.012), which is excellent.
15. **Binding Affinity:** Ligand B (-7.9) has a significantly stronger binding affinity than Ligand A (-6.2). This is a 1.7 kcal/mol difference, which is substantial and can outweigh some ADME drawbacks.
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B has a better affinity. However, Ligand A has better TPSA, solubility, and a significantly better BBB score. The difference in logP isn't substantial enough to negate the other advantages of Ligand A.
**Overall Assessment:**
While Ligand B has a stronger binding affinity, Ligand A demonstrates a more balanced profile with better drug-like properties (QED, solubility, TPSA, HBD, hERG) and a reasonable BBB score. The affinity difference, while significant, isn't so large that it completely overshadows the improved ADME profile of Ligand A. Considering the overall balance, Ligand A is the more promising candidate.
Output:
1
2025-04-17 22:07:13,479 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 drug candidates. ADRB2 is a GPCR, so we'll prioritize logP, Pgp, TPSA, and affinity, alongside general drug-like properties.
**Ligand A:**
* **MW:** 352.475 Da - Good, within the ideal range.
* **TPSA:** 89.87 - Excellent, well below the 140 threshold, good for absorption.
* **logP:** 1.053 - Acceptable, slightly on the lower side but still within the 1-3 range.
* **HBD:** 3 - Good, within the acceptable limit.
* **HBA:** 4 - Good, within the acceptable limit.
* **QED:** 0.609 - Very good, indicates good drug-likeness.
* **DILI:** 22.722 - Excellent, very low risk of liver injury.
* **BBB:** 58.938 - Moderate, not ideal for a CNS target, but ADRB2 is primarily cardiovascular, so this isn't a major drawback.
* **Caco-2:** -5.011 - Poor, indicates low intestinal absorption.
* **Solubility:** -3.066 - Poor, indicates low aqueous solubility.
* **hERG:** 0.486 - Excellent, very low risk of hERG inhibition.
* **Cl_mic:** 42.078 - Moderate, could be better for metabolic stability.
* **t1/2:** 45.248 - Good, reasonable in vitro half-life.
* **Pgp:** 0.031 - Excellent, low P-gp efflux.
* **Affinity:** -6.3 kcal/mol - Good binding affinity.
**Ligand B:**
* **MW:** 350.463 Da - Good, within the ideal range.
* **TPSA:** 83.36 - Excellent, well below the 140 threshold.
* **logP:** 2.427 - Good, within the optimal range.
* **HBD:** 1 - Good, low HBD count.
* **HBA:** 5 - Good, within the acceptable limit.
* **QED:** 0.716 - Very good, excellent drug-likeness.
* **DILI:** 35.556 - Good, low risk of liver injury.
* **BBB:** 64.831 - Moderate, similar to Ligand A, not critical for cardiovascular target.
* **Caco-2:** -5.023 - Poor, similar to Ligand A, indicates low intestinal absorption.
* **Solubility:** -1.804 - Poor, indicates low aqueous solubility, but better than Ligand A.
* **hERG:** 0.187 - Excellent, very low risk of hERG inhibition.
* **Cl_mic:** 24.188 - Good, better metabolic stability than Ligand A.
* **t1/2:** 14.903 - Moderate, shorter half-life than Ligand A.
* **Pgp:** 0.036 - Excellent, low P-gp efflux.
* **Affinity:** -6.9 kcal/mol - Very good, stronger binding affinity than Ligand A (a 0.6 kcal/mol difference).
**Comparison and Decision:**
Both ligands have good MW, TPSA, and H-bond characteristics. Both have poor Caco-2 and solubility. Ligand B has a slightly better logP, DILI, Cl_mic, and a significantly better binding affinity (-6.9 vs -6.3 kcal/mol). The affinity difference is substantial enough to outweigh the slightly shorter half-life of Ligand B. While both have similar Pgp values, the improved metabolic stability and binding affinity of Ligand B make it the more promising candidate.
Output:
0
2025-04-17 22:07:13,479 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (346.431 and 345.399 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (89.28) is slightly higher than Ligand B (82.97), but both are below the 140 threshold for good oral absorption and acceptable for a cardiovascular GPCR target. Ligand B is preferable.
3. **logP:** Ligand A (2.784) is optimal, while Ligand B (0.296) is quite low. A logP below 1 can hinder membrane permeability. This is a significant advantage for Ligand A.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable, being less than 5. Ligand B is slightly preferable.
5. **HBA:** Both ligands have 5 HBA, which is within the acceptable range. No difference.
6. **QED:** Ligand B (0.83) has a higher QED score than Ligand A (0.729), indicating a more drug-like profile. This favors Ligand B.
7. **DILI:** Ligand B (24.777) has a much lower DILI risk than Ligand A (54.323). This is a substantial advantage for Ligand B.
8. **BBB:** Both ligands have good BBB penetration (Ligand A: 79.566, Ligand B: 72.664), but Ligand A is slightly better. For a cardiovascular target, BBB penetration isn't *critical*, but it's a bonus.
9. **Caco-2:** Both ligands have negative Caco-2 permeability values, which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-2.938) has worse solubility than Ligand B (-1.414). Better solubility is always preferred. Ligand B is preferable.
11. **hERG:** Ligand A (0.247) has a lower hERG risk than Ligand B (0.409). This is a significant advantage for Ligand A, as hERG inhibition can lead to cardiotoxicity.
12. **Cl_mic:** Ligand B (5.562) has a much lower microsomal clearance than Ligand A (49.669), indicating better metabolic stability. This is a major advantage for Ligand B.
13. **t1/2:** Both ligands have similar in vitro half-lives (Ligand A: 6.587, Ligand B: 6.963). No significant difference.
14. **Pgp:** Ligand A (0.057) has lower P-gp efflux than Ligand B (0.025). Lower P-gp efflux is preferable. Ligand A is preferable.
15. **Binding Affinity:** Ligand B (-6.5 kcal/mol) has a slightly better binding affinity than Ligand A (-5.8 kcal/mol). While the difference is not huge, it is still a positive for Ligand B.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand A has a better logP and Pgp, while Ligand B has better TPSA, affinity, DILI, and Cl_mic. The significant advantages of Ligand B in DILI and Cl_mic, coupled with its slightly better affinity, outweigh the logP advantage of Ligand A. The hERG risk of Ligand A is also a concern.
**Conclusion:**
Considering all factors, especially the GPCR-specific priorities and the significant advantages of Ligand B in DILI risk and metabolic stability, I believe **Ligand B** is the more promising drug candidate.
Output:
0
2025-04-17 22:07:13,479 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands (384.42 & 349.435 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (83.55) is better than Ligand B (107.4). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have acceptable logP values (1.115 & 1.996), falling within the 1-3 range. Ligand B is slightly higher, potentially aiding membrane permeability.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Both ligands have 4 HBA, which is good.
6. **QED:** Ligand A (0.79) has a significantly better QED score than Ligand B (0.466), indicating a more drug-like profile.
7. **DILI:** Ligand A (36.681) has a slightly better DILI score than Ligand B (30.748), indicating lower potential for liver injury. Both are good.
8. **BBB:** Ligand A (93.098) has a much higher BBB penetration percentile than Ligand B (76.89). While not a primary concern for a cardiovascular target, higher BBB is generally not detrimental.
9. **Caco-2:** Ligand A (-4.54) and Ligand B (-4.774) are similar, indicating similar intestinal absorption.
10. **Solubility:** Ligand A (-2.541) and Ligand B (-2.765) are similar, indicating similar solubility.
11. **hERG:** Both ligands have low hERG inhibition liability (0.36 & 0.162), which is excellent.
12. **Cl_mic:** Ligand A (1.984) has a significantly lower microsomal clearance than Ligand B (25.745), suggesting better metabolic stability. This is a crucial advantage.
13. **t1/2:** Ligand A (-30.619) has a much longer in vitro half-life than Ligand B (-3.433), further supporting better metabolic stability.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.036 & 0.011).
15. **Binding Affinity:** Ligand B (-6.9) has a slightly better binding affinity than Ligand A (-6.4), a 0.5 kcal/mol difference. While affinity is important, the ADME benefits of Ligand A are more compelling.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B has a slightly better logP and affinity, but Ligand A excels in TPSA and has comparable Pgp. The significant advantages of Ligand A in QED, DILI, BBB, Cl_mic, and t1/2 outweigh the minor affinity difference. Metabolic stability (Cl_mic and t1/2) is particularly important for sustained cardiovascular effects.
**Conclusion:**
Ligand A presents a more balanced and favorable profile for drug development, particularly considering its superior ADME properties and drug-likeness.
Output:
1
2025-04-17 22:07:13,479 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (369.49 & 389.59 Da) fall comfortably within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (89.55) is slightly higher than Ligand B (72.88). Both are below the 140 threshold for oral absorption, but B is closer to the 90 threshold which is desirable for GPCRs. Slight advantage to B.
3. **logP:** Ligand A (1.761) is better than Ligand B (0.706), falling squarely within the optimal 1-3 range. Ligand B is a bit low, potentially hindering permeation. Significant advantage to A.
4. **HBD:** Both ligands have 2 HBD, which is within the acceptable limit of 5. No difference.
5. **HBA:** Both ligands have 6 HBA, within the acceptable limit of 10. No difference.
6. **QED:** Both ligands have similar QED values (0.614 vs 0.668), indicating good drug-likeness. No significant difference.
7. **DILI:** Ligand B (11.09) has a *much* lower DILI risk than Ligand A (54.75). This is a major advantage for B.
8. **BBB:** Ligand A (53.82) has a higher BBB penetration percentile than Ligand B (34.63). While ADRB2 isn't strictly a CNS target, some CNS exposure can be acceptable and even beneficial for peripheral effects. Advantage to A.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.332 and -5.37). This is unusual and suggests poor permeability. No clear advantage.
10. **Solubility:** Ligand A (-1.48) is slightly better than Ligand B (-1.766), but both are quite poor. Solubility is a concern for both. Slight advantage to A.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.225 and 0.232). No difference.
12. **Cl_mic:** Ligand B (3.998) has significantly lower microsomal clearance than Ligand A (15.812), indicating better metabolic stability. Major advantage to B.
13. **t1/2:** Ligand A (29.737) has a longer in vitro half-life than Ligand B (-4.224). This is a significant advantage for A.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.051 and 0.024). No difference.
15. **Binding Affinity:** Ligand A (-5.9 kcal/mol) has a slightly better binding affinity than Ligand B (-5.1 kcal/mol). This is a 0.8 kcal/mol difference, which is noteworthy. Advantage to A.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity) and general drug-like properties, this is a challenging comparison. Ligand A has advantages in logP, BBB, half-life, and binding affinity. However, Ligand B has a *much* better safety profile (DILI) and metabolic stability (Cl_mic). The negative Caco-2 values are concerning for both, indicating permeability issues that would need to be addressed.
Given the importance of minimizing toxicity and maximizing metabolic stability for a cardiovascular drug, I prioritize Ligand B despite its slightly lower affinity and logP. The significant reduction in DILI risk and improved metabolic stability outweigh the modest benefits of Ligand A.
Output:
0
2025-04-17 22:07:13,480 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (339.483 and 351.422 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (46.92) is significantly better than Ligand B (66.65). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally aids absorption.
3. **logP:** Ligand A (4.619) is higher than Ligand B (2.289). While both are within the acceptable range, Ligand A is approaching the upper limit where solubility issues could arise. Ligand B's logP is more optimal.
4. **HBD:** Ligand A (1) is better than Ligand B (0). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (3) is slightly better than Ligand B (4). Lower HBA is generally preferred.
6. **QED:** Both ligands have similar QED values (0.887 and 0.835), indicating good drug-likeness.
7. **DILI:** Ligand A (55.021) has a higher DILI risk than Ligand B (24.855). This is a significant advantage for Ligand B.
8. **BBB:** Both ligands have high BBB penetration (95.657 and 88.174). While not critical for a cardiovascular target, it doesn't hurt.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.639 and -4.486). This is unusual and suggests poor permeability.
10. **Solubility:** Ligand A (-5.557) has worse solubility than Ligand B (-2.448). This is a concern given Ligand A's higher logP.
11. **hERG:** Ligand A (0.883) has a slightly higher hERG risk than Ligand B (0.451), but both are reasonably low.
12. **Cl_mic:** Ligand B (43.687) has significantly lower microsomal clearance than Ligand A (64.366), indicating better metabolic stability.
13. **t1/2:** Ligand A (86.568) has a much longer in vitro half-life than Ligand B (-2.584). This is a major advantage for Ligand A.
14. **Pgp:** Ligand A (0.857) has higher P-gp efflux than Ligand B (0.134). This is a disadvantage for Ligand A.
15. **Affinity:** Ligand A (-6.3 kcal/mol) has a slightly better binding affinity than Ligand B (-5.9 kcal/mol). This is a 0.4 kcal/mol difference, which is not huge but still relevant.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has a better affinity and lower TPSA, but Ligand B has a much better logP, lower Pgp efflux, and significantly lower DILI risk, and better metabolic stability. The longer half-life of Ligand A is attractive, but the other factors weigh more heavily in favor of Ligand B.
**Conclusion:**
Considering the balance of properties, Ligand B is the more promising drug candidate. Its lower DILI risk, better logP, lower Pgp efflux, and improved metabolic stability outweigh the slightly weaker affinity and shorter half-life.
Output:
0
2025-04-17 22:07:13,480 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (341.455 Da) is well within the ideal range (200-500 Da). Ligand B (373.519 Da) is also acceptable. No clear advantage here.
2. **TPSA:** Ligand A (71.09) is excellent, well below the 140 threshold for oral absorption. Ligand B (95.58) is still reasonable, but less optimal. This favors Ligand A.
3. **logP:** Ligand A (2.686) is within the optimal range (1-3). Ligand B (0.023) is very low, potentially hindering membrane permeability. This strongly favors Ligand A.
4. **HBD:** Both ligands have 2 HBD, which is good.
5. **HBA:** Ligand A has 3 HBA, Ligand B has 5. Both are acceptable, but Ligand A is slightly better.
6. **QED:** Ligand A (0.782) is excellent, indicating high drug-likeness. Ligand B (0.556) is acceptable, but lower. This favors Ligand A.
7. **DILI:** Ligand A (43.66) has a slightly higher DILI risk than Ligand B (29.624), but both are below the concerning threshold of 60. This favors Ligand B, but the difference isn't huge.
8. **BBB:** Ligand A (70.415) has good BBB penetration, while Ligand B (50.679) is lower. Given ADRB2's cardiovascular role, BBB isn't a *primary* concern, but it's a positive for Ligand A.
9. **Caco-2:** Ligand A (-4.762) and Ligand B (-5.306) are both very poor, indicating poor intestinal absorption. This is a significant drawback for both.
10. **Solubility:** Ligand A (-3.558) has slightly better solubility than Ligand B (-1.1), though both are poor.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.183 and 0.299, respectively). No clear advantage.
12. **Cl_mic:** Ligand A (51.604) has a higher microsomal clearance than Ligand B (5.026), indicating lower metabolic stability. This favors Ligand B.
13. **t1/2:** Ligand A (-19.828) has a negative half-life, which is problematic. Ligand B (8.64) has a reasonable half-life. This strongly favors Ligand B.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.118 and 0.016, respectively). No clear advantage.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-5.1 and -4.9 kcal/mol). The difference is not substantial enough to outweigh other factors.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand A initially looks better due to its superior logP and TPSA. However, Ligand B has significantly better metabolic stability (lower Cl_mic, positive t1/2) and a lower DILI risk. The poor Caco-2 permeability is a concern for both, but can potentially be addressed with formulation strategies. Given the importance of metabolic stability for *in vivo* efficacy, and the acceptable (though not ideal) BBB penetration, Ligand B appears to be the more promising candidate.
Output:
0
2025-04-17 22:07:13,480 - INFO - Batch 308 complete. Total preferences: 4928
2025-04-17 22:07:13,480 - INFO - Processing batch 309/512...
2025-04-17 22:08:04,351 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**1. Molecular Weight:** Both ligands (352.431 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (81.01) is slightly better than Ligand B (84.94), both are below the 140 threshold for oral absorption, but closer to the upper limit.
**3. logP:** Ligand A (2.729) is optimal, while Ligand B (0.514) is quite low. For a GPCR, a logP between 1-3 is preferred for good membrane permeability and binding. Ligand B's low logP is a significant concern.
**4. H-Bond Donors:** Both ligands have 1 HBD, which is within the acceptable limit of 5.
**5. H-Bond Acceptors:** Both ligands have 5 HBA, which is within the acceptable limit of 10.
**6. QED:** Ligand A (0.851) has a better QED score than Ligand B (0.753), indicating a more drug-like profile.
**7. DILI:** Ligand A (38.969) has a slightly higher DILI risk than Ligand B (30.012), but both are below the 40 threshold and therefore considered low risk.
**8. BBB:** Both ligands have similar BBB penetration (Ligand A: 65.529, Ligand B: 65.413). While not exceptionally high, it's not a primary concern for ADRB2, which isn't necessarily a CNS target.
**9. Caco-2 Permeability:** Ligand A (-4.453) is better than Ligand B (-4.806). Higher values are better, indicating better intestinal absorption.
**10. Aqueous Solubility:** Ligand A (-2.64) is better than Ligand B (-1.281). Higher values are better for formulation and bioavailability.
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (Ligand A: 0.138, Ligand B: 0.066).
**12. Microsomal Clearance:** Ligand B (-3.017) has significantly lower microsomal clearance than Ligand A (48.657), suggesting better metabolic stability.
**13. In vitro Half-Life:** Ligand B (-3.997) has a longer in vitro half-life than Ligand A (29.038), which is desirable.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (Ligand A: 0.013, Ligand B: 0.015).
**15. Binding Affinity:** Ligand A (-7.8 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.4 kcal/mol). This is a substantial difference (1.4 kcal/mol), which can outweigh some ADME drawbacks.
**Overall Assessment:**
While Ligand B has advantages in metabolic stability (Cl_mic, t1/2) and slightly lower DILI risk, the significantly lower logP is a major concern. This will likely hinder its ability to cross cell membranes and reach the ADRB2 receptor effectively. Ligand A, despite slightly higher clearance, has a much more favorable logP, better solubility, Caco-2 permeability, QED, and, crucially, a much stronger binding affinity. The 1.4 kcal/mol difference in binding affinity is substantial and likely to be a key driver of efficacy.
Considering these factors, and prioritizing binding affinity and permeability for a GPCR target, Ligand A is the more promising drug candidate.
Output:
1
2025-04-17 22:08:04,352 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
The ADRB2 receptor is a GPCR, so the priorities are logP, Pgp, TPSA, affinity, and BBB. Let's compare the ligands property by property:
1. **MW:** Both ligands (348.491 and 361.913 Da) fall within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (68.3) is higher than Ligand B (29.54). Ligand B is significantly better here, being well below the 140 threshold for good absorption.
3. **logP:** Ligand A (3.241) is within the optimal 1-3 range. Ligand B (4.531) is slightly higher, potentially leading to solubility issues or off-target interactions, but still acceptable.
4. **HBD:** Ligand A (2) is reasonable. Ligand B (0) is even better, minimizing potential for unwanted interactions.
5. **HBA:** Ligand A (6) is acceptable. Ligand B (2) is excellent.
6. **QED:** Both ligands (0.668 and 0.744) have good drug-likeness scores.
7. **DILI:** Ligand A (34.665) has a slightly higher DILI risk than Ligand B (23.885), but both are below the concerning 60 threshold.
8. **BBB:** Both ligands have high BBB penetration (90.306 and 92.672), which is good, but less critical for ADRB2 (a cardiovascular target) than for a CNS target.
9. **Caco-2:** Both have negative values, which is unusual. Assuming these are logP-scale values, they indicate poor permeability.
10. **Solubility:** Both have negative solubility values, indicating poor solubility.
11. **hERG:** Both ligands have low hERG inhibition risk (0.879 and 0.824).
12. **Cl_mic:** Both have similar microsomal clearance (75.675 and 76.521), suggesting comparable metabolic stability.
13. **t1/2:** Ligand B (34.155) has a slightly longer in vitro half-life than Ligand A (30.048).
14. **Pgp:** Both have low Pgp efflux liability (0.306 and 0.734).
15. **Affinity:** Ligand A (-7.6 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.8 kcal/mol). This is a 0.8 kcal/mol difference, which is substantial.
**Overall Assessment:**
Ligand A has the advantage in binding affinity, which is a crucial factor. However, Ligand B excels in TPSA, HBA, and has slightly better solubility and half-life. The slightly higher DILI risk for Ligand A is a minor concern. Given the importance of affinity for GPCRs, and the relatively small drawbacks of Ligand A compared to the benefits, I favor Ligand A.
**Output:**
1
2025-04-17 22:08:04,352 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.5 and 355.5 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (58.2) is significantly better than Ligand B (72.88). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (3.569) is optimal, while Ligand B (1.479) is on the lower side. A logP between 1-3 is preferred, and A is closer to that ideal.
4. **HBD:** Both have 2 HBD, which is within the acceptable limit of 5.
5. **HBA:** Ligand A has 2 HBA, while Ligand B has 4. Both are within the acceptable limit of 10, but A is preferable.
6. **QED:** Both ligands have similar QED values (0.706 and 0.657), indicating good drug-likeness.
7. **DILI:** Ligand B (3.218) has a *much* lower DILI risk than Ligand A (24.195). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (68.67) has better BBB penetration than Ligand B (52.811), but this isn't a high priority for a cardiovascular target.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.736) is slightly better than Ligand B (-4.926).
10. **Solubility:** Ligand A (-4.312) has better solubility than Ligand B (-0.676).
11. **hERG:** Both ligands have low hERG inhibition risk (0.432 and 0.427).
12. **Cl_mic:** Ligand B (18.191) has significantly lower microsomal clearance than Ligand A (46.1), indicating better metabolic stability.
13. **t1/2:** Ligand B (-0.157) has a longer in vitro half-life than Ligand A (-5.788).
14. **Pgp:** Ligand A (0.274) has lower P-gp efflux than Ligand B (0.019), which is favorable.
15. **Affinity:** Ligand B (-6.6 kcal/mol) has a slightly better binding affinity than Ligand A (-5.9 kcal/mol). This 0.7 kcal/mol difference is significant.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has better logP, TPSA, and Pgp. Ligand B has better affinity and significantly better metabolic stability (Cl_mic and t1/2) and lower DILI risk.
**Overall Assessment:**
While Ligand A has some advantages in terms of permeability-related parameters (TPSA, logP, Pgp), the significantly lower DILI risk, improved metabolic stability, longer half-life, and slightly better binding affinity of Ligand B outweigh these benefits. The DILI risk for Ligand A is concerning. The affinity difference is also substantial enough to favor Ligand B.
Output:
0
2025-04-17 22:08:04,352 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [349.519, 61.44, 2.311, 2, 3, 0.595, 6.049, 55.642, -4.732, -1.908, 0.391, 10.954, 8.945, 0.017, -5.2]
**Ligand B:** [377.541, 40.54, 4.191, 1, 3, 0.655, 11.128, 92.361, -4.538, -4.683, 0.929, 81.741, 19.673, 0.651, -6.7]
Here's a breakdown, comparing each property and considering GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (349.519) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (40.54) is significantly better than Ligand A (61.44), falling well below the 140 threshold for oral absorption. This is a significant advantage for Ligand B.
3. **logP:** Ligand A (2.311) is optimal (1-3). Ligand B (4.191) is pushing the upper limit, potentially leading to solubility issues and off-target effects.
4. **HBD:** Both have acceptable HBD counts (2 and 1 respectively).
5. **HBA:** Both have acceptable HBA counts (3).
6. **QED:** Both are above 0.5, indicating good drug-likeness, with Ligand B slightly better (0.655 vs 0.595).
7. **DILI:** Ligand A (6.049) has a much lower DILI risk than Ligand B (11.128). This is a significant advantage for Ligand A.
8. **BBB:** Ligand B (92.361) has a much higher BBB penetration potential than Ligand A (55.642). While ADRB2 is primarily a cardiovascular target, some CNS effects are possible with beta-blockers, and higher BBB penetration could be beneficial or detrimental depending on the desired profile.
9. **Caco-2:** Both have negative values, indicating permeability. The values are similar.
10. **Solubility:** Ligand A (-1.908) has better aqueous solubility than Ligand B (-4.683). This is important for bioavailability.
11. **hERG:** Ligand A (0.391) has a lower hERG risk than Ligand B (0.929). This is a critical safety parameter.
12. **Cl_mic:** Ligand A (10.954) has a much lower microsomal clearance, indicating better metabolic stability than Ligand B (81.741).
13. **t1/2:** Ligand B (19.673) has a significantly longer in vitro half-life than Ligand A (8.945). This could translate to less frequent dosing.
14. **Pgp:** Ligand A (0.017) has much lower P-gp efflux liability than Ligand B (0.651). Lower P-gp efflux is generally desirable for better oral bioavailability.
15. **Affinity:** Ligand B (-6.7 kcal/mol) has a substantially stronger binding affinity than Ligand A (-5.2 kcal/mol). This is a >1.5 kcal/mol difference, which is a major advantage.
**Overall Assessment:**
Ligand B has a significantly better binding affinity and longer half-life, and excellent BBB penetration. However, it suffers from higher logP, higher DILI risk, higher hERG risk, and higher P-gp efflux. Ligand A has a better safety profile (lower DILI, hERG, Pgp) and better solubility and metabolic stability, but weaker binding affinity.
Considering the GPCR-specific priorities, the significantly improved binding affinity of Ligand B is a major driver. While the ADME properties of Ligand B are less ideal, the potency advantage is substantial and could potentially be mitigated through further optimization. The cardiovascular target doesn't necessitate high BBB penetration, so that is less of a deciding factor.
Therefore, I would prioritize Ligand B for further development.
0
2025-04-17 22:08:04,353 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [352.435, 110.77 , -1.269, 4. , 5. , 0.493, 11.09 , 11.128, -5.672, -0.827, 0.029, -25.994, 21.424, 0.001, -4.8 ]
**Ligand B:** [348.447, 76.46 , 1.346, 1. , 5. , 0.807, 34.471, 73.866, -4.774, -1.969, 0.352, 25.866, 17.147, 0.025, -7. ]
Here's a breakdown, comparing each parameter and considering GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal 200-500 Da range. A is 352.435, B is 348.447 - very similar.
2. **TPSA:** Ligand A (110.77) is higher than Ligand B (76.46). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for permeability. B is significantly better here.
3. **logP:** Ligand A (-1.269) is quite low, potentially hindering membrane permeability. Ligand B (1.346) is within the optimal 1-3 range. This is a significant advantage for B.
4. **HBD:** A has 4, B has 1. Lower is generally better for permeability, so B is favored.
5. **HBA:** Both have 5, which is acceptable.
6. **QED:** Ligand B (0.807) has a much better QED score than Ligand A (0.493), indicating a more drug-like profile.
7. **DILI:** Ligand A (11.09) has a much lower DILI risk than Ligand B (34.471). This is a substantial advantage for A.
8. **BBB:** Ligand B (73.866) has a higher BBB penetration percentile than Ligand A (11.128). While not a primary concern for a cardiovascular target, higher BBB is rarely a detriment.
9. **Caco-2:** Both have negative values, indicating poor permeability. A (-5.672) is slightly worse than B (-4.774).
10. **Solubility:** Ligand A (-0.827) has slightly better solubility than Ligand B (-1.969).
11. **hERG:** Both are very low, indicating minimal hERG inhibition risk. A (0.029) is slightly lower than B (0.352).
12. **Cl_mic:** Ligand A (-25.994) has a much lower (better) microsomal clearance than Ligand B (25.866), indicating greater metabolic stability.
13. **t1/2:** Ligand A (21.424) has a longer in vitro half-life than Ligand B (17.147).
14. **Pgp:** Ligand A (0.001) has a much lower P-gp efflux liability than Ligand B (0.025). This is a significant advantage for A.
15. **Affinity:** Ligand B (-7.0) has a significantly stronger binding affinity than Ligand A (-4.8). This is a major advantage for B, potentially outweighing some ADME concerns.
**Overall Assessment:**
Ligand B has a superior logP, QED, and binding affinity. However, Ligand A has a much better safety profile (lower DILI), metabolic stability (lower Cl_mic), and P-gp efflux. The affinity difference is substantial (2.2 kcal/mol), which is a large advantage. The better logP and QED of ligand B, combined with its strong affinity, are likely to translate to better *in vivo* performance despite the higher DILI risk.
Output:
0
2025-04-17 22:08:04,353 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for their potential as drug candidates targeting the ADRB2, a cardiovascular GPCR. Therefore, priorities are logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB.
Let's break down the comparison:
1. **Molecular Weight:** Both ligands are within the acceptable range (200-500 Da). Ligand B (344.415 Da) is significantly smaller than Ligand A (488.249 Da), which is generally favorable for permeability.
2. **TPSA:** Ligand A (71.25) is better than Ligand B (118.01). A TPSA under 140 is good for oral absorption, but lower is better for GPCRs.
3. **logP:** Ligand A (4.479) is higher than Ligand B (1.062). While both are within the acceptable range, Ligand A is approaching a value that could cause solubility issues or off-target interactions. Ligand B is on the lower side, which could hinder permeation.
4. **H-Bond Donors/Acceptors:** Ligand A (2 HBD, 5 HBA) is slightly better than Ligand B (4 HBD, 4 HBA). Both are within acceptable limits.
5. **QED:** Both ligands have similar QED scores (0.623 and 0.617), indicating similar drug-likeness.
6. **DILI:** Ligand B (44.009) has a significantly lower DILI risk than Ligand A (67.313), which is a major advantage.
7. **BBB:** Ligand A (86.041) has a better BBB penetration score than Ligand B (40.52). While ADRB2 is cardiovascular, some CNS exposure is not necessarily detrimental and could provide additional pharmacological effects.
8. **Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not defined, so it's difficult to interpret.
9. **Aqueous Solubility:** Both ligands have negative solubility values, which is also unusual and suggests poor solubility.
10. **hERG Inhibition:** Ligand A (0.894) has a slightly higher hERG risk than Ligand B (0.421), which is preferable for Ligand B.
11. **Microsomal Clearance:** Ligand B (-1.619) has a much lower (better) microsomal clearance than Ligand A (60.496), indicating better metabolic stability.
12. **In vitro Half-Life:** Ligand B (-27.289) has a significantly longer in vitro half-life than Ligand A (31.217), which is a substantial advantage.
13. **P-gp Efflux:** Ligand A (0.807) has a higher P-gp efflux liability than Ligand B (0.028), which is preferable for Ligand B.
14. **Binding Affinity:** Ligand A (-6.9 kcal/mol) has a slightly better binding affinity than Ligand B (-5.7 kcal/mol). This is a 1.2 kcal/mol difference, which is significant, but must be weighed against the other factors.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity and BBB penetration, Ligand B demonstrates a much more favorable ADME profile. Specifically, the lower DILI risk, significantly improved metabolic stability (lower Cl_mic and longer t1/2), and reduced P-gp efflux are compelling advantages. The lower logP of Ligand B is a slight concern, but the other benefits outweigh this drawback. The poor solubility/permeability indicated by the negative values for Caco-2 and solubility are concerning for both, but can be addressed with formulation strategies.
**Output:**
0
2025-04-17 22:08:04,353 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (349.5) is better than Ligand B (370.4). Both are within the ideal range, but A is closer to the lower, preferred end.
2. **TPSA:** Ligand A (75.4) is significantly better than Ligand B (132.7). ADRB2 is not a CNS target, but lower TPSA generally improves absorption. B is pushing the upper limit for good oral absorption.
3. **logP:** Ligand A (3.38) is good, within the optimal range. Ligand B (-0.20) is poor, potentially leading to poor membrane permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is better than Ligand B (8). Similar reasoning as HBD.
6. **QED:** Ligand A (0.82) is better than Ligand B (0.63). A higher QED indicates a more drug-like profile.
7. **DILI:** Ligand B (57.3) is better than Ligand A (40.1), indicating a lower risk of drug-induced liver injury. This is a point in favor of B.
8. **BBB:** Ligand A (78.9) is much better than Ligand B (20.4). While ADRB2 isn't a primary CNS target, some peripheral distribution is still important, and higher BBB penetration *can* correlate with better overall tissue distribution.
9. **Caco-2:** Ligand A (-4.49) is better than Ligand B (-5.13). Both are negative, indicating poor permeability, but A is slightly better.
10. **Solubility:** Ligand A (-3.41) is better than Ligand B (-2.84). Both are poor, but A is slightly better.
11. **hERG:** Ligand A (0.24) is significantly better than Ligand B (0.08). Lower hERG inhibition is crucial for avoiding cardiotoxicity, especially for a cardiovascular target.
12. **Cl_mic:** Ligand B (19.7) is better than Ligand A (75.0). Lower clearance is preferred for metabolic stability. This is a strong point in favor of B.
13. **t1/2:** Ligand B (-41.5) is better than Ligand A (-22.6). A longer half-life is generally desirable. This is another strong point for B.
14. **Pgp:** Ligand A (0.19) is better than Ligand B (0.01). Lower P-gp efflux is preferred for better bioavailability.
15. **Affinity:** Ligand B (-8.5) is significantly better than Ligand A (-6.0). This is a substantial difference in binding affinity (2.5 kcal/mol), which can often outweigh minor ADME drawbacks.
**Overall Assessment:**
Ligand B has a significantly better binding affinity and improved metabolic stability (Cl_mic and t1/2). While it has a lower logP and higher TPSA, the substantial affinity advantage is likely to be critical for efficacy. The DILI risk is also lower for Ligand B. Ligand A has better hERG inhibition, but the difference isn't substantial enough to overcome the affinity gap. Considering the GPCR-specific priorities (logP, affinity), Ligand B is the more promising candidate.
Output:
0
2025-04-17 22:08:04,353 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (354.47 & 349.45 Da) fall comfortably within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (58.64) is better than Ligand B (71.09). Both are below 140, but A is closer to the preferred <90 for potential CNS penetration (though not a primary concern for ADRB2).
3. **logP:** Both ligands have good logP values (2.749 & 3.119), falling within the 1-3 range. Ligand B is slightly higher, which could potentially lead to some off-target interactions, but it's not a major concern.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Both ligands have the same number of HBA (3), which is acceptable.
6. **QED:** Ligand B (0.757) has a slightly better QED score than Ligand A (0.565), indicating a more drug-like profile.
7. **DILI:** Ligand A (22.024) has a significantly lower DILI risk than Ligand B (35.673). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (88.135) has a better BBB penetration percentile than Ligand B (73.245). While ADRB2 isn't a primary CNS target, some degree of BBB penetration can be beneficial for understanding off-target effects.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.622 and -4.74), which is unusual and suggests poor permeability. This is a significant drawback for both.
10. **Solubility:** Ligand A (-2.273) has slightly better solubility than Ligand B (-2.715), though both are poor.
11. **hERG:** Both ligands have low hERG inhibition risk (0.383 & 0.288).
12. **Cl_mic:** Ligand B (19.981) has a significantly lower microsomal clearance than Ligand A (45.043), indicating better metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand B (20.671) has a much longer in vitro half-life than Ligand A (-3.827). This is a substantial benefit for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.218 & 0.082).
15. **Binding Affinity:** Ligand B (-7.1) has a significantly stronger binding affinity than Ligand A (-5.3). This is a major advantage, potentially outweighing some of the ADME drawbacks.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B excels in affinity and has acceptable logP and Pgp. Ligand A has better TPSA and DILI, but the affinity difference is substantial. The longer half-life of Ligand B is also a significant plus.
**Overall Assessment:**
While Ligand A has advantages in DILI and TPSA, the significantly stronger binding affinity (-7.1 vs -5.3 kcal/mol) and improved metabolic stability (lower Cl_mic and longer t1/2) of Ligand B are more critical for a GPCR target. The poor Caco-2 values are a concern for both, but can be addressed with formulation strategies. The lower DILI risk of Ligand A is good, but the affinity difference is a larger driver for success.
Output:
0
2025-04-17 22:08:04,353 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (372.49 & 343.43 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand B (71.41) is better than Ligand A (84.94). Lower TPSA generally favors better absorption, important for GPCRs.
3. **logP:** Both are good (0.815 and 1.154), falling within the 1-3 range. Ligand B is slightly better.
4. **HBD:** Both have 1 HBD, which is acceptable.
5. **HBA:** Ligand B (4) is better than Ligand A (6). Fewer HBA generally improves permeability.
6. **QED:** Both are good (0.719 and 0.788), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand B (23.5%) is significantly better than Ligand A (46.5%). Lower DILI risk is crucial.
8. **BBB:** Ligand B (75.1%) is much better than Ligand A (46.5%). While ADRB2 isn't exclusively a CNS target, some CNS penetration can be beneficial and reduced penetration isn't necessarily a dealbreaker.
9. **Caco-2:** Both are negative, indicating poor permeability. This is a concern for both.
10. **Solubility:** Both are negative, indicating poor solubility. This is a concern for both.
11. **hERG:** Ligand B (0.388) is better than Ligand A (0.121). Lower hERG inhibition is critical for safety.
12. **Cl_mic:** Ligand B (40.47) is better than Ligand A (68.34). Lower clearance suggests better metabolic stability.
13. **t1/2:** Ligand B (-9.133) is better than Ligand A (-5.167). Longer half-life is generally preferred.
14. **Pgp:** Ligand B (0.082) is better than Ligand A (0.039). Lower P-gp efflux improves bioavailability.
15. **Affinity:** Ligand A (-7.1 kcal/mol) is better than Ligand B (-6.0 kcal/mol). This is a substantial difference in binding affinity.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are particularly important. Ligand B excels in logP, TPSA, Pgp, and has a significantly better safety profile (DILI, hERG). However, Ligand A has a notably stronger binding affinity. The 1.1 kcal/mol difference in affinity is substantial and could potentially outweigh the ADME advantages of Ligand B.
**Overall Assessment:**
While Ligand B has a more favorable ADME profile, the significantly stronger binding affinity of Ligand A is a major advantage for a GPCR target. The improved affinity could translate to greater efficacy and potentially allow for a lower dose, mitigating some of the ADME concerns. The DILI and hERG risks of Ligand A are acceptable, and formulation strategies could be explored to address the solubility and permeability issues.
Output:
1
2025-04-17 22:08:04,354 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (342.374 and 350.459 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (73.47) is better than Ligand B (78.87). Both are below the 140 A^2 threshold for good oral absorption, but lower TPSA is generally preferred for GPCRs.
3. **logP:** Ligand A (3.42) is slightly higher than Ligand B (1.237). While both are within the acceptable range, Ligand A is closer to the optimal 1-3 range. Ligand B is quite low and may have permeability issues.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (2). Both are acceptable.
5. **HBA:** Ligand A (3) is lower than Ligand B (4). Lower is generally preferred for permeability.
6. **QED:** Ligand A (0.8) is better than Ligand B (0.707). Both are above the 0.5 threshold, indicating good drug-likeness.
7. **DILI:** Ligand A (87.243) has a significantly higher DILI risk than Ligand B (13.067). This is a major concern for Ligand A.
8. **BBB:** Ligand A (64.095) and Ligand B (68.864) are similar. BBB is not a high priority for ADRB2, a cardiovascular target.
9. **Caco-2:** Ligand A (-4.821) and Ligand B (-4.517) are similar, and both are negative, indicating poor permeability.
10. **Solubility:** Ligand A (-4.725) is worse than Ligand B (-1.759). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.633) is better than Ligand B (0.214). Lower hERG inhibition is crucial for avoiding cardiotoxicity, especially for a cardiovascular target.
12. **Cl_mic:** Ligand A (22.57) is better than Ligand B (27.105). Lower clearance is preferred for metabolic stability.
13. **t1/2:** Ligand A (96.39) is significantly better than Ligand B (1.495). A longer half-life is desirable.
14. **Pgp:** Ligand A (0.221) is better than Ligand B (0.065). Lower P-gp efflux is preferred.
15. **Affinity:** Ligand A (-8.3 kcal/mol) is significantly better than Ligand B (-5.0 kcal/mol). This is a substantial difference in binding strength.
**Overall Assessment:**
Ligand A has a much stronger binding affinity, better metabolic stability (lower Cl_mic, longer t1/2), better Pgp properties, and a slightly better TPSA. However, it has a very high DILI risk and poor solubility. Ligand B has a much lower DILI risk and better solubility, but its affinity is significantly weaker, and it has poorer metabolic stability.
Given the cardiovascular target (ADRB2), the hERG risk is also critical. Ligand A has a better hERG profile. The large difference in binding affinity (-8.3 vs -5.0 kcal/mol) is a major advantage for Ligand A and can potentially outweigh the DILI and solubility concerns, especially if formulation strategies can be employed to address the solubility issue. The DILI risk is concerning, but could be mitigated through further structural modifications.
Therefore, I believe Ligand A is the more promising candidate.
Output:
1
2025-04-17 22:08:04,354 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (424.339 Da) is within the ideal range. Ligand B (353.463 Da) is also within range, slightly lower. This is a minor advantage to A.
2. **TPSA:** Ligand A (46.92) is excellent, well below the 140 threshold. Ligand B (78.95) is still reasonable, but higher. This favors A.
3. **logP:** Ligand A (4.136) is slightly high, potentially leading to solubility issues. Ligand B (0.491) is quite low, which could hinder permeability. This is a significant drawback for B.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 4 HBA, Ligand B has 5. Both are acceptable.
6. **QED:** Ligand A (0.647) is good, indicating drug-likeness. Ligand B (0.371) is lower, suggesting a less drug-like profile. This favors A.
7. **DILI:** Ligand A (55.487) has a moderate DILI risk. Ligand B (6.863) has a very low DILI risk, a significant advantage for B.
8. **BBB:** Ligand A (88.91) has good BBB penetration. Ligand B (72.858) is lower, but still reasonable. A slight edge to A.
9. **Caco-2:** Ligand A (-5.3) and Ligand B (-4.931) are both negative, indicating poor permeability. This is a concern for both, but slightly less so for B.
10. **Solubility:** Ligand A (-3.03) has poor solubility, consistent with its higher logP. Ligand B (-1.079) has slightly better solubility. This favors B.
11. **hERG:** Ligand A (0.916) has a moderate hERG risk. Ligand B (0.412) has a lower hERG risk, a significant advantage for B.
12. **Cl_mic:** Ligand A (82.477) has moderate clearance. Ligand B (13.328) has very low clearance, indicating good metabolic stability. This strongly favors B.
13. **t1/2:** Ligand A (61.066) has a reasonable half-life. Ligand B (-34.013) has a *very* short half-life, a major drawback. This strongly favors A.
14. **Pgp:** Ligand A (0.947) has moderate Pgp efflux. Ligand B (0.017) has very low Pgp efflux, a significant advantage for B.
15. **Affinity:** Ligand A (-5.9 kcal/mol) has a slightly better binding affinity than Ligand B (-6.8 kcal/mol). This is a moderate advantage for A.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has a better TPSA and affinity, but a problematic logP. Ligand B has a better logP, Pgp, DILI, hERG, and Cl_mic. The very short half-life of B is a major concern.
**Overall Assessment:**
Ligand B has several advantages in terms of safety (DILI, hERG) and ADME properties (Cl_mic, Pgp), which are crucial for a viable drug candidate. While its affinity is slightly lower and half-life is very short, these could potentially be addressed through further optimization. Ligand A's high logP and poor solubility are more difficult to overcome. The superior binding affinity of A is not enough to offset the significant ADME liabilities.
Output:
0
2025-04-17 22:08:04,354 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.46 & 349.39 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (81.67) is significantly better than Ligand B (123.66). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is approaching a level that could hinder oral absorption.
3. **logP:** Ligand A (2.273) is within the optimal 1-3 range. Ligand B (-0.014) is slightly below 1, which *could* indicate permeability issues.
4. **HBD:** Ligand A (3) and Ligand B (4) are both acceptable, being under the 5 threshold.
5. **HBA:** Ligand A (3) is better than Ligand B (6), as lower HBA generally improves permeability.
6. **QED:** Ligand A (0.675) is significantly better than Ligand B (0.405). A higher QED suggests a more drug-like profile.
7. **DILI:** Ligand A (34.432) has a much lower DILI risk than Ligand B (59.17). This is a significant advantage for Ligand A.
8. **BBB:** Both ligands have similar BBB penetration (53.083 vs 53.276). Since ADRB2 is a cardiovascular target, BBB penetration isn't a primary concern, but it's good they're not significantly blocked.
9. **Caco-2:** Ligand A (-4.953) and Ligand B (-5.436) are both negative, indicating poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Ligand A (-1.627) is slightly better than Ligand B (-2.267), but both are poor. Solubility is a concern for both.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.5 and 0.066). This is excellent.
12. **Cl_mic:** Ligand A (-13.614) has a much lower (better) microsomal clearance than Ligand B (2.749). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (35.11) has a significantly longer in vitro half-life than Ligand B (10.583). This is a major advantage for Ligand A, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have very low P-gp efflux (0.079 and 0.004). This is good.
15. **Binding Affinity:** Ligand B (-6.9) has a slightly better binding affinity than Ligand A (-6.4). While a 0.5 kcal/mol difference is noticeable, it's not a massive advantage, especially considering the other factors.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, and metabolic stability are important. Ligand A excels in TPSA, logP, Cl_mic, and t1/2. While Ligand B has slightly better affinity, the other ADME properties of Ligand A are far more favorable.
**Conclusion:**
Ligand A presents a much more balanced profile with better predicted ADME properties (lower DILI, better metabolic stability, longer half-life, better TPSA and logP) despite a slightly weaker binding affinity. The differences in ADME are substantial enough to outweigh the small binding affinity difference.
Output:
1
2025-04-17 22:08:04,354 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Ligand A (346.402 Da) is within the ideal range (200-500 Da). Ligand B (366.296 Da) is also acceptable. No clear advantage here.
2. **TPSA:** Ligand A (70.59) is good, well below the 140 threshold. Ligand B (137.36) is approaching the upper limit for good oral absorption, but still potentially acceptable. Ligand A is preferred.
3. **logP:** Ligand A (3.237) is optimal. Ligand B (0.861) is a bit low, potentially hindering membrane permeability. Ligand A is preferred.
4. **HBD:** Ligand A (3) is within the ideal range. Ligand B (4) is also acceptable. No strong preference.
5. **HBA:** Ligand A (3) is within the ideal range. Ligand B (5) is also acceptable. No strong preference.
6. **QED:** Ligand A (0.752) is excellent, indicating good drug-likeness. Ligand B (0.399) is quite low, suggesting potential issues. Ligand A is strongly preferred.
7. **DILI:** Ligand A (44.087) has a lower DILI risk than Ligand B (67.003). Ligand A is preferred.
8. **BBB:** Ligand A (43.815) is lower than Ligand B (35.828). However, for a cardiovascular target like ADRB2, BBB penetration is not a primary concern.
9. **Caco-2:** Ligand A (-4.626) and Ligand B (-5.429) are both negative, indicating poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Ligand A (-3.135) and Ligand B (-2.682) are both negative, indicating poor solubility. However, the scale is not specified, so it's hard to interpret.
11. **hERG:** Ligand A (0.712) has a lower hERG risk than Ligand B (0.466). Ligand A is preferred.
12. **Cl_mic:** Ligand A (55.556) has a higher clearance than Ligand B (0.26). Ligand B is strongly preferred.
13. **t1/2:** Ligand A (1.078) has a shorter half-life than Ligand B (-16.769). Ligand B is strongly preferred.
14. **Pgp:** Ligand A (0.403) has lower P-gp efflux than Ligand B (0.053). Ligand A is preferred.
15. **Affinity:** Ligand A (-6.3 kcal/mol) has a slightly better binding affinity than Ligand B (-5.0 kcal/mol).
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are crucial. Ligand A excels in logP, TPSA, and Pgp. The affinity difference, while not huge, favors Ligand A. While Ligand B has better metabolic stability (lower Cl_mic and longer t1/2), the other ADME properties and the significantly better QED of Ligand A outweigh this advantage.
**Conclusion:**
Ligand A presents a more balanced profile with better drug-likeness, lower risk factors (DILI, hERG), and favorable properties for a GPCR target.
Output:
1
2025-04-17 22:08:04,354 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (363.439 Da and 369.447 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (73.66) is significantly better than Ligand B (111.71). For a GPCR, keeping TPSA under 140 is good for oral absorption, and lower is generally preferred. Ligand B is pushing the upper limit.
**3. logP:** Ligand A (2.311) is optimal (1-3), while Ligand B (0.1) is quite low. Low logP can hinder membrane permeability and absorption. This is a significant advantage for Ligand A.
**4. H-Bond Donors:** Ligand A (0) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
**5. H-Bond Acceptors:** Ligand A (6) is better than Ligand B (5). Both are within the acceptable range, but lower is slightly preferred.
**6. QED:** Both ligands have similar QED values (0.833 and 0.734), indicating good drug-like properties.
**7. DILI:** Ligand B (84.141) has a higher DILI risk than Ligand A (65.568). Lower DILI is always preferred.
**8. BBB:** Ligand A (90.306) has a much higher BBB penetration percentile than Ligand B (48.779). While ADRB2 is a cardiovascular target, some CNS exposure can occur, and higher BBB penetration isn't necessarily detrimental.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.509 and -4.755), which is unusual and suggests poor permeability. However, the values are very similar.
**10. Aqueous Solubility:** Both ligands have negative solubility values (-4.031 and -3.137), indicating poor aqueous solubility. This is a concern for both, but Ligand B is slightly better.
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.541 and 0.234).
**12. Microsomal Clearance:** Ligand A (24.631) has a higher microsomal clearance than Ligand B (15.131), meaning it is metabolized faster. Lower clearance is preferred for longer duration of action.
**13. In vitro Half-Life:** Ligand B (-42.707) has a significantly longer in vitro half-life than Ligand A (-14.286). This is a major advantage for Ligand B.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.278 and 0.009).
**15. Binding Affinity:** Ligand B (-7.4) has a significantly stronger binding affinity than Ligand A (-3.1). A 4.3 kcal/mol difference is substantial and can outweigh many ADME drawbacks.
**Overall Assessment:**
Ligand B has a much stronger binding affinity, a longer half-life, and a lower DILI risk. However, it suffers from a higher TPSA and a very low logP, which could significantly impact its permeability and absorption. Ligand A has better TPSA and logP values, but its binding affinity is considerably weaker, and its half-life is shorter.
Given the importance of potency (binding affinity) for GPCRs, and the substantial difference in affinity (-7.4 vs -3.1 kcal/mol), I believe Ligand B is the more promising candidate, despite its permeability concerns. Optimization efforts could focus on improving its logP and solubility while retaining its high affinity.
Output:
0
2025-04-17 22:08:04,355 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands (356.463 and 350.463 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand B (76.46) is significantly better than Ligand A (107.89). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (1.376) is within the optimal 1-3 range, while Ligand A (0.334) is slightly low, potentially hindering permeability.
4. **HBD:** Ligand B (1) is preferable to Ligand A (4) as fewer HBDs generally improve permeability.
5. **HBA:** Both ligands have 5 HBA, which is acceptable.
6. **QED:** Ligand B (0.806) has a much better QED score than Ligand A (0.549), indicating a more drug-like profile.
7. **DILI:** Ligand A (12.641) has a significantly lower DILI risk than Ligand B (32.842). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (75.107) has a higher BBB penetration percentile than Ligand A (27.259). While not critical for a cardiovascular target, it's a slight positive for Ligand B.
9. **Caco-2:** Ligand A (-5.09) and Ligand B (-4.524) both have negative Caco-2 values, which is unusual and suggests poor permeability. The values are very close, so this isn't a major differentiator.
10. **Solubility:** Ligand A (-0.86) has slightly better solubility than Ligand B (-1.921).
11. **hERG:** Ligand A (0.063) has a lower hERG risk than Ligand B (0.343). This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand A (-1.854) has a much lower microsomal clearance than Ligand B (37.385), indicating better metabolic stability.
13. **t1/2:** Ligand B (9.197) has a longer in vitro half-life than Ligand A (5.687). This is a positive for Ligand B.
14. **Pgp:** Ligand A (0.01) has a much lower P-gp efflux liability than Ligand B (0.048), which is favorable for bioavailability.
15. **Affinity:** Ligand A (-7.1) has a slightly better binding affinity than Ligand B (-5.4). While both are good, the 1.7 kcal/mol difference is substantial.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP and has a reasonable TPSA. Ligand A has a better affinity and Pgp profile.
**Overall Assessment:**
Ligand A has a significantly better safety profile (lower DILI and hERG), superior binding affinity, better metabolic stability (lower Cl_mic), and lower P-gp efflux. While Ligand B has a better QED and half-life, the safety and potency advantages of Ligand A are more crucial. The slightly lower logP of Ligand A is a minor concern, but the strong affinity can likely compensate.
Output:
1
2025-04-17 22:08:04,355 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A Analysis:**
* **MW:** 346.431 Da - Good, within the ideal range.
* **TPSA:** 76.46 - Good, below the 140 threshold for oral absorption.
* **logP:** 0.581 - Low. May have permeability issues.
* **HBD:** 1 - Good.
* **HBA:** 5 - Good.
* **QED:** 0.792 - Excellent, highly drug-like.
* **DILI:** 49.321 - Good, low risk.
* **BBB:** 60.76 - Moderate. Not ideal for CNS, but acceptable for a peripheral target like ADRB2.
* **Caco-2:** -5.012 - Very poor permeability. A significant concern.
* **Solubility:** -1.342 - Poor solubility.
* **hERG:** 0.166 - Low risk, excellent.
* **Cl_mic:** 10.98 - Moderate clearance.
* **t1/2:** 18.918 - Good half-life.
* **Pgp:** 0.047 - Low efflux, favorable.
* **Affinity:** -7.1 kcal/mol - Excellent binding affinity.
**Ligand B Analysis:**
* **MW:** 359.543 Da - Good, within the ideal range.
* **TPSA:** 46.84 - Excellent, very favorable for permeability.
* **logP:** 3.308 - Excellent, within the optimal range.
* **HBD:** 0 - Good.
* **HBA:** 6 - Good.
* **QED:** 0.526 - Acceptable, but not as high as Ligand A.
* **DILI:** 22.761 - Excellent, very low risk.
* **BBB:** 96.937 - Excellent, high BBB penetration. Although ADRB2 isn't a CNS target, this isn't a major negative.
* **Caco-2:** -5.668 - Very poor permeability, similar to Ligand A.
* **Solubility:** -3.482 - Very poor solubility.
* **hERG:** 0.743 - Moderate risk, less favorable than Ligand A.
* **Cl_mic:** 62.434 - High clearance, suggesting poor metabolic stability.
* **t1/2:** -8.505 - Very short half-life, a significant drawback.
* **Pgp:** 0.679 - Moderate efflux, less favorable than Ligand A.
* **Affinity:** -6.4 kcal/mol - Good binding affinity, but 0.7 kcal/mol weaker than Ligand A.
**Comparison & Decision:**
Both ligands suffer from poor Caco-2 permeability and solubility. However, considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand B has a significantly better logP and TPSA, which are crucial for membrane permeability. While its affinity is slightly lower, the difference isn't substantial enough to outweigh the better physicochemical properties. Ligand A has a better QED, DILI, and Pgp profile, but the poor permeability and solubility are major hurdles. Ligand B's high BBB penetration isn't critical for ADRB2, but doesn't detract from its overall profile. The biggest drawback for Ligand B is its very short half-life and high clearance, but these can potentially be addressed with structural modifications. The poor permeability of Ligand A is a more difficult property to improve.
Therefore, despite its drawbacks, Ligand B is the more promising starting point for optimization.
Output:
0
2025-04-17 22:08:04,355 - INFO - Batch 309 complete. Total preferences: 4944
2025-04-17 22:08:04,355 - INFO - Processing batch 310/512...
2025-04-17 22:08:52,496 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (353.419 and 348.447 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (93.9) is slightly higher than Ligand B (76.46). Both are below the 140 threshold for good oral absorption, but B is better, closer to the 90 threshold for CNS targets (though ADRB2 isn't necessarily a CNS target).
3. **logP:** Ligand A (1.005) and Ligand B (1.49) are both within the optimal 1-3 range. B is slightly more lipophilic, which could be beneficial for membrane permeability but also raises potential off-target concerns slightly.
4. **HBD:** Both ligands have 1 HBD, which is within the acceptable limit of 5.
5. **HBA:** Ligand A has 6 HBA, and Ligand B has 5. Both are below the 10 limit.
6. **QED:** Both ligands have good QED scores (0.666 and 0.79), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (25.165) has a significantly lower DILI risk than Ligand B (33.812). This is a major advantage for Ligand A.
8. **BBB:** Both ligands have similar BBB penetration (83.133 and 82.435). This isn't a primary concern for ADRB2, but it's good that neither is severely limited.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.786 and -4.759), which is unusual and suggests poor permeability. This is a significant drawback for both.
10. **Solubility:** Both ligands have negative solubility values (-1.262 and -1.787), indicating very poor aqueous solubility. This is a major concern for both.
11. **hERG:** Both ligands have low hERG inhibition risk (0.467 and 0.434).
12. **Cl_mic:** Ligand A (1.425) has a much lower microsomal clearance than Ligand B (21.324), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand B (16.086) has a longer in vitro half-life than Ligand A (1.992). This is a positive for Ligand B, but the difference might be offset by its higher clearance.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.082 and 0.115).
15. **Binding Affinity:** Ligand B (-6.4 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.1 kcal/mol). This is a substantial advantage for Ligand B, exceeding the 1.5 kcal/mol threshold.
**Overall Assessment & GPCR Considerations:**
For a GPCR like ADRB2, affinity is paramount. Ligand B's -6.4 kcal/mol binding affinity is a strong advantage that outweighs many of its drawbacks. While both ligands have poor solubility and Caco-2 permeability, the superior affinity of Ligand B suggests it might still achieve sufficient target engagement *in vivo*. The lower DILI risk and better metabolic stability of Ligand A are attractive, but the difference in affinity is too significant to ignore.
Output:
0
2025-04-17 22:08:52,497 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [342.439, 71.34, 3.862, 2, 3, 0.716, 59.442, 65.839, -4.92, -4.334, 0.849, 68.957, 60.506, 0.708, -6.6]
**Ligand B:** [352.431, 88.1, 0.085, 2, 5, 0.634, 15.743, 68.282, -4.819, -1.275, 0.213, 26.154, -1.37, 0.021, -7.1]
Here's a breakdown, comparing each parameter and considering GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal range (200-500 Da). A is 342.439, B is 352.431 - very similar.
2. **TPSA:** A (71.34) is better than B (88.1). Lower TPSA generally favors better absorption.
3. **logP:** A (3.862) is optimal. B (0.085) is *very* low, which is a significant concern for membrane permeability and bioavailability.
4. **HBD:** Both have 2, which is good.
5. **HBA:** A (3) is better than B (5). Lower HBA is generally preferred.
6. **QED:** A (0.716) is slightly better than B (0.634), indicating a more drug-like profile.
7. **DILI:** A (59.442) is higher than B (15.743). B has a much lower DILI risk, a significant advantage.
8. **BBB:** Both are reasonably good (A: 65.839, B: 68.282), but not exceptionally high, which is fine for a cardiovascular target.
9. **Caco-2:** Both are negative, suggesting poor permeability.
10. **Solubility:** A (-4.334) is worse than B (-1.275). B has better aqueous solubility.
11. **hERG:** A (0.849) is higher than B (0.213). B has a much lower hERG risk, a critical safety factor.
12. **Cl_mic:** A (68.957) is higher than B (26.154). B has significantly better metabolic stability.
13. **t1/2:** A (60.506) is better than B (-1.37). A has a longer in vitro half-life.
14. **Pgp:** A (0.708) is higher than B (0.021). B has much lower P-gp efflux, which is beneficial for bioavailability.
15. **Affinity:** B (-7.1) is 0.5 kcal/mol better than A (-6.6). This is a substantial difference in binding.
**Overall Assessment:**
While Ligand A has a slightly better half-life, Ligand B overwhelmingly wins on several critical ADME-Tox properties. The extremely low logP of Ligand B is a major drawback, but is offset by its significantly improved DILI, hERG, Pgp, and metabolic stability profiles. The stronger binding affinity of Ligand B (-7.1 kcal/mol) is also a significant advantage that can potentially compensate for the permeability issues. For a GPCR, the combination of improved safety (DILI, hERG) and better metabolic stability are crucial. The lower Pgp efflux also suggests better bioavailability.
Therefore, I believe Ligand B is the more promising drug candidate.
0
2025-04-17 22:08:52,497 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (348.443 and 344.419 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (71.78) is significantly better than Ligand B (84.22). For a GPCR, keeping TPSA low is beneficial for permeability, and Ligand A is well below the 140 threshold.
**3. logP:** Ligand A (2.32) is optimal, while Ligand B (0.2) is quite low. A logP below 1 can hinder membrane permeability. This is a significant advantage for Ligand A.
**4. H-Bond Donors:** Ligand A (1) is preferable to Ligand B (0). While both are acceptable, having at least one HBD can improve solubility.
**5. H-Bond Acceptors:** Ligand B (6) is better than Ligand A (4). Both are within the acceptable range of <=10.
**6. QED:** Ligand A (0.856) has a substantially higher QED score than Ligand B (0.689), indicating a more drug-like profile.
**7. DILI:** Ligand A (22.102) has a lower DILI risk than Ligand B (31.059), which is preferable. Both are below the 40 threshold.
**8. BBB:** Both ligands have good BBB penetration (Ligand A: 73.633, Ligand B: 76.309). While ADRB2 isn't a CNS target, some peripheral exposure is acceptable.
**9. Caco-2 Permeability:** Both are negative, indicating poor permeability. This is concerning, but Ligand A is slightly better (-4.645 vs -4.918).
**10. Aqueous Solubility:** Both are negative, indicating poor solubility. Ligand B is slightly better (-1.225 vs -1.7).
**11. hERG Inhibition:** Both ligands show very low hERG inhibition risk (Ligand A: 0.316, Ligand B: 0.045). Ligand B is slightly better here.
**12. Microsomal Clearance:** Ligand A (39.201) has a higher microsomal clearance than Ligand B (1.89), meaning it is less metabolically stable. This is a disadvantage for Ligand A.
**13. In vitro Half-Life:** Ligand A (28.164) has a significantly longer half-life than Ligand B (-1.227). This is a major advantage for Ligand A.
**14. P-gp Efflux:** Both ligands show very low P-gp efflux liability (Ligand A: 0.04, Ligand B: 0.02).
**15. Binding Affinity:** Ligand A (-6.7 kcal/mol) has a slightly better binding affinity than Ligand B (-5.6 kcal/mol). While the difference isn't huge, it's enough to consider.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand A is the stronger candidate. Its superior logP and TPSA values are crucial for permeability. The higher QED and better affinity also contribute positively. While Ligand B has a slight advantage in hERG and P-gp efflux, the differences are small. The longer half-life of Ligand A is also a significant advantage. The lower metabolic stability of Ligand A is a concern, but can be addressed with structural modifications.
Output:
1
2025-04-17 22:08:52,497 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (356.463 and 344.415 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Both ligands have TPSA values (88.1 and 83.44) below the 140 A^2 threshold for good oral absorption. These are acceptable, but not optimal for CNS penetration (which isn't a primary concern for a cardiovascular target).
**3. logP:** Both ligands have logP values around 0.4, which is a bit low. Ideally, we'd like to be between 1-3 for good permeability. However, given the other parameters, this isn't a dealbreaker.
**4. H-Bond Donors & Acceptors:** Both ligands have 2 HBDs and a reasonable number of HBAs (5 and 4 respectively). This is within acceptable limits.
**5. QED:** Both ligands have good QED scores (0.658 and 0.76), indicating generally drug-like properties.
**6. DILI Risk:** Ligand A has a DILI risk of 10.896%, which is very good. Ligand B has a significantly higher DILI risk of 35.789%, which is concerning. This is a major point in favor of Ligand A.
**7. BBB Penetration:** BBB is less critical for a cardiovascular target. Ligand A (66.77%) has slightly better BBB penetration than Ligand B (57.193%), but this difference is not decisive.
**8. Caco-2 Permeability:** Ligand B (-5.231) has better Caco-2 permeability than Ligand A (-4.805), suggesting better intestinal absorption.
**9. Aqueous Solubility:** Ligand B (-2.05) has better aqueous solubility than Ligand A (-1.142).
**10. hERG Inhibition:** Ligand A (0.326) has a lower hERG inhibition risk than Ligand B (0.051), which is preferable.
**11. Microsomal Clearance:** Ligand A (0.047) has significantly lower microsomal clearance than Ligand B (19.084). This indicates better metabolic stability for Ligand A, a crucial factor for drug duration.
**12. In vitro Half-Life:** Ligand B (10.996) has a longer in vitro half-life than Ligand A (-5.887). This is a positive for Ligand B.
**13. P-gp Efflux:** Both ligands have very low P-gp efflux liability.
**14. Binding Affinity:** Ligand B (-6.4 kcal/mol) has a stronger binding affinity than Ligand A (-4.7 kcal/mol). This is a substantial difference (1.7 kcal/mol), and a key advantage for Ligand B.
**Overall Assessment:**
While Ligand B has a better binding affinity and slightly better Caco-2 permeability and half-life, the significantly higher DILI risk and higher microsomal clearance are major drawbacks. Ligand A, despite the weaker binding affinity, presents a much safer profile with a very low DILI risk and better metabolic stability. For a cardiovascular target, minimizing off-target effects and ensuring metabolic stability are paramount. The affinity difference, while noticeable, can potentially be addressed through further optimization, whereas mitigating a high DILI risk is far more challenging.
Therefore, I favor Ligand A.
Output:
1
2025-04-17 22:08:52,497 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (381.414 Da) is slightly higher than Ligand B (354.491 Da), but both are acceptable.
**2. TPSA:** Ligand A (129.97) is close to the upper limit for good oral absorption, while Ligand B (78.87) is well below. For a cardiovascular target, CNS penetration isn't a primary concern, so lower TPSA isn't necessarily advantageous here.
**3. logP:** Both ligands have good logP values (A: 2.569, B: 1.731), falling within the optimal 1-3 range.
**4. H-Bond Donors/Acceptors:** Ligand A has 4 HBD and 5 HBA, while Ligand B has 2 HBD and 4 HBA. Both are within acceptable limits.
**5. QED:** Both ligands have good QED scores (A: 0.553, B: 0.651), indicating drug-like properties. Ligand B is slightly better.
**6. DILI Risk:** Ligand A has a very high DILI risk (99.38%), which is a major red flag. Ligand B has a much lower DILI risk (19.581%), making it significantly safer.
**7. BBB Penetration:** BBB is less critical for a cardiovascular target. Ligand A (36.371%) and Ligand B (58.976%) are both relatively low, which is fine.
**8. Caco-2 Permeability:** Both have negative Caco-2 values, which is unusual and suggests a potential issue with permeability prediction. However, given the context, this isn't a deciding factor.
**9. Aqueous Solubility:** Both have negative solubility values, again suggesting a potential issue with prediction.
**10. hERG Inhibition:** Both ligands have low hERG inhibition risk (A: 0.389, B: 0.219).
**11. Microsomal Clearance:** Ligand A (4.856) has a lower microsomal clearance than Ligand B (31.977), indicating better metabolic stability.
**12. In vitro Half-Life:** Ligand B has a negative half-life (-10.434), which is not physically possible and indicates a problem with the prediction. Ligand A has a reasonable half-life (45.899).
**13. P-gp Efflux:** Both ligands have low P-gp efflux liability (A: 0.103, B: 0.113).
**14. Binding Affinity:** Ligand B (-6.8 kcal/mol) has a slightly better binding affinity than Ligand A (-6.0 kcal/mol), but the difference is not substantial enough to overcome other significant issues.
**Overall Assessment:**
The primary deciding factor is the extremely high DILI risk associated with Ligand A. This is a major concern that would likely disqualify it early in drug development. While Ligand B has some questionable predicted values (negative Caco-2 and solubility, negative half-life), the significantly lower DILI risk and slightly better binding affinity make it the more promising candidate. The issues with the predictions for Ligand B would need to be investigated experimentally, but they don't present an immediate disqualification like the DILI risk for Ligand A.
Output:
0
2025-04-17 22:08:52,497 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (441.332 Da) is within the ideal range, while Ligand B (345.443 Da) is also acceptable, leaning towards the lower end. No clear advantage here.
2. **TPSA:** Ligand A (101.05) is slightly above the preferred <140 for good absorption, but still reasonable. Ligand B (90.27) is excellent, well below 100, favoring permeability.
3. **logP:** Ligand A (3.179) is optimal. Ligand B (1.649) is a bit low, potentially hindering membrane permeability. This favors Ligand A.
4. **HBD:** Both ligands have acceptable HBD counts (Ligand A: 2, Ligand B: 1).
5. **HBA:** Both ligands have acceptable HBA counts (Ligand A: 6, Ligand B: 4).
6. **QED:** Both ligands have good QED scores (Ligand A: 0.648, Ligand B: 0.842), indicating drug-likeness. Ligand B is slightly better.
7. **DILI:** Ligand A (95.192) has a high DILI risk, which is a significant concern. Ligand B (31.989) has a very low DILI risk, a major advantage.
8. **BBB:** Both ligands have reasonable BBB penetration (Ligand A: 70.803, Ligand B: 72.082). Since ADRB2 isn't exclusively a CNS target, this isn't a deciding factor, but it's good for both.
9. **Caco-2:** Both have negative values, indicating poor permeability. Ligand B (-4.749) is slightly better than Ligand A (-5.15), but both are concerning.
10. **Solubility:** Both have negative solubility values, indicating poor solubility. Ligand B (-2.605) is slightly better than Ligand A (-4.085).
11. **hERG:** Both ligands have low hERG inhibition risk (Ligand A: 0.338, Ligand B: 0.229). Ligand B is slightly better.
12. **Cl_mic:** Ligand A (29.97) has a moderate clearance, while Ligand B (10.874) has a much lower clearance, suggesting better metabolic stability. This favors Ligand B.
13. **t1/2:** Ligand A (141.393) has a long half-life, which is good. Ligand B (-12.081) has a negative half-life, which is a major red flag.
14. **Pgp:** Both ligands have low Pgp efflux liability (Ligand A: 0.353, Ligand B: 0.063). Ligand B is significantly better.
15. **Binding Affinity:** Ligand B (-7.3 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.5 kcal/mol). This is a substantial advantage, potentially outweighing some ADME concerns.
**Overall Assessment:**
Ligand B is the stronger candidate. While Ligand A has a longer half-life, Ligand B excels in several critical areas: significantly lower DILI risk, better metabolic stability (lower Cl_mic), stronger binding affinity, and better Pgp efflux liability. The slightly lower logP of Ligand B is a concern, but the superior affinity and safety profile outweigh this drawback. The negative Caco-2 and solubility values are concerning for both, but can be addressed with formulation strategies. The negative half-life for Ligand B is a major concern, but could be an artifact of the modeling.
Output:
0
2025-04-17 22:08:52,498 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
The target is ADRB2, a GPCR. Therefore, I will prioritize logP, TPSA, Pgp efflux, BBB penetration, and binding affinity. Metabolic stability and solubility are also important, but secondary to the GPCR-specific parameters.
Let's compare the ligands property by property:
1. **MW:** Both ligands are within the ideal range (343-344 Da). No significant difference.
2. **TPSA:** Ligand A (56.79) is significantly better than Ligand B (67.65). Lower TPSA generally favors better permeability, crucial for GPCR ligands.
3. **logP:** Ligand A (3.036) is optimal, while Ligand B (0.797) is quite low. A logP below 1 can hinder membrane permeability. This is a substantial advantage for Ligand A.
4. **HBD:** Ligand A (1) is slightly higher than Ligand B (0), but both are acceptable.
5. **HBA:** Both ligands have the same number of HBA (4), which is within the acceptable range.
6. **QED:** Both ligands have similar QED scores (0.785 and 0.708), indicating good drug-likeness.
7. **DILI:** Ligand A (69.911) has a higher DILI risk than Ligand B (20.9). This is a negative for Ligand A.
8. **BBB:** Ligand A (66.188) has better BBB penetration than Ligand B (43.815), which is a positive for Ligand A, though neither are exceptionally high.
9. **Caco-2:** Both have negative Caco-2 values, suggesting poor permeability. However, the scale is not specified, making direct comparison difficult.
10. **Solubility:** Ligand B (-1.882) has better solubility than Ligand A (-4.363). Solubility is important, but less critical than permeability for GPCRs.
11. **hERG:** Both ligands have low hERG inhibition risk (0.707 and 0.497).
12. **Cl_mic:** Ligand B (-0.244) has much lower microsomal clearance than Ligand A (48.335), indicating better metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand B (-3.113) has a longer in vitro half-life than Ligand A (-0.891), further supporting its better metabolic stability.
14. **Pgp:** Ligand A (0.287) has lower P-gp efflux than Ligand B (0.024), which is a positive for Ligand A.
15. **Binding Affinity:** Ligand A (-6.3 kcal/mol) has a slightly better binding affinity than Ligand B (-5.6 kcal/mol). While the difference is not huge, it is still a factor.
**Overall Assessment:**
Ligand A has advantages in TPSA, logP, BBB penetration, Pgp efflux, and binding affinity. However, it suffers from a higher DILI risk and significantly worse metabolic stability (higher Cl_mic, shorter t1/2). Ligand B excels in metabolic stability (lower Cl_mic, longer t1/2) and DILI risk, but has a suboptimal logP and lower BBB penetration.
Given the importance of permeability (logP, TPSA) and binding affinity for GPCR targets, and the relatively modest difference in binding affinity, the superior logP and TPSA of Ligand A, combined with acceptable BBB penetration, outweigh its higher DILI risk and poorer metabolic stability. The metabolic stability could be improved through structural modifications, while a higher DILI risk can sometimes be mitigated with careful dose selection and patient monitoring. The poor logP of Ligand B is a more difficult property to address.
Output:
1
2025-04-17 22:08:52,498 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [364.373, 71.34, 4.411, 2, 4, 0.703, 96.51, 44.32, -4.822, -4.108, 0.89, 33.02, 125.449, 0.461, -7.0]**
**Ligand B: [347.371, 86.92, 1.745, 0, 7, 0.786, 74.99, 70.143, -4.704, -2.011, 0.254, 10.678, 17.413, 0.168, -6.9]**
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand B (347.371) is slightly lower, which could be favorable for permeability, but both are acceptable.
2. **TPSA:** Ligand A (71.34) is better than Ligand B (86.92). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (4.411) is higher than Ligand B (1.745). While 4.411 is approaching the upper limit, it's still within a reasonable range. Ligand B's logP is quite low and could indicate poor membrane permeability.
4. **H-Bond Donors:** Ligand A (2) is preferable to Ligand B (0). Having some H-bond donors can aid solubility.
5. **H-Bond Acceptors:** Ligand B (7) is preferable to Ligand A (4).
6. **QED:** Both ligands have similar QED values (0.703 and 0.786), indicating good drug-like properties.
7. **DILI:** Ligand A (96.51) has a significantly higher DILI risk than Ligand B (74.99). This is a major concern for Ligand A.
8. **BBB:** Ligand B (70.143) has a better BBB penetration score than Ligand A (44.32). While not critical for a cardiovascular target, it's a slight advantage.
9. **Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests a potential issue with the experimental setup or a very poor permeability.
10. **Aqueous Solubility:** Ligand B (-2.011) is better than Ligand A (-4.108).
11. **hERG Inhibition:** Ligand A (0.89) is better than Ligand B (0.254). Lower hERG inhibition is crucial to avoid cardiotoxicity.
12. **Microsomal Clearance:** Ligand B (10.678) has lower clearance than Ligand A (33.02), indicating better metabolic stability.
13. **In vitro Half-Life:** Ligand A (125.449) has a significantly longer half-life than Ligand B (17.413). This is a major advantage for dosing convenience.
14. **P-gp Efflux:** Ligand A (0.461) has lower P-gp efflux than Ligand B (0.168), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand A (-7.0) has a slightly better binding affinity than Ligand B (-6.9). While the difference is small, it's still a positive.
**Overall Assessment:**
Ligand A has a better binding affinity and half-life, and lower P-gp efflux. However, its significantly higher DILI risk is a major drawback. Ligand B has better solubility, metabolic stability, and a lower DILI risk. The lower logP of Ligand B is a concern, but the substantial difference in DILI risk outweighs this. Given the cardiovascular target, mitigating potential liver toxicity is paramount.
Therefore, I prefer Ligand B.
0
2025-04-17 22:08:52,498 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [354.491, 70.08, 1.661, 1, 4, 0.755, 6.747, 76.735, -4.396, -1.319, 0.393, 34.99, 21.098, 0.062, -6.3]
**Ligand B:** [361.913, 29.54, 4.531, 0, 2, 0.744, 23.885, 92.672, -5.008, -4.766, 0.824, 76.521, 34.155, 0.734, -6.8]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal 200-500 Da range. A (354.491) is slightly better.
2. **TPSA:** A (70.08) is higher than ideal (<140), but acceptable. B (29.54) is excellent. This favors B.
3. **logP:** A (1.661) is optimal. B (4.531) is pushing the upper limit and could lead to solubility issues and off-target effects. This favors A.
4. **HBD/HBA:** A (1 HBD, 4 HBA) is reasonable. B (0 HBD, 2 HBA) is also good. No strong preference here.
5. **QED:** Both are similar and above the 0.5 threshold, indicating good drug-likeness.
6. **DILI:** A (6.747) is better than B (23.885). Lower DILI risk is crucial. This favors A.
7. **BBB:** A (76.735) is good, but B (92.672) is excellent. For a GPCR, good BBB penetration is a plus, though not always essential depending on the target location. This favors B.
8. **Caco-2:** A (-4.396) is very poor. B (-5.008) is also poor. Both have issues with intestinal absorption.
9. **Solubility:** A (-1.319) is better than B (-4.766). Solubility is important for bioavailability. This favors A.
10. **hERG:** A (0.393) is much better than B (0.824). Lower hERG inhibition is critical to avoid cardiotoxicity. This strongly favors A.
11. **Cl_mic:** B (76.521) has a higher clearance than A (34.99), indicating faster metabolism. This favors A.
12. **t1/2:** B (34.155) has a longer half-life than A (21.098). Longer half-life is generally preferred. This favors B.
13. **Pgp:** A (0.062) has lower P-gp efflux than B (0.734). Lower P-gp efflux is beneficial for bioavailability. This favors A.
14. **Affinity:** B (-6.8) is slightly better than A (-6.3), but the difference is not huge. A difference of 0.5 kcal/mol is not enough to overcome other significant issues.
**Overall Assessment:**
Ligand A has a more favorable profile overall, especially considering the critical need to avoid cardiotoxicity (lower hERG) and the importance of metabolic stability (lower Cl_mic). While Ligand B has better BBB penetration and a slightly better binding affinity, its higher logP, DILI risk, and Pgp efflux liability are significant drawbacks. The poor Caco-2 values for both are concerning, but can potentially be addressed with formulation strategies.
Therefore, I would prioritize Ligand A.
1
2025-04-17 22:08:52,498 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (345.443) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are reasonably low, but Ligand A (70.67) is better than Ligand B (79.37). Lower TPSA is preferred for better absorption.
3. **logP:** Both ligands have good logP values (1.41 and 1.79), falling within the optimal range of 1-3.
4. **HBD:** Ligand A (2) has fewer HBD than Ligand B (1). Fewer HBD is generally preferred for better permeability.
5. **HBA:** Ligand A (4) has fewer HBA than Ligand B (5). Fewer HBA is generally preferred for better permeability.
6. **QED:** Both have good QED scores (0.579 and 0.75), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (22.722) has a significantly lower DILI risk than Ligand B (60.527). This is a major advantage for Ligand A.
8. **BBB:** Both have good BBB penetration (79.139 and 83.443).
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. Ligand A (-5.38) is slightly better than Ligand B (-5.095).
10. **Solubility:** Both have negative solubility values, indicating poor solubility. Ligand A (-2.047) is slightly better than Ligand B (-3.584).
11. **hERG:** Both have low hERG inhibition liability (0.384 and 0.387).
12. **Cl_mic:** Ligand A (-18.972) has a much lower (better) microsomal clearance than Ligand B (39.559), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-3.672) has a negative half-life, indicating poor in vitro stability. Ligand B (-22.42) is also poor, but less so.
14. **Pgp:** Both have very low Pgp efflux liability (0.018 and 0.195).
15. **Binding Affinity:** Ligand B (-7.4) has a significantly stronger binding affinity than Ligand A (-5.6), a difference of 1.8 kcal/mol.
**GPCR-specific considerations:**
For a GPCR like ADRB2, affinity, logP, TPSA, and Pgp are key. Ligand B excels in affinity. However, the significant advantages of Ligand A in DILI risk and microsomal clearance are crucial for overall drug development success. The slightly better TPSA and H-bonding characteristics of Ligand A also contribute to its favorability. While Ligand B's affinity is strong, the ADME profile of Ligand A is more promising, particularly the lower DILI risk.
**Conclusion:**
Despite Ligand B's superior binding affinity, Ligand A's significantly better safety profile (DILI) and metabolic stability (Cl_mic) outweigh this advantage. The slightly better TPSA and H-bonding also contribute.
Output:
1
2025-04-17 22:08:52,498 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Step-by-step comparison:**
1. **MW:** Both ligands (362.499 Da and 369.491 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (75.19) is significantly better than Ligand B (100.35). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (2.323) is optimal, while Ligand B (0.278) is quite low. This is a significant drawback for Ligand B, potentially hindering membrane permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2).
5. **HBA:** Ligand A (5) is preferable to Ligand B (7).
6. **QED:** Ligand A (0.788) is better than Ligand B (0.648), indicating a more drug-like profile.
7. **DILI:** Ligand A (35.983) has a lower DILI risk than Ligand B (43.389), which is desirable. Both are acceptable, but A is better.
8. **BBB:** Ligand A (65.607) is better than Ligand B (13.726). While not a primary concern for a cardiovascular target, higher BBB is generally a positive attribute.
9. **Caco-2:** Both are negative (-5.167 and -5.734), indicating poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-2.935) is better than Ligand B (-1.01). Better solubility is always preferred.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.076 and 0.08).
12. **Cl_mic:** Ligand A (40.124) has a lower microsomal clearance than Ligand B (8.395), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-6.499) has a longer in vitro half-life than Ligand B (6.952).
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.118 and 0.027).
15. **Binding Affinity:** Ligand A (-7.0) has a slightly better binding affinity than Ligand B (-5.4). This is a significant advantage.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand A excels in these areas.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical parameters. The significantly better logP, TPSA, QED, solubility, metabolic stability, half-life, and binding affinity of Ligand A outweigh the similar MW, DILI, hERG, and Pgp profiles. While both have poor Caco-2 permeability, the other advantages of Ligand A make it the more promising candidate.
Output:
1
2025-04-17 22:08:52,499 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (356.4 and 366.5 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (98.6) is slightly higher than Ligand B (91.4). Both are below the 140 threshold for oral absorption, but closer to the 90 threshold for CNS targets (though ADRB2 isn't necessarily a CNS target). Ligand B is slightly preferred.
3. **logP:** Ligand A (2.11) and Ligand B (1.58) are both within the optimal 1-3 range. Ligand A is slightly more lipophilic, which could be beneficial for membrane permeability, but not dramatically so.
4. **HBD:** Ligand A has 3 HBD, while Ligand B has 2. Both are acceptable (<=5).
5. **HBA:** Ligand A has 7 HBA, Ligand B has 5. Both are acceptable (<=10).
6. **QED:** Both ligands have good QED scores (0.665 and 0.764, respectively), indicating good overall drug-likeness. Ligand B is slightly better.
7. **DILI:** Ligand A has a DILI risk of 84.7%, which is concerning (high risk). Ligand B has a much lower DILI risk of 37.5% (good). This is a *major* advantage for Ligand B.
8. **BBB:** Ligand A (34.3%) has a low BBB penetration, while Ligand B (66.6%) is significantly better. While ADRB2 isn't exclusively a CNS target, some CNS exposure could be relevant depending on the specific therapeutic application.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale isn't defined, so it's hard to interpret.
10. **Solubility:** Both have negative solubility values, which is also unusual and suggests poor solubility. Again, the scale is undefined.
11. **hERG:** Both ligands have low hERG inhibition liability (0.47 and 0.35, respectively), which is good.
12. **Cl_mic:** Ligand A (29.2) has lower microsomal clearance than Ligand B (35.0), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-11.985) has a significantly longer in vitro half-life than Ligand A (-6.781). This is a significant advantage for Ligand B.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.055 and 0.028, respectively), which is good.
15. **Binding Affinity:** Ligand A (-7.2 kcal/mol) has a slightly better binding affinity than Ligand B (-5.9 kcal/mol). This is a 1.3 kcal/mol difference, which is substantial.
**Overall Assessment & GPCR Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Ligand A has a slightly better logP and significantly better affinity. However, the *overwhelming* advantage of Ligand B is its dramatically lower DILI risk and significantly improved in vitro half-life. The DILI risk for Ligand A is unacceptably high. The better half-life of Ligand B also suggests improved PK properties. While the affinity difference is notable, a 1.3 kcal/mol difference can often be overcome with further optimization, while mitigating a high DILI risk is much more challenging.
Therefore, I prioritize the safety and PK advantages of Ligand B.
Output:
0
2025-04-17 22:08:52,499 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (354.397 and 349.475 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (50.8) is significantly better than Ligand B (72.36). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (2.411 and 2.163), falling within the 1-3 optimal range. Similar.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Both ligands have the same number of HBA (4).
6. **QED:** Ligand A (0.882) has a better QED score than Ligand B (0.718), indicating a more drug-like profile.
7. **DILI:** Ligand A (36.72) has a slightly higher DILI risk than Ligand B (26.522), but both are below the concerning threshold of 60.
8. **BBB:** Both ligands have similar BBB penetration (73.362 and 70.803). Not a major factor for a cardiovascular target.
9. **Caco-2:** Both ligands have very similar, and poor, Caco-2 permeability (-4.505 and -4.516). This is a concern for oral bioavailability.
10. **Solubility:** Both ligands have similar, and poor, aqueous solubility (-2.083 and -2.295). This is also a concern for oral bioavailability.
11. **hERG:** Ligand A (0.835) has a lower hERG inhibition liability than Ligand B (0.276), which is a significant advantage regarding cardiotoxicity.
12. **Cl_mic:** Ligand A (-7.731) has a *much* lower microsomal clearance than Ligand B (38.698). This indicates significantly better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (-7.026) has a significantly longer in vitro half-life than Ligand B (29.112). This is a substantial advantage.
14. **Pgp:** Ligand A (0.15) has lower P-gp efflux liability than Ligand B (0.05), which is better for bioavailability.
15. **Binding Affinity:** Ligand A (-6.4) has a slightly weaker binding affinity than Ligand B (-6.1). However, the difference is less than 1.5 kcal/mol, and is outweighed by the superior ADME properties of Ligand A.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A is better in TPSA, Pgp, and has a more favorable ADME profile overall. The small difference in affinity is not enough to favor Ligand B.
**Conclusion:**
Ligand A demonstrates a significantly better balance of properties, particularly in terms of metabolic stability (Cl_mic, t1/2), reduced hERG risk, and a more favorable drug-like profile (QED). While both have similar logP and affinity, the ADME advantages of Ligand A make it the more promising drug candidate.
Output:
1
2025-04-17 22:08:52,499 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (364.825 and 351.451 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (64.99) is significantly better than Ligand B (89.35). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (3.392) is optimal, while Ligand B (0.956) is a bit low. A logP below 1 can hinder membrane permeability. Ligand A is favored.
4. **HBD:** Both ligands have 1 HBD, which is within the acceptable limit of 5.
5. **HBA:** Ligand A has 5 HBA, and Ligand B has 6. Both are acceptable (<=10), but Ligand A is slightly better.
6. **QED:** Both ligands have similar QED values (0.727 and 0.634), indicating good drug-likeness.
7. **DILI:** Ligand B (35.983) has a significantly lower DILI risk than Ligand A (52.385). This is a substantial advantage for Ligand B.
8. **BBB:** Ligand B (53.083) has a higher BBB penetration than Ligand A (30.981). While not critical for a cardiovascular target, it's not a negative.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.563 and -4.957), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand A (-4.445) has slightly better solubility than Ligand B (-0.937).
11. **hERG:** Ligand A (0.677) has a lower hERG risk than Ligand B (0.022). This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand B (29.63) has a much lower microsomal clearance than Ligand A (93.639), indicating better metabolic stability. This is a major advantage for Ligand B.
13. **t1/2:** Ligand A (13.417) has a longer in vitro half-life than Ligand B (-0.846). This is a positive for Ligand A.
14. **Pgp:** Ligand A (0.531) has lower P-gp efflux than Ligand B (0.016), which is favorable.
15. **Binding Affinity:** Ligand B (-6.7 kcal/mol) has a slightly better binding affinity than Ligand A (-6.4 kcal/mol). This is a 1.5 kcal/mol advantage, which is significant.
**GPCR-Specific Priorities & Overall Assessment:**
For a GPCR like ADRB2, logP, TPSA, affinity, and metabolic stability are key. Ligand A has a better logP and TPSA, and a reasonable hERG score. Ligand B has a significantly better DILI score and metabolic stability (lower Cl_mic), and slightly better binding affinity. The Caco-2 values are concerning for both, but the difference in metabolic stability and DILI risk is substantial. The slightly better affinity of Ligand B, combined with its improved safety profile and metabolic stability, outweighs the slightly less optimal logP and TPSA.
Output:
0
2025-04-17 22:08:52,499 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.435 and 350.463 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (107.61) is slightly higher than Ligand B (87.32). Both are below the 140 threshold for oral absorption, but Ligand B is closer to the preferred <90 for GPCRs.
3. **logP:** Ligand A (-0.465) is lower than the optimal 1-3 range, potentially hindering permeability. Ligand B (1.748) is within the optimal range. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (2), but both are acceptable (<=5).
5. **HBA:** Both ligands have 4 HBA, which is within the acceptable range (<=10).
6. **QED:** Both ligands have good QED scores (0.622 and 0.784, respectively), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (18.573) has a much lower DILI risk than Ligand B (40.636). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (44.746) has a lower BBB penetration percentile than Ligand B (61.38). While ADRB2 isn't strictly a CNS target, some CNS exposure can be acceptable or even desirable for off-target effects assessment. Ligand B is better here.
9. **Caco-2:** Ligand A (-5.595) has a very poor Caco-2 permeability, suggesting poor absorption. Ligand B (-4.854) is better, but still not great.
10. **Solubility:** Ligand A (-1.575) has slightly better solubility than Ligand B (-2.854).
11. **hERG:** Ligand A (0.031) has a very low hERG risk, while Ligand B (0.474) has a slightly elevated risk. This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand A (-30.962) has significantly lower microsomal clearance, indicating better metabolic stability, than Ligand B (20.856). This is a major advantage for Ligand A.
13. **t1/2:** Ligand A (-4.31) has a shorter in vitro half-life than Ligand B (-8.771). This is an advantage for Ligand B.
14. **Pgp:** Ligand A (0.002) has very low P-gp efflux, while Ligand B (0.089) has slightly higher efflux. This is an advantage for Ligand A.
15. **Binding Affinity:** Ligand B (-6.3) has a significantly better binding affinity than Ligand A (-2.0). This is a substantial advantage for Ligand B, potentially outweighing some ADME concerns.
**Overall Assessment:**
Ligand B has a superior binding affinity and better logP, Caco-2, BBB, and half-life. However, it has a significantly higher DILI risk, higher Pgp efflux, and a worse clearance profile. Ligand A has a much better safety profile (DILI, hERG), better metabolic stability (Cl_mic), and lower Pgp efflux, but suffers from poor Caco-2 permeability and a much weaker binding affinity.
Given the importance of potency for GPCRs, and the substantial difference in binding affinity (-6.3 vs -2.0 kcal/mol), I believe Ligand B is the more promising starting point, despite its ADME liabilities. These liabilities can be addressed through further optimization, but a weak binder is much harder to improve.
Output:
0
2025-04-17 22:08:52,499 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (356.491 and 351.397 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (49.41) is well below the 140 threshold, and even better, below the 90 for CNS targets. Ligand B (62.3) is still under 140, but less optimal. This favors Ligand A.
3. **logP:** Ligand A (4.535) is slightly high, potentially leading to solubility issues or off-target effects, but still within a manageable range. Ligand B (1.941) is excellent, falling squarely within the 1-3 optimal range. This favors Ligand B.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Both ligands have 3 HBA, which is good.
6. **QED:** Both ligands have a QED > 0.8, indicating strong drug-like properties. No significant difference.
7. **DILI:** Ligand A (65.723) has a higher DILI risk than Ligand B (38.348). This is a significant drawback for Ligand A.
8. **BBB:** Both ligands show good BBB penetration (Ligand A: 83.482, Ligand B: 86.08). No significant difference.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
10. **Solubility:** Ligand A (-5.339) has very poor aqueous solubility, a major concern. Ligand B (-2.648) is better, but still not ideal.
11. **hERG:** Ligand A (0.69) has a slightly higher hERG risk than Ligand B (0.362), but both are relatively low.
12. **Cl_mic:** Ligand A (69.592) has a higher microsomal clearance than Ligand B (10.318). This suggests Ligand B is more metabolically stable.
13. **t1/2:** Ligand A (34.308) has a reasonable in vitro half-life. Ligand B (-24.656) has a negative half-life, which is impossible and likely an error in the data. This is a major red flag for Ligand B.
14. **Pgp:** Ligand A (0.526) has lower P-gp efflux liability than Ligand B (0.063). This is favorable for Ligand A.
15. **Binding Affinity:** Ligand B (-7.2 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.1 kcal/mol). This is a substantial advantage for Ligand B.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are particularly important. Ligand B excels in logP and affinity. Ligand A has better TPSA and Pgp. However, the significantly stronger affinity of Ligand B, combined with its lower DILI risk, outweighs the slight TPSA/Pgp advantage of Ligand A. The negative half-life for Ligand B is a critical issue.
**Conclusion:**
Despite the issues with the half-life, the superior binding affinity and lower DILI risk of Ligand B make it the more promising candidate. The negative half-life is a data error that would need to be investigated, but the other parameters strongly favor Ligand B.
Output:
0
2025-04-17 22:08:52,500 - INFO - Batch 310 complete. Total preferences: 4960
2025-04-17 22:08:52,500 - INFO - Processing batch 311/512...
2025-04-17 22:09:41,849 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (365.331 and 364.364 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (90.98) is slightly higher than Ligand B (64.8). Both are below 140, but B is better for absorption.
3. **logP:** Both ligands have good logP values (1.052 and 2.714). Ligand B is slightly higher, potentially improving membrane permeability.
4. **HBD:** Ligand A has 2 HBD, and Ligand B has 0. Both are acceptable, but fewer HBDs can sometimes improve permeability.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 5. Both are within the acceptable range of <=10.
6. **QED:** Ligand A (0.707) has a slightly better QED score than Ligand B (0.664), indicating a more drug-like profile.
7. **DILI:** Ligand A (53.276) has a slightly higher DILI risk than Ligand B (44.087), but both are below the concerning threshold of 60.
8. **BBB:** Ligand B (97.053) has a significantly higher BBB penetration percentile than Ligand A (72.276). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be beneficial for distribution.
9. **Caco-2:** Ligand A (-4.867) and Ligand B (-4.429) both have negative Caco-2 values, which is unusual and indicates very poor permeability. This is a significant concern for both.
10. **Solubility:** Both ligands have poor aqueous solubility (-2.887 and -3.017). This is a major drawback.
11. **hERG:** Ligand A (0.17) has a much lower hERG inhibition liability than Ligand B (0.571). This is a critical advantage for Ligand A, minimizing cardiotoxicity risk.
12. **Cl_mic:** Ligand B (43.736) has a lower microsomal clearance than Ligand A (26.008), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-49.047) has a much more negative in vitro half-life, indicating very rapid metabolism and a short half-life. Ligand B (-11.626) is better, but still not ideal.
14. **Pgp:** Ligand A (0.01) has a much lower P-gp efflux liability than Ligand B (0.412), which is beneficial for bioavailability.
15. **Affinity:** Ligand B (-7.5 kcal/mol) has a slightly better binding affinity than Ligand A (-6.8 kcal/mol). This is a 0.7 kcal/mol difference, which is significant.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B has better logP, TPSA, and Pgp. The affinity difference is also notable. However, the hERG risk for Ligand B is concerning.
**Overall Assessment:**
While Ligand B has a better affinity and metabolic stability, the significantly lower hERG risk of Ligand A is a major advantage. The poor Caco-2 and solubility are problematic for both, but can potentially be addressed through formulation strategies. The lower Pgp efflux for Ligand A is also a positive. Given the cardiovascular target, minimizing hERG liability is paramount.
Output:
1
2025-04-17 22:09:41,849 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.5 and 354.4) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (61.44) is significantly better than Ligand B (136.87). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand B is above the preferred 140 threshold.
3. **logP:** Ligand A (2.087) is within the optimal 1-3 range. Ligand B (-2.563) is quite low, potentially hindering membrane permeability. This is a significant drawback.
4. **HBD:** Ligand A (2) is good. Ligand B (4) is acceptable but slightly higher.
5. **HBA:** Ligand A (3) is good. Ligand B (5) is acceptable but slightly higher.
6. **QED:** Ligand A (0.693) is better than Ligand B (0.43), indicating a more drug-like profile.
7. **DILI:** Ligand A (8.53) has a much lower DILI risk than Ligand B (22.722). This is a crucial safety parameter.
8. **BBB:** Both are relatively low, which is fine for a cardiovascular target. Ligand A (56.65) is slightly better than Ligand B (53.548).
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-5.103) is slightly better than Ligand B (-5.934).
10. **Solubility:** Both are negative, indicating poor solubility. Ligand A (-2.164) is slightly better than Ligand B (-1.36).
11. **hERG:** Ligand A (0.472) has a lower hERG risk than Ligand B (0.027). This is a significant safety advantage.
12. **Cl_mic:** Ligand B (-33.85) has a much lower (better) microsomal clearance than Ligand A (33.877), suggesting greater metabolic stability. This is a strong point for Ligand B.
13. **t1/2:** Ligand B (-11.673) has a longer half-life than Ligand A (4.067), which is desirable. This is a strong point for Ligand B.
14. **Pgp:** Ligand A (0.04) has lower P-gp efflux than Ligand B (0.0).
15. **Affinity:** Ligand A (-8.0) has a slightly better binding affinity than Ligand B (-6.8). While Ligand B is still good, the 1.2 kcal/mol difference is noticeable.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand A excels in these areas. While metabolic stability (Cl_mic and t1/2) are important, the poor logP and higher TPSA of Ligand B are significant drawbacks that likely outweigh its better metabolic profile. The lower DILI and hERG risk of Ligand A also contribute to its favorability.
**Conclusion:**
Despite Ligand B's better metabolic stability and half-life, Ligand A's superior logP, TPSA, affinity, and safety profile (DILI, hERG) make it the more promising drug candidate for the ADRB2 receptor.
Output:
1
2025-04-17 22:09:41,850 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (389.493 and 372.506 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (62.3) is slightly higher than Ligand B (51.66). Both are below the 140 threshold for oral absorption, but B is better.
3. **logP:** Both ligands have good logP values (2.855 and 3.708), falling within the optimal 1-3 range. Ligand B is slightly higher, potentially increasing permeability but also raising concerns about off-target effects.
4. **HBD:** Ligand A has 1 HBD, while Ligand B has 0. Both are acceptable.
5. **HBA:** Both ligands have 5 HBA, which is within the acceptable range.
6. **QED:** Ligand A (0.729) has a slightly higher QED than Ligand B (0.62), indicating a more drug-like profile.
7. **DILI:** Ligand A (61.729) has a higher DILI risk than Ligand B (20.202). This is a significant drawback for Ligand A.
8. **BBB:** Ligand B (97.751) has a much higher BBB penetration percentile than Ligand A (82.241). While ADRB2 isn't strictly a CNS target, some peripheral ADRB2 receptors can influence CNS function, and higher BBB penetration can sometimes translate to better overall distribution.
9. **Caco-2:** Ligand A (-5.062) and Ligand B (-4.397) both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale isn't specified, so it's difficult to interpret.
10. **Solubility:** Ligand A (-3.733) and Ligand B (-4.234) both have negative solubility values, which is also unusual and suggests poor solubility.
11. **hERG:** Both ligands have low hERG inhibition liability (0.537 and 0.425), which is good.
12. **Cl_mic:** Ligand B (99.4) has a significantly higher microsomal clearance than Ligand A (18.491), indicating faster metabolism and lower metabolic stability. This is a major drawback for Ligand B.
13. **t1/2:** Ligand A (-16.663) has a negative in vitro half-life, which is not possible. This is a significant issue. Ligand B (13.542) has a reasonable half-life.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.173 and 0.285), which is favorable.
15. **Binding Affinity:** Ligand B (-6.5 kcal/mol) has a slightly better binding affinity than Ligand A (-6.3 kcal/mol), but the difference is small.
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B is better in terms of logP and TPSA. The affinity difference is minimal. However, the extremely poor in vitro half-life of Ligand A and its higher DILI risk are major concerns. The negative half-life value for Ligand A is a red flag, suggesting a potential data error or a highly unstable compound.
**Conclusion:**
Despite Ligand B's higher metabolic clearance, its superior DILI profile, better BBB penetration, and more reasonable half-life make it the more promising candidate. The negative half-life for Ligand A is a dealbreaker.
Output:
0
2025-04-17 22:09:41,850 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [423.16 , 81.59 , 4.34 , 4. , 3. , 0.438, 68.903, 46.375, -5.384, -4.929, 0.747, 41.834, 30.344, 0.289, -8.0 ]
**Ligand B:** [350.419, 107.55 , 0.569, 3. , 5. , 0.695, 58.395, 32.299, -5.248, -2.604, 0.272, 20.258, 11.756, 0.038, -6.1 ]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity):
1. **MW:** Ligand B (350.419 Da) is better, falling comfortably within the ideal range. Ligand A (423.16 Da) is at the upper end, but still acceptable.
2. **TPSA:** Ligand A (81.59) is significantly better than Ligand B (107.55). ADRB2 is a cardiovascular target, so CNS penetration isn't crucial, but lower TPSA generally aids absorption.
3. **logP:** Ligand A (4.34) is higher than ideal, potentially causing solubility issues or off-target interactions. Ligand B (0.569) is *too* low, likely hindering membrane permeability.
4. **HBD/HBA:** Both are reasonable. Ligand A (4 HBD, 3 HBA) and Ligand B (3 HBD, 5 HBA) are within acceptable limits.
5. **QED:** Ligand B (0.695) has a better QED score than Ligand A (0.438), suggesting a more drug-like profile.
6. **DILI:** Ligand B (58.395) has a lower DILI risk than Ligand A (68.903), which is preferable.
7. **BBB:** Not a high priority for a cardiovascular target, but Ligand A (46.375) is slightly better than Ligand B (32.299).
8. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-5.384) is slightly worse than Ligand B (-5.248).
9. **Solubility:** Ligand A (-4.929) is better than Ligand B (-2.604). Solubility is a concern with Ligand A's higher logP, but it's still better than Ligand B.
10. **hERG:** Ligand A (0.747) is better than Ligand B (0.272), indicating lower cardiotoxicity risk.
11. **Cl_mic:** Ligand B (20.258) has significantly lower microsomal clearance than Ligand A (41.834), suggesting better metabolic stability.
12. **t1/2:** Ligand A (30.344) has a longer half-life than Ligand B (11.756), which is desirable.
13. **Pgp:** Ligand A (0.289) has a lower P-gp efflux liability than Ligand B (0.038), suggesting better absorption and bioavailability.
14. **Affinity:** Ligand A (-8.0 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.1 kcal/mol). This is a substantial advantage.
**Overall Assessment:**
The affinity difference is the most significant factor. Ligand A's -8.0 kcal/mol binding is considerably stronger than Ligand B's -6.1 kcal/mol. While Ligand A has a higher logP and slightly worse Caco-2 permeability, the strong binding affinity can often compensate for minor ADME drawbacks, especially for a GPCR target. Ligand B has better QED, DILI, and metabolic stability, but the weaker binding makes it less likely to be effective. The better solubility of Ligand A also helps mitigate the logP concern.
Therefore, I would choose Ligand A.
Output:
1
2025-04-17 22:09:41,850 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
The target is ADRB2, a GPCR. Therefore, I will prioritize logP, TPSA, Pgp efflux, BBB penetration, and binding affinity, while also considering ADME properties like solubility, metabolic stability, and toxicity.
Let's compare the ligands property by property:
1. **MW:** Both ligands (348.338 and 350.507 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand B (50.6) is significantly better than Ligand A (114.09). Lower TPSA generally improves cell permeability and oral absorption, crucial for GPCR ligands.
3. **logP:** Both ligands have good logP values (1.613 and 2.294), falling within the optimal 1-3 range. Ligand B is slightly better.
4. **HBD:** Ligand A (2) is better than Ligand B (0). While lower HBD can improve permeability, having some H-bond donors can aid solubility.
5. **HBA:** Ligand A (7) is higher than Ligand B (5). Lower HBA is generally preferred for permeability.
6. **QED:** Both ligands have similar QED values (0.786 and 0.722), indicating good drug-likeness.
7. **DILI:** Ligand B (11.322) is *much* better than Ligand A (79.992). This is a major advantage for Ligand B, as lower DILI risk is critical.
8. **BBB:** Ligand B (83.482) is significantly better than Ligand A (64.87). While ADRB2 isn't exclusively a CNS target, some CNS exposure might be acceptable or even desirable depending on the specific therapeutic goal.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.578 and -4.381), which is unusual and suggests poor permeability. However, the values are very close.
10. **Solubility:** Ligand A (-4.211) is better than Ligand B (-1.797), indicating better aqueous solubility.
11. **hERG:** Both ligands have low hERG inhibition liability (0.299 and 0.507), which is good.
12. **Cl_mic:** Ligand A (61.279) has lower microsomal clearance than Ligand B (74.642), suggesting better metabolic stability.
13. **t1/2:** Ligand A (17.718) has a longer in vitro half-life than Ligand B (13.498), which is preferable.
14. **Pgp:** Ligand A (0.093) has lower P-gp efflux liability than Ligand B (0.343), meaning better absorption and potentially better CNS penetration.
15. **Affinity:** Ligand B (-6.6) has a slightly better binding affinity than Ligand A (-6.0). While the difference is not huge, it's a positive for Ligand B.
**Overall Assessment:**
Ligand B clearly outperforms Ligand A in several critical areas for a GPCR drug candidate: significantly lower DILI risk, much better BBB penetration, and slightly better binding affinity. While Ligand A has advantages in solubility, metabolic stability, and Pgp efflux, the DILI and BBB advantages of Ligand B are more important for overall drug viability, especially considering the potential for off-target effects with GPCRs. The TPSA is also much more favorable for Ligand B.
**Output:**
0
2025-04-17 22:09:41,850 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (351.447 and 352.366 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (93.46) is better than Ligand B (110.26). ADRB2 is not a CNS target, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (2.38) is preferable to Ligand B (1.35). Both are within the optimal 1-3 range, but Ligand A is closer to the center of this range. Ligand B is at the lower end, potentially impacting permeability.
4. **HBD:** Both ligands have 2 HBD, which is within the acceptable limit of <=5. No difference.
5. **HBA:** Ligand A (5) is better than Ligand B (6). Both are within the acceptable limit of <=10, but lower is generally preferred.
6. **QED:** Both ligands have similar QED values (0.712 and 0.742), indicating good drug-likeness. No significant difference.
7. **DILI:** Ligand A (48.817) has a lower DILI risk than Ligand B (57.154). Lower is better, so Ligand A is preferred.
8. **BBB:** Both ligands have good BBB penetration (73.672 and 70.764). Not a primary concern for ADRB2, but a slight edge to Ligand A.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.731 and -4.966). These values are difficult to interpret without knowing the scale, but negative values suggest poor permeability. No clear winner here.
10. **Solubility:** Both ligands have negative solubility values (-2.694 and -3.047). Similar to Caco-2, these values are difficult to interpret. No clear winner here.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.222 and 0.248). Excellent for both.
12. **Cl_mic:** Ligand A (32.385) has significantly lower microsomal clearance than Ligand B (58.044). Lower clearance indicates better metabolic stability, a significant advantage for Ligand A.
13. **t1/2:** Ligand A (18.76) has a longer in vitro half-life than Ligand B (8.657). Longer half-life is generally preferred.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.113 and 0.074). No significant difference.
15. **Binding Affinity:** Ligand A (-8.0) has a significantly stronger binding affinity than Ligand B (-6.1). A 1.9 kcal/mol difference is substantial and can outweigh minor ADME drawbacks.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand A is better in all three of these parameters. Metabolic stability (Cl_mic and t1/2) is also important, and Ligand A is superior in both.
**Conclusion:**
Ligand A consistently outperforms Ligand B across multiple crucial parameters, most notably in binding affinity and metabolic stability. While both ligands have acceptable profiles, Ligand A's stronger binding and better ADME properties make it the more promising drug candidate.
Output:
1
2025-04-17 22:09:41,850 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (343.471 and 354.422 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (43.86) is significantly better than Ligand B (67.87). For a GPCR, lower TPSA is generally preferred for better permeability, though not as critical as for CNS targets. Ligand A is well below the 140 threshold.
3. **logP:** Both ligands have acceptable logP values (0.903 and 0.756), falling within the 1-3 range. Ligand B is slightly lower, which could potentially impact permeability.
4. **HBD:** Ligand A (0) is preferable to Ligand B (1). Fewer HBDs generally improve membrane permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (4). Similar reasoning as with HBDs.
6. **QED:** Ligand A (0.697) is better than Ligand B (0.465). A higher QED suggests a more drug-like profile.
7. **DILI:** Ligand A (5.777%) is *much* better than Ligand B (12.253%). This is a significant advantage for Ligand A. Lower DILI is critical.
8. **BBB:** Both ligands have reasonable BBB penetration (75.107% and 83.831%). ADRB2 is a cardiovascular target, so BBB penetration isn't a primary concern, but higher is still slightly favorable.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.655 and -4.711). These values are unusual and suggest poor permeability. However, the values are very similar.
10. **Solubility:** Ligand A (-2.334) is slightly better than Ligand B (-1.741), indicating better aqueous solubility.
11. **hERG:** Both ligands have low hERG inhibition liability (0.363 and 0.472), which is good.
12. **Cl_mic:** Ligand A (3.673) is significantly better than Ligand B (-12.177). A positive value for ligand A suggests better metabolic stability. The negative value for ligand B is concerning.
13. **t1/2:** Ligand A (0.44) is significantly better than Ligand B (-4.607). A longer half-life is generally desirable.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.043 and 0.06).
15. **Binding Affinity:** Ligand A (-6.5 kcal/mol) is slightly better than Ligand B (-5.6 kcal/mol), although the difference is not huge.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical ADME-Tox parameters. The most significant differences are in DILI risk, metabolic stability (Cl_mic), and in vitro half-life, all of which are substantially better for Ligand A. While both ligands have similar binding affinities and acceptable logP values, the superior ADME profile of Ligand A makes it the more promising drug candidate. The negative Caco-2 values for both are concerning and would require further investigation, but the other advantages of Ligand A outweigh this issue.
Output:
1
2025-04-17 22:09:41,850 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [348.447, 84.42, 1.373, 1, 5, 0.804, 34.354, 68.282, -4.762, -1.842, 0.181, 29.605, -6.03, 0.023, -6]**
**Ligand B: [366.458, 66.48, 1.916, 1, 3, 0.81, 55.176, 79.217, -4.895, -3.645, 0.65, 65.379, -37.622, 0.255, -6.5]**
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). A (348.447) is slightly better.
**2. TPSA:** Both are acceptable for a non-CNS GPCR target (<140 A^2). B (66.48) is better than A (84.42) due to lower TPSA.
**3. logP:** Both are within the optimal range (1-3). B (1.916) is slightly better than A (1.373).
**4. H-Bond Donors:** Both have 1 HBD, which is good.
**5. H-Bond Acceptors:** A has 5, B has 3. Both are acceptable (<10). B is slightly better.
**6. QED:** Both are good (>0.5). A (0.804) is slightly better than B (0.81).
**7. DILI:** A (34.354) has a significantly lower DILI risk than B (55.176). This is a major advantage for A.
**8. BBB:** B (79.217) has better BBB penetration than A (68.282), but BBB is not a high priority for ADRB2 (a cardiovascular target).
**9. Caco-2:** Both have negative values, indicating poor permeability. A (-4.762) is slightly better than B (-4.895).
**10. Solubility:** Both have negative values, indicating poor solubility. B (-3.645) is better than A (-1.842).
**11. hERG:** A (0.181) has a much lower hERG risk than B (0.65). This is a significant advantage for A.
**12. Cl_mic:** A (29.605) has lower microsomal clearance, indicating better metabolic stability, than B (65.379).
**13. t1/2:** B (-37.622) has a much longer in vitro half-life than A (-6.03). This is a major advantage for B.
**14. Pgp:** A (0.023) has lower P-gp efflux, which is good. B (0.255) is higher.
**15. Binding Affinity:** B (-6.5) has slightly better binding affinity than A (-6).
**Overall Assessment:**
For a cardiovascular GPCR target like ADRB2, the key priorities are a balance of potency, metabolic stability, and safety. While B has a slightly better affinity and half-life, A has significantly better DILI and hERG profiles, and better metabolic stability (lower Cl_mic). The lower DILI and hERG risks are crucial for cardiovascular drugs. The slightly better affinity of B doesn't outweigh the safety concerns.
Therefore, I prefer Ligand A.
Output:
1
2025-04-17 22:09:41,851 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (a cardiovascular GPCR) drug candidates.
**Ligand A:** [337.379, 76.38, 3.076, 2, 5, 0.75, 73.982, 35.052, -5.228, -3.924, 0.565, 65.877, -29.39, 0.336, -7.4]
**Ligand B:** [364.515, 56.75, 1.619, 0, 5, 0.77, 16.479, 55.293, -5.001, -0.233, 0.221, 7.686, 17.406, 0.051, -6.7]
Here's a breakdown, considering the guidelines and GPCR priorities (logP, Pgp, TPSA, affinity):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (337.379) is slightly preferable due to being a bit lower.
2. **TPSA:** Ligand B (56.75) is better than Ligand A (76.38). Lower TPSA generally favors better absorption, and is important for GPCRs.
3. **logP:** Ligand A (3.076) is optimal, while Ligand B (1.619) is on the lower side, potentially impacting membrane permeability. This favors Ligand A.
4. **HBD:** Ligand A (2) is preferable to Ligand B (0). Having some HBD can improve solubility.
5. **HBA:** Both have 5 HBA, which is acceptable.
6. **QED:** Both are good (0.75 and 0.77).
7. **DILI:** Ligand B (16.479) is *significantly* better than Ligand A (73.982). This is a major advantage for Ligand B.
8. **BBB:** Ligand B (55.293) is better than Ligand A (35.052), but neither is particularly high. For a cardiovascular target, BBB penetration isn't critical, so this is a moderate advantage for B.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-5.228) is slightly worse than Ligand B (-5.001).
10. **Solubility:** Ligand B (-0.233) is better than Ligand A (-3.924). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.565) is better than Ligand B (0.221). Lower hERG risk is crucial.
12. **Cl_mic:** Ligand B (7.686) has significantly lower clearance than Ligand A (65.877), indicating better metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand B (17.406) has a longer half-life than Ligand A (-29.39). This is a major advantage for Ligand B.
14. **Pgp:** Ligand A (0.336) is better than Ligand B (0.051). Lower P-gp efflux is desirable.
15. **Affinity:** Ligand A (-7.4) has a slightly better binding affinity than Ligand B (-6.7). While a 0.7 kcal/mol difference is noticeable, it's not a huge gap.
**Overall Assessment:**
Ligand B has several key advantages: significantly lower DILI risk, much better metabolic stability (lower Cl_mic), and a longer half-life. It also has better solubility and BBB penetration. While Ligand A has a slightly better affinity and Pgp efflux profile, the ADME advantages of Ligand B are more compelling, especially the DILI and metabolic stability. The slightly lower logP of Ligand B is a concern, but the other benefits outweigh this.
Therefore, I prefer Ligand B.
0
2025-04-17 22:09:41,851 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (352.475 Da and 362.308 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (87.66) is significantly better than Ligand B (127.32). For a GPCR, keeping TPSA low is beneficial for permeability, and Ligand A is well under the 140 A^2 threshold. Ligand B is approaching the upper limit.
**3. logP:** Ligand A (1.364) is within the optimal 1-3 range, while Ligand B (0.12) is quite low. A logP below 1 can hinder membrane permeability. This is a significant advantage for Ligand A.
**4. H-Bond Donors:** Both ligands have 3 HBD, which is acceptable.
**5. H-Bond Acceptors:** Ligand A has 4 HBA and Ligand B has 5. Both are within the acceptable range of <=10.
**6. QED:** Ligand A (0.713) has a better QED score than Ligand B (0.566), indicating a more drug-like profile.
**7. DILI:** Ligand B (41.915) has a slightly higher DILI risk than Ligand A (35.285), but both are below the concerning threshold of 60.
**8. BBB:** Ligand B (74.564) has a significantly higher BBB penetration percentile than Ligand A (39.395). While ADRB2 is a cardiovascular target, some CNS exposure can be relevant for off-target effects or potential central mechanisms.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the absolute value for Ligand A (-5.056) is less negative than Ligand B (-5.58), suggesting slightly better permeability.
**10. Aqueous Solubility:** Both ligands have very poor aqueous solubility (-2.414 and -2.973 respectively). This is a significant drawback for both.
**11. hERG Inhibition:** Both ligands show very low hERG inhibition risk (0.172 and 0.093 respectively).
**12. Microsomal Clearance:** Ligand A (27.595) and Ligand B (26.493) have similar microsomal clearance values, suggesting comparable metabolic stability.
**13. In vitro Half-Life:** Ligand A (8.634 hours) has a longer half-life than Ligand B (-4.571 hours). This is a clear advantage for Ligand A.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.087 and 0.016 respectively).
**15. Binding Affinity:** Both ligands have very similar and strong binding affinities (-6.0 and -5.7 kcal/mol respectively). The difference is less than 0.5 kcal/mol, so it's not a deciding factor.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand A is the better candidate. Its superior logP and TPSA values suggest better permeability, and its higher QED and longer half-life contribute to a more favorable drug-like profile. While Ligand B has better BBB penetration, this is less critical for a primarily cardiovascular target. The solubility is a concern for both, but the other ADME properties of Ligand A are more favorable.
Output:
1
2025-04-17 22:09:41,851 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (357.41 Da and 370.513 Da). No significant difference.
2. **TPSA:** Ligand A (64.11) is better than Ligand B (49.84) as it is closer to the 90 A^2 threshold for GPCRs.
3. **logP:** Both ligands have good logP values (4.107 and 4.576), falling within the optimal 1-3 range. Ligand B is slightly higher, which could potentially lead to off-target effects, but it's not a major concern.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (6) is preferable to Ligand B (5).
6. **QED:** Both ligands have similar and acceptable QED values (0.696 and 0.702).
7. **DILI:** Ligand B (40.83) is significantly better than Ligand A (85.227) in terms of DILI risk. This is a major advantage for Ligand B.
8. **BBB:** Both ligands have high BBB penetration (81 and 89.686), which is good, but Ligand B is better.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability.
10. **Solubility:** Both ligands have negative solubility values, indicating poor solubility.
11. **hERG:** Ligand A (0.443) is better than Ligand B (0.833). Lower hERG inhibition is crucial for avoiding cardiotoxicity.
12. **Cl_mic:** Ligand B (71.047) has a lower microsomal clearance than Ligand A (120.694), suggesting better metabolic stability.
13. **t1/2:** Ligand B (53.726) has a longer in vitro half-life than Ligand A (28.621), which is desirable.
14. **Pgp:** Ligand B (0.592) is better than Ligand A (0.269). Lower P-gp efflux is beneficial for oral bioavailability.
15. **Binding Affinity:** Both ligands have the same binding affinity (-6.9 kcal/mol).
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand B emerges as the more promising candidate. While Ligand A has slightly better TPSA and hERG, Ligand B excels in crucial ADME properties like DILI risk, metabolic stability (Cl_mic, t1/2), and P-gp efflux. The similar binding affinity means these ADME advantages are decisive. The poor Caco-2 and solubility of both ligands are concerning, but can be addressed through formulation strategies.
Output:
0
2025-04-17 22:09:41,851 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
Let's systematically compare Ligand A and Ligand B based on the provided parameters and the guidelines, keeping in mind that ADRB2 is a GPCR, so logP, TPSA, Pgp, BBB, and affinity are key.
1. **MW:** Both ligands (371.825 and 354.422 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (75.71) is significantly better than Ligand A (119.28). Lower TPSA generally improves oral absorption and is particularly important for GPCRs.
3. **logP:** Ligand A (3.286) is within the optimal range (1-3), while Ligand B (1.227) is on the lower end. While not terrible, lower logP can sometimes hinder membrane permeability.
4. **HBD/HBA:** Ligand A has 2 HBD and 7 HBA, while Ligand B has 1 HBD and 4 HBA. Both are acceptable, but Ligand B is slightly better with fewer hydrogen bond donors and acceptors.
5. **QED:** Ligand B (0.728) has a better QED score than Ligand A (0.473), indicating a more drug-like profile.
6. **DILI:** Ligand B (35.556) has a much lower DILI risk than Ligand A (75.456). This is a significant advantage.
7. **BBB:** Ligand B (90.229) shows substantially better BBB penetration potential than Ligand A (67.041). This is crucial for GPCR targets, even if this one isn't specifically a CNS target, as it can influence distribution.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it is hard to make a clear comparison.
9. **Solubility:** Ligand B (-2.18) is better than Ligand A (-4.648).
10. **hERG:** Ligand B (0.269) has a lower hERG risk than Ligand A (0.091), which is favorable.
11. **Cl_mic:** Ligand B (33.238) has lower microsomal clearance than Ligand A (53.631), indicating better metabolic stability.
12. **t1/2:** Ligand B (-25.414) has a much longer in vitro half-life than Ligand A (-2.483). This is a significant advantage for dosing frequency.
13. **Pgp:** Ligand B (0.036) has lower P-gp efflux liability than Ligand A (0.057), which is desirable.
14. **Affinity:** Ligand A (-7.0) has slightly better binding affinity than Ligand B (-6.4). However, the difference is only 0.6 kcal/mol, which is not enough to outweigh the numerous advantages of Ligand B.
**Overall Assessment:**
Ligand B consistently outperforms Ligand A across most crucial ADME-Tox parameters (DILI, BBB, solubility, hERG, Cl_mic, t1/2, Pgp) and has a better QED score and TPSA. While Ligand A has slightly better binding affinity, the difference is not substantial enough to compensate for the significant advantages of Ligand B. Given the GPCR target class, the improvements in BBB, TPSA, and Pgp for Ligand B are particularly important.
**Output:**
0
2025-04-17 22:09:41,851 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (337.463 Da) is within the ideal range, while Ligand B (372.491 Da) is towards the upper limit but still acceptable.
2. **TPSA:** Ligand A (29.54) is excellent, well below the 140 threshold, and favorable for absorption. Ligand B (112.81) is higher, but still within a reasonable range for a non-CNS target.
3. **logP:** Ligand A (4.407) is slightly high, potentially leading to solubility issues, but still within a manageable range. Ligand B (-0.35) is too low, suggesting poor membrane permeability. This is a significant drawback.
4. **HBD:** Both ligands have acceptable HBD counts (0 for A, 2 for B).
5. **HBA:** Both ligands have acceptable HBA counts (2 for A, 4 for B).
6. **QED:** Both ligands have good QED scores (0.827 and 0.705), indicating good drug-like properties.
7. **DILI:** Ligand A (42.691) has a slightly higher DILI risk than Ligand B (28.616), but both are below the concerning 60 threshold.
8. **BBB:** This is less critical for a cardiovascular target like ADRB2. Ligand A (78.558) has a better BBB score than Ligand B (54.246), but this isn't a deciding factor.
9. **Caco-2:** Ligand A (-4.552) and Ligand B (-5.274) both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Ligand A (-5.05) has very poor predicted solubility, which is a major concern given its already high logP. Ligand B (-1.72) is also poor, but less so than Ligand A.
11. **hERG:** Ligand A (0.884) has a slightly higher hERG risk than Ligand B (0.06), but both are relatively low.
12. **Cl_mic:** Ligand A (70.124) has a higher microsomal clearance than Ligand B (-2.335), indicating lower metabolic stability. This is unfavorable.
13. **t1/2:** Ligand A (-14.985) has a negative in vitro half-life, which is not possible and indicates a problem with the prediction. Ligand B (2.441) has a short half-life, but it is at least a positive value.
14. **Pgp:** Ligand A (0.854) has a slightly higher Pgp efflux liability than Ligand B (0.005), indicating potentially lower bioavailability.
15. **Binding Affinity:** Ligand A (-7.6) has a significantly better binding affinity than Ligand B (-6.8). This is a 0.8 kcal/mol difference, which is substantial.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has a high logP and Pgp efflux, but a significantly better affinity. Ligand B has a very low logP, which is a major concern for permeability, even with its better Pgp profile. The solubility and metabolic stability are also better for Ligand B, but the affinity difference is too large to ignore.
**Conclusion:**
Despite the solubility and metabolic stability concerns, Ligand A's significantly stronger binding affinity (-7.6 kcal/mol vs -6.8 kcal/mol) and acceptable TPSA outweigh the drawbacks. The low logP of Ligand B is a critical issue that would likely prevent it from achieving sufficient bioavailability.
Output:
1
2025-04-17 22:09:41,852 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (349.435) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both ligands are below the 140 A^2 threshold for good oral absorption (A: 70.91, B: 66.22). This is good.
3. **logP:** Ligand A (-0.266) is quite low, potentially hindering membrane permeability. Ligand B (4.102) is higher, approaching the upper limit where solubility issues can arise, but still within an acceptable range.
4. **HBD:** Both have 0 HBD, which is acceptable.
5. **HBA:** Both have a reasonable number of HBA (A: 6, B: 5).
6. **QED:** Both have good QED scores (A: 0.732, B: 0.697), indicating drug-like properties.
7. **DILI:** Ligand A (25.165) has a significantly lower DILI risk than Ligand B (39.705), which is a major advantage.
8. **BBB:** Ligand B (76.309) has better BBB penetration than Ligand A (65.801). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant for off-target effects and overall safety assessment.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale isn't specified, so it's hard to interpret.
10. **Solubility:** Ligand A (0.19) has very poor aqueous solubility, while Ligand B (-4.486) is also poor. This is a significant concern for both.
11. **hERG:** Ligand A (0.321) has a lower hERG risk than Ligand B (0.693), which is desirable.
12. **Cl_mic:** Ligand A (-5.968) has a much lower microsomal clearance, indicating better metabolic stability, than Ligand B (105.179). This is a substantial advantage.
13. **t1/2:** Ligand A (-2.297) has a negative half-life, which is not possible. Ligand B (-14.877) also has a negative half-life, which is not possible. This suggests an issue with the data.
14. **Pgp:** Ligand A (0.02) has very low P-gp efflux, while Ligand B (0.402) has moderate efflux. Lower P-gp efflux is preferable.
15. **Binding Affinity:** Ligand A (-6.8 kcal/mol) has a slightly better binding affinity than Ligand B (-3.9 kcal/mol). This is a significant difference.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand B has a better logP and Pgp profile, but Ligand A has a significantly better affinity. The negative half-life values are concerning for both, but the difference in affinity and the much better DILI and Cl_mic values for Ligand A are compelling. The low solubility of both is a significant drawback, but can potentially be addressed with formulation strategies.
**Conclusion:**
Despite the solubility concerns, Ligand A's superior binding affinity, lower DILI risk, and better metabolic stability (lower Cl_mic) outweigh the slightly better BBB penetration of Ligand B. The significantly stronger binding affinity is a critical factor for a GPCR target.
Output:
1
2025-04-17 22:09:41,852 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (344.375 and 354.491 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand B (89.87) is significantly better than Ligand A (102.36). For a GPCR, lower TPSA is generally preferred to facilitate membrane permeability.
**3. logP:** Both ligands have acceptable logP values (1.143 and 1.299), falling within the optimal 1-3 range. Ligand B is slightly better.
**4. H-Bond Donors:** Ligand A has 1 HBD, while Ligand B has 3. Ligand A is preferable here, as fewer HBDs generally correlate with better permeability.
**5. H-Bond Acceptors:** Ligand A has 8 HBAs, and Ligand B has 4. Ligand B is preferable here, as fewer HBAs generally correlate with better permeability.
**6. QED:** Ligand A (0.861) has a significantly better QED score than Ligand B (0.671), indicating a more drug-like profile.
**7. DILI Risk:** Ligand A (93.757 percentile) has a substantially higher DILI risk than Ligand B (6.592 percentile). This is a major concern for Ligand A.
**8. BBB Penetration:** Ligand A (56.611 percentile) has slightly better BBB penetration than Ligand B (48.158 percentile), but this isn't a primary concern for a cardiovascular target.
**9. Caco-2 Permeability:** Ligand A (-4.501) has better Caco-2 permeability than Ligand B (-4.871).
**10. Aqueous Solubility:** Ligand A (-3.045) has better aqueous solubility than Ligand B (-1.627).
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (0.187 and 0.252, respectively). No significant difference.
**12. Microsomal Clearance:** Ligand B (17.686 mL/min/kg) has significantly lower microsomal clearance than Ligand A (29.048 mL/min/kg), suggesting better metabolic stability.
**13. In vitro Half-Life:** Ligand B (-19.615 hours) has a longer in vitro half-life than Ligand A (-30.036 hours).
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.011 and 0.04, respectively). No significant difference.
**15. Binding Affinity:** Ligand A (-6.6 kcal/mol) has a slightly better binding affinity than Ligand B (-5.1 kcal/mol). This is a 1.5 kcal/mol difference, which is significant.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity and QED, the significantly higher DILI risk is a major red flag. Ligand B, despite a slightly lower affinity, presents a much more favorable ADME-Tox profile, particularly the dramatically lower DILI risk and improved metabolic stability (lower Cl_mic and longer t1/2). The lower TPSA of Ligand B is also beneficial for a GPCR target. Considering the cardiovascular context, minimizing toxicity is paramount.
Output:
0
2025-04-17 22:09:41,852 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (423.336 Da) is within the ideal range, while Ligand B (346.435 Da) is towards the lower end but still acceptable.
2. **TPSA:** Ligand A (75.19) is better than Ligand B (107.83). Both are under 140, but A is closer to the preferred <90 for potential CNS penetration (though ADRB2 isn't strictly a CNS target, lower TPSA is generally favorable).
3. **logP:** Both ligands have good logP values (A: 2.625, B: 1.794), falling within the optimal 1-3 range.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (6). Lower HBA generally improves permeability.
6. **QED:** Both ligands have similar QED values (A: 0.771, B: 0.71), indicating good drug-likeness.
7. **DILI:** Ligand A (72.005) has a slightly higher DILI risk than Ligand B (52.346), but both are below the concerning threshold of 60.
8. **BBB:** Both ligands have similar BBB penetration (A: 68.127, B: 68.554).
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.1 and -5.195), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand A (-3.092) has slightly worse solubility than Ligand B (-2.34), but both are poor.
11. **hERG:** Ligand A (0.151) has a slightly higher hERG risk than Ligand B (0.06), but both are very low risk.
12. **Cl_mic:** Ligand A (63.88) has a higher microsomal clearance than Ligand B (21.329), indicating lower metabolic stability. This is a significant drawback for A.
13. **t1/2:** Ligand A (17.734) has a longer in vitro half-life than Ligand B (-1.237). This is a positive for A, but the negative value for B is concerning.
14. **Pgp:** Both ligands have very low P-gp efflux liability (A: 0.201, B: 0.214).
15. **Binding Affinity:** Ligand A (-6.7 kcal/mol) has a significantly stronger binding affinity than Ligand B (-3.6 kcal/mol). This is a substantial advantage for A, potentially outweighing some of its ADME drawbacks.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, affinity, logP, TPSA, and Pgp are key. Ligand A excels in affinity and has a favorable logP and TPSA. While both have poor Caco-2 and solubility, the significantly better binding affinity of Ligand A is a major advantage. The higher clearance of A is a concern, but the stronger binding could potentially allow for a lower dose, mitigating the impact of faster metabolism.
**Conclusion:**
Despite the concerns regarding clearance and solubility, the substantially stronger binding affinity of Ligand A makes it the more promising candidate. The difference in affinity is large enough to potentially overcome the ADME liabilities.
Output:
1
2025-04-17 22:09:41,852 - INFO - Batch 311 complete. Total preferences: 4976
2025-04-17 22:09:41,852 - INFO - Processing batch 312/512...
2025-04-17 22:10:33,429 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (340.427) is slightly lower, which can be favorable for permeability.
2. **TPSA:** Both are below the 140 A^2 threshold for good oral absorption. Ligand B (75.44) is slightly lower than Ligand A (80.2), which is a minor advantage.
3. **logP:** Both are within the optimal range (1-3). Ligand B (2.953) is slightly higher, which *could* indicate a potential for off-target effects, but is still acceptable.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 3 HBA, and Ligand B has 5. Both are acceptable, but Ligand A is slightly preferred.
6. **QED:** Ligand A (0.913) has a significantly higher QED score than Ligand B (0.782), indicating a more drug-like profile.
7. **DILI:** Both are reasonably low, with Ligand A (37.611) being slightly better than Ligand B (50.446).
8. **BBB:** Ligand B (71.19) has a better BBB penetration score than Ligand A (50.95). While ADRB2 isn't strictly a CNS target, some peripheral ADRB2 receptors can be affected by CNS penetration.
9. **Caco-2:** Ligand B (-5.103) has a much better Caco-2 permeability than Ligand A (-4.68). This suggests better intestinal absorption for Ligand B.
10. **Solubility:** Ligand B (-2.403) has better aqueous solubility than Ligand A (-4.139).
11. **hERG:** Both have low hERG inhibition liability, with Ligand A (0.616) being slightly better.
12. **Cl_mic:** Ligand A (38.877) has a significantly lower microsomal clearance than Ligand B (87.92), indicating better metabolic stability.
13. **t1/2:** Ligand B (8.008) has a much longer in vitro half-life than Ligand A (-13.474). This is a significant advantage.
14. **Pgp:** Both have low P-gp efflux liability, with Ligand A (0.044) being slightly better.
15. **Binding Affinity:** Ligand B (-7.5 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.3 kcal/mol). This is a substantial advantage that can outweigh some ADME concerns.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, affinity, logP, TPSA, and Pgp are key. Ligand B excels in affinity and has acceptable logP and TPSA. While Ligand A has better QED, DILI, and Cl_mic, the significantly stronger binding affinity of Ligand B is the most important factor, especially considering the acceptable ADME profile. The longer half-life of Ligand B is also a significant benefit.
**Conclusion:**
Despite Ligand A's slightly better drug-likeness and metabolic stability, Ligand B's superior binding affinity and improved Caco-2 permeability and solubility make it the more promising drug candidate for ADRB2.
Output:
0
2025-04-17 22:10:33,430 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (371.363) is slightly higher than Ligand B (350.463), but both are acceptable.
2. **TPSA:** Ligand A (55.63) is significantly better than Ligand B (84.42). ADRB2 is not a CNS target, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (4.017) is at the upper end of the optimal range, while Ligand B (1.952) is at the lower end. Ligand A's logP could potentially lead to solubility issues or off-target interactions, but for a GPCR, a higher logP is often tolerated and can be beneficial for membrane interactions.
4. **HBD:** Both ligands have 1 HBD, which is within the acceptable limit of 5.
5. **HBA:** Both ligands have 6 HBA, which is within the acceptable limit of 10.
6. **QED:** Both ligands have similar QED values (0.704 and 0.685), indicating good drug-likeness.
7. **DILI:** Ligand A (81.543) has a higher DILI risk than Ligand B (52.191). This is a significant negative for Ligand A.
8. **BBB:** This isn't a primary concern for ADRB2, but Ligand A (75.611) has a higher BBB penetration than Ligand B (44.281).
9. **Caco-2:** Both ligands have negative Caco-2 values which is unusual and suggests a potential issue with the data or modeling. However, we'll proceed assuming these represent low permeability.
10. **Solubility:** Ligand A (-4.888) has worse solubility than Ligand B (-2.047). This aligns with the higher logP of Ligand A.
11. **hERG:** Ligand A (0.453) has a slightly higher hERG risk than Ligand B (0.104). This is a concern, but not a dealbreaker.
12. **Cl_mic:** Ligand B (77.883) has a higher microsomal clearance than Ligand A (52.517), meaning Ligand A is more metabolically stable.
13. **t1/2:** Ligand B (4.482) has a longer in vitro half-life than Ligand A (3.388). This is a positive for Ligand B.
14. **Pgp:** Ligand A (0.61) has a higher Pgp efflux liability than Ligand B (0.03). This is a negative for Ligand A, potentially reducing bioavailability.
15. **Binding Affinity:** Ligand A (-7.6 kcal/mol) has a significantly stronger binding affinity than Ligand B (-3.6 kcal/mol). This is a substantial advantage for Ligand A. The difference of 4 kcal/mol is large enough to potentially overcome some of the ADME liabilities.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand A has a higher logP, but also a much higher affinity. Ligand B has better TPSA, Pgp, and solubility, but significantly weaker binding. The strong affinity of Ligand A is the most important factor here, outweighing its other drawbacks. The DILI risk is concerning, but could be addressed through structural modifications.
**Conclusion:**
Despite the higher DILI risk and Pgp efflux, the significantly stronger binding affinity of Ligand A makes it the more promising candidate.
Output:
1
2025-04-17 22:10:33,430 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.46 and 344.46 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand B (75.19) is significantly better than Ligand A (101.29). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (2.329) is slightly higher than Ligand A (1.686), both are within the optimal 1-3 range.
4. **HBD:** Ligand B (1) has fewer HBDs than Ligand A (3). Fewer HBDs are generally preferred for better permeability.
5. **HBA:** Ligand B (4) has slightly more HBAs than Ligand A (3). This isn't a major concern, as both are below the 10 threshold.
6. **QED:** Ligand B (0.824) has a better QED score than Ligand A (0.681), indicating a more drug-like profile.
7. **DILI:** Both ligands have similar DILI risk (31.02 and 31.563), and are both below the concerning 60 threshold.
8. **BBB:** Ligand B (74.292) shows better BBB penetration than Ligand A (56.65), but as this is a cardiovascular target, this is not a major factor.
9. **Caco-2:** Ligand A (-5.297) has slightly better Caco-2 permeability than Ligand B (-5.029).
10. **Solubility:** Ligand A (-2.901) has slightly better solubility than Ligand B (-2.139).
11. **hERG:** Both ligands have very low hERG inhibition risk (0.103 and 0.146).
12. **Cl_mic:** Ligand A (27.634) has lower microsomal clearance than Ligand B (31.69), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-9.413) has a significantly longer in vitro half-life than Ligand A (2.394). This is a substantial advantage.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.042 and 0.019).
15. **Binding Affinity:** Ligand A (-6.9 kcal/mol) has a slightly better binding affinity than Ligand B (-5.9 kcal/mol). This is a 1.0 kcal/mol difference, which is significant.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B has better logP, TPSA and Pgp values. Ligand A has a better binding affinity. The longer half-life of Ligand B is also a significant advantage. The difference in binding affinity is outweighed by the other factors.
**Conclusion:**
Considering the balance of properties, Ligand B is the more promising candidate. Its superior QED, TPSA, half-life, and acceptable binding affinity outweigh the slightly weaker affinity compared to Ligand A.
Output:
0
2025-04-17 22:10:33,430 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [378.47 , 112.81 , -0.795, 2. , 5. , 0.651, 44.668, 66.033, -5.477, -1.564, 0.283, -3.031, -26.171, 0.041, -8.3 ]**
**Ligand B: [352.406, 75.71 , 1.038, 1. , 4. , 0.767, 33.579, 83.715, -4.701, -2.296, 0.318, 21.48 , -3.197, 0.064, -7.6 ]**
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand B (352.406 Da) is slightly smaller, which could be advantageous for permeability, but the difference isn't substantial.
2. **TPSA:** Ligand A (112.81) is higher than Ligand B (75.71). Both are below 140, acceptable for oral absorption, but Ligand B is significantly better, increasing the likelihood of good absorption and potentially better BBB penetration.
3. **logP:** Ligand A (-0.795) is lower than the optimal range (1-3), potentially hindering permeability. Ligand B (1.038) is closer to the optimal range. This is a significant advantage for Ligand B.
4. **H-Bond Donors:** Both ligands have acceptable HBD counts (2 and 1 respectively), well within the limit of 5.
5. **H-Bond Acceptors:** Both ligands have acceptable HBA counts (5 and 4 respectively), well within the limit of 10.
6. **QED:** Both ligands have good QED scores (0.651 and 0.767), indicating drug-like properties. Ligand B is slightly better.
7. **DILI Risk:** Ligand A (44.668) has a slightly higher DILI risk than Ligand B (33.579), but both are below the concerning threshold of 60.
8. **BBB Penetration:** Ligand B (83.715) has a much higher predicted BBB penetration than Ligand A (66.033). For a GPCR, even one not directly in the CNS like ADRB2, some degree of BBB penetration can be beneficial for off-target profiling and understanding systemic effects.
9. **Caco-2 Permeability:** Ligand A (-5.477) has poor predicted Caco-2 permeability, while Ligand B (-4.701) is better, though still not ideal.
10. **Aqueous Solubility:** Both ligands have poor predicted aqueous solubility (-1.564 and -2.296 respectively). This could pose formulation challenges, but is less critical than permeability.
11. **hERG Inhibition:** Both ligands have low predicted hERG inhibition risk (0.283 and 0.318 respectively).
12. **Microsomal Clearance:** Ligand A (-3.031) has a lower (better) microsomal clearance than Ligand B (21.48), suggesting better metabolic stability.
13. **In vitro Half-Life:** Ligand A (-26.171) has a longer predicted half-life than Ligand B (-3.197), which is desirable.
14. **P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.041 and 0.064 respectively).
15. **Binding Affinity:** Ligand A (-8.3) has a slightly better binding affinity than Ligand B (-7.6). This is a 0.7 kcal/mol difference, which is significant, but must be weighed against the ADME properties.
**Overall Assessment:**
Ligand B has a significantly better profile regarding key GPCR properties like logP, TPSA, and BBB penetration. While Ligand A has a slightly better binding affinity and metabolic stability, the poor logP and TPSA of Ligand A are major drawbacks. The better permeability and CNS exposure potential of Ligand B are crucial for a GPCR target, even a peripheral one like ADRB2. The slightly weaker binding affinity of Ligand B is likely surmountable with further optimization.
Output:
0
2025-04-17 22:10:33,430 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.435 and 348.378 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (87.91 and 87.32) are below the 140 A^2 threshold for good oral absorption and acceptable for a non-CNS GPCR target like ADRB2. Very similar.
3. **logP:** Ligand A (0.559) is a bit low, potentially hindering membrane permeability. Ligand B (0.853) is still on the lower side but better than A. This is a slight advantage for B.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (6) is preferable to Ligand B (4). Fewer HBAs generally improve permeability.
6. **QED:** Both ligands (0.735 and 0.848) have good drug-likeness scores, exceeding the 0.5 threshold. Ligand B is slightly better.
7. **DILI:** Ligand A (29.236) has a significantly lower DILI risk than Ligand B (54.168). This is a substantial advantage for A.
8. **BBB:** Ligand A (61.497) has a lower BBB penetration percentile than Ligand B (89.802). Since ADRB2 is primarily a cardiovascular target, BBB penetration is not a high priority. This favors B, but not strongly.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.006 and -4.904). This is unusual and suggests poor permeability. However, the values are very close.
10. **Solubility:** Ligand A (-0.267) is slightly better than Ligand B (-3.015), indicating better aqueous solubility.
11. **hERG:** Ligand A (0.188) has a lower hERG inhibition liability than Ligand B (0.357), which is a significant safety advantage.
12. **Cl_mic:** Ligand B (1.645) has a much lower microsomal clearance than Ligand A (34.139), indicating better metabolic stability. This is a major advantage for B.
13. **t1/2:** Ligand B (10.154) has a significantly longer in vitro half-life than Ligand A (-11.389). This is a substantial advantage for B.
14. **Pgp:** Ligand A (0.005) has a much lower P-gp efflux liability than Ligand B (0.033), suggesting better oral bioavailability. This is a significant advantage for A.
15. **Binding Affinity:** Ligand B (-7.0) has a slightly better binding affinity than Ligand A (-5.3). This is a significant advantage for B, potentially outweighing some ADME drawbacks.
**Overall Assessment:**
Ligand B has a clear advantage in binding affinity, metabolic stability (Cl_mic), and in vitro half-life. It also has better BBB penetration, though this is less critical for a cardiovascular target. Ligand A excels in DILI risk, P-gp efflux, and hERG inhibition. The Caco-2 values are concerning for both.
Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity) and the overall balance, the stronger binding affinity and improved metabolic stability of Ligand B are more compelling. The slightly lower logP is a concern, but the better affinity could compensate. The lower DILI risk of Ligand A is attractive, but the substantial improvements in Cl_mic and t1/2 for Ligand B are more important for long-term drug development.
Output:
0
2025-04-17 22:10:33,431 - INFO - Reasoning:
Let's analyze both ligands based on the provided parameters and guidelines, with a focus on GPCR-specific priorities (logP, Pgp, TPSA, and affinity).
**Ligand A:**
* **MW:** 351.491 Da - Good, within the ideal range.
* **TPSA:** 72.88 - Excellent, well below the 140 threshold for oral absorption.
* **logP:** 1.295 - Good, within the optimal range.
* **HBD:** 2 - Acceptable.
* **HBA:** 4 - Acceptable.
* **QED:** 0.485 - Marginal, slightly below the preferred 0.5.
* **DILI:** 9.965 - Excellent, very low risk.
* **BBB:** 32.765 - Low, not a priority here but not ideal if CNS effects are desired.
* **Caco-2:** -5.006 - Poor permeability.
* **Solubility:** -1.426 - Poor solubility.
* **hERG:** 0.292 - Very low risk.
* **Cl_mic:** 31.408 - Moderate clearance, could be better.
* **t1/2:** -4.966 - Short half-life.
* **Pgp:** 0.214 - Low efflux, good.
* **Affinity:** -5.4 kcal/mol - Good binding affinity.
**Ligand B:**
* **MW:** 364.372 Da - Good, within the ideal range.
* **TPSA:** 93.96 - Acceptable, but approaching the upper limit for good absorption.
* **logP:** 0.603 - Acceptable, but on the lower side, potentially impacting permeability.
* **HBD:** 2 - Acceptable.
* **HBA:** 7 - Acceptable.
* **QED:** 0.656 - Good, above the preferred 0.5.
* **DILI:** 49.632 - Moderate risk, higher than Ligand A.
* **BBB:** 90.112 - High, potentially beneficial if CNS effects are desired.
* **Caco-2:** -5.132 - Poor permeability.
* **Solubility:** -2.062 - Poor solubility.
* **hERG:** 0.144 - Very low risk.
* **Cl_mic:** 14.182 - Low clearance, good metabolic stability.
* **t1/2:** -5.083 - Short half-life.
* **Pgp:** 0.056 - Very low efflux, excellent.
* **Affinity:** -6.7 kcal/mol - Excellent binding affinity, 1.3 kcal/mol better than Ligand A.
**Comparison and Decision:**
Both ligands suffer from poor Caco-2 permeability and aqueous solubility. However, Ligand B has a significantly better binding affinity (-6.7 vs -5.4 kcal/mol), which is a high priority for GPCRs. It also exhibits lower Pgp efflux and better metabolic stability (lower Cl_mic). While Ligand B has a higher DILI risk, the substantial improvement in affinity and favorable ADME properties (Pgp, Cl_mic) outweigh this concern, especially given the low hERG risk. The higher BBB value for Ligand B is also a plus.
Therefore, I prefer Ligand B.
Output:
0
2025-04-17 22:10:33,431 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [350.459, 75.71, 2.18, 1, 4, 0.538, 34.82, 69.213, -4.824, -2.255, 0.155, 52.558, -11.451, 0.138, -6.1]
**Ligand B:** [391.339, 49.85, 3.35, 0, 3, 0.626, 48.391, 80.419, -4.585, -3.585, 0.769, 84.391, 9.703, 0.643, -6.1]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (350.459) is slightly preferred due to being closer to the lower end, which can aid permeability.
2. **TPSA:** Ligand B (49.85) is better than Ligand A (75.71). Lower TPSA is generally preferred for GPCRs, aiding in brain penetration and overall absorption.
3. **logP:** Both are good (between 1-3), but Ligand B (3.35) is a bit higher. While acceptable, it's closer to the upper limit and could potentially cause solubility issues. Ligand A (2.18) is optimal.
4. **HBD:** Ligand A (1) is better than Ligand B (0). Having at least one HBD can improve solubility.
5. **HBA:** Ligand B (3) is better than Ligand A (4). Lower HBA is generally preferred for permeability.
6. **QED:** Ligand B (0.626) is slightly better than Ligand A (0.538), indicating a more drug-like profile.
7. **DILI:** Ligand A (34.82) is significantly better than Ligand B (48.391). Lower DILI risk is crucial.
8. **BBB:** Ligand B (80.419) is better than Ligand A (69.213). For a GPCR, higher BBB penetration is desirable, even if it's not a primary CNS target, as it can influence off-target effects.
9. **Caco-2:** Both are negative, indicating good permeability. Ligand A (-4.824) is slightly better.
10. **Solubility:** Ligand B (-3.585) is better than Ligand A (-2.255). Higher solubility is always a plus.
11. **hERG:** Ligand A (0.155) is better than Ligand B (0.769). Lower hERG inhibition is critical for avoiding cardiotoxicity, especially for a cardiovascular target.
12. **Cl_mic:** Ligand A (52.558) is better than Ligand B (84.391). Lower microsomal clearance indicates better metabolic stability.
13. **t1/2:** Ligand B (9.703) is better than Ligand A (-11.451). A positive half-life is preferable.
14. **Pgp:** Ligand A (0.138) is better than Ligand B (0.643). Lower P-gp efflux is favorable for bioavailability.
15. **Affinity:** Both have the same binding affinity (-6.1 kcal/mol).
**Overall Assessment:**
While Ligand B has some advantages (QED, BBB, solubility, t1/2), Ligand A demonstrates a significantly better safety profile (DILI, hERG) and metabolic stability (Cl_mic). The slightly better permeability (Caco-2) and HBD of Ligand A are also beneficial. Given the cardiovascular target (ADRB2), minimizing cardiotoxicity (hERG) and liver injury (DILI) are paramount. The difference in binding affinity is negligible.
Therefore, I would choose Ligand A.
1
2025-04-17 22:10:33,431 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's break down the comparison of Ligand A and Ligand B across the 15 parameters, keeping in mind the GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key).
1. **MW:** Both ligands are within the ideal 200-500 Da range. (A: 350.5, B: 354.4) - No significant difference.
2. **TPSA:** Ligand A (69.64) is higher than Ligand B (49.85). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is generally preferred for absorption. B is better.
3. **logP:** Both ligands have good logP values (A: 2.471, B: 2.122) falling within the optimal 1-3 range. A is slightly higher, potentially aiding membrane permeability.
4. **HBD:** Ligand A has 2 HBD, while Ligand B has 0. A slight advantage for A, as some HBD can aid solubility.
5. **HBA:** Both have 3 HBA. No significant difference.
6. **QED:** Ligand A (0.821) has a higher QED score than Ligand B (0.754), indicating a more drug-like profile. A is better.
7. **DILI:** Ligand B (23.536) has a significantly lower DILI risk than Ligand A (5.584). This is a major advantage for B.
8. **BBB:** Ligand B (96.006) has a much higher BBB penetration percentile than Ligand A (46.84). While ADRB2 isn't primarily a CNS target, some degree of BBB penetration can be relevant for off-target effects and overall safety. B is better.
9. **Caco-2:** Ligand A (-4.739) has a lower Caco-2 permeability than Ligand B (-4.305). B is better.
10. **Solubility:** Both have very poor solubility scores. A is slightly better (-2.534 vs -2.091), but both are problematic.
11. **hERG:** Ligand A (0.23) has a lower hERG inhibition liability than Ligand B (0.744). A is better.
12. **Cl_mic:** Ligand B (7.409) has a lower microsomal clearance than Ligand A (15.085), indicating better metabolic stability. B is better.
13. **t1/2:** Ligand B (5.936) has a longer in vitro half-life than Ligand A (4.374). B is better.
14. **Pgp:** Ligand A (0.036) has much lower P-gp efflux liability than Ligand B (0.098). A is better.
15. **Affinity:** Ligand A (-6.6 kcal/mol) has a stronger binding affinity than Ligand B (-5.0 kcal/mol). This is a substantial advantage for A, exceeding the 1.5 kcal/mol threshold.
**Overall Assessment:**
Ligand A has a significantly better binding affinity and lower P-gp efflux, which are critical for GPCR targets. It also has a better QED and hERG profile. However, Ligand B excels in safety (DILI), metabolic stability (Cl_mic, t1/2), BBB penetration, and Caco-2 permeability.
The difference in binding affinity (1.6 kcal/mol) is substantial enough to outweigh the advantages of Ligand B in terms of ADME properties, *especially* given that the solubility of both is poor and would likely require formulation strategies. The lower DILI risk of B is attractive, but can be addressed through further medicinal chemistry optimization. The better metabolic stability of B is also a plus, but can be improved.
Therefore, I believe Ligand A is the more promising starting point for a drug candidate.
**Output:**
1
2025-04-17 22:10:33,431 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**1. Molecular Weight (MW):** Both ligands (340.471 Da and 354.401 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. Topological Polar Surface Area (TPSA):** Ligand A (50.16) is significantly better than Ligand B (73.47). For a GPCR, keeping TPSA lower is beneficial for permeability. Ligand B is pushing the upper limit for good oral absorption.
**3. Lipophilicity (logP):** Ligand A (3.771) is within the optimal range (1-3), while Ligand B (1.442) is at the lower end. While not terrible, lower logP can sometimes hinder membrane permeability.
**4. H-Bond Donors (HBD):** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
**5. H-Bond Acceptors (HBA):** Ligand A (3) is preferable to Ligand B (4). Similar to HBDs, fewer HBAs are generally better for permeability.
**6. QED:** Ligand A (0.901) has a significantly better QED score than Ligand B (0.7), indicating a more drug-like profile.
**7. DILI Risk:** Ligand A (15.781) has a much lower DILI risk than Ligand B (53.509). This is a crucial advantage.
**8. BBB Penetration:** Ligand A (86.119) has better BBB penetration than Ligand B (62.466). While ADRB2 isn't exclusively a CNS target, some cardiovascular effects are mediated through CNS pathways, and better BBB penetration could be advantageous.
**9. Caco-2 Permeability:** Ligand A (-4.872) is better than Ligand B (-5.081), indicating better intestinal absorption.
**10. Aqueous Solubility:** Ligand A (-3.263) is better than Ligand B (-2.578), indicating better solubility.
**11. hERG Inhibition:** Both ligands (0.822 and 0.652) have relatively low hERG inhibition risk, which is good.
**12. Microsomal Clearance:** Ligand B (-4.962) has a *negative* clearance, which is highly unusual and suggests very high metabolic stability. Ligand A (32.41) is reasonable, but higher than ideal.
**13. In vitro Half-Life:** Ligand A (5.43) is better than Ligand B (-16.409). A negative half-life is not possible, and indicates an issue with the data.
**14. P-gp Efflux:** Both ligands (0.557 and 0.05) are relatively low, suggesting minimal P-gp efflux.
**15. Binding Affinity:** Both ligands have the same binding affinity (-6.8 kcal/mol).
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical ADME properties (TPSA, logP, HBD, HBA, QED, DILI, solubility, Caco-2, BBB). The negative half-life for Ligand B is a major red flag, and the unusually negative microsomal clearance is suspect. While Ligand B has excellent metabolic stability, the other issues outweigh this benefit. Ligand A presents a more balanced and favorable profile for a drug candidate targeting ADRB2.
Output:
1
2025-04-17 22:10:33,431 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**1. Molecular Weight:**
* Ligand A: 364.398 Da - Within the ideal range (200-500 Da).
* Ligand B: 349.337 Da - Also within the ideal range.
* *No clear advantage here.*
**2. TPSA:**
* Ligand A: 92.34 - Good, below 140, acceptable for oral absorption.
* Ligand B: 85.43 - Excellent, further below 140.
* *Ligand B has a slight advantage here.*
**3. logP:**
* Ligand A: 1.663 - Optimal.
* Ligand B: 1.43 - Optimal.
* *No clear advantage.*
**4. H-Bond Donors:**
* Ligand A: 2 - Acceptable.
* Ligand B: 3 - Acceptable.
* *No clear advantage.*
**5. H-Bond Acceptors:**
* Ligand A: 4 - Acceptable.
* Ligand B: 3 - Acceptable.
* *No clear advantage.*
**6. QED:**
* Ligand A: 0.815 - Excellent, well above 0.5.
* Ligand B: 0.781 - Excellent, well above 0.5.
* *No clear advantage.*
**7. DILI Risk:**
* Ligand A: 80.923 - High risk (above 60). Concerning.
* Ligand B: 56.34 - Moderate risk, but significantly better than Ligand A.
* *Ligand B has a significant advantage here.*
**8. BBB Penetration:**
* Ligand A: 67.119 - Moderate.
* Ligand B: 43.699 - Low.
* *Ligand A has an advantage, though ADRB2 isn't necessarily a CNS target.*
**9. Caco-2 Permeability:**
* Ligand A: -4.922 - Poor permeability.
* Ligand B: -4.753 - Poor permeability.
* *No clear advantage.*
**10. Aqueous Solubility:**
* Ligand A: -3.502 - Poor solubility.
* Ligand B: -2.716 - Poor solubility, but slightly better than A.
* *Ligand B has a slight advantage.*
**11. hERG Inhibition:**
* Ligand A: 0.344 - Low risk.
* Ligand B: 0.529 - Moderate risk.
* *Ligand A has a slight advantage.*
**12. Microsomal Clearance:**
* Ligand A: 37.246 - Moderate clearance.
* Ligand B: -17.779 - Negative clearance is unusual and suggests very high metabolic stability. This is a *major* advantage.
* *Ligand B has a huge advantage here.*
**13. In vitro Half-Life:**
* Ligand A: 63.649 - Good half-life.
* Ligand B: -13.164 - Extremely long half-life, likely related to the negative clearance.
* *Ligand B has a huge advantage here.*
**14. P-gp Efflux:**
* Ligand A: 0.294 - Low efflux, good.
* Ligand B: 0.045 - Very low efflux, excellent.
* *Ligand B has a slight advantage.*
**15. Binding Affinity:**
* Ligand A: 0.4 kcal/mol - Weak binding.
* Ligand B: -5.4 kcal/mol - Strong binding.
* *Ligand B has a massive advantage here.*
**Overall Assessment:**
Ligand B is significantly better. While Ligand A has slightly better BBB penetration and hERG inhibition, Ligand B excels in almost every other crucial parameter. The strong binding affinity (-5.4 kcal/mol) is a major win, and the extremely low microsomal clearance and P-gp efflux, coupled with a longer half-life, suggest excellent pharmacokinetic properties. The lower DILI risk is also a critical advantage. The slightly lower TPSA and better solubility are also beneficial. The weak binding of Ligand A is a dealbreaker.
Output:
0
2025-04-17 22:10:33,432 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.395 and 359.495 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand B (63.13) is significantly better than Ligand A (121.61). ADRB2 is not a CNS target, but lower TPSA generally improves absorption.
3. **logP:** Ligand B (3.513) is higher than Ligand A (-0.907). While slightly above the optimal range, it's not excessively high and could contribute to better membrane permeability. Ligand A's logP is quite low, potentially hindering absorption.
4. **HBD:** Ligand A (3) and Ligand B (2) are both acceptable.
5. **HBA:** Ligand A (7) and Ligand B (4) are both acceptable.
6. **QED:** Both ligands have good QED scores (0.645 and 0.709), indicating good drug-like properties.
7. **DILI:** Ligand B (53.432) has a lower DILI risk than Ligand A (62.776), which is preferable.
8. **BBB:** Not a primary concern for ADRB2, but Ligand A (63.862) is slightly better than Ligand B (49.826).
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand B (-5.251) is slightly better than Ligand A (-4.904).
10. **Solubility:** Ligand A (-0.717) is better than Ligand B (-3.648). Solubility is important, but can often be addressed with formulation.
11. **hERG:** Ligand A (0.024) is much better, indicating lower cardiotoxicity risk than Ligand B (0.499). This is a critical factor for cardiovascular targets.
12. **Cl_mic:** Ligand A (5.319) has significantly lower microsomal clearance than Ligand B (77.078), suggesting better metabolic stability.
13. **t1/2:** Ligand B (54.44) has a longer in vitro half-life than Ligand A (20.314), which is desirable.
14. **Pgp:** Ligand A (0.005) has much lower P-gp efflux liability than Ligand B (0.264), which is beneficial for bioavailability.
15. **Affinity:** Ligand A (-7.2) has a slightly better binding affinity than Ligand B (-5.5). While both are good, the 1.7 kcal/mol difference is significant.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B has a better logP and TPSA, but Ligand A has significantly better Pgp efflux and a better binding affinity. The hERG risk is also a major concern for cardiovascular drugs, and Ligand A is much better in this regard. The improved metabolic stability (lower Cl_mic) of Ligand A is also a significant advantage.
**Overall Assessment:**
While Ligand B has some advantages in terms of half-life, the combination of significantly better affinity, lower hERG risk, lower Pgp efflux, and lower Cl_mic for Ligand A outweighs the benefits of Ligand B. The solubility of Ligand A is a concern, but can be addressed through formulation.
Output:
1
2025-04-17 22:10:33,432 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (381.223) is slightly higher than Ligand B (358.479), but both are acceptable.
2. **TPSA:** Both ligands are below the 140 A^2 threshold for good oral absorption (A: 99.25, B: 96.89). This is good.
3. **logP:** Ligand A (3.059) is optimal, while Ligand B (0.989) is a bit low, potentially hindering permeability. This favors A.
4. **HBD:** Both have 3 HBD, which is within the acceptable limit of <=5.
5. **HBA:** Both have 5 HBA, which is within the acceptable limit of <=10.
6. **QED:** Ligand A (0.707) has a better QED score than Ligand B (0.541), suggesting a more drug-like profile. This favors A.
7. **DILI:** Ligand B (6.747) has a significantly lower DILI risk than Ligand A (97.829). This is a major advantage for B.
8. **BBB:** Ligand B (67.429) has a better BBB penetration score than Ligand A (60.876), but neither are particularly high. Since ADRB2 is a cardiovascular target, BBB penetration isn't a primary concern, but it's still a slight advantage for B.
9. **Caco-2:** Both have negative Caco-2 values (-4.784 and -4.794), which is unusual and suggests poor permeability.
10. **Solubility:** Ligand B (-1.189) has better solubility than Ligand A (-5.15). This favors B.
11. **hERG:** Both have very low hERG inhibition risk (A: 0.116, B: 0.167). This is excellent for both.
12. **Cl_mic:** Ligand A (10.783) has a much lower microsomal clearance than Ligand B (27.959), indicating better metabolic stability. This favors A.
13. **t1/2:** Ligand A (20.454) has a positive in vitro half-life, while Ligand B (-22.76) has a negative one, which is concerning. This strongly favors A.
14. **Pgp:** Both have very low Pgp efflux liability (A: 0.033, B: 0.006). This is excellent for both.
15. **Binding Affinity:** Ligand A (-7.5 kcal/mol) has a stronger binding affinity than Ligand B (-5.8 kcal/mol). This is a significant advantage for A.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, and affinity are important. Ligand A excels in logP and affinity, while Ligand B has a slight edge in TPSA and BBB. However, the significant difference in binding affinity and the better metabolic stability (lower Cl_mic) and half-life of Ligand A outweigh the benefits of Ligand B. The DILI risk for Ligand A is high, but the strong binding affinity and better ADME properties are more critical for initial optimization.
**Conclusion:**
Considering the balance of properties and the priorities for a GPCR target, Ligand A is the more promising drug candidate.
Output:
1
2025-04-17 22:10:33,432 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (333.435 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (48.13) is significantly better than Ligand B (84.23). ADRB2 is a cardiovascular target, not a CNS target, but lower TPSA is still desirable for absorption. Ligand B's TPSA is approaching a level that could hinder oral absorption.
3. **logP:** Ligand A (4.882) is higher than Ligand B (2.058). While both are within the acceptable range, Ligand A is pushing the upper limit and could potentially have solubility issues or off-target interactions. Ligand B's logP is very good.
4. **HBD:** Both have 2 HBD, which is within the ideal range.
5. **HBA:** Ligand A has 1 HBA, while Ligand B has 4. Both are acceptable, but Ligand A is preferable.
6. **QED:** Both ligands have similar QED values (0.69 and 0.699), indicating similar drug-likeness.
7. **DILI:** Ligand A (72.354) has a significantly higher DILI risk than Ligand B (35.75). This is a major concern for Ligand A.
8. **BBB:** Both have high BBB penetration (89.763 and 85.731). This isn't a primary concern for a cardiovascular target, but it doesn't hurt.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Ligand A (-5.697) has worse solubility than Ligand B (-2.61). This, combined with its higher logP, is concerning.
11. **hERG:** Ligand A (0.903) has a slightly higher hERG risk than Ligand B (0.252).
12. **Cl_mic:** Ligand B (25.905) has significantly lower microsomal clearance than Ligand A (74.61), indicating better metabolic stability.
13. **t1/2:** Ligand A (64.775) has a longer in vitro half-life than Ligand B (2.005). This is a positive for Ligand A.
14. **Pgp:** Ligand A (0.784) has higher P-gp efflux than Ligand B (0.02). This is unfavorable for Ligand A.
15. **Binding Affinity:** Ligand B (-7.8) has a significantly stronger binding affinity than Ligand A (-5.8). This is a substantial advantage for Ligand B, potentially outweighing some of its ADME drawbacks.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), we prioritize logP, Pgp, TPSA, and affinity. Ligand B excels in logP, has much lower Pgp efflux, better TPSA, and significantly better affinity. While Ligand A has a longer half-life, its high DILI risk, poor solubility, and higher Pgp efflux are major drawbacks. The substantial affinity difference is a key factor.
**Conclusion:**
Despite Ligand A's longer half-life, the combination of Ligand B's superior binding affinity, lower DILI risk, better solubility, and lower P-gp efflux makes it the more promising drug candidate.
Output:
0
2025-04-17 22:10:33,432 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [345.447, 80.55, 3.322, 2, 5, 0.871, 56.068, 86.778, -4.62, -3.976, 0.383, 40.959, 37.013, 0.083, -5.5]
**Ligand B:** [366.893, 97.11, 2.79, 3, 4, 0.616, 54.634, 61.38, -5.234, -3.269, 0.559, 40.314, 44.288, 0.093, -7.3]
Here's a breakdown, considering the GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal 200-500 Da range. Ligand A (345.447) is slightly preferred.
2. **TPSA:** Ligand A (80.55) is better than Ligand B (97.11). Both are below 140, but lower is better for absorption.
3. **logP:** Ligand A (3.322) is slightly higher than Ligand B (2.79), both within the optimal 1-3 range.
4. **HBD:** Ligand A (2) is better than Ligand B (3).
5. **HBA:** Ligand A (5) is better than Ligand B (4).
6. **QED:** Ligand A (0.871) is significantly better than Ligand B (0.616), indicating a more drug-like profile.
7. **DILI:** Both are acceptable (Ligand A: 56.068, Ligand B: 54.634), below the 60 threshold.
8. **BBB:** Ligand A (86.778) is significantly better than Ligand B (61.38). While ADRB2 isn't exclusively a CNS target, some peripheral effects are mediated by CNS pathways, and higher BBB penetration can be advantageous.
9. **Caco-2:** Ligand B (-5.234) is better than Ligand A (-4.62). Higher values indicate better absorption.
10. **Solubility:** Ligand B (-3.269) is better than Ligand A (-3.976).
11. **hERG:** Ligand A (0.383) is better than Ligand B (0.559), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Similar for both (Ligand A: 40.959, Ligand B: 40.314).
13. **t1/2:** Ligand B (44.288) is better than Ligand A (37.013).
14. **Pgp:** Ligand A (0.083) is better than Ligand B (0.093), indicating lower efflux.
15. **Affinity:** Ligand B (-7.3) has a significantly stronger binding affinity than Ligand A (-5.5) - a difference of 1.8 kcal/mol. This is a substantial advantage.
**Overall Assessment:**
Ligand B has a significantly better binding affinity, which is a crucial factor for GPCRs. While Ligand A has advantages in TPSA, QED, BBB, and hERG, the 1.8 kcal/mol difference in binding affinity is substantial enough to outweigh these benefits. The slightly better Caco-2 and t1/2 of Ligand B are also positive.
Therefore, I favor Ligand B.
0
2025-04-17 22:10:33,433 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (387.5) is slightly higher than Ligand B (348.5), but both are acceptable.
2. **TPSA:** Ligand A (73.74) is higher than Ligand B (59.07). Both are below 140, but Ligand B is preferable as lower TPSA generally correlates with better permeability.
3. **logP:** Ligand A (1.832) is within the optimal range (1-3). Ligand B (4.286) is a bit high, potentially leading to solubility issues and off-target interactions. This favors Ligand A.
4. **HBD:** Ligand A (1) and Ligand B (2) are both acceptable, below the threshold of 5.
5. **HBA:** Ligand A (6) and Ligand B (5) are both acceptable, below the threshold of 10.
6. **QED:** Both ligands have reasonable QED scores (A: 0.754, B: 0.661), indicating good drug-like properties. Ligand A is slightly better.
7. **DILI:** Ligand A (61.264) has a higher DILI risk than Ligand B (35.014). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (58.24) has a lower BBB penetration percentile than Ligand B (88.29). While ADRB2 isn't strictly a CNS target, some peripheral ADRB2 receptors can be affected by CNS-penetrant compounds, and higher BBB is generally favorable. Ligand B is preferred.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. Ligand A (-4.574) is slightly better than Ligand B (-4.842), but both are concerning.
10. **Solubility:** Ligand A (-1.995) has better solubility than Ligand B (-4.543). This is a positive for Ligand A, especially considering Ligand B's higher logP.
11. **hERG:** Ligand A (0.294) has a lower hERG risk than Ligand B (0.89). This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand B (75.331) has a higher microsomal clearance than Ligand A (23.029), indicating lower metabolic stability. This favors Ligand A.
13. **t1/2:** Ligand B (79.189) has a significantly longer in vitro half-life than Ligand A (-0.365). This is a major advantage for Ligand B.
14. **Pgp:** Ligand A (0.243) has lower P-gp efflux liability than Ligand B (0.345). This is a slight advantage for Ligand A.
15. **Affinity:** Ligand B (-5.3) has a better binding affinity than Ligand A (-6.6). This is a substantial advantage for Ligand B, potentially outweighing some ADME concerns.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand B excels in affinity and BBB penetration, while Ligand A has better logP, solubility, and hERG. The higher DILI risk for Ligand A is concerning. The longer half-life of Ligand B is also a significant benefit.
**Overall Assessment:**
While Ligand A has some advantages in terms of solubility, hERG, and metabolic stability, Ligand B's significantly stronger binding affinity and lower DILI risk are more critical for a GPCR target like ADRB2. The longer half-life is also a major plus. The higher logP of Ligand B is a concern, but can potentially be addressed through further optimization. The Caco-2 permeability is poor for both, but can also be addressed.
Output:
0
2025-04-17 22:10:33,433 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's break down the comparison of Ligand A and Ligand B based on the provided parameters and the guidelines, keeping in mind ADRB2 is a GPCR. GPCRs prioritize logP, Pgp, TPSA, and affinity.
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand B (349.435 Da) is slightly lower, which can be advantageous for permeability.
2. **TPSA:** Ligand A (46.92) is significantly better than Ligand B (100.35). A TPSA under 140 is good for oral absorption, but for a GPCR, lower is generally preferred. Ligand B is pushing the upper limit.
3. **logP:** Ligand A (4.136) is higher than Ligand B (0.357). While >4 can be problematic, 4.136 is acceptable, and a higher logP can aid membrane permeability. Ligand B's logP is quite low, potentially hindering permeation.
4. **H-Bond Donors:** Both are reasonable (1 and 2 respectively), well within the acceptable limit of 5.
5. **H-Bond Acceptors:** Both are reasonable (4 and 6 respectively), well within the acceptable limit of 10.
6. **QED:** Both have good QED scores (0.647 and 0.748), indicating drug-like properties.
7. **DILI:** Ligand A (55.487) is slightly higher than Ligand B (49.477), but both are below the concerning threshold of 60, suggesting acceptable liver safety profiles.
8. **BBB:** Ligand A (88.91) is significantly better than Ligand B (41.218). While ADRB2 isn't necessarily a CNS target, some peripheral distribution is still desirable, and higher BBB penetration can indicate better overall permeability.
9. **Caco-2:** Both have negative values, which is unusual. Assuming these are log scale values, lower values indicate poorer permeability. Both are poor.
10. **Solubility:** Ligand A (-3.03) is better than Ligand B (-1.404). Both are poor, but A is less poor.
11. **hERG:** Both are very low (0.916 and 0.198), indicating minimal hERG inhibition risk.
12. **Cl_mic:** Ligand A (82.477) is higher than Ligand B (10.785), meaning Ligand B has better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand A (61.066) is better than Ligand B (-6.278), indicating better in vitro half-life.
14. **Pgp:** Ligand A (0.947) is better than Ligand B (0.064), meaning Ligand A is a poorer substrate for P-glycoprotein efflux, which is desirable.
15. **Binding Affinity:** Both have excellent binding affinities (-5.9 and -5.4 kcal/mol). Ligand A is slightly better, but the difference is not huge.
**Overall Assessment:**
Ligand A has advantages in TPSA, logP, BBB, Pgp, and t1/2. Ligand B has a significantly better metabolic stability (Cl_mic). Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity), Ligand A is the more promising candidate. The slightly better affinity and significantly improved TPSA, logP, BBB, and Pgp properties outweigh the metabolic stability advantage of Ligand B. The poor Caco-2 and solubility of both are concerning, but can be addressed in later optimization stages.
**Output:**
1
2025-04-17 22:10:33,433 - INFO - Batch 312 complete. Total preferences: 4992
2025-04-17 22:10:33,433 - INFO - Processing batch 313/512...
2025-04-17 22:11:20,855 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [353.463, 98.74, 0.417, 3, 4, 0.589, 13.106, 29.081, -5.039, -1.718, 0.042, 43.879, -13.483, 0.013, -6]
**Ligand B:** [353.419, 113.69, 0.548, 3, 6, 0.566, 32.299, 55.68, -5.172, -0.779, 0.059, 37.938, -7.248, 0.031, -5.1]
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (around 353 Da). No significant difference.
2. **TPSA:** Ligand A (98.74) is better than Ligand B (113.69). We want TPSA <= 140 for oral absorption, both are acceptable, but A is preferable.
3. **logP:** Both are reasonably good (0.417 and 0.548), falling within the 1-3 range. B is slightly better.
4. **HBD:** Both have 3 HBD, which is acceptable.
5. **HBA:** Ligand A has 4 HBA, Ligand B has 6. Ligand A is better, as we want to keep HBA <= 10.
6. **QED:** Both are good (0.589 and 0.566), exceeding the 0.5 threshold.
7. **DILI:** Ligand A (13.106) has a significantly lower DILI risk than Ligand B (32.299). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (55.68) has a better BBB penetration score than Ligand A (29.081). For a cardiovascular target, BBB isn't *critical*, but it's a plus.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual. It suggests very poor permeability. Ligand A (-5.039) is slightly better than Ligand B (-5.172), but both are problematic.
10. **Solubility:** Ligand B (-0.779) is better than Ligand A (-1.718), indicating better aqueous solubility.
11. **hERG:** Both have very low hERG risk (0.042 and 0.059).
12. **Cl_mic:** Ligand B (37.938) has lower microsomal clearance than Ligand A (43.879), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-7.248) has a longer in vitro half-life than Ligand A (-13.483). This is a significant advantage for Ligand B.
14. **Pgp:** Both have very low Pgp efflux liability (0.013 and 0.031).
15. **Affinity:** Both have very similar and strong binding affinities (-6 and -5.1 kcal/mol). Ligand A is slightly better.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, and affinity. Ligand A has better TPSA, and comparable logP, Pgp, and affinity. The *significant* advantage of Ligand A is the much lower DILI risk. While BBB penetration is nice to have, it's not essential for a cardiovascular target. The better half-life of Ligand B is appealing, but the DILI risk is a major concern.
**Conclusion:**
Considering the balance of properties, particularly the significantly lower DILI risk and slightly better TPSA/affinity, Ligand A is the more promising candidate.
Output:
1
2025-04-17 22:11:20,855 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the acceptable range (200-500 Da). Ligand A (356.323 Da) is slightly lower, which is generally favorable for permeability.
**2. TPSA:** Ligand A (69.81) is significantly better than Ligand B (123.85). For a GPCR, a lower TPSA is preferred as it generally correlates with better membrane permeability and oral absorption.
**3. logP:** Ligand A (3.809) is within the optimal range (1-3), while Ligand B (-0.232) is quite low. A low logP can hinder membrane permeability and reduce absorption.
**4. H-Bond Donors:** Both ligands have a reasonable number of HBDs (Ligand A: 3, Ligand B: 2), falling within the acceptable limit of 5.
**5. H-Bond Acceptors:** Ligand A (2) is preferable to Ligand B (8). A higher number of HBAs can sometimes reduce permeability.
**6. QED:** Ligand A (0.732) has a higher QED score than Ligand B (0.595), indicating a more drug-like profile.
**7. DILI Risk:** Both ligands have relatively high DILI risk (Ligand A: 64.831, Ligand B: 79.139). Ligand A is slightly better here, but both are areas of concern that would require further investigation.
**8. BBB Penetration:** Ligand A (78.945) shows better BBB penetration than Ligand B (61.691). While ADRB2 is a cardiovascular target, some CNS effects are possible with GPCR ligands, and better BBB penetration isn't necessarily a negative.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability *in vitro*. However, the scale is not specified, so it's difficult to interpret.
**10. Aqueous Solubility:** Ligand A (-4.62) is better than Ligand B (-2.498), indicating better solubility.
**11. hERG Inhibition:** Ligand A (0.88) has a lower hERG inhibition risk than Ligand B (0.547), which is a significant advantage for cardiovascular drugs.
**12. Microsomal Clearance:** Ligand A (7.764) has a lower microsomal clearance than Ligand B (22.799), suggesting better metabolic stability.
**13. In vitro Half-Life:** Ligand B (-7.093) has a longer in vitro half-life than Ligand A (37.099). This is a positive for Ligand B.
**14. P-gp Efflux:** Ligand A (0.385) has lower P-gp efflux than Ligand B (0.03), which is better for bioavailability.
**15. Binding Affinity:** Ligand B (-5.8) has a slightly better binding affinity than Ligand A (-6.9). However, the difference is not substantial enough to outweigh the numerous ADME advantages of Ligand A.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand A is the more promising candidate. It has a better logP, significantly lower TPSA, better solubility, lower hERG risk, lower microsomal clearance, and lower P-gp efflux. While Ligand B has a slightly better binding affinity and longer half-life, the ADME profile of Ligand A is far superior, making it more likely to translate into a viable drug candidate.
Output:
1
2025-04-17 22:11:20,855 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (386.231 Da) is slightly higher than Ligand B (347.419 Da), but both are acceptable.
2. **TPSA:** Both are reasonably close to the 140 A^2 threshold for oral absorption. Ligand A (95.86) is slightly better than Ligand B (98.14).
3. **logP:** Ligand A (2.985) is optimal, while Ligand B (0.146) is quite low. This is a significant drawback for Ligand B, potentially hindering membrane permeability and bioavailability.
4. **HBD:** Both ligands have acceptable HBD counts (Ligand A: 3, Ligand B: 2), well below the threshold of 5.
5. **HBA:** Both ligands have acceptable HBA counts (Ligand A: 4, Ligand B: 6), below the threshold of 10.
6. **QED:** Both ligands have similar and acceptable QED values (Ligand A: 0.74, Ligand B: 0.684).
7. **DILI:** Both ligands have similar DILI risk (Ligand A: 65.452, Ligand B: 64.172), which is acceptable (below 60 is preferred, but these are close enough).
8. **BBB:** Ligand A (30.128) has a lower BBB penetration percentile than Ligand B (46.336). While ADRB2 isn't strictly a CNS target, some CNS exposure can be relevant for off-target effects, and higher BBB is generally preferred.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.482 and -5.242), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-3.701) has slightly better solubility than Ligand B (-1.534), though both are quite poor.
11. **hERG:** Both ligands have very low hERG inhibition risk (Ligand A: 0.091, Ligand B: 0.1).
12. **Cl_mic:** Ligand A (-2.359) has significantly lower (better) microsomal clearance than Ligand B (9.701), indicating better metabolic stability.
13. **t1/2:** Ligand A (15.983) has a much longer in vitro half-life than Ligand B (6.726), which is a significant advantage.
14. **Pgp:** Both ligands have very low Pgp efflux liability (Ligand A: 0.038, Ligand B: 0.019).
15. **Binding Affinity:** Ligand A (-7.4 kcal/mol) has a stronger binding affinity than Ligand B (-6.3 kcal/mol). This 1.1 kcal/mol difference is substantial and can outweigh some ADME drawbacks.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A excels in logP and affinity, while Ligand B has a better BBB score. However, the poor logP of Ligand B is a major concern. The better metabolic stability (Cl_mic and t1/2) and stronger binding of Ligand A are also highly desirable.
**Conclusion:**
Despite the slightly lower BBB score, Ligand A is the more promising candidate due to its optimal logP, significantly better metabolic stability, longer half-life, and stronger binding affinity. The poor Caco-2 values are a concern for both, but can be addressed with formulation strategies. The low logP of Ligand B is a more fundamental issue.
Output:
1
2025-04-17 22:11:20,855 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (344.455 and 372.462 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (58.64) is significantly better than Ligand B (83.55). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (2.019 and 1.119), falling within the optimal 1-3 range. Ligand A is slightly higher, which *could* be beneficial for membrane permeability, but not dramatically.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 3 HBA, while Ligand B has 4. Both are acceptable, but lower is generally preferred.
6. **QED:** Both ligands have similar QED scores (0.794 and 0.75), indicating good drug-likeness.
7. **DILI:** Ligand A (14.618) has a much lower DILI risk than Ligand B (52.074). This is a significant advantage for Ligand A.
8. **BBB:** Both have similar BBB penetration (78.519 and 78.868). Not a major factor for a cardiovascular target.
9. **Caco-2:** Ligand A (-4.76) and Ligand B (-5.205) both have negative Caco-2 values, indicating poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-3.259) is slightly better than Ligand B (-2.275), but both are poor. This is a significant drawback for both.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.211 and 0.167). This is excellent.
12. **Cl_mic:** Ligand B (-8.32) has a *much* lower microsomal clearance than Ligand A (21.058). This indicates significantly better metabolic stability for Ligand B.
13. **t1/2:** Ligand B (21.39) has a much longer in vitro half-life than Ligand A (0.249). This is a major advantage for Ligand B.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.032 and 0.13). This is good.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.1 and -6.2 kcal/mol). The difference is negligible.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, and affinity are important. Ligand A has a slightly better logP and TPSA, but the affinities are almost identical. However, the significant advantages of Ligand B in terms of metabolic stability (Cl_mic, t1/2) and lower DILI risk outweigh the minor benefits of Ligand A. The poor Caco-2 and solubility are concerning for both, but can be addressed with formulation strategies.
**Conclusion:**
Ligand B is the more promising candidate due to its significantly improved metabolic stability, longer half-life, and lower DILI risk. These factors are crucial for drug development and outweigh the slight advantages of Ligand A in TPSA and logP.
Output:
0
2025-04-17 22:11:20,856 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [352.356, 51.22, 4.892, 1, 4, 0.778, 64.793, 71.229, -4.693, -6.165, 0.769, 111.543, 14.139, 0.581, -6.6]
**Ligand B:** [375.441, 84.23, 2.067, 2, 5, 0.727, 70.841, 70.919, -5.185, -2.883, 0.168, 50.265, -33.698, 0.135, -7.3]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity, and BBB):
1. **MW:** Both are within the acceptable 200-500 Da range. Ligand A (352.356) is slightly preferred.
2. **TPSA:** Ligand A (51.22) is significantly better than Ligand B (84.23). GPCRs benefit from lower TPSA for better permeability.
3. **logP:** Ligand A (4.892) is a bit high, but still within a reasonable range. Ligand B (2.067) is quite low, potentially hindering membrane permeability.
4. **HBD/HBA:** Ligand A (1 HBD, 4 HBA) is preferable to Ligand B (2 HBD, 5 HBA). Lower counts are generally better for permeability.
5. **QED:** Both are good (A: 0.778, B: 0.727), indicating good drug-like properties.
6. **DILI:** Both have acceptable DILI risk (A: 64.793, B: 70.841).
7. **BBB:** Both have good BBB penetration (A: 71.229, B: 70.919), which is important for GPCRs, though less critical for ADRB2 than for CNS targets.
8. **Caco-2:** Ligand A (-4.693) is worse than Ligand B (-5.185) - both are very poor.
9. **Solubility:** Ligand A (-6.165) is worse than Ligand B (-2.883).
10. **hERG:** Ligand A (0.769) is better than Ligand B (0.168) - lower is better.
11. **Cl_mic:** Ligand B (50.265) has significantly lower microsomal clearance than Ligand A (111.543), suggesting better metabolic stability. This is a significant advantage.
12. **t1/2:** Ligand B (-33.698) has a much longer in vitro half-life than Ligand A (14.139). This is a strong positive for Ligand B.
13. **Pgp:** Ligand A (0.581) is better than Ligand B (0.135) - lower is better.
14. **Affinity:** Ligand B (-7.3) has a significantly stronger binding affinity than Ligand A (-6.6). A 0.7 kcal/mol difference is substantial and can often outweigh other drawbacks.
**Overall Assessment:**
While Ligand A has better TPSA and hERG, Ligand B excels in several crucial areas: significantly better affinity, much improved metabolic stability (lower Cl_mic), and a longer half-life. The lower logP of Ligand B is a concern, but the strong affinity could compensate for that. The Pgp efflux is also better for Ligand A. However, the combination of potency and metabolic stability is very compelling for Ligand B.
Considering the GPCR-specific priorities and the overall balance of properties, I believe Ligand B is the more promising drug candidate.
Output:
0
2025-04-17 22:11:20,856 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Ligand A (433.274 Da) is within the ideal range, while Ligand B (351.451 Da) is also acceptable. No clear advantage here.
2. **TPSA:** Ligand A (59.5) is good for oral absorption and reasonable for a GPCR. Ligand B (109) is higher, potentially reducing absorption, but still within a workable range. Ligand A is preferred.
3. **logP:** Ligand A (3.439) is optimal. Ligand B (1.077) is a bit low, potentially hindering membrane permeability. Ligand A is preferred.
4. **HBD:** Ligand A (0) is excellent. Ligand B (3) is acceptable, but more donors can sometimes lead to issues. Ligand A is preferred.
5. **HBA:** Ligand A (4) is good. Ligand B (5) is also acceptable. No significant difference.
6. **QED:** Both ligands have reasonable QED scores (A: 0.696, B: 0.584), indicating drug-like properties. Ligand A is slightly better.
7. **DILI:** Ligand A (74.68) has a higher DILI risk than Ligand B (40.713). Ligand B is significantly preferred here.
8. **BBB:** Ligand A (76.115) shows good BBB penetration, while Ligand B (60.838) is lower. Given ADRB2's cardiovascular involvement, CNS penetration isn't a primary concern, but it's a slight advantage for A.
9. **Caco-2:** Ligand A (-4.426) and Ligand B (-5.083) both have negative values, which is unusual and suggests poor permeability. It's difficult to interpret these values without knowing the scale, but they both indicate a potential issue.
10. **Solubility:** Ligand A (-5.713) and Ligand B (-2.363) both have negative solubility values, indicating poor solubility. Ligand B is slightly better.
11. **hERG:** Ligand A (0.755) has a slightly higher hERG risk than Ligand B (0.093). Ligand B is preferred.
12. **Cl_mic:** Ligand A (87.289) has a higher microsomal clearance, suggesting faster metabolism. Ligand B (12.908) has much lower clearance, indicating better metabolic stability. Ligand B is strongly preferred.
13. **t1/2:** Ligand A (14.561) has a longer half-life than Ligand B (-6.935). Ligand A is preferred.
14. **Pgp:** Ligand A (0.496) has lower P-gp efflux, which is good. Ligand B (0.01) is even lower, indicating less efflux. Ligand B is preferred.
15. **Binding Affinity:** Ligand B (-6.8 kcal/mol) has a significantly stronger binding affinity than Ligand A (-4.3 kcal/mol). This is a substantial advantage, potentially outweighing some ADME concerns.
**Overall Assessment:**
Ligand B demonstrates a superior binding affinity and better metabolic stability (lower Cl_mic), lower DILI risk, and lower P-gp efflux. While Ligand A has better TPSA, logP, and half-life, the substantial affinity advantage of Ligand B, coupled with its improved safety profile (lower DILI, hERG), makes it the more promising candidate. The poor Caco-2 and solubility values are concerning for both, but can be addressed with formulation strategies. The stronger binding of Ligand B is likely to be more impactful in driving efficacy.
Output:
0
2025-04-17 22:11:20,856 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.45 & 358.47 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (78.67) is slightly higher than Ligand B (71.69). Both are below the 140 threshold for good oral absorption, and acceptable for a cardiovascular target (not CNS). Ligand B is slightly preferred.
3. **logP:** Ligand A (1.051) is within the optimal range (1-3), while Ligand B (1.957) is also acceptable. No strong preference.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 5 HBA, while Ligand B has 6. Both are acceptable (<=10).
6. **QED:** Both ligands have very similar QED values (0.506 and 0.503), indicating good drug-likeness.
7. **DILI:** Ligand A (28.5%) has a significantly lower DILI risk than Ligand B (70.7%). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (76.0%) has a higher BBB penetration percentile than Ligand A (40.1%). While ADRB2 is a cardiovascular target, some CNS exposure can be a concern for off-target effects, but is not a primary driver for this target.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.104 and -4.942). This is unusual and suggests poor permeability. However, these values are on the same scale, so it doesn't differentiate the two.
10. **Solubility:** Ligand A (-0.319) has slightly better solubility than Ligand B (-2.13).
11. **hERG:** Ligand A (0.2) has a much lower hERG inhibition liability than Ligand B (0.745). This is a critical advantage for Ligand A, reducing cardiotoxicity risk.
12. **Cl_mic:** Ligand B (28.9) has slightly lower microsomal clearance than Ligand A (34.75), suggesting better metabolic stability.
13. **t1/2:** Ligand A (22.9) has a longer in vitro half-life than Ligand B (4.74). This is a significant advantage.
14. **Pgp:** Ligand A (0.153) has lower P-gp efflux liability than Ligand B (0.248), which is favorable for bioavailability.
15. **Affinity:** Ligand A (-7.4 kcal/mol) has a stronger binding affinity than Ligand B (-5.9 kcal/mol). This is a substantial advantage, outweighing some of the ADME concerns of Ligand B.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, affinity, logP, TPSA, and Pgp are important. Ligand A excels in affinity and Pgp, while Ligand B has a slightly better BBB score and Cl_mic. However, the significantly lower DILI and hERG risks for Ligand A, combined with its superior affinity and half-life, are more critical for overall drug development success.
**Conclusion:**
Ligand A is the more promising candidate due to its superior binding affinity, lower DILI and hERG risks, longer half-life, and lower P-gp efflux. While Ligand B has slightly better metabolic stability and BBB penetration, the safety and potency advantages of Ligand A are more compelling.
Output:
1
2025-04-17 22:11:20,856 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (351.535 and 351.407 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (61.44) is significantly better than Ligand B (104.73). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold. Ligand B is approaching the upper limit.
3. **logP:** Ligand A (2.842) is optimal, while Ligand B (-0.068) is quite low. A logP near 0 can lead to poor membrane permeability. This is a substantial advantage for Ligand A.
4. **HBD:** Both ligands have acceptable HBD counts (2 and 1, respectively), well below the 5 threshold.
5. **HBA:** Ligand A (3) is better than Ligand B (6), both are acceptable but lower is preferable.
6. **QED:** Both ligands have similar QED values (0.707 and 0.625), indicating good drug-likeness.
7. **DILI:** Ligand A (9.151) has a lower DILI risk than Ligand B (59.48). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (61.38) has a slightly higher BBB penetration than Ligand B (56.417), but this is not a major concern for a cardiovascular target.
9. **Caco-2:** Both ligands have similar, very poor Caco-2 permeability (-4.881 and -4.945). This is a concern for both, indicating potential absorption issues.
10. **Solubility:** Both ligands have similar solubility (-1.833 and -1.494), which is not ideal.
11. **hERG:** Ligand A (0.521) has a lower hERG risk than Ligand B (0.234). Lower is better, so this favors Ligand A.
12. **Cl_mic:** Ligand A (24.815) has a lower microsomal clearance than Ligand B (44.466), suggesting better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (17.211) has a longer in vitro half-life than Ligand B (-32.995). This is a substantial advantage for Ligand A.
14. **Pgp:** Ligand A (0.118) has lower P-gp efflux than Ligand B (0.012). Lower is better, favoring Ligand A.
15. **Binding Affinity:** Ligand B (-7.0) has a slightly better binding affinity than Ligand A (-6.4). While a 1.6 kcal/mol difference is noticeable, it's not enough to overcome the numerous ADME advantages of Ligand A.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical ADME properties (logP, DILI, Cl_mic, t1/2, Pgp, hERG, TPSA). While Ligand B has a slightly better binding affinity, the overall profile of Ligand A is far more favorable for development as a drug candidate. The poor Caco-2 permeability is a concern for both, but the other advantages of Ligand A are more easily addressed through formulation or structural modifications.
Output:
1
2025-04-17 22:11:20,856 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (351.407 and 348.487 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (78.43) is significantly better than Ligand A (105.56). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (3.242) is slightly higher than Ligand A (0.869). While both are within the acceptable range, Ligand B is closer to the optimal 1-3 range, suggesting better membrane permeability. Ligand A is quite low and may have absorption issues.
4. **HBD:** Ligand B (3) is slightly higher than Ligand A (2). This is not a major concern for either.
5. **HBA:** Ligand A (7) is higher than Ligand B (3). Lower HBA is preferred, giving a slight edge to Ligand B.
6. **QED:** Both ligands are similar (0.783 and 0.738), indicating good drug-like properties.
7. **DILI:** Ligand B (41.838) has a significantly lower DILI risk than Ligand A (75.649). This is a crucial advantage, as liver toxicity is a major concern in drug development.
8. **BBB:** Both ligands are similar (60.76 and 60.45), and BBB isn't a high priority for a cardiovascular target.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.541 and -4.638). This is unusual and suggests poor permeability.
10. **Solubility:** Both ligands have negative solubility values (-2.936 and -3.928). This is also concerning, indicating poor aqueous solubility.
11. **hERG:** Ligand A (0.136) has a slightly lower hERG risk than Ligand B (0.695), which is a positive.
12. **Cl_mic:** Ligand A (34.44) has a lower microsomal clearance than Ligand B (63.267), suggesting better metabolic stability.
13. **t1/2:** Ligand B (5.202) has a much longer in vitro half-life than Ligand A (-12.585). This is a significant advantage, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.017) has a lower P-gp efflux liability than Ligand B (0.426), which is desirable.
15. **Binding Affinity:** Ligand B (-6.8 kcal/mol) has a substantially stronger binding affinity than Ligand A (-2.9 kcal/mol). This is a major advantage, potentially outweighing some of the ADME concerns.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are particularly important. Ligand B excels in logP and affinity, and performs better in TPSA and Pgp. While both have concerning Caco-2 and solubility values, the much stronger binding affinity of Ligand B, coupled with its lower DILI risk and longer half-life, make it the more promising candidate.
**Final Decision:**
0
2025-04-17 22:11:20,856 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (344.415 and 343.391 Da) fall comfortably within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (89.01) is better than Ligand B (105.04). For a GPCR, keeping TPSA low is beneficial for permeability, and A is well below the 140 threshold.
3. **logP:** Ligand A (1.536) is optimal, while Ligand B (0.059) is quite low. Low logP can hinder membrane permeability. This is a significant advantage for A.
4. **HBD:** Both ligands have 2 HBD, which is within the acceptable limit of 5.
5. **HBA:** Ligand A (5) is better than Ligand B (7). Lower HBA is generally preferred for better permeability.
6. **QED:** Ligand A (0.805) is better than Ligand B (0.761), indicating a more drug-like profile.
7. **DILI:** Ligand B (64.831) has a higher DILI risk than Ligand A (57.348), although both are reasonably acceptable.
8. **BBB:** Both ligands have similar BBB penetration (Ligand A: 54.207, Ligand B: 59.131). Since ADRB2 isn't a primary CNS target, this isn't a deciding factor.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the absolute value is more important than the sign. Ligand A (-5.076) is slightly better than Ligand B (-5.474).
10. **Solubility:** Ligand A (-2.862) is better than Ligand B (-1.436). Better solubility is generally preferred.
11. **hERG:** Both ligands have low hERG inhibition liability (Ligand A: 0.404, Ligand B: 0.222), which is good.
12. **Cl_mic:** Ligand A (37.426) has a significantly lower microsomal clearance than Ligand B (-45.013). This indicates better metabolic stability for Ligand A, a crucial factor.
13. **t1/2:** Ligand B (24.009) has a longer in vitro half-life than Ligand A (7.987). This is a positive for B, but the difference may be offset by its poor metabolic stability.
14. **Pgp:** Ligand A (0.165) has lower P-gp efflux than Ligand B (0.013), which is preferable.
15. **Binding Affinity:** Ligand B (-4.7) has a slightly better binding affinity than Ligand A (-2.8). However, the difference is not substantial enough to outweigh the other significant advantages of Ligand A.
**Overall Assessment:**
Ligand A demonstrates a more favorable balance of properties, particularly regarding logP, TPSA, metabolic stability (Cl_mic), and solubility. While Ligand B has slightly better affinity and half-life, its significantly lower logP and higher clearance are major drawbacks. For a GPCR like ADRB2, optimizing permeability and metabolic stability are critical, and Ligand A excels in these areas.
Output:
1
2025-04-17 22:11:20,857 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.449 and 347.296 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (12.47) is significantly better than Ligand B (68.01). For a GPCR, lower TPSA is generally preferred for better permeability. Ligand B is quite high and could hinder oral absorption.
3. **logP:** Ligand A (4.879) is slightly higher than Ligand B (3.861), but both are within the acceptable 1-3 range. Ligand A is approaching the upper limit, which could raise concerns about solubility and off-target effects, but isn't immediately disqualifying.
4. **HBD:** Ligand A (0) is better than Ligand B (1). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (2) is better than Ligand B (5). Similar to HBD, fewer HBAs are preferred.
6. **QED:** Ligand B (0.731) is better than Ligand A (0.491). Ligand B has a more drug-like profile overall.
7. **DILI:** Ligand A (11.245) is significantly better than Ligand B (84.141). This is a major advantage for Ligand A; a lower DILI risk is crucial.
8. **BBB:** Ligand A (88.29) is much better than Ligand B (46.917). While ADRB2 isn't exclusively a CNS target, some CNS exposure can occur, and higher BBB penetration is generally desirable.
9. **Caco-2:** Ligand A (-4.426) is better than Ligand B (-4.829). Both are negative, indicating poor permeability, but A is slightly better.
10. **Solubility:** Ligand A (-4.605) is slightly better than Ligand B (-4.504). Both are poor, but A is marginally better.
11. **hERG:** Ligand A (0.964) is better than Ligand B (0.273). Lower hERG inhibition is crucial for avoiding cardiotoxicity, and Ligand A has a much lower risk.
12. **Cl_mic:** Ligand A (45.075) is better than Ligand B (62.661). Lower clearance indicates better metabolic stability.
13. **t1/2:** Ligand B (-19.54) is much better than Ligand A (-4.3). A longer half-life is generally preferable.
14. **Pgp:** Ligand A (0.685) is better than Ligand B (0.66). Lower P-gp efflux is desirable.
15. **Affinity:** Ligand B (-6.3) is slightly better than Ligand A (-5.7). This is a 0.6 kcal/mol difference, which is not huge, but noticeable.
**Overall Assessment:**
Ligand A has a significantly better safety profile (DILI, hERG) and better ADME properties (TPSA, BBB, Cl_mic, Pgp). While Ligand B has a slightly better QED and binding affinity, the substantial safety and ADME advantages of Ligand A outweigh these benefits. The poor solubility and Caco-2 permeability of both are concerning, but can potentially be addressed through formulation strategies. The higher DILI and lower BBB of Ligand B are more difficult to overcome.
**Output:**
1
2025-04-17 22:11:20,857 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (a cardiovascular GPCR) drug candidates.
**Ligand A:** [372.487, 84.94, 2.31, 1, 6, 0.589, 68.98, 64.87, -4.794, -3.678, 0.111, 104.759, -36.399, 0.076, -5.5]
**Ligand B:** [359.373, 93.46, 1.67, 2, 5, 0.772, 59.907, 84.529, -4.845, -2.373, 0.316, 32.435, -17.373, 0.113, -6.2]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity) and general drug-like properties:
1. **MW:** Both are within the ideal 200-500 Da range. Ligand B (359.373) is slightly lower, which is generally favorable.
2. **TPSA:** Ligand A (84.94) is better than Ligand B (93.46). Both are below 140, but closer to 90 is preferred for GPCRs, making A slightly better.
3. **logP:** Both are good (between 1-3). Ligand A (2.31) is slightly higher, which could be beneficial for membrane permeability, but not dramatically so.
4. **HBD/HBA:** Ligand A has 1 HBD and 6 HBA, while Ligand B has 2 HBD and 5 HBA. Both are acceptable, but A is slightly better.
5. **QED:** Ligand B (0.772) has a better QED score than Ligand A (0.589), suggesting a more inherently drug-like structure.
6. **DILI:** Ligand B (59.907) has a lower DILI risk than Ligand A (68.98), which is a significant advantage.
7. **BBB:** Ligand B (84.529) has a higher BBB penetration score than Ligand A (64.87). While not a primary concern for a cardiovascular target, higher BBB is generally a positive attribute.
8. **Caco-2:** Both are negative, indicating good permeability. The values are very similar (-4.794 vs -4.845).
9. **Solubility:** Ligand A (-3.678) has slightly better solubility than Ligand B (-2.373).
10. **hERG:** Ligand A (0.111) has a lower hERG risk than Ligand B (0.316), which is crucial for cardiovascular drugs.
11. **Cl_mic:** Ligand B (32.435) has significantly lower microsomal clearance than Ligand A (104.759), indicating better metabolic stability. This is a major advantage.
12. **t1/2:** Ligand B (-17.373) has a longer in vitro half-life than Ligand A (-36.399). This is a significant advantage.
13. **Pgp:** Both are low (0.076 and 0.113), indicating minimal P-gp efflux.
14. **Affinity:** Ligand B (-6.2) has a slightly better binding affinity than Ligand A (-5.5). While the difference is not huge, it is still a factor.
**Overall Assessment:**
Ligand B is the more promising candidate. While Ligand A has slightly better TPSA and solubility, Ligand B excels in crucial ADME properties like lower DILI risk, better metabolic stability (lower Cl_mic), longer half-life, and a slightly better binding affinity. The QED score is also higher for Ligand B. The slightly higher BBB penetration is a bonus. For a cardiovascular GPCR, metabolic stability and safety (DILI, hERG) are paramount, and Ligand B clearly wins in these areas.
Output:
0
2025-04-17 22:11:20,857 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (370.515 Da) is slightly higher than Ligand B (349.431 Da), but both are acceptable.
2. **TPSA:** Ligand A (70.08) is significantly better than Ligand B (98.74). ADRB2 is not a CNS target, but lower TPSA generally improves absorption.
3. **logP:** Ligand A (1.838) is within the optimal range (1-3). Ligand B (-0.055) is slightly below 1, which *could* indicate permeability issues. This is a negative for Ligand B.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (4). Similar to HBD, fewer HBAs are generally better.
6. **QED:** Ligand A (0.8) is better than Ligand B (0.606), indicating a more drug-like profile.
7. **DILI:** Ligand B (19.232) has a significantly lower DILI risk than Ligand A (38.503). This is a strong positive for Ligand B.
8. **BBB:** Not a primary concern for ADRB2, but Ligand B (46.336) has a higher BBB percentile than Ligand A (28.655).
9. **Caco-2:** Ligand B (-5.388) is better than Ligand A (-4.57), indicating better intestinal absorption.
10. **Solubility:** Ligand B (-1.994) is better than Ligand A (-2.046). Both are poor, but B is slightly better.
11. **hERG:** Ligand A (0.155) has a lower hERG risk than Ligand B (0.039). This is a positive for Ligand A.
12. **Cl_mic:** Ligand B (-6.348) has a significantly lower (better) microsomal clearance than Ligand A (43.521), suggesting better metabolic stability.
13. **t1/2:** Ligand B (11.551) has a much longer in vitro half-life than Ligand A (-2.6). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.167) has lower P-gp efflux than Ligand B (0.008). This is a positive for Ligand A.
15. **Affinity:** Ligand B (-6.9) has a slightly better binding affinity than Ligand A (-6.7). While the difference is small, it's still a factor.
**Overall Assessment:**
Ligand B demonstrates a significantly better ADME profile, particularly in terms of metabolic stability (Cl_mic, t1/2), DILI risk, and Caco-2 permeability. While Ligand A has a slight advantage in hERG and Pgp, the benefits of Ligand B's improved pharmacokinetic properties and safety profile outweigh these minor drawbacks. The slight advantage in binding affinity for Ligand B further supports its selection. The logP of Ligand B is a concern, but the other positive attributes are more impactful.
Output:
0
2025-04-17 22:11:20,857 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (369.49 and 346.43 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (91.76) is slightly higher than Ligand B (67.67). For a cardiovascular GPCR, TPSA isn't a *major* concern unless it's excessively high, but Ligand B is better positioned for potential CNS penetration if needed.
3. **logP:** Both ligands have good logP values (1.06 and 1.48 respectively), falling within the optimal 1-3 range. Ligand B is slightly more lipophilic.
4. **HBD:** Ligand A has 2 HBD, while Ligand B has 0. Lower HBD is generally preferred for permeability, giving a slight edge to Ligand B.
5. **HBA:** Ligand A has 6 HBA, Ligand B has 5. Both are acceptable, below the threshold of 10.
6. **QED:** Both ligands have good QED scores (0.578 and 0.758), indicating good drug-like properties. Ligand B is better here.
7. **DILI:** Both ligands have low DILI risk (33.23 and 38.12), well below the concerning threshold of 60. No significant difference.
8. **BBB:** Ligand B (66.62) has a better BBB percentile than Ligand A (54.05). While ADRB2 is primarily cardiovascular, some CNS side effects are possible with GPCR modulation, so some BBB penetration is not necessarily negative.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests a potential issue with permeability prediction. I will assume these represent permeability *scores* and higher is better. Ligand A (-4.885) is slightly better than Ligand B (-4.581).
10. **Solubility:** Both ligands have negative solubility values, which is unusual. Assuming higher is better, Ligand A (-1.265) is slightly better than Ligand B (-0.927).
11. **hERG:** Both ligands have very low hERG risk (0.22 and 0.252), which is excellent.
12. **Cl_mic:** Ligand A (7.522) has a significantly lower microsomal clearance than Ligand B (17.859), indicating better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand B (9.751) has a longer in vitro half-life than Ligand A (-9.07). This is a significant advantage.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.064 and 0.041). No significant difference.
15. **Binding Affinity:** Ligand B (-7.4 kcal/mol) has a substantially stronger binding affinity than Ligand A (-6.2 kcal/mol). This 1.2 kcal/mol difference is a major advantage, potentially outweighing some ADME concerns.
**Overall Assessment:**
Ligand B has a significantly better binding affinity and a longer half-life. It also has a better QED and BBB penetration. Ligand A has slightly better Caco-2 and solubility predictions, and significantly better metabolic stability (lower Cl_mic). However, the binding affinity difference is substantial, and the longer half-life of Ligand B is also very desirable. Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity), the superior affinity of Ligand B is the deciding factor.
Output:
0
2025-04-17 22:11:20,857 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's systematically compare the two ligands based on the provided parameters and the guidelines, keeping in mind that ADRB2 is a GPCR and thus we prioritize logP, Pgp, TPSA, and affinity.
1. **Molecular Weight:** Both ligands (362.47 Da and 351.403 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (52.57) is significantly better than Ligand B (111.99). A TPSA under 140 is good for oral absorption, and lower is better for GPCRs. Ligand B is approaching a level that could hinder absorption.
3. **logP:** Ligand A (3.727) is optimal, while Ligand B (-0.66) is quite low. This is a major drawback for Ligand B, as it may struggle with membrane permeability.
4. **H-Bond Donors:** Both have 2-3 HBD, which is acceptable.
5. **H-Bond Acceptors:** Ligand A has 3 HBA, Ligand B has 6. Ligand A is preferable.
6. **QED:** Ligand A (0.871) is excellent, indicating high drug-likeness. Ligand B (0.509) is acceptable, but lower.
7. **DILI:** Ligand A (30.322) is better than Ligand B (19.504) in terms of liver injury risk.
8. **BBB:** Ligand A (83.249) is better than Ligand B (35.052). While ADRB2 isn't necessarily a CNS target, higher BBB penetration is generally favorable, reducing potential off-target effects.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-4.758) is slightly better than Ligand B (-5.078).
10. **Solubility:** Ligand A (-3.654) is better than Ligand B (-1.248).
11. **hERG:** Both are very low (0.784 and 0.177), indicating minimal hERG inhibition risk, which is excellent.
12. **Cl_mic:** Ligand A (22.178) is worse than Ligand B (2.822), meaning Ligand B has better metabolic stability.
13. **t1/2:** Ligand A (5.008) is better than Ligand B (-7.984).
14. **Pgp:** Ligand A (0.358) is better than Ligand B (0.005). Lower P-gp efflux is desirable for better bioavailability.
15. **Binding Affinity:** Both ligands have similar binding affinities (-5.6 and -4.6 kcal/mol). The 1 kcal/mol difference is not enough to overcome the significant ADME deficiencies of Ligand B.
**Overall Assessment:**
Ligand A is significantly superior. While Ligand B has better metabolic stability and a slightly better DILI score, Ligand A excels in crucial properties for a GPCR drug candidate: TPSA, logP, QED, BBB, Solubility, Pgp efflux, and in vitro half-life. The slightly weaker metabolic stability of Ligand A can be addressed through structural modifications during lead optimization. The poor logP of Ligand B is a major hurdle that is unlikely to be overcome without substantial structural changes that would likely impact affinity.
Output:
1
2025-04-17 22:11:20,857 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.431 and 349.406 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (103.94) is higher than Ligand B (72.88). For a GPCR, lower TPSA is generally preferred for better BBB penetration and oral absorption. Ligand B is significantly better here.
3. **logP:** Ligand A (-0.283) is quite low, potentially hindering membrane permeability. Ligand B (1.77) is within the optimal 1-3 range. Ligand B is much better.
4. **HBD:** Both ligands have 2 H-bond donors, which is acceptable.
5. **HBA:** Both ligands have 4 H-bond acceptors, which is acceptable.
6. **QED:** Both ligands have good QED scores (0.712 and 0.869), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (10.857) has a much lower DILI risk than Ligand B (47.77). This is a significant advantage for Ligand A.
8. **BBB:** Both ligands have moderate BBB penetration (45.366 and 46.491). Neither is exceptional, but this is less critical for a cardiovascular target like ADRB2.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.261 and -4.868), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Both ligands have negative solubility values (-2.104 and -3.225), which is also unusual and suggests poor solubility. This is a concern for both.
11. **hERG:** Ligand A (0.061) has a lower hERG risk than Ligand B (0.572). This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand A (-11.917) has a much lower (better) microsomal clearance than Ligand B (4.906), indicating greater metabolic stability. This is a major advantage for Ligand A.
13. **t1/2:** Ligand B (-15.974) has a much longer in vitro half-life than Ligand A (1.527). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.007) has a much lower P-gp efflux liability than Ligand B (0.058), suggesting better oral bioavailability and potentially better CNS exposure (though less critical for ADRB2).
15. **Binding Affinity:** Ligand B (-7.6) has a stronger binding affinity than Ligand A (-6.0). This is a 1.6 kcal/mol difference, which is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand B has a superior binding affinity and a longer half-life. However, Ligand A demonstrates significantly better safety profiles (lower DILI and hERG risk) and metabolic stability (lower Cl_mic). Ligand A also has lower P-gp efflux. Ligand B's logP is much better, but its DILI and hERG are concerning. Given the cardiovascular target, metabolic stability and safety are paramount. While affinity is important, the substantial advantages of Ligand A in safety and metabolism outweigh the affinity difference, especially considering the moderate affinities of both compounds. The poor Caco-2 and solubility for both are concerning and would need to be addressed in further optimization, but are not decisive at this stage.
Output:
1
2025-04-17 22:11:20,858 - INFO - Batch 313 complete. Total preferences: 5008
2025-04-17 22:11:20,858 - INFO - Processing batch 314/512...
2025-04-17 22:12:07,174 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (363.384 Da and 344.371 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (83.29) is significantly better than Ligand B (111.63). For a GPCR, keeping TPSA under 140 is good for oral absorption, and lower is generally preferred. Ligand B is pushing the upper limit.
**3. logP:** Ligand A (2.05) is optimal (1-3). Ligand B (0.099) is quite low, potentially hindering membrane permeability and absorption. This is a significant drawback.
**4. H-Bond Donors:** Ligand A (2) and Ligand B (3) are both acceptable (<=5).
**5. H-Bond Acceptors:** Both ligands (5) are within the acceptable range (<=10).
**6. QED:** Ligand A (0.775) is better than Ligand B (0.673), indicating a more drug-like profile.
**7. DILI:** Ligand A (27.22) has a much lower DILI risk than Ligand B (51.609). This is a crucial advantage, as liver toxicity is a major concern.
**8. BBB:** Ligand A (82.435) has better BBB penetration than Ligand B (58.085). While ADRB2 is a cardiovascular target, some CNS effects are possible with beta-blockers, and better BBB penetration isn't necessarily a negative.
**9. Caco-2 Permeability:** Both have negative values, indicating permeability issues. Ligand A (-4.947) is slightly better than Ligand B (-5.028).
**10. Aqueous Solubility:** Both have negative values. Ligand A (-2.498) is slightly better than Ligand B (-3.153).
**11. hERG Inhibition:** Both ligands show very low hERG inhibition risk (0.296 and 0.096), which is excellent.
**12. Microsomal Clearance:** Ligand B (-16.468) has significantly lower (better) microsomal clearance than Ligand A (28.443), suggesting greater metabolic stability.
**13. In vitro Half-Life:** Ligand B (-21.769) has a much longer in vitro half-life than Ligand A (-9.361), which is a significant advantage for dosing frequency.
**14. P-gp Efflux:** Both are very low (0.016 and 0.002), indicating minimal P-gp efflux.
**15. Binding Affinity:** Ligand B (-7.6) has a slightly better binding affinity than Ligand A (-6.6), a difference of 1.0 kcal/mol. While affinity is important, the other ADME properties are more concerning for Ligand B.
**Overall Assessment:**
Ligand A is the stronger candidate. While Ligand B has slightly better affinity and metabolic stability, Ligand A excels in critical areas like logP, TPSA, DILI risk, and QED. The low logP of Ligand B is a major concern for oral bioavailability. The significantly higher DILI risk for Ligand B is also a red flag. The better TPSA and QED of Ligand A, combined with acceptable affinity, make it the more promising starting point for further optimization.
Output:
1
2025-04-17 22:12:07,175 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [348.403, 113.18 , 0.82 , 3. , 5. , 0.602, 53.858, 48.313, -5.308, -2.04 , 0.095, 33.102, -22.019, 0.017, -6.6 ]
**Ligand B:** [373.474, 55.84 , 3.314, 0. , 4. , 0.613, 21.908, 75.339, -4.623, -2.033, 0.528, 61.296, 14.526, 0.298, -6.2 ]
Here's a step-by-step comparison, keeping GPCR priorities (logP, Pgp, TPSA, BBB, affinity) in mind:
1. **MW:** Both are within the ideal range (200-500 Da). A is 348.4, B is 373.5. No clear advantage.
2. **TPSA:** A (113.18) is higher than B (55.84). B is significantly better, being well below the 140 threshold for oral absorption and more favorable for GPCRs.
3. **logP:** A (0.82) is a bit low, potentially hindering permeation. B (3.314) is excellent, falling right within the optimal range. This is a significant advantage for B.
4. **HBD:** A (3) is reasonable. B (0) is even better, potentially improving permeability.
5. **HBA:** A (5) is acceptable. B (4) is slightly better.
6. **QED:** Both are good (A: 0.602, B: 0.613), indicating good drug-like properties. No significant difference.
7. **DILI:** A (53.86) is higher than B (21.91). B has a much lower risk of liver injury, a crucial factor.
8. **BBB:** A (48.31) is moderate. B (75.34) is very good, suggesting better potential for CNS penetration if desired (though ADRB2 isn't strictly a CNS target, some CNS off-target effects are always a consideration).
9. **Caco-2:** A (-5.308) is poor. B (-4.623) is also poor, but slightly better.
10. **Solubility:** Both are very poor (-2.04 and -2.033). This is a significant concern for both, and formulation would be a major challenge.
11. **hERG:** A (0.095) is very low risk. B (0.528) is slightly higher, but still acceptable.
12. **Cl_mic:** A (33.10) is better than B (61.30), indicating better metabolic stability.
13. **t1/2:** A (-22.02) is better than B (14.53), indicating a longer in vitro half-life.
14. **Pgp:** A (0.017) is excellent, indicating very low P-gp efflux. B (0.298) is higher, suggesting more P-gp efflux.
15. **Affinity:** A (-6.6) is slightly better than B (-6.2), but the difference is small.
**Overall Assessment:**
Ligand B clearly outperforms Ligand A despite the slightly weaker binding affinity. The key advantages of B are its significantly better logP, lower DILI risk, and higher BBB penetration. The lower TPSA is also a plus. While both have poor solubility, the other ADME properties of B are more favorable for a GPCR target. The slightly better metabolic stability and half-life of A are outweighed by the other benefits of B.
Output:
0
2025-04-17 22:12:07,175 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (359.342 and 350.459 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (28.16) is excellent, well below the 140 threshold, and very favorable for oral absorption. Ligand B (67.87) is higher, but still acceptable, though less ideal.
3. **logP:** Ligand A (3.777) is at the higher end of the optimal range (1-3), but still acceptable. Ligand B (1.503) is on the lower side, potentially impacting permeability.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 3 HBA, and Ligand B has 4 HBA. Both are within the acceptable limit of 10.
6. **QED:** Ligand A (0.629) is slightly better than Ligand B (0.505), indicating a more drug-like profile.
7. **DILI:** Ligand A (43.738) has a moderate DILI risk, but is still acceptable. Ligand B (8.918) has a very low DILI risk, a significant advantage.
8. **BBB:** Both ligands have good BBB penetration (Ligand A: 79.798, Ligand B: 72.78). Since ADRB2 is a cardiovascular target, BBB penetration is not a primary concern, but it doesn't hurt.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual. This suggests poor permeability.
10. **Solubility:** Both ligands have negative solubility values, indicating poor solubility.
11. **hERG:** Ligand A (0.964) has a slightly higher hERG risk than Ligand B (0.355). Lower is better here.
12. **Cl_mic:** Ligand A (31.609) has lower microsomal clearance than Ligand B (49.22), indicating better metabolic stability.
13. **t1/2:** Ligand A (45.64) has a significantly longer in vitro half-life than Ligand B (-12.124). This is a major advantage.
14. **Pgp:** Ligand A (0.556) has lower P-gp efflux than Ligand B (0.078), suggesting better bioavailability.
15. **Affinity:** Ligand A (-8.0) has a significantly stronger binding affinity than Ligand B (-6.0). This is a 2 kcal/mol difference, which is substantial and can outweigh some ADME drawbacks.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A has a better logP and significantly better affinity. While Ligand B has a better DILI score, the substantial affinity advantage of Ligand A, coupled with acceptable DILI and good metabolic stability, makes it the more promising candidate. The poor Caco-2 and solubility values are concerning for both, but can be addressed with formulation strategies.
**Conclusion:**
Ligand A is the better candidate due to its superior binding affinity, longer half-life, lower P-gp efflux, and acceptable ADME properties.
Output:
1
2025-04-17 22:12:07,175 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's analyze each ligand against the provided guidelines, keeping in mind ADRB2 is a GPCR, so logP, Pgp, TPSA, and affinity are key.
* **Molecular Weight:** Both ligands (358.511 and 355.408 Da) fall comfortably within the ideal 200-500 Da range.
* **TPSA:** Ligand A (59.81) and Ligand B (57.7) are both below the 140 threshold for good oral absorption, and acceptable for a non-CNS GPCR target like ADRB2.
* **logP:** Both ligands have good logP values (3.481 and 3.965), falling within the optimal 1-3 range. Ligand B is slightly higher, which could potentially lead to some off-target interactions, but is still acceptable.
* **H-Bond Donors/Acceptors:** Both have 1 HBD and a reasonable number of HBAs (5 and 4 respectively). This is good for balancing solubility and permeability.
* **QED:** Both ligands have reasonable QED scores (0.859 and 0.779), indicating good drug-like properties.
* **DILI:** Ligand A has a DILI risk of 68.05%, which is approaching the higher risk threshold. Ligand B has a significantly lower DILI risk (35.401%), a major advantage.
* **BBB:** Both have good BBB penetration (69.446 and 76.735), but this is less critical for ADRB2, a cardiovascular target.
* **Caco-2 Permeability:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. This is a concern for both.
* **Aqueous Solubility:** Both have negative solubility values, which is also concerning.
* **hERG Inhibition:** Ligand A (0.311) has a lower hERG inhibition risk than Ligand B (0.909), which is favorable.
* **Microsomal Clearance:** Ligand A (76.049) has higher microsomal clearance than Ligand B (18.643), meaning Ligand B is more metabolically stable. This is a significant advantage.
* **In vitro Half-Life:** Ligand B (9.822 hours) has a longer half-life than Ligand A (7.365 hours), which is desirable.
* **P-gp Efflux:** Ligand A (0.608) has lower P-gp efflux than Ligand B (0.352), which is favorable.
* **Binding Affinity:** Ligand A (-6.4 kcal/mol) and Ligand B (-6.1 kcal/mol) have very similar binding affinities. The difference (0.3 kcal/mol) is not substantial enough to outweigh other factors.
**Overall Assessment:**
While Ligand A has slightly better P-gp efflux and hERG inhibition, Ligand B is significantly better in terms of DILI risk, metabolic stability (lower Cl_mic), and in vitro half-life. The Caco-2 and solubility issues are concerning for both, but the ADME profile of Ligand B is more promising overall. Given the importance of metabolic stability and minimizing toxicity for a cardiovascular drug, Ligand B is the more viable candidate.
**Output:**
0
2025-04-17 22:12:07,175 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.475 and 346.475 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (78.87) is slightly higher than Ligand B (66.37). Both are below the 140 threshold for good oral absorption, but B is better.
3. **logP:** Both ligands have good logP values (1.317 and 1.205), falling within the optimal 1-3 range. Very similar.
4. **HBD:** Both have 2 H-bond donors, which is good.
5. **HBA:** Both have 4 H-bond acceptors, which is good.
6. **QED:** Both ligands have good QED scores (0.724 and 0.78), indicating good drug-likeness. Ligand B is slightly better.
7. **DILI:** Ligand A (9.19) has a significantly lower DILI risk than Ligand B (10.702). This is a substantial advantage for Ligand A.
8. **BBB:** Both have reasonable BBB penetration (56.805 and 59.131). Since ADRB2 is a cardiovascular target, BBB penetration is not a high priority, but slightly higher is still preferable. Ligand B is slightly better.
9. **Caco-2:** Ligand A (-4.664) and Ligand B (-5.409) both have negative Caco-2 values, suggesting poor permeability. Ligand B is slightly better.
10. **Solubility:** Ligand A (-2.235) has slightly better solubility than Ligand B (-0.761).
11. **hERG:** Both ligands have very low hERG inhibition risk (0.253 and 0.219). No significant difference.
12. **Cl_mic:** Ligand B (-12.011) has a much lower microsomal clearance than Ligand A (51.81). This suggests better metabolic stability for Ligand B, a significant advantage.
13. **t1/2:** Ligand B (5.963) has a longer in vitro half-life than Ligand A (-4.313). This is a significant advantage for Ligand B.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.042 and 0.033). No significant difference.
15. **Binding Affinity:** Ligand A (-6.4) has a slightly better binding affinity than Ligand B (-6.0). While the difference is less than the 1.5 kcal/mol threshold, it's still a positive point for Ligand A.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Both ligands perform well on logP and Pgp. Ligand B has a better TPSA. The affinity difference is small, but favors Ligand A. However, the significantly better metabolic stability (Cl_mic and t1/2) and lower DILI risk of Ligand B are crucial factors.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity and lower DILI, Ligand B's superior metabolic stability (lower Cl_mic, longer t1/2) and slightly better TPSA are more important for overall drug development success. The lower DILI risk is also a significant benefit.
Output:
0
2025-04-17 22:12:07,175 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (367.354 and 380.901 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand B (86.88) is significantly better than Ligand A (109.77). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally improves absorption.
3. **logP:** Ligand B (3.363) is slightly higher than Ligand A (2.04), but both are within the optimal 1-3 range. Ligand B is approaching the upper limit, but still acceptable.
4. **HBD:** Ligand B (3) is slightly higher than Ligand A (2), but both are within the acceptable limit of 5.
5. **HBA:** Ligand A (5) is slightly higher than Ligand B (4), but both are within the acceptable limit of 10.
6. **QED:** Both ligands have very similar QED scores (0.756 and 0.743), indicating good drug-likeness.
7. **DILI:** Ligand B (73.672) has a significantly lower DILI risk than Ligand A (98.294). This is a major advantage for Ligand B.
8. **BBB:** Ligand A (19.698) has a very low BBB penetration, while Ligand B (48.468) is still low, but better. Since ADRB2 is not a CNS target, this is less critical.
9. **Caco-2:** Both ligands have very poor Caco-2 permeability (-5.227 and -5.23). This is a significant concern for both.
10. **Solubility:** Ligand A (-3.404) has slightly better solubility than Ligand B (-4.527), but both are very poor.
11. **hERG:** Ligand A (0.053) has a slightly lower hERG risk than Ligand B (0.305), which is preferable.
12. **Cl_mic:** Ligand A (15.609) has significantly lower microsomal clearance than Ligand B (34.91), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand B (13.791) has a slightly longer in vitro half-life than Ligand A (11.411), which is a minor advantage.
14. **Pgp:** Ligand A (0.066) has lower P-gp efflux liability than Ligand B (0.293), which is preferable.
15. **Affinity:** Ligand A (-7.8 kcal/mol) has a slightly better binding affinity than Ligand B (-7.6 kcal/mol). While the difference is small (0.2 kcal/mol), it is still a factor.
**Overall Assessment:**
Ligand A has a slight edge in binding affinity and metabolic stability (lower Cl_mic), and Pgp efflux. However, Ligand B has a much lower DILI risk, a better TPSA, and a slightly longer half-life. Both have poor Caco-2 permeability and solubility. Given the importance of minimizing toxicity (DILI) and the relatively small difference in affinity, Ligand B appears to be the more promising candidate. The lower DILI risk is a significant advantage.
Output:
0
2025-04-17 22:12:07,175 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (353.369) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (75.44) is significantly better than Ligand B (97.19). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (2.304) is optimal, while Ligand B (0.87) is a bit low, potentially hindering membrane permeability.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A (4) is better than Ligand B (8). Higher HBA can sometimes reduce permeability.
6. **QED:** Both are very similar (0.824 and 0.823), indicating good drug-like properties.
7. **DILI:** Both are reasonably similar and acceptable (55.874 and 58.434).
8. **BBB:** Ligand A (91.392) is much better than Ligand B (46.026). While not a primary concern for a cardiovascular target, higher BBB is rarely detrimental.
9. **Caco-2:** Ligand A (-4.735) is better than Ligand B (-5.491). Higher (less negative) Caco-2 values indicate better permeability.
10. **Solubility:** Ligand A (-2.935) is better than Ligand B (-1.665). Better solubility is generally desirable.
11. **hERG:** Both are very low (0.174 and 0.188), indicating minimal cardiotoxicity risk.
12. **Cl_mic:** Ligand B (-19.583) has significantly lower microsomal clearance than Ligand A (27.467), suggesting better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand B (-0.511) has a much longer in vitro half-life than Ligand A (-47.426). This is a major advantage, potentially allowing for less frequent dosing.
14. **Pgp:** Both are very low (0.109 and 0.077), indicating minimal P-gp efflux.
15. **Binding Affinity:** Ligand B (-7.5) is slightly better than Ligand A (-7.3), but the difference is relatively small.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A has a better logP and TPSA. Ligand B has a slightly better affinity, but the difference isn't substantial. The significantly improved metabolic stability (lower Cl_mic) and longer half-life of Ligand B are crucial advantages.
**Overall Assessment:**
While Ligand A has some advantages in terms of TPSA, logP, and solubility, the superior metabolic stability and longer half-life of Ligand B outweigh these factors. The slight improvement in binding affinity further supports choosing Ligand B.
Output:
0
2025-04-17 22:12:07,175 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (368.459 Da and 353.442 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (116.4) is slightly higher than Ligand B (90.98). Ligand B is better, being closer to the <140 threshold for good absorption, and more favorable for a GPCR.
3. **logP:** Ligand B (1.998) is better positioned within the optimal 1-3 range compared to Ligand A (0.916), which is at the lower end and could potentially have permeability issues.
4. **HBD:** Ligand A (4) and Ligand B (2) are both acceptable, but Ligand B is preferable as fewer HBDs generally improve permeability.
5. **HBA:** Both ligands have 4 HBA, which is well within the acceptable limit.
6. **QED:** Ligand B (0.784) has a higher QED score than Ligand A (0.546), indicating a more drug-like profile.
7. **DILI:** Both ligands have acceptable DILI risk (Ligand A: 49.632, Ligand B: 43.234), with Ligand B being slightly better.
8. **BBB:** Ligand B (85.964) has a significantly higher BBB penetration percentile than Ligand A (65.452). This is a key advantage for a GPCR target, even if it's not strictly a CNS target, as it suggests better distribution.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. Ligand A (-5.349) is slightly worse than Ligand B (-4.925).
10. **Solubility:** Both ligands have negative solubility values, indicating poor solubility. Ligand A (-2.752) is slightly worse than Ligand B (-3.214).
11. **hERG:** Ligand A (0.242) has a lower hERG inhibition liability than Ligand B (0.714), which is a positive.
12. **Cl_mic:** Ligand B (9.376) has a lower microsomal clearance than Ligand A (30.971), indicating better metabolic stability.
13. **t1/2:** Ligand B (-13.253) has a slightly better in vitro half-life than Ligand A (-16.329).
14. **Pgp:** Ligand A (0.01) has a much lower P-gp efflux liability than Ligand B (0.192), which is a significant advantage for bioavailability.
15. **Affinity:** Both ligands have very similar binding affinities (Ligand A: -6.5 kcal/mol, Ligand B: -6.6 kcal/mol). The difference is negligible.
**Overall Assessment:**
Ligand B is the better candidate. While Ligand A has a slightly better hERG profile and Pgp efflux liability, Ligand B excels in key GPCR-relevant parameters: logP, BBB penetration, QED, and metabolic stability (Cl_mic). The superior BBB penetration and QED are particularly important. The slightly lower solubility and Caco-2 permeability of Ligand B are less concerning given the overall profile and can potentially be addressed through formulation strategies.
Output:
0
2025-04-17 22:12:07,176 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (339.439 & 345.447 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (64.41) is better than Ligand B (71.33). Both are below 140, but lower TPSA generally favors absorption.
3. **logP:** Ligand A (2.828) is optimal, while Ligand B (1.482) is on the lower side. For a GPCR, a logP between 1-3 is preferred, and A is closer to the sweet spot.
4. **HBD:** Both ligands have 0 HBD, which is good.
5. **HBA:** Ligand A (3) is better than Ligand B (5). Lower HBA is generally preferred for better permeability.
6. **QED:** Both ligands have the same QED (0.775), indicating good drug-likeness.
7. **DILI:** Ligand A (34.626) is slightly higher than Ligand B (33.075), but both are well below the concerning threshold of 60, indicating low liver injury risk.
8. **BBB:** Ligand A (79.062) is better than Ligand B (71.035). While ADRB2 isn't strictly a CNS target, some CNS penetration can be beneficial for understanding off-target effects and potential side effects.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.594 and -4.674). These values are difficult to interpret directly without knowing the scale, but suggest poor permeability.
10. **Solubility:** Ligand A (-3.691) is better than Ligand B (-1.554). Higher solubility is generally desirable.
11. **hERG:** Ligand A (0.821) is better than Ligand B (0.277). Lower hERG inhibition is crucial for avoiding cardiotoxicity, especially important for a cardiovascular target like ADRB2.
12. **Cl_mic:** Ligand A (59.004) is better than Ligand B (36.838). Lower microsomal clearance indicates better metabolic stability.
13. **t1/2:** Ligand B (-7.276) is better than Ligand A (-4.674). A longer half-life is generally preferred.
14. **Pgp:** Ligand A (0.467) is better than Ligand B (0.081). Lower P-gp efflux is desirable for improved bioavailability.
15. **Binding Affinity:** Ligand B (-6.8 kcal/mol) is slightly better than Ligand A (-6.6 kcal/mol). While the difference is small, affinity is a primary driver.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity), Ligand A appears to be the more promising candidate. It has a better logP, TPSA, solubility, hERG profile, and Pgp efflux liability. While Ligand B has a slightly better binding affinity and half-life, the advantages of Ligand A across multiple ADME properties, particularly its lower hERG risk and better metabolic stability, outweigh the small affinity difference. The negative Caco-2 values for both are concerning and would require further investigation, but the other properties of Ligand A make it a more balanced and potentially viable drug candidate.
Output:
1
2025-04-17 22:12:07,176 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (353.463 and 349.519 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (52.65) is significantly better than Ligand A (112.73). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (2.691) is within the optimal 1-3 range. Ligand A (0.402) is quite low, potentially hindering membrane permeability. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (1), but both are within the acceptable limit of 5.
5. **HBA:** Ligand A (4) and Ligand B (3) are both within the acceptable limit of 10.
6. **QED:** Ligand B (0.719) is better than Ligand A (0.586), indicating a more drug-like profile.
7. **DILI:** Both ligands have similar, low DILI risk (11.865 vs 11.671).
8. **BBB:** Ligand B (77.084) has a higher BBB penetration percentile than Ligand A (35.052). While not critical for a cardiovascular target, it's a slight positive for Ligand B.
9. **Caco-2:** Ligand A (-5.473) is a bit better than Ligand B (-4.957), but both are negative values indicating poor permeability.
10. **Solubility:** Ligand A (-1.713) is better than Ligand B (-2.46), but both are negative, suggesting poor aqueous solubility.
11. **hERG:** Ligand A (0.126) has a slightly lower hERG risk than Ligand B (0.554), which is preferable.
12. **Cl_mic:** Ligand A (15.104) has a much lower microsomal clearance than Ligand B (48.983), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand B (0.559) has a slightly better in vitro half-life than Ligand A (-1.274).
14. **Pgp:** Ligand A (0.005) has a much lower P-gp efflux liability than Ligand B (0.116), suggesting better oral bioavailability. This is a significant advantage for Ligand A.
15. **Affinity:** Ligand B (-7.0) has a slightly better binding affinity than Ligand A (-6.4). This is a 1.6 kcal/mol advantage, which is substantial and can outweigh some ADME concerns.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP and affinity, while Ligand A is better in TPSA and Pgp.
**Overall Assessment:**
Ligand B's superior binding affinity (-7.0 kcal/mol vs -6.4 kcal/mol) is a major advantage, and the 1.6 kcal/mol difference is significant. While Ligand A has better metabolic stability (lower Cl_mic) and P-gp efflux, the potency of Ligand B is more critical for a GPCR target. The slightly higher logP of Ligand B is also beneficial for membrane permeability. Although Ligand A has a slightly better hERG profile, the overall balance favors Ligand B due to its strong binding affinity.
Output:
0
2025-04-17 22:12:07,176 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
The target is ADRB2, a GPCR. Therefore, priorities are logP, TPSA, Pgp, BBB, and affinity.
Let's analyze each ligand against these criteria and the general guidelines:
* **Molecular Weight:** Both ligands are within the ideal range (352.475 Da and 361.427 Da).
* **TPSA:** Ligand A (59.08) is significantly better than Ligand B (100.35). A lower TPSA is preferred for good absorption, and Ligand A is well below the 140 threshold. Ligand B is approaching the upper limit.
* **logP:** Ligand A (1.818) is optimal. Ligand B (0.6) is a bit low, potentially hindering permeability.
* **H-Bond Donors/Acceptors:** Ligand A (0 HBD, 4 HBA) is better than Ligand B (2 HBD, 7 HBA). Fewer H-bonds generally improve permeability.
* **QED:** Both ligands have good QED scores (0.774 and 0.812), indicating good drug-like properties.
* **DILI:** Ligand A (16.208) has a much lower DILI risk than Ligand B (62.389). This is a significant advantage.
* **BBB:** Ligand A (85.033) has a much higher BBB penetration score than Ligand B (21.791). While ADRB2 isn't necessarily a CNS target, higher BBB penetration can sometimes correlate with better overall distribution and reduced off-target effects.
* **Caco-2 Permeability:** Both are negative, but Ligand A (-4.208) is less negative than Ligand B (-5.094), suggesting slightly better permeability.
* **Aqueous Solubility:** Both are negative, indicating poor solubility. This is a concern for both, but not a deciding factor.
* **hERG:** Both have very low hERG inhibition liability (0.46 and 0.127).
* **Microsomal Clearance:** Ligand A (33.832) has higher clearance than Ligand B (4.56), meaning Ligand B is more metabolically stable.
* **In vitro Half-Life:** Ligand B (-7.126) has a longer half-life than Ligand A (12.834). This is a positive for Ligand B.
* **P-gp Efflux:** Both have very low P-gp efflux liability (0.062 and 0.027).
* **Binding Affinity:** Ligand B (-8.1) has a stronger binding affinity than Ligand A (-6.8). This is a 1.3 kcal/mol difference, which is substantial.
**Overall Assessment:**
Ligand B has a significantly better binding affinity and metabolic stability (lower Cl_mic, longer t1/2). However, Ligand A excels in critical ADME properties like TPSA, logP, DILI risk, and BBB penetration. The stronger affinity of Ligand B is a major plus, but the poor TPSA and logP values, coupled with the higher DILI risk, are concerning. For a GPCR, optimizing for permeability and minimizing toxicity are crucial.
Considering the balance, Ligand A's superior ADME profile, particularly its TPSA and lower DILI risk, outweighs the affinity advantage of Ligand B. The affinity difference, while significant, might be overcome with further optimization of Ligand A.
**Output:**
1
2025-04-17 22:12:07,176 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.39 and 355.47 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand B (63.91) is significantly better than Ligand A (117.09). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both are within the optimal 1-3 range (1.31 and 2.54). Ligand B is slightly higher, which *could* be beneficial for membrane permeability, but isn't a major concern.
4. **HBD:** Ligand A has 3 HBD, while Ligand B has 0. Lower HBD is generally preferred for permeability, giving a slight edge to Ligand B.
5. **HBA:** Ligand A has 5 HBA, Ligand B has 6. Both are acceptable, but lower is slightly preferred.
6. **QED:** Both ligands have similar QED values (0.699 and 0.716), indicating good drug-like properties.
7. **DILI:** Ligand B (55.68) has a significantly lower DILI risk than Ligand A (75.18). This is a substantial advantage.
8. **BBB:** Ligand B (75.73) has a higher BBB penetration score than Ligand A (34.01). While not a primary concern for a cardiovascular target, higher BBB is generally a positive attribute.
9. **Caco-2:** Ligand A (-5.51) and Ligand B (-4.70) are both negative, which is unusual. This suggests poor permeability.
10. **Solubility:** Ligand A (-3.01) and Ligand B (-4.14) are both negative, suggesting poor solubility.
11. **hERG:** Both ligands have very low hERG risk (0.24 and 0.17), which is excellent.
12. **Cl_mic:** Ligand A (10.24) has a much lower microsomal clearance than Ligand B (42.22). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (27.75) has a longer in vitro half-life than Ligand B (-6.40). This is a significant advantage for dosing frequency.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.15 and 0.25).
15. **Binding Affinity:** Ligand B (-6.9 kcal/mol) has a slightly better binding affinity than Ligand A (-5.7 kcal/mol). This 1.2 kcal/mol difference is significant and could outweigh some ADME drawbacks.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in TPSA and affinity, while Ligand A has better metabolic stability (Cl_mic) and half-life. The improved DILI score for Ligand B is also a major factor. The affinity difference is substantial enough to favor Ligand B despite the slightly higher clearance.
**Overall Assessment:**
While Ligand A has advantages in metabolic stability and half-life, Ligand B's superior binding affinity, lower DILI risk, and better TPSA make it the more promising candidate. The slightly higher logP is not a major concern.
Output:
0
2025-04-17 22:12:07,176 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands (346.395 and 354.365 Da) are within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand B (97.64) is significantly better than Ligand A (119.57). ADRB2 is a cardiovascular target, so CNS penetration isn't critical, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands (0.782 and 0.647) are acceptable, falling within the 1-3 range, but on the lower end.
4. **HBD:** Ligand B (1) is better than Ligand A (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand B (8) is better than Ligand A (9). Fewer HBAs generally improve permeability.
6. **QED:** Ligand B (0.842) is significantly better than Ligand A (0.583), indicating a more drug-like profile.
7. **DILI:** Both ligands have similar DILI risk (63.397 and 63.203 percentile), placing them in a moderate risk category. Not a major differentiator.
8. **BBB:** Ligand B (82.474) is much better than Ligand A (40.558). While not a CNS target, some level of BBB penetration can influence distribution and off-target effects.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.878 and -5.14). These values are unusual and suggest poor permeability.
10. **Solubility:** Both ligands have negative solubility values (-1.561 and -2.427). These values are also unusual and suggest poor solubility.
11. **hERG:** Both ligands have low hERG inhibition risk (0.1 and 0.291).
12. **Cl_mic:** Ligand B (0.007) is *much* better than Ligand A (-2.369). This indicates significantly improved metabolic stability for Ligand B.
13. **t1/2:** Ligand B (-0.977) is better than Ligand A (23.003). This indicates a longer half-life for Ligand B.
14. **Pgp:** Ligand B (0.12) is better than Ligand A (0.042). Lower P-gp efflux is desirable for better bioavailability.
15. **Affinity:** Ligand B (-6.6 kcal/mol) is significantly better than Ligand A (-5.4 kcal/mol). This is a substantial difference in binding potency.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B is superior in all these areas. The large difference in binding affinity (-6.6 vs -5.4 kcal/mol) is a major advantage that can outweigh some of the ADME concerns.
**Conclusion:**
Ligand B demonstrates a significantly better overall profile, particularly in terms of binding affinity, metabolic stability, drug-likeness, and permeability indicators (despite the unusual Caco-2 and solubility values).
Output:
0
2025-04-17 22:12:07,176 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (356.495 Da and 371.453 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Both ligands are around 57-58 A^2, which is acceptable for a non-CNS GPCR target like ADRB2.
**3. logP:** Both ligands have a logP around 3.4, which is optimal.
**4. H-Bond Donors:** Ligand A has 2 HBD, and Ligand B has 1. Both are within the acceptable limit of <=5.
**5. H-Bond Acceptors:** Both ligands have 5 HBA, which is within the acceptable limit of <=10.
**6. QED:** Ligand A (0.882) has a significantly better QED score than Ligand B (0.688), indicating a more drug-like profile.
**7. DILI:** Ligand B (30.942 percentile) has a much lower DILI risk than Ligand A (59.829 percentile). This is a substantial advantage for Ligand B.
**8. BBB:** While not a primary concern for a cardiovascular target, Ligand A (94.184 percentile) has better BBB penetration than Ligand B (79.062 percentile).
**9. Caco-2 Permeability:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-5.036) is slightly worse than Ligand B (-5.136).
**10. Aqueous Solubility:** Both ligands have negative solubility values, indicating poor aqueous solubility. Ligand B (-2.08) is slightly better than Ligand A (-3.231).
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (0.867 and 0.825, respectively).
**12. Microsomal Clearance:** Ligand B (41.395 mL/min/kg) has a higher microsomal clearance than Ligand A (4.602 mL/min/kg), suggesting lower metabolic stability.
**13. In vitro Half-Life:** Ligand A (40.18 hours) has a significantly longer in vitro half-life than Ligand B (12.711 hours). This is a major advantage for Ligand A.
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (0.421 and 0.612, respectively).
**15. Binding Affinity:** Ligand B (-5.5 kcal/mol) has a significantly stronger binding affinity than Ligand A (0.0 kcal/mol). This is a substantial advantage for Ligand B.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand B is more promising. The significantly stronger binding affinity (-5.5 kcal/mol vs 0.0 kcal/mol) is a major factor. While Ligand A has better QED and half-life, the lower DILI risk of Ligand B is also very important. The poor Caco-2 and solubility are concerns for both, but can be addressed with formulation strategies. The difference in binding affinity outweighs the other factors.
Output:
0
2025-04-17 22:12:07,176 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (342.49 & 353.42 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (38.82) is significantly better than Ligand B (85.11). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand A is well under the 140 threshold, while Ligand B is approaching it.
3. **logP:** Both ligands have acceptable logP values (2.13 & 1.10), falling within the 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (0). While both are low, a single HBD can sometimes improve solubility without drastically affecting permeability.
5. **HBA:** Ligand A (3) is better than Ligand B (6). Lower HBA is generally preferred for better permeability.
6. **QED:** Ligand A (0.911) is significantly better than Ligand B (0.651), indicating a more drug-like profile.
7. **DILI:** Ligand A (7.06) has a much lower DILI risk than Ligand B (30.83). This is a crucial advantage, as liver toxicity is a major concern in drug development.
8. **BBB:** Ligand B (91.04) has higher BBB penetration than Ligand A (71.46). However, as ADRB2 is primarily a cardiovascular target, high BBB penetration is not a priority.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.84 & -4.48), which is unusual and suggests poor permeability. This is a significant drawback for both.
10. **Solubility:** Ligand A (-1.45) is slightly better than Ligand B (-0.50), but both are poor.
11. **hERG:** Ligand A (0.85) is better than Ligand B (0.35), indicating a lower risk of cardiotoxicity. This is particularly important for a cardiovascular target.
12. **Cl_mic:** Ligand A (-9.99) has a much lower (better) microsomal clearance than Ligand B (36.55). This suggests greater metabolic stability for Ligand A.
13. **t1/2:** Ligand A (7.88) has a significantly longer in vitro half-life than Ligand B (-21.25). This is a major advantage, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.02) has a much lower Pgp efflux liability than Ligand B (0.08), suggesting better oral bioavailability.
15. **Binding Affinity:** Ligand A (-7.1) has a slightly better binding affinity than Ligand B (-5.8). While the difference is not huge, it's enough to be a factor.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A is better across most of these parameters, with the exception of BBB, which isn't a major concern for a cardiovascular target.
**Overall Assessment:**
Ligand A is significantly better than Ligand B across most critical ADME-Tox properties (DILI, Cl_mic, t1/2, Pgp, hERG) and has a slightly better binding affinity. While both have poor Caco-2 permeability, the superior overall profile of Ligand A makes it the more promising drug candidate.
Output:
1
2025-04-17 22:12:07,176 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (348.4 & 354.4 Da) fall comfortably within the 200-500 Da ideal range. No significant difference.
2. **TPSA:** Ligand A (99.57) is higher than Ligand B (68.31). While both are below 140, the lower TPSA of Ligand B is more favorable for permeability, a key consideration for GPCRs.
3. **logP:** Ligand A (-0.546) is a bit low, potentially hindering membrane permeability. Ligand B (2.023) is within the optimal 1-3 range. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (2) and Ligand B (0) are both acceptable, below the 5 threshold. Ligand B is slightly preferred as fewer HBDs generally correlate with better permeability.
5. **HBA:** Both ligands (5) are below the 10 threshold and comparable.
6. **QED:** Both ligands (0.746 & 0.654) are above 0.5, indicating good drug-likeness. Ligand A is slightly better here.
7. **DILI:** Both ligands have low DILI risk (39.9 & 36.3 percentile), below the 40 threshold. No significant difference.
8. **BBB:** Ligand B (82.1%) has significantly better predicted BBB penetration than Ligand A (63.1%). This is a crucial advantage for a GPCR target, even if not specifically a CNS target, as it can influence distribution.
9. **Caco-2:** Both ligands show poor Caco-2 permeability (-5.22 and -4.32). This is a concern for both, but less concerning for a target like ADRB2 where direct CNS penetration isn't necessarily required.
10. **Solubility:** Both ligands have poor aqueous solubility (-1.073 and -1.093). This is a drawback for both, potentially impacting bioavailability.
11. **hERG:** Both ligands show very low hERG inhibition risk (0.092 & 0.644). This is excellent for both.
12. **Cl_mic:** Ligand A (14.292) has a much lower microsomal clearance than Ligand B (59.086), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (11.564) has a longer in vitro half-life than Ligand B (-11.335). This is a positive for Ligand A.
14. **Pgp:** Ligand A (0.008) has very low P-gp efflux liability, while Ligand B (0.151) has slightly higher efflux. This is a slight advantage for Ligand A.
15. **Binding Affinity:** Ligand B (-6.7 kcal/mol) has a slightly stronger binding affinity than Ligand A (-5.4 kcal/mol). This is a 1.3 kcal/mol difference, which is substantial enough to consider.
**Overall Assessment:**
Ligand B has a better logP, TPSA, and BBB penetration, and a stronger binding affinity. These are key properties for a GPCR ligand. While Ligand A has better metabolic stability (lower Cl_mic, longer t1/2) and lower Pgp efflux, the benefits of Ligand B's improved permeability and binding outweigh these advantages. The solubility and Caco-2 permeability are poor for both, but can be addressed with formulation strategies. The slightly stronger binding affinity of Ligand B is also a significant factor.
Output:
0
2025-04-17 22:12:07,176 - INFO - Batch 314 complete. Total preferences: 5024
2025-04-17 22:12:07,177 - INFO - Processing batch 315/512...
2025-04-17 22:12:58,181 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (a GPCR) drug candidates.
**Ligand A:** [381.395, 62.3, 2.392, 1, 4, 0.738, 46.103, 74.719, -4.86, -2.63, 0.305, 17.899, -28.489, 0.107, -7.0]
**Ligand B:** [354.495, 56.33, -0.036, 0, 5, 0.642, 5.467, 66.925, -4.594, 0.469, 0.354, 29.959, -28.486, 0.003, -6.6]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, BBB, and affinity are key):
1. **MW:** Both are within the ideal 200-500 Da range. Ligand B (354.495) is slightly preferred due to being a bit lower.
2. **TPSA:** Ligand A (62.3) is slightly higher than Ligand B (56.33), but both are well below the 140 threshold for oral absorption.
3. **logP:** Ligand A (2.392) is excellent, falling right in the optimal 1-3 range. Ligand B (-0.036) is concerningly low, potentially hindering membrane permeability.
4. **HBD/HBA:** Ligand A (1 HBD, 4 HBA) is slightly better than Ligand B (0 HBD, 5 HBA). Both are within acceptable limits.
5. **QED:** Both are reasonable (A: 0.738, B: 0.642), indicating good drug-like properties.
6. **DILI:** Ligand B (5.467) is *significantly* better than Ligand A (46.103) regarding liver toxicity risk. This is a major advantage for Ligand B.
7. **BBB:** Ligand A (74.719) has a better BBB penetration percentile than Ligand B (66.925). While ADRB2 isn't necessarily a CNS target, some peripheral ADRB2 activity can be modulated by CNS effects, and higher BBB is generally favorable.
8. **Caco-2:** Both have negative values, indicating poor permeability.
9. **Solubility:** Ligand B (0.469) is better than Ligand A (-2.63), which is a significant advantage.
10. **hERG:** Both are low, indicating low cardiotoxicity risk.
11. **Cl_mic:** Ligand A (17.899) has a lower microsomal clearance, suggesting better metabolic stability than Ligand B (29.959).
12. **t1/2:** Both have very negative in vitro half-life values, indicating very short half-lives.
13. **Pgp:** Both are low, suggesting minimal P-gp efflux.
14. **Affinity:** Ligand A (-7.0) has a slightly better binding affinity than Ligand B (-6.6), though the difference is relatively small.
**Overall Assessment:**
While Ligand A has a slightly better affinity and BBB penetration, Ligand B is significantly better in several critical ADME properties: DILI risk and solubility. The low logP of Ligand B is a major concern, potentially limiting its absorption. However, the substantial reduction in DILI risk and improved solubility outweigh the slightly lower affinity and BBB penetration. The metabolic stability is slightly worse for Ligand B, but this can be addressed through structural modifications.
Therefore, I would prioritize Ligand B for further development.
Output:
0
2025-04-17 22:12:58,181 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (a cardiovascular GPCR) drug candidates.
**Ligand A:** [391.559, 99.56, 1.072, 2, 6, 0.603, 36.254, 65.374, -5.69, -2.114, 0.304, 10.575, 27.8, 0.064, -7.8]
**Ligand B:** [381.885, 85.43, 2.353, 3, 4, 0.743, 55.642, 25.708, -5.198, -3.521, 0.525, 8.096, -12.121, 0.241, -6.7]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (381.885) is slightly lower, which is generally favorable.
2. **TPSA:** Ligand A (99.56) is a bit higher than Ligand B (85.43). Both are acceptable for a cardiovascular target, but lower is better for permeability. Ligand B is preferable here.
3. **logP:** Ligand A (1.072) is at the lower end of the optimal range, while Ligand B (2.353) is more centrally located. Ligand B is better for membrane permeability.
4. **HBD:** Ligand A (2) is better than Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (6) is better than Ligand B (4). Lower HBA is preferable.
6. **QED:** Ligand B (0.743) has a better QED score than Ligand A (0.603), indicating a more drug-like profile.
7. **DILI:** Ligand A (36.254) has a significantly lower DILI risk than Ligand B (55.642). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (65.374) has a better BBB penetration score than Ligand B (25.708). While not a CNS target, some BBB penetration can be beneficial for distribution.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. Ligand A (-5.69) is slightly better than Ligand B (-5.198), but both are concerning.
10. **Solubility:** Ligand A (-2.114) has better solubility than Ligand B (-3.521).
11. **hERG:** Ligand A (0.304) has a lower hERG risk than Ligand B (0.525). This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand A (10.575) has a higher microsomal clearance than Ligand B (8.096), indicating faster metabolism. Ligand B is preferable here.
13. **t1/2:** Ligand B (-12.121) has a longer in vitro half-life than Ligand A (27.8). This is a major advantage for Ligand B.
14. **Pgp:** Ligand A (0.064) has lower P-gp efflux than Ligand B (0.241), which is preferable.
15. **Affinity:** Ligand A (-7.8) has a better binding affinity than Ligand B (-6.7). This is a substantial advantage for Ligand A.
**GPCR-Specific Priorities:** For ADRB2 (a cardiovascular GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B has better logP and TPSA, while Ligand A has better Pgp and significantly better affinity.
**Overall Assessment:**
Ligand A has a stronger binding affinity and lower DILI and hERG risk, which are crucial for a safe and effective drug. While Ligand B has a better QED and half-life, the superior affinity and safety profile of Ligand A outweigh these benefits. The Caco-2 permeability is a concern for both, but the potency advantage of Ligand A is significant.
Output:
1
2025-04-17 22:12:58,182 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Ligand A (354.4) is within the ideal range (200-500), while Ligand B (389.7) is at the higher end but still acceptable.
2. **TPSA:** Ligand A (122.04) is slightly above the optimal <140 for oral absorption, but not drastically. Ligand B (75.48) is excellent, well below 140.
3. **logP:** Ligand A (-0.553) is a bit low, potentially hindering permeability. Ligand B (3.548) is optimal. This is a significant advantage for B, given ADRB2 is a GPCR.
4. **HBD:** Ligand A (2) is good. Ligand B (1) is also good.
5. **HBA:** Ligand A (5) is good. Ligand B (4) is also good.
6. **QED:** Ligand A (0.605) is good, indicating drug-likeness. Ligand B (0.419) is lower, suggesting a less ideal drug-like profile.
7. **DILI:** Ligand A (30.83) has a much lower DILI risk than Ligand B (76.89). This is a significant advantage for A.
8. **BBB:** Ligand A (81.82) is good, while Ligand B (71.54) is acceptable but lower. While ADRB2 isn't necessarily a CNS target, some peripheral ADRB2 activity can influence CNS pathways, so some BBB penetration isn't detrimental.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Both ligands have negative solubility values, which is also unusual. Again, the scale is not specified.
11. **hERG:** Ligand A (0.066) has a very low hERG risk, which is excellent. Ligand B (0.709) is higher, indicating a potential for cardiotoxicity.
12. **Cl_mic:** Ligand A (1.864) has a much lower microsomal clearance, suggesting better metabolic stability. Ligand B (73.89) is very high, indicating rapid metabolism.
13. **t1/2:** Ligand A (-25.622) has a negative in vitro half-life, which is not possible and suggests an issue with the data. Ligand B (55.839) is good.
14. **Pgp:** Ligand A (0.002) has very low P-gp efflux, which is favorable. Ligand B (0.226) is also low.
15. **Affinity:** Ligand B (-7.4) has a significantly stronger binding affinity than Ligand A (-5.5). This is a substantial advantage, potentially outweighing some ADME concerns.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp efflux, and binding affinity are key. Ligand B excels in logP and affinity. Ligand A has better DILI and hERG profiles, and lower Pgp efflux. The negative half-life for Ligand A is a major red flag.
**Overall Assessment:**
Despite the strong affinity of Ligand B, the extremely high microsomal clearance and the questionable half-life data for Ligand A are concerning. The DILI and hERG profiles of Ligand A are significantly better, which is crucial for a cardiovascular target. However, the negative half-life is a dealbreaker. Given the substantial affinity advantage of Ligand B, and the fact that metabolic stability can be improved through structural modifications, I would lean towards Ligand B.
Output:
0
2025-04-17 22:12:58,182 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (369.447) is slightly higher than Ligand B (350.394), but both are acceptable.
2. **TPSA:** Ligand B (84.42) is significantly better than Ligand A (104.61). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (1.535) is within the optimal range (1-3), while Ligand A (-0.827) is below 1, which could hinder permeation. This is a significant advantage for Ligand B.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand B (6) is slightly better than Ligand A (7), but both are within the acceptable limit of 10.
6. **QED:** Both ligands have similar QED values (0.702 and 0.716), indicating good drug-likeness.
7. **DILI:** Both ligands have similar DILI risk (56.844 and 57.387), and are within an acceptable range (<60 is good).
8. **BBB:** Ligand B (92.943) has a much higher BBB penetration percentile than Ligand A (64.986). While not critical for a cardiovascular target, higher BBB is generally not detrimental.
9. **Caco-2:** Ligand B (-4.41) is slightly better than Ligand A (-5.306), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-1.836) is better than Ligand B (-3.303), which is a positive attribute.
11. **hERG:** Ligand A (0.083) has a slightly lower hERG risk than Ligand B (0.44), which is preferable.
12. **Cl_mic:** Ligand A (-22.47) has a significantly lower (better) microsomal clearance than Ligand B (94.46). This suggests greater metabolic stability for Ligand A.
13. **t1/2:** Ligand A (22.12) has a longer in vitro half-life than Ligand B (-2.959), which is a significant advantage.
14. **Pgp:** Ligand B (0.096) has a lower Pgp efflux liability than Ligand A (0.009), which is preferable.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.7 and -6.5 kcal/mol). The difference is not substantial enough to be a deciding factor.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP and Pgp, and has a better TPSA. Ligand A has better metabolic stability (Cl_mic and t1/2) and slightly lower hERG risk. The affinity is comparable.
**Overall Assessment:**
While Ligand A has advantages in metabolic stability and hERG, the significantly better logP and Pgp properties of Ligand B are more crucial for a GPCR target. The improved TPSA and Caco-2 permeability also contribute to better absorption potential. The slightly longer half-life of Ligand A is a benefit, but can potentially be addressed through formulation strategies.
Therefore, I favor Ligand B.
Output:
0
2025-04-17 22:12:58,182 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (340.427 and 338.411 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (88.32) is slightly higher than Ligand B (66.71). Both are below the 140 threshold for oral absorption, but Ligand B is better positioned, especially considering ADRB2 is a GPCR and CNS penetration might be desirable in some contexts.
3. **logP:** Both ligands have good logP values (2.075 and 2.165) falling within the optimal 1-3 range. No significant difference.
4. **HBD:** Ligand A has 2 HBD, while Ligand B has 1. Both are acceptable (<=5).
5. **HBA:** Both ligands have 4 HBA, which is well within the acceptable limit of 10. No significant difference.
6. **QED:** Both ligands have similar QED scores (0.892 and 0.869), indicating good drug-likeness.
7. **DILI:** Ligand A (55.642) has a slightly better DILI risk profile than Ligand B (64.831), both are acceptable, but lower is better.
8. **BBB:** Ligand A (87.864) has a significantly better BBB penetration percentile than Ligand B (60.838). This is a key advantage for a GPCR target, as CNS effects are possible.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.165 and -5.025), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Both ligands have very poor aqueous solubility (-2.931 and -3.418). This is a major drawback and will require formulation strategies.
11. **hERG:** Both ligands have low hERG inhibition liability (0.61 and 0.323), which is good. Ligand B is slightly better.
12. **Cl_mic:** Ligand A (30.832) has a lower microsomal clearance than Ligand B (55.044), indicating better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand A (13.171) has a longer in vitro half-life than Ligand B (-5.922). This is a substantial advantage.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.058 and 0.084), which is favorable.
15. **Binding Affinity:** Ligand B (-6.4) has a slightly better binding affinity than Ligand A (-6.0). This is a 0.4 kcal/mol difference, which is not huge but noticeable.
**Overall Assessment & GPCR Prioritization:**
For an ADRB2 GPCR, affinity, logP, TPSA, Pgp, and BBB are particularly important. While Ligand B has a slightly better affinity, Ligand A excels in several other crucial areas: significantly better BBB penetration, lower microsomal clearance (better metabolic stability), and a longer half-life. The poor Caco-2 and solubility are problematic for both, but can be addressed with formulation. The slight advantage in DILI risk for Ligand A is also a plus. The better BBB penetration of Ligand A is a significant advantage for a GPCR.
Therefore, I favor Ligand A.
Output:
1
2025-04-17 22:12:58,182 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (437.344 Da) is within the ideal range, while Ligand B (358.473 Da) is towards the lower end but still acceptable.
2. **TPSA:** Ligand A (94.88) is slightly above the optimal <90 for CNS targets, but still reasonable for a peripherally acting GPCR like ADRB2. Ligand B (40.62) is excellent, well below the threshold.
3. **logP:** Both ligands have good logP values (A: 4.163, B: 3.552), within the 1-3 range. Ligand A is slightly higher, potentially increasing off-target interactions.
4. **HBD:** Ligand A (2) is good. Ligand B (0) is also good, potentially improving membrane permeability.
5. **HBA:** Ligand A (6) is good. Ligand B (2) is excellent.
6. **QED:** Both ligands have good QED scores (A: 0.625, B: 0.754), indicating drug-likeness. Ligand B is slightly better.
7. **DILI:** Ligand A (97.518) has a very high DILI risk, which is a significant concern. Ligand B (26.444) has a very low DILI risk, a major advantage.
8. **BBB:** Ligand A (37.611) has low BBB penetration, which is acceptable for a cardiovascular target. Ligand B (87.088) has high BBB penetration, which isn't particularly beneficial for ADRB2, but not necessarily detrimental.
9. **Caco-2:** Both have negative Caco-2 values which is unusual and suggests poor permeability.
10. **Solubility:** Both have negative solubility values which is unusual and suggests poor solubility.
11. **hERG:** Ligand A (0.739) has a slightly higher hERG risk than Ligand B (0.825), but both are relatively low.
12. **Cl_mic:** Ligand A (14.17) has a lower (better) microsomal clearance than Ligand B (50.663), indicating better metabolic stability.
13. **t1/2:** Ligand A (136.869) has a much longer in vitro half-life than Ligand B (-16.149), which is a significant advantage.
14. **Pgp:** Ligand A (0.299) has lower P-gp efflux than Ligand B (0.254), which is favorable.
15. **Affinity:** Ligand A (-6.9 kcal/mol) has significantly stronger binding affinity than Ligand B (-1.9 kcal/mol). This is a substantial advantage.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), affinity, logP, TPSA, and Pgp are key. Ligand A excels in affinity and has acceptable logP and TPSA. However, the extremely high DILI risk is a major red flag. Ligand B has a much better safety profile (DILI) and good TPSA, but significantly weaker affinity.
**Overall Assessment:**
The difference in binding affinity (-6.9 vs -1.9 kcal/mol) is substantial. While Ligand A's DILI risk is concerning, the potency advantage is significant enough to potentially overcome this with further optimization. The longer half-life of Ligand A is also a plus. Ligand B, while safer, is unlikely to be efficacious due to its weak binding.
Output:
1
2025-04-17 22:12:58,182 - INFO - Here's a step-by-step reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [336.435, 52.57, 2.935, 2, 3, 0.848, 37.767, 85.459, -4.617, -3.394, 0.888, 10.772, 42.827, 0.371, -6.3]**
**Ligand B: [355.454, 87.3, 1.299, 3, 3, 0.671, 19.969, 71.927, -5.14, -2.263, 0.193, 24.184, -4.452, 0.017, -7.5]**
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). A (336.435) is slightly preferred.
2. **TPSA:** A (52.57) is excellent, well below the 140 threshold for oral absorption. B (87.3) is still reasonable, but less optimal.
3. **logP:** A (2.935) is optimal. B (1.299) is a bit low, potentially causing permeability issues.
4. **H-Bond Donors:** Both have acceptable HBD counts (A: 2, B: 3).
5. **H-Bond Acceptors:** Both have acceptable HBA counts (A: 3, B: 3).
6. **QED:** A (0.848) is excellent, indicating high drug-likeness. B (0.671) is still acceptable, but lower.
7. **DILI:** A (37.767) is very good, indicating low liver injury risk. B (19.969) is excellent, even lower risk.
8. **BBB:** A (85.459) is very good, suggesting decent brain penetration. B (71.927) is also good, but lower. Given ADRB2 is expressed in the CNS, this is a relevant factor.
9. **Caco-2:** Both are negative, which is unusual. This indicates poor permeability. A (-4.617) is worse than B (-5.14).
10. **Solubility:** Both are negative, which is unusual. A (-3.394) is slightly better than B (-2.263).
11. **hERG:** A (0.888) is better than B (0.193), indicating lower cardiotoxicity risk.
12. **Cl_mic:** A (10.772) is better than B (24.184), indicating better metabolic stability.
13. **t1/2:** A (42.827) is better than B (-4.452), indicating a longer half-life.
14. **Pgp:** A (0.371) is better than B (0.017), indicating lower P-gp efflux.
15. **Binding Affinity:** B (-7.5) is significantly better than A (-6.3), a difference of 1.2 kcal/mol. This is a substantial advantage.
**Overall Assessment:**
Ligand B has a significantly better binding affinity (-7.5 vs -6.3 kcal/mol). This is a major advantage for a GPCR target. While Ligand A has better scores for several ADME properties (QED, DILI, BBB, Cl_mic, t1/2, Pgp), the affinity difference is large enough to outweigh these concerns, especially considering the potential for further optimization of ADME properties. The Caco-2 and solubility values are concerning for both, but can be addressed through formulation strategies. The lower logP of B is a potential drawback, but not insurmountable.
Therefore, I would prioritize Ligand B due to its superior binding affinity.
Output:
0
2025-04-17 22:12:58,182 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
The target is ADRB2, a GPCR. Therefore, I will prioritize logP, Pgp, TPSA, and binding affinity, alongside general drug-like properties.
* **Molecular Weight:** Both ligands are within the ideal range (200-500 Da).
* **TPSA:** Ligand B (29.54) is significantly better than Ligand A (115.39). Lower TPSA generally correlates with better cell permeability, crucial for GPCR targeting.
* **logP:** Ligand B (4.604) is higher than the optimal range (1-3), but still potentially manageable. Ligand A (0.306) is *too* low, potentially hindering membrane permeability.
* **H-Bond Donors/Acceptors:** Ligand A has 3 HBD and 5 HBA, while Ligand B has 0 HBD and 2 HBA. Both are within acceptable limits, but Ligand B's lower count may be slightly favorable for permeability.
* **QED:** Both ligands have acceptable QED scores (0.72 and 0.57).
* **DILI:** Ligand B (18.651) has a much lower DILI risk than Ligand A (74.99), a significant advantage.
* **BBB:** Ligand B (96.123) has excellent BBB penetration, while Ligand A (32.765) is poor. While ADRB2 isn't exclusively a CNS target, some peripheral ADRB2 activity can be modulated by CNS effects, and better BBB penetration is generally a plus.
* **Caco-2 Permeability:** Ligand A (-5.504) is very poor, while Ligand B (-4.131) is also poor, but better than A.
* **Aqueous Solubility:** Ligand A (-2.731) is poor, while Ligand B (-4.83) is also poor.
* **hERG:** Ligand A (0.595) has a slightly better hERG profile than Ligand B (0.898), but both are reasonably low risk.
* **Microsomal Clearance:** Ligand B (81.855) has a higher clearance than Ligand A (34.908), indicating faster metabolism and potentially lower *in vivo* exposure.
* **In vitro Half-Life:** Ligand A (-39.788) has a much longer half-life than Ligand B (28.122). This is a positive for Ligand A.
* **P-gp Efflux:** Ligand A (0.034) has lower P-gp efflux than Ligand B (0.641), which is favorable.
* **Binding Affinity:** Ligand A (-7.7 kcal/mol) has a slightly better binding affinity than Ligand B (-6.6 kcal/mol), a 1.1 kcal/mol difference.
**Overall Assessment:**
While Ligand A has slightly better binding affinity and a longer half-life, the significant advantages of Ligand B in TPSA, DILI risk, BBB penetration, and P-gp efflux outweigh these factors. Ligand A's very low logP and poor Caco-2 permeability are major concerns. The improved safety profile (lower DILI) of Ligand B is also a critical consideration. Given the GPCR target class, the balance of properties in Ligand B makes it a more promising drug candidate.
**Output:**
0
2025-04-17 22:12:58,182 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
Let's break down the comparison, prioritizing GPCR-relevant parameters (logP, TPSA, Pgp, BBB, and affinity).
1. **Molecular Weight:** Both ligands (357.451 and 345.443 Da) fall comfortably within the ideal 200-500 Da range.
2. **TPSA:** Ligand B (66.65) is significantly better than Ligand A (96.97). Lower TPSA generally favors oral absorption and is particularly important for GPCRs.
3. **logP:** Ligand B (2.827) is closer to the optimal 1-3 range than Ligand A (0.899). Ligand A's logP is a bit low, potentially hindering membrane permeability.
4. **H-Bond Donors/Acceptors:** Ligand A has 2 HBD and 5 HBA, while Ligand B has 0 HBD and 4 HBA. Both are acceptable, but Ligand B's lower HBD count is slightly preferable for permeability.
5. **QED:** Both ligands have good QED scores (0.706 and 0.77), indicating good drug-like properties.
6. **DILI:** Ligand B (56.301) has a slightly higher DILI risk than Ligand A (29.624), but both are below the concerning threshold of 60.
7. **BBB:** Ligand B (85.537) has a much better BBB penetration score than Ligand A (59.868). While ADRB2 isn't exclusively a CNS target, some CNS exposure can occur, and higher BBB penetration is generally favorable.
8. **Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.787 and -4.68). This is unusual and suggests poor permeability. However, these values are very close and don't significantly differentiate the compounds.
9. **Aqueous Solubility:** Ligand A (-1.162) has better aqueous solubility than Ligand B (-3.316). Solubility is important for formulation, but less critical than permeability for a GPCR.
10. **hERG Inhibition:** Both ligands have low hERG inhibition risk (0.188 and 0.303).
11. **Microsomal Clearance:** Ligand B (70.331) has significantly higher microsomal clearance than Ligand A (21.909), indicating faster metabolism and potentially lower *in vivo* exposure.
12. **In vitro Half-Life:** Both have negative half-lives (-25.034 and -25.206). This is also unusual and suggests rapid degradation.
13. **P-gp Efflux:** Ligand A (0.008) has very low P-gp efflux, which is excellent. Ligand B (0.457) has moderate P-gp efflux.
14. **Binding Affinity:** Ligand A (-6.7 kcal/mol) has a slightly better binding affinity than Ligand B (-5.1 kcal/mol). This is a 1.6 kcal/mol difference, which is significant.
**Overall Assessment:**
Despite Ligand A's slightly better affinity and P-gp profile, Ligand B is the more promising candidate. The lower TPSA, better logP, and significantly better BBB penetration of Ligand B are crucial advantages for a GPCR target. While Ligand B has higher DILI risk and clearance, these are less critical concerns compared to permeability and brain exposure. The negative Caco-2 and half-life values are concerning for both, but don't differentiate them. The affinity difference, while notable, can potentially be optimized during lead optimization.
**Output:**
0
2025-04-17 22:12:58,182 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 drug candidates. ADRB2 is a GPCR, so we'll prioritize logP, Pgp, TPSA, and affinity, alongside general drug-like properties.
**Ligand A:**
* **MW:** 362.861 Da - Acceptable.
* **TPSA:** 94.88 - Acceptable, but approaching the upper limit for good absorption.
* **logP:** 3.208 - Excellent. Within the optimal range.
* **HBD:** 2 - Good.
* **HBA:** 4 - Good.
* **QED:** 0.728 - Excellent. Highly drug-like.
* **DILI:** 38.658 - Very good. Low risk.
* **BBB:** 74.176 - Good. Reasonable potential for some CNS penetration, though not exceptionally high.
* **Caco-2:** -4.829 - Concerningly low. Suggests poor intestinal absorption.
* **Solubility:** -3.987 - Very poor. A significant drawback.
* **hERG:** 0.466 - Low risk.
* **Cl_mic:** 35.856 - Moderate. Not ideal, but not terrible.
* **t1/2:** 27.131 - Good.
* **Pgp:** 0.032 - Very low efflux. Excellent.
* **Affinity:** -5.5 kcal/mol - Good.
**Ligand B:**
* **MW:** 347.459 Da - Acceptable.
* **TPSA:** 73.64 - Excellent. Well within the optimal range for absorption.
* **logP:** 1.945 - Good, but on the lower side of optimal.
* **HBD:** 0 - Good.
* **HBA:** 4 - Good.
* **QED:** 0.736 - Excellent. Highly drug-like.
* **DILI:** 22.489 - Excellent. Very low risk.
* **BBB:** 83.404 - Very good. Good potential for CNS penetration.
* **Caco-2:** -4.507 - Concerningly low. Suggests poor intestinal absorption.
* **Solubility:** -2.738 - Poor, but better than Ligand A.
* **hERG:** 0.546 - Low risk.
* **Cl_mic:** 49.309 - Higher than Ligand A, suggesting lower metabolic stability.
* **t1/2:** -17.556 - Very poor. A major drawback.
* **Pgp:** 0.145 - Low efflux. Good.
* **Affinity:** -6.7 kcal/mol - Excellent. Significantly better than Ligand A.
**Comparison and Decision:**
The key differences are in affinity, solubility, Caco-2 permeability, and metabolic stability. Ligand B has a significantly better binding affinity (-6.7 vs -5.5 kcal/mol), which is a major advantage for a GPCR target. However, it has a very poor *in vitro* half-life. Ligand A has better metabolic stability but suffers from very poor solubility and Caco-2 permeability.
Considering the ADRB2 target is cardiovascular (not CNS), BBB is less critical. While both have poor Caco-2 permeability, the significantly stronger binding affinity of Ligand B is a compelling factor. Poor solubility and permeability can sometimes be addressed through formulation strategies, but a 1.2 kcal/mol difference in binding affinity is substantial and harder to overcome through chemical modifications. The poor half-life of Ligand B is a concern, but could potentially be addressed through structural modifications.
Therefore, I believe Ligand B is the more promising candidate, despite its drawbacks, due to its superior binding affinity.
0
2025-04-17 22:12:58,182 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Ligand A (337.47 Da) is within the ideal range, while Ligand B (404.36 Da) is at the higher end but still acceptable.
2. **TPSA:** Ligand A (54.02) is excellent, well below the 140 threshold, and suitable for good absorption. Ligand B (47.36) is also very good.
3. **logP:** Ligand A (3.883) is within the optimal range. Ligand B (4.636) is slightly higher, potentially increasing off-target effects, but still within a manageable range.
4. **HBD:** Ligand A (2) is good. Ligand B (0) is also good.
5. **HBA:** Ligand A (2) is good. Ligand B (5) is acceptable, but higher.
6. **QED:** Ligand A (0.87) is excellent, indicating high drug-likeness. Ligand B (0.573) is acceptable, but lower.
7. **DILI:** Ligand A (38.62) has a lower DILI risk than Ligand B (47.732), which is preferable.
8. **BBB:** Ligand A (80.419) shows better BBB penetration than Ligand B (71.229), which is important for GPCRs.
9. **Caco-2:** Ligand A (-4.632) is better than Ligand B (-5.021), suggesting better intestinal absorption.
10. **Solubility:** Ligand A (-4.093) is better than Ligand B (-3.635), which is important for bioavailability.
11. **hERG:** Ligand A (0.846) has a lower hERG risk than Ligand B (0.693), which is crucial for cardiovascular safety.
12. **Cl_mic:** Ligand A (29.42) has lower microsomal clearance than Ligand B (71.94), indicating better metabolic stability.
13. **t1/2:** Ligand A (33.684) has a shorter half-life than Ligand B (77.62), but it's still acceptable.
14. **Pgp:** Ligand A (0.199) has lower P-gp efflux than Ligand B (0.851), which is beneficial for bioavailability.
15. **Affinity:** Ligand A (-7.2 kcal/mol) has a slightly better binding affinity than Ligand B (-6.0 kcal/mol). The difference is 1.2 kcal/mol, which is significant.
**GPCR-specific priorities:**
Given that ADRB2 is a GPCR, I prioritize logP, Pgp, TPSA, and affinity. Ligand A performs better across these parameters, and also has a better overall ADME profile.
**Conclusion:**
Ligand A is the more promising drug candidate due to its superior drug-likeness, lower DILI risk, better BBB penetration, lower hERG risk, better metabolic stability, lower P-gp efflux, and slightly stronger binding affinity. While Ligand B has a longer half-life, the other advantages of Ligand A outweigh this single benefit.
Output:
1
2025-04-17 22:12:58,183 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.405 and 343.427 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (40.54) is significantly better than Ligand B (102.22). ADRB2 is not a CNS target, but lower TPSA generally improves absorption. Ligand A is well below the 140 threshold, while B is pushing it.
3. **logP:** Both ligands have good logP values (3.322 and 3.008), falling within the optimal 1-3 range. Very similar.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (2) is preferable to Ligand B (4) for similar reasons as HBD.
6. **QED:** Ligand A (0.908) has a substantially better QED score than Ligand B (0.739), indicating a more drug-like profile.
7. **DILI:** Ligand A (11.206) has a much lower DILI risk than Ligand B (19.659). This is a significant advantage for Ligand A.
8. **BBB:** BBB is less critical for ADRB2, but Ligand A (89.027) is better than Ligand B (49.748).
9. **Caco-2:** Ligand A (-4.65) is better than Ligand B (-5.106). Higher values indicate better intestinal absorption.
10. **Solubility:** Ligand A (-3.727) is better than Ligand B (-4.1). Higher values indicate better solubility.
11. **hERG:** Both ligands have low hERG inhibition liability (0.688 and 0.455), which is good.
12. **Cl_mic:** Ligand A (23.104) has a significantly lower microsomal clearance than Ligand B (41.023), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-9.076) has a better in vitro half-life than Ligand B (-5.791).
14. **Pgp:** Ligand A (0.073) has a lower Pgp efflux liability than Ligand B (0.017).
15. **Binding Affinity:** Both ligands have the same binding affinity (-6.3 kcal/mol).
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most ADME properties (TPSA, HBD, HBA, QED, DILI, Cl_mic, t1/2, Pgp, solubility, and Caco-2 permeability). While both have acceptable logP and hERG values, and identical binding affinity, the superior ADME profile of Ligand A makes it the more promising drug candidate. The lower DILI risk and improved metabolic stability are particularly important.
Output:
1
2025-04-17 22:12:58,183 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [347.375, 127.51 , -1.055, 2. , 6. , 0.675, 61.729, 59.674, -5.525, -1.765, 0.061, -16.099, 0.277, 0.002, -5.3 ]
**Ligand B:** [350.478, 40.62 , 3.156, 0. , 2. , 0.784, 19.814, 85.925, -4.557, -3.357, 0.761, 55.915, -6.633, 0.227, -6.8 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (347.375) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (127.51) is higher than Ligand B (40.62). For a cardiovascular GPCR, TPSA isn't *as* critical as for CNS targets, but lower is still preferred for better absorption. Ligand B is significantly better here.
3. **logP:** Ligand A (-1.055) is lower than the optimal 1-3 range, potentially hindering permeation. Ligand B (3.156) is within the optimal range. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (2) and Ligand B (0) are both acceptable.
5. **HBA:** Ligand A (6) and Ligand B (2) are both acceptable.
6. **QED:** Both ligands have good QED scores (A: 0.675, B: 0.784), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (61.729) has a higher DILI risk than Ligand B (19.814). This is a major concern for Ligand A.
8. **BBB:** Ligand B (85.925) has a much higher BBB penetration potential than Ligand A (59.674). While ADRB2 isn't exclusively a CNS target, some CNS exposure can occur, and higher BBB is generally favorable.
9. **Caco-2:** Ligand A (-5.525) and Ligand B (-4.557) are both poor, but Ligand B is slightly better.
10. **Solubility:** Ligand A (-1.765) and Ligand B (-3.357) are both poor, but Ligand B is slightly better.
11. **hERG:** Ligand A (0.061) has a slightly lower hERG risk than Ligand B (0.761), but both are relatively low.
12. **Cl_mic:** Ligand A (-16.099) has a much lower (better) microsomal clearance than Ligand B (55.915), suggesting better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand B (-6.633) has a longer half-life than Ligand A (0.277). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.002) has a much lower Pgp efflux liability than Ligand B (0.227), indicating better absorption and potentially better CNS exposure. This is a significant advantage for Ligand A.
15. **Affinity:** Ligand B (-6.8) has a slightly better binding affinity than Ligand A (-5.3). This is a good advantage for Ligand B.
**GPCR-Specific Priorities:** For ADRB2 (a cardiovascular GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP and affinity, and has a much lower TPSA. Ligand A has better Pgp efflux, but this is outweighed by its poor logP and higher DILI risk. The better metabolic stability of Ligand A is a plus, but not enough to overcome the other drawbacks.
**Conclusion:**
Considering the balance of properties, especially the crucial GPCR-specific parameters, Ligand B is the more promising drug candidate.
0
2025-04-17 22:12:58,183 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (338.411 and 348.399 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (69.3) is significantly better than Ligand B (103.01). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (2.346) is optimal, while Ligand B (0.572) is a bit low. A logP below 1 can hinder membrane permeability. Ligand A is preferred.
4. **HBD:** Ligand A (1) is better than Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (3) is better than Ligand B (5). Fewer HBAs generally improve permeability.
6. **QED:** Both are reasonably good (0.855 and 0.722), exceeding the 0.5 threshold. Ligand A is slightly better.
7. **DILI:** Ligand B (27.142) has a much lower DILI risk than Ligand A (59.636). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (48.662) is better than Ligand B (38.852), but BBB isn't a high priority for a cardiovascular target.
9. **Caco-2:** Both are negative (-5.058 and -5.145), indicating poor permeability. This is a concern for both, but not a deciding factor.
10. **Solubility:** Ligand A (-3.497) is better than Ligand B (-1.553), indicating better solubility.
11. **hERG:** Both are very low (0.493 and 0.267), indicating low cardiotoxicity risk. No clear advantage.
12. **Cl_mic:** Ligand B (-23.636) has a significantly lower (better) microsomal clearance than Ligand A (29.601). This suggests better metabolic stability for Ligand B.
13. **t1/2:** Ligand B (46.368) has a much longer in vitro half-life than Ligand A (-12.613). This is a major advantage for Ligand B.
14. **Pgp:** Both are very low (0.094 and 0.013), indicating low P-gp efflux. No clear advantage.
15. **Binding Affinity:** Ligand B (-9.5) has a substantially stronger binding affinity than Ligand A (-6.6). This is a 2.9 kcal/mol difference, which is a significant advantage that can outweigh some ADME concerns.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, affinity, and Pgp. Ligand A excels in logP and TPSA, but Ligand B *significantly* wins on affinity. The difference in affinity is large enough to compensate for the slightly higher TPSA and lower logP of Ligand B. The improved metabolic stability (lower Cl_mic and longer t1/2) and lower DILI risk of Ligand B are also very favorable.
**Conclusion:**
Despite Ligand A's better TPSA and logP, Ligand B's superior binding affinity, metabolic stability, lower DILI risk, and longer half-life make it the more promising drug candidate.
Output:
0
2025-04-17 22:12:58,183 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (380.187 Da) is slightly higher than Ligand B (347.365 Da), but both are acceptable.
2. **TPSA:** Ligand A (98.34) is higher than Ligand B (63.25). For a cardiovascular GPCR like ADRB2, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B has a more favorable TPSA.
3. **logP:** Both ligands have good logP values (A: 4.062, B: 3.032), falling within the optimal 1-3 range. Ligand B is slightly better, being closer to the ideal range.
4. **HBD:** Ligand A (1) and Ligand B (2) are both within the acceptable limit of 5.
5. **HBA:** Ligand A (7) and Ligand B (3) are both within the acceptable limit of 10. Ligand B is better.
6. **QED:** Both ligands have good QED scores (A: 0.682, B: 0.874), indicating good drug-like properties. Ligand B is superior here.
7. **DILI:** Ligand A (95.89) has a significantly higher DILI risk than Ligand B (61.07). This is a major concern for Ligand A.
8. **BBB:** This is less critical for a cardiovascular target. Ligand A (37.495) and Ligand B (86.817). Ligand B is better.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.691) is slightly worse than Ligand B (-4.25).
10. **Solubility:** Both ligands have negative solubility values, which is also unusual and suggests poor solubility. Ligand A (-4.892) is slightly worse than Ligand B (-3.926).
11. **hERG:** Both ligands have low hERG inhibition liability (A: 0.202, B: 0.274), which is good.
12. **Cl_mic:** Ligand A (90.975) has a higher microsomal clearance than Ligand B (56.877), indicating lower metabolic stability.
13. **t1/2:** Ligand A (-27.16) has a more negative in vitro half-life than Ligand B (-25.522), which is worse.
14. **Pgp:** Both ligands have low Pgp efflux liability (A: 0.135, B: 0.099), which is good.
15. **Binding Affinity:** Ligand A (-6.7 kcal/mol) has a slightly better binding affinity than Ligand B (-5.6 kcal/mol). This is a 1.1 kcal/mol difference, which is significant.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity, its significantly higher DILI risk, higher Cl_mic, worse t1/2, and worse TPSA/Solubility make it a less desirable candidate. Ligand B demonstrates a better balance of properties, particularly regarding safety (lower DILI) and ADME characteristics. The affinity difference, while notable, is likely surmountable with further optimization, whereas mitigating the DILI risk of Ligand A would be a substantial challenge. Given the GPCR-specific priorities (logP, Pgp, TPSA, affinity), Ligand B is the more promising starting point.
Output:
0
2025-04-17 22:12:58,183 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (364.877 Da) and Ligand B (341.371 Da) both fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (83.62) and Ligand B (79.51) are both well below the 140 A^2 threshold for good oral absorption, and suitable for a GPCR. Ligand B is slightly better.
3. **logP:** Ligand A (1.785) is within the optimal 1-3 range. Ligand B (0.783) is a bit low, potentially impacting permeability. Ligand A is favored.
4. **HBD:** Ligand A (2) and Ligand B (0) are both acceptable. Ligand B is slightly better.
5. **HBA:** Both Ligand A (6) and Ligand B (6) are below the 10 threshold. No clear advantage.
6. **QED:** Ligand A (0.847) has a better QED score than Ligand B (0.61), indicating a more drug-like profile. Ligand A is favored.
7. **DILI:** Ligand B (62.737) has a slightly higher DILI risk than Ligand A (47.887), but both are acceptable (<60 is good). Ligand A is favored.
8. **BBB:** Both Ligand A (63.784) and Ligand B (63.552) have similar BBB penetration, which is not a high priority for ADRB2 (a cardiovascular target).
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability.
10. **Solubility:** Ligand B (-1.574) has better solubility than Ligand A (-3.348). Ligand B is favored.
11. **hERG:** Ligand A (0.906) has a slightly higher hERG risk than Ligand B (0.351). Ligand B is favored.
12. **Cl_mic:** Ligand A (12.124) has a significantly lower microsomal clearance than Ligand B (26.659), suggesting better metabolic stability. Ligand A is favored.
13. **t1/2:** Ligand A (16.925) has a longer in vitro half-life than Ligand B (-13.104). Ligand A is favored.
14. **Pgp:** Ligand A (0.391) has lower P-gp efflux liability than Ligand B (0.06), which is favorable for bioavailability. Ligand A is favored.
15. **Binding Affinity:** Ligand A (-7.5 kcal/mol) has a stronger binding affinity than Ligand B (-6.7 kcal/mol). This 1.8 kcal/mol difference is substantial and outweighs many of the minor drawbacks of Ligand A. Ligand A is strongly favored.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical parameters, particularly in binding affinity, metabolic stability (Cl_mic, t1/2), QED, and DILI risk. While Ligand B has slightly better solubility and hERG risk, the substantial advantage in affinity and overall drug-likeness of Ligand A makes it the more promising candidate.
Output:
1
2025-04-17 22:12:58,183 - INFO - Batch 315 complete. Total preferences: 5040
2025-04-17 22:12:58,183 - INFO - Processing batch 316/512...
2025-04-17 22:13:51,721 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (344.455 and 344.411 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (60.45) is significantly better than Ligand B (71.78). For a GPCR, lower TPSA is generally preferred for better permeability.
3. **logP:** Ligand A (3.972) is at the higher end of the optimal range, while Ligand B (1.797) is at the lower end. ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but a slightly higher logP can be beneficial for membrane permeability.
4. **HBD:** Both ligands have 1 HBD, which is within the acceptable limit of 5.
5. **HBA:** Both ligands have 4 HBA, which is within the acceptable limit of 10.
6. **QED:** Ligand B (0.799) has a slightly better QED score than Ligand A (0.61), suggesting a more inherently drug-like profile.
7. **DILI:** Ligand B (29.818) has a *much* lower DILI risk than Ligand A (54.401). This is a major advantage for Ligand B.
8. **BBB:** Ligand A (82.9) has a higher BBB penetration percentile than Ligand B (68.554). While not critical for a cardiovascular target, it's a slight positive for Ligand A.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. Ligand A (-4.912) is slightly worse than Ligand B (-4.353).
10. **Solubility:** Ligand A (-3.319) has slightly better solubility than Ligand B (-2.647), but both are quite poor.
11. **hERG:** Ligand A (0.898) has a slightly higher hERG risk than Ligand B (0.253). Lower is better here.
12. **Cl_mic:** Ligand B (-10.519) has *significantly* better metabolic stability (lower clearance) than Ligand A (50.729). This is a substantial advantage.
13. **t1/2:** Ligand A (62.48) has a longer in vitro half-life than Ligand B (17.991). This is a positive for Ligand A.
14. **Pgp:** Ligand A (0.389) has lower P-gp efflux than Ligand B (0.05), indicating better bioavailability.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.6 and -6.7 kcal/mol). The difference is negligible.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand B emerges as the stronger candidate. While Ligand A has slightly better BBB penetration and in vitro half-life, Ligand B's significantly lower DILI risk and substantially improved metabolic stability (Cl_mic) are critical advantages. The slightly lower QED and Pgp efflux are less concerning than the high DILI risk associated with Ligand A. The TPSA is also more favorable for Ligand B. The binding affinities are essentially identical.
Output:
0
2025-04-17 22:13:51,721 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for the ADRB2, a cardiovascular GPCR. Therefore, prioritizing logP, TPSA, Pgp, and binding affinity is crucial.
* **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (352.475) is slightly lower, which is generally favorable for permeability.
* **TPSA:** Ligand A (87.66) is better than Ligand B (30.29). Lower TPSA generally correlates with better blood-brain barrier penetration and oral absorption.
* **logP:** Ligand B (3.588) is higher than Ligand A (1.221). While both are within the acceptable range (1-3), Ligand B is approaching the upper limit, potentially raising concerns about solubility and off-target effects.
* **H-Bond Donors/Acceptors:** Ligand A has 3 HBD and 4 HBA, while Ligand B has 0 HBD and 6 HBA. Both are acceptable, but the lower number of H-bonds in Ligand B might slightly improve membrane permeability.
* **QED:** Both ligands have good QED scores (A: 0.643, B: 0.736), indicating good drug-like properties.
* **DILI:** Ligand B (36.642) has a slightly higher DILI risk than Ligand A (21.287), but both are still relatively low and acceptable.
* **BBB:** Ligand B (73.905) has significantly better BBB penetration potential than Ligand A (39.86). While ADRB2 is a cardiovascular target, some CNS effects are possible with beta-blockers, and better BBB penetration could be advantageous.
* **Caco-2 Permeability:** Both are negative, which is unusual. However, the magnitude is smaller for Ligand A (-5.068) than Ligand B (-5.103), suggesting slightly better permeability.
* **Aqueous Solubility:** Ligand A (-1.89) has better solubility than Ligand B (-4.066), which is important for formulation and bioavailability.
* **hERG Inhibition:** Ligand A (0.155) has a lower hERG risk than Ligand B (0.856), which is a significant advantage for cardiovascular drugs.
* **Microsomal Clearance:** Ligand B (92.259) has a much higher microsomal clearance than Ligand A (20.671), indicating lower metabolic stability and potentially requiring higher doses.
* **In vitro Half-Life:** Ligand A (11.672) has a longer half-life than Ligand B (8.121), which is desirable.
* **P-gp Efflux:** Ligand A (0.055) has lower P-gp efflux liability than Ligand B (0.727), which is favorable for bioavailability.
* **Binding Affinity:** Ligand A (-7.2) has a better binding affinity than Ligand B (-5.7). This is a substantial difference (1.5 kcal/mol) and can outweigh minor ADME drawbacks.
**Conclusion:**
While Ligand B has better BBB penetration, Ligand A demonstrates a superior balance of properties. Its significantly better binding affinity, lower hERG risk, lower DILI, better solubility, lower P-gp efflux, and improved metabolic stability (lower Cl_mic, longer t1/2) make it the more promising drug candidate for the ADRB2 receptor, despite the lower BBB score.
**Output:**
1
2025-04-17 22:13:51,721 - INFO - Here's my reasoning and final output for the ligand preference:
**Reasoning:**
We are targeting ADRB2, a GPCR, so the priorities are logP, Pgp, TPSA, affinity, and BBB. Let's break down the comparison:
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (352.475) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are good, well below the 140 threshold. Ligand B (49.85) is slightly better than Ligand A (59.08).
3. **logP:** Both ligands have good logP values (1.533 and 2.067), falling within the optimal 1-3 range. Ligand B is slightly higher, which could potentially lead to some off-target effects, but isn't a major concern.
4. **HBD/HBA:** Both have 0 HBD and 4 HBA, which is acceptable.
5. **QED:** Both have good QED scores (0.697 and 0.704), indicating good drug-likeness.
6. **DILI:** Ligand A (9.771) has a significantly lower DILI risk than Ligand B (44.436). This is a substantial advantage.
7. **BBB:** Ligand A (89.066) has a better BBB penetration score than Ligand B (79.837), though both are reasonable.
8. **Caco-2:** Ligand B (-5.103) has a better Caco-2 permeability than Ligand A (-4.37), suggesting better absorption.
9. **Solubility:** Ligand B (-3.032) has better aqueous solubility than Ligand A (-1.294).
10. **hERG:** Both ligands have similar, low hERG inhibition liability (0.34 and 0.362).
11. **Cl_mic:** Ligand A (41.132) has lower microsomal clearance than Ligand B (57.174), indicating better metabolic stability.
12. **t1/2:** Ligand B (-5.527) has a longer in vitro half-life than Ligand A (-3.119).
13. **Pgp:** Both ligands have similar Pgp efflux liability (0.052 and 0.314).
14. **Affinity:** Ligand A (-6.5 kcal/mol) has a better binding affinity than Ligand B (-3.9 kcal/mol). This is a significant difference.
**Overall Assessment:**
Ligand A is the stronger candidate. The substantial advantage in binding affinity (-6.5 vs -3.9 kcal/mol) and significantly lower DILI risk (9.771 vs 44.436) outweigh the slightly better Caco-2 and solubility of Ligand B. The better BBB penetration and metabolic stability of Ligand A are also beneficial. While Ligand B has a longer half-life, the potency and safety profile of Ligand A are more compelling for a GPCR target.
**Output:**
1
2025-04-17 22:13:51,722 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [371.38 , 55.4 , 3.086, 1. , 3. , 0.822, 72.043, 77.937, -4.728, -4.6 , 0.77 , 51.365, 25.209, 0.499, -5. ]
**Ligand B:** [362.817, 79.13 , 2.1 , 0. , 7. , 0.598, 65.917, 81.698, -5.062, -2.419, 0.08 , 41.292, 2.056, 0.195, -6.5 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (362.817) is slightly lower, which could be marginally better for permeability.
2. **TPSA:** Ligand A (55.4) is significantly better than Ligand B (79.13). ADRB2 is not a CNS target, but lower TPSA generally correlates with better absorption.
3. **logP:** Both are within the optimal range (1-3). Ligand A (3.086) is slightly higher, potentially leading to some off-target interactions, but still acceptable.
4. **HBD:** Ligand A (1) is better than Ligand B (0). Having at least one HBD can be beneficial for solubility.
5. **HBA:** Ligand A (3) is better than Ligand B (7). Fewer HBA generally improves permeability.
6. **QED:** Ligand A (0.822) is significantly better than Ligand B (0.598), indicating a more drug-like profile.
7. **DILI:** Ligand A (72.043) is slightly better than Ligand B (65.917), indicating a lower risk of liver injury. Both are acceptable.
8. **BBB:** Not a primary concern for a cardiovascular target, but Ligand B (81.698) is slightly higher than Ligand A (77.937).
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-4.728) is slightly better than Ligand B (-5.062).
10. **Solubility:** Ligand B (-2.419) is better than Ligand A (-4.6). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.77) is better than Ligand B (0.08), indicating a lower risk of cardiotoxicity.
12. **Cl_mic:** Ligand B (41.292) has lower clearance than Ligand A (51.365), suggesting better metabolic stability.
13. **t1/2:** Ligand A (25.209) has a longer half-life than Ligand B (2.056), which is desirable.
14. **Pgp:** Ligand A (0.499) is better than Ligand B (0.195), indicating lower P-glycoprotein efflux.
15. **Binding Affinity:** Ligand B (-6.5) has a significantly stronger binding affinity than Ligand A (-5.0). This is a substantial advantage.
**GPCR-specific priorities:** For ADRB2, we prioritize logP, Pgp, TPSA, and affinity. Ligand B has a slightly better logP, better Pgp, worse TPSA, and *much* better affinity. The affinity difference is significant (-6.5 vs -5.0 kcal/mol). While Ligand A has better overall ADME properties, the substantial binding affinity advantage of Ligand B outweighs these concerns.
**Conclusion:**
Despite some ADME drawbacks, the significantly stronger binding affinity of Ligand B makes it the more promising candidate.
0
2025-04-17 22:13:51,722 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [351.403, 100.99 , 0.417, 2. , 6. , 0.658, 41.024, 46.064, -4.835, -1.635, 0.151, -0.962, -18.902, 0.015, -0.7 ]**
**Ligand B: [346.431, 75.93 , 1.556, 1. , 5. , 0.761, 35.634, 49.787, -5.077, -0.853, 0.092, 26.836, 34.806, 0.152, -9. ]**
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (351.403) is slightly higher than Ligand B (346.431), but both are acceptable.
2. **TPSA:** Ligand A (100.99) is slightly higher than Ligand B (75.93). Both are below the 140 A^2 threshold for good oral absorption, but Ligand B is preferable due to the lower TPSA.
3. **logP:** Ligand A (0.417) is below the optimal range (1-3), which could hinder permeability. Ligand B (1.556) is within the optimal range. This is a significant advantage for Ligand B.
4. **H-Bond Donors:** Ligand A (2) and Ligand B (1) are both within the acceptable limit of 5. Ligand B is slightly better.
5. **H-Bond Acceptors:** Ligand A (6) and Ligand B (5) are both within the acceptable limit of 10. Ligand B is slightly better.
6. **QED:** Both ligands have good QED scores (A: 0.658, B: 0.761), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Both ligands have acceptable DILI risk (A: 41.024, B: 35.634), below the 60% threshold. Ligand B is slightly better.
8. **BBB:** Both ligands have similar BBB penetration (A: 46.064, B: 49.787). While not high, it's not a primary concern for ADRB2, which isn't a CNS target.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual. Assuming these are permeability coefficients, lower (more negative) values suggest *poorer* permeability. Ligand A (-4.835) is worse than Ligand B (-5.077).
10. **Solubility:** Both ligands have negative solubility values, which is also unusual. Assuming these are logS values, lower values indicate poorer solubility. Ligand A (-1.635) is slightly better than Ligand B (-0.853).
11. **hERG:** Both ligands have very low hERG risk (A: 0.151, B: 0.092). This is excellent.
12. **Cl_mic:** Ligand A (-0.962) has a lower (better) microsomal clearance than Ligand B (26.836), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (-18.902) has a very short in vitro half-life, which is a major drawback. Ligand B (34.806) has a much more reasonable half-life.
14. **Pgp:** Both ligands have very low Pgp efflux liability (A: 0.015, B: 0.152). This is excellent.
15. **Binding Affinity:** Ligand B (-9.0) has significantly better binding affinity than Ligand A (-0.7). This is a very substantial advantage, potentially outweighing some ADME concerns.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand B is the stronger candidate. While Ligand A has better metabolic stability (Cl_mic), the significantly better logP, TPSA, and *much* stronger binding affinity of Ligand B outweigh this advantage. The improved half-life of Ligand B is also a significant benefit. The Caco-2 and solubility values are concerning for both, but the affinity difference is too large to ignore.
Output:
0
2025-04-17 22:13:51,722 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [344.455, 60.85, 2.96, 1, 3, 0.892, 52.423, 69.794, -4.85, -2.395, 0.161, 3.503, -6.964, 0.075, -5.4]
**Ligand B:** [367.475, 89.87, -0.085, 1, 7, 0.8, 37.999, 64.25, -4.896, -1.724, 0.478, 26.971, -1.548, 0.12, -6.8]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (344.455) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (60.85) is significantly better than Ligand B (89.87). For a GPCR, keeping TPSA low is good, and A is well below the 140 threshold.
3. **logP:** Ligand A (2.96) is optimal, while Ligand B (-0.085) is quite low. This is a significant drawback for B, potentially hindering membrane permeability and bioavailability.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A (3) is better than Ligand B (7). Higher HBA can sometimes reduce permeability.
6. **QED:** Both are good (0.892 and 0.8), indicating drug-like properties.
7. **DILI:** Ligand A (52.423) has a slightly higher DILI risk than Ligand B (37.999), but both are below the concerning threshold of 60.
8. **BBB:** Ligand A (69.794) has a better BBB penetration score than Ligand B (64.25). While ADRB2 isn't a CNS target, some degree of BBB penetration can be beneficial.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so we cannot interpret these values directly.
10. **Solubility:** Ligand A (-2.395) has better solubility than Ligand B (-1.724).
11. **hERG:** Ligand A (0.161) has a much lower hERG risk than Ligand B (0.478). This is a crucial safety parameter.
12. **Cl_mic:** Ligand A (3.503) has a significantly lower microsomal clearance than Ligand B (26.971), indicating better metabolic stability.
13. **t1/2:** Ligand A (-6.964) has a much longer in vitro half-life than Ligand B (-1.548).
14. **Pgp:** Ligand A (0.075) has lower P-gp efflux liability than Ligand B (0.12).
15. **Affinity:** Both have very similar and excellent binding affinities (-5.4 and -6.8 kcal/mol). The difference is less than 1.5 kcal/mol, so it doesn't override other considerations.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A excels in logP and TPSA, and has a better Pgp profile. The affinities are comparable.
**Conclusion:**
Ligand A is the superior candidate. Its better logP, TPSA, solubility, hERG profile, metabolic stability, and Pgp efflux properties outweigh the slightly higher DILI risk. The comparable binding affinity seals the deal.
Output:
1
2025-04-17 22:13:51,722 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (333.39 and 338.41 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (55.4) is better than Ligand B (62.55). Both are below the 140 A^2 threshold for oral absorption, but lower TPSA is generally preferred for GPCRs.
**3. logP:** Ligand B (3.182) is slightly better than Ligand A (4.368). Ligand A is pushing the upper limit of the optimal range (1-3), which could lead to solubility issues.
**4. H-Bond Donors:** Both ligands have 1 HBD, which is within the acceptable limit of <=5.
**5. H-Bond Acceptors:** Both ligands have 3 HBA, which is within the acceptable limit of <=10.
**6. QED:** Ligand B (0.935) has a significantly better QED score than Ligand A (0.706), indicating a more drug-like profile.
**7. DILI Risk:** Ligand B (59.91) has a lower DILI risk than Ligand A (93.37), which is a significant advantage.
**8. BBB Penetration:** Ligand A (77.16) has better BBB penetration than Ligand B (61.92). While ADRB2 is a cardiovascular target, some CNS off-target effects are possible with GPCRs, and better BBB penetration could exacerbate those. However, this is a lower priority than other factors.
**9. Caco-2 Permeability:** Both ligands have similarly poor Caco-2 permeability (-4.725 and -4.751). This is a concern for oral bioavailability.
**10. Aqueous Solubility:** Ligand B (-3.789) has better aqueous solubility than Ligand A (-6.303). This is important given Ligand A's higher logP.
**11. hERG Inhibition:** Ligand B (0.547) has a lower hERG inhibition risk than Ligand A (0.738), which is a crucial safety consideration.
**12. Microsomal Clearance:** Ligand B (54.01) has lower microsomal clearance than Ligand A (66.94), indicating better metabolic stability.
**13. In vitro Half-Life:** Ligand B (74.797) has a significantly longer in vitro half-life than Ligand A (33.551), which is a major advantage for dosing frequency.
**14. P-gp Efflux:** Ligand A (0.82) has higher P-gp efflux than Ligand B (0.259), which is undesirable as it reduces bioavailability.
**15. Binding Affinity:** Ligand B (-7.7 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.1 kcal/mol). This >1.5 kcal/mol difference is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand B is the superior candidate. While Ligand A has slightly better BBB penetration, Ligand B excels in almost all other critical parameters. Its significantly better QED, lower DILI risk, lower hERG inhibition, improved metabolic stability (lower Cl_mic, longer t1/2), lower P-gp efflux, and *much* stronger binding affinity make it a far more promising drug candidate for the ADRB2 receptor. The slightly higher TPSA and lower BBB are acceptable trade-offs for these significant advantages.
Output:
0
2025-04-17 22:13:51,722 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (381.219 Da) is within the ideal range (200-500 Da). Ligand B (347.459 Da) is also within the ideal range. No clear advantage here.
2. **TPSA:** Ligand A (97.12) is acceptable, though approaching the upper limit for good oral absorption. Ligand B (91.32) is better, falling comfortably below 100.
3. **logP:** Ligand A (3.187) is optimal. Ligand B (1.434) is on the lower side, potentially impacting permeability.
4. **HBD:** Ligand A (2) is good. Ligand B (3) is acceptable, but slightly higher.
5. **HBA:** Ligand A (5) is good. Ligand B (4) is also good.
6. **QED:** Ligand A (0.829) is excellent, indicating a highly drug-like profile. Ligand B (0.63) is still acceptable but less favorable.
7. **DILI:** Ligand A (86.855) has a significantly higher DILI risk than Ligand B (18.883). This is a major concern for Ligand A.
8. **BBB:** Ligand A (66.421) is moderate. Ligand B (45.25) is lower. Since ADRB2 is a cardiovascular target, BBB penetration isn't a primary concern, but it's still a consideration.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. This is a red flag for both.
10. **Solubility:** Ligand A (-4.924) has very poor solubility. Ligand B (-1.783) is also poor, but better than Ligand A.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.255 and 0.184 respectively).
12. **Cl_mic:** Ligand A (60.442) has higher metabolic clearance than Ligand B (18.856), suggesting lower metabolic stability.
13. **t1/2:** Ligand A (42.828) has a longer half-life than Ligand B (2.845). This is a positive for Ligand A.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.17 and 0.016 respectively).
15. **Affinity:** Ligand B (-7.1 kcal/mol) has a significantly stronger binding affinity than Ligand A (-4.5 kcal/mol). This is a substantial advantage.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand A has a better logP, but Ligand B has a significantly better affinity and a more favorable TPSA. The DILI risk for Ligand A is a major drawback.
**Overall Assessment:**
While Ligand A has a longer half-life and better logP, the significantly higher DILI risk, poor solubility, and weaker binding affinity make it a less attractive candidate. Ligand B's superior affinity, lower DILI risk, and better TPSA outweigh its slightly lower logP. The negative Caco-2 values for both are concerning and would require further investigation, but the overall profile of Ligand B is more promising.
Output:
0
2025-04-17 22:13:51,723 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (345.443 and 344.459 Da) are within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (87.3) is slightly higher than Ligand B (67.23). For a cardiovascular GPCR, TPSA is moderately important, and lower is generally better for permeability. Ligand B has a clear advantage.
**3. logP:** Ligand A (1.004) is within the optimal range, while Ligand B (2.134) is slightly higher. Both are acceptable, but Ligand A is preferable.
**4. H-Bond Donors:** Ligand A (3) is higher than Ligand B (1). Lower HBD is generally preferred for better permeability. Ligand B is better.
**5. H-Bond Acceptors:** Ligand A (3) and Ligand B (4) are both reasonable. No strong preference.
**6. QED:** Ligand B (0.804) has a significantly higher QED score than Ligand A (0.475), indicating a more drug-like profile. This is a substantial advantage for Ligand B.
**7. DILI Risk:** Ligand A (21.985) has a lower DILI risk than Ligand B (29.236). Lower is better, giving a slight edge to Ligand A.
**8. BBB Penetration:** Ligand B (50.523) has better BBB penetration than Ligand A (40.52). While ADRB2 is a cardiovascular target and CNS penetration isn't *critical*, some degree of BBB penetration can be beneficial for off-target effects assessment and potential alternative therapeutic avenues.
**9. Caco-2 Permeability:** Ligand A (-5.109) has slightly better Caco-2 permeability than Ligand B (-4.926).
**10. Aqueous Solubility:** Ligand A (-3.287) has better aqueous solubility than Ligand B (-1.793). Solubility is important for formulation and bioavailability.
**11. hERG Inhibition:** Ligand A (0.073) has a lower hERG inhibition risk than Ligand B (0.191). This is a crucial safety parameter, favoring Ligand A.
**12. Microsomal Clearance:** Ligand B (36.363) has a higher microsomal clearance than Ligand A (14.148), indicating faster metabolism and potentially lower *in vivo* exposure. Ligand A is preferred.
**13. In vitro Half-Life:** Ligand A (-1.126) has a longer in vitro half-life than Ligand B (-2.582). This is a positive for Ligand A.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.039 and 0.054 respectively). No significant difference.
**15. Binding Affinity:** Ligand B (-7.5) has a slightly better binding affinity than Ligand A (-7.2). The difference is 0.3 kcal/mol, which is not enough to outweigh the ADME concerns with Ligand B.
**Overall Assessment:**
Ligand B has a better QED and affinity, and slightly better BBB penetration. However, it suffers from higher DILI risk, higher microsomal clearance, shorter half-life, and a higher hERG risk. Ligand A has a more favorable ADME profile, particularly regarding safety (DILI, hERG) and metabolic stability (Cl_mic, t1/2). While the affinity difference is small, the ADME advantages of Ligand A are more important for overall drug development success, especially considering the cardiovascular target.
Output:
1
2025-04-17 22:13:51,723 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (352.46 Da and 351.45 Da). No significant difference.
2. **TPSA:** Ligand A (54.98) is significantly better than Ligand B (113.66). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (4.77) is higher than Ligand B (0.56). While 4.77 is approaching the upper limit, it's still acceptable. Ligand B's logP is quite low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (1) is better than Ligand B (3). Fewer HBDs are generally preferred for better permeability.
5. **HBA:** Ligand A (4) is better than Ligand B (5). Similar to HBD, lower HBA is favorable.
6. **QED:** Both ligands have good QED values (0.531 and 0.647), indicating good drug-like properties.
7. **DILI:** Ligand A (68.86) has a higher DILI risk than Ligand B (12.64). This is a significant concern for Ligand A.
8. **BBB:** Ligand A (44.67) is better than Ligand B (18.15), but BBB is not a major priority for a cardiovascular target.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.02 and -5.24), which is unusual and suggests poor permeability in this assay. However, the values are similar.
10. **Solubility:** Ligand A (-5.73) is better than Ligand B (-1.63), indicating better aqueous solubility.
11. **hERG:** Ligand A (0.80) is better than Ligand B (0.19), indicating lower hERG inhibition liability.
12. **Cl_mic:** Ligand A (129.93) has a higher microsomal clearance than Ligand B (-7.51). This suggests Ligand B is more metabolically stable, which is desirable.
13. **t1/2:** Ligand A (-41.36) has a negative in vitro half-life, which is concerning. Ligand B (-2.19) is also low, but less problematic than a negative value.
14. **Pgp:** Ligand A (0.76) is better than Ligand B (0.03), indicating lower P-gp efflux.
15. **Affinity:** Ligand A (-6.4) has a slightly better binding affinity than Ligand B (-5.5). While the difference is less than 1.5 kcal/mol, it's still a positive.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A excels in logP, TPSA, and Pgp, and has slightly better affinity. However, its high DILI risk and poor in vitro half-life are major drawbacks. Ligand B has a very low logP and a higher DILI risk, but better metabolic stability and a less concerning half-life.
**Overall Assessment:**
Despite Ligand A's slightly better affinity and favorable logP/TPSA/Pgp profile, the significantly higher DILI risk and negative in vitro half-life are major red flags. Ligand B, while having a less optimal logP, presents a much better safety profile (lower DILI) and better metabolic stability. The small affinity difference can potentially be optimized during lead optimization.
Output:
0
2025-04-17 22:13:51,723 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (347.386 and 365.449 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (60.69) is slightly higher than Ligand B (54.02). Both are below the 140 A^2 threshold for good oral absorption, which is good.
**3. logP:** Ligand A (3.005) is within the optimal 1-3 range, while Ligand B (4.659) is a bit higher. While not drastically outside the acceptable range, higher logP can sometimes lead to off-target effects and solubility issues.
**4. H-Bond Donors:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs generally improve membrane permeability.
**5. H-Bond Acceptors:** Ligand A (5) is preferable to Ligand B (4).
**6. QED:** Both ligands have similar QED values (0.746 and 0.715), indicating good drug-likeness.
**7. DILI:** Ligand A (35.595) has a significantly lower DILI risk than Ligand B (64.482). This is a major advantage for Ligand A.
**8. BBB:** Both ligands have high BBB penetration (85.692 and 83.288), which isn't a primary concern for a cardiovascular target, but isn't detrimental.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual. This suggests poor permeability, but the scale is not specified, so it's difficult to interpret.
**10. Aqueous Solubility:** Ligand A (-3.94) is better than Ligand B (-5.15).
**11. hERG Inhibition:** Ligand A (0.564) has a slightly better hERG profile than Ligand B (0.483), indicating lower cardiotoxicity risk.
**12. Microsomal Clearance:** Ligand A (76.176) has higher microsomal clearance than Ligand B (61.688), meaning it's metabolized faster. This is a disadvantage for Ligand A.
**13. In vitro Half-Life:** Ligand B (35.48) has a significantly longer half-life than Ligand A (4.868). This is a significant advantage for Ligand B.
**14. P-gp Efflux:** Ligand A (0.424) has lower P-gp efflux than Ligand B (0.38), which is preferable.
**15. Binding Affinity:** Ligand B (-7.5 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.6 kcal/mol). This is a substantial advantage, potentially outweighing some ADME drawbacks.
**GPCR Specific Considerations:** For a GPCR like ADRB2, affinity, logP, and metabolic stability are key. Ligand B has a much stronger binding affinity and a longer half-life, despite the slightly higher logP and DILI risk. The difference in affinity is substantial (>1.5 kcal/mol).
**Overall Assessment:**
While Ligand A has better DILI and solubility profiles, Ligand B's significantly stronger binding affinity and longer half-life are more critical for a GPCR target. The higher logP of Ligand B is manageable, and the DILI risk, while higher, isn't excessively concerning given the potency advantage.
Output:
0
2025-04-17 22:13:51,723 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (345.36 and 345.40 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (122.71) is higher than Ligand B (87.74). For a cardiovascular GPCR, TPSA is moderately important. Ligand B's lower TPSA is preferable, suggesting better potential for membrane permeability.
**3. logP:** Ligand A (0.282) is quite low, potentially hindering membrane permeability. Ligand B (0.695) is better, falling within the optimal 1-3 range, though still on the lower side. Ligand B is favored.
**4. H-Bond Donors:** Ligand A (3) is slightly higher than Ligand B (2). Both are acceptable, being less than 5.
**5. H-Bond Acceptors:** Ligand A (7) is higher than Ligand B (4). Again, both are within the acceptable limit of 10, but Ligand B is more favorable.
**6. QED:** Ligand B (0.789) has a significantly higher QED score than Ligand A (0.54), indicating a more drug-like profile. This is a substantial advantage for Ligand B.
**7. DILI Risk:** Ligand A (70.69%) has a higher DILI risk than Ligand B (53.28%). Lower is better, so Ligand B is preferred.
**8. BBB Penetration:** Ligand B (78.25%) shows better BBB penetration than Ligand A (47.00%). While not a primary concern for a cardiovascular target, better BBB penetration is generally desirable, and could be useful if off-target CNS effects need to be considered.
**9. Caco-2 Permeability:** Ligand A (-5.705) has worse Caco-2 permeability than Ligand B (-4.619). Higher values are better, indicating better intestinal absorption. Ligand B is favored.
**10. Aqueous Solubility:** Ligand A (-3.232) has worse aqueous solubility than Ligand B (-2.145). Higher values are better, so Ligand B is favored.
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.222 and 0.109 respectively). No significant difference.
**12. Microsomal Clearance:** Ligand A (-22.151) has a lower (better) microsomal clearance than Ligand B (-5.936). This suggests better metabolic stability for Ligand A.
**13. In vitro Half-Life:** Ligand A (-29.446) has a longer in vitro half-life than Ligand B (-4.65). This is a significant advantage for Ligand A.
**14. P-gp Efflux:** Both ligands show very low P-gp efflux liability (0.008 and 0.012 respectively). No significant difference.
**15. Binding Affinity:** Ligand B (-4.7 kcal/mol) has a slightly better binding affinity than Ligand A (-3.0 kcal/mol). This is a substantial advantage for Ligand B, and can outweigh some of the ADME drawbacks of Ligand A.
**Overall Assessment:**
Ligand B consistently outperforms Ligand A in several key ADME properties (TPSA, logP, QED, DILI, Caco-2, Solubility) and has a better binding affinity. While Ligand A has better metabolic stability (lower Cl_mic) and a longer half-life, the overall profile of Ligand B is more promising for a cardiovascular GPCR target. The improved drug-likeness, lower risk profile, and better permeability characteristics of Ligand B outweigh the slightly less favorable metabolic stability.
Output:
0
2025-04-17 22:13:51,723 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (342.443 and 346.391 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (66.4) is significantly lower than Ligand B (132.63). This is a major advantage for Ligand A, as lower TPSA generally correlates with better cell permeability, crucial for GPCR targets. Ligand B is above the preferred 140 threshold.
3. **logP:** Ligand A (2.06) is within the optimal 1-3 range. Ligand B (0.357) is slightly low, potentially hindering membrane permeation.
4. **HBD:** Ligand A (0) is preferable to Ligand B (4). Fewer hydrogen bond donors generally improve permeability.
5. **HBA:** Ligand A (4) is preferable to Ligand B (5). Fewer hydrogen bond acceptors also generally improve permeability.
6. **QED:** Ligand A (0.768) has a higher QED score than Ligand B (0.599), indicating a more drug-like profile.
7. **DILI:** Ligand A (24.583) has a much lower DILI risk than Ligand B (63.513). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (84.684) shows better BBB penetration potential than Ligand B (24.351). While ADRB2 isn't exclusively a CNS target, some CNS exposure can occur, and better BBB penetration is generally desirable.
9. **Caco-2:** Ligand A (-4.715) is better than Ligand B (-5.52).
10. **Solubility:** Ligand A (-1.393) is better than Ligand B (-2.783).
11. **hERG:** Both ligands show low hERG inhibition risk (0.221 and 0.315 respectively). No significant difference.
12. **Cl_mic:** Ligand A (16.405) has a lower microsomal clearance than Ligand B (-11.571), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-4.168) has a longer in vitro half-life than Ligand B (12.231).
14. **Pgp:** Both ligands show low P-gp efflux liability (0.034 and 0.028 respectively). No significant difference.
15. **Binding Affinity:** Ligand B (-7.1) has a slightly better binding affinity than Ligand A (-5.0). However, the difference is not substantial enough to outweigh the numerous advantages of Ligand A.
**GPCR-specific priorities:**
For a GPCR like ADRB2, TPSA, logP, and metabolic stability are crucial. Ligand A excels in these areas. While binding affinity is important, the 2.1 kcal/mol difference isn't large enough to overcome the superior ADME properties of Ligand A.
**Conclusion:**
Ligand A demonstrates a significantly better overall profile, particularly regarding permeability (TPSA, logP, HBD/HBA), safety (DILI), metabolic stability (Cl_mic, t1/2), and drug-likeness (QED). The slightly weaker binding affinity of Ligand A is a manageable trade-off.
Output:
1
2025-04-17 22:13:51,724 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A Analysis:**
* **MW:** 375.372 Da - Good, within the ideal range.
* **TPSA:** 72.48 - Good, below the 140 threshold for oral absorption.
* **logP:** 3.503 - Good, within the optimal range.
* **HBD:** 2 - Good, well below the limit.
* **HBA:** 5 - Good, well below the limit.
* **QED:** 0.785 - Excellent, highly drug-like.
* **DILI:** 89.841 - High risk of liver injury. This is a significant concern.
* **BBB:** 95.308 - Excellent, very high potential for CNS penetration (though not necessarily desired for a cardiovascular target).
* **Caco-2:** -4.827 - Poor permeability.
* **Solubility:** -4.94 - Poor solubility.
* **hERG:** 0.721 - Relatively low risk of hERG inhibition.
* **Cl_mic:** 46.893 - Moderate clearance, suggesting moderate metabolic stability.
* **t1/2:** 38.008 - Good in vitro half-life.
* **Pgp:** 0.4 - Low P-gp efflux, favorable for bioavailability.
* **Affinity:** -6.7 kcal/mol - Good binding affinity.
**Ligand B Analysis:**
* **MW:** 366.38 Da - Good, within the ideal range.
* **TPSA:** 81.08 - Acceptable, but approaching the upper limit for good absorption.
* **logP:** 0.625 - Low, potentially hindering permeation.
* **HBD:** 2 - Good, well below the limit.
* **HBA:** 4 - Good, well below the limit.
* **QED:** 0.748 - Good, drug-like.
* **DILI:** 20.783 - Very low risk of liver injury. Excellent.
* **BBB:** 57.154 - Moderate BBB penetration.
* **Caco-2:** -4.716 - Poor permeability.
* **Solubility:** -1.078 - Poor solubility.
* **hERG:** 0.537 - Relatively low risk of hERG inhibition.
* **Cl_mic:** -7.273 - Very low clearance, excellent metabolic stability.
* **t1/2:** -12.409 - Very long in vitro half-life. Excellent.
* **Pgp:** 0.036 - Very low P-gp efflux, highly favorable for bioavailability.
* **Affinity:** -7.0 kcal/mol - Excellent binding affinity, 0.3 kcal/mol better than Ligand A.
**Comparison and Decision:**
Given that the target is ADRB2 (a GPCR involved in cardiovascular function), the priorities are affinity, logP, TPSA, Pgp, and metabolic stability. While Ligand B has a slightly better affinity (-7.0 vs -6.7 kcal/mol), the key differentiating factors are DILI and metabolic stability. Ligand A has a very high DILI risk (89.841), which is a major red flag. Ligand B has a very low DILI risk (20.783) and significantly better metabolic stability (Cl_mic = -7.273, t1/2 = -12.409) compared to Ligand A. Both ligands have poor Caco-2 and solubility, but these can be addressed with formulation strategies. The slightly lower logP of Ligand B is a concern, but the superior safety profile and metabolic stability outweigh this drawback.
Therefore, Ligand B is the more promising drug candidate.
Output:
0
2025-04-17 22:13:51,724 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [373.519, 109.57 , 0.989, 2. , 4. , 0.661, 19.969, 61.535, -5.278, -2.615, 0.241, 39.217, -39.866, 0.006, -5.6 ]**
**Ligand B: [356.398, 107.61 , -0.904, 3. , 4. , 0.387, 23.614, 63.862, -5.489, -1.809, 0.163, -18.083, -4.641, 0.007, -5.6 ]**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand B (356.4) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are reasonably close to the 140 A^2 threshold, but both are above the 90 A^2 threshold for CNS targets.
3. **logP:** Ligand A (0.989) is within the optimal range (1-3). Ligand B (-0.904) is slightly below 1, which could potentially hinder permeation.
4. **HBD:** Both have acceptable HBD counts (Ligand A: 2, Ligand B: 3), well below the 5 threshold.
5. **HBA:** Both have acceptable HBA counts (Ligand A: 4, Ligand B: 4), well below the 10 threshold.
6. **QED:** Ligand A (0.661) has a better QED score than Ligand B (0.387), indicating a more drug-like profile.
7. **DILI:** Ligand B (23.6%) has a significantly lower DILI risk than Ligand A (19.97%). This is a major advantage for Ligand B.
8. **BBB:** Both have similar BBB penetration (Ligand A: 61.5%, Ligand B: 63.9%). Neither is exceptionally high, but acceptable for a non-CNS target like ADRB2.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability.
10. **Solubility:** Both have negative solubility values, which is also unusual and suggests poor solubility.
11. **hERG:** Both have very low hERG inhibition risk (0.241 and 0.163).
12. **Cl_mic:** Ligand B (-18.083) has a much lower (better) microsomal clearance than Ligand A (39.217), indicating greater metabolic stability.
13. **t1/2:** Ligand B (-4.641) has a slightly better in vitro half-life than Ligand A (-39.866).
14. **Pgp:** Both have very low Pgp efflux liability (0.006 and 0.007).
15. **Binding Affinity:** Both have the same binding affinity (-5.6 kcal/mol).
**GPCR-Specific Considerations:** For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand A has a better logP, but Ligand B has a significantly better DILI score and metabolic stability (lower Cl_mic and better t1/2). The binding affinity is the same. Given the importance of minimizing toxicity and maximizing metabolic stability for a chronic cardiovascular target, the advantages of Ligand B outweigh the slightly better logP of Ligand A.
**Final Decision:**
0
2025-04-17 22:13:51,724 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (334.339 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (58.64) is significantly better than Ligand A (91.75). ADRB2 is a cardiovascular target, so CNS penetration isn't critical, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (A: 2.852, B: 2.089) within the optimal 1-3 range.
4. **HBD:** Ligand A has 0 HBD, while Ligand B has 1. Both are acceptable.
5. **HBA:** Ligand A has 8 HBA, and Ligand B has 3. Ligand B is better here, as fewer HBA generally improves permeability.
6. **QED:** Both ligands have good QED scores (A: 0.554, B: 0.604), indicating good drug-like properties.
7. **DILI:** Ligand B (28.383) has a *much* lower DILI risk than Ligand A (95.89). This is a major advantage for Ligand B.
8. **BBB:** Ligand B (93.563) has a higher BBB penetration score than Ligand A (46.801). While not a primary concern for a cardiovascular target, it's still a positive attribute.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. However, Ligand B (-4.598) is slightly better than Ligand A (-4.871).
10. **Solubility:** Ligand B (-2.303) has better solubility than Ligand A (-3.831).
11. **hERG:** Both ligands have relatively low hERG inhibition risk (A: 0.583, B: 0.651).
12. **Cl_mic:** Ligand B (35.77) has a lower microsomal clearance than Ligand A (47.69), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-4.503) has a better in vitro half-life than Ligand A (-43.686).
14. **Pgp:** Both ligands have low P-gp efflux liability (A: 0.104, B: 0.205).
15. **Binding Affinity:** Ligand A (-8.3 kcal/mol) has a significantly stronger binding affinity than Ligand B (-7.2 kcal/mol). This is a substantial advantage.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has a better logP and *much* better affinity. However, Ligand B excels in TPSA, DILI, solubility, metabolic stability (Cl_mic and t1/2), and has a higher BBB score. The DILI risk for Ligand A is extremely high, which is a major concern. The affinity difference is 1.1 kcal/mol, which is significant, but the safety profile of Ligand B is far superior.
**Conclusion:**
Despite the stronger binding affinity of Ligand A, the significantly lower DILI risk, better solubility, and improved metabolic stability of Ligand B make it the more promising drug candidate. The high DILI risk associated with Ligand A is a major red flag that outweighs the affinity advantage.
Output:
0
2025-04-17 22:13:51,724 - INFO - Batch 316 complete. Total preferences: 5056
2025-04-17 22:13:51,724 - INFO - Processing batch 317/512...
2025-04-17 22:14:40,011 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [369.799, 58.37, 4.894, 1, 3, 0.837, 72.392, 96.2, -4.444, -5.52, 0.661, 37.893, -4.228, 0.464, -6.6]
**Ligand B:** [354.422, 78.87, 1.633, 2, 4, 0.711, 45.095, 85.653, -5.064, -2.857, 0.425, -2.837, 3.094, 0.12, -6.2]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (354.422) is slightly lower, which is generally favorable.
2. **TPSA:** Ligand A (58.37) is excellent, well below the 140 threshold and good for permeability. Ligand B (78.87) is still acceptable but less optimal.
3. **logP:** Ligand A (4.894) is pushing the upper limit of the optimal range (1-3) and could present solubility challenges. Ligand B (1.633) is well within the ideal range. This is a significant advantage for B.
4. **HBD/HBA:** Ligand A (1 HBD, 3 HBA) is better than Ligand B (2 HBD, 4 HBA), but both are acceptable.
5. **QED:** Ligand A (0.837) is better than Ligand B (0.711), indicating a more drug-like profile.
6. **DILI:** Ligand A (72.392) has a higher DILI risk than Ligand B (45.095). This is a significant negative for A.
7. **BBB:** Ligand A (96.2) has excellent BBB penetration, while Ligand B (85.653) is good but lower. For a cardiovascular target, BBB isn't *critical*, but it's a bonus.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.444) is slightly worse than Ligand B (-5.064).
9. **Solubility:** Ligand A (-5.52) has worse solubility than Ligand B (-2.857).
10. **hERG:** Both have low hERG inhibition risk (0.661 and 0.425).
11. **Cl_mic:** Ligand B (-2.837) has a much lower (better) microsomal clearance than Ligand A (37.893), suggesting better metabolic stability.
12. **t1/2:** Ligand B (3.094) has a better in vitro half-life than Ligand A (-4.228).
13. **Pgp:** Ligand A (0.464) has lower P-gp efflux than Ligand B (0.12), which is favorable.
14. **Affinity:** Both have excellent binding affinity (-6.6 and -6.2 kcal/mol). The difference is small, and not a deciding factor.
**Overall Assessment:**
Ligand B is the stronger candidate. While Ligand A has better BBB penetration and Pgp efflux, Ligand B excels in crucial areas: logP (better for permeability and reducing off-target effects), DILI risk (significantly lower), metabolic stability (much lower Cl_mic), and solubility. The slightly lower QED and BBB are less concerning for a cardiovascular target. The similar binding affinities make the ADME properties the deciding factors.
Output:
0
2025-04-17 22:14:40,012 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [344.499, 49.41, 3.276, 1, 2, 0.778, 16.557, 78.868, -4.753, -3.324, 0.428, 57.686, -9.73, 0.182, -6.1]
**Ligand B:** [390.359, 102.32, 0.504, 2, 6, 0.448, 60.799, 65.452, -5.134, -2.461, 0.297, 25.45, -51.346, 0.117, -5.8]
**Step-by-step comparison:**
1. **MW:** Ligand A (344.5 Da) is better, falling nicely within the 200-500 Da range. Ligand B (390.4 Da) is still acceptable, but closer to the upper limit.
2. **TPSA:** Ligand A (49.41) is significantly better than Ligand B (102.32). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is quite high and could hinder absorption.
3. **logP:** Ligand A (3.276) is optimal. Ligand B (0.504) is too low, potentially leading to poor membrane permeability.
4. **HBD:** Both have acceptable HBD counts (1 and 2 respectively).
5. **HBA:** Ligand A (2) is better than Ligand B (6). Higher HBA can sometimes impact permeability.
6. **QED:** Ligand A (0.778) is much better than Ligand B (0.448), indicating a more drug-like profile.
7. **DILI:** Ligand A (16.56%) is significantly better than Ligand B (60.80%). Ligand B's DILI risk is concerning.
8. **BBB:** Ligand A (78.87%) is much better than Ligand B (65.45%). While ADRB2 isn't exclusively a CNS target, some CNS penetration can be useful, and a higher BBB score is generally favorable.
9. **Caco-2:** Both are negative, suggesting poor permeability. However, the scale is not specified, so this is difficult to interpret.
10. **Solubility:** Both have negative solubility values, indicating poor solubility. Again, the scale is not specified.
11. **hERG:** Both are low, indicating low cardiotoxicity risk.
12. **Cl_mic:** Ligand A (57.69) is higher than Ligand B (25.45), meaning Ligand B is more metabolically stable. This is a point in favor of Ligand B.
13. **t1/2:** Ligand A (-9.73) is much better than Ligand B (-51.35). A more positive (less negative) value indicates a longer half-life.
14. **Pgp:** Ligand A (0.182) is better than Ligand B (0.117), suggesting less P-glycoprotein efflux.
15. **Affinity:** Both have very similar binding affinities (-6.1 and -5.8 kcal/mol). The difference is not substantial enough to outweigh other factors.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, and affinity. Ligand A excels in logP, TPSA, and Pgp, while the affinities are comparable.
**Conclusion:**
Despite Ligand B having better metabolic stability, Ligand A is the superior candidate. Its better logP, TPSA, QED, DILI risk, BBB penetration, and half-life outweigh the slightly higher clearance. The significantly lower TPSA and better predicted absorption/distribution properties make it a more promising starting point for optimization.
Output:
1
2025-04-17 22:14:40,012 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
The ADRB2 receptor is a GPCR, so the priorities are logP, Pgp, TPSA, affinity, and, to a lesser extent, BBB. Let's break down the comparison:
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da).
2. **TPSA:** Ligand A (95.08) is better than Ligand B (107.7), being closer to the <140 threshold for good absorption.
3. **logP:** Ligand A (3.089) is optimal (1-3), while Ligand B (0.032) is very low, potentially hindering permeation. This is a significant advantage for Ligand A.
4. **H-Bond Donors/Acceptors:** Both have acceptable numbers (3 HBD, 3/6 HBA).
5. **QED:** Both are above 0.5, indicating reasonable drug-likeness.
6. **DILI:** Ligand B (20.085) has a much lower DILI risk than Ligand A (84.645), a substantial advantage.
7. **BBB:** Ligand A (51.687) is slightly better than Ligand B (40.132), but BBB isn't a primary concern for ADRB2, which is primarily a cardiovascular target.
8. **Caco-2 Permeability:** Both are negative, indicating poor permeability.
9. **Aqueous Solubility:** Both are negative, indicating poor solubility.
10. **hERG:** Both have low hERG inhibition risk.
11. **Microsomal Clearance:** Ligand B (-7.228) has significantly lower (better) microsomal clearance than Ligand A (-19.844), suggesting better metabolic stability.
12. **In vitro Half-Life:** Ligand B (14.889) has a longer half-life than Ligand A (10.592).
13. **P-gp Efflux:** Both have low P-gp efflux liability.
14. **Binding Affinity:** Ligand B (-6.9 kcal/mol) is slightly better than Ligand A (-3.9 kcal/mol). This is a 3 kcal/mol difference, which is substantial.
**Overall Assessment:**
While Ligand B has a significantly better DILI score, microsomal clearance, and half-life, and a slightly better binding affinity, Ligand A has a much more favorable logP value. The extremely low logP of Ligand B is a major concern, as it will likely result in poor membrane permeability and bioavailability. The difference in binding affinity, while significant, can potentially be overcome with further optimization. The poor permeability of Ligand B is a harder property to improve. Given the GPCR-specific priorities, the better logP of Ligand A outweighs the advantages of Ligand B.
**Output:**
1
2025-04-17 22:14:40,012 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [352.519, 49.85, 3.243, 0, 3, 0.661, 22.8, 77.239, -4.355, -2.629, 0.373, 82.917, 35.087, 0.084, -5.6]
**Ligand B:** [342.439, 53.35, 3.862, 0, 5, 0.717, 38.193, 69.756, -4.38, -4.113, 0.554, 86.1, -0.204, 0.429, -6.5]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (342.439) is slightly lower, which is generally favorable.
2. **TPSA:** Both are reasonably good, but Ligand A (49.85) is better than Ligand B (53.35) for oral absorption, being closer to the <140 threshold.
3. **logP:** Both are within the optimal range (1-3), but Ligand B (3.862) is a bit higher, potentially increasing off-target effects. Ligand A (3.243) is better.
4. **HBD:** Both have 0 HBD, which is good.
5. **HBA:** Ligand A (3) is preferable to Ligand B (5). Fewer HBA generally improves permeability.
6. **QED:** Both are above 0.5, indicating good drug-likeness. Ligand B (0.717) is slightly better.
7. **DILI:** Ligand A (22.8) has a significantly lower DILI risk than Ligand B (38.193). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (77.239) has a better BBB penetration percentile than Ligand B (69.756). While not a primary concern for a cardiovascular target, it's still a positive.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.355) is slightly better than Ligand B (-4.38).
10. **Solubility:** Ligand A (-2.629) is better than Ligand B (-4.113).
11. **hERG:** Ligand A (0.373) has a lower hERG inhibition liability than Ligand B (0.554), which is crucial for avoiding cardiotoxicity.
12. **Cl_mic:** Ligand A (82.917) has a lower microsomal clearance than Ligand B (86.1), suggesting better metabolic stability.
13. **t1/2:** Ligand A (35.087) has a longer in vitro half-life than Ligand B (-0.204). This is a significant advantage.
14. **Pgp:** Ligand A (0.084) has lower P-gp efflux liability than Ligand B (0.429), improving bioavailability.
15. **Affinity:** Ligand B (-6.5) has a slightly better binding affinity than Ligand A (-5.6). This is a 1.1 kcal/mol difference, which is substantial.
**GPCR-Specific Priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. While Ligand B has a slightly better affinity, Ligand A excels in most other crucial parameters, particularly DILI, hERG, metabolic stability (Cl_mic, t1/2), and Pgp efflux. The improved safety profile (lower DILI and hERG) and better ADME properties of Ligand A outweigh the slightly weaker binding affinity.
**Conclusion:**
Considering the balance of properties and the priorities for a GPCR target, Ligand A is the more promising drug candidate.
1
2025-04-17 22:14:40,012 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (364.43 and 361.52 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand B (70.15) is significantly better than Ligand A (93.12). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (1.989) is closer to the optimal 1-3 range than Ligand A (0.542). Ligand A is quite low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand B (6) is preferable to Ligand A (7). Fewer HBAs generally improve permeability.
6. **QED:** Ligand A (0.842) has a better QED score than Ligand B (0.617), indicating a more drug-like profile overall.
7. **DILI:** Ligand B (34.28) has a much lower DILI risk than Ligand A (62.66). This is a significant advantage for Ligand B.
8. **BBB:** Both ligands have reasonable BBB penetration (Ligand A: 71.50, Ligand B: 62.04). Not a major deciding factor here, as ADRB2 is not a CNS target.
9. **Caco-2:** Ligand B (-5.488) is better than Ligand A (-4.992). Higher Caco-2 permeability suggests better intestinal absorption.
10. **Solubility:** Ligand B (-2.108) is better than Ligand A (-2.667). Higher solubility is generally desirable.
11. **hERG:** Both ligands have low hERG inhibition risk (Ligand A: 0.157, Ligand B: 0.279). No significant difference.
12. **Cl_mic:** Both ligands have similar microsomal clearance (Ligand A: 16.795, Ligand B: 16.064).
13. **t1/2:** Ligand A (13.765) has a significantly longer in vitro half-life than Ligand B (4.766). This is a major advantage for Ligand A.
14. **Pgp:** Both ligands have low P-gp efflux liability (Ligand A: 0.077, Ligand B: 0.017). No significant difference.
15. **Binding Affinity:** Ligand A (-7.9) has a stronger binding affinity than Ligand B (-6.2). This is a substantial advantage.
**Overall Assessment:**
Ligand A has a superior binding affinity and longer half-life, which are critical for efficacy. While Ligand B has better DILI risk and some ADME properties (TPSA, logP, solubility, Caco-2), the difference in binding affinity (-1.7 kcal/mol) is substantial enough to outweigh these benefits. The slightly lower logP of Ligand A is a concern, but can potentially be addressed with further optimization. The longer half-life is also a significant advantage, potentially leading to less frequent dosing.
Output:
1
2025-04-17 22:14:40,013 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (340.383 and 366.487 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (78.15) is better than Ligand B (84.42). Both are below 140, but lower TPSA generally favors absorption.
3. **logP:** Both ligands have good logP values (1.519 and 2.166), falling within the optimal 1-3 range. Ligand B is slightly higher, which could potentially lead to distribution issues, but not drastically.
4. **HBD:** Both ligands have 1 HBD, which is within the acceptable limit of <=5.
5. **HBA:** Ligand A has 6 HBA, and Ligand B has 7. Both are within the acceptable limit of <=10.
6. **QED:** Both ligands have similar QED values (0.781 and 0.777), indicating good drug-likeness.
7. **DILI:** Ligand A (65.956) has a higher DILI risk than Ligand B (47.344). This is a significant negative for Ligand A.
8. **BBB:** Ligand B (71.927) has a significantly higher BBB penetration percentile than Ligand A (44.591). While ADRB2 isn't exclusively a CNS target, some CNS exposure can occur, and higher BBB is generally favorable.
9. **Caco-2:** Both ligands have similar, poor Caco-2 permeability (-4.71 and -4.732). This indicates potential absorption issues for both.
10. **Solubility:** Both ligands have very poor aqueous solubility (-2.803 and -3.044). This is a significant concern for both.
11. **hERG:** Ligand A (0.584) has a slightly higher hERG risk than Ligand B (0.329). Lower is better, so Ligand B is preferred.
12. **Cl_mic:** Ligand A (31.313) has a lower microsomal clearance than Ligand B (87.031), suggesting better metabolic stability. This is a positive for Ligand A.
13. **t1/2:** Ligand A (-15.559) has a much shorter in vitro half-life than Ligand B (-2.314). This is a significant negative for Ligand A.
14. **Pgp:** Ligand A (0.346) has lower P-gp efflux liability than Ligand B (0.102), which is favorable.
15. **Binding Affinity:** Ligand B (-7.6) has a significantly stronger binding affinity than Ligand A (-6.8). This >1.5 kcal/mol difference is substantial and outweighs many of the other drawbacks.
**Overall Assessment & GPCR Prioritization:**
Given that this is a GPCR target, affinity, logP, TPSA, and Pgp are key. Ligand B excels in affinity, has a reasonable logP, and better BBB penetration. While both have poor solubility and Caco-2 permeability, the superior binding affinity and lower DILI/hERG risk of Ligand B are decisive. The better metabolic stability of Ligand A is offset by its much shorter half-life.
Output:
0
2025-04-17 22:14:40,013 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (365.5 & 354.4 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (73.74) is significantly better than Ligand B (96.38). ADRB2 is a cardiovascular target, not CNS, but lower TPSA generally improves absorption.
3. **logP:** Ligand A (1.544) is within the optimal 1-3 range. Ligand B (-0.053) is slightly below 1, potentially hindering permeation. This is a notable advantage for A.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 5 HBA, and Ligand B has 6. Both are acceptable, but A is slightly better.
6. **QED:** Ligand A (0.859) is excellent, indicating high drug-likeness. Ligand B (0.699) is still acceptable, but less optimal.
7. **DILI:** Ligand A (30.13) has a lower DILI risk than Ligand B (42.92). This is a significant advantage for A.
8. **BBB:** Not a primary concern for a cardiovascular target. Ligand A (47.93) is lower than Ligand B (27.07), but this isn't a deciding factor.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual. I'll interpret this as very low permeability for both.
10. **Solubility:** Ligand A (-0.803) is better than Ligand B (-1.452), indicating higher solubility.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.28 and 0.141 respectively).
12. **Cl_mic:** Ligand A (-5.88) has a lower (better) microsomal clearance than Ligand B (-4.22), indicating greater metabolic stability.
13. **t1/2:** Ligand A (9.468 hours) has a significantly longer half-life than Ligand B (-21.239 hours - which is problematic). This is a major advantage for A.
14. **Pgp:** Both have very low Pgp efflux liability (0.157 and 0.037 respectively).
15. **Affinity:** Ligand B (-7.0 kcal/mol) has a significantly better binding affinity than Ligand A (-4.3 kcal/mol). This is a substantial advantage for B.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B has a better affinity, but Ligand A is better in terms of logP, TPSA, solubility, DILI, metabolic stability, and half-life. The difference in affinity is 2.7 kcal/mol, which is significant, but the overall profile of Ligand A is more balanced and suggests a higher probability of success as a drug candidate. The negative Caco-2 values for both are concerning, but the other advantages of A outweigh this issue.
**Conclusion:**
Considering the balance of properties, particularly the superior ADME profile of Ligand A, I believe it is the more viable drug candidate.
Output:
1
2025-04-17 22:14:40,013 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (378.259 Da and 338.459 Da) fall within the ideal 200-500 Da range. Ligand B is slightly smaller, which *could* be advantageous for permeability, but the difference isn't substantial.
2. **TPSA:** Both ligands (58.37 and 60.04) are below the 140 A^2 threshold for good oral absorption, and well below the 90 A^2 threshold for CNS targets (though ADRB2 isn't necessarily a CNS target). This is good for both.
3. **logP:** Both ligands have logP values within the optimal range (4.173 and 3.732). Ligand B is slightly lower, which could be beneficial for solubility, but both are acceptable.
4. **HBD:** Both have 1 HBD, which is within the ideal limit of <=5.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 6. Both are within the acceptable limit of <=10, but Ligand A is preferable.
6. **QED:** Both ligands have good QED scores (0.724 and 0.77), indicating good drug-like properties.
7. **DILI:** Ligand B has a significantly lower DILI risk (57.852 percentile) compared to Ligand A (78.17 percentile). This is a substantial advantage for Ligand B.
8. **BBB:** Ligand A has a higher BBB penetration (76.386 percentile) than Ligand B (82.047 percentile). While ADRB2 isn't a primary CNS target, some peripheral ADRB2 activity can influence CNS function, so some BBB penetration isn't necessarily negative.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.829 and -4.69). This is unusual and suggests poor permeability. However, the values are very close, so this isn't a major differentiator.
10. **Solubility:** Both ligands have very poor aqueous solubility (-5.101 and -4.387). This is a significant concern for both, and will require formulation strategies.
11. **hERG:** Both ligands have low hERG inhibition risk (0.853 and 0.841). This is good for both.
12. **Cl_mic:** Ligand B has a significantly lower microsomal clearance (56.079 mL/min/kg) compared to Ligand A (88.317 mL/min/kg). This indicates better metabolic stability for Ligand B, which is a major advantage.
13. **t1/2:** Ligand B has a much shorter in vitro half-life (25.007 hours) than Ligand A (171.3 hours). This is a significant drawback for Ligand B.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.73 and 0.684). This is good for both.
15. **Binding Affinity:** Ligand B has a slightly better binding affinity (-7.0 kcal/mol) than Ligand A (-6.9 kcal/mol). While the difference is small, it's still a positive for Ligand B.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are important. Both ligands perform similarly on logP, Pgp, and TPSA. Ligand B has a slightly better affinity. The biggest differences are in DILI and Cl_mic, where Ligand B is significantly better, and t1/2, where Ligand A is much better. The lower DILI and better metabolic stability of Ligand B are more critical than the longer half-life of Ligand A, especially considering the poor solubility of both compounds. Solubility issues can often be addressed with formulation, but mitigating toxicity and improving metabolic stability are more challenging.
**Conclusion:**
Despite the longer half-life of Ligand A, the significantly lower DILI risk and better metabolic stability of Ligand B make it the more promising drug candidate.
Output:
0
2025-04-17 22:14:40,013 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (382.511 and 348.487 Da) fall within the ideal 200-500 Da range. Ligand B is slightly smaller, which could be advantageous for permeability, but the difference isn't substantial.
2. **TPSA:** Ligand A (104.21) is higher than the preferred <140, but still reasonable. Ligand B (58.64) is excellent, well below 90, suggesting better permeability. This is a significant advantage for Ligand B.
3. **logP:** Both ligands (2.466 and 2.655) are within the optimal 1-3 range. No clear advantage here.
4. **HBD:** Ligand A has 3 HBD, while Ligand B has 1. Both are acceptable (<=5). Ligand B is slightly better.
5. **HBA:** Ligand A has 7 HBA, and Ligand B has 3. Both are acceptable (<=10). Ligand B is better.
6. **QED:** Both ligands have good QED scores (0.651 and 0.751), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (59.403) is approaching a moderate risk, while Ligand B (9.965) is very low risk. This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (54.634) has moderate BBB penetration, while Ligand B (72.392) is quite good. Considering ADRB2's role in cardiovascular function (and potentially CNS side effects), moderate CNS penetration isn't necessarily a negative, but higher is generally preferred. Ligand B is better.
9. **Caco-2:** Both have negative values, indicating poor permeability. Ligand B (-4.441) is slightly less negative than Ligand A (-5.384), suggesting marginally better absorption.
10. **Solubility:** Both ligands have very poor solubility (-2.839 and -2.939). This is a major concern for both, and formulation strategies would be critical.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.152 and 0.317). No significant difference.
12. **Cl_mic:** Ligand A (49.036) has lower microsomal clearance than Ligand B (75.684), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (40.051) has a longer in vitro half-life than Ligand B (-8.493). This is a significant advantage for Ligand A.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.15 and 0.147). No significant difference.
15. **Binding Affinity:** Ligand B (-7.2 kcal/mol) has a slightly better binding affinity than Ligand A (-6.1 kcal/mol). This 1.1 kcal/mol difference is substantial and could outweigh some of the ADME drawbacks of Ligand B.
**Overall Assessment:**
Ligand B has several advantages: significantly lower DILI risk, better TPSA, better QED, better BBB penetration, and slightly better binding affinity. The solubility is a concern for both, but the lower metabolic stability and shorter half-life of Ligand B are drawbacks. However, the superior safety profile (DILI) and potentially better absorption (TPSA, Caco-2) combined with the better binding affinity make Ligand B the more promising candidate.
Output:
0
2025-04-17 22:14:40,013 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (354.447) is slightly higher than Ligand B (345.487), but both are acceptable.
2. **TPSA:** Ligand A (95.94) is higher than Ligand B (43.86). For a cardiovascular GPCR, TPSA isn't a *major* concern unless targeting the CNS, but lower is generally preferred for better absorption. Ligand B is significantly better here.
3. **logP:** Both ligands have good logP values (A: 0.845, B: 1.437), falling within the 1-3 range. Ligand B is slightly better.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (0). Both are within the acceptable limit of 5.
5. **HBA:** Ligand A (5) is higher than Ligand B (3). Both are within the acceptable limit of 10.
6. **QED:** Both ligands have good QED scores (A: 0.598, B: 0.724), indicating good drug-like properties. Ligand B is better.
7. **DILI:** Ligand A (15.626) has a higher DILI risk than Ligand B (12.214). Lower is better, so Ligand B is preferred.
8. **BBB:** Ligand A (52.191) has a lower BBB penetration than Ligand B (69.639). Since ADRB2 is not a CNS target, this is less critical, but higher BBB is still generally favorable.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.704) is slightly worse than Ligand B (-4.264). This is a significant concern for both.
10. **Solubility:** Both ligands have negative solubility values, which is also unusual and suggests poor solubility. Ligand A (-1.217) is slightly worse than Ligand B (-2.076). This is a significant concern for both.
11. **hERG:** Both ligands have low hERG inhibition liability (A: 0.191, B: 0.294), which is good.
12. **Cl_mic:** Ligand A (51.519) has a higher microsomal clearance than Ligand B (44.849). Lower is better for metabolic stability, so Ligand B is preferred.
13. **t1/2:** Ligand B (-18.977) has a longer in vitro half-life than Ligand A (-13.899). Longer is better, so Ligand B is preferred.
14. **Pgp:** Both ligands have very low P-gp efflux liability (A: 0.03, B: 0.077), which is good.
15. **Affinity:** Ligand B (-6.5 kcal/mol) has a slightly better binding affinity than Ligand A (-6.0 kcal/mol). While the difference is not huge, it's a positive for Ligand B.
**GPCR-Specific Priorities:**
For ADRB2 (a cardiovascular GPCR), logP, TPSA, and affinity are important. Ligand B performs better on all three of these parameters. While BBB isn't critical here, Ligand B still has a better score. Metabolic stability (Cl_mic, t1/2) is also important, and Ligand B is better in both aspects.
**Overall Assessment:**
Ligand B consistently outperforms Ligand A across most key ADME properties (DILI, Cl_mic, t1/2, TPSA, QED) and has a slightly better binding affinity. The negative Caco-2 and solubility values are concerning for both, but Ligand B's profile is more favorable overall.
Output:
0
2025-04-17 22:14:40,014 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (380.495 and 348.491 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (74.77 and 74.33) are below the 140 A^2 threshold for good oral absorption, which is good.
3. **logP:** Both ligands (2.304 and 2.053) are within the optimal 1-3 range. Again, no major difference.
4. **HBD:** Ligand A (1) is better than Ligand B (2) as lower HBD generally improves permeability.
5. **HBA:** Ligand A (8) is better than Ligand B (4) as lower HBA generally improves permeability.
6. **QED:** Ligand A (0.821) has a slightly better QED score than Ligand B (0.716), indicating a more drug-like profile.
7. **DILI:** Ligand B (21.908) has a *much* lower DILI risk than Ligand A (93.253). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (65.529) has a better BBB penetration score than Ligand B (52.036). While ADRB2 isn't strictly a CNS target, some CNS exposure can occur, and higher BBB is generally favorable.
9. **Caco-2:** Ligand B (-5.107) has a more negative Caco-2 value, suggesting better intestinal absorption than Ligand A (-4.653).
10. **Solubility:** Ligand B (-1.346) has a better solubility score than Ligand A (-3.273).
11. **hERG:** Both ligands (0.69 and 0.47) have low hERG inhibition liability, which is good.
12. **Cl_mic:** Ligand B (19.449) has a significantly lower microsomal clearance than Ligand A (58.746), indicating better metabolic stability.
13. **t1/2:** Ligand B (59.219) has a significantly longer in vitro half-life than Ligand A (31.057).
14. **Pgp:** Ligand B (0.017) has a much lower P-gp efflux liability than Ligand A (0.445), suggesting better oral bioavailability and potentially better tissue distribution.
15. **Affinity:** Ligand A (-7.2 kcal/mol) has a slightly better binding affinity than Ligand B (-5.9 kcal/mol). This is a 1.3 kcal/mol difference, which is substantial.
**GPCR-Specific Priorities & Overall Assessment:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Both ligands perform well on logP and TPSA. Ligand B excels in Pgp efflux, solubility, metabolic stability (Cl_mic, t1/2), and DILI risk. Ligand A has a slightly better binding affinity. However, the significant advantages of Ligand B in ADME properties (especially DILI, Cl_mic, t1/2, and Pgp) outweigh the modest affinity difference. A slightly weaker binding affinity can often be compensated for with optimized formulation or dosing, whereas poor ADME properties are much harder to fix later in development. The lower DILI risk is a particularly important factor.
Therefore, I prefer Ligand B.
Output:
0
2025-04-17 22:14:40,014 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [368.415, 123.41 , 1.169, 2. , 7. , 0.717, 90.733, 17.642, -5.405, -3.516, 0.022, 11.921, -20.784, 0.026, -5.2 ]
**Ligand B:** [360.841, 51.66 , 2.983, 0. , 4. , 0.794, 36.409, 80.535, -4.765, -3.059, 0.5 , 63.953, 51.549, 0.255, -7.2 ]
Here's a breakdown, comparing each parameter and considering GPCR priorities (logP, Pgp, TPSA, affinity):
1. **MW:** Both are within the ideal 200-500 Da range. A (368.415) and B (360.841) are very similar.
2. **TPSA:** A (123.41) is slightly above the preferred <140 for oral absorption, but acceptable. B (51.66) is excellent, well below 140. This favors B.
3. **logP:** A (1.169) is good, within the 1-3 range. B (2.983) is also good, closer to the upper end of the range. Both are acceptable.
4. **HBD:** A (2) is good. B (0) is also good, potentially improving permeability.
5. **HBA:** A (7) is acceptable. B (4) is also good.
6. **QED:** Both A (0.717) and B (0.794) are above 0.5, indicating good drug-likeness. B is slightly better.
7. **DILI:** A (90.733) is concerning, indicating a high risk of liver injury. B (36.409) is excellent, low risk. This *strongly* favors B.
8. **BBB:** A (17.642) is very low, suggesting poor brain penetration. B (80.535) is excellent, indicating good brain penetration. While ADRB2 isn't necessarily a CNS target, higher BBB is generally preferable for GPCRs.
9. **Caco-2:** A (-5.405) is very poor. B (-4.765) is also poor, but slightly better.
10. **Solubility:** A (-3.516) is poor. B (-3.059) is also poor, but slightly better.
11. **hERG:** A (0.022) is very low risk. B (0.5) is slightly higher, but still relatively low.
12. **Cl_mic:** A (11.921) is relatively low, suggesting better metabolic stability. B (63.953) is significantly higher, indicating faster metabolism. This favors A.
13. **t1/2:** A (-20.784) is very poor. B (51.549) is good. This strongly favors B.
14. **Pgp:** A (0.026) is very low efflux, which is good. B (0.255) is also low efflux, but slightly higher.
15. **Affinity:** B (-7.2) is significantly stronger than A (-5.2), a difference of 2 kcal/mol. This is a substantial advantage.
**Overall Assessment:**
Ligand B is the clear winner. While both ligands have acceptable MW and logP values, Ligand B demonstrates significantly better safety (DILI), brain penetration (BBB), *in vitro* half-life, and, most importantly, binding affinity. The lower metabolic stability (higher Cl_mic) of B is a concern, but the 2 kcal/mol advantage in binding affinity and the much lower DILI risk outweigh this drawback. The superior TPSA is also a plus.
Output:
0
2025-04-17 22:14:40,014 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (340.379 and 353.482 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (88.52) is slightly higher than Ligand B (73.2). Both are below the 140 threshold for oral absorption, but B is better.
3. **logP:** Both ligands (3.166 and 3.199) are within the optimal 1-3 range. No significant difference.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1). Both are acceptable.
5. **HBA:** Ligand A (4) is slightly higher than Ligand B (3). Both are acceptable.
6. **QED:** Ligand A (0.892) is significantly better than Ligand B (0.728), indicating a more drug-like profile.
7. **DILI:** Ligand A (87.01) has a higher DILI risk than Ligand B (18.651). This is a significant concern for Ligand A.
8. **BBB:** Ligand B (89.919) has a much higher BBB penetration potential than Ligand A (34.548). While ADRB2 isn't necessarily a CNS target, higher BBB is generally favorable.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.87) is slightly worse than Ligand B (-4.273).
10. **Solubility:** Both ligands have negative solubility values, which is also unusual and suggests poor solubility. Ligand A (-4.306) is slightly worse than Ligand B (-3.564).
11. **hERG:** Ligand A (0.154) has a slightly lower hERG inhibition liability than Ligand B (0.872), which is preferable.
12. **Cl_mic:** Ligand A (6.35) has a significantly lower microsomal clearance than Ligand B (68.843), indicating better metabolic stability.
13. **t1/2:** Ligand A (18.44) has a longer in vitro half-life than Ligand B (-12.596). This is a major advantage for Ligand A.
14. **Pgp:** Ligand A (0.077) has a lower P-gp efflux liability than Ligand B (0.083), which is preferable.
15. **Binding Affinity:** Ligand A (-7.7) has a slightly better binding affinity than Ligand B (-7.0).
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Both ligands are good on logP. Ligand B has a better TPSA. Ligand A has better Pgp and affinity. The biggest concerns are the DILI risk for Ligand A and the poor Caco-2 and solubility for both. However, the significantly lower DILI risk for Ligand B and its better BBB penetration outweigh the slightly better affinity and metabolic stability of Ligand A.
**Conclusion:**
Considering the balance of properties, particularly the significantly lower DILI risk and better BBB penetration of Ligand B, it is the more promising drug candidate.
Output:
0
2025-04-17 22:14:40,014 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (358.43 & 339.31 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (94.82) is better than Ligand B (115.19). For a GPCR, keeping TPSA under 140 is good for oral absorption, and lower is generally preferred.
**3. logP:** Both ligands have good logP values (2.56 & 2.44), falling within the optimal 1-3 range.
**4. H-Bond Donors:** Both have 1 HBD, which is acceptable.
**5. H-Bond Acceptors:** Ligand A has 8 HBA, and Ligand B has 6. Both are within the acceptable limit of 10.
**6. QED:** Ligand A (0.728) has a significantly better QED score than Ligand B (0.319), indicating a more drug-like profile.
**7. DILI:** Ligand A (89.80) has a lower DILI risk than Ligand B (98.72), which is a crucial advantage.
**8. BBB:** Ligand A (45.13) has a lower BBB penetration than Ligand B (65.84). Since ADRB2 is a cardiovascular target, high BBB penetration isn't a priority, and is even undesirable.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.99 and -5.12), which is unusual and indicates poor permeability. However, the values are similar.
**10. Aqueous Solubility:** Both ligands have negative solubility values (-3.94 and -4.71), indicating poor solubility. This is a concern, but can be addressed with formulation strategies.
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (0.33 and 0.29).
**12. Microsomal Clearance:** Ligand A (63.99) has a lower microsomal clearance than Ligand B (102.73), indicating better metabolic stability.
**13. In vitro Half-Life:** Ligand A (-17.45) has a longer in vitro half-life than Ligand B (-22.70), which is preferable.
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (0.16 and 0.45).
**15. Binding Affinity:** Ligand A (-7.2) has a slightly better binding affinity than Ligand B (-6.5), though the difference is less than 1.5 kcal/mol.
**Overall Assessment:**
Ligand A is the stronger candidate. It has a significantly better QED score, lower DILI risk, better metabolic stability (lower Cl_mic, longer t1/2), and slightly better binding affinity. While both have poor Caco-2 and solubility, these are formulation challenges that can be addressed. The lower BBB penetration of Ligand A is actually *beneficial* for a cardiovascular target. Ligand B's higher BBB penetration is not desirable.
Output:
1
2025-04-17 22:14:40,014 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.415 and 354.51 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (84.67) is better than Ligand B (49.41). Both are below 140, but Ligand B is closer to the optimal range for GPCRs.
3. **logP:** Ligand A (1.056) is within the optimal 1-3 range, while Ligand B (3.838) is nearing the upper limit. This is a slight advantage for A.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 5 HBA, Ligand B has 2. Both are acceptable.
6. **QED:** Ligand A (0.88) is better than Ligand B (0.788), indicating a more drug-like profile.
7. **DILI:** Ligand A (41.877) has a slightly higher DILI risk than Ligand B (19.698), but both are below the concerning threshold of 60.
8. **BBB:** Ligand B (96.006) significantly outperforms Ligand A (71.501) in BBB penetration. This is a *major* advantage for Ligand B, given that ADRB2 is a GPCR and CNS penetration could be desirable.
9. **Caco-2:** Ligand A (-5.205) is worse than Ligand B (-4.659). Both are negative, indicating poor permeability, but B is slightly better.
10. **Solubility:** Ligand A (-0.864) is better than Ligand B (-3.502). Solubility is a concern for both, but A is preferable.
11. **hERG:** Ligand A (0.071) has a much lower hERG risk than Ligand B (0.676). This is a significant advantage for A.
12. **Cl_mic:** Ligand B (35.902) has a lower (better) microsomal clearance than Ligand A (26.764).
13. **t1/2:** Ligand B (-13.823) has a longer half-life than Ligand A (-11.274).
14. **Pgp:** Ligand A (0.046) has lower P-gp efflux than Ligand B (0.429).
15. **Binding Affinity:** Ligand A (-6.8) is slightly better than Ligand B (-6.5), but the difference is relatively small.
**Overall Assessment:**
Ligand B has a substantial advantage in BBB penetration, which is crucial for a GPCR target. It also has better metabolic stability (lower Cl_mic) and a longer half-life. Ligand A has better solubility and a significantly lower hERG risk. The affinity difference is small. Given the GPCR-specific priorities, the improved BBB penetration and metabolic stability of Ligand B outweigh the slightly higher hERG risk and lower solubility.
Output:
0
2025-04-17 22:14:40,015 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (339.439 and 348.418 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (45.67) is better than Ligand B (50.8), both are below the 140 threshold for oral absorption, and reasonably good for a GPCR.
3. **logP:** Both ligands (2.46 and 2.335) are within the optimal 1-3 range. Similar.
4. **HBD:** Ligand A (0) is preferable to Ligand B (1). Fewer HBDs generally improve permeability.
5. **HBA:** Both ligands (4) are within the acceptable limit of 10.
6. **QED:** Both ligands (0.862 and 0.887) have excellent drug-likeness scores.
7. **DILI:** Ligand B (13.61) is *significantly* better than Ligand A (47.421). This is a major advantage for Ligand B. A DILI percentile under 40 is highly desirable.
8. **BBB:** Both ligands have good BBB penetration (81.815 and 88.057). Since ADRB2 is a cardiovascular target, BBB penetration is not a primary concern, but higher is still slightly preferred.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. This is a significant drawback for both.
10. **Solubility:** Both ligands have poor aqueous solubility (-1.293 and -1.879). This is a concern for both, but slightly worse for Ligand B.
11. **hERG:** Both ligands have low hERG inhibition risk (0.632 and 0.634). Good.
12. **Cl_mic:** Ligand A (23.548) has a lower microsomal clearance than Ligand B (41.786), indicating better metabolic stability. This is a positive for Ligand A.
13. **t1/2:** Ligand A (36.545) has a significantly longer in vitro half-life than Ligand B (1.431). This is a substantial advantage for Ligand A.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.187 and 0.061). Good.
15. **Binding Affinity:** Ligand A (-6.6 kcal/mol) has a slightly better binding affinity than Ligand B (-5.4 kcal/mol). This is a 1.2 kcal/mol difference, which is a meaningful advantage.
**Overall Assessment:**
While both ligands have issues with Caco-2 permeability and solubility, Ligand B's significantly lower DILI risk is a major advantage. The improved metabolic stability and half-life of Ligand A are also beneficial, and its slightly better binding affinity is a plus. However, the DILI risk for Ligand A is concerning. Considering the balance, the lower DILI risk of Ligand B outweighs the other advantages of Ligand A.
Output:
0
2025-04-17 22:14:40,015 - INFO - Batch 317 complete. Total preferences: 5072
2025-04-17 22:14:40,015 - INFO - Processing batch 318/512...
2025-04-17 22:15:27,938 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, priorities are affinity, logP, TPSA, Pgp, and BBB.
* **Molecular Weight:** Both ligands are within the acceptable range (200-500 Da). Ligand A (357.841) is slightly higher than Ligand B (348.403), but this isn't a major concern.
* **TPSA:** Ligand A (62.3) is significantly better than Ligand B (127.32). A TPSA under 140 is good for oral absorption, but under 90 is preferred for CNS targets (though less critical for a cardiovascular target). Ligand B's TPSA is approaching a concerning level.
* **logP:** Ligand A (3.678) is optimal, while Ligand B (0.796) is quite low. Low logP can hinder membrane permeability.
* **H-Bond Donors/Acceptors:** Ligand A (1 HBD, 3 HBA) is preferable to Ligand B (3 HBD, 5 HBA). Fewer H-bonds generally improve permeability.
* **QED:** Both are acceptable, but Ligand A (0.83) is better than Ligand B (0.671), indicating a more drug-like profile.
* **DILI:** Ligand B (36.952) has a much lower DILI risk than Ligand A (62.117), which is a significant advantage.
* **BBB:** Ligand A (71.966) has better BBB penetration than Ligand B (58.434). While not a primary concern for a cardiovascular target, it's a positive attribute.
* **Caco-2:** Ligand A (-4.819) has a better Caco-2 permeability than Ligand B (-5.587).
* **Solubility:** Ligand A (-4.146) has better solubility than Ligand B (-2.676).
* **hERG:** Ligand A (0.329) has a better hERG profile than Ligand B (0.091).
* **Cl_mic:** Ligand B (-6.848) has significantly better metabolic stability (lower clearance) than Ligand A (29.743). This is a substantial advantage.
* **t1/2:** Ligand A (32.524) has a better in vitro half-life than Ligand B (15.027).
* **Pgp:** Ligand A (0.14) has better Pgp efflux profile than Ligand B (0.027).
* **Binding Affinity:** Ligand B (-8.6 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.8 kcal/mol). This is a >1.5 kcal/mol difference, which can outweigh many ADME drawbacks.
**Overall Assessment:**
Ligand B has a superior binding affinity and significantly better metabolic stability (Cl_mic), and lower DILI risk. However, its TPSA is higher and logP is lower, which are concerns. Ligand A has better TPSA, logP, solubility, and BBB penetration, but suffers from a weaker binding affinity and poorer metabolic stability.
Given the strong preference for binding affinity in GPCR drug discovery, and the significant difference in affinity (-8.6 vs -6.8 kcal/mol), I believe Ligand B is the more promising candidate despite its ADME liabilities. The metabolic stability issue could potentially be addressed through structural modifications.
Output:
0
2025-04-17 22:15:27,938 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (355.454 and 351.445 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (87.3) is higher than Ligand B (55.63). For a cardiovascular GPCR, TPSA is moderately important. Lower TPSA generally favors better permeability. Ligand B is significantly better.
**3. logP:** Both ligands have acceptable logP values (1.583 and 3.084), falling within the 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability, but isn't a major concern for either.
**4. H-Bond Donors:** Ligand A has 3 HBD, and Ligand B has 1. Both are within the acceptable limit of <=5. Ligand B is preferable.
**5. H-Bond Acceptors:** Ligand A has 3 HBA, and Ligand B has 5. Both are within the acceptable limit of <=10.
**6. QED:** Ligand A (0.587) has a better QED score than Ligand B (0.8). While both are above the 0.5 threshold, a higher QED is generally preferred, indicating better overall drug-likeness. Ligand B is better.
**7. DILI Risk:** Ligand A (38.116) has a lower DILI risk than Ligand B (44.436). Lower is better, so Ligand A is preferable.
**8. BBB Penetration:** Ligand B (91.586) has significantly higher BBB penetration than Ligand A (70.027). While ADRB2 is a cardiovascular target and CNS penetration isn't *essential*, some level of BBB penetration can be useful for off-target effects assessment and potential future therapeutic applications. Ligand B is better.
**9. Caco-2 Permeability:** Ligand A (-5.099) has worse Caco-2 permeability than Ligand B (-4.879). Higher is better, so Ligand B is preferred.
**10. Aqueous Solubility:** Ligand A (-2.681) has worse aqueous solubility than Ligand B (-3.759). Higher is better, so Ligand B is preferred.
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.264 and 0.443), which is excellent. No significant difference.
**12. Microsomal Clearance:** Ligand A (6.954) has significantly lower microsomal clearance than Ligand B (13.812). Lower clearance indicates better metabolic stability, which is a key advantage. Ligand A is much better.
**13. In vitro Half-Life:** Ligand A (-2.652) has a significantly longer in vitro half-life than Ligand B (16.124). Longer half-life is generally desirable. Ligand A is much better.
**14. P-gp Efflux:** Both ligands have low P-gp efflux (0.081 and 0.545). Ligand A is better.
**15. Binding Affinity:** Both ligands have excellent binding affinity (-4.9 and -4.4 kcal/mol). Ligand A has a slightly better affinity, but the difference is not substantial enough to outweigh other factors.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity) and general drug-like properties, **Ligand B** emerges as the more promising candidate. While Ligand A has better metabolic stability and half-life, Ligand B's superior TPSA, BBB penetration, Caco-2 permeability, solubility, and QED score are more critical for a GPCR target, particularly one where some level of systemic exposure is desired. The slight difference in binding affinity is less important than the ADME advantages of Ligand B.
Output:
0
2025-04-17 22:15:27,938 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (351.535 and 349.399 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (52.65) is significantly better than Ligand B (123.72). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary goal, but lower TPSA generally correlates with better absorption. Ligand B's TPSA is quite high, potentially hindering oral bioavailability.
3. **logP:** Ligand A (2.649) is within the optimal 1-3 range. Ligand B (-0.902) is below 1, which is a concern for membrane permeability.
4. **HBD:** Both ligands have 1 HBD, which is acceptable.
5. **HBA:** Ligand A has 3 HBA, while Ligand B has 9. Ligand B is pushing the upper limit for HBA, potentially impacting permeability.
6. **QED:** Ligand A (0.8) is better than Ligand B (0.589), indicating a more drug-like profile.
7. **DILI:** Ligand A (11.09) has a much lower DILI risk than Ligand B (60.14). This is a significant advantage for Ligand A.
8. **BBB:** This isn't a major concern for a cardiovascular target. Ligand A (68.592) is reasonable, while Ligand B (39.783) is lower.
9. **Caco-2:** Ligand A (-4.621) is better than Ligand B (-5.805), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-2.202) is better than Ligand B (-0.615), indicating better aqueous solubility.
11. **hERG:** Both ligands have very low hERG risk (0.364 and 0.03 respectively), which is excellent.
12. **Cl_mic:** Ligand B (34.429) has a lower microsomal clearance than Ligand A (43.532), suggesting better metabolic stability.
13. **t1/2:** Ligand B (15.809) has a significantly longer in vitro half-life than Ligand A (4.964). This is a positive for Ligand B.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.09 and 0.027 respectively), which is good.
15. **Binding Affinity:** Ligand B (-7.3 kcal/mol) has a slightly better binding affinity than Ligand A (-6.9 kcal/mol). This 0.4 kcal/mol difference is noticeable, but not overwhelmingly significant given the other factors.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand A performs better on logP and TPSA, while Ligand B has a slightly better affinity. However, the significant advantages of Ligand A in terms of DILI risk, QED, solubility, and Caco-2 permeability outweigh the small affinity difference.
**Conclusion:**
Considering the overall profile, Ligand A is the more promising drug candidate. Its superior ADME properties (lower DILI, better solubility, permeability, and QED) and acceptable affinity make it a better choice than Ligand B, despite Ligand B's slightly improved affinity and half-life.
Output:
1
2025-04-17 22:15:27,939 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (378.796 Da and 341.455 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (61.19) is better than Ligand B (81.99). GPCRs benefit from lower TPSA for permeability, and Ligand A is closer to the preferred <90 threshold.
**3. logP:** Ligand A (4.28) is slightly higher than Ligand B (3.017). While both are within the 1-3 range, Ligand A is approaching the upper limit and could potentially have solubility issues.
**4. H-Bond Donors:** Ligand A (0) is preferable to Ligand B (2). Fewer H-bond donors generally improve permeability.
**5. H-Bond Acceptors:** Ligand A (5) is preferable to Ligand B (3).
**6. QED:** Ligand B (0.762) has a slightly better QED score than Ligand A (0.575), indicating a more drug-like profile.
**7. DILI Risk:** Ligand B (41.76) is significantly better than Ligand A (61.807). Lower DILI risk is crucial.
**8. BBB Penetration:** Ligand A (67.197) is better than Ligand B (55.06), although BBB isn't a primary concern for a cardiovascular target.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.568 and -4.61). This is unusual and suggests poor permeability *in vitro*. However, the values are very similar.
**10. Aqueous Solubility:** Both ligands have negative solubility values (-3.822 and -4.189), indicating poor aqueous solubility.
**11. hERG Inhibition:** Both ligands have similar, low hERG inhibition liability (0.479 and 0.511).
**12. Microsomal Clearance:** Ligand B (26.85) has significantly lower microsomal clearance than Ligand A (74.709), indicating better metabolic stability.
**13. In vitro Half-Life:** Ligand B (6.12 hours) has a much longer half-life than Ligand A (1.987 hours). This is a significant advantage.
**14. P-gp Efflux:** Ligand A (0.665) is slightly better than Ligand B (0.092), indicating lower P-gp efflux.
**15. Binding Affinity:** Both ligands have the same binding affinity (-6.5 kcal/mol).
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand B is the more promising candidate. While Ligand A has slightly better TPSA and Pgp, Ligand B excels in critical areas like DILI risk, metabolic stability (lower Cl_mic and longer t1/2), and QED. The similar binding affinity makes these ADME properties the deciding factors. The poor Caco-2 and solubility are concerning for both, but can be addressed with formulation strategies. The lower DILI and better metabolic stability of Ligand B are more difficult to fix later in development.
Output:
0
2025-04-17 22:15:27,939 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (355.429 and 349.431 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (71.09) is significantly better than Ligand B (95.58). ADRB2 is a cardiovascular target, not CNS, but lower TPSA is generally favorable for absorption. Ligand A is well below the 140 threshold, while B is approaching it.
3. **logP:** Ligand A (2.692) is optimal, while Ligand B (0.378) is quite low. For a GPCR, logP between 1-3 is preferred, and B is below this range, potentially hindering membrane permeability.
4. **HBD:** Both ligands have 2 HBD, which is within the acceptable limit of <=5.
5. **HBA:** Ligand A has 3 HBA, and Ligand B has 4. Both are within the acceptable limit of <=10.
6. **QED:** Both ligands have good QED scores (0.715 and 0.75), indicating good drug-like properties.
7. **DILI:** Ligand A (40.016%) has a slightly higher DILI risk than Ligand B (24.544%), but both are below the concerning 60% threshold.
8. **BBB:** Not a primary concern for a cardiovascular target like ADRB2, but Ligand A (65.839%) is better than Ligand B (45.444%).
9. **Caco-2:** Ligand A (-4.917) and Ligand B (-5.257) are both negative, indicating poor permeability. This is concerning.
10. **Solubility:** Ligand A (-3.036) is better than Ligand B (-1.681), indicating better aqueous solubility.
11. **hERG:** Ligand A (0.556) has a slightly higher hERG risk than Ligand B (0.022), but both are low and acceptable.
12. **Cl_mic:** Ligand A (47.684) has a higher microsomal clearance than Ligand B (-10.797). This suggests Ligand B is more metabolically stable, which is desirable.
13. **t1/2:** Ligand A (10.291) has a shorter in vitro half-life than Ligand B (-13.368). Ligand B appears to have a much longer half-life.
14. **Pgp:** Ligand A (0.081) has lower P-gp efflux than Ligand B (0.007), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand B (-6.9 kcal/mol) has a slightly better binding affinity than Ligand A (-5.9 kcal/mol). This is a 1 kcal/mol difference, which is significant but not overwhelming.
**Overall Assessment:**
Ligand B has a clear advantage in metabolic stability (lower Cl_mic, longer t1/2) and binding affinity. However, its low logP is a major concern for permeability and overall drug-like properties. Ligand A, while having a slightly higher DILI risk and lower metabolic stability, has a much more favorable logP and TPSA, and better solubility. Considering the GPCR-specific priorities (logP, TPSA, affinity), and the fact that this is a cardiovascular target (BBB is less critical), the better balance of properties in Ligand A makes it the more promising candidate. The slightly better affinity of Ligand B isn't enough to overcome its poor logP.
Output:
1
2025-04-17 22:15:27,939 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.459 and 348.531 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (87.66) is higher than Ligand B (49.41). For a cardiovascular GPCR like ADRB2, TPSA isn't a *major* concern unless it's excessively high, but lower is generally preferred for better permeability. Ligand B is significantly better here.
3. **logP:** Ligand A (1.26) is within the optimal range, while Ligand B (3.911) is approaching the upper limit. While 3.911 isn't terrible, it could potentially lead to off-target interactions or solubility issues. Ligand A is slightly favored.
4. **HBD:** Ligand A (3) is higher than Ligand B (1). Lower HBD is generally preferred for permeability. Ligand B is better.
5. **HBA:** Ligand A (4) is higher than Ligand B (2). Similar to HBD, lower HBA is generally preferred. Ligand B is better.
6. **QED:** Both ligands have good QED scores (0.697 and 0.766), indicating good drug-like properties. No clear winner.
7. **DILI:** Ligand A (28.616) has a higher DILI risk than Ligand B (16.208). Lower DILI is crucial, making Ligand B significantly better.
8. **BBB:** Ligand A (28.81) has low BBB penetration, while Ligand B (73.711) has good BBB penetration. While ADRB2 isn't a CNS target, some degree of BBB penetration can be beneficial for understanding off-target effects and overall distribution. Ligand B is favored.
9. **Caco-2:** Ligand A (-5.095) has a worse Caco-2 permeability than Ligand B (-4.37). Higher Caco-2 is better, so Ligand B is slightly favored.
10. **Solubility:** Ligand A (-2.783) has a worse solubility than Ligand B (-4.415). Higher solubility is better, so Ligand B is favored.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.136 and 0.166). No significant difference.
12. **Cl_mic:** Ligand A (28.402) has a lower microsomal clearance than Ligand B (79.523). Lower clearance is desirable for metabolic stability. Ligand A is favored.
13. **t1/2:** Ligand A (15.624) has a longer in vitro half-life than Ligand B (3.824). Longer half-life is generally preferred. Ligand A is favored.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.046 and 0.071). No significant difference.
15. **Binding Affinity:** Ligand A (-7.5 kcal/mol) has a *much* stronger binding affinity than Ligand B (-1.8 kcal/mol). This is a substantial difference (5.7 kcal/mol) and is a major deciding factor.
**Overall Assessment:**
Ligand A has a significantly stronger binding affinity and better metabolic stability (lower Cl_mic, longer t1/2). However, Ligand B excels in ADME properties like TPSA, DILI risk, BBB penetration, solubility and Caco-2 permeability. The binding affinity difference is so large that it outweighs the ADME advantages of Ligand B. While Ligand B has a better ADME profile, a weak binder is unlikely to be a viable drug candidate.
Output:
1
2025-04-17 22:15:27,939 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (366.49 and 386.90 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (78.27) is better than Ligand B (86.71). Both are below 140, but lower TPSA generally favors better absorption.
**3. logP:** Both ligands have acceptable logP values (1.23 and 1.39), falling within the 1-3 range. No clear advantage.
**4. H-Bond Donors:** Ligand A (1) is preferable to Ligand B (2). Lower HBDs are generally better for permeability.
**5. H-Bond Acceptors:** Ligand A (7) is preferable to Ligand B (4). Lower HBA counts are generally better for permeability.
**6. QED:** Both ligands have similar QED scores (0.782 and 0.749), indicating good drug-like properties.
**7. DILI:** Ligand B (43.66) has a slightly lower DILI risk than Ligand A (48.31), which is a minor advantage.
**8. BBB:** Both ligands have similar BBB penetration (57.19 and 48.97). Given ADRB2 is a cardiovascular target, BBB penetration is not a high priority.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and requires further investigation. However, the values are similar (-5.55 and -5.19).
**10. Aqueous Solubility:** Both ligands have negative solubility values, which is also unusual and requires further investigation. Ligand A (-2.50) is slightly better than Ligand B (-3.43).
**11. hERG Inhibition:** Ligand A (0.084) has a much lower hERG inhibition risk than Ligand B (0.495). This is a significant advantage, as hERG inhibition can lead to cardiotoxicity.
**12. Microsomal Clearance:** Ligand A (22.67) has a lower microsomal clearance than Ligand B (42.27), suggesting better metabolic stability.
**13. In vitro Half-Life:** Ligand B (-37.09) has a significantly longer in vitro half-life than Ligand A (10.31). This is a major advantage, potentially allowing for less frequent dosing.
**14. P-gp Efflux:** Ligand A (0.063) has lower P-gp efflux liability than Ligand B (0.283), which is favorable for bioavailability.
**15. Binding Affinity:** Ligand B (-7.0) has a stronger binding affinity than Ligand A (-5.2). This is a substantial advantage, potentially outweighing some of the ADME drawbacks.
**Overall Assessment:**
While Ligand B has a significantly better binding affinity and a longer half-life, Ligand A demonstrates a superior safety profile with a much lower hERG inhibition risk and lower P-gp efflux. Considering the cardiovascular target, minimizing cardiotoxicity (hERG) is paramount. The slightly better metabolic stability (lower Cl_mic) and better TPSA/H-bond properties of Ligand A also contribute to its favorability. The negative solubility and Caco-2 values for both ligands are concerning and require further investigation, but the overall balance of properties leans towards Ligand A.
Output:
1
2025-04-17 22:15:27,940 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (354.407 and 352.431 Da) fall comfortably within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (108.05) is slightly higher than Ligand B (93.73). Both are below the 140 threshold for good oral absorption, but Ligand B is closer to the preferred <90 for GPCRs.
3. **logP:** Ligand A (-1.669) is lower than Ligand B (1.074). Ligand B is within the optimal 1-3 range, while Ligand A is slightly below 1, potentially impacting permeability.
4. **HBD:** Both ligands have 2 H-bond donors, which is within the acceptable limit of 5. No difference.
5. **HBA:** Ligand A has 6 H-bond acceptors, and Ligand B has 5. Both are below the 10 limit.
6. **QED:** Both ligands have similar QED values (0.552 and 0.503), indicating good drug-likeness.
7. **DILI:** Ligand A (26.755) has a significantly lower DILI risk than Ligand B (35.983). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (56.766) has a considerably higher BBB penetration percentile than Ligand A (29.74). While ADRB2 isn't strictly a CNS target, some CNS exposure can be tolerated and might even be beneficial depending on the specific therapeutic goal.
9. **Caco-2:** Both ligands have similar, very poor Caco-2 permeability (-5.175 and -5.179). This is a concern for both.
10. **Solubility:** Ligand A (-0.425) has slightly better aqueous solubility than Ligand B (-1.879).
11. **hERG:** Both ligands have very low hERG inhibition risk (0.021 and 0.082). This is positive for both.
12. **Cl_mic:** Ligand A (3.252) has a much lower microsomal clearance than Ligand B (34.574), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (-20.296) has a more negative in vitro half-life, which translates to a longer half-life, than Ligand B (-11.779). This is a strong advantage for Ligand A.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.003 and 0.028).
15. **Binding Affinity:** Both ligands have similar binding affinities (-5.9 and -5.6 kcal/mol), which are both good. The difference of 0.3 kcal/mol is not substantial enough to be a deciding factor.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B has a better logP and TPSA, but Ligand A has significantly better metabolic stability (Cl_mic and t1/2) and a much lower DILI risk. The affinity difference is minimal.
**Overall Assessment:**
While Ligand B has slightly better predicted permeability characteristics (TPSA, logP), the significant advantages of Ligand A in terms of metabolic stability, DILI risk, and half-life outweigh these minor differences. The poor Caco-2 permeability is a concern for both, but can be addressed with formulation strategies. The lower DILI risk is a critical factor for clinical development.
Output:
1
2025-04-17 22:15:27,940 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (346.446 Da and 366.527 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (41.57) is significantly better than Ligand B (67.34). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is getting a bit high, potentially hindering absorption.
**3. logP:** Both ligands have good logP values (4.089 and 2.98), falling within the optimal 1-3 range. Ligand A is slightly higher, which *could* be a minor concern for solubility, but is still acceptable.
**4. H-Bond Donors:** Ligand A has 1 HBD, Ligand B has 0. Both are good.
**5. H-Bond Acceptors:** Ligand A has 2 HBA, Ligand B has 4. Both are within the acceptable limit of 10, but Ligand A is preferred.
**6. QED:** Both ligands have reasonable QED values (0.876 and 0.744), indicating good drug-like properties. Ligand A is slightly better.
**7. DILI:** Both ligands have low DILI risk (37.611 and 31.718), both well below the 40% threshold. Ligand B is slightly better.
**8. BBB:** Both ligands have high BBB penetration (92.71 and 87.67). This is excellent for a GPCR target, even if not specifically in the CNS.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.399 and -4.741). This is unusual and requires further investigation, but doesn't immediately disqualify either. It suggests potential issues with permeability *in vitro*, but the negative values could be due to experimental artifacts.
**10. Aqueous Solubility:** Both ligands have poor aqueous solubility (-4.598 and -2.739). This is a concern, and formulation strategies would be needed. Ligand B is slightly better.
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (0.713 and 0.476). This is good. Ligand B is better.
**12. Microsomal Clearance:** Ligand A has higher microsomal clearance (85.414) than Ligand B (63.122). Lower clearance is preferred for better metabolic stability, so Ligand B is better.
**13. In vitro Half-Life:** Ligand A has a longer half-life (20.481 hours) than Ligand B (-2.383 hours). This is a significant advantage for Ligand A.
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (0.642 and 0.533). This is good.
**15. Binding Affinity:** Ligand B has a significantly stronger binding affinity (-5.1 kcal/mol) compared to Ligand A (-2.3 kcal/mol). This is a substantial difference and a major factor favoring Ligand B. A 2.8 kcal/mol difference is very significant.
**Overall Assessment:**
While Ligand A has some advantages (better TPSA, QED, and half-life), the dramatically superior binding affinity of Ligand B (-5.1 vs -2.3 kcal/mol) outweighs these benefits. The slightly higher TPSA and lower half-life of Ligand B are less critical given the strong binding. The solubility issues are similar for both, and can be addressed with formulation. The slightly better DILI and hERG scores for Ligand B are also positive.
Therefore, I recommend Ligand B.
0
2025-04-17 22:15:27,940 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (340.423 and 348.491 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (67.43) is significantly better than Ligand B (86.88). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (1.885 and 2.836), falling within the 1-3 range. Ligand B is slightly higher, which could potentially lead to some off-target interactions, but it's not a major concern.
4. **HBD:** Both ligands have acceptable HBD counts (2 and 3).
5. **HBA:** Both ligands have acceptable HBA counts (3).
6. **QED:** Both ligands have similar QED values (0.614 and 0.641), indicating good drug-likeness.
7. **DILI:** Ligand A (55.332) has a higher DILI risk than Ligand B (17.255). This is a significant negative for Ligand A.
8. **BBB:** Ligand B (63.164) has a higher BBB penetration percentile than Ligand A (49.864). While not crucial for a cardiovascular target, higher BBB is generally favorable.
9. **Caco-2:** Ligand A (-4.66) has a better Caco-2 permeability than Ligand B (-5.171).
10. **Solubility:** Ligand A (-3.109) has better aqueous solubility than Ligand B (-2.417).
11. **hERG:** Both ligands have very low hERG inhibition liability (0.171 and 0.361), which is excellent.
12. **Cl_mic:** Ligand A (13.432) has a significantly lower microsomal clearance than Ligand B (25.717), indicating better metabolic stability.
13. **t1/2:** Ligand B (-16.338) has a much longer in vitro half-life than Ligand A (-1.375). This is a substantial advantage for Ligand B.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.058 and 0.082).
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.2 and -6.4 kcal/mol). The difference is negligible.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has better TPSA and solubility, while Ligand B has better BBB and half-life. However, the significantly lower DILI risk for Ligand B and its longer half-life are more important considerations. The slight advantage in metabolic stability of Ligand A is outweighed by the DILI risk.
**Conclusion:**
Considering the balance of properties, particularly the lower DILI risk and longer half-life of Ligand B, it is the more promising drug candidate.
Output:
0
2025-04-17 22:15:27,940 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [348.487, 67.43, 2.559, 2, 3, 0.725, 18.418, 51.803, -4.682, -2.685, 0.211, 29.089, 13.951, 0.079, -5.9]
**Ligand B:** [361.475, 88.09, 2.072, 2, 9, 0.691, 78.907, 66.615, -5.247, -3.122, 0.587, 59.948, 22.702, 0.076, -5.4]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (348.487) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (67.43) is better than Ligand B (88.09), falling comfortably under the 140 threshold for oral absorption.
3. **logP:** Both are within the optimal 1-3 range. Ligand A (2.559) is slightly higher, which could be beneficial for membrane permeability but also carries a slightly higher risk of off-target interactions.
4. **HBD:** Both have 2 HBD, which is good.
5. **HBA:** Ligand A (3) is better than Ligand B (9). Lower HBA is generally preferred for better permeability.
6. **QED:** Both are above 0.5, indicating reasonable drug-likeness, but Ligand A (0.725) is slightly better.
7. **DILI:** Ligand A (18.418) has a significantly lower DILI risk than Ligand B (78.907). This is a major advantage.
8. **BBB:** Ligand B (66.615) has a better BBB penetration score than Ligand A (51.803). While ADRB2 isn't strictly a CNS target, some peripheral distribution is still important, and a higher BBB score can sometimes correlate with better overall distribution.
9. **Caco-2:** Ligand B (-5.247) has a slightly better Caco-2 permeability than Ligand A (-4.682).
10. **Solubility:** Ligand B (-3.122) has slightly better solubility than Ligand A (-2.685).
11. **hERG:** Ligand A (0.211) has a lower hERG risk than Ligand B (0.587). This is a significant advantage for cardiovascular safety.
12. **Cl_mic:** Ligand A (29.089) has a lower microsomal clearance, suggesting better metabolic stability, than Ligand B (59.948).
13. **t1/2:** Ligand B (22.702) has a longer in vitro half-life than Ligand A (13.951). This could translate to less frequent dosing.
14. **Pgp:** Both have very low Pgp efflux liability (0.079 and 0.076 respectively), which is good.
15. **Affinity:** Ligand A (-5.9) has a slightly better binding affinity than Ligand B (-5.4).
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, we prioritize logP, TPSA, Pgp, and affinity. Ligand A is better on TPSA, Pgp, and affinity. Ligand B is better on BBB and half-life. However, the substantial improvements in DILI and hERG risk for Ligand A, combined with its slightly better affinity, outweigh the benefits of Ligand B's slightly better BBB and half-life. The lower DILI and hERG risks are crucial for a cardiovascular target.
**Conclusion:**
Ligand A is the more promising candidate due to its superior safety profile (lower DILI and hERG), better TPSA, and slightly better binding affinity.
1
2025-04-17 22:15:27,940 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (347.5 and 351.4 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (62.3) is significantly better than Ligand B (116.68). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is quite high, potentially hindering absorption.
**3. logP:** Ligand A (3.437) is optimal, while Ligand B (-0.966) is too low. A negative logP can significantly reduce permeability and bioavailability. This is a major drawback for Ligand B.
**4. H-Bond Donors:** Both have acceptable HBD counts (1 and 3 respectively), within the guideline of <=5.
**5. H-Bond Acceptors:** Ligand A (3) is better than Ligand B (7). Lower HBA is generally preferred for better permeability.
**6. QED:** Both ligands have reasonable QED scores (0.66 and 0.524), indicating acceptable drug-likeness.
**7. DILI:** Ligand A (23.11) has a much lower DILI risk than Ligand B (31.097). Lower is better, and Ligand A is comfortably within the 'good' range.
**8. BBB:** Ligand A (67.701) has a better BBB penetration score than Ligand B (50.523), although neither is exceptionally high. For a cardiovascular target, BBB penetration is less critical than for CNS targets, but still a positive attribute.
**9. Caco-2 Permeability:** Ligand A (-4.618) is better than Ligand B (-5.139). Both are negative, indicating poor permeability, but A is slightly better.
**10. Aqueous Solubility:** Ligand A (-3.273) is better than Ligand B (-1.162). Both are negative, indicating poor solubility, but A is slightly better.
**11. hERG Inhibition:** Ligand A (0.76) has a much lower hERG inhibition liability than Ligand B (0.124). This is a critical safety parameter, and Ligand A is significantly safer.
**12. Microsomal Clearance:** Ligand B (-6.469) has a lower (better) microsomal clearance than Ligand A (79.415). This suggests better metabolic stability for Ligand B.
**13. In vitro Half-Life:** Ligand A (26.278) has a much longer in vitro half-life than Ligand B (-15.256). This is a significant advantage for Ligand A, potentially allowing for less frequent dosing.
**14. P-gp Efflux:** Ligand A (0.314) has a lower P-gp efflux liability than Ligand B (0.002). Lower efflux is preferred.
**15. Binding Affinity:** Ligand A (-7.4) has a slightly better binding affinity than Ligand B (-5.2). While both are good, the 1.5 kcal/mol difference is noticeable.
**Overall Assessment:**
Ligand A is the clear winner. While Ligand B has better metabolic stability (lower Cl_mic), its significantly lower logP, higher TPSA, and higher hERG risk are major liabilities. Ligand A balances potency, safety, and ADME properties much more effectively, particularly considering the GPCR target class. The better binding affinity, lower DILI, and improved BBB penetration further solidify its position as the more promising candidate.
Output:
1
2025-04-17 22:15:27,941 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (344.499 and 345.403 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (49.41) is significantly better than Ligand B (108.88). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand B's TPSA is quite high, potentially hindering oral bioavailability.
3. **logP:** Ligand A (2.966) is optimal. Ligand B (0.595) is quite low, potentially leading to poor membrane permeability. This is a significant drawback.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (2) is preferable to Ligand B (5). Similar reasoning as with HBDs.
6. **QED:** Ligand A (0.833) is better than Ligand B (0.651), indicating a more drug-like profile.
7. **DILI:** Ligand A (22.14) is *much* better than Ligand B (60.295). This is a critical advantage for Ligand A; a DILI percentile over 60 is concerning.
8. **BBB:** Ligand A (78.054) is better than Ligand B (32.765), although BBB isn't a high priority for a cardiovascular target.
9. **Caco-2:** Ligand A (-4.866) is better than Ligand B (-5.586). Both are negative, which is unusual and requires further investigation, but A is slightly better.
10. **Solubility:** Ligand A (-3.956) is better than Ligand B (-2.316). Higher solubility is generally preferred.
11. **hERG:** Ligand A (0.514) is better than Ligand B (0.152). Lower hERG inhibition is crucial for avoiding cardiotoxicity, especially given the cardiovascular target.
12. **Cl_mic:** Ligand A (26.651) is worse than Ligand B (10.905). Lower clearance is better, so Ligand B has an advantage here.
13. **t1/2:** Ligand A (5.145) is better than Ligand B (-19.397). A positive half-life is preferable to a negative one.
14. **Pgp:** Ligand A (0.161) is better than Ligand B (0.025). Lower P-gp efflux is generally desirable.
15. **Binding Affinity:** Ligand B (-6.9) is significantly better than Ligand A (-2.4). This is a substantial advantage for Ligand B. However, the other ADME properties of Ligand B are significantly worse.
**Overall Assessment:**
While Ligand B has a much stronger binding affinity, its significantly worse ADME profile, particularly the high TPSA, low logP, high DILI risk, and poor hERG profile, make it a less viable drug candidate. Ligand A presents a much more balanced profile, with acceptable binding affinity and significantly better predicted ADME properties. The difference in binding affinity, while substantial, is potentially surmountable with further optimization of Ligand A, whereas correcting the severe ADME issues of Ligand B would be a much larger undertaking. Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand A strikes a better balance.
Output:
1
2025-04-17 22:15:27,941 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 drug candidates. ADRB2 is a GPCR, so we'll prioritize logP, TPSA, Pgp, BBB, and affinity.
**Ligand A:**
* **MW:** 372.447 Da - Good, within the ideal range.
* **TPSA:** 110.6 - Acceptable, but approaching the upper limit for good absorption.
* **logP:** -0.191 - Too low. This is a significant concern for membrane permeability and bioavailability.
* **HBD:** 1 - Good.
* **HBA:** 7 - Good.
* **QED:** 0.717 - Excellent, very drug-like.
* **DILI:** 40.946 - Good, low risk.
* **BBB:** 64.482 - Moderate, not ideal for a GPCR, but not a dealbreaker for a peripherally acting one.
* **Caco-2:** -4.827 - Very poor permeability. Consistent with the low logP.
* **Solubility:** -2.156 - Poor solubility.
* **hERG:** 0.151 - Very low risk, excellent.
* **Cl_mic:** 43.07 - Moderate clearance, could be better.
* **t1/2:** -32.78 - Very short half-life, problematic.
* **Pgp:** 0.028 - Low efflux, good.
* **Affinity:** -6.7 kcal/mol - Good binding affinity.
**Ligand B:**
* **MW:** 349.431 Da - Good, within the ideal range.
* **TPSA:** 80.76 - Excellent, well within the optimal range.
* **logP:** 2.146 - Excellent, within the optimal range.
* **HBD:** 1 - Good.
* **HBA:** 5 - Good.
* **QED:** 0.824 - Excellent, very drug-like.
* **DILI:** 35.712 - Good, low risk.
* **BBB:** 80.07 - Good, potentially useful even for a peripherally acting GPCR.
* **Caco-2:** -4.378 - Poor permeability, but better than Ligand A.
* **Solubility:** -1.794 - Poor solubility, but better than Ligand A.
* **hERG:** 0.407 - Low risk, good.
* **Cl_mic:** 31.636 - Good, lower clearance than Ligand A.
* **t1/2:** -12.253 - Short half-life, but better than Ligand A.
* **Pgp:** 0.034 - Low efflux, good.
* **Affinity:** -5.7 kcal/mol - Good binding affinity, though slightly weaker than Ligand A.
**Comparison and Decision:**
Ligand A has a better binding affinity (-6.7 vs -5.7 kcal/mol). However, its extremely low logP and resulting poor Caco-2 permeability and solubility are major drawbacks. The short half-life is also a concern.
Ligand B, while having slightly weaker affinity, has a much more favorable logP, TPSA, and better predicted permeability and solubility. It also exhibits better metabolic stability (lower Cl_mic) and a slightly longer half-life. The BBB score is also significantly better.
For a GPCR, balancing permeability, solubility, and metabolic stability is crucial. The slightly weaker binding affinity of Ligand B can potentially be optimized in subsequent iterations, while fixing the severe ADME issues of Ligand A would likely require a more substantial redesign.
Therefore, I prefer Ligand B.
0
2025-04-17 22:15:27,941 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (408.351) is slightly higher than Ligand B (351.422), but both are acceptable.
2. **TPSA:** Both are below the 140 A^2 threshold for good oral absorption. Ligand A (74.58) is slightly higher than Ligand B (70.67), but still good.
3. **logP:** Both ligands have optimal logP values (1-3). Ligand A (2.504) and Ligand B (1.642) are both within the range, with A being slightly more lipophilic.
4. **HBD:** Both have 2 H-bond donors, which is within the acceptable limit of <=5.
5. **HBA:** Ligand A has 5 H-bond acceptors, and Ligand B has 4. Both are below the acceptable limit of <=10.
6. **QED:** Both ligands have good QED scores (>=0.5). Ligand B (0.552) is slightly better than Ligand A (0.511).
7. **DILI:** Both ligands have low DILI risk (<40). Ligand A (36.293) and Ligand B (35.479) are very similar and both favorable.
8. **BBB:** Ligand B (77.123) has a significantly higher BBB penetration percentile than Ligand A (65.801). Given ADRB2's involvement in cardiovascular function, CNS penetration isn't a primary requirement, but it isn't detrimental either.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-5.436) is slightly worse than Ligand B (-5.027).
10. **Solubility:** Both have negative solubility values, which is also unusual and suggests poor aqueous solubility. Ligand A (-3.112) is worse than Ligand B (-1.794).
11. **hERG:** Both ligands have very low hERG inhibition risk (0.263 and 0.552 respectively), which is excellent.
12. **Cl_mic:** Ligand B (-1.397) has a much lower (better) microsomal clearance than Ligand A (19.517). This indicates better metabolic stability for Ligand B.
13. **t1/2:** Ligand A (32.885) has a longer in vitro half-life than Ligand B (17.461). This is a positive for Ligand A.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.1 and 0.105 respectively), which is excellent.
15. **Binding Affinity:** Ligand A (-5.7 kcal/mol) has a slightly better binding affinity than Ligand B (-5.5 kcal/mol). This is a 0.2 kcal/mol difference, which is not substantial.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A has a slightly better logP and affinity, but Ligand B has better TPSA, and comparable Pgp. The biggest difference is in metabolic stability (Cl_mic) where Ligand B is significantly better, and solubility where Ligand B is better.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity and half-life, Ligand B demonstrates superior ADME properties, particularly its significantly lower microsomal clearance and better solubility. The slightly better BBB penetration of Ligand B is a minor benefit. Given the importance of metabolic stability and solubility for *in vivo* efficacy, and the relatively small difference in binding affinity, Ligand B is the more promising candidate.
Output:
0
2025-04-17 22:15:27,941 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands (347.419 and 345.403 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (107.19) is slightly higher than Ligand B (95.8). Both are below the 140 threshold for oral absorption, but B is closer to the preferred <90 for GPCRs.
3. **logP:** Ligand B (0.962) is closer to the optimal 1-3 range than Ligand A (0.075). A's logP is quite low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (2), but both are within the acceptable limit of 5.
5. **HBA:** Ligand A (4) is lower than Ligand B (5), both are within the acceptable limit of 10.
6. **QED:** Ligand A (0.701) has a better QED score than Ligand B (0.593), suggesting better overall drug-likeness.
7. **DILI:** Ligand A (42.691) has a significantly lower DILI risk than Ligand B (64.405). This is a major advantage for A.
8. **BBB:** Both ligands have the same BBB penetration (45.909). This isn't a high value, but acceptable for a peripherally acting ADRB2 target.
9. **Caco-2:** Both ligands have similar, poor Caco-2 permeability (-5.386 and -5.305).
10. **Solubility:** Ligand A (-2.852) has slightly worse solubility than Ligand B (-2.178), but both are quite poor.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.302 and 0.206).
12. **Cl_mic:** Ligand A (9.088) has a much lower microsomal clearance than Ligand B (15.877), indicating better metabolic stability.
13. **t1/2:** Ligand A (-2.84) has a slightly worse in vitro half-life than Ligand B (-2.301).
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.03 and 0.051).
15. **Binding Affinity:** Both ligands have very similar binding affinities (-5.8 and -5.7 kcal/mol). The difference is negligible.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, and metabolic stability are key. Ligand B has a better logP and TPSA, but Ligand A has a significantly better DILI score and lower Cl_mic. The binding affinity is almost identical. Given the importance of minimizing toxicity and maximizing metabolic stability for a chronic cardiovascular target, the lower DILI and Cl_mic of Ligand A are more valuable than the slightly better logP and TPSA of Ligand B.
**Conclusion:**
Ligand A is the more promising candidate due to its superior safety profile (lower DILI) and metabolic stability (lower Cl_mic), outweighing the minor advantages of Ligand B in logP and TPSA.
Output:
1
2025-04-17 22:15:27,942 - INFO - Batch 318 complete. Total preferences: 5088
2025-04-17 22:15:27,942 - INFO - Processing batch 319/512...
2025-04-17 22:16:16,146 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [366.487, 84.42, 1.827, 1, 6, 0.796, 55.758, 59.093, -4.867, -2.701, 0.187, 77.526, 9.112, 0.119, -6.8]
**Ligand B:** [354.491, 59.08, 1.781, 0, 4, 0.633, 9.926, 88.135, -4.271, -0.763, 0.337, 52.051, -5.606, 0.068, -7.1]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (354.491) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (84.42) is higher than Ligand B (59.08). Both are acceptable for a non-CNS GPCR, but Ligand B is better.
3. **logP:** Both are optimal (around 1.8). Very similar.
4. **HBD:** Ligand A (1) is slightly better than Ligand B (0). Fewer HBDs are generally preferred for permeability.
5. **HBA:** Ligand A (6) is higher than Ligand B (4). Ligand B is better.
6. **QED:** Ligand A (0.796) is better than Ligand B (0.633), indicating a more drug-like profile.
7. **DILI:** Ligand A (55.758) has a higher DILI risk than Ligand B (9.926). This is a significant advantage for Ligand B.
8. **BBB:** Ligand B (88.135) has significantly better BBB penetration potential than Ligand A (59.093). While ADRB2 isn't exclusively a CNS target, some cardiovascular effects are mediated by central pathways, and better BBB penetration isn't necessarily a negative.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand B (-4.271) is slightly less negative than Ligand A (-4.867), suggesting marginally better absorption.
10. **Solubility:** Ligand B (-0.763) is better than Ligand A (-2.701). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.187) has a slightly higher hERG risk than Ligand B (0.337). Lower is better.
12. **Cl_mic:** Ligand B (52.051) has lower microsomal clearance than Ligand A (77.526), indicating better metabolic stability.
13. **t1/2:** Ligand B (-5.606) has a longer in vitro half-life than Ligand A (9.112). This is a significant advantage.
14. **Pgp:** Ligand B (0.068) has lower P-gp efflux than Ligand A (0.119), which is favorable for bioavailability.
15. **Affinity:** Ligand B (-7.1) has a better binding affinity than Ligand A (-6.8). This is a crucial advantage, as a 0.3 kcal/mol difference is substantial.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B excels in these areas. The significantly better affinity, combined with lower DILI risk, better metabolic stability, longer half-life, and lower Pgp efflux, outweigh the slightly better QED of Ligand A.
**Conclusion:**
Ligand B is the more promising drug candidate.
0
2025-04-17 22:16:16,147 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (370.856 and 349.431 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (69.3) is significantly better than Ligand B (84.67). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (2.369 and 1.387), falling within the 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Both have 1 HBD, which is acceptable.
5. **HBA:** Ligand A has 3 HBA, while Ligand B has 5. Ligand A is preferable here, keeping the HBA count lower.
6. **QED:** Both have similar QED values (0.888 and 0.839), indicating good drug-likeness.
7. **DILI:** Ligand A (43.35) has a moderately higher DILI risk than Ligand B (13.067). This is a significant advantage for Ligand B.
8. **BBB:** Both have acceptable BBB penetration (74.292 and 73.827). Not a major differentiating factor for a cardiovascular target.
9. **Caco-2:** Both have negative Caco-2 values (-4.842 and -4.837), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-3.601) has slightly worse solubility than Ligand B (-1.787), but both are poor.
11. **hERG:** Ligand A (0.669) has a slightly higher hERG risk than Ligand B (0.147). This is a significant advantage for Ligand B.
12. **Cl_mic:** Ligand B (21.181) has a higher microsomal clearance than Ligand A (16.605), meaning faster metabolism and potentially lower exposure. Ligand A is preferable.
13. **t1/2:** Ligand A (-18.188) has a much longer *in vitro* half-life than Ligand B (6.471). This is a major advantage for Ligand A.
14. **Pgp:** Ligand A (0.186) has lower P-gp efflux than Ligand B (0.015), which is preferable.
15. **Binding Affinity:** Ligand A (-7.5 kcal/mol) has a slightly better binding affinity than Ligand B (-6.4 kcal/mol). This 1.1 kcal/mol difference is substantial and can outweigh some ADME concerns.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A performs better on logP, TPSA, and Pgp, and has a significantly higher affinity. While Ligand B has better DILI and hERG profiles, the affinity difference is substantial. The poor Caco-2 and solubility for both are concerning, but can potentially be addressed with formulation strategies.
**Overall Assessment:**
Despite the lower DILI and hERG scores of Ligand B, the significantly better binding affinity, longer half-life, and more favorable TPSA/Pgp profile of Ligand A make it the more promising candidate. The affinity difference is large enough to potentially overcome the slightly higher DILI and hERG risks, especially considering the target is cardiovascular and not CNS.
Output:
1
2025-04-17 22:16:16,147 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's break down the comparison based on the provided guidelines and GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key).
1. **Molecular Weight:** Both ligands (355.463 and 356.495 Da) fall comfortably within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (66.63) is higher than Ligand B (49.33). While both are below the 140 threshold for oral absorption, the lower TPSA of Ligand B is preferable for a GPCR, potentially aiding in membrane permeability.
3. **logP:** Both ligands have good logP values (3.612 and 2.964), falling within the optimal 1-3 range. Ligand B is slightly better.
4. **H-Bond Donors/Acceptors:** Ligand A has 2 HBD and 5 HBA, while Ligand B has 0 HBD and 5 HBA. The lower HBD count of Ligand B is slightly advantageous for permeability.
5. **QED:** Both have good QED scores (0.734 and 0.848), indicating good drug-like properties. Ligand B is slightly better.
6. **DILI:** Ligand B (41.993) has a significantly lower DILI risk than Ligand A (59.907). This is a major advantage for Ligand B.
7. **BBB:** Ligand B (77.821) exhibits better BBB penetration potential than Ligand A (51.415). While ADRB2 isn't exclusively a CNS target, some CNS exposure can occur, and higher BBB is generally favorable.
8. **Caco-2 Permeability:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand B (-4.78) is slightly better than Ligand A (-5.31).
9. **Aqueous Solubility:** Both have negative solubility values, which is also unusual. Ligand B (-2.085) is slightly better than Ligand A (-3.559).
10. **hERG Inhibition:** Ligand A (0.295) has a slightly lower hERG risk than Ligand B (0.794), which is a positive.
11. **Microsomal Clearance:** Ligand A (3.171) has significantly lower microsomal clearance than Ligand B (42.009), indicating better metabolic stability. This is a significant advantage for Ligand A.
12. **In vitro Half-Life:** Ligand A (8.786) has a shorter half-life than Ligand B (-11.096). The negative value for Ligand B is concerning and likely an error.
13. **P-gp Efflux:** Ligand A (0.157) has lower P-gp efflux liability than Ligand B (0.371), which is preferable.
14. **Binding Affinity:** Ligand A (-6.3 kcal/mol) has a slightly better binding affinity than Ligand B (-5.8 kcal/mol). While the difference is less than 1.5 kcal/mol, it contributes to the overall assessment.
**Overall Assessment:**
Ligand B demonstrates a superior profile in several key areas: DILI risk, BBB penetration, QED, and TPSA. The slightly better logP also contributes. While Ligand A has better metabolic stability (lower Cl_mic) and slightly better binding affinity, the lower DILI and improved permeability characteristics of Ligand B outweigh these advantages, especially considering the GPCR target class. The negative half-life for Ligand B is a major concern, and may indicate an issue with the data.
**Output:**
0
2025-04-17 22:16:16,147 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.431 and 352.435 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Both are good (91.4 and 89.57), being under 140, suggesting reasonable absorption.
3. **logP:** Ligand B (1.144) is better than Ligand A (0.422). ADRB2 is a cardiovascular target, so CNS penetration isn't critical, but a slightly higher logP is generally preferred for membrane permeability. Ligand A is quite low.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1), but both are within the acceptable limit of 5.
5. **HBA:** Ligand B (6) is higher than Ligand A (4), but both are under the limit of 10.
6. **QED:** Both are very similar (0.773 and 0.755), indicating good drug-likeness.
7. **DILI:** Ligand A (34.781) has a significantly lower DILI risk than Ligand B (47.499). This is a major advantage for Ligand A.
8. **BBB:** Not a primary concern for a cardiovascular target, but Ligand A (64.211) is slightly better than Ligand B (51.842).
9. **Caco-2:** Both are very poor (-5.019 and -5.204). This is a significant drawback for both.
10. **Solubility:** Both are very poor (-1.693 and -1.769). This is a significant drawback for both.
11. **hERG:** Both are very low (0.136 and 0.159), indicating low cardiotoxicity risk.
12. **Cl_mic:** Ligand A (-0.698) has *much* lower (better) microsomal clearance than Ligand B (22.867), suggesting better metabolic stability.
13. **t1/2:** Ligand B (15.372) has a significantly longer half-life than Ligand A (-14.686). This is a significant advantage for Ligand B.
14. **Pgp:** Both are very low (0.016 and 0.031), indicating minimal P-gp efflux.
15. **Binding Affinity:** Ligand B (-7.5 kcal/mol) has a substantially stronger binding affinity than Ligand A (-4.8 kcal/mol). This is a 2.7 kcal/mol difference, which is a very large advantage, and outweighs many of the ADME concerns.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand B excels in affinity. While Ligand A has better DILI and Cl_mic, the substantial binding affinity advantage of Ligand B is critical. The poor Caco-2 and solubility are concerning for both, but can be addressed with formulation strategies.
**Conclusion:**
Despite the better safety profile (DILI) and metabolic stability (Cl_mic) of Ligand A, the significantly stronger binding affinity of Ligand B (-7.5 vs -4.8 kcal/mol) is the deciding factor. The difference in affinity is large enough to overcome the moderate drawbacks in DILI and Cl_mic.
Output:
0
2025-04-17 22:16:16,148 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (351.403 and 352.475 Da) fall comfortably within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (70.08) is significantly better than Ligand A (116.76). ADRB2 is a cardiovascular target, not a CNS target, but lower TPSA generally improves absorption. This favors Ligand B.
3. **logP:** Ligand B (1.412) is within the optimal 1-3 range, while Ligand A (-1.32) is below 1, potentially hindering permeability. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (4) is slightly higher than Ligand B (1), but both are acceptable (<=5).
5. **HBA:** Both ligands have 4-5 HBA, which is within the acceptable range.
6. **QED:** Ligand B (0.834) has a much better QED score than Ligand A (0.425), indicating a more drug-like profile. This is a substantial advantage for Ligand B.
7. **DILI:** Ligand B (12.02) has a much lower DILI risk than Ligand A (33.695). This is a significant safety advantage for Ligand B.
8. **BBB:** Not a primary concern for a cardiovascular target, but Ligand B (49.011) is higher than Ligand A (29.003).
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, Ligand B (-4.494) is slightly less negative than Ligand A (-5.204).
10. **Solubility:** Both ligands have negative solubility values, which is also unusual. Ligand B (-1.162) is slightly better than Ligand A (-1.354).
11. **hERG:** Both ligands have very low hERG inhibition risk (0.101 and 0.176). No significant difference.
12. **Cl_mic:** Ligand A (4.168) has a lower microsomal clearance than Ligand B (5.627), suggesting better metabolic stability. This favors Ligand A.
13. **t1/2:** Ligand B (23.254) has a much longer in vitro half-life than Ligand A (-10.535). This is a significant advantage for Ligand B.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.007 and 0.061). No significant difference.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.8 and -6.9 kcal/mol). The difference is negligible.
**Overall Assessment:**
Ligand B clearly outperforms Ligand A across most critical parameters. It has a superior QED score, lower DILI risk, better logP and TPSA values, and a significantly longer half-life. While Ligand A has slightly better metabolic stability (lower Cl_mic), the other advantages of Ligand B outweigh this single benefit. Given the GPCR-specific priorities (logP, TPSA, and affinity), Ligand B is the more promising candidate.
Output:
0
2025-04-17 22:16:16,148 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.443 and 345.403 Da) fall comfortably within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (75.71) is better than Ligand B (106.1). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (1.508 and 1.074), falling within the 1-3 range. Ligand B is slightly lower, but still acceptable.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (4) is better than Ligand B (6). Similar to HBD, lower HBA is generally preferred.
6. **QED:** Ligand B (0.741) has a significantly better QED score than Ligand A (0.448), indicating a more drug-like profile overall. This is a point in favor of B.
7. **DILI:** Ligand A (25.785) has a much lower DILI risk than Ligand B (74.564). This is a *major* advantage for Ligand A. DILI is a serious concern in drug development.
8. **BBB:** Both ligands have similar BBB penetration (63.009 and 61.962). Not a critical factor for a cardiovascular target like ADRB2.
9. **Caco-2:** Ligand A (-4.641) and Ligand B (-5.198) are both very poor. This suggests poor intestinal absorption.
10. **Solubility:** Ligand A (-2.038) is slightly better than Ligand B (-2.877), but both are quite poor.
11. **hERG:** Ligand A (0.113) is better than Ligand B (0.322), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand B (46.448) has a slightly lower microsomal clearance than Ligand A (40.883), suggesting better metabolic stability.
13. **t1/2:** Ligand B (23.614) has a significantly longer in vitro half-life than Ligand A (-19.274). This is a substantial advantage for Ligand B.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.043 and 0.046).
15. **Binding Affinity:** Ligand B (-7.1) has a significantly stronger binding affinity than Ligand A (-4.8). This is a *major* advantage, potentially outweighing some ADME concerns. A 2.3 kcal/mol difference is substantial.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, affinity, logP, TPSA, and Pgp are key. Ligand B excels in affinity and has acceptable logP and Pgp. While its TPSA is higher, the significantly improved binding affinity is a strong driver. The DILI risk for Ligand B is concerning, but the affinity difference is large enough to warrant further investigation and potential mitigation strategies.
**Conclusion:**
Despite the higher DILI risk and slightly worse TPSA, the significantly stronger binding affinity of Ligand B, coupled with its better QED and longer half-life, make it the more promising candidate. The difference in binding affinity is substantial enough to prioritize over the ADME drawbacks, which could potentially be addressed through further optimization.
Output:
0
2025-04-17 22:16:16,148 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (341.543 and 352.41 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (18.51) is significantly lower than Ligand B (107.11). For a GPCR, lower TPSA is generally preferred for better permeability. Ligand B's TPSA is quite high, potentially hindering absorption.
**3. logP:** Ligand A (3.824) is within the optimal 1-3 range. Ligand B (1.197) is on the lower side, which could lead to permeability issues.
**4. H-Bond Donors:** Ligand A (1) is preferable to Ligand B (4). Fewer HBDs generally improve membrane permeability.
**5. H-Bond Acceptors:** Ligand A (3) is preferable to Ligand B (4).
**6. QED:** Ligand A (0.878) has a much better QED score than Ligand B (0.639), indicating a more drug-like profile.
**7. DILI Risk:** Ligand A (8.647) has a significantly lower DILI risk than Ligand B (61.691). This is a crucial advantage, as liver toxicity is a major concern in drug development.
**8. BBB Penetration:** Ligand A (98.022) shows excellent BBB penetration, while Ligand B (53.664) is much lower. While ADRB2 is primarily a cardiovascular target, some CNS effects are possible with beta-blockers, and good BBB penetration isn't necessarily detrimental.
**9. Caco-2 Permeability:** Both have negative values, indicating permeability issues, but Ligand A (-4.882) is better than Ligand B (-5.316).
**10. Aqueous Solubility:** Both have negative values, indicating poor solubility. Ligand A (-2.884) is slightly better than Ligand B (-3.142).
**11. hERG Inhibition:** Ligand A (0.983) has a lower hERG inhibition risk than Ligand B (0.34). This is a significant advantage, as hERG inhibition can cause cardiotoxicity.
**12. Microsomal Clearance:** Ligand B (-12.363) has a much lower (better) microsomal clearance than Ligand A (1.062), suggesting greater metabolic stability.
**13. In vitro Half-Life:** Ligand B (-2.006) has a better in vitro half-life than Ligand A (31.781).
**14. P-gp Efflux:** Ligand A (0.14) has a lower P-gp efflux than Ligand B (0.06), which is preferable.
**15. Binding Affinity:** Ligand B (-8.2) has a stronger binding affinity than Ligand A (-5.6). This is a 2.6 kcal/mol difference, which is substantial and could potentially outweigh some of the ADME drawbacks of Ligand B.
**Overall Assessment:**
Despite Ligand B's superior binding affinity, Ligand A is the more promising candidate. The combination of significantly lower DILI risk, better QED, lower TPSA, better BBB penetration, and lower hERG inhibition risk are critical advantages. While Ligand B has better metabolic stability and half-life, these can often be addressed through structural modifications during lead optimization. The high TPSA and DILI risk of Ligand B are more difficult to overcome. The affinity difference, while significant, isn't so large that it completely overrides the other crucial factors.
Output:
1
2025-04-17 22:16:16,148 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (384.845 Da) is slightly higher than Ligand B (344.459 Da), but both are acceptable.
**2. TPSA:** Ligand A (99.68) is higher than Ligand B (75.19). For a GPCR, keeping TPSA lower is preferable for better permeability, giving a slight edge to Ligand B.
**3. logP:** Ligand B (2.196) is within the optimal range (1-3), while Ligand A (0.666) is slightly below. This favors Ligand B, as a slightly higher logP can improve membrane permeability.
**4. H-Bond Donors:** Both ligands have 1 HBD, which is acceptable.
**5. H-Bond Acceptors:** Ligand A has 6 HBAs, and Ligand B has 4. Both are within the acceptable limit of 10.
**6. QED:** Both ligands have good QED scores (A: 0.726, B: 0.858), indicating good drug-like properties. Ligand B is slightly better.
**7. DILI Risk:** Ligand B (39.899) has a significantly lower DILI risk than Ligand A (71.384). This is a major advantage for Ligand B.
**8. BBB Penetration:** Both ligands have good BBB penetration (A: 75.107, B: 76.541), which is important for GPCR targets, but not critical for ADRB2 specifically.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. This is a concern for both, but the negative value is a data artifact and doesn't necessarily mean they are poorly permeable.
**10. Aqueous Solubility:** Both ligands have negative solubility values, which is also unusual. Similar to Caco-2, this is likely a data artifact.
**11. hERG Inhibition:** Ligand A (0.02) has a very low hERG risk, while Ligand B (0.254) is slightly higher. Ligand A is preferable here.
**12. Microsomal Clearance:** Ligand A (-5.409) has a much lower (better) microsomal clearance than Ligand B (40.68). This indicates better metabolic stability for Ligand A.
**13. In Vitro Half-Life:** Ligand A (-2.481) has a negative half-life, which is impossible. Ligand B (-10.545) also has a negative half-life. This is a clear data issue for both.
**14. P-gp Efflux:** Ligand A (0.02) has very low P-gp efflux, while Ligand B (0.077) is slightly higher. This favors Ligand A.
**15. Binding Affinity:** Ligand B (-8.0 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.7 kcal/mol). This is a substantial advantage for Ligand B, potentially outweighing some of the ADME drawbacks.
**Overall Assessment:**
Despite the data quality issues (negative solubility and half-life), Ligand B is the more promising candidate. The significantly stronger binding affinity (-8.0 vs -5.7 kcal/mol) is a major advantage for a GPCR target. The lower DILI risk is also crucial. While Ligand A has better hERG and P-gp profiles and better metabolic stability, the affinity difference is too large to ignore. The slightly better logP and TPSA of Ligand B are also beneficial.
Output:
0
2025-04-17 22:16:16,149 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (340.39 and 381.89 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (93.01) is slightly higher than Ligand B (88.91), but both are below the 140 threshold for good oral absorption. Given ADRB2 is a cardiovascular target, CNS penetration isn't paramount, so this isn't a major discriminator.
3. **logP:** Ligand A (0.827) is a bit low, potentially hindering permeation. Ligand B (2.321) is within the optimal 1-3 range. This favors Ligand B.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Both ligands have 6 HBA, which is acceptable.
6. **QED:** Both ligands have similar QED values (0.89 and 0.831), indicating good drug-likeness.
7. **DILI:** Ligand A (64.754) has a significantly lower DILI risk than Ligand B (78.945). This is a crucial advantage for Ligand A.
8. **BBB:** Ligand A (61.535) has a slightly better BBB penetration than Ligand B (50.446), but this isn't a major concern for a cardiovascular target.
9. **Caco-2:** Both ligands have very poor Caco-2 permeability (-5.144 and -5.168). This is a significant drawback for both.
10. **Solubility:** Ligand A (-1.655) has better solubility than Ligand B (-3.684). Solubility is important for bioavailability.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.143 and 0.25). This is good.
12. **Cl_mic:** Ligand A (11.611) has a lower microsomal clearance than Ligand B (6.65), suggesting better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand B (31.103) has a much longer in vitro half-life than Ligand A (8.26). This is a significant advantage for Ligand B.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.019 and 0.213).
15. **Binding Affinity:** Ligand B (-6.6) has a slightly better binding affinity than Ligand A (-6.3). However, the difference is only 0.3 kcal/mol, which isn't substantial enough to outweigh other factors.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand B has a better logP and slightly better affinity, but Ligand A has better DILI risk and metabolic stability (Cl_mic). The poor Caco-2 permeability is a concern for both, but can be addressed with formulation strategies.
**Overall Assessment:**
While Ligand B has a slightly better affinity and half-life, Ligand A's superior DILI profile, solubility, and metabolic stability are more critical for overall drug development success. The slightly lower logP of Ligand A is a manageable issue, while the higher DILI risk of Ligand B is a major red flag.
Output:
1
2025-04-17 22:16:16,149 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [378.395, 139.8 , 1.655, 2. , 9. , 0.516, 99.069, 23.149, -5.774, -3.191, 0.347, 19.387, 14.009, 0.089, -6.6 ]
**Ligand B:** [352.431, 93.73 , 1.074, 2. , 5. , 0.503, 35.983, 56.766, -5.179, -1.879, 0.082, 34.574, -11.779, 0.028, -5.6 ]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, Affinity, and to a lesser extent BBB):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (352.431) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (139.8) is close to the 140 cutoff, while Ligand B (93.73) is well below, indicating better potential for oral absorption and CNS penetration.
3. **logP:** Both are within the optimal 1-3 range. Ligand A (1.655) is slightly higher than Ligand B (1.074).
4. **HBD/HBA:** Both have 2 HBD and acceptable HBA counts (9 and 5 respectively).
5. **QED:** Both are very similar and above the 0.5 threshold, indicating good drug-likeness.
6. **DILI:** Ligand A has a very high DILI risk (99.069%), which is a major red flag. Ligand B is much better (35.983%).
7. **BBB:** Ligand B (56.766%) has a significantly higher BBB penetration potential than Ligand A (23.149%). While ADRB2 isn't exclusively a CNS target, some degree of BBB penetration can be beneficial, and a lower value is concerning.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
9. **Solubility:** Both have negative solubility values, again, the scale is not specified.
10. **hERG:** Both have very low hERG inhibition risk, which is excellent.
11. **Cl_mic:** Ligand A (19.387) has a lower microsomal clearance than Ligand B (34.574), suggesting better metabolic stability.
12. **t1/2:** Ligand A (14.009) has a longer in vitro half-life than Ligand B (-11.779), which is desirable.
13. **Pgp:** Ligand A (0.089) has a lower P-gp efflux liability than Ligand B (0.028), indicating potentially better absorption and bioavailability.
14. **Affinity:** Ligand A (-6.6 kcal/mol) has a slightly better binding affinity than Ligand B (-5.6 kcal/mol), a difference of 1.0 kcal/mol.
**Overall Assessment:**
Despite Ligand A having a slightly better binding affinity and metabolic stability, the extremely high DILI risk is a deal-breaker. The significantly lower DILI risk, better BBB penetration, and lower TPSA of Ligand B make it a much more promising candidate, even with slightly lower affinity and higher P-gp efflux. The difference in affinity (1.0 kcal/mol) is not large enough to overcome the substantial safety concerns associated with Ligand A.
Output:
0
2025-04-17 22:16:16,149 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (337.339) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (95.04) is better than Ligand A (115.98), being closer to the <140 threshold for good oral absorption.
3. **logP:** Both ligands have similar and optimal logP values (around 1.5), indicating good partitioning properties.
4. **HBD:** Ligand B (1) is preferable to Ligand A (4) as lower HBD generally improves permeability.
5. **HBA:** Ligand B (7) is acceptable, while Ligand A (4) is also good.
6. **QED:** Both ligands have good QED scores (A: 0.51, B: 0.699), suggesting drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand B (35.789) has a significantly lower DILI risk than Ligand A (85.537). This is a major advantage for Ligand B.
8. **BBB:** Ligand B (65.839) has a better BBB penetration score than Ligand A (40.558). While ADRB2 isn't exclusively a CNS target, some CNS exposure/off-target effects are possible, so higher BBB is a plus.
9. **Caco-2:** Both are negative, indicating poor permeability. This is a concern for both.
10. **Solubility:** Both ligands have negative solubility values, suggesting poor solubility. This is a concern for both.
11. **hERG:** Both ligands have low hERG inhibition liability, which is good.
12. **Cl_mic:** Ligand A (-4.185) has a lower (better) microsomal clearance than Ligand B (8.022), indicating better metabolic stability.
13. **t1/2:** Ligand B (-2.376) has a better in vitro half-life than Ligand A (66.321).
14. **Pgp:** Both ligands have low P-gp efflux liability, which is good.
15. **Binding Affinity:** Ligand A (-7.8) has a significantly stronger binding affinity than Ligand B (-5.5). This is a substantial advantage for Ligand A.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Both ligands have acceptable logP and Pgp values. Ligand B has a better TPSA. However, the substantial difference in binding affinity (-7.8 vs -5.5 kcal/mol) is a significant factor. A 2.3 kcal/mol difference is often enough to overcome minor ADME drawbacks. The lower DILI risk and better BBB penetration of Ligand B are also positive.
**Overall Assessment:**
While Ligand A has a superior binding affinity, Ligand B has a much better safety profile (DILI) and better BBB penetration. The affinity difference is significant, but the ADME/Tox profile of Ligand B is considerably more favorable. Considering the balance of properties, and the importance of minimizing toxicity in drug development, I favor Ligand B.
Output:
0
2025-04-17 22:16:16,149 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A: [346.406, 65.54, 1.74, 1, 4, 0.844, 60.915, 80.031, -4.578, -2.835, 0.431, 34.223, 12.196, 0.027, -6.3]**
**Ligand B: [344.415, 87.46, 0.982, 2, 5, 0.784, 41.877, 33.075, -4.871, -1.473, 0.336, 11.022, 20.857, 0.065, -3.3]**
Here's a breakdown, comparing each parameter and considering GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal range (200-500 Da). A is 346.4, B is 344.4 - very similar.
2. **TPSA:** A (65.54) is significantly better than B (87.46). ADRB2 is not a CNS target, but lower TPSA generally favors absorption.
3. **logP:** A (1.74) is optimal, while B (0.982) is a bit low, potentially hindering membrane permeability.
4. **HBD:** A (1) is preferable to B (2). Fewer HBDs generally improve permeability.
5. **HBA:** A (4) is better than B (5). Lower HBA also favors permeability.
6. **QED:** A (0.844) is better than B (0.784), indicating a more drug-like profile.
7. **DILI:** A (60.915) is higher risk than B (41.877). This is a significant drawback for A.
8. **BBB:** Not critical for a cardiovascular target. A (80.031) is higher than B (33.075), but this isn't a deciding factor.
9. **Caco-2:** Both are negative, indicating poor permeability. A (-4.578) is slightly worse than B (-4.871).
10. **Solubility:** Both are negative, indicating poor solubility. B (-1.473) is slightly better than A (-2.835).
11. **hERG:** Both are low risk (0.431 and 0.336).
12. **Cl_mic:** A (34.223) is higher than B (11.022), suggesting faster metabolism and lower stability for A.
13. **t1/2:** B (20.857) has a longer half-life than A (12.196), which is desirable.
14. **Pgp:** A (0.027) has much lower P-gp efflux than B (0.065), which is a significant advantage for bioavailability.
15. **Affinity:** A (-6.3 kcal/mol) has a significantly stronger binding affinity than B (-3.3 kcal/mol). This is a substantial advantage, potentially outweighing some ADME concerns.
**Overall Assessment:**
Ligand A has a significantly better binding affinity and lower P-gp efflux, which are crucial for a GPCR ligand. It also has better TPSA, logP, HBD, HBA, and QED scores. However, its DILI risk is higher, and its metabolic stability (Cl_mic) is lower. Ligand B has a lower DILI risk and better half-life, but its affinity is considerably weaker, and its logP is suboptimal.
The strong affinity of Ligand A is a major advantage. While the DILI risk is a concern, it's something that could potentially be addressed through further structural modifications. The weaker affinity of Ligand B makes it less likely to be effective at a reasonable dose.
Therefore, I would prioritize Ligand A.
1
2025-04-17 22:16:16,149 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [340.423, 71.34, 4.771, 2, 3, 0.713, 76.425, 49.244, -4.822, -5.375, 0.665, 60.772, 97.842, 0.704, -8.5]
**Ligand B:** [359.857, 54.43, 4.191, 1, 5, 0.717, 22.761, 28.81, -5.286, -3.694, 0.895, 55.584, 37.483, 0.439, -6.6]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal 200-500 Da range. Ligand A (340.423) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (71.34) is higher than Ligand B (54.43). Both are acceptable for a non-CNS GPCR target like ADRB2, but Ligand B is better.
3. **logP:** Both have good logP values (A: 4.771, B: 4.191), within the 1-3 range, although A is a bit high.
4. **HBD:** Ligand A (2) has fewer HBD than Ligand B (1), which is slightly preferable.
5. **HBA:** Ligand A (3) has fewer HBA than Ligand B (5), which is preferable.
6. **QED:** Both have similar and acceptable QED values (A: 0.713, B: 0.717).
7. **DILI:** Ligand A (76.425) has a significantly higher DILI risk than Ligand B (22.761). This is a major concern.
8. **BBB:** Not a primary concern for ADRB2 (cardiovascular target), but Ligand A (49.244) has a slightly higher BBB penetration than Ligand B (28.81).
9. **Caco-2:** Ligand A (-4.822) has a worse Caco-2 permeability than Ligand B (-5.286).
10. **Solubility:** Ligand A (-5.375) has worse solubility than Ligand B (-3.694).
11. **hERG:** Ligand A (0.665) has a lower hERG risk than Ligand B (0.895), which is good.
12. **Cl_mic:** Ligand B (55.584) has a slightly lower microsomal clearance than Ligand A (60.772), suggesting better metabolic stability.
13. **t1/2:** Ligand A (97.842) has a significantly longer in vitro half-life than Ligand B (37.483). This is a major advantage.
14. **Pgp:** Ligand A (0.704) has lower P-gp efflux than Ligand B (0.439), which is preferable.
15. **Affinity:** Ligand A (-8.5 kcal/mol) has a substantially stronger binding affinity than Ligand B (-6.6 kcal/mol). This is a significant advantage, potentially outweighing some ADME concerns.
**GPCR-Specific Priorities:** For ADRB2, we prioritize logP, Pgp, TPSA, and affinity. Ligand A excels in affinity and Pgp, while Ligand B has better TPSA. However, the *extremely* high DILI risk associated with Ligand A is a major red flag. While the affinity difference is substantial, the safety concern is too significant to ignore. The longer half-life of Ligand A is also a benefit.
**Conclusion:**
Despite the superior binding affinity and half-life of Ligand A, the significantly elevated DILI risk makes it a less desirable candidate. Ligand B, while having a weaker binding affinity, presents a much more favorable safety profile.
Output:
0
2025-04-17 22:16:16,150 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (343.358) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are reasonably low, but Ligand A (64.43) is better than Ligand B (67.87), increasing the likelihood of good oral absorption.
3. **logP:** Both ligands have good logP values (1.36-1.623), falling within the optimal range of 1-3.
4. **HBD:** Ligand A has 0 HBD, which is excellent. Ligand B has 1, still acceptable, but less ideal.
5. **HBA:** Ligand A has 5 HBA, and Ligand B has 4. Both are within the acceptable limit of 10.
6. **QED:** Both ligands have acceptable QED scores (0.85 and 0.696), indicating good drug-like properties. Ligand A is better.
7. **DILI:** Ligand A (67.778) has a higher DILI risk than Ligand B (32.842). This is a significant drawback for Ligand A.
8. **BBB:** Both ligands show high BBB penetration (91.625 and 90.694). This is less critical for ADRB2 (a cardiovascular target) but doesn't hurt either candidate.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
10. **Solubility:** Both ligands have negative solubility values, which is also unusual. Again, the scale is unclear, making interpretation difficult.
11. **hERG:** Both ligands have low hERG inhibition risk (0.606 and 0.447).
12. **Cl_mic:** Ligand B (-13.28) has a significantly lower (better) microsomal clearance than Ligand A (18.438), indicating better metabolic stability.
13. **t1/2:** Ligand B (-2.955) has a longer in vitro half-life than Ligand A (-16.919), which is favorable.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.102 and 0.025).
15. **Binding Affinity:** Ligand A (-5.9 kcal/mol) has a slightly better binding affinity than Ligand B (-4.7 kcal/mol). This is a 1.2 kcal/mol difference, which is substantial.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Both ligands perform well on logP and Pgp. Ligand A has a slightly better TPSA. The affinity difference is significant, favoring Ligand A. However, the DILI risk for Ligand A is concerning. The improved metabolic stability and half-life of Ligand B are also important considerations.
**Overall Assessment:**
While Ligand A has a better binding affinity and TPSA, the significantly higher DILI risk and poorer metabolic stability are major concerns. Ligand B, despite slightly lower affinity, presents a much more favorable safety and pharmacokinetic profile. The difference in affinity, while notable, can potentially be optimized in later stages of drug development.
Output:
0
2025-04-17 22:16:16,150 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (334.419 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (55.56) is significantly better than Ligand B (107.19). ADRB2 is not a CNS target, but lower TPSA generally correlates with better absorption. Ligand B is above the preferred 90 for CNS targets, and also less ideal for general absorption.
3. **logP:** Ligand A (4.366) is higher than the optimal range (1-3), but still potentially manageable. Ligand B (0.308) is *too* low, which could severely hinder membrane permeability and bioavailability.
4. **HBD:** Ligand A (1) is preferred over Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (2) is better than Ligand B (5). Similar reasoning as HBD.
6. **QED:** Both ligands have similar QED values (A: 0.681, B: 0.712), indicating good drug-likeness.
7. **DILI:** Ligand B (51.609) has a much lower DILI risk than Ligand A (72.858), which is a significant advantage.
8. **BBB:** Ligand A (82.047) has better BBB penetration than Ligand B (25.94), but BBB isn't a primary concern for ADRB2.
9. **Caco-2:** Ligand A (-4.645) is better than Ligand B (-5.668). Higher (less negative) values indicate better permeability.
10. **Solubility:** Ligand A (-5.047) is better than Ligand B (-2.023).
11. **hERG:** Ligand A (0.906) has a lower hERG risk than Ligand B (0.069). This is a crucial safety parameter, and Ligand A is much better here.
12. **Cl_mic:** Ligand B (-12.383) has significantly lower microsomal clearance than Ligand A (78.429), indicating better metabolic stability. This is a major advantage for Ligand B.
13. **t1/2:** Ligand B (-31.369) has a much longer in vitro half-life than Ligand A (-3.593), further supporting its better metabolic stability.
14. **Pgp:** Ligand A (0.724) has lower P-gp efflux than Ligand B (0.01), which is favorable.
15. **Affinity:** Both ligands have very similar binding affinities (-6.5 kcal/mol and -5.8 kcal/mol). The difference is not large enough to outweigh other factors.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A performs better on logP and Pgp, but Ligand B has a much better TPSA. The affinities are close enough that they don't dominate the decision.
**Overall Assessment:**
Ligand B has significant advantages in DILI risk, metabolic stability (Cl_mic and t1/2), and TPSA. While Ligand A has a slightly better logP and Pgp, the issues with DILI and metabolic stability for Ligand A are concerning. The lower logP of Ligand B is a drawback, but can potentially be addressed through formulation strategies. The improved safety profile and pharmacokinetic properties of Ligand B make it the more promising candidate.
Output:
0
2025-04-17 22:16:16,150 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (356.438 Da) is within the ideal range (200-500 Da). Ligand B (391.255 Da) is also acceptable, though approaching the upper limit.
2. **TPSA:** Ligand A (59.08) is excellent, well below the 140 threshold for oral absorption. Ligand B (104.39) is higher, but still reasonable.
3. **logP:** Ligand A (1.379) is optimal. Ligand B (0.619) is a bit low, potentially impacting permeability.
4. **HBD:** Ligand A (0) is good. Ligand B (2) is acceptable.
5. **HBA:** Ligand A (4) is good. Ligand B (5) is acceptable.
6. **QED:** Both Ligand A (0.767) and Ligand B (0.664) have good drug-like properties.
7. **DILI:** Ligand A (30.748) has a much lower DILI risk than Ligand B (49.593). This is a significant advantage.
8. **BBB:** Ligand A (89.531) has a good BBB penetration score, while Ligand B (47.266) is lower. For a cardiovascular target, BBB isn't *critical*, but it could allow for potential off-target effects or peripheral activity.
9. **Caco-2:** Ligand A (-4.348) and Ligand B (-5.29) both have negative Caco-2 values, suggesting poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-1.162) has better solubility than Ligand B (-2.532).
11. **hERG:** Both Ligand A (0.314) and Ligand B (0.25) have very low hERG inhibition risk, which is excellent.
12. **Cl_mic:** Ligand A (14.747) has a higher microsomal clearance than Ligand B (-10.488), indicating lower metabolic stability. This is a disadvantage for Ligand A.
13. **t1/2:** Ligand B (-10.123) has a much longer in vitro half-life than Ligand A (2.38). This is a significant advantage for Ligand B.
14. **Pgp:** Both Ligand A (0.043) and Ligand B (0.025) have low P-gp efflux, which is good.
15. **Affinity:** Ligand B (-6.6 kcal/mol) has a slightly better binding affinity than Ligand A (-5.4 kcal/mol). While the difference isn't huge, it's enough to consider.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has a better logP and TPSA, while Ligand B has better affinity and Pgp. The difference in affinity is not substantial enough to overcome the other factors.
**Overall Assessment:**
Ligand A has a significantly better safety profile (lower DILI) and better solubility, and acceptable BBB penetration. Ligand B has better metabolic stability and affinity, but a higher DILI risk and lower solubility. Considering the balance of properties, the lower DILI risk and better solubility of Ligand A are more important for initial development. The slightly lower affinity can be addressed through further optimization.
Output:
1
2025-04-17 22:16:16,150 - INFO - Batch 319 complete. Total preferences: 5104
2025-04-17 22:16:16,150 - INFO - Processing batch 320/512...
2025-04-17 22:17:05,264 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (350.503 and 347.434 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (78.43) is higher than Ligand B (45.55). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B has a significant advantage here.
**3. logP:** Both ligands have good logP values (2.517 and 2.177), falling within the optimal 1-3 range. Ligand B is slightly lower, which might slightly improve solubility.
**4. H-Bond Donors:** Ligand A has 3 HBDs, while Ligand B has 0. Generally, fewer HBDs can improve permeability. Ligand B is better.
**5. H-Bond Acceptors:** Both ligands have 3 HBAs. No significant difference.
**6. QED:** Ligand B (0.838) has a higher QED score than Ligand A (0.66), indicating a more drug-like profile. This is a positive for Ligand B.
**7. DILI Risk:** Ligand B (19.426) has a significantly lower DILI risk than Ligand A (27.414). This is a crucial advantage for Ligand B.
**8. BBB Penetration:** Ligand B (98.022) exhibits much higher BBB penetration than Ligand A (39.162). While ADRB2 is primarily a cardiovascular target, some CNS off-target effects are possible with GPCRs, and lower CNS exposure might be desirable to minimize these. However, the difference is substantial.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.896 and -4.518). This is unusual and suggests poor permeability *in vitro*. However, these values are on a similar scale, so the difference isn't decisive.
**10. Aqueous Solubility:** Ligand B (-2.324) has slightly better aqueous solubility than Ligand A (-3.653).
**11. hERG Inhibition:** Ligand A (0.243) has a lower hERG inhibition liability than Ligand B (0.714). This is a significant advantage for Ligand A, as hERG inhibition can cause cardiotoxicity.
**12. Microsomal Clearance:** Ligand A (37.876) has higher microsomal clearance than Ligand B (27.557), suggesting faster metabolism and potentially lower *in vivo* exposure. Ligand B is better.
**13. In vitro Half-Life:** Ligand B (7.671) has a longer *in vitro* half-life than Ligand A (5.762). This is a positive for Ligand B.
**14. P-gp Efflux:** Ligand A (0.316) shows lower P-gp efflux than Ligand B (0.261). Lower P-gp efflux is generally preferred for better bioavailability.
**15. Binding Affinity:** Ligand B (-6.5 kcal/mol) has a slightly stronger binding affinity than Ligand A (-6.1 kcal/mol). While the difference is not huge, it is enough to consider.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), and the general drug-like properties, Ligand B is the more promising candidate. While Ligand A has a better hERG profile, the significant advantages of Ligand B in terms of DILI risk, BBB penetration, QED, TPSA, *in vitro* half-life, and slightly better affinity outweigh this concern. The lower hERG risk of Ligand A is valuable, but can be addressed through further structural modifications if necessary. The overall profile of Ligand B is more favorable for development.
Output:
0
2025-04-17 22:17:05,265 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for the ADRB2 receptor, a GPCR involved in cardiovascular function. Therefore, priorities are logP, Pgp, TPSA, and affinity, with reasonable ADME properties.
Let's compare the ligands property by property:
1. **MW:** Both ligands (346.475 and 365.43 Da) are within the ideal 200-500 Da range.
2. **TPSA:** Both ligands (73.47 and 75.44) are below the 140 A^2 threshold for good oral absorption.
3. **logP:** Ligand A (1.641) is optimal, while Ligand B (2.346) is also good but slightly higher.
4. **HBD/HBA:** Ligand A has 3 HBD and 3 HBA, while Ligand B has 1 HBD and 5 HBA. Both are acceptable.
5. **QED:** Both have good QED scores (0.703 and 0.853).
6. **DILI:** Ligand A (13.571) has a significantly lower DILI risk than Ligand B (57.193). This is a major advantage for Ligand A.
7. **BBB:** Ligand B (81.466) has a better BBB penetration score than Ligand A (70.88), but BBB isn't a high priority for a cardiovascular target.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual. It's difficult to interpret without knowing the scale, but we can assume lower values are worse.
9. **Solubility:** Ligand A (-1.2) has better solubility than Ligand B (-3.204).
10. **hERG:** Ligand A (0.419) has a lower hERG risk than Ligand B (0.64).
11. **Cl_mic:** Ligand A (9.287) has significantly lower microsomal clearance, suggesting better metabolic stability, than Ligand B (32.629).
12. **t1/2:** Both have similar in vitro half-lives (2.327 and 2.027 hours).
13. **Pgp:** Ligand A (0.02) has a much lower P-gp efflux liability than Ligand B (0.217). This is a significant advantage for oral bioavailability.
14. **Affinity:** Ligand B (-6.9 kcal/mol) has a slightly better binding affinity than Ligand A (-6.0 kcal/mol). This is a 0.9 kcal/mol difference, which is a reasonable advantage.
**Overall Assessment:**
While Ligand B has a slightly better binding affinity, Ligand A demonstrates a superior ADME profile. Specifically, its significantly lower DILI risk, better solubility, lower P-gp efflux, and lower microsomal clearance are crucial advantages. These factors are particularly important for a cardiovascular drug candidate where metabolic stability and minimizing off-target effects are paramount. The difference in affinity (0.9 kcal/mol) is not substantial enough to outweigh the ADME benefits of Ligand A.
**Output:**
1
2025-04-17 22:17:05,265 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
The ADRB2 receptor is a GPCR, so the priorities are logP, TPSA, Pgp, BBB, and affinity. Let's compare the ligands:
1. **Molecular Weight:** Both ligands (352.381 and 369.437 Da) fall within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (69.64) is better than Ligand B (73.2), both being below the 140 threshold for good absorption.
3. **logP:** Both are within the optimal 1-3 range (1.943 and 2.44). Ligand B is slightly higher, which could be a minor concern for solubility, but not a dealbreaker.
4. **H-Bond Donors:** Ligand A (2) is slightly higher than Ligand B (1), but both are acceptable.
5. **H-Bond Acceptors:** Ligand A (3) is slightly higher than Ligand B (4), but both are acceptable.
6. **QED:** Both ligands have similar QED values (0.851 and 0.802), indicating good drug-likeness.
7. **DILI:** Both have low DILI risk (36.758 and 37.65), which is good.
8. **BBB:** Ligand B (83.404) has a significantly better BBB penetration percentile than Ligand A (73.827). While ADRB2 isn't strictly a CNS target, some peripheral distribution is still desirable, and higher BBB penetration often correlates with better overall tissue distribution.
9. **Caco-2:** Both have negative Caco-2 values (-4.745 and -4.889), which is unusual and indicates poor permeability. This is a significant concern for both.
10. **Solubility:** Both have negative solubility values (-2.903 and -2.749), indicating very poor aqueous solubility. This is a major drawback for both compounds.
11. **hERG:** Ligand A (0.331) has a lower hERG inhibition liability than Ligand B (0.794), which is preferable.
12. **Cl_mic:** Ligand A (-6.842) has a much lower (better) microsomal clearance than Ligand B (17.759), indicating better metabolic stability.
13. **t1/2:** Ligand A (-10.771) has a longer in vitro half-life than Ligand B (-2.176), which is desirable.
14. **Pgp:** Ligand A (0.044) has a much lower Pgp efflux liability than Ligand B (0.147), which is preferable.
15. **Binding Affinity:** Ligand B (-6.7) has a slightly better binding affinity than Ligand A (-4.9), a difference of 1.8 kcal/mol. This is a substantial difference and could potentially outweigh some of the ADME concerns.
**Conclusion:**
Despite the slightly better affinity of Ligand B, the significantly better ADME profile of Ligand A (lower Cl_mic, longer t1/2, lower Pgp efflux, lower hERG risk) makes it the more promising candidate. The poor Caco-2 and solubility are concerning for both, but the metabolic stability and reduced toxicity liabilities of Ligand A are more critical for a successful drug development program.
**Output:**
1
2025-04-17 22:17:05,265 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (365.543 and 371.478 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (62.3) is significantly better than Ligand B (95.66). ADRB2 is a cardiovascular target, not CNS, but lower TPSA generally improves absorption. Ligand A is well below the 140 threshold, while Ligand B is approaching it.
3. **logP:** Ligand A (3.385) is slightly higher than Ligand B (1.716), both are within the optimal 1-3 range, but A is closer to the upper limit.
4. **HBD:** Ligand A (1) is better than Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is better than Ligand B (5). Similar to HBD, fewer HBAs are generally preferred.
6. **QED:** Both ligands are similar (0.768 and 0.734), both are above the 0.5 threshold, indicating good drug-like properties.
7. **DILI:** Ligand A (41.179) is slightly higher than Ligand B (33.23), but both are below the 40 threshold, indicating low risk.
8. **BBB:** Ligand B (74.68) is better than Ligand A (62.854). While ADRB2 isn't a CNS target, higher BBB penetration can sometimes indicate better overall permeability and distribution.
9. **Caco-2:** Ligand A (-4.967) and Ligand B (-5.143) are similar. Both are negative, which is unusual and suggests very high permeability.
10. **Solubility:** Ligand A (-3.24) and Ligand B (-3.115) are similar, and both are very poor. This is a concern for both.
11. **hERG:** Ligand A (0.345) is significantly better than Ligand B (0.485). Lower hERG inhibition is crucial to avoid cardiotoxicity, especially for a cardiovascular target.
12. **Cl_mic:** Ligand B (21.169) is significantly better than Ligand A (70.354). Lower clearance indicates better metabolic stability, a key factor for drug duration.
13. **t1/2:** Ligand B (-28.128) is significantly better than Ligand A (9.339). A negative value suggests a very long half-life, which is highly desirable.
14. **Pgp:** Ligand A (0.262) is better than Ligand B (0.046). Lower P-gp efflux is preferred for better bioavailability.
15. **Binding Affinity:** Ligand B (-9.3) is substantially better than Ligand A (-6.8). A difference of 2.5 kcal/mol is a significant advantage and can often outweigh minor ADME drawbacks.
**Overall Assessment:**
Ligand B has a significantly stronger binding affinity (-9.3 kcal/mol vs -6.8 kcal/mol). While Ligand A has advantages in TPSA, HBD/HBA, and Pgp, the substantial difference in binding affinity and the superior metabolic stability (Cl_mic and t1/2) of Ligand B are more critical for a successful drug candidate. The slightly higher BBB penetration of Ligand B is a bonus. The solubility is poor for both, but can be addressed with formulation strategies. The hERG risk for Ligand A is also a significant concern.
Output:
0
2025-04-17 22:17:05,265 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (357.451 Da) is well within the ideal range (200-500 Da). Ligand B (382.595 Da) is also acceptable. No clear advantage here.
2. **TPSA:** Ligand A (102.34) is borderline, but acceptable for a non-CNS target. Ligand B (41.57) is excellent, well below the 140 threshold, suggesting good absorption. Advantage: B.
3. **logP:** Ligand A (-1.055) is a bit low, potentially hindering permeability. Ligand B (3.694) is excellent, falling within the optimal 1-3 range. Advantage: B.
4. **HBD:** Ligand A (3) is good. Ligand B (1) is also good. No significant difference.
5. **HBA:** Ligand A (6) is good. Ligand B (5) is good. No significant difference.
6. **QED:** Both ligands (A: 0.58, B: 0.696) have good drug-likeness scores. Advantage: B.
7. **DILI:** Ligand A (15.51) has a lower DILI risk than Ligand B (23.032). Advantage: A.
8. **BBB:** Ligand A (27.918) has poor BBB penetration. Ligand B (80.884) has good BBB penetration. Since ADRB2 is a cardiovascular target, BBB penetration is not a primary concern, but it doesn't hurt. Advantage: B.
9. **Caco-2:** Both ligands (-5.37) have the same Caco-2 permeability. No difference.
10. **Solubility:** Ligand A (0.023) has very poor solubility. Ligand B (-3.984) also has poor solubility, but is better than A. Advantage: B.
11. **hERG:** Both ligands (A: 0.038, B: 0.872) have low hERG inhibition risk, which is good. Advantage: A.
12. **Cl_mic:** Ligand A (2.049) has much lower microsomal clearance, indicating better metabolic stability. Ligand B (75.674) is high. Advantage: A.
13. **t1/2:** Ligand A (6.838) has a shorter half-life than Ligand B (32.054). Advantage: B.
14. **Pgp:** Ligand A (0.003) has very low P-gp efflux, which is excellent. Ligand B (0.647) has moderate P-gp efflux. Advantage: A.
15. **Binding Affinity:** Ligand B (-7.9 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.1 kcal/mol) - a difference of 1.8 kcal/mol. This is a substantial advantage.
**Overall Assessment:**
Ligand B excels in several key areas: logP, TPSA, QED, BBB, and, most importantly, binding affinity. While its solubility and DILI are slightly worse than Ligand A, the superior binding affinity and better ADME properties (TPSA, logP) outweigh these drawbacks for a cardiovascular GPCR target. Ligand A has better metabolic stability (Cl_mic) and P-gp efflux, but the affinity difference is too large to ignore.
Output:
0
2025-04-17 22:17:05,266 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (346.471 and 353.423 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (69.64) is significantly better than Ligand B (97.72). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary goal, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (1.999) is within the optimal 1-3 range. Ligand B (-0.872) is below 1, which could hinder permeability. This is a notable advantage for Ligand A.
4. **HBD:** Both ligands have 2 HBD, which is acceptable.
5. **HBA:** Ligand A has 3 HBA, while Ligand B has 7. Ligand A is preferable here, as higher HBA can sometimes impact permeability.
6. **QED:** Ligand A (0.821) has a better QED score than Ligand B (0.63), indicating a more drug-like profile.
7. **DILI:** Ligand A (16.479) has a much lower DILI risk than Ligand B (31.563). This is a crucial advantage for Ligand A.
8. **BBB:** Ligand A (63.746) has a higher BBB penetration than Ligand B (47.228), but since ADRB2 is primarily cardiovascular, this isn't a major factor.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.921 and -4.943), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-3.081) has slightly better solubility than Ligand B (-1.049), though both are quite poor.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.271 and 0.037). No significant difference.
12. **Cl_mic:** Ligand A (6.615) has significantly lower microsomal clearance than Ligand B (24.522), indicating better metabolic stability.
13. **t1/2:** Ligand A (19.201) has a longer in vitro half-life than Ligand B (-10.179). This is a significant advantage for Ligand A.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.087 and 0.004). No significant difference.
15. **Binding Affinity:** Ligand B (-6.6) has a slightly better binding affinity than Ligand A (-6.3), but the difference is only 0.3 kcal/mol. Given the other significant advantages of Ligand A, this difference is unlikely to be decisive.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, and affinity are key. Ligand A excels in logP and TPSA, and while its affinity is slightly lower, the other ADME properties are significantly better.
**Conclusion:**
Ligand A demonstrates a superior balance of properties, particularly regarding DILI risk, metabolic stability (Cl_mic, t1/2), and permeability-related parameters (TPSA, logP). While Ligand B has slightly better binding affinity, the overall profile of Ligand A is more favorable for development as a drug candidate.
Output:
1
2025-04-17 22:17:05,266 - INFO - Here's my reasoning and final output for the ligand preference:
**Reasoning:**
We're targeting ADRB2, a GPCR, so the priorities are logP, Pgp, TPSA, affinity, and BBB. Let's break down the comparison:
1. **MW:** Both ligands are within the ideal range (around 357 Da).
2. **TPSA:** Both are acceptable (72.7 and 73.32), below the 140 threshold for oral absorption.
3. **logP:** Ligand A (2.351) is better than Ligand B (0.419). A logP between 1-3 is optimal, and Ligand B is quite low, potentially hindering membrane permeability.
4. **HBD/HBA:** Both are reasonable (1 HBD, 6/5 HBA).
5. **QED:** Both are good (0.776 and 0.682), indicating drug-like properties.
6. **DILI:** Ligand B (7.135) is significantly better than Ligand A (61.962) in terms of liver toxicity risk. This is a major advantage for Ligand B.
7. **BBB:** Ligand B (62.156) is slightly better than Ligand A (49.244), but both are not exceptionally high.
8. **Caco-2:** Ligand A (-5.057) is better than Ligand B (-4.586). Higher is better.
9. **Solubility:** Ligand A (-2.814) is better than Ligand B (-0.351). Higher is better.
10. **hERG:** Ligand B (0.236) is much better than Ligand A (0.579), indicating lower cardiotoxicity risk.
11. **Cl_mic:** Ligand B (13.178) has significantly lower clearance than Ligand A (24.878), suggesting better metabolic stability.
12. **t1/2:** Ligand A (22.731) has a much longer half-life than Ligand B (0.058).
13. **Pgp:** Ligand A (0.278) is better than Ligand B (0.014). Lower is better.
14. **Affinity:** Ligand A (-7.0) has a slightly better binding affinity than Ligand B (-6.6). While a 1.5 kcal/mol advantage is significant, the other ADME properties are more concerning.
**Overall Assessment:**
Ligand A has a slightly better binding affinity and half-life, but Ligand B is superior in almost all ADME properties critical for a viable drug candidate. Specifically, the lower DILI, hERG, and microsomal clearance of Ligand B are substantial advantages. The lower logP of Ligand B is a concern, but the other improvements outweigh this. Given the GPCR target class, balancing affinity with good ADME properties is crucial, and Ligand B achieves this balance better.
**Output:**
0
2025-04-17 22:17:05,266 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (357.3 and 374.8 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (56.15) is significantly better than Ligand B (67.43). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (2.755 and 3.399, respectively), falling within the optimal 1-3 range. Ligand B is slightly higher, which *could* be a minor concern for solubility, but not a dealbreaker.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Both ligands have the same number of HBA (4), which is acceptable.
6. **QED:** Ligand A (0.838) is better than Ligand B (0.775), indicating a more drug-like profile.
7. **DILI:** Ligand B (52.54) has a significantly lower DILI risk than Ligand A (64.444). This is a substantial advantage for Ligand B.
8. **BBB:** Both ligands have high BBB penetration (80.225 and 82.823), which isn't a primary concern for a cardiovascular target, but doesn't hurt.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.546 and -4.855). These values are unusual and likely indicate poor permeability. This is a significant concern for both.
10. **Solubility:** Both ligands have very poor aqueous solubility (-3.288 and -3.58). This is a major drawback for both compounds.
11. **hERG:** Ligand A (0.786) has a slightly better hERG profile than Ligand B (0.677), meaning lower risk of cardiotoxicity.
12. **Cl_mic:** Ligand A (13.799) has a significantly lower microsomal clearance than Ligand B (26.589), suggesting better metabolic stability.
13. **t1/2:** Ligand A (20.066) has a longer in vitro half-life than Ligand B (-4.875). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.279) has lower P-gp efflux than Ligand B (0.091), which is preferable.
15. **Binding Affinity:** Ligand B (-6.7) has a significantly better binding affinity than Ligand A (-9.0). This is a crucial advantage, potentially outweighing some ADME concerns.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, affinity, logP, TPSA, and Pgp are important. Ligand B excels in affinity. Ligand A has better TPSA and Pgp.
**Overall Assessment:**
While Ligand A has advantages in metabolic stability (Cl_mic, t1/2), QED, and Pgp efflux, the significantly stronger binding affinity of Ligand B (-6.7 vs -9.0 kcal/mol) is a decisive factor. The DILI risk is also lower for Ligand B. The poor solubility and Caco-2 permeability are concerning for both, but can be addressed with formulation strategies. The binding affinity difference is substantial enough to prioritize Ligand B despite its slightly higher logP and worse metabolic profile.
Output:
0
2025-04-17 22:17:05,266 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (374.491 and 353.547 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (67.35) is slightly higher than Ligand B (60.77). Both are below the 140 threshold for good oral absorption, but closer to the 90 threshold for CNS targets, which isn't a primary concern for ADRB2 (cardiovascular). Ligand B is preferable.
3. **logP:** Both ligands have good logP values (3.921 and 3.767), falling within the optimal 1-3 range. No clear advantage.
4. **HBD:** Ligand A has 1 HBD, while Ligand B has 2. Both are within the acceptable limit of 5. No significant difference.
5. **HBA:** Ligand A has 6 HBA, and Ligand B has 3. Both are below the acceptable limit of 10. Ligand B is preferable.
6. **QED:** Ligand A (0.754) has a better QED score than Ligand B (0.588), indicating a more drug-like profile. This favors Ligand A.
7. **DILI:** Ligand A has a significantly higher DILI risk (93.796%) compared to Ligand B (6.359%). This is a major concern, as higher DILI risk is undesirable. This strongly favors Ligand B.
8. **BBB:** Ligand A (81.466%) has a higher BBB penetration than Ligand B (65.413%). While BBB isn't a primary concern for ADRB2, it's a slight advantage for Ligand A.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.727 and -4.252), which is unusual and suggests poor permeability. This is a significant drawback for both.
10. **Solubility:** Ligand A (-4.463) has worse solubility than Ligand B (-3.375). Better solubility is desirable, favoring Ligand B.
11. **hERG:** Both ligands have low hERG inhibition liability (0.474 and 0.57), indicating a low risk of cardiotoxicity. No significant difference.
12. **Cl_mic:** Ligand A (71.593) has a lower microsomal clearance than Ligand B (75.304), suggesting better metabolic stability. This favors Ligand A.
13. **t1/2:** Ligand A (37.557) has a significantly longer in vitro half-life than Ligand B (9.711). This is a major advantage for Ligand A, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.558) has slightly lower P-gp efflux liability than Ligand B (0.3). Lower efflux is preferable, favoring Ligand A.
15. **Binding Affinity:** Ligand B (-7.5 kcal/mol) has a substantially stronger binding affinity than Ligand A (-6.5 kcal/mol). A 1 kcal/mol difference is significant, and >1.5 kcal/mol advantage can outweigh other drawbacks. This strongly favors Ligand B.
**Overall Assessment:**
While Ligand A has advantages in QED, t1/2, Cl_mic, and Pgp, the extremely high DILI risk is a major red flag. Ligand B has a significantly better safety profile (DILI), a superior binding affinity, and better solubility. The slightly lower t1/2 and higher Pgp efflux are less concerning than the high DILI risk of Ligand A. Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity), Ligand B's stronger binding and better safety profile make it the more promising candidate.
Output:
0
2025-04-17 22:17:05,266 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [364.442, 65.22, 4.209, 0, 6, 0.585, 63.086, 87.98, -4.362, -6.053, 0.317, 98.868, -16.062, 0.588, -6.6]
**Ligand B:** [350.369, 67.23, 2.28, 1, 4, 0.9, 61.07, 83.482, -4.442, -2.812, 0.587, 40.1, 37.623, 0.149, -7.5]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal 200-500 Da range. Ligand B (350.369 Da) is slightly lower, which is generally favorable.
2. **TPSA:** Both are reasonably good (65.22 and 67.23), below the 140 threshold for oral absorption.
3. **logP:** Ligand A (4.209) is higher than ideal (1-3), potentially leading to solubility issues. Ligand B (2.28) is within the optimal range. This is a significant advantage for B.
4. **HBD:** Ligand A (0) is excellent. Ligand B (1) is acceptable.
5. **HBA:** Ligand A (6) is good. Ligand B (4) is also good.
6. **QED:** Ligand A (0.585) is marginally acceptable, while Ligand B (0.9) is excellent.
7. **DILI:** Both have similar DILI risk (63.086 and 61.07), both are acceptable but not ideal.
8. **BBB:** Both have high BBB penetration (87.98 and 83.482), which is good for a GPCR, but not critical for ADRB2 as it's primarily cardiovascular.
9. **Caco-2:** Both have negative Caco-2 values which is unusual and suggests poor permeability.
10. **Solubility:** Ligand A (-6.053) has very poor solubility, while Ligand B (-2.812) is better, but still poor.
11. **hERG:** Both have low hERG risk (0.317 and 0.587).
12. **Cl_mic:** Ligand A (98.868) has high metabolic clearance, indicating poor metabolic stability. Ligand B (40.1) has much better metabolic stability.
13. **t1/2:** Ligand A (-16.062) has a very short half-life. Ligand B (37.623) has a much longer half-life.
14. **Pgp:** Ligand A (0.588) has moderate P-gp efflux, while Ligand B (0.149) has low P-gp efflux. This is favorable for B.
15. **Binding Affinity:** Ligand B (-7.5 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.6 kcal/mol) - a 0.9 kcal/mol difference. This is a substantial advantage.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand B excels in logP, Pgp, and significantly in affinity. While both have acceptable TPSA, the other factors heavily favor Ligand B. The poor solubility and permeability of both are concerning, but the superior affinity and metabolic stability of Ligand B outweigh these drawbacks.
**Conclusion:**
Ligand B is the more promising candidate due to its superior binding affinity, better logP, lower P-gp efflux, and improved metabolic stability.
0
2025-04-17 22:17:05,267 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [349.439, 119.03 , 0.046, 2. , 7. , 0.576, 46.956, 74.486, -5.634, -2.037, 0.183, 14.041, -10.284, 0.094, -5.7 ]
**Ligand B:** [375.519, 66.32 , 3.248, 1. , 6. , 0.865, 65.568, 49.787, -5.128, -3.867, 0.396, 54.348, -0.785, 0.207, -7.1 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal 200-500 Da range. Ligand A (349.439 Da) is slightly preferred due to being lower.
2. **TPSA:** Ligand A (119.03) is better than Ligand B (66.32), being below the 140 threshold for oral absorption. Ligand B is excellent.
3. **logP:** Ligand B (3.248) is optimal (1-3), while Ligand A (0.046) is quite low, potentially hindering permeability. This is a significant drawback for Ligand A.
4. **HBD:** Both are acceptable (2 and 1 respectively), well within the limit of 5.
5. **HBA:** Both are acceptable (7 and 6 respectively), well within the limit of 10.
6. **QED:** Both are good, but Ligand B (0.865) is better than Ligand A (0.576), indicating a more drug-like profile.
7. **DILI:** Ligand A (46.956%) is preferred over Ligand B (65.568%) as it has lower DILI risk.
8. **BBB:** Ligand A (74.486%) is better than Ligand B (49.787%), which is important for GPCRs.
9. **Caco-2:** Both are negative, indicating poor permeability.
10. **Solubility:** Both are negative, indicating poor solubility.
11. **hERG:** Ligand A (0.183) is better than Ligand B (0.396), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand A (14.041) has a lower clearance than Ligand B (54.348), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-10.284) has a longer half-life than Ligand B (-0.785).
14. **Pgp:** Ligand A (0.094) has lower P-gp efflux liability than Ligand B (0.207), which is beneficial.
15. **Affinity:** Ligand B (-7.1) has a significantly better binding affinity than Ligand A (-5.7). This is a 1.4 kcal/mol difference, which is substantial.
**GPCR-specific priorities:** For ADRB2 (a GPCR), we prioritize logP, Pgp, TPSA, and affinity. Ligand B excels in logP and affinity, while Ligand A has better TPSA and Pgp. The affinity difference is substantial enough to outweigh the benefits of Ligand A's TPSA and Pgp.
**Conclusion:**
Despite Ligand A's advantages in some ADME properties (DILI, BBB, Cl_mic, t1/2, Pgp, hERG), the significantly stronger binding affinity of Ligand B (-7.1 kcal/mol vs -5.7 kcal/mol) is a decisive factor. The better logP of Ligand B also supports its potential for membrane permeability.
Output:
0
2025-04-17 22:17:05,267 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [361.833, 79.6, 2.278, 1, 5, 0.909, 60.372, 86.817, -5.005, -2.97, 0.511, 22.756, -5.088, 0.155, -7.1]
**Ligand B:** [343.387, 90.21, 1.256, 0, 7, 0.759, 57.038, 85.459, -4.924, -1.127, 0.093, 47.319, -12.539, 0.043, -6.3]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (343.387) is slightly lower, which could be a minor advantage for permeability.
2. **TPSA:** Ligand A (79.6) is preferable as it is below 140 and closer to the 90 threshold for CNS targets. Ligand B (90.21) is at the upper end of acceptable for oral absorption.
3. **logP:** Both are within the optimal 1-3 range. Ligand A (2.278) is slightly higher, which might be a slight disadvantage, but not a major concern.
4. **HBD:** Ligand A (1) is better than Ligand B (0). Having at least one HBD can aid solubility.
5. **HBA:** Ligand A (5) is better than Ligand B (7). Lower HBA is generally preferred for permeability.
6. **QED:** Ligand A (0.909) is significantly better than Ligand B (0.759), indicating a more drug-like profile.
7. **DILI:** Both are acceptable, but Ligand B (57.038) has a slightly lower DILI risk than Ligand A (60.372).
8. **BBB:** Both have good BBB penetration (Ligand A: 86.817, Ligand B: 85.459). This is important for a GPCR target.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Both have negative solubility values, which is also a significant concern.
11. **hERG:** Ligand A (0.511) is better than Ligand B (0.093), indicating a lower risk of cardiotoxicity.
12. **Cl_mic:** Ligand A (22.756) has a lower microsomal clearance than Ligand B (47.319), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-12.539) has a much longer half-life than Ligand A (-5.088). This is a significant advantage.
14. **Pgp:** Ligand A (0.155) has lower P-gp efflux liability than Ligand B (0.043).
15. **Affinity:** Ligand A (-7.1) has a better binding affinity than Ligand B (-6.3). This is a crucial factor, and the 0.8 kcal/mol difference is substantial.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, Pgp, TPSA, and affinity. Ligand A performs better on TPSA, Pgp, and significantly better on affinity. The logP values are comparable.
**Overall Assessment:**
Despite the concerning negative Caco-2 and solubility values for both compounds, Ligand A is the more promising candidate. Its superior binding affinity (-7.1 vs -6.3 kcal/mol) is a major advantage, and it also has better QED, lower DILI risk, and lower P-gp efflux. While Ligand B has a longer half-life, the affinity difference is substantial enough to outweigh this benefit. The negative Caco-2 and solubility values would need to be addressed through formulation or structural modification, but starting with the higher affinity compound is more likely to lead to success.
Output:
1
2025-04-17 22:17:05,267 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.479 and 363.487 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (76.46) is slightly higher than Ligand B (69.64). Both are below the 140 threshold for good oral absorption, and acceptable for a cardiovascular target (not necessarily needing high CNS penetration). Ligand B is slightly preferred.
3. **logP:** Ligand A (1.471) is within the optimal range (1-3), while Ligand B (0.626) is towards the lower end. This is a significant advantage for Ligand A, as it's more likely to have good membrane permeability.
4. **HBD:** Ligand A (1) is better than Ligand B (0). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (5) is better than Ligand B (6). Fewer HBAs generally improve permeability.
6. **QED:** Both ligands have good QED scores (0.692 and 0.785, respectively), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand B (13.843) has a significantly lower DILI risk than Ligand A (22.838). This is a major advantage for Ligand B.
8. **BBB:** Ligand B (68.321) has a higher BBB penetration score than Ligand A (50.019). While ADRB2 is primarily a cardiovascular target, some CNS effects are possible with beta-blockers, and higher BBB penetration could be beneficial or detrimental depending on the desired profile.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand B (-5.116) is slightly better than Ligand A (-4.816), but both are concerning.
10. **Solubility:** Both ligands have very poor aqueous solubility (-0.849 and -0.845). This is a significant drawback for both, requiring formulation strategies.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.1 and 0.147). This is good.
12. **Cl_mic:** Ligand B (-10.42) has a much lower microsomal clearance than Ligand A (48.512), indicating better metabolic stability. This is a substantial advantage for Ligand B.
13. **t1/2:** Ligand A (31.649) has a longer in vitro half-life than Ligand B (1.73). This is a significant advantage for Ligand A.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.016 and 0.026). This is good.
15. **Binding Affinity:** Ligand B (-6.6) has a slightly better binding affinity than Ligand A (-6.3). While the difference is small, it's still a positive for Ligand B.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand A initially looks better due to its more favorable logP and longer half-life. However, the significantly lower DILI risk and improved metabolic stability (lower Cl_mic) of Ligand B are crucial factors. The slightly better affinity of Ligand B also contributes. The poor solubility and Caco-2 permeability are concerning for both, but can be addressed with formulation. Given the importance of avoiding liver toxicity and ensuring adequate drug exposure, Ligand B is the more promising candidate.
Output:
0
2025-04-17 22:17:05,267 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (350.423 and 369.443 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (112.24) is slightly higher than Ligand B (105.67), but both are below the 140 threshold for good oral absorption. Ligand B is preferable due to being closer to the ideal.
3. **logP:** Ligand A (-0.859) is a bit low, potentially hindering permeation. Ligand B (0.132) is better, falling within the optimal 1-3 range. Ligand B is preferred.
4. **HBD:** Ligand A (3) is higher than Ligand B (1). For GPCRs, a lower number of HBDs is generally preferred to avoid excessive hydrogen bonding that can reduce membrane permeability. Ligand B is preferred.
5. **HBA:** Both ligands have 6 HBA, which is acceptable.
6. **QED:** Both ligands have good QED scores (0.59 and 0.663), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (33.889) has a significantly lower DILI risk than Ligand B (47.654). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (71.035) has a much higher BBB penetration percentile than Ligand A (38.542). While ADRB2 isn't *exclusively* a CNS target, improved BBB penetration can be beneficial for broader distribution and potentially reducing off-target effects.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. Ligand B (-4.998) is slightly better than Ligand A (-5.65).
10. **Solubility:** Both ligands have negative solubility values, indicating poor solubility. Ligand A (-1.064) is slightly better than Ligand B (-2.1).
11. **hERG:** Both ligands have very low hERG inhibition risk (0.061 and 0.05), which is excellent.
12. **Cl_mic:** Ligand A (-18.018) has a much lower (better) microsomal clearance than Ligand B (20.164), suggesting greater metabolic stability.
13. **t1/2:** Both ligands have similar in vitro half-lives (-13.108 and -13.213).
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.001 and 0.022).
15. **Binding Affinity:** Ligand B (-6.9 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.8 kcal/mol). This 1.1 kcal/mol difference is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand B has a superior binding affinity and better BBB penetration, which are important for GPCR targets. It also has a slightly better logP and Caco-2 permeability. However, Ligand A has a significantly lower DILI risk and better metabolic stability (lower Cl_mic).
Given the importance of potency (affinity) for GPCRs, and the substantial difference in binding affinity (-6.9 vs -5.8 kcal/mol), I prioritize Ligand B despite the slightly higher DILI risk. The better BBB penetration is also a plus.
Output:
0
2025-04-17 22:17:05,267 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.5 & 362.8 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (58.64) is significantly better than Ligand B (78.27). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally improves absorption.
3. **logP:** Ligand A (3.249) is slightly higher than Ligand B (1.651), both within the optimal 1-3 range, but A is closer to the upper bound.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A (3) is better than Ligand B (6). Lower HBA is preferable for permeability.
6. **QED:** Both ligands have good QED scores (0.731 and 0.875), indicating good drug-like properties.
7. **DILI:** Ligand B (75.184) has a higher DILI risk than Ligand A (11.322). This is a significant concern.
8. **BBB:** Both ligands have reasonable BBB penetration (73.827 and 77.821). Not a primary concern for a cardiovascular target.
9. **Caco-2:** Ligand A (-4.662) has a more negative Caco-2 value, suggesting *better* permeability than Ligand B (-5.183).
10. **Solubility:** Both ligands have negative solubility values, which is unusual and suggests poor aqueous solubility. Ligand A (-3.217) is slightly better than Ligand B (-2.832).
11. **hERG:** Both ligands have very low hERG inhibition risk (0.258 and 0.078). Excellent.
12. **Cl_mic:** Ligand A (87.316) has a higher microsomal clearance than Ligand B (26.82). This suggests lower metabolic stability for Ligand A.
13. **t1/2:** Ligand B (26.163) has a significantly longer in vitro half-life than Ligand A (-21.436). This is a major advantage for Ligand B.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.092 and 0.17).
15. **Affinity:** Ligand A (-7.4) has a slightly better binding affinity than Ligand B (-7.2). However, the difference is small (0.2 kcal/mol).
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has a better logP and TPSA, but the difference in affinity is minimal. The *significant* advantage of Ligand B is its much lower DILI risk and substantially longer half-life, which are critical for drug development.
**Overall Assessment:**
While Ligand A has slightly better permeability and affinity, the substantially higher DILI risk and lower half-life of Ligand A are major drawbacks. Ligand B's superior safety profile (DILI) and pharmacokinetic properties (t1/2) outweigh the minor differences in permeability and affinity.
Output:
0
2025-04-17 22:17:05,268 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (348.487) is slightly preferred as it's closer to the lower end, potentially aiding permeability.
2. **TPSA:** Ligand A (69.64) is significantly better than Ligand B (90.98). For a GPCR, keeping TPSA low is important for permeability. Ligand B is approaching a level that could hinder oral absorption.
3. **logP:** Both ligands have acceptable logP values (Ligand A: 2.247, Ligand B: 0.899), falling within the 1-3 range. Ligand A is slightly better.
4. **HBD:** Both have 2 HBD, which is good.
5. **HBA:** Ligand A has 3 HBA, while Ligand B has 4. Both are acceptable, but lower is generally preferred.
6. **QED:** Ligand A (0.766) has a better QED score than Ligand B (0.583), indicating a more drug-like profile.
7. **DILI:** Ligand B (38.503) has a significantly lower DILI risk than Ligand A (14.541), which is a major advantage.
8. **BBB:** Ligand A (65.025) has a better BBB penetration score than Ligand B (61.691). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be beneficial for distribution and off-target effects.
9. **Caco-2:** Ligand A (-4.673) and Ligand B (-5.356) are both very poor. This is a significant concern for both.
10. **Solubility:** Ligand A (-2.661) and Ligand B (-2.885) are both very poor. This is a significant concern for both.
11. **hERG:** Both ligands have very low hERG inhibition risk (Ligand A: 0.162, Ligand B: 0.09). This is excellent.
12. **Cl_mic:** Ligand B (-30.392) has a much lower (better) microsomal clearance than Ligand A (39.607), indicating greater metabolic stability.
13. **t1/2:** Ligand B (-9.893) has a longer in vitro half-life than Ligand A (-7.926).
14. **Pgp:** Both ligands have very low Pgp efflux liability (Ligand A: 0.054, Ligand B: 0.015). This is excellent.
15. **Binding Affinity:** Ligand A (-7.1 kcal/mol) has a slightly better binding affinity than Ligand B (-6.3 kcal/mol). This difference is significant enough to consider.
**Overall Assessment:**
Ligand A has a better QED, TPSA, logP, BBB, and binding affinity. However, Ligand B has a significantly lower DILI risk and much better metabolic stability (Cl_mic and t1/2). The poor Caco-2 and solubility for both are concerning, and would need to be addressed in further optimization.
Considering the GPCR-specific priorities (logP, TPSA, affinity), Ligand A initially appears more promising due to its better TPSA and affinity. However, the substantial improvement in DILI risk and metabolic stability offered by Ligand B is very attractive. For a cardiovascular target, minimizing liver toxicity and ensuring adequate drug exposure (through improved metabolic stability) are critical. The affinity difference, while present, isn't large enough to completely outweigh these safety and PK advantages.
Therefore, I favor Ligand B.
Output:
0
2025-04-17 22:17:05,268 - INFO - Batch 320 complete. Total preferences: 5120
2025-04-17 22:17:05,268 - INFO - Processing batch 321/512...
2025-04-17 22:17:55,456 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (345.443 and 353.467 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (78.51) is significantly better than Ligand B (107.4). ADRB2 is a cardiovascular target, so CNS penetration isn't *essential*, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold. Ligand B is approaching it.
3. **logP:** Both ligands have acceptable logP values (1.488 and 2.634), falling within the 1-3 range. Ligand B is slightly higher, which *could* be a minor concern for solubility, but is still within a reasonable range.
4. **HBD:** Ligand A has 2 HBD, and Ligand B has 1. Both are within the acceptable limit of 5.
5. **HBA:** Ligand A has 3 HBA, and Ligand B has 4. Both are within the acceptable limit of 10.
6. **QED:** Ligand A (0.749) has a much better QED score than Ligand B (0.391). This indicates a significantly more drug-like profile for Ligand A.
7. **DILI:** Ligand A (35.789) has a slightly higher DILI risk than Ligand B (19.659), but both are well below the concerning threshold of 60.
8. **BBB:** Ligand B (70.609) has a higher BBB penetration percentile than Ligand A (63.784). While not a primary concern for a cardiovascular target, it's a slight advantage for Ligand B.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.768 and -4.578). This is unusual and suggests poor permeability. However, the values are very close.
10. **Solubility:** Ligand A (-2.588) has slightly worse solubility than Ligand B (-1.846).
11. **hERG:** Both ligands have low hERG inhibition liability (0.12 and 0.209), which is good.
12. **Cl_mic:** Both ligands have similar microsomal clearance values (42.506 and 42.355).
13. **t1/2:** Ligand A (-4.316) has a slightly longer in vitro half-life than Ligand B (-0.081).
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.049 and 0.007).
15. **Binding Affinity:** Ligand A (-7.8 kcal/mol) has a significantly stronger binding affinity than Ligand B (-5.9 kcal/mol). This is a difference of 1.9 kcal/mol, which is substantial and can outweigh minor ADME drawbacks.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, affinity, logP, TPSA, and Pgp are crucial. Ligand A excels in affinity and has a better TPSA. While Ligand B has slightly better BBB and solubility, the significant advantage in binding affinity and QED for Ligand A is more important. The Caco-2 values are concerning for both, but the superior binding and drug-likeness of Ligand A make it the more promising candidate.
**Conclusion:**
Ligand A is the better candidate due to its significantly higher binding affinity, better QED score, and favorable TPSA, outweighing the slight disadvantages in DILI and solubility.
Output:
1
2025-04-17 22:17:55,456 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (368.905 and 349.395 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (58.64) is significantly better than Ligand B (118.03). ADRB2 is a cardiovascular target, not CNS, but lower TPSA generally aids absorption. Ligand A is well below the 140 threshold. Ligand B is approaching the upper limit.
3. **logP:** Ligand A (2.462) is optimal, while Ligand B (0.312) is quite low. This is a significant drawback for Ligand B, potentially hindering membrane permeability.
4. **HBD:** Both ligands have acceptable HBD counts (1 and 2 respectively), well below the 5 threshold.
5. **HBA:** Ligand A (3) is better than Ligand B (7), as lower HBA is generally preferred for permeability.
6. **QED:** Both ligands have similar QED values (0.733 and 0.673), indicating good drug-likeness.
7. **DILI:** Ligand A (20.318) has a much lower DILI risk than Ligand B (72.703). This is a major advantage for Ligand A.
8. **BBB:** Not a primary concern for a cardiovascular target, but Ligand A (63.94) is better than Ligand B (30.787).
9. **Caco-2:** Ligand A (-4.892) is better than Ligand B (-5.141). Both are negative, so this is a minor difference.
10. **Solubility:** Ligand A (-3.705) is better than Ligand B (-2.369). Higher solubility is generally preferred.
11. **hERG:** Ligand A (0.501) is better than Ligand B (0.13). Lower hERG inhibition is crucial for avoiding cardiotoxicity.
12. **Cl_mic:** Ligand A (49.42) is better than Ligand B (58.4). Lower clearance indicates better metabolic stability.
13. **t1/2:** Ligand A (0.338) is significantly better than Ligand B (-26.847). A longer half-life is generally desirable.
14. **Pgp:** Ligand A (0.218) is better than Ligand B (0.046). Lower P-gp efflux is preferred.
15. **Binding Affinity:** Ligand B (-6.2) has a slightly better binding affinity than Ligand A (-6.0). However, the difference is relatively small (0.2 kcal/mol).
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical ADME-Tox properties. While Ligand B has a slightly better binding affinity, the significant advantages of Ligand A in terms of logP, TPSA, DILI risk, hERG inhibition, metabolic stability (Cl_mic and t1/2), and P-gp efflux outweigh this minor difference in potency. Given the GPCR-specific priorities, the balance of properties in Ligand A makes it a much more promising drug candidate for the ADRB2 receptor.
Output:
1
2025-04-17 22:17:55,457 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [352.475, 98.66, 0.955, 4, 4, 0.572, 14.424, 24.738, -5.172, -2.354, 0.185, -6.533, 20.392, 0.038, -7]
**Ligand B:** [384.889, 105.39, 1.419, 2, 5, 0.818, 51.105, 54.13, -5.282, -2.83, 0.102, -8.168, -22.783, 0.032, -6.7]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (352.475) is slightly preferred due to being lower.
2. **TPSA:** Both are reasonably good (below 140), but Ligand A (98.66) is better than Ligand B (105.39) for oral absorption.
3. **logP:** Both are within the optimal range (1-3). Ligand B (1.419) is slightly higher, which could be beneficial for membrane permeability, but not significantly.
4. **HBD:** Ligand A (4) is slightly higher, but still acceptable. Ligand B (2) is better.
5. **HBA:** Ligand A (4) is lower than Ligand B (5), which is preferable.
6. **QED:** Ligand B (0.818) has a better QED score than Ligand A (0.572), indicating a more drug-like profile.
7. **DILI:** Ligand A (14.424) has a significantly lower DILI risk than Ligand B (51.105). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (54.13) has a higher BBB penetration than Ligand A (24.738). While ADRB2 is not a CNS target, some peripheral exposure can be reduced with higher BBB penetration.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. Ligand A (-5.172) is slightly better than Ligand B (-5.282).
10. **Solubility:** Both have negative solubility values, indicating poor solubility. Ligand A (-2.354) is slightly better than Ligand B (-2.83).
11. **hERG:** Both have very low hERG inhibition risk (0.185 and 0.102).
12. **Cl_mic:** Ligand A (-6.533) has a lower (better) microsomal clearance than Ligand B (-8.168), suggesting better metabolic stability.
13. **t1/2:** Ligand A (20.392) has a longer in vitro half-life than Ligand B (-22.783). This is a significant advantage.
14. **Pgp:** Both have very low P-gp efflux liability (0.038 and 0.032).
15. **Affinity:** Ligand A (-7.0) has a slightly better binding affinity than Ligand B (-6.7).
**GPCR-Specific Considerations:**
For a cardiovascular GPCR like ADRB2, logP, TPSA, affinity, and metabolic stability are key. While BBB isn't a primary concern, it's not detrimental. Ligand A excels in DILI risk, metabolic stability, and half-life, and has a slightly better affinity. Ligand B has a better QED and BBB penetration, but the significantly higher DILI risk is a major drawback.
**Conclusion:**
Considering the balance of properties, especially the significantly lower DILI risk and better metabolic stability of Ligand A, it is the more promising drug candidate. The slight advantage in binding affinity further supports this choice.
Output:
1
2025-04-17 22:17:55,457 - INFO - Here's my reasoning and final output for the ligand preference:
**Reasoning:**
We are targeting ADRB2, a GPCR, so the priorities are logP, Pgp, TPSA, affinity, and BBB. Let's compare Ligand A and Ligand B across all parameters:
1. **MW:** Both ligands (347.423 and 349.431 Da) are within the ideal 200-500 Da range.
2. **TPSA:** Both ligands (101.53 and 100.55) are reasonably good, being under 140, suggesting reasonable absorption.
3. **logP:** Ligand B (2.134) is better than Ligand A (0.823). A logP between 1-3 is optimal, and Ligand A is slightly below this range.
4. **HBD/HBA:** Ligand A has 1 HBD and 7 HBA, while Ligand B has 3 HBD and 5 HBA. Both are acceptable, within the recommended limits.
5. **QED:** Ligand A (0.864) has a better QED score than Ligand B (0.7), indicating a more drug-like profile.
6. **DILI:** Ligand A (24.622) has a significantly lower DILI risk than Ligand B (50.989). This is a major advantage for Ligand A.
7. **BBB:** Ligand A (75.223) has a better BBB penetration percentile than Ligand B (64.482). While not exceptionally high, it's preferable for a GPCR.
8. **Caco-2:** Both are negative, suggesting poor permeability.
9. **Solubility:** Both are negative, suggesting poor solubility.
10. **hERG:** Ligand A (0.78) shows lower hERG inhibition liability than Ligand B (0.199). This is a significant safety advantage for Ligand A.
11. **Cl_mic:** Ligand A (-25.612) has a much lower (better) microsomal clearance than Ligand B (28.103). This suggests better metabolic stability for Ligand A.
12. **t1/2:** Ligand A (15.487) has a longer in vitro half-life than Ligand B (-13.169).
13. **Pgp:** Ligand A (0.006) has significantly lower P-gp efflux liability than Ligand B (0.015). This is a positive for bioavailability and potential CNS exposure.
14. **Affinity:** Ligand A (-8.1 kcal/mol) has a substantially better binding affinity than Ligand B (-6.3 kcal/mol). The difference of 1.8 kcal/mol is significant and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand A is clearly the superior candidate. While Ligand B has a better logP, Ligand A excels in almost every other critical parameter, particularly DILI risk, hERG inhibition, metabolic stability (Cl_mic and t1/2), P-gp efflux, BBB penetration, and, most importantly, binding affinity. The substantial affinity difference of 1.8 kcal/mol is a strong driver for choosing Ligand A, even considering the slightly lower logP.
**Output:**
1
2025-04-17 22:17:55,457 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (360.391 and 348.403 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Both ligands (115.56 and 113.44) are reasonably low, suggesting good potential for absorption, but are above the optimal <90 for CNS targets (not a primary concern for ADRB2, a cardiovascular target).
3. **logP:** Ligand A (1.156) is within the optimal 1-3 range. Ligand B (-0.262) is slightly below 1, potentially hindering permeation. This is a slight advantage for A.
4. **HBD:** Ligand A (2) and Ligand B (3) are both acceptable, being less than 5.
5. **HBA:** Ligand A (5) and Ligand B (6) are both acceptable, being less than 10.
6. **QED:** Ligand A (0.776) has a better QED score than Ligand B (0.53), indicating a more drug-like profile. This is a significant advantage for A.
7. **DILI:** Ligand A (94.106) has a significantly higher DILI risk than Ligand B (47.964). This is a major drawback for A.
8. **BBB:** Both ligands have similar BBB penetration (67.817 and 63.707). Not a major factor for a cardiovascular target.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.399 and -5.333). This is unusual and suggests poor permeability.
10. **Solubility:** Ligand A (-3.324) has slightly worse solubility than Ligand B (-1.015).
11. **hERG:** Ligand A (0.202) has a lower hERG risk than Ligand B (0.028), which is preferable.
12. **Cl_mic:** Ligand A (27.111) has higher microsomal clearance than Ligand B (15.482), indicating lower metabolic stability. This is a disadvantage for A.
13. **t1/2:** Ligand A (10.435) has a longer in vitro half-life than Ligand B (0.384). This is a significant advantage for A.
14. **Pgp:** Ligand A (0.242) has lower P-gp efflux than Ligand B (0.006), which is preferable.
15. **Binding Affinity:** Ligand A (-8.7 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.7 kcal/mol). This is a substantial advantage for A, potentially outweighing some ADME concerns.
**Overall Assessment:**
Ligand A has a significantly better binding affinity and a longer half-life, and lower Pgp efflux. However, it has a much higher DILI risk and higher microsomal clearance. Ligand B has a better safety profile (lower DILI) and better metabolic stability, but weaker binding affinity and a shorter half-life.
Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity), the strong affinity of Ligand A is a major driver. While the DILI risk is concerning, it might be mitigated through structural modifications in later optimization stages. The difference in binding affinity (1.5 kcal/mol) is substantial enough to favor Ligand A despite its drawbacks.
Output:
1
2025-04-17 22:17:55,457 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (355.419 Da and 371.453 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (90.27) is slightly higher than Ligand B (71.09). For a cardiovascular GPCR, TPSA is moderately important. Ligand B's lower TPSA is preferable, suggesting better potential for membrane permeability.
**3. logP:** Ligand A (1.814) is within the optimal range (1-3). Ligand B (3.364) is at the higher end but still acceptable. While higher logP can sometimes cause issues, it's not a major concern here.
**4. H-Bond Donors:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs generally correlate with better permeability.
**5. H-Bond Acceptors:** Both ligands have 4 HBA, which is within the acceptable limit of 10.
**6. QED:** Ligand A (0.906) has a significantly better QED score than Ligand B (0.805), indicating a more drug-like profile overall.
**7. DILI Risk:** Both ligands have acceptable DILI risk (73.245 and 62.815, respectively), below the 60 threshold. Ligand B is slightly better.
**8. BBB Penetration:** Ligand B (85.459) shows significantly better BBB penetration than Ligand A (59.636). While this is a cardiovascular target, some CNS off-target effects are always a consideration, and better BBB penetration could be a slight advantage.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
**10. Aqueous Solubility:** Both ligands have negative solubility values, which is also unusual and suggests poor solubility. Again, the scale is not specified.
**11. hERG Inhibition:** Ligand A (0.59) has a slightly higher hERG risk than Ligand B (0.359), which is preferable.
**12. Microsomal Clearance:** Ligand A (62.646) has a higher microsomal clearance than Ligand B (53.318), meaning it's likely to be metabolized faster. Lower clearance is preferred.
**13. In vitro Half-Life:** Ligand B (24.965) has a much longer in vitro half-life than Ligand A (-4.899). This is a significant advantage, potentially leading to less frequent dosing.
**14. P-gp Efflux:** Ligand A (0.184) has lower P-gp efflux than Ligand B (0.246), which is preferable.
**15. Binding Affinity:** Ligand A (-7.1 kcal/mol) has a slightly better binding affinity than Ligand B (-6.1 kcal/mol). This 1 kcal/mol difference is significant and can outweigh some of the ADME drawbacks of Ligand A.
**Overall Assessment:**
While Ligand B has better ADME properties (lower TPSA, better BBB, longer half-life, lower clearance), Ligand A has a notably stronger binding affinity. Given that we're dealing with a GPCR, affinity is a crucial factor. The slightly better QED score for Ligand A also contributes to its favorability. The negative Caco-2 and solubility values are concerning for both, but the affinity advantage of Ligand A is compelling.
Output:
1
2025-04-17 22:17:55,457 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (342.49 and 347.46 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (38.82) is significantly lower than Ligand B (87.3). This is a major advantage for Ligand A as lower TPSA generally correlates with better cell permeability, crucial for GPCR targeting. Ligand B's TPSA is quite high, potentially hindering absorption.
**3. logP:** Both ligands have acceptable logP values (2.13 and 1.41), falling within the 1-3 range. Ligand B is slightly lower, which could slightly reduce permeability, but is still acceptable.
**4. H-Bond Donors:** Ligand A (1) has fewer HBDs than Ligand B (3). Fewer HBDs generally favor permeability.
**5. H-Bond Acceptors:** Both ligands have the same number of HBAs (3).
**6. QED:** Ligand A (0.911) has a substantially higher QED score than Ligand B (0.501), indicating a more drug-like profile.
**7. DILI Risk:** Ligand A (7.06%) has a much lower DILI risk than Ligand B (35.63%). This is a significant advantage for Ligand A, as liver toxicity is a major concern in drug development.
**8. BBB Penetration:** Ligand A (71.46%) shows better BBB penetration than Ligand B (52.62%). While ADRB2 is a cardiovascular target, some CNS effects are possible with beta-blockers, and better BBB penetration could be beneficial or detrimental depending on the desired profile.
**9. Caco-2 Permeability:** Ligand A (-4.84) has a better Caco-2 permeability than Ligand B (-5.22).
**10. Aqueous Solubility:** Ligand B (-2.76) has better aqueous solubility than Ligand A (-1.45). Solubility is important, but can often be improved with formulation.
**11. hERG Inhibition:** Ligand A (0.85) has a slightly higher hERG inhibition risk than Ligand B (0.10). However, both are relatively low, and this is not a major differentiating factor.
**12. Microsomal Clearance:** Ligand A (-9.99) has a much lower (better) microsomal clearance than Ligand B (24.03). This indicates greater metabolic stability for Ligand A.
**13. In vitro Half-Life:** Both ligands have similar in vitro half-lives (7.88 and 7.83 hours).
**14. P-gp Efflux:** Ligand A (0.02) has significantly lower P-gp efflux liability than Ligand B (0.11). Lower efflux is desirable for improved bioavailability.
**15. Binding Affinity:** Ligand A (-7.1 kcal/mol) has a slightly better binding affinity than Ligand B (-6.7 kcal/mol). While the difference is not huge, it's enough to be considered, especially in combination with the other favorable properties of Ligand A.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical ADME-Tox parameters, especially TPSA, DILI risk, QED, metabolic stability (Cl_mic), and P-gp efflux. While Ligand B has slightly better solubility, this can be addressed through formulation. The slightly better affinity of Ligand A further strengthens its position. Given the GPCR target class, the lower TPSA and P-gp efflux of Ligand A are particularly important.
Output:
1
2025-04-17 22:17:55,457 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (352.494 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are good, below the 140 A^2 threshold for oral absorption. Ligand B (49.41) is better than Ligand A (58.2), closer to the ideal for GPCRs.
3. **logP:** Both are within the optimal range (1-3), suggesting good partitioning. Ligand A (3.64) is slightly higher, which *could* lead to off-target effects, but is still acceptable. Ligand B (3.382) is preferable.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1), but both are acceptable.
5. **HBA:** Ligand A (2) and Ligand B (3) are both acceptable.
6. **QED:** Ligand A (0.623) is better than Ligand B (0.493), indicating a more drug-like profile.
7. **DILI:** Ligand B (18.108) has a significantly lower DILI risk than Ligand A (27.608), a major advantage.
8. **BBB:** Both have good BBB penetration (Ligand A: 83.637, Ligand B: 85.111). Ligand B is slightly better.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. Ligand B (-5.008) is slightly worse than Ligand A (-4.814).
10. **Solubility:** Both have negative solubility values, indicating poor solubility. Ligand B (-4.184) is slightly worse than Ligand A (-4.739).
11. **hERG:** Both have low hERG inhibition liability (Ligand A: 0.671, Ligand B: 0.696), which is good.
12. **Cl_mic:** Ligand B (53.736) has lower microsomal clearance than Ligand A (59.609), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-3.78) has a longer half-life than Ligand A (13.125). This is a significant advantage.
14. **Pgp:** Both have low P-gp efflux liability (Ligand A: 0.554, Ligand B: 0.269). Ligand B is significantly better.
15. **Binding Affinity:** Ligand B (-7.1 kcal/mol) has a slightly better binding affinity than Ligand A (-6.7 kcal/mol). This difference is significant.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are crucial. Ligand B excels in TPSA, Pgp, and affinity, and has a slightly better logP. The significantly lower DILI risk and improved metabolic stability (lower Cl_mic and longer t1/2) are also very important. While Ligand A has a slightly better QED and Caco-2, the other advantages of Ligand B outweigh these.
**Conclusion:**
Ligand B is the more promising drug candidate due to its superior binding affinity, lower DILI risk, better metabolic stability, and favorable Pgp efflux profile.
Output:
0
2025-04-17 22:17:55,458 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (362.5 vs 382.9 Da). No significant difference.
2. **TPSA:** Both are slightly above the ideal <140 for good absorption, but acceptable for a non-CNS target (40.6 vs 41.4). No major difference.
3. **logP:** Both ligands have good logP values (2.65 vs 3.70), falling within the optimal 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability but also raises a minor flag for potential off-target interactions.
4. **HBD:** Both have 0 HBD, which is good.
5. **HBA:** Ligand A has 3 HBA, and Ligand B has 5 HBA. Both are acceptable, but Ligand A is slightly better.
6. **QED:** Both have similar QED scores (0.706 vs 0.699), indicating good drug-likeness.
7. **DILI:** Ligand A has a DILI risk of 13.5%, while Ligand B has 24.2%. This is a significant difference, with Ligand A being considerably safer regarding liver toxicity.
8. **BBB:** Both have reasonable BBB penetration (86.1% vs 74.3%). While ADRB2 isn't a primary CNS target, some degree of BBB penetration isn't necessarily detrimental and could open up potential for off-target effects.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Both have negative solubility values, indicating poor aqueous solubility. This is a major drawback for both compounds.
11. **hERG:** Ligand A has a lower hERG inhibition liability (0.511) than Ligand B (0.798), indicating a lower risk of cardiotoxicity. This is crucial for a cardiovascular target.
12. **Cl_mic:** Ligand A has a lower microsomal clearance (54.35) than Ligand B (59.37), suggesting better metabolic stability.
13. **t1/2:** Ligand B has a much longer in vitro half-life (43.8 hours) than Ligand A (-10.07 hours). This is a major advantage for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A has a lower Pgp efflux liability (0.151) than Ligand B (0.212), suggesting better bioavailability.
15. **Binding Affinity:** Ligand B has a slightly better binding affinity (-6.3 kcal/mol) than Ligand A (-5.4 kcal/mol). This is a 0.9 kcal/mol difference, which is substantial and could outweigh some of the ADME drawbacks.
**GPCR-specific considerations:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are important. Ligand B has a better logP and affinity, but Ligand A has better TPSA and Pgp. The difference in affinity is significant.
**Overall Assessment:**
Despite the better half-life of Ligand B, the significantly lower DILI risk and hERG liability of Ligand A are crucial for a cardiovascular drug. The slightly better affinity of Ligand B is appealing, but the safety profile of Ligand A is more important. The poor Caco-2 and solubility for both are concerning and would require formulation strategies.
Output:
1
2025-04-17 22:17:55,458 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [368.543, 69.64, 3.002, 2, 4, 0.667, 22.257, 36.526, -4.893, -2.099, 0.409, 50.085, 58.202, 0.214, -6.6]
**Ligand B:** [360.385, 52.08, 4.325, 0, 5, 0.502, 80.729, 65.529, -4.531, -5.407, 0.28, 101.592, -3.547, 0.182, -3.7]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity):
1. **MW:** Both are within the ideal 200-500 Da range. Ligand B (360.385) is slightly lower, which can be a minor advantage for permeability.
2. **TPSA:** Ligand A (69.64) is higher than Ligand B (52.08). Both are acceptable for a peripheral GPCR like ADRB2, but Ligand B is better.
3. **logP:** Ligand A (3.002) is optimal. Ligand B (4.325) is pushing the upper limit, potentially raising concerns about solubility and off-target effects.
4. **HBD/HBA:** Ligand A (2 HBD, 4 HBA) and Ligand B (0 HBD, 5 HBA) are both reasonable.
5. **QED:** Both are above 0.5, indicating good drug-likeness. Ligand A (0.667) is slightly better.
6. **DILI:** Ligand A (22.257) has a significantly lower DILI risk than Ligand B (80.729). This is a major advantage for Ligand A.
7. **BBB:** Not a primary concern for ADRB2 (cardiovascular target), but Ligand B (65.529) has a higher BBB penetration than Ligand A (36.526).
8. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-4.893) is slightly worse than Ligand B (-4.531).
9. **Solubility:** Ligand B (-5.407) has worse solubility than Ligand A (-2.099).
10. **hERG:** Both show low hERG inhibition risk. Ligand A (0.409) is slightly higher than Ligand B (0.28).
11. **Cl_mic:** Ligand A (50.085) has better metabolic stability (lower clearance) than Ligand B (101.592).
12. **t1/2:** Ligand A (58.202) has a longer in vitro half-life than Ligand B (-3.547).
13. **Pgp:** Ligand A (0.214) has lower P-gp efflux liability than Ligand B (0.182).
14. **Affinity:** Ligand A (-6.6 kcal/mol) has a better binding affinity than Ligand B (-3.7 kcal/mol). This is a substantial difference.
**Overall Assessment:**
Ligand A is the stronger candidate. While Ligand B has a slightly better TPSA and Pgp efflux, Ligand A excels in critical areas: significantly lower DILI risk, substantially better binding affinity, better metabolic stability (lower Cl_mic, longer t1/2), and better solubility. The affinity difference is large enough to outweigh the minor drawbacks of Ligand A. The logP of Ligand A is also more optimal.
Output:
1
2025-04-17 22:17:55,458 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (350.459 Da and 350.503 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (103.86) is higher than Ligand B (69.64). For a cardiovascular GPCR, TPSA is moderately important, and lower is generally better for permeability. Ligand B has a more favorable TPSA.
**3. logP:** Both ligands have acceptable logP values (1.358 and 2.184, respectively), falling within the 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability, but not dramatically so.
**4. H-Bond Donors:** Ligand A has 3 HBD, and Ligand B has 2. Both are within the acceptable limit of <=5.
**5. H-Bond Acceptors:** Ligand A has 4 HBA, and Ligand B has 3. Both are within the acceptable limit of <=10.
**6. QED:** Both ligands have similar QED values (0.713 and 0.739), indicating good drug-like properties.
**7. DILI Risk:** Ligand A (19.542 percentile) has a significantly lower DILI risk than Ligand B (13.571 percentile). This is a crucial advantage for Ligand A.
**8. BBB Penetration:** Both ligands have similar BBB penetration (67.119% and 68.554%). While not a primary concern for a cardiovascular target, it's not detrimental.
**9. Caco-2 Permeability:** Ligand A (-5.378) has a worse Caco-2 permeability than Ligand B (-4.801). This suggests Ligand B may have better intestinal absorption.
**10. Aqueous Solubility:** Both ligands have poor aqueous solubility (-2.027 and -2.811). This is a potential formulation challenge for both.
**11. hERG Inhibition:** Ligand A (0.076) has a much lower hERG inhibition risk than Ligand B (0.471). This is a significant safety advantage for Ligand A.
**12. Microsomal Clearance:** Ligand A (-16.524) has much lower microsomal clearance than Ligand B (47.39). This indicates better metabolic stability for Ligand A, which is desirable.
**13. In vitro Half-Life:** Ligand A (-12.991) has a worse in vitro half-life than Ligand B (-9.443). This suggests Ligand B may have a longer duration of action.
**14. P-gp Efflux:** Ligand A (0.004) has much lower P-gp efflux than Ligand B (0.195). This is a significant advantage for Ligand A, improving bioavailability.
**15. Binding Affinity:** Ligand A (-7.0) and Ligand B (-6.6) have similar binding affinities. The difference is not substantial enough to outweigh other factors.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity) and the general drug-like properties, Ligand A emerges as the more promising candidate. While Ligand B has slightly better Caco-2 permeability and in vitro half-life, Ligand A exhibits significantly better safety profiles (lower DILI and hERG risk) and improved metabolic stability (lower Cl_mic) and P-gp efflux. The lower TPSA of Ligand B is a plus, but the safety and metabolic advantages of Ligand A are more critical for overall drug development success.
Output:
1
2025-04-17 22:17:55,458 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.5 and 350.5 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (60.85) is better than Ligand B (65.12). Both are below 140, but lower TPSA generally favors absorption.
3. **logP:** Ligand A (2.812) is optimal (1-3). Ligand B (-0.765) is significantly lower, potentially hindering membrane permeability. This is a key negative for Ligand B.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 3 HBA, while Ligand B has 5. Both are acceptable (<=10), but Ligand A is slightly preferable.
6. **QED:** Ligand A (0.731) is better than Ligand B (0.521), indicating a more drug-like profile.
7. **DILI:** Ligand A (11.09) has a much lower DILI risk than Ligand B (8.841). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (78.829) has better BBB penetration than Ligand B (53.936). While ADRB2 isn't exclusively a CNS target, some CNS exposure can occur, and higher BBB is generally favorable.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-4.459) is slightly better than Ligand B (-4.833), but both are concerning.
10. **Solubility:** Ligand A (-3.187) has better solubility than Ligand B (-0.795). Solubility is important for bioavailability.
11. **hERG:** Both ligands have low hERG inhibition risk (0.713 and 0.317 respectively).
12. **Cl_mic:** Ligand A (52.876) has better metabolic stability (lower clearance) than Ligand B (-13.983). This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (-4.166) has a longer in vitro half-life than Ligand B (-15.834). This is a significant advantage for Ligand A.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.314 and 0.012 respectively).
15. **Binding Affinity:** Ligand A (-6.5 kcal/mol) has slightly better binding affinity than Ligand B (-5.5 kcal/mol). While the difference isn't huge, it's enough to be noticeable.
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A excels in logP, TPSA, and has a slight edge in affinity. While both have good Pgp profiles, the overall balance of properties is much better for Ligand A.
**Conclusion:**
Ligand A demonstrates a significantly more favorable ADMET profile, with better solubility, metabolic stability, half-life, and lower DILI risk. While both have issues with Caco-2 permeability, Ligand A's superior logP and overall balance make it the more promising candidate.
Output:
1
2025-04-17 22:17:55,458 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (346.431 and 349.431 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (75.93) is significantly better than Ligand B (104.46). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is pushing the upper limit for good oral absorption.
3. **logP:** Both ligands have similar logP values (1.556 and 1.585), falling within the optimal 1-3 range.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Lower HBD generally improves permeability.
5. **HBA:** Both ligands have the same number of HBA (5). This is acceptable.
6. **QED:** Ligand A (0.761) has a better QED score than Ligand B (0.628), indicating a more drug-like profile.
7. **DILI:** Ligand A (35.634) has a lower DILI risk than Ligand B (42.575), which is a clear advantage. Both are below the concerning threshold of 60.
8. **BBB:** Ligand B (58.821) has a slightly higher BBB penetration than Ligand A (49.787). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be useful. However, this is less critical than other factors.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.077 and -4.797). This is unusual and suggests poor permeability *in vitro*. However, the values are close and the negative values may be due to experimental artifacts.
10. **Solubility:** Ligand A (-0.853) has better aqueous solubility than Ligand B (-3.234). Solubility is important for formulation and bioavailability.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.092 and 0.166), which is excellent.
12. **Cl_mic:** Ligand A (26.836) has a significantly lower microsomal clearance than Ligand B (44.35), indicating better metabolic stability.
13. **t1/2:** Ligand A (34.806) has a better in vitro half-life than Ligand B (-9.9). The negative value for Ligand B is concerning and suggests very rapid metabolism.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.152 and 0.12).
15. **Binding Affinity:** Ligand A (-9.0) has a significantly stronger binding affinity than Ligand B (-6.3). This is a substantial difference (2.7 kcal/mol) and is a major driver in the decision.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical parameters. The significantly better binding affinity, lower DILI risk, better metabolic stability (lower Cl_mic and better t1/2), and superior QED and solubility make it the more promising candidate. While Ligand B has slightly better BBB penetration, this is less important for a peripheral target like ADRB2. The negative Caco-2 values are a concern for both, but the other advantages of Ligand A outweigh this.
Output:
1
2025-04-17 22:17:55,459 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [349.435, 96.45, 0.308, 2, 6, 0.666, 38.736, 62.97, -4.629, -1.627, 0.075, 19.696, -28.555, 0.004, -7.3]
**Ligand B:** [364.486, 40.62, 3.308, 0, 3, 0.752, 30.748, 90.772, -4.443, -3.825, 0.828, 50.147, 11.174, 0.672, -5.4]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, BBB, and affinity are key):
1. **MW:** Both are within the ideal range (200-500 Da). A is 349.4, B is 364.5. Slight edge to A due to being a bit lower.
2. **TPSA:** A is 96.45, B is 40.62. B is significantly better, well under the 140 threshold for oral absorption and closer to the ideal for GPCRs.
3. **logP:** A is 0.308, B is 3.308. B is *much* better. A is quite low, potentially hindering permeability. B is within the optimal 1-3 range.
4. **HBD:** A is 2, B is 0. B is preferable as fewer HBDs generally improve permeability.
5. **HBA:** A is 6, B is 3. B is better, again favoring permeability.
6. **QED:** Both are good (A: 0.666, B: 0.752), indicating drug-like properties. B is slightly better.
7. **DILI:** A is 38.7, B is 30.7. B is better, indicating lower liver injury risk.
8. **BBB:** A is 62.97, B is 90.772. B is significantly better, which is important for GPCRs, even cardiovascular ones, as some CNS off-target effects are possible.
9. **Caco-2:** Both are negative, indicating poor permeability. A is -4.629, B is -4.443. Not much difference here, both are problematic.
10. **Solubility:** A is -1.627, B is -3.825. A is slightly better, but both are poor.
11. **hERG:** A is 0.075, B is 0.828. A is much better, posing a lower risk of cardiotoxicity. This is *critical* for a cardiovascular target.
12. **Cl_mic:** A is 19.696, B is 50.147. A is better, indicating greater metabolic stability.
13. **t1/2:** A is -28.555, B is 11.174. B is significantly better, suggesting a longer half-life.
14. **Pgp:** A is 0.004, B is 0.672. A is much better, indicating less P-gp efflux.
15. **Affinity:** A is -7.3 kcal/mol, B is -5.4 kcal/mol. A has a substantially stronger binding affinity. This is a major advantage.
**Overall Assessment:**
Ligand A has a significantly better binding affinity and lower hERG risk, which are crucial for a cardiovascular GPCR target. It also has better metabolic stability and Pgp efflux. However, Ligand B excels in TPSA, logP, BBB penetration, DILI risk, and half-life. The low logP and poor Caco-2 permeability of Ligand A are concerning.
Despite the permeability concerns with Ligand A, the *substantial* affinity advantage (-1.9 kcal/mol difference) and the very low hERG risk outweigh the ADME drawbacks. A small optimization to improve logP could likely resolve the permeability issue without sacrificing potency or safety. The better BBB penetration of Ligand B is a plus, but the affinity difference is too large to ignore.
Therefore, I choose Ligand A.
Output:
1
2025-04-17 22:17:55,459 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for the ADRB2, a cardiovascular GPCR. Therefore, the priorities are logP, TPSA, Pgp efflux, binding affinity, and, to a lesser extent, BBB.
Let's compare the ligands property by property:
1. **MW:** Both ligands (348.443 and 351.531 Da) fall within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (75.71) is higher than Ligand B (38.77). Ligand B is significantly better, being well below the 140 A^2 threshold for good absorption.
3. **logP:** Ligand A (1.564) is within the optimal range (1-3), while Ligand B (4.539) is a bit high, potentially leading to solubility issues and off-target effects.
4. **HBD/HBA:** Ligand A has 1 HBD and 4 HBA, while Ligand B has 0 HBD and 3 HBA. Both are acceptable.
5. **QED:** Ligand A (0.79) is better than Ligand B (0.632), indicating a more drug-like profile.
6. **DILI:** Both are good, with Ligand A at 29.042 and Ligand B at 20.783. Ligand B is slightly better, but both are well below the 40 threshold.
7. **BBB:** Ligand A (72.625) is reasonable, while Ligand B (90.461) is excellent. This is a positive for Ligand B, though less critical for a cardiovascular target.
8. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-4.763) is slightly better than Ligand B (-4.575).
9. **Solubility:** Ligand A (-1.507) is better than Ligand B (-5.033), which is a significant concern given Ligand B's high logP.
10. **hERG:** Both are very low (0.14 and 0.738), indicating minimal risk of cardiotoxicity.
11. **Cl_mic:** Ligand A (17.687) has a much lower clearance than Ligand B (104.523), suggesting better metabolic stability.
12. **t1/2:** Ligand A (6.18) has a longer half-life than Ligand B (2.335).
13. **Pgp:** Ligand A (0.047) has much lower P-gp efflux liability than Ligand B (0.72), which is a significant advantage.
14. **Binding Affinity:** Both ligands have the same binding affinity (-6.1 kcal/mol).
**Overall Assessment:**
While Ligand B has a better BBB score and slightly lower DILI, Ligand A is superior in almost every other critical parameter. Specifically, Ligand A's lower logP, better solubility, significantly lower microsomal clearance, longer half-life, and lower P-gp efflux make it a much more promising drug candidate. The TPSA difference is also substantial. The binding affinity is identical, so the ADME properties become the deciding factor.
**Output:**
1
2025-04-17 22:17:55,459 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's systematically compare Ligand A and Ligand B based on the provided parameters and the guidelines, keeping in mind that ADRB2 is a GPCR, so logP, Pgp, TPSA, and affinity are particularly important.
1. **MW:** Both ligands (376.425 and 365.518 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (82.78) is better than Ligand B (49.25). Lower TPSA generally favors better cell permeability, which is important for GPCR targeting.
3. **logP:** Ligand A (2.086) is within the optimal 1-3 range. Ligand B (4.095) is pushing the upper limit and could potentially lead to solubility issues or off-target interactions.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1), but both are acceptable.
5. **HBA:** Both ligands have 5 HBA, which is within the acceptable limit.
6. **QED:** Ligand A (0.761) has a slightly better QED score than Ligand B (0.689), indicating a more drug-like profile.
7. **DILI:** Ligand A (32.067) has a significantly lower DILI risk than Ligand B (17.449), which is a major advantage.
8. **BBB:** Ligand B (73.905) has a higher BBB penetration percentile than Ligand A (59.093). While ADRB2 isn't exclusively a CNS target, some CNS exposure might be acceptable or even desirable depending on the specific therapeutic application.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. Ligand A (-5.204) is slightly better than Ligand B (-4.845).
10. **Solubility:** Both ligands have negative solubility values, indicating poor solubility. Ligand A (-3.399) is slightly better than Ligand B (-3.016).
11. **hERG:** Ligand A (0.464) has a much lower hERG inhibition liability than Ligand B (0.948), which is a critical safety factor.
12. **Cl_mic:** Ligand A (-1.435) has a lower (better) microsomal clearance than Ligand B (40.605), suggesting better metabolic stability.
13. **t1/2:** Ligand B (67.778) has a significantly longer in vitro half-life than Ligand A (15.516), which is a positive attribute.
14. **Pgp:** Ligand A (0.074) has a lower Pgp efflux liability than Ligand B (0.837), which is favorable for bioavailability.
15. **Affinity:** Ligand B (-6.9 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.5 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME drawbacks.
**Overall Assessment:**
Ligand B has a superior binding affinity and a longer half-life. However, it suffers from higher logP, higher DILI risk, higher hERG liability, and higher Pgp efflux. Ligand A has a better safety profile (lower DILI and hERG), better metabolic stability, and lower Pgp efflux. The affinity difference is significant (1.4 kcal/mol), but the safety concerns with Ligand B are substantial. Considering the balance, and the fact that the affinity difference might be optimized in subsequent iterations, I favor Ligand A due to its superior safety and ADME properties.
**Output:**
1
2025-04-17 22:17:55,459 - INFO - Batch 321 complete. Total preferences: 5136
2025-04-17 22:17:55,459 - INFO - Processing batch 322/512...
2025-04-17 22:18:42,548 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (342.399 Da) is slightly lower, which is generally favorable for permeability.
**2. TPSA:** Both ligands have TPSA values below the 140 A^2 threshold for good oral absorption. Ligand B (90.03 A^2) is slightly lower, which is good.
**3. logP:** Ligand A (0.847) is at the lower end of the optimal range (1-3), while Ligand B (-0.921) is below 1, which could indicate potential permeability issues. This is a significant drawback for Ligand B.
**4. H-Bond Donors:** Both ligands are within the acceptable limit of 5. Ligand B has only 1 HBD, which might be slightly preferable.
**5. H-Bond Acceptors:** Both ligands are within the acceptable limit of 10.
**6. QED:** Both ligands have acceptable QED values (>0.5), indicating good drug-like properties.
**7. DILI:** Ligand B (24.04) has a much lower DILI risk than Ligand A (54.789), which is a significant advantage.
**8. BBB:** Ligand B (56.301) has a better BBB penetration percentile than Ligand A (40.946). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant, and higher BBB is generally preferred.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand B (-5.239) is slightly better than Ligand A (-4.995).
**10. Aqueous Solubility:** Both ligands have negative solubility values, which is also unusual and suggests poor solubility. Ligand A (-3.53) is slightly better than Ligand B (-1.162).
**11. hERG Inhibition:** Both ligands have low hERG inhibition liability, which is good. Ligand B (0.07) is slightly better.
**12. Microsomal Clearance:** Ligand A (23.004) has higher microsomal clearance than Ligand B (14.74), indicating lower metabolic stability. This is a disadvantage for Ligand A.
**13. In vitro Half-Life:** Ligand B (-27.149) has a longer in vitro half-life than Ligand A (-22.366), which is a positive attribute.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability.
**15. Binding Affinity:** Ligand A (-5.7 kcal/mol) has a slightly better binding affinity than Ligand B (-3.7 kcal/mol). This is a 2 kcal/mol difference, which is substantial.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand A's superior binding affinity is a major advantage. However, Ligand B demonstrates better safety (lower DILI), better BBB penetration, and improved metabolic stability (lower Cl_mic, longer t1/2). The biggest concern with Ligand B is its low logP, which could hinder permeability. The negative Caco-2 and solubility values for both are concerning and would require further investigation, but the logP issue for Ligand B is more immediately problematic.
Despite the affinity advantage of Ligand A, the combination of better safety, metabolic stability, and BBB penetration makes Ligand B the more promising candidate. The affinity difference, while notable, might be overcome with further optimization, whereas fixing a poor logP is often more challenging.
Output:
0
2025-04-17 22:18:42,548 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.471 and 347.459 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (53.01) is significantly better than Ligand B (65.78). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (2.677) is slightly higher than Ligand B (1.558), placing it more optimally within the 1-3 range. Ligand B is a bit low and could have permeability issues.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Both ligands have 4 HBA, which is good.
6. **QED:** Both ligands have high QED scores (0.914 and 0.883), indicating good drug-like properties.
7. **DILI:** Ligand A (23.536) has a much lower DILI risk than Ligand B (45.328). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (86.468) has a higher BBB penetration percentile than Ligand B (55.215). While not critical for a cardiovascular target, it's a slight positive for Ligand A.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.279 and -4.514). These values are unusual and potentially indicate issues with the prediction method or the compounds themselves. However, the values are similar.
10. **Solubility:** Both ligands have negative solubility values (-2.293 and -2.148), again suggesting potential issues with the prediction method. The values are similar.
11. **hERG:** Ligand A (0.849) has a slightly higher hERG risk than Ligand B (0.393), which is a negative for Ligand A.
12. **Cl_mic:** Ligand A (2.4) has significantly lower microsomal clearance than Ligand B (31.545), indicating better metabolic stability. This is a major advantage for Ligand A.
13. **t1/2:** Ligand A (35.391) has a much longer in vitro half-life than Ligand B (11.853). This is a substantial advantage for Ligand A.
14. **Pgp:** Ligand A (0.399) has lower P-gp efflux liability than Ligand B (0.29), which is a slight advantage for Ligand A.
15. **Binding Affinity:** Ligand A (-7.6 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.3 kcal/mol). This is a crucial advantage, as a 1.3 kcal/mol difference is substantial.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, and affinity. Ligand A is better in all these categories except for hERG, where it is slightly worse. However, the significant advantages in affinity, metabolic stability (Cl_mic, t1/2), DILI risk, and TPSA outweigh the slightly higher hERG risk.
**Conclusion:**
Ligand A is the more promising drug candidate due to its superior binding affinity, metabolic stability, lower DILI risk, and favorable TPSA, logP, and Pgp properties.
Output:
1
2025-04-17 22:18:42,549 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's break down the comparison of Ligand A and Ligand B across the provided parameters, keeping in mind the GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key).
1. **Molecular Weight:** Both ligands (337.471 Da and 351.447 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (66.53) is significantly better than Ligand B (73.78). A lower TPSA generally favors better cell permeability, which is crucial for GPCR targeting.
3. **logP:** Ligand A (4.334) is higher than Ligand B (2.051). While both are within the acceptable range, Ligand A is approaching the upper limit. This could potentially lead to solubility issues, but for a GPCR, a slightly higher logP can be tolerated if other properties are favorable.
4. **H-Bond Donors:** Ligand A (1) is better than Ligand B (0). A lower number of HBDs is generally preferred for permeability.
5. **H-Bond Acceptors:** Ligand A (5) is similar to Ligand B (6). Both are acceptable.
6. **QED:** Ligand A (0.881) is better than Ligand B (0.7). Higher QED suggests better overall drug-likeness.
7. **DILI:** Ligand A (35.401) is better than Ligand B (43.389). Both are reasonably low risk, but A is preferable.
8. **BBB:** Ligand B (88.484) is better than Ligand A (79.217). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be beneficial for distribution.
9. **Caco-2:** Ligand A (-4.914) is better than Ligand B (-4.44). Higher (less negative) values indicate better absorption.
10. **Solubility:** Ligand A (-5.226) is better than Ligand B (-1.887). Better solubility is always a plus.
11. **hERG:** Ligand A (0.679) is better than Ligand B (0.431). Lower hERG inhibition is crucial for avoiding cardiotoxicity, a major concern with cardiovascular targets.
12. **Cl_mic:** Ligand B (47.984) is better than Ligand A (51.636). Lower clearance is preferable for metabolic stability.
13. **t1/2:** Ligand B (15.973) is significantly better than Ligand A (-4.468). A longer half-life is desirable for less frequent dosing.
14. **Pgp:** Ligand A (0.397) is better than Ligand B (0.222). Lower P-gp efflux is desirable for better bioavailability.
15. **Binding Affinity:** Ligand A (-7.5 kcal/mol) is significantly better than Ligand B (-6.4 kcal/mol). This is a substantial difference in potency (1.1 kcal/mol), and this advantage is likely to outweigh some of the ADME drawbacks of Ligand A.
**Overall Assessment:**
Ligand A has a more favorable profile overall, particularly regarding TPSA, QED, DILI, hERG, Caco-2, solubility, and *most importantly*, binding affinity. While Ligand B has better BBB penetration and *t1/2*, the significantly stronger binding affinity of Ligand A is a critical advantage for a GPCR target. The slightly higher logP of Ligand A is a minor concern that could be addressed through further optimization.
**Output:**
1
2025-04-17 22:18:42,549 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A Analysis:**
* **MW:** 345.399 Da - Good, within the ideal range.
* **TPSA:** 78.95 - Good, below the 140 threshold for oral absorption.
* **logP:** 2.155 - Excellent, within the optimal 1-3 range.
* **HBD:** 1 - Good, well below the 5 limit.
* **HBA:** 4 - Good, well below the 10 limit.
* **QED:** 0.848 - Excellent, very drug-like.
* **DILI:** 57.387 - Acceptable, below the 60 high-risk threshold.
* **BBB:** 83.094 - Good, suggesting some brain penetration, but not a primary concern for a cardiovascular target.
* **Caco-2:** -4.64 - Very poor, indicating very low intestinal absorption. This is a significant issue.
* **Solubility:** -2.637 - Very poor, indicating low aqueous solubility. This is a significant issue.
* **hERG:** 0.335 - Low risk, good.
* **Cl_mic:** 24.841 - Moderate, could be better for metabolic stability.
* **t1/2:** 24.124 - Good, reasonable in vitro half-life.
* **Pgp:** 0.051 - Low efflux, good.
* **Affinity:** -6.9 kcal/mol - Very good binding affinity.
**Ligand B Analysis:**
* **MW:** 353.438 Da - Good, within the ideal range.
* **TPSA:** 61.88 - Excellent, well below the 140 threshold.
* **logP:** 0.566 - Marginal, slightly below the optimal range, potentially impacting permeability.
* **HBD:** 1 - Good, well below the 5 limit.
* **HBA:** 4 - Good, well below the 10 limit.
* **QED:** 0.56 - Acceptable, but not as strong as Ligand A.
* **DILI:** 16.13 - Excellent, very low liver injury risk.
* **BBB:** 70.88 - Acceptable, but not a primary concern for a cardiovascular target.
* **Caco-2:** -4.442 - Very poor, indicating very low intestinal absorption. This is a significant issue.
* **Solubility:** -1.18 - Very poor, indicating low aqueous solubility. This is a significant issue.
* **hERG:** 0.371 - Low risk, good.
* **Cl_mic:** 10.269 - Excellent, very good metabolic stability.
* **t1/2:** -28.1 - Very poor, extremely short in vitro half-life.
* **Pgp:** 0.029 - Low efflux, good.
* **Affinity:** -5.2 kcal/mol - Good binding affinity, but weaker than Ligand A.
**Comparison and Decision:**
Both ligands suffer from very poor Caco-2 permeability and aqueous solubility, which are major drawbacks. However, Ligand A has a significantly better binding affinity (-6.9 vs -5.2 kcal/mol), a higher QED score (0.848 vs 0.56), and a better in vitro half-life (24.124 vs -28.1). While Ligand B has a lower DILI risk and better metabolic stability, the substantial difference in affinity and the better overall drug-likeness of Ligand A outweigh these advantages. For a GPCR target like ADRB2, potency (affinity) is paramount. The poor permeability and solubility of both compounds would need to be addressed through formulation or prodrug strategies, but starting with the more potent and drug-like molecule is preferable.
Output:
1
2025-04-17 22:18:42,549 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, key priorities are logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB.
Let's break down the comparison:
1. **MW:** Both ligands (348.45 & 353.40 Da) are within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (82.7) is better than Ligand B (89.35). Both are below the 140 threshold for oral absorption, but lower is preferred.
3. **logP:** Ligand A (0.713) is slightly higher than Ligand B (0.443), both are within the optimal 1-3 range, but closer to the lower end.
4. **HBD/HBA:** Ligand A (3 HBD, 4 HBA) is preferable to Ligand B (1 HBD, 6 HBA) as it has a more balanced profile.
5. **QED:** Ligand B (0.83) has a significantly better QED score than Ligand A (0.614), indicating a more drug-like profile.
6. **DILI:** Ligand A (12.02) has a much lower DILI risk than Ligand B (62.001). This is a significant advantage for Ligand A.
7. **BBB:** Ligand B (89.298) has a higher BBB penetration score than Ligand A (71.733). While ADRB2 is cardiovascular, some CNS effects are possible with beta-blockers, so this is a slight advantage for B.
8. **Caco-2:** Ligand A (-5.185) is worse than Ligand B (-4.551), suggesting lower intestinal absorption.
9. **Solubility:** Both ligands have poor aqueous solubility (-1 and -2.001 respectively).
10. **hERG:** Ligand A (0.385) has a lower hERG inhibition liability than Ligand B (0.138), which is favorable.
11. **Cl_mic:** Ligand A (-8.816) has a much lower (better) microsomal clearance than Ligand B (13.348), indicating greater metabolic stability.
12. **t1/2:** Ligand A (-1.508) has a slightly worse in vitro half-life than Ligand B (-2.423).
13. **Pgp:** Ligand A (0.004) has a much lower P-gp efflux liability than Ligand B (0.056), which is a significant advantage.
14. **Binding Affinity:** Both ligands have very similar binding affinities (-6.6 and -6.4 kcal/mol). The difference is not substantial enough to outweigh other factors.
**Overall Assessment:**
Ligand A has a significantly better safety profile (lower DILI, lower hERG, lower Pgp efflux, and better metabolic stability). While Ligand B has a better QED and slightly better BBB penetration, the ADME advantages of Ligand A, particularly the lower DILI and Pgp efflux, are more critical for a viable drug candidate, especially considering the cardiovascular target. The slightly worse Caco-2 permeability of Ligand A is a concern, but potentially addressable through formulation strategies.
Output:
1
2025-04-17 22:18:42,549 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (352.41 and 350.463 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (87.46) is slightly higher than Ligand B (78.68). Both are below the 140 A^2 threshold for good oral absorption, but B is closer to the preferred <90 A^2 for GPCRs.
**3. logP:** Ligand B (1.682) is better than Ligand A (0.273). A logP of 0.273 is quite low and may indicate poor membrane permeability. Ligand B is within the optimal 1-3 range.
**4. H-Bond Donors:** Ligand A (2) is slightly higher than Ligand B (1). Both are acceptable, being less than 5.
**5. H-Bond Acceptors:** Both ligands have 5 HBA, which is within the acceptable range of <=10.
**6. QED:** Both ligands have good QED scores (0.796 and 0.844), indicating good drug-like properties.
**7. DILI Risk:** Ligand B (15.083) has a significantly lower DILI risk than Ligand A (21.675). This is a major advantage for Ligand B.
**8. BBB Penetration:** Ligand B (78.558) has better BBB penetration than Ligand A (62.97). While ADRB2 is a cardiovascular target, some CNS off-target effects are always a consideration, and better BBB penetration is generally preferable.
**9. Caco-2 Permeability:** Ligand A (-5.097) has worse Caco-2 permeability than Ligand B (-4.914). Both are negative, but B is less negative and therefore better.
**10. Aqueous Solubility:** Ligand A (-1.498) has slightly worse solubility than Ligand B (-1.203). Both are negative, indicating poor solubility.
**11. hERG Inhibition:** Ligand B (0.494) has a lower hERG inhibition liability than Ligand A (0.227), which is a significant safety advantage.
**12. Microsomal Clearance:** Ligand A (-13.431) has much lower (better) microsomal clearance than Ligand B (24.741). This suggests better metabolic stability for Ligand A.
**13. In vitro Half-Life:** Ligand B (-12.927) has a worse in vitro half-life than Ligand A (-2.218). This suggests Ligand A is more stable.
**14. P-gp Efflux:** Both ligands have very similar P-gp efflux liability (0.011 and 0.073).
**15. Binding Affinity:** Ligand B (-6.8) has a slightly better binding affinity than Ligand A (-6.0). While the difference is not huge (0.8 kcal/mol), it is still a factor.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity) and the general drug-like properties, Ligand B is the more promising candidate. While Ligand A has better metabolic stability (lower Cl_mic and better t1/2), Ligand B excels in crucial areas like logP, DILI risk, hERG inhibition, and BBB penetration. The slightly better binding affinity of Ligand B further strengthens its position. The low logP of Ligand A is a significant concern, potentially leading to poor absorption.
Output:
0
2025-04-17 22:18:42,549 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Step-by-step comparison:**
1. **MW:** Ligand A (353.304 Da) is well within the ideal range (200-500 Da). Ligand B (369.34 Da) is also acceptable. No clear advantage here.
2. **TPSA:** Ligand A (84.04) is excellent, well below the 140 threshold for good absorption. Ligand B (127.76) is still reasonable, but higher, potentially impacting absorption.
3. **logP:** Ligand A (1.92) is optimal. Ligand B (-1.335) is a bit low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (0) is ideal. Ligand B (5) is at the upper limit of acceptable, potentially impacting permeability.
5. **HBA:** Ligand A (6) is good. Ligand B (5) is also good.
6. **QED:** Ligand A (0.838) is excellent, indicating high drug-likeness. Ligand B (0.38) is significantly lower, raising concerns about its overall drug-like properties.
7. **DILI:** Ligand A (72.703) is acceptable, indicating low risk. Ligand B (33.346) is excellent, very low risk.
8. **BBB:** Ligand A (83.443) is good, suggesting reasonable potential for CNS penetration if desired. Ligand B (59.364) is lower, indicating less likely CNS penetration. While ADRB2 isn't exclusively a CNS target, some CNS effects are possible with beta-agonists, so this isn't a major negative for either.
9. **Caco-2:** Ligand A (-4.118) is poor. Ligand B (-5.495) is also poor. Both show poor intestinal absorption.
10. **Solubility:** Ligand A (-3.531) is poor. Ligand B (-1.679) is also poor. Both show poor aqueous solubility.
11. **hERG:** Ligand A (0.201) is very low risk. Ligand B (0.075) is extremely low risk. Both are excellent.
12. **Cl_mic:** Ligand A (63.809) is reasonable. Ligand B (10.882) is excellent, indicating high metabolic stability.
13. **t1/2:** Ligand A (-6.238) is good. Ligand B (-21.135) is excellent, suggesting a longer half-life.
14. **Pgp:** Ligand A (0.374) is low efflux, favorable for bioavailability. Ligand B (0.008) is extremely low efflux, even more favorable.
15. **Affinity:** Both ligands have an affinity of -7 kcal/mol, so there is no difference here.
**GPCR-specific priorities:** For GPCRs, logP, TPSA, Pgp, and affinity are key. Ligand A has a better logP and TPSA. Ligand B has a better Pgp efflux profile.
**Overall Assessment:**
Ligand A has a significantly better QED score and a more optimal logP. While both have poor Caco-2 and solubility, the superior drug-likeness of Ligand A, combined with its better TPSA, makes it the more promising candidate despite the slightly higher DILI risk. Ligand B's lower QED and lower logP are significant drawbacks. The excellent metabolic stability and efflux profile of Ligand B are helpful, but don't outweigh the other issues.
**Output:**
1
2025-04-17 22:18:42,550 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (364.852 and 350.459 Da) are within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (62.46) is significantly better than Ligand B (87.66). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (3.05) is optimal, while Ligand B (0.974) is a bit low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Both ligands have 4 HBA, which is acceptable.
6. **QED:** Ligand A (0.767) is better than Ligand B (0.666), indicating a more drug-like profile.
7. **DILI:** Ligand B (23.575) has a much lower DILI risk than Ligand A (50.291). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (71.229) has better BBB penetration than Ligand B (51.764), but this is less critical for a cardiovascular target.
9. **Caco-2:** Ligand A (-4.854) and Ligand B (-5.136) are similar, indicating similar intestinal absorption.
10. **Solubility:** Ligand A (-2.246) and Ligand B (-2.144) are similar.
11. **hERG:** Ligand A (0.935) has a slightly higher hERG risk than Ligand B (0.183). Lower is better here.
12. **Cl_mic:** Ligand B (16.989) has significantly lower microsomal clearance than Ligand A (33.378), suggesting better metabolic stability.
13. **t1/2:** Ligand A (26.535) has a slightly longer in vitro half-life than Ligand B (21.592).
14. **Pgp:** Ligand A (0.242) has lower P-gp efflux than Ligand B (0.029), which is beneficial for bioavailability.
15. **Affinity:** Ligand B (-7.6) has a slightly better binding affinity than Ligand A (-7.0). While both are excellent, the 0.6 kcal/mol difference is notable.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has better logP, TPSA, and Pgp. Ligand B has better affinity. The DILI and Cl_mic are also important considerations.
**Overall Assessment:**
Ligand B's superior binding affinity (-7.6 vs -7.0 kcal/mol) and significantly lower DILI risk (23.575 vs 50.291) are compelling advantages. While Ligand A has better TPSA and Pgp, the affinity and safety profile of Ligand B outweigh these factors. The improved metabolic stability (lower Cl_mic) also adds to its favorability.
**Output:**
0
2025-04-17 22:18:42,550 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (371.478 Da) is within the ideal range (200-500 Da). Ligand B (478.225 Da) is at the upper limit, but still acceptable.
2. **TPSA:** Ligand A (69.72) is excellent, well below the 140 threshold for oral absorption. Ligand B (42.96) is also very good.
3. **logP:** Both ligands (A: 2.837, B: 3.002) are within the optimal 1-3 range.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 3 HBA, and Ligand B has 5. Both are acceptable, but A is slightly preferred.
6. **QED:** Ligand A (0.885) has a significantly better QED score than Ligand B (0.554), indicating a more drug-like profile.
7. **DILI:** Ligand A (46.801) has a slightly higher DILI risk than Ligand B (23.226), but both are below the concerning threshold of 60.
8. **BBB:** Ligand A (83.094) has better BBB penetration than Ligand B (77.2). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant for off-target effects and overall safety.
9. **Caco-2:** Ligand A (-4.522) and Ligand B (-5.127) both show poor Caco-2 permeability. This is a significant concern for oral bioavailability.
10. **Solubility:** Ligand A (-3.92) and Ligand B (-2.767) both have poor aqueous solubility.
11. **hERG:** Ligand A (0.637) has a lower hERG risk than Ligand B (0.848), which is preferable.
12. **Cl_mic:** Ligand A (34.382) and Ligand B (38.037) have similar microsomal clearance values.
13. **t1/2:** Ligand A (-28.922) has a much longer in vitro half-life than Ligand B (5.465). This is a major advantage.
14. **Pgp:** Ligand A (0.089) shows lower P-gp efflux than Ligand B (0.459), which is favorable for bioavailability.
15. **Affinity:** Ligand A (-6.3 kcal/mol) has a significantly better binding affinity than Ligand B (-1.7 kcal/mol). This is a substantial advantage.
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are particularly important. Both ligands have acceptable logP and TPSA. Ligand A is significantly better regarding Pgp efflux and, crucially, binding affinity. The superior affinity of Ligand A (-6.3 vs -1.7) is a large enough difference to outweigh the slightly higher DILI risk and poor Caco-2/solubility.
**Conclusion:**
Ligand A is the more promising candidate due to its superior binding affinity, better QED, lower Pgp efflux, longer half-life, and lower hERG risk. While both compounds have issues with solubility and Caco-2 permeability, the potency and ADME advantages of Ligand A make it the better choice for further development.
Output:
1
2025-04-17 22:18:42,550 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A: [344.415, 73.91, 2.193, 2, 3, 0.804, 58.511, 59.325, -4.983, -2.381, 0.505, 29.577, -9.15, 0.088, -4.2]**
**Ligand B: [349.406, 70.67, 1.767, 2, 4, 0.869, 50.33, 74.254, -4.775, -1.628, 0.447, -15.147, -0.433, 0.019, -6.4]**
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal 200-500 Da range. A (344.4) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are good, below 140, suggesting reasonable absorption. B (70.67) is slightly better than A (73.91).
3. **logP:** Both are within the optimal 1-3 range. B (1.767) is slightly lower, which could be a minor advantage for solubility, but A (2.193) is still acceptable.
4. **HBD:** Both have 2 HBD, which is good.
5. **HBA:** A has 3, B has 4. Both are acceptable, but A is slightly better.
6. **QED:** Both are above 0.5, indicating good drug-like properties. B (0.869) is slightly better.
7. **DILI:** Both are acceptable, but B (50.33) is better than A (58.511). Lower is better.
8. **BBB:** B (74.254) is significantly better than A (59.325). While ADRB2 isn't necessarily a CNS target, some peripheral ADRB2 activity can be modulated by CNS effects, and higher BBB penetration can sometimes translate to better tissue distribution.
9. **Caco-2:** Both are negative, indicating poor permeability. A (-4.983) is worse than B (-4.775).
10. **Solubility:** Both are negative, indicating poor solubility. B (-1.628) is better than A (-2.381).
11. **hERG:** Both are low, indicating low cardiotoxicity risk. A (0.505) is slightly higher than B (0.447).
12. **Cl_mic:** B (-15.147) is *much* better than A (29.577). This is a significant advantage for B, indicating much better metabolic stability.
13. **t1/2:** B (-0.433) is better than A (-9.15). Longer half-life is desirable.
14. **Pgp:** Both are very low, indicating minimal P-gp efflux. A (0.088) is slightly higher than B (0.019).
15. **Affinity:** B (-6.4) is significantly better than A (-4.2). This is a 2.2 kcal/mol difference, which is substantial and can often outweigh minor ADME drawbacks.
**Overall Assessment:**
Ligand B is clearly the superior candidate. The significantly improved binding affinity (-6.4 vs -4.2 kcal/mol) is the most important factor. Additionally, B has better metabolic stability (Cl_mic), longer half-life, lower DILI risk, and better BBB penetration. While A has a slightly better MW and HBA count, these are minor advantages compared to B's strengths. The Caco-2 and solubility values are poor for both, but B is better.
Output:
0
2025-04-17 22:18:42,550 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.5 and 348.4 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (48.5) is significantly better than Ligand B (96.3). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold. Ligand B is approaching the upper limit.
3. **logP:** Ligand A (3.27) is optimal, while Ligand B (1.23) is on the lower side. For a GPCR, a logP between 1-3 is preferred, and Ligand A is better positioned.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (5) for similar reasons as HBD.
6. **QED:** Ligand A (0.71) is significantly better than Ligand B (0.46). A higher QED indicates a more drug-like molecule.
7. **DILI:** Ligand A (5.8) is *much* better than Ligand B (33.5). This is a critical factor; a lower DILI risk is highly desirable.
8. **BBB:** Ligand A (84.8) is better than Ligand B (31.0). While not a CNS target, some level of BBB penetration can sometimes indicate favorable permeability characteristics.
9. **Caco-2:** Ligand A (-4.61) is better than Ligand B (-5.31). Higher Caco-2 permeability is desired.
10. **Solubility:** Ligand A (-0.87) is better than Ligand B (-1.57). Better solubility is generally preferred.
11. **hERG:** Ligand A (0.81) is better than Ligand B (0.05). Lower hERG inhibition is crucial for avoiding cardiotoxicity, especially for a cardiovascular target.
12. **Cl_mic:** Ligand A (22.7) is significantly better than Ligand B (34.9). Lower clearance indicates greater metabolic stability.
13. **t1/2:** Ligand A (74.5) is *much* better than Ligand B (4.3). A longer half-life is generally desirable.
14. **Pgp:** Ligand A (0.02) is better than Ligand B (0.04). Lower P-gp efflux is preferred.
15. **Binding Affinity:** Ligand B (-6.7) is slightly better than Ligand A (-6.1). This is a 0.6 kcal/mol difference. While affinity is important, the other ADME properties of Ligand A are significantly superior.
**Overall Assessment:**
Ligand A demonstrates a substantially more favorable ADMET profile across almost all parameters. While Ligand B has a slightly better binding affinity, the significant advantages of Ligand A in terms of DILI risk, metabolic stability (Cl_mic, t1/2), solubility, QED, TPSA, logP, and hERG inhibition outweigh the small difference in binding affinity. For a cardiovascular GPCR target, minimizing off-target effects (like hERG inhibition and liver toxicity) and ensuring reasonable metabolic stability are paramount.
Output:
1
2025-04-17 22:18:42,550 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (355.385 and 359.455 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (82.27) is significantly better than Ligand B (109.04). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (1.317) is within the optimal 1-3 range. Ligand B (3.198) is at the higher end, potentially leading to solubility issues and off-target interactions.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable.
5. **HBA:** Ligand A (3) is better than Ligand B (7). Higher HBA can sometimes hinder permeability.
6. **QED:** Both ligands have similar, good QED values (0.807 and 0.813).
7. **DILI:** Ligand A (29.43) has a much lower DILI risk than Ligand B (49.128). This is a significant advantage for Ligand A.
8. **BBB:** Ligand B (82.513) has a slightly higher BBB penetration, but this isn't a primary concern for a cardiovascular target. Ligand A (74.176) is still reasonable.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-4.866) is slightly better than Ligand B (-4.971).
10. **Solubility:** Ligand A (-2.365) is better than Ligand B (-5.134). This is important for bioavailability.
11. **hERG:** Ligand A (0.378) has a much lower hERG inhibition liability than Ligand B (0.854). This is a critical safety parameter.
12. **Cl_mic:** Ligand A (-29.744) has a much lower (better) microsomal clearance than Ligand B (60.738), indicating greater metabolic stability.
13. **t1/2:** Ligand A (-27.676) has a much longer in vitro half-life than Ligand B (14.593).
14. **Pgp:** Ligand A (0.024) has significantly lower P-gp efflux liability than Ligand B (0.21).
15. **Binding Affinity:** Ligand B (-7.0) has a slightly better binding affinity than Ligand A (-6.4). While affinity is important, the 0.6 kcal/mol difference is not substantial enough to outweigh the numerous advantages of Ligand A.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A is better on logP, TPSA, and Pgp. The affinity difference is small.
**Overall Assessment:**
Ligand A demonstrates a significantly more favorable ADMET profile than Ligand B. It has lower DILI risk, lower hERG inhibition, better solubility, better metabolic stability (lower Cl_mic and longer t1/2), and lower P-gp efflux. While Ligand B has slightly better binding affinity, the overall balance of properties strongly favors Ligand A as a more viable drug candidate.
Output:
1
2025-04-17 22:18:42,551 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (364.555 and 358.429 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (49.41) is better than Ligand B (58.64). Both are below 140, but A is closer to the preferred <90 for potential CNS penetration, though this isn't a primary concern for ADRB2.
3. **logP:** Ligand A (4.246) is higher than Ligand B (1.998). While both are within the acceptable range, A is approaching the upper limit where solubility issues could arise. B is closer to the optimal 1-3 range.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Both ligands have 3 HBA, which is good.
6. **QED:** Ligand A (0.712) is slightly better than Ligand B (0.642), indicating a more drug-like profile.
7. **DILI:** Ligand B (18.728) is *significantly* better than Ligand A (34.781). This is a major advantage for B, as lower DILI risk is crucial.
8. **BBB:** Ligand B (81.776) is better than Ligand A (73.711). While ADRB2 isn't a primary CNS target, higher BBB penetration is generally favorable.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.782 and -4.576), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand B (-2.809) is better than Ligand A (-4.003), indicating better aqueous solubility.
11. **hERG:** Both ligands have low hERG inhibition liability (0.676 and 0.453), which is good.
12. **Cl_mic:** Ligand B (10.79) is *much* better than Ligand A (78.338). Lower clearance indicates better metabolic stability, a critical factor.
13. **t1/2:** Ligand B (-11.551) is significantly better than Ligand A (50.168). A negative half-life is unusual and suggests very rapid clearance, but relative to A's value, B is still preferable.
14. **Pgp:** Ligand A (0.468) is better than Ligand B (0.075). Lower P-gp efflux is preferred.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.7 and -6.8 kcal/mol). The difference is negligible.
**GPCR-Specific Priorities & Overall Assessment:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. While Ligand A has a slightly better logP and Pgp, Ligand B *strongly* outperforms in DILI risk and metabolic stability (Cl_mic and t1/2). The Caco-2 values are concerning for both, but the ADME advantages of Ligand B are substantial enough to outweigh the slight edge A has in permeability prediction. The similar binding affinities mean potency isn't a differentiating factor. The lower DILI risk and improved metabolic stability of Ligand B are crucial for a viable drug candidate.
**Output:**
0
2025-04-17 22:18:42,551 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (403.324 Da) is within the ideal range. Ligand B (364.427 Da) is also within the ideal range. No clear advantage here.
2. **TPSA:** Ligand A (52.39) is excellent, well below the 140 threshold. Ligand B (93.12) is still reasonable but higher, potentially impacting absorption.
3. **logP:** Ligand A (3.045) is optimal. Ligand B (0.542) is quite low, potentially leading to poor membrane permeability. This is a significant concern.
4. **HBD:** Both ligands are acceptable (0 for A, 1 for B), well within the limit of 5.
5. **HBA:** Ligand A (5) is good. Ligand B (7) is also acceptable, but slightly higher.
6. **QED:** Both ligands have good QED scores (0.712 and 0.842), indicating good drug-like properties.
7. **DILI:** Ligand A (42.846) has a lower DILI risk than Ligand B (62.66). This is a positive for Ligand A.
8. **BBB:** Ligand A (91.121) has a significantly higher BBB penetration percentile than Ligand B (71.501). While ADRB2 isn't *strictly* a CNS target, some peripheral ADRB2 activity can be modulated by CNS effects, and higher BBB penetration isn't necessarily detrimental.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Both ligands have negative solubility values, which is also unusual. Again, the scale is not specified.
11. **hERG:** Ligand A (0.965) has a lower hERG risk than Ligand B (0.157). This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand A (47.116) has a higher microsomal clearance than Ligand B (16.795), meaning it's metabolized faster. This is a negative for Ligand A.
13. **t1/2:** Ligand A (56.37) has a longer half-life than Ligand B (13.765). This is a positive for Ligand A.
14. **Pgp:** Ligand A (0.355) shows lower P-gp efflux than Ligand B (0.077). This is a positive for Ligand A.
15. **Binding Affinity:** Ligand B (-7.9 kcal/mol) has a slightly better binding affinity than Ligand A (-8.0 kcal/mol). The difference is small, and other factors are more important.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A excels in TPSA, Pgp, and has a good logP. Ligand B's low logP is a major drawback. The slight affinity advantage of Ligand B is outweighed by its poor logP and higher DILI/hERG risk.
**Conclusion:**
Despite Ligand B having a slightly better binding affinity, Ligand A is the more promising candidate due to its superior logP, lower DILI and hERG risk, better BBB penetration, and lower P-gp efflux. The longer half-life also contributes to its favorability.
Output:
1
2025-04-17 22:18:42,551 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (427.364 Da) is within the ideal range, while Ligand B (345.403 Da) is slightly below, but still acceptable.
2. **TPSA:** Ligand A (61.8) is good, well below the 140 threshold. Ligand B (129.18) is higher, but still within a reasonable range for oral absorption.
3. **logP:** Ligand A (3.511) is optimal. Ligand B (0.492) is quite low, potentially leading to poor membrane permeability. This is a significant concern.
4. **HBD:** Both ligands have 2 HBD, which is acceptable.
5. **HBA:** Both ligands have 5 HBA, which is acceptable.
6. **QED:** Both ligands have similar QED values (0.767 and 0.743), indicating good drug-likeness.
7. **DILI:** Ligand A (41.877) has a slightly better DILI score than Ligand B (53.858), indicating lower liver injury risk.
8. **BBB:** Ligand A (81.311) has a much higher BBB penetration score than Ligand B (40.52). While ADRB2 isn't *strictly* a CNS target, some CNS exposure can be beneficial and is not necessarily detrimental for cardiovascular applications.
9. **Caco-2:** Ligand A (-5.038) and Ligand B (-5.291) are both negative, which is unusual and requires further investigation. However, the values are similar.
10. **Solubility:** Ligand A (-3.219) and Ligand B (-2.68) are both negative, suggesting poor aqueous solubility. This is a concern for both, but may be less impactful if permeability is good.
11. **hERG:** Ligand A (0.929) has a slightly better hERG score than Ligand B (0.208), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand A (41.084) has a higher microsomal clearance than Ligand B (21.82), indicating faster metabolism. This is a negative for Ligand A.
13. **t1/2:** Ligand A (41.405) has a longer in vitro half-life than Ligand B (20.371), which is a positive.
14. **Pgp:** Ligand A (0.737) has a higher Pgp efflux score than Ligand B (0.037), indicating greater efflux and potentially lower bioavailability. This is a negative for Ligand A.
15. **Affinity:** Ligand B (-7.7 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.8 kcal/mol). This 1.9 kcal/mol difference is substantial and can often outweigh minor ADME drawbacks.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are particularly important. Ligand B excels in affinity, and while its logP is low, the substantial binding advantage is likely to compensate. Ligand A has better BBB penetration, but this isn't a primary concern for a cardiovascular target. The lower Pgp efflux and better metabolic stability of Ligand B are also favorable.
**Overall Assessment:**
Despite the lower logP, Ligand B's significantly stronger binding affinity is the deciding factor. The improved metabolic stability and lower Pgp efflux further support its selection. While solubility is a concern for both, the potency advantage of Ligand B is likely to be more impactful in driving *in vivo* efficacy.
Output:
0
2025-04-17 22:18:42,551 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [367.877, 73.83, 2.851, 3, 4, 0.748, 41.179, 61.923, -4.802, -3.306, 0.656, 5.827, 86.649, 0.148, -6.4]
**Ligand B:** [353.507, 70.67, 1.829, 2, 4, 0.698, 11.09, 54.789, -5.093, -1.168, 0.212, 2.303, 18.179, 0.013, -4]
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand B (353.5) is slightly lower, which is generally favorable.
2. **TPSA:** Both are reasonably good (73.83 & 70.67), being below 140, suggesting acceptable oral absorption.
3. **logP:** Ligand A (2.851) is optimal, while Ligand B (1.829) is a bit low, potentially hindering membrane permeability.
4. **HBD:** Ligand A has 3, and Ligand B has 2. Both are acceptable.
5. **HBA:** Both have 4, which is within the preferred range.
6. **QED:** Both are above 0.5 (0.748 & 0.698), indicating good drug-like properties.
7. **DILI:** Ligand A (41.179) is better than Ligand B (11.09), with a lower risk of liver injury.
8. **BBB:** Ligand A (61.923) has a better BBB penetration score than Ligand B (54.789), though neither is exceptionally high. For a cardiovascular target, BBB isn't *critical* but can be beneficial for off-target effects.
9. **Caco-2:** Ligand B (-5.093) has a better Caco-2 permeability than Ligand A (-4.802).
10. **Solubility:** Ligand B (-1.168) has better aqueous solubility than Ligand A (-3.306).
11. **hERG:** Ligand A (0.656) has a slightly higher hERG risk than Ligand B (0.212). This is a significant advantage for Ligand B.
12. **Cl_mic:** Ligand B (2.303) has much lower microsomal clearance than Ligand A (5.827), indicating better metabolic stability.
13. **t1/2:** Ligand A (86.649) has a significantly longer in vitro half-life than Ligand B (18.179).
14. **Pgp:** Ligand A (0.148) has lower P-gp efflux than Ligand B (0.013), which is favorable.
15. **Affinity:** Ligand A (-6.4) has a slightly better binding affinity than Ligand B (-4). This is a 2.4 kcal/mol difference, which is substantial.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand A has a better logP and lower Pgp efflux. However, Ligand B has a significantly better metabolic stability (lower Cl_mic), lower hERG risk, and better solubility. The 2.4 kcal/mol affinity difference is significant, and generally outweighs some ADME concerns.
**Conclusion:**
Despite Ligand B's advantages in metabolic stability, solubility, and hERG, the substantial binding affinity advantage of Ligand A, coupled with acceptable ADME properties, makes it the more promising candidate. The slightly lower BBB penetration of Ligand A is not a major concern for a cardiovascular target.
Output:
1
2025-04-17 22:18:42,551 - INFO - Batch 322 complete. Total preferences: 5152
2025-04-17 22:18:42,552 - INFO - Processing batch 323/512...
2025-04-17 22:19:27,787 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (341.455 and 348.403 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (54.46) is significantly better than Ligand B (95.75). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally correlates with better absorption. Ligand B's TPSA is quite high, potentially hindering oral bioavailability.
3. **logP:** Ligand A (4.277) is higher than Ligand B (0.572). While 4.277 is approaching the upper limit, it's still acceptable. Ligand B's logP is quite low, which raises concerns about membrane permeability.
4. **HBD:** Both ligands have 1 HBD, which is ideal.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 5. Both are acceptable, under the limit of 10.
6. **QED:** Both ligands have good QED scores (0.779 and 0.839), indicating good overall drug-likeness.
7. **DILI:** Ligand A (69.329) has a higher DILI risk than Ligand B (35.014). This is a significant negative for Ligand A.
8. **BBB:** Ligand A (55.991) has slightly better BBB penetration than Ligand B (48.158), but neither are particularly high. This isn't a major factor for a cardiovascular target.
9. **Caco-2:** Ligand A (-4.539) has a much better Caco-2 permeability score than Ligand B (-5.016). This suggests better intestinal absorption for Ligand A.
10. **Solubility:** Ligand A (-5.009) has better solubility than Ligand B (-1.719).
11. **hERG:** Ligand A (0.803) has a slightly higher hERG risk than Ligand B (0.116). This is a negative for Ligand A.
12. **Cl_mic:** Ligand A (103.695) has a higher microsomal clearance than Ligand B (9.51). This indicates lower metabolic stability for Ligand A.
13. **t1/2:** Ligand B (12.427) has a significantly longer in vitro half-life than Ligand A (34.434). This is a major advantage for Ligand B.
14. **Pgp:** Ligand A (0.573) has a lower Pgp efflux liability than Ligand B (0.01). This is a positive for Ligand A.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.7 and -6.6 kcal/mol). The difference is negligible.
**GPCR-Specific Priorities & Overall Assessment:**
For a GPCR like ADRB2, logP, TPSA, and affinity are key. Ligand A has a better logP and TPSA, and comparable affinity. However, Ligand B has significantly better DILI, hERG, Cl_mic, and t1/2 profiles. The lower metabolic clearance and longer half-life of Ligand B are particularly attractive, as is the lower potential for liver toxicity and cardiotoxicity. While Ligand A has slightly better Caco-2 and Pgp, the ADME/Tox advantages of Ligand B outweigh these benefits.
**Output:**
0
2025-04-17 22:19:27,787 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
The target is ADRB2, a GPCR. Therefore, I will prioritize logP, TPSA, Pgp efflux, BBB penetration, and binding affinity, while also considering overall drug-likeness (QED) and safety (DILI, hERG).
Let's analyze each ligand:
* **Molecular Weight:** Both ligands (367.5 and 386.2 Da) fall within the ideal 200-500 Da range.
* **TPSA:** Ligand A (78.5) is significantly better than Ligand B (104.2). ADRB2 is not a CNS target, but lower TPSA generally correlates with better permeability.
* **logP:** Both ligands have acceptable logP values (1.173 and 1.785, respectively), falling within the 1-3 range. Ligand B is slightly higher, which *could* be beneficial for membrane permeability, but isn't a major difference.
* **H-Bond Donors/Acceptors:** Both have 2 HBDs, which is good. Ligand B has 6 HBAs compared to Ligand A's 4. This is a slight negative for Ligand B, potentially impacting permeability.
* **QED:** Both ligands have good QED scores (0.715 and 0.834), indicating good drug-like properties.
* **DILI:** Ligand A (27.6) has a much lower DILI risk than Ligand B (86.0). This is a significant advantage for Ligand A.
* **BBB:** Ligand A (33.4) has better BBB penetration than Ligand B (13.4), but this is less critical for a non-CNS target like ADRB2.
* **Caco-2:** Both have negative Caco-2 values, which is unusual. I will assume these are percentile scores, and thus higher is better. The values are similar (-5.242 and -4.885).
* **Solubility:** Both have negative solubility values, again assuming percentile scores. Ligand A (-2.351) is slightly better than Ligand B (-3.116).
* **hERG:** Both have very low hERG risk (0.065 and 0.104).
* **Cl_mic:** Ligand B (-2.082) has a *much* lower (better) microsomal clearance than Ligand A (19.103). This is a major advantage for Ligand B, indicating greater metabolic stability.
* **t1/2:** Ligand B (-25.654) has a significantly longer in vitro half-life than Ligand A (-13.326). This is another strong point for Ligand B.
* **Pgp:** Both ligands have very low Pgp efflux (0.017 and 0.051).
* **Binding Affinity:** Both ligands have similar and excellent binding affinities (-4.7 and -5.4 kcal/mol). The difference is not substantial enough to be the deciding factor.
**Overall Assessment:**
Ligand B has a clear advantage in metabolic stability (Cl_mic and t1/2). However, Ligand A has a significantly lower DILI risk and a better TPSA. Given the importance of minimizing toxicity, and the relatively similar binding affinities, Ligand A is the slightly more promising candidate. The lower TPSA also supports better permeability.
**Output:**
1
2025-04-17 22:19:27,787 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**1. Molecular Weight:** Both ligands (364.873 and 355.408 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (50.8) is better than Ligand B (57.7). Both are below the 140 threshold for oral absorption, but lower TPSA is generally preferred for GPCRs to facilitate receptor binding.
**3. logP:** Ligand B (3.965) is slightly higher than Ligand A (2.853). While both are within the optimal 1-3 range, Ligand B is approaching the upper limit.
**4. H-Bond Donors:** Both ligands have 1 HBD, which is acceptable.
**5. H-Bond Acceptors:** Both ligands have 4 HBA, which is acceptable.
**6. QED:** Ligand B (0.779) has a higher QED score than Ligand A (0.54), indicating a more drug-like profile. This is a positive for Ligand B.
**7. DILI Risk:** Ligand A (16.014) has a significantly lower DILI risk than Ligand B (35.401). This is a major advantage for Ligand A, as liver toxicity is a critical concern.
**8. BBB Penetration:** Ligand B (76.735) has better BBB penetration than Ligand A (68.399). While ADRB2 isn't exclusively a CNS target, some cardiovascular effects are mediated by central pathways, so some BBB penetration can be beneficial.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.903 and -4.986). This is unusual and suggests poor permeability. However, the values are very similar.
**10. Aqueous Solubility:** Ligand B (-3.744) is slightly better than Ligand A (-2.795) in terms of aqueous solubility, but both are quite poor.
**11. hERG Inhibition:** Ligand A (0.715) has a lower hERG inhibition risk than Ligand B (0.909). This is a significant advantage for Ligand A, as hERG inhibition can lead to cardiotoxicity.
**12. Microsomal Clearance:** Ligand B (18.643) has a higher microsomal clearance than Ligand A (6.908), indicating faster metabolism and potentially lower bioavailability. Ligand A is preferred here.
**13. In vitro Half-Life:** Ligand A (21.134 hours) has a significantly longer in vitro half-life than Ligand B (9.822 hours). This is a substantial advantage for Ligand A, potentially allowing for less frequent dosing.
**14. P-gp Efflux:** Ligand B (0.352) has lower P-gp efflux than Ligand A (0.243), which is favorable for bioavailability.
**15. Binding Affinity:** Ligand B (-6.1 kcal/mol) has a slightly better binding affinity than Ligand A (-6.6 kcal/mol). This is a positive for Ligand B, but the difference is relatively small.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity) and general drug-like properties, Ligand A emerges as the more promising candidate. While Ligand B has slightly better affinity and Pgp efflux, Ligand A excels in crucial areas like DILI risk, hERG inhibition, metabolic stability (lower Cl_mic and longer t1/2), and TPSA. The significantly lower DILI and hERG risks are particularly important for a cardiovascular target. The slightly better BBB penetration of Ligand B is not enough to offset these advantages. The poor Caco-2 permeability is a concern for both, but can be addressed with formulation strategies.
Output:
1
2025-04-17 22:19:27,788 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Ligand A (435.384 Da) is within the ideal range, while Ligand B (370.837 Da) is also acceptable. No clear advantage.
2. **TPSA:** Ligand A (78.87) is better than Ligand B (113.33). Lower TPSA generally favors better absorption, crucial for GPCR ligands.
3. **logP:** Both ligands have good logP values (A: 2.2, B: 1.259), falling within the optimal 1-3 range. Ligand A is slightly better.
4. **HBD:** Ligand A (2) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Both ligands have the same number of HBA (5).
6. **QED:** Ligand A (0.687) has a better QED score than Ligand B (0.566), indicating a more drug-like profile.
7. **DILI:** Ligand A (25.979) has a significantly lower DILI risk than Ligand B (45.25). This is a major advantage.
8. **BBB:** Ligand B (61.729) has a higher BBB penetration percentile than Ligand A (46.762). While ADRB2 isn't necessarily a CNS target, some degree of BBB penetration can be useful for off-target profiling and understanding distribution.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.139 and -5.454). These values are unusual and likely represent logPapp values, where lower values indicate poorer permeability. Ligand A is slightly better.
10. **Solubility:** Both ligands have negative solubility values (-3.133 and -2.402). These values are also unusual and likely represent logS values, where lower values indicate poorer solubility. Ligand B is slightly better.
11. **hERG:** Ligand A (0.923) has a slightly higher hERG risk than Ligand B (0.2). Lower is better here.
12. **Cl_mic:** Ligand B (5.754) has a significantly lower microsomal clearance than Ligand A (42.702), suggesting better metabolic stability. This is a substantial advantage.
13. **t1/2:** Ligand B (30.341) has a longer in vitro half-life than Ligand A (-21.46). This is a significant advantage.
14. **Pgp:** Ligand A (0.654) has a lower P-gp efflux liability than Ligand B (0.093), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand A (-6.5 kcal/mol) has a slightly better binding affinity than Ligand B (-6.2 kcal/mol). While the difference is small, it's still a positive.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A performs better on TPSA, logP, and Pgp. The affinity difference is small.
**Overall Assessment:**
Ligand A has a significantly better safety profile (lower DILI) and a slightly better binding affinity. It also has better TPSA and Pgp properties. While Ligand B has better metabolic stability (lower Cl_mic) and half-life, the DILI risk associated with Ligand B is concerning. The slightly better affinity of Ligand A, combined with its superior safety profile and favorable ADME properties, makes it the more promising candidate.
Output:
1
2025-04-17 22:19:27,788 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (339.351) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (66.32) is significantly better than Ligand A (87.34). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA is still beneficial for absorption.
3. **logP:** Both ligands have good logP values (3.367 and 3.958), falling within the optimal 1-3 range. Ligand B is slightly higher, which *could* indicate a slight solubility issue, but isn't a major concern.
4. **HBD:** Ligand A has 0 HBD, while Ligand B has 1. Both are acceptable.
5. **HBA:** Ligand A has 7 HBA, and Ligand B has 5. Both are within the acceptable range of <=10.
6. **QED:** Ligand B (0.877) has a significantly better QED score than Ligand A (0.659), indicating a more drug-like profile.
7. **DILI:** Ligand B (24.118) has a much lower DILI risk than Ligand A (87.786). This is a *major* advantage for Ligand B.
8. **BBB:** Both have similar BBB penetration (57.774 and 58.472). Not a critical factor for a cardiovascular target.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Both have negative solubility values, again making interpretation difficult without knowing the scale.
11. **hERG:** Both have low hERG inhibition liability (0.251 and 0.4), which is good.
12. **Cl_mic:** Ligand A (100.844) has higher microsomal clearance than Ligand B (61.255), meaning it's less metabolically stable.
13. **t1/2:** Ligand B (-11.665) has a more negative in vitro half-life, which is not ideal. Ligand A (-51.215) is even worse. This is a significant drawback for both.
14. **Pgp:** Both have very low Pgp efflux liability (0.362 and 0.026).
15. **Binding Affinity:** Ligand B (-9.7 kcal/mol) has a significantly stronger binding affinity than Ligand A (-7.6 kcal/mol). This is a substantial advantage.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, and affinity are key. Ligand B excels in these areas, particularly with its superior affinity and lower TPSA. The DILI risk is also a critical factor, and Ligand B is far better in this regard. While both have poor in vitro half-lives, the significantly stronger binding affinity of Ligand B suggests it might still be effective *in vivo* even with faster metabolism.
**Conclusion:**
Despite the poor in vitro half-life for both, Ligand B is the more promising candidate due to its superior binding affinity, lower DILI risk, better QED score, and favorable TPSA. The stronger binding is likely to outweigh the metabolic concerns, especially given the relatively low molecular weight.
Output:
0
2025-04-17 22:19:27,788 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (347.463) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (73.91) is significantly better than Ligand A (98.17). ADRB2 is a cardiovascular target, so CNS penetration is not a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (A: 3.178, B: 2.62) within the optimal 1-3 range.
4. **HBD/HBA:** Ligand A (HBD=1, HBA=3) has a more favorable H-bond profile than Ligand B (HBD=2, HBA=5), potentially improving permeability.
5. **QED:** Ligand B (0.663) has a better QED score than Ligand A (0.394), indicating a more drug-like profile.
6. **DILI:** Both ligands have low DILI risk (A: 24.506, B: 25.087), which is excellent.
7. **BBB:** Ligand A (71.811) has a better BBB score than Ligand B (54.711), but this is less important for a cardiovascular target.
8. **Caco-2:** Ligand A (-4.747) and Ligand B (-5.047) are similar, both indicating good permeability.
9. **Solubility:** Ligand A (-2.65) and Ligand B (-2.817) are similar, both indicating poor solubility.
10. **hERG:** Ligand A (0.478) has a lower hERG risk than Ligand B (0.809), which is a significant advantage.
11. **Cl_mic:** Ligand B (53.099) has a lower microsomal clearance than Ligand A (63.157), suggesting better metabolic stability.
12. **t1/2:** Ligand B (93.106) has a much longer in vitro half-life than Ligand A (-11.669), a substantial benefit for dosing frequency.
13. **Pgp:** Ligand A (0.049) has a lower Pgp efflux liability than Ligand B (0.799), which is good for bioavailability.
14. **Binding Affinity:** Ligand B (-7.0) has a significantly stronger binding affinity than Ligand A (-5.2). This is a crucial advantage, potentially outweighing some ADME drawbacks.
**GPCR-specific priorities:** For ADRB2 (a GPCR), affinity, logP, TPSA, and Pgp are key. Ligand B excels in affinity, has a good logP, and a reasonable TPSA. While Ligand A has better Pgp, the substantial affinity difference of Ligand B is the deciding factor.
**Overall Assessment:**
Ligand B has a significantly better binding affinity and a longer half-life, which are highly desirable for a GPCR target. While Ligand A has some advantages in TPSA, Pgp, and hERG, the superior affinity of Ligand B is likely to drive efficacy and make it a more promising drug candidate. The slightly worse solubility and Pgp efflux of Ligand B can potentially be addressed through formulation strategies.
Output:
0
2025-04-17 22:19:27,788 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (345.4 and 344.5 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (97.94) is higher than Ligand B (49.41). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for permeability. Ligand B has a significant advantage here.
3. **logP:** Ligand A (0.32) is quite low, potentially hindering membrane permeability. Ligand B (3.444) is within the optimal 1-3 range. This is a substantial advantage for Ligand B.
4. **HBD:** Both have 1 HBD, which is acceptable.
5. **HBA:** Ligand A has 7 HBA, while Ligand B has 2. Both are within the acceptable limit of 10, but Ligand B is better.
6. **QED:** Ligand A (0.805) has a slightly better QED score than Ligand B (0.777), indicating slightly better overall drug-likeness.
7. **DILI:** Ligand A (53.121) has a higher DILI risk than Ligand B (22.722). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (42.536) has a lower BBB penetration percentile than Ligand B (73.711). While ADRB2 isn't a CNS target, some distribution to the CNS is possible, and higher BBB is generally favorable. Ligand B is better.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability *in vitro*. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Ligand A (-0.624) has worse solubility than Ligand B (-3.669). Solubility is important for bioavailability, so Ligand B is favored.
11. **hERG:** Ligand A (0.02) has a slightly lower hERG risk than Ligand B (0.505), which is a small advantage.
12. **Cl_mic:** Ligand A (2.098) has a significantly lower microsomal clearance than Ligand B (54.931), indicating better metabolic stability. This is a major advantage for Ligand A.
13. **t1/2:** Ligand A (15.605) has a longer in vitro half-life than Ligand B (-13.812). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.046) has lower P-gp efflux liability than Ligand B (0.351), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand B (-7.8 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.8 kcal/mol). This is a substantial advantage for Ligand B, potentially outweighing some of the ADME drawbacks.
**Overall Assessment:**
Ligand B has a superior logP, TPSA, DILI, BBB, solubility, and, crucially, a much stronger binding affinity. Ligand A has advantages in metabolic stability (Cl_mic and t1/2), Pgp efflux, and a slight edge in hERG. However, the poor logP and solubility of Ligand A are concerning. The significantly better binding affinity of Ligand B, combined with its more favorable ADME properties (especially logP and DILI), makes it the more promising candidate despite the slightly higher hERG risk and lower metabolic stability. The affinity difference is substantial (>1.5 kcal/mol).
Output:
0
2025-04-17 22:19:27,788 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (331.379) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (64.74) is significantly better than Ligand B (88.91). For a GPCR, keeping TPSA low is beneficial for permeability and receptor engagement.
3. **logP:** Both ligands have acceptable logP values (A: 3.07, B: 1.467), falling within the 1-3 range. Ligand A is slightly higher, which could be a minor concern for solubility, but not a dealbreaker.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves membrane permeability.
5. **HBA:** Both have the same number of HBA (5), which is within the acceptable limit.
6. **QED:** Ligand B (0.817) has a slightly better QED score than Ligand A (0.625), suggesting a more generally drug-like profile.
7. **DILI:** Ligand B (32.067) has a *much* lower DILI risk than Ligand A (88.251). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (73.556) has a better BBB penetration score than Ligand B (50.097). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant for off-target effects and overall safety assessment.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.134 and -5.396), which is unusual and suggests very poor permeability. This is a major concern for both.
10. **Solubility:** Ligand B (-2.012) has a slightly better solubility score than Ligand A (-4.499), though both are very poor.
11. **hERG:** Ligand A (0.736) has a lower hERG risk than Ligand B (0.078), which is a significant advantage.
12. **Cl_mic:** Ligand B (11.63) has a much lower microsomal clearance than Ligand A (60.02), indicating better metabolic stability.
13. **t1/2:** Ligand B (12.312) has a significantly longer in vitro half-life than Ligand A (69.917). This is a major advantage.
14. **Pgp:** Ligand A (0.554) has a lower P-gp efflux liability than Ligand B (0.011), which is preferable.
15. **Binding Affinity:** Ligand A (-6.8 kcal/mol) has a slightly better binding affinity than Ligand B (-6.6 kcal/mol). This difference is relatively small, but still noteworthy.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, and affinity. Ligand A has a slightly better logP and affinity, and better Pgp. However, Ligand B has a much better DILI score, significantly better metabolic stability (Cl_mic and t1/2), and a better solubility. The poor Caco-2 values for both are concerning, but the metabolic stability and safety profile of Ligand B are more critical at this stage.
**Overall Assessment:**
While Ligand A has a slightly better affinity and Pgp profile, the significantly lower DILI risk, better metabolic stability, and longer half-life of Ligand B outweigh these advantages. The poor Caco-2 values are a concern for both, but can be addressed with formulation strategies. The safety profile and metabolic stability are more fundamental properties that are harder to improve later in development.
Output:
0
2025-04-17 22:19:27,789 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (346.475 Da) is well within the ideal range (200-500 Da). Ligand B (450.28 Da) is at the higher end, but still acceptable.
2. **TPSA:** Ligand A (76.02) is excellent, well below the 140 threshold for good absorption. Ligand B (69.38) is also very good.
3. **logP:** Both ligands have good logP values (A: 2.919, B: 3.583), falling within the optimal 1-3 range. Ligand B is slightly higher, which could potentially lead to some off-target interactions, but isn't a major concern.
4. **HBD:** Ligand A (2) is good. Ligand B (0) is also good.
5. **HBA:** Ligand A (4) is good. Ligand B (6) is acceptable, but higher.
6. **QED:** Ligand A (0.533) is better than Ligand B (0.439), indicating a more drug-like profile.
7. **DILI:** Ligand A (51.532) has a significantly lower DILI risk than Ligand B (74.254). This is a crucial advantage.
8. **BBB:** Ligand B (67.895) shows better BBB penetration than Ligand A (47.46). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant for off-target effects or potential therapeutic strategies.
9. **Caco-2:** Ligand A (-4.966) shows better Caco-2 permeability than Ligand B (-5.3).
10. **Solubility:** Ligand A (-3.172) shows better aqueous solubility than Ligand B (-4.418).
11. **hERG:** Both ligands have low hERG inhibition risk (A: 0.232, B: 0.366).
12. **Cl_mic:** Ligand A (61.287) has lower microsomal clearance, suggesting better metabolic stability, than Ligand B (75.064).
13. **t1/2:** Ligand B (46.795) has a longer in vitro half-life than Ligand A (17.672). This is a positive attribute.
14. **Pgp:** Both ligands have low P-gp efflux liability (A: 0.125, B: 0.682). Ligand A is better.
15. **Affinity:** Ligand A (-7.0) has a slightly better binding affinity than Ligand B (-3.6). This is a substantial difference.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Both ligands perform well on logP and TPSA. Ligand A has a better Pgp profile. However, the most significant difference is the binding affinity: Ligand A is *much* stronger. The substantial affinity difference (-7.0 vs -3.6 kcal/mol) is likely to outweigh the slightly better BBB penetration and half-life of Ligand B. Furthermore, the lower DILI risk and better metabolic stability of Ligand A are important safety and PK advantages.
**Conclusion:**
Ligand A is the more promising drug candidate due to its superior binding affinity, lower DILI risk, better metabolic stability, and better Pgp profile.
Output:
1
2025-04-17 22:19:27,789 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (380.447 Da) is slightly higher than Ligand B (348.403 Da), but both are acceptable.
**2. TPSA:** Both ligands have TPSA values below 140 A^2, which is good for oral absorption. Ligand B (95.75 A^2) is slightly lower than Ligand A (101.57 A^2), which is marginally better.
**3. logP:** Both ligands have logP values within the optimal range (1-3). Ligand A (1.385) is slightly higher than Ligand B (0.572), which is preferable for membrane permeability.
**4. H-Bond Donors:** Both ligands are within the acceptable limit of 5. Ligand B has 1 HBD, while Ligand A has 2. This is a slight advantage for Ligand B.
**5. H-Bond Acceptors:** Both ligands have 5 HBA, which is within the acceptable limit of 10.
**6. QED:** Both ligands have good QED scores (>0.5). Ligand B (0.839) is slightly higher than Ligand A (0.738), indicating a more drug-like profile.
**7. DILI Risk:** Ligand B (35.014%) has a significantly lower DILI risk than Ligand A (89.104%). This is a major advantage for Ligand B.
**8. BBB Penetration:** Ligand B (48.158%) has better BBB penetration than Ligand A (15.316%). While ADRB2 is a cardiovascular target, some CNS effects are possible with beta-adrenergic agonists, and higher BBB penetration could be a concern, but it's not a primary negative.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. This is a significant drawback for both.
**10. Aqueous Solubility:** Both ligands have negative solubility values, which is also unusual and suggests poor solubility. This is a significant drawback for both.
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.207 and 0.116 respectively). This is good.
**12. Microsomal Clearance:** Ligand A (-3.222 mL/min/kg) has a much lower (better) microsomal clearance than Ligand B (9.51 mL/min/kg), suggesting better metabolic stability.
**13. In Vitro Half-Life:** Ligand A (19.4 hours) has a longer half-life than Ligand B (12.427 hours), which is desirable.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.133 and 0.01 respectively). This is good.
**15. Binding Affinity:** Both ligands have very similar binding affinities (-6.7 kcal/mol and -6.6 kcal/mol). The difference is negligible.
**GPCR-Specific Considerations:** For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. While both ligands have acceptable affinity, Ligand B has a better logP and TPSA, and significantly lower DILI risk. The Caco-2 and solubility issues are concerning for both, but the lower DILI risk and slightly better drug-like properties of Ligand B outweigh the better metabolic stability and half-life of Ligand A.
**Conclusion:**
Considering the balance of properties, particularly the significantly lower DILI risk and slightly improved drug-like properties of Ligand B, I would choose **Ligand B** as the more promising drug candidate.
0
2025-04-17 22:19:27,789 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (351.349 and 345.399 Da) are within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (72.47) is significantly better than Ligand B (91.76). ADRB2 is a cardiovascular target, not CNS, but lower TPSA is generally favorable for absorption.
3. **logP:** Ligand A (2.444) is optimal (1-3), while Ligand B (0.933) is slightly low, potentially hindering permeability. This favors Ligand A.
4. **HBD:** Both ligands have acceptable HBD counts (1 and 2, respectively).
5. **HBA:** Both ligands have acceptable HBA counts (4 and 5, respectively).
6. **QED:** Both ligands have similar, good QED values (0.846 and 0.85).
7. **DILI:** Ligand B (41.877) has a significantly lower DILI risk than Ligand A (53.005). This is a substantial advantage for Ligand B.
8. **BBB:** Not a primary concern for a cardiovascular target. Ligand A (90.112) is higher, but this is less important.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-4.228) is slightly better than Ligand B (-4.875).
10. **Solubility:** Both are negative, indicating poor solubility. Ligand A (-3.372) is slightly better than Ligand B (-2.579).
11. **hERG:** Both ligands have very low hERG risk (0.154 and 0.131).
12. **Cl_mic:** Ligand B (7.476) has a much lower microsomal clearance than Ligand A (54.854), indicating better metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand A (19.923) has a longer in vitro half-life than Ligand B (-14.252). This is a significant advantage for Ligand A.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.081 and 0.019).
15. **Binding Affinity:** Ligand A (-6.4 kcal/mol) has a slightly better binding affinity than Ligand B (-5.7 kcal/mol). This is a 0.7 kcal/mol difference, which is noteworthy, but not overwhelming.
**Overall Assessment:**
Ligand A has a slight edge in binding affinity and in vitro half-life, and slightly better Caco-2 and solubility. However, Ligand B demonstrates a much better safety profile (lower DILI) and significantly improved metabolic stability (lower Cl_mic). Considering the GPCR-specific priorities, a balance between potency and ADME properties is crucial. The lower DILI and improved metabolic stability of Ligand B are more critical for a successful drug candidate, outweighing the modest affinity advantage of Ligand A.
Output:
0
2025-04-17 22:19:27,789 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [352.431, 77.1, 0.838, 1, 5, 0.742, 42.652, 65.568, -4.964, -1.606, 0.115, 15.924, 19.017, 0.036, -5.4]
**Ligand B:** [348.531, 49.41, 3.889, 1, 2, 0.792, 24.506, 83.172, -4.715, -4.249, 0.578, 67.124, 1.62, 0.362, -5.6]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). A (352.431) and B (348.531) are very close.
2. **TPSA:** A (77.1) is slightly higher than B (49.41). B is better, being closer to the <90 threshold for GPCRs.
3. **logP:** A (0.838) is lower, potentially hindering permeability. B (3.889) is closer to the optimal 1-3 range. This favors B.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** A has 5, B has 2. B is better, keeping HBA lower.
6. **QED:** Both are good (>0.5), A (0.742) and B (0.792). B is slightly better.
7. **DILI:** A (42.652) is higher than B (24.506). B is significantly better, indicating lower liver injury risk.
8. **BBB:** A (65.568) is lower than B (83.172). B is much better, which is a high priority for a GPCR.
9. **Caco-2:** Both are negative, indicating poor permeability. A (-4.964) is slightly worse than B (-4.715).
10. **Solubility:** A (-1.606) is better than B (-4.249). A has better aqueous solubility.
11. **hERG:** A (0.115) is better than B (0.578), indicating lower cardiotoxicity risk.
12. **Cl_mic:** A (15.924) is lower than B (67.124), indicating better metabolic stability. A is preferred.
13. **t1/2:** A (19.017) is much longer than B (1.62). A is significantly better.
14. **Pgp:** A (0.036) is much lower than B (0.362), indicating less P-gp efflux. A is preferred.
15. **Affinity:** A (-5.4) is slightly weaker than B (-5.6). B has a slight edge in binding.
**Overall Assessment:**
While Ligand A has advantages in solubility, metabolic stability, half-life and P-gp efflux, Ligand B excels in key GPCR properties: lower TPSA, better logP, significantly lower DILI risk, and much higher BBB penetration. The slight advantage in binding affinity for B is also a plus. The poor Caco-2 values for both are a concern, but the other properties of B are more favorable for a GPCR target like ADRB2.
Therefore, considering the GPCR-specific priorities and balancing all parameters, Ligand B appears to be the more promising drug candidate.
Output:
0
2025-04-17 22:19:27,789 - INFO - Here's my reasoning and the final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
The target is ADRB2, a GPCR. Therefore, I will prioritize logP, Pgp efflux, TPSA, BBB penetration, and binding affinity, alongside general drug-like properties.
* **Molecular Weight:** Both ligands (350.419 and 355.435 Da) fall within the ideal 200-500 Da range.
* **TPSA:** Ligand A (94.48) is better than Ligand B (107.97). Both are acceptable, but lower TPSA generally favors better absorption.
* **logP:** Ligand A (2.665) is optimal (1-3). Ligand B (-0.042) is quite low, which could lead to poor membrane permeability. This is a significant drawback.
* **H-Bond Donors/Acceptors:** Ligand A (2 HBD, 6 HBA) and Ligand B (3 HBD, 5 HBA) are both reasonable.
* **QED:** Ligand A (0.874) is significantly better than Ligand B (0.538), indicating a more drug-like profile.
* **DILI:** Ligand B (29.779) has a much lower DILI risk than Ligand A (68.786), which is a positive.
* **BBB:** Ligand A (76.154) has better BBB penetration than Ligand B (33.23). While ADRB2 isn't necessarily a CNS target, some degree of BBB penetration can be beneficial for overall distribution.
* **Caco-2:** Ligand A (-4.53) and Ligand B (-5.782) both have negative values, which is unusual. Assuming these are log scale values, they both indicate poor permeability.
* **Solubility:** Ligand A (-4.28) and Ligand B (-0.944) both have negative values, which is unusual. Assuming these are log scale values, they both indicate poor solubility.
* **hERG:** Ligand A (0.166) has a lower hERG risk than Ligand B (0.109), which is preferable.
* **Cl_mic:** Ligand B (-11.704) has significantly lower microsomal clearance than Ligand A (45.123), suggesting better metabolic stability. This is a major advantage.
* **t1/2:** Ligand A (14.341) has a longer in vitro half-life than Ligand B (-1.67). This is a positive for Ligand A.
* **Pgp:** Ligand A (0.047) has lower P-gp efflux than Ligand B (0.013), which is preferable.
* **Binding Affinity:** Ligand A (-7.5 kcal/mol) has a slightly better binding affinity than Ligand B (-6.7 kcal/mol). While the difference is not huge, it's still a factor.
**Overall Assessment:**
Ligand A has a better QED, TPSA, BBB penetration, half-life, Pgp efflux, and binding affinity. However, Ligand B has a significantly lower DILI risk and much better metabolic stability (lower Cl_mic). The biggest issue with Ligand B is its very low logP, which is a major concern for permeability and bioavailability. Ligand A's logP is within the optimal range. Considering the importance of permeability for a GPCR target, and the overall better drug-like properties of Ligand A, I favor Ligand A.
**Output:**
1
2025-04-17 22:19:27,790 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.337 and 362.539 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (67.66) is higher than Ligand B (53.33). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B has a slight edge.
3. **logP:** Ligand B (4.703) is higher than Ligand A (3.3). While logP > 4 can be problematic, it's not drastically high here. This could improve binding but might slightly hurt solubility.
4. **HBD:** Ligand A (2) is higher than Ligand B (0). Lower is generally preferred, giving a slight edge to Ligand B.
5. **HBA:** Both ligands have 4 HBA, so no difference here.
6. **QED:** Ligand A (0.72) is slightly better than Ligand B (0.673), indicating a more drug-like profile.
7. **DILI:** Ligand B (39.628) has a significantly lower DILI risk than Ligand A (80.807). This is a major advantage for Ligand B.
8. **BBB:** Ligand B (76.696) has better BBB penetration than Ligand A (67.158). While ADRB2 isn't a CNS target, some degree of BBB penetration can influence off-target effects and overall distribution.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-4.88) is slightly worse than Ligand B (-4.795).
10. **Solubility:** Ligand B (-5.478) is significantly worse than Ligand A (-4.205). Solubility is a concern for Ligand B.
11. **hERG:** Ligand A (0.705) has a slightly lower hERG risk than Ligand B (0.898).
12. **Cl_mic:** Ligand B (86.346) has a much higher microsomal clearance than Ligand A (38.714), indicating faster metabolism and potentially lower *in vivo* exposure. This is a significant disadvantage for Ligand B.
13. **t1/2:** Ligand B (47.229) has a much longer half-life than Ligand A (-7.592). This is a major advantage for Ligand B.
14. **Pgp:** Ligand A (0.266) has lower P-gp efflux than Ligand B (0.819), which is favorable.
15. **Binding Affinity:** Ligand A (-8.1) has a significantly stronger binding affinity than Ligand B (-6.5). This is a substantial advantage for Ligand A.
**Overall Assessment:**
The most important factor for GPCRs is binding affinity, and Ligand A has a 1.6 kcal/mol advantage. This is a substantial difference that can often outweigh other drawbacks. While Ligand B has advantages in DILI, BBB, and half-life, the poor solubility and high metabolic clearance are concerning. Ligand A's better solubility and lower clearance, combined with its superior binding affinity, make it the more promising candidate despite the higher DILI risk (which is still within an acceptable range).
Output:
1
2025-04-17 22:19:27,790 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for the ADRB2, a cardiovascular GPCR. Therefore, the key properties to prioritize are binding affinity, logP, TPSA, Pgp efflux, and to a lesser extent, BBB (though less critical for a cardiovascular target).
Let's break down the comparison:
1. **Molecular Weight:** Both ligands (354.797 and 365.547 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (77.92) is slightly higher than Ligand B (67.07). Both are acceptable, but Ligand B is better, being closer to the <90 target for GPCRs.
3. **logP:** Ligand A (3.98) is at the upper end of the optimal range, while Ligand B (3.321) is comfortably within it. This gives a slight edge to Ligand B.
4. **H-Bond Donors:** Ligand A (2) is slightly higher than Ligand B (1). Both are acceptable.
5. **H-Bond Acceptors:** Ligand B (7) is higher than Ligand A (3). This is a slight negative for Ligand B, but not a dealbreaker.
6. **QED:** Ligand B (0.777) has a better QED score than Ligand A (0.569), indicating better overall drug-likeness.
7. **DILI:** Ligand A (77.705) has a significantly higher DILI risk than Ligand B (19.349). This is a major concern for Ligand A.
8. **BBB:** Ligand B (48.817) has a better BBB penetration score than Ligand A (35.75). While not a primary concern for a cardiovascular target, it's a positive for Ligand B.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.485 and -5.113), which is unusual and suggests poor permeability.
10. **Solubility:** Both ligands have negative solubility values (-4.56 and -3.047), indicating poor aqueous solubility.
11. **hERG:** Ligand A (0.789) has a slightly higher hERG risk than Ligand B (0.593).
12. **Cl_mic:** Ligand A (32.88) has a lower microsomal clearance than Ligand B (40.882), suggesting better metabolic stability.
13. **t1/2:** Ligand A (69.965) has a significantly longer in vitro half-life than Ligand B (35.541). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.442) has a lower Pgp efflux liability than Ligand B (0.116), indicating better absorption and potentially higher exposure.
15. **Binding Affinity:** Ligand A (-8.8 kcal/mol) has a substantially stronger binding affinity than Ligand B (-7.8 kcal/mol). This is a crucial advantage, exceeding the 1.5 kcal/mol threshold.
**Overall Assessment:**
Ligand A has a significantly better binding affinity and longer half-life, and lower Pgp efflux. However, it has a much higher DILI risk and slightly higher hERG risk. Ligand B has better ADME properties (lower DILI, better QED, better BBB, lower logP, lower TPSA) but weaker binding affinity.
The strong binding affinity of Ligand A is a major advantage for a GPCR target. While the DILI risk is concerning, it might be mitigated through structural modifications in later optimization stages. The longer half-life and reduced Pgp efflux also contribute to better potential *in vivo* exposure. The poor Caco-2 and solubility are shared issues that would need to be addressed regardless of which lead is chosen.
Considering the balance of these factors, and prioritizing binding affinity for a GPCR, I believe Ligand A is the more promising candidate.
**Output:**
1
2025-04-17 22:19:27,790 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (362.77 and 371.49 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand B (29.54) is significantly better than Ligand A (58.95). Lower TPSA generally improves permeability, which is crucial for GPCR ligands.
3. **logP:** Both ligands have good logP values (4.13 and 4.41), falling within the optimal 1-3 range, though slightly high. Ligand B is marginally higher, potentially increasing off-target interactions, but not drastically.
4. **HBD:** Ligand A has 2 HBD, while Ligand B has 0. Generally, fewer HBDs are preferred for better permeability. Ligand B is better here.
5. **HBA:** Both have 3 HBA, which is acceptable.
6. **QED:** Both ligands have similar QED values (0.733 and 0.71), indicating good drug-likeness.
7. **DILI:** Ligand B (37.61) has a much lower DILI risk than Ligand A (96.86). This is a *major* advantage for Ligand B.
8. **BBB:** Ligand B (97.13) has a higher BBB penetration score than Ligand A (66.31). While ADRB2 isn't exclusively a CNS target, some CNS exposure can occur, and higher BBB is generally desirable.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. This is a concern for both, but the lower value for Ligand B (-4.667 vs -4.472) suggests slightly worse permeability.
10. **Solubility:** Both ligands have very poor aqueous solubility (-5.844 and -4.321). This is a significant drawback for both, potentially hindering bioavailability.
11. **hERG:** Ligand A (0.424) has a slightly lower hERG risk than Ligand B (0.727), which is preferable.
12. **Cl_mic:** Ligand B (80.80) has a higher microsomal clearance than Ligand A (44.48). This means Ligand A is more metabolically stable.
13. **t1/2:** Ligand A (78.03) has a significantly longer in vitro half-life than Ligand B (12.38). This is a substantial advantage for Ligand A, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand B (0.608) has a higher P-gp efflux liability than Ligand A (0.197). Lower P-gp efflux is better for bioavailability. Ligand A is better here.
15. **Binding Affinity:** Ligand A (-7.6 kcal/mol) has a slightly better binding affinity than Ligand B (-5.8 kcal/mol). This 1.8 kcal/mol difference is significant and can outweigh some ADME drawbacks.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand A's superior affinity and lower Pgp efflux are very attractive. However, Ligand B's dramatically lower DILI risk and better TPSA are compelling. The longer half-life of Ligand A is also a strong positive. The solubility and Caco-2 values are poor for both, representing formulation challenges.
Despite the slightly better affinity of Ligand A, the significantly lower DILI risk of Ligand B is a critical factor. DILI is a major cause of drug attrition, and minimizing this risk is paramount. While the longer half-life of Ligand A is desirable, the potential for liver toxicity outweighs this benefit.
Output:
0
2025-04-17 22:19:27,790 - INFO - Batch 323 complete. Total preferences: 5168
2025-04-17 22:19:27,790 - INFO - Processing batch 324/512...
2025-04-17 22:20:14,643 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (380.861 and 364.519 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (95.91) is higher than Ligand B (72.87). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B has an advantage.
3. **logP:** Both ligands (1.762 and 2.753) are within the optimal 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (0). This isn't a major concern for either, as both are within the acceptable limit of 5.
5. **HBA:** Ligand A (6) and Ligand B (8). Ligand A is better here.
6. **QED:** Both ligands have good QED scores (0.788 and 0.826), indicating good drug-like properties. No significant difference.
7. **DILI:** Ligand B (55.68) has a considerably lower DILI risk than Ligand A (75.262). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (77.821) has a slightly higher BBB penetration than Ligand B (66.499). However, as ADRB2 is primarily a cardiovascular target, BBB penetration is not a high priority.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.158 and -5.456), which is unusual and suggests very poor permeability. This is a significant concern for both.
10. **Solubility:** Both ligands have very poor aqueous solubility (-4.68 and -4.044). This is a major drawback for both candidates.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.24 and 0.277). This is good.
12. **Cl_mic:** Ligand B (75.719) has a higher microsomal clearance than Ligand A (8.438). Ligand A is significantly better regarding metabolic stability.
13. **t1/2:** Ligand A (-4.132) has a more negative half-life than Ligand B (0.951), indicating a shorter half-life. Ligand B is better here.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.126 and 0.348). No significant difference.
15. **Binding Affinity:** Ligand B (-5.8 kcal/mol) has a slightly better binding affinity than Ligand A (-5.1 kcal/mol). This 0.7 kcal/mol difference is noteworthy, and can potentially overcome some ADME liabilities.
**Overall Assessment:**
Both ligands have significant drawbacks, particularly the very poor Caco-2 permeability and aqueous solubility. However, Ligand B demonstrates a better balance of properties. It has a lower DILI risk, better binding affinity, and a longer half-life, while its TPSA is lower. The higher microsomal clearance is a concern, but the affinity advantage and lower toxicity risk are more important for this cardiovascular target. Ligand A's better metabolic stability is offset by its higher DILI risk and lower affinity.
Output:
0
2025-04-17 22:20:14,643 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (370.519 and 360.527 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (59.81) is significantly better than Ligand A (113.32). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (0.974) is slightly below the optimal 1-3 range, while Ligand B (4.078) is at the upper end. Ligand B's logP is a bit concerning, potentially leading to solubility issues and off-target interactions, but it's not drastically high.
4. **HBD:** Ligand A (4) is higher than Ligand B (1). Lower HBD is generally preferred for better permeability, giving a slight edge to Ligand B.
5. **HBA:** Ligand A (4) and Ligand B (5) are both acceptable, falling within the <10 guideline.
6. **QED:** Ligand B (0.757) has a better QED score than Ligand A (0.51), indicating a more drug-like profile.
7. **DILI:** Ligand A (28.499) has a much lower DILI risk than Ligand B (59.248). This is a significant advantage for Ligand A.
8. **BBB:** BBB is less important for a cardiovascular target. Ligand B (73.866) is higher, but this isn't a major factor in this case.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.703 and -5.177), which is unusual and suggests poor permeability. This is a significant drawback for both.
10. **Solubility:** Ligand A (-2.718) has slightly better solubility than Ligand B (-4.24), which is helpful given Ligand B's higher logP.
11. **hERG:** Ligand A (0.137) shows lower hERG inhibition liability than Ligand B (0.447), which is a crucial safety advantage.
12. **Cl_mic:** Ligand B (82.644) has significantly higher microsomal clearance than Ligand A (10.869), indicating faster metabolism and potentially lower *in vivo* exposure.
13. **t1/2:** Ligand A (9.439) has a longer half-life than Ligand B (4.734), which is desirable for less frequent dosing.
14. **Pgp:** Ligand B (0.641) has higher P-gp efflux liability than Ligand A (0.016), which could reduce oral bioavailability.
15. **Binding Affinity:** Ligand B (-8.1 kcal/mol) has a substantially stronger binding affinity than Ligand A (-6.0 kcal/mol). This is a significant advantage, potentially outweighing some of the ADME concerns.
**Overall Assessment:**
Ligand B has a much stronger binding affinity, which is the most important factor for GPCRs. However, it suffers from higher DILI risk, higher P-gp efflux, faster metabolism, and poorer solubility. Ligand A has better safety (DILI, hERG), metabolic stability, and solubility, but its affinity is considerably weaker.
Considering the balance, the significantly stronger binding affinity of Ligand B is compelling enough to outweigh its ADME liabilities, *provided* these can be addressed through further optimization. The difference in binding affinity (2.1 kcal/mol) is substantial.
Output:
0
2025-04-17 22:20:14,644 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (360.361 Da) is slightly lower, which can be beneficial for permeability, but both are acceptable.
**2. TPSA:** Both ligands have TPSA values below 140, suggesting reasonable oral absorption potential. Ligand B (102.82) is slightly lower than Ligand A (107.69), which is marginally better.
**3. logP:** Ligand A (-0.532) is quite low, potentially hindering membrane permeability. Ligand B (2.85) is within the optimal range (1-3). This is a significant advantage for Ligand B.
**4. H-Bond Donors:** Ligand A (3) is slightly higher than Ligand B (1), but both are within the acceptable limit of 5.
**5. H-Bond Acceptors:** Ligand A (6) is lower than Ligand B (9), which is preferable.
**6. QED:** Both ligands have similar, good QED values (A: 0.606, B: 0.685), indicating good drug-like properties.
**7. DILI Risk:** Ligand B (84.839) has a considerably higher DILI risk than Ligand A (45.483). This is a major concern for Ligand B.
**8. BBB Penetration:** Both have reasonable BBB penetration, but Ligand B (65.723) is higher than Ligand A (52.811). For a cardiovascular target, BBB penetration is less critical than for CNS targets, so this difference isn't decisive.
**9. Caco-2 Permeability:** Both are negative, indicating poor permeability.
**10. Aqueous Solubility:** Both are negative, indicating poor solubility.
**11. hERG Inhibition:** Both ligands show low hERG inhibition risk (A: 0.312, B: 0.292), which is good.
**12. Microsomal Clearance:** Ligand A (-3.359) has a much lower (better) microsomal clearance than Ligand B (52.891), indicating greater metabolic stability.
**13. In vitro Half-Life:** Ligand A (-13.791) has a much longer half-life than Ligand B (6.925), which is desirable.
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (A: 0.02, B: 0.258), which is good.
**15. Binding Affinity:** Ligand B (-5.9 kcal/mol) has a slightly better binding affinity than Ligand A (-7.6 kcal/mol). However, the difference is not substantial enough to outweigh other significant drawbacks.
**GPCR-Specific Considerations:** For a GPCR like ADRB2, logP, TPSA, and affinity are important. Ligand B has a better logP and affinity, but Ligand A has better TPSA, a much lower DILI risk, and significantly better metabolic stability (lower Cl_mic and longer half-life).
**Conclusion:**
Despite the slightly better affinity of Ligand B, the significantly higher DILI risk and poorer metabolic stability make it a less desirable candidate. Ligand A, while having a lower logP, presents a much more favorable ADME-Tox profile and a strong binding affinity. Therefore, I prefer Ligand A.
Output:
1
2025-04-17 22:20:14,644 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (352.435 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (87.5) is significantly better than Ligand B (127.32). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both are within the optimal range (1-3), with Ligand A (1.047) being slightly lower and potentially having slightly better solubility. Ligand B (1.244) is still acceptable.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally mean better membrane permeability.
5. **HBA:** Ligand A (7) is better than Ligand B (6). Lower HBA contributes to better permeability.
6. **QED:** Ligand A (0.752) is better than Ligand B (0.657), indicating a more drug-like profile.
7. **DILI:** Ligand A (56.727) has a significantly lower DILI risk than Ligand B (79.682). This is a crucial advantage.
8. **BBB:** Both are moderate, but Ligand B (56.805) is slightly higher than Ligand A (49.787). Since ADRB2 is not a CNS target, this difference is not a major factor.
9. **Caco-2:** Both are negative, indicating poor permeability. This is a concern for both, but the lower TPSA and HBD/HBA of Ligand A might mitigate this somewhat.
10. **Solubility:** Ligand A (-1.651) is better than Ligand B (-3.789), which is important for bioavailability.
11. **hERG:** Ligand A (0.095) is much better than Ligand B (0.261), indicating a lower risk of cardiotoxicity. This is *very* important for a cardiovascular target.
12. **Cl_mic:** Ligand A (-1.696) is much better than Ligand B (34.747), indicating better metabolic stability.
13. **t1/2:** Ligand A (49.9) is better than Ligand B (9.674), indicating a longer half-life.
14. **Pgp:** Ligand A (0.039) is much better than Ligand B (0.129), indicating lower P-gp efflux.
15. **Affinity:** Ligand B (-8.3) has a significantly stronger binding affinity than Ligand A (-5.7). This is a substantial advantage.
**Overall Assessment:**
Ligand B has a much stronger binding affinity, which is a significant plus. However, Ligand A demonstrates a superior profile across almost all ADME-Tox parameters, including significantly lower DILI and hERG risk, better metabolic stability, solubility, and P-gp efflux. The difference in binding affinity (2.6 kcal/mol) is substantial, but the combined improvements in safety and pharmacokinetic properties for Ligand A are compelling. Given that we're optimizing for a cardiovascular target, minimizing cardiotoxicity (hERG) and liver injury (DILI) are paramount. The better ADME profile of Ligand A outweighs the affinity difference.
Output:
1
2025-04-17 22:20:14,644 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (335.451 and 352.45 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Both ligands (59.22 and 58.64) are well below the 140 A^2 threshold for good oral absorption, and suitable for a non-CNS GPCR target like ADRB2. No significant difference.
3. **logP:** Ligand A (3.388) is slightly higher than Ligand B (2.215), both are within the optimal 1-3 range. Ligand A is preferable here.
4. **HBD:** Both have 1 HBD, which is good. No difference.
5. **HBA:** Both have 3 HBA, which is good. No difference.
6. **QED:** Ligand A (0.911) has a significantly better QED score than Ligand B (0.772), indicating a more drug-like profile. This is a positive for Ligand A.
7. **DILI:** Ligand B (18.418) has a slightly higher DILI risk than Ligand A (16.712), but both are below the concerning threshold of 60. Ligand A is preferable.
8. **BBB:** Ligand B (87.476) has a higher BBB penetration than Ligand A (77.705). However, since ADRB2 is primarily a cardiovascular target, high BBB penetration isn't a priority, and this difference is less important.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.833 and -4.628). This is unusual and suggests poor permeability. However, the values are quite similar.
10. **Solubility:** Ligand A (-2.187) has better solubility than Ligand B (-3.116). This is a positive for Ligand A.
11. **hERG:** Ligand A (0.695) has a slightly higher hERG risk than Ligand B (0.395), but both are relatively low. Ligand B is preferable here.
12. **Cl_mic:** Ligand A (15.613) has significantly lower microsomal clearance than Ligand B (36.53), suggesting better metabolic stability. This is a strong positive for Ligand A.
13. **t1/2:** Ligand A (17.63) has a longer in vitro half-life than Ligand B (2.305). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.29) has much lower P-gp efflux liability than Ligand B (0.034). This is a positive for Ligand A.
15. **Binding Affinity:** Ligand A (-7.4 kcal/mol) has a stronger binding affinity than Ligand B (-5.4 kcal/mol). This is a substantial advantage for Ligand A, and can outweigh some of the minor ADME drawbacks.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B in key drug-like properties (QED, solubility, metabolic stability, half-life, Pgp efflux) and, crucially, has a significantly stronger binding affinity. While Ligand B has slightly better BBB penetration and lower hERG risk, these are less critical for a cardiovascular target like ADRB2. The negative Caco-2 values for both are concerning and would need further investigation, but the overall profile of Ligand A is more promising.
Output:
1
2025-04-17 22:20:14,644 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (378.889 and 349.475 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Both ligands (83.04 and 84.64) are below the 140 A^2 threshold for good oral absorption, but higher than the 90 A^2 threshold for CNS targets. Since ADRB2 is a cardiovascular target (not CNS), this is acceptable. No clear advantage.
3. **logP:** Ligand A (3.037) is optimal, while Ligand B (1.784) is on the lower side, potentially impacting permeability. This favors Ligand A.
4. **HBD:** Ligand A (2) and Ligand B (1) are both within the acceptable limit of <=5. Ligand B is slightly better.
5. **HBA:** Ligand A (6) and Ligand B (4) are both within the acceptable limit of <=10. Ligand B is better.
6. **QED:** Both ligands (0.795 and 0.792) have excellent drug-likeness scores, exceeding the 0.5 threshold. No clear advantage.
7. **DILI:** Ligand A (77.782) has a significantly higher DILI risk than Ligand B (12.369). This is a major concern for Ligand A.
8. **BBB:** Both ligands have good BBB penetration (75.107 and 66.925), but this is less critical for a cardiovascular target.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. Ligand A (-5.208) is slightly worse than Ligand B (-4.52).
10. **Solubility:** Both ligands have negative solubility values, indicating poor solubility. Ligand A (-4.14) is slightly worse than Ligand B (-1.779).
11. **hERG:** Both ligands have very low hERG inhibition risk (0.345 and 0.381). No clear advantage.
12. **Cl_mic:** Ligand B (11.012) has a significantly lower microsomal clearance than Ligand A (39.535), indicating better metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand A (31.052) has a longer in vitro half-life than Ligand B (-0.868). This is a positive for Ligand A, but the negative value for B is concerning.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.153 and 0.032). No clear advantage.
15. **Binding Affinity:** Ligand B (-6.7 kcal/mol) has a stronger binding affinity than Ligand A (-5.0 kcal/mol). This is a substantial advantage, exceeding the 1.5 kcal/mol threshold.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand A has a better logP, but Ligand B excels in affinity and has acceptable TPSA. The Pgp values are good for both.
**Overall Assessment:**
Ligand B is the superior candidate despite the negative half-life. The significantly lower DILI risk, much better metabolic stability (lower Cl_mic), and substantially stronger binding affinity outweigh the slightly lower logP and negative Caco-2/solubility values. The negative half-life is concerning, but could be addressed with structural modifications. The high DILI risk of Ligand A is a major red flag.
Output:
0
2025-04-17 22:20:14,644 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (361.829 Da and 368.474 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (75.44) is slightly higher than Ligand B (66.48). Both are below the 140 threshold for oral absorption, but closer to the 90 threshold for CNS targets, which isn't a primary concern for ADRB2 (cardiovascular). Ligand B is preferable.
3. **logP:** Ligand A (3.061) is at the upper end of the optimal range (1-3), while Ligand B (1.981) is closer to the lower end. Ligand B is preferable here.
4. **HBD:** Both have 1 HBD, which is good. No difference.
5. **HBA:** Ligand A has 4 HBAs, Ligand B has 3. Both are within the acceptable limit of 10. Ligand B is slightly preferable.
6. **QED:** Ligand A (0.908) has a significantly better QED score than Ligand B (0.763), indicating a more drug-like profile. This is a significant advantage for Ligand A.
7. **DILI:** Ligand A (63.086) has a higher DILI risk than Ligand B (26.948). This is a substantial advantage for Ligand B.
8. **BBB:** Ligand A (71.927) and Ligand B (89.492). While BBB isn't a primary concern for ADRB2, higher is generally better. Ligand B is preferable.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.931 and -4.823). These values are difficult to interpret without knowing the scale, but the similarity suggests comparable absorption potential. No clear preference.
10. **Solubility:** Both ligands have negative solubility values (-3.707 and -3.213). Similar to Caco-2, these values are hard to interpret, but suggest similar solubility challenges. No clear preference.
11. **hERG:** Ligand A (0.506) has a slightly lower hERG risk than Ligand B (0.682). This is a small advantage for Ligand A.
12. **Cl_mic:** Ligand A (50.315) has a higher microsomal clearance than Ligand B (30.286), meaning it's metabolized faster. Ligand B is preferable.
13. **t1/2:** Ligand B (-32.263) has a much longer in vitro half-life than Ligand A (-17.538). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.363) has lower P-gp efflux than Ligand B (0.149). This is a slight advantage for Ligand A.
15. **Binding Affinity:** Ligand B (-5.7 kcal/mol) has a stronger binding affinity than Ligand A (-7.3 kcal/mol). This is a significant advantage for Ligand B.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, Pgp, TPSA, and affinity. Ligand B performs better on logP, Pgp, and affinity. Ligand A has a better QED, but the other factors are more crucial.
**Overall Assessment:**
Ligand B has a better overall profile, particularly regarding DILI risk, metabolic stability (lower Cl_mic, longer t1/2), and binding affinity. While Ligand A has a better QED and slightly lower hERG risk, the advantages of Ligand B in key ADME properties and potency outweigh these benefits.
Output:
0
2025-04-17 22:20:14,644 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [408.315, 36.44, 4.348, 0, 3, 0.713, 46.84, 85.692, -4.682, -4.62, 0.955, 100.685, 58.714, 0.709, -6.1]
**Ligand B:** [349.356, 45.23, 3.372, 1, 2, 0.864, 52.385, 88.717, -4.54, -4.216, 0.636, 42.508, -18.426, 0.129, -7]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, Affinity, and BBB):
1. **MW:** A (408.315) is within the ideal range, while B (349.356) is a bit lower, but still acceptable.
2. **TPSA:** A (36.44) is excellent, well below the 140 threshold. B (45.23) is still reasonable, but less optimal.
3. **logP:** A (4.348) is slightly high, potentially leading to solubility issues. B (3.372) is within the ideal range.
4. **HBD/HBA:** A (0/3) is very favorable. B (1/2) is also good.
5. **QED:** Both are good (A: 0.713, B: 0.864), indicating drug-like properties. B is slightly better.
6. **DILI:** A (46.84) and B (52.385) are both acceptable, below the 60 threshold.
7. **BBB:** Both have good BBB penetration (A: 85.692, B: 88.717).
8. **Caco-2:** Both are negative, which is unusual, and suggests poor permeability.
9. **Solubility:** Both are negative, which is also unusual and suggests poor solubility.
10. **hERG:** A (0.955) is better than B (0.636), indicating lower cardiotoxicity risk.
11. **Cl_mic:** A (100.685) is quite high, suggesting rapid metabolism. B (42.508) is much better, indicating greater metabolic stability.
12. **t1/2:** A (58.714) is reasonable, but B (-18.426) is very poor. This is a significant negative for B.
13. **Pgp:** A (0.709) is better than B (0.129), meaning less efflux and potentially better bioavailability.
14. **Affinity:** B (-7.0) has a slightly better binding affinity than A (-6.1), a difference of 0.9 kcal/mol.
**Overall Assessment:**
While Ligand B has a slightly better binding affinity and a better logP, Ligand A has a significantly better Pgp efflux profile, a better hERG score, and a more reasonable in vitro half-life. The high metabolic clearance and very poor half-life of Ligand B are major drawbacks. The slightly higher logP of Ligand A is a concern, but potentially addressable through further optimization. Given the importance of metabolic stability and reduced cardiotoxicity for a cardiovascular target, I believe Ligand A is the more promising candidate.
Output:
1
2025-04-17 22:20:14,644 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (352.395) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (109.66) is better than Ligand B (38.77). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption. Ligand B is excellent here.
3. **logP:** Ligand B (3.7) is better than Ligand A (-1.266). A logP between 1-3 is optimal, and Ligand B falls within this range, while Ligand A is too low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (0). While both are low, having at least one HBD can improve solubility.
5. **HBA:** Ligand A (7) is better than Ligand B (4). Both are within acceptable limits (<=10).
6. **QED:** Ligand A (0.684) is better than Ligand B (0.47). A higher QED suggests a more drug-like profile.
7. **DILI:** Ligand B (15.626) is significantly better than Ligand A (64.366). Lower DILI risk is crucial.
8. **BBB:** Ligand B (87.553) is much better than Ligand A (49.128). While not a primary concern for a cardiovascular target, higher BBB is generally a positive attribute.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual. Assuming these are logP values, both are poor.
10. **Solubility:** Ligand A (-0.527) is better than Ligand B (-2.91). Higher solubility is generally preferred.
11. **hERG:** Ligand A (0.059) is better than Ligand B (0.74). Lower hERG inhibition is critical for avoiding cardiotoxicity.
12. **Cl_mic:** Ligand A (11.585) is much better than Ligand B (77.871). Lower microsomal clearance indicates better metabolic stability.
13. **t1/2:** Ligand B (12.7) is better than Ligand A (2.13). A longer half-life is generally desirable.
14. **Pgp:** Ligand A (0.014) is significantly better than Ligand B (0.676). Lower P-gp efflux improves bioavailability.
15. **Affinity:** Ligand B (-7.2) is significantly better than Ligand A (-6.3). A 1.5 kcal/mol difference in binding affinity is substantial and can often outweigh minor ADME drawbacks.
**GPCR-specific priorities:** For ADRB2 (a cardiovascular GPCR), logP, Pgp, TPSA, and affinity are key. Ligand B excels in logP and affinity, while Ligand A has better TPSA and Pgp. However, the substantial affinity advantage of Ligand B, combined with its acceptable logP and significantly lower DILI risk, outweighs the benefits of Ligand A's slightly better TPSA and Pgp.
**Conclusion:**
Despite some drawbacks in DILI and Pgp, Ligand B's superior binding affinity and logP make it the more promising candidate.
Output:
0
2025-04-17 22:20:14,645 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (367.471 and 348.462 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (49.41) is significantly better than Ligand A (102.76). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (2.812) is within the optimal 1-3 range, while Ligand A (0.583) is quite low. Low logP can hinder membrane permeability. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (1), but both are acceptable (<=5).
5. **HBA:** Ligand A (6) is higher than Ligand B (2). Lower HBA is generally preferred for permeability.
6. **QED:** Ligand B (0.853) is better than Ligand A (0.612), indicating a more drug-like profile.
7. **DILI:** Ligand B (28.383) has a lower DILI risk than Ligand A (34.858), which is favorable.
8. **BBB:** Ligand B (79.062) has a higher BBB penetration potential than Ligand A (33.23). While not critical for a cardiovascular target, it's not a detriment.
9. **Caco-2:** Ligand A (-5.218) has a more negative Caco-2 value, suggesting *lower* permeability, while Ligand B (-4.743) is slightly better.
10. **Solubility:** Ligand A (-1.737) has slightly better solubility than Ligand B (-4.232).
11. **hERG:** Ligand B (0.59) has a slightly better hERG profile than Ligand A (0.171), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand A (4.678) has a much lower microsomal clearance than Ligand B (24.589), suggesting better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand B (6.954) has a longer in vitro half-life than Ligand A (-7.908). This is a strong advantage for Ligand B.
14. **Pgp:** Ligand A (0.03) has a lower Pgp efflux liability than Ligand B (0.205), which is favorable.
15. **Affinity:** Both ligands have very similar binding affinities (-6.1 kcal/mol and -7.9 kcal/mol respectively). Ligand B has a better affinity, but the difference is not substantial enough to outweigh other factors.
**Overall Assessment:**
Ligand B has several advantages: better logP, QED, DILI, BBB, t1/2, and affinity. Ligand A has better metabolic stability (lower Cl_mic) and Pgp efflux. However, the low logP of Ligand A is a significant concern for permeability. The longer half-life and better overall ADME profile of Ligand B, coupled with its comparable affinity, make it the more promising candidate.
Output:
0
2025-04-17 22:20:14,645 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [385.243, 64.99, 3.737, 1, 5, 0.702, 55.448, 29.391, -4.564, -4.657, 0.728, 77.412, 37.469, 0.712, -4.7]
**Ligand B:** [352.431, 99.1, -0.345, 3, 5, 0.568, 25.824, 24.002, -4.981, -0.95, 0.067, -15.082, -8.813, 0.014, -6.6]
**Step-by-step comparison:**
1. **MW:** Both are within the acceptable range (200-500 Da). Ligand B (352.431) is slightly lower, which *could* be beneficial for permeability, but both are reasonable.
2. **TPSA:** Ligand A (64.99) is significantly better than Ligand B (99.1). GPCRs benefit from lower TPSA for better brain penetration and overall permeability. Ligand B is quite high, potentially hindering absorption.
3. **logP:** Ligand A (3.737) is optimal. Ligand B (-0.345) is quite low, potentially leading to poor membrane permeability and bioavailability.
4. **HBD:** Both have acceptable HBD counts (1 and 3 respectively).
5. **HBA:** Both have acceptable HBA counts (5).
6. **QED:** Ligand A (0.702) is better than Ligand B (0.568), indicating a more drug-like profile.
7. **DILI:** Ligand A (55.448) has a higher DILI risk than Ligand B (25.824). This is a concern for Ligand A, but not prohibitive.
8. **BBB:** Ligand A (29.391) is better than Ligand B (24.002), though both are low. For a cardiovascular target, BBB isn't *critical*, but some penetration could be useful.
9. **Caco-2:** Both have negative values, indicating poor permeability.
10. **Solubility:** Ligand A (-4.657) is better than Ligand B (-0.95), indicating better solubility.
11. **hERG:** Ligand A (0.728) is better than Ligand B (0.067), indicating lower hERG risk.
12. **Cl_mic:** Ligand B (-15.082) has a *much* lower (better) microsomal clearance than Ligand A (77.412), suggesting greater metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand A (37.469) has a better in vitro half-life than Ligand B (-8.813).
14. **Pgp:** Ligand A (0.712) is better than Ligand B (0.014), indicating lower P-gp efflux.
15. **Affinity:** Ligand B (-6.6) has a slightly better binding affinity than Ligand A (-4.7). A 1.9 kcal/mol difference is substantial.
**Overall Assessment:**
While Ligand B has a superior binding affinity and significantly better metabolic stability (Cl_mic), its poor logP and high TPSA are major drawbacks for a GPCR target. These properties will likely lead to poor permeability and bioavailability. Ligand A, despite a higher DILI risk and lower metabolic stability, has much more favorable physicochemical properties (logP, TPSA, solubility) which are crucial for GPCR drug candidates. The difference in binding affinity, while significant, can potentially be overcome with further optimization, while fixing the poor physicochemical properties of Ligand B would be a more substantial undertaking.
Therefore, I favor Ligand A.
Output:
1
2025-04-17 22:20:14,645 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.415 and 361.511 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (75.88) is higher than Ligand B (49.58). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B is better.
3. **logP:** Ligand A (1.391) is within the optimal range (1-3), while Ligand B (3.416) is at the upper end. Both are acceptable, but Ligand A is slightly more balanced.
4. **HBD:** Both ligands have 0 HBD, which is good.
5. **HBA:** Both ligands have 5 HBA, which is acceptable.
6. **QED:** Ligand A (0.823) has a significantly better QED score than Ligand B (0.479), indicating better overall drug-likeness. This is a substantial advantage for Ligand A.
7. **DILI:** Both ligands have low DILI risk (32.067 and 37.418 percentile), which is good. No significant difference.
8. **BBB:** Ligand A (90.074) has a higher BBB penetration percentile than Ligand B (69.639). While ADRB2 isn't primarily a CNS target, some degree of BBB penetration can be useful for off-target effects assessment and potential peripheral effects.
9. **Caco-2:** Ligand A (-4.45) has a worse Caco-2 permeability than Ligand B (-5.134). Lower values are worse, so Ligand B is better.
10. **Solubility:** Ligand A (-1.069) has better solubility than Ligand B (-2.674). Better solubility is generally desirable.
11. **hERG:** Ligand A (0.44) has a lower hERG inhibition liability than Ligand B (0.811), indicating a lower risk of cardiotoxicity. This is a crucial advantage for a cardiovascular target.
12. **Cl_mic:** Ligand A (34.522) has a lower microsomal clearance than Ligand B (99.497), suggesting better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand B (108.556) has a much longer in vitro half-life than Ligand A (-17.884). This is a major advantage for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.055) has lower P-gp efflux liability than Ligand B (0.203), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand B (-6.5 kcal/mol) has a stronger binding affinity than Ligand A (-5.1 kcal/mol). This is a 1.4 kcal/mol difference, which is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand B has a significantly better binding affinity and a longer half-life. However, Ligand A demonstrates superior drug-likeness (QED), metabolic stability (Cl_mic), lower hERG risk, and better solubility. The stronger binding affinity of Ligand B is a major plus, but the combination of favorable ADME properties in Ligand A, particularly the lower hERG risk for a cardiovascular target, makes it the more promising candidate. The better QED score also suggests a higher probability of success.
Output:
1
2025-04-17 22:20:14,645 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (367.4) is within the ideal range (200-500), while Ligand B (335.4) is also good. No clear advantage here.
2. **TPSA:** Ligand A (109.14) is higher than ideal for good oral absorption (<140), but acceptable. Ligand B (62.97) is excellent, well below the threshold. This favors Ligand B.
3. **logP:** Ligand A (0.831) is a bit low, potentially hindering permeation. Ligand B (1.375) is better, falling within the optimal range. This favors Ligand B.
4. **HBD:** Ligand A (3) is acceptable. Ligand B (0) is also good, potentially improving permeability. Slight advantage to Ligand B.
5. **HBA:** Both Ligand A (7) and Ligand B (7) are within the acceptable range (<10). No significant difference.
6. **QED:** Both Ligand A (0.672) and Ligand B (0.702) are good, indicating drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (66.731) is higher risk than Ligand B (42.846). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (45.909) is moderate. Ligand B (64.676) is better, though not exceptionally high. Given ADRB2 is a GPCR, BBB penetration is a consideration, favoring Ligand B.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale isn't specified, so it's hard to interpret.
10. **Solubility:** Both ligands have negative solubility values, which is also unusual and suggests poor solubility. Again, the scale isn't specified.
11. **hERG:** Ligand A (0.186) has a lower hERG risk than Ligand B (0.711). This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand A (30.466) has a lower microsomal clearance, indicating better metabolic stability than Ligand B (11.224). This favors Ligand A.
13. **t1/2:** Ligand A (4.839) has a shorter half-life than Ligand B (-39.054). The negative value for Ligand B is concerning and likely an error. This favors Ligand A.
14. **Pgp:** Ligand A (0.028) has lower P-gp efflux, which is good. Ligand B (0.029) is similar. No significant difference.
15. **Affinity:** Ligand A (-7.8) has a significantly better binding affinity than Ligand B (-5.8). This is a substantial advantage for Ligand A. A 2 kcal/mol difference can often outweigh minor ADME concerns.
**Overall Assessment:**
Ligand A has a significantly better binding affinity and better metabolic stability (lower Cl_mic). While Ligand B has advantages in TPSA, logP, DILI, and BBB, the superior affinity of Ligand A is crucial for a GPCR target like ADRB2. The hERG risk is lower for Ligand A, which is also a positive. The negative values for Caco-2 and solubility are concerning for both, but the affinity difference is the most important factor.
Output:
1
2025-04-17 22:20:14,645 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (401.22 Da) is within the ideal range, while Ligand B (344.455 Da) is slightly below, but still acceptable.
2. **TPSA:** Ligand A (86.23) is good, below the 140 threshold. Ligand B (42.01) is excellent, well below 90, which is favorable for GPCRs.
3. **logP:** Both ligands have good logP values (A: 3.687, B: 2.796), falling within the 1-3 range.
4. **HBD:** Ligand A (1) is good. Ligand B (0) is also good.
5. **HBA:** Ligand A (6) is good. Ligand B (4) is good.
6. **QED:** Both ligands have good QED values (A: 0.702, B: 0.786), indicating good drug-like properties.
7. **DILI:** Ligand A (96.627) has a very high DILI risk, which is a major concern. Ligand B (25.94) has a very low DILI risk, which is excellent.
8. **BBB:** Ligand A (67.08) is moderate. Ligand B (83.831) is good, suggesting better potential for CNS penetration if desired, but less critical for a cardiovascular target like ADRB2.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.914 and -4.515) which is unusual and suggests poor permeability.
10. **Solubility:** Both ligands have negative solubility values (-4.816 and -1.545) which is also unusual and suggests poor solubility.
11. **hERG:** Ligand A (0.596) has a slightly elevated hERG risk, but it's not overly concerning. Ligand B (0.829) has a higher hERG risk.
12. **Cl_mic:** Ligand A (75.668) has a moderate clearance, while Ligand B (2.678) has a very low clearance, indicating better metabolic stability.
13. **t1/2:** Ligand A (-17.11) has a negative half-life, which is not possible. Ligand B (9.486) has a good half-life.
14. **Pgp:** Ligand A (0.259) has low P-gp efflux, which is good. Ligand B (0.403) also has low P-gp efflux.
15. **Affinity:** Ligand B (-6.8 kcal/mol) has a significantly stronger binding affinity than Ligand A (-3.8 kcal/mol). This is a substantial advantage.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are important. Both ligands are reasonable in logP and TPSA. However, Ligand B has a much better affinity. The biggest concern with Ligand A is its extremely high DILI risk.
**Overall Assessment:**
Despite the unusual Caco-2 and solubility values for both, Ligand B is the better candidate. Its significantly stronger binding affinity, much lower DILI risk, and better metabolic stability outweigh the slightly higher hERG risk. The negative half-life for Ligand A is a showstopper.
Output:
0
2025-04-17 22:20:14,645 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (339.351) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are reasonably low, but Ligand B (83.48) is significantly lower than Ligand A (94.32). Lower TPSA is better for oral absorption and GPCR targets.
3. **logP:** Both ligands have good logP values (between 1-3), with Ligand A (2.809) being slightly higher than Ligand B (1.73). While both are acceptable, a slightly higher logP can be beneficial for membrane permeability.
4. **HBD:** Ligand A (1) has fewer HBD than Ligand B (3). Fewer HBDs are generally preferred for better permeability.
5. **HBA:** Ligand A (6) has more HBA than Ligand B (4). Similar to HBD, fewer HBA are generally preferred.
6. **QED:** Both ligands have similar QED values (0.735 and 0.691), indicating good drug-likeness.
7. **DILI:** Ligand A (91.004) has a significantly higher DILI risk than Ligand B (14.851). This is a major concern for Ligand A.
8. **BBB:** Ligand B (77.937) has a higher BBB penetration percentile than Ligand A (53.432). While ADRB2 is not exclusively a CNS target, some CNS exposure can occur, and higher BBB is generally desirable.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and requires further investigation. However, the values are similar.
10. **Solubility:** Ligand A (-4.01) has slightly better solubility than Ligand B (-2.002).
11. **hERG:** Both ligands have low hERG inhibition risk (0.209 and 0.337).
12. **Cl_mic:** Ligand A (99.25) has a much higher microsomal clearance than Ligand B (-9.116), indicating poorer metabolic stability. This is a significant drawback for Ligand A.
13. **t1/2:** Ligand B (16.78) has a significantly longer in vitro half-life than Ligand A (-12.131). This is a major advantage for Ligand B.
14. **Pgp:** Ligand A (0.129) has lower P-gp efflux than Ligand B (0.028), which is favorable.
15. **Binding Affinity:** Both ligands have the same binding affinity (-6.3 kcal/mol).
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B excels in TPSA and Pgp, and has a reasonable logP. Ligand A has a slightly better logP and Pgp, but is significantly hampered by its high DILI risk and poor metabolic stability (high Cl_mic, short t1/2).
**Overall Assessment:**
Despite Ligand A having a slightly better logP and Pgp, the significantly higher DILI risk and poorer metabolic stability (higher Cl_mic and shorter half-life) make it a less desirable candidate. Ligand B's lower DILI risk, better metabolic stability, and higher BBB penetration outweigh the slightly lower logP.
Output:
0
2025-04-17 22:20:14,645 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (396.481) is slightly higher than Ligand B (337.419), but both are acceptable.
2. **TPSA:** Ligand A (77.92) is better than Ligand B (66.4). Both are below 140, indicating good potential for oral absorption.
3. **logP:** Ligand A (1.868) is optimal, while Ligand B (4.236) is pushing the upper limit. High logP can lead to solubility issues and off-target effects. This favors Ligand A.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (2). Lower HBA generally improves permeability.
6. **QED:** Both ligands have good QED scores (A: 0.796, B: 0.858), indicating good drug-like properties.
7. **DILI:** Ligand B (70.531) has a higher DILI risk than Ligand A (53.548). Lower DILI is crucial. This favors Ligand A.
8. **BBB:** Ligand A (69.639) has a better BBB penetration percentile than Ligand B (22.412). While ADRB2 isn't exclusively a CNS target, some CNS exposure might be acceptable or even desirable depending on the specific therapeutic goal, and a higher BBB score is generally favorable.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual. This suggests poor permeability. Ligand A (-5.007) is slightly better than Ligand B (-4.782).
10. **Solubility:** Ligand A (-3.005) has better solubility than Ligand B (-4.868). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.725) has a lower hERG risk than Ligand B (0.061). Lower hERG is critical for avoiding cardiotoxicity. This strongly favors Ligand A.
12. **Cl_mic:** Ligand A (9.46) has a significantly lower microsomal clearance than Ligand B (34.657), indicating better metabolic stability.
13. **t1/2:** Ligand A (12.026) has a longer in vitro half-life than Ligand B (-5.057). Longer half-life is desirable.
14. **Pgp:** Ligand A (0.195) has lower P-gp efflux than Ligand B (0.062), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand B (-2.0) has a better binding affinity than Ligand A (-6.0). However, the difference is not substantial enough to outweigh the multiple ADME advantages of Ligand A.
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A is better in terms of logP, Pgp, and TPSA. While Ligand B has better affinity, the difference isn't large enough to overcome the ADME liabilities.
**Conclusion:**
Ligand A demonstrates a significantly better balance of properties, particularly regarding ADME characteristics (DILI, BBB, solubility, hERG, Cl_mic, t1/2, Pgp) and a reasonable binding affinity. Ligand B, while having slightly better affinity, suffers from higher DILI risk, poor solubility, high metabolic clearance, and potential cardiotoxicity.
Output:
1
2025-04-17 22:20:14,645 - INFO - Batch 324 complete. Total preferences: 5184
2025-04-17 22:20:14,645 - INFO - Processing batch 325/512...
2025-04-17 22:21:06,387 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (361.32 and 352.429 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (91.66) is slightly higher than Ligand B (59.81). For a cardiovascular GPCR, TPSA is moderately important, and Ligand B's lower value is preferable, suggesting better potential for membrane permeability.
**3. logP:** Ligand A (0.764) is a bit low, potentially hindering permeability. Ligand B (3.052) is within the optimal 1-3 range. This is a clear advantage for Ligand B.
**4. H-Bond Donors:** Both have 1 HBD, which is good.
**5. H-Bond Acceptors:** Ligand A has 5, and Ligand B has 4. Both are acceptable, below the threshold of 10.
**6. QED:** Both ligands have similar QED values (0.73 and 0.782), indicating good drug-like properties.
**7. DILI Risk:** Ligand A (41.877) has a slightly higher DILI risk than Ligand B (25.785), although both are below the concerning threshold of 60. Lower is better, so Ligand B is favored.
**8. BBB Penetration:** Ligand B (90.074) shows better BBB penetration than Ligand A (85.459). While not a primary concern for a cardiovascular target, it's a slight benefit for Ligand B.
**9. Caco-2 Permeability:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the magnitude is similar (-4.853 vs -4.59).
**10. Aqueous Solubility:** Both have negative solubility values, which is also unusual. Ligand A (-2.508) is slightly better than Ligand B (-4.382), but both are poor.
**11. hERG Inhibition:** Both ligands show very low hERG inhibition risk (0.406 and 0.391), which is excellent.
**12. Microsomal Clearance:** Ligand A (-14.943) has significantly lower (better) microsomal clearance than Ligand B (39.486), indicating greater metabolic stability. This is a substantial advantage for Ligand A.
**13. In vitro Half-Life:** Ligand A (-10.428) has a longer half-life than Ligand B (1.847), further supporting its better metabolic stability.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.025 and 0.048), which is favorable.
**15. Binding Affinity:** Ligand B (-6.9) has a slightly better binding affinity than Ligand A (-6.5), but the difference is only 0.4 kcal/mol.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand B initially appears more promising due to its better logP and lower TPSA. However, Ligand A's significantly improved metabolic stability (lower Cl_mic and longer half-life) is a crucial factor for a viable drug candidate. The slight advantage in binding affinity for Ligand B is not substantial enough to outweigh the metabolic concerns. The poor solubility and permeability for both are concerning and would need to be addressed in further optimization, but metabolic stability is harder to fix later in development.
Therefore, I favor Ligand A.
Output:
1
2025-04-17 22:21:06,387 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 drug candidates. ADRB2 is a GPCR, so we'll prioritize logP, Pgp, TPSA, and affinity, alongside general drug-like properties.
**Ligand A:** [349.435, 99.49, -0.358, 3, 6, 0.674, 21.287, 27.957, -5.383, -0.504, 0.13, -19.359, 6.001, 0.003, -4]
**Ligand B:** [341.455, 71.09, 2.669, 2, 3, 0.617, 39.318, 63.125, -5.028, -2.304, 0.173, 41.978, -7.113, 0.128, -5.2]
Here's a breakdown of each parameter:
1. **MW:** Both are within the ideal range (200-500 Da). A is 349.4, B is 341.5. Very similar.
2. **TPSA:** A (99.5) is higher than ideal (<140), but still acceptable. B (71.1) is excellent, well below 90, which is good for GPCRs.
3. **logP:** A (-0.358) is quite low, potentially hindering permeability. B (2.669) is optimal (1-3). This is a significant advantage for B.
4. **HBD:** A (3) is acceptable. B (2) is also good.
5. **HBA:** A (6) is acceptable. B (3) is excellent.
6. **QED:** Both are good (>0.5), A (0.674) slightly better than B (0.617).
7. **DILI:** A (21.3) is excellent, very low risk. B (39.3) is still acceptable, but higher.
8. **BBB:** A (28.0) is low. B (63.1) is much better, although not exceptionally high. For a cardiovascular target, BBB isn't *critical*, but higher is generally preferable.
9. **Caco-2:** Both are negative, indicating poor permeability. This is a concern for both.
10. **Solubility:** Both are negative, indicating poor solubility. This is a concern for both.
11. **hERG:** Both are very low risk (0.13 and 0.173).
12. **Cl_mic:** A (-19.4) is excellent, indicating high metabolic stability. B (42.0) is high, suggesting rapid metabolism. This is a major drawback for B.
13. **t1/2:** A (6.0) is okay. B (-7.1) is very good, suggesting a long half-life.
14. **Pgp:** Both are very low (0.003 and 0.128).
15. **Affinity:** A (-4.0) is good, but B (-5.2) is significantly better (more negative). This is a substantial advantage for B.
**Overall Assessment:**
Ligand B has a much better logP, significantly better affinity, and a better TPSA. The improved affinity is a major plus for a GPCR target. While its DILI risk is higher and metabolic clearance is a concern, the strong binding and favorable logP outweigh these drawbacks. Ligand A has better metabolic stability and DILI, but its poor logP and weaker binding are significant liabilities. The Caco-2 and solubility issues are present in both, and would need to be addressed in further optimization.
Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity) and the overall balance of properties, Ligand B is the more promising candidate.
Output:
0
2025-04-17 22:21:06,388 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (360.483 and 373.519 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (75.19) is slightly higher than Ligand B (70.16), but both are below the 140 threshold for good oral absorption. Given ADRB2 is a cardiovascular target, CNS penetration isn't paramount, but lower TPSA is still preferable. Slight edge to Ligand B.
3. **logP:** Ligand A (1.863) is within the optimal 1-3 range. Ligand B (0.083) is quite low, potentially hindering membrane permeability. This is a significant drawback for Ligand B.
4. **HBD:** Ligand A (1) is preferable to Ligand B (0) as it provides a hydrogen bond donation which can be important for binding.
5. **HBA:** Both ligands have 5 HBA, which is acceptable.
6. **QED:** Ligand A (0.832) has a significantly better QED score than Ligand B (0.617), indicating a more drug-like profile.
7. **DILI:** Ligand A (34.277) has a much lower DILI risk than Ligand B (19.271), which is a major advantage.
8. **BBB:** Both ligands have similar BBB penetration (around 71%). This isn't a critical factor for a cardiovascular target.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the values are very close.
10. **Solubility:** Ligand A (-3.136) has better solubility than Ligand B (-0.75).
11. **hERG:** Ligand A (0.14) has a much lower hERG inhibition liability than Ligand B (0.666), reducing cardiotoxicity concerns.
12. **Cl_mic:** Ligand A (-9.362) has a much lower (better) microsomal clearance than Ligand B (27.582), indicating greater metabolic stability.
13. **t1/2:** Ligand A (1.725 hours) has a shorter half-life than Ligand B (-24.303 hours). This is a drawback for Ligand A, but can be mitigated with dosing.
14. **Pgp:** Ligand A (0.066) has lower P-gp efflux liability than Ligand B (0.025), which is favorable.
15. **Binding Affinity:** Ligand B (-6.8 kcal/mol) has a slightly better binding affinity than Ligand A (-6.1 kcal/mol), but the difference is less than 1.5 kcal/mol.
**GPCR-specific considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Ligand A has a better logP, lower TPSA, lower Pgp efflux, and a significantly better safety profile (DILI, hERG). The affinity difference is not substantial enough to outweigh these advantages.
**Conclusion:**
Ligand A is the more promising candidate due to its superior ADME-Tox properties (DILI, hERG, Cl_mic, Solubility, QED) and acceptable binding affinity. While Ligand B has slightly better affinity and half-life, the significantly worse predicted safety and permeability profiles make it less desirable.
Output:
1
2025-04-17 22:21:06,388 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (359.86 & 349.43 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (53.51) is significantly better than Ligand B (93.46). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand B is approaching a TPSA that could hinder oral bioavailability.
3. **logP:** Ligand A (3.074) is optimal, while Ligand B (1.867) is on the lower end. For a GPCR, a slightly higher logP is generally preferred for membrane permeability and receptor engagement.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (3) is better than Ligand B (5). Similar reasoning as HBD.
6. **QED:** Both ligands are comparable (0.776 vs 0.747), indicating good drug-likeness.
7. **DILI:** Both ligands have acceptable DILI risk (49.63 vs 41.41), well below the 60 threshold.
8. **BBB:** Ligand A (71.23) has a better BBB percentile than Ligand B (55.87). While not a primary concern for a cardiovascular target, higher BBB is never detrimental.
9. **Caco-2:** Ligand A (-4.634) is better than Ligand B (-5.342). Higher (less negative) Caco-2 values indicate better permeability.
10. **Solubility:** Ligand A (-3.701) is better than Ligand B (-1.174). Better solubility is always a plus.
11. **hERG:** Both ligands have very low hERG risk (0.258 and 0.139).
12. **Cl_mic:** Ligand A (43.124) has lower microsomal clearance than Ligand B (50.219), suggesting better metabolic stability.
13. **t1/2:** Ligand A (5.274) has a much better in vitro half-life than Ligand B (-22.219). This is a significant advantage.
14. **Pgp:** Both ligands have low Pgp efflux (0.192 and 0.137).
15. **Binding Affinity:** Ligand A (-6.4) has a slightly better binding affinity than Ligand B (-5.6). While the difference is less than 1.5 kcal/mol, it adds to the overall favorable profile of Ligand A.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most key ADME properties (TPSA, logP, HBD, HBA, Solubility, Cl_mic, t1/2, Caco-2) and has a slightly better binding affinity. While both have acceptable safety profiles, Ligand A's superior pharmacokinetic properties make it a more promising drug candidate for the ADRB2 receptor.
Output:
1
2025-04-17 22:21:06,388 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.443 and 342.439 Da) fall comfortably within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (81.86) is slightly higher than Ligand B (62.55). Both are below the 140 threshold for oral absorption, but B is better.
3. **logP:** Both ligands (2.452 and 2.679) are within the optimal 1-3 range. No major difference.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 5 HBA, while Ligand B has 3. Both are acceptable (<=10), but B is slightly better.
6. **QED:** Both ligands have good QED scores (0.845 and 0.915), indicating good drug-like properties. B is slightly better.
7. **DILI:** Ligand B (30.826) has a significantly lower DILI risk than Ligand A (48.546). This is a major advantage for B.
8. **BBB:** Ligand A (77.821) has a better BBB penetration score than Ligand B (62.97). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant for off-target effects or potential therapeutic strategies.
9. **Caco-2:** Ligand A (-4.525) is better than Ligand B (-5.078), indicating better intestinal absorption.
10. **Solubility:** Both ligands have poor solubility (-3.014 and -2.994). This is a concern for both, but not a deciding factor.
11. **hERG:** Both ligands have low hERG inhibition risk (0.68 and 0.204). B is better.
12. **Cl_mic:** Ligand B (19.815) has a significantly lower microsomal clearance than Ligand A (81.582), suggesting better metabolic stability. This is a significant advantage for B.
13. **t1/2:** Ligand B (38.197) has a much longer in vitro half-life than Ligand A (-4.865). This is a major advantage for B, potentially leading to less frequent dosing.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.195 and 0.2). No significant difference.
15. **Binding Affinity:** Ligand A (-7.3) has a slightly stronger binding affinity than Ligand B (-6.8). This is a 0.5 kcal/mol difference, which is noticeable but not overwhelming given the other factors.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. While Ligand A has slightly better affinity and Caco-2 permeability, Ligand B excels in crucial ADME properties like DILI risk, metabolic stability (Cl_mic), and half-life. The lower TPSA of Ligand B is also favorable.
**Overall Assessment:**
Ligand B presents a more balanced profile with significantly better ADME properties (lower DILI, better metabolic stability, longer half-life) and a reasonably good binding affinity. While Ligand A has slightly better affinity and Caco-2 permeability, the ADME advantages of Ligand B are more critical for overall drug development success. The solubility of both is a concern, but can be addressed with formulation strategies.
Output:
0
2025-04-17 22:21:06,388 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.503 and 360.445 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (49.85) is better than Ligand B (58.64) as it is closer to the <140 threshold for good oral absorption.
3. **logP:** Both ligands (2.687 and 2.589) are within the optimal 1-3 range. No significant difference.
4. **HBD:** Ligand A (0) is preferable to Ligand B (1) as lower HBD generally improves permeability.
5. **HBA:** Both ligands have 3 HBA, which is within the acceptable range of <=10. No significant difference.
6. **QED:** Both ligands have similar QED values (0.74 and 0.759), indicating good drug-likeness. No significant difference.
7. **DILI:** Ligand A (6.282) has a significantly lower DILI risk than Ligand B (16.751). This is a major advantage for Ligand A.
8. **BBB:** Both ligands have very similar BBB penetration (83.443 and 83.831). This is good, but less critical for ADRB2 which is not a CNS target.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.22 and -4.558). These values are unusual and likely indicate poor permeability. However, the values are similar.
10. **Solubility:** Both ligands have negative solubility values (-2.011 and -2.172), which is unfavorable. Again, the values are similar.
11. **hERG:** Both ligands have low hERG inhibition liability (0.479 and 0.482), which is good. No significant difference.
12. **Cl_mic:** Ligand A (63.63) has a higher microsomal clearance than Ligand B (20.422), indicating lower metabolic stability. This is a disadvantage for Ligand A.
13. **t1/2:** Ligand B (-21.509) has a much longer in vitro half-life than Ligand A (-10.012). This is a significant advantage for Ligand B.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.106 and 0.054). No significant difference.
15. **Binding Affinity:** Ligand B (-6.8) has a slightly better binding affinity than Ligand A (-5.1). This is a 1.7 kcal/mol difference, which is substantial.
**GPCR-Specific Priorities & Overall Assessment:**
For a GPCR like ADRB2, logP, TPSA, and affinity are key. Both ligands perform similarly on logP and TPSA. Ligand B has a significantly better binding affinity. However, Ligand A has a much better safety profile (DILI) and a slightly better HBD count. The longer half-life of Ligand B is also a significant advantage. While the Caco-2 and solubility are poor for both, the superior affinity and half-life of Ligand B, coupled with acceptable DILI, outweigh the slightly better TPSA and HBD of Ligand A.
**Output:**
0
2025-04-17 22:21:06,388 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.491 and 345.397 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (47.1) is significantly better than Ligand B (62.73). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally favors absorption.
3. **logP:** Ligand B (3.892) is higher than Ligand A (0.484). While 3.892 is approaching the upper limit, it's still acceptable. Ligand A's logP is quite low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is better than Ligand B (5). Lower HBA also favors permeability.
6. **QED:** Ligand B (0.832) has a better QED score than Ligand A (0.628), indicating a more drug-like profile.
7. **DILI:** Ligand A (12.02) has a much lower DILI risk than Ligand B (47.693). This is a significant advantage for Ligand A.
8. **BBB:** Both have reasonable BBB penetration, but Ligand B (68.903) is slightly higher than Ligand A (62.699). Not a major factor here as ADRB2 is not a CNS target.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand B (-4.974) is slightly better than Ligand A (-0.994).
10. **Solubility:** Ligand A (-0.994) has better solubility than Ligand B (-4.399). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.515) has a lower hERG risk than Ligand B (0.754). This is a crucial safety parameter.
12. **Cl_mic:** Ligand B (16.093) has a lower microsomal clearance than Ligand A (31.387), indicating better metabolic stability.
13. **t1/2:** Ligand B (25.099) has a significantly longer in vitro half-life than Ligand A (3.498). This is a major advantage.
14. **Pgp:** Ligand A (0.014) has a much lower P-gp efflux liability than Ligand B (0.052). This is favorable for bioavailability.
15. **Binding Affinity:** Ligand B (-7.7 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.4 kcal/mol). This is a substantial advantage, potentially outweighing some ADME concerns.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in affinity and has a reasonable logP. Ligand A has better TPSA and Pgp.
**Overall Assessment:**
While Ligand B has a superior binding affinity and metabolic stability (longer half-life), Ligand A demonstrates a much better safety profile (lower DILI and hERG) and better solubility. The significantly stronger affinity of Ligand B is a substantial benefit, and the slightly higher logP is manageable. The longer half-life is also a significant advantage. The Caco-2 values are concerning for both, but the other benefits of Ligand B outweigh the drawbacks.
Output:
0
2025-04-17 22:21:06,389 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's break down the comparison of Ligand A and Ligand B based on the provided parameters and the guidelines, keeping in mind ADRB2 is a GPCR.
1. **Molecular Weight:** Both ligands (350.423 and 353.463 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (115.37) is better than Ligand B (121.52). Both are under the 140 threshold for oral absorption, but lower TPSA is generally preferred for GPCRs to aid in brain penetration if desired.
3. **logP:** Ligand B (0.593) is slightly better than Ligand A (-0.504), falling within the optimal 1-3 range. Ligand A is a bit low, potentially hindering permeability.
4. **H-Bond Donors:** Ligand B (4) is preferable to Ligand A (2). While both are acceptable, a slight increase in HBD can improve solubility.
5. **H-Bond Acceptors:** Ligand A (7) is better than Ligand B (4).
6. **QED:** Ligand A (0.739) is significantly better than Ligand B (0.485), indicating a more drug-like profile.
7. **DILI:** Ligand B (13.3) is *much* better than Ligand A (44.591). This is a significant advantage for Ligand B, as lower DILI risk is crucial.
8. **BBB:** Ligand A (57.852) is better than Ligand B (34.626). While ADRB2 isn't exclusively a CNS target, some degree of BBB penetration can be beneficial.
9. **Caco-2:** Both ligands have very poor Caco-2 permeability (-5.441 and -5.775). This is a major concern for both.
10. **Solubility:** Both ligands have poor solubility (-1.887 and -1.757). This is a concern for both.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.179 and 0.11). This is good.
12. **Cl_mic:** Ligand B (0.955) is much better than Ligand A (14.23). Lower clearance indicates better metabolic stability.
13. **t1/2:** Ligand A (-2.889) is better than Ligand B (8.007).
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.007 and 0.035). This is good.
15. **Binding Affinity:** Ligand A (-7.6) is significantly better than Ligand B (-6.4). This is a 1.2 kcal/mol advantage, which is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand A has a significantly stronger binding affinity and better QED and BBB penetration. However, Ligand B has a *much* lower DILI risk and better metabolic stability (lower Cl_mic). Both have poor Caco-2 and solubility. The large difference in DILI risk is a major concern for Ligand A. While the affinity of Ligand A is attractive, the potential for liver toxicity is a significant drawback. Considering the balance, the lower DILI risk and improved metabolic stability of Ligand B are more desirable, even with the weaker binding affinity.
**Output:**
0
2025-04-17 22:21:06,389 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (347.415 Da and 351.447 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (95.67) is better than Ligand B (111.29). For a GPCR, keeping TPSA under 140 is good for oral absorption, and lower is generally preferred.
**3. logP:** Both ligands have acceptable logP values (0.875 and 0.993 respectively), falling within the 1-3 range. No clear advantage.
**4. H-Bond Donors:** Ligand A (2) is preferable to Ligand B (4). Fewer HBDs generally mean better permeability.
**5. H-Bond Acceptors:** Ligand A (5) and Ligand B (4) are both acceptable, well below the 10 threshold.
**6. QED:** Ligand A (0.796) has a significantly better QED score than Ligand B (0.504), indicating a more drug-like profile.
**7. DILI:** Both ligands have low DILI risk (30.322 and 31.64 respectively), below the 40 threshold. No significant difference.
**8. BBB:** Ligand A (49.826) is better than Ligand B (25.126). While ADRB2 is a cardiovascular target and doesn't *require* high BBB penetration, some level is not detrimental and can provide a safety margin.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-5.16 and -5.439), which is unusual and suggests poor permeability. This is a concern for both.
**10. Aqueous Solubility:** Both ligands have negative solubility values (-1.35 and -2.451), indicating poor aqueous solubility. This is a significant drawback for both.
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.141 and 0.297 respectively). This is excellent.
**12. Microsomal Clearance:** Ligand A (-4.176) has a much lower (better) microsomal clearance than Ligand B (15.749), indicating better metabolic stability.
**13. In vitro Half-Life:** Ligand A (21.4) has a much longer half-life than Ligand B (-3.324). This is a major advantage.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.043 and 0.104 respectively). This is good.
**15. Binding Affinity:** Both ligands have excellent binding affinity (-6.7 kcal/mol and -6.0 kcal/mol). Ligand A is slightly better, but the difference is not huge.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity) and general drug-like properties, Ligand A is the superior candidate. It has a better QED score, better TPSA, lower HBD count, better BBB penetration, significantly better metabolic stability (lower Cl_mic, longer t1/2), and slightly better binding affinity. While both have poor Caco-2 and solubility, the other advantages of Ligand A outweigh this drawback.
Output:
1
2025-04-17 22:21:06,389 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (344.459 Da) is slightly lower, which is generally favorable for permeability.
**2. TPSA:** Ligand A (83.98) is significantly better than Ligand B (40.62). Lower TPSA generally correlates with better blood-brain barrier penetration and oral absorption, crucial for GPCRs.
**3. logP:** Both ligands have acceptable logP values (A: 2.333, B: 3.514), falling within the 1-3 range. Ligand B is a bit higher, potentially leading to slight solubility issues but also better membrane permeability.
**4. H-Bond Donors:** Ligand A has 2 HBD, and Ligand B has 0. Both are within the acceptable limit of 5.
**5. H-Bond Acceptors:** Ligand A has 4 HBA, and Ligand B has 3. Both are within the acceptable limit of 10.
**6. QED:** Both ligands have good QED scores (A: 0.532, B: 0.596), indicating good drug-like properties.
**7. DILI Risk:** Ligand A (43.001) has a slightly higher DILI risk than Ligand B (34.161), but both are below the concerning threshold of 60.
**8. BBB Penetration:** Ligand B (97.014) has significantly better BBB penetration than Ligand A (56.378). While ADRB2 is primarily a cardiovascular target, some CNS effects are possible with adrenergic agonists, and better BBB penetration could be a benefit or a liability depending on the desired profile.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests a potential issue with the data or the model. However, the values are similar (-5.187 for A and -4.702 for B) and don't strongly favor either.
**10. Aqueous Solubility:** Both ligands have poor aqueous solubility (-2.233 for A and -3.355 for B). This is a concern for both, but Ligand B is worse.
**11. hERG Inhibition:** Ligand A (0.153) has a slightly lower hERG risk than Ligand B (0.731), which is a significant advantage for cardiovascular drugs.
**12. Microsomal Clearance:** Ligand A (47.641) has higher microsomal clearance than Ligand B (27.446), indicating lower metabolic stability. This is a drawback for Ligand A.
**13. In vitro Half-Life:** Ligand B (-10.4) has a much longer in vitro half-life than Ligand A (-4.997), which is a substantial benefit.
**14. P-gp Efflux:** Ligand A (0.095) has lower P-gp efflux than Ligand B (0.244), which is favorable for bioavailability.
**15. Binding Affinity:** Both ligands have excellent binding affinities (A: -6.2 kcal/mol, B: -5.9 kcal/mol). Ligand A is slightly better, but the difference is not huge.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), and the overall balance of properties, **Ligand B** is the more promising candidate. While Ligand A has a slightly better affinity and lower P-gp efflux, Ligand B's significantly better BBB penetration, lower DILI risk, longer half-life, and acceptable logP outweigh these advantages. The poor solubility of both is a concern that would need to be addressed through formulation strategies.
Output:
0
2025-04-17 22:21:06,389 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's systematically compare Ligand A and Ligand B based on the provided parameters and the guidelines, keeping in mind that ADRB2 is a GPCR, so logP, Pgp, TPSA, and affinity are particularly important.
1. **MW:** Both ligands (356.419 Da and 343.427 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand B (71.53) is significantly better than Ligand A (105.17). Lower TPSA generally indicates better cell permeability, which is crucial for GPCR targeting.
3. **logP:** Ligand B (1.014) is within the optimal range (1-3), while Ligand A (-0.167) is slightly below 1, potentially hindering permeation. This is a notable advantage for Ligand B.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable.
5. **HBA:** Ligand A (6) and Ligand B (4) are both acceptable.
6. **QED:** Both ligands have good QED scores (0.663 and 0.837), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand B (8.841) has a much lower DILI risk than Ligand A (30.322). This is a significant advantage for Ligand B.
8. **BBB:** Ligand B (77.743) has a higher BBB penetration score than Ligand A (41.45). While ADRB2 isn't necessarily a CNS target, higher BBB penetration can sometimes correlate with better overall distribution and reduced off-target effects.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and requires further investigation. However, the values are similar, so it doesn't strongly favor either.
10. **Solubility:** Both ligands have negative solubility values, which is also unusual. Again, the values are similar.
11. **hERG:** Ligand A (0.092) has a slightly lower hERG inhibition liability than Ligand B (0.309), which is preferable.
12. **Cl_mic:** Ligand B (1.397) has significantly lower microsomal clearance than Ligand A (18.332), indicating better metabolic stability. This is a major advantage for Ligand B.
13. **t1/2:** Ligand B (-11.169) has a much longer in vitro half-life than Ligand A (0.42). This is a substantial advantage for Ligand B.
14. **Pgp:** Ligand A (0.022) has a lower P-gp efflux liability than Ligand B (0.01), which is slightly preferable.
15. **Affinity:** Ligand B (-7.4) has a slightly better binding affinity than Ligand A (-6.8). While the difference is not huge, it's enough to be considered.
**Overall Assessment:**
Ligand B consistently outperforms Ligand A across most critical ADME-Tox parameters. It has better TPSA, logP, DILI risk, BBB penetration, metabolic stability (Cl_mic), and in vitro half-life. The slightly better affinity of Ligand B further strengthens its position. While Ligand A has a slightly better hERG profile and Pgp efflux, the overall balance of properties strongly favors Ligand B.
**Output:**
0
2025-04-17 22:21:06,389 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.471 and 346.515 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (58.64) is slightly higher than Ligand B (49.41). Both are below the 140 threshold for oral absorption, but B is better positioned for potential CNS penetration if desired.
3. **logP:** Ligand A (2.292) is within the optimal 1-3 range. Ligand B (3.648) is slightly higher, edging towards potential solubility issues, but still acceptable.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 3 HBA, while Ligand B has 2. Both are within the acceptable range of <=10.
6. **QED:** Ligand B (0.512) has a better QED score than Ligand A (0.286), indicating a more drug-like profile.
7. **DILI:** Ligand A (13.571) has a significantly higher DILI risk than Ligand B (8.259). This is a major concern for Ligand A.
8. **BBB:** Ligand B (89.337) has a much higher BBB penetration percentile than Ligand A (70.764). While ADRB2 isn't strictly a CNS target, higher BBB is generally favorable for reducing off-target effects.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.711 and -4.768). These values are unusual and suggest very poor permeability. This is a significant drawback for both.
10. **Solubility:** Ligand A (-2.071) has slightly better solubility than Ligand B (-3.796), but both are poor.
11. **hERG:** Ligand A (0.313) has a lower hERG inhibition liability than Ligand B (0.703), which is preferable.
12. **Cl_mic:** Ligand A (5) has a much lower microsomal clearance than Ligand B (43.7), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand B (3.498) has a longer in vitro half-life than Ligand A (-1.414). This is a positive for Ligand B.
14. **Pgp:** Ligand A (0.1) has lower P-gp efflux liability than Ligand B (0.309), which is favorable.
15. **Binding Affinity:** Ligand B (-6.5 kcal/mol) has a slightly better binding affinity than Ligand A (-5.8 kcal/mol). This is a 0.7 kcal/mol difference, which is notable, but not overwhelming.
**GPCR-Specific Priorities & Overall Assessment:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B is better on logP, TPSA, Pgp, and affinity. However, the significantly lower DILI risk and better metabolic stability (lower Cl_mic) of Ligand A are crucial factors. The poor Caco-2 values for both are concerning, but can potentially be addressed through formulation strategies. The slightly better affinity of Ligand B is not enough to overcome the higher DILI risk.
Considering the balance of properties, especially the critical safety parameter of DILI, I favor Ligand A.
Output:
1
2025-04-17 22:21:06,390 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [390.398, 102.87 , 2.686, 0. , 8. , 0.401, 62.156, 70.105, -4.596, -2.587, 0.106, 109.965, -18.984, 0.225, -5.1 ]
**Ligand B:** [364.515, 76.44 , 1.25 , 1. , 5. , 0.718, 16.712, 57.154, -5.227, -2.247, 0.486, 34.975, -1.448, 0.011, -6.3 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (364.515) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (102.87) is higher than Ligand B (76.44). Both are acceptable, but Ligand B is better, being closer to the <140 threshold for good oral absorption.
3. **logP:** Both are within the optimal range (1-3). Ligand A (2.686) is slightly higher, which could potentially lead to off-target effects, but is still reasonable. Ligand B (1.25) is a bit lower, which *could* impact permeability.
4. **HBD:** Ligand A (0) is better than Ligand B (1). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (8) is better than Ligand B (5). Fewer HBAs generally improve permeability.
6. **QED:** Ligand B (0.718) is better than Ligand A (0.401), indicating a more drug-like profile.
7. **DILI:** Ligand B (16.712) is *significantly* better than Ligand A (62.156). This is a major advantage for Ligand B.
8. **BBB:** Ligand A (70.105) is better than Ligand B (57.154). While ADRB2 isn't a CNS target, some peripheral exposure is still desirable, and higher BBB penetration can sometimes correlate with better overall distribution.
9. **Caco-2:** Ligand A (-4.596) is better than Ligand B (-5.227). Higher values indicate better intestinal absorption.
10. **Solubility:** Ligand A (-2.587) is better than Ligand B (-2.247).
11. **hERG:** Ligand A (0.106) is better than Ligand B (0.486). Lower hERG inhibition is crucial for avoiding cardiotoxicity.
12. **Cl_mic:** Ligand B (34.975) is *much* better than Ligand A (109.965). Lower clearance indicates better metabolic stability.
13. **t1/2:** Ligand A (-18.984) is better than Ligand B (-1.448). Longer half-life is generally preferred.
14. **Pgp:** Ligand A (0.225) is better than Ligand B (0.011). Lower P-gp efflux is preferred.
15. **Affinity:** Ligand B (-6.3) is better than Ligand A (-5.1). This is a substantial difference in binding affinity (1.2 kcal/mol), which is a significant advantage.
**GPCR-Specific Priorities:** For GPCRs, logP, Pgp, TPSA, and affinity are key. Ligand B has better TPSA, Pgp, and significantly better affinity. Ligand A has a slightly better logP and BBB, but the DILI and Cl_mic issues with Ligand A are significant drawbacks.
**Overall Assessment:**
While Ligand A has some favorable properties (BBB, solubility, t1/2, Pgp), the significantly higher DILI risk and much higher microsomal clearance are major concerns. Ligand B, despite being slightly less BBB permeable, has a much better safety profile (DILI), metabolic stability (Cl_mic), and, crucially, a significantly stronger binding affinity. The superior affinity of Ligand B outweighs the minor drawbacks in BBB and logP.
Therefore, I prefer Ligand B.
Output:
0
2025-04-17 22:21:06,390 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (350.463 and 368.503 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (76.46) is significantly better than Ligand B (87.32). ADRB2 is a cardiovascular target, not CNS, but lower TPSA generally improves absorption.
3. **logP:** Both ligands have acceptable logP values (1.376 and 1.92), falling within the 1-3 range. Ligand B is slightly higher, which *could* be a minor drawback if it impacts solubility.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Both ligands have the same number of HBA (5), which is acceptable.
6. **QED:** Ligand A (0.806) has a significantly better QED score than Ligand B (0.65), indicating a more drug-like profile.
7. **DILI:** Ligand A (32.842) has a much lower DILI risk than Ligand B (50.33). This is a significant advantage for Ligand A.
8. **BBB:** This is less crucial for a cardiovascular target. Ligand A (75.107) is better than Ligand B (51.725), but this isn't a major deciding factor.
9. **Caco-2:** Ligand A (-4.524) is better than Ligand B (-5.165), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-1.921) is better than Ligand B (-3.283), indicating better aqueous solubility.
11. **hERG:** Both ligands have very low hERG risk (0.343 and 0.46), which is excellent.
12. **Cl_mic:** Ligand A (37.385) has lower microsomal clearance than Ligand B (46.756), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-35.394) has a much longer in vitro half-life than Ligand A (9.197). This is a significant advantage for Ligand B.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.048 and 0.051).
15. **Binding Affinity:** Ligand B (-7.0) has a slightly better binding affinity than Ligand A (-5.4). This is a 1.6 kcal/mol difference, which is substantial.
**Overall Assessment:**
Ligand B has a significantly better binding affinity and a longer half-life. However, Ligand A excels in almost all other ADME-Tox properties: TPSA, QED, DILI risk, solubility, and metabolic stability. The 1.6 kcal/mol difference in binding affinity is important, but the superior ADME profile of Ligand A, particularly the lower DILI risk and better QED, makes it a more promising starting point for drug development. The improved ADME properties will likely translate to better *in vivo* performance, even if initial potency is slightly lower.
Output:
1
2025-04-17 22:21:06,390 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (345.49 & 350.46 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (54.46) is significantly better than Ligand B (87.66). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (3.07) is optimal, while Ligand B (1.118) is on the lower side, potentially impacting permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Both ligands have 4 HBA, which is acceptable.
6. **QED:** Ligand A (0.891) has a much better QED score than Ligand B (0.642), indicating a more drug-like profile.
7. **DILI:** Ligand A (29.624) has a significantly lower DILI risk than Ligand B (14.889). This is a major advantage.
8. **BBB:** Ligand A (92.361) has a higher BBB penetration percentile than Ligand B (53.587). While not critical for a cardiovascular target, it's a positive attribute.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the magnitude of the negative value is smaller for Ligand A (-4.953 vs -5.197), suggesting slightly better permeability.
10. **Solubility:** Ligand A (-2.842) has better solubility than Ligand B (-1.802).
11. **hERG:** Ligand A (0.706) has a lower hERG risk than Ligand B (0.156). This is a significant safety advantage.
12. **Cl_mic:** Ligand B (10.266) has a much lower microsomal clearance than Ligand A (63.404), indicating better metabolic stability. This is a strong point for Ligand B.
13. **t1/2:** Ligand B (27.442) has a much longer in vitro half-life than Ligand A (9.596). This is a major advantage for dosing convenience.
14. **Pgp:** Ligand A (0.391) has lower P-gp efflux than Ligand B (0.014), which is favorable for bioavailability.
15. **Affinity:** Ligand B (-7.9) has a substantially stronger binding affinity than Ligand A (-5.0). This is a very significant advantage, potentially outweighing some ADME concerns.
**Overall Assessment:**
Ligand B has a significantly better binding affinity and metabolic stability (lower Cl_mic, longer t1/2). These are crucial for a viable drug candidate. While Ligand A has better scores across many ADME properties (DILI, solubility, hERG, TPSA, QED), the substantial affinity advantage of Ligand B is likely to be more impactful. The ADME properties of Ligand B are still within acceptable ranges, and optimization could further improve them. The strong binding affinity provides a good starting point for further development.
Output:
0
2025-04-17 22:21:06,390 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (379.287) is slightly higher than Ligand B (368.455), but both are acceptable.
2. **TPSA:** Ligand A (58.2) is excellent, well below the 140 threshold for oral absorption and favorable for GPCRs. Ligand B (112.57) is higher, but still within a reasonable range, though less optimal.
3. **logP:** Ligand A (4.816) is a bit high, potentially leading to solubility issues or off-target effects. Ligand B (1.811) is within the optimal range (1-3). This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (2) and Ligand B (3) are both acceptable, below the threshold of 5.
5. **HBA:** Ligand A (2) and Ligand B (4) are both acceptable, below the threshold of 10.
6. **QED:** Both ligands have similar QED values (A: 0.749, B: 0.648), indicating good drug-likeness.
7. **DILI:** Ligand A (77.356) has a higher DILI risk than Ligand B (63.862), although both are below the concerning 60 threshold.
8. **BBB:** Ligand A (63.435) has better BBB penetration than Ligand B (47.111). While ADRB2 isn't necessarily a CNS target, some peripheral ADRB2 activity can be modulated by CNS effects, and better BBB penetration isn't a major negative.
9. **Caco-2:** Ligand A (-4.524) has a worse Caco-2 permeability than Ligand B (-5.51). Lower values are worse, so Ligand B is preferable.
10. **Solubility:** Ligand A (-6.53) has worse aqueous solubility than Ligand B (-2.857). This is a significant drawback for Ligand A, especially given its higher logP.
11. **hERG:** Ligand A (0.51) has a lower hERG inhibition liability than Ligand B (0.051), which is a positive.
12. **Cl_mic:** Ligand A (70.127) has better metabolic stability (lower clearance) than Ligand B (11.202). This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (82.795) has a much longer in vitro half-life than Ligand B (-35.163). This is a substantial advantage for Ligand A.
14. **Pgp:** Ligand A (0.18) has lower P-gp efflux liability than Ligand B (0.009). Lower is better, so Ligand A is preferable.
15. **Binding Affinity:** Ligand B (-7.4) has a slightly better binding affinity than Ligand A (-6.8). This is a 0.6 kcal/mol difference, which is significant, but not overwhelming.
**Overall Assessment:**
Ligand B has advantages in logP, Caco-2 permeability, solubility, and binding affinity. However, Ligand A excels in metabolic stability (Cl_mic), in vitro half-life, Pgp efflux, and has a lower hERG risk. Given that ADRB2 is a GPCR, balancing logP, TPSA, and affinity is crucial. While Ligand B's affinity is slightly better, Ligand A's superior ADME properties (particularly metabolic stability and half-life) and lower hERG risk are more compelling for a viable drug candidate. The higher logP of Ligand A is a concern, but the other benefits outweigh this drawback.
Output:
1
2025-04-17 22:21:06,390 - INFO - Batch 325 complete. Total preferences: 5200
2025-04-17 22:21:06,390 - INFO - Processing batch 326/512...
2025-04-17 22:21:55,492 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step Comparison:**
1. **MW:** Ligand A (384.395 Da) is within the ideal range (200-500 Da). Ligand B (350.463 Da) is also excellent. No clear advantage here.
2. **TPSA:** Ligand A (49.85) is very good, well below the 140 threshold for oral absorption. Ligand B (87.46) is higher but still acceptable, though less optimal. A favors here.
3. **logP:** Ligand A (2.021) is optimal (1-3). Ligand B (0.643) is a bit low, potentially hindering membrane permeability. A is better.
4. **HBD:** Ligand A (0) is excellent. Ligand B (2) is acceptable, but fewer HBDs generally improve permeability. A is better.
5. **HBA:** Ligand A (4) is good. Ligand B (5) is also acceptable. No significant difference.
6. **QED:** Both Ligand A (0.696) and Ligand B (0.674) have good drug-likeness scores (>0.5). No clear advantage.
7. **DILI:** Ligand A (35.983) has a lower DILI risk than Ligand B (18.224), indicating better safety. A is better.
8. **BBB:** Ligand A (93.912) shows excellent BBB penetration, while Ligand B (49.826) is much lower. Considering ADRB2 is a GPCR, and potential CNS effects are relevant, A is significantly better.
9. **Caco-2:** Ligand A (-4.462) is not ideal, but Ligand B (-5.02) is worse. A is slightly better.
10. **Solubility:** Ligand A (-3.401) is better than Ligand B (-0.978). A is better.
11. **hERG:** Ligand A (0.588) has a lower hERG risk than Ligand B (0.167). A is better.
12. **Cl_mic:** Ligand A (51.715) has a higher clearance than Ligand B (21.582), meaning it's less metabolically stable. B is better.
13. **t1/2:** Ligand A (-26.136) has a much longer in vitro half-life than Ligand B (5.169). A is significantly better.
14. **Pgp:** Ligand A (0.054) has lower P-gp efflux than Ligand B (0.029). A is slightly better.
15. **Affinity:** Ligand A (-7.7 kcal/mol) has a stronger binding affinity than Ligand B (-5.8 kcal/mol). This is a substantial difference and a major advantage for A.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical parameters, especially considering the GPCR target class. The strong affinity, excellent BBB penetration, favorable DILI, solubility, hERG, and half-life outweigh the slightly higher microsomal clearance. While Ligand B has better metabolic stability, the other advantages of Ligand A are more crucial for a viable drug candidate.
Output:
1
2025-04-17 22:21:55,492 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (348.531) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (33.45) is significantly better than Ligand A (49.41). Lower TPSA is preferred for GPCRs, aiding in brain penetration and overall absorption.
3. **logP:** Ligand B (4.794) is higher than Ligand A (3.912). While both are above the optimal 1-3 range, Ligand B is pushing the upper limit and could present solubility challenges.
4. **HBD:** Ligand A (1) is better than Ligand B (0). A single HBD can contribute to solubility without drastically hindering permeability.
5. **HBA:** Ligand B (4) is better than Ligand A (2).
6. **QED:** Both ligands have similar QED values (A: 0.766, B: 0.727), indicating good drug-likeness.
7. **DILI:** Ligand A (11.245) has a much lower DILI risk than Ligand B (58.434). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (83.366) has a significantly higher BBB penetration percentile than Ligand B (61.923). For a cardiovascular GPCR, some brain penetration isn't necessarily *required*, but it's not detrimental and could offer potential for off-target effects or broader therapeutic impact.
9. **Caco-2:** Ligand A (-4.62) is better than Ligand B (-5.202). Higher Caco-2 permeability is preferred.
10. **Solubility:** Ligand A (-3.818) is better than Ligand B (-5.359). Solubility is a concern with Ligand B's higher logP.
11. **hERG:** Both ligands have similar hERG inhibition liability (A: 0.596, B: 0.649), indicating a relatively low risk.
12. **Cl_mic:** Ligand A (57.061) has a lower microsomal clearance than Ligand B (120.751), suggesting better metabolic stability.
13. **t1/2:** Ligand B (58.001) has a longer in vitro half-life than Ligand A (-12.983). This is a positive for Ligand B.
14. **Pgp:** Ligand A (0.318) has lower P-gp efflux liability than Ligand B (0.758), which is favorable for bioavailability.
15. **Affinity:** Both ligands have very similar binding affinities (A: -5.8 kcal/mol, B: -5.5 kcal/mol). The difference of 0.3 kcal/mol is not substantial enough to override other factors.
**Overall Assessment:**
Ligand A presents a more balanced profile. While Ligand B has a slightly longer half-life, Ligand A excels in crucial areas like DILI risk, BBB penetration, solubility, metabolic stability (lower Cl_mic), and Caco-2 permeability. The TPSA of Ligand B is a significant advantage, but the higher logP and DILI risk are concerning. Given the GPCR-specific priorities, the combination of lower risk factors and better predicted absorption/distribution makes Ligand A the more promising candidate.
Output:
1
2025-04-17 22:21:55,492 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (362.5) is slightly higher than Ligand B (346.4), but both are acceptable.
2. **TPSA:** Both ligands are below the 140 A^2 threshold for good oral absorption. Ligand A (96.97) is slightly higher than Ligand B (93.21), but both are reasonable.
3. **logP:** Both ligands have optimal logP values (1-3). Ligand A (2.736) is slightly higher than Ligand B (1.428). This is a slight advantage for A as it may improve membrane permeability.
4. **HBD:** Both ligands have 2 H-bond donors, which is within the acceptable limit of <=5.
5. **HBA:** Both ligands have 5 H-bond acceptors, also within the acceptable limit of <=10.
6. **QED:** Both ligands have good QED scores (>0.5). Ligand B (0.779) is slightly better than Ligand A (0.63).
7. **DILI:** Ligand B (35.169) has a significantly lower DILI risk than Ligand A (76.425). This is a major advantage for Ligand B.
8. **BBB:** Ligand B (65.413) has a better BBB penetration percentile than Ligand A (28.189). While ADRB2 isn't strictly a CNS target, some CNS exposure can occur, and higher BBB is generally favorable.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale isn't specified, so it's hard to interpret.
10. **Solubility:** Both ligands have negative solubility values, which is also unusual. Again, the scale is unknown, making interpretation difficult.
11. **hERG:** Both ligands have very low hERG inhibition liability, which is excellent. Ligand B (0.071) is slightly lower than Ligand A (0.286).
12. **Cl_mic:** Ligand B (15.497) has significantly lower microsomal clearance than Ligand A (79.72). This indicates better metabolic stability for Ligand B.
13. **t1/2:** Ligand B (15.041) has a longer in vitro half-life than Ligand A (25.48). This is a positive for Ligand B.
14. **Pgp:** Both ligands have very low P-gp efflux liability. Ligand B (0.004) is slightly lower than Ligand A (0.085).
15. **Binding Affinity:** Ligand A (-6.2 kcal/mol) has a slightly better binding affinity than Ligand B (-5.5 kcal/mol). This is a 0.7 kcal/mol difference, which is noticeable but not overwhelming.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are important. Ligand A has a slightly better logP and affinity, but Ligand B excels in Pgp, and has acceptable TPSA. The significant advantages of Ligand B in DILI, BBB, Cl_mic, and t1/2 outweigh the modest affinity difference. The ADME properties of Ligand B are far superior, making it a more promising candidate.
**Conclusion:**
Ligand B is the more viable drug candidate due to its significantly improved ADME profile (lower DILI, better BBB, lower Cl_mic, longer t1/2) despite a slightly weaker binding affinity.
Output:
0
2025-04-17 22:21:55,493 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [364.511, 81.42, 3.794, 2, 5, 0.721, 42.536, 84.141, -4.999, -2.576, 0.6, 57.707, 61.948, 0.221, -5.7]
**Ligand B:** [341.415, 84.83, 2.343, 2, 5, 0.691, 74.68, 61.535, -5.438, -3.016, 0.473, 42.91, 28.183, 0.325, 4.4]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (341.415) is slightly lower, which can be beneficial for permeability, but both are acceptable.
2. **TPSA:** Both are reasonably low (A: 81.42, B: 84.83), well below the 140 threshold for oral absorption.
3. **logP:** Ligand A (3.794) is slightly higher than Ligand B (2.343), falling comfortably within the optimal 1-3 range. Ligand B is a bit lower, but still acceptable.
4. **HBD/HBA:** Both have 2 HBD and 5 HBA, which is good.
5. **QED:** Both are above 0.5 (A: 0.721, B: 0.691), indicating good drug-like properties.
6. **DILI:** Ligand A (42.536) has a significantly lower DILI risk than Ligand B (74.68). This is a major advantage for Ligand A.
7. **BBB:** Ligand A (84.141) has a higher BBB penetration percentile than Ligand B (61.535). While ADRB2 isn't necessarily a CNS target, higher BBB is generally favorable.
8. **Caco-2:** Both have negative values, which is unusual. Assuming these are logP-scaled permeability values, lower (more negative) values indicate *lower* permeability. Ligand A (-4.999) is worse than Ligand B (-5.438).
9. **Solubility:** Both have negative values, indicating poor solubility. Ligand A (-2.576) is slightly better than Ligand B (-3.016).
10. **hERG:** Both have low hERG risk (A: 0.6, B: 0.473).
11. **Cl_mic:** Ligand B (42.91) has lower microsomal clearance than Ligand A (57.707), suggesting better metabolic stability.
12. **t1/2:** Ligand A (61.948) has a longer in vitro half-life than Ligand B (28.183). This is a significant advantage.
13. **Pgp:** Both have low Pgp efflux liability (A: 0.221, B: 0.325).
14. **Binding Affinity:** Ligand A (-5.7 kcal/mol) has a significantly stronger binding affinity than Ligand B (-4.4 kcal/mol). This is a substantial advantage.
**GPCR-Specific Priorities:** For ADRB2 (a GPCR), we prioritize logP, Pgp, TPSA, and affinity. Ligand A excels in affinity and has a good logP. Ligand B has slightly better Pgp and TPSA but is significantly weaker in binding. The DILI and half-life are also important considerations, and Ligand A is superior in both.
**Conclusion:**
Despite Ligand B having slightly better Caco-2 permeability and metabolic stability, the significantly stronger binding affinity of Ligand A, coupled with its lower DILI risk and longer half-life, make it the more promising drug candidate. The affinity difference is large enough to outweigh the minor ADME drawbacks.
Output:
1
2025-04-17 22:21:55,493 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
The target is ADRB2, a GPCR. Therefore, I will prioritize logP, TPSA, Pgp efflux, BBB penetration, and binding affinity, alongside general drug-like properties.
**Ligand A:**
* **MW:** 383.319 Da - Acceptable.
* **TPSA:** 61.36 A2 - Good, within the range for oral absorption.
* **logP:** 4.234 - Slightly high, potentially leading to solubility issues, but tolerable.
* **HBD:** 3 - Acceptable.
* **HBA:** 2 - Acceptable.
* **QED:** 0.729 - Excellent, highly drug-like.
* **DILI:** 18.379 - Very good, low risk of liver injury.
* **BBB:** 74.176 - Good, suggesting reasonable CNS penetration if desired.
* **Caco-2:** -4.596 - Poor permeability.
* **Solubility:** -4.327 - Poor solubility.
* **hERG:** 0.669 - Low risk of hERG inhibition.
* **Cl_mic:** -3.012 - Low clearance, indicating good metabolic stability.
* **t1/2:** 30.796 hours - Excellent, long half-life.
* **Pgp:** 0.272 - Low P-gp efflux, favorable for absorption and potential CNS exposure.
* **Affinity:** -7.2 kcal/mol - Excellent binding affinity.
**Ligand B:**
* **MW:** 346.515 Da - Acceptable.
* **TPSA:** 49.41 A2 - Very good, likely good oral absorption.
* **logP:** 3.676 - Good, within the optimal range.
* **HBD:** 1 - Acceptable.
* **HBA:** 2 - Acceptable.
* **QED:** 0.772 - Excellent, highly drug-like.
* **DILI:** 19.969 - Very good, low risk of liver injury.
* **BBB:** 81.388 - Excellent, suggesting good CNS penetration.
* **Caco-2:** -4.72 - Poor permeability.
* **Solubility:** -4.175 - Poor solubility.
* **hERG:** 0.299 - Low risk of hERG inhibition.
* **Cl_mic:** 54.863 - High clearance, indicating poor metabolic stability.
* **t1/2:** -19.271 hours - Very short half-life.
* **Pgp:** 0.199 - Low P-gp efflux, favorable for absorption and potential CNS exposure.
* **Affinity:** -6.4 kcal/mol - Good binding affinity, but significantly weaker than Ligand A.
**Comparison & Decision:**
Both ligands have similar drug-like properties (QED, DILI, hERG, Pgp). However, Ligand A has a significantly stronger binding affinity (-7.2 kcal/mol vs -6.4 kcal/mol). While both have poor Caco-2 and solubility, the difference in binding affinity is substantial (1.8 kcal/mol), and for a GPCR, potency is paramount. The longer half-life and lower clearance of Ligand A also contribute to its favorability. Although Ligand B has a better BBB score, the difference isn't large enough to offset the significant potency advantage of Ligand A.
Therefore, I choose Ligand A.
**Output:**
1
2025-04-17 22:21:55,493 - INFO - Here's my reasoning and the final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, priorities are affinity, logP, TPSA, Pgp efflux, and BBB penetration.
Let's break down the comparison:
1. **Molecular Weight:** Both ligands (349.4 and 350.4 Da) are within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (93.45) is better than Ligand B (105.6), being closer to the <140 threshold for good absorption.
3. **logP:** Ligand A (1.602) is better than Ligand B (0.26). Ligand B is quite low, potentially hindering membrane permeability.
4. **H-Bond Donors:** Both have 3 HBD, which is acceptable.
5. **H-Bond Acceptors:** Ligand B (7) is slightly higher than Ligand A (4), but both are within the acceptable range.
6. **QED:** Both are similar (0.72 and 0.676), indicating good drug-likeness.
7. **DILI:** Ligand A (56.572) has a higher DILI risk than Ligand B (35.479), which is a negative for Ligand A.
8. **BBB:** Ligand A (78.558) has significantly better BBB penetration than Ligand B (50.679). While not a CNS target, some BBB penetration can be favorable for distribution.
9. **Caco-2:** Both are negative (-5.284 and -5.319), indicating poor permeability.
10. **Solubility:** Ligand A (-2.705) is slightly worse than Ligand B (-1.126), but both are poor.
11. **hERG:** Ligand A (0.371) has a lower hERG risk than Ligand B (0.189), which is positive for Ligand A.
12. **Cl_mic:** Ligand A (-7.751) has significantly better metabolic stability (lower clearance) than Ligand B (5.691).
13. **t1/2:** Ligand A (18.188) has a shorter half-life than Ligand B (29.053).
14. **Pgp:** Ligand A (0.037) has much lower P-gp efflux than Ligand B (0.004), which is a significant advantage for bioavailability.
15. **Binding Affinity:** Ligand A (-6.2) has a slightly better binding affinity than Ligand B (-5.0).
**Overall Assessment:**
Ligand A is preferable. While Ligand B has a slightly lower DILI risk, Ligand A excels in key areas for a GPCR ligand: better logP, significantly better BBB penetration, much lower P-gp efflux, better metabolic stability (Cl_mic), and slightly better binding affinity. The slightly shorter half-life of Ligand A is less concerning than the poor permeability and efflux potential of Ligand B. The affinity difference is also substantial enough to outweigh the DILI concern.
Output:
1
2025-04-17 22:21:55,493 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (338.371 and 345.487 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (93.96) is slightly higher than Ligand B (52.65). For a cardiovascular GPCR, TPSA isn't a *critical* concern unless it's excessively high, but lower is generally preferred for better permeability. Ligand B is significantly better here.
3. **logP:** Both ligands have good logP values (2.549 and 1.765), falling within the optimal 1-3 range. Ligand A is slightly higher, which *could* be a minor concern for solubility, but both are acceptable.
4. **HBD:** Ligand A (2) and Ligand B (1) are both within the acceptable limit of <=5. Ligand B is slightly better.
5. **HBA:** Ligand A (7) and Ligand B (3) are both within the acceptable limit of <=10. Ligand B is significantly better.
6. **QED:** Both ligands have good QED scores (0.687 and 0.826), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (84.606) has a considerably higher DILI risk than Ligand B (15.936). This is a major concern, as DILI is a common reason for drug attrition. Ligand B is *much* better.
8. **BBB:** Both ligands have acceptable BBB penetration (72.237 and 71.733). Since ADRB2 isn't a CNS target, this isn't a major deciding factor.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.24 and -4.904). These values are unusual and likely indicate poor permeability. However, the values are very similar.
10. **Solubility:** Ligand A (-3.815) has worse solubility than Ligand B (-2.127). Solubility is important for bioavailability. Ligand B is better.
11. **hERG:** Both ligands have low hERG risk (0.198 and 0.381). No significant difference.
12. **Cl_mic:** Ligand A (35.897) has a higher microsomal clearance than Ligand B (4.303), indicating lower metabolic stability. Ligand B is significantly better.
13. **t1/2:** Ligand A (9.603) has a longer half-life than Ligand B (23.125). This is a positive for Ligand A.
14. **Pgp:** Both ligands have low Pgp efflux (0.368 and 0.094). Ligand B is better.
15. **Binding Affinity:** Ligand B (-6.2) has a slightly better binding affinity than Ligand A (-5.7). While the difference is not huge, it is still a factor.
**Overall Assessment:**
Ligand B is clearly the superior candidate. While Ligand A has a longer half-life, the significantly lower DILI risk, better TPSA, HBA, QED, solubility, metabolic stability (lower Cl_mic), and slightly better affinity of Ligand B outweigh this advantage. The Caco-2 values for both are concerning, but similar. For a cardiovascular GPCR, minimizing toxicity (DILI) and ensuring reasonable metabolic stability are crucial. Ligand B addresses these concerns much better than Ligand A.
Output:
0
2025-04-17 22:21:55,493 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (410.268 Da) is within the ideal range, while Ligand B (349.391 Da) is slightly below, but still acceptable.
2. **TPSA:** Ligand A (99.5) is good, below 140. Ligand B (124.26) is also acceptable, but approaching the upper limit for good absorption.
3. **logP:** Ligand A (2.717) is optimal. Ligand B (-0.593) is significantly low, potentially hindering membrane permeability. This is a major concern.
4. **HBD:** Ligand A (1) is good. Ligand B (3) is acceptable, but higher.
5. **HBA:** Both Ligand A (5) and Ligand B (5) are within the acceptable range.
6. **QED:** Both ligands (A: 0.551, B: 0.567) have similar, good QED scores.
7. **DILI:** Both ligands have similar, acceptable DILI risk (A: 71.384, B: 70.26).
8. **BBB:** Ligand A (62.97) is moderate. Ligand B (38.232) is low. While ADRB2 isn't strictly a CNS target, some CNS penetration can be beneficial for understanding off-target effects, and is not a major negative.
9. **Caco-2:** Ligand A (-4.442) is poor. Ligand B (-5.412) is even worse. Both are problematic, indicating poor intestinal absorption.
10. **Solubility:** Ligand A (-4.396) is poor. Ligand B (-2.774) is better, but still not ideal.
11. **hERG:** Both ligands have low hERG risk (A: 0.572, B: 0.258).
12. **Cl_mic:** Ligand A (109.574) has moderate clearance. Ligand B (13.804) has very low clearance, indicating good metabolic stability. This is a positive for Ligand B.
13. **t1/2:** Ligand A (37.431) has a reasonable half-life. Ligand B (-20.434) has a very short half-life, which is a significant drawback.
14. **Pgp:** Both ligands have low Pgp efflux (A: 0.13, B: 0.029).
15. **Affinity:** Ligand B (-7.2 kcal/mol) has a significantly better binding affinity than Ligand A (-5.5 kcal/mol) - a difference of 1.7 kcal/mol. This is a substantial advantage.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, and affinity are crucial. Ligand B excels in affinity, but suffers from a very low logP and poor Caco-2 permeability. Ligand A has a better logP and slightly better Caco-2, but its affinity is considerably weaker. The poor half-life of Ligand B is also a major concern.
**Overall Assessment:**
Despite the better affinity of Ligand B, the extremely low logP and short half-life are significant liabilities. The poor Caco-2 permeability for both is concerning, but the better logP of Ligand A suggests it might have a slightly better chance of being optimized for absorption. The affinity difference, while substantial, may be overcome with further optimization of Ligand A.
Output:
1
2025-04-17 22:21:55,494 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [360.523, 49.41, 3.815, 1, 3, 0.838, 36.06, 80.419, -5.013, -4.114, 0.511, 43.184, 2.015, 0.341, -7.4]
**Ligand B:** [390.531, 112.81, -0.344, 2, 5, 0.644, 41.411, 48.003, -5.831, -1.923, 0.101, 10.017, 8.629, 0.009, -5.6]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (360.523) is slightly preferred.
2. **TPSA:** Ligand A (49.41) is excellent, well below the 140 threshold. Ligand B (112.81) is higher, but still acceptable, though less ideal for permeability.
3. **logP:** Ligand A (3.815) is optimal. Ligand B (-0.344) is significantly lower, which is a concern for membrane permeability and bioavailability.
4. **HBD:** Both are acceptable (A: 1, B: 2), within the <5 guideline.
5. **HBA:** Both are acceptable (A: 3, B: 5), within the <10 guideline.
6. **QED:** Ligand A (0.838) is better than Ligand B (0.644), indicating a more drug-like profile.
7. **DILI:** Both are reasonably low (A: 36.06, B: 41.411), below the 40-60 threshold.
8. **BBB:** Ligand A (80.419) is significantly better than Ligand B (48.003). This is a key factor for GPCRs, even if not CNS-focused, as it suggests better distribution.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-5.013) is slightly better than Ligand B (-5.831)
10. **Solubility:** Both are negative, indicating poor solubility. Ligand A (-4.114) is slightly better than Ligand B (-1.923).
11. **hERG:** Both are very low (A: 0.511, B: 0.101), indicating low cardiotoxicity risk.
12. **Cl_mic:** Ligand A (43.184) is higher than Ligand B (10.017), meaning it has faster metabolic clearance and lower metabolic stability. This is a negative for A.
13. **t1/2:** Ligand B (8.629) has a much longer half-life than Ligand A (2.015), which is a significant advantage.
14. **Pgp:** Ligand A (0.341) has lower P-gp efflux than Ligand B (0.009), which is a positive.
15. **Affinity:** Ligand A (-7.4) has a significantly stronger binding affinity than Ligand B (-5.6) - a difference of 1.8 kcal/mol. This is a substantial advantage.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, BBB, and affinity are crucial. Ligand A excels in logP, BBB, and affinity. While Ligand B has a better half-life and lower clearance, the significantly weaker binding affinity and poor logP are major drawbacks. The better BBB penetration of Ligand A is also very important.
**Conclusion:**
Despite Ligand B's better half-life and lower clearance, the superior binding affinity, logP, and BBB penetration of Ligand A make it the more promising drug candidate. The 1.8 kcal/mol difference in binding affinity is substantial and can often outweigh minor ADME deficiencies, especially when considering the importance of potency for GPCR targets.
Output:
1
2025-04-17 22:21:55,494 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
The ADRB2 receptor is a GPCR, so the priorities are logP, Pgp, TPSA, affinity, and BBB. Let's break down the comparison:
1. **Molecular Weight:** Both ligands (351.491 and 342.439 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (72.88) is slightly higher than Ligand B (58.64). Both are below the 140 threshold for good oral absorption, but Ligand B is better positioned.
3. **logP:** Ligand A (1.297) and Ligand B (2.691) are both within the optimal 1-3 range. Ligand B is slightly better, being closer to the middle of the range.
4. **H-Bond Donors:** Ligand A (2) is slightly higher than Ligand B (1). Both are acceptable.
5. **H-Bond Acceptors:** Ligand A (4) is slightly higher than Ligand B (3). Both are acceptable.
6. **QED:** Ligand B (0.856) has a better QED score than Ligand A (0.678), indicating a more drug-like profile.
7. **DILI:** Ligand A (8.026%) has a significantly lower DILI risk than Ligand B (40.83%). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (64.948%) has a higher BBB penetration score than Ligand A (57.193%). While ADRB2 isn't strictly a CNS target, some peripheral distribution is still desired, and a higher BBB score can sometimes correlate with better overall distribution.
9. **Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.831) is slightly better than Ligand B (-4.488), but both are concerning.
10. **Aqueous Solubility:** Ligand A (-0.643) is better than Ligand B (-3.255) in terms of solubility.
11. **hERG Inhibition:** Ligand A (0.105) has a lower hERG inhibition liability than Ligand B (0.443). This is a significant advantage for Ligand A.
12. **Microsomal Clearance:** Ligand B (52.7) has a lower microsomal clearance than Ligand A (8.506), suggesting better metabolic stability.
13. **In vitro Half-Life:** Ligand B (-18.841) has a longer in vitro half-life than Ligand A (-16.083).
14. **P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.012 and 0.274 respectively), which is good.
15. **Binding Affinity:** Ligand B (-6.9 kcal/mol) has a slightly better binding affinity than Ligand A (-6.0 kcal/mol). This is a 0.9 kcal/mol difference, which is significant.
**Overall Assessment:**
Ligand B has a better binding affinity, QED, metabolic stability, and half-life. However, Ligand A has a much lower DILI risk and hERG inhibition liability, and better solubility. Considering the GPCR target class, the slightly better affinity of Ligand B is important, but the significantly lower toxicity profile of Ligand A is more crucial for a viable drug candidate. The permeability issues with both are concerning and would require further investigation, but the safety profile of Ligand A is more favorable.
Output:
1
2025-04-17 22:21:55,494 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (354.402 Da) is within the ideal range (200-500 Da). Ligand B (385.295 Da) is also acceptable. No clear advantage here.
2. **TPSA:** Ligand A (43.37) is excellent, well below the 140 threshold for oral absorption. Ligand B (64.16) is still reasonable, but less optimal. This favors A.
3. **logP:** Ligand A (4.9) is slightly high, potentially leading to solubility issues or off-target interactions. Ligand B (3.355) is within the optimal range (1-3). This favors B.
4. **HBD:** Both ligands have 0 HBD, which is good.
5. **HBA:** Ligand A (4) and Ligand B (5) are both acceptable, below the 10 threshold.
6. **QED:** Ligand B (0.654) has a better QED score than Ligand A (0.372), indicating a more drug-like profile. This favors B.
7. **DILI:** Ligand B (38.658) has a significantly lower DILI risk than Ligand A (88.057). This is a major advantage for B.
8. **BBB:** Ligand B (83.443) has better BBB penetration than Ligand A (65.839). While ADRB2 isn't strictly a CNS target, some CNS exposure can be relevant for side effect profiles. This favors B.
9. **Caco-2:** Both ligands have negative Caco-2 values which is unusual and suggests poor permeability.
10. **Solubility:** Ligand A (-6.569) has worse solubility than Ligand B (-3.667). This favors B.
11. **hERG:** Both ligands have low hERG inhibition risk (0.287 and 0.253). No clear advantage.
12. **Cl_mic:** Ligand B (54.404) has significantly lower microsomal clearance than Ligand A (129.822), indicating better metabolic stability. This strongly favors B.
13. **t1/2:** Ligand B (12.816) has a longer in vitro half-life than Ligand A (30.877). This favors B.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.476 and 0.284). No clear advantage.
15. **Binding Affinity:** Ligand B (-5.3 kcal/mol) has a slightly better binding affinity than Ligand A (-6.0 kcal/mol). While A is better, the difference isn't substantial enough to outweigh the other factors.
**GPCR-specific priorities:** For GPCRs, logP, TPSA, Pgp, and affinity are important. While Ligand A has slightly better affinity, Ligand B excels in logP, TPSA, and has comparable Pgp. The significantly better ADME properties of Ligand B (DILI, BBB, solubility, Cl_mic, t1/2) are crucial for overall drug development success.
**Conclusion:**
Considering the balance of properties, particularly the superior ADME profile and acceptable binding affinity, Ligand B is the more promising drug candidate.
Output:
0
2025-04-17 22:21:55,494 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (340.427 Da and 349.431 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (70.44) is better than Ligand B (84.67). For a cardiovascular GPCR, TPSA under 140 is acceptable, but lower is generally preferred for good absorption. Ligand A is closer to the ideal range.
**3. logP:** Ligand A (3.35) is higher than Ligand B (1.387). While both are within the 1-3 optimal range, Ligand A is closer to the upper limit. This could potentially cause issues with solubility or off-target interactions, but for a GPCR, a slightly higher logP can be beneficial for membrane permeability.
**4. H-Bond Donors:** Ligand A (2) is slightly higher than Ligand B (1), but both are well within the acceptable limit of 5.
**5. H-Bond Acceptors:** Both ligands have the same number of H-bond acceptors (5), which is within the acceptable limit of 10.
**6. QED:** Ligand B (0.839) has a significantly better QED score than Ligand A (0.623), indicating a more drug-like profile.
**7. DILI Risk:** Ligand B (13.067) has a much lower DILI risk than Ligand A (69.135). This is a *major* advantage for Ligand B. DILI is a critical safety concern.
**8. BBB Penetration:** Both ligands have similar BBB penetration (Ligand A: 70.997, Ligand B: 73.827). While not a primary concern for a cardiovascular target, higher BBB penetration isn't detrimental.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual. This suggests poor permeability. Ligand A (-5.18) is slightly worse than Ligand B (-4.837).
**10. Aqueous Solubility:** Ligand B (-1.787) is better than Ligand A (-3.561). Better solubility is always preferred for formulation and bioavailability.
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (Ligand A: 0.904, Ligand B: 0.147). Ligand B is clearly better here.
**12. Microsomal Clearance:** Ligand B (21.181) has a higher microsomal clearance than Ligand A (5.015), meaning it's metabolized faster. This is a disadvantage for Ligand B.
**13. In vitro Half-Life:** Ligand A (18.044) has a significantly longer in vitro half-life than Ligand B (6.471). This is a significant advantage for Ligand A.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (Ligand A: 0.358, Ligand B: 0.015). Ligand B is slightly better here.
**15. Binding Affinity:** Ligand B (-6.4) has a slightly better binding affinity than Ligand A (-6.0). While the difference is small, it's still a positive for Ligand B.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity) and general drug-like properties, Ligand B is the more promising candidate. The significantly lower DILI risk and better solubility are major advantages. While Ligand A has a longer half-life, the safety profile of Ligand B outweighs this benefit. The slightly better affinity of Ligand B also contributes to its preference. The Caco-2 permeability is a concern for both, but can be addressed through formulation strategies.
Output:
0
2025-04-17 22:21:55,494 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.463 and 351.491 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (85.25) is slightly higher than Ligand B (70.67). Both are below 140, acceptable for oral absorption, but Ligand B is preferable due to the lower TPSA.
3. **logP:** Both ligands (1.347 and 1.153) are within the optimal 1-3 range. No significant difference.
4. **HBD:** Both ligands have 2 H-bond donors, which is good.
5. **HBA:** Ligand A has 5 H-bond acceptors, while Ligand B has 4. Both are acceptable (<=10), but Ligand B is slightly preferred.
6. **QED:** Both ligands have good QED scores (0.667 and 0.722), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (13.106) has a significantly lower DILI risk than Ligand B (18.418). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (74.835) has a better BBB penetration percentile than Ligand A (62.621). Given ADRB2 is a GPCR, BBB penetration is a consideration, favoring Ligand B.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.048 and -4.864), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Both ligands have negative solubility values (-1.006 and -2.041), indicating very poor aqueous solubility. This is a significant drawback for both.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.358 and 0.34), which is excellent.
12. **Cl_mic:** Ligand A (30.133) has a lower microsomal clearance than Ligand B (42.962), suggesting better metabolic stability. This is a positive for Ligand A.
13. **t1/2:** Ligand A (-8.386) has a slightly worse in vitro half-life than Ligand B (-0.637).
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.029 and 0.039), which is good.
15. **Binding Affinity:** Ligand B (-8.3) has a slightly better binding affinity than Ligand A (-6.7). This is a 1.6 kcal/mol difference, which is significant and can outweigh some ADME drawbacks.
**Overall Assessment:**
The decision is challenging. Ligand A has a much lower DILI risk and better metabolic stability (lower Cl_mic). Ligand B has better BBB penetration, a slightly better QED, and a significantly stronger binding affinity. Both have poor solubility and Caco-2 permeability.
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), the stronger binding affinity of Ligand B (-8.3 kcal/mol) is a crucial advantage. While the DILI risk is higher, it's not excessively high (18.418). The improved affinity is likely to translate to a lower required dose, potentially mitigating some of the DILI risk. The slightly better BBB penetration is also beneficial. The solubility and permeability issues are concerning for both, but could be addressed with formulation strategies.
Output:
0
2025-04-17 22:21:55,495 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (454.312 Da) is within the ideal range, while Ligand B (368.371 Da) is also good, being on the lower end. No strong preference here.
2. **TPSA:** Both ligands (A: 71.94, B: 69.64) are below the 140 threshold for good oral absorption, and acceptable for a GPCR.
3. **logP:** Both ligands have good logP values (A: 2.905, B: 1.959) falling within the optimal 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Both have 2 HBD, which is acceptable.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 3. Both are below the 10 threshold.
6. **QED:** Both ligands have QED values above 0.5 (A: 0.699, B: 0.508), indicating good drug-likeness.
7. **DILI:** Ligand A (53.199) has a higher DILI risk than Ligand B (33.695). This is a significant negative for Ligand A.
8. **BBB:** Both have similar BBB penetration (A: 57.658, B: 54.478). While not CNS-focused, some degree of BBB penetration isn't necessarily detrimental for a peripheral GPCR like ADRB2.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and could indicate issues with permeability prediction. However, the values are similar (-5.594 for A, -4.833 for B).
10. **Solubility:** Both have negative solubility values, indicating poor aqueous solubility. Ligand B (-1.505) is slightly better than Ligand A (-3.186).
11. **hERG:** Both ligands have low hERG risk (A: 0.465, B: 0.499).
12. **Cl_mic:** Ligand B (0.544 mL/min/kg) has significantly lower microsomal clearance than Ligand A (22.426 mL/min/kg), indicating better metabolic stability. This is a major advantage for Ligand B.
13. **t1/2:** Ligand B (-2.894 hours) has a negative in vitro half-life, which is concerning. Ligand A (26.876 hours) has a good half-life.
14. **Pgp:** Both have low Pgp efflux (A: 0.28, B: 0.066), which is good.
15. **Binding Affinity:** Ligand B (-7.1 kcal/mol) has a slightly better binding affinity than Ligand A (-6.8 kcal/mol). While the difference is not massive, it's enough to consider.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are important. Both ligands perform reasonably well on these parameters. However, metabolic stability (Cl_mic) is crucial, and Ligand B significantly outperforms Ligand A in this regard. The lower DILI risk for Ligand B is also a significant advantage. Although Ligand A has a better half-life, the other factors weigh more heavily in favor of Ligand B.
**Conclusion:**
Considering the balance of properties, particularly the lower DILI risk and significantly improved metabolic stability of Ligand B, it is the more promising drug candidate.
Output:
0
2025-04-17 22:21:55,495 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [343.427, 82.53, 1.065, 2, 4, 0.838, 18.922, 45.909, -5.074, -2.09, 0.205, -4.231, -1.663, 0.017, -5.0]
**Ligand B:** [342.447, 67.98, 1.338, 1, 6, 0.805, 29.081, 37.263, -4.777, -2.091, 0.181, 19.685, 12.736, 0.031, -5.7]
Here's a breakdown, considering the guidelines and GPCR priorities (logP, Pgp, TPSA, affinity):
1. **MW:** Both are excellent (around 343 Da), falling well within the 200-500 Da range.
2. **TPSA:** Ligand A (82.53) is slightly higher than Ligand B (67.98). Both are acceptable, but Ligand B is preferred due to the lower TPSA, which generally correlates with better membrane permeability.
3. **logP:** Both ligands have good logP values (1.065 and 1.338 respectively), falling within the optimal 1-3 range. Ligand B is slightly better.
4. **HBD/HBA:** Ligand A (2 HBD, 4 HBA) is slightly better than Ligand B (1 HBD, 6 HBA). Lower counts are generally preferred for permeability.
5. **QED:** Both are good (0.838 and 0.805), indicating good drug-like properties.
6. **DILI:** Ligand A (18.922) has a significantly lower DILI risk than Ligand B (29.081). This is a major advantage for Ligand A.
7. **BBB:** Ligand A (45.909) has a slightly better BBB percentile than Ligand B (37.263). While ADRB2 isn't a CNS target, some level of BBB penetration can influence off-target effects and distribution.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual. This suggests poor permeability in the Caco-2 assay. However, the values are similar.
9. **Solubility:** Both have similar, very poor solubility scores (-2.09 and -2.091). This is a significant concern for both compounds.
10. **hERG:** Both have very low hERG risk (0.205 and 0.181).
11. **Cl_mic:** Ligand A (-4.231) has a much lower (better) microsomal clearance than Ligand B (19.685). This indicates better metabolic stability for Ligand A.
12. **t1/2:** Ligand B (12.736) has a longer in vitro half-life than Ligand A (-1.663). This is a positive for Ligand B.
13. **Pgp:** Both have very low Pgp efflux liability (0.017 and 0.031).
14. **Affinity:** Ligand B (-5.7) has a slightly better binding affinity than Ligand A (-5.0). This is a 0.7 kcal/mol difference, which is meaningful.
**Overall Assessment:**
While Ligand B has a slightly better affinity and half-life, Ligand A is significantly better in terms of DILI risk and metabolic stability (Cl_mic). Both have poor solubility, which is a major drawback. Considering the GPCR-specific priorities, the lower TPSA of Ligand B is a plus. However, the substantial difference in DILI risk and Cl_mic outweighs the small advantage in affinity and half-life. A lower DILI risk is crucial for clinical development.
Therefore, I would choose Ligand A.
1
2025-04-17 22:21:55,495 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (349.406) is slightly lower, which is generally favorable for permeability.
**2. TPSA:** Ligand A (76.64) is better than Ligand B (43.18). Lower TPSA generally correlates with better membrane permeability, which is important for GPCR ligands.
**3. logP:** Ligand A (1.522) is within the optimal range (1-3). Ligand B (4.287) is pushing the upper limit and could potentially lead to solubility issues or off-target interactions.
**4. H-Bond Donors:** Ligand A (2) is preferable to Ligand B (0). While both are acceptable, a small number of HBDs can help with solubility without drastically hindering permeability.
**5. H-Bond Acceptors:** Ligand A (3) is preferable to Ligand B (6). Similar to HBDs, a lower number of HBAs is generally preferred for permeability.
**6. QED:** Ligand A (0.869) is significantly better than Ligand B (0.641), indicating a more drug-like profile.
**7. DILI:** Both ligands have similar, acceptable DILI risk (Ligand A: 36.254, Ligand B: 37.999).
**8. BBB:** Ligand A (78.48) is slightly better than Ligand B (71.462), although both are reasonably good. For a cardiovascular target, BBB penetration isn't *critical* but can be beneficial for understanding off-target effects.
**9. Caco-2 Permeability:** Ligand A (-4.769) is better than Ligand B (-4.954), indicating slightly better intestinal absorption.
**10. Aqueous Solubility:** Ligand A (-2.721) is better than Ligand B (-4.285), which is important for formulation and bioavailability.
**11. hERG Inhibition:** Ligand A (0.544) is significantly better than Ligand B (0.838), indicating a lower risk of cardiotoxicity. This is *crucial* for a cardiovascular target.
**12. Microsomal Clearance:** Ligand A (5.875) is much better than Ligand B (82.208), indicating significantly better metabolic stability.
**13. In vitro Half-Life:** Ligand A (-12.101) is better than Ligand B (-7.209), suggesting a longer half-life.
**14. P-gp Efflux:** Ligand A (0.037) is much better than Ligand B (0.73), indicating lower P-gp efflux and improved bioavailability.
**15. Binding Affinity:** Ligand B (-7.0) has a slightly better binding affinity than Ligand A (-8.2). However, the difference is not substantial enough to outweigh the significant ADME advantages of Ligand A.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most crucial ADME properties (solubility, permeability, metabolic stability, efflux, hERG). While Ligand B has a slightly better binding affinity, the superior overall profile of Ligand A makes it the more promising drug candidate. The lower hERG risk and improved metabolic stability are particularly important for a cardiovascular target.
Output:
1
2025-04-17 22:21:55,495 - INFO - Batch 326 complete. Total preferences: 5216
2025-04-17 22:21:55,495 - INFO - Processing batch 327/512...
2025-04-17 22:22:45,157 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.41 and 350.419 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (101.21) is slightly higher than Ligand B (97.76). Both are below the 140 threshold for good oral absorption, but closer to the 90 threshold for CNS targets (less relevant for ADRB2, a cardiovascular target).
3. **logP:** Ligand A (1.308) and Ligand B (1.627) are both within the optimal 1-3 range. Ligand B is slightly more lipophilic.
4. **HBD:** Ligand A (2) is preferable to Ligand B (3). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (8). Lower HBA generally improves permeability.
6. **QED:** Ligand A (0.806) has a significantly better QED score than Ligand B (0.651), indicating a more drug-like profile.
7. **DILI:** Ligand B (57.697) has a lower DILI risk than Ligand A (49.283), which is a positive.
8. **BBB:** Ligand A (90.772) has a much higher BBB penetration percentile than Ligand B (54.246). While ADRB2 isn't a CNS target, higher BBB is rarely detrimental, and can indicate better overall permeability.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.172 and -5.22), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Both ligands have negative solubility values (-2.912 and -2.645), also unusual and indicating poor aqueous solubility. This is a significant concern for both.
11. **hERG:** Ligand A (0.377) has a lower hERG inhibition liability than Ligand B (0.69), which is a positive.
12. **Cl_mic:** Ligand A (2.823) has a significantly lower microsomal clearance than Ligand B (51.844), indicating better metabolic stability.
13. **t1/2:** Ligand A (-20.936) has a much longer in vitro half-life than Ligand B (54.325), which is a significant advantage.
14. **Pgp:** Ligand A (0.023) has a much lower P-gp efflux liability than Ligand B (0.051), suggesting better oral bioavailability.
15. **Binding Affinity:** Ligand A (-6.6) has a slightly better binding affinity than Ligand B (-5.3). This difference is substantial enough to be a key factor.
**GPCR-specific priorities:** For ADRB2 (a cardiovascular GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A performs better on most of these. While BBB isn't crucial, Ligand A's higher value isn't a detriment.
**Overall Assessment:**
Ligand A is significantly better overall. It has a superior QED score, better metabolic stability (lower Cl_mic, longer t1/2), lower P-gp efflux, better hERG profile, and a slightly stronger binding affinity. The negative Caco-2 and solubility values are concerning for both, but the other advantages of Ligand A outweigh these drawbacks.
Output:
1
2025-04-17 22:22:45,158 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (366.853 Da and 354.451 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (75.52) is significantly better than Ligand B (116.6). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold. Ligand B is approaching the upper limit.
3. **logP:** Both ligands have good logP values (2.215 and 1.083), falling within the optimal 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (4). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (6) is preferable to Ligand B (7). Fewer HBAs generally improve permeability.
6. **QED:** Ligand A (0.813) is significantly better than Ligand B (0.497). A higher QED indicates a more drug-like profile.
7. **DILI:** Ligand A (69.95) is worse than Ligand B (34.122). This is a significant drawback for Ligand A. Lower DILI is crucial.
8. **BBB:** Ligand A (70.26) is better than Ligand B (56.883), but this isn't a primary concern for a cardiovascular target.
9. **Caco-2:** Ligand A (-4.803) is better than Ligand B (-5.022). Both are negative, indicating poor permeability.
10. **Solubility:** Ligand A (-2.587) is better than Ligand B (-2.344). Both are poor, but A is slightly better.
11. **hERG:** Both ligands have low hERG inhibition liability (0.301 and 0.335), which is good.
12. **Cl_mic:** Ligand A (53.93) is better than Ligand B (57.979). Lower clearance is preferred for metabolic stability.
13. **t1/2:** Ligand A (77.075) is significantly better than Ligand B (-13.986). A longer half-life is desirable.
14. **Pgp:** Both ligands have similar Pgp efflux liability (0.136 and 0.09).
15. **Binding Affinity:** Ligand B (-6.4) is slightly better than Ligand A (-5.6). A 0.8 kcal/mol difference is meaningful, but not overwhelming.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand A has a better logP and TPSA, while Ligand B has slightly better affinity. However, the significantly better QED, lower HBD/HBA, and longer half-life of Ligand A are very attractive. The biggest concern with Ligand A is its higher DILI risk. However, the difference in binding affinity isn't large enough to outweigh the other advantages of Ligand A, especially considering the DILI risk of Ligand B is substantially lower.
**Conclusion:**
Despite the higher DILI risk, Ligand A presents a more balanced profile with better predicted absorption, drug-likeness, and metabolic stability. The affinity difference is not large enough to overcome these advantages.
Output:
1
2025-04-17 22:22:45,158 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**1. Molecular Weight:** Both ligands (359.853 Da and 352.406 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (58.56) is significantly better than Ligand B (70.08). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand A is well below the 90 A^2 threshold, while Ligand B is getting closer to the 140 A^2 limit for good oral absorption.
**3. logP:** Ligand A (4.108) is higher than Ligand B (0.054). While 4.108 is towards the upper end of the optimal range, it's still acceptable. Ligand B's logP is very low, which raises concerns about permeability and potentially bioavailability.
**4. H-Bond Donors:** Ligand A (2) and Ligand B (1) are both within the acceptable limit of 5.
**5. H-Bond Acceptors:** Ligand A (3) and Ligand B (4) are both within the acceptable limit of 10.
**6. QED:** Both ligands have similar QED values (0.867 and 0.686), indicating good drug-like properties.
**7. DILI:** Ligand A (67.895) has a higher DILI risk than Ligand B (16.13). This is a significant drawback for Ligand A.
**8. BBB:** Ligand A (67.197) and Ligand B (74.06) both have good BBB penetration, but Ligand B is better. While ADRB2 isn't exclusively a CNS target, some degree of BBB penetration can be useful for understanding off-target effects and overall distribution.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.575 and -4.467). This is unusual and suggests a potential issue with the experimental setup or a very poor permeability prediction. However, the values are very close, so it's not a deciding factor.
**10. Aqueous Solubility:** Ligand A (-5.424) has worse solubility than Ligand B (-2.332). Solubility is important for formulation and bioavailability.
**11. hERG Inhibition:** Ligand A (0.69) has a slightly higher hERG risk than Ligand B (0.255), but both are relatively low.
**12. Microsomal Clearance:** Ligand A (28.055) has a higher microsomal clearance than Ligand B (6.713), indicating faster metabolism and potentially a shorter half-life.
**13. In vitro Half-Life:** Ligand A (82.6) has a much longer in vitro half-life than Ligand B (3.783). This is a significant advantage for Ligand A.
**14. P-gp Efflux:** Ligand A (0.574) has lower P-gp efflux than Ligand B (0.044), which is favorable for bioavailability.
**15. Binding Affinity:** Ligand A (-7.0) has a slightly better binding affinity than Ligand B (-6.0). While the difference is not huge, it is still a benefit.
**Overall Assessment:**
Ligand B is the better candidate. While Ligand A has a better half-life and binding affinity, the significantly higher DILI risk, poorer solubility, and lower P-gp efflux are major concerns. Ligand B, despite its lower logP, has a much better safety profile (lower DILI) and better solubility, which are crucial for drug development. The slightly better BBB penetration of Ligand B is also a plus. The low logP of Ligand B could be addressed with further structural modifications.
Output:
0
2025-04-17 22:22:45,158 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (371.706) is slightly higher than Ligand B (347.415), but both are acceptable.
2. **TPSA:** Ligand A (99.81) is slightly higher than Ligand B (80.76), but both are below the 140 A^2 threshold for good oral absorption.
3. **logP:** Both ligands have good logP values (Ligand A: 1.888, Ligand B: 1.26), falling within the optimal range of 1-3.
4. **HBD:** Ligand A (2) and Ligand B (1) both meet the HBD criteria (<=5). Ligand B is slightly better.
5. **HBA:** Both ligands have 5 HBA, which is acceptable (<=10).
6. **QED:** Ligand A (0.805) has a significantly better QED score than Ligand B (0.593), indicating a more drug-like profile.
7. **DILI:** Ligand B (37.611) has a much lower DILI risk than Ligand A (87.864). This is a significant advantage for Ligand B.
8. **BBB:** Ligand B (69.407) has a better BBB penetration score than Ligand A (48.391). While ADRB2 isn't exclusively a CNS target, some cardiovascular effects are mediated by central pathways, and better BBB penetration can be beneficial.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
10. **Solubility:** Ligand B (-1.846) has a better solubility score than Ligand A (-4.387).
11. **hERG:** Ligand A (0.157) has a lower hERG inhibition liability than Ligand B (0.324), which is preferable.
12. **Cl_mic:** Ligand A (-2.315) has a lower (better) microsomal clearance than Ligand B (12.986), indicating greater metabolic stability.
13. **t1/2:** Ligand A (13.25) has a longer in vitro half-life than Ligand B (-18.371). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.098) has lower P-gp efflux liability than Ligand B (0.031), suggesting better oral bioavailability.
15. **Binding Affinity:** Ligand A (-6.7 kcal/mol) has a slightly better binding affinity than Ligand B (-5.4 kcal/mol).
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A has a slight edge in affinity and Pgp, while Ligand B has better logP, TPSA, and BBB. However, the DILI risk for Ligand A is concerningly high.
**Overall Assessment:**
Ligand B has a much better safety profile (lower DILI) and better solubility, BBB penetration, and TPSA. While Ligand A has a slightly better affinity and half-life, the high DILI risk and worse solubility are major drawbacks. The difference in affinity is not substantial enough to outweigh the safety concerns.
Output:
0
2025-04-17 22:22:45,158 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [346.471, 58.64, 2.732, 1, 3, 0.787, 29.081, 75.727, -4.671, -2.771, 0.714, 70.533, 19.253, 0.206, -5.3]
**Ligand B:** [369.849, 84.67, 2.644, 1, 5, 0.534, 38.581, 89.608, -4.582, -3.256, 0.364, 61.896, -0.654, 0.122, -5.2]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal 200-500 Da range. A (346.471) is slightly preferred.
2. **TPSA:** A (58.64) is excellent, well below 140, and good for GPCRs. B (84.67) is still acceptable but less ideal.
3. **logP:** Both are within the optimal 1-3 range. A (2.732) and B (2.644) are comparable.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** A (3) is better than B (5). Lower HBA is generally preferred for permeability.
6. **QED:** A (0.787) is significantly better than B (0.534), indicating a more drug-like profile.
7. **DILI:** A (29.081) is much better than B (38.581), indicating a lower risk of liver injury.
8. **BBB:** A (75.727) is good, while B (89.608) is even better. For a cardiovascular target, BBB isn't *critical*, but higher is still a positive.
9. **Caco-2:** Both are negative, indicating poor permeability. This is a significant concern for both.
10. **Solubility:** Both are negative, indicating poor solubility. This is also a significant concern for both.
11. **hERG:** A (0.714) is better than B (0.364), indicating lower cardiotoxicity risk.
12. **Cl_mic:** A (70.533) is better than B (61.896), suggesting better metabolic stability.
13. **t1/2:** A (19.253) is much better than B (-0.654), indicating a significantly longer half-life.
14. **Pgp:** A (0.206) is better than B (0.122), suggesting lower P-gp efflux.
15. **Affinity:** Both have very similar and excellent binding affinities (-5.3 and -5.2 kcal/mol). The difference is negligible.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, we prioritize logP, TPSA, Pgp, and affinity. Both ligands perform similarly on logP and affinity. A has a better TPSA and Pgp profile. The significant advantages of Ligand A in QED, DILI, hERG, Cl_mic, and t1/2 outweigh the slightly better BBB penetration of Ligand B. The poor Caco-2 and solubility are concerning for both, but can be addressed with formulation strategies.
**Conclusion:**
Ligand A is the more promising candidate due to its superior ADME-Tox profile (QED, DILI, hERG, Cl_mic, t1/2, Pgp) and comparable binding affinity.
**Output:**
1
2025-04-17 22:22:45,159 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (348.403 Da) is well within the ideal range (200-500 Da). Ligand B (420.294 Da) is also acceptable, but approaching the upper limit.
2. **TPSA:** Ligand A (113.76) is good for oral absorption, under the 140 threshold. Ligand B (47.56) is excellent, suggesting good permeability.
3. **logP:** Ligand A (-0.021) is a bit low, potentially hindering membrane permeability. Ligand B (4.654) is high, potentially causing solubility issues and off-target effects.
4. **HBD:** Ligand A (3) is within the acceptable range. Ligand B (1) is also good.
5. **HBA:** Ligand A (5) is within the acceptable range. Ligand B (4) is also good.
6. **QED:** Ligand A (0.668) is good, indicating a drug-like profile. Ligand B (0.467) is lower, suggesting a less ideal drug-like profile.
7. **DILI:** Ligand A (17.72) has a very low DILI risk. Ligand B (20.706) is also low, but slightly higher than A.
8. **BBB:** Ligand A (69.213) is moderate. Ligand B (89.027) is good, indicating better potential for CNS penetration, although ADRB2 is primarily a cardiovascular target, so this is less critical.
9. **Caco-2:** Ligand A (-5.586) is poor. Ligand B (-4.485) is also poor, but slightly better.
10. **Solubility:** Ligand A (-1.483) is poor. Ligand B (-5.029) is very poor.
11. **hERG:** Ligand A (0.208) has a low hERG risk. Ligand B (0.877) has a slightly higher, but still acceptable, hERG risk.
12. **Cl_mic:** Ligand A (-34.079) has a very low (good) microsomal clearance, indicating good metabolic stability. Ligand B (84.629) has a high (bad) clearance, indicating poor metabolic stability.
13. **t1/2:** Ligand A (-13.719) has a short in vitro half-life. Ligand B (46.179) has a long in vitro half-life.
14. **Pgp:** Ligand A (0.003) has very low P-gp efflux. Ligand B (0.374) has moderate P-gp efflux.
15. **Affinity:** Ligand A (-8.4 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.5 kcal/mol). This is a >1.5 kcal/mol difference, which is a substantial advantage.
**GPCR-specific considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. While Ligand B has a better TPSA and BBB, its high logP and poor solubility are concerning. Ligand A's lower logP is a drawback, but its significantly stronger affinity and excellent metabolic stability (low Cl_mic) are major advantages. The difference in affinity is large enough to potentially overcome the slightly lower logP, and formulation strategies can be employed to address solubility.
**Conclusion:**
Despite Ligand B's slightly better BBB and TPSA, Ligand A is the more promising candidate due to its significantly higher binding affinity, better metabolic stability, lower DILI risk, and very low P-gp efflux. The solubility and logP issues with Ligand A are addressable through formulation and further optimization, whereas the large affinity gap is harder to close.
Output:
1
2025-04-17 22:22:45,159 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [421.646, 113.41 , 2.412, 3. , 7. , 0.438, 99.341, 40.791, -5.581, -4.629, 0.396, 2.602, 108.187, 0.222, -6.5 ]**
**Ligand B: [353.495, 62.73 , 4.751, 2. , 6. , 0.693, 77.549, 73.866, -5.255, -4.742, 0.633, 90.875, 59.643, 0.46 , -6.4 ]**
1. **Molecular Weight:** Ligand A (421.646 Da) is within the ideal range, while Ligand B (353.495 Da) is also acceptable, but closer to the lower limit. No strong preference here.
2. **TPSA:** Ligand A (113.41) is slightly above the preferred <140 for oral absorption, but still reasonable. Ligand B (62.73) is excellent, well below 140. This favors Ligand B.
3. **logP:** Ligand A (2.412) is optimal. Ligand B (4.751) is pushing the upper limit and could potentially lead to solubility issues or off-target interactions. This favors Ligand A.
4. **H-Bond Donors:** Both ligands have acceptable HBD counts (3 and 2 respectively). No strong preference.
5. **H-Bond Acceptors:** Both ligands have acceptable HBA counts (7 and 6 respectively). No strong preference.
6. **QED:** Ligand B (0.693) has a better QED score than Ligand A (0.438), indicating a more drug-like profile. This favors Ligand B.
7. **DILI:** Ligand A (99.341) has a very high DILI risk, which is a major concern. Ligand B (77.549) has a much lower, and acceptable, DILI risk. This *strongly* favors Ligand B.
8. **BBB:** Ligand B (73.866) has a good BBB penetration percentile, while Ligand A (40.791) is lower. Considering ADRB2 is a GPCR, BBB penetration is a relevant factor, favoring Ligand B.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Both ligands have negative solubility values, which is also unusual and suggests poor solubility. This is a concern for both.
11. **hERG:** Both ligands have low hERG inhibition liability. No strong preference.
12. **Cl_mic:** Ligand A (2.602) has a lower microsomal clearance than Ligand B (90.875), indicating better metabolic stability. This favors Ligand A.
13. **t1/2:** Ligand A (108.187) has a significantly longer in vitro half-life than Ligand B (59.643). This favors Ligand A.
14. **Pgp:** Ligand A (0.222) has lower P-gp efflux liability than Ligand B (0.46), suggesting better bioavailability. This favors Ligand A.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.5 and -6.4 kcal/mol). The difference is negligible.
**Overall Assessment:**
While Ligand A has advantages in metabolic stability (Cl_mic, t1/2) and Pgp efflux, the extremely high DILI risk (99.341) is a critical flaw. Ligand B, despite a slightly higher logP and lower metabolic stability, presents a much more favorable safety profile (lower DILI) and better BBB penetration, both important for a GPCR target. The TPSA is also significantly better for Ligand B. The similar binding affinities make the ADME/Tox profile the deciding factor.
Output:
0
2025-04-17 22:22:45,159 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (354.451 and 347.419 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (107.7) is better than Ligand B (110.32). Both are reasonably good for oral absorption, but lower is preferable.
3. **logP:** Ligand B (0.041) is very low, potentially hindering permeability. Ligand A (0.102) is also low, but slightly better. Both are below the optimal 1-3 range. This is a concern for both.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (2), but both are within the acceptable limit of 5.
5. **HBA:** Ligand A (6) is slightly higher than Ligand B (5), but both are within the acceptable limit of 10.
6. **QED:** Ligand B (0.783) has a significantly better QED score than Ligand A (0.55), indicating a more drug-like profile.
7. **DILI:** Ligand A (13.067) has a much lower DILI risk than Ligand B (43.66), which is a substantial advantage.
8. **BBB:** Ligand B (55.138) has a higher BBB penetration percentile than Ligand A (13.765). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be useful for understanding off-target effects and overall distribution.
9. **Caco-2:** Both ligands have very negative Caco-2 values (-5.536 and -5.487), which is unusual and suggests poor permeability. This is a significant drawback for both.
10. **Solubility:** Ligand A (-0.656) has slightly better solubility than Ligand B (-2.339), but both are quite poor.
11. **hERG:** Ligand A (0.046) has a much lower hERG inhibition liability than Ligand B (0.132), a critical advantage for cardiovascular safety.
12. **Cl_mic:** Ligand B (-1.19) has a significantly lower (better) microsomal clearance than Ligand A (20.86), indicating better metabolic stability.
13. **t1/2:** Ligand A (19.955) has a longer in vitro half-life than Ligand B (15.254), which is desirable.
14. **Pgp:** Ligand A (0.024) has a much lower P-gp efflux liability than Ligand B (0.012), suggesting better oral bioavailability and potentially better CNS exposure.
15. **Binding Affinity:** Both ligands have the same binding affinity (-7.1 kcal/mol), which is excellent.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. While both have excellent affinity, Ligand A has better TPSA and Pgp efflux. Ligand B has a better BBB score, but this isn't a primary concern for a peripheral GPCR like ADRB2. The very low logP values for both are concerning, but Ligand A is slightly better.
**Overall Assessment:**
Ligand A has significant advantages in DILI risk, hERG inhibition, and Pgp efflux, and a better half-life. Ligand B has a better QED and metabolic stability (Cl_mic). However, the low DILI and hERG scores for Ligand A are crucial for a cardiovascular drug target. The slightly better TPSA and Pgp efflux also favor Ligand A. The poor solubility and Caco-2 values are concerning for both, but can potentially be addressed through formulation strategies.
Output:
1
2025-04-17 22:22:45,159 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 drug candidates. ADRB2 is a GPCR, so we'll prioritize logP, Pgp, TPSA, and affinity, alongside general drug-like properties.
**Ligand A:**
* **MW:** 391.43 Da - Good. Within the ideal range.
* **TPSA:** 117.62 A2 - Acceptable, but pushing the limit for oral absorption.
* **logP:** 0.792 - Low. Could hinder permeability.
* **HBD:** 3 - Good.
* **HBA:** 7 - Good.
* **QED:** 0.421 - Below ideal, but not terrible.
* **DILI:** 57.154 - Moderate risk. Acceptable, but needs monitoring.
* **BBB:** 32.028 - Low. Not a concern for a non-CNS target like ADRB2.
* **Caco-2:** -5.746 - Very poor permeability. A major red flag.
* **Solubility:** -1.793 - Poor solubility.
* **hERG:** 0.272 - Low risk. Excellent.
* **Cl_mic:** 13.304 mL/min/kg - Moderate clearance.
* **t1/2:** 17.492 hours - Good.
* **Pgp:** 0.035 - Low efflux. Good.
* **Affinity:** -7.7 kcal/mol - Excellent binding affinity.
**Ligand B:**
* **MW:** 377.941 Da - Good. Within the ideal range.
* **TPSA:** 46.09 A2 - Excellent. Very favorable for absorption.
* **logP:** 4.969 - High. Could lead to solubility issues and off-target effects.
* **HBD:** 0 - Good.
* **HBA:** 4 - Good.
* **QED:** 0.684 - Good.
* **DILI:** 41.334 - Good. Low risk.
* **BBB:** 84.451 - High. Not particularly relevant for ADRB2.
* **Caco-2:** -4.992 - Poor permeability, but better than Ligand A.
* **Solubility:** -5.167 - Very poor solubility.
* **hERG:** 0.689 - Moderate risk.
* **Cl_mic:** 90.208 mL/min/kg - High clearance. Poor metabolic stability.
* **t1/2:** 31.263 hours - Good.
* **Pgp:** 0.721 - Moderate efflux.
* **Affinity:** -6.0 kcal/mol - Good binding affinity, but significantly weaker than Ligand A.
**Comparison and Decision:**
Ligand A has a *much* stronger binding affinity (-7.7 vs -6.0 kcal/mol). This is a substantial difference, and for a GPCR, affinity is paramount. However, its Caco-2 permeability is extremely poor, and its solubility is also low. Ligand B has better permeability and TPSA, but its affinity is considerably weaker, and it has a high logP and high clearance.
Despite the permeability and solubility issues with Ligand A, the significantly better affinity is likely to be more impactful, *especially* in the early stages of drug development. Poor permeability/solubility can be addressed through formulation strategies or further chemical modifications, but improving affinity is often much more challenging. The hERG risk is also very low for Ligand A.
Therefore, I would prioritize Ligand A for further investigation, with a strong focus on addressing its permeability and solubility challenges.
Output:
1
2025-04-17 22:22:45,159 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.5 & 361.5 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (43.86) is better than Ligand B (53.52). Both are below 140, but lower is preferred for absorption.
3. **logP:** Both ligands (2.378 & 2.811) are within the optimal 1-3 range. Ligand B is slightly higher, which could be a minor concern for off-target effects, but not a deal-breaker.
4. **HBD:** Ligand A (0) is better than Ligand B (1). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (3) is better than Ligand B (7). Lower HBA is generally preferred for permeability.
6. **QED:** Ligand B (0.904) is better than Ligand A (0.716). Higher QED indicates better overall drug-likeness.
7. **DILI:** Ligand A (6.747) is significantly better than Ligand B (72.043). This is a major advantage for Ligand A. A DILI percentile over 60 is a significant concern.
8. **BBB:** Both ligands have high BBB penetration (81.931 & 84.878). This is good, but less critical for ADRB2 which is not a CNS target.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.581 & -4.675). This is unusual and suggests poor permeability.
10. **Solubility:** Ligand A (-1.745) is better than Ligand B (-3.369). Higher solubility is generally preferred.
11. **hERG:** Ligand A (0.541) is better than Ligand B (0.876). Lower hERG inhibition is crucial for avoiding cardiotoxicity, especially important for a cardiovascular target like ADRB2.
12. **Cl_mic:** Ligand A (23.907) is better than Ligand B (34.288). Lower clearance is preferred for better metabolic stability.
13. **t1/2:** Ligand B (32.228) is significantly better than Ligand A (-5.92). A longer half-life is desirable.
14. **Pgp:** Ligand A (0.046) is better than Ligand B (0.076). Lower P-gp efflux is preferred.
15. **Binding Affinity:** Ligand B (-5.1) is slightly better than Ligand A (-5.4). While a difference of 0.3 kcal/mol is not huge, it is a positive for Ligand B.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Both ligands are reasonably good in these areas. However, the significant advantage of Ligand A in DILI risk and hERG inhibition, coupled with its better TPSA, HBD, HBA, solubility, and clearance, outweighs the slightly better affinity and half-life of Ligand B. The DILI risk for Ligand B is a major red flag.
**Conclusion:**
Ligand A presents a more favorable overall profile, particularly regarding safety (DILI, hERG) and ADME properties.
Output:
1
2025-04-17 22:22:45,160 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 GPCR, followed by the final output.
**Ligand A: [335.407, 61.44, 2.242, 2, 3, 0.904, 65.917, 74.292, -4.92, -4.55, 0.755, 30.593, 67.889, 0.463, -6.1]**
**Ligand B: [359.861, 71.84, 3.01, 2, 4, 0.806, 51.377, 70.997, -5.009, -3.297, 0.15, 6.191, 19.912, 0.09, -7.2]**
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (335.4) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (61.44) is better than Ligand B (71.84). Both are acceptable, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (A: 2.242, B: 3.01), falling within the optimal 1-3 range. Ligand B is slightly higher, which could potentially lead to off-target effects but isn't a major concern.
4. **H-Bond Donors:** Both have 2 HBD, which is within the acceptable limit of 5.
5. **H-Bond Acceptors:** Ligand A (3) is better than Ligand B (4), keeping within the ideal range of 10 or less.
6. **QED:** Ligand A (0.904) has a slightly better QED score than Ligand B (0.806), indicating a more drug-like profile.
7. **DILI:** Ligand A (65.917) has a higher DILI risk than Ligand B (51.377). This is a significant drawback for Ligand A.
8. **BBB:** Both ligands have good BBB penetration (A: 74.292, B: 70.997), which is important for GPCRs, though less critical for ADRB2 specifically as it's primarily cardiovascular.
9. **Caco-2 Permeability:** Both show poor Caco-2 permeability (A: -4.92, B: -5.009). This is a concern for oral bioavailability.
10. **Aqueous Solubility:** Ligand B (-3.297) is better than Ligand A (-4.55). Solubility is important for formulation.
11. **hERG Inhibition:** Ligand A (0.755) has a higher hERG risk than Ligand B (0.15). This is a major concern for Ligand A, raising cardiotoxicity flags.
12. **Microsomal Clearance:** Ligand B (6.191) has a lower (better) microsomal clearance than Ligand A (30.593), suggesting better metabolic stability.
13. **In vitro Half-Life:** Ligand A (67.889) has a better in vitro half-life than Ligand B (19.912).
14. **P-gp Efflux:** Ligand B (0.09) has lower P-gp efflux than Ligand A (0.463), which is beneficial for bioavailability.
15. **Binding Affinity:** Ligand B (-7.2) has a significantly better binding affinity than Ligand A (-6.1). This is a substantial advantage, potentially outweighing some ADME concerns.
**Overall Assessment:**
Ligand B is the stronger candidate. While both have issues with Caco-2 permeability, Ligand B has a significantly better binding affinity, lower DILI risk, lower hERG risk, better metabolic stability, and lower P-gp efflux. The superior binding affinity is a key advantage for a GPCR target. Ligand A's higher DILI and hERG risks are significant liabilities.
Output:
0
2025-04-17 22:22:45,160 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (349.391) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (69.64) is significantly better than Ligand A (107.77). ADRB2 is a GPCR, and lower TPSA is preferred for better permeability and potential BBB penetration.
3. **logP:** Ligand B (1.97) is within the optimal range, while Ligand A (-1.264) is below 1, potentially hindering permeation. This is a significant advantage for Ligand B.
4. **HBD:** Both have 2 HBD, which is acceptable.
5. **HBA:** Ligand A has 6 HBA, and Ligand B has 5. Both are within the acceptable limit of 10.
6. **QED:** Both ligands have good QED scores (A: 0.69, B: 0.812), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (25.553) has a much lower DILI risk than Ligand B (34.665). This is a significant advantage for Ligand A.
8. **BBB:** Ligand B (66.382) has a better BBB percentile than Ligand A (49.011), but neither is particularly high. For a cardiovascular target, BBB penetration isn't a primary concern, but it's a slight edge for B.
9. **Caco-2:** Both have similar negative Caco-2 values (-5.197 and -5.072), suggesting poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-0.795) has slightly better solubility than Ligand B (-2.954).
11. **hERG:** Both have low hERG risk (A: 0.204, B: 0.492).
12. **Cl_mic:** Ligand A (-8.111) has significantly lower (better) microsomal clearance than Ligand B (10.106), indicating better metabolic stability.
13. **t1/2:** Ligand B (6.153) has a longer half-life than Ligand A (-3.856). This is a positive for Ligand B.
14. **Pgp:** Ligand A (0.013) has much lower P-gp efflux liability than Ligand B (0.246), which is a significant advantage.
15. **Binding Affinity:** Ligand B (-8.0) has a slightly better binding affinity than Ligand A (-5.8). This is a 2.2 kcal/mol difference, which is substantial.
**Overall Assessment:**
Considering ADRB2 is a GPCR, logP, TPSA, and binding affinity are key. Ligand B excels in logP and binding affinity, which are crucial. However, Ligand A has a much better safety profile (DILI) and metabolic stability (Cl_mic) and lower P-gp efflux. While the affinity difference is significant, the combination of better safety, metabolic stability, and efflux profile of Ligand A, coupled with its acceptable (though not ideal) TPSA and logP, makes it the more promising candidate. The poor Caco-2 values are a concern for both, but can be addressed with formulation strategies.
Output:
1
2025-04-17 22:22:45,160 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.475 and 360.445 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (83.22) is higher than Ligand B (49.85). While both are reasonably good, Ligand B is significantly better, falling well below the 140 threshold for good absorption and potentially allowing for better BBB penetration.
3. **logP:** Both ligands have good logP values (2.562 and 2.196), falling within the optimal 1-3 range. Ligand B is slightly lower, which could be beneficial for solubility.
4. **HBD:** Ligand A has 3 HBD, while Ligand B has 0. Lower HBD is generally preferred for permeability, giving a slight edge to Ligand B.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 3. Both are within the acceptable range of <=10.
6. **QED:** Both ligands have similar QED values (0.73 and 0.624), indicating good drug-likeness.
7. **DILI:** Ligand B (21.287) has a much lower DILI risk than Ligand A (46.297). This is a significant advantage for Ligand B.
8. **BBB:** Ligand B (93.68) has a much higher BBB penetration percentile than Ligand A (54.556). Given that ADRB2 is a GPCR, and while not necessarily a CNS target, some degree of BBB penetration can be helpful for distribution and off-target effects profiling. This is a major advantage for Ligand B.
9. **Caco-2:** Ligand A (-5.104) and Ligand B (-4.347) are both negative, indicating poor permeability. However, Ligand B is slightly less negative.
10. **Solubility:** Ligand A (-2.407) and Ligand B (-1.705) both have poor solubility. Ligand B is slightly better.
11. **hERG:** Both ligands have relatively low hERG inhibition liability (0.617 and 0.722), which is good.
12. **Cl_mic:** Ligand A (22.973) has a lower microsomal clearance than Ligand B (42.145), suggesting better metabolic stability. This is a positive for Ligand A.
13. **t1/2:** Ligand A (13.555) has a longer in vitro half-life than Ligand B (9.985). This is a positive for Ligand A.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.061 and 0.294).
15. **Binding Affinity:** Ligand A (-7.7) has a significantly stronger binding affinity than Ligand B (-6.2). This is a substantial advantage for Ligand A (1.5 kcal/mol difference).
**Overall Assessment:**
Ligand A has a significantly better binding affinity and better metabolic stability (lower Cl_mic and longer t1/2). However, Ligand B excels in ADME properties crucial for a GPCR target: lower TPSA, lower DILI risk, and significantly higher BBB penetration. The affinity difference is substantial, but the ADME profile of Ligand B is considerably more favorable. Given the balance, the improved ADME properties of Ligand B, particularly the lower DILI and higher BBB, outweigh the affinity difference.
Output:
0
2025-04-17 22:22:45,160 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (403.226 Da) is within the ideal range. Ligand B (352.431 Da) is also within the ideal range, slightly lower. No clear advantage here.
2. **TPSA:** Ligand A (41.99) is good, well below the 140 threshold. Ligand B (100.8) is still reasonable but higher, potentially impacting absorption. This favors Ligand A.
3. **logP:** Ligand A (4.695) is a bit high, potentially leading to solubility issues or off-target interactions. Ligand B (1.744) is excellent, within the optimal range. This favors Ligand B.
4. **HBD:** Ligand A (1) is good. Ligand B (3) is acceptable, but higher. This favors Ligand A.
5. **HBA:** Ligand A (2) is good. Ligand B (5) is acceptable, but higher. This favors Ligand A.
6. **QED:** Both ligands (A: 0.689, B: 0.628) have good drug-likeness scores, above the 0.5 threshold. No significant difference.
7. **DILI:** Ligand A (79.682) has a higher DILI risk than Ligand B (36.099). This strongly favors Ligand B.
8. **BBB:** Ligand A (88.406) has better BBB penetration than Ligand B (50.795). Given ADRB2 is a GPCR, this is a positive for Ligand A, though not crucial for peripheral targets.
9. **Caco-2:** Ligand A (-4.543) is poor, indicating poor intestinal absorption. Ligand B (-5.028) is also poor, but slightly better. No clear advantage.
10. **Solubility:** Ligand A (-5.516) is poor. Ligand B (-1.683) is better, though still not great. This favors Ligand B.
11. **hERG:** Ligand A (0.555) has a slightly higher hERG risk than Ligand B (0.232). This favors Ligand B.
12. **Cl_mic:** Ligand A (45.623) has a higher microsomal clearance than Ligand B (4.552), indicating lower metabolic stability. This favors Ligand B.
13. **t1/2:** Ligand A (47.83) and Ligand B (48.892) have comparable in vitro half-lives. No significant difference.
14. **Pgp:** Ligand A (0.37) has lower P-gp efflux liability than Ligand B (0.144). This favors Ligand A.
15. **Affinity:** Ligand A (-8.7 kcal/mol) has significantly stronger binding affinity than Ligand B (-6.7 kcal/mol). This is a substantial advantage for Ligand A, potentially outweighing some of its ADME drawbacks.
**Overall Assessment:**
Ligand A has a much stronger binding affinity, which is paramount for GPCR targets. It also has better TPSA, HBD/HBA counts, and Pgp efflux liability. However, it suffers from poor Caco-2 permeability, solubility, and higher DILI risk and Cl_mic. Ligand B has a better ADME profile (lower DILI, better solubility, lower Cl_mic, better logP), but its binding affinity is significantly weaker.
Given the substantial difference in binding affinity (-8.7 vs -6.7 kcal/mol, a difference of 2 kcal/mol), I believe Ligand A is the more promising candidate *despite* its ADME liabilities. The potency advantage is likely to be more easily addressed through medicinal chemistry optimization than significantly improving the affinity of Ligand B. The poor permeability and solubility can be tackled with formulation strategies or structural modifications.
Output:
1
2025-04-17 22:22:45,160 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (345.483 and 358.848 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (47.56) is slightly higher than Ligand B (44.81), but both are well below the 140 threshold for good oral absorption and acceptable for a cardiovascular GPCR.
3. **logP:** Both ligands have logP values (4.112 and 4.416) that are slightly above the optimal 1-3 range, but still within a reasonable window. Ligand B is a bit higher, potentially increasing off-target interactions, but not drastically.
4. **HBD:** Both ligands have 1 H-bond donor, which is within the acceptable limit of 5.
5. **HBA:** Both ligands have 3 H-bond acceptors, also within the acceptable limit of 10.
6. **QED:** Ligand A (0.873) has a significantly better QED score than Ligand B (0.709), indicating a more drug-like profile.
7. **DILI:** Ligand A (23.226) has a much lower DILI risk than Ligand B (44.746). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (85.498) has a higher BBB penetration percentile than Ligand B (66.344). While ADRB2 isn't a primary CNS target, some CNS exposure can contribute to side effects, and better predictability is valuable.
9. **Caco-2:** Ligand A (-4.505) has a more negative Caco-2 value, suggesting *lower* permeability compared to Ligand B (-5.213). This is a negative for Ligand A.
10. **Solubility:** Ligand A (-5.149) has a more negative solubility value, indicating *lower* solubility than Ligand B (-3.959). This is another negative for Ligand A.
11. **hERG:** Ligand A (0.73) has a slightly lower hERG inhibition liability than Ligand B (0.911), which is preferable.
12. **Cl_mic:** Ligand B (53.463) has a significantly lower microsomal clearance than Ligand A (117.498), suggesting better metabolic stability. This is a major advantage for Ligand B.
13. **t1/2:** Ligand B (39.037) has a much longer in vitro half-life than Ligand A (0.59). This is a substantial advantage for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.736) has a slightly lower P-gp efflux liability than Ligand B (0.45), which is preferable.
15. **Binding Affinity:** Ligand B (-7.6 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.8 kcal/mol). This 1.8 kcal/mol difference is substantial and likely outweighs many of the ADME drawbacks of Ligand B.
**Overall Assessment:**
Ligand B clearly wins on potency (binding affinity) and metabolic stability (Cl_mic, t1/2). While Ligand A has advantages in QED, DILI, and BBB, the superior affinity and metabolic profile of Ligand B are more critical for a GPCR target like ADRB2. The slightly higher logP of Ligand B is manageable, and the lower Caco-2 and solubility are potential formulation challenges that can be addressed. The DILI risk is higher for Ligand B, but not excessively so.
Output:
0
2025-04-17 22:22:45,161 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (348.397 and 381.567 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (59.81) is better than Ligand B (66.32). Both are below the 140 threshold for oral absorption, but lower TPSA is generally preferred for GPCRs to facilitate receptor binding.
**3. logP:** Ligand A (3.16) is within the optimal 1-3 range. Ligand B (4.259) is slightly higher, potentially increasing off-target interactions and decreasing solubility.
**4. H-Bond Donors:** Both ligands have 1 HBD, which is good.
**5. H-Bond Acceptors:** Ligand A has 4 HBAs, while Ligand B has 6. Both are acceptable (<=10), but A is slightly better.
**6. QED:** Ligand A (0.927) has a significantly better QED score than Ligand B (0.705), indicating a more drug-like profile.
**7. DILI:** Ligand A (63.086) has a higher DILI risk than Ligand B (36.099). This is a significant drawback for Ligand A.
**8. BBB:** Ligand A (93.563) has a much higher BBB penetration percentile than Ligand B (52.617). While ADRB2 is a cardiovascular target, some CNS exposure can occur, and higher BBB is generally favorable. However, for a cardiovascular target, this isn't the highest priority.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.582) is slightly better than Ligand B (-4.963).
**10. Aqueous Solubility:** Both ligands have negative solubility values, again suggesting poor solubility. Ligand A (-4.24) is slightly better than Ligand B (-4.079).
**11. hERG Inhibition:** Ligand A (0.677) has a lower hERG inhibition risk than Ligand B (0.8). This is a positive for Ligand A.
**12. Microsomal Clearance:** Ligand B (64.579) has a higher microsomal clearance than Ligand A (35.407), indicating lower metabolic stability. This is a significant advantage for Ligand A.
**13. In vitro Half-Life:** Ligand B (61.404) has a much longer in vitro half-life than Ligand A (19.274). This is a major advantage for Ligand B.
**14. P-gp Efflux:** Ligand A (0.234) has lower P-gp efflux liability than Ligand B (0.626), which is favorable.
**15. Binding Affinity:** Ligand B (-6.1 kcal/mol) has a slightly better binding affinity than Ligand A (-5.4 kcal/mol). This is a 0.7 kcal/mol difference, which is meaningful but not overwhelming.
**Overall Assessment:**
Ligand A has a better QED, lower DILI, lower P-gp efflux, lower microsomal clearance, and better TPSA. However, Ligand B has a significantly longer half-life and a slightly better binding affinity. The biggest concern with Ligand A is the higher DILI risk. The slightly better binding affinity of Ligand B, combined with the significantly improved half-life, outweighs the slightly worse DILI and other minor ADME properties.
Output:
0
2025-04-17 22:22:45,161 - INFO - Batch 327 complete. Total preferences: 5232
2025-04-17 22:22:45,161 - INFO - Processing batch 328/512...
2025-04-17 22:23:34,227 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [348.487, 60.85, 2.484, 1, 3, 0.797, 19.465, 50.523, -4.671, -1.941, 0.088, 19.313, 23.345, 0.151, -5.1]
**Ligand B:** [349.431, 80.76, 1.476, 1, 5, 0.754, 31.524, 77.472, -4.578, -1.421, 0.36, 8.876, 8.888, 0.03, -5.5]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal 200-500 Da range. (A: 348.487, B: 349.431) - No clear advantage.
2. **TPSA:** Ligand A (60.85) is significantly better than Ligand B (80.76). We want <140 for oral absorption, both are fine, but A is preferable.
3. **logP:** Both are within the optimal 1-3 range, but Ligand A (2.484) is slightly higher than Ligand B (1.476). Higher logP is generally favorable for GPCRs, aiding membrane permeability.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A (3) is better than Ligand B (5). Lower HBA is preferable for permeability.
6. **QED:** Both are good (>0.5), A (0.797) is slightly better than B (0.754).
7. **DILI:** Ligand A (19.465) has a much lower DILI risk than Ligand B (31.524). This is a significant advantage.
8. **BBB:** Ligand B (77.472) has a better BBB penetration score than Ligand A (50.523). While ADRB2 isn't necessarily a CNS target, some peripheral ADRB2 signaling can influence CNS function, and higher BBB is generally a plus.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. This is a concern for both, but the values are very similar.
10. **Solubility:** Both have negative solubility values, indicating poor solubility. This is a concern for both, but the values are very similar.
11. **hERG:** Ligand A (0.088) has a much lower hERG inhibition liability than Ligand B (0.36). This is a major advantage, as hERG inhibition can lead to cardiotoxicity.
12. **Cl_mic:** Ligand B (8.876) has a lower microsomal clearance than Ligand A (19.313), suggesting better metabolic stability.
13. **t1/2:** Ligand A (23.345) has a longer in vitro half-life than Ligand B (8.888). This is a significant advantage.
14. **Pgp:** Ligand A (0.151) has lower P-gp efflux liability than Ligand B (0.03). Lower Pgp is generally preferred.
15. **Affinity:** Ligand B (-5.5) has a slightly better binding affinity than Ligand A (-5.1). This is a 0.4 kcal/mol difference, which is not huge but still noticeable.
**Overall Assessment:**
While Ligand B has slightly better affinity and BBB penetration, Ligand A has significantly better DILI risk, hERG inhibition liability, half-life, Pgp efflux, TPSA and HBA. The lower DILI and hERG risks are critical for cardiovascular drug candidates. The better half-life and Pgp efflux also contribute to improved pharmacokinetic properties. The slightly better affinity of Ligand B is not enough to outweigh the safety and PK advantages of Ligand A.
Therefore, I prefer Ligand A.
1
2025-04-17 22:23:34,228 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's break down the comparison of Ligand A and Ligand B, considering the provided guidelines and the GPCR-specific priorities (logP, Pgp, TPSA, and affinity being key).
1. **Molecular Weight:** Both ligands (340.391 Da and 384.933 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand B (74.33) is significantly better than Ligand A (113.41). ADRB2 is not a CNS target, but lower TPSA generally aids absorption.
3. **logP:** Both ligands have acceptable logP values (1.644 and 2.296, respectively), falling within the 1-3 range. Ligand B is slightly better.
4. **H-Bond Donors:** Ligand A (3) is slightly higher than Ligand B (2), but both are within the acceptable limit of 5.
5. **H-Bond Acceptors:** Ligand A (6) is slightly higher than Ligand B (5), but both are within the acceptable limit of 10.
6. **QED:** Both ligands have good QED scores (0.631 and 0.789), indicating good drug-like properties. Ligand B is better.
7. **DILI:** Ligand B (46.336) has a significantly lower DILI risk than Ligand A (63.125). This is a major advantage for Ligand B.
8. **BBB:** Not a primary concern for ADRB2, but Ligand B (65.568) has a higher BBB penetration than Ligand A (32.299).
9. **Caco-2 Permeability:** Both are negative, indicating poor permeability. However, the scale is not specified, so it's hard to compare.
10. **Aqueous Solubility:** Both are negative, indicating poor solubility. Again, the scale is not specified.
11. **hERG Inhibition:** Ligand A (0.165) has a lower hERG inhibition liability than Ligand B (0.622), which is preferable.
12. **Microsomal Clearance:** Ligand A (-17.754) has much lower (better) microsomal clearance than Ligand B (4.564). This suggests better metabolic stability for Ligand A.
13. **In vitro Half-Life:** Ligand B (49.452) has a significantly longer in vitro half-life than Ligand A (-0.938). This is a substantial advantage for Ligand B.
14. **P-gp Efflux:** Ligand A (0.009) has a much lower P-gp efflux liability than Ligand B (0.209). This is a significant advantage for Ligand A.
15. **Binding Affinity:** Ligand B (-9.4 kcal/mol) has a substantially stronger binding affinity than Ligand A (-5.9 kcal/mol). This is a critical advantage, potentially outweighing some of the ADME drawbacks.
**Overall Assessment:**
Ligand B has a significantly better binding affinity, lower DILI risk, better QED, and longer half-life. While Ligand A has better metabolic stability (lower Cl_mic) and lower P-gp efflux, the superior affinity of Ligand B is a major driver for a GPCR target. The lower DILI risk is also very important. The slightly worse hERG and P-gp values for Ligand B are less concerning given the substantial affinity advantage.
**Output:**
0
2025-04-17 22:23:34,228 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (357.33 and 356.26 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (55.84) is significantly better than Ligand B (87.61). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold. Ligand B is approaching the upper limit.
3. **logP:** Both ligands have good logP values (2.88 and 2.42), falling within the optimal 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Both have 0 HBD, which is acceptable.
5. **HBA:** Ligand A has 4 HBA, while Ligand B has 7. Ligand A is preferable here, as lower HBA generally improves permeability.
6. **QED:** Both ligands have similar QED values (0.781 and 0.76), indicating good drug-likeness.
7. **DILI:** Ligand B (88.79) has a considerably higher DILI risk than Ligand A (52.66). This is a significant concern, and favors Ligand A.
8. **BBB:** Ligand A (94.03) has better BBB penetration than Ligand B (76.35). While not crucial for a cardiovascular target, it's a bonus.
9. **Caco-2:** Both have negative Caco-2 values (-4.203 and -4.263), which is unusual and suggests poor permeability *in vitro*. This is a red flag for both, but doesn't differentiate them.
10. **Solubility:** Both have negative solubility values (-3.532 and -4.218), indicating poor aqueous solubility. This is a concern for both, but doesn't differentiate them.
11. **hERG:** Both ligands have low hERG inhibition liability (0.457 and 0.283), which is good.
12. **Cl_mic:** Ligand B (84.23) has a significantly higher microsomal clearance than Ligand A (44.80). This suggests Ligand A will be more metabolically stable.
13. **t1/2:** Ligand A (-14.83) has a more negative in vitro half-life than Ligand B (-27.05). This is counterintuitive, as a more negative value suggests faster degradation. This favors Ligand B.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.171 and 0.194).
15. **Binding Affinity:** Ligand A (-8.6 kcal/mol) has a substantially stronger binding affinity than Ligand B (-6.6 kcal/mol). This is a 2.0 kcal/mol difference, which is a significant advantage and can outweigh some ADME concerns.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A excels in TPSA, affinity, and has a good logP. Ligand B has a higher Cl_mic and a slightly better t1/2, but the DILI risk and weaker binding are major drawbacks.
**Overall Assessment:**
Ligand A is the stronger candidate. The significantly better binding affinity, lower DILI risk, and favorable TPSA outweigh the slightly less favorable in vitro half-life. The poor Caco-2 and solubility are concerns for both, but can be addressed with formulation strategies. The higher metabolic stability of Ligand A is also a significant advantage.
Output:
1
2025-04-17 22:23:34,228 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (395.899 Da) is slightly higher than Ligand B (365.455 Da), but both are acceptable.
**2. TPSA:** Ligand A (66.4) is well below the 140 threshold and reasonable for a non-CNS GPCR target. Ligand B (77.69) is still acceptable, but higher.
**3. logP:** Both ligands have good logP values (A: 3.551, B: 2.41), falling within the optimal 1-3 range.
**4. H-Bond Donors:** Ligand A (2) is preferable to Ligand B (0) as it provides some hydrogen bonding potential.
**5. H-Bond Acceptors:** Ligand B (7) is higher than Ligand A (3). While both are under the 10 threshold, lower is generally preferred for permeability.
**6. QED:** Both ligands have similar QED values (A: 0.741, B: 0.669), indicating good drug-like properties.
**7. DILI:** Ligand A (43.389) has a slightly better DILI risk profile than Ligand B (51.26), both are acceptable.
**8. BBB:** Both ligands have high BBB penetration (A: 80.07, B: 83.133). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration isn't necessarily detrimental.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual. However, the values are similar (-4.807 for A, -4.623 for B), so this doesn't strongly favor either.
**10. Aqueous Solubility:** Ligand A (-4.878) has slightly better aqueous solubility than Ligand B (-1.875).
**11. hERG Inhibition:** Ligand A (0.827) has a lower hERG inhibition liability than Ligand B (0.147), which is a significant advantage for cardiovascular targets.
**12. Microsomal Clearance:** Ligand B (83.27) has a significantly higher microsomal clearance than Ligand A (39.557), indicating faster metabolism and potentially lower *in vivo* exposure.
**13. In vitro Half-Life:** Ligand A (-19.037) has a longer *in vitro* half-life than Ligand B (-14.399).
**14. P-gp Efflux:** Ligand A (0.36) has lower P-gp efflux than Ligand B (0.164), which is favorable for oral bioavailability.
**15. Binding Affinity:** Ligand A (-8.3 kcal/mol) has a significantly stronger binding affinity than Ligand B (-2.6 kcal/mol). This is a substantial advantage, potentially outweighing minor ADME drawbacks.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), and the general guidelines, Ligand A is the superior candidate. The substantially stronger binding affinity (-8.3 vs -2.6 kcal/mol) is the most important factor. Additionally, Ligand A exhibits better metabolic stability (lower Cl_mic, longer t1/2), lower hERG inhibition, and lower P-gp efflux. While Ligand B has slightly better BBB penetration, the other advantages of Ligand A make it the more promising drug candidate for ADRB2.
Output:
1
2025-04-17 22:23:34,229 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [380.725, 65.22, 4.463, 0, 5, 0.578, 77.627, 68.67, -4.414, -5.47, 0.221, 79.997, 7.522, 0.263, -6.3]
**Ligand B:** [378.485, 49.85, 2.107, 0, 4, 0.71, 31.485, 85.731, -4.464, -2.906, 0.643, 39.309, -6.872, 0.191, -6.5]
Here's a breakdown, considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal range (200-500 Da). A is 380.725, B is 378.485 - very similar.
2. **TPSA:** A is 65.22, B is 49.85. B is significantly better, falling comfortably under the 90 A^2 threshold for good absorption. A is still acceptable, but B has an advantage.
3. **logP:** A is 4.463, B is 2.107. A is pushing the upper limit and could have solubility/off-target issues. B is well within the optimal range (1-3). This is a substantial advantage for B.
4. **HBD:** Both are 0, which is excellent.
5. **HBA:** A is 5, B is 4. Both are good.
6. **QED:** A is 0.578, B is 0.71. B is better, indicating a more drug-like profile.
7. **DILI:** A is 77.627, B is 31.485. B is *much* better, indicating a significantly lower risk of liver injury. This is a critical advantage.
8. **BBB:** A is 68.67, B is 85.731. B is better, although ADRB2 isn't necessarily a CNS target, higher BBB penetration is generally favorable.
9. **Caco-2:** Both are negative (-4.414 and -4.464). This is unusual and suggests poor permeability. However, the values are very close.
10. **Solubility:** A is -5.47, B is -2.906. B is better, suggesting improved solubility.
11. **hERG:** A is 0.221, B is 0.643. A is better, indicating a lower risk of hERG inhibition.
12. **Cl_mic:** A is 79.997, B is 39.309. B is significantly better, indicating greater metabolic stability.
13. **t1/2:** A is 7.522, B is -6.872. B is better, indicating a longer half-life.
14. **Pgp:** A is 0.263, B is 0.191. B is slightly better, indicating lower P-gp efflux.
15. **Affinity:** A is -6.3 kcal/mol, B is -6.5 kcal/mol. B has a slightly better affinity, but the difference is small.
**Overall Assessment:**
Ligand B consistently outperforms Ligand A across most critical ADME-Tox properties. The lower logP, significantly lower DILI risk, better QED, improved metabolic stability (Cl_mic), longer half-life, and slightly better affinity make it a much more promising candidate. While Ligand A has a slightly better hERG profile, the other advantages of B outweigh this. The Caco-2 values are concerning for both, but the other properties of B make it more likely to be optimized to overcome this issue.
Output:
0
2025-04-17 22:23:34,229 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (339.42 & 354.50 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (47.67) is significantly better than Ligand B (104.53). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary goal, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold for oral absorption. Ligand B is pushing the limit.
3. **logP:** Ligand A (3.36) is slightly higher than Ligand B (1.76), both are within the optimal 1-3 range.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (3). Lower HBA is generally better for permeability.
6. **QED:** Ligand A (0.749) is better than Ligand B (0.521), indicating a more drug-like profile.
7. **DILI:** Ligand A (30.4%) is slightly higher than Ligand B (22.5%), but both are well below the concerning 60% threshold.
8. **BBB:** Ligand B (78.7%) is higher than Ligand A (69.4%). While not a primary concern for a cardiovascular target, higher BBB is generally favorable.
9. **Caco-2:** Both are negative (-5.205 and -5.131), indicating poor permeability. This is a significant drawback for both.
10. **Solubility:** Both are negative (-2.863 and -2.832), indicating poor solubility. This is also a significant drawback for both.
11. **hERG:** Ligand A (0.781) is slightly higher than Ligand B (0.367), indicating a slightly higher risk of hERG inhibition.
12. **Cl_mic:** Ligand A (12.6) has a significantly lower microsomal clearance than Ligand B (33.5), suggesting better metabolic stability.
13. **t1/2:** Ligand A (11.3) has a positive in vitro half-life, while Ligand B (-10.9) has a negative half-life. This is a major advantage for Ligand A.
14. **Pgp:** Ligand A (0.335) has lower P-gp efflux than Ligand B (0.056), suggesting better absorption and bioavailability.
15. **Binding Affinity:** Ligand A (-6.4 kcal/mol) is slightly better than Ligand B (-4.7 kcal/mol). This difference in affinity is substantial (1.7 kcal/mol), and can outweigh some of the ADME drawbacks.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A is superior in TPSA, Pgp, and affinity. While Ligand B has better BBB penetration, this is less critical for a cardiovascular target. The significantly better metabolic stability (Cl_mic and t1/2) of Ligand A is also a major advantage.
**Conclusion:**
Despite both compounds having poor Caco-2 and solubility, Ligand A's superior affinity, metabolic stability, lower P-gp efflux, and better drug-likeness (QED) outweigh the slightly higher hERG risk and lower BBB penetration. The substantial affinity difference is a key deciding factor.
Output:
1
2025-04-17 22:23:34,229 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [350.478, 49.41, 3.285, 1, 2, 0.799, 15.2, 96.045, -4.572, -3.877, 0.604, 43.834, -2.493, 0.105, -6.8]
**Ligand B:** [368.371, 69.64, 1.794, 2, 3, 0.507, 16.053, 94.029, -5.079, -2.444, 0.78, 17.961, -6.157, 0.135, -6.6]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (350.478) is slightly lower, which is generally favorable.
2. **TPSA:** Ligand A (49.41) is significantly better than Ligand B (69.64). A TPSA under 140 is good for oral absorption, and lower is preferred for GPCRs.
3. **logP:** Ligand A (3.285) is within the optimal range (1-3), while Ligand B (1.794) is on the lower side. Lower logP can hinder permeability.
4. **HBD:** Both have acceptable HBD counts (1 and 2 respectively), well below the threshold of 5.
5. **HBA:** Both have acceptable HBA counts (2 and 3 respectively), well below the threshold of 10.
6. **QED:** Ligand A (0.799) has a better QED score than Ligand B (0.507), indicating a more drug-like profile.
7. **DILI:** Both have relatively low DILI risk (15.2 and 16.053), both being below the 40% threshold.
8. **BBB:** Both have excellent BBB penetration (96.045 and 94.029), which is good, given this is a GPCR.
9. **Caco-2:** Ligand A (-4.572) and Ligand B (-5.079) are both negative, indicating poor permeability.
10. **Solubility:** Ligand A (-3.877) is slightly better than Ligand B (-2.444), but both are poor.
11. **hERG:** Both have low hERG inhibition risk (0.604 and 0.78).
12. **Cl_mic:** Ligand A (43.834) has significantly lower microsomal clearance than Ligand B (17.961), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-2.493) has a better in vitro half-life than Ligand B (-6.157).
14. **Pgp:** Both have low P-gp efflux liability (0.105 and 0.135).
15. **Affinity:** Ligand A (-6.8) has a slightly better binding affinity than Ligand B (-6.6), although the difference is small.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, we prioritize logP, TPSA, Pgp, and affinity. Ligand A is better in terms of TPSA, logP, and Cl_mic. While the affinity difference is small, it favors Ligand A. The solubility and Caco-2 values are poor for both, but the other properties of Ligand A make it more promising.
**Conclusion:**
Ligand A presents a more favorable balance of properties for a GPCR drug candidate, particularly due to its better TPSA, logP, metabolic stability, and QED score.
Output:
1
2025-04-17 22:23:34,229 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (364.364 and 364.823 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand B (33.2) is significantly better than Ligand A (84.5). ADRB2 is not a CNS target, but lower TPSA generally improves absorption.
3. **logP:** Ligand A (1.502) is within the optimal range (1-3), while Ligand B (4.192) is slightly above, potentially leading to solubility issues.
4. **HBD:** Ligand A (2) is acceptable, Ligand B (0) is also good.
5. **HBA:** Ligand A (4) is acceptable, Ligand B (2) is also good.
6. **QED:** Ligand B (0.72) is better than Ligand A (0.48), indicating a more drug-like profile.
7. **DILI:** Ligand B (33.773) has a much lower DILI risk than Ligand A (53.083). This is a significant advantage.
8. **BBB:** Both are reasonably high, but Ligand B (93.718) is substantially better than Ligand A (80.109). While ADRB2 isn't a primary CNS target, higher BBB is rarely detrimental.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-4.933) is slightly better than Ligand B (-4.319).
10. **Solubility:** Ligand A (-2.614) is better than Ligand B (-5.039). This is a concern for Ligand B given its higher logP.
11. **hERG:** Ligand A (0.318) has a lower hERG risk than Ligand B (0.677).
12. **Cl_mic:** Ligand A (27.007) has a lower microsomal clearance, suggesting better metabolic stability than Ligand B (55.945).
13. **t1/2:** Ligand A (-11.437) has a negative half-life, which is concerning. Ligand B (0.826) is positive, indicating a better in vitro half-life.
14. **Pgp:** Ligand A (0.047) has a lower Pgp efflux liability, which is preferable. Ligand B (0.449) is higher.
15. **Binding Affinity:** Ligand B (-7.3 kcal/mol) has a significantly stronger binding affinity than Ligand A (-8.4 kcal/mol). This is a substantial advantage and can often outweigh minor ADME concerns.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in affinity and TPSA, and has a reasonable logP and Pgp. Ligand A has better solubility and lower Pgp efflux, but its affinity is considerably weaker. The DILI risk is also much lower for Ligand B.
**Overall Assessment:**
Despite Ligand B's slightly higher logP and lower solubility, its significantly stronger binding affinity (-7.3 vs -8.4 kcal/mol) and lower DILI risk are compelling advantages. The better TPSA and BBB penetration also contribute to its favorability. The improved in vitro half-life is also a positive. The difference in binding affinity is large enough to compensate for the slightly less ideal logP and solubility.
Output:
0
2025-04-17 22:23:34,229 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (a cardiovascular GPCR) drug candidates.
**Ligand A:** [349.406, 57, 1.386, 0, 4, 0.81, 15.51, 93.37, -4.558, -2.017, 0.488, 4.371, 7.716, 0.062, -6.5]
**Ligand B:** [363.487, 80.12, 2.013, 1, 6, 0.776, 43.195, 64.793, -5.04, -3.111, 0.55, 53.175, -18.218, 0.14, -6]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal 200-500 Da range. A (349.4) is slightly better.
2. **TPSA:** A (57) is excellent, well below the 140 threshold. B (80.12) is still acceptable, but less ideal.
3. **logP:** A (1.386) is optimal. B (2.013) is also good, but edging towards the higher end of the preferred range.
4. **HBD:** A (0) is good. B (1) is acceptable.
5. **HBA:** A (4) is good. B (6) is acceptable.
6. **QED:** A (0.81) is very good, indicating high drug-likeness. B (0.776) is still reasonable, but slightly lower.
7. **DILI:** A (15.51) is *excellent* - very low risk. B (43.195) is moderate, but acceptable.
8. **BBB:** A (93.37) is *outstanding* - high penetration potential. B (64.793) is moderate, and less desirable for a GPCR.
9. **Caco-2:** A (-4.558) and B (-5.04) are both negative, which is unusual. Lower values indicate poorer permeability. A is slightly better.
10. **Solubility:** A (-2.017) and B (-3.111) are both negative, indicating poor solubility. B is worse.
11. **hERG:** A (0.488) is very good, low risk. B (0.55) is slightly higher, but still acceptable.
12. **Cl_mic:** A (4.371) is good, indicating reasonable metabolic stability. B (53.175) is significantly higher, suggesting faster metabolism.
13. **t1/2:** A (7.716) is good. B (-18.218) is *very* poor, suggesting rapid elimination.
14. **Pgp:** A (0.062) is very low efflux, excellent. B (0.14) is slightly higher, but still reasonable.
15. **Affinity:** Both are at -6.5 kcal/mol, essentially the same.
**Overall Assessment:**
Ligand A clearly outperforms Ligand B across several critical parameters. Its superior BBB penetration, lower DILI risk, better metabolic stability (lower Cl_mic, better t1/2), and lower Pgp efflux make it a much more promising candidate. While both have solubility issues, A's are less severe. The affinity is identical, so the ADME properties become the deciding factors. Given the GPCR target class, the excellent BBB score for Ligand A is a significant advantage.
Output:
1
2025-04-17 22:23:34,230 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A: [347.459, 75.44, 3.206, 1, 4, 0.802, 33.346, 70.609, -4.424, -3.002, 0.056, 68.963, 9.55, 0.076, -4.4]**
**Ligand B: [378.426, 138.67, -1.323, 3, 5, 0.526, 39.434, 54.013, -5.891, -1.973, 0.087, -27.934, 21.851, 0.016, -8.3]**
Here's a breakdown, prioritizing GPCR-relevant properties:
1. **Molecular Weight:** Both are within the ideal range (200-500 Da). A is 347.46, B is 378.43. No significant difference here.
2. **TPSA:** Ligand A (75.44) is excellent, well below the 140 threshold for oral absorption and good for GPCRs. Ligand B (138.67) is higher, but still acceptable, though less ideal.
3. **logP:** Ligand A (3.206) is optimal. Ligand B (-1.323) is quite low, potentially hindering membrane permeability and bioavailability. This is a significant negative for B.
4. **H-Bond Donors/Acceptors:** A (1/4) is better than B (3/5). Fewer H-bonds generally improve permeability.
5. **QED:** Ligand A (0.802) is excellent, indicating high drug-likeness. Ligand B (0.526) is acceptable but lower.
6. **DILI:** Both are reasonably low (A: 33.35, B: 39.43), indicating acceptable liver toxicity risk.
7. **BBB:** Ligand A (70.61) is good, suggesting reasonable CNS penetration. Ligand B (54.01) is lower, less desirable. While ADRB2 is primarily cardiovascular, some CNS effects can be relevant or off-target.
8. **Caco-2:** Both are negative, suggesting poor permeability. However, the scale is not specified, so it is difficult to assess the impact.
9. **Solubility:** Both are negative, suggesting poor solubility. However, the scale is not specified, so it is difficult to assess the impact.
10. **hERG:** Both are very low (A: 0.056, B: 0.087), indicating minimal cardiotoxicity risk.
11. **Cl_mic:** Ligand A (68.96) has a higher clearance than Ligand B (-27.93). B has a negative clearance, which is not possible and likely indicates a very slow metabolic rate. This is a significant advantage for B.
12. **t1/2:** Ligand B (21.85) has a longer half-life than Ligand A (9.55), which is desirable.
13. **Pgp:** Both are very low (A: 0.076, B: 0.016), suggesting minimal P-glycoprotein efflux.
14. **Binding Affinity:** Ligand B (-8.3) has a significantly stronger binding affinity than Ligand A (-4.4). This is a substantial advantage, a difference of 3.9 kcal/mol.
**Overall Assessment:**
Ligand B has a significantly better binding affinity, a longer half-life, and a much lower microsomal clearance. However, it suffers from a low logP, potentially leading to poor permeability and bioavailability. Ligand A has better physicochemical properties (TPSA, logP, QED) and a good BBB score, but its binding affinity is considerably weaker.
Given the GPCR target class, binding affinity is paramount. The 3.9 kcal/mol difference is substantial and likely outweighs the permeability concerns of Ligand B, *provided* formulation strategies can be employed to address the solubility and permeability issues. The negative clearance is also a very positive sign.
Therefore, I would prioritize Ligand B.
Output:
0
2025-04-17 22:23:34,230 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [444.738, 71.53, 3.406, 1, 5, 0.569, 85.227, 69.252, -4.793, -4.45, 0.21, 43.997, 16.302, 0.231, -7.2]
**Ligand B:** [351.403, 109.66, 0.133, 3, 6, 0.647, 54.827, 45.909, -5.169, -1.589, 0.124, -2.645, 15.408, 0.034, -6.9]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity, and to a lesser extent BBB):
1. **MW:** Ligand B (351.4) is better, falling comfortably within the ideal range, while Ligand A (444.7) is at the upper limit.
2. **TPSA:** Ligand A (71.53) is significantly better than Ligand B (109.66). Lower TPSA is crucial for GPCRs, aiding permeability.
3. **logP:** Ligand A (3.406) is optimal. Ligand B (0.133) is *very* low, potentially causing permeability issues and poor absorption. This is a major drawback.
4. **HBD/HBA:** Ligand B has more HBD (3) and HBA (6) than Ligand A (1 & 5 respectively). While not critical, fewer is generally preferable.
5. **QED:** Ligand B (0.647) is slightly better than Ligand A (0.569), indicating a slightly more drug-like profile.
6. **DILI:** Ligand B (54.827) has a much lower DILI risk than Ligand A (85.227). This is a significant advantage for Ligand B.
7. **BBB:** Ligand A (69.252) is better than Ligand B (45.909), although neither are exceptionally high. For a cardiovascular target, BBB isn't paramount, but a higher value is still preferred.
8. **Caco-2:** Ligand A (-4.793) is better than Ligand B (-5.169).
9. **Solubility:** Ligand A (-4.45) is better than Ligand B (-1.589).
10. **hERG:** Ligand A (0.21) is better than Ligand B (0.124).
11. **Cl_mic:** Ligand B (-2.645) has significantly better metabolic stability (lower clearance) than Ligand A (43.997).
12. **t1/2:** Ligand A (16.302) has a slightly longer half-life than Ligand B (15.408).
13. **Pgp:** Ligand A (0.231) has lower P-gp efflux than Ligand B (0.034), which is preferable.
14. **Affinity:** Ligand A (-7.2) has a slightly better binding affinity than Ligand B (-6.9). While the difference is not huge, it's a positive for Ligand A.
**Overall Assessment:**
Ligand B has advantages in DILI risk and metabolic stability. However, its extremely low logP is a major concern, likely leading to poor absorption and bioavailability. Ligand A, while having a higher DILI risk and slightly lower metabolic stability, has a much more favorable logP, better TPSA, and a slightly better binding affinity. The GPCR-specific priorities (logP, TPSA, affinity) heavily favor Ligand A.
Therefore, I would choose Ligand A as the more promising drug candidate.
1
2025-04-17 22:23:34,230 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (347.371 and 349.387 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (97.81) is slightly higher than Ligand B (93.37). Both are below the 140 A^2 threshold for good oral absorption, but closer to the upper end.
**3. logP:** Both ligands have good logP values (0.705 and 0.667), falling within the optimal 1-3 range. No clear advantage.
**4. H-Bond Donors:** Both ligands have 1 HBD, which is acceptable.
**5. H-Bond Acceptors:** Both ligands have 6 HBA, also acceptable.
**6. QED:** Ligand A (0.855) has a significantly better QED score than Ligand B (0.602), indicating a more drug-like profile.
**7. DILI:** Ligand B (46.801) has a lower DILI risk than Ligand A (57.076), which is a positive.
**8. BBB:** Ligand B (65.297) has a significantly higher BBB penetration percentile than Ligand A (48.701). While ADRB2 is cardiovascular, some CNS effects are possible with adrenergic agonists, and higher BBB penetration could be beneficial or detrimental depending on the desired effect profile.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-5.164 and -4.817), which is unusual and suggests poor permeability. This is a significant concern for both.
**10. Aqueous Solubility:** Both ligands have very poor aqueous solubility (-1.54 and -1.027). This is a major drawback for both compounds.
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (0.119 and 0.226).
**12. Microsomal Clearance:** Ligand B (9.806) has a much lower microsomal clearance than Ligand A (20.419), indicating better metabolic stability.
**13. In vitro Half-Life:** Ligand B (15.025 hours) has a longer half-life than Ligand A (22.581 hours).
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (0.041 and 0.051).
**15. Binding Affinity:** Ligand A (-7.1 kcal/mol) has a slightly better binding affinity than Ligand B (-6.5 kcal/mol). This is a 0.6 kcal/mol difference, which is not huge, but noticeable.
**GPCR-Specific Priorities:** For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Both ligands are reasonable in logP and Pgp. TPSA is borderline for both. Affinity favors Ligand A, but the difference isn't massive. Metabolic stability (Cl_mic) is also important, and Ligand B is significantly better here.
**Overall Assessment:**
While Ligand A has slightly better affinity and QED, Ligand B has a significantly better BBB penetration, lower DILI risk, and substantially improved metabolic stability (lower Cl_mic and longer half-life). The poor Caco-2 permeability and solubility are major concerns for both, but the improved ADME profile of Ligand B makes it a more promising starting point for optimization. The slightly better affinity of Ligand A is unlikely to overcome the significant ADME advantages of Ligand B.
Output:
0
2025-04-17 22:23:34,230 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for the ADRB2 receptor, a cardiovascular GPCR. Therefore, key priorities are logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB.
Let's compare the ligands property by property:
1. **MW:** Both ligands (379.479 and 349.479 Da) are within the ideal range (200-500 Da).
2. **TPSA:** Ligand B (53.96) is significantly better than Ligand A (136.82). Lower TPSA is preferred for GPCRs to enhance permeability.
3. **logP:** Ligand B (1.106) is within the optimal range (1-3), while Ligand A (-1.028) is below 1, potentially hindering permeation. This is a significant advantage for Ligand B.
4. **HBD/HBA:** Ligand A has 3 HBD and 6 HBA, while Ligand B has 0 HBD and 7 HBA. Both are acceptable, though Ligand B's lower HBD could be slightly beneficial for permeability.
5. **QED:** Ligand B (0.762) has a better QED score than Ligand A (0.469), indicating a more drug-like profile.
6. **DILI:** Both ligands have similar, acceptable DILI risk (39.511 vs 38.348).
7. **BBB:** Ligand B (88.833) has a much higher BBB penetration score than Ligand A (36.371). While not a primary concern for a cardiovascular target, higher BBB is generally favorable.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so this is hard to interpret.
9. **Solubility:** Both have negative solubility values, which is also unusual.
10. **hERG:** Ligand A (0.116) has a slightly lower hERG risk than Ligand B (0.847), which is good.
11. **Cl_mic:** Ligand A (26.422) has a lower microsomal clearance than Ligand B (33.266), suggesting better metabolic stability.
12. **t1/2:** Ligand B (19.131) has a longer in vitro half-life than Ligand A (-20.555). The negative value for Ligand A is concerning.
13. **Pgp:** Ligand A (0.01) has a much lower Pgp efflux liability than Ligand B (0.035), which is a significant advantage.
14. **Binding Affinity:** Ligand B (-7.0) has a slightly better binding affinity than Ligand A (-6.3). While the difference is not huge, it's still a positive for Ligand B.
**Overall Assessment:**
Ligand B demonstrates a superior profile regarding key GPCR properties (TPSA, logP, BBB) and has a better QED score and half-life. While Ligand A has a slight advantage in Pgp efflux and hERG, the benefits of Ligand B's permeability and drug-like properties outweigh these minor drawbacks. The negative half-life for Ligand A is a major red flag.
**Output:**
0
2025-04-17 22:23:34,230 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 GPCR, followed by the final output.
**Ligand A: [348.487, 78.43, 2.32, 3, 3, 0.53, 9.616, 66.227, -4.704, -2.646, 0.243, 53.418, 17.209, 0.081, -6.4]**
**Ligand B: [369.527, 73.91, 2.62, 2, 5, 0.663, 25.087, 54.711, -5.047, -2.817, 0.809, 53.099, 93.106, 0.799, -7]**
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). A (348.487) is slightly preferred.
2. **TPSA:** Both are reasonably good (A: 78.43, B: 73.91), below the 140 threshold for oral absorption. B is slightly better.
3. **logP:** Both are within the optimal range (1-3). A (2.32) and B (2.62) are comparable.
4. **H-Bond Donors:** Both are acceptable (A: 3, B: 2). B is slightly better.
5. **H-Bond Acceptors:** Both are acceptable (A: 3, B: 5). A is slightly better.
6. **QED:** Both are above 0.5, indicating drug-likeness (A: 0.53, B: 0.663). B is better.
7. **DILI:** A (9.616) is significantly better than B (25.087). This is a major advantage for A.
8. **BBB:** A (66.227) is better than B (54.711), though neither are exceptionally high. For a cardiovascular target, BBB isn't *critical*, but still a consideration.
9. **Caco-2:** Both are negative, indicating poor permeability. A (-4.704) is slightly worse than B (-5.047).
10. **Solubility:** Both are negative, indicating poor solubility. A (-2.646) is slightly better than B (-2.817).
11. **hERG:** Both are very low risk (A: 0.243, B: 0.809). A is much better.
12. **Cl_mic:** Both are similar (A: 53.418, B: 53.099).
13. **t1/2:** B (93.106) has a significantly longer half-life than A (17.209). This is a substantial advantage for B.
14. **Pgp:** A (0.081) is much better than B (0.799), indicating lower efflux.
15. **Binding Affinity:** B (-7 kcal/mol) has a 0.6 kcal/mol advantage over A (-6.4 kcal/mol). This is a significant difference.
**Overall Assessment:**
While Ligand B has a better binding affinity and a longer half-life, Ligand A demonstrates a significantly better safety profile (lower DILI and hERG risk) and better Pgp efflux properties. The affinity difference, while notable, can potentially be optimized in later stages of drug development. The safety concerns with Ligand B are more difficult to address. Considering this is a cardiovascular target, minimizing off-target effects and toxicity is paramount.
Therefore, I would choose Ligand A.
Output:
1
2025-04-17 22:23:34,231 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
Let's break down the comparison of Ligand A and Ligand B across the 15 parameters, keeping in mind the GPCR-centric priorities (logP, Pgp, TPSA, and affinity are key).
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand B (335.357 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (48.71) is significantly better than Ligand A (82.26). Lower TPSA is crucial for GPCRs, promoting better blood-brain barrier penetration and overall absorption.
3. **logP:** Both ligands have logP values within the optimal range (1-3), but Ligand B (4.874) is higher. While higher logP can sometimes cause issues, for a GPCR, it's less concerning than a very low logP and can aid in membrane interactions.
4. **HBD/HBA:** Ligand A has 4 HBD and 2 HBA, while Ligand B has 1 HBD and 3 HBA. Both are acceptable, but Ligand B is slightly better with fewer hydrogen bond donors.
5. **QED:** Both ligands have good QED scores (A: 0.627, B: 0.739), indicating good drug-like properties. Ligand B is slightly better.
6. **DILI:** Both have relatively high DILI risk (A: 88.329, B: 82.706). This is a concern for both, but B is marginally better.
7. **BBB:** Ligand B (76.309) has a better BBB percentile than Ligand A (68.127), which is important for GPCRs, even if not a CNS target.
8. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. This is a significant drawback for both.
9. **Solubility:** Both have very poor solubility (A: -5.874, B: -6.506). This is a major issue that would need to be addressed through formulation strategies.
10. **hERG:** Ligand A (0.481) has a lower hERG risk than Ligand B (0.771), which is a positive.
11. **Cl_mic:** Ligand A (41.722) has a lower microsomal clearance than Ligand B (46.279), suggesting better metabolic stability.
12. **t1/2:** Ligand A (87.727) has a much longer in vitro half-life than Ligand B (42.043), a significant advantage.
13. **Pgp:** Ligand A (0.136) has a much lower P-gp efflux liability than Ligand B (0.455), which is favorable for bioavailability.
14. **Affinity:** Ligand A (-6.6 kcal/mol) has a significantly better binding affinity than Ligand B (-12.4 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME drawbacks.
**Overall Assessment:**
While both ligands have significant ADME liabilities (poor solubility and Caco-2 permeability), Ligand A emerges as the more promising candidate primarily due to its *much* stronger binding affinity (-6.6 vs -12.4 kcal/mol) and better metabolic stability (lower Cl_mic, longer t1/2) and lower Pgp efflux. The lower hERG risk is also a plus. Ligand B has a better TPSA and QED, but the affinity difference is too large to ignore, especially for a GPCR target where potent binding is critical. The poor solubility of both compounds would need to be addressed during formulation.
Output:
1
2025-04-17 22:23:34,231 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, logP, TPSA, Pgp, and binding affinity are key.
* **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (351.4) is slightly higher than Ligand B (346.5), but both are acceptable.
* **TPSA:** Ligand A (104.9) is higher than Ligand B (67.23). While both are below 140, Ligand B's lower TPSA is more favorable for oral absorption and GPCR binding.
* **logP:** Ligand A (0.521) is quite low, potentially hindering membrane permeability. Ligand B (3.073) is within the optimal range (1-3). This is a significant advantage for Ligand B.
* **H-Bond Donors/Acceptors:** Ligand A has 2 HBD and 6 HBA, while Ligand B has 1 HBD and 4 HBA. Both are within acceptable limits.
* **QED:** Both ligands have good QED scores (A: 0.662, B: 0.699), indicating good drug-like properties.
* **DILI:** Ligand A (48.3) has a slightly higher DILI risk than Ligand B (36.5), but both are below the concerning threshold of 60.
* **BBB:** Ligand B (83.4) shows significantly better BBB penetration potential than Ligand A (49.6). While not a primary concern for a cardiovascular target, it's a positive attribute.
* **Caco-2 Permeability:** Both have negative values, which is unusual, but we can assume they represent low permeability. Ligand A (-4.833) is slightly worse than Ligand B (-4.607).
* **Aqueous Solubility:** Both have negative values, indicating poor solubility. Ligand A (-1.863) is slightly better than Ligand B (-3.635).
* **hERG Inhibition:** Both ligands show low hERG inhibition risk (A: 0.112, B: 0.331).
* **Microsomal Clearance:** Ligand A (16.975) has a lower Cl_mic than Ligand B (88.239), suggesting better metabolic stability. This is a positive for Ligand A.
* **In vitro Half-Life:** Ligand A (25.863) has a longer half-life than Ligand B (14.346), which is desirable.
* **P-gp Efflux:** Ligand A (0.06) has a much lower P-gp efflux liability than Ligand B (0.254), indicating better bioavailability.
* **Binding Affinity:** Ligand B (-7.2 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.6 kcal/mol). This 1.6 kcal/mol difference is substantial and can outweigh many ADME drawbacks.
**Conclusion:**
Despite Ligand A's better metabolic stability, longer half-life, and lower P-gp efflux, Ligand B's superior logP, lower TPSA, significantly stronger binding affinity, and better BBB penetration make it the more promising drug candidate for ADRB2. The binding affinity difference is the most critical factor, as it directly impacts efficacy.
**Output:**
0
2025-04-17 22:23:34,231 - INFO - Batch 328 complete. Total preferences: 5248
2025-04-17 22:23:34,231 - INFO - Processing batch 329/512...
2025-04-17 22:24:22,239 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (366.799 and 367.804 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands have TPSA values (58.12 and 57.65) below the 140 A^2 threshold for good oral absorption, and are reasonable for a GPCR target. Again, no major distinction.
3. **logP:** Ligand A (3.247) is within the optimal 1-3 range. Ligand B (4.174) is slightly higher, edging towards potential solubility issues, but still acceptable.
4. **HBD:** Ligand A has 1 HBD, while Ligand B has 0. Both are within the acceptable limit of <=5.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 5. Both are within the acceptable limit of <=10.
6. **QED:** Ligand A (0.844) has a better QED score than Ligand B (0.717), indicating a more drug-like profile.
7. **DILI:** Ligand A (85.653 percentile) has a significantly higher DILI risk than Ligand B (70.686 percentile). This is a substantial negative for Ligand A.
8. **BBB:** Ligand A (80.07 percentile) has a higher BBB penetration potential than Ligand B (65.607 percentile). While ADRB2 isn't strictly a CNS target, some CNS exposure can occur, and higher BBB is generally favorable.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.688 and -4.242), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-4.423) has slightly better solubility than Ligand B (-5.67).
11. **hERG:** Ligand A (0.566) has a slightly higher hERG risk than Ligand B (0.195). Lower is better, so Ligand B is preferable.
12. **Cl_mic:** Ligand B (125.686 mL/min/kg) has a significantly higher microsomal clearance than Ligand A (66.513 mL/min/kg), indicating faster metabolism and potentially lower *in vivo* exposure. This is a significant negative for Ligand B.
13. **t1/2:** Ligand A (31.202 hours) has a longer in vitro half-life than Ligand B (25.163 hours), which is desirable.
14. **Pgp:** Ligand A (0.236) has lower P-gp efflux liability than Ligand B (0.146), which is preferable.
15. **Binding Affinity:** Ligand A (-7.7 kcal/mol) has a better binding affinity than Ligand B (-6.8 kcal/mol). This is a 0.9 kcal/mol difference, which is substantial and can outweigh some ADME concerns.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand A has a better logP and Pgp profile, and a significantly better binding affinity. However, the high DILI risk for Ligand A is a major concern. Ligand B has a lower DILI risk, but higher Cl_mic. The affinity difference is large enough to potentially overcome the higher Cl_mic of Ligand B, especially considering the lower DILI risk.
**Overall Assessment:**
Despite the better affinity of Ligand A, the significantly higher DILI risk is a major red flag. DILI is a common reason for drug development failure. Ligand B, while having a slightly less optimal logP and Pgp profile, presents a much more favorable safety profile with a lower DILI risk. The difference in affinity, while substantial, isn't so large as to completely negate the safety concerns with Ligand A.
Output:
0
2025-04-17 22:24:22,239 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [351.403, 132.96 , -1.511, 4. , 5. , 0.489, 23.071, 22.063, -6.02 , -1.644, 0.041, -27.031, 4.9 , 0.003, -8.1 ]
**Ligand B:** [348.403, 113.44 , 0.128, 3. , 6. , 0.615, 38.038, 54.052, -4.844, -2.226, 0.083, 24.281, -35.159, 0.007, -7.3 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). A: 351.4, B: 348.4 - very similar.
2. **TPSA:** A: 132.96, B: 113.44. Both are acceptable for oral absorption (<140), but B is better, closer to the ideal for GPCRs.
3. **logP:** A: -1.511, B: 0.128. A is quite low, potentially hindering permeability. B is better, falling within the optimal 1-3 range.
4. **HBD:** A: 4, B: 3. Both are good.
5. **HBA:** A: 5, B: 6. Both are acceptable.
6. **QED:** A: 0.489, B: 0.615. B has a better drug-likeness score.
7. **DILI:** A: 23.071, B: 38.038. A has significantly lower DILI risk, a major advantage.
8. **BBB:** A: 22.063, B: 54.052. B has much better BBB penetration, which is important for a GPCR target.
9. **Caco-2:** A: -6.02, B: -4.844. B has better Caco-2 permeability.
10. **Solubility:** A: -1.644, B: -2.226. Both are poor, but A is slightly better.
11. **hERG:** A: 0.041, B: 0.083. A has a lower hERG risk, a critical safety parameter.
12. **Cl_mic:** A: -27.031, B: 24.281. A has much lower microsomal clearance, indicating better metabolic stability.
13. **t1/2:** A: 4.9, B: -35.159. A has a better in vitro half-life.
14. **Pgp:** A: 0.003, B: 0.007. A has lower P-gp efflux, which is favorable.
15. **Affinity:** A: -8.1, B: -7.3. A has a significantly stronger binding affinity (1.5 kcal/mol advantage).
**GPCR-Specific Considerations:**
For an ADRB2 (GPCR) target, we prioritize logP, TPSA, Pgp, BBB, and affinity. While B has better TPSA and BBB, A's superior affinity (-8.1 vs -7.3) is a substantial advantage. The difference in affinity is likely to outweigh the slightly less favorable BBB and TPSA of ligand A. Furthermore, A has a much better safety profile (lower DILI and hERG) and better metabolic stability (lower Cl_mic). The low logP of A is a concern, but the strong binding affinity might compensate for that.
**Conclusion:**
Considering the balance of properties, particularly the significantly stronger binding affinity, lower DILI/hERG risk, and better metabolic stability, **Ligand A** is the more promising drug candidate.
**Output:**
1
2025-04-17 22:24:22,240 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [360.801, 97.55, 2.317, 2, 5, 0.872, 85.653, 62.389, -5.017, -3.888, 0.298, -3.207, -2.887, 0.056, -7.7]
**Ligand B:** [368.459, 91.84, 0.741, 1, 6, 0.717, 59.093, 57.852, -4.872, -1.393, 0.225, 14.049, -8.656, 0.042, -5.6]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, Affinity, and to a lesser extent BBB):
1. **MW:** Both are within the ideal range (200-500 Da). A is 360.8, B is 368.5. No significant difference.
2. **TPSA:** A is 97.55, B is 91.84. Both are acceptable for a non-CNS GPCR target like ADRB2, but B is slightly better.
3. **logP:** A is 2.317, B is 0.741. A is much better here, falling squarely in the optimal 1-3 range. B is a bit low, potentially impacting permeability.
4. **HBD:** A is 2, B is 1. Both are good.
5. **HBA:** A is 5, B is 6. Both are acceptable.
6. **QED:** A is 0.872, B is 0.717. A is better, indicating a more drug-like profile.
7. **DILI:** A is 85.653, B is 59.093. B is significantly better, indicating a much lower risk of liver injury. This is a major advantage for B.
8. **BBB:** A is 62.389, B is 57.852. Not a primary concern for ADRB2, but A is slightly better.
9. **Caco-2:** Both are negative, indicating poor permeability. A is -5.017, B is -4.872. No significant difference.
10. **Solubility:** A is -3.888, B is -1.393. B is better, suggesting better aqueous solubility.
11. **hERG:** Both are very low (0.298 and 0.225), indicating a low risk of cardiotoxicity. No significant difference.
12. **Cl_mic:** A is -3.207, B is 14.049. A is *much* better, indicating significantly higher metabolic stability. This is a crucial advantage.
13. **t1/2:** A is -2.887, B is -8.656. A is better, indicating a longer in vitro half-life.
14. **Pgp:** Both are very low (0.056 and 0.042), indicating minimal P-gp efflux. No significant difference.
15. **Affinity:** A is -7.7 kcal/mol, B is -5.6 kcal/mol. A has a *substantially* better binding affinity (a 2.1 kcal/mol difference). This is a huge advantage.
**Overall Assessment:**
Ligand A excels in binding affinity, metabolic stability, and QED. Ligand B has a better DILI score and solubility. However, the significantly stronger binding affinity of Ligand A, coupled with its better metabolic stability, outweighs the benefits of Ligand B's lower DILI risk and solubility. The difference in affinity is large enough to potentially overcome any ADME challenges that might arise. While B has a better DILI profile, this can be addressed through further optimization. The strong binding of A is harder to achieve through optimization.
Therefore, I would choose Ligand A.
1
2025-04-17 22:24:22,240 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (342.46 and 341.37 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (23.55) is significantly better than Ligand B (86.48). For a GPCR, lower TPSA is generally preferred for better permeability, and Ligand A is well below the 140 threshold, while B is pushing it.
3. **logP:** Both ligands have good logP values (3.79 and 3.06), falling within the optimal 1-3 range. Ligand A is slightly higher, which *could* be a minor concern for solubility, but still acceptable.
4. **HBD:** Ligand A (0) is better than Ligand B (1). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (1) is significantly better than Ligand B (6). Lower HBA is favorable for permeability.
6. **QED:** Ligand A (0.802) is better than Ligand B (0.711), indicating a more drug-like profile.
7. **DILI:** Ligand A (18.2) is *much* better than Ligand B (89.6). This is a critical difference. A DILI percentile of under 40 is desirable, and A is well within that range, while B is very high risk.
8. **BBB:** Ligand A (82.4) is better than Ligand B (70.0), although both are reasonably good. For a cardiovascular target, BBB isn't *as* critical as it would be for a CNS target, but still a positive.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.504 and -4.542). This is unusual and suggests poor permeability *in vitro*. However, the values are very similar.
10. **Solubility:** Both ligands have negative solubility values (-4.445 and -4.066). This is also unusual and suggests poor aqueous solubility. Again, the values are similar.
11. **hERG:** Both ligands have low hERG risk (0.808 and 0.714). This is good.
12. **Cl_mic:** Ligand A (46.7) is better than Ligand B (79.3). Lower microsomal clearance indicates better metabolic stability.
13. **t1/2:** Ligand A (17.6) is better than Ligand B (14.9). A longer half-life is generally preferred.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.344 and 0.278). This is good.
15. **Binding Affinity:** Ligand A (-7.9) is significantly better than Ligand B (-6.7). A 1.2 kcal/mol difference in binding affinity is substantial and can often outweigh minor ADME drawbacks.
**Overall Assessment:**
Ligand A is clearly superior. While both ligands have issues with Caco-2 and solubility, Ligand A excels in almost all other critical parameters, especially DILI risk and binding affinity. The significantly lower DILI risk is a major advantage, and the stronger binding affinity provides a substantial benefit. The better TPSA, QED, Cl_mic, and t1/2 values further solidify its position as the more promising candidate.
Output:
1
2025-04-17 22:24:22,240 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [362.495, 62.55, 2.523, 1, 4, 0.845, 23.226, 64.482, -5.307, -2.875, 0.254, 32.204, 31.308, 0.149, -5.9]
**Ligand B:** [355.511, 46.84, 3.616, 0, 6, 0.619, 32.067, 71.733, -5.409, -2.904, 0.75, 52.797, 32.981, 0.297, -7.1]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (355.511) is slightly lower, which is generally favorable.
2. **TPSA:** Ligand A (62.55) is higher than Ligand B (46.84). Both are below 140, but B is better for permeability.
3. **logP:** Both are within the optimal range (1-3), but Ligand B (3.616) is pushing the upper limit. Ligand A (2.523) is more ideal.
4. **HBD:** Ligand A (1) is better than Ligand B (0). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is better than Ligand B (6). Lower HBA is preferred.
6. **QED:** Ligand A (0.845) is significantly better than Ligand B (0.619), indicating a more drug-like profile.
7. **DILI:** Both are good, below 40, with Ligand A (23.226) being slightly better.
8. **BBB:** Ligand B (71.733) is better than Ligand A (64.482), which is good for a GPCR.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-5.307) is slightly better than Ligand B (-5.409).
10. **Solubility:** Both are negative, indicating poor solubility. They are comparable.
11. **hERG:** Ligand A (0.254) is much better than Ligand B (0.75), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand A (32.204) is better than Ligand B (52.797), suggesting better metabolic stability.
13. **t1/2:** Comparable.
14. **Pgp:** Ligand A (0.149) is much better than Ligand B (0.297), indicating lower efflux and better bioavailability.
15. **Affinity:** Ligand B (-7.1) has a significantly stronger binding affinity than Ligand A (-5.9) - a difference of 1.2 kcal/mol. This is a substantial advantage.
**GPCR-specific priorities:** For ADRB2 (a GPCR), we prioritize logP, Pgp, TPSA, and affinity. Ligand B excels in affinity and has a better BBB score. Ligand A has better logP, TPSA, Pgp, QED, DILI, and hERG.
**Overall Assessment:**
The significantly stronger binding affinity of Ligand B (-7.1 kcal/mol vs -5.9 kcal/mol) is a major advantage that can potentially outweigh some of its drawbacks (higher logP, worse Pgp, lower QED, higher hERG). While Ligand A has a more balanced profile with better ADME properties, the potency difference is substantial. For a GPCR target, potency is often paramount, and a 1.2 kcal/mol difference is a significant gain.
Therefore, I would select Ligand B.
0
2025-04-17 22:24:22,240 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
The ADRB2 receptor is a GPCR, so the priorities are logP, TPSA, Pgp efflux, BBB penetration, and binding affinity. Let's compare the ligands step-by-step:
1. **MW:** Both ligands (349.435 and 348.447 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand B (96.25) is significantly better than Ligand A (110.93). Lower TPSA generally improves permeability, crucial for GPCR ligands.
3. **logP:** Both are good (0.952 and 0.732), falling within the 1-3 range. Ligand B is slightly better.
4. **HBD/HBA:** Ligand A has 4 HBD and 4 HBA, while Ligand B has 3 HBD and 5 HBA. Both are acceptable, but Ligand A is slightly more favorable.
5. **QED:** Ligand A (0.634) is slightly better than Ligand B (0.543), indicating a more drug-like profile.
6. **DILI:** Ligand B (25.359) has a much lower DILI risk than Ligand A (16.867), a significant advantage.
7. **BBB:** Ligand A (63.862) has a better BBB percentile than Ligand B (16.479). This is important for potential CNS effects, but less critical for ADRB2 which is primarily cardiovascular.
8. **Caco-2:** Both are negative, indicating poor permeability. However, the scale is not provided, so it's hard to interpret.
9. **Solubility:** Both are negative, indicating poor solubility. Again, the scale is not provided.
10. **hERG:** Both are very low (0.363 and 0.199), indicating minimal hERG inhibition risk.
11. **Cl_mic:** Ligand A (-4.654) has a lower (better) microsomal clearance than Ligand B (0.809), suggesting better metabolic stability.
12. **t1/2:** Ligand B (-18.314) has a much longer in vitro half-life than Ligand A (9.209). This is a significant advantage.
13. **Pgp:** Both are very low (0.017 and 0.036), indicating minimal P-gp efflux.
14. **Binding Affinity:** Ligand A (-5.8 kcal/mol) has a slightly better binding affinity than Ligand B (-5.7 kcal/mol). However, the difference is small.
**Overall Assessment:**
Ligand B is preferable. While Ligand A has a slightly better binding affinity and QED, Ligand B excels in critical ADME properties. Specifically, its significantly lower DILI risk and substantially longer half-life are major advantages. The lower TPSA is also beneficial. The slightly lower BBB penetration is not a major concern for a cardiovascular target. The difference in binding affinity is not large enough to outweigh the ADME benefits of Ligand B.
**Output:**
0
2025-04-17 22:24:22,240 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal 200-500 Da range (A: 371.277, B: 351.382). No clear advantage here.
2. **TPSA:** Ligand A (47.56) is significantly better than Ligand B (109.14). For a GPCR, lower TPSA is generally preferred for better permeability. Ligand B is quite high, potentially hindering absorption.
3. **logP:** Ligand A (4.056) is good, though on the higher end of the optimal range. Ligand B (-0.456) is too low, potentially leading to poor membrane permeability. A is favored.
4. **HBD:** Ligand A (1) is better than Ligand B (3). Lower HBDs generally improve permeability.
5. **HBA:** Ligand A (3) is better than Ligand B (6). Similar reasoning as HBD.
6. **QED:** Ligand A (0.768) is better than Ligand B (0.576), indicating a more drug-like profile.
7. **DILI:** Ligand A (42.264) is significantly better than Ligand B (68.166). Lower DILI risk is crucial.
8. **BBB:** Ligand A (88.135) is much better than Ligand B (42.148). While ADRB2 isn't exclusively a CNS target, some CNS penetration might be acceptable or even beneficial depending on the specific therapeutic goal. This is a strong advantage for A.
9. **Caco-2:** Ligand A (-4.258) is better than Ligand B (-5.314), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-5.249) is better than Ligand B (-1.917), suggesting better aqueous solubility.
11. **hERG:** Ligand A (0.783) is better than Ligand B (0.075). Lower hERG inhibition is critical for avoiding cardiotoxicity, especially for a cardiovascular target.
12. **Cl_mic:** Ligand B (-14.032) is much better than Ligand A (41.762). Lower clearance indicates greater metabolic stability. This is a significant advantage for B.
13. **t1/2:** Ligand B (-18.991) is much better than Ligand A (-0.683). Longer half-life is generally desirable. Another significant advantage for B.
14. **Pgp:** Ligand A (0.169) is better than Ligand B (0.017). Lower P-gp efflux is preferred.
15. **Binding Affinity:** Ligand B (-6.1) is slightly better than Ligand A (-5.3). This is a 0.8 kcal/mol difference, which is a good advantage, but not overwhelming given the other factors.
**Overall Assessment:**
Ligand B has a clear advantage in metabolic stability (Cl_mic and t1/2) and slightly better binding affinity. However, Ligand A excels in almost all other critical ADME properties, particularly TPSA, logP, solubility, DILI risk, and hERG inhibition. Given the cardiovascular target (ADRB2), minimizing cardiotoxicity (hERG) and ensuring reasonable absorption (TPSA, logP, solubility) are paramount. The substantial improvements in these areas with Ligand A outweigh the benefits of Ligand B's metabolic stability and slightly better affinity.
Output:
1
2025-04-17 22:24:22,240 - INFO - Here's my reasoning and final output for selecting the better drug candidate:
**Reasoning:**
We are targeting the ADRB2, a GPCR involved in cardiovascular function. Therefore, the priorities are logP, TPSA, Pgp, affinity, and to a lesser extent, BBB. Let's break down the comparison:
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (348.4) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (104.71) is better than Ligand B (33.2). While both are reasonably low, Ligand B's is exceptionally low, which *could* indicate poor aqueous solubility and potentially reduced binding interactions.
3. **logP:** Ligand A (2.142) is within the optimal range (1-3). Ligand B (4.539) is higher, potentially leading to solubility issues and off-target interactions. This is a significant drawback for Ligand B.
4. **H-Bond Donors:** Ligand A (3) is reasonable. Ligand B (0) is very low, potentially impacting solubility.
5. **H-Bond Acceptors:** Ligand A (5) is good. Ligand B (3) is also acceptable.
6. **QED:** Both ligands have good QED scores (A: 0.678, B: 0.805), indicating generally drug-like properties. Ligand B is slightly better here.
7. **DILI:** Ligand A (48.43) has a lower DILI risk than Ligand B (56.844), which is preferable.
8. **BBB:** Ligand B (86.817) has significantly better BBB penetration than Ligand A (32.454). However, since ADRB2 is cardiovascular, BBB penetration is not a primary concern.
9. **Caco-2 Permeability:** Both are negative, indicating poor permeability. This is a concern for both, but the scale suggests Ligand A (-5.086) is slightly better than Ligand B (-4.749).
10. **Aqueous Solubility:** Ligand A (-2.044) is better than Ligand B (-4.642). Solubility is crucial for bioavailability.
11. **hERG Inhibition:** Ligand A (0.33) has a much lower hERG risk than Ligand B (0.642). This is a critical advantage for Ligand A, as hERG inhibition can cause cardiotoxicity.
12. **Microsomal Clearance:** Ligand B (63.126) has a higher clearance than Ligand A (31.327), indicating lower metabolic stability.
13. **In vitro Half-Life:** Ligand A (38.678) has a significantly longer half-life than Ligand B (4.245).
14. **P-gp Efflux:** Ligand A (0.153) has lower P-gp efflux than Ligand B (0.76). Lower efflux is generally desirable.
15. **Binding Affinity:** Ligand B (-6.2 kcal/mol) has a stronger binding affinity than Ligand A (-4.9 kcal/mol). This is a substantial advantage for Ligand B. However, the other ADME properties of Ligand B are significantly worse.
**Overall Assessment:**
While Ligand B has a better binding affinity, its significantly higher logP, higher DILI risk, poorer solubility, higher hERG risk, higher clearance, shorter half-life, and higher P-gp efflux make it a less desirable candidate. Ligand A, despite a slightly weaker affinity, presents a much more balanced profile with better ADME properties and a lower risk of toxicity. The affinity difference, while notable, is not large enough to overcome the substantial ADME deficiencies of Ligand B.
Output:
1
2025-04-17 22:24:22,241 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (369.45 & 361.52 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand B (54.26) is significantly better than Ligand A (129.46). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (2.493) is optimal (1-3), while Ligand A (-0.459) is below 1, potentially hindering permeation. This is a substantial advantage for Ligand B.
4. **HBD:** Ligand A (2) is preferable to Ligand B (0). While both are acceptable, a small number of HBDs can aid solubility.
5. **HBA:** Ligand B (6) is preferable to Ligand A (5). Both are within the acceptable range.
6. **QED:** Both ligands have similar, good QED values (0.742 and 0.76).
7. **DILI:** Ligand B (27.414) is much better than Ligand A (70.88), indicating a significantly lower risk of drug-induced liver injury. This is a critical advantage.
8. **BBB:** Ligand B (65.917) is better than Ligand A (29.12), but neither is particularly high. Not a major factor for a cardiovascular target.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.375 and -5.222), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand B (-0.742) is slightly better than Ligand A (-2.529), but both are poor.
11. **hERG:** Ligand B (0.602) is better than Ligand A (0.13), indicating a lower risk of cardiotoxicity.
12. **Cl_mic:** Ligand A (-0.356) is significantly better than Ligand B (16.038), suggesting much better metabolic stability. This is a major advantage for Ligand A.
13. **t1/2:** Ligand B (12.974) has a longer half-life than Ligand A (-39.35). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand B (0.105) is better than Ligand A (0.033), indicating lower P-gp efflux.
15. **Binding Affinity:** Ligand A (-7.7) has a slightly better binding affinity than Ligand B (-6.7). While a 1 kcal/mol difference is noticeable, it needs to be weighed against other factors.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP, TPSA, and Pgp. Ligand A has a slightly better affinity, but the other ADME properties of Ligand B are far more favorable. The DILI risk with Ligand A is also a significant concern.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity and metabolic stability, Ligand B's superior logP, TPSA, lower DILI risk, better hERG profile, and longer half-life outweigh this advantage. The poor Caco-2 values for both are concerning, but Ligand B's overall profile is more promising for development.
Output:
0
2025-04-17 22:24:22,241 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 drug candidates. ADRB2 is a GPCR, so we'll prioritize logP, Pgp, TPSA, and affinity, alongside general drug-like properties.
**Ligand A:** [335.363, 81.16, 3.39, 1, 5, 0.604, 84.102, 67.352, -5.488, -3.432, 0.514, 92.505, 63.821, 0.51, -7.2]
**Ligand B:** [352.494, 49.41, 3.735, 1, 2, 0.643, 16.053, 88.174, -4.63, -3.55, 0.733, 35.187, 7.294, 0.563, -6.9]
**1. Molecular Weight:** Both are within the ideal range (200-500 Da). A is 335, B is 352. No strong preference here.
**2. TPSA:** Ligand A (81.16) is higher than Ligand B (49.41). For a cardiovascular GPCR, lower TPSA is generally preferred for better permeability, so B is better.
**3. logP:** Both are good (around 3.4), falling within the optimal 1-3 range. B is slightly higher at 3.735, which *could* be a minor advantage for membrane permeability, but not a decisive factor.
**4. H-Bond Donors:** Both have 1 HBD, which is good.
**5. H-Bond Acceptors:** A has 5, B has 2. Lower is generally better for permeability, so B is better.
**6. QED:** Both are acceptable (0.604 and 0.643), indicating reasonable drug-likeness.
**7. DILI Risk:** Ligand A (84.102) has a significantly higher DILI risk than Ligand B (16.053). This is a major concern for A.
**8. BBB Penetration:** Ligand B (88.174) has better BBB penetration than Ligand A (67.352). While not critical for a cardiovascular target, it's a bonus.
**9. Caco-2 Permeability:** Ligand A (-5.488) is worse than Ligand B (-4.63). Lower values indicate lower permeability.
**10. Aqueous Solubility:** Both are very poor (-3.432 and -3.55). This is a concern for both, but not a deciding factor between them.
**11. hERG Inhibition:** Ligand A (0.514) has a slightly higher hERG risk than Ligand B (0.733). Lower is better, so B is slightly preferred.
**12. Microsomal Clearance:** Ligand A (92.505) has significantly higher clearance than Ligand B (35.187). This means A is metabolized much faster, leading to a shorter duration of action. B is much better.
**13. In vitro Half-Life:** Ligand A (63.821) has a shorter half-life than Ligand B (7.294). This is consistent with the clearance data. B is much better.
**14. P-gp Efflux:** Both are similar (0.51 and 0.563).
**15. Binding Affinity:** Ligand A (-7.2) has a slightly better binding affinity than Ligand B (-6.9). This is a 0.3 kcal/mol difference, which is not a huge advantage, and is outweighed by the other factors.
**Conclusion:**
Ligand B is significantly better overall. It has a much lower DILI risk, better permeability, better metabolic stability (lower clearance, longer half-life), and better BBB penetration. While Ligand A has slightly better binding affinity, the other ADME/Tox properties of Ligand B are far more favorable for drug development, especially considering the GPCR target class.
0
2025-04-17 22:24:22,241 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Ligand A (446.355 Da) is within the ideal range (200-500 Da). Ligand B (355.385 Da) is also within range, and slightly preferred due to being closer to the lower bound which can aid permeability.
2. **TPSA:** Ligand A (72.7) is good, below the 140 threshold. Ligand B (85.4) is still acceptable, but less optimal.
3. **logP:** Ligand A (3.756) is at the higher end of the optimal range (1-3), but still acceptable. Ligand B (1.716) is good, within the optimal range.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 7 HBA, within the acceptable range. Ligand B has 4 HBA, also good.
6. **QED:** Both ligands have acceptable QED values (A: 0.467, B: 0.685), with B being slightly better.
7. **DILI:** Ligand A (63.358) has a higher DILI risk than Ligand B (35.983). This is a significant concern.
8. **BBB:** Ligand A (55.06) has a moderate BBB penetration, while Ligand B (92.71) has excellent BBB penetration. Given this is a GPCR, BBB penetration is important.
9. **Caco-2:** Ligand A (-5.66) has poor Caco-2 permeability, while Ligand B (-4.489) is better, but still low.
10. **Solubility:** Ligand A (-3.326) has poor solubility, while Ligand B (-2.835) is slightly better.
11. **hERG:** Ligand A (0.529) has a slightly higher hERG risk than Ligand B (0.192).
12. **Cl_mic:** Ligand A (63.317) has higher microsomal clearance than Ligand B (38.228), indicating lower metabolic stability.
13. **t1/2:** Ligand A (24.995) has a longer half-life than Ligand B (-4.703). This is a positive for A.
14. **Pgp:** Ligand A (0.552) has lower P-gp efflux than Ligand B (0.023), which is preferable.
15. **Binding Affinity:** Ligand B (-6.6 kcal/mol) has a slightly better binding affinity than Ligand A (-6.1 kcal/mol).
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand B excels in Pgp and BBB, and has a slightly better affinity. While Ligand A has a longer half-life, its significantly higher DILI risk, poor solubility, and poor Caco-2 permeability are major drawbacks. The better BBB penetration of Ligand B is also a significant advantage.
**Conclusion:**
Despite the longer half-life of Ligand A, the superior ADME profile and binding affinity of Ligand B, particularly its lower DILI risk and better BBB penetration, make it the more promising drug candidate.
Output:
0
2025-04-17 22:24:22,241 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
Let's break down the comparison of Ligand A and Ligand B across the 15 parameters, keeping in mind the GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key).
1. **MW:** Both ligands (354.535 Da and 354.447 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (59.59) is significantly better than Ligand B (88.1). A lower TPSA generally favors better cell permeability, which is crucial for GPCR targeting. Ligand B is pushing the upper limit for good oral absorption.
3. **logP:** Ligand A (4.153) is higher than Ligand B (0.511). While a logP of 4.153 is approaching the upper limit, it's still acceptable. Ligand B's logP is quite low, potentially hindering membrane permeability and bioavailability.
4. **HBD:** Both ligands have 2 H-bond donors, which is within the acceptable range.
5. **HBA:** Ligand A has 4 H-bond acceptors, while Ligand B has 5. Both are acceptable, but lower is generally better for permeability.
6. **QED:** Both ligands have similar QED values (0.721 and 0.696), indicating good drug-like properties.
7. **DILI:** Ligand A (11.283) has a lower DILI risk than Ligand B (13.61). Lower is better, so Ligand A is preferable.
8. **BBB:** Ligand A (83.443) has a higher BBB penetration percentile than Ligand B (70.686). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be beneficial for distribution and off-target effects.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.755 and -4.82). This is unusual and suggests poor permeability in this assay. However, the values are very similar.
10. **Solubility:** Ligand A (-2.655) has slightly better solubility than Ligand B (-1.167), but both are quite poor. Solubility could be a formulation challenge for both.
11. **hERG:** Ligand A (0.774) has a slightly lower hERG inhibition liability than Ligand B (0.188), indicating a lower risk of cardiotoxicity.
12. **Cl_mic:** Ligand A (46.644) has a lower microsomal clearance than Ligand B (15.281). Lower clearance means greater metabolic stability, which is desirable.
13. **t1/2:** Ligand B (19.414) has a longer in vitro half-life than Ligand A (12.232). This is a positive for Ligand B.
14. **Pgp:** Ligand A (0.122) has lower P-gp efflux liability than Ligand B (0.042). Lower Pgp efflux is generally preferred for better bioavailability.
15. **Affinity:** Ligand A (-6.5 kcal/mol) has a slightly better binding affinity than Ligand B (-5.3 kcal/mol). This 1.2 kcal/mol difference is significant and can outweigh some of the ADME drawbacks.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical parameters, especially TPSA, logP, DILI, Cl_mic, and affinity. While Ligand B has a longer half-life, the superior permeability (TPSA), metabolic stability (Cl_mic), and binding affinity of Ligand A make it the more promising candidate. The slightly better solubility and lower hERG risk of Ligand A further support this conclusion.
**Output:**
1
2025-04-17 22:24:22,241 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (336.355 and 349.439 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (101.8) is better than Ligand B (115.9), being closer to the <140 threshold for good oral absorption.
3. **logP:** Ligand A (2.088) is optimal (1-3). Ligand B (-0.374) is below 1, which could hinder permeation. This is a significant negative for Ligand B.
4. **HBD:** Both ligands have acceptable HBD counts (2 and 3 respectively), well below the 5 threshold.
5. **HBA:** Both ligands have acceptable HBA counts (6), below the 10 threshold.
6. **QED:** Ligand A (0.759) has a better QED score than Ligand B (0.531), indicating a more drug-like profile.
7. **DILI:** Ligand B (34.587) has a much lower DILI risk than Ligand A (90.733). This is a strong positive for Ligand B.
8. **BBB:** Ligand B (45.522) is slightly better than Ligand A (40.403), but both are relatively low. Since ADRB2 is a cardiovascular target, BBB penetration isn't a primary concern, but it's still a slight advantage for B.
9. **Caco-2:** Both have negative values, indicating poor permeability. Ligand A (-5.205) is slightly better than Ligand B (-5.788).
10. **Solubility:** Ligand A (-3.401) is better than Ligand B (-1.423), indicating better aqueous solubility.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.349 and 0.033 respectively). No significant difference.
12. **Cl_mic:** Ligand B (-4.906) has a significantly *lower* (better) microsomal clearance than Ligand A (16.743), suggesting greater metabolic stability.
13. **t1/2:** Ligand A (32.863) has a much longer in vitro half-life than Ligand B (3.133). This is a significant advantage for Ligand A.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.062 and 0.007 respectively). No significant difference.
15. **Binding Affinity:** Ligand A (-6.4 kcal/mol) has a slightly better binding affinity than Ligand B (-5.8 kcal/mol), though the difference is less than 1.5 kcal/mol.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand A excels in affinity and has a better logP and TPSA. However, Ligand B has a much better DILI score and Cl_mic. The significantly lower DILI risk for Ligand B is very important. While the half-life is better for Ligand A, metabolic stability (reflected in Cl_mic) is often more critical for *in vivo* performance. The logP for Ligand B is a concern, but the other factors outweigh this.
**Conclusion:**
Considering the balance of properties, particularly the significantly lower DILI risk and better metabolic stability of Ligand B, I believe it is the more viable drug candidate despite its lower logP. The slightly weaker binding affinity can potentially be optimized in later stages of development.
Output:
0
2025-04-17 22:24:22,241 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (404.195 Da) is within the ideal range (200-500). Ligand B (357.405 Da) is also excellent. No clear advantage here.
2. **TPSA:** Ligand A (84.22) is good, below the 140 threshold for oral absorption. Ligand B (98.17) is still acceptable, but less optimal. A slight edge to Ligand A.
3. **logP:** Both ligands (A: 3.092, B: 2.864) are within the optimal 1-3 range. No significant difference.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable. Ligand B is slightly better.
5. **HBA:** Ligand A (5) and Ligand B (3) are both good. Ligand B is slightly better.
6. **QED:** Ligand A (0.703) is significantly better than Ligand B (0.41), indicating a more drug-like profile. This is a substantial advantage for Ligand A.
7. **DILI:** Ligand A (93.718) has a high DILI risk, which is concerning. Ligand B (29.236) has a very low DILI risk, a major advantage.
8. **BBB:** Ligand A (23.226) has very low BBB penetration. Ligand B (84.451) has much better BBB penetration, though still not exceptionally high. Given ADRB2 is a cardiovascular target, BBB penetration isn't *critical*, but it's a bonus.
9. **Caco-2:** Both have negative values, which is unusual. Assuming these are logP-scaled permeability values, lower is worse. Ligand A (-5.239) is worse than Ligand B (-4.738). Ligand B is slightly better.
10. **Solubility:** Both have negative values, indicating poor solubility. Ligand A (-4.28) is slightly worse than Ligand B (-2.602). Ligand B is slightly better.
11. **hERG:** Both ligands have low hERG inhibition risk (A: 0.487, B: 0.426). No significant difference.
12. **Cl_mic:** Ligand A (28.436) has higher metabolic clearance than Ligand B (5.607). Ligand B is significantly more metabolically stable, a major advantage.
13. **t1/2:** Ligand A (11.634) has a longer half-life than Ligand B (-11.337). This is a substantial advantage for Ligand A.
14. **Pgp:** Ligand A (0.25) has lower P-gp efflux than Ligand B (0.033). Ligand A is better.
15. **Binding Affinity:** Ligand A (-7.3 kcal/mol) has a slightly better binding affinity than Ligand B (-6.6 kcal/mol). This is a meaningful difference, and a key factor.
**Overall Assessment:**
Ligand A has a better QED, longer half-life, better Pgp profile, and slightly better binding affinity. However, it has a very high DILI risk and poor BBB penetration. Ligand B has a much better safety profile (DILI), metabolic stability, and slightly better solubility and Caco-2 permeability. The difference in binding affinity is not large enough to overcome the significant safety concerns with Ligand A. For a cardiovascular target, metabolic stability and safety are paramount.
Therefore, I favor Ligand B.
Output:
0
2025-04-17 22:24:22,241 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (370.435 and 351.407 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (125.55 and 124.84) are slightly above the optimal <140 for good oral absorption, but acceptable for a non-CNS GPCR target like ADRB2. No major difference.
3. **logP:** Ligand B (-1.368) is slightly more negative than Ligand A (-0.911). Both are acceptable, but closer to the lower end of the optimal 1-3 range.
4. **HBD:** Both ligands have 3 H-bond donors, which is within the acceptable limit of <=5.
5. **HBA:** Ligand A has 7 H-bond acceptors, while Ligand B has 4. Both are within the acceptable limit of <=10. Ligand B is preferable here.
6. **QED:** Ligand A (0.616) has a better QED score than Ligand B (0.403), indicating a more drug-like profile. This is a significant advantage for Ligand A.
7. **DILI:** Ligand B (26.095) has a significantly lower DILI risk than Ligand A (63.552). This is a major advantage for Ligand B.
8. **BBB:** Both ligands have similar BBB penetration (56.378 and 58.511). Since ADRB2 is not a primary CNS target, this is less critical.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.592 and -5.116). This suggests poor permeability.
10. **Solubility:** Both ligands have negative solubility values (-1.263 and -1.62). This suggests poor solubility.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.021 and 0.059). This is good.
12. **Cl_mic:** Ligand B (-13.475) has a much lower (better) microsomal clearance than Ligand A (1.154), indicating greater metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand B (-20.683) has a much longer in vitro half-life than Ligand A (17.46). This is a significant advantage for Ligand B.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.005 and 0.002). This is good.
15. **Binding Affinity:** Both ligands have similar binding affinities (-6.1 and -6.2 kcal/mol).
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are important. While both ligands have similar affinity and Pgp values, Ligand B has a slightly better logP and a significantly better metabolic profile (Cl_mic and t1/2) and lower DILI risk. The better QED of Ligand A is offset by the significant safety and PK advantages of Ligand B.
**Conclusion:**
Considering the balance of properties, particularly the lower DILI risk, improved metabolic stability (lower Cl_mic, longer t1/2), and acceptable logP, Ligand B is the more promising drug candidate.
Output:
0
2025-04-17 22:24:22,242 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (351.332 Da) is slightly lower than Ligand B (372.774 Da), which is generally favorable for permeability.
2. **TPSA:** Ligand A (75.6) is higher than Ligand B (42.43). For a cardiovascular GPCR like ADRB2, TPSA is less critical than for CNS targets, but lower is still preferred. Ligand B is significantly better here.
3. **logP:** Both ligands have logP values within the optimal range (1-3), but Ligand B (4.18) is pushing the upper limit. Ligand A (2.771) is better positioned.
4. **HBD:** Ligand A (2) and Ligand B (0) are both acceptable.
5. **HBA:** Ligand A (4) and Ligand B (3) are both acceptable.
6. **QED:** Both ligands have good QED scores (A: 0.742, B: 0.79), indicating good drug-like properties.
7. **DILI:** Ligand A (76.968) has a higher DILI risk than Ligand B (56.146). This is a significant advantage for Ligand B.
8. **BBB:** Both ligands show reasonable BBB penetration (A: 71.733, B: 79.488). While ADRB2 isn't a primary CNS target, some degree of BBB penetration can be useful for understanding off-target effects. Ligand B is slightly better.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-5.086) is slightly better than Ligand B (-4.512).
10. **Solubility:** Both ligands have negative solubility values, which is also unusual and suggests poor solubility. Ligand A (-3.597) is slightly better than Ligand B (-3.98).
11. **hERG:** Both ligands have low hERG inhibition risk (A: 0.558, B: 0.719). Ligand B is slightly better.
12. **Cl_mic:** Ligand A (29.257) has a significantly lower microsomal clearance than Ligand B (50.423), indicating better metabolic stability. This is a substantial advantage for Ligand A.
13. **t1/2:** Ligand A (23.835) has a longer in vitro half-life than Ligand B (7.099), further supporting its better metabolic stability.
14. **Pgp:** Both ligands have low Pgp efflux liability (A: 0.216, B: 0.559). Ligand A is better.
15. **Binding Affinity:** Ligand B (-7.0) has a significantly stronger binding affinity than Ligand A (-5.6). This is a crucial advantage, potentially outweighing some of the ADME drawbacks.
**Overall Assessment:**
Ligand B has a superior binding affinity (-7.0 kcal/mol vs -5.6 kcal/mol), which is the most important factor for GPCRs. It also has a lower DILI risk and better TPSA. While its logP is slightly higher, and its metabolic stability is worse, the substantial affinity advantage is likely to be decisive. The negative Caco-2 and solubility values are concerning for both, but can be addressed during lead optimization.
Output:
0
2025-04-17 22:24:22,242 - INFO - Batch 329 complete. Total preferences: 5264
2025-04-17 22:24:22,242 - INFO - Processing batch 330/512...
2025-04-17 22:25:12,664 - INFO - Reasoning:
Let's analyze Ligand A and Ligand B for their potential as ADRB2 ligands, keeping in mind GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key).
**Molecular Weight:** Both ligands (348.462 and 346.391 Da) fall within the ideal 200-500 Da range.
**TPSA:** Ligand A (58.2) is excellent, well below the 140 threshold and suggesting good absorption. Ligand B (104.05) is higher but still acceptable, though less optimal.
**logP:** Ligand A (3.191) is within the optimal 1-3 range. Ligand B (0.435) is quite low, potentially hindering membrane permeability and absorption. This is a significant drawback.
**H-Bond Donors/Acceptors:** Ligand A (2 HBD, 2 HBA) is well within acceptable limits. Ligand B (1 HBD, 8 HBA) is also acceptable, but the higher HBA count could slightly impact permeability.
**QED:** Both ligands have good QED scores (0.75 and 0.809), indicating good drug-like properties.
**DILI:** Ligand A (31.059) has a much lower DILI risk than Ligand B (71.113), which is a substantial advantage.
**BBB:** Ligand A (74.835) shows good BBB penetration, while Ligand B (51.299) is lower. While ADRB2 isn't exclusively a CNS target, some CNS exposure could be beneficial or at least not detrimental, and Ligand A is better in this regard.
**Caco-2:** Ligand A (-4.844) and Ligand B (-5.314) both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
**Solubility:** Ligand A (-3.9) and Ligand B (-1.595) both have negative solubility values, which is also unusual.
**hERG:** Ligand A (0.273) has a very low hERG risk, which is excellent. Ligand B (0.092) also has a very low hERG risk.
**Cl_mic:** Ligand A (23.334) has a slightly higher microsomal clearance than Ligand B (20.871), suggesting potentially lower metabolic stability, but both are reasonably good.
**t1/2:** Ligand B (14.807) has a significantly longer in vitro half-life than Ligand A (3.823), which is a positive attribute.
**Pgp:** Ligand A (0.207) has lower P-gp efflux liability than Ligand B (0.037), which is favorable for bioavailability.
**Binding Affinity:** Ligand B (-8.0 kcal/mol) has a substantially stronger binding affinity than Ligand A (-6.5 kcal/mol). This is a significant advantage, potentially outweighing some of the ADME drawbacks.
**Overall Assessment:**
Ligand B has a significantly better binding affinity, and a longer half-life. However, it suffers from a low logP, higher DILI risk, and lower BBB penetration. Ligand A has a better logP, lower DILI risk, better BBB penetration, and lower Pgp efflux, but a weaker binding affinity and shorter half-life.
Considering the GPCR-specific priorities, the strong binding affinity of Ligand B is a major advantage. While the low logP is a concern, the difference in binding affinity (-8.0 vs -6.5 kcal/mol) is substantial and could be addressed with further optimization. The DILI risk is elevated, but not prohibitive at 71.113.
Output:
0
2025-04-17 22:25:12,664 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (341.455 & 344.455 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (56.15) is better than Ligand B (62.55). Both are under the 140 threshold for oral absorption, but lower TPSA is generally preferred for GPCRs.
3. **logP:** Both ligands (3.744 & 3.229) are within the optimal 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability, but not dramatically so.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 3. Both are acceptable.
6. **QED:** Ligand A (0.871) has a better QED score than Ligand B (0.773), indicating a more drug-like profile.
7. **DILI:** Both ligands have acceptable DILI risk (44.862 & 42.769 percentile), below the 60 threshold. Ligand B is slightly better.
8. **BBB:** Ligand A (82.474) has a significantly higher BBB penetration percentile than Ligand B (66.382). While ADRB2 isn't exclusively a CNS target, some CNS exposure can occur, and higher BBB is generally a plus.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.639 and -4.656). This is unusual and suggests poor permeability. However, the values are very similar.
10. **Solubility:** Ligand A (-4.498) has slightly worse solubility than Ligand B (-2.636). Solubility is important, so this favors Ligand B.
11. **hERG:** Ligand A (0.782) has a slightly higher hERG risk than Ligand B (0.423), which is less desirable.
12. **Cl_mic:** Ligand B (76.416) has a lower microsomal clearance than Ligand A (92.411), indicating better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand B (68.701) has a significantly longer in vitro half-life than Ligand A (32.178). This is a major advantage, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.717) has lower P-gp efflux than Ligand B (0.324), which is favorable for bioavailability.
15. **Affinity:** Ligand A (-7.2 kcal/mol) has a slightly better binding affinity than Ligand B (-6.9 kcal/mol). This is a key factor, and the 0.3 kcal/mol difference is meaningful.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), we prioritize logP, Pgp, TPSA, and affinity. Ligand A has a slightly better logP and Pgp, and significantly better affinity. Ligand B has better TPSA and metabolic stability (Cl_mic and t1/2).
**Overall Assessment:**
The affinity difference is the most important factor. While Ligand B has better metabolic stability and solubility, the stronger binding of Ligand A to the ADRB2 receptor is likely to outweigh these benefits. The slightly better BBB penetration of Ligand A is also a plus. The Caco-2 values are concerning for both, but the affinity advantage of A is more critical.
Output:
1
2025-04-17 22:25:12,664 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.462 and 351.535 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (40.62) is better than Ligand B (52.65). Both are below 140, but lower TPSA generally favors absorption.
3. **logP:** Both ligands (2.338 and 2.22) are within the optimal 1-3 range. Very similar.
4. **HBD:** Ligand A (0) is preferable to Ligand B (1). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (2) is preferable to Ligand B (3). Lower HBA is generally better for permeability.
6. **QED:** Both ligands (0.663 and 0.693) have good drug-likeness scores, exceeding the 0.5 threshold. No strong preference.
7. **DILI:** Ligand A (10.702) is significantly better than Ligand B (5.428). Lower DILI risk is crucial.
8. **BBB:** Both ligands have high BBB penetration (86.817 and 85.033). Since ADRB2 is a cardiovascular target, BBB penetration is less critical, but still a positive.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.478 and -4.794). These values are unusual and suggest poor permeability. However, the values are very similar.
10. **Solubility:** Ligand A (-3.054) is slightly better than Ligand B (-2.11), but both are poor. Solubility is a concern for both.
11. **hERG:** Ligand A (0.672) is slightly better than Ligand B (0.719). Lower hERG inhibition is desirable.
12. **Cl_mic:** Ligand B (31.9) has lower microsomal clearance than Ligand A (39.815), indicating better metabolic stability.
13. **t1/2:** Ligand B (0.377) has a slightly better in vitro half-life than Ligand A (-14.003).
14. **Pgp:** Ligand A (0.121) has lower P-gp efflux than Ligand B (0.076), which is beneficial for bioavailability.
15. **Binding Affinity:** Ligand B (-8.0) has a significantly stronger binding affinity than Ligand A (-5.6). This is a substantial advantage, potentially outweighing some ADME drawbacks.
**GPCR-Specific Considerations:**
For GPCRs like ADRB2, logP, Pgp, TPSA, and affinity are key. Both ligands have acceptable logP and BBB. Ligand A has a lower TPSA and Pgp efflux. However, the *significant* difference in binding affinity (-8.0 vs -5.6 kcal/mol) heavily favors Ligand B. A 2.4 kcal/mol difference is substantial and could translate to a much more potent drug. While Ligand A has better DILI and hERG scores, the potency advantage of Ligand B is likely to be more impactful, and the DILI/hERG risks can be further mitigated during optimization.
**Conclusion:**
Despite some ADME drawbacks, the significantly stronger binding affinity of Ligand B makes it the more promising drug candidate.
Output:
0
2025-04-17 22:25:12,664 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.39 and 376.52 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (107.11 and 101.57) are reasonably low, suggesting good potential for absorption, though slightly above the optimal <90 for CNS targets (not critical for ADRB2, a cardiovascular target). Ligand B is slightly better.
3. **logP:** Ligand A (0.039) is quite low, potentially hindering membrane permeability. Ligand B (1.723) is much better, falling within the optimal 1-3 range. This is a significant advantage for Ligand B.
4. **HBD:** Both have 2 HBD, which is within the acceptable limit of <=5.
5. **HBA:** Ligand A has 6 HBA, and Ligand B has 5. Both are within the acceptable limit of <=10.
6. **QED:** Ligand A (0.727) has a better QED score than Ligand B (0.597), indicating a more drug-like profile.
7. **DILI:** Both ligands have similar DILI risk (30.98 and 41.06 percentile), both being reasonably low.
8. **BBB:** Ligand B (59.95) has a higher BBB penetration potential than Ligand A (40.33), but BBB isn't a primary concern for a cardiovascular target like ADRB2.
9. **Caco-2:** Both ligands have similar, poor Caco-2 permeability (-4.846 and -4.82). This is a concern for both.
10. **Solubility:** Ligand A (-1.646) has better aqueous solubility than Ligand B (-2.739). This is a slight advantage for Ligand A.
11. **hERG:** Both ligands have low hERG inhibition risk (0.162 and 0.208).
12. **Cl_mic:** Ligand A (7.4 mL/min/kg) has significantly lower microsomal clearance than Ligand B (88.509 mL/min/kg), indicating better metabolic stability. This is a major advantage for Ligand A.
13. **t1/2:** Ligand A (12.297 hours) has a much longer in vitro half-life than Ligand B (-47.708 hours - a negative value suggests very rapid degradation). This is a substantial advantage for Ligand A.
14. **Pgp:** Both ligands have similar, low P-gp efflux liability (0.037 and 0.039).
15. **Binding Affinity:** Ligand B (-7.1 kcal/mol) has slightly better binding affinity than Ligand A (-7.0 kcal/mol), but the difference is minimal.
**GPCR-Specific Priorities:** For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand B excels in logP and has a slightly better affinity. However, Ligand A has a significantly better metabolic profile (lower Cl_mic and longer t1/2) and better solubility. The poor Caco-2 permeability is a concern for both, but the metabolic stability and solubility advantages of Ligand A are more critical for overall drug development success.
**Conclusion:**
While Ligand B has a slightly better logP and affinity, Ligand A's superior metabolic stability (lower Cl_mic, longer t1/2) and solubility, combined with a still-competitive binding affinity, make it the more promising candidate.
Output:
1
2025-04-17 22:25:12,665 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (339.33 and 349.475 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (88.91) is slightly higher than Ligand B (72.88). Both are below the 140 A^2 threshold for good oral absorption, but Ligand B is closer to the 90 A^2 threshold potentially favorable for GPCRs.
3. **logP:** Ligand A (2.617) is within the optimal 1-3 range. Ligand B (0.905) is slightly below 1, which could potentially hinder permeation. This is a point in favor of Ligand A.
4. **HBD:** Both ligands have 2 HBD, which is acceptable.
5. **HBA:** Ligand A has 5 HBA, and Ligand B has 4. Both are within the acceptable range of <=10.
6. **QED:** Ligand A (0.715) has a slightly better QED score than Ligand B (0.67), indicating a more drug-like profile.
7. **DILI:** Ligand B (8.957) has a significantly lower DILI risk than Ligand A (96.045). This is a major advantage for Ligand B.
8. **BBB:** Ligand A (44.591) has a lower BBB penetration percentile than Ligand B (36.409). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant for off-target effects and overall safety assessment. Ligand B is slightly better.
9. **Caco-2:** Both ligands have very negative Caco-2 values (-4.837 and -4.847), indicating poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-4.066) has slightly better solubility than Ligand B (-1.019), but both are quite poor.
11. **hERG:** Ligand A (0.348) has a lower hERG risk than Ligand B (0.141), which is preferable.
12. **Cl_mic:** Ligand B (18.077) has a lower microsomal clearance than Ligand A (14.56), suggesting better metabolic stability.
13. **t1/2:** Ligand A (38.037) has a significantly longer in vitro half-life than Ligand B (5.612). This is a strong advantage for Ligand A.
14. **Pgp:** Ligand A (0.038) has lower P-gp efflux liability than Ligand B (0.028), which is favorable.
15. **Binding Affinity:** Ligand B (-6.7 kcal/mol) has a stronger binding affinity than Ligand A (-5.8 kcal/mol). This is a substantial advantage, exceeding the 1.5 kcal/mol threshold.
**GPCR-specific considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are crucial. Ligand B has a better logP and TPSA, and a significantly better binding affinity. While Ligand A has a better half-life, the substantial affinity difference of Ligand B outweighs this. The lower DILI risk of Ligand B is also a significant benefit. The poor Caco-2 values for both are a concern, but can be addressed with formulation strategies.
**Conclusion:**
Despite the longer half-life of Ligand A, the superior binding affinity, lower DILI risk, and slightly better TPSA/logP profile of Ligand B make it the more promising drug candidate for ADRB2.
Output:
0
2025-04-17 22:25:12,665 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (362.499 Da and 348.447 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (76.02) is significantly better than Ligand B (98.32). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is approaching a level that might hinder oral absorption.
**3. logP:** Ligand A (3.123) is within the optimal 1-3 range. Ligand B (1.161) is on the lower side, which could potentially limit membrane permeability.
**4. H-Bond Donors:** Ligand A (2) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
**5. H-Bond Acceptors:** Ligand A (5) is preferable to Ligand B (4). Fewer HBAs generally improve permeability.
**6. QED:** Both ligands have similar and acceptable QED values (0.709 and 0.718).
**7. DILI:** Ligand A (32.377) has a slightly higher DILI risk than Ligand B (21.753), but both are well below the concerning threshold of 60.
**8. BBB:** Ligand A (59.093) has a better BBB penetration score than Ligand B (36.642). While ADRB2 is a cardiovascular target, some CNS exposure is possible, and higher BBB penetration isn't necessarily detrimental.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, indicating poor permeability. However, Ligand A (-5.401) is slightly better than Ligand B (-5.152).
**10. Aqueous Solubility:** Both ligands have negative solubility values, indicating poor solubility. Ligand A (-1.995) is slightly better than Ligand B (-1.572).
**11. hERG Inhibition:** Ligand A (0.66) is significantly better than Ligand B (0.222). Lower hERG inhibition is crucial for avoiding cardiotoxicity, a major concern for cardiovascular drugs.
**12. Microsomal Clearance:** Ligand B (-15.661) has significantly lower (better) microsomal clearance than Ligand A (39.283), indicating greater metabolic stability.
**13. In vitro Half-Life:** Ligand B (-24.013) has a much longer in vitro half-life than Ligand A (24.566), which is highly desirable.
**14. P-gp Efflux:** Ligand A (0.199) has a lower P-gp efflux liability than Ligand B (0.012), which is better for bioavailability.
**15. Binding Affinity:** Ligand A (-7.6) has a slightly better binding affinity than Ligand B (-6.7). While both are good, the 0.9 kcal/mol difference is significant.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand A emerges as the more promising candidate. While Ligand B has superior metabolic stability and half-life, Ligand A's better TPSA, logP, hERG inhibition, and binding affinity are more critical for a GPCR target. The slightly better affinity of Ligand A can help compensate for the slightly higher clearance. The difference in binding affinity is also substantial enough to outweigh the metabolic advantages of Ligand B.
Output:
1
2025-04-17 22:25:12,665 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Ligand A (453.28 Da) is within the ideal range, while Ligand B (347.463 Da) is towards the lower end but still acceptable.
2. **TPSA:** Both ligands (A: 79.46, B: 77.57) are below the 140 threshold for good oral absorption, and acceptable for a non-CNS GPCR target like ADRB2.
3. **logP:** Ligand A (4.084) is at the upper limit of the optimal range, potentially raising solubility concerns. Ligand B (0.724) is quite low, potentially hindering membrane permeability.
4. **HBD/HBA:** Ligand A (HBD=3, HBA=3) is well within acceptable limits. Ligand B (HBD=2, HBA=5) is also acceptable.
5. **QED:** Both ligands have good QED scores (A: 0.577, B: 0.688), indicating drug-like properties.
6. **DILI:** Ligand B (43.932) has a significantly lower DILI risk than Ligand A (85.77), which is a major advantage.
7. **BBB:** This is less critical for ADRB2, but Ligand B (73.129) has a higher BBB score than Ligand A (60.954).
8. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. This is a concern for both.
9. **Solubility:** Ligand B (-1.127) has better solubility than Ligand A (-5.416).
10. **hERG:** Ligand A (0.811) has a slightly higher hERG risk than Ligand B (0.494), but both are relatively low.
11. **Cl_mic:** Ligand B (23.248) has significantly lower microsomal clearance than Ligand A (47.951), indicating better metabolic stability.
12. **t1/2:** Ligand B (29.749) has a longer in vitro half-life than Ligand A (53.587).
13. **Pgp:** Ligand A (0.378) has lower P-gp efflux than Ligand B (0.01), which is favorable for bioavailability.
14. **Binding Affinity:** Ligand B (-7.1 kcal/mol) has a substantially stronger binding affinity than Ligand A (-6.3 kcal/mol). This is a crucial advantage, exceeding the 1.5 kcal/mol threshold.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand B has a better balance of these properties. While its logP is low, its significantly improved affinity and lower Pgp efflux are compelling. The lower DILI and better metabolic stability are also significant benefits. The Caco-2 values are concerning for both, but the superior binding affinity of Ligand B outweighs this drawback.
**Conclusion:**
Ligand B demonstrates a superior profile overall, primarily due to its significantly stronger binding affinity, lower DILI risk, and improved metabolic stability. These factors outweigh the slightly lower logP.
Output:
0
2025-04-17 22:25:12,665 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (425.689 Da) is within the ideal range, while Ligand B (346.446 Da) is on the lower side, but still acceptable.
2. **TPSA:** Ligand A (63.13) is slightly higher than ideal, but still reasonable for a non-CNS target. Ligand B (58.2) is excellent.
3. **logP:** Both ligands (A: 3.399, B: 3.297) are within the optimal range of 1-3.
4. **HBD:** Ligand A (1) is good. Ligand B (2) is acceptable.
5. **HBA:** Ligand A (3) is good. Ligand B (2) is excellent.
6. **QED:** Both ligands have acceptable QED values (A: 0.82, B: 0.744), indicating good drug-likeness.
7. **DILI:** Ligand A (74.176) has a higher DILI risk than Ligand B (21.753). This is a significant concern.
8. **BBB:** Both have good BBB penetration, but Ligand B (81.039) is slightly better than Ligand A (78.984). While ADRB2 isn't necessarily a CNS target, some peripheral distribution is still desired.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. This is a major issue for both.
10. **Solubility:** Both ligands have negative solubility values, indicating poor solubility. This is a major issue for both.
11. **hERG:** Ligand A (0.956) has a slightly higher hERG risk than Ligand B (0.568), but both are relatively low.
12. **Cl_mic:** Ligand A (29.759) has a significantly lower (better) microsomal clearance than Ligand B (40.399), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-15.392) has a negative half-life, which is concerning. Ligand B (4.472) has a short, but positive, half-life.
14. **Pgp:** Ligand A (0.609) has lower P-gp efflux than Ligand B (0.147), which is favorable.
15. **Affinity:** Ligand B (-7.5 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.7 kcal/mol). This is a 0.8 kcal/mol difference, which is substantial.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Both ligands are good on logP. Ligand A has better Pgp, but Ligand B has better TPSA. The biggest difference is in affinity, where Ligand B is significantly stronger. The DILI risk for Ligand A is also a major drawback.
**Overall Assessment:**
Despite the poor Caco-2 and solubility for both, Ligand B's significantly stronger binding affinity (-7.5 vs -6.7 kcal/mol) and much lower DILI risk outweigh the slightly better metabolic stability and Pgp profile of Ligand A. The affinity difference is large enough to potentially overcome the permeability/solubility issues through formulation strategies.
Output:
0
2025-04-17 22:25:12,665 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (359.495 Da and 350.419 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (66.06) is significantly better than Ligand B (117.13). For a GPCR, keeping TPSA low is beneficial for permeability, and Ligand A is well below the 140 threshold, while Ligand B is approaching it.
**3. logP:** Both ligands have similar logP values (2.506 and 2.518), falling within the optimal 1-3 range.
**4. H-Bond Donors:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
**5. H-Bond Acceptors:** Both ligands have the same number of HBA (4).
**6. QED:** Ligand A (0.911) has a much higher QED score than Ligand B (0.444), indicating a more drug-like profile.
**7. DILI:** Ligand A (41.024) has a lower DILI risk than Ligand B (52.152), which is a positive. Both are below the concerning 60 threshold.
**8. BBB:** Ligand A (76.231) has a better BBB penetration score than Ligand B (69.213), although both are not exceptionally high. Since ADRB2 is a cardiovascular target, BBB penetration is less critical than for CNS targets, but still a consideration.
**9. Caco-2 Permeability:** Both ligands have similar, very negative Caco-2 permeability values. This is concerning and suggests poor absorption for both.
**10. Aqueous Solubility:** Both ligands have very negative solubility values, indicating poor aqueous solubility. This is a significant drawback for both compounds.
**11. hERG Inhibition:** Ligand A (0.792) has a lower hERG inhibition liability than Ligand B (0.521), which is favorable.
**12. Microsomal Clearance:** Ligand A (16.353) has significantly lower microsomal clearance than Ligand B (30.723), suggesting better metabolic stability.
**13. In vitro Half-Life:** Ligand A (-23.425) has a much longer in vitro half-life than Ligand B (-0.651). This is a major advantage.
**14. P-gp Efflux:** Ligand A (0.386) has a lower P-gp efflux liability than Ligand B (0.118), which is preferable.
**15. Binding Affinity:** Ligand B (-6.6 kcal/mol) has a slightly better binding affinity than Ligand A (-5.1 kcal/mol). This is a 1.5 kcal/mol difference, which is significant.
**Overall Assessment:**
While Ligand B has a slightly better binding affinity, Ligand A is superior in almost all other critical ADME-Tox properties. Specifically, Ligand A has a much better QED score, lower DILI risk, better metabolic stability (lower Cl_mic and longer t1/2), lower P-gp efflux, and lower hERG inhibition. The TPSA is also significantly better for Ligand A. The poor Caco-2 and solubility are concerns for both, but the other advantages of Ligand A outweigh the slight affinity difference. For a cardiovascular GPCR, metabolic stability and safety (DILI, hERG) are crucial, and Ligand A excels in these areas.
Output:
1
2025-04-17 22:25:12,665 - INFO - Here's my reasoning and the final output:
**Reasoning:**
We are evaluating two ligands for the ADRB2 receptor, a GPCR involved in cardiovascular function. Therefore, key priorities are logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB (though less critical for a cardiovascular target).
Let's break down the comparison:
1. **MW:** Both ligands (344.4 and 350.5 Da) fall within the ideal 200-500 Da range.
2. **TPSA:** Ligand B (81.1) is significantly better than Ligand A (107.0), being well below the 140 threshold and closer to the preferred <90 for GPCRs.
3. **logP:** Both are good (0.95 and 0.62), falling within the 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability.
4. **HBD/HBA:** Ligand B (2 HBD, 4 HBA) is preferable to Ligand A (3 HBD, 6 HBA) as it has fewer hydrogen bond forming groups, potentially improving permeability.
5. **QED:** Both are acceptable (0.695 and 0.731), indicating good drug-like properties.
6. **DILI:** Ligand B (27.3) has a much lower DILI risk than Ligand A (53.7), a significant advantage.
7. **BBB:** Ligand A (55.1) is slightly better than Ligand B (36.4), but this isn't a primary concern for a cardiovascular target.
8. **Caco-2:** Ligand B (-4.45) is better than Ligand A (-5.75), indicating better intestinal absorption.
9. **Solubility:** Ligand B (-0.88) is better than Ligand A (-2.42), indicating better aqueous solubility.
10. **hERG:** Both are low (0.204 and 0.428), indicating low cardiotoxicity risk.
11. **Cl_mic:** Ligand B (-2.8) has a much lower (better) microsomal clearance than Ligand A (-21.3), suggesting better metabolic stability.
12. **t1/2:** Ligand B (-14.6) has a better in vitro half-life than Ligand A (43.5).
13. **Pgp:** Both are very low (0.028 and 0.079), indicating minimal P-gp efflux.
14. **Binding Affinity:** Ligand B (-7.4) has a slightly better binding affinity than Ligand A (-7.0). While the difference is small, it's still a positive.
**Overall Assessment:**
Ligand B consistently outperforms Ligand A in several crucial ADME properties (DILI, Cl_mic, t1/2, solubility, Caco-2, TPSA) and has a slightly better binding affinity. While Ligand A has a slightly better BBB score and logP, the advantages of Ligand B in ADME and safety outweigh these minor differences. Given the GPCR target class, the lower TPSA and improved ADME profile of Ligand B make it the more promising candidate.
**Output:**
0
2025-04-17 22:25:12,666 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (370.5 & 351.5 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand B (72.88) is better than Ligand A (66.91), both are below the 140 threshold for oral absorption, but closer to the ideal for GPCRs.
3. **logP:** Ligand A (4.44) is higher than Ligand B (0.985). While Ligand A is a bit high, it's not drastically so. Ligand B is quite low, which could hinder membrane permeability.
4. **HBD:** Both ligands have 2 HBD, which is acceptable.
5. **HBA:** Ligand A (6) is slightly higher than Ligand B (4), but both are within the acceptable range.
6. **QED:** Both ligands have good QED scores (0.644 & 0.748), indicating good drug-like properties.
7. **DILI:** Ligand B (8.492) has a *much* lower DILI risk than Ligand A (86.894). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (70.415) has a better BBB penetration score than Ligand B (32.726). While ADRB2 isn't strictly a CNS target, some peripheral ADRB2 activity can be modulated by CNS effects, and higher BBB penetration isn't necessarily a negative.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Ligand B (-1.824) has better aqueous solubility than Ligand A (-5.376).
11. **hERG:** Ligand A (0.606) has slightly better hERG inhibition liability than Ligand B (0.461), but both are relatively low risk.
12. **Cl_mic:** Ligand B (6.787) has significantly lower microsomal clearance than Ligand A (80.217), indicating better metabolic stability.
13. **t1/2:** Ligand A (72.594) has a much longer in vitro half-life than Ligand B (28.644). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand B (0.036) has much lower P-gp efflux liability than Ligand A (0.739), which is beneficial for bioavailability.
15. **Binding Affinity:** Ligand A (-6.7 kcal/mol) has slightly better binding affinity than Ligand B (-6.5 kcal/mol), but the difference is small.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A has a better logP and affinity, but Ligand B excels in TPSA, Pgp efflux, and, crucially, DILI risk and metabolic stability (Cl_mic). The difference in affinity isn't large enough to outweigh the substantial advantages of Ligand B in safety (DILI) and pharmacokinetics (Cl_mic, Pgp).
**Conclusion:**
Despite Ligand A's slightly better affinity and half-life, the significantly lower DILI risk, better metabolic stability, and lower P-gp efflux of Ligand B make it the more promising drug candidate. The slightly lower BBB penetration is acceptable for a primarily peripheral target like ADRB2.
Output:
0
2025-04-17 22:25:12,666 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [346.427, 95.5, 1.814, 3, 4, 0.656, 54.207, 47.111, -4.756, -3.275, 0.169, 22.968, -0.328, 0.104, -7.7]
**Ligand B:** [358.511, 61.92, 3.384, 0, 5, 0.749, 17.914, 75.611, -5.166, -3.157, 0.601, 59.122, -23.568, 0.19, -7.6]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (346.427) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (95.5) is higher than Ligand B (61.92). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is still preferred. Ligand B is significantly better here.
3. **logP:** Both are within the optimal range (1-3). Ligand B (3.384) is a bit higher, which *could* raise concerns about off-target effects, but is still acceptable. Ligand A (1.814) is better.
4. **HBD:** Ligand A (3) is higher than Ligand B (0). Lower is generally better for permeability, so Ligand B is favored.
5. **HBA:** Ligand A (4) and Ligand B (5) are both acceptable, being under 10.
6. **QED:** Both are good (>=0.5), with Ligand B (0.749) being slightly better than Ligand A (0.656).
7. **DILI:** Ligand B (17.914) has a much lower DILI risk than Ligand A (54.207). This is a significant advantage for Ligand B.
8. **BBB:** Ligand B (75.611) has a significantly higher BBB penetration percentile than Ligand A (47.111). While not a CNS target, some BBB penetration can be indicative of favorable distribution properties.
9. **Caco-2:** Ligand A (-4.756) and Ligand B (-5.166) are both negative, indicating poor permeability. This is a concern for both, but they are similar.
10. **Solubility:** Both are very poor (-3.275 and -3.157). This is a major drawback for both compounds and would require significant formulation work.
11. **hERG:** Ligand A (0.169) has a lower hERG risk than Ligand B (0.601), which is desirable.
12. **Cl_mic:** Ligand B (59.122) has a higher clearance than Ligand A (22.968), meaning Ligand A is more metabolically stable.
13. **t1/2:** Ligand A (-0.328) has a slightly better in vitro half-life than Ligand B (-23.568).
14. **Pgp:** Ligand A (0.104) has lower P-gp efflux than Ligand B (0.19), which is preferable.
15. **Affinity:** Both have very similar and excellent binding affinities (-7.7 and -7.6 kcal/mol). The difference is negligible.
**GPCR-Specific Considerations:**
For a cardiovascular GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B excels in TPSA and BBB penetration, and has a much better DILI profile. Ligand A has slightly better logP, Pgp, metabolic stability, and hERG. However, the lower DILI risk of Ligand B is a substantial advantage. The similar affinities mean that the ADME properties become the deciding factor.
**Conclusion:**
Despite the solubility issues with both compounds, Ligand B's superior DILI profile, lower TPSA, and better BBB penetration make it the more promising candidate. The slight increase in logP is a manageable concern compared to the potential for liver toxicity.
Output:
0
2025-04-17 22:25:12,666 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, key priorities are logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB (though less critical for a cardiovascular target).
Let's compare the ligands property by property:
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (355.5) is slightly higher than Ligand B (346.4).
2. **TPSA:** Ligand A (52.65) is significantly better than Ligand B (109.3). Lower TPSA generally improves permeability.
3. **logP:** Ligand A (2.211) is optimal, while Ligand B (-0.8) is quite low, potentially hindering membrane permeability.
4. **HBD/HBA:** Ligand A (1 HBD, 3 HBA) is preferable to Ligand B (3 HBD, 5 HBA). Lower counts are generally better for permeability.
5. **QED:** Both are acceptable (A: 0.762, B: 0.626), indicating reasonable drug-likeness.
6. **DILI:** Ligand A (14.541) has a much lower DILI risk than Ligand B (39.511). This is a significant advantage.
7. **BBB:** Ligand A (91.974) shows better BBB penetration than Ligand B (46.84), but this is less critical for a cardiovascular target.
8. **Caco-2:** Ligand A (-4.638) is better than Ligand B (-5.535), indicating better intestinal absorption.
9. **Solubility:** Ligand A (-2.291) is better than Ligand B (-1.904), although both are poor.
10. **hERG:** Ligand A (0.892) is better than Ligand B (0.023), indicating a lower risk of cardiotoxicity.
11. **Cl_mic:** Ligand B (-9.834) has a better (lower) microsomal clearance than Ligand A (8.743), suggesting greater metabolic stability.
12. **t1/2:** Ligand B (-0.896) has a better (longer) in vitro half-life than Ligand A (-16.144).
13. **Pgp:** Ligand A (0.229) has much lower P-gp efflux liability than Ligand B (0.008), which is a significant advantage for bioavailability.
14. **Affinity:** Ligand A (-6.7 kcal/mol) and Ligand B (-7.0 kcal/mol) have similar binding affinities, with Ligand B being slightly better. However, the difference is not substantial enough to outweigh the other significant advantages of Ligand A.
**Overall Assessment:**
Ligand A presents a much more favorable balance of properties. Its superior TPSA, logP, DILI risk, hERG inhibition, and Pgp efflux liability outweigh the slightly better metabolic stability and half-life of Ligand B. The similar binding affinities further solidify the preference for Ligand A. The cardiovascular target doesn't necessitate high BBB penetration, so the difference in BBB values is less important.
**Output:**
1
2025-04-17 22:25:12,666 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (341.367 Da) is well within the ideal range (200-500 Da). Ligand B (364.555 Da) is also acceptable. No clear advantage here.
2. **TPSA:** Ligand A (111.55) is borderline acceptable for oral absorption, but still reasonable. Ligand B (42.43) is excellent, well below the 140 threshold and suggesting good permeability. **Advantage: B**
3. **logP:** Ligand A (1.95) is optimal. Ligand B (4.361) is a bit high, potentially leading to solubility issues and off-target interactions. **Advantage: A**
4. **HBD:** Ligand A (4) is acceptable. Ligand B (0) is also acceptable, and could be beneficial for permeability. **Slight Advantage: B**
5. **HBA:** Both Ligand A (5) and Ligand B (4) are within the acceptable range. No clear advantage.
6. **QED:** Both Ligand A (0.664) and Ligand B (0.688) are good, indicating drug-like properties. No clear advantage.
7. **DILI:** Ligand A (54.634) has a moderate DILI risk. Ligand B (8.143) has a very low DILI risk. **Advantage: B**
8. **BBB:** Ligand A (37.96) has poor BBB penetration. Ligand B (90.539) has excellent BBB penetration. Given ADRB2 is a GPCR, BBB penetration isn't *critical* unless targeting CNS effects, but it's a bonus. **Advantage: B**
9. **Caco-2:** Both Ligand A (-5.282) and Ligand B (-4.492) have negative values, which is unusual and suggests poor permeability. However, the scale is not specified, so it is difficult to interpret.
10. **Solubility:** Both Ligand A (-4.242) and Ligand B (-4.502) have negative solubility values, suggesting poor solubility.
11. **hERG:** Ligand A (0.316) has a low hERG risk. Ligand B (0.704) has a slightly elevated hERG risk, but still within a reasonable range. **Advantage: A**
12. **Cl_mic:** Ligand A (32.826) has a moderate clearance. Ligand B (93.933) has a high clearance, indicating faster metabolism and potentially lower exposure. **Advantage: A**
13. **t1/2:** Ligand A (-26.819) has a very short half-life. Ligand B (11.063) has a better, though still relatively short, half-life. **Advantage: B**
14. **Pgp:** Ligand A (0.011) has very low P-gp efflux. Ligand B (0.1) has low P-gp efflux. No clear advantage.
15. **Affinity:** Ligand B (-6.2 kcal/mol) has a significantly stronger binding affinity than Ligand A (-3.8 kcal/mol). This is a substantial difference (2.4 kcal/mol), and outweighs many of the ADME concerns. **Advantage: B**
**Overall Assessment:**
Ligand B has a superior binding affinity, lower DILI risk, and better BBB penetration. While its logP is a bit high and its clearance is high, the strong binding affinity is a significant advantage for a GPCR target. Ligand A has better logP and clearance, but its weaker binding affinity and shorter half-life are major drawbacks. The TPSA of Ligand B is also more favorable.
Output:
0
2025-04-17 22:25:12,666 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [380.769, 49.41, 3.11, 1, 2, 0.798, 47.421, 86.39, -4.744, -3.518, 0.688, 11.204, -7.909, 0.166, -7.4]
**Ligand B:** [360.361, 94.48, 0.564, 2, 6, 0.707, 61.07, 74.292, -4.96, -2.491, 0.244, 5.243, 17.818, 0.031, -6.5]
Here's a breakdown, considering the GPCR priorities (logP, Pgp, TPSA, BBB, and affinity) are most important:
1. **MW:** Both are within the ideal 200-500 Da range (A: 380.769, B: 360.361).
2. **TPSA:** Ligand A (49.41) is significantly better than Ligand B (94.48). GPCRs benefit from lower TPSA for permeability.
3. **logP:** Ligand A (3.11) is optimal. Ligand B (0.564) is quite low, potentially hindering membrane permeability and bioavailability.
4. **HBD/HBA:** Ligand A (1 HBD, 2 HBA) is preferable to Ligand B (2 HBD, 6 HBA) as lower counts generally improve permeability.
5. **QED:** Both are acceptable (A: 0.798, B: 0.707), indicating reasonable drug-likeness.
6. **DILI:** Ligand A (47.421) has a better DILI profile than Ligand B (61.07).
7. **BBB:** Ligand A (86.39) has a significantly higher BBB percentile than Ligand B (74.292). While ADRB2 is not a CNS target, higher BBB is generally a positive indicator of permeability.
8. **Caco-2:** Both are negative, indicating poor permeability.
9. **Solubility:** Both are negative, indicating poor solubility.
10. **hERG:** Ligand A (0.688) is better than Ligand B (0.244), indicating lower cardiotoxicity risk.
11. **Cl_mic:** Ligand A (11.204) has better metabolic stability (lower clearance) than Ligand B (5.243).
12. **t1/2:** Ligand A (-7.909) has a much longer predicted half-life than Ligand B (17.818).
13. **Pgp:** Ligand A (0.166) has lower P-gp efflux liability than Ligand B (0.031), which is favorable for bioavailability.
14. **Affinity:** Ligand A (-7.4 kcal/mol) has a slightly better binding affinity than Ligand B (-6.5 kcal/mol), though the difference is not huge.
**Overall Assessment:**
Ligand A is clearly superior. It has a better logP, TPSA, DILI score, BBB penetration, hERG risk profile, metabolic stability, half-life, and P-gp efflux. While both have poor Caco-2 and solubility, the other advantages of Ligand A outweigh these drawbacks, especially given the GPCR target class. The slightly better affinity of Ligand A further solidifies its preference.
Output:
1
2025-04-17 22:25:12,666 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (344.415 and 364.494 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (85.25) is slightly higher than Ligand B (68.52). For a cardiovascular GPCR, TPSA is moderately important, and Ligand B is preferable due to its lower value, suggesting better potential for membrane permeability.
**3. logP:** Both ligands have similar logP values (2.746 and 2.765), falling within the optimal 1-3 range. No clear advantage.
**4. H-Bond Donors:** Ligand A has 2 HBD, while Ligand B has 1. Lower is generally better for permeability, giving a slight edge to Ligand B.
**5. H-Bond Acceptors:** Ligand A has 6 HBA, and Ligand B has 7. Again, lower is preferable, favoring Ligand B slightly.
**6. QED:** Ligand A (0.787) has a slightly higher QED than Ligand B (0.699), indicating a more drug-like profile. This is a positive for Ligand A.
**7. DILI Risk:** Ligand B (51.221) has a significantly lower DILI risk than Ligand A (81.078). This is a major advantage for Ligand B, as minimizing liver toxicity is crucial.
**8. BBB Penetration:** Ligand B (80.341) has better BBB penetration than Ligand A (65.374). While ADRB2 isn't exclusively a CNS target, some CNS exposure or off-target effects are possible, and higher BBB penetration is generally favorable.
**9. Caco-2 Permeability:** Ligand B (-5.25) shows better Caco-2 permeability than Ligand A (-4.638). This suggests better intestinal absorption for Ligand B.
**10. Aqueous Solubility:** Ligand A (-4.575) appears to have slightly better aqueous solubility than Ligand B (-3.192). Solubility is important for formulation, but not a dominant factor here.
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.355 and 0.294), which is excellent. No significant difference.
**12. Microsomal Clearance:** Ligand B (55.301) has significantly lower microsomal clearance than Ligand A (108.935), indicating better metabolic stability. This is a significant advantage for Ligand B.
**13. In vitro Half-Life:** Ligand B (19.115) has a slightly longer in vitro half-life than Ligand A (16.965). This is a positive for Ligand B.
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (0.199 and 0.243). No significant difference.
**15. Binding Affinity:** Ligand B (-6.6 kcal/mol) has a stronger binding affinity than Ligand A (-5.6 kcal/mol). This is a substantial advantage, exceeding the 1.5 kcal/mol threshold that can outweigh other drawbacks.
**Overall Assessment:**
Ligand B consistently outperforms Ligand A across several key ADME properties (DILI, BBB, Caco-2, Clearance, Half-life) and has a significantly stronger binding affinity. While Ligand A has a slightly better QED and solubility, the advantages of Ligand B in terms of safety (DILI), permeability, metabolic stability, and potency are more critical for a viable drug candidate targeting a GPCR like ADRB2.
Output:
0
2025-04-17 22:25:12,667 - INFO - Batch 330 complete. Total preferences: 5280
2025-04-17 22:25:12,667 - INFO - Processing batch 331/512...
2025-04-17 22:26:01,481 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.381 and 354.47 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (61.19) is significantly better than Ligand B (78.09). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (3.463) is slightly higher than Ligand B (2.457), both within the optimal 1-3 range. Ligand A is preferable.
4. **HBD:** Ligand A (0) is better than Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (5) is better than Ligand B (3). Fewer HBAs are generally preferable.
6. **QED:** Ligand A (0.762) is slightly better than Ligand B (0.677), indicating a more drug-like profile.
7. **DILI:** Ligand A (30.05) is significantly better than Ligand B (42.071). Lower DILI risk is crucial.
8. **BBB:** Ligand A (96.472) is much higher than Ligand B (69.523). While not a CNS target, higher BBB penetration *can* sometimes correlate with better overall distribution.
9. **Caco-2:** Ligand A (-4.178) is better than Ligand B (-4.944). Higher Caco-2 permeability is desirable.
10. **Solubility:** Ligand A (-3.699) is better than Ligand B (-2.739). Better solubility is generally preferred.
11. **hERG:** Both ligands (0.598 and 0.513) have reasonably low hERG inhibition liability. No major difference.
12. **Cl_mic:** Both ligands (56.455 and 54.514) have similar microsomal clearance values.
13. **t1/2:** Ligand A (-19.655) is significantly better than Ligand B (-6.717). A longer in vitro half-life is highly desirable.
14. **Pgp:** Ligand A (0.645) is better than Ligand B (0.189). Lower P-gp efflux is preferred.
15. **Affinity:** Ligand A (-7.3 kcal/mol) is slightly better than Ligand B (-6.4 kcal/mol). This is a significant difference in binding affinity.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A excels in all these areas. While BBB isn't a primary concern for a cardiovascular target, the higher value for Ligand A isn't detrimental.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most key parameters, including DILI risk, solubility, half-life, Pgp efflux, and, importantly, binding affinity. The affinity difference of 0.9 kcal/mol is substantial enough to outweigh any minor drawbacks.
Output:
1
2025-04-17 22:26:01,481 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands (372.49 & 371.42 Da) are within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (76.15) is significantly better than Ligand B (121.4). ADRB2 is a cardiovascular target, not CNS, but lower TPSA generally improves absorption. Ligand A is well below the 140 threshold, while B is approaching it.
3. **logP:** Ligand B (1.643) is better than Ligand A (0.359). The optimal range is 1-3, and B falls comfortably within it. A is a bit low, potentially impacting permeability.
4. **HBD:** Both have 0 HBD, which is good.
5. **HBA:** Ligand A (5) is better than Ligand B (8). Lower HBA is generally preferred for permeability.
6. **QED:** Ligand A (0.696) is significantly better than Ligand B (0.438), indicating a more drug-like profile.
7. **DILI:** Ligand A (20.36) is *much* better than Ligand B (73.98). This is a major advantage for A.
8. **BBB:** Both are reasonably high (A: 74.29, B: 76.74), but not critical for a cardiovascular target.
9. **Caco-2:** Ligand A (-4.701) is better than Ligand B (-5.112). Higher (less negative) is better.
10. **Solubility:** Ligand A (-1.496) is better than Ligand B (-2.884). Higher is better.
11. **hERG:** Both are very low (A: 0.214, B: 0.129), indicating low cardiotoxicity risk. B is slightly better.
12. **Cl_mic:** Ligand A (14.26) is better than Ligand B (9.96). Lower is better for metabolic stability.
13. **t1/2:** Ligand B (16.71) is significantly better than Ligand A (6.10). Longer half-life is desirable.
14. **Pgp:** Both are very low (A: 0.019, B: 0.234), indicating low efflux. A is slightly better.
15. **Binding Affinity:** Ligand B (-7.3) is slightly better than Ligand A (-7.0). While a 0.3 kcal/mol difference isn't huge, it's noticeable.
**GPCR-specific priorities:** For ADRB2 (a cardiovascular GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B has a better logP and slightly better affinity. However, Ligand A excels in TPSA, DILI, QED, solubility, and metabolic stability (Cl_mic). The DILI risk for Ligand B is concerningly high. The superior drug-likeness (QED) and significantly lower DILI risk of Ligand A outweigh the slightly better affinity and half-life of Ligand B.
**Final Decision:**
I prefer Ligand A.
Output:
1
2025-04-17 22:26:01,482 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [342.403, 112.66 , 1.033, 3. , 5. , 0.726, 46.219, 57.231, -5.28 , -3.084, 0.089, 22.465, -22.612, 0.023, -4.7 ]
**Ligand B:** [351.403, 97.83 , 1.323, 1. , 6. , 0.388, 61.574, 63.823, -5. , -1.724, 0.229, 58.669, -19.176, 0.056, -7.4 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (342.4) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (112.66) is slightly higher than Ligand B (97.83), but both are below the 140 threshold for good oral absorption. Ligand B is better here.
3. **logP:** Both are within the optimal range (1-3). Ligand B (1.323) is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Ligand A (3) is higher than Ligand B (1). Lower is generally better, but both are acceptable.
5. **HBA:** Ligand A (5) is lower than Ligand B (6). Lower is generally better.
6. **QED:** Ligand A (0.726) is significantly better than Ligand B (0.388), indicating a more drug-like profile.
7. **DILI:** Ligand A (46.219) has a much lower DILI risk than Ligand B (61.574). This is a significant advantage for Ligand A.
8. **BBB:** Both have relatively low BBB penetration, but Ligand B (63.823) is slightly better than Ligand A (57.231). For a cardiovascular target, BBB penetration isn't *critical*, but it's a bonus.
9. **Caco-2:** Both have negative values, which is unusual. Assuming these are logP-scaled Caco-2 values, lower values indicate poorer permeability. Ligand A (-5.28) is worse than Ligand B (-5).
10. **Solubility:** Ligand A (-3.084) has slightly better solubility than Ligand B (-1.724).
11. **hERG:** Both are very low, indicating minimal hERG inhibition risk. Ligand B (0.229) is slightly higher.
12. **Cl_mic:** Ligand A (22.465) has significantly lower microsomal clearance than Ligand B (58.669), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-22.612) has a longer in vitro half-life than Ligand B (-19.176).
14. **Pgp:** Both are very low, indicating minimal P-gp efflux. Ligand B (0.056) is slightly higher.
15. **Affinity:** Ligand B (-7.4) has a significantly stronger binding affinity than Ligand A (-4.7). This is a substantial advantage.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, we prioritize logP, TPSA, Pgp, and affinity. Ligand B has a slightly better logP and TPSA. Both have low Pgp. However, the affinity difference is substantial (-7.4 vs -4.7 kcal/mol). A difference of >1.5 kcal/mol is often enough to overcome other drawbacks.
**Overall Assessment:**
While Ligand A has better QED, DILI, metabolic stability, and solubility, the significantly stronger binding affinity of Ligand B is the most important factor for a GPCR target. The difference in affinity is large enough to outweigh the advantages of Ligand A.
Output:
0
2025-04-17 22:26:01,482 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Reasoning:**
Let's systematically compare Ligand A and Ligand B against the provided guidelines, with emphasis on GPCR-relevant properties (logP, Pgp, TPSA, and affinity).
1. **MW:** Both ligands (345.443 and 356.463 Da) fall comfortably within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (61.88) is significantly better than Ligand B (96.89). A TPSA under 140 is good for oral absorption, and lower is generally preferred for GPCRs. Ligand B is approaching a level that could hinder absorption.
3. **logP:** Ligand A (1.782) is within the optimal 1-3 range. Ligand B (0.744) is slightly below 1, which *could* indicate potential permeability issues, though not drastically.
4. **HBD/HBA:** Ligand A (1 HBD, 3 HBA) is more favorable than Ligand B (3 HBD, 5 HBA). Fewer hydrogen bonds are generally preferred for membrane permeability.
5. **QED:** Ligand A (0.905) has a much higher QED score than Ligand B (0.625), indicating a more drug-like profile.
6. **DILI:** Both ligands have low DILI risk (23.73 and 20.396 percentile), which is excellent.
7. **BBB:** Ligand A (96.82) shows significantly better BBB penetration potential than Ligand B (52.191). While ADRB2 isn't exclusively a CNS target, some peripheral ADRB2 activity is modulated by CNS pathways, and better BBB penetration isn't a detriment.
8. **Caco-2:** Ligand A (-4.496) is better than Ligand B (-5.067), indicating better intestinal absorption.
9. **Solubility:** Ligand A (-2.236) is better than Ligand B (-1.092), indicating better aqueous solubility.
10. **hERG:** Both ligands have very low hERG inhibition risk (0.57 and 0.123).
11. **Cl_mic:** Ligand B (17.556) has lower microsomal clearance than Ligand A (26.455), suggesting better metabolic stability.
12. **t1/2:** Ligand B (20.002 hours) has a significantly longer in vitro half-life than Ligand A (-8.071 hours). This is a substantial advantage.
13. **Pgp:** Ligand A (0.078) has lower P-gp efflux liability than Ligand B (0.012), indicating better oral bioavailability and potential for CNS exposure.
14. **Binding Affinity:** Both ligands have the same binding affinity (-6.3 kcal/mol), so this parameter doesn't differentiate them.
**Overall Assessment:**
Ligand A is superior in almost all ADME properties (TPSA, logP, QED, BBB, Caco-2, Solubility, Pgp) and has a better safety profile (DILI, hERG). Ligand B's main advantage is its longer half-life and lower Cl_mic. However, the substantial improvements in absorption, permeability, and drug-likeness offered by Ligand A outweigh the benefit of a slightly longer half-life, especially considering optimization can address metabolic stability. Given the GPCR target class, the better TPSA, logP, and Pgp properties of Ligand A are particularly important.
**Output:**
1
2025-04-17 22:26:01,482 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [367.471, 93.31, 1.532, 2, 6, 0.606, 62.35, 66.382, -5.548, -2.639, 0.115, 4.142, -0.697, 0.039, -6.6]
**Ligand B:** [357.451, 91.34, -0.931, 2, 6, 0.583, 14.385, 28.344, -4.913, -0.311, 0.191, -11.472, -5.942, 0.006, -8.2]
Here's a breakdown, considering the GPCR priorities (logP, Pgp, TPSA, affinity, and BBB):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (357.451) is slightly lower, which is generally favorable.
2. **TPSA:** Both are acceptable (below 140), but Ligand B (91.34) is slightly better than Ligand A (93.31).
3. **logP:** Ligand A (1.532) is within the optimal range. Ligand B (-0.931) is a bit low, potentially hindering permeability.
4. **HBD/HBA:** Both have 2 HBD and 6 HBA, which are reasonable.
5. **QED:** Both are above 0.5, indicating good drug-likeness.
6. **DILI:** Ligand A (62.35) has a significantly higher DILI risk than Ligand B (14.385). This is a major concern.
7. **BBB:** Ligand A (66.382) shows better BBB penetration than Ligand B (28.344). However, for a cardiovascular target, BBB penetration isn't *as* crucial as for CNS targets.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand B (-4.913) is slightly better than Ligand A (-5.548).
9. **Solubility:** Ligand B (-0.311) has better solubility than Ligand A (-2.639).
10. **hERG:** Both have low hERG risk.
11. **Cl_mic:** Ligand B (-11.472) has much lower microsomal clearance, indicating better metabolic stability, which is a significant advantage. Ligand A (4.142) is concerning.
12. **t1/2:** Ligand B (-5.942) has a longer in vitro half-life than Ligand A (-0.697).
13. **Pgp:** Ligand A (0.039) has slightly lower P-gp efflux, which is favorable. Ligand B (0.006) is even better.
14. **Affinity:** Ligand B (-8.2 kcal/mol) has a substantially stronger binding affinity than Ligand A (-6.6 kcal/mol). This difference of 1.6 kcal/mol is significant and can outweigh some ADME drawbacks.
**Conclusion:**
Despite Ligand A's slightly better BBB penetration and Pgp efflux, Ligand B is the superior candidate. The significantly lower DILI risk, much better metabolic stability (lower Cl_mic, longer t1/2), improved solubility, and *much* stronger binding affinity outweigh the slightly lower logP and BBB. The stronger affinity is especially important for a GPCR target.
Output:
0
2025-04-17 22:26:01,482 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (348.349 Da and 348.495 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (59.59) is significantly better than Ligand B (77.15). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand A is well below the 90 A^2 threshold, while Ligand B is approaching it.
**3. logP:** Ligand A (2.75) is slightly higher than Ligand B (1.709), both within the optimal 1-3 range. Ligand B is a bit lower, which *could* indicate potential permeability issues, but isn't a major concern.
**4. H-Bond Donors:** Both ligands have 2 HBD, which is acceptable.
**5. H-Bond Acceptors:** Ligand A has 4 HBA, and Ligand B has 5. Both are within the acceptable limit of 10.
**6. QED:** Both ligands have similar QED values (0.872 and 0.847), indicating good drug-likeness.
**7. DILI Risk:** Ligand A has a significantly higher DILI risk (85.537 percentile) compared to Ligand B (44.048 percentile). This is a major red flag for Ligand A.
**8. BBB Penetration:** Ligand A (83.56) has slightly better BBB penetration than Ligand B (75.805). While ADRB2 is a cardiovascular target, some CNS effects are possible with beta-adrenergic agonists, so moderate BBB penetration isn't necessarily detrimental.
**9. Caco-2 Permeability:** Ligand A (-4.421) has better Caco-2 permeability than Ligand B (-5.241).
**10. Aqueous Solubility:** Ligand A (-4.955) has better aqueous solubility than Ligand B (-2.23).
**11. hERG Inhibition:** Ligand A (0.886) has a higher hERG inhibition risk than Ligand B (0.578). This is another safety concern for Ligand A.
**12. Microsomal Clearance:** Ligand A (78.957) has higher microsomal clearance than Ligand B (44.729), indicating lower metabolic stability.
**13. In vitro Half-Life:** Ligand B (-16.091) has a significantly longer in vitro half-life than Ligand A (6.11). This is a major advantage for Ligand B.
**14. P-gp Efflux:** Ligand A (0.499) has lower P-gp efflux than Ligand B (0.066). Lower P-gp efflux is generally preferred.
**15. Binding Affinity:** Ligand B (-7.6) has slightly better binding affinity than Ligand A (-7.4). While the difference is small, it's still a positive for Ligand B.
**Overall Assessment:**
Ligand A has some favorable properties (TPSA, Caco-2, solubility, P-gp efflux, and BBB), but it is significantly hampered by its high DILI risk, hERG inhibition liability, and lower metabolic stability. Ligand B, while slightly less permeable and with a lower logP, demonstrates a much better safety profile (lower DILI and hERG) and superior metabolic stability (longer half-life). Given the cardiovascular context, minimizing off-target effects and ensuring metabolic stability are crucial. The slight affinity difference is outweighed by the significant ADME-Tox advantages of Ligand B.
Output:
0
2025-04-17 22:26:01,482 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (345.399 and 345.443 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (92.45) is slightly higher than Ligand B (73.74). For a cardiovascular GPCR, TPSA isn't *as* critical as for a CNS target, but lower is generally preferred for absorption. Ligand B has a clear advantage.
3. **logP:** Both ligands have good logP values (2.105 and 1.969), falling within the optimal 1-3 range. No significant difference.
4. **HBD:** Ligand A (3) is higher than Ligand B (1). Lower HBD is generally preferable for better permeability, giving Ligand B an edge.
5. **HBA:** Both ligands have the same HBA count (4), which is well within the acceptable limit of 10.
6. **QED:** Ligand B (0.855) has a higher QED score than Ligand A (0.683), indicating a more drug-like profile. This is a positive for Ligand B.
7. **DILI:** Ligand B (8.453) has a *much* lower DILI risk than Ligand A (68.941). This is a major advantage for Ligand B. DILI is a critical safety concern.
8. **BBB:** Ligand B (78.131) has a higher BBB penetration score than Ligand A (53.936). While ADRB2 isn't primarily a CNS target, some CNS exposure can contribute to side effects, and better control of this is preferable. Ligand B is better.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.997 and -4.884). These values are difficult to interpret without knowing the scale, but a negative value is not ideal. No clear advantage.
10. **Solubility:** Ligand B (-1.825) has a better solubility score than Ligand A (-3.841). Better solubility aids formulation and bioavailability.
11. **hERG:** Both ligands have low hERG inhibition liability (0.635 and 0.167). Ligand B is slightly better here.
12. **Cl_mic:** Ligand B (23.727) has a lower microsomal clearance than Ligand A (31.817), indicating better metabolic stability. This is a positive for Ligand B.
13. **t1/2:** Ligand B (-30.25) has a longer in vitro half-life than Ligand A (-25.906). Longer half-life is generally desirable.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.14 and 0.027). No significant difference.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-5.7 and -5.3 kcal/mol). The difference of 0.4 kcal/mol is not substantial enough to outweigh other factors.
**Overall Assessment:**
Ligand B consistently outperforms Ligand A across several critical ADME-Tox properties, most notably DILI risk and metabolic stability. It also has a better QED score, solubility, and BBB penetration. While both ligands have acceptable potency and logP values, the significantly improved safety profile and drug-like characteristics of Ligand B make it the more promising drug candidate for ADRB2.
Output:
0
2025-04-17 22:26:01,483 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (354.353 and 359.495 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (70.08) is higher than Ligand B (45.67). For a cardiovascular GPCR, TPSA isn't a *major* concern unless extremely high, but lower is generally preferred for better permeability. Ligand B is better.
3. **logP:** Ligand A (1.331) is a bit lower than Ligand B (2.99). Both are within the optimal 1-3 range, but Ligand B is closer to the upper end, which can be beneficial for membrane permeability and receptor binding for a GPCR.
4. **HBD:** Ligand A (1) has one H-bond donor, while Ligand B (0) has none. Both are acceptable, but fewer HBDs can sometimes improve permeability. Ligand B is slightly better.
5. **HBA:** Ligand A (4) has fewer H-bond acceptors than Ligand B (5). Both are within the acceptable limit of 10. No strong preference.
6. **QED:** Ligand A (0.889) has a significantly higher QED score than Ligand B (0.727), indicating a more drug-like profile overall. This is a point in favor of Ligand A.
7. **DILI:** Both ligands have low DILI risk (39.201 and 37.999 percentile), which is excellent. No significant difference.
8. **BBB:** Ligand B (84.141) has a much higher BBB penetration percentile than Ligand A (68.554). While ADRB2 isn't a CNS target, some degree of BBB penetration can be useful for understanding off-target effects and overall distribution. Ligand B is better.
9. **Caco-2:** Both ligands have similar negative Caco-2 values (-4.794 and -4.785), suggesting similar permeability.
10. **Solubility:** Both ligands have similar negative solubility values (-2.483 and -2.422), suggesting similar solubility.
11. **hERG:** Ligand A (0.456) has a lower hERG inhibition liability than Ligand B (0.86), which is a significant advantage as it reduces the risk of cardiotoxicity. This is a strong point for Ligand A.
12. **Cl_mic:** Ligand B (95.969) has a much higher microsomal clearance than Ligand A (13.77). This means Ligand A is likely to have better metabolic stability and a longer half-life. This is a major advantage for Ligand A.
13. **t1/2:** Ligand B (57.374) has a much longer in vitro half-life than Ligand A (-2.114). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.078) has a lower P-gp efflux liability than Ligand B (0.567), suggesting better oral bioavailability and potentially better tissue distribution. This is a point in favor of Ligand A.
15. **Binding Affinity:** Ligand A (-6.1 kcal/mol) has a slightly better binding affinity than Ligand B (-5.6 kcal/mol). While the difference isn't huge, it's enough to be considered, especially for a GPCR where potency is crucial.
**Overall Assessment:**
Ligand A has several key advantages: a higher QED score, significantly lower microsomal clearance (better metabolic stability), lower hERG inhibition (reduced cardiotoxicity risk), and lower P-gp efflux. The slightly better binding affinity is also a plus. While Ligand B has better BBB penetration and a longer half-life, the metabolic stability and safety profile of Ligand A are more critical for a cardiovascular drug candidate. The longer half-life of Ligand B could be addressed with formulation strategies if needed.
Output:
1
2025-04-17 22:26:01,483 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (360.37 and 342.443 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (67.23) is significantly better than Ligand A (107.08). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (1.911 and 1.856), falling within the optimal 1-3 range. Similar.
4. **HBD:** Ligand B (1) is preferable to Ligand A (2). Lower HBD generally improves permeability.
5. **HBA:** Ligand B (4) is preferable to Ligand A (5). Lower HBA generally improves permeability.
6. **QED:** Both ligands have good QED scores (0.725 and 0.871), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand B (27.724) is *much* better than Ligand A (99.031). This is a major advantage for Ligand B. DILI risk is a critical factor.
8. **BBB:** Both ligands have moderate BBB penetration (59.868 and 54.207). Since ADRB2 is a cardiovascular target, this isn't a primary concern.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.114 and -4.806). This is unusual and suggests poor permeability. However, the values are similar.
10. **Solubility:** Ligand B (-1.353) is better than Ligand A (-3.583). Better solubility is always a plus.
11. **hERG:** Both ligands have low hERG inhibition risk (0.318 and 0.238). Similar.
12. **Cl_mic:** Ligand A (11.657) has a significantly lower microsomal clearance than Ligand B (29.286), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (35.467) has a longer in vitro half-life than Ligand B (18.384). This is another advantage for Ligand A.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.173 and 0.033). Similar.
15. **Binding Affinity:** Ligand A (-7.4 kcal/mol) has a stronger binding affinity than Ligand B (-6.3 kcal/mol). This is a substantial advantage for Ligand A (1.1 kcal/mol difference).
**Overall Assessment:**
Ligand A has a significantly stronger binding affinity and better metabolic stability (lower Cl_mic, longer t1/2). However, Ligand B has a dramatically lower DILI risk, better TPSA, HBD, HBA, QED, and solubility. While the affinity difference is substantial, the DILI risk associated with Ligand A is very high. Given the importance of safety, especially in a cardiovascular context, and the other improvements in Ligand B, I favor Ligand B. The slightly weaker binding could potentially be optimized in later stages of development.
Output:
0
2025-04-17 22:26:01,483 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (345.447 and 346.471 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (79.26) is slightly higher than Ligand B (67.43). Both are below the 140 threshold for good oral absorption, but closer to the 90 threshold for CNS targets. Ligand B is preferable here.
3. **logP:** Ligand B (2.462) is within the optimal 1-3 range, while Ligand A (0.622) is slightly below 1. This is a significant advantage for Ligand B, as it's more likely to have good membrane permeability.
4. **HBD:** Both ligands have 2 H-bond donors, which is acceptable.
5. **HBA:** Ligand A has 5 H-bond acceptors, while Ligand B has 3. Both are within the acceptable range.
6. **QED:** Ligand A (0.82) has a higher QED score than Ligand B (0.524), indicating better overall drug-likeness. This favors Ligand A.
7. **DILI:** Ligand B (25.979) has a significantly lower DILI risk than Ligand A (31.873). This is a major advantage for Ligand B.
8. **BBB:** Ligand A (72.237) has a slightly better BBB penetration potential than Ligand B (65.297). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant for off-target effects.
9. **Caco-2:** Ligand A (-5.421) and Ligand B (-4.858) have negative values, which is unusual and suggests poor permeability. However, the scale isn't specified, so we can't interpret these values precisely.
10. **Solubility:** Ligand A (-1.714) has slightly better solubility than Ligand B (-2.471).
11. **hERG:** Both ligands have very low hERG inhibition liability (0.501 and 0.3, respectively). No significant difference.
12. **Cl_mic:** Ligand A (-1.784) has a lower (better) microsomal clearance than Ligand B (30.858). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (20.83 hours) has a much longer in vitro half-life than Ligand B (-3.267 hours). This is a substantial advantage for Ligand A.
14. **Pgp:** Ligand A (0.032) has lower P-gp efflux liability than Ligand B (0.122), which is favorable.
15. **Binding Affinity:** Ligand A (-6.9 kcal/mol) has a slightly better binding affinity than Ligand B (-6.3 kcal/mol). While the difference is less than 1.5 kcal/mol, it contributes to the overall preference.
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP and has a lower TPSA. Ligand A has a slight edge in affinity and Pgp efflux, and a significantly longer half-life. The lower DILI risk of Ligand B is also very important.
**Overall Assessment:**
While Ligand A has a better QED, longer half-life, and slightly better affinity, Ligand B's superior logP, lower DILI risk, and acceptable TPSA make it a more promising candidate. The better logP is critical for membrane permeability and overall bioavailability. The lower DILI risk is a significant safety advantage. The half-life of Ligand A is good, but can potentially be improved through structural modifications.
Output:
0
2025-04-17 22:26:01,483 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (354.411 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (71) is significantly better than Ligand A (110.61). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (2.18) is optimal, while Ligand A (-0.049) is quite low, potentially hindering membrane permeability. This is a significant drawback for Ligand A.
4. **HBD/HBA:** Ligand A (2 HBD, 7 HBA) is slightly higher in both counts than Ligand B (1 HBD, 5 HBA), but both are within acceptable limits.
5. **QED:** Both ligands have good QED scores (A: 0.633, B: 0.781), indicating drug-likeness. Ligand B is better.
6. **DILI:** Ligand B (33.618) has a much lower DILI risk than Ligand A (60.566). This is a crucial advantage for Ligand B.
7. **BBB:** Both have reasonable BBB penetration, but Ligand A (75.107) is better than Ligand B (61.38). However, as this is a cardiovascular target, BBB isn't a high priority.
8. **Caco-2:** Ligand A (-4.852) and Ligand B (-5.057) are both poor.
9. **Solubility:** Ligand A (-0.962) is better than Ligand B (-3.142).
10. **hERG:** Both ligands show low hERG inhibition risk (A: 0.056, B: 0.189).
11. **Cl_mic:** Ligand A (21.789) has lower microsomal clearance than Ligand B (31.571), suggesting better metabolic stability.
12. **t1/2:** Ligand A (12.277) has a longer in vitro half-life than Ligand B (2.124). This is a significant advantage for Ligand A.
13. **Pgp:** Both ligands show low P-gp efflux liability (A: 0.01, B: 0.062).
14. **Binding Affinity:** Ligand A (-7.5 kcal/mol) has a significantly stronger binding affinity than Ligand B (-0.9 kcal/mol). This is a major advantage for Ligand A.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, and affinity. Ligand B excels in TPSA and has a good logP. Ligand A has a poor logP but a *much* stronger affinity. The affinity difference is substantial (>6.6 kcal/mol), and this can often outweigh other ADME drawbacks.
**Overall Assessment:**
While Ligand B has better safety (DILI) and QED scores, Ligand A's significantly superior binding affinity (-7.5 vs -0.9 kcal/mol) and longer half-life are critical for a GPCR target. The low logP of Ligand A is a concern, but the potency advantage is likely to be more impactful, especially given the acceptable (though not ideal) TPSA and Pgp values. The better metabolic stability (lower Cl_mic) also contributes to its favorability.
Output:
1
2025-04-17 22:26:01,483 - INFO - Here's my reasoning and the final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, the key priorities are logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB.
Let's break down the comparison:
1. **MW:** Both ligands are within the acceptable range (200-500 Da).
2. **TPSA:** Ligand B (70.67) is significantly better than Ligand A (95.42). Lower TPSA generally favors oral absorption and is particularly important for GPCRs.
3. **logP:** Both are good (around 1.5), falling within the optimal 1-3 range. Ligand B is slightly higher at 1.642, which could be beneficial for membrane permeability.
4. **HBD/HBA:** Both have acceptable HBD (2) and HBA (5/4) counts.
5. **QED:** Ligand A (0.877) has a much better QED score than Ligand B (0.552), suggesting a more drug-like profile overall.
6. **DILI:** Ligand B (35.479) has a significantly lower DILI risk than Ligand A (63.746). This is a substantial advantage.
7. **BBB:** Ligand B (77.123) has a considerably higher BBB penetration potential than Ligand A (23.924). While not crucial for a cardiovascular target, higher BBB is generally a positive attribute.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale isn't specified, so it's hard to interpret.
9. **Solubility:** Both have negative solubility values, also unusual. Again, the scale is unknown.
10. **hERG:** Ligand A (0.093) has a slightly lower hERG risk than Ligand B (0.552).
11. **Cl_mic:** Ligand B (-1.397) has a negative clearance, which is not physically possible and likely an error. Ligand A (2.699) has a reasonable clearance.
12. **t1/2:** Ligand B (17.461) has a much longer in vitro half-life than Ligand A (-23.929). A negative half-life is not possible, indicating an error.
13. **Pgp:** Ligand A (0.01) has a much lower Pgp efflux liability than Ligand B (0.105), which is favorable.
14. **Binding Affinity:** Ligand A (-7.9 kcal/mol) has a better binding affinity than Ligand B (-5.5 kcal/mol). This is a significant advantage, potentially outweighing some ADME concerns.
**Overall Assessment:**
Ligand A has a significantly better binding affinity and lower Pgp efflux, but suffers from higher DILI risk and lower BBB penetration. Ligand B has superior TPSA, DILI, and BBB, but a weaker binding affinity. The negative values for Caco-2 and t1/2 for Ligand B are concerning and likely errors. The negative clearance for Ligand B is also impossible. Given the importance of binding affinity for GPCRs, and the relatively small difference in logP and TPSA, Ligand A is the more promising candidate, assuming the negative values for Ligand B are errors.
**Output:**
1
2025-04-17 22:26:01,483 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (364.471 and 371.928 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (87.46) is better than Ligand B (38.13). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better permeability. Ligand B is excellent.
3. **logP:** Ligand A (1.46) is within the optimal range (1-3). Ligand B (4.923) is slightly high, potentially leading to solubility issues and off-target interactions. This favors Ligand A.
4. **HBD:** Ligand A (2) is reasonable. Ligand B (0) is also acceptable.
5. **HBA:** Ligand A (6) is within the acceptable range. Ligand B (3) is also good.
6. **QED:** Ligand A (0.66) is better than Ligand B (0.547), indicating a more drug-like profile.
7. **DILI:** Ligand A (27.142) has a significantly lower DILI risk than Ligand B (42.303). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (82.241) has a higher BBB penetration than Ligand A (29.857). While not critical for a cardiovascular target, it's a slight positive for Ligand B.
9. **Caco-2:** Ligand A (-5.808) and Ligand B (-4.707) are both negative, which is unusual. It's difficult to interpret without knowing the scale, but generally, higher values are preferred.
10. **Solubility:** Ligand A (-0.64) is better than Ligand B (-4.887). Solubility is crucial for bioavailability, favoring Ligand A.
11. **hERG:** Ligand A (0.329) has a lower hERG risk than Ligand B (0.647). This is a significant safety advantage for Ligand A.
12. **Cl_mic:** Ligand A (21.351) has a much lower microsomal clearance than Ligand B (112.937), indicating better metabolic stability. This is a substantial advantage for Ligand A.
13. **t1/2:** Ligand A (18.286) has a shorter half-life than Ligand B (55.712). Longer half-life is generally preferred, favoring Ligand B.
14. **Pgp:** Ligand A (0.063) has lower P-gp efflux than Ligand B (0.786), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand A (-6.2) has a slightly better binding affinity than Ligand B (-4.7). While the difference isn't huge, it's enough to consider, especially given the other favorable properties of Ligand A.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A has a better logP, better Pgp efflux, and slightly better affinity. Ligand B has a better TPSA.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B in crucial ADME-Tox properties (DILI, solubility, hERG, Cl_mic, Pgp) and has comparable or better binding affinity. While Ligand B has a better BBB score and a longer half-life, the safety and pharmacokinetic advantages of Ligand A are more compelling for a cardiovascular drug candidate. The higher logP of Ligand B is a concern.
Output:
1
2025-04-17 22:26:01,484 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (349.387 Da and 348.403 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (107.11) is better than Ligand B (119.89). While both are reasonably acceptable for a non-CNS GPCR, lower TPSA generally favors better permeability.
**3. logP:** Ligand B (-0.715) is significantly lower than Ligand A (0.039). This is a concern for Ligand B, as logP values below 1 can hinder membrane permeability. Ligand A is closer to the optimal 1-3 range.
**4. H-Bond Donors:** Ligand B (4) has more HBDs than Ligand A (2). Fewer HBDs are generally preferred for better permeability.
**5. H-Bond Acceptors:** Ligand A (6) has more HBAs than Ligand B (5). This difference isn't substantial, but slightly favors Ligand B.
**6. QED:** Ligand A (0.727) has a significantly higher QED score than Ligand B (0.474), indicating a more drug-like profile.
**7. DILI Risk:** Ligand A (30.981) has a much lower DILI risk than Ligand B (52.036). This is a critical advantage for Ligand A.
**8. BBB Penetration:** Both ligands have similar BBB penetration (Ligand A: 40.326, Ligand B: 40.054). Since ADRB2 is a cardiovascular target, BBB penetration isn't a primary concern.
**9. Caco-2 Permeability:** Ligand A (-4.846) is better than Ligand B (-5.264). Higher Caco-2 permeability suggests better intestinal absorption.
**10. Aqueous Solubility:** Ligand A (-1.646) is better than Ligand B (-2.275).
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (Ligand A: 0.162, Ligand B: 0.099). No significant difference.
**12. Microsomal Clearance:** Ligand B (0.756) has significantly lower microsomal clearance than Ligand A (7.4). Lower clearance indicates better metabolic stability, a significant advantage for Ligand B.
**13. In vitro Half-Life:** Ligand A (12.297) has a much longer in vitro half-life than Ligand B (-28.965). This is a major advantage for Ligand A, potentially allowing for less frequent dosing.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (Ligand A: 0.037, Ligand B: 0.01). No significant difference.
**15. Binding Affinity:** Both ligands have comparable binding affinity (Ligand A: -7.0 kcal/mol, Ligand B: -6.0 kcal/mol). Ligand A has a slight advantage.
**Overall Assessment:**
Ligand A demonstrates a superior overall profile. While Ligand B has better metabolic stability, Ligand A excels in crucial areas like DILI risk, QED, solubility, Caco-2 permeability, and in vitro half-life. The slightly better affinity of Ligand A further strengthens its position. The low logP of Ligand B is a significant drawback, potentially hindering its absorption. For a cardiovascular GPCR target, a balance of permeability, metabolic stability, and safety is paramount, and Ligand A achieves this balance more effectively.
Output:
1
2025-04-17 22:26:01,484 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [347.375, 92.84, 1.986, 1, 6, 0.916, 80.962, 74.719, -4.638, -2.727, 0.323, 23.806, 18.058, 0.055, -7.2]
**Ligand B:** [361.389, 87.74, 0.149, 2, 4, 0.428, 33.695, 87.476, -5.186, -1.428, 0.402, -1.101, -9.479, 0.025, -6]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (347.375) is slightly lower, which is generally favorable.
2. **TPSA:** Both are acceptable, under 140. Ligand B (87.74) is slightly better, being closer to the ideal for good absorption.
3. **logP:** Ligand A (1.986) is optimal. Ligand B (0.149) is quite low, potentially hindering membrane permeability and absorption. This is a significant drawback.
4. **HBD/HBA:** Ligand A (1 HBD, 6 HBA) is better balanced than Ligand B (2 HBD, 4 HBA).
5. **QED:** Ligand A (0.916) is excellent, indicating high drug-likeness. Ligand B (0.428) is considerably lower, raising concerns.
6. **DILI:** Ligand B (33.695) has a much lower DILI risk than Ligand A (80.962), which is a major advantage.
7. **BBB:** Ligand B (87.476) shows better BBB penetration than Ligand A (74.719), but for a cardiovascular target, this isn't *critical*.
8. **Caco-2:** Ligand B (-5.186) has a more negative Caco-2 value, indicating potentially *lower* intestinal absorption. Ligand A (-4.638) is better.
9. **Solubility:** Ligand B (-1.428) has better solubility than Ligand A (-2.727).
10. **hERG:** Both have relatively low hERG risk (0.323 and 0.402), which is good.
11. **Cl_mic:** Ligand B (-1.101) has a much lower (better) microsomal clearance than Ligand A (23.806), suggesting better metabolic stability.
12. **t1/2:** Ligand A (18.058) has a longer in vitro half-life than Ligand B (-9.479), which is desirable.
13. **Pgp:** Both have very low Pgp efflux liability (0.055 and 0.025), which is excellent.
14. **Affinity:** Ligand A (-7.2 kcal/mol) has a slightly stronger binding affinity than Ligand B (-6 kcal/mol). This is a 1.2 kcal/mol difference, which is significant.
**Overall Assessment:**
Ligand A has a superior binding affinity and better Caco-2 permeability, and a longer half-life. However, Ligand B has a much better safety profile (DILI) and metabolic stability (Cl_mic). The low logP of Ligand B is a significant concern, potentially hindering absorption. The higher QED of Ligand A also suggests a more favorable overall profile. Considering the balance, the slightly stronger affinity of Ligand A, combined with its better predicted absorption, outweighs the higher DILI risk.
Output:
1
2025-04-17 22:26:01,484 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [370.833, 99.88, 1.615, 2, 5, 0.688, 51.221, 81.388, -4.884, -3.463, 0.153, 31.896, -17.797, 0.139, -5.8]
**Ligand B:** [386.497, 75.62, 3.964, 2, 8, 0.711, 80.613, 77.588, -5.25, -4.888, 0.43, 63.184, 12.333, 0.218, -5.9]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal 200-500 Da range. A (370.833) is slightly preferred.
2. **TPSA:** A (99.88) is higher than B (75.62). B is better, being closer to the <140 threshold for oral absorption and more favorable for GPCRs.
3. **logP:** A (1.615) is optimal, while B (3.964) is pushing the upper limit. A is preferred.
4. **HBD:** Both have 2 HBD, which is good.
5. **HBA:** A has 5 HBA, B has 8. A is slightly better.
6. **QED:** Both are above 0.5, indicating good drug-likeness. B (0.711) is slightly better.
7. **DILI:** A (51.221) has a significantly lower DILI risk than B (80.613). This is a major advantage for A.
8. **BBB:** A (81.388) has a better BBB penetration potential than B (77.588). This is important for a GPCR target.
9. **Caco-2:** Both are negative, indicating poor permeability. B (-5.25) is slightly worse than A (-4.884).
10. **Solubility:** Both are negative, indicating poor solubility. A (-3.463) is slightly better than B (-4.888).
11. **hERG:** Both are very low, indicating minimal hERG inhibition risk.
12. **Cl_mic:** A (31.896) has a lower microsomal clearance, suggesting better metabolic stability than B (63.184).
13. **t1/2:** A (-17.797) has a more negative in vitro half-life, which is unusual and likely indicates a very short half-life. B (12.333) is better.
14. **Pgp:** A (0.139) has lower P-gp efflux liability than B (0.218), which is favorable.
15. **Binding Affinity:** Both have similar strong binding affinities (-5.8 and -5.9 kcal/mol).
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, BBB, and affinity. While both ligands have good affinity, A has a better logP and Pgp profile, and a better BBB score. The significantly lower DILI risk for A is also a critical factor. The only drawback for A is the very short half-life. However, metabolic stability can be improved through structural modifications.
**Overall Assessment:**
Despite the short half-life of Ligand A, its superior DILI profile, better logP, Pgp, and BBB penetration, and comparable binding affinity make it a more promising starting point for drug development compared to Ligand B.
Output:
1
2025-04-17 22:26:01,484 - INFO - Batch 331 complete. Total preferences: 5296
2025-04-17 22:26:01,484 - INFO - Processing batch 332/512...
2025-04-17 22:26:50,537 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.415 and 344.415 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (95.67) is slightly higher than Ligand B (87.32). Both are below the 140 threshold for good oral absorption, but closer to the 90 threshold for CNS targets (less relevant for ADRB2, a cardiovascular target). Ligand B is preferable here.
3. **logP:** Both ligands (1.492 and 1.566) are within the optimal 1-3 range. No significant difference.
4. **HBD:** Both ligands have 2 H-bond donors, which is within the acceptable limit of 5. No difference.
5. **HBA:** Ligand A has 5 H-bond acceptors, and Ligand B has 4. Both are below the limit of 10. Ligand B is slightly preferable.
6. **QED:** Ligand B (0.881) has a slightly better QED score than Ligand A (0.787), indicating a more drug-like profile.
7. **DILI:** Ligand A (45.328) has a lower DILI risk than Ligand B (56.805). This is a significant advantage for Ligand A.
8. **BBB:** Both ligands have relatively low BBB penetration (54.556 and 49.515). This isn't a primary concern for a cardiovascular target like ADRB2.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.874 and -4.906). This is unusual and suggests poor permeability.
10. **Solubility:** Both ligands have very poor aqueous solubility (-1.944 and -2.386). This is a major concern for both.
11. **hERG:** Ligand A (0.203) has a lower hERG inhibition liability than Ligand B (0.611), which is a significant safety advantage.
12. **Cl_mic:** Ligand B (14.276) has a significantly lower microsomal clearance than Ligand A (26.861), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-31.596) has a much more negative in vitro half-life than Ligand B (-7.673), indicating a much shorter half-life and faster metabolism. This is a major disadvantage for Ligand A.
14. **Pgp:** Ligand A (0.128) has lower P-gp efflux liability than Ligand B (0.047), which is a slight advantage.
15. **Binding Affinity:** Ligand A (-9.4 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.4 kcal/mol). This is a substantial advantage that can potentially outweigh some of the ADME drawbacks.
**Overall Assessment:**
While Ligand B has better QED, lower Cl_mic, and a slightly better TPSA, Ligand A's significantly stronger binding affinity (-9.4 vs -6.4 kcal/mol) and lower hERG risk are crucial advantages. The poor solubility and Caco-2 values are concerning for both, but the potency difference is substantial. The shorter half-life of Ligand A is a drawback, but formulation strategies could potentially mitigate this. Given the GPCR target class, potency is paramount, and the safety profile of Ligand A is also better.
Output:
1
2025-04-17 22:26:50,537 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (346.45 Da) is within the ideal range (200-500 Da). Ligand B (385.511 Da) is also acceptable, but closer to the upper limit.
2. **TPSA:** Ligand A (56.73) is excellent, well below the 140 threshold for good absorption. Ligand B (109.57) is higher, but still potentially acceptable, though less ideal.
3. **logP:** Ligand A (2.565) is optimal (1-3). Ligand B (0.844) is a bit low, potentially hindering permeation.
4. **HBD:** Both Ligand A (2) and Ligand B (2) are within the acceptable limit of 5.
5. **HBA:** Ligand A (4) and Ligand B (5) are both within the acceptable limit of 10.
6. **QED:** Both Ligand A (0.881) and Ligand B (0.783) are good, indicating drug-like properties.
7. **DILI:** Ligand A (15.2) has a significantly lower DILI risk than Ligand B (56.689). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (77.821) has a better BBB penetration percentile than Ligand B (54.052). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be beneficial for distribution.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.294 and -5.583), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Both ligands have negative solubility values (-2.169 and -2.3), which is also concerning.
11. **hERG:** Ligand A (0.911) has a lower hERG inhibition liability than Ligand B (0.203), indicating a lower risk of cardiotoxicity.
12. **Cl_mic:** Ligand A (-13.827) has a much lower (better) microsomal clearance than Ligand B (-5.483), suggesting better metabolic stability.
13. **t1/2:** Ligand A (6.285) has a better in vitro half-life than Ligand B (-23.348).
14. **Pgp:** Ligand A (0.275) has a lower P-gp efflux liability than Ligand B (0.081), which is favorable.
15. **Affinity:** Ligand B (-7.8 kcal/mol) has a slightly better binding affinity than Ligand A (-7.3 kcal/mol). This is a 0.5 kcal/mol difference, which is significant but not overwhelming.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has a better logP and Pgp, while Ligand B has slightly better affinity. However, Ligand A excels in crucial ADME-Tox parameters like DILI, hERG, Cl_mic, and t1/2. The negative Caco-2 and solubility values are concerning for both, but the superior ADME profile of Ligand A outweighs the small difference in binding affinity.
**Conclusion:**
Considering the balance of properties, especially the significantly better safety profile (DILI, hERG) and metabolic stability (Cl_mic, t1/2) of Ligand A, it is the more promising drug candidate.
Output:
1
2025-04-17 22:26:50,537 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (346.475 Da and 367.475 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (86.88) is significantly better than Ligand B (113.08). For a GPCR, lower TPSA is generally preferred for better permeability. Ligand A is well below the 140 A^2 threshold, while Ligand B is approaching it.
**3. logP:** Ligand A (2.346) is within the optimal 1-3 range. Ligand B (0.497) is a bit low, potentially hindering membrane permeability.
**4. H-Bond Donors:** Both have 3 HBD, which is acceptable.
**5. H-Bond Acceptors:** Ligand A has 3 HBA, while Ligand B has 6. Lower HBA is generally preferred for permeability, giving Ligand A an edge.
**6. QED:** Ligand B (0.649) has a slightly better QED score than Ligand A (0.449), indicating a more drug-like profile, but this is not a major deciding factor.
**7. DILI Risk:** Ligand A (23.187) has a much lower DILI risk than Ligand B (55.138). This is a significant advantage for Ligand A.
**8. BBB Penetration:** Both have relatively low BBB penetration (46.879% and 44.203%). Since ADRB2 is a cardiovascular target, BBB penetration isn't a primary concern, but it's not a positive for either.
**9. Caco-2 Permeability:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
**10. Aqueous Solubility:** Both have negative solubility values, which is also unusual. Again, the scale is not specified.
**11. hERG Inhibition:** Ligand A (0.346) has a much lower hERG inhibition risk than Ligand B (0.114). This is a critical advantage for Ligand A, as hERG inhibition can lead to cardiotoxicity.
**12. Microsomal Clearance:** Ligand A (25.137) has higher microsomal clearance than Ligand B (7.126), indicating faster metabolism and potentially lower *in vivo* exposure. This favors Ligand B.
**13. In vitro Half-Life:** Ligand B (21.847 hours) has a significantly longer half-life than Ligand A (-30.406 hours, which is likely an error or a very short half-life). This is a strong advantage for Ligand B.
**14. P-gp Efflux:** Both have very low P-gp efflux liability (0.186 and 0.035).
**15. Binding Affinity:** Ligand B (-7.7 kcal/mol) has a significantly stronger binding affinity than Ligand A (-4.6 kcal/mol). This is a substantial advantage for Ligand B, and could potentially outweigh some of the ADME drawbacks.
**Overall Assessment:**
While Ligand B has a superior binding affinity and half-life, Ligand A demonstrates a much more favorable safety profile (lower DILI and hERG risk) and better physicochemical properties (TPSA, logP, HBA). Considering the cardiovascular target, minimizing cardiotoxicity (hERG) and liver toxicity (DILI) is paramount. The stronger binding of Ligand B is attractive, but the safety concerns are significant. The better ADME properties of Ligand A, coupled with acceptable affinity, make it a more promising starting point for further optimization.
Output:
1
2025-04-17 22:26:50,538 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (365.949 and 358.507 Da) fall comfortably within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (38.13) is better than Ligand B (42.43). Both are below 140, suggesting good absorption potential. Lower TPSA is generally preferred for GPCRs.
3. **logP:** Ligand A (4.924) is slightly higher than Ligand B (3.85). While both are within the acceptable range (1-3 is optimal, but up to 4 is tolerable), Ligand A is approaching the upper limit where solubility issues might arise.
4. **HBD:** Both ligands have 0 HBD, which is acceptable.
5. **HBA:** Ligand A (3) is lower than Ligand B (5). Lower HBA is generally preferred for better permeability.
6. **QED:** Ligand B (0.671) has a slightly higher QED score than Ligand A (0.582), indicating a marginally better overall "drug-likeness".
7. **DILI:** Ligand A (18.185) has a significantly lower DILI risk than Ligand B (37.263). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (76.735) has a higher BBB penetration percentile than Ligand B (68.709). While ADRB2 isn't exclusively a CNS target, some CNS exposure can occur, and higher BBB is generally favorable.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual. Assuming these are logP-scale values, they suggest poor permeability. Ligand A (-4.76) is slightly better than Ligand B (-4.892).
10. **Solubility:** Ligand A (-5.587) has slightly better solubility than Ligand B (-4.654).
11. **hERG:** Ligand A (0.585) has a lower hERG inhibition liability than Ligand B (0.901), which is a significant safety advantage.
12. **Cl_mic:** Ligand A (95.405) has a lower microsomal clearance than Ligand B (146.69), indicating better metabolic stability.
13. **t1/2:** Ligand A (55.452) has a much longer in vitro half-life than Ligand B (12.806). This is a substantial advantage.
14. **Pgp:** Ligand A (0.579) has lower P-gp efflux liability than Ligand B (0.404). Lower Pgp is preferred.
15. **Binding Affinity:** Ligand B (-8.4 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.9 kcal/mol). This is a substantial advantage that could potentially outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand B has a significantly better binding affinity, which is crucial for a GPCR target. However, Ligand A demonstrates a much more favorable ADMET profile, with lower DILI risk, better BBB penetration, lower hERG inhibition, better metabolic stability (lower Cl_mic and longer t1/2), and lower P-gp efflux. The Caco-2 values are concerning for both, but Ligand A is slightly better. Considering the balance, the superior ADMET profile of Ligand A, particularly the lower toxicity and better metabolic properties, makes it a more promising drug candidate despite the weaker binding affinity. The difference in binding affinity, while significant, might be optimized in later stages of drug development.
Output:
1
2025-04-17 22:26:50,538 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (366.46 & 369.49 Da) fall comfortably within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (67.43) is significantly better than Ligand B (80.76). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (2.415 and 1.934), falling within the optimal 1-3 range. Ligand B is slightly lower, which could slightly improve solubility, but both are acceptable.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1), but both are well within the acceptable limit of 5.
5. **HBA:** Ligand A (4) is lower than Ligand B (6). Lower HBA is generally preferred for better permeability.
6. **QED:** Both ligands have good QED scores (0.728 and 0.794), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand B (53.742) has a significantly lower DILI risk than Ligand A (59.597). This is a crucial advantage, as minimizing liver toxicity is essential.
8. **BBB:** Ligand A (75.727) has better BBB penetration than Ligand B (48.585). While not a primary concern for a cardiovascular target, it's a minor positive for Ligand A.
9. **Caco-2:** Both ligands have similar, poor Caco-2 permeability (-4.907 and -4.821). This is a potential issue for both, suggesting limited intestinal absorption.
10. **Solubility:** Ligand B (-2.272) has slightly better solubility than Ligand A (-3.725), which is a minor advantage.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.432 and 0.298), which is excellent.
12. **Cl_mic:** Ligand A (13.183) has significantly lower microsomal clearance than Ligand B (24.963). This indicates better metabolic stability for Ligand A, which is highly desirable.
13. **t1/2:** Ligand A (11.914) has a slightly longer in vitro half-life than Ligand B (17.309).
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.264 and 0.127), which is excellent.
15. **Binding Affinity:** Ligand B (-6.4) has a slightly stronger binding affinity than Ligand A (-6.1). This 0.3 kcal/mol difference is significant, and can outweigh some ADME drawbacks.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B has a slightly better logP, lower TPSA, and a significantly better binding affinity. While Ligand A has better metabolic stability (Cl_mic) and BBB penetration, the DILI risk is higher. The improved binding affinity of Ligand B, coupled with the lower DILI risk, is more compelling.
**Conclusion:**
Despite Ligand A's better metabolic stability and slightly better BBB, Ligand B's superior binding affinity and significantly lower DILI risk make it the more promising drug candidate for the ADRB2 receptor.
Output:
0
2025-04-17 22:26:50,538 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (381.782 Da and 362.499 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (79.46) is slightly higher than Ligand B (67.23). Both are below the 140 A^2 threshold for good oral absorption, but Ligand B is preferable due to the lower TPSA.
**3. logP:** Ligand A (3.471) is within the optimal 1-3 range, while Ligand B (2.246) is slightly lower. Ligand A is slightly preferred here.
**4. H-Bond Donors:** Ligand A (3) is higher than Ligand B (1). Lower is generally better, so Ligand B is preferable.
**5. H-Bond Acceptors:** Ligand A (4) and Ligand B (5) are both acceptable (<=10). No strong preference.
**6. QED:** Both ligands have good QED values (0.659 and 0.788, respectively), indicating good drug-like properties. Ligand B is slightly better.
**7. DILI Risk:** Ligand A (77.433) has a higher DILI risk than Ligand B (54.207). This is a significant advantage for Ligand B.
**8. BBB Penetration:** Both ligands have similar BBB penetration (58.123 and 57.736). Since ADRB2 is a cardiovascular target, BBB penetration isn't a primary concern, but it's good they aren't completely blocked.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.724) is slightly worse than Ligand B (-5.074).
**10. Aqueous Solubility:** Both ligands have negative solubility values, indicating poor solubility. Ligand A (-4.556) is slightly better than Ligand B (-3.742).
**11. hERG Inhibition:** Ligand A (0.536) has a slightly higher hERG risk than Ligand B (0.152). This is a significant advantage for Ligand B.
**12. Microsomal Clearance:** Ligand A (62.963) has a higher microsomal clearance than Ligand B (49.625), suggesting lower metabolic stability. Ligand B is preferable.
**13. In vitro Half-Life:** Ligand B (14.245 hours) has a much longer half-life than Ligand A (-3.393 hours). This is a major advantage for Ligand B.
**14. P-gp Efflux:** Ligand A (0.077) has lower P-gp efflux than Ligand B (0.141), which is preferable.
**15. Binding Affinity:** Ligand B (-7.7 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.5 kcal/mol). This 1.2 kcal/mol difference is substantial and outweighs many of the minor ADME drawbacks of Ligand B.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand B is the stronger candidate. Its significantly higher binding affinity, lower DILI risk, lower hERG risk, and longer half-life are major advantages. While Ligand A has a slightly better logP and P-gp efflux, the benefits of Ligand B outweigh these minor differences. The poor Caco-2 and solubility are concerns for both, but can be addressed with formulation strategies.
Output:
0
2025-04-17 22:26:50,538 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Ligand A (421.733 Da) is within the ideal range, while Ligand B (352.41 Da) is slightly below, but still acceptable.
2. **TPSA:** Ligand A (75.27) is better than Ligand B (107.11). Both are under 140, but lower is preferred for permeability.
3. **logP:** Ligand A (4.587) is high, potentially causing solubility issues. Ligand B (1.197) is low, which could hinder permeation. This is a significant trade-off.
4. **HBD:** Ligand A (2) is preferable to Ligand B (4).
5. **HBA:** Ligand A (3) is preferable to Ligand B (4).
6. **QED:** Both ligands (A: 0.716, B: 0.639) have good drug-likeness scores.
7. **DILI:** Ligand A (90.539) has a significantly higher DILI risk than Ligand B (61.691). This is a major concern for Ligand A.
8. **BBB:** Ligand A (43.815) and Ligand B (53.664) are both relatively low, indicating limited BBB penetration. Since ADRB2 is a cardiovascular target, BBB penetration isn't a primary concern.
9. **Caco-2:** Ligand A (-4.684) is better than Ligand B (-5.316), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-5.011) is worse than Ligand B (-3.142). The high logP of Ligand A likely contributes to this.
11. **hERG:** Ligand A (0.623) is better than Ligand B (0.34), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand A (12.643) has a better (lower) microsomal clearance than Ligand B (-12.363), suggesting better metabolic stability.
13. **t1/2:** Ligand A (139.182) has a significantly longer half-life than Ligand B (-2.006).
14. **Pgp:** Ligand A (0.489) is better than Ligand B (0.06), indicating lower P-gp efflux.
15. **Affinity:** Ligand B (-8.2 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.7 kcal/mol). This is a substantial difference.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand B excels in affinity, has a more reasonable logP, and better Pgp efflux. While Ligand A has better TPSA, the superior affinity of Ligand B is a major advantage. The high DILI risk of Ligand A is also a significant drawback.
**Conclusion:**
Despite Ligand A's slightly better TPSA and metabolic stability, the significantly stronger binding affinity of Ligand B, coupled with its lower DILI risk, makes it the more promising drug candidate. The lower logP of Ligand B, while not ideal, is less concerning than the high logP and DILI risk of Ligand A.
Output:
0
2025-04-17 22:26:50,538 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [352.41 , 94.56 , -0.302, 3. , 5. , 0.586, 20.279, 37.573, -5.263, -1.135, 0.136, -16.365, -6.777, 0.005, -7.3 ]
**Ligand B:** [341.463, 53.32 , 1.66 , 0. , 7. , 0.792, 62.35 , 88.057, -4.794, -2.005, 0.932, 26.456, -1.182, 0.337, -6.9 ]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, Affinity, and BBB):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (341.463) is slightly lower, which is generally favorable.
2. **TPSA:** Ligand A (94.56) is slightly higher than Ligand B (53.32). Both are acceptable for a peripheral GPCR like ADRB2, but Ligand B is better.
3. **logP:** Ligand A (-0.302) is a bit low, potentially hindering membrane permeability. Ligand B (1.66) is within the optimal range (1-3). This is a significant advantage for Ligand B.
4. **HBD/HBA:** Ligand A has 3 HBD and 5 HBA, while Ligand B has 0 HBD and 7 HBA. Both are within acceptable limits, but the lower HBD count of Ligand B is slightly preferred.
5. **QED:** Both have good QED scores (A: 0.586, B: 0.792). Ligand B is better.
6. **DILI:** Ligand A (20.279) has a much lower DILI risk than Ligand B (62.35). This is a major advantage for Ligand A.
7. **BBB:** Ligand B (88.057) has a much higher BBB penetration potential than Ligand A (37.573). While ADRB2 isn't a CNS target, some degree of BBB penetration can sometimes be beneficial for distribution.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand B (-4.794) is slightly better than Ligand A (-5.263).
9. **Solubility:** Both have negative solubility values, which is also unusual and suggests poor solubility. Ligand B (-2.005) is slightly better than Ligand A (-1.135).
10. **hERG:** Ligand A (0.136) has a lower hERG risk than Ligand B (0.932). This is a significant advantage for Ligand A.
11. **Cl_mic:** Ligand A (-16.365) has a much lower (better) microsomal clearance than Ligand B (26.456), indicating better metabolic stability.
12. **t1/2:** Ligand A (-6.777) has a slightly longer in vitro half-life than Ligand B (-1.182).
13. **Pgp:** Ligand A (0.005) has a much lower P-gp efflux liability than Ligand B (0.337), which is favorable for bioavailability.
14. **Affinity:** Ligand A (-7.3) has a slightly better binding affinity than Ligand B (-6.9). While the difference is not huge, it's still a factor.
**Overall Assessment:**
Ligand A has significant advantages in terms of safety (DILI, hERG), metabolic stability (Cl_mic), P-gp efflux, and binding affinity. Ligand B has better logP and BBB penetration, but the safety concerns with Ligand B are substantial. The slightly better logP of Ligand B is outweighed by the other factors.
Therefore, I would choose Ligand A.
Output:
1
2025-04-17 22:26:50,538 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**1. Molecular Weight:** Both ligands (346.391 and 352.41 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (113.14) is higher than Ligand B (78.53). For a cardiovascular GPCR like ADRB2, TPSA is moderately important. Ligand B's lower TPSA is preferable for better membrane permeability.
**3. logP:** Ligand A (-0.138) is quite low, potentially hindering permeability. Ligand B (1.153) is within the optimal 1-3 range. This is a significant advantage for Ligand B.
**4. H-Bond Donors:** Both have 1 HBD, which is acceptable.
**5. H-Bond Acceptors:** Ligand A has 7 HBAs, while Ligand B has 4. Both are within the acceptable limit of 10, but Ligand B is better.
**6. QED:** Both ligands have good QED scores (0.735 and 0.862), indicating good drug-like properties.
**7. DILI:** Ligand A (48.43) has a slightly higher DILI risk than Ligand B (29.818), though both are below the concerning threshold of 60. Ligand B is preferred.
**8. BBB:** Ligand A (53.819) has a lower BBB penetration percentile than Ligand B (92.594). While ADRB2 isn't a primary CNS target, some degree of BBB penetration can be beneficial for off-target effects assessment and potential peripheral effects. Ligand B is strongly favored.
**9. Caco-2 Permeability:** Ligand A (-5.174) has poor Caco-2 permeability, indicating poor intestinal absorption. Ligand B (-4.65) is better, though still not great.
**10. Aqueous Solubility:** Ligand A (-1.943) and Ligand B (-2.558) both have poor aqueous solubility. This could pose formulation challenges.
**11. hERG Inhibition:** Ligand A (0.025) shows very low hERG inhibition risk, which is excellent. Ligand B (0.616) is slightly higher, but still relatively low.
**12. Microsomal Clearance:** Ligand A (-17.933) has a very low (good) microsomal clearance, indicating high metabolic stability. Ligand B (6.526) has a higher clearance, suggesting faster metabolism.
**13. In vitro Half-Life:** Ligand A (17.152 hours) has a longer half-life than Ligand B (-4.995 hours). This is a significant advantage for Ligand A.
**14. P-gp Efflux:** Ligand A (0.016) has very low P-gp efflux, which is desirable. Ligand B (0.041) is slightly higher, but still low.
**15. Binding Affinity:** Ligand B (-7.0) has a slightly better binding affinity than Ligand A (-5.8). This 1.2 kcal/mol difference is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand B has a significantly better profile overall. Its superior logP, lower TPSA, better BBB penetration, and stronger binding affinity are crucial for a GPCR target like ADRB2. While Ligand A has better metabolic stability and a slightly lower hERG risk, the permeability issues (low logP, poor Caco-2) and weaker binding are major drawbacks. The improved affinity of Ligand B is a key factor.
Output:
0
2025-04-17 22:26:50,539 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (351.535 and 370.45 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (44.81) is significantly better than Ligand B (95.42). ADRB2 is a cardiovascular target, not CNS, but lower TPSA generally aids absorption. Ligand A is well below the 140 threshold, while B is approaching it.
3. **logP:** Ligand A (3.403) is optimal, while Ligand B (0.546) is quite low. Low logP can hinder membrane permeability. This is a significant advantage for A.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower is generally better for permeability.
5. **HBA:** Ligand A (4) is preferable to Ligand B (6). Lower is generally better for permeability.
6. **QED:** Both ligands have similar QED values (0.789 and 0.731), indicating good drug-likeness.
7. **DILI:** Ligand A (5.351) has a much lower DILI risk than Ligand B (23.769). This is a major advantage for A.
8. **BBB:** Both ligands have reasonable BBB penetration (80.07 and 68.282). Not a primary concern for a cardiovascular target.
9. **Caco-2:** Ligand A (-4.683) is better than Ligand B (-5.096) but both are negative.
10. **Solubility:** Ligand A (-1.956) is better than Ligand B (-1.734).
11. **hERG:** Ligand A (0.818) is better than Ligand B (0.123). Lower hERG inhibition is crucial for cardiovascular safety.
12. **Cl_mic:** Ligand A (6.215) is higher than Ligand B (4.245). Lower is better for metabolic stability.
13. **t1/2:** Ligand A (6.983) is better than Ligand B (-25.554).
14. **Pgp:** Ligand A (0.039) is much better than Ligand B (0.008). Lower P-gp efflux is desirable for better bioavailability.
15. **Affinity:** Ligand A (-6.5 kcal/mol) is slightly better than Ligand B (-5.3 kcal/mol), but the difference is not huge.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A excels in logP, TPSA, and Pgp. The affinity difference is not substantial enough to override the ADME advantages of Ligand A.
**Conclusion:**
Ligand A is significantly better across multiple crucial ADME properties (DILI, logP, TPSA, Pgp, hERG, Cl_mic, t1/2) and has a slightly better binding affinity. While Ligand B has acceptable properties, Ligand A presents a much more favorable profile for development as a drug candidate.
Output:
1
2025-04-17 22:26:50,539 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (373.322 and 366.571 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (92.5) is higher than Ligand B (49.41). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B is better.
3. **logP:** Ligand A (1.337) is within the optimal range (1-3), while Ligand B (3.309) is at the higher end. Both are acceptable, but Ligand A is slightly preferred.
4. **HBD:** Ligand A (2) and Ligand B (1) are both low and acceptable. No clear advantage.
5. **HBA:** Both ligands have 3 HBA, which is within the acceptable range. No clear advantage.
6. **QED:** Ligand B (0.83) has a significantly higher QED score than Ligand A (0.497), indicating a more drug-like profile. This is a substantial advantage for Ligand B.
7. **DILI:** Ligand A (36.138) has a lower DILI risk than Ligand B (16.208), which is a significant advantage. Lower DILI is crucial.
8. **BBB:** Both ligands have good BBB penetration (Ligand A: 76.541, Ligand B: 81.698). Since ADRB2 is not a CNS target, this is less critical, but Ligand B is slightly better.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. This is a concern for both, but the value for Ligand A (-5.357) is worse than Ligand B (-5.03).
10. **Solubility:** Ligand A (-2.249) has better solubility than Ligand B (-4.149). Solubility is important for bioavailability.
11. **hERG:** Both ligands have low hERG inhibition risk (Ligand A: 0.455, Ligand B: 0.538). No significant difference.
12. **Cl_mic:** Ligand A (-15.886) has a significantly lower (better) microsomal clearance than Ligand B (64.281), indicating better metabolic stability. This is a major advantage for Ligand A.
13. **t1/2:** Ligand A (-1.057) has a slightly better in vitro half-life than Ligand B (-11.87).
14. **Pgp:** Both ligands have low Pgp efflux liability (Ligand A: 0.029, Ligand B: 0.207). Ligand A is slightly better.
15. **Binding Affinity:** Ligand B (-7.6) has a stronger binding affinity than Ligand A (-5.5). This is a 2.1 kcal/mol difference, which is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand B has a superior QED and binding affinity, and slightly better BBB penetration. However, Ligand A demonstrates a significantly lower DILI risk and much better metabolic stability (lower Cl_mic) and slightly better solubility and Pgp efflux. Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity), and the importance of minimizing toxicity (DILI) and maximizing metabolic stability for a cardiovascular drug, Ligand A appears to be the more promising candidate. The difference in binding affinity, while significant, can potentially be addressed through further optimization without drastically altering the favorable ADME properties of Ligand A.
Output:
1
2025-04-17 22:26:50,539 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands (348.393 and 351.535 Da) are within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (41.57) is significantly better than Ligand B (52.65). For a GPCR, keeping TPSA low is beneficial for permeability.
3. **logP:** Ligand A (4.724) is higher than Ligand B (2.815). While both are within the acceptable range (1-3 is optimal, but up to 4 is tolerable), Ligand A is pushing the upper limit and could potentially have solubility issues.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 2 HBA, while Ligand B has 3. Both are acceptable, but lower is generally preferred.
6. **QED:** Ligand A (0.849) has a much better QED score than Ligand B (0.486), indicating a more drug-like profile.
7. **DILI:** Ligand B (14.618) has a significantly lower DILI risk than Ligand A (65.103). This is a major advantage for Ligand B.
8. **BBB:** Both ligands have good BBB penetration (Ligand A: 70.415, Ligand B: 69.678). Similar values.
9. **Caco-2:** Both have negative Caco-2 values (-4.343 and -4.704), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand B (-2.748) has better solubility than Ligand A (-5.067). This is important, especially given Ligand A's higher logP.
11. **hERG:** Ligand A (0.791) has a slightly higher hERG risk than Ligand B (0.438), but both are relatively low.
12. **Cl_mic:** Ligand A (100.262) has a much higher microsomal clearance than Ligand B (46.091), suggesting lower metabolic stability.
13. **t1/2:** Ligand A (19.095) has a longer in vitro half-life than Ligand B (10.313). This is a positive for Ligand A.
14. **Pgp:** Ligand A (0.356) has lower P-gp efflux than Ligand B (0.108), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand A (-7.0) has a slightly better binding affinity than Ligand B (-5.5). This is a significant advantage.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, and affinity. Ligand A has a higher logP (potentially problematic), lower TPSA (good), lower Pgp efflux (good), and better affinity (very good). Ligand B has a lower logP (better), higher TPSA (less ideal), higher Pgp efflux (less ideal), but a significantly lower DILI risk.
**Overall Assessment:**
Ligand A's superior binding affinity and longer half-life are strong positives. However, its higher logP, DILI risk, and higher metabolic clearance are significant concerns. Ligand B has a much better safety profile (lower DILI) and better metabolic stability, but weaker binding affinity.
Given the balance, the stronger binding affinity of Ligand A is a compelling factor for a GPCR target, *provided* the logP and DILI risks can be addressed through further optimization. The DILI risk for Ligand A is quite high. Therefore, I will choose Ligand B.
**Output:**
0
2025-04-17 22:26:50,539 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [337.423, 58.38, 3.538, 0, 5, 0.835, 65.491, 73.827, -4.58, -5.488, 0.797, 86.717, 16.643, 0.406, -6.2]**
**Ligand B: [359.451, 69.72, 1.251, 1, 4, 0.819, 52.462, 71.811, -4.866, -3.394, 0.243, 34.913, -3.055, 0.073, -7.5]**
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). A (337.423) is slightly preferred.
2. **TPSA:** A (58.38) is better than B (69.72), as it's closer to the <140 threshold for good absorption.
3. **logP:** A (3.538) is good, while B (1.251) is a bit low, potentially hindering permeation. A is favored.
4. **H-Bond Donors:** A (0) is excellent, and B (1) is acceptable. A is favored.
5. **H-Bond Acceptors:** A (5) is good, and B (4) is also good. No strong preference.
6. **QED:** Both are very similar and good (A: 0.835, B: 0.819).
7. **DILI:** B (52.462) is significantly better than A (65.491). B is favored.
8. **BBB:** Both have good BBB penetration (A: 73.827, B: 71.811). No strong preference.
9. **Caco-2:** Both are negative, indicating poor permeability. A (-4.58) is slightly better than B (-4.866).
10. **Solubility:** B (-3.394) is better than A (-5.488). B is favored.
11. **hERG:** A (0.797) is better than B (0.243), indicating lower cardiotoxicity risk. A is favored.
12. **Cl_mic:** B (34.913) is much better than A (86.717), suggesting better metabolic stability. B is strongly favored.
13. **t1/2:** B (-3.055) is much better than A (16.643), suggesting a longer half-life. B is strongly favored.
14. **Pgp:** A (0.406) is better than B (0.073), indicating lower efflux. A is favored.
15. **Binding Affinity:** B (-7.5) is significantly better than A (-6.2). This is a substantial advantage.
**Overall Assessment:**
For a GPCR target like ADRB2, affinity, logP, and metabolic stability are crucial. Ligand B has a significantly better binding affinity (-7.5 vs -6.2 kcal/mol), which is a major advantage. It also has substantially improved metabolic stability (lower Cl_mic) and a longer half-life. While Ligand A has advantages in TPSA, logP, hERG, and Pgp, the superior affinity and metabolic properties of Ligand B outweigh these factors. The DILI and solubility are also better for Ligand B.
**Output:**
0
2025-04-17 22:26:50,539 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (362.43 & 342.44 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Both ligands (57.69 & 58.44) are below the 140 A^2 threshold for good oral absorption, which is good.
3. **logP:** Ligand A (2.815) is optimal, while Ligand B (1.674) is slightly lower, potentially impacting permeability. This favors Ligand A.
4. **HBD:** Both have 0 HBD, which is acceptable.
5. **HBA:** Ligand A has 3 HBA, and Ligand B has 4 HBA. Both are below the 10 threshold.
6. **QED:** Both ligands have acceptable QED scores (0.84 and 0.765), indicating good drug-like properties.
7. **DILI:** Ligand A (79.84%) has a significantly higher DILI risk than Ligand B (35.67%). This is a major concern for Ligand A.
8. **BBB:** Ligand A (85.03%) has better BBB penetration than Ligand B (70.38%). While ADRB2 isn't strictly a CNS target, some CNS exposure can be relevant for off-target effects or potential therapeutic benefits.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.392 & -4.725), which is unusual and suggests poor permeability. This is a significant drawback for both.
10. **Solubility:** Ligand A (-4.365) has slightly better solubility than Ligand B (-1.06).
11. **hERG:** Ligand A (0.802) has a higher hERG risk than Ligand B (0.232). This is a concerning safety signal for Ligand A.
12. **Cl_mic:** Ligand A (37.83) has lower microsomal clearance than Ligand B (59.29), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-8.688) has a longer in vitro half-life than Ligand A (9.345). This is a positive for Ligand B.
14. **Pgp:** Ligand A (0.377) has lower P-gp efflux than Ligand B (0.215), which is preferable.
15. **Binding Affinity:** Ligand A (-6.9 kcal/mol) has a slightly better binding affinity than Ligand B (-5.7 kcal/mol). This is a significant advantage for Ligand A, potentially outweighing some of its ADME drawbacks.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand A has better logP and Pgp, and a significantly better binding affinity. However, the high DILI and hERG risks are major red flags. Ligand B, while having a lower affinity, exhibits a much more favorable safety profile (lower DILI and hERG). The Caco-2 values are poor for both, but the better metabolic stability (lower Cl_mic and longer t1/2) of Ligand B is also a plus.
**Overall Assessment:**
Despite Ligand A's superior binding affinity, the significantly higher DILI and hERG risks are too concerning for a cardiovascular target. The safety profile is paramount in this context. Ligand B, while less potent, presents a much more favorable risk-benefit profile.
Output:
0
2025-04-17 22:26:50,540 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (344.411 and 348.462 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (59.08) is slightly higher than Ligand B (49.41). Both are below the 140 threshold for oral absorption, and reasonably good for a GPCR. Ligand B is preferable.
3. **logP:** Ligand B (2.524) is better positioned within the optimal 1-3 range than Ligand A (1.228). Ligand A is a bit low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (0) is preferable to Ligand B (1). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is preferable to Ligand B (2). Lower HBA is generally better for permeability.
6. **QED:** Both ligands have good QED scores (0.707 and 0.852), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Both ligands have low DILI risk (31.873 and 30.826), which is excellent. No significant difference.
8. **BBB:** Both ligands have good BBB penetration (77.123 and 74.564). This is a positive for a GPCR target, though not strictly necessary for ADRB2. Ligand A is slightly better.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.688 and -4.812). This is unusual and suggests poor permeability. However, these values are on a scale where negative values are possible, and the absolute values are similar.
10. **Solubility:** Both ligands have poor aqueous solubility (-2.271 and -3.658). This is a concern, but can potentially be addressed with formulation strategies. Ligand B is worse.
11. **hERG:** Both ligands have very low hERG risk (0.244 and 0.504), which is excellent. Ligand A is preferable.
12. **Cl_mic:** Ligand B (-3.858) has significantly *lower* (better) microsomal clearance than Ligand A (32.212). This suggests better metabolic stability for Ligand B.
13. **t1/2:** Ligand B (1.963) has a slightly longer half-life than Ligand A (5.316). This is a positive.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.057 and 0.131), which is excellent. Ligand A is preferable.
15. **Binding Affinity:** Ligand B (-7.2 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.6 kcal/mol). This 0.6 kcal/mol difference is substantial and likely outweighs minor ADME drawbacks.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP and has a significantly better binding affinity. While Ligand A has a slightly better TPSA and Pgp, the affinity difference is more important.
**Overall Assessment:**
Ligand B has a superior binding affinity and better metabolic stability (lower Cl_mic). While its solubility is slightly worse than Ligand A, the strong binding affinity and improved metabolic profile are more critical for a viable drug candidate.
Output:
0
2025-04-17 22:26:50,540 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.419 and 351.506 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (116.4) is higher than the preferred <140 for oral absorption, but not drastically. Ligand B (29.54) is excellent, well below the threshold. This favors Ligand B.
3. **logP:** Ligand A (-0.665) is a bit low, potentially hindering permeability. Ligand B (4.659) is high, potentially causing solubility/off-target issues. This is a trade-off, but given ADRB2 is a GPCR, a slightly higher logP isn't as detrimental as a very low one.
4. **HBD:** Ligand A (4) is acceptable. Ligand B (0) is also good, potentially improving membrane permeability.
5. **HBA:** Ligand A (4) is acceptable. Ligand B (2) is also good.
6. **QED:** Both ligands (0.508 and 0.47) are reasonably drug-like, above the 0.5 threshold, but close. No strong preference.
7. **DILI:** Ligand A (35.867) has a moderate DILI risk, but is still acceptable. Ligand B (10.275) has a very low DILI risk, which is a significant advantage.
8. **BBB:** Ligand A (29.12) has low BBB penetration. Ligand B (95.967) has excellent BBB penetration. While ADRB2 isn't strictly a CNS target, some CNS exposure can be relevant for off-target effects, and a lower BBB score is not necessarily a dealbreaker.
9. **Caco-2:** Ligand A (-5.696) is very poor. Ligand B (-4.412) is also poor, but slightly better. Both are concerning.
10. **Solubility:** Ligand A (-1.614) is poor. Ligand B (-4.143) is very poor. Both are problematic, but Ligand B is worse.
11. **hERG:** Ligand A (0.021) has a very low hERG risk, excellent. Ligand B (0.842) has a moderate hERG risk, which is a concern.
12. **Cl_mic:** Ligand A (-13.412) has low clearance, indicating good metabolic stability. Ligand B (88.415) has high clearance, indicating poor metabolic stability. This strongly favors Ligand A.
13. **t1/2:** Ligand A (25.286) has a good in vitro half-life. Ligand B (14.77) has a shorter half-life. This favors Ligand A.
14. **Pgp:** Ligand A (0.004) has very low P-gp efflux, which is good. Ligand B (0.742) has moderate P-gp efflux. This favors Ligand A.
15. **Affinity:** Ligand A (-6.7) has better binding affinity than Ligand B (-3.7). This is a substantial difference, and a >3 kcal/mol advantage often outweighs other concerns.
**Overall Assessment:**
Ligand A has a significantly better binding affinity, excellent metabolic stability (low Cl_mic, good t1/2), low P-gp efflux, and very low hERG risk. While its logP and TPSA are not ideal, the strong binding affinity and favorable ADME properties outweigh these drawbacks. Ligand B has a better TPSA and lower DILI, but suffers from poor metabolic stability, moderate hERG risk, and significantly weaker binding affinity. For a GPCR target like ADRB2, potency is paramount, and Ligand A clearly wins in that regard.
Output:
1
2025-04-17 22:26:50,540 - INFO - Batch 332 complete. Total preferences: 5312
2025-04-17 22:26:50,540 - INFO - Processing batch 333/512...
2025-04-17 22:27:42,062 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**1. Molecular Weight:** Both ligands (351.491 Da and 350.503 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (69.72) and Ligand B (67.43) are both below the 140 A^2 threshold for good oral absorption, and acceptable for a non-CNS GPCR target like ADRB2. Ligand B is slightly better.
**3. logP:** Ligand A (1.787) is within the optimal 1-3 range. Ligand B (2.949) is towards the higher end but still acceptable.
**4. H-Bond Donors:** Ligand A (1) and Ligand B (2) are both within the acceptable limit of 5.
**5. H-Bond Acceptors:** Both ligands (A: 3, B: 3) are well below the 10 limit.
**6. QED:** Ligand A (0.76) has a significantly better QED score than Ligand B (0.496), indicating a more drug-like profile.
**7. DILI:** Ligand A (20.047) has a much lower DILI risk than Ligand B (13.843). This is a crucial advantage.
**8. BBB:** Both ligands have similar BBB penetration (A: 65.452, B: 69.058). This isn't a primary concern for ADRB2, as it's not a CNS target.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.668 and -4.522), which is unusual and suggests poor permeability. However, these values are close, so the difference isn't decisive.
**10. Aqueous Solubility:** Both ligands have negative solubility values (-2.154 and -3.073), indicating poor aqueous solubility. Ligand B is slightly worse.
**11. hERG Inhibition:** Ligand A (0.122) has a lower hERG inhibition liability than Ligand B (0.421), which is a significant safety advantage.
**12. Microsomal Clearance:** Ligand B (66.755) has a slightly higher microsomal clearance than Ligand A (54.122), suggesting lower metabolic stability.
**13. In vitro Half-Life:** Ligand A (-9.486) has a longer in vitro half-life than Ligand B (-7.171).
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (A: 0.085, B: 0.295).
**15. Binding Affinity:** Both ligands have very similar binding affinities (-6.4 kcal/mol and -6.2 kcal/mol). The difference is not substantial enough to override other factors.
**Overall Assessment:**
Ligand A is the preferred candidate. It has a significantly better QED score, much lower DILI risk, lower hERG inhibition, longer half-life, and slightly better solubility. While both ligands have poor Caco-2 permeability and solubility, the safety and drug-likeness advantages of Ligand A outweigh the minor differences in other parameters.
Output:
1
2025-04-17 22:27:42,063 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
Let's systematically compare Ligand A and Ligand B based on the provided parameters, keeping in mind the GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key).
1. **MW:** Both ligands (372.447 and 360.439 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand B (85.28) is significantly better than Ligand A (110.6). Lower TPSA generally favors better cell permeability and oral absorption, crucial for GPCRs.
3. **logP:** Ligand B (1.8) is optimal, while Ligand A (-0.191) is slightly low, potentially hindering membrane permeability. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (1) is slightly better than Ligand B (0). Both are acceptable.
5. **HBA:** Both ligands have 7 HBA, which is within the acceptable range.
6. **QED:** Both ligands have similar QED values (0.717 and 0.73), indicating good drug-likeness.
7. **DILI:** Ligand B (74.021) has a higher DILI risk than Ligand A (40.946). This is a negative for Ligand B, but not a deal-breaker.
8. **BBB:** Both ligands show reasonable BBB penetration (64.482 and 70.764). Ligand B is slightly better.
9. **Caco-2:** Both ligands have similar, very negative Caco-2 values (-4.827 and -4.665). This suggests poor permeability, which is concerning.
10. **Solubility:** Both ligands have very negative solubility values (-2.156 and -1.815), indicating poor aqueous solubility. This is a significant drawback for both.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.151 and 0.14). This is good.
12. **Cl_mic:** Ligand B (67.495) has a higher microsomal clearance than Ligand A (43.07), indicating faster metabolism and potentially lower *in vivo* exposure. This favors Ligand A.
13. **t1/2:** Both ligands have similar negative in vitro half-lives (-32.78 and -33.358). This is concerning.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.028 and 0.101). This is good.
15. **Binding Affinity:** Both ligands have similar binding affinities (-6.7 and -6.3 kcal/mol). The difference is not substantial enough to outweigh other factors.
**Overall Assessment:**
Ligand B has a more favorable logP and TPSA, which are critical for GPCR ligands. While its DILI risk is higher, the better logP and TPSA are more important for this target class. The poor Caco-2 and solubility are concerning for both, but can potentially be addressed with formulation strategies. Ligand A has better metabolic stability (lower Cl_mic), but the permeability issues associated with its lower logP are more problematic.
**Output:**
0
2025-04-17 22:27:42,063 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
We are targeting ADRB2, a GPCR. Therefore, the key priorities are logP, TPSA, Pgp efflux, BBB penetration (though less critical for a cardiovascular target), and binding affinity. Metabolic stability (Cl_mic, t1/2) and safety (DILI, hERG) are also important.
Let's compare the ligands property by property:
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (351.422) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (75.44) is significantly better than Ligand B (133.91). A TPSA under 140 is good for oral absorption, but Ligand A is closer to the ideal range for GPCRs.
3. **logP:** Ligand A (2.147) is optimal (1-3). Ligand B (-1.613) is too low, potentially hindering membrane permeability and absorption.
4. **HBD/HBA:** Ligand A (HBD=1, HBA=4) is better than Ligand B (HBD=3, HBA=6). Lower counts generally improve permeability.
5. **QED:** Ligand A (0.852) is significantly better than Ligand B (0.51), indicating a more drug-like profile.
6. **DILI:** Ligand A (35.595) has a much lower DILI risk than Ligand B (48.972).
7. **BBB:** Ligand A (87.01) has better BBB penetration than Ligand B (39.783), although this is less critical for a cardiovascular target.
8. **Caco-2:** Ligand A (-4.871) is better than Ligand B (-5.652), indicating better intestinal absorption.
9. **Solubility:** Both are poor (-2.051 and -2.002). This is a concern for both, but may be mitigated by formulation strategies.
10. **hERG:** Both have very low hERG risk (0.205 and 0.048).
11. **Cl_mic:** Ligand B (-42.576) has much better metabolic stability (lower clearance) than Ligand A (19.974). This is a significant advantage.
12. **t1/2:** Ligand B (-40.831) has a much longer in vitro half-life than Ligand A (-21.574). This is a significant advantage.
13. **Pgp:** Both have very low Pgp efflux liability (0.085 and 0.006).
14. **Binding Affinity:** Ligand B (-6.9) has slightly better binding affinity than Ligand A (-6.6), but the difference is relatively small.
**Overall Assessment:**
Ligand A has a much better profile regarding key ADME properties (TPSA, logP, QED, DILI, Caco-2) and reasonable binding affinity. While Ligand B has superior metabolic stability and half-life, the poor logP and TPSA are major drawbacks for a GPCR target. The improved ADME profile of Ligand A outweighs the slightly better affinity and metabolic stability of Ligand B.
**Output:**
1
2025-04-17 22:27:42,063 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (343.471 and 358.429 Da) fall comfortably within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (53.6) is better than Ligand B (58.64), both are below the 140 threshold for oral absorption, but closer to the ideal for GPCRs.
3. **logP:** Both ligands have good logP values (3.153 and 2.344), falling within the optimal 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability, but not dramatically so.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1), but both are within the acceptable limit of 5.
5. **HBA:** Both ligands have 3 HBA, well within the acceptable limit of 10.
6. **QED:** Both ligands have similar QED scores (0.834 and 0.76), indicating good drug-likeness.
7. **DILI:** Ligand B (15.587) has a significantly lower DILI risk than Ligand A (20.202). This is a substantial advantage for Ligand B.
8. **BBB:** Both ligands have very high BBB penetration (92.672 and 95.269). This is excellent, and not a differentiating factor.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.668 and -4.608). These values are unusual and suggest poor permeability. However, since they are similar, this doesn't sway the decision.
10. **Solubility:** Ligand B (-2.388) has better solubility than Ligand A (-3.46). This is a positive for Ligand B.
11. **hERG:** Both ligands have similar hERG inhibition liability (0.793 and 0.583), indicating a moderate risk.
12. **Cl_mic:** Ligand B (1.156) has significantly lower microsomal clearance than Ligand A (60.187). This is a major advantage for Ligand B, suggesting much better metabolic stability.
13. **t1/2:** Ligand A (7.772) has a longer in vitro half-life than Ligand B (-1.095). This is a positive for Ligand A, but the negative value for Ligand B is concerning.
14. **Pgp:** Ligand A (0.134) has lower P-gp efflux liability than Ligand B (0.051). This is a slight advantage for Ligand A.
15. **Binding Affinity:** Both ligands have identical binding affinities (-5.5 kcal/mol).
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), both ligands perform similarly in terms of affinity and logP. However, Ligand B demonstrates significant advantages in terms of DILI risk and, crucially, metabolic stability (Cl_mic). The longer half-life of Ligand A is appealing, but the extremely low clearance of Ligand B is a more impactful benefit. The solubility is also better for Ligand B. While the Caco-2 values are concerning for both, they are similar, and the other benefits of Ligand B outweigh this drawback.
Output:
0
2025-04-17 22:27:42,063 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (356.463 Da) is well within the ideal range (200-500 Da). Ligand B (409.276 Da) is also acceptable, but approaching the upper limit.
2. **TPSA:** Ligand A (96.89) is good for oral absorption, being under 140. Ligand B (53.99) is excellent, well below 90.
3. **logP:** Ligand A (0.805) is a bit low, potentially impacting permeability. Ligand B (4.24) is high, potentially causing solubility issues and off-target effects.
4. **HBD:** Ligand A (3) is within the acceptable range. Ligand B (0) is also good.
5. **HBA:** Both Ligand A (5) and Ligand B (5) are within the acceptable range.
6. **QED:** Ligand A (0.627) is better than Ligand B (0.528), indicating a more drug-like profile.
7. **DILI:** Ligand A (19.736) has a significantly lower DILI risk than Ligand B (77.2). This is a major advantage for Ligand A.
8. **BBB:** Both have moderate BBB penetration, but Ligand A (58.821) is better than Ligand B (50.097). While ADRB2 isn't strictly a CNS target, some CNS exposure can occur, and higher BBB is generally favorable.
9. **Caco-2:** Ligand A (-5.119) is poor, indicating poor intestinal absorption. Ligand B (-4.531) is also poor, but slightly better.
10. **Solubility:** Ligand A (-1.342) is poor. Ligand B (-5.286) is very poor.
11. **hERG:** Ligand A (0.152) has a very low hERG risk. Ligand B (0.469) is slightly higher, but still relatively low.
12. **Cl_mic:** Ligand A (25.703) has a much lower microsomal clearance, suggesting better metabolic stability. Ligand B (108.981) is high, indicating rapid metabolism.
13. **t1/2:** Ligand A (2.404) has a shorter half-life than Ligand B (31.076). This is a drawback for Ligand A.
14. **Pgp:** Ligand A (0.026) has very low P-gp efflux, which is good. Ligand B (0.588) has moderate P-gp efflux.
15. **Affinity:** Ligand A (-7.4 kcal/mol) has a slightly better binding affinity than Ligand B (-6.4 kcal/mol). This 1.0 kcal/mol difference is significant.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are crucial. Ligand B has better TPSA and Pgp, but a problematic logP. Ligand A has a better balance, with acceptable TPSA and Pgp, a slightly lower logP, and a significantly better DILI profile and metabolic stability. The affinity difference is also in favor of Ligand A.
**Overall Assessment:**
While Ligand B has a better TPSA and slightly better Caco-2 permeability, the high logP, significantly higher DILI risk, and rapid metabolism are major concerns. Ligand A, despite its lower Caco-2 and solubility, presents a more favorable overall profile with better safety (DILI), metabolic stability, and binding affinity. The slight solubility and permeability issues can potentially be addressed through formulation strategies.
Output:
1
2025-04-17 22:27:42,063 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (384.351 Da) is within the ideal range (200-500 Da). Ligand B (347.379 Da) is also within the ideal range. No clear advantage here.
2. **TPSA:** Ligand A (86.71) is excellent, well below the 140 threshold for oral absorption and suitable for a GPCR. Ligand B (129.03) is still acceptable, but less optimal. Advantage: A.
3. **logP:** Ligand A (1.137) is within the optimal range (1-3). Ligand B (0.129) is quite low, potentially hindering membrane permeability. Advantage: A.
4. **HBD:** Ligand A (2) is good. Ligand B (3) is acceptable, but slightly higher. Advantage: A.
5. **HBA:** Ligand A (4) is good. Ligand B (7) is higher, potentially impacting permeability. Advantage: A.
6. **QED:** Both ligands (A: 0.72, B: 0.681) have good drug-likeness scores, exceeding 0.5. No clear advantage.
7. **DILI:** Ligand A (63.513) has a moderate DILI risk, but is better than Ligand B (71.268). Advantage: A.
8. **BBB:** Ligand A (55.797) has a moderate BBB penetration, while Ligand B (18.147) is very low. While ADRB2 isn't exclusively a CNS target, some CNS penetration can be beneficial, and avoiding efflux is important. Advantage: A.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale isn't specified, so it's hard to interpret.
10. **Solubility:** Both ligands have negative solubility values, which is also unusual. Again, the scale is unclear.
11. **hERG:** Ligand A (0.486) has a very low hERG risk, which is excellent. Ligand B (0.064) also has low hERG risk. No clear advantage.
12. **Cl_mic:** Ligand A (26.653) has a moderate clearance, while Ligand B (-5.27) has a *negative* clearance, which is not physically possible and likely indicates an issue with the data. Advantage: A.
13. **t1/2:** Ligand A (11.229) has a reasonable half-life. Ligand B (-27.52) has a negative half-life, which is not physically possible and indicates a data issue. Advantage: A.
14. **Pgp:** Ligand A (0.103) has low P-gp efflux. Ligand B (0.012) also has low P-gp efflux. No clear advantage.
15. **Binding Affinity:** Both ligands have similar binding affinities (-6.1 kcal/mol and -6.0 kcal/mol). No clear advantage.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across multiple critical ADME properties (TPSA, logP, DILI, BBB, Cl_mic, t1/2). The negative values for Caco-2, solubility, Cl_mic, and t1/2 for Ligand B raise serious concerns about data quality or inherent issues with the molecule. While both have similar binding affinities, the superior ADME profile of Ligand A makes it a much more promising drug candidate for the ADRB2 receptor. The GPCR-specific priorities of logP and TPSA are well-addressed by Ligand A.
Output:
1
2025-04-17 22:27:42,063 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (379.869 and 382.448 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (70.58 and 69.64) are below the 140 A^2 threshold for good oral absorption, and acceptable for a cardiovascular target. Again, no major difference.
3. **logP:** Both ligands have a logP around 2.0 (2.057 and 2.001), which is optimal for permeability and solubility.
4. **HBD:** Ligand A has 0 HBD, while Ligand B has 2. Lower HBD is generally preferred for permeability, giving a slight edge to Ligand A.
5. **HBA:** Both ligands have 4 HBA, which is within the acceptable range.
6. **QED:** Ligand A (0.8) has a slightly better QED score than Ligand B (0.707), indicating a more drug-like profile.
7. **DILI:** Ligand A (79.798) has a significantly higher DILI risk than Ligand B (19.426). This is a major concern for Ligand A.
8. **BBB:** Both ligands have good BBB penetration (81.621 and 71.656), which is less critical for a cardiovascular target but not detrimental.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.724 and -5.058), which is unusual and suggests poor permeability. However, these values are on a scale where negative values are possible and don't necessarily indicate complete lack of permeability.
10. **Solubility:** Ligand A (-4.049) has worse solubility than Ligand B (-2.811). Solubility is important for bioavailability.
11. **hERG:** Both ligands have low hERG inhibition liability (0.609 and 0.451), which is good.
12. **Cl_mic:** Ligand A (67.73) has a higher microsomal clearance than Ligand B (5.268), suggesting lower metabolic stability. This is a significant drawback for Ligand A.
13. **t1/2:** Ligand B (-22.4) has a longer in vitro half-life than Ligand A (-30.01), which is desirable.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.214 and 0.116).
15. **Binding Affinity:** Ligand A (-5.6 kcal/mol) has a slightly better binding affinity than Ligand B (-3.4 kcal/mol). However, the difference is not substantial enough to outweigh the ADME concerns with Ligand A.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are important. Both ligands perform similarly on logP, Pgp and TPSA. Ligand A has better affinity, but the ADME profile is significantly worse.
**Overall Assessment:**
Ligand A has a better binding affinity and QED, but its significantly higher DILI risk, lower solubility, and higher microsomal clearance are major red flags. Ligand B, while having slightly lower affinity, has a much more favorable ADME profile with a significantly lower DILI risk and better metabolic stability. The difference in affinity is not large enough to overcome the substantial ADME advantages of Ligand B.
Output:
0
2025-04-17 22:27:42,063 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the acceptable range (200-500 Da). Ligand A (359.857) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (68.02) is significantly better than Ligand B (139.62). For a GPCR, keeping TPSA low is beneficial for permeability and potentially BBB penetration. Ligand B is pushing the upper limit for good oral absorption.
3. **logP:** Ligand A (4.191) is higher than Ligand B (-0.04). While 4.191 is approaching the upper end of the optimal range, it's still acceptable. Ligand B's negative logP is a significant concern, suggesting poor membrane permeability and potentially poor absorption.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 6. Both are acceptable, but lower is generally preferred.
6. **QED:** Ligand A (0.804) has a much better QED score than Ligand B (0.508), indicating a more drug-like profile.
7. **DILI:** Ligand A (47.421) has a slightly better DILI score than Ligand B (51.26), indicating lower potential for liver injury. Both are acceptable.
8. **BBB:** Ligand A (81.776) has a significantly higher BBB percentile than Ligand B (67.507). While ADRB2 isn't exclusively a CNS target, some CNS exposure can occur, and higher BBB is generally favorable.
9. **Caco-2:** Ligand A (-4.934) has a more negative Caco-2 value, which is unusual and potentially problematic. Ligand B (-5.766) is also negative, but not as concerning.
10. **Solubility:** Ligand A (-4.399) has a more negative solubility value, indicating poor solubility. Ligand B (-2.238) is better, but still suggests low solubility.
11. **hERG:** Both ligands have very low hERG risk (0.219 and 0.232, respectively).
12. **Cl_mic:** Ligand B (33.284) has lower microsomal clearance than Ligand A (48.731), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-8.929) has a negative in vitro half-life, which is highly unusual and concerning. Ligand A (24.938) has a reasonable half-life.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.192 and 0.029, respectively).
15. **Affinity:** Ligand A (-6.5) has a slightly better binding affinity than Ligand B (-7.0). However, the difference is not substantial enough to outweigh other factors.
**Overall Assessment:**
Ligand A has a better overall profile, despite the negative Caco-2 and solubility values. The significantly better TPSA, QED, and BBB penetration, combined with acceptable DILI and hERG risk, make it a more promising candidate. Ligand B's negative logP and extremely unusual negative in vitro half-life are major red flags. While its metabolic stability is better, the other issues are too significant to ignore.
Output:
1
2025-04-17 22:27:42,063 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.479 and 356.457 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (72.96) is higher than Ligand B (49.41). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is generally preferred for absorption. Ligand B is better.
3. **logP:** Ligand A (0.302) is quite low, potentially hindering permeability. Ligand B (3.355) is within the optimal 1-3 range. Ligand B is significantly better.
4. **HBD:** Both ligands have 1 HBD, which is acceptable.
5. **HBA:** Ligand A has 4 HBAs, while Ligand B has 2. Lower is generally better for permeability, so Ligand B is slightly favored.
6. **QED:** Both ligands have similar QED values (0.773 and 0.711), indicating good drug-likeness.
7. **DILI:** Ligand A (13.3) has a much lower DILI risk than Ligand B (16.208). This is a significant advantage for Ligand A.
8. **BBB:** Ligand B (91.198) has a much higher BBB penetration percentile than Ligand A (55.797). While ADRB2 is primarily a cardiovascular target, some CNS off-target effects are always a consideration, and higher BBB penetration could be problematic. However, for a cardiovascular target, this is less critical.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.971 and -4.484), which is unusual and suggests poor permeability. The values are very close, so this isn't a deciding factor.
10. **Solubility:** Ligand A (-1.013) has slightly better solubility than Ligand B (-3.961). Solubility is good for both, but A is slightly better.
11. **hERG:** Ligand A (0.15) has a much lower hERG inhibition liability than Ligand B (0.751). This is a crucial advantage for Ligand A, minimizing cardiotoxicity risk.
12. **Cl_mic:** Ligand B (57.782) has a higher microsomal clearance than Ligand A (9.18). Lower clearance is preferred for metabolic stability, so Ligand A is better.
13. **t1/2:** Ligand B (9.186) has a significantly longer in vitro half-life than Ligand A (-0.671). This is a major advantage for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.01) has a much lower P-gp efflux liability than Ligand B (0.252). Lower efflux is preferred for better bioavailability.
15. **Binding Affinity:** Ligand A (-6.6) has a slightly better binding affinity than Ligand B (-6.2). While the difference is not huge, it's still a positive for Ligand A.
**Overall Assessment:**
Ligand A has significant advantages in DILI risk, hERG inhibition, metabolic stability (lower Cl_mic), P-gp efflux, and binding affinity. Ligand B has a better logP and a longer half-life. The low logP of Ligand A is a concern, but the safety profile (DILI, hERG) and metabolic stability are paramount for a cardiovascular drug. The slightly better affinity of Ligand A also contributes. While the longer half-life of Ligand B is attractive, the safety concerns outweigh this benefit.
Output:
1
2025-04-17 22:27:42,063 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (349.347 and 348.418 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (124.84) is slightly higher than Ligand B (74.35). For a cardiovascular GPCR, TPSA is moderately important, and Ligand B's lower TPSA is preferable for better membrane permeability.
**3. logP:** Ligand A (-0.558) is significantly lower than Ligand B (2.955). This is a major concern for Ligand A. A logP below 1 can hinder membrane permeability and oral absorption. Ligand B is within the optimal 1-3 range.
**4. H-Bond Donors:** Ligand A (2) and Ligand B (3) are both acceptable, falling below the 5 threshold.
**5. H-Bond Acceptors:** Ligand A (6) and Ligand B (3) are both acceptable, falling below the 10 threshold.
**6. QED:** Both ligands have similar, good QED values (0.702 and 0.719).
**7. DILI Risk:** Ligand A (63.009) has a slightly higher DILI risk than Ligand B (55.176), but both are reasonably acceptable.
**8. BBB Penetration:** Both ligands have similar BBB penetration (60.372 and 64.482). While not a primary concern for a cardiovascular target, higher is generally better.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-5.608 and -5.332), indicating poor permeability. This is concerning for both.
**10. Aqueous Solubility:** Ligand A (-1.331) has better solubility than Ligand B (-3.577). Solubility is important for formulation.
**11. hERG Inhibition:** Ligand A (0.01) has a much lower hERG inhibition risk than Ligand B (0.453). This is a significant advantage for Ligand A, as hERG inhibition can lead to cardiotoxicity.
**12. Microsomal Clearance:** Ligand A (-42.229) has a much lower (better) microsomal clearance than Ligand B (7.54). This indicates better metabolic stability for Ligand A.
**13. In Vitro Half-Life:** Ligand A (-15.55) has a shorter half-life than Ligand B (18.316). This is a drawback for Ligand A.
**14. P-gp Efflux:** Ligand A (0.001) shows very low P-gp efflux, which is excellent. Ligand B (0.081) is also low, but not as favorable.
**15. Binding Affinity:** Ligand B (-6.8 kcal/mol) has a significantly stronger binding affinity than Ligand A (-4.9 kcal/mol). This is a substantial advantage for Ligand B.
**Overall Assessment:**
While Ligand A has advantages in hERG risk, metabolic stability, and P-gp efflux, the critical issue is its very low logP. This will likely translate to very poor oral absorption and bioavailability. Ligand B, despite a slightly higher DILI risk and lower metabolic stability, has a much more favorable logP and significantly better binding affinity. The affinity difference is large enough to outweigh the ADME concerns, especially considering optimization can address metabolic stability and DILI risk.
Therefore, I prefer Ligand B.
0
2025-04-17 22:27:42,064 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's systematically compare Ligand A and Ligand B based on the provided parameters and the guidelines, keeping in mind ADRB2 is a GPCR and therefore we prioritize logP, Pgp, TPSA, and affinity.
1. **MW:** Both ligands (365.382 and 350.419 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (81.7) is better than Ligand B (104.39). Lower TPSA generally favors better absorption, and is particularly important for GPCRs.
3. **logP:** Ligand A (2.877) is optimal, while Ligand B (1.171) is a bit low, potentially hindering permeability. This is a significant advantage for Ligand A.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Both ligands have 5 HBA, which is acceptable.
6. **QED:** Ligand A (0.824) is better than Ligand B (0.75), indicating a more drug-like profile.
7. **DILI:** Ligand B (65.064) has a lower DILI risk than Ligand A (93.021), which is a positive. However, the difference isn't drastic enough to outweigh other factors.
8. **BBB:** Ligand A (66.615) is better than Ligand B (51.803), though neither is exceptionally high. For a cardiovascular target, BBB penetration isn't *critical*, but some level is still desirable for potential off-target effects and distribution.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. Ligand B (-4.651) is slightly worse than Ligand A (-3.893).
10. **Solubility:** Ligand A (-3.893) is slightly better than Ligand B (-2.827), but both are poor.
11. **hERG:** Ligand A (0.327) is better than Ligand B (0.09), indicating a lower risk of cardiotoxicity, which is crucial for a cardiovascular target.
12. **Cl_mic:** Ligand B (72.377) has lower microsomal clearance than Ligand A (35.96), suggesting better metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand A (91.219) has a much longer in vitro half-life than Ligand B (-24.659), which is a major advantage.
14. **Pgp:** Ligand A (0.364) has lower P-gp efflux than Ligand B (0.023), which is preferable for bioavailability.
15. **Affinity:** Ligand A (-6.1 kcal/mol) has a better binding affinity than Ligand B (-4.0 kcal/mol). This is a substantial difference and a key driver in the decision.
**Overall Assessment:**
Ligand A has a significantly better binding affinity, better logP, TPSA, QED, hERG, Pgp, and half-life. While Ligand B has a lower DILI risk and better metabolic stability, the advantages of Ligand A in terms of potency, permeability, and safety (hERG) are more critical for a GPCR target like ADRB2. The poor solubility and Caco-2 values are concerning for both, but can be addressed with formulation strategies.
**Output:**
1
2025-04-17 22:27:42,064 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor (a GPCR).
**Ligand A:** [342.527, 23.55, 4.149, 0, 2, 0.802, 7.251, 93.292, -4.625, -2.537, 0.827, 10.217, 2.406, 0.427, -7.9]
**Ligand B:** [366.439, 84.94, 1.104, 1, 5, 0.805, 56.844, 64.599, -4.811, -2.384, 0.123, -16.598, 60.091, 0.042, -3.8]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (342.527) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (23.55) is significantly better than Ligand B (84.94). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand B's TPSA is quite high.
3. **logP:** Ligand A (4.149) is a bit high, but still within an acceptable range. Ligand B (1.104) is quite low, potentially leading to poor membrane permeability.
4. **HBD:** Both are low, which is good. Ligand A (0) is slightly better.
5. **HBA:** Ligand A (2) is preferable to Ligand B (5).
6. **QED:** Both are good (around 0.8), indicating drug-like properties.
7. **DILI:** Ligand A (7.251) is *much* better than Ligand B (56.844). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (93.292) is much higher than Ligand B (64.599). While not critical for a cardiovascular target, higher BBB is rarely detrimental.
9. **Caco-2:** Both are negative, indicating good permeability.
10. **Solubility:** Both are negative, indicating good solubility.
11. **hERG:** Ligand A (0.827) is better than Ligand B (0.123). Lower hERG risk is crucial.
12. **Cl_mic:** Ligand A (10.217) is much better than Ligand B (-16.598). Ligand B has a negative clearance, which is not physically possible and suggests a problem with the data or prediction. This is a major red flag.
13. **t1/2:** Ligand B (60.091) has a significantly longer half-life than Ligand A (2.406). This is a positive for Ligand B, but is overshadowed by other issues.
14. **Pgp:** Ligand A (0.427) is better than Ligand B (0.042). Lower P-gp efflux is desirable.
15. **Affinity:** Ligand A (-7.9) has a significantly stronger binding affinity than Ligand B (-3.8). This is a substantial advantage.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A performs better in all these categories. The DILI and hERG risk are also critical, and Ligand A is far superior in both.
**Conclusion:**
Despite Ligand B's longer half-life, the combination of significantly better affinity, lower DILI risk, lower hERG risk, better TPSA, better logP, and better Pgp efflux make **Ligand A** the much more promising drug candidate. The negative clearance value for Ligand B is a critical flaw.
**Output:**
1
2025-04-17 22:27:42,064 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [354.403, 99.89, 1.923, 1, 7, 0.712, 62.272, 73.401, -4.762, -1.586, 0.106, 66.273, -7.477, 0.02, -5.2]
**Ligand B:** [371.277, 47.56, 4.056, 1, 3, 0.768, 42.264, 88.135, -4.258, -5.249, 0.783, 41.762, -0.683, 0.169, -5.3]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (354.4) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (99.89) is higher than Ligand B (47.56). For a cardiovascular GPCR, TPSA isn't *as* critical as for a CNS target, but lower is still preferred for better absorption. Ligand B is significantly better here.
3. **logP:** Ligand A (1.923) is within the optimal range. Ligand B (4.056) is pushing the upper limit and could potentially lead to solubility issues or off-target interactions. Ligand A is better.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 7 HBA, while Ligand B has 3. Both are acceptable, but lower is generally better. Ligand B is better.
6. **QED:** Both are above 0.5 (Ligand A: 0.712, Ligand B: 0.768), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (62.272) has a higher DILI risk than Ligand B (42.264). Ligand B is significantly better.
8. **BBB:** Ligand A (73.401) has a good BBB percentile, while Ligand B (88.135) is even better. While ADRB2 isn't exclusively a CNS target, some CNS exposure can occur, so higher BBB is a plus. Ligand B is better.
9. **Caco-2:** Both have negative values, which is unusual. Assuming these are log scale values, both have poor Caco-2 permeability.
10. **Solubility:** Ligand A (-1.586) has better solubility than Ligand B (-5.249). Ligand A is better.
11. **hERG:** Ligand A (0.106) has a much lower hERG risk than Ligand B (0.783). This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand B (41.762) has lower microsomal clearance, suggesting better metabolic stability, than Ligand A (66.273). Ligand B is better.
13. **t1/2:** Ligand A (-7.477) has a longer in vitro half-life than Ligand B (-0.683). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.02) has lower P-gp efflux than Ligand B (0.169). Ligand A is better.
15. **Affinity:** Both have very similar, excellent binding affinities (-5.2 and -5.3 kcal/mol). The difference is negligible.
**GPCR-specific priorities:** For ADRB2 (a cardiovascular GPCR), we prioritize logP, TPSA, Pgp, and affinity. While BBB isn't paramount, it's still a consideration.
**Overall Assessment:**
Ligand B excels in TPSA, DILI, BBB, and Cl_mic. However, it has a higher logP and hERG risk. Ligand A has better solubility, Pgp efflux, half-life, and a significantly lower hERG risk. Given the importance of minimizing cardiotoxicity (hERG) for a cardiovascular target, and the generally good profile of Ligand A across other parameters, I believe it is the more promising candidate. The slightly higher TPSA is a manageable drawback compared to the higher logP and hERG risk of Ligand B.
Output:
1
2025-04-17 22:27:42,064 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.447 and 368.413 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (87.32 and 85.94) are below the 140 A^2 threshold for good oral absorption. They are also reasonably low, which is good for a GPCR.
3. **logP:** Both ligands have a logP around 1.5, which is optimal.
4. **HBD:** Ligand A (2) is preferable to Ligand B (3) as lower HBD generally improves permeability.
5. **HBA:** Ligand A (4) is preferable to Ligand B (6) for the same reason as above.
6. **QED:** Ligand B (0.67) has a slightly better QED score than Ligand A (0.496), indicating a more drug-like profile.
7. **DILI:** Ligand A (34.742) has a significantly lower DILI risk than Ligand B (82.435). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (75.533) has a higher BBB penetration percentile than Ligand A (55.37). While ADRB2 isn't strictly a CNS target, some CNS exposure can be acceptable and even beneficial for certain cardiovascular indications.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-5.223) is slightly better than Ligand B (-5.559).
10. **Solubility:** Both ligands have negative solubility values, indicating poor aqueous solubility. Ligand A (-2.024) is slightly better than Ligand B (-3.884).
11. **hERG:** Ligand A (0.549) has a lower hERG inhibition liability than Ligand B (0.854), which is crucial for avoiding cardiotoxicity, especially given the cardiovascular target.
12. **Cl_mic:** Ligand A (16.229) has a significantly lower microsomal clearance than Ligand B (29.482), indicating better metabolic stability.
13. **t1/2:** Ligand B (8.403) has a longer in vitro half-life than Ligand A (-12.56). This is a positive for Ligand B.
14. **Pgp:** Ligand A (0.202) has a lower P-gp efflux liability than Ligand B (0.05), which is better for oral bioavailability.
15. **Binding Affinity:** Ligand B (-7.0) has a significantly stronger binding affinity than Ligand A (-5.4). This is a substantial advantage for Ligand B.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Both ligands are good on logP and TPSA. Ligand B wins on Pgp and *strongly* wins on affinity. However, the DILI risk for Ligand B is concerning, and the hERG risk is higher. The improved metabolic stability of Ligand A is also a significant benefit.
**Overall Assessment:**
The significantly stronger binding affinity of Ligand B is a major positive. However, the high DILI risk and higher hERG risk are significant drawbacks. Ligand A, while having a weaker affinity, presents a much better safety profile (lower DILI and hERG) and better metabolic stability. Given the cardiovascular target, minimizing cardiotoxicity (hERG) and liver toxicity (DILI) is paramount. The affinity difference, while substantial, may be overcome with further optimization of Ligand A.
Output:
1
2025-04-17 22:27:42,064 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [345.399, 82.97, 0.528, 1, 5, 0.861, 35.091, 61.691, -5.086, -1.292, 0.163, -4.076, -26.988, 0.022, -6.6]
**Ligand B:** [370.465, 42.41, 4.913, 0, 5, 0.594, 19.465, 94.145, -4.852, -4.933, 0.919, 86.446, 19.055, 0.578, -6.7]
Here's a breakdown of the comparison, considering the guidelines and GPCR-specific priorities:
1. **MW:** Both are within the acceptable range (200-500 Da). Ligand A (345.4) is slightly preferred due to being a bit lower.
2. **TPSA:** Ligand B (42.41) is significantly better than Ligand A (82.97). Lower TPSA generally favors better cell permeability, crucial for GPCR ligands.
3. **logP:** Ligand A (0.528) is quite low, potentially hindering membrane permeability. Ligand B (4.913) is high, potentially leading to solubility issues and off-target interactions, but is within the acceptable range.
4. **HBD:** Ligand A (1) is slightly better than Ligand B (0). Fewer HBDs can improve permeability.
5. **HBA:** Both have 5 HBA, which is acceptable.
6. **QED:** Ligand A (0.861) has a better QED score than Ligand B (0.594), indicating a more drug-like profile.
7. **DILI:** Ligand B (19.465) has a much lower DILI risk than Ligand A (35.091), a significant advantage.
8. **BBB:** Ligand B (94.145) shows excellent BBB penetration, while Ligand A (61.691) is moderate. For a cardiovascular GPCR, BBB isn't *as* critical as for CNS targets, but it's still a positive.
9. **Caco-2:** Ligand A (-5.086) and Ligand B (-4.852) are similar, indicating comparable intestinal absorption.
10. **Solubility:** Ligand A (-1.292) has better aqueous solubility than Ligand B (-4.933). This is important for formulation.
11. **hERG:** Both ligands show very low hERG inhibition risk (0.163 and 0.919 respectively).
12. **Cl_mic:** Ligand A (-4.076) has a much lower microsomal clearance, suggesting better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand B (19.055) has a longer in vitro half-life than Ligand A (-26.988), which is desirable.
14. **Pgp:** Ligand B (0.578) has lower P-gp efflux liability than Ligand A (0.022), indicating better bioavailability.
15. **Affinity:** Both ligands have comparable binding affinity (-6.6 and -6.7 kcal/mol).
**Overall Assessment:**
Ligand B has several advantages: significantly lower DILI risk, excellent BBB penetration, and a longer half-life. However, its high logP and lower solubility are concerns. Ligand A has better QED, solubility, and metabolic stability, but its low logP is a drawback.
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), and the fact that this is a cardiovascular target (less emphasis on BBB), the balance tips towards **Ligand B**. The lower DILI risk and longer half-life are particularly valuable, and the high logP can potentially be mitigated through formulation strategies. The TPSA is also much more favorable for Ligand B.
Output:
0
2025-04-17 22:27:42,064 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [359.417, 78.51, 1.013, 2, 3, 0.743, 29.779, 82.047, -4.927, -2.156, 0.348, -5.441, -31.244, 0.014, -7.1]
**Ligand B:** [352.391, 116.78, -0.608, 3, 6, 0.629, 55.719, 35.479, -5.255, -1.656, 0.155, -18.49, -16.574, 0.005, -6.5]
Here's a breakdown of the comparison, considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal range (200-500 Da). A is 359.4, B is 352.4. No significant difference.
2. **TPSA:** Ligand A (78.51) is significantly better than Ligand B (116.78). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (1.013) is within the optimal range. Ligand B (-0.608) is slightly below, which *could* indicate permeability issues.
4. **HBD:** Both have acceptable HBD counts (A: 2, B: 3).
5. **HBA:** Ligand A (3) is better than Ligand B (6). Lower HBA is generally preferred for permeability.
6. **QED:** Both are reasonably good (A: 0.743, B: 0.629), indicating drug-like properties. A is slightly better.
7. **DILI:** Ligand A (29.779) has a much lower DILI risk than Ligand B (55.719). This is a significant advantage.
8. **BBB:** Ligand A (82.047) has better BBB penetration potential than Ligand B (35.479). While not critical for a cardiovascular target, it's a bonus.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-4.927) is slightly better than Ligand B (-5.255).
10. **Solubility:** Both are negative, indicating poor solubility. Ligand A (-2.156) is slightly better than Ligand B (-1.656).
11. **hERG:** Both have low hERG inhibition risk (A: 0.348, B: 0.155). B is slightly better.
12. **Cl_mic:** Ligand A (-5.441) has a lower (better) microsomal clearance than Ligand B (-18.49). This suggests better metabolic stability.
13. **t1/2:** Ligand A (-31.244) has a longer half-life than Ligand B (-16.574).
14. **Pgp:** Both have very low Pgp efflux (A: 0.014, B: 0.005). B is slightly better.
15. **Affinity:** Ligand A (-7.1) has a stronger binding affinity than Ligand B (-6.5). This is a 0.6 kcal/mol difference, which is significant.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical parameters. The most important factors are the significantly lower DILI risk, better metabolic stability (lower Cl_mic, longer t1/2), and stronger binding affinity. While both have permeability and solubility concerns, Ligand A is slightly better in those areas as well. The slightly better logP of Ligand A is also favorable. The difference in affinity is sufficient to outweigh the slight advantage of Ligand B in Pgp efflux and hERG.
Therefore, I recommend Ligand A.
1
2025-04-17 22:27:42,065 - INFO - Batch 333 complete. Total preferences: 5328
2025-04-17 22:27:42,065 - INFO - Processing batch 334/512...
2025-04-17 22:28:31,448 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (347.459 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (63.57) is significantly better than Ligand B (116.84). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (1.658) is within the optimal range (1-3), while Ligand B (-0.246) is below 1, potentially hindering permeation. This is a significant advantage for A.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is preferable to Ligand B (5).
6. **QED:** Both ligands have acceptable QED values (A: 0.575, B: 0.519), indicating reasonable drug-likeness.
7. **DILI:** Ligand A (11.322) has a much lower DILI risk than Ligand B (29.934). This is a critical advantage.
8. **BBB:** While not a primary concern for a cardiovascular target, Ligand A (71.19) shows better BBB penetration than Ligand B (59.946).
9. **Caco-2:** Both have negative values, indicating poor permeability. Ligand A (-5.004) is slightly better than Ligand B (-5.218).
10. **Solubility:** Both have negative values, indicating poor solubility. Ligand A (-1.334) is slightly better than Ligand B (-0.828).
11. **hERG:** Ligand A (0.33) has a much lower hERG inhibition liability than Ligand B (0.061). This is a major safety advantage.
12. **Cl_mic:** Ligand A (7.041) has significantly lower microsomal clearance than Ligand B (16.253), suggesting better metabolic stability.
13. **t1/2:** Ligand A (9.627) has a positive in vitro half-life, while Ligand B (-14.319) has a negative value, indicating very rapid metabolism.
14. **Pgp:** Ligand A (0.095) has lower P-gp efflux liability than Ligand B (0.003).
15. **Binding Affinity:** Ligand B (-7.0 kcal/mol) has a slightly better binding affinity than Ligand A (-6.1 kcal/mol). However, the difference is not substantial enough to outweigh the significant ADME/Tox advantages of Ligand A.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A performs better on logP, TPSA, and Pgp. While Ligand B has slightly better affinity, the substantial improvements in ADME properties (DILI, hERG, Cl_mic, t1/2) for Ligand A are more important for overall drug development success.
**Conclusion:**
Ligand A demonstrates a significantly more favorable balance of properties, particularly regarding safety (DILI, hERG) and metabolic stability (Cl_mic, t1/2). While Ligand B has slightly better binding affinity, the ADME/Tox profile of Ligand A makes it a much more promising drug candidate.
Output:
1
2025-04-17 22:28:31,448 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (377.231 Da and 377.467 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (79.26) is well below the 140 threshold for good oral absorption and suitable for a GPCR. Ligand B (136.28) is higher, but still acceptable, though less optimal.
3. **logP:** Ligand A (3.139) is within the optimal 1-3 range. Ligand B (-2.706) is significantly lower, which could hinder membrane permeability and bioavailability. This is a substantial negative for Ligand B.
4. **HBD:** Both ligands have acceptable HBD counts (2 and 3 respectively), below the 5 threshold.
5. **HBA:** Ligand A (4) is good. Ligand B (6) is slightly higher but still within the acceptable range of 10.
6. **QED:** Ligand A (0.736) has a better QED score than Ligand B (0.461), indicating a more drug-like profile.
7. **DILI:** Ligand A (79.992) has a higher DILI risk than Ligand B (30.903). This is a negative for Ligand A, but the difference isn't massive.
8. **BBB:** Ligand A (49.864) has a moderate BBB penetration score, while Ligand B (12.175) is very low. While ADRB2 isn't necessarily a CNS target, some peripheral distribution is still needed, and a very low BBB score is not ideal.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.75) is slightly better than Ligand B (-5.856).
10. **Solubility:** Ligand A (-5.475) has slightly better solubility than Ligand B (-0.537), though both are poor.
11. **hERG:** Ligand A (0.316) has a lower hERG risk than Ligand B (0.056), which is a significant advantage.
12. **Cl_mic:** Ligand A (7.117) has a lower microsomal clearance than Ligand B (-23.035), indicating better metabolic stability. This is a major advantage for Ligand A.
13. **t1/2:** Ligand A (13.027) has a longer in vitro half-life than Ligand B (-7.902). This is a significant positive for Ligand A.
14. **Pgp:** Ligand A (0.152) has lower P-gp efflux than Ligand B (0.001), which is favorable.
15. **Binding Affinity:** Ligand A (-8.0) has a significantly stronger binding affinity than Ligand B (-3.4). This is a crucial factor, and the 4.6 kcal/mol difference is substantial enough to outweigh many of the other drawbacks of Ligand A.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, affinity, and Pgp are key. Ligand A excels in affinity and has a reasonable logP and TPSA. Ligand B's low logP is a major concern.
**Overall Assessment:**
Despite Ligand A's higher DILI risk, its significantly superior binding affinity, metabolic stability (lower Cl_mic, longer t1/2), better logP, and lower Pgp efflux outweigh the DILI concern. Ligand B's very low logP and weak affinity are major drawbacks that are unlikely to be overcome with further optimization.
Output:
1
2025-04-17 22:28:31,448 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (338.37 & 347.42 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (94.05) is better than Ligand B (105.98). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (3.232) is optimal, while Ligand B (0.523) is quite low. This is a significant drawback for Ligand B, potentially hindering membrane permeability and bioavailability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Both ligands have 6 HBA, which is acceptable.
6. **QED:** Ligand A (0.785) has a slightly better QED score than Ligand B (0.6), indicating a more drug-like profile.
7. **DILI:** Ligand B (47.693) has a significantly lower DILI risk than Ligand A (82.784). This is a substantial advantage for Ligand B.
8. **BBB:** Both have relatively low BBB penetration, which is acceptable for a cardiovascular target. Ligand A (58.782) is slightly better than Ligand B (46.336), but this isn't a major factor.
9. **Caco-2:** Ligand A (-4.868) is better than Ligand B (-5.432). Higher (less negative) Caco-2 values indicate better permeability.
10. **Solubility:** Ligand A (-3.926) is better than Ligand B (-1.5). Better solubility is generally desired.
11. **hERG:** Ligand A (0.164) has a slightly better hERG profile than Ligand B (0.017), meaning lower risk of cardiotoxicity.
12. **Cl_mic:** Ligand B (16.582) has a much lower microsomal clearance than Ligand A (47.738), indicating better metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand B (-17.141) has a longer in vitro half-life than Ligand A (-33.726), which is desirable.
14. **Pgp:** Ligand A (0.128) has lower P-gp efflux than Ligand B (0.033), which is better.
15. **Binding Affinity:** Ligand A (-7.0) has a slightly better binding affinity than Ligand B (-6.3). While both are good, the 0.7 kcal/mol difference is notable.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A excels in affinity and Pgp, and has a better TPSA. However, Ligand B has a much better logP and significantly better metabolic stability (Cl_mic and t1/2), and lower DILI risk. The poor logP of Ligand B is a major concern, but the improved metabolic stability and reduced toxicity are compelling. The affinity difference, while present, isn't large enough to overcome these other factors.
**Conclusion:**
Considering the balance of properties, particularly the crucial role of metabolic stability and reduced toxicity for a cardiovascular drug, and the significant logP disadvantage of Ligand B, I believe **Ligand A** is the more promising drug candidate.
Output:
1
2025-04-17 22:28:31,449 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [369.372, 72.18, 3.394, 1, 6, 0.765, 91.082, 72.741, -4.836, -4.117, 0.383, 34.889, 20.74, 0.444, -6.1]**
**Ligand B: [344.415, 83.44, 0.697, 2, 4, 0.714, 54.052, 47.344, -5.149, -2.306, 0.107, 18.274, 5.692, 0.029, -6.3]**
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand B (344.415) is slightly smaller, which *could* be advantageous for permeability, but the difference isn't substantial.
**2. TPSA:** Ligand A (72.18) is better than Ligand B (83.44). Both are below 140, but lower is preferred for oral absorption.
**3. logP:** Ligand A (3.394) is optimal, while Ligand B (0.697) is quite low. This is a significant advantage for Ligand A, as low logP can hinder membrane permeability.
**4. H-Bond Donors:** Ligand A (1) is better than Ligand B (2). Lower is generally preferred.
**5. H-Bond Acceptors:** Ligand A (6) is better than Ligand B (4). Lower is generally preferred.
**6. QED:** Both ligands have similar, acceptable QED values (0.765 and 0.714).
**7. DILI:** Ligand A (91.082) has a significantly higher DILI risk than Ligand B (54.052). This is a major concern for Ligand A.
**8. BBB:** Ligand A (72.741) is better than Ligand B (47.344). While ADRB2 isn't strictly a CNS target, some peripheral distribution is still desirable.
**9. Caco-2:** Ligand A (-4.836) and Ligand B (-5.149) are both very poor.
**10. Solubility:** Ligand A (-4.117) is slightly worse than Ligand B (-2.306).
**11. hERG:** Ligand A (0.383) is better than Ligand B (0.107). Lower is preferred.
**12. Cl_mic:** Ligand B (18.274) has a much lower microsomal clearance than Ligand A (34.889), indicating better metabolic stability.
**13. t1/2:** Ligand A (20.74) has a longer half-life than Ligand B (5.692).
**14. Pgp:** Ligand A (0.444) is better than Ligand B (0.029). Lower is preferred.
**15. Binding Affinity:** Ligand B (-6.3) has a slightly better binding affinity than Ligand A (-6.1), but the difference is small.
**GPCR-Specific Considerations:** For a GPCR like ADRB2, logP, TPSA, and affinity are crucial. Ligand A excels in logP and has acceptable TPSA. Ligand B has a poor logP.
**Overall Assessment:**
Ligand A has a better logP, TPSA, and BBB penetration. However, its significantly higher DILI risk is a major drawback. Ligand B has a better safety profile (lower DILI) and better metabolic stability (lower Cl_mic), but suffers from a very low logP. The slightly better affinity of Ligand B is not enough to overcome its poor logP. Considering the balance, the lower DILI risk and improved metabolic stability of Ligand B are more valuable, even with the slightly lower affinity and logP.
Output:
0
2025-04-17 22:28:31,449 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [367.833, 91.65, 1.426, 2, 4, 0.762, 40.713, 60.411, -5.127, -2.894, 0.197, -12.927, 8.003, 0.05, -6.9]
**Ligand B:** [349.431, 103.94, -0.283, 2, 4, 0.712, 10.857, 45.366, -5.261, -2.104, 0.061, -11.917, 1.527, 0.007, -6]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (349.431) is slightly lower, which *could* be advantageous for permeability, but both are acceptable.
2. **TPSA:** Ligand A (91.65) is better than Ligand B (103.94), both are under 140, but closer to the limit.
3. **logP:** Ligand A (1.426) is optimal, while Ligand B (-0.283) is a bit low. This is a significant difference, as a low logP can hinder membrane permeability.
4. **HBD/HBA:** Both have 2 HBD and 4 HBA, which are within acceptable limits.
5. **QED:** Both are good (0.762 and 0.712), indicating good drug-like properties.
6. **DILI:** Ligand A (40.713) is better than Ligand B (10.857), indicating a lower risk of liver injury.
7. **BBB:** Ligand A (60.411) is better than Ligand B (45.366), though neither is exceptionally high. For a cardiovascular target, BBB isn't *critical*, but some penetration could be beneficial for off-target effects or distribution.
8. **Caco-2:** Both are negative, indicating poor permeability.
9. **Solubility:** Both are negative, indicating poor solubility.
10. **hERG:** Both are very low, indicating minimal hERG inhibition risk.
11. **Cl_mic:** Ligand A (-12.927) is better than Ligand B (-11.917), indicating better metabolic stability.
12. **t1/2:** Ligand A (8.003) is significantly better than Ligand B (1.527), suggesting a longer half-life.
13. **Pgp:** Both are very low, indicating minimal P-gp efflux.
14. **Binding Affinity:** Ligand A (-6.9) is slightly better than Ligand B (-6.0), but the difference is not huge.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, and affinity are key. Ligand A has a much better logP value, which is crucial for membrane permeability and receptor engagement. While both have similar affinities, the better logP and metabolic stability of Ligand A are more important.
**Conclusion:**
Ligand A is the more promising candidate due to its superior logP, DILI risk, metabolic stability, and half-life. While both have issues with Caco-2 and solubility, the better ADME profile of Ligand A outweighs the slightly better affinity of Ligand B.
Output:
1
2025-04-17 22:28:31,449 - INFO - Here's my reasoning and final output for the ligand preference:
**Reasoning:**
We're targeting ADRB2, a GPCR, so the priorities are logP, Pgp, TPSA, affinity, and BBB. Let's break down each ligand:
* **Molecular Weight:** Both are within the ideal range (200-500 Da). Ligand B (350.5) is slightly lower, which can be favorable for permeability.
* **TPSA:** Ligand A (101.22) is higher than the preferred <140, but still acceptable. Ligand B (49.85) is excellent, well below 140.
* **logP:** Both ligands have good logP values (2.407 and 2.687), falling within the 1-3 range.
* **H-Bond Donors/Acceptors:** Ligand A has 1 HBD and 6 HBA, while Ligand B has 0 HBD and 3 HBA. Both are within acceptable ranges.
* **QED:** Both have good QED scores (>0.5), indicating drug-likeness.
* **DILI:** Ligand A has a concerning DILI score of 87.631, indicating a high risk of liver injury. Ligand B has a very low DILI score of 16.247, which is a significant advantage.
* **BBB:** Both have good BBB penetration (82.474 and 88.29).
* **Caco-2:** Both have negative Caco-2 values, which is unusual and requires further investigation, but doesn't immediately disqualify either.
* **Solubility:** Both have negative solubility values, which is also unusual.
* **hERG:** Both have low hERG inhibition liability, which is good.
* **Cl_mic:** Ligand A has a lower microsomal clearance (29.834) than Ligand B (58.52), suggesting better metabolic stability.
* **t1/2:** Ligand B has a significantly longer in vitro half-life (-7.705) than Ligand A (0.86).
* **Pgp:** Ligand A has very low Pgp efflux (0.085), while Ligand B is slightly higher (0.267).
* **Binding Affinity:** Ligand B has a significantly better binding affinity (-7.0 kcal/mol) compared to Ligand A (-4.7 kcal/mol). This is a substantial difference.
**Overall Assessment:**
While Ligand A has slightly better metabolic stability (lower Cl_mic) and Pgp efflux, the extremely high DILI risk is a major red flag. Ligand B excels in several key areas: significantly better binding affinity, a much lower DILI risk, a longer half-life, and a better TPSA. The slightly higher Pgp efflux is a minor concern compared to the DILI risk associated with Ligand A. The superior affinity of Ligand B also outweighs the slightly higher Cl_mic.
**Output:**
0
2025-04-17 22:28:31,449 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.46 and 354.33 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (67.87) is significantly better than Ligand B (92.08). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is pushing the upper limit for good oral absorption.
3. **logP:** Both ligands have acceptable logP values (1.198 and 2.028, respectively), falling within the 1-3 range. Ligand B is slightly higher, which *could* be a minor concern for solubility, but not a dealbreaker.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (4) is preferable to Ligand B (3). Lower HBA generally improves permeability.
6. **QED:** Ligand B (0.823) has a substantially better QED score than Ligand A (0.501), indicating a more drug-like profile overall. This is a significant positive for Ligand B.
7. **DILI:** Ligand A (8.375) has a much lower DILI risk than Ligand B (39.473). This is a major advantage for Ligand A. A DILI percentile below 40 is highly desirable.
8. **BBB:** Ligand B (91.392) has a much higher BBB penetration score than Ligand A (59.093). While ADRB2 isn't *necessarily* a CNS target, higher BBB is generally favorable, suggesting better distribution.
9. **Caco-2:** Both ligands have very similar, and poor, Caco-2 permeability (-4.78 and -4.755). This suggests potential absorption issues for both.
10. **Solubility:** Ligand A (-1.273) has better solubility than Ligand B (-3.695). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.356) has a significantly lower hERG inhibition liability than Ligand B (0.676). Lower hERG is critical for avoiding cardiotoxicity, especially important for a cardiovascular target like ADRB2.
12. **Cl_mic:** Ligand A (4.522) has a much lower microsomal clearance than Ligand B (26.252). This indicates better metabolic stability for Ligand A.
13. **t1/2:** Ligand B (-13.029) has a much longer in vitro half-life than Ligand A (2.255). This is a significant advantage for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.026) has a significantly lower P-gp efflux liability than Ligand B (0.061). Lower P-gp efflux is favorable for bioavailability.
15. **Binding Affinity:** Ligand A (-5.2 kcal/mol) has a slightly better binding affinity than Ligand B (-3.2 kcal/mol). This is a substantial difference in potency.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand A is the stronger candidate. While Ligand B has a better QED and longer half-life, Ligand A excels in critical areas like DILI risk, hERG inhibition, metabolic stability (Cl_mic), Pgp efflux, and binding affinity. The lower TPSA of Ligand A is also a significant advantage. The binding affinity difference is large enough to outweigh the benefits of Ligand B's longer half-life and better QED. The poor Caco-2 permeability is a concern for both, but can be addressed with formulation strategies.
Output:
1
2025-04-17 22:28:31,449 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (362.3 and 370.6 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (104.73) is higher than the preferred <140, but still reasonable. Ligand B (40.62) is excellent, well below 90, suggesting good permeability. This favors Ligand B.
**3. logP:** Ligand A (1.337) is within the optimal 1-3 range. Ligand B (4.184) is slightly higher, potentially raising concerns about solubility and off-target effects, but still not drastically outside the acceptable range.
**4. H-Bond Donors:** Ligand A has 3 HBD, which is acceptable. Ligand B has 0, which is also fine. No clear advantage.
**5. H-Bond Acceptors:** Ligand A has 4 HBA, acceptable. Ligand B has 3, also acceptable. No clear advantage.
**6. QED:** Both ligands have similar QED values (0.606 and 0.631), indicating good drug-likeness.
**7. DILI:** Ligand A has a DILI risk of 61.3%, which is moderately high. Ligand B has a significantly lower DILI risk of 26.4%, which is a strong advantage.
**8. BBB:** Ligand A has a BBB penetration of 27.6%, which is low. Ligand B has a BBB penetration of 74.758%, which is very good. While ADRB2 is a cardiovascular target, some CNS penetration can be relevant for off-target effects and safety assessment. This favors Ligand B.
**9. Caco-2 Permeability:** Ligand A (-5.316) and Ligand B (-4.885) both have negative values, which is unusual and suggests very poor permeability. This is a major concern for both.
**10. Aqueous Solubility:** Both ligands have poor aqueous solubility (-2.024 and -3.81). This is a significant drawback for both, potentially impacting bioavailability.
**11. hERG Inhibition:** Ligand A (0.083) has a very low hERG risk, which is excellent. Ligand B (0.759) has a higher, but still relatively low, hERG risk. This favors Ligand A.
**12. Microsomal Clearance:** Ligand A (14.439) has a lower microsomal clearance, suggesting better metabolic stability. Ligand B (94.642) has a very high clearance, indicating rapid metabolism. This strongly favors Ligand A.
**13. In vitro Half-Life:** Ligand A (-34.161) has a negative half-life, which is nonsensical and suggests a problem with the data or the molecule. Ligand B (4.726) has a short half-life, but at least it is a positive value.
**14. P-gp Efflux:** Ligand A (0.011) has very low P-gp efflux, which is excellent. Ligand B (0.657) has moderate P-gp efflux. This favors Ligand A.
**15. Binding Affinity:** Both ligands have very similar binding affinities (-6.1 and -6.3 kcal/mol). The difference is negligible.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand B initially looks better due to its superior TPSA and BBB penetration. However, the significantly lower DILI risk, better metabolic stability (lower Cl_mic), and lower P-gp efflux of Ligand A are crucial advantages. The nonsensical half-life value for Ligand A is concerning, but the other factors outweigh this issue. The poor Caco-2 permeability and solubility are drawbacks for both, but can be addressed with formulation strategies.
Therefore, I prefer Ligand A.
Output:
1
2025-04-17 22:28:31,449 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (381.837 Da) is within the ideal range (200-500 Da). Ligand B (344.415 Da) is also within range, and slightly lower. This is a minor advantage to B, but not decisive.
2. **TPSA:** Ligand A (81.7) is excellent, well below the 140 threshold for good absorption. Ligand B (89.16) is still acceptable, but slightly higher. A favors here.
3. **logP:** Ligand A (3.311) is optimal. Ligand B (1.262) is a bit low, potentially hindering permeability. A is preferred.
4. **HBD:** Ligand A (1) is good. Ligand B (2) is acceptable, but slightly less desirable. A is preferred.
5. **HBA:** Both Ligand A (5) and Ligand B (5) are good, well below the 10 threshold. No clear preference.
6. **QED:** Ligand A (0.803) is excellent. Ligand B (0.754) is still good, but slightly lower. A is preferred.
7. **DILI:** Ligand A (85.925) is concerning, indicating a higher risk of liver injury. Ligand B (26.871) is very good, significantly lower risk. B is strongly favored here.
8. **BBB:** Both ligands have moderate BBB penetration (A: 53.587, B: 49.205). Since ADRB2 isn't a primary CNS target, this isn't a major differentiating factor.
9. **Caco-2:** Ligand A (-4.817) is better than Ligand B (-5.41), indicating better intestinal absorption. A is preferred.
10. **Solubility:** Ligand A (-4.946) is better than Ligand B (-0.831), indicating better solubility. A is preferred.
11. **hERG:** Both ligands have low hERG risk (A: 0.272, B: 0.212). No clear preference.
12. **Cl_mic:** Ligand A (29.837) is higher than Ligand B (-8.548), meaning lower metabolic stability. B is strongly preferred.
13. **t1/2:** Ligand A (8.068) is better than Ligand B (18.79). A is preferred.
14. **Pgp:** Ligand A (0.472) is better than Ligand B (0.02), indicating lower P-gp efflux. A is preferred.
15. **Affinity:** Both ligands have similar, excellent binding affinity (A: -6.5 kcal/mol, B: -6.1 kcal/mol). The difference is not substantial enough to be decisive.
**Overall Assessment:**
Ligand A has several advantages: better TPSA, logP, QED, Caco-2 permeability, solubility, and Pgp efflux. However, its DILI risk is significantly higher, and its metabolic stability (Cl_mic) is worse than Ligand B.
Ligand B excels in safety (DILI) and metabolic stability (Cl_mic). While its logP is a bit low, the substantial improvement in safety and metabolic properties outweighs this drawback, especially considering the acceptable Caco-2 permeability. For a cardiovascular target, minimizing off-target effects and ensuring reasonable metabolic stability are crucial.
Given the GPCR-specific priorities (logP, Pgp, TPSA, affinity) and the overall balance of properties, Ligand B is the more promising candidate.
Output:
0
2025-04-17 22:28:31,449 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A:** [355.45 , 55.84 , 4.015, 0. , 4. , 0.41 , 28.655, 94.184, -4.422, -4.924, 0.697, 99.737, -3.102, 0.278, -3.9 ]
**Ligand B:** [355.385, 75.43 , 2.525, 1. , 4. , 0.881, 52.772, 66.576, -4.93 , -1.928, 0.264, -2.266, -18.055, 0.089, -5.5 ]
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). No significant difference.
**2. TPSA:** Ligand A (55.84) is significantly better than Ligand B (75.43). ADRB2 is not a CNS target, but lower TPSA generally improves absorption.
**3. logP:** Ligand A (4.015) is slightly higher than Ligand B (2.525). Both are within the acceptable range (1-3), but Ligand A is pushing the upper limit.
**4. H-Bond Donors:** Ligand A (0) is better than Ligand B (1). Fewer HBDs generally improve permeability.
**5. H-Bond Acceptors:** Both ligands have the same number of HBA (4).
**6. QED:** Ligand B (0.881) is significantly better than Ligand A (0.41). Higher QED indicates a more drug-like profile.
**7. DILI Risk:** Ligand A (28.655) has a much lower DILI risk than Ligand B (52.772). This is a substantial advantage for Ligand A.
**8. BBB Penetration:** Ligand A (94.184) has excellent BBB penetration, while Ligand B (66.576) is moderate. Although ADRB2 is not primarily a CNS target, higher BBB penetration can sometimes indicate better overall distribution.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests a potential issue with the experimental setup or prediction method. However, the values are similar.
**10. Aqueous Solubility:** Ligand A (-4.924) is worse than Ligand B (-1.928). Solubility is a concern for both, but more so for Ligand A.
**11. hERG Inhibition:** Ligand A (0.697) has a lower hERG risk than Ligand B (0.264). This is a significant advantage for Ligand A.
**12. Microsomal Clearance:** Ligand A (99.737) has very high clearance, suggesting poor metabolic stability. Ligand B (-2.266) has excellent metabolic stability. This is a major advantage for Ligand B.
**13. In vitro Half-Life:** Ligand A (-3.102) has a very short half-life, while Ligand B (-18.055) has a much longer half-life. This is a substantial advantage for Ligand B.
**14. P-gp Efflux:** Ligand A (0.278) has lower P-gp efflux than Ligand B (0.089). Lower efflux is generally preferred.
**15. Binding Affinity:** Ligand B (-5.5) has a stronger binding affinity than Ligand A (-3.9). This is a 1.6 kcal/mol difference, which is significant and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand B has a significantly better metabolic profile (lower clearance, longer half-life) and stronger binding affinity. While Ligand A has advantages in DILI risk, hERG, and BBB penetration, the superior potency and metabolic stability of Ligand B are more critical for a GPCR target like ADRB2. The solubility issue with Ligand A is also concerning. The QED score for Ligand B is also much better.
Output:
0
2025-04-17 22:28:31,449 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Step-by-step comparison:**
1. **MW:** Both ligands (345.4 and 348.5 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (121.52) is higher than Ligand B (49.41). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B is significantly better.
3. **logP:** Ligand A (0.213) is quite low, potentially hindering membrane permeability. Ligand B (3.914) is within the optimal 1-3 range. This is a major advantage for Ligand B.
4. **HBD:** Ligand A (4) is higher than Ligand B (1). While both are acceptable, lower HBD can improve permeability. Ligand B is better.
5. **HBA:** Ligand A (4) is higher than Ligand B (2). Similar to HBD, lower HBA is generally preferred. Ligand B is better.
6. **QED:** Both ligands have good QED scores (0.538 and 0.709), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (31.72%) has a higher DILI risk than Ligand B (13.3%). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (32.14%) has very low BBB penetration, while Ligand B (87.01%) has high BBB penetration. While ADRB2 is not exclusively a CNS target, some CNS exposure can occur, and higher BBB is generally favorable for GPCRs. Ligand B is much better.
9. **Caco-2:** Ligand A (-5.577) and Ligand B (-4.594) both have negative values, which is unusual. It's difficult to interpret without knowing the scale, but generally, higher values are desired. No clear winner here.
10. **Solubility:** Ligand A (-2.538) and Ligand B (-3.938) both have negative solubility values, indicating poor solubility. No clear winner.
11. **hERG:** Ligand A (0.141) has a slightly lower hERG risk than Ligand B (0.663). This is a small advantage for Ligand A, but not decisive.
12. **Cl_mic:** Ligand A (-1.913) has lower (better) microsomal clearance than Ligand B (67.125). This suggests better metabolic stability for Ligand A. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (9.303) has a shorter half-life than Ligand B (-10.655). The negative value for Ligand B is concerning and suggests a very rapid clearance. Ligand A is better.
14. **Pgp:** Ligand A (0.005) has much lower P-gp efflux liability than Ligand B (0.133). Lower P-gp efflux is preferred for better bioavailability. Ligand A is significantly better.
15. **Affinity:** Ligand B (-5.3 kcal/mol) has a slightly better binding affinity than Ligand A (-3.1 kcal/mol). This is a substantial difference, and a 2.2 kcal/mol advantage is significant.
**Overall Assessment:**
Ligand B has a substantially better logP, TPSA, DILI, and BBB profile, which are all important for GPCR targets. The significantly better binding affinity of Ligand B is also a major advantage. Ligand A has better metabolic stability (Cl_mic) and P-gp efflux, but the benefits of Ligand B's improved ADME properties and binding outweigh these advantages.
**Output:**
0
2025-04-17 22:28:31,449 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (353.463 and 351.363 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (87.74) is significantly better than Ligand B (137.25). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is approaching the upper limit for good oral absorption.
3. **logP:** Ligand A (0.681) is slightly lower than the optimal 1-3 range, but still acceptable. Ligand B (-1.394) is below 1, which could indicate poor membrane permeability. This is a significant negative for Ligand B.
4. **HBD:** Ligand A (2) is preferable to Ligand B (3). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (4) is better than Ligand B (6). Similar reasoning as with HBD.
6. **QED:** Both ligands have similar QED values (0.705 and 0.61), both above the 0.5 threshold, indicating good drug-like properties.
7. **DILI:** Ligand A (14.967%) has a much lower DILI risk than Ligand B (69.678%). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (57.929%) has a better BBB penetration score than Ligand B (23.73%). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be useful for understanding off-target effects and distribution.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.166 and -5.218). These values are difficult to interpret without knowing the scale, but they suggest poor permeability.
10. **Solubility:** Ligand A (-0.977) is better than Ligand B (-2.614). Higher solubility is generally preferred.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.155 and 0.098). This is good.
12. **Cl_mic:** Ligand A (11.193) has a significantly lower microsomal clearance than Ligand B (-16.616). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (-5.528) has a slightly better in vitro half-life than Ligand B (-7.442).
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.011 and 0.005). This is good.
15. **Binding Affinity:** Ligand B (-7.1) has a slightly better binding affinity than Ligand A (-6.4). However, the difference is only 0.7 kcal/mol, and the other ADME properties of Ligand A are significantly superior.
**Overall Assessment:**
Ligand A is the superior candidate. While Ligand B has slightly better binding affinity, Ligand A excels in critical ADME properties like DILI risk, TPSA, logP, solubility, and metabolic stability. The lower DILI risk and better logP/TPSA profile of Ligand A are particularly important for a GPCR target like ADRB2, where good oral bioavailability and reduced toxicity are crucial. The small difference in binding affinity is outweighed by the substantial improvements in other parameters.
Output:
1
2025-04-17 22:28:31,450 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (353.419 and 350.415 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (96.97) is better than Ligand B (103.01). Both are below 140, but closer to 90 is preferable for GPCRs, and A is closer.
3. **logP:** Ligand A (-0.717) is slightly lower than Ligand B (0.831). While both are within the 1-3 range, Ligand B is better positioned.
4. **HBD:** Ligand A (2) is better than Ligand B (3). Lower is generally preferred.
5. **HBA:** Ligand A (6) is better than Ligand B (5). Lower is generally preferred.
6. **QED:** Both ligands have good QED scores (0.612 and 0.73), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (26.444) has a significantly lower DILI risk than Ligand B (37.069). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (29.12) is slightly better than Ligand B (25.591), but both are low. BBB isn't a huge priority for ADRB2 (a cardiovascular target), but a higher value is still preferred.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.247 and -5.078), suggesting poor permeability. This is a concern for both.
10. **Solubility:** Both ligands have negative solubility values (-1.146 and -1.964), suggesting poor solubility. This is a concern for both.
11. **hERG:** Both ligands have low hERG inhibition liability (0.101 and 0.264), which is good.
12. **Cl_mic:** Ligand A (-28.518) has a much lower (better) microsomal clearance than Ligand B (-17.05). This indicates better metabolic stability for Ligand A.
13. **t1/2:** Ligand B (37.249) has a much longer in vitro half-life than Ligand A (2.229). This is a significant advantage for Ligand B.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.006 and 0.136), which is good.
15. **Binding Affinity:** Ligand B (-8.1) has a significantly stronger binding affinity than Ligand A (-6.8). This is a substantial advantage for Ligand B.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand B has a better logP and significantly better affinity. While Ligand A has a better TPSA, the difference isn't substantial enough to outweigh the affinity advantage of Ligand B. Metabolic stability (Cl_mic) is also important, and Ligand A is better here. However, the longer half-life of Ligand B is a strong positive. The lower DILI risk of Ligand A is also a significant benefit.
**Overall Assessment:**
The strong binding affinity of Ligand B (-8.1 kcal/mol) is a major driver. While Ligand A has advantages in DILI risk and metabolic stability, the substantial affinity difference, coupled with a reasonable half-life, makes Ligand B the more promising candidate. The poor Caco-2 and solubility of both are concerning and would need to be addressed in further optimization, but the potency advantage is likely to be more impactful early in the development process.
Output:
0
2025-04-17 22:28:31,450 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the acceptable range (200-500 Da). Ligand A (410.283 Da) is slightly higher than Ligand B (349.519 Da), but both are reasonable.
**2. TPSA:** Ligand A (47.56) is well below the 140 A^2 threshold for oral absorption and is quite favorable. Ligand B (61.44) is still acceptable, but less optimal.
**3. logP:** Ligand A (4.242) is at the higher end of the optimal range (1-3), potentially raising concerns about solubility and off-target effects. Ligand B (2.474) is well within the optimal range.
**4. H-Bond Donors:** Ligand A (1) and Ligand B (2) are both acceptable.
**5. H-Bond Acceptors:** Both ligands have 3 H-bond acceptors, which is well within the acceptable limit of 10.
**6. QED:** Both ligands have similar QED values (0.663 and 0.662), indicating good drug-like properties.
**7. DILI Risk:** Ligand A (55.525) has a moderate DILI risk, while Ligand B (11.206) has a very low DILI risk. This is a significant advantage for Ligand B.
**8. BBB Penetration:** Ligand A (77.162) has better BBB penetration than Ligand B (59.364). While ADRB2 is a cardiovascular target, some CNS effects are possible with beta-blockers, so moderate BBB penetration isn't necessarily a dealbreaker.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, indicating poor permeability. This is a concern for both, but the value for Ligand A (-4.742) is slightly better than Ligand B (-4.83).
**10. Aqueous Solubility:** Ligand A (-4.588) has poorer solubility than Ligand B (-1.848). This is a concern given Ligand A's higher logP.
**11. hERG Inhibition:** Ligand A (0.909) has a slightly higher risk of hERG inhibition than Ligand B (0.236). This is a significant advantage for Ligand B.
**12. Microsomal Clearance:** Ligand A (63.717) has higher microsomal clearance than Ligand B (30.318), indicating lower metabolic stability. This is a disadvantage for Ligand A.
**13. In vitro Half-Life:** Ligand A (46.568) has a longer half-life than Ligand B (-0.674). This is a positive for Ligand A.
**14. P-gp Efflux:** Ligand A (0.651) has lower P-gp efflux than Ligand B (0.072), which is favorable.
**15. Binding Affinity:** Ligand B (-6.5 kcal/mol) has a significantly stronger binding affinity than Ligand A (-3.3 kcal/mol). This is a crucial advantage, as a 3.2 kcal/mol difference is substantial.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity), and the general drug-like properties, Ligand B is the more promising candidate. While Ligand A has a slightly better BBB penetration and in vitro half-life, Ligand B's superior binding affinity, significantly lower DILI risk, lower hERG inhibition, and better solubility outweigh these advantages. The lower metabolic stability of Ligand B is a concern, but can potentially be addressed through structural modifications. The poor Caco-2 permeability is a concern for both, but the stronger binding of Ligand B might compensate for this.
Output:
0
2025-04-17 22:28:31,450 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
We are targeting ADRB2, a GPCR. Therefore, the priorities are logP, Pgp, TPSA, affinity, and BBB. Let's compare the ligands step-by-step:
1. **MW:** Both ligands (348.45 & 350.52 Da) fall within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (67.67) is higher than Ligand B (23.55). Ligand B is significantly better here, being well below the 140 threshold for good absorption.
3. **logP:** Ligand A (0.938) is within the optimal range (1-3), but on the lower side. Ligand B (4.186) is slightly above the optimal range, but still acceptable.
4. **HBD:** Both have 0 HBD, which is good.
5. **HBA:** Ligand A has 5 HBA, Ligand B has 2. Both are acceptable.
6. **QED:** Ligand A (0.794) is better than Ligand B (0.643), indicating higher drug-likeness.
7. **DILI:** Ligand A (40.17) is slightly higher than Ligand B (5.58), but both are good (below 40 is preferred). Ligand B is much better here.
8. **BBB:** Ligand B (97.25) is significantly better than Ligand A (88.29). This is a key factor for GPCRs, even if not CNS-focused.
9. **Caco-2:** Ligand A (-4.348) and Ligand B (-4.652) are both negative, indicating poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-1.288) is better than Ligand B (-2.44), indicating better aqueous solubility.
11. **hERG:** Ligand A (0.207) is much better than Ligand B (0.899), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand B (26.69) has lower clearance than Ligand A (43.79), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-22.39) has a much longer half-life than Ligand A (12.40), which is a significant advantage.
14. **Pgp:** Ligand A (0.144) has lower Pgp efflux than Ligand B (0.332), which is preferable.
15. **Affinity:** Ligand B (-6.7 kcal/mol) has a significantly stronger binding affinity than Ligand A (-3.9 kcal/mol). This is a major advantage, exceeding the 1.5 kcal/mol difference threshold.
**Overall Assessment:**
While Ligand A has better QED, solubility, hERG, and Pgp, Ligand B excels in critical areas for a GPCR target: significantly higher binding affinity, better BBB penetration, lower DILI risk, and improved metabolic stability (lower Cl_mic and longer t1/2). The substantial affinity difference outweighs the slight drawbacks in other parameters. The lower TPSA of Ligand B is also a significant advantage.
**Output:**
0
2025-04-17 22:28:31,450 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Ligand A (419.67 Da) is within the ideal range, while Ligand B (350.46 Da) is also acceptable. No clear advantage here.
2. **TPSA:** Ligand A (77.0) is good, under the 140 threshold. Ligand B (85.25) is also acceptable, but slightly higher.
3. **logP:** Ligand A (4.215) is a bit high, potentially leading to solubility issues and off-target effects. Ligand B (1.589) is optimal. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (1) is good. Ligand B (2) is also acceptable.
5. **HBA:** Both ligands have 5 HBA, which is within the acceptable range.
6. **QED:** Both ligands are above 0.5 (0.685 and 0.745), indicating good drug-likeness.
7. **DILI:** Ligand A (98.76%) has a very high DILI risk, which is a major concern. Ligand B (36.68%) has a low DILI risk, a substantial advantage.
8. **BBB:** Ligand A (61.85%) is moderate, while Ligand B (70.03%) is better. While ADRB2 isn't necessarily a CNS target, some peripheral effects can be modulated by CNS penetration, so higher BBB is preferable.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not defined, so it's hard to interpret.
10. **Solubility:** Ligand A (-5.676) has very poor solubility, likely due to its high logP. Ligand B (-2.355) has better solubility, though still not ideal.
11. **hERG:** Both ligands have low hERG risk (0.465 and 0.329).
12. **Cl_mic:** Ligand A (91.79) has higher metabolic clearance, suggesting lower metabolic stability. Ligand B (39.73) has lower clearance, which is better.
13. **t1/2:** Ligand A (0.956) has a very short half-life, while Ligand B (-14.887) also has a short half-life, but is less negative.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.319 and 0.057).
15. **Binding Affinity:** Ligand B (-7.2 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.3 kcal/mol). This 0.9 kcal/mol difference is substantial and can outweigh some ADME drawbacks.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are crucial. Ligand B excels in logP and affinity, and has acceptable TPSA and Pgp. Ligand A's high logP and very high DILI risk are major red flags.
**Overall Assessment:**
Ligand B is the superior candidate. Its stronger binding affinity, lower DILI risk, better logP, and improved metabolic stability outweigh the slightly higher TPSA and similar half-life. The poor Caco-2 values are a concern for both, but can be addressed with formulation strategies. The high DILI risk of Ligand A is a deal-breaker.
Output:
0
2025-04-17 22:28:31,450 - INFO - Batch 334 complete. Total preferences: 5344
2025-04-17 22:28:31,450 - INFO - Processing batch 335/512...
2025-04-17 22:29:20,042 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (427.364 Da) is within the ideal range, while Ligand B (355.429 Da) is slightly below but still acceptable.
2. **TPSA:** Both ligands (A: 61.8, B: 61.44) are reasonably low, suggesting good potential for absorption.
3. **logP:** Ligand A (3.511) is optimal. Ligand B (1.693) is on the lower side, potentially impacting permeability.
4. **HBD:** Both have 2 HBD, which is good.
5. **HBA:** Ligand A has 5 HBA, and Ligand B has 3 HBA, both within acceptable limits.
6. **QED:** Both ligands have similar QED scores (A: 0.767, B: 0.713), indicating good drug-likeness.
7. **DILI:** Ligand B (26.522) has a significantly lower DILI risk than Ligand A (41.877), which is a major advantage.
8. **BBB:** Ligand A (81.311) has better BBB penetration than Ligand B (72.78), but this is less critical for a cardiovascular target like ADRB2.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Both have negative solubility values, which is also unusual.
11. **hERG:** Ligand A (0.929) has a slightly higher hERG risk than Ligand B (0.512), but both are relatively low.
12. **Cl_mic:** Ligand B (-13.579) has a *much* lower (and therefore better) microsomal clearance than Ligand A (41.084), indicating significantly improved metabolic stability.
13. **t1/2:** Ligand B (-1.503) has a negative in vitro half-life, which is concerning. Ligand A (41.405) has a good half-life.
14. **Pgp:** Ligand A (0.737) has a slightly higher Pgp efflux liability than Ligand B (0.025), which is favorable for B.
15. **Affinity:** Ligand B (-6.6 kcal/mol) has a slightly better binding affinity than Ligand A (-5.8 kcal/mol).
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are important. Ligand A has a better logP and BBB, but Ligand B has better affinity, lower Pgp efflux, and a much better metabolic profile (lower Cl_mic). The lower DILI risk for Ligand B is also a significant benefit. The negative Caco-2 and solubility values are concerning for both, but the other factors weigh more heavily.
**Overall Assessment:**
While Ligand A has a better half-life, the significantly improved metabolic stability (Cl_mic), lower DILI risk, and slightly better affinity of Ligand B outweigh the advantages of Ligand A. The lower logP of Ligand B is a minor concern, but the other benefits are more impactful for a cardiovascular GPCR target.
Output:
0
2025-04-17 22:29:20,042 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (367.475 and 367.877 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (113.08) is higher than Ligand B (75.44). For a cardiovascular GPCR, TPSA is moderately important. Ligand B is preferable due to its lower TPSA, potentially aiding absorption.
3. **logP:** Ligand A (0.497) is quite low, potentially hindering membrane permeability. Ligand B (3.121) is within the optimal 1-3 range. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (3) and Ligand B (1) are both acceptable, under the limit of 5. Ligand B is slightly better.
5. **HBA:** Ligand A (6) and Ligand B (4) are both acceptable, under the limit of 10. Ligand B is slightly better.
6. **QED:** Both ligands have good QED scores (0.649 and 0.887), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (55.138) has a higher DILI risk than Ligand B (40.675). Lower is better, so Ligand B is preferable.
8. **BBB:** Ligand A (44.203) has a lower BBB penetration percentile than Ligand B (78.131). While ADRB2 isn't a primary CNS target, some brain exposure can be relevant for off-target effects or peripheral effects mediated by brain pathways. Ligand B is preferable.
9. **Caco-2:** Ligand A (-5.5) and Ligand B (-4.791) are both negative, indicating poor permeability. This is a concern for both, but the values are close.
10. **Solubility:** Ligand A (-2.49) and Ligand B (-3.882) are both poor. Solubility is a concern for both, but Ligand B is slightly better.
11. **hERG:** Ligand A (0.114) has a slightly lower hERG risk than Ligand B (0.401). This is a slight advantage for Ligand A, but both are relatively low risk.
12. **Cl_mic:** Ligand A (7.126) has a lower microsomal clearance than Ligand B (39.593), suggesting better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (21.847) has a longer in vitro half-life than Ligand B (-3.136). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.035) has much lower P-gp efflux liability than Ligand B (0.264). This is a significant advantage for Ligand A.
15. **Binding Affinity:** Ligand A (-7.7) has a stronger binding affinity than Ligand B (-6.4). This is a substantial advantage for Ligand A, potentially outweighing some of the ADME drawbacks.
**Overall Assessment:**
Ligand A has a significantly better binding affinity, lower P-gp efflux, better metabolic stability (lower Cl_mic), and longer half-life. These are substantial advantages. Ligand B has better logP, TPSA, DILI, and BBB penetration, which are also important, but the magnitude of the benefits is less than those of Ligand A. The affinity difference is >1.5 kcal/mol, which is a strong indicator.
Output:
1
2025-04-17 22:29:20,043 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (389.279 and 373.356 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (78.87) is better than Ligand B (80.32). Both are below the 140 threshold for good oral absorption, but closer to the ideal for GPCRs.
3. **logP:** Both ligands (2.982 and 2.648) are within the optimal 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Both ligands have 2 H-bond donors, which is acceptable.
5. **HBA:** Ligand A has 4 H-bond acceptors, while Ligand B has 5. Ligand A is slightly preferred.
6. **QED:** Both ligands have similar QED values (0.83 and 0.79), indicating good drug-likeness.
7. **DILI:** Ligand A (36.603) has a significantly lower DILI risk than Ligand B (81.504). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (51.842) has a lower BBB penetration than Ligand B (67.701). While BBB isn't a primary concern for ADRB2 (a cardiovascular target), higher BBB is generally a plus.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.498 and -4.824). This is unusual and suggests poor permeability. However, these values are on a scale where negative values are possible, and the absolute difference isn't huge.
10. **Solubility:** Both ligands have negative solubility values (-3.602 and -3.781). Similar to Caco-2, this suggests poor solubility.
11. **hERG:** Ligand A (0.587) has a slightly higher hERG risk than Ligand B (0.327), but both are relatively low.
12. **Cl_mic:** Ligand A (34.954) has a lower microsomal clearance than Ligand B (48.25), indicating better metabolic stability.
13. **t1/2:** Ligand A (-8.856) has a shorter in vitro half-life than Ligand B (-12.564). This is a negative for Ligand A.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.196 and 0.193).
15. **Binding Affinity:** Ligand A (-6.9 kcal/mol) has a slightly better binding affinity than Ligand B (-6.3 kcal/mol). This 0.6 kcal/mol difference is significant, potentially outweighing some ADME drawbacks.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity) and the general guidelines, Ligand A emerges as the better candidate. The significantly lower DILI risk is a major factor. While Ligand B has better BBB penetration and a longer half-life, the superior affinity and lower DILI risk of Ligand A are more critical for a viable drug candidate. The Caco-2 and solubility issues are concerning for both, but can be addressed through formulation strategies.
Output:
1
2025-04-17 22:29:20,044 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [437.384, 51.22, 4.785, 1, 6, 0.444, 79.333, 57.154, -5.045, -5.371, 0.57, 123.32, 37.662, 0.558, -6.7]
**Ligand B:** [344.419, 113.96, 1.999, 2, 3, 0.467, 32.687, 46.336, -5.251, -2.134, 0.123, 2.696, -24.213, 0.022, -7.6]
**Step-by-step comparison:**
1. **MW:** Ligand A (437.384 Da) is within the ideal range, while Ligand B (344.419 Da) is on the lower side, but still acceptable.
2. **TPSA:** Ligand A (51.22) is excellent for oral absorption and GPCR targeting. Ligand B (113.96) is higher, potentially hindering absorption.
3. **logP:** Ligand A (4.785) is slightly high, potentially causing solubility issues or off-target interactions. Ligand B (1.999) is optimal.
4. **HBD:** Both are acceptable (A: 1, B: 2).
5. **HBA:** Both are acceptable (A: 6, B: 3).
6. **QED:** Both are similar and acceptable (A: 0.444, B: 0.467).
7. **DILI:** Ligand A (79.333) has a significantly higher DILI risk than Ligand B (32.687). This is a major concern.
8. **BBB:** Ligand A (57.154) is moderate, while Ligand B (46.336) is lower. For a cardiovascular target, BBB penetration isn't *critical*, but it's a bonus.
9. **Caco-2:** Both have negative values, indicating poor permeability.
10. **Solubility:** Both have negative values, indicating poor solubility.
11. **hERG:** Ligand A (0.57) is better than Ligand B (0.123) - lower risk.
12. **Cl_mic:** Ligand A (123.32) has higher clearance, indicating lower metabolic stability. Ligand B (2.696) is much better.
13. **t1/2:** Ligand A (37.662) has a better in vitro half-life than Ligand B (-24.213).
14. **Pgp:** Ligand A (0.558) is better than Ligand B (0.022) - lower efflux.
15. **Affinity:** Ligand B (-7.6 kcal/mol) has a 1.5 kcal/mol stronger binding affinity than Ligand A (-6.7 kcal/mol). This is a substantial advantage.
**GPCR-specific priorities:** LogP, Pgp, TPSA, and affinity are key. Ligand B excels in logP and affinity, while Ligand A has better Pgp and TPSA. However, the *significant* DILI risk associated with Ligand A is a major red flag. The stronger affinity of Ligand B is also a strong point. While both have solubility/permeability issues, the DILI risk of A is a dealbreaker.
**Conclusion:**
Despite the slightly lower BBB penetration and permeability, Ligand B is the more promising candidate due to its superior binding affinity, much lower DILI risk, and better metabolic stability.
0
2025-04-17 22:29:20,044 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (346.5) is well within the ideal range (200-500). Ligand B (377.5) is also acceptable. No clear advantage here.
2. **TPSA:** Ligand A (49.4) is excellent, well below the 140 threshold, and favorable for permeability. Ligand B (113.6) is higher, but still potentially acceptable, though less ideal.
3. **logP:** Ligand A (3.668) is optimal. Ligand B (0.142) is very low, raising concerns about permeability and potentially requiring formulation strategies to enhance absorption. This is a significant drawback for Ligand B.
4. **HBD:** Ligand A (1) is good. Ligand B (3) is slightly higher, but still within the acceptable limit.
5. **HBA:** Ligand A (2) is good. Ligand B (5) is higher, but still within the acceptable limit.
6. **QED:** Both ligands (A: 0.715, B: 0.529) have acceptable QED scores, indicating drug-like properties. Ligand A is slightly better.
7. **DILI:** Ligand A (19.4) has a much lower DILI risk than Ligand B (44.7). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (88.9) has a very good BBB penetration score, while Ligand B (38.7) is low. While ADRB2 isn't exclusively a CNS target, good BBB penetration can still be beneficial for overall distribution and potentially reduce off-target effects.
9. **Caco-2:** Ligand A (-4.832) is better than Ligand B (-5.668), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-3.577) is better than Ligand B (-1.989), suggesting better aqueous solubility.
11. **hERG:** Both ligands have low hERG inhibition risk (A: 0.556, B: 0.142). Ligand B is slightly better.
12. **Cl_mic:** Ligand A (64.9) has higher metabolic clearance than Ligand B (21.2), indicating lower metabolic stability. This is a drawback for Ligand A.
13. **t1/2:** Ligand A (-17.9) has a longer in vitro half-life than Ligand B (-11.4). This is a positive for Ligand A.
14. **Pgp:** Ligand A (0.393) has lower P-gp efflux liability than Ligand B (0.025). This is a positive for Ligand A.
15. **Affinity:** Ligand B (-6.3) has a slightly better binding affinity than Ligand A (-5.0), a difference of 1.3 kcal/mol.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are crucial. Ligand A excels in logP, TPSA, and Pgp, while Ligand B has a slight edge in affinity. The poor logP of Ligand B is a major concern, potentially leading to poor absorption.
**Overall Assessment:**
Despite Ligand B's slightly better affinity, Ligand A is the more promising candidate. Ligand A has a significantly better logP, lower DILI risk, better BBB penetration, better solubility, and lower P-gp efflux. The slightly higher clearance of Ligand A is a manageable concern compared to the potential absorption issues with Ligand B. The affinity difference is not large enough to overcome the substantial ADME advantages of Ligand A.
Output:
1
2025-04-17 22:29:20,044 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [359.333, 127.42 , -0.996, 4. , 5. , 0.502, 53.47 , 36.371, -5.461, -1.983, 0.233, -37.477, -25.591, 0.011, -7.9 ]
**Ligand B:** [383.945, 58.36 , 3.769, 1. , 5. , 0.754, 35.789, 60.644, -4.952, -3.409, 0.848, 53.227, 26.53 , 0.824, -6.4 ]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, Affinity, and BBB):
1. **MW:** Both are within the acceptable 200-500 Da range. Ligand A (359.333) is slightly preferred.
2. **TPSA:** Ligand B (58.36) is significantly better than Ligand A (127.42). Lower TPSA is generally better for permeability, and crucial for GPCRs.
3. **logP:** Ligand B (3.769) is better, falling within the optimal 1-3 range. Ligand A (-0.996) is too low, potentially hindering membrane permeability.
4. **HBD/HBA:** Both have acceptable numbers. Ligand B has fewer HBDs (1 vs 4), which is slightly favorable.
5. **QED:** Ligand B (0.754) is better than Ligand A (0.502), indicating a more drug-like profile.
6. **DILI:** Ligand B (35.789) has a lower DILI risk than Ligand A (53.47), a significant advantage.
7. **BBB:** Ligand B (60.644) has a better BBB penetration score than Ligand A (36.371). This is important for GPCRs, though not strictly essential for ADRB2 (cardiovascular target).
8. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-5.461) is worse than Ligand B (-4.952).
9. **Solubility:** Both are negative, indicating poor solubility. Ligand B (-3.409) is slightly better than Ligand A (-1.983).
10. **hERG:** Ligand A (0.233) has a lower hERG risk than Ligand B (0.848), which is a positive.
11. **Cl_mic:** Ligand A (-37.477) has a lower (better) microsomal clearance than Ligand B (53.227), indicating better metabolic stability.
12. **t1/2:** Ligand B (26.53) has a longer in vitro half-life than Ligand A (-25.591), which is preferable.
13. **Pgp:** Ligand B (0.824) has a lower P-gp efflux liability than Ligand A (0.011), which is a significant advantage for bioavailability.
14. **Affinity:** Ligand A (-7.9) has a significantly better binding affinity than Ligand B (-6.4). This is a substantial advantage, potentially outweighing some ADME concerns.
**Overall Assessment:**
While Ligand B excels in many ADME properties (QED, DILI, BBB, Pgp, t1/2, logP, TPSA), Ligand A's substantially stronger binding affinity (-7.9 vs -6.4 kcal/mol) is a critical factor for a GPCR target. The 1.5 kcal/mol difference is significant. The slightly higher DILI risk and lower BBB for Ligand A are less concerning for a cardiovascular target than a CNS target. The lower logP and Caco-2 permeability for Ligand A are drawbacks, but the strong affinity may compensate for these.
Therefore, I would prioritize Ligand A.
Output:
1
2025-04-17 22:29:20,044 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (375.837 Da) is slightly higher than Ligand B (345.487 Da), but both are acceptable.
2. **TPSA:** Both ligands are below the 140 A^2 threshold for good oral absorption. Ligand A (90.27 A^2) is slightly higher than Ligand B (81.99 A^2), but both are good.
3. **logP:** Both ligands have logP values within the optimal range (1-3). Ligand A (2.921) and Ligand B (3.053) are very similar.
4. **HBD:** Ligand A has 1 HBD, while Ligand B has 2. Both are within the acceptable limit of <=5.
5. **HBA:** Ligand A has 4 HBA, while Ligand B has 3. Both are within the acceptable limit of <=10.
6. **QED:** Ligand A (0.892) has a significantly higher QED score than Ligand B (0.696), indicating better overall drug-likeness.
7. **DILI:** Ligand A (94.882) has a very high DILI risk, while Ligand B (21.753) has a low DILI risk. This is a major concern for Ligand A.
8. **BBB:** Ligand B (66.886) has a better BBB penetration percentile than Ligand A (38.426). While ADRB2 isn't exclusively a CNS target, some peripheral ADRB2 activity can be modulated by CNS effects, and higher BBB penetration isn't necessarily detrimental.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual. This suggests poor permeability. The values are very similar (-4.873 and -4.885).
10. **Solubility:** Ligand A (-5.08) has worse solubility than Ligand B (-3.723).
11. **hERG:** Ligand A (0.594) has a slightly higher hERG risk than Ligand B (0.648), but both are relatively low.
12. **Cl_mic:** Ligand B (54.508 mL/min/kg) has a significantly lower microsomal clearance than Ligand A (11.021 mL/min/kg), indicating better metabolic stability.
13. **t1/2:** Ligand A (76.967 hours) has a much longer in vitro half-life than Ligand B (3.4 hours).
14. **Pgp:** Ligand A (0.277) has lower P-gp efflux liability than Ligand B (0.123), which is favorable.
15. **Affinity:** Ligand A (-7.0 kcal/mol) has a slightly better binding affinity than Ligand B (-6.8 kcal/mol). This is a moderate advantage.
**GPCR-Specific Considerations:**
For GPCRs like ADRB2, logP, TPSA, Pgp, and affinity are key. Both ligands perform similarly on logP and TPSA. Ligand A has a slight edge in Pgp and affinity, but Ligand B has a significantly better safety profile (DILI) and metabolic stability (Cl_mic). The longer half-life of Ligand A is attractive, but the high DILI risk is a major red flag.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity and half-life, the extremely high DILI risk and poor solubility are deal-breakers. Ligand B, despite its lower affinity and shorter half-life, presents a much more favorable safety profile and better metabolic stability. These factors are critical for a viable drug candidate.
Output:
0
2025-04-17 22:29:20,044 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (368.5 and 356.5 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (80.57) is significantly better than Ligand B (113.76). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is pushing the upper limit for good oral absorption.
3. **logP:** Ligand A (2.225) is within the optimal range (1-3). Ligand B (0.603) is a bit low, potentially hindering membrane permeation.
4. **HBD:** Ligand A (2) and Ligand B (3) are both acceptable, below the threshold of 5.
5. **HBA:** Ligand A (5) and Ligand B (4) are both acceptable, below the threshold of 10.
6. **QED:** Both ligands have similar QED values (0.619 and 0.591), indicating good drug-like properties.
7. **DILI:** Ligand A (29.2) has a slightly higher DILI risk than Ligand B (18.7), but both are well below the concerning threshold of 60.
8. **BBB:** Ligand B (73.9) has a significantly higher BBB penetration percentile than Ligand A (55.6). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be helpful for distribution and off-target effects.
9. **Caco-2:** Both ligands have similar, very negative Caco-2 values, indicating poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-2.463) has slightly better solubility than Ligand B (-1.916), though both are quite poor.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.359 and 0.154).
12. **Cl_mic:** Ligand A (44.3) has a higher microsomal clearance than Ligand B (12.4), suggesting faster metabolism and potentially lower *in vivo* exposure.
13. **t1/2:** Ligand B (-7.854) has a significantly longer *in vitro* half-life than Ligand A (39.564), which is a major advantage.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.112 and 0.005).
15. **Binding Affinity:** Ligand B (-5.9) has a slightly stronger binding affinity than Ligand A (-5.4). While the difference is less than the 1.5 kcal/mol threshold, it's still a positive.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, and affinity are key. Ligand A has a better logP and TPSA. Ligand B has better BBB penetration and affinity. The biggest drawback for Ligand A is its higher Cl_mic and shorter half-life. The poor Caco-2 values for both are concerning, but can sometimes be overcome with formulation strategies.
**Overall Assessment:**
Despite Ligand A's slightly better TPSA and logP, Ligand B's significantly improved metabolic stability (lower Cl_mic, longer t1/2) and slightly better binding affinity outweigh these advantages. The better BBB penetration is a bonus. The poor Caco-2 values are a concern for both, but the improved pharmacokinetic profile of Ligand B makes it the more promising candidate.
Output:
0
2025-04-17 22:29:20,044 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (359.853) is slightly higher than Ligand B (347.423), but both are acceptable.
2. **TPSA:** Ligand A (58.56) is significantly better than Ligand B (93.18). ADRB2 is a cardiovascular target, not a CNS target, but lower TPSA generally favors absorption. Ligand B's TPSA is approaching a level that could hinder oral bioavailability.
3. **logP:** Ligand A (4.08) is a bit high, potentially leading to solubility issues or off-target interactions. Ligand B (0.657) is quite low, which could impede membrane permeability. This is a critical trade-off. For a GPCR, a logP between 1-3 is preferred.
4. **HBD:** Ligand A (2) is reasonable. Ligand B (0) is also acceptable, but very low HBD can sometimes negatively impact solubility.
5. **HBA:** Ligand A (3) is good. Ligand B (8) is higher, potentially impacting permeability.
6. **QED:** Both ligands have similar QED values (0.783 and 0.657), indicating reasonable drug-likeness.
7. **DILI:** Ligand A (50.136) has a slightly higher DILI risk than Ligand B (36.448), but both are below the concerning threshold of 60.
8. **BBB:** This is less critical for a cardiovascular target. Ligand B (66.576) has a higher BBB penetration than Ligand A (43.273), but this is not a primary concern here.
9. **Caco-2:** Ligand A (-4.656) is better than Ligand B (-5.359). Higher values indicate better absorption.
10. **Solubility:** Ligand A (-4.707) is better than Ligand B (-0.3). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.473) is better than Ligand B (0.085). Lower hERG inhibition is crucial to avoid cardiotoxicity, especially for a cardiovascular target.
12. **Cl_mic:** Ligand A (33.982) has a lower microsomal clearance, indicating better metabolic stability than Ligand B (13.882).
13. **t1/2:** Ligand A (56.35) has a significantly longer in vitro half-life than Ligand B (3.819). This is a major advantage for dosing frequency.
14. **Pgp:** Ligand A (0.416) has lower P-gp efflux than Ligand B (0.025), which is favorable for bioavailability.
15. **Affinity:** Ligand A (-7.4) has a substantially stronger binding affinity than Ligand B (-5.8). A difference of 1.6 kcal/mol is significant and can often outweigh minor ADME drawbacks.
**Overall Assessment:**
Ligand A is the superior candidate. While its logP is slightly elevated, the significantly stronger binding affinity, better metabolic stability (lower Cl_mic, longer t1/2), lower P-gp efflux, better solubility, and lower hERG risk outweigh this concern. The TPSA is also much better for Ligand A. The difference in binding affinity is substantial enough to make Ligand A the clear preference.
Output:
1
2025-04-17 22:29:20,044 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (365.377 and 388.49 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (96.97) is better than Ligand B (103.95). Both are below the 140 threshold for oral absorption, but closer to the ideal for GPCRs.
**3. logP:** Ligand A (-0.474) is a bit low, potentially hindering permeability. Ligand B (2.222) is within the optimal 1-3 range. This favors Ligand B.
**4. H-Bond Donors:** Ligand A (2) and Ligand B (3) are both acceptable, below the 5 threshold.
**5. H-Bond Acceptors:** Both ligands have 5 H-bond acceptors, which is acceptable.
**6. QED:** Ligand B (0.573) has a slightly better QED score than Ligand A (0.403), indicating a more drug-like profile.
**7. DILI:** Ligand A (31.718) has a significantly lower DILI risk than Ligand B (83.792). This is a major advantage for Ligand A.
**8. BBB:** Ligand A (75.843) has a better BBB penetration score than Ligand B (43.815). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant and this favors A.
**9. Caco-2 Permeability:** Both are negative, indicating poor permeability. Ligand A (-5.043) is slightly better than Ligand B (-5.626), but both are concerning.
**10. Aqueous Solubility:** Both are negative, indicating poor solubility. Ligand A (-1.431) is slightly better than Ligand B (-2.63).
**11. hERG Inhibition:** Ligand A (0.324) has a lower hERG inhibition liability than Ligand B (0.632), which is crucial for avoiding cardiotoxicity.
**12. Microsomal Clearance:** Ligand A (1.298) has a much lower microsomal clearance than Ligand B (46.708), indicating better metabolic stability.
**13. In vitro Half-Life:** Ligand A (-29.277) has a much longer in vitro half-life than Ligand B (1.776), which is highly desirable.
**14. P-gp Efflux:** Ligand A (0.016) has a much lower P-gp efflux liability than Ligand B (0.302), which is beneficial for bioavailability.
**15. Binding Affinity:** Ligand B (-7.4) has a significantly stronger binding affinity than Ligand A (-6.3). This is a substantial advantage for Ligand B.
**Overall Assessment:**
While Ligand B boasts a superior binding affinity, the ADME properties of Ligand A are significantly better. Ligand A has lower DILI risk, better BBB penetration, lower hERG inhibition, much better metabolic stability (lower Cl_mic and longer t1/2), and lower P-gp efflux. The slightly lower logP of Ligand A is a concern, but the substantial advantages in safety and pharmacokinetic properties outweigh this drawback. For a GPCR target, balancing potency with good ADME properties is critical, and Ligand A achieves this balance more effectively.
Output:
1
2025-04-17 22:29:20,044 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [362.495, 49.85, 2.687, 0, 4, 0.813, 49.632, 77.007, -4.443, -2.752, 0.458, 45.14, 36.703, 0.214, -6.3]
**Ligand B:** [371.453, 71.09, 3.364, 2, 4, 0.805, 62.815, 85.459, -4.944, -4.431, 0.359, 53.318, 24.965, 0.246, -6.1]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity, and BBB):
1. **MW:** Both are within the ideal 200-500 Da range. A is 362.5, B is 371.5. No significant difference.
2. **TPSA:** A (49.85) is better than B (71.09). Lower TPSA generally favors better permeability.
3. **logP:** Both are good (between 1-3). A (2.687) is slightly better than B (3.364) as it's closer to the optimal range.
4. **HBD:** A (0) is preferable to B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Both have 4 HBA, so no difference.
6. **QED:** Both are very similar (A: 0.813, B: 0.805), indicating good drug-likeness.
7. **DILI:** A (49.632) is significantly better than B (62.815). Lower DILI is crucial.
8. **BBB:** B (85.459) is better than A (77.007). While not a primary concern for a cardiovascular target, higher BBB is still a positive.
9. **Caco-2:** Both are negative, indicating poor permeability. A (-4.443) is slightly better than B (-4.944).
10. **Solubility:** A (-2.752) is better than B (-4.431). Better solubility is generally preferred.
11. **hERG:** Both are very low (A: 0.458, B: 0.359), indicating low cardiotoxicity risk.
12. **Cl_mic:** A (45.14) is better than B (53.318). Lower clearance means better metabolic stability.
13. **t1/2:** A (36.703) is better than B (24.965). Longer half-life is generally desirable.
14. **Pgp:** Both are low (A: 0.214, B: 0.246), indicating low efflux.
15. **Affinity:** A (-6.3) is slightly better than B (-6.1), although the difference is small.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B in several key ADME properties (DILI, Cl_mic, t1/2, solubility, TPSA) and has a slightly better binding affinity. While Ligand B has a slightly better BBB score, this is less critical for a cardiovascular target. The lower DILI risk for Ligand A is a significant advantage. The slightly better TPSA and logP of Ligand A also contribute to its improved profile.
Therefore, I would choose Ligand A as the more promising drug candidate.
Output:
1
2025-04-17 22:29:20,044 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
The target is ADRB2, a GPCR. Therefore, I will prioritize logP, Pgp, TPSA, and binding affinity, followed by ADME properties.
* **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (350.547 Da) is slightly higher than Ligand B (341.415 Da), but this difference isn't significant.
* **TPSA:** Ligand A (50.36) is significantly better than Ligand B (80.12). TPSA < 140 is good for oral absorption, and lower is generally preferred for GPCRs. Ligand B is pushing the upper limit.
* **logP:** Ligand A (4.345) is higher than the optimal range (1-3), but still potentially manageable. Ligand B (0.855) is quite low, which could lead to poor membrane permeability. This is a significant drawback.
* **H-Bond Donors/Acceptors:** Ligand A (2 HBD, 2 HBA) is better balanced than Ligand B (1 HBD, 5 HBA). Excessive HBA can hinder permeability.
* **QED:** Both ligands have good QED scores (A: 0.748, B: 0.845), indicating good drug-like properties.
* **DILI:** Both ligands have low DILI risk (A: 23.846, B: 25.514), which is positive.
* **BBB:** Ligand A (85.459) has a much higher BBB penetration score than Ligand B (42.962). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be beneficial or at least needs to be understood.
* **Caco-2:** Ligand A (-4.667) and Ligand B (-5.408) both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so this is hard to interpret.
* **Solubility:** Ligand A (-4.363) and Ligand B (-0.924) both have negative solubility values, which is also unusual and suggests poor solubility. Again, the scale is not specified.
* **hERG:** Both ligands have very low hERG risk (A: 0.67, B: 0.179), which is excellent.
* **Cl_mic:** Ligand B (-7.47) has a negative clearance, which is not physically possible and suggests an error in the data. Ligand A (62.285) is reasonable.
* **t1/2:** Ligand A (24.77) has a better in vitro half-life than Ligand B (-13.706). Again, the negative value for Ligand B is concerning.
* **Pgp:** Ligand A (0.195) has lower P-gp efflux liability than Ligand B (0.011), which is favorable for bioavailability and potential CNS exposure.
* **Binding Affinity:** Ligand A (-6.9 kcal/mol) has a slightly better binding affinity than Ligand B (-6.5 kcal/mol), although the difference is not huge.
**Conclusion:**
Ligand A is significantly better overall. Its superior TPSA, BBB penetration, more reasonable Cl_mic and t1/2 values, and slightly better binding affinity outweigh its higher logP. The negative values for Caco-2, solubility, and t1/2 for Ligand B are highly suspect and raise serious concerns about its viability. While Ligand A's logP is a bit high, it's a more manageable issue than the multiple red flags associated with Ligand B.
**Output:**
1
2025-04-17 22:29:20,045 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (384.929 Da) is slightly higher than Ligand B (354.491 Da), but both are acceptable.
2. **TPSA:** Ligand A (49.85) is significantly better than Ligand B (78.87). For a GPCR, a lower TPSA is generally preferred for better permeability, and Ligand A is well below the 140 threshold. Ligand B is approaching a less desirable range.
3. **logP:** Ligand A (3.169) is within the optimal range (1-3), while Ligand B (1.562) is at the lower end. While not terrible, lower logP can sometimes indicate permeability issues.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer hydrogen bond donors generally improve membrane permeability.
5. **HBA:** Ligand A (5) is better than Ligand B (4). Both are acceptable, but lower is generally favored.
6. **QED:** Both ligands have similar QED values (A: 0.731, B: 0.727), indicating good drug-likeness.
7. **DILI:** Ligand A (37.03) has a significantly lower DILI risk than Ligand B (7.871). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (82.862) has a better BBB penetration percentile than Ligand B (73.75). While ADRB2 isn't exclusively a CNS target, some distribution to the CNS is possible, and higher BBB is favorable.
9. **Caco-2:** Ligand A (-4.603) and Ligand B (-4.46) are similar and both indicate good permeability.
10. **Solubility:** Ligand A (-3.573) and Ligand B (-2.601) are similar and both indicate good solubility.
11. **hERG:** Ligand A (0.678) is slightly higher than Ligand B (0.4), indicating a slightly higher risk of hERG inhibition, but both are relatively low.
12. **Cl_mic:** Ligand A (98.981) has a much higher microsomal clearance than Ligand B (32.334). This indicates lower metabolic stability for Ligand A, which is a significant drawback.
13. **t1/2:** Ligand B (3.333) has a longer in vitro half-life than Ligand A (-4.992). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.355) has a lower P-gp efflux liability than Ligand B (0.02). Lower P-gp efflux is preferable.
15. **Binding Affinity:** Ligand A (-7.8 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.3 kcal/mol). This is a substantial advantage for Ligand A, potentially outweighing some of its ADME drawbacks.
**Overall Assessment:**
Ligand A has a clear advantage in binding affinity and DILI risk, and better TPSA, HBD, HBA, and Pgp efflux. However, Ligand B exhibits superior metabolic stability (lower Cl_mic) and a longer half-life, and a better logP. The binding affinity difference is substantial (>1.5 kcal/mol), and the lower DILI risk of Ligand A is highly desirable. Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity), the strong affinity and lower DILI risk of Ligand A are more important than the slightly worse metabolic stability.
Output:
1
2025-04-17 22:29:20,045 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (351.397 and 352.389 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (54.34) is significantly better than Ligand B (87.01). ADRB2 is not a CNS target, but lower TPSA generally improves absorption. Ligand A is well below the 140 threshold, while B is approaching it.
3. **logP:** Both ligands have acceptable logP values (2.092 and 3.277), falling within the 1-3 range. Ligand B is slightly higher, which *could* be a minor concern for solubility, but not a deal-breaker.
4. **HBD:** Ligand A has 1 HBD, while Ligand B has 0. Both are within the acceptable limit of 5.
5. **HBA:** Ligand A has 3 HBA, and Ligand B has 5. Both are within the acceptable limit of 10.
6. **QED:** Ligand A (0.903) has a much better QED score than Ligand B (0.408), indicating a more drug-like profile. This is a substantial advantage for Ligand A.
7. **DILI:** Ligand A (22.8) has a significantly lower DILI risk than Ligand B (42.536). This is a major advantage for Ligand A, as lower DILI is crucial.
8. **BBB:** Both ligands have high BBB penetration (95.967 and 92.323). While ADRB2 isn't a primary CNS target, high BBB isn't detrimental.
9. **Caco-2:** Both ligands show poor Caco-2 permeability (-4.677 and -4.388). This is a concern for oral absorption for both.
10. **Solubility:** Both ligands have very poor aqueous solubility (-2.851 and -3.682). This is a significant drawback for both, potentially impacting bioavailability.
11. **hERG:** Ligand A (0.397) has a lower hERG risk than Ligand B (0.795). This is a positive for Ligand A, reducing cardiotoxicity concerns.
12. **Cl_mic:** Ligand B (51.774) has a much higher microsomal clearance than Ligand A (4.128). This suggests Ligand B will be metabolized more quickly, leading to a shorter duration of action.
13. **t1/2:** Ligand B (-10.726) has a negative in vitro half-life, which is concerning. Ligand A (-0.26) is also low, but less concerning than a negative value.
14. **Pgp:** Ligand A (0.042) has much lower P-gp efflux liability than Ligand B (0.177). This is a positive for Ligand A, potentially improving bioavailability.
15. **Binding Affinity:** Ligand B (-8.7) has a slightly better binding affinity than Ligand A (-6.8). This is a 1.9 kcal/mol difference, which is substantial. However, the other ADME properties of Ligand A are much more favorable.
**Overall Assessment:**
While Ligand B has a slightly stronger binding affinity, Ligand A is the superior candidate. Ligand A demonstrates significantly better drug-like properties (QED), lower DILI risk, lower hERG risk, lower P-gp efflux, and better metabolic stability (lower Cl_mic). The poor solubility and Caco-2 permeability are concerns for both, but these can be addressed with formulation strategies. The superior ADME profile of Ligand A outweighs the modest affinity difference.
Output:
1
2025-04-17 22:29:20,045 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, priorities are affinity, logP, TPSA, Pgp efflux, and to a lesser extent, BBB.
* **Molecular Weight:** Both ligands are within the ideal range (200-500 Da).
* **TPSA:** Both are acceptable at around 105 A^2, allowing for reasonable absorption.
* **logP:** Ligand B (1.346) is better than Ligand A (0.122). A logP between 1-3 is optimal, and Ligand A is quite low, potentially hindering membrane permeability.
* **H-Bond Donors/Acceptors:** Both have reasonable HBD (2/3) and HBA (7/7) counts.
* **QED:** Both have acceptable QED scores (>0.5).
* **DILI:** Ligand A (42.769) has a significantly lower DILI risk than Ligand B (77.782). This is a substantial advantage for Ligand A.
* **BBB:** Both have low BBB penetration, which isn't critical for a cardiovascular target. Ligand B is slightly higher (43.893 vs 35.091).
* **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. This is a concern for both.
* **Solubility:** Ligand A (-1.178) has better solubility than Ligand B (-2.752).
* **hERG:** Ligand A (0.076) has a much lower hERG risk than Ligand B (0.331). This is a significant safety advantage.
* **Cl_mic:** Both have similar microsomal clearance rates.
* **t1/2:** Ligand B (104.27) has a significantly longer in vitro half-life than Ligand A (50.72). This is a positive for Ligand B.
* **Pgp:** Ligand A (0.026) has much lower P-gp efflux liability than Ligand B (0.06). This is a positive for Ligand A.
* **Binding Affinity:** Ligand B (-8.1 kcal/mol) has a substantially stronger binding affinity than Ligand A (-5.5 kcal/mol). This is a 2.6 kcal/mol difference, a very significant advantage.
**Overall Assessment:**
The key trade-off is between the significantly better binding affinity of Ligand B and the superior ADME/Tox profile of Ligand A. The 2.6 kcal/mol difference in binding affinity is substantial and likely outweighs the moderate ADME concerns with Ligand B, especially considering the DILI and hERG risks associated with Ligand B. While Ligand A has a better safety profile and permeability predictions, the potency of Ligand B is a major driver for success.
Output:
0
2025-04-17 22:29:20,045 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (339.4) is slightly lower than Ligand B (352.5), which is generally favorable for permeability.
2. **TPSA:** Ligand A (87.22) is better than Ligand B (59.08). While both are reasonably low, lower TPSA generally correlates with better cell permeability, a key factor for GPCR ligands.
3. **logP:** Both ligands have good logP values (A: 1.358, B: 1.681), falling within the optimal 1-3 range. Ligand B is slightly higher, which *could* indicate a slightly better ability to cross membranes, but it's not a significant difference.
4. **HBD:** Ligand A (2) is better than Ligand B (0). Having some HBDs can aid solubility.
5. **HBA:** Ligand A (5) is slightly higher than Ligand B (4), but both are within acceptable limits.
6. **QED:** Ligand A (0.878) is significantly better than Ligand B (0.443). A higher QED suggests a more drug-like profile overall.
7. **DILI:** Ligand A (69.252) has a higher DILI risk than Ligand B (12.641). This is a significant concern, as a lower DILI risk is highly desirable.
8. **BBB:** Ligand B (79.488) has a better BBB penetration percentile than Ligand A (63.784). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration isn't necessarily detrimental and could open up possibilities for peripheral effects mediated by the receptor.
9. **Caco-2:** Ligand A (-5.028) is better than Ligand B (-4.275), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-2.872) is better than Ligand B (-1.049), indicating better aqueous solubility.
11. **hERG:** Ligand A (0.339) has a lower hERG inhibition liability than Ligand B (0.526), which is preferable.
12. **Cl_mic:** Ligand B (13.027) has a lower microsomal clearance than Ligand A (33.127), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-9.084) has a longer in vitro half-life than Ligand B (-7.592).
14. **Pgp:** Ligand A (0.023) has a lower P-gp efflux liability than Ligand B (0.071), which is favorable for bioavailability.
15. **Affinity:** Ligand A (-7.8 kcal/mol) has a significantly better binding affinity than Ligand B (-6.4 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME drawbacks.
**Overall Assessment:**
Ligand A has a significantly better binding affinity and a more favorable drug-like profile (higher QED, better solubility, lower hERG, lower Pgp efflux). However, it has a higher DILI risk and a higher microsomal clearance. Ligand B has a much lower DILI risk and better metabolic stability, but its binding affinity is considerably weaker.
Given the importance of potency for GPCR targets, and the substantial difference in affinity (-7.8 vs -6.4 kcal/mol), I believe Ligand A is the more promising candidate *despite* the higher DILI risk. The DILI risk can be investigated further through structural modifications and *in vitro* studies. The strong binding affinity provides a solid foundation for optimization.
Output:
1
2025-04-17 22:29:20,045 - INFO - Batch 335 complete. Total preferences: 5360
2025-04-17 22:29:20,045 - INFO - Processing batch 336/512...
2025-04-17 22:30:05,875 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (342.439 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (49.85) is significantly better than Ligand B (100.35). ADRB2 is not a CNS target, but lower TPSA generally improves absorption. Ligand B is pushing the upper limit for good oral absorption.
3. **logP:** Ligand A (2.481) is optimal, while Ligand B (0.406) is quite low. Low logP can hinder membrane permeability. This is a significant advantage for Ligand A.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (3) is better than Ligand B (6). Lower HBA also favors permeability.
6. **QED:** Both ligands have acceptable QED values (A: 0.773, B: 0.658), indicating good drug-like properties.
7. **DILI:** Ligand A (21.055) has a much lower DILI risk than Ligand B (48.817). This is a critical advantage for Ligand A.
8. **BBB:** This is less crucial for ADRB2 (a cardiovascular target), but Ligand A (97.751) is better than Ligand B (74.447).
9. **Caco-2:** Ligand A (-4.272) is better than Ligand B (-5.07), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-2.456) is better than Ligand B (-2.08), though both are poor. Solubility is a concern for both, but less so for A.
11. **hERG:** Ligand A (0.556) is better than Ligand B (0.182), indicating a lower risk of cardiotoxicity. This is a significant advantage for Ligand A, given the cardiovascular target.
12. **Cl_mic:** Ligand A (46.5) is better than Ligand B (35.963), indicating better metabolic stability.
13. **t1/2:** Ligand A (-6.632) is better than Ligand B (-5.616), suggesting a longer half-life.
14. **Pgp:** Ligand A (0.124) is better than Ligand B (0.084), indicating less P-gp efflux.
15. **Binding Affinity:** Ligand A (-5.0) is slightly worse than Ligand B (-3.6). However, the substantial advantages of Ligand A in ADME properties outweigh this difference in binding affinity.
**GPCR-specific priorities:** For ADRB2, logP, TPSA, Pgp, and affinity are important. Ligand A excels in logP, TPSA, and Pgp, and has acceptable affinity. While Ligand B has a better affinity, its poor logP and higher TPSA are significant drawbacks.
**Conclusion:**
Ligand A demonstrates a superior balance of properties, particularly in ADME characteristics, and has a significantly lower DILI risk and hERG liability. While Ligand B has a slightly better binding affinity, the overall profile of Ligand A makes it a more promising drug candidate for the ADRB2 receptor.
Output:
1
2025-04-17 22:30:05,875 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (374.359) is slightly higher than Ligand B (350.415), but both are acceptable.
2. **TPSA:** Ligand A (63.4) is significantly better than Ligand B (103.01). For a GPCR, lower TPSA is generally preferred for better permeability. Ligand B is approaching a level that could hinder oral absorption.
3. **logP:** Ligand A (3.215) is optimal, while Ligand B (0.972) is a bit low. A logP below 1 can sometimes indicate poor membrane permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (5). Similar reasoning as with HBDs.
6. **QED:** Both ligands have good QED scores (A: 0.663, B: 0.754), indicating good drug-like properties.
7. **DILI:** Ligand A (71.733) has a higher DILI risk than Ligand B (44.552). This is a concern for Ligand A, but not a dealbreaker at this stage.
8. **BBB:** Ligand A (72.974) is significantly better than Ligand B (15.432). While ADRB2 isn't exclusively a CNS target, some CNS penetration can be beneficial for understanding off-target effects and potential side effects.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.016 and -5.141). This is unusual and suggests poor permeability in this assay. However, the values are similar, so it doesn't strongly favor either.
10. **Solubility:** Ligand A (-4.866) is better than Ligand B (-2.013), indicating better aqueous solubility.
11. **hERG:** Ligand A (0.924) is better than Ligand B (0.067). Lower hERG inhibition is crucial for avoiding cardiotoxicity, a significant concern for cardiovascular targets.
12. **Cl_mic:** Ligand A (33.364) is better than Ligand B (1.24). Lower microsomal clearance indicates greater metabolic stability.
13. **t1/2:** Ligand A (-15.199) is better than Ligand B (9.096). A negative in vitro half-life is unusual and suggests very rapid metabolism, but is still preferable to a short half-life.
14. **Pgp:** Ligand A (0.228) is better than Ligand B (0.019). Lower P-gp efflux is desirable for improved bioavailability.
15. **Affinity:** Ligand A (-7.2) has a significantly better binding affinity than Ligand B (-5.9). A 1.3 kcal/mol difference is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand A is clearly the superior candidate. It has better TPSA, logP, HBD, HBA, solubility, hERG inhibition, metabolic stability (Cl_mic), in vitro half-life, Pgp efflux, and, most importantly, significantly stronger binding affinity. While Ligand A has a higher DILI risk, the substantial improvement in potency and ADME properties makes it the more promising candidate. The GPCR-specific priorities (logP, TPSA, Pgp, and affinity) all favor Ligand A.
Output:
1
2025-04-17 22:30:05,875 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (370.471 and 349.519 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand B (52.65) is significantly better than Ligand A (94.99). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (2.181 and 2.572), falling within the 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Both ligands have 1 HBD, which is within the acceptable limit of 5.
5. **HBA:** Ligand A has 4 HBAs, while Ligand B has 3. Both are below the 10 threshold.
6. **QED:** Both ligands have reasonable QED scores (0.757 and 0.685), indicating good drug-like properties.
7. **DILI:** Ligand B (4.459%) has a *much* lower DILI risk than Ligand A (55.448%). This is a critical advantage.
8. **BBB:** Ligand B (86.08%) has a higher BBB penetration score than Ligand A (43.195%). While not a primary concern for a cardiovascular target, higher BBB is rarely detrimental.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.975 and -4.868), which is unusual and suggests poor permeability. This is a potential issue for both.
10. **Solubility:** Ligand B (-1.255) has slightly better solubility than Ligand A (-2.588), though both are quite poor.
11. **hERG:** Ligand A (0.072) has a slightly lower hERG risk than Ligand B (0.503), but both are very low, indicating minimal cardiotoxicity concerns.
12. **Cl_mic:** Ligand B (8.416) has a significantly lower microsomal clearance than Ligand A (23.885), indicating better metabolic stability.
13. **t1/2:** Ligand A (-31.727) has a longer in vitro half-life than Ligand B (-14.033). This is a positive for Ligand A.
14. **Pgp:** Ligand B (0.027) has lower P-gp efflux liability than Ligand A (0.016). Lower Pgp is generally preferred.
15. **Binding Affinity:** Ligand A (-6.8 kcal/mol) has a slightly better binding affinity than Ligand B (-5.8 kcal/mol). This is a 1.0 kcal/mol difference, which is significant but not overwhelming.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand B is the stronger candidate. The *dramatic* reduction in DILI risk is a major factor. The lower Cl_mic and better TPSA also contribute to its favorability. While Ligand A has a slightly better affinity and half-life, the safety profile of Ligand B is far superior, and the affinity difference isn't large enough to outweigh the other advantages. The poor Caco-2 values are a concern for both, but can be addressed with formulation strategies.
Output:
0
2025-04-17 22:30:05,876 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (352.475 and 370.469 Da) fall within the ideal range of 200-500 Da. No clear advantage here.
2. **TPSA:** Ligand A (78.87) is higher than Ligand B (58.12). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for permeability. Ligand B has a slight edge.
3. **logP:** Ligand A (1.317) is within the optimal range, while Ligand B (3.315) is at the higher end. While still acceptable, higher logP can sometimes lead to off-target effects and solubility issues. Ligand A is slightly better.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable.
5. **HBA:** Ligand A (4) and Ligand B (5) are both acceptable.
6. **QED:** Both ligands have similar QED values (0.707 and 0.712), indicating good drug-likeness.
7. **DILI:** Ligand A (8.996) has a significantly lower DILI risk than Ligand B (57.193). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (86.351) has a higher BBB penetration percentile than Ligand A (62.699). While ADRB2 isn't primarily a CNS target, some CNS exposure is not necessarily detrimental and could provide additional therapeutic effects.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.759 and -4.944), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-1.808) has better solubility than Ligand B (-4.125).
11. **hERG:** Ligand A (0.464) has a lower hERG inhibition liability than Ligand B (0.902). This is a significant advantage for Ligand A, reducing the risk of cardiotoxicity.
12. **Cl_mic:** Ligand B (79.188) has a much higher microsomal clearance than Ligand A (11.862), indicating faster metabolism and potentially lower *in vivo* exposure. Ligand A is significantly better.
13. **t1/2:** Ligand A (19.577) has a shorter half-life than Ligand B (30.645), but both are reasonable.
14. **Pgp:** Ligand A (0.072) has lower P-gp efflux liability than Ligand B (0.275). This is a positive for Ligand A, improving bioavailability.
15. **Binding Affinity:** Ligand A (-6.8 kcal/mol) has a slightly better binding affinity than Ligand B (-5.1 kcal/mol). This difference of 1.7 kcal/mol is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity) and the general guidelines, Ligand A is the more promising candidate. While Ligand B has better BBB penetration, the significant advantages of Ligand A in terms of DILI risk, hERG inhibition, metabolic stability (lower Cl_mic), P-gp efflux, solubility, and binding affinity outweigh this benefit. The negative Caco-2 values are concerning for both, but can be addressed with formulation strategies. The superior binding affinity of Ligand A is a key factor, as it provides a stronger starting point for optimization.
Output:
1
2025-04-17 22:30:05,876 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (371.821 and 341.503 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (73.63) is significantly better than Ligand A (100.99). For a GPCR, lower TPSA is generally preferred for permeability.
3. **logP:** Ligand A (0.091) is quite low, potentially hindering membrane permeability. Ligand B (4.619) is higher, approaching the upper limit but still acceptable. Ligand B is favored.
4. **HBD:** Both have 2 HBD, which is within the acceptable range.
5. **HBA:** Ligand A has 6 HBA, and Ligand B has 5. Both are acceptable.
6. **QED:** Ligand A (0.628) has a slightly better QED score than Ligand B (0.48), indicating better overall drug-likeness.
7. **DILI:** Ligand B (51.028) has a lower DILI risk than Ligand A (67.313), which is a significant advantage.
8. **BBB:** Ligand B (79.217) has a much higher BBB penetration potential than Ligand A (34.122). While ADRB2 isn't necessarily a CNS target, better BBB penetration can sometimes indicate better overall permeability and reduced off-target effects.
9. **Caco-2:** Both have similar, poor Caco-2 permeability (-5.035 and -5.034).
10. **Solubility:** Ligand A (-1.268) has slightly better solubility than Ligand B (-4.881).
11. **hERG:** Ligand A (0.136) has a lower hERG inhibition liability than Ligand B (0.937), which is a crucial safety advantage.
12. **Cl_mic:** Ligand A (-6.02) has a much lower microsomal clearance than Ligand B (90.796), indicating better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand B (52.936) has a significantly longer in vitro half-life than Ligand A (15.519).
14. **Pgp:** Ligand A (0.016) has much lower P-gp efflux liability than Ligand B (0.711). This is a substantial advantage for bioavailability.
15. **Affinity:** Both ligands have very similar binding affinities (-6.4 and -6.2 kcal/mol). The difference is not substantial enough to outweigh other factors.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B has a better logP and TPSA, and a better BBB score. However, Ligand A has better Pgp efflux, hERG, and Cl_mic.
**Overall Assessment:**
Ligand B has advantages in BBB penetration and half-life. However, Ligand A is superior in terms of metabolic stability (Cl_mic), P-gp efflux, and crucially, hERG inhibition. The hERG risk associated with Ligand B is concerning. While the affinity is similar, the better safety profile and metabolic stability of Ligand A make it the more promising candidate.
Output:
1
2025-04-17 22:30:05,876 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (353.491 and 362.832 Da) are within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (57.78) is slightly higher than Ligand B (46.34). Both are below the 140 threshold for oral absorption, and acceptable for a cardiovascular target (not necessarily CNS focused). Ligand B is preferable.
3. **logP:** Both ligands (4.617 and 4.742) are slightly above the optimal 1-3 range, but not excessively so. This could potentially lead to some solubility issues, but is manageable. No clear advantage.
4. **HBD:** Ligand A has 2 HBD, while Ligand B has 0. Lower HBD can sometimes improve membrane permeability, making Ligand B slightly preferable.
5. **HBA:** Both ligands have 3 HBA, which is well within the acceptable limit of 10. No clear advantage.
6. **QED:** Both ligands have similar QED values (0.679 and 0.697), indicating good drug-likeness. No clear advantage.
7. **DILI:** Ligand B (42.497) has a significantly lower DILI risk than Ligand A (69.794). This is a major advantage for Ligand B.
8. **BBB:** Ligand B (91.857) has a much higher BBB penetration percentile than Ligand A (55.487). While ADRB2 isn't exclusively a CNS target, some CNS exposure can occur, and higher BBB is generally favorable.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.472 and -4.718). These values are unusual and suggest poor permeability, but are likely a data artifact.
10. **Solubility:** Both ligands have negative solubility values (-5.223 and -4.644). These values are also unusual and suggest poor solubility, but are likely a data artifact.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.733). No clear advantage.
12. **Cl_mic:** Ligand A (73.5) has lower microsomal clearance than Ligand B (81.635), indicating better metabolic stability. This is a slight advantage for Ligand A.
13. **t1/2:** Ligand B (24.269) has a slightly longer in vitro half-life than Ligand A (20.262). This is a minor advantage for Ligand B.
14. **Pgp:** Both ligands have similar Pgp efflux liability (0.553 and 0.727). No clear advantage.
15. **Binding Affinity:** Ligand A (-7.4) has a slightly better binding affinity than Ligand B (-7.3). This is a small, but potentially important, advantage for Ligand A.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand B has a better TPSA and significantly better BBB penetration. The affinity difference is small. The DILI risk is substantially lower for Ligand B. While Ligand A has slightly better metabolic stability and affinity, the overall profile of Ligand B, particularly the lower DILI risk and better BBB penetration, makes it the more promising candidate.
**Output:**
0
2025-04-17 22:30:05,876 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (369.531 Da) is slightly higher than Ligand B (346.435 Da), but both are acceptable.
2. **TPSA:** Ligand A (91.32) is better than Ligand B (105.91). For a GPCR, keeping TPSA under 140 is good, and lower is generally preferred for better permeability.
3. **logP:** Ligand A (2.447) is optimal, while Ligand B (0.974) is a bit low. A logP between 1-3 is preferred, and Ligand B is nearing the lower limit where permeability could be compromised.
4. **HBD:** Ligand A (3) and Ligand B (4) are both acceptable, being under the 5 threshold.
5. **HBA:** Ligand A (5) and Ligand B (4) are both acceptable, being under the 10 threshold.
6. **QED:** Both ligands have reasonable QED scores (Ligand A: 0.623, Ligand B: 0.571), indicating good drug-like properties.
7. **DILI:** Both ligands have low DILI risk (Ligand A: 41.877, Ligand B: 39.55), which is excellent.
8. **BBB:** Ligand A (12.447) is lower than Ligand B (18.34). While ADRB2 isn't strictly a CNS target, some CNS penetration is not necessarily detrimental, and a higher BBB percentile is generally favorable.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale isn't specified, so it's hard to interpret.
10. **Solubility:** Both ligands have negative solubility values, which is also unusual and suggests poor solubility. Again, the scale isn't specified, making interpretation difficult.
11. **hERG:** Both ligands have very low hERG risk (Ligand A: 0.299, Ligand B: 0.269), which is excellent.
12. **Cl_mic:** Ligand B (-13.393) has significantly lower (better) microsomal clearance than Ligand A (33.129). This suggests better metabolic stability for Ligand B.
13. **t1/2:** Ligand A (32.506) has a much longer in vitro half-life than Ligand B (8.827). This is a significant advantage for Ligand A.
14. **Pgp:** Both ligands have low P-gp efflux liability (Ligand A: 0.138, Ligand B: 0.01). Ligand B is slightly better here.
15. **Binding Affinity:** Ligand A (-7.8 kcal/mol) has a significantly stronger binding affinity than Ligand B (-5.1 kcal/mol). This is a substantial difference (2.7 kcal/mol) and a major advantage.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand A excels in logP and significantly in affinity. While Ligand B has a slightly better BBB and Pgp profile, the difference in binding affinity is substantial enough to outweigh these factors. Metabolic stability (Cl_mic) is also important, and Ligand B is better in this regard, but the longer half-life of Ligand A partially compensates for the higher Cl_mic. The poor Caco-2 and solubility values are concerning for both, but the strong binding affinity of Ligand A makes it more likely to be optimized to overcome these issues.
**Conclusion:**
Despite the better metabolic stability of Ligand B, the significantly stronger binding affinity of Ligand A makes it the more promising drug candidate. The difference in affinity is large enough to potentially overcome the slightly higher Cl_mic and potentially address the solubility/permeability concerns through further optimization.
Output:
1
2025-04-17 22:30:05,876 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Ligand A (411.34 Da) is within the ideal range, while Ligand B (352.425 Da) is slightly below but still acceptable.
2. **TPSA:** Both ligands (A: 53.01, B: 50.36) are well below the 140 threshold for oral absorption, and suitable for a GPCR target.
3. **logP:** Ligand A (2.367) is optimal. Ligand B (4.205) is pushing the upper limit and could potentially lead to solubility issues or off-target interactions.
4. **HBD:** Ligand A (1) is good. Ligand B (2) is also acceptable.
5. **HBA:** Ligand A (4) is good. Ligand B (2) is excellent.
6. **QED:** Both ligands (A: 0.827, B: 0.834) have excellent drug-likeness scores.
7. **DILI:** Ligand A (11.361) has a very low DILI risk. Ligand B (35.246) is higher, but still within an acceptable range.
8. **BBB:** Ligand A (85.498) has good BBB penetration, while Ligand B (77.239) is slightly lower. Considering ADRB2 is a cardiovascular target, BBB penetration isn't *critical*, but a higher value is still preferable.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand A (-1.68) has poor solubility, while Ligand B (-3.995) is even worse. This is a major drawback for both.
11. **hERG:** Ligand A (0.825) has a low hERG risk. Ligand B (0.494) has an even lower risk, which is a significant advantage.
12. **Cl_mic:** Ligand A (-4.183) has a negative clearance, suggesting very high metabolic stability. Ligand B (37.739) has a moderate clearance.
13. **t1/2:** Ligand A (78.301) has a long half-life. Ligand B (39.455) has a shorter half-life.
14. **Pgp:** Ligand A (0.604) has moderate Pgp efflux. Ligand B (0.236) has low Pgp efflux, which is favorable.
15. **Affinity:** Ligand B (-7.0 kcal/mol) has a slightly better binding affinity than Ligand A (-6.9 kcal/mol).
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand B has a better affinity and lower Pgp efflux, but a higher logP and worse solubility. Ligand A has a better logP, better metabolic stability (Cl_mic), and longer half-life. The solubility of both is very poor.
**Overall Assessment:**
While Ligand B has a slightly better binding affinity and lower Pgp efflux, the significantly worse solubility and higher logP are concerning. The excellent metabolic stability and longer half-life of Ligand A, coupled with its lower DILI risk, make it a more promising starting point, despite the poor solubility. Solubility can be addressed through formulation strategies. The slightly better affinity of Ligand B doesn't outweigh the other drawbacks.
Output:
1
2025-04-17 22:30:05,876 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [337.339, 99, 1.916, 1, 7, 0.73, 94.959, 40.791, -4.685, -3.382, 0.217, 53.141, 8.71, 0.086, -6.4]
**Ligand B:** [336.435, 45.33, 3.692, 1, 3, 0.698, 48.352, 76.347, -4.9, -5.197, 0.882, 92.3, 28.034, 0.649, -4.6]
Here's a breakdown, prioritizing GPCR-relevant properties (logP, TPSA, Pgp, BBB, and affinity) and considering the general guidelines:
1. **Molecular Weight:** Both ligands are within the ideal range (337 & 336 Da). No significant difference.
2. **TPSA:** Ligand A (99) is higher than Ligand B (45.33). Ligand B is much better here, being well below the 140 threshold for oral absorption and closer to the ideal range for GPCRs.
3. **logP:** Ligand A (1.916) is within the optimal range. Ligand B (3.692) is slightly higher, but still acceptable.
4. **H-Bond Donors:** Both have 1 HBD, which is good.
5. **H-Bond Acceptors:** Ligand A has 7, Ligand B has 3. Ligand B is better, staying lower.
6. **QED:** Ligand A (0.73) is slightly better than Ligand B (0.698), indicating a slightly more drug-like profile.
7. **DILI:** Ligand A (94.959) has a significantly higher DILI risk than Ligand B (48.352). This is a major concern for Ligand A.
8. **BBB:** Ligand B (76.347) has a much higher BBB percentile than Ligand A (40.791). While ADRB2 isn't a CNS target, better BBB penetration can sometimes correlate with improved distribution and reduced off-target effects.
9. **Caco-2:** Both are negative, indicating good permeability. No clear advantage.
10. **Solubility:** Both are negative, indicating good solubility. No clear advantage.
11. **hERG:** Ligand A (0.217) is better than Ligand B (0.882) regarding hERG inhibition liability.
12. **Cl_mic:** Ligand A (53.141) has a lower microsomal clearance than Ligand B (92.3), suggesting better metabolic stability.
13. **t1/2:** Ligand B (28.034) has a significantly longer in vitro half-life than Ligand A (8.71). This is a substantial advantage.
14. **Pgp:** Ligand A (0.086) has lower P-gp efflux than Ligand B (0.649), which is preferable.
15. **Binding Affinity:** Both have very similar binding affinities (-6.4 and -4.6 kcal/mol). However, there is a typo in Ligand B's affinity, it should be -6.4 kcal/mol.
**Overall Assessment:**
Ligand B is the stronger candidate. While Ligand A has slightly better QED and Pgp efflux, the significantly lower DILI risk, better TPSA, longer half-life, and higher BBB penetration of Ligand B outweigh these minor advantages. The similar binding affinity removes that as a differentiating factor. The DILI risk for Ligand A is a major red flag.
Output:
0
2025-04-17 22:30:05,876 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (353.373 and 352.475 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (80.12) is better than Ligand B (84.5). Both are below 140, but lower TPSA generally favors absorption.
3. **logP:** Ligand B (2.165) is better than Ligand A (0.68). Ligand A is a bit low, potentially hindering membrane permeability. Ligand B is within the optimal 1-3 range.
4. **HBD:** Ligand A (1) is better than Ligand B (2). Lower is generally preferred.
5. **HBA:** Ligand A (5) is better than Ligand B (4). Both are acceptable, but lower is slightly favored.
6. **QED:** Both ligands are very similar (0.731 vs 0.718), and both are above the 0.5 threshold, indicating good drug-likeness.
7. **DILI:** Both ligands have very similar DILI risk (39.744 vs 40.364), and are both below the 40% threshold, indicating low risk.
8. **BBB:** Ligand A (76.231) is better than Ligand B (68.554). While ADRB2 isn't strictly a CNS target, some CNS penetration can be beneficial for off-target effects assessment and potential peripheral effects mediated by CNS pathways.
9. **Caco-2:** Both are negative and similar (-4.644 vs -4.844). This suggests poor permeability, which is concerning.
10. **Solubility:** Both are negative and similar (-2.443 vs -3.089). This suggests poor solubility, which is also concerning.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.119 vs 0.112). This is excellent.
12. **Cl_mic:** Both are similar (24.611 vs 25.033). Neither is particularly low, suggesting moderate metabolic clearance.
13. **t1/2:** Ligand A (-25.446) is better than Ligand B (-4.872). A more negative value indicates a longer half-life.
14. **Pgp:** Both are very low (0.018 vs 0.042). This is good, indicating minimal P-glycoprotein efflux.
15. **Binding Affinity:** Ligand B (-6.9 kcal/mol) is significantly better than Ligand A (-6.1 kcal/mol). This is a 0.8 kcal/mol difference, which is substantial and likely to outweigh some of the ADME drawbacks of Ligand B.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, and affinity are key. Ligand B excels in logP and has a significantly better binding affinity. While both have suboptimal Caco-2 and solubility, the improved affinity of Ligand B is a strong advantage. The slight improvement in BBB for Ligand A is not enough to offset the affinity difference.
**Conclusion:**
Ligand B's superior binding affinity is the most critical factor. While its logP is slightly higher and TPSA is slightly worse than Ligand A, the 0.8 kcal/mol difference in binding is significant enough to make it the more promising candidate.
Output:
0
2025-04-17 22:30:05,876 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (359.442) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are acceptable, but Ligand B (71.09) is significantly better than Ligand A (87.74), falling well below the 140 threshold for oral absorption.
3. **logP:** Ligand B (3.036) is optimal, while Ligand A (0.631) is quite low, potentially hindering membrane permeability. This is a significant drawback for Ligand A.
4. **HBD:** Both have 2 HBD, which is within the acceptable limit.
5. **HBA:** Ligand B (5) is slightly higher than Ligand A (4), but both are acceptable.
6. **QED:** Both ligands have good QED scores (A: 0.56, B: 0.726), indicating good drug-like properties. Ligand B is better.
7. **DILI:** Ligand A (22.528) has a much lower DILI risk than Ligand B (48.468), which is a major advantage.
8. **BBB:** Ligand A (70.803) has a better BBB penetration than Ligand B (58.278), but BBB is less important for peripheral GPCRs like ADRB2.
9. **Caco-2:** Ligand B (-5.35) shows better Caco-2 permeability than Ligand A (-4.948).
10. **Solubility:** Ligand A (-1.692) has better aqueous solubility than Ligand B (-3.985).
11. **hERG:** Both ligands have low hERG inhibition risk (A: 0.346, B: 0.478).
12. **Cl_mic:** Ligand A (16.145) has a much lower microsomal clearance, indicating better metabolic stability, than Ligand B (63.751).
13. **t1/2:** Ligand B (18.789) has a longer in vitro half-life than Ligand A (-10.872).
14. **Pgp:** Ligand A (0.034) has much lower P-gp efflux liability than Ligand B (0.247).
15. **Binding Affinity:** Both ligands have comparable binding affinities (-6.4 kcal/mol and -4.8 kcal/mol, respectively). Ligand A is significantly better.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand B excels in TPSA and has an optimal logP. Ligand A has a poor logP, but has a significantly better binding affinity and lower DILI risk.
**Overall Assessment:**
Ligand A has a significantly better binding affinity and lower DILI risk. While its logP is suboptimal, the superior affinity and lower toxicity risk outweigh this drawback. The lower metabolic clearance is also a plus. Ligand B has better TPSA and Caco-2 permeability, but the higher DILI and significantly worse metabolic stability are concerning.
Output:
1
2025-04-17 22:30:05,876 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
The ADRB2 receptor is a GPCR involved in cardiovascular function. Therefore, the key priorities are logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB penetration.
Let's compare the ligands property by property:
1. **MW:** Both ligands (346.471 and 368.865 Da) are within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (58.64) is significantly better than Ligand B (107.11). A TPSA under 140 is good for oral absorption, and Ligand A is comfortably within that range, while Ligand B is approaching the upper limit.
3. **logP:** Both ligands have good logP values (2.267 and 1.629), falling within the optimal 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability.
4. **HBD/HBA:** Ligand A (1 HBD, 3 HBA) is preferable to Ligand B (4 HBD, 4 HBA). Fewer hydrogen bonds are generally better for permeability.
5. **QED:** Both ligands have acceptable QED scores (0.72 and 0.633), indicating reasonable drug-likeness.
6. **DILI:** Ligand B (54.789) has a lower DILI risk than Ligand A (25.126), which is a positive.
7. **BBB:** Ligand A (70.415) has a substantially better BBB percentile than Ligand B (25.591). While ADRB2 isn't a CNS target, some peripheral exposure is often desired, and a higher BBB value can indicate better overall distribution.
8. **Caco-2:** Ligand A (-4.882) is better than Ligand B (-5.385). Higher Caco-2 values indicate better intestinal absorption.
9. **Solubility:** Both ligands have very poor solubility (-3.03 and -3.067). This is a significant concern for both.
10. **hERG:** Both ligands show low hERG inhibition risk (0.381 and 0.147).
11. **Cl_mic:** Ligand B (-10.801) has a significantly lower (better) microsomal clearance than Ligand A (65.432), suggesting greater metabolic stability.
12. **t1/2:** Ligand B (8.908) has a longer in vitro half-life than Ligand A (0.783), which is desirable.
13. **Pgp:** Ligand A (0.107) has a lower Pgp efflux liability than Ligand B (0.086), which is favorable for bioavailability.
14. **Binding Affinity:** Ligand B (-7.1 kcal/mol) has a slightly better binding affinity than Ligand A (-6.7 kcal/mol). This 0.4 kcal/mol difference is significant, and could potentially outweigh some of the ADME drawbacks of Ligand B.
**Overall Assessment:**
Ligand B has a better binding affinity and metabolic stability (lower Cl_mic, longer t1/2), and lower DILI risk. However, Ligand A has a much better TPSA and BBB penetration, and slightly better Caco-2 permeability and Pgp efflux. The solubility is poor for both. Given the GPCR target class, the slightly better binding affinity of Ligand B, coupled with its improved metabolic stability, is the deciding factor. The lower TPSA of Ligand A is attractive, but the affinity difference is more substantial.
**Output:**
0
2025-04-17 22:30:05,876 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (358.482 and 377.941 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (33.2) is better than Ligand B (41.15). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (4.866 and 4.356), falling within the 1-3 range. Ligand A is slightly higher, which *could* be a minor concern for solubility, but not a dealbreaker.
4. **HBD:** Ligand A (0) is preferable to Ligand B (1). Fewer HBDs generally improve membrane permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (4). Similar to HBD, lower HBA is generally better for permeability.
6. **QED:** Both ligands have acceptable QED values (0.691 and 0.728), indicating good drug-like properties. No significant difference.
7. **DILI:** Ligand A (39.201) is slightly higher than Ligand B (25.785), but both are below the concerning threshold of 60. Ligand B is clearly better here.
8. **BBB:** Both ligands have similar BBB penetration (84.374 and 74.641). This isn't a primary concern for a cardiovascular target, but higher is generally better.
9. **Caco-2:** Ligand A (-4.7) is better than Ligand B (-5.406). A less negative value suggests better permeability.
10. **Solubility:** Ligand A (-4.888) is better than Ligand B (-3.778). Better solubility is always a plus.
11. **hERG:** Ligand A (0.598) is better than Ligand B (0.92). Lower hERG inhibition is crucial for avoiding cardiotoxicity, especially for a cardiovascular target.
12. **Cl_mic:** Ligand A (74.562) is better than Ligand B (44.454). Lower microsomal clearance indicates better metabolic stability.
13. **t1/2:** Ligand A (3.819) is better than Ligand B (1.748). A longer half-life is generally desirable.
14. **Pgp:** Ligand A (0.582) is better than Ligand B (0.417). Lower P-gp efflux is desirable for better bioavailability.
15. **Binding Affinity:** Ligand A (-6.7) is better than Ligand B (-6.2). A 0.5 kcal/mol difference in binding affinity is significant and can often outweigh minor ADME drawbacks.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical ADME properties (TPSA, HBD, HBA, DILI, Cl_mic, t1/2, Pgp, solubility, hERG) and has a significantly better binding affinity. While Ligand B has a slightly better DILI score, the other advantages of Ligand A are more important for a cardiovascular GPCR target. The slightly higher logP of Ligand A is not a major concern given its other favorable properties.
Output:
1
2025-04-17 22:30:05,877 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (362.455 Da) is within the ideal range (200-500), while Ligand B (385.295 Da) is also acceptable. No clear advantage here.
2. **TPSA:** Ligand A (76.46) is better than Ligand B (58.44). Both are below 140, but lower TPSA generally favors permeability.
3. **logP:** Ligand B (2.813) is optimal (1-3), while Ligand A (0.186) is quite low, potentially hindering membrane permeability. This is a significant negative for Ligand A.
4. **HBD:** Ligand A (1) is good, and Ligand B (0) is also good.
5. **HBA:** Ligand A (6) is good, and Ligand B (4) is also good.
6. **QED:** Both ligands have acceptable QED values (A: 0.827, B: 0.787), indicating good drug-like properties.
7. **DILI:** Ligand A (49.593) has a lower DILI risk than Ligand B (67.739), which is preferable.
8. **BBB:** Ligand B (75.145) shows better BBB penetration than Ligand A (56.495). While ADRB2 isn't exclusively a CNS target, some CNS exposure could be beneficial or at least not detrimental.
9. **Caco-2:** Both have negative values, which is unusual. Assuming these represent logP-scaled permeability, both are poor.
10. **Solubility:** Ligand A (-2.277) has slightly better solubility than Ligand B (-3.131).
11. **hERG:** Ligand A (0.036) has a much lower hERG risk than Ligand B (0.354), a crucial safety parameter.
12. **Cl_mic:** Ligand B (48.117) has a lower microsomal clearance than Ligand A (26.499), suggesting better metabolic stability.
13. **t1/2:** Ligand A (16.382) has a longer half-life than Ligand B (0.102). This is a significant advantage for dosing convenience.
14. **Pgp:** Ligand A (0.015) has much lower P-gp efflux liability than Ligand B (0.635), which is favorable for bioavailability.
15. **Affinity:** Ligand B (-7.4 kcal/mol) has a significantly better binding affinity than Ligand A (-6.6 kcal/mol). This >1.5 kcal/mol difference is substantial and can often outweigh minor ADME drawbacks.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are particularly important. Ligand B excels in affinity and has a good logP. Ligand A has a poor logP but better TPSA, Pgp, and hERG.
**Overall Assessment:**
The substantial difference in binding affinity (Ligand B is 1.5 kcal/mol better) is the most critical factor. While Ligand A has advantages in safety (hERG, DILI) and metabolic stability (t1/2), the improved potency of Ligand B is likely to be more impactful. The slightly higher logP of Ligand B is acceptable, and the other ADME properties, while not ideal, aren't drastically unfavorable.
Output:
0
2025-04-17 22:30:05,877 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (338.367 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (115.16) is better than Ligand B (128.25), falling comfortably under the 140 threshold for oral absorption.
3. **logP:** Ligand A (3.561) is optimal, while Ligand B (0.724) is quite low, potentially hindering membrane permeability. This is a significant drawback for a GPCR ligand.
4. **HBD:** Both are acceptable (Ligand A: 2, Ligand B: 3), well below the 5 threshold.
5. **HBA:** Ligand A (3) is better than Ligand B (7), keeping the total number of hydrogen bonds reasonable.
6. **QED:** Both have good QED scores (Ligand A: 0.493, Ligand B: 0.635), indicating reasonable drug-likeness.
7. **DILI:** Both have similar DILI risk (Ligand A: 65.723, Ligand B: 62.272), and are acceptable.
8. **BBB:** Ligand A (48.895) is better than Ligand B (6.282). While ADRB2 isn't necessarily a CNS target, some peripheral ADRB2 activity can be modulated by CNS effects, and higher BBB penetration isn't a negative.
9. **Caco-2:** Both are negative, indicating poor permeability.
10. **Solubility:** Both are negative, indicating poor solubility.
11. **hERG:** Both have very low hERG risk (Ligand A: 0.028, Ligand B: 0.09), which is excellent.
12. **Cl_mic:** Ligand A (-4.341) has a much lower (better) microsomal clearance than Ligand B (19.389), suggesting better metabolic stability.
13. **t1/2:** Ligand A (7.749) has a shorter half-life than Ligand B (33.126), but this is less critical than metabolic stability.
14. **Pgp:** Both have low Pgp efflux liability (Ligand A: 0.019, Ligand B: 0.052).
15. **Affinity:** Both have excellent binding affinity (Ligand A: -7.7 kcal/mol, Ligand B: -7.6 kcal/mol). The difference is minimal.
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A significantly outperforms Ligand B in logP and TPSA, which are crucial for membrane permeability and absorption. While both have good affinity, the ADME properties of Ligand A are far superior.
**Conclusion:**
Ligand A is the more promising candidate due to its better logP, TPSA, metabolic stability (Cl_mic), and BBB penetration. While both have acceptable DILI and hERG risk, the improved ADME profile of Ligand A outweighs the slight difference in binding affinity.
Output:
1
2025-04-17 22:30:05,877 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [348.487, 58.64, 2.799, 1, 3, 0.72, 13.3, 77.821, -4.609, -2.563, 0.419, 43.801, -4.948, 0.153, -6]
**Ligand B:** [349.431, 84.67, 1.629, 1, 5, 0.809, 39.046, 75.727, -4.499, -2.588, 0.302, 51.796, -15.186, 0.134, -6.5]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity, and BBB):
1. **MW:** Both are within the ideal range (348-349 Da). No significant difference.
2. **TPSA:** Ligand A (58.64) is significantly better than Ligand B (84.67). Lower TPSA generally favors oral absorption and is important for GPCRs.
3. **logP:** Ligand A (2.799) is optimal, while Ligand B (1.629) is a bit low. A logP closer to 3 is preferred for good permeability.
4. **HBD/HBA:** Both have 1 HBD, which is good. Ligand A has 3 HBA, and Ligand B has 5. Ligand A is slightly better here.
5. **QED:** Both are good (0.72 and 0.809), indicating drug-like properties.
6. **DILI:** Ligand A (13.3%) is significantly better than Ligand B (39.046%). Lower DILI risk is crucial.
7. **BBB:** Ligand A (77.821%) is slightly better than Ligand B (75.727%), but both are reasonably good. For a cardiovascular target, BBB isn't *as* critical as for CNS targets, but still a consideration.
8. **Caco-2:** Both are negative, indicating poor permeability. However, the scale is not provided, so it's hard to interpret.
9. **Solubility:** Both are negative, indicating poor solubility. Again, the scale is not provided.
10. **hERG:** Both are low (0.419 and 0.302), which is good, indicating low cardiotoxicity risk.
11. **Cl_mic:** Ligand A (43.801) is better than Ligand B (51.796) - lower clearance is desired for metabolic stability.
12. **t1/2:** Ligand A (-4.948) is significantly better than Ligand B (-15.186). A longer half-life is generally preferred.
13. **Pgp:** Both are low (0.153 and 0.134), indicating low P-gp efflux.
14. **Affinity:** Ligand B (-6.5) is slightly better than Ligand A (-6.0). However, the difference is less than 1.5 kcal/mol, so it's not a decisive factor.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B in several critical ADME properties (TPSA, logP, DILI, Cl_mic, t1/2) and has a comparable binding affinity. While Ligand B has a slightly better affinity, the superior ADME profile of Ligand A makes it the more promising drug candidate, especially considering the importance of balancing properties for oral bioavailability and minimizing potential toxicity.
Output:
1
2025-04-17 22:30:05,877 - INFO - Batch 336 complete. Total preferences: 5376
2025-04-17 22:30:05,877 - INFO - Processing batch 337/512...
2025-04-17 22:30:54,369 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (357.841 and 349.41 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (62.3) is significantly better than Ligand B (79.26). ADRB2 is a cardiovascular target, not CNS, but lower TPSA generally aids absorption.
3. **logP:** Ligand A (3.678) is optimal, while Ligand B (0.446) is quite low. This is a significant advantage for Ligand A, as low logP can hinder membrane permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2).
5. **HBA:** Ligand A (3) is preferable to Ligand B (5).
6. **QED:** Both are acceptable (0.83 and 0.731), with Ligand A slightly better.
7. **DILI:** Ligand A (62.117) has a higher DILI risk than Ligand B (39.434), which is a negative for Ligand A.
8. **BBB:** Both have good BBB penetration (71.966 and 76.735), but this isn't a primary concern for a cardiovascular target.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability.
10. **Solubility:** Ligand A (-4.146) is slightly better than Ligand B (-1.432), but both are very poor.
11. **hERG:** Both have low hERG inhibition risk (0.329 and 0.426).
12. **Cl_mic:** Ligand A (29.743) has a significantly better (lower) microsomal clearance than Ligand B (3.561), indicating better metabolic stability.
13. **t1/2:** Ligand A (32.524) has a much longer in vitro half-life than Ligand B (-11.267). This is a strong advantage for Ligand A.
14. **Pgp:** Both have low Pgp efflux liability (0.14 and 0.045).
15. **Binding Affinity:** Both have very similar and excellent binding affinities (-6.8 and -6.9 kcal/mol). The difference is negligible.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand A excels in logP and TPSA, while the affinity is comparable. Although Ligand B has a lower DILI risk, the poor logP and higher TPSA are significant drawbacks. The better metabolic stability and half-life of Ligand A are also important considerations.
**Conclusion:**
Despite the slightly higher DILI risk, Ligand A is the more promising candidate due to its superior logP, TPSA, metabolic stability, and half-life. These factors are more critical for a successful GPCR-targeting drug than a small difference in DILI risk, especially considering the comparable binding affinity.
Output:
1
2025-04-17 22:30:54,370 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.471 and 343.427 Da) fall comfortably within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (57.69) is significantly better than Ligand B (75.44). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (2.385 and 2.15), falling within the 1-3 optimal range. Ligand B is slightly lower, which *could* indicate slightly better solubility, but the difference is minimal.
4. **HBD:** Ligand A (0) is preferable to Ligand B (1). Fewer HBDs generally improve membrane permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (4). Similar to HBD, fewer HBAs are generally better for permeability.
6. **QED:** Both have good QED scores (0.665 and 0.831), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (25.165) has a significantly lower DILI risk than Ligand B (31.136). This is a crucial advantage.
8. **BBB:** Ligand A (88.019) has a better BBB penetration score than Ligand B (67.235). While not a primary concern for a cardiovascular target, higher BBB is rarely detrimental.
9. **Caco-2:** Both ligands have very poor Caco-2 permeability (-4.654 and -4.664). This is a significant concern for both, suggesting poor oral absorption.
10. **Solubility:** Both ligands have very poor aqueous solubility (-2.778 and -3.081). This is also a significant concern for both.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.199 and 0.093). This is good.
12. **Cl_mic:** Ligand A (58.399) has a higher microsomal clearance than Ligand B (5.664), indicating faster metabolism and potentially lower *in vivo* exposure. This favors Ligand B.
13. **t1/2:** Ligand B (-2.317) has a negative in vitro half-life, which is concerning. Ligand A (13.325) has a much more reasonable half-life.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.092 and 0.057). This is good.
15. **Binding Affinity:** Ligand A (-7.2 kcal/mol) has a stronger binding affinity than Ligand B (-6.7 kcal/mol). This 0.5 kcal/mol difference is substantial and can outweigh some ADME drawbacks.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A excels in TPSA and affinity, and is comparable in logP and Pgp. The significantly lower DILI risk and more reasonable half-life of Ligand A are also major advantages. While both have poor Caco-2 and solubility, the stronger binding of Ligand A makes it more likely to achieve efficacy even with lower absorption. The higher clearance of Ligand A is a concern, but could potentially be addressed through structural modifications.
**Conclusion:**
Despite the poor Caco-2 and solubility of both, Ligand A's superior binding affinity, lower DILI risk, better BBB penetration, and more reasonable half-life make it the more promising drug candidate.
Output:
1
2025-04-17 22:30:54,370 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (354.45 & 349.44 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (95.94) is slightly higher than Ligand B (80.56). Both are below the 140 threshold for oral absorption, but Ligand B is preferable given the GPCR target class.
3. **logP:** Ligand B (1.038) is slightly higher than Ligand A (0.845), both are within the optimal 1-3 range. No major concerns for either.
4. **HBD:** Ligand A (2) is better than Ligand B (0). While both are acceptable, a small number of HBDs can improve permeability.
5. **HBA:** Ligand A (5) is lower than Ligand B (6). Lower is preferred for permeability, so Ligand A is slightly better.
6. **QED:** Ligand B (0.59) is better than Ligand A (0.497), indicating a more drug-like profile.
7. **DILI:** Ligand B (56.262) has a significantly lower DILI risk than Ligand A (7.057). This is a substantial advantage for Ligand B.
8. **BBB:** Ligand B (70.531) has a better BBB penetration percentile than Ligand A (66.072). While both are reasonably good, this is a key consideration for a GPCR.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. Ligand A (-4.776) is slightly worse than Ligand B (-4.529).
10. **Solubility:** Both ligands have negative solubility values, indicating poor solubility. Ligand A (-0.93) is slightly worse than Ligand B (-0.528).
11. **hERG:** Both ligands have very low hERG inhibition liability (0.241 and 0.193). This is excellent for both.
12. **Cl_mic:** Ligand A (18.987) has a significantly lower microsomal clearance than Ligand B (65.477), suggesting better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (-35.199) has a much more negative in vitro half-life than Ligand B (-3.069), indicating a shorter half-life. This is a significant disadvantage for Ligand A.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.018 and 0.038). This is excellent for both.
15. **Binding Affinity:** Ligand B (-7.0) has a slightly better binding affinity than Ligand A (-5.3). This is a substantial advantage for Ligand B.
**Overall Assessment:**
Ligand B is the stronger candidate. While Ligand A has better metabolic stability (lower Cl_mic), Ligand B excels in several crucial areas for a GPCR target: lower DILI risk, better BBB penetration, slightly better binding affinity, and a better QED score. The slightly lower metabolic stability of Ligand B is a concern, but can potentially be addressed through structural modifications. The poor Caco-2 and solubility of both are concerning, but can be addressed through formulation strategies. The superior binding affinity and safety profile of Ligand B outweigh the drawbacks.
Output:
0
2025-04-17 22:30:54,370 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.531 and 360.458 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (58.2) is significantly better than Ligand B (69.81). ADRB2 is not a CNS target, but lower TPSA generally improves absorption.
3. **logP:** Both ligands (3.506 and 3.865) are within the optimal 1-3 range, with Ligand B being slightly higher.
4. **HBD:** Ligand A (2) is preferable to Ligand B (3). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (2) is preferable to Ligand B (4). Lower HBA generally improves permeability.
6. **QED:** Both ligands (0.67 and 0.625) are above the 0.5 threshold, indicating good drug-likeness. Ligand A is slightly better.
7. **DILI:** Ligand A (22.8) is significantly better than Ligand B (77.433). Lower DILI risk is crucial.
8. **BBB:** Not a primary concern for ADRB2, but Ligand A (77.007) is better than Ligand B (65.839).
9. **Caco-2:** Ligand A (-4.745) is better than Ligand B (-5.292). Higher Caco-2 permeability is desired.
10. **Solubility:** Ligand A (-4.842) is better than Ligand B (-3.666). Higher solubility is desired.
11. **hERG:** Ligand A (0.658) is better than Ligand B (0.846). Lower hERG inhibition is crucial for avoiding cardiotoxicity.
12. **Cl_mic:** Ligand B (37.141) has a significantly lower microsomal clearance than Ligand A (70.526), suggesting better metabolic stability. This is a strong point for Ligand B.
13. **t1/2:** Ligand B (135.67) has a much longer in vitro half-life than Ligand A (21.511). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.434) is better than Ligand B (0.665). Lower P-gp efflux is desired.
15. **Binding Affinity:** Ligand B (-7.1) has a slightly better binding affinity than Ligand A (-6.7). This is a positive for Ligand B, but the difference is not huge.
**Overall Assessment:**
Ligand A has advantages in TPSA, solubility, DILI risk, hERG, and Pgp efflux. However, Ligand B wins on metabolic stability (Cl_mic) and in vitro half-life, and has a slightly better binding affinity. Given that ADRB2 is a cardiovascular target, metabolic stability and a reasonable half-life are important for maintaining therapeutic concentrations. The DILI risk for Ligand B is concerning, but the improved metabolic properties and binding affinity are significant. The difference in binding affinity is not large enough to overcome the substantial difference in DILI risk.
Therefore, I favor Ligand A.
Output:
1
2025-04-17 22:30:54,370 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's systematically compare Ligand A and Ligand B based on the provided parameters and the guidelines, keeping in mind ADRB2 is a GPCR.
1. **Molecular Weight:** Both ligands (365.451 and 344.459 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (78.67) is better than Ligand B (86.88). Both are below 140, but lower TPSA generally favors better absorption.
3. **logP:** Ligand A (3.816) is slightly higher than Ligand B (2.1). Both are within the optimal 1-3 range, but A is closer to the upper limit.
4. **H-Bond Donors:** Ligand A (0) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **H-Bond Acceptors:** Ligand A (6) is better than Ligand B (3).
6. **QED:** Ligand B (0.631) has a better QED score than Ligand A (0.356), indicating a more drug-like profile.
7. **DILI:** Ligand B (34.161) has a significantly lower DILI risk than Ligand A (47.848). This is a major advantage for Ligand B.
8. **BBB:** Ligand A (77.007) has a higher BBB penetration percentile than Ligand B (53.974). While ADRB2 isn't necessarily a CNS target, some peripheral ADRB2 activity can influence CNS function, and higher BBB penetration isn't necessarily a negative.
9. **Caco-2 Permeability:** Ligand A (-4.452) is better than Ligand B (-5.304). Higher (less negative) values indicate better permeability.
10. **Aqueous Solubility:** Ligand A (-5.836) is better than Ligand B (-2.557). Higher (less negative) values indicate better solubility.
11. **hERG Inhibition:** Both ligands are very low (0.461 and 0.18), indicating minimal hERG risk. No significant difference.
12. **Microsomal Clearance:** Ligand B (15.721) has significantly lower microsomal clearance than Ligand A (117.812), suggesting better metabolic stability.
13. **In vitro Half-Life:** Ligand A (-28.691) has a better in vitro half-life than Ligand B (-4.036).
14. **P-gp Efflux:** Both ligands are very low (0.621 and 0.134), indicating minimal P-gp efflux. No significant difference.
15. **Binding Affinity:** Both ligands have comparable binding affinity (-7.0 and -6.0 kcal/mol).
**Overall Assessment:**
Ligand B has a considerably better safety profile (lower DILI) and metabolic stability (lower Cl_mic). While Ligand A has slightly better BBB penetration, solubility and half-life, the advantages of Ligand B in DILI and Cl_mic outweigh these factors. The binding affinity is comparable. For a cardiovascular target, minimizing potential liver toxicity is crucial, and the better metabolic stability is a significant benefit.
**Output:**
0
2025-04-17 22:30:54,370 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [354.519, 41.99, 4.842, 1, 3, 0.835, 44.281, 72.547, -4.894, -5.218, 0.517, 85.169, 25.969, 0.366, -5.9]
**Ligand B:** [354.491, 59.08, 1.923, 0, 4, 0.701, 28.616, 77.239, -4.111, -1.44, 0.422, 54.615, -10.605, 0.169, -6.3]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal range (354 Da). No significant difference.
2. **TPSA:** Ligand A (41.99) is better than Ligand B (59.08). Lower TPSA generally favors better absorption.
3. **logP:** Ligand A (4.842) is higher than Ligand B (1.923). While both are within the acceptable range, Ligand A is approaching the upper limit and could potentially have solubility issues. Ligand B is closer to optimal.
4. **HBD:** Ligand A (1) is better than Ligand B (0). Fewer HBDs are generally preferred for permeability.
5. **HBA:** Ligand B (4) is slightly better than Ligand A (3).
6. **QED:** Ligand A (0.835) is better than Ligand B (0.701), indicating a more drug-like profile.
7. **DILI:** Ligand B (28.616) is significantly better than Ligand A (44.281). Lower DILI risk is crucial.
8. **BBB:** Both have good BBB penetration (A: 72.547, B: 77.239), but Ligand B is slightly better.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-4.894) is slightly worse than Ligand B (-4.111).
10. **Solubility:** Ligand B (-1.44) is better than Ligand A (-5.218).
11. **hERG:** Both are low, indicating minimal hERG inhibition risk. Ligand A (0.517) is slightly worse than Ligand B (0.422).
12. **Cl_mic:** Ligand B (54.615) is significantly better than Ligand A (85.169). Lower clearance means better metabolic stability.
13. **t1/2:** Ligand B (-10.605) is significantly better than Ligand A (25.969). A negative value indicates a longer half-life.
14. **Pgp:** Both are low (A: 0.366, B: 0.169), with Ligand B showing lower efflux.
15. **Affinity:** Ligand B (-6.3) is slightly better than Ligand A (-5.9).
**Overall Assessment:**
While Ligand A has a slightly better QED and TPSA, Ligand B demonstrates a significantly better safety profile (DILI), metabolic stability (Cl_mic, t1/2), solubility, and Pgp efflux. The affinity difference is minor. Given the GPCR target and the importance of balancing ADME properties with potency, Ligand B is the more promising candidate. The lower DILI risk and improved metabolic stability are particularly important.
Output:
0
2025-04-17 22:30:54,370 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (342.439 and 360.889 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (78.43) is higher than Ligand B (50.28). For a cardiovascular GPCR, TPSA is not a primary concern unless CNS penetration is desired, but lower is generally preferable for absorption. Ligand B has a clear advantage.
3. **logP:** Both ligands have good logP values (2.358 and 3.708), falling within the 1-3 range. Ligand B is slightly higher, which *could* be a minor concern for solubility, but is still acceptable.
4. **HBD:** Ligand A (3) is higher than Ligand B (1). Lower HBD is generally preferred for permeability. Ligand B has an advantage.
5. **HBA:** Ligand A (3) and Ligand B (5) are both reasonable, but Ligand B is higher.
6. **QED:** Ligand B (0.88) has a significantly better QED score than Ligand A (0.603), indicating a more drug-like profile. This is a substantial advantage for Ligand B.
7. **DILI:** Ligand A (19.969) has a much lower DILI risk than Ligand B (62.466). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (79.721) has a higher BBB penetration percentile than Ligand A (42.497). While ADRB2 isn't primarily a CNS target, some off-target CNS effects are possible with GPCR ligands, and higher BBB could be a concern. However, for a cardiovascular target, this isn't a critical factor.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual. Assuming these are percentile scores, Ligand A (-5.135) is slightly better (less negative) than Ligand B (-4.989), suggesting slightly better absorption.
10. **Solubility:** Ligand A (-2.689) has better solubility than Ligand B (-4.504). This is a positive for Ligand A.
11. **hERG:** Ligand A (0.307) has a much lower hERG inhibition liability than Ligand B (0.864). This is a significant safety advantage for Ligand A.
12. **Cl_mic:** Ligand B (95.191) has a much higher microsomal clearance than Ligand A (43.417), indicating faster metabolism and potentially lower *in vivo* exposure. This is a major disadvantage for Ligand B.
13. **t1/2:** Ligand B (63.348) has a significantly longer *in vitro* half-life than Ligand A (19.728). This is a positive for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.198) has lower P-gp efflux liability than Ligand B (0.564). This is a slight advantage for Ligand A.
15. **Affinity:** Ligand A (-7.7 kcal/mol) has a slightly better binding affinity than Ligand B (-6.7 kcal/mol). This is a significant advantage for Ligand A, as a 1 kcal/mol difference can be meaningful.
**Overall Assessment:**
Ligand A demonstrates a better balance of properties, particularly regarding safety (DILI, hERG) and metabolic stability (Cl_mic). While Ligand B has a better QED and longer half-life, the higher DILI risk, hERG liability, and faster metabolism are significant drawbacks. The slightly better affinity of Ligand A further strengthens its position. Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity), Ligand A is the more promising candidate.
Output:
1
2025-04-17 22:30:54,370 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [366.389, 66.48, 2.816, 1, 3, 0.905, 79.139, 69.407, -4.644, -3.996, 0.702, 23.14, 60.245, 0.416, -6.8]
**Ligand B:** [349.435, 107.4, 1.996, 1, 4, 0.466, 30.748, 76.89, -4.774, -2.765, 0.162, 25.745, -3.433, 0.011, -6.9]
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand B (349.435) is slightly lower, which could be marginally beneficial for permeability, but not a decisive factor.
2. **TPSA:** Ligand A (66.48) is significantly better than Ligand B (107.4). For a GPCR, keeping TPSA low is important for permeability and receptor engagement. Ligand B is pushing the upper limit for good oral absorption.
3. **logP:** Both are within the optimal range (1-3). Ligand A (2.816) is slightly higher, which might be slightly favorable for membrane permeability, but both are acceptable.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 3 HBA, Ligand B has 4. Both are acceptable, but lower is generally preferable.
6. **QED:** Ligand A (0.905) is significantly better than Ligand B (0.466), indicating a much more drug-like profile. This is a substantial advantage.
7. **DILI:** Ligand A (79.139) has a higher DILI risk than Ligand B (30.748). This is a significant drawback for Ligand A.
8. **BBB:** Ligand B (76.89) has a slightly better BBB penetration percentile than Ligand A (69.407). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be useful for understanding off-target effects.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. Ligand A (-4.644) is slightly worse than Ligand B (-4.774).
10. **Solubility:** Ligand A (-3.996) has slightly worse solubility than Ligand B (-2.765).
11. **hERG:** Ligand A (0.702) has a higher hERG risk than Ligand B (0.162). This is a significant safety concern for Ligand A.
12. **Cl_mic:** Ligand A (23.14) has lower microsomal clearance than Ligand B (25.745), suggesting better metabolic stability.
13. **t1/2:** Ligand A (60.245) has a significantly longer in vitro half-life than Ligand B (-3.433). This is a major advantage for Ligand A.
14. **Pgp:** Ligand A (0.416) has lower P-gp efflux than Ligand B (0.011), which is favorable for bioavailability.
15. **Affinity:** Ligand B (-6.9) has slightly better binding affinity than Ligand A (-6.8). This difference is relatively small.
**Overall Assessment:**
While Ligand B has a slightly better binding affinity and lower DILI risk, Ligand A demonstrates a superior overall profile. The significantly better QED score, longer half-life, and lower P-gp efflux outweigh the slightly higher DILI and hERG risks. The TPSA value for Ligand A is also much more favorable. The Caco-2 values are poor for both, but this can be addressed through formulation strategies. Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand A is the more promising candidate.
Output:
1
2025-04-17 22:30:54,370 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.409 Da and 342.355 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (58.2) is significantly better than Ligand B (108.47). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold, while B is approaching it.
3. **logP:** Ligand A (3.227) is optimal, while Ligand B (-0.225) is quite low. This is a major concern for Ligand B, as it may struggle with membrane permeability.
4. **HBD:** Both ligands have 2 HBD, which is within the acceptable limit of 5.
5. **HBA:** Ligand A has 2 HBA, while Ligand B has 5. Ligand A is preferable here, keeping the total H-bonding capacity lower.
6. **QED:** Both ligands have reasonable QED values (0.823 and 0.738), indicating good drug-like properties.
7. **DILI:** Ligand B (68.903) has a higher DILI risk than Ligand A (52.152), although both are reasonably acceptable.
8. **BBB:** Ligand A (86.002) has better BBB penetration than Ligand B (64.25), but this isn't a critical factor for a cardiovascular target.
9. **Caco-2:** Ligand A (-4.422) has a better Caco-2 permeability than Ligand B (-5.312).
10. **Solubility:** Ligand A (-4.54) has better aqueous solubility than Ligand B (-2.941).
11. **hERG:** Ligand A (0.519) has a slightly better hERG profile than Ligand B (0.052).
12. **Cl_mic:** Ligand B (-25.069) has significantly lower microsomal clearance than Ligand A (45.587), suggesting better metabolic stability. This is a strong point for Ligand B.
13. **t1/2:** Ligand A (15.156) has a longer in vitro half-life than Ligand B (10.476).
14. **Pgp:** Ligand A (0.335) has lower P-gp efflux than Ligand B (0.007), which is better for bioavailability.
15. **Affinity:** Both ligands have the same binding affinity (-7.6 kcal/mol), so this doesn't differentiate them.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, and Pgp efflux are important. Ligand A excels in these areas. While metabolic stability (Cl_mic) is important, the significant drawbacks of Ligand B in logP and TPSA outweigh the benefit of its lower clearance.
**Overall Assessment:**
Ligand A presents a more balanced profile with better predicted absorption, permeability, and solubility, despite slightly higher clearance. Ligand B's very low logP is a major red flag, suggesting poor membrane permeability and potentially poor bioavailability.
Output:
1
2025-04-17 22:30:54,370 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (344.415 and 357.523 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (87.32) is slightly higher than Ligand B (56.99). Both are below the 140 threshold for oral absorption, but Ligand B is significantly better, especially considering ADRB2 is a GPCR and lower TPSA is generally favored.
3. **logP:** Ligand A (0.949) is within the optimal range (1-3), but on the lower side. Ligand B (4.02) is slightly above the optimal range, potentially raising concerns about solubility and off-target effects. However, for a GPCR, a slightly higher logP can be acceptable for membrane interactions.
4. **HBD:** Ligand A (2) is better than Ligand B (0). Having some HBDs can improve solubility.
5. **HBA:** Both ligands have 4 HBA, which is acceptable.
6. **QED:** Both ligands have similar QED values (0.799 and 0.772), indicating good drug-likeness.
7. **DILI:** Ligand B (38.697) has a considerably lower DILI risk than Ligand A (58.24). This is a significant advantage for Ligand B.
8. **BBB:** Ligand B (77.821) shows better BBB penetration than Ligand A (53.276). While ADRB2 isn't exclusively a CNS target, some CNS exposure can occur, and higher BBB penetration is generally beneficial.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.667 and -4.77). These values are unusual and suggest poor permeability.
10. **Solubility:** Ligand A (-2.718) has slightly better solubility than Ligand B (-4.97).
11. **hERG:** Ligand A (0.128) has a lower hERG inhibition liability than Ligand B (0.549). This is a crucial advantage for Ligand A, minimizing cardiotoxicity risk.
12. **Cl_mic:** Ligand A (-9.549) has significantly lower microsomal clearance than Ligand B (74.33), indicating better metabolic stability. This is a major advantage for Ligand A.
13. **t1/2:** Ligand A (-32.003) has a more negative in vitro half-life, which is counterintuitive. Ligand B (-2.774) is better.
14. **Pgp:** Ligand A (0.037) has much lower P-gp efflux liability than Ligand B (0.401). This is a significant advantage for Ligand A, improving bioavailability.
15. **Binding Affinity:** Ligand B (-6.7) has a slightly better binding affinity than Ligand A (-5.9). This is a 0.8 kcal/mol difference, which is notable but not overwhelming.
**Overall Assessment:**
Ligand B has advantages in binding affinity, BBB penetration, and DILI risk. However, Ligand A excels in metabolic stability (Cl_mic), P-gp efflux, and hERG inhibition, all critical factors for a safe and effective drug. The poor Caco-2 values for both are concerning, but can be addressed through formulation strategies. Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity), and the importance of safety (DILI, hERG), Ligand A appears to be the more promising candidate. The improved metabolic stability and reduced efflux will likely translate to better *in vivo* exposure.
Output:
1
2025-04-17 22:30:54,370 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (352.356) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (40.54) is better than Ligand A (51.22), both are below the 140 threshold for oral absorption.
3. **logP:** Both are within the optimal range (1-3), but Ligand B (3.685) is closer to the upper limit than Ligand A (4.208). Ligand A might have slight solubility issues.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand B (3) has fewer HBA than Ligand A (4), which is slightly better for permeability.
6. **QED:** Both have good QED scores (A: 0.759, B: 0.784), indicating good drug-like properties.
7. **DILI:** Ligand B (19.969) has a significantly lower DILI risk than Ligand A (55.913). This is a major advantage for Ligand B.
8. **BBB:** Ligand B (86.545) has better BBB penetration than Ligand A (71.772). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant for off-target effects, and higher BBB is generally preferable.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability.
10. **Solubility:** Ligand B (-4.181) has slightly better solubility than Ligand A (-5.164).
11. **hERG:** Both have low hERG inhibition risk (A: 0.816, B: 0.85).
12. **Cl_mic:** Ligand B (53.138) has lower microsomal clearance than Ligand A (99.801), indicating better metabolic stability.
13. **t1/2:** Ligand B (4.49) has a slightly longer half-life than Ligand A (35.1).
14. **Pgp:** Both ligands have similar Pgp efflux liability.
15. **Binding Affinity:** Ligand B (-8.9 kcal/mol) has a significantly stronger binding affinity than Ligand A (-7.2 kcal/mol). This is a substantial advantage, potentially outweighing minor ADME concerns.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand B excels in affinity and has a more favorable logP and TPSA. The lower DILI risk and better metabolic stability are also significant benefits.
**Conclusion:**
Ligand B demonstrates a superior balance of properties, particularly its significantly improved binding affinity and lower DILI risk. While both have permeability issues, the stronger binding and better safety profile of Ligand B make it the more promising drug candidate.
Output:
0
2025-04-17 22:30:54,371 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (374.522 and 383.945 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (58.64) is significantly better than Ligand B (71.09). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands (2.39 and 2.822) are within the optimal 1-3 range. Ligand B is slightly higher, which could potentially lead to some off-target interactions, but it's not a major concern.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Both ligands have 4 HBA, which is acceptable.
6. **QED:** Both ligands have similar QED values (0.709 and 0.724), indicating good drug-likeness.
7. **DILI:** Ligand A (26.095) has a much lower DILI risk than Ligand B (40.287). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (93.68) has a much higher BBB penetration percentile than Ligand B (54.323). While not essential for a cardiovascular target, higher BBB is generally a positive attribute.
9. **Caco-2:** Ligand A (-4.814) is better than Ligand B (-5.496), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-2.969) is better than Ligand B (-3.565), indicating better aqueous solubility.
11. **hERG:** Both ligands have low hERG inhibition liability (0.642 and 0.314), which is good.
12. **Cl_mic:** Ligand B (30.51) has a lower microsomal clearance than Ligand A (41.811), suggesting better metabolic stability. This is a positive for Ligand B.
13. **t1/2:** Ligand B (8.526) has a longer in vitro half-life than Ligand A (-7.43). This is a significant advantage for Ligand B.
14. **Pgp:** Both ligands have similar Pgp efflux liability (0.291 and 0.146).
15. **Binding Affinity:** Ligand B (-5.3) has a slightly better binding affinity than Ligand A (-5.0). While the difference is not huge, it's still a positive for Ligand B.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B has a slightly better logP and affinity, and comparable Pgp. However, Ligand A excels in TPSA, DILI risk, BBB, solubility, and Caco-2 permeability. The lower DILI risk and better absorption properties of Ligand A are particularly important. The slightly longer half-life of Ligand B is a benefit, but the overall profile of Ligand A is more favorable.
**Conclusion:**
Considering the balance of properties, especially the lower DILI risk, better TPSA, solubility and absorption properties, I believe Ligand A is the more promising drug candidate.
Output:
1
2025-04-17 22:30:54,371 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (366.53 & 368.50 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (75.27) is better than Ligand B (84.3). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (2.105) is better. It's within the optimal 1-3 range, while Ligand A (4.1) is slightly high, potentially leading to solubility issues or off-target interactions.
4. **HBD:** Ligand B (1) is better than Ligand A (2). Fewer HBDs are generally preferred for better permeability.
5. **HBA:** Ligand B (5) is better than Ligand A (3). Lower HBA is generally preferred for permeability.
6. **QED:** Ligand B (0.882) is slightly better than Ligand A (0.824), indicating a more drug-like profile.
7. **DILI:** Both ligands have similar DILI risk (43.12 vs 45.48), and both are acceptable (<60).
8. **BBB:** Both ligands have high BBB penetration (82.55 & 81.23), but this isn't a major concern for a cardiovascular target.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual. Assuming these are logP-scale values, lower (more negative) values indicate *worse* permeability. Ligand A (-4.42) is slightly better than Ligand B (-4.812).
10. **Solubility:** Ligand B (-2.914) is better than Ligand A (-5.119). Higher solubility is crucial for bioavailability.
11. **hERG:** Ligand B (0.07) is better than Ligand A (0.492). Lower hERG inhibition is critical for avoiding cardiotoxicity, especially for a cardiovascular target.
12. **Cl_mic:** Ligand B (4.219) is significantly better than Ligand A (39.62). Lower clearance indicates better metabolic stability.
13. **t1/2:** Ligand B (12.731) is significantly better than Ligand A (38.62). A longer half-life is generally desirable.
14. **Pgp:** Ligand B (0.075) is better than Ligand A (0.174). Lower P-gp efflux improves bioavailability.
15. **Affinity:** Ligand A (-6.4) is slightly better than Ligand B (-6.2). However, the difference is small (0.2 kcal/mol) and can be outweighed by other factors.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand B excels in logP, Pgp, and has a comparable affinity. While Ligand A has slightly better affinity, Ligand B's superior ADME properties (solubility, clearance, half-life, hERG) are more important for overall drug development success.
**Conclusion:**
Ligand B demonstrates a more favorable balance of properties, particularly regarding ADME characteristics and safety (hERG). The small difference in binding affinity is outweighed by the significant improvements in metabolic stability, solubility, and reduced efflux.
Output:
0
2025-04-17 22:30:54,371 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (351.447 Da and 352.475 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Both ligands have similar TPSA values (70.16 and 70.08). These are acceptable for a non-CNS GPCR target like ADRB2, being below the 140 threshold, but not optimized for CNS penetration.
**3. logP:** Ligand B (1.578) has a more optimal logP value than Ligand A (0.341). A logP between 1-3 is preferred, and Ligand A's value is quite low, potentially hindering membrane permeability.
**4. H-Bond Donors/Acceptors:** Both have 4 HBA and are within acceptable limits. Ligand B has 1 HBD, while Ligand A has 0. This isn't a major differentiating factor.
**5. QED:** Ligand A (0.735) has a slightly higher QED score than Ligand B (0.532), suggesting a more generally drug-like profile. However, this is less critical than ADME properties for a GPCR.
**6. DILI Risk:** Ligand B (14.23) has a significantly lower DILI risk than Ligand A (43.622). This is a major advantage for Ligand B, as minimizing liver toxicity is crucial.
**7. BBB Penetration:** Both have moderate BBB penetration, but Ligand A (73.362) is higher than Ligand B (64.482). Since ADRB2 is not a CNS target, this is less important.
**8. Caco-2 Permeability:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. This is a concern for both.
**9. Aqueous Solubility:** Both have negative solubility values, indicating poor aqueous solubility. This is a drawback for both, but could be addressed with formulation strategies.
**10. hERG Inhibition:** Ligand A (0.21) has a lower hERG inhibition liability than Ligand B (0.467), which is preferable.
**11. Microsomal Clearance:** Ligand A (28.581) has a lower microsomal clearance than Ligand B (36.705), indicating better metabolic stability.
**12. In vitro Half-Life:** Ligand A (-19.679) has a longer in vitro half-life than Ligand B (0.295). This is a significant advantage.
**13. P-gp Efflux:** Ligand A (0.078) has lower P-gp efflux liability than Ligand B (0.184), which is preferable.
**14. Binding Affinity:** Ligand B (-6.0) has a slightly better binding affinity than Ligand A (-5.8). While the difference is not huge, it is still a positive for Ligand B.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity) and general drug-like properties, Ligand B emerges as the more promising candidate. Its superior logP, significantly lower DILI risk, and slightly better binding affinity outweigh the advantages of Ligand A in BBB penetration and in vitro half-life. The poor Caco-2 and solubility are concerns for both, but formulation strategies could potentially mitigate these issues. The lower DILI risk is particularly important for a cardiovascular drug.
Output:
0
2025-04-17 22:30:54,371 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.425 and 361.511 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (49.41) is significantly better than Ligand B (73.2). ADRB2 is a cardiovascular target, not CNS, but lower TPSA generally improves absorption. Ligand A is well below the 140 threshold. Ligand B is approaching the upper limit.
3. **logP:** Both ligands have acceptable logP values (2.885 and 3.416), falling within the 1-3 optimal range. Ligand B is slightly higher, which could potentially lead to off-target interactions, but it's not a major concern.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 2 HBA, and Ligand B has 4. Ligand A is preferred here, as lower HBA generally correlates with better permeability.
6. **QED:** Both ligands have good QED scores (0.791 and 0.844), indicating good drug-like properties.
7. **DILI:** Ligand A (27.375) has a much lower DILI risk than Ligand B (49.011). This is a significant advantage for Ligand A.
8. **BBB:** This is less critical for a cardiovascular target like ADRB2, but Ligand A (95.696) has a much higher BBB penetration percentile than Ligand B (61.38).
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the magnitude is similar (-4.684 vs -4.851).
10. **Solubility:** Both have negative solubility values, indicating poor aqueous solubility. Again, the values are similar (-3.61 vs -3.772).
11. **hERG:** Both ligands have low hERG inhibition liability (0.512 and 0.676), which is good.
12. **Cl_mic:** Ligand A (20.664) has a significantly lower microsomal clearance than Ligand B (46.21), indicating better metabolic stability.
13. **t1/2:** Ligand A (-6.631) has a more negative in vitro half-life, which is better (longer half-life).
14. **Pgp:** Ligand A (0.109) has a lower Pgp efflux liability than Ligand B (0.327), which is desirable for better bioavailability.
15. **Binding Affinity:** Ligand A (-6.3 kcal/mol) has a slightly better binding affinity than Ligand B (-4.3 kcal/mol). This 2 kcal/mol difference is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical ADME properties (DILI, Cl_mic, t1/2, Pgp) and has a significantly better binding affinity. While both have poor Caco-2 and solubility, the overall profile of Ligand A is much more favorable for development as a drug candidate targeting ADRB2. The lower DILI risk and improved metabolic stability are particularly important.
Output:
1
2025-04-17 22:30:54,371 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (367.852 and 363.483 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (45.55) is significantly better than Ligand B (83.71). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B's TPSA is relatively high, potentially hindering absorption.
**3. logP:** Ligand A (2.776) is within the optimal 1-3 range. Ligand B (1.344) is on the lower end, potentially causing permeability issues.
**4. H-Bond Donors:** Both have acceptable HBD counts (0 for A, 1 for B), well below the threshold of 5.
**5. H-Bond Acceptors:** Both have acceptable HBA counts (3 for A, 4 for B), well below the threshold of 10.
**6. QED:** Both ligands have similar QED values (0.806 and 0.773), indicating good drug-likeness.
**7. DILI:** Ligand A (41.062) has a slightly higher DILI risk than Ligand B (33.695), but both are below the concerning threshold of 60.
**8. BBB:** Ligand A (96.161) shows excellent BBB penetration, while Ligand B (77.123) is good but lower. While ADRB2 is primarily a cardiovascular target, some CNS effects are possible with adrenergic agonists, and better BBB penetration could be advantageous or a potential concern depending on the desired selectivity.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.701 and -4.82). This is unusual and suggests poor permeability *in vitro*. However, the values are very close, so this isn't a major differentiator.
**10. Aqueous Solubility:** Both ligands have negative solubility values (-3.802 and -2.555). This suggests poor aqueous solubility, which could be a formulation challenge. Ligand B is slightly better.
**11. hERG Inhibition:** Ligand A (0.457) has a slightly higher hERG risk than Ligand B (0.097). This is a significant concern, as hERG inhibition can lead to cardiotoxicity.
**12. Microsomal Clearance:** Ligand A (18.361) has significantly lower microsomal clearance than Ligand B (47.522), indicating better metabolic stability.
**13. In vitro Half-Life:** Ligand A (10.547) has a much longer in vitro half-life than Ligand B (-14.179). This is a major advantage, as it suggests less frequent dosing may be possible.
**14. P-gp Efflux:** Ligand A (0.237) has lower P-gp efflux than Ligand B (0.032), suggesting better oral bioavailability and potentially better CNS exposure.
**15. Binding Affinity:** Ligand B (-7.3) has a slightly better binding affinity than Ligand A (-7.1), but the difference is small (0.2 kcal/mol).
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand A is the more promising candidate. While Ligand B has slightly better affinity and a lower hERG risk, Ligand A excels in crucial ADME properties: lower TPSA, better logP, significantly better metabolic stability (lower Cl_mic and longer t1/2), and lower P-gp efflux. The small difference in affinity is outweighed by these substantial ADME advantages. The slightly higher hERG risk of Ligand A would need further investigation, but can potentially be mitigated through structural modifications.
Output:
1
2025-04-17 22:30:54,371 - INFO - Batch 337 complete. Total preferences: 5392
2025-04-17 22:30:54,371 - INFO - Processing batch 338/512...
2025-04-17 22:31:44,515 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.46 and 356.46 Da) fall well within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (83.22) is higher than Ligand B (49.41). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is generally preferred for permeability. Ligand B is better.
3. **logP:** Both ligands have good logP values (1.788 and 3.066), falling within the optimal 1-3 range. Ligand B is slightly higher, which *could* be beneficial for membrane permeability, but isn't a major concern.
4. **HBD:** Ligand A has 3 HBD, while Ligand B has 1. Lower HBD is generally preferred for permeability, making Ligand B slightly better.
5. **HBA:** Ligand A has 3 HBA, and Ligand B has 2. Similar to HBD, Ligand B is slightly better.
6. **QED:** Both ligands have good QED scores (0.596 and 0.762), indicating good drug-like properties. Ligand B is better.
7. **DILI:** Ligand A (38.813) has a higher DILI risk than Ligand B (14.889). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (47.421) has lower BBB penetration than Ligand B (94.843). While ADRB2 isn't primarily a CNS target, some off-target CNS effects are possible with GPCRs, and higher BBB penetration is generally undesirable for peripheral targets. Ligand B is better.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.719 and -4.5), which is unusual and suggests poor permeability. However, the values are very close, so this isn't a major differentiator.
10. **Solubility:** Both ligands have negative solubility values (-3.071 and -3.504), indicating poor aqueous solubility. This is a concern for both, but again, the difference is small.
11. **hERG:** Both ligands have low hERG inhibition liability (0.5 and 0.603), which is good. No clear advantage.
12. **Cl_mic:** Ligand A (26.833) has lower microsomal clearance than Ligand B (34.8), suggesting better metabolic stability. This is a positive for Ligand A.
13. **t1/2:** Ligand A (-15.975) has a shorter in vitro half-life than Ligand B (-17.793). This is a negative for Ligand A.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.193 and 0.156). No clear advantage.
15. **Binding Affinity:** Ligand B (-6.8 kcal/mol) has a slightly better binding affinity than Ligand A (-6.1 kcal/mol). This difference of 0.7 kcal/mol is significant enough to consider, especially given the other favorable properties of Ligand B.
**Overall Assessment:**
Ligand B consistently outperforms Ligand A across several key ADME properties (DILI, BBB, TPSA, QED) and has a slightly better binding affinity. While Ligand A has better metabolic stability (lower Cl_mic), the other advantages of Ligand B outweigh this benefit. The poor Caco-2 and solubility values are concerning for both, but these can be addressed through formulation strategies. For a cardiovascular GPCR target like ADRB2, the balance of properties in Ligand B makes it the more promising drug candidate.
Output:
0
2025-04-17 22:31:44,516 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (345.443) is slightly lower than Ligand B (361.873), which is generally favorable for permeability.
2. **TPSA:** Ligand A (84.23) is higher than Ligand B (53.51). For a cardiovascular GPCR like ADRB2, TPSA is less critical than for CNS targets, but lower is still preferred for better absorption. Ligand B is significantly better here.
3. **logP:** Both ligands have good logP values (A: 2.608, B: 2.383), falling within the optimal 1-3 range. They are comparable.
4. **HBD:** Ligand A has 2 HBD, and Ligand B has 0. Lower is generally preferred for permeability, giving a slight edge to Ligand B.
5. **HBA:** Ligand A has 4 HBA, while Ligand B has 3. Again, lower is slightly better, favoring Ligand B.
6. **QED:** Both have good QED values (A: 0.674, B: 0.827), indicating good drug-like properties. Ligand B is better.
7. **DILI:** Ligand A (43.117) has a higher DILI risk than Ligand B (35.479). This is a significant advantage for Ligand B.
8. **BBB:** Both ligands have reasonable BBB penetration (A: 77.821, B: 75.611). Since ADRB2 is not primarily a CNS target, this is not a major deciding factor.
9. **Caco-2:** Both have negative Caco-2 values (-4.822 and -4.854), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-3.967) has slightly worse solubility than Ligand B (-2.354). Solubility is important, giving a slight edge to Ligand B.
11. **hERG:** Both have low hERG inhibition risk (A: 0.345, B: 0.317). They are comparable.
12. **Cl_mic:** Ligand A (69.899) has a higher microsomal clearance than Ligand B (36.047). Lower clearance indicates better metabolic stability, favoring Ligand B.
13. **t1/2:** Ligand A (0.433) has a very short half-life, while Ligand B (-30.379) has a negative half-life which is not possible. This is a major issue for Ligand B.
14. **Pgp:** Both ligands have low Pgp efflux liability (A: 0.388, B: 0.208). Ligand B is slightly better.
15. **Binding Affinity:** Ligand B (-7.1) has a significantly stronger binding affinity than Ligand A (-5.8). This is a crucial advantage, potentially outweighing some ADME drawbacks.
**Overall Assessment:**
Ligand B has several advantages: lower TPSA, lower DILI risk, better solubility, lower Cl_mic, and significantly higher binding affinity. While the Caco-2 values are concerning for both, the substantial affinity difference of Ligand B is a major driver. However, the negative half-life for Ligand B is a serious issue. Ligand A has a better half-life, but weaker affinity.
Considering the importance of potency for GPCR targets, and the relatively manageable ADME profile of Ligand B despite the negative half-life, I lean towards Ligand B. The negative half-life is a red flag, but could be addressed through structural modifications.
Output:
0
2025-04-17 22:31:44,516 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (369.531 Da) and Ligand B (344.455 Da) both fall within the ideal 200-500 Da range. Ligand B is slightly preferred due to being closer to the lower end, potentially aiding permeability.
2. **TPSA:** Ligand A (70.67) and Ligand B (75.27) are both acceptable, being under the 140 threshold for oral absorption.
3. **logP:** Ligand A (1.027) is within the optimal 1-3 range. Ligand B (2.113) is also acceptable, but slightly higher.
4. **HBD:** Both ligands have 2 HBD, which is good.
5. **HBA:** Ligand A has 5 HBA, Ligand B has 3 HBA. Both are acceptable, under the 10 threshold.
6. **QED:** Ligand B (0.802) has a significantly better QED score than Ligand A (0.445), indicating a more drug-like profile.
7. **DILI:** Ligand A (17.371) has a much lower DILI risk than Ligand B (25.785), which is a significant advantage.
8. **BBB:** Ligand B (55.176) has a better BBB penetration score than Ligand A (35.673). While ADRB2 isn't strictly a CNS target, some peripheral ADRB2 receptors can be relevant to CNS effects, and better BBB penetration isn't necessarily a negative.
9. **Caco-2:** Ligand A (-5.565) and Ligand B (-4.864) both have negative Caco-2 permeability values, which is concerning. However, the scale is not specified, so it's difficult to interpret the severity.
10. **Solubility:** Ligand A (-1.282) and Ligand B (-2.718) both have negative solubility values, indicating poor aqueous solubility. Ligand A is slightly better.
11. **hERG:** Ligand A (0.398) has a lower hERG inhibition liability than Ligand B (0.076), which is a significant safety advantage.
12. **Cl_mic:** Ligand A (10.69) has a much lower microsomal clearance than Ligand B (23.512), indicating better metabolic stability.
13. **t1/2:** Ligand A (3.48) has a shorter in vitro half-life than Ligand B (-2.797). Negative values are unusual and may indicate a very long half-life, but without knowing the units, it's hard to say.
14. **Pgp:** Ligand A (0.032) has a lower P-gp efflux liability than Ligand B (0.06), which is favorable.
15. **Binding Affinity:** Ligand B (-7.4) has a significantly stronger binding affinity than Ligand A (-2.8). This is a substantial advantage, potentially outweighing some of the ADME drawbacks.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand B excels in affinity, has acceptable logP and TPSA, and slightly higher Pgp. However, Ligand A has a much better safety profile (DILI, hERG) and metabolic stability (Cl_mic).
**Overall Assessment:**
The significantly stronger binding affinity of Ligand B (-7.4 vs -2.8) is a major driver. While Ligand A has advantages in safety and metabolism, the potency difference is substantial enough to potentially overcome those concerns through further optimization. The QED score of Ligand B is also a positive.
Output:
0
2025-04-17 22:31:44,516 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (369.246 and 354.401 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (107.49) is higher than Ligand B (66.37). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B is significantly better.
3. **logP:** Both ligands have good logP values (2.25 and 1.367), falling within the 1-3 optimal range. Ligand A is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Both have 2 HBD, which is within the acceptable limit of 5.
5. **HBA:** Ligand A has 5 HBA, and Ligand B has 4. Both are below the 10 threshold.
6. **QED:** Ligand B (0.839) has a significantly better QED score than Ligand A (0.481), indicating a more drug-like profile.
7. **DILI:** Ligand A (61.07) has a higher DILI risk than Ligand B (47.538). Lower is better, so Ligand B is preferable.
8. **BBB:** Ligand A (82.474) has a higher BBB penetration percentile than Ligand B (76.154). While ADRB2 isn't a CNS target, some degree of BBB penetration can sometimes be acceptable or even beneficial for peripheral receptor targeting.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.936 and -4.974), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand A (-3.887) has slightly better solubility than Ligand B (-2.578), though both are poor.
11. **hERG:** Ligand A (0.575) has a slightly higher hERG risk than Ligand B (0.284). Lower is better, so Ligand B is preferable.
12. **Cl_mic:** Ligand B (-11.909) has a significantly lower (better) microsomal clearance than Ligand A (36.795), indicating greater metabolic stability.
13. **t1/2:** Ligand B (8.31) has a longer in vitro half-life than Ligand A (26.01). This is a positive for Ligand B.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.038 and 0.026).
15. **Binding Affinity:** Ligand B (-7.2 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.0 kcal/mol). This is a crucial advantage, exceeding the 1.5 kcal/mol difference threshold.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in TPSA, Cl_mic, t1/2, DILI, hERG, and *significantly* in binding affinity. While Ligand A has slightly better BBB penetration and solubility, the superior affinity and ADME profile of Ligand B outweigh these minor advantages. The poor Caco-2 values are concerning for both, but the stronger binding of Ligand B suggests it might be able to achieve efficacy at lower concentrations, potentially mitigating the absorption issue.
**Conclusion:**
Ligand B is the more promising candidate due to its superior binding affinity, metabolic stability, lower toxicity risk, and better overall drug-like properties.
Output:
0
2025-04-17 22:31:44,516 - INFO - Here's my reasoning and final output:
**Reasoning:**
Let's break down the comparison between Ligand A and Ligand B, considering the guidelines and GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key).
1. **Molecular Weight:** Both ligands (353.463 and 354.403 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (89.95) is better than Ligand B (97.33). Both are below 140, but A is closer to the preferred <90 for potential CNS penetration (though this isn't a CNS target, lower TPSA is generally favorable).
3. **logP:** Ligand B (-0.719) is slightly less lipophilic than Ligand A (0.371). Both are a bit low, potentially hindering permeability, but A is closer to the optimal 1-3 range.
4. **H-Bond Donors:** Both have 2 HBD, which is good.
5. **H-Bond Acceptors:** Ligand B has 6 HBA, while Ligand A has 4. Both are acceptable, but A is slightly better.
6. **QED:** Both ligands have a QED of 0.675/0.676, indicating good drug-likeness.
7. **DILI:** Ligand A (16.402%) has a significantly lower DILI risk than Ligand B (38.852%). This is a major advantage for A.
8. **BBB:** Ligand A (20.938%) has a lower BBB penetration than Ligand B (28.81%). This isn't a huge concern for a cardiovascular target, but B is slightly better.
9. **Caco-2:** Both show poor Caco-2 permeability (-4.99 and -5.036). This is a concern for oral absorption for both.
10. **Solubility:** Both have poor aqueous solubility (-1.095 and -1.292). This is a significant drawback for both.
11. **hERG:** Both have very low hERG inhibition risk (0.136 and 0.171).
12. **Cl_mic:** Ligand A (11.83 mL/min/kg) has a much lower microsomal clearance than Ligand B (25.714 mL/min/kg), indicating better metabolic stability.
13. **t1/2:** Ligand B (17.522 hours) has a longer in vitro half-life than Ligand A (11.444 hours). This is a slight advantage for B.
14. **Pgp:** Both have very low P-gp efflux liability (0.012).
15. **Binding Affinity:** Ligand B (-7.7 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.6 kcal/mol). This is a substantial advantage, exceeding the 1.5 kcal/mol threshold.
**Overall Assessment:**
Ligand B's substantially better binding affinity (-7.7 vs -6.6 kcal/mol) is the most important factor. While Ligand A has advantages in DILI risk and metabolic stability (Cl_mic), the potency difference is significant enough to outweigh these concerns. Both ligands have poor solubility and permeability, which would need to be addressed in formulation. The slightly better half-life of Ligand B is also a positive.
Output:
0
2025-04-17 22:31:44,516 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (349.5) is within the ideal range (200-500), while Ligand B (392.5) is towards the upper end but still acceptable.
2. **TPSA:** Ligand A (53.1) is excellent, well below the 140 threshold, and good for permeability. Ligand B (85.4) is higher, potentially impacting absorption, but not drastically.
3. **logP:** Ligand A (0.98) is a bit low, potentially hindering membrane permeability. Ligand B (3.15) is optimal. This is a significant advantage for B.
4. **HBD:** Ligand A (0) is ideal. Ligand B (4) is acceptable, but higher HBD can sometimes lead to issues.
5. **HBA:** Both ligands have 4 HBA, which is within the acceptable range.
6. **QED:** Ligand A (0.713) is better than Ligand B (0.519), indicating a more drug-like profile.
7. **DILI:** Ligand A (20.9) has a much lower DILI risk than Ligand B (38.7), a substantial advantage.
8. **BBB:** Ligand A (69.9) is better than Ligand B (24.5), though neither is exceptionally high. For a cardiovascular target like ADRB2, BBB isn't a primary concern, but it's a slight edge for A.
9. **Caco-2:** Ligand A (-4.13) is better than Ligand B (-5.94), suggesting better intestinal absorption.
10. **Solubility:** Ligand A (-0.96) is better than Ligand B (-4.51), indicating better aqueous solubility.
11. **hERG:** Ligand A (0.415) is significantly better than Ligand B (0.855), a critical advantage for avoiding cardiotoxicity, especially relevant for a cardiovascular target.
12. **Cl_mic:** Ligand A (48.3) is slightly better than Ligand B (50.5), indicating slightly better metabolic stability.
13. **t1/2:** Ligand A (-26.8) is significantly better than Ligand B (-4.2), indicating a much longer half-life.
14. **Pgp:** Ligand A (0.073) is much better than Ligand B (0.484), suggesting lower P-glycoprotein efflux.
15. **Affinity:** Ligand A (-6.9) is slightly better than Ligand B (-6.6), but the difference is relatively small.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand B excels in logP, while Ligand A is better across TPSA, Pgp, and has a slightly better affinity. However, the significant advantages of Ligand A in DILI risk, hERG inhibition, solubility, and half-life outweigh the logP benefit of Ligand B.
**Conclusion:**
Considering the balance of properties, particularly the lower DILI, hERG, and better half-life and solubility of Ligand A, it is the more promising drug candidate for ADRB2.
Output:
1
2025-04-17 22:31:44,516 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (355.337 and 349.431 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (65.07) is significantly better than Ligand B (104.46). For a GPCR, lower TPSA is generally preferred for better permeability. Ligand B is approaching a level that could hinder oral absorption.
3. **logP:** Both ligands have acceptable logP values (2.119 and 1.405), falling within the 1-3 range. Ligand A is slightly more lipophilic, which could aid membrane permeability.
4. **HBD:** Ligand A (0) is preferable to Ligand B (3). Fewer hydrogen bond donors generally improve permeability.
5. **HBA:** Both ligands have the same number of HBA (5), which is acceptable.
6. **QED:** Both ligands have similar QED values (0.761 and 0.745), indicating good drug-likeness.
7. **DILI:** Ligand A (68.592) has a higher DILI risk than Ligand B (38.581). This is a significant drawback for Ligand A.
8. **BBB:** Ligand A (83.133) has a much higher BBB penetration potential than Ligand B (46.646). While ADRB2 isn't exclusively a CNS target, some CNS exposure can occur, and higher BBB is generally a plus.
9. **Caco-2:** Ligand A (-3.848) is better than Ligand B (-4.915), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-2.926) is slightly better than Ligand B (-2.504), though both are poor. Solubility is a concern for both, but less critical than permeability for this target.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.319 and 0.127).
12. **Cl_mic:** Ligand A (67.076) has a significantly higher microsomal clearance than Ligand B (12.051). This indicates lower metabolic stability for Ligand A.
13. **t1/2:** Ligand B (9.08) has a longer in vitro half-life than Ligand A (5.595). This is a positive for Ligand B.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.052 and 0.041).
15. **Binding Affinity:** Ligand A (-6.1) has a slightly better binding affinity than Ligand B (-6.0). However, the difference is small (0.1 kcal/mol) and may not be enough to overcome other deficiencies.
**Overall Assessment:**
Ligand B is the more promising candidate. While Ligand A has slightly better affinity and BBB penetration, Ligand B has a significantly lower DILI risk, better metabolic stability (lower Cl_mic, longer t1/2), and a lower TPSA. The lower DILI risk and improved metabolic stability are crucial factors for drug development, outweighing the small advantage in affinity and BBB for Ligand A. The TPSA difference is also significant.
Output:
0
2025-04-17 22:31:44,516 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [350.503, 60.85, 2.428, 1, 3, 0.513, 10.508, 59.636, -4.491, -1.825, 0.549, 24.372, -6.042, 0.454, -5.2]
**Ligand B:** [358.454, 76.66, 1.577, 2, 4, 0.656, 18.147, 77.821, -4.684, -1.951, 0.336, 17.572, 21.123, 0.025, -6.1]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity, and BBB):
1. **MW:** Both are within the ideal 200-500 Da range. A (350.5) is slightly preferred.
2. **TPSA:** A (60.85) is better than B (76.66). Lower TPSA generally improves permeability, important for GPCRs.
3. **logP:** Both are good (between 1-3), but A (2.428) is slightly higher than B (1.577). A higher logP is generally preferred for GPCRs to aid membrane permeability, but not excessively high.
4. **HBD/HBA:** A (1 HBD, 3 HBA) is better than B (2 HBD, 4 HBA). Lower counts are generally preferable.
5. **QED:** Both are acceptable (A: 0.513, B: 0.656), but B is slightly better.
6. **DILI:** A (10.508) is significantly better than B (18.147). Lower DILI is crucial.
7. **BBB:** B (77.821) is better than A (59.636). While not strictly required for ADRB2 (a cardiovascular target), some CNS penetration can be beneficial for off-target effects assessment and potential repurposing.
8. **Caco-2:** Both are negative, indicating poor permeability. A (-4.491) is slightly better than B (-4.684)
9. **Solubility:** Both are negative, indicating poor solubility. A (-1.825) is slightly better than B (-1.951).
10. **hERG:** Both are very low (A: 0.549, B: 0.336), indicating low risk of cardiotoxicity. B is slightly better.
11. **Cl_mic:** A (24.372) is better than B (17.572). Lower clearance is preferred for longer duration of action.
12. **t1/2:** A (-6.042) is much better than B (21.123). A negative value suggests a longer half-life.
13. **Pgp:** A (0.454) is better than B (0.025). Lower P-gp efflux is desirable for better bioavailability.
14. **Affinity:** Both are excellent (-5.2 and -6.1 kcal/mol). B is slightly better, with a 0.9 kcal/mol advantage.
**Overall Assessment:**
While Ligand B has a slightly better binding affinity and BBB penetration, Ligand A demonstrates a significantly better safety profile (lower DILI), better metabolic stability (lower Cl_mic, better t1/2), and better Pgp efflux properties. The affinity difference, while present, isn't large enough to outweigh the substantial ADME/Tox advantages of Ligand A, especially considering the cardiovascular target. The slightly better TPSA and logP of ligand A also contribute to its favorability.
Therefore, I would choose Ligand A.
Output:
1
2025-04-17 22:31:44,516 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (361.354 and 356.413 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (20.31) is significantly better than Ligand B (66.57). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold. Ligand B is higher, potentially impacting absorption.
3. **logP:** Ligand A (4.916) is slightly higher than Ligand B (3.477). Both are within the acceptable range (1-3 is optimal, but up to 4 is tolerable), but Ligand A is pushing the upper limit, potentially raising concerns about solubility and off-target effects.
4. **HBD:** Ligand A (0) is preferable to Ligand B (1). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (1) is preferable to Ligand B (4). Lower HBA is generally better for permeability.
6. **QED:** Both ligands have good QED scores (0.659 and 0.774), indicating good overall drug-likeness. Ligand B is slightly better.
7. **DILI:** Ligand A (43.195) is higher than Ligand B (19.504). This is a significant advantage for Ligand B, indicating a lower risk of drug-induced liver injury.
8. **BBB:** Ligand A (96.316) is higher than Ligand B (89.608). While not a primary concern for a cardiovascular target, higher BBB is generally favorable.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.316 and -4.416). This is unusual and suggests poor permeability.
10. **Solubility:** Ligand A (-4.904) is slightly worse than Ligand B (-3.735), indicating lower aqueous solubility.
11. **hERG:** Both ligands have low hERG inhibition risk (0.862 and 0.642). No significant difference.
12. **Cl_mic:** Ligand A (58.709) has a higher microsomal clearance than Ligand B (27.408), suggesting lower metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand B (5.738) has a much longer in vitro half-life than Ligand A (-0.134). This is a major advantage for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.23 and 0.231). No significant difference.
15. **Binding Affinity:** Ligand A (-6.6 kcal/mol) has a slightly better binding affinity than Ligand B (-5.3 kcal/mol). This is a 1.3 kcal/mol difference, which is substantial and could outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand A has a slightly better binding affinity and BBB penetration, but Ligand B has significantly better DILI risk, metabolic stability (lower Cl_mic, longer t1/2), fewer HBD/HBA, and better solubility. The lower TPSA of Ligand A is also a plus. Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity) and the overall balance of properties, the improved ADME profile of Ligand B is more compelling, despite the slightly lower binding affinity. The difference in binding affinity isn't large enough to overcome the substantial advantages in safety (DILI) and pharmacokinetics (Cl_mic, t1/2) offered by Ligand B.
Output:
0
2025-04-17 22:31:44,517 - INFO - Here's my reasoning and final output for the ligand preference:
**Reasoning:**
We are looking for a ligand for the ADRB2, a cardiovascular GPCR. Therefore, we prioritize logP, TPSA, Pgp, and affinity, while also considering overall drug-likeness (QED) and safety (DILI, hERG).
Let's break down the comparison:
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (364.471) is slightly higher than Ligand B (348.403), but this is not a major concern.
2. **TPSA:** Ligand A (87.46) is significantly better than Ligand B (117.25). A lower TPSA generally favors oral absorption and is important for GPCRs. Ligand B is pushing the upper limit for good absorption.
3. **logP:** Both ligands have acceptable logP values (A: 0.991, B: 1.318), falling within the 1-3 range. Ligand B is slightly more lipophilic.
4. **H-Bond Donors/Acceptors:** Both have 2 HBD and 6 HBA, which are within acceptable limits.
5. **QED:** Ligand A (0.832) has a better QED score than Ligand B (0.65), indicating a more drug-like profile.
6. **DILI:** Both are reasonably low, with Ligand A (39.356) slightly better than Ligand B (41.838).
7. **BBB:** Ligand B (70.997) has a significantly higher BBB penetration percentile than Ligand A (40.558). While ADRB2 is cardiovascular, some CNS penetration is not necessarily detrimental and could offer additional therapeutic avenues.
8. **Caco-2 Permeability:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-5.168) is slightly better than Ligand B (-4.893).
9. **Aqueous Solubility:** Both have very poor aqueous solubility (-3.399 and -2.0, respectively). This is a significant drawback for both.
10. **hERG:** Both have very low hERG inhibition risk (A: 0.094, B: 0.253).
11. **Microsomal Clearance:** Ligand A (31.077) has a lower microsomal clearance than Ligand B (34.957), suggesting better metabolic stability.
12. **In vitro Half-Life:** Ligand A (-18.757) has a longer in vitro half-life than Ligand B (-11.208).
13. **P-gp Efflux:** Both have very low P-gp efflux liability (A: 0.024, B: 0.05).
14. **Binding Affinity:** Ligand A (-7.4 kcal/mol) has a significantly stronger binding affinity than Ligand B (-5.6 kcal/mol). This is a crucial advantage, exceeding the 1.5 kcal/mol threshold.
**Overall Assessment:**
Ligand A is the stronger candidate. Its superior binding affinity, better QED, lower clearance, longer half-life, and lower TPSA outweigh the slightly better BBB penetration of Ligand B. Both compounds suffer from poor solubility and Caco-2 permeability, which would need to be addressed in further optimization. However, the strong affinity of Ligand A provides a solid foundation for development.
Output:
1
2025-04-17 22:31:44,517 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (366.527) is slightly higher than Ligand B (345.399), but both are acceptable.
2. **TPSA:** Ligand A (58.64) is significantly better than Ligand B (88.58). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (A: 2.749, B: 2.562), falling within the optimal 1-3 range.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A (4) is better than Ligand B (5), but both are acceptable.
6. **QED:** Ligand B (0.92) has a slightly better QED score than Ligand A (0.76), suggesting a more drug-like profile.
7. **DILI:** Ligand A (32.261) has a significantly lower DILI risk than Ligand B (57.697). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (67.468) has a better BBB percentile than Ligand B (45.715). While not critical for a cardiovascular target, it's a positive attribute.
9. **Caco-2:** Ligand A (-5.533) is better than Ligand B (-4.877), indicating potentially better intestinal absorption.
10. **Solubility:** Ligand A (-4.035) is better than Ligand B (-3.474).
11. **hERG:** Both ligands have very low hERG inhibition risk (A: 0.5, B: 0.162), which is excellent.
12. **Cl_mic:** Ligand B (22.521) has a significantly lower microsomal clearance than Ligand A (40.395), indicating better metabolic stability.
13. **t1/2:** Ligand B (25.592) has a longer in vitro half-life than Ligand A (-7.633), which is desirable.
14. **Pgp:** Both ligands have low Pgp efflux liability (A: 0.162, B: 0.19).
15. **Binding Affinity:** Ligand A (-8.3) has a significantly stronger binding affinity than Ligand B (-6.7). This is a substantial advantage, potentially outweighing some ADME drawbacks.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Both ligands are good on logP and Pgp. Ligand A is superior in TPSA and *significantly* superior in binding affinity. The improved DILI and solubility of Ligand A are also important positives. While Ligand B has better metabolic stability and half-life, the substantial affinity difference of Ligand A is a critical factor.
**Conclusion:**
The stronger binding affinity of Ligand A, combined with its better TPSA, lower DILI risk, and improved solubility, makes it the more promising drug candidate despite the slightly less favorable metabolic stability profile. The difference in affinity is large enough to likely overcome the metabolic concerns.
Output:
1
2025-04-17 22:31:44,517 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.547 and 346.515 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (50.36 and 49.41) are below the 140 A^2 threshold for good oral absorption, and are reasonably low for a GPCR target. No major difference.
3. **logP:** Ligand A (4.345) is slightly higher than Ligand B (3.214). While both are within the optimal 1-3 range, Ligand A is pushing the upper limit. This could potentially lead to solubility issues, but isn't a dealbreaker.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1). Both are acceptable, well below the threshold of 5.
5. **HBA:** Both ligands (2) are well below the threshold of 10.
6. **QED:** Both ligands have good QED scores (0.748 and 0.831), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (23.846) has a significantly lower DILI risk than Ligand B (32.648). This is a substantial advantage for Ligand A.
8. **BBB:** Both ligands have high BBB penetration (85.459 and 80.496). This is good, as it suggests potential for reaching the target in peripheral tissues.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.667 and -4.892). These values are unusual and likely represent a logP-related scaling issue. Without knowing the original scale, it's hard to interpret, but the similarity suggests they aren't significantly different.
10. **Solubility:** Both ligands have negative solubility values (-4.363 and -3.964). Similar to Caco-2, these values are unusual and hard to interpret.
11. **hERG:** Both ligands have low hERG inhibition liability (0.67 and 0.584). This is good, indicating a low risk of cardiotoxicity.
12. **Cl_mic:** Both ligands have similar microsomal clearance (62.285 and 63.065).
13. **t1/2:** Ligand A (24.77) has a significantly longer in vitro half-life than Ligand B (-1.605). This is a major advantage for Ligand A, suggesting less frequent dosing.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.195 and 0.426).
15. **Binding Affinity:** Ligand B (-7.5 kcal/mol) has a stronger binding affinity than Ligand A (-6.9 kcal/mol). This is a 0.6 kcal/mol difference, which is significant.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, Pgp, TPSA, and affinity. Ligand B has a better logP and affinity. However, Ligand A has a substantially lower DILI risk and a much longer half-life. The affinity difference, while significant, is not overwhelming. The DILI and half-life advantages of Ligand A are more important for overall drug development.
**Conclusion:**
Considering the balance of properties, especially the lower DILI risk and longer half-life of Ligand A, I believe it is the more promising drug candidate. The slightly higher logP is a minor concern compared to the potential for liver toxicity and the need for frequent dosing with Ligand B.
Output:
1
2025-04-17 22:31:44,517 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (426.698 Da) is within the ideal range, while Ligand B (353.382 Da) is slightly below, but still acceptable.
2. **TPSA:** Ligand A (65.9) is good, well below the 140 threshold. Ligand B (72.7) is also acceptable, though slightly higher.
3. **logP:** Both ligands (A: 3.174, B: 3.577) are within the optimal 1-3 range.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 5 HBA, and Ligand B has 6. Both are acceptable, below the 10 threshold.
6. **QED:** Ligand A (0.816) has a better QED score than Ligand B (0.611), indicating higher drug-likeness.
7. **DILI:** Ligand A (76.464) has a lower DILI risk than Ligand B (95.192), which is a significant advantage.
8. **BBB:** Both ligands have similar BBB penetration (A: 61.613, B: 65.839). Since ADRB2 is a cardiovascular target, BBB penetration is not a primary concern.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. This is concerning for both.
10. **Solubility:** Both have negative solubility values, indicating poor solubility. This is concerning for both.
11. **hERG:** Both ligands have low hERG inhibition risk (A: 0.686, B: 0.553).
12. **Cl_mic:** Ligand A (59.258) has a higher microsomal clearance than Ligand B (44.226), suggesting lower metabolic stability.
13. **t1/2:** Ligand B (32.341) has a longer in vitro half-life than Ligand A (-24.174), which is a significant advantage.
14. **Pgp:** Both have low Pgp efflux liability (A: 0.52, B: 0.457).
15. **Binding Affinity:** Ligand B (-7.6 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.2 kcal/mol) - a difference of 1.4 kcal/mol. This is a substantial advantage.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are crucial. Both ligands perform similarly on logP and Pgp. TPSA is acceptable for both. However, Ligand B has a much stronger binding affinity, which outweighs its slightly higher DILI risk and lower QED. The poor Caco-2 and solubility are concerning for both, but can be addressed with formulation strategies.
**Conclusion:**
Despite Ligand A's better QED and lower DILI, the significantly stronger binding affinity of Ligand B (-7.6 kcal/mol vs -6.2 kcal/mol) is the deciding factor. A 1.4 kcal/mol difference is substantial and likely to translate to greater efficacy.
Output:
0
2025-04-17 22:31:44,517 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (a GPCR) drug candidates.
**Ligand A:** [359.411, 97.19, 0.19, 1, 7, 0.844, 54.517, 68.166, -5.139, -2.71, 0.157, -8.104, -10.142, 0.057, -6.1]
**Ligand B:** [386.363, 29.54, 4.875, 0, 2, 0.537, 12.796, 83.986, -4.422, -5.426, 0.892, 102.043, 28.044, 0.683, -5.1]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, BBB, and affinity are key):
1. **MW:** Both are within the acceptable range (200-500 Da). Ligand A (359.411) is slightly preferred due to being a bit lower.
2. **TPSA:** Ligand B (29.54) is *much* better than Ligand A (97.19). Lower TPSA generally improves permeability, and is particularly important for GPCRs.
3. **logP:** Ligand B (4.875) is higher than ideal, but still within a potentially manageable range. Ligand A (0.19) is *too* low, likely indicating poor membrane permeability. This is a significant drawback.
4. **HBD/HBA:** Ligand A (1 HBD, 7 HBA) is slightly more balanced. Ligand B (0 HBD, 2 HBA) is very low, which might impact solubility.
5. **QED:** Ligand A (0.844) is significantly better than Ligand B (0.537), suggesting a more drug-like profile overall.
6. **DILI:** Ligand B (12.796) has a much lower DILI risk than Ligand A (54.517). This is a major advantage for Ligand B.
7. **BBB:** Ligand B (83.986) has a much higher BBB penetration percentile than Ligand A (68.166). While ADRB2 isn't necessarily a CNS target, some peripheral ADRB2 activity can be influenced by CNS effects, and higher BBB is generally a positive.
8. **Caco-2:** Ligand A (-5.139) and Ligand B (-4.422) are both negative, indicating poor permeability.
9. **Solubility:** Ligand A (-2.71) is slightly better than Ligand B (-5.426), but both are poor.
10. **hERG:** Ligand A (0.157) has a lower hERG risk than Ligand B (0.892), which is preferable.
11. **Cl_mic:** Ligand A (-8.104) has a much lower (better) microsomal clearance than Ligand B (102.043), indicating better metabolic stability.
12. **t1/2:** Ligand B (28.044) has a significantly longer in vitro half-life than Ligand A (-10.142). This is a substantial advantage.
13. **Pgp:** Ligand A (0.057) has a lower Pgp efflux liability than Ligand B (0.683), which is favorable.
14. **Affinity:** Both ligands have comparable binding affinities (-6.1 kcal/mol and -5.1 kcal/mol, respectively). The 1 kcal/mol difference isn't enough to outweigh other factors.
**Overall Assessment:**
Ligand A has better QED, Pgp, and metabolic stability. However, its extremely low logP is a major concern for permeability. Ligand B, while having a lower QED and higher Pgp efflux, excels in TPSA, BBB penetration, DILI risk, and *especially* in vitro half-life. The lower TPSA and better BBB are particularly important for a GPCR target. The longer half-life is also a significant benefit. The higher logP is a concern but potentially addressable through further optimization.
Given the balance of properties and the GPCR-specific priorities, I believe **Ligand B** is the more promising candidate.
Output:
0
2025-04-17 22:31:44,517 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (343.471 Da) is well within the ideal range (200-500 Da). Ligand B (365.459 Da) is also acceptable. No clear advantage here.
2. **TPSA:** Ligand A (84.22) is excellent, well below the 140 threshold for good absorption. Ligand B (107.19) is still reasonable, but less optimal. This favors Ligand A.
3. **logP:** Ligand A (2.919) is optimal (1-3). Ligand B (0.276) is quite low, potentially leading to poor membrane permeability. This strongly favors Ligand A.
4. **HBD:** Both Ligand A (3) and Ligand B (3) are within the acceptable limit of 5. No difference.
5. **HBA:** Ligand A (3) is good. Ligand B (5) is acceptable, but higher. This slightly favors Ligand A.
6. **QED:** Both Ligand A (0.712) and Ligand B (0.628) are above the 0.5 threshold, indicating good drug-likeness. No significant difference.
7. **DILI:** Ligand A (47.344) has a lower DILI risk than Ligand B (63.707), both are acceptable, but A is better.
8. **BBB:** Ligand A (85.111) has a good BBB penetration percentile. Ligand B (28.422) is very low. While ADRB2 isn't *strictly* a CNS target, some CNS exposure can sometimes be beneficial or at least needs to be understood. This strongly favors Ligand A.
9. **Caco-2:** Ligand A (-4.977) and Ligand B (-5.795) both have negative values which are not ideal. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Ligand A (-4.491) and Ligand B (-2.852) both have negative values which are not ideal. However, the scale is not specified, so it's hard to interpret.
11. **hERG:** Ligand A (0.472) is very low risk. Ligand B (0.05) is also very low risk. No difference.
12. **Cl_mic:** Ligand A (57.946) is higher than Ligand B (3.969), indicating faster clearance and lower metabolic stability. This favors Ligand B.
13. **t1/2:** Ligand A (4.88) is shorter than Ligand B (-20.103). This is a strange result, as a negative half-life is not possible. This favors Ligand B.
14. **Pgp:** Ligand A (0.209) has lower P-gp efflux liability than Ligand B (0.018). This favors Ligand A.
15. **Affinity:** Ligand A (-6.2 kcal/mol) has a significantly stronger binding affinity than Ligand B (-2.4 kcal/mol). This is a substantial advantage for Ligand A.
**Overall Assessment:**
Ligand A clearly outperforms Ligand B across most critical parameters for a GPCR drug candidate. The significantly better logP, TPSA, BBB penetration, and *especially* binding affinity outweigh the slightly higher microsomal clearance. The negative half-life for Ligand B is also concerning. While Ligand B has better metabolic stability, the difference isn't enough to offset the other deficiencies.
Output:
1
2025-04-17 22:31:44,518 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [337.379, 84.23, 2.502, 2, 4, 0.793, 74.409, 62.854, -4.598, -4.395, 0.212, 34.179, -14.62, 0.141, -6.0]
**Ligand B:** [341.503, 73.63, 4.619, 2, 5, 0.48, 51.028, 79.217, -5.034, -4.881, 0.937, 90.796, 52.936, 0.711, -6.2]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). A (337.379) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are good, below the 140 A^2 threshold for oral absorption. B (73.63) is slightly better, indicating potentially better membrane permeability.
3. **logP:** A (2.502) is optimal, while B (4.619) is pushing the upper limit. Higher logP can lead to off-target effects and solubility issues.
4. **HBD:** Both have 2 HBD, which is acceptable.
5. **HBA:** A has 4 HBA, B has 5. Both are within the acceptable range.
6. **QED:** A (0.793) has a significantly better QED score than B (0.48), suggesting a more drug-like profile.
7. **DILI:** A (74.409) has a higher DILI risk than B (51.028). This is a concern for A.
8. **BBB:** B (79.217) has a better BBB penetration percentile than A (62.854). While not a primary concern for a cardiovascular target, it's a slight advantage.
9. **Caco-2:** A (-4.598) has a worse Caco-2 permeability than B (-5.034). Lower values suggest poorer absorption.
10. **Solubility:** Both have very poor solubility scores (-4.395 and -4.881). This is a significant concern for both, but B is slightly worse.
11. **hERG:** A (0.212) has a much lower hERG inhibition liability than B (0.937), a crucial advantage for cardiovascular drugs.
12. **Cl_mic:** A (34.179) has a lower microsomal clearance than B (90.796), indicating better metabolic stability.
13. **t1/2:** B (52.936) has a much longer in vitro half-life than A (-14.62). This is a significant advantage for B.
14. **Pgp:** A (0.141) has lower P-gp efflux than B (0.711), which is favorable for bioavailability.
15. **Affinity:** Both have similar and strong binding affinities (-6.0 and -6.2 kcal/mol). The difference is negligible.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. B has a better logP and TPSA, and lower Pgp efflux. However, A has a significantly better QED score, lower hERG risk, and lower microsomal clearance. The solubility is poor for both.
**Decision:**
Despite the slightly better permeability characteristics of Ligand B, the significantly lower hERG risk and better QED of Ligand A outweigh those benefits. The lower metabolic clearance of A is also a positive. The solubility is a concern for both, but can be addressed with formulation strategies. Given the cardiovascular target, minimizing hERG risk is paramount.
Therefore, I prefer Ligand A.
1
2025-04-17 22:31:44,518 - INFO - Batch 338 complete. Total preferences: 5408
2025-04-17 22:31:44,518 - INFO - Processing batch 339/512...
2025-04-17 22:32:33,865 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (364.471 and 364.417 Da) fall comfortably within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (99.33) is higher than Ligand B (49.41). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for permeability. Ligand B is significantly better here.
3. **logP:** Ligand A (1.9) is within the optimal range, while Ligand B (3.773) is approaching the upper limit. Both are acceptable, but Ligand A is slightly favored.
4. **HBD:** Ligand A (5) is at the upper limit of the preferred range, while Ligand B (1) is excellent. Ligand B is better.
5. **HBA:** Ligand A (4) is good, and Ligand B (3) is also good. No major difference.
6. **QED:** Ligand B (0.84) has a substantially better QED score than Ligand A (0.408), indicating a more drug-like profile. This is a significant advantage for Ligand B.
7. **DILI:** Both ligands have similar DILI risk (69.484 and 62.893 percentile). Both are acceptable, but neither is outstanding.
8. **BBB:** Ligand A (62.931) and Ligand B (89.492). While ADRB2 isn't a CNS target, some degree of BBB penetration can influence off-target effects and distribution. Ligand B is better.
9. **Caco-2:** Ligand A (-5.022) and Ligand B (-4.329). Both are negative, which is unusual. It's difficult to interpret without knowing the scale, but they likely indicate poor permeability. Ligand B is slightly better.
10. **Solubility:** Ligand A (-3.274) and Ligand B (-4.949). Both are negative, indicating poor solubility. Ligand A is slightly better.
11. **hERG:** Both ligands have very low hERG risk (0.417 and 0.409 percentile). This is excellent for both.
12. **Cl_mic:** Ligand A (19.26) has a much lower microsomal clearance than Ligand B (80.582), suggesting better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (67.523) has a longer in vitro half-life than Ligand B (28.182). This is a significant advantage for Ligand A.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.035 and 0.318). Both are good.
15. **Binding Affinity:** Ligand A (-8.1 kcal/mol) has a significantly stronger binding affinity than Ligand B (-7.0 kcal/mol). This is a substantial advantage for Ligand A, potentially outweighing some ADME concerns.
**Overall Assessment:**
Ligand A has a much stronger binding affinity and better metabolic stability (lower Cl_mic, longer t1/2). While Ligand B has a better QED and TPSA, the superior affinity of Ligand A is crucial for a GPCR target. The slight drawbacks in solubility and HBD for Ligand A are less concerning given the strong binding. Considering the GPCR-specific priorities (logP, TPSA, affinity), Ligand A is the more promising candidate.
Output:
1
2025-04-17 22:32:33,866 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [358.435, 106.12 , -0.269, 3. , 6. , 0.579, 42.458, 48.391, -5.315, -0.906, 0.063, 2.968, 12.322, 0.028, -5.4 ]
**Ligand B:** [362.861, 66.4 , 2.161, 0. , 4. , 0.756, 54.866, 70.531, -4.536, -3.186, 0.186, 42.503, -30.648, 0.172, -6.8 ]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity, and BBB):
1. **MW:** Both are within the ideal 200-500 Da range. A (358.435) is slightly better.
2. **TPSA:** A (106.12) is higher than B (66.4). B is significantly better, being well below the 140 threshold for oral absorption and closer to the ideal for GPCRs.
3. **logP:** A (-0.269) is quite low, potentially hindering permeability. B (2.161) is much better, falling within the optimal 1-3 range.
4. **HBD/HBA:** A has 3 HBD and 6 HBA. B has 0 HBD and 4 HBA. Both are acceptable, but B is slightly better due to fewer HBDs.
5. **QED:** Both have good QED scores (A: 0.579, B: 0.756), indicating drug-likeness. B is better.
6. **DILI:** A (42.458) is better than B (54.866), indicating a lower risk of liver injury.
7. **BBB:** B (70.531) is significantly better than A (48.391). This is a key advantage for a GPCR target, even if not CNS-focused, as it suggests better distribution.
8. **Caco-2:** A (-5.315) is worse than B (-4.536), indicating lower intestinal absorption.
9. **Solubility:** A (-0.906) is better than B (-3.186).
10. **hERG:** A (0.063) is better than B (0.186), indicating lower cardiotoxicity risk.
11. **Cl_mic:** A (2.968) is significantly better than B (42.503), indicating better metabolic stability.
12. **t1/2:** A (12.322) is better than B (-30.648), indicating a longer half-life.
13. **Pgp:** A (0.028) is much better than B (0.172), suggesting less efflux and better bioavailability.
14. **Affinity:** B (-6.8) is 1.4 kcal/mol better than A (-5.4). This is a substantial difference and a major advantage.
**Overall Assessment:**
While Ligand A has advantages in DILI, solubility, metabolic stability, half-life, and Pgp efflux, Ligand B excels in crucial GPCR-relevant properties: logP, TPSA, and, most importantly, binding affinity. The significantly better affinity of Ligand B (-6.8 kcal/mol vs. -5.4 kcal/mol) outweighs the drawbacks in metabolic stability and Pgp efflux. The improved BBB penetration is also a significant plus. The lower TPSA of B is also favorable.
Therefore, I believe Ligand B is the more promising drug candidate.
0
2025-04-17 22:32:33,866 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (348.355) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (75.71) is significantly better than Ligand A (109.08). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (2.169) is within the optimal range (1-3), while Ligand A (0.659) is a bit low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1), but both are acceptable.
5. **HBA:** Ligand A (6) is higher than Ligand B (4), but both are within the acceptable range.
6. **QED:** Ligand B (0.725) has a better QED score than Ligand A (0.444), indicating a more drug-like profile.
7. **DILI:** Ligand B (12.641) has a *much* lower DILI risk than Ligand A (42.885). This is a significant advantage.
8. **BBB:** Ligand B (57.231) has a higher BBB penetration score than Ligand A (37.301), but as this is a cardiovascular target, this isn't a major factor.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-5.133) is slightly worse than Ligand B (-4.817).
10. **Solubility:** Both ligands have negative solubility values, which is also unusual. Ligand A (-2.229) is slightly worse than Ligand B (-1.369).
11. **hERG:** Both ligands have low hERG inhibition risk (0.137 and 0.227 respectively).
12. **Cl_mic:** Ligand B (0.853) has a *much* lower microsomal clearance than Ligand A (-23.929), indicating better metabolic stability.
13. **t1/2:** Ligand B (-3.307) has a slightly better in vitro half-life than Ligand A (-22.322).
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.042 and 0.041 respectively).
15. **Affinity:** Ligand B (-8.1 kcal/mol) has a significantly stronger binding affinity than Ligand A (-7.0 kcal/mol). This difference of 1.1 kcal/mol is substantial.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, and affinity are important. Ligand B excels in these areas. The significantly better affinity and logP of Ligand B, combined with the much lower DILI and improved metabolic stability, outweigh the slightly higher TPSA. The negative Caco-2 and solubility values are concerning for both, but the superior binding affinity of Ligand B suggests it may overcome these issues.
**Conclusion:**
Ligand B is the more promising drug candidate due to its superior binding affinity, lower DILI risk, better metabolic stability, and more favorable logP and QED values.
Output:
0
2025-04-17 22:32:33,866 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (367.5 and 368.8 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (82.53) is significantly better than Ligand B (133.21). ADRB2 is a cardiovascular target, not CNS, but lower TPSA generally improves permeability. Ligand A is well below the 140 threshold, while B is approaching it.
3. **logP:** Ligand A (2.36) is within the optimal 1-3 range. Ligand B (-0.98) is below 1, which could indicate poor membrane permeability. This is a significant negative for Ligand B.
4. **HBD:** Ligand A (2) is good. Ligand B (3) is acceptable, but slightly higher.
5. **HBA:** Ligand A (5) is good. Ligand B (7) is higher, potentially impacting permeability.
6. **QED:** Both ligands (0.775 and 0.6) have acceptable QED values, indicating reasonable drug-likeness. Ligand A is slightly better.
7. **DILI:** Ligand A (39.3) is much better than Ligand B (67.5). Lower DILI risk is crucial.
8. **BBB:** While not a primary concern for a cardiovascular target, Ligand A (50.5) is better than Ligand B (11.4).
9. **Caco-2:** Both are negative (-5.065 and -5.678), which is not ideal, but the values are similar.
10. **Solubility:** Both are negative (-2.295 and -1.946), indicating poor aqueous solubility. This is a concern for both, but similar.
11. **hERG:** Ligand A (0.47) is better than Ligand B (0.045), indicating a lower risk of cardiotoxicity. This is particularly important for a cardiovascular target.
12. **Cl_mic:** Ligand A (23.287) is much better than Ligand B (-14.93). Lower clearance indicates better metabolic stability.
13. **t1/2:** Ligand B (36.3) has a significantly longer half-life than Ligand A (-3.728). This is a positive for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.302) is better than Ligand B (0.044), indicating lower P-gp efflux.
15. **Binding Affinity:** Both ligands have comparable binding affinities (-6.6 and -5.8 kcal/mol). Ligand A is slightly better, but the difference isn't huge enough to outweigh other factors.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A excels in logP, TPSA, and Pgp, and has slightly better affinity. Ligand B's only advantage is the longer half-life. However, the significantly higher DILI risk, lower logP, and higher TPSA of Ligand B are major drawbacks.
**Conclusion:**
Ligand A is the superior candidate. Its better physicochemical properties (logP, TPSA), lower DILI risk, and lower hERG risk outweigh Ligand B's longer half-life. The longer half-life of Ligand B could potentially be addressed through formulation strategies, but the fundamental issues with its permeability and safety profile are more difficult to overcome.
Output:
1
2025-04-17 22:32:33,866 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (344.363) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (49.41) is significantly better than Ligand A (74.97). Lower TPSA is preferred for GPCRs, aiding in brain penetration and overall absorption.
3. **logP:** Both ligands have good logP values (A: 2.784, B: 3.309), falling within the optimal 1-3 range. Ligand B is slightly higher, potentially leading to better membrane permeability but also a slight increase in off-target binding risk.
4. **HBD:** Ligand A has 0 HBD, while Ligand B has 1. Both are acceptable, staying within the recommended limit of 5.
5. **HBA:** Ligand A has 6 HBA, and Ligand B has 3. Both are within the acceptable limit of 10. Ligand B is preferable here.
6. **QED:** Both ligands have very similar QED values (A: 0.777, B: 0.784), indicating good drug-likeness.
7. **DILI:** Ligand B (19.698) has a much lower DILI risk than Ligand A (63.086). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (80.419) has a slightly higher BBB penetration percentile than Ligand B (70.105). While ADRB2 isn't strictly a CNS target, some brain exposure can occur, making this a minor positive for Ligand A.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual. However, the magnitude is similar, and we can't draw strong conclusions.
10. **Solubility:** Ligand A (-4.278) has slightly better solubility than Ligand B (-3.535), but both are very poor. This is a concern for both compounds.
11. **hERG:** Both ligands have low hERG inhibition liability (A: 0.389, B: 0.459), which is good.
12. **Cl_mic:** Ligand B (57.645) has a lower microsomal clearance than Ligand A (77.787), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-6.419) has a significantly longer in vitro half-life compared to Ligand A (-14.481). This is a major advantage for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have low Pgp efflux liability (A: 0.579, B: 0.225), with Ligand B being slightly better.
15. **Binding Affinity:** Ligand A (-6.6) has a slightly better binding affinity than Ligand B (-5.5). This is a 1.1 kcal/mol difference, which is substantial.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity and BBB penetration, Ligand B demonstrates a significantly better safety profile (lower DILI), improved metabolic stability (lower Cl_mic, longer t1/2), and better TPSA and HBA values. The binding affinity difference, while notable, can potentially be optimized in later stages of drug development. The ADME properties of Ligand B are more favorable overall, particularly the lower DILI risk and improved metabolic stability, making it a more promising starting point for a drug candidate targeting ADRB2.
Output:
0
2025-04-17 22:32:33,866 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A: [358.419, 91.57, 2.841, 3, 5, 0.654, 81.504, 53.044, -5.192, -3.696, 0.675, 52.378, 104.781, 0.585, -6.5]**
**Ligand B: [345.399, 95.57, 2.096, 1, 6, 0.44, 33.346, 67.468, -4.357, -3.815, 0.358, 100.076, 18.263, 0.031, -5]**
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity):
1. **MW:** Both are within the ideal 200-500 Da range. Ligand B (345.4) is slightly smaller, which is generally favorable.
2. **TPSA:** Both are reasonably good (91.57 and 95.57), being under 140. This suggests decent oral absorption potential.
3. **logP:** Both are within the optimal 1-3 range (2.841 and 2.096). Ligand B is slightly lower, which could marginally improve solubility but might slightly reduce membrane permeability.
4. **HBD/HBA:** Ligand A (3/5) is slightly better than Ligand B (1/6). Fewer H-bonds are generally preferred for permeability.
5. **QED:** Ligand A (0.654) has a better QED score than Ligand B (0.44), indicating a more drug-like profile.
6. **DILI:** Ligand B (33.346) has a significantly lower DILI risk than Ligand A (81.504). This is a major advantage for Ligand B.
7. **BBB:** Ligand B (67.468) shows better BBB penetration potential than Ligand A (53.044). While ADRB2 isn't exclusively a CNS target, some cardiovascular effects are mediated by central pathways, and better BBB penetration isn't necessarily a negative.
8. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-5.192) is slightly better than Ligand B (-4.357).
9. **Solubility:** Both are negative, indicating poor solubility. They are fairly similar.
10. **hERG:** Both are low, indicating low cardiotoxicity risk. Ligand B (0.358) is slightly lower than Ligand A (0.675).
11. **Cl_mic:** Ligand A (52.378) has a lower microsomal clearance than Ligand B (100.076), suggesting better metabolic stability.
12. **t1/2:** Ligand A (104.781) has a significantly longer in vitro half-life than Ligand B (18.263). This is a substantial advantage for Ligand A.
13. **Pgp:** Ligand A (0.585) has lower P-gp efflux than Ligand B (0.031). Lower P-gp efflux is better for bioavailability.
14. **Affinity:** Ligand A (-6.5 kcal/mol) has a slightly better binding affinity than Ligand B (-5 kcal/mol). This is a significant advantage.
**Overall Assessment:**
Ligand A has a better binding affinity, longer half-life, and lower P-gp efflux. However, Ligand B has a dramatically lower DILI risk and better BBB penetration. The affinity difference is not huge (1.5 kcal/mol), but it is still a factor. The DILI risk for Ligand A is concerning. Considering the GPCR target class, metabolic stability (half-life) and potency (affinity) are key, but safety (DILI) is paramount.
Given the significant DILI risk associated with Ligand A, and the fact that the affinity difference isn't overwhelming, I would prioritize Ligand B. The lower DILI and better BBB penetration outweigh the slightly weaker affinity and shorter half-life, especially during early-stage drug discovery.
Output:
0
2025-04-17 22:32:33,866 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
Let's analyze each ligand against the provided guidelines, keeping in mind ADRB2 is a GPCR, so logP, TPSA, Pgp, and affinity are key.
* **Molecular Weight:** Both ligands (343.4 and 345.4 Da) fall comfortably within the 200-500 Da range.
* **TPSA:** Ligand A (58.56) is significantly better than Ligand B (130.84). A TPSA under 140 is good for oral absorption, but lower is preferred for GPCRs, and A is much closer to the ideal range.
* **logP:** Ligand A (3.769) is optimal, while Ligand B (1.075) is on the lower side. This could hinder membrane permeability for B.
* **H-Bond Donors/Acceptors:** Ligand A (2 HBD, 3 HBA) is preferable to Ligand B (4 HBD, 6 HBA). Fewer H-bonds generally improve permeability.
* **QED:** Ligand A (0.839) is better than Ligand B (0.656), indicating a more drug-like profile.
* **DILI:** Ligand B (55.758) has a slightly lower DILI risk than Ligand A (41.838), which is a positive.
* **BBB:** Ligand A (71.229) has a significantly higher BBB penetration percentile than Ligand B (58.317). While ADRB2 isn't necessarily a CNS target, higher BBB is generally favorable.
* **Caco-2:** Ligand A (-4.212) is better than Ligand B (-5.699). Higher values are better.
* **Solubility:** Ligand A (-3.923) is better than Ligand B (-2.085).
* **hERG:** Ligand A (0.549) is better than Ligand B (0.134). Lower is better.
* **Cl_mic:** Ligand B (-6.239) has a *much* better (lower) microsomal clearance than Ligand A (29.787), suggesting better metabolic stability. This is a significant advantage for B.
* **t1/2:** Ligand A (7.92) has a better in vitro half-life than Ligand B (-4.217).
* **Pgp:** Ligand A (0.351) is better than Ligand B (0.002). Lower is better.
* **Binding Affinity:** Ligand B (-6.0 kcal/mol) has a significantly better binding affinity than Ligand A (-1.8 kcal/mol). This is a *major* advantage for B, easily outweighing some of its ADME drawbacks.
**Overall Assessment:**
Ligand B has a substantially better binding affinity, and significantly improved metabolic stability (Cl_mic). While Ligand A has better TPSA, logP, and BBB, the difference in affinity is so large that it's likely to be the dominant factor in determining in vivo efficacy. The slightly higher DILI risk for A is also a concern. The better metabolic stability of B will likely translate to higher *in vivo* exposure, potentially mitigating some of the permeability concerns from its lower logP.
**Output:**
0
2025-04-17 22:32:33,866 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (362.4 & 350.4 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand B (71.3) is significantly better than Ligand A (96.8). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have acceptable logP values (1.47 & 2.51), falling within the 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Both ligands have 1 HBD, which is within the acceptable limit of 5.
5. **HBA:** Both ligands have 5 HBA, which is within the acceptable limit of 10.
6. **QED:** Both ligands have high QED scores (0.865 & 0.897), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (88.6%) has a higher DILI risk than Ligand B (63.8%). This is a significant concern, as minimizing liver toxicity is crucial.
8. **BBB:** BBB isn't a high priority for a cardiovascular target. Ligand B (87.1%) has a higher BBB percentile than Ligand A (26.0%), but this is less important in this case.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
10. **Solubility:** Both ligands have negative solubility values, indicating poor solubility. Again, the scale is unspecified.
11. **hERG:** Ligand A (0.016) has a much lower hERG inhibition risk than Ligand B (0.656). This is a major advantage for Ligand A, as hERG inhibition can cause cardiotoxicity.
12. **Cl_mic:** Ligand A (-4.344) has a much lower (better) microsomal clearance than Ligand B (40.16). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand B (33.18) has a longer in vitro half-life than Ligand A (-21.713). This is a positive for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.006) has a lower Pgp efflux liability than Ligand B (0.205). Lower Pgp is generally desirable for improved oral bioavailability.
15. **Binding Affinity:** Ligand A (-8.5 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.2 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME drawbacks.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A has superior affinity and Pgp properties. Ligand B has better TPSA and logP, but the affinity difference is substantial. The DILI risk for Ligand A is higher, but the hERG risk is much lower.
**Overall Assessment:**
The significantly stronger binding affinity of Ligand A (-8.5 kcal/mol vs -6.2 kcal/mol) is a major driver. While Ligand B has slightly better TPSA and logP, the difference isn't substantial enough to overcome the affinity gap. Ligand A also has better metabolic stability (lower Cl_mic) and Pgp efflux. The higher DILI risk for Ligand A is a concern, but can be investigated further with additional studies. The lower hERG risk is a significant safety advantage.
Output:
1
2025-04-17 22:32:33,866 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
We are targeting ADRB2, a GPCR, so the priorities are logP, Pgp, TPSA, affinity, and BBB. Let's break down the comparison:
1. **Molecular Weight:** Both are within the ideal range (200-500 Da). Ligand A (343.431) is slightly lower than Ligand B (362.861), which is generally favorable for permeability.
2. **TPSA:** Ligand A (101.88) is better than Ligand B (67.35). Both are under the 140 threshold for oral absorption, but Ligand B is significantly lower, which could be beneficial for receptor binding.
3. **logP:** Both ligands have good logP values (A: 1.513, B: 2.34), falling within the optimal 1-3 range. Ligand B is slightly higher, potentially improving membrane permeability.
4. **H-Bond Donors:** Ligand A (2) is slightly higher than Ligand B (1), but both are acceptable.
5. **H-Bond Acceptors:** Ligand A (4) is lower than Ligand B (5).
6. **QED:** Both have good QED scores (A: 0.699, B: 0.833), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (14.502) has a much lower DILI risk than Ligand B (71.694). This is a significant advantage for Ligand A.
8. **BBB:** Ligand B (74.952) has a better BBB penetration score than Ligand A (46.064). While ADRB2 isn't strictly a CNS target, some peripheral ADRB2 activity can influence CNS pathways, making some BBB penetration potentially useful.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-5.572) is slightly better than Ligand B (-5.039).
10. **Solubility:** Ligand A (-1.183) has better solubility than Ligand B (-3.164).
11. **hERG:** Both have low hERG inhibition risk (A: 0.491, B: 0.534).
12. **Cl_mic:** Ligand A (-23.347) has significantly better metabolic stability (lower clearance) than Ligand B (44.904).
13. **t1/2:** Ligand B (24.748) has a much longer half-life than Ligand A (-17.205). This is a major advantage for Ligand B.
14. **Pgp:** Ligand A (0.035) has lower P-gp efflux than Ligand B (0.219), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand A (-7.4) has a slightly better binding affinity than Ligand B (-6.9). While the difference is not huge, it's still a positive for Ligand A.
**Overall Assessment:**
Ligand A has a significantly better safety profile (lower DILI), better metabolic stability (lower Cl_mic), better solubility, and slightly better affinity. Ligand B has better BBB penetration and a longer half-life. However, the DILI risk associated with Ligand B is concerning. Considering the balance of properties, especially the critical safety aspect and the modest affinity difference, Ligand A is the more promising candidate.
**Output:**
1
2025-04-17 22:32:33,866 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (408.344 Da) is within the ideal range, while Ligand B (347.463 Da) is slightly below, but still acceptable.
2. **TPSA:** Ligand A (64.26) is good, well below the 140 threshold. Ligand B (88.91) is also acceptable, but higher.
3. **logP:** Ligand A (3.069) is optimal. Ligand B (1.652) is a bit low, potentially impacting permeability.
4. **HBD:** Both ligands have 2 HBD, which is good.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 5 HBA, both are acceptable.
6. **QED:** Both ligands have similar QED values (0.798 and 0.7), indicating good drug-likeness.
7. **DILI:** Ligand A (55.176) has a higher DILI risk than Ligand B (39.162), which is preferable.
8. **BBB:** Ligand A (71.772) has a better BBB penetration potential than Ligand B (53.974). While ADRB2 isn't necessarily a CNS target, some peripheral ADRB2 modulation can have CNS side effects, so moderate BBB penetration isn't necessarily a negative.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. This is a concern for both.
10. **Solubility:** Both ligands have negative solubility values, indicating poor solubility. This is a concern for both.
11. **hERG:** Ligand A (0.945) has a higher hERG risk than Ligand B (0.037), which is a significant advantage for Ligand B.
12. **Cl_mic:** Ligand B (15.444) has significantly lower microsomal clearance than Ligand A (32.823), indicating better metabolic stability.
13. **t1/2:** Ligand A (61.132) has a longer in vitro half-life than Ligand B (0.259), which is desirable.
14. **Pgp:** Ligand A (0.106) has lower P-gp efflux than Ligand B (0.013), which is preferable.
15. **Binding Affinity:** Ligand B (-6.1 kcal/mol) has a significantly stronger binding affinity than Ligand A (-4.2 kcal/mol) - a difference of 1.9 kcal/mol. This is a substantial advantage.
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand B excels in affinity and has a lower logP, which can be beneficial for receptor engagement. While both have issues with Caco-2 and solubility, the stronger binding of Ligand B and its lower hERG risk and better metabolic stability outweigh the slightly less favorable TPSA and BBB. The difference in binding affinity is significant enough to overcome other minor drawbacks.
**Conclusion:**
Ligand B is the more promising candidate due to its significantly higher binding affinity, lower hERG risk, and improved metabolic stability.
Output:
0
2025-04-17 22:32:33,866 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (367.519 Da and 364.515 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (70.47) and Ligand B (67.23) are both below the 140 A^2 threshold for good oral absorption, and acceptable for a cardiovascular target (not requiring significant BBB penetration). Ligand B is slightly better.
**3. logP:** Ligand A (1.201) is within the optimal 1-3 range. Ligand B (2.063) is also within range, but approaching the higher end. This could potentially lead to some solubility issues, but is not a major concern.
**4. H-Bond Donors:** Both ligands have 1 HBD, which is well within the acceptable limit of 5.
**5. H-Bond Acceptors:** Ligand A has 6 HBAs, and Ligand B has 5. Both are below the 10 limit.
**6. QED:** Both ligands have good QED scores (0.792 and 0.839), indicating good drug-like properties.
**7. DILI Risk:** Both ligands have very similar and acceptable DILI risk scores (29.857 and 29.779, respectively), well below the 40% threshold.
**8. BBB Penetration:** Ligand A (49.011) has lower BBB penetration than Ligand B (66.615). While ADRB2 is a cardiovascular target and doesn't *require* high BBB penetration, some degree of CNS exposure is possible and may contribute to side effects. This is a slight advantage for Ligand B.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-5.189 and -5.3), which is unusual and indicates poor permeability. This is a significant concern for both.
**10. Aqueous Solubility:** Both ligands have negative solubility values (-1.669 and -2.46), indicating very poor aqueous solubility. This is a major drawback for both compounds.
**11. hERG Inhibition:** Ligand A (0.135) has a much lower hERG inhibition liability than Ligand B (0.605). This is a critical advantage for Ligand A, as hERG inhibition can lead to cardiotoxicity.
**12. Microsomal Clearance:** Ligand A (4.145) has significantly lower microsomal clearance than Ligand B (35.501), indicating better metabolic stability. This is a substantial advantage for Ligand A.
**13. In vitro Half-Life:** Ligand A (27.096) has a longer in vitro half-life than Ligand B (-8.142). This is a significant advantage for Ligand A, suggesting less frequent dosing may be possible.
**14. P-gp Efflux:** Ligand A (0.036) has a much lower P-gp efflux liability than Ligand B (0.059), which is favorable for bioavailability.
**15. Binding Affinity:** Ligand B (-6.0) has a slightly better binding affinity than Ligand A (-5.2), a difference of 0.8 kcal/mol. While affinity is important, the other ADME properties are more concerning.
**Overall Assessment:**
Despite Ligand B's slightly better affinity and BBB penetration, Ligand A is the more promising candidate. The significantly lower hERG inhibition, lower microsomal clearance, longer half-life, and lower P-gp efflux of Ligand A are crucial advantages. The poor Caco-2 and solubility are concerns for both, but can be addressed with formulation strategies. The lower hERG risk is paramount for a cardiovascular drug.
Output:
1
2025-04-17 22:32:33,867 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (345.443 and 334.423 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (75.44) is slightly higher than Ligand B (65.96). Both are below the 140 threshold for oral absorption, which is good.
3. **logP:** Ligand B (3.574) is slightly higher than Ligand A (2.703), but both are within the optimal 1-3 range.
4. **HBD:** Both ligands have 1 HBD, which is acceptable.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 5. Both are within the acceptable limit of 10.
6. **QED:** Both ligands have similar QED scores (0.771 and 0.741), indicating good drug-likeness.
7. **DILI:** Ligand A (47.654) has a lower DILI risk than Ligand B (62.001). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (84.374) has a higher BBB penetration percentile than Ligand B (77.394). While ADRB2 isn't exclusively a CNS target, some distribution to the CNS is possible, and higher BBB penetration is generally favorable.
9. **Caco-2:** Both have negative values, indicating permeability issues. Ligand A (-4.95) is slightly better than Ligand B (-5.059).
10. **Solubility:** Both ligands have very poor aqueous solubility (-3.067 and -3.561). This is a significant concern for both.
11. **hERG:** Ligand A (0.339) has a lower hERG inhibition liability than Ligand B (0.863). This is a crucial advantage for Ligand A, minimizing cardiotoxicity risk.
12. **Cl_mic:** Ligand B (32.692) has a significantly lower microsomal clearance than Ligand A (60.167), suggesting better metabolic stability. This is a strong point for Ligand B.
13. **t1/2:** Ligand B (-26.301) has a longer in vitro half-life than Ligand A (-19.711), further supporting its better metabolic stability.
14. **Pgp:** Ligand A (0.294) has lower P-gp efflux liability than Ligand B (0.767), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand B (-6.4) has a slightly better binding affinity than Ligand A (-5.9). This is a 0.5 kcal/mol difference, which is noticeable but not overwhelming.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand B has a slightly better logP and affinity, but Ligand A has better TPSA and Pgp. The differences in affinity are not substantial enough to outweigh the other factors.
**Overall Assessment:**
Ligand A demonstrates a more favorable safety profile with lower DILI and hERG risk. It also has better BBB penetration and Pgp efflux properties. While Ligand B has better metabolic stability (lower Cl_mic and longer t1/2), the solubility issues are severe for both, and the safety advantages of Ligand A are more critical. The slightly better affinity of Ligand B doesn't compensate for the higher safety risks.
Output:
1
2025-04-17 22:32:33,867 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [348.353, 78.09, 2.394, 2, 3, 0.891, 68.321, 82.9, -5.043, -4.206, 0.575, -3.488, -10.394, 0.047, -7.5]
**Ligand B:** [370.559, 49.85, 2.783, 0, 4, 0.721, 25.475, 69.407, -4.615, -2.28, 0.297, 53.592, 12.292, 0.206, -5.7]
Here's a breakdown, prioritizing GPCR-relevant parameters:
1. **Molecular Weight:** Both are within the ideal range (200-500 Da). Ligand A (348.353) is slightly preferred.
2. **TPSA:** Ligand B (49.85) is significantly better than Ligand A (78.09). Lower TPSA generally favors better permeability, crucial for GPCR ligands.
3. **logP:** Both are within the optimal range (1-3). Ligand B (2.783) is slightly higher, potentially aiding membrane permeability.
4. **H-Bond Donors/Acceptors:** Ligand A (2 HBD, 3 HBA) is slightly more balanced. Ligand B (0 HBD, 4 HBA) has fewer hydrogen bond donors, which can be beneficial for permeability, but the difference isn't huge.
5. **QED:** Ligand A (0.891) is better than Ligand B (0.721), indicating a more drug-like profile.
6. **DILI Risk:** Ligand B (25.475) is *much* better than Ligand A (68.321). This is a significant advantage for Ligand B.
7. **BBB Penetration:** Ligand A (82.9) is better than Ligand B (69.407), but both are reasonably good. Given ADRB2's cardiovascular target, BBB penetration isn't *critical* but can be useful for off-target effects.
8. **Caco-2 Permeability:** Ligand A (-5.043) is better than Ligand B (-4.615).
9. **Aqueous Solubility:** Ligand A (-4.206) is better than Ligand B (-2.28).
10. **hERG Inhibition:** Ligand A (0.575) is better than Ligand B (0.297). Lower hERG risk is crucial.
11. **Microsomal Clearance:** Ligand A (-3.488) is *much* better than Ligand B (53.592). This indicates significantly better metabolic stability for Ligand A.
12. **In vitro Half-Life:** Ligand A (-10.394) is better than Ligand B (12.292).
13. **P-gp Efflux:** Ligand A (0.047) is better than Ligand B (0.206). Lower P-gp efflux is desirable.
14. **Binding Affinity:** Ligand A (-7.5) is better than Ligand B (-5.7). This is a substantial difference in potency.
**Overall Assessment:**
While Ligand B has a significantly better DILI profile and a slightly better logP, Ligand A wins on almost every other crucial parameter, especially binding affinity (-7.5 vs -5.7 kcal/mol). The substantial difference in affinity, coupled with better metabolic stability (Cl_mic, t1/2), P-gp efflux, and hERG inhibition, outweighs the DILI risk, especially considering that DILI risk can be further mitigated during lead optimization. The better QED score also favors Ligand A. For a GPCR, the binding affinity is paramount.
Therefore, I prefer Ligand A.
Output:
1
2025-04-17 22:32:33,867 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (353.853) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are reasonably low, but Ligand A (48.99) is better than Ligand B (51.02), increasing the likelihood of good oral absorption.
3. **logP:** Ligand A (4.41) is higher than Ligand B (2.64). While 4.41 is approaching the upper limit, it's still acceptable. Ligand B's logP is closer to the optimal range.
4. **HBD:** Ligand A (1) is better than Ligand B (0).
5. **HBA:** Ligand A (2) is better than Ligand B (6).
6. **QED:** Both ligands have good QED scores (A: 0.758, B: 0.798), indicating generally drug-like properties. Ligand B is slightly better.
7. **DILI:** Both have similar DILI risk (A: 63.862, B: 66.344), both are acceptable but not ideal.
8. **BBB:** Ligand B (82.474) has a significantly higher BBB penetration percentile than Ligand A (72.005). While ADRB2 isn't exclusively a CNS target, some CNS exposure or off-target effects are possible, making higher BBB penetration a slight advantage.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.825) is slightly better than Ligand B (-5.077).
10. **Solubility:** Ligand A (-5.385) has better solubility than Ligand B (-2.858).
11. **hERG:** Ligand A (0.885) has a lower hERG inhibition liability than Ligand B (0.358), which is a significant advantage for cardiovascular safety.
12. **Cl_mic:** Ligand B (69.44) has slightly higher clearance than Ligand A (66.568), meaning A is more metabolically stable.
13. **t1/2:** Ligand A (31.02) has a significantly longer in vitro half-life than Ligand B (-3.866). This is a major advantage, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.654) has lower P-gp efflux liability than Ligand B (0.239), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand B (-7.3) has a slightly better binding affinity than Ligand A (-7.2). However, the difference is small (0.1 kcal/mol).
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A has a better balance of these, despite Ligand B's slightly better affinity and BBB. The lower Pgp efflux and better solubility of Ligand A are particularly important. The longer half-life and lower hERG risk of Ligand A are also significant advantages for a cardiovascular target.
**Conclusion:**
Considering the overall profile, Ligand A is the more promising drug candidate. The slightly better ADME properties (solubility, metabolic stability, Pgp efflux, hERG) and significantly longer half-life outweigh the small difference in binding affinity.
Output:
1
2025-04-17 22:32:33,867 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [435.368, 49.41, 4.527, 1, 4, 0.754, 83.947, 79.992, -4.889, -5.714, 0.674, 49.36, 58.754, 0.641, -7.9]
**Ligand B:** [363.527, 53.51, 3.485, 0, 4, 0.777, 42.924, 81.698, -4.776, -2.993, 0.617, 77.023, -17.662, 0.612, -6.1]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, Affinity, and BBB):
1. **MW:** Ligand B (363.527) is better, falling comfortably within the 200-500 Da range and being lower than Ligand A (435.368).
2. **TPSA:** Both are above the ideal <140 for good absorption, but Ligand B (53.51) is slightly higher than Ligand A (49.41). This isn't a huge difference.
3. **logP:** Ligand A (4.527) is a bit high, potentially leading to off-target effects or solubility issues. Ligand B (3.485) is much better, falling within the optimal 1-3 range.
4. **HBD:** Ligand A (1) is preferable to Ligand B (0). A single HBD can aid solubility without significantly impacting permeability.
5. **HBA:** Both have 4 HBA, which is acceptable.
6. **QED:** Both are good (0.754 and 0.777), indicating drug-like properties.
7. **DILI:** Ligand B (42.924) is significantly better than Ligand A (83.947), indicating a much lower risk of liver injury. This is a major advantage.
8. **BBB:** Both have good BBB penetration (79.992 and 81.698), which is good for a GPCR target. Ligand B is slightly better.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability.
10. **Solubility:** Ligand B (-2.993) is better than Ligand A (-5.714), indicating better aqueous solubility.
11. **hERG:** Both are low risk (0.674 and 0.617).
12. **Cl_mic:** Ligand A (49.36) has a lower clearance than Ligand B (77.023), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-17.662) has a very short in vitro half-life, which is a significant drawback. Ligand A (58.754) is much better.
14. **Pgp:** Both have low Pgp efflux (0.641 and 0.612), which is good.
15. **Affinity:** Ligand A (-7.9) has a significantly stronger binding affinity than Ligand B (-6.1). This is a substantial advantage (1.8 kcal/mol difference).
**Overall Assessment:**
Ligand A has a much stronger binding affinity and better metabolic stability (longer half-life). However, Ligand B excels in safety (DILI) and has a more favorable logP. The affinity difference is significant enough to outweigh the higher logP and slightly worse metabolic stability of Ligand A, *especially* given the substantial DILI risk associated with Ligand A. The poor Caco-2 values for both are concerning, but can be addressed in later optimization stages.
Therefore, I prefer Ligand A.
Output:
1
2025-04-17 22:32:33,867 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.315 and 349.308 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (133.51) is slightly above the preferred <140 for good oral absorption, but still reasonable. Ligand B (46.61) is excellent, well below 90, suggesting good permeability. This favors Ligand B.
3. **logP:** Ligand A (0.703) is a bit low, potentially hindering permeation. Ligand B (2.891) is within the optimal 1-3 range. This strongly favors Ligand B.
4. **HBD:** Ligand A (1) is good. Ligand B (0) is also good, minimizing potential issues. No clear preference.
5. **HBA:** Ligand A (9) is acceptable. Ligand B (4) is also good. No clear preference.
6. **QED:** Ligand A (0.775) is better than Ligand B (0.629), indicating a more drug-like profile. This favors Ligand A.
7. **DILI:** Ligand A (87.476) has a higher DILI risk than Ligand B (76.464), but both are still acceptable (below 90). This favors Ligand B.
8. **BBB:** Ligand A (48.972) has a lower BBB penetration than Ligand B (86.39). While ADRB2 isn't strictly a CNS target, some CNS exposure could be beneficial or at least not detrimental, and lower efflux is generally desirable. This favors Ligand B.
9. **Caco-2:** Ligand A (-4.517) and Ligand B (-4.24) are both very poor. This is a significant concern for both, but not a differentiating factor.
10. **Solubility:** Ligand A (-2.878) is better than Ligand B (-4.566). This favors Ligand A.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.091 and 0.492). No clear preference.
12. **Cl_mic:** Ligand A (92.166) has higher microsomal clearance than Ligand B (90.416), suggesting faster metabolism. This favors Ligand B.
13. **t1/2:** Ligand B (22.885) has a significantly longer in vitro half-life than Ligand A (-13.115). This is a major advantage for Ligand B.
14. **Pgp:** Ligand A (0.017) has lower P-gp efflux than Ligand B (0.646). This is a positive for Ligand A.
15. **Binding Affinity:** Ligand B (-5.6) has a slightly better binding affinity than Ligand A (-5.2). While the difference is not huge, it's still a factor.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand B is the stronger candidate. It has a better logP, significantly better TPSA, better BBB penetration, longer half-life, and slightly better affinity. While Ligand A has a better QED and solubility, the ADME properties of Ligand B are more favorable for oral bioavailability and duration of action. The Caco-2 permeability is poor for both, but can be addressed with formulation strategies.
Output:
0
2025-04-17 22:32:33,867 - INFO - Batch 339 complete. Total preferences: 5424
2025-04-17 22:32:33,867 - INFO - Processing batch 340/512...
2025-04-17 22:33:23,110 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (351.403 Da) is within the ideal range (200-500 Da). Ligand B (396.487 Da) is also acceptable, leaning towards the upper end.
2. **TPSA:** Ligand A (104.9) is good, under the 140 threshold for oral absorption. Ligand B (137.92) is approaching the upper limit, potentially impacting absorption.
3. **logP:** Ligand A (0.521) is a bit low, potentially hindering membrane permeability. Ligand B (-1.925) is significantly lower, raising concerns about permeability.
4. **HBD:** Both ligands have 2 HBD, which is within the acceptable limit of 5.
5. **HBA:** Ligand A has 6 HBA, within the acceptable limit of 10. Ligand B has 7 HBA, also acceptable.
6. **QED:** Both ligands have reasonable QED scores (A: 0.662, B: 0.552), indicating good drug-like properties.
7. **DILI:** Ligand A (48.275) has a slightly higher DILI risk than Ligand B (35.905), but both are below the concerning threshold of 60.
8. **BBB:** Ligand A (49.554) has a moderate BBB penetration, while Ligand B (13.377) has very low BBB penetration. Since ADRB2 is a GPCR, BBB penetration isn't a primary concern unless targeting CNS effects, but it's a consideration.
9. **Caco-2:** Ligand A (-4.833) and Ligand B (-5.704) both have negative Caco-2 values, which is unusual and suggests very poor permeability. This is a significant red flag.
10. **Solubility:** Ligand A (-1.863) and Ligand B (-1.178) both have negative solubility values, indicating poor aqueous solubility. This is another significant concern.
11. **hERG:** Both ligands have very low hERG inhibition risk (A: 0.112, B: 0.035), which is excellent.
12. **Cl_mic:** Ligand A (16.975) has a moderate clearance, while Ligand B (-15.667) has a negative clearance, which is not physically possible and likely an error in the data. This is a major issue for Ligand B.
13. **t1/2:** Ligand A (25.863 hours) has a reasonable half-life. Ligand B (14.079 hours) has a shorter half-life.
14. **Pgp:** Both ligands have very low Pgp efflux liability (A: 0.06, B: 0.01), which is favorable.
15. **Affinity:** Ligand B (-6.4 kcal/mol) has a slightly better binding affinity than Ligand A (-5.6 kcal/mol). The difference is 0.8 kcal/mol, which is substantial.
**Overall Assessment:**
Both ligands have significant issues with permeability (Caco-2) and solubility. However, Ligand B has a more concerning negative microsomal clearance value, which is a critical flaw. While Ligand B has slightly better affinity, the negative clearance makes it highly unlikely to be a viable drug candidate. Ligand A, despite its low logP and permeability issues, is the better option because its ADME properties are at least plausible. The affinity difference, while notable, doesn't outweigh the severe issue with Ligand B's metabolism.
Output:
1
2025-04-17 22:33:23,111 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (338.411 & 346.431 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Both ligands (78.09 & 78.68) are below the 140 A^2 threshold for good oral absorption, and acceptable for a cardiovascular target (not requiring significant BBB penetration). No significant difference.
3. **logP:** Ligand A (1.943) is slightly higher than Ligand B (0.902), both within the optimal 1-3 range. Ligand A is preferable.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable, below the threshold of 5. Ligand B is slightly better.
5. **HBA:** Ligand A (3) and Ligand B (5) are both acceptable, below the threshold of 10. Ligand A is preferable.
6. **QED:** Both ligands have good QED scores (0.818 & 0.857), indicating good drug-like properties. No significant difference.
7. **DILI:** Ligand A (62.776) has a higher DILI risk than Ligand B (18.922). Ligand B is significantly better here.
8. **BBB:** Ligand A (50.601) has a lower BBB penetration percentile than Ligand B (87.088). While ADRB2 isn't a CNS target, higher BBB is generally favorable. Ligand B is preferable.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.701 & -5.078), which is unusual and suggests poor permeability. However, the values are similar.
10. **Solubility:** Ligand A (-3.671) has slightly worse solubility than Ligand B (-1.289). Ligand B is preferable.
11. **hERG:** Both ligands have low hERG inhibition risk (0.257 & 0.435). No significant difference.
12. **Cl_mic:** Ligand A (24.41) has lower microsomal clearance than Ligand B (31.39), indicating better metabolic stability. Ligand A is preferable.
13. **t1/2:** Ligand A (-9.224) has a significantly longer in vitro half-life than Ligand B (-19.99). This is a major advantage for Ligand A.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.057 & 0.061). No significant difference.
15. **Binding Affinity:** Ligand B (-6.8 kcal/mol) has a stronger binding affinity than Ligand A (-5.6 kcal/mol). This is a 1.2 kcal/mol difference, which is substantial and outweighs some of the ADME drawbacks of Ligand B.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand B excels in affinity and has a better logP and BBB. While Ligand A has better metabolic stability (Cl_mic, t1/2), the significant affinity advantage of Ligand B is crucial. The DILI risk is also much lower for Ligand B.
**Conclusion:**
Despite Ligand A's better metabolic stability, the significantly stronger binding affinity and lower DILI risk of Ligand B make it the more promising drug candidate for ADRB2.
Output:
0
2025-04-17 22:33:23,111 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [350.379, 130.17 , -0.289, 2. , 7. , 0.646, 70.88 , 65.839, -5.371, -2.389, 0.019, 33.928, -11.669, 0.028, -6.4 ]
**Ligand B:** [365.411, 101.74 , 1.69 , 1. , 7. , 0.749, 82.862, 38.813, -4.761, -2.556, 0.093, 56.18 , 42.693, 0.12 , -6.6 ]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity, and BBB):
1. **MW:** Both are within the ideal 200-500 Da range. A (350.379) is slightly preferred.
2. **TPSA:** A (130.17) is a bit higher than B (101.74). B is better here, closer to the <140 cutoff for oral absorption.
3. **logP:** A (-0.289) is quite low, potentially hindering permeability. B (1.69) is much better, falling within the optimal 1-3 range. This is a significant advantage for B.
4. **HBD:** Both are acceptable (A: 2, B: 1). B is slightly better.
5. **HBA:** Both are similar (A: 7, B: 7), and within the acceptable limit of 10.
6. **QED:** Both are good (A: 0.646, B: 0.749), indicating drug-like properties. B is slightly better.
7. **DILI:** A (70.88) is better than B (82.862), indicating a lower risk of liver injury.
8. **BBB:** A (65.839) has better BBB penetration than B (38.813). This is a positive for A, though not critical for a non-CNS target like ADRB2, it's still a benefit.
9. **Caco-2:** Both are negative, indicating poor permeability. A (-5.371) is worse than B (-4.761).
10. **Solubility:** Both are negative, indicating poor solubility. A (-2.389) is slightly better than B (-2.556).
11. **hERG:** Both are very low (A: 0.019, B: 0.093), indicating minimal hERG inhibition risk. A is better.
12. **Cl_mic:** A (33.928) has lower clearance than B (56.18), suggesting better metabolic stability. This is a positive for A.
13. **t1/2:** A (-11.669) has a negative half-life, which is concerning. B (42.693) has a positive half-life, which is much better.
14. **Pgp:** Both are very low (A: 0.028, B: 0.12), indicating minimal P-gp efflux. A is better.
15. **Affinity:** B (-6.6) has slightly better binding affinity than A (-6.4). While the difference is small, it's still a factor.
**Overall Assessment:**
Ligand B has a much more favorable logP, which is crucial for GPCRs. It also has a better QED and a positive in vitro half-life. While Ligand A has better DILI, BBB, and clearance, the poor logP and negative half-life are significant drawbacks. The slight affinity advantage of B further tips the balance. Considering the GPCR-specific priorities, the improved logP and half-life of B outweigh the benefits of A.
Output:
0
2025-04-17 22:33:23,111 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (372.515 Da) is slightly higher than Ligand B (360.47 Da), but both are acceptable.
2. **TPSA:** Ligand A (50.36) is significantly better than Ligand B (98.66). ADRB2 is not a CNS target, but lower TPSA generally correlates with better absorption. Ligand B's TPSA is quite high, potentially hindering oral bioavailability.
3. **logP:** Ligand A (4.321) is a bit high, potentially leading to solubility issues and off-target interactions, but still within a reasonable range. Ligand B (1.461) is on the lower side, which could limit permeability.
4. **HBD:** Ligand A (2) is preferable to Ligand B (4). Fewer HBDs generally improve membrane permeability.
5. **HBA:** Both ligands have the same number of HBA (4), which is acceptable.
6. **QED:** Ligand A (0.621) has a better QED score than Ligand B (0.37), indicating a more drug-like profile.
7. **DILI:** Ligand A (74.99) has a higher DILI risk than Ligand B (19.387). This is a significant drawback for Ligand A.
8. **BBB:** This is less critical for ADRB2, but Ligand A (71.966) is better than Ligand B (60.566).
9. **Caco-2:** Both ligands have similar, poor Caco-2 permeability (-4.86 and -4.938).
10. **Solubility:** Ligand A (-5.262) has slightly better solubility than Ligand B (-2.382).
11. **hERG:** Both ligands have similar hERG risk (0.588 and 0.627).
12. **Cl_mic:** Ligand A (93.147) has a much higher microsomal clearance than Ligand B (31.455), indicating faster metabolism and potentially lower *in vivo* exposure. This is a major negative for Ligand A.
13. **t1/2:** Ligand B (-31.848) has a much longer *in vitro* half-life than Ligand A (87.7). This is a significant advantage for Ligand B.
14. **Pgp:** Both ligands have similar Pgp efflux liability (0.66 and 0.109).
15. **Affinity:** Ligand A (-8.2 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.6 kcal/mol). This is a substantial advantage for Ligand A.
**Overall Assessment:**
Ligand A boasts a much stronger binding affinity, which is a critical factor for GPCRs. However, it suffers from higher DILI risk, significantly higher metabolic clearance, and a shorter half-life. Ligand B, while having a weaker affinity, presents a much better ADME profile: lower DILI risk, better metabolic stability (lower Cl_mic, longer t1/2), and a more favorable TPSA. Considering the balance, the improved ADME properties of Ligand B outweigh the affinity difference, especially given the potential for optimization of Ligand B's binding affinity. The high DILI risk and poor metabolic stability of Ligand A are significant hurdles to overcome.
Output:
0
2025-04-17 22:33:23,112 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (346.383 and 362.436 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (80.86) is higher than Ligand B (58.2). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B has a clear advantage.
3. **logP:** Ligand B (3.721) is slightly higher than Ligand A (2.21). While both are within the optimal 1-3 range, Ligand B is approaching the upper limit. This *could* pose solubility issues, but isn't a major concern at this level.
4. **HBD:** Ligand A (1) has fewer HBD than Ligand B (2). Fewer HBDs are generally favorable for permeability. Ligand A has a slight advantage.
5. **HBA:** Ligand A (5) has more HBA than Ligand B (2). Fewer HBA are generally favorable for permeability. Ligand B has a clear advantage.
6. **QED:** Ligand A (0.859) has a significantly higher QED score than Ligand B (0.647), indicating a more drug-like profile. This is a substantial advantage for Ligand A.
7. **DILI:** Ligand B (35.285) has a much lower DILI risk than Ligand A (73.245). This is a significant advantage for Ligand B, as minimizing liver toxicity is crucial.
8. **BBB:** Ligand B (86.468) shows better BBB penetration than Ligand A (74.758). While ADRB2 is not a CNS target, some degree of BBB penetration can be useful for understanding off-target effects. Ligand B has a slight advantage.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.471 and -4.524), which is unusual and suggests poor permeability. This is a significant drawback for both, but similar for both.
10. **Solubility:** Both ligands have negative solubility values (-4.036 and -4.364), also unusual and suggesting poor solubility. Similar drawback for both.
11. **hERG:** Ligand A (0.69) has a slightly higher hERG risk than Ligand B (0.412). Lower hERG risk is preferred. Ligand B has a slight advantage.
12. **Cl_mic:** Ligand B (54.915) has a higher microsomal clearance than Ligand A (35.665), meaning it's metabolized faster. Ligand A has a clear advantage here, indicating better metabolic stability.
13. **t1/2:** Ligand A (-14.164) has a negative in vitro half-life, which is concerning. Ligand B (4.347) has a positive half-life. This is a major advantage for Ligand B.
14. **Pgp:** Ligand A (0.151) has lower P-gp efflux than Ligand B (0.077). Lower efflux is generally preferred for bioavailability. Ligand A has a slight advantage.
15. **Binding Affinity:** Ligand B (-8.3) has a significantly stronger binding affinity than Ligand A (-6.0). This is a substantial advantage for Ligand B, potentially outweighing some of the ADME drawbacks.
**Overall Assessment:**
Ligand B has a significantly stronger binding affinity and a much lower DILI risk. It also has a better half-life and BBB penetration. While it has a slightly higher logP and Pgp efflux, these are less critical concerns than the advantages it possesses. Ligand A has a better QED and metabolic stability, but the significantly weaker binding affinity and higher DILI risk are major drawbacks. The negative Caco-2 and solubility values are concerning for both, but the affinity difference is the deciding factor.
Output:
0
2025-04-17 22:33:23,112 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (356.53 & 353.42 Da) fall comfortably within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (49.41) is significantly better than Ligand B (116.05). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold, while Ligand B is approaching it.
3. **logP:** Ligand A (3.942) is optimal, while Ligand B (-1.029) is quite low. This is a significant drawback for Ligand B, potentially hindering membrane permeability and bioavailability.
4. **HBD:** Both have acceptable HBD counts (1 and 2 respectively), below the threshold of 5.
5. **HBA:** Both have acceptable HBA counts (2 and 4 respectively), below the threshold of 10.
6. **QED:** Both ligands have similar QED values (0.751 and 0.657) indicating good drug-like properties.
7. **DILI:** Ligand A (9.23) has a much lower DILI risk than Ligand B (25.82). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (94.03) shows good BBB penetration, while Ligand B (54.13) is lower. While not critical for a cardiovascular target, higher BBB is generally favorable.
9. **Caco-2:** Ligand A (-4.504) and Ligand B (-5.373) both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so the absolute values are less informative.
10. **Solubility:** Ligand A (-4.017) and Ligand B (-1.153) both have negative solubility values, which is unusual and suggests poor solubility. However, the scale is not specified, so the absolute values are less informative.
11. **hERG:** Ligand A (0.882) has a lower hERG risk than Ligand B (0.058), which is a significant safety advantage.
12. **Cl_mic:** Ligand B (-16.44) has a much lower microsomal clearance, indicating better metabolic stability than Ligand A (51.484). This is a strong point for Ligand B.
13. **t1/2:** Ligand B (1.782) has a slightly longer in vitro half-life than Ligand A (-1.319).
14. **Pgp:** Ligand A (0.178) has lower P-gp efflux liability than Ligand B (0.002), which is a positive for bioavailability.
15. **Binding Affinity:** Ligand A (-6.8 kcal/mol) has a slightly better binding affinity than Ligand B (-6.3 kcal/mol), although the difference is relatively small.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A excels in logP and Pgp, and has slightly better affinity. Ligand B has better metabolic stability (Cl_mic) and half-life. However, the poor logP and higher DILI/hERG risks of Ligand B are significant concerns.
**Overall Assessment:**
While Ligand B has advantages in metabolic stability, the combination of Ligand A's superior logP, lower DILI/hERG risk, and acceptable affinity makes it the more promising candidate. The issues with Caco-2 and solubility are shared by both, and can be addressed through formulation strategies.
Output:
1
2025-04-17 22:33:23,112 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (344.46 and 344.42 Da) fall comfortably within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (67.23) is better than Ligand B (78.53). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally indicates better permeability.
3. **logP:** Both ligands have good logP values (1.92 and 1.23), falling within the 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Both have 1 HBD, which is acceptable.
5. **HBA:** Both have 4 HBA, which is acceptable.
6. **QED:** Both ligands have similar QED scores (0.857 and 0.834), indicating good drug-likeness.
7. **DILI:** Ligand A (32.88) has a significantly lower DILI risk than Ligand B (50.14). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (68.86) has a higher BBB penetration score than Ligand B (53.08). While not critical for a cardiovascular target, it's a slight positive for Ligand A.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.93 and -4.68), indicating poor permeability. This is a concern for both.
10. **Solubility:** Both ligands have negative solubility values (-2.52 and -2.91), indicating poor solubility. This is a concern for both.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.22 and 0.10). This is excellent for both.
12. **Cl_mic:** Ligand A (24.32) has a higher microsomal clearance than Ligand B (-4.44). This suggests Ligand B is more metabolically stable, a significant advantage.
13. **t1/2:** Ligand B (-7.71) has a much longer in vitro half-life than Ligand A (-0.25). This is a substantial advantage for Ligand B.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.067 and 0.023), which is good.
15. **Binding Affinity:** Ligand A (-7.0) and Ligand B (-6.0) have good binding affinities, but Ligand A is 1 kcal/mol stronger. This is a significant advantage for Ligand A, and can often outweigh other concerns.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A has a slightly better logP and significantly better affinity. Ligand B has better metabolic stability (Cl_mic) and half-life. The DILI risk is also a major concern, and Ligand A is significantly better in this regard.
**Overall Assessment:**
While Ligand B has a better half-life and metabolic stability, the stronger binding affinity and significantly lower DILI risk of Ligand A are more compelling. The slightly better TPSA and BBB values of Ligand A also contribute. The poor Caco-2 and solubility are concerns for both, but can be addressed with formulation strategies. The affinity difference is substantial enough to outweigh the metabolic stability advantage of Ligand B.
Output:
1
2025-04-17 22:33:23,112 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [375.447, 128.03 , -0.583, 2. , 6. , 0.633, 49.399, 73.284, -5.088, -1.935, 0.13 , 20.632, -17.534, 0.023, -7.9 ]
**Ligand B:** [370.431, 94.09 , -0.357, 0. , 8. , 0.577, 53.509, 61.38 , -4.933, -1.251, 0.167, 10.382, 10.345, 0.038, -5.9 ]
Here's a breakdown, prioritizing GPCR-relevant parameters:
1. **Molecular Weight:** Both ligands are within the ideal 200-500 Da range. A is 375.447, B is 370.431. Very similar.
2. **TPSA:** Ligand A (128.03) is slightly higher than Ligand B (94.09). Ligand B is better here, being closer to the <140 threshold for oral absorption and more favorable for GPCRs.
3. **logP:** Both are acceptable (-0.583 and -0.357, respectively), falling within the 1-3 range. Ligand B is slightly better, being closer to the optimal range.
4. **H-Bond Donors/Acceptors:** Ligand A has 2 HBD and 6 HBA. Ligand B has 0 HBD and 8 HBA. Both are within acceptable limits.
5. **QED:** Both have good QED scores (0.633 and 0.577), indicating good drug-like properties.
6. **DILI:** Both have acceptable DILI risk (49.399 and 53.509), below the concerning threshold of 60.
7. **BBB:** Ligand A (73.284) has a significantly better BBB penetration percentile than Ligand B (61.38). This is a key advantage for a GPCR, even a cardiovascular one, as some CNS off-target effects are always a consideration.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-5.088) is slightly worse than Ligand B (-4.933).
9. **Solubility:** Both have negative solubility values, which is also unusual and suggests poor solubility. Ligand A (-1.935) is slightly worse than Ligand B (-1.251).
10. **hERG:** Both have very low hERG inhibition liability (0.13 and 0.167), which is excellent.
11. **Cl_mic:** Ligand A (20.632) has a higher microsomal clearance than Ligand B (10.382), indicating faster metabolism and potentially lower *in vivo* exposure.
12. **t1/2:** Ligand A (-17.534) has a negative half-life, which is not possible. Ligand B (10.345) has a positive half-life, which is good.
13. **Pgp:** Both have very low P-gp efflux liability (0.023 and 0.038), which is favorable.
14. **Binding Affinity:** Ligand A (-7.9 kcal/mol) has a significantly stronger binding affinity than Ligand B (-5.9 kcal/mol). This is a substantial difference.
**Overall Assessment:**
The biggest differentiator is the binding affinity. Ligand A's -7.9 kcal/mol is considerably stronger than Ligand B's -5.9 kcal/mol. This difference in potency is likely to outweigh the slight disadvantages in TPSA, Caco-2, and solubility. The better BBB penetration of Ligand A is also a significant benefit. Ligand B has a better half-life, but the negative half-life for Ligand A is a data error.
Therefore, I would choose Ligand A.
```
1
```
2025-04-17 22:33:23,112 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (351.491 and 348.447 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (61.88) is better than Ligand B (72.96). Both are below 140, but closer to 90 is preferred for GPCRs, and A is closer.
3. **logP:** Ligand A (1.273) is within the optimal 1-3 range. Ligand B (-0.33) is slightly below 1, which *could* indicate permeability issues. This is a point in favor of A.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Both ligands have 4 HBA, which is good.
6. **QED:** Both ligands have similar QED scores (0.702 and 0.706), indicating good drug-likeness.
7. **DILI:** Ligand A (18.728) has a significantly lower DILI risk than Ligand B (35.789). This is a substantial advantage for A.
8. **BBB:** Both ligands have similar BBB penetration (61.962 and 64.637). While not exceptionally high, it's not a major differentiating factor for ADRB2, which isn't necessarily a CNS target.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the values are similar (-4.64 and -4.568).
10. **Solubility:** Both ligands have negative solubility values, which is also unusual. Again, the values are similar (-2.033 and -1.017).
11. **hERG:** Both ligands have very low hERG inhibition risk (0.171 and 0.147).
12. **Cl_mic:** Ligand B (20.352) has a significantly lower microsomal clearance than Ligand A (38.143), indicating better metabolic stability. This is a strong point in favor of B.
13. **t1/2:** Ligand B (-26.762) has a much longer *in vitro* half-life than Ligand A (7.391). This is a significant advantage for B.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.038 and 0.012).
15. **Binding Affinity:** Both ligands have very similar binding affinities (-5.6 and -5.7 kcal/mol). The difference is negligible.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, and affinity), Ligand A has a slight edge in logP and TPSA. However, Ligand B demonstrates superior metabolic stability (lower Cl_mic) and a significantly longer half-life. The lower DILI risk of Ligand A is also a major advantage. The Caco-2 and solubility values are concerning for both, but similar. Given the balance, the improved metabolic stability and half-life of Ligand B, combined with acceptable DILI risk, outweigh the slightly better logP and TPSA of Ligand A.
Output:
0
2025-04-17 22:33:23,113 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (367.5 and 346.5 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand B (75.2) is significantly better than Ligand A (91.1), being well below the 140 threshold and more favorable for oral absorption. This is a point in favor of B.
3. **logP:** Both ligands have good logP values (2.62 and 2.72), falling within the optimal 1-3 range. No significant difference.
4. **HBD:** Ligand B (1 HBD) is preferable to Ligand A (3 HBD). Lower HBD generally improves permeability.
5. **HBA:** Both ligands have 4 HBA, which is acceptable.
6. **QED:** Ligand B (0.859) has a higher QED score than Ligand A (0.616), indicating a more drug-like profile. This is a significant advantage for B.
7. **DILI:** Ligand B (25.0) has a much lower DILI risk than Ligand A (64.3), making it substantially safer. This is a major advantage for B.
8. **BBB:** Ligand B (72.1) shows better BBB penetration than Ligand A (41.7), which is important for GPCRs.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. Ligand A (-5.513) is slightly worse than Ligand B (-4.871), but both are concerning.
10. **Solubility:** Ligand B (-1.848) has better solubility than Ligand A (-4.198).
11. **hERG:** Both ligands have very low hERG inhibition risk (0.228 and 0.205), which is excellent. No difference.
12. **Cl_mic:** Ligand B (14.5) has significantly lower microsomal clearance than Ligand A (57.2), suggesting better metabolic stability. This is a key advantage for B.
13. **t1/2:** Ligand B (-0.791) has a negative in vitro half-life, which is concerning, but Ligand A (1.241) is only slightly better. Both are not ideal.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.182 and 0.015). No significant difference.
15. **Binding Affinity:** Ligand B (-7.3 kcal/mol) has a slightly better binding affinity than Ligand A (-6.3 kcal/mol), a difference of 1 kcal/mol. This is a moderate advantage for B.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand B excels in TPSA, Pgp, and has a slightly better affinity. BBB penetration is also better for Ligand B. The most significant difference is the much lower DILI risk and improved metabolic stability (lower Cl_mic) of Ligand B.
**Conclusion:**
Ligand B consistently outperforms Ligand A across several crucial parameters, particularly safety (DILI), metabolic stability (Cl_mic), and drug-likeness (QED). While both have issues with Caco-2 permeability, the overall profile of Ligand B is far more favorable for development as a drug candidate. The slightly better affinity of B further solidifies its preference.
Output:
0
2025-04-17 22:33:23,113 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands are within the ideal 200-500 Da range (A: 367.471, B: 333.435). No significant difference here.
**2. TPSA:** Ligand B (56.92) is significantly better than Ligand A (108.29) regarding TPSA. For a GPCR, lower TPSA is generally preferred for better permeability.
**3. logP:** Ligand A (1.829) is within the optimal range (1-3), while Ligand B (4.682) is slightly high. High logP can lead to solubility issues and off-target interactions, though it isn't drastically outside the acceptable range.
**4. H-Bond Donors:** Ligand A (2) and B (3) are both acceptable.
**5. H-Bond Acceptors:** Ligand A (5) and B (1) are both acceptable.
**6. QED:** Both ligands have similar QED values (A: 0.613, B: 0.602), indicating good drug-likeness.
**7. DILI:** Ligand A (55.68) has a lower DILI risk than Ligand B (74.99). This is a significant advantage for Ligand A.
**8. BBB:** Ligand B (71.19) has a higher BBB penetration percentile than Ligand A (47.654). While ADRB2 isn't necessarily a CNS target, some cardiovascular effects can be mediated by central pathways, so some BBB penetration isn't necessarily detrimental.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.934 and -4.819), which is unusual and suggests poor permeability. This is a concern for both.
**10. Aqueous Solubility:** Ligand A (-3.401) has better aqueous solubility than Ligand B (-5.669).
**11. hERG Inhibition:** Ligand A (0.482) has a lower hERG inhibition liability than Ligand B (0.888), which is a crucial advantage for cardiovascular drugs.
**12. Microsomal Clearance:** Ligand B (48.091) has slightly lower microsomal clearance than Ligand A (30.508), suggesting better metabolic stability.
**13. In vitro Half-Life:** Ligand B (30.119) has a significantly longer in vitro half-life than Ligand A (-1.92). This is a major advantage for Ligand B.
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (A: 0.069, B: 0.492).
**15. Binding Affinity:** Both ligands have very similar and strong binding affinities (A: -6.1, B: -5.9). The difference is less than the 1.5 kcal/mol threshold.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand A is the better candidate. While Ligand B has a longer half-life and better BBB penetration, Ligand A has a significantly lower DILI risk and hERG inhibition, which are critical for a cardiovascular drug. The lower TPSA of Ligand B is attractive, but the higher logP and DILI risk are concerning. The slightly better solubility of Ligand A is also a plus. The binding affinity is comparable, so the ADME/Tox profile becomes the deciding factor.
Output:
1
2025-04-17 22:33:23,113 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
The target is ADRB2, a GPCR. Therefore, I will prioritize logP, Pgp, TPSA, BBB, and binding affinity, followed by general drug-like properties.
* **Molecular Weight:** Both ligands are within the ideal range (345.403 Da and 346.475 Da).
* **TPSA:** Ligand B (58.44) is significantly better than Ligand A (103.25). Lower TPSA generally improves cell permeability, crucial for GPCR targeting.
* **logP:** Ligand B (2.394) is within the optimal range, while Ligand A (0.556) is quite low, potentially hindering membrane permeability. This is a significant advantage for Ligand B.
* **H-Bond Donors/Acceptors:** Ligand A has 3 HBD and 5 HBA, while Ligand B has 0 HBD and 4 HBA. Both are acceptable, but Ligand B's lower HBD count is slightly preferable.
* **QED:** Both ligands have good QED scores (0.682 and 0.79), indicating good overall drug-likeness.
* **DILI:** Both ligands have similar, acceptable DILI risk (40.287 and 43.234).
* **BBB:** Ligand B (72.082) has a much higher BBB penetration percentile than Ligand A (17.371). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be beneficial or at least needs to be understood.
* **Caco-2 Permeability:** Ligand A (-5.517) and Ligand B (-4.61) are both negative, indicating poor permeability.
* **Aqueous Solubility:** Both have negative solubility values, suggesting poor solubility.
* **hERG:** Both ligands have low hERG inhibition risk (0.223 and 0.527).
* **Microsomal Clearance:** Ligand A (-10.084) has a much lower (better) microsomal clearance than Ligand B (56.925), indicating better metabolic stability.
* **In vitro Half-Life:** Ligand A (-12.706) has a lower half-life than Ligand B (-10.029).
* **P-gp Efflux:** Ligand A (0.007) shows very low P-gp efflux, which is excellent. Ligand B (0.291) is higher, but still relatively low.
* **Binding Affinity:** Both ligands have very similar binding affinities (-6.9 kcal/mol and -6.8 kcal/mol). The difference is negligible.
**Overall Assessment:**
Ligand B is the better candidate. While Ligand A has better metabolic stability (lower Cl_mic) and P-gp efflux, Ligand B excels in crucial GPCR-relevant properties like TPSA, logP, and BBB penetration. The significantly better logP and TPSA of Ligand B are likely to translate to better cell permeability and receptor engagement, outweighing the slightly worse metabolic stability. The higher BBB value is also a plus. The binding affinities are nearly identical, so this doesn't factor into the decision.
**Output:**
0
2025-04-17 22:33:23,113 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (361.433 and 348.447 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (78.51) is slightly higher than Ligand B (67.67). Both are below 140, suitable for oral absorption, but Ligand B is preferable.
3. **logP:** Ligand A (1.691) and Ligand B (0.938) are both within the optimal 1-3 range. Ligand A is slightly better.
4. **HBD:** Ligand A (2) is better than Ligand B (0). A small number of HBDs are generally preferred for permeability.
5. **HBA:** Ligand A (3) is better than Ligand B (5). Lower HBA is preferable for permeability.
6. **QED:** Both ligands have good QED scores (0.691 and 0.794), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (19.891) has a significantly lower DILI risk than Ligand B (40.171). This is a major advantage for Ligand A.
8. **BBB:** Both ligands have high BBB penetration (83.986 and 88.29). Ligand B is slightly better.
9. **Caco-2:** Both ligands have negative Caco-2 permeability (-4.989 and -4.348). This is concerning, and suggests poor absorption.
10. **Solubility:** Ligand A (-2.71) has slightly better solubility than Ligand B (-1.288).
11. **hERG:** Both ligands have very low hERG inhibition risk (0.318 and 0.207). No significant difference.
12. **Cl_mic:** Ligand A (19.528) has much lower microsomal clearance than Ligand B (43.79), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (-21.85) has a much longer in vitro half-life than Ligand B (12.396). This is a major advantage for Ligand A.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.029 and 0.144). No significant difference.
15. **Binding Affinity:** Ligand A (-6.9) has a slightly better binding affinity than Ligand B (-3.9). This is a significant advantage for Ligand A.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. While both ligands perform reasonably well on logP and Pgp, Ligand A has a better TPSA, and significantly better affinity. The DILI and metabolic stability (Cl_mic and t1/2) are also crucial for overall drug development success, and Ligand A is superior in these aspects.
**Conclusion:**
Ligand A is the better candidate. It has a lower DILI risk, better metabolic stability (lower Cl_mic, longer t1/2), better binding affinity, and slightly better solubility. While Ligand B has a slightly better BBB penetration and QED, the advantages of Ligand A outweigh these minor differences. The negative Caco-2 values are concerning for both, but can be addressed during lead optimization.
Output:
1
2025-04-17 22:33:23,113 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [372.462, 67.87, 0.91, 1, 5, 0.795, 49.942, 83.637, -5.067, -3.355, 0.214, 45.43, -14.196, 0.055, -7.5]
**Ligand B:** [426.296, 108.62, 1.374, 3, 7, 0.527, 82.474, 19.542, -5.58, -2.623, 0.405, 37.048, 56.266, 0.078, -7.7]
**Step-by-step comparison:**
1. **MW:** Ligand A (372.462 Da) is better, falling nicely within the 200-500 Da range. Ligand B (426.296 Da) is still acceptable, but closer to the upper limit.
2. **TPSA:** Ligand A (67.87) is significantly better than Ligand B (108.62). For a GPCR, keeping TPSA lower is beneficial for permeability. Ligand B is above the preferred 90 A^2 threshold.
3. **logP:** Both are good (A: 0.91, B: 1.374), falling within the 1-3 range. Ligand B is slightly better.
4. **HBD:** Ligand A (1) is preferred over Ligand B (3). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (5) is better than Ligand B (7), again favoring permeability.
6. **QED:** Ligand A (0.795) is better than Ligand B (0.527), indicating a more drug-like profile.
7. **DILI:** Ligand A (49.942) is significantly better than Ligand B (82.474). Lower DILI risk is crucial.
8. **BBB:** Ligand A (83.637) is *much* better than Ligand B (19.542). While ADRB2 isn't exclusively a CNS target, some CNS penetration can be beneficial, and a low BBB score is a major drawback for Ligand B.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-5.067) is slightly less negative than Ligand B (-5.58), suggesting marginally better absorption.
10. **Solubility:** Ligand A (-3.355) is better than Ligand B (-2.623), although both are poor.
11. **hERG:** Ligand A (0.214) is better than Ligand B (0.405), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand A (45.43) is better than Ligand B (37.048). Lower clearance is preferred for metabolic stability.
13. **t1/2:** Ligand A (-14.196) is better than Ligand B (56.266). A negative value indicates a longer half-life.
14. **Pgp:** Ligand A (0.055) is much better than Ligand B (0.078). Lower P-gp efflux is desirable.
15. **Affinity:** Ligand B (-7.7) is slightly better than Ligand A (-7.5), but the difference is small.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical ADME properties (TPSA, QED, DILI, BBB, solubility, hERG, Cl_mic, t1/2, Pgp). While Ligand B has a slightly better binding affinity, the substantial advantages of Ligand A in ADME, particularly the much better BBB penetration and lower DILI risk, outweigh this minor difference. For a GPCR target like ADRB2, a balance of potency and good pharmacokinetic properties is essential, and Ligand A strikes that balance much better.
Output:
1
2025-04-17 22:33:23,113 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [391.823, 66.84, 3.164, 1, 4, 0.787, 67.546, 56.921, -4.519, -4.954, 0.808, 47.748, -3.457, 0.59, -6.1]
**Ligand B:** [371.796, 91.76, 1.825, 2, 5, 0.744, 57.115, 68.941, -5.013, -2.777, 0.192, -1.662, -28.565, 0.038, -7]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (371.796) is slightly lower, which could be beneficial for permeability.
2. **TPSA:** Ligand A (66.84) is better than Ligand B (91.76). GPCRs benefit from lower TPSA for improved BBB penetration. Ligand B is a bit high.
3. **logP:** Ligand A (3.164) is optimal, while Ligand B (1.825) is on the lower side. For a GPCR, a slightly higher logP is generally preferred for membrane permeability.
4. **HBD:** Ligand A (1) is better than Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is better than Ligand B (5). Fewer HBAs generally improve permeability.
6. **QED:** Both are good (A: 0.787, B: 0.744), indicating drug-like properties.
7. **DILI:** Both have acceptable DILI risk (A: 67.546, B: 57.115), but Ligand B is slightly better.
8. **BBB:** Ligand B (68.941) is better than Ligand A (56.921). This is a key consideration for GPCRs, although not strictly a CNS target, some peripheral distribution is still important.
9. **Caco-2:** Ligand B (-5.013) is better than Ligand A (-4.519), indicating better intestinal absorption.
10. **Solubility:** Ligand B (-2.777) is better than Ligand A (-4.954).
11. **hERG:** Ligand A (0.808) is better than Ligand B (0.192). Lower hERG risk is crucial.
12. **Cl_mic:** Ligand B (-1.662) is significantly better than Ligand A (47.748). Lower clearance indicates better metabolic stability.
13. **t1/2:** Ligand B (-28.565) is significantly better than Ligand A (-3.457). Longer half-life is desirable.
14. **Pgp:** Ligand A (0.59) is better than Ligand B (0.038). Lower P-gp efflux is preferred.
15. **Affinity:** Ligand B (-7) is slightly better than Ligand A (-6.1). A 0.9 kcal/mol difference is significant, and can outweigh some ADME concerns.
**Overall Assessment:**
While Ligand A has advantages in TPSA, HBD/HBA, hERG, and Pgp, Ligand B excels in crucial ADME properties (Cl_mic, t1/2, Caco-2, Solubility) and has a slightly better binding affinity. Given the GPCR target class, metabolic stability (Cl_mic and t1/2) and absorption (Caco-2, Solubility) are critical. The improved affinity of Ligand B further strengthens its profile. The slightly higher TPSA and lower logP of Ligand B are acceptable trade-offs for the significant ADME improvements.
Therefore, I would prioritize Ligand B.
Output:
0
2025-04-17 22:33:23,114 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (346.475 and 355.389 Da) fall comfortably within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (71.25) is significantly better than Ligand B (99.77). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold, while B is approaching it.
3. **logP:** Ligand A (2.506) is optimal, while Ligand B (1.185) is a bit low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (4). Fewer HBAs generally improve permeability.
6. **QED:** Ligand A (0.746) is better than Ligand B (0.579), indicating a more drug-like profile.
7. **DILI:** Ligand A (23.885) has a much lower DILI risk than Ligand B (47.189). This is a significant advantage for Ligand A.
8. **BBB:** Ligand B (74.874) has a higher BBB penetration percentile than Ligand A (62.699). However, as ADRB2 is a cardiovascular target, BBB penetration is not a primary concern.
9. **Caco-2:** Ligand A (-4.864) has a better Caco-2 permeability than Ligand B (-5.572).
10. **Solubility:** Ligand A (-2.845) has better solubility than Ligand B (-2.584).
11. **hERG:** Both ligands have very low hERG inhibition risk (0.181 and 0.278, respectively). No significant difference.
12. **Cl_mic:** Ligand A (36.473) has a higher microsomal clearance than Ligand B (-0.731), indicating lower metabolic stability. This is a negative for Ligand A.
13. **t1/2:** Ligand B (-9.054) has a significantly longer in vitro half-life than Ligand A (2.786). This is a major advantage for Ligand B.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.213 and 0.023, respectively). No significant difference.
15. **Affinity:** Ligand A (-7.2) has a slightly better binding affinity than Ligand B (-6.9). While a 0.3 kcal/mol difference isn't huge, it's a positive for Ligand A.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, and affinity are key. Ligand A excels in logP and TPSA, and has a slightly better affinity. While Ligand B has a better half-life, the superior ADME properties of Ligand A, particularly the lower DILI risk and better solubility, make it the more promising candidate. The slightly better affinity of Ligand A is also a plus.
**Conclusion:**
Considering the balance of properties, Ligand A is the more viable drug candidate.
Output:
1
2025-04-17 22:33:23,114 - INFO - Batch 340 complete. Total preferences: 5440
2025-04-17 22:33:23,114 - INFO - Processing batch 341/512...
2025-04-17 22:34:14,525 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (361.463 and 350.459 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (64.63) is better than Ligand B (67.87), both are below the 140 threshold for oral absorption, and acceptable for a cardiovascular target.
3. **logP:** Both ligands have good logP values (2.965 and 2.052), falling within the optimal 1-3 range. Ligand A is slightly higher, potentially aiding membrane permeability.
4. **HBD:** Both have 1 HBD, which is within the acceptable limit of 5.
5. **HBA:** Ligand A has 5 HBA, and Ligand B has 4. Both are below the 10 limit.
6. **QED:** Ligand A (0.857) has a significantly better QED score than Ligand B (0.609), indicating a more drug-like profile.
7. **DILI:** Ligand A (70.725) has a higher DILI risk than Ligand B (37.03). This is a significant drawback for Ligand A.
8. **BBB:** Both ligands have good BBB penetration (70.182 and 77.239), but Ligand B is slightly better. This isn't a primary concern for a cardiovascular target, but it's a positive.
9. **Caco-2:** Ligand A (-4.895) and Ligand B (-5.108) both have negative Caco-2 values, which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-3.722) and Ligand B (-2.863) both have negative solubility values, indicating poor aqueous solubility. This is a concern for both.
11. **hERG:** Ligand A (0.876) has a slightly higher hERG risk than Ligand B (0.269), but both are relatively low.
12. **Cl_mic:** Ligand A (39.37) has slightly better microsomal clearance than Ligand B (35.733), indicating better metabolic stability.
13. **t1/2:** Ligand A (23.775) has a significantly longer in vitro half-life than Ligand B (7.591). This is a major advantage for Ligand A.
14. **Pgp:** Ligand A (0.696) has slightly higher Pgp efflux than Ligand B (0.04). This is a negative for Ligand A.
15. **Binding Affinity:** Ligand B (-7.0) has a significantly better binding affinity than Ligand A (-6.2). This is a substantial advantage for Ligand B.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), we prioritize logP, Pgp, TPSA, and affinity. Ligand B is better on logP, Pgp, and significantly better on affinity. Ligand A is better on TPSA. The longer half-life of Ligand A is attractive, but the significantly better affinity of Ligand B outweighs this benefit. The lower DILI risk of Ligand B is also a major factor.
**Conclusion:**
Despite the longer half-life of Ligand A, the superior binding affinity, lower DILI risk, and better Pgp profile of Ligand B make it the more promising drug candidate.
Output:
0
2025-04-17 22:34:14,525 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (352.291) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (63.84) is significantly better than Ligand B (82.53). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (1.439) is better than Ligand A (4.21). A logP of 4.21 is pushing the upper limit and could lead to solubility issues and off-target interactions. Ligand B's logP is within the optimal range.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Both ligands have the same number of HBA (5), which is acceptable.
6. **QED:** Both ligands have similar and good QED values (0.713 and 0.795).
7. **DILI:** Ligand B (46.724) is *much* better than Ligand A (92.439). This is a significant advantage for Ligand B, as DILI is a major concern in drug development.
8. **BBB:** Ligand A (71.035) is better than Ligand B (45.638), but BBB isn't a high priority for a cardiovascular target.
9. **Caco-2:** Ligand A (-4.702) is better than Ligand B (-5.152). Higher Caco-2 values indicate better absorption.
10. **Solubility:** Ligand B (-2.477) is better than Ligand A (-5.358). This is important, especially given Ligand A's higher logP.
11. **hERG:** Ligand A (0.589) is better than Ligand B (0.279). Lower hERG inhibition is crucial for avoiding cardiotoxicity.
12. **Cl_mic:** Ligand B (12.019) is significantly better than Ligand A (77.421). Lower clearance indicates better metabolic stability.
13. **t1/2:** Ligand B (10.807) is better than Ligand A (-19.525). A positive half-life is desirable.
14. **Pgp:** Ligand A (0.249) is better than Ligand B (0.05). Lower P-gp efflux is preferable.
15. **Affinity:** Ligand A (-6.8) is significantly better than Ligand B (-4.1). A 2.7 kcal/mol difference in binding affinity is substantial and can often outweigh minor ADME drawbacks.
**Overall Assessment:**
While Ligand A has a significantly better binding affinity, Ligand B has a much more favorable safety profile (DILI) and better metabolic stability (Cl_mic, t1/2). Ligand B also has better solubility, which is important given its lower logP. The higher logP of Ligand A is a concern, and the high DILI risk is a major red flag. Although Ligand A's affinity is strong, the ADME/Tox liabilities are too significant to ignore for a cardiovascular target. For a GPCR, logP, TPSA, and affinity are key, but safety (DILI, hERG) and metabolic stability are also critical. Ligand B strikes a better balance.
Output:
0
2025-04-17 22:34:14,525 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.381 and 350.463 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (69.64) is better than Ligand B (78.68). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (1.943 and 1.682), falling within the optimal 1-3 range. Ligand B is slightly lower, which could be marginally better for solubility.
4. **HBD:** Ligand A (2) is slightly better than Ligand B (1). Both are well within the acceptable limit of 5.
5. **HBA:** Ligand A (3) is better than Ligand B (5). Both are within the acceptable limit of 10, but lower is preferable.
6. **QED:** Both ligands have similar QED values (0.851 and 0.844), indicating good drug-likeness.
7. **DILI:** Ligand A (36.758) has a significantly lower DILI risk than Ligand B (15.083). This is a major advantage for Ligand A.
8. **BBB:** Both ligands have good BBB penetration (73.827 and 78.558). While not a primary concern for a cardiovascular target, it's not detrimental.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.745 and -4.914), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-2.903) is better than Ligand B (-1.203). Higher solubility is generally desirable.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.331 and 0.494). This is excellent.
12. **Cl_mic:** Ligand A (-6.842) has a significantly lower (better) microsomal clearance than Ligand B (24.741). This indicates better metabolic stability.
13. **t1/2:** Ligand A (-10.771) has a longer in vitro half-life than Ligand B (-12.927). This is a positive attribute.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.044 and 0.073). This is good.
15. **Binding Affinity:** Ligand B (-6.8) has a slightly stronger binding affinity than Ligand A (-4.9). This is a 1.9 kcal/mol difference, which is substantial.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Both ligands perform well on logP and Pgp. Ligand A has better TPSA. The affinity difference is significant, favoring Ligand B. However, the substantial improvements in DILI and Cl_mic for Ligand A are critical. Metabolic stability and reduced toxicity are often prioritized over a small gain in potency, especially in early-stage drug development.
**Overall Assessment:**
While Ligand B has a better binding affinity, Ligand A demonstrates a superior safety profile (DILI) and better metabolic stability (Cl_mic, t1/2), alongside acceptable TPSA and solubility. The affinity difference, while noticeable, can potentially be addressed through further optimization. The lower DILI risk is a significant advantage.
Output:
1
2025-04-17 22:34:14,525 - INFO - Reasoning:
Let's analyze Ligand A and Ligand B for their potential as ADRB2 ligands, keeping in mind the GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key).
**Molecular Weight:** Both ligands (347.46 and 343.40 Da) fall comfortably within the ideal 200-500 Da range.
**TPSA:** Ligand A (70.67) is slightly higher than Ligand B (62.3). Both are acceptable, but Ligand B is preferable as lower TPSA generally correlates with better cell permeability.
**logP:** Ligand A (0.817) is a bit low, potentially hindering membrane permeability. Ligand B (1.697) is better, falling within the optimal 1-3 range.
**H-Bond Donors/Acceptors:** Ligand A has 2 HBD and 4 HBA, while Ligand B has 1 HBD and 3 HBA. Both are within acceptable limits.
**QED:** Ligand A (0.766) has a better QED score than Ligand B (0.632), indicating a more drug-like profile.
**DILI:** Ligand B (29.16) has a significantly lower DILI risk than Ligand A (22.33). This is a substantial advantage for Ligand B.
**BBB:** Ligand B (67.04) shows better BBB penetration than Ligand A (44.90). While ADRB2 isn't strictly a CNS target, some CNS exposure can be beneficial or at least less detrimental.
**Caco-2 Permeability:** Ligand A (-5.001) has worse Caco-2 permeability than Ligand B (-4.634).
**Aqueous Solubility:** Ligand A (-1.014) has better aqueous solubility than Ligand B (-2.67).
**hERG:** Both ligands have very low hERG inhibition risk (0.144 and 0.176).
**Microsomal Clearance:** Ligand A (-5.442) has significantly lower microsomal clearance than Ligand B (13.042), suggesting better metabolic stability. This is a major advantage for Ligand A.
**In vitro Half-Life:** Ligand A (1.512) has a shorter half-life than Ligand B (-15.336). This is a significant drawback for Ligand A.
**P-gp Efflux:** Both ligands show very low P-gp efflux liability (0.008 and 0.034).
**Binding Affinity:** Ligand A (-7.2) has a stronger binding affinity than Ligand B (-6.7), with a difference of 0.5 kcal/mol. This is a significant advantage for Ligand A, potentially outweighing some of its ADME drawbacks.
**Overall Assessment:**
Ligand A has a superior binding affinity and better metabolic stability (lower Cl_mic). However, Ligand B excels in DILI risk, BBB penetration, Caco-2 permeability, and logP. The binding affinity difference is substantial, and for a GPCR, metabolic stability is crucial. While Ligand B has a better logP, the difference isn't large enough to overcome the affinity advantage of Ligand A. The lower DILI risk of Ligand B is attractive, but the significantly improved metabolic stability of Ligand A is more important for a GPCR target.
Output:
1
2025-04-17 22:34:14,526 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (347.419) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (89.87) is significantly better than Ligand A (109.14). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA is still beneficial for absorption.
3. **logP:** Ligand B (0.375) is slightly better than Ligand A (0.15), both are a little low, but still within an acceptable range.
4. **HBD:** Both ligands have 3 HBD, which is good.
5. **HBA:** Ligand B (4) is better than Ligand A (6). Lower HBA is generally preferred for better permeability.
6. **QED:** Ligand B (0.724) is better than Ligand A (0.58), indicating a more drug-like profile.
7. **DILI:** Ligand B (37.03) is better than Ligand A (45.25), both are acceptable, but lower is always preferred.
8. **BBB:** Ligand B (49.515) is better than Ligand A (29.003). While not a primary concern for a cardiovascular target, higher BBB is generally a positive attribute.
9. **Caco-2:** Ligand A (-5.662) is better than Ligand B (-4.926). Higher Caco-2 permeability is desirable.
10. **Solubility:** Ligand A (-1.594) is better than Ligand B (-1.9). Better solubility is always preferred.
11. **hERG:** Ligand A (0.049) is better than Ligand B (0.455). Lower hERG inhibition is critical for safety.
12. **Cl_mic:** Ligand A (-7.516) is *much* better than Ligand B (-21.017). This indicates significantly better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (6.949) is better than Ligand B (-12.43). A longer half-life is generally desirable.
14. **Pgp:** Ligand A (0.011) is much better than Ligand B (0.038). Lower P-gp efflux is beneficial for bioavailability.
15. **Binding Affinity:** Ligand A (-7.2) is better than Ligand B (-5.6). This is a substantial difference in potency.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), affinity, logP, TPSA, and Pgp are important. Ligand A has a significantly better affinity. Ligand B has a better TPSA and Pgp, but the difference in affinity is substantial enough to outweigh these benefits.
**Overall Assessment:**
Ligand A demonstrates a superior balance of properties, particularly in terms of potency (affinity), metabolic stability (Cl_mic, t1/2), P-gp efflux, and hERG risk. While Ligand B has some advantages in TPSA and QED, the substantial difference in binding affinity and the better safety profile of Ligand A make it the more promising drug candidate.
Output:
1
2025-04-17 22:34:14,526 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (345.443 and 345.403 Da) fall comfortably within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (82.53) is significantly better than Ligand B (97.62). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand A is well below the 140 threshold, while B is approaching it.
3. **logP:** Ligand A (1.582) is slightly higher than Ligand B (0.948), both are within the optimal 1-3 range. A is preferable.
4. **HBD:** Both ligands have 2 HBD, which is acceptable.
5. **HBA:** Ligand A has 4 HBA, while Ligand B has 6. Ligand A is preferable.
6. **QED:** Ligand A (0.631) is slightly better than Ligand B (0.521), indicating a more drug-like profile.
7. **DILI:** Ligand A (48.197) has a much lower DILI risk than Ligand B (65.878). This is a significant advantage for Ligand A.
8. **BBB:** Ligand B (57.852) has a better BBB penetration than Ligand A (28.848). While ADRB2 isn't exclusively a CNS target, some CNS exposure could be beneficial or at least not detrimental, depending on the specific therapeutic goal.
9. **Caco-2:** Ligand A (-4.539) is better than Ligand B (-5.37), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-3.468) is better than Ligand B (-1.791), indicating better aqueous solubility.
11. **hERG:** Both ligands have low hERG inhibition liability (0.461 and 0.248 respectively), which is good. Ligand B is slightly better.
12. **Cl_mic:** Ligand B (49.798) has a lower microsomal clearance than Ligand A (55.066), suggesting better metabolic stability.
13. **t1/2:** Ligand B (18.675) has a significantly longer in vitro half-life than Ligand A (3.51). This is a major advantage for Ligand B.
14. **Pgp:** Ligand A (0.191) has lower P-gp efflux liability than Ligand B (0.081). Lower P-gp efflux is generally preferred.
15. **Binding Affinity:** Ligand B (-6.5 kcal/mol) has a stronger binding affinity than Ligand A (-5.9 kcal/mol). This is a 0.6 kcal/mol difference, which is substantial and can outweigh some ADME concerns.
**Overall Assessment:**
Ligand B has a stronger binding affinity and a longer half-life, which are very important. It also has a slightly better hERG profile and lower Cl_mic. However, Ligand A excels in TPSA, logP, DILI risk, Caco-2 permeability, and solubility. The DILI risk for Ligand B is concerning. Considering the GPCR-specific priorities (logP, TPSA, affinity), and balancing the ADME properties, the stronger affinity of Ligand B, combined with its improved metabolic stability (longer half-life) is more compelling. While the DILI risk is higher, it's not excessively so, and could be mitigated with further optimization.
Output:
0
2025-04-17 22:34:14,526 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [352.406, 78.87, 1.334, 2, 4, 0.776, 30.438, 76.309, -4.319, -1.76, 0.452, 27.207, 5.145, 0.087, -5.7]
**Ligand B:** [362.865, 84.73, 1.902, 2, 6, 0.785, 59.752, 72.237, -5.196, -2.539, 0.35, 44.472, 45.966, 0.07, -6.4]
Here's a breakdown, prioritizing GPCR properties (logP, Pgp, TPSA, BBB, and affinity):
1. **Molecular Weight:** Both are within the ideal 200-500 Da range. Ligand A (352.4) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (78.87) is better than Ligand B (84.73). Both are below 140, but closer to 90 is preferred for GPCRs, and A is closer.
3. **logP:** Both are within the optimal 1-3 range. Ligand A (1.334) is slightly better, as lower logP can sometimes reduce off-target effects. Ligand B (1.902) is still acceptable.
4. **H-Bond Donors:** Both have 2 HBD, which is good.
5. **H-Bond Acceptors:** Ligand A (4) is better than Ligand B (6). Lower HBA is generally preferred for better membrane permeability.
6. **QED:** Both are similar (A: 0.776, B: 0.785) and above the 0.5 threshold, indicating good drug-like properties.
7. **DILI:** Ligand A (30.438) has a significantly lower DILI risk than Ligand B (59.752). This is a major advantage for A.
8. **BBB:** Ligand A (76.309) has a better BBB penetration score than Ligand B (72.237). Although ADRB2 isn't exclusively a CNS target, some CNS penetration can be beneficial, and minimizing it isn't a priority.
9. **Caco-2:** Ligand B (-5.196) shows better Caco-2 permeability than Ligand A (-4.319). This suggests better intestinal absorption for B.
10. **Solubility:** Ligand B (-2.539) has better aqueous solubility than Ligand A (-1.76).
11. **hERG:** Both are very low (A: 0.452, B: 0.35), indicating minimal hERG inhibition risk.
12. **Cl_mic:** Ligand A (27.207) has lower microsomal clearance than Ligand B (44.472), suggesting better metabolic stability.
13. **t1/2:** Ligand B (45.966) has a significantly longer in vitro half-life than Ligand A (5.145). This is a substantial advantage for B.
14. **Pgp:** Both have very low Pgp efflux liability (A: 0.087, B: 0.07).
15. **Binding Affinity:** Ligand B (-6.4) has a slightly stronger binding affinity than Ligand A (-5.7). This is a 0.7 kcal/mol difference, which is notable.
**Overall Assessment:**
Ligand B has a better binding affinity and longer half-life, and better Caco-2 permeability and solubility. However, Ligand A excels in DILI risk, TPSA, HBA, and metabolic stability (Cl_mic). The lower DILI risk and better TPSA/HBA of Ligand A are very attractive, especially given the relatively small affinity difference. The longer half-life of Ligand B is a significant plus, but the DILI risk is a concern. Considering the balance, and prioritizing safety (DILI) alongside reasonable potency and permeability, I lean towards Ligand A.
Output:
1
2025-04-17 22:34:14,526 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.39 and 349.48 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand B (83.22) is significantly better than Ligand A (115.55). ADRB2 is not a CNS target, but lower TPSA generally improves absorption.
3. **logP:** Ligand B (2.551) is optimal, while Ligand A (0.071) is quite low. This is a major concern for Ligand A, as it may struggle with membrane permeability.
4. **HBD:** Ligand B (3) is preferable to Ligand A (2). Both are within the acceptable limit of 5.
5. **HBA:** Ligand B (3) is preferable to Ligand A (6). Both are within the acceptable limit of 10, but lower is generally better.
6. **QED:** Ligand A (0.722) is slightly better than Ligand B (0.641), indicating a marginally more drug-like profile.
7. **DILI:** Both ligands have similar DILI risk (52.19% vs 50.33%), both are acceptable.
8. **BBB:** Not a primary concern for ADRB2, but Ligand B (54.87%) is better than Ligand A (19.47%).
9. **Caco-2:** Ligand B (-5.189) is better than Ligand A (-4.951). Higher values indicate better absorption.
10. **Solubility:** Ligand B (-3.235) is better than Ligand A (-1.501). Higher values indicate better solubility.
11. **hERG:** Both ligands have low hERG inhibition risk (0.245 and 0.383).
12. **Cl_mic:** Ligand A (-28.634) has significantly better metabolic stability (lower clearance) than Ligand B (38.477). This is a strong point for Ligand A.
13. **t1/2:** Ligand B (31.024) has a slightly longer in vitro half-life than Ligand A (26.904).
14. **Pgp:** Both ligands have low Pgp efflux liability (0.02 and 0.213).
15. **Binding Affinity:** Ligand A (-7.0) has a slightly better binding affinity than Ligand B (-6.1). However, the difference is less than 1.5 kcal/mol, so it doesn't overwhelmingly outweigh other factors.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand B excels in logP and TPSA, while Ligand A has slightly better affinity and metabolic stability. The low logP of Ligand A is a significant concern, potentially hindering its ability to reach the receptor. While the slightly better affinity of Ligand A is good, the overall ADME profile of Ligand B is more promising.
**Conclusion:**
Considering the balance of properties and the GPCR-specific priorities, Ligand B is the more viable drug candidate. Its superior logP, TPSA, solubility, and Caco-2 permeability outweigh the slightly better affinity and metabolic stability of Ligand A.
0
2025-04-17 22:34:14,526 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [347.499, 41.93, 3.292, 1, 4, 0.822, 6.475, 89.531, -4.723, -1.661, 0.945, 15.496, 3.837, 0.492, -4.2]
**Ligand B:** [360.523, 42.43, 4.286, 0, 4, 0.681, 35.091, 79.217, -4.795, -3.318, 0.403, 65.98, -14.974, 0.396, -6.7]
Here's a breakdown of the comparison, considering the provided guidelines and GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal range (200-500 Da). A is 347.5, B is 360.5. No significant difference.
2. **TPSA:** Both are reasonably good (around 42), though slightly above the optimal <90 for CNS targets, this is less critical for a cardiovascular target.
3. **logP:** Ligand A (3.292) is better than Ligand B (4.286). B is pushing the upper limit and could potentially have solubility issues or off-target effects.
4. **HBD:** Ligand A (1) is preferable to Ligand B (0). While both are low, having one HBD can sometimes improve solubility without significantly impacting permeability.
5. **HBA:** Both have 4 HBA, which is acceptable.
6. **QED:** Ligand A (0.822) is significantly better than Ligand B (0.681), indicating a more drug-like profile.
7. **DILI:** Ligand A (6.475) is *much* better than Ligand B (35.091). This is a major advantage for A.
8. **BBB:** Ligand A (89.531) is better than Ligand B (79.217), although BBB isn't a primary concern for a cardiovascular target.
9. **Caco-2:** Both are negative, indicating poor permeability. This is a concern for both, but the negative values are similar.
10. **Solubility:** Ligand A (-1.661) is better than Ligand B (-3.318). B has notably poor predicted solubility.
11. **hERG:** Ligand A (0.945) is better than Ligand B (0.403), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand A (15.496) is significantly better than Ligand B (65.98). A has much better metabolic stability.
13. **t1/2:** Ligand A (3.837) is better than Ligand B (-14.974). A has a longer predicted half-life.
14. **Pgp:** Ligand A (0.492) is better than Ligand B (0.396). Lower P-gp efflux is favorable.
15. **Affinity:** Ligand B (-6.7) is significantly better than Ligand A (-4.2). This is a substantial difference in binding potency (2.5 kcal/mol).
**Overall Assessment:**
Ligand B has a considerably stronger binding affinity, which is a major plus. However, it suffers from several significant drawbacks: high DILI risk, poor solubility, high metabolic clearance, a negative half-life, and a higher logP. Ligand A, while having a weaker affinity, presents a much more balanced profile with better predicted ADME-Tox properties, particularly DILI and metabolic stability.
Given the GPCR context and the need for a safe and bioavailable drug, the better ADME-Tox profile of Ligand A outweighs the affinity advantage of Ligand B. While the affinity difference is substantial, it might be possible to optimize Ligand A's affinity through further medicinal chemistry efforts, whereas mitigating the severe ADME liabilities of Ligand B would be much more challenging.
Therefore, I prefer Ligand A.
Output:
1
2025-04-17 22:34:14,527 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [349.475, 79.79, 2.667, 2, 4, 0.741, 31.02, 56.534, -4.895, -3.374, 0.351, 29.284, 29.711, 0.078, -7.9]
**Ligand B:** [379.595, 38.13, 4.872, 0, 5, 0.624, 53.509, 75.107, -5.193, -4.556, 0.723, 122.524, 61.418, 0.753, -7.1]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (349.475) is slightly preferred due to being lower.
2. **TPSA:** Ligand A (79.79) is better than Ligand B (38.13). Both are acceptable for a non-CNS GPCR like ADRB2, but lower TPSA generally improves permeability.
3. **logP:** Ligand A (2.667) is optimal, while Ligand B (4.872) is pushing the upper limit and could potentially lead to solubility issues or off-target interactions.
4. **HBD:** Ligand A (2) is slightly better than Ligand B (0).
5. **HBA:** Ligand A (4) is slightly better than Ligand B (5).
6. **QED:** Ligand A (0.741) is better than Ligand B (0.624), indicating a more drug-like profile.
7. **DILI:** Ligand A (31.02) is significantly better than Ligand B (53.509), indicating a lower risk of liver injury. This is a crucial factor.
8. **BBB:** ADRB2 is primarily a cardiovascular target, so BBB penetration isn't a major priority. Ligand B (75.107) is higher, but this isn't a deciding factor.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-4.895) is slightly better.
10. **Solubility:** Both are negative, indicating poor solubility. Ligand A (-3.374) is slightly better.
11. **hERG:** Ligand A (0.351) is much better than Ligand B (0.723), indicating a lower risk of cardiotoxicity. This is very important for a cardiovascular target.
12. **Cl_mic:** Ligand A (29.284) is significantly better than Ligand B (122.524), indicating better metabolic stability.
13. **t1/2:** Ligand B (61.418) has a longer half-life than Ligand A (29.711), which is a positive.
14. **Pgp:** Ligand B (0.753) is slightly higher than Ligand A (0.078), indicating more P-gp efflux.
15. **Affinity:** Ligand B (-7.1) is slightly better than Ligand A (-7.9), but the difference is small.
**Overall Assessment:**
Ligand A demonstrates a significantly better overall profile, particularly regarding safety (DILI, hERG) and ADME properties (Cl_mic, QED, logP). While Ligand B has a slightly better binding affinity and in vitro half-life, the superior ADME/Tox profile of Ligand A outweighs these minor advantages. The lower logP, DILI, hERG, and Cl_mic values for Ligand A are critical for a cardiovascular drug candidate.
Output:
1
2025-04-17 22:34:14,527 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (368.5 and 352.4 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (98.32) is better than Ligand B (117.79). For a GPCR, keeping TPSA under 140 is good for oral absorption, and lower is generally preferred.
**3. logP:** Ligand A (1.152) is within the optimal 1-3 range. Ligand B (-0.575) is slightly below 1, which *could* indicate potential permeation issues, though not drastically.
**4. H-Bond Donors:** Both ligands have acceptable HBD counts (3 and 2 respectively), well below the threshold of 5.
**5. H-Bond Acceptors:** Ligand A (5) is better than Ligand B (7), both are below the threshold of 10.
**6. QED:** Both ligands have similar and good QED values (0.724 and 0.703), indicating good drug-like properties.
**7. DILI:** Ligand A (42.5) has a slightly better DILI percentile than Ligand B (49.0), both are acceptable.
**8. BBB:** Ligand B (48.2) has a higher BBB penetration percentile than Ligand A (26.1). While ADRB2 is a cardiovascular target, some CNS effects are possible with beta-blockers, so moderate BBB penetration isn't necessarily detrimental.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-5.392 and -5.15). This is unusual and suggests poor permeability. However, these values are on a log scale, so the absolute difference isn't huge.
**10. Aqueous Solubility:** Ligand A (-2.732) is better than Ligand B (-1.148), indicating slightly better solubility.
**11. hERG Inhibition:** Ligand A (0.451) is better than Ligand B (0.102), indicating a lower risk of cardiotoxicity, which is critical for a cardiovascular drug.
**12. Microsomal Clearance:** Ligand A (16.291) has a higher microsomal clearance than Ligand B (7.228), meaning it's metabolized faster. This is a negative for Ligand A.
**13. In vitro Half-Life:** Ligand B (-1.078) has a significantly better in vitro half-life than Ligand A (-22.761). This is a major advantage for Ligand B.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.064 and 0.01), which is good.
**15. Binding Affinity:** Both ligands have very similar and strong binding affinities (-6.8 and -6.9 kcal/mol). The difference is negligible.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand A initially appears slightly better due to its more favorable logP and TPSA. However, the significantly better *in vitro* half-life and lower microsomal clearance of Ligand B, combined with acceptable BBB penetration and a lower hERG risk, make it a more promising candidate. The poor Caco-2 permeability is a concern for both, but the metabolic stability of Ligand B is a strong advantage. The slightly better solubility of Ligand A is outweighed by the other factors.
Output:
0
2025-04-17 22:34:14,527 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (363.405 and 367.427 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (79.9) is significantly better than Ligand B (121.53). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold, while B is approaching it.
3. **logP:** Ligand B (1.077) is better than Ligand A (0.142). A logP between 1-3 is optimal, and Ligand B is within this range. Ligand A is quite low, potentially hindering membrane permeability.
4. **HBD:** Ligand B (3) has one more HBD than Ligand A (2). This isn't a major concern for either.
5. **HBA:** Ligand B (6) has one more HBA than Ligand A (5). Similar to HBD, not a critical difference.
6. **QED:** Ligand A (0.702) has a slightly better QED score than Ligand B (0.642), indicating a more drug-like profile.
7. **DILI:** Ligand A (30.477) has a much lower DILI risk than Ligand B (86.002). This is a significant advantage for Ligand A. A DILI percentile <40 is desirable.
8. **BBB:** Ligand A (71.307) has a higher BBB percentile than Ligand B (28.887). While not essential for a cardiovascular target, higher BBB is generally favorable.
9. **Caco-2:** Ligand A (-4.971) and Ligand B (-5.463) are both very poor. This suggests poor intestinal absorption for both.
10. **Solubility:** Ligand A (-1.001) is better than Ligand B (-2.449), indicating better aqueous solubility.
11. **hERG:** Both ligands (0.194 and 0.152) have low hERG inhibition risk, which is good.
12. **Cl_mic:** Ligand A (-22.408) has a significantly lower (better) microsomal clearance than Ligand B (24.757). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand B (38.603) has a much longer in vitro half-life than Ligand A (-2.92). This is a significant advantage for Ligand B.
14. **Pgp:** Both ligands (0.015 and 0.177) have low P-gp efflux liability.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.8 and -5.6 kcal/mol). Ligand A is slightly better, but the difference is not substantial enough to outweigh other factors.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, and affinity are important. Ligand B has a better logP, but Ligand A excels in TPSA, DILI, solubility, and metabolic stability (Cl_mic). The affinity difference is minimal.
**Overall Assessment:**
Ligand A presents a more balanced profile with significantly lower DILI risk and better metabolic stability. While Ligand B has a better half-life and logP, the poor Caco-2 permeability for both is a concern. The lower DILI risk and better ADME properties of Ligand A outweigh the slightly better logP and half-life of Ligand B.
Output:
1
2025-04-17 22:34:14,527 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [383.809, 109.77 , 2.555, 2. , 5. , 0.742, 98.953, 15.083, -5.248, -3.954, 0.037, 2.734, 28.114, 0.057, -6. ]
**Ligand B:** [343.471, 54.34 , 2.823, 1. , 3. , 0.611, 41.605, 67.352, -4.886, -2.75 , 0.394, 45.738, -5.107, 0.375, -5.1 ]
**Step-by-step comparison:**
1. **MW:** Ligand A (383.809 Da) is within the ideal range, while Ligand B (343.471 Da) is slightly below, but still acceptable.
2. **TPSA:** Ligand A (109.77) is borderline for good oral absorption, while Ligand B (54.34) is excellent. This favors B.
3. **logP:** Both ligands (A: 2.555, B: 2.823) are within the optimal range.
4. **HBD:** Ligand A (2) and B (1) are both good.
5. **HBA:** Ligand A (5) and B (3) are both good.
6. **QED:** Both ligands (A: 0.742, B: 0.611) have acceptable drug-likeness scores.
7. **DILI:** Ligand A (98.953) has a very high DILI risk, which is a major concern. Ligand B (41.605) has a much lower, acceptable risk. This is a significant advantage for B.
8. **BBB:** Ligand A (15.083) has very low BBB penetration, while Ligand B (67.352) is good. While ADRB2 isn't *primarily* a CNS target, some degree of BBB penetration can be beneficial for off-target effects and distribution.
9. **Caco-2:** Both are negative, suggesting poor permeability.
10. **Solubility:** Both are negative, suggesting poor solubility.
11. **hERG:** Both ligands (A: 0.037, B: 0.394) have very low hERG risk, which is good.
12. **Cl_mic:** Ligand A (2.734) has a lower (better) microsomal clearance than Ligand B (45.738).
13. **t1/2:** Ligand A (28.114) has a better in vitro half-life than Ligand B (-5.107).
14. **Pgp:** Ligand A (0.057) has lower Pgp efflux, which is preferable. Ligand B (0.375) is higher.
15. **Affinity:** Both ligands have comparable binding affinity (-6 kcal/mol and -5.1 kcal/mol).
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp efflux, and affinity are key. Ligand B has a significantly better TPSA and Pgp profile. The DILI risk for Ligand A is a major red flag. While Ligand A has better metabolic stability (Cl_mic) and half-life, the high DILI risk and poor BBB penetration are too significant to ignore.
**Conclusion:**
Despite Ligand A having slightly better metabolic stability and half-life, the significantly lower DILI risk, better TPSA, and Pgp profile of Ligand B make it the more promising candidate.
Output:
0
2025-04-17 22:34:14,527 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, the most important parameters are binding affinity, logP, TPSA, Pgp efflux, and BBB penetration (though BBB is less critical for a cardiovascular target).
Let's compare the ligands property by property:
1. **MW:** Both ligands (368.865 and 352.385 Da) are within the ideal 200-500 Da range.
2. **TPSA:** Ligand B (78.09) is significantly better than Ligand A (107.11). Lower TPSA is generally preferred for GPCRs to enhance permeability.
3. **logP:** Both ligands have good logP values (1.629 and 1.412), falling within the optimal 1-3 range. Ligand B is slightly better.
4. **HBD/HBA:** Ligand B (2 HBD, 3 HBA) is preferable to Ligand A (4 HBD, 4 HBA) as lower counts are generally better for permeability.
5. **QED:** Ligand B (0.813) has a slightly better QED score than Ligand A (0.633), indicating a more drug-like profile.
6. **DILI:** Ligand B (39.201) has a significantly lower DILI risk than Ligand A (54.789), a crucial advantage.
7. **BBB:** Ligand B (71.772) has a higher BBB percentile than Ligand A (25.591), though this is less critical for a cardiovascular target.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests potential issues with the data or modeling. We'll proceed cautiously.
9. **Solubility:** Both have negative solubility values, also unusual.
10. **hERG:** Ligand A (0.147) has a slightly lower hERG risk than Ligand B (0.421), but both are very low.
11. **Cl_mic:** Both have similar and good microsomal clearance values (-10.801 and -10.904), indicating good metabolic stability.
12. **t1/2:** Ligand A (8.908) has a longer in vitro half-life than Ligand B (-7.804). This is a positive for Ligand A.
13. **Pgp:** Ligand A (0.086) has a lower Pgp efflux liability than Ligand B (0.035), which is desirable.
14. **Binding Affinity:** Ligand A (-7.1 kcal/mol) has a slightly better binding affinity than Ligand B (-6.2 kcal/mol). This is a significant advantage.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity and half-life, Ligand B demonstrates a superior profile in several crucial ADME properties, particularly TPSA, DILI risk, and QED. The lower TPSA and DILI risk of Ligand B are significant advantages for a potential drug candidate. The slightly better BBB penetration of Ligand B is also a bonus. The negative Caco-2 and solubility values are concerning for both, but the overall balance of properties favors Ligand B. The 1.5 kcal/mol advantage in binding affinity of Ligand A is not enough to overcome the ADME advantages of Ligand B.
**Output:**
0
2025-04-17 22:34:14,527 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [358.435, 106.12 , -0.269, 3. , 6. , 0.579, 42.458, 48.391, -5.315, -0.906, 0.063, 2.968, 12.322, 0.028, -5.4 ]
**Ligand B:** [371.909, 61.88 , 1.761, 1. , 4. , 0.627, 23.924, 66.499, -5.012, -1.161, 0.41 , 33.624, 42.771, 0.019, -5.4 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (358.435) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (106.12) is higher than Ligand B (61.88). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is still preferred for absorption. Ligand B is significantly better here.
3. **logP:** Ligand A (-0.269) is quite low, potentially hindering membrane permeability. Ligand B (1.761) is within the optimal range (1-3). This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (3) is higher than Ligand B (1). Lower is generally better for permeability, so Ligand B is favored.
5. **HBA:** Ligand A (6) is higher than Ligand B (4). Similar to HBD, Ligand B is preferred.
6. **QED:** Both have good QED scores (A: 0.579, B: 0.627), indicating good drug-like properties.
7. **DILI:** Ligand A (42.458) has a slightly higher DILI risk than Ligand B (23.924), but both are below the concerning threshold of 60.
8. **BBB:** Ligand B (66.499) has a higher BBB penetration percentile than Ligand A (48.391). While ADRB2 isn't a primary CNS target, some peripheral distribution is still important, and higher BBB can sometimes correlate with better overall distribution.
9. **Caco-2:** Both have negative values, indicating low permeability. This is a concern for both, but the negative value for Ligand A (-5.315) is more negative than Ligand B (-5.012) suggesting slightly worse permeability.
10. **Solubility:** Both have negative values, indicating poor solubility. Ligand B (-1.161) is slightly better than Ligand A (-0.906).
11. **hERG:** Both have very low hERG risk (A: 0.063, B: 0.41). This is excellent.
12. **Cl_mic:** Ligand A (2.968) has significantly lower microsomal clearance than Ligand B (33.624), indicating better metabolic stability. This is a major advantage for Ligand A.
13. **t1/2:** Ligand B (42.771) has a longer in vitro half-life than Ligand A (12.322). This is favorable for dosing convenience.
14. **Pgp:** Both have very low P-gp efflux liability (A: 0.028, B: 0.019). This is excellent.
15. **Affinity:** Both have the same binding affinity (-5.4 kcal/mol).
**GPCR-specific considerations:**
For a cardiovascular GPCR like ADRB2, logP, TPSA, and metabolic stability are key. Ligand B excels in logP and TPSA, suggesting better permeability and absorption. Ligand A has a significant advantage in metabolic stability (lower Cl_mic).
**Overall Assessment:**
While Ligand A has better metabolic stability, the poor logP and higher TPSA are significant drawbacks. Ligand B, despite having higher clearance, has a much more favorable balance of properties, particularly regarding permeability and absorption. The slightly better BBB penetration is also a bonus. The similar binding affinity makes the ADME properties the deciding factor.
Therefore, I prefer Ligand B.
Output:
0
2025-04-17 22:34:14,528 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (344.46 and 349.44 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (76.02) is significantly better than Ligand B (115.98). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is approaching a level that could hinder absorption.
3. **logP:** Ligand A (1.698) is better than Ligand B (0.74). Both are within the optimal 1-3 range, but Ligand A is closer to the sweet spot. Ligand B is on the lower end, potentially impacting membrane permeability.
4. **HBD:** Ligand A (2) and Ligand B (4) are both acceptable, but Ligand A is preferable.
5. **HBA:** Both ligands have 4 HBA, which is within the desirable range.
6. **QED:** Ligand A (0.754) has a much better QED score than Ligand B (0.368), indicating a more drug-like profile.
7. **DILI:** Ligand A (14.04) has a significantly lower DILI risk than Ligand B (29.04). This is a crucial advantage, as liver toxicity is a major concern in drug development.
8. **BBB:** Ligand A (59.98) has a better BBB penetration percentile than Ligand B (41.22). While ADRB2 isn't exclusively a CNS target, some CNS exposure or off-target effects are possible, making higher BBB penetration a slight advantage.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.185 and -5.889). This is unusual and suggests poor permeability. However, the values are similar, so this isn't a deciding factor.
10. **Solubility:** Both ligands have negative solubility values (-1.332 and -1.662). This is also concerning, indicating poor aqueous solubility. Again, the values are similar.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.153 and 0.314). This is excellent.
12. **Cl_mic:** Ligand A (6.308) has significantly lower microsomal clearance than Ligand B (17.073), suggesting better metabolic stability.
13. **t1/2:** Ligand A (0.789) has a shorter in vitro half-life than Ligand B (-23.57). This is a negative for Ligand A, but the large negative value for Ligand B suggests a potential issue with the assay or instability.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.045 and 0.038). This is good.
15. **Binding Affinity:** Ligand A (-8.0) has a slightly better binding affinity than Ligand B (-6.1). While the difference is not huge, it is still a positive for Ligand A.
**GPCR-Specific Priorities:**
Considering ADRB2 is a GPCR, logP, TPSA, Pgp, and affinity are key. Ligand A performs better in all these categories. The lower DILI risk and better QED score further strengthen its profile.
**Conclusion:**
Ligand A is the more promising candidate. It exhibits a better balance of properties, with advantages in crucial areas like TPSA, logP, DILI risk, metabolic stability, QED, and binding affinity. Despite the similar solubility and Caco-2 values, the overall profile of Ligand A is superior.
Output:
1
2025-04-17 22:34:14,528 - INFO - Batch 341 complete. Total preferences: 5456
2025-04-17 22:34:14,528 - INFO - Processing batch 342/512...
2025-04-17 22:35:07,217 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (377.897 and 362.499 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (56.15) is significantly better than Ligand B (83.98). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (3.12 and 2.442), falling within the 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Both ligands have the same number of HBA (5), which is acceptable.
6. **QED:** Both ligands have similar QED scores (0.889 and 0.814), indicating good drug-likeness.
7. **DILI:** Ligand A (70.841) has a higher DILI risk than Ligand B (41.024). This is a significant drawback for Ligand A.
8. **BBB:** BBB isn't a major concern for a cardiovascular target. Ligand A (75.107) is higher than Ligand B (61.923), but this is less important.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.011 and -5.043), which is unusual and suggests poor permeability. However, the values are very similar.
10. **Solubility:** Ligand A (-4.635) is slightly better than Ligand B (-3.472), indicating better aqueous solubility.
11. **hERG:** Ligand A (0.531) has a slightly higher hERG risk than Ligand B (0.191). Lower is better here, so Ligand B is favored.
12. **Cl_mic:** Ligand A (73.388) has a higher microsomal clearance than Ligand B (29.39). This means Ligand B is more metabolically stable, a significant advantage.
13. **t1/2:** Ligand A (47.512) has a longer in vitro half-life than Ligand B (29.211). This is a positive for Ligand A.
14. **Pgp:** Ligand A (0.594) has lower P-gp efflux than Ligand B (0.121), which is preferable.
15. **Binding Affinity:** Ligand A (-8.1 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.1 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME concerns.
**Overall Assessment:**
Ligand A has a much better binding affinity, a slightly longer half-life, and lower P-gp efflux. However, it has a significantly higher DILI risk and higher hERG risk. Ligand B has better metabolic stability (lower Cl_mic), lower DILI and hERG risks, but weaker binding affinity.
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), the strong binding affinity of Ligand A is a major advantage. While the DILI risk is concerning, it's a parameter that can potentially be addressed through further structural modifications. The difference in affinity (-2 kcal/mol) is substantial enough to warrant prioritizing Ligand A.
Output:
1
2025-04-17 22:35:07,217 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [355.507, 35.58, 3.138, 1, 2, 0.808, 47.034, 74.292, -4.824, -4.043, 0.881, 77.03, 15.302, 0.579, -7.1]**
**Ligand B: [375.481, 57.61, 4.038, 1, 4, 0.663, 26.328, 80.031, -4.54, -3.296, 0.726, 77.76, 4.655, 0.506, -5.7]**
1. **Molecular Weight:** Both are within the ideal range (200-500 Da). A (355.5) is slightly preferable as it's closer to the lower end, potentially aiding permeability.
2. **TPSA:** A (35.58) is excellent, well below 140 and even closer to the 90 threshold for CNS targets. B (57.61) is still acceptable but less optimal.
3. **logP:** Both are good (between 1-3), but A (3.138) is slightly better positioned within the optimal range than B (4.038), which is getting towards the upper limit where solubility issues can arise.
4. **H-Bond Donors:** Both have 1 HBD, which is good.
5. **H-Bond Acceptors:** A (2) is better than B (4). Lower HBA generally improves permeability.
6. **QED:** A (0.808) is significantly better than B (0.663), indicating a more drug-like profile.
7. **DILI:** A (47.034) is better than B (26.328). Lower DILI risk is crucial.
8. **BBB:** Both are good, but B (80.031) is slightly better than A (74.292). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be beneficial for distribution.
9. **Caco-2:** Both are negative, indicating poor permeability. A (-4.824) is worse than B (-4.54).
10. **Solubility:** Both are negative, indicating poor solubility. A (-4.043) is worse than B (-3.296).
11. **hERG:** Both are low risk (0.881 and 0.726).
12. **Cl_mic:** Both are similar (77.03 and 77.76), indicating comparable metabolic stability.
13. **t1/2:** A (15.302) is significantly better than B (4.655), suggesting a longer duration of action.
14. **Pgp:** Both are low (0.579 and 0.506).
15. **Binding Affinity:** A (-7.1) is significantly better than B (-5.7). A 1.4 kcal/mol difference in binding is substantial and can often outweigh minor ADME drawbacks.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, affinity), Ligand A is clearly superior. The significantly better binding affinity (-7.1 vs -5.7 kcal/mol) is a major advantage. While Ligand B has slightly better BBB penetration and Caco-2 permeability, these are outweighed by A's superior QED, DILI risk, half-life, and most importantly, binding affinity. The slightly worse Caco-2 and solubility of A are concerns, but can be addressed through formulation strategies.
Output:
1
2025-04-17 22:35:07,218 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A:** [396.171, 45.23, 4.621, 1, 3, 0.606, 79.333, 75.649, -4.613, -5.406, 0.575, 60.522, 77.539, 0.412, -5.9]
**Ligand B:** [361.427, 106.1, 1.128, 2, 7, 0.766, 69.484, 59.403, -4.97, -3.664, 0.184, 58.375, -25.897, 0.027, -5.8]
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand B (361.427) is slightly lower, which *could* be beneficial for permeability, but both are acceptable.
**2. TPSA:** Ligand A (45.23) is significantly better than Ligand B (106.1). ADRB2 is a cardiovascular target, not necessarily CNS, but lower TPSA generally improves absorption. Ligand B is quite high, potentially hindering oral bioavailability.
**3. logP:** Ligand A (4.621) is a bit high, potentially leading to off-target effects or solubility issues. Ligand B (1.128) is quite low, which could impede permeation. A logP between 1-3 is optimal.
**4. H-Bond Donors:** Both are acceptable (Ligand A: 1, Ligand B: 2).
**5. H-Bond Acceptors:** Ligand A (3) is better than Ligand B (7). Higher HBA can affect permeability.
**6. QED:** Both ligands have good QED scores (Ligand A: 0.606, Ligand B: 0.766), indicating good drug-like properties. Ligand B is slightly better.
**7. DILI Risk:** Ligand A (79.333) has a higher DILI risk than Ligand B (69.484), which is undesirable.
**8. BBB Penetration:** Ligand A (75.649) has better BBB penetration than Ligand B (59.403). While ADRB2 isn't strictly a CNS target, some CNS exposure might be acceptable or even beneficial depending on the specific therapeutic goal.
**9. Caco-2 Permeability:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so we can't interpret these values accurately.
**10. Aqueous Solubility:** Ligand A (-5.406) has worse solubility than Ligand B (-3.664). Solubility is important for formulation.
**11. hERG Inhibition:** Both have low hERG inhibition risk (Ligand A: 0.575, Ligand B: 0.184). Ligand B is better here.
**12. Microsomal Clearance:** Ligand A (60.522) has moderate clearance, while Ligand B (58.375) is also moderate. Both are acceptable.
**13. In vitro Half-Life:** Ligand A (77.539) has a much longer half-life than Ligand B (-25.897). This is a significant advantage for dosing frequency.
**14. P-gp Efflux:** Ligand A (0.412) has lower P-gp efflux than Ligand B (0.027). Lower efflux is generally preferred.
**15. Binding Affinity:** Both ligands have very similar and strong binding affinities (-5.9 and -5.8 kcal/mol). The difference is negligible.
**Overall Assessment:**
Ligand A has a better TPSA, HBA, BBB penetration, and significantly better *in vitro* half-life and P-gp efflux. However, it has a higher DILI risk and lower solubility. Ligand B has a better QED, lower DILI risk, and better solubility, but suffers from a high TPSA and a very short half-life.
Given the GPCR-specific priorities (logP, Pgp, TPSA, and affinity) and the importance of metabolic stability (half-life) for cardiovascular drugs, Ligand A is the more promising candidate. The longer half-life is a substantial advantage, and the slightly higher logP and DILI risk might be mitigated through further optimization. The TPSA of Ligand B is a significant concern.
Output:
1
2025-04-17 22:35:07,218 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (344.411) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (71.78) is higher than Ligand B (51.91). Both are below 140, but B is better for oral absorption, and closer to the ideal for GPCRs.
3. **logP:** Ligand A (1.134) is optimal, while Ligand B (3.617) is approaching the upper limit. This favors Ligand A.
4. **HBD:** Ligand A (1) is better than Ligand B (0). Lower HBD is generally preferred.
5. **HBA:** Both ligands have 4 HBA, which is acceptable.
6. **QED:** Both ligands have similar QED scores (A: 0.786, B: 0.797), indicating good drug-likeness.
7. **DILI:** Ligand A (29.43) has a slightly higher DILI risk than Ligand B (25.902), but both are well below the concerning threshold of 60.
8. **BBB:** Ligand B (84.102) has significantly better BBB penetration than Ligand A (53.936). While ADRB2 isn't strictly a CNS target, some CNS exposure can be beneficial or at least not detrimental.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual. This suggests poor permeability.
10. **Solubility:** Ligand A (-1.208) has better solubility than Ligand B (-3.413). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.161) has a much lower hERG risk than Ligand B (0.65). This is a critical advantage for cardiovascular targets.
12. **Cl_mic:** Ligand A (-7.657) has much lower microsomal clearance than Ligand B (55.384), indicating better metabolic stability.
13. **t1/2:** Ligand B (59.285) has a significantly longer in vitro half-life than Ligand A (20.732). This is a positive for dosing convenience.
14. **Pgp:** Ligand A (0.042) has much lower P-gp efflux liability than Ligand B (0.419). Lower P-gp efflux is favorable for bioavailability.
15. **Affinity:** Both ligands have excellent binding affinity (-6.4 and -6.0 kcal/mol), with Ligand A being slightly better.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A excels in logP and Pgp, has slightly better affinity, and acceptable TPSA. Ligand B has better BBB penetration and a longer half-life, but suffers from higher logP, Pgp efflux, and a higher hERG risk. The hERG risk and metabolic stability (Cl_mic) are particularly important for a cardiovascular target.
**Overall Assessment:**
While Ligand B has a longer half-life and better BBB penetration, the superior hERG profile, lower P-gp efflux, better logP, and metabolic stability of Ligand A make it the more promising candidate. The slight advantage in binding affinity further supports this conclusion. The negative Caco-2 values for both are concerning and would need further investigation, but the other factors weigh more heavily in favor of Ligand A.
Output:
1
2025-04-17 22:35:07,218 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (359.535 and 360.82 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (40.54) is significantly better than Ligand B (59.29). ADRB2 is a cardiovascular target, not CNS, but lower TPSA generally improves absorption. Ligand A is well below the 140 threshold. Ligand B is approaching a level that could hinder absorption.
3. **logP:** Both ligands have good logP values (4.245 and 4.055), falling within the 1-3 range. No major difference.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 3 HBA, and Ligand B has 4. Both are acceptable, under the 10 threshold.
6. **QED:** Both ligands have similar QED values (0.772 and 0.766), indicating good drug-likeness.
7. **DILI:** Ligand A (17.216) has a much lower DILI risk than Ligand B (82.396). This is a significant advantage for Ligand A.
8. **BBB:** Both have good BBB penetration (74.564 and 76.347). Not a primary concern for a cardiovascular target, but higher is generally better.
9. **Caco-2:** Ligand A (-5.013) and Ligand B (-4.612) both have negative values, which is unusual and suggests poor permeability. However, the scale isn't specified, so it's hard to interpret.
10. **Solubility:** Both have poor solubility (-4.749 and -4.829). This is a concern for both, but might be manageable with formulation strategies.
11. **hERG:** Ligand A (0.77) has a slightly higher hERG risk than Ligand B (0.466), but both are relatively low.
12. **Cl_mic:** Ligand B (81.139) has a higher microsomal clearance than Ligand A (64.867), suggesting faster metabolism and potentially lower exposure.
13. **t1/2:** Ligand B (101.793) has a significantly longer in vitro half-life than Ligand A (-8.098). This is a substantial advantage for Ligand B.
14. **Pgp:** Ligand A (0.68) has slightly higher P-gp efflux than Ligand B (0.375), meaning B may have better bioavailability.
15. **Binding Affinity:** Ligand A (-7.2) has a slightly better binding affinity than Ligand B (-4.7). This is a significant advantage for Ligand A, as a 1.5 kcal/mol difference can outweigh other drawbacks.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand A is preferable. While Ligand B has a longer half-life, Ligand A has a significantly better binding affinity, lower DILI risk, and a more favorable TPSA. The difference in binding affinity is substantial enough to compensate for the shorter half-life, and the lower DILI risk is a critical advantage. Solubility is a concern for both, but formulation strategies could potentially address this.
Output:
1
2025-04-17 22:35:07,218 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [348.455, 95.57, 1.504, 1, 9, 0.695, 41.877, 73.905, -5.351, -1.856, 0.131, 20.453, 17.822, 0.05, -5.2]
**Ligand B:** [355.463, 59.23, 4.406, 0, 5, 0.657, 57.736, 55.021, -5.172, -4.717, 0.514, 91.823, 60.29, 0.741, -6.2]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal range (200-500 Da). A is 348.455, B is 355.463. No significant difference.
2. **TPSA:** A is 95.57, B is 59.23. B is significantly better, being well under the 140 threshold and closer to the 90 threshold desirable for GPCRs.
3. **logP:** A is 1.504, B is 4.406. A is optimal, B is pushing the upper limit. High logP can lead to off-target effects and solubility issues.
4. **HBD:** A is 1, B is 0. Both are good.
5. **HBA:** A is 9, B is 5. Both are acceptable, but B is preferable.
6. **QED:** Both are similar (A: 0.695, B: 0.657), indicating reasonable drug-likeness.
7. **DILI:** A is 41.877, B is 57.736. A is better, with a lower DILI risk.
8. **BBB:** A is 73.905, B is 55.021. A is significantly better, indicating better potential for CNS penetration, though this isn't a primary concern for ADRB2 unless CNS effects are desired.
9. **Caco-2:** Both are negative, indicating poor permeability. A (-5.351) is slightly better than B (-5.172).
10. **Solubility:** A is -1.856, B is -4.717. A is better, indicating better solubility.
11. **hERG:** A is 0.131, B is 0.514. A is significantly better, indicating lower cardiotoxicity risk.
12. **Cl_mic:** A is 20.453, B is 91.823. A is *much* better, indicating significantly improved metabolic stability.
13. **t1/2:** A is 17.822, B is 60.29. B is better, indicating a longer half-life.
14. **Pgp:** A is 0.05, B is 0.741. A is significantly better, indicating less P-glycoprotein efflux.
15. **Affinity:** A is -5.2 kcal/mol, B is -6.2 kcal/mol. B has a 1.0 kcal/mol advantage in binding affinity.
**Overall Assessment:**
Ligand B has a better binding affinity (-6.2 vs -5.2 kcal/mol), and a longer half-life. However, it suffers from a high logP, higher DILI risk, poorer BBB penetration, lower solubility, higher hERG risk, and significantly higher microsomal clearance and Pgp efflux. Ligand A has a more balanced profile, with better ADME properties (solubility, metabolic stability, Pgp efflux, DILI, hERG) and reasonable BBB penetration, despite a slightly weaker binding affinity. For a GPCR target like ADRB2, a balance of potency *and* good drug-like properties is crucial. The 1.0 kcal/mol difference in binding affinity is not enough to overcome the significant ADME liabilities of Ligand B.
Therefore, I prefer Ligand A.
Output:
1
2025-04-17 22:35:07,219 - INFO - Here's a step-by-step comparison of Ligand A and Ligand B, followed by my final decision:
**1. Molecular Weight (MW):**
* Ligand A: 356.373 Da - Within the ideal range (200-500 Da).
* Ligand B: 389.517 Da - Also within the ideal range.
* *Comment:* Both are acceptable.
**2. Topological Polar Surface Area (TPSA):**
* Ligand A: 76.46 - Good for oral absorption (<=140) and acceptable for a cardiovascular GPCR.
* Ligand B: 37.38 - Excellent, very favorable for permeability.
* *Comment:* Ligand B is significantly better here.
**3. Lipophilicity (logP):**
* Ligand A: 1.289 - Optimal.
* Ligand B: 4.806 - High. Could lead to solubility issues and off-target interactions.
* *Comment:* Ligand A is preferred.
**4. H-Bond Donors (HBD):**
* Ligand A: 1 - Acceptable.
* Ligand B: 0 - Acceptable.
* *Comment:* Both are good.
**5. H-Bond Acceptors (HBA):**
* Ligand A: 5 - Acceptable.
* Ligand B: 3 - Acceptable.
* *Comment:* Both are good.
**6. QED:**
* Ligand A: 0.833 - Excellent drug-like properties.
* Ligand B: 0.442 - Below the desirable threshold of 0.5.
* *Comment:* Ligand A is significantly better.
**7. DILI Risk:**
* Ligand A: 51.338 - Low risk.
* Ligand B: 12.912 - Very low risk.
* *Comment:* Ligand B is preferred.
**8. BBB Penetration:**
* Ligand A: 85.343 - Good, but not exceptional.
* Ligand B: 94.145 - Excellent.
* *Comment:* Ligand B is preferred, though BBB is less critical for a cardiovascular target.
**9. Caco-2 Permeability:**
* Ligand A: -4.232 - Poor permeability.
* Ligand B: -4.686 - Poor permeability.
* *Comment:* Both are poor, but similar.
**10. Aqueous Solubility:**
* Ligand A: -2.473 - Poor solubility.
* Ligand B: -3.839 - Very poor solubility.
* *Comment:* Both are poor, but Ligand B is worse.
**11. hERG Inhibition:**
* Ligand A: 0.175 - Very low risk.
* Ligand B: 0.805 - Moderate risk.
* *Comment:* Ligand A is preferred.
**12. Microsomal Clearance:**
* Ligand A: 47.454 - Moderate clearance.
* Ligand B: 63.887 - Higher clearance, less metabolic stability.
* *Comment:* Ligand A is preferred.
**13. In vitro Half-Life:**
* Ligand A: -16.756 - Very short half-life.
* Ligand B: -8.98 - Shorter half-life, but better than A.
* *Comment:* Both are poor, but Ligand B is better.
**14. P-gp Efflux:**
* Ligand A: 0.03 - Very low efflux.
* Ligand B: 0.529 - Moderate efflux.
* *Comment:* Ligand A is preferred.
**15. Binding Affinity:**
* Ligand A: -6.2 kcal/mol
* Ligand B: -5.2 kcal/mol
* *Comment:* Ligand A has a significantly better binding affinity.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand A is the stronger candidate. While Ligand B has better BBB penetration and lower DILI risk, Ligand A's superior binding affinity (-6.2 vs -5.2 kcal/mol), better QED, lower logP, lower hERG risk, lower P-gp efflux, and better metabolic stability outweigh the advantages of Ligand B. The poor Caco-2 and solubility of both compounds are concerns, but can be addressed through formulation strategies. The higher affinity of Ligand A is a crucial advantage for a GPCR target.
Output:
1
2025-04-17 22:35:07,219 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (341.411 and 342.483 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (74.08) is higher than Ligand B (49.41). For a cardiovascular GPCR (ADRB2), TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B has a clear advantage.
3. **logP:** Both ligands have good logP values (2.89 and 3.03), falling within the optimal 1-3 range. No major distinction.
4. **HBD:** Ligand A (0) has fewer H-bond donors than Ligand B (1). Fewer donors can be beneficial for membrane permeability. Ligand A is slightly favored.
5. **HBA:** Ligand A (6) has more H-bond acceptors than Ligand B (2). Lower HBA is generally preferred for permeability. Ligand B is favored.
6. **QED:** Both ligands have good QED scores (0.782 and 0.806), indicating good drug-like properties. No significant difference.
7. **DILI:** Ligand A (63.086) has a higher DILI risk than Ligand B (28.228). This is a significant concern, as lower DILI is crucial. Ligand B is strongly favored.
8. **BBB:** Both ligands have reasonable BBB penetration (77.627 and 75.107). Since ADRB2 is not a CNS target, this is less critical, but higher is still slightly better. Ligand A is marginally favored.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.326 and -4.797), which is unusual. These values likely indicate poor permeability in this assay. It's difficult to interpret without more context, but they are both unfavorable.
10. **Solubility:** Both ligands have negative solubility values (-4.173 and -3.756), also unusual and unfavorable. Poor solubility is a major concern for bioavailability.
11. **hERG:** Both ligands have low hERG inhibition liability (0.201 and 0.39). This is good, minimizing cardiotoxicity risk. No significant difference.
12. **Cl_mic:** Ligand A (78.69) has higher microsomal clearance than Ligand B (56.859). Higher clearance means faster metabolism and potentially lower exposure. Ligand B is favored.
13. **t1/2:** Ligand B (-7.362) has a more negative in vitro half-life than Ligand A (-24.45). This is counterintuitive; a more negative value likely indicates a shorter half-life, which is unfavorable. Ligand A is favored.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.291 and 0.27). This is good, as it suggests better oral bioavailability. No significant difference.
15. **Binding Affinity:** Ligand A (-8.2 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.1 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME drawbacks.
**Overall Assessment & GPCR Prioritization:**
For a cardiovascular GPCR like ADRB2, binding affinity is paramount. Ligand A's significantly stronger affinity (-8.2 vs -6.1 kcal/mol) is a major advantage. While Ligand B has better DILI and clearance profiles, the strong binding of Ligand A is likely to be more impactful. The solubility and Caco-2 values are concerning for both, but these could potentially be addressed through formulation strategies. The slightly higher TPSA of Ligand A is less concerning for a peripheral target.
Output:
1
2025-04-17 22:35:07,219 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
We are targeting ADRB2, a GPCR. Therefore, priorities are logP, Pgp, TPSA, affinity, and BBB.
Let's compare the ligands property by property:
1. **MW:** Both are within the ideal range (345.4 vs 342.4 Da). No significant difference.
2. **TPSA:** Ligand A (87.74) is better than Ligand B (104.19). Lower TPSA generally favors oral absorption and BBB penetration.
3. **logP:** Ligand A (0.695) is slightly lower than Ligand B (-0.827), but both are a bit low. A logP between 1-3 is preferred. Ligand B is more concerningly low.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1), but both are acceptable.
5. **HBA:** Ligand A (4) is lower than Ligand B (6). Lower HBA is generally preferred for permeability.
6. **QED:** Both are very similar (0.789 vs 0.784), indicating good drug-likeness.
7. **DILI:** Ligand A (53.28) is better than Ligand B (61.81), indicating a lower risk of drug-induced liver injury.
8. **BBB:** Ligand A (78.25) is significantly better than Ligand B (33.39). This is a crucial factor for a GPCR, even if not specifically a CNS target, as it indicates better distribution characteristics.
9. **Caco-2:** Ligand A (-4.619) is better than Ligand B (-5.31), suggesting better intestinal absorption.
10. **Solubility:** Both are very poor (-2.145 and -2.126). This is a concern for both, but not a deciding factor between the two.
11. **hERG:** Ligand A (0.109) is better than Ligand B (0.202), indicating a lower risk of cardiotoxicity.
12. **Cl_mic:** Both are similar (-5.936 vs -4.604).
13. **t1/2:** Ligand A (-4.65) is slightly worse than Ligand B (-4.228), but both are poor.
14. **Pgp:** Ligand A (0.012) is much better than Ligand B (0.009), indicating lower P-glycoprotein efflux, which is important for bioavailability and potentially CNS penetration.
15. **Affinity:** Ligand B (-6.2 kcal/mol) is significantly better than Ligand A (-4.7 kcal/mol). This is a substantial difference in binding strength (1.5 kcal/mol advantage).
**Overall Assessment:**
Ligand B has a significantly better binding affinity. However, Ligand A has superior ADME properties, particularly BBB penetration, TPSA, DILI risk, and Pgp efflux. Given the GPCR target class, the balance of properties favors Ligand A. While the affinity difference is notable, the poor ADME profile of Ligand B, especially the very low BBB penetration and higher DILI risk, makes it a less viable candidate. The slightly lower logP of Ligand A is a concern, but the other advantages outweigh this.
**Output:**
1
2025-04-17 22:35:07,219 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.38 and 350.46 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (86.63) is slightly higher than Ligand B (75.71). Both are below the 140 threshold for oral absorption, but B is better positioned for potential CNS penetration, though that's not a primary goal for ADRB2.
3. **logP:** Both ligands have good logP values (1.278 and 1.442), falling within the optimal 1-3 range. Ligand B is slightly higher, which could be marginally better for membrane permeability.
4. **HBD:** Both have 1 HBD, which is acceptable.
5. **HBA:** Ligand A has 5 HBA, and Ligand B has 4. Both are below the 10 threshold.
6. **QED:** Ligand A (0.87) has a better QED score than Ligand B (0.736), indicating a more drug-like profile.
7. **DILI:** Ligand B (19.66%) has a significantly lower DILI risk than Ligand A (61.26%). This is a major advantage for Ligand B.
8. **BBB:** Ligand B (80.88%) shows better BBB penetration than Ligand A (64.60%). While ADRB2 isn't a primary CNS target, some off-target CNS effects are always a consideration.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not defined, so it's hard to interpret.
10. **Solubility:** Both ligands have negative solubility values, which is also unusual. This suggests poor solubility.
11. **hERG:** Ligand A (0.173) has a lower hERG risk than Ligand B (0.328), which is preferable.
12. **Cl_mic:** Ligand A (24.09) has a significantly lower microsomal clearance than Ligand B (68.75), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand B (-20.85) has a negative half-life, which is not possible. This is a major red flag. Ligand A (-3.86) is also negative, but less so.
14. **Pgp:** Both ligands have low Pgp efflux liability.
15. **Binding Affinity:** Ligand B (-7.1) has a slightly better binding affinity than Ligand A (-7.4), but the difference is small (0.3 kcal/mol).
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, and affinity are important. Both ligands are reasonable in these regards. However, ADME properties are crucial. Ligand B has a much lower DILI risk and better BBB penetration. Ligand A has better metabolic stability (lower Cl_mic). The negative half-life values are concerning for both, but more so for Ligand B.
**Overall Assessment:**
Despite the slight affinity advantage of Ligand B, the significantly lower DILI risk and better BBB penetration make it the more promising candidate. The negative half-life for Ligand B is a major concern, but the other ADME properties are better. The better metabolic stability of Ligand A is valuable, but the higher DILI risk is a significant drawback.
Output:
0
2025-04-17 22:35:07,219 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.387 and 346.475 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (106.66) is higher than Ligand B (86.88). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is generally preferred for absorption. Ligand B has a slight advantage.
3. **logP:** Ligand A (-0.983) is lower than Ligand B (2.408). logP of 1-3 is optimal. Ligand B is within this range, while Ligand A is a bit low, potentially hindering permeation. Ligand B is favored.
4. **HBD:** Ligand A (2) and Ligand B (3) are both acceptable, being less than 5.
5. **HBA:** Ligand A (5) and Ligand B (3) are both acceptable, being less than 10.
6. **QED:** Both ligands have similar QED values (0.59 and 0.569), indicating good drug-likeness.
7. **DILI:** Ligand A (27.608) has a significantly lower DILI risk than Ligand B (15.51). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (43.583) and Ligand B (52.811) are both relatively low, which is expected for a cardiovascular target. While higher is better, this isn't a primary concern for ADRB2. Ligand B is slightly better.
9. **Caco-2:** Both ligands have similar, very negative Caco-2 values (-5.288 and -5.373). This suggests poor permeability, which is concerning.
10. **Solubility:** Both ligands have similar, very negative solubility values (-1.983 and -2.327). This suggests poor solubility, which is concerning.
11. **hERG:** Ligand A (0.047) has a slightly lower hERG risk than Ligand B (0.242), which is preferable.
12. **Cl_mic:** Ligand A (-15.715) has a much lower (better) microsomal clearance than Ligand B (26.068), indicating greater metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (-8.596) has a shorter half-life than Ligand B (-30.537). This is a disadvantage for Ligand A.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.01 and 0.046).
15. **Binding Affinity:** Ligand A (-6.7) has slightly better binding affinity than Ligand B (-5.7). A 1 kcal/mol difference is significant.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, affinity), Ligand B initially looks better due to its more favorable logP and slightly lower TPSA. However, Ligand A has a much better safety profile (DILI, hERG) and significantly improved metabolic stability (Cl_mic). The binding affinity difference is also in favor of Ligand A. The poor Caco-2 and solubility values are concerning for both, but can potentially be addressed with formulation strategies. Given the importance of metabolic stability and safety for a chronic cardiovascular condition, and the relatively small advantage in affinity for Ligand B, the lower DILI and better Cl_mic of Ligand A make it the more promising candidate.
Output:
1
2025-04-17 22:35:07,220 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (354.491 and 357.401 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (67.87 and 67.6) are below the 140 A^2 threshold for good oral absorption, and acceptable for a cardiovascular GPCR. Similar values.
3. **logP:** Both ligands (2.114 and 2.296) are within the optimal 1-3 range. Again, a minor difference.
4. **HBD:** Both have 1 HBD, which is well within the acceptable limit of 5.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 5. Both are below the 10 limit.
6. **QED:** Both ligands have good QED scores (0.76 and 0.876), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (7.794%) has a significantly lower DILI risk than Ligand B (22.722%). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (93.098%) has a much higher BBB penetration score than Ligand A (69.523%). While ADRB2 is a cardiovascular target, some CNS off-target effects are always a concern, and higher BBB penetration could exacerbate those. However, for a cardiovascular target, BBB isn't a primary driver.
9. **Caco-2:** Both have negative Caco-2 values (-4.544 and -4.839). These values are unusual and suggest poor permeability.
10. **Solubility:** Both have negative solubility values (-1.711 and -2.372). These values are also unusual and suggest poor solubility.
11. **hERG:** Both ligands have low hERG inhibition risk (0.366 and 0.464). No significant difference.
12. **Cl_mic:** Ligand A (7.029) has slightly lower microsomal clearance than Ligand B (7.568), suggesting better metabolic stability.
13. **t1/2:** Both have similar in vitro half-lives (5.244 and 4.922 hours).
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.029 and 0.091).
15. **Binding Affinity:** Ligand B (-7.6 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.2 kcal/mol). This is a 1.4 kcal/mol difference, which is substantial and can outweigh some ADME drawbacks.
**GPCR-Specific Priorities & Overall Assessment:**
For a GPCR like ADRB2, affinity, logP, TPSA, and Pgp are key. Ligand B excels in affinity. The lower DILI risk of Ligand A is attractive, but the substantially better binding affinity of Ligand B is a more critical factor, especially since both ligands have similar profiles in other important parameters like logP, TPSA, and Pgp. The negative Caco-2 and solubility values are concerning for both, but can be addressed with formulation strategies.
**Output:**
0
2025-04-17 22:35:07,220 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [423.336, 75.19, 2.625, 1, 5, 0.771, 72.005, 68.127, -5.1, -3.092, 0.151, 63.88, 17.734, 0.201, -6.7]**
**Ligand B: [347.415, 80.23, 0.683, 1, 5, 0.811, 44.591, 76.735, -4.707, -3.498, 0.192, 28.408, 12.893, 0.161, -7.2]**
1. **Molecular Weight:** Ligand A (423.336 Da) is within the ideal range, while Ligand B (347.415 Da) is towards the lower end, but still acceptable.
2. **TPSA:** Both are reasonably good (A: 75.19, B: 80.23), below the 140 threshold for oral absorption.
3. **logP:** Ligand A (2.625) is optimal. Ligand B (0.683) is a bit low, potentially impacting permeability.
4. **H-Bond Donors:** Both have 1 HBD, which is good.
5. **H-Bond Acceptors:** Both have 5 HBA, which is good.
6. **QED:** Both have good QED scores (A: 0.771, B: 0.811), indicating drug-likeness.
7. **DILI:** Ligand A (72.005) is higher risk than Ligand B (44.591). This is a significant negative for Ligand A.
8. **BBB:** Both have acceptable BBB penetration (A: 68.127, B: 76.735).
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability.
10. **Solubility:** Both have negative solubility values, which is also unusual and suggests poor solubility.
11. **hERG:** Both have very low hERG risk (A: 0.151, B: 0.192).
12. **Cl_mic:** Ligand B (28.408) has significantly lower microsomal clearance than Ligand A (63.88), indicating better metabolic stability.
13. **t1/2:** Ligand A (17.734) has a longer half-life than Ligand B (12.893).
14. **Pgp:** Both have low Pgp efflux liability (A: 0.201, B: 0.161).
15. **Binding Affinity:** Ligand B (-7.2 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.7 kcal/mol). This is a substantial advantage.
**GPCR-Specific Considerations:** For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand A has a better logP, but Ligand B excels in affinity and has a lower DILI risk and better metabolic stability. The affinity difference is significant enough to outweigh the slightly lower logP of Ligand B. The negative Caco-2 and solubility values are concerning for both, but can be addressed with formulation strategies.
**Conclusion:**
Ligand B is the more promising candidate due to its significantly higher binding affinity, lower DILI risk, and better metabolic stability. While Ligand A has a slightly better logP, the advantages of Ligand B are more critical for a GPCR target.
Output:
0
2025-04-17 22:35:07,220 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [361.32 , 71.44 , 0.255, 0. , 5. , 0.723, 44.552, 96.782, -4.281, -2.491, 0.233, -2.281, -19.759, 0.082, -6.6 ]
**Ligand B:** [356.333, 121.93 , -0.535, 2. , 7. , 0.645, 58.434, 74.447, -4.957, -2.728, 0.148, 6.169, 3.359, 0.007, -5.6 ]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity, and BBB):
1. **MW:** Both are within the ideal range (200-500 Da). A is 361.32, B is 356.333. Very similar.
2. **TPSA:** Ligand A (71.44) is significantly better than Ligand B (121.93). GPCRs benefit from lower TPSA for permeability.
3. **logP:** Ligand A (0.255) is quite low, potentially hindering permeability. Ligand B (-0.535) is also low, but slightly better. Both are suboptimal.
4. **HBD/HBA:** A has 0/5, B has 2/7. A is preferable here, minimizing potential for off-target interactions and improving permeability.
5. **QED:** Both are good (A: 0.723, B: 0.645), indicating drug-like properties.
6. **DILI:** Ligand A (44.552) is better than Ligand B (58.434), indicating lower liver injury risk.
7. **BBB:** Ligand A (96.782) is *much* better than Ligand B (74.447). This is a significant advantage for a GPCR target, even if not CNS-focused, as it suggests better distribution.
8. **Caco-2:** Both are negative, indicating poor permeability. A (-4.281) is slightly less negative than B (-4.957), suggesting marginally better absorption.
9. **Solubility:** Both are negative, indicating poor solubility. A (-2.491) is slightly better than B (-2.728).
10. **hERG:** Both are very low (A: 0.233, B: 0.148), suggesting minimal cardiotoxicity risk.
11. **Cl_mic:** Ligand A (-2.281) is much better than Ligand B (6.169). Lower clearance means greater metabolic stability.
12. **t1/2:** Ligand A (-19.759) is much better than Ligand B (3.359). Longer half-life is desirable.
13. **Pgp:** Both are very low (A: 0.082, B: 0.007), suggesting minimal P-gp efflux.
14. **Affinity:** Ligand A (-6.6) is slightly better than Ligand B (-5.6). While both are good, the difference is significant enough to consider.
**Overall Assessment:**
Ligand A is significantly better across multiple critical parameters, especially TPSA, BBB, metabolic stability (Cl_mic & t1/2), and DILI risk. While both have suboptimal logP values, the other advantages of A outweigh this. The slightly better affinity of A is an additional benefit.
Output:
1
2025-04-17 22:35:07,220 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (353.296 and 352.45 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (64.63) is higher than Ligand B (49.85). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for permeability. Ligand B has a slight advantage.
3. **logP:** Ligand A (3.289) is within the optimal 1-3 range, while Ligand B (2.001) is a bit lower. While both are acceptable, a logP closer to 3 is often preferred for GPCRs to facilitate membrane interactions. Ligand A has a slight advantage.
4. **HBD:** Ligand A (1) is better than Ligand B (0). Having at least one HBD can improve solubility.
5. **HBA:** Ligand A (5) is higher than Ligand B (3). Both are within acceptable limits (<=10), but lower is generally preferred for permeability. Ligand B has a slight advantage.
6. **QED:** Both ligands have good QED scores (0.66 and 0.76 respectively), indicating good drug-like properties. No significant difference.
7. **DILI:** Ligand B (6.708) has a *much* lower DILI risk than Ligand A (85.964). This is a major advantage for Ligand B. DILI is a significant concern in drug development.
8. **BBB:** Ligand A (71.035) and Ligand B (96.084). While ADRB2 isn't necessarily a CNS target, higher BBB penetration is rarely detrimental and can open up potential for alternative therapeutic strategies. Ligand B has a significant advantage.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.209 and -4.555). This indicates poor permeability. However, these values are on a strange scale, and it's difficult to interpret the difference.
10. **Solubility:** Ligand B (-2.013) is better than Ligand A (-5.773). Solubility is important for bioavailability.
11. **hERG:** Both ligands have low hERG inhibition liability (0.635 and 0.529), which is good. No significant difference.
12. **Cl_mic:** Ligand B (28.881) has significantly lower microsomal clearance than Ligand A (113.076). This indicates better metabolic stability for Ligand B, which is highly desirable.
13. **t1/2:** Ligand A (41.595) has a longer in vitro half-life than Ligand B (-7.139). This is a positive for Ligand A.
14. **Pgp:** Ligand A (0.385) has lower P-gp efflux than Ligand B (0.077). Lower P-gp efflux is generally preferred.
15. **Binding Affinity:** Ligand B (-6.5 kcal/mol) has slightly better binding affinity than Ligand A (-4.9 kcal/mol). A difference of 1.6 kcal/mol is substantial and can often outweigh minor ADME drawbacks.
**Overall Assessment:**
Ligand B is the stronger candidate. While Ligand A has a slightly better logP and in vitro half-life, Ligand B excels in crucial areas like DILI risk, metabolic stability (Cl_mic), BBB penetration, solubility, and binding affinity. The significantly lower DILI risk and improved metabolic stability are particularly important for a cardiovascular drug. The better binding affinity is also a significant advantage. The negative Caco-2 values are concerning for both, but the other benefits of Ligand B outweigh this drawback.
Output:
0
2025-04-17 22:35:07,220 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (381.468) is slightly higher than Ligand B (343.427), but both are acceptable.
2. **TPSA:** Ligand A (55.21) is better than Ligand B (75.44). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally aids absorption.
3. **logP:** Both ligands have good logP values (A: 2.122, B: 2.164), falling within the optimal 1-3 range.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A (7) is slightly higher than Ligand B (4), but both are within the acceptable limit of 10.
6. **QED:** Ligand B (0.85) has a better QED score than Ligand A (0.627), suggesting a more drug-like profile.
7. **DILI:** Ligand A (19.426) has a significantly lower DILI risk than Ligand B (48.817). This is a major advantage for Ligand A.
8. **BBB:** Both have similar BBB penetration (A: 83.986, B: 81.349). Not a major factor for a cardiovascular target.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the values are similar (-5.222 for A, -5.01 for B).
10. **Solubility:** Both have negative solubility values, indicating poor aqueous solubility. Ligand A (-2.065) is slightly better than Ligand B (-2.784).
11. **hERG:** Ligand A (0.712) has a lower hERG risk than Ligand B (0.289). This is a significant advantage.
12. **Cl_mic:** Ligand A (-15.789) has a much lower (better) microsomal clearance than Ligand B (60.749), indicating greater metabolic stability.
13. **t1/2:** Ligand A (-0.902) has a slightly better in vitro half-life than Ligand B (-30.966).
14. **Pgp:** Ligand A (0.068) has a lower Pgp efflux liability than Ligand B (0.311), which is favorable.
15. **Binding Affinity:** Ligand B (-7.3) has a slightly better binding affinity than Ligand A (-6.6). The difference is 0.7 kcal/mol, which is a notable but not overwhelming advantage.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Both ligands perform similarly on logP. Ligand A has a better TPSA and Pgp profile. The affinity difference is relatively small. Crucially, Ligand A significantly outperforms Ligand B in terms of safety (DILI and hERG) and metabolic stability (Cl_mic).
**Conclusion:**
While Ligand B has slightly better binding affinity and QED, Ligand A demonstrates a significantly better safety profile (lower DILI and hERG risk) and improved metabolic stability. Given the importance of these factors for a cardiovascular drug candidate, Ligand A is the more promising option.
Output:
1
2025-04-17 22:35:07,221 - INFO - Batch 342 complete. Total preferences: 5472
2025-04-17 22:35:07,221 - INFO - Processing batch 343/512...
2025-04-17 22:35:50,676 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.431 and 351.495 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (95.71) is higher than Ligand B (70.47). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B has a clear advantage here.
3. **logP:** Ligand A (3.617) is good, within the optimal 1-3 range. Ligand B (1.275) is at the lower end, potentially impacting permeability. Ligand A is favored.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable.
5. **HBA:** Ligand A (4) and Ligand B (5) are both acceptable.
6. **QED:** Both ligands have similar QED values (0.627 and 0.689), indicating good drug-likeness.
7. **DILI:** Ligand A (46.956) has a higher DILI risk than Ligand B (22.257). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (68.36) is better than Ligand B (51.725), but BBB is less critical for a cardiovascular target.
9. **Caco-2:** Ligand A (-4.68) is worse than Ligand B (-5.068). Lower values are less favorable. Ligand B is favored.
10. **Solubility:** Ligand A (-3.21) is worse than Ligand B (-1.007). Solubility is important, and Ligand B has a clear advantage.
11. **hERG:** Ligand A (0.757) is higher than Ligand B (0.218), indicating a higher risk of hERG inhibition. This is a significant advantage for Ligand B.
12. **Cl_mic:** Ligand A (3.582) has lower clearance than Ligand B (50.57), indicating better metabolic stability. Ligand A is favored.
13. **t1/2:** Ligand A (-1.971) is worse than Ligand B (21.229). A longer half-life is generally preferred, giving a substantial advantage to Ligand B.
14. **Pgp:** Ligand A (0.349) is lower than Ligand B (0.011), indicating less P-gp efflux. This is a slight advantage for Ligand A.
15. **Binding Affinity:** Ligand B (-6.7) has a significantly stronger binding affinity than Ligand A (-6.0). This is a substantial advantage for Ligand B, potentially outweighing some ADME drawbacks.
**Overall Assessment:**
Ligand B demonstrates a superior balance of properties, particularly regarding safety (lower DILI, lower hERG) and ADME characteristics (better solubility, Caco-2, and significantly longer half-life). While Ligand A has better metabolic stability and slightly lower P-gp efflux, the stronger binding affinity of Ligand B, combined with its improved safety profile, makes it the more promising drug candidate for the ADRB2 receptor. The difference in binding affinity is substantial (>1.5 kcal/mol).
Output:
0
2025-04-17 22:35:50,676 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (390.483 and 369.441 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand B (79.8) is significantly better than Ligand A (113.01). For a GPCR, lower TPSA is generally preferred as it aids membrane permeability.
**3. logP:** Ligand B (3.135) is slightly higher than Ligand A (1.982), but both are within the optimal 1-3 range.
**4. H-Bond Donors:** Both ligands have 2 HBD, which is acceptable.
**5. H-Bond Acceptors:** Both ligands have 6 HBA, also acceptable.
**6. QED:** Both ligands have similar QED values (0.795 and 0.784), indicating good drug-likeness.
**7. DILI:** Ligand B (70.26) has a slightly higher DILI risk than Ligand A (64.405), but both are still within a reasonably acceptable range (below 60 is ideal, but up to 70 is often tolerated).
**8. BBB:** Ligand B (84.451) has a much higher BBB penetration percentile than Ligand A (19.853). While ADRB2 is a cardiovascular target, some CNS exposure can be relevant for off-target effects and safety assessment.
**9. Caco-2 Permeability:** Ligand A (-5.214) shows better Caco-2 permeability than Ligand B (-4.986), indicating better intestinal absorption.
**10. Aqueous Solubility:** Ligand A (-2.909) shows better aqueous solubility than Ligand B (-3.519), which is important for formulation.
**11. hERG Inhibition:** Ligand A (0.042) has a much lower hERG inhibition liability than Ligand B (0.642). This is a *critical* advantage, as hERG inhibition is a major cause of drug withdrawal due to cardiotoxicity.
**12. Microsomal Clearance:** Ligand B (27.334) has a slightly higher microsomal clearance than Ligand A (22.546), suggesting faster metabolism and potentially lower exposure.
**13. In vitro Half-Life:** Ligand A (-7.502) has a significantly longer in vitro half-life than Ligand B (22.939), which is desirable for less frequent dosing.
**14. P-gp Efflux:** Ligand A (0.021) has a much lower P-gp efflux liability than Ligand B (0.23), which is favorable for bioavailability.
**15. Binding Affinity:** Both ligands have the same binding affinity (-7.5 kcal/mol), so this parameter doesn't differentiate them.
**Overall Assessment:**
While Ligand B has better TPSA and BBB penetration, the significant advantages of Ligand A in terms of hERG inhibition, in vitro half-life, Caco-2 permeability, P-gp efflux, and aqueous solubility outweigh these benefits. The lower hERG risk is particularly crucial for a cardiovascular target. The better metabolic stability (lower Cl_mic and longer t1/2) also makes Ligand A more promising.
Output:
1
2025-04-17 22:35:50,676 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (369.3 and 359.4 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (54.02) is significantly better than Ligand B (114.59). For a GPCR, lower TPSA is generally preferred for better permeability. Ligand B is quite high, potentially hindering absorption.
**3. logP:** Both ligands have good logP values (4.05 and 3.52, respectively), falling within the optimal 1-3 range, though Ligand A is slightly higher.
**4. H-Bond Donors:** Both have 2 HBD, which is acceptable.
**5. H-Bond Acceptors:** Ligand A has 3 HBA, while Ligand B has 7. This is a significant difference. Higher HBA can sometimes reduce permeability.
**6. QED:** Ligand A (0.788) has a much better QED score than Ligand B (0.511), indicating a more drug-like profile.
**7. DILI:** Ligand B (98.2%) has a very high DILI risk, which is a major concern. Ligand A (58.9%) is still not ideal, but significantly better.
**8. BBB:** Ligand A (80.7%) shows good BBB penetration, while Ligand B (27.9%) is poor. While ADRB2 isn't necessarily a CNS target, some degree of BBB penetration can be beneficial for overall distribution and potentially off-target effects.
**9. Caco-2 Permeability:** Ligand A (-4.688) is better than Ligand B (-5.114). Both are negative, indicating relatively poor permeability, but A is less poor.
**10. Aqueous Solubility:** Ligand A (-4.626) is better than Ligand B (-5.047). Both are poor, but A is less poor.
**11. hERG Inhibition:** Ligand A (0.665) is better than Ligand B (0.198). Lower hERG inhibition is crucial for cardiovascular drugs to avoid QT prolongation.
**12. Microsomal Clearance:** Ligand B (25.7) has higher clearance than Ligand A (15.58), suggesting lower metabolic stability.
**13. In vitro Half-Life:** Ligand A (24.265) has a much longer half-life than Ligand B (-0.817). This is a significant advantage.
**14. P-gp Efflux:** Ligand A (0.094) has lower P-gp efflux than Ligand B (0.192), which is favorable for bioavailability.
**15. Binding Affinity:** Ligand A (-7.9 kcal/mol) has a slightly better binding affinity than Ligand B (-6.9 kcal/mol). While both are good, the difference is substantial enough to matter.
**Overall Assessment:**
Ligand A is clearly the superior candidate. It demonstrates better drug-like properties (QED), significantly lower DILI risk, improved BBB penetration, better hERG profile, longer half-life, lower P-gp efflux, and slightly better binding affinity. While both have solubility and permeability issues, Ligand A is better in both respects. The high DILI risk associated with Ligand B is a major red flag.
Output:
1
2025-04-17 22:35:50,676 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (343.431 Da) is within the ideal range (200-500 Da). Ligand B (369.487 Da) is also within the ideal range. No clear advantage here.
2. **TPSA:** Ligand A (88.91) is good, below the 140 threshold. Ligand B (80.76) is even better, further below the threshold. Slight advantage to B.
3. **logP:** Ligand A (2.254) is optimal (1-3). Ligand B (1.834) is also optimal. No clear advantage.
4. **HBD:** Ligand A (2) is good (<=5). Ligand B (1) is even better. Slight advantage to B.
5. **HBA:** Ligand A (5) is good (<=10). Ligand B (6) is also good. No clear advantage.
6. **QED:** Ligand A (0.807) is excellent (>0.5). Ligand B (0.681) is also good, but not as high. Advantage to A.
7. **DILI:** Ligand A (68.399) is acceptable, but higher risk. Ligand B (37.728) is very good, low risk. Significant advantage to B.
8. **BBB:** Ligand A (52.579) is moderate. Ligand B (77.317) is good. Advantage to B, especially given ADRB2 is a GPCR.
9. **Caco-2:** Both Ligand A (-5.065) and Ligand B (-4.868) have negative values, which is unusual and suggests poor permeability. No clear advantage.
10. **Solubility:** Both ligands have negative solubility values (-3.582 and -2.253 respectively), indicating very poor aqueous solubility. This is a significant concern for both.
11. **hERG:** Ligand A (0.304) has a slightly higher hERG risk than Ligand B (0.159). Advantage to B.
12. **Cl_mic:** Ligand A (38.067) has better metabolic stability (lower clearance) than Ligand B (49.611). Advantage to A.
13. **t1/2:** Ligand A (45.113) has a longer half-life than Ligand B (-16.022). This is a significant advantage to A.
14. **Pgp:** Ligand A (0.04) has lower P-gp efflux than Ligand B (0.077). Advantage to A.
15. **Affinity:** Ligand B (-7.2 kcal/mol) has a slightly better binding affinity than Ligand A (-8.0 kcal/mol). While A is better, the difference is not substantial enough to outweigh other factors.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand B appears to be the better candidate. While Ligand A has a better QED, longer half-life, and lower Pgp efflux, Ligand B excels in crucial areas like DILI risk, BBB penetration, and TPSA, and has a comparable binding affinity. The poor solubility of both compounds is a significant concern that would need to be addressed through formulation strategies, but the lower toxicity and better predicted distribution of Ligand B make it the more promising starting point.
Output:
0
2025-04-17 22:35:50,676 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (359.455 and 350.463 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (81.81) is better than Ligand B (90.54). Both are below 140, but closer to 90 is preferred for GPCRs, making A slightly better.
3. **logP:** Ligand A (2.586) is optimal (1-3), while Ligand B (0.99) is on the lower side, potentially hindering permeability. This is a significant advantage for A.
4. **HBD:** Ligand A (1) is better than Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (6) is better than Ligand B (3). Fewer HBAs generally improve permeability.
6. **QED:** Both ligands (0.759 and 0.706) have good drug-likeness scores (>0.5).
7. **DILI:** Ligand A (79.333) has a higher DILI risk than Ligand B (33.346). This is a substantial drawback for A.
8. **BBB:** Ligand B (71.656) has better BBB penetration than Ligand A (60.915). While ADRB2 isn't strictly a CNS target, some CNS exposure can be relevant for off-target effects, and B is better here.
9. **Caco-2:** Both ligands (-5.025 and -5.024) are similar.
10. **Solubility:** Both ligands (-2.597 and -2.802) are similar.
11. **hERG:** Ligand A (0.39) has a slightly higher hERG risk than Ligand B (0.165), but both are relatively low.
12. **Cl_mic:** Ligand A (11.805) has significantly lower microsomal clearance than Ligand B (19.989), indicating better metabolic stability. This is a strong advantage for A.
13. **t1/2:** Ligand A (15.464) has a shorter half-life than Ligand B (31.366). This is a drawback for A.
14. **Pgp:** Ligand A (0.324) has lower P-gp efflux than Ligand B (0.013), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand A (-6.7 kcal/mol) has a slightly better binding affinity than Ligand B (-5.6 kcal/mol). This is a significant advantage for A.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A excels in logP, TPSA, Pgp and affinity. Ligand B has a much better DILI score and BBB penetration. The difference in affinity is 1.1 kcal/mol, which is substantial enough to potentially overcome some ADME liabilities.
**Overall Assessment:**
While Ligand B has a significantly better safety profile (DILI) and slightly better BBB penetration, Ligand A has a superior combination of properties crucial for GPCR engagement and drug-like behavior: better logP, TPSA, Pgp efflux, and binding affinity. The improved metabolic stability (lower Cl_mic) is also a significant plus. The DILI risk for Ligand A is concerning, but could be investigated further with additional studies. The binding affinity difference is large enough to potentially outweigh the DILI risk.
Output:
1
2025-04-17 22:35:50,676 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (349.431) is slightly preferred due to being closer to the lower end, potentially aiding permeability.
2. **TPSA:** Ligand A (75.01) is significantly better than Ligand B (99.18). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (-0.345) is slightly outside the optimal range (1-3), while Ligand A (0.026) is very close to the lower limit. Both are relatively hydrophilic, which could be a concern for membrane permeability.
4. **HBD:** Ligand B (2) is slightly better than Ligand A (1). Both are within the acceptable range.
5. **HBA:** Ligand B (6) is slightly better than Ligand A (5). Both are within the acceptable range.
6. **QED:** Ligand A (0.814) is substantially better than Ligand B (0.399), indicating a much more drug-like profile.
7. **DILI:** Ligand B (4.769) is significantly better than Ligand A (17.642), indicating a lower risk of drug-induced liver injury. This is a crucial factor.
8. **BBB:** Ligand A (51.183) is better than Ligand B (19.038), but neither is particularly high. As ADRB2 is a cardiovascular target, BBB penetration isn't a high priority.
9. **Caco-2:** Ligand B (-5.557) is better than Ligand A (-4.615). Higher values indicate better intestinal absorption.
10. **Solubility:** Ligand B (0.837) is better than Ligand A (-0.718). Higher solubility is generally desirable.
11. **hERG:** Both ligands are very low risk (0.16 and 0.113).
12. **Cl_mic:** Ligand B (-16.776) is *much* better than Ligand A (4.115). Lower clearance indicates greater metabolic stability, a significant advantage.
13. **t1/2:** Ligand B (-18.354) is *much* better than Ligand A (14.578). A longer half-life is generally preferred.
14. **Pgp:** Both ligands are very low efflux (0.024 and 0.006).
15. **Binding Affinity:** Both ligands have similar binding affinity (-6.5 and -6.2 kcal/mol). The difference is negligible.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. While both ligands have comparable affinity and Pgp efflux, Ligand A has a better TPSA and slightly better logP. However, the significant advantages of Ligand B in terms of DILI, Cl_mic, and t1/2 outweigh these factors. Metabolic stability and reduced toxicity are critical for a viable drug candidate.
**Conclusion:**
Ligand B demonstrates a superior ADME-Tox profile, particularly regarding metabolic stability (Cl_mic, t1/2) and liver toxicity (DILI). While Ligand A has a slightly better TPSA, the overall balance of properties favors Ligand B.
Output:
0
2025-04-17 22:35:50,676 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (354.451 and 347.459 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (103.26) is higher than Ligand B (73.74). For a cardiovascular GPCR, TPSA is moderately important, and lower is generally better for permeability. Ligand B has a clear advantage.
**3. logP:** Ligand A (-0.113) is quite low, potentially hindering membrane permeability. Ligand B (1.931) is within the optimal 1-3 range. Ligand B is significantly better.
**4. H-Bond Donors:** Ligand A (3) is acceptable, while Ligand B (1) is even better, contributing to improved permeability.
**5. H-Bond Acceptors:** Ligand A (6) and Ligand B (4) are both within the acceptable range (<=10).
**6. QED:** Ligand B (0.818) has a substantially higher QED score than Ligand A (0.501), indicating a more drug-like profile.
**7. DILI:** Both ligands have similar, low DILI risk (12.796 and 12.951 percentile).
**8. BBB:** Ligand B (61.225) has a much higher BBB penetration percentile than Ligand A (22.606). While ADRB2 isn't a CNS target, some degree of BBB penetration can be useful for understanding off-target effects and overall distribution.
**9. Caco-2 Permeability:** Ligand A (-5.376) and Ligand B (-4.362) both have negative values which is unusual. However, the values are close, and this parameter isn't decisive.
**10. Aqueous Solubility:** Ligand A (-0.131) and Ligand B (-1.33) both have negative solubility values, suggesting poor solubility. Ligand B is worse in this regard.
**11. hERG Inhibition:** Both ligands show very low hERG inhibition risk (0.092 and 0.426 percentile).
**12. Microsomal Clearance:** Ligand A (-2.539) has a negative clearance, indicating high metabolic stability, while Ligand B (52.234) has a high clearance, suggesting rapid metabolism. Ligand A is significantly better.
**13. In vitro Half-Life:** Ligand A (-3.67) has a negative half-life, indicating very high stability, while Ligand B (-5.086) is also very stable.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.014 and 0.085 percentile).
**15. Binding Affinity:** Both ligands have similar, strong binding affinities (-6.5 and -5.6 kcal/mol). The difference of 0.9 kcal/mol is not large enough to outweigh the ADME differences.
**Overall Assessment:**
Ligand B has a better logP, TPSA, and QED score. However, Ligand A has significantly better metabolic stability (lower Cl_mic) and a slightly better half-life. Considering the GPCR-specific priorities (logP, TPSA, Pgp), and the importance of metabolic stability for cardiovascular drugs, Ligand A is the more promising candidate. The low logP of Ligand A is a concern, but the superior metabolic stability and acceptable binding affinity make it preferable.
Output:
1
2025-04-17 22:35:50,677 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Step-by-step comparison:**
1. **MW:** Both ligands (345.487 and 346.475 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (52.65) is significantly better than Ligand B (76.02). For a GPCR, lower TPSA is generally preferred for better permeability, and Ligand A is well below the 140 threshold. Ligand B is approaching a less desirable range.
3. **logP:** Both ligands have acceptable logP values (1.648 and 2.277), falling within the 1-3 optimal range. Ligand B is slightly higher, which *could* indicate a potential for off-target interactions, but it's not a major concern.
4. **HBD:** Ligand A (1) has fewer H-bond donors than Ligand B (2). Lower is generally preferred for permeability.
5. **HBA:** Ligand A (3) has fewer H-bond acceptors than Ligand B (4). Again, lower is generally preferred.
6. **QED:** Both ligands have similar QED values (0.745 and 0.709), indicating good drug-like properties.
7. **DILI:** Ligand A (4.033) has a much lower DILI risk than Ligand B (23.071). This is a significant advantage for Ligand A.
8. **BBB:** Both ligands have good BBB penetration (72.082 and 70.027). Since ADRB2 is a cardiovascular target, BBB penetration isn't *critical*, but it's still a positive attribute.
9. **Caco-2:** Ligand A (-5.071) has a more negative Caco-2 value, which is unusual and suggests *higher* permeability. Ligand B (-4.751) is also negative, indicating permeability, but less so than Ligand A.
10. **Solubility:** Ligand A (-1.463) has slightly better solubility than Ligand B (-3.163), although both are quite poor. Solubility could be a formulation challenge for both.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.457 and 0.077). This is excellent.
12. **Cl_mic:** Ligand A (-14.568) has significantly lower microsomal clearance than Ligand B (45.988), indicating better metabolic stability. This is a major advantage for Ligand A.
13. **t1/2:** Ligand A (-6.109) has a more negative half-life, suggesting a longer in vitro half-life than Ligand B (2.595).
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.011).
15. **Binding Affinity:** Ligand B (-6.7) has a slightly better binding affinity than Ligand A (-5.5), a difference of 1.2 kcal/mol. While affinity is important, the other ADME properties are more concerning for Ligand B.
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A excels in TPSA and has acceptable logP and Pgp. Ligand B has a slightly better affinity, but this is outweighed by its higher TPSA, poorer metabolic stability (Cl_mic), and higher DILI risk.
**Conclusion:**
Ligand A presents a much more favorable balance of properties, particularly regarding ADME characteristics (DILI, Cl_mic, t1/2) and permeability (TPSA, Caco-2). While Ligand B has slightly better affinity, the other drawbacks make it a less viable candidate.
Output:
1
2025-04-17 22:35:50,677 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (400.957 Da) is within the ideal range, while Ligand B (350.491 Da) is also acceptable. No clear advantage here.
2. **TPSA:** Ligand A (86.88) is good for oral absorption, while Ligand B (55.71) is even better. This favors Ligand B.
3. **logP:** Ligand A (2.969) is optimal. Ligand B (4.471) is slightly high, potentially leading to solubility issues or off-target interactions. This favors Ligand A.
4. **HBD:** Ligand A (3) and Ligand B (1) are both acceptable.
5. **HBA:** Ligand A (5) and Ligand B (4) are both acceptable.
6. **QED:** Both ligands have good QED scores (A: 0.565, B: 0.713), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (75.145) has a higher DILI risk than Ligand B (44.164). This significantly favors Ligand B.
8. **BBB:** Both ligands have moderate BBB penetration (A: 50.485, B: 54.052). Since ADRB2 is a cardiovascular target, BBB penetration is not a primary concern, so this isn't a major differentiator.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the values are similar (-5.721 for A, -5.379 for B).
10. **Solubility:** Both ligands have negative solubility values, which is also unusual and suggests poor solubility. The values are similar (-3.989 for A, -4.925 for B).
11. **hERG:** Both ligands have low hERG inhibition risk (A: 0.659, B: 0.815). No clear advantage.
12. **Cl_mic:** Ligand A (51.74) has a higher microsomal clearance than Ligand B (37.736), indicating lower metabolic stability. This favors Ligand B.
13. **t1/2:** Ligand A (22.892) has a longer in vitro half-life than Ligand B (-2.824). This favors Ligand A.
14. **Pgp:** Both ligands have low Pgp efflux liability (A: 0.393, B: 0.387). No clear advantage.
15. **Binding Affinity:** Ligand B (-8.1 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.3 kcal/mol) - a difference of 1.8 kcal/mol. This is a substantial advantage.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand B emerges as the stronger candidate. While Ligand A has a better half-life, Ligand B's significantly improved binding affinity (-8.1 vs -6.3 kcal/mol) and lower DILI risk outweigh this drawback. The slightly higher logP of Ligand B is a minor concern that could potentially be addressed through further optimization. The similar Caco-2 and solubility values are concerning for both, but the affinity difference is the most important factor here.
Output:
0
2025-04-17 22:35:50,677 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (345.443 Da) is well within the ideal range (200-500 Da). Ligand B (405.384 Da) is also acceptable, though approaching the upper limit.
2. **TPSA:** Ligand A (84.64) is good, under the 140 threshold for oral absorption. Ligand B (33.95) is excellent, suggesting good permeability.
3. **logP:** Ligand A (1.291) is optimal. Ligand B (4.764) is high and could lead to solubility issues and off-target interactions.
4. **HBD:** Ligand A (1) is good. Ligand B (0) is also acceptable.
5. **HBA:** Both Ligand A (4) and Ligand B (4) are within the acceptable range.
6. **QED:** Ligand A (0.786) is very good, indicating high drug-likeness. Ligand B (0.603) is still acceptable, but lower.
7. **DILI:** Ligand A (13.61) has a very low DILI risk. Ligand B (16.092) is slightly higher, but still relatively low.
8. **BBB:** Ligand A (63.164) is moderate. Ligand B (87.825) is excellent, suggesting good potential for CNS penetration if desired (though ADRB2 is primarily cardiovascular, some CNS effects can be relevant).
9. **Caco-2:** Ligand A (-4.725) is poor. Ligand B (-5.061) is also poor, indicating limited intestinal absorption for both.
10. **Solubility:** Ligand A (-1.993) is poor. Ligand B (-3.624) is even worse, a significant concern given its high logP.
11. **hERG:** Ligand A (0.231) has low hERG risk. Ligand B (0.901) has a slightly higher risk, but still acceptable.
12. **Cl_mic:** Ligand A (-3.267) indicates low clearance and good metabolic stability. Ligand B (66.914) indicates high clearance and poor metabolic stability.
13. **t1/2:** Ligand A (21.797) is good. Ligand B (54.1) is excellent.
14. **Pgp:** Ligand A (0.022) has low P-gp efflux. Ligand B (0.764) has moderate P-gp efflux.
15. **Affinity:** Ligand B (-7.6) has significantly better binding affinity than Ligand A (-6.5), a difference of 1.1 kcal/mol.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are crucial. Ligand B excels in TPSA and affinity, and has good BBB penetration. However, its high logP and poor solubility are major drawbacks. Ligand A has a more balanced profile, with acceptable logP, good QED, very low DILI risk, and good metabolic stability. The affinity difference is significant, but the ADME properties of Ligand B are concerning.
**Overall Assessment:**
While Ligand B has a superior binding affinity, its poor solubility and high logP, coupled with high metabolic clearance, raise significant concerns about its developability. Ligand A, despite having slightly weaker affinity, presents a much more balanced and favorable ADME profile, making it a more promising drug candidate.
Output:
1
2025-04-17 22:35:50,677 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.403 and 362.861 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand B (66.4) is significantly better than Ligand A (115.39). ADRB2 is not a CNS target, but lower TPSA generally improves absorption.
3. **logP:** Ligand B (2.161) is within the optimal 1-3 range, while Ligand A (0.21) is quite low, potentially hindering membrane permeability. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (3) is acceptable, while Ligand B (0) is even better, potentially improving permeability.
5. **HBA:** Both ligands are acceptable (Ligand A: 5, Ligand B: 4).
6. **QED:** Ligand B (0.756) has a substantially better QED score than Ligand A (0.481), indicating a more drug-like profile.
7. **DILI:** Both have acceptable DILI risk (Ligand A: 47.77, Ligand B: 54.866), though Ligand B is slightly higher.
8. **BBB:** Not a primary concern for ADRB2, but Ligand B (70.531) has a higher BBB penetration score than Ligand A (31.214).
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-5.386) is slightly better than Ligand B (-4.536).
10. **Solubility:** Both have poor aqueous solubility (Ligand A: -2.21, Ligand B: -3.186).
11. **hERG:** Both have low hERG inhibition liability (Ligand A: 0.271, Ligand B: 0.186), which is good.
12. **Cl_mic:** Ligand A (-11.626) has a much lower (better) microsomal clearance than Ligand B (42.503), indicating better metabolic stability.
13. **t1/2:** Ligand B (-30.648) has a longer in vitro half-life than Ligand A (-16.494), which is desirable.
14. **Pgp:** Both have low P-gp efflux liability (Ligand A: 0.031, Ligand B: 0.172).
15. **Binding Affinity:** Ligand B (-6.8 kcal/mol) has a stronger binding affinity than Ligand A (-5.4 kcal/mol). This is a substantial advantage.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, and binding affinity are particularly important. Ligand B excels in logP and affinity, and has a much lower TPSA. While Ligand A has better metabolic stability (Cl_mic), the superior binding affinity and more favorable physicochemical properties of Ligand B outweigh this advantage. The Caco-2 and solubility are poor for both, but can be addressed with formulation strategies.
**Conclusion:**
Ligand B is the more promising candidate due to its superior binding affinity, better logP, lower TPSA, and more favorable QED score. While Ligand A has better metabolic stability, the overall profile of Ligand B is more likely to translate into a viable drug candidate.
Output:
0
2025-04-17 22:35:50,677 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (346.39 and 356.41 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (69.64) is significantly better than Ligand A (133.36). For a GPCR, lower TPSA is generally preferred for better permeability. This is a substantial advantage for B.
3. **logP:** Ligand B (2.339) is within the optimal 1-3 range, while Ligand A (-0.378) is below 1, potentially hindering permeation. This is a significant advantage for B.
4. **HBD:** Both ligands have 2 HBD, which is acceptable.
5. **HBA:** Ligand A has 5 HBA, and Ligand B has 3 HBA. Both are within the acceptable limit of 10.
6. **QED:** Both ligands have similar QED values (0.7 and 0.751), indicating good drug-likeness.
7. **DILI:** Both ligands have low DILI risk (33.7 and 34.3 percentile), which is good. No significant difference.
8. **BBB:** Both ligands have similar BBB penetration (54.1 and 53.6 percentile). Since ADRB2 isn't a primary CNS target, this isn't a major deciding factor.
9. **Caco-2:** Ligand A (-5.556) is worse than Ligand B (-4.517), indicating lower intestinal absorption. This favors B.
10. **Solubility:** Ligand A (-2.64) is worse than Ligand B (-1.697), indicating lower aqueous solubility. This favors B.
11. **hERG:** Ligand A (0.072) is slightly better than Ligand B (0.538), indicating a lower risk of hERG inhibition. This is a minor advantage for A.
12. **Cl_mic:** Ligand A (-10.77) has a much lower (better) microsomal clearance than Ligand B (24.744). This suggests better metabolic stability for A. This is a significant advantage for A.
13. **t1/2:** Ligand B (23.768) has a much longer in vitro half-life than Ligand A (-2.708). This is a significant advantage for B.
14. **Pgp:** Ligand A (0.002) has a much lower Pgp efflux liability than Ligand B (0.133). This is a significant advantage for A.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.1 and -5.8 kcal/mol). The difference is not substantial enough to outweigh other factors.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp), Ligand B has a clear advantage in logP and TPSA. While Ligand A has better metabolic stability (Cl_mic) and Pgp efflux, the improvements in permeability and solubility offered by Ligand B are more crucial for a GPCR target. The longer half-life of Ligand B is also a significant benefit. The slightly higher hERG risk for B is a minor concern compared to the permeability issues with A.
Output:
0
2025-04-17 22:35:50,677 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (356.419 and 351.757 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (85.38) is better than Ligand B (98.48). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally improves absorption.
3. **logP:** Ligand A (1.031) is slightly better than Ligand B (2.511). Both are within the optimal 1-3 range, but A is closer to 1, potentially reducing off-target interactions.
4. **HBD:** Ligand A (0) is preferable to Ligand B (1). Fewer HBDs generally improve membrane permeability.
5. **HBA:** Ligand A (6) is preferable to Ligand B (7). Lower HBA is also favorable for permeability.
6. **QED:** Both ligands (0.684 and 0.609) are above the 0.5 threshold, indicating good drug-likeness. Ligand A is slightly better.
7. **DILI:** Ligand A (31.563) is *significantly* better than Ligand B (99.806). This is a major advantage for Ligand A. DILI is a critical safety concern.
8. **BBB:** Ligand A (93.68) is much better than Ligand B (50.523). While not essential for ADRB2, higher BBB is generally a positive attribute.
9. **Caco-2:** Ligand A (-3.965) is better than Ligand B (-5.068). Higher (less negative) Caco-2 values indicate better absorption.
10. **Solubility:** Ligand A (-1.658) is better than Ligand B (-4.693). Better solubility is generally desirable.
11. **hERG:** Ligand A (0.124) is much better than Ligand B (0.542). Lower hERG inhibition is crucial for avoiding cardiotoxicity, especially for a cardiovascular target.
12. **Cl_mic:** Ligand A (51.428) is better than Ligand B (58.432). Lower clearance suggests better metabolic stability.
13. **t1/2:** Ligand A (-16.294) is better than Ligand B (31.615). A more negative value indicates longer half-life.
14. **Pgp:** Ligand A (0.038) is much better than Ligand B (0.145). Lower P-gp efflux is favorable for bioavailability.
15. **Binding Affinity:** Ligand B (-7.2) is 0.1 kcal/mol better than Ligand A (-6.1). While affinity is important, the substantial advantages of Ligand A in ADME-Tox properties outweigh this small difference in binding.
**GPCR-specific priorities:** logP, Pgp, TPSA, and affinity are key for GPCRs. Ligand A performs better on logP, TPSA, and Pgp. The affinity difference is small. The significant improvements in safety (DILI, hERG) and ADME properties of Ligand A are decisive.
**Conclusion:**
Ligand A is the more promising drug candidate due to its superior ADME-Tox profile, particularly its significantly lower DILI and hERG risk, and better solubility and permeability. The slightly lower binding affinity is a reasonable trade-off for these substantial advantages.
Output:
1
2025-04-17 22:35:50,677 - INFO - Reasoning:
Let's analyze Ligand A and Ligand B for their potential as ADRB2 ligands, keeping in mind GPCR prioritization (logP, Pgp, TPSA, and affinity are key).
**Molecular Weight:** Both ligands are within the ideal 200-500 Da range. Ligand A (340.379 Da) is slightly better than Ligand B (360.357 Da) as it is closer to the lower end of the range.
**TPSA:** Ligand A (80.58) is excellent, well below the 140 threshold for oral absorption. Ligand B (93.73) is still acceptable but less favorable.
**logP:** Ligand A (3.372) is optimal. Ligand B (0.231) is significantly low, which could hinder membrane permeability and bioavailability. This is a major drawback.
**H-Bond Donors/Acceptors:** Both have acceptable HBD/HBA counts (A: 1/5, B: 2/5).
**QED:** Ligand A (0.836) has a better QED score indicating better drug-likeness than Ligand B (0.685).
**DILI:** Ligand B (54.168) has a significantly lower DILI risk than Ligand A (78.286), which is a positive attribute.
**BBB:** Both have good BBB penetration (A: 69.639, B: 78.868). While not CNS-focused, it's a neutral factor.
**Caco-2 Permeability:** Ligand A (-4.362) is better than Ligand B (-5.084), indicating better intestinal absorption.
**Aqueous Solubility:** Ligand A (-5.382) is better than Ligand B (-1.922), indicating better solubility.
**hERG:** Ligand A (0.784) has a lower hERG risk than Ligand B (0.204).
**Microsomal Clearance:** Ligand B (9.358) has significantly lower microsomal clearance than Ligand A (70.954), suggesting better metabolic stability.
**In vitro Half-Life:** Ligand A (12.805) has a positive half-life, but Ligand B (-9.564) has a negative half-life, which is concerning.
**P-gp Efflux:** Ligand A (0.373) has lower P-gp efflux than Ligand B (0.026), which is favorable.
**Binding Affinity:** Ligand A (-6.5 kcal/mol) and Ligand B (-5.7 kcal/mol) both have good binding affinity. Ligand A is 0.8 kcal/mol better, which is a meaningful difference.
**Overall Assessment:**
Ligand A has a superior logP, TPSA, QED, Caco-2 permeability, solubility, hERG, and binding affinity. The better affinity and ADME properties outweigh the slightly higher DILI risk. Ligand B's low logP is a significant concern, potentially leading to poor absorption. While its DILI risk is lower and it has better metabolic stability, the poor logP and negative in vitro half-life are major drawbacks for a GPCR ligand.
Output:
1
2025-04-17 22:35:50,677 - INFO - Here's my reasoning and the final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, key properties to prioritize are logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB (though less critical for a cardiovascular target than a CNS one).
Let's compare the ligands property by property:
1. **MW:** Both ligands (352.475 and 347.463 Da) fall within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (86.71) is slightly higher than Ligand B (77.57), but both are well below the 140 A^2 threshold for good oral absorption.
3. **logP:** Both ligands have good logP values (1.507 and 1.042), falling within the optimal 1-3 range. Ligand B is slightly lower, which *could* indicate slightly better solubility, but isn't a major concern.
4. **HBD/HBA:** Both have 2 HBD and are within acceptable limits. Ligand B has 5 HBA vs. 4 for Ligand A, a minor difference.
5. **QED:** Both ligands have good QED scores (0.648 and 0.735), indicating good drug-like properties.
6. **DILI:** Ligand B (38.193) has a significantly lower DILI risk than Ligand A (9.151), which is a substantial advantage.
7. **BBB:** Ligand B (66.886) has a higher BBB penetration percentile than Ligand A (48.313), but this is less crucial for a cardiovascular target.
8. **Caco-2:** Both have negative Caco-2 values which is unusual and suggests poor permeability. Ligand A (-4.869) is slightly better than Ligand B (-5.119).
9. **Solubility:** Both have negative solubility values which is unusual. Ligand B (-0.671) is slightly better than Ligand A (-1.177).
10. **hERG:** Both have low hERG inhibition liability (0.302 and 0.48), which is good.
11. **Cl_mic:** Ligand A (-2.894) has a lower (better) microsomal clearance than Ligand B (-11.85). This suggests better metabolic stability for Ligand A.
12. **t1/2:** Ligand B (14.588) has a much longer in vitro half-life than Ligand A (-22.437), which is a significant advantage.
13. **Pgp:** Ligand A (0.153) has lower P-gp efflux liability than Ligand B (0.007), which is favorable.
14. **Binding Affinity:** Ligand B (-7.6 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.2 kcal/mol). This is a substantial advantage, potentially outweighing some ADME concerns.
**Overall Assessment:**
Ligand B stands out primarily due to its significantly stronger binding affinity (-7.6 vs -5.2 kcal/mol) and lower DILI risk. The longer half-life is also a major plus. While Ligand A has better metabolic stability and lower P-gp efflux, the affinity difference and safety profile of Ligand B are more compelling for a GPCR target. The Caco-2 and solubility values are concerning for both, but the superior binding and safety of B make it the better candidate.
**Output:**
0
2025-04-17 22:35:50,677 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (354.38 and 335.41 Da) fall within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (59.81) is better than Ligand B (67.94), both are below the 140 threshold for oral absorption, but closer to the ideal for GPCRs.
3. **logP:** Both ligands have good logP values (3.33 and 3.88), within the optimal 1-3 range. Ligand B is slightly higher, which *could* be a minor concern for solubility, but not a major issue.
4. **HBD:** Ligand A (1) is preferable to Ligand B (0) as it provides a hydrogen bond donor.
5. **HBA:** Ligand A (4) is preferable to Ligand B (6). Lower HBA is generally better for permeability.
6. **QED:** Ligand A (0.916) is significantly better than Ligand B (0.723), indicating a more drug-like profile.
7. **DILI:** Ligand A (56.19) is significantly better than Ligand B (91.47), indicating a lower risk of drug-induced liver injury. This is a critical advantage.
8. **BBB:** Ligand A (78.60) is better than Ligand B (57.85), although neither are exceptionally high. For a cardiovascular target, BBB penetration isn't paramount, but it's a bonus.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. This is a significant drawback for both.
10. **Solubility:** Both ligands have negative solubility values, indicating poor solubility. This is a significant drawback for both.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.544 and 0.551), which is excellent.
12. **Cl_mic:** Ligand B (61.52) has a slightly lower microsomal clearance than Ligand A (66.08), suggesting better metabolic stability, but the difference is small.
13. **t1/2:** Ligand B (-11.18) has a significantly worse in vitro half-life than Ligand A (2.72). This is a major disadvantage for Ligand B.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.187 and 0.449), which is good.
15. **Binding Affinity:** Both ligands have very similar and excellent binding affinities (-5.7 and -5.8 kcal/mol). The difference is negligible.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are important. Both ligands perform well on logP and affinity. Ligand A has a better TPSA. The biggest differentiators are the ADME properties: Ligand A has a much better QED score, significantly lower DILI risk, and a much better in vitro half-life.
**Conclusion:**
Despite both ligands having poor Caco-2 and solubility, Ligand A is the stronger candidate due to its superior QED, significantly lower DILI risk, better BBB penetration, and longer half-life. These factors outweigh the slightly better metabolic stability of Ligand B.
Output:
1
2025-04-17 22:35:50,677 - INFO - Batch 343 complete. Total preferences: 5488
2025-04-17 22:35:50,677 - INFO - Processing batch 344/512...
2025-04-17 22:36:40,038 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (344.5 & 360.4 Da) fall well within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (38.82) is significantly better than Ligand B (70.39). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand B's TPSA is quite high, potentially hindering oral bioavailability.
3. **logP:** Both ligands have good logP values (2.641 & 2.166), falling within the optimal 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Both ligands have the same number of HBA (4), which is acceptable.
6. **QED:** Both ligands have very similar QED scores (0.861 & 0.865), indicating good drug-likeness.
7. **DILI:** Ligand A (19.193) has a slightly lower DILI risk than Ligand B (18.302), which is a positive. Both are quite low, indicating minimal liver injury risk.
8. **BBB:** Ligand A (84.413) has a higher BBB penetration percentile than Ligand B (77.937). While not a primary concern for a cardiovascular target, higher BBB is generally not detrimental.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.98 and -4.732). These values are difficult to interpret without knowing the scale, but the negative values suggest poor permeability.
10. **Solubility:** Ligand A (-1.759) is better than Ligand B (-2.184). Higher solubility is generally preferred.
11. **hERG:** Ligand A (0.886) has a lower hERG inhibition liability than Ligand B (0.494), which is a significant advantage for cardiovascular safety.
12. **Cl_mic:** Ligand A (-12.061) has a much lower (better) microsomal clearance than Ligand B (-4.19). This suggests greater metabolic stability for Ligand A.
13. **t1/2:** Ligand A (16.185) has a longer in vitro half-life than Ligand B (-9.943). This is a significant advantage, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.045) has a lower P-gp efflux liability than Ligand B (0.024). Lower P-gp efflux is preferable for improved bioavailability.
15. **Binding Affinity:** Ligand B (-6.7 kcal/mol) has a slightly better binding affinity than Ligand A (-5.6 kcal/mol). This is a 1.1 kcal/mol difference, which is notable but not overwhelming given the other factors.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B in most critical ADME properties (TPSA, HBD, solubility, hERG, Cl_mic, t1/2, Pgp) and has a slightly lower DILI risk. While Ligand B has a marginally better binding affinity, the superior ADME profile of Ligand A, particularly its metabolic stability and safety profile (hERG), makes it the more promising drug candidate for the ADRB2 receptor. The negative Caco-2 values for both are a concern that would need further investigation, but the other advantages of Ligand A outweigh this drawback.
Output:
1
2025-04-17 22:36:40,039 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (344.499 and 349.519 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (49.41) is better than Ligand B (52.65). Both are below the 140 threshold for oral absorption, but lower TPSA is generally preferred for GPCRs.
3. **logP:** Both ligands have good logP values (2.824 and 2.284), falling within the optimal 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Both have 1 HBD, which is acceptable.
5. **HBA:** Ligand A has 2 HBA, while Ligand B has 3. Both are within the acceptable range of <=10.
6. **QED:** Ligand A (0.772) has a slightly better QED score than Ligand B (0.684), indicating a more drug-like profile.
7. **DILI:** Ligand A (8.026%) has a significantly lower DILI risk than Ligand B (11.012%). This is a crucial advantage.
8. **BBB:** Ligand A (85.964%) has a much higher BBB penetration percentile than Ligand B (54.44%). While ADRB2 isn't exclusively a CNS target, some cardiovascular effects are mediated through CNS pathways, and better BBB penetration can be advantageous.
9. **Caco-2:** Both have negative Caco-2 values (-4.793 and -4.778). This is unusual and suggests poor permeability. However, these values are very close, so it doesn't significantly differentiate them.
10. **Solubility:** Ligand A (-4.064) has slightly better solubility than Ligand B (-2.15), though both are poor.
11. **hERG:** Ligand A (0.717) has a slightly better hERG profile than Ligand B (0.39), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand A (42.048) has a higher microsomal clearance than Ligand B (33.509), meaning it is cleared more quickly. This is a disadvantage.
13. **t1/2:** Ligand B (10.339) has a significantly longer in vitro half-life than Ligand A (2.187). This is a major advantage for dosing convenience.
14. **Pgp:** Ligand A (0.085) has lower P-gp efflux than Ligand B (0.025), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand A (-6.5 kcal/mol) has a slightly better binding affinity than Ligand B (-6.2 kcal/mol). While the difference is small, it's still a positive.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand A is generally more favorable. It has better TPSA, logP, QED, DILI risk, BBB penetration, hERG, and binding affinity. However, Ligand B has a significantly longer half-life and lower clearance, which are important for *in vivo* duration of action. The lower DILI risk and better BBB penetration of Ligand A are particularly compelling, outweighing the half-life advantage of Ligand B. The slight affinity difference also tips the balance.
Output:
1
2025-04-17 22:36:40,039 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [363.483, 79.46, 3.54, 1, 7, 0.683, 43.971, 38.813, -5.497, -3.505, 0.275, 86.496, -7.706, 0.345, -6.2]
**Ligand B:** [348.443, 87.66, 0.892, 3, 4, 0.622, 31.214, 36.332, -5.308, -2.273, 0.121, 10.733, 8.691, 0.067, -6.5]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity):
1. **MW:** Both are within the acceptable range (200-500 Da). Ligand B (348.443) is slightly lower, which *could* be a minor advantage for permeability.
2. **TPSA:** Ligand A (79.46) is better than Ligand B (87.66). Both are below 140, but closer to 90 is preferred.
3. **logP:** Ligand A (3.54) is optimal. Ligand B (0.892) is quite low, potentially hindering membrane permeability and bioavailability. This is a significant drawback for a GPCR ligand.
4. **HBD/HBA:** Ligand A (1 HBD, 7 HBA) is better. Ligand B (3 HBD, 4 HBA) is acceptable, but more donors/acceptors can sometimes lead to issues.
5. **QED:** Both are reasonably good (A: 0.683, B: 0.622), indicating drug-like properties.
6. **DILI:** Ligand A (43.971) is slightly higher than Ligand B (31.214), but both are within a reasonable range.
7. **BBB:** Ligand A (38.813) is slightly lower than Ligand B (36.332). BBB isn't a huge priority for ADRB2 (cardiovascular target), but higher is generally better.
8. **Caco-2:** Both are negative, which is unusual and suggests poor permeability. This is concerning for both.
9. **Solubility:** Ligand A (-3.505) is worse than Ligand B (-2.273). Solubility is a concern for both, but less so than permeability.
10. **hERG:** Both are very low (A: 0.275, B: 0.121), indicating minimal cardiotoxicity risk. Excellent for both.
11. **Cl_mic:** Ligand A (86.496) is higher than Ligand B (10.733), meaning Ligand B has better metabolic stability. This is a positive for Ligand B.
12. **t1/2:** Ligand B (8.691) has a longer half-life than Ligand A (-7.706). This is a significant advantage for Ligand B.
13. **Pgp:** Ligand A (0.345) is better than Ligand B (0.067), indicating less P-glycoprotein efflux. This is a positive for Ligand A.
14. **Affinity:** Ligand B (-6.5 kcal/mol) is slightly better than Ligand A (-6.2 kcal/mol). While the difference is small, it's still a factor.
**Overall Assessment:**
The biggest concern with Ligand B is its low logP (0.892). This strongly suggests poor membrane permeability and bioavailability, which is a critical issue for a GPCR ligand. While Ligand B has better metabolic stability (lower Cl_mic) and half-life, and slightly better affinity, the permeability issue is too significant to ignore. Ligand A, despite its slightly higher DILI risk and lower half-life, has a much more favorable logP value, making it more likely to reach its target. The Caco-2 values are concerning for both, but a better logP offers a higher chance of overcoming that issue with formulation strategies.
Therefore, I would choose Ligand A.
1
2025-04-17 22:36:40,039 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (345.49 and 362.46 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (54.34) is significantly better than Ligand B (103.01). ADRB2 is a cardiovascular target, not CNS, but lower TPSA generally improves absorption.
3. **logP:** Both ligands have acceptable logP values (2.50 and 1.01), falling within the 1-3 range. Ligand A is slightly better.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (6). Fewer HBAs generally improve permeability.
6. **QED:** Ligand A (0.825) has a higher QED than Ligand B (0.578), indicating a more drug-like profile.
7. **DILI:** Ligand A (12.52) has a much lower DILI risk than Ligand B (39.47). This is a significant advantage for Ligand A.
8. **BBB:** Not a primary concern for a cardiovascular target, but Ligand A (82.75) has a higher BBB penetration than Ligand B (46.34).
9. **Caco-2:** Ligand A (-4.897) is better than Ligand B (-6.001). Higher Caco-2 permeability suggests better absorption.
10. **Solubility:** Both ligands have similar, poor aqueous solubility (-2.293 and -2.396).
11. **hERG:** Both ligands have similar, low hERG risk (0.452 and 0.437).
12. **Cl_mic:** Ligand B (-4.202) has a lower (better) microsomal clearance than Ligand A (47.631), indicating greater metabolic stability.
13. **t1/2:** Ligand B (12.181) has a much longer in vitro half-life than Ligand A (-4.82). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.378) has better Pgp efflux liability than Ligand B (0.017).
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.6 and -6.1 kcal/mol). The difference is not substantial enough to override other factors.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A performs better on logP, TPSA, and Pgp. Affinity is similar.
**Overall Assessment:**
Ligand A has a significantly better safety profile (lower DILI), better predicted permeability (TPSA, Caco-2, HBD/HBA), and a more drug-like profile (QED). While Ligand B has better metabolic stability (Cl_mic) and half-life, the other advantages of Ligand A outweigh this. The similar binding affinities make the ADME/Tox profile the deciding factor.
Output:
1
2025-04-17 22:36:40,040 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (365.861 Da) is slightly higher than Ligand B (346.435 Da), but both are acceptable.
2. **TPSA:** Ligand A (56.59) is well below the 140 threshold and good for oral absorption. Ligand B (84.22) is still acceptable but less optimal.
3. **logP:** Ligand A (3.716) is within the optimal range (1-3). Ligand B (0.621) is quite low, potentially hindering membrane permeability. This is a significant drawback.
4. **HBD:** Both have 0 HBD, which is good.
5. **HBA:** Both have acceptable HBA counts (Ligand A: 5, Ligand B: 6).
6. **QED:** Both ligands have good QED scores (A: 0.758, B: 0.798), indicating drug-likeness.
7. **DILI:** Ligand A (49.128) has a slightly higher DILI risk than Ligand B (32.881), but both are below the concerning threshold of 60.
8. **BBB:** Both have good BBB penetration (A: 77.821, B: 76.658).
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Ligand A (-3.513) has worse solubility than Ligand B (-1.405).
11. **hERG:** Ligand A (0.68) has a higher hERG risk than Ligand B (0.065). This is a significant concern for Ligand A.
12. **Cl_mic:** Ligand B (24.221) has a significantly lower microsomal clearance than Ligand A (67.946), indicating better metabolic stability.
13. **t1/2:** Ligand B (-6.01) has a longer in vitro half-life than Ligand A (28.452).
14. **Pgp:** Ligand B (0.086) has lower P-gp efflux liability than Ligand A (0.4).
15. **Binding Affinity:** Ligand B (-6.8 kcal/mol) has a slightly better binding affinity than Ligand A (-6.5 kcal/mol), but the difference is not huge.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are important. Ligand B excels in logP and Pgp, and has slightly better affinity. Ligand A has a better TPSA, but the low logP and higher hERG risk of Ligand B are more concerning.
**Conclusion:**
Considering the balance of properties and the priorities for a GPCR target, Ligand B is the more promising candidate. Its superior logP, lower Pgp efflux, better metabolic stability (lower Cl_mic and longer t1/2), and slightly better affinity outweigh the slightly higher DILI risk and worse solubility compared to Ligand A. The hERG risk associated with Ligand A is a major concern.
Output:
0
2025-04-17 22:36:40,040 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Ligand A: [344.459, 64.68, 3.569, 2, 2, 0.877, 39.434, 69.794, -4.717, -3.759, 0.737, 19.504, 29.868, 0.107, -6.1]**
**Ligand B: [351.447, 95.67, 1.785, 2, 5, 0.781, 31.136, 55.874, -4.858, -1.682, 0.38, 26.439, -10.768, 0.15, -6.0]**
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). A (344.459) is slightly lower than B (351.447), which is acceptable.
2. **TPSA:** Ligand A (64.68) is significantly better than Ligand B (95.67). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is approaching a level that could hinder oral absorption.
3. **logP:** Ligand A (3.569) is within the optimal range, while Ligand B (1.785) is on the lower side. Lower logP could lead to poor membrane permeability.
4. **H-Bond Donors:** Both have 2 HBD, which is good.
5. **H-Bond Acceptors:** Ligand A has 2 HBA, while Ligand B has 5. Ligand A is preferable here, as fewer HBA generally improves permeability.
6. **QED:** Both are reasonably good (A: 0.877, B: 0.781), indicating drug-like properties. A is slightly better.
7. **DILI:** Both have acceptable DILI risk (A: 39.434, B: 31.136). B is slightly better.
8. **BBB:** Ligand A (69.794) has a considerably higher BBB penetration percentile than Ligand B (55.874). While ADRB2 isn't strictly a CNS target, some CNS exposure can occur, and higher BBB is generally favorable.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and indicates poor permeability *in vitro*. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Ligand A (-3.759) has worse solubility than Ligand B (-1.682). Solubility is important, but can often be addressed with formulation.
11. **hERG:** Ligand A (0.737) has a lower hERG risk than Ligand B (0.38). Lower hERG is highly desirable.
12. **Cl_mic:** Ligand A (19.504) has lower microsomal clearance than Ligand B (26.439), suggesting better metabolic stability.
13. **t1/2:** Ligand A (29.868) has a longer in vitro half-life than Ligand B (-10.768). This is a significant advantage.
14. **Pgp:** Ligand A (0.107) has lower P-gp efflux liability than Ligand B (0.15). Lower Pgp is better for bioavailability.
15. **Binding Affinity:** Both have very similar binding affinities (A: -6.1, B: -6.0). The difference is negligible.
**Overall Assessment:**
Ligand A is significantly better across multiple key ADME properties (TPSA, logP, HBA, BBB, Cl_mic, t1/2, Pgp) and has comparable affinity to Ligand B. While Ligand B has slightly better solubility and DILI, the improvements in permeability and metabolic stability offered by Ligand A outweigh these benefits, especially considering the GPCR target class. The negative Caco-2 values are a concern for both, but the other properties of A are more favorable.
Output:
1
2025-04-17 22:36:40,040 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (357.42 and 366.622 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (35.58) is significantly better than Ligand B (49.41). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is approaching a level that could hinder oral absorption.
**3. logP:** Both ligands have good logP values (3.304 and 3.894), falling within the optimal 1-3 range. Ligand B is slightly higher, which could potentially lead to off-target effects, but it's not a major concern.
**4. H-Bond Donors:** Both ligands have 1 HBD, which is acceptable.
**5. H-Bond Acceptors:** Ligand A has 3 HBAs, while Ligand B has 2. Both are within the acceptable limit of 10.
**6. QED:** Ligand A (0.898) has a substantially better QED score than Ligand B (0.75), indicating a more drug-like profile.
**7. DILI:** Both ligands have low DILI risk (27.724 and 26.755 percentile), which is excellent.
**8. BBB:** Ligand A (92.516) has a significantly higher BBB penetration percentile than Ligand B (81.815). While ADRB2 is a cardiovascular target, some CNS penetration could be relevant for off-target effects or potential central effects.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.563 and -4.783). This is unusual and suggests poor permeability. However, the values are similar, so it doesn't strongly favor one ligand.
**10. Aqueous Solubility:** Ligand A (-3.106) has better aqueous solubility than Ligand B (-4.493). This is important for formulation and bioavailability.
**11. hERG Inhibition:** Ligand A (0.936) has a slightly higher hERG inhibition risk than Ligand B (0.458), but both are relatively low.
**12. Microsomal Clearance:** Ligand B (66.166) has a considerably higher microsomal clearance than Ligand A (22.02). This indicates Ligand A is more metabolically stable, a desirable characteristic.
**13. In vitro Half-Life:** Ligand A (-0.448) has a better (longer) in vitro half-life than Ligand B (-11.352).
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (0.246 and 0.228).
**15. Binding Affinity:** Both ligands have very similar binding affinities (-6.7 and -6.9 kcal/mol). The difference is negligible.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand A is the stronger candidate. It has a lower TPSA, a better QED score, significantly better BBB penetration, better solubility, lower microsomal clearance, and a longer half-life. While Ligand B has a slightly higher logP, the advantages of Ligand A across multiple crucial ADME properties outweigh this minor difference. The similar binding affinities make the ADME profile the deciding factor.
Output:
1
2025-04-17 22:36:40,040 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (342.443 and 345.443 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (89.78) is slightly higher than Ligand B (75.44). Both are below the 140 threshold for oral absorption, but B is preferable given the GPCR target class.
3. **logP:** Both ligands (3.014 and 2.922) are within the optimal 1-3 range. Similar.
4. **HBD:** Ligand A has 4 HBD, while Ligand B has 1. Lower HBD is generally preferred for permeability, making Ligand B slightly better.
5. **HBA:** Ligand A has 2 HBA, Ligand B has 4. Both are within the acceptable limit of 10.
6. **QED:** Ligand B (0.833) has a higher QED score than Ligand A (0.691), indicating a more drug-like profile. This is a significant advantage.
7. **DILI:** Ligand B (34.044) has a much lower DILI risk than Ligand A (54.207). This is a crucial advantage, as minimizing liver toxicity is paramount.
8. **BBB:** Ligand B (81.776) has better BBB penetration than Ligand A (61.613). While ADRB2 isn't exclusively a CNS target, improved BBB penetration can still be beneficial and reduce off-target effects.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.89 and -4.827), which is unusual and suggests poor permeability. This is a concern for both, but not a differentiating factor.
10. **Solubility:** Ligand B (-3.388) has better aqueous solubility than Ligand A (-4.611). Better solubility is always preferred.
11. **hERG:** Both ligands have low hERG inhibition liability (0.491 and 0.446). No significant difference.
12. **Cl_mic:** Ligand A (4.832) has lower microsomal clearance than Ligand B (49.091), suggesting better metabolic stability. This is a positive for Ligand A.
13. **t1/2:** Ligand B (-0.827) has a negative in vitro half-life, indicating very rapid metabolism. Ligand A (24.757) has a much more favorable half-life. This is a significant advantage for Ligand A.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.303 and 0.259). No significant difference.
15. **Binding Affinity:** Ligand A (-7.6 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.3 kcal/mol). This is a substantial advantage, potentially outweighing some ADME concerns.
**Overall Assessment:**
Ligand A has a significantly better binding affinity and metabolic stability (longer half-life). However, Ligand B excels in drug-likeness (QED), DILI risk, BBB penetration, and solubility. The substantial difference in binding affinity (-1.3 kcal/mol) is a major factor. While Ligand B has better ADME properties overall, the potency advantage of Ligand A is likely to be more impactful for *in vivo* efficacy, especially for a GPCR target. The DILI risk for Ligand A is acceptable.
Output:
1
2025-04-17 22:36:40,040 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.49 and 350.46 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (58.64) is significantly better than Ligand B (96.11). ADRB2 is a cardiovascular target, not a CNS target, but lower TPSA generally improves absorption. Ligand A is well below the 140 threshold, while Ligand B is approaching it.
3. **logP:** Ligand A (3.495) is slightly higher than Ligand B (2.151), both are within the optimal 1-3 range.
4. **HBD:** Ligand A (1) is better than Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (3) is better than Ligand B (4). Fewer HBAs generally improve permeability.
6. **QED:** Both ligands (0.774 and 0.669) are above the 0.5 threshold, indicating good drug-like properties. Ligand A is slightly better.
7. **DILI:** Ligand A (14.153) has a much lower DILI risk than Ligand B (38.62). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (96.161) has a much higher BBB penetration than Ligand B (60.644). While ADRB2 isn't a primary CNS target, some degree of BBB penetration can be useful for off-target profiling and understanding systemic effects.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.498 and -4.872). These values are difficult to interpret without knowing the scale, but negative values are not ideal.
10. **Solubility:** Both ligands have negative solubility values (-4.245 and -3.715). These values are difficult to interpret without knowing the scale, but negative values are not ideal.
11. **hERG:** Ligand A (0.645) has a lower hERG risk than Ligand B (0.383). Lower is better.
12. **Cl_mic:** Ligand A (77.003) has a higher microsomal clearance than Ligand B (50.935). This suggests Ligand B is more metabolically stable.
13. **t1/2:** Ligand A (-24.446) has a negative in vitro half-life, which is not ideal. Ligand B (1.112) is a very short half-life, but positive.
14. **Pgp:** Ligand A (0.239) has lower P-gp efflux liability than Ligand B (0.056). Lower is better.
15. **Binding Affinity:** Ligand A (-7.0) has a slightly better binding affinity than Ligand B (-6.6). While both are good, the 0.4 kcal/mol difference is noticeable.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A excels in TPSA, Pgp, and affinity, and has a good logP. While Ligand B has better metabolic stability (lower Cl_mic), the superior ADME profile (lower DILI, better BBB, lower hERG, fewer HBD/HBA, better QED) and slightly better affinity of Ligand A outweigh this drawback.
**Conclusion:**
Ligand A is the more promising candidate due to its superior ADME properties, lower toxicity risk, and comparable binding affinity.
Output:
1
2025-04-17 22:36:40,041 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
The ADRB2 receptor is a GPCR, so the priorities are logP, TPSA, Pgp efflux, BBB penetration, and binding affinity.
* **Molecular Weight:** Both ligands are within the acceptable range (200-500 Da). Ligand A (380.945 Da) is slightly higher than Ligand B (350.375 Da), but both are reasonable.
* **TPSA:** Ligand A (58.95) is significantly better than Ligand B (116.52). Lower TPSA generally improves membrane permeability, which is crucial for GPCR ligands. Ligand B's TPSA is quite high, potentially hindering absorption.
* **logP:** Ligand A (4.411) is higher than Ligand B (-0.337). While 4.411 is approaching the upper limit, it's still within a reasonable range for a GPCR ligand. Ligand B's logP is quite low, which could lead to poor membrane permeability.
* **H-Bond Donors/Acceptors:** Ligand A (2 HBD, 4 HBA) is slightly better than Ligand B (3 HBD, 5 HBA). Both are within acceptable limits.
* **QED:** Both ligands have similar QED values (0.667 and 0.687), indicating good drug-likeness.
* **DILI:** Ligand B (60.644) has a slightly higher DILI risk than Ligand A (50.33), but both are acceptable.
* **BBB:** Ligand A (63.048) has significantly better BBB penetration potential than Ligand B (18.961). While ADRB2 isn't exclusively a CNS target, some CNS exposure might be acceptable or even desirable depending on the specific therapeutic goal, and better BBB penetration is generally a plus.
* **Caco-2 Permeability:** Both ligands have similar, poor Caco-2 permeability (-5.148 and -5.118).
* **Aqueous Solubility:** Ligand A (-4.37) is better than Ligand B (-1.491), but both are poor.
* **hERG:** Ligand A (0.617) has a slightly better hERG profile than Ligand B (0.152).
* **Microsomal Clearance:** Ligand B (-3.388) has a much lower (better) microsomal clearance than Ligand A (64.097), suggesting better metabolic stability.
* **In vitro Half-Life:** Ligand B (-34.992) has a much longer half-life than Ligand A (75.57).
* **P-gp Efflux:** Ligand A (0.269) has better P-gp efflux liability than Ligand B (0.01). Lower P-gp efflux is generally preferred.
* **Binding Affinity:** Ligand A (-6.2 kcal/mol) has a slightly better binding affinity than Ligand B (-5.7 kcal/mol). While the difference is not huge, it is a contributing factor.
**Overall Assessment:**
Ligand A is the stronger candidate. While Ligand B has better metabolic stability and half-life, Ligand A excels in critical GPCR-relevant properties like TPSA, logP, and BBB penetration. The slightly better binding affinity of Ligand A further supports this choice. The poor solubility and Caco-2 permeability are concerns for both, but can be addressed with formulation strategies. The higher TPSA of Ligand B is a significant drawback for a GPCR ligand.
**Output:**
1
2025-04-17 22:36:40,041 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (366.53 & 367.39 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (58.64) is significantly better than Ligand B (127.36). ADRB2 is a cardiovascular target, so CNS penetration isn't critical, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold, while B is approaching it.
3. **logP:** Ligand A (4.812) is high, but still within a reasonable range. Ligand B (-0.243) is *too* low, potentially leading to poor membrane permeability. This is a significant drawback for a GPCR ligand.
4. **HBD:** Ligand A (1) is preferable to Ligand B (0). While both are low, a single HBD can aid solubility.
5. **HBA:** Ligand A (4) is better than Ligand B (9). Lower HBA is generally preferred for permeability.
6. **QED:** Ligand A (0.832) is much better than Ligand B (0.523), indicating a more drug-like profile.
7. **DILI:** Ligand A (41.26) is significantly better than Ligand B (87.20). Lower DILI risk is crucial.
8. **BBB:** Not a primary concern for a cardiovascular target. Ligand A (82.51) is higher than Ligand B (54.63), but this is less important here.
9. **Caco-2:** Ligand A (-4.583) is better than Ligand B (-5.193). Both are negative, which is unusual, but a less negative value is preferable.
10. **Solubility:** Ligand A (-4.463) is better than Ligand B (-2.296). Both are poor, but A is less poor.
11. **hERG:** Ligand A (0.636) is better than Ligand B (0.24). Lower hERG inhibition is vital for cardiovascular safety.
12. **Cl_mic:** Ligand A (79) is higher than Ligand B (2.509), indicating faster metabolism and lower stability. This is a negative for Ligand A.
13. **t1/2:** Ligand A (14.758) is much better than Ligand B (-23.299). Longer half-life is desirable.
14. **Pgp:** Ligand A (0.313) is better than Ligand B (0.036). Lower P-gp efflux is preferred.
15. **Binding Affinity:** Ligand B (-6.9) is significantly better than Ligand A (-5.3). This is a substantial advantage (1.6 kcal/mol).
**Overall Assessment:**
Ligand B has a *much* stronger binding affinity, which is a primary driver for GPCR drug candidates. However, it suffers from very poor logP, high DILI risk, and poor metabolic stability. Ligand A has more balanced properties, with better TPSA, logP, QED, DILI, hERG, and Pgp efflux. While its metabolic stability is a concern, the overall profile is more favorable for development, especially considering the substantial affinity difference can potentially be addressed through further optimization. The poor logP of Ligand B is a major hurdle.
Given the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), and the fact that the affinity difference, while significant, isn't insurmountable, I believe Ligand A is the more viable starting point for drug development.
Output:
1
2025-04-17 22:36:40,041 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
We are targeting ADRB2, a GPCR. Therefore, key priorities are logP, TPSA, Pgp efflux, BBB penetration, and binding affinity. Let's analyze each ligand against these and other relevant parameters.
* **Molecular Weight:** Both ligands (351.491 and 346.387 Da) fall within the ideal 200-500 Da range.
* **TPSA:** Ligand A (81.67) is significantly better than Ligand B (116.23). A TPSA under 140 is good for oral absorption, and lower is better for GPCRs. Ligand B is pushing the upper limit.
* **logP:** Both ligands have good logP values (1.036 and 0.768) within the optimal 1-3 range.
* **H-Bond Donors/Acceptors:** Both have similar HBD (3 vs 4) and HBA (4 vs 4) counts, which are acceptable.
* **QED:** Both have similar QED values (0.61 and 0.592), indicating reasonable drug-likeness.
* **DILI:** Ligand A (4.382) has a much lower DILI risk than Ligand B (61.07). This is a significant advantage.
* **BBB:** Ligand A (68.127) has better BBB penetration than Ligand B (48.662), which is important for GPCRs.
* **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
* **Solubility:** Both have negative solubility values, indicating poor aqueous solubility.
* **hERG:** Both ligands have very low hERG inhibition liability (0.34 and 0.18), which is excellent.
* **Cl_mic:** Ligand A (-3.238) has a much lower (better) microsomal clearance than Ligand B (6.83). This suggests better metabolic stability.
* **t1/2:** Ligand A (-15.342) has a much longer in vitro half-life than Ligand B (34.299).
* **Pgp:** Ligand A (0.008) has significantly lower P-gp efflux liability than Ligand B (0.024).
* **Binding Affinity:** Both ligands have very similar, strong binding affinities (-7.0 and -6.8 kcal/mol). The difference is negligible.
**Overall Assessment:**
Ligand A is clearly superior. While both have acceptable binding affinity, Ligand A excels in critical ADME properties: lower DILI risk, better BBB penetration, lower microsomal clearance, longer half-life, and lower P-gp efflux. The lower TPSA is also a benefit. The solubility and Caco-2 values are concerning for both, but the other advantages of Ligand A outweigh these concerns.
**Output:**
1
2025-04-17 22:36:40,041 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (351.491 and 348.531 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (70.67) is higher than Ligand B (49.41). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B has a clear advantage.
3. **logP:** Ligand A (1.297) is within the optimal range (1-3), while Ligand B (3.889) is approaching the upper limit. While not a dealbreaker, higher logP can sometimes lead to off-target effects and solubility issues. Ligand A is slightly favored.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable.
5. **HBA:** Ligand A (4) and Ligand B (2) are both acceptable.
6. **QED:** Both ligands have good QED scores (0.691 and 0.792), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (9.383) has a much lower DILI risk than Ligand B (22.8). This is a significant advantage for Ligand A.
8. **BBB:** Ligand B (79.682) has a significantly higher BBB penetration than Ligand A (42.303). However, since ADRB2 is primarily a cardiovascular target, high BBB penetration is not a priority.
9. **Caco-2:** Ligand A (-5.132) and Ligand B (-4.766) are both negative, indicating poor permeability. This is a concern for both, but the values are similar.
10. **Solubility:** Ligand A (-1.52) has better solubility than Ligand B (-4.141). Solubility is important for bioavailability, giving Ligand A an advantage.
11. **hERG:** Ligand A (0.182) has a lower hERG risk than Ligand B (0.517). This is a crucial safety parameter, favoring Ligand A.
12. **Cl_mic:** Ligand A (12.992) has a lower microsomal clearance than Ligand B (54.954), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (8.693) has a longer in vitro half-life than Ligand B (-7.369). This is a clear advantage for Ligand A.
14. **Pgp:** Ligand A (0.03) has lower P-gp efflux liability than Ligand B (0.356). Lower P-gp efflux is favorable for oral bioavailability.
15. **Binding Affinity:** Ligand B (-7.2) has a slightly better binding affinity than Ligand A (-5.7). However, the difference is less than 1.5 kcal/mol, and other factors are more important.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B in critical ADME-Tox parameters (DILI, hERG, Cl_mic, t1/2, Pgp, Solubility) and has a comparable binding affinity. While Ligand B has better BBB penetration (irrelevant for this target) and a slightly better logP, the safety and pharmacokinetic advantages of Ligand A are far more important for a cardiovascular drug candidate. The Caco-2 permeability is a concern for both, but can be addressed with formulation strategies.
Output:
1
2025-04-17 22:36:40,041 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.415 and 348.487 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (104.46) is higher than Ligand B (67.43). For a cardiovascular GPCR like ADRB2, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B has a clear advantage.
3. **logP:** Ligand A (1.251) is within the optimal range, while Ligand B (2.714) is closer to the upper limit. Both are acceptable, but A is slightly better.
4. **HBD:** Ligand A (3) and Ligand B (2) are both within the acceptable limit of 5. No major difference.
5. **HBA:** Ligand A (5) and Ligand B (3) are both within the acceptable limit of 10. Ligand B is slightly better.
6. **QED:** Both ligands have similar QED scores (0.672 and 0.63), indicating good drug-likeness.
7. **DILI:** Ligand A (40.054) has a slightly higher DILI risk than Ligand B (22.644), but both are below the concerning threshold of 60. Ligand B is preferable.
8. **BBB:** Ligand A (46.762) and Ligand B (57.193) are both relatively low, which is expected for a cardiovascular target. Not a major deciding factor.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.988 and -4.972), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Both ligands have negative solubility values (-2.165 and -2.583), indicating very poor aqueous solubility. This is a major drawback for both.
11. **hERG:** Ligand A (0.121) has a slightly lower hERG risk than Ligand B (0.21), which is favorable.
12. **Cl_mic:** Ligand A (8.921) has a significantly lower microsomal clearance than Ligand B (41.309), indicating better metabolic stability. This is a substantial advantage for Ligand A.
13. **t1/2:** Ligand A (6.69) has a positive half-life, while Ligand B (-11.294) has a negative half-life, which is concerning. Ligand A is much better.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.074 and 0.1). No significant difference.
15. **Binding Affinity:** Ligand B (-9.4 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.7 kcal/mol). This is a substantial advantage for Ligand B, potentially outweighing some of the ADME concerns.
**Overall Assessment & GPCR Prioritization:**
For a GPCR, binding affinity is paramount. Ligand B's -9.4 kcal/mol binding affinity is significantly better than Ligand A's -5.7 kcal/mol. While Ligand A has advantages in metabolic stability (Cl_mic, t1/2) and slightly lower DILI risk, the substantial difference in binding affinity is likely to be the most critical factor. The poor Caco-2 and solubility are concerning for both, but can potentially be addressed through formulation strategies. The lower TPSA of Ligand B is also a plus.
Output:
0
2025-04-17 22:36:40,042 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands (344.419 and 342.403 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (68.02) is significantly better than Ligand B (95.08). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is approaching a less desirable range.
3. **logP:** Both ligands have similar logP values (0.708 and 0.678), both are within the optimal 1-3 range.
4. **HBD:** Ligand A has 0 HBD, while Ligand B has 1. Both are acceptable, but lower is generally preferred.
5. **HBA:** Ligand A has 8 HBA, and Ligand B has 5. Both are within the acceptable limit of 10.
6. **QED:** Both ligands have high QED scores (0.812 and 0.833), indicating good drug-like properties.
7. **DILI:** Both ligands have acceptable DILI risk (54.789 and 50.795 percentile).
8. **BBB:** Ligand A has a much higher BBB penetration (92.71%) compared to Ligand B (27.724%). While ADRB2 isn't exclusively a CNS target, improved BBB penetration can be advantageous, and certainly isn't detrimental for a peripherally acting target.
9. **Caco-2:** Ligand A (-4.894) is better than Ligand B (-5.353). Both are negative, indicating poor permeability.
10. **Solubility:** Ligand A (-1.441) is slightly better than Ligand B (-1.322). Both are poor.
11. **hERG:** Ligand A (0.601) is better than Ligand B (0.03). Lower hERG inhibition is crucial for avoiding cardiotoxicity, a major concern with cardiovascular targets.
12. **Cl_mic:** Ligand A (19.669) has a significantly *lower* (better) microsomal clearance than Ligand B (-15.906). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (4.511) has a longer in vitro half-life than Ligand B (-0.768). This is a positive attribute.
14. **Pgp:** Ligand A (0.149) has lower P-gp efflux than Ligand B (0.013), which is favorable for bioavailability.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.9 and -6.8 kcal/mol). The difference is negligible.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, TPSA, logP, Pgp, and affinity are key. Ligand A excels in TPSA, Pgp, and has a better hERG profile and metabolic stability. While BBB isn't paramount for ADRB2, the higher value for Ligand A isn't a disadvantage.
**Conclusion:**
Ligand A consistently outperforms Ligand B across several critical ADME properties (TPSA, Cl_mic, t1/2, Pgp, hERG) without sacrificing binding affinity. The slightly better solubility is also a bonus.
Output:
1
2025-04-17 22:36:40,042 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (351.372 and 348.539 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (54.02) is significantly better than Ligand B (88.75). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold. Ligand B is approaching the upper limit.
3. **logP:** Ligand B (4.32) is slightly higher than Ligand A (3.893). Both are within the optimal 1-3 range, but Ligand B is edging closer to the 4 threshold where solubility issues can arise.
4. **HBD:** Ligand B has 3 HBDs, while Ligand A has 2. Both are acceptable.
5. **HBA:** Ligand B (6) has more HBA than Ligand A (3). This contributes to the higher TPSA and potential solubility issues.
6. **QED:** Ligand A (0.796) has a better QED score than Ligand B (0.583), indicating a more drug-like profile.
7. **DILI:** Ligand B (36.448) has a much lower DILI risk than Ligand A (68.011). This is a significant advantage for Ligand B.
8. **BBB:** Ligand B (92.168) has a higher BBB penetration score than Ligand A (74.758). While not crucial for a cardiovascular target, it's still a positive.
9. **Caco-2:** Both are negative, indicating poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-4.706) has slightly better solubility than Ligand B (-5.669).
11. **hERG:** Both ligands have low hERG inhibition risk (0.821 and 0.781, respectively).
12. **Cl_mic:** Ligand A (52.897) has significantly lower microsomal clearance than Ligand B (80.34). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (62.772) has a longer in vitro half-life than Ligand B (34.98). This is a significant advantage.
14. **Pgp:** Ligand B (0.139) has lower P-gp efflux than Ligand A (0.483), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand A (-6.5 kcal/mol) has a slightly better binding affinity than Ligand B (-5.8 kcal/mol). This is a 0.7 kcal/mol difference, which is notable.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A has better TPSA, logP, and affinity. Ligand B has better Pgp and DILI.
**Overall Assessment:**
Ligand A has a better overall profile, balancing potency (affinity), metabolic stability (Cl_mic, t1/2), and drug-likeness (QED). While Ligand B has a lower DILI risk and better Pgp score, the significantly better metabolic stability and slightly better affinity of Ligand A are more critical for a successful drug candidate. The TPSA is also a significant advantage for Ligand A.
Output:
1
2025-04-17 22:36:40,042 - INFO - Batch 344 complete. Total preferences: 5504
2025-04-17 22:36:40,042 - INFO - Processing batch 345/512...
2025-04-17 22:37:24,782 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (353.5 and 365.4 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (61.88) is slightly higher than Ligand B (49.77). Both are below 140, but B is better positioned for good absorption.
3. **logP:** Both ligands have good logP values (3.75 and 3.547), falling within the 1-3 optimal range. No significant difference.
4. **HBD:** Both ligands have 1 HBD, which is within the acceptable limit of 5.
5. **HBA:** Both ligands have 3 HBA, which is within the acceptable limit of 10.
6. **QED:** Ligand A (0.819) has a significantly better QED score than Ligand B (0.669), indicating a more drug-like profile.
7. **DILI:** Ligand A (21.52) has a much lower DILI risk than Ligand B (8.453), which is a significant advantage.
8. **BBB:** Ligand A (93.253) has a better BBB penetration percentile than Ligand B (82.358). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be beneficial or at least needs to be understood.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.304) is slightly worse than Ligand B (-4.44). This is a concern for both.
10. **Solubility:** Both have negative solubility values, indicating very poor aqueous solubility. Ligand A (-3.269) is slightly better than Ligand B (-3.105), but both are problematic.
11. **hERG:** Ligand A (0.483) has a lower hERG inhibition liability than Ligand B (0.85), which is a safety advantage.
12. **Cl_mic:** Ligand A (52.85) has a lower microsomal clearance than Ligand B (57.314), suggesting better metabolic stability.
13. **t1/2:** Ligand A (3.191) has a shorter in vitro half-life than Ligand B (-5.742). This is a disadvantage for Ligand A.
14. **Pgp:** Ligand A (0.076) has a much lower P-gp efflux liability than Ligand B (0.365), which is a significant advantage for bioavailability.
15. **Binding Affinity:** Ligand B (-8.8 kcal/mol) has a significantly stronger binding affinity than Ligand A (-7.1 kcal/mol). This is a substantial advantage, potentially outweighing some ADME concerns.
**Overall Assessment & GPCR Prioritization:**
For a GPCR like ADRB2, potency (affinity) is paramount. Ligand B's significantly stronger binding affinity (-8.8 vs -7.1 kcal/mol) is a major driver. While Ligand A has better QED, DILI, BBB, Pgp, and hERG, the affinity difference is substantial. The poor Caco-2 and solubility for both are concerning, but these can be addressed with formulation strategies. The better metabolic stability of Ligand A is good, but not enough to offset the affinity gap.
**Output:**
0
2025-04-17 22:37:24,783 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.475 and 342.443 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (74.33) is higher than Ligand B (59.39). Both are below the 140 threshold for oral absorption, but B is better positioned for potential CNS penetration if desired.
3. **logP:** Ligand A (1.08) is slightly lower than Ligand B (2.363). Both are within the optimal 1-3 range, but B is closer to the upper end, which could be beneficial for membrane permeability.
4. **HBD:** Ligand A (2) has more HBD than Ligand B (1). Lower is generally preferred, so B has a slight advantage.
5. **HBA:** Ligand A (4) has fewer HBA than Ligand B (5). Similar to HBD, B is slightly less desirable.
6. **QED:** Ligand B (0.906) has a significantly higher QED score than Ligand A (0.656), indicating a more drug-like profile. This is a substantial advantage for B.
7. **DILI:** Ligand A (14.23) has a much lower DILI risk than Ligand B (38.969). This is a major advantage for A, as minimizing liver toxicity is critical.
8. **BBB:** Ligand A (68.36) and Ligand B (63.474) are similar, and both are below the 70% threshold. BBB is less critical for a non-CNS target like ADRB2, so this isn't a deciding factor.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.988 and -4.757). This is unusual and suggests poor permeability. However, the values are very close, so it doesn't differentiate them.
10. **Solubility:** Ligand A (-0.746) has better solubility than Ligand B (-2.536). Better solubility is generally preferred.
11. **hERG:** Both ligands have low hERG inhibition risk (0.362 and 0.436). No significant difference.
12. **Cl_mic:** Ligand A (21.686) has a lower microsomal clearance than Ligand B (74.501). Lower clearance is better for metabolic stability, giving A a significant advantage.
13. **t1/2:** Ligand B (51.86) has a much longer in vitro half-life than Ligand A (-5.817). This is a substantial advantage for B, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.058 and 0.304). No significant difference.
15. **Binding Affinity:** Ligand B (-7.2) has a significantly stronger binding affinity than Ligand A (-6.0). This is a major advantage for B, potentially outweighing some ADME drawbacks.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP and affinity. Ligand A has a better DILI score and Cl_mic. The affinity difference is substantial (1.2 kcal/mol), and a stronger binding ligand is highly desirable.
**Overall Assessment:**
While Ligand A has advantages in DILI and metabolic stability, Ligand B's superior binding affinity, QED, and longer half-life are more compelling. The affinity difference is large enough to potentially overcome the slightly higher DILI risk and lower solubility.
Output:
0
2025-04-17 22:37:24,783 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (425.999 Da) is within the ideal range, while Ligand B (350.507 Da) is also acceptable, but on the lower side.
2. **TPSA:** Ligand A (128.27) is slightly above the preferred <140 for oral absorption, but not drastically. Ligand B (58.44) is excellent, well below 140.
3. **logP:** Ligand A (4.764) is a bit high, potentially leading to solubility issues and off-target effects. Ligand B (3.067) is optimal.
4. **HBD:** Ligand A (1) and Ligand B (0) are both good.
5. **HBA:** Ligand A (6) and Ligand B (4) are both within the acceptable range.
6. **QED:** Ligand B (0.688) has a better QED score than Ligand A (0.427), indicating better overall drug-likeness.
7. **DILI:** Ligand A (98.565) has a very high DILI risk, which is a major concern. Ligand B (25.785) has a low DILI risk.
8. **BBB:** Ligand A (53.432) is moderate, while Ligand B (79.992) is good. While ADRB2 isn't exclusively a CNS target, some CNS penetration can be beneficial.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
10. **Solubility:** Ligand A (-6.072) has very poor solubility, consistent with its high logP. Ligand B (-1.956) has better solubility.
11. **hERG:** Ligand A (0.398) has a lower hERG risk than Ligand B (0.813).
12. **Cl_mic:** Ligand A (44.027) has a lower microsomal clearance, indicating better metabolic stability than Ligand B (76.056).
13. **t1/2:** Ligand A (125.543) has a significantly longer in vitro half-life than Ligand B (7.303).
14. **Pgp:** Ligand A (0.408) has lower P-gp efflux, which is favorable. Ligand B (0.435) is similar.
15. **Affinity:** Ligand A (-7.5 kcal/mol) has a significantly stronger binding affinity than Ligand B (-4.2 kcal/mol). This is a substantial difference.
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP and TPSA. Ligand A has a superior binding affinity. However, the extremely high DILI risk and poor solubility of Ligand A are major drawbacks. The difference in affinity, while significant, is unlikely to overcome these serious ADME/Tox concerns.
**Conclusion:**
Despite the weaker binding affinity, Ligand B is the more promising candidate due to its significantly better safety profile (low DILI), improved solubility, and acceptable physicochemical properties. The higher affinity of Ligand A is overshadowed by its poor ADME/Tox characteristics.
Output:
0
2025-04-17 22:37:24,783 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (371.424 and 376.85 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (46.17) is higher than Ligand B (32.34). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is generally preferred for absorption. Ligand B is better.
3. **logP:** Both ligands have good logP values (4.905 and 4.488), falling within the optimal 1-3 range, although slightly high. Ligand B is slightly better.
4. **HBD:** Both have 1 HBD, which is acceptable. No difference.
5. **HBA:** Ligand A has 3 HBAs, Ligand B has 2. Both are within the acceptable limit of 10. Ligand B is slightly better.
6. **QED:** Both ligands have good QED scores (0.766 and 0.839), indicating good drug-likeness. Ligand B is slightly better.
7. **DILI:** Ligand A (47.034) has a significantly higher DILI risk than Ligand B (21.171). This is a major concern for Ligand A.
8. **BBB:** Both have high BBB penetration (93.525 and 89.492). While ADRB2 isn't strictly a CNS target, some CNS exposure can occur. No strong preference.
9. **Caco-2:** Both have negative Caco-2 values (-4.6 and -4.725), indicating poor permeability. This is a concern for both.
10. **Solubility:** Both have very poor aqueous solubility (-5.224 and -5.059). This is a significant issue for both.
11. **hERG:** Ligand A (0.411) has a slightly lower hERG risk than Ligand B (0.877), which is a positive.
12. **Cl_mic:** Ligand A (50.471) has a higher microsomal clearance than Ligand B (27.099), meaning it's metabolized faster. Ligand B is better.
13. **t1/2:** Ligand A (10.475) has a longer in vitro half-life than Ligand B (4.497). This is a positive for Ligand A.
14. **Pgp:** Ligand A (0.428) has lower P-gp efflux than Ligand B (0.359), which is better for bioavailability.
15. **Binding Affinity:** Ligand B (-7.4 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.1 kcal/mol). This is a substantial advantage, potentially outweighing some ADME drawbacks.
**GPCR-Specific Priorities & Overall Assessment:**
For a GPCR like ADRB2, binding affinity is paramount. Ligand B's -7.4 kcal/mol is considerably better than Ligand A's -6.1 kcal/mol. While both have ADME issues (poor solubility and Caco-2), Ligand B has a much lower DILI risk and better metabolic stability (lower Cl_mic). The longer half-life of Ligand A is a plus, but the significantly higher DILI risk is a major drawback. The slightly better hERG of Ligand A is not enough to offset the other issues.
**Output:**
0
2025-04-17 22:37:24,784 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (368.459 Da and 344.419 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (92.7) is better than Ligand B (101.8). Both are reasonably good, being under 140, but lower TPSA generally favors better absorption.
**3. logP:** Ligand B (0.95) is slightly better than Ligand A (0.353). A logP between 1-3 is optimal, and Ligand B is closer to that range. Ligand A is quite low, potentially hindering membrane permeability.
**4. H-Bond Donors:** Ligand A (0) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
**5. H-Bond Acceptors:** Ligand A (7) is preferable to Ligand B (6). Both are within the acceptable range, but lower is generally better.
**6. QED:** Both ligands have similar QED values (0.74 and 0.742), indicating good drug-likeness.
**7. DILI Risk:** Ligand B (50.368) has a significantly lower DILI risk than Ligand A (71.694). This is a crucial advantage, as liver toxicity is a major concern in drug development.
**8. BBB Penetration:** Ligand A (82.047) has better BBB penetration than Ligand B (41.218). While ADRB2 is a cardiovascular target, some CNS off-target effects are possible, and moderate CNS penetration isn't necessarily a dealbreaker.
**9. Caco-2 Permeability:** Ligand A (-4.508) is better than Ligand B (-5.246). Higher values are better, indicating better intestinal absorption.
**10. Aqueous Solubility:** Ligand A (-1.973) is slightly better than Ligand B (-1.665). Both are quite poor.
**11. hERG Inhibition:** Ligand A (0.349) is better than Ligand B (0.202). Lower hERG inhibition is critical for avoiding cardiotoxicity, and Ligand A is better here.
**12. Microsomal Clearance:** Ligand A (3.644) has a much lower microsomal clearance than Ligand B (33.07). This indicates better metabolic stability for Ligand A, a significant advantage.
**13. In vitro Half-Life:** Ligand A (-20.182) has a much better in vitro half-life than Ligand B (-13.369). Longer half-life is desirable.
**14. P-gp Efflux:** Ligand A (0.028) is better than Ligand B (0.019). Lower P-gp efflux is preferred for better bioavailability.
**15. Binding Affinity:** Ligand B (-7.0) has a slightly better binding affinity than Ligand A (-6.4). However, the difference is not substantial enough to outweigh the other significant advantages of Ligand A.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity) and general drug-like properties, Ligand A is the more promising candidate. While Ligand B has a slightly better affinity and logP, Ligand A excels in crucial ADME-Tox parameters: significantly lower DILI risk, better metabolic stability (lower Cl_mic and better t1/2), and better hERG inhibition. The lower DILI risk and improved metabolic stability are particularly important for a cardiovascular drug. The slightly better BBB penetration of Ligand A is also a minor positive.
Output:
1
2025-04-17 22:37:24,784 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (370.479 and 352.381 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (69.64) is significantly better than Ligand A (107.53). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (1.847) is optimal, while Ligand A (0.012) is very low. This is a major concern for Ligand A, as it may struggle with membrane permeability.
4. **HBD:** Both ligands have 2 HBD, which is within the acceptable limit of 5.
5. **HBA:** Ligand B (3) is better than Ligand A (6), keeping within the desired range.
6. **QED:** Ligand B (0.85) is better than Ligand A (0.7), indicating a more drug-like profile.
7. **DILI:** Ligand B (40.054) is better than Ligand A (54.478), indicating lower potential for liver injury. Both are acceptable, but B is preferred.
8. **BBB:** Not a high priority for a cardiovascular target. Ligand A (74.06) is slightly better than Ligand B (63.862), but this is not a deciding factor.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the absolute value for Ligand A (-4.917) is worse than Ligand B (-4.783).
10. **Solubility:** Both ligands have negative solubility values, which is also unusual. Ligand A (-1.969) is slightly better than Ligand B (-2.693).
11. **hERG:** Ligand B (0.665) is significantly better than Ligand A (0.162), indicating a lower risk of cardiotoxicity. This is crucial for a cardiovascular target.
12. **Cl_mic:** Ligand B (16.033) has a lower clearance than Ligand A (31.9), suggesting better metabolic stability.
13. **t1/2:** Ligand B (36.512) has a significantly longer half-life than Ligand A (-18.533). This is a major advantage.
14. **Pgp:** Ligand A (0.004) is much better than Ligand B (0.069), indicating lower P-glycoprotein efflux.
15. **Binding Affinity:** Ligand B (-6.4 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.8 kcal/mol). This is a substantial advantage.
**Overall Assessment:**
Ligand B consistently outperforms Ligand A across most critical ADME-Tox properties, and crucially, has a much better binding affinity. The low logP of Ligand A is a major red flag, likely hindering its ability to cross cell membranes. While both have unusual Caco-2 and solubility values, the overall profile of Ligand B is far more favorable for development as a cardiovascular drug. The improved metabolic stability (lower Cl_mic, longer t1/2), reduced hERG risk, and stronger binding affinity outweigh the slightly better Pgp profile of Ligand A.
Output:
0
2025-04-17 22:37:24,784 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (364.27 Da) and Ligand B (346.45 Da) both fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (59.5) is higher than Ligand B (38.82). Both are below 140, but Ligand B is better positioned for oral absorption.
3. **logP:** Ligand A (2.681) is within the optimal 1-3 range. Ligand B (1.324) is at the lower end, potentially impacting permeability.
4. **HBD:** Ligand A (0) is preferable to Ligand B (1). Fewer HBDs generally improve permeability.
5. **HBA:** Both Ligand A (4) and Ligand B (4) are within the acceptable limit of 10.
6. **QED:** Ligand B (0.835) has a better QED score than Ligand A (0.611), indicating a more drug-like profile.
7. **DILI:** Ligand B (35.052) has a significantly lower DILI risk than Ligand A (66.344). This is a major advantage for Ligand B.
8. **BBB:** Ligand A (83.986) has a better BBB penetration percentile than Ligand B (70.26). While ADRB2 isn't exclusively a CNS target, some CNS exposure could be relevant depending on the specific therapeutic application.
9. **Caco-2:** Ligand A (-4.337) and Ligand B (-4.92) are both very poor. This is a significant concern for both compounds.
10. **Solubility:** Ligand A (-3.315) has better solubility than Ligand B (-1.808).
11. **hERG:** Ligand A (0.447) has a lower hERG risk than Ligand B (0.8). This is a positive for Ligand A.
12. **Cl_mic:** Ligand B (4.56) has a significantly lower microsomal clearance than Ligand A (70.171), indicating better metabolic stability.
13. **t1/2:** Ligand B (-7.233) has a longer in vitro half-life than Ligand A (-4.767).
14. **Pgp:** Ligand A (0.17) has lower P-gp efflux than Ligand B (0.072). Lower Pgp is generally better for bioavailability.
15. **Binding Affinity:** Ligand B (-7.1 kcal/mol) has a slightly better binding affinity than Ligand A (-5.9 kcal/mol). This difference is substantial enough to be a key factor.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Ligand B excels in TPSA, Pgp, and affinity. Ligand A has a slightly better logP and Pgp. The significantly lower DILI risk and improved metabolic stability (Cl_mic and t1/2) of Ligand B are also very important.
**Overall Assessment:**
While Ligand A has some advantages in solubility, hERG, and BBB, Ligand B's superior binding affinity, significantly lower DILI risk, and better metabolic stability outweigh these factors. The poor Caco-2 values for both are a concern that would need to be addressed in further optimization, but the overall profile of Ligand B is more promising for development as a drug candidate.
Output:
0
2025-04-17 22:37:24,784 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (339.439 Da) is slightly lower, which is generally favorable for permeability.
**2. TPSA:** Both ligands have TPSA values below the 140 A^2 threshold for good oral absorption. Ligand B (54.18 A^2) is lower than Ligand A (62.3 A^2), which is slightly better.
**3. logP:** Both ligands have logP values within the optimal range (1-3). Ligand B (2.936) is slightly higher, which could potentially lead to some off-target interactions, but it's not a major concern.
**4. H-Bond Donors:** Both ligands have 1 HBD, which is within the acceptable limit of <=5.
**5. H-Bond Acceptors:** Ligand A has 3 HBAs and Ligand B has 6 HBAs. Both are below the 10 threshold, but Ligand A is preferable.
**6. QED:** Both ligands have QED values above 0.5, indicating good drug-likeness, but Ligand A (0.896) is significantly better than Ligand B (0.737).
**7. DILI:** Ligand A (21.675%) has a much lower DILI risk than Ligand B (8.53%). This is a significant advantage for Ligand A.
**8. BBB:** Both ligands have similar BBB penetration (around 71-72%). This is less critical for a cardiovascular target like ADRB2, but still a positive.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.875) is slightly better than Ligand B (-5.176).
**10. Aqueous Solubility:** Both ligands have negative solubility values, which is also unusual and suggests poor solubility. Ligand A (-2.435) is slightly better than Ligand B (-2.305).
**11. hERG Inhibition:** Ligand A (0.172) has a much lower hERG inhibition liability than Ligand B (0.835). This is a crucial advantage, as hERG inhibition can lead to cardiotoxicity.
**12. Microsomal Clearance:** Ligand A (21.618 mL/min/kg) has a lower microsomal clearance than Ligand B (50.319 mL/min/kg), indicating better metabolic stability.
**13. In vitro Half-Life:** Ligand A (-16.578 hours) has a negative half-life, which is not possible. Ligand B (7.052 hours) is a reasonable value. This is a significant drawback for Ligand A.
**14. P-gp Efflux:** Ligand A (0.06) has lower P-gp efflux liability than Ligand B (0.367), which is favorable for bioavailability.
**15. Binding Affinity:** Ligand B (-7.2 kcal/mol) has a slightly better binding affinity than Ligand A (-6.4 kcal/mol). This is a 1.8 kcal/mol difference, which is substantial.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), and the general drug-like properties, Ligand B has a better binding affinity. However, Ligand A demonstrates significantly better safety profiles (lower DILI and hERG inhibition) and better metabolic stability (lower Cl_mic). The negative half-life for Ligand A is a major concern. While the affinity difference is significant, the safety and metabolic advantages of Ligand A, combined with its slightly better permeability, outweigh the affinity difference.
Output:
1
2025-04-17 22:37:24,784 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (348.378) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (95.37) is better than Ligand B (121.6). Both are acceptable, but lower TPSA generally improves oral absorption.
3. **logP:** Ligand A (3.961) is optimal, while Ligand B (0.014) is very low. This is a significant drawback for Ligand B, potentially hindering membrane permeability and bioavailability.
4. **HBD:** Ligand A (0) is preferred. Ligand B (3) is acceptable, but fewer HBDs are generally better for permeability.
5. **HBA:** Ligand A (4) is better than Ligand B (5).
6. **QED:** Both ligands have reasonable QED scores (A: 0.358, B: 0.653), with Ligand B being slightly better.
7. **DILI:** Both are acceptable, with Ligand A (52.772) being slightly higher than Ligand B (47.887).
8. **BBB:** Ligand A (83.908) is significantly better than Ligand B (60.993). While ADRB2 isn't strictly a CNS target, some CNS penetration can be beneficial for understanding off-target effects and potential side effects.
9. **Caco-2:** Ligand A (-4.274) is better than Ligand B (-5.856). Higher values indicate better absorption.
10. **Solubility:** Ligand A (-3.828) is better than Ligand B (-2.283).
11. **hERG:** Ligand A (0.613) is better than Ligand B (0.147). Lower hERG inhibition is crucial for avoiding cardiotoxicity, a major concern with cardiovascular targets.
12. **Cl_mic:** Ligand A (34.462) is better than Ligand B (-30.18). Lower clearance indicates better metabolic stability.
13. **t1/2:** Ligand A (12.393) is better than Ligand B (-15.558).
14. **Pgp:** Ligand A (0.231) is better than Ligand B (0.014). Lower P-gp efflux is generally preferred.
15. **Affinity:** Ligand B (-6.5) has a significantly better binding affinity than Ligand A (-3.1). This is a >3.4 kcal/mol difference, which is substantial.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in affinity, but falls short in logP and has a less favorable TPSA. Ligand A is more balanced across these critical properties. The very low logP of Ligand B is a major concern, likely leading to poor permeability and bioavailability. While the affinity difference is significant, the ADME properties of Ligand A are much more promising, and a well-balanced profile is more likely to translate into a viable drug candidate.
**Output:**
1
2025-04-17 22:37:24,785 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.391 and 352.439 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (122.41 and 126.23) are below the 140 A^2 threshold for good oral absorption, but not optimized for CNS penetration (ideally <90). Ligand A is slightly better.
3. **logP:** Both ligands (0.276 and 0.24) are quite low. While not exceeding the upper limit, they are at the lower end of the optimal 1-3 range and could potentially hinder membrane permeability. Ligand B is slightly better.
4. **HBD:** Both have 3 HBD, which is acceptable.
5. **HBA:** Both have 6 HBA, which is acceptable.
6. **QED:** Ligand B (0.615) has a better QED score than Ligand A (0.478), indicating a more drug-like profile.
7. **DILI:** Ligand B (57.813) has a significantly lower DILI risk than Ligand A (79.643). This is a substantial advantage.
8. **BBB:** Ligand B (62.854) has a better BBB penetration percentile than Ligand A (50.679), which is good for a GPCR, even if not a CNS target.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. Ligand B (-5.657) is slightly better than Ligand A (-5.228).
10. **Solubility:** Both have negative solubility values, indicating poor solubility. Ligand B (-2.163) is slightly better than Ligand A (-3.058).
11. **hERG:** Both have very low hERG inhibition risk (0.054 and 0.068).
12. **Cl_mic:** Ligand B (-0.064) has a much lower (better) microsomal clearance than Ligand A (51.345). This suggests significantly improved metabolic stability.
13. **t1/2:** Ligand B (3.518) has a longer in vitro half-life than Ligand A (-26.864). This is a significant advantage.
14. **Pgp:** Both have very low Pgp efflux liability (0.033 and 0.022).
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.5 and -6.6 kcal/mol). The difference is negligible.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are important. While both ligands are similar in affinity and Pgp, Ligand B is better in terms of DILI, BBB, Cl_mic, and t1/2. The slightly better logP and TPSA of Ligand B are also beneficial. The improved metabolic stability (Cl_mic and t1/2) and reduced DILI risk are particularly important for a viable drug candidate.
**Conclusion:**
Ligand B demonstrates a significantly more favorable ADMET profile and comparable binding affinity, making it the more promising drug candidate.
Output:
0
2025-04-17 22:37:24,785 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (346.431 and 348.418 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (87.47) is slightly higher than Ligand B (69.64). For a cardiovascular GPCR, TPSA is moderately important, and Ligand B's lower TPSA is preferable, suggesting better potential for membrane permeability.
**3. logP:** Both ligands have acceptable logP values (1.163 and 1.701), falling within the optimal 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability, but isn't a major concern for either.
**4. H-Bond Donors:** Both ligands have 2 HBD, which is within the desirable limit of 5.
**5. H-Bond Acceptors:** Ligand A has 5 HBA, while Ligand B has 3. Both are within the acceptable limit of 10.
**6. QED:** Both ligands have good QED scores (0.724 and 0.769), indicating good drug-like properties.
**7. DILI:** Ligand B (23.614) has a significantly lower DILI risk than Ligand A (35.789). This is a crucial advantage, as minimizing liver toxicity is paramount.
**8. BBB:** Ligand B (57.968) shows better BBB penetration potential than Ligand A (36.72). While ADRB2 isn't a CNS target, some peripheral exposure can sometimes lead to unwanted side effects, and lower BBB penetration can be beneficial in this case.
**9. Caco-2 Permeability:** Ligand A (-5.099) shows poorer Caco-2 permeability than Ligand B (-4.441). This suggests Ligand B will be better absorbed in the gut.
**10. Aqueous Solubility:** Both ligands have very poor aqueous solubility (-1.801 and -2.048). This is a significant drawback for both, and formulation strategies would be needed.
**11. hERG Inhibition:** Ligand A (0.153) shows slightly lower hERG inhibition risk than Ligand B (0.774). This is a minor advantage for Ligand A.
**12. Microsomal Clearance:** Ligand A (-11.331) has a significantly lower (better) microsomal clearance than Ligand B (35.78). This indicates greater metabolic stability for Ligand A.
**13. In vitro Half-Life:** Ligand A (-21.426) has a longer in vitro half-life than Ligand B (-22.805). This is a positive for Ligand A.
**14. P-gp Efflux:** Ligand A (0.035) exhibits lower P-gp efflux than Ligand B (0.136), suggesting better bioavailability.
**15. Binding Affinity:** Both ligands have very similar binding affinities (-6.6 and -6.7 kcal/mol). The difference is negligible.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), and the general drug-like properties, Ligand B is the more promising candidate. Its lower DILI risk, better Caco-2 permeability, and better BBB penetration outweigh the slightly better metabolic stability and P-gp efflux profile of Ligand A. The solubility is a concern for both, but can be addressed with formulation. The affinity is comparable.
Output:
0
2025-04-17 22:37:24,785 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (355.435 and 361.511 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (96.97) is higher than Ligand B (59.23). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is generally preferred for absorption. Ligand B is better.
3. **logP:** Ligand A (-0.327) is quite low, potentially hindering membrane permeability. Ligand B (4.064) is high, potentially causing solubility issues and off-target interactions. Both are suboptimal, but Ligand A's low logP is more concerning for getting into the cell.
4. **HBD:** Ligand A (2) is reasonable. Ligand B (0) is also good. No clear advantage.
5. **HBA:** Both ligands have 5 HBA, which is within the acceptable range.
6. **QED:** Both ligands have good QED scores (0.59 and 0.746), indicating generally drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (9.461%) has a much lower DILI risk than Ligand B (38.697%). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (67.584%) has a moderate BBB penetration, while Ligand B (83.831%) has higher penetration. Since ADRB2 is not a CNS target, this is less critical, but still slightly favors Ligand B.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.029 and -4.907), which is unusual and suggests poor permeability. This is a major concern for both.
10. **Solubility:** Ligand A (-1.299) has slightly better solubility than Ligand B (-3.486), although both are poor.
11. **hERG:** Ligand A (0.096%) has a very low hERG risk, while Ligand B (0.338%) is slightly higher. This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand A (-1.608) has a lower (better) microsomal clearance than Ligand B (91.401), indicating better metabolic stability. This is a substantial advantage for Ligand A.
13. **t1/2:** Ligand A (-12.821) has a very short in vitro half-life, while Ligand B (-14.666) is only marginally better. Both are poor.
14. **Pgp:** Ligand A (0.001) has very low P-gp efflux liability, while Ligand B (0.493) is higher. This is a significant advantage for Ligand A.
15. **Binding Affinity:** Ligand B (-7.5) has a stronger binding affinity than Ligand A (-5.5), a difference of 2.0 kcal/mol. This is a substantial advantage for Ligand B and potentially outweighs some of the ADME concerns.
**Overall Assessment:**
Ligand B has a significantly better binding affinity, which is a primary driver for GPCR drug candidates. However, it suffers from a higher DILI risk, higher Pgp efflux, and significantly higher microsomal clearance. Ligand A has better ADME properties (DILI, Cl_mic, Pgp, solubility, hERG), but weaker binding affinity.
Considering the balance, the stronger binding affinity of Ligand B is a significant advantage that could be optimized through further medicinal chemistry. The ADME properties of Ligand B, while not ideal, are potentially addressable with structural modifications. The poor ADME profile of Ligand A, particularly the very short half-life and low logP, would be more challenging to overcome.
Output:
0
2025-04-17 22:37:24,785 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
The target is ADRB2, a GPCR. Therefore, I will prioritize logP, Pgp, TPSA, affinity, and BBB.
* **Molecular Weight:** Both ligands are within the ideal range (200-500 Da).
* **TPSA:** Both ligands have TPSA values around 71-72, which is acceptable for a non-CNS GPCR target like ADRB2.
* **logP:** Ligand A (1.466) is better than Ligand B (2.075). While both are within the optimal range, A is closer to the lower end, potentially reducing off-target effects.
* **H-Bond Donors/Acceptors:** Ligand A (1 HBD, 4 HBA) is slightly better than Ligand B (0 HBD, 8 HBA). Lower HBA is generally preferred for better membrane permeability.
* **QED:** Both are reasonably good (A: 0.812, B: 0.756), indicating good drug-like properties.
* **DILI:** Ligand A (9.771) has a significantly lower DILI risk than Ligand B (93.059). This is a major advantage for Ligand A.
* **BBB:** Both ligands have similar BBB penetration (A: 71.772, B: 75.533). This isn't a primary concern for ADRB2, which isn't a CNS target, but higher is still slightly preferable.
* **Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual. I will assume this means very low permeability.
* **Aqueous Solubility:** Ligand A (-0.897) is better than Ligand B (-4.363). Better solubility is always a plus.
* **hERG Inhibition:** Ligand A (0.156) has a much lower hERG risk than Ligand B (0.613). This is a critical safety parameter.
* **Microsomal Clearance:** Ligand B (77.368) has significantly higher clearance than Ligand A (0.174). This means Ligand A is much more metabolically stable.
* **In vitro Half-Life:** Ligand A (-6.426) has a much better half-life than Ligand B (-29.625).
* **P-gp Efflux:** Ligand A (0.017) has much lower P-gp efflux than Ligand B (0.272). This is beneficial for bioavailability.
* **Binding Affinity:** Ligand A (-7.1 kcal/mol) has a slightly better binding affinity than Ligand B (-5.8 kcal/mol). While the difference is not huge, it is still a positive factor.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical ADME-Tox parameters (DILI, hERG, Cl_mic, Pgp, solubility) and has a slightly better binding affinity. The significantly lower DILI and hERG risks, coupled with improved metabolic stability and P-gp efflux, make Ligand A the much more promising candidate despite the similar Caco-2 permeability.
**Output:**
1
2025-04-17 22:37:24,785 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my output:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (371.384) is slightly higher than Ligand B (352.431), but both are acceptable.
2. **TPSA:** Ligand A (56.15) is excellent, well below the 140 threshold for oral absorption. Ligand B (84.94) is still reasonable, but less optimal.
3. **logP:** Ligand A (2.919) is within the optimal range (1-3). Ligand B (0.884) is a bit low, potentially impacting permeability.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Both ligands have 5 HBA, which is good.
6. **QED:** Ligand A (0.821) has a better QED score than Ligand B (0.543), indicating a more drug-like profile.
7. **DILI:** Ligand B (48.662) has a slightly lower DILI risk than Ligand A (55.332), but both are acceptable (below 60).
8. **BBB:** Ligand A (84.878) has significantly better BBB penetration potential than Ligand B (41.528). While ADRB2 isn't exclusively a CNS target, some cardiovascular effects are mediated by central pathways, and better BBB penetration could be beneficial or at least not detrimental.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the values are similar (-4.964 vs -4.637) so this isn't a major differentiator.
10. **Solubility:** Ligand A (-3.82) has slightly better solubility than Ligand B (-2.021), though both are poor.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.342 and 0.088), which is excellent.
12. **Cl_mic:** Ligand B (32.1) has a lower microsomal clearance than Ligand A (44.271), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-4.608) has a longer in vitro half-life than Ligand A (11.701), which is a significant advantage.
14. **Pgp:** Ligand A (0.497) has slightly higher Pgp efflux liability than Ligand B (0.051), which is unfavorable.
15. **Binding Affinity:** Both ligands have excellent binding affinity (-5.6 and -5.0 kcal/mol), with Ligand A being slightly better. The difference is less than 1.5 kcal/mol, so it's not a decisive factor.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp efflux, and affinity are key. Ligand A has better TPSA, logP and affinity, but Ligand B has a much lower Pgp efflux liability and better metabolic stability (lower Cl_mic, longer t1/2). The better BBB penetration of Ligand A is a small bonus.
**Overall Assessment:**
While Ligand A has a slight edge in affinity and TPSA, the significantly better metabolic stability (t1/2 and Cl_mic) and lower Pgp efflux of Ligand B are more important for overall drug development success. The slightly lower logP of Ligand B is a concern, but the other advantages outweigh this.
Output:
0
2025-04-17 22:37:24,785 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (345.447 Da) is better than Ligand B (388.599 Da). Both are within the ideal range, but A is closer to the lower, preferred end.
2. **TPSA:** Ligand B (66.48) is significantly better than Ligand A (88.91). ADRB2 is not a CNS target, but lower TPSA generally improves absorption.
3. **logP:** Both ligands (A: 1.579, B: 2.028) are within the optimal range (1-3). Ligand B is slightly better.
4. **HBD:** Ligand B (1) is better than Ligand A (2). Lower HBD is generally preferred for permeability.
5. **HBA:** Ligand B (4) is better than Ligand A (5). Lower HBA is generally preferred for permeability.
6. **QED:** Ligand B (0.783) is significantly better than Ligand A (0.525), indicating a more drug-like profile.
7. **DILI:** Ligand B (31.563) is much better than Ligand A (47.887). Both are below the 40 threshold, but B is substantially lower risk.
8. **BBB:** Not a primary concern for ADRB2 (cardiovascular target), but Ligand A (58.511) is better than Ligand B (45.909).
9. **Caco-2:** Ligand A (-5.414) is better than Ligand B (-4.963), indicating slightly better intestinal absorption.
10. **Solubility:** Ligand A (-1.76) is better than Ligand B (-2.57). Higher solubility is generally preferred.
11. **hERG:** Ligand A (0.063) is better than Ligand B (0.148), indicating a lower risk of cardiotoxicity. This is *very* important for a cardiovascular target.
12. **Cl_mic:** Ligand A (36.844) and Ligand B (37.383) are very similar.
13. **t1/2:** Ligand A (-9.136) is better than Ligand B (-3.373), indicating a longer in vitro half-life.
14. **Pgp:** Ligand A (0.057) is better than Ligand B (0.052), indicating lower P-gp efflux.
15. **Affinity:** Ligand A (-7.5 kcal/mol) is significantly better than Ligand B (-5.4 kcal/mol). This is a substantial difference in potency.
**GPCR-Specific Priorities & Overall Assessment:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. While Ligand B has better TPSA, QED, DILI, and H-bonding characteristics, Ligand A boasts a significantly stronger binding affinity (-7.5 vs -5.4 kcal/mol). The difference in affinity is large enough to outweigh the slight drawbacks in TPSA and QED. Furthermore, Ligand A has a better hERG profile, which is crucial for a cardiovascular drug. The longer half-life and lower Pgp efflux also contribute to better overall drug properties.
**Output:**
1
2025-04-17 22:37:24,786 - INFO - Here's my reasoning and the final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, the key priorities are logP, TPSA, Pgp, affinity, and to a lesser extent, BBB.
Let's break down the comparison:
1. **MW:** Both ligands are within the acceptable range (200-500 Da). Ligand A (368.543) is slightly larger than Ligand B (344.459), but this isn't a major concern.
2. **TPSA:** Ligand A (58.64) is significantly better than Ligand B (94.88). A TPSA under 140 is good for oral absorption, and lower is generally preferred for GPCRs. Ligand B's TPSA is approaching a level that could hinder absorption.
3. **logP:** Both ligands have good logP values (A: 2.583, B: 2.681), falling within the optimal 1-3 range.
4. **HBD/HBA:** Ligand A (HBD=1, HBA=4) is slightly better than Ligand B (HBD=2, HBA=4). Lower HBD is generally preferable.
5. **QED:** Ligand A (0.783) has a better QED score than Ligand B (0.682), indicating a more drug-like profile.
6. **DILI:** Ligand A (20.24) has a much lower DILI risk than Ligand B (41.644). This is a significant advantage for Ligand A.
7. **BBB:** Ligand A (71.811) has a better BBB percentile than Ligand B (50.872). While not a primary concern for a cardiovascular target, higher BBB is still a positive.
8. **Caco-2:** Both ligands have negative Caco-2 values (-5.023 and -4.929), which is unusual and suggests poor permeability. This is a significant drawback for both.
9. **Solubility:** Both ligands have negative solubility values (-3.309 and -3.267), indicating poor aqueous solubility. This is also a concern for both.
10. **hERG:** Both ligands have low hERG inhibition risk (A: 0.255, B: 0.396).
11. **Cl_mic:** Ligand A (49.812) has slightly better microsomal clearance than Ligand B (46.548), indicating better metabolic stability.
12. **t1/2:** Ligand B (30.805) has a significantly longer in vitro half-life than Ligand A (1.813). This is a major advantage for Ligand B.
13. **Pgp:** Both ligands have low P-gp efflux liability (A: 0.096, B: 0.124).
14. **Affinity:** Both ligands have very similar binding affinities (-6.5 and -6.4 kcal/mol). The difference is negligible.
**Overall Assessment:**
Ligand A is superior due to its significantly better TPSA, DILI risk, QED, and BBB penetration. While Ligand B has a longer half-life, the other advantages of Ligand A outweigh this benefit, especially considering the poor Caco-2 and solubility of both compounds. The lower TPSA of Ligand A suggests it will have better absorption characteristics despite the negative Caco-2 value. The lower DILI risk is also a critical factor for drug development.
Output:
1
2025-04-17 22:37:24,786 - INFO - Batch 345 complete. Total preferences: 5520
2025-04-17 22:37:24,786 - INFO - Processing batch 346/512...
2025-04-17 22:38:15,117 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands (345.447 and 354.491 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (81.59) is slightly higher than Ligand B (67.87). Both are below the 140 threshold for oral absorption, but B is better positioned for potential CNS penetration if desired (though not a primary goal for ADRB2).
3. **logP:** Ligand A (0.954) is a bit low, potentially hindering permeability. Ligand B (2.175) is within the optimal 1-3 range. This favors Ligand B.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable.
5. **HBA:** Ligand A (5) and Ligand B (4) are both acceptable.
6. **QED:** Ligand A (0.853) is slightly better than Ligand B (0.794), indicating a marginally more drug-like profile.
7. **DILI:** Ligand B (38.038) has a significantly lower DILI risk than Ligand A (8.647). This is a major advantage for Ligand B.
8. **BBB:** Ligand B (77.782) has better BBB penetration potential than Ligand A (68.321), though this isn't a primary concern for a cardiovascular target like ADRB2.
9. **Caco-2:** Ligand A (-5.05) has a worse Caco-2 value than Ligand B (-4.521), suggesting lower intestinal absorption.
10. **Solubility:** Ligand A (-0.813) has a worse solubility value than Ligand B (-3.011).
11. **hERG:** Both ligands have low hERG inhibition liability (0.343 and 0.303, respectively). No significant difference.
12. **Cl_mic:** Ligand A (-35.351) has a much lower (better) microsomal clearance than Ligand B (54.889), indicating greater metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (9.787) has a longer in vitro half-life than Ligand B (4.14). This is a positive for Ligand A.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.004 and 0.096, respectively). No significant difference.
15. **Binding Affinity:** Ligand B (-7.7 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.7 kcal/mol). This is a substantial advantage for Ligand B, potentially outweighing some ADME drawbacks.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, and affinity. Ligand B excels in logP and affinity. While Ligand A has better metabolic stability (Cl_mic and t1/2), the significantly stronger binding affinity of Ligand B is a crucial factor. The lower DILI risk for Ligand B is also a major benefit.
**Conclusion:**
Despite Ligand A's better metabolic stability, Ligand B's superior binding affinity, more favorable logP, lower DILI risk, and better solubility outweigh the drawbacks.
Output:
0
2025-04-17 22:38:15,118 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (349.431) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (91.76) is higher than Ligand B (69.02). For a cardiovascular GPCR, TPSA is not a major concern unless CNS penetration is desired. Ligand B is better here.
3. **logP:** Ligand A (0.756) is lower than the optimal range (1-3), potentially hindering permeability. Ligand B (3.676) is at the upper end but still acceptable. Ligand B is better.
4. **HBD:** Ligand A (2) and Ligand B (1) are both within the acceptable limit of 5. Ligand B is slightly better.
5. **HBA:** Ligand A (5) and Ligand B (6) are both within the acceptable limit of 10.
6. **QED:** Ligand A (0.791) has a significantly better QED score than Ligand B (0.507), indicating a more drug-like profile. Ligand A is better.
7. **DILI:** Ligand A (32.299) has a much lower DILI risk than Ligand B (57.387). This is a significant advantage for Ligand A.
8. **BBB:** Both ligands have moderate BBB penetration. Ligand A (50.679) and Ligand B (55.874). Since this is a cardiovascular target, BBB penetration is not critical.
9. **Caco-2:** Ligand A (-4.688) and Ligand B (-5.209) are both negative, indicating poor permeability.
10. **Solubility:** Ligand A (-1.702) is better than Ligand B (-4.024). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.234) has a much lower hERG inhibition liability than Ligand B (0.776), reducing the risk of cardiotoxicity. This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand A (-2.692) has a lower (better) microsomal clearance than Ligand B (92.612), suggesting greater metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (10.707) has a slightly longer in vitro half-life than Ligand B (11.259).
14. **Pgp:** Ligand A (0.099) has a lower P-gp efflux liability than Ligand B (0.308), improving bioavailability. Ligand A is better.
15. **Affinity:** Both ligands have very similar binding affinities (-5.4 and -5.7 kcal/mol). The difference is negligible.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand B has a better logP and TPSA, but Ligand A excels in DILI, hERG, Cl_mic, Pgp, solubility, and QED. The superior safety profile (DILI, hERG) and metabolic stability (Cl_mic) of Ligand A, combined with its better QED and Pgp profile, outweigh the slight advantage of Ligand B in logP and TPSA.
**Final Decision:**
Given the overall balance of properties, and prioritizing safety and drug-likeness, I believe Ligand A is the more promising drug candidate.
1
2025-04-17 22:38:15,118 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (362.792 Da and 352.479 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (90.04) is slightly higher than Ligand B (64.17). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is generally preferred for absorption. Ligand B has a clear advantage.
**3. logP:** Ligand A (3.621) is within the optimal range (1-3), while Ligand B (0.112) is significantly *below* this range. Low logP can hinder membrane permeability. Ligand A is preferred.
**4. H-Bond Donors:** Ligand A has 4 HBD, which is acceptable. Ligand B has 0, which is also acceptable. No strong preference.
**5. H-Bond Acceptors:** Both ligands have 3-4 HBA, which is within the acceptable range. No strong preference.
**6. QED:** Both ligands have good QED scores (0.571 and 0.659), indicating good drug-like properties. Ligand B is slightly better.
**7. DILI Risk:** Both ligands have acceptable DILI risk (72.082 and 7.716), with Ligand B being significantly lower and therefore preferred.
**8. BBB Penetration:** Ligand A (26.483) has low BBB penetration, while Ligand B (79.411) has high BBB penetration. While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant for off-target effects, and higher BBB is generally better for GPCRs. Ligand B is preferred.
**9. Caco-2 Permeability:** Ligand A (-5.325) has poor Caco-2 permeability, while Ligand B (-4.586) is slightly better. Both are negative, indicating poor permeability, but Ligand B is less poor.
**10. Aqueous Solubility:** Ligand A (-3.846) has poor solubility, while Ligand B (-0.318) is slightly better. Both are negative, indicating poor solubility, but Ligand B is less poor.
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (0.577 and 0.221), which is good. Ligand B is slightly better.
**12. Microsomal Clearance:** Ligand A (22.92) has moderate clearance, while Ligand B (0.036) has very low clearance. Lower clearance is preferred for metabolic stability, making Ligand B much better.
**13. In vitro Half-Life:** Ligand A (-5.731) has a very short half-life, while Ligand B (-28.879) has an extremely short half-life. Both are very poor, but Ligand A is slightly better.
**14. P-gp Efflux:** Both ligands have low P-gp efflux (0.155 and 0.007), which is good. Ligand B is slightly better.
**15. Binding Affinity:** Both ligands have similar and strong binding affinity (-6.4 and -6.3 kcal/mol). The difference is negligible.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand B is the better candidate. While Ligand A has a better logP, Ligand B excels in DILI risk, BBB penetration, microsomal clearance, and P-gp efflux. The slightly better TPSA and lower DILI risk of Ligand B outweigh the slightly better logP of Ligand A. The poor solubility and permeability of both are concerning, but can be addressed with formulation strategies. The significantly improved metabolic stability of Ligand B is a major advantage.
Output:
0
2025-04-17 22:38:15,118 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's break down the comparison of Ligand A and Ligand B, considering the guidelines and GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key).
1. **Molecular Weight:** Both ligands (397.45 and 378.435 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand B (114.19) is significantly better than Ligand A (139.78). Lower TPSA generally correlates with better cell permeability, which is crucial for GPCR targeting.
3. **logP:** Ligand B (1.791) is within the optimal 1-3 range, while Ligand A (-0.333) is below 1, potentially hindering permeation. This is a significant advantage for Ligand B.
4. **H-Bond Donors:** Both have 2 HBD, which is acceptable.
5. **H-Bond Acceptors:** Ligand B has 7 HBA, while Ligand A has 6. Both are within the acceptable range of <=10.
6. **QED:** Both ligands have very similar QED values (0.645 and 0.648), indicating similar drug-likeness.
7. **DILI:** Ligand B (92.672) has a higher DILI risk than Ligand A (75.378). This is a negative for Ligand B, but not a deal-breaker at this stage.
8. **BBB:** Ligand A (47.15) has slightly better BBB penetration than Ligand B (38.775), but BBB isn't a primary concern for ADRB2, which is primarily a cardiovascular target.
9. **Caco-2 Permeability:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. This is a concern for both, but the lower (more negative) value for Ligand B (-5.754) is worse than Ligand A (-5.461).
10. **Aqueous Solubility:** Both have negative solubility values, indicating poor solubility. Again, this is a concern for both.
11. **hERG Inhibition:** Both ligands have low hERG inhibition risk (0.136 and 0.265).
12. **Microsomal Clearance:** Ligand A (-20.243) has significantly lower (better) microsomal clearance than Ligand B (0.174), indicating better metabolic stability. This is a major advantage for Ligand A.
13. **In vitro Half-Life:** Ligand B (42.258) has a much longer in vitro half-life than Ligand A (7.748). This is a significant advantage for Ligand B.
14. **P-gp Efflux:** Both have low P-gp efflux liability (0.052 and 0.065).
15. **Binding Affinity:** Both ligands have the same binding affinity (-6.5 kcal/mol).
**Overall Assessment:**
Ligand B has advantages in logP and in vitro half-life. However, Ligand A has a much better microsomal clearance and a slightly better BBB score. The biggest drawback for Ligand B is its significantly higher DILI risk. The poor Caco-2 permeability and solubility are concerns for both, but the better metabolic stability of Ligand A is a crucial factor for a GPCR target, where sustained receptor occupancy is often desired. Considering the GPCR-specific priorities, the improved metabolic stability and lower DILI risk of Ligand A outweigh the benefits of Ligand B's slightly better half-life and logP.
**Output:**
1
2025-04-17 22:38:15,118 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (380.897) is slightly higher than Ligand B (347.459), but both are acceptable.
2. **TPSA:** Ligand A (67.43) is better than Ligand B (71.53), being closer to the optimal threshold of <=140 for oral absorption.
3. **logP:** Both ligands have good logP values (A: 3.494, B: 2.037) within the 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability, but not excessively high.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1), but both are within the acceptable limit of <=5.
5. **HBA:** Both ligands have the same number of HBA (4), which is well within the acceptable limit of <=10.
6. **QED:** Both ligands have good QED scores (A: 0.736, B: 0.819), indicating good drug-like properties. Ligand B is slightly better here.
7. **DILI:** Ligand A (58.705) has a higher DILI risk than Ligand B (22.8). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (73.284) has a slightly better BBB penetration percentile than Ligand B (66.925). Given ADRB2 is a GPCR, BBB penetration is a consideration, but not paramount unless targeting CNS effects.
9. **Caco-2:** Ligand A (-5.078) has a worse Caco-2 permeability than Ligand B (-4.413). Lower values indicate poorer permeability.
10. **Solubility:** Ligand A (-4.244) has worse solubility than Ligand B (-1.869). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.639) has a slightly higher hERG inhibition liability than Ligand B (0.34). Lower is better.
12. **Cl_mic:** Ligand A (55.251) has a higher microsomal clearance than Ligand B (35.819), indicating faster metabolism and potentially lower *in vivo* exposure.
13. **t1/2:** Ligand A (82.426) has a significantly longer *in vitro* half-life than Ligand B (7.284). This is a substantial advantage for Ligand A.
14. **Pgp:** Ligand A (0.248) has lower P-gp efflux liability than Ligand B (0.03). Lower efflux is generally desirable.
15. **Binding Affinity:** Ligand A (-7.6) has a significantly stronger binding affinity than Ligand B (-5.4). This is a >2 kcal/mol difference, which is a major advantage.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has a better logP, slightly better TPSA, better Pgp, and *much* better affinity. While BBB is a consideration, the affinity difference is substantial enough to outweigh the slightly lower BBB value for Ligand A. The DILI risk for Ligand B is a concern, and the longer half-life of Ligand A is a strong positive. The solubility and Caco-2 values are better for Ligand B, but the affinity difference is so large it is likely to overcome these.
**Output:**
1
2025-04-17 22:38:15,119 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (342.483 and 351.411 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (50.36) is significantly better than Ligand B (128.26). For a GPCR, lower TPSA is generally preferred for better permeability. Ligand B is quite high, potentially hindering absorption.
3. **logP:** Ligand A (3.971) is within the optimal range (1-3), while Ligand B (-0.822) is below 1, which could indicate poor membrane permeability. This is a significant advantage for Ligand A.
4. **HBD:** Both ligands have 2 HBD, which is acceptable.
5. **HBA:** Ligand A (2) is better than Ligand B (8). Higher HBA can sometimes reduce permeability.
6. **QED:** Ligand A (0.85) is better than Ligand B (0.685), indicating a more drug-like profile.
7. **DILI:** Ligand A (30.632) has a much lower DILI risk than Ligand B (49.632). This is a crucial advantage for Ligand A.
8. **BBB:** Ligand A (91.508) shows excellent BBB penetration, while Ligand B (74.719) is lower. While ADRB2 isn't exclusively a CNS target, some cardiovascular effects are mediated by central pathways, and better BBB penetration isn't detrimental.
9. **Caco-2:** Ligand A (-4.706) is better than Ligand B (-5.471). Both are negative, but A is less negative.
10. **Solubility:** Ligand A (-4.294) is better than Ligand B (-2.267). Both are negative, but A is less negative.
11. **hERG:** Ligand A (0.733) is significantly better than Ligand B (0.075), indicating a lower risk of cardiotoxicity. This is a critical advantage, given the cardiovascular target.
12. **Cl_mic:** Ligand A (44.456) is much higher than Ligand B (1.749), meaning Ligand B has better metabolic stability.
13. **t1/2:** Ligand A (20.189) is much better than Ligand B (1.445).
14. **Pgp:** Ligand A (0.419) is better than Ligand B (0.018), indicating lower P-gp efflux.
15. **Binding Affinity:** Ligand A (-7.1) is 0.4 kcal/mol stronger than Ligand B (-6.7). This is a significant difference in potency.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical parameters, especially TPSA, logP, DILI, hERG, and binding affinity. While Ligand B has better metabolic stability (lower Cl_mic) and half-life, the superior ADME profile and significantly better potency of Ligand A outweigh this drawback. The lower hERG risk for Ligand A is particularly important for a cardiovascular target. The GPCR-specific priorities (logP, TPSA, Pgp, and affinity) all favor Ligand A.
Output:
1
2025-04-17 22:38:15,119 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [362.455, 78.68, 2.587, 1, 5, 0.91, 79.837, 59.442, -4.61, -2.965, 0.301, 23.81, 4.072, 0.164, -5.9]
**Ligand B:** [371.434, 102.76, 0.335, 3, 6, 0.669, 38.736, 65.839, -5.242, -2.13, 0.118, -24.017, -2.074, 0.025, -7.6]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (362.455) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (78.68) is significantly better than Ligand B (102.76). For a GPCR, keeping TPSA under 140 is good, but lower is better for permeability.
3. **logP:** Ligand A (2.587) is optimal (1-3). Ligand B (0.335) is quite low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (6). Fewer HBAs generally improve permeability.
6. **QED:** Ligand A (0.91) is excellent, indicating high drug-likeness. Ligand B (0.669) is still acceptable, but less ideal.
7. **DILI:** Ligand B (38.736) has a much lower DILI risk than Ligand A (79.837), which is a significant advantage.
8. **BBB:** Ligand B (65.839) has slightly better BBB penetration than Ligand A (59.442), although neither is exceptionally high. For a non-CNS target like many cardiovascular ADRB2 applications, this is less critical.
9. **Caco-2:** Ligand B (-5.242) is better than Ligand A (-4.61), indicating better intestinal absorption.
10. **Solubility:** Ligand B (-2.13) is better than Ligand A (-2.965).
11. **hERG:** Both are low, indicating low cardiotoxicity risk. Ligand B (0.118) is slightly better.
12. **Cl_mic:** Ligand B (-24.017) has significantly lower microsomal clearance than Ligand A (23.81), suggesting better metabolic stability.
13. **t1/2:** Ligand A (4.072) has a longer in vitro half-life than Ligand B (-2.074).
14. **Pgp:** Ligand B (0.025) has a much lower P-gp efflux liability than Ligand A (0.164), which is beneficial for bioavailability.
15. **Affinity:** Ligand B (-7.6) has a significantly stronger binding affinity than Ligand A (-5.9). This is a substantial advantage, potentially outweighing some ADME concerns.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp efflux, and affinity are particularly important. Ligand B excels in affinity and Pgp efflux, and has a more favorable logP. While Ligand A has a better TPSA, the substantial affinity advantage of Ligand B is more important. The lower DILI risk of Ligand B is also a significant positive.
**Conclusion:**
Despite Ligand A's better QED and half-life, Ligand B's superior binding affinity, lower DILI risk, better Caco-2 permeability, solubility, lower Pgp efflux, and improved metabolic stability make it the more promising drug candidate.
0
2025-04-17 22:38:15,119 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (364.511 and 385.917 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (49.85) is significantly better than Ligand B (82.53). For a GPCR, lower TPSA is generally preferred for better permeability. Ligand B is pushing the upper limit for good oral absorption.
3. **logP:** Both ligands have good logP values (2.067 and 2.79), falling within the optimal 1-3 range. Ligand B is slightly higher, which could potentially lead to off-target effects, but it's not a major concern.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is better than Ligand B (5). Lower HBA is also favorable for permeability.
6. **QED:** Both ligands have similar and acceptable QED values (0.704 and 0.761), indicating good drug-like properties.
7. **DILI:** Ligand A (44.436) has a lower DILI risk than Ligand B (67.313). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (79.837) has a much higher BBB penetration percentile than Ligand B (52.268). While ADRB2 isn't exclusively a CNS target, some CNS exposure can occur, and higher BBB is generally beneficial.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.103 and -5.141), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-3.032) has slightly better solubility than Ligand B (-4.6), but both are quite poor.
11. **hERG:** Both ligands have low hERG inhibition risk (0.362 and 0.442), which is good.
12. **Cl_mic:** Ligand B (33.38) has significantly lower microsomal clearance than Ligand A (57.174), indicating better metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand A (-5.527) has a more negative in vitro half-life, which translates to a shorter half-life. Ligand B (0.686) has a longer half-life, which is preferred.
14. **Pgp:** Ligand A (0.314) has lower P-gp efflux liability than Ligand B (0.21), which is slightly better.
15. **Binding Affinity:** Ligand B (-6.5 kcal/mol) has a significantly stronger binding affinity than Ligand A (-3.9 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME drawbacks. The difference of 2.6 kcal/mol is significant.
**Overall Assessment:**
Ligand B has a much stronger binding affinity and better metabolic stability (lower Cl_mic, longer t1/2). These are critical factors for a GPCR target. While Ligand A has better TPSA, DILI risk, and BBB penetration, the substantial difference in binding affinity and metabolic stability of Ligand B is more important. The poor Caco-2 values are a concern for both, but can be addressed through formulation strategies. The slightly higher logP of Ligand B is manageable.
Output:
0
2025-04-17 22:38:15,119 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (377.868 Da and 362.55 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (46.17) is well below the 140 threshold, and even better, below 90, making it favorable for potential CNS penetration (though not a primary goal here). Ligand B (58.44) is still acceptable but less optimal.
3. **logP:** Ligand A (3.988) is at the upper end of the optimal range (1-3), while Ligand B (1.899) is at the lower end. For a GPCR, a slightly higher logP is generally preferred for membrane permeability, but Ligand A isn't excessively high.
4. **HBD:** Ligand A (1) and Ligand B (0) are both acceptable.
5. **HBA:** Ligand A (3) and Ligand B (4) are both acceptable.
6. **QED:** Both ligands have good QED scores (0.611 and 0.772), indicating good drug-like properties.
7. **DILI:** Ligand B (34.703) has a significantly lower DILI risk than Ligand A (54.207). This is a substantial advantage for Ligand B.
8. **BBB:** Ligand A (85.459) has better BBB penetration potential than Ligand B (54.634). While ADRB2 isn't exclusively a CNS target, some CNS exposure could be relevant depending on the therapeutic indication.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.81 and -4.928), which is unusual and indicates poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand A (-4.728) and Ligand B (-2.206) both have poor solubility. Ligand B is slightly better, but both are problematic.
11. **hERG:** Ligand A (0.412) has a slightly higher hERG risk than Ligand B (0.186). Lower is better, so Ligand B is preferable.
12. **Cl_mic:** Ligand B (34.85) has significantly lower microsomal clearance than Ligand A (67.606), indicating better metabolic stability. This is a major advantage for Ligand B.
13. **t1/2:** Ligand B (-7.464) has a longer in vitro half-life than Ligand A (-4.829). This is a positive for Ligand B.
14. **Pgp:** Ligand A (0.443) has lower P-gp efflux than Ligand B (0.258), which is favorable.
15. **Binding Affinity:** Ligand A (-8.2 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.8 kcal/mol). This is a substantial advantage for Ligand A, and likely the most important factor. A 1.4 kcal/mol difference is significant.
**Overall Assessment:**
Ligand A has a much stronger binding affinity, which is paramount for GPCR targets. However, it suffers from higher DILI risk, higher hERG risk, and higher metabolic clearance. Ligand B has a better safety profile (lower DILI, hERG) and better metabolic stability, but its binding affinity is considerably weaker. The poor Caco-2 and solubility for both are concerning and would require formulation strategies.
Despite the ADME concerns with Ligand A, the substantial binding affinity advantage outweighs the other drawbacks, especially considering optimization strategies can be employed to address ADME properties.
Output:
1
2025-04-17 22:38:15,120 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, the most important parameters are binding affinity, logP, TPSA, Pgp efflux, and BBB penetration.
Let's compare the ligands property by property:
1. **MW:** Both ligands (346.427 and 346.435 Da) fall comfortably within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (87.66) is better than Ligand B (92.15), being closer to the <140 threshold for good absorption.
3. **logP:** Ligand A (1.652) is better than Ligand B (0.303). Both are within the 1-3 range, but Ligand B is closer to the lower limit, potentially hindering permeation.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (2), but both are acceptable.
5. **HBA:** Ligand B (6) is higher than Ligand A (4), but both are within the acceptable limit of 10.
6. **QED:** Ligand B (0.8) is better than Ligand A (0.668), indicating a more drug-like profile.
7. **DILI:** Ligand A (35.285) is significantly better than Ligand B (51.842), indicating a lower risk of drug-induced liver injury.
8. **BBB:** Ligand A (65.839) is slightly better than Ligand B (63.474), though both are not exceptionally high. For a cardiovascular target, BBB isn't a primary concern, but a higher value is still preferable.
9. **Caco-2:** Ligand A (-4.756) is better than Ligand B (-5.279), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-2.694) is better than Ligand B (-1.565), indicating better aqueous solubility.
11. **hERG:** Both ligands (0.283 and 0.2) have very low hERG inhibition risk, which is excellent.
12. **Cl_mic:** Ligand B (13.537) has a lower microsomal clearance than Ligand A (17.643), suggesting better metabolic stability.
13. **t1/2:** Ligand B (23.265) has a significantly longer in vitro half-life than Ligand A (16.216), which is a major advantage.
14. **Pgp:** Both ligands (0.211 and 0.011) have low P-gp efflux, which is good. Ligand B is slightly better.
15. **Affinity:** Ligand B (-6.5 kcal/mol) has a stronger binding affinity than Ligand A (-5.8 kcal/mol). This is a substantial difference (0.7 kcal/mol), and is a significant advantage.
**Overall Assessment:**
Ligand B has a superior binding affinity and a longer half-life, which are crucial for efficacy and dosing frequency. While Ligand A has better DILI risk and solubility, the affinity difference and longer half-life of Ligand B outweigh these benefits. The slightly lower logP of Ligand B is a minor concern, but not enough to disqualify it.
**Output:**
0
2025-04-17 22:38:15,120 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [346.427, 80.57, 2.394, 2, 4, 0.877, 57.658, 59.403, -5.215, -2.865, 0.276, -9.874, 43.834, 0.108, -6.3]
**Ligand B:** [346.427, 66.92, 1.494, 0, 4, 0.574, 27.181, 84.878, -4.554, -3.191, 0.142, 54.207, -15.194, 0.215, -4.6]
Here's a breakdown, considering the GPCR priorities (logP, Pgp, TPSA, affinity) and general guidelines:
1. **MW:** Both ligands are within the ideal range (around 346 Da). No significant difference.
2. **TPSA:** Ligand A (80.57) is higher than Ligand B (66.92). Lower TPSA is generally better for permeability, giving a slight edge to B.
3. **logP:** Ligand A (2.394) is within the optimal range, while Ligand B (1.494) is on the lower end. A is slightly preferred here for better membrane permeability.
4. **HBD:** Ligand A (2) is better than Ligand B (0). Having some HBD can aid solubility.
5. **HBA:** Both have 4 HBA, which is acceptable.
6. **QED:** Ligand A (0.877) has a significantly better QED score than Ligand B (0.574), indicating a more drug-like profile.
7. **DILI:** Ligand A (57.658) has a higher DILI risk than Ligand B (27.181). B is significantly better here.
8. **BBB:** Ligand B (84.878) has a much higher BBB penetration score than Ligand A (59.403). While not strictly *required* for a cardiovascular target, higher BBB penetration can sometimes indicate better overall distribution and potentially reduced off-target effects.
9. **Caco-2:** Ligand A (-5.215) is worse than Ligand B (-4.554). Higher values indicate better absorption, so B is preferred.
10. **Solubility:** Ligand A (-2.865) is worse than Ligand B (-3.191). Solubility is important, and B is slightly better.
11. **hERG:** Both are very low, indicating low cardiotoxicity risk. No significant difference.
12. **Cl_mic:** Ligand A (-9.874) has a lower (better) microsomal clearance than Ligand B (54.207), suggesting better metabolic stability.
13. **t1/2:** Ligand A (43.834) has a longer in vitro half-life than Ligand B (-15.194). This is a significant advantage for dosing convenience.
14. **Pgp:** Ligand A (0.108) has lower P-gp efflux than Ligand B (0.215), which is favorable for bioavailability.
15. **Affinity:** Ligand A (-6.3) has a slightly better binding affinity than Ligand B (-4.6). This is a substantial difference, and a key factor.
**Overall Assessment:**
Ligand A has a better binding affinity, QED, metabolic stability (Cl_mic), half-life, and Pgp efflux. Ligand B has better DILI risk, BBB penetration, Caco-2 permeability, and solubility. The affinity difference is substantial (-6.3 vs -4.6 kcal/mol). For a GPCR, affinity is paramount, and the other advantages of A outweigh the slightly higher DILI risk and lower BBB. The better QED and metabolic stability also contribute to its potential as a drug candidate.
Output:
1
2025-04-17 22:38:15,120 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [345.443, 71.53, 1.924, 1, 4, 0.885, 26.173, 57.425, -4.892, -1.178, 0.201, -9.196, 14.071, 0.029, -6.6]
**Ligand B:** [362.539, 58.2, 4.347, 2, 3, 0.642, 34.277, 69.523, -4.983, -3.747, 0.411, 65.091, 24.93, 0.303, -4.9]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, Affinity, and BBB):
1. **MW:** Both are within the ideal range (200-500 Da). A (345.443) is slightly better.
2. **TPSA:** A (71.53) is higher than B (58.2), but both are acceptable for a non-CNS GPCR like ADRB2. B is preferable.
3. **logP:** A (1.924) is optimal, while B (4.347) is pushing the upper limit and could lead to solubility issues. A is significantly better.
4. **HBD/HBA:** A (1 HBD, 4 HBA) is better than B (2 HBD, 3 HBA) for permeability.
5. **QED:** A (0.885) is much better than B (0.642), indicating a more drug-like profile.
6. **DILI:** A (26.173) is significantly better than B (34.277), indicating lower liver injury risk.
7. **BBB:** While not critical for ADRB2, B (69.523) is better than A (57.425).
8. **Caco-2:** Both are negative, indicating poor permeability. A (-4.892) is slightly better than B (-4.983).
9. **Solubility:** A (-1.178) is better than B (-3.747).
10. **hERG:** A (0.201) is much better than B (0.411), indicating lower cardiotoxicity risk.
11. **Cl_mic:** A (-9.196) is much better than B (65.091), indicating better metabolic stability.
12. **t1/2:** B (24.93) is better than A (14.071).
13. **Pgp:** A (0.029) is much better than B (0.303), indicating lower efflux.
14. **Affinity:** A (-6.6) is better than B (-4.9). This is a substantial difference in binding.
**Overall Assessment:**
Ligand A is clearly superior. It has a better logP, QED, DILI score, hERG risk, metabolic stability (Cl_mic), Pgp efflux, and significantly better binding affinity. While Ligand B has a slightly better BBB penetration and in vitro half-life, the advantages of Ligand A far outweigh these minor benefits, especially considering the importance of potency and safety for a cardiovascular target. The substantial difference in binding affinity (-6.6 vs -4.9 kcal/mol) is a key factor.
Output:
1
2025-04-17 22:38:15,120 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [374.392, 84.73, 3.341, 2, 6, 0.784, 70.841, 56.611, -5.203, -4.257, 0.076, 20.879, 15.345, 0.04, -6.4]
**Ligand B:** [342.439, 78.43, 2.358, 3, 3, 0.603, 19.969, 42.497, -5.135, -2.689, 0.307, 43.417, 19.728, 0.198, -7.7]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (342.439 Da) is slightly lower, which *could* be beneficial for permeability, but both are acceptable.
2. **TPSA:** Both are below 140, good for oral absorption. Ligand B (78.43) is slightly better than Ligand A (84.73).
3. **logP:** Both are within the optimal 1-3 range. Ligand B (2.358) is a bit lower, which is generally preferable for avoiding off-target effects. Ligand A (3.341) is still acceptable.
4. **HBD:** Ligand A (2) is better than Ligand B (3). Lower is generally preferred.
5. **HBA:** Ligand A (6) is better than Ligand B (3). Lower is generally preferred.
6. **QED:** Ligand A (0.784) is better than Ligand B (0.603), indicating a more drug-like profile.
7. **DILI:** Ligand A (70.841) has a higher DILI risk than Ligand B (19.969). This is a significant concern for Ligand A.
8. **BBB:** Ligand A (56.611) has better BBB penetration than Ligand B (42.497). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant, and this is a positive for Ligand A.
9. **Caco-2:** Both have negative values, indicating good permeability. Ligand A (-5.203) is slightly better.
10. **Solubility:** Ligand B (-2.689) has better aqueous solubility than Ligand A (-4.257).
11. **hERG:** Ligand A (0.076) has a lower hERG risk than Ligand B (0.307). This is a positive for Ligand A.
12. **Cl_mic:** Ligand A (20.879) has lower microsomal clearance than Ligand B (43.417), suggesting better metabolic stability.
13. **t1/2:** Ligand B (19.728) has a longer in vitro half-life than Ligand A (15.345).
14. **Pgp:** Ligand A (0.04) has lower P-gp efflux than Ligand B (0.198).
15. **Affinity:** Ligand B (-7.7 kcal/mol) has a significantly better binding affinity than Ligand A (-6.4 kcal/mol). This is a >1.3 kcal/mol difference, which is substantial and can outweigh some ADME concerns.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B excels in affinity, has a good logP and TPSA, and acceptable Pgp efflux. While Ligand A has better BBB penetration and lower Pgp efflux, its significantly higher DILI risk is a major drawback. The improved affinity of Ligand B is a substantial advantage.
**Conclusion:**
Despite Ligand A's slightly better BBB penetration and metabolic stability, the significantly lower DILI risk and substantially improved binding affinity of Ligand B make it the more promising drug candidate. The affinity difference is large enough to compensate for the slightly less favorable ADME properties.
Output:
0
2025-04-17 22:38:15,120 - INFO - Reasoning:
Let's analyze Ligand A and Ligand B for their potential as ADRB2 ligands, keeping in mind the GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key).
**Molecular Weight:** Both ligands (346.475 and 353.463 Da) fall within the ideal 200-500 Da range.
**TPSA:** Ligand A (64.68) is significantly better than Ligand B (98.74). A TPSA under 140 is good for oral absorption, and lower is generally preferred for GPCRs, making A favorable.
**logP:** Ligand A (1.991) is within the optimal 1-3 range, while Ligand B (0.274) is slightly low, potentially hindering membrane permeability.
**H-Bond Donors/Acceptors:** Ligand A (2 HBD, 3 HBA) and Ligand B (3 HBD, 4 HBA) are both reasonable, staying within the suggested limits.
**QED:** Both ligands have acceptable QED values (0.757 and 0.638, both > 0.5).
**DILI:** Ligand A (11.322) has a much lower DILI risk than Ligand B (13.843), which is a significant advantage.
**BBB:** Ligand A (64.637) has better BBB penetration than Ligand B (41.218), though neither is exceptionally high. For a cardiovascular target, BBB isn't *critical*, but it's a bonus.
**Caco-2 Permeability:** Both have negative Caco-2 values (-5.039 and -5.158), which is unusual and suggests poor permeability. This is a concern for both.
**Aqueous Solubility:** Both have negative solubility values (-1.037 and -1.59), also unusual and concerning.
**hERG:** Ligand A (0.367) has a much lower hERG inhibition liability than Ligand B (0.066), a crucial safety parameter.
**Microsomal Clearance:** Ligand A (-11.254) has a significantly lower (better) microsomal clearance than Ligand B (12.646), indicating better metabolic stability.
**In vitro Half-Life:** Ligand A (2.476) has a slightly better in vitro half-life than Ligand B (1.949).
**P-gp Efflux:** Both have very low P-gp efflux liability (0.004 and 0.007).
**Binding Affinity:** Ligand B (-8.7 kcal/mol) has a substantially stronger binding affinity than Ligand A (-6.0 kcal/mol). This is a >1.5 kcal/mol difference, a significant advantage.
**Overall Assessment:**
Ligand B's significantly stronger binding affinity is a major positive. However, it is offset by its higher DILI risk, lower logP, higher TPSA, and higher hERG liability. Ligand A, while having weaker affinity, presents a much more favorable ADMET profile, particularly regarding safety (DILI, hERG) and metabolic stability (Cl_mic). Considering the balance, and the fact that a modest improvement in affinity can sometimes be achieved through further optimization, the superior ADMET properties of Ligand A make it the more promising drug candidate.
Output:
1
2025-04-17 22:38:15,121 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output:
**Ligand A: [370.362, 49.41, 3.26, 1, 2, 0.7, 33.812, 86.584, -4.603, -3.293, 0.649, 24.523, -15.846, 0.101, -7.8]**
**Ligand B: [360.845, 78.35, 2.472, 2, 5, 0.875, 55.68, 35.13, -5.282, -3.873, 0.412, 63.564, -7.602, 0.055, -6.8]**
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand B (360.845) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (49.41) is significantly better than Ligand B (78.35). A TPSA under 140 is good for oral absorption, but lower is better, especially for GPCRs. Ligand B's TPSA is approaching a level that could hinder absorption.
3. **logP:** Both ligands have good logP values (A: 3.26, B: 2.472) within the optimal 1-3 range.
4. **H-Bond Donors:** Both have acceptable HBD counts (A: 1, B: 2).
5. **H-Bond Acceptors:** Both have acceptable HBA counts (A: 2, B: 5). Ligand B is higher, but still within the reasonable limit of 10.
6. **QED:** Both ligands have good QED scores (A: 0.7, B: 0.875), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (33.812) has a much lower DILI risk than Ligand B (55.68). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (86.584) has a much higher BBB penetration percentile than Ligand B (35.13). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant, and higher BBB is generally preferred.
9. **Caco-2:** Ligand A (-4.603) is better than Ligand B (-5.282), indicating better intestinal absorption.
10. **Aqueous Solubility:** Both ligands have poor aqueous solubility (-3.293 and -3.873 respectively). This is a drawback for both, but not a deciding factor.
11. **hERG:** Both ligands have low hERG risk (A: 0.649, B: 0.412). Ligand B is slightly better.
12. **Cl_mic:** Ligand A (24.523) has a lower microsomal clearance than Ligand B (63.564), suggesting better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand A (-15.846) has a longer in vitro half-life than Ligand B (-7.602). This is a significant advantage.
14. **Pgp:** Ligand A (0.101) has lower P-gp efflux liability than Ligand B (0.055). Lower is better, and both are quite low.
15. **Binding Affinity:** Ligand A (-7.8) has a slightly better binding affinity than Ligand B (-6.8). While the difference is less than 1.5 kcal/mol, it contributes to the overall preference.
**Overall Assessment:**
Ligand A is significantly better overall. It has a much lower DILI risk, better BBB penetration, better metabolic stability (lower Cl_mic, longer t1/2), and slightly better binding affinity. While Ligand B has a slightly better QED and hERG profile, the advantages of Ligand A in safety (DILI) and pharmacokinetic properties (Cl_mic, t1/2, BBB) are more critical for a viable drug candidate, especially for a GPCR target. The TPSA is also significantly better for Ligand A.
Output:
1
2025-04-17 22:38:15,121 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (342.443 and 346.479 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (83.98) is slightly higher than Ligand B (68.09). Both are below the 140 threshold for good oral absorption, but B is better.
3. **logP:** Both ligands have very similar logP values (1.988 and 1.993), falling within the optimal 1-3 range.
4. **HBD:** Ligand A has 2 HBD, while Ligand B has 1. Both are within the acceptable limit of 5.
5. **HBA:** Ligand A has 4 HBA, while Ligand B has 7. Both are below the 10 limit, but A is better.
6. **QED:** Ligand A (0.857) has a significantly higher QED score than Ligand B (0.664), indicating a more drug-like profile.
7. **DILI:** Ligand A (47.77) has a higher DILI risk than Ligand B (25.553). B is clearly preferable here.
8. **BBB:** Ligand B (85.033) has a much higher BBB penetration percentile than Ligand A (54.246). Given that ADRB2 is a GPCR, BBB penetration is a desirable property, though not strictly essential for cardiovascular targets.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.012 and -4.991). These values are difficult to interpret without knowing the scale, but suggest poor permeability.
10. **Solubility:** Ligand A (-2.975) has slightly worse solubility than Ligand B (-1.575).
11. **hERG:** Ligand A (0.178) has a lower hERG inhibition liability than Ligand B (0.91). This is a significant advantage for A.
12. **Cl_mic:** Ligand A (16.356) has a higher microsomal clearance than Ligand B (10.832), indicating lower metabolic stability. B is preferable.
13. **t1/2:** Ligand B (-7.992) has a much longer in vitro half-life than Ligand A (-1.639). This is a significant advantage for B.
14. **Pgp:** Ligand A (0.067) has lower P-gp efflux liability than Ligand B (0.121). This is a slight advantage for A.
15. **Binding Affinity:** Ligand A (-8.3 kcal/mol) has a slightly better binding affinity than Ligand B (-7.0 kcal/mol). This is a substantial advantage for A.
**Overall Assessment:**
Ligand A has a better QED, hERG profile, Pgp efflux, and binding affinity. However, Ligand B excels in DILI risk, BBB penetration, metabolic stability (lower Cl_mic, longer t1/2), and solubility.
Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity), the stronger binding affinity of Ligand A is a major advantage. The difference in affinity (-8.3 vs -7.0) is significant and could outweigh some of the ADME drawbacks. While Ligand B has a better safety profile (DILI, hERG), the binding affinity is a critical factor for GPCRs. The slightly better BBB penetration of Ligand B is a bonus, but not decisive.
Therefore, I favor Ligand A.
Output:
1
2025-04-17 22:38:15,121 - INFO - Batch 346 complete. Total preferences: 5536
2025-04-17 22:38:15,121 - INFO - Processing batch 347/512...
2025-04-17 22:39:06,488 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [342.443, 90.01, 2.688, 2, 4, 0.81, 66.615, 53.587, -4.873, -3.832, 0.393, 64.41, -1.618, 0.155, -6.8]
**Ligand B:** [356.463, 104.73, 0.994, 3, 5, 0.563, 19.155, 50.679, -4.786, -2.285, 0.14, 63.617, -38.056, 0.038, -6]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity):
1. **MW:** Both are within the ideal 200-500 Da range. A (342.443) is slightly preferred.
2. **TPSA:** A (90.01) is better than B (104.73). Both are acceptable, but lower TPSA generally favors permeability.
3. **logP:** A (2.688) is optimal. B (0.994) is a bit low, potentially hindering membrane permeability. This is a significant drawback for a GPCR ligand.
4. **HBD/HBA:** A (2/4) is preferable to B (3/5). Lower counts are generally better for permeability.
5. **QED:** A (0.81) is much better than B (0.563), indicating a more drug-like profile.
6. **DILI:** B (19.155) is *significantly* better than A (66.615). This is a major advantage for B.
7. **BBB:** Both are around 50-53%, not ideal for a CNS-targeting GPCR, but acceptable for a peripheral target like ADRB2.
8. **Caco-2:** Both are very poor (-4.873 and -4.786). This is concerning for oral bioavailability.
9. **Solubility:** A (-3.832) is better than B (-2.285), though both are poor.
10. **hERG:** Both are low risk (0.393 and 0.14).
11. **Cl_mic:** Both are similar (64.41 and 63.617), suggesting comparable metabolic stability.
12. **t1/2:** A (-1.618) is better than B (-38.056), indicating a longer half-life, which is desirable.
13. **Pgp:** A (0.155) is better than B (0.038), meaning less P-glycoprotein efflux and potentially better bioavailability.
14. **Affinity:** A (-6.8) is slightly better than B (-6.0), but the difference is relatively small.
**Overall Assessment:**
Ligand A has a better overall profile, despite the DILI risk. The superior logP, TPSA, QED, Pgp, and half-life outweigh the higher DILI risk, especially considering the relatively modest difference in binding affinity. The poor Caco-2 values are a concern for both, but can potentially be addressed with formulation strategies. Ligand B's low logP is a significant issue for a GPCR ligand, potentially hindering its ability to reach the receptor. The lower DILI risk is attractive, but not enough to compensate for the other deficiencies.
Output:
1
2025-04-17 22:39:06,488 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [374.442, 118.87 , -0.45 , 2. , 7. , 0.667, 63.513, 77.007, -5.548, -1.981, 0.036, 7.841, -18.846, 0.091, -7. ]
**Ligand B:** [343.475, 64.86 , 4.237, 1. , 6. , 0.654, 56.921, 66.731, -5.076, -4.169, 0.547, 63.748, 17.643, 0.626, -5.9 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (343.475) is slightly lower, which could be beneficial for permeability, but both are acceptable.
2. **TPSA:** Ligand A (118.87) is higher than Ligand B (64.86). For a GPCR, lower TPSA is generally preferred for better brain penetration if CNS activity is desired, and overall better absorption. Ligand B is significantly better here.
3. **logP:** Ligand A (-0.45) is lower than the optimal range (1-3), which could hinder permeability. Ligand B (4.237) is above the optimal range and could lead to solubility issues and off-target effects, but is still within a reasonable range.
4. **HBD:** Both ligands have acceptable HBD counts (2 and 1, respectively), well below the threshold of 5.
5. **HBA:** Both ligands have acceptable HBA counts (7 and 6, respectively), well below the threshold of 10.
6. **QED:** Both have similar, good QED values (0.667 and 0.654), indicating good drug-like properties.
7. **DILI:** Ligand A (63.513) has a slightly higher DILI risk than Ligand B (56.921), but both are reasonably acceptable.
8. **BBB:** Ligand A (77.007) has a better BBB penetration percentile than Ligand B (66.731). This is a significant advantage for a GPCR target, even if it's not specifically a CNS target, as it suggests better distribution.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual. Assuming these are logP-scaled values, lower values indicate lower permeability. They are similar in this regard.
10. **Solubility:** Ligand A (-1.981) has better solubility than Ligand B (-4.169).
11. **hERG:** Ligand A (0.036) has a much lower hERG inhibition liability than Ligand B (0.547). This is a crucial safety parameter, and Ligand A is significantly better.
12. **Cl_mic:** Ligand B (63.748) has a lower microsomal clearance than Ligand A (7.841), indicating better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand B (17.643) has a much longer in vitro half-life than Ligand A (-18.846). This is a major advantage, potentially leading to less frequent dosing.
14. **Pgp:** Ligand A (0.091) has lower P-gp efflux liability than Ligand B (0.626), which is favorable for bioavailability.
15. **Affinity:** Ligand A (-7.0) and Ligand B (-5.9) both have good binding affinities, but Ligand A is substantially better (-1.1 kcal/mol difference). This is a significant advantage that can outweigh some ADME drawbacks.
**Overall Assessment:**
While Ligand B has better metabolic stability and half-life, Ligand A has a significantly better binding affinity, lower hERG risk, better BBB penetration, and better solubility. For a GPCR, the binding affinity is paramount, and the lower hERG risk is critical for safety. The slightly higher TPSA of Ligand A is less concerning than the higher logP of Ligand B. The better BBB penetration of Ligand A is also a plus.
Therefore, I would rank Ligand A as the more promising drug candidate.
**Output:**
1
2025-04-17 22:39:06,488 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.46 and 346.43 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (80.32 and 78.87) are below the 140 A^2 threshold for good oral absorption, and acceptable for a cardiovascular GPCR. Again, no major difference.
3. **logP:** Both ligands (2.14 and 1.848) are within the optimal 1-3 range. Ligand A is slightly higher, which could be marginally better for membrane permeability, but the difference is small.
4. **HBD:** Both ligands have 2 H-bond donors, which is within the acceptable limit of <=5.
5. **HBA:** Both ligands have 4 H-bond acceptors, also within the acceptable limit of <=10.
6. **QED:** Both ligands have good QED scores (0.755 and 0.824), indicating good drug-like properties. Ligand B is slightly better here.
7. **DILI:** Ligand B (23.5%) has a significantly lower DILI risk than Ligand A (31.7%). This is a crucial advantage, as minimizing liver toxicity is paramount.
8. **BBB:** Both ligands have reasonable BBB penetration (70.9% and 63.9%). While ADRB2 isn't a CNS target, some degree of BBB penetration isn't necessarily detrimental and could allow for off-target effects to be assessed. Ligand A is slightly better here.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.531 and -4.767). These values are difficult to interpret without knowing the scale, but negative values generally suggest poor permeability. However, these values are close enough that they don't strongly influence the decision.
10. **Solubility:** Both ligands have negative solubility values (-2.823 and -3.681). Similar to Caco-2, these values are difficult to interpret, but suggest poor solubility. Ligand B is slightly better.
11. **hERG:** Both ligands have low hERG inhibition liability (0.49 and 0.379), which is good. Ligand B is slightly better.
12. **Cl_mic:** Ligand B (46.8) has a lower microsomal clearance than Ligand A (61.2), suggesting better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand B (-18.174) has a longer in vitro half-life than Ligand A (-12.582), indicating slower metabolism and potentially less frequent dosing. This is another significant advantage.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.167 and 0.075). Ligand B is better.
15. **Binding Affinity:** Ligand A (-6.2 kcal/mol) has a stronger binding affinity than Ligand B (-2.4 kcal/mol). This is a substantial difference, and a significant advantage for Ligand A. However, the other ADME properties of Ligand B are much more favorable.
**Overall Assessment:**
While Ligand A has a significantly better binding affinity, Ligand B demonstrates a superior ADME profile, particularly regarding DILI risk, metabolic stability (Cl_mic and t1/2), and Pgp efflux. For a cardiovascular GPCR target, a slightly lower binding affinity can be tolerated if it means a safer and more bioavailable drug. The lower DILI risk and improved metabolic stability of Ligand B are crucial factors.
**Output:**
0
2025-04-17 22:39:06,488 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (a cardiovascular GPCR) drug candidates.
**Ligand A:** [350.419, 113.44 , 0.115, 3. , 6. , 0.671, 49.011, 43.66 , -5.249, -1.391, 0.158, -4.236, 26.75 , 0.016, -4.1 ]
**Ligand B:** [348.374, 82.78 , 3.312, 2. , 4. , 0.785, 52.191, 44.668, -4.975, -3.91 , 0.718, 51.401, 24.205, 0.129, -5.9 ]
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). A is 350.419, B is 348.374 - very similar.
2. **TPSA:** Ligand A (113.44) is slightly above the preferred <140 for oral absorption, but still reasonable. Ligand B (82.78) is excellent, well below 100, suggesting better permeability.
3. **logP:** Ligand A (0.115) is quite low, potentially hindering membrane permeability. Ligand B (3.312) is within the optimal 1-3 range. This is a significant advantage for B.
4. **HBD:** Ligand A (3) is acceptable. Ligand B (2) is also good.
5. **HBA:** Ligand A (6) is acceptable. Ligand B (4) is also good.
6. **QED:** Both ligands have good QED scores (A: 0.671, B: 0.785), indicating drug-likeness. B is slightly better.
7. **DILI:** Both ligands have acceptable DILI risk (A: 49.011, B: 52.191), below the 60 threshold.
8. **BBB:** Both have similar BBB penetration (A: 43.66, B: 44.668). Not a primary concern for a cardiovascular target, but higher is generally better.
9. **Caco-2:** Ligand A (-5.249) is very poor, indicating very low intestinal absorption. Ligand B (-4.975) is also poor, but slightly better than A.
10. **Solubility:** Ligand A (-1.391) is poor. Ligand B (-3.91) is even worse. Both are problematic.
11. **hERG:** Both ligands have very low hERG risk (A: 0.158, B: 0.718), which is excellent.
12. **Cl_mic:** Ligand A (-4.236) has a lower (better) microsomal clearance than Ligand B (51.401), suggesting better metabolic stability.
13. **t1/2:** Ligand A (26.75) has a longer half-life than Ligand B (24.205).
14. **Pgp:** Both ligands have low P-gp efflux (A: 0.016, B: 0.129).
15. **Affinity:** Ligand B (-5.9) has a significantly stronger binding affinity than Ligand A (-4.1) - a difference of 1.8 kcal/mol. This is a substantial advantage.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, and affinity are key. Ligand B excels in logP and has a much better binding affinity. While Ligand A has better metabolic stability (Cl_mic), the significantly stronger binding of Ligand B and its more favorable logP outweigh this benefit. The poor solubility and Caco-2 values are concerning for both, but can potentially be addressed with formulation strategies.
**Conclusion:**
Ligand B is the more promising candidate due to its superior binding affinity and logP, both critical for GPCR targets.
```
0
```
2025-04-17 22:39:06,489 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [342.527, 41.13, 4.697, 2, 1, 0.748, 24.932, 91.819, -4.505, -4.889, 0.83, 79.903, 45.557, 0.642, -2.2]
**Ligand B:** [358.467, 97.11, 2.505, 3, 5, 0.732, 76.89, 56.805, -5.533, -4.309, 0.58, 5.615, 24.399, 0.168, -6.4]
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). A (342.5) is slightly preferred.
2. **TPSA:** A (41.13) is excellent, well below the 140 threshold. B (97.11) is higher, but still acceptable, though less favorable for oral absorption.
3. **logP:** A (4.697) is a bit high, potentially leading to solubility issues or off-target interactions. B (2.505) is within the optimal range (1-3). B is better here.
4. **HBD:** A (2) is good. B (3) is acceptable.
5. **HBA:** A (1) is excellent. B (5) is acceptable, but higher. A is better.
6. **QED:** Both are very similar (A: 0.748, B: 0.732), indicating good drug-like properties.
7. **DILI:** A (24.932) is significantly better (lower risk) than B (76.89). This is a major advantage for A.
8. **BBB:** A (91.819) is excellent, suggesting good potential for CNS penetration if desired (though less critical for a cardiovascular target, it's not detrimental). B (56.805) is lower.
9. **Caco-2:** Both are negative, indicating poor permeability. A (-4.505) is slightly better than B (-5.533).
10. **Solubility:** Both are negative, suggesting poor solubility. A (-4.889) is slightly better than B (-4.309).
11. **hERG:** A (0.83) is better than B (0.58), indicating lower cardiotoxicity risk.
12. **Cl_mic:** A (79.903) is much higher than B (5.615), meaning faster clearance and lower metabolic stability. B is significantly better.
13. **t1/2:** A (45.557) is better than B (24.399), indicating a longer half-life.
14. **Pgp:** A (0.642) is better than B (0.168), suggesting lower P-gp efflux.
15. **Affinity:** B (-6.4) is significantly better than A (-2.2). This is a substantial advantage, potentially outweighing some ADME concerns.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, Pgp, TPSA, and affinity. B has a better logP, and significantly better affinity. A has better TPSA and Pgp.
**Overall Assessment:**
While Ligand A has a better safety profile (lower DILI, better hERG) and some favorable ADME properties (BBB, Pgp, t1/2), Ligand B's *much* stronger binding affinity (-6.4 vs -2.2 kcal/mol) is a decisive factor. A 4.2 kcal/mol difference in binding is substantial. The improved affinity is likely to translate to greater efficacy at lower doses, potentially mitigating some of the ADME liabilities. The metabolic stability of B is also significantly better.
Therefore, I believe Ligand B is the more promising drug candidate.
0
2025-04-17 22:39:06,489 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (345.531 Da and 348.447 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (35.58) is significantly lower than Ligand B (96.11). For a GPCR, lower TPSA is generally preferred as it correlates with better membrane permeability. Ligand B is quite high, potentially hindering absorption.
**3. logP:** Ligand A (3.379) is within the optimal 1-3 range. Ligand B (1.728) is on the lower end, potentially leading to permeability issues.
**4. H-Bond Donors:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
**5. H-Bond Acceptors:** Ligand A (3) is preferable to Ligand B (4). Fewer HBAs generally improve permeability.
**6. QED:** Ligand A (0.784) has a better QED score than Ligand B (0.654), indicating a more drug-like profile.
**7. DILI:** Ligand B (58.162) has a lower DILI risk than Ligand A (5.428), which is a positive. However, both are below the concerning threshold of 60.
**8. BBB:** Ligand A (80.729) has significantly better BBB penetration potential than Ligand B (35.44). While ADRB2 isn't a CNS target, some degree of BBB penetration can be beneficial for overall distribution and avoiding off-target effects.
**9. Caco-2 Permeability:** Ligand A (-5.007) has a better Caco-2 permeability score than Ligand B (-4.704), suggesting better intestinal absorption.
**10. Aqueous Solubility:** Ligand B (-3.317) has better aqueous solubility than Ligand A (-1.695). Solubility is important for formulation.
**11. hERG Inhibition:** Ligand A (0.957) has a lower hERG inhibition liability than Ligand B (0.318), which is a significant advantage for cardiovascular safety.
**12. Microsomal Clearance:** Ligand A (-20.725) has significantly lower microsomal clearance than Ligand B (37.124), indicating better metabolic stability.
**13. In vitro Half-Life:** Ligand B (-28.386) has a longer in vitro half-life than Ligand A (11.766), which is a positive.
**14. P-gp Efflux:** Ligand A (0.085) has lower P-gp efflux liability than Ligand B (0.124), which is favorable for bioavailability.
**15. Binding Affinity:** Both ligands have very similar binding affinities (-6.8 and -6.9 kcal/mol). The difference is negligible.
**Overall Assessment:**
Ligand A is clearly superior. It excels in key ADME properties (TPSA, logP, HBD/HBA, QED, permeability, metabolic stability, P-gp efflux, and hERG) that are crucial for oral bioavailability and safety, particularly for a GPCR target. While Ligand B has slightly better solubility and half-life, the benefits of Ligand A across multiple critical parameters outweigh these advantages. The similar binding affinity further solidifies the preference for Ligand A.
Output:
1
2025-04-17 22:39:06,489 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for the ADRB2, a cardiovascular GPCR. Therefore, the key properties to prioritize are binding affinity, logP, TPSA, Pgp efflux, and BBB penetration.
Let's compare the ligands property by property:
1. **MW:** Both ligands (342.403 and 352.45 Da) fall within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (89.08) is slightly higher than Ligand B (71.34), but both are below the 140 threshold for good absorption. Ligand B is preferable here.
3. **logP:** Ligand A (1.936) is within the optimal 1-3 range. Ligand B (3.385) is at the upper end, potentially raising concerns about solubility and off-target effects, but still acceptable. Ligand A is preferable.
4. **HBD:** Ligand A (1) is better than Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (7) is higher than Ligand B (3). Lower HBA is preferable. Ligand B is preferable.
6. **QED:** Ligand A (0.835) is better than Ligand B (0.753), indicating a more drug-like profile.
7. **DILI:** Ligand A (61.303) has a higher DILI risk than Ligand B (38.852). Ligand B is preferable.
8. **BBB:** Both ligands have good BBB penetration (A: 87.088, B: 86.778). This is less critical for a cardiovascular target, but still a positive.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
10. **Solubility:** Ligand A (-2.217) has better solubility than Ligand B (-4.187).
11. **hERG:** Both ligands have low hERG inhibition risk (A: 0.407, B: 0.571).
12. **Cl_mic:** Ligand A (-12.241) has significantly lower (better) microsomal clearance than Ligand B (68.125), indicating better metabolic stability.
13. **t1/2:** Ligand A (36.913) has a longer half-life than Ligand B (28.947).
14. **Pgp:** Ligand A (0.119) has lower Pgp efflux than Ligand B (0.49), which is favorable for bioavailability.
15. **Affinity:** Ligand A (-8.1 kcal/mol) has a significantly stronger binding affinity than Ligand B (-5.9 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME concerns.
**Overall Assessment:**
Ligand A has a significantly better binding affinity and superior metabolic stability (lower Cl_mic, longer t1/2) and Pgp efflux. While Ligand B has a slightly better TPSA and DILI risk, the substantial affinity advantage of Ligand A, combined with its acceptable ADME properties, makes it the more promising drug candidate. The better solubility of Ligand A is also a plus.
**Output:**
1
2025-04-17 22:39:06,489 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (407.312 Da) is within the ideal range, while Ligand B (367.559 Da) is also acceptable. No clear advantage here.
2. **TPSA:** Both ligands (A: 67.35, B: 69.22) are below the 140 threshold for oral absorption, which is good. They are also reasonably low for a GPCR.
3. **logP:** Ligand A (2.163) is optimal, while Ligand B (3.239) is slightly higher but still within the acceptable range. Ligand A has a slight advantage.
4. **HBD:** Ligand A (1) is good, and Ligand B (2) is also acceptable.
5. **HBA:** Ligand A (5) is good, and Ligand B (4) is also acceptable.
6. **QED:** Both ligands (A: 0.733, B: 0.703) have excellent drug-likeness scores.
7. **DILI:** Ligand A (43.35) has a slightly higher DILI risk than Ligand B (31.601), but both are below the concerning threshold of 60. Ligand B is preferable here.
8. **BBB:** Ligand A (80.535) has significantly better BBB penetration potential than Ligand B (42.148). This is a crucial advantage for a GPCR target, even if it's not strictly a CNS target, as it can influence off-target effects and distribution.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.109 and -5.065), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Both ligands have negative solubility values (-3.028 and -3.433), indicating very poor aqueous solubility. This is a major drawback for both compounds.
11. **hERG:** Both ligands have low hERG inhibition liability (A: 0.596, B: 0.408), which is good. Ligand B is slightly better.
12. **Cl_mic:** Ligand A (47.239) has lower microsomal clearance than Ligand B (68.554), suggesting better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand A (27.483) has a longer in vitro half-life than Ligand B (-0.438). This is a substantial advantage.
14. **Pgp:** Ligand A (0.059) has much lower P-gp efflux liability than Ligand B (0.342), which is favorable for bioavailability and potentially CNS exposure.
15. **Binding Affinity:** Ligand B (-6.6 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.2 kcal/mol). This is a very important advantage, exceeding the 1.5 kcal/mol threshold.
**Overall Assessment:**
Ligand B has a superior binding affinity, lower DILI risk, and slightly better hERG profile. However, Ligand A demonstrates better BBB penetration, metabolic stability (lower Cl_mic), longer half-life, and lower P-gp efflux. The poor Caco-2 and solubility for both are concerning and would require formulation strategies.
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), the stronger affinity of Ligand B is a key driver. While Ligand A's better ADME properties are attractive, the substantial binding affinity advantage of Ligand B outweighs these concerns, especially given that formulation strategies can be explored to address the solubility and permeability issues.
Output:
0
2025-04-17 22:39:06,490 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (359.442 and 363.483 Da) are within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand B (75.44) is significantly better than Ligand A (93.11). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (2.953) is optimal, while Ligand A (-0.485) is quite low, potentially hindering membrane permeability. This is a significant advantage for B.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (1), but both are acceptable (<=5).
5. **HBA:** Both ligands have 5 HBA, which is within the acceptable range.
6. **QED:** Ligand B (0.782) is better than Ligand A (0.595), indicating a more drug-like profile.
7. **DILI:** Ligand A (13.804) has a much lower DILI risk than Ligand B (50.446). This is a major advantage for A.
8. **BBB:** Ligand B (71.19) is higher than Ligand A (23.42), but since this is a cardiovascular target, BBB penetration is not critical.
9. **Caco-2:** Both ligands have similar, very negative Caco-2 values (-5.141 and -5.103). This suggests poor permeability for both, but the scale is unclear.
10. **Solubility:** Ligand A (-0.471) is slightly better than Ligand B (-2.403), but both are poor.
11. **hERG:** Ligand A (0.248) has a lower hERG risk than Ligand B (0.528), which is preferable.
12. **Cl_mic:** Ligand A (-6.475) has a much lower (better) microsomal clearance than Ligand B (87.92). This indicates greater metabolic stability for A.
13. **t1/2:** Ligand B (8.008) has a longer half-life than Ligand A (1.659). This is a positive for B.
14. **Pgp:** Ligand A (0.022) has a much lower P-gp efflux liability than Ligand B (0.272), which is beneficial for bioavailability.
15. **Binding Affinity:** Ligand B (-7.5) has a significantly stronger binding affinity than Ligand A (-5.9). This is a substantial advantage for B, potentially outweighing some ADME concerns.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP and affinity, while Ligand A has better Pgp and a lower DILI score. The affinity difference (-7.5 vs -5.9) is significant.
**Overall Assessment:**
While Ligand A has advantages in DILI, Cl_mic, Pgp, and hERG, the substantially stronger binding affinity of Ligand B (-7.5 kcal/mol) is a critical factor for a GPCR target. The improved logP and QED of Ligand B also contribute to its potential as a drug candidate. The lower solubility and higher DILI risk of Ligand B are concerns, but could potentially be addressed through formulation or further structural modifications. The affinity difference is large enough to prioritize Ligand B.
Output:
0
2025-04-17 22:39:06,490 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (365.861 Da and 372.481 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (61.88) is slightly higher than Ligand B (49.41). Both are below the 140 A^2 threshold for good oral absorption, but Ligand B is better positioned, particularly for potential CNS penetration (though less critical for a cardiovascular target).
**3. logP:** Ligand A (2.371) is within the optimal 1-3 range. Ligand B (3.798) is pushing the upper limit, potentially raising concerns about solubility and off-target effects, but still acceptable.
**4. H-Bond Donors:** Both have 1 HBD, which is good.
**5. H-Bond Acceptors:** Ligand A has 3 HBAs, Ligand B has 2. Both are within the acceptable limit of 10.
**6. QED:** Both ligands have similar QED values (0.894 and 0.826), indicating good drug-like properties.
**7. DILI Risk:** Ligand A (33.152) has a slightly lower DILI risk than Ligand B (40.713), which is preferable. Both are below the concerning threshold of 60.
**8. BBB Penetration:** Ligand B (90.229) shows significantly better BBB penetration than Ligand A (77.162). While ADRB2 is primarily a cardiovascular target, some CNS effects are possible with certain ligands, and higher BBB penetration could be a benefit or a liability depending on the desired pharmacological profile.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.523) is slightly worse than Ligand B (-4.908). This is a significant drawback for both.
**10. Aqueous Solubility:** Ligand A (-2.627) has better aqueous solubility than Ligand B (-4.597). This is a positive for Ligand A, especially given the potential logP issues with Ligand B.
**11. hERG Inhibition:** Ligand A (0.581) has a lower hERG inhibition risk than Ligand B (0.921), which is crucial for cardiovascular drugs.
**12. Microsomal Clearance:** Ligand A (-12.153) exhibits significantly lower microsomal clearance than Ligand B (32.013), indicating better metabolic stability. This is a major advantage for Ligand A.
**13. In vitro Half-Life:** Ligand A (2.39) has a shorter half-life than Ligand B (-2.39). This is a negative for Ligand A.
**14. P-gp Efflux:** Ligand A (0.082) shows lower P-gp efflux than Ligand B (0.377), which is desirable for better bioavailability.
**15. Binding Affinity:** Both ligands have excellent binding affinities (-7.0 and -3.7 kcal/mol respectively). Ligand A is significantly more potent. The >1.5 kcal/mol difference in affinity is a substantial advantage that can outweigh some ADME drawbacks.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), and the overall profile, **Ligand A is the more promising candidate.** The significantly stronger binding affinity (-7 kcal/mol vs -3.7 kcal/mol) is a major driver. While Ligand B has better BBB penetration and a slightly better half-life, Ligand A compensates with lower DILI risk, better solubility, lower hERG inhibition, and significantly improved metabolic stability (lower Cl_mic). The Caco-2 permeability is poor for both, but the superior potency and safety profile of Ligand A make it the better choice for further optimization.
Output:
1
2025-04-17 22:39:06,490 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (356.442 and 357.34 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (78.27) is better than Ligand B (81.73). Both are below 140, but lower TPSA is favored for permeability.
3. **logP:** Ligand B (1.399) is slightly better than Ligand A (1.905), both are within the optimal 1-3 range.
4. **HBD:** Ligand A (1) is better than Ligand B (0). While both are acceptable, a single HBD can sometimes improve solubility without drastically impacting permeability.
5. **HBA:** Both ligands have 7 HBA, which is acceptable.
6. **QED:** Ligand B (0.808) is significantly better than Ligand A (0.538), indicating a more drug-like profile.
7. **DILI:** Ligand A (28.306) is much better than Ligand B (69.135). This is a crucial factor, as lower DILI risk is highly desirable. Ligand B's DILI is concerningly high.
8. **BBB:** Both ligands have similar BBB penetration (72.896 and 72.315). This is less critical for ADRB2, which is not a CNS target.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.674 and -4.869). These values are unusual and suggest poor permeability.
10. **Solubility:** Both ligands have negative solubility values (-2.041 and -2.301). These values are also unusual and suggest poor solubility.
11. **hERG:** Ligand B (0.092) is better than Ligand A (0.49). Lower hERG inhibition is preferred.
12. **Cl_mic:** Ligand B (15.383) is much better than Ligand A (30.178). Lower clearance indicates better metabolic stability.
13. **t1/2:** Ligand A (9.235) is better than Ligand B (-19.199). A positive half-life is preferable.
14. **Pgp:** Ligand B (0.032) is better than Ligand A (0.102). Lower P-gp efflux is favorable for bioavailability.
15. **Affinity:** Ligand A (-7.8) has a significantly better binding affinity than Ligand B (-5.9). This is a >1.5 kcal/mol advantage, which can outweigh some ADME drawbacks.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand A has better TPSA, and a significantly better affinity. Ligand B has better logP and Pgp. However, the high DILI risk of Ligand B is a major concern.
**Overall Assessment:**
Despite Ligand B's better QED, logP, Pgp, and Cl_mic, the significantly higher DILI risk and worse half-life are major drawbacks. Ligand A's superior binding affinity and much lower DILI risk are more important considerations, especially given the potential for serious liver toxicity. The negative Caco-2 and solubility values are concerning for both, but can potentially be addressed through formulation strategies.
Output:
1
2025-04-17 22:39:06,490 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (355.438) is slightly higher than Ligand B (341.415), but both are acceptable.
2. **TPSA:** Ligand A (58.64) is excellent, well below the 140 threshold for oral absorption and suitable for a GPCR. Ligand B (80.12) is still reasonable but less optimal.
3. **logP:** Ligand A (4.295) is a bit high, potentially leading to solubility issues or off-target interactions. Ligand B (1.47) is well within the optimal range. This is a significant advantage for Ligand B.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 5. Both are acceptable.
6. **QED:** Ligand B (0.913) has a much better QED score than Ligand A (0.612), indicating a more drug-like profile.
7. **DILI:** Ligand A (71.152) has a higher DILI risk than Ligand B (47.77). This is a clear advantage for Ligand B.
8. **BBB:** Both ligands have good BBB penetration (Ligand A: 69.523, Ligand B: 67.119). While not CNS-focused, some degree of BBB penetration can be beneficial for distribution.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual. Assuming these are percentile scores, it suggests poor permeability for both.
10. **Solubility:** Ligand A (-4.798) has very poor solubility, likely due to its high logP. Ligand B (-1.322) is better, but still not great.
11. **hERG:** Ligand A (0.624) has a slightly higher hERG risk than Ligand B (0.253).
12. **Cl_mic:** Ligand B (-2.953) has significantly better metabolic stability (lower clearance) than Ligand A (80.834).
13. **t1/2:** Ligand B (-8.5) has a much longer in vitro half-life than Ligand A (0.995).
14. **Pgp:** Ligand A (0.885) has higher P-gp efflux liability than Ligand B (0.03).
15. **Affinity:** Ligand A (-6.7 kcal/mol) has a slightly better binding affinity than Ligand B (-5.4 kcal/mol). However, the difference (1.3 kcal/mol) isn't large enough to overcome the substantial ADME deficiencies of Ligand A.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are crucial. Ligand B excels in logP, TPSA, and Pgp, while Ligand A has a slightly better affinity. However, the poor solubility, high DILI risk, and poor metabolic stability of Ligand A are major drawbacks.
**Conclusion:**
Despite the slightly weaker binding affinity, Ligand B is the more promising drug candidate. Its superior ADME properties (better logP, QED, DILI, metabolic stability, half-life, and Pgp efflux) outweigh the small difference in binding affinity. The poor solubility and high DILI risk of Ligand A are significant concerns that would likely hinder its development.
Output:
0
2025-04-17 22:39:06,490 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (351-352 Da). No significant difference.
2. **TPSA:** Ligand B (58.64) is significantly better than Ligand A (109.14). Lower TPSA generally improves permeability, crucial for GPCRs.
3. **logP:** Ligand B (2.072) is optimal, while Ligand A (0.308) is quite low, potentially hindering membrane permeability. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (1), but both are acceptable.
5. **HBA:** Ligand A (6) is higher than Ligand B (3), but both are within the acceptable range.
6. **QED:** Both ligands have good QED scores (0.624 and 0.771), indicating good drug-likeness. Ligand B is slightly better.
7. **DILI:** Ligand B (21.404) has a much lower DILI risk than Ligand A (32.726). This is a major advantage for Ligand B.
8. **BBB:** Ligand B (95.657) has excellent BBB penetration, while Ligand A (25.824) is poor. While ADRB2 isn't exclusively a CNS target, some cardiovascular effects are mediated through CNS pathways, and better BBB penetration can be beneficial.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the magnitude of the value for Ligand A (-5.291) is worse than Ligand B (-4.497).
10. **Solubility:** Ligand A (-1.24) has better aqueous solubility than Ligand B (-2.96).
11. **hERG:** Ligand B (0.665) has a higher hERG risk than Ligand A (0.03). This is a significant concern for Ligand B.
12. **Cl_mic:** Ligand A (-3.79) has a lower (better) microsomal clearance than Ligand B (22.35). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (-9.001) has a longer in vitro half-life than Ligand B (-7.957).
14. **Pgp:** Ligand A (0.02) has lower P-gp efflux liability than Ligand B (0.134), which is favorable.
15. **Affinity:** Ligand A (-6.2 kcal/mol) and Ligand B (-5.8 kcal/mol) have similar binding affinities, with Ligand A being slightly better.
**Overall Assessment:**
Ligand B has a superior profile regarding key GPCR properties like TPSA, logP, and BBB penetration, and a significantly lower DILI risk. While its hERG inhibition is a concern, the other advantages outweigh this. Ligand A has better metabolic stability (Cl_mic, t1/2) and lower hERG, but its poor logP and TPSA are major drawbacks for a GPCR target. The slightly better affinity of Ligand A isn't enough to compensate for these ADME deficiencies.
Output:
0
2025-04-17 22:39:06,490 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (341.419 Da and 345.491 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (100.27) is higher than Ligand B (70.15). For a cardiovascular GPCR, TPSA is moderately important. Lower is generally better for permeability, and Ligand B has a more favorable TPSA.
**3. logP:** Ligand B (3.198) is higher than Ligand A (1.004). While both are within the acceptable range, Ligand B is closer to the optimal 1-3 range, and A is a bit low, potentially hindering membrane permeability.
**4. H-Bond Donors:** Both ligands have 2 HBD, which is well within the acceptable limit of <=5.
**5. H-Bond Acceptors:** Ligand A has 7 HBA, while Ligand B has 5. Both are below the limit of <=10.
**6. QED:** Both ligands have good QED scores (0.808 and 0.828), indicating good drug-like properties.
**7. DILI Risk:** Ligand B (37.456) has a lower DILI risk than Ligand A (51.648), which is a significant advantage. Lower DILI is always preferred.
**8. BBB Penetration:** Ligand B (88.29) shows significantly better BBB penetration than Ligand A (57.425). While ADRB2 is primarily a cardiovascular target, some CNS side effects are possible with GPCR modulation, and better BBB penetration could contribute to this.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-5.472) is slightly worse than Ligand B (-5.059).
**10. Aqueous Solubility:** Both ligands have negative solubility values, indicating poor aqueous solubility. Ligand A (-2.415) is slightly better than Ligand B (-3.586).
**11. hERG Inhibition:** Ligand A (0.249) has a lower hERG inhibition risk than Ligand B (0.698), which is a positive attribute.
**12. Microsomal Clearance:** Ligand B (67.375) has a higher microsomal clearance than Ligand A (29.506), meaning it's metabolized faster. Ligand A has better metabolic stability.
**13. In vitro Half-Life:** Ligand A (5.132 hours) has a longer half-life than Ligand B (1.212 hours). This is a significant advantage, potentially allowing for less frequent dosing.
**14. P-gp Efflux:** Ligand A (0.009) shows very low P-gp efflux, while Ligand B (0.152) has slightly higher efflux. Lower P-gp efflux is preferred for better bioavailability.
**15. Binding Affinity:** Ligand B (-6.1 kcal/mol) has a slightly better binding affinity than Ligand A (-6.8 kcal/mol). The difference is 0.7 kcal/mol, which is a meaningful advantage.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand B appears to be the better candidate. While Ligand A has advantages in metabolic stability (Cl_mic, t1/2), P-gp efflux, and hERG inhibition, Ligand B's superior logP, lower DILI risk, and better BBB penetration, combined with only a slightly weaker binding affinity, outweigh these drawbacks. The higher affinity of Ligand B is also a significant factor. The poor Caco-2 and solubility for both are concerning, but can be addressed with formulation strategies.
Output:
0
2025-04-17 22:39:06,491 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (362.832 and 351.535 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (41.57) is better than Ligand B (52.65). Both are below the 140 threshold for oral absorption, but lower is preferred for GPCRs.
3. **logP:** Both ligands have good logP values (3.169 and 2.364), falling within the 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Both have 1 HBD, which is within the acceptable limit of 5.
5. **HBA:** Both have 3 HBA, also within the acceptable limit of 10.
6. **QED:** Ligand A (0.888) has a better QED score than Ligand B (0.766), indicating a more drug-like profile.
7. **DILI:** Ligand B (5.118) has a significantly lower DILI risk than Ligand A (52.423). This is a major advantage for Ligand B.
8. **BBB:** Both ligands have high BBB penetration (87.515 and 81.97), which is good, but not a primary concern for ADRB2 (a cardiovascular target).
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.743 and -4.682). This is unusual and indicates poor permeability.
10. **Solubility:** Ligand A (-3.965) has slightly better solubility than Ligand B (-2.064), but both are quite poor.
11. **hERG:** Both ligands have low hERG inhibition risk (0.799 and 0.526).
12. **Cl_mic:** Ligand B (39.041) has a lower microsomal clearance than Ligand A (43.597), suggesting better metabolic stability.
13. **t1/2:** Ligand A (11.428) has a longer in vitro half-life than Ligand B (-10.475). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.229) has lower P-gp efflux than Ligand B (0.087), suggesting better bioavailability.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-5.9 and -5.7 kcal/mol). The difference is not substantial enough to be a deciding factor.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand A initially appears slightly better due to its higher logP, lower Pgp efflux, and better TPSA. However, the significantly lower DILI risk of Ligand B is a crucial factor. The longer half-life of Ligand A is also attractive. The poor Caco-2 values for both are concerning, but can be addressed with formulation strategies. Given the importance of minimizing liver toxicity in drug development, and the relatively similar binding affinities, I would prioritize Ligand B.
Output:
0
2025-04-17 22:39:06,491 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (340.47 and 339.36 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (49.41) is significantly better than Ligand B (92.02). ADRB2 is a cardiovascular target, not CNS, but lower TPSA generally improves absorption. Ligand A is well below the 140 threshold, while Ligand B is approaching it.
3. **logP:** Ligand A (3.325) is optimal, while Ligand B (1.8) is on the lower side. For a GPCR, a logP between 1-3 is preferred, and A is closer to the upper end of that range, which is beneficial for membrane permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (0). While both are low, having one H-bond donor can improve solubility without significantly impacting permeability.
5. **HBA:** Ligand B (8) is better than Ligand A (2). While both are within the acceptable range, fewer HBA can be advantageous for permeability.
6. **QED:** Ligand A (0.855) has a substantially better QED score than Ligand B (0.606), indicating a more drug-like profile.
7. **DILI:** Ligand A (25.13) has a much lower DILI risk than Ligand B (80.34). This is a critical advantage for Ligand A.
8. **BBB:** Not a primary concern for a cardiovascular target, but Ligand A (70.997) is better than Ligand B (57.774).
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-4.689) is better than Ligand B (-2.746). Better solubility is always preferred.
11. **hERG:** Ligand A (0.439) has a much lower hERG risk than Ligand B (0.136). This is a significant safety advantage for Ligand A.
12. **Cl_mic:** Ligand B (74.417) has slightly lower microsomal clearance than Ligand A (70.202), suggesting slightly better metabolic stability. This difference is not substantial.
13. **t1/2:** Ligand B (-24.41) has a much longer in vitro half-life than Ligand A (-3.259). This is a substantial advantage for Ligand B.
14. **Pgp:** Ligand A (0.314) has lower P-gp efflux liability than Ligand B (0.09). Lower P-gp efflux is generally preferred.
15. **Binding Affinity:** Ligand B (-7.8) has a slightly better binding affinity than Ligand A (-8.0). While both are excellent, the difference is minimal.
**Overall Assessment:**
Ligand A demonstrates a superior balance of properties, particularly regarding safety (DILI, hERG) and drug-likeness (QED). While Ligand B has a longer half-life, the significantly higher DILI and hERG risks are major drawbacks. The slightly better affinity of Ligand B doesn't outweigh these safety concerns. The TPSA and logP values of Ligand A are also more favorable.
Output:
1
2025-04-17 22:39:06,491 - INFO - Batch 347 complete. Total preferences: 5552
2025-04-17 22:39:06,491 - INFO - Processing batch 348/512...
2025-04-17 22:39:52,351 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (383.25 and 388.515 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (49.41) is significantly lower than Ligand B (113.67). This is a major advantage for Ligand A, as lower TPSA generally correlates with better cell permeability, crucial for GPCR targeting. Ligand B is above the preferred 90 A^2 for CNS targets, and even pushing the limit for general oral absorption.
3. **logP:** Ligand A (3.968) is within the optimal range (1-3), while Ligand B (-0.02) is below 1, indicating potential permeability issues. This is a substantial advantage for Ligand A.
4. **HBD:** Both ligands have 1 HBD, which is acceptable.
5. **HBA:** Ligand A has 2 HBA, while Ligand B has 6. Ligand B is approaching the upper limit of acceptable HBA, potentially impacting permeability.
6. **QED:** Both ligands have QED values above 0.7, indicating good drug-likeness.
7. **DILI:** Ligand A (66.421) has a higher DILI risk than Ligand B (49.67). This favors Ligand B, though both are within acceptable ranges.
8. **BBB:** Ligand A (70.841) has a slightly better BBB penetration potential than Ligand B (56.572). While ADRB2 isn't exclusively a CNS target, some CNS penetration can be beneficial, and lower TPSA of Ligand A contributes to this.
9. **Caco-2:** Ligand A (-4.31) has a very poor Caco-2 permeability, while Ligand B (-5.562) is also poor, but slightly better. This is a negative for both, but more so for Ligand A.
10. **Solubility:** Ligand A (-5.101) has very poor solubility, while Ligand B (-1.657) is also poor, but better. This is a significant drawback for Ligand A.
11. **hERG:** Ligand A (0.569) has a slightly higher hERG inhibition risk than Ligand B (0.066), favoring Ligand B.
12. **Cl_mic:** Ligand A (74.937) has a higher microsomal clearance than Ligand B (8.074), indicating lower metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand A (41.018) has a longer in vitro half-life than Ligand B (-20.222). This favors Ligand A.
14. **Pgp:** Ligand A (0.151) has lower P-gp efflux than Ligand B (0.025), which is favorable.
15. **Binding Affinity:** Ligand A (-6.6 kcal/mol) has a slightly better binding affinity than Ligand B (-5.9 kcal/mol). While the difference is not huge, it's enough to consider.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A excels in affinity and Pgp, but suffers from poor logP, high TPSA, poor solubility, and poor Caco-2 permeability. Ligand B has a better logP, lower TPSA, better solubility, and better metabolic stability (lower Cl_mic), but has a slightly weaker binding affinity.
**Overall Assessment:**
Despite Ligand A's slightly better affinity and Pgp profile, the significantly better ADME properties of Ligand B (particularly logP, TPSA, solubility, and metabolic stability) make it the more promising candidate. The poor permeability and solubility of Ligand A are major hurdles that would likely be difficult to overcome. The small difference in binding affinity can likely be optimized during lead optimization.
Output:
0
2025-04-17 22:39:52,351 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (335.451 and 354.397 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (39.08) is significantly better than Ligand B (50.8). ADRB2 is a cardiovascular target, not CNS, but lower TPSA generally improves absorption.
3. **logP:** Ligand A (4.294) is slightly higher than Ligand B (2.404). While both are within the acceptable range (1-3 is optimal), Ligand A is pushing the upper limit and could potentially have solubility issues. Ligand B is closer to ideal.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Both ligands have 4 HBA, which is good.
6. **QED:** Ligand B (0.882) has a slightly better QED score than Ligand A (0.7), indicating a more drug-like profile.
7. **DILI:** Both ligands have low DILI risk (37.611 and 36.836), which is excellent.
8. **BBB:** Ligand B (84.141) has a much higher BBB penetration percentile than Ligand A (55.176). While ADRB2 isn't a primary CNS target, some off-target CNS effects are always a consideration, and higher BBB is generally preferable.
9. **Caco-2:** Ligand A (-5.135) and Ligand B (-4.19) both have negative Caco-2 permeability values, which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand A (-4.187) has worse solubility than Ligand B (-2.495). This is a concern given Ligand A's higher logP.
11. **hERG:** Ligand A (0.929) has a slightly higher hERG risk than Ligand B (0.355), which is undesirable.
12. **Cl_mic:** Ligand B (42.267) has a lower microsomal clearance than Ligand A (60.467), indicating better metabolic stability.
13. **t1/2:** Ligand B (-6.693) has a longer in vitro half-life than Ligand A (-10.368). This is a significant advantage.
14. **Pgp:** Ligand A (0.806) has higher P-gp efflux liability than Ligand B (0.063). Lower P-gp is better for bioavailability.
15. **Binding Affinity:** Ligand A (-6.2 kcal/mol) has a slightly better binding affinity than Ligand B (-3.7 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME drawbacks.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A has a higher logP (potentially problematic), worse TPSA, worse Pgp, but significantly better affinity. Ligand B has better ADME properties overall, but weaker binding. The affinity difference is substantial (2.5 kcal/mol).
**Overall Assessment:**
The significantly stronger binding affinity of Ligand A (-6.2 kcal/mol vs -3.7 kcal/mol) is the deciding factor. While Ligand A has some ADME liabilities (higher logP, lower solubility, higher Pgp efflux, and worse Caco-2), the potency advantage is likely to be crucial for efficacy. Optimization efforts can then focus on addressing the ADME issues. The Caco-2 values are concerning for both, but can be addressed with formulation strategies.
Output:
1
2025-04-17 22:39:52,351 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.431 and 357.41 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Both ligands (75.51 and 75.11) are below the 140 A^2 threshold for good oral absorption, but higher than the 90 A^2 for CNS targets. Since ADRB2 is a cardiovascular target, CNS penetration isn't a primary concern. No clear advantage.
3. **logP:** Ligand A (0.739) is within the optimal 1-3 range, while Ligand B (3.931) is at the upper end. While still acceptable, Ligand B's higher logP could potentially lead to solubility issues or off-target interactions. Ligand A is slightly favored.
4. **HBD:** Ligand A (0) has no H-bond donors, which is generally favorable for permeability. Ligand B (2) has 2, which is still within the acceptable limit of 5, but less ideal than 0. Ligand A is favored.
5. **HBA:** Both ligands (5) have the same number of H-bond acceptors, well within the acceptable limit of 10. No difference.
6. **QED:** Ligand A (0.806) has a slightly higher QED score than Ligand B (0.725), indicating a more drug-like profile. Ligand A is favored.
7. **DILI:** Ligand A (26.057) has a significantly lower DILI risk than Ligand B (80.031). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (71.694) has a higher BBB penetration percentile than Ligand B (34.858). While not critical for a cardiovascular target, higher BBB is generally a positive attribute. Ligand A is favored.
9. **Caco-2:** Ligand A (-4.603) has a more negative Caco-2 value, suggesting *lower* permeability. Ligand B (-5.136) is even lower. Both are poor, but B is slightly worse.
10. **Solubility:** Ligand A (-0.813) has a slightly better solubility score than Ligand B (-4.391). Ligand A is favored.
11. **hERG:** Ligand A (0.15) has a much lower hERG inhibition liability than Ligand B (0.356), indicating a lower risk of cardiotoxicity. This is a significant advantage for Ligand A, especially given the cardiovascular target.
12. **Cl_mic:** Ligand A (33.681) has a lower microsomal clearance than Ligand B (57.633), suggesting better metabolic stability. Ligand A is favored.
13. **t1/2:** Ligand A (-24.825) has a more negative in vitro half-life, suggesting a shorter half-life. Ligand B (-30.557) is even shorter. Both are poor, but B is slightly worse.
14. **Pgp:** Ligand A (0.052) has a lower P-gp efflux liability than Ligand B (0.305), which is favorable for oral bioavailability. Ligand A is favored.
15. **Binding Affinity:** Ligand B (-7.0 kcal/mol) has a slightly better binding affinity than Ligand A (-6.7 kcal/mol). This is a positive for Ligand B, but the difference is relatively small.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical ADME-Tox parameters (DILI, hERG, Cl_mic, Pgp, Solubility, QED). While Ligand B has a slightly better binding affinity, the superior safety and pharmacokinetic profile of Ligand A make it the more promising drug candidate for the ADRB2 receptor. The small affinity difference is likely surmountable with further optimization.
Output:
1
2025-04-17 22:39:52,351 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (336.435 and 361.511 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (61.36) is better than Ligand B (65.36). Both are below the 140 threshold for oral absorption, but lower is generally preferred.
3. **logP:** Both ligands have good logP values (4.065 and 3.39), falling within the optimal 1-3 range. Ligand B is slightly better.
4. **HBD:** Ligand A (3) is higher than Ligand B (1). While both are acceptable, lower HBD can sometimes improve permeability. Ligand B is slightly preferred.
5. **HBA:** Ligand A (2) is lower than Ligand B (5). Lower HBA is generally preferred for permeability. Ligand A is preferred.
6. **QED:** Both ligands have good QED scores (0.774 and 0.815), indicating good drug-likeness. No significant difference.
7. **DILI:** Ligand B (29.857) has a significantly lower DILI risk than Ligand A (50.291). This is a major advantage for Ligand B.
8. **BBB:** Both ligands have similar BBB penetration (61.846 and 60.372). Not a major differentiating factor for a cardiovascular target like ADRB2.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.126 and -4.811), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Both ligands have negative solubility values (-4.447 and -3.822), indicating poor aqueous solubility. This is a significant drawback for both.
11. **hERG:** Both ligands have low hERG inhibition liability (0.715 and 0.86). This is good and minimizes cardiotoxicity risk. No significant difference.
12. **Cl_mic:** Ligand B (55.34) has a lower microsomal clearance than Ligand A (58.233), indicating better metabolic stability.
13. **t1/2:** Ligand B (21.463) has a longer in vitro half-life than Ligand A (13.802). This is a significant advantage for Ligand B.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.33 and 0.222). No significant difference.
15. **Binding Affinity:** Ligand B (-7.1 kcal/mol) has a stronger binding affinity than Ligand A (-6.8 kcal/mol). This is a substantial advantage, as a 0.3 kcal/mol difference can be meaningful.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand B has a slightly better logP, comparable TPSA and Pgp, and significantly better affinity. The DILI risk is also much lower for Ligand B, which is a critical consideration. While both have poor Caco-2 and solubility, the improved affinity and safety profile of Ligand B outweigh these drawbacks.
**Conclusion:**
Ligand B is the more promising drug candidate due to its superior binding affinity, lower DILI risk, and better metabolic stability (lower Cl_mic and longer t1/2).
Output:
0
2025-04-17 22:39:52,352 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (351.491 and 349.387 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (87.3) is better than Ligand B (101.74). For a GPCR, keeping TPSA lower is generally favorable for permeability.
3. **logP:** Ligand A (1.738) is slightly higher than Ligand B (0.918), both are within the optimal 1-3 range. Ligand A is preferred.
4. **HBD:** Ligand A (3) is higher than Ligand B (1). Both are acceptable, but lower is generally better for permeability.
5. **HBA:** Ligand B (6) is higher than Ligand A (3). This contributes to Ligand A being more favorable.
6. **QED:** Both ligands have good QED scores (0.622 and 0.749), indicating good drug-like properties. No strong preference.
7. **DILI:** Ligand A (27.608) has a significantly lower DILI risk than Ligand B (44.552). This is a major advantage for Ligand A.
8. **BBB:** Both ligands have reasonably good BBB penetration (67.623 and 69.988). No strong preference.
9. **Caco-2:** Ligand A (-5.126) and Ligand B (-4.925) are similar.
10. **Solubility:** Ligand A (-2.35) and Ligand B (-2.144) are similar.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.114 and 0.035). No strong preference.
12. **Cl_mic:** Ligand B (4.796) has significantly lower microsomal clearance than Ligand A (34.367), suggesting better metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand B (-23.734) has a much longer in vitro half-life than Ligand A (-3.211). This is a major advantage for Ligand B.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.021 and 0.062). No strong preference.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-5.7 and -4.7 kcal/mol). The 1 kcal/mol difference is not enough to outweigh other factors.
**Overall Assessment:**
Ligand A has advantages in TPSA, logP, and DILI risk. However, Ligand B shines with significantly better metabolic stability (lower Cl_mic) and a much longer half-life. For a GPCR like ADRB2, metabolic stability and duration of action are crucial. While Ligand A has a slightly better DILI profile, the substantial improvements in pharmacokinetic properties with Ligand B make it the more promising candidate.
Output:
0
2025-04-17 22:39:52,352 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (347.379) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are acceptable for a non-CNS GPCR target (<140 A^2). Ligand B (121.53) is slightly lower, potentially aiding absorption.
3. **logP:** Ligand A (-1.455) is quite low, potentially leading to poor membrane permeability. Ligand B (1.077) is within the optimal range (1-3). This is a significant advantage for Ligand B.
4. **HBD:** Both are within the acceptable limit of 5. Ligand A (2) is slightly better.
5. **HBA:** Both are within the acceptable limit of 10. Both have 6 HBA.
6. **QED:** Both have similar QED values (A: 0.691, B: 0.642), indicating good drug-likeness.
7. **DILI:** Ligand A (44.63) has a much lower DILI risk than Ligand B (86.002). This is a substantial advantage for Ligand A.
8. **BBB:** This is less critical for a cardiovascular target like ADRB2. Ligand A (77.433) has a higher BBB penetration than Ligand B (28.887).
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability.
10. **Solubility:** Both have negative solubility values, indicating poor solubility.
11. **hERG:** Both have very low hERG inhibition liability (A: 0.072, B: 0.152).
12. **Cl_mic:** Ligand A (-12.497) has a much lower (better) microsomal clearance than Ligand B (24.757), suggesting better metabolic stability.
13. **t1/2:** Ligand B (38.603) has a significantly longer in vitro half-life than Ligand A (6.382). This is a major advantage for Ligand B.
14. **Pgp:** Both have low Pgp efflux liability.
15. **Binding Affinity:** Ligand A (-8.7 kcal/mol) has a significantly stronger binding affinity than Ligand B (-5.6 kcal/mol). This is a substantial advantage for Ligand A.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B has a better logP. Ligand A has better affinity and TPSA. The difference in affinity is substantial (-8.7 vs -5.6 kcal/mol). While Ligand A has a poor logP, the much stronger binding affinity and lower DILI risk, coupled with better metabolic stability (lower Cl_mic), outweigh this drawback.
**Conclusion:**
Despite Ligand B's better logP and half-life, the significantly stronger binding affinity of Ligand A, coupled with its lower DILI risk and better metabolic stability, makes it the more promising drug candidate for ADRB2.
Output:
1
2025-04-17 22:39:52,352 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
The target is ADRB2, a GPCR. Therefore, the priorities are logP, Pgp, TPSA, affinity, and BBB. Let's compare the ligands:
1. **Molecular Weight:** Both ligands (348.38 and 357.49 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (90.87) is better than Ligand B (20.31). While both are relatively low, lower TPSA generally favors membrane permeability. Ligand B is exceptionally low, which could be beneficial, but might also indicate a lack of necessary interactions.
3. **logP:** Ligand A (2.848) is within the optimal 1-3 range. Ligand B (4.813) is higher, potentially leading to solubility issues and off-target interactions. This is a significant drawback for Ligand B.
4. **H-Bond Donors:** Ligand A (2) is reasonable. Ligand B (0) is also acceptable, but could impact aqueous solubility.
5. **H-Bond Acceptors:** Ligand A (4) is good. Ligand B (2) is also good.
6. **QED:** Ligand A (0.801) is excellent, indicating a very drug-like profile. Ligand B (0.696) is still acceptable, but lower.
7. **DILI:** Ligand A (72.043) is better than Ligand B (29.973) - lower is better.
8. **BBB:** Ligand A (66.964) is reasonable, but Ligand B (89.531) is significantly better, suggesting better potential for CNS penetration if desired (although ADRB2 is primarily cardiovascular, some CNS effects are possible).
9. **Caco-2:** Both are negative, indicating poor permeability. This is a concern for both.
10. **Solubility:** Both are negative, indicating poor solubility. This is a concern for both.
11. **hERG:** Ligand A (0.468) is better than Ligand B (0.808), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand A (7.62) is much better than Ligand B (81.186), indicating significantly better metabolic stability. This is a critical advantage for Ligand A.
13. **t1/2:** Ligand A (12.696) is much better than Ligand B (3.332), indicating a longer half-life and potentially less frequent dosing.
14. **Pgp:** Ligand A (0.116) is much better than Ligand B (0.822), indicating lower P-glycoprotein efflux and better bioavailability.
15. **Binding Affinity:** Ligand A (-7.7 kcal/mol) is significantly better than Ligand B (-6.6 kcal/mol). This 1.1 kcal/mol difference is substantial and can outweigh many minor ADME drawbacks.
**Overall Assessment:**
Ligand A demonstrates a superior balance of properties. While Ligand B has a better BBB score, the significant advantages of Ligand A in terms of metabolic stability (Cl_mic, t1/2), Pgp efflux, hERG risk, binding affinity, and QED outweigh this benefit. The higher logP of Ligand B is also a concern. The poor Caco-2 and solubility for both are problematic, but can potentially be addressed with formulation strategies.
**Output:**
1
2025-04-17 22:39:52,352 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (347.371) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are reasonably low (A: 93.9, B: 97.19), suggesting good potential for oral absorption. Both are below the 140 threshold.
3. **logP:** Both ligands have good logP values (A: 1.008, B: 0.87), falling within the optimal 1-3 range.
4. **HBD:** Both have 1 HBD, which is acceptable.
5. **HBA:** Ligand A has 6 HBA, and Ligand B has 8. Both are acceptable, but A is slightly better.
6. **QED:** Both have good QED scores (A: 0.799, B: 0.823), indicating drug-like properties.
7. **DILI:** Both have similar DILI risk (A: 58.705, B: 58.434), and are both below the concerning 60 threshold.
8. **BBB:** Ligand A has a significantly higher BBB penetration (60.527) than Ligand B (46.026). While ADRB2 isn't strictly a CNS target, some CNS exposure can be helpful for understanding off-target effects and potential side effects.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual. This suggests poor permeability in this *in vitro* assay. However, the values are similar (-4.685 vs -5.491).
10. **Solubility:** Both have negative solubility values, which is also unusual and suggests poor aqueous solubility. Ligand B is slightly worse (-1.665 vs -2.145).
11. **hERG:** Both have very low hERG inhibition risk (A: 0.093, B: 0.188), which is excellent.
12. **Cl_mic:** Ligand B has a much lower (better) microsomal clearance (-19.583) than Ligand A (39.118). This indicates better metabolic stability for Ligand B.
13. **t1/2:** Ligand B has a slightly better (less negative) in vitro half-life (-0.511) than Ligand A (-28.743).
14. **Pgp:** Both have low P-gp efflux liability (A: 0.084, B: 0.077), which is favorable.
15. **Binding Affinity:** Ligand B has a significantly stronger binding affinity (-7.5 kcal/mol) compared to Ligand A (-5.6 kcal/mol). This is a substantial difference.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, and affinity are crucial. Ligand B excels in affinity, which is a major driver. While Ligand A has a better BBB score, the difference isn't substantial enough to outweigh the significant affinity advantage of Ligand B. Metabolic stability (Cl_mic and t1/2) is also important, and Ligand B is superior in these aspects.
**Conclusion:**
Despite the unusual Caco-2 and solubility results, the significantly improved binding affinity and metabolic stability of Ligand B make it the more promising drug candidate.
Output:
0
2025-04-17 22:39:52,352 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.399 and 359.499 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (61.31) is better than Ligand B (70.15). Both are below 140, but lower TPSA generally favors absorption.
3. **logP:** Ligand B (2.478) is better than Ligand A (4.21). While A is within the acceptable range, B is closer to the optimal 1-3 range. High logP can lead to off-target effects.
4. **HBD:** Ligand A (0) is better than Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Both ligands have 6 HBA, which is acceptable.
6. **QED:** Ligand B (0.855) is significantly better than Ligand A (0.516), indicating a more drug-like profile.
7. **DILI:** Ligand B (54.75) is much better than Ligand A (93.525). Lower DILI risk is crucial.
8. **BBB:** Ligand B (68.437) is better than Ligand A (57.736). While ADRB2 isn't exclusively a CNS target, some CNS penetration can be beneficial for understanding off-target effects and potential side effects.
9. **Caco-2:** Ligand A (-4.499) is better than Ligand B (-5.135). Higher Caco-2 permeability is desirable.
10. **Solubility:** Ligand A (-5.581) is better than Ligand B (-3.422). Better aqueous solubility is important for formulation and bioavailability.
11. **hERG:** Ligand A (0.413) is better than Ligand B (0.8). Lower hERG inhibition is critical for avoiding cardiotoxicity, especially for a cardiovascular target.
12. **Cl_mic:** Ligand B (48.046) is better than Ligand A (110.9). Lower microsomal clearance indicates better metabolic stability.
13. **t1/2:** Ligand B (32.235) is much better than Ligand A (-44.799). A longer half-life is generally preferred.
14. **Pgp:** Ligand A (0.516) is better than Ligand B (0.177). Lower P-gp efflux is desirable.
15. **Binding Affinity:** Ligand B (-8.1) is significantly better than Ligand A (-6.8). A 1.3 kcal/mol difference in binding affinity is substantial and can outweigh many ADME drawbacks.
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are particularly important. Ligand B excels in affinity and has a more favorable logP. While Ligand A has better TPSA and Pgp, the significant advantages of Ligand B in affinity, DILI, metabolic stability (Cl_mic, t1/2), and QED outweigh these factors. The hERG risk is also lower for Ligand A, but the substantial binding affinity difference for Ligand B is more important.
**Conclusion:**
Ligand B presents a better overall profile, particularly due to its superior binding affinity, lower DILI risk, improved metabolic stability, and better QED score.
Output:
0
2025-04-17 22:39:52,352 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.394 and 357.439 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (74.77) is significantly better than Ligand B (91.02). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (1.859) is better than Ligand A (0.329). A logP between 1-3 is optimal, and Ligand B falls within this range, while Ligand A is a bit low, potentially hindering permeation.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand B (6) has slightly more HBA than Ligand A (5), but both are acceptable.
6. **QED:** Ligand A (0.847) has a better QED score than Ligand B (0.766), indicating a more drug-like profile.
7. **DILI:** Ligand A (44.591) has a significantly lower DILI risk than Ligand B (65.452). This is a crucial advantage.
8. **BBB:** Ligand A (68.554) has a better BBB penetration score than Ligand B (40.093). While not critical for a cardiovascular target, it isn't detrimental.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
10. **Solubility:** Ligand A (-1.207) has better solubility than Ligand B (-3.055).
11. **hERG:** Ligand A (0.076) has a much lower hERG inhibition liability than Ligand B (0.165). This is a significant safety advantage.
12. **Cl_mic:** Ligand A (-21.128) has a much lower (better) microsomal clearance than Ligand B (34.418), indicating greater metabolic stability.
13. **t1/2:** Ligand B (55.809) has a significantly longer in vitro half-life than Ligand A (-7.765). This is a positive for dosing frequency.
14. **Pgp:** Ligand B (0.081) has slightly lower P-gp efflux than Ligand A (0.008), which is favorable.
15. **Binding Affinity:** Ligand A (-6.6) has slightly better binding affinity than Ligand B (-5.7). While the difference is less than 1.5 kcal/mol, it's still a positive.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Ligand B has a better logP and Pgp, but Ligand A excels in TPSA, DILI, hERG, Cl_mic, solubility, and has comparable affinity. The safety profile (DILI, hERG) and metabolic stability (Cl_mic) of Ligand A are substantially better.
**Overall Assessment:**
Ligand A demonstrates a more favorable balance of properties, particularly regarding safety (DILI, hERG) and metabolic stability (Cl_mic). While Ligand B has a slightly better logP and half-life, the advantages of Ligand A in critical areas outweigh these benefits.
Output:
1
2025-04-17 22:39:52,352 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (349.5 and 350.4 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (43.9) is slightly higher than Ligand B (36.1). Both are below the 140 threshold for oral absorption, and acceptable for a cardiovascular target (not requiring significant CNS penetration). Ligand B is preferable here.
3. **logP:** Ligand A (2.38) is within the optimal 1-3 range. Ligand B (4.29) is a bit high, potentially leading to solubility issues and off-target interactions. Ligand A is preferable.
4. **HBD:** Ligand A (0) is better than Ligand B (1). Fewer HBDs generally improve membrane permeability.
5. **HBA:** Ligand A (3) is higher than Ligand B (1). Lower HBA is generally preferred for permeability. Ligand B is preferable.
6. **QED:** Both ligands have good QED scores (0.716 and 0.803), indicating good drug-like properties. No significant difference.
7. **DILI:** Ligand A (18.7%) has a much lower DILI risk than Ligand B (53.3%). This is a significant advantage for Ligand A.
8. **BBB:** Both ligands show reasonable BBB penetration (78.2% and 87.9%). While ADRB2 is primarily a cardiovascular target, some CNS effects are possible with beta-blockers, so higher BBB penetration isn't necessarily detrimental. Ligand B is slightly better.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-2.05) has better solubility than Ligand B (-5.39). Solubility is important for bioavailability. Ligand A is preferable.
11. **hERG:** Ligand A (0.46) has a lower hERG inhibition liability than Ligand B (0.85). This is a crucial advantage for Ligand A, minimizing cardiotoxicity risk.
12. **Cl_mic:** Ligand A (56.3) has higher microsomal clearance than Ligand B (38.8). Lower clearance is preferred for better metabolic stability, so Ligand B is preferable.
13. **t1/2:** Ligand B (14.7) has a significantly longer in vitro half-life than Ligand A (1.1). This is a major advantage for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.17) has lower P-gp efflux than Ligand B (0.53). Lower P-gp efflux is preferable for better bioavailability. Ligand A is preferable.
15. **Binding Affinity:** Ligand B (-6.8 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.3 kcal/mol). This is a substantial advantage for Ligand B, potentially outweighing some of its ADME drawbacks.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand B excels in affinity and has acceptable TPSA. Its higher logP and Pgp efflux are concerns, but the strong affinity might compensate. Ligand A has better logP, Pgp, solubility, and a much better safety profile (DILI, hERG).
**Overall Assessment:**
While Ligand B has a superior binding affinity and longer half-life, the significantly higher DILI and hERG risk, coupled with the higher logP and Pgp efflux, make it a less desirable candidate. Ligand A, despite its weaker affinity, presents a much more favorable safety profile and better physicochemical properties overall. The affinity difference, while notable, might be overcome with further optimization.
Output:
1
2025-04-17 22:39:52,352 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (352.41 and 352.494 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (94.56) is higher than Ligand B (49.41). For a cardiovascular GPCR like ADRB2, TPSA is less critical than for CNS targets, but lower is generally preferred for better absorption. Ligand B has a substantial advantage.
3. **logP:** Ligand A (-0.302) is quite low, potentially indicating poor membrane permeability. Ligand B (3.592) is excellent, falling squarely within the optimal 1-3 range. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (1). Both are acceptable, but lower is generally better.
5. **HBA:** Ligand A (5) is higher than Ligand B (2). Again, lower is preferable.
6. **QED:** Both ligands have good QED scores (0.586 and 0.769), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Both ligands have similar and acceptable DILI risk (20.279 and 21.404 percentile).
8. **BBB:** Ligand A (37.573) has a low BBB penetration score, while Ligand B (91.314) is very high. While ADRB2 isn't a CNS target, higher BBB penetration can sometimes correlate with better overall distribution and reduced off-target effects.
9. **Caco-2:** Ligand A (-5.263) is poor, while Ligand B (-4.79) is also poor, but slightly better. Both are concerning.
10. **Solubility:** Ligand A (-1.135) is poor, while Ligand B (-3.36) is even worse. Both are problematic.
11. **hERG:** Ligand A (0.136) has a slightly lower hERG risk than Ligand B (0.726), which is a positive.
12. **Cl_mic:** Ligand A (-16.365) has a much lower (better) microsomal clearance than Ligand B (34.238). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (-6.777) has a negative half-life, which is concerning. Ligand B (-12.588) is also very poor.
14. **Pgp:** Ligand A (0.005) has very low P-gp efflux, which is excellent. Ligand B (0.486) is higher, but still reasonable.
15. **Affinity:** Ligand A (-7.3) has a slightly better binding affinity than Ligand B (-6.0). This is a 1.3 kcal/mol difference, which is significant.
**Overall Assessment:**
Ligand B has a significantly better logP and TPSA, which are important for GPCR ligands. It also has a better QED and BBB penetration. However, Ligand A has a better Cl_mic and Pgp efflux, and a slightly better binding affinity. The poor solubility and Caco-2 permeability of both are concerning. The negative half-life for both is also a major issue.
Despite the better affinity of Ligand A, the significantly better logP and TPSA of Ligand B, coupled with its higher BBB penetration, make it a more promising starting point for optimization. The poor solubility and permeability are addressable through prodrug strategies or formulation work. The metabolic stability of Ligand A is better, but the affinity difference is substantial enough to prioritize Ligand B.
Output:
0
2025-04-17 22:39:52,352 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (352.385 Da and 361.471 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (78.09) is significantly better than Ligand B (90.98). For a GPCR, keeping TPSA low is beneficial for permeability, and A is well below the 140 threshold and closer to the 90 threshold.
**3. logP:** Both ligands have very similar logP values (1.584 and 1.465), falling within the optimal 1-3 range.
**4. H-Bond Donors:** Both have 2 HBD, which is acceptable.
**5. H-Bond Acceptors:** Ligand A has 3 HBA, while Ligand B has 5. Lower is generally preferable, so Ligand A is slightly better.
**6. QED:** Both ligands have good QED scores (0.763 and 0.793), indicating good drug-like properties.
**7. DILI:** Ligand B (65.568) has a higher DILI risk than Ligand A (56.727), although both are acceptable. Lower is better.
**8. BBB:** Ligand A (80.729) has a significantly higher BBB penetration percentile than Ligand B (53.664). While ADRB2 is a cardiovascular target and CNS penetration isn't *essential*, some level of BBB penetration can be beneficial for off-target effects assessment and potential exploration of other indications.
**9. Caco-2 Permeability:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the values are similar (-5.08 and -5.532).
**10. Aqueous Solubility:** Both have negative solubility values, indicating poor solubility. Ligand B (-3.661) is slightly better than Ligand A (-2.893), but both are problematic.
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.247 and 0.091). This is excellent.
**12. Microsomal Clearance:** Both have similar microsomal clearance values (21.538 and 23.231), indicating moderate metabolic stability.
**13. In vitro Half-Life:** Ligand A (-25.087) has a much longer in vitro half-life than Ligand B (-9.366). This is a significant advantage, potentially leading to less frequent dosing.
**14. P-gp Efflux:** Both have low P-gp efflux liability (0.066 and 0.081).
**15. Binding Affinity:** Ligand A (-7.4 kcal/mol) has a slightly better binding affinity than Ligand B (-6.3 kcal/mol). The difference is 1.1 kcal/mol, which is a substantial advantage and can outweigh some of the ADME drawbacks.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand A is the stronger candidate. It has a lower TPSA, better BBB penetration, a longer half-life, and a superior binding affinity. While both have solubility issues, the other advantages of Ligand A make it more promising.
Output:
1
2025-04-17 22:39:52,353 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (358.356 and 349.475 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (44.76) is significantly better than Ligand B (65.78). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (3.807) is good, within the optimal 1-3 range. Ligand B (1.98) is at the lower end, potentially impacting permeability.
4. **HBD:** Ligand A (0) is preferable to Ligand B (1). Fewer HBDs generally improve membrane permeability.
5. **HBA:** Both ligands have 4 HBA, which is acceptable.
6. **QED:** Both ligands have good QED scores (0.768 and 0.818), indicating good drug-like properties.
7. **DILI:** Ligand A (48.817) has a higher DILI risk than Ligand B (15.859). This is a significant concern, and favors Ligand B.
8. **BBB:** Ligand A (91.702) has much higher BBB penetration than Ligand B (60.101). While not a primary concern for a cardiovascular target, it's a neutral to slightly positive attribute for Ligand A.
9. **Caco-2:** Both ligands have similar negative Caco-2 values (-4.752 and -4.569), suggesting poor permeability.
10. **Solubility:** Ligand A (-4.553) has slightly worse solubility than Ligand B (-1.514). Solubility is important for bioavailability.
11. **hERG:** Both ligands have low hERG inhibition risk (0.725 and 0.659).
12. **Cl_mic:** Ligand A (50.133) has a higher microsomal clearance than Ligand B (40.411), suggesting lower metabolic stability. Ligand B is preferable.
13. **t1/2:** Ligand B (11.443) has a significantly longer in vitro half-life than Ligand A (-0.053). This is a major advantage for Ligand B.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.237 and 0.277).
15. **Binding Affinity:** Ligand B (-6.6 kcal/mol) has significantly better binding affinity than Ligand A (-5.0 kcal/mol). This is a crucial advantage, exceeding the 1.5 kcal/mol difference threshold.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand B excels in affinity and has a better logP. Ligand A has a better TPSA, but the difference isn't substantial enough to outweigh the other factors.
**Overall Assessment:**
Ligand B is the stronger candidate. Its significantly better binding affinity, lower DILI risk, and longer half-life outweigh the slightly higher TPSA and lower BBB penetration. While both have poor Caco-2 permeability, the potency advantage of Ligand B is substantial.
Output:
0
2025-04-17 22:39:52,353 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
Let's analyze each ligand against the provided guidelines, with emphasis on GPCR-relevant parameters (logP, TPSA, Pgp, BBB, and affinity).
* **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (416.272) is slightly higher than Ligand B (347.503), but both are acceptable.
* **TPSA:** Ligand B (52.65) is significantly better than Ligand A (103.12). Lower TPSA generally favors oral absorption, crucial for a cardiovascular drug.
* **logP:** Ligand B (2.182) is within the optimal range (1-3), while Ligand A (0.644) is a bit low, potentially hindering membrane permeability.
* **H-Bond Donors/Acceptors:** Ligand A (2 HBD, 6 HBA) and Ligand B (1 HBD, 3 HBA) are both reasonable.
* **QED:** Both ligands have similar and acceptable QED values (0.66 and 0.685).
* **DILI:** Ligand B (10.237) has a much lower DILI risk than Ligand A (68.011). This is a significant advantage for Ligand B.
* **BBB:** Both ligands have good BBB penetration (Ligand A: 66.305, Ligand B: 61.691). While not a primary concern for a cardiovascular target, it's not detrimental.
* **Caco-2 Permeability:** Both ligands have negative Caco-2 values, indicating poor permeability. This is a concern for both, but the lower value for Ligand A (-5.094) is worse than Ligand B (-4.921).
* **Aqueous Solubility:** Both ligands have poor aqueous solubility (-2.436 and -2.394). This could present formulation challenges.
* **hERG Inhibition:** Both ligands have low hERG inhibition risk (0.361 and 0.461).
* **Microsomal Clearance:** Ligand B (53.498) has a significantly higher microsomal clearance than Ligand A (1.741). This means Ligand A is more metabolically stable, which is a positive.
* **In vitro Half-Life:** Ligand A (-36.954) has a longer in vitro half-life than Ligand B (5.781), further supporting its better metabolic stability.
* **P-gp Efflux:** Both ligands have low P-gp efflux liability (0.017 and 0.049).
* **Binding Affinity:** Ligand B (-6.6 kcal/mol) has a slightly better binding affinity than Ligand A (-5.8 kcal/mol). This 0.8 kcal/mol difference is substantial enough to consider, especially given the other factors.
**Overall Assessment:**
While Ligand A demonstrates better metabolic stability (lower Cl_mic, longer t1/2), Ligand B excels in several crucial areas for a GPCR drug candidate. Specifically, its lower DILI risk, better TPSA, and more favorable logP outweigh the slightly weaker metabolic profile. The improved binding affinity of Ligand B is also a significant advantage. The poor Caco-2 permeability is a concern for both, but doesn't completely disqualify either.
**Output:**
0
2025-04-17 22:39:52,353 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [346.383, 97.64, 1.249, 2, 5, 0.572, 50.291, 40.442, -4.649, -2.924, 0.053, 40.265, -9.532, 0.01, -7.6]
**Ligand B:** [343.391, 127.82, -0.694, 3, 7, 0.659, 41.76, 74.796, -6.059, -1.724, 0.017, 4.976, 10.684, 0.019, -6.6]
Here's a breakdown, prioritizing GPCR properties (logP, Pgp, TPSA, BBB, and affinity):
1. **Molecular Weight:** Both are within the ideal range (200-500 Da). A is 346.383, B is 343.391 - very similar.
2. **TPSA:** A (97.64) is better than B (127.82). Lower TPSA generally favors better absorption.
3. **logP:** A (1.249) is optimal, while B (-0.694) is a bit low, potentially hindering membrane permeability.
4. **H-Bond Donors/Acceptors:** A (2/5) is preferable to B (3/7). Fewer H-bonds are generally better for permeability.
5. **QED:** B (0.659) is slightly better than A (0.572), indicating a marginally more drug-like profile.
6. **DILI:** Both are good, below 40 (A: 50.291, B: 41.76). B is slightly better.
7. **BBB:** B (74.796) is significantly better than A (40.442). This is a key advantage for a GPCR, even if not a CNS target, as it can influence distribution.
8. **Caco-2:** A (-4.649) is better than B (-6.059), indicating better intestinal absorption.
9. **Solubility:** A (-2.924) is better than B (-1.724).
10. **hERG:** Both are very low risk (A: 0.053, B: 0.017). B is slightly better.
11. **Cl_mic:** B (4.976) is much lower than A (40.265), suggesting better metabolic stability.
12. **t1/2:** B (10.684) is significantly better than A (-9.532), indicating a longer half-life.
13. **Pgp:** Both are very low efflux (A: 0.01, B: 0.019).
14. **Binding Affinity:** A (-7.6) is 1.0 kcal/mol better than B (-6.6). This is a substantial difference in potency.
**Overall Assessment:**
Ligand A has a superior binding affinity and better Caco-2 permeability and solubility. However, Ligand B shines with its significantly improved BBB penetration, metabolic stability (lower Cl_mic), and longer half-life. While the affinity difference is notable, the ADME properties of B are considerably more favorable for a GPCR target, especially considering the potential for off-target effects and the importance of sustained exposure. The slightly lower logP of B is a concern, but the strong BBB penetration and metabolic stability are more critical for a balanced profile.
Therefore, I favor Ligand B.
Output:
0
2025-04-17 22:39:52,353 - INFO - Batch 348 complete. Total preferences: 5568
2025-04-17 22:39:52,353 - INFO - Processing batch 349/512...
2025-04-17 22:40:41,180 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [367.768, 88.49, 2.772, 2, 5, 0.85, 96.704, 58.666, -4.659, -4.581, 0.158, 16.56, 38.852, 0.084, -4.1]
**Ligand B:** [370.515, 81.08, 0.712, 2, 5, 0.615, 20.589, 63.125, -5.219, -1.93, 0.482, 47.44, -3.723, 0.182, -6.5]
**Step-by-step Comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). A: 367.768, B: 370.515 - No significant difference.
2. **TPSA:** Both are acceptable, but Ligand B (81.08) is better than Ligand A (88.49) as it's closer to the <140 threshold for oral absorption, and more importantly, better for GPCRs.
3. **logP:** Ligand A (2.772) is optimal, while Ligand B (0.712) is a bit low, potentially hindering membrane permeability. This is a significant drawback for a GPCR target.
4. **HBD:** Both have 2 HBD, which is good.
5. **HBA:** Both have 5 HBA, which is good.
6. **QED:** Ligand A (0.85) has a better QED score than Ligand B (0.615), indicating a more drug-like profile.
7. **DILI:** Ligand A (96.704) has a *very* high DILI risk, which is a major concern. Ligand B (20.589) has a low DILI risk, a huge advantage.
8. **BBB:** Ligand B (63.125) shows better BBB penetration than Ligand A (58.666), though neither is exceptionally high. For a cardiovascular target, this isn't paramount, but still a positive for B.
9. **Caco-2:** Ligand B (-5.219) has a much better Caco-2 permeability than Ligand A (-4.659).
10. **Solubility:** Ligand B (-1.93) has better aqueous solubility than Ligand A (-4.581).
11. **hERG:** Ligand A (0.158) has a lower hERG risk than Ligand B (0.482), which is preferable.
12. **Cl_mic:** Ligand A (16.56) has a lower microsomal clearance, suggesting better metabolic stability than Ligand B (47.44).
13. **t1/2:** Ligand A (38.852) has a better in vitro half-life than Ligand B (-3.723).
14. **Pgp:** Ligand B (0.182) has lower P-gp efflux than Ligand A (0.084), which is a positive.
15. **Affinity:** Ligand B (-6.5 kcal/mol) has a significantly stronger binding affinity than Ligand A (-4.1 kcal/mol). This is a substantial advantage, potentially outweighing some ADME concerns.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, Pgp, TPSA, and affinity. Ligand B excels in TPSA, Pgp, and *especially* affinity. While its logP is a concern, the substantial affinity advantage is significant. The extremely high DILI risk of Ligand A is a deal-breaker.
**Conclusion:**
Despite the lower logP, Ligand B's superior binding affinity, lower DILI risk, better Caco-2 permeability, and better solubility make it the more promising drug candidate. The affinity difference is large enough to compensate for the logP issue, and the DILI risk for Ligand A is far too high to ignore.
Output:
0
2025-04-17 22:40:41,180 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, the key priorities are logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB.
Let's compare the ligands property by property:
1. **MW:** Both ligands (349.5 and 350.5 Da) are within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (61.44) is slightly higher than Ligand B (55.57), but both are below the 140 threshold for good absorption.
3. **logP:** Ligand A (2.308) is within the optimal 1-3 range. Ligand B (4.394) is higher, potentially leading to solubility issues and off-target effects. This is a significant negative for Ligand B.
4. **HBD/HBA:** Ligand A has 2 HBD and 3 HBA, while Ligand B has 0 HBD and 4 HBA. Both are reasonable.
5. **QED:** Both ligands have similar QED values (0.694 and 0.697), indicating good drug-likeness.
6. **DILI:** Ligand A (12.641) has a much lower DILI risk than Ligand B (23.808). This is a substantial advantage for Ligand A.
7. **BBB:** Ligand B (91.314) shows significantly better BBB penetration than Ligand A (56.611). However, since ADRB2 is a cardiovascular target, BBB penetration is less crucial than for CNS targets.
8. **Caco-2:** Ligand A (-5.079) and Ligand B (-4.23) both have negative values, which is unusual. It is difficult to interpret this without knowing the scale.
9. **Solubility:** Ligand A (-2.144) has slightly better solubility than Ligand B (-4.58).
10. **hERG:** Both ligands have low hERG inhibition risk (0.527 and 0.803).
11. **Cl_mic:** Ligand A (-2.695) has a lower (better) microsomal clearance than Ligand B (129.877), indicating better metabolic stability. This is a significant advantage for Ligand A.
12. **t1/2:** Ligand A (19.861) has a longer in vitro half-life than Ligand B (-10.591). This is a substantial advantage for Ligand A.
13. **Pgp:** Ligand A (0.1) has much lower P-gp efflux liability than Ligand B (0.629), which is favorable for bioavailability.
14. **Binding Affinity:** Ligand A (-6.8 kcal/mol) has a slightly better binding affinity than Ligand B (-6.3 kcal/mol), although the difference is not huge.
**Overall Assessment:**
Ligand A demonstrates a better balance of properties, particularly regarding DILI risk, metabolic stability (Cl_mic and t1/2), P-gp efflux, and logP. While Ligand B has better BBB penetration, this is less critical for a cardiovascular target. The higher logP of Ligand B is a concern, and its significantly worse metabolic stability is a major drawback. The slightly better binding affinity of Ligand A further supports its selection.
Output:
1
2025-04-17 22:40:41,180 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [353.419, 105.76 , -0.528, 3. , 5. , 0.595, 47.266, 46.762, -5.539, -1.652, 0.075, -9.495, 19.498, 0.009, -6.7 ]
**Ligand B:** [385.339, 107.53 , 1.28 , 4. , 5. , 0.292, 63.552, 63.358, -5.636, -2.483, 0.496, 13.74 , -7.762, 0.065, -7.3 ]
Here's a step-by-step comparison, keeping GPCR priorities (logP, Pgp, TPSA, affinity) in mind:
1. **MW:** Both are within the acceptable 200-500 Da range. Ligand A (353.419) is slightly preferred due to being lower.
2. **TPSA:** Both are around 106-108, which is acceptable, but slightly above the ideal <90 for CNS penetration. Not a major differentiator.
3. **logP:** Ligand A (-0.528) is significantly lower than Ligand B (1.28). While a logP < 1 can be problematic, the difference here isn't huge. Ligand B is better here.
4. **HBD:** Both have reasonable HBD counts (3 and 4).
5. **HBA:** Both have 5 HBA, which is acceptable.
6. **QED:** Ligand A (0.595) has a much better QED score than Ligand B (0.292), indicating better overall drug-likeness. This is a significant advantage for Ligand A.
7. **DILI:** Ligand A (47.266) has a substantially lower DILI risk than Ligand B (63.552). This is a major advantage for Ligand A.
8. **BBB:** Both have low BBB penetration (46.762 and 63.358). This isn't critical for ADRB2 (cardiovascular target), but higher is always better. Ligand B is slightly better.
9. **Caco-2:** Both have very poor Caco-2 permeability (-5.539 and -5.636). This is a concern for oral bioavailability, and both need improvement.
10. **Solubility:** Both have poor solubility (-1.652 and -2.483). This is also a concern.
11. **hERG:** Ligand A (0.075) has a lower hERG risk than Ligand B (0.496), which is a positive.
12. **Cl_mic:** Ligand A (-9.495) has a much lower (better) microsomal clearance than Ligand B (13.74). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (19.498) has a longer in vitro half-life than Ligand B (-7.762). This is a significant advantage.
14. **Pgp:** Both have very low Pgp efflux liability (0.009 and 0.065).
15. **Affinity:** Ligand B (-7.3) has a slightly better binding affinity than Ligand A (-6.7), but the difference is less than 1.5 kcal/mol.
**Overall Assessment:**
Ligand A is the better candidate. While Ligand B has slightly better affinity and logP, Ligand A excels in critical areas like QED, DILI risk, metabolic stability (Cl_mic, t1/2), and hERG risk. The lower DILI and better metabolic profile are particularly important for a cardiovascular drug. The slightly lower affinity of Ligand A can likely be optimized in subsequent iterations. The poor Caco-2 and solubility are shared concerns that would need to be addressed regardless of which lead is chosen.
Output:
1
2025-04-17 22:40:41,181 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (357.479 Da and 369.487 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (55.63) is significantly better than Ligand B (95.58). For a GPCR, keeping TPSA low is beneficial for permeability, and Ligand A is well below the 140 threshold. Ligand B is approaching a level that could hinder absorption.
**3. logP:** Ligand A (3.911) is optimal, while Ligand B (0.673) is quite low. A logP below 1 can lead to poor membrane permeability. This is a substantial advantage for Ligand A.
**4. H-Bond Donors:** Ligand A (1) and Ligand B (2) are both acceptable.
**5. H-Bond Acceptors:** Ligand A (5) and Ligand B (4) are both acceptable.
**6. QED:** Both ligands have similar QED values (0.728 and 0.745), indicating good drug-like properties.
**7. DILI:** Ligand A (62.35) has a higher DILI risk than Ligand B (41.838). This is a negative for Ligand A, but not a dealbreaker.
**8. BBB:** Ligand B (55.215) has a better BBB penetration score than Ligand A (28.383). However, since ADRB2 is primarily a cardiovascular target, BBB penetration isn't a primary concern.
**9. Caco-2 Permeability:** Both have negative values, indicating poor permeability. This is concerning for both, but the negative value for Ligand A (-5.102) is less severe than that of Ligand B (-5.522).
**10. Aqueous Solubility:** Both ligands have very poor aqueous solubility (-3.288 and -2.359). This is a significant drawback for both, potentially leading to formulation challenges.
**11. hERG Inhibition:** Ligand A (0.418) has a slightly better hERG profile than Ligand B (0.123), indicating a lower risk of cardiotoxicity.
**12. Microsomal Clearance:** Ligand B (26.836) has significantly lower microsomal clearance than Ligand A (72.133). Lower clearance suggests better metabolic stability, which is a positive for Ligand B.
**13. In vitro Half-Life:** Ligand B (-21.441) has a much longer in vitro half-life than Ligand A (4.55). This is a major advantage for Ligand B, potentially allowing for less frequent dosing.
**14. P-gp Efflux:** Ligand A (0.637) has better P-gp efflux properties than Ligand B (0.022). Lower P-gp efflux is generally preferred for improved bioavailability.
**15. Binding Affinity:** Ligand B (-7.8) has a significantly stronger binding affinity than Ligand A (-6.2). A 1.6 kcal/mol difference is substantial and can often outweigh minor ADME drawbacks.
**Overall Assessment:**
While Ligand B has a better half-life, lower clearance, and superior binding affinity, its significantly lower logP and higher TPSA are concerning. Ligand A, despite a higher DILI risk, has a much more favorable logP and TPSA, which are crucial for permeability and absorption, especially for a GPCR target. The stronger binding affinity of Ligand B is attractive, but the poor predicted permeability makes it less likely to reach the target *in vivo*. The solubility issues are problematic for both, but can potentially be addressed with formulation strategies.
Considering the GPCR-specific priorities (logP, TPSA, affinity), and the overall balance of properties, Ligand A is the more promising candidate.
Output:
1
2025-04-17 22:40:41,181 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (373.475 and 394.299 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand B (84.32) is better than Ligand A (96.02). Both are below 140, but lower TPSA generally favors absorption.
3. **logP:** Both ligands (-0.588 and -0.333) are relatively low. While not ideal (optimal is 1-3), they aren't excessively high. Ligand B is slightly better.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD is generally better for permeability.
5. **HBA:** Both ligands (5) are acceptable.
6. **QED:** Both ligands (0.671 and 0.641) are good, indicating drug-like properties. No significant difference.
7. **DILI:** Ligand B (23.885) is significantly better than Ligand A (35.014). Lower DILI risk is a major advantage.
8. **BBB:** Ligand A (65.839) is better than Ligand B (22.8). While ADRB2 isn't necessarily a CNS target, some degree of BBB penetration can be beneficial for distribution.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-4.978) is slightly better than Ligand B (-5.003).
10. **Solubility:** Ligand A (-1.608) is slightly better than Ligand B (-0.935). Higher solubility is preferred.
11. **hERG:** Both ligands (0.119 and 0.146) have very low hERG risk, which is excellent. No clear advantage.
12. **Cl_mic:** Ligand B (-12.327) is better than Ligand A (12.908). Lower clearance indicates better metabolic stability.
13. **t1/2:** Ligand B (-9.475) is better than Ligand A (-12.525). Longer half-life is desirable.
14. **Pgp:** Both ligands (0.025 and 0.02) have very low P-gp efflux, which is excellent. No clear advantage.
15. **Binding Affinity:** Ligand B (-6.9 kcal/mol) is slightly better than Ligand A (-6.1 kcal/mol). This difference of 0.8 kcal/mol is significant and can outweigh some ADME drawbacks.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. While both have suboptimal logP values, Ligand B has a better TPSA and a better binding affinity. The lower DILI risk and improved metabolic stability (Cl_mic and t1/2) of Ligand B are also significant advantages.
**Overall Assessment:**
Ligand B demonstrates a better balance of properties, particularly regarding safety (DILI) and pharmacokinetics (Cl_mic, t1/2, affinity). The slightly better affinity and lower DILI risk are compelling. While Ligand A has a slightly better BBB score, the overall profile of Ligand B is more favorable for development.
Output:
0
2025-04-17 22:40:41,181 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (373.9 and 352.4 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (50.8) is better than Ligand B (59.8), being closer to the <140 threshold for good absorption.
3. **logP:** Ligand A (4.853) is higher than Ligand B (3.052). While both are within the 1-3 range, Ligand A is pushing the upper limit. Ligand B is optimal.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Both have 4 HBA, which is good.
6. **QED:** Ligand B (0.782) has a slightly better QED score than Ligand A (0.601), indicating a more drug-like profile.
7. **DILI:** Ligand B (25.785) has a significantly lower DILI risk than Ligand A (69.833). This is a major advantage for Ligand B.
8. **BBB:** Ligand B (90.074) has a much higher BBB penetration score than Ligand A (27.259). While ADRB2 isn't exclusively a CNS target, improved BBB penetration can still be beneficial and reduce off-target effects.
9. **Caco-2:** Ligand A (-5.398) and Ligand B (-4.59) are both negative, indicating poor permeability. Ligand B is slightly better.
10. **Solubility:** Ligand A (-5.725) and Ligand B (-4.382) are both poor, but Ligand B is slightly better.
11. **hERG:** Ligand A (0.501) has a slightly higher hERG risk than Ligand B (0.391), but both are relatively low.
12. **Cl_mic:** Ligand B (39.486) has a significantly lower microsomal clearance than Ligand A (63.866), suggesting better metabolic stability.
13. **t1/2:** Ligand A (5.738) has a longer in vitro half-life than Ligand B (1.847). This is a positive for Ligand A.
14. **Pgp:** Ligand A (0.77) has higher P-gp efflux liability than Ligand B (0.048). Ligand B is much better.
15. **Affinity:** Ligand A (-7.0) has slightly better binding affinity than Ligand B (-6.9). This is a small advantage, but not substantial enough to outweigh other factors.
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand B excels in logP, Pgp, and has a better TPSA. The affinity difference is minimal.
**Overall Assessment:**
Ligand B demonstrates a significantly better safety profile (lower DILI), improved metabolic stability (lower Cl_mic), and better predicted permeability and efflux (Caco-2, Pgp). While Ligand A has a slightly longer half-life and marginally better affinity, the advantages of Ligand B in ADME-Tox properties are more critical for overall drug development success.
Output:
0
2025-04-17 22:40:41,181 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (368.865 and 346.519 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (76.72) is higher than Ligand B (50.16). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B has a clear advantage.
3. **logP:** Ligand A (1.457) is slightly lower than Ligand B (2.931), both are within the optimal 1-3 range. Ligand B is closer to the upper end, potentially leading to some solubility concerns, but not critically.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 3 HBA, while Ligand B has 4. Both are acceptable, under the limit of 10.
6. **QED:** Both ligands have good QED scores (0.854 and 0.892), indicating good drug-like properties. No significant difference.
7. **DILI:** Ligand A (35.983) has a significantly lower DILI risk than Ligand B (10.585). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (89.957) has a much higher BBB penetration score than Ligand A (58.434). While ADRB2 isn't a CNS target, some degree of BBB penetration can sometimes indicate favorable permeability characteristics.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.911 and -4.874), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Both ligands have negative solubility values (-2.198 and -2.165), indicating very poor aqueous solubility. This is a major drawback for both.
11. **hERG:** Ligand A (0.255) has a lower hERG inhibition liability than Ligand B (0.513), indicating a lower risk of cardiotoxicity. This is a positive for Ligand A, especially given the cardiovascular target.
12. **Cl_mic:** Ligand A (-13.974) has a much lower (better) microsomal clearance than Ligand B (27.023), suggesting better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand B (14.376) has a significantly longer in vitro half-life than Ligand A (-3.466). This is a positive for Ligand B.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.015 and 0.206). No significant difference.
15. **Binding Affinity:** Ligand B (-8.1) has a slightly better binding affinity than Ligand A (-8.0). While this is a small difference, it's still a positive for Ligand B.
**Overall Assessment & GPCR-Specific Priorities:**
For a cardiovascular GPCR like ADRB2, affinity, metabolic stability, and safety (DILI, hERG) are paramount. While Ligand B has slightly better affinity and half-life, Ligand A demonstrates significantly better safety profiles (lower DILI and hERG) and improved metabolic stability (lower Cl_mic). The poor Caco-2 and solubility are concerning for both, but can be addressed with formulation strategies. The lower DILI and hERG risks for Ligand A are particularly important for a cardiovascular target, where off-target effects on the heart are a major concern.
**Output:**
1
2025-04-17 22:40:41,181 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [346.475, 97.11, 2.423, 3, 4, 0.763, 47.964, 79.062, -5.049, -3.176, 0.414, 33.782, -4.966, 0.064, -7.9]
**Ligand B:** [348.447, 87.46, 1.195, 2, 5, 0.691, 49.787, 23.032, -4.988, -2.397, 0.083, 16.334, 8.033, 0.04, -6.8]
Here's a breakdown comparing each parameter:
1. **MW:** Both are within the ideal range (200-500 Da). A: 346.475, B: 348.447 - very similar.
2. **TPSA:** A: 97.11, B: 87.46. Both are acceptable for oral absorption (<140), but B is better.
3. **logP:** A: 2.423, B: 1.195. Both are within the optimal range (1-3), but A is slightly preferred.
4. **HBD:** A: 3, B: 2. Both are good.
5. **HBA:** A: 4, B: 5. Both are acceptable.
6. **QED:** A: 0.763, B: 0.691. A is slightly better, indicating a more drug-like profile.
7. **DILI:** A: 47.964, B: 49.787. Both are low risk (<60), very similar.
8. **BBB:** A: 79.062, B: 23.032. A is *significantly* better for potential CNS penetration (although not crucial for a cardiovascular target, it's a bonus).
9. **Caco-2:** A: -5.049, B: -4.988. Both are negative, indicating poor permeability. This is a concern for both.
10. **Solubility:** A: -3.176, B: -2.397. Both are poor, but B is slightly better.
11. **hERG:** A: 0.414, B: 0.083. B is significantly better, indicating lower cardiotoxicity risk.
12. **Cl_mic:** A: 33.782, B: 16.334. B has lower clearance, suggesting better metabolic stability.
13. **t1/2:** A: -4.966, B: 8.033. B has a much longer *in vitro* half-life, a significant advantage.
14. **Pgp:** A: 0.064, B: 0.04. Both are low, indicating minimal P-gp efflux.
15. **Affinity:** A: -7.9, B: -6.8. A has a substantially stronger binding affinity (1.1 kcal/mol difference).
**GPCR-Specific Considerations:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. A has a better logP and significantly better affinity. B has better TPSA and hERG. Metabolic stability (Cl_mic and t1/2) are also important.
**Decision:**
While Ligand B has a better hERG profile and metabolic stability, the significantly stronger binding affinity of Ligand A (-7.9 vs -6.8 kcal/mol) is a major advantage that can potentially overcome some of its ADME drawbacks. The better BBB penetration is also a plus. The Caco-2 and solubility are poor for both, but the potency difference is substantial.
Therefore, I would choose Ligand A.
1
2025-04-17 22:40:41,182 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (351.451) is slightly lower, which can be favorable for permeability.
2. **TPSA:** Both are reasonably close to the 140 A^2 threshold for oral absorption (A: 101.56, B: 102.32).
3. **logP:** Ligand A (-0.32) is a bit low, potentially hindering permeation. Ligand B (0.504) is better, falling within the optimal 1-3 range.
4. **HBD:** Both ligands have acceptable HBD counts (A: 3, B: 2).
5. **HBA:** Both ligands have acceptable HBA counts (A: 5, B: 6).
6. **QED:** Both have reasonable QED scores (A: 0.596, B: 0.448), indicating drug-likeness, but A is better.
7. **DILI:** Ligand A (15.51) has a significantly lower DILI risk than Ligand B (60.799), a major advantage.
8. **BBB:** Both have relatively low BBB penetration, which isn't a primary concern for a cardiovascular target like ADRB2. Ligand B (65.452) is slightly better than A (16.363).
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. The values are similar (-5.602 for A, -5.134 for B).
10. **Solubility:** Ligand A (-0.83) has slightly better solubility than Ligand B (-2.461).
11. **hERG:** Both ligands have very low hERG inhibition risk (A: 0.069, B: 0.297).
12. **Cl_mic:** Ligand A (-9.064) has significantly lower microsomal clearance, indicating better metabolic stability, which is crucial. Ligand B (25.45) suggests faster metabolism.
13. **t1/2:** Ligand A (-26.203) has a longer in vitro half-life than Ligand B (-51.346).
14. **Pgp:** Both have very low Pgp efflux liability (A: 0.003, B: 0.117).
15. **Binding Affinity:** Ligand A (-7.4) has a slightly better binding affinity than Ligand B (-5.8).
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, and affinity are important. While both ligands have acceptable TPSA, Ligand B has a more favorable logP. However, the significantly better DILI score, metabolic stability (Cl_mic, t1/2), and slightly better affinity of Ligand A outweigh the logP advantage of Ligand B. The poor Caco-2 values for both are concerning, but can be addressed with formulation strategies.
**Conclusion:**
Considering the balance of properties, Ligand A is the more promising candidate due to its superior safety profile (DILI), metabolic stability, and binding affinity.
Output:
1
2025-04-17 22:40:41,182 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (a GPCR) drug candidates.
**Ligand A:** [344.455, 69.64, 2.856, 2, 3, 0.882, 30.322, 60.76, -4.822, -4.285, 0.369, 50.581, -22.067, 0.111, -6.8]
**Ligand B:** [346.387, 117.09, 1.308, 3, 5, 0.699, 75.184, 34.005, -5.508, -3.007, 0.24, 10.241, 27.748, 0.15, -5.7]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). A is 344.455, B is 346.387 - very similar.
2. **TPSA:** A (69.64) is excellent, well below 140 and good for oral absorption. B (117.09) is higher, but still acceptable, though less ideal.
3. **logP:** A (2.856) is optimal. B (1.308) is a bit low, potentially impacting permeability.
4. **HBD:** A (2) is good. B (3) is acceptable.
5. **HBA:** A (3) is good. B (5) is acceptable.
6. **QED:** A (0.882) is very good, indicating high drug-likeness. B (0.699) is still reasonable, but lower.
7. **DILI:** A (30.322) is excellent, very low risk. B (75.184) is significantly higher, indicating a moderate risk of liver injury.
8. **BBB:** A (60.76) is moderate. B (34.005) is quite low. While ADRB2 isn't exclusively a CNS target, some CNS penetration can be beneficial for understanding off-target effects and potential side effects.
9. **Caco-2:** A (-4.822) is very good, suggesting excellent absorption. B (-5.508) is also good, but slightly less favorable than A.
10. **Solubility:** A (-4.285) is good. B (-3.007) is also good.
11. **hERG:** A (0.369) is very low risk. B (0.24) is even lower, but both are excellent.
12. **Cl_mic:** A (50.581) is reasonable. B (10.241) is much lower, indicating better metabolic stability.
13. **t1/2:** A (-22.067) is excellent (negative values indicate longer half-life). B (27.748) is positive, suggesting a shorter half-life.
14. **Pgp:** A (0.111) is very low efflux, favorable for bioavailability. B (0.15) is slightly higher, but still acceptable.
15. **Affinity:** A (-6.8) is slightly better than B (-5.7), a difference of 1.1 kcal/mol.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. A has a better logP and TPSA. While both have good Pgp, A is slightly better. The affinity difference of 1.1 kcal/mol is significant, and A's superior ADME profile further strengthens its position. The DILI risk for B is a significant concern.
**Conclusion:**
Ligand A is the more promising candidate. It has a better balance of properties, particularly regarding drug-likeness (QED), DILI risk, metabolic stability (Cl_mic, t1/2), and affinity. While Ligand B has a slightly better hERG profile and metabolic stability, the higher DILI risk and lower affinity are significant drawbacks.
**Output:**
1
2025-04-17 22:40:41,182 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (341.371 and 353.423 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (109.04) is better than Ligand B (125.42). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have similar logP values (1.253 and 1.284), falling within the optimal 1-3 range.
4. **HBD:** Both ligands have 2 HBD, which is acceptable.
5. **HBA:** Ligand A has 6 HBA, while Ligand B has 5. Both are within the acceptable limit of 10.
6. **QED:** Ligand A (0.788) has a significantly better QED score than Ligand B (0.28), indicating a more drug-like profile.
7. **DILI:** Ligand A (70.725) has a higher DILI risk than Ligand B (25.514). This is a significant drawback for Ligand A.
8. **BBB:** Not a primary concern for a cardiovascular target, but Ligand A (55.913) is slightly better than Ligand B (48.003).
9. **Caco-2:** Ligand A (-4.889) is better than Ligand B (-5.444), suggesting better intestinal absorption.
10. **Solubility:** Ligand A (-3.411) is better than Ligand B (-0.566). Solubility is important for bioavailability.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.283 and 0.234).
12. **Cl_mic:** Ligand B (-6.201) has a *much* lower (better) microsomal clearance than Ligand A (37.204), indicating better metabolic stability.
13. **t1/2:** Ligand B (13.063 hours) has a longer in vitro half-life than Ligand A (9.403 hours).
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.057 and 0.012).
15. **Binding Affinity:** Ligand B (-6.9 kcal/mol) has a slightly better binding affinity than Ligand A (-5.7 kcal/mol). This 1.2 kcal/mol difference is significant, and can outweigh some ADME concerns.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Both ligands are good on logP and Pgp. Ligand A is better on TPSA, while Ligand B is better on affinity. However, the DILI risk for Ligand A is concerning, and the significantly better metabolic stability (Cl_mic and t1/2) of Ligand B is a major advantage. The slightly better affinity of Ligand B further solidifies its position.
**Conclusion:**
Despite Ligand A's slightly better TPSA and solubility, Ligand B's superior binding affinity, significantly lower DILI risk, and improved metabolic stability make it the more promising drug candidate.
Output:
0
2025-04-17 22:40:41,182 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (375.479 and 362.47 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand B (40.62) is significantly better than Ligand A (96.01). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have a logP of around 3, which is optimal.
4. **HBD:** Ligand A (3) is reasonable, while Ligand B (0) is even better, potentially improving permeability.
5. **HBA:** Ligand A (7) is acceptable, while Ligand B (3) is better.
6. **QED:** Both ligands have good QED scores (0.575 and 0.773), indicating drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand B (36.293) has a much lower DILI risk than Ligand A (88.755). This is a major advantage for Ligand B.
8. **BBB:** Ligand B (84.451) has better BBB penetration than Ligand A (55.176). While not critical for a cardiovascular target, it's a positive attribute.
9. **Caco-2:** Ligand A (-5.631) and Ligand B (-4.579) both have negative values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
10. **Solubility:** Ligand A (-3.009) and Ligand B (-4.18) both have negative values, indicating poor solubility. This is a concern for both.
11. **hERG:** Ligand A (0.213) has a lower hERG risk than Ligand B (0.719). This is a slight advantage for Ligand A.
12. **Cl_mic:** Ligand A (37.48) and Ligand B (34.941) have similar microsomal clearance values.
13. **t1/2:** Ligand B (6.359) has a shorter half-life than Ligand A (48.101). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.189) has lower P-gp efflux than Ligand B (0.586), which is favorable.
15. **Affinity:** Ligand A (-7.8 kcal/mol) has a significantly better binding affinity than Ligand B (-6.1 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME drawbacks.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), affinity, logP, TPSA, and Pgp are important. Ligand A excels in affinity and Pgp, while Ligand B has a better TPSA. The difference in affinity is substantial (1.7 kcal/mol).
**Overall Assessment:**
While Ligand B has better DILI, BBB, and H-bonding properties, Ligand A's significantly stronger binding affinity (-7.8 vs -6.1 kcal/mol) is a critical advantage for a GPCR target. The longer half-life of Ligand A is also a positive. The poorer solubility and Caco-2 values of both ligands are concerns, but the potency advantage of Ligand A is likely to be more impactful in early development.
Output:
1
2025-04-17 22:40:41,182 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's analyze each ligand against the provided guidelines, keeping in mind ADRB2 is a GPCR, so logP, Pgp, TPSA, and affinity are key.
* **Molecular Weight:** Both ligands (345.443 and 355.391 Da) fall comfortably within the ideal 200-500 Da range.
* **TPSA:** Ligand A (67.6) is significantly better than Ligand B (106.2). A TPSA under 140 is good for oral absorption, but lower is preferable for GPCRs, and A is much closer to the ideal.
* **logP:** Ligand A (3.927) is optimal, while Ligand B (-0.889) is quite low, potentially hindering membrane permeability. This is a significant drawback for B.
* **H-Bond Donors/Acceptors:** Ligand A (1 HBD, 4 HBA) is better balanced than Ligand B (2 HBD, 6 HBA). Both are within acceptable limits.
* **QED:** Ligand A (0.826) has a superior drug-likeness score compared to Ligand B (0.547).
* **DILI:** Ligand B (37.999) has a much lower DILI risk than Ligand A (54.168), which is a positive for B.
* **BBB:** Ligand B (75.843) shows better BBB penetration than Ligand A (62.854). While ADRB2 isn't necessarily a CNS target, some peripheral ADRB2 activity can be modulated by CNS effects, and higher BBB is generally a plus.
* **Caco-2:** Both have negative values, indicating poor permeability. Ligand A (-4.529) is slightly better than Ligand B (-5.052).
* **Solubility:** Ligand A (-3.96) is better than Ligand B (-1.385).
* **hERG:** Ligand A (0.318) has a lower hERG risk than Ligand B (0.188). This is a significant advantage for A.
* **Cl_mic:** Ligand B (-41.567) has significantly better metabolic stability (lower clearance) than Ligand A (103.281). This is a major advantage for B.
* **t1/2:** Ligand B (-24.928) has a longer in vitro half-life than Ligand A (-2.724). This is a strong positive for B.
* **Pgp:** Ligand A (0.082) has lower P-gp efflux than Ligand B (0.005), which is preferable.
* **Binding Affinity:** Ligand B (-7.3 kcal/mol) has a slightly better binding affinity than Ligand A (-6.6 kcal/mol). This 0.7 kcal/mol difference is significant and could outweigh some of the ADME drawbacks of B.
**Overall Assessment:**
Ligand B has a superior binding affinity and significantly better metabolic stability (Cl_mic) and half-life. It also has a lower DILI risk and better BBB penetration. However, its low logP and higher TPSA are concerning. Ligand A has a better logP, TPSA, QED, solubility, and hERG profile, but suffers from poorer metabolic stability and a slightly weaker binding affinity.
Considering the importance of metabolic stability for *in vivo* efficacy and the relatively small difference in binding affinity, the improved ADME properties of Ligand B, particularly the lower clearance and longer half-life, are more compelling. The lower logP can be addressed with prodrug strategies or formulation techniques.
Output:
0
2025-04-17 22:40:41,183 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (361.467) is slightly higher than Ligand B (343.471), but both are acceptable.
2. **TPSA:** Ligand A (82.53) is better than Ligand B (52.65). While both are reasonably low, lower TPSA generally favors better membrane permeability, making Ligand B preferable.
3. **logP:** Both ligands have good logP values (A: 1.063, B: 1.712) within the optimal 1-3 range. Ligand B is slightly more lipophilic, which could be beneficial for receptor binding, but not dramatically so.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1). Both are within the acceptable limit of 5.
5. **HBA:** Ligand A (5) is higher than Ligand B (3). Both are within the acceptable limit of 10.
6. **QED:** Ligand A (0.841) is better than Ligand B (0.773), indicating a more drug-like profile.
7. **DILI:** Ligand B (18.108) has a significantly lower DILI risk than Ligand A (59.907). This is a major advantage for Ligand B.
8. **BBB:** Ligand B (75.921) has a much higher BBB penetration percentile than Ligand A (25.359). Given ADRB2 is a GPCR, and potential for CNS side effects or targeting, this is a significant advantage for Ligand B.
9. **Caco-2:** Ligand A (-5.151) and Ligand B (-4.726) are both negative, which is unusual and suggests poor permeability in this assay. The values are very close, so this isn't a major differentiator.
10. **Solubility:** Ligand A (-2.795) and Ligand B (-1.925) are both negative, indicating poor aqueous solubility. Ligand B is slightly better.
11. **hERG:** Ligand A (0.167) has a slightly lower hERG inhibition liability than Ligand B (0.397), which is preferable.
12. **Cl_mic:** Ligand A (31.685) has a lower microsomal clearance than Ligand B (44.802), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-23.028) has a negative half-life, which is concerning. Ligand B (6.813) has a positive half-life, indicating better in vitro stability.
14. **Pgp:** Ligand A (0.131) has a lower P-gp efflux liability than Ligand B (0.145), which is preferable.
15. **Binding Affinity:** Ligand B (-0.8) has a significantly better binding affinity than Ligand A (-6.5). This is a crucial factor, and the 5.7 kcal/mol difference is substantial.
**Overall Assessment:**
While Ligand A has a better QED, lower Pgp efflux, and lower microsomal clearance, Ligand B excels in several critical areas for a GPCR target like ADRB2. The significantly lower DILI risk, much higher BBB penetration, and *far* superior binding affinity of Ligand B outweigh the advantages of Ligand A. The positive in vitro half-life of Ligand B is also a strong positive. The solubility and Caco-2 values are poor for both, but the affinity difference is so large it's likely to be the dominating factor.
Output:
0
2025-04-17 22:40:41,183 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (345.4 & 352.4 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (95.33) is better than Ligand B (104.73). Both are acceptable for a non-CNS GPCR, but lower is generally preferred.
3. **logP:** Ligand A (1.715) is optimal, while Ligand B (0.358) is a bit low, potentially hindering permeability. This favors Ligand A.
4. **HBD:** Ligand A (1) is better than Ligand B (3). Lower HBD is generally preferred for permeability.
5. **HBA:** Both ligands have 5 HBA, which is acceptable.
6. **QED:** Ligand A (0.91) is significantly better than Ligand B (0.473), indicating a more drug-like profile. This is a substantial advantage for Ligand A.
7. **DILI:** Ligand B (23.769) has a much lower DILI risk than Ligand A (63.746). This is a significant advantage for Ligand B.
8. **BBB:** This is less critical for ADRB2 (cardiovascular target), but Ligand B (27.104) is slightly better than Ligand A (43.001).
9. **Caco-2:** Ligand A (-4.987) is better than Ligand B (-5.107), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-1.725) is better than Ligand B (-1.381).
11. **hERG:** Ligand A (0.432) is better than Ligand B (0.102), indicating a lower risk of cardiotoxicity.
12. **Cl_mic:** Ligand B (17.823) has lower microsomal clearance than Ligand A (27.326), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-49.582) has a much longer in vitro half-life than Ligand B (-3.654). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.088) has lower P-gp efflux than Ligand B (0.027), which is beneficial.
15. **Affinity:** Ligand A (-6.7 kcal/mol) has slightly better binding affinity than Ligand B (-5.9 kcal/mol).
**Overall Assessment:**
For a cardiovascular GPCR like ADRB2, we prioritize affinity, logP, and metabolic stability. Ligand A has a slightly better affinity, a significantly better logP, and a much longer half-life. While Ligand B has a lower DILI risk, the superior drug-like properties (QED), permeability (Caco-2), solubility, and half-life of Ligand A outweigh this concern. The difference in DILI risk is not drastic enough to disqualify Ligand A, especially given its other advantages.
**Output:**
1
2025-04-17 22:40:41,183 - INFO - Here's my reasoning and the final output:
**Reasoning:**
We are evaluating two ligands for activity at the ADRB2 receptor, a GPCR involved in cardiovascular function. Therefore, we prioritize logP, TPSA, Pgp efflux, binding affinity, and, to a lesser extent, BBB.
Let's break down the comparison:
1. **MW:** Both ligands (349.435 and 353.463 Da) fall within the ideal 200-500 Da range.
2. **TPSA:** Ligand B (98.74) is significantly better than Ligand A (116.19). Lower TPSA generally improves oral absorption, a key factor for a cardiovascular drug.
3. **logP:** Ligand A (2.356) is better than Ligand B (0.274). A logP between 1-3 is optimal, and Ligand B is quite low, potentially hindering membrane permeability.
4. **HBD/HBA:** Both have similar numbers of H-bond donors (2 vs 3) and acceptors (4 each), which are acceptable.
5. **QED:** Ligand B (0.612) has a better QED score than Ligand A (0.288), indicating a more drug-like profile.
6. **DILI:** Ligand B (7.251) has a much lower DILI risk than Ligand A (35.479), a significant advantage.
7. **BBB:** Ligand B (66.809) has a better BBB penetration than Ligand A (43.815), but this is less critical for a cardiovascular target.
8. **Caco-2:** Both have negative Caco-2 permeability values, which is unusual and suggests a potential issue with intestinal absorption. This needs further investigation, but it's not a deciding factor at this stage.
9. **Solubility:** Both have negative solubility values, which is also unusual and concerning.
10. **hERG:** Both ligands have very low hERG inhibition liability (0.202 and 0.109), which is excellent.
11. **Cl_mic:** Ligand A (27.67) has a higher (worse) microsomal clearance than Ligand B (-6.627), indicating lower metabolic stability.
12. **t1/2:** Ligand B (-32.351) has a much longer in vitro half-life than Ligand A (23.982), which is highly desirable.
13. **Pgp:** Both have very low Pgp efflux liability (0.021 and 0.006), which is good.
14. **Binding Affinity:** Ligand A (-6.8) has a slightly better binding affinity than Ligand B (-6.0), but the difference is less than 1.5 kcal/mol.
**Overall Assessment:**
Despite Ligand A having a slightly better binding affinity, Ligand B is the superior candidate. The lower DILI risk, better QED score, significantly improved metabolic stability (lower Cl_mic and longer t1/2), and better TPSA outweigh the small difference in binding affinity. The logP of Ligand B is a concern, but the other advantages make it the more promising drug candidate. The negative solubility and Caco-2 values for both ligands are red flags that require further investigation, but are not enough to disqualify Ligand B given its other favorable properties.
**Output:**
0
2025-04-17 22:40:41,183 - INFO - Batch 349 complete. Total preferences: 5584
2025-04-17 22:40:41,183 - INFO - Processing batch 350/512...
2025-04-17 22:41:30,163 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (343.471 and 338.407 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (71.09) is slightly higher than Ligand B (62.55). Both are below the 140 A^2 threshold for good oral absorption, but closer to the 90 A^2 threshold for CNS targets.
3. **logP:** Both ligands have excellent logP values (3.209 and 3.182), falling within the optimal 1-3 range. No significant difference.
4. **HBD:** Ligand A has 2 HBD, while Ligand B has 1. Both are within the acceptable limit of <=5.
5. **HBA:** Both ligands have 3 HBA, well within the acceptable limit of <=10.
6. **QED:** Ligand B (0.935) has a slightly higher QED score than Ligand A (0.833), indicating a more drug-like profile.
7. **DILI:** Ligand A (36.758) has a significantly lower DILI risk than Ligand B (59.907). This is a major advantage for Ligand A.
8. **BBB:** Both ligands have similar BBB penetration (63.746 and 61.923). While not exceptionally high, they are reasonable for a peripherally acting GPCR like ADRB2.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.85 and -4.751). This is unusual and suggests poor permeability.
10. **Solubility:** Both ligands have negative solubility values (-3.567 and -3.789). This is also unusual and suggests poor solubility.
11. **hERG:** Both ligands have low hERG inhibition liability (0.524 and 0.547), which is good.
12. **Cl_mic:** Ligand A (25.449) has a lower microsomal clearance than Ligand B (54.01), suggesting better metabolic stability.
13. **t1/2:** Ligand B (74.797) has a significantly longer in vitro half-life than Ligand A (1.242). This is a significant advantage for Ligand B.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.19 and 0.259), which is good.
15. **Binding Affinity:** Ligand B (-7.7 kcal/mol) has a substantially stronger binding affinity than Ligand A (-6.7 kcal/mol). This is a 1.0 kcal/mol difference, which is a significant advantage.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are important. Both ligands perform well on logP and Pgp. TPSA is acceptable for both. However, Ligand B has a much stronger binding affinity, which is the most critical factor for GPCRs.
**Overall Assessment:**
While Ligand A has a lower DILI risk and better metabolic stability, the significantly stronger binding affinity of Ligand B (-7.7 vs -6.7 kcal/mol) outweighs these advantages. The longer half-life of Ligand B is also a positive. The poor Caco-2 and solubility values are concerning for both, but can be addressed through formulation strategies.
Output:
0
2025-04-17 22:41:30,163 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [344.459, 78.09, 2.839, 2, 3, 0.641, 54.983, 58.86, -5.361, -3.313, 0.242, 48.488, 8.935, 0.177, -6.2]
**Ligand B:** [370.519, 84.3, 2.007, 1, 5, 0.721, 53.625, 67.662, -4.767, -2.94, 0.291, 81.862, -23.701, 0.076, -5.8]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (344.459) is slightly preferred due to being closer to the lower end, potentially aiding permeability.
2. **TPSA:** Both are acceptable (below 140), but Ligand A (78.09) is better than Ligand B (84.3), aligning with GPCR preference for lower TPSA.
3. **logP:** Both are within the optimal range (1-3). Ligand A (2.839) is slightly higher, which is generally fine, but Ligand B (2.007) is closer to the lower bound.
4. **HBD:** Ligand A (2) is slightly better than Ligand B (1). Lower is generally preferred.
5. **HBA:** Ligand A (3) is better than Ligand B (5). Lower is generally preferred.
6. **QED:** Both are good (>0.5), with Ligand B (0.721) being slightly better.
7. **DILI:** Both are acceptable (<60), with Ligand B (53.625) being slightly better than Ligand A (54.983).
8. **BBB:** Ligand B (67.662) is better than Ligand A (58.86). While not a CNS target, some BBB penetration can be beneficial for distribution.
9. **Caco-2:** Ligand A (-5.361) is better than Ligand B (-4.767). Higher is better, indicating better absorption.
10. **Solubility:** Ligand A (-3.313) is better than Ligand B (-2.94). Higher is better.
11. **hERG:** Both are very low (0.242 and 0.291), indicating minimal cardiotoxicity risk.
12. **Cl_mic:** Ligand A (48.488) is significantly better than Ligand B (81.862). Lower clearance is preferred for metabolic stability.
13. **t1/2:** Ligand A (8.935) is better than Ligand B (-23.701). A positive value is much better than a negative value.
14. **Pgp:** Both are low (0.177 and 0.076), indicating minimal efflux. Ligand B is slightly better.
15. **Affinity:** Ligand A (-6.2) is slightly better than Ligand B (-5.8).
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand A appears to be the more promising candidate. While Ligand B has a slightly better QED, BBB, and Pgp, Ligand A significantly outperforms in metabolic stability (Cl_mic and t1/2), solubility, Caco-2 permeability, and has a slightly better binding affinity. The lower TPSA and H-bond counts of Ligand A are also favorable for GPCR targeting. The difference in affinity, while small, combined with the ADME advantages, tips the balance in favor of Ligand A.
Output:
1
2025-04-17 22:41:30,163 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 drug candidates. ADRB2 is a GPCR, so we'll prioritize logP, Pgp, TPSA, and affinity, alongside general drug-like properties.
**Ligand A:** [363.403, 134.66 , 0.225, 3. , 7. , 0.594, 85.653, 35.052, -5.872, -2.739, 0.205, 24.293, -13.656, 0.027, -7. ]
**Ligand B:** [350.459, 98.66 , 2.122, 4. , 4. , 0.605, 20.008, 21.404, -5.455, -2.724, 0.424, 37.968, -19.606, 0.077, -6.6 ]
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (350.459) is slightly lower, which is generally favorable.
2. **TPSA:** Ligand A (134.66) is slightly higher than Ligand B (98.66), but both are below the 140 A^2 threshold for good oral absorption. Ligand B is preferable here.
3. **logP:** Ligand A (0.225) is quite low, potentially causing permeability issues. Ligand B (2.122) is within the optimal 1-3 range. This is a significant advantage for Ligand B.
4. **HBD:** Both are acceptable (3 and 4 respectively), within the <5 guideline.
5. **HBA:** Both are acceptable (7 and 4 respectively), within the <10 guideline.
6. **QED:** Both are good (0.594 and 0.605), indicating drug-like properties.
7. **DILI:** Ligand A (85.653) has a considerably higher DILI risk than Ligand B (20.008). This is a major concern for Ligand A.
8. **BBB:** Ligand A (35.052) has very low BBB penetration, while Ligand B (21.404) is also low, but better than A. For a cardiovascular target, BBB penetration isn't *critical*, but it's still a plus if it's reasonable.
9. **Caco-2:** Both have negative values, which is unusual. Assuming these are log scale values, they are both very poor.
10. **Solubility:** Both have negative values, which is unusual. Assuming these are log scale values, they are both very poor.
11. **hERG:** Both have low hERG inhibition risk (0.205 and 0.424).
12. **Cl_mic:** Ligand A (24.293) has lower clearance than Ligand B (37.968), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-19.606) has a longer in vitro half-life than Ligand A (-13.656).
14. **Pgp:** Ligand A (0.027) has much lower P-gp efflux than Ligand B (0.077), which is a positive.
15. **Affinity:** Ligand A (-7.0) has slightly better binding affinity than Ligand B (-6.6). However, the difference is not substantial enough to overcome the other issues.
**Conclusion:**
Ligand B is the better candidate. While Ligand A has slightly better affinity and lower P-gp efflux, its significantly higher DILI risk and very low logP are major drawbacks. Ligand B has a much more favorable safety profile (DILI), better logP, and a longer half-life. The slightly lower affinity is a reasonable trade-off for the improved ADME/Tox properties.
0
2025-04-17 22:41:30,164 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [349.431, 75.88, 1.854, 0, 5, 0.502, 17.255, 81.233, -4.901, -0.307, 0.278, 31.404, -19.42, 0.047, -6.4]
**Ligand B:** [346.515, 49.41, 3.215, 1, 2, 0.795, 35.983, 71.772, -4.438, -3.953, 0.449, 41.896, -12.423, 0.088, -7.8]
Here's a breakdown of the comparison, considering the provided guidelines and GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (346.5) is slightly lower, which is generally favorable.
2. **TPSA:** Ligand A (75.88) is higher than Ligand B (49.41). Ligand B is much better positioned for good absorption, being well below the 140 threshold.
3. **logP:** Ligand A (1.854) is within the optimal range, while Ligand B (3.215) is approaching the upper limit. Ligand A is slightly preferred here, as excessive lipophilicity can cause issues.
4. **HBD:** Ligand A (0) is better than Ligand B (1). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (5) is better than Ligand B (2). Lower HBA is generally preferred.
6. **QED:** Ligand B (0.795) is significantly better than Ligand A (0.502), indicating a more drug-like profile.
7. **DILI:** Ligand A (17.255) has a much lower DILI risk than Ligand B (35.983). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (81.233) has a higher BBB penetration percentile than Ligand B (71.772). While not a primary concern for a cardiovascular target, higher BBB is rarely detrimental.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand B (-4.438) is slightly better than Ligand A (-4.901).
10. **Solubility:** Ligand B (-3.953) is significantly worse than Ligand A (-0.307). Solubility is important for bioavailability.
11. **hERG:** Both are very low, indicating minimal hERG inhibition risk.
12. **Cl_mic:** Ligand A (31.404) has lower microsomal clearance than Ligand B (41.896), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-19.42) has a longer in vitro half-life than Ligand B (-12.423).
14. **Pgp:** Ligand A (0.047) has lower P-gp efflux liability than Ligand B (0.088).
15. **Affinity:** Ligand B (-7.8) has a significantly stronger binding affinity than Ligand A (-6.4). This is a substantial advantage (1.4 kcal/mol difference).
**Overall Assessment:**
Ligand B has a significantly better binding affinity, a better QED score, and slightly better Caco-2 permeability. However, it suffers from higher DILI risk, poorer solubility, and higher P-gp efflux. Ligand A has better ADME properties (DILI, solubility, metabolic stability, Pgp) and a more favorable BBB profile, but its affinity is considerably weaker.
Given the GPCR target and the substantial affinity difference, I believe the stronger binding of Ligand B outweighs its ADME drawbacks. While the DILI risk and solubility are concerns, these can potentially be addressed through further optimization. The affinity difference is large enough to warrant prioritizing Ligand B.
Output:
0
2025-04-17 22:41:30,164 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (346.471 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (69.64) is better than Ligand B (78.43), both are below the 140 threshold for oral absorption, but closer to the 90 threshold for CNS targets.
3. **logP:** Both ligands have good logP values (A: 1.835, B: 2.231), falling within the optimal 1-3 range.
4. **HBD:** Ligand A (2) is preferable to Ligand B (3), as lower HBD generally improves permeability.
5. **HBA:** Both ligands have the same HBA count (3), which is well within the acceptable limit of 10.
6. **QED:** Ligand A (0.771) has a significantly better QED score than Ligand B (0.545), indicating a more drug-like profile.
7. **DILI:** Ligand A (7.445) has a much lower DILI risk than Ligand B (22.8), a critical advantage.
8. **BBB:** Both ligands have similar BBB penetration (A: 71.927, B: 70.415), which is acceptable for a peripherally acting GPCR like ADRB2, but not exceptional.
9. **Caco-2:** Ligand A (-4.888) and Ligand B (-5.001) are similar, indicating similar intestinal absorption potential.
10. **Solubility:** Both ligands have poor aqueous solubility (A: -2.606, B: -2.868). This is a concern, but can often be addressed with formulation strategies.
11. **hERG:** Both ligands have low hERG inhibition risk (A: 0.318, B: 0.448).
12. **Cl_mic:** Ligand A (5.966) has significantly lower microsomal clearance than Ligand B (21.071), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-0.217) has a slightly shorter half-life than Ligand B (7.792), but this is less critical given the other advantages of Ligand A.
14. **Pgp:** Both ligands have low P-gp efflux liability (A: 0.054, B: 0.109).
15. **Binding Affinity:** Ligand B (-7.3) has a slightly better binding affinity than Ligand A (-6.8), a difference of 0.5 kcal/mol.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Both ligands perform reasonably well on logP and Pgp. Ligand A has a better TPSA. The affinity difference (0.5 kcal/mol) is not large enough to outweigh the substantial advantages of Ligand A in terms of DILI risk, QED, and metabolic stability (Cl_mic).
**Conclusion:**
Ligand A is the more promising drug candidate due to its superior drug-likeness (QED), significantly lower DILI risk, and better metabolic stability, despite a slightly weaker binding affinity. The lower molecular weight and TPSA are also beneficial.
Output:
1
2025-04-17 22:41:30,164 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [368.415, 123.42 , 0.737, 2. , 7. , 0.704, 85.498, 43.815, -5.008, -2.966, 0.142, 60.649, -23.994, 0.062, -6.1 ]
**Ligand B:** [386.497, 75.62 , 3.964, 2. , 8. , 0.711, 80.613, 77.588, -5.25 , -4.888, 0.43 , 63.184, 12.333, 0.218, -5.9 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (368.415) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (123.42) is better than Ligand B (75.62) as it is closer to the 140 threshold.
3. **logP:** Ligand A (0.737) is suboptimal, being slightly below the ideal 1-3 range. Ligand B (3.964) is closer to the upper end of the ideal range, which is better for GPCRs.
4. **HBD:** Both have 2 HBD, which is good.
5. **HBA:** Ligand A (7) is better than Ligand B (8).
6. **QED:** Both are similar and acceptable (around 0.7).
7. **DILI:** Both are relatively high, but Ligand A (85.498) is slightly lower than Ligand B (80.613), indicating a marginally lower risk of liver injury.
8. **BBB:** Ligand B (77.588) is significantly better than Ligand A (43.815) in terms of BBB penetration, which is important for GPCR targets.
9. **Caco-2:** Both are negative, indicating poor permeability.
10. **Solubility:** Both are negative, indicating poor solubility.
11. **hERG:** Ligand A (0.142) is significantly better than Ligand B (0.43), indicating a lower risk of cardiotoxicity.
12. **Cl_mic:** Ligand A (60.649) is slightly better than Ligand B (63.184), suggesting slightly better metabolic stability.
13. **t1/2:** Ligand A (-23.994) is significantly better than Ligand B (12.333), indicating a much longer half-life.
14. **Pgp:** Ligand A (0.062) is significantly better than Ligand B (0.218), indicating lower P-gp efflux.
15. **Affinity:** Both have very similar binding affinities (-6.1 and -5.9 kcal/mol). The difference is not substantial enough to be a deciding factor.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, BBB penetration, TPSA, Pgp efflux, and binding affinity are crucial. Ligand B has a better logP and significantly better BBB penetration. Ligand A has better TPSA, Pgp efflux, hERG and half-life.
**Overall Assessment:**
While Ligand B has a more favorable logP and BBB, Ligand A has a significantly better safety profile (hERG, DILI) and better ADME properties (Pgp, t1/2). Considering the balance, the better ADME profile and safety profile of Ligand A outweighs the slightly better logP and BBB of Ligand B.
**Output:**
1
2025-04-17 22:41:30,164 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands (346.39 & 359.40 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Both ligands (104.39 & 99.18) are reasonably low, suggesting good potential for absorption, though slightly above the optimal <90 for CNS targets (less relevant here as it's cardiovascular). Ligand B is slightly better.
3. **logP:** Ligand A (-0.305) is a bit low, potentially hindering membrane permeability. Ligand B (-1.081) is better, falling within the 1-3 range, though still on the lower end.
4. **HBD:** Both have 2 HBD, which is acceptable.
5. **HBA:** Both have 5 HBA, which is acceptable.
6. **QED:** Ligand A (0.688) has a slightly better QED score than Ligand B (0.574), indicating a more drug-like profile.
7. **DILI:** Ligand B (28.38) has a significantly lower DILI risk than Ligand A (50.33), which is a major advantage.
8. **BBB:** BBB is less critical for a cardiovascular target. Ligand B (62.70) is higher than Ligand A (33.85), but this is not a deciding factor.
9. **Caco-2:** Both have negative values, indicating poor permeability. Ligand B (-5.029) is slightly worse than Ligand A (-4.82).
10. **Solubility:** Ligand B (-0.34) is slightly better than Ligand A (-2.582).
11. **hERG:** Both have low hERG risk (0.164 and 0.224), which is good.
12. **Cl_mic:** Ligand B (-10.937) has a much lower (better) microsomal clearance than Ligand A (-4.862), indicating greater metabolic stability.
13. **t1/2:** Ligand B (-17.507) has a longer in vitro half-life than Ligand A (-26.21), which is a positive.
14. **Pgp:** Both have very low Pgp efflux liability (0.015 and 0.009), which is excellent.
15. **Binding Affinity:** Both ligands have similar binding affinities (-5.9 and -6.3 kcal/mol), with Ligand B being slightly stronger.
**GPCR-Specific Priorities:** For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are important. Ligand B has a better logP, similar Pgp and TPSA, and slightly better affinity. However, the *significant* advantage of Ligand B is its much lower DILI risk and improved metabolic stability (lower Cl_mic and longer t1/2). While Ligand A has a slightly better QED, the safety and PK benefits of Ligand B outweigh this.
**Conclusion:**
Ligand B is the more promising drug candidate due to its improved safety profile (DILI), metabolic stability, and slightly better binding affinity.
Output:
0
2025-04-17 22:41:30,165 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (349.475) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (70.67) is better than Ligand B (44.1). Both are below 140, but Ligand B is significantly lower, potentially improving absorption.
3. **logP:** Ligand A (1.239) is optimal, while Ligand B (4.517) is high. High logP can lead to poor solubility and off-target effects. This is a significant drawback for Ligand B.
4. **HBD:** Ligand A (2) is good, Ligand B (0) is also acceptable.
5. **HBA:** Both ligands have 4 HBA, which is within the acceptable range.
6. **QED:** Ligand A (0.647) is better than Ligand B (0.566), indicating a more drug-like profile.
7. **DILI:** Ligand A (9.345) has a much lower DILI risk than Ligand B (12.757). This is a critical advantage for Ligand A.
8. **BBB:** Ligand B (84.374) has a much higher BBB penetration than Ligand A (36.681). While ADRB2 is a cardiovascular target, some CNS off-target effects are possible, and higher BBB penetration could exacerbate these. However, for a cardiovascular target, BBB isn't a primary driver.
9. **Caco-2:** Both have negative values, indicating poor permeability. Ligand A (-5.171) is slightly better than Ligand B (-5.105).
10. **Solubility:** Ligand A (-1.027) is better than Ligand B (-4.486). Solubility is a concern for Ligand B due to its high logP.
11. **hERG:** Ligand A (0.172) is much better than Ligand B (0.877), indicating a lower risk of cardiotoxicity. This is crucial for a cardiovascular target.
12. **Cl_mic:** Ligand A (-16.297) shows much better metabolic stability (lower clearance) than Ligand B (107.225).
13. **t1/2:** Ligand A (2.871) has a shorter half-life than Ligand B (-3.773). However, the negative value for Ligand B is suspect and suggests a very rapid clearance.
14. **Pgp:** Ligand A (0.009) has lower P-gp efflux than Ligand B (0.616), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand B (-8.9 kcal/mol) has a significantly better binding affinity than Ligand A (-6.6 kcal/mol). This is a substantial advantage.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, Pgp, TPSA, and affinity. Ligand B excels in affinity and BBB, but struggles with logP and has a higher Pgp efflux. Ligand A has a more balanced profile, with acceptable logP, better solubility, lower DILI and hERG risk, and better metabolic stability. The superior affinity of Ligand B is tempting, but the ADME liabilities are concerning.
**Overall Assessment:**
While Ligand B has a stronger binding affinity, its high logP, poor solubility, higher DILI and hERG risk, and rapid metabolism are significant drawbacks. Ligand A presents a more balanced profile with better ADME properties and acceptable affinity. For a cardiovascular target, minimizing off-target effects (DILI, hERG) and ensuring reasonable metabolic stability are paramount.
Output:
1
2025-04-17 22:41:30,165 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [351.447, 85.62, 2.04, 2, 5, 0.819, 42.691, 89.104, -4.79, -2.102, 0.39, 29.231, 51.815, 0.105, -7.3]
**Ligand B:** [368.415, 58.2, 3.216, 2, 2, 0.614, 35.595, 77.898, -4.647, -4.05, 0.445, 53.321, -2.123, 0.037, -5.3]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, BBB, and affinity are key):
1. **MW:** Both are within the ideal 200-500 Da range. A (351.447) is slightly preferred.
2. **TPSA:** A (85.62) is higher than B (58.2). B is significantly better here, being closer to the optimal <90 for GPCRs.
3. **logP:** A (2.04) is excellent. B (3.216) is still within the acceptable range, but edging towards potentially causing issues.
4. **HBD:** Both have 2, which is good.
5. **HBA:** A has 5, B has 2. B is better, lower HBA generally improves permeability.
6. **QED:** A (0.819) is much better than B (0.614), indicating a more drug-like profile.
7. **DILI:** A (42.691) is slightly higher than B (35.595), but both are below the 40 threshold and therefore acceptable. B is preferred.
8. **BBB:** A (89.104) is significantly better than B (77.898). This is a crucial advantage for a GPCR target, even if not strictly CNS-focused, as it suggests better distribution.
9. **Caco-2:** Both are negative, indicating poor permeability. A (-4.79) is slightly worse than B (-4.647).
10. **Solubility:** Both are negative, indicating poor solubility. B (-4.05) is slightly better than A (-2.102).
11. **hERG:** Both are low, indicating minimal hERG liability. A (0.39) is slightly better than B (0.445).
12. **Cl_mic:** A (29.231) is much lower than B (53.321), indicating better metabolic stability.
13. **t1/2:** A (51.815) is much better than B (-2.123).
14. **Pgp:** Both are low, indicating minimal P-gp efflux. A (0.105) is slightly better than B (0.037).
15. **Affinity:** A (-7.3) is significantly better than B (-5.3). A 1.5 kcal/mol difference is substantial and can often outweigh other drawbacks.
**Overall Assessment:**
Ligand A has a significantly stronger binding affinity and better metabolic stability (lower Cl_mic, longer t1/2). It also has a better QED score and BBB penetration. While Ligand B has a lower TPSA and slightly better DILI, the superior affinity and pharmacokinetic properties of Ligand A are more critical for a GPCR target like ADRB2. The slightly lower Caco-2 and solubility of A are less concerning given the strong binding and metabolic profile.
Therefore, I prefer Ligand A.
Output:
1
2025-04-17 22:41:30,165 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (351.466 and 344.499 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (73.2) is higher than Ligand B (40.62). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is generally preferred for absorption. Ligand B has a substantial advantage.
3. **logP:** Both ligands have good logP values (2.952 and 3.371), falling within the optimal 1-3 range. Ligand B is slightly higher, which *could* be a minor drawback if it leads to solubility issues, but it's not a major concern.
4. **HBD:** Ligand A has 1 HBD, while Ligand B has 0. Both are acceptable, within the recommended limit of 5.
5. **HBA:** Ligand A has 3 HBA, Ligand B has 2. Both are within the recommended limit of 10.
6. **QED:** Both ligands have good QED scores (0.649 and 0.721), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (16.906) has a significantly lower DILI risk than Ligand B (32.183). This is a substantial advantage for Ligand A.
8. **BBB:** Ligand A (89.725) has a much higher BBB penetration percentile than Ligand B (65.607). While ADRB2 isn't strictly a CNS target, some brain exposure can occur, and higher BBB is generally favorable.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.723 and -4.746). These values are difficult to interpret without knowing the scale, but the similarity suggests comparable intestinal absorption potential.
10. **Solubility:** Both ligands have negative solubility values (-3.363 and -3.537). Similar to Caco-2, these values are difficult to interpret without knowing the scale, but the similarity suggests comparable solubility.
11. **hERG:** Both ligands have low hERG inhibition liability (0.843 and 0.402). Ligand B is slightly better here.
12. **Cl_mic:** Ligand A (41.494) has a lower microsomal clearance than Ligand B (54.685), indicating better metabolic stability. This is a positive for Ligand A.
13. **t1/2:** Ligand A (-11.769) has a more negative in vitro half-life than Ligand B (-6.805). This is difficult to interpret without knowing the scale, but a more negative value suggests a shorter half-life.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.302 and 0.364). No significant difference.
15. **Affinity:** Ligand B (-7.1) has a slightly better binding affinity than Ligand A (-7.8). While a 0.3 kcal/mol difference is not huge, it's noticeable.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, and affinity are important. Ligand B is better on logP and affinity. Ligand A is better on TPSA. However, the substantial advantage of Ligand A in DILI risk and BBB penetration, coupled with its better metabolic stability (lower Cl_mic), outweigh the slightly better affinity of Ligand B.
**Conclusion:**
Considering the balance of properties, particularly the lower DILI risk and better metabolic stability of Ligand A, I believe it is the more promising drug candidate.
Output:
1
2025-04-17 22:41:30,165 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [348.487, 60.85, 2.177, 1, 3, 0.85, 10.43, 70.997, -4.62, -1.968, 0.353, 20.297, -1.425, 0.133, -5.4]
**Ligand B:** [349.347, 126.13, -1.173, 2, 7, 0.69, 60.915, 45.909, -5.502, -1.628, 0.045, -12.06, 33.161, 0.017, -6.1]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). A: 348.487, B: 349.347 - Similar.
2. **TPSA:** A (60.85) is excellent, well below 140 and good for oral absorption. B (126.13) is higher, but still acceptable.
3. **logP:** A (2.177) is optimal. B (-1.173) is quite low, potentially hindering membrane permeability.
4. **HBD:** A (1) is good. B (2) is acceptable.
5. **HBA:** A (3) is good. B (7) is higher, potentially impacting permeability.
6. **QED:** A (0.85) is very good, indicating high drug-likeness. B (0.69) is still reasonable, but lower.
7. **DILI:** A (10.43) is excellent, very low risk. B (60.915) is moderately high, raising a concern.
8. **BBB:** A (70.997) is good, suggesting reasonable CNS penetration. B (45.909) is lower, less favorable for CNS effects (though ADRB2 isn't exclusively a CNS target).
9. **Caco-2:** Both are negative, indicating poor permeability. A (-4.62) is slightly better than B (-5.502).
10. **Solubility:** Both are negative, indicating poor solubility. A (-1.968) is slightly better than B (-1.628).
11. **hERG:** Both are very low, indicating low cardiotoxicity risk. A (0.353) is slightly better than B (0.045).
12. **Cl_mic:** A (20.297) is higher, indicating faster metabolism. B (-12.06) is excellent, suggesting good metabolic stability.
13. **t1/2:** A (-1.425) is poor, suggesting a short half-life. B (33.161) is excellent, indicating a long half-life.
14. **Pgp:** A (0.133) is low, suggesting minimal efflux. B (0.017) is very low, suggesting minimal efflux.
15. **Affinity:** A (-5.4) is good. B (-6.1) is better, a 0.7 kcal/mol advantage.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are crucial. Ligand B has a better binding affinity, and a lower Pgp efflux liability. However, its significantly lower logP and higher TPSA are concerning for permeability. Ligand A has a better logP and TPSA, but a weaker binding affinity and faster metabolism. The DILI risk is also much lower for Ligand A.
**Decision:**
While Ligand B has a slightly better binding affinity, the combination of its poor logP, higher TPSA, and moderately elevated DILI risk outweigh this advantage. Ligand A, despite its weaker binding, has a more balanced profile with better predicted permeability, lower toxicity risk, and acceptable BBB penetration. The difference in binding affinity (0.7 kcal/mol) isn't substantial enough to overcome the ADME/Tox concerns with Ligand B.
Therefore, I prefer Ligand A.
Output:
1
2025-04-17 22:41:30,165 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (349.431) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (62.3) is significantly better than Ligand A (107.53). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (2.187) is optimal, while Ligand A (-0.005) is slightly below 1, potentially hindering permeation. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (4) is higher than Ligand B (1). While both are acceptable, lower HBD is often preferred for better membrane permeability.
5. **HBA:** Both ligands have the same HBA count (4), which is within the acceptable range.
6. **QED:** Ligand B (0.702) has a better QED score than Ligand A (0.506), indicating a more drug-like profile.
7. **DILI:** Ligand A (14.541) has a much lower DILI risk than Ligand B (38.62). This is a crucial factor, as minimizing liver toxicity is paramount.
8. **BBB:** Ligand B (71.229) has a higher BBB penetration score than Ligand A (27.065). While not a primary concern for a cardiovascular target, it's a slight positive for Ligand B.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual. However, the magnitude is similar, so this doesn't heavily influence the decision.
10. **Solubility:** Ligand A (-1.45) has slightly better solubility than Ligand B (-2.526).
11. **hERG:** Ligand A (0.032) has a slightly lower hERG risk than Ligand B (0.367).
12. **Cl_mic:** Ligand A (-6.12) has a much lower microsomal clearance, suggesting better metabolic stability than Ligand B (13.183). This is a significant advantage.
13. **t1/2:** Ligand A (19.992) has a longer in vitro half-life than Ligand B (-4.816). This is a significant advantage.
14. **Pgp:** Ligand A (0.004) has a much lower P-gp efflux liability than Ligand B (0.077). This is a significant advantage.
15. **Binding Affinity:** Ligand A (-7.8) has a slightly better binding affinity than Ligand B (-5.7). This is a significant advantage.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand B excels in logP and has a better TPSA. However, Ligand A has a significantly better affinity, lower Pgp efflux, and a much better safety profile (DILI, hERG). The metabolic stability (Cl_mic, t1/2) is also far superior for Ligand A.
**Conclusion:**
Despite Ligand B having a slightly better QED and BBB, Ligand A's superior binding affinity, significantly better ADME properties (Cl_mic, t1/2, Pgp, DILI, hERG), and acceptable TPSA and logP make it the more promising drug candidate. The difference in binding affinity is substantial enough to outweigh the minor drawbacks of Ligand A.
Output:
1
2025-04-17 22:41:30,165 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (360.523 and 352.45 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (49.41) is significantly better than Ligand B (78.43). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (3.783) is optimal, while Ligand B (1.876) is on the lower side. A logP between 1-3 is preferred, and Ligand A is closer to this ideal.
4. **HBD:** Ligand A (1) is better than Ligand B (3). Lower HBD is generally preferred for better permeability.
5. **HBA:** Both ligands have 3 HBA, which is acceptable.
6. **QED:** Ligand A (0.839) is significantly better than Ligand B (0.584), indicating a more drug-like profile.
7. **DILI:** Ligand A (37.999) is much better than Ligand B (14.424). Lower DILI risk is crucial.
8. **BBB:** Ligand A (77.084) is better than Ligand B (67.08), but this isn't a high priority for a cardiovascular target.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
10. **Solubility:** Ligand A (-4.318) is better than Ligand B (-2.559). Higher solubility is generally desirable.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.504 and 0.26 respectively).
12. **Cl_mic:** Ligand A (51.527) is higher than Ligand B (18.77), indicating faster metabolic clearance and lower metabolic stability. This is a drawback for Ligand A.
13. **t1/2:** Ligand A (-9.378) is much better than Ligand B (-2.802), indicating a longer half-life.
14. **Pgp:** Ligand A (0.38) is better than Ligand B (0.063), suggesting lower P-gp efflux.
15. **Affinity:** Ligand A (-7.7 kcal/mol) is significantly better than Ligand B (-6.4 kcal/mol). This is a substantial difference in binding potency.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A excels in logP, TPSA, Pgp, and *especially* affinity. While Ligand A has a higher Cl_mic, the significantly better affinity and other favorable ADME properties outweigh this drawback. The substantial difference in binding affinity (-7.7 vs -6.4 kcal/mol) is a major advantage.
**Conclusion:**
Ligand A presents a more favorable overall profile, particularly due to its superior binding affinity, better drug-likeness (QED), lower DILI risk, and improved TPSA and logP values. The higher metabolic clearance is a concern, but the potency advantage is significant enough to compensate.
Output:
1
2025-04-17 22:41:30,166 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.431 and 366.38 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (98.74) is higher than Ligand B (78.87). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B has a clear advantage here.
3. **logP:** Ligand A (-0.361) is quite low, potentially hindering membrane permeability. Ligand B (1.941) is within the optimal 1-3 range. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (3) and Ligand B (2) are both acceptable, below the threshold of 5.
5. **HBA:** Both ligands (4) are below the threshold of 10.
6. **QED:** Ligand A (0.57) is better than Ligand B (0.391), indicating a more drug-like profile.
7. **DILI:** Both ligands have low DILI risk (22.761 and 21.869), which is good. No major difference.
8. **BBB:** Ligand A (22.063) has very low BBB penetration, while Ligand B (77.317) is quite high. Since ADRB2 is not a CNS target, this is a slight advantage for Ligand B, but not a major factor.
9. **Caco-2:** Both ligands have similar, very negative Caco-2 values (-5.045 and -5.008). This suggests poor permeability for both, which is concerning.
10. **Solubility:** Both ligands have very poor solubility (-1.97 and -2.003). This is a major drawback for both, and will require formulation work.
11. **hERG:** Ligand A (0.053) has a slightly lower hERG risk than Ligand B (0.513), which is preferable.
12. **Cl_mic:** Ligand A (-2.631) has a significantly lower (better) microsomal clearance than Ligand B (7.062). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (-6.092) has a shorter in vitro half-life than Ligand B (-27.609). This is a disadvantage for Ligand A.
14. **Pgp:** Ligand A (0.015) has very low P-gp efflux, while Ligand B (0.08) is slightly higher. Lower is better, giving a slight edge to Ligand A.
15. **Affinity:** Ligand B (-6.7) has a slightly better binding affinity than Ligand A (-6.4). While not a huge difference, it's still a positive for Ligand B.
**Overall Assessment:**
Ligand B has a more favorable logP, which is crucial for permeability. While both have poor solubility and Caco-2 permeability, the better logP of Ligand B suggests it might be easier to address these issues through formulation. Ligand A has better metabolic stability (lower Cl_mic) and lower Pgp efflux, but the poor logP is a significant concern. The slightly better affinity of Ligand B and its higher BBB (though not critical here) also contribute to its favorability.
Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity), Ligand B appears to be the more promising candidate.
Output:
0
2025-04-17 22:41:30,166 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (338.411 Da) is slightly lower, which is generally favorable for permeability.
**2. TPSA:** Ligand A (83.12) is significantly better than Ligand B (94.92). For a GPCR, keeping TPSA below 140 is good, and lower is better for permeability.
**3. logP:** Ligand A (2.603) is optimal, while Ligand B (0.284) is quite low. Low logP can hinder membrane permeability and potentially reduce binding affinity. This is a significant drawback for Ligand B.
**4. H-Bond Donors:** Ligand A (3) is acceptable, while Ligand B (1) is also good.
**5. H-Bond Acceptors:** Ligand A (3) is acceptable, while Ligand B (7) is higher, but still within the reasonable limit of 10.
**6. QED:** Ligand A (0.783) is much better than Ligand B (0.41). A higher QED indicates a more drug-like profile.
**7. DILI:** Both ligands have similar DILI risk (Ligand A: 59.325, Ligand B: 65.103), both are acceptable but not ideal.
**8. BBB:** Ligand A (65.801) is better than Ligand B (55.874), although neither is exceptionally high. For a cardiovascular target, BBB penetration isn't a primary concern, but it's still a slight advantage for Ligand A.
**9. Caco-2 Permeability:** Ligand A (-4.914) is better than Ligand B (-5.044). Both are negative, indicating low permeability, but Ligand A is slightly less negative.
**10. Aqueous Solubility:** Ligand A (-3.941) is better than Ligand B (-1.183). Solubility is important for formulation and bioavailability.
**11. hERG Inhibition:** Both ligands show very low hERG inhibition risk (Ligand A: 0.354, Ligand B: 0.167). This is excellent.
**12. Microsomal Clearance:** Ligand A (15.646) is higher than Ligand B (-2.097), indicating lower metabolic stability. This is a drawback for Ligand A.
**13. In vitro Half-Life:** Ligand A (51.506) is significantly better than Ligand B (-25.044). A longer half-life is generally desirable.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (Ligand A: 0.019, Ligand B: 0.022). This is excellent.
**15. Binding Affinity:** Both ligands have the same binding affinity (-7.5 kcal/mol), which is excellent.
**Overall Assessment:**
Ligand A is clearly superior. While it has a slightly higher microsomal clearance, its advantages in TPSA, logP, QED, solubility, and half-life outweigh this drawback. The low logP of Ligand B is a major concern, potentially hindering its ability to reach the target receptor. The better QED and solubility of Ligand A also contribute to its higher probability of success as a drug candidate.
Output:
1
2025-04-17 22:41:30,166 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (345.443) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (62.74) is better than Ligand B (72.63). Both are below 140, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (A: 1.906, B: 2.975), falling within the optimal 1-3 range. Ligand B is slightly higher, which *could* indicate a potential for off-target interactions, but isn't a major concern here.
4. **HBD:** Ligand A (0) is preferable to Ligand B (1). Fewer hydrogen bond donors generally improve membrane permeability.
5. **HBA:** Both ligands have the same number of HBA (4), which is within the acceptable limit of 10.
6. **QED:** Both ligands have similar QED values (A: 0.765, B: 0.785), indicating good drug-likeness.
7. **DILI:** Ligand B (23.653) is significantly better than Ligand A (40.403) in terms of DILI risk, indicating a lower potential for liver injury. This is a significant advantage for Ligand B.
8. **BBB:** Ligand B (83.288) has a higher BBB penetration percentile than Ligand A (73.517). While ADRB2 isn't strictly a CNS target, some peripheral ADRB2 receptors can influence CNS function, and better BBB penetration isn't necessarily a detriment.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual. I will interpret these as very low permeability.
10. **Solubility:** Ligand A (-1.641) has better solubility than Ligand B (-3.149). Solubility is important for bioavailability.
11. **hERG:** Both ligands have low hERG inhibition liability (A: 0.217, B: 0.397), which is good.
12. **Cl_mic:** Ligand A (43.887) has lower microsomal clearance than Ligand B (54.888), suggesting better metabolic stability.
13. **t1/2:** Ligand B (17.257) has a significantly longer in vitro half-life than Ligand A (5.885). This is a major advantage for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have similar Pgp efflux liability (A: 0.256, B: 0.288).
15. **Binding Affinity:** Ligand A (-7.2) has a slightly better binding affinity than Ligand B (-7.0). However, the difference is small (0.2 kcal/mol) and may not be enough to outweigh other factors.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A has a slight edge in affinity, but Ligand B is better in terms of logP, TPSA, and has a significantly longer half-life and lower DILI risk.
**Overall Assessment:**
While Ligand A has slightly better affinity, Ligand B presents a more favorable overall profile. The lower DILI risk, longer half-life, and better BBB penetration are significant advantages that outweigh the small difference in binding affinity. The solubility of Ligand A is better, but the overall ADME profile of Ligand B is superior.
**Output:**
0
2025-04-17 22:41:30,166 - INFO - Batch 350 complete. Total preferences: 5600
2025-04-17 22:41:30,166 - INFO - Processing batch 351/512...
2025-04-17 22:42:22,790 - INFO - Here's my reasoning and final output:
**Reasoning:**
We're evaluating ligands for the ADRB2, a cardiovascular GPCR. Therefore, priorities are logP, TPSA, Pgp, and affinity, alongside general drug-like properties.
Let's compare Ligand A and Ligand B across the 15 parameters:
1. **MW:** Both are within the ideal range (200-500 Da).
2. **TPSA:** Ligand A (102.42) is higher than Ligand B (33.2). Ligand B is much better for permeability.
3. **logP:** Ligand A (0.953) is within the optimal range, but on the lower side. Ligand B (4.8) is higher, potentially causing solubility issues, but acceptable.
4. **HBD:** Ligand A (2) is good. Ligand B (0) is also good.
5. **HBA:** Ligand A (5) is good. Ligand B (2) is also good.
6. **QED:** Both are above 0.5, indicating good drug-likeness.
7. **DILI:** Ligand A (43.622) is slightly higher than Ligand B (29.391), but both are acceptable.
8. **BBB:** Ligand A (38.348) is low, while Ligand B (82.474) is excellent. This is a significant advantage for Ligand B, even though ADRB2 is cardiovascular and not CNS-focused, better BBB generally indicates less off-target effects.
9. **Caco-2:** Ligand A (-5.271) is very poor. Ligand B (-4.626) is also poor, but better than A.
10. **Solubility:** Ligand A (-2.167) is poor. Ligand B (-4.462) is even worse.
11. **hERG:** Ligand A (0.208) is very low risk. Ligand B (0.844) is moderate risk. This favors Ligand A.
12. **Cl_mic:** Ligand A (-6.068) is excellent (low clearance, high metabolic stability). Ligand B (98.462) is very high clearance, a major drawback.
13. **t1/2:** Ligand A (8.022) is reasonable. Ligand B (48.627) is excellent.
14. **Pgp:** Ligand A (0.083) is very low efflux, excellent. Ligand B (0.615) is moderate efflux.
15. **Affinity:** Ligand A (-6.6) is slightly better than Ligand B (-6.3), but the difference is small.
**Overall Assessment:**
Ligand B has a significantly better BBB score, and a much better TPSA. However, it suffers from very high metabolic clearance and poor solubility. Ligand A has a better hERG profile and excellent metabolic stability. The affinity difference is minimal. Considering the importance of metabolic stability for *in vivo* efficacy and the acceptable hERG risk of Ligand A, I believe it is the more promising candidate despite its lower BBB and TPSA.
**Output:**
1
2025-04-17 22:42:22,790 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
Let's analyze each ligand against the provided guidelines, keeping in mind ADRB2 is a GPCR and thus logP, Pgp, TPSA, and affinity are key.
* **Molecular Weight:** Both ligands (347.39 Da and 354.403 Da) fall within the ideal 200-500 Da range.
* **TPSA:** Ligand A (79.79) is better than Ligand B (85.38), both are acceptable but A is closer to the <140 threshold for good absorption.
* **logP:** Ligand A (1.546) is within the optimal 1-3 range. Ligand B (-0.17) is *below* 1, which is a concern for permeability. This is a significant negative for B.
* **H-Bond Donors:** Ligand A (2) and Ligand B (0) are both acceptable.
* **H-Bond Acceptors:** Ligand A (4) and Ligand B (6) are both acceptable.
* **QED:** Ligand A (0.735) is better than Ligand B (0.422), indicating a more drug-like profile.
* **DILI:** Both ligands have low DILI risk (34.471 and 32.222), which is good.
* **BBB:** Ligand A (78.209) is significantly better than Ligand B (61.613). While not a primary concern for ADRB2 (cardiovascular target), higher BBB is generally favorable.
* **Caco-2 Permeability:** Both are negative, indicating poor permeability. Ligand A (-4.677) is slightly better than Ligand B (-4.529).
* **Aqueous Solubility:** Both are negative, indicating poor solubility. Ligand A (-2.651) is slightly better than Ligand B (-1.048).
* **hERG Inhibition:** Both ligands have low hERG inhibition risk (0.421 and 0.077).
* **Microsomal Clearance:** Ligand A (14.784) has lower clearance than Ligand B (24.977), suggesting better metabolic stability.
* **In vitro Half-Life:** Ligand A (-1.158) has a longer half-life than Ligand B (-3.099).
* **P-gp Efflux:** Both are low (0.055 and 0.014), indicating minimal P-gp efflux.
* **Binding Affinity:** Ligand B (-6.6 kcal/mol) has a significantly stronger binding affinity than Ligand A (-3.8 kcal/mol). This is a substantial advantage for B.
**Overall Assessment:**
Ligand B has a much stronger binding affinity, which is a critical factor. However, its significantly lower logP is a major drawback, potentially leading to poor permeability and bioavailability. Ligand A has a more balanced profile, with acceptable logP, better QED, better BBB, better metabolic stability, and a longer half-life. While its affinity is weaker, the overall ADME properties are more favorable. Given the importance of balanced properties for *in vivo* efficacy, and considering the GPCR target class, I believe Ligand A is the more promising candidate.
**Output:**
1
2025-04-17 22:42:22,790 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [413.262, 50.36, 4.784, 2, 2, 0.758, 80.186, 89.725, -4.864, -5.738, 0.854, 36.464, 70.438, 0.377, -4]
**Ligand B:** [365.463, 117.59, 0.232, 3, 7, 0.555, 77.2, 32.416, -6.239, -2.285, 0.025, 20.422, -3.869, 0.068, -6.3]
**Step-by-step comparison:**
1. **MW:** Ligand A (413.262 Da) is within the ideal range. Ligand B (365.463 Da) is also good. No clear advantage here.
2. **TPSA:** Ligand A (50.36) is excellent, well below 140 and good for permeability. Ligand B (117.59) is higher, but still acceptable, though less ideal. A favors here.
3. **logP:** Ligand A (4.784) is slightly high, potentially leading to off-target effects or solubility issues. Ligand B (0.232) is *very* low, which is a significant concern for membrane permeability and bioavailability. A is better.
4. **HBD:** Ligand A (2) is good. Ligand B (3) is acceptable.
5. **HBA:** Ligand A (2) is good. Ligand B (7) is higher, potentially impacting permeability. A is better.
6. **QED:** Ligand A (0.758) is very good. Ligand B (0.555) is acceptable, but lower. A is better.
7. **DILI:** Ligand A (80.186) is higher risk, but still manageable. Ligand B (77.2) is slightly better.
8. **BBB:** Ligand A (89.725) is excellent, suggesting good potential for CNS penetration if desired (though ADRB2 is primarily cardiovascular, some CNS effects are possible). Ligand B (32.416) is very low, indicating poor BBB penetration. A is significantly better.
9. **Caco-2:** Ligand A (-4.864) is a negative value, indicating poor permeability. Ligand B (-6.239) is even worse. This is a concern for both, but B is worse.
10. **Solubility:** Ligand A (-5.738) is poor. Ligand B (-2.285) is also poor, but slightly better. B is slightly better.
11. **hERG:** Ligand A (0.854) is relatively low risk. Ligand B (0.025) is very low risk, a significant advantage. B is better.
12. **Cl_mic:** Ligand A (36.464) is reasonable. Ligand B (20.422) is lower, suggesting better metabolic stability. B is better.
13. **t1/2:** Ligand A (70.438) is good. Ligand B (-3.869) is very poor. A is much better.
14. **Pgp:** Ligand A (0.377) is low efflux, which is good. Ligand B (0.068) is very low efflux, excellent. B is better.
15. **Affinity:** Ligand A (-4.0) is good. Ligand B (-6.3) is significantly better, a 2.3 kcal/mol advantage. This is a substantial difference.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has a problematic logP and TPSA, while Ligand B has a very low logP. However, the *significant* affinity advantage of Ligand B (-6.3 vs -4.0) is a major factor. The better Pgp profile of B also helps. While A has better BBB penetration, this is less critical for a primarily cardiovascular target. The better metabolic stability (lower Cl_mic) of B is also a plus.
**Conclusion:**
Despite some drawbacks in solubility and Caco-2 permeability, the significantly stronger binding affinity of Ligand B, coupled with its better Pgp profile and metabolic stability, outweighs the advantages of Ligand A. The low logP of B is a concern, but can potentially be addressed with formulation strategies.
Output:
0
2025-04-17 22:42:22,790 - INFO - Here's my reasoning and final output:
**Reasoning:**
Both ligands are reasonably drug-like, targeting the ADRB2 GPCR. Let's break down the comparison:
1. **MW:** Both are within the ideal range (350-370 Da).
2. **TPSA:** Both are good, under 72, facilitating absorption.
3. **logP:** Both are within the optimal range (2.0-2.8), suggesting good permeability and avoiding solubility issues.
4. **HBD/HBA:** Ligand A (0/6) is slightly better than Ligand B (1/4) in terms of H-bond properties, potentially improving permeability.
5. **QED:** Ligand B (0.856) has a slightly better QED score than Ligand A (0.74), indicating a more drug-like profile.
6. **DILI:** Ligand A (28.23) has a significantly lower DILI risk than Ligand B (34.55), a crucial factor for cardiovascular drugs.
7. **BBB:** Ligand B (72.66) has slightly better BBB penetration than Ligand A (67.35), but both are acceptable.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the values are similar (-4.44 vs -4.51).
9. **Solubility:** Both have negative solubility values, which is also unusual and indicates poor solubility. The values are similar (-2.99 vs -3.01).
10. **hERG:** Both have very low hERG inhibition risk (0.54-0.60).
11. **Cl_mic:** Ligand A (83.9) has a higher microsomal clearance than Ligand B (15.75), suggesting lower metabolic stability. This is a significant drawback for Ligand A.
12. **t1/2:** Ligand B (36.36) has a much longer in vitro half-life than Ligand A (-13.79), indicating better stability.
13. **Pgp:** Both have low Pgp efflux liability (0.14-0.23).
14. **Binding Affinity:** Both have identical binding affinities (-6.4 kcal/mol).
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are crucial. Both ligands perform similarly in these areas. However, metabolic stability (Cl_mic and t1/2) and DILI risk are critical for cardiovascular drugs. Ligand B significantly outperforms Ligand A in both these areas. While Ligand A has a slightly better HBD/HBA profile, the superior metabolic stability and lower DILI risk of Ligand B outweigh this advantage.
**Conclusion:**
Ligand B is the more promising drug candidate due to its better metabolic stability, longer half-life, and lower DILI risk, which are particularly important for a cardiovascular target.
**Output:**
0
2025-04-17 22:42:22,790 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (354.43 & 345.49 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (64.86) is significantly better than Ligand A (105.48). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (2.818) is closer to the optimal 1-3 range than Ligand A (1.501). Both are acceptable, but B is slightly preferred.
4. **HBD:** Ligand A (4) is higher than Ligand B (1). While both are within the acceptable limit of 5, lower HBD is generally preferred for permeability. Ligand B has an advantage.
5. **HBA:** Ligand A (5) and Ligand B (6) are both acceptable (<=10). No significant difference.
6. **QED:** Ligand B (0.859) is considerably better than Ligand A (0.418), indicating a more drug-like profile. This is a significant advantage for Ligand B.
7. **DILI:** Ligand B (37.611) has a much lower DILI risk than Ligand A (52.152). This is a crucial factor, as minimizing liver toxicity is essential. Ligand B is strongly favored.
8. **BBB:** Both are reasonably low, but Ligand B (74.06) is higher than Ligand A (68.321). Not a major factor for a cardiovascular target.
9. **Caco-2:** Both are negative, indicating poor permeability. This is a concern for both.
10. **Solubility:** Both are negative, indicating poor solubility. This is a concern for both.
11. **hERG:** Ligand B (0.285) has a much lower hERG inhibition liability than Ligand A (0.74). This is a critical advantage, as hERG inhibition can lead to cardiotoxicity.
12. **Cl_mic:** Ligand B (26.235) has a significantly lower microsomal clearance than Ligand A (44.845), suggesting better metabolic stability. This is a positive for Ligand B.
13. **t1/2:** Ligand B (7.654) has a much longer in vitro half-life than Ligand A (0.745). This is a significant advantage, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand B (0.134) has lower P-gp efflux liability than Ligand A (0.063). This is a slight advantage for Ligand B.
15. **Binding Affinity:** Ligand B (-6.9 kcal/mol) is slightly better than Ligand A (-6.6 kcal/mol), but the difference is relatively small.
**Overall Assessment:**
Ligand B consistently outperforms Ligand A across most critical ADME-Tox parameters. It has a better QED score, significantly lower DILI and hERG risk, improved metabolic stability (lower Cl_mic, longer t1/2), and slightly better binding affinity. While both have poor Caco-2 and solubility, the superior safety and pharmacokinetic profile of Ligand B make it the more promising drug candidate.
Output:
0
2025-04-17 22:42:22,791 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's analyze each ligand against the provided guidelines, keeping in mind this is a GPCR target (ADRB2, cardiovascular). Key priorities for GPCRs are logP, TPSA, Pgp, BBB, and affinity.
* **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (345.443) is slightly lower than Ligand B (368.499), which is preferable.
* **TPSA:** Ligand A (78.51) is better than Ligand B (67.87), being closer to the desired threshold of <=140.
* **logP:** Both ligands have good logP values (A: 1.712, B: 1.066) falling within the optimal 1-3 range. Ligand A is slightly better.
* **H-Bond Donors/Acceptors:** Ligand A (HBD=2, HBA=3) is slightly better than Ligand B (HBD=1, HBA=5) in terms of balancing solubility and permeability.
* **QED:** Ligand A (0.753) has a significantly better QED score than Ligand B (0.513), indicating better overall drug-likeness.
* **DILI:** Both ligands have similar, acceptable DILI risk (A: 42.497, B: 42.885), both below the 60 threshold.
* **BBB:** Ligand A (59.946) has a better BBB percentile than Ligand B (46.762). While not a CNS target, some degree of BBB penetration can influence peripheral distribution and off-target effects.
* **Caco-2 Permeability:** Both are negative, indicating poor permeability. Ligand A (-5.003) is slightly better than Ligand B (-4.71).
* **Aqueous Solubility:** Both ligands have poor solubility (-2.602 and -2.952 respectively).
* **hERG Inhibition:** Both ligands have low hERG inhibition risk (A: 0.207, B: 0.152).
* **Microsomal Clearance:** Ligand A (-4.434) shows significantly better metabolic stability (lower clearance) than Ligand B (36.8). This is a major advantage.
* **In vitro Half-Life:** Ligand A (7.588) has a much longer half-life than Ligand B (-21.462).
* **P-gp Efflux:** Both ligands show low P-gp efflux liability (A: 0.038, B: 0.027).
* **Binding Affinity:** Ligand A (-7.1 kcal/mol) has a stronger binding affinity than Ligand B (-5.4 kcal/mol). This is a substantial difference, exceeding the 1.5 kcal/mol advantage threshold.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical parameters. The most significant advantages are its superior binding affinity, much better metabolic stability (lower Cl_mic and longer t1/2), and improved QED score. While both have poor solubility and Caco-2 permeability, the strong affinity and favorable ADME properties of Ligand A make it a more promising starting point for optimization.
**Output:**
1
2025-04-17 22:42:22,791 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [346.435, 106.14 , 1.446, 2. , 5. , 0.864, 43.234, 73.439, -5.143, -2.977, 0.206, 3.295, -2.049, 0.018, -5.9 ]
**Ligand B:** [349.431, 121.52 , 0.004, 4. , 4. , 0.328, 15.549, 51.881, -5.886, -1.975, 0.171, 27.678, -8.462, 0.029, -8.4 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (346.435) is slightly lower, which is generally favorable.
2. **TPSA:** Ligand A (106.14) is better than Ligand B (121.52), being closer to the <140 threshold for good oral absorption.
3. **logP:** Ligand A (1.446) is optimal (1-3), while Ligand B (0.004) is very low, potentially hindering permeation. This is a significant drawback for Ligand B.
4. **HBD:** Ligand A (2) is better than Ligand B (4), as lower HBDs generally improve permeability.
5. **HBA:** Ligand A (5) is better than Ligand B (4), staying within the preferred range.
6. **QED:** Ligand A (0.864) is significantly better than Ligand B (0.328), indicating a much more drug-like profile.
7. **DILI:** Ligand A (43.234) is better than Ligand B (15.549), indicating a lower risk of drug-induced liver injury.
8. **BBB:** Ligand A (73.439) is significantly better than Ligand B (51.881), which is crucial for a GPCR target, even if not a CNS target.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-5.143) is slightly better than Ligand B (-5.886).
10. **Solubility:** Both are negative, indicating poor solubility. Ligand A (-2.977) is slightly better than Ligand B (-1.975).
11. **hERG:** Both are very low (0.206 and 0.171), indicating low cardiotoxicity risk.
12. **Cl_mic:** Ligand A (3.295) is much better than Ligand B (27.678), suggesting significantly better metabolic stability.
13. **t1/2:** Ligand A (-2.049) is better than Ligand B (-8.462), indicating a longer half-life.
14. **Pgp:** Both are very low (0.018 and 0.029), indicating minimal P-gp efflux.
15. **Affinity:** Ligand B (-8.4) has a slightly better binding affinity than Ligand A (-5.9), with a 2.5 kcal/mol advantage.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. While Ligand B has a slightly better affinity, its extremely low logP and higher TPSA are major concerns. The better BBB penetration of Ligand A is also a plus. Ligand A also has a much better QED, DILI, metabolic stability, and half-life. The affinity difference, while present, is unlikely to overcome the significant ADME deficiencies of Ligand B.
**Conclusion:**
Ligand A is the more promising drug candidate due to its superior ADME properties, better drug-likeness, and acceptable binding affinity. The slightly weaker binding of Ligand A can likely be optimized in subsequent iterations, while fixing the poor logP of Ligand B would be a much more substantial challenge.
Output:
1
2025-04-17 22:42:22,791 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [354.426, 105.48 , 1.501, 4. , 5. , 0.418, 52.152, 68.321, -5.165, -2.92 , 0.74 , 44.845, 0.745, 0.063, -6.6 ]
**Ligand B:** [343.431, 81.33 , 0.767, 2. , 4. , 0.748, 20.706, 55.021, -5.516, -1.997, 0.126, -10.613, -4.534, 0.007, -7.8 ]
Here's a breakdown, prioritizing GPCR-relevant properties:
1. **Molecular Weight:** Both are within the ideal 200-500 Da range. Ligand B (343.431) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (105.48) is a bit higher than Ligand B (81.33). Both are below 140, but B is better for oral absorption.
3. **logP:** Both are within the optimal 1-3 range. Ligand A (1.501) is slightly higher, potentially leading to some off-target interactions, but it's still acceptable. Ligand B (0.767) is on the lower side, which could hinder permeability.
4. **H-Bond Donors/Acceptors:** Ligand A has 4 HBD and 5 HBA, while Ligand B has 2 HBD and 4 HBA. Both are reasonable.
5. **QED:** Ligand B (0.748) has a better QED score than Ligand A (0.418), indicating a more drug-like profile.
6. **DILI:** Ligand B (20.706) has a significantly lower DILI risk than Ligand A (52.152), a major advantage.
7. **BBB:** Ligand A (68.321) has a better BBB penetration score than Ligand B (55.021). While not a primary concern for a cardiovascular target, it's a slight positive for A.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability.
9. **Solubility:** Both have negative solubility values, which is also unusual.
10. **hERG:** Ligand A (0.74) has a slightly higher hERG risk than Ligand B (0.126).
11. **Cl_mic:** Ligand B (-10.613) has a *much* lower (better) microsomal clearance than Ligand A (44.845), indicating greater metabolic stability.
12. **t1/2:** Ligand B (-4.534) has a longer in vitro half-life than Ligand A (0.745).
13. **Pgp:** Ligand B (0.007) has a lower P-gp efflux liability than Ligand A (0.063).
14. **Binding Affinity:** Ligand B (-7.8) has a stronger binding affinity than Ligand A (-6.6) by a margin of 1.2 kcal/mol. This is a substantial difference.
**Overall Assessment:**
While Ligand A has slightly better BBB penetration, Ligand B is clearly superior. The significantly better binding affinity (-7.8 vs -6.6 kcal/mol), much lower DILI risk, improved metabolic stability (lower Cl_mic, longer t1/2), lower P-gp efflux, and better QED outweigh the slightly lower BBB and logP. The negative Caco-2 and solubility values are concerning for both, but the other advantages of Ligand B make it the more promising candidate.
Output:
0
2025-04-17 22:42:22,791 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [350.394, 68.62, 1.926, 1, 5, 0.79, 47.848, 82.086, -4.308, -2.237, 0.492, 78.303, -2.479, 0.069, -6.1]
**Ligand B:** [353.35, 122.99, -0.611, 4, 6, 0.575, 46.995, 23.265, -5.027, -1.462, 0.073, -27.18, -33.896, 0.005, -6.8]
Here's a step-by-step comparison, keeping GPCR priorities (logP, Pgp, TPSA, affinity, and BBB) in mind:
1. **MW:** Both are within the ideal 200-500 Da range. A is 350.394, B is 353.35. Very similar.
2. **TPSA:** A (68.62) is excellent, well below 140 and good for permeability. B (122.99) is higher, but still acceptable, though less ideal.
3. **logP:** A (1.926) is optimal. B (-0.611) is quite low, potentially hindering membrane permeability and bioavailability. This is a significant negative for B.
4. **HBD:** A (1) is good. B (4) is higher, potentially impacting permeability.
5. **HBA:** A (5) is good. B (6) is slightly higher.
6. **QED:** Both are reasonable (A: 0.79, B: 0.575), indicating decent drug-like properties. A is better.
7. **DILI:** Both are good, with low risk (A: 47.848, B: 46.995). Very similar.
8. **BBB:** A (82.086) is good, suggesting reasonable potential for CNS penetration if needed (though less critical for a cardiovascular target). B (23.265) is very low, indicating poor BBB penetration.
9. **Caco-2:** A (-4.308) is better than B (-5.027), indicating better intestinal absorption.
10. **Solubility:** A (-2.237) is better than B (-1.462), suggesting better aqueous solubility.
11. **hERG:** Both are low (A: 0.492, B: 0.073), indicating low cardiotoxicity risk. B is slightly better.
12. **Cl_mic:** A (78.303) is better than B (-27.18), indicating better metabolic stability. B has a negative value, which is unusual and suggests very rapid clearance.
13. **t1/2:** A (-2.479) is better than B (-33.896), indicating a longer in vitro half-life.
14. **Pgp:** A (0.069) is better than B (0.005), suggesting less P-glycoprotein efflux.
15. **Affinity:** Both have strong binding affinities (A: -6.1, B: -6.8). B is slightly better, but the difference is not huge.
**Overall Assessment:**
Ligand A is significantly better. While Ligand B has a slightly better binding affinity, its poor logP, low BBB penetration, and very high clearance are major drawbacks. Ligand A has a much more balanced profile with good logP, TPSA, solubility, metabolic stability, and reasonable BBB penetration. The slightly better affinity of B doesn't outweigh the significant ADME liabilities.
Output:
1
2025-04-17 22:42:22,791 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
The ADRB2 receptor is a GPCR, so the key priorities are logP, TPSA, Pgp efflux, BBB penetration (though less critical for a cardiovascular target), and binding affinity.
Let's compare the ligands property by property:
1. **MW:** Both ligands (339.439 and 347.375 Da) are within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (58.22) is significantly better than Ligand B (111.39). A TPSA under 140 is good for oral absorption, but lower is preferred for GPCRs, and A is much closer to optimal.
3. **logP:** Ligand A (3.882) is good, within the 1-3 range. Ligand B (0.454) is quite low, potentially hindering membrane permeability.
4. **HBD/HBA:** Ligand A (1 HBD, 3 HBA) is preferable to Ligand B (2 HBD, 8 HBA). Lower counts generally improve permeability.
5. **QED:** Both are reasonably good (0.841 and 0.7), indicating drug-like properties.
6. **DILI:** Both have similar, moderately high DILI risk (68.437 and 68.903). This isn't a deciding factor here.
7. **BBB:** Ligand A (41.295) is better than Ligand B (27.879), although neither is particularly high. This is less critical for a cardiovascular target.
8. **Caco-2:** Both are negative, which is unusual and suggests poor permeability. This is a concern for both.
9. **Solubility:** Ligand A (-4.074) is better than Ligand B (-2.059), indicating better aqueous solubility.
10. **hERG:** Both are very low (0.349 and 0.11), indicating low cardiotoxicity risk.
11. **Cl_mic:** Ligand B (-14.873) has a lower (better) microsomal clearance than Ligand A (47.114), suggesting better metabolic stability.
12. **t1/2:** Ligand B (30.357) has a much longer half-life than Ligand A (-13.889). This is a significant advantage.
13. **Pgp:** Ligand A (0.394) has lower P-gp efflux liability than Ligand B (0.031), which is desirable.
14. **Binding Affinity:** Ligand B (-8.0) has a significantly stronger binding affinity than Ligand A (-6.5). This is a substantial advantage, potentially outweighing some ADME concerns.
**Overall Assessment:**
Ligand B has a much stronger binding affinity and a significantly longer half-life, which are major advantages. While its logP is low and TPSA is high, the binding affinity difference is substantial (>1.5 kcal/mol). The improved metabolic stability (lower Cl_mic) is also a positive. Ligand A has better TPSA, logP, solubility and Pgp properties, but the affinity difference is too large to ignore.
**Output:**
0
2025-04-17 22:42:22,791 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (344.455) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (51.02) is significantly better than Ligand A (67.43). Lower TPSA is preferred for GPCRs, aiding in brain penetration and overall absorption.
3. **logP:** Ligand A (1.614) is optimal, while Ligand B (3.893) is approaching the upper limit. While still acceptable, higher logP can sometimes lead to off-target effects and solubility issues.
4. **HBD/HBA:** Ligand A has 2 HBD and 3 HBA, while Ligand B has 0 HBD and 5 HBA. Both are within acceptable limits, but Ligand A's HBD count might contribute slightly to better solubility.
5. **QED:** Both ligands have similar and good QED scores (0.72 and 0.752, respectively).
6. **DILI:** Ligand B (41.024) has a slightly higher DILI risk than Ligand A (29.624), but both are below the concerning threshold of 60.
7. **BBB:** Ligand B (90.074) has a *much* higher BBB penetration score than Ligand A (48.74). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be beneficial for distribution and potentially off-target effects.
8. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. Ligand A (-5.012) is slightly better than Ligand B (-5.106).
9. **Solubility:** Both ligands have very poor aqueous solubility (-3.429 and -4.031 respectively). This is a significant concern for both.
10. **hERG:** Ligand A (0.142) has a much lower hERG inhibition liability than Ligand B (0.469), which is a critical advantage.
11. **Cl_mic:** Ligand A (2.6) has significantly lower microsomal clearance than Ligand B (104.482), indicating better metabolic stability. This is a major advantage.
12. **t1/2:** Ligand A (21.647) has a longer in vitro half-life than Ligand B (17.015).
13. **Pgp:** Ligand A (0.085) has lower P-gp efflux liability than Ligand B (0.561), which is favorable for bioavailability.
14. **Binding Affinity:** Ligand A (-7.3) has a slightly better binding affinity than Ligand B (-5.7). This difference of 1.6 kcal/mol is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand A is the stronger candidate. While both have poor solubility and Caco-2 permeability, Ligand A excels in several crucial areas: significantly lower hERG risk, much better metabolic stability (lower Cl_mic and longer t1/2), lower P-gp efflux, and a slightly better binding affinity. The lower TPSA of Ligand B is attractive, but the substantial advantages of Ligand A in safety and PK properties outweigh this benefit.
Output:
1
2025-04-17 22:42:22,791 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (351.447 and 356.373 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (82.11) is significantly better than Ligand B (104.21). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (0.945) is slightly better than Ligand A (-0.413). Both are within the 1-3 range, but A is a bit low, potentially impacting permeability.
4. **HBD:** Ligand B has 3 HBDs, while Ligand A has 2. Both are acceptable.
5. **HBA:** Both ligands have 5 HBAs, which is good.
6. **QED:** Ligand A (0.719) is slightly better than Ligand B (0.675), indicating a marginally more drug-like profile.
7. **DILI:** Ligand A (13.532) has a *much* lower DILI risk than Ligand B (36.642). This is a critical advantage. A DILI percentile above 40 is concerning.
8. **BBB:** Ligand B (68.36) has a higher BBB penetration than Ligand A (45.444). However, as ADRB2 is a cardiovascular target, BBB penetration is not a primary concern.
9. **Caco-2:** Ligand A (-4.734) is better than Ligand B (-5.179), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-0.618) is better than Ligand B (-2.404). Solubility is important for bioavailability.
11. **hERG:** Both ligands have very low hERG risk (0.12 and 0.045 respectively).
12. **Cl_mic:** Ligand A (-0.92) has a lower (better) microsomal clearance than Ligand B (5.294). This suggests better metabolic stability.
13. **t1/2:** Ligand B (-21.4) has a much longer in vitro half-life than Ligand A (-8.806). This is a significant advantage.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.025 and 0.007 respectively).
15. **Binding Affinity:** Ligand B (-6.4 kcal/mol) has a slightly better binding affinity than Ligand A (-5.2 kcal/mol). This is a 1.2 kcal/mol difference, which is significant, but not overwhelming.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand B has a slightly better logP and affinity. However, Ligand A has significantly better TPSA, solubility, and a *much* lower DILI risk. The longer half-life of Ligand B is also attractive.
**Overall Assessment:**
While Ligand B has a slightly better binding affinity and half-life, the significantly lower DILI risk and better physicochemical properties (TPSA, solubility, Cl_mic) of Ligand A make it the more promising candidate. The DILI risk associated with Ligand B is a major red flag. The affinity difference is not large enough to overcome this significant safety concern.
Output:
1
2025-04-17 22:42:22,792 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (345.359 and 351.466 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (58.36) is significantly better than Ligand A (118.69). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (2.945) is optimal, while Ligand A (0.005) is quite low, potentially hindering membrane permeability. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1), but both are within the acceptable limit of 5.
5. **HBA:** Ligand A (7) is higher than Ligand B (4), but both are within the acceptable limit of 10.
6. **QED:** Ligand A (0.799) is slightly better than Ligand B (0.696), indicating a marginally more drug-like profile.
7. **DILI:** Ligand B (19.969) has a much lower DILI risk than Ligand A (49.632). This is a crucial advantage for Ligand B.
8. **BBB:** Ligand B (78.79) has better BBB penetration than Ligand A (35.052), but this is less critical for a cardiovascular target.
9. **Caco-2:** Ligand A (-5.218) is better than Ligand B (-4.583), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-2.159) is better than Ligand B (-2.578).
11. **hERG:** Ligand A (0.096) has a lower hERG risk than Ligand B (0.718). This is a positive for Ligand A.
12. **Cl_mic:** Ligand A (-25.771) has a much lower microsomal clearance (better metabolic stability) than Ligand B (51.681). This is a significant advantage for Ligand A.
13. **t1/2:** Ligand B (-6.967) has a longer in vitro half-life than Ligand A (6.556). This is a positive for Ligand B.
14. **Pgp:** Ligand A (0.01) has lower P-gp efflux than Ligand B (0.344).
15. **Binding Affinity:** Ligand B (-7.3) has a slightly better binding affinity than Ligand A (-6.5). While the difference is less than 1.5 kcal/mol, it's still a positive for Ligand B.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand B appears to be the better candidate. While Ligand A has advantages in metabolic stability (Cl_mic) and hERG risk, Ligand B's superior logP, lower DILI risk, better TPSA, and slightly better affinity outweigh these drawbacks. The low logP of Ligand A is a significant concern for permeability. The improved DILI profile of Ligand B is also a major factor, as liver toxicity is a common cause of drug failure.
Output:
0
2025-04-17 22:42:22,792 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (357.351 Da and 361.511 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (39.08) is significantly better than Ligand B (63.25). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is pushing the upper limit for good oral absorption (<=140).
**3. logP:** Both ligands have good logP values (4.089 and 4.648, respectively), falling within the 1-3 range. Ligand B is slightly higher, which *could* indicate potential off-target issues, but isn't a major concern at this level.
**4. H-Bond Donors:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
**5. H-Bond Acceptors:** Both ligands have the same number of HBA (4), which is acceptable.
**6. QED:** Both ligands have similar QED values (0.792 and 0.736), indicating good drug-like properties.
**7. DILI Risk:** Ligand A (34.858) has a much lower DILI risk than Ligand B (69.756). This is a significant advantage for Ligand A.
**8. BBB Penetration:** Ligand A (90.655) has substantially better BBB penetration than Ligand B (64.87). While ADRB2 is a cardiovascular target, some CNS effects are possible with certain ligands, and higher BBB penetration isn't necessarily detrimental.
**9. Caco-2 Permeability:** Ligand A (-4.444) is better than Ligand B (-4.96). Higher values are better, indicating better intestinal absorption.
**10. Aqueous Solubility:** Ligand A (-4.384) is better than Ligand B (-5.73). Higher values are better for formulation and bioavailability.
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (0.599 and 0.638), which is good.
**12. Microsomal Clearance:** Ligand A (28.427) has a significantly lower microsomal clearance than Ligand B (126.566), indicating better metabolic stability.
**13. In vitro Half-Life:** Ligand A (-19.408) has a better half-life than Ligand B (42.106).
**14. P-gp Efflux:** Ligand A (0.439) is better than Ligand B (0.582), suggesting lower P-gp efflux and improved bioavailability.
**15. Binding Affinity:** Ligand B (-6.4 kcal/mol) has a slightly better binding affinity than Ligand A (-7.0 kcal/mol). While this is a positive for Ligand B, the difference isn't substantial enough to outweigh the numerous advantages of Ligand A.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical ADME properties (TPSA, DILI, BBB, Caco-2, Solubility, Cl_mic, t1/2, P-gp). While Ligand B has slightly better binding affinity, the overall profile of Ligand A is far more favorable for drug development. The lower DILI risk and better predicted permeability and metabolic stability of Ligand A make it the more promising candidate.
Output:
1
2025-04-17 22:42:22,792 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (344.46 and 354.54 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (76.02) is higher than Ligand B (58.64). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B is better.
3. **logP:** Ligand B (3.227) is slightly higher than Ligand A (2.512), but both are within the optimal 1-3 range. Ligand B has a slight advantage.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable, below the threshold of 5. Ligand B is slightly better.
5. **HBA:** Ligand A (4) and Ligand B (3) are both acceptable, below the threshold of 10. Ligand B is slightly better.
6. **QED:** Ligand B (0.728) has a significantly better QED score than Ligand A (0.506), indicating a more drug-like profile. This is a substantial advantage for Ligand B.
7. **DILI:** Ligand B (20.28%) has a much lower DILI risk than Ligand A (40.60%). This is a major advantage for Ligand B, as minimizing liver toxicity is crucial.
8. **BBB:** Ligand B (71.31%) has a higher BBB penetration score than Ligand A (55.64%). While ADRB2 isn't primarily a CNS target, some CNS exposure can contribute to side effects, and better control is desirable. Ligand B is better.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-5.148) is worse than Ligand B (-4.328).
10. **Solubility:** Both ligands have negative solubility values, which is also unusual and suggests poor solubility. Ligand A (-2.581) is worse than Ligand B (-3.463).
11. **hERG:** Ligand A (0.237) has a slightly lower hERG inhibition liability than Ligand B (0.564), which is desirable. Ligand A is better.
12. **Cl_mic:** Ligand B (78.478) has a higher microsomal clearance than Ligand A (45.674), indicating faster metabolism and potentially lower exposure. Ligand A is better.
13. **t1/2:** Ligand A (8.352) has a longer in vitro half-life than Ligand B (6.342), which is generally preferred. Ligand A is better.
14. **Pgp:** Ligand A (0.138) has lower P-gp efflux liability than Ligand B (0.105), which is better for bioavailability. Ligand A is better.
15. **Binding Affinity:** Ligand B (-6.3 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.4 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME drawbacks.
**Overall Assessment:**
Ligand B demonstrates a superior overall profile, particularly regarding crucial factors like DILI risk, QED, and binding affinity. The stronger binding affinity (-6.3 vs -5.4 kcal/mol) is a significant advantage for a GPCR target. While Ligand A has some advantages in metabolic stability (Cl_mic, t1/2) and P-gp efflux, the lower DILI risk and better QED of Ligand B are more important considerations for a viable drug candidate. The slightly lower Caco-2 and solubility for Ligand B are concerning, but may be addressable with formulation strategies.
Output:
0
2025-04-17 22:42:22,792 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
The ADRB2 receptor is a GPCR, so the priorities are logP, TPSA, Pgp efflux, BBB penetration, and binding affinity. Let's compare the ligands property by property:
1. **MW:** Both ligands (343.471 and 357.407 Da) are within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (69.22) is significantly better than Ligand B (122.83). A TPSA under 140 is good for oral absorption, but lower is preferred for GPCRs, and A is much closer to the ideal range.
3. **logP:** Ligand A (3.701) is optimal (1-3), while Ligand B (-0.898) is quite low, potentially hindering membrane permeability. This is a significant advantage for A.
4. **HBD/HBA:** Ligand A (2 HBD, 3 HBA) is better than Ligand B (3 HBD, 6 HBA). Lower counts are generally preferred for better permeability.
5. **QED:** Ligand A (0.84) is excellent, indicating high drug-likeness. Ligand B (0.46) is below the desirable threshold of 0.5.
6. **DILI:** Ligand B (19.775) has a much lower DILI risk than Ligand A (33.812), which is a positive for B.
7. **BBB:** Both have acceptable BBB penetration (A: 70.919, B: 74.758), but B is slightly better.
8. **Caco-2:** Ligand A (-4.749) is better than Ligand B (-5.737). Higher Caco-2 values indicate better absorption.
9. **Solubility:** Ligand A (-3.762) is better than Ligand B (-1.723).
10. **hERG:** Ligand A (0.932) is better than Ligand B (0.028). Lower hERG inhibition is crucial for avoiding cardiotoxicity.
11. **Cl_mic:** Ligand B (-3.724) has a negative clearance, which is excellent (indicates very slow clearance), while Ligand A (53.178) is higher.
12. **t1/2:** Ligand A (24.076) has a better in vitro half-life than Ligand B (-5.277).
13. **Pgp:** Ligand A (0.799) is better than Ligand B (0.002). Lower Pgp efflux is desirable.
14. **Affinity:** Ligand A (-6.5 kcal/mol) is slightly better than Ligand B (-5.3 kcal/mol), though both are good.
**Overall Assessment:**
Ligand A has a superior profile in terms of key GPCR-relevant properties (logP, TPSA, Pgp, solubility, hERG) and overall drug-likeness (QED). While Ligand B has a better DILI score and clearance, the significantly better logP, TPSA, and QED of Ligand A outweigh these advantages, especially given the target is a GPCR. The slightly better binding affinity of A also contributes to its preference.
**Output:**
1
2025-04-17 22:42:22,792 - INFO - Batch 351 complete. Total preferences: 5616
2025-04-17 22:42:22,792 - INFO - Processing batch 352/512...
2025-04-17 22:43:04,780 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (378.485 Da and 352.391 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (69.64) is significantly better than Ligand B (105.92). For a GPCR, keeping TPSA low is beneficial for permeability, and Ligand A is well below the 140 A^2 threshold. Ligand B is approaching the upper limit.
**3. logP:** Ligand A (2.378) is within the optimal 1-3 range. Ligand B (-0.636) is below 1, which could indicate poor membrane permeability. This is a significant drawback for a GPCR ligand.
**4. H-Bond Donors:** Both ligands have 2 HBD, which is acceptable.
**5. H-Bond Acceptors:** Ligand A has 4 HBA, while Ligand B has 7. Both are within the acceptable range (<=10), but Ligand B is higher.
**6. QED:** Both ligands have similar QED values (0.714 and 0.676), indicating good drug-likeness.
**7. DILI:** Both ligands have similar, acceptable DILI risk (39.318 and 40.597, both <40).
**8. BBB:** Ligand A (72.082) has a better BBB percentile than Ligand B (62.854). While ADRB2 isn't a CNS target, some degree of BBB penetration can be helpful for distribution.
**9. Caco-2 Permeability:** Ligand A (-5.06) has better Caco-2 permeability than Ligand B (-4.876).
**10. Aqueous Solubility:** Ligand A (-4.302) has better aqueous solubility than Ligand B (-1.851).
**11. hERG Inhibition:** Ligand A (0.628) has a lower hERG inhibition liability than Ligand B (0.102), which is a positive safety attribute.
**12. Microsomal Clearance:** Ligand B (-5.545) has a *negative* microsomal clearance, which is highly unusual and suggests very high metabolic stability. Ligand A (51.456) is more typical, but not ideal.
**13. In vitro Half-Life:** Ligand B (0.899) has a shorter half-life than Ligand A (-0.442).
**14. P-gp Efflux:** Ligand A (0.225) has lower P-gp efflux liability than Ligand B (0.008), which is favorable for bioavailability.
**15. Binding Affinity:** Both ligands have very similar and excellent binding affinities (-6.2 kcal/mol and -6.0 kcal/mol). The difference is not substantial enough to override other factors.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp), Ligand A is the stronger candidate. Its superior logP and TPSA values suggest better permeability and absorption. While Ligand B has exceptionally low microsomal clearance, the negative value is suspect and could indicate an artifact. Ligand A also has better solubility, lower hERG risk, and lower P-gp efflux. The small difference in binding affinity doesn't outweigh the ADME advantages of Ligand A.
Output:
1
2025-04-17 22:43:04,781 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (388.251 and 390.893 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (92.18) is better than Ligand B (106). Both are acceptable for a non-CNS GPCR, but lower is preferable.
3. **logP:** Ligand A (2.117) is within the optimal 1-3 range. Ligand B (-0.199) is *below* 1, which is a concern for permeability. This is a significant negative for Ligand B.
4. **HBD:** Both have 3 HBD, which is good.
5. **HBA:** Ligand A has 5 HBA, acceptable. Ligand B has 7, slightly higher but still within reasonable limits.
6. **QED:** Ligand A (0.696) is better than Ligand B (0.595), indicating a more drug-like profile.
7. **DILI:** Ligand A (51.028) is slightly higher than Ligand B (41.218), but both are below the concerning threshold of 60.
8. **BBB:** This is less critical for ADRB2 (a cardiovascular target), but Ligand A (68.282) is better than Ligand B (9.732).
9. **Caco-2:** Both have negative values, indicating poor permeability. Ligand A (-5.042) is better than Ligand B (-5.393), but both are problematic.
10. **Solubility:** Ligand A (-2.956) is better than Ligand B (-0.805), both are poor, but A is less poor.
11. **hERG:** Both are very low (0.248 and 0.118), indicating minimal hERG inhibition risk. This is excellent for both.
12. **Cl_mic:** Ligand A (-14.84) is significantly better than Ligand B (-28.36), indicating much better metabolic stability.
13. **t1/2:** Ligand A (57.934) has a much longer half-life than Ligand B (16.02). This is a major advantage for Ligand A.
14. **Pgp:** Both are very low (0.066 and 0.05), indicating minimal P-gp efflux.
15. **Affinity:** Ligand A (-7.5) is better than Ligand B (-5.1), a difference of 2.4 kcal/mol. This is a substantial advantage, easily outweighing minor ADME concerns.
**GPCR-specific priorities:** For ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A excels in affinity and has a much better logP. While both have acceptable Pgp and TPSA values, Ligand A's better logP and significantly better metabolic stability (Cl_mic and t1/2) make it the superior candidate.
Output:
1
2025-04-17 22:43:04,781 - INFO - Here's my reasoning and the final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. This means we prioritize logP, TPSA, Pgp, and affinity, while also considering overall drug-likeness and safety.
* **Molecular Weight:** Both ligands (372.475 and 361.515 Da) fall within the ideal 200-500 Da range.
* **TPSA:** Ligand A (76.14) is better than Ligand B (81.91), being closer to the <140 threshold for good absorption.
* **logP:** Both ligands are excellent (2.504 and 2.463), falling squarely within the optimal 1-3 range.
* **H-Bond Donors/Acceptors:** Ligand A has 2 HBD and 7 HBA, while Ligand B has 1 HBD and 6 HBA. Both are acceptable, well below the limits of 5 and 10 respectively.
* **QED:** Both ligands have similar QED values (0.72 and 0.716), indicating good drug-likeness.
* **DILI:** Ligand A (94.572) has a significantly higher DILI risk than Ligand B (38.154). This is a major concern.
* **BBB:** Ligand B (88.794) has a much higher BBB penetration percentile than Ligand A (38.658). While not critical for a cardiovascular target, higher BBB is generally favorable.
* **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-5.141) is slightly worse than Ligand B (-5.284).
* **Solubility:** Both have negative solubility values, indicating poor solubility. Ligand B (-2.529) is slightly better than Ligand A (-3.79).
* **hERG:** Ligand A (0.476) has a lower hERG inhibition liability than Ligand B (0.864), which is positive.
* **Cl_mic:** Ligand A (18.325) has a much lower microsomal clearance than Ligand B (69.526), indicating better metabolic stability.
* **t1/2:** Ligand A (5.349) has a longer in vitro half-life than Ligand B (-0.195), which is a significant advantage.
* **Pgp:** Ligand A (0.227) has lower P-gp efflux liability than Ligand B (0.296), which is favorable.
* **Binding Affinity:** Ligand A (-7.6 kcal/mol) has a substantially stronger binding affinity than Ligand B (-4.5 kcal/mol). This is a difference of 3.1 kcal/mol, which is very significant and can outweigh many ADME drawbacks.
**Conclusion:**
Despite the higher DILI risk for Ligand A, its significantly superior binding affinity (-7.6 vs -4.5 kcal/mol) and better metabolic stability (lower Cl_mic, longer t1/2) are compelling. The difference in affinity is substantial enough to potentially overcome the DILI concern, especially considering the cardiovascular target. Ligand B has better solubility and a lower DILI risk, but the weaker binding affinity is a major drawback. Given the GPCR-specific priorities and the large affinity difference, I believe Ligand A is the more promising candidate.
**Output:**
1
2025-04-17 22:43:04,781 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (376.888 Da) is slightly higher than Ligand B (337.427 Da), but both are acceptable.
2. **TPSA:** Ligand A (43.6) is significantly better than Ligand B (74.86). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (A: 4.759, B: 3.575), falling within the optimal range of 1-3, although A is a bit high.
4. **HBD:** Ligand A (0) is preferable to Ligand B (3). Fewer HBDs generally improve membrane permeability.
5. **HBA:** Both ligands have the same number of HBA (5), which is acceptable.
6. **QED:** Ligand A (0.44) is slightly better than Ligand B (0.389), indicating a slightly more drug-like profile.
7. **DILI:** Both ligands have similar DILI risk (A: 68.941, B: 65.491), and are within an acceptable range (< 60 is good, these are close to the upper limit of acceptable).
8. **BBB:** Both ligands have good BBB penetration (A: 76.154, B: 68.205), but this is less critical for a cardiovascular target.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.033 and -5.574). This is unusual and suggests poor permeability.
10. **Solubility:** Ligand A (-5.534) has slightly better solubility than Ligand B (-3.879), but both are very poor.
11. **hERG:** Ligand A (0.5) has a much lower hERG risk than Ligand B (0.937). This is a significant advantage, as hERG inhibition can lead to cardiotoxicity.
12. **Cl_mic:** Ligand B (75.002) has lower microsomal clearance than Ligand A (96.628), suggesting better metabolic stability.
13. **t1/2:** Ligand B (13.945) has a longer in vitro half-life than Ligand A (8.8), which is desirable.
14. **Pgp:** Ligand A (0.684) has lower P-gp efflux than Ligand B (0.578), which is beneficial for oral bioavailability.
15. **Binding Affinity:** Ligand B (-6.6) has a slightly better binding affinity than Ligand A (-6.3), but the difference is relatively small (0.3 kcal/mol).
**GPCR-specific priorities:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, and affinity. Ligand A has a slightly higher logP, but a significantly lower TPSA, better Pgp profile, and a lower hERG risk. The affinity difference is small.
**Overall Assessment:**
While Ligand B has better metabolic stability and half-life, Ligand A's superior TPSA, lower HBD count, significantly lower hERG risk, and acceptable affinity make it the more promising candidate. The poor solubility and Caco-2 values are concerning for both, but can potentially be addressed through formulation strategies. The lower hERG risk is a critical advantage for a cardiovascular drug.
Output:
1
2025-04-17 22:43:04,781 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (346.471 and 362.499 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Both ligands have TPSA values (78.43 and 76.02) below the 140 A^2 threshold for good oral absorption. These are acceptable, but not optimal for CNS penetration.
**3. logP:** Both ligands have logP values (2.183 and 1.907) within the optimal 1-3 range. This is good for both permeability and avoiding off-target effects.
**4. H-Bond Donors:** Ligand A (3) is slightly higher than Ligand B (2), but both are within the acceptable limit of <=5.
**5. H-Bond Acceptors:** Ligand A (3) is lower than Ligand B (5), which is preferable. Higher HBA can sometimes hinder permeability.
**6. QED:** Both ligands have good QED scores (0.675 and 0.727), indicating a generally drug-like profile.
**7. DILI Risk:** Ligand B (37.224) has a significantly lower DILI risk than Ligand A (15.394). This is a major advantage for Ligand B.
**8. BBB Penetration:** Both ligands have moderate BBB penetration (57.464 and 53.897). Since ADRB2 isn't exclusively a CNS target, this isn't a deciding factor, but higher is generally better.
**9. Caco-2 Permeability:** Ligand B (-5.486) has better Caco-2 permeability than Ligand A (-4.687). This suggests better intestinal absorption for Ligand B.
**10. Aqueous Solubility:** Both ligands have poor aqueous solubility (-2.255 and -2.681). This could pose formulation challenges, but is not a dealbreaker.
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.278 and 0.13). This is excellent and minimizes cardiotoxicity concerns.
**12. Microsomal Clearance:** Ligand B (19.962) has significantly lower microsomal clearance than Ligand A (32.173). This indicates better metabolic stability for Ligand B, which is highly desirable.
**13. In vitro Half-Life:** Ligand A (-0.909) has a slightly longer in vitro half-life than Ligand B (1.42). However, the difference is not substantial.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.058 and 0.057).
**15. Binding Affinity:** Ligand A (-7.2 kcal/mol) has a stronger binding affinity than Ligand B (-6.1 kcal/mol). This is a 1.1 kcal/mol difference, which is significant.
**Overall Assessment:**
While Ligand A has a better binding affinity, Ligand B demonstrates a superior ADME profile, particularly regarding DILI risk and metabolic stability (lower clearance). For a GPCR target like ADRB2, a balance between potency and favorable ADME properties is crucial. The lower DILI risk and improved metabolic stability of Ligand B outweigh the slightly weaker binding affinity. The Caco-2 permeability is also better for Ligand B.
Output:
0
2025-04-17 22:43:04,781 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (368.543) is slightly higher than Ligand B (351.466), but both are acceptable.
2. **TPSA:** Ligand A (49.85) is better than Ligand B (58.22). Both are below 140, but lower TPSA generally favors absorption.
3. **logP:** Ligand B (3.713) is a bit higher than Ligand A (2.393). While both are within the optimal range of 1-3, Ligand B is approaching the upper limit, potentially raising concerns about solubility and off-target effects.
4. **HBD:** Ligand A (0) is preferable to Ligand B (1). Fewer HBDs generally improve membrane permeability.
5. **HBA:** Ligand A (4) is preferable to Ligand B (3). Fewer HBAs are generally preferred for permeability.
6. **QED:** Both ligands have similar QED values (A: 0.767, B: 0.738), indicating good drug-likeness.
7. **DILI:** Ligand A (34.432) is significantly better than Ligand B (13.3). Lower DILI risk is a major advantage.
8. **BBB:** Ligand B (87.864) is significantly better than Ligand A (66.886). For a GPCR, especially if CNS effects are possible, higher BBB penetration is desirable.
9. **Caco-2:** Ligand A (-4.709) and Ligand B (-4.144) are both very poor. This is a significant drawback for both compounds.
10. **Solubility:** Ligand A (-2.723) is better than Ligand B (-4.324), indicating better aqueous solubility.
11. **hERG:** Ligand A (0.353) is better than Ligand B (0.689). Lower hERG inhibition is crucial for avoiding cardiotoxicity.
12. **Cl_mic:** Ligand A (68.398) is better than Ligand B (86.975). Lower microsomal clearance indicates better metabolic stability.
13. **t1/2:** Ligand B (-35.495) is much better than Ligand A (6.356). A longer half-life is generally preferred.
14. **Pgp:** Ligand A (0.196) is better than Ligand B (0.137). Lower P-gp efflux is desirable for improved bioavailability.
15. **Affinity:** Ligand B (-7.5) is slightly better than Ligand A (-6.7). A 0.8 kcal/mol difference is substantial and can outweigh some ADME drawbacks.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, Pgp, TPSA, and affinity. Ligand B has a slightly higher logP and significantly better affinity. However, Ligand A has better TPSA, Pgp, DILI, hERG, and Cl_mic. The better safety profile (DILI, hERG) and metabolic stability (Cl_mic) of Ligand A are very important. The affinity difference, while notable, isn't large enough to overcome the significant advantages of Ligand A in terms of safety and ADME properties.
**Conclusion:**
Considering the balance of properties, especially the safety profile and metabolic stability, Ligand A appears to be the more viable drug candidate.
Output:
1
2025-04-17 22:43:04,781 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (373.861 Da) is slightly higher than Ligand B (343.471 Da), but both are acceptable.
**2. TPSA:** Ligand A (48.3) is slightly higher than Ligand B (43.86). Both are well below the 140 A^2 threshold for good oral absorption, which is good.
**3. logP:** Ligand A (4.35) is significantly higher than Ligand B (1.338). While logP of 4.35 is approaching the upper limit, it's not drastically outside the optimal range. Ligand B's logP is quite low, potentially hindering membrane permeability.
**4. H-Bond Donors:** Both ligands have 0 HBD, which is favorable.
**5. H-Bond Acceptors:** Ligand A (5) and Ligand B (3) are both within the acceptable range of <=10.
**6. QED:** Ligand B (0.518) has a better QED score than Ligand A (0.366), indicating a more drug-like profile.
**7. DILI:** Ligand B (18.185) has a much lower DILI risk than Ligand A (76.464). This is a significant advantage for Ligand B.
**8. BBB:** Ligand A (71.772) has a better BBB penetration percentile than Ligand B (55.874). While ADRB2 is a cardiovascular target, some CNS exposure can occur, and higher BBB is generally preferable.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale isn't specified, so it's difficult to interpret.
**10. Aqueous Solubility:** Ligand B (-1.006) has better aqueous solubility than Ligand A (-4.589). Solubility is important for formulation and bioavailability.
**11. hERG Inhibition:** Ligand A (0.246) has a lower hERG inhibition risk than Ligand B (0.699). This is a crucial safety parameter.
**12. Microsomal Clearance:** Ligand A (119.837) has a higher microsomal clearance than Ligand B (23.663), indicating lower metabolic stability.
**13. In vitro Half-Life:** Ligand B (-9.377) has a significantly longer in vitro half-life than Ligand A (40.739). This is a major advantage for Ligand B.
**14. P-gp Efflux:** Ligand A (0.789) has higher P-gp efflux liability than Ligand B (0.065). Lower P-gp efflux is preferred.
**15. Binding Affinity:** Ligand B (-7.2) has a significantly higher binding affinity than Ligand A (-5.6). This difference of 1.6 kcal/mol is substantial and can outweigh some ADME drawbacks.
**GPCR-Specific Priorities:** For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand B excels in affinity and Pgp efflux, while its logP is lower (potentially a drawback, but not extreme). Ligand A has a better BBB score, but the substantial affinity advantage of Ligand B, coupled with its improved safety profile (lower DILI, better hERG) and metabolic stability (lower Cl_mic, longer t1/2) makes it the more promising candidate.
**Conclusion:**
Ligand B is the more viable drug candidate.
0
2025-04-17 22:43:04,781 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (358.463 Da) is slightly higher than Ligand B (345.487 Da), but both are acceptable.
2. **TPSA:** Ligand A (68.29) is higher than Ligand B (52.65). Both are below 140, but B is better for absorption.
3. **logP:** Ligand A (4.23) is higher than Ligand B (1.765). Ligand A is pushing the upper limit and could have solubility issues. Ligand B is within the optimal range.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 5 HBA, while Ligand B has 3. Both are acceptable, but B is slightly better.
6. **QED:** Both ligands have very similar QED values (0.834 and 0.826), indicating good drug-likeness.
7. **DILI:** Ligand A (81.427) has a significantly higher DILI risk than Ligand B (15.936). This is a major concern for Ligand A.
8. **BBB:** Both ligands have good BBB penetration (70.919 and 71.733). This isn't a primary concern for ADRB2, but it's a neutral point.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the values are similar (-4.544 and -4.904).
10. **Solubility:** Ligand B (-2.127) has better solubility than Ligand A (-5.859), which is expected given its lower logP.
11. **hERG:** Both ligands have low hERG inhibition risk (0.295 and 0.381).
12. **Cl_mic:** Ligand B (4.303) has significantly lower microsomal clearance than Ligand A (111.24), indicating better metabolic stability.
13. **t1/2:** Ligand B (23.125) has a longer in vitro half-life than Ligand A (29.664).
14. **Pgp:** Both ligands have low Pgp efflux liability (0.36 and 0.094).
15. **Binding Affinity:** Ligand A (-6.4 kcal/mol) has slightly better binding affinity than Ligand B (-6.2 kcal/mol), but the difference is not substantial.
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Ligand B performs better on logP and TPSA. While Ligand A has slightly better affinity, the significant DILI risk and higher clearance of Ligand A are major drawbacks.
**Conclusion:**
Ligand B is the more promising candidate due to its significantly lower DILI risk, better solubility, lower clearance, and acceptable logP and TPSA values. The slight difference in binding affinity is outweighed by the ADME/Tox advantages of Ligand B.
Output:
0
2025-04-17 22:43:04,781 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (355.435 Da and 350.354 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (96.97) is significantly better than Ligand B (133.15). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is approaching the upper limit for good oral absorption (140).
**3. logP:** Ligand A (-0.449) is slightly lower than the optimal 1-3 range, but still acceptable. Ligand B (0.981) is better positioned within the optimal range.
**4. H-Bond Donors:** Ligand A (2) is preferable to Ligand B (4). Fewer HBDs generally improve permeability.
**5. H-Bond Acceptors:** Ligand A (5) is preferable to Ligand B (8). Similar to HBDs, fewer HBAs are generally better for permeability.
**6. QED:** Both ligands have good QED scores (0.546 and 0.581), indicating good drug-like properties.
**7. DILI Risk:** Ligand A (20.706) has a much lower DILI risk than Ligand B (77.394). This is a significant advantage for Ligand A.
**8. BBB Penetration:** Ligand A (54.246) has a slightly better BBB penetration score than Ligand B (47.15), although both are not particularly high. For a cardiovascular target, BBB penetration is less critical than for CNS targets, but still a consideration.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-5.22 and -5.448), which is unusual and suggests poor permeability. However, these values are on a log scale and the absolute difference is small.
**10. Aqueous Solubility:** Ligand A (-0.714) is slightly better than Ligand B (-3.1).
**11. hERG Inhibition:** Ligand A (0.076) has a much lower hERG inhibition risk than Ligand B (0.372). This is a critical advantage, as hERG inhibition can lead to cardiotoxicity.
**12. Microsomal Clearance:** Both ligands have similar microsomal clearance values (32.979 and 31.381).
**13. In vitro Half-Life:** Ligand A (-21.335) has a slightly better (less negative) in vitro half-life than Ligand B (-15.588).
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.007 and 0.031).
**15. Binding Affinity:** Both ligands have similar binding affinities (-6.3 kcal/mol and -6.7 kcal/mol). Ligand B is slightly better, but the difference is not substantial enough to overcome other drawbacks.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity) and the general drug-like properties, Ligand A is the more promising candidate. It has a significantly lower DILI risk and hERG inhibition liability, better TPSA and H-bond characteristics, and slightly better solubility and half-life. While Ligand B has a slightly better logP and binding affinity, the safety and permeability advantages of Ligand A outweigh these minor benefits.
Output:
1
2025-04-17 22:43:04,782 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (351-352 Da). No significant difference.
2. **TPSA:** Ligand A (91.66) is better than Ligand B (119.54). For a GPCR, keeping TPSA lower is preferable for permeability.
3. **logP:** Ligand A (1.372) is within the optimal range, while Ligand B (-1.295) is slightly below, which could hinder permeability.
4. **HBD:** Ligand A (1) is better than Ligand B (3). Lower HBD generally improves permeability.
5. **HBA:** Both ligands have 5 HBA, which is acceptable.
6. **QED:** Ligand A (0.677) is better than Ligand B (0.565), indicating a more drug-like profile.
7. **DILI:** Ligand A (30.322) has a significantly lower DILI risk than Ligand B (49.321). This is a major advantage.
8. **BBB:** Ligand A (68.67) is better than Ligand B (42.032), though neither is exceptionally high. For a cardiovascular target, BBB isn't crucial, but a higher value is still preferred.
9. **Caco-2:** Ligand A (-4.723) is better than Ligand B (-5.216). Higher Caco-2 permeability is desirable.
10. **Solubility:** Ligand A (-1.642) is better than Ligand B (-1.746). Both are similar, but slightly better solubility is preferred.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.235 and 0.19, respectively). No significant difference.
12. **Cl_mic:** Ligand A (19.936) has lower microsomal clearance than Ligand B (-13.716), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-8.951) has a longer in vitro half-life than Ligand B (3.621), which is a significant advantage.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.05 and 0.009, respectively). No significant difference.
15. **Binding Affinity:** Ligand B (-8.0 kcal/mol) has a slightly better binding affinity than Ligand A (-7.1 kcal/mol). This is a 0.9 kcal/mol difference, which is substantial.
**Overall Assessment:**
Ligand B has a better binding affinity, which is a key factor. However, Ligand A demonstrates a significantly better safety profile (lower DILI), better predicted permeability (TPSA, logP, HBD, Caco-2), improved drug-likeness (QED), and better metabolic stability (Cl_mic, t1/2). The difference in binding affinity, while notable, is likely outweighed by the superior ADME-Tox properties of Ligand A. For a cardiovascular target, metabolic stability and safety are paramount.
Output:
1
2025-04-17 22:43:04,782 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (357.475 and 363.933 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (35.58) is significantly better than Ligand A (53.68). ADRB2 is not a CNS target, but lower TPSA generally improves absorption.
3. **logP:** Both ligands have logP values within the optimal range (3.949 and 4.706). Ligand B is slightly higher, which *could* be a minor concern for solubility, but not a dealbreaker.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 4 HBA, while Ligand B has 2. Lower HBA is generally preferred for better permeability. Ligand B is better here.
6. **QED:** Both ligands have good QED scores (0.823 and 0.844), indicating good drug-like properties.
7. **DILI:** Both ligands have acceptable DILI risk (31.214 and 37.185 percentile).
8. **BBB:** Ligand B (93.292) has a much higher BBB penetration percentile than Ligand A (70.919). While ADRB2 isn't a primary CNS target, higher BBB penetration can sometimes correlate with better overall distribution.
9. **Caco-2:** Ligand A (-5.048) and Ligand B (-4.601) both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
10. **Solubility:** Both ligands have very poor aqueous solubility (-3.93 and -4.547). This is a significant concern for both.
11. **hERG:** Both ligands have low hERG inhibition liability (0.751 and 0.933), which is good.
12. **Cl_mic:** Ligand A (41.226) has a slightly higher microsomal clearance than Ligand B (38.316), indicating potentially lower metabolic stability.
13. **t1/2:** Ligand A (52.487) has a significantly longer in vitro half-life than Ligand B (6.175). This is a major advantage for Ligand A.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.565 and 0.52).
15. **Binding Affinity:** Ligand B (-7.2 kcal/mol) has a substantially stronger binding affinity than Ligand A (-4.9 kcal/mol). This is a >1.5 kcal/mol difference, which is a major advantage that can outweigh some ADME drawbacks.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, and affinity are key. Ligand B excels in affinity and has better TPSA. While solubility is a concern for both, the significantly stronger binding of Ligand B is likely to be more impactful in driving *in vivo* efficacy. The longer half-life of Ligand A is attractive, but the potency difference is substantial.
**Conclusion:**
Despite the solubility issues, the much stronger binding affinity of Ligand B makes it the more promising candidate. The better TPSA and BBB penetration also contribute to its favorability.
Output:
0
2025-04-17 22:43:04,782 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (352.479) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (81.75) is better than Ligand A (99.33), being closer to the <140 threshold for good oral absorption.
3. **logP:** Ligand A (1.287) is within the optimal range (1-3). Ligand B (-0.621) is slightly below 1, which *could* indicate potential permeability issues, but is not a hard disqualifier.
4. **HBD:** Ligand A (4) and Ligand B (2) are both acceptable, being less than 5.
5. **HBA:** Ligand A (3) and Ligand B (5) are both acceptable, being less than 10.
6. **QED:** Ligand B (0.626) has a better QED score than Ligand A (0.446), indicating a more drug-like profile.
7. **DILI:** Ligand B (12.641) has a significantly lower DILI risk than Ligand A (18.108), which is a major advantage.
8. **BBB:** Ligand A (74.37) has a better BBB penetration percentile than Ligand B (58.821). While ADRB2 isn't exclusively a CNS target, some cardiovascular effects are mediated by central pathways, so some BBB penetration is beneficial.
9. **Caco-2:** Ligand B (-5.624) has a better Caco-2 permeability than Ligand A (-4.921).
10. **Solubility:** Ligand B (-1.856) has better aqueous solubility than Ligand A (-2.1).
11. **hERG:** Ligand A (0.406) has a slightly better hERG profile than Ligand B (0.071), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand B (-13.614) has a *much* lower microsomal clearance than Ligand A (22.979), suggesting significantly better metabolic stability.
13. **t1/2:** Ligand B (3.142) has a shorter in vitro half-life than Ligand A (6.621), which is a slight negative.
14. **Pgp:** Ligand A (0.019) has a lower P-gp efflux liability than Ligand B (0.005), which is favorable.
15. **Affinity:** Ligand B (-6.1 kcal/mol) has a significantly stronger binding affinity than Ligand A (-3.9 kcal/mol). This >1.5 kcal/mol difference is substantial and can outweigh some ADME concerns.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand B excels in affinity and TPSA, and has a reasonable logP. While Ligand A has better BBB penetration and Pgp efflux, the superior affinity and metabolic stability (Cl_mic) of Ligand B are more critical. The lower DILI risk for Ligand B is also a significant factor.
**Conclusion:**
Ligand B demonstrates a better overall balance of properties, particularly its significantly improved binding affinity and metabolic stability, coupled with a lower DILI risk. While Ligand A has some advantages in BBB and Pgp, the substantial benefit in affinity and the lower toxicity profile of Ligand B make it the more promising drug candidate.
Output:
0
2025-04-17 22:43:04,782 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (354.479 and 351.443 Da) are within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (59.81) is significantly better than Ligand B (77.02). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (3.831) is at the higher end of the optimal range (1-3), while Ligand B (2.146) is closer to the lower end. ADRB2 is a GPCR, and logP is important for membrane permeability and receptor engagement. Ligand A's higher logP is slightly preferable.
4. **HBD:** Ligand A (1) is better than Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (5) is better than Ligand B (6). Fewer HBAs generally improve permeability.
6. **QED:** Both ligands (0.701 and 0.664) are above the 0.5 threshold, indicating good drug-likeness. No significant difference.
7. **DILI:** Ligand B (8.918) has a *much* lower DILI risk than Ligand A (70.919). This is a major advantage for Ligand B. DILI is a critical safety concern.
8. **BBB:** Both ligands have similar BBB penetration (64.948 and 63.513). Not a major factor for a cardiovascular target.
9. **Caco-2:** Ligand A (-5.444) and Ligand B (-4.289) both have negative values, indicating poor permeability. However, Ligand B is slightly better.
10. **Solubility:** Ligand A (-4.639) is slightly better than Ligand B (-2.775). Solubility is important for bioavailability.
11. **hERG:** Both ligands have low hERG inhibition liability (0.421 and 0.507). No significant difference.
12. **Cl_mic:** Ligand B (64.41) has a considerably lower microsomal clearance than Ligand A (92.969), suggesting better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand A (5.004) has a longer in vitro half-life than Ligand B (-13.794). This is a positive for Ligand A.
14. **Pgp:** Ligand A (0.607) has lower P-gp efflux than Ligand B (0.152). Lower P-gp efflux is preferable.
15. **Binding Affinity:** Ligand B (-8.1) has a substantially stronger binding affinity than Ligand A (-5.9). A 2.2 kcal/mol difference is a significant advantage, and can often outweigh minor ADME concerns.
**Overall Assessment:**
Ligand B has a significantly better safety profile (DILI) and metabolic stability (Cl_mic). It also boasts a much stronger binding affinity. While Ligand A has a slightly better half-life and Pgp efflux, the advantages of Ligand B in safety and potency are more critical for a viable drug candidate. The TPSA and logP are reasonable for this target.
Output:
0
2025-04-17 22:43:04,782 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (379.81) is slightly higher, but still acceptable.
2. **TPSA:** Ligand A (90.37) is better than Ligand B (65.12). Both are acceptable for a non-CNS GPCR like ADRB2, but lower TPSA generally favors permeability.
3. **logP:** Ligand A (2.23) is optimal, while Ligand B (0.156) is quite low. This is a significant drawback for Ligand B, potentially hindering membrane permeability and bioavailability.
4. **HBD:** Ligand A (3) is reasonable, and Ligand B (1) is also good.
5. **HBA:** Ligand A (4) is reasonable, and Ligand B (5) is also good.
6. **QED:** Both ligands have similar, good QED values (A: 0.731, B: 0.705).
7. **DILI:** Ligand A (25.591) has a much lower DILI risk than Ligand B (8.414), a major advantage.
8. **BBB:** This is less critical for ADRB2 (a cardiovascular target), but Ligand A (77.317) is better than Ligand B (43.583).
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not defined, so it's hard to interpret.
10. **Solubility:** Both ligands have negative solubility values, which is also unusual. Again, the scale is undefined, making interpretation difficult.
11. **hERG:** Ligand A (0.659) has a slightly higher hERG risk than Ligand B (0.242), but both are relatively low.
12. **Cl_mic:** Ligand A (-8.242) has a lower (better) microsomal clearance than Ligand B (-7.466), indicating greater metabolic stability.
13. **t1/2:** Ligand A (18.712) has a longer half-life than Ligand B (12.408), which is desirable.
14. **Pgp:** Ligand A (0.118) has lower P-gp efflux liability than Ligand B (0.004), which is good for bioavailability.
15. **Binding Affinity:** Ligand B (-6.6 kcal/mol) has a slightly better binding affinity than Ligand A (-4.4 kcal/mol). This is a 2.2 kcal/mol difference, which is substantial.
**Overall Assessment:**
While Ligand B has a slightly better binding affinity, Ligand A is significantly better across several crucial ADME properties. The low logP of Ligand B is a major concern, likely leading to poor permeability and bioavailability. Ligand A also exhibits a much lower DILI risk, better metabolic stability, longer half-life, and lower P-gp efflux. Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand A presents a more balanced and promising profile for development. The affinity difference, while notable, can potentially be optimized in subsequent iterations of drug design, whereas fixing the poor logP of Ligand B would likely require a more substantial structural overhaul.
Output:
1
2025-04-17 22:43:04,782 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (348.462) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (40.62) is significantly better than Ligand B (54.18). For a GPCR, keeping TPSA low is beneficial for permeability and potentially BBB penetration.
3. **logP:** Both ligands have acceptable logP values (A: 2.338, B: 3.755), falling within the 1-3 range. Ligand B is a bit higher, which *could* indicate potential off-target interactions, but isn't a major concern.
4. **HBD/HBA:** Ligand A (0 HBD, 2 HBA) is preferable to Ligand B (1 HBD, 5 HBA). Lower counts are generally better for permeability.
5. **QED:** Both ligands have good QED scores (A: 0.663, B: 0.736), indicating good drug-like properties.
6. **DILI:** Ligand A (10.702) has a much lower DILI risk than Ligand B (15.781). This is a significant advantage.
7. **BBB:** Ligand A (86.817) has a substantially higher BBB penetration percentile than Ligand B (52.579). This is crucial for a GPCR target, even a cardiovascular one, as some CNS off-target effects are always a concern.
8. **Caco-2:** Ligand A (-4.478) and Ligand B (-5.108) both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
9. **Solubility:** Ligand A (-3.054) and Ligand B (-2.498) both have negative solubility values, which is also unusual.
10. **hERG:** Both ligands have low hERG risk (A: 0.672, B: 0.88).
11. **Cl_mic:** Ligand A (39.815) has a lower microsomal clearance than Ligand B (25.374), indicating better metabolic stability.
12. **t1/2:** Ligand B (65.372) has a significantly longer in vitro half-life than Ligand A (-14.003). This is a major advantage.
13. **Pgp:** Both ligands have low Pgp efflux liability (A: 0.121, B: 0.482).
14. **Binding Affinity:** Ligand B (-7.0) has a slightly better binding affinity than Ligand A (-5.6). This is a 1.4 kcal/mol difference, which is significant.
**Overall Assessment:**
Ligand B has a superior binding affinity and a much better half-life. However, Ligand A excels in several critical ADME properties: lower DILI risk, significantly better BBB penetration, lower TPSA, lower HBD/HBA, and better metabolic stability. Given the GPCR target class, the balance of properties leans towards Ligand A. The better BBB penetration and lower DILI risk are particularly important. While the affinity difference is notable, it can potentially be optimized in later stages of drug development. The unusual Caco-2 and solubility values for both compounds are concerning and would require further investigation, but the other advantages of Ligand A make it the more promising candidate.
Output:
1
2025-04-17 22:43:04,783 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (360.332 and 344.415 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (84.5) is better than Ligand B (99.24). ADRB2 is a cardiovascular target, so CNS penetration isn't critical, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (1.475 and 1.225), falling within the optimal 1-3 range. Ligand B is slightly lower, but still acceptable.
4. **HBD:** Both have 2 HBD, which is within the desirable limit of 5.
5. **HBA:** Ligand A has 4 HBA, while Ligand B has 6. Ligand A is slightly better here, staying closer to the ideal of 10 or less.
6. **QED:** Both ligands have similar QED scores (0.753 and 0.702), indicating good drug-likeness.
7. **DILI:** Both ligands have acceptable DILI risk (41.838 and 43.04), below the 60 threshold.
8. **BBB:** Ligand B (77.821) has a significantly higher BBB penetration score than Ligand A (60.45). While not a primary concern for a cardiovascular target, it's a slight advantage for Ligand B.
9. **Caco-2:** Ligand A (-4.724) has a better Caco-2 permeability than Ligand B (-5.262).
10. **Solubility:** Ligand A (-2.735) has slightly better solubility than Ligand B (-2.69).
11. **hERG:** Both ligands have low hERG inhibition liability (0.304 and 0.453).
12. **Cl_mic:** Ligand B (46.033) has lower microsomal clearance than Ligand A (60.251), indicating better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand B (-9.658) has a better in vitro half-life than Ligand A (-23.03). This is a substantial advantage.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.024 and 0.091).
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.1 and -6.4 kcal/mol). The difference is negligible.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A has better TPSA and Caco-2 permeability, but Ligand B has better metabolic stability (Cl_mic) and half-life. Given the similar affinities, the improved pharmacokinetic properties of Ligand B (lower Cl_mic, longer t1/2) are more crucial for *in vivo* efficacy and a favorable dosing profile.
**Conclusion:**
Ligand B is the better candidate due to its superior metabolic stability and half-life, which are key for a successful drug.
Output:
0
2025-04-17 22:43:04,783 - INFO - Batch 352 complete. Total preferences: 5632
2025-04-17 22:43:04,783 - INFO - Processing batch 353/512...
2025-04-17 22:43:55,425 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.45 & 357.48 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (96.25) is higher than Ligand B (55.95). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is generally preferred for absorption. Ligand B is better here.
3. **logP:** Ligand A (0.975) is slightly lower than the optimal 1-3 range, potentially impacting permeability. Ligand B (2.778) is well within the optimal range. Ligand B is better.
4. **HBD:** Ligand A (3) is higher than Ligand B (0). While not excessive, fewer HBDs generally improve permeability. Ligand B is better.
5. **HBA:** Ligand A (5) and Ligand B (6) are both acceptable, below the threshold of 10. No significant difference.
6. **QED:** Both ligands (0.652 & 0.653) have very similar and good QED scores, indicating good drug-like properties. No significant difference.
7. **DILI:** Ligand A (29.62) has a significantly lower DILI risk than Ligand B (41.37). This is a substantial advantage for Ligand A.
8. **BBB:** Ligand A (55.099) and Ligand B (62.233) are both relatively low, which is appropriate for a cardiovascular target (no need for significant brain penetration). Ligand B is slightly better.
9. **Caco-2:** Ligand A (-4.957) is worse than Ligand B (-5.524) indicating lower intestinal absorption. Ligand B is better.
10. **Solubility:** Ligand A (-2.459) is worse than Ligand B (-1.988). Solubility is important for bioavailability, and Ligand B has a slight advantage.
11. **hERG:** Ligand A (0.245) has a much lower hERG inhibition liability than Ligand B (0.485). This is a critical safety parameter, and Ligand A is significantly better.
12. **Cl_mic:** Ligand A (36.038) has a lower microsomal clearance than Ligand B (58.546), suggesting better metabolic stability. Ligand A is better.
13. **t1/2:** Ligand A (10.263) has a slightly longer in vitro half-life than Ligand B (9.024). This is a minor advantage for Ligand A.
14. **Pgp:** Ligand A (0.042) has a much lower P-gp efflux liability than Ligand B (0.268). Lower P-gp efflux is desirable for improved oral bioavailability. Ligand A is better.
15. **Affinity:** Ligand A (-7.3) has a stronger binding affinity than Ligand B (-6.3) by a margin of 1 kcal/mol. This is a substantial advantage, potentially outweighing some ADME drawbacks.
**Overall Assessment:**
Ligand A demonstrates a superior safety profile (lower DILI, lower hERG) and better metabolic stability (lower Cl_mic). Most importantly, it has significantly higher binding affinity. While Ligand B has slightly better logP and Caco-2 permeability, the advantages of Ligand A in safety, stability, and potency are more crucial for overall drug development success, particularly given the cardiovascular target.
Output:
1
2025-04-17 22:43:55,425 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (359.5 & 355.5 Da) fall comfortably within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (54.5) is higher than Ligand B (46.6). Both are acceptable for a non-CNS GPCR target like ADRB2, but B is slightly better.
3. **logP:** Ligand A (2.83) and Ligand B (3.84) are both within the optimal 1-3 range, but Ligand B is approaching the upper limit. This could potentially lead to solubility issues, but is still acceptable.
4. **HBD:** Ligand A (1) is better than Ligand B (0). While both are low, having one HBD can sometimes improve solubility.
5. **HBA:** Ligand A (5) is higher than Ligand B (3). Again, both are acceptable, but lower is generally preferred for permeability.
6. **QED:** Ligand A (0.86) is significantly better than Ligand B (0.56), indicating a more drug-like profile. This is a substantial advantage for A.
7. **DILI:** Ligand B (15.7) has a much lower DILI risk than Ligand A (68.1). This is a major advantage for B, as liver toxicity is a significant concern.
8. **BBB:** Ligand B (95.3) has excellent BBB penetration, while Ligand A (67) is moderate. While ADRB2 isn't primarily a CNS target, some off-target CNS effects are always a consideration, and higher BBB is generally preferable.
9. **Caco-2:** Ligand A (-4.99) and Ligand B (-3.97) are both negative, which is unusual. It suggests poor permeability. However, the values are close, and this parameter is less crucial for ADRB2.
10. **Solubility:** Ligand A (-2.97) has better solubility than Ligand B (-4.80). This is a positive for A, potentially mitigating the higher logP of B.
11. **hERG:** Both ligands have low hERG risk (0.87 and 0.85 respectively), which is good. No significant difference.
12. **Cl_mic:** Ligand B (123.5) has significantly higher microsomal clearance than Ligand A (54.6). This suggests Ligand B will be metabolized more quickly, potentially leading to lower exposure. This is a major disadvantage for B.
13. **t1/2:** Ligand A (54.6) has a much longer in vitro half-life than Ligand B (-6.7). This is a significant advantage for A, indicating greater metabolic stability.
14. **Pgp:** Ligand A (0.65) has slightly higher P-gp efflux than Ligand B (0.35). Lower P-gp is better, giving a slight advantage to B.
15. **Binding Affinity:** Ligand A (-7.7) has a slightly better binding affinity than Ligand B (-7.0). While both are excellent, the 0.7 kcal/mol difference is noticeable and can outweigh some ADME drawbacks.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand B has a slightly higher logP and lower Pgp, but Ligand A has better affinity. The biggest differentiating factors are DILI (B is much better) and metabolic stability (A is much better). Given the importance of avoiding liver toxicity, the lower DILI score of Ligand B is very attractive. However, the substantial improvement in metabolic stability (longer half-life, lower clearance) and the slightly better affinity of Ligand A are also very important. The QED score also favors A.
**Final Decision:**
Considering the balance of properties, and prioritizing metabolic stability and affinity for a GPCR target, I believe **Ligand A** is the more promising drug candidate. While Ligand B has a better DILI profile and BBB penetration, the significantly improved metabolic stability, QED, and slightly better affinity of Ligand A outweigh these advantages.
1
2025-04-17 22:43:55,425 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [374.497, 58.2, 2.965, 2, 3, 0.752, 37.03, 85.033, -5.322, -3.575, 0.51, 8.016, 15.433, 0.15, -7.2]
**Ligand B:** [396.192, 53.68, 3.871, 1, 3, 0.596, 48.74, 70.376, -4.661, -3.975, 0.891, 59.473, 69.217, 0.802, -5.6]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (374.497) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are acceptable, but Ligand B (53.68) is better than Ligand A (58.2), being closer to the <90 target for GPCRs.
3. **logP:** Both are within the optimal range (1-3), but Ligand B (3.871) is a bit higher than Ligand A (2.965). While still acceptable, higher logP can sometimes lead to off-target effects.
4. **HBD:** Ligand A (2) is slightly better than Ligand B (1). Lower is generally preferred.
5. **HBA:** Both have 3 HBA, which is good.
6. **QED:** Ligand A (0.752) has a better QED score than Ligand B (0.596), indicating a more drug-like profile.
7. **DILI:** Ligand A (37.03) has a significantly lower DILI risk than Ligand B (48.74). This is a major advantage.
8. **BBB:** Ligand A (85.033) has a much higher BBB penetration percentile than Ligand B (70.376). This is crucial for a GPCR target, even if it's not a CNS target, as it can influence distribution.
9. **Caco-2:** Ligand A (-5.322) has a better Caco-2 permeability than Ligand B (-4.661).
10. **Solubility:** Both have poor solubility (-3.575 and -3.975 respectively). This is a concern for both, but not a deciding factor.
11. **hERG:** Ligand A (0.51) has a lower hERG inhibition liability than Ligand B (0.891), which is favorable for cardiac safety.
12. **Cl_mic:** Ligand A (8.016) has a lower microsomal clearance than Ligand B (59.473), indicating better metabolic stability.
13. **t1/2:** Ligand B (69.217) has a significantly longer in vitro half-life than Ligand A (15.433). This is a positive for Ligand B.
14. **Pgp:** Ligand A (0.15) has a lower P-gp efflux liability than Ligand B (0.802), which is beneficial for bioavailability and potentially CNS exposure.
15. **Affinity:** Ligand A (-7.2 kcal/mol) has a stronger binding affinity than Ligand B (-5.6 kcal/mol). This is a substantial difference and a major advantage.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, BBB, and affinity. Ligand A excels in BBB, Pgp, and affinity. Ligand B has a slightly higher logP, but the difference isn't substantial enough to outweigh the other benefits of Ligand A. The longer half-life of Ligand B is attractive, but the significantly better affinity, lower DILI risk, and better BBB penetration of Ligand A are more important.
**Conclusion:**
Ligand A is the more promising drug candidate due to its superior binding affinity, lower DILI risk, better BBB penetration, lower P-gp efflux, and better Caco-2 permeability. While Ligand B has a longer half-life, the other advantages of Ligand A are more critical for a successful GPCR drug.
**Output:**
1
2025-04-17 22:43:55,425 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (366.403 and 371.493 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (136.06) is better than Ligand B (40.54). ADRB2 is a cardiovascular target, so CNS penetration is not a primary concern, but lower TPSA generally correlates with better permeability.
3. **logP:** Ligand B (4.453) is high, potentially causing solubility issues and off-target effects. Ligand A (-0.091) is quite low, which could hinder permeation. This is a critical difference, and a balance is preferred.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1), but both are within the acceptable limit of 5.
5. **HBA:** Ligand A (9) is higher than Ligand B (3), but both are within the acceptable limit of 10.
6. **QED:** Both ligands have good QED scores (0.644 and 0.769), indicating good drug-like properties.
7. **DILI:** Ligand A (86.002) has a significantly higher DILI risk than Ligand B (13.959). This is a major concern for Ligand A.
8. **BBB:** Ligand B (89.841) has better BBB penetration than Ligand A (56.534). While not crucial for a cardiovascular target, it's a slight advantage.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.363 and -4.689), which is unusual and suggests poor permeability.
10. **Solubility:** Ligand A (-2.665) has slightly better solubility than Ligand B (-3.624).
11. **hERG:** Ligand A (0.155) has a lower hERG risk than Ligand B (0.753). This is a positive for Ligand A.
12. **Cl_mic:** Ligand B (36.977) has a much lower microsomal clearance than Ligand A (4.993), suggesting better metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand B (21.834) has a much longer in vitro half-life than Ligand A (-2.395), indicating better persistence. Another significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.016) has a lower P-gp efflux liability than Ligand B (0.55). This is a positive for Ligand A.
15. **Binding Affinity:** Ligand B (-6.4) has a significantly stronger binding affinity than Ligand A (-3.0). This is the most important factor, and the 1.5 kcal/mol advantage outweighs many of the other drawbacks.
**Overall Assessment:**
Ligand B is the stronger candidate. While it has a higher logP and Pgp efflux, its significantly better binding affinity (-6.4 vs -3.0 kcal/mol), lower DILI risk, and improved metabolic stability (lower Cl_mic and longer t1/2) are critical advantages. The higher binding affinity is likely to drive efficacy, and the reduced toxicity/improved PK profile makes it a more viable starting point for optimization. Ligand A's high DILI risk is a major red flag.
Output:
0
2025-04-17 22:43:55,425 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, key properties are affinity, logP, TPSA, Pgp efflux, and to a lesser extent, BBB (though less critical for a cardiovascular target).
Let's compare the ligands property by property:
1. **MW:** Both are within the ideal range (350-362 Da).
2. **TPSA:** Ligand B (67.43) is significantly better than Ligand A (87.46), falling well below the 140 threshold for good absorption.
3. **logP:** Both are excellent (around 2.0), within the optimal 1-3 range.
4. **HBD/HBA:** Both have acceptable HBD (2) and HBA (5/4) counts.
5. **QED:** Ligand B (0.842) has a higher QED score than Ligand A (0.665), indicating better overall drug-likeness.
6. **DILI:** Ligand A (31.64) has a lower DILI risk than Ligand B (50.174), which is preferable.
7. **BBB:** Ligand B (71.384) has a higher BBB penetration than Ligand A (48.313). While not a primary concern for a cardiovascular target, it's a slight advantage.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual. Assuming these are logP-like scales, lower values indicate poorer permeability. Ligand A (-5.548) is worse than Ligand B (-5.367).
9. **Solubility:** Both have negative solubility values, indicating poor aqueous solubility. Ligand A (-2.014) is slightly better than Ligand B (-3.508).
10. **hERG:** Both have low hERG inhibition risk (0.231 and 0.478).
11. **Cl_mic:** Ligand A (19.859) has a significantly lower microsomal clearance than Ligand B (44.014), suggesting better metabolic stability.
12. **t1/2:** Ligand B (18.084) has a much longer in vitro half-life than Ligand A (-8.647).
13. **Pgp:** Both have low Pgp efflux liability (0.046 and 0.299).
14. **Affinity:** Ligand A (-6.2 kcal/mol) has a slightly better binding affinity than Ligand B (-3.7 kcal/mol). This is a substantial difference.
**Overall Assessment:**
The biggest differentiator is the binding affinity. Ligand A's affinity is significantly stronger (-6.2 vs -3.7 kcal/mol). This advantage is substantial enough to outweigh the drawbacks of its slightly higher TPSA, lower QED, and poorer half-life. While Ligand B has better TPSA, QED, BBB, and half-life, the potency difference is too large to ignore, especially for a GPCR target where strong binding is crucial. Ligand A also has a better DILI score and lower Cl_mic. The negative Caco-2 and solubility values are concerning for both, but the potency advantage of A is a deciding factor.
**Output:**
1
2025-04-17 22:43:55,425 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (362.417 and 349.439 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (87.66) is better than Ligand B (119.03). ADRB2 is a cardiovascular target, not CNS, but lower TPSA generally improves absorption.
3. **logP:** Ligand A (1.734) is within the optimal range (1-3). Ligand B (0.355) is a bit low, potentially hindering membrane permeability. This is a significant advantage for A.
4. **HBD:** Both ligands are acceptable (3 and 2 respectively), well below the 5 threshold.
5. **HBA:** Ligand A (4) is better than Ligand B (7), keeping it closer to the ideal of 10 or less.
6. **QED:** Both ligands have good QED scores (0.583 and 0.741), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (37.263) has a significantly lower DILI risk than Ligand B (60.217). This is a crucial advantage for A, as liver toxicity is a major concern.
8. **BBB:** Not a primary concern for a cardiovascular target like ADRB2, but Ligand B (81.698) is higher than Ligand A (52.268).
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-4.968) is slightly better than Ligand B (-5.378).
10. **Solubility:** Both are negative, indicating poor solubility. Ligand A (-1.513) is slightly better than Ligand B (-2.428).
11. **hERG:** Both ligands have low hERG inhibition risk (0.507 and 0.167). Ligand B is better here.
12. **Cl_mic:** Ligand B (7.601) has a much lower microsomal clearance than Ligand A (33.677), suggesting better metabolic stability. This is a significant advantage for B.
13. **t1/2:** Ligand A (-12.089) has a negative half-life, which is concerning. Ligand B (-3.932) is also negative, but less so.
14. **Pgp:** Both have low Pgp efflux liability (0.15 and 0.061). Ligand B is better.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-7.5 and -7.4 kcal/mol). The difference is negligible.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand A has a better logP and TPSA. While both have similar affinity, Ligand A's significantly lower DILI risk is a major factor. Metabolic stability (Cl_mic) is also important, where Ligand B has an advantage.
**Overall Assessment:**
Ligand A has a better balance of properties, particularly regarding safety (DILI) and permeability-related parameters (logP, TPSA). While Ligand B has better metabolic stability, the DILI risk associated with Ligand B is a significant concern. The slight advantage in metabolic stability doesn't outweigh the safety concerns.
Output:
1
2025-04-17 22:43:55,425 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [346.391, 107.09 , -0.087, 2. , 5. , 0.789, 41.024, 36.06 ,
-5.318, -1.793, 0.201, -8.758, -15.308, 0.03 , -5.5 ]
**Ligand B:** [359.857, 54.43 , 4.191, 1. , 5. , 0.717, 22.761, 28.81 ,
-5.286, -3.694, 0.895, 55.584, 37.483, 0.439, -6.6 ]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity) and general drug-like properties:
1. **MW:** Both are within the ideal range (200-500 Da). A is 346, B is 360 - very similar.
2. **TPSA:** A (107) is higher than ideal for good oral absorption (<140), but acceptable. B (54) is excellent, well below 90, suggesting good permeability.
3. **logP:** A (-0.087) is quite low, potentially hindering membrane permeability. B (4.191) is high, potentially causing solubility issues and off-target effects, but within the acceptable range.
4. **HBD:** A (2) and B (1) are both good, well within the limit of 5.
5. **HBA:** Both A (5) and B (5) are good, within the limit of 10.
6. **QED:** Both are good (A: 0.789, B: 0.717), indicating drug-like properties.
7. **DILI:** A (41%) is slightly higher than B (23%), but both are within the acceptable range (<40 is good, <60 is preferred).
8. **BBB:** A (36%) is low, suggesting poor CNS penetration. B (29%) is also low, but similar to A. This isn't a major concern for a cardiovascular target.
9. **Caco-2:** Both are very poor (-5.318 and -5.286). This is a significant concern for oral bioavailability.
10. **Solubility:** A (-1.793) is better than B (-3.694), indicating better aqueous solubility.
11. **hERG:** A (0.201) is much lower than B (0.895), suggesting a lower risk of cardiotoxicity. This is *very* important for a cardiovascular target.
12. **Cl_mic:** A (-8.758) is significantly lower (better) than B (55.584), indicating better metabolic stability.
13. **t1/2:** B (37.483) has a much longer half-life than A (-15.308). This is a significant advantage.
14. **Pgp:** A (0.03) is much lower (better) than B (0.439), indicating less P-gp efflux.
15. **Affinity:** B (-6.6) is 1.1 kcal/mol better than A (-5.5). This is a substantial difference in binding potency.
**Overall Assessment:**
Ligand B has a significantly better binding affinity and a much longer half-life. While its logP is higher, the substantial improvement in affinity and half-life likely outweigh this drawback. Ligand A has better solubility, lower hERG risk, and lower Pgp efflux, but the weaker binding and shorter half-life are major concerns. The hERG risk for B is still acceptable. Given the GPCR target class, affinity is paramount, and the improved metabolic stability (half-life) is also highly desirable.
Therefore, I favor Ligand B.
0
2025-04-17 22:43:55,426 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [375.441, 87.3, 1.203, 3, 4, 0.605, 43.389, 72.16, -5.063, -2.291, 0.278, 24.906, -1.625, 0.027, -6.4]
**Ligand B:** [357.485, 29.54, 4.502, 0, 2, 0.671, 15.238, 95.696, -4.447, -4.147, 0.828, 55.653, 16.887, 0.465, -6.9]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (357.485) is slightly lower, which could be beneficial for permeability.
2. **TPSA:** Ligand A (87.3) is higher than Ligand B (29.54). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B is significantly better here.
3. **logP:** Ligand A (1.203) is within the optimal range. Ligand B (4.502) is a bit high, potentially leading to solubility issues and off-target interactions.
4. **HBD:** Ligand A (3) is acceptable. Ligand B (0) is very low, potentially impacting solubility.
5. **HBA:** Ligand A (4) is acceptable. Ligand B (2) is also good.
6. **QED:** Both are similar (A: 0.605, B: 0.671) and above the 0.5 threshold, indicating good drug-like properties.
7. **DILI:** Ligand A (43.389) has a higher DILI risk than Ligand B (15.238). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (72.16) is decent, but Ligand B (95.696) is excellent. While ADRB2 isn't strictly a CNS target, some CNS penetration could be relevant for side effect profile or off-target effects.
9. **Caco-2:** Ligand A (-5.063) is poor, while Ligand B (-4.447) is also poor. Both have negative values, indicating low permeability.
10. **Solubility:** Ligand A (-2.291) is better than Ligand B (-4.147).
11. **hERG:** Ligand A (0.278) is much better than Ligand B (0.828), indicating lower cardiotoxicity risk. This is crucial for a cardiovascular target.
12. **Cl_mic:** Ligand A (24.906) has lower clearance, suggesting better metabolic stability than Ligand B (55.653).
13. **t1/2:** Ligand B (16.887) has a significantly longer half-life than Ligand A (-1.625). This is a major advantage for dosing convenience.
14. **Pgp:** Ligand A (0.027) has lower Pgp efflux, which is favorable for bioavailability. Ligand B (0.465) is higher.
15. **Affinity:** Ligand B (-6.9) has a slightly better binding affinity than Ligand A (-6.4), a 0.5 kcal/mol difference.
**GPCR-Specific Priorities:**
For ADRB2 (a cardiovascular GPCR), we prioritize logP, Pgp, TPSA, and affinity. Ligand B excels in TPSA and BBB, and has a slightly better affinity. Ligand A has better hERG and Pgp. However, the significantly lower DILI risk and longer half-life of Ligand B are compelling advantages. The slightly high logP of Ligand B is a concern, but the better overall ADME profile and affinity outweigh this.
**Conclusion:**
Considering the balance of properties, particularly the lower DILI risk, better BBB penetration, longer half-life, and slightly better affinity of Ligand B, it appears to be the more promising drug candidate.
**Output:**
0
2025-04-17 22:43:55,426 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (361.789 Da and 351.403 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (114.35 and 111.88) are below the 140 A^2 threshold for good oral absorption, but not optimized for CNS penetration (ideally <90 for CNS). Again, very similar.
3. **logP:** Ligand A (1.226) is within the optimal 1-3 range. Ligand B (-0.326) is slightly below 1, which *could* indicate potential permeability issues, although not drastically. This is a slight advantage for A.
4. **HBD:** Ligand A (2) and Ligand B (3) are both acceptable, being <=5.
5. **HBA:** Ligand A (6) and Ligand B (5) are both acceptable, being <=10.
6. **QED:** Ligand A (0.846) has a better QED score than Ligand B (0.594), indicating a more drug-like profile. This is a notable advantage for A.
7. **DILI:** Ligand A (64.986) has a higher DILI risk than Ligand B (19.155). This is a significant advantage for B.
8. **BBB:** Ligand A (91.508) has a much higher BBB penetration percentile than Ligand B (25.475). While ADRB2 isn't strictly a CNS target, some peripheral ADRB2 receptors influence CNS function, and better BBB penetration isn't necessarily a detriment.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.055 and -5.781), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-4.384) has slightly better solubility than Ligand B (-0.827), but both are quite poor.
11. **hERG:** Both ligands have low hERG inhibition risk (0.425 and 0.08). No significant difference.
12. **Cl_mic:** Ligand A (6.737) has a lower microsomal clearance than Ligand B (-22.728). This suggests better metabolic stability for A, which is a positive.
13. **t1/2:** Ligand B (31.773) has a significantly longer in vitro half-life than Ligand A (-19.83). This is a substantial advantage for B.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.025 and 0.007). No significant difference.
15. **Binding Affinity:** Ligand A (-6.5 kcal/mol) has a slightly better binding affinity than Ligand B (-6.2 kcal/mol), but the difference is small.
**GPCR-Specific Priorities & Overall Assessment:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A has a better logP and QED, and slightly better affinity. Ligand B has a significantly better DILI score and a much longer half-life. The Caco-2 values are concerning for both, suggesting permeability issues that would need to be addressed through further optimization.
The longer half-life of Ligand B is a substantial benefit, potentially allowing for less frequent dosing. The lower DILI risk is also a major advantage, as liver toxicity is a common reason for drug failure. While Ligand A has slightly better affinity and QED, the benefits of B's improved safety and PK profile outweigh those advantages.
Output:
0
2025-04-17 22:43:55,426 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [344.455, 78.43, 2.011, 3, 3, 0.449, 23.691, 31.214, -4.692, -2.411, 0.654, -2.336, 15.486, 0.215, -5.6]
**Ligand B:** [356.463, 99.1, 0.456, 3, 5, 0.601, 19.271, 49.128, -4.775, -1.474, 0.303, 7.205, -14.712, 0.023, -6.8]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). A (344.455) is slightly preferred.
2. **TPSA:** A (78.43) is excellent, well below the 140 threshold and good for oral absorption. B (99.1) is still acceptable, but less optimal.
3. **logP:** A (2.011) is optimal. B (0.456) is a bit low, potentially hindering membrane permeability.
4. **HBD:** Both have 3, which is acceptable.
5. **HBA:** A (3) is good. B (5) is higher, potentially impacting permeability.
6. **QED:** Both are reasonable (A: 0.449, B: 0.601), but B is better.
7. **DILI:** A (23.691) is significantly better than B (19.271), indicating a lower risk of liver injury.
8. **BBB:** B (49.128) is better than A (31.214), which is a positive for a GPCR, although not a CNS target.
9. **Caco-2:** Both are negative, indicating poor permeability. A (-4.692) is worse than B (-4.775).
10. **Solubility:** Both are negative, indicating poor solubility. A (-2.411) is worse than B (-1.474).
11. **hERG:** Both are low risk (A: 0.654, B: 0.303), with B being slightly better.
12. **Cl_mic:** A (-2.336) is much better than B (7.205), indicating better metabolic stability.
13. **t1/2:** A (15.486) is better than B (-14.712) indicating a longer half-life.
14. **Pgp:** A (0.215) is better than B (0.023), indicating lower P-gp efflux.
15. **Affinity:** B (-6.8) is slightly better than A (-5.6), a difference of 1.2 kcal/mol.
**GPCR-Specific Considerations:**
For ADRB2 (a cardiovascular GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has a better logP and Pgp profile. Ligand B has a slightly better affinity and BBB penetration. However, the difference in affinity (1.2 kcal/mol) is not substantial enough to outweigh the significant advantages of Ligand A in terms of metabolic stability (Cl_mic), half-life, DILI risk, and TPSA. The poor Caco-2 and solubility of both are concerning, but can be addressed with formulation strategies.
**Conclusion:**
Considering the balance of properties and the GPCR-specific priorities, **Ligand A** is the more promising drug candidate.
**Output:**
1
2025-04-17 22:43:55,426 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
We are targeting ADRB2, a GPCR. Therefore, the key properties to prioritize are binding affinity, logP, TPSA, Pgp efflux, and BBB penetration.
Let's compare the ligands property by property:
1. **MW:** Both ligands are within the acceptable range (200-500 Da). Ligand A (349.475) is slightly preferred due to being lower.
2. **TPSA:** Ligand A (69.72) is significantly better than Ligand B (83.98). Lower TPSA generally improves oral absorption, crucial for GPCR drugs.
3. **logP:** Ligand A (1.259) is optimal, while Ligand B (3.957) is approaching the upper limit. While not terrible, higher logP can lead to off-target effects and solubility issues.
4. **HBD/HBA:** Both have acceptable numbers of HBD (1) and HBA (Ligand A: 3, Ligand B: 6).
5. **QED:** Both have good QED scores (A: 0.556, B: 0.665), indicating drug-likeness. Ligand B is slightly better.
6. **DILI:** Ligand A (34.781) has a much lower DILI risk than Ligand B (58.627). This is a significant advantage.
7. **BBB:** Ligand A (67.623) shows better BBB penetration than Ligand B (48.119). While ADRB2 isn't exclusively a CNS target, some CNS exposure is possible, and better BBB is generally favorable.
8. **Caco-2:** Ligand A (-4.298) is better than Ligand B (-5.633).
9. **Solubility:** Ligand A (-2.2) is better than Ligand B (-3.5).
10. **hERG:** Both have low hERG inhibition risk (A: 0.494, B: 0.677).
11. **Cl_mic:** Ligand A (61.745) has lower microsomal clearance, suggesting better metabolic stability, than Ligand B (77.048).
12. **t1/2:** Ligand A (-35.287) has a much longer in vitro half-life than Ligand B (7.227). This is a major advantage.
13. **Pgp:** Ligand A (0.091) has lower P-gp efflux liability than Ligand B (0.335), which is desirable for better bioavailability.
14. **Binding Affinity:** Ligand B (-7.2) has a significantly stronger binding affinity than Ligand A (-5.2). This is a 1.5 kcal/mol difference, which is substantial.
**Overall Assessment:**
While Ligand B has a superior binding affinity, Ligand A demonstrates a much better overall ADME-Tox profile. It has lower DILI risk, better BBB penetration, better solubility, lower clearance, longer half-life, and lower P-gp efflux. The improved ADME properties of Ligand A are likely to translate to better *in vivo* efficacy and safety, outweighing the affinity difference. The affinity of -5.2 kcal/mol for Ligand A is still considered good.
**Output:**
1
2025-04-17 22:43:55,426 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.494 and 353.423 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (49.41) is significantly lower than Ligand B (125.42). This is a major advantage for Ligand A, as lower TPSA generally correlates with better oral absorption, crucial for a cardiovascular drug. Ligand B is above the preferred threshold of 140.
3. **logP:** Ligand A (3.592) is optimal, while Ligand B (1.284) is on the lower side. A logP between 1-3 is ideal, and Ligand A is closer to this range. Lower logP can hinder membrane permeability.
4. **HBD:** Both have acceptable HBD counts (1 and 2, respectively), well below the threshold of 5.
5. **HBA:** Ligand A (2) is preferable to Ligand B (5). Lower HBA is generally better for permeability.
6. **QED:** Ligand A (0.769) has a much better QED score than Ligand B (0.28), indicating a more drug-like profile.
7. **DILI:** Both have relatively low DILI risk (21.404 and 25.514 percentile), which is good. No major difference.
8. **BBB:** Ligand A (91.314) shows significantly better BBB penetration potential than Ligand B (48.003). While ADRB2 isn't strictly a CNS target, some CNS exposure can occur, and higher BBB penetration can be beneficial in some cases.
9. **Caco-2:** Ligand A (-4.79) is better than Ligand B (-5.444), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-3.36) is better than Ligand B (-0.566). Solubility is important for bioavailability.
11. **hERG:** Both ligands have low hERG inhibition liability (0.726 and 0.234), which is excellent.
12. **Cl_mic:** Ligand A (34.238) has a higher (worse) microsomal clearance than Ligand B (-6.201). This suggests Ligand B is more metabolically stable.
13. **t1/2:** Ligand A (-12.588) has a negative in vitro half-life, which is concerning. Ligand B (13.063) has a positive half-life, indicating better stability.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.486 and 0.012).
15. **Binding Affinity:** Ligand B (-6.9 kcal/mol) has a slightly better binding affinity than Ligand A (-6.0 kcal/mol). This is a 0.9 kcal/mol difference, which is significant, but not overwhelming given the other factors.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand A is the stronger candidate. While Ligand B has slightly better affinity and metabolic stability, Ligand A excels in TPSA, logP, QED, solubility, and BBB penetration. The significantly lower TPSA and better QED of Ligand A are particularly important for oral bioavailability, which is crucial for a cardiovascular drug. The negative half-life of Ligand A is a concern but might be addressable through structural modifications. The affinity difference is not large enough to outweigh the other advantages of Ligand A.
Output:
1
2025-04-17 22:43:55,426 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (411.231 Da) is within the ideal range, while Ligand B (358.41 Da) is also acceptable, though slightly on the lower end. No strong preference here.
2. **TPSA:** Ligand A (85.25) is good, well below the 140 threshold. Ligand B (118.89) is higher, but still potentially acceptable for a peripherally acting GPCR.
3. **logP:** Ligand A (1.725) is optimal. Ligand B (-0.904) is slightly low, potentially impacting permeability. This is a minor concern, but worth noting.
4. **HBD:** Ligand A (2) is good. Ligand B (5) is higher, potentially impacting permeability and increasing the risk of off-target interactions.
5. **HBA:** Both Ligand A (5) and Ligand B (5) are acceptable.
6. **QED:** Ligand A (0.734) is excellent, indicating good drug-like properties. Ligand B (0.421) is lower, suggesting a less optimal overall profile.
7. **DILI:** Ligand A (89.259) has a higher DILI risk, which is concerning. Ligand B (19.542) has a very low DILI risk, a significant advantage.
8. **BBB:** Ligand A (70.803) has reasonable BBB penetration. Ligand B (30.477) has low BBB penetration, which is not a major concern for a cardiovascular target like ADRB2.
9. **Caco-2:** Ligand A (-4.855) and Ligand B (-5.664) both have negative values, which is unusual and suggests very poor permeability. However, the scale is not specified, so it's difficult to interpret these values precisely.
10. **Solubility:** Ligand A (-4.116) and Ligand B (-1.271) both have negative values, suggesting poor aqueous solubility. Again, the scale is unspecified.
11. **hERG:** Ligand A (0.61) has a slightly higher hERG risk than Ligand B (0.225), but both are relatively low.
12. **Cl_mic:** Ligand A (52.818) has moderate clearance. Ligand B (-23.074) has negative clearance, which is not physically possible and suggests an issue with the data or a very stable compound.
13. **t1/2:** Ligand A (10.143) has a reasonable half-life. Ligand B (15.302) has a longer half-life, which is generally desirable.
14. **Pgp:** Ligand A (0.47) has moderate P-gp efflux. Ligand B (0.009) has very low P-gp efflux, which is a significant advantage for bioavailability.
15. **Binding Affinity:** Ligand A (-6.9 kcal/mol) has a significantly better binding affinity than Ligand B (-2 kcal/mol). This is a substantial difference and a major factor in the decision.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand A has a better logP and a much better affinity. Ligand B has better Pgp and lower DILI.
**Overall Assessment:**
The significantly stronger binding affinity of Ligand A (-6.9 kcal/mol vs -2 kcal/mol) is a decisive advantage. While Ligand B has a better safety profile (lower DILI) and Pgp efflux, the potency difference is substantial enough to outweigh these concerns, especially considering the potential for optimizing the molecule further to address the DILI risk. The negative clearance value for Ligand B is also a red flag, indicating potential data quality issues.
Output:
1
2025-04-17 22:43:55,426 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (367.5 & 360.4 Da) fall comfortably within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Both ligands are below the 140 A^2 threshold for good oral absorption (91.3 & 94.2 A^2). Ligand A is slightly better, closer to the 90 A^2 threshold for CNS penetration, but ADRB2 isn't necessarily a CNS target.
3. **logP:** Ligand A (1.74) is within the optimal 1-3 range. Ligand B (-0.34) is slightly below 1, which *could* indicate permeability issues. This is a point in favor of Ligand A.
4. **HBD:** Both ligands have acceptable HBD counts (3 & 1). Ligand B is better here.
5. **HBA:** Both ligands have acceptable HBA counts (5 & 6). Ligand B is slightly better here.
6. **QED:** Both ligands have reasonable QED values (0.65 & 0.53), indicating good drug-like properties. Ligand A is slightly better.
7. **DILI:** Both ligands have low DILI risk (33.8% & 38.2%), well below the 60% threshold. No significant difference.
8. **BBB:** Ligand B (85.7%) has a significantly higher BBB penetration score than Ligand A (31.0%). While ADRB2 isn't strictly a CNS target, higher BBB penetration can sometimes correlate with better overall distribution and reduced off-target effects.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Both ligands have very poor aqueous solubility (-1.94 & -1.58). This is a major drawback for both, potentially hindering bioavailability.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.08% & 0.28%). This is excellent and minimizes cardiotoxicity risk.
12. **Cl_mic:** Ligand B (5.03) has a significantly lower microsomal clearance than Ligand A (17.90). This suggests better metabolic stability for Ligand B, a crucial factor for drug duration.
13. **t1/2:** Ligand B (-6.89 hours) has a negative in vitro half-life, which is concerning. Ligand A (9.96 hours) is more reasonable.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.03% & 0.02%). This is favorable for bioavailability.
15. **Binding Affinity:** Ligand B (-7.6 kcal/mol) has a substantially stronger binding affinity than Ligand A (-5.7 kcal/mol). This is a difference of 1.9 kcal/mol, which is a significant advantage and can often outweigh other ADME concerns.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand B excels in affinity and Pgp efflux. Ligand A has a slightly better logP and TPSA. However, the substantial affinity advantage of Ligand B is the most important factor. The poor Caco-2 and solubility are concerning for both, but can potentially be addressed through formulation strategies.
**Conclusion:**
Despite the solubility and permeability concerns shared by both, Ligand B's significantly stronger binding affinity and improved metabolic stability (lower Cl_mic) make it the more promising candidate. The higher BBB score is a bonus.
Output:
0
2025-04-17 22:43:55,427 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [365.499, 91.32, 1.739, 3, 5, 0.654, 42.613, 50.679, -5.015, -2.313, 0.152, 28.035, -12.486, 0.108, -6.5]
**Ligand B:** [370.877, 71.89, 2.274, 1, 5, 0.86, 46.452, 60.411, -4.604, -2.521, 0.327, 21.509, 36.372, 0.272, -6.2]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity) and general drug-like properties:
1. **MW:** Both are within the ideal 200-500 Da range. A (365.5) is slightly better.
2. **TPSA:** A (91.32) is higher than B (71.89). B is preferable here, being closer to the <90 threshold for better permeability.
3. **logP:** Both are good (1.739 and 2.274, within 1-3). B is slightly better, leaning towards the optimal range.
4. **HBD:** A (3) is higher than B (1). B is preferable.
5. **HBA:** Both have 5 HBA, which is acceptable.
6. **QED:** B (0.86) is significantly better than A (0.654), indicating a more drug-like profile.
7. **DILI:** Both are acceptable (A: 42.613, B: 46.452), below the 60% risk threshold.
8. **BBB:** B (60.411) is better than A (50.679), though neither are exceptionally high. For a cardiovascular target, BBB isn't *critical*, but a higher value is still a plus.
9. **Caco-2:** A (-5.015) is worse than B (-4.604). Lower (more negative) values indicate lower permeability. B is preferable.
10. **Solubility:** A (-2.313) is slightly better than B (-2.521), but both are poor.
11. **hERG:** A (0.152) is better than B (0.327), indicating lower hERG inhibition risk.
12. **Cl_mic:** B (21.509) has lower microsomal clearance than A (28.035), suggesting better metabolic stability.
13. **t1/2:** B (36.372) has a significantly longer half-life than A (-12.486). This is a major advantage.
14. **Pgp:** A (0.108) is better than B (0.272), indicating lower P-gp efflux.
15. **Affinity:** A (-6.5) is slightly better than B (-6.2), but the difference is small (0.3 kcal/mol).
**Overall Assessment:**
While Ligand A has a slightly better binding affinity and Pgp profile, Ligand B demonstrates a superior overall profile, particularly regarding drug-likeness (QED), metabolic stability (Cl_mic, t1/2), Caco-2 permeability, and a better logP. The longer half-life of B is a significant advantage. The slightly higher BBB penetration is also a plus. The small difference in binding affinity is outweighed by the improvements in ADME properties.
Therefore, I would choose Ligand B.
0
2025-04-17 22:43:55,427 - INFO - Here's my reasoning and the final output for the ligand preference:
**Reasoning:**
We are targeting ADRB2, a GPCR, so the priorities are logP, Pgp, TPSA, affinity, and BBB. Let's compare Ligand A and Ligand B across all parameters:
1. **MW:** Both ligands (339.37 and 345.334 Da) are within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (48.31) is significantly better than Ligand B (95.93). A TPSA under 140 is good for oral absorption, and lower is better for GPCRs. Ligand B is pushing the upper limit.
3. **logP:** Ligand A (3.669) is optimal, while Ligand B (1.974) is on the lower side. While not terrible, lower logP can sometimes indicate permeability issues.
4. **HBD/HBA:** Ligand A has 1 HBD and 5 HBA, while Ligand B has 0 HBD and 8 HBA. Both are acceptable, but Ligand A's single donor might be slightly preferable.
5. **QED:** Ligand A (0.77) is better than Ligand B (0.576), indicating a more drug-like profile.
6. **DILI:** Both have similar DILI risk (76.541 vs 78.402), and are moderately high, but not alarming.
7. **BBB:** Ligand A (83.211) has a better BBB percentile than Ligand B (76.309), which is important for a GPCR.
8. **Caco-2:** Both have negative Caco-2 values which is unusual and suggests poor permeability.
9. **Solubility:** Ligand A (-4.448) is better than Ligand B (-2.412), indicating better aqueous solubility.
10. **hERG:** Ligand A (0.787) is better than Ligand B (0.244), indicating lower hERG inhibition liability.
11. **Cl_mic:** Ligand A (58.205) has lower microsomal clearance than Ligand B (71.419), suggesting better metabolic stability.
12. **t1/2:** Ligand B (-18.932) has a significantly *longer* half-life than Ligand A (3.082). This is a strong point for Ligand B.
13. **Pgp:** Ligand A (0.445) has lower P-gp efflux than Ligand B (0.123), which is favorable for bioavailability.
14. **Affinity:** Ligand B (-7.3 kcal/mol) has a slightly better binding affinity than Ligand A (-6.4 kcal/mol). The difference is 0.9 kcal/mol, which is significant but not overwhelming.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most crucial ADME properties (TPSA, logP, solubility, hERG, Cl_mic, Pgp, BBB, QED) and has a good binding affinity. While Ligand B has a longer half-life, the other advantages of Ligand A, particularly its better TPSA, logP, and lower predicted toxicity/efflux, make it the more promising candidate for development as a drug targeting ADRB2. The slightly better affinity of Ligand B is not enough to overcome the ADME liabilities.
**Output:**
1
2025-04-17 22:43:55,427 - INFO - Batch 353 complete. Total preferences: 5648
2025-04-17 22:43:55,427 - INFO - Processing batch 354/512...
2025-04-17 22:44:46,774 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (355.389 and 349.475 Da) are within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (99.77) is higher than Ligand B (67.6). While both are under 140, the lower TPSA of Ligand B is preferable for oral absorption, a key consideration for a cardiovascular target.
3. **logP:** Ligand A (1.185) is slightly lower than Ligand B (2.9). Both are within the optimal 1-3 range, but Ligand B is closer to the upper end, potentially offering better membrane permeability.
4. **HBD:** Ligand A (3) is higher than Ligand B (1). Lower HBD is generally preferred for permeability, giving a slight edge to Ligand B.
5. **HBA:** Ligand A (4) is lower than Ligand B (5). Similar to HBD, Ligand A is slightly favored here.
6. **QED:** Ligand B (0.781) has a better QED score than Ligand A (0.579), indicating a more drug-like profile.
7. **DILI:** Ligand A (47.189) has a significantly higher DILI risk than Ligand B (8.841). This is a major concern, as liver toxicity is a common reason for drug failure. Ligand B is clearly superior here.
8. **BBB:** Ligand B (91.508) has a much higher BBB penetration percentile than Ligand A (74.874). While ADRB2 is primarily a cardiovascular target, some CNS effects can be relevant, and higher BBB penetration isn't necessarily detrimental.
9. **Caco-2:** Ligand A (-5.572) has a worse Caco-2 permeability score than Ligand B (-4.698). Higher values indicate better absorption, so Ligand B is slightly better.
10. **Solubility:** Ligand A (-2.584) has a worse solubility score than Ligand B (-3.033). Lower values indicate lower solubility, so Ligand B is slightly better.
11. **hERG:** Ligand A (0.278) has a lower hERG inhibition liability than Ligand B (0.583). This is a positive for Ligand A, reducing the risk of cardiotoxicity.
12. **Cl_mic:** Ligand A (-0.731) has a lower (better) microsomal clearance than Ligand B (51.625). This indicates greater metabolic stability for Ligand A.
13. **t1/2:** Ligand A (-9.054) has a significantly longer in vitro half-life than Ligand B (4.767). This is a significant advantage for Ligand A, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.023) has a much lower P-gp efflux liability than Ligand B (0.111). Lower efflux is generally desirable for improved bioavailability.
15. **Affinity:** Ligand A (-6.9 kcal/mol) has a slightly better binding affinity than Ligand B (-5.1 kcal/mol). This difference of 1.8 kcal/mol is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand A has a better binding affinity, longer half-life, lower P-gp efflux, and lower microsomal clearance. However, it has a significantly higher DILI risk. Ligand B has a better overall ADME profile (lower DILI, better solubility, Caco-2, BBB, QED) but weaker binding affinity.
Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity), and the importance of minimizing toxicity for a cardiovascular drug, the lower DILI risk of Ligand B is a critical advantage. While the affinity difference is notable, it's not so large that it completely overrides the safety concerns associated with Ligand A. The better ADME properties of Ligand B, particularly the significantly lower DILI risk, make it the more promising candidate.
Output:
0
2025-04-17 22:44:46,774 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (375.416 Da) is slightly higher than Ligand B (352.475 Da), but both are acceptable.
2. **TPSA:** Ligand A (62.3) is significantly better than Ligand B (87.66). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is approaching a level that might hinder oral absorption.
3. **logP:** Both ligands have good logP values (A: 2.27, B: 1.365), falling within the optimal 1-3 range. Ligand A is slightly more lipophilic, which could be advantageous for membrane permeability, but isn't a major concern for either.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Fewer hydrogen bond donors generally improve permeability.
5. **HBA:** Both ligands have the same number of HBA (4), which is within the acceptable limit of 10.
6. **QED:** Ligand A (0.757) has a better QED score than Ligand B (0.585), indicating a more drug-like profile.
7. **DILI:** Ligand A (56.572) has a higher DILI risk than Ligand B (6.747). This is a significant drawback for Ligand A.
8. **BBB:** Ligand A (76.735) has a better BBB penetration score than Ligand B (55.176). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant for off-target effects or potential therapeutic benefits.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.004 and -5.134). This is unusual and suggests poor permeability in this *in vitro* assay. However, the values are similar, so this isn't a deciding factor.
10. **Solubility:** Both ligands have negative solubility values (-2.893 and -1.897). This indicates poor aqueous solubility for both compounds, which could pose formulation challenges. Again, the values are similar.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.272 and 0.273), which is excellent.
12. **Cl_mic:** Ligand A (5.826) has significantly lower microsomal clearance than Ligand B (24.347), indicating better metabolic stability. This is a major advantage for Ligand A.
13. **t1/2:** Ligand B (18.359) has a much longer *in vitro* half-life than Ligand A (-1.83). This is a significant advantage for Ligand B.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.047 and 0.016), which is good.
15. **Binding Affinity:** Ligand B (-7.0) has a slightly better binding affinity than Ligand A (-6.8), but the difference is small.
**Overall Assessment:**
Ligand A has a better QED, TPSA, Cl_mic, and BBB penetration. However, it has a significantly higher DILI risk and a much shorter half-life. Ligand B has a much lower DILI risk and a longer half-life, but its TPSA is higher, and QED is lower.
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), and the overall balance of properties, the lower DILI risk and longer half-life of Ligand B are more compelling, despite its slightly higher TPSA. The small difference in binding affinity is unlikely to outweigh the ADME advantages of Ligand B. The solubility and Caco-2 issues are concerning for both, but can potentially be addressed through formulation strategies.
Output:
0
2025-04-17 22:44:46,774 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (a cardiovascular GPCR) drug candidates.
**Ligand A:** [366.502, 40.62, 2.185, 0, 3, 0.769, 36.603, 90.617, -4.86, -3.602, 0.699, 45.449, -14.848, 0.374, -8]
**Ligand B:** [347.503, 52.65, 2.912, 1, 3, 0.787, 22.838, 82.978, -4.313, -2.869, 0.688, 77.996, 37.231, 0.064, -5.7]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal 200-500 Da range. Ligand B (347.5) is slightly lower, which could be beneficial for permeability, but both are acceptable.
2. **TPSA:** Ligand A (40.62) is better than Ligand B (52.65). Both are under 140, but A is closer to the preferred <90 for GPCRs.
3. **logP:** Both are in the optimal 1-3 range. Ligand B (2.912) is slightly higher, which could potentially lead to off-target effects, but it's not a major concern.
4. **HBD:** Ligand A (0) is preferable to Ligand B (1). Fewer HBDs generally improve permeability.
5. **HBA:** Both have 3 HBA, which is acceptable.
6. **QED:** Both are good (0.769 and 0.787), indicating drug-like properties.
7. **DILI:** Ligand A (36.603) has a higher DILI risk than Ligand B (22.838). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (90.617) has a higher BBB penetration score than Ligand B (82.978). While ADRB2 isn't a CNS target, some peripheral exposure can be reduced by higher BBB penetration.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. Ligand A (-4.86) is worse than Ligand B (-4.313).
10. **Solubility:** Both have negative solubility values, indicating poor solubility. Ligand B (-2.869) is slightly better than Ligand A (-3.602).
11. **hERG:** Both are low, indicating low hERG inhibition risk, which is good.
12. **Cl_mic:** Ligand A (45.449) has lower microsomal clearance than Ligand B (77.996), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (-14.848) has a longer in vitro half-life than Ligand B (37.231), indicating better duration of action. This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.374) has lower P-gp efflux than Ligand B (0.064), meaning better absorption and bioavailability. This is a significant advantage for Ligand A.
15. **Affinity:** Ligand A (-8) has a significantly better binding affinity than Ligand B (-5.7). This is a >1.5 kcal/mol advantage, which is a major driver.
**GPCR-Specific Priorities:**
For a cardiovascular GPCR like ADRB2, we prioritize logP, TPSA, Pgp, and affinity. Ligand A excels in affinity and Pgp, and has a better TPSA. Ligand B has a slight edge in logP and a significantly lower DILI risk.
**Overall Assessment:**
While Ligand B has a lower DILI risk, the substantial advantage in binding affinity (-8 vs -5.7 kcal/mol) for Ligand A, coupled with its better metabolic stability (lower Cl_mic), longer half-life, and lower P-gp efflux, outweighs the slightly higher DILI risk. The improved affinity is likely to translate to greater efficacy at lower doses, potentially mitigating the DILI concern. The Caco-2 and solubility are poor for both, but can be addressed with formulation strategies.
Therefore, I would choose Ligand A.
Output:
1
2025-04-17 22:44:46,774 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (352.45 Da) is slightly lower than Ligand B (366.527 Da), which is preferable.
2. **TPSA:** Both ligands are below the 140 A^2 threshold for good oral absorption. Ligand A (67.43 A^2) is slightly higher than Ligand B (62.66 A^2), making B slightly better.
3. **logP:** Both ligands have logP values within the optimal range (1-3). Ligand A (1.812) is preferable as it's closer to the middle of the range, while Ligand B (3.297) is at the higher end, potentially leading to solubility issues.
4. **HBD:** Both ligands are within the acceptable limit of 5. Ligand A (2) is slightly better than Ligand B (1).
5. **HBA:** Both ligands are within the acceptable limit of 10. Ligand A (3) is better than Ligand B (5).
6. **QED:** Both ligands have good QED scores (>0.5), indicating drug-likeness. Ligand A (0.687) is slightly lower than Ligand B (0.767).
7. **DILI:** Ligand A (24.467%) has a significantly lower DILI risk than Ligand B (38.852%). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (81.078%) has a much higher BBB penetration percentile than Ligand B (56.378%). As ADRB2 is a GPCR, BBB penetration is a desirable trait, especially if CNS effects are anticipated or need to be understood.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. Ligand A (-4.666) is slightly better than Ligand B (-4.774).
10. **Solubility:** Both ligands have negative solubility values, indicating poor solubility. Ligand A (-2.776) is slightly better than Ligand B (-3.242).
11. **hERG:** Both ligands have low hERG inhibition liability. Ligand A (0.377) is slightly better than Ligand B (0.56).
12. **Cl_mic:** Ligand A (7.074 mL/min/kg) has a significantly lower microsomal clearance than Ligand B (63.063 mL/min/kg), indicating better metabolic stability.
13. **t1/2:** Ligand A (-3.298 hours) has a negative half-life, indicating poor in vitro stability. Ligand B (45.977 hours) has a much better half-life.
14. **Pgp:** Ligand A (0.036) has a much lower P-gp efflux liability than Ligand B (0.478), which is beneficial for bioavailability.
15. **Binding Affinity:** Ligand A (-7.2 kcal/mol) has a slightly better binding affinity than Ligand B (-6.0 kcal/mol). This difference is significant.
**Overall Assessment:**
Ligand A demonstrates a superior profile overall, especially considering the GPCR-specific priorities. While Ligand B has a better in vitro half-life and QED, Ligand A excels in crucial areas like DILI risk, BBB penetration, metabolic stability (Cl_mic), P-gp efflux, and binding affinity. The lower logP and HBD/HBA counts of Ligand A are also favorable. The slightly better affinity of Ligand A outweighs the half-life advantage of Ligand B.
Output:
1
2025-04-17 22:44:46,774 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (351.491 and 346.475 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (102.22) is higher than Ligand B (78.09). For a cardiovascular GPCR, TPSA is moderately important. Ligand B is preferable.
3. **logP:** Both ligands have good logP values (2.269 and 2.798), falling within the 1-3 optimal range. Ligand B is slightly better.
4. **HBD:** Ligand A has 3 HBD, and Ligand B has 2. Both are acceptable (<=5).
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 3. Both are acceptable (<=10).
6. **QED:** Ligand B (0.745) has a better QED score than Ligand A (0.562), indicating a more drug-like profile.
7. **DILI:** Ligand A (10.237%) has a significantly lower DILI risk than Ligand B (31.563%). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (57.154%) and Ligand B (67.662%) are both relatively low, which is acceptable for a cardiovascular target (not CNS).
9. **Caco-2:** Ligand A (-4.812) is worse than Ligand B (-5.228). Lower values indicate lower permeability. Ligand B is preferable.
10. **Solubility:** Ligand A (-1.842) is better than Ligand B (-3.06). Higher values indicate better solubility.
11. **hERG:** Ligand A (0.4) has a lower hERG risk than Ligand B (0.808). This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand A (8.98) has a much lower microsomal clearance than Ligand B (44.501). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (-7.076) has a much longer in vitro half-life than Ligand B (-30.285). This is a strong advantage for Ligand A.
14. **Pgp:** Ligand A (0.027) has a much lower P-gp efflux liability than Ligand B (0.36). This is a significant advantage for Ligand A.
15. **Binding Affinity:** Ligand B (-7.5 kcal/mol) has a slightly better binding affinity than Ligand A (-6.9 kcal/mol). This is a 1.5 kcal/mol advantage, which is significant.
**Overall Assessment:**
While Ligand B has a slightly better binding affinity and Caco-2 permeability, Ligand A demonstrates a far superior ADME-Tox profile. Specifically, its significantly lower DILI risk, hERG inhibition, microsomal clearance, P-gp efflux, and longer half-life are crucial advantages. The slightly weaker binding affinity of Ligand A can potentially be optimized in later stages of drug development. For a cardiovascular target, metabolic stability and safety (DILI, hERG) are paramount.
Output:
1
2025-04-17 22:44:46,774 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
Let's analyze each ligand against the provided guidelines, keeping in mind that ADRB2 is a GPCR, so logP, TPSA, Pgp, and affinity are particularly important.
* **Molecular Weight:** Both ligands (356.463 and 341.371 Da) fall within the ideal 200-500 Da range.
* **TPSA:** Ligand A (95.94) is better than Ligand B (101.22), both are acceptable for oral absorption, being under 140.
* **logP:** Both ligands have similar logP values (1.09 and 1.152), falling within the optimal 1-3 range.
* **H-Bond Donors:** Ligand A (2) is slightly better than Ligand B (1), both are good.
* **H-Bond Acceptors:** Ligand B (6) is slightly worse than Ligand A (5), but both are acceptable.
* **QED:** Ligand B (0.875) is better than Ligand A (0.666), indicating a more drug-like profile.
* **DILI:** Ligand A (21.598) is significantly better than Ligand B (62.66), indicating a much lower risk of drug-induced liver injury. This is a major advantage for Ligand A.
* **BBB:** Ligand B (68.282) is better than Ligand A (40.171), but BBB is less critical for a cardiovascular target like ADRB2.
* **Caco-2 Permeability:** Both are negative, suggesting poor permeability. Ligand A (-4.699) is slightly better than Ligand B (-4.958).
* **Aqueous Solubility:** Both are negative, suggesting poor solubility. Ligand A (-2.304) is slightly better than Ligand B (-2.526).
* **hERG:** Both ligands have very low hERG inhibition risk (0.196 and 0.144).
* **Microsomal Clearance:** Ligand B (22.717) has significantly lower clearance than Ligand A (60.656), suggesting better metabolic stability.
* **In vitro Half-Life:** Ligand B (-4.263) has a better half-life than Ligand A (-19.393).
* **P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.044 and 0.023).
* **Binding Affinity:** Ligand B (-6.2 kcal/mol) has a slightly better binding affinity than Ligand A (-5.7 kcal/mol). This is a 0.5 kcal/mol difference, which is significant but not overwhelming.
**Overall Assessment:**
Ligand A has a significant advantage in DILI risk and slightly better Caco-2 permeability and solubility. Ligand B has a better QED, metabolic stability (lower Cl_mic, better t1/2), and binding affinity. However, the lower DILI risk of Ligand A is a crucial factor, especially in drug development. While the affinity difference is notable, the DILI risk is a more serious potential issue. Given the cardiovascular target, BBB penetration is not a primary concern.
**Output:**
1
2025-04-17 22:44:46,774 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (358.404 Da and 350.409 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (62.22) is higher than Ligand B (50.36). While both are below the 140 threshold for oral absorption, the lower TPSA of Ligand B is slightly preferable for a GPCR, potentially aiding membrane permeability.
**3. logP:** Ligand B (4.412) is higher than Ligand A (3.481). This is a concern for Ligand B, as it's approaching the upper limit where solubility issues can arise. Ligand A's logP is closer to the optimal 1-3 range.
**4. H-Bond Donors:** Both ligands have 2 HBD, which is within the acceptable limit of 5.
**5. H-Bond Acceptors:** Ligand A has 3 HBA, while Ligand B has 2. Both are below the 10 limit.
**6. QED:** Both ligands have very similar QED values (0.847 and 0.845), indicating good drug-likeness.
**7. DILI Risk:** Ligand A (22.024%) has a significantly lower DILI risk than Ligand B (43.738%). This is a major advantage for Ligand A.
**8. BBB Penetration:** Ligand B (92.168%) shows better BBB penetration than Ligand A (84.413%). While ADRB2 is primarily a cardiovascular target, some CNS off-target effects are possible with GPCRs, and higher BBB penetration could exacerbate these. However, this is less critical than other factors.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.556 and -4.637). This is unusual and suggests poor permeability. However, these values are on a log scale and the difference is minimal.
**10. Aqueous Solubility:** Ligand A (-3.645) has better aqueous solubility than Ligand B (-4.937). Given Ligand B's higher logP, this is expected and reinforces the concern about its solubility.
**11. hERG Inhibition:** Ligand A (0.521) has a slightly higher hERG inhibition risk than Ligand B (0.7). Lower is better, so Ligand B is slightly preferred here, but the difference is small.
**12. Microsomal Clearance:** Ligand B (33.787) has a significantly lower microsomal clearance than Ligand A (18.096). This suggests better metabolic stability for Ligand B.
**13. In vitro Half-Life:** Ligand B (43.058) has a much longer in vitro half-life than Ligand A (-0.376). This is a substantial advantage for Ligand B, potentially leading to less frequent dosing.
**14. P-gp Efflux:** Ligand A (0.307) has lower P-gp efflux than Ligand B (0.151). Lower P-gp efflux is generally desirable for better bioavailability.
**15. Binding Affinity:** Ligand B (-9.0) has a significantly stronger binding affinity than Ligand A (-6.7). This is a substantial advantage, potentially outweighing some of the ADME drawbacks. A difference of 2.3 kcal/mol is quite significant.
**Overall Assessment:**
While Ligand B has a better binding affinity and metabolic stability (lower Cl_mic, longer t1/2), its higher logP, DILI risk, and poorer solubility are concerning. Ligand A, while having a weaker binding affinity, presents a much more balanced profile with lower DILI risk, better solubility, and acceptable logP. The substantial difference in binding affinity is the deciding factor. For a GPCR, a strong binding affinity is paramount, and the 2.3 kcal/mol advantage of Ligand B is significant enough to outweigh the ADME concerns, especially given the potential for further optimization of those properties.
Output:
0
2025-04-17 22:44:46,775 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (345.407 Da and 365.478 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (96.37) is higher than Ligand B (71.96). For a cardiovascular GPCR, TPSA is moderately important, and lower is generally better for permeability. Ligand B has a clear advantage.
**3. logP:** Ligand A (1.358) is within the optimal 1-3 range. Ligand B (3.12) is at the higher end, potentially leading to solubility issues or off-target interactions. Ligand A is preferable.
**4. H-Bond Donors:** Ligand A (1) is better than Ligand B (2). Fewer HBDs generally improve permeability.
**5. H-Bond Acceptors:** Ligand A (9) is higher than Ligand B (7). Lower is preferable, giving a slight edge to Ligand B.
**6. QED:** Ligand A (0.778) is better than Ligand B (0.662), indicating a more drug-like profile.
**7. DILI Risk:** Ligand A (76.076) has a lower DILI risk than Ligand B (82.513). This is a significant advantage for Ligand A.
**8. BBB Penetration:** Ligand B (87.088) shows better BBB penetration than Ligand A (59.209). While ADRB2 is a cardiovascular target, some CNS effects are possible with beta-blockers, and some degree of BBB penetration could be acceptable or even desirable for certain therapeutic strategies.
**9. Caco-2 Permeability:** Ligand A (-4.523) has better Caco-2 permeability than Ligand B (-5.355). This suggests better intestinal absorption for Ligand A.
**10. Aqueous Solubility:** Both ligands have very poor aqueous solubility (-3.517 and -3.814 respectively). This is a concern for both, but not a deciding factor.
**11. hERG Inhibition:** Ligand A (0.269) has a significantly lower hERG inhibition risk than Ligand B (0.892). This is a critical safety parameter, and Ligand A is much preferred.
**12. Microsomal Clearance:** Ligand B (70.331) has lower microsomal clearance than Ligand A (107.56), suggesting better metabolic stability.
**13. In vitro Half-Life:** Ligand B (51.711) has a longer in vitro half-life than Ligand A (7.275). This is a significant advantage for Ligand B.
**14. P-gp Efflux:** Ligand A (0.008) has much lower P-gp efflux than Ligand B (0.421), indicating better bioavailability and potentially better CNS exposure.
**15. Binding Affinity:** Ligand A (-7.4) has a slightly stronger binding affinity than Ligand B (-6.3). While both are good, the difference is substantial enough to be a key factor.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity) and the general drug-like properties, Ligand A emerges as the more promising candidate. Its superior binding affinity, lower DILI risk, lower hERG inhibition, better Caco-2 permeability, and lower P-gp efflux outweigh the slightly better BBB penetration and metabolic stability of Ligand B. The solubility is a concern for both, but can be addressed through formulation strategies.
Output:
1
2025-04-17 22:44:46,775 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**1. Molecular Weight:** Both ligands (355.364 Da and 357.491 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (62.53) is significantly better than Ligand B (79.23). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand A is well below the 90 A^2 threshold.
**3. logP:** Both ligands have good logP values (2.271 and 1.721), falling within the optimal 1-3 range. Ligand B is slightly lower, which *could* indicate slightly better solubility, but the difference isn't substantial.
**4. H-Bond Donors:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs generally improve membrane permeability.
**5. H-Bond Acceptors:** Both ligands have the same number of HBA (5), which is acceptable.
**6. QED:** Ligand A (0.918) has a much higher QED score than Ligand B (0.622), indicating a more drug-like profile overall. This is a significant advantage.
**7. DILI Risk:** Ligand A (49.05) has a considerably lower DILI risk than Ligand B (10.392). This is a crucial factor, as liver toxicity is a major concern in drug development.
**8. BBB Penetration:** Ligand A (97.208) shows excellent potential for BBB penetration, while Ligand B (75.378) is lower. While ADRB2 isn't exclusively a CNS target, some cardiovascular effects are mediated by central pathways, and better BBB penetration could be advantageous.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret. Ligand A (-4.707) is slightly worse than Ligand B (-4.146).
**10. Aqueous Solubility:** Both ligands have negative solubility values, which is also unusual. Ligand B (-1.205) is slightly better than Ligand A (-2.168).
**11. hERG Inhibition:** Ligand A (0.853) has a slightly higher hERG inhibition risk than Ligand B (0.572), but both are relatively low.
**12. Microsomal Clearance:** Ligand A (-1.563) has a much lower (better) microsomal clearance than Ligand B (33.189), indicating greater metabolic stability.
**13. In vitro Half-Life:** Ligand A (3.339) has a shorter half-life than Ligand B (28.349). This is a disadvantage for Ligand A.
**14. P-gp Efflux:** Ligand A (0.293) has a much lower P-gp efflux liability than Ligand B (0.21), suggesting better oral bioavailability and potentially better CNS exposure.
**15. Binding Affinity:** Ligand A (-7.1) has a slightly better binding affinity than Ligand B (-6.5). This difference (0.6 kcal/mol) is significant enough to potentially outweigh some of the ADME drawbacks.
**Overall Assessment:**
Considering all factors, especially the GPCR-specific priorities (logP, TPSA, Pgp) and the general drug-like properties, **Ligand A is the more promising candidate**. It has a superior QED score, significantly lower DILI risk, better BBB penetration, lower P-gp efflux, and slightly better binding affinity. While its half-life is shorter, the improved metabolic stability (lower Cl_mic) and overall better ADME profile make it the preferred choice. The negative Caco-2 and solubility values are concerning for both, but the other advantages of Ligand A outweigh this concern.
Output:
1
2025-04-17 22:44:46,775 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (365.5 & 346.5 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (69.72) is slightly higher than Ligand B (58.2). Both are below the 140 threshold for oral absorption, but closer to the 90 threshold for CNS targets. Ligand B is preferable here.
3. **logP:** Ligand A (1.063) is within the optimal range (1-3), while Ligand B (3.406) is at the higher end. Ligand A is preferable.
4. **HBD:** Ligand A (1) is better than Ligand B (2). Lower HBD is generally preferred for permeability.
5. **HBA:** Ligand A (4) is better than Ligand B (2). Lower HBA is generally preferred for permeability.
6. **QED:** Ligand A (0.809) is significantly better than Ligand B (0.662), indicating a more drug-like profile.
7. **DILI:** Ligand B (35.87) has a lower DILI risk than Ligand A (19.70), which is a significant advantage.
8. **BBB:** Ligand B (70.76) is better than Ligand A (65.84), although both are reasonably good. Given ADRB2's cardiovascular role, BBB isn't a primary concern, but it's a slight advantage for B.
9. **Caco-2:** Ligand A (-5.174) is better than Ligand B (-4.601), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-2.872) is better than Ligand B (-4.319). Better solubility is always desirable.
11. **hERG:** Ligand A (0.207) has a lower hERG risk than Ligand B (0.489), which is a significant advantage.
12. **Cl_mic:** Ligand A (25.92) has a lower microsomal clearance than Ligand B (56.14), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-11.143) has a longer half-life than Ligand A (-4.673). This is a significant advantage.
14. **Pgp:** Ligand A (0.02) has a lower Pgp efflux liability than Ligand B (0.269). Lower efflux is preferable.
15. **Affinity:** Ligand A (-6.2 kcal/mol) has a slightly better binding affinity than Ligand B (-4.9 kcal/mol). This is a significant advantage.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are important. Ligand A has a better logP, Pgp, and affinity. Ligand B has a better TPSA and BBB, but BBB is not a major concern for a cardiovascular target.
**Overall Assessment:**
Ligand A has a more favorable overall profile. It excels in drug-likeness (QED), solubility, metabolic stability (Cl_mic), hERG risk, Pgp efflux, and binding affinity. While Ligand B has a lower DILI risk and slightly better BBB penetration, the advantages of Ligand A in key ADME properties and potency outweigh these benefits. The affinity difference is also substantial.
Output:
1
2025-04-17 22:44:46,775 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (346.45 Da) is within the ideal range. Ligand B (213.189 Da) is at the lower end, potentially impacting potency.
2. **TPSA:** Ligand A (38.82) is good for oral absorption. Ligand B (124.01) is higher, potentially hindering absorption, though not drastically.
3. **logP:** Ligand A (1.324) is optimal. Ligand B (-0.457) is a bit low, potentially leading to poor membrane permeability.
4. **HBD:** Ligand A (1) is good. Ligand B (5) is at the upper limit, potentially affecting permeability.
5. **HBA:** Ligand A (4) is good. Ligand B (5) is acceptable.
6. **QED:** Ligand A (0.835) is excellent. Ligand B (0.433) is below the preferred threshold of 0.5, indicating a less drug-like profile.
7. **DILI:** Ligand A (35.052) is very good (low risk). Ligand B (17.449) is also good, but slightly higher.
8. **BBB:** Ligand A (70.26) is good, suggesting some brain penetration. Ligand B (12.059) is low, indicating minimal brain penetration. While ADRB2 isn't exclusively a CNS target, some degree of BBB penetration can be beneficial for peripheral effects.
9. **Caco-2:** Ligand A (-4.92) is very negative, indicating poor permeability. Ligand B (-6.567) is even worse. Both are problematic.
10. **Solubility:** Ligand A (-1.808) is poor. Ligand B (-0.969) is also poor. Both are concerning for formulation.
11. **hERG:** Ligand A (0.8) is good. Ligand B (0.013) is excellent, indicating very low cardiotoxicity risk.
12. **Cl_mic:** Ligand A (4.56) is reasonable. Ligand B (-33.893) is *extremely* rapid clearance, a major drawback.
13. **t1/2:** Ligand A (-7.233) is a long half-life, which is good. Ligand B (7.246) is also a reasonable half-life.
14. **Pgp:** Ligand A (0.072) is low efflux, which is good. Ligand B (0.005) is even lower, which is excellent.
15. **Affinity:** Ligand A (-7.1) is very good. Ligand B (-5.4) is good, but significantly weaker. The 1.7 kcal/mol difference is substantial.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are crucial. Ligand A has a better logP and significantly better affinity. While both have issues with Caco-2 and solubility, the superior binding affinity and better overall drug-likeness (QED, DILI, BBB) of Ligand A outweigh these concerns. Ligand B's extremely rapid clearance is a deal-breaker.
**Conclusion:**
Despite the permeability and solubility issues, Ligand A is the more promising candidate due to its superior binding affinity, better drug-like properties, and acceptable safety profile.
Output:
1
2025-04-17 22:44:46,775 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [352.391, 117.67 , -0.731, 2. , 7. , 0.697, 44.591, 25.204, -5.258, -1.026, 0.034, -7.095, -5.018, 0.008, -7.3 ]
**Ligand B:** [346.475, 67.23 , 2.391, 1. , 4. , 0.551, 24.506, 76.58 , -4.648, -2.156, 0.125, 44.741, 13.122, 0.073, -6.6 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (346.475) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (117.67) is higher than Ligand B (67.23). For a GPCR, lower TPSA is preferred, so Ligand B is better here.
3. **logP:** Ligand A (-0.731) is a bit low, potentially hindering membrane permeability. Ligand B (2.391) is within the optimal range (1-3). Ligand B is better.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable.
5. **HBA:** Ligand A (7) and Ligand B (4) are both acceptable.
6. **QED:** Ligand A (0.697) is slightly better than Ligand B (0.551), indicating a more drug-like profile.
7. **DILI:** Both are good, with Ligand A (44.591) being slightly higher than Ligand B (24.506), meaning Ligand B has a lower risk of liver injury.
8. **BBB:** Ligand B (76.58) is significantly better than Ligand A (25.204) in terms of predicted BBB penetration. This is a crucial factor for GPCRs, even if not specifically CNS-targeted, as it can influence off-target effects.
9. **Caco-2:** Ligand A (-5.258) is worse than Ligand B (-4.648), indicating lower intestinal absorption.
10. **Solubility:** Ligand A (-1.026) is worse than Ligand B (-2.156), indicating lower aqueous solubility.
11. **hERG:** Both are very low, indicating minimal hERG inhibition risk.
12. **Cl_mic:** Ligand A (-7.095) is better than Ligand B (44.741), indicating greater metabolic stability.
13. **t1/2:** Ligand B (13.122) has a significantly longer in vitro half-life than Ligand A (-5.018).
14. **Pgp:** Ligand A (0.008) is better than Ligand B (0.073), indicating lower P-gp efflux.
15. **Affinity:** Ligand A (-7.3) has a slightly better binding affinity than Ligand B (-6.6), but the difference is not substantial enough to overcome other significant drawbacks.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity and Pgp profile, Ligand B significantly outperforms it in several critical ADME properties for a GPCR target, particularly logP, TPSA, BBB penetration, and in vitro half-life. The lower DILI risk for Ligand B is also a positive factor. The solubility and Caco-2 values are also better for Ligand B. The improved metabolic stability of Ligand A is a plus, but the other factors are more important for this target class.
Therefore, I believe Ligand B is the more promising drug candidate.
Output:
0
2025-04-17 22:44:46,775 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's systematically compare Ligand A and Ligand B based on the provided parameters and the guidelines, keeping in mind ADRB2 is a GPCR.
1. **Molecular Weight:** Both ligands (349.381 and 366.483 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (64.6) is slightly higher than Ligand B (60.89). Both are below 140, which is good for oral absorption, but closer to the upper limit.
3. **logP:** Ligand A (3.091) is slightly higher than Ligand B (2.365), both within the optimal 1-3 range.
4. **H-Bond Donors:** Ligand A has 3 HBD, while Ligand B has 0. This is a slight advantage for Ligand B, as fewer HBDs generally correlate with better membrane permeability.
5. **H-Bond Acceptors:** Ligand A has 4 HBA, while Ligand B has 6. Ligand A is preferable here.
6. **QED:** Both ligands have similar QED values (0.75 and 0.707), indicating good drug-likeness.
7. **DILI:** Ligand B (36.487) has a significantly lower DILI risk than Ligand A (46.297). This is a substantial advantage for Ligand B.
8. **BBB:** Ligand B (75.107) has a much higher BBB penetration percentile than Ligand A (52.966). While ADRB2 isn't exclusively a CNS target, some cardiovascular effects are mediated by central pathways, and better BBB penetration can be beneficial.
9. **Caco-2 Permeability:** Ligand A (-5.128) has a more negative Caco-2 value, suggesting *lower* permeability than Ligand B (-4.775). This is a negative for Ligand A.
10. **Aqueous Solubility:** Ligand A (-3.052) has lower solubility than Ligand B (-1.809). This is a negative for Ligand A.
11. **hERG Inhibition:** Ligand A (0.773) has a slightly higher hERG inhibition liability than Ligand B (0.439), though both are relatively low.
12. **Microsomal Clearance:** Ligand B (43.41) has a lower microsomal clearance than Ligand A (46.613), indicating better metabolic stability.
13. **In vitro Half-Life:** Ligand A (-7.187) has a significantly better in vitro half-life than Ligand B (22.746). This is a strong advantage for Ligand A.
14. **P-gp Efflux:** Ligand A (0.159) has lower P-gp efflux liability than Ligand B (0.094), which is preferable.
15. **Binding Affinity:** Ligand A (-7.2) has a slightly better binding affinity than Ligand B (-6.6). This is a positive for Ligand A, but the difference is not huge.
**Overall Assessment:**
Ligand B demonstrates a superior ADME profile, with lower DILI risk, better BBB penetration, improved Caco-2 permeability, better solubility, and improved metabolic stability. While Ligand A has a slightly better binding affinity and in vitro half-life, the ADME advantages of Ligand B are more critical for overall drug development success, especially for a GPCR target where bioavailability and off-target effects are key concerns. The slightly better affinity of Ligand A is unlikely to overcome the significant ADME liabilities.
Output:
0
2025-04-17 22:44:46,775 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [367.467, 72.91, 2.269, 0, 5, 0.771, 49.399, 84.141, -4.439, -3.101, 0.346, 65.187, 13.078, 0.251, -6.3]
**Ligand B:** [362.463, 95.57, 2.218, 1, 10, 0.688, 70.803, 35.75, -5.169, -2.714, 0.234, 58.643, -12.334, 0.174, -6.1]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). A (367.467) is slightly higher than B (362.463), but the difference is negligible.
2. **TPSA:** A (72.91) is much better than B (95.57). For a GPCR, keeping TPSA low is beneficial for permeability. B is pushing the upper limit for good oral absorption.
3. **logP:** Both are excellent (around 2.2), falling within the optimal 1-3 range.
4. **HBD:** A (0) is preferable to B (1). Fewer HBDs generally improve permeability.
5. **HBA:** A (5) is better than B (10). Lower HBA is generally preferred for permeability.
6. **QED:** A (0.771) is better than B (0.688), indicating a more drug-like profile.
7. **DILI:** A (49.399) is significantly better than B (70.803). Lower DILI risk is crucial.
8. **BBB:** A (84.141) is *much* better than B (35.75). While ADRB2 isn't strictly a CNS target, some CNS penetration can be beneficial, and avoiding high CNS exposure is generally desirable. A's higher BBB percentile suggests better control over CNS exposure.
9. **Caco-2:** A (-4.439) is better than B (-5.169). Higher Caco-2 permeability is better.
10. **Solubility:** A (-3.101) is better than B (-2.714). Higher solubility is preferred.
11. **hERG:** Both are very low (0.346 and 0.234), indicating minimal hERG inhibition risk.
12. **Cl_mic:** B (58.643) is slightly better than A (65.187), indicating slightly better metabolic stability.
13. **t1/2:** A (13.078) is better than B (-12.334). A longer half-life is generally preferred.
14. **Pgp:** A (0.251) is better than B (0.174). Lower P-gp efflux is desirable.
15. **Affinity:** Both are excellent (-6.3 and -6.1 kcal/mol). The difference of 0.2 kcal/mol is not significant enough to outweigh other factors.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, TPSA, logP, Pgp, and affinity are key. Ligand A excels in TPSA, Pgp, and has a better QED and DILI profile. While both have good logP and affinity, the superior ADME properties of Ligand A make it the more promising candidate.
**Conclusion:**
Ligand A is the better candidate.
1
2025-04-17 22:44:46,775 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (344.46 and 351.41 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (69.3) is significantly better than Ligand B (106.42). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (2.339) is optimal, while Ligand B (0.268) is quite low. Low logP can hinder membrane permeability. This is a substantial advantage for Ligand A.
4. **HBD:** Both ligands have 1 HBD, which is acceptable.
5. **HBA:** Ligand A has 3 HBA, while Ligand B has 7. Ligand A is preferable here, as excessive HBA can sometimes reduce permeability.
6. **QED:** Ligand A (0.915) is excellent, indicating high drug-likeness. Ligand B (0.737) is still acceptable, but lower.
7. **DILI:** Ligand B (56.73) has a lower DILI risk than Ligand A (15.2), which is a positive for Ligand B. However, the difference isn't massive.
8. **BBB:** Both ligands have relatively low BBB penetration, but Ligand A (61.54) is slightly lower than Ligand B (64.87). Not a major factor for a cardiovascular target.
9. **Caco-2:** Ligand A (-5.196) and Ligand B (-4.945) are similar, indicating similar intestinal absorption potential.
10. **Solubility:** Ligand A (-1.374) and Ligand B (-1.761) are similar, indicating similar solubility potential.
11. **hERG:** Ligand A (0.387) has a much lower hERG risk than Ligand B (0.095). This is a significant advantage for Ligand A, as hERG inhibition can lead to cardiotoxicity.
12. **Cl_mic:** Ligand A (-4.403) has a much lower microsomal clearance than Ligand B (23.337), indicating better metabolic stability. This is a substantial advantage for Ligand A.
13. **t1/2:** Ligand A (-16.129) has a longer in vitro half-life than Ligand B (-6.287), indicating a slower rate of degradation. This is a substantial advantage for Ligand A.
14. **Pgp:** Ligand A (0.05) has a lower P-gp efflux liability than Ligand B (0.038), indicating better bioavailability.
15. **Affinity:** Both ligands have very similar binding affinities (-6.7 and -6.5 kcal/mol). The difference is negligible.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, and metabolic stability (Cl_mic, t1/2) are important. Ligand A excels in logP, TPSA, Cl_mic, and t1/2. While BBB isn't a primary concern for a cardiovascular target, the lower TPSA of Ligand A is still beneficial for absorption. The lower hERG risk for Ligand A is also a critical advantage.
**Conclusion:**
Ligand A is significantly better overall. Its superior logP, TPSA, metabolic stability, hERG profile, and QED outweigh the slightly higher DILI risk compared to Ligand B. The binding affinities are comparable, making the ADME/Tox advantages of Ligand A decisive.
Output:
1
2025-04-17 22:44:46,776 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (421.291 Da) is slightly higher than Ligand B (392.909 Da), but both are acceptable.
**2. TPSA:** Ligand A (62.22) is significantly better than Ligand B (112.81). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is above the preferred threshold of 140, which is a concern.
**3. logP:** Ligand A (4.908) is higher than Ligand B (0.557). While logP > 4 can be problematic, it's less concerning for a peripherally acting GPCR like ADRB2. Ligand B's logP is quite low, potentially hindering membrane permeability.
**4. H-Bond Donors:** Both ligands have 2 HBD, which is within the acceptable limit of 5.
**5. H-Bond Acceptors:** Both ligands have 4 HBA, which is within the acceptable limit of 10.
**6. QED:** Both ligands have similar QED values (0.63 and 0.665), indicating good drug-likeness.
**7. DILI Risk:** Ligand A (87.553) has a significantly higher DILI risk than Ligand B (31.214). This is a major drawback for Ligand A.
**8. BBB Penetration:** Ligand B (81.698) has better BBB penetration than Ligand A (45.134), though BBB isn't a primary concern for ADRB2 (a cardiovascular target).
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual. However, the magnitude of the negative value for Ligand A (-5.097) is less than Ligand B (-5.704), suggesting slightly better permeability.
**10. Aqueous Solubility:** Ligand A (-5.152) has worse solubility than Ligand B (-2.818). Solubility is important for bioavailability.
**11. hERG Inhibition:** Ligand A (0.558) has a slightly higher hERG risk than Ligand B (0.184), but both are relatively low.
**12. Microsomal Clearance:** Ligand B (2.677) has significantly lower microsomal clearance than Ligand A (79.668), indicating better metabolic stability.
**13. In vitro Half-Life:** Ligand B (-6.007) has a longer in vitro half-life than Ligand A (-14.555). This is a significant advantage.
**14. P-gp Efflux:** Ligand A (0.64) has higher P-gp efflux than Ligand B (0.024). Lower P-gp efflux is preferred.
**15. Binding Affinity:** Ligand B (-7.8 kcal/mol) has a slightly better binding affinity than Ligand A (-7.5 kcal/mol). While the difference is small, it's still a factor.
**Overall Assessment:**
Ligand B is the more promising candidate. While Ligand A has a slightly better logP and Caco-2 permeability, Ligand B excels in critical ADME properties: significantly lower DILI risk, better metabolic stability (lower Cl_mic, longer t1/2), lower P-gp efflux, and slightly better solubility and binding affinity. The higher TPSA of Ligand A is also a concern. The small advantage in binding affinity of Ligand B, combined with its superior ADME profile, outweighs the minor differences in other parameters.
Output:
0
2025-04-17 22:44:46,776 - INFO - Batch 354 complete. Total preferences: 5664
2025-04-17 22:44:46,776 - INFO - Processing batch 355/512...
2025-04-17 22:45:33,486 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (369.447 and 362.396 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (129.46) is higher than Ligand B (50.6). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B is significantly better here.
3. **logP:** Ligand A (-0.459) is a bit low, potentially hindering permeability. Ligand B (1.73) is within the optimal 1-3 range. Ligand B is favored.
4. **HBD:** Ligand A (2) is acceptable. Ligand B (0) is also good, potentially improving permeability. No strong preference.
5. **HBA:** Both ligands have 5 HBA, which is acceptable.
6. **QED:** Both ligands have similar QED scores (0.742 and 0.694), indicating good drug-likeness.
7. **DILI:** Ligand A (70.88) has a higher DILI risk than Ligand B (12.02). This is a significant concern, as we want to minimize liver toxicity. Ligand B is strongly favored.
8. **BBB:** Ligand A (29.12) has low BBB penetration, which isn't a major concern for a cardiovascular target. Ligand B (92.943) has high BBB penetration, which isn't necessarily *bad*, but also doesn't offer an advantage here.
9. **Caco-2:** Ligand A (-5.375) and Ligand B (-4.589) are both negative, which is unusual. It suggests poor permeability.
10. **Solubility:** Ligand A (-2.529) has poorer solubility than Ligand B (-1.006). Solubility is important for bioavailability. Ligand B is favored.
11. **hERG:** Ligand A (0.13) has a slightly lower hERG risk than Ligand B (0.684), which is good.
12. **Cl_mic:** Ligand A (-0.356) has a lower (better) microsomal clearance than Ligand B (0.177), indicating greater metabolic stability.
13. **t1/2:** Ligand A (-39.35) has a much shorter in vitro half-life than Ligand B (-22.307). This is a significant drawback for Ligand A.
14. **Pgp:** Ligand A (0.033) has lower P-gp efflux than Ligand B (0.065), which is favorable.
15. **Binding Affinity:** Ligand A (-7.7) has a slightly better binding affinity than Ligand B (-7.2). This is a 0.5 kcal/mol difference, which is significant but not overwhelming.
**Overall Assessment:**
While Ligand A has slightly better binding affinity and lower P-gp efflux, Ligand B is significantly better in several critical ADME properties. Specifically, the much lower DILI risk, better logP, and improved solubility of Ligand B are compelling advantages. The longer half-life of Ligand B is also a major plus. The TPSA of Ligand B is also much more favorable. The small difference in binding affinity is outweighed by the superior ADME profile of Ligand B.
**Output:**
0
2025-04-17 22:45:33,486 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (355.341 and 366.38 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (67.87) is significantly better than Ligand A (91.76). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (1.744 and 1.486), falling within the optimal 1-3 range. Ligand B is slightly better.
4. **HBD:** Ligand A has 2 HBD, while Ligand B has 1. Both are acceptable, but lower is generally preferred for permeability. Ligand B is slightly better.
5. **HBA:** Ligand A has 5 HBA, and Ligand B has 4. Both are within the acceptable range of <=10. Ligand B is slightly better.
6. **QED:** Both ligands have identical QED scores (0.8), indicating excellent drug-likeness.
7. **DILI:** Ligand B (41.838) has a significantly lower DILI risk than Ligand A (80.109). This is a major advantage for Ligand B.
8. **BBB:** Ligand B (92.943) has a much higher BBB penetration score than Ligand A (48.042). While not a primary concern for a cardiovascular target, higher BBB is rarely detrimental.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.976 and -4.492). These values are difficult to interpret without knowing the scale, but negative values are not ideal.
10. **Solubility:** Both ligands have negative solubility values (-2.451 and -2.622). Similar to Caco-2, these are not ideal, and suggest poor aqueous solubility.
11. **hERG:** Ligand A (0.056) has a slightly lower hERG inhibition liability than Ligand B (0.186), which is preferable.
12. **Cl_mic:** Ligand A (-21.566) has a much lower (better) microsomal clearance than Ligand B (24.455). This indicates better metabolic stability.
13. **t1/2:** Ligand A (-30.524) has a more negative (longer) in vitro half-life than Ligand B (-10.357). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.002) has a significantly lower P-gp efflux liability than Ligand B (0.015). This is a major advantage for Ligand A.
15. **Binding Affinity:** Ligand B (-8.0) has a slightly better binding affinity than Ligand A (-7.2). This is a 1.5kcal/mol advantage.
**Overall Assessment:**
Ligand B has a substantial advantage in DILI risk and BBB penetration, and a slightly better affinity. However, Ligand A has a significantly better metabolic stability (Cl_mic and t1/2) and P-gp efflux profile, and a slightly better hERG profile. Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), and the fact that this is a cardiovascular target (less emphasis on BBB), the improved metabolic stability and reduced efflux of Ligand A are more crucial. The affinity difference is not large enough to overcome the ADME advantages of Ligand A.
**Output:**
1
2025-04-17 22:45:33,487 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
The ADRB2 receptor is a GPCR, so the priorities are logP, TPSA, Pgp efflux, BBB penetration, and binding affinity. Let's break down each ligand against these and other important parameters:
* **Molecular Weight:** Both ligands are within the ideal range (200-500 Da).
* **TPSA:** Ligand A (41.3) is significantly better than Ligand B (83.55). Lower TPSA generally favors oral absorption and is crucial for GPCRs.
* **logP:** Ligand A (3.688) is good, while Ligand B (1.211) is on the lower side, potentially hindering membrane permeability.
* **H-Bond Donors/Acceptors:** Both have 1 HBD and 4 HBA, which are acceptable.
* **QED:** Ligand A (0.922) has a superior QED score compared to Ligand B (0.762), indicating better overall drug-likeness.
* **DILI:** Ligand B (26.755) has a lower DILI risk than Ligand A (13.532), which is a positive.
* **BBB:** Ligand A (91.857) has a much higher BBB penetration percentile than Ligand B (61.535). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant, and higher BBB is generally favorable.
* **Caco-2 Permeability:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the absolute value is less important than the trend.
* **Aqueous Solubility:** Both have very poor aqueous solubility (-2.174 and -2.148 respectively). This is a significant concern for both compounds.
* **hERG Inhibition:** Both ligands have low hERG inhibition risk (0.904 and 0.188 respectively).
* **Microsomal Clearance:** Ligand B (15.003) has lower microsomal clearance than Ligand A (36.735), suggesting better metabolic stability.
* **In vitro Half-Life:** Ligand B (14.663) has a significantly longer in vitro half-life than Ligand A (-3.302). This is a major advantage.
* **P-gp Efflux:** Ligand B (0.019) has a much lower P-gp efflux liability than Ligand A (0.545), which is beneficial for bioavailability.
* **Binding Affinity:** Both ligands have the same binding affinity (-6.5 kcal/mol), so this parameter doesn't differentiate them.
**Overall Assessment:**
Ligand A excels in TPSA, QED, and BBB penetration, which are important for a GPCR target. However, Ligand B demonstrates superior metabolic stability (lower Cl_mic, longer t1/2), lower P-gp efflux, and lower DILI risk. The poor solubility is a concern for both, but the ADME properties of Ligand B are generally more favorable. The slightly lower logP of Ligand B is a drawback, but the other advantages outweigh it.
**Output:**
0
2025-04-17 22:45:33,487 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (357.426 and 350.434 Da) fall comfortably within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (78.95) is slightly higher than Ligand B (69.64). Both are below the 140 threshold for good oral absorption, but B is better.
3. **logP:** Ligand B (2.076) is within the optimal 1-3 range, while Ligand A (0.337) is quite low. This is a significant advantage for B, as low logP can hinder membrane permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2), as fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (3).
6. **QED:** Both ligands have similar, good QED values (0.734 and 0.721).
7. **DILI:** Both ligands have low DILI risk (28.306 and 26.134), indicating a relatively safe profile. No clear difference.
8. **BBB:** Ligand B (89.608) has a significantly higher BBB penetration percentile than Ligand A (79.217). While ADRB2 isn't exclusively a CNS target, some CNS exposure could be beneficial or at least not detrimental, and higher BBB is generally favorable.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
10. **Solubility:** Ligand A (-1.363) has better solubility than Ligand B (-2.315).
11. **hERG:** Both ligands have low hERG inhibition liability (0.51 and 0.563), indicating a low risk of cardiotoxicity.
12. **Cl_mic:** Ligand B (18.505) has significantly lower microsomal clearance than Ligand A (43.995), suggesting better metabolic stability. This is a major advantage for B.
13. **t1/2:** Ligand B (-1.096) has a longer in vitro half-life than Ligand A (-8.688), further supporting its better metabolic stability.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.015 and 0.056).
15. **Binding Affinity:** Ligand A (-8.0) has a slightly better binding affinity than Ligand B (-5.7). However, the difference is 2.3 kcal/mol, which isn't large enough to overcome the ADME deficiencies of Ligand A.
**GPCR-specific priorities:** For GPCRs, logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP, has a better TPSA, and comparable Pgp. While Ligand A has a slightly better affinity, the significant improvements in ADME properties of Ligand B, particularly its logP and metabolic stability, outweigh this difference.
**Conclusion:**
Ligand B is the more promising drug candidate due to its superior logP, metabolic stability (lower Cl_mic and longer t1/2), and better BBB penetration. These factors are crucial for oral bioavailability and achieving therapeutic concentrations *in vivo*. The slightly weaker binding affinity of Ligand B can potentially be optimized in subsequent iterations of drug design.
Output:
0
2025-04-17 22:45:33,487 - INFO - Reasoning:
Let's analyze Ligand A and Ligand B for their potential as ADRB2 ligands, keeping in mind the GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key).
**Molecular Weight:** Both ligands (381.93 and 352.52 Da) fall within the ideal 200-500 Da range.
**TPSA:** Ligand A (71.09) is slightly higher than Ligand B (55.89). Both are below the 140 threshold for oral absorption, but B is better.
**logP:** Ligand A (3.392) is within the optimal 1-3 range, while Ligand B (1.025) is at the lower end. This favors A, as a slightly higher logP can aid membrane permeability for a GPCR.
**H-Bond Donors/Acceptors:** Ligand A has 2 HBD and 4 HBA, while Ligand B has 1 HBD and 4 HBA. Both are within acceptable limits.
**QED:** Both ligands have reasonable QED values (0.821 and 0.743), indicating good drug-like properties.
**DILI:** Ligand B (6.049) has a significantly lower DILI risk than Ligand A (49.942). This is a substantial advantage for B.
**BBB:** Ligand B (67.468) has a better BBB penetration percentile than Ligand A (56.495), but neither are particularly high. Since ADRB2 is a cardiovascular target, BBB penetration is not a primary concern, but it's still a positive for B.
**Caco-2 Permeability:** Both have negative Caco-2 values, which is unusual and suggests a potential issue with permeability prediction.
**Aqueous Solubility:** Ligand B (-0.79) has better aqueous solubility than Ligand A (-4.253).
**hERG:** Ligand A (0.337) has a slightly better hERG profile than Ligand B (0.495), but both are relatively low risk.
**Microsomal Clearance:** Ligand B (12.106) has a significantly lower microsomal clearance than Ligand A (36.87), indicating better metabolic stability.
**In vitro Half-Life:** Ligand B (-12.336) has a negative half-life, which is not physically possible and indicates a problem with the prediction. Ligand A (25.43) is reasonable.
**P-gp Efflux:** Ligand A (0.362) has lower P-gp efflux liability than Ligand B (0.006), which is favorable.
**Binding Affinity:** Ligand B (-6.2 kcal/mol) has a significantly stronger binding affinity than Ligand A (-2.8 kcal/mol). This is a major advantage for B, potentially outweighing some of the ADME concerns.
**Overall Assessment:**
Ligand B has a much stronger binding affinity and better metabolic stability (lower Cl_mic). It also has a lower DILI risk and better solubility. While Ligand A has slightly better P-gp efflux, the substantial advantage in binding affinity and the lower DILI risk of Ligand B are more important for a GPCR target. The negative half-life for Ligand B is a red flag, but the large difference in binding affinity is compelling.
Output:
0
2025-04-17 22:45:33,487 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (376.375) is slightly higher than Ligand B (340.423), but both are acceptable.
2. **TPSA:** Ligand A (59.06) is better than Ligand B (69.64). Both are below the 140 threshold for oral absorption, but lower TPSA is generally preferred for GPCRs, aiding permeability.
3. **logP:** Both ligands have good logP values (A: 3.241, B: 2.122) falling within the 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability, but also raises a slight concern for off-target effects.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD is generally better for permeability.
5. **HBA:** Ligand A (4) is preferable to Ligand B (3). Lower HBA is generally better for permeability.
6. **QED:** Both ligands have acceptable QED values (A: 0.814, B: 0.712), indicating good drug-like properties. Ligand A is slightly better.
7. **DILI:** Ligand A (52.772) has a higher DILI risk than Ligand B (35.673). Ligand B is significantly better here, a crucial factor for safety.
8. **BBB:** Ligand A (75.843) has a better BBB penetration percentile than Ligand B (50.523). While ADRB2 isn't strictly a CNS target, some peripheral ADRB2 activity can influence CNS pathways, and better BBB penetration isn't necessarily a negative.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.894) is slightly better than Ligand B (-4.444), but both are concerning.
10. **Solubility:** Both ligands have very poor aqueous solubility (A: -3.907, B: -3.211). This is a significant drawback for both.
11. **hERG:** Both ligands have low hERG inhibition risk (A: 0.782, B: 0.606), which is good.
12. **Cl_mic:** Ligand A (15.275) has a lower microsomal clearance than Ligand B (23.07). Lower clearance indicates better metabolic stability, a significant advantage.
13. **t1/2:** Ligand A (54.884) has a much longer in vitro half-life than Ligand B (2.674). This is a major advantage for dosing frequency.
14. **Pgp:** Ligand A (0.597) has lower P-gp efflux liability than Ligand B (0.129). Lower Pgp is favorable for bioavailability.
15. **Binding Affinity:** Ligand A (-8.6 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.5 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME concerns.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A performs better on logP, TPSA, Pgp, and *significantly* better on affinity. While DILI is a concern for Ligand A, the substantial improvement in binding affinity and metabolic stability (Cl_mic, t1/2) are compelling. The poor solubility and Caco-2 values are concerning for both, but can potentially be addressed with formulation strategies.
**Conclusion:**
Despite the higher DILI risk, the significantly improved binding affinity, metabolic stability, and Pgp profile of Ligand A make it the more promising candidate. The strong binding is likely to be critical for efficacy, and the other advantages outweigh the DILI concern, which can be further investigated and potentially mitigated.
Output:
1
2025-04-17 22:45:33,487 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (a cardiovascular GPCR) drug candidates.
**Ligand A:** [351.403, 104.9, 0.488, 2, 6, 0.773, 47.034, 62.621, -4.842, -1.55, 0.198, 4.847, -7.632, 0.045, -5.7]
**Ligand B:** [346.475, 76.02, 3.026, 2, 4, 0.745, 39.395, 82.241, -4.845, -3.439, 0.472, 53.553, 29.211, 0.408, -7.4]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity) and general drug-like properties:
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (346.475) is slightly lower, which is generally favorable.
2. **TPSA:** Ligand A (104.9) is a bit higher than Ligand B (76.02). Ligand B is better here, being closer to the preferred <140 for oral absorption.
3. **logP:** Ligand B (3.026) is optimal (1-3). Ligand A (0.488) is quite low, which could hinder membrane permeability and bioavailability. This is a significant drawback for Ligand A.
4. **HBD:** Both have 2 HBD, which is good.
5. **HBA:** Ligand A has 6 HBA, while Ligand B has 4. Ligand B is slightly better.
6. **QED:** Both are good (>0.5), indicating reasonable drug-likeness.
7. **DILI:** Ligand B (39.395) has a lower DILI risk than Ligand A (47.034), which is preferable.
8. **BBB:** Ligand B (82.241) has a much higher BBB penetration potential than Ligand A (62.621). While not a primary concern for a cardiovascular target, higher BBB is rarely detrimental.
9. **Caco-2:** Both have similar, poor Caco-2 permeability.
10. **Solubility:** Ligand B (-3.439) has better solubility than Ligand A (-1.55).
11. **hERG:** Both have very low hERG risk, which is excellent.
12. **Cl_mic:** Ligand A (4.847) has a lower microsomal clearance than Ligand B (53.553), suggesting better metabolic stability. This is a positive for Ligand A.
13. **t1/2:** Ligand B (29.211) has a longer in vitro half-life than Ligand A (-7.632). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.045) has lower P-gp efflux than Ligand B (0.408), which is favorable for bioavailability.
15. **Affinity:** Ligand B (-7.4) has slightly better binding affinity than Ligand A (-5.7). While the difference is not huge (1.7 kcal/mol), it's enough to consider.
**Overall Assessment:**
Ligand B is the stronger candidate. The biggest issue with Ligand A is its low logP, which will likely cause significant absorption problems. While Ligand A has better metabolic stability (lower Cl_mic) and lower Pgp efflux, these benefits are outweighed by the poor logP and lower binding affinity. Ligand B has a more balanced profile, with better logP, solubility, BBB penetration, and half-life, and only slightly worse metabolic stability. The slightly better affinity of Ligand B further solidifies its preference.
Output:
0
2025-04-17 22:45:33,487 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
The target is ADRB2, a GPCR. Therefore, I will prioritize logP, Pgp efflux, TPSA, BBB penetration, and binding affinity.
**Ligand A:**
* **MW:** 350.419 Da - Good. Within the ideal range.
* **TPSA:** 104.39 - Acceptable, but approaching the upper limit for good oral absorption.
* **logP:** 1.596 - Good, within the optimal range.
* **HBD:** 2 - Good.
* **HBA:** 5 - Good.
* **QED:** 0.843 - Excellent, highly drug-like.
* **DILI:** 59.636 - Moderate risk, but acceptable.
* **BBB:** 55.642 - Moderate. Not ideal for a CNS target, but ADRB2 isn't always targeted for CNS effects.
* **Caco-2:** -4.758 - Poor permeability. A significant concern.
* **Solubility:** -2.901 - Poor solubility. Another significant concern.
* **hERG:** 0.301 - Low risk, good.
* **Cl_mic:** -2.256 - Good, suggests good metabolic stability.
* **t1/2:** -27.428 - Very long half-life, excellent.
* **Pgp:** 0.038 - Low efflux, excellent.
* **Affinity:** -7.0 kcal/mol - Excellent binding affinity.
**Ligand B:**
* **MW:** 383.627 Da - Good. Within the ideal range.
* **TPSA:** 38.13 - Excellent, very favorable for absorption and potentially BBB penetration.
* **logP:** 4.157 - High. Could lead to solubility issues and off-target effects.
* **HBD:** 0 - Good, but potentially too lipophilic.
* **HBA:** 5 - Good.
* **QED:** 0.608 - Acceptable, but lower than Ligand A.
* **DILI:** 14.23 - Very low risk, excellent.
* **BBB:** 83.133 - Excellent, high potential for CNS penetration.
* **Caco-2:** -4.854 - Poor permeability. Similar to Ligand A.
* **Solubility:** -3.875 - Poor solubility. Similar to Ligand A.
* **hERG:** 0.556 - Moderate risk.
* **Cl_mic:** 110.074 - High clearance, poor metabolic stability. A significant concern.
* **t1/2:** 21.498 - Moderate half-life.
* **Pgp:** 0.421 - Moderate efflux.
* **Affinity:** -5.8 kcal/mol - Good binding affinity, but 1.2 kcal/mol weaker than Ligand A.
**Comparison and Decision:**
Both ligands have poor Caco-2 permeability and solubility, which are major drawbacks. However, Ligand A has a significantly better binding affinity (-7.0 vs -5.8 kcal/mol). It also has better metabolic stability (lower Cl_mic) and a much longer half-life. While Ligand B has a better BBB score and lower DILI risk, the substantial difference in binding affinity and metabolic stability of Ligand A outweighs these benefits, especially considering ADRB2 is not necessarily a CNS target. The higher logP of Ligand B is also a concern.
Therefore, I choose Ligand A.
**Output:**
1
2025-04-17 22:45:33,487 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (345.403) is slightly lower, which can be beneficial for permeability.
2. **TPSA:** Ligand A (93.26) is better than Ligand B (59.22), falling comfortably under the 140 threshold for oral absorption.
3. **logP:** Ligand A (1.487) is optimal, while Ligand B (3.815) is approaching the upper limit. Higher logP can lead to off-target effects and solubility issues.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A (6) is slightly higher than Ligand B (4), but both are acceptable.
6. **QED:** Ligand A (0.856) has a better QED score than Ligand B (0.762), indicating a more drug-like profile.
7. **DILI:** Ligand B (42.962) has a slightly lower DILI risk than Ligand A (54.634), which is a positive.
8. **BBB:** Ligand B (86.817) has significantly higher BBB penetration than Ligand A (68.282). While ADRB2 isn't strictly a CNS target, some CNS exposure can be acceptable and even beneficial depending on the desired therapeutic profile.
9. **Caco-2:** Both show negative values, which is unusual. Assuming these are logP-scaled values, lower values indicate poorer permeability. They are comparable.
10. **Solubility:** Ligand A (-1.788) has better aqueous solubility than Ligand B (-3.705). Solubility is crucial for bioavailability.
11. **hERG:** Ligand A (0.084) has a lower hERG risk than Ligand B (0.964), which is a significant advantage for cardiovascular targets.
12. **Cl_mic:** Ligand A (48.946) has lower microsomal clearance than Ligand B (87.657), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-23.603) has a longer in vitro half-life than Ligand B (18.576).
14. **Pgp:** Ligand A (0.057) has lower P-gp efflux than Ligand B (0.595), which is beneficial for bioavailability.
15. **Affinity:** Ligand B (-8.0) has a slightly better binding affinity than Ligand A (-7.1). This is a 0.9 kcal/mol difference, which is substantial.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand B excels in affinity and BBB penetration, but struggles with logP and Pgp. Ligand A has a more balanced profile, with better logP, solubility, metabolic stability, and lower hERG risk. The affinity difference, while significant, is potentially outweighed by the more favorable ADME properties of Ligand A.
**Conclusion:**
Considering the balance of properties, particularly the lower hERG risk, better solubility, metabolic stability, and Pgp efflux profile of Ligand A, I believe it is the more viable drug candidate despite the slightly weaker binding affinity.
Output:
1
2025-04-17 22:45:33,487 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [386.319, 49.77, 3.072, 1, 4, 0.817, 13.067, 76.735, -4.73, -3.682, 0.862, 19.685, 34.006, 0.832, -8.6]
**Ligand B:** [361.829, 79.24, 4.493, 1, 3, 0.325, 64.754, 64.482, -5.026, -5.487, 0.822, 79.374, 11.805, 0.602, -4.8]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (361.829) is slightly lower, which could be beneficial for permeability.
2. **TPSA:** Ligand A (49.77) is significantly better than Ligand B (79.24). For a cardiovascular GPCR, TPSA < 140 is acceptable, but lower is preferred. Ligand B is pushing the upper limit.
3. **logP:** Ligand A (3.072) is optimal. Ligand B (4.493) is higher, potentially leading to solubility issues and off-target interactions.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 4 HBA, Ligand B has 3. Both are acceptable.
6. **QED:** Ligand A (0.817) is excellent, indicating strong drug-likeness. Ligand B (0.325) is poor, raising concerns about developability.
7. **DILI:** Ligand A (13.067) has a much lower DILI risk than Ligand B (64.754). This is a significant advantage.
8. **BBB:** Ligand A (76.735) has better BBB penetration than Ligand B (64.482). While not a primary concern for a cardiovascular target, it's a positive attribute.
9. **Caco-2:** Both have negative values, indicating poor permeability. Ligand A (-4.73) is slightly better than Ligand B (-5.026).
10. **Solubility:** Ligand A (-3.682) is better than Ligand B (-5.487).
11. **hERG:** Both are low risk (0.862 and 0.822).
12. **Cl_mic:** Ligand A (19.685) has a lower clearance, suggesting better metabolic stability than Ligand B (79.374).
13. **t1/2:** Ligand A (34.006) has a longer half-life than Ligand B (11.805).
14. **Pgp:** Ligand A (0.832) has slightly lower P-gp efflux than Ligand B (0.602).
15. **Affinity:** Ligand A (-8.6 kcal/mol) has significantly stronger binding affinity than Ligand B (-4.8 kcal/mol). This is a substantial advantage.
**GPCR-Specific Priorities:** For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A excels in these areas. While BBB isn't critical for a cardiovascular target, Ligand A's better BBB score is a bonus.
**Conclusion:**
Ligand A is clearly the superior candidate. Its significantly better QED, DILI risk, metabolic stability, half-life, and *especially* its much stronger binding affinity outweigh any minor drawbacks in Caco-2 permeability. Ligand B's poor QED, high DILI risk, and weaker affinity make it a less attractive option.
Output:
1
2025-04-17 22:45:33,487 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
Let's break down the comparison of Ligand A and Ligand B based on the provided parameters, keeping in mind the GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key).
1. **Molecular Weight:** Both ligands (367.5 and 355.4 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (61.88) is significantly better than Ligand B (96.53). A TPSA under 140 is good for oral absorption, and lower is generally preferred for GPCRs. Ligand B is pushing the upper limit, potentially hindering absorption.
3. **logP:** Both ligands have good logP values (1.954 and 1.331), falling within the optimal 1-3 range. Ligand B is slightly lower, which *could* indicate slightly reduced membrane permeability, but it's not a major concern.
4. **H-Bond Donors:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **H-Bond Acceptors:** Ligand A (5) is preferable to Ligand B (4). Lower HBA is generally better for permeability.
6. **QED:** Ligand A (0.864) is significantly better than Ligand B (0.6). A higher QED indicates a more drug-like profile.
7. **DILI:** Ligand A (30.83) is significantly better than Ligand B (48.51). Lower DILI risk is crucial. Ligand B is approaching a moderate risk level.
8. **BBB:** Ligand B (65.92) is better than Ligand A (55.64), but for a cardiovascular target like ADRB2, BBB penetration isn't a primary concern.
9. **Caco-2:** Ligand A (-4.799) is better than Ligand B (-5.164). Higher Caco-2 permeability is desirable.
10. **Solubility:** Ligand A (-1.044) is better than Ligand B (-2.329). Higher solubility is generally preferred.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.194 and 0.087). This is excellent.
12. **Cl_mic:** Ligand B (-2.441) is significantly better than Ligand A (12.524). Lower microsomal clearance indicates better metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand B (-6.03) is better than Ligand A (18.398). A negative value indicates a longer half-life, which is preferable.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.02 and 0.038). This is excellent.
15. **Binding Affinity:** Ligand A (-6.8) is slightly better than Ligand B (-5.7). A 1.1 kcal/mol difference in affinity is substantial and can often outweigh minor ADME drawbacks.
**Overall Assessment:**
Ligand A has a superior profile in terms of drug-likeness (QED), DILI risk, solubility, Caco-2 permeability, and most importantly, binding affinity. While Ligand B has better metabolic stability (Cl_mic and t1/2), the difference in affinity is significant. For a GPCR target, a strong binding affinity is paramount. The slightly higher TPSA of Ligand B is a concern, and the better overall drug-like properties of Ligand A make it the more promising candidate.
**Output:**
1
2025-04-17 22:45:33,488 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.475 Da and 342.443 Da) are within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (74.57) is better than Ligand B (88.32). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands (1.936 and 2.153) are within the optimal 1-3 range. Similar.
4. **HBD:** Both ligands have 2 HBD, which is acceptable. Similar.
5. **HBA:** Both ligands have 4 HBA, which is acceptable. Similar.
6. **QED:** Both ligands (0.634 and 0.743) are above the 0.5 threshold, indicating good drug-likeness. Ligand B is slightly better.
7. **DILI:** Ligand A (16.053) has a significantly lower DILI risk than Ligand B (37.611). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (78.519) has a higher BBB percentile than Ligand A (55.021). While not a primary concern for a cardiovascular target, it's a slight positive for Ligand B.
9. **Caco-2:** Ligand B (-5.207) has a better Caco-2 permeability than Ligand A (-4.888). This suggests better intestinal absorption for Ligand B.
10. **Solubility:** Ligand B (-2.634) has slightly worse solubility than Ligand A (-2.1). While both are negative, indicating poor solubility, A is preferable.
11. **hERG:** Ligand A (0.757) has a slightly higher hERG risk than Ligand B (0.563). This is a minor negative for Ligand A, but both are relatively low.
12. **Cl_mic:** Ligand B (-12.79) has a much lower (better) microsomal clearance than Ligand A (45.354). This indicates better metabolic stability for Ligand B.
13. **t1/2:** Ligand B (-11.997) has a much longer in vitro half-life than Ligand A (8.333). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand B (0.028) has a much lower Pgp efflux liability than Ligand A (0.218). This is a significant advantage for Ligand B.
15. **Binding Affinity:** Ligand A (-6.1) has a slightly better binding affinity than Ligand B (-4.9). This is a 1.2 kcal/mol difference, which is significant enough to consider.
**Overall Assessment:**
While Ligand B has advantages in Caco-2 permeability, metabolic stability (Cl_mic and t1/2), and Pgp efflux, Ligand A's significantly lower DILI risk and slightly better binding affinity are crucial. For a cardiovascular target, minimizing liver toxicity is paramount. The affinity difference is also substantial enough to outweigh the ADME benefits of Ligand B. Considering ADRB2 is a GPCR, logP and TPSA are important, and Ligand A is better in TPSA.
Output:
1
2025-04-17 22:45:33,488 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (343.471 Da and 352.454 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (53.6) is significantly better than Ligand B (87.46). For a GPCR, keeping TPSA lower is beneficial for permeability. Ligand B is approaching a level that could hinder absorption.
**3. logP:** Ligand A (3.153) is optimal, while Ligand B (1.539) is a bit low. A logP between 1-3 is preferred, and Ligand B is at the lower end, potentially impacting membrane permeability.
**4. H-Bond Donors:** Ligand A (2) and Ligand B (3) are both acceptable, being under the 5 threshold.
**5. H-Bond Acceptors:** Ligand A (3) and Ligand B (4) are both acceptable, being under the 10 threshold.
**6. QED:** Ligand A (0.834) has a significantly better QED score than Ligand B (0.619), indicating a more drug-like profile.
**7. DILI:** Ligand A (20.202) has a much lower DILI risk than Ligand B (24.506), which is a significant advantage.
**8. BBB:** Ligand A (92.672) has a much higher BBB penetration percentile than Ligand B (67.701). While ADRB2 is a cardiovascular target, some CNS penetration isn't necessarily detrimental and could offer additional therapeutic avenues or highlight potential off-target effects.
**9. Caco-2 Permeability:** Ligand A (-4.668) is better than Ligand B (-5.297), suggesting better intestinal absorption.
**10. Aqueous Solubility:** Ligand A (-3.46) is better than Ligand B (-1.97), indicating better solubility.
**11. hERG Inhibition:** Ligand A (0.793) is better than Ligand B (0.7), indicating a lower risk of cardiotoxicity.
**12. Microsomal Clearance:** Ligand A (60.187) has a better (lower) microsomal clearance than Ligand B (11.295), suggesting better metabolic stability.
**13. In vitro Half-Life:** Ligand A (7.772) has a better half-life than Ligand B (-1.286).
**14. P-gp Efflux:** Ligand A (0.134) is better than Ligand B (0.015), indicating lower P-gp efflux.
**15. Binding Affinity:** Ligand B (-6.9) has a slightly better binding affinity than Ligand A (-5.5). However, the difference of 1.4 kcal/mol, while noticeable, is not substantial enough to outweigh the numerous advantages of Ligand A across other crucial ADME-Tox properties.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across almost all critical ADME-Tox parameters. While Ligand B has a slightly better binding affinity, Ligand A's superior drug-likeness (QED), lower DILI risk, better BBB penetration, improved permeability, solubility, metabolic stability, and reduced efflux make it a far more promising drug candidate for the ADRB2 receptor. The small difference in binding affinity is easily compensated for through further optimization of Ligand A.
Output:
1
2025-04-17 22:45:33,488 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (342.399 Da and 348.491 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (90.54) is slightly higher than Ligand B (67.23). Both are below the 140 threshold for oral absorption, but Ligand B is better positioned for potential CNS penetration if desired (though ADRB2 is primarily cardiovascular).
3. **logP:** Ligand B (2.371) is slightly higher than Ligand A (1.175), both are within the optimal 1-3 range.
4. **HBD:** Ligand A (3) is higher than Ligand B (1). Both are acceptable, but lower HBD is generally preferred for permeability.
5. **HBA:** Ligand A (3) and Ligand B (4) are both acceptable, below the 10 threshold.
6. **QED:** Both ligands have similar QED values (0.754 and 0.706), indicating good drug-likeness.
7. **DILI:** Ligand B (19.504) has a significantly lower DILI risk than Ligand A (39.977). This is a major advantage for Ligand B.
8. **BBB:** Ligand B (75.107) has a higher BBB penetration percentile than Ligand A (65.529). While ADRB2 is cardiovascular, some CNS effects are possible with beta-blockers, and higher BBB penetration could be a consideration.
9. **Caco-2:** Ligand A (-5.281) has a worse Caco-2 permeability than Ligand B (-4.652).
10. **Solubility:** Both ligands have very poor aqueous solubility (-2.886 and -2.707). This is a significant drawback for both, but may be addressable through formulation.
11. **hERG:** Both ligands have low hERG inhibition liability (0.148 and 0.295).
12. **Cl_mic:** Ligand A (-36.237) has a much lower (better) microsomal clearance than Ligand B (72.36). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (21.422) has a longer in vitro half-life than Ligand B (10.486). This is a positive for Ligand A.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.008 and 0.09).
15. **Binding Affinity:** Ligand B (-7.3) has a slightly better binding affinity than Ligand A (-7.0). While the difference is small, it's within the range where it could outweigh some ADME drawbacks.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B is better in terms of TPSA and affinity, while Ligand A is better in terms of logP. However, the significantly lower DILI risk for Ligand B is a major factor. Metabolic stability (Cl_mic and t1/2) is also important, and Ligand A is better here, but the DILI risk is a more critical concern.
**Overall Assessment:**
Despite Ligand A's better metabolic stability and half-life, the significantly lower DILI risk of Ligand B, coupled with its slightly better affinity and TPSA, makes it the more promising candidate. The solubility issues are a concern for both, but formulation strategies can be explored.
Output:
0
2025-04-17 22:45:33,488 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (358.43 and 352.49 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (69.64) is higher than Ligand B (40.62). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B is better.
3. **logP:** Ligand A (1.899) is within the optimal range (1-3), while Ligand B (3.258) is at the higher end. Both are acceptable, but Ligand A is slightly better balanced.
4. **HBD:** Ligand A (2) and Ligand B (0) are both reasonable.
5. **HBA:** Ligand A (3) and Ligand B (2) are both reasonable.
6. **QED:** Both ligands have good QED scores (0.738 and 0.782), indicating good drug-like properties. No significant difference.
7. **DILI:** Both ligands have very similar, low DILI risk (12.33 and 12.29). No significant difference.
8. **BBB:** Ligand B (96.743) has a significantly higher BBB penetration percentile than Ligand A (81.427). While ADRB2 isn't primarily a CNS target, some CNS exposure can be a concern for off-target effects. However, for a cardiovascular target, this isn't a major drawback for Ligand A.
9. **Caco-2:** Ligand A (-4.895) and Ligand B (-4.533) are both negative, indicating poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-2.123) and Ligand B (-3.671) are both negative, indicating poor solubility. This is a concern for both.
11. **hERG:** Ligand A (0.297) has a lower hERG inhibition liability than Ligand B (0.765), which is a significant advantage. Lower hERG risk is crucial for cardiovascular drugs.
12. **Cl_mic:** Ligand A (-15.805) has a much lower (better) microsomal clearance than Ligand B (56.523). This suggests greater metabolic stability for Ligand A.
13. **t1/2:** Ligand A (-15.062) has a more negative (longer) in vitro half-life than Ligand B (-13.183), suggesting a longer duration of action.
14. **Pgp:** Ligand A (0.038) has a lower P-gp efflux liability than Ligand B (0.2). This is favorable for bioavailability.
15. **Binding Affinity:** Ligand A (-6.8) has a slightly better binding affinity than Ligand B (-6.3). While the difference is not huge, it's still a positive factor.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand B has better TPSA and BBB, but Ligand A has better logP, Pgp, Cl_mic, t1/2, hERG, and slightly better affinity. The improvements in metabolic stability (Cl_mic and t1/2) and reduced hERG risk for Ligand A are particularly important for a cardiovascular drug. The slightly better affinity also contributes.
**Conclusion:**
Considering the balance of properties and the priorities for a cardiovascular GPCR target, Ligand A is the more promising candidate. Its superior metabolic stability, lower hERG risk, and better Pgp profile outweigh the slightly higher TPSA and lower BBB penetration compared to Ligand B.
Output:
1
2025-04-17 22:45:33,488 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (341.411 and 364.515 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (73.1 and 75.19) are below the 140 A^2 threshold for good oral absorption, and are reasonable for a cardiovascular target (not CNS). No major difference.
3. **logP:** Both ligands (2.397 and 2.721) are within the optimal 1-3 range. Ligand B is slightly higher, which *could* be a minor drawback if it impacts solubility, but is not a major concern.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Both have 5 HBA, which is good.
6. **QED:** Both ligands have high QED scores (0.928 and 0.872), indicating good drug-like properties.
7. **DILI:** Ligand A (64.754) has a higher DILI risk than Ligand B (51.881). This is a significant negative for Ligand A.
8. **BBB:** Both are reasonably low, as expected for a cardiovascular target. Ligand A (75.572) is slightly higher than Ligand B (62.97), but this isn't a critical factor here.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.509 and -4.858) which is unusual and suggests poor permeability. This is a concern for both, but the values are similar.
10. **Solubility:** Both ligands have negative solubility values (-3.369 and -3.685), which is also unusual and suggests poor solubility. This is a concern for both, but the values are similar.
11. **hERG:** Both ligands have low hERG inhibition risk (0.443 and 0.305). Ligand B is slightly better here.
12. **Cl_mic:** Ligand A (10.426) has significantly lower microsomal clearance than Ligand B (59.641). This suggests better metabolic stability for Ligand A, which is a positive.
13. **t1/2:** Both ligands have similar in vitro half-lives (11.631 and 11.759 hours).
14. **Pgp:** Both ligands have low Pgp efflux liability (0.193 and 0.463). Ligand A is slightly better.
15. **Binding Affinity:** Both ligands have very similar and excellent binding affinities (-6.7 and -6.8 kcal/mol). The difference is negligible.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are important. Both ligands perform well on these. However, DILI risk is a major concern, and Ligand B has a considerably lower DILI risk. Metabolic stability (Cl_mic) is also important, and Ligand A is better.
**Overall Assessment:**
While Ligand A has better metabolic stability and slightly better Pgp profile, the significantly higher DILI risk is a major drawback. Ligand B, despite slightly higher clearance, presents a much safer profile regarding potential liver toxicity. Given the importance of safety in drug development, and the similar affinities, Ligand B is the more promising candidate.
Output:
0
2025-04-17 22:45:33,488 - INFO - Batch 355 complete. Total preferences: 5680
2025-04-17 22:45:33,488 - INFO - Processing batch 356/512...
2025-04-17 22:46:21,499 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [344.361, 53.33, 3.897, 0, 3, 0.799, 63.164, 73.943, -3.896, -4.569, 0.787, 103.069, -8.353, 0.445, -7.4]
**Ligand B:** [361.793, 108.06, 2.725, 3, 6, 0.659, 98.953, 51.725, -5.006, -5.073, 0.472, 48.258, 49.414, 0.056, -6.2]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, Affinity, and BBB):
1. **MW:** Both are within the ideal range (200-500 Da). A is slightly lower (344) vs B (362), which is fine.
2. **TPSA:** A (53.33) is excellent, well below the 140 threshold. B (108.06) is higher, but still acceptable.
3. **logP:** A (3.897) is optimal. B (2.725) is also good, but a bit lower.
4. **HBD/HBA:** A (0/3) is better than B (3/6) as fewer H-bonds generally improve permeability.
5. **QED:** A (0.799) is better than B (0.659), indicating a more drug-like profile.
6. **DILI:** A (63.164) is better than B (98.953). Lower is better, and B is approaching a high-risk level.
7. **BBB:** A (73.943) is significantly better than B (51.725). While not a CNS target, some level of BBB penetration can be beneficial for distribution.
8. **Caco-2:** A (-3.896) is better than B (-5.006). Higher is better, indicating better absorption.
9. **Solubility:** A (-4.569) is better than B (-5.073). Higher is better.
10. **hERG:** A (0.787) is better than B (0.472). Lower is better.
11. **Cl_mic:** A (103.069) is higher than B (48.258), meaning *lower* metabolic stability. This is a drawback for A.
12. **t1/2:** A (-8.353) is better than B (49.414), meaning a longer half-life.
13. **Pgp:** A (0.445) is better than B (0.056). Lower is better, indicating less efflux.
14. **Affinity:** A (-7.4) is better than B (-6.2). This is a substantial difference (1.2 kcal/mol), which can outweigh some ADME concerns.
**Overall Assessment:**
Ligand A clearly wins on most critical parameters for a GPCR drug candidate, especially affinity, DILI, BBB, solubility, and Pgp efflux. The primary drawback for A is the higher microsomal clearance, suggesting faster metabolism. However, the significantly stronger binding affinity and better safety profile (lower DILI, hERG) outweigh this concern. The better TPSA, logP, and QED also favor A.
Output:
1
2025-04-17 22:46:21,499 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.341 and 353.423 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (88.91) is better than Ligand B (113.53). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (1.578 and 1.386), falling within the optimal 1-3 range. Again, no major difference.
4. **HBD:** Both have 2 HBD, which is acceptable.
5. **HBA:** Ligand A has 5 HBA, while Ligand B has 7. Ligand A is slightly better here, staying closer to the preferred <10.
6. **QED:** Ligand A (0.794) has a significantly better QED score than Ligand B (0.539), indicating a more drug-like profile.
7. **DILI:** Ligand A (76.425) has a higher DILI risk than Ligand B (54.401). This is a significant negative for Ligand A.
8. **BBB:** Ligand A (73.75) has slightly better BBB penetration than Ligand B (56.029), but this isn't critical for a cardiovascular target.
9. **Caco-2:** Both have negative Caco-2 values (-5.293 and -5.127), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-3.18) has slightly better solubility than Ligand B (-2.545), but both are quite poor.
11. **hERG:** Ligand A (0.223) has a much lower hERG inhibition liability than Ligand B (0.587). This is a major advantage for Ligand A.
12. **Cl_mic:** Ligand A (3.311) has a much lower microsomal clearance than Ligand B (45.353), indicating better metabolic stability. This is a significant positive for Ligand A.
13. **t1/2:** Ligand A (17.163) has a longer in vitro half-life than Ligand B (-5.132). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.028) has much lower P-gp efflux liability than Ligand B (0.278), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand A (-8.3 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.0 kcal/mol). This is a substantial advantage that can outweigh some of the ADME concerns.
**Overall Assessment:**
Ligand A is clearly superior despite the higher DILI risk. The significantly stronger binding affinity (-8.3 vs -6.0 kcal/mol) is a major driver. Furthermore, Ligand A demonstrates better QED, lower Cl_mic, longer t1/2, and lower Pgp efflux. While both have poor Caco-2 permeability and solubility, the superior potency and metabolic stability of Ligand A make it the more promising candidate. The DILI risk is a concern, but can be investigated further with structural modifications.
Output:
1
2025-04-17 22:46:21,499 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
The target is ADRB2, a GPCR. Therefore, the priorities are logP, Pgp efflux, TPSA, BBB penetration, and binding affinity.
Let's analyze each ligand against these criteria and the general guidelines:
* **Molecular Weight:** Both ligands (371.459 and 367.427 Da) fall within the ideal 200-500 Da range.
* **TPSA:** Ligand A (103.86) is better than Ligand B (121.53), being closer to the <140 threshold for good absorption.
* **logP:** Ligand A (-0.852) is slightly lower than ideal (1-3), but still acceptable. Ligand B (1.077) is within the optimal range.
* **H-Bond Donors/Acceptors:** Ligand A (1 HBD, 5 HBA) is preferable to Ligand B (3 HBD, 6 HBA) as it has fewer potential issues with permeability.
* **QED:** Both ligands have similar QED scores (0.678 and 0.642), indicating good drug-likeness.
* **DILI:** Ligand A (35.712) has a significantly lower DILI risk than Ligand B (86.002). This is a major advantage.
* **BBB:** Ligand A (65.801) has better BBB penetration than Ligand B (28.887), which is important for GPCRs.
* **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability.
* **Solubility:** Both ligands have negative solubility values, which is also unusual and suggests poor solubility.
* **hERG:** Both ligands have very low hERG inhibition risk (0.029 and 0.152).
* **Cl_mic:** Ligand A (-3.579) has a lower (better) microsomal clearance than Ligand B (24.757), indicating better metabolic stability.
* **t1/2:** Ligand B (38.603) has a longer half-life than Ligand A (14.028), which is generally desirable.
* **Pgp:** Ligand A (0.011) has much lower P-gp efflux liability than Ligand B (0.177), which is crucial for bioavailability and potential CNS exposure.
* **Binding Affinity:** Both ligands have very similar binding affinities (-5.9 and -5.6 kcal/mol). The difference is not substantial enough to outweigh other factors.
**Overall Assessment:**
Ligand A is the stronger candidate. It has a significantly lower DILI risk, better BBB penetration, lower P-gp efflux, and better metabolic stability. While Ligand B has a longer half-life, the other advantages of Ligand A, particularly the lower DILI and P-gp efflux, are more critical for a successful drug candidate, especially for a GPCR target. The unusual Caco-2 and solubility values for both ligands are concerning and would require further investigation, but the other properties of Ligand A make it the more promising starting point.
**Output:**
1
2025-04-17 22:46:21,499 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (344.459 Da and 354.441 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (83.98) is higher than Ligand B (49.41). For a cardiovascular GPCR like ADRB2, TPSA is less critical than for CNS targets, but lower is still preferable for permeability. Ligand B is significantly better.
3. **logP:** Both ligands have good logP values (1.776 and 2.823), falling within the optimal 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable, below the threshold of 5. Ligand B is slightly better.
5. **HBA:** Ligand A (4) and Ligand B (2) are both acceptable, below the threshold of 10. Ligand B is better.
6. **QED:** Both ligands have similar and good QED scores (0.79 and 0.797), indicating good drug-like properties.
7. **DILI:** Ligand A (21.714) has a lower DILI risk than Ligand B (16.44). Lower is better, so Ligand A is preferable here.
8. **BBB:** Ligand B (96.937) has a much higher BBB penetration percentile than Ligand A (57.076). While ADRB2 isn't a primary CNS target, some degree of BBB penetration can be beneficial for off-target effects or distribution.
9. **Caco-2:** Ligand A (-5.283) and Ligand B (-4.652) are both negative, indicating poor permeability. This is a concern for both, but Ligand B is slightly better.
10. **Solubility:** Ligand A (-1.337) has better solubility than Ligand B (-3.603). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.092) has a lower hERG inhibition liability than Ligand B (0.797). This is a significant advantage for Ligand A, as hERG inhibition can lead to cardiotoxicity.
12. **Cl_mic:** Ligand B (20.893) has a higher microsomal clearance than Ligand A (1.632), indicating faster metabolism and potentially lower *in vivo* exposure. Ligand A is preferable.
13. **t1/2:** Ligand A (14.39) has a longer in vitro half-life than Ligand B (-4.808). This is a significant advantage for Ligand A, suggesting less frequent dosing.
14. **Pgp:** Ligand A (0.012) has much lower P-gp efflux liability than Ligand B (0.2). Lower efflux is better for bioavailability.
15. **Binding Affinity:** Ligand B (-8.4) has a significantly stronger binding affinity than Ligand A (-7.0). A 1.4 kcal/mol difference is substantial and can often outweigh minor ADME drawbacks.
**Overall Assessment:**
Ligand B has a superior binding affinity and better TPSA, logP, and BBB penetration. However, it suffers from higher DILI, hERG, Pgp efflux, and significantly higher metabolic clearance and shorter half-life. Ligand A has better solubility, lower DILI and hERG, lower Pgp efflux, and better metabolic stability (lower Cl_mic, longer t1/2).
Given the cardiovascular target (ADRB2), minimizing cardiotoxicity (hERG) and ensuring adequate metabolic stability (Cl_mic, t1/2) are paramount. The substantial difference in binding affinity is tempting, but the ADME liabilities of Ligand B are concerning. The improved ADME profile of Ligand A, particularly the lower hERG and better metabolic stability, makes it the more promising candidate.
Output:
1
2025-04-17 22:46:21,499 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (357.479 and 349.519 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (43.86) is significantly better than Ligand A (75.11). ADRB2 is not a CNS target, but lower TPSA generally improves absorption.
3. **logP:** Ligand A (4.283) is slightly higher than Ligand B (2.382). While both are within the acceptable range (1-3), Ligand A is pushing the upper limit, potentially leading to solubility issues.
4. **HBD:** Ligand A (2) is better than Ligand B (0). Having some HBD can help with solubility.
5. **HBA:** Ligand A (5) is better than Ligand B (3). Similar to HBD, a moderate number of HBA is generally favorable.
6. **QED:** Ligand B (0.692) has a slightly better QED score than Ligand A (0.593), indicating a more drug-like profile.
7. **DILI:** Ligand B (8.918) is *much* better than Ligand A (80.651). This is a critical difference. High DILI risk is a major red flag.
8. **BBB:** Not a primary concern for ADRB2, but Ligand B (82.047) is better than Ligand A (49.011).
9. **Caco-2:** Ligand A (-5.183) and Ligand B (-4.584) are both negative, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Ligand B (-1.278) is better than Ligand A (-5.167). Solubility is a concern for Ligand A given its higher logP.
11. **hERG:** Ligand A (0.082) is better than Ligand B (0.723). Lower hERG inhibition is preferred.
12. **Cl_mic:** Ligand B (28.297) has significantly lower microsomal clearance than Ligand A (61.272), indicating better metabolic stability.
13. **t1/2:** Ligand B (-11.262) has a much longer in vitro half-life than Ligand A (-3.21). This is a significant advantage.
14. **Pgp:** Ligand A (0.122) is better than Ligand B (0.149). Lower P-gp efflux is preferred.
15. **Binding Affinity:** Ligand A (-6.1 kcal/mol) is slightly better than Ligand B (-4.5 kcal/mol). This is a 1.6 kcal/mol difference, which is substantial.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity and Pgp profile, Ligand B is significantly superior in almost all ADME-Tox parameters. The most critical factor is the drastically lower DILI risk for Ligand B. The better solubility, metabolic stability (lower Cl_mic, longer t1/2), and QED score also strongly favor Ligand B. The affinity difference, while notable, can potentially be optimized in later stages of drug development. For a GPCR target like ADRB2, a balance of potency and favorable ADME properties is crucial, and Ligand B offers a much better balance.
Output:
0
2025-04-17 22:46:21,500 - INFO - Reasoning:
Let's analyze Ligand A and Ligand B for their potential as ADRB2 ligands, keeping in mind GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key).
**Molecular Weight:** Both ligands (365.861 and 365.905 Da) are within the ideal 200-500 Da range.
**TPSA:** Ligand A (82.53) is slightly higher than Ligand B (61.38). Both are below the 140 threshold for oral absorption, but B is better positioned for potential CNS penetration if desired, being closer to the 90 threshold.
**logP:** Ligand A (1.282) is within the optimal 1-3 range. Ligand B (3.462) is at the upper end, potentially increasing off-target effects and decreasing solubility, but still acceptable.
**H-Bond Donors/Acceptors:** Both have 2 HBD and 4 HBA, which are within acceptable limits.
**QED:** Both ligands have similar QED values (0.744 and 0.752), indicating good drug-likeness.
**DILI:** Ligand A (23.226) has a significantly lower DILI risk than Ligand B (37.922), which is a major advantage.
**BBB:** Ligand B (63.164) has a higher BBB penetration percentile than Ligand A (34.393). While ADRB2 isn't strictly a CNS target, some peripheral ADRB2 activity can influence CNS pathways, so this is a slight advantage for B.
**Caco-2 Permeability:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the values are similar (-5.295 vs -5.391).
**Aqueous Solubility:** Ligand A (-1.677) has better aqueous solubility than Ligand B (-3.575). This is important for formulation and bioavailability.
**hERG:** Ligand A (0.256) has a much lower hERG inhibition liability than Ligand B (0.91), which is a critical safety consideration.
**Microsomal Clearance:** Ligand A (-14.545) has a much lower (better) microsomal clearance than Ligand B (30.274), indicating greater metabolic stability.
**In vitro Half-Life:** Ligand B (109.046) has a significantly longer in vitro half-life than Ligand A (0.979). This is a positive for dosing frequency.
**P-gp Efflux:** Ligand A (0.034) shows much lower P-gp efflux liability than Ligand B (0.771), which is favorable for bioavailability and potential CNS exposure.
**Binding Affinity:** Both ligands have the same binding affinity (-6.3 kcal/mol), so this parameter doesn't differentiate them.
**Overall Assessment:**
Ligand A is clearly superior due to its significantly better safety profile (lower DILI, lower hERG) and improved ADME properties (better solubility, lower clearance, lower P-gp efflux). While Ligand B has a longer half-life and slightly better BBB penetration, the safety concerns and ADME liabilities associated with B outweigh these benefits. The similar binding affinity makes the ADME/Tox differences the deciding factor.
Output:
1
2025-04-17 22:46:21,500 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (380.794 Da and 367.808 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (68.29) is significantly better than Ligand B (93.43). For a GPCR, keeping TPSA under 140 is good for oral absorption, and lower is generally preferred. Ligand B is approaching a level that could hinder absorption.
**3. logP:** Ligand A (3.85) is slightly higher than Ligand B (2.547). Both are within the optimal 1-3 range, but Ligand A is closer to the upper limit.
**4. H-Bond Donors:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
**5. H-Bond Acceptors:** Both ligands have the same number of HBA (4).
**6. QED:** Both ligands have similar QED values (0.761 and 0.782), indicating good drug-likeness.
**7. DILI:** Ligand B (52.734) has a significantly lower DILI risk than Ligand A (67.313). This is a substantial advantage for Ligand B.
**8. BBB:** Ligand A (67.468) has a slightly better BBB penetration potential than Ligand B (59.597). While ADRB2 is a cardiovascular target, some CNS effects are possible with adrenergic agonists, so moderate BBB penetration isn't necessarily a negative.
**9. Caco-2 Permeability:** Both ligands have similar, very poor Caco-2 permeability (-4.539 and -4.66). This is a concern for both, suggesting potential absorption issues.
**10. Aqueous Solubility:** Ligand A (-4.272) has slightly better solubility than Ligand B (-3.597), but both are poor.
**11. hERG Inhibition:** Ligand A (0.282) has a lower hERG inhibition liability than Ligand B (0.583). This is a crucial advantage for Ligand A, as hERG inhibition can lead to cardiotoxicity.
**12. Microsomal Clearance:** Ligand B (2.398) has significantly lower microsomal clearance than Ligand A (76.342). Lower clearance indicates better metabolic stability, a major benefit for Ligand B.
**13. In vitro Half-Life:** Ligand B (3.037) has a slightly longer half-life than Ligand A (11.848).
**14. P-gp Efflux:** Ligand A (0.133) has lower P-gp efflux liability than Ligand B (0.092). Lower efflux is generally desirable.
**15. Binding Affinity:** Ligand B (-7.0) has a significantly stronger binding affinity than Ligand A (-6.3). This is a substantial advantage, potentially outweighing some ADME drawbacks.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand B is the more promising candidate. The significantly stronger binding affinity (-7.0 vs -6.3 kcal/mol) is a major advantage. While Ligand A has better hERG and P-gp profiles, the lower DILI risk and improved metabolic stability (lower Cl_mic and longer half-life) of Ligand B are more critical for a cardiovascular drug. The TPSA difference is also significant. The poor Caco-2 permeability is a concern for both, but can be addressed with formulation strategies.
Output:
0
2025-04-17 22:46:21,500 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.5 & 363.5 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (49.85) is better than Ligand B (42.68). Both are below the 140 threshold for oral absorption.
3. **logP:** Ligand A (2.687) is optimal (1-3), while Ligand B (4.22) is pushing the upper limit and could lead to solubility issues. This favors Ligand A.
4. **HBD:** Both have 0 HBD, which is acceptable.
5. **HBA:** Ligand A (3) is better than Ligand B (4). Both are below the 10 threshold.
6. **QED:** Ligand A (0.74) is better than Ligand B (0.487), indicating a more drug-like profile.
7. **DILI:** Ligand A (16.25) is significantly better than Ligand B (27.14). Lower DILI risk is crucial.
8. **BBB:** Ligand A (88.29) is better than Ligand B (77.24). While ADRB2 isn't exclusively a CNS target, some CNS penetration can be beneficial for understanding off-target effects and potential side effects.
9. **Caco-2:** Ligand A (-4.345) is better than Ligand B (-5.149). Higher is better.
10. **Solubility:** Ligand A (-1.838) is better than Ligand B (-4.126). Solubility is important for bioavailability.
11. **hERG:** Both ligands have low hERG risk (0.428 and 0.741 respectively).
12. **Cl_mic:** Ligand A (58.52) is better than Ligand B (89.613). Lower clearance indicates better metabolic stability.
13. **t1/2:** Ligand A (-7.705) is better than Ligand B (44.325). Longer half-life is generally preferred.
14. **Pgp:** Both ligands have low Pgp efflux (0.267 and 0.75 respectively).
15. **Affinity:** Both ligands have the same binding affinity (-7 kcal/mol).
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A is superior in logP, TPSA, and solubility. While both have good affinity and Pgp profiles, Ligand A's better ADME properties (DILI, BBB, Cl_mic, t1/2, solubility, QED) make it a more promising candidate.
**Conclusion:**
Ligand A consistently outperforms Ligand B across several crucial ADME parameters, and has a better QED score. While both have equivalent binding affinity, the superior ADME profile of Ligand A makes it the more viable drug candidate.
Output:
1
2025-04-17 22:46:21,500 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (344.419 Da) is well within the ideal range (200-500 Da). Ligand B (402.34 Da) is also acceptable, but closer to the upper limit.
2. **TPSA:** Ligand A (93.84) is good for oral absorption, being under 140. Ligand B (47.15) is excellent.
3. **logP:** Ligand A (1.419) is optimal. Ligand B (4.679) is a bit high, potentially leading to solubility issues and off-target interactions.
4. **HBD:** Both ligands are acceptable (Ligand A: 2, Ligand B: 1), well below the 5 threshold.
5. **HBA:** Both ligands are acceptable (Ligand A: 6, Ligand B: 5), below the 10 threshold.
6. **QED:** Both ligands are similar and acceptable (Ligand A: 0.612, Ligand B: 0.692), exceeding the 0.5 threshold.
7. **DILI:** Ligand A (55.603) is better than Ligand B (60.682), indicating a lower risk of liver injury. Both are still acceptable.
8. **BBB:** Ligand A (57.852) is lower than Ligand B (68.399). While ADRB2 isn't strictly a CNS target, some CNS penetration can be beneficial for understanding off-target effects and potential side effects.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-5.186) is slightly better than Ligand B (-4.719).
10. **Solubility:** Ligand A (-2.471) is better than Ligand B (-4.425). Solubility is a concern with Ligand B due to its higher logP.
11. **hERG:** Ligand A (0.276) is significantly better than Ligand B (0.887), indicating a lower risk of cardiotoxicity. This is *critical* for a cardiovascular target.
12. **Cl_mic:** Ligand A (23.184) has a lower clearance than Ligand B (45.59), suggesting better metabolic stability.
13. **t1/2:** Ligand B (86.75) has a much longer half-life than Ligand A (13.149). This is a significant advantage.
14. **Pgp:** Ligand A (0.08) has lower P-gp efflux liability than Ligand B (0.818), which is favorable for bioavailability.
15. **Affinity:** Ligand A (-7.4 kcal/mol) has a slightly better binding affinity than Ligand B (-6.1 kcal/mol). This is a 1.3 kcal/mol difference, which is significant.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. While Ligand B has a better BBB score and half-life, its high logP, poor solubility, and higher hERG risk are concerning. Ligand A has a more balanced profile, with good affinity, acceptable logP, better solubility, and a significantly lower hERG risk. The slightly shorter half-life of Ligand A can be addressed through formulation strategies.
**Conclusion:**
Considering the balance of properties and the specific requirements for a cardiovascular GPCR target, Ligand A is the more promising candidate. The lower hERG risk and better solubility outweigh the longer half-life of Ligand B.
Output:
1
2025-04-17 22:46:21,500 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.475 and 365.459 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (70.08) is significantly better than Ligand B (100.35). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (1.271) is slightly better than Ligand B (0.786), both being within the optimal 1-3 range.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is better than Ligand B (7). Lower HBA also supports permeability.
6. **QED:** Both ligands are good (0.809 and 0.785), exceeding the 0.5 threshold.
7. **DILI:** Ligand A (7.871) is significantly better than Ligand B (64.133). This is a major advantage for Ligand A, as DILI risk is a critical safety concern.
8. **BBB:** Ligand A (67.158) is better than Ligand B (22.412), but neither is particularly high. Since ADRB2 is not a CNS target, this isn't a major deciding factor.
9. **Caco-2:** Ligand A (-4.452) and Ligand B (-5.419) are both negative, indicating poor permeability. Ligand B is slightly worse.
10. **Solubility:** Ligand A (-1.114) is better than Ligand B (-2.456), indicating better aqueous solubility.
11. **hERG:** Both ligands are very low (0.358 and 0.277), indicating minimal hERG inhibition risk.
12. **Cl_mic:** Ligand A (15.905) is significantly better than Ligand B (21.628). Lower clearance suggests better metabolic stability.
13. **t1/2:** Ligand A (1.533) is better than Ligand B (-0.714). A positive half-life is preferable.
14. **Pgp:** Both ligands are very low (0.061 and 0.03), indicating minimal P-gp efflux.
15. **Binding Affinity:** Ligand B (-6.9) is slightly better than Ligand A (-6.0), providing a 0.9 kcal/mol advantage.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Ligand B has slightly better affinity, but Ligand A excels in TPSA, logP, and crucially, DILI risk and metabolic stability (Cl_mic). The 0.9 kcal/mol difference in binding affinity is not substantial enough to overcome the significant safety and pharmacokinetic advantages of Ligand A.
**Conclusion:**
Ligand A presents a more balanced profile with a significantly lower DILI risk, better metabolic stability, and favorable physicochemical properties. While Ligand B has a slightly better binding affinity, the other advantages of Ligand A make it the more promising drug candidate.
Output:
1
2025-04-17 22:46:21,500 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (350.459 Da) is slightly preferred as it's closer to the lower end, potentially aiding permeability.
**2. TPSA:** Both ligands have TPSA values below 140, which is good for oral absorption. Ligand B (72.38) is slightly lower than Ligand A (76.66), which is favorable.
**3. logP:** Ligand A (1.549) is within the optimal range (1-3). Ligand B (4.249) is higher, pushing towards the upper limit and potentially causing solubility issues or off-target interactions. This is a significant negative for Ligand B.
**4. H-Bond Donors:** Both ligands have acceptable HBD counts (Ligand A: 2, Ligand B: 3).
**5. H-Bond Acceptors:** Both ligands have acceptable HBA counts (Ligand A: 4, Ligand B: 4).
**6. QED:** Both ligands have similar QED values (Ligand A: 0.696, Ligand B: 0.64), indicating good drug-like properties.
**7. DILI:** Both ligands have low DILI risk (Ligand A: 32.377, Ligand B: 28.616), which is excellent.
**8. BBB:** Ligand A (57.115) has a moderately good BBB penetration score, while Ligand B (20.938) is quite low. While ADRB2 isn't a CNS target, some peripheral exposure can be beneficial.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual. However, the magnitude of negativity is important. Ligand A (-4.807) is less negative than Ligand B (-5.363), suggesting slightly better permeability.
**10. Aqueous Solubility:** Both ligands have negative solubility values, which is also unusual. Again, Ligand A (-2.727) is slightly better (less negative) than Ligand B (-4.669).
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (Ligand A: 0.181, Ligand B: 0.826), which is highly desirable.
**12. Microsomal Clearance:** Both ligands have similar microsomal clearance values (Ligand A: 50.343, Ligand B: 54.331).
**13. In vitro Half-Life:** Ligand A (-8.747) has a more negative half-life, which is unusual, but in this context, it suggests a longer half-life compared to Ligand B (18.525).
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (Ligand A: 0.135, Ligand B: 0.364).
**15. Binding Affinity:** Ligand A (-6.9 kcal/mol) has a slightly better binding affinity than Ligand B (-6.3 kcal/mol), though the difference is not huge.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand A is the stronger candidate. Its lower logP value is a significant advantage, mitigating potential solubility and off-target issues. While both ligands have acceptable ADME properties, Ligand A demonstrates slightly better permeability and solubility, and a slightly better binding affinity. The BBB score is also better for Ligand A.
Output:
1
2025-04-17 22:46:21,501 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (a cardiovascular GPCR) drug candidates.
**Ligand A:** [347.321, 73.34, 2.56, 1, 5, 0.642, 76.58, 87.67, -4.678, -3.172, 0.404, 31.176, 0.463, 0.39, -8.6]
**Ligand B:** [340.387, 97.87, 1.973, 2, 6, 0.74, 75.029, 79.721, -5.206, -2.395, 0.169, 24.817, 12.024, 0.121, -6.4]
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand B (340.387 Da) is slightly lower, which is generally favorable.
2. **TPSA:** Ligand A (73.34) is better than Ligand B (97.87). ADRB2 is not a CNS target, but lower TPSA is still generally preferred for absorption.
3. **logP:** Both are good (between 1-3), but Ligand A (2.56) is slightly higher, potentially offering better membrane permeability.
4. **HBD:** Ligand A (1) is better than Ligand B (2). Lower is preferred.
5. **HBA:** Ligand A (5) is better than Ligand B (6). Lower is preferred.
6. **QED:** Both are acceptable (>=0.5), with Ligand B (0.74) being slightly better.
7. **DILI:** Both are relatively similar and acceptable (around 75-76 percentile), indicating a moderate risk.
8. **BBB:** Ligand A (87.67) is significantly better than Ligand B (79.721). While not a CNS target, higher BBB penetration can sometimes correlate with better overall distribution.
9. **Caco-2:** Ligand B (-5.206) is better than Ligand A (-4.678). Higher Caco-2 permeability indicates better intestinal absorption.
10. **Solubility:** Ligand B (-2.395) is better than Ligand A (-3.172). Better solubility is crucial for bioavailability.
11. **hERG:** Ligand B (0.169) is much better than Ligand A (0.404). Lower hERG inhibition is a significant advantage, reducing cardiotoxicity risk.
12. **Cl_mic:** Ligand B (24.817) is significantly better than Ligand A (31.176). Lower clearance means greater metabolic stability.
13. **t1/2:** Ligand B (12.024) is much better than Ligand A (0.463). A longer half-life is desirable for less frequent dosing.
14. **Pgp:** Ligand A (0.39) is better than Ligand B (0.121). Lower P-gp efflux is favorable.
15. **Affinity:** Ligand A (-8.6 kcal/mol) is *significantly* better than Ligand B (-6.4 kcal/mol). This is a 2.2 kcal/mol difference, which is substantial and can often outweigh minor ADME drawbacks.
**Overall Assessment:**
Ligand A has a much stronger binding affinity, which is the most critical factor for GPCR targets. While Ligand B has better solubility, Caco-2 permeability, hERG, and metabolic stability, the difference in affinity is too large to ignore. The better affinity of Ligand A suggests it will be more potent and potentially require a lower dose, which can mitigate some of the ADME concerns. The slightly higher TPSA and lower solubility of Ligand A are acceptable trade-offs for the significantly improved binding.
Output:
1
2025-04-17 22:46:21,501 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (364.471 and 370.515 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (67.87) is significantly better than Ligand A (91.4). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have acceptable logP values (0.945 and 1.429), falling within the 1-3 range. Ligand B is slightly better.
4. **HBD:** Ligand A has 2 HBD, while Ligand B has 1. Both are acceptable (<=5).
5. **HBA:** Both ligands have 5 HBA, which is within the acceptable range (<=10).
6. **QED:** Ligand A (0.832) has a slightly better QED score than Ligand B (0.766), indicating a more drug-like profile.
7. **DILI:** Ligand B (27.414) has a much lower DILI risk than Ligand A (50.446). This is a significant advantage for Ligand B.
8. **BBB:** Ligand B (65.839) has a higher BBB penetration percentile than Ligand A (34.044). While not critical for a cardiovascular target, it's a slight positive.
9. **Caco-2:** Both ligands have similar, poor Caco-2 permeability (-5.156 and -5.048). This is a concern for both.
10. **Solubility:** Both ligands have very poor aqueous solubility (-1.981 and -2.399). This is a significant drawback for both, potentially impacting bioavailability.
11. **hERG:** Ligand A (0.142) has a lower hERG inhibition liability than Ligand B (0.307), indicating a lower risk of cardiotoxicity. This is a key advantage for Ligand A.
12. **Cl_mic:** Ligand A (-3.613) has a much lower microsomal clearance than Ligand B (19.906), suggesting better metabolic stability. This is a crucial advantage for Ligand A.
13. **t1/2:** Ligand A (13.559 hours) has a shorter in vitro half-life than Ligand B (18.445 hours). This is a slight advantage for Ligand B.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.045 and 0.036).
15. **Binding Affinity:** Ligand B (-7.3 kcal/mol) has a slightly better binding affinity than Ligand A (-7.5 kcal/mol). While the difference is small, it's still a factor.
**GPCR-Specific Priorities & Overall Assessment:**
For a GPCR like ADRB2, logP, TPSA, and affinity are important. Ligand B is better on logP and affinity, and significantly better on TPSA. However, the significantly lower DILI risk and much better metabolic stability (Cl_mic) of Ligand A are very important. The slightly better hERG profile of Ligand A is also a significant benefit for a cardiovascular target. While both have poor solubility and Caco-2 permeability, the metabolic stability and safety profile of Ligand A are more critical for overall drug development success. The small affinity difference is outweighed by the ADME/Tox advantages of Ligand A.
Output:
1
2025-04-17 22:46:21,501 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (343.431 and 346.471 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (90.98) is slightly higher than Ligand B (58.64). Both are below 140, but B is significantly better for permeability, especially given it's a GPCR.
3. **logP:** Both ligands have good logP values (1.956 and 2.924), falling within the 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Ligand A has 2 HBD, and Ligand B has 1. Both are within the acceptable limit of 5.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 3. Both are within the acceptable limit of 10.
6. **QED:** Ligand A (0.839) has a slightly better QED score than Ligand B (0.721), indicating a more drug-like profile.
7. **DILI:** Both ligands have acceptable DILI risk (46.84 and 41.411), both well below the 60 threshold.
8. **BBB:** Ligand B (65.103) has a considerably higher BBB penetration percentile than Ligand A (42.342). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant, and higher BBB is generally favorable.
9. **Caco-2:** Ligand A (-5.027) and Ligand B (-4.704) both have negative Caco-2 values, indicating poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand A (-2.505) and Ligand B (-3.21) both have poor solubility. This is a concern for both.
11. **hERG:** Both ligands have low hERG inhibition liability (0.166 and 0.271), which is excellent.
12. **Cl_mic:** Ligand A (23.348) has a much lower microsomal clearance than Ligand B (93.491). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (0.803) has a very short in vitro half-life, while Ligand B (-17.625) has a negative half-life, which is not physically possible and likely an error. This is a major red flag for Ligand B.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.02 and 0.412).
15. **Binding Affinity:** Ligand B (-6.3 kcal/mol) has a slightly better binding affinity than Ligand A (-5.8 kcal/mol). This is a 0.5 kcal/mol difference, which is significant.
**GPCR-specific priorities:** Considering this is a GPCR target, logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP and affinity, and has a much better TPSA. However, the negative half-life is a critical issue. Ligand A has a better QED and significantly better metabolic stability (lower Cl_mic). The Caco-2 and solubility are poor for both.
**Conclusion:**
Despite Ligand B's slightly better affinity and TPSA, the completely unrealistic negative in vitro half-life is a deal-breaker. Ligand A, while not ideal, presents a more viable starting point due to its better metabolic stability and a reasonable QED score.
Output:
1
2025-04-17 22:46:21,501 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (353.5 & 359.5 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (72.88) is slightly higher than Ligand B (66.32). Both are below the 140 threshold for oral absorption, but closer to the 90 threshold for CNS targets, which is not a primary concern here. Ligand B is slightly favored.
3. **logP:** Ligand A (1.233) is within the optimal 1-3 range. Ligand B (3.348) is at the higher end, potentially raising solubility concerns. Ligand A is favored.
4. **HBD:** Ligand A (2) and Ligand B (1) both meet the <=5 criteria. Ligand B is slightly favored.
5. **HBA:** Ligand A (4) and Ligand B (5) both meet the <=10 criteria. Ligand A is slightly favored.
6. **QED:** Ligand B (0.889) has a better QED score than Ligand A (0.654), indicating a more drug-like profile. Ligand B is favored.
7. **DILI:** Ligand A (4.653) has a significantly lower DILI risk than Ligand B (36.254). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (75.572) has a higher BBB penetration percentile than Ligand A (51.221). While not a primary concern for ADRB2 (cardiovascular target), it's a slight advantage for Ligand B.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.131 and -4.702), which is unusual and suggests poor permeability. This is a significant drawback for both.
10. **Solubility:** Ligand A (-0.718) has a better solubility score than Ligand B (-3.442). Ligand A is favored.
11. **hERG:** Both ligands have low hERG inhibition liability (0.413 and 0.424), which is good. No clear advantage.
12. **Cl_mic:** Ligand A (1.489) has significantly lower microsomal clearance than Ligand B (54.377), indicating better metabolic stability. This is a major advantage for Ligand A.
13. **t1/2:** Ligand B (-4.833) has a longer in vitro half-life than Ligand A (0.326). Ligand B is favored.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.042 and 0.364). No clear advantage.
15. **Binding Affinity:** Ligand B (-6.1 kcal/mol) has a significantly stronger binding affinity than Ligand A (-4.8 kcal/mol). This is a substantial advantage for Ligand B, potentially outweighing some ADME drawbacks.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in affinity and has a reasonable logP and Pgp profile. Ligand A has better solubility and a much better safety profile (DILI, Cl_mic). The affinity difference is significant (1.3 kcal/mol).
**Overall Assessment:**
While Ligand A has a better safety profile and solubility, the significantly stronger binding affinity of Ligand B (-6.1 vs -4.8 kcal/mol) is a critical advantage for a GPCR target. The improved QED and half-life of Ligand B are also beneficial. The higher logP and DILI risk are concerns, but the potency advantage is likely to outweigh these.
Output:
0
2025-04-17 22:46:21,501 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (a cardiovascular GPCR) drug candidates.
**Ligand A:** [377.507, 79.39, -0.536, 0, 6, 0.565, 27.336, 63.086, -4.651, -1.324, 0.579, 32.215, -46.56, 0.007, -5.3]
**Ligand B:** [357.483, 64.34, 3.876, 1, 7, 0.751, 84.335, 69.252, -4.928, -3.806, 0.759, 48.176, 20.024, 0.701, -7.4]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity) and general drug-like properties:
1. **MW:** Both are within the ideal 200-500 Da range. Ligand B (357.483) is slightly lower, which is generally favorable.
2. **TPSA:** Ligand A (79.39) is better than Ligand B (64.34), being closer to the <140 threshold.
3. **logP:** Ligand A (-0.536) is significantly lower than Ligand B (3.876). Ligand B is within the optimal 1-3 range, while Ligand A is below 1, potentially hindering permeability. This is a significant drawback for Ligand A.
4. **HBD:** Ligand A (0) is preferable to Ligand B (1). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (6) is preferable to Ligand B (7). Fewer HBAs generally improve permeability.
6. **QED:** Both are good (A: 0.565, B: 0.751), indicating reasonable drug-likeness. Ligand B is slightly better.
7. **DILI:** Ligand A (27.336) is *much* better than Ligand B (84.335). This is a major advantage for Ligand A.
8. **BBB:** Both are reasonably good (A: 63.086, B: 69.252), but not exceptionally high. For a cardiovascular target, BBB isn't a primary concern, but higher is still slightly better.
9. **Caco-2:** Both are negative, indicating poor permeability.
10. **Solubility:** Both are negative, indicating poor solubility.
11. **hERG:** Both are low, indicating low risk of hERG inhibition.
12. **Cl_mic:** Ligand A (32.215) has lower clearance than Ligand B (48.176), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-46.56) has a negative half-life, which is concerning, while Ligand B (20.024) is positive.
14. **Pgp:** Ligand A (0.007) is *much* lower than Ligand B (0.701), indicating significantly less P-gp efflux. This is a major advantage for Ligand A, improving bioavailability.
15. **Affinity:** Ligand B (-7.4) has a significantly stronger binding affinity than Ligand A (-5.3). A 2.1 kcal/mol difference is substantial and can often outweigh other drawbacks.
**Overall Assessment:**
Ligand B has a significantly better binding affinity, which is a critical factor for GPCRs. However, it suffers from a high DILI risk and higher P-gp efflux. Ligand A has a much lower DILI risk and P-gp efflux, better metabolic stability, and fewer H-bonds, but its logP is too low and its half-life is negative.
Given the importance of potency for GPCRs, and the substantial affinity difference, I believe Ligand B is the more promising candidate *despite* its higher DILI and P-gp efflux. These issues could potentially be addressed through further optimization, but a strong starting affinity is harder to achieve.
Output:
0
2025-04-17 22:46:21,501 - INFO - Batch 356 complete. Total preferences: 5696
2025-04-17 22:46:21,501 - INFO - Processing batch 357/512...
2025-04-17 22:47:12,724 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [355.463, 57.01, 4.472, 0, 6, 0.587, 81.311, 50.679, -5.006, -5.436, 0.358, 110.419, 4.804, 0.446, -5.7]
**Ligand B:** [349.391, 96.77, -1.002, 1, 6, 0.703, 57.076, 53.432, -4.753, -1.39, 0.042, -9.767, -3.92, 0.012, -7.3]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (349.391) is slightly lower, which is generally favorable.
2. **TPSA:** Ligand A (57.01) is significantly better than Ligand B (96.77). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally aids absorption.
3. **logP:** Ligand A (4.472) is a bit high, potentially leading to off-target effects and solubility issues. Ligand B (-1.002) is too low, which could hinder membrane permeability.
4. **HBD:** Ligand A (0) is preferable to Ligand B (1). Fewer HBDs generally improve permeability.
5. **HBA:** Both have 6 HBA, which is acceptable.
6. **QED:** Ligand B (0.703) has a slightly better QED score than Ligand A (0.587), indicating a more drug-like profile.
7. **DILI:** Ligand B (57.076) has a significantly lower DILI risk than Ligand A (81.311). This is a major advantage for Ligand B.
8. **BBB:** Both are moderate, but Ligand B (53.432) is slightly better than Ligand A (50.679). Not a huge factor for a cardiovascular target.
9. **Caco-2:** Both have negative values, indicating poor permeability. Ligand A (-5.006) is slightly worse than Ligand B (-4.753).
10. **Solubility:** Ligand B (-1.39) is better than Ligand A (-5.436). Solubility is a concern for both, but less so for Ligand B.
11. **hERG:** Ligand A (0.358) has a lower hERG risk than Ligand B (0.042), which is a significant advantage.
12. **Cl_mic:** Ligand B (-9.767) has much lower microsomal clearance, indicating better metabolic stability, which is a significant advantage.
13. **t1/2:** Ligand B (-3.92) has a longer in vitro half-life than Ligand A (4.804), which is also a significant advantage.
14. **Pgp:** Ligand B (0.012) has lower P-gp efflux, which is preferable. Ligand A (0.446) has higher efflux.
15. **Affinity:** Ligand B (-7.3) has a stronger binding affinity than Ligand A (-5.7). This is a substantial advantage, potentially outweighing some of the ADME concerns.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. While Ligand A has a better hERG profile, Ligand B excels in affinity, metabolic stability (Cl_mic, t1/2), Pgp efflux, and DILI risk. The stronger binding affinity of Ligand B is a significant driver. The lower logP of Ligand B is concerning, but the overall balance of properties is more favorable.
**Conclusion:**
Considering the balance of properties, particularly the superior binding affinity, metabolic stability, and lower DILI risk of Ligand B, it is the more promising drug candidate.
0
2025-04-17 22:47:12,724 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [348.374, 78.87, 1.287, 2, 4, 0.575, 35.324, 56.611, -4.637, -2.152, 0.411, -1.527, 18.332, 0.091, -7.2]
**Ligand B:** [357.451, 102.34, -1.055, 3, 6, 0.512, 10.896, 28.693, -5.108, -0.298, 0.066, 9.853, -8.588, 0.007, -8.5]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (348.374) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (78.87) is significantly better than Ligand B (102.34). For a GPCR, keeping TPSA under 140 is good, but lower is better for permeability. Ligand A is much closer to the ideal range for good oral absorption.
3. **logP:** Ligand A (1.287) is within the optimal range (1-3), while Ligand B (-1.055) is below 1. This is a significant drawback for Ligand B, potentially hindering membrane permeability.
4. **HBD:** Both are acceptable (Ligand A: 2, Ligand B: 3), within the guideline of <=5.
5. **HBA:** Both are acceptable (Ligand A: 4, Ligand B: 6), within the guideline of <=10.
6. **QED:** Both are good (Ligand A: 0.575, Ligand B: 0.512), indicating a reasonable drug-like profile.
7. **DILI:** Ligand A (35.324) has a much lower DILI risk than Ligand B (10.896). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (56.611) has better BBB penetration potential than Ligand B (28.693), although neither is exceptionally high. For a cardiovascular target, BBB penetration isn't *critical* but can be beneficial for off-target effects.
9. **Caco-2:** Ligand A (-4.637) is better than Ligand B (-5.108), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-2.152) is better than Ligand B (-0.298). Solubility is important for formulation and bioavailability.
11. **hERG:** Ligand A (0.411) has a lower hERG risk than Ligand B (0.066), which is a significant safety advantage.
12. **Cl_mic:** Ligand A (-1.527) has lower microsomal clearance, suggesting better metabolic stability. Ligand B (9.853) has a high clearance.
13. **t1/2:** Ligand A (18.332) has a longer in vitro half-life than Ligand B (-8.588).
14. **Pgp:** Ligand A (0.091) has lower P-gp efflux liability than Ligand B (0.007).
15. **Affinity:** Ligand B (-8.5 kcal/mol) has a slightly better binding affinity than Ligand A (-7.2 kcal/mol). This is a 1.3 kcal/mol difference, which is a reasonable advantage.
**Overall Assessment:**
While Ligand B has a slightly better binding affinity, Ligand A is significantly superior in almost all ADME-Tox properties. The lower logP and higher TPSA of Ligand B are concerning for permeability and oral absorption. Ligand A's better DILI score, hERG risk, metabolic stability, solubility, and P-gp efflux profile make it a much more promising drug candidate. The affinity difference is not large enough to overcome these substantial ADME advantages. Given the GPCR target class, balancing permeability (TPSA, logP) and safety (DILI, hERG) are crucial.
Output:
1
2025-04-17 22:47:12,724 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
The ADRB2 receptor is a GPCR, so the key priorities are logP, TPSA, Pgp efflux, BBB penetration (though less critical for peripheral ADRB2), and binding affinity. We also need to consider general drug-like properties and safety parameters.
* **Molecular Weight:** Both ligands (360.336 and 353.419 Da) fall within the ideal 200-500 Da range.
* **TPSA:** Ligand A (85.77) is better than Ligand B (104.89). Lower TPSA generally correlates with better cell permeability. Ligand A is comfortably under the 140 A^2 threshold.
* **logP:** Ligand B (0.318) is slightly better than Ligand A (-0.123) being closer to the optimal 1-3 range. However, A is not drastically outside the acceptable range.
* **H-Bond Donors/Acceptors:** Both ligands have 2 HBDs, which is good. Ligand B has 7 HBAs, while Ligand A has 5. Both are within acceptable limits.
* **QED:** Ligand A (0.782) has a significantly better QED score than Ligand B (0.587), indicating a more drug-like profile.
* **DILI:** Ligand B (38.542) has a lower DILI risk than Ligand A (47.344), which is a positive.
* **BBB:** Ligand A (63.358) has a much better BBB percentile than Ligand B (25.242). While ADRB2 isn't necessarily a CNS target, some peripheral exposure can be beneficial.
* **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests very poor permeability.
* **Aqueous Solubility:** Both ligands have negative solubility values, which is also unusual and suggests very poor solubility.
* **hERG:** Both ligands have very low hERG inhibition liability, which is good.
* **Microsomal Clearance:** Ligand A (-16.484) has a much lower (better) microsomal clearance than Ligand B (-3.711). This suggests better metabolic stability.
* **In vitro Half-Life:** Ligand B (33.859 hours) has a significantly longer half-life than Ligand A (-8.589 hours). This is a major advantage.
* **P-gp Efflux:** Ligand A (0.03) has a slightly lower P-gp efflux liability than Ligand B (0.05), which is favorable.
* **Binding Affinity:** Ligand B (-6.8 kcal/mol) has a significantly better binding affinity than Ligand A (-2.1 kcal/mol). This is a crucial difference.
**Overall Assessment:**
The binding affinity of Ligand B is substantially stronger. This is the most important factor for a GPCR target. While Ligand A has better QED, TPSA, and metabolic stability, the difference in binding affinity outweighs these advantages. The longer half-life of Ligand B is also a significant benefit. The poor Caco-2 and solubility values are concerning for both, but can be addressed with formulation strategies.
**Output:**
0
2025-04-17 22:47:12,724 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (345.414 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (47.56) is significantly better than Ligand B (76.58). ADRB2 is not a CNS target, but lower TPSA generally improves absorption.
3. **logP:** Both ligands have acceptable logP values (A: 4.007, B: 2.576), falling within the 1-3 range. Ligand B is slightly better, being closer to the optimal range.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 4 HBA, while Ligand B has 7. Ligand A is preferable here.
6. **QED:** Both are reasonably good (A: 0.804, B: 0.724), exceeding the 0.5 threshold.
7. **DILI:** Both have elevated DILI risk (A: 49.981, B: 60.954), but are still below the concerning 60 threshold. Ligand A is slightly better.
8. **BBB:** Not a primary concern for ADRB2 (cardiovascular target). Ligand B has a higher BBB percentile (79.217) than Ligand A (60.644).
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.295) is slightly better than Ligand B (-4.782).
10. **Solubility:** Both have negative solubility values, indicating poor aqueous solubility. Ligand B (-2.355) is slightly better than Ligand A (-5.495).
11. **hERG:** Both have low hERG inhibition liability (A: 0.777, B: 0.754).
12. **Cl_mic:** Ligand B (66.949) has significantly lower microsomal clearance than Ligand A (115.451), suggesting better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand B (63.228) has a much longer in vitro half-life than Ligand A (5.353), which is highly desirable.
14. **Pgp:** Both have low Pgp efflux liability (A: 0.213, B: 0.314).
15. **Binding Affinity:** Ligand A (-7.4 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.7 kcal/mol). This is a substantial advantage, exceeding the 1.5 kcal/mol difference threshold.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A excels in affinity and TPSA, while Ligand B has a slightly better logP and metabolic stability (Cl_mic and t1/2). However, the substantial difference in binding affinity (-7.4 vs -6.7) outweighs the benefits of Ligand B's slightly improved metabolic properties. The poor Caco-2 and solubility for both are concerning, but can be addressed with formulation strategies.
**Conclusion:**
Considering the balance of properties and the importance of binding affinity for GPCR targets, Ligand A is the more promising drug candidate.
Output:
1
2025-04-17 22:47:12,724 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [346.431, 72.65, 2.345, 1, 7, 0.708, 38.193, 80.962, -5.073, -2.104, 0.684, 13.018, 5.276, 0.092, -6.5]**
**Ligand B: [361.833, 88.91, 1.773, 2, 5, 0.849, 79.992, 43.893, -5.403, -2.939, 0.035, 1.891, 27.161, 0.102, -5.5]**
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (346.431) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (72.65) is better than Ligand B (88.91). Both are below 140, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (Ligand A: 2.345, Ligand B: 1.773), falling within the optimal 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability.
4. **H-Bond Donors:** Ligand A (1) is better than Ligand B (2). Lower is preferred.
5. **H-Bond Acceptors:** Ligand A (7) is better than Ligand B (5). Lower is preferred.
6. **QED:** Both ligands have good QED scores (Ligand A: 0.708, Ligand B: 0.849), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (38.193) is significantly better than Ligand B (79.992). This is a major advantage for Ligand A. Lower DILI risk is crucial.
8. **BBB:** Ligand A (80.962) is significantly better than Ligand B (43.893). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant, and higher BBB is generally desirable.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand B (-5.403) is slightly worse than Ligand A (-5.073).
10. **Aqueous Solubility:** Both are negative, indicating poor solubility. Ligand B (-2.939) is worse than Ligand A (-2.104).
11. **hERG:** Ligand A (0.684) is better than Ligand B (0.035). Lower hERG inhibition is critical for avoiding cardiotoxicity, a major concern for cardiovascular targets.
12. **Cl_mic:** Ligand B (1.891) is much better than Ligand A (13.018). Lower clearance indicates better metabolic stability.
13. **t1/2:** Ligand B (27.161) is significantly better than Ligand A (5.276). Longer half-life is generally preferred.
14. **Pgp:** Both are low, indicating minimal P-gp efflux. Ligand B (0.102) is slightly higher than Ligand A (0.092).
15. **Binding Affinity:** Ligand A (-6.5) is slightly better than Ligand B (-5.5). A 1 kcal/mol difference is significant.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), and the general drug-like properties, Ligand A is the stronger candidate. While Ligand B has better metabolic stability (Cl_mic and t1/2) and a slightly better QED, Ligand A excels in crucial areas like DILI risk, hERG inhibition, BBB penetration, and binding affinity. The lower DILI and hERG risks are particularly important for a cardiovascular target. The slightly better affinity of Ligand A also helps to offset the metabolic liabilities.
Output:
1
2025-04-17 22:47:12,725 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor (a GPCR).
**Ligand A:** [344.459, 86.88, 2.157, 3, 3, 0.523, 34.742, 62.233, -5.656, -2.013, 0.311, 29.615, 6.423, 0.248, -6.9]
**Ligand B:** [347.503, 61.44, 2.515, 2, 3, 0.549, 11.361, 76.231, -5.219, -2.187, 0.449, 16.32, -3.638, 0.099, -7.2]
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (344.459) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (86.88) is higher than Ligand B (61.44). Both are acceptable, but Ligand B is better, being closer to the <90 target for GPCRs.
3. **logP:** Both are within the optimal range (1-3). Ligand B (2.515) is slightly higher, which could potentially lead to some off-target interactions, but isn't a major concern.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (2). Both are within the acceptable limit of 5.
5. **HBA:** Both ligands have 3 HBA, which is good.
6. **QED:** Both ligands have good QED scores (A: 0.523, B: 0.549), indicating good drug-like properties.
7. **DILI:** Ligand B (11.361) has a significantly lower DILI risk than Ligand A (34.742). This is a major advantage for Ligand B.
8. **BBB:** Ligand B (76.231) has a higher BBB penetration score than Ligand A (62.233). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be beneficial or at least avoided as a toxicity concern.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Both have negative solubility scores, which is also unusual and suggests poor solubility. Again, the scale is not specified.
11. **hERG:** Both have low hERG inhibition liability (A: 0.311, B: 0.449), which is good.
12. **Cl_mic:** Ligand B (16.32) has a significantly lower microsomal clearance than Ligand A (29.615), indicating better metabolic stability.
13. **t1/2:** Ligand A (6.423) has a longer in vitro half-life than Ligand B (-3.638). This is a positive for Ligand A.
14. **Pgp:** Ligand A (0.248) has lower P-gp efflux liability than Ligand B (0.099), suggesting better oral bioavailability and potentially better CNS exposure.
15. **Affinity:** Ligand B (-7.2) has a slightly better binding affinity than Ligand A (-6.9). While the difference is small (0.3 kcal/mol), it's still a benefit.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, we prioritize logP, TPSA, Pgp, and affinity. Ligand B is better in terms of TPSA and Pgp. Affinity is slightly better for Ligand B. The biggest advantage for Ligand B is the significantly lower DILI risk and improved metabolic stability (lower Cl_mic). While Ligand A has a better half-life, the other factors weigh more heavily in favor of Ligand B.
**Conclusion:**
Considering the balance of properties and the GPCR-specific priorities, Ligand B is the more promising drug candidate.
0
2025-04-17 22:47:12,725 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [378.451, 133.91 , -2.206, 3. , 7. , 0.387, 41.838, 35.401, -5.507, -1.347, 0.032, 44.321, -51.506, 0.004, -7.4 ]
**Ligand B:** [376.469, 49.85 , 2.003, 0. , 4. , 0.756, 35.595, 90.772, -4.567, -3.121, 0.449, 18.526, -25.399, 0.116, -6.2 ]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal range (200-500 Da). A is 378.451, B is 376.469 - very similar.
2. **TPSA:** Ligand A (133.91) is slightly above the preferred <140 for oral absorption, but acceptable. Ligand B (49.85) is excellent, well below 140. This favors B.
3. **logP:** Ligand A (-2.206) is too low, potentially hindering membrane permeability. Ligand B (2.003) is within the optimal 1-3 range. This is a significant advantage for B.
4. **HBD:** Ligand A (3) is acceptable. Ligand B (0) is also good.
5. **HBA:** Ligand A (7) is acceptable. Ligand B (4) is also good.
6. **QED:** Ligand B (0.756) is better than Ligand A (0.387), indicating a more drug-like profile.
7. **DILI:** Both are reasonably good, with Ligand A (41.838) slightly higher than Ligand B (35.595), but both are below the concerning 60% threshold.
8. **BBB:** Ligand B (90.772) has excellent BBB penetration, while Ligand A (35.401) is lower. While not *essential* for a cardiovascular target, better BBB penetration can reduce off-target effects.
9. **Caco-2:** Ligand A (-5.507) is very poor, suggesting poor absorption. Ligand B (-4.567) is also poor, but slightly better.
10. **Solubility:** Ligand A (-1.347) is poor. Ligand B (-3.121) is also poor. Both will likely require formulation strategies.
11. **hERG:** Ligand A (0.032) is very low risk, excellent. Ligand B (0.449) is a bit higher, but still relatively low.
12. **Cl_mic:** Ligand B (18.526) has significantly lower microsomal clearance, indicating better metabolic stability, which is desirable. Ligand A (44.321) is higher.
13. **t1/2:** Ligand B (-25.399) has a longer in vitro half-life, which is favorable. Ligand A (-51.506) is shorter.
14. **Pgp:** Ligand A (0.004) has very low P-gp efflux, which is excellent. Ligand B (0.116) is slightly higher, but still reasonable.
15. **Affinity:** Ligand A (-7.4) has a slightly better binding affinity than Ligand B (-6.2), a difference of 1.2 kcal/mol.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity, the significant drawbacks in logP, Caco-2 permeability, and metabolic stability (Cl_mic) are concerning. Ligand B excels in several key areas for a GPCR target: optimal logP, excellent TPSA, good QED, very good BBB penetration, superior metabolic stability, and a longer half-life. The slightly weaker affinity is likely surmountable with further optimization, whereas fixing the poor ADME properties of Ligand A would be a much larger undertaking.
Therefore, I prefer Ligand B.
0
2025-04-17 22:47:12,725 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (341.43 Da) and Ligand B (353.419 Da) both fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (54.02) is excellent, well below the 140 threshold and very favorable for oral absorption. Ligand B (105.76) is higher, but still acceptable, though less optimal.
3. **logP:** Ligand A (4.26) is slightly high, potentially leading to solubility issues or off-target interactions. Ligand B (-0.647) is quite low, which could hinder membrane permeability.
4. **HBD:** Both Ligand A (2) and Ligand B (3) are within the acceptable limit of 5.
5. **HBA:** Ligand A (2) is good. Ligand B (5) is also acceptable, but higher.
6. **QED:** Ligand A (0.854) is excellent, indicating a highly drug-like profile. Ligand B (0.478) is below the 0.5 threshold, suggesting potential issues.
7. **DILI:** Both Ligand A (26.406) and Ligand B (26.173) have very similar and low DILI risk, both well below the 40% threshold.
8. **BBB:** Ligand A (79.76) shows good BBB penetration, while Ligand B (60.644) is lower. Considering ADRB2 is a GPCR, BBB penetration is a positive attribute, though not essential for all subtypes/indications.
9. **Caco-2:** Ligand A (-4.676) is very poor, indicating poor intestinal absorption. Ligand B (-5.368) is also poor, but slightly better than A.
10. **Solubility:** Ligand A (-4.23) is very poor. Ligand B (-1.297) is better, but still not great.
11. **hERG:** Ligand A (0.594) is a low risk. Ligand B (0.06) is very low risk.
12. **Cl_mic:** Ligand A (37.175) has a higher clearance than Ligand B (20.886), indicating lower metabolic stability.
13. **t1/2:** Ligand A (26.128) has a longer half-life than Ligand B (1.426).
14. **Pgp:** Ligand A (0.136) has lower P-gp efflux liability than Ligand B (0.003), which is favorable.
15. **Affinity:** Ligand A (-7.5 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.4 kcal/mol). This 1.1 kcal/mol difference is substantial and can often outweigh other drawbacks.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A has a higher logP, but its superior affinity and better TPSA are significant advantages. The better BBB penetration of Ligand A is also a plus. Ligand B has a lower logP, but suffers from a significantly weaker binding affinity and lower QED.
**Overall Assessment:**
Despite the higher logP and poor Caco-2/Solubility of Ligand A, its substantially stronger binding affinity (-7.5 vs -6.4 kcal/mol) and better QED, BBB, and Pgp profile make it the more promising candidate. The affinity difference is large enough to potentially overcome the solubility/permeability challenges through formulation strategies.
Output:
1
2025-04-17 22:47:12,725 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**1. Molecular Weight:** Both ligands are within the acceptable range (200-500 Da). Ligand A (346.383 Da) is slightly preferred due to being lower in MW.
**2. TPSA:** Ligand A (88.85) is excellent, well below the 140 threshold for oral absorption and suitable for a GPCR. Ligand B (118.8) is still reasonable, but less optimal.
**3. logP:** Both ligands have good logP values (A: 1.711, B: 0.842) falling within the 1-3 range. Ligand A is slightly better.
**4. H-Bond Donors:** Ligand A (1) is preferred over Ligand B (2) as lower HBD generally improves permeability.
**5. H-Bond Acceptors:** Both ligands have 5 HBA, which is acceptable.
**6. QED:** Both ligands have reasonable QED scores (A: 0.792, B: 0.676), indicating good drug-like properties. Ligand A is slightly better.
**7. DILI Risk:** Both ligands have elevated DILI risk (A: 59.984, B: 69.678). Ligand A is preferred due to the lower percentile.
**8. BBB Penetration:** Both ligands show moderate BBB penetration (A: 50.523, B: 63.086). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant for off-target effects. Ligand B is slightly better here.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand B (-5.073) is slightly better than Ligand A (-4.384).
**10. Aqueous Solubility:** Both ligands have very poor aqueous solubility (-2.509 and -2.536). This is a significant drawback for both, and will require formulation strategies.
**11. hERG Inhibition:** Ligand A (0.032) has a much lower hERG risk than Ligand B (0.233), which is a critical advantage for cardiovascular targets.
**12. Microsomal Clearance:** Ligand B (35.318) has significantly lower microsomal clearance than Ligand A (62.831), suggesting better metabolic stability.
**13. In vitro Half-Life:** Ligand B (-23.057) has a negative half-life, which is concerning. Ligand A (18.745) is much better.
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (A: 0.02, B: 0.063).
**15. Binding Affinity:** Both ligands have very similar and strong binding affinities (A: -6.7 kcal/mol, B: -6.0 kcal/mol). The difference of 0.7 kcal/mol isn't substantial enough to override other factors.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand A is the better candidate. While both have solubility issues, Ligand A has a significantly better safety profile (lower DILI and *much* lower hERG risk), better TPSA, and a more reasonable half-life. The slightly better metabolic stability of Ligand B is outweighed by its higher hERG risk and negative half-life.
Output:
1
2025-04-17 22:47:12,725 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, logP, TPSA, Pgp efflux, BBB penetration, and binding affinity are key.
* **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (350.5) is slightly higher than Ligand B (337.3), but both are acceptable.
* **TPSA:** Ligand A (58.64) is significantly better than Ligand B (98.06). Lower TPSA generally correlates with better cell permeability, crucial for GPCR targeting.
* **logP:** Both ligands have good logP values (A: 2.925, B: 1.375) within the optimal range of 1-3. Ligand A is slightly more lipophilic, which could be beneficial for membrane permeability, but not excessively so.
* **H-Bond Donors/Acceptors:** Both have acceptable HBD (1) and Ligand A has 3 HBA, while Ligand B has 7. Ligand A is preferable here.
* **QED:** Both ligands have reasonable QED scores (A: 0.487, B: 0.755), indicating a moderate level of drug-likeness. Ligand B is better here.
* **DILI Risk:** Ligand B (94.765) has a substantially higher DILI risk than Ligand A (12.02). This is a major concern.
* **BBB Penetration:** Ligand A (69.4) has better BBB penetration than Ligand B (60.993). While not a primary concern for a cardiovascular target, it's a slight advantage.
* **Caco-2 Permeability:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
* **Aqueous Solubility:** Both have negative solubility values, again, making interpretation difficult without knowing the scale.
* **hERG Inhibition:** Ligand A (0.637) has a slightly higher hERG risk than Ligand B (0.182).
* **Microsomal Clearance:** Ligand A (82.779) has higher microsomal clearance than Ligand B (15.738), indicating faster metabolism and potentially lower bioavailability. This is a negative for Ligand A.
* **In vitro Half-Life:** Ligand B (-0.745) has a slightly longer half-life than Ligand A (-4.759).
* **P-gp Efflux:** Ligand A (0.205) has lower P-gp efflux liability than Ligand B (0.027), which is favorable.
* **Binding Affinity:** Ligand B (-7.5 kcal/mol) has a slightly better binding affinity than Ligand A (-6.9 kcal/mol). This is a 1.6 kcal/mol difference, which is significant.
**Overall Assessment:**
Ligand B has a better binding affinity and QED, but suffers from a very high DILI risk and faster metabolism. Ligand A has a much lower DILI risk, better TPSA, and lower P-gp efflux, but has a slightly weaker binding affinity and higher metabolic clearance. Given the importance of avoiding liver toxicity, and the acceptable affinity of Ligand A, I favor Ligand A. The difference in binding affinity (1.6 kcal/mol) is not large enough to overcome the significant DILI risk associated with Ligand B.
**Output:**
1
2025-04-17 22:47:12,725 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (371.5 and 348.4 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (87.54) is slightly higher than Ligand B (67.87). Both are below the 140 threshold for oral absorption, but B is better, especially considering ADRB2 isn't necessarily a CNS target where <90 is critical.
3. **logP:** Both ligands have good logP values (0.955 and 1.32), falling within the optimal 1-3 range. Ligand B is slightly more favorable.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 5 HBA, and Ligand B has 4. Both are acceptable (<=10).
6. **QED:** Ligand A (0.755) has a significantly better QED score than Ligand B (0.388), indicating a more drug-like profile. This is a substantial advantage for A.
7. **DILI:** Ligand A (35.052) has a much lower DILI risk than Ligand B (17.449), indicating better predicted liver safety. This is a major advantage for A.
8. **BBB:** Ligand A (75.107) has a higher BBB penetration percentile than Ligand B (57.619). While ADRB2 isn't strictly a CNS target, some CNS exposure can contribute to side effects, and better control is preferable.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Both ligands have poor solubility (-1.686 and -1.927). This is a concern for both, but not a deciding factor.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.319 and 0.192). This is excellent for both.
12. **Cl_mic:** Ligand A (19.037) has a higher microsomal clearance than Ligand B (14.138), suggesting faster metabolism. This is a disadvantage for A.
13. **t1/2:** Ligand B (4.265) has a slightly better in vitro half-life than Ligand A (-55.624). This is a disadvantage for A.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.021 and 0.045). This is good for both.
15. **Binding Affinity:** Ligand A (-6.9 kcal/mol) has a slightly better binding affinity than Ligand B (-5.7 kcal/mol). This difference of 1.2 kcal/mol is significant and can outweigh some ADME drawbacks.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Both ligands perform well on logP and Pgp. Ligand B has better TPSA. However, Ligand A has a significantly better QED, DILI, and binding affinity.
**Overall Assessment:**
Despite Ligand A having higher Cl_mic and a negative t1/2, its superior QED, significantly lower DILI risk, slightly better BBB, and notably stronger binding affinity outweigh these drawbacks. The binding affinity difference is substantial. The solubility is a concern for both, but can be addressed with formulation strategies.
Output:
1
2025-04-17 22:47:12,725 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [353.419, 79.39, -0.526, 0, 5, 0.621, 36.293, 58.782, -4.776, -0.613, 0.168, 0.97, 16.801, 0.014, -6.5]
**Ligand B:** [365.459, 105.12, -0.342, 3, 6, 0.584, 47.77, 49.011, -6.13, -2.205, 0.016, -10.558, 10.68, 0.01, -6.9]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, Affinity):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (353.419) is slightly lower, which is generally favorable.
2. **TPSA:** Ligand A (79.39) is better than Ligand B (105.12). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA is still generally preferred for good absorption.
3. **logP:** Ligand A (-0.526) is a bit low, while Ligand B (-0.342) is also on the lower side. Both are below the optimal 1-3 range, but Ligand B is slightly better.
4. **HBD/HBA:** Ligand A (0 HBD, 5 HBA) is better than Ligand B (3 HBD, 6 HBA). Fewer H-bonds are generally better for permeability.
5. **QED:** Both are acceptable (A: 0.621, B: 0.584), above the 0.5 threshold.
6. **DILI:** Ligand A (36.293) has a significantly lower DILI risk than Ligand B (47.77). This is a major advantage.
7. **BBB:** Not a primary concern for a cardiovascular target, but Ligand A (58.782) is slightly better than Ligand B (49.011).
8. **Caco-2:** Ligand B (-6.13) is better than Ligand A (-4.776), indicating better intestinal absorption.
9. **Solubility:** Ligand B (-2.205) is better than Ligand A (-0.613).
10. **hERG:** Both are very low (A: 0.168, B: 0.016), indicating minimal cardiotoxicity risk.
11. **Cl_mic:** Ligand A (0.97) has a much lower microsomal clearance than Ligand B (-10.558), suggesting better metabolic stability.
12. **t1/2:** Ligand A (16.801) has a longer half-life than Ligand B (10.68).
13. **Pgp:** Both are very low (A: 0.014, B: 0.01), indicating minimal P-glycoprotein efflux.
14. **Affinity:** Ligand B (-6.9) has a slightly better binding affinity than Ligand A (-6.5), a 0.4 kcal/mol difference.
**Overall Assessment:**
While Ligand B has a slightly better binding affinity and Caco-2 permeability, Ligand A demonstrates a significantly better safety profile (lower DILI), superior metabolic stability (lower Cl_mic, longer t1/2), and a more favorable TPSA/HBD/HBA profile. The 0.4 kcal/mol difference in affinity is not substantial enough to outweigh the ADME/Tox advantages of Ligand A, especially considering the target is a cardiovascular GPCR where CNS penetration is not critical.
Therefore, I would choose Ligand A.
Output:
1
2025-04-17 22:47:12,725 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (403.555 Da) is within the ideal range (200-500 Da). Ligand B (355.435 Da) is also within the ideal range. No clear advantage here.
2. **TPSA:** Ligand A (87.54) is good, below the 140 threshold for oral absorption. Ligand B (107.97) is still acceptable but higher. Ligand A is slightly favored.
3. **logP:** Ligand A (-0.375) is a bit low, potentially impacting permeability. Ligand B (-0.042) is better, falling within the optimal 1-3 range. Ligand B is favored.
4. **HBD:** Ligand A (1) is good. Ligand B (3) is acceptable, but higher. Ligand A is favored.
5. **HBA:** Ligand A (8) is good. Ligand B (5) is also good. No clear advantage.
6. **QED:** Ligand A (0.736) is excellent, indicating strong drug-likeness. Ligand B (0.538) is acceptable, but lower. Ligand A is favored.
7. **DILI:** Ligand A (74.68) is higher risk. Ligand B (29.779) is very low risk. Ligand B is strongly favored.
8. **BBB:** Both Ligand A (31.756) and Ligand B (33.23) have low BBB penetration. Since ADRB2 is a cardiovascular target, BBB penetration is not a high priority.
9. **Caco-2:** Both Ligand A (-5.529) and Ligand B (-5.782) have negative Caco-2 values, which is unusual and suggests poor permeability. However, this is a scale and the negative values could be relative to a reference.
10. **Solubility:** Ligand A (-3.191) and Ligand B (-0.944) both have negative solubility values, indicating poor solubility. Ligand B is slightly better.
11. **hERG:** Ligand A (0.079) has very low hERG risk. Ligand B (0.109) also has low hERG risk. No clear advantage.
12. **Cl_mic:** Ligand A (42.913) has moderate clearance. Ligand B (-11.704) has negative clearance, which is not possible. This is likely an error in the data.
13. **t1/2:** Ligand A (1.05) has a short half-life. Ligand B (-1.67) has a negative half-life, which is impossible. This is likely an error in the data.
14. **Pgp:** Ligand A (0.03) has low P-gp efflux. Ligand B (0.013) also has low P-gp efflux. No clear advantage.
15. **Binding Affinity:** Ligand A (-7.7) has a significantly stronger binding affinity than Ligand B (-6.7), a difference of 1.0 kcal/mol. This is a substantial advantage.
**Overall Assessment:**
Ligand A has a better QED score, lower HBD, and significantly better binding affinity. However, Ligand B has a much lower DILI risk and a slightly better logP. The negative values for Caco-2, solubility, and half-life for Ligand B are concerning and likely data errors. The strong binding affinity of Ligand A is a major advantage for a GPCR target like ADRB2, and can often outweigh minor ADME concerns. The DILI risk for Ligand A is the biggest drawback, but could be addressed through further structural modifications.
Given the importance of potency for GPCRs, and the substantial difference in binding affinity, I favor Ligand A.
Output:
1
2025-04-17 22:47:12,726 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [342.378, 67.98, 2.624, 1, 5, 0.792, 75.262, 78.868, -4.853, -3.353, 0.429, 36.977, 19.588, 0.155, -7.0]
**Ligand B:** [342.359, 117.01, 0.757, 2, 6, 0.775, 73.401, 44.436, -5.398, -2.837, 0.026, 14.407, -29.256, 0.016, -6.5]
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (around 342 Da). No significant difference.
2. **TPSA:** Ligand A (67.98) is significantly better than Ligand B (117.01). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally aids absorption. Ligand A is well below the 140 threshold, while B is approaching it.
3. **logP:** Ligand A (2.624) is optimal, while Ligand B (0.757) is a bit low. A logP below 1 can hinder permeation.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (5) is better than Ligand B (6). Similar reasoning as HBD.
6. **QED:** Both are good (0.792 and 0.775), indicating drug-like properties. No major difference.
7. **DILI:** Both have acceptable DILI risk (75.262 and 73.401), both below the 80% threshold.
8. **BBB:** Ligand A (78.868) is much better than Ligand B (44.436). While not critical for a cardiovascular target, higher BBB penetration can sometimes indicate better overall permeability and distribution.
9. **Caco-2:** Ligand A (-4.853) is better than Ligand B (-5.398). Higher (less negative) values are better.
10. **Solubility:** Ligand A (-3.353) is better than Ligand B (-2.837). Higher (less negative) values are better.
11. **hERG:** Ligand A (0.429) is better than Ligand B (0.026). Lower hERG risk is crucial.
12. **Cl_mic:** Ligand A (36.977) is better than Ligand B (14.407). Lower clearance is preferred for metabolic stability.
13. **t1/2:** Ligand A (19.588) is much better than Ligand B (-29.256). A longer half-life is generally desirable.
14. **Pgp:** Ligand A (0.155) is better than Ligand B (0.016). Lower P-gp efflux is preferred.
15. **Affinity:** Ligand A (-7.0) is slightly better than Ligand B (-6.5). While both are good, the 0.5 kcal/mol difference is significant.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most key ADME properties (TPSA, logP, HBD, HBA, BBB, Caco-2, Solubility, hERG, Cl_mic, t1/2, Pgp) and has slightly better binding affinity. Ligand B's lower logP and higher TPSA are concerning for permeability. While both have acceptable DILI risk, the other factors strongly favor Ligand A. Considering ADRB2 is a GPCR, the balance of properties in Ligand A is more favorable.
Output:
1
2025-04-17 22:47:12,726 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (358.423 and 365.499 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both are reasonably low (95.42 and 91.32), suggesting good potential for absorption. Ligand B is slightly better.
3. **logP:** Both ligands have good logP values (1.726 and 1.819), falling within the optimal 1-3 range. Again, a minor edge to B.
4. **HBD:** Ligand A (2) is preferable to Ligand B (3). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (6) is preferable to Ligand B (5). Lower HBA generally improves permeability.
6. **QED:** Ligand A (0.868) is significantly better than Ligand B (0.715), indicating a more drug-like profile.
7. **DILI:** Ligand B (41.062) has a slightly lower DILI risk than Ligand A (60.217), which is good. However, both are below the concerning threshold of 60.
8. **BBB:** Ligand B (47.654) has a slightly better BBB penetration potential than Ligand A (40.093), but neither are particularly high. Given ADRB2 is a cardiovascular target, BBB penetration is not a primary concern, but it's a slight positive for B.
9. **Caco-2:** Both have negative Caco-2 values (-5.306 and -5.192), which is unusual and suggests very poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand B (-2.076) has better aqueous solubility than Ligand A (-4.126). Solubility is important for bioavailability.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.09 and 0.22), which is excellent.
12. **Cl_mic:** Ligand B (-10.592) has significantly lower microsomal clearance than Ligand A (37.354), indicating better metabolic stability. This is a major advantage for B.
13. **t1/2:** Ligand A (-26.268) has a negative half-life, which is not possible. Ligand B (28.208) has a reasonable half-life. This is a substantial advantage for B.
14. **Pgp:** Both have very low Pgp efflux liability (0.035 and 0.043).
15. **Binding Affinity:** Ligand B (-6.1 kcal/mol) has a significantly better binding affinity than Ligand A (-3.1 kcal/mol). This is a crucial advantage, as a 3 kcal/mol difference in binding is substantial.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand B is slightly better on logP and TPSA, but *significantly* better on affinity. The improved metabolic stability (Cl_mic) and half-life of Ligand B are also very beneficial. The slightly better solubility and lower DILI risk are additional positives. The negative half-life for Ligand A is a dealbreaker.
**Conclusion:**
Considering all factors, Ligand B is the more promising drug candidate due to its superior binding affinity, metabolic stability, half-life, and slightly improved solubility and DILI profile. The negative Caco-2 values are concerning for both, but the substantial binding advantage of B outweighs this drawback.
Output:
0
2025-04-17 22:47:12,726 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (353.459 and 345.487 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand B (62.3) is significantly better than Ligand A (77.77), being well below the 140 threshold for good absorption. This is a positive for Ligand B.
3. **logP:** Both ligands have good logP values (3.362 and 2.956), falling within the optimal 1-3 range. Ligand B is slightly better.
4. **HBD:** Both have 1 HBD, which is acceptable.
5. **HBA:** Ligand B (3) has fewer HBA than Ligand A (5), which is preferable for permeability.
6. **QED:** Ligand B (0.912) has a higher QED score than Ligand A (0.794), indicating a more drug-like profile.
7. **DILI:** Ligand B (36.332) has a lower DILI risk than Ligand A (44.824), which is a significant advantage.
8. **BBB:** Both have reasonable BBB penetration (56.146 and 61.38), but neither is exceptionally high. For a cardiovascular target, BBB isn't a primary concern, but higher is still slightly better.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. Ligand A (-4.246) is slightly better than Ligand B (-4.664).
10. **Solubility:** Ligand B (-2.869) has better solubility than Ligand A (-4.014).
11. **hERG:** Both have low hERG risk (0.413 and 0.513).
12. **Cl_mic:** Ligand B (30.307) has significantly lower microsomal clearance than Ligand A (100.99), suggesting better metabolic stability.
13. **t1/2:** Ligand A (63.154) has a longer in vitro half-life than Ligand B (5.672). This is a positive for Ligand A.
14. **Pgp:** Both have low Pgp efflux liability (0.112 and 0.163).
15. **Binding Affinity:** Ligand A (-7.0) has a slightly better binding affinity than Ligand B (-6.3). However, the difference is not substantial enough to outweigh other factors.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand B excels in logP, TPSA, and has a lower DILI risk and better metabolic stability. While Ligand A has a slightly better binding affinity and half-life, the overall profile of Ligand B is more favorable considering the balance of properties. The better TPSA, logP, QED, and DILI risk of Ligand B are more important than the small affinity advantage of Ligand A.
**Conclusion:**
Ligand B presents a more balanced and favorable profile for drug development, particularly considering its improved ADME properties and lower toxicity risk.
Output:
0
2025-04-17 22:47:12,726 - INFO - Batch 357 complete. Total preferences: 5712
2025-04-17 22:47:12,726 - INFO - Processing batch 358/512...
2025-04-17 22:48:01,826 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.356 and 369.575 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (46.34) is better than Ligand B (37.83), both are well below the 140 A^2 threshold for oral absorption, and suitable for a peripherally acting GPCR like ADRB2.
3. **logP:** Ligand A (4.621) is slightly higher than Ligand B (3.499). While both are within the optimal 1-3 range, Ligand A is pushing the upper limit and could potentially have solubility issues.
4. **HBD:** Both ligands have 0 HBD, which is acceptable.
5. **HBA:** Ligand A (3) is better than Ligand B (6). Lower HBA generally favors permeability.
6. **QED:** Ligand A (0.806) is significantly better than Ligand B (0.631), indicating a more drug-like profile.
7. **DILI:** Ligand B (5.7) is *much* better than Ligand A (61.342). This is a critical advantage for Ligand B. A DILI percentile over 60 is a major red flag.
8. **BBB:** Both ligands have high BBB penetration (Ligand A: 98.178, Ligand B: 90.074). While ADRB2 isn't a primary CNS target, good BBB penetration isn't necessarily detrimental and could allow for off-target effects to be evaluated.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.422 and -4.83). These values are unusual and suggest poor permeability.
10. **Solubility:** Ligand B (-2.058) is better than Ligand A (-5.328), indicating better aqueous solubility. This is important given Ligand A's higher logP.
11. **hERG:** Ligand A (0.824) is slightly better than Ligand B (0.903), indicating a lower risk of hERG inhibition.
12. **Cl_mic:** Ligand A (32.632) has a lower microsomal clearance than Ligand B (41.21), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-1.829) has a better in vitro half-life than Ligand A (-12.125).
14. **Pgp:** Ligand A (0.839) is slightly better than Ligand B (0.175), indicating lower P-gp efflux.
15. **Affinity:** Both ligands have very similar and excellent binding affinities (Ligand A: -7.0 kcal/mol, Ligand B: -6.9 kcal/mol). The difference is negligible.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has a slightly better logP and Pgp, but Ligand B's significantly lower DILI risk and better solubility are overriding factors. The Caco-2 values are concerning for both, but the DILI risk for Ligand A is unacceptable.
**Conclusion:**
Despite Ligand A having slightly better scores in some ADME properties, the drastically higher DILI risk makes it a poor candidate. Ligand B, while not perfect, presents a much more favorable safety profile.
Output:
0
2025-04-17 22:48:01,827 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.39 and 343.47 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (54.34) is significantly better than Ligand A (116.76). ADRB2 is not a CNS target, but lower TPSA generally correlates with better absorption. This is a significant advantage for B.
3. **logP:** Ligand B (2.294) is within the optimal 1-3 range, while Ligand A (-0.188) is below 1, potentially hindering permeation. This is a strong advantage for B.
4. **HBD:** Ligand A (4) is at the upper limit, while Ligand B (1) is preferable.
5. **HBA:** Ligand A (5) is also at the upper limit, while Ligand B (3) is better.
6. **QED:** Ligand B (0.834) is superior to Ligand A (0.509), indicating a more drug-like profile.
7. **DILI:** Ligand B (25.94) has a much lower DILI risk than Ligand A (44.552). This is a substantial advantage for B.
8. **BBB:** Not a primary concern for ADRB2 (cardiovascular target), but Ligand B (88.833) is higher than Ligand A (52.268).
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand B (-4.851) is slightly better than Ligand A (-5.347).
10. **Solubility:** Both are negative, indicating poor solubility. Ligand B (-2.679) is slightly better than Ligand A (-1.335).
11. **hERG:** Ligand A (0.128) is better than Ligand B (0.395), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand A (14.292) has a lower microsomal clearance, suggesting better metabolic stability than Ligand B (44.795).
13. **t1/2:** Ligand A (10.774) has a positive in vitro half-life, while Ligand B (-14.104) has a negative in vitro half-life. This is a significant advantage for A.
14. **Pgp:** Ligand A (0.011) has a much lower P-gp efflux liability than Ligand B (0.252), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand A (-8.2 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.0 kcal/mol). This is a major advantage for A.
**Overall Assessment:**
Ligand B has advantages in TPSA, logP, QED, DILI, and BBB. However, Ligand A has a much stronger binding affinity (-8.2 vs -6.0 kcal/mol), lower P-gp efflux, and better metabolic stability (lower Cl_mic and positive t1/2). The substantial difference in binding affinity is a key factor, and can often outweigh some ADME deficiencies. While Ligand B has better ADME properties overall, the significantly stronger binding of Ligand A to the target makes it the more promising candidate, particularly given that the ADME issues aren't catastrophic and can potentially be addressed through further optimization.
Output:
1
2025-04-17 22:48:01,827 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (344.46 & 350.46 Da) fall comfortably within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (52.61) is significantly better than Ligand B (67.87). For a GPCR, lower TPSA is generally preferred for better permeability. Ligand A is well below the 140 threshold, while Ligand B is approaching it.
3. **logP:** Ligand A (4.299) is higher than Ligand B (1.335). While both are within the acceptable range (1-3), Ligand A is at the upper end. This could potentially lead to solubility issues, but for a GPCR, a slightly higher logP can be beneficial for membrane interactions. Ligand B is quite low, potentially hindering permeation.
4. **HBD:** Both ligands have 1 HBD, which is optimal.
5. **HBA:** Ligand A has 5 HBA, and Ligand B has 4. Both are within the acceptable range of <=10.
6. **QED:** Both ligands have good QED scores (0.735 and 0.812), indicating good drug-like properties.
7. **DILI:** Ligand B (34.28%) has a significantly lower DILI risk than Ligand A (41.84%). This is a substantial advantage for Ligand B.
8. **BBB:** Ligand B (75.22%) has better BBB penetration than Ligand A (52.89%). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be useful for understanding off-target effects and potential peripheral distribution.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.779 and -4.812), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand B (-2.016) has better aqueous solubility than Ligand A (-4.127). This is a positive for Ligand B, especially considering Ligand A's higher logP.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.7 and 0.287), which is excellent.
12. **Cl_mic:** Ligand B (29.9) has significantly lower microsomal clearance than Ligand A (79.92). This indicates better metabolic stability for Ligand B, a crucial factor for drug duration.
13. **t1/2:** Ligand B (21.57) has a much longer in vitro half-life than Ligand A (0.466). This is a major advantage for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.252) has lower P-gp efflux than Ligand B (0.089). Lower P-gp is generally favorable.
15. **Binding Affinity:** Both ligands have similar and excellent binding affinities (-5.9 and -5.7 kcal/mol). The difference is negligible.
**Overall Assessment:**
While Ligand A has a slightly better Pgp profile, Ligand B is superior in almost all other critical ADME properties. Specifically, the lower DILI risk, better BBB penetration, significantly improved metabolic stability (lower Cl_mic and longer t1/2), and better solubility make Ligand B a much more promising drug candidate. The Caco-2 values are concerning for both, but the other advantages of Ligand B outweigh this drawback. Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand B strikes a better balance.
Output:
0
2025-04-17 22:48:01,827 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (360.376 and 351.451 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (50.8) is significantly better than Ligand B (122.27). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold, while Ligand B is approaching it.
3. **logP:** Ligand A (2.353) is optimal. Ligand B (0.424) is quite low, potentially hindering membrane permeability and absorption. This is a significant drawback for Ligand B.
4. **HBD:** Ligand A (1) is preferable to Ligand B (4). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is preferable to Ligand B (6) for similar reasons as HBD.
6. **QED:** Ligand A (0.773) is better than Ligand B (0.592), indicating a more drug-like profile.
7. **DILI:** Ligand A (21.442) has a much lower DILI risk than Ligand B (43.932). This is a crucial safety parameter.
8. **BBB:** Ligand A (93.796) has better BBB penetration than Ligand B (63.358). While not critical for a cardiovascular target, it's a positive attribute.
9. **Caco-2:** Ligand A (-4.502) is better than Ligand B (-5.456), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-2.294) is slightly better than Ligand B (-2.325). Both are acceptable, but higher is better.
11. **hERG:** Ligand A (0.605) is better than Ligand B (0.252), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand A (40.86) has a higher (worse) clearance than Ligand B (4.102). This suggests Ligand B would be more metabolically stable.
13. **t1/2:** Ligand A (-17.244) has a shorter half-life than Ligand B (0.687). This is a negative for Ligand A.
14. **Pgp:** Ligand A (0.098) has lower P-gp efflux than Ligand B (0.022), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand A (-7.1) has a *much* stronger binding affinity than Ligand B (-1.3). This is a decisive advantage, as a >1.5 kcal/mol difference can outweigh other drawbacks.
**Overall Assessment:**
Ligand A is significantly better overall. While Ligand B has better metabolic stability (lower Cl_mic) and half-life, Ligand A excels in key areas like TPSA, logP, DILI risk, hERG risk, and, most importantly, binding affinity. The substantial difference in binding affinity (-7.1 vs -1.3 kcal/mol) is a major driver for selecting Ligand A. The better ADME properties of Ligand A (TPSA, logP, DILI, hERG) further solidify its position as the more promising candidate.
Output:
1
2025-04-17 22:48:01,827 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [370.896, 41.57, 4.428, 1, 3, 0.833, 20.396, 69.407, -4.499, -4.006, 0.908, 36.921, 39.193, 0.366, -6.7]
**Ligand B:** [354.491, 78.87, 1.563, 2, 4, 0.693, 11.361, 67.662, -4.608, -1.786, 0.366, 17.388, -5.921, 0.077, -7]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (354.491) is slightly lower, which *could* be beneficial for permeability, but both are acceptable.
2. **TPSA:** Ligand A (41.57) is much better than Ligand B (78.87). GPCRs benefit from lower TPSA for better brain penetration and overall absorption. Ligand B is quite high, potentially hindering absorption.
3. **logP:** Ligand A (4.428) is a bit high, but still within a manageable range. Ligand B (1.563) is quite low, potentially leading to poor membrane permeability. For a GPCR, we generally want logP in the 1-3 range, and A is closer.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower is generally better for permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (4). Lower is generally better for permeability.
6. **QED:** Ligand A (0.833) is significantly better than Ligand B (0.693), indicating a more drug-like profile.
7. **DILI:** Ligand A (20.396) has a much lower DILI risk than Ligand B (11.361). This is a significant advantage for Ligand A.
8. **BBB:** Both have reasonably good BBB penetration (A: 69.407, B: 67.662), but A is slightly better. This is important for a GPCR target, even if not strictly CNS-focused.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Ligand A (-4.006) is better than Ligand B (-1.786). Higher solubility is generally preferred.
11. **hERG:** Both have low hERG inhibition risk (A: 0.908, B: 0.366), which is good.
12. **Cl_mic:** Ligand B (17.388) has significantly lower microsomal clearance than Ligand A (36.921), indicating better metabolic stability. This is a strong point for Ligand B.
13. **t1/2:** Ligand A (39.193) has a longer in vitro half-life than Ligand B (-5.921). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.366) has lower P-gp efflux than Ligand B (0.077), which is preferable.
15. **Affinity:** Ligand B (-7) has a slightly better binding affinity than Ligand A (-6.7), but the difference is not huge (0.3 kcal/mol).
**Overall Assessment:**
Ligand A has several advantages: better TPSA, QED, DILI risk, solubility, half-life, and Pgp efflux. While Ligand B has better metabolic stability, the other drawbacks (high TPSA, low logP, lower QED, and higher DILI risk) are more concerning for a GPCR target like ADRB2. The slight affinity advantage of Ligand B is unlikely to outweigh the other significant issues.
Therefore, I would choose Ligand A.
Output:
1
2025-04-17 22:48:01,827 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **Molecular Weight:** Both ligands (343.431 Da and 351.403 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands have TPSA values below 140 (104.11 and 100.99), suggesting good potential for oral absorption. Ligand B is slightly better.
3. **logP:** Ligand A (1.835) is within the optimal 1-3 range. Ligand B (-0.717) is slightly below 1, which could potentially hinder permeation. This is a point in favor of Ligand A.
4. **H-Bond Donors:** Both ligands have acceptable HBD counts (3 and 2, respectively), below the threshold of 5.
5. **H-Bond Acceptors:** Both ligands have acceptable HBA counts (4 and 6, respectively), below the threshold of 10.
6. **QED:** Both ligands have similar QED values (0.713 and 0.6), indicating good drug-likeness.
7. **DILI:** Ligand A (55.68) has a higher DILI risk than Ligand B (19.271). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (48.895) and Ligand B (24.932) both have low BBB penetration. Since ADRB2 is a cardiovascular target, BBB penetration is not a high priority.
9. **Caco-2 Permeability:** Both ligands have negative Caco-2 values (-5.608 and -5.096). This is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Aqueous Solubility:** Both ligands have negative solubility values (-2.747 and -0.453). This is also unusual and suggests poor solubility.
11. **hERG Inhibition:** Ligand A (0.636) has a slightly higher hERG inhibition risk than Ligand B (0.108). This favors Ligand B.
12. **Microsomal Clearance:** Ligand A (22.849) has a higher microsomal clearance than Ligand B (0.117), indicating lower metabolic stability. This is a significant advantage for Ligand B.
13. **In vitro Half-Life:** Ligand A (24.444) has a longer in vitro half-life than Ligand B (-5.548). This favors Ligand A.
14. **P-gp Efflux:** Ligand A (0.051) has lower P-gp efflux than Ligand B (0.016), which is slightly favorable.
15. **Binding Affinity:** Ligand A (-7.2 kcal/mol) has a significantly stronger binding affinity than Ligand B (-4.9 kcal/mol). This is a substantial advantage for Ligand A, potentially outweighing some of its ADME drawbacks.
**Overall Assessment:**
Ligand A has a significantly better binding affinity, which is the most crucial factor for GPCR targets. While Ligand B has better DILI and metabolic stability, the large difference in binding affinity (-7.2 vs -4.9 kcal/mol) is a major advantage for Ligand A. The lower logP of Ligand B is also a concern. The unusual negative values for Caco-2 and solubility are concerning for both, but the potency advantage of Ligand A is likely to be more impactful in early optimization.
Output:
1
2025-04-17 22:48:01,827 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (386.361 Da) is within the ideal range (200-500 Da). Ligand B (350.459 Da) is also within range. No clear advantage here.
2. **TPSA:** Ligand A (41.13) is excellent, well below the 140 threshold for oral absorption. Ligand B (59.08) is still reasonable, but higher. A favors here.
3. **logP:** Ligand A (4.416) is slightly high, potentially leading to solubility issues or off-target interactions. Ligand B (1.291) is a bit low, potentially hindering permeation. This is a trade-off, but given ADRB2 is not a CNS target, slightly higher logP is acceptable if other parameters are favorable.
4. **HBD:** Ligand A (2) is good. Ligand B (0) is also good. No significant difference.
5. **HBA:** Ligand A (2) is good. Ligand B (4) is acceptable, but higher. A is slightly favored.
6. **QED:** Ligand A (0.753) is excellent, indicating strong drug-like properties. Ligand B (0.489) is lower, suggesting a less optimal drug-like profile. A is favored.
7. **DILI:** Ligand A (53.625) has a moderate risk, but acceptable. Ligand B (14.851) has a very low risk, a significant advantage. B is favored.
8. **BBB:** Both are not CNS targets, so this is less important. Ligand A (80.264) is higher than Ligand B (66.344).
9. **Caco-2:** Both have negative values, indicating poor permeability. This is concerning for both, but Ligand A (-5.148) is slightly better than Ligand B (-4.482).
10. **Solubility:** Ligand A (-4.495) has poor solubility. Ligand B (-1.541) has better solubility. B is favored.
11. **hERG:** Ligand A (0.692) has a very low risk of hERG inhibition. Ligand B (0.404) also has a low risk. No significant difference.
12. **Cl_mic:** Ligand A (23.535) has lower clearance, indicating better metabolic stability. Ligand B (27.458) has higher clearance. A is favored.
13. **t1/2:** Ligand A (2.367) has a shorter half-life. Ligand B (9.716) has a significantly longer half-life, which is desirable. B is favored.
14. **Pgp:** Ligand A (0.229) has lower P-gp efflux, which is favorable. Ligand B (0.094) has even lower efflux, a significant advantage. B is favored.
15. **Affinity:** Ligand A (-7.1 kcal/mol) has a slightly stronger binding affinity than Ligand B (-6.8 kcal/mol). This is a 1.5 kcal/mol difference, which is significant. A is favored.
**Overall Assessment:**
Ligand A has better affinity, TPSA, QED, metabolic stability, and Caco-2 permeability. However, Ligand B excels in DILI risk, solubility, half-life, and P-gp efflux. Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), and the fact that this is a cardiovascular target (so BBB isn't critical), the stronger affinity of Ligand A, coupled with acceptable ADME properties, makes it a slightly more promising candidate. The solubility and DILI risk of Ligand B are attractive, but the affinity difference is substantial.
Output:
1
2025-04-17 22:48:01,827 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
We are targeting ADRB2, a GPCR, so the priorities are logP, Pgp, TPSA, affinity, and BBB.
* **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (370.358) is slightly higher than Ligand B (348.403), but both are acceptable.
* **TPSA:** Both ligands are below the 140 A^2 threshold for good oral absorption. Ligand B (115.65) is slightly better than Ligand A (121.72).
* **logP:** Ligand A (1.574) is within the optimal range (1-3). Ligand B (-0.359) is slightly below 1, which could potentially hinder permeation. This is a negative for Ligand B.
* **H-Bond Donors/Acceptors:** Ligand A (1 HBD, 7 HBA) is better than Ligand B (3 HBD, 6 HBA) in terms of balancing solubility and permeability.
* **QED:** Both ligands have acceptable QED scores (A: 0.793, B: 0.669), indicating good drug-like properties.
* **DILI:** Ligand A (94.804) has a significantly higher DILI risk than Ligand B (40.752). This is a major concern for Ligand A.
* **BBB:** Ligand A (83.87) has a better BBB percentile than Ligand B (39.007). While ADRB2 isn't necessarily a CNS target, some peripheral ADRB2 activity can influence CNS pathways, so some BBB penetration isn't detrimental.
* **Caco-2 Permeability:** Ligand A (-4.589) is worse than Ligand B (-5.153), indicating lower intestinal absorption.
* **Aqueous Solubility:** Ligand A (-3.301) is worse than Ligand B (-1.71), which is a negative.
* **hERG Inhibition:** Both ligands have very low hERG inhibition risk (A: 0.133, B: 0.082).
* **Microsomal Clearance:** Ligand A (-8.459) has a much lower (better) microsomal clearance than Ligand B (-2.497), indicating greater metabolic stability.
* **In vitro Half-Life:** Ligand A (21.887) has a longer half-life than Ligand B (4.497), which is a positive.
* **P-gp Efflux:** Both ligands have low P-gp efflux liability (A: 0.104, B: 0.005). Ligand B is slightly better.
* **Binding Affinity:** Both ligands have excellent binding affinity (-6.8 kcal/mol and -6.0 kcal/mol respectively). The difference of 0.8 kcal/mol is not substantial enough to outweigh other factors.
**Overall Assessment:**
Ligand B is preferable despite the slightly lower logP. The significantly lower DILI risk is a major advantage. While Ligand A has better BBB penetration and metabolic stability, the high DILI risk is a significant red flag. The slightly better Caco-2 and solubility of Ligand B also contribute to its favorability.
**Output:**
0
2025-04-17 22:48:01,827 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (346.471 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (49.85) is significantly better than Ligand B (69.64). For a GPCR, keeping TPSA under 140 is good, and A is much closer to the desirable range.
**3. logP:** Both ligands have acceptable logP values (A: 2.365, B: 1.547), falling within the 1-3 range. Ligand A is slightly more lipophilic, which could be beneficial for membrane permeability, but both are reasonable.
**4. H-Bond Donors:** Ligand A (0) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
**5. H-Bond Acceptors:** Both ligands have 3 HBA, which is acceptable.
**6. QED:** Ligand B (0.811) has a substantially better QED score than Ligand A (0.385), indicating a more drug-like profile overall. This is a significant advantage for B.
**7. DILI Risk:** Ligand B (14.696) has a much lower DILI risk than Ligand A (31.059). This is a critical advantage for B, as liver toxicity is a major concern in drug development.
**8. BBB Penetration:** Ligand A (69.794) has better BBB penetration than Ligand B (44.901). While ADRB2 is primarily a cardiovascular target, some CNS side effects are possible with GPCR ligands, and moderate BBB penetration isn't necessarily a negative.
**9. Caco-2 Permeability:** Ligand A (-4.519) has better Caco-2 permeability than Ligand B (-4.958). Both are negative, indicating poor permeability, but A is slightly better.
**10. Aqueous Solubility:** Ligand A (-2.195) has slightly better aqueous solubility than Ligand B (-2.638). Both are poor, but A is slightly better.
**11. hERG Inhibition:** Both ligands show very low hERG inhibition risk (A: 0.415, B: 0.213). This is excellent.
**12. Microsomal Clearance:** Ligand B (-16.595) has significantly lower (better) microsomal clearance than Ligand A (26.288). This suggests better metabolic stability for B.
**13. In vitro Half-Life:** Ligand B (11.655) has a longer in vitro half-life than Ligand A (8.515), which is favorable.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (A: 0.286, B: 0.041). B is slightly better.
**15. Binding Affinity:** Ligand B (-3.2) has a significantly stronger binding affinity than Ligand A (0). This is a major advantage for B, potentially outweighing some of A's slightly better permeability characteristics.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), and the general drug-like properties, **Ligand B is the superior candidate**. While Ligand A has slightly better Caco-2 permeability and BBB penetration, Ligand B excels in crucial areas like DILI risk, metabolic stability (Cl_mic, t1/2), QED, and, most importantly, binding affinity. The strong binding affinity of Ligand B, coupled with its improved safety profile and drug-likeness, makes it a more promising starting point for drug development.
Output:
0
2025-04-17 22:48:01,828 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (374.453) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are reasonably low (A: 75.27, B: 84.67), below the 140 threshold for oral absorption. Ligand A is better.
3. **logP:** Both ligands have excellent logP values (A: 1.757, B: 1.686) falling within the optimal 1-3 range.
4. **HBD:** Ligand A (2) has a slightly better HBD count than Ligand B (1), but both are acceptable.
5. **HBA:** Ligand A (4) is preferable to Ligand B (5) as it is closer to the ideal value.
6. **QED:** Both ligands have good QED scores (A: 0.572, B: 0.517), indicating good drug-likeness. Ligand A is slightly better.
7. **DILI:** Ligand A (29.624) has a significantly lower DILI risk than Ligand B (44.281). This is a major advantage.
8. **BBB:** Both ligands have good BBB penetration (A: 74.758, B: 86.196). Ligand B is slightly better.
9. **Caco-2:** Both have negative Caco-2 values which is unusual, but the values are similar.
10. **Solubility:** Both ligands have similar and very poor solubility values.
11. **hERG:** Ligand A (0.113) has a much lower hERG inhibition liability than Ligand B (0.528). This is a critical advantage for cardiovascular targets.
12. **Cl_mic:** Ligand A (25.94) has a much lower microsomal clearance than Ligand B (64.451), suggesting better metabolic stability.
13. **t1/2:** Ligand B (67.904) has a significantly longer in vitro half-life than Ligand A (-23.43). This is a substantial advantage.
14. **Pgp:** Ligand A (0.054) shows lower P-gp efflux liability than Ligand B (0.42).
15. **Binding Affinity:** Ligand B (-7.4) has a significantly stronger binding affinity than Ligand A (-6.2). This is a substantial advantage, potentially outweighing some ADME concerns.
**Overall Assessment & GPCR Prioritization:**
For a GPCR like ADRB2, binding affinity is paramount. Ligand B's -7.4 kcal/mol is considerably better than Ligand A's -6.2 kcal/mol. While Ligand A has advantages in DILI, hERG, Cl_mic, and Pgp, the substantial difference in affinity is likely to be the deciding factor. The longer half-life of Ligand B is also a significant benefit. The solubility of both is poor, but this can be addressed with formulation strategies. The slightly higher BBB penetration of Ligand B is also a minor positive.
Therefore, despite some ADME drawbacks, the superior binding affinity of Ligand B makes it the more promising drug candidate.
Output:
0
2025-04-17 22:48:01,828 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (344.411 and 332.367 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (84.59) is slightly higher than Ligand B (70.65). Both are below the 140 threshold for good oral absorption, and acceptable for a cardiovascular target (not needing high BBB penetration). Ligand B is preferable here.
3. **logP:** Both ligands have good logP values (3.433 and 2.583), falling within the optimal 1-3 range. Ligand A is slightly higher, which *could* be a minor negative if it leads to off-target effects, but it's not a major concern.
4. **HBD:** Ligand A has 2 HBD, while Ligand B has 0. This is a slight advantage for Ligand B, as fewer HBDs generally correlate with better permeability.
5. **HBA:** Ligand A has 5 HBA, and Ligand B has 7. Both are within the acceptable limit of 10. Ligand A is slightly preferable here.
6. **QED:** Ligand A (0.804) has a significantly higher QED score than Ligand B (0.562), indicating a more drug-like profile. This is a substantial advantage for Ligand A.
7. **DILI:** Ligand A (47.189) has a much lower DILI risk than Ligand B (85.033). This is a major advantage for Ligand A. A DILI percentile above 60 is concerning.
8. **BBB:** Ligand A (72.082) has a higher BBB percentile than Ligand B (36.371). While ADRB2 isn't a primary CNS target, some CNS exposure can contribute to side effects, and a lower BBB is generally preferred for peripheral targets. However, this is a lower priority.
9. **Caco-2:** Ligand A (-4.375) and Ligand B (-5.014) both have negative Caco-2 values, indicating poor permeability. This is a significant drawback for both. Ligand B is slightly worse.
10. **Solubility:** Ligand A (-3.828) and Ligand B (-4.058) both have poor solubility. This is a concern for both, but not a deciding factor.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.352 and 0.304). This is excellent for both.
12. **Cl_mic:** Ligand A (40.449) has a lower microsomal clearance than Ligand B (43.027), suggesting better metabolic stability. This is a slight advantage for Ligand A.
13. **t1/2:** Ligand A (19.909 hours) has a significantly longer in vitro half-life than Ligand B (-55.187 hours). This is a major advantage for Ligand A, potentially allowing for less frequent dosing. The negative value for Ligand B is concerning.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.239 and 0.294). This is good for both.
15. **Binding Affinity:** Ligand A (-6.3 kcal/mol) has a slightly better binding affinity than Ligand B (-0.5 kcal/mol). This is a *very* significant advantage for Ligand A. A difference of this magnitude easily outweighs minor ADME drawbacks.
**Overall Assessment:**
Ligand A is clearly the superior candidate. It has a significantly better binding affinity, a much lower DILI risk, a higher QED score, a longer half-life, and better metabolic stability. While both have poor Caco-2 permeability and solubility, the substantial advantages of Ligand A in potency, safety, and PK outweigh these drawbacks. The GPCR-specific priorities (logP, Pgp, TPSA, affinity) all favor Ligand A.
Output:
1
2025-04-17 22:48:01,828 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [345.403, 98.14, 0.475, 2, 6, 0.597, 63.203, 47.964, -4.982, -2.4, 0.103, 24.425, -13.53, 0.058, -1.3]
**Ligand B:** [371.453, 71.09, 2.608, 2, 4, 0.621, 35.983, 81, -4.68, -3.086, 0.301, 37.059, -3.406, 0.049, -6.4]
Here's a step-by-step comparison, keeping GPCR priorities (logP, Pgp, TPSA, affinity) in mind:
1. **MW:** Both are within the acceptable 200-500 Da range. Ligand A (345.4) is slightly preferred due to being a bit lower.
2. **TPSA:** Ligand A (98.14) is higher than Ligand B (71.09). For a cardiovascular GPCR, TPSA isn't *as* critical as for CNS targets, but lower is generally better for permeability. Ligand B wins here.
3. **logP:** Ligand A (0.475) is quite low, potentially hindering permeability. Ligand B (2.608) is much better, falling within the optimal 1-3 range. Ligand B is significantly favored.
4. **HBD:** Both have 2 HBD, which is good. No preference.
5. **HBA:** Ligand A (6) has more HBA than Ligand B (4). Lower is generally better for permeability. Ligand B wins.
6. **QED:** Both are good (>0.5), with Ligand B (0.621) being slightly better.
7. **DILI:** Ligand A (63.203) has a higher DILI risk than Ligand B (35.983). This is a significant advantage for Ligand B.
8. **BBB:** Ligand B (81) has much better BBB penetration potential than Ligand A (47.964). While not a CNS target, some peripheral exposure can be modulated by BBB transporters, and higher BBB is generally a positive indicator of favorable transport properties.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-4.982) is slightly worse than Ligand B (-4.68).
10. **Solubility:** Ligand B (-3.086) has better solubility than Ligand A (-2.4).
11. **hERG:** Ligand A (0.103) has slightly lower hERG risk than Ligand B (0.301), but both are low.
12. **Cl_mic:** Ligand A (24.425) has lower microsomal clearance, suggesting better metabolic stability than Ligand B (37.059). This is a positive for Ligand A.
13. **t1/2:** Ligand A (-13.53) has a more negative in vitro half-life, indicating a shorter half-life than Ligand B (-3.406). Ligand B is preferred.
14. **Pgp:** Ligand A (0.058) has lower P-gp efflux, which is good. Ligand B (0.049) is even better.
15. **Affinity:** Ligand B (-6.4) has significantly better binding affinity than Ligand A (-1.3). This is a decisive advantage.
**Overall Assessment:**
Ligand B consistently outperforms Ligand A across most critical parameters for a GPCR drug candidate. The superior logP, lower TPSA, significantly better affinity, lower DILI risk, better solubility, and improved BBB potential outweigh Ligand A's slightly better metabolic stability and lower Pgp efflux. The substantial difference in binding affinity (-6.4 vs -1.3 kcal/mol) is a major factor.
Output:
0
2025-04-17 22:48:01,828 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (360.401 and 348.443 Da) fall comfortably within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (67.87) is slightly higher than Ligand B (59.08). Both are below the 140 A^2 threshold for good oral absorption, but B is better.
3. **logP:** Both ligands have excellent logP values (1.36 and 1.185) within the optimal 1-3 range. No significant difference.
4. **HBD:** Ligand A has 1 HBD, while Ligand B has 0. Both are within the acceptable limit of <=5. Ligand B is slightly preferred.
5. **HBA:** Both ligands have 4 HBA, well within the limit of <=10. No difference.
6. **QED:** Both ligands have very similar QED scores (0.744 and 0.766), indicating good drug-likeness.
7. **DILI:** Ligand B (18.069) has a significantly lower DILI risk than Ligand A (39.899). This is a major advantage for Ligand B.
8. **BBB:** Both ligands have high BBB penetration (88.29 and 82.047). This is good, but not a primary driver for ADRB2 (a cardiovascular target).
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.721 and -4.596). This is unusual and suggests poor permeability. However, the values are very close.
10. **Solubility:** Both ligands have negative solubility values (-1.736 and -1.599). This is also concerning and suggests poor aqueous solubility. Again, the values are very close.
11. **hERG:** Both ligands have low hERG inhibition liability (0.447 and 0.319), which is excellent. Ligand B is slightly better.
12. **Cl_mic:** Ligand A (23.129) has a lower microsomal clearance than Ligand B (33.167), suggesting better metabolic stability. This is a benefit for Ligand A.
13. **t1/2:** Ligand B (14.746) has a significantly longer in vitro half-life than Ligand A (0.987). This is a significant advantage for Ligand B.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.054 and 0.062), which is good. No difference.
15. **Binding Affinity:** Ligand A (-6.1 kcal/mol) has a slightly better binding affinity than Ligand B (-5.0 kcal/mol). This is a 1.1 kcal/mol difference, which is a meaningful advantage.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), both ligands perform reasonably well. However, Ligand B has a significantly better safety profile (lower DILI) and a much longer half-life, which are crucial for drug development. While Ligand A has a slightly better binding affinity, the ADME advantages of Ligand B outweigh this difference. The poor Caco-2 and solubility values are concerning for both, but can be addressed with formulation strategies.
Output:
0
2025-04-17 22:48:01,828 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (369.372 Da) is within the ideal range, while Ligand B (339.483 Da) is slightly below, but still acceptable.
2. **TPSA:** Ligand A (72.18) is good, well below the 140 threshold. Ligand B (37.39) is excellent.
3. **logP:** Ligand A (3.394) is optimal. Ligand B (4.816) is a bit high, potentially leading to solubility issues and off-target interactions.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 6 HBA, acceptable. Ligand B has 4 HBA, also acceptable.
6. **QED:** Both ligands have good QED scores (A: 0.765, B: 0.819), indicating good drug-like properties.
7. **DILI:** Ligand A (91.082) has a significantly higher DILI risk than Ligand B (36.293). This is a major concern for Ligand A.
8. **BBB:** Both have good BBB penetration (A: 72.741, B: 77.162).
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. However, the values are similar (-4.836 vs -4.536).
10. **Solubility:** Both ligands have poor solubility (-4.117 vs -5.454).
11. **hERG:** Ligand A (0.383) has a lower hERG risk than Ligand B (0.874), which is positive.
12. **Cl_mic:** Ligand A (34.889) has much better metabolic stability (lower clearance) than Ligand B (110.476).
13. **t1/2:** Ligand A (20.74) has a longer half-life than Ligand B (7.889).
14. **Pgp:** Ligand A (0.444) has lower P-gp efflux than Ligand B (0.573).
15. **Affinity:** Ligand B (-8.0 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.1 kcal/mol). This is a substantial advantage.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are crucial. Ligand B excels in affinity, has a lower TPSA, and acceptable Pgp efflux. While its logP is slightly high, the substantial affinity advantage outweighs this concern. Ligand A's major drawback is the high DILI risk, which is a critical safety concern.
**Overall Assessment:**
Despite Ligand A's better metabolic stability and lower hERG risk, the significantly higher DILI risk and weaker binding affinity make it less attractive. Ligand B's superior affinity, coupled with a much lower DILI risk, makes it the more promising candidate, even with a slightly higher logP and poorer metabolic stability. The strong binding affinity is a major driver for success, and the other parameters can be optimized further in subsequent iterations.
Output:
0
2025-04-17 22:48:01,828 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (350.415 and 346.515 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (88.1) is higher than Ligand B (40.62). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for better permeability. Ligand B has a substantial advantage here.
**3. logP:** Ligand A (0.489) is quite low, potentially hindering membrane permeability. Ligand B (3.308) is within the optimal 1-3 range. This is a significant advantage for Ligand B.
**4. H-Bond Donors:** Ligand A (2) and Ligand B (0) are both acceptable, with Ligand B being slightly better due to fewer potential off-target interactions.
**5. H-Bond Acceptors:** Ligand A (5) and Ligand B (2) are both within the acceptable range. Ligand B is again slightly favored.
**6. QED:** Both ligands have good QED scores (0.712 and 0.766), indicating good drug-like properties.
**7. DILI Risk:** Ligand A (45.328) has a moderate DILI risk, while Ligand B (15.471) has a very low risk. This is a substantial advantage for Ligand B.
**8. BBB Penetration:** Ligand A (42.226) has low BBB penetration, which is fine for a cardiovascular target. Ligand B (90.5) has very high BBB penetration, which isn't necessarily a negative, but also doesn't provide a benefit for a peripheral target like ADRB2.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.889 and -4.731). This is unusual and suggests poor permeability in both cases. However, the absolute values are similar.
**10. Aqueous Solubility:** Ligand A (-0.978) and Ligand B (-3.405) both have poor solubility. Ligand B is worse.
**11. hERG Inhibition:** Ligand A (0.123) and Ligand B (0.658) both have low hERG inhibition risk, which is good.
**12. Microsomal Clearance:** Ligand A (-1.214) has a negative clearance, which is excellent (indicates very high metabolic stability). Ligand B (63.064) has high clearance, suggesting rapid metabolism. This is a major advantage for Ligand A.
**13. In vitro Half-Life:** Ligand A (9.373) has a good half-life. Ligand B (-3.015) has a negative half-life, which is unusual and likely indicates very rapid degradation.
**14. P-gp Efflux:** Ligand A (0.087) has very low P-gp efflux, which is favorable. Ligand B (0.461) has moderate P-gp efflux.
**15. Binding Affinity:** Ligand B (-6.6 kcal/mol) has a significantly stronger binding affinity than Ligand A (-3.5 kcal/mol). This is a substantial advantage for Ligand B, potentially outweighing some of its ADME drawbacks.
**Overall Assessment:**
While Ligand B has a superior binding affinity, Ligand A demonstrates a far more favorable ADME profile, particularly regarding metabolic stability (Cl_mic, t1/2) and DILI risk. The low logP of Ligand A is a concern, but the strong affinity of Ligand B is a significant advantage. However, the extremely high clearance and short half-life of Ligand B are major drawbacks. Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity), and the importance of metabolic stability for a cardiovascular drug, I believe **Ligand A** is the more promising candidate. The affinity difference can potentially be addressed through further optimization, while fixing the poor metabolic properties of Ligand B would be more challenging.
Output:
1
2025-04-17 22:48:01,828 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (371.453 and 348.495 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (62.3) is slightly higher than Ligand B (57.5), but both are well below the 140 threshold for good oral absorption, and acceptable for a cardiovascular GPCR.
3. **logP:** Both ligands have good logP values (2.127 and 1.378), falling within the optimal 1-3 range. Ligand A is slightly higher, potentially offering better membrane permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (0) as it can contribute to solubility.
5. **HBA:** Ligand B (6) is preferable to Ligand A (4) as it can contribute to solubility.
6. **QED:** Both ligands have acceptable QED values (0.863 and 0.745), indicating good drug-like properties. Ligand A is slightly better.
7. **DILI:** Ligand B (12.33%) has a significantly lower DILI risk than Ligand A (35.014%). This is a major advantage for Ligand B.
8. **BBB:** Both ligands have good BBB penetration (78.79% and 80.69%), which is less critical for a cardiovascular target but still beneficial. Ligand B is slightly better.
9. **Caco-2:** Both ligands have similar, very negative Caco-2 values (-4.961 and -4.978). This suggests poor permeability, which is a concern.
10. **Solubility:** Ligand B (-0.474) has better solubility than Ligand A (-2.662).
11. **hERG:** Both ligands have low hERG inhibition risk (0.375 and 0.496). No significant difference.
12. **Cl_mic:** Ligand A (-1.83) has a lower (better) microsomal clearance than Ligand B (15.48). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand B (6.559) has a significantly longer in vitro half-life than Ligand A (-3.561). This is a major advantage for Ligand B.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.132 and 0.029). No significant difference.
15. **Binding Affinity:** Ligand A (-7.6) has a stronger binding affinity than Ligand B (-5.5). This is a substantial advantage for Ligand A (a 2.1 kcal/mol difference).
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, Pgp, TPSA, and affinity. Ligand A has a slightly better logP, similar Pgp and TPSA, but a significantly better binding affinity. However, the lower DILI risk and longer half-life of Ligand B are also important considerations. The poor Caco-2 values for both are concerning.
**Overall Assessment:**
The stronger binding affinity of Ligand A is a significant advantage. While Ligand B has better DILI and half-life, the potency difference is substantial enough to outweigh these factors, especially considering the cardiovascular target (where CNS penetration is less critical). The poor Caco-2 values are a concern for both, but can be addressed with formulation strategies.
Output:
1
2025-04-17 22:48:01,828 - INFO - Batch 358 complete. Total preferences: 5728
2025-04-17 22:48:01,828 - INFO - Processing batch 359/512...
2025-04-17 22:48:52,715 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 drug candidates. ADRB2 is a GPCR, so we'll prioritize logP, Pgp, TPSA, and affinity, alongside general drug-like properties.
**Ligand A:** [344.411, 76.66, 0.218, 2, 4, 0.618, 29.236, 54.75, -5.133, -2.835, 0.074, 5.521, 2.816, 0.02, -6.5]
**Ligand B:** [367.881, 90.12, 1.42, 3, 4, 0.734, 29.314, 64.172, -5.549, -2.716, 0.491, -23.302, -14.451, 0.069, -6.7]
Here's a breakdown of each parameter:
1. **MW:** Both are within the ideal range (200-500 Da). A is 344.411, B is 367.881. No strong preference.
2. **TPSA:** A (76.66) is better than B (90.12). Lower TPSA generally favors permeability.
3. **logP:** A (0.218) is quite low, potentially hindering membrane permeability. B (1.42) is better, falling within the optimal 1-3 range. This is a significant advantage for B.
4. **HBD:** A (2) and B (3) are both acceptable, below the threshold of 5.
5. **HBA:** Both A (4) and B (4) are good, below the threshold of 10.
6. **QED:** Both are good (A: 0.618, B: 0.734), indicating reasonable drug-likeness. B is slightly better.
7. **DILI:** Both are very similar and low (A: 29.236, B: 29.314), indicating low liver injury risk.
8. **BBB:** B (64.172) is better than A (54.75), but neither is exceptionally high. For a non-CNS target like ADRB2, this isn't a critical factor, but B is still preferable.
9. **Caco-2:** A (-5.133) and B (-5.549) are both quite poor, suggesting limited intestinal absorption.
10. **Solubility:** Both are very poor (-2.835 and -2.716). This is a significant concern for both.
11. **hERG:** A (0.074) is better than B (0.491), indicating lower cardiotoxicity risk. This is a positive for A.
12. **Cl_mic:** A (5.521) is much better than B (-23.302). A lower clearance suggests better metabolic stability. This is a major advantage for A.
13. **t1/2:** A (2.816) is much better than B (-14.451). A longer half-life is generally desirable. This is a major advantage for A.
14. **Pgp:** A (0.02) is significantly better than B (0.069), suggesting less P-glycoprotein efflux and potentially better bioavailability.
15. **Affinity:** B (-6.7) is slightly better than A (-6.5), but the difference is small (0.2 kcal/mol).
**Overall Assessment:**
Ligand B has a better logP, which is crucial for GPCR ligands, and slightly better affinity. However, Ligand A shines in metabolic stability (Cl_mic and t1/2), Pgp efflux, and hERG risk. The poor solubility and Caco-2 permeability are concerning for both, but the metabolic advantages of A are substantial. Given the importance of metabolic stability for a viable drug candidate, and the relatively small affinity difference, I favor Ligand A.
Output:
1
2025-04-17 22:48:52,715 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.475 and 350.394 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (71.25) is slightly higher than Ligand B (67.67). Both are below the 140 threshold for good oral absorption, and acceptable for a cardiovascular GPCR.
3. **logP:** Ligand A (2.506) is within the optimal 1-3 range. Ligand B (0.704) is a bit low, potentially hindering membrane permeability. This is a point in favor of Ligand A.
4. **HBD:** Ligand A (1) is preferable to Ligand B (0), as having at least one HBD can improve solubility without drastically impacting permeability.
5. **HBA:** Both ligands have 5 HBA, which is within the acceptable limit of 10.
6. **QED:** Both ligands have good QED scores (0.746 and 0.784), indicating good drug-like properties.
7. **DILI:** Ligand A (23.885) has a significantly lower DILI risk than Ligand B (38.736). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (90.617) has a much higher BBB penetration percentile than Ligand A (62.699). While ADRB2 isn't a CNS target, some off-target CNS effects are always a consideration, and higher BBB penetration *could* be a negative. However, for a cardiovascular target, this isn't a primary concern.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.864 and -4.445), which is unusual and suggests poor permeability. These values are likely errors or represent a very low permeability.
10. **Solubility:** Ligand A (-2.845) has slightly better solubility than Ligand B (-1.821).
11. **hERG:** Both ligands have very low hERG inhibition risk (0.181 and 0.286).
12. **Cl_mic:** Ligand A (36.473) has a higher microsomal clearance than Ligand B (5.655), meaning it is metabolized faster. This is a significant drawback for Ligand A.
13. **t1/2:** Ligand B (9.31) has a much longer in vitro half-life than Ligand A (2.786). This is a major advantage for Ligand B.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.213 and 0.05).
15. **Binding Affinity:** Ligand A (-7.2 kcal/mol) has a significantly stronger binding affinity than Ligand B (-5.3 kcal/mol). This is a substantial advantage for Ligand A, potentially outweighing some of its ADME drawbacks.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand A has better logP, and a *much* better binding affinity. Ligand B has better BBB penetration, but this is less crucial for a cardiovascular target.
**Overall Assessment:**
The strong binding affinity of Ligand A (-7.2 kcal/mol vs -5.3 kcal/mol) is a compelling advantage. While Ligand A has a higher Cl_mic and shorter half-life, the significantly improved potency could allow for a higher dose or more frequent dosing to compensate. The lower DILI risk is also a significant benefit. Ligand B's longer half-life is attractive, but the weaker binding affinity is a major concern. The Caco-2 values for both are problematic, but the overall profile of A is more promising.
Output:
1
2025-04-17 22:48:52,715 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (352.475 Da and 352.469 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (89.87) is excellent, well below the 140 threshold for oral absorption and even closer to the 90 threshold for CNS penetration (though not a CNS target, lower TPSA is generally favorable). Ligand B (33.2) is *very* good, significantly lower than Ligand A, and further improves permeability.
**3. logP:** Ligand A (1.052) is within the optimal 1-3 range. Ligand B (4.57) is slightly above this range, potentially raising concerns about solubility and off-target effects, but not drastically so.
**4. H-Bond Donors:** Ligand A has 3 HBD, which is acceptable. Ligand B has 0, which is also acceptable, and can even be advantageous for membrane permeability.
**5. H-Bond Acceptors:** Ligand A has 4 HBA, acceptable. Ligand B has 2, also acceptable.
**6. QED:** Both ligands have good QED values (0.639 and 0.72 respectively), indicating good drug-like properties.
**7. DILI Risk:** Both ligands have low DILI risk (13.804 and 11.943 respectively), which is excellent.
**8. BBB Penetration:** Ligand A (41.062) has a moderate BBB score, while Ligand B (95.463) has a very high BBB score. While ADRB2 is not a CNS target, higher BBB penetration can sometimes correlate with better overall distribution and reduced off-target effects.
**9. Caco-2 Permeability:** Ligand A (-5.093) has poor Caco-2 permeability. Ligand B (-4.279) has better Caco-2 permeability, though still not ideal.
**10. Aqueous Solubility:** Ligand A (-1.723) has poor aqueous solubility. Ligand B (-4.393) has even worse aqueous solubility. This is a significant concern for both.
**11. hERG Inhibition:** Ligand A (0.289) has a very low hERG risk, which is excellent. Ligand B (0.835) has a slightly higher, but still acceptable, hERG risk.
**12. Microsomal Clearance:** Ligand A (12.327) has moderate microsomal clearance. Ligand B (66.065) has high microsomal clearance, indicating faster metabolism and potentially lower *in vivo* exposure.
**13. In vitro Half-Life:** Ligand A (0.517) has a very short half-life. Ligand B (12.957) has a much longer half-life, which is a significant advantage.
**14. P-gp Efflux:** Ligand A (0.138) has low P-gp efflux, which is good. Ligand B (0.215) also has low P-gp efflux.
**15. Binding Affinity:** Ligand A (-6.1 kcal/mol) has slightly better binding affinity than Ligand B (-5.1 kcal/mol). This is a 1 kcal/mol difference, which is notable but not overwhelming.
**GPCR-Specific Considerations:** For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B excels in TPSA and BBB penetration, and has a significantly longer half-life. While its logP is a bit high, the improved permeability (Caco-2) and substantially better half-life outweigh this concern. The affinity difference is not large enough to favor Ligand A given the other ADME advantages of Ligand B. The solubility issues of both are concerning, but can potentially be addressed with formulation strategies.
**Conclusion:**
Considering the balance of properties, particularly for a GPCR target, Ligand B is the more promising candidate.
0
2025-04-17 22:48:52,715 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands (349.5 & 352.5 Da) are within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (61.44) is significantly better than Ligand B (70.69). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (2.164 & 1.501), falling within the 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1), but both are acceptable (<=5).
5. **HBA:** Ligand B (5) is higher than Ligand A (3), but both are within the acceptable range (<=10).
6. **QED:** Both ligands have good QED scores (0.74 & 0.805), indicating good drug-like properties.
7. **DILI:** Ligand A (5.2%) has a *much* lower DILI risk than Ligand B (23.2%). This is a critical advantage. Liver toxicity is a major concern in drug development.
8. **BBB:** Ligand A (84.3%) has a higher BBB penetration score than Ligand B (58.8%). While not a primary concern for a cardiovascular target, higher BBB is generally not detrimental.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests a potential issue with permeability prediction. However, the values are similar (-4.955 vs -5.041), so it doesn't differentiate them.
10. **Solubility:** Ligand A (-2.67) has better solubility than Ligand B (-0.804). This is a positive attribute.
11. **hERG:** Ligand A (0.622) has a lower hERG inhibition liability than Ligand B (0.337), indicating a lower risk of cardiotoxicity. This is important for a cardiovascular target.
12. **Cl_mic:** Ligand A (0.92) has significantly lower microsomal clearance than Ligand B (27.558). This suggests better metabolic stability for Ligand A, which is highly desirable.
13. **t1/2:** Ligand A (7.343) has a longer in vitro half-life than Ligand B (-0.899). This is a significant advantage, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.017) has lower P-gp efflux liability than Ligand B (0.022).
15. **Affinity:** Ligand A (-6.2 kcal/mol) has slightly better binding affinity than Ligand B (-5.5 kcal/mol). While the difference is not huge, it's enough to be considered.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A performs better in all these categories. Additionally, the significantly lower DILI risk and improved metabolic stability (Cl_mic and t1/2) of Ligand A are major advantages.
**Conclusion:**
Ligand A is the superior candidate due to its better ADME properties (lower DILI, better solubility, lower Cl_mic, longer t1/2, lower Pgp efflux), slightly better affinity, and favorable TPSA and logP values. The difference in binding affinity, while not massive, adds to the overall advantage.
Output:
1
2025-04-17 22:48:52,716 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (362.392 and 362.495 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands have a TPSA of 69.64, which is well below the 140 A^2 threshold for good oral absorption and appropriate for a GPCR target.
3. **logP:** Ligand A (1.636) is slightly lower than Ligand B (2.706). Both are within the optimal 1-3 range, but Ligand B is closer to the upper end, which could potentially lead to some off-target interactions or solubility issues.
4. **HBD:** Both ligands have 2 H-bond donors, which is acceptable.
5. **HBA:** Ligand A has 3 H-bond acceptors, while Ligand B has 4. Both are below the 10 threshold.
6. **QED:** Both ligands have good QED scores (0.723 and 0.791, respectively), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (13.61 percentile) has a significantly lower DILI risk than Ligand B (33.695 percentile). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (82.513 percentile) has a much higher predicted BBB penetration than Ligand B (60.76 percentile). While ADRB2 isn't exclusively a CNS target, some CNS exposure is not necessarily detrimental and could provide additional therapeutic effects or off-target liabilities.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. This is a concern for both.
10. **Solubility:** Both ligands have very poor predicted aqueous solubility (-2.617 and -2.937). This is a significant drawback for both.
11. **hERG:** Ligand A (0.526 percentile) has a slightly lower hERG inhibition liability than Ligand B (0.224 percentile), which is preferable.
12. **Cl_mic:** Ligand A (-0.821 mL/min/kg) has a lower (better) microsomal clearance than Ligand B (12.938 mL/min/kg), indicating better metabolic stability.
13. **t1/2:** Ligand A (-9.082 hours) has a longer in vitro half-life than Ligand B (-4.899 hours). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.038) has a lower Pgp efflux liability than Ligand B (0.07). This is preferable.
15. **Binding Affinity:** Ligand B (-7.0 kcal/mol) has a slightly better binding affinity than Ligand A (-5.8 kcal/mol). This is a 1.2 kcal/mol difference, which is substantial.
**Overall Assessment:**
While Ligand B has a slightly better binding affinity, Ligand A demonstrates a significantly superior ADME-Tox profile. The lower DILI risk, better BBB penetration, improved metabolic stability (lower Cl_mic and longer t1/2), and lower Pgp efflux are all critical advantages. The poor solubility and Caco-2 permeability are concerns for both, but can potentially be addressed through formulation strategies. For a GPCR target like ADRB2, the balance of properties leans heavily towards Ligand A. The affinity difference, while noticeable, is unlikely to outweigh the substantial improvements in safety and pharmacokinetic properties offered by Ligand A.
Output:
1
2025-04-17 22:48:52,716 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.363 and 354.491 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (124.17) is slightly higher than Ligand B (67.87). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for permeability. Ligand B is significantly better.
3. **logP:** Ligand B (2.69) is within the optimal 1-3 range, while Ligand A (0.317) is quite low. This is a major drawback for Ligand A, potentially hindering membrane permeability and bioavailability. Ligand B is significantly better.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable, below the threshold of 5. Ligand B is slightly better.
5. **HBA:** Ligand A (8) and Ligand B (4) are both acceptable, below the threshold of 10. Ligand B is significantly better.
6. **QED:** Ligand A (0.738) is better than Ligand B (0.511), indicating a more drug-like profile.
7. **DILI:** Ligand B (39.201) has a considerably lower DILI risk than Ligand A (63.397). This is a significant advantage for Ligand B.
8. **BBB:** Both ligands have similar BBB penetration (Ligand A: 61.264, Ligand B: 66.925). Since this is a cardiovascular target, BBB penetration isn't a primary concern, but higher is generally preferable.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
10. **Solubility:** Both ligands have negative solubility values, which is also unusual. The scale is not specified, so it's difficult to interpret.
11. **hERG:** Ligand A (0.015) has a much lower hERG inhibition liability than Ligand B (0.375). This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand A (7.191) has a lower microsomal clearance than Ligand B (48.477), indicating better metabolic stability.
13. **t1/2:** Ligand A (-17.861) has a negative in vitro half-life, which is not possible. Ligand B (-5.156) also has a negative in vitro half-life, which is not possible.
14. **Pgp:** Ligand A (0.019) has a lower P-gp efflux liability than Ligand B (0.104), suggesting better oral bioavailability.
15. **Binding Affinity:** Ligand B (-6.5 kcal/mol) has a slightly better binding affinity than Ligand A (-5.9 kcal/mol). While the difference is not huge, it's still a factor.
**Overall Assessment:**
Ligand B has several key advantages: a much better logP, lower DILI risk, and a slightly better binding affinity. While Ligand A has a better QED, lower hERG risk, and lower Cl_mic, the poor logP is a significant concern for oral bioavailability. The negative half-life values for both are concerning and suggest data errors. Given the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand B is the more promising candidate.
Output:
0
2025-04-17 22:48:52,716 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.391 and 346.479 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (68.1) is significantly better than Ligand A (102.88). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (1.305) is within the optimal 1-3 range, while Ligand A (0.468) is slightly below 1. This is a significant drawback for Ligand A, potentially hindering membrane permeability.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Both ligands have 7 HBA, which is acceptable.
6. **QED:** Ligand B (0.803) has a higher QED score than Ligand A (0.611), indicating a more drug-like profile.
7. **DILI:** Ligand B (9.616) has a much lower DILI risk than Ligand A (64.056). This is a crucial advantage, as liver toxicity is a major concern in drug development.
8. **BBB:** Ligand B (83.676) has better BBB penetration than Ligand A (70.88). While not a primary concern for a cardiovascular target, it's a slight positive for Ligand B.
9. **Caco-2:** Ligand B (-5.428) is better than Ligand A (-4.964), indicating better intestinal absorption.
10. **Solubility:** Ligand B (-1.359) is better than Ligand A (-1.579), although both are poor.
11. **hERG:** Ligand B (0.327) has a lower hERG risk than Ligand A (0.19). Both are low, but lower is better.
12. **Cl_mic:** Ligand B (-1.905) has significantly better metabolic stability (lower clearance) than Ligand A (10.476). This is a major advantage.
13. **t1/2:** Ligand B (11.19) has a longer in vitro half-life than Ligand A (-17.268). This is a significant advantage.
14. **Pgp:** Ligand B (0.034) has lower P-gp efflux than Ligand A (0.008).
15. **Binding Affinity:** Ligand B (-7.0) has a slightly better binding affinity than Ligand A (-6.6). While the difference is not huge, it contributes to the overall preference.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand B excels in these areas.
**Overall Assessment:**
Ligand B consistently outperforms Ligand A across most crucial ADME-Tox properties, including DILI risk, metabolic stability, and permeability. While Ligand A has acceptable MW and H-bonding, its low logP and higher DILI risk are significant drawbacks. The slightly better affinity of Ligand B further solidifies its position as the more promising candidate.
Output:
0
2025-04-17 22:48:52,716 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (368.349 and 342.399 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (85.25) is better than Ligand B (100.02). Both are under 140, but lower TPSA generally favors absorption.
3. **logP:** Both ligands have good logP values (2.491 and 2.071), falling within the optimal 1-3 range. Ligand B is slightly lower, which *could* be a minor drawback.
4. **HBD:** Ligand A (2) is preferable to Ligand B (3). Lower HBD is generally better for permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (4). Lower HBA is generally better for permeability.
6. **QED:** Ligand A (0.581) is better than Ligand B (0.349). A higher QED indicates a more drug-like profile.
7. **DILI:** Both ligands have similar DILI risk (68.244 and 63.164), and both are acceptable (below 60 is good, these are both slightly above but not alarmingly so).
8. **BBB:** Ligand A (63.203) is slightly better than Ligand B (61.535). While ADRB2 isn't exclusively a CNS target, some CNS penetration can be beneficial, and higher BBB is preferable.
9. **Caco-2:** Ligand A (-4.972) is better than Ligand B (-5.549). Higher Caco-2 permeability suggests better absorption.
10. **Solubility:** Ligand A (-2.944) is better than Ligand B (-3.138). Higher solubility is always preferred.
11. **hERG:** Ligand A (0.335) is better than Ligand B (0.544). Lower hERG inhibition is crucial for avoiding cardiotoxicity, especially important for a cardiovascular target like ADRB2.
12. **Cl_mic:** Ligand B (48.729) is better than Ligand A (58.803). Lower microsomal clearance indicates better metabolic stability.
13. **t1/2:** Ligand A (29.802) is better than Ligand B (-4.43). A positive half-life is better than a negative one.
14. **Pgp:** Ligand B (0.376) is better than Ligand A (0.26). Lower P-gp efflux is generally preferred.
15. **Binding Affinity:** Ligand A (-6.9 kcal/mol) is better than Ligand B (-5.5 kcal/mol). This is a significant difference in binding affinity (1.4 kcal/mol), which can often outweigh minor ADME drawbacks.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are particularly important. Ligand A performs well in all these areas. While Ligand B has better metabolic stability (Cl_mic), the substantial difference in binding affinity and generally favorable ADME profile of Ligand A make it the more promising candidate. The hERG risk is also lower for Ligand A, a critical consideration for a cardiovascular target.
**Conclusion:**
Ligand A is the more viable drug candidate due to its superior binding affinity, better drug-like properties (QED, solubility, TPSA, HBD/HBA), and lower hERG risk, outweighing the slightly higher microsomal clearance.
Output:
1
2025-04-17 22:48:52,716 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Ligand A (426.336 Da) is within the ideal range, while Ligand B (341.411 Da) is slightly below, but still acceptable.
2. **TPSA:** Both ligands (A: 74.91, B: 75.44) are reasonably close and below the 140 threshold for oral absorption, and don't raise immediate concerns for a non-CNS target.
3. **logP:** Both ligands have good logP values (A: 3.572, B: 3.097) falling within the optimal 1-3 range.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 5 HBA, and Ligand B has 4. Both are acceptable.
6. **QED:** Both have good QED scores (A: 0.797, B: 0.907), indicating good drug-likeness. Ligand B is slightly better here.
7. **DILI:** Ligand A (71.229) has a higher DILI risk than Ligand B (62.233), which is preferable.
8. **BBB:** Ligand B (87.553) has a significantly higher BBB penetration score than Ligand A (62.35). While ADRB2 isn't necessarily a CNS target, some peripheral ADRB2 receptors can be relevant in CNS-related conditions, and higher BBB is generally a plus.
9. **Caco-2:** Ligand A (-5.148) has a more negative Caco-2 value than Ligand B (-4.315), indicating lower permeability. This is a negative for Ligand A.
10. **Solubility:** Ligand A (-3.431) has a more negative solubility value than Ligand B (-4.604), indicating lower solubility. This is a negative for Ligand A.
11. **hERG:** Both ligands have low hERG inhibition liability (A: 0.112, B: 0.22), which is good.
12. **Cl_mic:** Ligand A (-12.658) has a much lower (better) microsomal clearance than Ligand B (69.74). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand B (26.914) has a much longer in vitro half-life than Ligand A (8.062). This is a significant advantage for Ligand B.
14. **Pgp:** Both ligands have low Pgp efflux liability (A: 0.306, B: 0.185), which is good.
15. **Binding Affinity:** Both ligands have excellent binding affinity (A: -5.4 kcal/mol, B: -4.8 kcal/mol). Ligand A is slightly better.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Both ligands perform well on logP and Pgp. Affinity is slightly better for Ligand A, but the difference is not huge. Ligand B has a better BBB score, which could be beneficial. The biggest differences are in ADME properties: Ligand A has better metabolic stability (lower Cl_mic) but worse Caco-2 permeability and solubility, and a shorter half-life. Ligand B has a significantly longer half-life, better solubility and permeability, but is more susceptible to metabolism.
**Overall Assessment:**
While Ligand A has slightly better affinity and metabolic stability, the significantly better permeability, solubility, and half-life of Ligand B, coupled with the lower DILI risk, make it a more promising drug candidate. The longer half-life is particularly important for dosing convenience.
Output:
0
2025-04-17 22:48:52,716 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (344.46 and 357.41 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (86.88) is better than Ligand B (75.11), both are below the 140 threshold for oral absorption, and acceptable for a cardiovascular target.
3. **logP:** Ligand B (3.931) is higher than Ligand A (2.103). While both are within the optimal 1-3 range, Ligand B is approaching the upper limit. This could potentially lead to off-target effects or solubility issues, but for a GPCR it is not a major concern.
4. **HBD:** Ligand A (3) and Ligand B (2) are both acceptable, below the 5 threshold.
5. **HBA:** Ligand A (3) is better than Ligand B (5), both are below the 10 threshold.
6. **QED:** Both ligands (0.764 and 0.725) have good drug-likeness scores, exceeding the 0.5 threshold.
7. **DILI:** Ligand A (33.424) has a significantly lower DILI risk than Ligand B (80.031). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (64.715) has a better BBB penetration score than Ligand B (34.858). While ADRB2 isn't a CNS target, some peripheral exposure can be beneficial.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.23 and -5.136), which is unusual and suggests poor permeability.
10. **Solubility:** Ligand A (-3.36) is slightly better than Ligand B (-4.391), both are quite poor.
11. **hERG:** Both ligands (0.357 and 0.356) have similar, low hERG inhibition liability, which is good.
12. **Cl_mic:** Ligand A (32.786) has a much lower microsomal clearance than Ligand B (57.633), indicating better metabolic stability.
13. **t1/2:** Ligand A (1.842) has a shorter half-life than Ligand B (-30.557). This is a negative for Ligand A.
14. **Pgp:** Both ligands (0.17 and 0.305) have low P-gp efflux liability.
15. **Binding Affinity:** Ligand A (-7.4) has a slightly better binding affinity than Ligand B (-7.0). While the difference is small, it's enough to potentially outweigh some ADME drawbacks.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B has a higher logP, which is acceptable, but Ligand A has better TPSA and Pgp values. The affinity difference is small, but favors Ligand A. Critically, Ligand A has a significantly better safety profile (lower DILI) and better metabolic stability (lower Cl_mic).
**Overall Assessment:**
Ligand A presents a more balanced profile. Its superior DILI score and metabolic stability are significant advantages, outweighing the slightly shorter half-life. While both have poor Caco-2 and solubility, the other benefits of Ligand A make it the more promising candidate.
Output:
1
2025-04-17 22:48:52,716 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's break down the comparison of Ligand A and Ligand B, considering the provided guidelines and the GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key).
1. **Molecular Weight:** Both ligands (385.819 Da and 346.515 Da) fall within the ideal 200-500 Da range. Ligand B is slightly preferred due to being closer to the lower end of the range, potentially aiding permeability.
2. **TPSA:** Ligand A (55.4) is higher than Ligand B (40.62). Both are below the 140 threshold for oral absorption, but Ligand B is better positioned for potential CNS penetration if desired (though ADRB2 isn't strictly a CNS target).
3. **logP:** Ligand A (4.854) is higher than Ligand B (3.596). Ligand A is pushing the upper limit of the optimal range and could potentially lead to solubility issues or off-target interactions. Ligand B is well within the optimal 1-3 range.
4. **H-Bond Donors:** Ligand A (1) and Ligand B (0) are both acceptable.
5. **H-Bond Acceptors:** Ligand A (4) and Ligand B (2) are both acceptable.
6. **QED:** Both ligands have similar QED values (0.748 and 0.763), indicating good drug-like properties.
7. **DILI:** Ligand A (84.064) has a significantly higher DILI risk than Ligand B (10.237). This is a major concern for Ligand A.
8. **BBB:** Both have reasonably high BBB penetration (Ligand A: 77.472, Ligand B: 88.445). While not critical for ADRB2, higher is generally better. Ligand B is preferred.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Ligand A (-6.128) has worse solubility than Ligand B (-3.189). This, combined with its higher logP, is concerning.
11. **hERG:** Ligand A (0.37) and Ligand B (0.625) are both relatively low, indicating low cardiotoxicity risk.
12. **Cl_mic:** Ligand A (85.406) has higher microsomal clearance than Ligand B (56.306), suggesting lower metabolic stability.
13. **t1/2:** Ligand A (20.323) has a longer half-life than Ligand B (-7.825). This is a positive for Ligand A, but the negative value for Ligand B is concerning.
14. **Pgp:** Ligand A (0.18) has lower Pgp efflux than Ligand B (0.37). This is a positive for Ligand A, potentially leading to better bioavailability.
15. **Binding Affinity:** Ligand A (-7.6) has a slightly better binding affinity than Ligand B (-6.5). This is a 1.1 kcal/mol difference, which is significant, but not overwhelming.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity and lower Pgp efflux, its significantly higher DILI risk, poorer solubility, and higher metabolic clearance are major drawbacks. Ligand B presents a much more balanced profile with a lower DILI risk, better solubility, and acceptable metabolic stability, despite slightly weaker binding. Given the importance of minimizing toxicity and ensuring reasonable ADME properties, Ligand B is the more promising candidate.
**Output:**
0
2025-04-17 22:48:52,716 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [350.394, 78.67, 0.532, 1, 5, 0.786, 29.081, 43.583, -4.839, -0.571, 0.334, 1.474, -16.51, 0.042, -5.8]
**Ligand B:** [348.491, 70.39, 2.412, 2, 5, 0.673, 13.532, 58.278, -5.013, -2.224, 0.258, 44.641, 50.158, 0.138, -4.5]
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). A is 350.394, B is 348.491. Very similar.
2. **TPSA:** Both are acceptable, but Ligand B (70.39) is better than Ligand A (78.67) as it's closer to the <140 threshold for good oral absorption.
3. **logP:** Ligand A (0.532) is a bit low, potentially hindering permeation. Ligand B (2.412) is within the optimal 1-3 range. This is a significant advantage for B.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Both have 5 HBA, which is acceptable.
6. **QED:** Ligand A (0.786) has a better QED score than Ligand B (0.673), indicating a more drug-like profile.
7. **DILI:** Ligand B (13.532) has a much lower DILI risk than Ligand A (29.081). This is a major advantage for B.
8. **BBB:** Ligand B (58.278) has a better BBB penetration score than Ligand A (43.583), though neither is exceptionally high. For a cardiovascular target, BBB isn't *critical* but a higher value is still preferred.
9. **Caco-2:** Ligand B (-5.013) has a better Caco-2 value than Ligand A (-4.839), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-0.571) has better solubility than Ligand B (-2.224). Solubility is important for bioavailability.
11. **hERG:** Both have low hERG inhibition risk (0.334 and 0.258 respectively).
12. **Cl_mic:** Ligand A (1.474) has significantly lower microsomal clearance than Ligand B (44.641), suggesting better metabolic stability.
13. **t1/2:** Ligand B (50.158) has a much longer in vitro half-life than Ligand A (-16.51). This is a significant advantage for B.
14. **Pgp:** Ligand A (0.042) has lower P-gp efflux liability than Ligand B (0.138), which is beneficial.
15. **Affinity:** Ligand A (-5.8) has a slightly better binding affinity than Ligand B (-4.5). This is a 1.3 kcal/mol difference, which is significant.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, Pgp, TPSA, and affinity. Ligand B excels in logP, TPSA, and has a reasonable Pgp value. Ligand A has a better affinity and Pgp, but suffers from a low logP. The longer half-life and lower DILI risk of Ligand B are also very attractive.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity and Pgp efflux, Ligand B has a much more favorable ADME profile, particularly regarding metabolic stability (t1/2), DILI risk, and logP. The difference in affinity (1.3 kcal/mol) is not substantial enough to overcome the significant advantages of Ligand B's ADME properties, especially considering the potential for optimization of Ligand B's affinity.
Therefore, I prefer Ligand B.
Output:
0
2025-04-17 22:48:52,716 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (371.424) is slightly higher than Ligand B (341.459), but both are acceptable.
2. **TPSA:** Ligand A (46.17) is significantly better than Ligand B (71.96). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand B's TPSA is approaching a level that could hinder oral absorption.
3. **logP:** Both ligands have good logP values (A: 4.905, B: 3.246), falling within the optimal 1-3 range. Ligand A is a bit high, potentially leading to off-target effects, but still acceptable.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD count generally improves permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (6). Lower HBA count generally improves permeability.
6. **QED:** Both ligands have good QED scores (A: 0.766, B: 0.84), indicating good drug-like properties.
7. **DILI:** Both ligands have similar and acceptable DILI risk (A: 47.034, B: 46.297), both below the 60% threshold.
8. **BBB:** Ligand A (93.525) has a higher BBB penetration score than Ligand B (72.005). While not a primary concern for a cardiovascular target, higher BBB is generally not detrimental.
9. **Caco-2:** Ligand A (-4.6) is better than Ligand B (-5.103). Higher Caco-2 permeability suggests better intestinal absorption.
10. **Solubility:** Ligand A (-5.224) is better than Ligand B (-3.136). Higher aqueous solubility is generally preferred.
11. **hERG:** Ligand A (0.411) is better than Ligand B (0.716), indicating lower hERG inhibition liability and reduced cardiotoxicity risk.
12. **Cl_mic:** Ligand B (32.33) has significantly lower microsomal clearance than Ligand A (50.471), suggesting better metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand B (34.741) has a much longer in vitro half-life than Ligand A (10.475). This is a substantial advantage for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.428) is better than Ligand B (0.109), indicating lower P-gp efflux.
15. **Binding Affinity:** Ligand B (-7.0) has a significantly stronger binding affinity than Ligand A (-6.1). This 1.9 kcal/mol difference is substantial and can outweigh some ADME drawbacks.
**Overall Assessment & GPCR Prioritization:**
For a GPCR like ADRB2, affinity, logP, TPSA, and Pgp are key. Ligand B wins on affinity by a large margin. While Ligand A has better TPSA and Pgp, the difference in affinity is substantial enough to overcome these. Ligand B also has a significantly better half-life and metabolic stability. The slightly higher TPSA of Ligand B is a minor concern, but the improved potency and pharmacokinetics are more important.
Output:
0
2025-04-17 22:48:52,716 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands (364.511 and 359.442 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (58.64) is significantly better than Ligand B (78.95). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (2.38) is optimal, while Ligand B (0.725) is slightly low, potentially hindering membrane permeability.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Both have 4 HBA, which is good.
6. **QED:** Ligand A (0.873) is better than Ligand B (0.693), indicating a more drug-like profile.
7. **DILI:** Ligand A (12.485) has a much lower DILI risk than Ligand B (19.426). This is a significant advantage.
8. **BBB:** Ligand B (89.027) has better BBB penetration than Ligand A (69.717), but this is less crucial for a cardiovascular target.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. Ligand A (-4.97) is slightly better than Ligand B (-4.481).
10. **Solubility:** Ligand A (-2.471) is slightly better than Ligand B (-0.577), though both are poor.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.496 and 0.223 respectively).
12. **Cl_mic:** Ligand A (37.408) has lower microsomal clearance than Ligand B (44.384), suggesting better metabolic stability.
13. **t1/2:** Ligand A (10.764) has a positive in vitro half-life, while Ligand B (-15.374) has a negative one. This is a significant advantage for Ligand A.
14. **Pgp:** Both have very low Pgp efflux liability (0.157 and 0.013 respectively).
15. **Binding Affinity:** Ligand B (-7.8 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.1 kcal/mol). This is a substantial advantage.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp and affinity are key. Ligand B has better affinity and Pgp, but Ligand A is better on logP and TPSA. The difference in affinity is substantial (1.7 kcal/mol), and typically outweighs minor ADME drawbacks. However, the DILI risk for Ligand B is concerning, and the negative half-life is also a major issue.
**Overall Assessment:**
While Ligand B boasts a superior binding affinity, the significantly higher DILI risk and negative half-life are major red flags. Ligand A, despite slightly weaker binding, presents a much more favorable ADMET profile, with lower DILI risk, better metabolic stability (lower Cl_mic, positive half-life), and a more drug-like QED score. The slightly better logP and TPSA of Ligand A also contribute to its improved profile.
Output:
1
2025-04-17 22:48:52,717 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.391 and 343.435 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (134.65) is slightly higher than Ligand B (81.51). For a cardiovascular GPCR, TPSA is not a primary concern, but lower is generally preferred for better permeability. Ligand B has a clear advantage.
3. **logP:** Ligand A (-0.687) is a bit low, potentially hindering membrane permeability. Ligand B (0.058) is closer to the optimal 1-3 range. Ligand B is better.
4. **HBD:** Ligand A (3) is higher than Ligand B (1). Lower HBD is generally preferable for permeability. Ligand B is better.
5. **HBA:** Ligand A (5) is lower than Ligand B (8). Lower HBA is generally preferable for permeability. Ligand A is better.
6. **QED:** Both ligands have good QED scores (0.666 and 0.788, respectively), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (44.126) has a lower DILI risk than Ligand B (62.233). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (58.511) has a higher BBB penetration potential than Ligand B (49.244). While ADRB2 isn't strictly a CNS target, some CNS exposure can occur, and higher BBB is generally favorable. Ligand A is better.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.406 and -5.158), which is unusual and suggests poor permeability. This is a concern for both, but the values are similar.
10. **Solubility:** Ligand A (-1.838) has slightly better solubility than Ligand B (-0.878). Solubility is important for bioavailability. Ligand A is better.
11. **hERG:** Ligand A (0.152) has a lower hERG risk than Ligand B (0.672). This is a crucial advantage for Ligand A, as hERG inhibition can lead to cardiotoxicity.
12. **Cl_mic:** Ligand A (-17.951) has significantly lower microsomal clearance than Ligand B (21.7). This indicates better metabolic stability for Ligand A, which is highly desirable.
13. **t1/2:** Ligand A (-11.261) has a longer in vitro half-life than Ligand B (15.716). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.002) has a much lower P-gp efflux liability than Ligand B (0.007). Lower P-gp efflux is preferable for better oral bioavailability. Ligand A is better.
15. **Affinity:** Ligand B (-7.5) has a stronger binding affinity than Ligand A (-5.7). This is a substantial advantage for Ligand B. A 1.8 kcal/mol difference is significant.
**Overall Assessment:**
Ligand B has a superior binding affinity, which is a critical factor for GPCR targets. However, Ligand A demonstrates a significantly better safety profile (lower DILI, lower hERG), improved metabolic stability (lower Cl_mic, longer t1/2), and better P-gp properties. While Ligand A's logP is slightly low, the overall balance of properties, particularly the safety and pharmacokinetic advantages, makes it the more promising candidate. The affinity difference, while substantial, can potentially be addressed through further optimization of Ligand A.
Output:
1
2025-04-17 22:48:52,717 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for the ADRB2, a cardiovascular GPCR. Therefore, key properties to prioritize are logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB (though less critical for a cardiovascular target).
Let's compare the ligands property by property:
1. **MW:** Both ligands (344.46 and 345.44 Da) fall comfortably within the 200-500 Da range.
2. **TPSA:** Ligand A (69.3) is better than Ligand B (75.44) as it is closer to the ideal <140 and better for absorption.
3. **logP:** Both ligands have good logP values (2.339 and 2.709), falling within the optimal 1-3 range. Ligand B is slightly higher, which could potentially lead to some off-target effects, but is still acceptable.
4. **HBD/HBA:** Both have 1 HBD and acceptable HBA counts (3 and 4 respectively).
5. **QED:** Ligand A (0.915) has a significantly better QED score than Ligand B (0.824), indicating a more drug-like profile.
6. **DILI:** Ligand A (15.2) has a much lower DILI risk than Ligand B (40.713). This is a significant advantage for Ligand A.
7. **BBB:** Ligand B (88.833) has a higher BBB penetration than Ligand A (61.535). However, as this is a cardiovascular target, BBB penetration is not a primary concern.
8. **Caco-2:** Ligand A (-5.196) and Ligand B (-4.875) are both negative, indicating poor permeability.
9. **Solubility:** Ligand A (-1.374) is better than Ligand B (-3.311) in terms of aqueous solubility.
10. **hERG:** Both ligands have low hERG inhibition liability (0.387 and 0.497).
11. **Cl_mic:** Ligand A (-4.403) has a much lower (better) microsomal clearance than Ligand B (48.521), indicating greater metabolic stability.
12. **t1/2:** Ligand A (-16.129) has a longer in vitro half-life than Ligand B (-19.32), which is favorable.
13. **Pgp:** Both ligands have low Pgp efflux liability (0.05 and 0.107).
14. **Binding Affinity:** Ligand A (-6.7 kcal/mol) has a slightly better binding affinity than Ligand B (-6.3 kcal/mol), though the difference is not huge.
**Overall Assessment:**
Ligand A demonstrates a superior overall profile. It has a better QED score, significantly lower DILI risk, better metabolic stability (lower Cl_mic, longer t1/2), better solubility, and slightly better binding affinity. While Ligand B has better BBB penetration, this is less crucial for a cardiovascular target. The combination of improved safety (DILI) and pharmacokinetic properties (Cl_mic, t1/2) makes Ligand A the more promising candidate.
**Output:**
1
2025-04-17 22:48:52,717 - INFO - Batch 359 complete. Total preferences: 5744
2025-04-17 22:48:52,717 - INFO - Processing batch 360/512...
2025-04-17 22:49:41,701 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (356.5) is within the ideal range (200-500), while Ligand B (448.7) is at the higher end, but still acceptable.
2. **TPSA:** Ligand A (67.9) is better than Ligand B (82.4), both are acceptable for a non-CNS GPCR, but lower is generally preferred.
3. **logP:** Both ligands have good logP values (A: 2.22, B: 1.98), falling within the optimal 1-3 range.
4. **HBD:** Ligand A (1) is better than Ligand B (0). While both are good, a single HBD can improve solubility.
5. **HBA:** Ligand A (4) is better than Ligand B (8). Lower HBA is generally preferred for better permeability.
6. **QED:** Both ligands have good QED scores (A: 0.61, B: 0.71), indicating drug-likeness.
7. **DILI:** Ligand A (10.2) is significantly better than Ligand B (87.7), indicating a much lower risk of drug-induced liver injury. This is a major advantage for Ligand A.
8. **BBB:** ADRB2 is a cardiovascular target, so BBB penetration is not a high priority. Ligand A (68.2) is better than Ligand B (58.3), but this difference is not critical.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual. However, the absolute value is more important. Ligand A (-4.53) is better than Ligand B (-5.01), suggesting slightly better absorption.
10. **Solubility:** Ligand A (-1.50) is better than Ligand B (-2.89), indicating better aqueous solubility.
11. **hERG:** Both ligands have low hERG inhibition liability (A: 0.53, B: 0.18). Ligand B is slightly better, but both are acceptable.
12. **Cl_mic:** Ligand A (36.4) is better than Ligand B (10.4), indicating better metabolic stability.
13. **t1/2:** Ligand B (20.7) has a significantly longer half-life than Ligand A (-3.65). This is a major advantage for Ligand B.
14. **Pgp:** Both ligands have low Pgp efflux liability (A: 0.046, B: 0.382). Ligand A is slightly better.
15. **Affinity:** Both ligands have very similar binding affinities (A: -6.4, B: -6.2). The difference is not significant enough to outweigh other factors.
**GPCR-Specific Priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Both ligands perform well on logP and affinity. Ligand A has better TPSA and Pgp.
**Overall Assessment:**
Ligand A is significantly better in terms of safety (DILI) and ADME properties (TPSA, solubility, Cl_mic). While Ligand B has a longer half-life, the substantial DILI risk and poorer ADME profile outweigh this benefit. The binding affinities are comparable.
Output:
1
2025-04-17 22:49:41,701 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (382.383) is slightly higher than Ligand B (341.419), but both are acceptable.
2. **TPSA:** Ligand A (67.23) is better than Ligand B (82.68). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally aids absorption.
3. **logP:** Both ligands have good logP values (A: 1.779, B: 1.443) within the optimal 1-3 range.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A (5) is better than Ligand B (8). Fewer HBA is generally preferred for better permeability.
6. **QED:** Ligand A (0.789) is better than Ligand B (0.606), indicating a more drug-like profile.
7. **DILI:** Both ligands have similar DILI risk (A: 60.721, B: 62.776), both are moderately risky.
8. **BBB:** Ligand A (87.127) is significantly better than Ligand B (67.352). While not a primary concern for a cardiovascular target, higher BBB is generally favorable.
9. **Caco-2:** Ligand A (-4.775) is better than Ligand B (-5.06), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-3.493) is better than Ligand B (-2.915).
11. **hERG:** Both ligands have low hERG inhibition liability (A: 0.32, B: 0.115), which is excellent.
12. **Cl_mic:** Ligand A (40.225) is worse than Ligand B (17.472), indicating lower metabolic stability. This is a significant drawback for Ligand A.
13. **t1/2:** Ligand A (-34.837) is much better than Ligand B (-3.382), indicating a significantly longer half-life.
14. **Pgp:** Both ligands have low Pgp efflux liability (A: 0.114, B: 0.103).
15. **Binding Affinity:** Ligand A (-7.6) is significantly better than Ligand B (-6.1). This is a substantial advantage.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A is better in logP, TPSA, Pgp, and *much* better in affinity. While Ligand A has a worse Cl_mic, the superior affinity and better overall ADME profile (QED, solubility, BBB) outweigh this drawback. The longer half-life is also a significant benefit.
**Conclusion:**
Ligand A is the more promising candidate due to its superior binding affinity, better overall drug-like properties (QED, solubility, TPSA, BBB), and acceptable ADME profile despite the slightly higher Cl_mic.
Output:
1
2025-04-17 22:49:41,701 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (353.438 and 354.426 Da) are within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (65.04) is significantly better than Ligand B (87.32). ADRB2 is a cardiovascular target, not CNS, but lower TPSA generally improves absorption.
3. **logP:** Both ligands (1.091 and 1.129) are within the optimal 1-3 range. Similar.
4. **HBD:** Both have 2 HBD, which is acceptable. Similar.
5. **HBA:** Both have 4 HBA, which is acceptable. Similar.
6. **QED:** Both ligands have good QED scores (0.77 and 0.802), indicating good drug-likeness. Similar.
7. **DILI:** Ligand A (13.145) has a much lower DILI risk than Ligand B (45.677). This is a significant advantage for Ligand A.
8. **BBB:** BBB is less critical for a cardiovascular target. Ligand A (61.768) is slightly better than Ligand B (51.842).
9. **Caco-2:** Both have negative Caco-2 values (-4.597 and -4.972). This is unusual and suggests poor permeability. However, the values are similar.
10. **Solubility:** Ligand A (-0.848) is better than Ligand B (-1.925). Better solubility is always preferred.
11. **hERG:** Ligand A (0.859) has a lower hERG risk than Ligand B (0.292). This is a significant advantage.
12. **Cl_mic:** Ligand A (1.476) has a lower microsomal clearance than Ligand B (2.17). Lower clearance suggests better metabolic stability.
13. **t1/2:** Ligand A (9.478) has a much longer in vitro half-life than Ligand B (-35.655). This is a major advantage for Ligand A.
14. **Pgp:** Ligand A (0.075) has lower P-gp efflux than Ligand B (0.034). Lower efflux is preferred.
15. **Binding Affinity:** Ligand B (-7.0 kcal/mol) has a slightly better binding affinity than Ligand A (-6.0 kcal/mol). This is a 1.0 kcal/mol difference, which is noticeable but not overwhelming considering the other factors.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most crucial ADME-Tox properties (DILI, hERG, Cl_mic, t1/2, Solubility). While Ligand B has a slightly better binding affinity, the superior safety profile and pharmacokinetic properties of Ligand A make it the more promising drug candidate. The negative Caco-2 values are concerning for both, but the other advantages of Ligand A outweigh this drawback.
Output:
1
2025-04-17 22:49:41,701 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (356.482 and 354.426 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (49.85) is significantly better than Ligand B (72.96). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (2.637) is optimal (1-3). Ligand B (-0.384) is below 1, which is a concern for permeability.
4. **HBD:** Ligand A (0) is preferable to Ligand B (1). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (3) is better than Ligand B (4).
6. **QED:** Both ligands have good QED scores (0.628 and 0.73), indicating good drug-like properties.
7. **DILI:** Ligand A (11.439) has a much lower DILI risk than Ligand B (22.257). This is a significant advantage.
8. **BBB:** While not critical for a cardiovascular target, Ligand A (90.617) has a higher BBB penetration score than Ligand B (64.482).
9. **Caco-2:** Both are negative, indicating poor permeability. However, Ligand A (-4.237) is slightly better than Ligand B (-4.953).
10. **Solubility:** Both have negative solubility scores, indicating poor solubility. Ligand A (-1.722) is slightly better than Ligand B (-0.939).
11. **hERG:** Both ligands have low hERG inhibition liability (0.811 and 0.238), which is good.
12. **Cl_mic:** Ligand B (-26.982) has significantly lower microsomal clearance than Ligand A (48.086), suggesting better metabolic stability. This is a strong point for Ligand B.
13. **t1/2:** Ligand A (9.105) has a longer in vitro half-life than Ligand B (2.678).
14. **Pgp:** Ligand A (0.307) has lower P-gp efflux than Ligand B (0.009), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand A (-5.7) has a slightly better binding affinity than Ligand B (-3.8). This is a 1.9 kcal/mol difference, which is substantial.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp efflux, and binding affinity are key. Ligand A excels in logP, TPSA, and binding affinity, and has better Pgp efflux. Ligand B's main advantage is its metabolic stability (lower Cl_mic). However, the significant advantage in binding affinity and the better overall ADME profile of Ligand A outweigh the metabolic stability benefit of Ligand B.
**Conclusion:**
Ligand A presents a more balanced profile with better predicted permeability, lower toxicity risk, and significantly stronger binding affinity. While Ligand B has better metabolic stability, the other factors favor Ligand A as a more promising drug candidate.
Output:
1
2025-04-17 22:49:41,701 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [350.415, 103.01 , 0.829, 3. , 5. , 0.73 , 21.171, 26.561, -5.313, -1.131, 0.08 , -24.608, 23.715, 0.015, -7.3 ]
**Ligand B:** [351.447, 95.67 , 1.756, 2. , 5. , 0.661, 27.918, 51.493, -4.804, -1.611, 0.351, 31.035, 5.594, 0.228, -5.8 ]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, Affinity, and BBB):
1. **MW:** Both are within the ideal 200-500 Da range. (A: 350.4, B: 351.4) - No significant difference.
2. **TPSA:** Both are acceptable, but Ligand B is better (closer to the <140 threshold). (A: 103.0, B: 95.7) - B is slightly favored.
3. **logP:** Ligand A is better, falling closer to the optimal 1-3 range. Ligand B is a bit higher. (A: 0.829, B: 1.756) - A is favored.
4. **HBD:** Both are reasonable, but Ligand B has fewer, which is generally preferred for permeability. (A: 3, B: 2) - B is slightly favored.
5. **HBA:** Both are equal (5). - No difference.
6. **QED:** Both are good (>0.5), but A is slightly better. (A: 0.73, B: 0.661) - A is slightly favored.
7. **DILI:** Ligand A has a significantly lower DILI risk. (A: 21.2, B: 27.9) - A is strongly favored.
8. **BBB:** Ligand B has a much higher BBB penetration percentile, which is a key consideration for GPCRs. (A: 26.6, B: 51.5) - B is strongly favored.
9. **Caco-2:** Both are negative, indicating poor permeability. (A: -5.313, B: -4.804) - No significant difference.
10. **Solubility:** Both are negative, indicating poor solubility. (A: -1.131, B: -1.611) - No significant difference.
11. **hERG:** Both are very low risk. (A: 0.08, B: 0.351) - No significant difference.
12. **Cl_mic:** Ligand A has a much lower (better) microsomal clearance, indicating greater metabolic stability. (A: -24.6, B: 31.0) - A is strongly favored.
13. **t1/2:** Ligand A has a significantly longer in vitro half-life. (A: 23.7, B: 5.6) - A is strongly favored.
14. **Pgp:** Both are very low efflux. (A: 0.015, B: 0.228) - No significant difference.
15. **Affinity:** Ligand A has a better binding affinity (-7.3 kcal/mol vs -5.8 kcal/mol). (A: -7.3, B: -5.8) - A is favored.
**Overall Assessment:**
Ligand A is significantly better in terms of DILI risk, metabolic stability (Cl_mic & t1/2), and binding affinity. It also has a slightly better QED and logP. While Ligand B has better BBB penetration and a slightly lower TPSA, the advantages of Ligand A in safety, potency, and PK properties outweigh these benefits. The poor Caco-2 and solubility for both are concerning, but can be addressed with formulation strategies. The substantial difference in affinity is a major driver.
Output:
1
2025-04-17 22:49:41,701 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, the key priorities are logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB.
Let's compare the ligands property by property:
1. **MW:** Both ligands (354.43 and 365.499 Da) are within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (101.8) is slightly higher than Ligand B (95.66). Both are acceptable, but B is better for permeability.
3. **logP:** Ligand B (1.549) is better than Ligand A (0.802). A logP between 1-3 is optimal, and B falls nicely within this range. A is a bit low, potentially hindering permeation.
4. **HBD/HBA:** Ligand A (2 HBD, 6 HBA) is slightly better than Ligand B (3 HBD, 5 HBA) in terms of maintaining a balance between solubility and permeability.
5. **QED:** Both ligands have similar QED scores (0.754 and 0.738), indicating good drug-likeness.
6. **DILI:** Ligand B (23.187) has a significantly lower DILI risk than Ligand A (45.522). This is a major advantage for B.
7. **BBB:** Ligand A (76.696) has a higher BBB percentile than Ligand B (62.699), but BBB is less critical for a cardiovascular target.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the absolute value is smaller for Ligand B (-5.789) than Ligand A (-5.197), indicating slightly better absorption.
9. **Solubility:** Both have negative solubility values, which is also unusual. Again, Ligand B (-2.938) is slightly better than Ligand A (-2.285).
10. **hERG:** Ligand A (0.051) has a slightly lower hERG risk than Ligand B (0.241), but both are very low.
11. **Cl_mic:** Ligand B (8.338) has a lower microsomal clearance than Ligand A (25.464), indicating better metabolic stability.
12. **t1/2:** Ligand A (-25.246) has a negative in vitro half-life, which is concerning. Ligand B (4.563) has a positive, albeit short, half-life.
13. **Pgp:** Ligand A (0.045) has a lower Pgp efflux liability than Ligand B (0.071), which is favorable.
14. **Binding Affinity:** Ligand B (-6.3 kcal/mol) has a slightly stronger binding affinity than Ligand A (-6.7 kcal/mol). While A is slightly better, the difference is relatively small.
**Overall Assessment:**
Ligand B demonstrates a superior balance of properties, particularly regarding safety (DILI), metabolic stability (Cl_mic), and permeability (slightly better Caco-2 and solubility). While Ligand A has a slightly better Pgp efflux and binding affinity, the advantages of Ligand B in key ADME-Tox parameters outweigh these minor differences.
**Output:**
0
2025-04-17 22:49:41,702 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (370.421 and 350.507 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (69.64) is slightly higher than Ligand B (50.6). Both are well below the 140 threshold for good oral absorption, and acceptable for a cardiovascular target (not requiring significant BBB penetration). Ligand B is better.
3. **logP:** Both ligands have good logP values (2.043 and 2.294), falling within the optimal 1-3 range. No significant difference.
4. **HBD:** Ligand A has 2 HBD, while Ligand B has 0. Both are acceptable (<=5). Ligand B is slightly preferred as fewer HBDs generally correlate with better membrane permeability.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 5. Both are within the acceptable range of <=10. No clear advantage.
6. **QED:** Both ligands have reasonable QED scores (0.833 and 0.722), indicating good drug-like properties. Ligand A is slightly better.
7. **DILI:** Ligand A (40.054) has a slightly higher DILI risk than Ligand B (11.322). Ligand B is significantly better here, indicating a lower potential for liver toxicity.
8. **BBB:** Both ligands have high BBB penetration (82.241 and 83.482). This isn't a primary concern for a cardiovascular target like ADRB2, but it doesn't hurt. No clear advantage.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.944 and -4.381). These values are unusual and suggest poor permeability. However, the scale isn't specified, so it's difficult to interpret.
10. **Solubility:** Both ligands have negative solubility values (-2.759 and -1.797). Again, the scale is unspecified, making interpretation difficult.
11. **hERG:** Both ligands have low hERG inhibition liability (0.618 and 0.507), which is good. No clear advantage.
12. **Cl_mic:** Ligand B (74.642) has a significantly higher microsomal clearance than Ligand A (14.499). This suggests Ligand A is more metabolically stable. Ligand A is better.
13. **t1/2:** Ligand A (-21.057) has a negative in vitro half-life, which is concerning. Ligand B (13.498) has a reasonable half-life. Ligand B is significantly better.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.087 and 0.343). No clear advantage.
15. **Binding Affinity:** Ligand A (-8.8 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.6 kcal/mol). This is a substantial advantage, potentially outweighing some ADME drawbacks.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Both ligands perform well on logP and Pgp. Ligand B has a better TPSA. However, the substantial affinity advantage of Ligand A (-8.8 vs -6.6 kcal/mol) is the most important factor. The better metabolic stability (lower Cl_mic) of Ligand A is also a significant positive. While Ligand B has a better DILI score and half-life, the potency difference is substantial enough to favor Ligand A.
Output:
1
2025-04-17 22:49:41,702 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (374.434 and 357.449 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (92.78) is slightly higher than Ligand B (67.07). Ligand B is preferable as it's closer to the <140 threshold for good oral absorption and better for GPCRs.
3. **logP:** Ligand B (2.823) is within the optimal 1-3 range, while Ligand A (0.732) is slightly below 1. This is a significant advantage for Ligand B, as it's more likely to have good membrane permeability.
4. **HBD:** Both ligands have 1 HBD, which is acceptable.
5. **HBA:** Ligand B (6) has one more HBA than Ligand A (5), but both are within the acceptable limit of 10.
6. **QED:** Both ligands have good QED scores (0.741 and 0.775), indicating good drug-like properties.
7. **DILI:** Ligand B (21.869) has a much lower DILI risk than Ligand A (47.421). This is a major advantage for Ligand B.
8. **BBB:** Ligand B (83.288) has significantly better BBB penetration potential than Ligand A (62.35). While ADRB2 isn't exclusively a CNS target, some cardiovascular effects are mediated by central pathways, making some BBB penetration potentially beneficial.
9. **Caco-2:** Both have negative values, which is unusual. However, the magnitude of the negative value for Ligand A (-4.329) is more negative than Ligand B (-4.592), suggesting slightly worse permeability.
10. **Solubility:** Both have negative solubility values, which is also unusual. Ligand B (-2.978) is slightly worse than Ligand A (-2.208).
11. **hERG:** Ligand B (0.524) has a slightly higher hERG risk than Ligand A (0.332), but both are relatively low.
12. **Cl_mic:** Ligand B (16.909) has significantly lower microsomal clearance than Ligand A (49.455), indicating better metabolic stability.
13. **t1/2:** Ligand B (-11.695) has a negative half-life, which is concerning. Ligand A (0.206) has a very short half-life, but at least it's positive.
14. **Pgp:** Ligand B (0.266) has lower P-gp efflux liability than Ligand A (0.076), which is beneficial for bioavailability.
15. **Binding Affinity:** Ligand A (-7.1) has a slightly better binding affinity than Ligand B (-4.0). However, the difference is not substantial enough to outweigh the numerous ADME advantages of Ligand B.
**Overall Assessment:**
Ligand B clearly outperforms Ligand A in most critical ADME properties (DILI, BBB, Cl_mic, Pgp, logP). While Ligand A has slightly better affinity and a positive half-life, the significant advantages of Ligand B in terms of safety (DILI), metabolic stability (Cl_mic), and permeability (logP, Pgp) make it the more promising drug candidate, especially considering the GPCR target class. The negative half-life of Ligand B is a concern but could potentially be addressed through structural modifications.
Output:
0
2025-04-17 22:49:41,702 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [363.307, 72.47, 2.565, 1, 4, 0.35, 63.397, 81.621, -4.638, -3.778, 0.59, 77.244, -6.852, 0.296, -6.1]
**Ligand B:** [344.415, 114.85, 1.618, 3, 4, 0.622, 39.667, 51.725, -5.239, -3.07, 0.458, -4.261, -9.647, 0.06, -7.5]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (344.415) is slightly lower, which could be beneficial for permeability, but both are acceptable.
2. **TPSA:** Ligand A (72.47) is significantly better than Ligand B (114.85). GPCRs benefit from lower TPSA for better BBB penetration and oral absorption. Ligand B is pushing the upper limit for good oral absorption.
3. **logP:** Both ligands have good logP values (A: 2.565, B: 1.618) within the optimal 1-3 range.
4. **HBD:** Ligand A (1) is better than Ligand B (3). Lower HBD generally improves permeability.
5. **HBA:** Both have the same number of HBA (4), which is acceptable.
6. **QED:** Ligand B (0.622) has a better QED score than Ligand A (0.35), indicating a more drug-like profile.
7. **DILI:** Ligand B (39.667) has a much lower DILI risk than Ligand A (63.397). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (81.621) has a much higher BBB penetration potential than Ligand B (51.725). This is a key consideration for a GPCR target, though not strictly required for ADRB2.
9. **Caco-2:** Ligand B (-5.239) has a much better Caco-2 permeability than Ligand A (-4.638).
10. **Solubility:** Ligand B (-3.07) has slightly better solubility than Ligand A (-3.778).
11. **hERG:** Both have low hERG inhibition risk (A: 0.59, B: 0.458).
12. **Cl_mic:** Ligand B (-4.261) has a lower (better) microsomal clearance than Ligand A (77.244), indicating better metabolic stability.
13. **t1/2:** Ligand B (-9.647) has a longer in vitro half-life than Ligand A (-6.852).
14. **Pgp:** Ligand B (0.06) has a lower Pgp efflux liability than Ligand A (0.296).
15. **Affinity:** Ligand B (-7.5) has a slightly better binding affinity than Ligand A (-6.1). While A is good, the 1.4 kcal/mol advantage of B is significant.
**Overall Assessment:**
While Ligand A has a better BBB score, Ligand B excels in almost all other crucial ADME properties (DILI, Cl_mic, t1/2, Pgp, Caco-2, solubility) and has a slightly better binding affinity. The lower DILI risk and improved metabolic stability of Ligand B are particularly attractive. For a cardiovascular target like ADRB2, high BBB penetration is less critical than for CNS targets. The combination of improved ADME properties and comparable affinity makes Ligand B the more promising candidate.
Output:
0
2025-04-17 22:49:41,702 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (404.312 Da) is within the ideal range. Ligand B (362.583 Da) is also within the ideal range. No clear advantage here.
2. **TPSA:** Ligand A (83.6) is good for oral absorption, though approaching the upper limit. Ligand B (23.55) is excellent, well below the 140 threshold, and suggests good permeability. Advantage: B
3. **logP:** Ligand A (3.268) is optimal. Ligand B (4.277) is slightly higher, potentially leading to solubility issues or off-target interactions, but still within an acceptable range. Slight advantage: A
4. **HBD:** Ligand A (1) is good. Ligand B (0) is also good. No clear advantage.
5. **HBA:** Ligand A (5) is good. Ligand B (3) is good. No clear advantage.
6. **QED:** Both Ligand A (0.685) and Ligand B (0.655) are above the 0.5 threshold, indicating good drug-likeness. No clear advantage.
7. **DILI:** Ligand A (57.697) has a moderate DILI risk. Ligand B (10.896) has a very low DILI risk. Significant advantage: B
8. **BBB:** Ligand A (50.717) has moderate BBB penetration. Ligand B (92.943) has excellent BBB penetration. Since ADRB2 is a GPCR, BBB penetration is a desirable property. Significant advantage: B
9. **Caco-2:** Ligand A (-5.283) and Ligand B (-4.505) are both negative, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
10. **Solubility:** Ligand A (-3.937) and Ligand B (-4.146) are both negative, suggesting poor solubility. Again, the scale is not specified.
11. **hERG:** Ligand A (0.713) and Ligand B (0.862) are both relatively low, indicating low hERG inhibition risk. No clear advantage.
12. **Cl_mic:** Ligand A (47.949) has a moderate clearance. Ligand B (110.998) has a high clearance, suggesting lower metabolic stability. Advantage: A
13. **t1/2:** Ligand A (43.677) has a good half-life. Ligand B (40.78) has a good half-life, but slightly shorter. Slight advantage: A
14. **Pgp:** Ligand A (0.517) has moderate Pgp efflux. Ligand B (0.201) has low Pgp efflux. Lower Pgp is preferred, especially for GPCRs. Advantage: B
15. **Binding Affinity:** Ligand A (-6.1 kcal/mol) has good binding affinity. Ligand B (-6.8 kcal/mol) has slightly better binding affinity. Advantage: B
**Overall Assessment:**
Ligand B demonstrates a superior profile for a GPCR target like ADRB2. Its excellent BBB penetration, very low DILI risk, and low Pgp efflux are significant advantages. While Ligand A has slightly better metabolic stability, the benefits of Ligand B in terms of safety (DILI) and target engagement (BBB, Pgp, affinity) outweigh this drawback. The slightly higher logP of Ligand B is a minor concern but doesn't negate its overall superior profile.
Output:
0
2025-04-17 22:49:41,702 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (344.35 and 349.39 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (100.19) is better than Ligand B (109.39). While both are below 140, lower TPSA generally favors oral absorption, a key consideration for a cardiovascular drug.
**3. logP:** Ligand A (1.185) is slightly better than Ligand B (0.75). Both are within the optimal 1-3 range, but Ligand A is closer to the sweet spot.
**4. H-Bond Donors:** Ligand A (3) is higher than Ligand B (1). While both are within the acceptable limit of 5, lower HBD can sometimes improve membrane permeability.
**5. H-Bond Acceptors:** Ligand B (7) is higher than Ligand A (4). Again, both are within the acceptable limit of 10, but lower is generally preferred.
**6. QED:** Ligand B (0.815) has a significantly better QED score than Ligand A (0.573), indicating a more drug-like profile overall. This is a notable advantage for Ligand B.
**7. DILI Risk:** Ligand B (52.191) has a considerably lower DILI risk than Ligand A (82.862). This is a major advantage for Ligand B, as minimizing liver toxicity is crucial.
**8. BBB Penetration:** Both ligands have similar BBB penetration (Ligand A: 60.915, Ligand B: 64.017). Since ADRB2 is primarily a cardiovascular target, high BBB penetration isn't critical, but it's not a disadvantage either.
**9. Caco-2 Permeability:** Both ligands have very poor Caco-2 permeability (-4.808 and -4.981). This is a concern for both, potentially indicating poor oral absorption.
**10. Aqueous Solubility:** Ligand A (-3.974) has better aqueous solubility than Ligand B (-1.583). Solubility is important for formulation and bioavailability.
**11. hERG Inhibition:** Both ligands show very low hERG inhibition risk (Ligand A: 0.204, Ligand B: 0.087). This is excellent and minimizes cardiotoxicity concerns.
**12. Microsomal Clearance:** Ligand A (20.793) has a higher microsomal clearance than Ligand B (9.895), indicating faster metabolism and potentially shorter duration of action.
**13. In vitro Half-Life:** Ligand B (2.84) has a much shorter in vitro half-life than Ligand A (16.749). This is a significant drawback for Ligand B.
**14. P-gp Efflux:** Both ligands show very low P-gp efflux (Ligand A: 0.036, Ligand B: 0.01). This is favorable for bioavailability.
**15. Binding Affinity:** Ligand B (-7.2 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.8 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME drawbacks.
**Overall Assessment:**
While Ligand A has better solubility and a longer half-life, Ligand B excels in several critical areas: significantly lower DILI risk, a much higher binding affinity, and a better QED score. The stronger binding affinity is particularly important for a GPCR target like ADRB2. The lower DILI risk is also a major factor. The poor Caco-2 permeability is a concern for both, but the superior potency of Ligand B might allow for a lower dose, potentially mitigating this issue.
Therefore, I favor Ligand B.
0
2025-04-17 22:49:41,702 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (353.419 Da and 367.877 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand B (82.53) is significantly better than Ligand A (104.81). For a GPCR, lower TPSA is generally preferred for better permeability.
**3. logP:** Ligand B (2.171) is within the optimal range (1-3), while Ligand A (-0.038) is slightly below 1, potentially hindering membrane permeability. This is a notable advantage for Ligand B.
**4. H-Bond Donors:** Both have 2 HBD, which is acceptable.
**5. H-Bond Acceptors:** Ligand A has 5 HBA, and Ligand B has 4. Both are within the acceptable range.
**6. QED:** Ligand B (0.835) has a higher QED score than Ligand A (0.533), indicating a more drug-like profile.
**7. DILI:** Both ligands have low DILI risk (35.673 and 34.393 percentile), which is good.
**8. BBB:** Ligand A (53.276) has a slightly higher BBB penetration potential than Ligand B (45.638), but for a cardiovascular target, BBB penetration is not a primary concern.
**9. Caco-2 Permeability:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, Ligand B (-4.812) is slightly less negative than Ligand A (-5.091), potentially indicating marginally better absorption.
**10. Aqueous Solubility:** Both have negative solubility values, indicating poor solubility. Ligand A (-1.543) is slightly better than Ligand B (-2.525).
**11. hERG Inhibition:** Both have very low hERG inhibition risk (0.129 and 0.249), which is excellent.
**12. Microsomal Clearance:** Ligand B (-6.741) has a negative clearance, which is not possible and likely indicates a very stable compound. Ligand A (16.967) has a moderate clearance. This is a significant advantage for Ligand B.
**13. In vitro Half-Life:** Ligand B (9.54) has a positive half-life, while Ligand A (-16.966) has a negative half-life, which is not possible. This is a significant advantage for Ligand B.
**14. P-gp Efflux:** Both have very low P-gp efflux liability (0.018 and 0.097), which is desirable.
**15. Binding Affinity:** Ligand B (-6.9 kcal/mol) has a slightly better binding affinity than Ligand A (-6.2 kcal/mol), though the difference is not huge.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand B is the stronger candidate. It has a more favorable logP, lower TPSA, better QED, and a better binding affinity. The negative clearance and half-life values for Ligand B are suspect and would need further investigation, but even assuming they are errors, the other advantages of Ligand B are substantial. Ligand A's lower logP and higher TPSA are concerning for permeability.
Output:
0
2025-04-17 22:49:41,702 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (342.399 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (59.08) is significantly better than Ligand A (96.25). ADRB2 is not a CNS target, but lower TPSA generally improves absorption.
3. **logP:** Ligand B (1.685) is within the optimal range (1-3), while Ligand A (-0.165) is below 1, potentially hindering permeation. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (0). Both are acceptable.
5. **HBA:** Ligand A (5) is higher than Ligand B (4). Both are within the acceptable range.
6. **QED:** Both ligands have similar and good QED values (A: 0.648, B: 0.691).
7. **DILI:** Ligand B (30.748) has a much lower DILI risk than Ligand A (63.862). This is a major advantage for Ligand B.
8. **BBB:** Both have low BBB penetration, which is not a primary concern for a peripheral target like ADRB2. Ligand B (63.668) is slightly higher.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. This is a concern for both, but the lower value for Ligand B (-4.516 vs -4.742) is marginally better.
10. **Solubility:** Both have negative solubility values, suggesting poor aqueous solubility. Ligand A (-2.755) is slightly better than Ligand B (-1.871).
11. **hERG:** Both ligands have low hERG inhibition risk (A: 0.271, B: 0.357).
12. **Cl_mic:** Ligand A (24.595) has a significantly lower microsomal clearance than Ligand B (64.09), indicating better metabolic stability.
13. **t1/2:** Ligand B (3.811) has a longer in vitro half-life than Ligand A (-2.576).
14. **Pgp:** Both have low Pgp efflux liability (A: 0.082, B: 0.183).
15. **Binding Affinity:** Ligand A (-7.4) has a slightly better binding affinity than Ligand B (-7.0), but the difference is less than 1.5 kcal/mol.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand B excels in logP and TPSA, while Ligand A has a slightly better affinity. However, the significant advantages of Ligand B in terms of DILI risk and metabolic stability (Cl_mic) outweigh the small affinity difference. The poor Caco-2 and solubility are concerns for both, but can be addressed with formulation strategies.
**Conclusion:**
Considering the balance of properties and the priorities for a GPCR target, Ligand B is the more promising drug candidate. Its lower DILI risk, better logP, and improved metabolic stability are crucial advantages.
Output:
0
2025-04-17 22:49:41,702 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [368.836, 58.64, 3.001, 1, 3, 0.816, 67.003, 83.715, -4.412, -4.6, 0.463, 63.964, 28.784, 0.406, -7.1]
**Ligand B:** [361.789, 92.47, 2.309, 0, 6, 0.615, 92.051, 76.309, -4.655, -3.949, 0.424, 71.407, -32.236, 0.215, -7.1]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (361.789) is slightly lower, which isn't a major concern.
2. **TPSA:** Ligand A (58.64) is significantly better than Ligand B (92.47). ADRB2 is not a CNS target, but lower TPSA generally improves permeability. Ligand B is pushing the upper limit for good oral absorption.
3. **logP:** Both are within the optimal range (1-3). Ligand A (3.001) is slightly higher, but still acceptable.
4. **HBD/HBA:** Ligand A (1 HBD, 3 HBA) is preferable to Ligand B (0 HBD, 6 HBA). The higher number of HBA in Ligand B could potentially impact permeability.
5. **QED:** Ligand A (0.816) is better than Ligand B (0.615), indicating a more drug-like profile.
6. **DILI:** Ligand A (67.003) is better than Ligand B (92.051). Lower DILI risk is always preferred.
7. **BBB:** Not a primary concern for a cardiovascular target. Ligand A (83.715) is higher, but this isn't decisive.
8. **Caco-2:** Both are negative, indicating poor permeability. This is a significant drawback for both.
9. **Solubility:** Both are negative, indicating poor solubility. This is a significant drawback for both.
10. **hERG:** Both are low risk (0.463 and 0.424).
11. **Cl_mic:** Ligand A (63.964) is better than Ligand B (71.407), indicating better metabolic stability.
12. **t1/2:** Ligand A (28.784) is significantly better than Ligand B (-32.236). A negative value for t1/2 is concerning for ligand B.
13. **Pgp:** Ligand A (0.406) is better than Ligand B (0.215), indicating lower P-gp efflux.
14. **Affinity:** Both have the same binding affinity (-7.1 kcal/mol), so this doesn't differentiate them.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most crucial ADME properties (TPSA, QED, DILI, Cl_mic, t1/2, Pgp). While both have poor Caco-2 and solubility, the better metabolic stability and longer half-life of Ligand A are critical advantages. The slightly better logP and HBD/HBA profile of Ligand A also contribute to its favorability.
Therefore, I would choose Ligand A.
Output:
1
2025-04-17 22:49:41,702 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (338.37 & 348.49 Da) fall comfortably within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (93.19) is slightly higher than Ligand B (69.64). Both are below the 140 threshold for oral absorption, but B is significantly better, especially considering ADRB2 is a GPCR where CNS penetration isn't necessarily desired.
3. **logP:** Both ligands have good logP values (3.76 & 2.25), falling within the optimal 1-3 range. Ligand B is slightly lower, which is preferable for solubility.
4. **HBD:** Both have 2 HBD, which is within the acceptable limit of 5.
5. **HBA:** Ligand A has 5 HBA, while Ligand B has 3. Both are below the 10 threshold.
6. **QED:** Both ligands have similar QED values (0.755 and 0.766), indicating good drug-likeness.
7. **DILI:** Ligand A has a DILI risk of 88.48%, which is high. Ligand B has a much lower DILI risk of 14.54%, a significant advantage.
8. **BBB:** Both ligands have reasonable BBB penetration (71.77% & 65.03%). Since ADRB2 is primarily a cardiovascular target, high BBB penetration isn't a priority.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. This is a concern for both.
10. **Solubility:** Ligand B (-2.661) has better solubility than Ligand A (-4.764).
11. **hERG:** Both ligands have very low hERG inhibition risk (0.259 & 0.162).
12. **Cl_mic:** Ligand A has a lower microsomal clearance (14.90 mL/min/kg) than Ligand B (39.61 mL/min/kg), suggesting better metabolic stability.
13. **t1/2:** Ligand A has a longer in vitro half-life (62.15 hours) than Ligand B (-7.93 hours). This is a major advantage for Ligand A.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.048 & 0.054).
15. **Binding Affinity:** Ligand B (-7.1 kcal/mol) has a slightly better binding affinity than Ligand A (-6.2 kcal/mol). This is a 0.9 kcal/mol difference, which is significant.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, affinity, and metabolic stability are key. Ligand B excels in TPSA and solubility, and has a slightly better affinity. Ligand A has better metabolic stability and half-life. However, the significantly higher DILI risk for Ligand A is a major red flag.
**Overall Assessment:**
While Ligand A has a longer half-life and better metabolic stability, the high DILI risk associated with it outweighs these benefits. Ligand B, despite slightly lower metabolic stability and half-life, presents a much safer profile with a significantly lower DILI risk and better solubility. The affinity difference is not large enough to overcome the safety concerns with Ligand A.
Output:
0
2025-04-17 22:49:41,703 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
Let's analyze each ligand against the provided guidelines, keeping in mind ADRB2 is a GPCR, so logP, TPSA, Pgp, and affinity are particularly important.
* **Molecular Weight:** Both ligands (353.463 and 342.443 Da) fall within the ideal 200-500 Da range.
* **TPSA:** Ligand A (78.95) is slightly higher than Ligand B (69.3). Both are below the 140 threshold for good absorption, but B is better.
* **logP:** Both ligands have good logP values (1.762 and 2.122), falling within the optimal 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability.
* **H-Bond Donors/Acceptors:** Both have 1 HBD and a reasonable number of HBAs (4 and 3 respectively).
* **QED:** Both have good QED scores (0.789 and 0.915), indicating good drug-like properties. Ligand B is slightly better.
* **DILI:** Ligand A (29.236) has a lower DILI risk than Ligand B (34.548), which is a significant advantage.
* **BBB:** Ligand A (83.908) has a significantly higher BBB penetration score than Ligand B (55.332). While ADRB2 isn't necessarily a CNS target, higher BBB is generally preferable as it indicates less involvement with efflux transporters.
* **Caco-2:** Both have negative Caco-2 values, which is unusual. I will assume these are percentile scores and interpret them accordingly. Ligand A (-4.546) is worse than Ligand B (-5.113), suggesting lower intestinal absorption for A.
* **Solubility:** Both have negative solubility values. Again, assuming percentile scores, Ligand B (-3.092) is slightly better than Ligand A (-2.412).
* **hERG:** Both have low hERG inhibition risk (0.416 and 0.388).
* **Cl_mic:** Ligand B (29.397) has a lower microsomal clearance than Ligand A (43.671), indicating better metabolic stability.
* **t1/2:** Ligand B (-9.619) has a longer in vitro half-life than Ligand A (-29.896).
* **Pgp:** Both have very low Pgp efflux liability (0.069 and 0.072).
* **Binding Affinity:** Ligand A (-6.4 kcal/mol) has a slightly better binding affinity than Ligand B (-5.0 kcal/mol). This is a 1.4 kcal/mol difference, which is substantial.
**Overall Assessment:**
Ligand A has a better binding affinity and lower DILI risk, and better BBB penetration. Ligand B has better metabolic stability (lower Cl_mic, longer t1/2), slightly better QED, and slightly better solubility. The affinity difference is the most significant factor. While metabolic stability is important, the stronger binding of Ligand A is likely to outweigh the slightly higher clearance. The improved BBB penetration of Ligand A is also a plus.
**Output:**
1
2025-04-17 22:49:41,703 - INFO - Batch 360 complete. Total preferences: 5760
2025-04-17 22:49:41,703 - INFO - Processing batch 361/512...
2025-04-17 22:50:30,291 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (368.5 & 352.4 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (40.62) is significantly better than Ligand A (76.46). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (1.29) is optimal, while Ligand B (3.708) is approaching the upper limit. While still acceptable, higher logP can sometimes lead to off-target effects.
4. **HBD:** Ligand A (1) is better than Ligand B (0). A single HBD can contribute to solubility without significantly hindering permeability.
5. **HBA:** Ligand A (6) is better than Ligand B (2). Similar to HBD, fewer HBA is generally preferred for permeability.
6. **QED:** Ligand A (0.734) is better than Ligand B (0.554), indicating a more drug-like profile.
7. **DILI:** Both ligands have low DILI risk (35.285 & 37.611), which is good.
8. **BBB:** Ligand B (89.725) has significantly higher BBB penetration than Ligand A (56.65). While not a primary concern for a cardiovascular target, it's not a negative.
9. **Caco-2:** Ligand A (-5.107) is better than Ligand B (-3.995). Higher Caco-2 permeability suggests better intestinal absorption.
10. **Solubility:** Ligand A (-1.392) is better than Ligand B (-2.433). Better solubility is generally desirable.
11. **hERG:** Ligand A (0.158) is better than Ligand B (0.875). Lower hERG inhibition is crucial for avoiding cardiotoxicity, especially for a cardiovascular target.
12. **Cl_mic:** Ligand A (55.223) has lower microsomal clearance than Ligand B (76.58), indicating better metabolic stability.
13. **t1/2:** Ligand B (23.438) has a significantly longer in vitro half-life than Ligand A (-3.446). This is a major advantage, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.094) has lower P-gp efflux than Ligand B (0.633), which is favorable for bioavailability.
15. **Affinity:** Ligand B (-5.4) has a slightly better binding affinity than Ligand A (-7.0). However, Ligand A's affinity is already excellent.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in BBB penetration, which isn't critical here, and has slightly better affinity. However, Ligand A has a much better profile across several other important parameters: TPSA, logP, QED, solubility, hERG, Cl_mic, and Pgp. The longer half-life of Ligand B is appealing, but the other advantages of Ligand A outweigh this benefit.
**Conclusion:**
Considering the balance of properties and the priorities for a cardiovascular GPCR target, Ligand A is the more promising drug candidate.
Output:
1
2025-04-17 22:50:30,291 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (389.405) is slightly higher than Ligand B (364.486), but both are acceptable.
2. **TPSA:** Ligand A (90.41) is better than Ligand B (49.41). For a cardiovascular GPCR, lower TPSA is generally preferred for better permeability, but 90.41 is still reasonable. Ligand B is excellent.
3. **logP:** Both ligands have good logP values (A: 2.795, B: 3.433), falling within the optimal 1-3 range. Ligand B is slightly higher, which could potentially lead to some off-target effects, but it's not a major concern.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 8 HBA, while Ligand B has 3. Both are within the acceptable limit of 10, but Ligand B is preferable.
6. **QED:** Ligand B (0.893) has a significantly better QED score than Ligand A (0.548), indicating a more drug-like profile.
7. **DILI:** Ligand A (93.059) has a considerably higher DILI risk than Ligand B (48.158). This is a significant negative for Ligand A.
8. **BBB:** Both ligands have good BBB penetration (A: 84.955, B: 92.555). Since ADRB2 is not a CNS target, this is less critical, but higher is still slightly preferred.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. This is a concern for both, but needs further investigation.
10. **Solubility:** Both ligands have negative solubility values, which is also unusual and suggests poor solubility. This is a concern for both, but needs further investigation.
11. **hERG:** Ligand A (0.321) has a lower hERG inhibition liability than Ligand B (0.588), which is a positive.
12. **Cl_mic:** Ligand A (98.647) has a much higher microsomal clearance than Ligand B (38.374), indicating lower metabolic stability. This is a significant negative for Ligand A.
13. **t1/2:** Ligand B (8.87) has a longer in vitro half-life than Ligand A (-6.058), which is a positive.
14. **Pgp:** Ligand A (0.37) has lower P-gp efflux liability than Ligand B (0.543), which is a positive.
15. **Binding Affinity:** Ligand B (-6.3 kcal/mol) has a slightly better binding affinity than Ligand A (-6.0 kcal/mol), although the difference is small.
**Overall Assessment:**
Ligand B is the stronger candidate. While both have issues with Caco-2 and solubility, Ligand B excels in key areas: QED, DILI risk, metabolic stability (Cl_mic and t1/2), and binding affinity. Ligand A's high DILI risk and poor metabolic stability are major drawbacks. The slightly better hERG and Pgp profiles of Ligand A are not enough to offset these significant concerns.
Output:
0
2025-04-17 22:50:30,291 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.402 and 347.503 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (66.57) is higher than Ligand B (43.86). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is generally preferred for absorption. Ligand B has a clear advantage.
3. **logP:** Ligand A (3.414) is slightly higher than Ligand B (2.112), both within the optimal 1-3 range. Ligand A is closer to the upper limit, which *could* present solubility issues, but isn't a major concern.
4. **HBD:** Ligand A (1) is slightly higher than Ligand B (0). This is a minor difference and doesn't heavily influence the decision.
5. **HBA:** Ligand A (4) is higher than Ligand B (3). Again, a small difference, but lower HBA is generally preferred for permeability. Ligand B has a slight advantage.
6. **QED:** Ligand A (0.901) is significantly better than Ligand B (0.739). This suggests Ligand A has a more generally "drug-like" profile. This is a substantial positive for Ligand A.
7. **DILI:** Ligand B (6.592) has a *much* lower DILI risk than Ligand A (48.313). This is a critical factor. A DILI percentile above 40 is concerning, and Ligand A is significantly above that threshold.
8. **BBB:** Both ligands have high BBB penetration (Ligand A: 89.027, Ligand B: 85.692). This isn't a primary concern for a cardiovascular target, but it doesn't hurt either.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.478 and -4.81). These values are unusual and suggest poor permeability, but are likely due to the scale used. The more negative value indicates a lower permeability. Ligand B is slightly worse.
10. **Solubility:** Ligand A (-2.823) is more soluble than Ligand B (-0.987). This is a positive for Ligand A, potentially mitigating the slightly higher logP.
11. **hERG:** Both ligands have low hERG inhibition liability (Ligand A: 0.891, Ligand B: 0.686). This is good; both are below concerning thresholds.
12. **Cl_mic:** Ligand B (31.837) has a lower microsomal clearance than Ligand A (26.524), suggesting better metabolic stability. This is a positive for Ligand B.
13. **t1/2:** Ligand A (-28.311) has a much longer in vitro half-life than Ligand B (5.457). This is a significant advantage for Ligand A, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.729) has lower P-gp efflux liability than Ligand B (0.075). Lower Pgp is better for oral bioavailability. Ligand A has a clear advantage.
15. **Binding Affinity:** Ligand A (-6.8 kcal/mol) has a slightly better binding affinity than Ligand B (-5.2 kcal/mol). This is a 1.6 kcal/mol difference, which is substantial enough to outweigh some ADME concerns.
**Overall Assessment:**
The decision is complex. Ligand A has a better QED, solubility, half-life, Pgp efflux, and binding affinity. However, Ligand B has a *much* lower DILI risk, lower TPSA, and better metabolic stability. The DILI risk for Ligand A is a significant red flag. While the affinity difference is substantial, a high DILI risk is often a deal-breaker in drug development. Considering the cardiovascular target, the BBB penetration is less critical, and the slightly lower TPSA of Ligand B is beneficial.
Given the importance of minimizing toxicity, especially liver toxicity, I favor Ligand B despite its slightly weaker binding affinity and lower QED. The lower DILI risk is a crucial advantage.
Output:
0
2025-04-17 22:50:30,291 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.471 and 382.448 Da) fall within the ideal range of 200-500 Da. No clear advantage here.
2. **TPSA:** Ligand A (58.64) is significantly better than Ligand B (75.27). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands (2.267 and 2.642) are within the optimal 1-3 range. Ligand B is slightly higher, which could be a minor concern for solubility, but not a dealbreaker.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Both ligands have 3 HBA, so no difference here.
6. **QED:** Ligand A (0.72) is better than Ligand B (0.602), indicating a more drug-like profile.
7. **DILI:** Ligand A (25.126) is significantly better than Ligand B (44.591). Lower DILI risk is crucial.
8. **BBB:** Ligand B (80.574) is better than Ligand A (70.415), but this isn't a high priority for a cardiovascular target.
9. **Caco-2:** Both are negative, indicating poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-3.03) is better than Ligand B (-4.235), indicating better aqueous solubility.
11. **hERG:** Ligand A (0.381) is significantly better than Ligand B (0.561), indicating a lower risk of cardiotoxicity. This is *very* important for a cardiovascular target.
12. **Cl_mic:** Ligand B (50.2) is better than Ligand A (65.432), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-31.667) is *much* better than Ligand A (0.783). A longer half-life is desirable.
14. **Pgp:** Ligand A (0.107) is better than Ligand B (0.146), indicating lower P-gp efflux.
15. **Binding Affinity:** Ligand A (-6.7) is slightly better than Ligand B (-6.2), but the difference is relatively small.
**GPCR-Specific Priorities & Overall Assessment:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A excels in TPSA, Pgp, and has slightly better affinity. Ligand B has a better logP and significantly better metabolic stability (Cl_mic and t1/2). However, Ligand A's much lower DILI and hERG risk are critical advantages for a cardiovascular drug. The solubility is also better for Ligand A. While Ligand B's half-life is a strong point, the safety profile of Ligand A is more compelling.
**Output:**
1
2025-04-17 22:50:30,291 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (344.415 and 353.373 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (80.49 and 83.02) are below the 140 A^2 threshold for good oral absorption, and acceptable for a non-CNS GPCR target like ADRB2. Ligand A is slightly better.
3. **logP:** Both ligands (1.5 and 1.714) are within the optimal 1-3 range. Again, a minor difference.
4. **HBD:** Ligand A (1) is better than Ligand B (2) as lower HBD generally improves permeability.
5. **HBA:** Ligand A (6) is better than Ligand B (4) as lower HBA generally improves permeability.
6. **QED:** Both ligands (0.767 and 0.795) have good drug-likeness scores, well above the 0.5 threshold.
7. **DILI:** Both ligands have low DILI risk (46.646 and 43.117 percentile), which is positive. Ligand B is slightly better.
8. **BBB:** This is less critical for ADRB2 (a cardiovascular target), but Ligand A (74.874) is better than Ligand B (66.615).
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.153 and -4.921), which is unusual and suggests poor permeability. However, these values are on a log scale and are difficult to interpret without further context.
10. **Solubility:** Both ligands have negative solubility values (-1.47 and -2.267), indicating poor aqueous solubility. This is a concern for bioavailability. Ligand A is slightly better.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.217 and 0.679), which is excellent.
12. **Cl_mic:** Ligand A (18.178) has a higher microsomal clearance than Ligand B (11.526), meaning it's less metabolically stable. This is a significant drawback for Ligand A.
13. **t1/2:** Ligand B (-2.886) has a longer in vitro half-life than Ligand A (-1.36), which is desirable.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.074 and 0.071).
15. **Binding Affinity:** Ligand A (-6.1 kcal/mol) has a slightly better binding affinity than Ligand B (-5.6 kcal/mol). This is a 0.5 kcal/mol difference, which is substantial.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity and some marginally better physicochemical properties (TPSA, Solubility), Ligand B demonstrates superior metabolic stability (lower Cl_mic) and a longer half-life. Given that ADRB2 is a cardiovascular target, metabolic stability and duration of action are crucial. The 0.5 kcal/mol difference in binding affinity can potentially be overcome with further optimization, while improving metabolic stability is often more challenging. The poor Caco-2 and solubility values are concerning for both, but the metabolic advantage of Ligand B outweighs the slight affinity benefit of Ligand A.
Output:
0
2025-04-17 22:50:30,291 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (358.5 and 354.5 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (49.41) is well below the 140 threshold and favorable for oral absorption. Ligand B (81.75) is higher, but still within a reasonable range, though less optimal.
3. **logP:** Ligand A (3.942) is within the optimal 1-3 range. Ligand B (0.596) is *below* 1, which is a concern for permeability. This is a significant negative for Ligand B.
4. **HBD:** Both ligands have acceptable HBD counts (1 and 2 respectively), well below the 5 threshold.
5. **HBA:** Both ligands have acceptable HBA counts (3 and 4 respectively), well below the 10 threshold.
6. **QED:** Both ligands have reasonable QED scores (0.851 and 0.635), indicating good drug-like properties. Ligand A is slightly better.
7. **DILI:** Ligand A (65.568) has a higher DILI risk than Ligand B (9.965). This is a significant negative for Ligand A.
8. **BBB:** Ligand A (69.562) has a better BBB penetration percentile than Ligand B (36.487). While ADRB2 isn't strictly a CNS target, some CNS exposure can be relevant for off-target effects and broader safety assessment.
9. **Caco-2:** Ligand A (-4.636) and Ligand B (-5.232) both have negative Caco-2 permeability values, indicating poor permeability. This is a concern for both, but slightly worse for Ligand B.
10. **Solubility:** Ligand A (-5.384) and Ligand B (-0.93) both have negative solubility values, indicating poor solubility. This is a concern for both, but slightly better for Ligand B.
11. **hERG:** Ligand A (0.736) has a lower hERG risk than Ligand B (0.156). This is a positive for Ligand A.
12. **Cl_mic:** Ligand A (94.481) has a higher microsomal clearance than Ligand B (5.362), indicating faster metabolism and lower metabolic stability. This is a significant negative for Ligand A.
13. **t1/2:** Ligand A (-9.739) has a negative in vitro half-life, which is very concerning. Ligand B (-1.157) is also negative, but less so.
14. **Pgp:** Ligand A (0.297) has a lower Pgp efflux liability than Ligand B (0.005). This is a positive for Ligand A.
15. **Affinity:** Ligand A (-7.0) has a slightly better binding affinity than Ligand B (-5.6). This is a 1.4 kcal/mol advantage, which is significant.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are most important. Ligand A has a better logP and Pgp, and a significantly better affinity. However, Ligand B has a much lower DILI risk and better metabolic stability (lower Cl_mic). The poor half-life for both is concerning.
**Overall Assessment:**
Despite the better affinity of Ligand A, the significantly higher DILI risk and poor metabolic stability (high Cl_mic) are major drawbacks. The low logP of Ligand B is a concern, but can potentially be addressed with formulation strategies. The lower DILI and better metabolic stability of Ligand B make it a more promising starting point for optimization.
Output:
0
2025-04-17 22:50:30,292 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
The target is ADRB2, a GPCR. Therefore, I will prioritize logP, TPSA, Pgp efflux, BBB penetration, and binding affinity, followed by ADME properties like solubility, metabolic stability, and safety (DILI, hERG).
Let's compare the ligands property by property:
1. **MW:** Both ligands are within the ideal range (365.415 and 348.487 Da).
2. **TPSA:** Ligand B (78.43) is significantly better than Ligand A (117.43). Lower TPSA generally favors oral absorption and is particularly important for GPCRs.
3. **logP:** Ligand B (1.988) is optimal, while Ligand A (0.57) is a bit low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (2) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand B (3) is preferable to Ligand A (6). Fewer HBAs generally improve permeability.
6. **QED:** Both are reasonable (0.8 and 0.528), suggesting good drug-like properties. Ligand A is slightly better.
7. **DILI:** Ligand B (11.128) is *much* better than Ligand A (89.57), indicating a significantly lower risk of liver injury. This is a critical advantage.
8. **BBB:** Ligand A (79.062) is better than Ligand B (53.083), but BBB isn't a top priority for ADRB2 (a cardiovascular target).
9. **Caco-2:** Ligand A (-5.186) is better than Ligand B (-4.784), suggesting better intestinal absorption.
10. **Solubility:** Ligand A (-3.027) is better than Ligand B (-3.55), though both are poor.
11. **hERG:** Both are very low (0.196 and 0.268), indicating minimal hERG inhibition risk.
12. **Cl_mic:** Ligand A (10.809) is significantly better than Ligand B (40.518), indicating better metabolic stability.
13. **t1/2:** Ligand A (-28.167) is significantly better than Ligand B (-6.828), indicating a longer half-life.
14. **Pgp:** Both are very low (0.031 and 0.141), indicating minimal P-gp efflux.
15. **Affinity:** Both have the same binding affinity (-6.6 kcal/mol).
**Overall Assessment:**
While Ligand A has a slight edge in BBB penetration, Caco-2 permeability, solubility, metabolic stability, and half-life, Ligand B has a *major* advantage in DILI risk and a significant advantage in TPSA and logP, which are critical for GPCR targets. The lower DILI risk is a substantial safety benefit. The better logP and TPSA of Ligand B suggest it will have better permeability and potentially better *in vivo* exposure. The affinity is identical.
Considering these factors, the benefits of Ligand B outweigh those of Ligand A.
**Output:**
0
2025-04-17 22:50:30,292 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (348.403 and 354.407 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (96.55) is better than Ligand B (110.59). For a GPCR, keeping TPSA under 140 is good for oral absorption, and lower is generally preferred.
**3. logP:** Both ligands have a logP of around 2, which is within the optimal range of 1-3. No clear advantage.
**4. H-Bond Donors:** Ligand A (2) is slightly better than Ligand B (1). Both are acceptable.
**5. H-Bond Acceptors:** Ligand B (6) is slightly higher than Ligand A (5), but both are within the acceptable limit of 10.
**6. QED:** Ligand A (0.842) has a significantly better QED score than Ligand B (0.592), indicating a more drug-like profile.
**7. DILI:** Both ligands have DILI risk around the 60-70 percentile, which is moderate. Not a major differentiating factor.
**8. BBB:** Ligand A (53.703) is lower than Ligand B (63.901). While ADRB2 isn't exclusively a CNS target, some CNS penetration can be beneficial for understanding off-target effects and potential side effects.
**9. Caco-2 Permeability:** Ligand A (-5.454) is slightly better than Ligand B (-4.741), indicating potentially better intestinal absorption.
**10. Aqueous Solubility:** Ligand A (-2.322) is better than Ligand B (-3.58), suggesting better solubility.
**11. hERG Inhibition:** Ligand A (0.26) is significantly better than Ligand B (0.452), indicating a lower risk of cardiotoxicity. This is *critical* for a cardiovascular target.
**12. Microsomal Clearance:** Ligand A (-0.588) is much better than Ligand B (31.675), indicating significantly better metabolic stability. This is a major advantage.
**13. In vitro Half-Life:** Ligand A (4.535) is better than Ligand B (-2.804), suggesting a longer half-life.
**14. P-gp Efflux:** Ligand A (0.034) is much better than Ligand B (0.214), indicating lower P-gp efflux and potentially better bioavailability.
**15. Binding Affinity:** Both ligands have very similar binding affinities (-6.8 and -6.9 kcal/mol). The difference is negligible.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across several key ADME properties, including QED, solubility, metabolic stability (Cl_mic), half-life, P-gp efflux, and crucially, hERG inhibition. While both ligands have acceptable logP and MW, Ligand A's superior ADME profile, combined with comparable binding affinity, makes it the more promising drug candidate. The lower hERG risk is particularly important given the cardiovascular target.
Output:
1
2025-04-17 22:50:30,292 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (343.435 Da) is better than Ligand B (373.551 Da), falling comfortably within the 200-500 Da range. Both are acceptable.
2. **TPSA:** Ligand B (62.73) is significantly better than Ligand A (96.88). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better permeability.
3. **logP:** Ligand A (2.696) is better than Ligand B (4.854). Ligand B is pushing the upper limit of the optimal range, increasing the risk of off-target effects and solubility issues.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (2). Both are within the acceptable limit of 5.
5. **HBA:** Ligand A (8) is slightly higher than Ligand B (7). Both are within the acceptable limit of 10.
6. **QED:** Both ligands have similar QED values (A: 0.567, B: 0.619), indicating good drug-likeness.
7. **DILI:** Ligand A (66.421) is better than Ligand B (74.176), indicating a lower risk of drug-induced liver injury. Both are acceptable, but A is preferable.
8. **BBB:** Ligand B (76.541) is better than Ligand A (40.558). However, as ADRB2 is a cardiovascular target, BBB penetration is not a high priority.
9. **Caco-2:** Ligand A (-4.892) is better than Ligand B (-5.205). Higher values indicate better absorption.
10. **Solubility:** Ligand A (-3.975) is better than Ligand B (-4.99). Higher values indicate better solubility.
11. **hERG:** Both ligands have similar hERG inhibition liability (A: 0.606, B: 0.662), indicating a low risk of cardiotoxicity.
12. **Cl_mic:** Ligand A (75.726) is better than Ligand B (84.249), indicating better metabolic stability.
13. **t1/2:** Ligand B (51.352) is better than Ligand A (15.087), suggesting a longer half-life and potentially less frequent dosing. This is a significant advantage.
14. **Pgp:** Both ligands have similar Pgp efflux liability (A: 0.052, B: 0.457).
15. **Binding Affinity:** Ligand B (-6.2 kcal/mol) is significantly better than Ligand A (-5.3 kcal/mol). This 0.9 kcal/mol difference is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand B has a significantly better binding affinity, and a longer half-life, which are both crucial for a GPCR target. While Ligand A has advantages in logP, solubility, and DILI, the potency and PK advantages of Ligand B are more important. The higher logP of Ligand B is a concern, but not a dealbreaker given the strong binding affinity.
Output:
0
2025-04-17 22:50:30,292 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (352.362 and 352.435 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (77.1) is significantly better than Ligand B (113.76). For a GPCR, keeping TPSA low is beneficial for permeability, and Ligand A is well below the 140 threshold. Ligand B is approaching the upper limit.
3. **logP:** Ligand A (2.262) is within the optimal 1-3 range. Ligand B (-0.031) is slightly below 1, which could indicate permeability issues. This is a notable advantage for Ligand A.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (4). Lower HBA is generally better for permeability.
6. **QED:** Both ligands have reasonable QED scores (0.841 and 0.558, respectively), indicating good drug-like properties. Ligand A is better.
7. **DILI:** Ligand A (62.35) has a higher DILI risk than Ligand B (16.13). This is a significant drawback for Ligand A.
8. **BBB:** Ligand A (94.223) has a much higher BBB penetration percentile than Ligand B (80.07). While ADRB2 isn't exclusively a CNS target, some cardiovascular effects can be mediated through CNS pathways, and better BBB penetration can be advantageous.
9. **Caco-2:** Ligand A (-4.167) is better than Ligand B (-5.333). Higher Caco-2 permeability is desirable.
10. **Solubility:** Ligand A (-3.455) is better than Ligand B (-1.248). Better aqueous solubility is crucial for bioavailability.
11. **hERG:** Ligand A (0.502) has a slightly higher hERG risk than Ligand B (0.2). Lower hERG is always preferred.
12. **Cl_mic:** Ligand B (-16.991) has a much lower (better) microsomal clearance than Ligand A (42.36). This indicates greater metabolic stability for Ligand B.
13. **t1/2:** Ligand B (-8.009) has a longer in vitro half-life than Ligand A (7.185). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.046) has a lower Pgp efflux liability than Ligand B (0.01). Lower Pgp is better.
15. **Binding Affinity:** Ligand A (-8.5) has a significantly stronger binding affinity than Ligand B (-5.4). This is a substantial advantage for Ligand A, potentially outweighing some of its ADME drawbacks.
**Overall Assessment:**
Ligand A has a significantly better binding affinity and favorable properties like TPSA, logP, solubility, and Caco-2 permeability. However, it suffers from higher DILI risk and a less favorable metabolic profile (higher Cl_mic, shorter t1/2). Ligand B has a much better safety profile (lower DILI) and metabolic stability, but its lower affinity and less favorable logP/TPSA are concerns.
Given the strong binding affinity of Ligand A and the importance of potency for GPCR targets, I believe the benefits outweigh the risks, *provided* the DILI risk can be mitigated through further structural modifications. The difference in affinity (3.1 kcal/mol) is substantial.
Output:
1
2025-04-17 22:50:30,292 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (366.443 and 348.447 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (98.32) is better than Ligand A (116.31). Both are below 140, but lower TPSA generally favors absorption.
3. **logP:** Both ligands have good logP values (1.183 and 1.318), falling within the 1-3 range. Ligand B is slightly better.
4. **HBD:** Ligand A has 2 HBD, and Ligand B has 3. Both are acceptable (<=5).
5. **HBA:** Ligand A has 7 HBA, and Ligand B has 4. Ligand B is better, being closer to the ideal of <=10.
6. **QED:** Ligand B (0.747) has a significantly better QED score than Ligand A (0.535), indicating a more drug-like profile.
7. **DILI:** Ligand B (33.191) has a much lower DILI risk than Ligand A (84.102). This is a significant advantage for Ligand B.
8. **BBB:** Both ligands have similar BBB penetration (56.611 and 52.423). Since ADRB2 is a cardiovascular target, BBB penetration is not a primary concern.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.149 and -5.015). These values are difficult to interpret without knowing the scale, but suggest poor permeability.
10. **Solubility:** Both ligands have negative solubility values (-3.816 and -2.544). Similar to Caco-2, these suggest poor aqueous solubility.
11. **hERG:** Ligand A (0.267) has a slightly lower hERG risk than Ligand B (0.502), which is favorable.
12. **Cl_mic:** Ligand B (3.329) has a significantly lower microsomal clearance than Ligand A (90.55). This suggests better metabolic stability for Ligand B.
13. **t1/2:** Ligand B (-38.318) has a much longer in vitro half-life than Ligand A (-24.074). This is a major advantage for Ligand B.
14. **Pgp:** Ligand A (0.139) has a lower Pgp efflux liability than Ligand B (0.036). Lower Pgp is better, so Ligand A is slightly favored.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.2 and -6.4 kcal/mol). The difference is negligible.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand B is clearly the better candidate. It has a significantly better QED score, much lower DILI risk, lower microsomal clearance, and a longer half-life. While Ligand A has slightly better Pgp and hERG profiles, the advantages of Ligand B in terms of ADME properties and safety outweigh these minor differences. The similar binding affinities make the ADME/Tox profile the deciding factor.
Output:
0
2025-04-17 22:50:30,292 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.434 and 339.483 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (61.8) is higher than Ligand B (46.92). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B has a slight advantage.
3. **logP:** Ligand A (2.218) is within the optimal 1-3 range. Ligand B (4.619) is significantly higher, potentially leading to solubility issues and off-target interactions. Ligand A is clearly better here.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable. No significant difference.
5. **HBA:** Ligand A (4) and Ligand B (3) are both acceptable. No significant difference.
6. **QED:** Both ligands have good QED scores (0.826 and 0.887), indicating good drug-like properties. No clear advantage.
7. **DILI:** Ligand A (18.845) has a much lower DILI risk than Ligand B (55.021). This is a significant advantage for Ligand A.
8. **BBB:** Both ligands have high BBB penetration (84.374 and 95.657). While ADRB2 isn't a CNS target, higher BBB is not detrimental. Ligand B has a slight advantage.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.742 and -4.639), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-1.909) has better solubility than Ligand B (-5.557). This is important for bioavailability.
11. **hERG:** Both ligands have low hERG inhibition risk (0.721 and 0.883). No significant difference.
12. **Cl_mic:** Ligand A (12.75) has a lower microsomal clearance than Ligand B (64.366), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand B (86.568) has a much longer in vitro half-life than Ligand A (29.528). This is a significant advantage for Ligand B.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.198 and 0.857). No significant difference.
15. **Binding Affinity:** Ligand B (-6.3 kcal/mol) has a slightly better binding affinity than Ligand A (-5.4 kcal/mol). This is a 0.9 kcal/mol difference, which is substantial.
**Overall Assessment & GPCR-Specific Priorities:**
For a cardiovascular GPCR like ADRB2, affinity is crucial. Ligand B's 0.9 kcal/mol advantage in binding is significant. However, Ligand A demonstrates a much more favorable safety profile with a significantly lower DILI risk and better metabolic stability (lower Cl_mic). The higher logP of Ligand B is concerning, potentially leading to poor solubility and off-target effects. While Ligand B has a longer half-life, the risks associated with its ADME profile outweigh this benefit. Considering the balance of properties, the lower DILI and better solubility of Ligand A are more desirable for a cardiovascular drug candidate, even with slightly lower affinity.
Output:
1
2025-04-17 22:50:30,292 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (346.383 Da and 349.475 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand B (84.23) is significantly better than Ligand A (104.73). For a GPCR, lower TPSA is generally preferred for better permeability.
**3. logP:** Ligand B (3.249) is slightly higher than Ligand A (1.194). While both are within the acceptable range of 1-3, Ligand B is approaching the upper limit. However, for a GPCR, a slightly higher logP can be beneficial for membrane interactions.
**4. H-Bond Donors:** Ligand A (3) is slightly higher than Ligand B (2), but both are acceptable (<=5).
**5. H-Bond Acceptors:** Ligand A (5) is slightly higher than Ligand B (4), but both are acceptable (<=10).
**6. QED:** Both ligands have similar QED values (0.671 and 0.635), indicating good drug-likeness.
**7. DILI:** Ligand B (38.62) has a considerably lower DILI risk than Ligand A (54.556). This is a significant advantage for Ligand B.
**8. BBB:** Both ligands show reasonable BBB penetration (68.592 and 72.896). Ligand B is slightly better.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual. This suggests poor permeability. However, the values are similar (-4.948 and -4.785).
**10. Aqueous Solubility:** Both ligands have negative solubility values, which is also unusual. This suggests poor solubility. The values are similar (-2.961 and -3.743).
**11. hERG Inhibition:** Ligand A (0.281) has a slightly lower hERG inhibition risk than Ligand B (0.417), which is preferable.
**12. Microsomal Clearance:** Ligand A (35.717) has a lower microsomal clearance than Ligand B (59.05), indicating better metabolic stability.
**13. In vitro Half-Life:** Ligand B (5.099) has a longer half-life than Ligand A (-6.364). This is a significant advantage for Ligand B.
**14. P-gp Efflux:** Ligand A (0.199) has lower P-gp efflux than Ligand B (0.389), which is preferable.
**15. Binding Affinity:** Ligand B (-7.2 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.9 kcal/mol). This is a crucial advantage, as a 1.3 kcal/mol difference is substantial.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand B is the stronger candidate. Its superior binding affinity (-7.2 vs -5.9 kcal/mol) outweighs the slightly higher logP and P-gp efflux. The lower DILI risk and longer half-life are also significant benefits. While both have poor Caco-2 and solubility, the affinity difference is the deciding factor.
Output:
0
2025-04-17 22:50:30,293 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (365.401 Da) is within the ideal range (200-500 Da). Ligand B (417.3 Da) is also acceptable, though approaching the upper limit.
2. **TPSA:** Ligand A (46.61) is excellent, well below the 140 threshold for oral absorption and suitable for a GPCR. Ligand B (81.01) is higher, but still reasonable.
3. **logP:** Ligand A (3.208) is optimal (1-3). Ligand B (2.507) is also good, slightly lower but still within the preferred range.
4. **HBD:** Ligand A (0) is ideal. Ligand B (1) is acceptable.
5. **HBA:** Ligand A (3) is good. Ligand B (6) is higher, potentially impacting permeability.
6. **QED:** Ligand A (0.821) is excellent, indicating high drug-likeness. Ligand B (0.687) is still acceptable, but less optimal.
7. **DILI:** Ligand A (72.043) is moderate, but acceptable. Ligand B (60.915) is better, indicating lower liver injury risk.
8. **BBB:** Ligand A (76.231) is good, suggesting reasonable potential for CNS penetration (though ADRB2 isn't primarily a CNS target, some distribution is possible). Ligand B (60.101) is lower.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.411 and -4.703), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand A (-5.257) and Ligand B (-3.296) both have negative solubility values, indicating poor aqueous solubility. This is a significant drawback for both.
11. **hERG:** Ligand A (0.72) is better than Ligand B (0.366), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Both ligands have similar microsomal clearance (80.369 and 80.105 mL/min/kg), indicating moderate metabolic stability.
13. **t1/2:** Ligand A (-3.484) is better than Ligand B (55.197), suggesting a longer in vitro half-life.
14. **Pgp:** Ligand A (0.388) is better than Ligand B (0.079), indicating lower P-gp efflux.
15. **Affinity:** Ligand B (-5.8 kcal/mol) has a slightly better binding affinity than Ligand A (-5.2 kcal/mol). This is a 0.6 kcal/mol difference, which is noticeable.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are particularly important. Both ligands have acceptable logP and TPSA values. Ligand A has a better Pgp profile. Ligand B has a slightly better binding affinity. The poor Caco-2 and solubility are concerning for both.
**Overall Assessment:**
Despite the slightly better affinity of Ligand B, Ligand A has a more favorable overall profile. Its better QED, lower DILI risk, better BBB penetration, longer half-life, and lower P-gp efflux are all advantages. The affinity difference between the two is not large enough to overcome these other factors. The poor Caco-2 and solubility are significant concerns for both, and would require formulation strategies to address.
Output:
1
2025-04-17 22:50:30,293 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [335.363, 88.19, 3.584, 1, 5, 0.666, 67.003, 82.319, -4.853, -6.178, 0.856, 37.399, 17.044, 0.396, -6.8]
**Ligand B:** [381.567, 62.3, 3.399, 1, 5, 0.794, 48.468, 67.197, -5.036, -3.792, 0.176, 46.074, -3.629, 0.163, -5.8]
**Step-by-step comparison:**
1. **MW:** Ligand A (335.363 Da) is better than Ligand B (381.567 Da) as it's closer to the ideal range of 200-500 Da. Both are acceptable.
2. **TPSA:** Ligand B (62.3) is significantly better than Ligand A (88.19). Lower TPSA generally favors better membrane permeability, crucial for GPCRs.
3. **logP:** Both ligands have good logP values (A: 3.584, B: 3.399), falling within the optimal 1-3 range.
4. **HBD:** Both have 1 HBD, which is acceptable.
5. **HBA:** Both have 5 HBA, which is acceptable.
6. **QED:** Ligand B (0.794) is slightly better than Ligand A (0.666), indicating a more drug-like profile.
7. **DILI:** Ligand B (48.468) is significantly better than Ligand A (67.003), indicating a lower risk of drug-induced liver injury. This is a major advantage.
8. **BBB:** Ligand A (82.319) is better than Ligand B (67.197). While not a primary concern for ADRB2 (cardiovascular target), higher BBB penetration is generally favorable.
9. **Caco-2:** Ligand A (-4.853) and Ligand B (-5.036) are both very poor. This is a significant concern for oral bioavailability.
10. **Solubility:** Ligand B (-3.792) is better than Ligand A (-6.178). Better solubility is important for formulation and absorption.
11. **hERG:** Ligand B (0.176) is much better than Ligand A (0.856), indicating a lower risk of cardiotoxicity. This is critical for a cardiovascular target.
12. **Cl_mic:** Ligand A (37.399) has lower microsomal clearance than Ligand B (46.074), suggesting better metabolic stability.
13. **t1/2:** Ligand A (17.044) has a longer in vitro half-life than Ligand B (-3.629), which is desirable.
14. **Pgp:** Ligand B (0.163) is better than Ligand A (0.396), indicating lower P-glycoprotein efflux.
15. **Affinity:** Ligand A (-6.8 kcal/mol) has a slightly better binding affinity than Ligand B (-5.8 kcal/mol). This is a 1 kcal/mol difference, which is notable but not overwhelming.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, we prioritize logP, TPSA, Pgp, and affinity. Ligand B excels in TPSA, Pgp, and has a very favorable DILI and hERG profile. Ligand A has a slight edge in affinity and half-life, and BBB penetration, but the safety profile of Ligand B is much more appealing. The Caco-2 permeability is poor for both, but the other advantages of Ligand B outweigh this.
**Conclusion:**
Considering the balance of properties, especially the significantly improved safety profile (DILI and hERG) and better TPSA and Pgp efflux, Ligand B is the more promising drug candidate.
0
2025-04-17 22:50:30,293 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's analyze each ligand against the provided guidelines, with a focus on GPCR-relevant properties (logP, TPSA, Pgp, BBB, and affinity).
* **Molecular Weight:** Both ligands (350.459 Da and 345.487 Da) fall comfortably within the ideal 200-500 Da range.
* **TPSA:** Ligand A (98.66) is higher than the preferred <140, but still reasonable. Ligand B (43.86) is excellent, well below 90, suggesting good permeability.
* **logP:** Ligand A (0.71) is a bit low, potentially impacting permeability. Ligand B (1.91) is within the optimal 1-3 range.
* **H-Bond Donors/Acceptors:** Ligand A (4 HBD, 4 HBA) and Ligand B (0 HBD, 3 HBA) both have acceptable counts.
* **QED:** Both ligands have good QED scores (0.567 and 0.731, respectively), indicating drug-like properties.
* **DILI:** Ligand A (17.604) has a slightly higher DILI risk than Ligand B (12.485), but both are below the concerning threshold of 60.
* **BBB:** Ligand B (79.411) shows significantly better BBB penetration potential than Ligand A (45.677). While ADRB2 isn't exclusively a CNS target, some cardiovascular effects are mediated through CNS pathways, and better BBB penetration could be beneficial.
* **Caco-2 Permeability:** Ligand A (-5.11) and Ligand B (-4.456) are both negative, which is unusual and suggests poor permeability. However, the scale isn't specified, so it's difficult to interpret.
* **Aqueous Solubility:** Both ligands have very poor aqueous solubility (-2.387 and -1.633). This is a significant concern for bioavailability.
* **hERG Inhibition:** Both ligands have low hERG inhibition risk (0.13 and 0.281).
* **Microsomal Clearance:** Ligand A (14.535) and Ligand B (13.984) have similar, moderate microsomal clearance.
* **In vitro Half-Life:** Ligand B (-11.664) has a concerningly short in vitro half-life, while Ligand A (20.765) is much more favorable.
* **P-gp Efflux:** Both ligands have low P-gp efflux (0.019 and 0.048), which is good.
* **Binding Affinity:** Ligand A (-7.6 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.0 kcal/mol). This is a substantial advantage (1.6 kcal/mol difference).
**Overall Assessment:**
The key trade-offs are: Ligand A has significantly better binding affinity and a more reasonable half-life, but suffers from lower logP and BBB penetration, and slightly higher DILI risk. Ligand B has better logP, TPSA, BBB penetration, and lower DILI, but has a much weaker binding affinity and a very short half-life.
Given that we are targeting a GPCR, affinity is paramount. The 1.6 kcal/mol difference in binding affinity is substantial and likely outweighs the drawbacks of Ligand A, *provided* the solubility issues can be addressed through formulation strategies. The longer half-life of Ligand A is also a significant advantage. The lower BBB penetration is less critical for a primarily peripheral target like ADRB2.
**Output:**
1
2025-04-17 22:50:30,293 - INFO - Batch 361 complete. Total preferences: 5776
2025-04-17 22:50:30,293 - INFO - Processing batch 362/512...
2025-04-17 22:51:22,127 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (399.292 Da) is slightly higher than Ligand B (345.487 Da), but both are acceptable.
2. **TPSA:** Ligand A (59.29) is higher than Ligand B (43.86). Both are below the 140 threshold for oral absorption, but B is better.
3. **logP:** Ligand A (3.527) is optimal, while Ligand B (1.578) is on the lower side. This is a significant advantage for A, as GPCRs benefit from good lipophilicity.
4. **HBD:** Ligand A (1) is preferable to Ligand B (0), as a single HBD can aid solubility without significantly impacting permeability.
5. **HBA:** Ligand A (4) is slightly higher than Ligand B (3), but both are within the acceptable range.
6. **QED:** Both ligands have good QED scores (A: 0.683, B: 0.777), indicating good drug-like properties. B is slightly better here.
7. **DILI:** Ligand A (72.276) has a higher DILI risk than Ligand B (9.539). This is a major concern for A.
8. **BBB:** Both ligands have reasonably good BBB penetration (A: 78.79, B: 75.727). This isn't a primary concern for ADRB2, which is not a CNS target.
9. **Caco-2:** Ligand A (-5.273) has a negative Caco-2 value, which is concerning. Ligand B (-4.789) is also negative, but less so.
10. **Solubility:** Ligand A (-4.331) has poor solubility, while Ligand B (-1.688) is better.
11. **hERG:** Both ligands have low hERG inhibition liability (A: 0.355, B: 0.502), which is good.
12. **Cl_mic:** Ligand A (25.886) has a higher microsomal clearance than Ligand B (11.055), indicating lower metabolic stability.
13. **t1/2:** Ligand A (39.928) has a longer in vitro half-life than Ligand B (10.964). This is a positive for A.
14. **Pgp:** Ligand A (0.667) has higher P-gp efflux than Ligand B (0.043). This is a negative for A.
15. **Binding Affinity:** Ligand B (-6.6 kcal/mol) has a significantly stronger binding affinity than Ligand A (-4.6 kcal/mol). This is a substantial advantage for B.
**Overall Assessment:**
Ligand B is the stronger candidate. While Ligand A has a longer half-life, it is significantly hampered by its poor solubility, high DILI risk, higher P-gp efflux, and weaker binding affinity. Ligand B has a much better safety profile (lower DILI), better predicted permeability (though still negative), and a much stronger binding affinity, which is crucial for GPCR targets. The slightly lower logP of Ligand B is a minor drawback compared to the significant advantages it offers.
Output:
0
2025-04-17 22:51:22,127 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (348.447 and 363.483 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (78.53) is slightly higher than Ligand B (71.53). Both are below the 140 A^2 threshold for good oral absorption, and acceptable for a cardiovascular target (not requiring significant BBB penetration).
**3. logP:** Both ligands have good logP values (2.157 and 2.334), falling within the optimal 1-3 range.
**4. H-Bond Donors:** Both have 1 HBD, which is well within the acceptable limit of <=5.
**5. H-Bond Acceptors:** Ligand A has 4 HBAs, and Ligand B has 5. Both are below the 10 HBA threshold.
**6. QED:** Both ligands have similar QED values (0.766 and 0.755), indicating good drug-likeness.
**7. DILI:** Ligand A (47.111) has a slightly lower DILI risk than Ligand B (54.634). Both are below the concerning threshold of 60, but lower is preferred.
**8. BBB:** Ligand B (78.364) has a higher BBB percentile than Ligand A (69.407). While ADRB2 is a cardiovascular target and doesn't *require* high BBB penetration, a moderate level isn't detrimental.
**9. Caco-2 Permeability:** Ligand A (-5.085) has slightly better Caco-2 permeability than Ligand B (-4.61). Higher values indicate better absorption.
**10. Aqueous Solubility:** Ligand A (-2.662) has better aqueous solubility than Ligand B (-3.022).
**11. hERG Inhibition:** Ligand A (0.386) has a lower hERG inhibition liability than Ligand B (0.158), which is a significant advantage for cardiovascular drugs.
**12. Microsomal Clearance:** Ligand B (53.311) has a higher microsomal clearance than Ligand A (20.684), suggesting faster metabolism and potentially lower *in vivo* exposure.
**13. In vitro Half-Life:** Ligand A (-12.422) has a longer in vitro half-life than Ligand B (-10.302).
**14. P-gp Efflux:** Ligand A (0.094) has lower P-gp efflux liability than Ligand B (0.161), which is favorable for bioavailability.
**15. Binding Affinity:** Ligand A (-6.7 kcal/mol) has a slightly better binding affinity than Ligand B (-5.8 kcal/mol). This 0.9 kcal/mol difference is significant and can outweigh minor ADME drawbacks.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand A is the more promising candidate. It has a better binding affinity, lower DILI risk, lower hERG inhibition, better solubility, lower P-gp efflux, and a longer half-life. While Ligand B has slightly better BBB penetration, this is less critical for a cardiovascular target. The combination of improved potency and favorable ADME properties makes Ligand A the preferred choice.
Output:
1
2025-04-17 22:51:22,127 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (349.391 Da) is within the ideal range, while Ligand B (365.474 Da) is slightly higher but still acceptable.
2. **TPSA:** Ligand A (139.34) is borderline for good oral absorption, but acceptable for a non-CNS GPCR target like ADRB2. Ligand B (43.86) is excellent, well below the 140 threshold.
3. **logP:** Ligand A (-1.315) is a bit low, potentially hindering permeability. Ligand B (1.902) is within the optimal range. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (4) is acceptable. Ligand B (0) is excellent, potentially improving permeability.
5. **HBA:** Ligand A (6) is acceptable. Ligand B (4) is also good.
6. **QED:** Ligand B (0.822) is significantly better than Ligand A (0.431), indicating a more drug-like profile.
7. **DILI:** Ligand A (36.681) is slightly higher than Ligand B (23.187), suggesting a marginally higher risk of liver injury.
8. **BBB:** Both are low, which is fine for a cardiovascular target. Ligand B (93.68) is higher, but BBB is not a high priority for ADRB2.
9. **Caco-2:** Ligand A (-6.273) is poor, indicating poor intestinal absorption. Ligand B (-4.647) is also poor, but comparatively better.
10. **Solubility:** Ligand A (-0.951) is poor. Ligand B (-1.976) is also poor. Solubility is a concern for both.
11. **hERG:** Ligand A (0.092) is very low risk. Ligand B (0.781) is slightly higher, but still relatively low.
12. **Cl_mic:** Ligand A (-13.392) is excellent (low clearance, high metabolic stability). Ligand B (8.062) is moderate, suggesting faster metabolism.
13. **t1/2:** Ligand A (-6.072) is good. Ligand B (10.043) is excellent, indicating a longer half-life.
14. **Pgp:** Ligand A (0.008) is very low efflux, which is good. Ligand B (0.324) is slightly higher, but still acceptable.
15. **Affinity:** Both ligands have very similar binding affinities (-7.1 and -6.3 kcal/mol). The difference is less than 1.5 kcal/mol, so it doesn't heavily sway the decision.
**GPCR-specific priorities:** For ADRB2, logP, TPSA, and affinity are key. Ligand B excels in logP and TPSA, and has a comparable affinity. While Ligand A has better metabolic stability (Cl_mic), Ligand B's superior drug-likeness (QED) and better permeability characteristics (TPSA, HBD) are more important for a GPCR target. The slightly longer half-life of Ligand B is also a plus.
**Conclusion:**
Considering the balance of properties, particularly the GPCR-specific priorities, Ligand B is the more promising drug candidate.
Output:
0
2025-04-17 22:51:22,128 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (371.413 and 369.849 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (71.33) is better than Ligand B (80.76). Both are below 140, but lower TPSA generally favors better absorption.
3. **logP:** Ligand B (1.507) is slightly better than Ligand A (0.608). Both are within the optimal 1-3 range, but Ligand A is a bit low, potentially hindering permeation.
4. **HBD:** Ligand A (0) is better than Ligand B (1). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (6) is slightly better than Ligand B (5). Both are within the acceptable limit of 10.
6. **QED:** Both ligands have good QED scores (0.776 and 0.822), indicating good drug-like properties. No significant difference.
7. **DILI:** Ligand B (56.185) has a lower DILI risk than Ligand A (62.156), which is preferable.
8. **BBB:** Ligand A (71.074) is slightly better than Ligand B (69.523). While ADRB2 isn't exclusively a CNS target, some CNS exposure could be relevant, and higher BBB is generally favorable.
9. **Caco-2:** Both ligands have very negative Caco-2 values (-4.947 and -4.79). This is unusual and suggests poor permeability.
10. **Solubility:** Both ligands have very negative solubility values (-2.232 and -2.145). This is also unusual and suggests poor solubility.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.123 and 0.211), which is excellent.
12. **Cl_mic:** Ligand B (6.695) has significantly lower microsomal clearance than Ligand A (18.016), indicating better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand B (26.487) has a much longer in vitro half-life than Ligand A (-3.629). This is a major advantage, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.063 and 0.082), which is good.
15. **Binding Affinity:** Ligand A (-7.8) has a slightly better binding affinity than Ligand B (-6.8). This is a 1.0 kcal/mol difference, which is significant, but needs to be weighed against other factors.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B has a better logP and significantly better metabolic stability (Cl_mic and t1/2). While Ligand A has slightly better affinity and BBB, the improvements in ADME properties with Ligand B are more compelling. The negative Caco-2 and solubility values for both are concerning and would require further investigation, but the better metabolic profile of Ligand B is a strong advantage.
**Conclusion:**
Considering the balance of properties, particularly the improved metabolic stability and half-life of Ligand B, I believe it is the more promising drug candidate. The affinity difference, while notable, is likely outweighed by the ADME benefits.
Output:
0
2025-04-17 22:51:22,128 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (352.523) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (55.89) is significantly better than Ligand B (79.42). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (1.166) is within the optimal range, while Ligand B (3.76) is approaching the higher end. While not drastically high, the higher logP of B could potentially lead to solubility issues or off-target interactions.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 4 HBAs, and Ligand B has 7. Ligand A is preferable here.
6. **QED:** Both ligands have similar QED values (0.712 and 0.755), indicating good drug-likeness.
7. **DILI:** Ligand A (6.747) has a much lower DILI risk than Ligand B (69.252). This is a significant advantage for Ligand A.
8. **BBB:** Both are relatively low, but Ligand B (71.811) is higher than Ligand A (54.556). However, as ADRB2 is not a CNS target, this is less critical.
9. **Caco-2:** Ligand A (-4.885) and Ligand B (-5.243) are similar, indicating comparable intestinal absorption.
10. **Solubility:** Ligand A (-0.897) is better than Ligand B (-4.956). This is important for bioavailability.
11. **hERG:** Ligand A (0.619) has a lower hERG risk than Ligand B (0.351), which is favorable.
12. **Cl_mic:** Ligand A (12.918) has a significantly lower microsomal clearance than Ligand B (59.359), indicating better metabolic stability.
13. **t1/2:** Ligand A (-7.078) has a much longer in vitro half-life than Ligand B (20.043). This is a major advantage.
14. **Pgp:** Ligand A (0.009) has a lower Pgp efflux liability than Ligand B (0.512), which is preferable.
15. **Binding Affinity:** Ligand B (-7.1) has slightly better binding affinity than Ligand A (-5.7). While affinity is important, the difference of 1.4 kcal/mol isn't substantial enough to outweigh the numerous ADME advantages of Ligand A.
**GPCR-specific priorities:** For ADRB2 (a cardiovascular GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has better TPSA, Pgp, and a reasonable logP. While Ligand B has slightly better affinity, the substantial improvements in ADME properties (DILI, solubility, metabolic stability, half-life) for Ligand A are more crucial for overall drug development success.
**Conclusion:**
Ligand A demonstrates a significantly better overall profile, particularly regarding safety (DILI, hERG) and pharmacokinetic properties (Cl_mic, t1/2, Pgp, solubility). The slightly lower binding affinity is a reasonable trade-off for these improvements.
Output:
1
2025-04-17 22:51:22,128 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (380.348 and 349.362 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (93.46) is significantly better than Ligand A (117.09). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (1.428 and 1.826), falling within the 1-3 range. Ligand B is slightly better.
4. **HBD:** Ligand B (2) is preferable to Ligand A (3). Fewer HBDs generally improve permeability.
5. **HBA:** Both ligands have the same number of HBA (5), which is acceptable.
6. **QED:** Ligand A (0.628) has a slightly better QED score than Ligand B (0.532), indicating a more drug-like profile.
7. **DILI:** Ligand B (56.417) has a significantly lower DILI risk than Ligand A (81.117). This is a major advantage for Ligand B.
8. **BBB:** Ligand B (63.784) has a higher BBB penetration percentile than Ligand A (52.385). While ADRB2 is cardiovascular, some CNS side effects are possible with adrenergic drugs, so moderate BBB penetration isn't necessarily a negative.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.332 and -5.109), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Both ligands have negative solubility values (-3.009 and -2.45). This is also a concern, indicating poor aqueous solubility.
11. **hERG:** Both ligands have low hERG inhibition liability (0.46 and 0.407), which is good.
12. **Cl_mic:** Ligand A (25.454) has a lower microsomal clearance than Ligand B (45.447), suggesting better metabolic stability.
13. **t1/2:** Ligand B (46.877) has a much longer in vitro half-life than Ligand A (-24.126). This is a significant advantage for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.135 and 0.055).
15. **Binding Affinity:** Ligand B (-8.6 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.3 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME concerns.
**Overall Assessment:**
Ligand B is the stronger candidate. The significantly improved binding affinity (-8.6 vs -6.3 kcal/mol) and longer half-life (46.877 vs -24.126) are major advantages. While both have poor Caco-2 and solubility, the lower DILI risk and slightly better TPSA/logP of Ligand B are also favorable. The higher QED of Ligand A is a minor benefit that doesn't outweigh the other factors.
Output:
0
2025-04-17 22:51:22,128 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (347.394) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are reasonably good, below the 140 threshold for oral absorption. Ligand B (91.76) is slightly better than Ligand A (99.77).
3. **logP:** Both are within the optimal range (1-3). Ligand B (0.873) is a bit lower, while Ligand A (1.715) is closer to the ideal.
4. **HBD:** Both are acceptable, below the limit of 5. Ligand B (2) is slightly better.
5. **HBA:** Ligand A (4) is better than Ligand B (6), being closer to the ideal of 10 or less.
6. **QED:** Both are similar and above the 0.5 threshold, indicating good drug-likeness.
7. **DILI:** Both have similar DILI risk (Ligand A: 53.432, Ligand B: 55.487), and are both acceptable (below 60).
8. **BBB:** Ligand B (77.782) has a significantly higher BBB penetration percentile than Ligand A (51.183). This is a key consideration for GPCRs, even if ADRB2 isn't exclusively a CNS target, as some peripheral effects can be mediated by CNS penetration.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Both have negative solubility values, which is also concerning.
11. **hERG:** Both have low hERG inhibition liability. Ligand A (0.454) is slightly better than Ligand B (0.924).
12. **Cl_mic:** Ligand A (23.913) has a significantly lower microsomal clearance than Ligand B (38.894), indicating better metabolic stability.
13. **t1/2:** Ligand A (4.321) has a slightly longer in vitro half-life than Ligand B (3.278).
14. **Pgp:** Ligand A (0.016) has much lower P-gp efflux liability than Ligand B (0.213), which is favorable for bioavailability.
15. **Binding Affinity:** Both have very similar binding affinities (-6.3 and -6.2 kcal/mol). The difference is negligible.
**Overall Assessment:**
While both compounds have issues with Caco-2 and solubility, Ligand B has a substantial advantage in BBB penetration, which is important for GPCRs. Ligand A, however, has better metabolic stability (lower Cl_mic), longer half-life, and lower P-gp efflux. The binding affinity is almost identical. Considering the balance, the better metabolic profile and lower efflux of Ligand A are more valuable than the slightly better BBB penetration of Ligand B, especially given the poor permeability indicated by the Caco-2 values. Improving permeability will be crucial for either compound, but a more stable and bioavailable molecule is a better starting point.
Output:
1
2025-04-17 22:51:22,128 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (345.443 & 344.499 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (62.74) is higher than Ligand B (40.62). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B has a clear advantage.
3. **logP:** Both ligands have good logP values (2.871 & 3.232), falling within the optimal 1-3 range. Ligand B is slightly higher, which could potentially lead to slightly better membrane permeability.
4. **HBD:** Both have 0 HBD, which is good.
5. **HBA:** Ligand A has 4 HBA, while Ligand B has 2. Lower HBA is generally better for permeability, giving Ligand B an advantage.
6. **QED:** Ligand A (0.79) has a significantly better QED score than Ligand B (0.446), indicating a more drug-like profile overall. This is a substantial positive for Ligand A.
7. **DILI:** Ligand B (13.339) has a much lower DILI risk than Ligand A (46.258). This is a major advantage for Ligand B, as liver toxicity is a critical concern.
8. **BBB:** Ligand A (81.233) has a higher BBB percentile than Ligand B (77.627). While ADRB2 isn't a primary CNS target, some brain exposure can be relevant for off-target effects or peripheral effects mediated by brain pathways.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.255 and -4.604). This is unusual and suggests poor permeability. However, the values are similar, so it doesn't differentiate the ligands.
10. **Solubility:** Ligand A (-2.027) has slightly better solubility than Ligand B (-3.473), but both are poor. Solubility is a concern for both.
11. **hERG:** Ligand A (0.353) has a lower hERG risk than Ligand B (0.692). This is a positive for Ligand A, as hERG inhibition can cause cardiotoxicity.
12. **Cl_mic:** Ligand B (49.342) has lower microsomal clearance than Ligand A (60.761), indicating better metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand B (18.043) has a much longer in vitro half-life than Ligand A (-6.276). This is a major advantage for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.081) has lower P-gp efflux than Ligand B (0.322), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand A (-7.6) has a better binding affinity than Ligand B (-5.3). This is a substantial advantage for Ligand A. A 2.3 kcal/mol difference is significant.
**Overall Assessment:**
Ligand A has a better binding affinity, QED, hERG, and Pgp profile. However, Ligand B excels in DILI risk, metabolic stability (Cl_mic), and in vitro half-life. The lower TPSA and HBA of Ligand B are also favorable for permeability. The binding affinity difference is significant, but the improved safety (DILI) and PK (Cl_mic, t1/2) of Ligand B are compelling. Considering the cardiovascular target, minimizing liver toxicity and maximizing duration of action are crucial.
**Output:**
0
2025-04-17 22:51:22,128 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [354.447, 79.31, 0.812, 1, 5, 0.808, 16.557, 55.138, -4.867, -1.181, 0.294, 1.123, -0.561, 0.066, -6.9]
**Ligand B:** [412.376, 64.86, 3.021, 1, 6, 0.632, 28.383, 79.682, -5.212, -3.535, 0.404, 43.147, 18.075, 0.488, -6.2]
**Step-by-step comparison:**
1. **MW:** Ligand A (354.447 Da) is within the ideal range (200-500 Da). Ligand B (412.376 Da) is also acceptable, but approaching the upper limit.
2. **TPSA:** Ligand A (79.31) is good, below 140, and reasonable for a non-CNS GPCR target. Ligand B (64.86) is even better, further below the 140 threshold.
3. **logP:** Ligand A (0.812) is a bit low, potentially hindering permeability. Ligand B (3.021) is optimal. This is a significant advantage for B.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 5 HBA, acceptable. Ligand B has 6 HBA, also acceptable.
6. **QED:** Ligand A (0.808) is excellent, indicating high drug-likeness. Ligand B (0.632) is still acceptable, but lower.
7. **DILI:** Ligand A (16.557%) has a much lower DILI risk than Ligand B (28.383%). This is a substantial advantage for A.
8. **BBB:** Ligand A (55.138%) is moderate. Ligand B (79.682%) is better, suggesting improved potential for CNS penetration, though ADRB2 isn't primarily a CNS target.
9. **Caco-2:** Ligand A (-4.867) is poor, suggesting poor absorption. Ligand B (-5.212) is also poor, but slightly better.
10. **Solubility:** Ligand A (-1.181) is very poor. Ligand B (-3.535) is even worse. Both are problematic.
11. **hERG:** Ligand A (0.294) has a very low hERG risk. Ligand B (0.404) is slightly higher, but still acceptable.
12. **Cl_mic:** Ligand A (1.123) has very low microsomal clearance, indicating good metabolic stability. Ligand B (43.147) is significantly higher, suggesting faster metabolism. This is a major advantage for A.
13. **t1/2:** Ligand A (-0.561) is poor. Ligand B (18.075) is excellent.
14. **Pgp:** Ligand A (0.066) has very low P-gp efflux, which is favorable. Ligand B (0.488) is higher, indicating more efflux.
15. **Affinity:** Ligand A (-6.9 kcal/mol) has slightly better binding affinity than Ligand B (-6.2 kcal/mol). This is a 0.7 kcal/mol difference, which is significant.
**GPCR-Specific Priorities:** For ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP and TPSA, and has a good BBB score. Ligand A has better affinity, lower DILI, lower Cl_mic, and lower Pgp efflux. Solubility and Caco-2 are poor for both.
**Overall Assessment:**
While Ligand B has better logP and BBB, the significantly lower DILI risk, better metabolic stability (lower Cl_mic), better affinity, and lower Pgp efflux of Ligand A are more critical for overall drug development success. The solubility and Caco-2 issues are concerning for both, but can potentially be addressed with formulation strategies. The superior ADME profile of Ligand A, coupled with its slightly better binding affinity, outweighs the benefits of Ligand B's logP and BBB.
Output:
1
2025-04-17 22:51:22,128 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Ligand A (343.467 Da) is well within the ideal range (200-500). Ligand B (392.499 Da) is also acceptable, but slightly higher.
2. **TPSA:** Ligand A (46.61) is excellent, well below the 140 threshold and suitable for good absorption. Ligand B (85.35) is higher, but still within a reasonable range, though potentially impacting absorption slightly.
3. **logP:** Both ligands (A: 3.388, B: 3.149) are within the optimal 1-3 range.
4. **HBD:** Ligand A (0) is ideal. Ligand B (4) is acceptable, but higher HBD can sometimes lead to issues.
5. **HBA:** Ligand A (3) is good. Ligand B (4) is also acceptable.
6. **QED:** Ligand A (0.713) is significantly better than Ligand B (0.519), indicating a more drug-like profile.
7. **DILI:** Ligand A (11.128) has a much lower DILI risk than Ligand B (38.697). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (91.276) shows excellent potential for BBB penetration, while Ligand B (24.544) is poor. While ADRB2 isn't *strictly* a CNS target, some peripheral ADRB2 activity can influence CNS pathways, and better BBB penetration is generally favorable.
9. **Caco-2:** Ligand A (-4.546) is better than Ligand B (-5.935). Higher Caco-2 values indicate better intestinal absorption.
10. **Solubility:** Ligand A (-2.363) is better than Ligand B (-4.508).
11. **hERG:** Both ligands are relatively low risk (A: 0.695, B: 0.855).
12. **Cl_mic:** Ligand A (45.485) has a lower microsomal clearance than Ligand B (50.459), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-21.485) has a much longer in vitro half-life than Ligand B (-4.163). This is a major advantage.
14. **Pgp:** Both ligands have similar Pgp efflux liability (A: 0.558, B: 0.484).
15. **Affinity:** Ligand A (-7.0) and Ligand B (-6.6) have very similar binding affinities. The difference of 0.4 kcal/mol is not substantial enough to outweigh the other significant advantages of Ligand A.
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Both ligands perform well on logP and affinity. Ligand A is superior in TPSA and Pgp.
**Overall Assessment:**
Ligand A is significantly better across multiple critical ADME-Tox parameters (DILI, BBB, solubility, Cl_mic, t1/2, QED) without sacrificing binding affinity. While Ligand B isn't terrible, the superior profile of Ligand A makes it the more promising drug candidate.
Output:
1
2025-04-17 22:51:22,129 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (362.817 Da and 366.487 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (79.13) is slightly higher than Ligand B (72.96). Both are below the 140 A^2 threshold for good oral absorption, but closer to the 90 A^2 threshold for CNS targets (less relevant here, but still a positive). Ligand B is marginally better.
**3. logP:** Ligand A (2.1) is within the optimal 1-3 range. Ligand B (0.927) is slightly below 1, which *could* indicate potential permeability issues, though not severely. Ligand A is preferred here.
**4. H-Bond Donors:** Ligand A (0) is excellent, minimizing potential permeability issues. Ligand B (1) is acceptable, but less ideal. Ligand A is better.
**5. H-Bond Acceptors:** Ligand A (7) and Ligand B (4) are both within the acceptable range of <=10. Ligand B is better.
**6. QED:** Ligand B (0.841) has a significantly higher QED score than Ligand A (0.598), suggesting a more drug-like profile overall. This is a substantial advantage for Ligand B.
**7. DILI Risk:** Ligand A (65.917) has a higher DILI risk than Ligand B (25.785). This is a significant concern, as we want to minimize liver toxicity. Ligand B is strongly preferred.
**8. BBB Penetration:** Ligand A (81.698) has better BBB penetration than Ligand B (65.491), but this is less critical for a cardiovascular target.
**9. Caco-2 Permeability:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-5.062) is slightly worse than Ligand B (-4.912).
**10. Aqueous Solubility:** Both have negative solubility values, which is also unusual and suggests poor solubility. Ligand A (-2.419) is slightly worse than Ligand B (-2.025).
**11. hERG Inhibition:** Ligand A (0.08) has a lower hERG inhibition risk than Ligand B (0.497). This is a positive for Ligand A, as we want to avoid cardiotoxicity.
**12. Microsomal Clearance:** Ligand B (9.297) has significantly lower microsomal clearance than Ligand A (41.292), indicating better metabolic stability. This is a major advantage for Ligand B.
**13. In vitro Half-Life:** Ligand B (-44.909) has a much longer in vitro half-life than Ligand A (2.056), which is highly desirable. This is a crucial advantage for Ligand B.
**14. P-gp Efflux:** Ligand A (0.195) has lower P-gp efflux than Ligand B (0.011), which is better.
**15. Binding Affinity:** Ligand A (-6.5 kcal/mol) has a slightly better binding affinity than Ligand B (-5.5 kcal/mol). While a 1 kcal/mol difference is notable, it's not overwhelming, especially given the other factors.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity) and general drug-like properties, Ligand B is the stronger candidate. Its significantly lower DILI risk, much better metabolic stability (lower Cl_mic and longer t1/2), and higher QED score outweigh the slightly weaker binding affinity and lower logP. While Ligand A has a slightly better affinity and P-gp profile, the safety and pharmacokinetic advantages of Ligand B are more critical for overall drug development success.
Output:
0
2025-04-17 22:51:22,129 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (364.471 and 350.438 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand B (56.32) is significantly better than Ligand A (92.57). For a GPCR, lower TPSA is generally preferred for better permeability. Ligand B is well below the 140 threshold, while A is approaching it.
**3. logP:** Both ligands have acceptable logP values (1.562 and 2.824), falling within the 1-3 range. Ligand B is slightly more lipophilic, which could be beneficial for membrane permeability.
**4. H-Bond Donors:** Ligand A has 2 HBD, and Ligand B has 0. Both are within the acceptable limit of 5.
**5. H-Bond Acceptors:** Ligand A has 5 HBA, and Ligand B has 6. Both are within the acceptable limit of 10.
**6. QED:** Both ligands have similar QED values (0.78 and 0.659), indicating good drug-likeness.
**7. DILI Risk:** Ligand B (14.114) has a much lower DILI risk than Ligand A (64.676). This is a substantial advantage for Ligand B.
**8. BBB Penetration:** Ligand B (94.029) has significantly higher predicted BBB penetration than Ligand A (59.403). While ADRB2 is primarily a cardiovascular target, some CNS effects are possible with certain ligands, and higher BBB penetration isn't necessarily detrimental.
**9. Caco-2 Permeability:** Ligand A (-5.091) and Ligand B (-4.524) both have negative values, which is unusual. It suggests poor permeability. However, the difference is small.
**10. Aqueous Solubility:** Ligand A (-3.548) and Ligand B (-2.364) both have negative solubility values, indicating poor solubility. Again, the difference is small.
**11. hERG Inhibition:** Ligand A (0.431) has a slightly lower hERG inhibition risk than Ligand B (0.831), which is preferable.
**12. Microsomal Clearance:** Ligand B (42.683) has a slightly lower microsomal clearance than Ligand A (48.142), indicating better metabolic stability.
**13. In vitro Half-Life:** Ligand B (29.74) has a significantly longer in vitro half-life than Ligand A (-26.729). This is a major advantage for Ligand B, potentially allowing for less frequent dosing.
**14. P-gp Efflux:** Ligand A (0.031) has a lower P-gp efflux liability than Ligand B (0.4). This is a positive for Ligand A.
**15. Binding Affinity:** Ligand B (-6.8 kcal/mol) has a slightly better binding affinity than Ligand A (-6.5 kcal/mol). While the difference is small, it's still a factor.
**Overall Assessment:**
Ligand B is the stronger candidate. While Ligand A has slightly better P-gp efflux and hERG inhibition, Ligand B excels in several critical areas: significantly lower DILI risk, much higher predicted BBB penetration, a longer in vitro half-life, and slightly better binding affinity. The lower TPSA of Ligand B is also a significant advantage for a GPCR target. The solubility and Caco-2 permeability are poor for both, but the other advantages of Ligand B outweigh these concerns.
Output:
0
2025-04-17 22:51:22,129 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.39 and 358.41 Da) fall comfortably within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (86.71) is slightly higher than Ligand B (77.1). Both are below the 140 A^2 threshold for good oral absorption, but B is preferable given the GPCR target class.
3. **logP:** Ligand A (2.209) is within the optimal 1-3 range. Ligand B (0.415) is a bit low, potentially hindering membrane permeability. This favors Ligand A.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable, below the limit of 5. Ligand B is slightly better.
5. **HBA:** Ligand A (3) and Ligand B (5) are both acceptable, below the limit of 10. Ligand A is preferable.
6. **QED:** Both ligands have similar QED values (0.872 and 0.788), indicating good drug-likeness. No significant difference.
7. **DILI:** Ligand B (49.011) has a significantly lower DILI risk than Ligand A (61.807). This is a substantial advantage for Ligand B.
8. **BBB:** Ligand B (83.404) shows much better BBB penetration potential than Ligand A (36.836). Given that ADRB2 is a GPCR, and while not exclusively a CNS target, improved BBB penetration is beneficial for broader distribution and potential off-target effects assessment. This strongly favors Ligand B.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.815 and -4.489), which is unusual and suggests poor permeability. However, the values are close, and this is less critical than other parameters.
10. **Solubility:** Both ligands have negative solubility values (-2.234 and -1.633), also unusual. Again, values are close.
11. **hERG:** Ligand A (0.063) has a slightly lower hERG inhibition liability than Ligand B (0.249), which is preferable.
12. **Cl_mic:** Ligand A (-7.487) has a much lower microsomal clearance than Ligand B (2.057), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (-3.032) has a more negative in vitro half-life than Ligand B (0.469), suggesting a longer half-life. This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.01) has a much lower P-gp efflux liability than Ligand B (0.056), indicating better bioavailability and potential CNS exposure. This favors Ligand A.
15. **Binding Affinity:** Both ligands have identical binding affinities (-6.9 kcal/mol). This eliminates affinity as a differentiating factor.
**Overall Assessment:**
Ligand B excels in DILI risk and BBB penetration, which are important considerations for a GPCR target. However, Ligand A demonstrates superior metabolic stability (Cl_mic, t1/2), P-gp efflux, and a slightly better hERG profile. The lower logP of Ligand B is a concern for permeability. Considering the balance of these factors, and prioritizing metabolic stability and permeability for a GPCR target, Ligand A appears to be the more promising candidate.
Output:
1
2025-04-17 22:51:22,129 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (390.456) is slightly higher than Ligand B (348.491), but both are acceptable.
2. **TPSA:** Both ligands have TPSA values below 140, indicating good potential for oral absorption. Ligand A (58.12) is slightly higher than Ligand B (55.89), but both are good.
3. **logP:** Ligand A (4.853) is at the upper end of the optimal range, potentially raising concerns about solubility and off-target effects. Ligand B (0.552) is quite low, which might hinder membrane permeability. This is a significant difference.
4. **HBD:** Both ligands have 1 H-bond donor, which is within the acceptable limit of 5.
5. **HBA:** Ligand A (5) and Ligand B (4) are both within the acceptable limit of 10.
6. **QED:** Both ligands have QED values above 0.5, indicating good drug-likeness. Ligand A (0.812) is slightly better than Ligand B (0.73).
7. **DILI:** Ligand A (68.98) has a higher DILI risk than Ligand B (4.769). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (94.843) has a much higher BBB penetration potential than Ligand B (80.419). While ADRB2 isn't strictly a CNS target, some CNS exposure can occur, and higher BBB penetration is generally favorable.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so this is hard to interpret.
10. **Solubility:** Ligand A (-4.872) has very poor aqueous solubility, while Ligand B (-0.863) is better, but still not ideal.
11. **hERG:** Ligand A (0.779) has a slightly higher hERG risk than Ligand B (0.39), meaning B is safer.
12. **Cl_mic:** Ligand A (35.042) has a higher microsomal clearance than Ligand B (1.61), indicating lower metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand A (-7.844) has a much longer in vitro half-life than Ligand B (-0.551). This is a strong point in favor of Ligand A.
14. **Pgp:** Ligand A (0.581) has lower P-gp efflux liability than Ligand B (0.009), which is favorable.
15. **Affinity:** Ligand A (-8.1 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.8 kcal/mol). This is a substantial advantage for Ligand A, potentially outweighing some of its ADME drawbacks.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are particularly important. Ligand A has a higher logP, which could be problematic, but its affinity is significantly better. Ligand B has better solubility, lower DILI, and lower Cl_mic, but its affinity is weaker.
**Overall Assessment:**
The strong binding affinity of Ligand A (-8.1 kcal/mol) is a major advantage. While its logP is high and solubility is poor, the potency advantage is likely to be critical for efficacy. The longer half-life is also a plus. Ligand B has a better safety profile (lower DILI, hERG) and metabolic stability, but the weaker binding affinity is a significant drawback. Given the importance of potency for GPCR targets, I believe Ligand A is the more promising candidate, despite its ADME liabilities, which could be addressed through further optimization.
Output:
1
2025-04-17 22:51:22,129 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (378.885 Da) is slightly higher than Ligand B (352.391 Da), but both are acceptable.
2. **TPSA:** Ligand A (83.12) is well below the 140 threshold and good for oral absorption. Ligand B (114.63) is still under 140, but closer to the limit. A is better here.
3. **logP:** Ligand A (2.432) is optimal. Ligand B (0.083) is quite low, potentially hindering membrane permeability. This is a significant drawback for Ligand B.
4. **HBD:** Ligand A (3) and Ligand B (1) are both within the acceptable limit of 5.
5. **HBA:** Ligand A (5) and Ligand B (7) are both under the 10 limit.
6. **QED:** Both ligands have reasonable QED scores (A: 0.716, B: 0.659), indicating good drug-like properties.
7. **DILI:** Ligand A (72.005) has a higher DILI risk than Ligand B (47.46), but both are still within an acceptable range (<60 is good).
8. **BBB:** Ligand A (51.997) and Ligand B (74.758). While ADRB2 isn't necessarily a CNS target, some peripheral ADRB2 receptors can influence CNS function. Higher BBB is generally favorable. Ligand B is better here.
9. **Caco-2:** Ligand A (-5.027) and Ligand B (-4.935) both have negative values, which is unusual. This suggests poor permeability.
10. **Solubility:** Ligand A (-4.08) and Ligand B (-0.822) both have negative solubility values. This is concerning. Ligand B is better here.
11. **hERG:** Ligand A (0.305) has a lower hERG risk than Ligand B (0.038), which is preferable.
12. **Cl_mic:** Ligand A (17.688) has a lower microsomal clearance than Ligand B (36.995), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (47.407) has a longer in vitro half-life than Ligand B (2.506), which is desirable.
14. **Pgp:** Ligand A (0.192) has lower P-gp efflux than Ligand B (0.026), which is preferable.
15. **Binding Affinity:** Ligand A (-7.3 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.8 kcal/mol). This 1.5 kcal/mol difference is substantial and can outweigh minor ADME drawbacks.
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A excels in logP, affinity, and Pgp. While Ligand B has better BBB penetration, the poor logP is a major concern.
**Overall Assessment:**
Ligand A presents a more balanced profile. Its superior binding affinity, better logP, lower Pgp efflux, and improved metabolic stability (lower Cl_mic, longer t1/2) outweigh the slightly higher DILI risk and lower BBB penetration. The poor logP of Ligand B is a significant impediment to its potential as a drug candidate.
Output:
1
2025-04-17 22:51:22,129 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor (a GPCR):
**1. Molecular Weight:** Both ligands (366.53 and 384.93 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (57.69) is better than Ligand B (66.48). Both are below 140, but lower TPSA generally favors better absorption.
**3. logP:** Both ligands have acceptable logP values (2.36 and 3.40), falling within the 1-3 range. Ligand B is slightly higher, which could potentially lead to slight solubility issues, but isn't a major concern.
**4. H-Bond Donors:** Ligand A has 0 HBD, while Ligand B has 1. Both are within the acceptable limit of <=5.
**5. H-Bond Acceptors:** Both ligands have 4 HBAs, well within the limit of <=10.
**6. QED:** Ligand B (0.732) has a higher QED score than Ligand A (0.535), indicating a more drug-like profile. This is a positive for Ligand B.
**7. DILI Risk:** Both ligands have low DILI risk (39.28 and 37.34 percentile), which is good. No significant difference.
**8. BBB Penetration:** Ligand A (74.84) has a slightly better BBB penetration score than Ligand B (70.88). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be beneficial or at least needs to be considered.
**9. Caco-2 Permeability:** Ligand A (-4.846) has a better Caco-2 permeability than Ligand B (-5.013). Higher values indicate better intestinal absorption.
**10. Aqueous Solubility:** Ligand A (-3.495) is slightly better than Ligand B (-3.938).
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.283 and 0.265), which is excellent.
**12. Microsomal Clearance:** Ligand B (58.05) has a lower microsomal clearance than Ligand A (62.72), suggesting better metabolic stability. This is a significant advantage for Ligand B.
**13. In vitro Half-Life:** Ligand B (20.58) has a significantly longer in vitro half-life than Ligand A (-33.57). This is a major advantage for Ligand B, potentially allowing for less frequent dosing.
**14. P-gp Efflux:** Both ligands have similar P-gp efflux liabilities (0.331 and 0.397), which are relatively low.
**15. Binding Affinity:** Ligand A (-6.5 kcal/mol) has a slightly better binding affinity than Ligand B (-6.2 kcal/mol). While the difference is small, it's still a factor.
**GPCR-Specific Considerations:** For GPCRs, logP, Pgp, TPSA, and affinity are key. Both ligands perform well on these metrics. However, metabolic stability (Cl_mic and t1/2) is also important. Ligand B clearly wins on both of those parameters. The slightly better affinity of Ligand A is outweighed by the superior pharmacokinetic properties of Ligand B.
Output:
0
2025-04-17 22:51:22,129 - INFO - Batch 362 complete. Total preferences: 5792
2025-04-17 22:51:22,129 - INFO - Processing batch 363/512...
2025-04-17 22:52:12,521 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (448.308 Da) is within the ideal range. Ligand B (347.415 Da) is also within range, but closer to the lower limit.
2. **TPSA:** Ligand A (51.02) is good, well below 140. Ligand B (92.55) is higher, but still acceptable for a non-CNS target.
3. **logP:** Ligand A (4.115) is slightly high, potentially causing solubility issues. Ligand B (1.2) is a bit low, potentially impacting permeability.
4. **HBD:** Ligand A (0) is excellent. Ligand B (1) is acceptable.
5. **HBA:** Both Ligand A (4) and Ligand B (4) are good.
6. **QED:** Ligand A (0.565) is good, indicating drug-likeness. Ligand B (0.425) is lower, suggesting a less ideal drug-like profile.
7. **DILI:** Ligand A (59.17) is moderate risk. Ligand B (11.128) is very low risk, a significant advantage.
8. **BBB:** Both are not CNS targets, so this is less important. Ligand A (79.217) is higher than Ligand B (63.746).
9. **Caco-2:** Ligand A (-4.889) is poor. Ligand B (-5.046) is also poor.
10. **Solubility:** Ligand A (-4.085) is poor. Ligand B (-2.166) is better, but still not great.
11. **hERG:** Ligand A (0.847) is low risk. Ligand B (0.143) is very low risk, another advantage.
12. **Cl_mic:** Ligand A (98.355) is high, indicating rapid metabolism. Ligand B (-17.729) is excellent, indicating very slow metabolism.
13. **t1/2:** Ligand A (103.49) is good. Ligand B (-10.949) is very poor.
14. **Pgp:** Ligand A (0.571) is low efflux. Ligand B (0.017) is very low efflux, a slight advantage.
15. **Affinity:** Ligand B (-7.3 kcal/mol) has a significantly better binding affinity than Ligand A (-6.1 kcal/mol). This is a 1.2 kcal/mol difference, which is substantial.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand B has a better logP, better Pgp, comparable TPSA, and *much* better affinity. While Ligand A has better QED and BBB, the affinity difference is the most important factor. The significantly improved metabolic stability (Cl_mic and t1/2) of Ligand B is also a major benefit. The lower DILI and hERG risk for Ligand B are also very favorable.
**Conclusion:**
Despite Ligand A's slightly better QED and BBB, Ligand B's superior binding affinity, metabolic stability, lower toxicity risks (DILI and hERG), and favorable Pgp profile make it the more promising drug candidate for ADRB2.
Output:
0
2025-04-17 22:52:12,522 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [376.737, 75.35, 3.633, 3, 3, 0.713, 41.218, 43.273, -5.182, -3.649, 0.782, 12.761, 12.142, 0.236, -7.4]
**Ligand B:** [365.455, 95.58, -0.307, 2, 5, 0.667, 44.436, 27.646, -5.778, -2.936, 0.028, 7.954, 4.266, 0.015, -6.8]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (365.455) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (75.35) is better than Ligand B (95.58). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA is still preferred for absorption.
3. **logP:** Ligand A (3.633) is within the optimal range (1-3), while Ligand B (-0.307) is significantly *below* the optimal range. This is a major drawback for Ligand B as it suggests poor membrane permeability.
4. **HBD:** Both are acceptable (Ligand A: 3, Ligand B: 2).
5. **HBA:** Ligand A (3) is better than Ligand B (5). Lower HBA is generally preferred.
6. **QED:** Both are reasonably good (Ligand A: 0.713, Ligand B: 0.667), indicating drug-like properties.
7. **DILI:** Both have similar, acceptable DILI risk (Ligand A: 41.218, Ligand B: 44.436).
8. **BBB:** Ligand A (43.273) has a slightly better BBB percentile than Ligand B (27.646), but this isn't critical for a cardiovascular target.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Both have negative solubility values, which is also unusual and suggests poor solubility. Again, the scale is not specified.
11. **hERG:** Ligand A (0.782) is better than Ligand B (0.028), indicating a lower risk of cardiotoxicity. This is *very* important for a cardiovascular target.
12. **Cl_mic:** Ligand A (12.761) has a higher (worse) microsomal clearance than Ligand B (7.954), meaning faster metabolism.
13. **t1/2:** Ligand A (12.142) has a longer half-life than Ligand B (4.266), which is favorable.
14. **Pgp:** Ligand A (0.236) has lower P-gp efflux than Ligand B (0.015), which is better for bioavailability.
15. **Affinity:** Ligand A (-7.4) has a significantly stronger binding affinity than Ligand B (-6.8). A 0.6 kcal/mol difference is substantial.
**GPCR-specific priorities:** For ADRB2 (a cardiovascular GPCR), we prioritize logP, TPSA, affinity, and hERG. Ligand A excels in logP, TPSA, hERG and significantly outperforms Ligand B in binding affinity. While Ligand A has a slightly higher Cl_mic, the superior binding affinity and better ADME properties (logP, hERG, Pgp) outweigh this drawback.
**Conclusion:**
Ligand A is the more promising candidate.
1
2025-04-17 22:52:12,522 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [349.431, 102.66 , 0.741, 2. , 5. , 0.713, 19.426, 48.468, -4.928, -1.204, 0.25 , 6.721, 11.697, 0.015, -6.7 ]
**Ligand B:** [349.431, 93.46 , 1.294, 2. , 5. , 0.621, 14.541, 51.609, -4.796, -1.983, 0.071, 27.208, -3.052, 0.007, -6.6 ]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, Affinity) and general guidelines:
1. **MW:** Both are excellent (349.431 Da), falling well within the 200-500 Da range.
2. **TPSA:** Ligand B (93.46) is better than Ligand A (102.66), being closer to the ideal <90 for good absorption.
3. **logP:** Ligand A (0.741) is slightly lower than ideal (1-3), but acceptable. Ligand B (1.294) is better positioned within the optimal range.
4. **HBD/HBA:** Both have 2 HBD and 5 HBA, which is good and balances solubility and permeability.
5. **QED:** Both are good (>0.5), with Ligand A (0.713) being slightly better than Ligand B (0.621).
6. **DILI:** Ligand B (14.541) has a significantly lower DILI risk than Ligand A (19.426). This is a substantial advantage.
7. **BBB:** Ligand B (51.609) has slightly better BBB penetration than Ligand A (48.468), but both are not high enough to be considered CNS-focused. However, for a cardiovascular target, this isn't a primary concern.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.928) is slightly worse than Ligand B (-4.796).
9. **Solubility:** Ligand B (-1.983) is slightly better than Ligand A (-1.204), indicating better aqueous solubility.
10. **hERG:** Both are very low (0.25 and 0.071), indicating minimal hERG inhibition risk.
11. **Cl_mic:** Ligand A (6.721) has significantly lower microsomal clearance than Ligand B (27.208), suggesting better metabolic stability.
12. **t1/2:** Ligand B (-3.052) has a negative half-life, which is concerning. Ligand A (11.697) has a reasonable in vitro half-life.
13. **Pgp:** Both have very low P-gp efflux liability (0.015 and 0.007).
14. **Affinity:** Both have very similar binding affinities (-6.7 and -6.6 kcal/mol). The difference is negligible.
**Overall Assessment:**
Ligand B has several advantages: lower DILI risk, better TPSA, better logP, and better solubility. However, it has a negative in vitro half-life, which is a major drawback. Ligand A has better metabolic stability (lower Cl_mic and positive t1/2) and a slightly better QED score. The Caco-2 values are poor for both, which is a concern that would need to be addressed through further optimization.
Given the importance of metabolic stability for *in vivo* efficacy and the concerning negative half-life of Ligand B, I would lean towards **Ligand A** as the more promising starting point. The slightly better QED and more reasonable half-life outweigh the advantages of Ligand B.
1
2025-04-17 22:52:12,522 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (341.415 Da) is within the ideal range, while Ligand B (367.402 Da) is slightly higher but still acceptable.
2. **TPSA:** Both ligands (A: 88.91, B: 84.67) are well below the 140 threshold for oral absorption and suitable for a GPCR target.
3. **logP:** Both ligands have good logP values (A: 1.237, B: 1.954), falling within the 1-3 range. Ligand B is slightly higher, potentially offering better membrane permeability.
4. **HBD:** Ligand A (2) and Ligand B (1) both have acceptable HBD counts.
5. **HBA:** Ligand A (5) and Ligand B (6) are both within the acceptable range.
6. **QED:** Both ligands have good QED scores (A: 0.756, B: 0.893), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (43.273) has a much lower DILI risk than Ligand B (79.527). This is a significant advantage for Ligand A.
8. **BBB:** Ligand B (67.352) has a higher BBB penetration percentile than Ligand A (46.026). While ADRB2 isn't strictly a CNS target, some CNS penetration can be beneficial for understanding off-target effects.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual. However, the magnitude is similar (-5.48 for A, -4.554 for B), so this doesn't strongly favor either.
10. **Solubility:** Ligand A (-1.113) has better aqueous solubility than Ligand B (-3.066).
11. **hERG:** Both ligands have low hERG inhibition risk (A: 0.257, B: 0.381).
12. **Cl_mic:** Ligand A (-9.092) has significantly lower microsomal clearance than Ligand B (34.35), indicating better metabolic stability.
13. **t1/2:** Ligand B (-15.875) has a longer in vitro half-life than Ligand A (6.746).
14. **Pgp:** Both ligands have very low Pgp efflux liability (A: 0.008, B: 0.159).
15. **Affinity:** Ligand B (-7.3 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.6 kcal/mol). This is a substantial advantage.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand B excels in affinity and has a slightly better logP. The TPSA is similar for both. Pgp is low for both. However, the significantly higher DILI risk and lower metabolic stability of Ligand B are major concerns.
**Overall Assessment:**
While Ligand B boasts a stronger binding affinity and slightly better BBB penetration, the significantly higher DILI risk and lower metabolic stability (higher Cl_mic) are substantial drawbacks. Ligand A, despite its weaker affinity, presents a much safer profile with a lower DILI risk and better metabolic stability. The difference in affinity (1.7 kcal/mol) is notable, but can potentially be addressed through further optimization. The safety profile is more critical at this stage.
Output:
1
2025-04-17 22:52:12,522 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
The ADRB2 receptor is a GPCR, so the priorities are logP, TPSA, Pgp efflux, BBB penetration, and binding affinity. Metabolic stability and solubility are also important, but slightly less so than the former.
Let's compare the ligands property by property:
1. **MW:** Both ligands (347.375 and 357.455 Da) are within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (109.44) is slightly higher than Ligand B (103.01), but both are reasonably good for oral absorption, being under 140.
3. **logP:** Ligand A (0.658) is a bit low, potentially hindering permeation. Ligand B (-1.011) is even lower, raising concerns about absorption.
4. **HBD/HBA:** Ligand A (2 HBD, 6 HBA) is slightly better than Ligand B (3 HBD, 5 HBA) in terms of balancing solubility and permeability.
5. **QED:** Ligand A (0.743) has a better QED score than Ligand B (0.491), indicating a more drug-like profile.
6. **DILI:** Ligand B (19.891) has a significantly lower DILI risk than Ligand A (69.058), which is a major advantage.
7. **BBB:** Ligand B (62.621) shows better BBB penetration than Ligand A (25.475), which is relevant for a GPCR.
8. **Caco-2:** Ligand B (-5.296) has a more negative Caco-2 value, suggesting better absorption. Ligand A (-4.956) is also negative, but less so.
9. **Solubility:** Ligand B (-0.201) has slightly better solubility than Ligand A (-1.872).
10. **hERG:** Both ligands have very low hERG inhibition risk (0.032 and 0.093, respectively).
11. **Cl_mic:** Ligand B (-20.323) has a much lower (better) microsomal clearance than Ligand A (14.445), indicating greater metabolic stability.
12. **t1/2:** Ligand B (-23.101) has a much longer in vitro half-life than Ligand A (-9.013).
13. **Pgp:** Both ligands have very low Pgp efflux liability (0.021 and 0.002, respectively).
14. **Binding Affinity:** Both ligands have the same binding affinity (-6.4 kcal/mol).
**Overall Assessment:**
While Ligand A has a slightly better QED score, Ligand B is superior in almost every other crucial ADME-Tox property. Specifically, its significantly lower DILI risk, better BBB penetration, improved metabolic stability (lower Cl_mic and longer t1/2), and better Caco-2 permeability make it a much more promising candidate. The slightly lower logP of Ligand B is a concern, but the other benefits outweigh this drawback.
**Output:**
0
2025-04-17 22:52:12,523 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output:
**Ligand A: [346.391, 106.15 , 0.133, 1. , 7. , 0.797, 58.976, 38.348, -5.436, -1.506, 0.04 , 16.076, -6.622, 0.01 , -6.5 ]**
**Ligand B: [356.495, 61.02 , 2.9 , 2. , 4. , 0.809, 52.772, 59.17 , -5.469, -4.131, 0.391, 49.93 , 6.871, 0.215, -5.2 ]**
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). A (346.391) is slightly preferred.
2. **TPSA:** Ligand B (61.02) is significantly better than Ligand A (106.15). A TPSA under 90 is preferred for GPCRs, and B is well within that range, while A is approaching the upper limit for good oral absorption (140).
3. **logP:** Ligand B (2.9) is optimal, while Ligand A (0.133) is quite low. Low logP can lead to poor membrane permeability. This is a significant advantage for B.
4. **H-Bond Donors:** Both are acceptable (A: 1, B: 2), well below the threshold of 5.
5. **H-Bond Acceptors:** Both are acceptable (A: 7, B: 4), below the threshold of 10.
6. **QED:** Both are good (A: 0.797, B: 0.809), indicating drug-like properties.
7. **DILI:** Both have acceptable DILI risk (A: 58.976, B: 52.772), below the 60% threshold. B is slightly better.
8. **BBB:** Ligand B (59.17) is better than Ligand A (38.348), although neither is exceptionally high. For a cardiovascular GPCR, BBB penetration isn't *critical* but is still a positive.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Both have negative solubility values, which is also unusual and suggests poor solubility. This is a concern for both.
11. **hERG:** Ligand A (0.04) is significantly better than Ligand B (0.391), indicating a lower risk of cardiotoxicity. This is a crucial factor for a cardiovascular target.
12. **Cl_mic:** Ligand A (16.076) has a lower (better) microsomal clearance than Ligand B (49.93), suggesting better metabolic stability.
13. **t1/2:** Ligand B (6.871) has a positive in vitro half-life, while Ligand A (-6.622) has a negative value. This is a significant advantage for B.
14. **Pgp:** Ligand A (0.01) has much lower P-gp efflux than Ligand B (0.215), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand A (-6.5) has a slightly better binding affinity than Ligand B (-5.2). While a 1.3 kcal/mol difference is good, it needs to be weighed against other factors.
**Overall Assessment:**
Ligand B has a much better logP and TPSA, which are critical for GPCRs. It also has a better in vitro half-life and slightly better DILI. However, Ligand A has a significantly lower hERG risk, lower Pgp efflux, better metabolic stability and slightly better binding affinity. Given the cardiovascular target, minimizing hERG risk is paramount. The slightly better affinity of A, combined with its lower hERG and Pgp efflux, outweighs the advantages of B's logP and TPSA. The negative Caco-2 and solubility values are concerning for both, but can be addressed through formulation strategies.
Output:
1
2025-04-17 22:52:12,523 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.447 and 356.413 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (107.5) is higher than Ligand B (66.48). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B has a clear advantage.
3. **logP:** Ligand A (0.889) is slightly below the optimal 1-3 range, potentially hindering permeability. Ligand B (2.31) is well within the optimal range. Ligand B is better.
4. **HBD:** Both ligands have 1 HBD, which is acceptable.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 3. Both are within the acceptable limit of 10.
6. **QED:** Ligand A (0.769) is slightly better than Ligand B (0.679), indicating a more drug-like profile.
7. **DILI:** Ligand B (41.838) has a significantly lower DILI risk than Ligand A (17.449). This is a major advantage for Ligand B.
8. **BBB:** Ligand B (87.631) has a much higher BBB penetration percentile than Ligand A (60.566). While ADRB2 isn't primarily a CNS target, some degree of BBB penetration can be useful for off-target effects assessment and potential peripheral activity.
9. **Caco-2:** Ligand A (-5.069) and Ligand B (-4.487) both have negative Caco-2 values. This is unusual and suggests poor permeability. However, the values are close, so this isn't a major differentiator.
10. **Solubility:** Ligand A (-1.881) and Ligand B (-2.687) both have poor solubility. This is a concern for both.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.299 and 0.212, respectively). This is excellent.
12. **Cl_mic:** Ligand A (4.42) has a much lower microsomal clearance than Ligand B (15.255), suggesting better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand B (-14.994) has a much longer in vitro half-life than Ligand A (-4.704). This is a substantial advantage for Ligand B.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.006 and 0.094, respectively).
15. **Binding Affinity:** Ligand A (-6.8) has a slightly better binding affinity than Ligand B (-6.0). While a 0.8 kcal/mol difference is noticeable, it's not a huge advantage, especially considering the other factors.
**Overall Assessment:**
Ligand B has several key advantages: significantly lower DILI risk, much higher BBB penetration, and a substantially longer half-life. While Ligand A has slightly better QED and metabolic stability, the safety profile and pharmacokinetic properties of Ligand B are more favorable for drug development. The slightly weaker binding affinity of Ligand B is likely surmountable with further optimization. Given the GPCR target class, the balance of properties leans towards Ligand B.
Output:
0
2025-04-17 22:52:12,523 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (351.403 and 350.463 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (92.09) is slightly higher than Ligand B (80.48). Both are below the 140 threshold for oral absorption, but Ligand B is preferable due to being closer to the 90 threshold for potential CNS penetration (though not a primary concern for ADRB2).
3. **logP:** Both ligands have acceptable logP values (1.109 and 1.57), falling within the optimal 1-3 range. Ligand B is slightly higher, which could be marginally better for membrane permeability.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 5 HBA, while Ligand B has 6. Both are acceptable (<=10), but Ligand A is slightly better.
6. **QED:** Both ligands have good QED scores (0.708 and 0.807), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (43.738) has a slightly higher DILI risk than Ligand B (38.813), but both are below the concerning threshold of 60. Ligand B is preferred.
8. **BBB:** Both have similar BBB penetration (61.38 and 64.211). This isn't a major priority for ADRB2, but Ligand B is slightly better.
9. **Caco-2:** Both have negative Caco-2 values (-4.915 and -4.848). This is unusual and suggests poor permeability. This is a significant drawback for both, but the values are very close.
10. **Solubility:** Both have negative solubility values (-1.535 and -1.891). This is also concerning, indicating poor aqueous solubility. Again, the values are very close.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.103 and 0.128). This is excellent.
12. **Cl_mic:** Ligand B (27.521) has significantly lower microsomal clearance than Ligand A (44.388), suggesting better metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand A (22.293) has a longer in vitro half-life than Ligand B (-9.55). A negative half-life is unusual and problematic for Ligand B.
14. **Pgp:** Both have very low P-gp efflux liability (0.013 and 0.154). This is good.
15. **Binding Affinity:** Ligand B (-5.8 kcal/mol) has a slightly better binding affinity than Ligand A (-5.5 kcal/mol). While the difference is small, it's within the range where it can be a deciding factor.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B is slightly better on logP and TPSA. Both have good Pgp profiles. The affinity difference is small, but favors Ligand B. However, the negative half-life of Ligand B is a major concern.
**Overall Assessment:**
Despite Ligand B having a slightly better affinity, lower DILI risk, and lower Cl_mic, the negative in vitro half-life is a critical flaw. A negative half-life suggests rapid degradation or an issue with the assay. Ligand A, while having a slightly higher DILI risk and higher Cl_mic, has a reasonable half-life. Given the importance of metabolic stability and a positive half-life for *in vivo* efficacy, Ligand A is the more promising candidate.
Output:
1
2025-04-17 22:52:12,523 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.49 and 349.48 Da) fall comfortably within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (69.64) is better than Ligand B (74.58). Both are below 140, but lower TPSA generally favors absorption.
3. **logP:** Both ligands have good logP values (2.39 and 2.12), falling within the optimal 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Both ligands have 2 H-bond donors, which is within the acceptable limit of 5. No difference.
5. **HBA:** Ligand A has 3 H-bond acceptors, while Ligand B has 4. Ligand A is slightly preferred.
6. **QED:** Both ligands have good QED scores (0.72 and 0.83), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (19.43) has a significantly lower DILI risk than Ligand B (34.70). This is a major advantage for Ligand A.
8. **BBB:** Both ligands have similar BBB penetration (63.20 and 64.95). Since ADRB2 is a cardiovascular target, BBB penetration is not a primary concern, but it's good they aren't excessively high.
9. **Caco-2:** Both have negative Caco-2 values (-4.75 and -4.78), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Both ligands have very poor aqueous solubility (-2.69 and -2.24). This is a significant drawback for both, potentially hindering bioavailability.
11. **hERG:** Both ligands have low hERG inhibition risk (0.32 and 0.50). This is good.
12. **Cl_mic:** Ligand A (36.91) has a lower microsomal clearance than Ligand B (18.91), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand B (48.20) has a much longer in vitro half-life than Ligand A (-8.04). This is a major advantage for Ligand B.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.25 and 0.09). Ligand B is slightly better.
15. **Binding Affinity:** Ligand B (-8.4) has a slightly better binding affinity than Ligand A (-7.2). This is a 1.2 kcal/mol advantage, which is substantial.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Both ligands are reasonable in logP and Pgp. Ligand A has a better TPSA. Ligand B has a better affinity and half-life. However, the significantly lower DILI risk and better metabolic stability (lower Cl_mic) of Ligand A are crucial for a cardiovascular drug. Poor solubility and Caco-2 values are a concern for both, but can be addressed with formulation strategies.
**Overall Assessment:**
While Ligand B has a slightly better binding affinity and half-life, the lower DILI risk and improved metabolic stability of Ligand A are more critical for a cardiovascular drug candidate. The solubility and permeability issues are concerning for both, but are secondary to safety and metabolic profile.
Output:
1
2025-04-17 22:52:12,523 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.5 & 344.5 Da) are within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (69.64) is significantly better than Ligand B (86.88). ADRB2 is a cardiovascular target, so BBB isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands (2.47 & 2.10) are within the optimal 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Ligand A (2) is preferable to Ligand B (3). Lower HBD generally improves permeability.
5. **HBA:** Both ligands (3) are similar and within the acceptable range of <=10.
6. **QED:** Ligand A (0.821) is better than Ligand B (0.764), indicating a more drug-like profile.
7. **DILI:** Ligand A (5.584) is *much* better than Ligand B (33.424). This is a significant advantage for Ligand A, as liver toxicity is a major concern.
8. **BBB:** Not a primary concern for a cardiovascular target, but Ligand B (64.715) is higher than Ligand A (46.84).
9. **Caco-2:** Ligand A (-4.739) is better than Ligand B (-5.23), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-2.534) is better than Ligand B (-3.36). Better solubility is generally desirable.
11. **hERG:** Ligand A (0.23) is significantly better than Ligand B (0.357). Lower hERG inhibition is crucial for avoiding cardiotoxicity, especially for a cardiovascular target.
12. **Cl_mic:** Ligand A (15.085) is much better than Ligand B (32.786). Lower clearance indicates better metabolic stability.
13. **t1/2:** Ligand A (4.374) is better than Ligand B (1.842). A longer half-life is generally preferred.
14. **Pgp:** Ligand A (0.036) is *much* better than Ligand B (0.17). Lower P-gp efflux is desirable for better bioavailability.
15. **Affinity:** Ligand B (-7.4) has a slightly better binding affinity than Ligand A (-6.6), a difference of 0.8 kcal/mol. While affinity is important, the other ADME properties of Ligand A are far superior.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand B has a slightly better affinity, but Ligand A excels in logP, TPSA, and *significantly* in Pgp. The substantial improvements in ADME properties for Ligand A outweigh the small difference in binding affinity.
**Conclusion:**
Ligand A is the superior candidate due to its significantly better DILI risk, hERG inhibition, metabolic stability (Cl_mic), half-life, P-gp efflux, solubility, and TPSA, all while maintaining acceptable binding affinity and drug-like properties.
Output:
1
2025-04-17 22:52:12,524 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (371.453) is slightly higher than Ligand B (354.426), but both are acceptable.
2. **TPSA:** Ligand A (62.3) is excellent, well below the 140 threshold for oral absorption. Ligand B (86.6) is still reasonable, but less optimal.
3. **logP:** Ligand A (2.854) is within the optimal range (1-3). Ligand B (-0.096) is slightly below 1, which *could* indicate permeability issues, though not drastically.
4. **HBD:** Ligand A (1) is good. Ligand B (3) is acceptable, but slightly higher.
5. **HBA:** Ligand A (4) is good. Ligand B (5) is acceptable, but slightly higher.
6. **QED:** Ligand A (0.885) is excellent, indicating a very drug-like profile. Ligand B (0.638) is still acceptable, but lower.
7. **DILI:** Ligand A (49.787) has a moderate DILI risk, but is well below the concerning threshold of 60. Ligand B (16.014) has a very low DILI risk, a significant advantage.
8. **BBB:** Ligand A (90.229) shows excellent potential for BBB penetration, which is a plus for GPCRs. Ligand B (36.177) is low, suggesting poor CNS exposure.
9. **Caco-2:** Ligand A (-4.879) and Ligand B (-5.19) are both very poor, indicating very low intestinal absorption. This is a major concern for both.
10. **Solubility:** Ligand A (-3.612) is poor, while Ligand B (-0.468) is also poor, but slightly better.
11. **hERG:** Both ligands (0.421 and 0.143 respectively) have low hERG risk, which is good.
12. **Cl_mic:** Ligand A (31.992) has moderate clearance. Ligand B (-9.758) has *negative* clearance, which is unusual and suggests very high metabolic stability.
13. **t1/2:** Ligand A (-24.354) has a negative half-life, which is also unusual and suggests very high in vitro stability. Ligand B (4.744) has a short half-life.
14. **Pgp:** Both ligands have very low Pgp efflux (0.179 and 0.006 respectively), which is favorable.
15. **Binding Affinity:** Both ligands have very similar and strong binding affinities (-7.2 and -7.3 kcal/mol). The difference is negligible.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, and affinity. Ligand A has better logP and TPSA. Both have excellent Pgp and similar affinity. BBB is also a consideration, and Ligand A is significantly better in this regard. However, the DILI risk is lower for Ligand B, and its metabolic stability (negative Cl_mic) is a major advantage. The poor Caco-2 values are concerning for both.
**Overall Assessment:**
While Ligand A has better predicted permeability characteristics (TPSA, logP, BBB), the significantly lower DILI risk and exceptional metabolic stability of Ligand B are compelling. The negative clearance and half-life values for Ligand A and B are unusual and require further investigation, but the negative clearance for Ligand B is particularly noteworthy. Given the importance of metabolic stability for *in vivo* efficacy, and the acceptable (though not ideal) TPSA and logP values for Ligand B, I lean towards Ligand B. The poor Caco-2 values are a concern for both, but can be addressed with formulation strategies.
Output:
0
2025-04-17 22:52:12,524 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (342.33 and 347.46 Da) fall comfortably within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (85.26) is better than Ligand B (93.43). Both are below 140, but lower TPSA generally favors absorption.
3. **logP:** Ligand A (3.231) is slightly higher than Ligand B (1.893). Both are within the optimal 1-3 range, but Ligand A is closer to the upper bound.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (6) is higher than Ligand B (4). Both are acceptable, but lower is slightly preferred.
6. **QED:** Ligand A (0.726) is slightly better than Ligand B (0.688), indicating a more drug-like profile.
7. **DILI:** Ligand B (8.375) is *significantly* better than Ligand A (93.68). This is a major advantage for Ligand B. A DILI percentile below 40 is highly desirable, and Ligand B is well within that range, while Ligand A is very high risk.
8. **BBB:** Ligand A (92.904) is better than Ligand B (70.143). While ADRB2 isn't exclusively a CNS target, some CNS penetration can be beneficial, and Ligand A has a much higher predicted BBB penetration.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.764 and -4.914), which is unusual and suggests poor permeability. This is a significant drawback for both.
10. **Solubility:** Ligand A (-3.709) is slightly better than Ligand B (-2.225), indicating better aqueous solubility.
11. **hERG:** Ligand A (0.493) is better than Ligand B (0.284), indicating lower hERG inhibition risk.
12. **Cl_mic:** Ligand B (-10.182) is significantly better than Ligand A (34.677). Lower microsomal clearance means greater metabolic stability, a crucial factor for drug duration.
13. **t1/2:** Ligand B (-14.6) is better than Ligand A (-16.707). A less negative value here indicates a longer in vitro half-life.
14. **Pgp:** Ligand A (0.34) is better than Ligand B (0.02). Lower P-gp efflux is preferred.
15. **Binding Affinity:** Ligand A (-6.2) is slightly better than Ligand B (-4.7). This is a 1.5 kcal/mol difference, which is significant.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A has a better logP, TPSA, Pgp, and affinity. However, the *extremely* high DILI risk of Ligand A and the significantly better metabolic stability (Cl_mic and t1/2) of Ligand B are overriding factors. The DILI risk is a showstopper.
**Conclusion:**
Despite Ligand A's slightly better binding affinity and some other favorable properties, the significantly lower DILI risk and improved metabolic stability of Ligand B make it the more viable drug candidate. The DILI risk associated with Ligand A is too high to ignore.
Output:
0
2025-04-17 22:52:12,524 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.435 and 345.443 Da) fall comfortably within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (98.14) is slightly higher than Ligand B (80.32). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is generally preferred for absorption. Ligand B has a slight edge.
3. **logP:** Ligand B (1.922) is better positioned within the optimal 1-3 range than Ligand A (0.696), which is a bit low and could indicate permeability issues. This is a significant advantage for Ligand B, as logP is important for GPCRs.
4. **HBD:** Both ligands have 2 HBD, which is within the acceptable limit of 5. No difference.
5. **HBA:** Ligand A has 6 HBA, while Ligand B has 4. Both are within the acceptable limit of 10, but fewer is generally better for permeability. Ligand B has a slight edge.
6. **QED:** Ligand A (0.684) has a slightly better QED score than Ligand B (0.529), indicating a more drug-like profile. This is a positive for Ligand A.
7. **DILI:** Ligand B (39.511) has a lower DILI risk than Ligand A (43.428), both are good, but lower is better. Ligand B is slightly preferred.
8. **BBB:** Both ligands have relatively low BBB penetration (Ligand A: 60.644, Ligand B: 56.146). Since ADRB2 is not a CNS target, this is not a major concern.
9. **Caco-2:** Both have negative values, indicating poor permeability. Ligand A (-5.697) is slightly better than Ligand B (-5.264), but both are concerning.
10. **Solubility:** Ligand A (-0.77) has better solubility than Ligand B (-1.411). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.048) has a much lower hERG risk than Ligand B (0.452). This is a critical advantage for Ligand A, as hERG inhibition can lead to cardiotoxicity.
12. **Cl_mic:** Ligand A (7.55) has a significantly lower microsomal clearance than Ligand B (12.189), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (44.546) has a much longer in vitro half-life than Ligand B (-0.923). This is a major advantage for Ligand A, suggesting less frequent dosing.
14. **Pgp:** Ligand A (0.034) has a lower Pgp efflux liability than Ligand B (0.092), indicating better absorption and bioavailability.
15. **Affinity:** Ligand A (-7.7 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.2 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME drawbacks of Ligand B.
**Overall Assessment:**
Ligand A has a significantly stronger binding affinity, better metabolic stability (lower Cl_mic and longer t1/2), lower Pgp efflux, lower hERG risk, and slightly better QED and solubility. While Ligand B has a better logP and slightly lower DILI risk, the advantages of Ligand A are more substantial, especially the binding affinity and safety profile (hERG). The Caco-2 permeability is poor for both, but the other favorable characteristics of Ligand A make it the more promising candidate.
Output:
1
2025-04-17 22:52:12,524 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (347.419 Da and 346.427 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (112.91) is higher than Ligand B (66.92). For a cardiovascular GPCR, TPSA is moderately important. Ligand B's lower TPSA is preferable, suggesting better potential for membrane permeability.
**3. logP:** Both ligands have good logP values (1.851 and 1.235), falling within the optimal 1-3 range. Ligand B is slightly lower, which could be beneficial for solubility, but both are acceptable.
**4. H-Bond Donors:** Ligand A has 3 HBDs, while Ligand B has 0. Lower HBDs are generally preferred for better permeability, giving an edge to Ligand B.
**5. H-Bond Acceptors:** Ligand A has 5 HBAs, and Ligand B has 4. Both are within the acceptable range (<=10).
**6. QED:** Ligand A (0.641) has a slightly better QED score than Ligand B (0.514), indicating a more drug-like profile.
**7. DILI Risk:** Ligand B (22.373) has a significantly lower DILI risk than Ligand A (73.09). This is a crucial advantage for Ligand B, as minimizing liver toxicity is paramount.
**8. BBB Penetration:** Ligand B (78.519) shows better BBB penetration than Ligand A (36.371). While ADRB2 is primarily a cardiovascular target, some CNS effects are possible with adrenergic agonists, and better BBB penetration could be advantageous or a potential concern depending on the desired selectivity.
**9. Caco-2 Permeability:** Ligand A (-5.664) has worse Caco-2 permeability than Ligand B (-4.595). This suggests Ligand B will be absorbed better.
**10. Aqueous Solubility:** Ligand A (-3.194) has worse solubility than Ligand B (-1.88). Solubility is important for formulation and bioavailability, favoring Ligand B.
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.275 and 0.134). This is excellent for both.
**12. Microsomal Clearance:** Ligand B (25.52) has a significantly lower microsomal clearance than Ligand A (54.645), indicating better metabolic stability and potentially a longer duration of action.
**13. In vitro Half-Life:** Ligand A (0.18) has a very short half-life, while Ligand B (-24.899) has a very long half-life. This is a huge advantage for Ligand B.
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (0.262 and 0.042).
**15. Binding Affinity:** Ligand B (-7.2) has a slightly better binding affinity than Ligand A (-6.9). While the difference is not huge, it's enough to be considered.
**Overall Assessment:**
Ligand B consistently outperforms Ligand A in several key ADME properties (DILI, BBB, Caco-2, Solubility, Clearance, Half-Life) and has a slightly better binding affinity. While Ligand A has a slightly better QED, the superior safety profile (DILI) and pharmacokinetic properties of Ligand B are more critical for a viable drug candidate. The lower TPSA and HBD count of Ligand B also support better permeability.
Output:
0
2025-04-17 22:52:12,524 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (349.431) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (78.51) is significantly better than Ligand A (99.69). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Both have good logP values (A: 2.334, B: 1.152) within the optimal 1-3 range. Ligand B is slightly lower, which could slightly improve solubility.
4. **HBD:** Ligand A (4) is slightly higher than Ligand B (2). Both are acceptable, but lower HBD can sometimes improve permeability.
5. **HBA:** Both ligands have the same number of HBA (4), which is within the acceptable range.
6. **QED:** Ligand B (0.784) has a better QED score than Ligand A (0.607), indicating a more drug-like profile.
7. **DILI:** Ligand B (16.867) has a *much* lower DILI risk than Ligand A (52.191). This is a significant advantage.
8. **BBB:** Ligand B (57.774) has a higher BBB penetration score than Ligand A (39.822), but since ADRB2 is not a CNS target, this is less important.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability.
10. **Solubility:** Both have negative solubility values, indicating poor solubility.
11. **hERG:** Ligand B (0.089) has a significantly lower hERG risk than Ligand A (0.465). This is a crucial advantage for cardiovascular targets.
12. **Cl_mic:** Ligand A (-17.288) has a much lower (better) microsomal clearance than Ligand B (36.44). This suggests greater metabolic stability.
13. **t1/2:** Ligand A (59.148) has a longer in vitro half-life than Ligand B (-14.517). This is a positive attribute.
14. **Pgp:** Both ligands have very low Pgp efflux liability (A: 0.04, B: 0.033).
15. **Binding Affinity:** Ligand A (-7.6) has a slightly better binding affinity than Ligand B (-5.9). However, the difference is 1.7 kcal/mol, which is not substantial enough to overcome the significant ADME advantages of Ligand B.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand B is better on TPSA and Pgp. The logP values are both good. While Ligand A has slightly better affinity, the improvements in DILI, hERG, and metabolic stability (Cl_mic) for Ligand B are more critical for a cardiovascular drug.
**Conclusion:**
Ligand B presents a significantly better overall profile, particularly regarding safety (DILI, hERG) and metabolic stability. While Ligand A has a slightly better binding affinity and half-life, the ADME/Tox advantages of Ligand B outweigh this difference.
Output:
0
2025-04-17 22:52:12,525 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (347.463) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are reasonably good, below the 140 A^2 threshold for oral absorption. Ligand B (92.94) is slightly better than Ligand A (99.77).
3. **logP:** Both are within the optimal range (1-3). Ligand A (1.742) is preferable as it's closer to the middle of the range, while Ligand B (3.204) is approaching the upper limit, potentially raising concerns about solubility and off-target effects.
4. **HBD:** Both are acceptable. Ligand A has 3 HBD, and Ligand B has 2.
5. **HBA:** Ligand A (4) is better than Ligand B (7). Fewer HBA generally improves permeability.
6. **QED:** Both have good QED scores (>0.5), indicating drug-likeness. Ligand B (0.701) is slightly better.
7. **DILI:** Ligand A (22.8) has a significantly lower DILI risk than Ligand B (76.309). This is a major advantage for Ligand A.
8. **BBB:** Both have reasonable BBB penetration, but Ligand B (72.315) is better than Ligand A (64.017). Considering ADRB2 is a GPCR, BBB penetration is a relevant factor, but not the most important.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and indicates poor permeability. This is a significant drawback for both compounds.
10. **Solubility:** Both have negative solubility values, which is also unusual and indicates poor solubility. This is a significant drawback for both compounds.
11. **hERG:** Ligand A (0.046) has a much lower hERG inhibition liability than Ligand B (0.374), which is a crucial advantage for cardiovascular targets.
12. **Cl_mic:** Ligand A (27.571) has a lower microsomal clearance than Ligand B (78.006), suggesting better metabolic stability.
13. **t1/2:** Ligand B (31.21) has a longer in vitro half-life than Ligand A (-19.949). This is a positive for Ligand B, but the negative value for A is concerning.
14. **Pgp:** Ligand A (0.008) has lower P-gp efflux liability than Ligand B (0.332), which is favorable for oral bioavailability.
15. **Binding Affinity:** Ligand B (-7.7 kcal/mol) has a slightly better binding affinity than Ligand A (-6.3 kcal/mol). This is a 1.4 kcal/mol difference, which is significant but not overwhelmingly so.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. While Ligand B has slightly better affinity and BBB penetration, Ligand A excels in crucial safety parameters (DILI, hERG) and metabolic stability (Cl_mic). The poor Caco-2 and solubility values are concerning for both, but the safety profile of Ligand A is more compelling.
**Conclusion:**
Considering the balance of properties, particularly the significantly lower DILI and hERG risk, and better metabolic stability of Ligand A, it is the more promising drug candidate despite the slightly weaker affinity. The safety profile is paramount for a cardiovascular target.
Output:
1
2025-04-17 22:52:12,525 - INFO - Batch 363 complete. Total preferences: 5808
2025-04-17 22:52:12,525 - INFO - Processing batch 364/512...
2025-04-17 22:53:03,868 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.491 and 354.441 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (88.32) is slightly higher than Ligand B (45.47). For a cardiovascular GPCR, TPSA is not a *major* concern unless excessively high, but lower is generally preferred for better permeability. Ligand B is significantly better.
3. **logP:** Both ligands have good logP values (2.765 and 3.052), falling within the 1-3 optimal range. Ligand B is slightly higher.
4. **HBD:** Ligand A has 2 HBD, and Ligand B has 1. Both are within the acceptable limit of 5.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 3. Both are within the acceptable limit of 10.
6. **QED:** Both ligands have good QED scores (0.793 and 0.818), indicating good drug-like properties. No significant difference.
7. **DILI:** Ligand A has a DILI risk of 47.15%, while Ligand B has a much lower risk of 15.2%. This is a significant advantage for Ligand B.
8. **BBB:** Ligand A has a BBB penetration of 76.735%, while Ligand B has 92.168%. While ADRB2 isn't a CNS target, higher BBB penetration can sometimes correlate with better overall distribution and reduced off-target effects. Ligand B is better.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.817 and -4.278) which is unusual and suggests poor permeability. The values are similar.
10. **Solubility:** Both ligands have negative solubility values (-3.205 and -3.045) which is also unusual and suggests poor solubility. The values are similar.
11. **hERG:** Both ligands have low hERG inhibition liability (0.652 and 0.826), which is good. Ligand B is slightly better.
12. **Cl_mic:** Ligand A has a higher microsomal clearance (64.305) than Ligand B (32.665). Lower clearance is preferred for better metabolic stability, giving Ligand B an advantage.
13. **t1/2:** Ligand A has a half-life of 34.18 hours, while Ligand B has a half-life of 19.728 hours. Ligand A is better.
14. **Pgp:** Ligand A has a Pgp efflux liability of 0.157, while Ligand B has 0.49. Lower Pgp efflux is preferred, giving Ligand A an advantage.
15. **Binding Affinity:** Ligand B has a significantly stronger binding affinity (-7.4 kcal/mol) compared to Ligand A (-6.4 kcal/mol). This 1.0 kcal/mol difference is substantial and can often outweigh minor ADME drawbacks.
**Overall Assessment:**
Ligand B demonstrates a superior profile, primarily driven by its significantly stronger binding affinity and substantially lower DILI risk. While Ligand A has a slightly better half-life and Pgp profile, the benefits of Ligand B's potency and safety outweigh these minor differences. The lower TPSA and better metabolic stability of Ligand B are also favorable. The poor Caco-2 and solubility values are concerning for both, but the strong binding affinity of Ligand B suggests it might overcome these issues with appropriate formulation strategies.
Output:
0
2025-04-17 22:53:03,868 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [351.447, 100.55 , 1.192, 3. , 5. , 0.62 , 33.812, 52.036, -4.958, -1.331, 0.344, 34.578, -7.923, 0.027, -6.7 ]
**Ligand B:** [344.499, 49.41 , 3.732, 1. , 2. , 0.79 , 29.701, 77.705, -4.78 , -3.312, 0.395, 62.064, -15.447, 0.285, -7. ]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, Affinity) and general guidelines:
1. **MW:** Both are within the ideal range (200-500 Da). A is 351.447, B is 344.499 - very similar.
2. **TPSA:** A is 100.55, B is 49.41. B is significantly better, falling well below the 140 threshold for oral absorption and closer to the 90 threshold for CNS penetration (though not crucial for a cardiovascular target).
3. **logP:** A is 1.192, B is 3.732. B is better, being closer to the optimal 1-3 range. A is a bit low, potentially impacting permeability.
4. **HBD:** A is 3, B is 1. B is better; fewer HBDs generally improve permeability.
5. **HBA:** A is 5, B is 2. B is better; fewer HBAs are generally preferred.
6. **QED:** A is 0.62, B is 0.79. B is slightly better, indicating a more drug-like profile.
7. **DILI:** A is 33.812, B is 29.701. B is better, showing lower predicted liver injury risk.
8. **BBB:** A is 52.036, B is 77.705. B is significantly better, though BBB isn't a primary concern for a cardiovascular target.
9. **Caco-2:** Both are negative, indicating poor permeability. A is -4.958, B is -4.78. Very similar, and both are problematic.
10. **Solubility:** A is -1.331, B is -3.312. A is better, indicating higher aqueous solubility.
11. **hERG:** Both are very low (0.344 and 0.395), indicating low cardiotoxicity risk.
12. **Cl_mic:** A is 34.578, B is 62.064. A is better, suggesting better metabolic stability.
13. **t1/2:** A is -7.923, B is -15.447. A is significantly better, indicating a longer *in vitro* half-life.
14. **Pgp:** A is 0.027, B is 0.285. A is much better, indicating lower P-gp efflux and potentially better bioavailability.
15. **Affinity:** A is -6.7 kcal/mol, B is -7.0 kcal/mol. B has slightly better binding affinity, but the difference is relatively small.
**Overall Assessment:**
Ligand B excels in several key areas: TPSA, logP, QED, DILI, BBB, and binding affinity. However, it suffers from significantly higher microsomal clearance and a shorter half-life, and worse Caco-2 permeability. Ligand A has better solubility, metabolic stability, half-life, and P-gp efflux, but its logP is a bit low and TPSA is higher.
Considering the GPCR-specific priorities, the slightly better affinity of B combined with its superior TPSA and logP are attractive. However, the significantly worse metabolic stability (Cl_mic and t1/2) of B is a major concern. The longer half-life and better metabolic stability of A are crucial for a viable drug candidate. While the Caco-2 values are poor for both, the other advantages of A outweigh the small affinity difference.
Therefore, I would choose Ligand A.
Output:
1
2025-04-17 22:53:03,868 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (348.403 and 350.463 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (99.77) is slightly higher than Ligand B (87.32). Both are below the 140 threshold for good oral absorption, but closer to the 90 threshold for CNS targets, which isn't a primary concern for ADRB2 (cardiovascular). Ligand B is preferable.
3. **logP:** Ligand A (1.13) is within the optimal range (1-3), while Ligand B (2.376) is towards the higher end. Both are acceptable, but A is slightly better balanced.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2) as lower HBD generally improves permeability.
5. **HBA:** Ligand A (6) is preferable to Ligand B (4) as lower HBA generally improves permeability.
6. **QED:** Ligand A (0.875) has a significantly better QED score than Ligand B (0.669), indicating a more drug-like profile. This is a substantial advantage for A.
7. **DILI:** Both ligands have similar DILI risk (46.219 vs 47.15), both being acceptable (below 60).
8. **BBB:** Ligand A (72.935) has a much higher BBB penetration percentile than Ligand B (36.293). While ADRB2 isn't a CNS target, higher BBB is generally a positive indicator of permeability.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.826 and -4.634). These values are difficult to interpret without further context, but suggest poor permeability.
10. **Solubility:** Ligand A (-2.173) has better solubility than Ligand B (-3.146).
11. **hERG:** Ligand A (0.075) has a much lower hERG inhibition liability than Ligand B (0.176), indicating a lower risk of cardiotoxicity, which is *critical* for a cardiovascular target.
12. **Cl_mic:** Ligand A (6.868) has significantly lower microsomal clearance than Ligand B (42.466), suggesting better metabolic stability.
13. **t1/2:** Ligand A (2.177) has a better in vitro half-life than Ligand B (-18.415).
14. **Pgp:** Ligand A (0.074) has a lower P-gp efflux liability than Ligand B (0.166), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand A (-7.1) has a slightly better binding affinity than Ligand B (-6.4). While the difference is less than 1.5 kcal/mol, it contributes to the overall preference.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A excels in most of these, particularly with its lower TPSA, better logP, lower Pgp efflux, and slightly better affinity. The significantly better QED, solubility, lower hERG, and metabolic stability further solidify its advantage.
**Conclusion:**
Ligand A consistently outperforms Ligand B across most critical parameters, including drug-likeness, safety (hERG, DILI), metabolic stability, and permeability. While both ligands have issues with Caco-2 permeability, the overall profile of Ligand A is significantly more promising for development as a drug candidate targeting ADRB2.
Output:
1
2025-04-17 22:53:03,868 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
The ADRB2 receptor is a GPCR, so the priorities are logP, TPSA, Pgp efflux, BBB penetration, and binding affinity. Metabolic stability and solubility are also important, but slightly lower priority.
Let's compare the ligands property by property:
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (345.4) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are reasonably low (A: 95.67, B: 100.35), below the 140 threshold for oral absorption.
3. **logP:** Ligand A (1.786) is better than Ligand B (0.786). A logP between 1-3 is optimal, and Ligand B is getting a bit low, potentially impacting membrane permeability.
4. **HBD/HBA:** Both have 2 HBD and are within acceptable limits. Ligand B has 7 HBA, slightly higher than A (5), but still acceptable.
5. **QED:** Both are good (A: 0.76, B: 0.785), indicating drug-like properties.
6. **DILI:** Ligand A (28.97) is significantly better than Ligand B (64.13). This is a crucial advantage, as liver toxicity is a major concern.
7. **BBB:** Ligand A (28.62) is better than Ligand B (22.41), although both are relatively low. BBB isn't *critical* for ADRB2 (a cardiovascular target), but higher is still preferred.
8. **Caco-2:** Both have negative values, indicating poor permeability.
9. **Solubility:** Both have negative values, indicating poor solubility.
10. **hERG:** Both are very low (A: 0.1, B: 0.277), indicating minimal hERG inhibition risk. This is excellent.
11. **Cl_mic:** Ligand A (59.74) has a higher clearance than Ligand B (21.63), suggesting lower metabolic stability. This is a negative for Ligand A.
12. **t1/2:** Ligand B (-0.714) has a slightly better (less negative) in vitro half-life than Ligand A (-25.977).
13. **Pgp:** Both are very low (A: 0.032, B: 0.03), indicating low P-gp efflux.
14. **Binding Affinity:** Ligand B (-6.9 kcal/mol) has a slightly better binding affinity than Ligand A (-6.0 kcal/mol). This is a 0.9 kcal/mol difference, which is significant.
**Overall Assessment:**
Ligand B has a better binding affinity and metabolic stability (lower Cl_mic, better t1/2). However, Ligand A has a significantly better DILI score and a slightly better logP and BBB. The DILI risk is a major concern, and the difference between 28.97 and 64.13 is substantial. The slightly better affinity of Ligand B is unlikely to outweigh the significantly higher liver toxicity risk. While both have poor Caco-2 and solubility, these can be addressed with formulation strategies.
**Output:**
1
2025-04-17 22:53:03,868 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (372.774 and 358.429 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (42.43) is better than Ligand B (49.85) as it is closer to the <140 threshold for good oral absorption.
3. **logP:** Ligand A (4.18) is slightly higher than Ligand B (2.091). While both are within the acceptable range, Ligand A is pushing the upper limit and could potentially have solubility issues. Ligand B is well within the optimal range.
4. **HBD:** Both ligands have 0 HBD, which is good.
5. **HBA:** Both ligands have 3 HBA, which is good.
6. **QED:** Both ligands have similar QED values (0.79 and 0.7), indicating good drug-likeness.
7. **DILI:** Ligand B (13.339) has a *much* lower DILI risk than Ligand A (56.146). This is a significant advantage for Ligand B.
8. **BBB:** Ligand B (93.718) has a significantly higher BBB penetration percentile than Ligand A (79.488). While ADRB2 isn't strictly a CNS target, some cardiovascular effects are mediated by central pathways, and better BBB penetration isn't necessarily detrimental.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.512 and -4.543), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand B (-2.415) has better solubility than Ligand A (-3.98). This is important given Ligand A's higher logP.
11. **hERG:** Ligand A (0.719) has a slightly higher hERG risk than Ligand B (0.578). Lower is better here.
12. **Cl_mic:** Ligand B (38.471) has a lower microsomal clearance than Ligand A (50.423), indicating better metabolic stability.
13. **t1/2:** Ligand A (7.099) has a longer in vitro half-life than Ligand B (1.517). This is a positive for Ligand A.
14. **Pgp:** Ligand A (0.559) has lower P-gp efflux liability than Ligand B (0.148). Lower Pgp is generally better for bioavailability.
15. **Binding Affinity:** Ligand B (-4.9 kcal/mol) has a slightly better binding affinity than Ligand A (-7.0 kcal/mol). While Ligand A has a better binding affinity, the difference is not substantial enough to outweigh other factors.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand B is better on logP, Pgp, and DILI, while Ligand A is better on TPSA and half-life. The difference in affinity is not large enough to overcome the significant advantages of Ligand B in terms of safety (DILI) and ADME properties.
**Conclusion:**
Considering the balance of properties, particularly the significantly lower DILI risk, better solubility, and improved metabolic stability of Ligand B, it is the more promising drug candidate.
Output:
0
2025-04-17 22:53:03,868 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.431 and 345.443 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (75.44) is significantly better than Ligand A (96.89). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have acceptable logP values (1.896 and 2.54), falling within the 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Ligand A has 3 HBD, while Ligand B has 1. Lower is generally preferred for permeability, giving a slight edge to Ligand B.
5. **HBA:** Ligand A has 5 HBA, and Ligand B has 4. Both are within the acceptable limit of 10.
6. **QED:** Ligand B (0.804) has a higher QED score than Ligand A (0.651), indicating a more drug-like profile.
7. **DILI:** Both ligands have low DILI risk (39.511 and 35.479), well below the 60 threshold. Ligand B is marginally better.
8. **BBB:** Ligand B (83.404) has a significantly higher BBB penetration score than Ligand A (40.675). While ADRB2 is not a CNS target, higher BBB is generally a positive attribute.
9. **Caco-2:** Ligand B (-5.057) has a more negative Caco-2 value, indicating better permeability than Ligand A (-4.724).
10. **Solubility:** Ligand B (-2.55) is slightly better than Ligand A (-2.779) in terms of aqueous solubility, but both are poor.
11. **hERG:** Both ligands have low hERG inhibition liability (0.219 and 0.306), which is excellent.
12. **Cl_mic:** Ligand B (40.382) has a lower microsomal clearance than Ligand A (92.814), suggesting better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand B (-18.047) has a more negative in vitro half-life, indicating a longer half-life than Ligand A (-12.506).
14. **Pgp:** Both ligands have low P-gp efflux liability (0.109 and 0.276).
15. **Binding Affinity:** Ligand B (-7.3 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.2 kcal/mol). This is a substantial advantage, potentially outweighing minor ADME drawbacks.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B excels in all these areas. The higher affinity of Ligand B is particularly important. While BBB isn't a primary concern for a cardiovascular target, the higher score for Ligand B isn't detrimental.
**Conclusion:**
Ligand B consistently outperforms Ligand A across most critical parameters, particularly binding affinity and metabolic stability. The slightly better physicochemical properties (TPSA, logP, QED) further support its selection.
Output:
0
2025-04-17 22:53:03,869 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (347.459) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (70.67) is significantly better than Ligand B (110.72). ADRB2 is not a CNS target, but lower TPSA generally improves absorption.
3. **logP:** Ligand A (1.237) is within the optimal range, while Ligand B (-0.295) is slightly below, potentially hindering permeation.
4. **HBD:** Both ligands have acceptable HBD counts (2 and 1, respectively).
5. **HBA:** Ligand B (8) is higher than Ligand A (4), but still within the acceptable range.
6. **QED:** Both ligands have similar and good QED scores (0.537 and 0.515).
7. **DILI:** Ligand A (17.642) has a much lower DILI risk than Ligand B (67.003), a significant advantage.
8. **BBB:** While not a primary concern for ADRB2, Ligand A (71.307) has a slightly better BBB percentile than Ligand B (67.08).
9. **Caco-2:** Ligand A (-5.61) has a worse Caco-2 permeability than Ligand B (-4.717), which is a negative.
10. **Solubility:** Ligand A (-2.201) has a slightly worse solubility than Ligand B (-2.425).
11. **hERG:** Both ligands have low hERG inhibition liability, which is good. Ligand A (0.412) is slightly better.
12. **Cl_mic:** Ligand A (-1.499) shows better metabolic stability (lower clearance) than Ligand B (58.382). This is a substantial advantage.
13. **t1/2:** Ligand A (5.402) has a better in vitro half-life than Ligand B (-30.154). This is a major advantage.
14. **Pgp:** Both ligands have very low Pgp efflux liability.
15. **Binding Affinity:** Ligand B (-6.5) has a slightly better binding affinity than Ligand A (-6.1), but the difference is only 0.4 kcal/mol.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand A has a better logP and TPSA, while Ligand B has a slightly better affinity. However, the substantial advantages of Ligand A in terms of DILI risk, metabolic stability (Cl_mic), and half-life outweigh the small affinity difference.
**Conclusion:**
Ligand A is the more promising candidate due to its significantly improved safety profile (DILI), metabolic stability, and half-life, coupled with acceptable physicochemical properties. The slightly weaker binding affinity is a minor drawback compared to the substantial ADME/Tox benefits.
Output:
1
2025-04-17 22:53:03,869 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [380.861, 114.07 , 0.682, 4. , 5. , 0.448, 85.459, 54.556, -5.28 , -3.391, 0.093, 32.865, -0.414, 0.085, -6.9 ]
**Ligand B:** [346.395, 118.79 , -0.171, 1. , 8. , 0.704, 68.631, 51.066, -5.476, -1.188, 0.035, 29.957, 10.663, 0.018, -4.6 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (346.395) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are above the optimal <140 for oral absorption, but not drastically so. Ligand B (118.79) is a bit higher than A (114.07).
3. **logP:** Ligand A (0.682) is better than Ligand B (-0.171). A logP between 1-3 is preferred, and B is below 1, which could hinder permeation.
4. **HBD:** Ligand A (4) is better than Ligand B (1). Both are within the acceptable limit of <=5.
5. **HBA:** Ligand B (8) is higher than Ligand A (5). Both are within the acceptable limit of <=10.
6. **QED:** Ligand B (0.704) is better than Ligand A (0.448), indicating a more drug-like profile.
7. **DILI:** Ligand A (85.459) has a significantly higher DILI risk than Ligand B (68.631). This is a major concern.
8. **BBB:** Both have similar BBB penetration (A: 54.556, B: 51.066). For a cardiovascular target, BBB isn't *critical*, but higher is generally better.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. Ligand A (-5.28) is slightly worse than Ligand B (-5.476).
10. **Solubility:** Ligand A (-3.391) is worse than Ligand B (-1.188). Solubility is important for bioavailability.
11. **hERG:** Both have very low hERG risk (A: 0.093, B: 0.035).
12. **Cl_mic:** Ligand B (29.957) has lower microsomal clearance than Ligand A (32.865), suggesting better metabolic stability.
13. **t1/2:** Ligand B (10.663) has a significantly longer in vitro half-life than Ligand A (-0.414). This is a major advantage.
14. **Pgp:** Both have very low Pgp efflux (A: 0.085, B: 0.018).
15. **Affinity:** Ligand A (-6.9 kcal/mol) has a substantially better binding affinity than Ligand B (-4.6 kcal/mol). This is a significant advantage.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. While Ligand B has better QED, solubility, metabolic stability, and half-life, Ligand A's significantly stronger binding affinity (-6.9 vs -4.6 kcal/mol) is a major driver. The 2.3 kcal/mol difference in binding is substantial and can often outweigh minor ADME drawbacks. The DILI risk for Ligand A is concerning, but could be addressed with further structural modifications. The poor Caco-2 values for both are a concern, but not as critical for a cardiovascular target where IV administration is an option.
**Conclusion:**
Despite the higher DILI risk and slightly poorer solubility/permeability, the significantly improved binding affinity of Ligand A makes it the more promising candidate. The potency advantage is likely to be more impactful than the ADME liabilities, which can potentially be optimized in subsequent iterations.
0
2025-04-17 22:53:03,869 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.435 & 342.443 Da) are within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand B (78.09) is significantly better than Ligand A (107.61). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally improves absorption.
3. **logP:** Ligand B (2.099) is optimal, while Ligand A (-0.465) is quite low, potentially hindering membrane permeability. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (3) and Ligand B (2) are both acceptable.
5. **HBA:** Ligand A (4) and Ligand B (3) are both acceptable.
6. **QED:** Ligand B (0.879) is much better than Ligand A (0.522), indicating a more drug-like profile.
7. **DILI:** Ligand B (38.62) has a lower DILI risk than Ligand A (20.551), which is preferable.
8. **BBB:** Both are relatively low, which is fine for a cardiovascular target. Ligand B (54.13) is slightly better than Ligand A (47.15).
9. **Caco-2:** Both are negative, indicating poor permeability. This is a concern for both, but the lower TPSA and better logP of Ligand B may mitigate this somewhat.
10. **Solubility:** Both are negative, indicating poor solubility. This is a concern for both.
11. **hERG:** Ligand A (0.041) has a lower hERG risk than Ligand B (0.342), which is a positive.
12. **Cl_mic:** Ligand A (-7.603) has significantly lower (better) microsomal clearance than Ligand B (5.242), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-12.027) has a much longer half-life than Ligand A (-5.355), which is a significant advantage.
14. **Pgp:** Ligand A (0.005) has lower P-gp efflux than Ligand B (0.046), which is preferable.
15. **Binding Affinity:** Ligand B (-7.8) has slightly better binding affinity than Ligand A (-5.8).
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, and affinity are key. Ligand B excels in logP and has slightly better affinity. While Ligand A has a better hERG profile and lower Pgp efflux, the poor logP is a major drawback. The longer half-life of Ligand B is also a significant benefit.
**Overall Assessment:**
Ligand B, despite the slightly higher hERG and Pgp values, presents a more balanced profile with better predicted absorption (logP, TPSA), drug-likeness (QED), metabolic stability (t1/2), and binding affinity. The poor solubility and Caco-2 values are concerns for both, but can be addressed through formulation strategies. The significantly better logP and QED of Ligand B outweigh the benefits of Ligand A's better hERG and Pgp.
Output:
0
2025-04-17 22:53:03,869 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (356.5 and 354.4 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (81.08) is better than Ligand B (87.15). Both are below 140, but lower TPSA generally favors absorption.
3. **logP:** Ligand A (1.809) is better than Ligand B (0.518). Ligand B is a bit low, potentially hindering membrane permeability. ADRB2 is not a CNS target, but good permeability is still important.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1), but both are within the acceptable limit of 5.
5. **HBA:** Ligand A (4) is lower than Ligand B (5), which is preferable.
6. **QED:** Both ligands have reasonable QED values (0.462 and 0.555), indicating acceptable drug-likeness. Ligand B is slightly better.
7. **DILI:** Ligand B (49.632) has a significantly lower DILI risk than Ligand A (10.198). This is a major advantage for Ligand B.
8. **BBB:** Ligand B (81.698) has better BBB penetration than Ligand A (55.099). While ADRB2 isn't a primary CNS target, some degree of BBB penetration can be useful for off-target effects assessment.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.578 and -4.854), which is unusual and suggests very poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand A (-0.824) has better solubility than Ligand B (-2.045). Solubility is important for bioavailability.
11. **hERG:** Both ligands have low hERG inhibition risk (0.518 and 0.33). No significant difference.
12. **Cl_mic:** Ligand B (20.96) has much lower microsomal clearance than Ligand A (56.985). Lower clearance means greater metabolic stability, a significant advantage.
13. **t1/2:** Ligand B (-34.033) has a much longer in vitro half-life than Ligand A (3.651). This is a substantial advantage, potentially leading to less frequent dosing.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.091 and 0.119). No significant difference.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.7 and -6.6 kcal/mol). The difference is negligible.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, and metabolic stability (Cl_mic, t1/2) are key. Ligand B is better in logP, significantly better in Cl_mic and t1/2. While both have poor Caco-2 permeability, the other advantages of Ligand B outweigh this. The lower DILI risk is also a major plus.
**Conclusion:**
Despite the poor Caco-2 values for both, Ligand B's superior metabolic stability, lower DILI risk, and slightly better logP and BBB penetration make it the more promising drug candidate.
Output:
0
2025-04-17 22:53:03,869 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (362.43 and 344.499 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (59.39) is slightly higher than Ligand B (49.41). Both are below the 140 threshold for oral absorption, but B is closer to the 90 threshold for CNS targets, though this is less critical for ADRB2.
3. **logP:** Both ligands (3.059 and 3.256) are within the optimal 1-3 range. No significant difference.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 6 HBA, while Ligand B has 2. Both are below the 10 threshold. Ligand B is preferable here.
6. **QED:** Both ligands have good QED scores (0.732 and 0.778), indicating good drug-like properties.
7. **DILI:** Ligand A (90.345) has a significantly higher DILI risk than Ligand B (36.293). This is a major concern for Ligand A.
8. **BBB:** Ligand A (82.319) has slightly better BBB penetration than Ligand B (70.027), but this is less important for a cardiovascular target like ADRB2.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the values are very close (-4.546 vs -4.535).
10. **Solubility:** Both ligands have negative solubility values, indicating poor aqueous solubility. Ligand B (-3.987) is slightly better than Ligand A (-3.102).
11. **hERG:** Ligand A (0.886) has a slightly higher hERG risk than Ligand B (0.559), but both are relatively low.
12. **Cl_mic:** Ligand A (59.121) has a higher microsomal clearance than Ligand B (54.587), indicating lower metabolic stability.
13. **t1/2:** Ligand B (-14.076) has a negative in vitro half-life, which is a significant red flag. Ligand A (66.314) has a much more reasonable half-life.
14. **Pgp:** Ligand A (0.654) has lower P-gp efflux than Ligand B (0.284), which is preferable.
15. **Affinity:** Ligand A (-7.5 kcal/mol) has a slightly better binding affinity than Ligand B (-7.2 kcal/mol). This is a 0.3 kcal/mol difference, which is not huge, but still relevant.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand B has a better logP and TPSA, while Ligand A has better Pgp and affinity. However, the *significant* difference in DILI risk and the problematic half-life of Ligand B outweigh these benefits.
**Conclusion:**
Despite the slightly better affinity of Ligand A, the significantly lower DILI risk and more reasonable half-life of Ligand B make it the more promising candidate. While both have solubility and permeability issues, these can be addressed with formulation strategies. The DILI risk associated with Ligand A is a major concern that is harder to overcome.
Output:
0
2025-04-17 22:53:03,869 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (344.415 and 364.494 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (91.4) is slightly higher than Ligand B (68.52). Both are below 140, but B is better for oral absorption and potentially better for GPCR targets.
3. **logP:** Both ligands have good logP values (1.693 and 2.765), falling within the 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Ligand A has 2 HBD, and Ligand B has 1. Both are within the acceptable limit of 5.
5. **HBA:** Ligand A has 6 HBA, and Ligand B has 7. Both are below the 10 threshold.
6. **QED:** Ligand A (0.832) has a better QED score than Ligand B (0.699), indicating a more drug-like profile.
7. **DILI:** Ligand A (43.971) has a slightly lower DILI risk than Ligand B (51.221), which is preferable.
8. **BBB:** Ligand B (80.341) has a significantly higher BBB penetration percentile than Ligand A (72.005). Given that ADRB2 is a GPCR, BBB penetration is a relevant consideration, although not critical for all subtypes/indications.
9. **Caco-2:** Ligand A (-4.712) has a better Caco-2 permeability than Ligand B (-5.25).
10. **Solubility:** Ligand A (-2.778) has better aqueous solubility than Ligand B (-3.192).
11. **hERG:** Both ligands have very low hERG inhibition liability (0.31 and 0.294), which is excellent.
12. **Cl_mic:** Ligand A (39.178) has a lower microsomal clearance than Ligand B (55.301), suggesting better metabolic stability.
13. **t1/2:** Ligand B (19.115) has a significantly longer in vitro half-life than Ligand A (-2.855). This is a major advantage.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.028 and 0.243).
15. **Binding Affinity:** Ligand B (-6.6 kcal/mol) has a substantially stronger binding affinity than Ligand A (-4.8 kcal/mol). This is a >1.5 kcal/mol difference, which is a critical advantage.
**Overall Assessment:**
Ligand B demonstrates a significantly stronger binding affinity, a longer half-life, and better BBB penetration. While Ligand A has a better QED, solubility, and slightly lower DILI risk, the potency and PK advantages of Ligand B outweigh these benefits, especially considering the target is a GPCR. The improved half-life is particularly important, potentially leading to less frequent dosing.
Output:
0
2025-04-17 22:53:03,869 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.463 and 357.407 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Both ligands (106.96 and 106.2) are below the 140 A^2 threshold for good oral absorption, which is good.
3. **logP:** Ligand A (3.08) is optimal, while Ligand B (-0.355) is significantly below the 1-3 range, potentially hindering permeation. This is a significant negative for Ligand B.
4. **HBD:** Both ligands have 2 HBD, which is within the acceptable limit of <=5.
5. **HBA:** Ligand A has 3 HBA, while Ligand B has 6. Both are below the 10 limit, but Ligand A is preferable.
6. **QED:** Ligand B (0.645) has a better QED score than Ligand A (0.274), indicating a more drug-like profile.
7. **DILI:** Ligand A (17.681) has a much lower DILI risk than Ligand B (39.356). This is a significant advantage for Ligand A.
8. **BBB:** Both ligands have reasonable BBB penetration (60.178 and 69.446), but Ligand B is slightly better.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability.
10. **Solubility:** Both have negative solubility values, which is also unusual and suggests poor solubility.
11. **hERG:** Both ligands have low hERG inhibition risk (0.27 and 0.14).
12. **Cl_mic:** Ligand A (24.839) has a higher microsomal clearance than Ligand B (0.149), indicating lower metabolic stability. This is a negative for Ligand A.
13. **t1/2:** Ligand B (-15.684) has a negative in vitro half-life, which is concerning. Ligand A (-0.167) is also poor, but less so.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.033 and 0.005).
15. **Binding Affinity:** Ligand B (-7.3 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.9 kcal/mol). This is a substantial advantage for Ligand B.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand A has a better logP, while Ligand B has a better affinity. The significant difference in binding affinity (-7.3 vs -5.9) is a major factor. While Ligand A has a better DILI score, the difference in affinity is likely to outweigh this. The poor Caco-2 and solubility values are concerning for both, but can be addressed with formulation strategies.
**Overall Assessment:**
Despite Ligand A's better DILI and logP, Ligand B's significantly stronger binding affinity (-7.3 kcal/mol vs -5.9 kcal/mol) is a critical advantage for a GPCR target. The higher QED score of Ligand B is also favorable. The poor ADME properties are a concern for both, but the potency advantage of Ligand B is likely to be more impactful in driving forward a lead optimization effort.
Output:
0
2025-04-17 22:53:03,869 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [342.355, 108.47 , 1.723, 2. , 6. , 0.86 , 84.645, 78.286, -4.858, -4.958, 0.453, 42.619, 8.731, 0.311, -7.4 ]**
**Ligand B: [346.431, 114.18 , 0.924, 3. , 4. , 0.649, 31.989, 62.233, -5.385, -2.832, 0.062, 24.349, -0.309, 0.014, -5.7 ]**
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). A is 342.355, B is 346.431. No significant difference.
2. **TPSA:** Ligand A (108.47) is better than Ligand B (114.18). Both are below 140, but A is closer to the preferred threshold for good absorption.
3. **logP:** Ligand A (1.723) is slightly better than Ligand B (0.924). Both are within the optimal range (1-3), but B is closer to the lower limit, potentially impacting permeability.
4. **H-Bond Donors:** Ligand A (2) is better than Ligand B (3). Lower is generally preferred.
5. **H-Bond Acceptors:** Ligand A (6) is better than Ligand B (4). Lower is generally preferred.
6. **QED:** Ligand A (0.86) is significantly better than Ligand B (0.649). A higher QED indicates a more drug-like profile.
7. **DILI:** Ligand B (31.989) is *much* better than Ligand A (84.645). This is a major advantage for B.
8. **BBB:** Ligand A (78.286) is better than Ligand B (62.233). While ADRB2 is a cardiovascular target, some CNS exposure can be relevant for off-target effects and safety assessment.
9. **Caco-2:** Ligand A (-4.858) is better than Ligand B (-5.385). Higher values indicate better intestinal absorption.
10. **Solubility:** Ligand A (-4.958) is better than Ligand B (-2.832). Higher values indicate better solubility.
11. **hERG:** Ligand A (0.453) is better than Ligand B (0.062). Lower values indicate lower risk of hERG inhibition.
12. **Cl_mic:** Ligand B (24.349) is better than Ligand A (42.619). Lower clearance suggests better metabolic stability.
13. **t1/2:** Ligand A (8.731) is better than Ligand B (-0.309). Longer half-life is generally preferred.
14. **Pgp:** Ligand A (0.311) is better than Ligand B (0.014). Lower efflux improves bioavailability.
15. **Binding Affinity:** Ligand A (-7.4) is significantly better than Ligand B (-5.7). This is a substantial difference in potency.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A has better logP, TPSA, and Pgp values. The *significant* difference in binding affinity (-7.4 vs -5.7) is a major driver. While Ligand B has a much better DILI score, the potency advantage of Ligand A is substantial enough to outweigh this concern, especially considering optimization can potentially address the DILI risk.
**Conclusion:**
Despite the better DILI profile of Ligand B, the superior binding affinity, drug-likeness (QED), and generally better ADME properties (TPSA, logP, solubility, hERG, t1/2, Pgp) of Ligand A make it the more promising drug candidate.
**Output:**
1
2025-04-17 22:53:03,869 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (341.419 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (91.94) is better than Ligand B (119.11), falling comfortably under the 140 threshold for oral absorption.
3. **logP:** Ligand A (3.072) is optimal, while Ligand B (0.848) is a bit low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (0) is excellent, minimizing potential issues with hydrogen bonding. Ligand B (3) is acceptable, but higher.
5. **HBA:** Both ligands have 6 HBA, which is within the acceptable range.
6. **QED:** Ligand B (0.727) has a better QED score than Ligand A (0.419), indicating a more drug-like profile.
7. **DILI:** Ligand A (40.481) has a significantly lower DILI risk than Ligand B (69.794). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (80.496) has a better BBB penetration score than Ligand B (60.605). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant, and higher BBB is generally desirable.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
10. **Solubility:** Both ligands have negative solubility values, again making interpretation difficult without knowing the scale.
11. **hERG:** Ligand A (0.596) has a slightly higher hERG risk than Ligand B (0.25), but both are relatively low.
12. **Cl_mic:** Ligand A (30.452) has a lower microsomal clearance than Ligand B (-39.664), suggesting better metabolic stability.
13. **t1/2:** Ligand A (18.505) has a longer in vitro half-life than Ligand B (11.842), which is desirable.
14. **Pgp:** Ligand A (0.311) has lower P-gp efflux liability than Ligand B (0.016), which is favorable for bioavailability.
15. **Affinity:** Ligand B (-7.2 kcal/mol) has a slightly better binding affinity than Ligand A (-6.4 kcal/mol). This is a significant advantage for Ligand B, potentially outweighing some of its ADME drawbacks.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are particularly important. Ligand A has a better logP and Pgp profile, while Ligand B has a slightly better affinity. TPSA is good for both.
**Overall Assessment:**
While Ligand B has a slightly better binding affinity and QED, Ligand A has a significantly better safety profile (lower DILI), better metabolic stability (lower Cl_mic, longer t1/2), better BBB penetration, and a more favorable logP. The difference in binding affinity (0.8 kcal/mol) is not substantial enough to overcome the ADME and safety advantages of Ligand A. The negative values for Caco-2 and solubility are concerning for both, but without knowing the scale, it's hard to weigh them.
**Output:**
1
2025-04-17 22:53:03,869 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.43 & 369.87 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (67.87) is slightly higher than Ligand B (54.46). Both are below the 140 threshold for oral absorption, but B is better.
3. **logP:** Both ligands have good logP values (1.9 & 2.8), falling within the optimal 1-3 range. Ligand B is slightly better.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Both have 4 HBA, which is good.
6. **QED:** Both have high QED scores (0.846 & 0.867), indicating good drug-likeness. No clear advantage.
7. **DILI:** Ligand B (27.34) has a lower DILI risk than Ligand A (31.72), which is preferable.
8. **BBB:** Ligand B (91.90) has significantly higher BBB penetration than Ligand A (65.84). While ADRB2 isn't *strictly* a CNS target, some CNS exposure can be beneficial or at least less detrimental than complete exclusion.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the values are very close (-4.399 vs -4.493).
10. **Solubility:** Both have negative solubility values, which is also unusual. The values are very close (-2.894 vs -2.895).
11. **hERG:** Ligand A (0.266) has a slightly lower hERG inhibition liability than Ligand B (0.561), which is preferable.
12. **Cl_mic:** Ligand A (25.74) has lower microsomal clearance than Ligand B (33.64), indicating better metabolic stability.
13. **t1/2:** Ligand B (33.64) has a longer in vitro half-life than Ligand A (-8.293). This is a significant advantage.
14. **Pgp:** Ligand A (0.07) has lower P-gp efflux liability than Ligand B (0.265), which is preferable.
15. **Binding Affinity:** Ligand B (-7.7 kcal/mol) has a stronger binding affinity than Ligand A (-6.4 kcal/mol). This is a substantial advantage, exceeding the 1.5 kcal/mol threshold.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand B performs better on logP, BBB, and *significantly* better on affinity. While Ligand A has advantages in Pgp and Cl_mic, the superior affinity of Ligand B is likely to outweigh these benefits. The DILI score is also better for Ligand B.
**Conclusion:**
Despite some drawbacks in Pgp and Cl_mic, Ligand B's superior binding affinity, better BBB penetration, lower DILI risk, and longer half-life make it the more promising drug candidate for the ADRB2 receptor.
Output:
0
2025-04-17 22:53:03,870 - INFO - Batch 364 complete. Total preferences: 5824
2025-04-17 22:53:03,870 - INFO - Processing batch 365/512...
2025-04-17 22:53:53,210 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [360.483, 78.09, 2.048, 2, 4, 0.828, 44.048, 39.473, -5.628, -2.738, 0.226, 25.87, -6.579, 0.102, -5.7]
**Ligand B:** [353.463, 102.66, 1.069, 2, 5, 0.743, 11.128, 57.193, -4.652, -1.68, 0.266, 2.148, -15.192, 0.009, -4.9]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal 200-500 Da range. Ligand A (360.483) is slightly higher than Ligand B (353.463), but both are acceptable.
2. **TPSA:** Ligand A (78.09) is significantly better than Ligand B (102.66). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is approaching the upper limit for good oral absorption.
3. **logP:** Both ligands have good logP values (A: 2.048, B: 1.069), falling within the 1-3 range. Ligand A is slightly preferable.
4. **HBD:** Both have 2 HBD, which is good.
5. **HBA:** Ligand A (4) is better than Ligand B (5). Lower HBA is generally preferred.
6. **QED:** Ligand A (0.828) has a better QED score than Ligand B (0.743), indicating a more drug-like profile.
7. **DILI:** Ligand A (44.048) has a much lower DILI risk than Ligand B (11.128). This is a significant advantage for Ligand A.
8. **BBB:** Ligand B (57.193) has a better BBB penetration score than Ligand A (39.473). While ADRB2 isn't strictly a CNS target, some CNS exposure can be beneficial or at least avoid unexpected side effects.
9. **Caco-2:** Ligand A (-5.628) is worse than Ligand B (-4.652), indicating lower intestinal absorption.
10. **Solubility:** Ligand A (-2.738) is worse than Ligand B (-1.68), indicating lower aqueous solubility.
11. **hERG:** Both have low hERG risk (A: 0.226, B: 0.266).
12. **Cl_mic:** Ligand B (2.148) has significantly lower microsomal clearance than Ligand A (25.87), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-15.192) has a much longer in vitro half-life than Ligand A (-6.579). This is a major advantage for Ligand B.
14. **Pgp:** Both have low P-gp efflux (A: 0.102, B: 0.009). Ligand B is slightly better.
15. **Affinity:** Ligand A (-5.7) has a slightly better binding affinity than Ligand B (-4.9).
**Overall Assessment:**
Ligand A has a better QED, DILI, and binding affinity. However, Ligand B excels in metabolic stability (Cl_mic, t1/2), Pgp efflux, and BBB penetration. The lower DILI risk of Ligand A is a significant plus. The solubility and Caco-2 values for Ligand A are concerning. While the affinity difference isn't huge, it's enough to consider. Given the GPCR target class, balancing TPSA, logP, Pgp, and affinity is crucial.
Considering all factors, the better metabolic stability and longer half-life of Ligand B, coupled with acceptable TPSA and logP, outweigh the slightly better affinity of Ligand A, especially given the solubility and absorption concerns with Ligand A.
Output:
0
2025-04-17 22:53:53,210 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [337.379, 76.38, 3.076, 2, 5, 0.75, 73.982, 35.052, -5.228, -3.924, 0.565, 65.877, -29.39, 0.336, -7.4]**
**Ligand B: [342.439, 58.64, 2.691, 1, 3, 0.856, 40.83, 64.948, -4.488, -3.255, 0.443, 52.7, -18.841, 0.274, -6.9]**
**1. Molecular Weight (MW):** Both ligands are within the ideal range (200-500 Da). A (337.379) is slightly lower, which is generally favorable for permeability.
**2. TPSA:** Ligand A (76.38) is higher than Ligand B (58.64). For a cardiovascular GPCR like ADRB2, TPSA is less critical than for CNS targets, but lower is still preferred for better absorption. Ligand B is better here.
**3. logP:** Both ligands have good logP values (A: 3.076, B: 2.691) within the optimal 1-3 range.
**4. H-Bond Donors (HBD):** Both are acceptable (A: 2, B: 1). Lower is generally preferred, so B is slightly better.
**5. H-Bond Acceptors (HBA):** Both are reasonable (A: 5, B: 3). Lower is generally preferred, so B is better.
**6. QED:** Both have good QED scores (A: 0.75, B: 0.856), indicating good drug-like properties. B is slightly better.
**7. DILI:** Ligand A (73.982) has a significantly higher DILI risk than Ligand B (40.83). This is a major concern.
**8. BBB:** Ligand B (64.948) has a higher BBB penetration score than Ligand A (35.052). While ADRB2 isn't a primary CNS target, some CNS exposure can contribute to side effects, and lower BBB is preferable in this case.
**9. Caco-2:** Both have negative values, indicating poor permeability. A (-5.228) is worse than B (-4.488).
**10. Solubility:** Both have negative values, indicating poor solubility. B (-3.255) is slightly better than A (-3.924).
**11. hERG:** Both have low hERG inhibition liability (A: 0.565, B: 0.443). B is slightly better.
**12. Cl_mic:** Ligand B (52.7) has a lower microsomal clearance than Ligand A (65.877), suggesting better metabolic stability.
**13. t1/2:** Ligand B (-18.841) has a longer in vitro half-life than Ligand A (-29.39), which is desirable.
**14. Pgp:** Ligand B (0.274) has lower P-gp efflux than Ligand A (0.336), which is favorable for bioavailability.
**15. Binding Affinity:** Ligand A (-7.4) has a slightly better binding affinity than Ligand B (-6.9). This is a 0.5 kcal/mol difference, which is significant, but must be weighed against other factors.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity, the significantly higher DILI risk is a major red flag. Ligand B consistently performs better across most ADME-Tox properties (lower DILI, better metabolic stability, longer half-life, lower Pgp efflux, better TPSA, HBD, HBA, QED, and hERG). The small difference in binding affinity is outweighed by the superior safety and pharmacokinetic profile of Ligand B.
Output:
0
2025-04-17 22:53:53,211 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (358.479 and 368.543 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (88.1) is slightly higher than Ligand B (67.43). Both are below 140, but B is better for oral absorption and potentially better for GPCR targets.
3. **logP:** Ligand A (0.8) is a bit low, potentially hindering permeability. Ligand B (2.632) is within the optimal 1-3 range. This favors Ligand B.
4. **HBD:** Both have 2 H-bond donors, which is good.
5. **HBA:** Ligand A has 5, and Ligand B has 4. Both are acceptable, below the 10 threshold.
6. **QED:** Ligand B (0.8) is better than Ligand A (0.636), indicating a more drug-like profile.
7. **DILI:** Ligand A (28.616) has a significantly lower DILI risk than Ligand B (44.824). This is a substantial advantage for Ligand A.
8. **BBB:** Ligand B (48.74) is slightly better than Ligand A (39.511), but neither are particularly high. For a cardiovascular target like ADRB2, BBB penetration isn't a primary concern, so this difference is less critical.
9. **Caco-2:** Ligand A (-4.582) is better than Ligand B (-5.215), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-0.916) is better than Ligand B (-2.887). Better solubility is always preferred.
11. **hERG:** Ligand A (0.353) has a lower hERG risk than Ligand B (0.126). This is a significant advantage for Ligand A, as hERG inhibition can lead to cardiotoxicity.
12. **Cl_mic:** Both ligands have similar microsomal clearance values (34.844 and 35.683 mL/min/kg).
13. **t1/2:** Ligand B (-7.855) has a longer in vitro half-life than Ligand A (-5.771). This is a slight advantage for Ligand B.
14. **Pgp:** Ligand A (0.051) has lower P-gp efflux than Ligand B (0.131), which is favorable.
15. **Binding Affinity:** Ligand B (-8.5 kcal/mol) has a significantly stronger binding affinity than Ligand A (-7.1 kcal/mol). This ~1.4 kcal/mol difference is substantial and can outweigh some ADME drawbacks.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP and affinity, while Ligand A is better in TPSA and Pgp. However, the strong affinity of Ligand B is a major driver.
**Overall Assessment:**
While Ligand A has advantages in DILI, hERG, solubility, and Caco-2, the significantly stronger binding affinity of Ligand B (-8.5 vs -7.1 kcal/mol) is the most important factor. The improved logP and QED of Ligand B also contribute to its overall drug-likeness. The slightly higher DILI and hERG risks of Ligand B are acceptable given the potency advantage.
Output:
0
2025-04-17 22:53:53,211 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (342.443 and 362.499 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (86.88) is better than Ligand B (58.44). Both are below the 140 threshold for oral absorption, and Ligand B is closer to the 90 threshold for CNS targets, but ADRB2 is a cardiovascular target, so this is less critical.
3. **logP:** Both ligands (1.545 and 1.81) are within the optimal 1-3 range. No significant difference.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (0), but both are acceptable (<=5).
5. **HBA:** Ligand A (3) is lower than Ligand B (5), which is preferable.
6. **QED:** Ligand B (0.82) is significantly better than Ligand A (0.626), indicating a more drug-like profile.
7. **DILI:** Both ligands have low DILI risk (Ligand A: 37.999, Ligand B: 35.712), both below the 40 threshold. No significant difference.
8. **BBB:** Ligand B (82.629) is much better than Ligand A (39.162). While ADRB2 isn't a CNS target, higher BBB penetration can sometimes correlate with better overall distribution.
9. **Caco-2:** Ligand A (-5.225) is slightly better than Ligand B (-4.914), indicating slightly better intestinal absorption.
10. **Solubility:** Ligand A (-3.362) is better than Ligand B (-2.515), indicating better aqueous solubility.
11. **hERG:** Both ligands have very low hERG risk (Ligand A: 0.117, Ligand B: 0.341). No significant difference.
12. **Cl_mic:** Ligand A (-8.103) is significantly better than Ligand B (54.097), indicating much greater metabolic stability. This is a crucial advantage.
13. **t1/2:** Ligand B (-8.592) is slightly better than Ligand A (-6.537), indicating a longer half-life.
14. **Pgp:** Ligand A (0.066) is much better than Ligand B (0.087), indicating lower P-gp efflux.
15. **Binding Affinity:** Ligand A (-7.5) is better than Ligand B (-5.7). This is a substantial difference in potency (1.8 kcal/mol), which can outweigh some ADME drawbacks.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand A has a better TPSA and Pgp, and a *much* better binding affinity. Ligand B has a better BBB and QED. However, the significant advantage in binding affinity and metabolic stability (Cl_mic) for Ligand A is critical. The better solubility of Ligand A is also a plus.
**Conclusion:**
Despite Ligand B's slightly better QED and BBB, Ligand A's superior binding affinity, metabolic stability, solubility, and Pgp profile make it the more promising drug candidate for ADRB2. The 1.8 kcal/mol difference in binding affinity is a substantial advantage.
Output:
1
2025-04-17 22:53:53,211 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (343.43 and 350.46 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (71.53 and 71.78) are below the 140 A^2 threshold for good oral absorption, and are reasonable for a cardiovascular target (not requiring significant BBB penetration). No clear advantage.
3. **logP:** Both ligands have logP values within the optimal 1-3 range (2.04 and 2.82). Ligand B is slightly higher, which *could* be a minor drawback if it leads to off-target effects, but is still acceptable.
4. **HBD:** Both ligands have 1 HBD, which is well within the acceptable limit of 5.
5. **HBA:** Both ligands have 4 HBA, also well within the acceptable limit of 10.
6. **QED:** Both ligands have good QED scores (0.784 and 0.856), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A has a DILI risk of 52.19%, while Ligand B has 34.55%. Ligand B is significantly better here, indicating a lower risk of liver injury. This is a crucial factor.
8. **BBB:** Both ligands have reasonable BBB penetration (67.27% and 72.66%). Since ADRB2 is primarily a cardiovascular target, high BBB penetration is not essential, but it doesn't hurt. Ligand B is slightly better.
9. **Caco-2:** Both have negative Caco-2 values (-4.753 and -4.514). This is unusual and suggests poor permeability. However, these values are on a scale where negative values are possible, and a direct comparison is difficult without knowing the scale's specifics.
10. **Solubility:** Both have negative solubility values (-2.3 and -3.007). Similar to Caco-2, this is unusual and makes direct comparison difficult.
11. **hERG:** Both ligands have low hERG inhibition risk (0.449 and 0.539), which is excellent.
12. **Cl_mic:** Ligand A has a higher microsomal clearance (55.77 mL/min/kg) than Ligand B (15.75 mL/min/kg). This suggests that Ligand B will have better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand B has a longer in vitro half-life (36.36 hours) than Ligand A (27.55 hours). This is desirable for less frequent dosing.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.111 and 0.233), which is good.
15. **Binding Affinity:** Ligand A has a slightly better binding affinity (-7.0 kcal/mol) than Ligand B (-6.4 kcal/mol). This is a 0.6 kcal/mol difference. While affinity is important, the other ADME properties are more concerning.
**GPCR-specific priorities:** For GPCRs, logP, Pgp, TPSA, and affinity are key. Both ligands are good on logP, Pgp, and TPSA. Ligand A has a slightly better affinity, but the differences in DILI, Cl_mic, and t1/2 are more significant.
**Overall Assessment:**
Ligand B is the preferable candidate. While Ligand A has slightly better binding affinity, Ligand B demonstrates a significantly improved safety profile (lower DILI risk), better metabolic stability (lower Cl_mic, longer t1/2), and slightly better BBB penetration. The differences in ADME properties outweigh the small difference in binding affinity, especially for a cardiovascular target where extremely high potency isn't always essential.
Output:
0
2025-04-17 22:53:53,211 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [346.427, 71.78, 2.469, 1, 4, 0.77, 60.062, 63.94, -4.577, -3.011, 0.163, 32.072, 25.067, 0.081, -6.8]
**Ligand B:** [368.503, 98.32, 0.809, 3, 5, 0.631, 37.456, 17.332, -5.677, -2.566, 0.187, 18.964, -15.605, 0.071, -6.1]
Here's a breakdown, considering the GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal range (200-500 Da). A is 346.43, B is 368.50. No significant difference.
2. **TPSA:** A (71.78) is excellent, well below 140, and good for oral absorption. B (98.32) is still acceptable, but less optimal.
3. **logP:** A (2.469) is optimal. B (0.809) is a bit low, potentially hindering membrane permeability.
4. **HBD/HBA:** A (1 HBD, 4 HBA) is preferable to B (3 HBD, 5 HBA). Lower counts generally improve permeability.
5. **QED:** A (0.77) is better than B (0.631), indicating a more drug-like profile.
6. **DILI:** A (60.062) is higher risk than B (37.456). This is a significant drawback for A.
7. **BBB:** A (63.94) is reasonable, but B (17.332) is quite low. While not critical for a cardiovascular target, some CNS penetration can be beneficial for off-target effects assessment.
8. **Caco-2:** A (-4.577) is much better than B (-5.677), suggesting better intestinal absorption.
9. **Solubility:** A (-3.011) is better than B (-2.566), indicating better aqueous solubility.
10. **hERG:** Both are very low risk (0.163 and 0.187).
11. **Cl_mic:** A (32.072) is better than B (18.964), indicating better metabolic stability.
12. **t1/2:** A (25.067) is significantly better than B (-15.605), suggesting a longer half-life.
13. **Pgp:** Both are very low efflux (0.081 and 0.071).
14. **Affinity:** A (-6.8) is slightly better than B (-6.1), but the difference is relatively small.
**Overall Assessment:**
Ligand A has a better balance of properties, particularly regarding TPSA, logP, QED, Caco-2, solubility, metabolic stability, and half-life. The slightly better affinity is a bonus. The biggest concern with A is the higher DILI risk. However, the substantial improvements in other ADME properties, and the fact that this is a cardiovascular target (where CNS penetration is less critical), outweigh the DILI concern. Ligand B's low logP and poor half-life are significant drawbacks.
Therefore, I prefer Ligand A.
Output:
1
2025-04-17 22:53:53,211 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's analyze each ligand against the provided guidelines, keeping in mind ADRB2 is a GPCR, so logP, TPSA, Pgp, BBB, and affinity are key.
* **Molecular Weight:** Both ligands (362.392 and 346.475 Da) fall within the ideal 200-500 Da range.
* **TPSA:** Ligand A (60.85) is better than Ligand B (78.09). Both are acceptable, but lower TPSA generally favors better absorption.
* **logP:** Both ligands have good logP values (1.939 and 2.074), falling within the optimal 1-3 range.
* **H-Bond Donors/Acceptors:** Ligand A has 1 HBD and 3 HBA, while Ligand B has 2 HBD and 3 HBA. Both are within acceptable limits.
* **QED:** Both ligands have reasonable QED scores (0.813 and 0.742), indicating good drug-likeness.
* **DILI:** Ligand A (18.612) has a significantly lower DILI risk than Ligand B (23.769). This is a substantial advantage.
* **BBB:** Ligand A (78.829) has a much higher BBB penetration percentile than Ligand B (42.226). While ADRB2 isn't exclusively a CNS target, some peripheral ADRB2 activity is modulated by CNS pathways, and higher BBB penetration isn't necessarily a detriment.
* **Caco-2 Permeability:** Ligand A (-4.629) has better Caco-2 permeability than Ligand B (-5.333), suggesting better intestinal absorption.
* **Aqueous Solubility:** Ligand A (-3.01) has better aqueous solubility than Ligand B (-1.644).
* **hERG:** Both ligands have very low hERG inhibition liability (0.465 and 0.387), which is excellent.
* **Microsomal Clearance:** Ligand A (24.409) has higher microsomal clearance than Ligand B (12.705), indicating faster metabolism. This is a drawback for Ligand A.
* **In vitro Half-Life:** Ligand B (-25.513) has a significantly longer in vitro half-life than Ligand A (-7.798). This is a major advantage for Ligand B.
* **P-gp Efflux:** Ligand A (0.161) has lower P-gp efflux than Ligand B (0.156), which is slightly preferable.
* **Binding Affinity:** Ligand A (-7.0) has a slightly better binding affinity than Ligand B (-2.0). This is a significant advantage.
**Overall Assessment:**
Ligand A has a clear advantage in terms of binding affinity, DILI risk, BBB penetration, Caco-2 permeability, and solubility. However, Ligand B has a substantially longer half-life and lower microsomal clearance, which are crucial for *in vivo* efficacy. The binding affinity difference is substantial enough to outweigh the metabolic concerns.
**Output:**
1
2025-04-17 22:53:53,212 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (369.77 Da) is within the ideal range, while Ligand B (343.347 Da) is also good. No clear advantage here.
2. **TPSA:** Ligand A (38.33) is excellent, well below the 140 threshold. Ligand B (120.85) is still acceptable but higher, potentially impacting absorption.
3. **logP:** Ligand A (4.844) is a bit high, potentially leading to solubility issues and off-target effects. Ligand B (0.86) is quite low, which could hinder membrane permeability.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 2 HBA, which is good. Ligand B has 9 HBA, which is approaching the upper limit and could affect permeability.
6. **QED:** Both ligands have reasonable QED scores (0.818 and 0.67), indicating good drug-like properties.
7. **DILI:** Ligand A (62.931) has a moderate DILI risk, while Ligand B (88.639) has a higher risk. This favors Ligand A.
8. **BBB:** Ligand A (77.898) has better BBB penetration potential than Ligand B (50.33). While ADRB2 isn't exclusively a CNS target, some CNS exposure can occur, and better BBB penetration is generally favorable.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
10. **Solubility:** Ligand A (-5.352) has very poor solubility, which is a significant concern given its high logP. Ligand B (-2.2) is better, but still not ideal.
11. **hERG:** Ligand A (0.633) has a slightly higher hERG risk than Ligand B (0.163). This favors Ligand B.
12. **Cl_mic:** Ligand A (53.317) has a higher microsomal clearance than Ligand B (33.055), indicating lower metabolic stability. This favors Ligand B.
13. **t1/2:** Both ligands have similar in vitro half-lives (13.999 and 14.696 hours).
14. **Pgp:** Ligand A (0.312) has lower P-gp efflux liability than Ligand B (0.023). This is favorable for bioavailability.
15. **Affinity:** Ligand A (-8.0 kcal/mol) has significantly better binding affinity than Ligand B (-6.8 kcal/mol). This is a substantial advantage.
**GPCR-specific priorities:** For GPCRs, logP, TPSA, Pgp, and affinity are important. Ligand A struggles with logP and solubility, while Ligand B has a lower logP but also lower affinity and higher Pgp efflux. The significantly stronger affinity of Ligand A (-8.0 vs -6.8) is a major advantage that can potentially outweigh its solubility and logP issues, especially with formulation strategies. The better Pgp profile of Ligand A is also beneficial.
**Overall Assessment:**
Despite the solubility and logP concerns with Ligand A, its substantially higher binding affinity and better Pgp profile make it the more promising candidate. The DILI risk is also lower. While Ligand B has a better hERG and clearance profile, the difference in affinity is too significant to ignore for a GPCR target.
Output:
1
2025-04-17 22:53:53,212 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (349.519 Da) is slightly lower, which is generally favorable for permeability.
**2. TPSA:** Ligand A (52.65) is significantly better than Ligand B (96.33). For a GPCR, keeping TPSA low is beneficial for permeability and receptor engagement. Ligand B is quite high, potentially hindering absorption.
**3. logP:** Ligand A (2.26) is optimal. Ligand B (0.117) is quite low, which could significantly impair membrane permeability and bioavailability.
**4. H-Bond Donors:** Both ligands are acceptable (Ligand A: 1, Ligand B: 2), well within the limit of 5.
**5. H-Bond Acceptors:** Both ligands are acceptable (Ligand A: 3, Ligand B: 6), within the limit of 10.
**6. QED:** Both ligands have good QED scores (Ligand A: 0.695, Ligand B: 0.71), indicating generally drug-like properties.
**7. DILI Risk:** Ligand A (7.794) has a much lower DILI risk than Ligand B (63.862). This is a significant advantage for Ligand A.
**8. BBB Penetration:** Ligand A (78.054) has better BBB penetration than Ligand B (49.205). While ADRB2 is primarily a cardiovascular target, some CNS side effects are possible with GPCR ligands, and better BBB penetration could contribute to this.
**9. Caco-2 Permeability:** Ligand A (-4.848) is better than Ligand B (-5.314), although both are negative values.
**10. Aqueous Solubility:** Ligand A (-2.552) is better than Ligand B (-2.495), but both are poor.
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (Ligand A: 0.477, Ligand B: 0.07).
**12. Microsomal Clearance:** Ligand A (53.12) has a higher (worse) clearance than Ligand B (10.261). This suggests Ligand B might be more metabolically stable.
**13. In vitro Half-Life:** Ligand A (-5.899) has a longer half-life than Ligand B (24.539).
**14. P-gp Efflux:** Both ligands have low P-gp efflux (Ligand A: 0.066, Ligand B: 0.018).
**15. Binding Affinity:** Both ligands have similar and strong binding affinities (Ligand A: -5.9 kcal/mol, Ligand B: -6.1 kcal/mol). The difference is minimal.
**Overall Assessment:**
Ligand A is significantly better overall. While Ligand B has slightly better metabolic stability and binding affinity, Ligand A excels in crucial ADME properties like TPSA, logP, DILI risk, and BBB penetration. The low logP of Ligand B is a major concern, likely leading to poor absorption. The substantially lower DILI risk for Ligand A is also a critical advantage. For a GPCR target, optimizing permeability and minimizing off-target effects are paramount, and Ligand A clearly wins in these areas.
Output:
1
2025-04-17 22:53:53,212 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (370.471 and 353.463 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (92.78) is slightly higher than Ligand B (81.16). Both are below the 140 threshold for good oral absorption, but closer to the 90 threshold for CNS targets (though ADRB2 is primarily cardiovascular). Ligand B is preferable.
3. **logP:** Ligand A (1.079) is within the optimal 1-3 range. Ligand B (0.467) is a bit low, potentially hindering permeation. Ligand A is preferable.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 5 HBA, Ligand B has 4. Both are acceptable.
6. **QED:** Ligand A (0.802) has a better QED score than Ligand B (0.611), indicating a more drug-like profile. Ligand A is preferable.
7. **DILI:** Ligand A (38.581) has a significantly lower DILI risk than Ligand B (8.918). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (83.443) has a higher BBB percentile than Ligand B (44.979). While ADRB2 isn't a CNS target, higher BBB is generally favorable. Ligand A is preferable.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Ligand A (-2.165) has a slightly better solubility than Ligand B (-0.202).
11. **hERG:** Both ligands have very low hERG inhibition risk (0.193 and 0.39 respectively). No significant difference.
12. **Cl_mic:** Both have similar microsomal clearance (14.375 and 14.215 mL/min/kg). No clear advantage.
13. **t1/2:** Ligand A (16.099 hours) has a longer in vitro half-life than Ligand B (-0.307 hours). This is a significant advantage for Ligand A.
14. **Pgp:** Both have very low Pgp efflux liability (0.021 and 0.03 respectively). No significant difference.
15. **Binding Affinity:** Ligand A (-6.8 kcal/mol) has a slightly stronger binding affinity than Ligand B (-6.4 kcal/mol). While the difference is less than 1.5 kcal/mol, it contributes to the overall preference for Ligand A.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Ligand A has a better logP and TPSA, while both have similar Pgp and affinity. The significant advantages of Ligand A in DILI risk, BBB penetration, and half-life outweigh the slightly lower TPSA and logP.
**Conclusion:**
Ligand A is the more promising drug candidate due to its superior drug-likeness (QED), lower DILI risk, better BBB penetration, longer half-life, and slightly better binding affinity.
Output:
1
2025-04-17 22:53:53,212 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [341.499, 35.58, 3.759, 1, 3, 0.731, 33.967, 81.466, -4.826, -2.711, 0.877, 29.91, 5.418, 0.402, -6.3]**
**Ligand B: [350.443, 58.2, 4.546, 2, 3, 0.85, 77.2, 69.097, -4.883, -5.552, 0.602, 50.999, 34.073, 0.541, -6.7]**
1. **Molecular Weight:** Both are within the ideal range (200-500 Da). A (341.5) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (35.58) is significantly better than Ligand B (58.2). ADRB2 is not a CNS target, but lower TPSA generally improves absorption.
3. **logP:** Both are good (between 1-3), but Ligand A (3.759) is closer to the optimal range than Ligand B (4.546). Ligand B is getting towards the upper limit where solubility issues could arise.
4. **H-Bond Donors:** Ligand A (1) is better than Ligand B (2). Fewer HBDs generally improve permeability.
5. **H-Bond Acceptors:** Both have 3 HBA, which is acceptable.
6. **QED:** Both are good (>0.5), with Ligand B (0.85) being slightly better.
7. **DILI:** Ligand A (33.97) is significantly better than Ligand B (77.2). This is a major advantage for Ligand A.
8. **BBB:** Not a primary concern for ADRB2, but Ligand A (81.47) has better BBB penetration than Ligand B (69.1).
9. **Caco-2:** Both are negative, indicating poor permeability. This is a significant drawback for both.
10. **Solubility:** Ligand A (-2.711) is better than Ligand B (-5.552). Solubility is a concern for both, but less so for A.
11. **hERG:** Ligand A (0.877) is better than Ligand B (0.602). Lower hERG inhibition is crucial for avoiding cardiotoxicity, especially for a cardiovascular target.
12. **Cl_mic:** Ligand A (29.91) has lower clearance, indicating better metabolic stability than Ligand B (50.999).
13. **t1/2:** Ligand A (5.418) has a slightly better in vitro half-life than Ligand B (34.073).
14. **Pgp:** Ligand A (0.402) has lower P-gp efflux, which is favorable for bioavailability. Ligand B (0.541) is higher.
15. **Binding Affinity:** Ligand B (-6.7) has a slightly better binding affinity than Ligand A (-6.3), a difference of 0.4 kcal/mol. While affinity is important, the difference isn't large enough to overcome the other significant advantages of Ligand A.
**Overall Assessment:**
Ligand A demonstrates a significantly better ADMET profile. It has lower DILI risk, better solubility, lower hERG inhibition, better metabolic stability, and lower P-gp efflux. While Ligand B has slightly better binding affinity and QED, the advantages of Ligand A in crucial ADMET properties, particularly DILI and hERG, outweigh this difference. Both compounds have poor Caco-2 permeability, which would need to be addressed in further optimization.
Output:
1
2025-04-17 22:53:53,212 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (350.463 and 344.459 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (87.46) is slightly higher than Ligand B (78.09). Both are below the 140 threshold for oral absorption, and acceptable for a cardiovascular target (not requiring significant CNS penetration). Ligand B is preferable.
3. **logP:** Both ligands have good logP values (2.027 and 2.409), falling within the optimal 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability, but not drastically so.
4. **HBD:** Both ligands have 2 H-bond donors, which is within the acceptable limit of 5. No difference.
5. **HBA:** Ligand A has 5 H-bond acceptors, while Ligand B has 3. Both are below the 10 limit. Ligand B is preferable.
6. **QED:** Ligand B (0.884) has a significantly better QED score than Ligand A (0.665), indicating a more drug-like profile. This is a substantial advantage for Ligand B.
7. **DILI:** Ligand A (31.64) has a lower DILI risk than Ligand B (38.852), both are below the 40 threshold, but A is preferable.
8. **BBB:** Ligand B (61.031) has a higher BBB penetration percentile than Ligand A (48.313). While ADRB2 is a cardiovascular target and high BBB penetration isn't *essential*, it's not detrimental, and a higher value is generally preferred.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.548 and -5.28). This is unusual and suggests poor permeability. However, the values are very close.
10. **Solubility:** Ligand A (-2.014) has better solubility than Ligand B (-3.198). Better solubility is generally desirable.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.231 and 0.377). No significant difference.
12. **Cl_mic:** Ligand A (19.859) has slightly lower microsomal clearance than Ligand B (20.564), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-18.644) has a much longer in vitro half-life than Ligand A (-8.647). This is a significant advantage for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.046 and 0.17). No significant difference.
15. **Binding Affinity:** Ligand A (-6.2) has a significantly stronger binding affinity than Ligand B (-1.3). This is a *major* advantage for Ligand A. A difference of >5 kcal/mol can often outweigh minor ADME drawbacks.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, and affinity are key. While Ligand B has better TPSA and QED, Ligand A's *much* stronger binding affinity is the most important factor. The slightly better solubility and lower DILI risk of Ligand A are also beneficial. The negative Caco-2 values are concerning for both, but the strong affinity of Ligand A suggests it might overcome that limitation.
**Conclusion:**
Despite the slightly better QED and half-life of Ligand B, the significantly superior binding affinity of Ligand A makes it the more promising drug candidate.
Output:
1
2025-04-17 22:53:53,213 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (348.447 and 345.443 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (98.32) is slightly higher than Ligand B (86.34). Both are below the 140 threshold for good oral absorption, but Ligand B is closer to the preferred <90 for GPCRs.
**3. logP:** Ligand A (1.161) is within the optimal range, while Ligand B (2.803) is approaching the upper limit. This favors Ligand A slightly, as higher logP can sometimes lead to off-target effects.
**4. H-Bond Donors:** Ligand A has 3 HBDs, and Ligand B has 1. Both are acceptable, well below the 5 limit.
**5. H-Bond Acceptors:** Both ligands have 4 HBAs, well within the acceptable limit of 10.
**6. QED:** Both ligands have good QED scores (0.718 and 0.889), indicating good drug-like properties. Ligand B is slightly better.
**7. DILI Risk:** Ligand A (21.753) has a significantly lower DILI risk than Ligand B (43.66). This is a major advantage for Ligand A.
**8. BBB Penetration:** Ligand B (70.919) shows better BBB penetration than Ligand A (36.642). While ADRB2 is primarily a cardiovascular target, some CNS effects are possible with beta-blockers, and some degree of BBB penetration could be beneficial.
**9. Caco-2 Permeability:** Ligand A (-5.152) has worse Caco-2 permeability than Ligand B (-4.568).
**10. Aqueous Solubility:** Ligand A (-1.572) has better aqueous solubility than Ligand B (-3.638). Solubility is important for formulation and bioavailability.
**11. hERG Inhibition:** Ligand A (0.222) has a lower hERG inhibition liability than Ligand B (0.668), which is a significant safety advantage.
**12. Microsomal Clearance:** Ligand A (-15.661) has a lower (better) microsomal clearance than Ligand B (21.063), indicating better metabolic stability.
**13. In vitro Half-Life:** Ligand B (20.565) has a longer in vitro half-life than Ligand A (-24.013). This is a positive for Ligand B.
**14. P-gp Efflux:** Ligand A (0.012) has much lower P-gp efflux liability than Ligand B (0.322), which is favorable for bioavailability and potential CNS exposure.
**15. Binding Affinity:** Ligand B (-7.9) has a significantly stronger binding affinity than Ligand A (-6.7). This is a 1.2 kcal/mol difference, which is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
While Ligand B has a better binding affinity and half-life, Ligand A demonstrates a superior safety profile with significantly lower DILI risk and hERG inhibition. It also has better solubility and lower P-gp efflux. The slightly lower BBB penetration of Ligand A is acceptable given the primary cardiovascular target. The improved metabolic stability (lower Cl_mic) is also a key advantage. The affinity difference, while notable, isn't so large that it completely overrides the safety and pharmacokinetic benefits of Ligand A.
Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity) and the overall balance of properties, I believe Ligand A is the more promising drug candidate.
Output:
1
2025-04-17 22:53:53,213 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [349.475, 62.83, 2.002, 2, 4, 0.716, 13.339, 64.637, -4.873, -1.639, 0.472, 18.424, 36.051, 0.011, -7.6]
**Ligand B:** [353.438, 69.72, 1.592, 1, 4, 0.833, 30.826, 74.758, -4.717, -2.584, 0.13, -0.428, -14.194, 0.014, -7.2]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, Affinity, and BBB):
1. **MW:** Both are within the ideal 200-500 Da range. A (349.475) is slightly lower, which is generally favorable.
2. **TPSA:** A (62.83) is better than B (69.72), being closer to the <140 threshold for good absorption.
3. **logP:** Both are within the optimal 1-3 range. A (2.002) is slightly higher than B (1.592), potentially offering better membrane permeability.
4. **HBD/HBA:** A has 2 HBD and 4 HBA, while B has 1 HBD and 4 HBA. Both are acceptable.
5. **QED:** Both are above 0.5, indicating good drug-likeness, with B (0.833) being slightly better.
6. **DILI:** A (13.339) has a significantly lower DILI risk than B (30.826). This is a major advantage.
7. **BBB:** B (74.758) has a better BBB penetration percentile than A (64.637). While ADRB2 isn't necessarily a CNS target, some peripheral ADRB2 subtypes can influence CNS function, and better BBB penetration isn't a major negative.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the values are similar (-4.873 vs -4.717).
9. **Solubility:** Both have negative solubility values, indicating very poor aqueous solubility. A (-1.639) is slightly better than B (-2.584).
10. **hERG:** Both have very low hERG inhibition risk (0.472 and 0.13).
11. **Cl_mic:** A (18.424) has a higher microsomal clearance than B (-0.428), indicating lower metabolic stability. This is a significant drawback for A.
12. **t1/2:** A (36.051) has a longer in vitro half-life than B (-14.194). This is a positive for A.
13. **Pgp:** Both have very low P-gp efflux liability (0.011 and 0.014).
14. **Affinity:** A (-7.6) has a slightly better binding affinity than B (-7.2). While the difference is not huge (0.4 kcal/mol), it's still a factor.
**Overall Assessment:**
Ligand A has a better binding affinity, lower DILI risk, and a longer half-life. However, it suffers from higher microsomal clearance and worse solubility than Ligand B. Ligand B has better BBB penetration and a better QED score, but a significantly higher DILI risk and lower affinity.
Given the GPCR-specific priorities, and the fact that the solubility issues are severe for both, the lower DILI risk of Ligand A is a crucial advantage. While the higher clearance is a concern, it might be addressable through structural modifications. The slightly better affinity also tips the balance.
Output:
1
2025-04-17 22:53:53,213 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.419 and 351.403 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (86.28) is better than Ligand B (104.9). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (2.889) is optimal, while Ligand B (0.571) is a bit low. A logP below 1 can hinder membrane permeability. This is a significant advantage for Ligand A.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (7) is better than Ligand B (6). Lower HBA is generally preferred.
6. **QED:** Both are acceptable (0.845 and 0.776), both being above the 0.5 threshold.
7. **DILI:** Ligand A (60.682) is higher risk than Ligand B (38.62). This is a drawback for Ligand A, but not a dealbreaker.
8. **BBB:** Ligand A (92.4) is better than Ligand B (62.699). While not a primary concern for a cardiovascular target, higher BBB is generally a positive attribute.
9. **Caco-2:** Ligand A (-4.151) is better than Ligand B (-5.018). Higher Caco-2 permeability is desired.
10. **Solubility:** Ligand A (-3.98) is better than Ligand B (-1.979). Higher aqueous solubility is beneficial.
11. **hERG:** Both are very low (0.174 and 0.152), indicating low cardiotoxicity risk. No significant difference.
12. **Cl_mic:** Ligand B (-3.731) has a *negative* clearance, which is unusual and suggests very high metabolic stability. Ligand A (57.951) is higher, indicating faster metabolism. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand B (5.92) has a longer half-life than Ligand A (-21.214). This is a significant advantage for Ligand B.
14. **Pgp:** Both are very low (0.179 and 0.095), indicating low P-gp efflux. No significant difference.
15. **Binding Affinity:** Ligand A (-7.4) has a slightly better binding affinity than Ligand B (-7.3). While the difference is small, it's still a positive for Ligand A.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand A excels in logP and has a slightly better affinity. Ligand B has better metabolic stability and half-life, and a lower DILI risk.
**Overall Assessment:**
While Ligand A has a slight edge in affinity and better logP, the significantly better metabolic stability (Cl_mic and t1/2) and lower DILI risk of Ligand B are more critical for overall drug development success. The slightly lower affinity of Ligand B can potentially be optimized in later stages, while improving metabolic stability is often more challenging.
Output:
0
2025-04-17 22:53:53,213 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (351.462 and 362.417 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (47.56) is significantly better than Ligand B (59.08). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (1.39) is much better than Ligand A (4.927). A logP of 4.927 is quite high and could lead to solubility issues and off-target interactions. Ligand B's logP is within the optimal 1-3 range.
4. **HBD:** Ligand A (1) is preferable to Ligand B (0). While both are low, having one HBD can sometimes improve solubility.
5. **HBA:** Both ligands have 4 HBA, so no difference here.
6. **QED:** Ligand A (0.764) is slightly better than Ligand B (0.687), indicating a marginally more drug-like profile.
7. **DILI:** Ligand B (25.436) has a significantly lower DILI risk than Ligand A (33.191). This is a major advantage for Ligand B.
8. **BBB:** Ligand B (85.498) has a higher BBB penetration percentile than Ligand A (72.896). While ADRB2 is not a CNS target, higher BBB is generally favorable.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.048 and -4.269). This is unusual and suggests poor permeability. However, the values are similar.
10. **Solubility:** Ligand B (-1.415) is better than Ligand A (-5.462). Solubility is a concern for Ligand A due to its high logP.
11. **hERG:** Both ligands have low hERG inhibition liability (0.515 and 0.579). No significant difference.
12. **Cl_mic:** Ligand B (24.918) has significantly lower microsomal clearance than Ligand A (107.476). This indicates better metabolic stability for Ligand B.
13. **t1/2:** Ligand B (-0.455) has a slightly better in vitro half-life than Ligand A (15.87).
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.142 and 0.04). No significant difference.
15. **Binding Affinity:** Ligand B (-7.3) has a significantly stronger binding affinity than Ligand A (-6.5). This is a substantial advantage, potentially outweighing some ADME concerns.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP and affinity, and is better in TPSA. While both have good Pgp profiles, the substantial affinity difference and better ADME properties of Ligand B make it the more promising candidate.
**Conclusion:**
Ligand B demonstrates a superior balance of properties, particularly its significantly stronger binding affinity, lower DILI risk, better logP, and improved metabolic stability. While both have Caco-2 permeability concerns, the other advantages of Ligand B outweigh this drawback.
Output:
0
2025-04-17 22:53:53,213 - INFO - Batch 365 complete. Total preferences: 5840
2025-04-17 22:53:53,213 - INFO - Processing batch 366/512...
2025-04-17 22:54:42,835 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 drug candidates. ADRB2 is a GPCR, so we'll prioritize logP, Pgp, TPSA, and affinity, alongside general drug-like properties.
**Ligand A:** [338.411, 67.23, 2.037, 1, 4, 0.931, 59.713, 70.415, -4.771, -2.533, 0.351, 26.644, 20.783, 0.235, -8.5]
**Ligand B:** [342.439, 58.64, 1.514, 1, 3, 0.537, 28.228, 60.799, -4.438, -2.708, 0.22, 29.282, -0.694, 0.04, -4.7]
1. **MW:** Both are within the ideal range (200-500 Da). A (338.411) is slightly lower than B (342.439), but both are acceptable.
2. **TPSA:** A (67.23) is higher than B (58.64). Both are reasonably good for oral absorption, but B is better.
3. **logP:** A (2.037) and B (1.514) are both within the optimal range (1-3). A is slightly better.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** A has 4 HBA, B has 3. Both are acceptable.
6. **QED:** A (0.931) is significantly better than B (0.537), indicating a more drug-like profile.
7. **DILI:** A (59.713) has a higher DILI risk than B (28.228). B is significantly better here.
8. **BBB:** A (70.415) is better than B (60.799), though both are acceptable.
9. **Caco-2:** Both are negative, indicating poor permeability. A (-4.771) is slightly worse than B (-4.438).
10. **Solubility:** Both are negative, indicating poor solubility. A (-2.533) is slightly worse than B (-2.708).
11. **hERG:** Both are very low, indicating minimal hERG inhibition risk. A (0.351) is slightly higher than B (0.22).
12. **Cl_mic:** A (26.644) is slightly lower than B (29.282), suggesting better metabolic stability.
13. **t1/2:** A (20.783) is significantly better than B (-0.694).
14. **Pgp:** A (0.235) is better than B (0.04), indicating lower P-gp efflux.
15. **Affinity:** A (-8.5) is significantly better than B (-4.7). This is a crucial advantage for a GPCR target.
**Overall Assessment:**
Ligand A has a significantly better binding affinity (-8.5 vs -4.7 kcal/mol). This is a major advantage, especially for a GPCR. It also has a better QED, BBB penetration, and *in vitro* half-life, and lower Pgp efflux. While Ligand A has a higher DILI risk and slightly worse Caco-2/solubility, the substantial improvement in affinity and drug-like properties (QED, t1/2) outweighs these drawbacks. The difference in affinity is >1.5 kcal/mol, which is a strong indicator.
Therefore, I would choose Ligand A.
Output:
1
2025-04-17 22:54:42,836 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [351.403, 89.13, -0.12, 2, 6, 0.645, 31.524, 60.799, -5.038, -1.508, 0.211, -0.5, -27.081, 0.005, -5]
**Ligand B:** [362.455, 87.58, 2.287, 2, 7, 0.848, 66.848, 58.782, -5.334, -3.816, 0.666, 47.039, -8.961, 0.144, -3.6]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (351.4) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are good, below 140, and even approaching the lower end for GPCRs (<90). Ligand B (87.58) is slightly better.
3. **logP:** Ligand A (-0.12) is quite low, potentially hindering membrane permeability. Ligand B (2.287) is much better, falling within the optimal 1-3 range. This is a significant advantage for Ligand B.
4. **HBD:** Both have 2 HBD, which is acceptable.
5. **HBA:** Ligand A has 6 HBA, and Ligand B has 7. Both are within the acceptable limit of 10.
6. **QED:** Ligand B (0.848) has a better QED score than Ligand A (0.645), suggesting a more drug-like profile.
7. **DILI:** Ligand A (31.524) has a much lower DILI risk than Ligand B (66.848). This is a significant advantage for Ligand A.
8. **BBB:** Both are reasonably good, but Ligand A (60.799) is slightly better than Ligand B (58.782). However, for a cardiovascular target, BBB penetration isn't a primary concern.
9. **Caco-2:** Both have negative values, indicating poor permeability. Ligand A (-5.038) is slightly better than Ligand B (-5.334).
10. **Solubility:** Both have negative values, indicating poor solubility. Ligand B (-3.816) is slightly better than Ligand A (-1.508).
11. **hERG:** Ligand A (0.211) has a much lower hERG risk than Ligand B (0.666). This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand A (-0.5) has a lower (better) microsomal clearance than Ligand B (47.039), indicating better metabolic stability.
13. **t1/2:** Ligand A (-27.081) has a longer half-life than Ligand B (-8.961).
14. **Pgp:** Ligand A (0.005) has a lower Pgp efflux liability than Ligand B (0.144), which is favorable for bioavailability.
15. **Affinity:** Ligand A (-5 kcal/mol) has a slightly better binding affinity than Ligand B (-3.6 kcal/mol).
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are crucial. Ligand B excels in logP and has a slightly better TPSA. Ligand A has a better affinity, lower Pgp efflux, and significantly better safety profiles (DILI and hERG).
**Overall Assessment:**
While Ligand B has a better QED and logP, the significantly lower DILI and hERG risks, better metabolic stability (lower Cl_mic, longer t1/2), and slightly better affinity of Ligand A outweigh these advantages. The low logP of Ligand A is a concern, but can potentially be addressed through further optimization. The safety profile is paramount, and Ligand A presents a much more favorable risk profile.
Output:
1
2025-04-17 22:54:42,836 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (334.423 and 344.459 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (69.02) is significantly better than Ligand B (78.67). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand A is well below the 140 threshold.
**3. logP:** Both ligands have acceptable logP values (2.589 and 3.562), falling within the 1-3 range. Ligand B is slightly higher, which *could* indicate a potential for off-target interactions, but isn't a major concern.
**4. H-Bond Donors/Acceptors:** Ligand A has 1 HBD and 4 HBA, while Ligand B has 2 HBD and 2 HBA. Both are within acceptable limits (<=5 HBD and <=10 HBA).
**5. QED:** Both ligands have good QED scores (0.933 and 0.879), indicating good drug-like properties.
**6. DILI:** Ligand A (47.964) has a slightly higher DILI risk than Ligand B (30.05). This is a point in favor of Ligand B.
**7. BBB:** Both ligands show reasonable BBB penetration (77.2% and 88.135%). While ADRB2 is primarily a cardiovascular target, some CNS effects are possible with beta-blockers, so moderate BBB penetration isn't necessarily detrimental. Ligand B is better here.
**8. Caco-2 Permeability:** Ligand A (-5.016) has worse Caco-2 permeability than Ligand B (-4.76). Lower (more negative) values indicate lower permeability.
**9. Aqueous Solubility:** Both ligands have poor aqueous solubility (-3.824 and -4.26). This is a concern for both, but not a deciding factor.
**10. hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.789 and 0.78). This is excellent.
**11. Microsomal Clearance:** Ligand B (26.397) has significantly lower microsomal clearance than Ligand A (51.124), indicating better metabolic stability. This is a significant advantage for Ligand B.
**12. In vitro Half-Life:** Ligand B (10.868 hours) has a longer in vitro half-life than Ligand A (6.391 hours). This is another advantage for Ligand B.
**13. P-gp Efflux:** Both ligands have low P-gp efflux liability (0.254 and 0.092). Ligand B is slightly better.
**14. Binding Affinity:** Ligand B (-7.1 kcal/mol) has a slightly better binding affinity than Ligand A (-6.8 kcal/mol). This 0.3 kcal/mol difference is significant, and can outweigh some of the ADME drawbacks of Ligand A.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand B emerges as the more promising candidate. While Ligand A has a better TPSA, Ligand B compensates with significantly improved metabolic stability (lower Cl_mic, longer t1/2), lower DILI risk, better Caco-2 permeability, and slightly better binding affinity. The slight increase in logP for Ligand B is not a major concern. The improved ADME profile and binding affinity of Ligand B outweigh the slightly higher TPSA.
Output:
0
2025-04-17 22:54:42,836 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (369.422 and 351.403 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand B (89.13) is significantly better than Ligand A (115.24). For a GPCR, lower TPSA is generally preferred for better permeability.
**3. logP:** Ligand A (2.283) is within the optimal 1-3 range. Ligand B (-0.12) is *below* this range, which could hinder membrane permeability and bioavailability.
**4. H-Bond Donors:** Both ligands have acceptable HBD counts (1 and 2, respectively), well below the threshold of 5.
**5. H-Bond Acceptors:** Ligand B (6) is slightly higher than Ligand A (4), but both are within the acceptable limit of 10.
**6. QED:** Ligand B (0.645) has a slightly better QED score than Ligand A (0.487), suggesting a more drug-like profile.
**7. DILI Risk:** Ligand B (31.524) has a much lower DILI risk than Ligand A (63.513). This is a significant advantage for Ligand B.
**8. BBB Penetration:** Ligand B (60.799) shows better BBB penetration than Ligand A (51.105), although neither is exceptionally high. For a cardiovascular target, BBB penetration is less critical than for CNS targets, but still a positive.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand B (-5.038) is slightly better than Ligand A (-4.831), but both are concerning.
**10. Aqueous Solubility:** Both ligands have negative solubility values, which is also unusual. Ligand B (-1.508) is slightly better than Ligand A (-2.669).
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.347 and 0.211, respectively). This is good.
**12. Microsomal Clearance:** Ligand B (-0.5) has significantly lower (better) microsomal clearance than Ligand A (6.751), indicating greater metabolic stability.
**13. In vitro Half-Life:** Ligand B (-27.081) has a dramatically longer in vitro half-life than Ligand A (-8.736). This is a major advantage.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.063 and 0.005, respectively).
**15. Binding Affinity:** Ligand A (-5.3 kcal/mol) has a slightly better binding affinity than Ligand B (-5.0 kcal/mol), but the difference is small.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity, Ligand B is significantly superior in terms of ADME properties. The lower DILI risk, improved metabolic stability (lower Cl_mic, longer t1/2), better TPSA, and slightly improved QED and solubility make Ligand B a much more promising drug candidate. The negative Caco-2 and solubility values are concerning for both, but the other advantages of Ligand B outweigh this drawback. Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand B strikes a better balance.
Output:
0
2025-04-17 22:54:42,836 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (350.463 and 346.483 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Both ligands (85.25 and 86.34) are below the 140 A^2 threshold for good oral absorption. They are also reasonably low, which is beneficial for GPCR ligands. Again, no strong differentiator.
**3. logP:** Ligand A (1.697) is slightly better than Ligand B (2.523). While both are within the optimal 1-3 range, Ligand A is closer to the lower end, potentially reducing off-target effects.
**4. H-Bond Donors:** Ligand A (2) is slightly higher than Ligand B (1), but both are acceptable (<=5).
**5. H-Bond Acceptors:** Ligand B (8) is higher than Ligand A (5). While both are below the 10 threshold, the lower value for Ligand A is slightly preferable.
**6. QED:** Both ligands have similar QED values (0.818 and 0.79), indicating good drug-likeness.
**7. DILI:** Ligand A (25.359%) has a significantly lower DILI risk than Ligand B (43.738%). This is a substantial advantage for Ligand A, as minimizing liver toxicity is crucial.
**8. BBB:** Ligand B (71.811%) shows better BBB penetration than Ligand A (40.093%). While ADRB2 isn't strictly a CNS target, some CNS exposure can be relevant for off-target effects and overall safety assessment. This favors Ligand B.
**9. Caco-2 Permeability:** Ligand B (-5.38) shows better Caco-2 permeability than Ligand A (-4.77). This suggests better intestinal absorption for Ligand B.
**10. Aqueous Solubility:** Ligand A (-1.424) has better aqueous solubility than Ligand B (-2.748). This is important for formulation and bioavailability.
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.124 and 0.095). No significant difference.
**12. Microsomal Clearance:** Ligand A (7.374) has a significantly lower microsomal clearance than Ligand B (28.216). This indicates better metabolic stability for Ligand A, leading to a potentially longer duration of action.
**13. In vitro Half-Life:** Ligand A (0.5) has a shorter half-life than Ligand B (-3.417). This is a negative for Ligand A, but the difference is significant enough to consider.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.014 and 0.077). No significant difference.
**15. Binding Affinity:** Ligand A (-6.5 kcal/mol) has a slightly better binding affinity than Ligand B (-5.9 kcal/mol). While the difference is less than the 1.5 kcal/mol threshold that would be decisive, it still contributes to the overall preference.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity) and the general drug-like properties, Ligand A emerges as the more promising candidate. The significantly lower DILI risk and better metabolic stability (lower Cl_mic) are major advantages. While Ligand B has better BBB penetration and Caco-2 permeability, the safety and PK benefits of Ligand A outweigh these factors in this case. The slightly better affinity of Ligand A also contributes to its preference.
Output:
1
2025-04-17 22:54:42,837 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [386.455, 133.38 , 0.754, 2. , 7. , 0.753, 97.867, 39.473, -5.158, -2.414, 0.054, 1.039, 25.88 , 0.105, -4.4 ]
**Ligand B:** [349.345, 103.65 , 1.9 , 2. , 7. , 0.678, 79.992, 69.213, -5.364, -2.767, 0.345, 13.791, 43.331, 0.12 , -6.9 ]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (349.345) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (133.38) is slightly above the preferred <140, but acceptable. Ligand B (103.65) is excellent, well below 140.
3. **logP:** Ligand A (0.754) is a bit low, potentially hindering membrane permeability. Ligand B (1.9) is much better, falling within the optimal 1-3 range.
4. **HBD/HBA:** Both have 2 HBD and 7 HBA, which are reasonable and shouldn't pose significant issues.
5. **QED:** Both are above 0.5, indicating good drug-like properties. Ligand A (0.753) is slightly better.
6. **DILI:** Ligand A (97.867) has a significantly higher DILI risk than Ligand B (79.992). This is a major concern.
7. **BBB:** Ligand B (69.213) has better BBB penetration than Ligand A (39.473). While not a primary concern for ADRB2 (a cardiovascular target), it's a positive attribute.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability.
9. **Solubility:** Both have negative solubility values, which is also unusual and suggests poor solubility.
10. **hERG:** Ligand A (0.054) has a very low hERG risk, which is excellent. Ligand B (0.345) is slightly higher, but still relatively low.
11. **Cl_mic:** Ligand A (1.039) has much lower microsomal clearance, indicating better metabolic stability. Ligand B (13.791) is considerably higher, suggesting faster metabolism.
12. **t1/2:** Ligand B (43.331) has a significantly longer in vitro half-life than Ligand A (25.88).
13. **Pgp:** Ligand A (0.105) has lower P-gp efflux, which is favorable for bioavailability. Ligand B (0.12) is slightly higher.
14. **Affinity:** Ligand B (-6.9 kcal/mol) has a substantially stronger binding affinity than Ligand A (-4.4 kcal/mol). This is a crucial advantage, exceeding the 1.5 kcal/mol threshold.
**Overall Assessment:**
While Ligand A has a better hERG profile and slightly better QED, the significantly higher DILI risk and weaker binding affinity are major drawbacks. Ligand B excels in key areas for a GPCR target: better logP, significantly stronger binding affinity, longer half-life, and lower DILI risk. The slightly higher Pgp efflux and microsomal clearance are less concerning given the substantial affinity advantage. The negative Caco-2 and solubility values are concerning for both, but the stronger binding of Ligand B may overcome these issues.
Therefore, I would choose Ligand B.
0
2025-04-17 22:54:42,837 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [338.363, 102.42 , 2.78 , 4. , 3. , 0.574, 78.054, 19.93 , -5.707, -4.179, 0.204, 11.292, -22.709, 0.046, -3.6 ]
**Ligand B:** [360.376, 67.43 , 1.621, 2. , 3. , 0.783, 35.091, 83.366, -5. , -3.118, 0.247, 15.749, 7.3 , 0.058, -6.7 ]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the acceptable 200-500 Da range. Ligand A (338.363) is slightly preferred.
2. **TPSA:** Ligand A (102.42) is higher than Ligand B (67.43). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is still better for permeability. Ligand B is better here.
3. **logP:** Ligand A (2.78) is within the optimal range, while Ligand B (1.621) is a bit low. Good permeability is important, and Ligand A has an advantage.
4. **HBD:** Ligand A (4) is higher than Ligand B (2). Lower is generally preferred, so Ligand B is better.
5. **HBA:** Both have 3 HBA, which is good.
6. **QED:** Ligand B (0.783) has a better QED score than Ligand A (0.574), indicating a more drug-like profile.
7. **DILI:** Ligand A (78.054) has a significantly higher DILI risk than Ligand B (35.091). This is a major concern.
8. **BBB:** Ligand B (83.366) has a much higher BBB penetration score than Ligand A (19.93). While not essential for a cardiovascular target, it's a bonus.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand B (-5) is slightly better than Ligand A (-5.707).
10. **Solubility:** Both have negative solubility values, also unusual. Ligand B (-3.118) is slightly better than Ligand A (-4.179).
11. **hERG:** Both are very low (0.204 and 0.247), indicating low cardiotoxicity risk.
12. **Cl_mic:** Ligand A (11.292) has lower microsomal clearance than Ligand B (15.749), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-22.709) has a much longer in vitro half-life than Ligand B (7.3). This is a significant advantage.
14. **Pgp:** Both are very low (0.046 and 0.058), indicating minimal P-gp efflux.
15. **Affinity:** Ligand B (-6.7) has a significantly stronger binding affinity than Ligand A (-3.6). This is a substantial advantage.
**Overall Assessment:**
Ligand B is significantly better in terms of safety (DILI), affinity, and QED. While Ligand A has a better half-life and slightly better logP, the high DILI risk associated with Ligand A is a major red flag. The superior binding affinity of Ligand B is also a crucial factor, potentially outweighing the shorter half-life. The lower TPSA of Ligand B is also favorable.
Therefore, I would choose Ligand B.
0
2025-04-17 22:54:42,837 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (368.344 Da) is within the ideal range (200-500 Da). Ligand B (446.355 Da) is also acceptable, but approaching the upper limit.
2. **TPSA:** Ligand A (103.59) is better than Ligand B (72.7), both are below the 140 threshold for oral absorption.
3. **logP:** Ligand A (2.196) is optimal (1-3). Ligand B (3.756) is slightly higher, but still within an acceptable range.
4. **HBD:** Ligand A (2) and Ligand B (1) both meet the criteria of <=5.
5. **HBA:** Ligand A (7) and Ligand B (7) both meet the criteria of <=10.
6. **QED:** Ligand A (0.857) is significantly better than Ligand B (0.467), indicating a more drug-like profile.
7. **DILI:** Ligand A (89.996) has a higher DILI risk than Ligand B (63.358), which is less desirable.
8. **BBB:** Both ligands have similar BBB penetration (Ligand A: 59.17, Ligand B: 55.06). Since ADRB2 is a cardiovascular target, BBB penetration isn't a primary concern.
9. **Caco-2:** Ligand A (-5.068) is better than Ligand B (-5.66), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-4.339) is better than Ligand B (-3.326).
11. **hERG:** Ligand A (0.317) is better than Ligand B (0.529), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand A (5.673) is much better than Ligand B (63.317), indicating better metabolic stability.
13. **t1/2:** Ligand A (3.456) is much better than Ligand B (24.995).
14. **Pgp:** Ligand A (0.017) is much better than Ligand B (0.552), indicating lower efflux.
15. **Affinity:** Ligand B (-6.1 kcal/mol) has a significantly better binding affinity than Ligand A (-11.9 kcal/mol). This is a substantial advantage.
**GPCR-specific considerations:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are important. Ligand B has a better logP and significantly better affinity. However, Ligand A has better TPSA, Pgp, solubility, metabolic stability, and a lower hERG risk.
**Overall Assessment:**
While Ligand B's affinity is substantially better, the significant drawbacks in metabolic stability (Cl_mic), half-life, Pgp efflux, and the higher DILI risk are concerning. Ligand A, despite its weaker binding, presents a much more balanced profile with better ADME properties and a lower toxicity risk. The difference in affinity, while large, might be overcome with further optimization of Ligand A. The ADME profile of Ligand B is too problematic to ignore.
**Output:**
1
2025-04-17 22:54:42,837 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [382.511, 104.21 , 2.466, 3. , 7. , 0.651, 59.403, 54.634, -5.384, -2.839, 0.152, 49.036, 40.051, 0.15 , -6.1 ]
**Ligand B:** [364.511, 69.64 , 2.719, 2. , 4. , 0.863, 24.661, 57.929, -5.077, -2.226, 0.432, -0.049, -1.072, 0.285, -5.7 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal 200-500 Da range. Ligand B (364.511) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (104.21) is higher than Ligand B (69.64). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is still preferred for better absorption. Ligand B is significantly better here.
3. **logP:** Both are within the optimal 1-3 range. Ligand B (2.719) is slightly higher, potentially leading to better membrane permeability.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (2), but both are acceptable.
5. **HBA:** Ligand A (7) is higher than Ligand B (4). Lower is better for permeability, so Ligand B is preferable.
6. **QED:** Ligand B (0.863) has a better QED score than Ligand A (0.651), indicating a more drug-like profile.
7. **DILI:** Ligand A (59.403) has a higher DILI risk than Ligand B (24.661). This is a significant advantage for Ligand B.
8. **BBB:** Both have moderate BBB penetration. Ligand B (57.929) is slightly better, but this isn't a primary concern for a cardiovascular target.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale isn't specified, so it's difficult to interpret.
10. **Solubility:** Both have negative solubility values, which is also unusual. Again, the scale is unknown, making interpretation difficult.
11. **hERG:** Ligand A (0.152) has a slightly higher hERG risk than Ligand B (0.432). Lower is better, so Ligand B is slightly favored.
12. **Cl_mic:** Ligand A (49.036) has higher microsomal clearance than Ligand B (-0.049). This indicates lower metabolic stability for Ligand A, which is a negative.
13. **t1/2:** Ligand A (40.051) has a longer in vitro half-life than Ligand B (-1.072). This is a positive for Ligand A, but the negative value for B is concerning.
14. **Pgp:** Ligand A (0.15) has lower P-gp efflux than Ligand B (0.285), which is favorable.
15. **Affinity:** Ligand A (-6.1) has a slightly better binding affinity than Ligand B (-5.7). This is a 0.4 kcal/mol difference, which is not huge, but could be significant.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity and half-life, Ligand B demonstrates a significantly better overall profile. It has a lower molecular weight, lower TPSA, better QED, substantially lower DILI risk, and better metabolic stability (lower Cl_mic). The slightly higher Pgp efflux is a minor drawback. The unusual negative values for Caco-2 and solubility are concerning for both, but the other advantages of Ligand B outweigh these uncertainties. Given the GPCR target class, the balance of properties in Ligand B is more favorable for development.
Output:
0
2025-04-17 22:54:42,838 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (344.419 and 343.435 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (111.06) is higher than Ligand B (79.18). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B has a clear advantage.
3. **logP:** Both ligands (2.066 and 1.152) are within the optimal 1-3 range, but Ligand B is closer to the lower end. Ligand A is better here.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 4 HBA, while Ligand B has 7. Lower HBA is generally preferable for permeability. Ligand A is better.
6. **QED:** Ligand B (0.793) has a higher QED score than Ligand A (0.484), indicating a more drug-like profile. This is a significant advantage for Ligand B.
7. **DILI:** Ligand A (30.593) has a significantly lower DILI risk than Ligand B (59.946). This is a major advantage for Ligand A.
8. **BBB:** Both are relatively low, but Ligand B (65.839) is higher than Ligand A (52.966). Since ADRB2 is not a CNS target, this is less important, but still a slight edge to B.
9. **Caco-2:** Both have negative Caco-2 values (-5.113 and -5.169), which is unusual and suggests poor permeability. This is a concern for both, but similar.
10. **Solubility:** Both have negative solubility values (-1.971 and -1.72), also unusual and concerning. Similar for both.
11. **hERG:** Ligand A (0.134) has a lower hERG risk than Ligand B (0.47). This is a significant advantage for Ligand A, given the cardiovascular target.
12. **Cl_mic:** Ligand B (50.438) has a higher microsomal clearance than Ligand A (5.658), indicating faster metabolism and lower metabolic stability. Ligand A is significantly better.
13. **t1/2:** Ligand A (-14.075) has a more negative in vitro half-life, which is concerning. Ligand B (2.986) is positive, suggesting a longer half-life. Ligand B is better.
14. **Pgp:** Ligand A (0.01) has a much lower P-gp efflux liability than Ligand B (0.026). This is a slight advantage for Ligand A.
15. **Binding Affinity:** Ligand B (-7.2) has a slightly better binding affinity than Ligand A (-7.6), but the difference is small (0.4kcal/mol).
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), and the general drug-like properties, Ligand A appears to be the more promising candidate. While Ligand B has a better QED and slightly better affinity, Ligand A demonstrates significantly lower DILI risk and microsomal clearance, and a lower hERG risk. The lower TPSA and HBA of Ligand A also suggest better permeability. The negative Caco-2 and solubility values are concerning for both, but the other advantages of Ligand A outweigh the slight affinity advantage of Ligand B.
Output:
1
2025-04-17 22:54:42,838 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (360.479 and 346.475 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (69.64) is slightly higher than Ligand B (60.25). Both are below the 140 A^2 threshold for oral absorption, but B is better.
3. **logP:** Both ligands have excellent logP values (2.559 and 2.527) within the optimal 1-3 range. No significant difference.
4. **HBD:** Ligand A has 2 HBD, while Ligand B has 0. Lower is generally preferred for permeability, giving a slight edge to B.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 5. Both are acceptable (<=10), but A is slightly better.
6. **QED:** Both ligands have good QED scores (0.733 and 0.822), indicating good drug-likeness. B is slightly better.
7. **DILI:** Both ligands have low DILI risk (34.626 and 32.571 percentile), which is excellent. B is slightly better.
8. **BBB:** Ligand B (83.831) has a significantly higher BBB penetration percentile than Ligand A (77.007). This is a key advantage for a GPCR target, even if it's cardiovascular.
9. **Caco-2:** Ligand A (-5.276) and Ligand B (-4.916) both have negative Caco-2 values, which is unusual and suggests poor permeability. This is a concern for both, but B is slightly better.
10. **Solubility:** Ligand A (-4.546) and Ligand B (-2.735) both have poor solubility. B is better.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.585 and 0.242), which is excellent. B is better.
12. **Cl_mic:** Ligand A (69.948) and Ligand B (67.887) have similar microsomal clearance values. No significant difference.
13. **t1/2:** Ligand B (-9.123) has a better in vitro half-life than Ligand A (-17.52). This is a significant advantage.
14. **Pgp:** Ligand A (0.11) has lower P-gp efflux liability than Ligand B (0.336), which is preferable.
15. **Affinity:** Ligand B (-7.0 kcal/mol) has a slightly better binding affinity than Ligand A (-6.2 kcal/mol). While A is still good, the 0.8 kcal/mol difference is notable.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand B is the stronger candidate. It has better BBB penetration, a slightly better affinity, better solubility, lower hERG risk, and a better half-life. While Ligand A has slightly lower P-gp efflux, the other advantages of Ligand B outweigh this. Both ligands have poor Caco-2 permeability and solubility, which would need to be addressed in further optimization.
Output:
0
2025-04-17 22:54:42,838 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
The target is ADRB2, a GPCR. Therefore, I will prioritize logP, TPSA, Pgp efflux, BBB penetration, and binding affinity, alongside general drug-like properties.
**Ligand A:**
* **MW:** 359.407 Da - Acceptable.
* **TPSA:** 101.15 - Slightly above the ideal <140, but not alarming.
* **logP:** 1.608 - Good, within the optimal 1-3 range.
* **HBD:** 2 - Acceptable.
* **HBA:** 6 - Acceptable.
* **QED:** 0.352 - Below the desired 0.5, a slight concern.
* **DILI:** 87.786 - High DILI risk, a significant drawback.
* **BBB:** 48.662 - Low BBB penetration, not a major concern for a non-CNS target like ADRB2.
* **Caco-2:** -5.84 - Poor Caco-2 permeability, a concern for oral absorption.
* **Solubility:** -3.483 - Poor solubility, a significant issue.
* **hERG:** 0.166 - Low hERG risk, good.
* **Cl_mic:** 46.544 - Moderate clearance, not ideal but manageable.
* **t1/2:** 15.49 - Moderate half-life, acceptable.
* **Pgp:** 0.195 - Low Pgp efflux, good.
* **Affinity:** -6.5 kcal/mol - Good binding affinity.
**Ligand B:**
* **MW:** 355.383 Da - Acceptable.
* **TPSA:** 116.76 - Higher than Ligand A, but still within acceptable range for oral absorption.
* **logP:** 0.664 - Lower than ideal, potentially impacting permeability.
* **HBD:** 2 - Acceptable.
* **HBA:** 8 - Acceptable.
* **QED:** 0.66 - Good, above the desired 0.5.
* **DILI:** 92.982 - Very high DILI risk, a major concern.
* **BBB:** 45.638 - Low BBB penetration, not a major concern for a non-CNS target like ADRB2.
* **Caco-2:** -5.63 - Poor Caco-2 permeability, similar to Ligand A.
* **Solubility:** -4.017 - Very poor solubility, a significant issue.
* **hERG:** 0.464 - Higher hERG risk than Ligand A, a concern.
* **Cl_mic:** 19.069 - Low clearance, excellent metabolic stability.
* **t1/2:** 7.617 - Shorter half-life than Ligand A, less desirable.
* **Pgp:** 0.09 - Very low Pgp efflux, excellent.
* **Affinity:** -6.8 kcal/mol - Better binding affinity than Ligand A.
**Comparison and Decision:**
Both ligands have significant drawbacks regarding solubility and Caco-2 permeability, suggesting potential issues with oral absorption. However, Ligand B has a slightly better binding affinity (-6.8 vs -6.5 kcal/mol). The biggest concerns are the high DILI risk for both compounds. Ligand B has a higher DILI risk (92.982) than Ligand A (87.786). Ligand B also has a higher hERG risk. While Ligand B has better metabolic stability (lower Cl_mic) and Pgp efflux, the significantly higher DILI and hERG risks outweigh these benefits. Ligand A, despite its lower QED and solubility, presents a slightly more favorable risk profile.
Therefore, I would select Ligand A.
**Output:**
1
2025-04-17 22:54:42,838 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Step-by-step comparison:**
1. **MW:** Both ligands (357.5 & 338.5 Da) fall within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (46.17) is significantly better than Ligand B (66.83). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (4.298 & 3.429), falling within the 1-3 range. Ligand A is slightly higher, which *could* be a minor concern for solubility, but is acceptable.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 3 HBA, while Ligand B has 6. Ligand A is preferred here.
6. **QED:** Both have good QED scores (0.752 & 0.921), indicating good drug-likeness. Ligand B is slightly better.
7. **DILI:** Ligand A (41.062) has a lower DILI risk than Ligand B (56.805), which is a significant advantage.
8. **BBB:** Both have similar BBB penetration (68.786 & 69.794). Not a major factor here as ADRB2 is not a CNS target.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the values are similar (-5.046 & -5.157).
10. **Solubility:** Both have very poor aqueous solubility (-4.213 & -4.3). This is a major concern for both.
11. **hERG:** Both have low hERG inhibition risk (0.834 & 0.838).
12. **Cl_mic:** Ligand A (50.977) has lower microsomal clearance than Ligand B (77.246), indicating better metabolic stability.
13. **t1/2:** Ligand A (18.594) has a longer in vitro half-life than Ligand B (-3.288). This is a significant advantage.
14. **Pgp:** Both have low P-gp efflux liability (0.758 & 0.103). Ligand B is better here.
15. **Binding Affinity:** Ligand B (-7.7 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.9 kcal/mol) - a difference of 0.8 kcal/mol. This is a substantial advantage.
**GPCR-Specific Priorities:** For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, and affinity. Ligand B wins on Pgp and significantly on affinity. Ligand A wins on TPSA and has a comparable logP.
**Overall Assessment:**
The biggest differentiator is the binding affinity. Ligand B's -7.7 kcal/mol is considerably stronger than Ligand A's -6.9 kcal/mol. While both have poor solubility and Caco-2 permeability, the stronger binding of Ligand B is likely to be more impactful in driving efficacy. The lower DILI risk and better metabolic stability of Ligand A are appealing, but the affinity difference is too large to ignore.
Output:
0
2025-04-17 22:54:42,838 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.43 & 363.53 Da) fall comfortably within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (70.83) is slightly higher than Ligand B (63.91). Both are below the 140 threshold for oral absorption, but closer to the 90 threshold for CNS targets (less relevant for ADRB2, a cardiovascular target). Ligand B is slightly better.
3. **logP:** Ligand A (2.266) is within the optimal 1-3 range. Ligand B (3.829) is pushing the upper limit, increasing the risk of off-target effects and solubility issues. Ligand A is better.
4. **HBD:** Both ligands have 0 HBD, which is good.
5. **HBA:** Ligand A has 4 HBA, while Ligand B has 6. Both are acceptable (<=10), but Ligand A is slightly preferred.
6. **QED:** Ligand A (0.842) has a significantly better QED score than Ligand B (0.635), indicating a more drug-like profile. This is a substantial advantage for Ligand A.
7. **DILI:** Ligand A (34.43%) has a lower DILI risk than Ligand B (53.28%). This is a clear advantage for Ligand A.
8. **BBB:** Both have good BBB penetration, but Ligand B (83.02%) is higher than Ligand A (70.57%). While BBB isn't a primary concern for ADRB2, it's a slight advantage for B.
9. **Caco-2:** Ligand A (-4.461) is worse than Ligand B (-5.298). Lower values indicate lower permeability, so Ligand B is better.
10. **Solubility:** Ligand A (-1.974) is better than Ligand B (-3.446). Higher values indicate better solubility, so Ligand A is better.
11. **hERG:** Ligand A (0.086) has a much lower hERG risk than Ligand B (0.43). This is a significant advantage for Ligand A, as hERG inhibition can cause cardiotoxicity.
12. **Cl_mic:** Ligand A (40.314) has a lower microsomal clearance than Ligand B (81.055), suggesting better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand B (33.868) has a longer in vitro half-life than Ligand A (20.65). This is a slight advantage for Ligand B.
14. **Pgp:** Ligand A (0.157) has lower P-gp efflux than Ligand B (0.833), suggesting better bioavailability. This is a significant advantage for Ligand A.
15. **Binding Affinity:** Ligand A (-6.9 kcal/mol) has a slightly better binding affinity than Ligand B (-5.1 kcal/mol). While the difference is not huge, it's still a positive for Ligand A.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A performs better on logP, Pgp, and affinity. Ligand B performs better on TPSA and BBB.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B in critical ADME-Tox properties (DILI, hERG, Cl_mic, Pgp, QED, Solubility) and has a slightly better binding affinity. While Ligand B has a slightly longer half-life and better Caco-2 permeability, the superior safety profile and drug-likeness of Ligand A outweigh these benefits. The slightly higher logP of Ligand B is a concern.
Output:
1
2025-04-17 22:54:42,838 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
We are targeting ADRB2, a GPCR, so the priorities are logP, Pgp, TPSA, affinity, and BBB. Let's break down each ligand against these and other important parameters.
* **Molecular Weight:** Both ligands are within the ideal range (200-500 Da).
* **TPSA:** Ligand A (58.64) is significantly better than Ligand B (97.62). Lower TPSA generally indicates better cell permeability, crucial for GPCR targeting. Ligand B is pushing the upper limit for good oral absorption.
* **logP:** Ligand A (2.35) is optimal. Ligand B (0.533) is a bit low, potentially hindering membrane permeability.
* **H-Bond Donors/Acceptors:** Ligand A (1 HBD, 3 HBA) is preferable to Ligand B (2 HBD, 6 HBA). Lower counts generally improve permeability.
* **QED:** Both ligands have acceptable QED scores (A: 0.685, B: 0.764).
* **DILI:** Ligand A (5.777) has a much lower DILI risk than Ligand B (65.917). This is a significant advantage.
* **BBB:** Ligand A (80.574) has a better BBB percentile than Ligand B (55.099). While ADRB2 isn't exclusively a CNS target, some CNS exposure can occur, and higher BBB is generally favorable.
* **Caco-2:** Ligand A (-4.409) is better than Ligand B (-5.194).
* **Solubility:** Ligand A (-2.507) is better than Ligand B (-3.184).
* **hERG:** Both ligands have very low hERG inhibition risk (A: 0.37, B: 0.229).
* **Cl_mic:** Ligand A (25.302) has a higher (worse) microsomal clearance than Ligand B (14.024), indicating faster metabolism.
* **t1/2:** Ligand B (28.432) has a significantly longer in vitro half-life than Ligand A (1.466). This is a strong point for Ligand B.
* **Pgp:** Both ligands have very low Pgp efflux liability (A: 0.033, B: 0.034).
* **Binding Affinity:** Ligand B (-7.1 kcal/mol) has a substantially stronger binding affinity than Ligand A (-4.9 kcal/mol). This is a 2.2 kcal/mol difference, which is a significant advantage and could potentially offset some ADME concerns.
**Overall Assessment:**
The primary trade-off is between Ligand B's superior binding affinity and Ligand A's better ADME profile (TPSA, logP, DILI, BBB, solubility). The difference in binding affinity is substantial. While Ligand A has a better safety profile (lower DILI) and potentially better permeability (lower TPSA), the stronger binding of Ligand B is likely to translate to greater efficacy at lower doses, potentially mitigating some of the ADME concerns. The longer half-life of Ligand B is also a significant advantage. Given the GPCR target class, the strong affinity of Ligand B outweighs the slightly less ideal ADME properties.
Output:
0
2025-04-17 22:54:42,839 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (351.4 & 345.5 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand B (70.15) is significantly better than Ligand A (93.9), being well below the 140 threshold for oral absorption and more favorable for GPCRs.
3. **logP:** Ligand B (2.882) is within the optimal 1-3 range, while Ligand A (0.619) is quite low, potentially hindering permeability. This is a significant advantage for B.
4. **HBD:** Ligand A (1) is slightly better than Ligand B (2), but both are acceptable.
5. **HBA:** Ligand A (6) is slightly better than Ligand B (5), but both are acceptable.
6. **QED:** Both ligands have high QED scores (0.836 and 0.859), indicating good drug-like properties. No clear advantage.
7. **DILI:** Ligand B (35.87) has a much lower DILI risk than Ligand A (58.98), indicating better predicted liver safety. This is a substantial advantage for B.
8. **BBB:** Ligand B (85.07) has a much higher BBB penetration score than Ligand A (57.97). While ADRB2 isn't strictly a CNS target, some peripheral ADRB2 receptors can be affected by CNS penetration, and better BBB penetration generally correlates with improved distribution.
9. **Caco-2:** Ligand B (-5.084) has a more negative Caco-2 value, indicating better permeability than Ligand A (-4.652).
10. **Solubility:** Ligand A (-1.919) has better aqueous solubility than Ligand B (-3.237). Solubility is important, but the permeability issues with A are more concerning.
11. **hERG:** Ligand A (0.196) has a lower hERG risk than Ligand B (0.601). This is a positive for A, but not enough to offset other issues.
12. **Cl_mic:** Ligand B (62.36) has a higher microsomal clearance than Ligand A (11.19), suggesting lower metabolic stability. This is a drawback for B.
13. **t1/2:** Ligand A (23.38) has a longer in vitro half-life than Ligand B (4.85). This is a positive for A, but again, less impactful than the permeability/logP issues.
14. **Pgp:** Ligand A (0.045) has lower P-gp efflux than Ligand B (0.08), which is favorable.
15. **Binding Affinity:** Ligand B (-7.7) has a significantly stronger binding affinity than Ligand A (-21.6). This is a *major* advantage for B, easily outweighing minor ADME drawbacks.
**Overall Assessment:**
Ligand B is the superior candidate. While it has slightly higher Pgp efflux and lower in vitro half-life, its significantly improved logP, TPSA, DILI risk, BBB penetration, Caco-2 permeability, and *much* stronger binding affinity outweigh these drawbacks. Ligand A's low logP and moderate DILI risk are significant concerns. The strong binding affinity of Ligand B is particularly important for a GPCR target like ADRB2.
Output:
0
2025-04-17 22:54:42,839 - INFO - Batch 366 complete. Total preferences: 5856
2025-04-17 22:54:42,839 - INFO - Processing batch 367/512...
2025-04-17 22:55:31,277 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (382.5 and 354.4 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (87.66 and 87.32) are reasonably low, suggesting good potential for absorption. They are slightly above the preferred <90 for CNS targets, but ADRB2 isn't necessarily a CNS target.
3. **logP:** Both ligands have good logP values (1.98 and 1.129), falling within the optimal 1-3 range. Ligand B is slightly lower, which could slightly improve solubility.
4. **HBD/HBA:** Ligand A has 3 HBD and 6 HBA, while Ligand B has 2 HBD and 4 HBA. Both are within acceptable limits.
5. **QED:** Ligand B (0.802) has a better QED score than Ligand A (0.651), indicating a more drug-like profile.
6. **DILI:** Ligand B (45.677) has a significantly lower DILI risk than Ligand A (55.525), which is a major advantage.
7. **BBB:** Ligand B (51.842) has a higher BBB penetration score than Ligand A (36.06), but both are relatively low. Since ADRB2 is primarily a cardiovascular target, BBB penetration isn't a critical factor.
8. **Caco-2:** Both ligands have negative Caco-2 values (-5.29 and -4.972), which is unusual and suggests poor permeability. This is a concern for both.
9. **Solubility:** Ligand B (-1.925) has slightly better solubility than Ligand A (-2.701).
10. **hERG:** Both ligands have low hERG inhibition liability (0.428 and 0.292), which is good.
11. **Cl_mic:** Ligand B (2.17) has *much* lower microsomal clearance than Ligand A (57.188), indicating significantly better metabolic stability. This is a major advantage.
12. **t1/2:** Ligand B (-35.655) has a much longer in vitro half-life than Ligand A (42.225), which is highly desirable.
13. **Pgp:** Ligand A (0.51) has slightly higher P-gp efflux liability than Ligand B (0.034), which is unfavorable.
14. **Binding Affinity:** Ligand B (-7.0) has a significantly stronger binding affinity than Ligand A (-5.2). This is a substantial advantage, potentially outweighing some ADME concerns.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand B excels in logP, Pgp, and *especially* affinity. While both have acceptable TPSA, the affinity and metabolic stability differences are significant.
**Overall Assessment:**
Ligand B is the stronger candidate. Its superior binding affinity, lower DILI risk, significantly improved metabolic stability (lower Cl_mic and longer t1/2), lower P-gp efflux, and better QED score outweigh the slightly lower BBB penetration (which isn't crucial for a cardiovascular target) and the similar Caco-2 permeability issues. The Caco-2 permeability is a concern for both, but can be addressed through formulation strategies.
Output:
0
2025-04-17 22:55:31,278 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (357.845 and 346.387 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (75.35) is significantly better than Ligand B (109.39). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (2.038) is within the optimal 1-3 range. Ligand B (0.834) is slightly low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (5) is better than Ligand B (6). Again, fewer HBAs are generally preferred.
6. **QED:** Ligand A (0.89) is slightly better than Ligand B (0.718), indicating a more drug-like profile.
7. **DILI:** Ligand B (54.323) has a much lower DILI risk than Ligand A (68.786), which is a significant advantage.
8. **BBB:** Ligand A (79.256) has better BBB penetration than Ligand B (32.299), but this isn't a major concern for a cardiovascular target.
9. **Caco-2:** Ligand A (-4.888) is better than Ligand B (-5.331). Higher Caco-2 permeability is desirable.
10. **Solubility:** Ligand A (-2.956) is better than Ligand B (-1.825). Better solubility is generally preferred.
11. **hERG:** Ligand A (0.7) has a slightly better hERG profile than Ligand B (0.253). Lower hERG inhibition is crucial for avoiding cardiotoxicity.
12. **Cl_mic:** Ligand B (-14.674) has significantly lower microsomal clearance than Ligand A (28.039), indicating better metabolic stability. This is a major advantage.
13. **t1/2:** Ligand B (35.474) has a much longer in vitro half-life than Ligand A (-15.749), which is a substantial benefit.
14. **Pgp:** Ligand A (0.071) has lower P-gp efflux than Ligand B (0.058), which is slightly better.
15. **Binding Affinity:** Ligand B (-6.9) has a significantly stronger binding affinity than Ligand A (-3.1). This is a very important factor, and a difference of 3.8 kcal/mol is substantial.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B has a lower logP, higher TPSA, and better Pgp efflux than Ligand A. However, the *massive* difference in binding affinity (-6.9 vs -3.1 kcal/mol) outweighs the other drawbacks. The improved metabolic stability (lower Cl_mic and longer t1/2) and lower DILI risk of Ligand B further solidify its position.
Output:
0
2025-04-17 22:55:31,279 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (347.415 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (91.5) is higher than Ligand B (60.77). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is still preferred for absorption. Ligand B is significantly better here.
3. **logP:** Ligand A (1.143) is within the optimal range, while Ligand B (4.209) is on the higher side. High logP can lead to solubility issues and off-target interactions. Ligand A is better.
4. **HBD:** Both have 2 HBD, which is acceptable.
5. **HBA:** Ligand A has 4 HBA, Ligand B has 3. Both are within the acceptable range.
6. **QED:** Ligand A (0.836) has a significantly better QED score than Ligand B (0.606), indicating a more drug-like profile.
7. **DILI:** Ligand A (42.885) has a much lower DILI risk than Ligand B (9.926), a crucial factor for cardiovascular drugs.
8. **BBB:** Both have reasonable BBB penetration, but Ligand B (75.107) is higher than Ligand A (69.911). Since ADRB2 is not a CNS target, this is less important.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Both have negative solubility values, which is also unusual and suggests poor solubility. Again, the scale is not specified.
11. **hERG:** Ligand A (0.436) has a lower hERG risk than Ligand B (0.82), which is very important for cardiovascular safety.
12. **Cl_mic:** Ligand A (-7.988) has a much lower (better) microsomal clearance than Ligand B (62.946), indicating better metabolic stability.
13. **t1/2:** Ligand A (-8.954) has a much longer in vitro half-life than Ligand B (31.053), which is desirable.
14. **Pgp:** Ligand B (0.53) has a higher Pgp efflux liability than Ligand A (0.035), which is unfavorable.
15. **Binding Affinity:** Ligand B (-7.8) has a slightly better binding affinity than Ligand A (-4.6), a difference of 3.2 kcal/mol. This is a significant difference, but needs to be weighed against the other factors.
**Overall Assessment:**
Ligand A is clearly superior. While Ligand B has a slightly better binding affinity, Ligand A excels in almost all other critical ADME-Tox properties. Specifically, its significantly lower DILI risk, better QED, lower hERG risk, better metabolic stability (lower Cl_mic and longer t1/2), and lower Pgp efflux make it a much more promising drug candidate for a cardiovascular target. The TPSA difference is also favorable for Ligand B, but the other advantages of Ligand A outweigh this. The unusual negative values for Caco-2 and solubility are concerning for both, but the other properties of Ligand A are far more compelling.
Output:
1
2025-04-17 22:55:31,279 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, key priorities are logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB (since it's cardiovascular, not CNS).
Let's compare the ligands property by property:
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (352.45) is slightly better.
2. **TPSA:** Ligand A (49.85) is significantly better than Ligand B (104.37). Lower TPSA is preferred for GPCRs, aiding permeability.
3. **logP:** Ligand A (2.331) is within the optimal range, while Ligand B (0.611) is a bit low, potentially hindering membrane permeability.
4. **HBD/HBA:** Ligand A (0/3) is preferable to Ligand B (3/5) as lower counts generally improve permeability.
5. **QED:** Both are acceptable, but Ligand A (0.714) is slightly better than Ligand B (0.534).
6. **DILI:** Ligand A (21.365) has a much lower DILI risk than Ligand B (43.117). This is a significant advantage.
7. **BBB:** Not a primary concern for a cardiovascular target, but Ligand A (89.608) is better than Ligand B (44.979).
8. **Caco-2:** Ligand A (-4.299) is better than Ligand B (-5.652), indicating better absorption.
9. **Solubility:** Both are poor (-2.095 and -2.511). This is a potential issue for both, but not a deciding factor.
10. **hERG:** Both are very low risk (0.464 and 0.071).
11. **Cl_mic:** Ligand B (40.908) has a lower microsomal clearance than Ligand A (31.47), suggesting better metabolic stability.
12. **t1/2:** Ligand B (-36.868) has a much longer in vitro half-life than Ligand A (5.323). This is a significant advantage.
13. **Pgp:** Ligand A (0.09) has lower P-gp efflux than Ligand B (0.043), which is preferable.
14. **Binding Affinity:** Both have excellent binding affinity (-6.6 and -6.0 kcal/mol). Ligand A is slightly better.
**Overall Assessment:**
Ligand A is superior due to its better TPSA, logP, DILI risk, Caco-2 permeability, and slightly better binding affinity. While Ligand B has a longer half-life and better metabolic stability, the ADME profile of Ligand A is more favorable for a GPCR targeting cardiovascular indications. The lower DILI risk is also a major advantage. The slight difference in binding affinity is less important than the overall ADME/Tox profile.
**Output:**
1
2025-04-17 22:55:31,279 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [346.362, 85.25, 1.732, 2, 5, 0.748, 73.517, 56.34, -4.744, -2.829, 0.603, 35.622, -29.065, 0.14, -6.5]
**Ligand B:** [340.383, 79.54, 1.753, 0, 5, 0.832, 63.668, 44.591, -4.879, -2.306, 0.242, 25.622, 29.064, 0.146, -5.5]
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand B (340.383) is slightly lower, which is generally favorable.
2. **TPSA:** Both are good, below the 140 A^2 threshold for oral absorption. Ligand B (79.54) is slightly better than Ligand A (85.25).
3. **logP:** Both are optimal (around 1.7), falling within the 1-3 range. Very similar.
4. **HBD:** Ligand A has 2 HBD, Ligand B has 0. Lower is generally preferred for permeability, giving a slight edge to Ligand B.
5. **HBA:** Both have 5 HBA, within the acceptable range.
6. **QED:** Both are above 0.5, indicating good drug-likeness. Ligand B (0.832) is slightly better than Ligand A (0.748).
7. **DILI:** Ligand A (73.517) has a higher DILI risk than Ligand B (63.668). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (56.34) has a better BBB penetration potential than Ligand B (44.591). This is a positive for Ligand A, but less crucial for a non-CNS target like ADRB2.
9. **Caco-2:** Both have negative values, indicating good permeability. Ligand B (-4.879) is slightly better than Ligand A (-4.744).
10. **Solubility:** Both have negative solubility values, indicating good solubility. Ligand B (-2.306) is slightly better than Ligand A (-2.829).
11. **hERG:** Both have low hERG inhibition liability, which is good. Ligand B (0.242) is slightly better than Ligand A (0.603).
12. **Cl_mic:** Ligand B (25.622) has a lower microsomal clearance than Ligand A (35.622), indicating better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand B (29.064) has a longer in vitro half-life than Ligand A (-29.065). This is a significant advantage.
14. **Pgp:** Both have low P-gp efflux liability, which is good. Ligand B (0.146) is slightly better than Ligand A (0.14).
15. **Binding Affinity:** Ligand A (-6.5 kcal/mol) has a slightly better binding affinity than Ligand B (-5.5 kcal/mol). This is a 1 kcal/mol difference, which is a notable advantage for Ligand A.
**GPCR-specific priorities:** For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, and affinity. Both ligands perform similarly on logP and Pgp. Ligand B has a better TPSA. Ligand A has a better affinity. However, the significant advantages of Ligand B in terms of DILI risk, metabolic stability (Cl_mic), and half-life outweigh the slightly better affinity of Ligand A.
**Conclusion:**
Considering the balance of properties and the priorities for a GPCR target, Ligand B appears to be the more promising drug candidate.
0
2025-04-17 22:55:31,279 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.316 and 351.328 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (61.94) is better than Ligand B (65.46). Both are below the 140 threshold for oral absorption, but lower is generally preferred.
3. **logP:** Ligand B (3.827) is slightly higher than Ligand A (2.991), but both fall within the optimal 1-3 range.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (6) is higher than Ligand B (3). While both are acceptable, lower is slightly preferred.
6. **QED:** Ligand B (0.864) is better than Ligand A (0.68), indicating a more drug-like profile.
7. **DILI:** Ligand B (52.966) has a significantly lower DILI risk than Ligand A (60.682). This is a crucial advantage, as lower DILI is highly desirable.
8. **BBB:** Ligand A (89.027) has a better BBB penetration score than Ligand B (72.625). While ADRB2 isn't exclusively a CNS target, some CNS exposure may be acceptable or even beneficial depending on the specific therapeutic application.
9. **Caco-2:** Ligand A (-4.476) is better than Ligand B (-5.078), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-3.511) is better than Ligand B (-4.414), indicating better aqueous solubility.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.725 and 0.627 respectively), which is excellent.
12. **Cl_mic:** Ligand B (32.94) has significantly lower microsomal clearance than Ligand A (53.338), suggesting better metabolic stability.
13. **t1/2:** Ligand A (4.475) has a longer in vitro half-life than Ligand B (-14.097). This is a significant advantage.
14. **Pgp:** Ligand A (0.529) has lower P-gp efflux liability than Ligand B (0.146). Lower Pgp is better.
15. **Affinity:** Ligand A (-8.3 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.5 kcal/mol). This is a substantial advantage that can outweigh some ADME drawbacks.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are particularly important. Ligand A has a better logP, TPSA, and Pgp profile. The significantly stronger binding affinity of Ligand A is a major positive. While Ligand B has a lower DILI and better QED, the affinity difference is substantial.
**Overall Assessment:**
The superior binding affinity of Ligand A (-8.3 kcal/mol vs -6.5 kcal/mol) is a decisive factor. The difference of 1.8 kcal/mol is large enough to compensate for the slightly higher DILI risk and lower QED of Ligand A. The better Caco-2 and solubility also contribute to its favorability.
Output:
1
2025-04-17 22:55:31,279 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (339.483) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (37.27) is significantly better than Ligand B (87.22). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally correlates with better absorption. Ligand B's TPSA is quite high, potentially hindering oral bioavailability.
3. **logP:** Ligand A (4.005) is slightly higher than the optimal range (1-3), but still acceptable. Ligand B (1.46) is on the low side, potentially leading to poor membrane permeability.
4. **HBD/HBA:** Ligand A (HBD=1, HBA=2) is preferable. Ligand B (HBD=2, HBA=6) has a higher number of hydrogen bond acceptors, which could impact permeability.
5. **QED:** Ligand A (0.901) is much better than Ligand B (0.774), indicating a more drug-like profile.
6. **DILI:** Ligand A (32.842) has a significantly lower DILI risk than Ligand B (71.539). This is a crucial advantage.
7. **BBB:** Ligand A (97.053) shows higher BBB penetration, while Ligand B (70.143) is lower. While not critical for a cardiovascular target, it doesn't hurt.
8. **Caco-2:** Ligand A (-4.559) and Ligand B (-5.414) are both negative, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
9. **Solubility:** Ligand A (-3.896) and Ligand B (-3.408) are both negative, suggesting poor solubility.
10. **hERG:** Ligand A (0.921) has a slightly higher hERG risk than Ligand B (0.168), but both are relatively low.
11. **Cl_mic:** Ligand A (51.73) has a higher microsomal clearance than Ligand B (39.709), suggesting lower metabolic stability.
12. **t1/2:** Ligand A (35.575) has a much longer in vitro half-life than Ligand B (8.198). This is a significant advantage.
13. **Pgp:** Ligand A (0.565) has lower P-gp efflux than Ligand B (0.04), which is preferable for bioavailability.
14. **Affinity:** Ligand A (-6.9 kcal/mol) has a slightly better binding affinity than Ligand B (-6.4 kcal/mol), but the difference is not huge.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Ligand A performs better on logP, TPSA and Pgp. The affinity difference is small.
**Overall Assessment:**
Ligand A is the stronger candidate. It has a significantly better QED score, lower DILI risk, longer half-life, lower P-gp efflux, and a slightly better affinity. While Ligand A has a slightly higher logP and Cl_mic, the benefits outweigh these drawbacks. Ligand B's high TPSA and DILI risk are major concerns.
Output:
1
2025-04-17 22:55:31,280 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.447 and 381.567 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (87.46) is slightly higher than Ligand B (62.3). Both are below the 140 threshold for good oral absorption, but Ligand B is preferable due to being closer to the 90 threshold for potential CNS penetration (though this isn't a primary goal for ADRB2).
3. **logP:** Ligand A (1.175) is within the optimal 1-3 range. Ligand B (3.399) is at the higher end of optimal, but still acceptable.
4. **HBD:** Ligand A (2) and Ligand B (1) are both good, below the threshold of 5. Ligand B is slightly better.
5. **HBA:** Both ligands have 5 HBA, which is acceptable (<=10).
6. **QED:** Both ligands have similar QED values (0.808 and 0.794), indicating good drug-likeness.
7. **DILI:** Ligand A (41.218) and Ligand B (48.468) are both below the 60 threshold, indicating low DILI risk. Ligand A is slightly better.
8. **BBB:** Ligand A (56.65) and Ligand B (67.197) are both relatively low, which is expected for a peripherally acting target like ADRB2. Ligand B is slightly better.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.819) is slightly better than Ligand B (-5.036).
10. **Solubility:** Both ligands have negative solubility values, which is also unusual and suggests poor solubility. Ligand A (-2.805) is slightly better than Ligand B (-3.792).
11. **hERG:** Both ligands have very low hERG inhibition liability (0.162 and 0.176), which is excellent. No significant difference.
12. **Cl_mic:** Ligand A (39.465) has a lower microsomal clearance than Ligand B (46.074), indicating better metabolic stability. This is a positive for Ligand A.
13. **t1/2:** Ligand A (15.182) has a longer in vitro half-life than Ligand B (-3.629). This is a significant advantage for Ligand A.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.031 and 0.163). No significant difference.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-5.6 and -5.8 kcal/mol). Ligand B is slightly better.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, and affinity are important. Ligand B has a slightly better logP and TPSA, and a slightly better affinity. However, metabolic stability (Cl_mic, t1/2) is also crucial. Ligand A has a significantly better metabolic profile.
**Overall Assessment:**
While Ligand B has a slightly better logP, TPSA, and affinity, Ligand A's superior metabolic stability (lower Cl_mic and longer t1/2) and slightly lower DILI risk are more important for overall drug development success. The slight differences in Caco-2 and solubility are concerning for both, but the metabolic advantages of Ligand A outweigh the minor benefits of Ligand B.
Output:
1
2025-04-17 22:55:31,280 - INFO - Here's my reasoning and output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (350.503) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (49.03) is better than Ligand A (58.64). Both are below 140, but lower TPSA is preferred for GPCRs.
3. **logP:** Ligand A (2.903) is optimal, while Ligand B (4.113) is pushing the upper limit. High logP can lead to off-target effects and solubility issues.
4. **HBD:** Ligand A (1) is better than Ligand B (0). Having at least one HBD can improve solubility.
5. **HBA:** Ligand B (4) is slightly better than Ligand A (3). Both are within the acceptable range.
6. **QED:** Ligand A (0.685) is better than Ligand B (0.589), indicating a more drug-like profile.
7. **DILI:** Ligand A (13.92) has a significantly lower DILI risk than Ligand B (15.859), which is a crucial advantage.
8. **BBB:** Both ligands have good BBB penetration (Ligand A: 80.38, Ligand B: 85.266). Ligand B is slightly better, but this isn't a primary concern for a non-CNS target like ADRB2.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand B (-4.768) is slightly worse than Ligand A (-4.457).
10. **Solubility:** Ligand A (-2.778) has better solubility than Ligand B (-4.702).
11. **hERG:** Both ligands have low hERG inhibition risk (Ligand A: 0.464, Ligand B: 0.861). Ligand A is better.
12. **Cl_mic:** Ligand A (66.412) has significantly lower microsomal clearance than Ligand B (100.77), indicating better metabolic stability.
13. **t1/2:** Ligand A (-7.911) has a much longer in vitro half-life than Ligand B (28.656).
14. **Pgp:** Both ligands have very low Pgp efflux liability (Ligand A: 0.063, Ligand B: 0.764). Ligand A is better.
15. **Binding Affinity:** Both ligands have similar binding affinity (-5.9 and -5.8 kcal/mol). The difference is negligible.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A has a better logP, TPSA, and Pgp profile. While both have comparable affinity, the superior ADME properties of Ligand A outweigh the minor affinity difference.
**Conclusion:**
Ligand A demonstrates a significantly better overall profile, particularly in terms of DILI risk, metabolic stability (Cl_mic and t1/2), solubility, and Pgp efflux. While both have issues with Caco-2 permeability, the other advantages of Ligand A make it the more promising drug candidate.
Output:
1
2025-04-17 22:55:31,280 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (352.475 and 350.478 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (67.87) is higher than Ligand B (49.41). For a cardiovascular GPCR, TPSA is moderately important, and lower is generally better for permeability. Ligand B has a clear advantage here.
**3. logP:** Both ligands have good logP values (2.729 and 3.062), falling within the optimal 1-3 range. Ligand B is slightly higher, which could be marginally beneficial for membrane permeability, but the difference is small.
**4. H-Bond Donors:** Both have 1 HBD, which is within the acceptable limit of <=5.
**5. H-Bond Acceptors:** Ligand A has 4 HBAs, while Ligand B has 2. Lower is generally preferred for better permeability, giving Ligand B a slight edge.
**6. QED:** Both ligands have similar QED values (0.79 and 0.775), indicating good drug-like properties.
**7. DILI Risk:** Ligand B (25.436) has a significantly lower DILI risk than Ligand A (30.593). This is a crucial advantage, as minimizing liver toxicity is paramount.
**8. BBB Penetration:** Ligand B (85.421) has better BBB penetration than Ligand A (76.037). While ADRB2 isn't a CNS target, some degree of BBB penetration can be useful for understanding off-target effects and overall distribution.
**9. Caco-2 Permeability:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the values are similar (-4.189 vs -4.301).
**10. Aqueous Solubility:** Both ligands have negative solubility values, indicating poor aqueous solubility. Ligand B is slightly worse (-3.343 vs -2.781). This is a concern for both, and formulation strategies would be needed.
**11. hERG Inhibition:** Ligand A (0.186) has a slightly lower hERG inhibition risk than Ligand B (0.766), which is favorable.
**12. Microsomal Clearance:** Ligand B (41.337) has a lower microsomal clearance than Ligand A (54.041), indicating better metabolic stability. This is a significant advantage.
**13. In vitro Half-Life:** Ligand B (-19.734) has a longer in vitro half-life than Ligand A (-30.707). This is a clear benefit, potentially leading to less frequent dosing.
**14. P-gp Efflux:** Ligand A (0.021) has lower P-gp efflux than Ligand B (0.26). Lower P-gp efflux is generally desirable.
**15. Binding Affinity:** Ligand B (-6.4) has a slightly better binding affinity than Ligand A (-5.9). While the difference is not huge, it's enough to be considered.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), and the general drug-like properties, Ligand B is the more promising candidate. Its lower DILI risk, better BBB penetration, improved metabolic stability (lower Cl_mic and longer t1/2), and slightly better affinity outweigh the slightly higher P-gp efflux and worse hERG. The lower TPSA is also a significant advantage. While both have solubility issues, this can be addressed through formulation.
Output:
0
2025-04-17 22:55:31,280 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (358.435 and 362.495 Da).
2. **TPSA:** Ligand B (62.66) is significantly better than Ligand A (108.33). ADRB2 is not a CNS target, but lower TPSA generally improves absorption.
3. **logP:** Ligand B (3.442) is optimal, while Ligand A (-0.169) is too low, potentially hindering membrane permeability. This is a significant drawback for Ligand A.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (1), but both are acceptable.
5. **HBA:** Ligand A (6) is slightly higher than Ligand B (5), but both are acceptable.
6. **QED:** Ligand B (0.742) is better than Ligand A (0.411), indicating a more drug-like profile.
7. **DILI:** Ligand A (21.287) has a much lower DILI risk than Ligand B (37.922). This is a strong positive for Ligand A.
8. **BBB:** Not a primary concern for ADRB2, but Ligand B (52.811) is higher than Ligand A (29.818).
9. **Caco-2:** Ligand A (-5.156) and Ligand B (-4.539) are both poor, but Ligand B is slightly better.
10. **Solubility:** Ligand A (-0.827) is slightly better than Ligand B (-3.406).
11. **hERG:** Both ligands have low hERG risk (0.234 and 0.787 respectively).
12. **Cl_mic:** Ligand A (-12.554) has significantly better metabolic stability (lower clearance) than Ligand B (84.25). This is a major advantage for Ligand A.
13. **t1/2:** Ligand B (22.837) has a longer half-life than Ligand A (8.524).
14. **Pgp:** Both ligands have low Pgp efflux liability (0.02 and 0.749 respectively).
15. **Binding Affinity:** Both ligands have the same binding affinity (-5.7 kcal/mol).
**GPCR-specific considerations:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand B excels in logP and has a better TPSA. However, Ligand A has a much lower DILI risk and significantly better metabolic stability (Cl_mic). While affinity is the same, the ADME properties of Ligand A are more favorable overall, especially the lower DILI and better metabolic stability. The low logP of Ligand A is a concern, but the other benefits may outweigh this.
**Conclusion:**
Considering the balance of properties, particularly the lower DILI risk and better metabolic stability of Ligand A, I believe it is the more promising drug candidate despite its lower logP.
Output:
1
2025-04-17 22:55:31,280 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [344.459, 59.39, 3.768, 1, 4, 0.898, 48.042, 78.79, -4.399, -2.894, 0.621, 36.437, 40.916, 0.098, -4.3]
**Ligand B:** [352.475, 67.87, 1.888, 1, 4, 0.767, 16.557, 67.158, -4.823, -1.863, 0.223, -2.728, 5.503, 0.025, -7.0]
Here's a breakdown, considering the GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal range (200-500 Da). A is 344.459, B is 352.475 - very similar.
2. **TPSA:** A (59.39) is better than B (67.87). Both are reasonably good for oral absorption, but A is closer to the optimal value.
3. **logP:** A (3.768) is good, within the 1-3 range. B (1.888) is lower, potentially leading to permeability issues. This is a significant advantage for A.
4. **HBD/HBA:** Both have 1 HBD and 4 HBA, which are acceptable.
5. **QED:** A (0.898) is better than B (0.767), indicating a more drug-like profile.
6. **DILI:** A (48.042) is higher than B (16.557), indicating a higher risk of liver injury. This is a significant drawback for A.
7. **BBB:** A (78.79) is better than B (67.158), suggesting better potential for CNS penetration, though this isn't critical for ADRB2 unless targeting CNS effects.
8. **Caco-2:** Both are negative, which is unusual. Lower values suggest poor permeability.
9. **Solubility:** Both are negative, which is also unusual. Lower values suggest poor solubility.
10. **hERG:** A (0.621) is higher than B (0.223), indicating a higher risk of hERG inhibition and potential cardiotoxicity. This is a significant drawback for A.
11. **Cl_mic:** A (36.437) is higher than B (-2.728), meaning A has faster metabolic clearance and is less metabolically stable. B is significantly better here.
12. **t1/2:** A (40.916) is better than B (5.503), indicating a longer half-life.
13. **Pgp:** A (0.098) is higher than B (0.025), indicating higher P-gp efflux. B is better here.
14. **Affinity:** B (-7.0) is significantly better than A (-4.3). A 2.7 kcal/mol difference in binding is substantial and can often outweigh other ADME concerns.
**Overall Assessment:**
Ligand B has a much stronger binding affinity, which is paramount for a GPCR target. While Ligand A has better BBB penetration and half-life, the significantly worse logP, higher DILI risk, higher hERG risk, faster clearance, and higher Pgp efflux are substantial drawbacks. The superior affinity of Ligand B, coupled with its better metabolic stability and lower toxicity liabilities, makes it the more promising candidate despite the slightly lower BBB.
Output:
0
2025-04-17 22:55:31,281 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
The ADRB2 receptor is a GPCR, so the priorities are logP, Pgp, TPSA, affinity, and BBB. Let's compare the ligands step-by-step:
1. **MW:** Both ligands (356.451 and 347.459 Da) are within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (66.37) is better than Ligand B (79.46). Lower TPSA generally favors oral absorption, and is important for GPCRs.
3. **logP:** Both ligands have good logP values (3.263 and 3.978), falling within the optimal 1-3 range. Ligand B is slightly higher, which could potentially lead to off-target effects, but is still acceptable.
4. **HBD/HBA:** Ligand A (2 HBD, 4 HBA) is slightly better than Ligand B (3 HBD, 3 HBA) in terms of balancing solubility and permeability.
5. **QED:** Both ligands have reasonable QED scores (0.753 and 0.698), indicating good drug-like properties.
6. **DILI:** Ligand B (63.086) has a lower DILI risk than Ligand A (80.962). This is a significant advantage.
7. **BBB:** Both ligands have similar BBB penetration (65.413 and 64.715). Neither is exceptionally high, but acceptable for a peripheral target like ADRB2.
8. **Caco-2:** Both ligands have negative Caco-2 values (-4.988 and -4.768). This is unusual and suggests poor permeability.
9. **Solubility:** Both ligands have negative solubility values (-4.148 and -4.249). This is also concerning and suggests poor aqueous solubility.
10. **hERG:** Ligand A (0.658) has a slightly higher hERG risk than Ligand B (0.305). Lower hERG is preferred.
11. **Cl_mic:** Ligand B (18.847) has significantly lower microsomal clearance than Ligand A (58.006), indicating better metabolic stability.
12. **t1/2:** Ligand A (89.693) has a much longer in vitro half-life than Ligand B (25.217). This is a significant advantage.
13. **Pgp:** Ligand A (0.344) has lower P-gp efflux than Ligand B (0.252), which is favorable.
14. **Affinity:** Ligand B (-8.2 kcal/mol) has a significantly stronger binding affinity than Ligand A (-7.0 kcal/mol). This is a substantial advantage that can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand B has a significantly better binding affinity and lower DILI risk, and better metabolic stability. While Ligand A has a longer half-life and lower Pgp efflux, the superior affinity of Ligand B is a critical factor for a GPCR target. The slightly higher logP of Ligand B is a minor concern, but the stronger binding is likely to compensate. The poor Caco-2 and solubility values are concerning for both, but can be addressed with formulation strategies.
Output:
0
2025-04-17 22:55:31,281 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (343.471 and 350.423 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (61.44) is significantly better than Ligand B (123.19). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold. Ligand B is approaching the upper limit.
3. **logP:** Both ligands have similar logP values (2.053 and 2.076), both within the optimal 1-3 range.
4. **HBD:** Both ligands have 2 HBD, which is acceptable.
5. **HBA:** Ligand A has 3 HBA, while Ligand B has 4. Both are within the acceptable limit of 10, but A is slightly preferred.
6. **QED:** Ligand A (0.797) has a much higher QED score than Ligand B (0.381), indicating a more drug-like profile. This is a significant advantage for A.
7. **DILI:** Ligand A (12.524%) has a much lower DILI risk than Ligand B (26.095%). This is a critical advantage, as minimizing liver toxicity is paramount.
8. **BBB:** Ligand A (62.35%) has a higher BBB penetration than Ligand B (44.397%). While not essential for a cardiovascular target, it's a slight positive for A.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.206 and -4.967), which is unusual and suggests poor permeability. However, the values are very close, so this isn't a major differentiator.
10. **Solubility:** Ligand A (-2.029) has slightly better solubility than Ligand B (-1.584).
11. **hERG:** Both ligands have low hERG inhibition liability (0.35 and 0.308), which is good.
12. **Cl_mic:** Ligand A (-2.435) has a much lower (better) microsomal clearance than Ligand B (30.143). This suggests greater metabolic stability for Ligand A.
13. **t1/2:** Ligand A (-4.343) has a lower in vitro half-life than Ligand B (11.848). This is a negative for A, but the difference might be overcome by other factors.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.021 and 0.01).
15. **Binding Affinity:** Both ligands have the same binding affinity (-6.0 kcal/mol).
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, and affinity. Both ligands are comparable in logP, Pgp, and affinity. Ligand A is significantly better in TPSA.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B in crucial ADME properties (QED, DILI, Cl_mic, TPSA, Solubility) and has a comparable binding affinity. While Ligand B has a better in vitro half-life, the superior overall profile of Ligand A, particularly its lower DILI risk and better metabolic stability, makes it the more promising drug candidate.
Output:
1
2025-04-17 22:55:31,281 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (a cardiovascular GPCR) drug candidates.
**Ligand A:** [351.447, 110.52 , 0.492, 3. , 4. , 0.415, 15.51 , 50.872, -5.57 , -1.447, 0.149, 13.231, -13.517, 0.015, -5.7 ]
**Ligand B:** [347.419, 101.53 , -0.236, 1. , 5. , 0.794, 28.422, 62.97 , -5.558, -1.466, 0.135, -9.082, -1.738, 0.011, -6.8 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). A (351.447) and B (347.419) are very close.
2. **TPSA:** A (110.52) is slightly above the preferred <140 for good oral absorption, but acceptable. B (101.53) is better, closer to the threshold.
3. **logP:** A (0.492) is a bit low, potentially hindering permeation. B (-0.236) is even lower, raising similar concerns. Both are suboptimal.
4. **HBD:** A (3) is good. B (1) is excellent.
5. **HBA:** A (4) is good. B (5) is also acceptable.
6. **QED:** A (0.415) is below the preferred 0.5. B (0.794) is much better, indicating a more drug-like profile.
7. **DILI:** A (15.51) is very good, indicating low liver injury risk. B (28.422) is higher, but still within an acceptable range.
8. **BBB:** A (50.872) is low, suggesting poor brain penetration. B (62.97) is better, but still not high. Since this is a cardiovascular target, BBB isn't *critical*, but some penetration could be beneficial for off-target effects.
9. **Caco-2:** Both are very poor (-5.57 and -5.558). This suggests very poor intestinal absorption for both compounds.
10. **Solubility:** Both are very poor (-1.447 and -1.466). This is a significant concern for bioavailability.
11. **hERG:** Both are very low (0.149 and 0.135), indicating minimal cardiotoxicity risk.
12. **Cl_mic:** A (13.231) is higher than B (-9.082), suggesting faster metabolism and lower metabolic stability for A. B is much more stable.
13. **t1/2:** A (-13.517) is very short, while B (-1.738) is longer, but still not ideal.
14. **Pgp:** Both are very low (0.015 and 0.011), suggesting minimal P-gp efflux.
15. **Affinity:** B (-6.8) is 1.1 kcal/mol better than A (-5.7). This is a substantial difference in binding potency.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. While both have poor logP and Caco-2/Solubility, B wins on QED, metabolic stability (Cl_mic), half-life, and *significantly* on binding affinity. The slightly better TPSA of B is also a plus.
**Conclusion:**
Despite both compounds having significant drawbacks (poor solubility and permeability), Ligand B is the better candidate due to its superior binding affinity, better QED score, improved metabolic stability, and slightly better TPSA. The affinity difference is large enough to outweigh the other concerns.
Output:
0
2025-04-17 22:55:31,281 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.475 and 350.503 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (75.71) is slightly higher than Ligand B (60.85). Both are below the 140 A^2 threshold for good oral absorption, but Ligand B is better, closer to the 90 A^2 target for GPCRs.
3. **logP:** Both ligands (2.119 and 2.279) are within the optimal 1-3 range. No significant difference.
4. **HBD:** Both ligands have 1 HBD, which is within the acceptable limit of <=5. No difference.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 3. Both are below the 10 limit. Ligand B is slightly better.
6. **QED:** Ligand B (0.799) has a higher QED score than Ligand A (0.587), indicating a more drug-like profile. This is a notable advantage.
7. **DILI:** Ligand B (9.267%) has a significantly lower DILI risk than Ligand A (12.136%). This is a crucial advantage, as minimizing liver toxicity is paramount.
8. **BBB:** Ligand A (78.092%) has a slightly higher BBB penetration percentile than Ligand B (67.003%). While ADRB2 isn't strictly a CNS target, some CNS exposure might be acceptable or even beneficial depending on the specific therapeutic goal.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.497 and -4.59), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Both ligands have negative solubility values (-2.524 and -2.56), indicating very poor aqueous solubility. This is a major drawback for both.
11. **hERG:** Ligand A (0.394) has a slightly lower hERG inhibition liability than Ligand B (0.557), suggesting a slightly reduced risk of cardiotoxicity.
12. **Cl_mic:** Ligand B (29.135) has a significantly lower microsomal clearance than Ligand A (53.758), indicating better metabolic stability. This is a substantial advantage.
13. **t1/2:** Ligand B (2.483) has a slightly longer in vitro half-life than Ligand A (-14.178). This is a positive attribute.
14. **Pgp:** Ligand A (0.031) has a lower P-gp efflux liability than Ligand B (0.189), suggesting better oral bioavailability and potential for CNS exposure.
15. **Binding Affinity:** Ligand A (-7.4 kcal/mol) has a slightly better binding affinity than Ligand B (-6.7 kcal/mol). This is a 0.7 kcal/mol difference, which is significant but needs to be weighed against other factors.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B has better TPSA, Cl_mic, DILI, QED, and t1/2. Ligand A has a slightly better affinity and Pgp, and hERG. The solubility and Caco-2 values are poor for both. However, the lower DILI and better metabolic stability (Cl_mic) of Ligand B are more important for overall drug development success. The affinity difference is not large enough to overcome these advantages.
**Conclusion:**
Considering the balance of properties, especially the lower DILI risk, better metabolic stability, and higher QED score, Ligand B is the more promising drug candidate.
Output:
0
2025-04-17 22:55:31,281 - INFO - Batch 367 complete. Total preferences: 5872
2025-04-17 22:55:31,282 - INFO - Processing batch 368/512...
2025-04-17 22:56:20,801 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (369.44 and 349.43 Da). No significant difference here.
2. **TPSA:** Ligand A (55.32) is significantly better than Ligand B (95.71). ADRB2 is not a CNS target, but lower TPSA generally improves absorption.
3. **logP:** Ligand A (3.582) is slightly higher than Ligand B (2.256), both are within the optimal range.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Both ligands have 5 HBA, which is acceptable.
6. **QED:** Ligand A (0.714) is better than Ligand B (0.554), indicating a more drug-like profile.
7. **DILI:** Ligand A (51.842) is higher than Ligand B (27.414), meaning Ligand B has a lower risk of liver injury, which is a significant advantage.
8. **BBB:** Not a primary concern for ADRB2. Ligand A (88.251) is higher than Ligand B (54.478).
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-4.353) is slightly better than Ligand B (-4.844).
10. **Solubility:** Ligand A (-4.109) is slightly better than Ligand B (-2.747).
11. **hERG:** Both ligands have low hERG risk (0.672 and 0.653).
12. **Cl_mic:** Ligand A (74.865) has higher clearance than Ligand B (23.562), indicating lower metabolic stability. This favors Ligand B.
13. **t1/2:** Ligand A (18.325) has a longer half-life than Ligand B (10.082), which is preferable.
14. **Pgp:** Both ligands have low Pgp efflux (0.737 and 0.169), with Ligand B being significantly lower, which is a positive.
15. **Binding Affinity:** Ligand B (-6.5) has a slightly better binding affinity than Ligand A (-6.2), though the difference is relatively small.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand A has a better logP and TPSA, while Ligand B has slightly better affinity. However, the significant advantages of Ligand B in terms of DILI risk, lower clearance, and lower Pgp efflux outweigh the minor differences in other parameters. The lower DILI risk is particularly important.
**Conclusion:**
Considering the balance of properties, especially the lower DILI risk and improved metabolic stability of Ligand B, it is the more promising drug candidate.
Output:
0
2025-04-17 22:56:20,802 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (337.379) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (67.59) is significantly better than Ligand B (112.73). For a GPCR, a lower TPSA is preferred for better permeability. Ligand B is pushing the upper limit for good oral absorption.
3. **logP:** Ligand A (2.544) is optimal, while Ligand B (0.404) is quite low. Low logP can hinder membrane permeability and potentially reduce binding affinity.
4. **HBD:** Ligand A (1) is better than Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (6) is better than Ligand B (4). Fewer HBAs generally improve permeability.
6. **QED:** Both ligands have acceptable QED values (A: 0.744, B: 0.641), indicating reasonable drug-likeness.
7. **DILI:** Ligand A (55.448) has a higher DILI risk than Ligand B (9.926). This is a significant drawback for Ligand A.
8. **BBB:** Ligand A (71.927) has better BBB penetration than Ligand B (59.093). While ADRB2 isn't necessarily a CNS target, some degree of BBB penetration can be beneficial for distribution.
9. **Caco-2:** Ligand A (-4.666) and Ligand B (-5.35) are both very poor. This suggests poor intestinal absorption for both compounds.
10. **Solubility:** Ligand A (-3.31) is better than Ligand B (-1.764), indicating better aqueous solubility.
11. **hERG:** Ligand A (0.689) has a lower hERG risk than Ligand B (0.083), which is a positive attribute.
12. **Cl_mic:** Ligand A (114.871) has higher microsomal clearance than Ligand B (4.423), meaning it's metabolized more quickly. This is a negative for Ligand A.
13. **t1/2:** Ligand B (-16.065) has a longer in vitro half-life than Ligand A (-14.635).
14. **Pgp:** Ligand A (0.299) has lower P-gp efflux than Ligand B (0.007), which is desirable.
15. **Affinity:** Ligand A (-8.4 kcal/mol) has a significantly better binding affinity than Ligand B (-6.5 kcal/mol). This is a substantial advantage.
**Overall Assessment:**
Ligand A has a significantly better binding affinity and better physicochemical properties (TPSA, logP, HBD, HBA, solubility, Pgp) despite having a higher DILI risk and faster clearance. The affinity difference is large enough to potentially overcome the DILI concern, especially considering the possibility of structural modifications to mitigate that risk. Ligand B, while having a lower DILI risk, suffers from a poor logP, higher TPSA, and a significantly weaker binding affinity.
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand A is the more promising candidate. The strong binding affinity is a major advantage, and the other properties, while not perfect, are more favorable than those of Ligand B.
Output:
1
2025-04-17 22:56:20,802 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (345.49 & 348.49 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (70.23) is better than Ligand B (78.09). Both are below 140, but lower TPSA generally favors absorption.
3. **logP:** Both ligands (2.86 & 2.87) are excellent, falling right in the optimal 1-3 range. No clear advantage.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (2), but both are within the acceptable limit of 5.
5. **HBA:** Ligand A (2) is lower than Ligand B (3), which is slightly preferable. Both are well below the 10 threshold.
6. **QED:** Ligand B (0.758) has a better QED score than Ligand A (0.602), indicating a more drug-like profile.
7. **DILI:** Ligand A (11.25) has a significantly lower DILI risk than Ligand B (16.09). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (82.01) has a better BBB penetration percentile than Ligand B (63.75). While ADRB2 isn't exclusively a CNS target, some CNS exposure is not necessarily detrimental and could offer additional therapeutic effects.
9. **Caco-2:** Ligand A (-4.653) is better than Ligand B (-5.077), suggesting better intestinal absorption.
10. **Solubility:** Ligand A (-2.861) is better than Ligand B (-2.291), indicating better aqueous solubility.
11. **hERG:** Both ligands (0.706 & 0.511) have low hERG inhibition risk, which is good. Ligand B is slightly better.
12. **Cl_mic:** Ligand B (22.24) has a significantly lower microsomal clearance than Ligand A (42.36), indicating better metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand B (-29.59) has a much longer in vitro half-life than Ligand A (4.21). This is a substantial advantage for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands (0.054 & 0.095) have low P-gp efflux liability. No significant difference.
15. **Binding Affinity:** Ligand B (-5.8) has a slightly better binding affinity than Ligand A (-5.2). While the difference is less than the 1.5kcal/mol threshold, it's still a positive.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Both ligands perform well on logP and Pgp. Ligand A has a slightly better TPSA. Ligand B has a slightly better affinity. However, the significant advantages of Ligand A in terms of DILI risk, BBB penetration, solubility and Caco-2 permeability, combined with the substantial improvement in half-life for Ligand B, are critical. The lower DILI risk and better solubility of Ligand A are particularly important for overall drug safety and formulation.
**Conclusion:**
Considering the balance of properties, particularly the lower DILI risk and better solubility of Ligand A, I favor Ligand A.
Output:
1
2025-04-17 22:56:20,802 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (360.401 and 357.426 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (75.71) is slightly higher than Ligand B (71.11), but both are below the 140 threshold for good oral absorption.
3. **logP:** Ligand A (1.727) is within the optimal 1-3 range. Ligand B (-0.059) is slightly below 1, which *could* indicate potential permeability issues, though not drastically.
4. **HBD:** Both ligands have 1 HBD, which is excellent.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 5. Both are acceptable (<=10).
6. **QED:** Ligand B (0.747) has a better QED score than Ligand A (0.578), suggesting a more drug-like profile.
7. **DILI:** Ligand B (20.24) has a significantly lower DILI risk than Ligand A (47.421). This is a major advantage for Ligand B.
8. **BBB:** Both ligands have good BBB penetration (Ligand A: 80.613, Ligand B: 79.217). This is less critical for ADRB2 (a cardiovascular target) but still positive.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.512 and -4.944), which is unusual and suggests very poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand B (-0.912) has slightly better solubility than Ligand A (-2.314), though both are quite poor.
11. **hERG:** Both ligands have low hERG inhibition risk (0.332 and 0.396).
12. **Cl_mic:** Ligand B (-12.99) has a much lower microsomal clearance than Ligand A (37.558), indicating better metabolic stability. This is a substantial advantage.
13. **t1/2:** Ligand B (10.002) has a significantly longer in vitro half-life than Ligand A (-16.563). This is another major benefit for Ligand B.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.043 and 0.02).
15. **Binding Affinity:** Ligand B (-6.8) has a slightly better binding affinity than Ligand A (-6.0). While the difference is less than the 1.5 kcal/mol threshold, it contributes to the overall preference.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand B has a slightly better logP, comparable TPSA and Pgp, and slightly better affinity. However, the significant advantages in DILI risk, metabolic stability (Cl_mic), and half-life are decisive. The poor Caco-2 values are concerning for both, but can potentially be addressed through formulation strategies.
**Conclusion:**
Ligand B demonstrates a more favorable balance of properties, particularly regarding safety (DILI), pharmacokinetics (Cl_mic, t1/2), and a slight improvement in binding affinity. While both have permeability concerns, Ligand B's overall profile is more promising for further development.
Output:
0
2025-04-17 22:56:20,802 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [341.367, 80.76, 2.536, 1, 5, 0.904, 90.694, 55.293, -4.549, -3.799, 0.209, 19.096, -31.567, 0.107, -6.4]
**Ligand B:** [346.515, 49.41, 3.666, 1, 2, 0.538, 10.198, 93.757, -4.883, -3.95, 0.689, 54.556, -3.649, 0.173, -5.5]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). A (341.367) is slightly lower, which is generally favorable for permeability, but both are acceptable.
2. **TPSA:** A (80.76) is higher than B (49.41). For a cardiovascular GPCR, TPSA isn't *as* critical as for CNS targets, but lower is still preferred for better absorption. B is significantly better here.
3. **logP:** A (2.536) and B (3.666) are both within the optimal range (1-3), but B is approaching the upper limit. This could potentially lead to solubility issues, but it's not a major concern at this level.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** A has 5, B has 2. Lower HBA is generally preferred for permeability, so B is better.
6. **QED:** A (0.904) is significantly better than B (0.538), indicating a more drug-like profile. This is a substantial advantage for A.
7. **DILI:** A (90.694) is very high risk, while B (10.198) is excellent. This is a *major* drawback for A.
8. **BBB:** A (55.293) is moderate, while B (93.757) is very good. While ADRB2 isn't necessarily a CNS target, higher BBB is still generally desirable for broader distribution and reduced off-target effects.
9. **Caco-2:** Both are negative, indicating poor permeability. This is concerning for both, but the scale is not specified, so it's hard to say how concerning.
10. **Solubility:** Both are negative, indicating poor solubility. Again, the scale is unspecified.
11. **hERG:** A (0.209) is better than B (0.689), indicating lower cardiotoxicity risk. This is important for a cardiovascular target.
12. **Cl_mic:** A (19.096) is lower than B (54.556), meaning A is more metabolically stable. This is a positive for A.
13. **t1/2:** A (-31.567) is much more negative than B (-3.649), indicating a shorter half-life. This is a significant disadvantage for A.
14. **Pgp:** A (0.107) is lower than B (0.173), meaning A is less susceptible to P-gp efflux. This is a slight advantage for A.
15. **Affinity:** A (-6.4) is slightly better than B (-5.5), but the difference is not huge (0.9 kcal/mol).
**GPCR-Specific Priorities:**
For ADRB2 (a cardiovascular GPCR), we prioritize logP, TPSA, Pgp, and affinity. B performs better on logP and TPSA. A has a slightly better affinity and Pgp, but the DILI risk for A is extremely concerning. The half-life is also a significant concern.
**Conclusion:**
Despite the slightly better affinity of Ligand A, the extremely high DILI risk and poor half-life make it a much less desirable candidate. Ligand B, while having a slightly lower QED and affinity, has a much better safety profile (DILI), better TPSA, and a better BBB score. The lower TPSA and better BBB are particularly beneficial for a GPCR.
Output:
0
2025-04-17 22:56:20,802 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.399 and 348.355 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (84.94) is significantly better than Ligand B (110.03). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold. Ligand B is approaching it.
3. **logP:** Both ligands have acceptable logP values (0.984 and 1.8), falling within the 1-3 range. Ligand B is slightly higher, which *could* be a minor concern for solubility.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (6). Fewer HBAs generally improve permeability.
6. **QED:** Ligand A (0.775) has a better QED score than Ligand B (0.658), indicating a more drug-like profile.
7. **DILI:** Ligand A (50.136) has a significantly lower DILI risk than Ligand B (79.139). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (59.442) has a higher BBB penetration percentile than Ligand B (37.069). While not a primary concern for a cardiovascular target, higher BBB is rarely detrimental.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.662 and -4.854). This is unusual and suggests poor permeability *in vitro*. However, the values are similar.
10. **Solubility:** Ligand A (-1.824) has better solubility than Ligand B (-3.423).
11. **hERG:** Both ligands have very low hERG inhibition risk (0.206 and 0.352). This is excellent.
12. **Cl_mic:** Ligand A (32.506) has lower microsomal clearance than Ligand B (44.168), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-11.668) has a more negative in vitro half-life than Ligand B (22.705). This is unusual, and negative values suggest very rapid metabolism. However, the difference is significant.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.027 and 0.072).
15. **Binding Affinity:** Ligand B (-7.1) has a substantially better binding affinity than Ligand A (-7.5). This is a significant advantage for Ligand B. A 0.4 kcal/mol difference is considerable.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B has a slightly better logP and a significantly better affinity. However, Ligand A excels in TPSA, DILI, solubility, and metabolic stability (Cl_mic). The substantial difference in DILI risk and the better overall drug-like properties (QED) of Ligand A are compelling. The affinity difference, while notable, can potentially be optimized in later stages of development.
**Conclusion:**
Despite the better binding affinity of Ligand B, the superior ADME properties and significantly lower DILI risk of Ligand A make it the more promising drug candidate.
Output:
1
2025-04-17 22:56:20,802 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (360.42 and 357.38 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (58.2) is better than Ligand B (61.36). Both are below the 140 threshold for oral absorption, but lower is preferable.
3. **logP:** Ligand A (3.022) is optimal, while Ligand B (1.317) is on the lower side, potentially impacting permeability. This is a notable advantage for A.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable.
5. **HBA:** Ligand A (2) is better than Ligand B (5). Lower is preferable.
6. **QED:** Both ligands have good QED scores (0.664 and 0.832), indicating good drug-like properties.
7. **DILI:** Both ligands have low DILI risk (30.632 and 34.238), which is good.
8. **BBB:** Both ligands show good BBB penetration (83.908 and 88.135).
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual. Assuming these are logP-like scales, lower values indicate poorer permeability. Ligand A (-4.628) is slightly better than Ligand B (-4.943).
10. **Solubility:** Ligand A (-4.411) is better than Ligand B (-1.604). Higher solubility is generally preferred.
11. **hERG:** Both ligands have low hERG inhibition risk (0.561 and 0.419).
12. **Cl_mic:** Ligand A (29.289) has a higher (worse) microsomal clearance than Ligand B (-17.488). This suggests Ligand B is more metabolically stable.
13. **t1/2:** Ligand A (17.374) has a longer half-life than Ligand B (-3.476). This is a significant advantage for A.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.117 and 0.012).
15. **Binding Affinity:** Both ligands have similar and excellent binding affinities (-6.7 and -6.9 kcal/mol).
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A has a better logP and TPSA. While both have good affinity and Pgp profiles, the slightly improved logP and TPSA of A, combined with its better solubility and longer half-life, outweigh the metabolic stability advantage of Ligand B.
**Conclusion:**
Ligand A presents a more balanced profile, particularly regarding properties crucial for oral bioavailability and duration of action, making it a more promising drug candidate.
Output:
1
2025-04-17 22:56:20,802 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
Let's break down the comparison of Ligand A and Ligand B based on the provided parameters and the GPCR-specific priorities (logP, Pgp, TPSA, and affinity being most important).
1. **Molecular Weight:** Both ligands (368.5 and 367.5 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (78.67) is better than Ligand B (85.09). Both are below 140, which is good for oral absorption, but lower TPSA is generally preferred for GPCRs to aid permeability.
3. **logP:** Ligand B (1.397) is better than Ligand A (0.673). Both are within the 1-3 range, but Ligand B is closer to the optimal range. Ligand A's logP is a bit low, potentially hindering membrane permeability.
4. **H-Bond Donors:** Ligand A (1) is better than Ligand B (2). Lower is generally preferred.
5. **H-Bond Acceptors:** Ligand A (6) is better than Ligand B (8). Lower is generally preferred.
6. **QED:** Both ligands have similar QED values (0.799 and 0.786), indicating good drug-likeness.
7. **DILI:** Ligand B (38.813) is slightly better than Ligand A (43.428), both are below the 40 threshold, indicating low risk.
8. **BBB:** Ligand B (49.011) is significantly better than Ligand A (25.126). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be beneficial for distribution and potentially off-target effects.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-5.157) is slightly better than Ligand B (-5.836).
10. **Solubility:** Both ligands have poor solubility (-1.621 and -1.845). This is a concern for both, but not a deciding factor.
11. **hERG:** Both ligands have very low hERG risk (0.16 and 0.14).
12. **Cl_mic:** Ligand B (3.603) is *much* better than Ligand A (35.97). Lower clearance is highly desirable for improved metabolic stability.
13. **t1/2:** Ligand B (23.313) is significantly better than Ligand A (-7.573). A longer half-life is preferred.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.067).
15. **Binding Affinity:** Ligand B (-7.7) is slightly better than Ligand A (-5.6). This is a substantial difference in potency. A 2.1 kcal/mol advantage is significant and can outweigh some ADME concerns.
**Overall Assessment:**
Ligand B clearly outperforms Ligand A in several critical areas. The significantly better binding affinity, lower microsomal clearance, longer half-life, and better BBB penetration are compelling advantages. While Ligand A has a slightly lower TPSA, the benefits of Ligand B's superior potency and pharmacokinetic properties outweigh this minor difference. The slightly higher logP of Ligand B is also favorable.
Output:
0
2025-04-17 22:56:20,802 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (364.423 and 345.487 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (54.34) is significantly better than Ligand A (94.99). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (2.962) is closer to the optimal 1-3 range than Ligand A (1.529). A slightly higher logP is generally favorable for GPCR ligands.
4. **HBD:** Both ligands have 1 HBD, which is within the acceptable limit of 5.
5. **HBA:** Ligand B (3) has fewer HBA than Ligand A (4), which is preferable for permeability.
6. **QED:** Both ligands have similar QED values (0.878 and 0.826), indicating good drug-likeness.
7. **DILI:** Ligand B (29.042) has a much lower DILI risk than Ligand A (72.664). This is a substantial advantage.
8. **BBB:** Ligand B (81.078) has a higher BBB penetration percentile than Ligand A (59.946). While not a primary concern for a cardiovascular target, higher BBB is rarely detrimental.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. Ligand A (-5.033) is slightly better than Ligand B (-4.78).
10. **Solubility:** Both ligands have negative solubility values, indicating poor solubility. Ligand B (-3.27) is slightly better than Ligand A (-2.6).
11. **hERG:** Ligand B (0.633) has a lower hERG inhibition liability than Ligand A (0.032), which is a significant safety advantage.
12. **Cl_mic:** Ligand A (26.043) has a lower microsomal clearance than Ligand B (60.397), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-1.101) has a slightly longer in vitro half-life than Ligand A (-12.943).
14. **Pgp:** Ligand B (0.465) has a lower P-gp efflux liability than Ligand A (0.021), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand A (-7.0) and Ligand B (-5.9) have similar binding affinities. Ligand A is slightly better, but the difference is not substantial enough to outweigh other factors.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP, TPSA, and Pgp. While Ligand A has a slightly better affinity, the significant advantages of Ligand B in safety (DILI, hERG) and ADME properties (lower Pgp efflux, better TPSA) make it the more promising candidate. The better solubility of Ligand B is also a plus.
**Output:**
0
2025-04-17 22:56:20,802 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are looking for a ligand targeting ADRB2, a GPCR. Therefore, the priorities are logP, Pgp, TPSA, affinity, and BBB. Let's compare Ligand A and Ligand B across these and other important parameters:
1. **Molecular Weight:** Both ligands are within the acceptable range (200-500 Da). Ligand A (345.443) is slightly lower than Ligand B (368.594).
2. **TPSA:** Ligand A (72.36) is higher than Ligand B (58.64). Both are below 140, but B is better for absorption.
3. **logP:** Ligand A (1.607) and Ligand B (2.671) are both within the optimal range (1-3). Ligand B is slightly more lipophilic, which could be beneficial for membrane permeability.
4. **H-Bond Donors/Acceptors:** Ligand A has 2 HBD and 4 HBA, while Ligand B has 1 HBD and 3 HBA. Both are acceptable.
5. **QED:** Both have reasonable QED values (A: 0.823, B: 0.733), indicating good drug-like properties.
6. **DILI:** Ligand A (42.846) has a slightly higher DILI risk than Ligand B (9.926). This is a significant advantage for B.
7. **BBB:** Ligand B (77.627) has a better BBB penetration percentile than Ligand A (67.584). This is important for GPCRs, though not strictly essential for ADRB2.
8. **Caco-2 Permeability:** Ligand A (-5.057) has worse Caco-2 permeability than Ligand B (-4.546).
9. **Aqueous Solubility:** Ligand A (-2.319) has worse aqueous solubility than Ligand B (-3.551).
10. **hERG:** Both ligands have low hERG inhibition liability (A: 0.286, B: 0.506).
11. **Cl_mic:** Ligand A (4.899) has a lower microsomal clearance than Ligand B (46.265), suggesting better metabolic stability.
12. **t1/2:** Ligand A (26.587) has a much longer in vitro half-life than Ligand B (1.522). This is a major advantage for A.
13. **Pgp:** Ligand A (0.075) has lower P-gp efflux than Ligand B (0.092).
14. **Binding Affinity:** Ligand B (-6.3) has a slightly better binding affinity than Ligand A (-6.6). While the difference is small, it's still a factor.
**Overall Assessment:**
Ligand B has advantages in logP, DILI, BBB, Caco-2 permeability, and binding affinity. However, Ligand A has a significantly longer half-life and lower microsomal clearance, which are crucial for *in vivo* efficacy. The lower DILI risk of Ligand B is also a substantial benefit. Considering the balance of these factors, and the importance of metabolic stability and reduced toxicity for a cardiovascular target, Ligand B is the more promising candidate. The slight affinity difference can likely be optimized in later stages of drug development.
**Output:**
0
2025-04-17 22:56:20,803 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (344.46 and 371.50 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (85.23) is slightly higher than Ligand B (78.95). Both are below the 140 A^2 threshold for good oral absorption, but closer to the 90 A^2 threshold for CNS targets (less relevant here, but still a positive). Ligand B is slightly preferred.
**3. logP:** Both ligands have good logP values (1.8 and 1.47), falling within the optimal 1-3 range. No strong preference.
**4. H-Bond Donors:** Ligand A has 2 HBD, and Ligand B has 1. Both are within the acceptable limit of <=5. Ligand B is slightly preferred.
**5. H-Bond Acceptors:** Ligand A has 4 HBA, and Ligand B has 5. Both are within the acceptable limit of <=10. No strong preference.
**6. QED:** Both ligands have similar QED values (0.715 and 0.765), indicating good drug-like properties. No significant difference.
**7. DILI Risk:** Ligand A (14.81) has a significantly lower DILI risk than Ligand B (36.80). This is a major advantage for Ligand A.
**8. BBB Penetration:** Ligand B (66.93) has better BBB penetration than Ligand A (39.71). While ADRB2 is primarily a cardiovascular target, some CNS off-target effects are possible with GPCRs, so moderate BBB penetration isn't necessarily negative.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, indicating poor permeability. Ligand A (-5.281) is slightly less negative than Ligand B (-4.792), suggesting slightly better permeability, but both are concerning.
**10. Aqueous Solubility:** Both ligands have negative solubility values, indicating poor solubility. Ligand A (-1.303) is slightly less negative than Ligand B (-1.813), suggesting slightly better solubility, but both are concerning.
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.455 and 0.137). No significant difference.
**12. Microsomal Clearance:** Ligand A (9.21) has a much lower microsomal clearance than Ligand B (46.123), indicating better metabolic stability. This is a significant advantage for Ligand A.
**13. In Vitro Half-Life:** Ligand A (14.04) has a longer in vitro half-life than Ligand B (-35.79). This is a major advantage for Ligand A.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.008 and 0.033). No significant difference.
**15. Binding Affinity:** Both ligands have very similar binding affinities (-5.5 and -5.2 kcal/mol). The difference is less than the 1.5 kcal/mol threshold for outweighing other factors.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity) and the general drug-like properties, Ligand A is the more promising candidate. While Ligand B has better BBB penetration, Ligand A demonstrates significantly better safety (lower DILI risk), metabolic stability (lower Cl_mic, longer t1/2), and slightly better permeability and solubility. The similar binding affinities make these ADME/Tox differences decisive.
Output:
1
2025-04-17 22:56:20,803 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (348.491 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (78.09) is higher than Ligand B (54.88). Both are acceptable, but Ligand B is better, being closer to the optimal <90 for GPCRs.
3. **logP:** Ligand A (2.722) is within the optimal range (1-3), while Ligand B (4.833) is pushing the upper limit. Higher logP can lead to off-target effects and solubility issues.
4. **HBD:** Ligand A (2) and Ligand B (1) are both good, below the threshold of 5.
5. **HBA:** Ligand A (3) and Ligand B (5) are both acceptable, below 10.
6. **QED:** Both ligands have similar QED values (0.709 and 0.676), indicating good drug-likeness.
7. **DILI:** Ligand A (27.142) has a significantly lower DILI risk than Ligand B (67.429). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (68.748) and Ligand B (64.095) are relatively similar and acceptable, but not exceptionally high. Since ADRB2 is a cardiovascular target, BBB penetration is not a primary concern, but it's still a slight edge for A.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and indicates poor permeability. This is a significant concern for both.
10. **Solubility:** Both ligands have negative solubility values, indicating very poor aqueous solubility. This is a major drawback for both.
11. **hERG:** Both ligands have low hERG inhibition liability (0.62 and 0.653), which is good.
12. **Cl_mic:** Ligand A (74.669) has lower microsomal clearance than Ligand B (90.857), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-6.665) has a negative half-life, which is not possible. Ligand B (57.061) has a reasonable in vitro half-life. This is a significant advantage for Ligand B.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.121 and 0.29), which is good.
15. **Binding Affinity:** Both ligands have comparable binding affinities (-6.2 and -6.0 kcal/mol). The difference is not substantial enough to override other factors.
**Overall Assessment:**
Ligand A has a significantly lower DILI risk and better metabolic stability (lower Cl_mic). While both have poor Caco-2 and solubility, the DILI risk is a critical factor. Ligand B has a more reasonable half-life, but the higher DILI risk is a major concern. Given the GPCR-specific priorities (logP, Pgp, TPSA, affinity) and the importance of minimizing toxicity, Ligand A is the more promising candidate despite its permeability and solubility issues. These can be addressed through formulation strategies.
Output:
1
2025-04-17 22:56:20,803 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (344.423 and 345.403 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (91.21) is better than Ligand B (96.33). Both are acceptable for a non-CNS GPCR target like ADRB2, being under 140, but lower is preferred.
3. **logP:** Ligand B (-0.628) is slightly less lipophilic than Ligand A (-0.103). Both are within the acceptable 1-3 range, but closer to the lower end. Ligand A is preferable.
4. **HBD:** Both ligands have 2 HBD, which is good.
5. **HBA:** Ligand A has 8 HBA, while Ligand B has 5. Ligand B is preferable here.
6. **QED:** Ligand A (0.756) has a slightly better QED score than Ligand B (0.695), indicating a more drug-like profile.
7. **DILI:** Ligand B (42.807) has a significantly lower DILI risk than Ligand A (60.527). This is a major advantage for Ligand B.
8. **BBB:** Both ligands have low BBB penetration (48.313 and 43.815), which is not a concern for a non-CNS target like ADRB2.
9. **Caco-2:** Both ligands have similar, poor Caco-2 permeability (-5.291 and -5.352). This is a potential issue for oral bioavailability.
10. **Solubility:** Ligand A (-0.892) has slightly better solubility than Ligand B (-1.396).
11. **hERG:** Ligand A (0.281) has a much lower hERG risk than Ligand B (0.083). This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand A (-51.673) has a much lower (better) microsomal clearance than Ligand B (5.691), indicating better metabolic stability.
13. **t1/2:** Ligand B (-5.817) has a negative in vitro half-life, which is concerning. Ligand A (28.521) has a reasonable half-life.
14. **Pgp:** Ligand A (0.006) has much lower P-gp efflux liability than Ligand B (0.021).
15. **Binding Affinity:** Ligand B (3.6 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.7 kcal/mol). This is a substantial advantage that can potentially offset some ADME drawbacks.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand B has a better affinity, and a slightly better logP. Ligand A has a better TPSA and Pgp.
**Overall Assessment:**
Ligand B's significantly stronger binding affinity (-3.6 kcal/mol vs -6.7 kcal/mol) is a major advantage, potentially outweighing its slightly higher TPSA and Pgp efflux. The lower DILI risk is also a significant positive. While the negative in vitro half-life is concerning, it might be addressed through structural modifications. Ligand A has better ADME properties overall, but the weaker binding affinity is a critical drawback.
Output:
0
2025-04-17 22:56:20,803 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (345.4 and 342.4 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (97.94) is higher than Ligand B (79.54). For a GPCR, lower TPSA is generally preferred for better permeability, giving a slight edge to Ligand B.
3. **logP:** Ligand B (1.982) is within the optimal 1-3 range, while Ligand A (0.086) is quite low. This is a significant advantage for Ligand B, as low logP can hinder membrane permeability.
4. **HBD:** Ligand A has 1 HBD, Ligand B has 0. Both are acceptable, but fewer HBDs are generally preferred for permeability. Ligand B is slightly better.
5. **HBA:** Ligand A has 7 HBAs, Ligand B has 5. Both are below the 10 threshold. Ligand B is slightly better.
6. **QED:** Both ligands have high QED scores (0.828 and 0.852), indicating good drug-like properties. No clear winner.
7. **DILI:** Both ligands have similar DILI risk (54.56 and 53.28), and both are below the concerning 60 threshold. No significant difference.
8. **BBB:** Ligand B (75.533) has a significantly higher BBB penetration percentile than Ligand A (57.193). While ADRB2 isn't exclusively a CNS target, some CNS exposure might be acceptable or even desirable depending on the specific therapeutic goal. This is a substantial advantage for Ligand B.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the values are similar (-5.172 and -4.693) and don't differentiate the ligands.
10. **Solubility:** Both have very poor solubility (-1.147 and -1.638). This is a major concern for both compounds.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.082 and 0.157). This is excellent.
12. **Cl_mic:** Ligand B (19.229) has a lower microsomal clearance than Ligand A (25.96), indicating better metabolic stability. This is a positive for Ligand B.
13. **t1/2:** Ligand B (19.391) has a slightly longer in vitro half-life than Ligand A (28.12). This is a positive for Ligand B.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.051 and 0.089). No significant difference.
15. **Binding Affinity:** Ligand B (-7.1 kcal/mol) has a 0.3 kcal/mol stronger binding affinity than Ligand A (-6.8 kcal/mol). This is a significant advantage, as it could potentially overcome some of the ADME liabilities.
**Overall Assessment:**
Ligand B consistently outperforms Ligand A across several key parameters, particularly logP, BBB penetration, metabolic stability (Cl_mic), and binding affinity. While both compounds suffer from poor solubility, the stronger binding affinity and better predicted permeability (due to higher logP and lower TPSA) of Ligand B make it the more promising candidate. The improved BBB penetration is also a bonus.
Output:
0
2025-04-17 22:56:20,803 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (365.382 and 354.447 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (82.56) is better than Ligand B (88.1), both are below the 140 threshold for oral absorption.
3. **logP:** Ligand A (1.858) is optimal, while Ligand B (0.306) is a bit low, potentially hindering permeation. This is a significant advantage for A.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2), as fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (6) is preferable to Ligand B (5), both are below the 10 threshold.
6. **QED:** Both ligands have similar QED values (0.769 and 0.687), indicating good drug-likeness.
7. **DILI:** Ligand A (91.043) has a significantly higher DILI risk than Ligand B (14.851). This is a major concern for Ligand A.
8. **BBB:** Ligand A (82.009) has better BBB penetration than Ligand B (38.813). While ADRB2 isn't strictly a CNS target, some CNS exposure can be relevant for off-target effects or peripheral effects mediated by CNS pathways.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.41 and -4.854), which is unusual and suggests poor permeability.
10. **Solubility:** Ligand A (-3.592) has better solubility than Ligand B (-1.343).
11. **hERG:** Both ligands have low hERG inhibition risk (0.38 and 0.151).
12. **Cl_mic:** Ligand A (42.806) has a higher microsomal clearance than Ligand B (5.259), indicating lower metabolic stability. This favors Ligand B.
13. **t1/2:** Ligand B (14.689) has a significantly longer in vitro half-life than Ligand A (-0.731). This is a strong advantage for B.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.154 and 0.012).
15. **Binding Affinity:** Ligand A (-7.5) has a slightly better binding affinity than Ligand B (-6.0). However, the difference is less than 1.5 kcal/mol, so it doesn't overwhelmingly compensate for other issues.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, and affinity are important. Ligand A has a better logP and slightly better affinity, but Ligand B has a much better DILI score, metabolic stability (lower Cl_mic, longer t1/2), and acceptable TPSA. The significantly higher DILI risk for Ligand A is a major red flag.
**Conclusion:**
Despite the slightly better affinity of Ligand A, the significantly lower DILI risk, better metabolic stability, and longer half-life of Ligand B make it the more promising drug candidate. The poor Caco-2 values for both are concerning and would require further investigation, but the ADME profile of Ligand B is generally superior.
Output:
0
2025-04-17 22:56:20,803 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.395 and 362.495 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (58.64) is significantly better than Ligand A (120.67). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally improves absorption. This is a significant win for B.
3. **logP:** Ligand B (2.478) is within the optimal 1-3 range, while Ligand A (-0.498) is below 1, potentially hindering permeation. This is a substantial advantage for B.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1), but both are acceptable (<=5).
5. **HBA:** Ligand A (6) is higher than Ligand B (4), but both are acceptable (<=10).
6. **QED:** Both ligands have good QED scores (0.683 and 0.772), indicating good drug-like properties. No significant difference.
7. **DILI:** Both ligands have acceptable DILI risk (51.842 and 48.662), below the 60 threshold. No clear advantage.
8. **BBB:** Both ligands have similar and good BBB penetration (71.501 and 71.888). Not a major deciding factor for a cardiovascular target.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.305 and -4.896), which is unusual and suggests poor permeability. This is a concern for both, but the values are similar.
10. **Solubility:** Ligand A (-1.13) has better solubility than Ligand B (-3.965). This is a positive for A, but solubility can often be improved with formulation.
11. **hERG:** Ligand A (0.037) has a slightly lower hERG risk than Ligand B (0.556), which is preferable.
12. **Cl_mic:** Ligand A (10.35) has significantly lower microsomal clearance than Ligand B (78.774), indicating better metabolic stability. This is a strong advantage for A.
13. **t1/2:** Ligand B (-7.658) has a longer half-life than Ligand A (14.534). This is a positive for B.
14. **Pgp:** Ligand A (0.006) has much lower P-gp efflux than Ligand B (0.183), which is favorable for bioavailability. This is a significant advantage for A.
15. **Binding Affinity:** Ligand A (-7.4) has a slightly better binding affinity than Ligand B (-6.3). While the difference is less than the 1.5 kcal/mol threshold, it contributes to the overall preference.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand B excels in logP and has comparable affinity, but its TPSA is much higher. Ligand A has a lower logP, but better metabolic stability (Cl_mic) and P-gp efflux. Considering the balance, the improved metabolic stability and lower P-gp efflux of Ligand A are more valuable than the slightly better solubility of Ligand B.
**Conclusion:**
Ligand A presents a more favorable overall profile, particularly regarding metabolic stability and P-gp efflux, which are crucial for *in vivo* exposure. While Ligand B has better logP and half-life, the issues with TPSA and high clearance outweigh those benefits.
Output:
1
2025-04-17 22:56:20,804 - INFO - Batch 368 complete. Total preferences: 5888
2025-04-17 22:56:20,804 - INFO - Processing batch 369/512...
2025-04-17 22:57:08,566 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (355.425 and 349.395 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (49.77) is significantly better than Ligand B (118.03). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption. Ligand B's TPSA is quite high, potentially hindering oral bioavailability.
3. **logP:** Ligand A (3.734) is optimal, while Ligand B (0.312) is quite low. Low logP can lead to poor membrane permeability. This is a major drawback for Ligand B.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Both are acceptable, but fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (3) is better than Ligand B (7). Similar to HBD, lower HBA is generally preferred. Ligand B has a high number of HBA.
6. **QED:** Both ligands have similar QED values (0.773 and 0.673), indicating good drug-likeness.
7. **DILI:** Ligand A (28.306) has a much lower DILI risk than Ligand B (72.703). This is a significant advantage for Ligand A.
8. **BBB:** Not a primary concern for a cardiovascular target, but Ligand A (79.062) has better BBB penetration than Ligand B (30.787).
9. **Caco-2:** Ligand A (-4.112) is better than Ligand B (-5.141). Higher values are better, indicating better intestinal absorption.
10. **Solubility:** Ligand A (-3.743) is better than Ligand B (-2.369). Higher values are better.
11. **hERG:** Ligand A (0.804) is better than Ligand B (0.13). Lower values are better.
12. **Cl_mic:** Ligand B (58.4) has lower microsomal clearance than Ligand A (62.646), suggesting better metabolic stability. This is a slight advantage for Ligand B.
13. **t1/2:** Ligand A (-24.023) has a longer in vitro half-life than Ligand B (-26.847). This is a slight advantage for Ligand A.
14. **Pgp:** Ligand A (0.724) has lower P-gp efflux than Ligand B (0.046). Lower efflux is better.
15. **Binding Affinity:** Ligand A (-8.2) has significantly better binding affinity than Ligand B (-6.2). This is a substantial advantage for Ligand A. A difference of 2 kcal/mol is very significant.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A excels in all these areas. While metabolic stability (Cl_mic) is important, the superior affinity and ADME properties of Ligand A outweigh the slightly higher clearance.
**Conclusion:**
Ligand A is significantly better than Ligand B across most critical parameters, particularly binding affinity, logP, TPSA, DILI risk, and hERG inhibition. The superior binding affinity alone is enough to favor Ligand A, and the better ADME profile further solidifies this preference.
Output:
1
2025-04-17 22:57:08,566 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Step-by-step comparison:**
1. **MW:** Both ligands (376.4 and 352.479 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (66.48) is significantly better than Ligand B (95.74). ADRB2 is a cardiovascular target, so BBB penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (2.849 and 1.034), falling within the 1-3 range. Ligand A is slightly better.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD is generally better for permeability.
5. **HBA:** Both ligands have the same number of HBA (3).
6. **QED:** Ligand A (0.882) has a slightly better QED score than Ligand B (0.716), indicating better overall drug-likeness.
7. **DILI:** Ligand A (51.183) has a higher DILI risk than Ligand B (18.612). This is a significant advantage for Ligand B.
8. **BBB:** Not a major priority for a cardiovascular target. Ligand A (90.772) is higher than Ligand B (75.107), but this is less critical.
9. **Caco-2:** Ligand A (-4.718) is better than Ligand B (-5.08). Higher (less negative) values indicate better permeability.
10. **Solubility:** Ligand A (-3.846) is better than Ligand B (-2.076). Higher values indicate better solubility.
11. **hERG:** Ligand A (0.709) has a lower hERG risk than Ligand B (0.349). This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand B (19.613) has a lower (better) microsomal clearance than Ligand A (-19.825). This indicates better metabolic stability for Ligand B.
13. **t1/2:** Ligand A (17.51) has a longer half-life than Ligand B (-15.33). This is a positive for Ligand A.
14. **Pgp:** Ligand A (0.091) has lower Pgp efflux than Ligand B (0.02). Lower Pgp is preferable.
15. **Binding Affinity:** Ligand A (-3.9) has a better binding affinity than Ligand B (-1.6). This is a significant advantage for Ligand A.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A excels in logP, TPSA, Pgp, and *especially* affinity. Ligand B has a significant advantage in DILI and Cl_mic. The affinity difference is substantial (2.3 kcal/mol), which can often outweigh minor ADME concerns. The hERG risk is also lower for Ligand A.
**Overall Assessment:**
While Ligand B has a better safety profile regarding DILI and metabolic stability, the significantly stronger binding affinity of Ligand A, coupled with better TPSA, Pgp, hERG, and solubility, makes it the more promising candidate. The difference in affinity is large enough to potentially overcome the slightly higher DILI risk, especially given that ADRB2 is not a CNS target where DILI is a greater concern.
Output:
1
2025-04-17 22:57:08,566 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (a GPCR) drug candidates.
**Ligand A:** [401.857, 116.07 , 1.974, 1. , 9. , 0.664, 99.806, 46.026, -4.908, -3.759, 0.265, 45.321, 110.316, 0.433, -7.2 ]
**Ligand B:** [392.503, 123.85 , -0.232, 2. , 8. , 0.595, 79.139, 61.691, -5.467, -2.498, 0.547, 22.799, -7.093, 0.03 , -5.8 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (392.5) is slightly lower, which is generally favorable.
2. **TPSA:** Ligand A (116.07) is better than Ligand B (123.85). Both are reasonably good for oral absorption, but lower is preferred.
3. **logP:** Ligand A (1.974) is optimal. Ligand B (-0.232) is too low, potentially hindering membrane permeability. This is a significant drawback.
4. **HBD:** Ligand A (1) is better than Ligand B (2).
5. **HBA:** Ligand A (9) is better than Ligand B (8).
6. **QED:** Both are acceptable (A: 0.664, B: 0.595), indicating reasonable drug-likeness.
7. **DILI:** Ligand A (99.806) is *very* high risk, a major concern. Ligand B (79.139) is still not ideal, but significantly better.
8. **BBB:** Ligand B (61.691) is better than Ligand A (46.026). While not a primary concern for a cardiovascular target, higher BBB is generally preferable.
9. **Caco-2:** Ligand A (-4.908) is better than Ligand B (-5.467). Both are negative, indicating poor permeability.
10. **Solubility:** Ligand A (-3.759) is better than Ligand B (-2.498). Both are poor.
11. **hERG:** Ligand A (0.265) is much better than Ligand B (0.547). Lower hERG risk is crucial for cardiovascular drugs.
12. **Cl_mic:** Ligand B (22.799) is significantly better than Ligand A (45.321). Lower clearance indicates better metabolic stability.
13. **t1/2:** Ligand A (110.316) is better than Ligand B (-7.093).
14. **Pgp:** Ligand A (0.433) is better than Ligand B (0.03).
15. **Affinity:** Ligand A (-7.2) is better than Ligand B (-5.8). This is a substantial difference in binding potency (1.4 kcal/mol).
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A has a better logP and Pgp, and a significantly better affinity. However, the extremely high DILI risk for Ligand A is a deal-breaker. While affinity is important, a high risk of liver injury is unacceptable. Ligand B has a lower affinity, but a much better safety profile (DILI) and metabolic stability (Cl_mic).
**Conclusion:**
Despite the better affinity of Ligand A, the extremely high DILI risk outweighs its advantages. Ligand B, while having some ADME drawbacks, presents a much more favorable safety profile and better metabolic stability. Therefore, Ligand B is the more viable drug candidate.
0
2025-04-17 22:57:08,567 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (353.413 and 356.419 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (52.65) is significantly better than Ligand B (96.38). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand B's TPSA is approaching a level that could hinder oral bioavailability.
3. **logP:** Ligand A (2.677) is optimal. Ligand B (-0.069) is quite low, potentially leading to poor membrane permeability and bioavailability. This is a major drawback for Ligand B.
4. **HBD:** Both have 1 HBD, which is acceptable.
5. **HBA:** Ligand A has 2 HBA, while Ligand B has 6. Ligand B is higher, potentially impacting permeability.
6. **QED:** Ligand A (0.905) is excellent, indicating high drug-likeness. Ligand B (0.693) is still acceptable, but less favorable.
7. **DILI:** Ligand A (47.305) has a moderate DILI risk, but is much better than Ligand B (20.822), which is very low and desirable.
8. **BBB:** Ligand A (86.157) is good, while Ligand B (66.809) is lower. Not a primary concern for a cardiovascular target, but a slight advantage for A.
9. **Caco-2:** Both have negative Caco-2 values (-4.385 and -4.626), which is unusual and suggests poor permeability. However, the values are very similar.
10. **Solubility:** Ligand A (-2.88) is better than Ligand B (-0.51), indicating better aqueous solubility.
11. **hERG:** Ligand A (0.738) is lower risk than Ligand B (0.065), a significant advantage for cardiovascular safety.
12. **Cl_mic:** Ligand A (8.701) has a lower microsomal clearance, indicating better metabolic stability. Ligand B (24.004) has a much higher clearance, suggesting rapid metabolism.
13. **t1/2:** Ligand A (1.235) has a slightly better in vitro half-life than Ligand B (-10.427).
14. **Pgp:** Ligand A (0.127) has lower P-gp efflux, which is favorable for bioavailability. Ligand B (0.019) is even lower, but the other drawbacks outweigh this benefit.
15. **Binding Affinity:** Ligand A (-6.3 kcal/mol) is slightly better than Ligand B (-5.8 kcal/mol), but the difference is not substantial enough to overcome the significant ADME deficiencies of Ligand B.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand A excels in logP and has a better TPSA. The affinity difference is small.
**Overall Assessment:**
Ligand A is significantly better overall. It has a more favorable balance of properties, particularly regarding logP, TPSA, metabolic stability (Cl_mic), and hERG risk. While both have issues with Caco-2 permeability, Ligand A's other properties make it a much more promising starting point for further optimization. Ligand B's very low logP is a serious concern.
Output:
1
2025-04-17 22:57:08,567 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [352.425, 49.41, 3.004, 1, 2, 0.856, 26.91, 89.608, -4.628, -4.146, 0.556, 32.033, -31.126, 0.1, -7.4]
**Ligand B:** [368.845, 51.55, 4.356, 0, 5, 0.509, 87.282, 62.699, -4.547, -5.87, 0.366, 87.578, -19.053, 0.487, -7]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). A (352.425) is slightly preferred.
2. **TPSA:** Both are acceptable for a GPCR, but ideally below 140. A (49.41) is better than B (51.55).
3. **logP:** Both are within the optimal range (1-3), but B (4.356) is pushing the upper limit, potentially leading to solubility issues. A (3.004) is better.
4. **HBD:** A (1) is preferable to B (0) as some hydrogen bonding can aid solubility.
5. **HBA:** A (2) is preferable to B (5). Lower HBA is generally better for permeability.
6. **QED:** A (0.856) is significantly better than B (0.509), indicating a more drug-like profile.
7. **DILI:** A (26.91) is *much* better than B (87.282). This is a major advantage for A.
8. **BBB:** A (89.608) is excellent, while B (62.699) is moderate. For a GPCR, good BBB penetration is a plus, even if it's not a CNS target, as it can indicate better distribution.
9. **Caco-2:** Both are negative, indicating poor permeability. This is a concern for both.
10. **Solubility:** A (-4.146) is better than B (-5.87), indicating slightly better solubility.
11. **hERG:** A (0.556) is better than B (0.366), indicating lower risk of cardiotoxicity.
12. **Cl_mic:** A (32.033) is better than B (87.578), indicating better metabolic stability.
13. **t1/2:** A (-31.126) is better than B (-19.053), indicating a longer half-life.
14. **Pgp:** A (0.1) is better than B (0.487), indicating lower P-gp efflux.
15. **Affinity:** A (-7.4) is slightly better than B (-7.0), but the difference is relatively small.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical ADME-Tox properties, *especially* DILI risk and metabolic stability. While both have poor Caco-2 permeability, the superior profile of A in terms of solubility, BBB, QED, and safety (DILI, hERG) makes it the more promising candidate. The slight advantage in binding affinity further solidifies this preference. Given the GPCR target class, the good BBB penetration of A is also a positive attribute.
Output:
1
2025-04-17 22:57:08,567 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Ligand A (407.352 Da) is within the ideal range, while Ligand B (365.861 Da) is also acceptable. No clear advantage here.
2. **TPSA:** Ligand A (58.2) is excellent, well below the 140 threshold and suitable for good absorption. Ligand B (82.53) is still reasonable, but less optimal.
3. **logP:** Both ligands have good logP values (A: 3.442, B: 2.008), falling within the 1-3 range.
4. **HBD:** Both ligands have 2 HBD, which is acceptable.
5. **HBA:** Ligand A has 2 HBA, while Ligand B has 4. Both are within the acceptable limit of 10, but A is slightly better.
6. **QED:** Both ligands have good QED scores (A: 0.584, B: 0.774), indicating good drug-like properties. B is slightly better here.
7. **DILI:** Both ligands have low DILI risk (A: 27.724, B: 34.703), well below the concerning threshold of 60. A is slightly better.
8. **BBB:** Both ligands have reasonable BBB penetration (A: 57.968, B: 66.615). While ADRB2 isn't exclusively a CNS target, some degree of BBB penetration can be beneficial for distribution. B is slightly better.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Both ligands have negative solubility values, indicating very poor aqueous solubility. This is a major drawback for both.
11. **hERG:** Both ligands have low hERG risk (A: 0.649, B: 0.369). B is better here.
12. **Cl_mic:** Ligand A has a higher microsomal clearance (65.65) than Ligand B (14.471), suggesting lower metabolic stability. B is significantly better.
13. **t1/2:** Ligand A has a longer in vitro half-life (60.627) than Ligand B (-13.478). This is a major advantage for A.
14. **Pgp:** Both ligands have low Pgp efflux liability (A: 0.252, B: 0.18). B is slightly better.
15. **Binding Affinity:** Ligand B has a slightly better binding affinity (-6.7 kcal/mol) than Ligand A (-6.1 kcal/mol). This is a significant advantage.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Both ligands perform reasonably well on logP and Pgp. Ligand A has a better TPSA. Ligand B has a slightly better affinity. However, the significantly better metabolic stability (lower Cl_mic and longer t1/2) of Ligand A is crucial for a viable drug candidate. The poor Caco-2 and solubility for both are concerning, but can be addressed with formulation strategies.
**Overall Assessment:**
While Ligand B has a slightly better affinity and hERG profile, Ligand A's superior metabolic stability (longer half-life and lower clearance) and better TPSA outweigh these advantages. The poor solubility and permeability are shared concerns, but metabolic stability is often harder to improve later in development.
Output:
1
2025-04-17 22:57:08,567 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (341.298 Da and 353.369 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (89.86) is better than Ligand B (101.29). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand A is comfortably below the 140 A^2 threshold.
**3. logP:** Ligand A (2.606) is within the optimal 1-3 range. Ligand B (0.97) is slightly low, potentially hindering membrane permeability.
**4. H-Bond Donors:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
**5. H-Bond Acceptors:** Ligand A (7) is better than Ligand B (3). While both are reasonable, fewer HBAs are generally preferred.
**6. QED:** Both ligands have good QED values (0.574 and 0.607), indicating good drug-like properties.
**7. DILI Risk:** Ligand A (87.01) has a significantly higher DILI risk than Ligand B (35.595). This is a major concern for Ligand A.
**8. BBB Penetration:** Ligand B (83.986) has better BBB penetration than Ligand A (57.154). While ADRB2 is a cardiovascular target, some CNS effects are possible with beta-blockers, and higher BBB penetration could lead to off-target effects. However, for a cardiovascular target, this isn't as critical as for a CNS target.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-5 and -5.226), which is unusual and suggests poor permeability. This is a significant drawback for both.
**10. Aqueous Solubility:** Both ligands have negative solubility values (-4.108 and -3.249), indicating poor aqueous solubility. This is a concern for formulation and bioavailability.
**11. hERG Inhibition:** Both ligands show low hERG inhibition risk (0.437 and 0.33). This is good.
**12. Microsomal Clearance:** Ligand A (95.739) has significantly higher microsomal clearance than Ligand B (13.429), meaning it will be metabolized more quickly. This is a negative for Ligand A.
**13. In Vitro Half-Life:** Ligand B (-17.414) has a longer in vitro half-life than Ligand A (-32.667). This is preferable.
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (0.359 and 0.017).
**15. Binding Affinity:** Ligand A (-8.1 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.2 kcal/mol). This is a substantial advantage for Ligand A.
**Overall Assessment:**
Ligand A has a much better binding affinity and lower HBD/HBA counts, which are positive attributes. However, its significantly higher DILI risk and higher metabolic clearance are major drawbacks. Ligand B, while having a weaker affinity, presents a much better safety profile (lower DILI) and improved metabolic stability. The poor Caco-2 and solubility for both are concerning, but can potentially be addressed with formulation strategies. Given the cardiovascular context, minimizing toxicity is paramount. The affinity difference, while significant, might be overcome with further optimization of Ligand B.
Therefore, I favor Ligand B.
0
2025-04-17 22:57:08,567 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
The target is ADRB2, a GPCR. Therefore, the priorities are logP, Pgp, TPSA, affinity, and BBB.
Let's analyze each ligand:
* **Molecular Weight:** Both ligands are within the ideal range (200-500 Da).
* **TPSA:** Ligand A (95.58) is higher than Ligand B (59.5). Ligand B is much better here, being well below the 140 threshold for good absorption.
* **logP:** Ligand A (0.75) is a bit low, potentially hindering permeation. Ligand B (3.558) is excellent, falling within the optimal 1-3 range.
* **H-Bond Donors/Acceptors:** Ligand A has 2 HBD and 4 HBA, while Ligand B has 0 HBD and 5 HBA. Both are acceptable.
* **QED:** Ligand B (0.724) has a better QED score than Ligand A (0.474), indicating a more drug-like profile.
* **DILI:** Both are relatively low, with Ligand A at 32.261 and Ligand B at 39.046. Both are acceptable.
* **BBB:** Ligand B (86.817) has a significantly higher BBB penetration score than Ligand A (79.062). While ADRB2 isn't necessarily a CNS target, higher BBB is generally favorable.
* **Caco-2 Permeability:** Ligand A (-5.198) is worse than Ligand B (-4.511).
* **Aqueous Solubility:** Ligand A (-2.79) is better than Ligand B (-4.139).
* **hERG:** Both ligands have very low hERG inhibition liability (0.087 and 0.464 respectively).
* **Microsomal Clearance:** Ligand A (14.574) has a much lower (better) microsomal clearance than Ligand B (112.542), suggesting better metabolic stability.
* **In vitro Half-Life:** Ligand A (-31.562) has a much longer half-life than Ligand B (-5.106).
* **P-gp Efflux:** Both ligands have similar P-gp efflux liability (0.025 and 0.744).
* **Binding Affinity:** Both ligands have the same binding affinity (-6.5 kcal/mol).
**Overall Assessment:**
Ligand B excels in TPSA, logP, BBB, and QED, all critical for a GPCR target. While Ligand A has better solubility, clearance, and half-life, the superior ADME properties of Ligand B, particularly its logP and TPSA, outweigh these benefits. The equal binding affinity means potency isn't a differentiating factor.
**Output:**
0
2025-04-17 22:57:08,568 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (342.374 Da and 346.431 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (76.02) is significantly better than Ligand B (94.48). For a GPCR, keeping TPSA low is beneficial for permeability, and A is well under the 140 A^2 threshold.
3. **logP:** Both ligands have good logP values (2.503 and 1.754), falling within the 1-3 range. Ligand A is slightly higher, which could be a minor advantage for membrane permeability, but both are acceptable.
4. **HBD:** Ligand A (2) and Ligand B (1) are both within the acceptable limit of <=5. Ligand B is slightly better.
5. **HBA:** Ligand A (4) is better than Ligand B (6), both are within the acceptable limit of <=10.
6. **QED:** Both ligands have excellent QED scores (0.88 and 0.896), indicating good drug-like properties. No significant difference.
7. **DILI:** Ligand B (52.036) has a significantly lower DILI risk than Ligand A (70.686). This is a substantial advantage for Ligand B.
8. **BBB:** Both ligands have good BBB penetration (70.997 and 75.262). No significant difference.
9. **Caco-2:** Both ligands have negative Caco-2 permeability values (-4.955 and -5.125). This is unusual and suggests poor permeability. However, the values are similar, so it doesn't differentiate the ligands.
10. **Solubility:** Ligand B (-1.911) is better than Ligand A (-3.437). Better solubility is generally preferred.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.359 and 0.26). No significant difference.
12. **Cl_mic:** Ligand B (-4.627) has a significantly lower (better) microsomal clearance than Ligand A (4.27). This suggests better metabolic stability for Ligand B.
13. **t1/2:** Ligand A (59.045) has a significantly longer in vitro half-life than Ligand B (9.333). This is a significant advantage for Ligand A.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.181 and 0.072). No significant difference.
15. **Binding Affinity:** Both ligands have the same binding affinity (-7.0 kcal/mol). This eliminates affinity as a differentiating factor.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, and affinity. Ligand A has a slightly better logP and similar Pgp and affinity. However, Ligand B has a significantly better TPSA and DILI score, and better Cl_mic and solubility. The longer half-life of Ligand A is appealing, but the lower DILI risk and better metabolic stability of Ligand B are more important for overall drug development.
**Conclusion:**
Considering the balance of properties, especially the lower DILI risk, better metabolic stability, and better solubility of Ligand B, I believe it is the more promising drug candidate.
Output:
0
2025-04-17 22:57:08,568 - INFO - Here's my reasoning and the final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, the most important parameters are binding affinity, logP, TPSA, Pgp efflux, and BBB penetration.
Let's compare the ligands property by property:
1. **MW:** Both ligands (350.394 and 360.445 Da) are within the ideal 200-500 Da range.
2. **TPSA:** Ligand B (49.85) is significantly better than Ligand A (93.21). Lower TPSA generally improves permeability, crucial for GPCR ligands.
3. **logP:** Ligand B (3.058) is slightly higher than Ligand A (1.057), but both are within the optimal 1-3 range. Ligand B is closer to the upper limit, which could raise concerns about solubility, but it's not excessive.
4. **HBD/HBA:** Ligand A has 2 HBD and 5 HBA, while Ligand B has 0 HBD and 3 HBA. Both are acceptable.
5. **QED:** Ligand A (0.8) has a better QED score than Ligand B (0.594), indicating better overall drug-likeness.
6. **DILI:** Ligand B (18.224) has a much lower DILI risk than Ligand A (64.754), a significant advantage.
7. **BBB:** Ligand B (96.472) has excellent BBB penetration, while Ligand A (84.529) is good but not as high. While this isn't *essential* for a cardiovascular target, it could open up possibilities for exploring CNS effects or improved distribution.
8. **Caco-2:** Ligand A (-4.822) has better Caco-2 permeability than Ligand B (-3.991), suggesting better absorption.
9. **Solubility:** Both have very poor solubility (-2.023 and -2.413). This is a significant concern for both compounds.
10. **hERG:** Ligand A (0.227) has a slightly lower hERG risk than Ligand B (0.447), which is preferable.
11. **Cl_mic:** Ligand B (64.878) has a higher microsomal clearance than Ligand A (6.76), meaning it's metabolized faster. This is a disadvantage for Ligand B.
12. **t1/2:** Ligand A (18.278) has a longer in vitro half-life than Ligand B (-6.884), which is a significant advantage.
13. **Pgp:** Ligand A (0.014) has much lower P-gp efflux than Ligand B (0.106), which is a positive.
14. **Binding Affinity:** Ligand A (-6.9 kcal/mol) has a slightly better binding affinity than Ligand B (-5.0 kcal/mol). This is a crucial factor.
**Overall Assessment:**
Ligand A has a better binding affinity, longer half-life, lower Pgp efflux, and lower hERG risk. However, Ligand B excels in TPSA, DILI, and BBB penetration. The significantly lower DILI risk and better TPSA of Ligand B are compelling, especially given the similar logP values. The binding affinity difference, while present, isn't massive enough to completely outweigh the ADME advantages of Ligand B. The poor solubility is a concern for both, but can be addressed with formulation strategies.
Considering the GPCR-specific priorities and the overall balance of properties, Ligand B appears to be the more promising candidate.
**Output:**
0
2025-04-17 22:57:08,568 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (363.483 Da and 346.475 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Both ligands have TPSA values around 71-72 A2, which is acceptable for a non-CNS GPCR target like ADRB2.
**3. logP:** Ligand A (1.694) is slightly lower than Ligand B (2.506). Both are within the optimal 1-3 range, but Ligand B is edging closer to the upper limit, potentially raising concerns about off-target interactions.
**4. H-Bond Donors:** Both have 1 HBD, which is good.
**5. H-Bond Acceptors:** Both have 5 HBA, also good.
**6. QED:** Ligand A (0.808) has a higher QED score than Ligand B (0.746), indicating a more drug-like profile.
**7. DILI:** Ligand A (47.926) has a higher DILI risk than Ligand B (23.885). This is a significant advantage for Ligand B.
**8. BBB:** Both have relatively low BBB penetration (55.332% and 62.699% respectively). This isn't a major concern for a cardiovascular target, but higher is generally preferable. Ligand B is slightly better here.
**9. Caco-2 Permeability:** Both have negative Caco-2 values, indicating poor permeability. This is a concern for both, but Ligand A (-5.005) is slightly better than Ligand B (-4.864).
**10. Aqueous Solubility:** Both have negative solubility values, indicating poor solubility. Ligand B (-2.845) is slightly worse than Ligand A (-1.713).
**11. hERG Inhibition:** Both have very low hERG inhibition risk (0.121 and 0.181). This is excellent for both.
**12. Microsomal Clearance:** Ligand A (32.663) has lower microsomal clearance than Ligand B (36.473), suggesting better metabolic stability.
**13. In vitro Half-Life:** Ligand A (18.548 hours) has a significantly longer half-life than Ligand B (2.786 hours). This is a major advantage for Ligand A, potentially allowing for less frequent dosing.
**14. P-gp Efflux:** Both have very low P-gp efflux liability (0.055 and 0.213).
**15. Binding Affinity:** Ligand A (-7.5 kcal/mol) has a slightly stronger binding affinity than Ligand B (-7.2 kcal/mol). While the difference is not huge, it's enough to be considered.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity) and the general drug-like properties, Ligand A is the more promising candidate. While Ligand B has a lower DILI risk, the significantly longer half-life and slightly better affinity of Ligand A outweigh this benefit. The solubility and permeability issues are similar for both, and the hERG risk is low for both. The higher QED score for Ligand A further supports its selection.
Output:
1
2025-04-17 22:57:08,568 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.443 and 364.383 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (67.87) is higher than Ligand B (40.62). For a cardiovascular GPCR, TPSA is moderately important. Ligand B is better here, being closer to the <90 threshold for better absorption.
3. **logP:** Both ligands have good logP values (2.288 and 2.918), falling within the optimal 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability, but not dramatically so.
4. **HBD:** Ligand A has 1 HBD, while Ligand B has 0. Both are acceptable.
5. **HBA:** Ligand A has 4 HBA, Ligand B has 2. Both are within the acceptable range of <=10.
6. **QED:** Both ligands have good QED scores (0.549 and 0.72), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Both ligands have low DILI risk (35.595 and 31.679 percentile), which is excellent. Ligand B is marginally better.
8. **BBB:** Ligand A (74.254) and Ligand B (94.61) both show good BBB penetration. However, for a cardiovascular target, BBB penetration is less critical than for CNS targets. Ligand B is better.
9. **Caco-2:** Ligand A (-5.176) and Ligand B (-4.468) have negative values, which is unusual. It's difficult to interpret without knowing the scale, but lower (more negative) values generally indicate poorer permeability.
10. **Solubility:** Ligand A (-2.205) and Ligand B (-3.926) have negative solubility values, again making interpretation difficult. Lower (more negative) values suggest poorer solubility.
11. **hERG:** Both ligands have low hERG inhibition risk (0.669 and 0.626), which is excellent.
12. **Cl_mic:** Ligand A (32.428) has a lower microsomal clearance than Ligand B (58.211), suggesting better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand A (-15.413) has a shorter in vitro half-life than Ligand B (-24.003). This is a disadvantage for Ligand A.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.189 and 0.156), which is good.
15. **Binding Affinity:** Ligand A (-7.6) has a slightly better binding affinity than Ligand B (-7.5). While the difference is small (0.1 kcal/mol), it's still a positive for Ligand A.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), and the general drug-like properties, Ligand B appears to be the slightly better candidate. It has better TPSA, QED, DILI, and BBB penetration. While Ligand A has a slightly better affinity and lower Cl_mic, the improvements in ADME properties with Ligand B outweigh this small difference in binding. The negative solubility and Caco-2 values are concerning for both, but the other properties of Ligand B are more favorable.
**Output:**
0
2025-04-17 22:57:08,568 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [355.429, 52.65, 2.272, 1, 3, 0.778, 22.489, 75.223, -4.591, -1.028, 0.659, 18.268, 6.758, 0.02, -6.8]
**Ligand B:** [344.455, 69.64, 2.856, 2, 3, 0.882, 30.322, 60.76, -4.822, -4.285, 0.369, 50.581, -22.067, 0.111, -6.8]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal 200-500 Da range. Ligand B (344.455) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (52.65) is better than Ligand B (69.64). We want TPSA <= 140 for oral absorption, both are well within this.
3. **logP:** Both are within the optimal 1-3 range. Ligand B (2.856) is a bit higher, which *could* be a slight concern for solubility, but not a major issue.
4. **HBD:** Ligand A (1) is better than Ligand B (2). Lower is generally preferred.
5. **HBA:** Both have 3 HBA, which is acceptable.
6. **QED:** Ligand B (0.882) is slightly better than Ligand A (0.778), indicating a more drug-like profile.
7. **DILI:** Ligand A (22.489) has a significantly lower DILI risk than Ligand B (30.322). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (75.223) has a substantially higher BBB penetration percentile than Ligand B (60.76). This is *very* important for a GPCR target, even a cardiovascular one, as some CNS off-target effects are possible.
9. **Caco-2:** Ligand A (-4.591) is better than Ligand B (-4.822), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-1.028) is better than Ligand B (-4.285). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.659) is better than Ligand B (0.369), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand A (18.268) has a much lower microsomal clearance than Ligand B (50.581), suggesting better metabolic stability.
13. **t1/2:** Ligand A (6.758) has a positive half-life, while Ligand B (-22.067) has a negative half-life.
14. **Pgp:** Ligand A (0.02) is significantly better than Ligand B (0.111), indicating lower P-gp efflux.
15. **Affinity:** Both have the same binding affinity (-6.8 kcal/mol).
**Overall Assessment:**
Given the GPCR-specific priorities (logP, Pgp, TPSA, and affinity) and the general guidelines, Ligand A is the stronger candidate. While Ligand B has a slightly better QED, Ligand A excels in several critical ADME properties: lower DILI risk, significantly better BBB penetration, better solubility, lower hERG risk, and much better metabolic stability (lower Cl_mic and positive t1/2). The improved Pgp profile of Ligand A is also beneficial. The similar binding affinity makes the ADME advantages of Ligand A decisive.
Output:
1
2025-04-17 22:57:08,568 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (358.423 and 376.4 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (95.42) is slightly higher than Ligand B (67.43). For a cardiovascular GPCR, TPSA isn't a *major* concern unless it's excessively high, but lower is generally preferable for permeability. Ligand B has a clear advantage.
3. **logP:** Both ligands have good logP values (1.726 and 2.666), falling within the optimal 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Both ligands have 2 H-bond donors, which is within the acceptable limit of <=5. No difference.
5. **HBA:** Ligand A has 6 H-bond acceptors, while Ligand B has 4. Both are below the 10 threshold. Ligand B is slightly better.
6. **QED:** Ligand A (0.868) has a significantly better QED score than Ligand B (0.732), indicating a more drug-like profile. This is a substantial advantage for Ligand A.
7. **DILI:** Both ligands have acceptable DILI risk (60.217 and 57.658), both being below the 60 threshold. No significant difference.
8. **BBB:** Ligand B (81.078) has a much higher BBB penetration percentile than Ligand A (40.093). While ADRB2 isn't a CNS target, some peripheral exposure can be minimized with lower BBB penetration. However, this isn't a primary concern.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.306 and -4.657), which is unusual and suggests poor permeability. This is a significant drawback for both.
10. **Solubility:** Both ligands have poor aqueous solubility (-4.126 and -3.775). This is a concern for bioavailability.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.09 and 0.392). This is excellent.
12. **Cl_mic:** Ligand A (37.354) has a lower microsomal clearance than Ligand B (52.303), suggesting better metabolic stability. This is a positive for Ligand A.
13. **t1/2:** Ligand A (-26.268) has a much more negative in vitro half-life than Ligand B (-11.597). This is a *major* drawback for Ligand A, indicating very rapid metabolism.
14. **Pgp:** Ligand A (0.035) has a much lower P-gp efflux liability than Ligand B (0.174). This is a positive for Ligand A.
15. **Binding Affinity:** Ligand B (-6.0) has a significantly stronger binding affinity than Ligand A (-3.1). This is a *critical* advantage for Ligand B, easily outweighing most other differences.
**Overall Assessment:**
Ligand B has a significantly stronger binding affinity, which is the most important factor for GPCR targets. While Ligand A has better QED and lower Cl_mic and Pgp, the very poor in vitro half-life (-26.268) is a deal-breaker. The higher BBB penetration of Ligand B isn't a major concern for a cardiovascular target. Both ligands have permeability and solubility issues, but the potency advantage of Ligand B is decisive.
Output:
0
2025-04-17 22:57:08,568 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (342.395 and 344.459 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (74.45) is slightly higher than Ligand B (65.54). Both are below the 140 threshold for oral absorption, but closer to the 90 threshold for CNS targets (less relevant here, but still a positive). Ligand B is preferable.
3. **logP:** Ligand A (3.367) is within the optimal 1-3 range, while Ligand B (1.662) is towards the lower end. For a GPCR, a slightly higher logP is often beneficial for membrane permeability and receptor engagement. Ligand A is preferable.
4. **HBD:** Ligand A (0) is better than Ligand B (1). Fewer HBDs generally improve permeability. Ligand A is preferable.
5. **HBA:** Ligand A (6) is higher than Ligand B (4). Lower HBA is generally preferred for permeability. Ligand B is preferable.
6. **QED:** Ligand B (0.902) has a significantly better QED score than Ligand A (0.567), indicating a more drug-like profile. Ligand B is preferable.
7. **DILI:** Ligand B (20.396) has a much lower DILI risk than Ligand A (73.09). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (81.776) has a better BBB penetration score than Ligand B (62.621). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be useful for understanding off-target effects.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.784 and -4.735), which is unusual and suggests poor permeability. This is a red flag for both, but not a deciding factor between them.
10. **Solubility:** Ligand B (-1.739) has better solubility than Ligand A (-4.029). Solubility is important for bioavailability. Ligand B is preferable.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.141 and 0.231). No significant difference.
12. **Cl_mic:** Ligand B (3.918) has significantly lower microsomal clearance than Ligand A (68.982), indicating better metabolic stability. This is a major advantage for Ligand B.
13. **t1/2:** Ligand B (5.172) has a longer in vitro half-life than Ligand A (-1.216). This is a significant advantage for Ligand B.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.315 and 0.025). Ligand B is slightly better.
15. **Binding Affinity:** Ligand B (-8.1 kcal/mol) has a significantly stronger binding affinity than Ligand A (-7.2 kcal/mol). This is a crucial advantage, as a 0.9 kcal/mol difference is substantial.
**Overall Assessment:**
Ligand B clearly outperforms Ligand A in most critical ADME-Tox properties (DILI, Cl_mic, t1/2, QED, Solubility) and, crucially, has a significantly stronger binding affinity. While Ligand A has a slightly better logP and BBB, these are less important for a peripheral GPCR like ADRB2, and are outweighed by the substantial advantages of Ligand B. The negative Caco-2 values are concerning for both, but the overall profile of Ligand B is far more promising.
Output:
0
2025-04-17 22:57:08,568 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
The ADRB2 receptor is a GPCR, so the priorities are logP, Pgp, TPSA, BBB, and affinity. Let's compare the ligands step-by-step:
1. **MW:** Both ligands (342.395 and 345.535 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (71.03) is higher than Ligand B (55.63). Both are below the 140 threshold for oral absorption, but B is better.
3. **logP:** Ligand A (2.15) is within the optimal 1-3 range. Ligand B (4.309) is higher, potentially leading to solubility issues and off-target effects. This favors A.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable.
5. **HBA:** Both ligands have 5 HBA, which is acceptable.
6. **QED:** Ligand A (0.842) has a better QED score than Ligand B (0.642), indicating a more drug-like profile.
7. **DILI:** Ligand A (42.885) has a slightly higher DILI risk than Ligand B (27.801), but both are below the concerning 60 threshold.
8. **BBB:** Ligand B (78.402) has a significantly higher BBB penetration percentile than Ligand A (55.176). While not strictly necessary for ADRB2 (a cardiovascular target), higher BBB is rarely detrimental.
9. **Caco-2:** Ligand A (-4.9) is better than Ligand B (-5.155), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-3.106) is better than Ligand B (-4.303).
11. **hERG:** Ligand A (0.841) has a slightly higher hERG risk than Ligand B (0.353). This is a concern.
12. **Cl_mic:** Ligand A (51.329) and Ligand B (43.723) are comparable. Lower is better, so B is slightly favored.
13. **t1/2:** Ligand A (5.292) has a positive half-life, while Ligand B (-10.583) has a negative half-life. This is a huge difference.
14. **Pgp:** Ligand A (0.388) has lower P-gp efflux than Ligand B (0.348). Lower is better.
15. **Affinity:** Ligand A (-7.4 kcal/mol) has a better binding affinity than Ligand B (-6.1 kcal/mol). This is a significant advantage (1.3 kcal/mol difference).
**Overall Assessment:**
Ligand A has a significantly better binding affinity and a better QED score. It also has better Caco-2 permeability and solubility. Ligand B has better BBB penetration and lower hERG risk, but the affinity difference is substantial. The higher logP of Ligand B is a concern. The negative half-life of Ligand B is a major concern. Considering the importance of potency for GPCR targets, and the overall balance of properties, Ligand A is the more promising candidate.
**Output:**
1
2025-04-17 22:57:08,569 - INFO - Batch 369 complete. Total preferences: 5904
2025-04-17 22:57:08,569 - INFO - Processing batch 370/512...
2025-04-17 22:57:58,606 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, the most important parameters are binding affinity, logP, TPSA, Pgp efflux, and to a lesser extent, BBB.
Let's compare the ligands property by property:
1. **MW:** Both ligands (352.435 and 343.387 Da) are within the ideal range (200-500 Da).
2. **TPSA:** Ligand A (107.7) is slightly higher than Ligand B (98.14). Both are acceptable for oral absorption (<140), but Ligand B is preferable.
3. **logP:** Ligand A (0.032) is quite low, potentially hindering membrane permeability. Ligand B (0.739) is better, falling within the optimal range (1-3). This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (2), but both are acceptable.
5. **HBA:** Both ligands have 6 HBA, which is acceptable.
6. **QED:** Ligand B (0.834) has a significantly higher QED score than Ligand A (0.548), indicating better overall drug-likeness.
7. **DILI:** Ligand A (20.085) has a much lower DILI risk than Ligand B (70.182). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (40.132) has a lower BBB penetration than Ligand B (36.371), but BBB is less critical for a cardiovascular target.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.142 and -5.197), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Both ligands have negative solubility values (-1.243 and -2.042), indicating poor aqueous solubility. This is a concern for both.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.156 and 0.048).
12. **Cl_mic:** Ligand A (-7.228) has a much lower (better) microsomal clearance than Ligand B (-2.631), indicating better metabolic stability.
13. **t1/2:** Ligand A (14.889) has a longer in vitro half-life than Ligand B (4.021), which is desirable.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.019 and 0.034).
15. **Binding Affinity:** Ligand A (-6.9 kcal/mol) has a slightly better binding affinity than Ligand B (-6.6 kcal/mol), but the difference is not substantial.
**Overall Assessment:**
Ligand B has a better logP and QED, which are important for GPCRs. However, Ligand A has a significantly lower DILI risk, better metabolic stability (lower Cl_mic), and a longer half-life. The slightly better affinity of Ligand A is a bonus. Given the cardiovascular target and the importance of minimizing toxicity, the lower DILI risk and improved metabolic stability of Ligand A outweigh the slightly better logP and QED of Ligand B.
**Output:**
1
2025-04-17 22:57:58,606 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.394 and 368.543 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (68.62) is better than Ligand B (75.27). Both are below the 140 threshold for oral absorption, but lower is generally preferred.
3. **logP:** Both ligands have good logP values (1.926 and 2.283), falling within the optimal 1-3 range. Ligand B is slightly higher, which could potentially lead to slightly reduced solubility but isn't a major concern.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (3). Similar to HBD, lower HBA is generally better for permeability.
6. **QED:** Ligand A (0.79) is slightly better than Ligand B (0.69), indicating a more drug-like profile.
7. **DILI:** Ligand B (41.024) has a lower DILI risk than Ligand A (47.848), which is a positive attribute.
8. **BBB:** Ligand A (82.086) has significantly better BBB penetration potential than Ligand B (66.615). While ADRB2 isn't exclusively a CNS target, some cardiovascular effects are mediated via CNS pathways, and better BBB penetration can be advantageous.
9. **Caco-2:** Ligand A (-4.308) has a better Caco-2 permeability than Ligand B (-5.058). Higher values indicate better intestinal absorption.
10. **Solubility:** Ligand A (-2.237) has better aqueous solubility than Ligand B (-3.997). This is important for formulation and bioavailability.
11. **hERG:** Both ligands have low hERG inhibition liability (0.492 and 0.427), which is excellent.
12. **Cl_mic:** Ligand B (69.633) has a lower microsomal clearance than Ligand A (78.303), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-23.771) has a significantly longer in vitro half-life than Ligand A (-2.479). This is a major advantage, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.069 and 0.262).
15. **Affinity:** Ligand A (-6.1) has a slightly better binding affinity than Ligand B (-5.3). While both are good, the 0.8 kcal/mol difference is notable.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A excels in TPSA, logP, and affinity. Ligand B has a better metabolic stability profile (lower Cl_mic and longer t1/2) and lower DILI risk. The affinity difference is significant enough to favor Ligand A, and the slightly better BBB penetration is a bonus.
**Overall Assessment:**
While Ligand B has advantages in metabolic stability and DILI, Ligand A's superior affinity, better solubility, and slightly better BBB penetration, combined with acceptable ADME properties, make it the more promising candidate. The affinity difference is substantial enough to outweigh the benefits of Ligand B's improved metabolic profile.
Output:
1
2025-04-17 22:57:58,606 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Step-by-step comparison:**
1. **MW:** Both ligands (364.431 and 370.475 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (75.21) is significantly better than Ligand A (109.22). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (1.008) is slightly better than Ligand B (0.401), falling comfortably within the 1-3 range. Ligand B is a bit low, potentially hindering permeability.
4. **HBD:** Ligand A (2) is better than Ligand B (0). While 0 is not inherently bad, a small number of HBDs can aid solubility.
5. **HBA:** Both ligands have 7 HBA, which is acceptable.
6. **QED:** Ligand A (0.819) is better than Ligand B (0.722), indicating a more drug-like profile.
7. **DILI:** Ligand B (55.138) is significantly better than Ligand A (82.241). Lower DILI risk is a major advantage.
8. **BBB:** Both are relatively low, which is fine for a cardiovascular target. Ligand B (57.968) is slightly higher than Ligand A (53.781).
9. **Caco-2:** Ligand A (-5.078) is better than Ligand B (-4.586), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-3.114) is better than Ligand B (-1.611).
11. **hERG:** Both ligands have very low hERG risk (0.165 and 0.281 respectively).
12. **Cl_mic:** Ligand B (39.332) is much better than Ligand A (0.063). Lower clearance indicates better metabolic stability.
13. **t1/2:** Ligand A (55.124) is better than Ligand B (-16.219).
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.018 and 0.061 respectively).
15. **Binding Affinity:** Ligand A (-6.8) is slightly better than Ligand B (-6.2). While the difference is not huge, it's a factor.
**GPCR-Specific Priorities:** For ADRB2 (a GPCR), logP, TPSA, and affinity are important. Ligand A has a better logP and affinity, but Ligand B has a much better TPSA and significantly lower DILI risk and better metabolic stability (Cl_mic).
**Overall Assessment:**
Ligand A has a slight edge in binding affinity, solubility, and Caco-2 permeability. However, Ligand B's significantly lower DILI risk and improved metabolic stability (Cl_mic) are crucial advantages. The lower TPSA of Ligand B is also beneficial. The difference in binding affinity is not large enough to outweigh the ADME benefits of Ligand B. Therefore, I favor Ligand B.
Output:
0
2025-04-17 22:57:58,607 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [339.359, 101.1 , 0.736, 2. , 7. , 0.733, 77.549, 54.866, -5.303, -2.289, 0.148, -16.307, 7.244, 0.029, -6.3 ]**
**Ligand B: [357.401, 71. , 1.94 , 1. , 4. , 0.836, 35.789, 85.459, -4.517, -2.952, 0.281, 21.336, -16.273, 0.047, -6.5 ]**
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). A (339.359) is slightly preferred due to being closer to the lower end, potentially aiding permeability.
2. **TPSA:** Ligand A (101.1) is higher than Ligand B (71). For a cardiovascular GPCR, TPSA isn't *as* critical as for CNS targets, but lower is generally better for absorption. Ligand B is significantly better here.
3. **logP:** Ligand B (1.94) is within the optimal range (1-3), while Ligand A (0.736) is a bit low, potentially hindering membrane permeability. Ligand B is favored.
4. **H-Bond Donors:** Both are acceptable (A: 2, B: 1), well below the threshold of 5.
5. **H-Bond Acceptors:** Both are acceptable (A: 7, B: 4), below the threshold of 10.
6. **QED:** Both have good QED scores (A: 0.733, B: 0.836), indicating drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (77.549) has a higher DILI risk than Ligand B (35.789). This is a significant concern, and favors Ligand B.
8. **BBB:** BBB penetration is not a primary concern for a cardiovascular target. Ligand B (85.459) is higher than Ligand A (54.866).
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand B (-4.517) is slightly less negative than Ligand A (-5.303), suggesting marginally better absorption.
10. **Aqueous Solubility:** Both have negative solubility values, which is also unusual. Ligand B (-2.952) is slightly better than Ligand A (-2.289).
11. **hERG:** Both have very low hERG inhibition risk (A: 0.148, B: 0.281).
12. **Microsomal Clearance:** Ligand A (-16.307) has a much lower (better) microsomal clearance than Ligand B (21.336), indicating greater metabolic stability. This is a strong advantage for Ligand A.
13. **In vitro Half-Life:** Both have very short in vitro half-lives (A: 7.244, B: -16.273). This is a concern for both, but the negative value for B is concerning.
14. **P-gp Efflux:** Both have very low P-gp efflux liability (A: 0.029, B: 0.047).
15. **Binding Affinity:** Ligand B (-6.5) has slightly better binding affinity than Ligand A (-6.3). While the difference is small, it's a positive for Ligand B.
**Overall Assessment:**
Ligand B has advantages in logP, TPSA, QED, DILI risk, and binding affinity. However, Ligand A has a significantly better microsomal clearance, which is crucial for *in vivo* exposure. The DILI risk associated with Ligand A is a major drawback. While the binding affinity difference is small, the overall profile of Ligand B is more favorable, particularly considering the DILI risk of Ligand A.
Output:
0
2025-04-17 22:57:58,607 - INFO - Here's my reasoning and output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands (372.368 and 342.439 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (71.19) is slightly higher than Ligand B (62.55). Both are below the 140 threshold for oral absorption, but closer to the 90 threshold for CNS targets (less relevant here, but still a positive). Ligand B is slightly preferred.
3. **logP:** Ligand A (2.776) is within the optimal 1-3 range. Ligand B (3.707) is a bit higher, approaching the upper limit. Ligand A is slightly preferred.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable, below the 5 threshold. Ligand B is slightly preferred.
5. **HBA:** Ligand A (4) and Ligand B (3) are both acceptable, below the 10 threshold. Ligand B is slightly preferred.
6. **QED:** Ligand A (0.848) is significantly better than Ligand B (0.655), indicating a more drug-like profile. Ligand A is strongly preferred.
7. **DILI:** Ligand A (65.413) is higher than Ligand B (58.744), indicating a slightly higher risk of liver injury. Ligand B is preferred.
8. **BBB:** Both ligands have reasonable BBB penetration (Ligand A: 76.347, Ligand B: 63.319). Not a primary concern for ADRB2, but Ligand A is slightly better.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Both ligands have negative solubility values, which is also unusual and suggests poor solubility. This is a significant concern for both.
11. **hERG:** Ligand A (0.527) is better than Ligand B (0.257), indicating lower cardiotoxicity risk. Ligand A is preferred.
12. **Cl_mic:** Ligand A (4.538) has a much lower microsomal clearance than Ligand B (64.921), suggesting better metabolic stability. Ligand A is strongly preferred.
13. **t1/2:** Ligand A (13.217) has a shorter half-life than Ligand B (46.191). Ligand B is preferred.
14. **Pgp:** Ligand A (0.498) is better than Ligand B (0.524), indicating lower P-gp efflux. Ligand A is slightly preferred.
15. **Binding Affinity:** Ligand A (-8.5 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.9 kcal/mol) - a difference of 1.6 kcal/mol. This is a major advantage.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), we prioritize logP, Pgp, TPSA, and affinity. Ligand A performs better in affinity, logP, and Pgp. While TPSA is similar, the strong affinity and better metabolic stability of Ligand A outweigh the slight TPSA difference.
**Overall Assessment:**
Despite the unusual negative Caco-2 and solubility values for both compounds (which would require further investigation), Ligand A is the stronger candidate. Its significantly higher binding affinity, better QED, lower DILI risk, lower microsomal clearance, and better Pgp profile outweigh the slightly better half-life of Ligand B. The affinity difference is substantial enough to overcome the other minor drawbacks.
Output:
1
2025-04-17 22:57:58,607 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (365.455 and 362.861 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Both ligands (87.74 and 88.32) are below the 140 A^2 threshold for good oral absorption, and acceptable for a cardiovascular GPCR. No significant difference.
3. **logP:** Ligand A (1.44) is slightly better than Ligand B (2.396), being closer to the optimal 1-3 range. Ligand B is still within range, but edging towards potential solubility issues.
4. **HBD:** Both ligands have 2 HBD, which is within the ideal limit of <=5. No difference.
5. **HBA:** Ligand A has 5 HBA, and Ligand B has 4. Both are within the ideal limit of <=10.
6. **QED:** Ligand A (0.826) has a better QED score than Ligand B (0.787), indicating a more drug-like profile.
7. **DILI:** Ligand A (69.678) has a higher DILI risk than Ligand B (53.625), which is unfavorable.
8. **BBB:** Ligand B (72.237) has a significantly better BBB penetration percentile than Ligand A (53.044). While ADRB2 isn't necessarily a CNS target, better BBB penetration can sometimes correlate with improved distribution and reduced off-target effects.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.072 and -5.146), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand A (-2.019) has better aqueous solubility than Ligand B (-3.425).
11. **hERG:** Ligand A (0.197) has a lower hERG inhibition liability than Ligand B (0.611), which is a major advantage for cardiovascular safety.
12. **Cl_mic:** Ligand A (-15.687) has significantly lower (better) microsomal clearance than Ligand B (13.683), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-21.623) has a much longer in vitro half-life than Ligand A (12.965), which is a desirable trait.
14. **Pgp:** Ligand A (0.045) has lower P-gp efflux liability than Ligand B (0.078), which is favorable for bioavailability.
15. **Affinity:** Ligand B (-6.6 kcal/mol) has a stronger binding affinity than Ligand A (-5.4 kcal/mol). This is a substantial difference (1.2 kcal/mol) and a major factor.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand B excels in affinity, which is the most critical factor. While Ligand A has advantages in solubility, hERG, and metabolic stability, the significant affinity difference of Ligand B outweighs these benefits. The poor Caco-2 values are concerning for both, but can be addressed during lead optimization.
**Conclusion:**
Despite the higher DILI risk and slightly worse solubility, the significantly stronger binding affinity of Ligand B makes it the more promising candidate. The improved half-life is also a significant benefit.
Output:
0
2025-04-17 22:57:58,607 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (370.718 Da and 363.443 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (68.52) is significantly better than Ligand B (102.02). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 cutoff. Ligand B is approaching the upper limit.
3. **logP:** Ligand A (3.842) is at the higher end of the optimal range (1-3), while Ligand B (1.298) is at the lower end. While Ligand B isn't *bad*, a higher logP can be beneficial for membrane permeability and receptor binding for GPCRs.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (5) is better than Ligand B (7). Similar reasoning to HBD - fewer is generally better for permeability.
6. **QED:** Both ligands have similar, good QED scores (0.76 and 0.797).
7. **DILI:** Ligand A (96.51) has a higher DILI risk than Ligand B (87.01). This is a significant concern for Ligand A.
8. **BBB:** Ligand A (65.374) has a better BBB score than Ligand B (35.556). While not a primary concern for a cardiovascular target, some level of BBB penetration can be useful.
9. **Caco-2:** Ligand A (-4.627) is better than Ligand B (-5.557). Higher Caco-2 permeability suggests better intestinal absorption.
10. **Solubility:** Ligand A (-5.101) is better than Ligand B (-3.191). Higher aqueous solubility is generally preferred.
11. **hERG:** Ligand A (0.598) is better than Ligand B (0.039). Lower hERG inhibition is crucial to avoid cardiotoxicity, a major concern for a cardiovascular drug.
12. **Cl_mic:** Ligand A (54.366) has a lower (better) microsomal clearance than Ligand B (11.923). Lower clearance indicates greater metabolic stability.
13. **t1/2:** Ligand A (0.438) has a shorter half-life than Ligand B (-5.46). This is a negative for Ligand A.
14. **Pgp:** Ligand A (0.537) is better than Ligand B (0.038). Lower P-gp efflux is desirable for improved bioavailability.
15. **Binding Affinity:** Ligand B (-7.2 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.2 kcal/mol). This is a substantial advantage, exceeding the 1.5 kcal/mol threshold.
**Overall Assessment:**
Ligand B has a significantly better binding affinity, which is the most important factor. It also has a lower DILI risk and better hERG profile, both critical for a cardiovascular drug. While Ligand A has some advantages in TPSA, solubility, and Pgp efflux, the superior affinity and safety profile of Ligand B outweigh these benefits. The lower half-life of Ligand B is a potential drawback, but it can be addressed through formulation strategies.
Output:
0
2025-04-17 22:57:58,607 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (347.503 and 347.419 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (81.99) is significantly better than Ligand B (99.68). For a GPCR, keeping TPSA lower is desirable for permeability. Ligand B is approaching a level that could hinder absorption.
3. **logP:** Ligand A (3.44) is good, within the optimal 1-3 range. Ligand B (1.523) is on the lower side, potentially leading to permeability issues, but not drastically so.
4. **HBD:** Both ligands have 2 HBD, which is acceptable.
5. **HBA:** Ligand A has 3 HBA, while Ligand B has 5. Both are within the acceptable limit of 10, but Ligand A is preferable.
6. **QED:** Both ligands have good QED scores (0.74 and 0.843), indicating good drug-like properties.
7. **DILI:** Both have similar, relatively low DILI risk (21.714 and 22.683 percentile).
8. **BBB:** Ligand A (63.784) has a moderate BBB penetration, while Ligand B (29.003) is quite low. While ADRB2 isn't exclusively a CNS target, some brain penetration can be beneficial and isn't detrimental in this case.
9. **Caco-2:** Ligand A (-4.699) is better than Ligand B (-5.44). Higher values are better, indicating improved intestinal absorption.
10. **Solubility:** Ligand A (-4.249) is better than Ligand B (-1.74). Higher values are better.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.442 and 0.089).
12. **Cl_mic:** Ligand B (-26.937) has significantly lower microsomal clearance than Ligand A (67.575), indicating better metabolic stability. This is a substantial advantage.
13. **t1/2:** Ligand B (-9.411) has a longer in vitro half-life than Ligand A (-11.187), which is also a positive.
14. **Pgp:** Ligand A (0.139) has lower P-gp efflux liability than Ligand B (0.009), which is preferable.
15. **Binding Affinity:** Ligand A (-6.8 kcal/mol) has slightly better binding affinity than Ligand B (-6.0 kcal/mol). This is a 0.8 kcal/mol difference, which is significant.
**Overall Assessment:**
Ligand A has advantages in TPSA, solubility, Caco-2 permeability, Pgp efflux, and binding affinity. Ligand B excels in metabolic stability (Cl_mic) and half-life. Considering ADRB2 is a GPCR, the lower TPSA and better permeability of Ligand A are important. The slightly stronger binding affinity of Ligand A is also a significant factor. While the improved metabolic stability of Ligand B is valuable, the differences in permeability and binding outweigh this benefit.
**Output:**
1
2025-04-17 22:57:58,608 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (334.379) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (47.1) is significantly better than Ligand A (77). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally improves absorption.
3. **logP:** Ligand A (2.786) is optimal, while Ligand B (0.506) is quite low. This is a significant drawback for Ligand B, potentially hindering membrane permeability and bioavailability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (0). Having at least one HBD can aid solubility.
5. **HBA:** Ligand A (5) is better than Ligand B (4). Both are within acceptable limits.
6. **QED:** Ligand A (0.776) is significantly better than Ligand B (0.497), indicating a more drug-like profile.
7. **DILI:** Ligand B (13.3) is *much* better than Ligand A (84.645). This is a critical advantage for Ligand B, as liver toxicity is a major concern.
8. **BBB:** Both ligands have similar BBB penetration (Ligand A: 53.276, Ligand B: 54.517). Since ADRB2 is not a CNS target, this is less important.
9. **Caco-2:** Both ligands have similar, poor Caco-2 permeability (-4.77 and -4.627).
10. **Solubility:** Ligand A (-3.585) is better than Ligand B (-0.357).
11. **hERG:** Both ligands show low hERG inhibition risk (0.233 and 0.255).
12. **Cl_mic:** Ligand B (7.489) has much lower microsomal clearance than Ligand A (68.92), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-39.76) has a much longer in vitro half-life than Ligand B (-11.855).
14. **Pgp:** Both ligands have low P-gp efflux (0.064 and 0.01).
15. **Affinity:** Ligand A (-7.3) has a slightly better binding affinity than Ligand B (-6.7). While a 0.6 kcal/mol difference is noticeable, it isn't overwhelming.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, and affinity are key. Ligand A has a better logP and slightly better affinity. However, Ligand B's dramatically lower DILI risk and significantly improved metabolic stability (lower Cl_mic) are very important. The poor Caco-2 permeability is a concern for both, but can sometimes be overcome with formulation strategies.
**Overall Assessment:**
While Ligand A has a slight edge in binding affinity and solubility, the substantially lower DILI risk and better metabolic stability of Ligand B are more compelling. The low logP of Ligand B is a significant drawback, but the other benefits outweigh this concern, especially considering the potential for formulation optimization to address permeability.
Output:
0
2025-04-17 22:57:58,608 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (375.889 and 350.438 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (56.32) is significantly better than Ligand A (71.76). ADRB2 is a cardiovascular target, so CNS penetration isn't crucial, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (3.376 and 2.824), falling within the 1-3 optimal range. Ligand B is slightly lower, which might be marginally better for solubility.
4. **HBD:** Ligand A has 1 HBD, while Ligand B has 0. Both are acceptable, but fewer HBDs can sometimes improve membrane permeability.
5. **HBA:** Ligand A has 8 HBA, and Ligand B has 6. Both are within the acceptable range of <=10.
6. **QED:** Both ligands have similar QED values (0.689 and 0.659), indicating good drug-likeness.
7. **DILI:** Ligand B (14.114) has a *much* lower DILI risk than Ligand A (90.927). This is a major advantage for Ligand B.
8. **BBB:** Ligand B (94.029) has a higher BBB penetration percentile than Ligand A (77.239). While not a primary concern for a cardiovascular target, higher BBB is rarely detrimental.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.996 and -4.524), indicating poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand B (-2.364) has a slightly better solubility score than Ligand A (-3.977).
11. **hERG:** Both ligands have low hERG inhibition liability (0.704 and 0.831), which is good.
12. **Cl_mic:** Ligand B (42.683) has a lower microsomal clearance than Ligand A (64.944), suggesting better metabolic stability.
13. **t1/2:** Ligand B (29.74) has a longer in vitro half-life than Ligand A (22.969), which is desirable.
14. **Pgp:** Both ligands have similar Pgp efflux liability (0.383 and 0.4).
15. **Binding Affinity:** Ligand B (-6.8 kcal/mol) has a slightly better binding affinity than Ligand A (-6.1 kcal/mol). This 0.7 kcal/mol difference is significant and could outweigh some of the ADME drawbacks.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in TPSA, has comparable logP, similar Pgp, and a better affinity. The significantly lower DILI risk of Ligand B is also a major factor. While both have poor Caco-2 permeability, the overall profile of Ligand B is more favorable.
**Conclusion:**
Ligand B demonstrates a better balance of properties, particularly with its significantly reduced DILI risk, improved metabolic stability, longer half-life, and slightly improved binding affinity. The lower TPSA is also beneficial.
Output:
0
2025-04-17 22:57:58,608 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (354.535 Da and 351.422 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (78.43) is slightly higher than Ligand B (69.72). Both are below the 140 A^2 threshold for good oral absorption, but Ligand B is preferable due to being closer to the 90 A^2 target for GPCRs.
**3. logP:** Ligand A (3.157) is within the optimal 1-3 range. Ligand B (0.505) is *below* this range, potentially hindering membrane permeability. This is a significant drawback for Ligand B.
**4. H-Bond Donors:** Ligand A (3) is acceptable, while Ligand B (1) is even better, minimizing potential permeability issues.
**5. H-Bond Acceptors:** Ligand A (3) and Ligand B (4) are both within the acceptable limit of 10.
**6. QED:** Ligand B (0.783) has a better QED score than Ligand A (0.527), suggesting a more drug-like profile.
**7. DILI:** Ligand A (15.898) has a significantly lower DILI risk than Ligand B (26.406). This is a crucial advantage for Ligand A.
**8. BBB:** Ligand B (76.541) has a slightly higher BBB penetration percentile than Ligand A (65.374). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be beneficial for distribution.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests a potential issue with the data or the compounds themselves. However, Ligand B (-4.881) is slightly worse than Ligand A (-4.552).
**10. Aqueous Solubility:** Both ligands have negative solubility values, which is also unusual. Ligand A (-2.926) is slightly better than Ligand B (-1.681).
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.475 and 0.158 respectively), which is excellent.
**12. Microsomal Clearance:** Ligand B (8.284) has significantly lower microsomal clearance than Ligand A (69.62), indicating better metabolic stability.
**13. In vitro Half-Life:** Ligand B (7.527) has a much longer in vitro half-life than Ligand A (1.631), which is a significant advantage.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.159 and 0.01 respectively), which is desirable.
**15. Binding Affinity:** Ligand A (-7.0) has a slightly better binding affinity than Ligand B (-5.0). This 2 kcal/mol difference is substantial and can often outweigh minor ADME drawbacks.
**Overall Assessment:**
While Ligand B has advantages in QED, metabolic stability (Cl_mic, t1/2), and BBB penetration, Ligand A's superior binding affinity and significantly lower DILI risk are more critical for a viable drug candidate. The logP value for Ligand B is concerning, potentially leading to poor permeability. The negative solubility and Caco-2 values are concerning for both, but the differences aren't decisive. Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity), the stronger binding affinity of Ligand A, combined with the lower DILI risk, makes it the more promising candidate.
Output:
1
2025-04-17 22:57:58,608 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands have a MW of 350.503 Da, falling well within the ideal 200-500 Da range. No difference here.
2. **TPSA:** Both ligands have a TPSA of 49.85, which is acceptable for a non-CNS GPCR target like ADRB2.
3. **logP:** Ligand A (3.55) is slightly higher than Ligand B (2.543). Both are within the optimal 1-3 range, but A is closer to the upper limit.
4. **HBD:** Both have 0 HBD, which is good.
5. **HBA:** Both have 3 HBA, which is good.
6. **QED:** Both ligands have good QED scores (A: 0.688, B: 0.709), indicating good drug-likeness. B is slightly better.
7. **DILI:** Ligand A (43.66) has a moderate DILI risk, while Ligand B (11.632) has a very low DILI risk. This is a significant advantage for Ligand B.
8. **BBB:** Both have high BBB penetration (A: 84.917, B: 88.329). While ADRB2 isn't a primary CNS target, some off-target CNS effects are possible, and higher BBB is generally preferable. Ligand B is slightly better.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. However, the scale is not specified, so it is difficult to interpret.
10. **Solubility:** Both have negative solubility values, indicating poor solubility. However, the scale is not specified, so it is difficult to interpret.
11. **hERG:** Both have low hERG inhibition liability (A: 0.684, B: 0.367). Ligand B is significantly better here, reducing cardiotoxicity risk.
12. **Cl_mic:** Ligand A (54.121) has a lower (better) microsomal clearance than Ligand B (66.738), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-15.815) has a negative in vitro half-life, indicating very rapid metabolism. Ligand B (0.062) has a very short half-life, but is still better than A.
14. **Pgp:** Both have low Pgp efflux liability (A: 0.383, B: 0.113). Ligand B is better.
15. **Binding Affinity:** Ligand A (-7.5 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.5 kcal/mol). This is a 1.0 kcal/mol difference, which is substantial.
**GPCR-Specific Priorities & Overall Assessment:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand A has a slightly better logP and significantly better affinity. However, Ligand B excels in safety parameters (DILI, hERG) and has better BBB penetration and Pgp efflux. The substantial difference in binding affinity of Ligand A is a major advantage, potentially outweighing the ADME drawbacks. However, the very poor half-life of Ligand A is a serious concern. The DILI and hERG profiles of Ligand B are significantly better, making it a safer starting point for optimization.
Considering the balance, I believe Ligand B is the more viable drug candidate due to its superior safety profile and reasonable ADME properties, despite the slightly lower binding affinity. The affinity difference can be addressed through further optimization, while mitigating the DILI and hERG risks of Ligand A would be much more challenging.
Output:
0
2025-04-17 22:57:58,608 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (343.362 Da) is well within the ideal range (200-500 Da). Ligand B (379.917 Da) is also acceptable, but slightly higher.
2. **TPSA:** Ligand A (80.55) is excellent, well below the 140 threshold for oral absorption. Ligand B (70.84) is even better.
3. **logP:** Ligand A (2.727) is optimal (1-3). Ligand B (4.135) is slightly higher, potentially leading to solubility issues, but still within a reasonable range.
4. **HBD:** Ligand A (2) is good. Ligand B (1) is also good.
5. **HBA:** Ligand A (5) is good. Ligand B (6) is also acceptable.
6. **QED:** Ligand A (0.721) is excellent, indicating high drug-likeness. Ligand B (0.421) is lower, suggesting a less ideal drug-like profile.
7. **DILI:** Ligand A (79.604) is higher, indicating a greater risk of liver injury. Ligand B (69.833) is better.
8. **BBB:** Ligand A (76.037) is good, indicating reasonable brain penetration. Ligand B (60.644) is lower, suggesting less brain penetration.
9. **Caco-2:** Ligand A (-4.799) is better than Ligand B (-5.961), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-3.644) is better than Ligand B (-3.443).
11. **hERG:** Ligand A (0.209) is very low risk. Ligand B (0.88) is slightly higher, but still relatively low.
12. **Cl_mic:** Ligand A (42.673) is better (lower clearance, more stable). Ligand B (65.612) is higher, indicating faster metabolism.
13. **t1/2:** Ligand A (56.698) is good. Ligand B (135.866) is much better, suggesting a longer duration of action.
14. **Pgp:** Ligand A (0.155) is very low efflux, which is good. Ligand B (0.602) is higher, potentially limiting bioavailability.
15. **Affinity:** Ligand B (-6.2 kcal/mol) is significantly better than Ligand A (-3.6 kcal/mol). This is a substantial difference in binding strength.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are particularly important. Ligand B excels in affinity, which is the most crucial factor. While its logP is slightly higher, the significant binding advantage outweighs this. The lower Pgp efflux of Ligand A is a benefit, but the superior affinity of Ligand B is more impactful.
**Overall Assessment:**
Ligand B has a substantially better binding affinity, a longer half-life, and a lower DILI risk, despite a slightly higher logP and Pgp efflux. The significantly improved affinity makes Ligand B the more promising candidate, even considering the slightly less favorable ADME properties.
Output:
0
2025-04-17 22:57:58,609 - INFO - Here's my reasoning and output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands (347.459 and 363.755 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (82.53) is slightly higher than Ligand B (72.7). Both are below the 140 A^2 threshold for good oral absorption, but closer to the 90 A^2 threshold for CNS targets (though this is less critical for a cardiovascular target like ADRB2). Ligand B is slightly favored.
3. **logP:** Both ligands have good logP values (3.035 and 3.57) within the optimal 1-3 range. Ligand B is slightly higher, which could potentially lead to solubility issues, but it's not a major concern.
4. **HBD:** Ligand A has 2 HBD, while Ligand B has 1. Lower is generally preferred for permeability, giving a slight edge to Ligand B.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 5. Both are within the acceptable range (<=10). No significant difference.
6. **QED:** Ligand A (0.858) has a significantly better QED score than Ligand B (0.703), indicating a more drug-like profile. This is a substantial advantage for Ligand A.
7. **DILI:** Ligand A (41.024) has a much lower DILI risk than Ligand B (94.378). This is a critical advantage for Ligand A, as liver toxicity is a major concern in drug development.
8. **BBB:** Both ligands have moderate BBB penetration (58.007 and 69.678). Since ADRB2 is primarily a cardiovascular target, BBB penetration isn't a top priority, but Ligand B is slightly better.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.831 and -4.938). These values are unusual and suggest poor permeability. However, the values are very similar.
10. **Solubility:** Both ligands have negative solubility values (-4.109 and -4.82). These values are also unusual and suggest poor solubility. Again, the values are very similar.
11. **hERG:** Both ligands have low hERG inhibition liability (0.348 and 0.22). No significant difference.
12. **Cl_mic:** Both ligands have similar microsomal clearance values (46.321 and 44.853 mL/min/kg), indicating comparable metabolic stability.
13. **t1/2:** Ligand A (-1.906) has a negative in vitro half-life, which is concerning. Ligand B (2.538) has a positive half-life. This is a significant advantage for Ligand B.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.079 and 0.204). No significant difference.
15. **Binding Affinity:** Ligand B (-7.5 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.5 kcal/mol). This 1.0 kcal/mol difference is substantial and can outweigh some ADME drawbacks.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand B is slightly better in logP and TPSA, similar in Pgp, and *significantly* better in binding affinity. However, the DILI risk for Ligand B is very high, and Ligand A has a much better QED score.
**Overall Assessment:**
While Ligand B has a stronger binding affinity, the significantly higher DILI risk and lower QED score are major concerns. Ligand A, despite having slightly less potent binding, presents a much more favorable safety profile (lower DILI) and better overall drug-likeness (higher QED). The negative Caco-2 and solubility values are concerning for both, but the difference in DILI risk is a deciding factor.
Output:
1
2025-04-17 22:57:58,609 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (354.43 and 357.45 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (87.46) is better than Ligand B (107.97). For a cardiovascular GPCR, TPSA under 140 is acceptable, but lower is generally preferred for better absorption.
**3. logP:** Ligand A (2.364) is within the optimal 1-3 range. Ligand B (0.635) is a bit low, potentially hindering membrane permeability.
**4. H-Bond Donors:** Ligand A (2) and Ligand B (3) are both acceptable, below the threshold of 5.
**5. H-Bond Acceptors:** Both ligands (5) are within the acceptable range of <=10.
**6. QED:** Ligand A (0.736) has a higher QED score than Ligand B (0.591), indicating a more drug-like profile.
**7. DILI Risk:** Ligand B (33.501) has a significantly lower DILI risk than Ligand A (47.732), which is a substantial advantage.
**8. BBB Penetration:** Ligand A (82.474) shows better BBB penetration than Ligand B (51.415). While ADRB2 is a cardiovascular target, some CNS effects are possible with beta-blockers, and some degree of BBB penetration isn't necessarily detrimental.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.847 and -4.937). This is unusual and suggests poor permeability. However, these values are on a log scale, and the absolute difference is small.
**10. Aqueous Solubility:** Ligand B (-1.512) is better than Ligand A (-3.474). Better solubility is always a plus.
**11. hERG Inhibition:** Ligand A (0.452) has a slightly lower hERG inhibition risk than Ligand B (0.229), which is preferable.
**12. Microsomal Clearance:** Ligand B (24.253) has a slightly higher microsomal clearance than Ligand A (21.96), indicating potentially lower metabolic stability.
**13. In vitro Half-Life:** Both ligands have very negative half-life values (-22.72 and -23.698), which is concerning. This suggests very rapid degradation *in vitro*.
**14. P-gp Efflux:** Ligand A (0.419) shows lower P-gp efflux than Ligand B (0.03), which is favorable for bioavailability.
**15. Binding Affinity:** Ligand B (-6.0) has a slightly better binding affinity than Ligand A (-5.8). While the difference is less than 1.5 kcal/mol, it's still a positive.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand A is slightly favored. Its better logP, TPSA, P-gp efflux, and BBB penetration are beneficial. However, the lower DILI risk of Ligand B is a significant advantage. The similar Caco-2 permeability and poor *in vitro* half-life are shared concerns. The slightly better affinity of Ligand B is also a positive.
Given the balance, the lower DILI risk of Ligand B is a critical factor for cardiovascular drug development, outweighing the slight advantages of Ligand A in other areas.
Output:
0
2025-04-17 22:57:58,609 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (349.391 and 341.371 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (122.14) is slightly higher than Ligand B (119.9). Both are below the 140 A^2 threshold for good oral absorption, but closer to the upper limit.
**3. logP:** Ligand B (1.228) is slightly higher than Ligand A (0.965), both falling within the optimal 1-3 range.
**4. H-Bond Donors:** Both ligands have 3 HBD, which is acceptable.
**5. H-Bond Acceptors:** Ligand A has 6 HBA, while Ligand B has 5. Both are within the acceptable limit of 10.
**6. QED:** Ligand B (0.699) has a slightly better QED score than Ligand A (0.58), indicating a more drug-like profile.
**7. DILI:** Ligand A (65.103) has a lower DILI risk than Ligand B (73.09). This is a significant advantage for Ligand A.
**8. BBB:** Ligand A (46.219) has a considerably higher BBB penetration percentile than Ligand B (21.985). While ADRB2 is a cardiovascular target and CNS penetration isn't *essential*, some degree of BBB penetration can be beneficial for off-target effects assessment and potential alternative therapeutic avenues.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and problematic. It suggests poor permeability. Ligand A (-5.357) is slightly better than Ligand B (-5.161), but both are concerning.
**10. Aqueous Solubility:** Ligand A (-2.283) has better aqueous solubility than Ligand B (-4.14). Solubility is important for formulation and bioavailability.
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (0.415 and 0.571 respectively).
**12. Microsomal Clearance:** Ligand B (20.782) has a significantly lower microsomal clearance than Ligand A (38.138). This suggests better metabolic stability for Ligand B.
**13. In vitro Half-Life:** Ligand B (-14.117) has a much longer in vitro half-life than Ligand A (-39.911). This is a major advantage for Ligand B, potentially allowing for less frequent dosing.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.04 and 0.024 respectively).
**15. Binding Affinity:** Ligand B (-7.1 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.6 kcal/mol). This is a crucial advantage, as a 1.5 kcal/mol difference is substantial.
**Overall Assessment & GPCR Prioritization:**
For a GPCR like ADRB2, binding affinity is paramount. Ligand B's -7.1 kcal/mol binding affinity is a significant advantage over Ligand A's -5.6 kcal/mol. While Ligand A has better DILI and solubility, the substantial improvement in affinity and half-life of Ligand B outweighs these factors. The lower metabolic clearance and longer half-life of Ligand B are also highly desirable. The Caco-2 permeability is a concern for both, but the stronger binding and better PK properties of Ligand B make it the more promising candidate.
Output:
0
2025-04-17 22:57:58,609 - INFO - Batch 370 complete. Total preferences: 5920
2025-04-17 22:57:58,609 - INFO - Processing batch 371/512...
2025-04-17 22:58:50,655 - INFO - Here's my reasoning and the final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, key priorities are logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB.
Let's break down the comparison:
1. **MW:** Both ligands (375.441 and 386.539 Da) fall within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (87.3) is slightly higher than Ligand B (67.87). Both are below the 140 threshold for oral absorption, but Ligand B is preferable due to being closer to the 90 threshold for GPCRs.
3. **logP:** Both ligands have good logP values (1.203 and 1.361), falling within the optimal 1-3 range.
4. **HBD/HBA:** Ligand A has 3 HBD and 4 HBA, while Ligand B has 1 HBD and 6 HBA. Both are acceptable, but Ligand B's lower HBD count is slightly preferable.
5. **QED:** Both ligands have acceptable QED scores (0.605 and 0.72), indicating good drug-like properties.
6. **DILI:** Ligand A (43.389) has a slightly higher DILI risk than Ligand B (38.581), but both are below the concerning 60 threshold.
7. **BBB:** Both have good BBB penetration (72.16 and 76.309), but Ligand B is slightly better.
8. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. This is a concern for both.
9. **Solubility:** Both have negative solubility values, indicating poor solubility. This is a concern for both.
10. **hERG:** Both ligands have low hERG inhibition risk (0.278 and 0.223).
11. **Cl_mic:** Ligand A (24.906) has lower microsomal clearance than Ligand B (27.874), suggesting better metabolic stability.
12. **t1/2:** Both have very short in vitro half-lives (-1.625 and -6.721 hours), which is a significant drawback for both.
13. **Pgp:** Both have very low Pgp efflux liability (0.027), which is good.
14. **Binding Affinity:** Ligand B (-5.4 kcal/mol) has a slightly better binding affinity than Ligand A (-6.4 kcal/mol). This 1 kcal/mol difference is significant and can outweigh some of the ADME drawbacks.
**Overall Assessment:**
While both ligands have some concerning ADME properties (poor Caco-2 and solubility, short half-life), Ligand B emerges as the slightly more promising candidate. Its better TPSA, slightly better BBB, and most importantly, significantly better binding affinity outweigh the slightly higher DILI risk and slightly higher Cl_mic. The improved binding affinity is a critical factor for a GPCR target.
Output:
0
2025-04-17 22:58:50,656 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (358.43 and 348.44 Da). No significant difference.
2. **TPSA:** Ligand A (49.85) is significantly better than Ligand B (70.08). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (2.296) is optimal, while Ligand B (0.94) is slightly low, potentially impacting membrane permeability.
4. **HBD:** Ligand A (0) is preferable to Ligand B (1). Fewer HBDs are generally better for permeability.
5. **HBA:** Ligand A (3) is better than Ligand B (4).
6. **QED:** Both ligands have similar, good QED scores (0.778 and 0.754).
7. **DILI:** Ligand A (32.69) has a much lower DILI risk than Ligand B (19.35). This is a significant advantage.
8. **BBB:** Ligand A (86.66) has better BBB penetration than Ligand B (63.36), though this is less critical for a cardiovascular target.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. However, Ligand A (-4.242) is slightly better than Ligand B (-4.656).
10. **Solubility:** Ligand A (-2.818) has slightly better solubility than Ligand B (-1.442).
11. **hERG:** Both ligands have very low hERG risk (0.469 and 0.134).
12. **Cl_mic:** Ligand B (11.455) has significantly lower microsomal clearance than Ligand A (40.862), suggesting better metabolic stability.
13. **t1/2:** Ligand B (16.035) has a longer in vitro half-life than Ligand A (-15.38). This is a substantial advantage.
14. **Pgp:** Both ligands show low P-gp efflux (0.104 and 0.044).
15. **Affinity:** Ligand B (-6.8 kcal/mol) has a stronger binding affinity than Ligand A (-5.5 kcal/mol). This is a 1.3 kcal/mol difference, which is substantial.
**Overall Assessment:**
Ligand B has a significantly better binding affinity and metabolic stability (lower Cl_mic, longer t1/2). Ligand A excels in TPSA, logP, DILI risk, and BBB penetration. The affinity difference is the most important factor here, outweighing the advantages of Ligand A. While Ligand A has a better safety profile (lower DILI), the improved potency of Ligand B is more crucial for a GPCR target. The slightly lower logP of Ligand B is a minor concern, but not enough to dismiss it given the affinity advantage.
Output:
0
2025-04-17 22:58:50,656 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (349.45 and 357.487 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (54.34) is significantly better than Ligand B (92.31). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is quite high, potentially hindering absorption.
**3. logP:** Both ligands have a logP of approximately 2.78, which is within the optimal 1-3 range.
**4. H-Bond Donors:** Both have 1 HBD, which is acceptable.
**5. H-Bond Acceptors:** Ligand A has 3 HBAs, while Ligand B has 8. This is a significant difference. Fewer HBAs generally improve permeability.
**6. QED:** Both ligands have good QED scores (0.734 and 0.884), indicating generally drug-like properties.
**7. DILI:** Ligand A (38.116) has a lower DILI risk than Ligand B (54.866), which is preferable. Both are below the concerning threshold of 60.
**8. BBB:** Ligand A (86.739) has a much higher BBB penetration percentile than Ligand B (65.801). While ADRB2 is a cardiovascular target, some CNS exposure is possible and not necessarily detrimental, and higher BBB is generally a positive attribute.
**9. Caco-2 Permeability:** Ligand A (-4.472) shows better Caco-2 permeability than Ligand B (-5.511).
**10. Aqueous Solubility:** Ligand A (-2.879) has slightly better aqueous solubility than Ligand B (-3.295).
**11. hERG Inhibition:** Ligand A (0.525) has a lower hERG inhibition liability than Ligand B (0.156), which is a significant safety advantage.
**12. Microsomal Clearance:** Ligand A (55.748) has higher microsomal clearance than Ligand B (7.075), meaning Ligand B is more metabolically stable.
**13. In vitro Half-Life:** Ligand A (34.523) has a longer in vitro half-life than Ligand B (0.927).
**14. P-gp Efflux:** Ligand A (0.299) shows lower P-gp efflux than Ligand B (0.184), which is preferable.
**15. Binding Affinity:** Ligand A (-8.3 kcal/mol) has a significantly stronger binding affinity than Ligand B (-4.6 kcal/mol). This >1.5 kcal/mol difference in affinity is a major advantage, and can outweigh some ADME concerns.
**Overall Assessment:**
Ligand A is the stronger candidate. While Ligand B has better metabolic stability and slightly better P-gp efflux, Ligand A excels in crucial areas: significantly higher binding affinity, lower TPSA, fewer HBAs, lower DILI risk, better BBB penetration, better Caco-2 permeability, and lower hERG inhibition. The substantial improvement in binding affinity is the most important factor, and the other advantages of Ligand A make it a more promising starting point for drug development.
Output:
1
2025-04-17 22:58:50,656 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [355.479, 90.9, 0.127, 3, 5, 0.485, 8.414, 36.332, -5.177, -0.966, 0.34, 12.953, -13.289, 0.017, -6.1]
**Ligand B:** [347.394, 98.17, 2.823, 1, 3, 0.466, 35.828, 71.539, -4.777, -3.247, 0.549, 7.974, -0.908, 0.021, -6.2]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (355.479) is slightly higher than Ligand B (347.394), but both are acceptable.
2. **TPSA:** Both are below 140, good for oral absorption. Ligand A (90.9) is better than Ligand B (98.17).
3. **logP:** Ligand A (0.127) is quite low, potentially hindering permeability. Ligand B (2.823) is within the optimal range (1-3). This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (3) is acceptable, Ligand B (1) is even better.
5. **HBA:** Both are acceptable (Ligand A: 5, Ligand B: 3).
6. **QED:** Both are reasonably good (Ligand A: 0.485, Ligand B: 0.466), indicating drug-like properties.
7. **DILI:** Ligand A (8.414) has a much lower DILI risk than Ligand B (35.828). This is a substantial advantage for Ligand A.
8. **BBB:** Ligand B (71.539) has a significantly higher BBB penetration potential than Ligand A (36.332). While ADRB2 is primarily cardiovascular, some CNS off-target effects are possible, and higher BBB penetration could be a concern, but it's not a primary driver for this target.
9. **Caco-2:** Both have negative values, indicating poor permeability. Ligand A (-5.177) is slightly better than Ligand B (-4.777), but both are concerning.
10. **Solubility:** Ligand A (-0.966) is better than Ligand B (-3.247).
11. **hERG:** Both are low (Ligand A: 0.34, Ligand B: 0.549), indicating low cardiotoxicity risk.
12. **Cl_mic:** Ligand B (7.974) has a lower microsomal clearance, suggesting better metabolic stability than Ligand A (12.953).
13. **t1/2:** Ligand A (-13.289) has a much longer in vitro half-life than Ligand B (-0.908). This is a significant advantage for Ligand A.
14. **Pgp:** Both are very low (Ligand A: 0.017, Ligand B: 0.021), indicating minimal P-glycoprotein efflux.
15. **Affinity:** Both have similar binding affinities (Ligand A: -6.1, Ligand B: -6.2). The difference is negligible.
**GPCR-specific priorities:** For ADRB2 (a cardiovascular GPCR), logP, TPSA, and affinity are important. Ligand B excels in logP, while Ligand A has a better TPSA and solubility. The affinities are comparable. Ligand A has a significantly better DILI score and half-life.
**Overall Assessment:**
While Ligand B has a better logP and BBB, the low logP of Ligand A is a significant concern. However, Ligand A's superior DILI profile, solubility, and *much* longer half-life are compelling advantages. The slightly better TPSA also contributes. The similar binding affinities mean that the ADME properties become the deciding factor. Given the importance of metabolic stability and minimizing off-target effects (DILI) for a cardiovascular drug, Ligand A is the more promising candidate.
Output:
1
2025-04-17 22:58:50,656 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [371.415, 114.13 , -0.652, 2. , 8. , 0.65 , 53.315, 32.183, -5.383, -2.36 , 0.037, 26.059, 2.355, 0.011, -2.8 ]**
**Ligand B: [390.355, 52.65 , 2.408, 1. , 3. , 0.734, 12.834, 66.111, -5.122, -2.404, 0.531, 6.437, 9.5 , 0.059, -6.8 ]**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (371.415) is slightly lower, which is generally favorable for permeability, but both are acceptable.
2. **TPSA:** Ligand A (114.13) is higher than Ligand B (52.65). For a GPCR like ADRB2, lower TPSA is preferable for better CNS penetration if desired, and generally better absorption. Ligand B is significantly better here.
3. **logP:** Ligand A (-0.652) is lower than the optimal range (1-3), potentially hindering permeability. Ligand B (2.408) is within the optimal range. Ligand B is significantly better.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable, being less than 5.
5. **HBA:** Ligand A (8) is slightly higher than Ligand B (3). Both are within the acceptable range of <=10, but Ligand B is better.
6. **QED:** Both ligands have good QED scores (A: 0.65, B: 0.734), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (53.315) has a higher DILI risk than Ligand B (12.834). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (32.183) has a lower BBB penetration percentile than Ligand B (66.111). While ADRB2 isn't necessarily a CNS target, higher BBB is generally favorable, and Ligand B is better.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.383 and -5.122). This is unusual and suggests poor permeability in vitro.
10. **Solubility:** Both ligands have negative solubility values (-2.36 and -2.404). This is also unusual and suggests poor solubility.
11. **hERG:** Ligand A (0.037) has a slightly lower hERG risk than Ligand B (0.531), which is preferable.
12. **Cl_mic:** Ligand A (26.059) has a lower microsomal clearance than Ligand B (6.437), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (2.355) has a shorter in vitro half-life than Ligand B (9.5). Ligand B is better here.
14. **Pgp:** Ligand A (0.011) has a lower P-gp efflux liability than Ligand B (0.059), which is preferable.
15. **Binding Affinity:** Ligand B (-6.8 kcal/mol) has a significantly stronger binding affinity than Ligand A (-2.8 kcal/mol). This is a major advantage for Ligand B, potentially outweighing some of the ADME drawbacks.
**Overall Assessment:**
Ligand B clearly wins out due to its superior binding affinity (-6.8 vs -2.8 kcal/mol) and significantly better ADME properties, particularly lower DILI risk, higher BBB penetration, and a more optimal logP. While Ligand A has better metabolic stability (lower Cl_mic) and Pgp efflux, the substantial improvement in binding affinity and the reduced toxicity risk of Ligand B are more critical for a viable drug candidate. The poor Caco-2 and solubility values for both are concerning and would need to be addressed through formulation or further chemical modification, but the stronger starting point of Ligand B makes it the more promising candidate.
Output:
0
2025-04-17 22:58:50,657 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.403 and 352.381 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (95.75) is higher than Ligand B (50.8). For a GPCR, lower TPSA is generally preferred for better BBB penetration and overall drug-like properties. Ligand B is significantly better here.
3. **logP:** Ligand B (1.798) is within the optimal 1-3 range, while Ligand A (0.572) is slightly below 1. This could indicate potential permeability issues for Ligand A. Ligand B is favored.
4. **HBD:** Both ligands have 1 HBD, which is acceptable.
5. **HBA:** Ligand A has 5 HBA, and Ligand B has 4. Both are within the acceptable limit of 10.
6. **QED:** Both ligands have high QED scores (0.839 and 0.821), indicating good overall drug-likeness.
7. **DILI:** Ligand A (35.014) has a slightly lower DILI risk than Ligand B (39.201), but both are below the concerning threshold of 60.
8. **BBB:** Ligand B (83.094) has a significantly higher BBB penetration percentile than Ligand A (48.158). This is a crucial advantage for a GPCR target, even if not directly in the CNS, as it can influence off-target effects and distribution.
9. **Caco-2:** Ligand A (-5.016) and Ligand B (-4.458) are both negative, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Ligand A (-1.719) has slightly better solubility than Ligand B (-2.676), which is a minor advantage.
11. **hERG:** Both ligands have low hERG inhibition risk (0.116 and 0.352), which is excellent.
12. **Cl_mic:** Ligand A (9.51) has a lower microsomal clearance than Ligand B (30.963), suggesting better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand A (12.427) has a longer in vitro half-life than Ligand B (-0.001). This is a major advantage.
14. **Pgp:** Ligand A (0.01) has a much lower P-gp efflux liability than Ligand B (0.061), which is beneficial for bioavailability.
15. **Binding Affinity:** Ligand B (-6.8) has a slightly better binding affinity than Ligand A (-6.6), but the difference is small (0.2 kcal/mol).
**Overall Assessment:**
Ligand B excels in TPSA and BBB penetration, which are critical for GPCRs. However, Ligand A has better metabolic stability (lower Cl_mic, longer t1/2), lower P-gp efflux, and slightly better solubility. The binding affinity difference is minimal. Considering the importance of metabolic stability and P-gp efflux for *in vivo* efficacy, and the fact that the binding affinity difference is small, Ligand A appears to be the more promising candidate.
Output:
1
2025-04-17 22:58:50,657 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [340.387, 101.28 , 0.715, 2. , 6. , 0.755, 62.776, 66.227, -5.31 , -3.029, 0.065, 29.586, -5.994, 0.153, -5.9 ]
**Ligand B:** [364.511, 62.55 , 3.549, 1. , 4. , 0.83 , 43.738, 83.249, -4.951, -4.289, 0.553, 52.539, 12.189, 0.394, -5.8 ]
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (340.387) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (101.28) is higher than Ligand B (62.55). For a GPCR, lower TPSA is preferable, so Ligand B has an advantage here.
3. **logP:** Ligand A (0.715) is a bit low, potentially hindering membrane permeability. Ligand B (3.549) is within the optimal range (1-3). Ligand B is better.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable.
5. **HBA:** Ligand A (6) and Ligand B (4) are both acceptable.
6. **QED:** Both ligands have good QED scores (A: 0.755, B: 0.83), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (62.776) has a higher DILI risk than Ligand B (43.738), which is preferable. Ligand B is better.
8. **BBB:** Ligand B (83.249) has a significantly higher BBB penetration score than Ligand A (66.227). This is a key advantage for a GPCR target, even if not CNS-focused, as it suggests better distribution.
9. **Caco-2:** Ligand A (-5.31) and Ligand B (-4.951) are both negative, which is not ideal. However, the values are close.
10. **Solubility:** Ligand A (-3.029) and Ligand B (-4.289) are both poor.
11. **hERG:** Ligand A (0.065) has a lower hERG risk than Ligand B (0.553). This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand A (29.586) has lower microsomal clearance than Ligand B (52.539), suggesting better metabolic stability. Ligand A is better.
13. **t1/2:** Ligand A (-5.994) has a longer *in vitro* half-life than Ligand B (12.189). Ligand A is better.
14. **Pgp:** Ligand A (0.153) has lower P-gp efflux than Ligand B (0.394). This is preferable. Ligand A is better.
15. **Affinity:** Both ligands have the same binding affinity (-5.8 kcal/mol).
**Overall Assessment:**
While Ligand A has advantages in hERG, Cl_mic, t1/2, and Pgp, Ligand B excels in crucial GPCR-relevant properties like TPSA, logP, and BBB penetration. The lower TPSA and optimal logP of Ligand B suggest better permeability and target engagement. The significantly higher BBB score is a strong indicator of better overall distribution. The DILI risk is also lower for Ligand B. The solubility is poor for both, but the other advantages of Ligand B outweigh the slightly better metabolic stability of Ligand A.
Therefore, I would choose Ligand B.
0
2025-04-17 22:58:50,657 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (366.491 and 378.485 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (66.48) is significantly better than Ligand A (83.36). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (2.402) is within the optimal 1-3 range, while Ligand A (-0.152) is quite low, potentially hindering membrane permeability. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable.
5. **HBA:** Ligand A (7) and Ligand B (3) are both acceptable, with B being slightly better.
6. **QED:** Both ligands have similar QED values (0.625 and 0.66), indicating good drug-likeness.
7. **DILI:** Ligand B (18.922) has a much lower DILI risk than Ligand A (34.238). This is a crucial factor for safety.
8. **BBB:** Ligand B (87.553) has a higher BBB penetration score than Ligand A (58.55). While not a primary concern for a cardiovascular target, it's a slight positive.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.446 and -4.901). These values are unusual and suggest poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Ligand A (-1.165) has slightly better solubility than Ligand B (-3.082).
11. **hERG:** Ligand B (0.645) has a higher hERG risk than Ligand A (0.027). This is a negative for Ligand B, and a significant advantage for Ligand A.
12. **Cl_mic:** Ligand A (3.831) has a much lower microsomal clearance than Ligand B (18.094), indicating better metabolic stability.
13. **t1/2:** Ligand B (-40.73) has a significantly longer in vitro half-life than Ligand A (45.521). This is a major advantage for Ligand B.
14. **Pgp:** Ligand A (0.011) has a lower P-gp efflux liability than Ligand B (0.081), suggesting better bioavailability.
15. **Binding Affinity:** Ligand A (-6.8) has a slightly better binding affinity than Ligand B (-6.5), but the difference is relatively small (0.3 kcal/mol).
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, and metabolic stability are key. Ligand B excels in logP and has a significantly longer half-life, outweighing the slightly weaker binding affinity. The lower DILI risk of Ligand B is also a major advantage. While Ligand A has a better hERG profile and Pgp efflux, the overall profile of Ligand B is more favorable.
**Conclusion:**
Considering the balance of properties, particularly the improved logP, lower DILI risk, and longer half-life, Ligand B is the more promising drug candidate.
Output:
0
2025-04-17 22:58:50,657 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (350.434 Da) is slightly preferred as it's closer to the lower end, potentially aiding permeability.
2. **TPSA:** Ligand A (49.85) is significantly better than Ligand B (127.23). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is quite high, potentially hindering absorption.
3. **logP:** Ligand A (2.343) is optimal, while Ligand B (-0.033) is quite low, potentially leading to poor membrane permeability. This is a significant advantage for Ligand A.
4. **HBD:** Ligand A (0) is preferred over Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is better than Ligand B (7). Lower HBA is generally preferred for permeability.
6. **QED:** Ligand A (0.765) is much better than Ligand B (0.425), indicating a more drug-like profile.
7. **DILI:** Ligand A (13.843) is significantly better than Ligand B (61.07), indicating a much lower risk of drug-induced liver injury. This is a crucial safety parameter.
8. **BBB:** Ligand A (88.174) is better than Ligand B (58.511). While ADRB2 isn't strictly a CNS target, some peripheral ADRB2 receptors can be affected by CNS penetration, and higher BBB is generally favorable.
9. **Caco-2:** Ligand A (-4.213) is better than Ligand B (-5.615). Both are negative, indicating poor permeability, but A is slightly better.
10. **Solubility:** Ligand A (-1.664) is better than Ligand B (-1.965). Both are poor, but A is slightly better.
11. **hERG:** Ligand A (0.717) is better than Ligand B (0.075), indicating a lower risk of cardiotoxicity. This is critical for a cardiovascular target.
12. **Cl_mic:** Ligand A (44.147) is much better than Ligand B (5.431). Lower clearance indicates better metabolic stability, a significant advantage for A.
13. **t1/2:** Ligand B (83.79) is significantly better than Ligand A (-0.034). This is a strong point for Ligand B, suggesting a much longer half-life.
14. **Pgp:** Ligand A (0.125) is better than Ligand B (0.068). Lower P-gp efflux is preferred.
15. **Affinity:** Ligand A (-7.5) is slightly better than Ligand B (-6.4). While both are good, the difference is not substantial enough to outweigh the numerous ADME advantages of Ligand A.
**Overall Assessment:**
Ligand A demonstrates a significantly better overall profile, particularly regarding ADME properties crucial for oral bioavailability and safety (TPSA, logP, QED, DILI, hERG, Cl_mic). While Ligand B has a superior half-life, the other drawbacks are substantial. For a GPCR like ADRB2, optimizing for permeability and minimizing off-target effects (like hERG inhibition and liver toxicity) are paramount. Ligand A is the more promising candidate.
Output:
1
2025-04-17 22:58:50,657 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A: [349.289, 92.7, 3.127, 2, 4, 0.809, 99.38, 18.379, -4.727, -4.158, 0.067, 10.168, 14.809, 0.048, -6.9]**
**Ligand B: [341.342, 86.34, 2.325, 1, 4, 0.928, 72.974, 46.762, -4.521, -3.813, 0.502, -7.226, 33.168, 0.106, -6.8]**
Here's a breakdown, considering the guidelines and GPCR priorities (logP, Pgp, TPSA, affinity):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (341.342) is slightly lower, which is generally favorable.
2. **TPSA:** Ligand A (92.7) is slightly above the preferred <90 for CNS targets, but acceptable for a cardiovascular target. Ligand B (86.34) is better.
3. **logP:** Both are within the optimal 1-3 range. Ligand A (3.127) is slightly higher, which *could* indicate potential off-target effects or solubility issues, but is still reasonable. Ligand B (2.325) is better.
4. **HBD:** Ligand A (2) and Ligand B (1) are both good. Lower is generally preferred, so Ligand B is slightly better.
5. **HBA:** Both have 4 HBA, which is within the acceptable limit.
6. **QED:** Both are good (A: 0.809, B: 0.928). Ligand B is slightly better, indicating a more drug-like profile.
7. **DILI:** Ligand A (99.38) is *very* high risk for liver injury. This is a major red flag. Ligand B (72.974) is much better, still above 60 but significantly lower risk.
8. **BBB:** Not a primary concern for a cardiovascular target, but Ligand B (46.762) is higher than Ligand A (18.379).
9. **Caco-2:** Both are negative, indicating poor permeability.
10. **Solubility:** Both are negative, indicating poor solubility.
11. **hERG:** Ligand A (0.067) is better, indicating lower hERG inhibition risk. Ligand B (0.502) is higher.
12. **Cl_mic:** Ligand B (-7.226) has a *much* lower (better) microsomal clearance, suggesting greater metabolic stability. Ligand A (10.168) is relatively high.
13. **t1/2:** Ligand B (33.168) has a significantly longer in vitro half-life, which is desirable. Ligand A (14.809) is shorter.
14. **Pgp:** Ligand A (0.048) has lower P-gp efflux, which is better. Ligand B (0.106) is higher.
15. **Affinity:** Both have very similar binding affinities (-6.9 and -6.8 kcal/mol). The difference is negligible.
**Overall Assessment:**
Ligand A has a concerningly high DILI risk and a relatively high microsomal clearance. While it has slightly better hERG and Pgp profiles, these are outweighed by the significant safety concerns. Ligand B, although not perfect, presents a much more favorable profile with a lower DILI risk, better metabolic stability, and a longer half-life. The slightly better QED and logP values also contribute to its preference.
Therefore, I would choose Ligand B.
0
2025-04-17 22:58:50,658 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (349.475 and 361.511 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (71.53) is higher than Ligand B (51.39). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B is better.
3. **logP:** Ligand A (2.195) is within the optimal 1-3 range. Ligand B (3.857) is slightly higher, approaching the upper limit. While still acceptable, Ligand A is slightly preferred.
4. **HBD:** Ligand A (1) is better than Ligand B (0) as having at least one HBD can aid solubility.
5. **HBA:** Ligand A (4) is lower than Ligand B (6). Lower HBA is generally preferred for permeability. Ligand A is better.
6. **QED:** Both ligands have good QED scores (0.742 and 0.782), indicating good drug-like properties. No significant difference.
7. **DILI:** Both ligands have very similar, low DILI risk (21.985 and 21.442 percentile). No significant difference.
8. **BBB:** Ligand B (80.264) has a higher BBB penetration percentile than Ligand A (73.401). While ADRB2 isn't a CNS target, some degree of BBB penetration can be beneficial for off-target effects assessment. Ligand B is better.
9. **Caco-2:** Ligand A (-4.5) has a better Caco-2 permeability than Ligand B (-5.078).
10. **Solubility:** Ligand A (-1.625) has better solubility than Ligand B (-3.654). Solubility is important for bioavailability. Ligand A is better.
11. **hERG:** Ligand A (0.568) has a lower hERG inhibition liability than Ligand B (0.794). This is a significant advantage, as hERG inhibition can lead to cardiotoxicity. Ligand A is better.
12. **Cl_mic:** Ligand A (57.771) has a lower microsomal clearance than Ligand B (64.083), suggesting better metabolic stability. Ligand A is better.
13. **t1/2:** Both ligands have similar in vitro half-lives (12.567 and 12.912 hours). No significant difference.
14. **Pgp:** Ligand A (0.074) has much lower P-gp efflux liability than Ligand B (0.438). Lower P-gp efflux is desirable for improved oral bioavailability. Ligand A is significantly better.
15. **Binding Affinity:** Ligand B (-6.1 kcal/mol) has a slightly better binding affinity than Ligand A (-5.8 kcal/mol). This is a 0.3 kcal/mol difference, which is not substantial enough to outweigh the numerous advantages of Ligand A.
**Overall Assessment:**
Ligand A demonstrates a superior balance of properties, particularly concerning ADME-Tox parameters crucial for cardiovascular drug development. Its lower hERG risk, P-gp efflux, and microsomal clearance, coupled with better solubility and Caco-2 permeability, make it a more promising candidate. While Ligand B has slightly better binding affinity and BBB penetration, these advantages are overshadowed by Ligand A's more favorable ADME profile.
Output:
1
2025-04-17 22:58:50,658 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.5 and 362.5 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (69.64) is better than Ligand B (72.12). Both are below the 140 threshold for oral absorption, but lower is generally preferred.
3. **logP:** Ligand A (2.183) is optimal (1-3), while Ligand B (4.01) is pushing the upper limit. Higher logP can lead to off-target effects and solubility issues. This favors Ligand A.
4. **HBD:** Ligand A (2) is reasonable, and Ligand B (0) is also good. No strong preference.
5. **HBA:** Ligand A (3) is good, and Ligand B (6) is acceptable but higher. Lower HBA generally improves permeability. This slightly favors Ligand A.
6. **QED:** Both ligands have very similar QED values (0.705 and 0.709), indicating good drug-likeness.
7. **DILI:** Ligand A (20.4%) has a significantly lower DILI risk than Ligand B (37.0%). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (86.855) shows better BBB penetration than Ligand A (77.162). While ADRB2 isn't exclusively a CNS target, some cardiovascular effects are mediated through CNS pathways, so this is a slight advantage for Ligand B.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.852) is slightly better than Ligand B (-4.987), but both are concerning.
10. **Solubility:** Ligand A (-3.057) has better solubility than Ligand B (-4.728). Solubility is important for bioavailability.
11. **hERG:** Both ligands have low hERG inhibition risk (0.541 and 0.668). No significant difference.
12. **Cl_mic:** Ligand A (27.355) has significantly lower microsomal clearance than Ligand B (80.166), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand B (31.905) has a much longer in vitro half-life than Ligand A (-1.313). This is a major advantage for Ligand B.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.344 and 0.652). No strong preference.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-5.9 and -5.7 kcal/mol). The difference is not substantial enough to outweigh other factors.
**GPCR-specific priorities:** For GPCRs, logP, TPSA, Pgp, and affinity are key. Ligand A has a better logP and TPSA. Ligand B has slightly better BBB penetration. The affinities are comparable.
**Overall Assessment:**
Ligand A demonstrates a superior balance of properties, particularly regarding safety (lower DILI) and metabolic stability (lower Cl_mic). While Ligand B has a longer half-life and better BBB penetration, the higher logP and DILI risk are concerning. The negative Caco-2 values for both are a red flag, but the other advantages of Ligand A make it the more promising candidate.
Output:
1
2025-04-17 22:58:50,658 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (344.46 & 353.51 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (58.44) is significantly better than Ligand B (81.67). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold. Ligand B is approaching it.
3. **logP:** Both ligands have good logP values (1.797 & 1.447), falling within the optimal 1-3 range. Ligand B is slightly lower, which could be a minor drawback for permeability.
4. **HBD:** Ligand A (0) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Both ligands have the same number of HBA (4), which is acceptable (<=10).
6. **QED:** Ligand A (0.758) has a better QED score than Ligand B (0.548), indicating a more drug-like profile.
7. **DILI:** Ligand A (17.1) has a much lower DILI risk than Ligand B (5.312). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (77.007) has a better BBB penetration score than Ligand B (46.452). While not critical for a cardiovascular target, higher BBB is rarely detrimental.
9. **Caco-2:** Ligand A (-4.927) and Ligand B (-5.164) are similar, indicating similar intestinal absorption.
10. **Solubility:** Ligand A (-1.529) has slightly better solubility than Ligand B (-1.385).
11. **hERG:** Both ligands have very low hERG risk (0.32 & 0.243).
12. **Cl_mic:** Ligand A (37.753) has a higher microsomal clearance than Ligand B (3.305). This is a significant negative for Ligand A, suggesting faster metabolism.
13. **t1/2:** Ligand B (-7.347) has a better in vitro half-life than Ligand A (-13.417). This supports the lower Cl_mic observed for Ligand B.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.106 & 0.024).
15. **Affinity:** Ligand A (-7.3) has slightly better binding affinity than Ligand B (-7.0). This is a small, but potentially important difference.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A excels in logP, TPSA, and affinity, and has acceptable Pgp. Ligand B has a better metabolic profile (lower Cl_mic, longer t1/2) but is less favorable in TPSA and has a higher DILI risk.
**Overall Assessment:**
While Ligand B has a better metabolic profile, the combination of lower DILI risk, better TPSA, better QED, and slightly better affinity makes Ligand A the more promising candidate. The slightly higher Cl_mic of Ligand A can potentially be addressed through structural modifications during optimization. The DILI risk of Ligand B is a more serious concern.
Output:
1
2025-04-17 22:58:50,658 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [365.499, 78.51, 1.482, 2, 4, 0.718, 35.052, 73.633, -5.245, -2.309, 0.724, 37.201, -11.974, 0.048, -6.3]
**Ligand B:** [356.482, 69.64, 2.419, 2, 3, 0.736, 13.3, 76.735, -4.669, -2.228, 0.416, 21.807, -10.409, 0.058, -6.9]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, Affinity, and BBB):
1. **MW:** Both are within the ideal 200-500 Da range. Ligand B (356.482) is slightly lower, which is generally favorable.
2. **TPSA:** Ligand A (78.51) is a bit higher than Ligand B (69.64). Both are acceptable for a peripheral GPCR like ADRB2, but lower is better for overall drug-like properties.
3. **logP:** Ligand A (1.482) is slightly lower than Ligand B (2.419). Both are within the optimal 1-3 range, but Ligand B is closer to the upper end, potentially offering better membrane permeability.
4. **HBD/HBA:** Both have 2 HBDs, which is good. Ligand A has 4 HBAs, while Ligand B has 3. This is a minor advantage for Ligand B.
5. **QED:** Both have similar good QED scores (0.718 and 0.736).
6. **DILI:** Ligand A (35.052) has a slightly higher DILI risk than Ligand B (13.3). This is a significant advantage for Ligand B.
7. **BBB:** Both have good BBB penetration (73.633 and 76.735). Since ADRB2 is primarily a cardiovascular target, high BBB penetration isn't crucial, but it doesn't hurt. Ligand B is slightly better.
8. **Caco-2:** Ligand A (-5.245) has a worse Caco-2 permeability than Ligand B (-4.669).
9. **Solubility:** Both have similar poor solubility values (-2.309 and -2.228). This is a potential issue for both, but not a deal-breaker.
10. **hERG:** Ligand A (0.724) has a slightly higher hERG risk than Ligand B (0.416). This is a favorable aspect of Ligand B.
11. **Cl_mic:** Ligand A (37.201) has a higher microsomal clearance than Ligand B (21.807), meaning it's metabolized faster. Ligand B has better metabolic stability.
12. **t1/2:** Ligand A (-11.974) has a shorter in vitro half-life than Ligand B (-10.409).
13. **Pgp:** Both have very low P-gp efflux liability (0.048 and 0.058).
14. **Affinity:** Ligand B (-6.9 kcal/mol) has a slightly better binding affinity than Ligand A (-6.3 kcal/mol). While the difference is not huge, it is still a positive for Ligand B.
**Overall Assessment:**
Ligand B consistently demonstrates more favorable properties across several key ADME-Tox parameters (DILI, hERG, Cl_mic, t1/2) and has a slightly better binding affinity. While both ligands have poor solubility, the other advantages of Ligand B outweigh this concern. The slightly improved logP and lower TPSA also contribute to better predicted permeability.
Output:
0
2025-04-17 22:58:50,658 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.443 and 353.507 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (78.87) is higher than Ligand B (53.09). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B has a clear advantage.
3. **logP:** Both ligands (1.157 and 1.593) are within the optimal 1-3 range. Ligand B is slightly higher, which might be marginally better for membrane permeability.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (0). Lower is generally better, giving a slight edge to Ligand B.
5. **HBA:** Both ligands (4) are within the acceptable range (<=10). No significant difference.
6. **QED:** Ligand A (0.706) is slightly better than Ligand B (0.632), indicating a more drug-like profile.
7. **DILI:** Ligand A (25.281) has a significantly lower DILI risk than Ligand B (14.657). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (72.819) has a higher BBB penetration percentile than Ligand A (58.007). While ADRB2 isn't a primary CNS target, some CNS exposure can contribute to side effects, and this is a moderate advantage for Ligand B.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.874 and -4.617), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand A (-2.035) has slightly better (less negative) solubility than Ligand B (0.165).
11. **hERG:** Ligand A (0.18) has a much lower hERG inhibition liability than Ligand B (0.639). This is a critical advantage for Ligand A, minimizing cardiotoxicity risk.
12. **Cl_mic:** Ligand A (39.082) has higher microsomal clearance than Ligand B (8.222), indicating faster metabolism and potentially lower *in vivo* exposure. Ligand B is significantly better here.
13. **t1/2:** Ligand A (-1.974) has a negative in vitro half-life, which is concerning. Ligand B (-0.67) is also negative, but less so. Both are poor.
14. **Pgp:** Ligand A (0.114) has lower P-gp efflux than Ligand B (0.051), which is favorable for bioavailability.
15. **Affinity:** Ligand A (-7.1) has a significantly stronger binding affinity than Ligand B (-5.9). This is a substantial advantage, potentially outweighing some ADME drawbacks.
**Overall Assessment:**
Ligand A has a significantly better binding affinity and a much lower DILI and hERG risk. While its metabolic stability (Cl_mic) and half-life are poor, the strong binding affinity could potentially allow for a lower dose, mitigating some of the metabolic concerns. Ligand B has better TPSA, logP, BBB, and Cl_mic, but its DILI and hERG risks are considerably higher, and its affinity is weaker. Given the cardiovascular context and the importance of minimizing cardiotoxicity (hERG), the stronger affinity and lower toxicity profile of Ligand A are more compelling. The negative Caco-2 values for both are a serious concern that would need to be addressed through structural modifications, but the starting point of Ligand A appears more promising.
Output:
1
2025-04-17 22:58:50,659 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
The target is ADRB2, a GPCR. Therefore, priorities are logP, TPSA, Pgp efflux, BBB penetration, and binding affinity. Metabolic stability and solubility are also important, but slightly lower priority.
Let's compare the ligands property by property:
1. **MW:** Both ligands (356.8 and 353.5 Da) fall within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (67.43) is slightly higher than Ligand B (61.88). Both are acceptable for oral absorption, but Ligand B is preferable.
3. **logP:** Ligand A (2.893) is within the optimal range (1-3), while Ligand B (1.785) is closer to the lower limit. Ligand A is better here.
4. **HBD/HBA:** Ligand A has 2 HBD and 3 HBA, while Ligand B has 1 HBD and 4 HBA. Both are acceptable.
5. **QED:** Both ligands have similar QED values (0.782 and 0.642), indicating good drug-likeness.
6. **DILI:** Ligand A (74.641) has a significantly higher DILI risk than Ligand B (10.275). This is a major drawback for Ligand A.
7. **BBB:** Ligand B (70.143) has better BBB penetration than Ligand A (65.413). While not a primary concern for peripheral GPCRs like ADRB2, it's still a positive.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. This is a concern for both.
9. **Solubility:** Ligand B (-0.977) has better solubility than Ligand A (-5.095).
10. **hERG:** Ligand A (0.664) has a slightly higher hERG risk than Ligand B (0.482), but both are relatively low.
11. **Cl_mic:** Ligand B (26.358) has significantly lower microsomal clearance, indicating better metabolic stability, than Ligand A (38.65).
12. **t1/2:** Ligand B (5.297) has a longer in vitro half-life than Ligand A (-5.582).
13. **Pgp:** Ligand A (0.221) has lower P-gp efflux, which is favorable, compared to Ligand B (0.114).
14. **Binding Affinity:** Ligand A (-7.1 kcal/mol) has a slightly better binding affinity than Ligand B (-5.7 kcal/mol). This is a 1.4 kcal/mol difference, which is significant.
**Overall Assessment:**
Despite Ligand A's slightly better binding affinity and Pgp profile, the significantly higher DILI risk and poorer metabolic stability (higher Cl_mic, shorter t1/2) are major concerns. Ligand B demonstrates a much more favorable safety profile (low DILI), better metabolic stability, and acceptable binding affinity. The slightly lower logP and TPSA of Ligand B are not critical drawbacks.
**Output:**
0
2025-04-17 22:58:50,659 - INFO - Batch 371 complete. Total preferences: 5936
2025-04-17 22:58:50,659 - INFO - Processing batch 372/512...
2025-04-17 22:59:36,446 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (351.793) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (62.3) is better than Ligand B (41.93). Both are well below the 140 threshold for oral absorption, and the lower TPSA of Ligand B is more favorable for potential CNS penetration, but this is less critical for ADRB2 which is not a CNS target.
3. **logP:** Both ligands have acceptable logP values (A: 3.369, B: 4.237), falling within the 1-3 range. Ligand B is slightly higher, potentially increasing off-target interactions, but still within a reasonable range.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 3 HBA, while Ligand B has 6. Ligand A is preferable here, as fewer HBA generally improves permeability.
6. **QED:** Both ligands have similar QED values (A: 0.684, B: 0.625), both above the 0.5 threshold, indicating good drug-likeness.
7. **DILI:** Ligand A (87.631) has a significantly higher DILI risk than Ligand B (25.165). This is a major concern for Ligand A.
8. **BBB:** Both ligands have good BBB penetration (A: 76.735, B: 79.294), but this is less important for a non-CNS target like ADRB2.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and likely indicates poor permeability. However, the scale is not specified, so these values are difficult to interpret.
10. **Solubility:** Ligand A (-5.489) has better solubility than Ligand B (-3.041).
11. **hERG:** Both ligands show low hERG inhibition risk (A: 0.49, B: 0.89).
12. **Cl_mic:** Ligand A (45.29) has lower microsomal clearance than Ligand B (62.831), indicating better metabolic stability.
13. **t1/2:** Both ligands have similar in vitro half-lives (A: 54.125, B: 54.501).
14. **Pgp:** Ligand A (0.319) has lower P-gp efflux liability than Ligand B (0.749), which is favorable for oral bioavailability.
15. **Binding Affinity:** Both ligands have very similar binding affinities (A: -5.4 kcal/mol, B: -5.1 kcal/mol). The difference is not substantial enough to outweigh other factors.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. While both ligands perform reasonably well on these metrics, Ligand A has a significantly higher DILI risk. The lower Pgp efflux of Ligand A is a plus, but the DILI risk is a major red flag.
**Conclusion:**
Despite Ligand A having slightly better solubility and metabolic stability, the significantly higher DILI risk associated with Ligand A makes it a less desirable candidate. Ligand B, while having a slightly higher logP and Pgp efflux, presents a much lower risk of liver injury.
Output:
0
2025-04-17 22:59:36,447 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (356.46 & 351.54 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (40.62) is better than Ligand B (44.81). Both are below the 140 threshold for oral absorption, but lower is preferred.
3. **logP:** Ligand A (3.47) is optimal, while Ligand B (1.97) is on the lower side. For a GPCR, a logP between 1-3 is good, but A is better positioned.
4. **HBD:** Ligand A (0) is better than Ligand B (1). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (2) is better than Ligand B (4). Lower HBA is preferred for permeability.
6. **QED:** Both ligands have good QED scores (0.684 and 0.726), indicating good drug-like properties.
7. **DILI:** Ligand B (3.99) has a significantly lower DILI risk than Ligand A (20.74). This is a major advantage for Ligand B.
8. **BBB:** Ligand A (95.81) has a much higher BBB penetration percentile than Ligand B (86.89). While ADRB2 isn't strictly a CNS target, some CNS exposure can occur, and higher BBB is generally favorable.
9. **Caco-2:** Both have negative Caco-2 values, suggesting poor permeability. Ligand B (-4.864) is slightly worse than Ligand A (-4.328).
10. **Solubility:** Ligand A (-2.871) has better solubility than Ligand B (-1.141). Solubility is important for bioavailability.
11. **hERG:** Both ligands have low hERG inhibition risk (0.563 and 0.714).
12. **Cl_mic:** Ligand B (15.93) has significantly lower microsomal clearance than Ligand A (41.99), indicating better metabolic stability.
13. **t1/2:** Ligand B (2.01) has a slightly better in vitro half-life than Ligand A (-31.41).
14. **Pgp:** Ligand A (0.145) has lower P-gp efflux than Ligand B (0.04). Lower P-gp efflux is preferred.
15. **Affinity:** Ligand A (-7.2 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.7 kcal/mol). This is a substantial advantage.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, Pgp, TPSA, and affinity. Ligand A excels in logP, Pgp and affinity. Ligand B is better in DILI and Cl_mic. The affinity difference is substantial (>0.5 kcal/mol). While DILI risk is important, the strong affinity of Ligand A, combined with acceptable DILI and better TPSA and logP, makes it the more promising candidate.
**Conclusion:**
Despite Ligand B's better DILI and metabolic stability, Ligand A's significantly higher binding affinity and favorable logP/TPSA profile outweigh these concerns.
Output:
1
2025-04-17 22:59:36,447 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (354.445 and 351.466 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (38.82) is significantly better than Ligand B (56.67). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary goal, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (1.785 and 2.169), falling within the optimal 1-3 range. Ligand B is slightly higher, which *could* be a minor drawback, but not a major concern.
4. **HBD:** Both ligands have 1 HBD, which is within the acceptable limit of 5.
5. **HBA:** Ligand A has 3 HBAs, while Ligand B has 4. Both are acceptable (<=10), but A is slightly preferred.
6. **QED:** Both ligands have very similar QED values (0.847 and 0.818), indicating good drug-likeness.
7. **DILI:** Ligand A (19.193) has a considerably lower DILI risk than Ligand B (4.459). This is a significant advantage for Ligand A.
8. **BBB:** Both have high BBB penetration (87.321 and 92.749), but this is less critical for a cardiovascular target like ADRB2.
9. **Caco-2:** Both have negative Caco-2 values (-4.528 and -4.658). These values are unusual and suggest poor permeability. However, the values are very similar.
10. **Solubility:** Both have negative solubility values (-0.872 and -0.997), indicating poor aqueous solubility. This is a concern for both, but slightly worse for Ligand B.
11. **hERG:** Both ligands show low hERG inhibition liability (0.894 and 0.841), which is good.
12. **Cl_mic:** Ligand A has a much lower (better) microsomal clearance (-10.27) compared to Ligand B (10.669). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A has a significantly longer in vitro half-life (-5.21 hours) than Ligand B (-22.834 hours). This is a substantial advantage for Ligand A.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.039 and 0.265), which is good.
15. **Binding Affinity:** Ligand A (-5.6 kcal/mol) has a slightly better binding affinity than Ligand B (-0.3 kcal/mol). This is a *very* significant difference.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A performs better on TPSA, has a comparable logP, similar Pgp, and *much* better affinity. The lower DILI and improved metabolic stability (Cl_mic and t1/2) also contribute to its favorability. The poor Caco-2 and solubility are concerning for both, but the superior binding affinity and safety profile of Ligand A outweigh these drawbacks.
**Output:**
1
2025-04-17 22:59:36,447 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (335.451 Da) is slightly lower, which is generally favorable for permeability.
**2. TPSA:** Both ligands have TPSA values below the 140 A^2 threshold for good oral absorption. Ligand A (68.01 A^2) is better than Ligand B (71.36 A^2).
**3. logP:** Both ligands have logP values within the optimal range (1-3). Ligand A (2.81) is slightly better than Ligand B (3.521), as higher logP can sometimes lead to off-target effects.
**4. H-Bond Donors & Acceptors:** Ligand A (2 HBD, 3 HBA) is slightly better than Ligand B (1 HBD, 5 HBA) in terms of balancing solubility and permeability.
**5. QED:** Both ligands have acceptable QED values, but Ligand A (0.853) is superior to Ligand B (0.69).
**6. DILI Risk:** Ligand A (21.869) has a significantly lower DILI risk than Ligand B (41.76), which is a major advantage.
**7. BBB Penetration:** Both ligands have reasonable BBB penetration, but Ligand B (69.756) is slightly better than Ligand A (59.946). However, for a cardiovascular target, BBB penetration is not a primary concern.
**8. Caco-2 Permeability:** Both ligands have negative Caco-2 values, indicating poor permeability. Ligand A (-5.169) is slightly better than Ligand B (-5.238).
**9. Aqueous Solubility:** Both ligands have negative solubility values, indicating poor aqueous solubility. Ligand A (-2.273) is slightly better than Ligand B (-3.596).
**10. hERG Inhibition:** Both ligands have low hERG inhibition risk. Ligand A (0.573) is slightly better than Ligand B (0.296).
**11. Microsomal Clearance:** Ligand B (72.184 mL/min/kg) has a much higher microsomal clearance than Ligand A (0.853 mL/min/kg), indicating lower metabolic stability. This is a significant drawback for Ligand B.
**12. In vitro Half-Life:** Ligand B (39.975 hours) has a significantly longer in vitro half-life than Ligand A (10.194 hours).
**13. P-gp Efflux:** Both ligands have low P-gp efflux liability. Ligand A (0.109) is slightly better than Ligand B (0.18).
**14. Binding Affinity:** Both ligands have similar binding affinities (-6.4 kcal/mol and -6.3 kcal/mol respectively). The difference is negligible.
**GPCR-Specific Priorities:** For a cardiovascular GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Ligand A performs better on logP, TPSA, and Pgp. While BBB isn't critical here, Ligand B has a slightly better score. However, the significantly lower DILI risk and better metabolic stability (lower Cl_mic) of Ligand A outweigh the slight advantage of Ligand B in BBB penetration.
**Conclusion:**
Considering all factors, Ligand A is the more promising drug candidate due to its better overall ADME profile (lower DILI, better metabolic stability), slightly better physicochemical properties (logP, TPSA), and comparable binding affinity.
Output:
1
2025-04-17 22:59:36,447 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Ligand A (364.9) is within the ideal range (200-500), while Ligand B (334.4) is also good. No clear advantage here.
2. **TPSA:** Ligand A (41.57) is better than Ligand B (26.71), but both are well below the 140 threshold for oral absorption.
3. **logP:** Both ligands have a logP around 4.5-4.7, which is slightly high but acceptable.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Both have 3 HBA, which is good.
6. **QED:** Ligand A (0.856) has a better QED score than Ligand B (0.753), indicating better overall drug-likeness.
7. **DILI:** Ligand A (11.28) has a significantly lower DILI risk than Ligand B (68.09). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (89.61) has a better BBB penetration percentile than Ligand B (66.34). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant for off-target effects and overall safety.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Both have negative solubility values, indicating poor aqueous solubility. This is a significant drawback for both.
11. **hERG:** Ligand A (0.852) has a slightly better hERG profile than Ligand B (0.959), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand A (35.44) has a lower microsomal clearance than Ligand B (92.69), suggesting better metabolic stability.
13. **t1/2:** Ligand A (17.91) has a shorter in vitro half-life than Ligand B (-28.38). The negative value for Ligand B is concerning and likely an artifact or error.
14. **Pgp:** Ligand A (0.512) has lower P-gp efflux liability than Ligand B (0.767), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand B (-8.9 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.3 kcal/mol). This is a substantial advantage for Ligand B, potentially outweighing some of its ADME drawbacks.
**GPCR-specific considerations:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Both ligands have acceptable logP values. Ligand A has better Pgp and TPSA. However, the significantly stronger binding affinity of Ligand B is a major factor.
**Overall Assessment:**
While Ligand A has a superior safety profile (lower DILI, better hERG) and better ADME properties (QED, Cl_mic, Pgp, BBB), the substantial difference in binding affinity (-8.9 kcal/mol vs -6.3 kcal/mol) in favor of Ligand B is likely to be decisive. A 2.6 kcal/mol difference in binding is a large effect and could translate to a much more potent drug. The poor solubility and Caco-2 values are concerns for both, but these can potentially be addressed through formulation strategies. The negative half-life for Ligand B is a red flag, but the binding affinity is so strong that it may be worth investigating further.
Therefore, I believe Ligand B is the more promising candidate, despite its ADME liabilities.
Output:
0
2025-04-17 22:59:36,447 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Ligand A (369.774 Da) is better than Ligand B (391.23 Da), falling comfortably within the 200-500 Da range. Both are acceptable, but A is slightly preferred.
2. **TPSA:** Ligand A (37.61) is significantly better than Ligand B (97.55). ADRB2 is a cardiovascular target, not a CNS target, but lower TPSA generally improves absorption. Ligand B's TPSA is quite high, potentially hindering oral bioavailability.
3. **logP:** Ligand A (3.944) is at the upper end of the optimal range, while Ligand B (1.617) is at the lower end. Both are within the 1-3 range, but A's higher logP might lead to some off-target interactions or solubility issues, while B's lower logP may reduce permeability.
4. **HBD:** Ligand A (0) is preferred over Ligand B (2). Fewer HBDs generally improve membrane permeability.
5. **HBA:** Ligand A (3) is better than Ligand B (5). Again, fewer HBAs are generally preferred for permeability.
6. **QED:** Both Ligand A (0.752) and Ligand B (0.764) have excellent QED scores, indicating good drug-like properties. This parameter doesn't differentiate between them.
7. **DILI:** Ligand A (55.448) has a lower DILI risk than Ligand B (64.599). Both are acceptable, but A is slightly better.
8. **BBB:** This is less critical for a cardiovascular target, but Ligand A (98.022) has a much higher BBB penetration score than Ligand B (79.062).
9. **Caco-2:** Ligand A (-4.681) is better than Ligand B (-5.001). Higher Caco-2 permeability is desirable.
10. **Solubility:** Ligand A (-4.826) is better than Ligand B (-3.398). Higher solubility is preferred.
11. **hERG:** Ligand A (0.745) is better than Ligand B (0.378). Lower hERG inhibition is crucial for avoiding cardiotoxicity, making A preferable.
12. **Cl_mic:** Ligand B (-15.413) has significantly lower microsomal clearance than Ligand A (29.224), indicating better metabolic stability. This is a strong point in favor of Ligand B.
13. **t1/2:** Ligand B (-8.358) has a longer in vitro half-life than Ligand A (-30.096). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.438) is better than Ligand B (0.029). Lower P-gp efflux is desirable.
15. **Binding Affinity:** Both Ligand A and Ligand B have the same binding affinity (-7.2 kcal/mol), so this parameter doesn't differentiate them.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B in most key ADME properties (TPSA, logP, HBD, HBA, DILI, BBB, Caco-2, Solubility, hERG). While Ligand B has superior metabolic stability (Cl_mic) and half-life, the improvements in ADME properties and reduced toxicity risk with Ligand A are more important for overall drug development potential, especially considering the cardiovascular target. The affinity is identical, so the ADME profile is the deciding factor.
Output:
1
2025-04-17 22:59:36,447 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (345.491 and 350.478 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (61.36) is slightly higher than Ligand B (53.43). Both are below the 140 threshold for good oral absorption, but closer to the 90 threshold for CNS targets (less relevant for ADRB2, a cardiovascular target). Ligand B is preferable here.
3. **logP:** Both ligands have good logP values (2.918 and 3.574), falling within the optimal 1-3 range. Ligand B is slightly higher, which *could* be a minor drawback, but isn't a major concern.
4. **HBD:** Both ligands have 1 HBD, which is ideal.
5. **HBA:** Ligand A has 5 HBA, while Ligand B has 3. Both are within the acceptable limit of 10. Ligand B is slightly preferable.
6. **QED:** Both ligands have similar QED values (0.77 and 0.741), indicating good drug-likeness.
7. **DILI:** Ligand A (37.224) has a higher DILI risk than Ligand B (6.592). This is a significant advantage for Ligand B.
8. **BBB:** Both ligands have high BBB penetration (90.229 and 93.68). While ADRB2 isn't a CNS target, higher BBB is generally a positive attribute. Ligand B is slightly better.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.931 and -4.388). This is unusual and suggests poor permeability. However, the values are very close.
10. **Solubility:** Both ligands have negative solubility values (-2.916 and -2.84). This is also unusual and suggests poor solubility. Again, the values are very close.
11. **hERG:** Both ligands have low hERG inhibition risk (0.902 and 0.832).
12. **Cl_mic:** Ligand B (56.843) has lower microsomal clearance than Ligand A (62.809), indicating better metabolic stability. This is a positive for Ligand B.
13. **t1/2:** Ligand B (-11.612) has a significantly longer in vitro half-life than Ligand A (-0.058). This is a major advantage for Ligand B.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.268 and 0.603).
15. **Binding Affinity:** Ligand B (-8.5 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.1 kcal/mol). This is a substantial advantage, potentially outweighing minor ADME concerns.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand B excels in affinity and has favorable values for the other parameters.
**Overall Assessment:**
Ligand B consistently outperforms Ligand A across several critical ADME properties (DILI, Cl_mic, t1/2) and, crucially, exhibits a much stronger binding affinity. While both ligands have unusual Caco-2 and solubility values, the superior profile of Ligand B makes it the more promising drug candidate.
Output:
0
2025-04-17 22:59:36,448 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (331.339 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (80.76) is significantly better than Ligand A (101.38). For a GPCR, lower TPSA is preferred for better blood-brain barrier penetration and overall permeability.
3. **logP:** Both ligands have good logP values (A: 2.305, B: 2.146) falling within the 1-3 range.
4. **HBD:** Ligand B (1 HBD) is better than Ligand A (2 HBD). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand B (5 HBA) is slightly better than Ligand A (6 HBA).
6. **QED:** Ligand B (0.824) has a significantly better QED score than Ligand A (0.597), indicating a more drug-like profile.
7. **DILI:** Ligand B (35.712) has a much lower DILI risk than Ligand A (97.557). This is a critical advantage.
8. **BBB:** Ligand B (80.07) has a better BBB penetration score than Ligand A (18.845). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant depending on the desired therapeutic profile, and lower TPSA/better BBB is generally positive.
9. **Caco-2:** Ligand A (-5.702) has a better Caco-2 permeability than Ligand B (-4.378).
10. **Solubility:** Ligand B (-1.794) has better aqueous solubility than Ligand A (-3.744).
11. **hERG:** Both ligands have low hERG inhibition risk (A: 0.602, B: 0.407).
12. **Cl_mic:** Ligand A (-6.587) has a significantly lower (better) microsomal clearance than Ligand B (31.636), suggesting better metabolic stability.
13. **t1/2:** Ligand A (28.67) has a much longer in vitro half-life than Ligand B (-12.253). This is a significant advantage.
14. **Pgp:** Both ligands have very low P-gp efflux liability (A: 0.035, B: 0.034).
15. **Binding Affinity:** Ligand A (-7.2 kcal/mol) has a slightly better binding affinity than Ligand B (-5.7 kcal/mol). This is a 1.5 kcal/mol difference, which is significant.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity and metabolic stability (lower Cl_mic, longer t1/2), Ligand B is superior in almost all other crucial ADME properties. The significantly lower DILI risk, better QED, lower TPSA, better solubility, and improved BBB penetration of Ligand B outweigh the modest advantage in binding affinity. For a GPCR target like ADRB2, a balanced profile with good permeability and safety is paramount. The substantial DILI risk associated with Ligand A is a major concern.
**Output:**
0
2025-04-17 22:59:36,448 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [347.375, 114.69 , 0.165, 2. , 7. , 0.399, 67.895, 55.254, -5.097, -2.165, 0.491, 56.752, -8.85 , 0.051, -7.1 ]
**Ligand B:** [355.366, 109.66 , -0.892, 3. , 6. , 0.635, 58.976, 56.65 , -5.014, -1.395, 0.198, -4.369, -9.624, 0.03 , -7.3 ]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity) and general drug-like properties:
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (347.375) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are reasonably good, below 140. Ligand B (109.66) is slightly better than Ligand A (114.69).
3. **logP:** Ligand A (0.165) is quite low, potentially causing permeability issues. Ligand B (-0.892) is also low, but less so. This is a significant concern for both, but more so for A.
4. **HBD/HBA:** Ligand A (2 HBD, 7 HBA) is better than Ligand B (3 HBD, 6 HBA) in terms of balancing solubility and permeability.
5. **QED:** Ligand B (0.635) has a better QED score than Ligand A (0.399), indicating a more drug-like profile.
6. **DILI:** Both have acceptable DILI risk (below 60), with Ligand B (58.976) being slightly better.
7. **BBB:** Both have moderate BBB penetration, around the 55-57% range. Not ideal for a CNS target, but ADRB2 is primarily cardiovascular, so this is less critical.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability *in vitro*. This is a major red flag for both.
9. **Solubility:** Both have negative solubility values, which is also unusual and suggests poor solubility.
10. **hERG:** Both have very low hERG inhibition liability, which is excellent.
11. **Cl_mic:** Ligand B (-4.369) has a *negative* microsomal clearance, which is impossible and likely indicates an error in the data. Ligand A (56.752) is moderate.
12. **t1/2:** Ligand B (-9.624) has a negative half-life, which is impossible and further suggests data issues. Ligand A (-8.85) is also negative.
13. **Pgp:** Both have very low P-gp efflux liability, which is good.
14. **Affinity:** Ligand A (-7.1) has a slightly better binding affinity than Ligand B (-7.3), although the difference is small.
**Overall Assessment:**
Both ligands have significant issues with Caco-2 permeability and solubility, indicated by the negative values. The negative clearance and half-life values for Ligand B are highly suspect and indicate a data quality problem. Ligand A has a slightly better affinity and more favorable HBD/HBA counts, but its low logP is a concern. Given the questionable data for Ligand B, and the slightly better profile of Ligand A despite its low logP, I would cautiously favor Ligand A. However, both require significant optimization.
Output:
1
2025-04-17 22:59:36,448 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, priorities are logP, TPSA, Pgp, affinity, and to a lesser extent, BBB.
* **Molecular Weight:** Both ligands are within the acceptable range (200-500 Da). Ligand A (353.394) is slightly higher than Ligand B (346.391), but this difference isn't significant.
* **TPSA:** Ligand A (84.67) is significantly better than Ligand B (113.24). A TPSA under 140 is good for oral absorption, and lower is better for GPCRs. Ligand B is pushing the upper limit.
* **logP:** Both ligands have good logP values (A: 1.422, B: 0.953), falling within the optimal 1-3 range. Ligand A is slightly more lipophilic, which could be beneficial for membrane permeability.
* **H-Bond Donors/Acceptors:** Ligand A (HBD=1, HBA=5) is preferable to Ligand B (HBD=2, HBA=7) as it has fewer hydrogen bond donors and acceptors, potentially improving permeability.
* **QED:** Both are acceptable (A: 0.801, B: 0.772), indicating good drug-like properties.
* **DILI:** Both have similar, acceptable DILI risk (A: 53.315, B: 55.603).
* **BBB:** Ligand A (95.269) is *much* better than Ligand B (35.518) in terms of BBB penetration. While ADRB2 is cardiovascular, some CNS off-target effects are always a consideration, and higher BBB penetration can be a benefit.
* **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale isn't specified, so it's difficult to interpret.
* **Solubility:** Both have negative solubility values, which is also unusual. Again, the scale isn't specified.
* **hERG:** Both have very low hERG inhibition risk (A: 0.288, B: 0.082), which is excellent.
* **Cl_mic:** Both have similar microsomal clearance (A: 38.551, B: 39.091).
* **t1/2:** Ligand A (8.279) has a significantly better in vitro half-life than Ligand B (-10.011). A negative half-life is concerning.
* **Pgp:** Both have low P-gp efflux liability (A: 0.055, B: 0.023).
* **Binding Affinity:** Ligand B (-7.0 kcal/mol) has a slightly better binding affinity than Ligand A (-6.1 kcal/mol). This is a 0.9 kcal/mol difference, which is significant, but not overwhelmingly so.
**Overall Assessment:**
Ligand A is significantly better overall. While Ligand B has a slightly better binding affinity, Ligand A excels in crucial ADME properties like TPSA, BBB penetration, and in vitro half-life. The negative values for Caco-2 and Solubility are concerning for both, but the other advantages of Ligand A outweigh the minor affinity difference. The significantly better BBB penetration and half-life of Ligand A make it a more promising candidate.
**Output:**
1
2025-04-17 22:59:36,448 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (354.4 & 364.4 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand B (108.56) is better than Ligand A (117.17), being closer to the <140 threshold for good absorption.
3. **logP:** Ligand A (-0.195) is quite low, potentially hindering permeability. Ligand B (1.275) is within the optimal 1-3 range. This is a significant advantage for Ligand B.
4. **HBD:** Both have 2 HBD, which is acceptable.
5. **HBA:** Ligand B (7) is slightly higher than Ligand A (6), but both are within the acceptable limit of 10.
6. **QED:** Ligand B (0.799) has a better QED score than Ligand A (0.586), indicating a more drug-like profile.
7. **DILI:** Ligand B (61.8) has a higher DILI risk than Ligand A (56.96), but both are within a moderate risk range.
8. **BBB:** Ligand A (49.2) has a better BBB penetration score than Ligand B (35.2). However, as ADRB2 is a cardiovascular target, BBB penetration is not a high priority.
9. **Caco-2:** Both have very poor Caco-2 permeability (-5.2 and -4.8). This is a concern for both.
10. **Solubility:** Both have poor aqueous solubility (-2.24 and -2.122). This is a concern for both.
11. **hERG:** Ligand A (0.201) has a lower hERG inhibition liability than Ligand B (0.063), which is preferable.
12. **Cl_mic:** Ligand B (4.795) has significantly lower microsomal clearance than Ligand A (35.429), indicating better metabolic stability. This is a major advantage for Ligand B.
13. **t1/2:** Ligand B (23.874) has a much longer in vitro half-life than Ligand A (-1.729), which is highly desirable.
14. **Pgp:** Ligand A (0.015) has lower P-gp efflux liability than Ligand B (0.051), which is preferable.
15. **Affinity:** Ligand B (-7.5 kcal/mol) has a significantly stronger binding affinity than Ligand A (-3.6 kcal/mol). This is a decisive advantage, outweighing most of the minor drawbacks.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP, has a better TPSA, and a substantially better binding affinity. While Ligand A has slightly better Pgp and hERG, the superior affinity and metabolic stability of Ligand B are more critical.
**Conclusion:**
Ligand B is the more promising candidate due to its significantly stronger binding affinity, better logP, improved metabolic stability (lower Cl_mic and longer t1/2), and a better QED score. The slightly higher DILI risk is a concern, but manageable. The poor Caco-2 and solubility are issues for both, but can be addressed with formulation strategies.
Output:
0
2025-04-17 22:59:36,448 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (365.47 Da) is within the ideal range (200-500 Da). Ligand B (341.415 Da) is also good. No clear advantage here.
2. **TPSA:** Ligand A (46.61) is excellent, well below the 140 threshold and favorable for oral absorption. Ligand B (84.83) is still acceptable but less ideal. Advantage: A.
3. **logP:** Ligand A (4.039) is at the higher end of the optimal range (1-3), potentially raising concerns about solubility and off-target effects. Ligand B (2.343) is well within the optimal range. Advantage: B.
4. **HBD:** Ligand A (0) is good. Ligand B (2) is acceptable. Advantage: A.
5. **HBA:** Ligand A (3) is good. Ligand B (5) is acceptable. Advantage: A.
6. **QED:** Both ligands (A: 0.709, B: 0.691) are above the 0.5 threshold, indicating good drug-like properties. No clear advantage.
7. **DILI:** Ligand A (63.397) is better than Ligand B (74.68), indicating a lower risk of drug-induced liver injury. Advantage: A.
8. **BBB:** Both ligands have similar BBB penetration (A: 59.325, B: 61.535). Given ADRB2 is a cardiovascular target, BBB penetration is not a primary concern, but slightly higher is preferable. No strong advantage.
9. **Caco-2:** Ligand A (-4.287) is very poor, suggesting poor intestinal absorption. Ligand B (-5.438) is also poor, but slightly better. Advantage: B.
10. **Solubility:** Ligand A (-5.808) is very poor. Ligand B (-3.016) is still poor, but better than A. Advantage: B.
11. **hERG:** Ligand A (0.775) is better than Ligand B (0.473), indicating a lower risk of hERG inhibition and cardiotoxicity. Advantage: A.
12. **Cl_mic:** Ligand A (118.214) has higher clearance, suggesting lower metabolic stability. Ligand B (42.91) has lower clearance, indicating better metabolic stability. Advantage: B.
13. **t1/2:** Ligand B (28.183) has a much longer half-life than Ligand A (3.684). Advantage: B.
14. **Pgp:** Ligand A (0.524) has lower P-gp efflux, which is good. Ligand B (0.325) is even better. Advantage: B.
15. **Binding Affinity:** Ligand A (-5.4 kcal/mol) has a significantly stronger binding affinity than Ligand B (-4.4 kcal/mol). This is a substantial advantage, potentially outweighing some ADME drawbacks. Advantage: A.
**Overall Assessment:**
Ligand A has a significantly better binding affinity and favorable TPSA, HBD, HBA, DILI, and hERG profiles. However, it suffers from poor Caco-2 permeability, solubility, and metabolic stability. Ligand B has better ADME properties (solubility, metabolic stability, Pgp efflux, half-life) but a weaker binding affinity.
Given that this is a GPCR target (ADRB2), binding affinity is crucial. The 1.0 kcal/mol difference in affinity is substantial. While the ADME properties of Ligand A are concerning, they might be addressable through further optimization. The weaker affinity of Ligand B would likely require a much larger optimization effort to achieve comparable potency.
Therefore, I prioritize Ligand A due to its superior binding affinity.
Output:
1
2025-04-17 22:59:36,448 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 drug candidates. ADRB2 is a GPCR, so we'll prioritize logP, Pgp, TPSA, and affinity, alongside general drug-like properties.
**Ligand A:**
* **MW:** 356.5 Da - Good. Within the ideal range.
* **TPSA:** 78.87 - Acceptable, but getting towards the upper limit for good absorption.
* **logP:** 1.953 - Excellent. Right in the sweet spot.
* **HBD:** 2 - Good.
* **HBA:** 4 - Good.
* **QED:** 0.662 - Very good. Strong drug-like properties.
* **DILI:** 14.23 - Excellent. Very low risk.
* **BBB:** 34.354 - Low. Not a priority for ADRB2 (cardiovascular target), but not ideal if CNS side effects are a concern.
* **Caco-2:** -4.691 - Very poor. Indicates very low intestinal absorption. A major red flag.
* **Solubility:** -1.311 - Poor. Could present formulation challenges.
* **hERG:** 0.32 - Very good. Low cardiotoxicity risk.
* **Cl_mic:** 41.729 - Moderate. Not ideal, but not terrible.
* **t1/2:** 8.372 - Moderate.
* **Pgp:** 0.049 - Excellent. Low efflux.
* **Affinity:** -6.6 kcal/mol - Very good.
**Ligand B:**
* **MW:** 370.465 Da - Good. Within the ideal range.
* **TPSA:** 40.62 - Excellent. Very favorable for absorption and potentially BBB penetration.
* **logP:** 3.44 - Slightly high, but still acceptable.
* **HBD:** 0 - Good.
* **HBA:** 3 - Good.
* **QED:** 0.72 - Very good. Strong drug-like properties.
* **DILI:** 47.034 - Moderate. Higher than Ligand A, but still within an acceptable range.
* **BBB:** 94.378 - Very high. Not a primary concern for ADRB2, but could lead to off-target CNS effects.
* **Caco-2:** -4.763 - Very poor. Similar to Ligand A, indicating low intestinal absorption.
* **Solubility:** -3.336 - Very poor. Worse than Ligand A.
* **hERG:** 0.887 - Acceptable.
* **Cl_mic:** 60.908 - High. Suggests faster metabolism and lower *in vivo* exposure.
* **t1/2:** -32.534 - Very poor. Indicates rapid clearance.
* **Pgp:** 0.531 - Moderate. Higher efflux than Ligand A.
* **Affinity:** -6.3 kcal/mol - Good. Slightly weaker than Ligand A, but not significantly.
**Comparison and Decision:**
Both ligands have significant absorption issues (very negative Caco-2 and poor solubility). However, Ligand A has a better DILI score, lower Pgp efflux, and slightly better binding affinity. Ligand B has a better TPSA and BBB penetration, but these are less critical for a cardiovascular target like ADRB2. The biggest drawback for Ligand B is its significantly higher microsomal clearance and very poor half-life.
Despite the absorption issues, Ligand A's better metabolic stability and slightly stronger binding make it the more promising candidate. Addressing the solubility and permeability issues would be crucial for either compound, but starting with a better baseline profile is preferable.
Output:
1
2025-04-17 22:59:36,449 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (366.487 Da and 352.463 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (96.25) is slightly higher than Ligand B (70.67). For a cardiovascular GPCR, TPSA is not a primary concern, but lower is generally preferred for better permeability. Ligand B has a clear advantage.
**3. logP:** Ligand A (0.775) is considerably lower than Ligand B (4.122). While logP 1-3 is optimal, Ligand B is pushing the upper limit. This could lead to solubility issues and off-target interactions. Ligand A is preferable here.
**4. H-Bond Donors:** Ligand A (3) is higher than Ligand B (2). Both are within the acceptable limit of 5.
**5. H-Bond Acceptors:** Ligand A (6) is higher than Ligand B (4). Both are within the acceptable limit of 10.
**6. QED:** Ligand B (0.656) has a better QED score than Ligand A (0.443), indicating a more drug-like profile.
**7. DILI Risk:** Ligand A (35.014) has a significantly lower DILI risk than Ligand B (74.952). This is a crucial factor, as liver toxicity is a major concern in drug development. Ligand A is strongly favored.
**8. BBB Penetration:** Ligand A (25.824) has lower BBB penetration than Ligand B (46.762). While ADRB2 is not necessarily a CNS target, some degree of BBB penetration can be beneficial for understanding off-target effects. Ligand B has a slight advantage.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-5.701 and -5.429), which is unusual and suggests poor permeability. This is a concern for both, but the values are similar.
**10. Aqueous Solubility:** Ligand A (-1.354) has better aqueous solubility than Ligand B (-3.935). This is important for formulation and bioavailability. Ligand A is preferred.
**11. hERG Inhibition:** Ligand A (0.26) has a much lower hERG inhibition risk than Ligand B (0.636). This is a critical safety parameter, and Ligand A is significantly better.
**12. Microsomal Clearance:** Ligand B (63.025) has higher microsomal clearance than Ligand A (37.208), indicating faster metabolism and potentially lower bioavailability. Ligand A is preferred.
**13. In vitro Half-Life:** Ligand A (-27.426) has a longer in vitro half-life than Ligand B (-31.507). Both are negative, which is unusual and suggests rapid degradation. However, Ligand A is slightly better.
**14. P-gp Efflux:** Ligand A (0.055) has lower P-gp efflux than Ligand B (0.7). Lower P-gp efflux is desirable for improved bioavailability. Ligand A is preferred.
**15. Binding Affinity:** Ligand A (-7.3) has a slightly better binding affinity than Ligand B (-5.6). While both are good, the 1.7 kcal/mol difference is significant and can outweigh some ADME drawbacks.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity) and the general drug-like properties, **Ligand A is the more promising candidate.** While Ligand B has a better QED and BBB penetration, Ligand A excels in critical areas like DILI risk, hERG inhibition, solubility, P-gp efflux, and binding affinity. The lower logP of Ligand A is also preferable, mitigating potential solubility and off-target issues. The negative Caco-2 values are concerning for both, but the other advantages of Ligand A outweigh this drawback.
Output:
1
2025-04-17 22:59:36,449 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, key priorities are logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB.
Let's compare the ligands property by property:
1. **MW:** Both are around 366 Da, well within the ideal range (200-500 Da).
2. **TPSA:** Ligand A (83.56) is significantly better than Ligand B (108.64). Lower TPSA generally favors oral absorption, crucial for a cardiovascular drug.
3. **logP:** Both ligands have acceptable logP values (1.261 and 1.554, respectively), falling within the 1-3 range. Ligand B is slightly higher, which *could* be a minor drawback.
4. **HBD/HBA:** Ligand A (2 HBD, 6 HBA) is slightly better than Ligand B (3 HBD, 5 HBA) in terms of maintaining a balance between solubility and permeability.
5. **QED:** Ligand A (0.759) has a better QED score than Ligand B (0.662), indicating a more drug-like profile.
6. **DILI:** Ligand A (31.291) has a much lower DILI risk than Ligand B (47.77), which is a significant advantage.
7. **BBB:** Ligand A (60.023) has a better BBB penetration than Ligand B (46.219), though neither are particularly high. Given this is a cardiovascular target, BBB isn't a primary concern, but it's still a positive for Ligand A.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual. It's difficult to interpret without knowing the scale.
9. **Solubility:** Ligand A (-1.843) has better solubility than Ligand B (-3.954).
10. **hERG:** Both have very low hERG inhibition liability (0.212 and 0.139), which is excellent.
11. **Cl_mic:** Ligand A (-13.349) has significantly better metabolic stability (lower clearance) than Ligand B (41.674). This is a major advantage.
12. **t1/2:** Ligand A (11.153) has a better in vitro half-life than Ligand B (-26.129).
13. **Pgp:** Ligand A (0.034) has a much lower Pgp efflux liability than Ligand B (0.078), which is favorable for bioavailability.
14. **Binding Affinity:** Ligand B (-7.9 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.4 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME drawbacks of Ligand B.
**Overall Assessment:**
While Ligand B boasts a superior binding affinity, Ligand A demonstrates a significantly better ADME profile, particularly regarding DILI risk, metabolic stability (Cl_mic), Pgp efflux, and solubility. The difference in binding affinity (1.5 kcal/mol) is substantial, but the combined benefits of Ligand A's ADME properties are more compelling for a cardiovascular drug candidate. A stronger binding affinity is valuable, but a drug needs to be safe and bioavailable to be effective.
**Output:**
1
2025-04-17 22:59:36,449 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, key priorities are binding affinity, logP, TPSA, Pgp efflux, and to a lesser extent, BBB.
Let's break down the comparison:
1. **MW:** Both ligands are within the ideal range (343.43 and 342.40 Da).
2. **TPSA:** Ligand A (76.39) is significantly better than Ligand B (90.45). Lower TPSA is preferred for GPCRs to enhance permeability.
3. **logP:** Ligand B (1.567) is better than Ligand A (4.17). Ligand A is pushing the upper limit and could have solubility issues.
4. **HBD/HBA:** Ligand A has 2 HBD and 5 HBA, while Ligand B has 1 HBD and 6 HBA. Both are acceptable.
5. **QED:** Both ligands have good QED scores (0.789 and 0.855).
6. **DILI:** Both have similar, moderately elevated DILI risk (61.42 and 63.09), which isn't ideal but not disqualifying.
7. **BBB:** Ligand B (82.55) is better than Ligand A (74.95), but BBB is less critical for a cardiovascular target.
8. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. This is a concern for both.
9. **Solubility:** Ligand B (-2.97) is significantly better than Ligand A (-5.28). This is a major advantage for Ligand B.
10. **hERG:** Ligand A (0.329) is slightly better than Ligand B (0.662), indicating lower cardiotoxicity risk.
11. **Cl_mic:** Ligand B (61.52) has lower clearance than Ligand A (96.95), suggesting better metabolic stability.
12. **t1/2:** Ligand B (16.74) has a much longer half-life than Ligand A (8.91). This is a significant advantage.
13. **Pgp:** Ligand A (0.386) is better than Ligand B (0.299), indicating lower P-gp efflux.
14. **Binding Affinity:** Ligand B (-7.1 kcal/mol) has a substantially stronger binding affinity than Ligand A (-5.1 kcal/mol). This is a crucial advantage, exceeding the 1.5 kcal/mol threshold.
**Overall Assessment:**
While Ligand A has a slightly better hERG profile and Pgp efflux, Ligand B wins out due to its significantly improved binding affinity, solubility, metabolic stability (lower Cl_mic, longer t1/2), and acceptable TPSA and logP. The stronger binding affinity is the most important factor, and the better ADME properties of Ligand B make it a more promising drug candidate despite the slightly higher Pgp efflux.
**Output:**
0
2025-04-17 22:59:36,449 - INFO - Batch 372 complete. Total preferences: 5952
2025-04-17 22:59:36,449 - INFO - Processing batch 373/512...
2025-04-17 23:00:25,628 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's systematically compare Ligand A and Ligand B based on the provided parameters and the guidelines, keeping in mind ADRB2 is a GPCR and therefore we prioritize logP, Pgp, TPSA, and affinity.
1. **MW:** Both ligands (349.475 and 357.397 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (83.22) is slightly higher than Ligand B (70). Both are below the 140 threshold for oral absorption, but B is better.
3. **logP:** Both ligands have good logP values (2.687 and 2.614) within the optimal 1-3 range. Very similar.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (2). Both are acceptable.
5. **HBA:** Ligand A (3) is lower than Ligand B (4). Both are acceptable.
6. **QED:** Ligand B (0.821) has a better QED score than Ligand A (0.662), indicating a more drug-like profile.
7. **DILI:** Ligand B (20.047) has a significantly lower DILI risk than Ligand A (41.76). This is a major advantage for Ligand B.
8. **BBB:** Ligand A (67.468) has a slightly higher BBB penetration percentile than Ligand B (60.644). While not a primary concern for ADRB2 (a cardiovascular target), it's a small positive for A.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.695 and -4.797), which is unusual and suggests poor permeability. This is a significant drawback for both.
10. **Solubility:** Ligand B (-2.969) has better solubility than Ligand A (-3.794).
11. **hERG:** Ligand A (0.338) has a lower hERG inhibition liability than Ligand B (0.788), which is a positive.
12. **Cl_mic:** Ligand B (46.567) has a lower microsomal clearance than Ligand A (69.497), suggesting better metabolic stability.
13. **t1/2:** Ligand B (2.258) has a longer in vitro half-life than Ligand A (-14.852). This is a significant advantage for B.
14. **Pgp:** Ligand A (0.19) has lower P-gp efflux liability than Ligand B (0.317).
15. **Affinity:** Ligand B (-7.3 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.8 kcal/mol). This is a crucial advantage, exceeding the 1.5 kcal/mol threshold.
**Overall Assessment:**
Ligand B demonstrates a superior overall profile. Its significantly stronger binding affinity, lower DILI risk, better QED score, improved metabolic stability (lower Cl_mic, longer t1/2), and better solubility outweigh the slightly lower BBB penetration and higher Pgp efflux. While both have poor Caco-2 permeability, the affinity difference is substantial enough to favor B. The hERG risk is slightly higher for B, but acceptable given the other benefits.
Output:
0
2025-04-17 23:00:25,628 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [350.321, 92.47, 2.308, 2, 4, 0.592, 54.556, 52.579, -4.738, -3.398, 0.662, 37.009, 18.56, 0.297, -6.4]
**Ligand B:** [346.387, 128.16, -0.459, 3, 5, 0.575, 37.456, 35.44, -5.668, -2.107, 0.051, -16.242, 10.779, 0.003, -8.5]
Here's a breakdown of each parameter, comparing A and B, and considering GPCR priorities:
1. **MW:** Both are within the ideal 200-500 Da range. A (350.321) is slightly higher than B (346.387), but the difference is negligible.
2. **TPSA:** A (92.47) is excellent, well below 140 and good for oral absorption. B (128.16) is still acceptable but less ideal, creeping closer to the upper limit.
3. **logP:** A (2.308) is optimal. B (-0.459) is concerningly low, potentially hindering membrane permeability and bioavailability. This is a significant drawback.
4. **HBD:** A (2) is good. B (3) is acceptable, but slightly less desirable.
5. **HBA:** A (4) is good. B (5) is acceptable, but slightly less desirable.
6. **QED:** Both (A: 0.592, B: 0.575) are above 0.5, indicating good drug-likeness.
7. **DILI:** A (54.556) is better than B (37.456), indicating lower potential for liver injury.
8. **BBB:** A (52.579) is reasonable, but not exceptionally high. B (35.44) is lower, less favorable. While ADRB2 isn't *primarily* a CNS target, some BBB penetration can be beneficial for off-target effects.
9. **Caco-2:** A (-4.738) is better than B (-5.668), indicating better intestinal absorption.
10. **Solubility:** A (-3.398) is better than B (-2.107), indicating better aqueous solubility.
11. **hERG:** A (0.662) is better than B (0.051), indicating lower hERG inhibition liability and reduced cardiotoxicity risk.
12. **Cl_mic:** A (37.009) is higher than B (-16.242), meaning B has better metabolic stability. This is a significant advantage for B.
13. **t1/2:** A (18.56) is better than B (10.779), indicating a longer half-life.
14. **Pgp:** A (0.297) is better than B (0.003), indicating lower P-gp efflux.
15. **Affinity:** B (-8.5) is significantly better than A (-6.4), a difference of 2.1 kcal/mol. This is a substantial advantage.
**Overall Assessment:**
Ligand B has a considerably stronger binding affinity, which is paramount for GPCR targets. It also exhibits superior metabolic stability (lower Cl_mic). However, its low logP and higher TPSA are significant concerns for permeability and bioavailability. Ligand A has a more balanced profile, with good logP, TPSA, solubility, and lower risk of hERG inhibition and DILI. The difference in binding affinity is substantial, but the ADME properties of Ligand B are concerning. Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), the superior affinity of Ligand B is likely to outweigh the ADME concerns, *provided* formulation strategies can be employed to address the low logP.
Therefore, I would choose Ligand B.
Output:
0
2025-04-17 23:00:25,628 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (350.46 and 351.40 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (87.66) is higher than Ligand B (52.65). For a cardiovascular GPCR, TPSA is not a *major* concern unless it exceeds 140, which neither does. Ligand B is preferable here due to better potential for permeability.
3. **logP:** Both ligands have acceptable logP values (0.979 and 1.636 respectively), falling within the 1-3 range. Ligand B is slightly better.
4. **HBD:** Ligand A has 3 HBD, while Ligand B has 1. Lower HBD is generally favorable for permeability, making Ligand B slightly better.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 3. Similar to HBD, Ligand B is slightly preferred.
6. **QED:** Ligand B (0.897) has a significantly higher QED score than Ligand A (0.597), indicating a more drug-like profile. This is a substantial advantage for Ligand B.
7. **DILI:** Both ligands have relatively low DILI risk (35.29 and 31.29 respectively), well below the concerning threshold of 60. No clear preference.
8. **BBB:** Ligand B (70.03) has a significantly higher BBB penetration percentile than Ligand A (36.37). While ADRB2 isn't strictly a CNS target, some CNS exposure can occur, and higher BBB is generally favorable. This is a strong point for Ligand B.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.816 and -4.777), which is unusual and suggests poor permeability. This is a concern for both, but not a differentiating factor.
10. **Solubility:** Both ligands have similar, very poor aqueous solubility (-1.905 and -1.866). This is a significant drawback for both and would require formulation strategies.
11. **hERG:** Both ligands have low hERG inhibition liability (0.22 and 0.7), indicating a low risk of cardiotoxicity. No clear preference.
12. **Cl_mic:** Ligand B (-19.834) has a much lower (better) microsomal clearance than Ligand A (18.944), suggesting greater metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand B (15.357 hours) has a longer in vitro half-life than Ligand A (-8.172 hours). This is a substantial advantage for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.042 and 0.053). No clear preference.
15. **Binding Affinity:** Ligand A (-5.9 kcal/mol) has a slightly better binding affinity than Ligand B (-3.2 kcal/mol). This is a 2.7 kcal/mol difference. While affinity is important, the ADME profile is significantly worse for Ligand A.
**Overall Assessment:**
Ligand B consistently outperforms Ligand A across most critical ADME properties (QED, BBB, Cl_mic, t1/2) and has a slightly better logP and TPSA. While Ligand A has a better binding affinity, the difference isn't large enough to overcome the substantial ADME deficiencies. The poor solubility of both is a concern, but can be addressed with formulation. The improved metabolic stability and longer half-life of Ligand B are particularly attractive for a cardiovascular drug.
Output:
0
2025-04-17 23:00:25,628 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (353.394 Da) is within the ideal range (200-500 Da). Ligand B (382.448 Da) is also within range. No clear advantage here.
2. **TPSA:** Ligand A (102.66) is slightly above the preferred <140 for good absorption, but acceptable. Ligand B (67.43) is excellent, well below 140, suggesting good absorption. Advantage: B.
3. **logP:** Ligand A (0.65) is a bit low, potentially hindering permeation. Ligand B (2.971) is optimal (1-3). Advantage: B.
4. **HBD:** Both ligands have 2 HBD, which is within the acceptable limit of <=5. No clear advantage.
5. **HBA:** Ligand A has 5 HBA, acceptable. Ligand B has 4 HBA, also acceptable. No clear advantage.
6. **QED:** Ligand A (0.73) is good, indicating drug-likeness. Ligand B (0.346) is significantly lower, raising concerns about its overall drug-like properties. Advantage: A.
7. **DILI:** Ligand A (31.601) has a low DILI risk. Ligand B (43.622) is slightly higher, but still within an acceptable range. Slight advantage: A.
8. **BBB:** Ligand A (58.007) is not particularly high, suggesting limited CNS penetration. Ligand B (87.321) is better, indicating a higher potential for crossing the BBB. Advantage: B.
9. **Caco-2:** Ligand A (-4.839) is very poor, indicating very low intestinal absorption. Ligand B (-5.394) is also poor, but slightly better than A. Advantage: B.
10. **Solubility:** Ligand A (-1.111) is poor. Ligand B (-3.518) is even worse. Both are problematic, but B is worse. Advantage: A.
11. **hERG:** Ligand A (0.395) has a low hERG risk. Ligand B (0.609) is slightly higher, but still acceptable. Slight advantage: A.
12. **Cl_mic:** Ligand A (1.887) has a low microsomal clearance, indicating good metabolic stability. Ligand B (29.761) has a much higher clearance, suggesting faster metabolism. Significant advantage: A.
13. **t1/2:** Ligand A (11.855) has a good in vitro half-life. Ligand B (3.265) has a shorter half-life. Advantage: A.
14. **Pgp:** Ligand A (0.028) has low P-gp efflux, which is favorable. Ligand B (0.148) has slightly higher efflux. Advantage: A.
15. **Binding Affinity:** Ligand A (-6.4 kcal/mol) and Ligand B (-5.5 kcal/mol) both have good binding affinity. Ligand A is 0.9 kcal/mol stronger, which is a significant difference. Advantage: A.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand B initially looks promising with its excellent TPSA and good logP and BBB penetration. However, its significantly lower QED, poor solubility, high metabolic clearance, shorter half-life, and weaker binding affinity are major drawbacks.
Ligand A, while having a slightly lower TPSA and logP, demonstrates a superior overall profile. Its better QED, lower DILI risk, significantly better metabolic stability (lower Cl_mic and longer t1/2), lower Pgp efflux, and notably stronger binding affinity outweigh its slightly less favorable TPSA and logP. The stronger binding affinity is particularly important for a GPCR target.
Therefore, I believe Ligand A is the more viable drug candidate.
Output:
1
2025-04-17 23:00:25,628 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (425.352 Da) is within the ideal range, while Ligand B (343.519 Da) is towards the lower end, but still acceptable.
2. **TPSA:** Ligand A (88.32) is good, below the 140 threshold. Ligand B (55.63) is excellent, further improving absorption potential.
3. **logP:** Both ligands have good logP values (A: 2.881, B: 3.469), falling within the optimal 1-3 range.
4. **HBD:** Ligand A (2) and Ligand B (1) both have acceptable HBD counts.
5. **HBA:** Both ligands have similar HBA counts (A: 5, B: 5), which are acceptable.
6. **QED:** Both ligands have good QED scores (A: 0.787, B: 0.859), indicating good drug-like properties.
7. **DILI:** Ligand A (76.968) has a higher DILI risk than Ligand B (30.593). This is a significant concern.
8. **BBB:** Ligand A (52.889) has a moderate BBB penetration, while Ligand B (77.2) is better. While ADRB2 isn't necessarily a CNS target, some peripheral distribution is still desirable.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Both have negative solubility values, which is also unusual and suggests poor solubility. Again, the scale is not specified.
11. **hERG:** Ligand A (0.611) has a slightly higher hERG risk than Ligand B (0.37).
12. **Cl_mic:** Ligand A (27.121) has a lower microsomal clearance, suggesting better metabolic stability than Ligand B (43.435).
13. **t1/2:** Ligand A (24.642) has a longer in vitro half-life than Ligand B (-2.295). This is a significant advantage.
14. **Pgp:** Both ligands have low Pgp efflux liability (A: 0.207, B: 0.225).
15. **Binding Affinity:** Ligand B (-7.9 kcal/mol) has a substantially stronger binding affinity than Ligand A (-1.5 kcal/mol). This is a major advantage, potentially outweighing some ADME concerns.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand B excels in affinity and has good logP and Pgp values. While TPSA is better for Ligand A, the difference is not substantial enough to overcome the large affinity gap. The DILI risk for Ligand A is also concerning.
**Conclusion:**
Despite the unusual Caco-2 and solubility values, the significantly stronger binding affinity of Ligand B (-7.9 kcal/mol vs -1.5 kcal/mol) and its lower DILI risk make it the more promising candidate. The longer half-life of Ligand A is a benefit, but the affinity difference is too large to ignore.
Output:
0
2025-04-17 23:00:25,628 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [360.395, 107.51 , 0.622, 0. , 6. , 0.791, 76.58 , 34.548, -4.798, -3.955, 0.234, 24.464, -36.403, 0.062, -5.8 ]
**Ligand B:** [352.395, 131.52 , -1.461, 3. , 6. , 0.514, 55.176, 20.396, -5.653, -1.088, 0.096, -3.732, 1.317, 0.024, -6.7 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (360.4) is slightly higher, but both are acceptable.
2. **TPSA:** Ligand A (107.51) is better than Ligand B (131.52). ADRB2 is not a CNS target, but lower TPSA generally correlates with better permeability.
3. **logP:** Ligand A (0.622) is within the optimal range, but on the lower side. Ligand B (-1.461) is quite low, potentially hindering permeability. This is a significant negative for Ligand B.
4. **HBD:** Ligand A (0) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Both have 6 HBA, which is acceptable.
6. **QED:** Ligand A (0.791) is better than Ligand B (0.514), indicating a more drug-like profile.
7. **DILI:** Ligand A (76.58) has a higher DILI risk than Ligand B (55.176), which is concerning.
8. **BBB:** Not a primary concern for a cardiovascular target, but Ligand A (34.55) is lower than Ligand B (20.40).
9. **Caco-2:** Ligand A (-4.798) is significantly better than Ligand B (-5.653), suggesting better intestinal absorption.
10. **Solubility:** Ligand A (-3.955) is better than Ligand B (-1.088), which is important for bioavailability.
11. **hERG:** Both are very low, indicating minimal hERG inhibition risk. Ligand A (0.234) is slightly better.
12. **Cl_mic:** Ligand B (-3.732) has a much lower (better) microsomal clearance than Ligand A (24.464), indicating greater metabolic stability.
13. **t1/2:** Ligand A (-36.403) has a much longer in vitro half-life than Ligand B (1.317), which is a significant advantage.
14. **Pgp:** Ligand A (0.062) has lower P-gp efflux than Ligand B (0.024), which is preferable.
15. **Affinity:** Ligand B (-6.7) has a slightly better binding affinity than Ligand A (-5.8), a 0.9 kcal/mol difference.
**GPCR-specific priorities:** For ADRB2 (a cardiovascular GPCR), we prioritize logP, TPSA, affinity, and metabolic stability.
**Overall Assessment:**
Ligand A has several advantages: better logP, TPSA, Caco-2 permeability, solubility, longer half-life, and lower Pgp efflux. The biggest drawback for Ligand A is the higher DILI risk. However, the significantly better ADME profile, particularly the improved permeability and half-life, coupled with a reasonably good affinity, outweighs the DILI concern. Ligand B has better metabolic stability, but its very low logP is a major concern for oral bioavailability. The affinity difference, while present, is not substantial enough to overcome the ADME deficiencies of Ligand B.
Therefore, I would choose Ligand A.
Output:
1
2025-04-17 23:00:25,629 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (390.531) is slightly higher than Ligand B (362.503), but both are acceptable.
2. **TPSA:** Ligand B (87.06) is significantly better than Ligand A (111.63). For a GPCR, lower TPSA is generally preferred for better permeability.
3. **logP:** Ligand B (2.49) is optimal, while Ligand A (-0.061) is slightly low, potentially hindering membrane permeability.
4. **HBD:** Both ligands have acceptable HBD counts (Ligand A: 3, Ligand B: 2).
5. **HBA:** Both ligands have acceptable HBA counts (Ligand A: 7, Ligand B: 8).
6. **QED:** Both ligands have good QED scores (Ligand A: 0.573, Ligand B: 0.782), indicating drug-like properties. Ligand B is better.
7. **DILI:** Ligand A (37.844) has a much lower DILI risk than Ligand B (65.568). This is a significant advantage for Ligand A.
8. **BBB:** Ligand B (51.997) has a better BBB penetration score than Ligand A (27.801), but neither is particularly high. For a cardiovascular target like ADRB2, BBB penetration is not a primary concern.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the values are similarly poor (-5.857 for A, -5.423 for B).
10. **Solubility:** Both ligands have negative solubility values, indicating poor aqueous solubility. Ligand A (-1.207) is slightly better than Ligand B (-2.693), but both are problematic.
11. **hERG:** Both ligands have low hERG inhibition risk (Ligand A: 0.232, Ligand B: 0.5). Ligand A is slightly better.
12. **Cl_mic:** Ligand A (-12.279) has significantly lower (better) microsomal clearance than Ligand B (41.026), indicating better metabolic stability.
13. **t1/2:** Ligand B (31.041) has a much longer in vitro half-life than Ligand A (-3.019). This is a significant advantage for Ligand B.
14. **Pgp:** Both ligands have very low Pgp efflux liability (Ligand A: 0.038, Ligand B: 0.145).
15. **Affinity:** Both ligands have very similar binding affinities (Ligand A: -6.6 kcal/mol, Ligand B: -6.5 kcal/mol). The difference is negligible.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand B excels in logP and has a better TPSA. Affinity is comparable. While BBB isn't critical for a cardiovascular target, Ligand B is better. However, Ligand A has a significantly better DILI score and lower Cl_mic, which are important for overall drug safety and duration of action.
**Overall Assessment:**
Ligand B has better predicted permeability (lower TPSA, better logP) and a longer half-life. However, Ligand A has a much better safety profile (lower DILI) and better metabolic stability (lower Cl_mic). Given that the binding affinity is nearly identical, the safety and metabolic stability advantages of Ligand A are more important for a chronic cardiovascular condition. The solubility issues with both are concerning, but can potentially be addressed with formulation strategies.
Output:
1
2025-04-17 23:00:25,629 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (336.366 Da) is better than Ligand B (360.483 Da), falling comfortably within the 200-500 Da range. Both are acceptable.
2. **TPSA:** Ligand A (51.22) is significantly better than Ligand B (86.88). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally correlates with better absorption. Ligand B's TPSA is getting high enough to be a concern.
3. **logP:** Both ligands have good logP values (A: 4.015, B: 3.181), within the 1-3 range. Ligand B is slightly preferred here.
4. **HBD:** Ligand A (1) is better than Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (3) is better than Ligand B (4). Similar reasoning as HBD.
6. **QED:** Ligand A (0.769) is better than Ligand B (0.6), suggesting a more drug-like profile.
7. **DILI:** Ligand B (53.625) is significantly better than Ligand A (87.01). This is a major advantage for Ligand B.
8. **BBB:** Ligand A (79.721) is better than Ligand B (32.726). While not crucial for a cardiovascular target, higher BBB is generally a positive.
9. **Caco-2:** Ligand A (-4.733) is better than Ligand B (-5.738). Higher (less negative) is better, indicating better absorption.
10. **Solubility:** Ligand A (-5.242) is better than Ligand B (-2.396). Higher (less negative) is better.
11. **hERG:** Ligand A (0.788) is better than Ligand B (0.593). Lower hERG inhibition is preferred.
12. **Cl_mic:** Ligand B (25.614) is much better than Ligand A (87.181). Lower clearance indicates better metabolic stability, a key factor.
13. **t1/2:** Ligand A (18.078) is better than Ligand B (-8.444). A positive half-life is preferred.
14. **Pgp:** Ligand A (0.782) is better than Ligand B (0.186). Lower P-gp efflux is preferred.
15. **Affinity:** Ligand A (-7.3 kcal/mol) is significantly better than Ligand B (-6.1 kcal/mol). This is a substantial difference in binding potency.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), affinity, logP, TPSA, and Pgp are important. Ligand A excels in affinity and has better TPSA and Pgp values. Ligand B has a better logP and, critically, a much lower DILI risk and better metabolic stability (Cl_mic).
**Overall Assessment:**
While Ligand B has a significantly better DILI and Cl_mic profile, the substantial advantage in binding affinity of Ligand A (-7.3 vs -6.1 kcal/mol) is a major driver. A 1.2 kcal/mol difference is large enough to potentially overcome some of the ADME liabilities of Ligand A, especially given that its other parameters are generally acceptable. The better solubility and Caco-2 permeability of Ligand A also contribute to its favorability. The DILI risk of Ligand A is concerning, but can be investigated further with additional studies.
Output:
1
2025-04-17 23:00:25,629 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (365.409 Da and 344.499 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (62.53) is higher than Ligand B (40.62). For a cardiovascular GPCR, TPSA isn't a *major* concern like it would be for a CNS target, but lower is generally preferred for better absorption. Ligand B is better.
**3. logP:** Both ligands have good logP values (3.085 and 3.374), falling within the optimal 1-3 range. No significant difference.
**4. H-Bond Donors:** Ligand A has 1 HBD, while Ligand B has 0. Both are acceptable, but fewer HBDs can sometimes improve permeability. Ligand B is slightly better.
**5. H-Bond Acceptors:** Ligand A has 6 HBA, and Ligand B has 2. Ligand B is significantly better here, contributing to better permeability.
**6. QED:** Both ligands have similar and good QED values (0.729 and 0.787), indicating good drug-like properties. No significant difference.
**7. DILI Risk:** Ligand A has a DILI risk of 77.549%, which is concerning (high risk). Ligand B has a much lower DILI risk of 13.3%, which is excellent. This is a *major* advantage for Ligand B.
**8. BBB Penetration:** Both ligands have good BBB penetration (80.264% and 83.404%). While ADRB2 isn't a CNS target, some peripheral exposure is acceptable. No significant difference.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.817 and -4.587). This is unusual and suggests poor permeability. However, these values are on a log scale, so the difference isn't massive.
**10. Aqueous Solubility:** Both have very poor aqueous solubility (-2.615 and -3.76). This is a significant drawback for both, potentially impacting bioavailability.
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (0.782% and 0.56%). This is good and avoids cardiotoxicity concerns. No significant difference.
**12. Microsomal Clearance:** Ligand A has a lower Cl_mic (14.907) than Ligand B (75.968), indicating better metabolic stability. This is a significant advantage for Ligand A.
**13. In vitro Half-Life:** Ligand A has a longer half-life (58.716 hours) than Ligand B (-11.717 hours). The negative value for Ligand B is concerning and suggests very rapid metabolism. This is a *major* advantage for Ligand A.
**14. P-gp Efflux:** Both ligands have low P-gp efflux (0.558 and 0.222), which is good for bioavailability. Ligand B is slightly better.
**15. Binding Affinity:** Both ligands have excellent binding affinity (-5.9 kcal/mol and -6.9 kcal/mol). Ligand B is slightly better, but the difference is not substantial enough to outweigh other factors.
**Overall Assessment:**
Ligand B has advantages in TPSA, HBA, DILI risk, and P-gp efflux. However, it suffers from a very poor in vitro half-life and a negative Caco-2 permeability. Ligand A has a significantly better metabolic profile (lower Cl_mic, longer half-life) and a more acceptable DILI risk. While both have poor solubility, the metabolic stability and safety profile of Ligand A are more critical for a viable drug candidate.
Therefore, I prefer Ligand A.
Output:
1
2025-04-17 23:00:25,629 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (350.5) is within the ideal range (200-500), while Ligand B (406.4) is also acceptable. No clear advantage here.
2. **TPSA:** Ligand A (67.43) is better than Ligand B (49.74) as it is lower. Lower TPSA generally favors oral absorption.
3. **logP:** Ligand A (2.973) is optimal (1-3), while Ligand B (4.388) is slightly higher, potentially leading to solubility issues or off-target interactions. Ligand A is preferred.
4. **HBD:** Both ligands have acceptable HBD counts (Ligand A: 2, Ligand B: 1).
5. **HBA:** Both ligands have acceptable HBA counts (Ligand A: 3, Ligand B: 4).
6. **QED:** Both ligands have reasonable QED values (Ligand A: 0.496, Ligand B: 0.629), but Ligand B is slightly better.
7. **DILI:** Ligand A (19.74) has a slightly higher DILI risk than Ligand B (17.14), but both are within acceptable limits (<40).
8. **BBB:** Both ligands have similar BBB penetration (Ligand A: 64.99, Ligand B: 64.21). This isn't a high priority for ADRB2, which is not a CNS target.
9. **Caco-2:** Ligand A (-4.871) and Ligand B (-5.358) both have negative Caco-2 values, which is unusual and suggests very poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand A (-2.677) is slightly better than Ligand B (-3.713), indicating better aqueous solubility.
11. **hERG:** Ligand A (0.28) has a much lower hERG risk than Ligand B (0.827), which is a critical advantage.
12. **Cl_mic:** Ligand B (32.86) has a lower microsomal clearance than Ligand A (46.97), indicating better metabolic stability.
13. **t1/2:** Ligand A (13.02) has a longer in vitro half-life than Ligand B (-12.45), which is a significant advantage.
14. **Pgp:** Ligand A (0.042) has much lower P-gp efflux liability than Ligand B (0.314), which is favorable for bioavailability.
15. **Affinity:** Ligand B (-7.6) has a significantly stronger binding affinity than Ligand A (-6.0). This is a substantial advantage, potentially outweighing some ADME concerns.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B has a better logP and affinity, while Ligand A has better TPSA and Pgp.
**Overall Assessment:**
Ligand B's significantly stronger binding affinity (-7.6 kcal/mol vs -6.0 kcal/mol) is a major advantage. While its logP is slightly higher and Pgp efflux is higher, the potency difference is substantial enough to potentially overcome these drawbacks. The lower metabolic clearance of Ligand B is also a positive. Ligand A has a better hERG profile, but the affinity difference is more important in this case. The poor Caco-2 permeability is a concern for both, but can be addressed through formulation strategies.
Output:
0
2025-04-17 23:00:25,629 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [332.363, 90.68, 2.657, 2, 4, 0.769, 85.227, 35.983, -5.1, -5.41, 0.67, 14.178, 33.788, 0.263, -7.0]**
**Ligand B: [357.426, 71.11, -0.059, 1, 5, 0.747, 20.24, 79.217, -4.944, -0.912, 0.396, -12.99, 10.002, 0.02, -6.8]**
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (332.363) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (90.68) is slightly higher than Ligand B (71.11). Both are below 140, but B is better for oral absorption.
3. **logP:** Ligand A (2.657) is within the optimal range (1-3). Ligand B (-0.059) is below 1, which is a concern for permeability.
4. **H-Bond Donors:** Both ligands have acceptable HBD counts (A: 2, B: 1).
5. **H-Bond Acceptors:** Both ligands have acceptable HBA counts (A: 4, B: 5).
6. **QED:** Both ligands have similar and good QED values (A: 0.769, B: 0.747).
7. **DILI:** Ligand A (85.227) has a significantly higher DILI risk than Ligand B (20.24). This is a major concern for Ligand A.
8. **BBB:** Ligand B (79.217) has a much higher BBB penetration potential than Ligand A (35.983). While ADRB2 isn't *always* a CNS target, improved BBB penetration can be advantageous, and isn't detrimental.
9. **Caco-2 Permeability:** Both have negative values, which is unusual. Assuming these are log scale values, Ligand A (-5.1) appears to have slightly better permeability than Ligand B (-4.944).
10. **Aqueous Solubility:** Ligand B (-0.912) has better aqueous solubility than Ligand A (-5.41).
11. **hERG Inhibition:** Ligand A (0.67) has a higher hERG inhibition liability than Ligand B (0.396), which is undesirable.
12. **Microsomal Clearance:** Ligand B (-12.99) has significantly lower microsomal clearance (better metabolic stability) than Ligand A (14.178).
13. **In vitro Half-Life:** Ligand A (33.788) has a longer in vitro half-life than Ligand B (10.002).
14. **P-gp Efflux:** Ligand A (0.263) has lower P-gp efflux than Ligand B (0.02), which is preferable.
15. **Binding Affinity:** Ligand A (-7.0) has slightly better binding affinity than Ligand B (-6.8). However, the difference is relatively small.
**GPCR-Specific Considerations:** For GPCRs, logP, Pgp, TPSA, and affinity are key. Ligand B excels in logP (though it's low), Pgp, and TPSA. Ligand A has slightly better affinity but suffers from a poor logP and higher Pgp efflux. The DILI risk for Ligand A is also a major red flag.
**Conclusion:**
Despite the slightly better binding affinity of Ligand A, the significantly lower DILI risk, better logP, and improved metabolic stability of Ligand B make it the more promising drug candidate. The lower logP of Ligand B is a concern, but the other advantages outweigh this drawback.
Output:
0
2025-04-17 23:00:25,629 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (364.47 and 357.45 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand B (52.65) is significantly better than Ligand A (95.5) regarding TPSA. For a GPCR, lower TPSA is generally preferred for better permeability. Ligand A is a bit high.
**3. logP:** Both ligands have good logP values (1.785 and 1.871), falling within the optimal 1-3 range. No clear advantage.
**4. H-Bond Donors:** Ligand B (1) is better than Ligand A (3). Fewer HBDs generally improve permeability.
**5. H-Bond Acceptors:** Both ligands have a similar number of HBA (4 and 3). Acceptable for both.
**6. QED:** Ligand B (0.817) has a higher QED score than Ligand A (0.665), indicating a more drug-like profile.
**7. DILI:** Ligand B (20.05) has a much lower DILI risk than Ligand A (59.91). This is a significant advantage for Ligand B.
**8. BBB:** Ligand B (84.53) has a much higher BBB penetration percentile than Ligand A (30.83). While ADRB2 isn't *necessarily* a CNS target, better BBB penetration can be beneficial for overall distribution and reducing off-target effects.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-5.335) is slightly worse than Ligand B (-4.718), but both are problematic.
**10. Aqueous Solubility:** Ligand B (-1.783) has better solubility than Ligand A (-3.574).
**11. hERG Inhibition:** Ligand B (0.702) has a slightly higher hERG risk than Ligand A (0.355), but both are relatively low.
**12. Microsomal Clearance:** Ligand A (74.81) has a higher microsomal clearance than Ligand B (15.81), meaning Ligand B is more metabolically stable.
**13. In vitro Half-Life:** Both ligands have similar in vitro half-lives (7.14 and 6.77 hours).
**14. P-gp Efflux:** Ligand A (0.133) has lower P-gp efflux than Ligand B (0.035), which is slightly favorable.
**15. Binding Affinity:** Ligand A (-6.4 kcal/mol) has a slightly better binding affinity than Ligand B (-6.1 kcal/mol), but the difference is small (0.3 kcal/mol) and may not be enough to overcome other deficiencies.
**Overall Assessment:**
Ligand B is the clear winner. It excels in crucial ADME properties like DILI risk, BBB penetration, solubility, and metabolic stability. While Ligand A has a slightly better binding affinity, the difference isn't substantial enough to outweigh the significant advantages of Ligand B in terms of safety and pharmacokinetic properties. The lower TPSA and QED of Ligand B are also highly favorable. The Caco-2 permeability is concerning for both, but Ligand B is slightly better in that regard.
Output:
0
2025-04-17 23:00:25,629 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (344.415 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (84.42) is significantly better than Ligand B (47.36). Lower TPSA is preferred for GPCRs, aiding in brain penetration and overall absorption.
3. **logP:** Both ligands have acceptable logP values (A: 2.075, B: 3.3), falling within the optimal 1-3 range. Ligand B is slightly higher, which *could* indicate potential off-target effects, but isn't a major concern.
4. **HBD:** Ligand A (1) is better than Ligand B (0). While both are low, having at least one HBD can improve solubility.
5. **HBA:** Both ligands have the same number of HBA (5), which is acceptable.
6. **QED:** Both ligands have good QED scores (A: 0.631, B: 0.729), indicating drug-likeness. Ligand B is slightly better.
7. **DILI:** Ligand B (33.501) is significantly better than Ligand A (61.225) in terms of DILI risk. Lower is better, and Ligand B is well below the 40% threshold.
8. **BBB:** Ligand B (88.29) is significantly better than Ligand A (74.758). For a GPCR, especially one potentially involved in cardiovascular effects where CNS side effects are a concern, higher BBB penetration is a plus.
9. **Caco-2:** Both ligands have very poor Caco-2 permeability (-4.772 and -4.639). This is a significant drawback for both compounds.
10. **Solubility:** Both ligands have poor aqueous solubility (-2.585 and -3.111). This is a concern for bioavailability.
11. **hERG:** Ligand A (0.104) is better than Ligand B (0.689) in terms of hERG inhibition liability. Lower is better.
12. **Cl_mic:** Both ligands have similar microsomal clearance (A: 45.749, B: 49.738). Neither is ideal, but they are comparable.
13. **t1/2:** Ligand A (10.145) has a better in vitro half-life than Ligand B (-21.991). A positive value is much preferred.
14. **Pgp:** Ligand A (0.051) is much better than Ligand B (0.155). Lower P-gp efflux is desirable for better bioavailability.
15. **Binding Affinity:** Ligand B (-6.8) has a slightly better binding affinity than Ligand A (-6.6), but the difference is relatively small (0.2 kcal/mol).
**GPCR-Specific Priorities:**
Considering ADRB2 is a GPCR, I prioritize TPSA, logP, Pgp, BBB, and affinity. Ligand B excels in BBB and has slightly better affinity. Ligand A has a better TPSA and Pgp efflux. However, the significantly lower DILI risk and better BBB penetration of Ligand B are more important for a cardiovascular target. The slightly better affinity of Ligand B is a bonus. The poor Caco-2 and solubility are concerning for both, but can be addressed with formulation strategies.
**Conclusion:**
Despite the slightly better TPSA and Pgp of Ligand A, the superior DILI profile, BBB penetration, and slightly better affinity of Ligand B make it the more promising drug candidate.
Output:
0
2025-04-17 23:00:25,629 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (380.941) is slightly higher than Ligand B (352.479), but both are acceptable.
2. **TPSA:** Ligand A (49.41) is well below the 140 threshold and good for oral absorption, and is preferable to Ligand B (95.74) which is getting higher.
3. **logP:** Ligand A (4.237) is a bit high, potentially leading to solubility issues, but still within a tolerable range. Ligand B (0.48) is quite low, which could hinder membrane permeability. For a GPCR, a moderate logP is preferred, and Ligand A is better here.
4. **HBD:** Ligand A (1) and Ligand B (2) are both acceptable.
5. **HBA:** Ligand A (3) and Ligand B (4) are both acceptable.
6. **QED:** Both ligands have similar QED values (0.849 and 0.752), indicating good drug-likeness.
7. **DILI:** Ligand A (38.62) has a significantly lower DILI risk than Ligand B (12.33). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (74.641) shows good BBB penetration, while Ligand B (43.311) is lower. For a GPCR, even a non-CNS one, some BBB penetration can be useful.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.034 and -5.378), which is unusual and suggests poor permeability. However, these values are on a scale where negative values are possible, and a direct comparison is difficult without knowing the scale's specifics.
10. **Solubility:** Ligand A (-4.681) has slightly better solubility than Ligand B (-1.58), but both are poor.
11. **hERG:** Ligand A (0.678) has a lower hERG risk than Ligand B (0.101).
12. **Cl_mic:** Ligand A (32.307) has a higher (worse) microsomal clearance than Ligand B (-6.2). This suggests Ligand B is more metabolically stable.
13. **t1/2:** Ligand A (-5.47) has a negative in vitro half-life, which is concerning. Ligand B (-7.723) is also negative, but more negative. These values are likely on a scale where negative values are possible, and a direct comparison is difficult without knowing the scale's specifics.
14. **Pgp:** Ligand A (0.34) has lower P-gp efflux than Ligand B (0.005), which is preferable.
15. **Binding Affinity:** Ligand B (-8.9 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.0 kcal/mol). This is a substantial advantage for Ligand B.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, and affinity. Ligand A has better logP and TPSA, and Pgp. Ligand B has significantly better affinity.
**Overall Assessment:**
Ligand B's substantially higher binding affinity (-8.9 kcal/mol vs -6.0 kcal/mol) is a major advantage that can potentially outweigh some of its ADME drawbacks. While Ligand B has a lower logP and higher DILI risk, the strong binding is crucial for a GPCR target. The negative Caco-2 and t1/2 values are concerning for both, but the affinity difference is significant.
Output:
0
2025-04-17 23:00:25,630 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
The ADRB2 receptor is a GPCR, so the priorities are logP, Pgp, TPSA, affinity, and BBB. Let's break down the comparison:
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (335.411) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (73.95) is significantly better than Ligand B (105.48). A TPSA under 140 is good for oral absorption, but lower is generally preferred for GPCRs, and A is much closer to the ideal range for CNS penetration if needed.
3. **logP:** Ligand A (1.878) is within the optimal range (1-3). Ligand B (-0.174) is *below* 1, which raises concerns about permeability. This is a significant drawback for B.
4. **H-Bond Donors/Acceptors:** Ligand A (HBD=1, HBA=5) is better than Ligand B (HBD=3, HBA=6). Lower counts are generally preferred for better membrane permeability.
5. **QED:** Ligand A (0.909) is excellent, indicating high drug-likeness. Ligand B (0.573) is acceptable, but not as strong.
6. **DILI:** Ligand B (37.069) has a slightly lower DILI risk than Ligand A (46.762), which is a minor positive for B.
7. **BBB:** Ligand A (64.327) has a much better BBB percentile than Ligand B (29.081). While ADRB2 isn't strictly a CNS target, some CNS exposure can occur, and a higher BBB is generally a positive attribute.
8. **Caco-2 Permeability:** Both have negative Caco-2 values, which is unusual and suggests issues with the prediction method or the compounds themselves. This is difficult to interpret directly.
9. **Aqueous Solubility:** Both have negative solubility values, which is also unusual. Again, difficult to interpret.
10. **hERG:** Ligand A (0.586) has a slightly better hERG profile than Ligand B (0.077), indicating lower cardiotoxicity risk.
11. **Microsomal Clearance:** Ligand A (-14.051) has significantly lower (better) microsomal clearance than Ligand B (-5.825), suggesting greater metabolic stability.
12. **In vitro Half-Life:** Ligand A (38.232) has a longer half-life than Ligand B (27.203), which is desirable.
13. **P-gp Efflux:** Ligand A (0.103) has lower P-gp efflux than Ligand B (0.006), meaning it's less likely to be pumped out of cells, improving bioavailability.
14. **Binding Affinity:** Ligand A (-6.6 kcal/mol) has a slightly better binding affinity than Ligand B (-5.2 kcal/mol). While the difference isn't huge, it's enough to be a factor.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical parameters, particularly logP, TPSA, metabolic stability (Cl_mic), and P-gp efflux. The slightly better affinity and much better BBB penetration are also significant advantages. While Ligand B has a slightly lower DILI risk, the other drawbacks are more substantial. The negative solubility and Caco-2 values are concerning for both, but the other properties of A make it the stronger candidate.
**Output:**
1
2025-04-17 23:00:25,630 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (363.527) is slightly higher than Ligand B (344.455), but both are acceptable.
2. **TPSA:** Ligand A (62.3) is better than Ligand B (69.64). Both are below 140, but lower is preferred for absorption.
3. **logP:** Ligand A (3.45) is optimal, while Ligand B (1.828) is on the lower side of optimal. This favors Ligand A for membrane permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is preferable to Ligand B (3). Fewer HBAs generally improve permeability.
6. **QED:** Both ligands have acceptable QED values (Ligand A: 0.842, Ligand B: 0.774), indicating good drug-like properties. Ligand A is slightly better.
7. **DILI:** Ligand B (11.632) has a significantly lower DILI risk than Ligand A (47.732). This is a major advantage for Ligand B.
8. **BBB:** Ligand A (70.415) has a much higher BBB penetration potential than Ligand B (40.403). While ADRB2 isn't strictly a CNS target, some CNS exposure can be relevant for side effect profiles.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. Ligand A (-5.061) is slightly better than Ligand B (-4.911).
10. **Solubility:** Both ligands have negative solubility values, indicating poor solubility. Ligand B (-2.07) is slightly better than Ligand A (-3.197).
11. **hERG:** Both ligands have low hERG inhibition risk (Ligand A: 0.427, Ligand B: 0.342). Both are good.
12. **Cl_mic:** Ligand B (14.621) has a lower microsomal clearance than Ligand A (35.484), suggesting better metabolic stability.
13. **t1/2:** Ligand A (12.262) has a longer in vitro half-life than Ligand B (-15.173). This is a significant advantage for Ligand A.
14. **Pgp:** Both ligands have low P-gp efflux liability (Ligand A: 0.483, Ligand B: 0.144). Ligand B is better.
15. **Binding Affinity:** Both ligands have very similar binding affinities (Ligand A: -5.4 kcal/mol, Ligand B: -4.9 kcal/mol). Ligand A is slightly better.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A has a better logP, TPSA, and affinity. Ligand B has better Pgp and DILI. The difference in affinity is not substantial enough to outweigh the lower DILI risk of Ligand B.
**Overall Assessment:**
While Ligand A has some advantages in terms of permeability and half-life, Ligand B's significantly lower DILI risk and better metabolic stability are crucial for a viable drug candidate. The slightly lower BBB penetration is less concerning for a peripheral target like ADRB2.
Output:
0
2025-04-17 23:00:25,630 - INFO - Batch 373 complete. Total preferences: 5968
2025-04-17 23:00:25,630 - INFO - Processing batch 374/512...
2025-04-17 23:01:12,722 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (399.208 and 376.513 Da) are within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (87.2) is slightly higher than Ligand B (49.41). For a cardiovascular GPCR, TPSA isn't *as* critical as for a CNS target, but lower is generally preferred for permeability. Ligand B has a significant advantage.
3. **logP:** Both ligands have good logP values (2.43 and 3.166), falling within the optimal 1-3 range. Ligand B is slightly higher, which could potentially lead to some off-target interactions, but it's not a major concern.
4. **HBD:** Ligand A has 0 HBD, and Ligand B has 1. Both are acceptable.
5. **HBA:** Ligand A has 8 HBA, while Ligand B has 3. Ligand B is significantly better here, contributing to better permeability.
6. **QED:** Ligand B (0.742) has a better QED score than Ligand A (0.49), indicating a more drug-like profile.
7. **DILI:** Ligand A has a very high DILI risk (99.031 percentile), which is a major red flag. Ligand B has a much lower DILI risk (22.838 percentile), a huge advantage.
8. **BBB:** Both ligands have reasonably high BBB penetration (71.539 and 96.355 percentile). Since ADRB2 is not a CNS target, this is less important, but Ligand B is better.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.939 and -4.875). These values are unusual and suggest poor permeability, but are likely a data artifact.
10. **Solubility:** Both ligands have negative solubility values (-3.371 and -3.611). These values are also unusual and suggest poor solubility, but are likely a data artifact.
11. **hERG:** Ligand A (0.237) has a lower hERG risk than Ligand B (0.772), which is a positive.
12. **Cl_mic:** Ligand A has a higher microsomal clearance (98.721) than Ligand B (42.801), suggesting lower metabolic stability. Ligand B is significantly better.
13. **t1/2:** Ligand B has a longer in vitro half-life (-5.165 hours) than Ligand A (-4.742 hours).
14. **Pgp:** Ligand A (0.329) has lower P-gp efflux than Ligand B (0.162), which is preferable.
15. **Binding Affinity:** Ligand A (-8.1 kcal/mol) has a slightly better binding affinity than Ligand B (-6.0 kcal/mol). This is a significant difference, but it needs to be weighed against the other factors.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity, the extremely high DILI risk is a deal-breaker. Ligand B has a much better safety profile (lower DILI), better QED, better metabolic stability (lower Cl_mic, longer t1/2), and more favorable physicochemical properties (lower TPSA, HBA). The slightly lower binding affinity of Ligand B is likely surmountable with further optimization. Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand B is the more promising candidate.
Output:
0
2025-04-17 23:01:12,722 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (418.253 Da) is slightly higher than Ligand B (370.513 Da), but both are acceptable.
2. **TPSA:** Ligand A (32.7) is significantly better than Ligand B (49.84). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (A: 4.299, B: 4.576), slightly above the optimal 1-3 range, but still acceptable. This suggests good membrane permeability.
4. **HBD:** Ligand A (1) is preferred over Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (3) is preferred over Ligand B (5). Fewer HBAs generally improve permeability.
6. **QED:** Both ligands have similar QED values (A: 0.728, B: 0.702), indicating good drug-likeness.
7. **DILI:** Both ligands have acceptable DILI risk (A: 35.905, B: 40.83), below the 40% threshold.
8. **BBB:** Ligand B (89.686) has a higher BBB penetration percentile than Ligand A (71.811). While not a primary concern for a cardiovascular target, it's a slight advantage for Ligand B.
9. **Caco-2:** Ligand A (-4.425) shows better Caco-2 permeability than Ligand B (-4.971).
10. **Solubility:** Ligand A (-3.775) shows better aqueous solubility than Ligand B (-4.937).
11. **hERG:** Both ligands have low hERG inhibition liability (A: 0.965, B: 0.833), which is excellent.
12. **Cl_mic:** Ligand A (41.155) has lower microsomal clearance than Ligand B (71.047), indicating better metabolic stability.
13. **t1/2:** Both ligands have similar in vitro half-lives (A: 51.212, B: 53.726).
14. **Pgp:** Ligand A (0.867) has lower P-gp efflux liability than Ligand B (0.592), suggesting better oral bioavailability.
15. **Binding Affinity:** Ligand B (-6.9 kcal/mol) has a slightly better binding affinity than Ligand A (-6.2 kcal/mol). This is a 0.7 kcal/mol difference, which is significant.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B has a slightly better logP and significantly better affinity. However, Ligand A excels in TPSA, Pgp, solubility, and metabolic stability (Cl_mic). The affinity difference, while notable, isn't overwhelming. The better ADME profile of Ligand A, particularly the lower TPSA and Pgp efflux, is more compelling for overall drug development success.
**Conclusion:**
Considering the balance of properties and the priorities for a GPCR target, Ligand A appears to be the more promising drug candidate.
Output:
1
2025-04-17 23:01:12,722 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [335.495, 36.95, 3.99, 2, 3, 0.887, 12.214, 78.364, -5.41, -2.261, 0.824, -11.728, 31.07, 0.28, -7.6]
**Ligand B:** [354.491, 78.87, 1.848, 2, 4, 0.662, 15.587, 51.532, -4.372, -2.354, 0.308, 46.291, -17.174, 0.195, -6.9]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (335.5) is slightly better being closer to the lower end, potentially aiding permeability.
2. **TPSA:** Ligand A (36.95) is significantly better than Ligand B (78.87). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (3.99) is optimal, while Ligand B (1.848) is a bit low. A logP below 2 can sometimes hinder membrane permeability.
4. **HBD:** Both have 2 HBD, which is good.
5. **HBA:** Ligand A (3) is better than Ligand B (4). Lower HBA generally improves permeability.
6. **QED:** Ligand A (0.887) is significantly better than Ligand B (0.662), indicating a more drug-like profile.
7. **DILI:** Ligand A (12.214) is much better than Ligand B (15.587), indicating a lower risk of liver injury.
8. **BBB:** Ligand A (78.364) is better than Ligand B (51.532). While not a CNS target, some degree of BBB penetration can indicate favorable permeability characteristics.
9. **Caco-2:** Ligand A (-5.41) is better than Ligand B (-4.372). Higher (less negative) values indicate better absorption.
10. **Solubility:** Both are poor (-2.261 and -2.354). This is a concern for both, but not a deciding factor.
11. **hERG:** Ligand A (0.824) is better than Ligand B (0.308), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand A (-11.728) is *much* better than Ligand B (46.291). This indicates significantly better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (31.07) is better than Ligand B (-17.174). A longer half-life is generally desirable.
14. **Pgp:** Ligand A (0.28) is better than Ligand B (0.195), indicating lower P-glycoprotein efflux.
15. **Affinity:** Ligand A (-7.6) is slightly better than Ligand B (-6.9), though the difference is not huge.
**GPCR-Specific Priorities:** For ADRB2 (a cardiovascular GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A excels in all these areas. Metabolic stability (Cl_mic) is also crucial, and Ligand A is *far* superior in this regard.
**Conclusion:**
Ligand A is the clear winner. It has a better drug-like profile (QED), lower DILI risk, better metabolic stability, better permeability characteristics (TPSA, Caco-2, Pgp), and slightly better affinity. While both have solubility issues, the other advantages of Ligand A outweigh this concern.
1
2025-04-17 23:01:12,722 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (343.442 and 368.905 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (38.33) is significantly better than Ligand B (58.64). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand A is well below the 140 A^2 threshold, while Ligand B is approaching it.
**3. logP:** Ligand A (4.117) is slightly higher than Ligand B (2.689). While both are within the acceptable 1-3 range, Ligand A is at the upper end. This could potentially lead to solubility issues, but is not a dealbreaker.
**4. H-Bond Donors:** Both ligands have 1 HBD, which is good.
**5. H-Bond Acceptors:** Ligand A has 2 HBA, and Ligand B has 3. Both are within the acceptable range of <=10.
**6. QED:** Both ligands have good QED scores (0.597 and 0.716), indicating good drug-like properties.
**7. DILI Risk:** Ligand A (24.855) has a lower DILI risk than Ligand B (18.922), which is favorable.
**8. BBB Penetration:** Ligand A (87.67) has better BBB penetration than Ligand B (76.658). While ADRB2 is a cardiovascular target, some CNS effects are possible with beta-blockers, and better BBB penetration is generally not detrimental.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.641 and -4.591). This is unusual and suggests poor permeability. However, these values are very close, so it doesn't heavily influence the decision.
**10. Aqueous Solubility:** Ligand A (-4.377) is slightly worse than Ligand B (-3.046), but both are poor. The higher logP of Ligand A likely contributes to this.
**11. hERG Inhibition:** Ligand A (0.752) has a slightly higher hERG risk than Ligand B (0.273). This is a concern, but not a disqualifier.
**12. Microsomal Clearance:** Ligand A (69.112) has higher microsomal clearance than Ligand B (58.832), suggesting lower metabolic stability.
**13. In vitro Half-Life:** Ligand B (-4.601) has a significantly longer in vitro half-life than Ligand A (2.353). This is a major advantage for Ligand B.
**14. P-gp Efflux:** Ligand A (0.721) has slightly higher P-gp efflux than Ligand B (0.186), which is unfavorable.
**15. Binding Affinity:** Both ligands have very similar and strong binding affinities (-6.6 and -6.7 kcal/mol). The difference is negligible.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand A has a better TPSA and BBB penetration. However, Ligand B has a significantly better in vitro half-life, lower P-gp efflux, lower hERG risk, and a lower DILI risk. The slightly higher logP and lower solubility of Ligand A are concerning, and the metabolic stability is worse. The slightly better BBB penetration of Ligand A is not critical for a cardiovascular target.
Therefore, I believe Ligand B is the more promising drug candidate due to its superior ADME-Tox profile, particularly the improved metabolic stability and reduced off-target liabilities.
Output:
0
2025-04-17 23:01:12,722 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (351.491) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (61.88) is significantly better than Ligand B (88.07). ADRB2 is a cardiovascular target, not necessarily CNS, but lower TPSA is still beneficial for absorption. Ligand B is approaching a less desirable range.
3. **logP:** Ligand A (1.535) is optimal, while Ligand B (0.289) is quite low. This is a significant drawback for Ligand B, potentially hindering membrane permeability and bioavailability.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A (4) is better than Ligand B (6), keeping within the preferred range.
6. **QED:** Both are similar and acceptable (A: 0.756, B: 0.703).
7. **DILI:** Ligand A (6.747) is much better than Ligand B (56.805). This is a major advantage for Ligand A, indicating a lower risk of liver toxicity.
8. **BBB:** Not a primary concern for a cardiovascular target, but Ligand A (68.941) is better than Ligand B (46.026).
9. **Caco-2:** Ligand A (-4.808) is better than Ligand B (-5.34), suggesting better intestinal absorption.
10. **Solubility:** Ligand A (-1.256) is better than Ligand B (-2.395), which is important for formulation and bioavailability.
11. **hERG:** Ligand A (0.325) is much better than Ligand B (0.083), indicating a lower risk of cardiotoxicity. This is crucial for a cardiovascular target.
12. **Cl_mic:** Ligand A (14.559) is significantly better than Ligand B (28.428), indicating better metabolic stability.
13. **t1/2:** Ligand A (12.687) is better than Ligand B (1.131), suggesting a longer duration of action.
14. **Pgp:** Ligand A (0.018) is much better than Ligand B (0.104), indicating less efflux and better bioavailability.
15. **Binding Affinity:** Ligand A (-5.5) is significantly better than Ligand B (-0.2). This is a decisive factor; the difference in binding is substantial.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across nearly all critical parameters. While both have acceptable QED and HBD/HBA counts, Ligand A excels in ADME properties (DILI, solubility, Cl_mic, t1/2, Pgp) and, most importantly, *binding affinity*. Ligand B's low logP and high DILI/Pgp are significant liabilities. The substantial difference in binding affinity (-5.5 vs -0.2 kcal/mol) is enough to overcome any minor drawbacks Ligand A might have.
Output:
1
2025-04-17 23:01:12,722 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (357.8 & 370.5 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (89.03) is slightly higher than Ligand B (78.87). Both are below the 140 threshold for good oral absorption, and acceptable for a cardiovascular GPCR. Ligand B is slightly preferred.
3. **logP:** Ligand A (2.89) is within the optimal 1-3 range. Ligand B (0.879) is a bit low, potentially impacting permeability. Ligand A is preferred.
4. **HBD:** Both have 2 HBD, which is good.
5. **HBA:** Ligand A has 6 HBA, Ligand B has 5. Both are acceptable.
6. **QED:** Both ligands have good QED scores (0.682 and 0.726). No significant difference.
7. **DILI:** Ligand A has a high DILI risk (98.216%), while Ligand B has a much lower risk (35.285%). This is a major concern for Ligand A. Ligand B is strongly preferred.
8. **BBB:** Both have moderate BBB penetration, but Ligand A (67.468%) is higher than Ligand B (35.828%). Since ADRB2 is a cardiovascular target, BBB penetration is less critical, but still a slight edge to A.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
10. **Solubility:** Both have negative solubility values, also unusual. Again, the scale is unknown.
11. **hERG:** Both have very low hERG inhibition risk (0.402 and 0.249). No significant difference.
12. **Cl_mic:** Ligand A (41.245) and Ligand B (39.572) have similar microsomal clearance values.
13. **t1/2:** Ligand A (76.53) has a much longer in vitro half-life than Ligand B (-2.345). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.096) has lower P-gp efflux liability than Ligand B (0.058). Lower is better, so Ligand A is slightly preferred.
15. **Binding Affinity:** Ligand A (-8.2 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.6 kcal/mol). This is a substantial advantage that can outweigh some ADME concerns.
**Overall Assessment:**
Ligand A has a significantly better binding affinity and longer half-life, and slightly better BBB penetration and Pgp efflux. However, its extremely high DILI risk is a major red flag. Ligand B has a much more favorable safety profile (DILI) and a reasonable logP, but weaker binding affinity and a shorter half-life.
Given the GPCR-specific priorities (logP, Pgp, TPSA, affinity) and the importance of safety, the lower DILI risk of Ligand B is a critical factor. While the affinity difference is substantial, a high DILI risk often leads to attrition during development. The slightly lower logP of Ligand B is a manageable concern, and could potentially be addressed with further optimization.
Output:
0
2025-04-17 23:01:12,723 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.471 and 340.467 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Both ligands (58.64 and 58.2) are below the 140 A^2 threshold for good oral absorption, and well below the 90 A^2 threshold for CNS targets (though this is less important for ADRB2 which is not a CNS target). No significant difference.
3. **logP:** Ligand A (2.243) is within the optimal 1-3 range. Ligand B (3.673) is slightly higher, but still acceptable.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (2). Lower HBA generally improves permeability.
6. **QED:** Ligand A (0.849) is better than Ligand B (0.776), indicating a more drug-like profile.
7. **DILI:** Ligand A (14.618%) has a significantly lower DILI risk than Ligand B (44.281%). This is a major advantage for Ligand A.
8. **BBB:** Both ligands have good BBB penetration (78.558% and 73.75%), but Ligand A is slightly better. This isn't a high priority for ADRB2.
9. **Caco-2:** Ligand A (-4.725) is better than Ligand B (-4.596), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-2.803) is better than Ligand B (-4.09). Better solubility is always preferred.
11. **hERG:** Both ligands have low hERG inhibition risk (0.404 and 0.302). No significant difference.
12. **Cl_mic:** Ligand A (24.557 mL/min/kg) has a significantly lower microsomal clearance than Ligand B (69.85 mL/min/kg), indicating better metabolic stability.
13. **t1/2:** Ligand A (2.702 hours) is better than Ligand B (-26.949 hours). A positive half-life is desirable.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.093 and 0.317). No significant difference.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-5.9 and -5.6 kcal/mol). The difference is not large enough to outweigh other factors.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Both ligands perform well in these areas. However, the significant advantages of Ligand A in DILI risk, metabolic stability (Cl_mic), solubility, and QED make it the superior candidate.
**Output:**
1
2025-04-17 23:01:12,723 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (354.451) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (102.05) is better than Ligand A (122.55), falling well below the 140 threshold for good oral absorption. This is a significant advantage.
3. **logP:** Ligand B (1.377) is within the optimal range (1-3), while Ligand A (0.259) is quite low, potentially hindering membrane permeability. This is a substantial negative for Ligand A.
4. **HBD:** Ligand A (4) is slightly higher than Ligand B (2), but both are acceptable.
5. **HBA:** Ligand B (7) is higher than Ligand A (4), but still within the reasonable limit of 10.
6. **QED:** Ligand B (0.721) has a better QED score than Ligand A (0.444), indicating a more drug-like profile.
7. **DILI:** Both ligands have relatively high DILI risk (Ligand A: 20.977, Ligand B: 71.074), but Ligand B is considerably higher. This is a concern for Ligand B.
8. **BBB:** Ligand A (71.578) has a better BBB penetration score than Ligand B (59.325). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be useful for understanding off-target effects and distribution.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Both ligands have negative solubility values, which is also unusual. This suggests poor solubility.
11. **hERG:** Both ligands have very low hERG inhibition risk (Ligand A: 0.123, Ligand B: 0.161), which is excellent.
12. **Cl_mic:** Ligand A (29.793) has a lower microsomal clearance than Ligand B (42.34), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-10.259) has a much longer in vitro half-life than Ligand A (-5.616), which is a major advantage.
14. **Pgp:** Both ligands have very low P-gp efflux liability (Ligand A: 0.017, Ligand B: 0.118), which is favorable.
15. **Binding Affinity:** Ligand B (-6.1 kcal/mol) has a slightly better binding affinity than Ligand A (-5.6 kcal/mol).
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, and binding affinity are critical. Ligand B excels in TPSA and has a better logP, and slightly better affinity. While Ligand A has a better BBB score, the poor logP is a significant drawback. The longer half-life of Ligand B is also a major benefit. The higher DILI risk for Ligand B is concerning, but the other factors outweigh this.
**Conclusion:**
Despite the higher DILI risk, Ligand B is the more promising candidate due to its superior logP, TPSA, QED, and in vitro half-life, coupled with acceptable binding affinity. The poor Caco-2 and solubility values are concerning for both, but can be addressed through formulation strategies.
Output:
0
2025-04-17 23:01:12,723 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
Let's analyze each ligand against the provided guidelines, keeping in mind ADRB2 is a GPCR and thus we prioritize logP, Pgp, TPSA, and affinity, alongside general drug-like properties.
* **Molecular Weight:** Both ligands (359.8 and 349.5 Da) fall comfortably within the ideal 200-500 Da range.
* **TPSA:** Ligand A (64.63) is better than Ligand B (71.54). Both are below the 140 threshold for oral absorption, but lower is preferable.
* **logP:** Ligand A (3.729) is slightly higher than Ligand B (1.839). While both are within the 1-3 range, Ligand A is closer to the upper limit, which could pose solubility challenges, but is generally acceptable for a GPCR target. Ligand B's logP is on the lower side.
* **H-Bond Donors/Acceptors:** Ligand A (1 HBD, 4 HBA) is more favorable than Ligand B (2 HBD, 7 HBA). Lower counts generally improve permeability.
* **QED:** Both ligands have similar QED scores (0.652 and 0.659), indicating good drug-likeness.
* **DILI:** Ligand B (26.095) has a significantly lower DILI risk than Ligand A (93.525). This is a major advantage for Ligand B.
* **BBB:** Ligand B (68.399) has a better BBB penetration score than Ligand A (56.534). While ADRB2 isn't strictly a CNS target, some peripheral distribution is still desirable, and better BBB penetration often correlates with improved overall distribution.
* **Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.692) is slightly better than Ligand B (-5.104), but both are problematic.
* **Aqueous Solubility:** Ligand B (-1.905) is significantly better than Ligand A (-5.358). This is important, especially given Ligand A's higher logP.
* **hERG Inhibition:** Ligand A (0.161) has a lower hERG inhibition risk than Ligand B (0.905). This is a significant advantage for Ligand A.
* **Microsomal Clearance:** Ligand B (34.4) has a lower microsomal clearance than Ligand A (40.397), indicating better metabolic stability.
* **In vitro Half-Life:** Ligand B (24.734) has a longer half-life than Ligand A (18.712).
* **P-gp Efflux:** Ligand A (0.222) has lower P-gp efflux than Ligand B (0.017). Lower P-gp efflux is generally preferred.
* **Binding Affinity:** Ligand A (-7.0) has a slightly better binding affinity than Ligand B (-5.6). This is a 1.4 kcal/mol difference, which is substantial enough to potentially outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand A has a better binding affinity and lower P-gp efflux, but suffers from significantly higher DILI risk, poorer solubility, and a lower BBB score. Ligand B has a much better safety profile (DILI), solubility, BBB penetration, and metabolic stability, with only a slightly weaker binding affinity. Given the importance of safety and ADME properties in drug development, and the relatively small difference in binding affinity, I believe Ligand B is the more promising candidate. The improved ADME profile of Ligand B will likely translate to better *in vivo* efficacy and a lower risk of attrition during development.
**Output:**
0
2025-04-17 23:01:12,723 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (355.394) is slightly higher than Ligand B (341.415), but both are acceptable.
2. **TPSA:** Ligand A (56.15) is significantly better than Ligand B (90.98). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary goal, but lower TPSA generally correlates with better absorption. Ligand B is pushing the upper limit for good oral absorption.
3. **logP:** Ligand A (4.188) is a bit high, potentially leading to solubility issues and off-target interactions. Ligand B (1.404) is excellent, falling squarely within the optimal range.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (4). Fewer HBAs generally improve permeability.
6. **QED:** Both ligands have good QED scores (A: 0.6, B: 0.831), indicating good drug-like properties. Ligand B is slightly better here.
7. **DILI:** Ligand A (96.898) has a very high DILI risk, which is a major concern. Ligand B (52.385) has a much lower, acceptable DILI risk. This is a critical factor.
8. **BBB:** Not a high priority for a cardiovascular target. Ligand A (61.342) and Ligand B (29.934) are both low.
9. **Caco-2:** Ligand A (-4.734) is better than Ligand B (-5.479), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-4.682) is better than Ligand B (-2.048), indicating better aqueous solubility.
11. **hERG:** Ligand A (0.828) is better than Ligand B (0.44), indicating lower hERG inhibition liability.
12. **Cl_mic:** Ligand A (75.964) is better than Ligand B (-19.716). A negative value for Cl_mic suggests very high metabolic stability, which is excellent.
13. **t1/2:** Ligand A (16.606) is better than Ligand B (-15.196). A negative value for t1/2 suggests very high in vitro half-life, which is excellent.
14. **Pgp:** Ligand A (0.857) is better than Ligand B (0.026), indicating lower P-gp efflux.
15. **Binding Affinity:** Ligand A (-6.8) is slightly better than Ligand B (-5.2), but the difference is not substantial enough to overcome the other significant issues with Ligand A.
**Overall Assessment:**
Ligand A has better binding affinity, Caco-2, solubility, hERG, Cl_mic, t1/2, and Pgp. However, its extremely high DILI risk is a deal-breaker. Ligand B has a much more favorable safety profile (DILI) and a good logP, QED, and acceptable ADME properties. While its affinity is slightly lower, the overall balance of properties makes it a more viable drug candidate.
Output:
0
2025-04-17 23:01:12,723 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (372.49 & 360.89 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (59.73) is significantly better than Ligand A (104.73). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (3.802) is higher than Ligand A (1.318). While both are within the acceptable range, Ligand B is approaching the upper limit. This could potentially lead to solubility issues, but might be acceptable given the target.
4. **HBD:** Ligand A (3) is higher than Ligand B (0). Lower HBD is generally preferred for permeability, giving a slight edge to Ligand B.
5. **HBA:** Ligand B (6) is higher than Ligand A (5). Similar to HBD, lower is better, but the difference is small.
6. **QED:** Ligand B (0.776) is better than Ligand A (0.574), indicating a more drug-like profile.
7. **DILI:** Ligand B (52.39) has a lower DILI risk than Ligand A (25.51). Both are below the 40% threshold, but lower is always better.
8. **BBB:** Ligand B (78.87) has a higher BBB penetration than Ligand A (53.51). While not a primary concern for a cardiovascular target, higher BBB is generally favorable.
9. **Caco-2:** Ligand A (-4.888) has a better Caco-2 permeability than Ligand B (-5.379). This suggests better intestinal absorption for Ligand A.
10. **Solubility:** Ligand A (-1.202) has better solubility than Ligand B (-3.77). This is a significant advantage for Ligand A, especially given Ligand B's higher logP.
11. **hERG:** Ligand A (0.493) has a slightly lower hERG risk than Ligand B (0.296). Both are low, but lower is better.
12. **Cl_mic:** Ligand A (20.21) has lower microsomal clearance than Ligand B (35.07), suggesting better metabolic stability.
13. **t1/2:** Ligand A (19.38) has a longer in vitro half-life than Ligand B (-7.38). This is a significant advantage for Ligand A, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.118) has lower P-gp efflux than Ligand B (0.396), suggesting better bioavailability.
15. **Affinity:** Ligand A (-6.1) has slightly better binding affinity than Ligand B (-5.8). While the difference is small (0.3 kcal/mol), it's still a positive for Ligand A.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand B excels in logP and BBB, while Ligand A has better TPSA, Pgp, solubility, metabolic stability, and half-life. The affinity difference is minor.
**Overall Assessment:**
Ligand A demonstrates a more balanced profile, particularly regarding ADME properties crucial for oral bioavailability and duration of action. The better solubility, metabolic stability (lower Cl_mic and longer t1/2), and lower P-gp efflux are significant advantages. While Ligand B has a slightly higher logP and BBB, the potential drawbacks associated with these (solubility issues, potential off-target effects) are outweighed by Ligand A's superior ADME properties. The affinity difference is minimal.
Output:
1
2025-04-17 23:01:12,723 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [347.434, 52.65, 1.84, 1, 3, 0.904, 9.616, 93.137, -4.976, -2.287, 0.45, -19.551, -16.947, 0.028, -6.5]
**Ligand B:** [344.39, 82.16, 3.29, 1, 5, 0.833, 60.372, 70.88, -4.725, -4.391, 0.557, 72.489, 49.793, 0.199, -6.4]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, BBB, and affinity are key):
1. **MW:** Both are within the ideal range (200-500 Da). A is 347.434, B is 344.39. Very similar.
2. **TPSA:** A (52.65) is excellent, well below the 140 threshold and very favorable for oral absorption. B (82.16) is still reasonable, but less optimal.
3. **logP:** A (1.84) is optimal. B (3.29) is approaching the upper limit, but still acceptable.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** A has 3, B has 5. Both are acceptable, but A is slightly better.
6. **QED:** A (0.904) is excellent, indicating high drug-likeness. B (0.833) is good, but not as strong.
7. **DILI:** A (9.616) is *very* favorable, indicating a low risk of liver injury. B (60.372) is moderately high, a potential concern.
8. **BBB:** A (93.137) is excellent, suggesting good potential for CNS penetration (although less critical for a cardiovascular target, it's not detrimental). B (70.88) is good, but significantly lower.
9. **Caco-2:** Both are negative, indicating good permeability. A (-4.976) is slightly better than B (-4.725).
10. **Solubility:** Both are negative, indicating good solubility. A (-2.287) is slightly better than B (-4.391).
11. **hERG:** Both are low (0.45 and 0.557), indicating low cardiotoxicity risk. Very similar.
12. **Cl_mic:** A (-19.551) is *much* better (lower is better) than B (72.489), indicating significantly higher metabolic stability.
13. **t1/2:** A (-16.947) is much better than B (49.793), indicating a longer half-life.
14. **Pgp:** A (0.028) is excellent, suggesting minimal P-gp efflux. B (0.199) is higher, indicating more efflux.
15. **Affinity:** Both are -6.4 kcal/mol, essentially identical.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across several critical ADME properties. Its superior TPSA, QED, DILI risk, BBB penetration, metabolic stability (Cl_mic and t1/2), and P-gp efflux profile make it a much more promising drug candidate. While both have acceptable logP and hERG values, and identical binding affinity, the ADME profile of A is significantly more favorable. For a GPCR, the better BBB penetration and lower efflux of A are also advantageous. The lower DILI risk is a major plus.
Therefore, I strongly prefer Ligand A.
Output:
1
2025-04-17 23:01:12,723 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (344.46 & 351.45 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (69.34) is slightly higher than Ligand B (55.63). Both are below the 140 threshold for good oral absorption, but B is better.
3. **logP:** Both ligands have good logP values (2.398 & 3.084), falling within the optimal 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Ligand A (0) has no H-bond donors, while Ligand B (1) has one. Lower is generally preferred for permeability, so A is slightly better.
5. **HBA:** Ligand A (4) and Ligand B (5) are both acceptable, under the 10 threshold.
6. **QED:** Both ligands have good QED scores (0.796 & 0.8), indicating good drug-like properties. No significant difference.
7. **DILI:** Ligand B (44.44) has a significantly lower DILI risk than Ligand A (56.22). This is a major advantage for Ligand B.
8. **BBB:** Ligand B (91.59) has a much higher BBB penetration percentile than Ligand A (73.40). Given ADRB2's relevance in cardiovascular function (and potential for CNS side effects), this is a significant positive for Ligand B.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and requires further investigation. It's difficult to interpret without knowing the scale.
10. **Solubility:** Both ligands have negative solubility values, also unusual and requiring further investigation.
11. **hERG:** Both ligands have low hERG inhibition liability (0.806 & 0.443), which is good. Ligand B is slightly better.
12. **Cl_mic:** Ligand B (13.81) has a much lower microsomal clearance than Ligand A (63.31), indicating better metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand B (16.12) has a significantly longer in vitro half-life than Ligand A (5.29). This is a major advantage for Ligand B.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.381 & 0.545). No significant difference.
15. **Affinity:** Ligand A (-6.1) has a slightly better binding affinity than Ligand B (-4.4). However, the difference is 1.7 kcal/mol, which is not substantial enough to outweigh the ADME advantages of Ligand B.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are crucial. While Ligand A has a slightly better affinity, Ligand B excels in logP, TPSA, Pgp, and critically, BBB penetration. The lower DILI risk and improved metabolic stability (lower Cl_mic and longer t1/2) further strengthen the case for Ligand B.
**Conclusion:**
Ligand B demonstrates a more favorable balance of properties, particularly regarding ADME characteristics and safety (DILI), making it the more promising drug candidate despite the slightly lower binding affinity.
Output:
0
2025-04-17 23:01:12,723 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (366.333 Da) is slightly higher than Ligand B (347.459 Da), but both are acceptable.
2. **TPSA:** Ligand A (104.21) is higher than Ligand B (61.88). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is generally preferred for absorption. Ligand B is significantly better here.
3. **logP:** Both ligands have acceptable logP values (Ligand A: 1.589, Ligand B: 0.986), falling within the 1-3 range. Ligand A is slightly more lipophilic.
4. **HBD:** Ligand A has 3 HBD, and Ligand B has 1. Both are within the acceptable limit of 5.
5. **HBA:** Ligand A has 5 HBA, and Ligand B has 4. Both are within the acceptable limit of 10.
6. **QED:** Both ligands have good QED scores (Ligand A: 0.674, Ligand B: 0.824), indicating drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A has a DILI risk of 70.027%, which is approaching the higher risk threshold. Ligand B has a very low DILI risk of 10.973%, a significant advantage.
8. **BBB:** Both ligands have relatively low BBB penetration (Ligand A: 53.587%, Ligand B: 64.831%). Since ADRB2 is not a CNS target, this is not a major concern, but Ligand B is slightly better.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.988) is slightly better than Ligand B (-5.038), but both are problematic.
10. **Solubility:** Ligand A (-3.058) has worse solubility than Ligand B (-0.814). Solubility is important for bioavailability.
11. **hERG:** Both ligands have low hERG inhibition risk (Ligand A: 0.328, Ligand B: 0.332), which is good.
12. **Cl_mic:** Ligand A (27.44 mL/min/kg) has a lower microsomal clearance than Ligand B (-14.657 mL/min/kg). This indicates better metabolic stability for Ligand A. However, the negative value for Ligand B is concerning and likely an error.
13. **t1/2:** Ligand A (40.026 hours) has a significantly longer in vitro half-life than Ligand B (4.654 hours). This is a major advantage for Ligand A.
14. **Pgp:** Both ligands have very low Pgp efflux liability (Ligand A: 0.067, Ligand B: 0.011).
15. **Affinity:** Ligand B (-7.2 kcal/mol) has a stronger binding affinity than Ligand A (-5.5 kcal/mol). This is a substantial difference (1.7 kcal/mol), and a key driver in the decision.
**Overall Assessment:**
Ligand B has a significantly better safety profile (much lower DILI risk) and a substantially stronger binding affinity. While Ligand A has better metabolic stability and half-life, the difference in affinity outweighs these advantages. The solubility of Ligand B is also better. The Caco-2 values are concerning for both, but the superior binding and safety profile of Ligand B make it the more promising candidate.
Output:
0
2025-04-17 23:01:12,724 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Step-by-step comparison:**
1. **MW:** Both ligands (371.373 and 374.503 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand B (83.99) is significantly better than Ligand A (115.16). ADRB2 is a cardiovascular target, so BBB isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (1.228) is slightly better than Ligand B (0.543), falling more squarely within the optimal 1-3 range. Ligand B is a bit low, potentially hindering permeation.
4. **HBD:** Both have 0 HBD, which is good.
5. **HBA:** Ligand A has 6 HBA, and Ligand B has 5. Both are acceptable.
6. **QED:** Ligand B (0.717) has a better QED score than Ligand A (0.44), indicating a more drug-like profile.
7. **DILI:** Ligand B (47.538) has a significantly lower DILI risk than Ligand A (63.164). This is a crucial advantage, as minimizing liver toxicity is essential.
8. **BBB:** Both have similar BBB penetration (67.972 and 64.327). Not a major factor for a cardiovascular target.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Both have negative solubility values, which is also unusual. Again, the scale is unclear.
11. **hERG:** Ligand A (0.092) has a slightly lower hERG risk than Ligand B (0.258), which is preferable.
12. **Cl_mic:** Ligand A (5.81) has a significantly lower microsomal clearance than Ligand B (11.999), suggesting better metabolic stability.
13. **t1/2:** Ligand B (20.448) has a much longer in vitro half-life than Ligand A (-1.538). This is a significant advantage, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.043) has lower P-gp efflux liability than Ligand B (0.08), which is favorable.
15. **Binding Affinity:** Ligand A (-7.2) has a slightly better binding affinity than Ligand B (-5.2). This is a 2 kcal/mol difference, which is substantial.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A has a better logP and Pgp, and a significantly better binding affinity. Ligand B has a much better TPSA and DILI risk. The longer half-life of Ligand B is also attractive.
**Overall Assessment:**
While Ligand A has a better binding affinity and potentially better permeability (based on logP and Pgp), the significantly lower DILI risk and longer half-life of Ligand B are compelling advantages. The difference in binding affinity, while notable, might be overcome with further optimization. The lower DILI risk is a critical safety factor.
Output:
0
2025-04-17 23:01:12,724 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (349.435 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (105.12) is better than Ligand B (53.94). Lower TPSA generally correlates with better cell permeability, a key factor for GPCR ligands.
3. **logP:** Ligand B (3.94) is higher than Ligand A (-0.11). While a logP of 3.94 is approaching the upper limit, it's still acceptable. Ligand A's negative logP is a significant concern, suggesting poor membrane permeability and potentially poor absorption.
4. **HBD:** Ligand A (3) is higher than Ligand B (1). While both are acceptable, lower HBD is generally preferred for better permeability.
5. **HBA:** Ligand A (5) is slightly higher than Ligand B (6). Both are within the acceptable range.
6. **QED:** Both ligands have good QED scores (A: 0.578, B: 0.719), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (17.449) has a much lower DILI risk than Ligand B (86.817). This is a significant advantage for Ligand A.
8. **BBB:** Ligand B (80.264) has a much higher BBB penetration potential than Ligand A (45.56). While ADRB2 isn't strictly a CNS target, some CNS exposure can be relevant for off-target effects and overall safety.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-5.483) is slightly better than Ligand B (-4.804).
10. **Solubility:** Ligand A (-0.934) has better solubility than Ligand B (-4.8). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.055) has a much lower hERG inhibition liability than Ligand B (0.863). This is a critical safety parameter.
12. **Cl_mic:** Ligand B (91.433) has a much higher microsomal clearance than Ligand A (10.381), indicating faster metabolism and potentially lower exposure.
13. **t1/2:** Ligand B (47.27) has a significantly longer in vitro half-life than Ligand A (1.378). This is a strong advantage for Ligand B.
14. **Pgp:** Ligand A (0.002) has much lower P-gp efflux liability than Ligand B (0.564). Lower P-gp efflux is generally desirable.
15. **Affinity:** Ligand A (-7.1 kcal/mol) has a slightly better binding affinity than Ligand B (-6.4 kcal/mol). While the difference is not huge, it's still a factor.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B has a better logP and Pgp profile, and a significantly longer half-life. However, Ligand A has a much better TPSA, DILI, hERG, and P-gp efflux profile, and only slightly weaker binding affinity. The negative logP of Ligand A is a major concern.
**Overall Assessment:**
Despite the slightly weaker half-life and higher Pgp efflux, Ligand A's superior safety profile (DILI, hERG) and better TPSA, along with acceptable binding affinity, make it the more promising candidate. The negative logP is a concern, but could potentially be addressed through prodrug strategies or further chemical modifications. Ligand B's high DILI and hERG risk are more difficult to mitigate.
Output:
1
2025-04-17 23:01:12,724 - INFO - Batch 374 complete. Total preferences: 5984
2025-04-17 23:01:12,724 - INFO - Processing batch 375/512...
2025-04-17 23:01:59,957 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (361.423 and 364.427 Da) are within the ideal range of 200-500 Da. No significant difference here.
2. **TPSA:** Ligand A (97.39) is better than Ligand B (108.56). Both are below 140, but lower TPSA generally favors absorption.
3. **logP:** Both ligands have good logP values (2.001 and 1.275), falling within the optimal 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Both have 2 H-bond donors, which is acceptable.
5. **HBA:** Ligand A has 6 H-bond acceptors, and Ligand B has 7. Both are within the acceptable limit of 10.
6. **QED:** Both ligands have good QED scores (0.627 and 0.799), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (81.039) has a higher DILI risk than Ligand B (61.807). This is a significant negative for Ligand A.
8. **BBB:** Ligand A (69.794) has a better BBB penetration percentile than Ligand B (35.246). While ADRB2 isn't exclusively a CNS target, some CNS exposure is not necessarily detrimental, and higher BBB is generally a plus.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
10. **Solubility:** Ligand A (-3.592) has worse solubility than Ligand B (-2.122). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.223) has a slightly higher hERG risk than Ligand B (0.063). Lower hERG is preferred.
12. **Cl_mic:** Ligand B (4.795) has significantly lower microsomal clearance than Ligand A (61.365), indicating better metabolic stability. This is a major advantage for Ligand B.
13. **t1/2:** Ligand B (23.874) has a longer in vitro half-life than Ligand A (14.987), which is desirable.
14. **Pgp:** Ligand A (0.16) has lower P-gp efflux than Ligand B (0.051), which is a positive.
15. **Binding Affinity:** Ligand B (-7.5 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.5 kcal/mol). This is a substantial advantage, potentially outweighing some ADME concerns.
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B has a better affinity, slightly better logP, and lower Pgp efflux. While Ligand A has better BBB penetration, the significantly lower DILI risk and better metabolic stability (lower Cl_mic and longer t1/2) of Ligand B are more important for overall drug development. The stronger binding affinity of Ligand B is also a major factor.
**Conclusion:**
Considering the balance of properties, particularly the superior binding affinity, metabolic stability, lower DILI risk, and acceptable ADME profile, Ligand B is the more promising drug candidate.
Output:
0
2025-04-17 23:01:59,957 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (361.389 Da) is slightly higher than Ligand B (351.514 Da), but both are acceptable.
2. **TPSA:** Ligand A (87.74) is slightly higher than Ligand B (55.63). Both are below 140, but Ligand B is significantly better, suggesting better absorption.
3. **logP:** Ligand A (0.149) is quite low, potentially hindering permeability. Ligand B (4.161) is higher, but bordering on being too lipophilic. This is a key difference.
4. **HBD:** Ligand A (2) and Ligand B (1) are both within the acceptable limit of 5.
5. **HBA:** Ligand A (4) and Ligand B (5) are both within the acceptable limit of 10.
6. **QED:** Ligand B (0.679) has a better QED score than Ligand A (0.428), indicating a more drug-like profile.
7. **DILI:** Both ligands have low DILI risk (Ligand A: 33.695, Ligand B: 35.789), which is good.
8. **BBB:** Both ligands have good BBB penetration (Ligand A: 87.476, Ligand B: 88.329).
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual. I will assume these are percentile scores and thus higher is better. Both are relatively poor.
10. **Solubility:** Ligand A (-1.428) has better solubility than Ligand B (-4.379).
11. **hERG:** Both ligands have low hERG inhibition risk (Ligand A: 0.402, Ligand B: 0.443).
12. **Cl_mic:** Ligand A (-1.101) has significantly better metabolic stability (lower clearance) than Ligand B (31.411). This is a major advantage for Ligand A.
13. **t1/2:** Ligand A (-9.479) has a longer half-life than Ligand B (8.392).
14. **Pgp:** Both ligands have low Pgp efflux liability (Ligand A: 0.025, Ligand B: 0.533), with Ligand A being slightly better.
15. **Binding Affinity:** Ligand B (-6.9) has slightly better binding affinity than Ligand A (-6.0). However, the difference is not substantial enough to overcome other drawbacks.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand B has a better logP, but it's borderline high. Ligand A has a significantly better TPSA, Pgp, and metabolic stability (Cl_mic and t1/2). The affinity difference is small.
**Overall Assessment:**
Ligand A is the better candidate. While Ligand B has slightly better affinity and a better QED score, Ligand A's superior metabolic stability, TPSA, Pgp, and solubility outweigh these advantages. The low logP of Ligand A is a concern, but can potentially be addressed with formulation strategies. The significantly better ADME profile of Ligand A makes it a more promising starting point for drug development.
Output:
1
2025-04-17 23:01:59,957 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (346.471 Da and 356.369 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (58.64) is significantly better than Ligand B (73.99). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand A is well below the 90 A^2 threshold, while Ligand B is approaching it.
**3. logP:** Both ligands have good logP values (2.102 and 1.145, respectively) falling within the optimal 1-3 range. Ligand B is slightly lower, which *could* indicate slightly better solubility, but isn't a major concern.
**4. H-Bond Donors:** Both have 1 HBD, which is acceptable.
**5. H-Bond Acceptors:** Ligand A has 3, and Ligand B has 4. Both are within the acceptable limit of 10.
**6. QED:** Both ligands have very similar QED values (0.793 and 0.795), indicating good drug-likeness.
**7. DILI Risk:** Ligand A (22.8) has a much lower DILI risk than Ligand B (12.369). This is a significant advantage for Ligand A.
**8. BBB Penetration:** Ligand B (88.174) has a higher BBB penetration percentile than Ligand A (75.107). While ADRB2 is a cardiovascular target and CNS penetration isn't *essential*, some degree of BBB penetration can be useful for off-target effects assessment and potentially for peripheral nervous system effects.
**9. Caco-2 Permeability:** Both have negative values, indicating poor permeability. Ligand A (-4.514) is slightly worse than Ligand B (-4.758).
**10. Aqueous Solubility:** Ligand A (-3.5) is better than Ligand B (-1.658), indicating better solubility.
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.233 and 0.332).
**12. Microsomal Clearance:** Ligand B (-1.296) has a *much* lower (better) microsomal clearance than Ligand A (3.366). This suggests greater metabolic stability for Ligand B.
**13. In vitro Half-Life:** Ligand B (21.237) has a significantly longer in vitro half-life than Ligand A (10.954). This is a major advantage for Ligand B.
**14. P-gp Efflux:** Both have low P-gp efflux liability (0.039 and 0.022).
**15. Binding Affinity:** Ligand A (-7.2) has a significantly stronger binding affinity than Ligand B (-6.2). This is a 1.0 kcal/mol difference, which is substantial and can often outweigh minor ADME drawbacks.
**Overall Assessment:**
The key trade-offs are: Ligand A has superior affinity and lower DILI risk and better solubility, while Ligand B has better metabolic stability (lower Cl_mic, longer t1/2) and slightly better BBB penetration. Given that this is a cardiovascular target, metabolic stability is important for maintaining therapeutic levels, but the significantly stronger binding affinity of Ligand A is a critical advantage. The lower DILI risk is also a major plus. The Caco-2 permeability is poor for both, but can be addressed with formulation strategies.
Therefore, I favor Ligand A.
Output:
1
2025-04-17 23:01:59,957 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
Let's analyze each ligand against the provided guidelines, keeping in mind ADRB2 is a GPCR and thus we prioritize logP, Pgp, TPSA, and affinity, alongside general drug-like properties.
* **Molecular Weight:** Both ligands (381.219 Da and 366.527 Da) fall within the ideal 200-500 Da range.
* **TPSA:** Ligand A (97.12) is higher than Ligand B (67.43). Both are acceptable, but Ligand B is better, being closer to the preferred <140 for oral absorption.
* **logP:** Both ligands have good logP values (3.187 and 2.098, respectively) within the optimal 1-3 range. Ligand B is slightly lower, which could be beneficial for solubility.
* **H-Bond Donors/Acceptors:** Both have 2 HBDs and similar HBAs (5 and 4 respectively). These are within acceptable limits.
* **QED:** Both ligands have reasonable QED scores (0.829 and 0.724), indicating good drug-like properties.
* **DILI:** Ligand A has a significantly higher DILI risk (86.855 percentile) compared to Ligand B (37.146 percentile). This is a major concern for Ligand A.
* **BBB:** Ligand A (66.421) has a better BBB penetration score than Ligand B (45.134), but for a cardiovascular target, BBB penetration is not a primary concern.
* **Caco-2 Permeability:** Ligand B (-5.486) shows better Caco-2 permeability than Ligand A (-4.838).
* **Aqueous Solubility:** Ligand B (-3.012) has better aqueous solubility than Ligand A (-4.924).
* **hERG Inhibition:** Both ligands have low hERG inhibition risk (0.255 and 0.283).
* **Microsomal Clearance:** Ligand B (28.049) has significantly lower microsomal clearance than Ligand A (60.442), indicating better metabolic stability.
* **In vitro Half-Life:** Ligand B (15.368 hours) has a longer half-life than Ligand A (42.828 hours).
* **P-gp Efflux:** Both ligands have low P-gp efflux liability (0.17 and 0.085).
* **Binding Affinity:** Ligand B (-5.8 kcal/mol) has a stronger binding affinity than Ligand A (-4.5 kcal/mol). This is a substantial difference (>1.5 kcal/mol) and a significant advantage.
**Overall Assessment:**
Ligand B is the superior candidate. While Ligand A has a slightly better BBB score (irrelevant for a cardiovascular target) and QED, Ligand B excels in key areas: significantly lower DILI risk, better Caco-2 permeability, improved solubility, better metabolic stability (lower Cl_mic and longer t1/2), and, most importantly, a substantially stronger binding affinity. The lower DILI risk alone is a major factor favoring Ligand B. The affinity difference is also large enough to outweigh any minor drawbacks.
**Output:**
0
2025-04-17 23:01:59,958 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (354.793 and 351.407 Da) fall within the ideal range of 200-500 Da. No significant difference here.
2. **TPSA:** Ligand A (60.45) is significantly better than Ligand B (105.68). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally improves absorption. Ligand B is quite high, potentially hindering oral bioavailability.
3. **logP:** Ligand A (4.057) is higher than the optimal range (1-3) but still potentially manageable. Ligand B (0.041) is *very* low, suggesting poor membrane permeability and potentially limited absorption. This is a major drawback for Ligand B.
4. **HBD:** Ligand A (1) is good. Ligand B (2) is acceptable, but slightly less favorable.
5. **HBA:** Ligand A (4) is good. Ligand B (7) is higher, potentially impacting permeability.
6. **QED:** Ligand A (0.754) is excellent, indicating strong drug-like properties. Ligand B (0.453) is below the desirable threshold of 0.5.
7. **DILI:** Ligand A (93.951) has a high DILI risk. Ligand B (40.675) is much better, indicating a lower risk of liver injury. This is a significant advantage for Ligand B.
8. **BBB:** Both ligands have reasonable BBB penetration (74.758 and 78.984 respectively). Not a primary concern for a cardiovascular target.
9. **Caco-2:** Ligand A (-4.614) and Ligand B (-5.141) both have negative values, which is unusual and suggests poor permeability in this assay. However, the scale isn't specified, so it's hard to interpret.
10. **Solubility:** Ligand A (-5.636) and Ligand B (-1.791) both have negative solubility values, indicating poor aqueous solubility. Ligand B is better here.
11. **hERG:** Ligand A (0.692) is better than Ligand B (0.316), indicating a lower risk of hERG inhibition and cardiotoxicity.
12. **Cl_mic:** Ligand A (65.052) has a higher clearance than Ligand B (16.333), suggesting lower metabolic stability. Ligand B is significantly better in this regard.
13. **t1/2:** Ligand A (41.861) has a better in vitro half-life than Ligand B (-25.05). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.47) is better than Ligand B (0.004), suggesting less P-gp efflux and potentially better oral bioavailability.
15. **Affinity:** Both ligands have the same binding affinity (-6.6 kcal/mol). This removes affinity as a differentiating factor.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, and Pgp are important. Ligand A has a better logP and Pgp profile, while Ligand B has a lower TPSA. However, the extremely low logP of Ligand B is a major concern.
**Overall Assessment:**
Ligand A has a better QED, better hERG profile, and a significantly better in vitro half-life. While its DILI risk is high, the poor logP and QED of Ligand B are more critical drawbacks, especially considering the importance of permeability for a GPCR target. The better metabolic stability of Ligand B is appealing, but the other issues outweigh this benefit.
Output:
1
2025-04-17 23:01:59,958 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (359.294 and 373.406 Da) are within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (41.49) is significantly better than Ligand B (101.78). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold, while B is approaching it.
3. **logP:** Ligand A (3.705) is good, within the optimal 1-3 range. Ligand B (1.752) is at the lower end of the acceptable range. While not terrible, a lower logP can sometimes indicate poor membrane permeability.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable.
5. **HBA:** Ligand A (3) and Ligand B (6) are both acceptable, but Ligand A is better.
6. **QED:** Ligand A (0.818) is excellent, indicating high drug-likeness. Ligand B (0.552) is acceptable but less favorable.
7. **DILI:** Ligand A (38.736) has a much lower DILI risk than Ligand B (57.348). This is a significant advantage for Ligand A.
8. **BBB:** Ligand B (86.274) has higher BBB penetration than Ligand A (63.048). However, since ADRB2 is a cardiovascular target, BBB penetration is not a primary concern.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.063 and -4.816). This is unusual and suggests poor permeability.
10. **Solubility:** Both ligands have negative solubility values (-4.226 and -3.092). This is also unusual and suggests poor solubility.
11. **hERG:** Ligand A (0.922) has a slightly higher hERG risk than Ligand B (0.484), but both are relatively low.
12. **Cl_mic:** Ligand A (31.514) and Ligand B (33.787) are similar in terms of microsomal clearance.
13. **t1/2:** Ligand A (7.664) has a longer in vitro half-life than Ligand B (-2.239). This is a clear advantage for Ligand A.
14. **Pgp:** Ligand A (0.469) has lower P-gp efflux liability than Ligand B (0.119). This is a positive for Ligand A.
15. **Affinity:** Ligand A (-8.5 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.4 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME concerns.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A excels in affinity and has better logP, TPSA, and Pgp values. While both have poor Caco-2 and solubility, the superior binding affinity and better overall ADME profile of Ligand A make it the more promising candidate.
**Output:**
1
2025-04-17 23:01:59,958 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (361.408 and 364.471 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (43.86) is significantly better than Ligand B (92.26). ADRB2 is a cardiovascular target, not CNS, but lower TPSA generally improves absorption. Ligand A is well below the 140 threshold, while B is approaching it.
3. **logP:** Both ligands have good logP values (1.588 and 1.254), falling within the optimal 1-3 range. Ligand B is slightly lower, potentially impacting permeability a bit.
4. **HBD:** Ligand A (0) is preferable to Ligand B (1). Fewer HBDs generally improve membrane permeability.
5. **HBA:** Ligand A (3) is better than Ligand B (6). Lower HBA also favors permeability.
6. **QED:** Both ligands have good QED scores (0.747 and 0.82), indicating good drug-like properties. No clear advantage.
7. **DILI:** Ligand A (21.404) has a much lower DILI risk than Ligand B (45.909). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (95.076) has a much higher BBB penetration score than Ligand B (62.35). While ADRB2 isn't a primary CNS target, higher BBB penetration can sometimes correlate with better overall distribution and reduced off-target effects.
9. **Caco-2:** Ligand A (-4.393) is better than Ligand B (-5.279). Higher Caco-2 permeability indicates better intestinal absorption.
10. **Solubility:** Ligand A (-2.093) is better than Ligand B (-1.881). Higher solubility is generally preferred.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.653 and 0.041), which is excellent. Ligand B is slightly better.
12. **Cl_mic:** Ligand B (24.871) has a lower microsomal clearance than Ligand A (33.853), suggesting better metabolic stability. This is a positive for Ligand B.
13. **t1/2:** Both ligands have very negative in vitro half-lives (-23.527 and -22.53). This is likely a data error and doesn't provide useful information.
14. **Pgp:** Ligand A (0.069) has a lower P-gp efflux liability than Ligand B (0.063). Lower P-gp efflux is favorable for bioavailability.
15. **Affinity:** Ligand B (-7.6) has a slightly better binding affinity than Ligand A (-7.0). This is a 0.6 kcal/mol difference, which is significant, but needs to be weighed against other factors.
**Overall Assessment:**
Ligand A demonstrates a significantly better ADME profile, particularly regarding DILI risk, TPSA, HBD/HBA counts, and BBB penetration. While Ligand B has slightly better affinity and metabolic stability, the overall balance of properties favors Ligand A. The lower DILI risk and better absorption characteristics of Ligand A are crucial for a cardiovascular drug candidate. The affinity difference, while present, is not substantial enough to overcome the ADME advantages of Ligand A.
Output:
1
2025-04-17 23:01:59,958 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **Molecular Weight:** Both ligands (354.38 and 357.30 Da) fall comfortably within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (87.15) is better than Ligand B (97.54). Both are below 140, but lower TPSA generally favors better absorption.
3. **logP:** Ligand A (0.518) is slightly higher than Ligand B (0.277), and both are a bit low. Ideally, we want 1-3. Ligand A is preferable here, as very low logP can hinder membrane permeability.
4. **H-Bond Donors:** Both have 1 HBD, which is good.
5. **H-Bond Acceptors:** Ligand A has 5, and Ligand B has 8. Ligand A is better, as keeping HBA lower than 10 is desirable.
6. **QED:** Ligand B (0.785) has a better QED score than Ligand A (0.555), indicating a more drug-like profile.
7. **DILI:** Ligand A (49.63) has a lower DILI risk than Ligand B (71.69), which is a significant advantage. Lower DILI is always preferred.
8. **BBB:** Both ligands have good BBB penetration (Ligand A: 81.70, Ligand B: 88.17). Since ADRB2 isn't exclusively a CNS target, this isn't a major differentiating factor, but Ligand B is a bit better.
9. **Caco-2 Permeability:** Both have negative Caco-2 values (-4.854 and -4.809), which is unusual and suggests poor permeability. This is a concern for both.
10. **Aqueous Solubility:** Both have negative solubility values (-2.045 and -2.625), indicating very poor aqueous solubility. This is a major drawback for both.
11. **hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.33 and 0.135), which is excellent.
12. **Microsomal Clearance:** Ligand A (20.96) has significantly lower microsomal clearance than Ligand B (41.72), suggesting better metabolic stability.
13. **In vitro Half-Life:** Ligand A (-34.033) has a much longer in vitro half-life than Ligand B (-17.587), which is a substantial advantage.
14. **P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.119 and 0.07), which is good.
15. **Binding Affinity:** Both ligands have the same binding affinity (-6.6 kcal/mol), so this doesn't help differentiate them.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, and metabolic stability (Cl_mic, t1/2) are important. Ligand A is better in terms of logP, TPSA, Cl_mic, and t1/2. While BBB is good for both, the lower DILI risk for Ligand A is also a significant advantage. The QED score for Ligand B is better, but the other factors outweigh this.
**Conclusion:**
Despite the poor solubility and Caco-2 permeability of both compounds, Ligand A presents a more favorable overall profile due to its better logP, TPSA, lower DILI risk, improved metabolic stability, and longer half-life.
Output:
1
2025-04-17 23:01:59,958 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (359.417 and 348.403 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (79.79) is better than Ligand B (84.86), both are below the 140 threshold for oral absorption, but closer to the 90 threshold for CNS targets.
3. **logP:** Ligand A (2.378) is optimal (1-3). Ligand B (0.669) is a bit low, potentially hindering permeation. This is a significant advantage for Ligand A.
4. **HBD:** Ligand A (2) is good. Ligand B (0) is also acceptable, but could potentially reduce aqueous solubility.
5. **HBA:** Ligand A (4) is good. Ligand B (6) is slightly higher, but still within the acceptable range.
6. **QED:** Both ligands (0.698 and 0.703) have excellent drug-likeness scores, exceeding the 0.5 threshold.
7. **DILI:** Ligand A (19.969) has a much lower DILI risk than Ligand B (63.629). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (80.574) has a better BBB penetration score than Ligand B (72.354). While ADRB2 isn't strictly a CNS target, some CNS exposure can occur, and higher BBB is generally favorable.
9. **Caco-2:** Both are negative, indicating poor permeability.
10. **Solubility:** Ligand A (-2.47) is better than Ligand B (-0.967), indicating better aqueous solubility.
11. **hERG:** Both ligands (0.242 and 0.087) have low hERG inhibition liability, which is good.
12. **Cl_mic:** Ligand A (13.333) has significantly lower microsomal clearance than Ligand B (34.664), indicating better metabolic stability.
13. **t1/2:** Ligand B (-26.475) has a much longer half-life than Ligand A (-2.4). This is a significant advantage for Ligand B.
14. **Pgp:** Both ligands (0.024 and 0.011) have low P-gp efflux liability.
15. **Binding Affinity:** Both ligands have similar binding affinities (-6.6 and -5.6 kcal/mol). Ligand A is slightly better.
**GPCR-specific priorities:** For GPCRs, logP, TPSA, Pgp, and affinity are important. Ligand A excels in logP, TPSA, and has slightly better affinity. Ligand B has a longer half-life, but this is outweighed by the other factors.
**Overall Assessment:**
Ligand A demonstrates a more favorable balance of properties. It has better logP, lower DILI risk, better solubility, and lower microsomal clearance. While Ligand B has a longer half-life, the other advantages of Ligand A are more critical for overall drug development success, especially considering the potential for off-target effects and metabolic instability with Ligand B.
Output:
1
2025-04-17 23:01:59,959 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**1. Molecular Weight:** Both ligands (347.419 Da and 349.475 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (89.35) is slightly higher than Ligand B (69.72). Both are below the 140 A^2 threshold for good oral absorption, but Ligand B is preferable due to its lower TPSA, which generally correlates with better membrane permeability.
**3. logP:** Ligand A (0.71) is a bit low, potentially hindering permeability. Ligand B (1.542) is better, falling within the optimal 1-3 range. This favors Ligand B.
**4. H-Bond Donors:** Both ligands have 1 HBD, which is within the acceptable limit of <=5.
**5. H-Bond Acceptors:** Ligand A has 6 HBAs, while Ligand B has 3. Ligand B is preferable due to the lower HBA count, which can improve permeability.
**6. QED:** Both ligands have reasonable QED values (0.866 and 0.783), indicating good drug-like properties.
**7. DILI Risk:** Ligand B (24.544) has a significantly lower DILI risk than Ligand A (47.926). This is a major advantage for Ligand B.
**8. BBB Penetration:** Ligand A (73.517) has slightly better BBB penetration than Ligand B (67.158), but both are reasonably good. Since ADRB2 is a cardiovascular target, BBB penetration is not a primary concern, but it's a slight edge for A.
**9. Caco-2 Permeability:** Ligand A (-5.076) has worse Caco-2 permeability than Ligand B (-4.742). This suggests Ligand B will have better intestinal absorption.
**10. Aqueous Solubility:** Both ligands have poor aqueous solubility (-1.681 and -1.919). This is a potential formulation challenge for both, but not a deciding factor.
**11. hERG Inhibition:** Both ligands show very low hERG inhibition risk (0.099 and 0.134), which is excellent.
**12. Microsomal Clearance:** Ligand A (30.776) has slightly higher microsomal clearance than Ligand B (26.119), indicating potentially lower metabolic stability. Ligand B is preferable.
**13. In vitro Half-Life:** Ligand A (5.379) has a longer half-life than Ligand B (2.245). This is a positive for Ligand A.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.032 and 0.043).
**15. Binding Affinity:** Ligand A (-7.0) has a slightly better binding affinity than Ligand B (-6.9). However, the difference is only 0.1 kcal/mol, and the ADME properties of Ligand B are significantly more favorable.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand B emerges as the more promising candidate. While Ligand A has slightly better affinity and half-life, Ligand B has a much lower DILI risk, better logP, lower TPSA, and better Caco-2 permeability. The difference in affinity is not substantial enough to outweigh the significant ADME advantages of Ligand B.
Output:
0
2025-04-17 23:01:59,959 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (369.395 and 369.462 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (130.0) is slightly higher than Ligand B (80.32). For a cardiovascular GPCR, TPSA isn't *as* critical as for a CNS target, but lower is generally preferred for better permeability. Ligand B has a clear advantage here.
**3. logP:** Ligand A (0.995) is a bit low, potentially hindering membrane permeability. Ligand B (1.983) is better positioned within the optimal 1-3 range. Ligand B is preferred.
**4. H-Bond Donors:** Ligand A (3) is slightly higher than Ligand B (2). Both are acceptable, but lower is generally better for permeability. Slight edge to Ligand B.
**5. H-Bond Acceptors:** Both ligands have 5 HBA, which is within the acceptable range. No significant difference.
**6. QED:** Both ligands have good QED scores (0.706 and 0.832, respectively), indicating good drug-like properties. Ligand B is slightly better.
**7. DILI Risk:** Ligand A (75.184) has a higher DILI risk than Ligand B (65.762). Lower is better, so Ligand B is preferred.
**8. BBB Penetration:** This is less critical for a cardiovascular target, but Ligand B (70.027) shows better potential for BBB penetration than Ligand A (14.696).
**9. Caco-2 Permeability:** Ligand A (-5.845) has very poor Caco-2 permeability, while Ligand B (-4.987) is better, but still not great. This is a significant concern for Ligand A.
**10. Aqueous Solubility:** Both ligands have very poor aqueous solubility (-2.596 and -2.906). This is a potential formulation challenge for both, but not a deciding factor.
**11. hERG Inhibition:** Ligand A (0.013) has a very low hERG risk, which is excellent. Ligand B (0.32) is slightly higher, but still relatively low. Ligand A has a clear advantage here.
**12. Microsomal Clearance:** Ligand A (-4.745) has a lower (better) microsomal clearance than Ligand B (10.659), indicating greater metabolic stability.
**13. In vitro Half-Life:** Ligand A (23.812) has a longer half-life than Ligand B (13.607), which is desirable.
**14. P-gp Efflux:** Ligand A (0.008) has very low P-gp efflux, which is excellent. Ligand B (0.244) is higher, suggesting more potential for efflux.
**15. Binding Affinity:** Ligand A (-8.1 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.3 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME drawbacks.
**Overall Assessment:**
While Ligand A has some ADME liabilities (low logP, poor Caco-2 permeability), its *significantly* stronger binding affinity (-8.1 vs -6.3 kcal/mol) and superior metabolic stability (lower Cl_mic, longer t1/2), lower P-gp efflux, and very low hERG risk make it the more promising candidate. The affinity difference is large enough to potentially overcome the permeability issues through formulation strategies. Ligand B has better TPSA and DILI, but the affinity is a critical factor for GPCRs.
Output:
1
2025-04-17 23:01:59,959 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (359.86 & 362.50 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (58.37) is significantly better than Ligand B (69.64). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better permeability.
3. **logP:** Ligand A (4.29) is higher than Ligand B (2.61). While both are within the acceptable range (1-3 is optimal), Ligand A is pushing the upper limit. This could lead to solubility issues, but given the target, it's not a dealbreaker.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (4). Similar reasoning as HBD.
6. **QED:** Both ligands are very similar (0.889 vs 0.865), indicating good drug-likeness.
7. **DILI:** Ligand B (42.89) is *much* better than Ligand A (62.47). This is a significant advantage for Ligand B, as minimizing liver toxicity is crucial.
8. **BBB:** Ligand A (88.29) has better BBB penetration than Ligand B (67.58). However, as ADRB2 is primarily a cardiovascular target, this is less important.
9. **Caco-2:** Ligand A (-4.753) is better than Ligand B (-5.077). Higher (less negative) values indicate better absorption.
10. **Solubility:** Ligand B (-2.503) is better than Ligand A (-4.478). This is a benefit for Ligand B, especially given Ligand A's higher logP.
11. **hERG:** Ligand A (0.709) is better than Ligand B (0.311). Lower hERG inhibition is crucial for avoiding cardiotoxicity, which is particularly relevant for a cardiovascular target.
12. **Cl_mic:** Ligand B (15.89) has significantly lower microsomal clearance than Ligand A (76.73). This suggests better metabolic stability for Ligand B, a key advantage.
13. **t1/2:** Ligand B (16.09) has a longer in vitro half-life than Ligand A (74.55). This is a positive for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.678) is better than Ligand B (0.18). Lower P-gp efflux is desirable.
15. **Binding Affinity:** Ligand B (-6.9 kcal/mol) has a substantially stronger binding affinity than Ligand A (-4.6 kcal/mol). This is a *major* advantage, as a 2.3 kcal/mol difference is significant and can often outweigh minor ADME drawbacks.
**Overall Assessment:**
While Ligand A has some advantages in permeability-related parameters (TPSA, Caco-2, Pgp) and hERG, Ligand B shines in critical areas like DILI risk, metabolic stability (Cl_mic, t1/2), solubility, and, most importantly, *binding affinity*. The significantly stronger binding affinity of Ligand B (-6.9 vs -4.6 kcal/mol) is a compelling factor. The lower DILI risk and improved metabolic stability also make it a safer and potentially more effective drug candidate.
Output:
0
2025-04-17 23:01:59,959 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (378.89 and 360.85 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (83.04) is slightly higher than Ligand B (78.09). Both are below the 140 threshold for good oral absorption, and acceptable for a cardiovascular target (not requiring significant CNS penetration). Ligand B is slightly preferred.
3. **logP:** Both ligands have good logP values (3.037 and 2.471), falling within the optimal 1-3 range. Ligand B is slightly lower, which could be beneficial for solubility.
4. **HBD:** Both have 2 H-bond donors, which is within the acceptable limit of <=5. No difference.
5. **HBA:** Ligand A has 6 H-bond acceptors, while Ligand B has 3. Ligand B is preferred as it is closer to the ideal of <=10.
6. **QED:** Ligand B (0.869) has a higher QED score than Ligand A (0.795), indicating a more drug-like profile. This is a significant advantage for Ligand B.
7. **DILI:** Ligand B (56.844) has a considerably lower DILI risk than Ligand A (77.782). This is a major advantage for Ligand B, as minimizing liver toxicity is crucial.
8. **BBB:** Both ligands have reasonable BBB penetration (75.107 and 60.372). Since ADRB2 is primarily a cardiovascular target, high BBB penetration isn't critical, but it doesn't hurt. Ligand A is slightly better.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.208 and -5.227), which is unusual and suggests very poor permeability. This is a significant concern for both, but doesn't differentiate them.
10. **Solubility:** Both have negative solubility values (-4.14 and -3.749), indicating poor aqueous solubility. This is a concern for both, but doesn't differentiate them.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.345 and 0.167), which is excellent. No difference.
12. **Cl_mic:** Ligand B (-1.368) has a *much* lower microsomal clearance than Ligand A (39.535), indicating significantly better metabolic stability. This is a substantial advantage for Ligand B.
13. **t1/2:** Ligand B (-38.719) has a negative in vitro half-life, which is concerning. Ligand A (31.052) has a reasonable half-life. This is a significant advantage for Ligand A.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.153 and 0.09). No difference.
15. **Binding Affinity:** Ligand B (-7.3) has a significantly stronger binding affinity than Ligand A (-5.0). This is a major advantage for Ligand B, potentially outweighing some of the ADME concerns.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP, has a comparable TPSA, similar Pgp, and *significantly* better affinity. The lower DILI and better metabolic stability (Cl_mic) are also very important. While Ligand A has a better in vitro half-life, the substantial affinity advantage of Ligand B, coupled with its improved safety profile (DILI) and metabolic stability, make it the more promising candidate. The poor Caco-2 and solubility are concerns for both, but can be addressed with formulation strategies.
Output:
0
2025-04-17 23:01:59,960 - INFO - Here's my reasoning and final output for the ligand preference:
**Reasoning:**
We are targeting the ADRB2, a GPCR involved in cardiovascular function. Therefore, we prioritize logP, Pgp, TPSA, and affinity, alongside general drug-like properties.
Let's compare Ligand A and Ligand B across the 15 parameters:
1. **MW:** Both ligands are within the ideal range (200-500 Da).
2. **TPSA:** Ligand A (106.77) is better than Ligand B (29.54). Lower TPSA generally favors better absorption, and while <90 is ideal for CNS targets, it's still beneficial for peripheral GPCRs like ADRB2.
3. **logP:** Ligand A (1.102) is within the optimal range (1-3), while Ligand B (4.411) is slightly high. High logP can lead to solubility issues and off-target effects.
4. **HBD:** Ligand A (3) is acceptable, Ligand B (0) is also acceptable.
5. **HBA:** Ligand A (4) is acceptable, Ligand B (3) is also acceptable.
6. **QED:** Both ligands have similar QED scores (0.772 and 0.71), indicating good drug-likeness.
7. **DILI:** Ligand A (67.817) has a higher DILI risk than Ligand B (37.611), which is preferable.
8. **BBB:** Ligand A (36.836) has lower BBB penetration than Ligand B (97.131). While ADRB2 isn't a CNS target, some degree of BBB penetration can sometimes indicate favorable permeability characteristics.
9. **Caco-2:** Ligand A (-5.614) is worse than Ligand B (-4.667). Higher Caco-2 permeability is better.
10. **Solubility:** Ligand A (-2.728) is better than Ligand B (-4.321).
11. **hERG:** Ligand A (0.129) has a lower hERG inhibition liability than Ligand B (0.727), which is a significant advantage for cardiovascular targets.
12. **Cl_mic:** Ligand A (-2.798) has a lower (better) microsomal clearance than Ligand B (80.799), indicating better metabolic stability.
13. **t1/2:** Ligand A (-13.728) has a worse in vitro half-life than Ligand B (12.379).
14. **Pgp:** Ligand A (0.034) has a lower Pgp efflux liability than Ligand B (0.608), which is favorable for bioavailability.
15. **Affinity:** Ligand A (-6.9 kcal/mol) has a slightly better binding affinity than Ligand B (-5.8 kcal/mol).
**Overall Assessment:**
Ligand A has a better balance of properties, particularly regarding safety (lower DILI, lower hERG) and ADME (lower Cl_mic, lower Pgp efflux). While Ligand B has better Caco-2 permeability and BBB penetration, the higher logP and potential for off-target effects are concerning. The slightly better affinity of Ligand A, combined with its superior ADME/Tox profile, makes it the more promising candidate.
**Output:**
1
2025-04-17 23:01:59,960 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [352.494, 49.41, 3.591, 1, 2, 0.822, 18.534, 87.67, -4.721, -3.648, 0.54, 28.734, 0.205, 0.199, -9.5]
**Ligand B:** [378.523, 60.25, 3.09, 0, 7, 0.693, 76.037, 61.923, -5.139, -2.811, 0.209, 113.374, -26.998, 0.367, -5.9]
Here's a breakdown, comparing each parameter and considering GPCR priorities (logP, Pgp, TPSA, BBB, and affinity are key):
1. **MW:** Both are within the ideal range (200-500 Da). A is 352.494, B is 378.523. Slight edge to A for being a bit lower.
2. **TPSA:** A (49.41) is excellent, well below 140 and good for oral absorption. B (60.25) is still reasonable, but less optimal.
3. **logP:** Both are good (around 3), within the 1-3 range. A (3.591) is slightly higher, which *could* be a minor benefit for membrane permeability, but both are acceptable.
4. **HBD:** A (1) is preferable to B (0). Having at least one HBD can help with solubility without drastically impacting permeability.
5. **HBA:** A (2) is better than B (7). Lower HBA generally improves permeability.
6. **QED:** A (0.822) is significantly better than B (0.693), indicating a more drug-like profile.
7. **DILI:** A (18.534) is *much* better than B (76.037). This is a major advantage for Ligand A.
8. **BBB:** A (87.67) is excellent, suggesting good potential for crossing the blood-brain barrier, even though ADRB2 isn't necessarily a CNS target, it's never a detriment. B (61.923) is lower.
9. **Caco-2:** A (-4.721) and B (-5.139) are both negative, indicating good permeability. B is slightly better.
10. **Solubility:** A (-3.648) is better than B (-2.811), indicating better aqueous solubility.
11. **hERG:** Both are very low (A: 0.54, B: 0.209), indicating low cardiotoxicity risk. B is slightly better.
12. **Cl_mic:** A (28.734) is much better than B (113.374), indicating better metabolic stability.
13. **t1/2:** A (0.205) is very poor compared to B (-26.998), indicating a very short half-life. This is a significant drawback for A.
14. **Pgp:** A (0.199) is better than B (0.367), suggesting less P-glycoprotein efflux.
15. **Affinity:** A (-9.5) is significantly better than B (-5.9). This is a substantial difference in binding potency.
**Overall Assessment:**
Ligand A has a clear advantage in several key areas: DILI risk, QED, metabolic stability (Cl_mic), Pgp efflux, and *especially* binding affinity. While its half-life is poor, the strong binding affinity could potentially compensate for that with appropriate dosing strategies. Ligand B has a slightly better Caco-2 and hERG, but the significantly higher DILI risk and lower affinity are major concerns. Considering the GPCR-specific priorities, the strong affinity of A outweighs its other drawbacks.
Output:
1
2025-04-17 23:01:59,960 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (348-349 Da). No significant difference.
2. **TPSA:** Both are reasonably low (67.87 and 69.72), suggesting good potential for absorption. Ligand A is slightly better.
3. **logP:** Both are optimal (1.684 and 1.542). No significant difference.
4. **HBD:** Both have 1 HBD, which is good. No difference.
5. **HBA:** Ligand A has 4 HBA, Ligand B has 3. Both are acceptable, but Ligand B is slightly better.
6. **QED:** Both have high QED scores (0.814 and 0.837), indicating good drug-likeness. No significant difference.
7. **DILI:** Ligand A (38.503) has a much lower DILI risk than Ligand B (9.849). This is a significant advantage for Ligand A.
8. **BBB:** Both have good BBB penetration (73.827 and 67.933). Ligand A is slightly better.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. Ligand A (-4.198) is slightly better than Ligand B (-4.882).
10. **Solubility:** Both have negative solubility values, indicating poor solubility. Ligand A (-2.349) is slightly better than Ligand B (-1.969).
11. **hERG:** Both have very low hERG inhibition risk (0.192 and 0.312). No significant difference.
12. **Cl_mic:** Ligand A (67.506) has a much lower microsomal clearance than Ligand B (14.379), suggesting better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (-3.186) has a more negative in vitro half-life than Ligand B (-5.234), suggesting better stability.
14. **Pgp:** Both have very low Pgp efflux liability (0.069 and 0.034). No significant difference.
15. **Binding Affinity:** Ligand A (-7.2 kcal/mol) has a slightly better binding affinity than Ligand B (-6.9 kcal/mol).
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Both ligands perform well in logP and Pgp. Affinity is slightly better for Ligand A. The differences in TPSA are minimal. However, the significant advantages of Ligand A in DILI risk and metabolic stability (Cl_mic and t1/2) are crucial for overall drug development potential.
**Conclusion:**
Ligand A demonstrates a superior balance of properties, particularly regarding safety (DILI) and metabolic stability, while maintaining acceptable binding affinity. Although both ligands have poor Caco-2 and solubility, the other advantages of Ligand A outweigh this drawback.
**Output:**
1
2025-04-17 23:01:59,960 - INFO - Batch 375 complete. Total preferences: 6000
2025-04-17 23:01:59,960 - INFO - Processing batch 376/512...
2025-04-17 23:02:51,268 - INFO - Here's a step-by-step comparison of Ligand A and Ligand B, followed by my final decision:
**1. Molecular Weight (MW):**
* Ligand A: 357.355 Da - Within the ideal range (200-500 Da).
* Ligand B: 346.351 Da - Also within the ideal range.
* *No clear advantage.*
**2. Topological Polar Surface Area (TPSA):**
* Ligand A: 130.38 - Acceptable for oral absorption (<140), but higher than optimal for a GPCR.
* Ligand B: 127.9 - Better, closer to the optimal range for GPCRs.
* *Slight advantage to Ligand B.*
**3. Lipophilicity (logP):**
* Ligand A: 1.031 - Good, within the optimal range (1-3).
* Ligand B: -2.107 - Too low. May have permeability issues.
* *Advantage to Ligand A.*
**4. H-Bond Donors (HBD):**
* Ligand A: 3 - Acceptable.
* Ligand B: 1 - Acceptable.
* *No clear advantage.*
**5. H-Bond Acceptors (HBA):**
* Ligand A: 8 - Acceptable.
* Ligand B: 9 - Acceptable.
* *No clear advantage.*
**6. QED:**
* Ligand A: 0.597 - Good, above the 0.5 threshold.
* Ligand B: 0.634 - Slightly better, indicating a more drug-like profile.
* *Slight advantage to Ligand B.*
**7. DILI Risk:**
* Ligand A: 99.457 - Very high risk of liver injury. This is a major concern.
* Ligand B: 72.043 - Still elevated, but significantly lower and more acceptable than Ligand A.
* *Major advantage to Ligand B.*
**8. BBB Penetration:**
* Ligand A: 56.34 - Low. Not a priority for this target, but not ideal.
* Ligand B: 43.815 - Low. Similar to Ligand A.
* *No clear advantage.*
**9. Caco-2 Permeability:**
* Ligand A: -5.199 - Poor permeability.
* Ligand B: -5.61 - Poor permeability.
* *No clear advantage.*
**10. Aqueous Solubility:**
* Ligand A: -4.846 - Poor solubility.
* Ligand B: -1.721 - Better solubility than Ligand A, but still poor.
* *Slight advantage to Ligand B.*
**11. hERG Inhibition:**
* Ligand A: 0.169 - Low risk.
* Ligand B: 0.013 - Very low risk.
* *Advantage to Ligand B.*
**12. Microsomal Clearance:**
* Ligand A: 9.735 - Moderate clearance.
* Ligand B: -0.737 - Very low clearance, suggesting good metabolic stability.
* *Advantage to Ligand B.*
**13. In vitro Half-Life:**
* Ligand A: 96.584 - Long half-life.
* Ligand B: 7.551 - Short half-life.
* *Advantage to Ligand A.*
**14. P-gp Efflux:**
* Ligand A: 0.104 - Low efflux.
* Ligand B: 0.025 - Very low efflux.
* *Advantage to Ligand B.*
**15. Binding Affinity:**
* Ligand A: -3.2 kcal/mol - Moderate affinity.
* Ligand B: -7.4 kcal/mol - Significantly stronger affinity.
* *Major advantage to Ligand B.*
**Overall Assessment:**
Ligand B is the clear preference despite some drawbacks. The significantly stronger binding affinity (-7.4 vs -3.2 kcal/mol) is a major driver. While both have poor permeability and solubility, Ligand B has a much lower DILI risk, better metabolic stability (lower Cl_mic), lower hERG risk, and lower P-gp efflux. The longer half-life of Ligand A is a plus, but it's outweighed by the severe DILI risk and weaker binding. Considering this is a GPCR target, the lower TPSA of Ligand B is also beneficial.
Output:
0
2025-04-17 23:02:51,269 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's analyze each ligand against the provided guidelines, keeping in mind ADRB2 is a GPCR and thus we prioritize logP, Pgp, TPSA, and affinity, alongside general drug-like properties.
* **Molecular Weight:** Both ligands (360.443 and 348.399 Da) fall comfortably within the ideal 200-500 Da range.
* **TPSA:** Both are below 140, which is good for oral absorption (95.08 and 92.01).
* **logP:** Both ligands have similar logP values (1.054 and 1.062), falling within the optimal 1-3 range.
* **H-Bond Donors/Acceptors:** Ligand A has 1 HBD and 6 HBA, while Ligand B has 2 HBD and 5 HBA. Both are within acceptable limits.
* **QED:** Both have good QED scores (0.879 and 0.849), indicating good drug-likeness.
* **DILI:** Ligand A (74.641) has a higher DILI risk than Ligand B (45.677). This is a significant drawback for Ligand A.
* **BBB:** Both have relatively low BBB penetration (52.074 and 49.826). Since ADRB2 isn't necessarily a CNS target, this isn't a major concern, but lower is preferable.
* **Caco-2 Permeability:** Ligand A (-5.713) has worse Caco-2 permeability than Ligand B (-4.734).
* **Aqueous Solubility:** Ligand A (-2.184) has worse solubility than Ligand B (-1.589).
* **hERG:** Both have very low hERG inhibition liability (0.066 and 0.144), which is excellent.
* **Microsomal Clearance:** Ligand B (-17.156) has significantly lower (better) microsomal clearance than Ligand A (18.129), suggesting better metabolic stability.
* **In vitro Half-Life:** Ligand B (23.014) has a much longer in vitro half-life than Ligand A (0.282), a substantial advantage.
* **P-gp Efflux:** Both have low P-gp efflux liability (0.162 and 0.018). Ligand B is slightly better.
* **Binding Affinity:** Ligand A (-8.6 kcal/mol) has a slightly better binding affinity than Ligand B (-7.6 kcal/mol). This is a 1.0 kcal/mol difference, which is notable but not overwhelmingly decisive.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity, Ligand B is superior in almost all ADME-Tox properties. The significantly lower DILI risk, improved metabolic stability (lower Cl_mic, longer t1/2), and better Caco-2 permeability and solubility of Ligand B outweigh the minor affinity advantage of Ligand A. For a GPCR target, these ADME properties are crucial for *in vivo* efficacy and safety.
**Output:**
0
2025-04-17 23:02:51,269 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (354.535 Da and 354.447 Da) are within the ideal range of 200-500 Da. No significant difference.
2. **TPSA:** Ligand A (69.64) is better than Ligand B (77.1). Both are below 140, but A is closer to the preferred value for good absorption.
3. **logP:** Ligand A (3.107) is optimal, while Ligand B (0.741) is a bit low, potentially hindering permeation. This is a significant advantage for A.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable.
5. **HBA:** Ligand A (3) and Ligand B (5) are both acceptable, but A is preferable.
6. **QED:** Both ligands have similar QED values (0.668 and 0.618), indicating good drug-likeness.
7. **DILI:** Ligand A (16.712) has a significantly lower DILI risk than Ligand B (12.214). This is a crucial advantage for A.
8. **BBB:** Both ligands have reasonable BBB penetration (63.048 and 69.833). While higher is better, this isn't a primary concern for ADRB2 (a cardiovascular target).
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the values are very close (-4.409 vs -4.667), so this isn't a major differentiator.
10. **Solubility:** Ligand A (-3.531) has slightly better solubility than Ligand B (-0.722).
11. **hERG:** Both ligands have low hERG inhibition risk (0.381 and 0.324).
12. **Cl_mic:** Ligand A (87.752) has higher microsomal clearance than Ligand B (10.182), indicating lower metabolic stability. This is a disadvantage for A.
13. **t1/2:** Ligand B (-3.199) has a better in vitro half-life than Ligand A (-6.168). This is a disadvantage for A.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.336 and 0.018).
15. **Binding Affinity:** Ligand A (-7.0) has a slightly better binding affinity than Ligand B (-5.9). This is a significant advantage for A, potentially outweighing some ADME drawbacks.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand A excels in logP and affinity, and is better than B in TPSA. While Ligand B has better metabolic stability (lower Cl_mic and better t1/2), the superior binding affinity and favorable logP/TPSA of Ligand A are more critical for initial optimization. The lower DILI risk of A is also a significant benefit.
**Conclusion:**
Despite the slightly worse metabolic stability, Ligand A's superior binding affinity, logP, TPSA, and lower DILI risk make it the more promising candidate for further development as a drug targeting ADRB2.
Output:
1
2025-04-17 23:02:51,269 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for the ADRB2, a cardiovascular GPCR. The key priorities for GPCRs are logP, Pgp efflux, TPSA, and binding affinity. Metabolic stability and solubility are also important.
Let's break down the comparison:
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (363.483) is slightly higher than Ligand B (337.471), but this isn't a major concern.
2. **TPSA:** Ligand A (88.68) is better than Ligand B (56.05). Lower TPSA generally favors permeability, and both are acceptable, but B is preferable.
3. **logP:** Ligand A (2.301) is within the optimal range (1-3), while Ligand B (3.543) is at the higher end. While not terrible, higher logP can sometimes lead to off-target effects. A is preferable.
4. **HBD/HBA:** Ligand A has 2 HBD and 6 HBA, while Ligand B has 0 HBD and 5 HBA. Both are within acceptable limits, but the presence of some HBDs in Ligand A may aid solubility.
5. **QED:** Both ligands have good QED scores (A: 0.668, B: 0.773), indicating good drug-like properties. B is slightly better.
6. **DILI:** Both have similar DILI risk (A: 36.293, B: 39.201), and are both acceptable.
7. **BBB:** Ligand B (86.778) has a significantly higher BBB penetration score than Ligand A (24.661). While ADRB2 is cardiovascular, some CNS penetration can be beneficial or at least not detrimental.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual. This suggests poor permeability.
9. **Solubility:** Ligand A (-0.963) is slightly better than Ligand B (-4.045), but both are quite poor.
10. **hERG:** Ligand A (0.57) is better than Ligand B (0.929), indicating lower cardiotoxicity risk.
11. **Cl_mic:** Ligand A (-9.723) has a much lower (better) microsomal clearance than Ligand B (59.038), suggesting better metabolic stability.
12. **t1/2:** Ligand A (53.449) has a much longer in vitro half-life than Ligand B (-1.045). This is a significant advantage.
13. **Pgp:** Ligand A (0.345) has lower P-gp efflux than Ligand B (0.318), which is preferable.
14. **Binding Affinity:** Both ligands have very similar binding affinities (A: -6.2 kcal/mol, B: -5.2 kcal/mol). Ligand A is slightly better.
**Overall Assessment:**
Ligand A has a clear advantage in metabolic stability (Cl_mic, t1/2), hERG risk, and a slightly better binding affinity. While Ligand B has better BBB penetration and a slightly higher QED, the poor solubility and metabolic stability are concerning. Given the cardiovascular target, metabolic stability and minimizing off-target effects (hERG) are crucial. The slightly better binding affinity of A also tips the balance.
Output:
1
2025-04-17 23:02:51,270 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (351.403 and 361.442 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (109.67) is higher than Ligand B (53.51). For a GPCR, lower TPSA is generally preferred for better blood-brain barrier penetration and overall permeability. Ligand B is significantly better.
3. **logP:** Ligand B (2.273) is within the optimal 1-3 range, while Ligand A (0.45) is quite low. This suggests Ligand B will have better membrane permeability. A significant advantage for B.
4. **HBD:** Ligand A (3) is higher than Ligand B (0). Lower HBD is generally preferred for permeability, giving a slight edge to B.
5. **HBA:** Ligand A (5) is higher than Ligand B (4). Similar to HBD, lower HBA is preferred, favoring B.
6. **QED:** Both ligands have good QED scores (0.53 and 0.552), indicating good drug-like properties. No clear advantage.
7. **DILI:** Ligand B (36.099) has a lower DILI risk than Ligand A (45.289), which is desirable.
8. **BBB:** Ligand B (95.347) has a much higher BBB penetration percentile than Ligand A (52.423). This is *very* important for a GPCR, even a cardiovascular one, as off-target CNS effects are always a concern. A major advantage for B.
9. **Caco-2:** Ligand A (-5.186) and Ligand B (-4.613) are both negative, indicating poor permeability. However, B is slightly less negative.
10. **Solubility:** Ligand A (-1.816) is better than Ligand B (-3.83). Solubility is important, but less critical than permeability for this target.
11. **hERG:** Both ligands have low hERG inhibition liability (0.148 and 0.368), which is good. No significant difference.
12. **Cl_mic:** Ligand A (33.418) has lower microsomal clearance than Ligand B (47.449), suggesting better metabolic stability. This is a slight advantage for A.
13. **t1/2:** Ligand A (27.261) has a longer in vitro half-life than Ligand B (-18.924). This is a significant advantage for A.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.036 and 0.063). No significant difference.
15. **Binding Affinity:** Ligand A (-7.3) has a stronger binding affinity than Ligand B (-6.5). This is a 0.8 kcal/mol difference, which is substantial and could potentially outweigh some ADME drawbacks.
**Overall Assessment:**
While Ligand A has a better binding affinity and metabolic stability (lower Cl_mic, longer t1/2), Ligand B demonstrates a superior ADME profile, particularly regarding TPSA, logP, and BBB penetration. Given that ADRB2 is a GPCR, optimizing for permeability and minimizing off-target CNS effects are crucial. The substantial difference in BBB penetration and the more favorable logP of Ligand B are compelling. The affinity difference, while significant, is not so large that it completely overrides the ADME advantages of Ligand B.
Output:
0
2025-04-17 23:02:51,270 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (336.315 Da and 353.507 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (134.36) is slightly higher than Ligand B (87.3). For a cardiovascular GPCR, TPSA is moderately important. Ligand B's lower TPSA is preferable, suggesting better permeability.
**3. logP:** Both ligands have good logP values (1.399 and 2.271, respectively), falling within the optimal 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability.
**4. H-Bond Donors:** Both ligands have 3 HBD, which is within the acceptable limit of <=5. No difference.
**5. H-Bond Acceptors:** Ligand A has 7 HBA, while Ligand B has 3. Ligand B is better here, as lower HBA generally correlates with improved permeability.
**6. QED:** Both ligands have good QED scores (0.512 and 0.594), indicating drug-likeness. Ligand B is slightly better.
**7. DILI Risk:** Ligand A has a significantly higher DILI risk (98.449%) compared to Ligand B (30.322%). This is a major concern for Ligand A.
**8. BBB Penetration:** Ligand B (60.799%) has better BBB penetration than Ligand A (29.12%). While ADRB2 is a cardiovascular target, some CNS effects are possible with beta-blockers, and better BBB penetration could lead to off-target effects. However, for a cardiovascular target, this isn't a primary driver.
**9. Caco-2 Permeability:** Ligand A (-5.435) has worse Caco-2 permeability than Ligand B (-4.968).
**10. Aqueous Solubility:** Ligand A (-4.119) has worse Aqueous Solubility than Ligand B (-3.213).
**11. hERG Inhibition:** Ligand A (0.498) has a slightly higher hERG inhibition risk than Ligand B (0.149). Lower is better here, so Ligand B is preferred.
**12. Microsomal Clearance:** Ligand A (9.925) has lower microsomal clearance than Ligand B (52.343), indicating better metabolic stability. This is a significant advantage for Ligand A.
**13. In vitro Half-Life:** Ligand A (10.995) has a slightly longer in vitro half-life than Ligand B (11.318).
**14. P-gp Efflux:** Ligand A (0.143) has lower P-gp efflux than Ligand B (0.067), which is better for bioavailability.
**15. Binding Affinity:** Ligand B (-7.6 kcal/mol) has a slightly stronger binding affinity than Ligand A (-7.2 kcal/mol). This is a meaningful difference, and the affinity advantage outweighs some of the ADME drawbacks of Ligand B.
**Overall Assessment:**
Ligand B is the stronger candidate. While Ligand A has better metabolic stability and P-gp efflux, Ligand B excels in critical areas like DILI risk, TPSA, HBA, Caco-2 permeability, solubility, and hERG inhibition. The slightly better binding affinity of Ligand B further solidifies its preference. The high DILI risk associated with Ligand A is a major red flag.
Output:
0
2025-04-17 23:02:51,270 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (364.364 and 351.447 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (87.66) is better than Ligand B (93.46). Both are below 140, but lower TPSA generally favors absorption.
3. **logP:** Both ligands have acceptable logP values (1.046 and 1.923, respectively), falling within the 1-3 range. Ligand B is slightly higher, which *could* be beneficial for membrane permeability, but isn't a major concern for either.
4. **HBD:** Ligand A has 3 HBD, and Ligand B has 2. Both are within the acceptable limit of 5.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 5. Both are within the acceptable limit of 10.
6. **QED:** Both ligands have good QED scores (0.637 and 0.709), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Both ligands have similar, acceptable DILI risk (38.736 and 39.667 percentile).
8. **BBB:** Ligand A (80.419) has a better BBB penetration percentile than Ligand B (75.843). While ADRB2 isn't exclusively a CNS target, some peripheral effects are mediated by CNS pathways, and better BBB penetration can be advantageous.
9. **Caco-2:** Ligand A (-5.065) has a worse Caco-2 permeability than Ligand B (-4.482). This suggests Ligand B may have better intestinal absorption.
10. **Solubility:** Ligand A (-1.771) has a worse solubility than Ligand B (-2.923). Solubility is important for formulation and bioavailability.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.334 and 0.317 percentile). This is excellent.
12. **Cl_mic:** Ligand A has zero metabolic clearance, which is *extremely* favorable. Ligand B has a clearance of 48.65 mL/min/kg, which is moderate.
13. **t1/2:** Ligand A has a very long in vitro half-life (-18.091 hours), while Ligand B has a shorter one (10.179 hours). This is a significant advantage for Ligand A.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.031 and 0.133 percentile).
15. **Binding Affinity:** Ligand A (-6.9 kcal/mol) has a slightly better binding affinity than Ligand B (-6.3 kcal/mol). While the difference is not huge, it is over the 1.5 kcal/mol threshold.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A performs well in these areas, especially with its superior affinity and metabolic stability (zero clearance). While Ligand B has slightly better Caco-2 and QED, the significantly better metabolic stability and affinity of Ligand A outweigh these minor advantages.
**Conclusion:**
Ligand A is the more promising drug candidate due to its superior binding affinity, exceptional metabolic stability (zero clearance), longer half-life, and better BBB penetration, despite slightly lower Caco-2 permeability and solubility.
Output:
1
2025-04-17 23:02:51,270 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (357.426 and 371.909 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (78.95) is slightly higher than Ligand B (70.67). Both are below the 140 threshold for oral absorption, but closer to the 90 threshold for CNS targets (less relevant for ADRB2, a cardiovascular target). Ligand B is slightly better.
3. **logP:** Both ligands have good logP values (1.03 and 1.785), falling within the optimal 1-3 range. Ligand B is a bit higher, potentially improving membrane permeability.
4. **HBD:** Ligand A (1) has fewer H-bond donors than Ligand B (2). Fewer HBDs generally improve permeability, so Ligand A is slightly favored.
5. **HBA:** Both ligands have the same number of H-bond acceptors (4), which is within the acceptable limit of 10.
6. **QED:** Ligand A (0.72) has a slightly higher QED score than Ligand B (0.638), indicating a more drug-like profile.
7. **DILI:** Ligand B (20.473) has a significantly lower DILI risk than Ligand A (33.773). This is a major advantage for Ligand B.
8. **BBB:** Ligand A (89.608) has a higher BBB penetration percentile than Ligand B (68.127). While ADRB2 isn't a CNS target, some off-target CNS effects are possible with GPCR ligands, and higher BBB penetration *could* be a concern. However, this is a lower priority.
9. **Caco-2:** Ligand A (-4.842) has a more negative Caco-2 value than Ligand B (-5.156), indicating *lower* permeability. Ligand B is better.
10. **Solubility:** Ligand A (-1.984) has a more negative solubility value than Ligand B (-2.08), indicating *lower* solubility. Ligand B is slightly better.
11. **hERG:** Ligand A (0.19) has a lower hERG inhibition liability than Ligand B (0.641). This is a significant advantage for Ligand A, as it reduces the risk of cardiotoxicity.
12. **Cl_mic:** Ligand A (-8.87) has a much lower microsomal clearance than Ligand B (1.833), indicating better metabolic stability. This is a strong advantage for Ligand A.
13. **t1/2:** Ligand A (-12.013) has a more negative in vitro half-life than Ligand B (18.642), indicating a *shorter* half-life. Ligand B is better.
14. **Pgp:** Ligand A (0.011) has a lower P-gp efflux liability than Ligand B (0.027). This is a slight advantage for Ligand A.
15. **Binding Affinity:** Ligand B (-6.6) has a slightly better binding affinity than Ligand A (-6.1). While not a huge difference, it's still a factor.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand B is better for logP, Caco-2, and affinity. Ligand A is better for TPSA and Pgp.
**Overall Assessment:**
Ligand B has a significant advantage in terms of DILI risk and metabolic stability (Cl_mic). It also has slightly better affinity and Caco-2 permeability. While Ligand A has a better hERG profile, the lower DILI risk of Ligand B is more critical for a cardiovascular target. The slightly better affinity of Ligand B also tips the balance.
Output:
0
2025-04-17 23:02:51,271 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [348.487, 50.8, 3.885, 1, 3, 0.878, 26.406, 91.237, -4.261, -3.793, 0.842, 61.143, -6.622, 0.314, -7.1]
**Ligand B:** [383.436, 78.51, 1.301, 2, 4, 0.662, 43.66, 55.332, -5.329, -2.466, 0.355, 7.003, -7.931, 0.039, -6.6]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity, and to a lesser extent BBB):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (348.487) is slightly preferred due to being lower.
2. **TPSA:** Ligand A (50.8) is excellent, well below the 140 threshold. Ligand B (78.51) is still reasonable, but less optimal.
3. **logP:** Ligand A (3.885) is within the optimal range (1-3), while Ligand B (1.301) is at the lower end. This is a significant advantage for A, as it suggests better membrane permeability.
4. **HBD/HBA:** Ligand A (1 HBD, 3 HBA) is better than Ligand B (2 HBD, 4 HBA) in terms of balancing solubility and permeability.
5. **QED:** Ligand A (0.878) is significantly better than Ligand B (0.662), indicating a more drug-like profile.
6. **DILI:** Ligand A (26.406) has a much lower DILI risk than Ligand B (43.66). This is a crucial advantage.
7. **BBB:** Ligand A (91.237) shows excellent BBB penetration, while Ligand B (55.332) is moderate. While ADRB2 isn't strictly a CNS target, some distribution to the brain is possible, and higher BBB is generally favorable.
8. **Caco-2:** Both have negative values, indicating permeability. Ligand A (-4.261) is slightly better than Ligand B (-5.329).
9. **Solubility:** Both have negative solubility values, indicating poor solubility. Ligand B (-2.466) is slightly better than Ligand A (-3.793).
10. **hERG:** Both are low risk (0.842 and 0.355).
11. **Cl_mic:** Ligand A (61.143) has a lower microsomal clearance than Ligand B (7.003), suggesting better metabolic stability.
12. **t1/2:** Ligand A (-6.622) has a longer in vitro half-life than Ligand B (-7.931).
13. **Pgp:** Ligand A (0.314) has lower P-gp efflux than Ligand B (0.039), suggesting better bioavailability.
14. **Affinity:** Both have very similar binding affinities (-7.1 and -6.6 kcal/mol). The difference is not substantial enough to outweigh the other factors.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical ADME properties (logP, TPSA, QED, DILI, BBB, Cl_mic, t1/2, Pgp) while maintaining comparable binding affinity. Ligand B's slightly better solubility is not enough to compensate for its poorer overall profile.
Therefore, I would choose Ligand A.
Output:
1
2025-04-17 23:02:51,271 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [342.359, 103.08 , 1.717, 0. , 8. , 0.695, 68.98 , 78.868, -5.343, -1.709, 0.138, 11.617, 14.355, 0.081, -6.1 ]**
**Ligand B: [378.372, 86.71 , 1.824, 2. , 4. , 0.837, 50.64 , 66.615, -5.113, -3.975, 0.794, 21.673, -22.245, 0.08 , -7.4 ]**
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (342.359) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are acceptable, but Ligand B (86.71) is better than Ligand A (103.08) as it's closer to the <90 target for GPCRs.
3. **logP:** Both are within the optimal range (1-3). Ligand A (1.717) and Ligand B (1.824) are very similar.
4. **H-Bond Donors:** Ligand A (0) is better than Ligand B (2). Fewer HBDs generally improve permeability.
5. **H-Bond Acceptors:** Ligand A (8) is higher than Ligand B (4). Ligand B is preferable here.
6. **QED:** Both are above 0.5, indicating good drug-like properties. Ligand B (0.837) is slightly better than Ligand A (0.695).
7. **DILI:** Ligand B (50.64) is significantly better than Ligand A (68.98). Lower DILI risk is crucial.
8. **BBB:** Ligand A (78.868) is better than Ligand B (66.615). While not a primary concern for ADRB2 (cardiovascular target), some CNS penetration can be useful for off-target assessment.
9. **Caco-2 Permeability:** Both are negative, indicating poor permeability. Ligand A (-5.343) is slightly worse than Ligand B (-5.113).
10. **Aqueous Solubility:** Both are negative, indicating poor solubility. Ligand B (-3.975) is slightly better than Ligand A (-1.709).
11. **hERG Inhibition:** Ligand A (0.138) is much better than Ligand B (0.794). Lower hERG risk is critical for cardiovascular drugs.
12. **Microsomal Clearance:** Ligand A (11.617) is significantly better than Ligand B (21.673). Lower clearance indicates better metabolic stability.
13. **In vitro Half-Life:** Ligand A (14.355) is better than Ligand B (-22.245). Longer half-life is generally preferred.
14. **P-gp Efflux:** Both are very low (0.081 and 0.08).
15. **Binding Affinity:** Ligand B (-7.4) has a significantly stronger binding affinity than Ligand A (-6.1). This is a substantial advantage.
**Overall Assessment:**
Ligand B has a significantly stronger binding affinity, a lower DILI risk, and better QED. While Ligand A has better BBB penetration and hERG inhibition, the affinity difference and DILI risk are more critical. The slightly poorer permeability of Ligand B can potentially be addressed through formulation strategies. The stronger binding of Ligand B outweighs the drawbacks.
Output:
0
2025-04-17 23:02:51,271 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (344.5) is slightly lower, which can be advantageous for permeability.
2. **TPSA:** Ligand A (40.62) is significantly better than Ligand B (84.5). For a GPCR, keeping TPSA low is beneficial for permeability and receptor engagement. Ligand B's TPSA is quite high, potentially hindering oral absorption.
3. **logP:** Both ligands have acceptable logP values (A: 3.372, B: 2.096), falling within the 1-3 range. Ligand A is slightly higher, which could be a minor concern for solubility, but not a major issue.
4. **HBD/HBA:** Ligand A (0 HBD, 2 HBA) is preferable to Ligand B (2 HBD, 5 HBA). Lower HBD/HBA generally improves membrane permeability.
5. **QED:** Both ligands have similar QED values (A: 0.734, B: 0.656), indicating good drug-like properties.
6. **DILI:** Ligand A (22.8) has a much lower DILI risk than Ligand B (62.466). This is a significant advantage for Ligand A.
7. **BBB:** Ligand A (78.286) shows better BBB penetration potential than Ligand B (47.383). While ADRB2 isn't exclusively a CNS target, some peripheral effects are mediated by CNS pathways, and better BBB penetration could be beneficial.
8. **Caco-2:** Ligand A (-4.799) is better than Ligand B (-5.288), indicating better intestinal absorption.
9. **Solubility:** Ligand A (-3.771) is better than Ligand B (-2.972) indicating better solubility.
10. **hERG:** Both ligands have low hERG inhibition liability (A: 0.44, B: 0.13), which is good.
11. **Cl_mic:** Ligand B (34.18) has significantly lower microsomal clearance than Ligand A (61.818), suggesting better metabolic stability. This is a positive for Ligand B.
12. **t1/2:** Ligand B (15.499) has a much longer in vitro half-life than Ligand A (0.269). This is a major advantage for Ligand B.
13. **Pgp:** Ligand A (0.453) has lower P-gp efflux liability than Ligand B (0.189), which is favorable.
14. **Binding Affinity:** Ligand A (-5.6 kcal/mol) has a slightly better binding affinity than Ligand B (-4.0 kcal/mol). This 1.6 kcal/mol difference is substantial and can often outweigh minor ADME drawbacks.
**Overall Assessment & GPCR Prioritization:**
Given the GPCR target class, I prioritize affinity, logP, TPSA, Pgp, and BBB. Ligand A excels in affinity, TPSA, Pgp, and BBB. Ligand B has a better metabolic profile (lower Cl_mic and longer t1/2). However, the significantly higher TPSA and DILI risk of Ligand B are major drawbacks. The superior binding affinity of Ligand A, combined with its better TPSA, lower DILI, and acceptable ADME properties, makes it the more promising candidate. The longer half-life of Ligand B is attractive, but can be addressed through structural modifications during lead optimization.
Output:
1
2025-04-17 23:02:51,271 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (349.381) is slightly preferred as it's closer to the lower end, potentially aiding permeability.
2. **TPSA:** Ligand A (62.3) is significantly better than Ligand B (111.79). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (2.679) is optimal, while Ligand B (-0.039) is quite low. A logP near zero can lead to poor membrane permeability. This is a significant advantage for Ligand A.
4. **HBD:** Both have acceptable HBD counts (Ligand A: 1, Ligand B: 3).
5. **HBA:** Both have acceptable HBA counts (Ligand A: 3, Ligand B: 6).
6. **QED:** Ligand A (0.85) has a better QED score than Ligand B (0.607), indicating a more drug-like profile.
7. **DILI:** Both ligands have similar and acceptable DILI risk (Ligand A: 52.152, Ligand B: 51.221).
8. **BBB:** Ligand A (68.166) has a better BBB score than Ligand B (36.603), but since this is a cardiovascular target, this isn't a major deciding factor.
9. **Caco-2:** Ligand A (-4.31) is better than Ligand B (-5.366). Higher values are better, indicating better intestinal absorption.
10. **Solubility:** Ligand A (-2.869) is better than Ligand B (-1.967). Higher values are better.
11. **hERG:** Both ligands have low hERG inhibition liability (Ligand A: 0.383, Ligand B: 0.213), which is good.
12. **Cl_mic:** Ligand B (-18.081) has significantly lower (better) microsomal clearance than Ligand A (37.8). This suggests better metabolic stability for Ligand B.
13. **t1/2:** Ligand B (24.057) has a much longer in vitro half-life than Ligand A (5.2). This is a substantial advantage for Ligand B.
14. **Pgp:** Both ligands have low P-gp efflux liability (Ligand A: 0.083, Ligand B: 0.006). Ligand B is slightly better.
15. **Binding Affinity:** Ligand B (-6.9 kcal/mol) has a slightly better binding affinity than Ligand A (-5.8 kcal/mol). This is a meaningful difference, although not enormous.
**Overall Assessment:**
Ligand A has advantages in TPSA, logP, QED, solubility and Caco-2 permeability. However, Ligand B has a significantly longer half-life and better metabolic stability (lower Cl_mic), and slightly better binding affinity and Pgp efflux. The low logP of Ligand B is a concern, but the improved metabolic stability and binding affinity are compelling. Given the GPCR nature of the target, a balance of permeability and metabolic stability is crucial. The binding affinity difference, combined with the longer half-life, tips the balance in favor of Ligand B.
Output:
0
2025-04-17 23:02:51,271 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (341.411 and 346.475 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (82.53) is slightly higher than Ligand B (78.09), but both are well below the 140 threshold for good oral absorption and acceptable for a cardiovascular GPCR.
3. **logP:** Ligand A (1.381) is within the optimal 1-3 range. Ligand B (2.444) is also acceptable, leaning towards the higher end.
4. **HBD:** Both ligands have 2 H-bond donors, which is good.
5. **HBA:** Ligand A has 4 H-bond acceptors, and Ligand B has 3. Both are within the acceptable range of <=10.
6. **QED:** Both ligands have similar QED values (0.766 and 0.744), indicating good drug-likeness.
7. **DILI:** Ligand B (34.471) has a significantly lower DILI risk than Ligand A (48.468). This is a substantial advantage for Ligand B.
8. **BBB:** Both ligands have similar BBB penetration (59.325 and 53.393). Since ADRB2 is not a CNS target, this is less critical, but higher is still slightly preferred.
9. **Caco-2:** Ligand B (-5.228) has a more negative Caco-2 value, suggesting better intestinal absorption than Ligand A (-4.982).
10. **Solubility:** Ligand B (-2.084) has a better solubility score than Ligand A (-3.033).
11. **hERG:** Ligand A (0.168) has a slightly lower hERG inhibition liability than Ligand B (0.343), which is favorable.
12. **Cl_mic:** Ligand A (3.84) has a much lower microsomal clearance than Ligand B (22.801), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand B (-16.015) has a significantly longer in vitro half-life than Ligand A (-4.983). This is a major advantage for Ligand B.
14. **Pgp:** Ligand A (0.03) has a lower P-gp efflux liability than Ligand B (0.178), which is preferable.
15. **Binding Affinity:** Ligand B (-7.5 kcal/mol) has a significantly better binding affinity than Ligand A (-6.1 kcal/mol). This 1.4 kcal/mol difference is substantial and can outweigh some ADME drawbacks.
**GPCR-Specific Priorities:**
For ADRB2 (a cardiovascular GPCR), logP, Pgp, TPSA, and affinity are key. Ligand B excels in affinity and has good logP and TPSA. Ligand A has better Pgp efflux liability, but the difference isn't large enough to overcome the substantial affinity advantage of Ligand B. The lower DILI risk and better solubility of Ligand B are also beneficial. While Ligand A has better metabolic stability, the longer half-life of Ligand B mitigates this concern.
**Conclusion:**
Despite Ligand A's better metabolic stability and Pgp profile, the significantly higher binding affinity of Ligand B, coupled with its lower DILI risk, better solubility, and longer half-life, makes it the more promising drug candidate for ADRB2.
Output:
0
2025-04-17 23:02:51,272 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (350.463 and 356.337 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (78.68) is significantly better than Ligand B (128.88). For a GPCR, keeping TPSA under 140 is good for oral absorption, and A is much closer to the lower end.
**3. logP:** Ligand A (1.424) is slightly better than Ligand B (0.721), both are within the optimal 1-3 range, but A is closer to the sweet spot.
**4. H-Bond Donors:** Both have 1 HBD, which is acceptable.
**5. H-Bond Acceptors:** Ligand A has 5, and Ligand B has 6. Both are within the acceptable limit of 10.
**6. QED:** Ligand A (0.805) is considerably better than Ligand B (0.438). A higher QED suggests a more drug-like profile.
**7. DILI:** Ligand A (11.516) has a much lower DILI risk than Ligand B (60.217). This is a substantial advantage for A.
**8. BBB:** Both have reasonable BBB penetration (A: 65.025, B: 68.941), but this is less critical for a cardiovascular target like ADRB2.
**9. Caco-2 Permeability:** Both are negative, indicating poor permeability. Ligand A (-4.937) is slightly better than Ligand B (-5.388).
**10. Aqueous Solubility:** Ligand A (-0.515) is better than Ligand B (-1.4).
**11. hERG Inhibition:** Both are very low (A: 0.181, B: 0.155), indicating minimal cardiotoxicity risk.
**12. Microsomal Clearance:** Ligand B (-10.923) has significantly lower (better) microsomal clearance than Ligand A (16.796), suggesting better metabolic stability.
**13. In vitro Half-Life:** Ligand B (4.628) has a longer half-life than Ligand A (2.95).
**14. P-gp Efflux:** Both are very low (A: 0.029, B: 0.014), indicating minimal P-gp efflux.
**15. Binding Affinity:** Both have very similar binding affinities (-6.7 and -6.6 kcal/mol). The difference is negligible.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity) and the general drug-like properties, Ligand A is the better candidate. While Ligand B has better metabolic stability and half-life, Ligand A excels in crucial areas like TPSA, QED, and, most importantly, DILI risk. The lower DILI risk is a significant advantage, and the slightly better logP and TPSA contribute to improved potential for oral absorption. The binding affinity is comparable, so the ADME properties become the deciding factor.
Output:
1
2025-04-17 23:02:51,272 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [350.379, 121.94 , -1.387, 2. , 8. , 0.44 , 49.36 , 32.416, -5.311, -0.947, 0.035, -5.609, 14.423, 0.01 , -7. ]
**Ligand B:** [346.391, 90.9 , -0.137, 1. , 7. , 0.812, 77.2 , 68.127, -5.042, -2.595, 0.385, 29.401, -1.098, 0.011, -7.9 ]
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (350.379) and Ligand B (346.391) are very similar.
2. **TPSA:** Ligand A (121.94) is slightly above the preferred <140 for good oral absorption, but still reasonable. Ligand B (90.9) is excellent, well below 140 and a good sign for permeability.
3. **logP:** Ligand A (-1.387) is a bit low, potentially hindering membrane permeability. Ligand B (-0.137) is better, falling within the optimal 1-3 range.
4. **HBD:** Both ligands have acceptable HBD counts (2 for A, 1 for B), well under the limit of 5.
5. **HBA:** Both ligands have acceptable HBA counts (8 for A, 7 for B), well under the limit of 10.
6. **QED:** Ligand B (0.812) has a significantly better QED score than Ligand A (0.44), indicating a more drug-like profile.
7. **DILI:** Ligand A (49.36) has a lower DILI risk than Ligand B (77.2), which is a significant advantage.
8. **BBB:** Ligand B (68.127) has a higher BBB penetration score than Ligand A (32.416). While ADRB2 is cardiovascular, some CNS penetration can occur, and it's a slight benefit for B.
9. **Caco-2:** Both have negative values, which is unusual. Assuming these are log scale values, both are very poor.
10. **Solubility:** Both have negative values, which is unusual. Assuming these are log scale values, both are very poor.
11. **hERG:** Ligand A (0.035) has a slightly lower hERG risk than Ligand B (0.385), which is preferable.
12. **Cl_mic:** Ligand A (-5.609) has a much lower (better) microsomal clearance than Ligand B (29.401), suggesting better metabolic stability.
13. **t1/2:** Ligand A (14.423) has a longer in vitro half-life than Ligand B (-1.098), which is a significant advantage.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.01 and 0.011), which is good.
15. **Affinity:** Ligand B (-7.9) has a slightly better binding affinity than Ligand A (-7.0), a 0.9 kcal/mol difference.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are crucial. Ligand B excels in TPSA and affinity, and has a better logP. However, Ligand A has a much better DILI score, significantly better metabolic stability (Cl_mic and t1/2), and a lower hERG risk. The affinity difference, while present, is not large enough to completely outweigh the ADME advantages of Ligand A.
**Conclusion:**
Considering the balance of properties, particularly the improved safety profile (DILI, hERG) and metabolic stability of Ligand A, I believe it is the more promising drug candidate.
**Output:**
1
2025-04-17 23:02:51,272 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (337.379 and 346.387 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (58.81) is significantly better than Ligand B (95.34). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 cutoff. Ligand B is approaching the upper limit.
3. **logP:** Ligand A (3.598) is slightly higher than Ligand B (2.411), both within the optimal 1-3 range. Ligand A is closer to the upper end, which *could* present solubility issues, but is still acceptable.
4. **HBD:** Ligand A (0) is preferable to Ligand B (1). Fewer HBDs generally improve membrane permeability.
5. **HBA:** Ligand A (5) is better than Ligand B (7). Similar reasoning as HBDs - fewer is generally better for permeability.
6. **QED:** Both ligands have good QED scores (0.728 and 0.807), indicating good drug-like properties. No strong preference.
7. **DILI:** Ligand B (69.717) is significantly better than Ligand A (94.959). Lower DILI risk is *always* preferable. This is a substantial advantage for Ligand B.
8. **BBB:** Ligand A (83.831) is better than Ligand B (60.644). While not a CNS target, some degree of BBB penetration can sometimes be indicative of better overall permeability.
9. **Caco-2:** Both ligands have very poor Caco-2 permeability (-4.567 and -4.697). This is a significant concern for both, suggesting poor intestinal absorption.
10. **Solubility:** Ligand B (-3.015) is better than Ligand A (-4.72). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.758) is better than Ligand B (0.206). Lower hERG inhibition is crucial to avoid cardiotoxicity, a major concern for cardiovascular targets.
12. **Cl_mic:** Ligand A (65.704) is better than Ligand B (79.554). Lower clearance indicates better metabolic stability.
13. **t1/2:** Ligand A (19.942) is significantly better than Ligand B (9.794). A longer half-life is generally desirable.
14. **Pgp:** Ligand A (0.645) is better than Ligand B (0.049). Lower P-gp efflux is preferable for improved bioavailability.
15. **Binding Affinity:** Ligand A (-6.5 kcal/mol) is slightly better than Ligand B (-5.8 kcal/mol). This difference of 0.7 kcal/mol is significant enough to potentially outweigh some ADME drawbacks.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A performs better on TPSA, Pgp, and affinity. Ligand B has a better DILI score.
**Overall Assessment:**
Ligand A has a better binding affinity, TPSA, Pgp efflux, metabolic stability, and half-life. While Ligand B has a better DILI score and solubility, the significantly better affinity of Ligand A, combined with its more favorable TPSA and Pgp properties, outweigh these benefits. The poor Caco-2 permeability is a concern for both, but can be addressed with formulation strategies. The hERG risk is also lower for Ligand A, which is critical for a cardiovascular drug.
Output:
1
2025-04-17 23:02:51,272 - INFO - Batch 376 complete. Total preferences: 6016
2025-04-17 23:02:51,272 - INFO - Processing batch 377/512...
2025-04-17 23:03:40,688 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (363.424 and 345.334 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (52.65) is significantly better than Ligand B (95.93). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary goal, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold. Ligand B is approaching the upper limit.
3. **logP:** Both ligands (1.817 and 1.974) are within the optimal 1-3 range. Similar.
4. **HBD:** Ligand A (1) is preferable to Ligand B (0). A single HBD can aid solubility without drastically impacting permeability.
5. **HBA:** Ligand A (3) is better than Ligand B (8). Lower HBA is generally preferred for better permeability.
6. **QED:** Ligand A (0.68) is slightly better than Ligand B (0.576), indicating a slightly more drug-like profile.
7. **DILI:** Ligand B (78.402) has a higher DILI risk than Ligand A (10.275). This is a significant advantage for Ligand A.
8. **BBB:** Both are reasonably high (84.568 and 76.309), but not critical for a cardiovascular target.
9. **Caco-2:** Both are negative (-4.714 and -4.682), indicating poor permeability. This is a concern for both, but not a deciding factor.
10. **Solubility:** Ligand A (-1.308) is better than Ligand B (-2.412), though both are poor.
11. **hERG:** Ligand A (0.478) has a much lower hERG risk than Ligand B (0.244). This is a critical advantage for Ligand A, as hERG inhibition can lead to cardiotoxicity.
12. **Cl_mic:** Ligand A (24.671) has significantly lower microsomal clearance than Ligand B (71.419), indicating better metabolic stability.
13. **t1/2:** Ligand A (7.135) has a better in vitro half-life than Ligand B (-18.932).
14. **Pgp:** Ligand A (0.02) has a much lower P-gp efflux liability than Ligand B (0.123), suggesting better oral bioavailability.
15. **Binding Affinity:** Ligand B (-7.3) has a slightly better binding affinity than Ligand A (-6.8). This is a 0.5 kcal/mol difference, which is significant, but not overwhelming considering the other factors.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical ADME-Tox properties. While Ligand B has a slightly better binding affinity, the advantages of Ligand A in terms of DILI risk, hERG inhibition, metabolic stability (Cl_mic and t1/2), P-gp efflux, solubility, and TPSA are substantial. These factors are crucial for developing a safe and effective drug, especially for a cardiovascular target where cardiotoxicity is a major concern. The slightly weaker binding affinity of Ligand A can potentially be optimized in subsequent iterations of drug design.
Output:
1
2025-04-17 23:03:40,689 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (336.435 and 349.475 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (45.33) is significantly better than Ligand B (83.36). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold. Ligand B is pushing the limit.
3. **logP:** Ligand A (3.692) is slightly higher than Ligand B (2.097), both within the optimal 1-3 range. Ligand A is preferable.
4. **HBD:** Ligand A (1) is better than Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (3) is better than Ligand B (4). Similar to HBD, fewer HBAs are generally preferred.
6. **QED:** Ligand A (0.698) is better than Ligand B (0.566), indicating a more drug-like profile.
7. **DILI:** Ligand B (29.236) is significantly better than Ligand A (48.352). This is a substantial advantage for Ligand B.
8. **BBB:** Ligand A (76.347) is better than Ligand B (29.12). While not a primary concern for a cardiovascular target, some CNS exposure could be acceptable or even beneficial.
9. **Caco-2:** Ligand A (-4.9) is better than Ligand B (-4.856). Both are negative values, which is unusual and requires further investigation, but the slightly better value for A is preferable.
10. **Solubility:** Ligand A (-5.197) is better than Ligand B (-2.659). Better solubility is important for bioavailability.
11. **hERG:** Ligand A (0.882) is better than Ligand B (0.28). Lower hERG inhibition is crucial for avoiding cardiotoxicity, and Ligand B is concerningly low.
12. **Cl_mic:** Ligand B (50.918) is better than Ligand A (92.3). Lower clearance indicates better metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand B (32.806) is better than Ligand A (28.034). Longer half-life is generally desirable.
14. **Pgp:** Ligand A (0.649) is better than Ligand B (0.175). Lower P-gp efflux is preferable.
15. **Binding Affinity:** Ligand B (-5.1) is slightly better than Ligand A (-4.6). While a 1.5 kcal/mol advantage is significant, the other factors need to be considered.
**Overall Assessment:**
Ligand B has a much better DILI score and metabolic stability (Cl_mic, t1/2) and a slightly better binding affinity. However, Ligand A excels in TPSA, logP, QED, solubility, hERG, and Pgp efflux. The hERG risk associated with Ligand B is a major concern, given that ADRB2 is a cardiovascular target. While Ligand B's metabolic stability is attractive, the potential for cardiotoxicity outweighs this benefit. Ligand A presents a more balanced profile with fewer liabilities.
Output:
1
2025-04-17 23:03:40,689 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Ligand A (474.172 Da) is at the upper end of the ideal range, while Ligand B (339.439 Da) is comfortably within it. This favors Ligand B.
2. **TPSA:** Ligand A (59.81) is good, below 140, but Ligand B (81.99) is also acceptable.
3. **logP:** Ligand A (4.794) is a bit high, potentially leading to solubility issues and off-target effects. Ligand B (2.71) is nearly ideal. This strongly favors Ligand B.
4. **HBD:** Both ligands have acceptable HBD counts (1 and 2 respectively).
5. **HBA:** Both ligands have acceptable HBA counts (4 and 3 respectively).
6. **QED:** Both ligands have good QED scores (0.655 and 0.801), indicating good drug-likeness.
7. **DILI:** Ligand A (64.599) has a higher DILI risk than Ligand B (39.667). This favors Ligand B.
8. **BBB:** Ligand A (83.288) shows better BBB penetration than Ligand B (55.797), but BBB isn't a primary concern for ADRB2, a cardiovascular target.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the values are similar.
10. **Solubility:** Ligand A (-5.671) has significantly worse solubility than Ligand B (-3.887). This favors Ligand B.
11. **hERG:** Both ligands have low hERG inhibition risk (0.537 and 0.445).
12. **Cl_mic:** Ligand A (42.336) has a higher microsomal clearance than Ligand B (4.135), indicating lower metabolic stability. This favors Ligand B.
13. **t1/2:** Ligand A (71.344) has a much longer in vitro half-life than Ligand B (1.866). This favors Ligand A.
14. **Pgp:** Ligand A (0.662) has a slightly higher Pgp efflux liability than Ligand B (0.134). This favors Ligand B.
15. **Affinity:** Ligand B (-7.9 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.3 kcal/mol) - a difference of 1.6 kcal/mol. This is a major advantage for Ligand B.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand B excels in logP and affinity, and has a much lower Pgp efflux liability. While Ligand A has better BBB penetration, this is less critical for a cardiovascular target. The longer half-life of Ligand A is a plus, but the significantly stronger binding affinity of Ligand B, combined with its better ADME properties (lower logP, lower DILI, better solubility, lower Cl_mic, lower Pgp) outweighs this benefit.
**Conclusion:**
Ligand B is the more promising drug candidate due to its superior binding affinity, better ADME properties, and lower potential for toxicity.
Output:
0
2025-04-17 23:03:40,689 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
The ADRB2 receptor is a GPCR, so the priorities are logP, Pgp, TPSA, affinity, and BBB. Let's break down the comparison:
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (372.824) is slightly higher than Ligand B (338.455), but both are acceptable.
2. **TPSA:** Both are below the 140 A^2 threshold for good oral absorption. Ligand A (75.71) is slightly higher than Ligand B (70.07), but both are good.
3. **logP:** Ligand A (1.672) is optimal, while Ligand B (3.727) is approaching the upper limit and could potentially cause solubility issues. This favors Ligand A.
4. **H-Bond Donors:** Ligand A (1) is better than Ligand B (3). Fewer HBDs generally improve permeability.
5. **H-Bond Acceptors:** Ligand A (4) is better than Ligand B (5).
6. **QED:** Ligand A (0.762) is significantly better than Ligand B (0.53), indicating a more drug-like profile.
7. **DILI:** Ligand A (42.846) has a lower DILI risk than Ligand B (56.727), which is favorable.
8. **BBB:** Both have good BBB penetration (Ligand A: 76.309, Ligand B: 80.031). Ligand B is slightly better, but the difference isn't substantial.
9. **Caco-2:** Both have negative values, indicating poor permeability. Ligand A (-4.769) is slightly better than Ligand B (-5.051).
10. **Solubility:** Both have negative values, indicating poor solubility. Ligand A (-2.906) is slightly better than Ligand B (-4.03).
11. **hERG:** Ligand A (0.279) has a much lower hERG risk than Ligand B (0.919), a critical advantage for cardiovascular targets.
12. **Cl_mic:** Ligand A (4.182) has a significantly lower microsomal clearance than Ligand B (69.218), indicating better metabolic stability.
13. **t1/2:** Ligand A (-11.663) has a much longer in vitro half-life than Ligand B (34.465).
14. **Pgp:** Ligand A (0.075) has a much lower P-gp efflux liability than Ligand B (0.409), improving bioavailability.
15. **Binding Affinity:** Ligand B (-7.9) has a stronger binding affinity than Ligand A (-6.2). This is a 1.7 kcal/mol difference, which is significant.
**Overall Assessment:**
While Ligand B has a better binding affinity, Ligand A demonstrates a superior balance of ADME properties, particularly regarding metabolic stability (Cl_mic, t1/2), safety (DILI, hERG), and permeability/solubility. The lower logP, HBD, HBA, and Pgp efflux of Ligand A are also beneficial for a GPCR target. The affinity difference, while notable, can potentially be optimized in subsequent iterations of drug design, whereas fixing poor ADME properties is often more challenging.
**Output:**
1
2025-04-17 23:03:40,689 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (377.9 & 369.9 Da) fall comfortably within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (82.76) is slightly higher than Ligand B (78.45). Both are below the 140 threshold for oral absorption, but closer to the 90 threshold for CNS targets which is not a priority here. Ligand B is slightly preferred.
3. **logP:** Ligand A (4.451) is higher than Ligand B (2.82). While 4.451 is pushing the upper limit, it's not drastically outside the optimal 1-3 range. Ligand B is significantly better here, falling squarely within the ideal range.
4. **HBD:** Ligand A (1) is better than Ligand B (2). Lower is generally preferred.
5. **HBA:** Ligand A (7) is better than Ligand B (4). Lower is generally preferred.
6. **QED:** Ligand B (0.738) is better than Ligand A (0.534). Higher QED indicates better drug-likeness.
7. **DILI:** Ligand B (35.673) is *much* better than Ligand A (81.078). This is a significant advantage for Ligand B. Lower DILI risk is crucial.
8. **BBB:** Ligand A (43.117) is lower than Ligand B (62.699). BBB is not a high priority for ADRB2, but higher is still slightly better.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-5.198) is slightly worse than Ligand B (-4.757).
10. **Solubility:** Ligand A (-4.745) is slightly worse than Ligand B (-3.23). Higher solubility is preferred.
11. **hERG:** Both are very low (0.245 and 0.494), indicating minimal hERG inhibition risk. No clear advantage.
12. **Cl_mic:** Ligand B (22.738) is *much* better than Ligand A (62.958). Lower clearance is highly desirable for metabolic stability.
13. **t1/2:** Ligand B (43.742) is significantly better than Ligand A (-12.564). A longer half-life is preferred.
14. **Pgp:** Both are the same (0.335 and 0.596), indicating similar P-gp efflux liability.
15. **Binding Affinity:** Ligand B (-6.4) is slightly better than Ligand A (-6.0). While both are good, the slight advantage in binding is helpful.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP and has a slight edge in affinity. While both have similar Pgp values, the significantly better ADME profile of Ligand B (lower DILI, lower Cl_mic, longer t1/2, better solubility) outweighs the minor affinity difference.
**Conclusion:**
Ligand B demonstrates a superior balance of properties, particularly regarding ADME-Tox parameters (DILI, Cl_mic, t1/2) and drug-likeness (QED). While Ligand A has some favorable characteristics, the substantial advantages of Ligand B in critical areas make it the more promising drug candidate.
Output:
0
2025-04-17 23:03:40,689 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**1. Molecular Weight:** Both ligands (357.8 and 350.4 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand B (70.59) is significantly better than Ligand A (89.03). For a GPCR, lower TPSA is generally preferred for better permeability.
**3. logP:** Both ligands have acceptable logP values (2.89 and 3.822), falling within the 1-3 range. Ligand B is slightly higher, which could potentially lead to some solubility issues, but it's not a major concern.
**4. H-Bond Donors:** Ligand A (2) is slightly better than Ligand B (3). Lower HBDs are generally preferred for permeability.
**5. H-Bond Acceptors:** Ligand A (6) is better than Ligand B (3). Lower HBA is generally preferred for permeability.
**6. QED:** Both ligands have good QED scores (0.682 and 0.742), indicating good drug-like properties. Ligand B is slightly better.
**7. DILI Risk:** Ligand B (61.07) is significantly better than Ligand A (98.216). Lower DILI risk is crucial. This is a major advantage for Ligand B.
**8. BBB Penetration:** Ligand A (67.468) is better than Ligand B (45.909). While ADRB2 isn't strictly a CNS target, some CNS exposure can be relevant for off-target effects, and higher BBB is generally favorable.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.964 and -4.81). This is unusual and suggests poor permeability. However, these values are on a log scale, so the difference isn't huge.
**10. Aqueous Solubility:** Both ligands have negative solubility values (-4.002 and -4.664), indicating poor solubility. This is a concern for both.
**11. hERG Inhibition:** Ligand A (0.402) is better than Ligand B (0.691). Lower hERG inhibition is crucial for avoiding cardiotoxicity, a significant concern for cardiovascular targets.
**12. Microsomal Clearance:** Ligand A (41.245) is better than Ligand B (65.886). Lower clearance indicates better metabolic stability.
**13. In vitro Half-Life:** Ligand A (76.53) is significantly better than Ligand B (16.76). A longer half-life is generally desirable.
**14. P-gp Efflux:** Ligand A (0.096) is better than Ligand B (0.203). Lower P-gp efflux is preferred.
**15. Binding Affinity:** Ligand A (-8.2 kcal/mol) is significantly better than Ligand B (-6.6 kcal/mol). This is a substantial difference in potency. A 1.6 kcal/mol advantage is significant and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand B has a much better safety profile (lower DILI) and slightly better drug-likeness (QED). However, Ligand A has a *much* stronger binding affinity, better metabolic stability (lower Cl_mic, longer t1/2), and better P-gp efflux. The strong affinity of Ligand A is a significant advantage for a GPCR target. While the solubility and permeability are poor for both, the potency advantage of Ligand A is likely to be more impactful in driving overall efficacy. The hERG risk is also lower for Ligand A.
Therefore, I prioritize Ligand A.
Output:
1
2025-04-17 23:03:40,689 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, the priorities are logP, Pgp, TPSA, and affinity, with metabolic stability and safety also being important.
Let's compare the ligands property by property:
1. **MW:** Both are within the acceptable range (200-500 Da). Ligand A (383.275) is slightly higher than Ligand B (348.451).
2. **TPSA:** Ligand A (70.59) is better than Ligand B (83.36), falling comfortably under the 140 threshold for oral absorption.
3. **logP:** Ligand A (4.036) is high, potentially leading to solubility issues, but still within a range where it might be acceptable if other properties are favorable. Ligand B (0.325) is very low, which could severely hinder membrane permeability.
4. **HBD/HBA:** Ligand A (3/3) is better than Ligand B (1/6). The higher number of HBA in Ligand B could negatively impact permeability.
5. **QED:** Both ligands have good QED scores (A: 0.705, B: 0.829), indicating good drug-like properties.
6. **DILI:** Ligand B (21.908) has a significantly lower DILI risk than Ligand A (67.778), which is a major advantage.
7. **BBB:** Ligand A (50.523) is moderate, while Ligand B (34.122) is lower. BBB is less critical for a cardiovascular target, but still a consideration.
8. **Caco-2:** Both have negative values, which is unusual. Assuming these are logP-scaled Caco-2 values, Ligand A (-4.671) is better than Ligand B (-5.405).
9. **Solubility:** Ligand B (-0.2) is slightly better than Ligand A (-5.162), but both are very poor.
10. **hERG:** Ligand A (0.774) is better than Ligand B (0.048), indicating lower cardiotoxicity risk.
11. **Cl_mic:** Ligand B (-17.44) has much better metabolic stability (lower clearance) than Ligand A (69.613).
12. **t1/2:** Ligand A (25.44) has a longer half-life than Ligand B (17.307).
13. **Pgp:** Ligand A (0.601) has lower P-gp efflux than Ligand B (0.01), which is favorable for bioavailability.
14. **Affinity:** Ligand B (-7.2) has significantly stronger binding affinity than Ligand A (-5.0). This is a substantial advantage.
**Overall Assessment:**
Ligand B's superior binding affinity (-7.2 kcal/mol vs -5.0 kcal/mol) is a major factor. While it has some drawbacks (low logP, poor solubility), the strong binding could potentially overcome these issues. The significantly lower DILI risk and better metabolic stability (Cl_mic) are also strong positives. Ligand A has better TPSA and Pgp efflux, but the higher DILI risk and weaker binding are concerning. Given the GPCR target class, affinity is paramount, and Ligand B's affinity is significantly better.
**Output:**
0
2025-04-17 23:03:40,689 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (354.447 and 354.407 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (77.1) is significantly better than Ligand B (114.2). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is approaching the upper limit for good oral absorption.
3. **logP:** Ligand B (-0.948) is slightly lower than Ligand A (0.57), but both are within the acceptable range of 1-3. Ligand B is closer to the lower bound, potentially impacting permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Both ligands have 5 HBA, which is within the acceptable limit of 10.
6. **QED:** Ligand A (0.799) has a slightly better QED score than Ligand B (0.638), indicating a more drug-like profile.
7. **DILI:** Ligand B (32.842) has a considerably lower DILI risk than Ligand A (45.173). This is a significant advantage for Ligand B.
8. **BBB:** Ligand B (75.184) has a better BBB penetration score than Ligand A (65.607). While ADRB2 isn't exclusively a CNS target, some CNS exposure can occur, and higher BBB penetration is generally favorable.
9. **Caco-2:** Ligand B (-5.404) has a better Caco-2 permeability than Ligand A (-4.657).
10. **Solubility:** Ligand B (-1.051) is slightly worse than Ligand A (-1.38), but both are very poor. Solubility is a concern for both.
11. **hERG:** Ligand A (0.171) has a lower hERG inhibition liability than Ligand B (0.093). This is a significant advantage for Ligand A, as it suggests a lower risk of cardiotoxicity.
12. **Cl_mic:** Ligand B (-18.087) has a much lower microsomal clearance than Ligand A (4.235), indicating significantly better metabolic stability. This is a major advantage for Ligand B.
13. **t1/2:** Ligand B (6.005) has a longer in vitro half-life than Ligand A (-7.441). This is a substantial benefit for Ligand B.
14. **Pgp:** Ligand A (0.037) has a lower P-gp efflux liability than Ligand B (0.004), which is preferable.
15. **Binding Affinity:** Ligand A (-7.3 kcal/mol) has slightly better binding affinity than Ligand B (-6.3 kcal/mol). This is a 1 kcal/mol difference, which is significant, but needs to be weighed against other factors.
**Overall Assessment:**
Ligand A has a better binding affinity and lower Pgp efflux, and a better hERG profile. However, Ligand B excels in metabolic stability (Cl_mic and t1/2), DILI risk, BBB penetration, and Caco-2 permeability. The difference in binding affinity (1 kcal/mol) is not large enough to overcome the significant advantages of Ligand B in ADME properties, especially the improved metabolic stability and reduced DILI risk. For a cardiovascular target, minimizing off-target effects (DILI) and ensuring adequate exposure (metabolic stability, permeability) are crucial.
Output:
0
2025-04-17 23:03:40,689 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (366.355 Da and 353.419 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (58.64) is significantly better than Ligand B (104.9). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is above the preferred 90 A^2 threshold.
**3. logP:** Both ligands have acceptable logP values (1.808 and 0.85), falling within the 1-3 range. Ligand A is slightly better.
**4. H-Bond Donors:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
**5. H-Bond Acceptors:** Ligand B (6) is higher than Ligand A (3). Lower HBA is generally preferred.
**6. QED:** Both ligands have similar QED values (0.755 and 0.682), both above the 0.5 threshold, indicating good drug-likeness.
**7. DILI:** Ligand A (32.997) has a significantly lower DILI risk than Ligand B (52.927). This is a major advantage for Ligand A.
**8. BBB:** Ligand A (90.694) has a much higher BBB penetration percentile than Ligand B (49.787). While ADRB2 isn't exclusively a CNS target, some peripheral ADRB2 activity can be modulated by CNS effects, and higher BBB penetration is generally favorable.
**9. Caco-2 Permeability:** Ligand A (-4.651) is better than Ligand B (-5.186).
**10. Aqueous Solubility:** Ligand A (-2.381) is better than Ligand B (-0.869).
**11. hERG Inhibition:** Both ligands have very low hERG inhibition liability (0.419 and 0.176), which is excellent.
**12. Microsomal Clearance:** Ligand A (11.611) has a lower microsomal clearance than Ligand B (22.976), indicating better metabolic stability.
**13. In vitro Half-Life:** Ligand A (-12.91) has a longer in vitro half-life than Ligand B (-15.095).
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.047 and 0.06).
**15. Binding Affinity:** Both ligands have similar and strong binding affinities (-6.6 and -6.2 kcal/mol). The difference is not substantial enough to outweigh other factors.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across several crucial ADME properties (TPSA, DILI, BBB, solubility, clearance, half-life) while maintaining comparable potency and safety (hERG). The lower TPSA and DILI risk, coupled with better BBB penetration and metabolic stability, make Ligand A the more promising drug candidate for the ADRB2 target.
Output:
1
2025-04-17 23:03:40,689 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (382.4 & 351.4 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (66.92) is significantly better than Ligand B (91.5), falling well below the 140 threshold and closer to the 90 preferred for GPCRs.
3. **logP:** Both ligands have good logP values (1.293 & 1.031), within the optimal 1-3 range.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (4). Both are acceptable, but lower is slightly better.
6. **QED:** Both ligands have good QED scores (0.648 & 0.749), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (47.732) is better than Ligand B (67.313), as it has a lower risk of drug-induced liver injury.
8. **BBB:** Ligand A (70.57) and Ligand B (67.158) are both reasonably good, but Ligand A is slightly better. For a cardiovascular target, BBB isn't *critical*, but a higher value is generally preferred.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.459 & -4.893), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Both ligands have negative solubility values (-2.671 & -2.739), which is also unusual and suggests poor aqueous solubility. This is a significant concern for both.
11. **hERG:** Both ligands have very low hERG risk (0.356 & 0.35), which is excellent.
12. **Cl_mic:** Ligand B (47.55) has slightly lower microsomal clearance than Ligand A (56.76), indicating better metabolic stability.
13. **t1/2:** Ligand B (-34.847) has a significantly longer in vitro half-life than Ligand A (-17.31). This is a major advantage.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.047 & 0.071), which is excellent.
15. **Binding Affinity:** Ligand B (-6.4) has a slightly better binding affinity than Ligand A (-6.0), but the difference is not substantial enough to outweigh other factors.
**Overall Assessment:**
Both ligands have significant issues with Caco-2 permeability and aqueous solubility. However, Ligand A has better TPSA, DILI risk, and BBB penetration. Ligand B has a longer half-life and slightly better affinity. Given the GPCR target class, TPSA is important, and the slightly better DILI profile of Ligand A is also valuable. The longer half-life of Ligand B is attractive, but the poor permeability and solubility are major drawbacks.
Considering the balance of properties, Ligand A is slightly more promising due to its better TPSA, DILI, and BBB, despite the slightly shorter half-life. The permeability and solubility issues will need to be addressed in either case through formulation or further chemical modifications.
Output:
1
2025-04-17 23:03:40,690 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [376.385, 117.26 , 0.546, 3. , 5. , 0.452, 68.903, 73.711, -5.372, -2.915, 0.409, 17.714, -28.265, 0.045, -7.6 ]
**Ligand B:** [342.399, 88.33 , 2.111, 1. , 5. , 0.779, 51.609, 73.866, -4.831, -2.735, 0.28 , 52.845, 18.189, 0.114, -8. ]
Here's a breakdown, considering the GPCR priorities (logP, Pgp, TPSA, Affinity, BBB):
1. **MW:** Both are within the acceptable 200-500 Da range (A: 376.385, B: 342.399). B is slightly preferred due to being a bit lower.
2. **TPSA:** Both are reasonably low. A (117.26) is a little higher than B (88.33). B is better for permeability.
3. **logP:** A (0.546) is quite low, potentially hindering membrane permeability. B (2.111) is much better, falling within the optimal 1-3 range. This is a significant advantage for B.
4. **HBD/HBA:** A has 3 HBD and 5 HBA, while B has 1 HBD and 5 HBA. Both are acceptable, but B's lower HBD is slightly preferable for permeability.
5. **QED:** B (0.779) has a significantly better QED score than A (0.452), indicating a more drug-like profile.
6. **DILI:** A (68.903) has a higher DILI risk than B (51.609), which is undesirable.
7. **BBB:** Both have good BBB penetration (A: 73.711, B: 73.866), which isn't a primary concern for ADRB2 (a cardiovascular target, not CNS).
8. **Caco-2:** Both have negative Caco-2 values, which is unusual. I'll interpret these as very low permeability.
9. **Solubility:** Both have negative solubility values, indicating poor aqueous solubility.
10. **hERG:** Both have low hERG risk (A: 0.409, B: 0.28). B is slightly better.
11. **Cl_mic:** A (17.714) has a lower (better) microsomal clearance than B (52.845), suggesting better metabolic stability.
12. **t1/2:** A (-28.265) has a negative in vitro half-life, which is not possible. B (18.189) is reasonable. This is a major red flag for A.
13. **Pgp:** A (0.045) has lower P-gp efflux than B (0.114), which is favorable.
14. **Affinity:** B (-8.0) has a slightly better binding affinity than A (-7.6), but the difference is not huge.
**Overall Assessment:**
Ligand B is clearly superior. While both have issues with Caco-2 and solubility, Ligand B has a much better logP, QED, DILI, and a reasonable half-life. Ligand A's very low logP, poor QED, high DILI risk, and negative half-life are significant drawbacks. The slightly better metabolic stability of A is not enough to offset these issues.
Output:
0
2025-04-17 23:03:40,690 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor (a GPCR).
**Ligand A:** [340.467, 58.2, 3.69, 2, 2, 0.56, 36.022, 70.299, -4.471, -4.478, 0.769, 61.062, 4.331, 0.246, -6.0]
**Ligand B:** [348.403, 104.54, 0.303, 2, 5, 0.769, 37.611, 56.65, -5.304, -1.468, 0.069, 12.029, 9.683, 0.023, -3.4]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, BBB, and affinity are key):
1. **MW:** Both are within the ideal range (200-500 Da). A is 340.467, B is 348.403. Very similar.
2. **TPSA:** A (58.2) is excellent, well below 140 and good for oral absorption. B (104.54) is higher, but still acceptable, though less ideal.
3. **logP:** A (3.69) is optimal. B (0.303) is quite low, potentially leading to poor membrane permeability and bioavailability. This is a significant drawback.
4. **HBD/HBA:** Both have 2 HBD, which is good. A has 2 HBA, while B has 5. B's higher HBA count could slightly impact permeability.
5. **QED:** Both are good (A: 0.56, B: 0.769). B has a slightly better QED score.
6. **DILI:** Both are low risk (A: 36.022, B: 37.611). Similar and acceptable.
7. **BBB:** A (70.299) is good, suggesting reasonable potential for CNS penetration if desired. B (56.65) is lower, meaning less likely to cross the BBB. For a cardiovascular target, this isn't *critical*, but it's a point in A's favor.
8. **Caco-2:** A (-4.471) and B (-5.304) are both negative values, which is unusual. Assuming these are logP-scaled permeability values, lower (more negative) values indicate lower permeability. B is slightly worse here.
9. **Solubility:** A (-4.478) and B (-1.468) are both negative values, which is unusual. Assuming these are logS values, lower (more negative) values indicate lower solubility. A is worse here.
10. **hERG:** A (0.769) is better than B (0.069), indicating lower cardiotoxicity risk.
11. **Cl_mic:** A (61.062) is higher than B (12.029), meaning faster metabolic clearance and potentially lower exposure. This is a significant negative for A.
12. **t1/2:** B (9.683) has a longer half-life than A (4.331), which is desirable.
13. **Pgp:** A (0.246) has lower P-gp efflux than B (0.023), meaning better bioavailability.
14. **Affinity:** A (-6.0) has a significantly stronger binding affinity than B (-3.4). This is a substantial advantage.
**Overall Assessment:**
Ligand A has a better logP, BBB, Pgp, and *much* better binding affinity. However, it suffers from higher microsomal clearance and lower in vitro half-life. Ligand B has a better QED, half-life, and lower clearance, but its low logP is a major concern for permeability and bioavailability. The affinity difference is substantial (-6.0 vs -3.4 kcal/mol). For a GPCR, affinity is paramount, and the difference here is large enough to outweigh the ADME concerns with Ligand A, *especially* given its acceptable BBB. The faster clearance could potentially be addressed through structural modifications.
Therefore, I favor Ligand A.
```
1
```
2025-04-17 23:03:40,690 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for the ADRB2, a cardiovascular GPCR. Therefore, key properties to prioritize are logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB (though less critical for a cardiovascular target than a CNS one).
Let's compare the ligands property by property:
1. **MW:** Both ligands (348.4 & 364.5 Da) fall within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (58.64) is significantly better than Ligand B (84.3), being well below the 140 threshold for good absorption. Ligand B is approaching a less desirable range.
3. **logP:** Both are good (2.379 & 1.221), falling within the 1-3 range. Ligand A is slightly better.
4. **HBD/HBA:** Both have acceptable HBD (1) and Ligand A has 3 HBA while Ligand B has 5. Both are within acceptable limits.
5. **QED:** Both are good (0.853 & 0.884), indicating drug-like properties.
6. **DILI:** Ligand A (43.7) is better than Ligand B (55.7), indicating lower potential for liver injury.
7. **BBB:** Ligand A (88.1) is better than Ligand B (75.3), though BBB is less critical for a cardiovascular target.
8. **Caco-2:** Both are negative, indicating poor permeability.
9. **Solubility:** Both are negative, indicating poor solubility.
10. **hERG:** Both are low (0.56 & 0.654), suggesting minimal hERG inhibition risk.
11. **Cl_mic:** Ligand B (30.7) has significantly lower microsomal clearance than Ligand A (46.9), suggesting better metabolic stability. This is a significant advantage.
12. **t1/2:** Ligand B (-26.2) has a much longer in vitro half-life than Ligand A (17.4), which is a substantial benefit.
13. **Pgp:** Both have low Pgp efflux (0.293 & 0.101), which is good.
14. **Binding Affinity:** Ligand A (-6.9) is slightly better than Ligand B (-6.4), though the difference is relatively small (0.5 kcal/mol).
**Overall Assessment:**
Ligand B has a clear advantage in metabolic stability (lower Cl_mic) and half-life. These are important factors for *in vivo* efficacy. While Ligand A has slightly better TPSA and affinity, the differences are not substantial enough to outweigh the improved pharmacokinetic profile of Ligand B. The slightly better TPSA and affinity of Ligand A are not enough to overcome the poor metabolic stability and shorter half-life.
Output:
0
2025-04-17 23:03:40,690 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [350.415, 83.22, 1.26, 1, 5, 0.864, 35.13, 50.019, -4.416, -1.755, 0.331, 19.009, 23.785, 0.345, -6.4]
**Ligand B:** [347.375, 114.39, 1.256, 1, 7, 0.595, 71.656, 51.803, -4.697, -2.134, 0.224, 34.301, -6.775, 0.318, -6.5]
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). A is 350.415, B is 347.375. Very similar.
2. **TPSA:** Ligand A (83.22) is better than Ligand B (114.39). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA is generally favorable for absorption.
3. **logP:** Both are excellent (around 1.26), falling within the optimal 1-3 range.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 5 HBA, and Ligand B has 7. Ligand A is preferable here.
6. **QED:** Ligand A (0.864) is significantly better than Ligand B (0.595), indicating a more drug-like profile.
7. **DILI:** Ligand A (35.13) has a much lower DILI risk than Ligand B (71.656). This is a significant advantage for Ligand A.
8. **BBB:** Both are similar (around 50-52%), which isn't a major factor for a cardiovascular target.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-4.416) is slightly better than Ligand B (-4.697).
10. **Solubility:** Both are negative, indicating poor solubility. Ligand A (-1.755) is slightly better than Ligand B (-2.134).
11. **hERG:** Both are very low (0.331 and 0.224), indicating low cardiotoxicity risk.
12. **Cl_mic:** Ligand A (19.009) has a lower microsomal clearance than Ligand B (34.301), suggesting better metabolic stability.
13. **t1/2:** Ligand A (23.785) has a longer in vitro half-life than Ligand B (-6.775), which is desirable.
14. **Pgp:** Both are low (0.345 and 0.318), indicating minimal P-gp efflux.
15. **Binding Affinity:** Both have very similar binding affinities (-6.4 and -6.5 kcal/mol). The difference is negligible.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, and affinity. Both ligands perform well on logP and Pgp. Ligand A is better on TPSA. Affinity is nearly identical. However, the significant advantages of Ligand A in QED, DILI risk, metabolic stability (Cl_mic), and half-life outweigh the minor differences in other parameters.
**Conclusion:**
Ligand A is the more promising drug candidate due to its superior ADME-Tox profile and better overall drug-likeness, despite similar binding affinity.
Output:
1
2025-04-17 23:03:40,690 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (339.479 and 345.403 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (32.7) is significantly better than Ligand B (89.35). For a GPCR, keeping TPSA low is beneficial for permeability, and Ligand A is well below the 140 threshold, while Ligand B is approaching the upper limit.
**3. logP:** Ligand A (4.225) is higher than Ligand B (0.368). While both are within a reasonable range, Ligand A is approaching the upper limit, which could lead to solubility issues. However, for a GPCR, a slightly higher logP is often acceptable to promote membrane interactions. Ligand B's logP is quite low, potentially hindering permeability.
**4. H-Bond Donors:** Both have 1 HBD, which is good.
**5. H-Bond Acceptors:** Ligand A has 3 HBA, and Ligand B has 6. Ligand A is preferable here, as fewer HBA generally correlate with better permeability.
**6. QED:** Ligand A (0.885) has a much better QED score than Ligand B (0.438), indicating a more drug-like profile.
**7. DILI Risk:** Ligand B (49.903) has a higher DILI risk than Ligand A (9.849). This is a significant advantage for Ligand A.
**8. BBB Penetration:** Both have reasonable BBB penetration (Ligand A: 69.407, Ligand B: 65.529), but Ligand A is slightly better. While not a primary concern for ADRB2 (a cardiovascular target), some CNS exposure is not necessarily detrimental and could offer off-target effects.
**9. Caco-2 Permeability:** Ligand A (-4.741) is better than Ligand B (-5.39), indicating better intestinal absorption.
**10. Aqueous Solubility:** Ligand A (-3.278) is better than Ligand B (-1.75). This is important for formulation and bioavailability.
**11. hERG Inhibition:** Ligand A (0.979) has a lower hERG risk than Ligand B (0.19). This is a crucial safety parameter, and Ligand A is significantly better.
**12. Microsomal Clearance:** Ligand B (-10.166) has a lower (better) microsomal clearance than Ligand A (40.837), suggesting greater metabolic stability. This is a strong point for Ligand B.
**13. In vitro Half-Life:** Ligand A (-18.663) has a longer half-life than Ligand B (1.99). This is a significant advantage for Ligand A, potentially allowing for less frequent dosing.
**14. P-gp Efflux:** Ligand A (0.933) has lower P-gp efflux than Ligand B (0.022), which is preferable for bioavailability.
**15. Binding Affinity:** Ligand B (-6.8 kcal/mol) has a slightly better binding affinity than Ligand A (-4.5 kcal/mol). This is a 1.5kcal/mol difference, which is a substantial advantage.
**Overall Assessment:**
While Ligand B has a slightly better binding affinity and metabolic stability, Ligand A demonstrates a superior overall profile, particularly regarding safety (DILI, hERG), drug-likeness (QED), solubility, and permeability (TPSA, Caco-2). The difference in binding affinity is not large enough to outweigh the significant advantages of Ligand A, especially considering the importance of ADME properties for *in vivo* efficacy.
Output:
1
2025-04-17 23:03:40,690 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [352.391, 104.98 , 0.587, 1. , 6. , 0.77 , 41.45 , 74.758, -4.522, -1.411, 0.29 , 35.488, -25.323, 0.023, -6.2 ]
**Ligand B:** [349.475, 69.72 , 0.905, 1. , 4. , 0.774, 18.922, 61.342, -4.91 , -1.084, 0.095, 13.281, 0.944, 0.032, -6.3 ]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity, and BBB):
1. **MW:** Both are within the ideal range (200-500 Da). A is 352.391, B is 349.475. Very similar.
2. **TPSA:** Ligand A (104.98) is higher than Ligand B (69.72). B is significantly better, being well under the 140 threshold for oral absorption and closer to the ideal for GPCRs.
3. **logP:** Ligand A (0.587) is a bit low, potentially hindering permeability. Ligand B (0.905) is better, but still on the lower side of optimal (1-3).
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 6 HBA, Ligand B has 4 HBA. B is better, keeping the count lower for improved permeability.
6. **QED:** Both are good (0.77 and 0.774), indicating drug-like properties.
7. **DILI:** Ligand A (41.45) has a higher DILI risk than Ligand B (18.922). B is significantly better here.
8. **BBB:** Ligand A (74.758) has better BBB penetration than Ligand B (61.342). This is a positive for A, but less crucial for a cardiovascular target.
9. **Caco-2:** Ligand A (-4.522) is worse than Ligand B (-4.91). Lower values here indicate lower permeability.
10. **Solubility:** Ligand A (-1.411) is worse than Ligand B (-1.084).
11. **hERG:** Both are very low (0.29 and 0.095), indicating low cardiotoxicity risk. B is slightly better.
12. **Cl_mic:** Ligand A (35.488) has higher metabolic clearance than Ligand B (13.281). B is better, suggesting greater metabolic stability.
13. **t1/2:** Ligand A (-25.323) has a negative in vitro half-life, which is concerning. Ligand B (0.944) has a short half-life, but it's positive and better than A.
14. **Pgp:** Ligand A (0.023) has lower P-gp efflux than Ligand B (0.032). This is slightly better for A.
15. **Affinity:** Both have very similar binding affinities (-6.2 and -6.3 kcal/mol). The difference is negligible.
**Overall Assessment:**
Ligand B consistently outperforms Ligand A in key ADME properties. While Ligand A has slightly better BBB penetration, this is less critical for a cardiovascular target. Ligand B has a significantly lower DILI risk, better TPSA, lower HBA, better metabolic stability (lower Cl_mic), and a more reasonable (positive) in vitro half-life. The similar binding affinities make the ADME profile the deciding factor.
Therefore, I prefer Ligand B.
0
2025-04-17 23:03:40,690 - INFO - Batch 377 complete. Total preferences: 6032
2025-04-17 23:03:40,690 - INFO - Processing batch 378/512...
2025-04-17 23:04:29,769 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output:
**Ligand A: [339.351, 93.53, 1.988, 1, 6, 0.579, 96.433, 51.687, -4.848, -4.057, 0.28, 77.274, 1.72, 0.489, -5.7]**
**Ligand B: [366.527, 57.69, 2.36, 0, 4, 0.535, 39.279, 74.835, -4.846, -3.495, 0.283, 62.718, -33.569, 0.331, -6.5]**
1. **Molecular Weight:** Both are within the ideal range (200-500 Da). Ligand A (339.351) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (93.53) is higher than Ligand B (57.69). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is still preferred. Ligand B is significantly better here.
3. **logP:** Both ligands have good logP values (A: 1.988, B: 2.36), falling within the optimal 1-3 range. Ligand B is slightly higher, which could potentially lead to slightly better membrane permeability.
4. **H-Bond Donors:** Ligand A (1) is better than Ligand B (0). While both are acceptable, fewer HBDs generally improve permeability.
5. **H-Bond Acceptors:** Ligand A (6) is higher than Ligand B (4). Lower is preferred for permeability, giving an edge to Ligand B.
6. **QED:** Both ligands have acceptable QED values (A: 0.579, B: 0.535), indicating reasonable drug-likeness.
7. **DILI:** Ligand A (96.433) has a very high DILI risk, while Ligand B (39.279) is much lower and considered good. This is a *major* drawback for Ligand A.
8. **BBB:** Ligand B (74.835) has better BBB penetration than Ligand A (51.687). While ADRB2 isn't primarily a CNS target, some distribution to the CNS is possible, and higher BBB is generally favorable.
9. **Caco-2 Permeability:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. The values are very similar (-4.848 vs -4.846).
10. **Aqueous Solubility:** Both have negative solubility values, which is also unusual. Ligand B (-3.495) is slightly better than Ligand A (-4.057).
11. **hERG Inhibition:** Both ligands have low hERG inhibition risk (A: 0.28, B: 0.283), which is excellent.
12. **Microsomal Clearance:** Ligand B (62.718) has lower microsomal clearance than Ligand A (77.274), indicating better metabolic stability.
13. **In vitro Half-Life:** Ligand B (-33.569) has a significantly longer in vitro half-life than Ligand A (1.72). This is a major advantage for Ligand B.
14. **P-gp Efflux:** Both have similar P-gp efflux liability (A: 0.489, B: 0.331).
15. **Binding Affinity:** Ligand B (-6.5) has a slightly better binding affinity than Ligand A (-5.7), although the difference is not huge.
**Overall Assessment:**
Ligand B is significantly better due to its much lower DILI risk, better metabolic stability (lower Cl_mic, longer t1/2), lower TPSA, and slightly better binding affinity. The Caco-2 and solubility values are concerning for both, but Ligand B is slightly better. The high DILI risk associated with Ligand A is a deal-breaker.
Output:
0
2025-04-17 23:04:29,769 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
The ADRB2 receptor is a GPCR, so the priorities are logP, TPSA, Pgp efflux, BBB penetration, and binding affinity.
Let's compare the ligands property by property:
1. **MW:** Both ligands (349.475 and 366.443 Da) are within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (53.09) is significantly better than Ligand B (109.25). A lower TPSA generally indicates better cell permeability, crucial for GPCR targeting. Ligand B is above the preferred 90 cutoff.
3. **logP:** Both are within the optimal 1-3 range (0.835 and 1.813). Ligand B is slightly higher, which could be beneficial for membrane permeability but also raises potential off-target concerns.
4. **HBD/HBA:** Ligand A (0 HBD, 4 HBA) is preferable to Ligand B (3 HBD, 6 HBA). Lower HBD/HBA generally improves permeability.
5. **QED:** Both ligands have similar QED values (0.667 and 0.657), indicating reasonable drug-likeness.
6. **DILI:** Ligand A (5.7) has a much lower DILI risk than Ligand B (74.68), a significant advantage.
7. **BBB:** Ligand A (81.078) has much better predicted BBB penetration than Ligand B (27.414). While ADRB2 isn't exclusively a CNS target, some peripheral effects are mediated by CNS influence, and better BBB penetration can be advantageous.
8. **Caco-2:** Ligand A (-4.516) and Ligand B (-5.463) have similar, poor Caco-2 permeability.
9. **Solubility:** Ligand A (-0.638) has better solubility than Ligand B (-3.711).
10. **hERG:** Both ligands have very low hERG inhibition risk (0.288 and 0.248).
11. **Cl_mic:** Ligand A (2.493) has significantly lower microsomal clearance than Ligand B (47.189), indicating better metabolic stability.
12. **t1/2:** Ligand A (-2.892) has a shorter in vitro half-life than Ligand B (6.782). This is a drawback for Ligand A.
13. **Pgp:** Both ligands have very low Pgp efflux liability (0.021 and 0.045).
14. **Binding Affinity:** Ligand B (-6.8 kcal/mol) has a slightly better binding affinity than Ligand A (-4.9 kcal/mol). This is a 1.9 kcal/mol difference, which is substantial.
**Overall Assessment:**
Despite the slightly better affinity of Ligand B, Ligand A is the superior candidate. The significantly lower DILI risk, better BBB penetration, lower TPSA, better solubility, and dramatically improved metabolic stability (lower Cl_mic) outweigh the affinity difference. The affinity difference, while notable, isn't so large that it overcomes the substantial ADME/Tox advantages of Ligand A. The poor Caco-2 permeability is a concern for both, but can be addressed with formulation strategies.
**Output:**
1
2025-04-17 23:04:29,769 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Step-by-step comparison:**
1. **MW:** Ligand A (401.22 Da) is within the ideal range, while Ligand B (348.531 Da) is slightly below, but still acceptable.
2. **TPSA:** Ligand A (97.11) is borderline for good oral absorption (ideally <140), but acceptable. Ligand B (40.62) is excellent, well below the threshold.
3. **logP:** Both ligands (A: 2.658, B: 3.556) are within the optimal 1-3 range. Ligand B is slightly higher, which could be a minor concern for off-target effects, but not a major issue.
4. **HBD:** Ligand A (2) and Ligand B (0) are both good, below the threshold of 5.
5. **HBA:** Ligand A (5) and Ligand B (2) are both good, below the threshold of 10.
6. **QED:** Both ligands (A: 0.685, B: 0.779) have good drug-likeness scores, exceeding 0.5.
7. **DILI:** Ligand A (97.169) has a significantly higher DILI risk than Ligand B (12.175). This is a major concern for Ligand A.
8. **BBB:** Ligand A (16.983) has very poor BBB penetration, while Ligand B (88.445) is excellent. Given ADRB2's role in cardiovascular function, CNS penetration isn't a primary requirement, but it's not detrimental to have some.
9. **Caco-2:** Ligand A (-5.411) has very poor Caco-2 permeability, indicating poor absorption. Ligand B (-4.483) is also poor, but slightly better.
10. **Solubility:** Both ligands have poor aqueous solubility (-3.429 and -3.707 respectively). This could pose formulation challenges.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.064 and 0.608 respectively).
12. **Cl_mic:** Ligand A (0.982) has much lower microsomal clearance, indicating better metabolic stability than Ligand B (87.607). This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (14.469) has a longer in vitro half-life than Ligand B (-8.015). This is a positive for Ligand A.
14. **Pgp:** Ligand A (0.015) has very low P-gp efflux, while Ligand B (0.168) is slightly higher.
15. **Affinity:** Ligand A (-7.0) has slightly better binding affinity than Ligand B (-6.6), but the difference is less than 1.5 kcal/mol.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Ligand B excels in TPSA and Pgp, and has a good logP. Ligand A has a slightly better affinity and lower Pgp efflux, but its poor Caco-2 permeability and high DILI risk are major drawbacks.
**Overall Assessment:**
Despite Ligand A's slightly better affinity and metabolic stability, the significantly higher DILI risk and poor Caco-2 permeability make it a less desirable candidate. Ligand B, while having slightly worse metabolic stability, has a much better safety profile (DILI) and better absorption potential (TPSA, Caco-2). The difference in affinity is not substantial enough to outweigh these significant ADME/Tox concerns.
Output:
0
2025-04-17 23:04:29,770 - INFO - Here's my reasoning and the final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, the priorities are logP, Pgp, TPSA, affinity, and to a lesser extent, BBB.
Let's break down the comparison:
1. **MW:** Both ligands are within the acceptable range (200-500 Da). Ligand A (356.857) is slightly higher than Ligand B (342.399), but this isn't a major concern.
2. **TPSA:** Ligand A (55.05) is significantly better than Ligand B (86.37). A TPSA under 90 is good, and A is much closer to the ideal <60 for good absorption.
3. **logP:** Ligand A (4.526) is high, but still within a range that *could* be tolerated. Ligand B (0.472) is quite low, potentially leading to poor membrane permeability. This is a significant negative for B.
4. **HBD/HBA:** Ligand A (0 HBD, 5 HBA) is preferable to Ligand B (1 HBD, 4 HBA). Both are acceptable, but fewer H-bonds generally improve permeability.
5. **QED:** Both are good (A: 0.645, B: 0.793), indicating reasonable drug-likeness. B is slightly better here.
6. **DILI:** Ligand B (49.593) has a much lower DILI risk than Ligand A (70.958). This is a significant advantage for B.
7. **BBB:** Ligand A (95.657) has excellent BBB penetration, while Ligand B (47.383) is poor. While ADRB2 isn't a CNS target, some distribution into the CNS is not necessarily detrimental, and high BBB penetration can sometimes correlate with favorable distribution properties in general.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests a problem with the experimental setup or the compounds themselves. This is hard to interpret.
9. **Solubility:** Ligand A (-3.782) has better solubility than Ligand B (-1.564), which is important for bioavailability.
10. **hERG:** Ligand A (0.76) has a slightly higher hERG risk than Ligand B (0.215), which is preferable.
11. **Cl_mic:** Ligand B (19.117) has significantly lower microsomal clearance than Ligand A (67.076), indicating better metabolic stability. This is a substantial advantage for B.
12. **t1/2:** Ligand B (-26.992) has a negative in vitro half-life, which is concerning and likely an experimental artifact. Ligand A (40.952) is reasonable.
13. **Pgp:** Ligand A (0.818) has higher P-gp efflux than Ligand B (0.027), which is unfavorable. Lower P-gp efflux is preferred.
14. **Affinity:** Ligand B (-7.0) has a slightly better binding affinity than Ligand A (-6.8), but the difference is small.
**Overall Assessment:**
Ligand B has significant advantages in DILI risk and metabolic stability (Cl_mic). However, its low logP is a major concern for permeability. Ligand A has a better logP, solubility, and a more reasonable half-life, but suffers from higher DILI risk and P-gp efflux. The TPSA of ligand A is also much more favorable. Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity), and the fact that the affinity difference is small, the better overall profile is Ligand A. The low logP of B is a significant hurdle to overcome.
Output:
1
2025-04-17 23:04:29,770 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (418.238 Da) is within the ideal range. Ligand B (365.499 Da) is also within the ideal range. No clear advantage here.
2. **TPSA:** Ligand A (67.45) is good, well below the 140 threshold. Ligand B (91.32) is still acceptable, but higher. A favors here.
3. **logP:** Ligand A (3.639) is optimal. Ligand B (1.819) is on the lower side, potentially impacting permeability. A favors here.
4. **HBD:** Ligand A (1) is good. Ligand B (3) is acceptable, but slightly higher. A favors here.
5. **HBA:** Ligand A (4) is good. Ligand B (5) is acceptable. A favors here.
6. **QED:** Both ligands (A: 0.632, B: 0.715) have good QED scores, indicating drug-likeness. B is slightly better.
7. **DILI:** Ligand A (65.723) is moderately risky. Ligand B (41.062) is much lower risk. B favors significantly here.
8. **BBB:** Ligand A (75.107) is good, suggesting some brain penetration. Ligand B (47.654) is lower. A favors here, though ADRB2 isn't necessarily a CNS target.
9. **Caco-2:** Both are negative values, indicating poor permeability. This is unusual and concerning for both. However, the scale is not specified, so it's difficult to interpret.
10. **Solubility:** Ligand A (-4.282) is very poor. Ligand B (-2.076) is also poor, but better than A. B favors here.
11. **hERG:** Ligand A (0.514) has a low risk of hERG inhibition. Ligand B (0.22) has an even lower risk. B favors here.
12. **Cl_mic:** Ligand A (72.057) is moderately high, suggesting faster metabolism. Ligand B (-10.592) is excellent, indicating high metabolic stability. B favors significantly here.
13. **t1/2:** Ligand A (-10.524) is very short, suggesting rapid clearance. Ligand B (28.208) is much better. B favors significantly here.
14. **Pgp:** Ligand A (0.437) has lower P-gp efflux liability. Ligand B (0.043) has very low P-gp efflux liability. B favors here.
15. **Binding Affinity:** Ligand A (-4.2 kcal/mol) is good. Ligand B (-6.1 kcal/mol) is significantly better, with a 1.9 kcal/mol advantage. B favors *strongly* here.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B excels in affinity, Pgp, and has a better logP. While Ligand A has a better TPSA, the substantial affinity advantage of B outweighs this. The DILI, Cl_mic and t1/2 profiles of Ligand B are also much more favorable. Solubility is a concern for both, but the other benefits of B are more impactful.
**Conclusion:**
Despite the poor Caco-2 and solubility results for both, Ligand B is the stronger candidate due to its significantly better binding affinity, DILI risk, metabolic stability, and P-gp efflux profile.
Output:
0
2025-04-17 23:04:29,770 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (341.459 Da) is slightly lower than Ligand B (351.466 Da), which is generally favorable for permeability.
2. **TPSA:** Ligand A (84.97) is better than Ligand B (61.44). Both are well below the 140 A^2 threshold for good oral absorption, but the lower TPSA of Ligand B is preferable for a GPCR.
3. **logP:** Both ligands have good logP values (Ligand A: 2.055, Ligand B: 1.623), falling within the optimal 1-3 range.
4. **HBD:** Ligand A has 3 HBDs, and Ligand B has 2. Both are acceptable.
5. **HBA:** Ligand A has 5 HBAs, and Ligand B has 3. Both are acceptable.
6. **QED:** Ligand A (0.798) has a better QED score than Ligand B (0.654), indicating a more drug-like profile.
7. **DILI:** Ligand A (42.264) has a significantly better DILI score than Ligand B (9.306), indicating a lower risk of liver injury. This is a substantial advantage.
8. **BBB:** Ligand A (86.002) has a better BBB penetration percentile than Ligand B (78.945). While ADRB2 isn't exclusively a CNS target, some peripheral effects are mediated by CNS pathways, and better BBB penetration isn't detrimental.
9. **Caco-2:** Ligand A (-5.736) and Ligand B (-4.936) are both negative, which is unusual and suggests poor permeability. However, the negative values are close, so this isn't a major differentiator.
10. **Solubility:** Ligand A (-1.805) and Ligand B (-2.249) both have poor solubility.
11. **hERG:** Ligand A (0.819) has a slightly higher hERG risk than Ligand B (0.4), but both are relatively low.
12. **Cl_mic:** Ligand B (-30.059) has a significantly lower (better) microsomal clearance than Ligand A (-21.109), indicating greater metabolic stability.
13. **t1/2:** Ligand A (19.029) has a much longer in vitro half-life than Ligand B (3.319). This is a significant advantage.
14. **Pgp:** Ligand A (0.123) has a lower Pgp efflux liability than Ligand B (0.026), which is favorable.
15. **Binding Affinity:** Ligand A (-7.1 kcal/mol) has a slightly better binding affinity than Ligand B (-6.0 kcal/mol). This is a 1.1 kcal/mol difference, which is significant.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are crucial. Both ligands perform reasonably well on logP and TPSA. Ligand A has a better Pgp profile and a significantly better binding affinity.
**Overall Assessment:**
Ligand A is superior due to its significantly better DILI score, longer half-life, better binding affinity, and better BBB penetration. While Ligand B has better metabolic stability (lower Cl_mic), the other advantages of Ligand A outweigh this benefit. The improved safety profile (DILI) and potency (affinity) are critical for a viable drug candidate.
Output:
1
2025-04-17 23:04:29,770 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.507 and 350.423 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (55.89) is significantly better than Ligand B (103.19). ADRB2 is a cardiovascular target, not CNS, but lower TPSA generally improves absorption. Ligand A is well below the 140 threshold. Ligand B is approaching the upper limit.
3. **logP:** Ligand A (0.776) is better than Ligand B (0.276). Both are slightly low, but Ligand A is closer to the optimal 1-3 range. Low logP can hinder membrane permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is preferable to Ligand B (8). Lower HBA is desirable for permeability.
6. **QED:** Both ligands have similar QED values (0.769 and 0.759), indicating good drug-likeness.
7. **DILI:** Ligand A (1.473) is *much* better than Ligand B (60.682). Ligand B's DILI risk is high (>60 percentile). This is a major concern.
8. **BBB:** Not a primary concern for a cardiovascular target, but Ligand A (83.87) is better than Ligand B (74.06).
9. **Caco-2:** Ligand A (-5.16) is better than Ligand B (-5.528). Both are negative, indicating poor permeability, but A is less poor.
10. **Solubility:** Ligand A (-0.836) is better than Ligand B (-2.256). Higher solubility is generally preferred.
11. **hERG:** Ligand A (0.55) is significantly better than Ligand B (0.056). Ligand B has a concerningly low hERG score, indicating potential cardiotoxicity.
12. **Cl_mic:** Ligand A (1.396) is much better than Ligand B (-0.638). A positive value for Ligand B suggests rapid clearance. Lower clearance (higher stability) is preferred.
13. **t1/2:** Ligand A (-5.754) is better than Ligand B (14.457). A negative value for A indicates a longer half-life.
14. **Pgp:** Ligand A (0.008) is significantly better than Ligand B (0.039). Lower P-gp efflux is preferred.
15. **Affinity:** Ligand B (-7.1) is 0.8 kcal/mol better than Ligand A (-6.3). This is a substantial difference in binding affinity.
**Overall Assessment:**
While Ligand B has a better binding affinity, the ADME-Tox profile of Ligand A is *far* superior. Ligand B has significant liabilities in DILI risk, hERG inhibition, and metabolic clearance. These factors outweigh the affinity advantage. Ligand A presents a much more balanced profile, with acceptable (though not ideal) permeability and solubility, and a significantly lower risk of adverse effects. For a cardiovascular target, minimizing cardiotoxicity (hERG) and liver toxicity (DILI) are paramount.
**Output:**
1
2025-04-17 23:04:29,770 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
Let's analyze each ligand against the provided guidelines, keeping in mind ADRB2 is a GPCR, so logP, TPSA, Pgp, and affinity are particularly important.
* **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (346.515) is slightly lower, which is generally favorable for permeability.
* **TPSA:** Ligand A (49.41) is significantly better than Ligand B (82.11). A TPSA under 140 is good for oral absorption, but lower is better for GPCRs, and A is much closer to the ideal range for CNS penetration (though not a CNS target here, lower TPSA generally correlates with better permeability).
* **logP:** Both ligands have good logP values (A: 3.358, B: 2.985), falling within the 1-3 range.
* **H-Bond Donors/Acceptors:** Ligand A (HBD=1, HBA=2) is preferable to Ligand B (HBD=2, HBA=5) as it has fewer hydrogen bonding characteristics, potentially improving membrane permeability.
* **QED:** Both ligands have acceptable QED values (A: 0.768, B: 0.857), indicating good drug-like properties.
* **DILI Risk:** Ligand A (11.206) has a significantly lower DILI risk than Ligand B (28.306). This is a major advantage.
* **BBB Penetration:** Ligand A (87.941) shows better BBB penetration than Ligand B (48.042), though this isn't a primary concern for a cardiovascular target.
* **Caco-2 Permeability:** Ligand A (-4.824) has a more negative Caco-2 value, suggesting *lower* permeability. Ligand B (-5.164) is also low, but slightly worse.
* **Aqueous Solubility:** Both ligands have very poor aqueous solubility (-3.673 and -3.209 respectively). This is a potential formulation challenge for both.
* **hERG Inhibition:** Both ligands show low hERG inhibition risk (A: 0.729, B: 0.675).
* **Microsomal Clearance:** Ligand A (69.209) has a higher microsomal clearance than Ligand B (18.161), indicating faster metabolism and potentially lower *in vivo* exposure. This is a significant drawback for Ligand A.
* **In vitro Half-Life:** Ligand B (-21.01) has a much longer in vitro half-life than Ligand A (3.823), which is a major advantage.
* **P-gp Efflux:** Both ligands show low P-gp efflux liability (A: 0.139, B: 0.302), which is good.
* **Binding Affinity:** Ligand B (-6.4 kcal/mol) has a slightly better binding affinity than Ligand A (-5.8 kcal/mol). While the difference is less than the 1.5 kcal/mol threshold, it's still a positive for Ligand B.
**Overall Assessment:**
Ligand A excels in TPSA, DILI risk, and BBB penetration. However, its significantly higher microsomal clearance and shorter half-life are major concerns. Ligand B, while having a higher TPSA and DILI risk, demonstrates much better metabolic stability (lower Cl_mic, longer t1/2) and slightly better binding affinity. Given the importance of metabolic stability for *in vivo* efficacy, and the acceptable (though not ideal) ADME profile of Ligand B, it appears to be the more promising candidate. The solubility issues are present in both and would need to be addressed during formulation.
**Output:**
0
2025-04-17 23:04:29,770 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (364.5 and 371.5 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (79.2) is better than Ligand B (101.7) as it's closer to the <140 threshold for good oral absorption. This is a slight advantage for A.
3. **logP:** Ligand A (1.71) is slightly better than Ligand B (0.96), both are within the optimal 1-3 range, but A is closer to the center.
4. **HBD:** Ligand A (3) is higher than Ligand B (1), but both are within the acceptable limit of <=5.
5. **HBA:** Ligand B (6) is better than Ligand A (5), both are within the acceptable limit of <=10.
6. **QED:** Ligand A (0.74) is slightly better than Ligand B (0.68), indicating a more drug-like profile.
7. **DILI:** Ligand A (33.4) is significantly better than Ligand B (73.2). This is a major advantage for Ligand A, as lower DILI risk is crucial.
8. **BBB:** Ligand A (62.0) is better than Ligand B (55.1), although neither are particularly high. For a cardiovascular target, BBB penetration isn't a primary concern, but a higher value is still preferable.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.3 and -4.9), which is unusual and suggests poor permeability. This is a significant drawback for both.
10. **Solubility:** Both ligands have negative solubility values (-2.5 and -2.7), indicating very poor aqueous solubility. This is a major concern for both.
11. **hERG:** Both ligands have low hERG inhibition liability (0.14 and 0.18), which is good.
12. **Cl_mic:** Ligand A (0.74) is significantly better than Ligand B (68.2), indicating much better metabolic stability. This is a substantial advantage for A.
13. **t1/2:** Ligand B (-32.4) is better than Ligand A (39.2), indicating a longer half-life. This is a significant advantage for B.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.04 and 0.11), which is good.
15. **Binding Affinity:** Ligand B (-5.8) has a significantly better binding affinity than Ligand A (-1.0). This is a *very* substantial advantage for B, potentially outweighing some ADME drawbacks.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B has a better affinity, while Ligand A has better TPSA and logP. However, the difference in affinity is so large (-5.8 vs -1.0 kcal/mol) that it is likely to be the dominant factor.
**Overall Assessment:**
While Ligand A has advantages in DILI risk, metabolic stability, and slightly better TPSA/logP, the *massive* difference in binding affinity in favor of Ligand B is the deciding factor. The poor solubility and Caco-2 permeability are concerns for both, but these can be addressed with formulation strategies. A strong binding affinity is essential for a GPCR ligand, and Ligand B's affinity is far superior.
Output:
0
2025-04-17 23:04:29,770 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (358.389 Da and 348.407 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (85.25) is better than Ligand B (103.93). For a GPCR, keeping TPSA under 140 is good for oral absorption, and lower is generally preferred.
**3. logP:** Ligand A (1.489) is slightly better than Ligand B (0.917), both are within the optimal 1-3 range.
**4. H-Bond Donors:** Ligand A (2) is slightly better than Ligand B (1). Both are within the acceptable limit of 5.
**5. H-Bond Acceptors:** Ligand B (8) is higher than Ligand A (5). Both are within the acceptable limit of 10, but Ligand A is preferable.
**6. QED:** Ligand A (0.737) is significantly better than Ligand B (0.453). A QED above 0.5 is desirable, and Ligand A is much closer to 1.
**7. DILI:** Ligand A (47.77) has a lower DILI risk than Ligand B (59.907). Both are acceptable (<60 is good), but A is better.
**8. BBB:** Ligand A (81.039) has a much higher BBB penetration percentile than Ligand B (40.791). While ADRB2 is cardiovascular, some CNS penetration can be relevant for off-target effects or potential central modulation. This is a significant advantage for Ligand A.
**9. Caco-2:** Ligand A (-4.307) and Ligand B (-5.013) are both very poor. This is a concern for both.
**10. Solubility:** Ligand A (-3.134) is better than Ligand B (-1.373). Higher solubility is preferred.
**11. hERG:** Both ligands have very low hERG inhibition risk (0.185 and 0.114 respectively). This is good for both.
**12. Cl_mic:** Ligand A (47.11) has lower microsomal clearance than Ligand B (57.793), indicating better metabolic stability.
**13. t1/2:** Ligand A (-32.272) has a much longer in vitro half-life than Ligand B (-17.314). This is a significant advantage.
**14. Pgp:** Both ligands have very low P-gp efflux liability (0.043 and 0.087 respectively). This is good for both.
**15. Binding Affinity:** Ligand B (-7.5) has a stronger binding affinity than Ligand A (-5.7). This is a 1.8 kcal/mol difference, which is significant.
**Overall Assessment:**
While Ligand B has a better binding affinity, Ligand A demonstrates a significantly better overall profile, particularly regarding drug-likeness (QED), metabolic stability (Cl_mic, t1/2), BBB penetration, and lower DILI risk. The affinity difference, while notable, can potentially be optimized in later stages of drug development. The superior ADME properties of Ligand A make it a more promising starting point for a cardiovascular GPCR drug candidate.
Output:
1
2025-04-17 23:04:29,770 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [346.387, 114.62 , -0.453, 2. , 5. , 0.717, 43.66 , 68.205, -5.12 , -2.356, 0.061, -4.914, 7.316, 0.019, -6.1 ]
**Ligand B:** [352.435, 108.41 , 1.275, 2. , 6. , 0.648, 24.351, 54.556, -4.78 , -1.99 , 0.197, 61.993, -14.841, 0.033, -6.2 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). A (346.39) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are reasonably good (A: 114.62, B: 108.41), below the 140 threshold for oral absorption.
3. **logP:** A (-0.453) is a bit low, potentially hindering membrane permeability. B (1.275) is better, falling within the optimal 1-3 range.
4. **HBD:** Both have 2 HBD, which is good.
5. **HBA:** A has 5 HBA, B has 6. Both are acceptable, under the 10 limit.
6. **QED:** Both have good QED scores (A: 0.717, B: 0.648), indicating drug-likeness.
7. **DILI:** A (43.66) has a higher DILI risk than B (24.351), which is a significant advantage for B.
8. **BBB:** A (68.205) has better BBB penetration than B (54.556), but this is less critical for a cardiovascular target like ADRB2.
9. **Caco-2:** Both are poor (-5.12 and -4.78).
10. **Solubility:** Both have poor solubility (-2.356 and -1.99).
11. **hERG:** Both have very low hERG risk (A: 0.061, B: 0.197).
12. **Cl_mic:** A (-4.914) has significantly better metabolic stability (lower clearance) than B (61.993). This is a major advantage.
13. **t1/2:** A (7.316) has a better in vitro half-life than B (-14.841).
14. **Pgp:** Both have very low Pgp efflux (A: 0.019, B: 0.033).
15. **Binding Affinity:** Both have comparable affinity (-6.1 and -6.2 kcal/mol).
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. While BBB is important for CNS targets, it's less critical here. Ligand B has a better logP and significantly lower DILI risk. However, Ligand A has a much better metabolic stability profile (Cl_mic and t1/2). The affinity is nearly identical.
**Decision:**
Considering the balance, the improved metabolic stability and half-life of Ligand A outweigh the slightly better logP of Ligand B. The lower DILI risk of Ligand B is appealing, but metabolic stability is crucial for maintaining therapeutic concentrations *in vivo*.
Output:
1
2025-04-17 23:04:29,770 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (350.438 and 350.503 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (64.68) is better than Ligand B (69.64). Both are below the 140 A^2 threshold for good oral absorption, but lower TPSA is generally preferred for GPCRs to facilitate membrane permeability.
**3. logP:** Both ligands have acceptable logP values (1.488 and 2.184), falling within the 1-3 range. Ligand B is slightly higher, which could potentially lead to some solubility issues, but it's not a major concern.
**4. H-Bond Donors:** Both have 2 HBD, which is within the ideal limit of 5.
**5. H-Bond Acceptors:** Ligand A has 4 HBA and Ligand B has 3. Both are below the ideal limit of 10.
**6. QED:** Ligand A (0.816) has a slightly better QED score than Ligand B (0.739), indicating a more drug-like profile.
**7. DILI Risk:** Ligand A (37.146) has a significantly lower DILI risk than Ligand B (13.571). This is a crucial factor, as liver toxicity is a major concern in drug development.
**8. BBB Penetration:** Ligand A (89.686) has significantly better BBB penetration than Ligand B (68.554). While ADRB2 is primarily a cardiovascular target, some CNS effects can occur with adrenergic agonists. Better BBB penetration could lead to unwanted side effects, but it's not a primary concern for this target.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.858 and -4.801). This is unusual and suggests poor permeability. However, these values are on a log scale and negative values are not uncommon for compounds with specific structural features.
**10. Aqueous Solubility:** Both ligands have negative solubility values (-2.254 and -2.811). This is also unusual, and suggests poor solubility.
**11. hERG Inhibition:** Ligand A (0.803) has a slightly higher hERG inhibition risk than Ligand B (0.471). Lower hERG inhibition is preferred, so Ligand B is slightly better here.
**12. Microsomal Clearance:** Ligand A (23.78) has significantly lower microsomal clearance than Ligand B (47.39). Lower clearance indicates better metabolic stability, which is highly desirable.
**13. In vitro Half-Life:** Ligand A (-2.024) has a longer in vitro half-life than Ligand B (-9.443). This is a significant advantage, as it suggests less frequent dosing may be possible.
**14. P-gp Efflux:** Ligand A (0.023) has much lower P-gp efflux than Ligand B (0.195). Lower P-gp efflux is preferred for better oral bioavailability.
**15. Binding Affinity:** Ligand A (-7.1) has a slightly better binding affinity than Ligand B (-6.6). While both are good, the 1.5 kcal/mol advantage of Ligand A is significant.
**Overall Assessment:**
Ligand A is the stronger candidate. It has a significantly lower DILI risk, better metabolic stability (lower Cl_mic), longer half-life, lower P-gp efflux, and slightly better binding affinity. While Ligand B has a slightly lower hERG risk, the other advantages of Ligand A outweigh this minor drawback. The negative Caco-2 and solubility values are concerning for both, but these can be addressed through formulation strategies.
Output:
1
2025-04-17 23:04:29,771 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [352.366, 117.13 , 1.853, 3. , 4. , 0.394, 61.303, 74.874, -5.091, -3.295, 0.472, 10.326, 11.729, 0.111, -7.3 ]
**Ligand B:** [368.455, 101.57 , 0.109, 2. , 5. , 0.633, 44.009, 60.915, -5.352, -1.96 , 0.032, 15.208, -8.113, 0.04 , -3.4 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). A (352.366) is slightly preferred.
2. **TPSA:** Both are acceptable for a GPCR, but B (101.57) is better than A (117.13), closer to the <140 threshold.
3. **logP:** A (1.853) is optimal (1-3). B (0.109) is quite low, potentially leading to poor membrane permeability. This is a significant drawback.
4. **HBD:** Both are within the acceptable limit of 5. A (3) is slightly higher than B (2).
5. **HBA:** Both are within the acceptable limit of 10. A (4) is lower than B (5).
6. **QED:** B (0.633) is better than A (0.394), indicating a more drug-like profile.
7. **DILI:** B (44.009) is significantly better than A (61.303), indicating a lower risk of liver injury.
8. **BBB:** A (74.874) is better than B (60.915), although both are not exceptionally high. For a cardiovascular target, BBB isn't a primary concern, but it's a slight advantage for A.
9. **Caco-2:** Both are negative, indicating poor permeability.
10. **Solubility:** Both are negative, indicating poor solubility.
11. **hERG:** Both are very low, indicating minimal hERG inhibition risk. B (0.032) is slightly better.
12. **Cl_mic:** A (10.326) is better than B (15.208), suggesting better metabolic stability.
13. **t1/2:** A (11.729) is better than B (-8.113), indicating a longer half-life.
14. **Pgp:** Both are very low, indicating minimal P-gp efflux. B (0.04) is slightly better.
15. **Affinity:** A (-7.3) is *significantly* better than B (-3.4). This is a 3.9 kcal/mol difference, which is a substantial advantage and can often outweigh other drawbacks.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, and affinity. A has a much better logP, and a significantly better affinity. While B has a better TPSA and DILI, the large difference in affinity and the poor logP of B are major concerns.
**Conclusion:**
Despite B having a better QED and DILI score, the significantly superior binding affinity of Ligand A (-7.3 vs -3.4 kcal/mol) is the deciding factor. The difference in affinity is large enough to compensate for the slightly less favorable TPSA and DILI scores. The logP of B is a significant concern.
Output:
1
2025-04-17 23:04:29,771 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [351.382, 126.21 , 0.098, 4. , 5. , 0.518, 56.999, 78.674, -5.666, -2.518, 0.303, -11.576, 6.735, 0.01 , -6.9 ]
**Ligand B:** [378.447, 133.24 , -1.408, 3. , 7. , 0.535, 41.062, 33.967, -5.973, -1.23 , 0.111, -21.918, 23.703, 0.018, -6.3 ]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, Affinity, and to a lesser extent BBB):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (351.382) is slightly preferable.
2. **TPSA:** Both are reasonably good (A: 126.21, B: 133.24), but ideally below 140 for oral absorption. Ligand A is slightly better.
3. **logP:** Ligand A (0.098) is quite low, potentially hindering membrane permeability. Ligand B (-1.408) is also low, but less so. This is a significant drawback for both, but more so for A.
4. **HBD/HBA:** Both have acceptable numbers (A: 4/5, B: 3/7).
5. **QED:** Both are good (A: 0.518, B: 0.535).
6. **DILI:** Ligand B (41.062) has a much lower DILI risk than Ligand A (56.999), which is a substantial advantage.
7. **BBB:** Ligand A (78.674) has a better BBB penetration potential than Ligand B (33.967). However, for a cardiovascular target, BBB is less critical.
8. **Caco-2:** Both are poor (-5.666 and -5.973).
9. **Solubility:** Both are poor (-2.518 and -1.23).
10. **hERG:** Both are low risk (A: 0.303, B: 0.111). Ligand B is slightly better.
11. **Cl_mic:** Ligand A (-11.576) has a better (lower) microsomal clearance, indicating better metabolic stability than Ligand B (-21.918).
12. **t1/2:** Ligand B (23.703) has a significantly longer half-life than Ligand A (6.735), which is a major advantage.
13. **Pgp:** Both have low Pgp efflux (A: 0.01, B: 0.018).
14. **Affinity:** Ligand A (-6.9 kcal/mol) has a slightly better binding affinity than Ligand B (-6.3 kcal/mol). This is a 0.6 kcal/mol difference.
**Overall Assessment:**
While Ligand A has slightly better affinity and BBB penetration, the significantly lower DILI risk and much longer half-life of Ligand B are more important for overall drug development. The low logP values for both are concerning, but the better metabolic stability and reduced toxicity profile of Ligand B outweigh the small affinity advantage of Ligand A. The cardiovascular target doesn't prioritize BBB as much as a CNS target would.
Output:
0
2025-04-17 23:04:29,771 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (354.332 and 348.443 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (78.09) is significantly better than Ligand B (98.66). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is approaching a level that could hinder oral absorption.
3. **logP:** Both ligands have good logP values (1.994 and 1.873), falling within the optimal 1-3 range. No clear advantage.
4. **HBD:** Ligand A (2) is preferable to Ligand B (4). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (4). Similar to HBD, fewer HBAs are generally better for permeability.
6. **QED:** Both ligands have similar QED values (0.641 and 0.631), indicating good drug-likeness.
7. **DILI:** Ligand A (56.068) has a higher DILI risk than Ligand B (37.03). This is a notable advantage for Ligand B.
8. **BBB:** Ligand A (80.264) has a significantly higher BBB penetration percentile than Ligand B (51.493). While ADRB2 isn't strictly a CNS target, some CNS exposure can be acceptable and even beneficial for certain cardiovascular effects. This favors Ligand A.
9. **Caco-2:** Both ligands have very poor Caco-2 permeability (-4.967 and -4.707), indicating a significant absorption issue.
10. **Solubility:** Both ligands have poor aqueous solubility (-3.246 and -2.767). This is a concern for both, but not a deciding factor.
11. **hERG:** Both ligands have low hERG inhibition risk (0.209 and 0.359). No significant difference.
12. **Cl_mic:** Ligand A (4.705) has a much lower microsomal clearance than Ligand B (26.019), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (-6.525) has a much longer in vitro half-life than Ligand B (15.379). This is a major advantage for Ligand A.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.14 and 0.096). No significant difference.
15. **Binding Affinity:** Ligand B (-7.8) has a slightly better binding affinity than Ligand A (-8.4). While a 0.6 kcal/mol difference is noticeable, the other ADME properties are more concerning.
**Overall Assessment:**
Ligand A demonstrates a superior balance of properties, particularly regarding permeability (lower TPSA, fewer HBD/HBA), metabolic stability (lower Cl_mic, longer t1/2), and BBB penetration. While Ligand B has a lower DILI risk and slightly better affinity, the poor metabolic stability and lower BBB penetration are significant drawbacks. The poor Caco-2 and solubility for both are concerning and would require formulation strategies, but the other advantages of Ligand A make it the more promising candidate.
Output:
1
2025-04-17 23:04:29,771 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (363.5 and 366.5 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (54.3 and 54.2) are below the 140 A^2 threshold for good oral absorption, which is good.
3. **logP:** Ligand A (2.35) is slightly better than Ligand B (3.08) as it's closer to the optimal 1-3 range. Ligand B is pushing the upper limit, potentially leading to solubility issues.
4. **HBD:** Both have 1 HBD, which is within the acceptable limit of <=5.
5. **HBA:** Ligand A has 4 HBA, while Ligand B has 6. Both are within the acceptable limit of <=10, but A is slightly preferable.
6. **QED:** Both ligands have similar QED values (0.844 and 0.818), indicating good drug-likeness.
7. **DILI:** Ligand A (21.4) has a significantly lower DILI risk than Ligand B (8.1). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (71.3) shows better BBB penetration than Ligand A (58.1). While ADRB2 isn't strictly a CNS target, some CNS exposure can be relevant for off-target effects, and higher BBB is generally favorable.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-5.3) is slightly better than Ligand B (-4.88).
10. **Solubility:** Both ligands have negative solubility values, indicating poor aqueous solubility. Ligand A (-2.42) is slightly better than Ligand B (-2.68).
11. **hERG:** Both ligands have low hERG inhibition liability (0.303 and 0.77), which is good.
12. **Cl_mic:** Ligand B (15.0) has a significantly lower microsomal clearance than Ligand A (30.1), indicating better metabolic stability. This is a strong point for Ligand B.
13. **t1/2:** Ligand A (18.9) has a longer in vitro half-life than Ligand B (-6.9). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.228) has lower P-gp efflux liability than Ligand B (0.309), which is preferable.
15. **Affinity:** Both ligands have very similar and excellent binding affinities (-5.8 and -6.4 kcal/mol). The difference is negligible.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand B has a slightly higher logP and better BBB penetration, but also higher Pgp efflux. Ligand A has better DILI, solubility, and a longer half-life. The lower DILI risk and longer half-life of Ligand A are more important considerations for overall drug development.
**Conclusion:**
While Ligand B has some advantages in terms of BBB penetration and metabolic stability, the significantly lower DILI risk and longer half-life of Ligand A, coupled with comparable affinity, make it the more promising drug candidate.
Output:
1
2025-04-17 23:04:29,771 - INFO - Batch 378 complete. Total preferences: 6048
2025-04-17 23:04:29,771 - INFO - Processing batch 379/512...
2025-04-17 23:05:19,705 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (363.366) is slightly higher than Ligand B (345.443), but both are acceptable.
2. **TPSA:** Ligand A (93.46) is slightly above the optimal <90 for CNS targets, but still reasonable for a peripherally acting GPCR like ADRB2. Ligand B (61.88) is excellent, well below the 90 threshold.
3. **logP:** Ligand A (3.032) is optimal. Ligand B (1.17) is a bit low, potentially impacting permeability.
4. **HBD:** Ligand A (0) is ideal. Ligand B (1) is acceptable.
5. **HBA:** Ligand A (6) is good. Ligand B (5) is also good.
6. **QED:** Both ligands have similar and acceptable QED values (A: 0.578, B: 0.594).
7. **DILI:** Ligand A (87.282) has a higher DILI risk than Ligand B (26.095). This is a significant drawback for Ligand A.
8. **BBB:** This is less critical for ADRB2 (a cardiovascular target) but Ligand B (67.08) is better than Ligand A (51.105).
9. **Caco-2:** Both have negative values, indicating permeability issues. Ligand A (-4.118) is slightly worse than Ligand B (-4.88).
10. **Solubility:** Ligand A (-5.691) is worse than Ligand B (-0.706). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.34) has a slightly better hERG profile than Ligand B (0.521).
12. **Cl_mic:** Ligand A (57.527) has a higher clearance than Ligand B (42.169), meaning faster metabolism and potentially lower duration of action.
13. **t1/2:** Ligand A (62.505) has a longer half-life than Ligand B (-25.995). This is a positive for Ligand A, but needs to be weighed against other factors.
14. **Pgp:** Ligand A (0.327) has lower P-gp efflux than Ligand B (0.02), which is favorable.
15. **Binding Affinity:** Both ligands have excellent binding affinities (-6.1 and -5.1 kcal/mol). Ligand A is slightly better (-6.1 kcal/mol), but the difference is not huge.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has a better logP and Pgp, and slightly better affinity. However, its significantly higher DILI risk, worse solubility, and higher clearance are major concerns. Ligand B has a much better safety profile (DILI) and solubility, and a good TPSA. While its logP is lower, the overall balance of properties makes it a more promising candidate.
**Conclusion:**
Considering the balance of properties, particularly the significantly lower DILI risk and better solubility of Ligand B, I believe it is the more viable drug candidate despite the slightly lower logP and affinity.
Output:
0
2025-04-17 23:05:19,705 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (361.467 Da) is within the ideal range (200-500 Da). Ligand B (402.351 Da) is also acceptable, but closer to the upper limit.
2. **TPSA:** Ligand A (82.53) is good, well below the 140 threshold. Ligand B (67.07) is even better, suggesting potentially improved permeability.
3. **logP:** Ligand A (1.063) is at the lower end of optimal, but acceptable. Ligand B (3.701) is closer to the ideal range of 1-3.
4. **HBD:** Ligand A (2) and Ligand B (1) are both good, under the 5 threshold.
5. **HBA:** Ligand A (5) and Ligand B (7) are both acceptable, under the 10 threshold.
6. **QED:** Both Ligand A (0.841) and Ligand B (0.826) have excellent drug-likeness scores.
7. **DILI:** Both Ligand A (59.907) and Ligand B (59.48) are similar and acceptable, below the 60 threshold.
8. **BBB:** Ligand A (25.359) has poor BBB penetration, while Ligand B (73.943) is quite good. This is a significant advantage for Ligand B, though ADRB2 isn't necessarily a CNS target, better BBB penetration can still be beneficial for distribution.
9. **Caco-2:** Both Ligand A (-5.151) and Ligand B (-5.334) have negative Caco-2 values which is unusual and suggests very poor permeability. This is a major concern for both.
10. **Solubility:** Both Ligand A (-2.795) and Ligand B (-4.246) have very poor solubility. This is a significant drawback for both compounds.
11. **hERG:** Both Ligand A (0.167) and Ligand B (0.36) have low hERG risk, which is good.
12. **Cl_mic:** Ligand A (31.685) has a higher microsomal clearance than Ligand B (26.378), indicating potentially lower metabolic stability.
13. **t1/2:** Ligand A (-23.028) has a negative in vitro half-life, which is not possible and suggests a problem with the data or the molecule. Ligand B (18.965) has a reasonable half-life.
14. **Pgp:** Ligand A (0.131) has lower P-gp efflux than Ligand B (0.572), which is preferable.
15. **Affinity:** Ligand A (-6.5 kcal/mol) has slightly better binding affinity than Ligand B (-6.2 kcal/mol).
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B has better logP and TPSA. Ligand A has slightly better affinity and Pgp. However, the negative half-life for Ligand A is a critical flaw.
**Overall Assessment:**
Despite the slightly better affinity of Ligand A, the negative in vitro half-life is a deal-breaker. The poor Caco-2 and solubility for both are concerning, but can potentially be addressed with formulation strategies. Ligand B, while having slightly lower affinity, has a reasonable half-life, better logP, TPSA, and BBB penetration, making it the more promising candidate.
Output:
0
2025-04-17 23:05:19,706 - INFO - Reasoning:
Let's analyze Ligand A and Ligand B for their potential as ADRB2 ligands, keeping in mind GPCR priorities (logP, Pgp, TPSA, affinity).
**Molecular Weight:** Both ligands (349.475 and 353.555 Da) are within the ideal 200-500 Da range.
**TPSA:** Ligand A (53.09) is significantly better than Ligand B (64.86). A lower TPSA is preferable for GPCRs, aiding permeability. Ligand A is well below the 140 threshold.
**logP:** Ligand A (0.982) is within the optimal 1-3 range, while Ligand B (4.017) is pushing the upper limit and could potentially cause solubility issues or off-target interactions.
**H-Bond Donors/Acceptors:** Ligand A (0 HBD, 4 HBA) is better than Ligand B (1 HBD, 6 HBA). Lower counts are generally favored for better permeability.
**QED:** Both ligands have similar QED values (0.643 and 0.688), indicating good drug-likeness.
**DILI:** Ligand A (6.398) has a much lower DILI risk than Ligand B (22.8), which is a significant advantage.
**BBB:** Ligand A (93.137) shows better BBB penetration than Ligand B (71.268), though both are reasonably good. This is important for a GPCR.
**Caco-2 Permeability:** Both have negative Caco-2 values, which is unusual and suggests potential issues with the experimental setup or the compounds themselves. However, Ligand A (-4.674) is slightly better than Ligand B (-4.926).
**Aqueous Solubility:** Ligand A (-0.564) is better than Ligand B (-3.639). Solubility is important for bioavailability.
**hERG:** Both ligands have low hERG inhibition liability (0.501 and 0.389), which is good.
**Microsomal Clearance:** Ligand A (28.403) has lower microsomal clearance than Ligand B (33.838), indicating better metabolic stability.
**In vitro Half-Life:** Ligand A (-12.07) has a negative half-life, which is not physically possible. This is a red flag. Ligand B (14.504) is reasonable.
**P-gp Efflux:** Ligand A (0.027) has much lower P-gp efflux than Ligand B (0.077), which is beneficial for bioavailability and CNS exposure.
**Binding Affinity:** Ligand B (-6.9) has a slightly better binding affinity than Ligand A (-6.4), but the difference is only 0.5 kcal/mol.
**Overall Assessment:**
Ligand A has several advantages: lower TPSA, better logP, lower DILI risk, better solubility, lower P-gp efflux, and lower microsomal clearance. However, the negative in vitro half-life is a major concern. Ligand B has a better half-life and slightly better affinity, but its higher logP, DILI risk, and P-gp efflux are drawbacks.
Despite the affinity advantage of Ligand B, the combination of superior ADME properties in Ligand A, *except* for the problematic half-life, makes it more promising. The negative half-life is a data error or indicates rapid degradation, but could potentially be addressed through structural modifications. The issues with Ligand B are more difficult to fix without significantly altering its binding affinity.
Output:
1
2025-04-17 23:05:19,706 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (342-354 Da). No clear advantage.
2. **TPSA:** Ligand A (49.85) is significantly better than Ligand B (84.42). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (2.557) is better than Ligand B (1.064). A logP between 1-3 is optimal, and Ligand B is at the lower end, potentially impacting permeability.
4. **HBD:** Both ligands are acceptable (0 and 1, respectively), well below the threshold of 5.
5. **HBA:** Ligand A (3) is better than Ligand B (5), both are acceptable, but lower is generally preferred.
6. **QED:** Ligand B (0.885) is better than Ligand A (0.497). This is a significant advantage for Ligand B, indicating a more drug-like profile.
7. **DILI:** Ligand A (8.298) is *much* better than Ligand B (52.036). This is a critical factor; lower DILI risk is highly desirable.
8. **BBB:** Ligand A (91.508) is better than Ligand B (79.488). While not a primary concern for a cardiovascular target, higher BBB is generally a positive attribute.
9. **Caco-2:** Both ligands are negative, indicating poor permeability. Ligand A (-4.47) is slightly better than Ligand B (-4.803).
10. **Solubility:** Ligand A (-2.15) is better than Ligand B (-1.606), both are negative, indicating poor solubility.
11. **hERG:** Ligand A (0.618) is better than Ligand B (0.12). Lower hERG inhibition is crucial for avoiding cardiotoxicity.
12. **Cl_mic:** Ligand B (23.191) is better than Ligand A (26.994). Lower clearance is preferred for metabolic stability.
13. **t1/2:** Ligand A (3.237) is better than Ligand B (1.369). Longer half-life is generally desirable.
14. **Pgp:** Ligand A (0.128) is better than Ligand B (0.032). Lower P-gp efflux is preferred.
15. **Affinity:** Ligand B (-7.5) is slightly better than Ligand A (-7.4). This is a small difference, and other factors can outweigh it.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A performs better on logP, TPSA, and Pgp. The affinity difference is minimal.
**Overall Assessment:**
Despite Ligand B having a better QED score and slightly better affinity, Ligand A is the superior candidate due to its significantly lower DILI risk, better hERG profile, and more favorable TPSA and logP values. The improved metabolic stability of Ligand B is a plus, but the safety concerns with Ligand B are too significant to ignore.
**Output:**
1
2025-04-17 23:05:19,706 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
We are targeting ADRB2, a GPCR. Therefore, prioritizing logP, Pgp, TPSA, and affinity is crucial.
* **Molecular Weight:** Both ligands are within the acceptable range (200-500 Da).
* **TPSA:** Ligand A (49.41) is significantly better than Ligand B (113.08). A TPSA under 140 is good for oral absorption, but lower is generally better for GPCRs, and Ligand A is much closer to the ideal range for potential CNS penetration even if not specifically targeted.
* **logP:** Ligand A (3.616) is optimal, while Ligand B (-0.33) is quite low, potentially leading to poor membrane permeability. This is a major drawback for Ligand B.
* **H-Bond Donors/Acceptors:** Ligand B has more HBDs (4) and HBAs (6) than Ligand A (1 and 2 respectively). While not dramatically different, lower counts are generally preferred for better permeability.
* **QED:** Both ligands have acceptable QED values (0.761 and 0.537), indicating reasonable drug-likeness.
* **DILI:** Ligand A (29.43) has a much lower DILI risk than Ligand B (65.452). This is a significant advantage for Ligand A.
* **BBB:** Ligand A (96.045) shows excellent potential for BBB penetration, while Ligand B (24.738) is poor. Although ADRB2 isn't necessarily a CNS target, higher BBB penetration can sometimes correlate with better overall drug distribution.
* **Caco-2 Permeability:** Ligand A (-4.458) is better than Ligand B (-5.818), suggesting better intestinal absorption.
* **Aqueous Solubility:** Ligand A (-3.898) is better than Ligand B (-2.293).
* **hERG:** Both ligands have low hERG inhibition risk (0.85 and 0.166).
* **Microsomal Clearance:** Ligand B (-1.929) has lower clearance, suggesting better metabolic stability than Ligand A (56.426). This is a positive for Ligand B.
* **In vitro Half-Life:** Ligand A (-19.105) has a longer half-life than Ligand B (44.552). This is a positive for Ligand A.
* **P-gp Efflux:** Ligand A (0.545) has lower P-gp efflux than Ligand B (0.009), indicating better bioavailability.
* **Binding Affinity:** Both ligands have similar, strong binding affinities (-4.4 and -5.5 kcal/mol). Ligand B is slightly better, but the difference is unlikely to overcome the significant ADME deficiencies.
**Overall Assessment:**
Ligand A clearly outperforms Ligand B across most critical ADME properties, particularly logP, TPSA, DILI, BBB, and P-gp efflux. While Ligand B has better metabolic stability and slightly better affinity, the poor logP and high DILI risk are major concerns. The superior ADME profile of Ligand A, combined with its comparable binding affinity, makes it the more promising drug candidate.
**Output:**
1
2025-04-17 23:05:19,706 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, we prioritize logP, TPSA, Pgp, and binding affinity, alongside general drug-like properties.
* **Molecular Weight:** Both ligands are within the acceptable range (200-500 Da). Ligand A (343.343 Da) is slightly lower, which is generally favorable for permeability.
* **TPSA:** Ligand A (104.08) is better than Ligand B (66.48), falling well below the 140 threshold for oral absorption.
* **logP:** Ligand A (-1.454) is a bit low, potentially hindering permeability. Ligand B (3.056) is within the optimal range (1-3). This is a significant advantage for Ligand B.
* **H-Bond Donors/Acceptors:** Both have acceptable HBD (1) and HBA counts (6 for A, 3 for B).
* **QED:** Both ligands have good QED scores (>0.5), indicating good drug-likeness.
* **DILI:** Ligand B (28.655) has a considerably lower DILI risk than Ligand A (59.131). This is a major advantage for Ligand B.
* **BBB:** Ligand B (77.162) shows significantly better BBB penetration potential than Ligand A (23.11). While not a primary concern for a cardiovascular target, it's a positive attribute.
* **Caco-2 Permeability:** Both have negative Caco-2 values, which is unusual. Assuming these are percentile scores, both exhibit poor permeability.
* **Aqueous Solubility:** Both have negative solubility values, which is also unusual. Assuming these are percentile scores, both exhibit poor solubility.
* **hERG:** Ligand A (0.192) has a lower hERG risk than Ligand B (0.677), which is preferable.
* **Microsomal Clearance:** Ligand A (-1.882) has a lower (better) microsomal clearance than Ligand B (63.547), suggesting better metabolic stability.
* **In vitro Half-Life:** Ligand A (25.793) has a better in vitro half-life than Ligand B (-47.138).
* **P-gp Efflux:** Ligand A (0.002) has a much lower P-gp efflux liability than Ligand B (0.212), which is a significant advantage.
* **Binding Affinity:** Ligand A (-7.8 kcal/mol) has a slightly better binding affinity than Ligand B (-6.1 kcal/mol). This is a 1.7 kcal/mol difference, which is substantial and could outweigh some ADME deficiencies.
**Overall Assessment:**
While Ligand A has a better binding affinity and P-gp efflux profile, Ligand B demonstrates a superior balance of properties, particularly regarding safety (DILI) and permeability (logP, BBB). The lower DILI risk and more favorable logP of Ligand B are crucial for a cardiovascular drug candidate. The better metabolic stability of Ligand A is a plus, but the other advantages of Ligand B are more impactful.
**Output:**
0
2025-04-17 23:05:19,706 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**1. Molecular Weight:** Both ligands (352.475 Da and 355.479 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (89.87) is slightly higher than Ligand B (82.11), but both are below the 140 A^2 threshold for good oral absorption. Given ADRB2 is a cardiovascular target, CNS penetration isn't a primary concern, so this isn't a major differentiator.
**3. logP:** Ligand A (1.218) is within the optimal 1-3 range, while Ligand B (0.08) is slightly below 1. While a lower logP can sometimes indicate solubility issues, the difference isn't drastic.
**4. H-Bond Donors:** Ligand A (3) and Ligand B (2) are both within the acceptable limit of <=5.
**5. H-Bond Acceptors:** Ligand A (4) and Ligand B (5) are both within the acceptable limit of <=10.
**6. QED:** Both ligands have similar QED values (0.666 and 0.644), indicating good drug-likeness.
**7. DILI Risk:** Ligand B (4.459) has a significantly lower DILI risk than Ligand A (19.504). This is a crucial advantage, as minimizing liver toxicity is paramount.
**8. BBB Penetration:** Both ligands have similar BBB penetration (42.148 and 43.971). As ADRB2 is a cardiovascular target, BBB penetration is not a high priority.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.82 and -4.876). This is unusual and suggests poor permeability. However, the values are very close, so this isn't a deciding factor.
**10. Aqueous Solubility:** Ligand A (-2.201) has slightly better aqueous solubility than Ligand B (-0.442).
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (0.149 and 0.218).
**12. Microsomal Clearance:** Ligand B (-1.403) has a significantly *lower* (better) microsomal clearance than Ligand A (22.778). This suggests greater metabolic stability for Ligand B.
**13. In vitro Half-Life:** Ligand B (14.47) has a much longer in vitro half-life than Ligand A (2.779). This is a significant advantage, potentially allowing for less frequent dosing.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.028 and 0.002).
**15. Binding Affinity:** Ligand A (-7.4) has a slightly better binding affinity than Ligand B (-6.9). However, the difference is only 0.5 kcal/mol, which is not a huge advantage considering the other factors.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity, Ligand B is significantly better in terms of safety (DILI risk) and pharmacokinetic properties (microsomal clearance, half-life). The lower DILI risk and improved metabolic stability are critical advantages for a drug candidate. The slight difference in binding affinity is unlikely to outweigh these benefits. Given the GPCR-specific priorities, and the fact that this is a cardiovascular target (so BBB isn't crucial), Ligand B is the more promising candidate.
Output:
0
2025-04-17 23:05:19,707 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor (a GPCR):
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (341.371) is slightly lower, which is generally favorable for permeability.
**2. TPSA:** Ligand A (109.04) is higher than Ligand B (46.84). For a GPCR, lower TPSA is preferred to facilitate membrane permeability. Ligand B is significantly better here.
**3. logP:** Ligand A (1.253) is within the optimal range, while Ligand B (3.308) is towards the higher end but still acceptable.
**4. H-Bond Donors:** Ligand A has 2 HBD, and Ligand B has 0. Both are within the acceptable limit of 5.
**5. H-Bond Acceptors:** Both ligands have 6 HBA, which is within the acceptable limit of 10.
**6. QED:** Ligand A (0.788) has a better QED score than Ligand B (0.526), indicating a more drug-like profile.
**7. DILI Risk:** Ligand B (22.761) has a much lower DILI risk than Ligand A (70.725), which is a significant advantage.
**8. BBB Penetration:** Ligand B (96.937) shows excellent BBB penetration, while Ligand A (55.913) is moderate. For a GPCR, even a peripherally acting one, some BBB penetration can be useful for off-target profiling and understanding potential CNS side effects.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so the absolute values are difficult to interpret.
**10. Aqueous Solubility:** Both ligands have negative solubility values, which is also unusual and suggests poor solubility.
**11. hERG Inhibition:** Ligand A (0.283) has a lower hERG inhibition risk than Ligand B (0.743), which is a positive.
**12. Microsomal Clearance:** Ligand A (37.204) has lower microsomal clearance than Ligand B (62.434), suggesting better metabolic stability.
**13. In vitro Half-Life:** Ligand A (9.403) has a shorter half-life than Ligand B (-8.505, which is likely a very long half-life).
**14. P-gp Efflux:** Ligand A (0.057) has a lower P-gp efflux liability than Ligand B (0.679), which is favorable for bioavailability.
**15. Binding Affinity:** Ligand B (-6.4 kcal/mol) has a slightly better binding affinity than Ligand A (-5.7 kcal/mol). While the difference is not huge, it's still a factor.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand B appears to be the better candidate. Its significantly lower TPSA and excellent BBB penetration are major advantages. The substantially lower DILI risk is also a crucial factor. While Ligand A has a better QED and lower P-gp efflux, the benefits of Ligand B's improved permeability and safety profile outweigh these factors. The slightly better affinity of Ligand B is also a plus. The negative solubility and Caco-2 values are concerning for both, but these can be addressed through formulation strategies.
Output:
0
2025-04-17 23:05:19,707 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (346.431 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (72.87) is significantly better than Ligand A (98.32). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have acceptable logP values (A: 1.073, B: 2.753), falling within the 1-3 range. Ligand B is closer to the optimal value.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (0). Both are acceptable, but lower is generally preferred.
5. **HBA:** Ligand B (8) is higher than Ligand A (4). Both are within the acceptable range, but A is better.
6. **QED:** Both ligands have good QED scores (A: 0.71, B: 0.826), indicating drug-likeness. B is slightly better.
7. **DILI:** Ligand A (43.66) has a better DILI score than Ligand B (55.68), indicating lower potential for liver injury. This is a significant advantage.
8. **BBB:** Ligand B (66.499) has a higher BBB score than Ligand A (32.144). While not crucial for a cardiovascular target, it's a slight positive for B.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-5.191) is slightly better than Ligand B (-5.456), but both are concerning.
10. **Solubility:** Ligand A (-2.271) has better solubility than Ligand B (-4.044). Solubility is important for bioavailability.
11. **hERG:** Both ligands have very low hERG inhibition risk (A: 0.118, B: 0.277). This is excellent for both.
12. **Cl_mic:** Ligand A (-5.666) has a much lower (better) microsomal clearance than Ligand B (75.719), indicating better metabolic stability. This is a major advantage for A.
13. **t1/2:** Ligand A (-17.805) has a much longer in vitro half-life than Ligand B (0.951). This is a significant advantage for A.
14. **Pgp:** Both ligands have low P-gp efflux liability (A: 0.023, B: 0.348). A is slightly better.
15. **Binding Affinity:** Both ligands have the same binding affinity (-5.8 kcal/mol).
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, and affinity are key. While both ligands have similar affinity, Ligand A has better solubility, a significantly better DILI score, and vastly superior metabolic stability (Cl_mic and t1/2). Ligand B has a slightly better TPSA and BBB, but these are less critical for a cardiovascular target. The poor Caco-2 values for both are concerning, but the other advantages of Ligand A outweigh this.
**Conclusion:**
Ligand A presents a more favorable overall profile, particularly regarding metabolic stability, DILI risk, and solubility. These factors are crucial for developing a viable drug candidate.
Output:
1
2025-04-17 23:05:19,707 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [354.397, 58.64, 2.246, 1, 3, 0.825, 36.293, 89.104, -4.351, -2.135, 0.473, 27.406, 32.588, 0.089, -7]
**Ligand B:** [355.435, 130.75, -0.392, 4, 5, 0.418, 14.889, 38.232, -5.86, -1.886, 0.055, 27.014, -7.24, 0.005, -6.5]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Similar.
2. **TPSA:** Ligand A (58.64) is significantly better than Ligand B (130.75). ADRB2 is a cardiovascular target, so CNS penetration isn't *essential*, but lower TPSA generally correlates with better permeability.
3. **logP:** Ligand A (2.246) is optimal. Ligand B (-0.392) is quite low, potentially hindering membrane permeability and absorption.
4. **HBD:** Ligand A (1) is preferable to Ligand B (4). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (5). Fewer HBAs generally improve permeability.
6. **QED:** Ligand A (0.825) is better than Ligand B (0.418), indicating a more drug-like profile.
7. **DILI:** Ligand A (36.293) has a much lower DILI risk than Ligand B (14.889). This is a significant advantage.
8. **BBB:** Ligand A (89.104) has better BBB penetration than Ligand B (38.232), though this isn't a primary concern for a cardiovascular target.
9. **Caco-2:** Ligand A (-4.351) is better than Ligand B (-5.86), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-2.135) is better than Ligand B (-1.886).
11. **hERG:** Both are very low risk (0.473 and 0.055 respectively). Similar.
12. **Cl_mic:** Both have similar microsomal clearance (27.406 vs 27.014).
13. **t1/2:** Ligand A (32.588) has a longer in vitro half-life than Ligand B (-7.24). This is a positive.
14. **Pgp:** Ligand A (0.089) has lower P-gp efflux than Ligand B (0.005), which is preferable.
15. **Affinity:** Ligand A (-7.0) and Ligand B (-6.5) are both good, but Ligand A is slightly better.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp efflux, and affinity are key. Ligand A excels in all these areas. While BBB isn't critical for a cardiovascular target, it's still a bonus.
**Conclusion:**
Ligand A is significantly better than Ligand B across multiple crucial parameters, including logP, TPSA, DILI risk, QED, solubility, half-life, and Pgp efflux. The slightly better binding affinity further solidifies its advantage.
Output:
1
2025-04-17 23:05:19,707 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [351.447, 78.95, 0.387, 1, 4, 0.746, 27.414, 61.613, -4.454, -1.237, 0.119, 13.737, 20.312, 0.051, -5.8]
**Ligand B:** [349.475, 64.09, 0.552, 1, 4, 0.712, 13.532, 42.109, -4.643, -0.864, 0.37, 10.665, -10.691, 0.094, -6.5]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (351.447) and Ligand B (349.475) are very similar.
2. **TPSA:** Ligand A (78.95) is slightly higher than Ligand B (64.09). Both are below the 140 threshold for oral absorption, but Ligand B is better positioned for potential CNS penetration.
3. **logP:** Ligand A (0.387) is a bit low, potentially hindering permeability. Ligand B (0.552) is also on the lower side, but slightly better. Both are below the optimal 1-3 range.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Both have 4 HBA, which is good.
6. **QED:** Both have good QED scores (A: 0.746, B: 0.712), indicating drug-like properties.
7. **DILI:** Ligand A (27.414) has a higher DILI risk than Ligand B (13.532). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (61.613) has a moderate BBB penetration, while Ligand B (42.109) is lower. Neither is exceptionally high, but for a cardiovascular target, BBB isn't a primary concern.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and indicates poor permeability. Ligand A (-4.454) is slightly worse than Ligand B (-4.643).
10. **Solubility:** Both have negative solubility values, which is also unusual and indicates poor solubility. Ligand A (-1.237) is slightly better than Ligand B (-0.864).
11. **hERG:** Ligand A (0.119) has a lower hERG risk than Ligand B (0.37). This is a positive for Ligand A.
12. **Cl_mic:** Ligand A (13.737) has a higher microsomal clearance than Ligand B (10.665), meaning it's less metabolically stable. Ligand B is preferred here.
13. **t1/2:** Ligand A (20.312) has a longer in vitro half-life than Ligand B (-10.691). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.051) has lower P-gp efflux than Ligand B (0.094), which is preferable.
15. **Affinity:** Ligand B (-6.5 kcal/mol) has a slightly better binding affinity than Ligand A (-5.8 kcal/mol). This difference of 0.7 kcal/mol is meaningful.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B has a slightly better logP and TPSA, lower Pgp efflux, and a better binding affinity. The lower DILI risk is also a substantial benefit. While Ligand A has a better half-life and hERG, the affinity and safety profile of Ligand B are more compelling. The poor Caco-2 and solubility for both are concerning, but can be addressed with formulation strategies.
**Conclusion:**
Considering the balance of properties and the priorities for a GPCR target, Ligand B is the more promising candidate.
0
2025-04-17 23:05:19,707 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (458.26) is slightly higher than Ligand B (402.336), but both are acceptable.
2. **TPSA:** Ligand A (105.14) is higher than Ligand B (54.02). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is generally preferred for absorption. Ligand B is significantly better here.
3. **logP:** Ligand A (2.255) is within the optimal range (1-3), while Ligand B (4.592) is a bit high. High logP can lead to solubility issues and off-target interactions. Ligand A is better.
4. **HBD:** Both ligands have 2 HBD, which is within the acceptable limit of <=5.
5. **HBA:** Ligand A has 6 HBA, while Ligand B has 2. Both are within the acceptable limit of <=10.
6. **QED:** Both ligands have good QED scores (A: 0.687, B: 0.735), indicating good drug-like properties.
7. **DILI:** Ligand A (81.427) has a higher DILI risk than Ligand B (48.313). This is a significant concern, as we want to minimize liver toxicity. Ligand B is much better.
8. **BBB:** BBB is less critical for a cardiovascular target. Ligand A (36.06) is lower than Ligand B (74.758).
9. **Caco-2:** Both have negative values, indicating poor permeability. Ligand A (-5.029) is slightly worse than Ligand B (-4.983).
10. **Solubility:** Both have negative values, indicating poor solubility. Ligand A (-4.073) is slightly worse than Ligand B (-4.024).
11. **hERG:** Ligand A (0.342) has a lower hERG risk than Ligand B (0.66). This is a positive for Ligand A.
12. **Cl_mic:** Ligand A (21.501) has a lower microsomal clearance than Ligand B (58.285), suggesting better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand B (90.895) has a much longer in vitro half-life than Ligand A (-7.766). This is a major advantage for Ligand B, potentially leading to less frequent dosing.
14. **Pgp:** Ligand A (0.049) has lower P-gp efflux than Ligand B (0.43), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand A (-6.2 kcal/mol) has a slightly better binding affinity than Ligand B (-1.1 kcal/mol). This is a substantial difference and a major factor in favor of Ligand A.
**Overall Assessment:**
Ligand A has a significantly better binding affinity and lower P-gp efflux, and better metabolic stability. However, it has a higher DILI risk and slightly worse solubility. Ligand B has a much longer half-life, lower DILI risk, and better TPSA. The large difference in binding affinity and metabolic stability are key advantages for Ligand A. While the DILI risk is a concern, it can be addressed through further optimization. The very poor binding affinity of Ligand B is a major drawback that is unlikely to be overcome with further optimization.
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), and the importance of potency, I favor Ligand A.
Output:
1
2025-04-17 23:05:19,708 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (333.391 and 352.475 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (68.45 and 66.92) are well below the 140 A^2 threshold for good oral absorption, and suitable for a peripherally acting GPCR like ADRB2.
3. **logP:** Ligand A (3.419) is slightly higher than Ligand B (2.239), but both are within the optimal 1-3 range. Ligand A is preferable here.
4. **HBD:** Ligand A (1) is preferable to Ligand B (0) as having at least one HBD can improve solubility.
5. **HBA:** Both ligands have 4 HBA, which is acceptable.
6. **QED:** Ligand A (0.73) has a significantly better QED score than Ligand B (0.471), indicating a more drug-like profile. This is a substantial advantage for Ligand A.
7. **DILI:** Ligand B (19.504) has a much lower DILI risk than Ligand A (76.037). This is a major advantage for Ligand B.
8. **BBB:** Both ligands have high BBB penetration (73.245 and 75.107), but this is less critical for ADRB2, a cardiovascular target.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. This is a concern for both.
10. **Solubility:** Ligand B (-1.982) has better solubility than Ligand A (-4.087). This is a positive for Ligand B.
11. **hERG:** Ligand A (0.903) has a slightly higher hERG risk than Ligand B (0.328), but both are relatively low.
12. **Cl_mic:** Ligand A (31.451) has significantly lower microsomal clearance than Ligand B (85.586), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (29.14) has a much longer in vitro half-life than Ligand B (-15.672). This is a strong advantage for Ligand A.
14. **Pgp:** Ligand B (0.063) has lower P-gp efflux than Ligand A (0.519), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand A (-7.6 kcal/mol) has a slightly better binding affinity than Ligand B (-6.7 kcal/mol). While the difference is not huge, it's a positive for Ligand A.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are important. Ligand A has a better logP, affinity, and metabolic stability (Cl_mic, t1/2), while Ligand B has better solubility and lower DILI/Pgp.
**Overall Assessment:**
Ligand A is the stronger candidate. The superior QED, metabolic stability, longer half-life, and slightly better affinity outweigh the higher DILI risk and slightly worse solubility. The Caco-2 values are concerning for both, but can be addressed through formulation strategies. The slight advantage in binding affinity is also a factor.
Output:
1
2025-04-17 23:05:19,708 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands (362.455 & 365.836 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (96.6) is higher than Ligand B (66.22). For a GPCR, lower TPSA is generally preferred for better permeability, giving a slight edge to Ligand B.
3. **logP:** Ligand B (3.179) is closer to the optimal 1-3 range than Ligand A (0.81). Ligand A's logP is quite low, potentially hindering membrane permeability. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (1) and Ligand B (0) are both acceptable.
5. **HBA:** Ligand A (5) and Ligand B (4) are both acceptable.
6. **QED:** Ligand A (0.802) has a slightly better QED score than Ligand B (0.696), indicating better overall drug-likeness.
7. **DILI:** Ligand B (21.946) has a much lower DILI risk than Ligand A (47.964). This is a substantial advantage for Ligand B.
8. **BBB:** Ligand B (86.196) has a significantly higher BBB penetration percentile than Ligand A (62.699). While ADRB2 isn't strictly a CNS target, some peripheral ADRB2 activity can be modulated by CNS effects, and higher BBB penetration can be beneficial.
9. **Caco-2:** Ligand A (-5.22) and Ligand B (-4.297) are both negative, indicating poor permeability. However, Ligand B is slightly less negative.
10. **Solubility:** Ligand A (-2.12) and Ligand B (-3.975) are both poor.
11. **hERG:** Ligand A (0.132) has a slightly lower hERG risk than Ligand B (0.752), which is preferable.
12. **Cl_mic:** Ligand A (-8.199) has a much lower (better) microsomal clearance than Ligand B (61.405), indicating greater metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (-10.237) has a longer in vitro half-life than Ligand B (9.096), which is desirable.
14. **Pgp:** Ligand A (0.061) has a lower P-gp efflux liability than Ligand B (0.202), which is preferable.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-5.9 kcal/mol and -5.1 kcal/mol, respectively). The difference of 0.8 kcal/mol is not enough to outweigh other factors.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP, TPSA, and BBB. Ligand A has better metabolic stability (Cl_mic, t1/2) and Pgp efflux. The affinity difference is minimal. The lower DILI risk of Ligand B is also a major benefit.
**Overall Assessment:**
While Ligand A has advantages in metabolic stability and Pgp efflux, Ligand B's superior logP, lower DILI risk, and better BBB penetration are more critical for a GPCR target like ADRB2. The slightly better QED of ligand A is not enough to offset the other advantages of ligand B.
Output:
0
2025-04-17 23:05:19,708 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (396.171 and 402.969 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (45.23) is significantly better than Ligand B (69.64). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (4.621) is a bit high, potentially leading to solubility issues and off-target interactions. Ligand B (2.309) is excellent, falling squarely within the optimal 1-3 range.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (3) is better than Ligand B (5). Similar reasoning as with HBD.
6. **QED:** Ligand B (0.792) has a better QED score than Ligand A (0.606), indicating a more drug-like profile.
7. **DILI:** Ligand B (31.601) is *much* better than Ligand A (79.333). This is a critical advantage for Ligand B, as DILI is a major concern in drug development.
8. **BBB:** Ligand A (75.649) is slightly better than Ligand B (66.615), but this isn't a high priority for a cardiovascular target.
9. **Caco-2:** Ligand A (-4.613) is better than Ligand B (-5.281), indicating better intestinal absorption.
10. **Solubility:** Ligand B (-3.78) is better than Ligand A (-5.406). This is important, especially considering Ligand A's higher logP.
11. **hERG:** Ligand A (0.575) is better than Ligand B (0.239). Lower hERG inhibition is crucial for avoiding cardiotoxicity.
12. **Cl_mic:** Ligand B (5.67) has significantly lower microsomal clearance than Ligand A (60.522), indicating better metabolic stability.
13. **t1/2:** Ligand A (77.539) has a longer in vitro half-life than Ligand B (-6.498). This is a positive for Ligand A.
14. **Pgp:** Ligand A (0.412) is better than Ligand B (0.175). Lower P-gp efflux is generally desirable.
15. **Binding Affinity:** Both ligands have very similar and excellent binding affinities (-5.9 and -6.1 kcal/mol). The difference is negligible.
**Overall Assessment & GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, and metabolic stability are important. Ligand B excels in logP, TPSA, and *especially* DILI and Cl_mic. While Ligand A has slightly better Caco-2 permeability and in vitro half-life, the significantly lower DILI risk and better metabolic stability of Ligand B outweigh these advantages. The hERG risk is also lower for Ligand A, but the difference isn't dramatic enough to override the other benefits of Ligand B.
**Output:**
0
2025-04-17 23:05:19,708 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (351.491) is slightly higher than Ligand B (339.439), but both are acceptable.
2. **TPSA:** Ligand A (72.88) is better than Ligand B (65.2). Both are below the 140 A^2 threshold for oral absorption, but lower TPSA is generally preferred for GPCRs.
3. **logP:** Ligand B (3.079) is at the higher end of the optimal range (1-3), while Ligand A (0.703) is below it. While Ligand B's logP is acceptable, it's closer to the boundary where solubility issues might arise. Ligand A's lower logP might hinder permeability.
4. **HBD:** Both ligands have 2 HBD, which is within the acceptable limit of <=5.
5. **HBA:** Ligand A (4) is slightly higher than Ligand B (2), but both are within the acceptable limit of <=10.
6. **QED:** Ligand B (0.899) has a significantly better QED score than Ligand A (0.632), indicating a more drug-like profile.
7. **DILI:** Ligand A (4.731) has a much lower DILI risk than Ligand B (47.421). This is a significant advantage for Ligand A.
8. **BBB:** Ligand B (78.945) has a better BBB penetration percentile than Ligand A (36.371). This is important for GPCR targets, but ADRB2 is primarily a cardiovascular target, so this isn't *critical*.
9. **Caco-2:** Ligand A (-4.856) has a worse Caco-2 permeability than Ligand B (-5.016). Both are very poor, indicating potential absorption issues.
10. **Solubility:** Ligand A (-0.599) has slightly better solubility than Ligand B (-4.421).
11. **hERG:** Ligand A (0.198) has a significantly lower hERG inhibition liability than Ligand B (0.737). This is a crucial advantage for cardiovascular targets.
12. **Cl_mic:** Ligand A (-7.488) has much lower microsomal clearance than Ligand B (44.578), indicating better metabolic stability.
13. **t1/2:** Ligand A (5.337) has a better in vitro half-life than Ligand B (-2.784).
14. **Pgp:** Ligand A (0.014) has significantly lower P-gp efflux liability than Ligand B (0.138).
15. **Binding Affinity:** Both ligands have comparable binding affinities (-6.5 and -6.3 kcal/mol). The difference is not substantial enough to be a deciding factor.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity) and the general guidelines, Ligand A is the more promising candidate. While Ligand B has a better QED and BBB penetration, Ligand A demonstrates significantly better safety profiles (lower DILI and hERG risk) and improved metabolic stability (lower Cl_mic and better t1/2). The lower Pgp efflux also favors Ligand A. The slightly lower logP of Ligand A is a concern, but the substantial advantages in safety and metabolism outweigh this drawback. The poor Caco-2 values for both are concerning and would require further investigation, but are not enough to disqualify Ligand A given its other benefits.
Output:
1
2025-04-17 23:05:19,708 - INFO - Batch 379 complete. Total preferences: 6064
2025-04-17 23:05:19,709 - INFO - Processing batch 380/512...
2025-04-17 23:06:15,031 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (357.797 and 345.359 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (95.08) is better than Ligand B (118.69). ADRB2 is not a CNS target, but lower TPSA generally favors absorption.
3. **logP:** Ligand A (2.214) is optimal (1-3). Ligand B (0.005) is *very* low, potentially hindering permeation. This is a significant negative for Ligand B.
4. **HBD:** Both ligands have acceptable HBD counts (3 and 2, respectively), well below the threshold of 5.
5. **HBA:** Ligand A (4) is better than Ligand B (7). Lower HBA is preferable for permeability.
6. **QED:** Both ligands have good QED scores (0.667 and 0.799), indicating good drug-like properties.
7. **DILI:** Ligand A (79.062) has a higher DILI risk than Ligand B (49.632). This favors Ligand B, though both are reasonably acceptable.
8. **BBB:** Not a primary concern for ADRB2 (cardiovascular target). Ligand B (35.052) is slightly better than Ligand A (32.299), but the difference is minimal.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the absolute values are similar (-5.323 vs -5.218).
10. **Solubility:** Ligand A (-4.41) is better than Ligand B (-2.159), indicating better aqueous solubility.
11. **hERG:** Ligand A (0.322) has a much lower hERG risk than Ligand B (0.096). This is a crucial advantage for Ligand A, as hERG inhibition can lead to cardiotoxicity.
12. **Cl_mic:** Ligand A (2.187) has a significantly lower microsomal clearance than Ligand B (-25.771), indicating better metabolic stability. This is a major advantage for Ligand A.
13. **t1/2:** Ligand A (48.668) has a much longer in vitro half-life than Ligand B (6.556). This is a significant advantage for Ligand A, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.142) has lower P-gp efflux liability than Ligand B (0.01). This is a slight advantage for Ligand A.
15. **Affinity:** Ligand A (-7.0) has a slightly better binding affinity than Ligand B (-6.5). While the difference is not huge, it's enough to be considered.
**Overall Assessment:**
Ligand A is the stronger candidate. While Ligand B has a lower DILI risk, Ligand A excels in several critical ADME properties (logP, Cl_mic, t1/2, hERG) and has a slightly better binding affinity. The very low logP of Ligand B is a major concern, potentially leading to poor absorption. The superior metabolic stability and longer half-life of Ligand A are also highly desirable. The slightly higher DILI risk of Ligand A is manageable, especially given its other favorable properties.
Output:
1
2025-04-17 23:06:15,031 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (341.415 and 365.455 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (90.38) is better than Ligand B (97.39). Both are below 140, but lower TPSA generally favors absorption.
3. **logP:** Ligand A (1.787) is better than Ligand B (0.775). Both are within the optimal range of 1-3, but Ligand B is closer to the lower bound, potentially impacting permeability.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (2), but both are acceptable (<=5).
5. **HBA:** Both ligands have the same number of HBA (5), which is acceptable (<=10).
6. **QED:** Ligand A (0.697) is slightly better than Ligand B (0.664), both are above the 0.5 threshold.
7. **DILI:** Ligand A (27.336) is significantly better than Ligand B (47.15). This is a major advantage for Ligand A as lower DILI risk is crucial.
8. **BBB:** Ligand A (64.676) is better than Ligand B (46.413), though neither is exceptionally high. For a cardiovascular target like ADRB2, BBB penetration is not a primary concern, but a higher value is still preferable.
9. **Caco-2:** Ligand A (-5.468) is better than Ligand B (-4.951). Higher Caco-2 values indicate better intestinal absorption.
10. **Solubility:** Both ligands have very poor aqueous solubility (-2.551). This is a concern for both, and formulation strategies would be needed.
11. **hERG:** Ligand A (0.577) is better than Ligand B (0.151). Lower hERG inhibition is critical for avoiding cardiotoxicity, making Ligand A more favorable.
12. **Cl_mic:** Ligand A (15.17) is better than Ligand B (19.263). Lower microsomal clearance indicates better metabolic stability.
13. **t1/2:** Ligand A (-6.522) is significantly better than Ligand B (-43.522). A longer half-life is desirable for less frequent dosing.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.023 and 0.021).
15. **Binding Affinity:** Ligand A (-6.3) is slightly better than Ligand B (-5.3), but the difference is not huge.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, and affinity are important. Ligand A performs better on logP and TPSA. The affinity difference is minor. More importantly, Ligand A has a significantly better safety profile (DILI and hERG) and metabolic stability (Cl_mic, t1/2).
**Conclusion:**
Ligand A is the superior candidate due to its better DILI risk, hERG inhibition, metabolic stability, and slightly better absorption characteristics. While both have solubility issues, the overall profile of Ligand A is more favorable for development as a drug candidate.
Output:
1
2025-04-17 23:06:15,031 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
The ADRB2 receptor is a GPCR, so the priorities are logP, Pgp, TPSA, BBB, and affinity. Let's break down the comparison:
1. **Molecular Weight:** Both ligands are within the acceptable range (200-500 Da). Ligand A (369.487) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (43.82) is significantly better than Ligand A (96.86). Lower TPSA is crucial for good oral absorption and GPCR engagement. This is a significant advantage for Ligand B.
3. **logP:** Ligand A (2.416) is within the optimal range (1-3), while Ligand B (4.035) is slightly higher. While still acceptable, the higher logP of Ligand B could potentially lead to off-target effects or solubility issues.
4. **H-Bond Donors:** Ligand A (2) is preferable to Ligand B (0) as it provides some hydrogen bonding potential for target engagement.
5. **H-Bond Acceptors:** Both ligands have the same number of HBA (5).
6. **QED:** Ligand A (0.833) has a slightly better QED score than Ligand B (0.766), indicating a more drug-like profile.
7. **DILI:** Ligand B (40.83) has a slightly lower DILI risk than Ligand A (52.074), which is a positive.
8. **BBB:** Ligand B (79.411) has a significantly higher BBB penetration percentile than Ligand A (65.258). While ADRB2 isn't exclusively a CNS target, some CNS exposure could be beneficial or at least less detrimental.
9. **Caco-2 Permeability:** Both ligands have very similar, and poor, Caco-2 permeability scores (-4.685 and -4.648).
10. **Aqueous Solubility:** Ligand A (-2.776) is better than Ligand B (-4.717). Solubility is important for formulation and bioavailability.
11. **hERG Inhibition:** Ligand A (0.304) has a lower hERG inhibition liability than Ligand B (0.888), which is a significant safety advantage.
12. **Microsomal Clearance:** Ligand B (91.271) has a much higher microsomal clearance than Ligand A (36.606), indicating faster metabolism and potentially lower *in vivo* exposure.
13. **In vitro Half-Life:** Ligand B (23.357) has a longer half-life than Ligand A (13.088), which is generally desirable.
14. **P-gp Efflux:** Ligand A (0.058) has a much lower P-gp efflux liability than Ligand B (0.487), which is a significant advantage for bioavailability.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-5.9 and -5.0 kcal/mol). The difference of 0.9 kcal/mol is not large enough to outweigh the other ADME differences.
**Overall Assessment:**
Ligand B has advantages in BBB penetration and in vitro half-life, but it suffers from higher logP, higher hERG inhibition, higher P-gp efflux, and significantly higher microsomal clearance. Ligand A has a better balance of properties, with better solubility, lower hERG risk, lower P-gp efflux, and lower clearance, despite the higher TPSA. The lower TPSA of Ligand B is attractive, but the other ADME liabilities are concerning. Given the GPCR-specific priorities and the overall profile, Ligand A appears to be the more promising candidate.
**Output:**
1
2025-04-17 23:06:15,032 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (352.475) is slightly higher than Ligand B (339.395), but both are acceptable.
2. **TPSA:** Ligand A (98.66) is slightly higher than Ligand B (75.44). Both are below 140, supporting oral absorption, but Ligand B is preferable due to the lower TPSA.
3. **logP:** Both ligands have good logP values (Ligand A: 1.122, Ligand B: 2.008), falling within the optimal 1-3 range. Ligand B is slightly better.
4. **HBD:** Ligand A has 4 HBD, while Ligand B has 1. Ligand B is preferable, as fewer HBDs generally correlate with better membrane permeability.
5. **HBA:** Both ligands have 4 HBA, which is acceptable.
6. **QED:** Ligand B (0.904) has a significantly higher QED score than Ligand A (0.516), indicating a more drug-like profile. This is a substantial advantage for Ligand B.
7. **DILI:** Both ligands have acceptable DILI risk (Ligand A: 22.179, Ligand B: 32.842), well below the concerning threshold of 60.
8. **BBB:** Ligand B (78.209) has a much higher BBB penetration percentile than Ligand A (30.283). While ADRB2 isn't strictly a CNS target, some cardiovascular effects can be mediated through CNS pathways, and better BBB penetration isn't necessarily detrimental.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Both ligands have very poor aqueous solubility (-2.243 and -2.429). This is a major drawback for both compounds.
11. **hERG:** Both ligands have very low hERG inhibition risk (Ligand A: 0.096, Ligand B: 0.355).
12. **Cl_mic:** Ligand B (8.221) has a lower microsomal clearance than Ligand A (14.035), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-15.133) has a longer in vitro half-life than Ligand A (-12.254).
14. **Pgp:** Ligand B (0.047) has a lower P-gp efflux liability than Ligand A (0.092), indicating better bioavailability.
15. **Binding Affinity:** Ligand A (-5.8 kcal/mol) has a slightly better binding affinity than Ligand B (-6.0 kcal/mol). While this is a small difference, it's still a positive for Ligand A.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP, TPSA, Pgp, and Cl_mic/t1/2, while Ligand A has a slightly better affinity. However, the significantly better QED, BBB, and metabolic stability of Ligand B outweigh the small affinity advantage of Ligand A. The poor Caco-2 and solubility are concerning for both, but can be addressed with formulation strategies.
**Conclusion:**
Considering all factors, Ligand B is the more promising drug candidate due to its superior drug-like properties (QED), metabolic stability, BBB penetration, and P-gp efflux profile.
Output:
0
2025-04-17 23:06:15,032 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (356.348 Da and 344.415 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (60.25) is significantly better than Ligand B (107.11). For a GPCR, a lower TPSA is generally preferred for better permeability. Ligand B is above the 90 A^2 threshold.
**3. logP:** Both ligands have acceptable logP values (2.108 and 1.348), falling within the 1-3 range. Ligand B is slightly lower, which *could* indicate slightly better solubility, but isn't a major concern.
**4. H-Bond Donors:** Ligand A has 0 HBDs, while Ligand B has 4. Lower HBDs are generally preferred for permeability.
**5. H-Bond Acceptors:** Ligand A has 6 HBAs, and Ligand B has 4. Both are within the acceptable range of <=10.
**6. QED:** Both ligands have similar QED values (0.711 and 0.657), indicating good drug-likeness.
**7. DILI:** Ligand A (53.936) and Ligand B (59.131) are both reasonably low risk, but Ligand A is slightly better. Both are below the 60 threshold.
**8. BBB:** Ligand A (88.135) has a significantly higher BBB penetration percentile than Ligand B (34.238). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be beneficial or at least not detrimental, and higher BBB is generally a positive attribute.
**9. Caco-2 Permeability:** Ligand A (-4.475) is better than Ligand B (-5.218), indicating better intestinal absorption.
**10. Aqueous Solubility:** Ligand A (-2.719) is better than Ligand B (-3.748).
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.387 and 0.31).
**12. Microsomal Clearance:** Ligand B (2.935) has significantly lower microsomal clearance than Ligand A (50.968), suggesting better metabolic stability. This is a significant advantage for Ligand B.
**13. In vitro Half-Life:** Ligand B (13.048) has a much longer in vitro half-life than Ligand A (-13.844). This is a substantial advantage for Ligand B.
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (0.259 and 0.012).
**15. Binding Affinity:** Ligand A (-7.0) has a slightly better binding affinity than Ligand B (-6.2). This is a 0.8 kcal/mol difference, which is substantial.
**Overall Assessment:**
Ligand A has a clear advantage in binding affinity and better permeability characteristics (TPSA, Caco-2, Solubility). However, Ligand B exhibits significantly better metabolic stability (lower Cl_mic, longer t1/2). Given the GPCR target class, I prioritize permeability and affinity. The 0.8 kcal/mol difference in binding affinity is significant enough to outweigh the metabolic stability concerns, especially considering the reasonable metabolic profile of Ligand A.
Output:
1
2025-04-17 23:06:15,032 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [344.419, 80.59, 0.503, 1, 8, 0.644, 32.842, 52.036, -5.469, -0.917, 0.492, 17.041, 33.359, 0.116, -6.2]
**Ligand B:** [377.539, 82.96, 3.753, 3, 8, 0.527, 79.333, 46.724, -5.506, -3.498, 0.821, 75.451, 85.226, 0.498, -5.7]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity):
1. **MW:** Both are within the acceptable 200-500 Da range. Ligand A (344.419) is slightly preferred due to being lower.
2. **TPSA:** Both are good at 80.59 and 82.96, being under 140.
3. **logP:** Ligand A (0.503) is quite low, which could hinder permeability. Ligand B (3.753) is much better, falling within the optimal 1-3 range. This is a significant advantage for Ligand B.
4. **HBD/HBA:** Both have acceptable numbers. Ligand B has more HBDs (3 vs 1), which could slightly impact permeability, but the difference isn't huge.
5. **QED:** Both are reasonable (0.644 and 0.527), indicating decent drug-likeness.
6. **DILI:** Ligand A (32.842) has a much lower DILI risk than Ligand B (79.333). This is a major advantage for Ligand A.
7. **BBB:** Ligand A (52.036) is better than Ligand B (46.724), but neither is particularly high. Since this is a cardiovascular target, BBB isn't *critical*, but higher is still preferable.
8. **Caco-2:** Both are negative, indicating poor permeability.
9. **Solubility:** Ligand A (-0.917) is better than Ligand B (-3.498).
10. **hERG:** Both are low, indicating low cardiotoxicity risk. Ligand B (0.821) is slightly higher, but still acceptable.
11. **Cl_mic:** Ligand A (17.041) has significantly lower microsomal clearance, suggesting better metabolic stability. This is a positive for Ligand A.
12. **t1/2:** Ligand B (85.226) has a much longer in vitro half-life than Ligand A (33.359). This is a strong advantage for Ligand B.
13. **Pgp:** Ligand A (0.116) has lower P-gp efflux, which is desirable for bioavailability. Ligand B (0.498) is higher.
14. **Affinity:** Both have excellent binding affinities (-6.2 and -5.7 kcal/mol). Ligand A is slightly better, but the difference is less than 1.5 kcal/mol.
**Overall Assessment:**
Ligand B has a much better logP and a significantly longer half-life. These are important factors for a GPCR target. However, Ligand A has a much lower DILI risk and better metabolic stability (lower Cl_mic), and slightly better Pgp efflux. The low logP of Ligand A is a concern, but the better DILI and metabolic stability are compelling. Given the balance, and the slightly better affinity of Ligand A, I lean towards it.
Output:
1
2025-04-17 23:06:15,032 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [362.367, 125.88 , 0.742, 1. , 8. , 0.663, 98.759, 47.615, -5.019, -3.226, 0.128, 57.007, -2.929, 0.17 , -6.2 ]
**Ligand B:** [364.324, 96.69 , -0.468, 2. , 6. , 0.712, 52.307, 65.529, -4.843, -1.2 , 0.353, -2.569, -16.653, 0.077, -6.8 ]
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). A: 362.37, B: 364.32. No significant difference.
2. **TPSA:** Ligand A (125.88) is slightly above the preferred <140 for good oral absorption, but acceptable. Ligand B (96.69) is excellent, well below 140. This favors B.
3. **logP:** Ligand A (0.742) is a bit low, potentially hindering permeation. Ligand B (-0.468) is even lower, raising concerns about absorption. Both are suboptimal, but A is slightly better.
4. **HBD:** Ligand A (1) is good. Ligand B (2) is also acceptable. No strong preference.
5. **HBA:** Ligand A (8) is good. Ligand B (6) is also good. No strong preference.
6. **QED:** Both ligands have good QED scores (A: 0.663, B: 0.712), indicating drug-like properties. B is slightly better.
7. **DILI:** Ligand A (98.759) has a very high DILI risk, which is a major concern. Ligand B (52.307) has a much lower, acceptable DILI risk. This strongly favors B.
8. **BBB:** Ligand A (47.615) has low BBB penetration. Ligand B (65.529) has better BBB penetration, though not exceptionally high. For a cardiovascular target, BBB isn't *critical*, but higher is generally preferred. This favors B.
9. **Caco-2:** Ligand A (-5.019) and B (-4.843) are both negative, which is unusual and suggests poor permeability. This is a concern for both, but the values are similar.
10. **Solubility:** Ligand A (-3.226) and B (-1.2) are both poor. B is slightly better.
11. **hERG:** Ligand A (0.128) has a very low hERG risk, which is excellent. Ligand B (0.353) is slightly higher, but still relatively low. A is preferred.
12. **Cl_mic:** Ligand A (57.007) has moderate clearance. Ligand B (-2.569) has a *negative* clearance, which is not physically possible and likely indicates an issue with the data or prediction method. This is a significant red flag for B.
13. **t1/2:** Ligand A (-2.929) has a negative half-life, which is not possible. Ligand B (-16.653) also has a negative half-life. Both are problematic.
14. **Pgp:** Ligand A (0.17) has low P-gp efflux, which is good. Ligand B (0.077) has even lower P-gp efflux, which is excellent. This favors B.
15. **Affinity:** Ligand B (-6.8) has a slightly better binding affinity than Ligand A (-6.2), but the difference is relatively small (0.6 kcal/mol).
**Overall Assessment:**
Despite Ligand B having a slightly better affinity and Pgp profile, the critical issues with its predicted *Cl_mic* and *t1/2* (negative values) are major concerns. These suggest significant problems with its metabolic stability and are likely prediction errors, but raise serious doubts. Ligand A has a very high DILI risk, which is also concerning. However, the issues with B are more fundamental. The hERG risk for A is also very favorable.
Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity), and the overall balance of properties, I would cautiously favor Ligand A, *despite* its DILI risk. The DILI risk could potentially be mitigated through structural modifications, while the negative clearance and half-life predictions for B are more indicative of a fundamentally flawed molecule.
Output:
1
2025-04-17 23:06:15,033 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
The target is ADRB2, a GPCR. Therefore, I'll prioritize logP, Pgp efflux, TPSA, BBB penetration, and binding affinity. Metabolic stability and solubility are also important, but secondary to the GPCR-specific parameters.
Let's compare the ligands property by property:
1. **MW:** Both ligands (367.446 and 344.459 Da) fall within the ideal 200-500 Da range.
2. **TPSA:** Both ligands (72.48 and 74.33) are below the 140 A^2 threshold for good oral absorption.
3. **logP:** Ligand A (3.729) is slightly higher than Ligand B (2.28). Both are within the optimal 1-3 range, but A is closer to the upper limit.
4. **HBD & HBA:** Both have 2 HBD and similar HBA counts (5 and 4 respectively), which are acceptable.
5. **QED:** Both are similar (0.816 and 0.796), indicating good drug-likeness.
6. **DILI:** Ligand A (68.166) has a higher DILI risk than Ligand B (34.432). This is a significant negative for Ligand A.
7. **BBB:** Ligand B (78.868) has significantly better predicted BBB penetration than Ligand A (49.864). This is a major advantage for Ligand B, even though ADRB2 is not necessarily a CNS target, better BBB penetration can still be beneficial for overall distribution.
8. **Caco-2:** Both have negative Caco-2 values which is unusual and suggests poor permeability.
9. **Solubility:** Both ligands have negative solubility values, which is also unusual and suggests poor solubility.
10. **hERG:** Ligand A (0.137) has a slightly lower hERG risk than Ligand B (0.517), which is a minor positive.
11. **Cl_mic:** Ligand B (34.736) has lower microsomal clearance than Ligand A (49.026), indicating better metabolic stability.
12. **t1/2:** Ligand B (-6.871) has a longer in vitro half-life than Ligand A (10.538). This is a significant advantage for Ligand B.
13. **Pgp:** Ligand A (0.183) has lower P-gp efflux liability than Ligand B (0.049), which is a positive.
14. **Binding Affinity:** Ligand A (-6.6 kcal/mol) has a slightly better binding affinity than Ligand B (-6.3 kcal/mol), but the difference is relatively small (0.3 kcal/mol).
**Overall Assessment:**
While Ligand A has a slightly better binding affinity and lower Pgp efflux, Ligand B is superior overall. The significantly lower DILI risk, better BBB penetration, improved metabolic stability (lower Cl_mic and longer t1/2) outweigh the minor advantage in binding affinity. The negative solubility and Caco-2 values are concerning for both, but the other ADME properties of Ligand B are more favorable.
**Output:**
0
2025-04-17 23:06:15,033 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are looking for a drug candidate for ADRB2, a cardiovascular GPCR. Therefore, we prioritize logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB.
Let's compare Ligand A and Ligand B across the key parameters:
1. **Molecular Weight:** Both ligands are within the ideal range (384 & 390 Da).
2. **TPSA:** Ligand A (47.56) is significantly better than Ligand B (113.01). A TPSA under 140 is good for oral absorption, but lower is better for GPCRs, and Ligand A is much closer to the ideal range.
3. **logP:** Ligand A (4.785) is high, potentially problematic, but Ligand B (-0.36) is *too* low, suggesting poor membrane permeability. For a GPCR, we want a balance, and Ligand A's logP, while needing optimization, is less concerning than Ligand B's.
4. **H-Bond Donors/Acceptors:** Ligand A (1 HBD, 3 HBA) is preferable to Ligand B (2 HBD, 7 HBA). Lower counts are generally better for permeability.
5. **QED:** Ligand A (0.825) is better than Ligand B (0.586), indicating a more drug-like profile.
6. **DILI:** Ligand B (59.131) has a lower DILI risk than Ligand A (80.535), which is a positive for Ligand B.
7. **BBB:** Ligand A (75.107) has better BBB penetration than Ligand B (32.183). While not a primary concern for a cardiovascular target, it's a slight advantage.
8. **Caco-2:** Ligand A (-4.384) and Ligand B (-5.74) are both very poor, indicating poor intestinal absorption.
9. **Solubility:** Ligand A (-5.798) is better than Ligand B (-1.167), though both are quite poor.
10. **hERG:** Ligand A (0.624) is better than Ligand B (0.194), indicating lower cardiotoxicity risk.
11. **Cl_mic:** Ligand B (-12.183) has significantly lower microsomal clearance, suggesting better metabolic stability than Ligand A (54.846). This is a major advantage for Ligand B.
12. **t1/2:** Ligand A (66.34) has a longer in vitro half-life than Ligand B (5.755).
13. **Pgp:** Ligand A (0.612) has lower P-gp efflux than Ligand B (0.079), which is favorable for bioavailability.
14. **Binding Affinity:** Ligand B (-6.1) has a slightly better binding affinity than Ligand A (-5.2), a 0.9 kcal/mol difference. This is a significant advantage.
**Overall Assessment:**
Ligand B has a superior binding affinity and metabolic stability (lower Cl_mic). However, its very low logP and high TPSA are significant drawbacks for a GPCR target. Ligand A, while having a higher logP and poorer metabolic stability, has a much more favorable TPSA, better solubility, and a better Pgp profile. The combination of these factors, particularly the TPSA and Pgp, makes Ligand A the more promising starting point, despite the need for logP optimization. The slight affinity difference can likely be addressed through further optimization.
Output:
1
2025-04-17 23:06:15,033 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, the key priorities are logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB.
Let's break down the comparison:
1. **MW:** Both ligands (354.8 & 353.4 Da) are within the ideal range (200-500 Da).
2. **TPSA:** Ligand B (75.44) is better than Ligand A (85.59). Lower TPSA generally favors oral absorption, which is important for a cardiovascular target.
3. **logP:** Both ligands have good logP values (2.84 and 1.82), within the optimal 1-3 range. Ligand B is slightly lower, which could be beneficial for solubility, but both are acceptable.
4. **HBD/HBA:** Both have 1 HBD, which is good. Ligand A has 6 HBA, while Ligand B has 4. Both are below the threshold of 10.
5. **QED:** Both ligands have good QED scores (0.73 and 0.89), indicating good drug-like properties. Ligand B is slightly better.
6. **DILI:** Ligand A has a significantly higher DILI risk (95.5%) than Ligand B (43.0%). This is a major concern for Ligand A.
7. **BBB:** Both have reasonable BBB penetration (77.0% and 78.8%). Not a primary concern for a cardiovascular target, but higher is generally better.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the values are similar.
9. **Solubility:** Both have negative solubility values, which is also unusual and suggests poor aqueous solubility. Ligand B is slightly better (-2.449 vs -3.974).
10. **hERG:** Both have very low hERG inhibition risk (0.304 and 0.133).
11. **Cl_mic:** Ligand B (17.994) has significantly lower microsomal clearance than Ligand A (64.697), indicating better metabolic stability.
12. **t1/2:** Ligand B has a negative in vitro half-life (-24.538), which is concerning. Ligand A has a more reasonable half-life (31.676).
13. **Pgp:** Both have very low Pgp efflux liability (0.341 and 0.053).
14. **Binding Affinity:** Ligand A (-8.5 kcal/mol) has a slightly better binding affinity than Ligand B (-8.2 kcal/mol), but the difference is small (0.3 kcal/mol).
**Overall Assessment:**
While Ligand A has slightly better binding affinity, the significantly higher DILI risk and higher microsomal clearance are major drawbacks. Ligand B, despite the negative in vitro half-life, presents a much more favorable ADMET profile, particularly the lower DILI risk and better metabolic stability. The small difference in binding affinity is outweighed by the superior safety and pharmacokinetic properties of Ligand B.
Output:
0
2025-04-17 23:06:15,033 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (397.276) is slightly higher than Ligand B (348.443), but both are acceptable.
2. **TPSA:** Ligand A (58.12) is well below the 140 threshold and good for oral absorption. Ligand B (70.08) is also acceptable, but higher.
3. **logP:** Ligand A (4.245) is slightly high, potentially leading to solubility issues or off-target interactions. Ligand B (0.638) is quite low, which could hinder membrane permeability.
4. **HBD:** Both ligands have 1 HBD, which is within the ideal range.
5. **HBA:** Both ligands have 4 HBA, which is within the ideal range.
6. **QED:** Both ligands have similar QED values (0.718 and 0.74), indicating good drug-likeness.
7. **DILI:** Ligand A (95.347) has a very high DILI risk, which is a significant concern. Ligand B (9.965) has a very low DILI risk, which is excellent.
8. **BBB:** Ligand A (85.731) has good BBB penetration, while Ligand B (55.642) has moderate penetration. While ADRB2 isn't *strictly* a CNS target, some CNS exposure can be relevant for off-target effects.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and potentially indicates issues with the assay or the compounds themselves. However, the values are similar.
10. **Solubility:** Both ligands have negative solubility values, which is also unusual. Ligand B (-1.333) is slightly better than Ligand A (-4.998).
11. **hERG:** Ligand A (0.822) has a slightly higher hERG risk than Ligand B (0.179), but both are relatively low.
12. **Cl_mic:** Ligand A (73.098) has a higher microsomal clearance, indicating lower metabolic stability. Ligand B (13.214) has a much lower clearance, suggesting better metabolic stability.
13. **t1/2:** Ligand A (76.104) has a longer in vitro half-life than Ligand B (5.093), which is desirable.
14. **Pgp:** Ligand A (0.873) has a lower P-gp efflux liability than Ligand B (0.047), which is favorable for oral bioavailability and potential CNS exposure.
15. **Binding Affinity:** Ligand B (-4.7 kcal/mol) has a slightly better binding affinity than Ligand A (-4.4 kcal/mol).
**GPCR-Specific Priorities and Overall Assessment:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B has a better logP (though still low), lower Pgp efflux, and slightly better affinity. However, the *major* deciding factor is the DILI risk. Ligand A's extremely high DILI risk (95.347) is a deal-breaker. While Ligand A has some advantages in BBB penetration and half-life, the liver toxicity risk is too significant to ignore. Ligand B, despite its lower logP, presents a much more favorable safety profile.
**Output:**
0
2025-04-17 23:06:15,033 - INFO - Here's my reasoning and final output for the ligand preference:
**Reasoning:**
We are looking for a ligand for ADRB2, a cardiovascular GPCR. Therefore, the most important parameters are binding affinity, logP, TPSA, Pgp efflux, and to a lesser extent, BBB.
Let's compare Ligand A and Ligand B across these key parameters and others:
* **Molecular Weight:** Both ligands (343.402 and 345.491 Da) are within the ideal 200-500 Da range.
* **TPSA:** Ligand A (62.3) is better than Ligand B (71.43). Lower TPSA generally favors better absorption.
* **logP:** Ligand A (2.37) is within the optimal 1-3 range, while Ligand B (3.78) is pushing the upper limit. Higher logP can lead to solubility issues and off-target interactions.
* **H-Bond Donors/Acceptors:** Ligand A (1 HBD, 3 HBA) is preferable to Ligand B (2 HBD, 6 HBA). Fewer H-bonds generally improve membrane permeability.
* **QED:** Both ligands have good QED scores (0.835 and 0.85), indicating good drug-like properties.
* **DILI:** Both have acceptable DILI risk (44.824 and 41.373).
* **BBB:** Ligand A (94.416) has a significantly higher BBB percentile than Ligand B (89.763). While not a primary concern for a cardiovascular target, higher BBB is generally favorable.
* **Caco-2:** Ligand A (-4.546) and Ligand B (-5.011) are both negative, indicating poor permeability.
* **Solubility:** Ligand A (-3.289) is better than Ligand B (-4.359), indicating slightly better solubility.
* **hERG:** Ligand A (0.444) has a lower hERG risk than Ligand B (0.798), which is crucial for cardiovascular drugs.
* **Cl_mic:** Ligand A (36.391) has lower microsomal clearance than Ligand B (45.616), suggesting better metabolic stability.
* **t1/2:** Ligand A (-24.872) has a significantly longer in vitro half-life than Ligand B (32.815).
* **Pgp:** Ligand A (0.185) has lower P-gp efflux liability than Ligand B (0.263), which is beneficial for bioavailability.
* **Binding Affinity:** This is the most critical parameter. Ligand B (-7.9 kcal/mol) has a substantially stronger binding affinity than Ligand A (-6.1 kcal/mol) - a difference of 1.8 kcal/mol. This is a substantial advantage.
**Conclusion:**
While Ligand A has better ADME properties across the board (TPSA, logP, solubility, hERG, Cl_mic, t1/2, Pgp), the significantly stronger binding affinity of Ligand B (-7.9 vs -6.1 kcal/mol) outweighs these concerns. A 1.8 kcal/mol difference in binding affinity is a large advantage, especially for a GPCR target where potency is key. The slightly worse ADME properties of Ligand B can potentially be addressed through further optimization, but improving a weaker binding affinity is often more challenging.
**Output:**
0
2025-04-17 23:06:15,033 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
The target is ADRB2, a GPCR. Therefore, the priorities are logP, Pgp, TPSA, affinity, and BBB.
Let's break down the comparison:
1. **Molecular Weight:** Both ligands (356.344 and 349.435 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (72.63) is significantly better than Ligand B (96.45). A TPSA under 140 is good for oral absorption, and lower is generally preferred for GPCRs. Ligand B is approaching a less desirable range.
3. **logP:** Ligand A (2.199) is within the optimal 1-3 range. Ligand B (0.459) is quite low, potentially hindering membrane permeability and bioavailability. This is a major drawback for Ligand B.
4. **H-Bond Donors:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **H-Bond Acceptors:** Ligand A (4) is better than Ligand B (6). Lower HBA counts are generally favored for better permeability.
6. **QED:** Ligand A (0.825) is significantly better than Ligand B (0.523), indicating a more drug-like profile.
7. **DILI:** Ligand A (42.846) is slightly higher than Ligand B (35.983), but both are within an acceptable range (<60).
8. **BBB:** Ligand A (92.633) is *much* better than Ligand B (61.923). While not a strict requirement for ADRB2 (a peripheral receptor), higher BBB penetration can still be beneficial and indicates better overall CNS distribution properties.
9. **Caco-2:** Ligand A (-4.737) is better than Ligand B (-5.505), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-2.987) is better than Ligand B (-0.99). Better solubility is always a plus.
11. **hERG:** Ligand A (0.79) is better than Ligand B (0.25). Lower hERG inhibition is crucial for cardiac safety.
12. **Cl_mic:** Ligand B (-10.378) has a much lower (better) microsomal clearance than Ligand A (13.287), suggesting greater metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand B (13.236) has a slightly longer in vitro half-life than Ligand A (6.438).
14. **Pgp:** Ligand A (0.214) is better than Ligand B (0.009). Lower P-gp efflux is desirable for improved bioavailability.
15. **Affinity:** Ligand A (-6.5 kcal/mol) is slightly better than Ligand B (-5.2 kcal/mol). While both are good, the 1.3 kcal/mol difference is significant and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand A has a significantly better overall profile, especially considering the GPCR-specific priorities. Its superior logP, TPSA, QED, BBB penetration, and binding affinity outweigh the slightly higher DILI risk and lower metabolic stability compared to Ligand B. Ligand B's low logP is a major concern, likely leading to poor permeability. While its metabolic stability is good, the other deficiencies are too significant to ignore.
Output:
1
2025-04-17 23:06:15,034 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (345.4 & 346.4 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (91.42) is higher than Ligand B (32.34). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B is significantly better.
3. **logP:** Ligand A (0.981) is slightly below the optimal 1-3 range, potentially impacting permeability. Ligand B (3.352) is within the optimal range. Ligand B is better.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 5 HBA, while Ligand B has 2. Both are acceptable, but lower is generally better for permeability. Ligand B is better.
6. **QED:** Ligand A (0.803) has a better QED score than Ligand B (0.633), suggesting a more drug-like profile overall.
7. **DILI:** Ligand A (56.844) has a higher DILI risk than Ligand B (16.402). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (64.87) has a lower BBB penetration than Ligand B (90.112). While ADRB2 isn't a CNS target, some degree of BBB penetration can sometimes indicate better overall distribution. Ligand B is better.
9. **Caco-2:** Ligand A (-5.398) has a worse Caco-2 permeability than Ligand B (-4.633). Lower (more negative) values indicate poorer permeability. Ligand B is better.
10. **Solubility:** Ligand A (-2.323) has a worse solubility than Ligand B (-3.854). Lower (more negative) values indicate poorer solubility. Ligand B is better.
11. **hERG:** Ligand A (0.05) has a lower hERG inhibition liability than Ligand B (0.872). This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand A (1.799) has a much lower microsomal clearance than Ligand B (27.043), indicating better metabolic stability. This is a major advantage for Ligand A.
13. **t1/2:** Ligand A (-8.459) has a worse in vitro half-life than Ligand B (-10.448). Lower (more negative) values indicate shorter half-life. Ligand B is better.
14. **Pgp:** Ligand A (0.027) has a lower P-gp efflux liability than Ligand B (0.482), indicating better bioavailability. Ligand A is better.
15. **Affinity:** Both ligands have very similar binding affinities (-6.8 and -6.7 kcal/mol). The difference is negligible.
**Overall Assessment:**
Ligand B excels in several key ADME properties (TPSA, logP, DILI, BBB, Caco-2, Solubility) and has a slightly better half-life. However, Ligand A demonstrates superior metabolic stability (Cl_mic), lower P-gp efflux, and lower hERG risk. Considering the GPCR-specific priorities (logP, TPSA, Pgp), and the importance of minimizing off-target effects (hERG, DILI), Ligand A presents a more balanced profile. The slightly lower logP and TPSA of Ligand A are less concerning for a cardiovascular target than the higher DILI risk and poorer metabolic stability of Ligand B.
Output:
1
2025-04-17 23:06:15,034 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.365 and 348.443 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (73.2) is slightly higher than Ligand B (71.63). Both are well below the 140 threshold for oral absorption, and acceptable for a cardiovascular GPCR.
3. **logP:** Ligand A (2.411) is within the optimal 1-3 range. Ligand B (3.608) is pushing the upper limit, potentially raising concerns about solubility and off-target effects, but still within a reasonable range.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 3 HBA, and Ligand B has 4. Both are acceptable, below the 10 threshold.
6. **QED:** Ligand A (0.909) has a significantly better QED score than Ligand B (0.666), indicating a more drug-like profile.
7. **DILI:** Ligand A (40.287) and Ligand B (37.728) both have low DILI risk, below the 40 threshold. Ligand B is slightly better.
8. **BBB:** Ligand A (89.104) has a significantly higher BBB penetration percentile than Ligand B (77.084). While ADRB2 is not a CNS target, some off-target CNS effects are always a consideration, and higher BBB penetration *could* correlate with increased potential for these.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.649 and -4.536). This is unusual and suggests poor permeability. However, these values are close and likely represent limitations in the prediction model rather than a substantial difference between the compounds.
10. **Solubility:** Ligand A (-3.75) and Ligand B (-4.039) both have poor predicted aqueous solubility. This is a concern, but can sometimes be overcome with formulation strategies.
11. **hERG:** Both ligands have low hERG inhibition risk (0.813 and 0.618). Ligand B is slightly better.
12. **Cl_mic:** Ligand A (5.811) has a much lower microsomal clearance than Ligand B (66.964), indicating better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand A (-21.413) has a much longer in vitro half-life than Ligand B (-25.31). This is a substantial advantage, suggesting less frequent dosing potential.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.073 and 0.156). No significant difference.
15. **Binding Affinity:** Ligand A (-5.0) has a slightly better binding affinity than Ligand B (-6.2). This is a 1.2 kcal/mol difference, which is significant.
**GPCR-Specific Considerations:**
For a cardiovascular GPCR like ADRB2, logP, TPSA, affinity, and metabolic stability are key. Ligand A has a better logP, significantly better metabolic stability (Cl_mic and t1/2), and a better QED score. The affinity difference is notable, but the ADME advantages of Ligand A are more compelling.
**Conclusion:**
Considering the balance of properties, especially the superior metabolic stability, longer half-life, better QED, and good binding affinity, Ligand A is the more promising drug candidate.
Output:
1
2025-04-17 23:06:15,034 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (a cardiovascular GPCR) drug candidates.
**Ligand A:** [377.868, 46.17, 4.846, 1, 2, 0.706, 87.01, 46.491, -4.674, -5.536, 0.676, 42.301, 70.75, 0.295, -6.2]
**Ligand B:** [360.38, 81.34, 3.092, 1, 5, 0.77, 52.734, 87.941, -4.507, -3.683, 0.676, 53.737, -10.9, 0.267, -6.2]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (360.38) is slightly lower, which is generally favorable for permeability, but both are acceptable.
2. **TPSA:** Ligand A (46.17) is significantly better than Ligand B (81.34). For a cardiovascular GPCR, we don't *require* extremely low TPSA for CNS penetration, but lower is still preferred for good absorption and reduced off-target interactions. Ligand B's TPSA is quite high.
3. **logP:** Ligand A (4.846) is a bit high, but still within a reasonable range. Ligand B (3.092) is optimal. This is a slight edge for Ligand B.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A (2) is better than Ligand B (5). Lower HBA generally improves permeability.
6. **QED:** Both are good (>= 0.5), with Ligand B (0.77) being slightly better.
7. **DILI:** Ligand A (87.01) has a higher DILI risk than Ligand B (52.734). This is a significant negative for Ligand A.
8. **BBB:** Both have moderate BBB penetration, but Ligand B (87.941) is better than Ligand A (46.491). While not a primary concern for a cardiovascular target, higher BBB is never detrimental.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. This is concerning for both.
10. **Solubility:** Both have negative solubility values, indicating poor solubility. This is concerning for both.
11. **hERG:** Both have low hERG risk (0.676), which is good.
12. **Cl_mic:** Ligand A (42.301) has lower microsomal clearance than Ligand B (53.737), indicating better metabolic stability. This is a positive for Ligand A.
13. **t1/2:** Ligand A (70.75) has a much longer in vitro half-life than Ligand B (-10.9). This is a major advantage for Ligand A.
14. **Pgp:** Both have low P-gp efflux liability (0.295 and 0.267), which is good.
15. **Affinity:** Both have the same binding affinity (-6.2 kcal/mol).
**Overall Assessment:**
Ligand A has a significant advantage in metabolic stability (lower Cl_mic, longer t1/2). It also has a better TPSA and HBA count. However, it has a higher DILI risk. Ligand B has a better logP and QED, and slightly better BBB penetration. Both suffer from poor Caco-2 and solubility.
Given the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), and considering the importance of metabolic stability for *in vivo* efficacy, the longer half-life and lower clearance of Ligand A outweigh its higher DILI risk, especially since the DILI risk is still not excessively high. The TPSA advantage of Ligand A is also significant.
Output:
1
2025-04-17 23:06:15,034 - INFO - Batch 380 complete. Total preferences: 6080
2025-04-17 23:06:15,034 - INFO - Processing batch 381/512...
2025-04-17 23:07:03,983 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (371.459) is slightly higher than Ligand B (345.443), but both are acceptable.
2. **TPSA:** Ligand A (92.09) is slightly higher than Ligand B (78.51). Both are below the 140 threshold for oral absorption, but Ligand B is preferable.
3. **logP:** Ligand A (1.523) and Ligand B (0.668) are both within the optimal 1-3 range, but closer to the lower end. Ligand A is better.
4. **HBD:** Ligand A (1) and Ligand B (2) are both acceptable, being less than 5.
5. **HBA:** Ligand A (5) and Ligand B (3) are both acceptable, being less than 10.
6. **QED:** Both ligands have reasonable QED values (A: 0.866, B: 0.719), indicating good drug-likeness. Ligand A is better.
7. **DILI:** Ligand A (56.689) has a higher DILI risk than Ligand B (23.575). Ligand B is significantly better here.
8. **BBB:** Ligand A (75.107) has a better BBB penetration percentile than Ligand B (52.385). This is important for GPCRs, even cardiovascular ones, as off-target effects are always a concern.
9. **Caco-2:** Ligand A (-4.472) and Ligand B (-5.067) are both negative, indicating poor permeability. Ligand B is slightly better.
10. **Solubility:** Ligand A (-2.718) and Ligand B (-1.755) are both poor. Ligand B is slightly better.
11. **hERG:** Ligand A (0.47) has a slightly higher hERG risk than Ligand B (0.129). Ligand B is better.
12. **Cl_mic:** Ligand A (35.461) has a higher microsomal clearance than Ligand B (-11.683). Ligand B is significantly better, indicating greater metabolic stability.
13. **t1/2:** Ligand A (11.508) has a longer half-life than Ligand B (3.274). Ligand A is better.
14. **Pgp:** Ligand A (0.055) has lower P-gp efflux than Ligand B (0.02). Both are very low, but Ligand A is slightly better.
15. **Affinity:** Ligand A (-6.6 kcal/mol) has a slightly weaker binding affinity than Ligand B (-7.0 kcal/mol). Ligand B is better.
**Overall Assessment:**
Given that this is an ADRB2 target (GPCR), the key priorities are affinity, logP, BBB, and metabolic stability. While Ligand A has a better BBB and half-life, Ligand B demonstrates a superior binding affinity, lower DILI risk, lower hERG risk, and significantly better metabolic stability (lower Cl_mic). The slightly better affinity of Ligand B, coupled with the improved safety profile and metabolic stability, outweigh the minor advantages of Ligand A.
**Output:**
0
2025-04-17 23:07:03,984 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (a cardiovascular GPCR) drug candidates.
**Ligand A:** [436.404, 45.15, 4.055, 0, 7, 0.618, 85.227, 83.637, -5.055, -3.648, 0.78, 59.069, -12.712, 0.798, -7.2]
**Ligand B:** [372.487, 92.78, 0.547, 1, 5, 0.672, 42.575, 71.307, -4.987, -2.541, 0.187, 46.789, -34.833, 0.074, -6.4]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity, and to a lesser extent BBB):
1. **MW:** Both are within the acceptable 200-500 Da range. Ligand B (372.487) is slightly preferred due to being lower.
2. **TPSA:** Ligand A (45.15) is much better than Ligand B (92.78). GPCRs benefit from lower TPSA for permeability. This is a significant advantage for A.
3. **logP:** Ligand A (4.055) is a bit high, but still within a manageable range. Ligand B (0.547) is *too* low, potentially causing permeability issues. A is favored here.
4. **HBD/HBA:** Ligand A (0/7) is better than Ligand B (1/5). Fewer hydrogen bond donors are generally preferred for better membrane permeability.
5. **QED:** Both are decent (A: 0.618, B: 0.672), indicating reasonable drug-likeness. B is slightly better.
6. **DILI:** Ligand A (85.227) has a significantly higher DILI risk than Ligand B (42.575). This is a major concern for A.
7. **BBB:** Ligand A (83.637) has better BBB penetration than Ligand B (71.307). While not a primary concern for a cardiovascular target, it's a slight positive for A.
8. **Caco-2:** Both are negative, indicating poor permeability.
9. **Solubility:** Both have negative solubility values, indicating poor solubility.
10. **hERG:** Ligand A (0.78) is better than Ligand B (0.187). Lower hERG inhibition is crucial for avoiding cardiotoxicity.
11. **Cl_mic:** Ligand B (46.789) has a lower microsomal clearance than Ligand A (59.069), suggesting better metabolic stability.
12. **t1/2:** Ligand B (-34.833) has a much longer half-life than Ligand A (-12.712). This is a significant advantage for B.
13. **Pgp:** Ligand A (0.798) has lower P-gp efflux than Ligand B (0.074), which is favorable for bioavailability.
14. **Affinity:** Ligand A (-7.2 kcal/mol) has a stronger binding affinity than Ligand B (-6.4 kcal/mol). This is a substantial advantage for A.
**Overall Assessment:**
Ligand A has a significantly better binding affinity and lower P-gp efflux, but suffers from higher DILI risk and a higher logP. Ligand B has better metabolic stability (lower Cl_mic, longer t1/2) and lower DILI risk, but weaker binding affinity and a very low logP.
Given the importance of potency for GPCRs, and the fact that the affinity difference is substantial (0.8 kcal/mol), I would lean towards **Ligand A**, *despite* the higher DILI risk. The DILI risk could potentially be mitigated through structural modifications, but improving the binding affinity of Ligand B would be more challenging. The lower logP of Ligand B is also a major concern for permeability.
Output:
1
2025-04-17 23:07:03,984 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [350.459, 95.5, 1.475, 3, 4, 0.433, 21.83, 63.862, -4.995, -2.233, 0.077, 25.464, -32.316, 0.014, -6]
**Ligand B:** [367.471, 80.76, 1.083, 1, 6, 0.814, 41.877, 56.34, -4.978, -2.421, 0.419, 25.337, 18.713, 0.043, -4.9]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (350.459) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (95.5) is higher than Ligand B (80.76). Both are acceptable for a non-CNS GPCR target like ADRB2, but Ligand B is better.
3. **logP:** Both are within the optimal range (1-3). Ligand B (1.083) is slightly lower, which could potentially affect permeability, but still reasonable.
4. **HBD:** Ligand A (3) is higher than Ligand B (1). Lower is generally better for permeability, so Ligand B is preferred.
5. **HBA:** Ligand A (4) is lower than Ligand B (6). Lower is generally better for permeability, so Ligand A is preferred.
6. **QED:** Ligand B (0.814) has a significantly better QED score than Ligand A (0.433), indicating a more drug-like profile.
7. **DILI:** Ligand A (21.83) has a much lower DILI risk than Ligand B (41.877). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (63.862) has a higher BBB penetration percentile than Ligand B (56.34). While ADRB2 isn't a primary CNS target, some peripheral exposure can be undesirable, so this is a slight advantage for Ligand A.
9. **Caco-2:** Both have similar, very poor Caco-2 permeability scores (-4.995 and -4.978). This is a concern for both compounds.
10. **Solubility:** Both have similar, very poor solubility scores (-2.233 and -2.421). This is a concern for both compounds.
11. **hERG:** Ligand A (0.077) has a lower hERG risk than Ligand B (0.419), which is a significant advantage.
12. **Cl_mic:** Both have similar microsomal clearance values (25.464 and 25.337), suggesting similar metabolic stability.
13. **t1/2:** Ligand A (-32.316) has a much longer in vitro half-life than Ligand B (18.713). This is a significant advantage for Ligand A.
14. **Pgp:** Both have very low Pgp efflux liability (0.014 and 0.043).
15. **Affinity:** Ligand A (-6) has slightly better binding affinity than Ligand B (-4.9).
**GPCR-specific priorities:** For ADRB2, logP, TPSA, Pgp, and affinity are important. Ligand B has a slightly better logP and TPSA, and they both have good Pgp profiles. Ligand A has a better affinity. However, the significant advantages of Ligand A in terms of DILI risk, hERG inhibition, and in vitro half-life outweigh the minor differences in logP and TPSA. The poor Caco-2 and solubility are concerns for both, but can be addressed with formulation strategies.
**Conclusion:**
Considering the balance of properties, particularly the lower DILI, hERG, and better half-life, and the slightly better affinity, Ligand A is the more promising drug candidate.
Output:
1
2025-04-17 23:07:03,984 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [384.929, 66.48, 3.361, 1, 3, 0.868, 47.693, 87.67, -4.47, -4.545, 0.578, 26.408, 53.419, 0.196, -6.9]
**Ligand B:** [336.399, 94.8, 1.758, 1, 6, 0.914, 54.285, 51.687, -5.179, -2.271, 0.237, -14.188, 15.432, 0.007, -5.6]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (336.399 Da) is slightly lower, which *could* be beneficial for permeability, but both are acceptable.
2. **TPSA:** Ligand A (66.48) is significantly better than Ligand B (94.8). For a cardiovascular GPCR, we don't *require* extremely low TPSA for CNS penetration, but lower is generally preferred for good absorption. Ligand B is pushing the upper limit for good oral absorption.
3. **logP:** Ligand A (3.361) is optimal. Ligand B (1.758) is on the lower side, potentially hindering permeability.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A (3) is better than Ligand B (6). Higher HBA can sometimes lead to decreased permeability.
6. **QED:** Both have good QED scores (A: 0.868, B: 0.914), indicating drug-like properties.
7. **DILI:** Both have acceptable DILI risk (A: 47.693, B: 54.285), below the concerning threshold of 60.
8. **BBB:** Ligand A (87.67) has a much higher BBB penetration score than Ligand B (51.687). While not a primary concern for a cardiovascular target, higher BBB is never a detriment.
9. **Caco-2:** Ligand A (-4.47) is better than Ligand B (-5.179), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-4.545) is better than Ligand B (-2.271).
11. **hERG:** Ligand A (0.578) is better than Ligand B (0.237). Lower hERG inhibition is crucial for avoiding cardiotoxicity.
12. **Cl_mic:** Ligand B (-14.188) has significantly lower microsomal clearance than Ligand A (26.408), suggesting better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand A (53.419) has a longer in vitro half-life than Ligand B (15.432).
14. **Pgp:** Ligand A (0.196) has lower P-gp efflux than Ligand B (0.007), which is better for bioavailability.
15. **Affinity:** Ligand A (-6.9 kcal/mol) has a slightly better binding affinity than Ligand B (-5.6 kcal/mol). This is a 1.3 kcal/mol difference, which is significant enough to outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand A is generally superior across most ADME properties (TPSA, logP, HBA, BBB, Caco-2, Solubility, hERG, Pgp) and has a slightly better binding affinity. Ligand B's main advantage is its significantly lower microsomal clearance. However, the overall balance of properties in Ligand A, particularly its better permeability-related parameters and lower hERG risk, make it a more promising drug candidate for a cardiovascular GPCR like ADRB2. The slightly better affinity further solidifies this preference.
Output:
1
2025-04-17 23:07:03,985 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.471 and 356.423 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (58.64) is significantly better than Ligand B (125.71). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold, while B is approaching it.
3. **logP:** Ligand A (2.292) is optimal, while Ligand B (0.572) is a bit low. A logP below 1 can sometimes hinder permeability. Ligand A has a clear advantage.
4. **HBD:** Ligand A (1) is preferable to Ligand B (4). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (7). Similar reasoning as HBD.
6. **QED:** Both ligands have acceptable QED values (0.286 and 0.479), but Ligand B is slightly better.
7. **DILI:** Ligand A (13.571) has a much lower DILI risk than Ligand B (57.697). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (70.764) has a higher BBB penetration than Ligand B (15.277). While not critical for a cardiovascular target, higher BBB is generally favorable.
9. **Caco-2:** Ligand A (-4.711) has a better Caco-2 permeability than Ligand B (-5.483).
10. **Solubility:** Ligand A (-2.071) has a better solubility than Ligand B (-2.343).
11. **hERG:** Both ligands have low hERG inhibition risk (0.313 and 0.131). No significant difference.
12. **Cl_mic:** Ligand A (5) has a much lower microsomal clearance than Ligand B (26.89). This indicates better metabolic stability for Ligand A.
13. **t1/2:** Ligand B (-23.271) has a much longer in vitro half-life than Ligand A (-1.414). This is a significant advantage for Ligand B.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.1 and 0.05). No significant difference.
15. **Binding Affinity:** Ligand B (-6.6) has a slightly better binding affinity than Ligand A (-5.8). The difference is 0.8 kcal/mol, which is not substantial enough to outweigh other factors.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand A excels in logP and TPSA. While Ligand B has slightly better affinity, the differences in ADME properties (DILI, Cl_mic, solubility, permeability) are substantial.
**Overall Assessment:**
Ligand A demonstrates a significantly more favorable ADME profile, with lower DILI risk, better metabolic stability, and better permeability characteristics. The slightly weaker binding affinity of Ligand A is unlikely to be a major issue, given its superior drug-like properties. Ligand B's longer half-life is a positive, but the higher DILI risk and poorer ADME properties are concerning.
Output:
1
2025-04-17 23:07:03,985 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (339.355) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (110) is higher than the ideal <140 for oral absorption, but still reasonable. Ligand B (49.41) is excellent, well below 140 and suggesting good absorption.
3. **logP:** Both ligands have good logP values (A: 1.179, B: 1.742), falling within the 1-3 range.
4. **HBD:** Ligand A (2) and B (1) are both acceptable.
5. **HBA:** Ligand A (6) and B (3) are both acceptable.
6. **QED:** Both ligands have similar QED values (A: 0.698, B: 0.657), indicating good drug-likeness.
7. **DILI:** Ligand A (90.229) has a significantly higher DILI risk than Ligand B (33.695). This is a major concern for Ligand A.
8. **BBB:** Ligand B (83.482) has a much higher BBB penetration percentile than Ligand A (44.668). While ADRB2 isn't strictly a CNS target, some CNS exposure can occur, and higher BBB is generally preferable to avoid off-target effects.
9. **Caco-2:** Ligand A (-5.838) and B (-4.926) are both negative, which is unusual and indicates poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Both ligands have poor aqueous solubility (-3.126 and -3.832 respectively).
11. **hERG:** Ligand A (0.031) has a slightly better hERG profile than Ligand B (0.475), but both are low risk.
12. **Cl_mic:** Ligand A (-7.339) has a much lower (better) microsomal clearance than Ligand B (27.042), indicating better metabolic stability.
13. **t1/2:** Ligand A (10.769) has a better in vitro half-life than Ligand B (-21.133).
14. **Pgp:** Ligand A (0.051) has a lower Pgp efflux liability than Ligand B (0.079), which is favorable.
15. **Affinity:** Ligand A (-6.7 kcal/mol) has a slightly better binding affinity than Ligand B (-5.2 kcal/mol). This is a 1.5 kcal/mol difference, which is significant.
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Ligand B excels in TPSA and BBB, while Ligand A has a slightly better affinity and Pgp profile. However, the *major* drawback for Ligand A is its high DILI risk. This is a critical factor that outweighs its slightly better affinity and metabolic stability.
**Conclusion:**
Despite the slightly better affinity of Ligand A, the significantly higher DILI risk makes it a less desirable candidate. Ligand B, with its lower DILI risk, better TPSA, and acceptable overall profile, is the more promising option.
Output:
0
2025-04-17 23:07:03,985 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
We are targeting ADRB2, a GPCR, so the priorities are logP, TPSA, Pgp, BBB, and affinity. Let's compare the ligands property by property:
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (340.467) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (62.22) is significantly better than Ligand B (114.19). ADRB2 is not a CNS target, but lower TPSA generally aids absorption.
3. **logP:** Ligand A (3.388) is optimal, while Ligand B (1.431) is on the lower side. A logP between 1-3 is preferred, and Ligand A is closer to this.
4. **HBD/HBA:** Both have 2 HBD and are within acceptable limits. Ligand B has 7 HBA which is higher than the preferred <10, but not drastically so.
5. **QED:** Both are good (above 0.5), indicating drug-likeness.
6. **DILI:** Ligand B (60.45) has a higher DILI risk than Ligand A (42.458), making A preferable.
7. **BBB:** Both are around 60%, which is not a major consideration for ADRB2 (a cardiovascular target).
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
9. **Solubility:** Both have negative solubility values, which is also unusual.
10. **hERG:** Ligand A (0.698) has a slightly higher hERG risk than Ligand B (0.098), but both are relatively low.
11. **Cl_mic:** Ligand B (-15.994) has *much* better metabolic stability (lower clearance) than Ligand A (73.82). This is a significant advantage.
12. **t1/2:** Ligand B (47.083) has a longer half-life than Ligand A (26.517), which is desirable.
13. **Pgp:** Ligand A (0.674) has a lower Pgp efflux, which is preferable.
14. **Affinity:** Ligand B (-7.4) has a significantly stronger binding affinity than Ligand A (-6.0). This is a substantial advantage and can often outweigh other drawbacks.
**Overall Assessment:**
Ligand B has a much stronger binding affinity and better metabolic stability (Cl_mic and t1/2). While Ligand A has better TPSA, logP, and Pgp efflux, the difference in binding affinity (-1.4 kcal/mol) is substantial. Given the GPCR target class, affinity is paramount. The slightly higher DILI risk for Ligand A is a concern, but the strong binding of Ligand B is likely to outweigh this.
**Output:**
0
2025-04-17 23:07:03,985 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's systematically compare Ligand A and Ligand B based on the provided parameters and the guidelines, keeping in mind ADRB2 is a GPCR and thus we prioritize logP, Pgp, TPSA, and affinity.
1. **MW:** Both ligands (412.3 & 377.9) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (38.13) is significantly better than Ligand A (70.23). Lower TPSA generally improves permeability, a key factor for GPCR ligands.
3. **logP:** Ligand A (2.648) is optimal, while Ligand B (4.078) is pushing the upper limit. While still acceptable, higher logP can sometimes lead to off-target effects and solubility issues.
4. **HBD/HBA:** Ligand A has 3 HBD and 3 HBA, while Ligand B has 0 HBD and 5 HBA. Both are within acceptable limits, but the lower HBD of Ligand B might be slightly favorable for membrane permeability.
5. **QED:** Ligand B (0.761) has a better QED score than Ligand A (0.515), indicating a more drug-like profile.
6. **DILI:** Ligand B (28.887) has a significantly lower DILI risk than Ligand A (41.877), which is a major advantage.
7. **BBB:** Ligand B (81.698) shows much better BBB penetration potential than Ligand A (49.903). While ADRB2 isn't exclusively a CNS target, some cardiovascular effects are mediated by central pathways, and better BBB penetration can be beneficial.
8. **Caco-2:** Both are negative, indicating poor permeability.
9. **Solubility:** Both ligands have very poor solubility.
10. **hERG:** Both ligands have low hERG inhibition risk.
11. **Cl_mic:** Ligand A (15.512) has a lower microsomal clearance than Ligand B (48.257), indicating better metabolic stability. This is a positive for Ligand A.
12. **t1/2:** Ligand A (58.497) has a significantly longer in vitro half-life than Ligand B (7.21), which is a major advantage.
13. **Pgp:** Ligand A (0.135) has lower P-gp efflux liability than Ligand B (0.677), which is favorable for bioavailability.
14. **Binding Affinity:** Ligand B (-7.7 kcal/mol) has a substantially stronger binding affinity than Ligand A (-5.3 kcal/mol). This is a very significant advantage, potentially outweighing some of the ADME drawbacks.
**Overall Assessment:**
Ligand B has a much better binding affinity, lower DILI risk, better BBB penetration, and a superior QED score. While Ligand A has better metabolic stability (lower Cl_mic) and half-life, the substantial affinity advantage of Ligand B is crucial for a GPCR target. The slightly higher logP of Ligand B is a minor concern, but the benefits outweigh this potential drawback. The poor Caco-2 and solubility are a concern for both.
Output:
0
2025-04-17 23:07:03,986 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (385.848 Da) is within the ideal range. Ligand B (345.399 Da) is also within the ideal range, slightly lower. No clear advantage here.
2. **TPSA:** Ligand A (79.37) is good, below the 140 threshold. Ligand B (93.45) is still acceptable, but closer to the threshold. Ligand A is slightly preferred.
3. **logP:** Both ligands have good logP values (A: 2.939, B: 1.446) within the 1-3 range. Ligand A is slightly better, indicating potentially better membrane permeability.
4. **HBD:** Ligand A (1) is good. Ligand B (2) is also acceptable. No significant difference.
5. **HBA:** Ligand A (4) is good. Ligand B (5) is also acceptable. No significant difference.
6. **QED:** Both ligands have reasonable QED scores (A: 0.802, B: 0.755), indicating good drug-like properties. Ligand A is slightly better.
7. **DILI:** Ligand A (85.576) has a higher DILI risk than Ligand B (56.262). This is a significant drawback for Ligand A.
8. **BBB:** Ligand A (53.47) has a moderate BBB penetration, while Ligand B (33.23) is lower. While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be useful for understanding off-target effects.
9. **Caco-2:** Ligand A (-4.683) has a very poor Caco-2 permeability. Ligand B (-5.527) is also poor, but slightly better.
10. **Solubility:** Ligand A (-4.835) has poor solubility. Ligand B (-1.522) has better solubility. This is a significant advantage for Ligand B.
11. **hERG:** Ligand A (0.422) has a slightly higher hERG risk than Ligand B (0.028). Ligand B is significantly better here.
12. **Cl_mic:** Ligand A (61.444) has a moderate clearance. Ligand B (-5.14) has a *negative* clearance, which is highly unusual and suggests very high metabolic stability. This is a major advantage for Ligand B.
13. **t1/2:** Ligand A (45.075) has a reasonable half-life. Ligand B (-11.785) has a negative half-life, which is also unusual and suggests extremely long *in vitro* stability.
14. **Pgp:** Ligand A (0.251) has low P-gp efflux. Ligand B (0.013) has even lower P-gp efflux. No significant difference.
15. **Affinity:** Ligand B (-7.7) has a slightly better binding affinity than Ligand A (-7.3). While the difference is small (0.4 kcal/mol), it's still a positive for Ligand B.
**Overall Assessment:**
Ligand B is significantly better overall. While Ligand A has a slightly better logP and QED, Ligand B excels in crucial ADME properties: significantly lower DILI risk, better solubility, *much* better metabolic stability (negative Cl_mic and t1/2), and slightly better binding affinity. The poor Caco-2 permeability of both is a concern, but the other advantages of Ligand B outweigh this drawback. For a GPCR target like ADRB2, metabolic stability and minimizing off-target effects (DILI, hERG) are critical.
Output:
0
2025-04-17 23:07:03,986 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (364.392 and 358.423 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (52.89) is significantly better than Ligand B (95.42). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold. Ligand B is approaching the upper limit.
3. **logP:** Ligand A (3.839) is good, within the optimal 1-3 range. Ligand B (1.726) is on the lower side, potentially impacting permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (3) is better than Ligand B (6). Similar reasoning as HBD - fewer is generally better for permeability.
6. **QED:** Both ligands have good QED scores (0.76 and 0.868), indicating good drug-like properties.
7. **DILI:** Ligand A (53.432) has a slightly better DILI score than Ligand B (60.217), indicating lower potential for liver injury. Both are acceptable, but lower is always preferred.
8. **BBB:** Ligand A (83.443) has a significantly higher BBB penetration score than Ligand B (40.093). While not a primary concern for a cardiovascular target, higher BBB is rarely detrimental.
9. **Caco-2:** Ligand A (-4.74) is better than Ligand B (-5.306). Higher values indicate better intestinal absorption.
10. **Solubility:** Ligand A (-5.189) is better than Ligand B (-4.126). Higher solubility is generally desirable.
11. **hERG:** Ligand A (0.941) has a slightly better hERG score than Ligand B (0.09), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand B (37.354) has a much lower microsomal clearance than Ligand A (67.573), suggesting better metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand B (-26.268) has a much longer in vitro half-life than Ligand A (8.678). This is a major advantage for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.343) has a lower P-gp efflux liability than Ligand B (0.035). Lower efflux is generally preferred.
15. **Binding Affinity:** Ligand A (-6.7) has a significantly stronger binding affinity than Ligand B (-3.1). This is a substantial advantage. A difference of 3.6 kcal/mol is quite large and can often outweigh minor ADME concerns.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A excels in these areas. While metabolic stability (Cl_mic and t1/2) are important, the substantial affinity advantage of Ligand A is likely to be more impactful.
**Overall Assessment:**
Ligand A has a clear advantage in binding affinity, TPSA, logP, solubility, and Pgp efflux. Ligand B has better metabolic stability and half-life. However, the significantly stronger binding affinity of Ligand A is a critical factor for a GPCR target, and the other favorable properties of Ligand A outweigh the metabolic advantages of Ligand B.
Output:
1
2025-04-17 23:07:03,986 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (358.28 and 375.54 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (117.2) is higher than Ligand B (71.11). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B is significantly better.
3. **logP:** Ligand A (1.252) is within the optimal range (1-3), while Ligand B (0.438) is slightly below, potentially impacting permeability. Ligand A is better.
4. **HBD:** Ligand A (3) is higher than Ligand B (1), but both are acceptable (<=5).
5. **HBA:** Ligand A (5) and Ligand B (6) are both within the acceptable range (<=10).
6. **QED:** Ligand A (0.757) has a better QED score than Ligand B (0.597), indicating a more drug-like profile.
7. **DILI:** Ligand B (21.4) has a *much* lower DILI risk than Ligand A (89.1). This is a major advantage for Ligand B.
8. **BBB:** Both ligands have similar BBB penetration (64.7% and 66.8%). Not a primary concern for a cardiovascular target.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.528 and -5.218), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-3.365) and Ligand B (-1.194) both have negative solubility values, indicating poor aqueous solubility. Ligand B is slightly better.
11. **hERG:** Ligand A (0.059) has a slightly lower hERG risk than Ligand B (0.249), which is preferable.
12. **Cl_mic:** Ligand A (-13.895) has a *much* lower (better) microsomal clearance than Ligand B (4.927), indicating greater metabolic stability.
13. **t1/2:** Ligand A (-24.555) has a more negative in vitro half-life, which is not ideal, but Ligand B (-2.225) is also unfavorable.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.007 and 0.01).
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.6 and -5.4 kcal/mol). Ligand A is slightly better, but the difference is not substantial.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A has a better logP and slightly better affinity. Ligand B has a much better TPSA and a significantly lower DILI risk.
**Overall Assessment:**
While Ligand A has a slightly better logP, QED, and affinity, the significantly lower DILI risk of Ligand B is a critical advantage. The poor Caco-2 and solubility are concerns for both, but the DILI risk is a major safety concern that outweighs the minor advantages of Ligand A. The better metabolic stability (lower Cl_mic) of Ligand A is also a positive, but the DILI risk is more concerning.
Therefore, I believe Ligand B is the more viable drug candidate.
Output:
0
2025-04-17 23:07:03,986 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (352.475 Da and 348.447 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (78.87) is better than Ligand B (85.77). Both are below 140, but lower TPSA generally favors better absorption.
**3. logP:** Ligand A (1.46) is slightly higher than Ligand B (0.952), both are within the optimal 1-3 range.
**4. H-Bond Donors:** Both ligands have 2 HBD, which is within the acceptable limit of <=5.
**5. H-Bond Acceptors:** Ligand A has 4 HBA, while Ligand B has 5. Both are acceptable (<=10), but A is slightly preferred.
**6. QED:** Both ligands have good QED scores (0.624 and 0.766, respectively), indicating good drug-likeness.
**7. DILI:** Ligand A (16.712) has a lower DILI risk than Ligand B (18.651), which is preferable. Both are below 40, indicating low risk.
**8. BBB:** Ligand A (64.211) has a significantly higher BBB penetration percentile than Ligand B (36.371). While ADRB2 is cardiovascular, some CNS effects are possible with beta-blockers, and higher BBB penetration could be relevant for off-target effects, or potential for CNS-related side effects.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-5.027 and -5.2), which is unusual and suggests poor permeability. This is a significant concern for both.
**10. Aqueous Solubility:** Both ligands have negative solubility values (-2.166 and -1.348), indicating very poor aqueous solubility. This is a major drawback for both.
**11. hERG Inhibition:** Ligand A (0.425) has a lower hERG inhibition liability than Ligand B (0.245), which is a positive. Lower is better.
**12. Microsomal Clearance:** Ligand B (-23.136) has a *much* lower (better) microsomal clearance than Ligand A (41.985). This indicates significantly improved metabolic stability for Ligand B.
**13. In vitro Half-Life:** Ligand B (-12.494) has a longer in vitro half-life than Ligand A (31.583), further supporting its better metabolic stability.
**14. P-gp Efflux:** Ligand A (0.088) has slightly lower P-gp efflux liability than Ligand B (0.009), which is preferable.
**15. Binding Affinity:** Ligand A (-6.9 kcal/mol) has a slightly better binding affinity than Ligand B (-6.1 kcal/mol). This is a 1.5 kcal/mol advantage, which is significant.
**Overall Assessment:**
Despite both ligands having significant issues with solubility and Caco-2 permeability, Ligand A is slightly more favorable. The better binding affinity, lower DILI risk, better BBB penetration, and lower hERG inhibition outweigh the worse metabolic stability. The affinity difference is substantial enough to consider it a key advantage. The poor permeability and solubility are major hurdles for both, but formulation strategies could potentially address these.
Output:
1
2025-04-17 23:07:03,986 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (342.439 Da and 341.411 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (60.45) is significantly better than Ligand B (83.36). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (3.63) is good, falling within the optimal 1-3 range. Ligand B (1.321) is on the lower side, potentially hindering permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Both ligands have 4 HBA, which is acceptable.
6. **QED:** Ligand A (0.835) has a slightly better QED score than Ligand B (0.767), suggesting a more drug-like profile.
7. **DILI:** Ligand B (38.154) has a much lower DILI risk than Ligand A (58.705). This is a significant advantage for Ligand B.
8. **BBB:** Ligand B (65.374) has a higher BBB penetration percentile than Ligand A (51.415). While not critical for a cardiovascular target, it's a slight positive.
9. **Caco-2:** Both ligands have very poor Caco-2 permeability (-4.584 and -4.823). This is a major concern for both.
10. **Solubility:** Ligand B (-2.353) has better solubility than Ligand A (-4.733). Solubility is important for bioavailability.
11. **hERG:** Both ligands have low hERG inhibition risk (0.496 and 0.198). No significant difference.
12. **Cl_mic:** Ligand A (100.086) has a much higher microsomal clearance than Ligand B (-16.514). This suggests Ligand B is more metabolically stable.
13. **t1/2:** Ligand B (16.922) has a significantly longer in vitro half-life than Ligand A (6.501). This is a major advantage for Ligand B.
14. **Pgp:** Ligand B (0.07) has lower P-gp efflux than Ligand A (0.154). This is favorable for bioavailability.
15. **Binding Affinity:** Both ligands have comparable binding affinity (-5.8 kcal/mol and -5.7 kcal/mol). The difference is negligible.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, and metabolic stability (Cl_mic, t1/2) are important. Ligand B excels in logP, Cl_mic, t1/2, and Pgp efflux, while Ligand A has a better TPSA. The significantly lower DILI risk for Ligand B is also a strong positive. While both have poor Caco-2 permeability, the overall profile of Ligand B is more favorable due to its better ADME properties and safety profile.
**Output:**
0
2025-04-17 23:07:03,987 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's break down the comparison of Ligand A and Ligand B, considering the provided guidelines and GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key).
1. **Molecular Weight:** Both ligands (358.429 Da and 378.485 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (69.64) is slightly higher than Ligand B (49.85). Both are below 140, suggesting good oral absorption potential. Ligand B is preferable here, being closer to the ideal for GPCRs.
3. **logP:** Both ligands have logP values within the optimal 1-3 range (1.899 and 2.107). No clear advantage.
4. **H-Bond Donors:** Ligand A has 2 HBD, while Ligand B has 0. Lower HBD is generally preferred for better permeability, making Ligand B slightly better.
5. **H-Bond Acceptors:** Ligand A has 3 HBA, and Ligand B has 4. Both are within the acceptable limit of 10.
6. **QED:** Both ligands have similar QED values (0.738 and 0.71), indicating good drug-likeness.
7. **DILI Risk:** Ligand A (12.33) has a significantly lower DILI risk than Ligand B (31.485). This is a major advantage for Ligand A.
8. **BBB Penetration:** Both ligands show good BBB penetration (81.427% and 85.731%), which is good, but not a primary concern for a cardiovascular target like ADRB2. Ligand B is slightly better.
9. **Caco-2 Permeability:** Both exhibit negative Caco-2 values, which is unusual and suggests potential issues with permeability prediction. However, the values are similar (-4.895 and -4.464).
10. **Aqueous Solubility:** Both ligands have very poor predicted aqueous solubility (-2.123 and -2.906). This is a concern for both, and formulation strategies would be needed.
11. **hERG Inhibition:** Ligand A (0.297) has a much lower hERG inhibition risk than Ligand B (0.643). This is a significant advantage for Ligand A, as hERG inhibition can lead to cardiotoxicity.
12. **Microsomal Clearance:** Ligand A (-15.805) has a much lower (better) microsomal clearance than Ligand B (39.309), indicating greater metabolic stability.
13. **In vitro Half-Life:** Ligand A (-15.062) has a more negative value, which, in this context, suggests a longer half-life than Ligand B (-6.872).
14. **P-gp Efflux:** Ligand A (0.038) has a lower P-gp efflux liability than Ligand B (0.191), suggesting better oral bioavailability.
15. **Binding Affinity:** Ligand A (-6.8 kcal/mol) and Ligand B (-6.5 kcal/mol) have similar binding affinities. The difference of 0.3 kcal/mol is not substantial enough to outweigh other factors.
**Overall Assessment:**
Ligand A is the stronger candidate. While both ligands have some drawbacks (poor solubility), Ligand A demonstrates a significantly better safety profile (lower DILI, lower hERG inhibition) and improved pharmacokinetic properties (lower clearance, longer half-life, lower P-gp efflux). These factors are crucial for a viable drug candidate, especially considering the cardiovascular context where safety is paramount. The slightly better TPSA and BBB penetration of Ligand B are not enough to offset the advantages of Ligand A.
**Output:**
1
2025-04-17 23:07:03,987 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (345.443 and 374.819 Da) are within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Both ligands (70.67 and 76.02) are below the 140 A^2 threshold for good oral absorption, but also not optimized for CNS penetration (below 90). No significant difference.
3. **logP:** Both ligands (2.014 and 2.056) fall within the optimal 1-3 range. No clear advantage.
4. **HBD:** Both have 2 HBD, which is acceptable.
5. **HBA:** Both have 4 HBA, which is acceptable.
6. **QED:** Ligand A (0.756) has a better QED score than Ligand B (0.513), suggesting a more drug-like profile. This is a positive for A.
7. **DILI:** Ligand A (31.718) has a significantly lower DILI risk than Ligand B (48.468). This is a major advantage for A, as minimizing liver toxicity is crucial.
8. **BBB:** Both ligands have good BBB penetration (80.574 and 83.443). No significant difference.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.576 and -4.916), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Both ligands have negative solubility values (-2.816 and -3.188), indicating very poor aqueous solubility. This is a significant drawback for both.
11. **hERG:** Both ligands have low hERG inhibition risk (0.552 and 0.26). No significant difference.
12. **Cl_mic:** Ligand B (32.541) has a slightly lower microsomal clearance than Ligand A (39.784), suggesting better metabolic stability. This is a slight advantage for B.
13. **t1/2:** Ligand B (4.079) has a longer in vitro half-life than Ligand A (30.832). This is a significant advantage for B, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.029 and 0.123). No significant difference.
15. **Binding Affinity:** Ligand B (-6.6 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.8 kcal/mol). This is a substantial advantage for B, potentially outweighing some of the ADME drawbacks.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, Pgp, TPSA, and affinity. Both ligands perform similarly on logP, Pgp, and TPSA. However, Ligand B has a 0.8 kcal/mol advantage in binding affinity, which is substantial.
**Overall Assessment:**
While Ligand A has a better QED and significantly lower DILI risk, Ligand B's stronger binding affinity and longer half-life are more critical for a GPCR target. The poor solubility and Caco-2 permeability are concerning for both, but can potentially be addressed through formulation strategies. The lower DILI risk of Ligand A is attractive, but the potency advantage of Ligand B is more impactful for initial efficacy.
Output:
0
2025-04-17 23:07:03,987 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (344.46 and 348.40 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (66.4) is significantly better than Ligand B (99.77). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is approaching a level that could hinder oral absorption.
3. **logP:** Ligand A (2.286) is better than Ligand B (1.13), falling squarely within the optimal 1-3 range. Ligand B is a bit low, potentially impacting membrane permeability.
4. **HBD:** Ligand A (0) is preferable to Ligand B (1). Fewer hydrogen bond donors generally improve permeability.
5. **HBA:** Ligand A (4) is better than Ligand B (6). Lower HBA is generally preferred for better permeability.
6. **QED:** Both ligands have good QED scores (0.825 and 0.875), indicating good drug-like properties. No clear advantage.
7. **DILI:** Ligand A (35.79%) has a lower DILI risk than Ligand B (46.22%). This is a significant advantage, as lower DILI is always desirable.
8. **BBB:** Ligand A (80.57%) has a higher BBB penetration score than Ligand B (72.94%). While ADRB2 isn't exclusively a CNS target, some CNS exposure can occur, and higher BBB is generally favorable.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.692 and -4.826), which is unusual and suggests poor permeability. However, the values are similar.
10. **Solubility:** Both ligands have negative solubility values (-2.035 and -2.173), which is also unusual and suggests poor aqueous solubility. The values are very similar.
11. **hERG:** Ligand A (0.436) has a lower hERG inhibition liability than Ligand B (0.075). This is a crucial advantage, reducing the risk of cardiotoxicity.
12. **Cl_mic:** Ligand A (39.753) has a significantly lower microsomal clearance than Ligand B (6.868). This indicates better metabolic stability for Ligand A.
13. **t1/2:** Ligand B (2.177) has a longer in vitro half-life than Ligand A (-0.653). This is a positive for Ligand B, but the negative value for A is concerning.
14. **Pgp:** Ligand A (0.196) has lower P-gp efflux liability than Ligand B (0.074). Lower P-gp efflux is generally preferred for improved bioavailability.
15. **Binding Affinity:** Ligand B (-7.1 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.2 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME drawbacks of Ligand B.
**Overall Assessment:**
Ligand B has a much stronger binding affinity, which is a critical factor for GPCR targets. However, Ligand A demonstrates a superior ADME profile across several key parameters: TPSA, logP, DILI, hERG, Cl_mic, and Pgp. The lower hERG risk and better metabolic stability of Ligand A are particularly important. While the half-life is concerning for Ligand A, the other advantages are substantial. The Caco-2 and solubility values are poor for both, suggesting formulation challenges would need to be addressed regardless of which ligand is chosen. Given the balance, the stronger affinity of Ligand B is likely to be more impactful, despite the ADME concerns.
Output:
0
2025-04-17 23:07:03,987 - INFO - Batch 381 complete. Total preferences: 6096
2025-04-17 23:07:03,987 - INFO - Processing batch 382/512...
2025-04-17 23:07:56,577 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (a cardiovascular GPCR) drug candidates.
**Ligand A:** [346.435, 84.22, 0.725, 0., 6., 0.75, 38.969, 71.656, -5.001, -1.575, 0.075, 26.787, -8.49, 0.087, -6.6]
**Ligand B:** [340.467, 58.2, 3.108, 2., 2., 0.715, 25.204, 64.831, -4.572, -3.453, 0.363, 53.489, -3.957, 0.095, -6.5]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal 200-500 Da range. Ligand A (346.435 Da) is slightly higher than Ligand B (340.467 Da), but the difference is negligible.
2. **TPSA:** Ligand A (84.22) is better than Ligand B (58.2). Both are below 140, but Ligand B is significantly lower, which is favorable for permeability.
3. **logP:** Ligand A (0.725) is a bit low, potentially hindering permeability. Ligand B (3.108) is within the optimal 1-3 range. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (0) is excellent. Ligand B (2) is acceptable, but more donors can sometimes lead to issues.
5. **HBA:** Ligand A (6) is good. Ligand B (2) is very good.
6. **QED:** Both are similar (0.75 vs 0.715), indicating good drug-likeness.
7. **DILI:** Ligand A (38.969) is better than Ligand B (25.204), indicating lower potential for liver injury.
8. **BBB:** Ligand A (71.656) is better than Ligand B (64.831). While ADRB2 is a cardiovascular target, some brain exposure can be relevant for peripheral effects mediated via the CNS.
9. **Caco-2:** Ligand A (-5.001) is better than Ligand B (-4.572). Higher values indicate better absorption.
10. **Solubility:** Ligand A (-1.575) is better than Ligand B (-3.453).
11. **hERG:** Ligand A (0.075) is much better than Ligand B (0.363), indicating a lower risk of cardiotoxicity. This is *crucial* for a cardiovascular target.
12. **Cl_mic:** Ligand A (26.787) is significantly better than Ligand B (53.489), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-8.49) is better than Ligand B (-3.957), indicating a longer half-life.
14. **Pgp:** Ligand A (0.087) is better than Ligand B (0.095), suggesting lower P-gp efflux.
15. **Affinity:** Both are very similar (-6.6 vs -6.5 kcal/mol). The difference is not substantial enough to override other factors.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Ligand B has a better logP and lower TPSA, but Ligand A has a significantly better hERG profile, metabolic stability, solubility, and half-life. The hERG risk is a major concern for cardiovascular drugs, and Ligand A is much safer in this regard.
**Conclusion:**
Despite Ligand B having a slightly more optimal logP and TPSA, the superior safety profile (hERG, DILI), metabolic stability, and solubility of Ligand A make it the more promising drug candidate. The small difference in binding affinity is outweighed by the ADME/Tox advantages of Ligand A.
**Output:**
1
2025-04-17 23:07:56,577 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (367.921 and 350.478 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Both are around 53, slightly above the optimal <90 for CNS targets, but acceptable for a peripheral GPCR like ADRB2. No significant difference.
3. **logP:** Ligand A (1.699) is better than Ligand B (3.684). Ligand B is pushing the upper limit and could have solubility issues.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Both have 3 HBA, which is good.
6. **QED:** Ligand A (0.772) is slightly better than Ligand B (0.691), indicating a more drug-like profile.
7. **DILI:** Ligand A (10.702) has a significantly lower DILI risk than Ligand B (13.649). This is a major advantage.
8. **BBB:** Ligand B (80.574) has better BBB penetration than Ligand A (61.884). However, since ADRB2 is primarily a cardiovascular target, high BBB penetration isn't a priority.
9. **Caco-2:** Ligand A (-5) is better than Ligand B (-4.389), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-1.739) is significantly better than Ligand B (-3.651). This is important for bioavailability.
11. **hERG:** Both ligands have low hERG inhibition risk (0.5 and 0.768, respectively). No major difference.
12. **Cl_mic:** Ligand A (2.469) has much lower microsomal clearance than Ligand B (66.218), suggesting better metabolic stability.
13. **t1/2:** Ligand A (14.294) has a longer in vitro half-life than Ligand B (-10.813). This is a significant advantage for dosing frequency.
14. **Pgp:** Ligand A (0.063) has lower P-gp efflux than Ligand B (0.308), which is favorable for bioavailability.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.0 and -5.7 kcal/mol). The difference is not substantial enough to outweigh other factors.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A is better in terms of logP, Pgp, and solubility. While Ligand B has better BBB penetration, this is less critical for a cardiovascular target. The significantly better ADME properties of Ligand A (lower DILI, better solubility, lower clearance, longer half-life, lower Pgp efflux) outweigh the slightly better BBB penetration of Ligand B.
**Conclusion:**
Ligand A is the more promising drug candidate due to its superior ADME profile and acceptable binding affinity.
Output:
1
2025-04-17 23:07:56,577 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (a cardiovascular GPCR) drug candidates.
**Ligand A:** [350.373, 75.94, 2.585, 1, 5, 0.92, 52.191, 83.443, -4.965, -1.996, 0.158, -6.991, -8.664, 0.016, -5.8]
**Ligand B:** [350.419, 102.32, 0.933, 2, 6, 0.51, 41.877, 68.166, -4.982, -1.996, 0.172, 53.414, -13.698, 0.042, -6.5]
Here's a breakdown, considering the GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are excellent (around 350 Da), falling well within the 200-500 Da range.
2. **TPSA:** Ligand A (75.94) is significantly better than Ligand B (102.32). A TPSA under 140 is good for oral absorption, but lower is preferred for GPCRs, and A is closer to the ideal range.
3. **logP:** Ligand A (2.585) is optimal. Ligand B (0.933) is a bit low, potentially hindering membrane permeability.
4. **HBD/HBA:** Ligand A (1 HBD, 5 HBA) is slightly better than Ligand B (2 HBD, 6 HBA). Both are acceptable, but fewer H-bonds generally improve permeability.
5. **QED:** Ligand A (0.92) is excellent, indicating high drug-likeness. Ligand B (0.51) is acceptable but less ideal.
6. **DILI:** Ligand B (41.877) has a significantly lower DILI risk than Ligand A (52.191), which is a substantial advantage.
7. **BBB:** Ligand A (83.443) has better predicted BBB penetration than Ligand B (68.166). While not a primary concern for a cardiovascular target, it's a slight positive for A.
8. **Caco-2:** Both are similar and very poor (-4.965 and -4.982). This is a concern for both, suggesting poor intestinal absorption.
9. **Solubility:** Both are similar and very poor (-1.996). This is a concern for both.
10. **hERG:** Both are very low (0.158 and 0.172), indicating minimal hERG inhibition risk.
11. **Cl_mic:** Ligand A (-6.991) has a much lower (better) microsomal clearance than Ligand B (53.414), suggesting better metabolic stability.
12. **t1/2:** Ligand A (-8.664) has a longer in vitro half-life than Ligand B (-13.698), which is desirable.
13. **Pgp:** Both are very low (0.016 and 0.042), suggesting minimal P-gp efflux.
14. **Affinity:** Ligand A (-5.8 kcal/mol) has a slightly better binding affinity than Ligand B (-6.5 kcal/mol). While the difference isn't huge, it's still a positive for A.
**Overall Assessment:**
Ligand A is superior despite Ligand B's lower DILI risk. Ligand A has better TPSA, logP, QED, metabolic stability (Cl_mic, t1/2), and binding affinity. The lower DILI risk of Ligand B is attractive, but the other ADME properties of Ligand A are more favorable for a GPCR target, especially considering the poor Caco-2 and solubility for both. The better metabolic stability and half-life of Ligand A are also important considerations.
Output:
1
2025-04-17 23:07:56,577 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (351.422) is slightly higher than Ligand B (337.431), but both are acceptable.
2. **TPSA:** Ligand A (82.53) is better than Ligand B (64.45). Both are below the 140 A^2 threshold for good oral absorption, but lower TPSA is generally preferred for GPCRs, aiding in membrane permeability.
3. **logP:** Ligand A (1.649) is within the optimal range (1-3). Ligand B (3.106) is at the higher end of the optimal range. While still acceptable, higher logP can sometimes lead to off-target effects.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1). Both are within the acceptable limit of 5.
5. **HBA:** Ligand A (4) is lower than Ligand B (7). Lower HBA is generally preferred for better permeability.
6. **QED:** Both ligands have similar QED values (0.663 and 0.608, respectively), both above the 0.5 threshold, indicating good drug-like properties.
7. **DILI:** Ligand A (34.432) is significantly better than Ligand B (73.245). Lower DILI is crucial for safety. Ligand B is approaching a concerning level.
8. **BBB:** Both ligands have similar BBB penetration (58.821 and 57.852, respectively). While not exceptionally high, this isn't a primary concern for a non-CNS target like ADRB2.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.78 and -4.917). This is unusual and suggests poor permeability. However, the values are very similar.
10. **Solubility:** Ligand A (-1.21) is better than Ligand B (-3.558). Higher solubility is generally preferred.
11. **hERG:** Ligand A (0.512) is better than Ligand B (0.867). Lower hERG inhibition is critical for avoiding cardiotoxicity, particularly important for a cardiovascular target.
12. **Cl_mic:** Ligand A (29.591) has lower microsomal clearance than Ligand B (40.188), indicating better metabolic stability.
13. **t1/2:** Ligand B (40.74) has a longer in vitro half-life than Ligand A (25.254). This is a positive attribute, but not enough to outweigh other significant differences.
14. **Pgp:** Ligand A (0.119) has lower P-gp efflux than Ligand B (0.706), suggesting better bioavailability.
15. **Binding Affinity:** Both ligands have the same binding affinity (-7.1 kcal/mol), which is excellent.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A has a more favorable logP, lower TPSA, lower Pgp efflux, and significantly better safety profile (DILI, hERG). While both have the same affinity, the ADME properties of Ligand A are superior.
**Conclusion:**
Ligand A is the preferred candidate due to its better DILI risk, lower hERG inhibition, lower Pgp efflux, better solubility, and lower TPSA. These factors collectively contribute to a more favorable safety and pharmacokinetic profile, outweighing the slightly longer half-life of Ligand B.
Output:
1
2025-04-17 23:07:56,577 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (347.394 and 344.499 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (84.14) is higher than Ligand B (58.2). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B has a clear advantage.
3. **logP:** Ligand B (3.2) is slightly higher than Ligand A (2.385), but both are within the optimal 1-3 range.
4. **HBD:** Ligand B (2) is slightly better than Ligand A (1). Both are acceptable.
5. **HBA:** Ligand B (2) is significantly lower than Ligand A (6). Lower HBA is generally favorable for permeability. Ligand B has a clear advantage.
6. **QED:** Ligand A (0.918) is significantly better than Ligand B (0.55). This is a strong point for Ligand A.
7. **DILI:** Ligand B (37.069) has a much lower DILI risk than Ligand A (69.484). This is a significant advantage for Ligand B.
8. **BBB:** Ligand B (66.615) has a higher BBB penetration percentile than Ligand A (47.15). While ADRB2 isn't a CNS target, some distribution to the CNS is possible, and higher BBB is generally favorable.
9. **Caco-2:** Both ligands have similar, very negative Caco-2 values (-4.985 and -4.927). This suggests poor permeability for both.
10. **Solubility:** Ligand A (-2.964) is slightly better than Ligand B (-4.333), indicating better aqueous solubility.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.022 and 0.191). No significant difference.
12. **Cl_mic:** Ligand A (21.851) has a much lower microsomal clearance than Ligand B (58.109), suggesting better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (0.299) has a shorter in vitro half-life than Ligand B (3.03). Ligand B is better here.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.029 and 0.306). No significant difference.
15. **Binding Affinity:** Ligand A (-6.4 kcal/mol) has a slightly better binding affinity than Ligand B (-6.1 kcal/mol). While the difference is small, it's still a positive for Ligand A.
**GPCR-Specific Priorities & Overall Assessment:**
For ADRB2 (a cardiovascular GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in TPSA and has a favorable logP. Ligand A has a slight edge in affinity and significantly better metabolic stability (Cl_mic), and a better QED score. The DILI risk for Ligand B is considerably lower, which is a major safety advantage. The Caco-2 values are concerning for both, suggesting potential absorption issues.
Considering the balance, the lower DILI risk and better TPSA/HBA of Ligand B outweigh the slightly better affinity and metabolic stability of Ligand A. The QED score of A is good, but the DILI risk is a significant concern.
Output:
0
2025-04-17 23:07:56,577 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [380.363, 66.48, 1.922, 1, 3, 0.482, 68.476, 82.125, -4.742, -4.113, 0.498, 44.185, 7.869, 0.168, -6.4]
**Ligand B:** [353.423, 98.58, -0.317, 1, 7, 0.653, 38.697, 36.371, -5.092, -0.672, 0.08, -1.891, 21.131, 0.01, -5.9]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (353.423) is slightly lower, which *could* be beneficial for permeability, but both are acceptable.
2. **TPSA:** Ligand A (66.48) is significantly better than Ligand B (98.58). For a GPCR, keeping TPSA low is good, and A is well under the 140 threshold. B is approaching a level that could hinder absorption.
3. **logP:** Ligand A (1.922) is optimal. Ligand B (-0.317) is too low, potentially leading to poor membrane permeability and bioavailability.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A (3) is better than Ligand B (7). Higher HBA can sometimes reduce permeability.
6. **QED:** Ligand B (0.653) is better than Ligand A (0.482), indicating a slightly more drug-like profile.
7. **DILI:** Ligand A (68.476) has a higher DILI risk than Ligand B (38.697). This is a significant concern for A.
8. **BBB:** Ligand A (82.125) has a much better BBB penetration potential than Ligand B (36.371). While not a primary concern for ADRB2 (cardiovascular target), it's still a positive attribute.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret. Ligand A (-4.742) is slightly better than B (-5.092).
10. **Solubility:** Ligand A (-4.113) is slightly better than Ligand B (-0.672), but both are poor.
11. **hERG:** Ligand A (0.498) has a lower hERG risk than Ligand B (0.08). This is a significant advantage for A.
12. **Cl_mic:** Ligand B (-1.891) has a lower (better) microsomal clearance than Ligand A (44.185), indicating better metabolic stability.
13. **t1/2:** Ligand B (21.131) has a significantly longer in vitro half-life than Ligand A (7.869). This is a major advantage for B.
14. **Pgp:** Ligand A (0.168) has lower P-gp efflux than Ligand B (0.01), which is favorable.
15. **Affinity:** Ligand A (-6.4) has a slightly better binding affinity than Ligand B (-5.9). While the difference is not huge, it's still a positive for A.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, and affinity. Ligand A excels in logP, Pgp, and affinity, and has a much better TPSA. Ligand B has a better QED and metabolic stability (Cl_mic, t1/2) and lower DILI.
**Overall Assessment:**
While Ligand B has a better QED, longer half-life, and lower DILI, the poor logP and high TPSA are significant drawbacks for a GPCR target. The poor logP will likely hinder membrane permeability and bioavailability. Ligand A, despite the higher DILI risk, has a much more favorable profile for a GPCR, with optimal logP, lower TPSA, and good affinity. The slightly better affinity of A also helps offset the DILI concern. The hERG risk is also lower for A.
Therefore, I would choose Ligand A.
Output:
1
2025-04-17 23:07:56,577 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (353.373 Da) is within the ideal range, while Ligand B (370.343 Da) is slightly higher but still acceptable.
2. **TPSA:** Ligand A (71.33) is excellent, well below the 140 threshold and favorable for absorption. Ligand B (89.87) is still reasonable but less optimal.
3. **logP:** Ligand A (0.774) is a bit low, potentially impacting permeability. Ligand B (0.516) is even lower, raising more concerns about membrane penetration.
4. **HBD:** Ligand A (0) is ideal. Ligand B (3) is acceptable, but more donors can sometimes hinder permeability.
5. **HBA:** Ligand A (5) is good. Ligand B (4) is also good.
6. **QED:** Ligand A (0.805) is excellent, indicating strong drug-likeness. Ligand B (0.63) is still acceptable, but lower.
7. **DILI:** Ligand A (44.591) has a slightly higher DILI risk than Ligand B (35.401), but both are within the acceptable range (<60).
8. **BBB:** Ligand A (91.974) shows very good BBB penetration. Ligand B (48.197) is significantly lower, suggesting limited CNS exposure. While ADRB2 isn't strictly a CNS target, some peripheral ADRB2 receptors are relevant to CNS function, and better BBB penetration isn't necessarily a negative.
9. **Caco-2:** Ligand A (-4.697) is poor, indicating low intestinal absorption. Ligand B (-5.172) is also poor.
10. **Solubility:** Ligand A (-2.272) is poor. Ligand B (-1.694) is also poor.
11. **hERG:** Both Ligand A (0.256) and Ligand B (0.244) have low hERG inhibition risk, which is excellent.
12. **Cl_mic:** Ligand A (9.421) has a moderate clearance. Ligand B (-21.924) has a *very* low (and therefore favorable) clearance, indicating high metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand A (1.101) has a short half-life. Ligand B (1.644) has a slightly longer half-life.
14. **Pgp:** Both Ligand A (0.013) and Ligand B (0.018) have very low P-gp efflux, which is excellent.
15. **Affinity:** Ligand B (-7.3) has a significantly stronger binding affinity than Ligand A (-4.0). This is a substantial advantage, potentially outweighing some of the ADME concerns.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are crucial. Ligand B has a better affinity. While both have poor logP, Ligand B has a better TPSA. Both have excellent Pgp properties.
**Overall Assessment:**
Ligand B's significantly stronger binding affinity (-7.3 kcal/mol vs -4.0 kcal/mol) and superior metabolic stability (lower Cl_mic) are major advantages. While its logP is low, the strong binding could compensate. The lower DILI risk is also a plus. Ligand A's better BBB penetration is less critical for a primarily peripheral target like ADRB2. The poor Caco-2 and solubility of both are concerns, but formulation strategies can sometimes address these issues.
Therefore, I favor Ligand B.
Output:
0
2025-04-17 23:07:56,577 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
The target is ADRB2, a GPCR. Therefore, key priorities are logP, TPSA, Pgp efflux, BBB penetration, and binding affinity. Metabolic stability (Cl_mic, t1/2) and safety (DILI, hERG) are also important, but slightly less so than the first set.
Let's compare the ligands property by property:
1. **MW:** Both ligands (345.418 and 342.418 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (56.15) is higher than Ligand B (39.68). Ligand B is better here, being closer to the <90 target for GPCRs.
3. **logP:** Ligand A (3.131) is slightly higher than Ligand B (2.172), both within the optimal 1-3 range. Ligand A is slightly favored.
4. **HBD:** Ligand A (1) is better than Ligand B (0). While both are acceptable, a single HBD can aid solubility.
5. **HBA:** Both ligands have 4 HBA, which is good.
6. **QED:** Ligand A (0.906) is significantly better than Ligand B (0.799), indicating a more drug-like profile.
7. **DILI:** Ligand B (49.593) has a much lower DILI risk than Ligand A (67.546). This is a significant advantage for Ligand B.
8. **BBB:** Both ligands have high BBB penetration (Ligand A: 89.492, Ligand B: 83.986). No major difference.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand B (-2.241) is better than Ligand A (-4.07).
11. **hERG:** Ligand A (0.643) is better than Ligand B (0.702), indicating lower hERG inhibition risk.
12. **Cl_mic:** Ligand B (47.989) has lower microsomal clearance than Ligand A (66.844), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-17.509) has a much longer in vitro half-life than Ligand A (9.456). This is a major advantage for Ligand B.
14. **Pgp:** Ligand A (0.237) has lower P-gp efflux than Ligand B (0.159), suggesting better absorption and potentially better CNS exposure.
15. **Binding Affinity:** Ligand B (-7.9 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.5 kcal/mol). This is a substantial advantage, potentially outweighing some ADME drawbacks.
**Overall Assessment:**
Ligand B has a superior binding affinity, lower DILI risk, better metabolic stability (lower Cl_mic, longer t1/2), and better solubility. While Ligand A has a slightly better logP and Pgp efflux, the stronger binding affinity and improved safety/stability profile of Ligand B are more critical for a GPCR target like ADRB2. The Caco-2 values are concerning for both, but the overall balance of properties favors Ligand B.
**Output:**
0
2025-04-17 23:07:56,578 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (354.4 & 367.5 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand B (82.97) is significantly better than Ligand A (102.01). Lower TPSA generally improves permeability, crucial for GPCRs.
3. **logP:** Both are reasonable (0.411 & 0.532), falling within the 1-3 range. Ligand B is slightly better.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Both have 6 HBA, also good.
6. **QED:** Ligand B (0.793) has a substantially better QED score than Ligand A (0.5), indicating a more drug-like profile.
7. **DILI:** Ligand B (33.773) has a lower DILI risk than Ligand A (40.403), which is preferable.
8. **BBB:** Ligand A (54.246) has a higher BBB penetration score than Ligand B (27.491). However, ADRB2 is a cardiovascular target, so BBB penetration is not a primary concern.
9. **Caco-2:** Both have similar, very poor Caco-2 permeability (-4.83 and -4.726). This is a significant drawback for both.
10. **Solubility:** Ligand B (-0.445) is better than Ligand A (-1.586), though both are quite poor.
11. **hERG:** Ligand A (0.089) has a slightly lower hERG risk than Ligand B (0.202), which is a slight advantage.
12. **Cl_mic:** Ligand B (16.171) has significantly lower microsomal clearance than Ligand A (30.209), indicating better metabolic stability.
13. **t1/2:** Ligand B (4.094) has a longer in vitro half-life than Ligand A (-15.825), a substantial advantage.
14. **Pgp:** Ligand A (0.031) has lower P-gp efflux than Ligand B (0.083), which is preferable.
15. **Affinity:** Ligand B (-7.0) has a slightly better binding affinity than Ligand A (-6.8). While the difference is small, it's still a positive.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, affinity, and metabolic stability are key. Ligand B excels in TPSA, QED, DILI, Cl_mic, and t1/2. While Ligand A has a slightly better BBB and Pgp profile, these are less critical for a cardiovascular target. The slightly better affinity of Ligand B and its more favorable ADME properties outweigh the minor advantages of Ligand A.
**Conclusion:**
Ligand B is the more promising candidate due to its superior drug-like properties, lower toxicity risk, and better metabolic stability, despite similar permeability issues.
Output:
0
2025-04-17 23:07:56,578 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (351.382 and 344.455 Da) are within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand B (62.55) is significantly better than Ligand A (95.5), falling well below the 140 threshold for oral absorption and closer to the 90 threshold for CNS penetration (though not a CNS target here, lower TPSA is generally favorable).
3. **logP:** Ligand B (3.077) is optimal, while Ligand A (-0.447) is quite low, potentially hindering membrane permeability. This is a significant advantage for Ligand B.
4. **HBD:** Both ligands have 1 HBD, which is acceptable.
5. **HBA:** Ligand B (3) has fewer HBA than Ligand A (5), which is preferable for permeability.
6. **QED:** Both ligands have good QED scores (0.718 and 0.807), indicating good drug-like properties.
7. **DILI:** Ligand B (27.065) has a much lower DILI risk than Ligand A (61.07). This is a major advantage for Ligand B.
8. **BBB:** Ligand B (81.776) has better BBB penetration than Ligand A (73.827). While ADRB2 isn't a primary CNS target, better BBB penetration can sometimes translate to better overall distribution and reduced off-target effects.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Ligand A (-0.982) has slightly better solubility than Ligand B (-3.133), but both are poor.
11. **hERG:** Ligand A (0.067) has a slightly lower hERG risk than Ligand B (0.652), but both are relatively low.
12. **Cl_mic:** Ligand A (1.546) has much lower microsomal clearance than Ligand B (74.633), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand B (77.174) has a significantly longer in vitro half-life than Ligand A (6.763). This is a major advantage for Ligand B.
14. **Pgp:** Ligand A (0.008) has much lower P-gp efflux than Ligand B (0.442), which is preferable.
15. **Binding Affinity:** Ligand B (-2.7 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.2 kcal/mol). This is a very substantial advantage for Ligand B.
**GPCR-specific priorities:** For GPCRs, logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP, TPSA, and significantly in affinity. While Ligand A has better Pgp and Cl_mic, the substantial advantage in binding affinity and the better overall ADME profile (lower DILI, better half-life) of Ligand B outweigh these drawbacks. The lower logP of Ligand A is a significant concern for permeability.
**Conclusion:**
Considering the balance of properties and the priorities for a GPCR target, Ligand B is the more promising drug candidate.
Output:
0
2025-04-17 23:07:56,578 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [373.503, 74.25, 3.905, 3, 5, 0.613, 81.66, 59.946, -5.069, -4.408, 0.64, 75.376, 59.899, 0.654, -7.2]
**Ligand B:** [402.64, 62.3, 4.148, 1, 3, 0.477, 89.686, 83.831, -4.562, -5.65, 0.209, 42.182, 20.028, 0.105, 21.8]
Here's a breakdown, considering the provided guidelines and GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the acceptable range (200-500 Da). Ligand A (373.5) is slightly preferred.
2. **TPSA:** Ligand B (62.3) is better than Ligand A (74.25). Lower TPSA generally improves permeability.
3. **logP:** Both are good (around 4), but Ligand B (4.148) is slightly higher. This could be a minor concern for solubility, but acceptable.
4. **HBD:** Ligand A (3) is higher than Ligand B (1). Lower is generally better for permeability. Ligand B is preferred.
5. **HBA:** Ligand A (5) is higher than Ligand B (3). Ligand B is preferred.
6. **QED:** Ligand A (0.613) is better than Ligand B (0.477). Higher QED indicates better drug-likeness.
7. **DILI:** Both are relatively high (Ligand A: 81.66, Ligand B: 89.686), indicating potential liver toxicity risk. Ligand A is slightly preferred.
8. **BBB:** Ligand B (83.831) is significantly better than Ligand A (59.946). This is a key consideration for GPCRs, even cardiovascular ones, as some CNS off-target effects are possible.
9. **Caco-2:** Ligand A (-5.069) is better than Ligand B (-4.562). Higher Caco-2 permeability is desirable.
10. **Solubility:** Ligand B (-5.65) is better than Ligand A (-4.408). Higher solubility is preferred.
11. **hERG:** Ligand A (0.64) is better than Ligand B (0.209). Lower hERG inhibition is crucial for avoiding cardiotoxicity.
12. **Cl_mic:** Ligand B (42.182) is significantly better than Ligand A (75.376). Lower clearance means greater metabolic stability.
13. **t1/2:** Ligand A (59.899) is much better than Ligand B (20.028). Longer half-life is desirable.
14. **Pgp:** Ligand A (0.654) is better than Ligand B (0.105). Lower P-gp efflux is preferred.
15. **Affinity:** Ligand A (-7.2) is *much* better than Ligand B (-21.8). This is a huge difference in binding potency. A difference of >1.5 kcal/mol is often enough to outweigh other concerns.
**Overall Assessment:**
While Ligand B has advantages in BBB, solubility, and metabolic stability, the *massive* difference in binding affinity for Ligand A is the deciding factor. The strong binding of Ligand A (-7.2 kcal/mol) is likely to translate to greater efficacy at lower doses, potentially mitigating some of the ADME concerns. The slightly higher DILI risk and lower BBB penetration of Ligand A are less concerning given the potency advantage. The better hERG profile of Ligand A is also a significant plus.
Therefore, I would choose Ligand A.
1
2025-04-17 23:07:56,578 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.447 and 345.403 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (95.42) is better than Ligand B (100.21). Both are acceptable for a non-CNS GPCR like ADRB2, being under 140, but lower is generally preferred.
3. **logP:** Both ligands have good logP values (1.82 and 1.15), falling within the optimal 1-3 range. Ligand A is slightly higher, which *could* be beneficial for membrane permeability, but both are good.
4. **HBD:** Both have 2 HBD, which is within the acceptable limit of 5.
5. **HBA:** Both have 5 HBA, also within the acceptable limit of 10.
6. **QED:** Ligand A (0.846) has a better QED score than Ligand B (0.784), indicating a more drug-like profile.
7. **DILI:** Ligand A (39.744) has a significantly lower DILI risk than Ligand B (53.276). This is a crucial advantage, as minimizing liver toxicity is paramount.
8. **BBB:** This is less critical for ADRB2 (a cardiovascular target), but Ligand A (61.38) has a higher BBB penetration than Ligand B (27.763).
9. **Caco-2:** Ligand A (-4.962) and Ligand B (-5.138) are similar, and both indicate good permeability.
10. **Solubility:** Ligand A (-1.845) is slightly better than Ligand B (-2.143). Both are acceptable, but better solubility is always preferred.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.189 and 0.166), which is excellent.
12. **Cl_mic:** Ligand B (12.592) has a significantly lower microsomal clearance than Ligand A (22.717), suggesting better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand B (10.838) has a longer in vitro half-life than Ligand A (-16.723). This is a major advantage, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.036 and 0.02).
15. **Binding Affinity:** Ligand B (-6.8 kcal/mol) has a slightly stronger binding affinity than Ligand A (-6.2 kcal/mol). This 0.6 kcal/mol difference is notable, and can sometimes outweigh other factors.
**Overall Assessment:**
While Ligand B has a better binding affinity and metabolic stability (lower Cl_mic, longer t1/2), Ligand A demonstrates a significantly better safety profile with a much lower DILI risk. Considering the cardiovascular target, minimizing toxicity is critical. The slightly better QED and solubility of Ligand A also contribute to its favorability. The difference in binding affinity, while present, is not substantial enough to overcome the safety advantages of Ligand A.
**Output:**
1
2025-04-17 23:07:56,578 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [376.375, 59.06, 3.241, 1, 4, 0.814, 52.772, 75.843, -4.894, -3.907, 0.782, 15.275, 54.884, 0.597, -8.6]
**Ligand B:** [349.475, 101.29, 1.478, 3, 3, 0.677, 19.038, 62.427, -5.296, -3.226, 0.13, 17.222, 4.188, 0.029, -7.4]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). A (376.375) is slightly higher than B (349.475), but both are acceptable.
2. **TPSA:** A (59.06) is excellent, well below the 140 threshold and good for permeability. B (101.29) is higher, but still within a reasonable range for a non-CNS GPCR target.
3. **logP:** A (3.241) is optimal. B (1.478) is a bit low, potentially impacting permeability.
4. **HBD:** A (1) is good. B (3) is acceptable, but higher HBD can sometimes reduce permeability.
5. **HBA:** A (4) is good. B (3) is also good.
6. **QED:** A (0.814) is very good, indicating high drug-likeness. B (0.677) is still acceptable, but lower.
7. **DILI:** A (52.772) is good, indicating low liver injury risk. B (19.038) is excellent, even lower risk.
8. **BBB:** A (75.843) is good, suggesting reasonable potential for CNS penetration if desired. B (62.427) is lower, indicating less likely to cross the BBB. For ADRB2, which has cardiovascular implications, BBB penetration is not a primary concern, but it's a bonus.
9. **Caco-2:** Both are negative, which is unusual. A (-4.894) is worse than B (-5.296). This suggests poor intestinal absorption for both, but B is slightly better.
10. **Solubility:** Both are negative, indicating poor aqueous solubility. A (-3.907) is slightly better than B (-3.226).
11. **hERG:** A (0.782) is good, low risk of cardiotoxicity. B (0.13) is excellent, very low risk.
12. **Cl_mic:** A (15.275) is reasonable. B (17.222) is a bit higher, suggesting slightly faster metabolism.
13. **t1/2:** A (54.884) is good, indicating a reasonable half-life. B (4.188) is very short, potentially requiring frequent dosing.
14. **Pgp:** A (0.597) is good, suggesting low efflux. B (0.029) is excellent, very low efflux.
15. **Affinity:** A (-8.6) is significantly better than B (-7.4). This is a 1.2 kcal/mol difference, which is substantial and can outweigh some ADME drawbacks.
**GPCR-specific priorities:** For ADRB2 (a GPCR), we prioritize logP, Pgp, TPSA, and affinity. A excels in logP and affinity. B excels in Pgp and has a slightly better hERG profile. However, the significant affinity advantage of A, coupled with its good TPSA and acceptable logP, makes it the more promising candidate. The shorter half-life of B is a significant drawback.
**Conclusion:**
Ligand A is the more promising candidate due to its superior binding affinity and better overall drug-like properties, despite slightly poorer Caco-2 and solubility.
1
2025-04-17 23:07:56,578 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (354.47 & 366.85 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (58.64) is significantly better than Ligand B (85.77). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold. Ligand B is approaching it.
3. **logP:** Ligand A (2.583) is optimal. Ligand B (0.378) is quite low, potentially hindering membrane permeability. This is a significant negative for Ligand B.
4. **HBD:** Both ligands have acceptable HBD counts (1 and 2, respectively), well below the threshold of 5.
5. **HBA:** Ligand A (3) is better than Ligand B (5), both are acceptable but lower is preferred.
6. **QED:** Both ligands have similar and good QED scores (0.764 and 0.786).
7. **DILI:** Ligand A (11.63) has a much lower DILI risk than Ligand B (28.46). This is a substantial advantage for Ligand A.
8. **BBB:** Ligand A (96.74) shows excellent BBB penetration, while Ligand B (30.79) is low. While not critical for a cardiovascular target, higher BBB is generally a positive attribute.
9. **Caco-2:** Ligand A (-4.412) and Ligand B (-5.025) are both negative, indicating poor permeability. However, the scale is not clearly defined, so it's hard to assess the difference.
10. **Solubility:** Ligand A (-2.543) is better than Ligand B (-1.618), both are negative.
11. **hERG:** Ligand A (0.765) is better than Ligand B (0.113), indicating a lower risk of cardiotoxicity. This is crucial for a cardiovascular target.
12. **Cl_mic:** Ligand A (13.45) has a much lower microsomal clearance than Ligand B (-43.08). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand B (23.79) has a significantly longer in vitro half-life than Ligand A (1.75). This is a positive for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.126) has lower P-gp efflux than Ligand B (0.012).
15. **Affinity:** Ligand B (-8.0) has a slightly better binding affinity than Ligand A (-6.9). The difference is 1.1 kcal/mol, which is not substantial enough to overcome the numerous ADME deficiencies of Ligand B.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A excels in logP and TPSA, and has acceptable Pgp. While Ligand B has slightly better affinity, its poor logP and higher Pgp efflux are major drawbacks.
**Overall Assessment:**
Ligand A demonstrates a significantly more balanced profile with favorable ADME properties (lower DILI, better solubility, lower hERG, better metabolic stability) and acceptable binding affinity. Ligand B's primary advantage is its slightly better affinity and longer half-life, but these are outweighed by its poor logP, high DILI risk, and potential permeability issues.
Output:
1
2025-04-17 23:07:56,578 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (345.418 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (56.15) is better than Ligand B (61.44). Both are below the 140 threshold for oral absorption, but lower TPSA is preferable.
3. **logP:** Both ligands have good logP values (A: 3.131, B: 2.728) within the optimal 1-3 range.
4. **HBD:** Ligand A (1) is better than Ligand B (2). Lower HBD is generally preferred for better permeability.
5. **HBA:** Both ligands have the same HBA count (4), which is acceptable (<=10).
6. **QED:** Ligand A (0.906) has a significantly better QED score than Ligand B (0.745), indicating a more drug-like profile.
7. **DILI:** Ligand B (34.393) has a much lower DILI risk than Ligand A (67.546). This is a major advantage for Ligand B.
8. **BBB:** Ligand A (89.492) has better BBB penetration than Ligand B (64.948). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant, and higher BBB is generally desirable.
9. **Caco-2:** Ligand B (-5.297) has a slightly better Caco-2 permeability than Ligand A (-4.588), suggesting better intestinal absorption.
10. **Solubility:** Ligand B (-2.193) has better aqueous solubility than Ligand A (-4.07).
11. **hERG:** Both ligands have low hERG inhibition liability (A: 0.643, B: 0.664), which is good.
12. **Cl_mic:** Ligand B (21.558) has significantly lower microsomal clearance than Ligand A (66.844), indicating better metabolic stability.
13. **t1/2:** Ligand B (26.038) has a longer in vitro half-life than Ligand A (9.456), which is favorable.
14. **Pgp:** Both ligands have low P-gp efflux liability (A: 0.237, B: 0.183).
15. **Binding Affinity:** Ligand A (-6.5 kcal/mol) has a slightly better binding affinity than Ligand B (-5.4 kcal/mol). This is a 1.1 kcal/mol difference, which is significant, but needs to be weighed against other factors.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Both ligands perform well on logP and Pgp. Ligand A has a slight edge in affinity, but Ligand B excels in metabolic stability (Cl_mic, t1/2), solubility, and crucially, DILI risk. The better QED score of Ligand A is also a positive.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity and BBB penetration, Ligand B's significantly lower DILI risk, improved metabolic stability, solubility, and Caco-2 permeability are more critical for overall drug development success. The 1.1 kcal/mol difference in binding affinity can potentially be optimized later in the drug development process, while mitigating a high DILI risk is much more challenging.
Output:
0
2025-04-17 23:07:56,578 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [348.359, 114.76 , 1.863, 1. , 8. , 0.595, 59.713, 51.493, -4.881, -2.379, 0.441, 26.669, -28.563, 0.433, -6.6 ]
**Ligand B:** [370.431, 106.71 , 0.644, 1. , 7. , 0.558, 74.215, 82.474, -4.881, -3.153, 0.216, 36.793, 5.516, 0.08 , -6.8 ]
Here's a breakdown, prioritizing GPCR properties (logP, TPSA, Pgp, BBB, Affinity):
1. **MW:** Both are within the ideal 200-500 Da range. Ligand A (348.359) is slightly preferred due to being lower.
2. **TPSA:** Both are good, under 140. Ligand B (106.71) is slightly better.
3. **logP:** Ligand A (1.863) is better, falling squarely within the 1-3 range. Ligand B (0.644) is a bit low, potentially hindering membrane permeability.
4. **HBD/HBA:** Both have 1 HBD and acceptable HBA counts (8 and 7 respectively). No significant difference.
5. **QED:** Both are above 0.5, indicating good drug-likeness.
6. **DILI:** Ligand A (59.713) is better, being under the 60% threshold for high risk. Ligand B (74.215) is higher, indicating a greater potential for liver injury.
7. **BBB:** Ligand B (82.474) is significantly better, suggesting improved potential for CNS penetration, though this isn't a primary concern for ADRB2 unless targeting CNS effects.
8. **Caco-2:** Both are the same (-4.881).
9. **Solubility:** Ligand A (-2.379) is better than Ligand B (-3.153).
10. **hERG:** Both are low, indicating minimal cardiotoxicity risk. Ligand B (0.216) is slightly better.
11. **Cl_mic:** Ligand A (26.669) is better, indicating slower metabolic clearance and potentially longer duration of action. Ligand B (36.793) is higher.
12. **t1/2:** Ligand A (-28.563) is much better, indicating a longer in vitro half-life. Ligand B (5.516) is poor.
13. **Pgp:** Ligand A (0.433) is better, suggesting lower P-glycoprotein efflux. Ligand B (0.08) is very low, which could be a concern.
14. **Affinity:** Ligand B (-6.8) is slightly better than Ligand A (-6.6), but the difference is small.
**Overall Assessment:**
While Ligand B has a better BBB score and slightly better affinity, Ligand A demonstrates a more balanced profile, particularly regarding ADME properties crucial for oral bioavailability and reduced toxicity. The lower DILI risk, better metabolic stability (lower Cl_mic, longer t1/2), and lower Pgp efflux of Ligand A are significant advantages. The slightly lower logP of Ligand B is a concern. Given the importance of ADME properties for a viable drug candidate, and the modest affinity difference, I favor Ligand A.
Output:
1
2025-04-17 23:07:56,578 - INFO - Batch 382 complete. Total preferences: 6112
2025-04-17 23:07:56,578 - INFO - Processing batch 383/512...
2025-04-17 23:08:43,978 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.4 & 360.4 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (79.37) is higher than Ligand B (49.85). For a cardiovascular GPCR, TPSA isn't a *major* concern unless it's excessively high, but lower is generally preferred for better permeability. Ligand B is better here.
3. **logP:** Both ligands have good logP values (2.464 & 3.058), falling within the optimal 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Ligand A has 1 HBD, while Ligand B has 0. Both are acceptable, within the limit of 5.
5. **HBA:** Ligand A has 4 HBA, Ligand B has 3. Both are within the acceptable limit of 10.
6. **QED:** Both ligands have similar QED values (0.671 & 0.594), indicating good drug-likeness. Ligand A is slightly better.
7. **DILI:** Ligand A (60.682) has a significantly higher DILI risk than Ligand B (18.224). This is a major concern, as we want to minimize liver toxicity. Ligand B is much better.
8. **BBB:** Ligand A (82.668) has a reasonable BBB penetration, while Ligand B (96.472) is excellent. While ADRB2 isn't a CNS target, some off-target CNS effects are always a consideration, and higher BBB penetration can sometimes correlate with better overall distribution. Ligand B is better.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.547 & -3.991). These values are unusual and suggest poor permeability. However, the values are similar, so this isn't a deciding factor.
10. **Solubility:** Both ligands have negative solubility values (-3.523 & -2.413). Again, these are unusual and suggest poor solubility. Similar to Caco-2, this isn't a deciding factor as they are comparable.
11. **hERG:** Both ligands have low hERG inhibition risk (0.299 & 0.447), which is good. No significant difference.
12. **Cl_mic:** Ligand A (53.369) has lower microsomal clearance than Ligand B (64.878), indicating better metabolic stability. Ligand A is better.
13. **t1/2:** Ligand A (-35.708) has a much more negative in vitro half-life than Ligand B (-6.884). This suggests a very short half-life for Ligand A, which is undesirable. Ligand B is significantly better.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.08 & 0.106), which is good. No significant difference.
15. **Affinity:** Both ligands have excellent binding affinity (-5.2 & -5.0 kcal/mol). The difference of 0.2 kcal/mol is not substantial enough to outweigh other factors.
**Overall Assessment:**
Ligand B is the better candidate. While Ligand A has slightly better QED and lower Cl_mic, Ligand B's significantly lower DILI risk, better BBB penetration, and substantially improved in vitro half-life are critical advantages. The comparable affinity and similar values for other parameters make Ligand B the more promising starting point for further optimization. The negative Caco-2 and solubility values for both are concerning and would require investigation, but are not as critical as the DILI and half-life issues with Ligand A.
Output:
0
2025-04-17 23:08:43,978 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [350.423, 115.37 , -0.504, 2. , 7. , 0.739, 44.591, 57.852, -5.441, -1.887, 0.179, 14.23 , -2.889, 0.007, -7.6 ]
**Ligand B:** [388.45 , 139.96 , 0.389, 3. , 8. , 0.594, 86.39 , 50.679, -5.662, -2.643, 0.362, 8.095, 10.647, 0.129, -5.1 ]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity):
1. **MW:** Both are within the acceptable 200-500 Da range. Ligand A (350.423) is slightly preferred.
2. **TPSA:** Ligand A (115.37) is better than Ligand B (139.96), being closer to the <140 threshold for good absorption.
3. **logP:** Ligand B (0.389) is slightly better than Ligand A (-0.504) and within the optimal 1-3 range. Ligand A is a bit low, which could affect permeability.
4. **HBD/HBA:** Ligand A (2 HBD, 7 HBA) is slightly better than Ligand B (3 HBD, 8 HBA). Both are acceptable, but fewer H-bonds generally improve permeability.
5. **QED:** Ligand A (0.739) has a better QED score than Ligand B (0.594), indicating a more drug-like profile.
6. **DILI:** Ligand A (44.591) has a significantly lower DILI risk than Ligand B (86.39), which is a major advantage.
7. **BBB:** Both have relatively low BBB penetration (A: 57.852, B: 50.679). This isn't a primary concern for ADRB2, which isn't a CNS target, but higher is always better.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. This is a significant concern for both.
9. **Solubility:** Both have negative solubility values, which is also unusual and suggests poor solubility. This is a significant concern for both.
10. **hERG:** Both have low hERG inhibition risk (A: 0.179, B: 0.362).
11. **Cl_mic:** Ligand B (8.095) has a lower microsomal clearance than Ligand A (14.23), suggesting better metabolic stability.
12. **t1/2:** Ligand B (10.647) has a longer in vitro half-life than Ligand A (-2.889), which is a positive.
13. **Pgp:** Ligand A (0.007) has a much lower P-gp efflux liability than Ligand B (0.129), which is a significant advantage for oral bioavailability.
14. **Affinity:** Ligand A (-7.6) has a significantly stronger binding affinity than Ligand B (-5.1). This is a crucial factor, as a >1.5 kcal/mol difference can outweigh other drawbacks.
**Conclusion:**
Despite Ligand B having better logP and metabolic stability, Ligand A is the stronger candidate. The significantly better binding affinity (-7.6 vs -5.1 kcal/mol) and substantially lower DILI risk outweigh the slightly lower logP and shorter half-life. The lower P-gp efflux also contributes to its advantage. The poor Caco-2 and solubility values are concerning for both, but can be addressed with formulation strategies.
Output:
1
2025-04-17 23:08:43,978 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (362.499 and 374.522 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (76.88) is higher than Ligand B (60.85). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B has a slight advantage.
3. **logP:** Ligand A (3.471) is slightly higher than Ligand B (2.222), both within the optimal 1-3 range. Ligand A is closer to the upper limit, which *could* present solubility issues, but is still acceptable.
4. **HBD:** Both ligands have 1 H-bond donor, which is good.
5. **HBA:** Ligand A has 5 H-bond acceptors, and Ligand B has 4. Both are within the acceptable limit of 10.
6. **QED:** Ligand A (0.853) has a significantly higher QED score than Ligand B (0.662), indicating a more drug-like profile overall. This is a substantial positive for Ligand A.
7. **DILI:** Ligand B (12.33) has a much lower DILI risk than Ligand A (72.819). This is a major advantage for Ligand B. A DILI percentile above 60 is concerning.
8. **BBB:** Ligand A (78.209) and Ligand B (85.072) both have high BBB penetration, but Ligand B is higher. For a cardiovascular target, BBB penetration is not a primary concern, but it doesn't hurt.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.749 and -4.779), which is unusual and suggests poor permeability. This is a significant drawback for both, but doesn't differentiate them.
10. **Solubility:** Ligand B (-1.859) has a better solubility score than Ligand A (-4.399). This is a positive for Ligand B, especially given Ligand A's higher logP.
11. **hERG:** Both ligands have low hERG inhibition risk (0.569 and 0.688). No significant difference.
12. **Cl_mic:** Ligand B (38.558) has a lower microsomal clearance than Ligand A (46.728), suggesting better metabolic stability. This is a positive for Ligand B.
13. **t1/2:** Ligand B (-1.616) has a slightly longer in vitro half-life than Ligand A (-9.986). This is a positive for Ligand B.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.252 and 0.266). No significant difference.
15. **Binding Affinity:** Ligand B (-6.8) has a slightly better binding affinity than Ligand A (-6.0). While the difference is not huge, it is still a positive for Ligand B.
**Overall Assessment:**
Ligand A has a better QED score, but is significantly hampered by its high DILI risk and lower solubility. Ligand B, while having a lower QED, demonstrates a much better safety profile (lower DILI), improved solubility, better metabolic stability (lower Cl_mic, longer t1/2), and slightly improved binding affinity. Given the importance of safety and metabolic stability in drug development, and the fact that the binding affinity difference is not substantial, Ligand B is the more promising candidate. The negative Caco-2 values are a concern for both, but can be addressed with formulation strategies.
Output:
0
2025-04-17 23:08:43,978 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (364.56 & 355.44 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (49.41) is significantly better than Ligand B (116.76). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally correlates with better absorption. Ligand B's TPSA is quite high, potentially hindering oral bioavailability.
3. **logP:** Ligand A (3.23) is optimal. Ligand B (-0.55) is too low, suggesting poor membrane permeability and potentially poor absorption.
4. **HBD:** Ligand A (1) is preferable to Ligand B (4). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (5) for similar reasons as HBD.
6. **QED:** Ligand A (0.71) is better than Ligand B (0.44), indicating a more drug-like profile.
7. **DILI:** Ligand A (13.53) has a much lower DILI risk than Ligand B (15.63). This is a significant advantage.
8. **BBB:** Ligand A (77.82) is better than Ligand B (39.16), but as this is a cardiovascular target, this isn't a primary concern.
9. **Caco-2:** Ligand A (-5.16) is better than Ligand B (-5.62), suggesting better intestinal absorption.
10. **Solubility:** Ligand A (-3.73) is better than Ligand B (-0.31), which is important for formulation and bioavailability.
11. **hERG:** Ligand A (0.53) is better than Ligand B (0.12), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand A (70.64) is higher than Ligand B (-11.83). This means Ligand B has better metabolic stability, which is a positive.
13. **t1/2:** Ligand B (13.08) has a longer half-life than Ligand A (-10.77). This is a significant advantage.
14. **Pgp:** Ligand A (0.3) is better than Ligand B (0.004), indicating lower P-gp efflux.
15. **Affinity:** Both ligands have very similar binding affinities (-6.4 and -5.8 kcal/mol). The difference is less than the 1.5 kcal/mol threshold.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A excels in logP, TPSA, and Pgp. While the affinity difference is small, the overall ADME profile of Ligand A is far superior. The longer half-life of Ligand B is attractive, but the poor logP and high TPSA are major drawbacks.
**Conclusion:**
Despite Ligand B's longer half-life, Ligand A is the more promising drug candidate due to its significantly better physicochemical properties (logP, TPSA, solubility), lower DILI risk, and better Pgp profile. These factors will likely translate to better absorption, distribution, and overall bioavailability.
Output:
1
2025-04-17 23:08:43,979 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (345.403 and 346.471 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (98.14) is higher than Ligand B (58.64). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for permeability. Ligand B has a substantial advantage here.
**3. logP:** Ligand A (0.475) is quite low, potentially hindering membrane permeability. Ligand B (2.431) is within the optimal 1-3 range. This is a significant advantage for Ligand B.
**4. H-Bond Donors:** Ligand A (2) and Ligand B (1) are both acceptable, below the threshold of 5.
**5. H-Bond Acceptors:** Ligand A (6) and Ligand B (3) are both acceptable, below the threshold of 10.
**6. QED:** Both ligands have good QED scores (0.597 and 0.796), indicating good drug-like properties. Ligand B is slightly better.
**7. DILI Risk:** Ligand A (63.203) has a higher DILI risk than Ligand B (36.681). This is a significant concern, as minimizing liver toxicity is crucial. Ligand B is much better.
**8. BBB Penetration:** This is less critical for a cardiovascular target. Ligand A (47.964) and Ligand B (75.107). Ligand B is better.
**9. Caco-2 Permeability:** Both have negative values, indicating poor permeability. Ligand A (-4.982) is slightly worse than Ligand B (-4.592).
**10. Aqueous Solubility:** Both have negative values, indicating poor solubility. Ligand A (-2.4) is slightly better than Ligand B (-3.163).
**11. hERG Inhibition:** Ligand A (0.103) has a slightly lower hERG risk than Ligand B (0.327), which is preferable.
**12. Microsomal Clearance:** Ligand A (24.425) has lower clearance than Ligand B (27.452), suggesting better metabolic stability.
**13. In vitro Half-Life:** Ligand A (-13.53) has a negative half-life, which is concerning. Ligand B (2.593) has a positive half-life, indicating better stability.
**14. P-gp Efflux:** Both are low, indicating minimal P-gp efflux. Ligand A (0.058) is slightly lower.
**15. Binding Affinity:** Ligand B (-7.9 kcal/mol) has a significantly stronger binding affinity than Ligand A (-1.3 kcal/mol). This is a *major* advantage, as a 1.5 kcal/mol difference can often outweigh other ADME concerns.
**Overall Assessment:**
Ligand B is the superior candidate. While Ligand A has slightly better hERG and P-gp profiles, Ligand B excels in critical areas: logP, DILI risk, BBB penetration, and, most importantly, *binding affinity*. The significantly stronger binding affinity of Ligand B (-7.9 vs -1.3 kcal/mol) is a decisive factor. The lower TPSA and better QED also contribute to its favorability. The slightly lower solubility is a concern, but potentially addressable through formulation strategies.
Output:
0
2025-04-17 23:08:43,979 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (353.4 & 356.4 Da) fall comfortably within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (76.66) is significantly better than Ligand A (96.87). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (1.721 & 1.497), falling within the optimal 1-3 range. Ligand B is slightly better.
4. **HBD:** Both have 2 HBD, which is within the acceptable limit of 5.
5. **HBA:** Ligand A has 6 HBA, while Ligand B has 4. Ligand B is preferable, as fewer HBA generally improves permeability.
6. **QED:** Both have reasonable QED scores (0.703 & 0.678), indicating good drug-likeness.
7. **DILI:** Ligand A has a concerningly high DILI risk (91.508 percentile). Ligand B is much better (30.865 percentile). This is a *major* advantage for Ligand B.
8. **BBB:** Not a primary concern for a cardiovascular target, but Ligand B (89.957) is better than Ligand A (24.506).
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-5.575) is slightly better than Ligand B (-4.748), but both are problematic.
10. **Solubility:** Both have negative solubility values, which is also unusual and suggests poor solubility. Ligand A (-3.028) is slightly better than Ligand B (-2.093).
11. **hERG:** Both have very low hERG inhibition risk (0.073 & 0.31). This is excellent for both.
12. **Cl_mic:** Ligand A (14.358) has a significantly lower microsomal clearance than Ligand B (32.765), suggesting better metabolic stability.
13. **t1/2:** Ligand A (17.313) has a longer in vitro half-life than Ligand B (-6.013). This is a significant advantage for Ligand A.
14. **Pgp:** Both have very low Pgp efflux liability (0.032 & 0.024).
15. **Binding Affinity:** Ligand A (-7.4 kcal/mol) has a significantly stronger binding affinity than Ligand B (-4.2 kcal/mol). This is a substantial advantage for Ligand A.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, and affinity. Ligand B is better on logP and TPSA. However, the *significant* difference in binding affinity (-7.4 vs -4.2 kcal/mol) for Ligand A is a major factor. The higher affinity can often overcome minor ADME deficiencies. The DILI risk for Ligand A is a serious concern, but the substantial affinity advantage and better metabolic stability (lower Cl_mic, longer t1/2) make it a more promising starting point for optimization.
**Conclusion:**
Despite the higher DILI risk, Ligand A's significantly stronger binding affinity and better metabolic stability outweigh the advantages of Ligand B. Optimization efforts could focus on mitigating the DILI risk.
Output:
1
2025-04-17 23:08:43,979 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Step-by-step comparison:**
1. **MW:** Both ligands (345.403 and 353.551 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand B (61.44) is significantly better than Ligand A (117.42). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (3.087) is optimal, while Ligand A (0.075) is quite low. This is a major concern for Ligand A, as low logP can hinder membrane permeability and bioavailability.
4. **HBD:** Ligand A (3) and Ligand B (2) are both acceptable.
5. **HBA:** Ligand A (5) and Ligand B (3) are both acceptable.
6. **QED:** Both ligands have similar, good QED values (0.668 and 0.669).
7. **DILI:** Ligand B (10.585) has a much lower DILI risk than Ligand A (68.941). This is a significant advantage for Ligand B.
8. **BBB:** Ligand B (66.033) has a slightly higher BBB penetration than Ligand A (55.37), but this isn't a critical factor for a cardiovascular target.
9. **Caco-2:** Ligand A (-5.288) is worse than Ligand B (-4.85). Both are negative, which is not ideal, but Ligand B is slightly better.
10. **Solubility:** Ligand A (-2.814) is worse than Ligand B (-2.506). Both are negative, which is not ideal, but Ligand B is slightly better.
11. **hERG:** Ligand A (0.153) has a slightly lower hERG risk than Ligand B (0.404), but both are relatively low.
12. **Cl_mic:** Ligand A (8.62) has significantly lower microsomal clearance than Ligand B (20.478), indicating better metabolic stability. This is a positive for Ligand A.
13. **t1/2:** Ligand A (-32.706) has a much longer in vitro half-life than Ligand B (12.211). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.015) has much lower P-gp efflux than Ligand B (0.028). This is a positive for Ligand A.
15. **Binding Affinity:** Ligand B (-6.2) has a slightly better binding affinity than Ligand A (-5.8). While a difference of 0.4 kcal/mol is noticeable, it's not a huge advantage, especially considering the other factors.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand B excels in logP and has a slightly better affinity. Ligand A has a poor logP.
**Overall Assessment:**
While Ligand A has advantages in metabolic stability (Cl_mic, t1/2) and P-gp efflux, its extremely low logP is a major drawback that will likely severely limit its bioavailability. The significantly lower DILI risk of Ligand B, combined with its better logP and acceptable other properties, makes it the more promising candidate. The slight advantage in binding affinity further supports this conclusion.
Output:
0
2025-04-17 23:08:43,979 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [351.491, 81.67, 1.199, 3, 4, 0.517, 5.312, 34.199, -5.285, -1.013, 0.211, -3.693, -17.421, 0.021, -5.5]
**Ligand B:** [344.419, 101.06, 1.355, 3, 7, 0.631, 45.638, 52.036, -5.301, -1.917, 0.236, 31.899, 24.668, 0.006, -5.5]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (351.491) is slightly higher, but both are acceptable.
2. **TPSA:** Ligand A (81.67) is better than Ligand B (101.06). ADRB2 is not a CNS target, but lower TPSA generally aids absorption.
3. **logP:** Both are good (around 1.2-1.35). Ligand B is slightly higher, but both are within the optimal 1-3 range.
4. **HBD:** Both have 3 HBD, which is acceptable.
5. **HBA:** Ligand A (4) is better than Ligand B (7). Lower HBA is generally preferred.
6. **QED:** Ligand B (0.631) is better than Ligand A (0.517), indicating a slightly more drug-like profile.
7. **DILI:** Ligand A (5.312) is significantly better than Ligand B (45.638). This is a major advantage for Ligand A.
8. **BBB:** Not a primary concern for a cardiovascular target. Ligand B (52.036) is higher, but this isn't a deciding factor.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-5.285) is slightly better than Ligand B (-5.301), but both are concerning.
10. **Solubility:** Both are negative, indicating poor solubility. Ligand A (-1.013) is slightly better than Ligand B (-1.917).
11. **hERG:** Both are very low (0.211 and 0.236), indicating minimal hERG inhibition risk.
12. **Cl_mic:** Ligand A (-3.693) is significantly better than Ligand B (31.899). Lower clearance is highly desirable for metabolic stability.
13. **t1/2:** Ligand B (24.668) has a better in vitro half-life than Ligand A (-17.421).
14. **Pgp:** Both are very low (0.021 and 0.006), indicating minimal P-gp efflux.
15. **Binding Affinity:** Both have the same binding affinity (-5.5 kcal/mol).
**GPCR-Specific Considerations:**
For a cardiovascular GPCR like ADRB2, logP, TPSA, and metabolic stability (Cl_mic, t1/2) are important. While BBB isn't a priority, good permeability is.
**Overall Assessment:**
Ligand A has a significantly better DILI score and a much better microsomal clearance, which are critical for avoiding toxicity and ensuring reasonable drug exposure. While Ligand B has a slightly better QED and in vitro half-life, the DILI and Cl_mic advantages of Ligand A are far more important. The Caco-2 and solubility are poor for both, but can be addressed through formulation strategies. The binding affinity is identical.
Therefore, I would choose Ligand A.
Output:
1
2025-04-17 23:08:43,979 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [338.371, 111.9 , 3.177, 2. , 7. , 0.546, 78.402, 65.452, -5.2 , -4.172, 0.672, 25.375, -2.43 , 0.186, -7.1 ]
**Ligand B:** [350.384, 36.1 , 4.285, 1. , 1. , 0.803, 53.276, 87.864, -4.255, -5.394, 0.847, 38.848, 14.743, 0.528, -6.8 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). A (338) is slightly preferred.
2. **TPSA:** A (111.9) is higher than ideal for good oral absorption (<140), but B (36.1) is excellent. This is a significant advantage for B.
3. **logP:** Both are good (A: 3.177, B: 4.285), but B is pushing the upper limit, potentially leading to solubility issues.
4. **HBD:** A (2) and B (1) are both acceptable.
5. **HBA:** A (7) and B (1) are both acceptable, B is better.
6. **QED:** Both are reasonable (A: 0.546, B: 0.803), B is better.
7. **DILI:** A (78.4) is higher risk than B (53.3), favoring B.
8. **BBB:** A (65.5) is moderate, while B (87.9) is excellent. This is a significant advantage for B, given it's a GPCR.
9. **Caco-2:** Both are negative, indicating poor permeability. This is a concern for both, but A (-5.2) is slightly better than B (-4.255).
10. **Solubility:** Both are very poor (-4.172 and -5.394 respectively).
11. **hERG:** Both are low risk (A: 0.672, B: 0.847).
12. **Cl_mic:** A (25.4) is better than B (38.8), indicating better metabolic stability.
13. **t1/2:** B (14.7) is significantly better than A (-2.43).
14. **Pgp:** A (0.186) is better than B (0.528), indicating lower efflux.
15. **Binding Affinity:** A (-7.1) is slightly better than B (-6.8), but the difference is not huge.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, BBB, and affinity. B excels in TPSA and BBB, which are crucial for GPCRs. While its logP is a bit high, the excellent BBB penetration and lower DILI risk outweigh this concern. A has a slightly better affinity and Pgp profile, but the significantly worse BBB and higher DILI risk are major drawbacks.
**Conclusion:**
Considering the balance of properties and the specific priorities for a GPCR target, **Ligand B** is the more promising drug candidate. Its superior BBB penetration, lower DILI risk, and better QED outweigh the slightly higher logP and lower affinity.
Output:
0
2025-04-17 23:08:43,979 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.47 & 355.39 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (131.84) is slightly higher than Ligand B (71.51). For a cardiovascular GPCR, TPSA isn't a major concern unless aiming for CNS penetration, but lower is generally preferred for permeability. Ligand B is significantly better.
3. **logP:** Ligand B (3.477) is higher than Ligand A (1.902). While both are within the optimal 1-3 range, Ligand B is closer to the upper limit. This *could* present solubility issues, but isn't a dealbreaker.
4. **HBD:** Ligand A (4) has more HBDs than Ligand B (1). Lower HBDs are generally preferred for better permeability, favoring Ligand B.
5. **HBA:** Ligand A (7) has more HBAs than Ligand B (5). Similar to HBDs, lower HBAs are generally preferred, favoring Ligand B.
6. **QED:** Ligand B (0.785) has a higher QED score than Ligand A (0.528), indicating a more drug-like profile. This is a significant advantage for Ligand B.
7. **DILI:** Both ligands have acceptable DILI risk (42.46% and 44.59%). No clear advantage.
8. **BBB:** Ligand A (81.97%) has a slightly higher BBB penetration potential than Ligand B (77.28%). However, since ADRB2 is primarily a cardiovascular target, high BBB penetration isn't a priority.
9. **Caco-2:** Ligand A (-5.387) has a worse Caco-2 permeability than Ligand B (-4.63). Lower values indicate poorer permeability, favoring Ligand B.
10. **Solubility:** Ligand A (-3.391) has slightly worse solubility than Ligand B (-3.1). Solubility is important, but not a major deciding factor here.
11. **hERG:** Both ligands have low hERG inhibition risk (0.494% and 0.523%). No significant difference.
12. **Cl_mic:** Ligand B (52.069) has a lower microsomal clearance than Ligand A (58.313), indicating better metabolic stability. This is a positive for Ligand B.
13. **t1/2:** Ligand B (31.909 hours) has a significantly longer in vitro half-life than Ligand A (-12.874 hours). This is a major advantage for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.033% and 0.116%). No significant difference.
15. **Binding Affinity:** Ligand B (-6.0 kcal/mol) has a slightly better binding affinity than Ligand A (-5.8 kcal/mol). While the difference is not huge, it's still a positive for Ligand B.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in these areas. While BBB isn't critical for a cardiovascular target, Ligand A has a slightly higher value, but the other advantages of Ligand B outweigh this.
**Conclusion:**
Ligand B demonstrates a superior balance of properties, particularly in terms of drug-likeness (QED), metabolic stability (Cl_mic), half-life (t1/2), permeability (Caco-2), and binding affinity. The lower TPSA and HBD/HBA counts are also beneficial.
Output:
0
2025-04-17 23:08:43,979 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (348.49 and 352.37 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (58.64) is significantly better than Ligand B (104.39). For a GPCR, a lower TPSA is generally preferred for better permeability, and Ligand A is well below the 140 threshold. Ligand B is pushing the limit.
**3. logP:** Ligand A (2.654) is within the optimal 1-3 range. Ligand B (0.34) is quite low, potentially hindering membrane permeability and absorption.
**4. H-Bond Donors:** Both are acceptable (1 and 2 respectively), well below the 5 threshold.
**5. H-Bond Acceptors:** Ligand A (3) is better than Ligand B (5), but both are within the acceptable range of 10.
**6. QED:** Both ligands have good QED scores (0.686 and 0.744), indicating good drug-like properties.
**7. DILI Risk:** Ligand B (63.862) has a higher DILI risk than Ligand A (16.906). This is a significant advantage for Ligand A.
**8. BBB Penetration:** Both ligands have reasonably good BBB penetration (64.482 and 68.282). While higher is better, this isn't a critical differentiator here, as ADRB2 isn't necessarily a CNS target.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, indicating poor permeability. This is concerning for both, but the lower (more negative) value for Ligand B (-4.911) is worse than Ligand A (-4.888).
**10. Aqueous Solubility:** Both ligands have negative solubility values, indicating poor solubility. This is concerning for both, but the lower (more negative) value for Ligand B (-2.566) is worse than Ligand A (-2.958).
**11. hERG Inhibition:** Ligand A (0.366) has a slightly lower hERG risk than Ligand B (0.215), which is preferable.
**12. Microsomal Clearance:** Ligand A (42.468) has a higher (worse) microsomal clearance than Ligand B (16.78). This suggests Ligand B is more metabolically stable.
**13. In vitro Half-Life:** Ligand B (-27.417) has a significantly longer half-life than Ligand A (6.926). This is a major advantage for Ligand B.
**14. P-gp Efflux:** Ligand A (0.147) has a lower P-gp efflux liability than Ligand B (0.016), which is preferable.
**15. Binding Affinity:** Ligand A (-5.7 kcal/mol) has a stronger binding affinity than Ligand B (-3.3 kcal/mol). This is a substantial difference and a key factor.
**Overall Assessment:**
While Ligand B has a better half-life and metabolic stability, Ligand A is superior overall. The significantly stronger binding affinity (-5.7 vs -3.3 kcal/mol) is a major advantage, and the lower DILI risk is crucial. The lower TPSA and logP of Ligand A are also more favorable for a GPCR target. The permeability and solubility issues are concerning for both, but the other advantages of Ligand A outweigh these drawbacks.
Output:
1
2025-04-17 23:08:43,979 - INFO - Here's my reasoning and the final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, key priorities are logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB (though less critical for a cardiovascular target).
Let's break down the comparison:
1. **MW:** Both ligands are within the acceptable range (200-500 Da).
2. **TPSA:** Ligand A (131.36) is much better than Ligand B (21.06) as it is closer to the ideal <140 for good absorption. Ligand B is very low, potentially indicating poor solubility.
3. **logP:** Ligand A (-2.427) is within the optimal range (1-3), while Ligand B (4.987) is high, potentially leading to solubility issues and off-target effects.
4. **HBD/HBA:** Ligand A has 5 HBD and 7 HBA, which is acceptable. Ligand B has 0 HBD and 5 HBA, also acceptable, but the lack of HBD could impact solubility.
5. **QED:** Both have reasonable QED scores (A: 0.342, B: 0.649), with B being slightly better.
6. **DILI:** Ligand A (12.136) has a significantly lower DILI risk than Ligand B (26.173). This is a major advantage for Ligand A.
7. **BBB:** Ligand B (84.141) has a higher BBB penetration than Ligand A (18.534), but BBB is not a high priority for a cardiovascular target.
8. **Caco-2:** Both have similar negative values (-5.737 and -5.583), indicating poor permeability.
9. **Solubility:** Ligand A (0.046) has extremely poor solubility, while Ligand B (-3.891) is also poor, but less so.
10. **hERG:** Both ligands show very low hERG inhibition risk (A: 0.034, B: 0.893).
11. **Cl_mic:** Ligand A (2.322) has much lower microsomal clearance than Ligand B (64.445), indicating better metabolic stability.
12. **t1/2:** Ligand B (-14.241) has a much longer in vitro half-life than Ligand A (-7.161).
13. **Pgp:** Ligand A (0.002) has very low P-gp efflux liability, whereas Ligand B (0.729) is higher. This is a positive for Ligand A.
14. **Binding Affinity:** Ligand A (-6.6) has a slightly better binding affinity than Ligand B (-6.1). While the difference is not huge, it's a contributing factor.
**Overall Assessment:**
Ligand A is significantly better despite its poor solubility. The lower DILI risk, lower Cl_mic (better metabolic stability), lower Pgp efflux, and slightly better affinity outweigh the solubility concern. Ligand B's high logP and high DILI risk are major drawbacks. The poor Caco-2 values for both are concerning, but can be addressed with formulation strategies.
Output:
1
2025-04-17 23:08:43,980 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [346.427, 56.1, 3.131, 1, 6, 0.792, 47.421, 73.594, -4.589, -3.186, 0.862, 17.123, 52.893, 0.194, -6.7]
**Ligand B:** [368.507, 99.25, 0.491, 3, 7, 0.314, 34.277, 70.997, -5.715, -1.775, 0.209, 68.793, 26.23, 0.017, -8.6]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, BBB, and affinity are key):
1. **MW:** Both are within the acceptable 200-500 Da range. A (346.4) is slightly better.
2. **TPSA:** A (56.1) is excellent, well below the 140 threshold. B (99.25) is higher, but still potentially acceptable.
3. **logP:** A (3.131) is optimal. B (0.491) is quite low, potentially causing permeability issues. This is a significant drawback for B.
4. **HBD/HBA:** A (1 HBD, 6 HBA) is good. B (3 HBD, 7 HBA) is also acceptable, but slightly higher.
5. **QED:** A (0.792) is strong, indicating good drug-like properties. B (0.314) is considerably lower, raising concerns.
6. **DILI:** A (47.421) is good, low risk. B (34.277) is even better, lower risk.
7. **BBB:** Both have good BBB penetration (A: 73.594, B: 70.997).
8. **Caco-2:** A (-4.589) is not ideal, suggesting poor permeability. B (-5.715) is also poor.
9. **Solubility:** A (-3.186) is poor. B (-1.775) is better, but still not great.
10. **hERG:** A (0.862) is acceptable. B (0.209) is very good, low risk of cardiotoxicity.
11. **Cl_mic:** A (17.123) is relatively low, suggesting better metabolic stability. B (68.793) is much higher, indicating faster metabolism.
12. **t1/2:** A (52.893) is reasonable. B (26.23) is shorter, potentially requiring more frequent dosing.
13. **Pgp:** A (0.194) is good, indicating low efflux. B (0.017) is excellent, very low efflux.
14. **Affinity:** A (-6.7) is good. B (-8.6) is *significantly* better, a 1.9 kcal/mol advantage.
**Overall Assessment:**
Ligand B has a superior binding affinity, a lower DILI risk, and better P-gp efflux properties. However, it suffers from a low logP, a lower QED score, and higher metabolic clearance. Ligand A has a better logP and QED, and better metabolic stability, but its Caco-2 permeability and solubility are poor.
The affinity difference is substantial. For a GPCR, a 1.9 kcal/mol difference in binding is a significant advantage and can often outweigh some ADME liabilities, *especially* if those liabilities can be addressed through formulation or minor structural modifications. The low logP of B is a concern, but not insurmountable. The improved Pgp and DILI profiles are also valuable.
Therefore, despite the slightly worse ADME profile, the substantially improved binding affinity of Ligand B makes it the more promising candidate.
Output:
0
2025-04-17 23:08:43,980 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (343.467) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (55.4) is better than Ligand B (61.28). Both are below the 140 threshold for oral absorption, but lower is preferred.
3. **logP:** Both ligands have similar logP values (A: 3.808, B: 3.894), falling within the optimal 1-3 range.
4. **HBD:** Ligand A (1) is better than Ligand B (2). Lower HBD is generally preferred for better permeability.
5. **HBA:** Ligand A (3) is better than Ligand B (6). Lower HBA is generally preferred for better permeability.
6. **QED:** Ligand A (0.799) is significantly better than Ligand B (0.497), indicating a more drug-like profile.
7. **DILI:** Ligand A (32.299) has a much lower DILI risk than Ligand B (68.709). This is a significant advantage.
8. **BBB:** Ligand A (71.035) has a better BBB penetration score than Ligand B (60.45). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be beneficial or at least needs to be considered.
9. **Caco-2:** Ligand A (-4.313) is better than Ligand B (-5.128), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-4.611) is better than Ligand B (-3.573), indicating better aqueous solubility.
11. **hERG:** Ligand A (0.511) has a lower hERG risk than Ligand B (0.9). This is a crucial safety parameter.
12. **Cl_mic:** Ligand A (109.652) has a better (lower) microsomal clearance than Ligand B (92.647), suggesting better metabolic stability.
13. **t1/2:** Ligand B (108.878) has a much longer in vitro half-life than Ligand A (-18.341). This is a significant advantage.
14. **Pgp:** Ligand A (0.437) has a better (lower) Pgp efflux liability than Ligand B (0.643).
15. **Affinity:** Ligand B (-6.6) has a slightly better binding affinity than Ligand A (-8.0). However, the difference is not substantial enough to outweigh the numerous advantages of Ligand A.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Both ligands are good on logP. Ligand A is better on TPSA and Pgp. The affinity difference is small.
**Overall Assessment:**
Ligand A demonstrates a significantly more favorable overall profile. It excels in drug-likeness (QED), safety (DILI, hERG), absorption (Caco-2, Solubility), and metabolic stability (Cl_mic). While Ligand B has a longer half-life and slightly better affinity, the substantial advantages of Ligand A across multiple critical ADME-Tox parameters make it the more promising drug candidate.
Output:
1
2025-04-17 23:08:43,980 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.5 and 359.5 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (55.81) is better than Ligand B (62.3), being closer to the <140 threshold for good absorption. This is a slight advantage for A, particularly for a GPCR.
3. **logP:** Both ligands have good logP values (2.235 and 3.25), falling within the 1-3 range. Ligand B is slightly higher, which *could* be a minor concern for solubility, but is still acceptable.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1), but both are well within the acceptable limit of 5.
5. **HBA:** Ligand A (3) is slightly higher than Ligand B (4), both are within the acceptable limit of 10.
6. **QED:** Both ligands have similar QED values (0.859 and 0.825), indicating good drug-likeness.
7. **DILI:** Ligand A (22.84) has a significantly lower DILI risk than Ligand B (44.44). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (66.58) has a better BBB percentile than Ligand B (54.87), although neither are exceptionally high. This is a moderate advantage for A, as ADRB2 is a GPCR.
9. **Caco-2:** Ligand A (-4.658) is better than Ligand B (-5.035). Higher values indicate better intestinal absorption.
10. **Solubility:** Ligand A (-1.864) is better than Ligand B (-3.41). Higher values indicate better solubility.
11. **hERG:** Ligand A (0.935) has a slightly better hERG profile than Ligand B (0.601), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand A (34.26) has significantly lower microsomal clearance than Ligand B (84.97), suggesting better metabolic stability. This is a significant advantage for A.
13. **t1/2:** Ligand B (12.92) has a longer in vitro half-life than Ligand A (7.379). This is an advantage for B.
14. **Pgp:** Ligand A (0.492) has lower P-gp efflux than Ligand B (0.287), suggesting better bioavailability.
15. **Affinity:** Ligand A (-6.9 kcal/mol) has a slightly better binding affinity than Ligand B (-6.1 kcal/mol). While the difference is not huge, it's enough to be considered.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most crucial ADME properties (DILI, Cl_mic, Solubility, BBB, Pgp, hERG) and has a slightly better binding affinity. While Ligand B has a longer half-life, the superior overall profile of Ligand A, particularly its lower toxicity risk and better predicted absorption/distribution, makes it the more promising drug candidate for the ADRB2 receptor. The GPCR-specific priorities (logP, Pgp, TPSA, and affinity) are all reasonably well addressed by Ligand A.
**Output:**
1
2025-04-17 23:08:43,980 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (379.375) is slightly higher than Ligand B (357.401), but both are acceptable.
2. **TPSA:** Ligand B (78.51) is significantly better than Ligand A (120.62). For a GPCR, lower TPSA is generally preferred for better permeability.
3. **logP:** Both ligands have good logP values (A: 2.204, B: 1.22), falling within the optimal 1-3 range. Ligand B is slightly lower, which could potentially affect permeability, but is still reasonable.
4. **HBD:** Both have acceptable HBD counts (A: 1, B: 2).
5. **HBA:** Both have acceptable HBA counts (A: 9, B: 3). Ligand B is significantly better here.
6. **QED:** Both have similar and acceptable QED values (A: 0.685, B: 0.702), indicating good drug-like properties.
7. **DILI:** Ligand A has a very high DILI risk (99.496%), which is a major concern. Ligand B has a much lower, and acceptable, DILI risk (38.581%).
8. **BBB:** Ligand B (78.209%) has better BBB penetration than Ligand A (61.691%), which is a positive for a GPCR target, even if not strictly CNS-focused.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual. Assuming these are percentile scores, both have poor permeability.
10. **Solubility:** Ligand A (-4.009) and Ligand B (-2.573) both have poor solubility.
11. **hERG:** Both ligands have low hERG inhibition liability (A: 0.335, B: 0.269), which is good.
12. **Cl_mic:** Ligand B (-3.154) has significantly better metabolic stability (lower clearance) than Ligand A (29.753).
13. **t1/2:** Ligand B (-13.391) has a longer half-life than Ligand A (45.942).
14. **Pgp:** Both have very low Pgp efflux liability (A: 0.239, B: 0.017).
15. **Binding Affinity:** Ligand A (-7.3) has a slightly better binding affinity than Ligand B (-7.1), but the difference is small (0.2 kcal/mol).
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand B excels in TPSA, Pgp, and Cl_mic, and has acceptable logP. The small difference in affinity is outweighed by the significantly lower DILI risk and improved ADME properties of Ligand B.
**Conclusion:**
Ligand A's extremely high DILI risk is a deal-breaker. While it has slightly better affinity, the other properties of Ligand B are superior, making it a much more promising drug candidate.
Output:
0
2025-04-17 23:08:43,980 - INFO - Batch 383 complete. Total preferences: 6128
2025-04-17 23:08:43,980 - INFO - Processing batch 384/512...
2025-04-17 23:09:34,291 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [343.391, 105.04 , 0.059, 2. , 7. , 0.761, 64.831, 59.131, -5.474, -1.436, 0.222, -45.013, 24.009, 0.013, -4.7 ]
**Ligand B:** [362.392, 58.64 , 2.622, 1. , 3. , 0.757, 36.293, 90.074, -4.441, -2.117, 0.358, 29.171, -23.535, 0.09 , -7.2 ]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity) and general drug-like properties:
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (343.391) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (105.04) is higher than Ligand B (58.64). For a cardiovascular GPCR, TPSA isn't *as* critical as for a CNS target, but lower is still preferred for better absorption. Ligand B is significantly better here.
3. **logP:** Ligand A (0.059) is very low, potentially causing permeability issues. Ligand B (2.622) is within the optimal range (1-3). This is a significant advantage for Ligand B.
4. **HBD/HBA:** Ligand A has 2 HBD and 7 HBA, while Ligand B has 1 HBD and 3 HBA. Both are acceptable, but Ligand B is slightly more balanced.
5. **QED:** Both ligands have similar QED scores (0.761 and 0.757), indicating good drug-like properties.
6. **DILI:** Ligand A (64.831) has a higher DILI risk than Ligand B (36.293). This is a clear advantage for Ligand B.
7. **BBB:** Ligand A (59.131) has a lower BBB penetration than Ligand B (90.074). While ADRB2 isn't a CNS target, some off-target CNS effects are possible with GPCRs, and higher BBB is generally preferable to avoid these.
8. **Caco-2:** Ligand A (-5.474) has a very poor Caco-2 permeability, suggesting poor absorption. Ligand B (-4.441) is better, but still not great.
9. **Solubility:** Ligand A (-1.436) and Ligand B (-2.117) both have poor solubility.
10. **hERG:** Ligand A (0.222) has a slightly lower hERG risk than Ligand B (0.358), which is good.
11. **Cl_mic:** Ligand A (-45.013) has a much lower (better) microsomal clearance than Ligand B (29.171), indicating greater metabolic stability.
12. **t1/2:** Ligand A (24.009) has a longer half-life than Ligand B (-23.535). This is a positive for Ligand A.
13. **Pgp:** Ligand A (0.013) has a much lower Pgp efflux liability than Ligand B (0.09), indicating better bioavailability.
14. **Affinity:** Ligand B (-7.2) has a significantly stronger binding affinity than Ligand A (-4.7). This is a crucial advantage, as a >1.5 kcal/mol difference can outweigh other drawbacks.
**Overall Assessment:**
Ligand B clearly wins out due to its superior binding affinity and more favorable logP, TPSA, and DILI risk. While Ligand A has better metabolic stability (Cl_mic) and Pgp efflux, the significantly stronger binding of Ligand B and its better physicochemical properties are more critical for a GPCR target. The poor logP and Caco-2 permeability of Ligand A are major concerns.
Output:
0
2025-04-17 23:09:34,291 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (350.5 and 352.4 Da) are within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (78.43) is significantly better than Ligand B (110.69). For a GPCR, lower TPSA is generally preferred for better permeability. Ligand B is above the 90 A^2 threshold.
**3. logP:** Both ligands have acceptable logP values (2.231 and 1.571, respectively), falling within the 1-3 range. Ligand B is slightly lower, which *could* indicate slightly better solubility, but isn't a major concern for either.
**4. H-Bond Donors:** Ligand A has 3 HBD, and Ligand B has 2. Both are within the acceptable limit of <=5.
**5. H-Bond Acceptors:** Ligand A has 3 HBA, while Ligand B has 6. Ligand B is approaching the upper limit of 10, potentially impacting permeability.
**6. QED:** Both ligands have good QED scores (0.628 and 0.77), indicating good drug-like properties.
**7. DILI Risk:** Ligand A (12.524) has a much lower DILI risk than Ligand B (53.354). This is a significant advantage for Ligand A.
**8. BBB Penetration:** Ligand B (68.748) has better BBB penetration than Ligand A (56.65). While ADRB2 is primarily a cardiovascular target, some CNS off-target effects are possible and moderate BBB penetration isn't necessarily detrimental.
**9. Caco-2 Permeability:** Ligand A (-4.814) has better Caco-2 permeability than Ligand B (-5.268), indicating better intestinal absorption.
**10. Aqueous Solubility:** Ligand A (-3.23) has slightly better solubility than Ligand B (-1.958).
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (0.292 and 0.312), which is good.
**12. Microsomal Clearance:** Ligand B (21.657) has lower microsomal clearance than Ligand A (29.118), suggesting better metabolic stability.
**13. In vitro Half-Life:** Ligand A (1.293) has a slightly longer half-life than Ligand B (-15.55). However, the negative value for Ligand B is concerning and suggests a very short half-life.
**14. P-gp Efflux:** Both ligands have similar P-gp efflux liability (0.162 and 0.014).
**15. Binding Affinity:** Ligand A (-7.3) has a slightly better binding affinity than Ligand B (-7.1). While the difference is small, it's still a positive for Ligand A.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand A is the stronger candidate. Its lower TPSA, lower DILI risk, better Caco-2 permeability, and slightly better binding affinity outweigh Ligand B's slightly better BBB penetration and lower clearance. The negative in vitro half-life for Ligand B is a major red flag. The combination of favorable ADME properties and potency makes Ligand A the more promising drug candidate.
Output:
1
2025-04-17 23:09:34,292 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (359.897 and 359.495 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (38.33) is significantly better than Ligand B (66.32). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is quite high, potentially hindering absorption.
3. **logP:** Both ligands have acceptable logP values (4.981 and 3.348). Ligand A is a bit high, potentially leading to off-target effects, but still within a reasonable range. Ligand B is closer to the optimal 1-3 range.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 2 HBA, while Ligand B has 5. Ligand A is preferable here, as fewer HBA generally improves permeability.
6. **QED:** Ligand B (0.889) has a better QED score than Ligand A (0.685), indicating a more drug-like profile overall.
7. **DILI:** Both have acceptable DILI risk (39.667 and 36.254), below the 40 threshold. Ligand B is slightly better.
8. **BBB:** Ligand B (75.572) has a much higher BBB penetration percentile than Ligand A (40.403). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant for off-target effects assessment.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.938 and -4.702). This is unusual and suggests poor permeability in this *in vitro* assay. However, the values are quite similar.
10. **Solubility:** Ligand A (-5.199) has slightly worse solubility than Ligand B (-3.442), but both are poor. Solubility is a concern for both.
11. **hERG:** Ligand A (0.795) shows a slightly higher hERG risk than Ligand B (0.424), but both are reasonably low.
12. **Cl_mic:** Ligand B (54.377) has a significantly lower microsomal clearance than Ligand A (94.692), suggesting better metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand A (41.022) has a longer *in vitro* half-life than Ligand B (-4.833). This is a positive for Ligand A, potentially allowing for less frequent dosing. However, the negative value for Ligand B is concerning and likely an artifact of the prediction method.
14. **Pgp:** Ligand A (0.692) has slightly lower P-gp efflux liability than Ligand B (0.364), which is preferable.
15. **Binding Affinity:** Ligand A (-7.6 kcal/mol) has a considerably stronger binding affinity than Ligand B (-6.1 kcal/mol). This 1.5 kcal/mol difference is substantial and can outweigh many ADME drawbacks.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, TPSA, logP, Pgp, and affinity are key. Ligand A excels in binding affinity, which is paramount. While Ligand B has better BBB penetration and metabolic stability, the significant affinity difference of Ligand A is a strong driver. The higher TPSA of Ligand B is a concern.
**Overall Assessment:**
Despite Ligand B's better QED, DILI, and metabolic stability, the significantly stronger binding affinity of Ligand A (-7.6 vs -6.1 kcal/mol) is the deciding factor. The affinity difference is large enough to potentially overcome the slightly higher TPSA and lower QED of Ligand A. The negative Caco-2 values for both are concerning, but can be addressed through formulation strategies.
Output:
1
2025-04-17 23:09:34,292 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (378.372 and 362.499 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (72.64) is well below the 140 threshold and favorable for oral absorption. Ligand B (97.11) is still acceptable, but less optimal. This favors A.
3. **logP:** Both ligands (2.73 and 2.24) are within the optimal 1-3 range. No major difference.
4. **HBD:** Ligand A (0) is excellent, minimizing potential issues with hydrogen bonding. Ligand B (3) is acceptable, but A is preferred.
5. **HBA:** Both ligands (5) are within the acceptable limit of 10. No significant difference.
6. **QED:** Both ligands (0.671 and 0.718) have good drug-likeness scores, exceeding the 0.5 threshold. No significant difference.
7. **DILI:** Ligand A (69.407) and Ligand B (62.466) both have acceptable DILI risk, below the 60 threshold. B is slightly better.
8. **BBB:** Ligand A (88.833) has a much higher BBB penetration percentile than Ligand B (61.923). This is a significant advantage for a GPCR target, even if it's not a CNS target, as it indicates better distribution.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.513 and -4.989). This is unusual and suggests poor permeability. However, the values are relatively similar.
10. **Solubility:** Both ligands have negative solubility values (-4.056 and -3.786), indicating poor aqueous solubility. This is a concern for both.
11. **hERG:** Both ligands have low hERG inhibition risk (0.843 and 0.507). No significant difference.
12. **Cl_mic:** Ligand A (79.563) has a higher microsomal clearance than Ligand B (-0.848). This suggests Ligand B is more metabolically stable, which is desirable.
13. **t1/2:** Ligand A (-33.771) has a negative in vitro half-life, which is concerning. Ligand B (22.619) has a positive half-life, indicating better stability. This is a significant advantage for B.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.398 and 0.078). B is slightly better.
15. **Binding Affinity:** Ligand B (-7.0) has a slightly better binding affinity than Ligand A (-6.0). This is a substantial advantage, potentially outweighing some ADME drawbacks.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand B emerges as the more promising candidate. While Ligand A has better TPSA and BBB, Ligand B has a significantly stronger binding affinity and better metabolic stability (lower Cl_mic, positive t1/2). The slightly better DILI and Pgp profiles of Ligand B are also beneficial. The solubility and Caco-2 issues are present in both, and would require formulation strategies to address. The affinity difference is substantial enough to outweigh the advantages of Ligand A.
Output:
0
2025-04-17 23:09:34,292 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (365.543 and 370.49 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (47.36) is significantly better than Ligand B (66.48). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (3.182) is slightly higher than Ligand B (1.939), both are within the optimal 1-3 range. Ligand A is preferable.
4. **HBD:** Ligand A (0) is better than Ligand B (1). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (5) is slightly better than Ligand B (4). Both are within the acceptable limit of 10.
6. **QED:** Both ligands have good QED scores (0.664 and 0.777), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (26.638) has a much lower DILI risk than Ligand B (39.124). This is a significant advantage for Ligand A.
8. **BBB:** Both ligands have similar BBB penetration (83.249 and 81.698). Not a major factor for a cardiovascular target.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. This is a concern for both.
10. **Solubility:** Both ligands have negative solubility values, indicating poor solubility. This is a concern for both.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.649 and 0.632). This is good for both.
12. **Cl_mic:** Ligand A (93.131) has a higher microsomal clearance than Ligand B (39.037). This means Ligand B is more metabolically stable, which is a significant advantage.
13. **t1/2:** Ligand A (29.854) has a longer in vitro half-life than Ligand B (16.995). This is a positive for Ligand A.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.365 and 0.244).
15. **Binding Affinity:** Ligand B (-7.5 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.7 kcal/mol). This is a substantial advantage for Ligand B, potentially outweighing some of the ADME concerns.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A has better logP and TPSA, while Ligand B has a much stronger affinity. The difference in affinity (-1.8 kcal/mol) is substantial. While both have poor Caco-2 and solubility, the superior affinity of Ligand B is likely to be more critical for achieving efficacy. The lower DILI risk of Ligand A is appealing, but the significantly improved binding of Ligand B is a stronger driver.
**Conclusion:**
Despite the lower DILI score and slightly better TPSA of Ligand A, the significantly stronger binding affinity of Ligand B (-7.5 kcal/mol vs -5.7 kcal/mol) makes it the more promising drug candidate. The difference in affinity is large enough to potentially overcome the slightly higher DILI risk and similar permeability/solubility issues.
Output:
0
2025-04-17 23:09:34,292 - INFO - Here's my reasoning and the final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, prioritizing logP, TPSA, Pgp, and binding affinity is crucial.
* **Molecular Weight:** Both ligands are within the acceptable range (200-500 Da).
* **TPSA:** Ligand A (54.02) is significantly better than Ligand B (69.72). Lower TPSA generally favors oral absorption, which is important for a cardiovascular drug.
* **logP:** Ligand A (4.697) is higher than Ligand B (1.063). While a logP of 4.697 is approaching the upper limit, it's still reasonable. Ligand B's logP is quite low, potentially hindering membrane permeability.
* **H-Bond Donors/Acceptors:** Both are within acceptable limits.
* **QED:** Both have good QED scores (>0.5), indicating drug-likeness.
* **DILI:** Ligand B (19.698) has a much lower DILI risk than Ligand A (38.813), which is a significant advantage.
* **BBB:** Ligand A (79.488) has better BBB penetration than Ligand B (65.839). While not a primary concern for a cardiovascular target, some CNS off-target effects could be relevant.
* **Caco-2 Permeability:** Ligand A (-4.951) is better than Ligand B (-5.174), suggesting better intestinal absorption.
* **Aqueous Solubility:** Ligand B (-2.872) has better solubility than Ligand A (-4.195).
* **hERG:** Ligand A (0.67) has a slightly higher hERG risk than Ligand B (0.207).
* **Microsomal Clearance:** Ligand B (25.918) has lower microsomal clearance than Ligand A (64.022), indicating better metabolic stability.
* **In vitro Half-Life:** Ligand B (-4.673) has a negative half-life, which is unusual and suggests very rapid metabolism or instability. Ligand A (24.199) is much better.
* **P-gp Efflux:** Ligand A (0.64) has higher P-gp efflux than Ligand B (0.02), which is less desirable.
* **Binding Affinity:** Ligand A (-7.3) has a significantly better binding affinity than Ligand B (-6.2). This 1.1 kcal/mol difference is substantial and can outweigh some of the ADME drawbacks.
**Overall Assessment:**
Ligand A has a much stronger binding affinity and better Caco-2 permeability, which are crucial for efficacy. While Ligand B has a better safety profile (lower DILI, lower hERG, better solubility, and lower P-gp efflux), its significantly weaker binding affinity and negative half-life are major concerns. The slightly elevated DILI and hERG risk of Ligand A can be addressed during further optimization, but improving a weak binder is often more challenging. Given the GPCR target class, the binding affinity is the most important factor here.
**Output:**
1
2025-04-17 23:09:34,292 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [343.427, 74.69, 2.027, 2, 5, 0.869, 45.522, 66.654, -4.689, -2.651, 0.807, 14.84, 15.223, 0.155, -7.2]
**Ligand B:** [384.542, 49.41, 3.672, 1, 4, 0.787, 51.609, 82.784, -4.835, -4.468, 0.694, 44.765, 10.916, 0.427, -6.6]
Here's a breakdown, prioritizing GPCR properties (logP, Pgp, TPSA, BBB, and affinity):
1. **Molecular Weight:** Both are within the ideal range (200-500 Da). A is slightly lower (343) than B (384).
2. **TPSA:** A (74.69) is higher than B (49.41). B is much better here, falling well below the 140 threshold for oral absorption and closer to the ideal for GPCRs.
3. **logP:** A (2.027) is within the optimal range, while B (3.672) is a bit higher. Both are acceptable, but A is slightly preferred.
4. **H-Bond Donors/Acceptors:** A has 2 HBD and 5 HBA, B has 1 HBD and 4 HBA. Both are reasonable.
5. **QED:** A (0.869) is better than B (0.787), indicating a more drug-like profile.
6. **DILI:** Both are acceptable, but A (45.522) is slightly better than B (51.609).
7. **BBB:** B (82.784) is significantly better than A (66.654). This is a key advantage for a GPCR, even a cardiovascular one, as some CNS off-target effects are always a consideration.
8. **Caco-2:** Both are negative, indicating poor permeability. This is a concern for both.
9. **Solubility:** Both are negative, indicating poor solubility. This is a concern for both.
10. **hERG:** A (0.807) is slightly higher than B (0.694), indicating a slightly higher risk of hERG inhibition. B is preferred.
11. **Cl_mic:** A (14.84) is lower than B (44.765), suggesting better metabolic stability. This is a significant advantage for A.
12. **t1/2:** A (15.223) is much longer than B (10.916), indicating a longer half-life. This is a major advantage for A.
13. **Pgp:** A (0.155) is much lower than B (0.427), indicating lower P-gp efflux. This is a significant advantage for A.
14. **Binding Affinity:** A (-7.2) is significantly better than B (-6.6). A 1.5 kcal/mol difference is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand A has a significantly better binding affinity, lower P-gp efflux, better metabolic stability (lower Cl_mic), and a longer half-life. These are substantial advantages. While Ligand B has a better TPSA and BBB, the affinity difference is too large to ignore, and the improvements in metabolic stability and efflux for A are highly desirable. The Caco-2 and solubility are poor for both, but these can be addressed with formulation strategies.
Therefore, I prefer Ligand A.
Output:
1
2025-04-17 23:09:34,292 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (341.455 and 355.483 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (73.99) is significantly better than Ligand B (93.78). For a GPCR, keeping TPSA low is beneficial for permeability, and A is well under the 140 threshold.
3. **logP:** Ligand A (2.763) is optimal (1-3). Ligand B (-0.985) is below 1, which could hinder permeation. This is a significant advantage for A.
4. **HBD:** Both ligands have 3 HBD, which is within the acceptable limit of 5.
5. **HBA:** Ligand A has 2 HBA, while Ligand B has 5. Lower HBA is generally preferred for permeability, giving A an edge.
6. **QED:** Ligand A (0.636) is better than Ligand B (0.494), indicating a more drug-like profile.
7. **DILI:** Ligand A (26.173) has a much lower DILI risk than Ligand B (18.457). This is a crucial advantage for A.
8. **BBB:** Ligand A (65.374) has a better BBB penetration percentile than Ligand B (35.207). While ADRB2 isn't exclusively a CNS target, some cardiovascular effects are mediated through CNS pathways, and better BBB penetration isn't detrimental.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.171 and -5.422). These values are unusual and difficult to interpret without context. However, a more negative value *might* indicate lower permeability.
10. **Solubility:** Ligand A (-3.13) is better than Ligand B (-0.785). Higher solubility is generally preferred.
11. **hERG:** Ligand A (0.312) has a lower hERG inhibition risk than Ligand B (0.1). This is a significant safety advantage for A.
12. **Cl_mic:** Ligand A (23.075) has a higher (worse) microsomal clearance than Ligand B (10.167), indicating faster metabolism. This is a disadvantage for A.
13. **t1/2:** Ligand A (-20.267) has a shorter in vitro half-life than Ligand B (-11.839). This is a disadvantage for A.
14. **Pgp:** Ligand A (0.12) has a lower Pgp efflux liability than Ligand B (0.001). Lower Pgp is generally preferred.
15. **Binding Affinity:** Ligand A (-7.2 kcal/mol) has a slightly better binding affinity than Ligand B (-6.4 kcal/mol). This difference (0.8 kcal/mol) is significant enough to consider.
**Overall Assessment:**
Ligand A is significantly better across several key ADME properties (logP, TPSA, DILI, hERG, Solubility, Pgp) and has a slightly better binding affinity. While Ligand B has better metabolic stability (lower Cl_mic) and a longer half-life, the advantages of Ligand A in terms of safety (DILI, hERG) and permeability (logP, TPSA) are more critical for a GPCR target like ADRB2. The slightly lower affinity of Ligand B is unlikely to outweigh these substantial ADME benefits.
Output:
1
2025-04-17 23:09:34,292 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [369.418, 94.75, 2.167, 1, 6, 0.752, 66.693, 68.282, -4.579, -4.437, 0.462, 53.013, -9.514, 0.08, -6.1]
**Ligand B:** [344.459, 67.23, 2.081, 1, 4, 0.832, 19.426, 67.08, -4.912, -1.491, 0.218, 27.991, -13.175, 0.049, -7.7]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (344.459) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (94.75) is higher than Ligand B (67.23). Both are acceptable for a non-CNS GPCR, but Ligand B is better.
3. **logP:** Both are within the optimal range (1-3). Very similar values.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 6 HBA, while Ligand B has 4. Ligand B is slightly better here.
6. **QED:** Both are above 0.5, indicating good drug-likeness. Ligand B (0.832) is better than Ligand A (0.752).
7. **DILI:** Ligand A (66.693) has a significantly higher DILI risk than Ligand B (19.426). This is a major concern for Ligand A.
8. **BBB:** Both have similar BBB penetration, around 67-68%, which isn't a primary concern for a non-CNS target like ADRB2, but it's not detrimental.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. Ligand A (-4.579) is slightly worse than Ligand B (-4.912).
10. **Solubility:** Ligand B (-1.491) has better solubility than Ligand A (-4.437).
11. **hERG:** Both have very low hERG inhibition risk.
12. **Cl_mic:** Ligand B (27.991) has significantly lower microsomal clearance than Ligand A (53.013), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-13.175) has a longer in vitro half-life than Ligand A (-9.514).
14. **Pgp:** Both have very low Pgp efflux liability.
15. **Affinity:** Ligand B (-7.7 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.1 kcal/mol). This is a substantial advantage.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, and affinity. Both ligands are good on logP and Pgp. Ligand B is better on TPSA, and significantly better on affinity. The biggest difference is the DILI risk and metabolic stability. Ligand A's high DILI risk is a significant red flag. Ligand B's better metabolic stability (lower Cl_mic and longer t1/2) is also a major advantage. The affinity difference is also substantial.
**Conclusion:**
Ligand B is the superior candidate due to its significantly lower DILI risk, better metabolic stability, better solubility, and substantially stronger binding affinity. While both have poor Caco-2 permeability, the other advantages of Ligand B outweigh this drawback.
0
2025-04-17 23:09:34,293 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [340.471, 50.16, 3.771, 1, 3, 0.901, 15.781, 86.119, -4.872, -3.263, 0.822, 32.41, 5.43, 0.557, -6.8]
**Ligand B:** [358.41, 99.1, -0.232, 3, 5, 0.63, 24.506, 71.384, -4.876, -1.309, 0.337, -19.355, -10.585, 0.025, -8.8]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity, and BBB):
1. **MW:** Both are within the acceptable 200-500 Da range. Ligand A (340.471) is slightly preferred.
2. **TPSA:** Ligand A (50.16) is significantly better than Ligand B (99.1). Below 140 is good for oral absorption, and lower is better for GPCRs. Ligand A is much more favorable.
3. **logP:** Ligand A (3.771) is within the optimal 1-3 range. Ligand B (-0.232) is quite low, potentially hindering membrane permeability. This is a significant negative for Ligand B.
4. **HBD/HBA:** Both are reasonable. Ligand A (1 HBD, 3 HBA) is slightly better than Ligand B (3 HBD, 5 HBA).
5. **QED:** Ligand A (0.901) is excellent, indicating high drug-likeness. Ligand B (0.63) is acceptable, but lower.
6. **DILI:** Ligand A (15.781) has a much lower DILI risk than Ligand B (24.506).
7. **BBB:** Ligand A (86.119) has a better BBB penetration percentile than Ligand B (71.384). While ADRB2 isn't exclusively a CNS target, some peripheral effects are mediated by CNS pathways, and better BBB penetration is generally a plus.
8. **Caco-2:** Both are negative, indicating poor permeability. This is a concern for both.
9. **Solubility:** Both are negative, indicating poor solubility. This is a concern for both.
10. **hERG:** Ligand A (0.822) has a lower hERG risk than Ligand B (0.337).
11. **Cl_mic:** Ligand A (32.41) has a better (lower) microsomal clearance than Ligand B (-19.355). This suggests better metabolic stability for Ligand A.
12. **t1/2:** Ligand A (5.43) has a longer in vitro half-life than Ligand B (-10.585).
13. **Pgp:** Ligand A (0.557) shows lower P-gp efflux than Ligand B (0.025). This is favorable for bioavailability.
14. **Affinity:** Ligand B (-8.8) has a stronger binding affinity than Ligand A (-6.8) by 2 kcal/mol. This is a substantial difference.
**Overall Assessment:**
While Ligand B has a superior binding affinity, the significant drawbacks in logP, TPSA, DILI, metabolic stability (Cl_mic and t1/2), and Pgp efflux are major concerns. Ligand A, while having a slightly weaker affinity, presents a much more balanced profile with better physicochemical properties, lower toxicity risk, and improved ADME characteristics. The better logP, TPSA, and BBB penetration of Ligand A are particularly important for a GPCR target. The 2 kcal/mol affinity difference can potentially be overcome with further optimization of Ligand A.
Therefore, I would choose Ligand A as the more viable drug candidate.
1
2025-04-17 23:09:34,293 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [362.455, 78.68, 2.587, 1, 5, 0.91, 79.837, 59.442, -4.61, -2.965, 0.301, 23.81, 4.072, 0.164, -5.9]
**Ligand B:** [338.411, 78.09, 1.943, 2, 3, 0.818, 62.776, 50.601, -4.701, -3.671, 0.257, 24.41, -9.224, 0.057, -5.6]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (338.411) is slightly lower, which is generally favorable for permeability, but both are acceptable.
2. **TPSA:** Both are around 78-79, which is good, but slightly above the optimal <140 for oral absorption. Not a major concern for a cardiovascular target.
3. **logP:** Both have good logP values (2.587 and 1.943), falling within the 1-3 range. Ligand B is a bit lower, which could slightly impact permeability.
4. **HBD:** Ligand A has 1 HBD, Ligand B has 2. Both are acceptable (<=5).
5. **HBA:** Ligand A has 5 HBA, Ligand B has 3. Both are acceptable (<=10).
6. **QED:** Ligand A (0.91) has a better QED score than Ligand B (0.818), indicating a more drug-like profile.
7. **DILI:** Ligand A (79.837) has a higher DILI risk than Ligand B (62.776). This is a significant negative for Ligand A.
8. **BBB:** Both have moderate BBB penetration (59.442 and 50.601). Not a primary concern for a cardiovascular target, but lower is fine.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. This is a concern for both.
10. **Solubility:** Both have negative solubility values, indicating poor solubility. This is a concern for both.
11. **hERG:** Both have low hERG inhibition liability (0.301 and 0.257), which is good.
12. **Cl_mic:** Both have similar microsomal clearance values (23.81 and 24.41).
13. **t1/2:** Ligand B has a significantly longer in vitro half-life (-9.224) than Ligand A (4.072). This is a major advantage for Ligand B.
14. **Pgp:** Ligand A (0.164) has lower P-gp efflux liability than Ligand B (0.057), which is favorable.
15. **Affinity:** Both have excellent binding affinity (-5.9 and -5.6 kcal/mol). The difference is minor.
**GPCR-Specific Priorities:**
For ADRB2 (a cardiovascular GPCR), logP, Pgp, TPSA, and affinity are key. Both ligands perform reasonably well on these parameters. However, the DILI risk for Ligand A is concerning, and the longer half-life of Ligand B is a significant advantage.
**Conclusion:**
Despite Ligand A having a slightly better QED and lower Pgp efflux, the significantly higher DILI risk and shorter half-life make Ligand B the more promising candidate. The longer half-life of Ligand B is particularly valuable for a cardiovascular drug, potentially allowing for less frequent dosing.
Output:
0
2025-04-17 23:09:34,293 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [340.379, 77.52, 1.995, 1, 5, 0.865, 74.021, 78.79, -4.493, -3.546, 0.51, 70.87, 14.986, 0.137, -6.4]
**Ligand B:** [351.422, 93.45, 1.623, 3, 4, 0.621, 44.087, 82.862, -4.834, -3.042, 0.603, 33.007, 0.73, 0.052, -5.8]
**Step-by-step Comparison:**
1. **MW:** Both are within the ideal 200-500 Da range. Ligand A (340.379) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (77.52) is significantly better than Ligand B (93.45). ADRB2 is a cardiovascular target, so CNS penetration isn't critical, but lower TPSA generally correlates with better absorption.
3. **logP:** Both are within the optimal 1-3 range. Ligand A (1.995) is slightly higher, which could be a minor advantage.
4. **HBD:** Ligand A (1) is better than Ligand B (3). Fewer HBDs are generally preferred for better permeability.
5. **HBA:** Ligand A (5) is better than Ligand B (4). Fewer HBAs are generally preferred for better permeability.
6. **QED:** Ligand A (0.865) is significantly better than Ligand B (0.621), indicating a more drug-like profile.
7. **DILI:** Ligand B (44.087) is much better than Ligand A (74.021). This is a significant advantage for Ligand B.
8. **BBB:** Ligand B (82.862) is better than Ligand A (78.79). While not a primary concern for a cardiovascular target, higher BBB is rarely detrimental.
9. **Caco-2:** Both are negative, indicating good permeability. Ligand B (-4.834) is slightly better than Ligand A (-4.493).
10. **Solubility:** Both are negative, indicating good solubility. Ligand B (-3.042) is slightly better than Ligand A (-3.546).
11. **hERG:** Both are low, indicating low cardiotoxicity risk. Ligand A (0.51) is slightly better than Ligand B (0.603).
12. **Cl_mic:** Ligand B (33.007) is significantly better than Ligand A (70.87), indicating better metabolic stability.
13. **t1/2:** Ligand A (14.986) is better than Ligand B (0.73). A longer half-life is generally preferred.
14. **Pgp:** Ligand A (0.137) is significantly better than Ligand B (0.052), indicating lower P-gp efflux.
15. **Affinity:** Ligand A (-6.4) is better than Ligand B (-5.8). This is a 1.5 kcal/mol difference, which is a significant advantage.
**GPCR-Specific Priorities:** For ADRB2, we prioritize logP, Pgp, TPSA, and affinity. Ligand A excels in affinity and Pgp, and has a better TPSA. Ligand B has a better logP and DILI.
**Overall Assessment:**
While Ligand B has a significantly lower DILI risk and better metabolic stability, Ligand A's superior binding affinity (-6.4 vs -5.8 kcal/mol) is a major advantage, especially for a GPCR. The difference in affinity is likely to outweigh the slightly higher DILI risk and lower metabolic stability. Furthermore, Ligand A has better QED, HBD, HBA, and Pgp values.
Therefore, I would choose Ligand A.
Output:
1
2025-04-17 23:09:34,293 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (384.219 Da) is slightly higher than Ligand B (346.471 Da), but both are acceptable.
2. **TPSA:** Ligand B (69.64) is significantly better than Ligand A (107.49). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (4.191) is higher than Ligand B (1.858). While both are within the acceptable range, Ligand A is approaching a value where solubility could become an issue. Ligand B's logP is closer to optimal.
4. **HBD:** Both ligands have 2 HBD, which is good.
5. **HBA:** Ligand A has 6 HBA, and Ligand B has 3. Ligand B is preferable here, as fewer HBA generally improves permeability.
6. **QED:** Ligand B (0.747) has a better QED score than Ligand A (0.346), indicating a more drug-like profile.
7. **DILI:** Ligand B (8.181) has a much lower DILI risk than Ligand A (90.423). This is a significant advantage for Ligand B.
8. **BBB:** Ligand B (79.992) has a higher BBB penetration score than Ligand A (54.478). While not critical for a cardiovascular target, it's a neutral benefit.
9. **Caco-2:** Both ligands have similar negative Caco-2 values (-4.853 and -4.755), suggesting similar permeability issues. These values are unusual and suggest poor permeability.
10. **Solubility:** Ligand B (-3.111) has better solubility than Ligand A (-6.481). This is important given Ligand A's higher logP.
11. **hERG:** Ligand B (0.372) has a lower hERG risk than Ligand A (0.647). This is a crucial advantage, as hERG inhibition can lead to cardiotoxicity.
12. **Cl_mic:** Ligand B (33.595) has significantly lower microsomal clearance than Ligand A (80.792), indicating better metabolic stability.
13. **t1/2:** Ligand B (11.035 hours) has a longer half-life than Ligand A (30.5 hours). This is a positive attribute.
14. **Pgp:** Ligand B (0.038) has much lower P-gp efflux liability than Ligand A (0.26). This is beneficial for oral bioavailability.
15. **Binding Affinity:** Both ligands have very similar and excellent binding affinities (-7.9 and -7.8 kcal/mol). The difference is negligible.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP, TPSA, Pgp, and has comparable affinity. The lower DILI and hERG risks are also major advantages.
**Conclusion:**
Ligand B is the superior candidate. It has a better overall ADME-Tox profile, lower risk of adverse effects (DILI, hERG), better solubility, and comparable binding affinity to Ligand A. While both have permeability concerns (negative Caco-2 values), Ligand B's other advantages outweigh this drawback.
Output:
0
2025-04-17 23:09:34,293 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (386.514) is slightly higher than Ligand B (345.487), but both are acceptable.
2. **TPSA:** Both ligands have TPSA values below 140, suggesting good oral absorption potential. Ligand A (69.64) is slightly higher than Ligand B (64.41), but both are good.
3. **logP:** Both ligands have logP values within the optimal range (1-3). Ligand B (2.812) is slightly higher than Ligand A (1.97), which is acceptable.
4. **HBD:** Ligand A (2) and Ligand B (0) are both within the acceptable limit of <=5.
5. **HBA:** Ligand A (5) and Ligand B (3) are both within the acceptable limit of <=10.
6. **QED:** Both ligands have reasonable QED scores (A: 0.812, B: 0.679), indicating good drug-like properties. Ligand A is better here.
7. **DILI:** Ligand A (34.665) has a significantly lower DILI risk than Ligand B (18.418). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (78.984) has a better BBB penetration score than Ligand A (66.382). Since ADRB2 is a GPCR, BBB penetration is a consideration, but not paramount for cardiovascular targets.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and potentially problematic. However, the magnitude is similar (-5.072 for A, -4.591 for B).
10. **Solubility:** Both ligands have negative solubility values, which is also unusual and potentially problematic. The magnitude is similar (-2.954 for A, -3.093 for B).
11. **hERG:** Both ligands have low hERG inhibition liability (A: 0.492, B: 0.609), which is good.
12. **Cl_mic:** Ligand A (10.106) has a lower microsomal clearance than Ligand B (58.325), indicating better metabolic stability.
13. **t1/2:** Ligand B (-9.981) has a negative in vitro half-life, which is concerning. Ligand A (6.153) has a positive half-life.
14. **Pgp:** Both ligands have low P-gp efflux liability (A: 0.246, B: 0.384).
15. **Binding Affinity:** Ligand A (-8.0) has a significantly stronger binding affinity than Ligand B (-2.9). This is a substantial advantage.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, Pgp, TPSA, and affinity. Ligand A performs better in affinity and has acceptable values for the other parameters. While Ligand B has better BBB penetration, the difference isn't substantial enough to outweigh the significant advantages of Ligand A in affinity, DILI risk, and metabolic stability. The negative Caco-2 and solubility values are concerning for both, but the superior binding affinity and lower toxicity of Ligand A make it the more promising candidate.
**Output:**
1
2025-04-17 23:09:34,293 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [418.257, 56.92, 3.295, 3, 2, 0.714, 61.884, 84.917, -5.198, -3.925, 0.904, 17.74, 33.806, 0.558, -8.4]
**Ligand B:** [349.406, 85.43, 1.734, 3, 3, 0.708, 47.77, 63.28, -5.239, -2.909, 0.412, 10.887, 0.051, 0.085, -5.5]
**Step-by-step comparison:**
1. **MW:** Ligand A (418.257) is within the ideal range (200-500 Da). Ligand B (349.406) is also within range. No clear advantage here.
2. **TPSA:** Ligand A (56.92) is good, well below 140. Ligand B (85.43) is still acceptable, but higher. A is better.
3. **logP:** Ligand A (3.295) is optimal (1-3). Ligand B (1.734) is on the lower side, potentially impacting permeability. A is better.
4. **HBD:** Both have 3 HBD, acceptable.
5. **HBA:** Ligand A has 2 HBA, Ligand B has 3. Both are acceptable.
6. **QED:** Both are very similar (0.714 and 0.708), indicating good drug-likeness.
7. **DILI:** Ligand A (61.884) is higher risk than Ligand B (47.77). B is better.
8. **BBB:** Ligand A (84.917) is significantly better than Ligand B (63.28). This is important for a GPCR, even a cardiovascular one, as off-target CNS effects are always a concern. A is much better.
9. **Caco-2:** Both are negative, indicating poor permeability. This is a concern for both.
10. **Solubility:** Both are negative, indicating poor solubility. This is a concern for both.
11. **hERG:** Ligand A (0.904) is higher risk than Ligand B (0.412). B is better.
12. **Cl_mic:** Ligand A (17.74) has higher clearance than Ligand B (10.887), suggesting lower metabolic stability. B is better.
13. **t1/2:** Ligand A (33.806) has a much longer half-life than Ligand B (0.051). A is much better.
14. **Pgp:** Ligand A (0.558) has lower P-gp efflux than Ligand B (0.085). A is better.
15. **Affinity:** Ligand A (-8.4) has a significantly stronger binding affinity than Ligand B (-5.5) - a difference of 2.9 kcal/mol. This is a substantial advantage.
**Overall Assessment:**
Ligand A has a significantly stronger binding affinity, better BBB penetration, a longer half-life, and lower P-gp efflux. While it has a higher DILI risk and hERG inhibition liability, the substantial advantage in binding affinity and the good BBB penetration outweigh these concerns. The lower logP and Caco-2/Solubility for both are problematic, but the stronger binding of A makes it more likely to be effective even with less-than-ideal absorption.
Therefore, I prefer Ligand A.
Output:
1
2025-04-17 23:09:34,293 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A: [348.487, 58.64, 3.352, 1, 3, 0.567, 21.093, 70.609, -5.121, -3.141, 0.309, 40.718, -15.79, 0.131, -6.1]**
**Ligand B: [354.332, 92.08, 2.028, 2, 3, 0.823, 39.473, 91.392, -4.755, -3.695, 0.676, 26.252, -13.029, 0.061, -3.2]**
Here's a breakdown, considering the guidelines and GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal range (200-500 Da). A is 348.487, B is 354.332. Very similar.
2. **TPSA:** A (58.64) is excellent, well below the 140 threshold and good for permeability. B (92.08) is higher, but still acceptable, though less optimal.
3. **logP:** A (3.352) is optimal. B (2.028) is good but a bit lower, potentially impacting membrane permeability.
4. **HBD:** A (1) is good. B (2) is acceptable.
5. **HBA:** Both A (3) and B (3) are good.
6. **QED:** A (0.567) is good, indicating drug-likeness. B (0.823) is even better.
7. **DILI:** A (21.093) is very good, low risk. B (39.473) is also good, but slightly higher risk than A.
8. **BBB:** A (70.609) is good. B (91.392) is excellent. While ADRB2 is cardiovascular, some CNS penetration can be relevant for off-target effects or potential central modulation.
9. **Caco-2:** Both are negative, indicating poor permeability. A (-5.121) is worse than B (-4.755).
10. **Solubility:** Both are negative, indicating poor solubility. A (-3.141) is worse than B (-3.695).
11. **hERG:** Both are very low, indicating low risk of cardiotoxicity. A (0.309) is slightly better than B (0.676).
12. **Cl_mic:** A (40.718) is higher than B (26.252), indicating faster metabolism and lower metabolic stability. This is a significant drawback for A.
13. **t1/2:** A (-15.79) is worse than B (-13.029), indicating a shorter half-life.
14. **Pgp:** A (0.131) is much lower than B (0.061), indicating lower P-gp efflux and potentially better bioavailability.
15. **Affinity:** A (-6.1) is significantly better than B (-3.2). This is a substantial advantage.
**Overall Assessment:**
Ligand A has a much stronger binding affinity, which is a critical factor for GPCRs. It also has a lower DILI risk and slightly better hERG profile. However, it suffers from significantly worse metabolic stability (higher Cl_mic, shorter half-life) and permeability/solubility. Ligand B has better QED, BBB penetration, metabolic stability, and permeability/solubility, but its affinity is considerably weaker.
Considering the balance, the strong affinity of Ligand A is a major advantage that can potentially be overcome with further optimization to improve its metabolic stability and solubility. The difference in affinity (-6.1 vs -3.2 kcal/mol) is substantial (a 2.9 kcal/mol difference), and this outweighs the ADME concerns *at this stage*. Optimization strategies targeting metabolic hotspots and solubility enhancement are well-established.
Therefore, I would prioritize Ligand A for further development.
Output:
1
2025-04-17 23:09:34,293 - INFO - Batch 384 complete. Total preferences: 6144
2025-04-17 23:09:34,293 - INFO - Processing batch 385/512...
2025-04-17 23:10:23,013 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (380.853 Da) is slightly higher than Ligand B (367.804 Da), but both are acceptable.
2. **TPSA:** Ligand A (86.71) is better than Ligand B (57.65). For a cardiovascular GPCR, TPSA is not a critical factor, but lower is generally preferred for permeability.
3. **logP:** Ligand B (4.174) is slightly higher than the optimal range (1-3), while Ligand A (3.146) is within the optimal range. This favors Ligand A. High logP can lead to off-target effects.
4. **HBD:** Ligand A (2) is better than Ligand B (0). Having some HBDs can improve solubility.
5. **HBA:** Ligand A (4) and Ligand B (5) are both reasonable, but Ligand A is slightly better.
6. **QED:** Both ligands have similar QED values (A: 0.856, B: 0.717), indicating good drug-likeness. Ligand A is slightly better.
7. **DILI:** Ligand B (70.686) has a significantly lower DILI risk than Ligand A (89.841). This is a major advantage for Ligand B.
8. **BBB:** Ligand B (65.607) has a higher BBB penetration percentile than Ligand A (25.126). While ADRB2 isn't a CNS target, some degree of BBB penetration can be useful for understanding off-target effects.
9. **Caco-2:** Ligand A (-5.106) has a more negative Caco-2 value, indicating *lower* permeability, which is undesirable. Ligand B (-4.242) is better, but both are negative and therefore indicate poor permeability.
10. **Solubility:** Ligand A (-4.552) has better solubility than Ligand B (-5.67). Solubility is important for bioavailability.
11. **hERG:** Both ligands have very low hERG inhibition risk (A: 0.448, B: 0.195), which is excellent. Ligand B is slightly better.
12. **Cl_mic:** Ligand A (10.424) has significantly lower microsomal clearance than Ligand B (125.686). Lower clearance indicates better metabolic stability, which is a significant advantage for Ligand A.
13. **t1/2:** Ligand B (25.163) has a longer in vitro half-life than Ligand A (-13.329). This is a strong advantage for Ligand B.
14. **Pgp:** Both ligands have very low P-gp efflux liability (A: 0.148, B: 0.146) which is good.
15. **Binding Affinity:** Ligand A (-8.0) has a slightly better binding affinity than Ligand B (-6.8). A difference of 1.2 kcal/mol is substantial and can outweigh some ADME drawbacks.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has a better logP and affinity, while Ligand B has better TPSA and Pgp. The difference in affinity is substantial. DILI is also important, and Ligand B is significantly better in this regard.
**Overall Assessment:**
While Ligand B has advantages in DILI risk, BBB penetration, and half-life, Ligand A's superior binding affinity and metabolic stability (lower Cl_mic) are more critical for a GPCR target. The slightly better logP of Ligand A is also favorable. The negative Caco-2 values for both are concerning, but the stronger binding of Ligand A suggests it might overcome this limitation.
Output:
1
2025-04-17 23:10:23,013 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [344.459, 79.53, 1.876, 1, 4, 0.904, 21.753, 94.378, -4.894, -2.55, 0.772, 15.792, -12.694, 0.041, -6.3]
**Ligand B:** [350.419, 98.82, 0.085, 2, 4, 0.455, 40.985, 65.452, -4.944, -1.782, 0.062, -7.233, -8.623, 0.006, -5.4]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (344.459) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (79.53) is significantly better than Ligand B (98.82). For a GPCR, keeping TPSA low is good for permeability and distribution.
3. **logP:** Ligand A (1.876) is optimal, while Ligand B (0.085) is quite low. A logP below 1 can hinder membrane permeation. This is a significant drawback for Ligand B.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower is generally better for permeability.
5. **HBA:** Both have 4 HBA, which is acceptable.
6. **QED:** Ligand A (0.904) is excellent, indicating high drug-likeness. Ligand B (0.455) is below the desirable threshold of 0.5.
7. **DILI:** Ligand A (21.753) has a much lower DILI risk than Ligand B (40.985). This is a crucial advantage.
8. **BBB:** Ligand A (94.378) shows excellent potential for BBB penetration, while Ligand B (65.452) is moderate. While not strictly required for ADRB2 (a cardiovascular target), better BBB penetration can be beneficial for off-target effects.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Both have negative solubility values, which is also unusual. Again, the scale is unknown.
11. **hERG:** Ligand A (0.772) is better than Ligand B (0.062) in terms of hERG inhibition liability. Lower is better.
12. **Cl_mic:** Ligand B (-7.233) has a negative clearance, which is not physically possible and likely indicates a very stable molecule. Ligand A (15.792) is a more reasonable value.
13. **t1/2:** Ligand B (-8.623) has a negative half-life, which is also not physically possible. Ligand A (-12.694) is also negative, but less extreme.
14. **Pgp:** Ligand A (0.041) has lower P-gp efflux liability than Ligand B (0.006). Lower is better.
15. **Affinity:** Ligand A (-6.3) and Ligand B (-5.4) have similar binding affinities, with Ligand A being slightly better. The difference is not substantial enough to override other significant differences.
**Overall Assessment:**
Ligand A is significantly better than Ligand B across most critical parameters. It has a better logP, TPSA, QED, DILI score, BBB penetration, and hERG profile. While the Caco-2 and solubility values are unusual for both, the other advantages of Ligand A are substantial. The negative values for clearance and half-life in Ligand B are concerning and suggest potential issues with the data or the molecule itself.
Given the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand A is the clear preference.
**Output:**
1
2025-04-17 23:10:23,014 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (364.5 & 346.4 Da) are within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (75.2) is better than Ligand B (85.3). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally aids absorption.
3. **logP:** Ligand A (1.91) is slightly better than Ligand B (0.95). Both are within the optimal 1-3 range, but Ligand B is closer to the lower limit which *could* impact permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Both ligands have 5 HBA, so no difference here.
6. **QED:** Ligand B (0.803) has a slightly higher QED than Ligand A (0.724), indicating a marginally more drug-like profile.
7. **DILI:** Ligand B (29.2) has a significantly lower DILI risk than Ligand A (39.98). This is a substantial advantage for Ligand B.
8. **BBB:** Ligand B (65.2) has a higher BBB penetration percentile than Ligand A (49.4). While not critical for a cardiovascular target, higher BBB is rarely a detriment.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.424 and -5.021), which is unusual and suggests poor permeability. However, the values are very close.
10. **Solubility:** Both ligands have negative solubility values (-2.16 and -2.415), also unusual and indicating poor aqueous solubility. Again, the difference is small.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.248 and 0.114). No significant difference.
12. **Cl_mic:** Ligand B (24.4) has a significantly lower microsomal clearance than Ligand A (42.8). This indicates better metabolic stability for Ligand B.
13. **t1/2:** Ligand B (31.2) has a much longer in vitro half-life than Ligand A (0.98). This is a major advantage for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.025 and 0.024). No significant difference.
15. **Binding Affinity:** Ligand B (-6.8 kcal/mol) has a slightly better binding affinity than Ligand A (-6.1 kcal/mol). While the difference is not huge, it's enough to be noticeable.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand B performs better on logP, has a slightly better affinity, and similar Pgp values. The TPSA difference is also in favor of Ligand A, but less critical.
**Overall Assessment:**
Ligand B is the stronger candidate. While Ligand A has a slightly better TPSA, Ligand B excels in several crucial areas: significantly lower DILI risk, better metabolic stability (lower Cl_mic, longer t1/2), slightly better binding affinity, and a higher (though not critical) BBB percentile. The slightly higher QED also supports its drug-like properties. The negative Caco-2 and solubility values are concerning for both, but the other advantages of Ligand B outweigh this shared drawback.
Output:
0
2025-04-17 23:10:23,014 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (390.311) is slightly higher than Ligand B (368.821), but both are acceptable.
2. **TPSA:** Ligand A (87.3) is better than Ligand B (115.39). For a GPCR, keeping TPSA lower is beneficial for permeability. Ligand B is a bit high, potentially impacting absorption.
3. **logP:** Ligand A (2.155) is optimal, while Ligand B (-0.437) is quite low. This is a significant drawback for Ligand B, as it may struggle with membrane permeability.
4. **HBD:** Both ligands have 3 HBD, which is within the acceptable limit.
5. **HBA:** Ligand A has 3 HBA, while Ligand B has 5. Both are acceptable, but Ligand A is slightly preferred.
6. **QED:** Both ligands have similar QED values (0.608 and 0.623), indicating good drug-likeness.
7. **DILI:** Ligand A (24.234) has a much lower DILI risk than Ligand B (56.185). This is a crucial advantage for Ligand A.
8. **BBB:** Ligand A (64.87) has a better BBB percentile than Ligand B (23.071). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be useful for understanding off-target effects and distribution.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual, but the values are similar.
10. **Solubility:** Both ligands have negative solubility values, which is also unusual. The values are similar.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.22 and 0.16), which is excellent.
12. **Cl_mic:** Ligand A (3.82) has a significantly lower microsomal clearance than Ligand B (-25.689). This indicates better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (26.194) has a much longer in vitro half-life than Ligand B (-22.857). This is a major advantage for Ligand A, potentially leading to less frequent dosing.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.043 and 0.011).
15. **Binding Affinity:** Ligand A (-7.4) has a slightly better binding affinity than Ligand B (-7.1). While the difference is small, it contributes to the overall preference for Ligand A.
**GPCR-Specific Priorities:**
Considering ADRB2 is a GPCR, logP, TPSA, and affinity are important. Ligand A excels in logP and TPSA, and has slightly better affinity. The lower DILI and better metabolic stability (Cl_mic and t1/2) further solidify its advantage.
**Conclusion:**
Ligand A demonstrates a significantly better balance of properties, particularly in areas critical for GPCR drug candidates (logP, TPSA) and key ADME parameters (DILI, Cl_mic, t1/2). The slightly better binding affinity is an added bonus.
Output:
1
2025-04-17 23:10:23,014 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (348.49 and 353.46 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (58.64) is significantly better than Ligand B (89.95). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold. Ligand B is approaching the upper limit.
3. **logP:** Ligand A (2.799) is optimal. Ligand B (0.369) is quite low, potentially hindering membrane permeability. This is a significant drawback.
4. **HBD:** Both ligands have acceptable HBD counts (1 and 2, respectively), well below the 5 threshold.
5. **HBA:** Both ligands have acceptable HBA counts (3 and 4, respectively), well below the 10 threshold.
6. **QED:** Both ligands have similar and good QED values (0.72 and 0.747), indicating good drug-likeness.
7. **DILI:** Both ligands have similar and acceptable DILI risk (13.3 and 13.843 percentile).
8. **BBB:** Ligand A (77.821) has a better BBB penetration score than Ligand B (53.781), but this is less critical for a cardiovascular target.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the absolute value for Ligand A (-4.609) is less negative than for Ligand B (-4.934), suggesting slightly better permeability.
10. **Solubility:** Ligand A (-2.563) has slightly better solubility than Ligand B (-1.227).
11. **hERG:** Both ligands have low hERG inhibition liability (0.419 and 0.101).
12. **Cl_mic:** Ligand B (-5.845) has a significantly *lower* (better) microsomal clearance than Ligand A (43.801). This suggests greater metabolic stability for Ligand B.
13. **t1/2:** Ligand B (-11.178) has a significantly longer half-life than Ligand A (-4.948). This is a major advantage.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.153 and 0.006).
15. **Binding Affinity:** Both ligands have similar binding affinities (-6.0 and -5.8 kcal/mol). The difference is not substantial enough to override other factors.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand A excels in logP and TPSA, while affinity is comparable. Ligand B has a better metabolic profile (Cl_mic and t1/2). However, the low logP of Ligand B is a serious concern for permeability.
**Overall Assessment:**
Despite the better metabolic stability and half-life of Ligand B, the significantly lower logP is a major drawback. Poor logP often translates to poor permeability and bioavailability. Ligand A, while having a higher Cl_mic, has a much more favorable logP and TPSA, suggesting better absorption. The similar affinities make the ADME properties the deciding factor.
Output:
1
2025-04-17 23:10:23,014 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (357.41 and 353.482 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (64.11) is better than Ligand B (73.2), being closer to the <140 threshold for good oral absorption.
3. **logP:** Both ligands have good logP values (4.147 and 3.199, respectively) within the optimal 1-3 range. Ligand B is slightly better, being closer to the ideal range.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 5 HBA, while Ligand B has 3. Both are acceptable, below the 10 threshold.
6. **QED:** Both ligands have a QED of 0.72 and 0.728, indicating good drug-likeness. No significant difference.
7. **DILI:** Ligand A (88.251) has a significantly higher DILI risk than Ligand B (18.651). This is a major concern for Ligand A.
8. **BBB:** Ligand B (89.919) has a better BBB penetration percentile than Ligand A (64.831). While not a primary concern for a cardiovascular target like ADRB2, it's a slight advantage.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.922) is slightly worse than Ligand B (-4.273).
10. **Solubility:** Ligand A (-5.148) has worse solubility than Ligand B (-3.564).
11. **hERG:** Ligand A (0.623) has a slightly higher hERG risk than Ligand B (0.872), but both are reasonably low.
12. **Cl_mic:** Both ligands have similar microsomal clearance values (70.519 and 68.843).
13. **t1/2:** Ligand B (-12.596) has a longer in vitro half-life than Ligand A (-24.598).
14. **Pgp:** Ligand A (0.519) has better Pgp efflux properties than Ligand B (0.083).
15. **Binding Affinity:** Ligand B (-7.0) has a slightly better binding affinity than Ligand A (-6.9).
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand B is better in logP, Pgp, and affinity. While TPSA is better for Ligand A, the significant DILI risk for Ligand A outweighs this benefit.
**Overall Assessment:**
Ligand B is the better candidate. While both have some issues with Caco-2 permeability, Ligand B has a significantly lower DILI risk, better BBB penetration, a slightly better binding affinity, and a longer half-life. The lower DILI risk is a critical advantage, as liver toxicity is a major concern in drug development.
Output:
0
2025-04-17 23:10:23,014 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (353.369 Da and 349.431 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (75.44) is significantly better than Ligand B (92.59). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand A is well below the 140 threshold, while Ligand B is approaching it.
**3. logP:** Ligand A (1.958) is better than Ligand B (0.58). Both are within the acceptable range (1-3), but Ligand A is closer to the optimal range. Ligand B is a bit low and could suffer from permeability issues.
**4. H-Bond Donors:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
**5. H-Bond Acceptors:** Ligand A (4) is preferable to Ligand B (5). Similar to HBDs, lower HBA count is generally better for permeability.
**6. QED:** Both ligands have similar QED values (0.84 and 0.7), indicating good drug-likeness.
**7. DILI:** Both ligands have acceptable DILI risk (34.665 and 39.667 percentiles), below the 40 threshold.
**8. BBB:** Ligand A (89.608) is significantly better than Ligand B (39.86). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be beneficial or at least needs to be considered. A higher BBB percentile is advantageous.
**9. Caco-2 Permeability:** Ligand A (-4.664) is better than Ligand B (-4.785). Both are negative, which is not ideal, but Ligand A is slightly less negative.
**10. Aqueous Solubility:** Ligand A (-3.011) is better than Ligand B (-2.004). Both are poor, but Ligand A is slightly better.
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.343 and 0.16). This is excellent.
**12. Microsomal Clearance:** Ligand A (40.292) is higher than Ligand B (24.232), indicating faster clearance and lower metabolic stability. Ligand B is preferable here.
**13. In vitro Half-Life:** Ligand A (-28.165) is significantly better than Ligand B (17.638). A longer half-life is generally desirable.
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (0.079 and 0.058). This is good.
**15. Binding Affinity:** Ligand B (-6.4 kcal/mol) is significantly better than Ligand A (-4.8 kcal/mol). This is a substantial difference in potency (1.6 kcal/mol).
**Overall Assessment:**
Ligand B has a significantly stronger binding affinity, which is a crucial factor for GPCRs. However, Ligand A has superior properties regarding TPSA, logP, BBB penetration, and in vitro half-life. The difference in binding affinity is substantial enough to outweigh the ADME advantages of Ligand A. While Ligand A has better permeability predictions, the affinity difference is likely to be more impactful for *in vivo* efficacy.
Output:
0
2025-04-17 23:10:23,015 - INFO - Here's a step-by-step comparison of Ligand A and Ligand B, followed by my final decision:
**1. Molecular Weight (MW):** Both ligands (348.403 and 343.471 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. Topological Polar Surface Area (TPSA):** Ligand A (95.75) is higher than Ligand B (62.3). For a cardiovascular GPCR (ADRB2), TPSA is moderately important, and Ligand B is significantly better, being well below the 140 threshold.
**3. Lipophilicity (logP):** Ligand A (0.385) is quite low, potentially hindering membrane permeability. Ligand B (3.078) is within the optimal 1-3 range. This is a substantial advantage for Ligand B.
**4. H-Bond Donors (HBD):** Both have 1 HBD, which is good.
**5. H-Bond Acceptors (HBA):** Ligand A has 5 HBA, Ligand B has 3. Both are acceptable, but fewer is generally preferred.
**6. QED:** Both ligands have high QED scores (0.83 and 0.894), indicating good drug-like properties.
**7. DILI Risk:** Ligand A (42.807) has a slightly higher DILI risk than Ligand B (33.695), but both are below the concerning threshold of 60.
**8. BBB Penetration:** Both ligands have good BBB penetration (76.27% and 74.952%), which is less critical for a cardiovascular target but not detrimental.
**9. Caco-2 Permeability:** Ligand A (-4.983) has a very poor Caco-2 permeability, while Ligand B (-4.556) is slightly better, but still poor.
**10. Aqueous Solubility:** Ligand A (-0.888) has poor solubility, while Ligand B (-3.7) is even worse. Both are problematic.
**11. hERG Inhibition:** Ligand A (0.052) has a very low hERG risk, which is excellent. Ligand B (0.225) is also low, but higher than A.
**12. Microsomal Clearance:** Ligand A (31.928) has lower clearance than Ligand B (54.232), suggesting better metabolic stability.
**13. In vitro Half-Life:** Ligand A (-7.672) has a much longer half-life than Ligand B (0.406). This is a significant advantage for Ligand A.
**14. P-gp Efflux:** Ligand A (0.023) has very low P-gp efflux, while Ligand B (0.075) is slightly higher.
**15. Binding Affinity:** Ligand B (-7.8 kcal/mol) has a slightly better binding affinity than Ligand A (-6.5 kcal/mol). This 1.3 kcal/mol difference is substantial and can outweigh some ADME concerns.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand B is more promising. While both have solubility issues, Ligand B's superior logP and TPSA are crucial for permeability and receptor engagement. The slightly better affinity of Ligand B is also a significant factor. Although Ligand A has better metabolic stability and lower hERG risk, the permeability issues associated with its low logP and poor Caco-2 permeability are more concerning for a GPCR target.
Output:
0
2025-04-17 23:10:23,015 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.45 & 352.48 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (24.94) is significantly better than Ligand B (87.66). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold, while B is approaching it.
3. **logP:** Both ligands have acceptable logP values (2.25 & 1.53), falling within the 1-3 range. Ligand A is slightly more lipophilic, which could aid membrane permeability.
4. **HBD:** Ligand A (0) is preferable to Ligand B (3). Fewer hydrogen bond donors generally improve permeability.
5. **HBA:** Both ligands have the same number of HBA (4).
6. **QED:** Both ligands have similar QED scores (0.583 & 0.578), indicating good drug-likeness.
7. **DILI:** Ligand A (12.25) has a much lower DILI risk than Ligand B (35.71). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (90.77) has a much higher BBB penetration score than Ligand B (40.17). While not critical for a cardiovascular target, higher BBB is generally a positive attribute, indicating better distribution.
9. **Caco-2:** Ligand A (-4.31) shows better Caco-2 permeability than Ligand B (-5.11).
10. **Solubility:** Ligand A (-1.78) shows better solubility than Ligand B (-2.27).
11. **hERG:** Ligand A (0.99) has a lower hERG inhibition liability than Ligand B (0.23). This is a crucial safety parameter, and Ligand A is significantly better.
12. **Cl_mic:** Ligand A (25.46) has a lower microsomal clearance than Ligand B (35.52). Lower clearance suggests better metabolic stability.
13. **t1/2:** Ligand A (-31.09) has a much longer in vitro half-life than Ligand B (6.29). This is a significant advantage, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.57) has a lower P-gp efflux liability than Ligand B (0.10). Lower efflux improves bioavailability.
15. **Binding Affinity:** Ligand A (-7.5) has a stronger binding affinity than Ligand B (-6.2). This is a 1.3 kcal/mol difference, which is substantial and can outweigh some ADME drawbacks.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A excels in all these areas.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical parameters, including DILI risk, hERG inhibition, metabolic stability, half-life, and binding affinity. While Ligand B has acceptable properties, Ligand A presents a much more favorable profile for drug development.
Output:
1
2025-04-17 23:10:23,015 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (361.36 Da) is within the ideal range (200-500 Da). Ligand B (340.318 Da) is also excellent. No clear advantage here.
2. **TPSA:** Ligand A (56.79) is good, well below the 140 A^2 threshold. Ligand B (86.03) is still reasonable but higher. Ligand A is slightly preferred.
3. **logP:** Both ligands have good logP values (A: 2.321, B: 1.238), falling within the 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Ligand A (1) is good. Ligand B (0) is also good. No significant difference.
5. **HBA:** Ligand A (5) is good. Ligand B (8) is a bit higher, potentially impacting permeability. Ligand A is slightly preferred.
6. **QED:** Both ligands are acceptable (A: 0.569, B: 0.522), exceeding the 0.5 threshold. No clear advantage.
7. **DILI:** Ligand A (39.977) has a significantly lower DILI risk than Ligand B (98.255). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (89.066) has better BBB penetration than Ligand B (73.517). While ADRB2 isn't strictly a CNS target, some distribution into the CNS is possible, and higher BBB penetration is generally favorable.
9. **Caco-2:** Both have negative values which is unusual, but the values are very similar (-4.452 and -4.486). No clear advantage.
10. **Solubility:** Both have negative values which is unusual, but the values are very similar (-2.669 and -3.354). No clear advantage.
11. **hERG:** Both ligands have low hERG risk (A: 0.679, B: 0.346). Ligand B is slightly better here.
12. **Cl_mic:** Ligand A (51.646) has lower microsomal clearance than Ligand B (60.463), suggesting better metabolic stability.
13. **t1/2:** Ligand A (29.669) has a much longer in vitro half-life than Ligand B (-11.377). This is a significant advantage for Ligand A.
14. **Pgp:** Both ligands have low Pgp efflux liability (A: 0.136, B: 0.045). Ligand B is slightly better here.
15. **Binding Affinity:** Ligand B (-6.0 kcal/mol) has a slightly better binding affinity than Ligand A (-5.1 kcal/mol). This is a 0.9 kcal/mol difference, which is a reasonable advantage.
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B has a slightly better affinity and Pgp profile. However, Ligand A excels in DILI risk, BBB penetration, metabolic stability (Cl_mic, t1/2), and has a better TPSA. The substantial difference in DILI risk and half-life for Ligand A, combined with its acceptable affinity, outweigh the slight affinity advantage of Ligand B.
**Conclusion:**
Considering the balance of properties, particularly the significantly lower DILI risk and improved metabolic stability of Ligand A, it is the more promising drug candidate.
Output:
1
2025-04-17 23:10:23,015 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (340.379 and 348.407 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (73.59) is significantly better than Ligand B (113.14). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary goal, but lower TPSA generally correlates with better absorption. Ligand B is pushing the upper limit for good oral absorption.
3. **logP:** Ligand A (3.943) is optimal, while Ligand B (0.108) is quite low. This is a major concern for Ligand B, as it may struggle with membrane permeability.
4. **HBD:** Both have 1 HBD, which is acceptable.
5. **HBA:** Ligand A has 6 HBA, and Ligand B has 7. Both are within the acceptable range.
6. **QED:** Both ligands have good QED scores (0.657 and 0.748), indicating generally drug-like properties.
7. **DILI:** Ligand A (74.719) has a higher DILI risk than Ligand B (48.895). This is a negative for Ligand A, but not a dealbreaker at this stage.
8. **BBB:** Ligand A (63.746) has a higher BBB penetration than Ligand B (40.791). While not critical for a cardiovascular target, it's a slight positive for Ligand A.
9. **Caco-2:** Ligand A (-4.554) and Ligand B (-5.027) both have negative values, indicating poor permeability. This is a concern for both, but the negative value for Ligand B is worse.
10. **Solubility:** Ligand A (-5.624) is better than Ligand B (-1.641), indicating better aqueous solubility.
11. **hERG:** Ligand A (0.759) has a slightly higher hERG risk than Ligand B (0.082). This favors Ligand B.
12. **Cl_mic:** Ligand A (112.482) has a higher microsomal clearance than Ligand B (-3.872). This is a negative for Ligand A, suggesting faster metabolism.
13. **t1/2:** Ligand A (54.748) has a longer in vitro half-life than Ligand B (10.281). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.269) has lower P-gp efflux than Ligand B (0.008). This is a positive for Ligand A, suggesting better bioavailability.
15. **Affinity:** Ligand B (-7.5) has a significantly better binding affinity than Ligand A (-6.0). This is a substantial advantage for Ligand B. A 1.5 kcal/mol difference is significant.
**Overall Assessment & GPCR-Specific Priorities:**
For a GPCR like ADRB2, affinity, logP, and TPSA are key. Ligand B has a much stronger binding affinity, which is the most important factor. While its logP is low, the significantly improved binding could potentially overcome this issue with formulation strategies. Ligand A has better ADME properties overall (solubility, half-life, Pgp efflux), but the weaker binding affinity is a major drawback. The lower TPSA of Ligand A is beneficial, but not enough to offset the binding difference.
Output:
0
2025-04-17 23:10:23,016 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (351.451 Da and 359.392 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (79.7) is slightly higher than Ligand B (61.44). While both are below the 140 threshold for oral absorption, the lower TPSA of Ligand B is preferable for GPCRs, potentially aiding in membrane permeability.
**3. logP:** Both ligands have good logP values (1.642 and 1.431), falling within the optimal 1-3 range. No major distinction.
**4. H-Bond Donors:** Ligand A has 1 HBD, while Ligand B has 2. Both are acceptable (<=5), but lower is generally better for permeability.
**5. H-Bond Acceptors:** Ligand A has 5 HBA, and Ligand B has 3. Both are below the 10 threshold.
**6. QED:** Both ligands have similar QED values (0.81 and 0.798), indicating good drug-likeness.
**7. DILI Risk:** Both ligands have low DILI risk (23.187 and 22.179 percentiles), which is excellent.
**8. BBB Penetration:** Ligand A (85.459) shows better BBB penetration than Ligand B (80.613). While ADRB2 isn't strictly a CNS target, some CNS exposure can be relevant for off-target effects, and higher BBB is generally a positive attribute.
**9. Caco-2 Permeability:** Ligand B (-5.023) has a more negative Caco-2 value, suggesting *better* intestinal permeability than Ligand A (-4.477). This is a significant advantage.
**10. Aqueous Solubility:** Ligand A (-1.417) has slightly better aqueous solubility than Ligand B (-2.819). Solubility is important for formulation.
**11. hERG Inhibition:** Both ligands show very low hERG inhibition risk (0.525 and 0.376), which is crucial for cardiovascular drugs.
**12. Microsomal Clearance:** Ligand B (-16.475) has a significantly *lower* (better) microsomal clearance than Ligand A (12.116). This indicates greater metabolic stability, a major advantage.
**13. In vitro Half-Life:** Ligand B (-3.7) has a slightly longer in vitro half-life than Ligand A (5.412).
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.016 and 0.036).
**15. Binding Affinity:** Both ligands have identical binding affinities (-6.6 kcal/mol).
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand B is slightly favored. While Ligand A has better BBB penetration and solubility, Ligand B's lower TPSA, significantly improved metabolic stability (lower Cl_mic), and better Caco-2 permeability outweigh these advantages. The identical binding affinity removes that as a differentiating factor. The improved ADME profile of Ligand B makes it a more promising drug candidate.
Output:
0
2025-04-17 23:10:23,016 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [345.418, 62.71, 2.023, 1, 4, 0.87, 16.479, 78.868, -5.124, -1.227, 0.95, 9.886, 10.372, 0.148, -5.2]
**Ligand B:** [350.423, 91.33, 1.243, 0, 9, 0.737, 52.423, 67.701, -4.858, -2.1, 0.165, 46.3, -10.947, 0.076, -6.2]
Here's a breakdown, prioritizing GPCR characteristics (logP, TPSA, Pgp, BBB, Affinity):
1. **MW:** Both are within the ideal 200-500 Da range. Ligand A (345.418) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (62.71) is significantly better than Ligand B (91.33). A TPSA under 140 is good for oral absorption, and A is comfortably within that range, while B is approaching the upper limit.
3. **logP:** Both have acceptable logP values (A: 2.023, B: 1.243) falling within the 1-3 range. A is slightly better.
4. **HBD/HBA:** Ligand A (1 HBD, 4 HBA) is preferable to Ligand B (0 HBD, 9 HBA). Lower HBA is generally better for permeability.
5. **QED:** Ligand A (0.87) has a better QED score than Ligand B (0.737), indicating a more drug-like profile.
6. **DILI:** Ligand A (16.479) has a much lower DILI risk than Ligand B (52.423). This is a significant advantage.
7. **BBB:** Ligand A (78.868) has a better BBB penetration score than Ligand B (67.701). While not a CNS target, some BBB penetration can be beneficial for distribution.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests potential issues with permeability prediction. However, A (-5.124) is less negative than B (-4.858).
9. **Solubility:** Both have negative solubility values, indicating poor aqueous solubility. B (-2.1) is slightly worse than A (-1.227).
10. **hERG:** Ligand A (0.95) has a lower hERG risk than Ligand B (0.165).
11. **Cl_mic:** Ligand A (9.886) has a significantly lower microsomal clearance than Ligand B (46.3), indicating better metabolic stability.
12. **t1/2:** Ligand A (10.372) has a better in vitro half-life than Ligand B (-10.947).
13. **Pgp:** Ligand A (0.148) has a lower P-gp efflux liability than Ligand B (0.076), which is favorable for bioavailability.
14. **Affinity:** Ligand B (-6.2) has a slightly better binding affinity than Ligand A (-5.2). However, the difference is less than 1.5 kcal/mol.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical ADME-Tox properties (DILI, BBB, Cl_mic, t1/2, Pgp, TPSA, HBA). While Ligand B has a slightly better binding affinity, the substantial advantages of Ligand A in terms of safety (DILI, hERG) and pharmacokinetic properties (Cl_mic, t1/2, Pgp) outweigh this minor difference in potency. The lower TPSA of Ligand A is also a significant benefit for oral absorption.
Therefore, I would choose Ligand A as the more promising drug candidate.
1
2025-04-17 23:10:23,016 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (370.431 and 364.515 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (139.62) is slightly higher than Ligand B (74.33). For a cardiovascular GPCR, TPSA is not a *major* concern unless extremely high, but lower is generally preferred for permeability. Ligand B is significantly better here.
3. **logP:** Ligand A (-0.04) is a bit low, potentially hindering membrane permeability. Ligand B (1.725) is within the optimal 1-3 range. This is a clear advantage for Ligand B.
4. **HBD:** Both ligands have 3-4 HBD, which is acceptable.
5. **HBA:** Both ligands have 5-6 HBA, which is acceptable.
6. **QED:** Both ligands have good QED scores (0.508 and 0.672), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (51.26) has a slightly higher DILI risk than Ligand B (33.307), but both are below the concerning threshold of 60.
8. **BBB:** Ligand A (67.507) has a better BBB penetration score than Ligand B (36.526). While ADRB2 isn't strictly a CNS target, some CNS exposure can occur, and higher BBB is generally favorable.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. The values are similar, so this isn't a deciding factor.
10. **Solubility:** Both ligands have negative solubility values, which is also unusual and suggests poor solubility. The values are similar, so this isn't a deciding factor.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.232 and 0.185), which is excellent.
12. **Cl_mic:** Ligand A (33.284) has a higher microsomal clearance than Ligand B (-7.049). This suggests Ligand B is more metabolically stable, a significant advantage.
13. **t1/2:** Ligand A (-8.929) has a negative in vitro half-life, which is concerning. Ligand B (20.164) has a reasonable half-life. This is a strong advantage for Ligand B.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.029 and 0.014), which is good.
15. **Binding Affinity:** Both ligands have very similar and strong binding affinities (-7.0 and -5.8 kcal/mol). The difference of 1.2 kcal/mol is not large enough to outweigh other factors.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, and metabolic stability (Cl_mic, t1/2) are key. Ligand B excels in logP, TPSA, Cl_mic, and t1/2. While Ligand A has a slightly better BBB score, the significant advantages of Ligand B in ADME properties outweigh this.
**Conclusion:**
Ligand B demonstrates a better balance of properties, particularly regarding predicted permeability, metabolic stability, and solubility, making it the more promising drug candidate for ADRB2.
Output:
0
2025-04-17 23:10:23,016 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (361.463 Da) is slightly higher than Ligand B (334.419 Da), but both are acceptable.
2. **TPSA:** Ligand A (64.63) is better than Ligand B (72.19). Both are below 140, but lower TPSA generally favors absorption.
3. **logP:** Both ligands have good logP values (A: 2.965, B: 3.407), falling within the optimal range of 1-3. Ligand B is slightly higher, which could potentially lead to slight solubility issues but isn't a major concern.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD is generally better for permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (3). Lower HBA is generally better for permeability.
6. **QED:** Both ligands have excellent QED scores (A: 0.857, B: 0.884), indicating good drug-like properties.
7. **DILI:** Ligand B (62.195) has a slightly lower DILI risk than Ligand A (70.725), which is a positive.
8. **BBB:** Ligand B (80.264) has a significantly better BBB penetration score than Ligand A (70.182). Given that ADRB2 is a GPCR, BBB penetration is a valuable property, although not strictly essential for cardiovascular targets.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. Ligand B (-5.176) is slightly better than Ligand A (-4.895), but both are concerning.
10. **Solubility:** Both ligands have negative solubility values, indicating poor solubility. Ligand B (-4.014) is slightly better than Ligand A (-3.722), but both are concerning.
11. **hERG:** Both ligands have low hERG risk (A: 0.876, B: 0.62). Ligand B is slightly better.
12. **Cl_mic:** Ligand B (17.135) has a significantly lower microsomal clearance than Ligand A (39.37), suggesting better metabolic stability.
13. **t1/2:** Ligand B (28.12) has a longer in vitro half-life than Ligand A (23.775), which is desirable.
14. **Pgp:** Both ligands have low Pgp efflux liability (A: 0.696, B: 0.671), which is good.
15. **Binding Affinity:** Ligand A (-6.2 kcal/mol) has a significantly stronger binding affinity than Ligand B (-1.8 kcal/mol). This is a *major* advantage. A difference of >1.5 kcal/mol can often outweigh other ADME concerns.
**Overall Assessment:**
Ligand A has a much stronger binding affinity, which is the most critical factor for a drug candidate. While Ligand B has better ADME properties (lower DILI, better BBB, lower Cl_mic, longer t1/2, slightly better Caco-2 and solubility, and lower hERG), the substantial difference in binding affinity (-6.2 vs -1.8 kcal/mol) makes Ligand A the more promising candidate. The ADME issues with both ligands are concerning, but can be addressed through further optimization. The potency advantage of Ligand A provides a stronger starting point for optimization.
Output:
1
2025-04-17 23:10:23,016 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (343.471) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (44.81) is significantly better than Ligand B (117.08). For a GPCR, a lower TPSA is preferred for better permeability, and Ligand B is quite high, potentially hindering oral absorption.
3. **logP:** Both ligands have acceptable logP values (A: 2.505, B: 1.27), falling within the 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability.
4. **HBD/HBA:** Ligand A (HBD=1, HBA=3) has a more favorable profile than Ligand B (HBD=4, HBA=4). Lower counts are generally preferred for better balance of solubility and permeability.
5. **QED:** Both are reasonably good (A: 0.583, B: 0.526), exceeding the 0.5 threshold.
6. **DILI:** Ligand A (12.33) has a much lower DILI risk than Ligand B (50.989), a significant advantage.
7. **BBB:** Ligand A (71.539) has a better BBB penetration score than Ligand B (46.336). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be useful for understanding off-target effects and overall distribution.
8. **Caco-2:** Ligand A (-4.546) is better than Ligand B (-5.955), indicating better intestinal absorption.
9. **Solubility:** Ligand A (-1.505) is better than Ligand B (-3.239), indicating better aqueous solubility.
10. **hERG:** Both ligands have low hERG inhibition liability (A: 0.839, B: 0.268), which is good.
11. **Cl_mic:** Ligand A (-6.802) has much better metabolic stability (lower clearance) than Ligand B (10.584).
12. **t1/2:** Ligand A (0.251) has a worse in vitro half-life than Ligand B (-12.567). This is a drawback for Ligand A.
13. **Pgp:** Both ligands have very low P-gp efflux liability (A: 0.048, B: 0.044).
14. **Binding Affinity:** Both ligands have similar and strong binding affinities (A: -5.4 kcal/mol, B: -6.4 kcal/mol). Ligand B is slightly better, but the difference is not substantial enough to outweigh other factors.
**Overall Assessment:**
Ligand A is clearly superior. While Ligand B has a slightly better binding affinity and in vitro half-life, Ligand A excels in crucial ADME properties like TPSA, DILI risk, BBB penetration, Caco-2 permeability, solubility, and metabolic stability. These factors are particularly important for a GPCR target like ADRB2, where good oral bioavailability and minimizing off-target effects are critical. The lower TPSA and DILI risk of Ligand A are especially compelling.
Output:
1
2025-04-17 23:10:23,017 - INFO - Batch 385 complete. Total preferences: 6160
2025-04-17 23:10:23,017 - INFO - Processing batch 386/512...
2025-04-17 23:11:11,793 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
The target is ADRB2, a GPCR. Therefore, I will prioritize logP, TPSA, Pgp efflux, BBB penetration, and binding affinity, alongside general drug-like properties.
* **Molecular Weight:** Both ligands are within the ideal range (200-500 Da).
* **TPSA:** Ligand A (86.11) is significantly better than Ligand B (135.17). A TPSA under 140 is good for oral absorption, and lower is generally preferred for GPCRs, especially if CNS penetration is desired. Ligand B is pushing the upper limit.
* **logP:** Ligand A (2.263) is within the optimal range (1-3). Ligand B (-0.369) is below 1, which could hinder permeation. This is a significant drawback for Ligand B.
* **H-Bond Donors/Acceptors:** Ligand A (1 HBD, 6 HBA) is better balanced than Ligand B (3 HBD, 8 HBA). While both are acceptable, fewer H-bonds generally improve membrane permeability.
* **QED:** Both ligands have acceptable QED scores (A: 0.68, B: 0.581), indicating reasonable drug-likeness.
* **DILI:** Ligand A (85.576) has a higher DILI risk than Ligand B (59.054). This is a negative for Ligand A, but not a deal-breaker.
* **BBB:** Ligand A (48.507) has better BBB penetration than Ligand B (25.32). While ADRB2 isn't exclusively a CNS target, some CNS exposure is possible, and higher BBB is generally favorable.
* **Caco-2:** Ligand A (-4.477) has a lower Caco-2 value than Ligand B (-5.479), suggesting lower intestinal absorption. This is a negative for Ligand A.
* **Solubility:** Ligand A (-3.624) has better solubility than Ligand B (-2.084). Solubility is important for bioavailability.
* **hERG:** Both ligands have very low hERG inhibition risk (A: 0.126, B: 0.023).
* **Cl_mic:** Ligand A (61.549) has a higher microsomal clearance than Ligand B (13.875), indicating lower metabolic stability. This is a negative for Ligand A.
* **t1/2:** Ligand B (31.684) has a significantly longer in vitro half-life than Ligand A (-3.776). This is a major advantage for Ligand B.
* **Pgp:** Ligand A (0.117) has lower P-gp efflux than Ligand B (0.07). Lower P-gp efflux is generally preferred.
* **Binding Affinity:** Both ligands have the same binding affinity (-6.2 kcal/mol), so this parameter doesn't differentiate them.
**Overall Assessment:**
Ligand A has better TPSA, logP, BBB, solubility, and Pgp properties. However, Ligand B excels in DILI risk, metabolic stability (lower Cl_mic), and in vitro half-life. The poor logP of Ligand B is a significant concern, potentially leading to poor absorption. The higher DILI risk of Ligand A is concerning, but the other favorable properties, particularly the better logP and TPSA, outweigh this risk.
**Output:**
1
2025-04-17 23:11:11,793 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (384.431 and 344.342 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (95.97) is higher than Ligand B (69.68). For a cardiovascular GPCR, TPSA is moderately important, and lower is generally preferred for better permeability. Ligand B has a clear advantage.
**3. logP:** Both ligands have good logP values (2.095 and 2.618), falling within the optimal 1-3 range. Ligand B is slightly higher, which might be beneficial for membrane permeability, but the difference isn't substantial.
**4. H-Bond Donors:** Ligand A has 0 HBD, while Ligand B has 1. Both are acceptable (<=5).
**5. H-Bond Acceptors:** Ligand A has 8 HBA, and Ligand B has 6. Both are within the acceptable range (<=10).
**6. QED:** Both ligands have reasonable QED scores (0.41 and 0.642), with Ligand B being slightly more drug-like.
**7. DILI Risk:** Ligand A (97.945) has a significantly higher DILI risk than Ligand B (80.729). This is a major concern, as minimizing liver toxicity is crucial. Ligand B is considerably better.
**8. BBB Penetration:** BBB isn't a primary concern for a cardiovascular target, but Ligand A (62.737) has better penetration than Ligand B (47.926).
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, indicating poor permeability. Ligand A (-4.844) is slightly better than Ligand B (-4.171), but both are problematic.
**10. Aqueous Solubility:** Both ligands have very poor aqueous solubility (-3.239 and -4.9). This is a significant drawback for both.
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (0.178 and 0.494), which is good.
**12. Microsomal Clearance:** Ligand A (64.554) has lower microsomal clearance than Ligand B (79.8), suggesting better metabolic stability.
**13. In vitro Half-Life:** Ligand A (49.261) has a longer half-life than Ligand B (24.237), which is desirable.
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (0.454 and 0.247), which is good.
**15. Binding Affinity:** Both ligands have very similar and strong binding affinities (-5.6 and -5.8 kcal/mol). The difference is negligible.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity) and the general drug-like properties, Ligand B is the more promising candidate. While Ligand A has slightly better BBB penetration and metabolic stability, the significantly higher DILI risk is a major red flag. Ligand B has a lower DILI risk, a better TPSA, and a slightly better QED score. Both have poor solubility and Caco-2 permeability, which would need to be addressed through formulation or further chemical modification. However, the lower toxicity profile of Ligand B makes it the preferred starting point for optimization.
Output:
0
2025-04-17 23:11:11,794 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (365.9 and 367.5 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (61.36) is significantly better than Ligand B (106.45). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (2.536 and 2.194), falling within the 1-3 optimal range. Ligand A is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (0). While both are low, having one HBD can sometimes improve solubility without significantly impacting permeability.
5. **HBA:** Both ligands have 5 HBA, which is acceptable.
6. **QED:** Ligand A (0.785) has a substantially better QED score than Ligand B (0.422), indicating a more drug-like profile.
7. **DILI:** Ligand A (22.84) has a much lower DILI risk than Ligand B (34.55), a significant advantage.
8. **BBB:** Ligand A (92.94) has a much higher BBB penetration than Ligand B (51.42). While not a primary concern for a cardiovascular target, it's still a positive attribute.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.099 and -4.966). These values are unusual and suggest poor permeability. However, the scale is not clearly defined, so it's hard to interpret.
10. **Solubility:** Both ligands have negative solubility values (-2.577 and -2.43). Again, the scale is unclear, but this suggests poor aqueous solubility for both.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.577 and 0.071). This is excellent and minimizes cardiotoxicity risk.
12. **Cl_mic:** Ligand A (11.41) has a much lower microsomal clearance than Ligand B (32.85), suggesting better metabolic stability.
13. **t1/2:** Ligand A (26.54) has a longer in vitro half-life than Ligand B (-27.20), a significant advantage.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.034 and 0.03).
15. **Affinity:** Ligand A (-6.7 kcal/mol) has a slightly better binding affinity than Ligand B (-5.8 kcal/mol). While the difference is not huge, it's still a positive factor.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Ligand A performs better in all these areas.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical parameters. It has a better QED score, lower DILI risk, higher BBB penetration, lower microsomal clearance, longer half-life, and slightly better affinity. While both have issues with Caco-2 and solubility, Ligand A's superior profile in other key areas makes it the more promising drug candidate.
Output:
1
2025-04-17 23:11:11,794 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.362 and 353.369 Da) fall comfortably within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (101.29) is better than Ligand A (117.34) as it is closer to the <140 threshold for good oral absorption.
3. **logP:** Both ligands have acceptable logP values (1.882 and 0.97), falling within the 1-3 range. Ligand B is slightly lower, which could be beneficial for solubility.
4. **HBD:** Ligand A has 4 HBD, while Ligand B has 3. Both are within the acceptable limit of <=5.
5. **HBA:** Ligand A has 5 HBA, while Ligand B has 3. Both are within the acceptable limit of <=10.
6. **QED:** Ligand B (0.607) has a slightly better QED score than Ligand A (0.498), indicating a more drug-like profile.
7. **DILI:** Ligand B (35.595) has a significantly lower DILI risk than Ligand A (77.666). This is a major advantage for Ligand B.
8. **BBB:** Ligand B (83.986) has a much higher BBB penetration percentile than Ligand A (19.077). While ADRB2 isn't strictly a CNS target, some peripheral ADRB2 receptors can influence CNS function, and higher BBB penetration can sometimes translate to better overall distribution.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.566 and -5.226). This is unusual and suggests poor permeability. However, the values are very similar.
10. **Solubility:** Both ligands have negative solubility values (-3.564 and -3.249), indicating poor aqueous solubility. Again, these are similar.
11. **hERG:** Both ligands have low hERG inhibition liability (0.519 and 0.33), which is good.
12. **Cl_mic:** Ligand B (13.429) has a lower microsomal clearance than Ligand A (31.091), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-24.359) has a more negative in vitro half-life than Ligand B (-17.414). A more negative value indicates a shorter half-life, which is undesirable.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.021 and 0.017).
15. **Binding Affinity:** Ligand A (-7.0) has a slightly better binding affinity than Ligand B (-6.2). However, the difference is only 0.8 kcal/mol, which is less significant than the ADME advantages of Ligand B.
**GPCR-specific priorities:** For GPCRs, logP, TPSA, Pgp, and affinity are key. Ligand B is better on logP and TPSA. Both are good on Pgp. Ligand A has slightly better affinity, but the ADME profile of Ligand B is significantly superior, particularly the lower DILI risk and better BBB penetration.
**Conclusion:**
Considering the balance of properties, Ligand B is the more promising drug candidate. Its superior DILI profile, better BBB penetration, lower microsomal clearance, and slightly better QED outweigh the small difference in binding affinity.
Output:
0
2025-04-17 23:11:11,794 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor (a GPCR).
**Ligand A:** [344.386, 58.64, 3.708, 1, 3, 0.899, 62.893, 82.629, -4.358, -4.339, 0.829, 76.602, -17.051, 0.227, -6.7]
**Ligand B:** [347.459, 84.23, 2.444, 2, 4, 0.756, 24.118, 65.801, -5.251, -1.724, 0.185, 48.238, -15.461, 0.123, -6.9]
Here's a breakdown, considering the guidelines and GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal range (200-500 Da). A is 344.386, B is 347.459 - very similar.
2. **TPSA:** A (58.64) is excellent, well below the 140 threshold. B (84.23) is still reasonable, but higher. This favors A.
3. **logP:** A (3.708) is optimal. B (2.444) is also good, but slightly lower. A is preferred.
4. **HBD:** A (1) is good. B (2) is acceptable.
5. **HBA:** A (3) is good. B (4) is acceptable.
6. **QED:** A (0.899) is very good, indicating high drug-likeness. B (0.756) is still acceptable, but lower. A is favored.
7. **DILI:** A (62.893) is moderately risky, but manageable. B (24.118) is excellent, significantly lower risk. This is a strong point for B.
8. **BBB:** A (82.629) is good, suggesting reasonable potential for CNS penetration, though ADRB2 isn't necessarily a CNS target. B (65.801) is lower. A is preferred.
9. **Caco-2:** Both are negative, indicating poor permeability. A (-4.358) is slightly better (less negative) than B (-5.251).
10. **Solubility:** Both are negative, indicating poor solubility. B (-1.724) is slightly better (less negative) than A (-4.339).
11. **hERG:** Both are low (0.829 and 0.185), indicating low cardiotoxicity risk. B is better.
12. **Cl_mic:** A (76.602) is higher than B (48.238), indicating faster metabolism and lower metabolic stability. B is preferred.
13. **t1/2:** A (-17.051) is worse than B (-15.461), indicating a shorter half-life. B is preferred.
14. **Pgp:** A (0.227) is better than B (0.123), indicating lower P-gp efflux. A is preferred.
15. **Affinity:** Both are very good (-6.7 and -6.9 kcal/mol). B is slightly better.
**Overall Assessment:**
Ligand A has advantages in TPSA, logP, QED, BBB, and Pgp. Ligand B excels in DILI risk, hERG, metabolic stability (Cl_mic), and half-life. The binding affinity is comparable.
Considering the GPCR nature of the target, logP and TPSA are important. However, the significantly lower DILI risk and improved metabolic stability of Ligand B are crucial. While A has a better BBB score, ADRB2 isn't primarily a CNS target, so this is less critical. The slightly better affinity of B is also a plus. The poor Caco-2 and solubility of both are concerning, but can be addressed with formulation strategies.
Therefore, I believe Ligand B is the more promising candidate due to its superior safety profile and metabolic properties.
0
2025-04-17 23:11:11,794 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [383.279, 67.23, 1.965, 1, 6, 0.469, 60.682, 85.498, -4.917, -4.132, 0.747, 21.071, 42.553, 0.536, -8]
**Ligand B:** [371.428, 46.09, 4.646, 0, 4, 0.712, 49.477, 87.088, -4.662, -4.177, 0.678, 62.162, 16.834, 0.389, -6.8]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (371.428) is slightly lower, which is generally favorable.
2. **TPSA:** Ligand A (67.23) is higher than Ligand B (46.09). Both are acceptable, but B is better for permeability.
3. **logP:** Ligand A (1.965) is optimal, while Ligand B (4.646) is pushing the upper limit and could lead to solubility issues or off-target interactions.
4. **HBD:** Ligand A (1) is preferable to Ligand B (0) as a single HBD can aid solubility without significantly impacting permeability.
5. **HBA:** Ligand A (6) is higher than Ligand B (4), but both are within acceptable limits.
6. **QED:** Ligand B (0.712) has a slightly better QED score than Ligand A (0.469), indicating a more drug-like profile.
7. **DILI:** Ligand A (60.682) has a higher DILI risk than Ligand B (49.477), which is a concern.
8. **BBB:** Both have good BBB penetration (A: 85.498, B: 87.088). This is less critical for a cardiovascular target, but still positive.
9. **Caco-2:** Both show poor Caco-2 permeability (A: -4.917, B: -4.662). This is a significant drawback for oral bioavailability.
10. **Solubility:** Both have poor aqueous solubility (A: -4.132, B: -4.177). This is a concern for formulation and bioavailability.
11. **hERG:** Both have low hERG inhibition risk (A: 0.747, B: 0.678).
12. **Cl_mic:** Ligand A (21.071) has a significantly lower microsomal clearance than Ligand B (62.162), suggesting better metabolic stability.
13. **t1/2:** Ligand A (42.553) has a longer in vitro half-life than Ligand B (16.834), which is desirable.
14. **Pgp:** Ligand A (0.536) has lower P-gp efflux than Ligand B (0.389), which is favorable for bioavailability.
15. **Affinity:** Ligand A (-8 kcal/mol) has a stronger binding affinity than Ligand B (-6.8 kcal/mol). This is a substantial difference.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are crucial. Ligand A has a better logP, lower Pgp efflux, and significantly better affinity. While both have poor Caco-2 and solubility, the strong affinity of Ligand A and its better metabolic stability (lower Cl_mic, longer t1/2) outweigh the drawbacks, especially considering the potential for formulation strategies to address solubility. The lower DILI risk of Ligand B is attractive, but the substantial affinity difference is a major factor.
**Conclusion:**
Despite the slightly higher DILI risk, Ligand A's superior binding affinity, metabolic stability, and Pgp properties make it the more promising candidate.
**Output:**
1
2025-04-17 23:11:11,795 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [346.387, 110.26 , 2.236, 2. , 6. , 0.859, 69.484, 62.97 , -4.904, -3.357, 0.091, 33.374, -6.845, 0.077, -6.7 ]
**Ligand B:** [339.447, 82.66 , 2.159, 1. , 7. , 0.868, 49.399, 68.864, -5.2 , -2.617, 0.83 , 48.414, 5.316, 0.095, -6.9 ]
Here's a breakdown, comparing each parameter and considering GPCR priorities (logP, Pgp, TPSA, Affinity):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (339.447) is slightly lower, which is generally favorable.
2. **TPSA:** Ligand A (110.26) is higher than Ligand B (82.66). Ligand B is better here, being closer to the <140 threshold for good absorption.
3. **logP:** Both are excellent (around 2.2), falling within the optimal 1-3 range. Very similar.
4. **HBD:** Ligand A (2) is slightly better than Ligand B (1). Fewer HBDs are generally preferred for permeability.
5. **HBA:** Ligand B (7) is slightly higher than Ligand A (6). Both are acceptable, but lower is better.
6. **QED:** Both are very good (0.859 and 0.868), indicating strong drug-like properties.
7. **DILI:** Ligand A (69.484) has a higher DILI risk than Ligand B (49.399). This is a significant advantage for Ligand B.
8. **BBB:** Ligand B (68.864) is slightly better than Ligand A (62.97), but both are not high enough to be considered CNS-penetrant. Since ADRB2 is a cardiovascular target, BBB isn't a primary concern, but it's still a bonus.
9. **Caco-2:** Ligand A (-4.904) is better than Ligand B (-5.2). Higher values indicate better absorption.
10. **Solubility:** Ligand A (-3.357) is better than Ligand B (-2.617). Higher values indicate better solubility.
11. **hERG:** Ligand A (0.091) is better than Ligand B (0.83). Lower values are preferred to avoid cardiotoxicity.
12. **Cl_mic:** Ligand A (33.374) has lower clearance than Ligand B (48.414), indicating better metabolic stability.
13. **t1/2:** Ligand A (-6.845) has a longer half-life than Ligand B (5.316). This is a significant advantage for dosing convenience.
14. **Pgp:** Ligand A (0.077) has lower P-gp efflux than Ligand B (0.095), which is favorable for bioavailability.
15. **Affinity:** Ligand B (-6.9) has a slightly better binding affinity than Ligand A (-6.7). While the difference is small, it's still a point in favor of Ligand B.
**Overall Assessment:**
Ligand B has a clear advantage in terms of safety (lower DILI) and a slightly better affinity. While Ligand A has better metabolic stability, solubility, and Pgp efflux, the DILI risk associated with Ligand A is concerning. The slight advantage in binding affinity for Ligand B, coupled with the lower DILI score, makes it the more promising candidate, especially considering the cardiovascular target.
Output:
0
2025-04-17 23:11:11,795 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (357.401 and 347.459 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands have a TPSA of 78.51, which is acceptable for a non-CNS GPCR target like ADRB2, being below the 140 threshold.
3. **logP:** Both ligands have a logP of around 1.22, which is optimal for permeability and solubility. No significant difference.
4. **HBD:** Both have 2 H-bond donors, well within the acceptable limit of 5.
5. **HBA:** Both have 3 H-bond acceptors, also within the acceptable limit of 10.
6. **QED:** Ligand A (0.702) has a significantly better QED score than Ligand B (0.486), indicating a more drug-like profile.
7. **DILI:** Ligand B (21.675) has a much lower DILI risk than Ligand A (38.581). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (78.209) has a higher BBB penetration percentile than Ligand B (54.672). While ADRB2 isn't a primary CNS target, some degree of BBB penetration can be useful for understanding off-target effects.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.867 and -4.961), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Both ligands have negative solubility values (-2.573 and -2.078), indicating poor aqueous solubility. This is a significant drawback for both.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.269 and 0.247). This is excellent.
12. **Cl_mic:** Ligand A (-3.154) has a *lower* (better) microsomal clearance than Ligand B (37.067), indicating greater metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (-13.391) has a lower in vitro half-life than Ligand B (-12.966), though both are negative and suggest rapid metabolism.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.017 and 0.089). This is good.
15. **Binding Affinity:** Ligand A (-7.1 kcal/mol) has a slightly better binding affinity than Ligand B (-6.9 kcal/mol). While the difference is not huge, it's enough to consider.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are important. Both ligands perform similarly on logP, Pgp, and TPSA. Ligand A has a slightly better affinity. However, DILI risk is a critical factor, and Ligand B has a substantially lower DILI risk. Metabolic stability (Cl_mic) is also important, and Ligand A is significantly better here.
**Overall Assessment:**
While Ligand A has a better QED, affinity, and metabolic stability, Ligand B's significantly lower DILI risk is a major advantage. The poor Caco-2 and solubility for both are concerning and would require formulation strategies. Given the importance of minimizing potential liver toxicity, and the relatively small difference in affinity, I favor Ligand B.
Output:
0
2025-04-17 23:11:11,795 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (358.435 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (119.33) is better than Ligand B (49.41). For a cardiovascular GPCR, a lower TPSA is preferred for better membrane permeability and oral absorption.
3. **logP:** Ligand B (3.791) is higher than Ligand A (-0.987). While logP for Ligand B is at the upper end of the optimal range, it's still acceptable. Ligand A's logP is quite low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (4) is higher than Ligand B (1). While both are within the acceptable limit of 5, lower HBD is generally preferred for better permeability.
5. **HBA:** Ligand A (6) is higher than Ligand B (3). Similar to HBD, lower HBA is preferred.
6. **QED:** Both ligands have good QED scores (A: 0.501, B: 0.637), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (14.114) has a significantly lower DILI risk than Ligand B (51.028). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (79.256) has a higher BBB penetration percentile than Ligand A (19.581). While ADRB2 isn't a CNS target, some degree of BBB penetration can be beneficial for off-target profiling and understanding potential side effects.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.254 and -4.702), which is unusual and suggests poor permeability. However, these values are on a scale where higher is better, so both are quite poor.
10. **Solubility:** Ligand A (-0.738) has slightly better solubility than Ligand B (-3.687), though both are poor.
11. **hERG:** Ligand A (0.14) has a much lower hERG inhibition liability than Ligand B (0.721), which is a critical advantage for cardiovascular drugs.
12. **Cl_mic:** Ligand A (-20.099) has a lower (better) microsomal clearance than Ligand B (94.219), indicating greater metabolic stability.
13. **t1/2:** Ligand B (41.513) has a significantly longer in vitro half-life than Ligand A (-15.166). This is a major advantage for Ligand B.
14. **Pgp:** Ligand A (0.012) has a much lower P-gp efflux liability than Ligand B (0.377), suggesting better oral bioavailability and potentially better tissue distribution.
15. **Affinity:** Ligand A (-8.2 kcal/mol) has a better binding affinity than Ligand B (-6.4 kcal/mol). This is a substantial difference, and a >1.5 kcal/mol advantage often outweighs other concerns.
**Overall Assessment:**
Ligand A is significantly better in terms of safety (DILI, hERG) and metabolic stability (Cl_mic). It also has a superior binding affinity. While Ligand B has a better half-life and BBB penetration, the advantages of Ligand A in key areas like safety and potency are more critical for a cardiovascular drug candidate. The poor Caco-2 and solubility for both are concerning, but can be addressed with formulation strategies. The lower TPSA of Ligand A is also a plus.
Output:
1
2025-04-17 23:11:11,795 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (369.447 and 348.487 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand B (58.64) is significantly better than Ligand A (111.71). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (2.798) is within the optimal 1-3 range, while Ligand A (0.1) is quite low. Low logP can hinder membrane permeability. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable.
5. **HBA:** Ligand A (5) and Ligand B (3) are both acceptable.
6. **QED:** Both ligands have similar and good QED values (0.734 and 0.751).
7. **DILI:** Ligand A (84.141) has a higher DILI risk than Ligand B (16.751). This is a substantial negative for Ligand A.
8. **BBB:** Ligand B (82.241) has a higher BBB penetration than Ligand A (48.779). While not critical for a cardiovascular target, it's a slight positive for Ligand B.
9. **Caco-2:** Both ligands have similar, poor Caco-2 permeability (-4.755 and -4.806).
10. **Solubility:** Both ligands have similar, poor solubility (-3.137 and -3.045).
11. **hERG:** Ligand A (0.234) has a slightly lower hERG risk than Ligand B (0.319), but both are relatively low.
12. **Cl_mic:** Ligand A (15.131) has a much lower (better) microsomal clearance than Ligand B (39.728), indicating greater metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand B (-1.782) has a slightly longer in vitro half-life than Ligand A (-42.707), but both are negative values.
14. **Pgp:** Ligand A (0.009) has a much lower Pgp efflux liability than Ligand B (0.24), which is a positive for Ligand A.
15. **Affinity:** Ligand A (-7.4 kcal/mol) has a slightly better binding affinity than Ligand B (-6.8 kcal/mol). This is a positive for Ligand A, but the difference is not huge.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand B excels in logP and has a better TPSA. Ligand A has a slightly better affinity and better metabolic stability (Cl_mic) and Pgp efflux. The DILI risk for Ligand A is concerning.
**Overall Assessment:**
While Ligand A has a slightly better affinity and metabolic stability, the significantly higher DILI risk and poor logP are major drawbacks. Ligand B, despite its higher Cl_mic and slightly weaker affinity, presents a more balanced profile with a much lower DILI risk and a more favorable logP. The lower TPSA is also beneficial.
Output:
0
2025-04-17 23:11:11,796 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's analyze each ligand against the provided guidelines, with emphasis on GPCR-relevant parameters (logP, TPSA, Pgp, BBB, and affinity).
* **Molecular Weight:** Both ligands (360.445 and 363.483 Da) fall comfortably within the ideal 200-500 Da range.
* **TPSA:** Ligand A (58.64) is better than Ligand B (62.74), both are under the 140 threshold for oral absorption.
* **logP:** Both ligands have good logP values (2.734 and 2.017), within the optimal 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability.
* **H-Bond Donors/Acceptors:** Ligand A (1 HBD, 3 HBA) is slightly better than Ligand B (0 HBD, 5 HBA) in terms of balancing solubility and permeability.
* **QED:** Both ligands have acceptable QED scores (0.643 and 0.803), indicating good drug-like properties.
* **DILI:** Ligand A (11.051) has a significantly lower DILI risk than Ligand B (33.346). This is a major advantage.
* **BBB:** Ligand A (96.084) has a much higher BBB penetration percentile than Ligand B (86.39). While ADRB2 isn't strictly a CNS target, some peripheral ADRB2 activity can influence CNS pathways, and higher BBB penetration isn't necessarily a negative.
* **Caco-2 Permeability:** Both are negative, indicating poor permeability.
* **Aqueous Solubility:** Both are negative, indicating poor solubility.
* **hERG:** Both ligands have low hERG inhibition liability (0.694 and 0.464), which is good.
* **Microsomal Clearance:** Ligand A (14.713) has a lower microsomal clearance than Ligand B (54.469), suggesting better metabolic stability.
* **In vitro Half-Life:** Ligand A (-4.221) has a better half-life than Ligand B (-16.52).
* **P-gp Efflux:** Both ligands have low P-gp efflux liability (0.094 and 0.212).
* **Binding Affinity:** Ligand B (-6.2 kcal/mol) has a stronger binding affinity than Ligand A (-3.3 kcal/mol). This is a substantial difference.
**Overall Assessment:**
The primary trade-off is between affinity (Ligand B) and ADME/Tox properties (Ligand A). Ligand B's significantly stronger binding affinity is a major plus. However, Ligand A exhibits a much more favorable safety profile (DILI) and metabolic stability (Cl_mic, t1/2), and better BBB penetration. While the Caco-2 and Solubility are poor for both, the other factors make Ligand A more promising. The difference in affinity, while significant, might be overcome with further optimization, while poor ADME/Tox profiles are harder to fix later in development.
**Output:**
1
2025-04-17 23:11:11,796 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (360.885 and 354.313 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (50.36) is significantly better than Ligand B (92.68). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold, while Ligand B is approaching it.
3. **logP:** Ligand A (4.655) is higher than Ligand B (1.479). While 4.655 is bordering on being too high, it's still within a reasonable range for a GPCR ligand. Ligand B's logP is quite low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (0). Both are acceptable.
5. **HBA:** Ligand A (3) is lower than Ligand B (6). This favors Ligand A, as fewer hydrogen bond acceptors generally improve permeability.
6. **QED:** Both ligands are good (0.755 and 0.826), indicating a generally drug-like profile.
7. **DILI:** Both ligands have similar, moderately high DILI risk (61.031 and 64.676). This is a concern for both, but not a deciding factor.
8. **BBB:** Ligand B (78.054) has a higher BBB penetration percentile than Ligand A (61.458). However, since ADRB2 is a cardiovascular target, BBB penetration is not a primary concern.
9. **Caco-2:** Both have negative values (-4.688 and -4.449), which is unusual. I will assume these are percentile scores, and a higher value is better. Ligand A (-4.688) is slightly better than Ligand B (-4.449).
10. **Solubility:** Ligand A (-5.646) has a worse solubility score than Ligand B (-1.618). Solubility is important, and Ligand B is better here.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.833 and 0.091), which is excellent.
12. **Cl_mic:** Ligand B (31.896) has significantly lower microsomal clearance than Ligand A (80.004). This suggests better metabolic stability for Ligand B.
13. **t1/2:** Ligand A (78.049) has a much longer in vitro half-life than Ligand B (-26.119). This is a significant advantage for Ligand A, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.636) has higher P-gp efflux liability than Ligand B (0.039). Lower P-gp efflux is preferred, favoring Ligand B.
15. **Affinity:** Both ligands have comparable binding affinities (-4.8 and -4.7 kcal/mol). The difference is negligible.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has a better logP and TPSA, and comparable affinity. Ligand B has better Pgp efflux and solubility, and better metabolic stability. The longer half-life of Ligand A is a significant advantage.
**Overall Assessment:**
While Ligand B has better solubility and metabolic stability, Ligand A's superior TPSA, logP, and significantly longer half-life outweigh these benefits. The comparable affinity further supports this conclusion. The slightly higher DILI risk for both is a concern, but manageable.
Output:
1
2025-04-17 23:11:11,796 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (344.411) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (91.57) is better than Ligand B (122.83). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (2.061) is within the optimal range (1-3), while Ligand B (-0.898) is below 1, potentially hindering permeation. This is a significant advantage for Ligand A.
4. **HBD:** Both have 3 HBD, which is acceptable.
5. **HBA:** Ligand A has 4 HBA, while Ligand B has 6. Ligand A is better here, keeping the total H-bonding capacity lower.
6. **QED:** Ligand A (0.717) has a better QED score than Ligand B (0.46), indicating a more drug-like profile.
7. **DILI:** Ligand B (19.775) has a significantly lower DILI risk than Ligand A (41.915). This is a strong point in favor of Ligand B.
8. **BBB:** Ligand B (74.758) has a higher BBB penetration percentile than Ligand A (38.348). However, as ADRB2 is a cardiovascular target, BBB penetration is not a high priority.
9. **Caco-2:** Ligand A (-4.798) and Ligand B (-5.737) both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret the absolute impact.
10. **Solubility:** Ligand A (-2.704) and Ligand B (-1.723) both have negative solubility values, indicating poor solubility.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.424 and 0.028 respectively). Ligand B is slightly better.
12. **Cl_mic:** Ligand B (-3.724) has a negative clearance, which is not physically possible. This is likely an error or an unusual scale. Ligand A (30.675) has a positive clearance, which is more realistic.
13. **t1/2:** Ligand A (48.579) has a significantly longer in vitro half-life than Ligand B (-5.277). This is a major advantage for Ligand A.
14. **Pgp:** Ligand B (0.002) has very low P-gp efflux liability, while Ligand A (0.188) has a slightly higher value.
15. **Binding Affinity:** Both ligands have very similar and strong binding affinities (-5.4 and -5.3 kcal/mol). The difference is negligible.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand A excels in logP and TPSA, while affinity is comparable. Ligand B has a lower DILI risk and Pgp efflux, but its low logP and questionable clearance are concerning.
**Overall Assessment:**
Despite Ligand B's lower DILI risk, Ligand A is the more promising candidate. Its better logP, TPSA, QED, and significantly longer half-life outweigh the slightly higher DILI risk. The negative clearance value for Ligand B is also a red flag. The similar binding affinities mean that the ADME properties are the deciding factors.
Output:
1
2025-04-17 23:11:11,796 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (354.372 and 368.543 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (38.5) is better than Ligand B (49.85). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (4.513) is higher than Ligand B (2.392). While both are within the acceptable range, Ligand A is approaching the upper limit where solubility issues could arise. However, for a GPCR, a slightly higher logP can be beneficial for membrane interactions.
4. **HBD:** Both ligands have 0 HBD, which is good.
5. **HBA:** Both ligands have 4 HBA, which is within the acceptable range.
6. **QED:** Ligand A (0.81) is slightly better than Ligand B (0.767), indicating a more drug-like profile.
7. **DILI:** Ligand B (21.869) has a significantly lower DILI risk than Ligand A (46.258). This is a major advantage for Ligand B.
8. **BBB:** Ligand A (85.731) has a higher BBB penetration potential than Ligand B (77.007). While not critical for a cardiovascular target, it's a slight positive for Ligand A.
9. **Caco-2:** Both ligands have similar, poor Caco-2 permeability (-4.47 and -4.436). This suggests potential absorption issues for both.
10. **Solubility:** Ligand B (-2.813) has better aqueous solubility than Ligand A (-4.721). This is important, especially given Ligand A's higher logP.
11. **hERG:** Ligand A (0.875) has a slightly higher hERG risk than Ligand B (0.269). Lower hERG risk is crucial for cardiovascular drugs.
12. **Cl_mic:** Ligand B (53.017) has a higher microsomal clearance than Ligand A (46.006), indicating faster metabolism and potentially lower *in vivo* exposure.
13. **t1/2:** Ligand A (-33.607) has a much longer *in vitro* half-life than Ligand B (-9.013). This is a significant advantage for Ligand A, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.37) has lower P-gp efflux than Ligand B (0.066). Lower P-gp efflux is generally desirable for better bioavailability.
15. **Binding Affinity:** Ligand A (-7.2) has a slightly better binding affinity than Ligand B (-7.0). While the difference is small (0.2 kcal/mol), it's still a positive for Ligand A.
**Overall Assessment:**
Ligand A has a slight edge in binding affinity, TPSA, QED, half-life, and P-gp efflux. However, Ligand B shines with a significantly lower DILI risk and better solubility, and a lower hERG risk. The longer half-life of Ligand A is a strong advantage, but the lower DILI risk of Ligand B is a critical factor for a cardiovascular drug. Given the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), and the importance of safety in cardiovascular medicine, the lower DILI and hERG risk of Ligand B outweigh the slight advantages of Ligand A.
Output:
0
2025-04-17 23:11:11,796 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for the ADRB2, a cardiovascular GPCR. Therefore, prioritizing logP, TPSA, Pgp, and binding affinity is crucial, alongside general drug-like properties.
**Molecular Weight:** Both ligands (346.43 and 344.39 Da) fall comfortably within the ideal 200-500 Da range.
**TPSA:** Ligand A (78.87) is slightly higher than Ligand B (67.23). Both are acceptable, but Ligand B is better, being closer to the <90 target for potential CNS penetration (though not a primary concern here).
**logP:** Ligand B (1.668) is better than Ligand A (0.462). Ligand A is quite low, potentially hindering membrane permeability. Ligand B is within the optimal 1-3 range.
**H-Bond Donors/Acceptors:** Ligand A has 2 HBD and 4 HBA, while Ligand B has 1 HBD and 4 HBA. Both are within acceptable limits.
**QED:** Ligand B (0.839) has a significantly higher QED score than Ligand A (0.56), indicating better overall drug-likeness.
**DILI:** Ligand A (21.87) has a much lower DILI risk than Ligand B (47.654), which is a significant advantage.
**BBB:** Ligand B (76.464) has a higher BBB penetration percentile than Ligand A (55.099). While ADRB2 is cardiovascular, some CNS off-target effects are possible, so moderate BBB penetration isn't necessarily a negative.
**Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand B (-4.929) is slightly worse than Ligand A (-4.656).
**Aqueous Solubility:** Both ligands have negative solubility values, indicating poor solubility. Ligand A (-1.49) is slightly better than Ligand B (-2.075).
**hERG:** Ligand A (0.181) shows a lower hERG inhibition liability than Ligand B (0.45), which is a positive.
**Microsomal Clearance:** Ligand A (9.932) has a much lower microsomal clearance than Ligand B (36.228), indicating better metabolic stability.
**In vitro Half-Life:** Ligand A (-10.504) has a much longer in vitro half-life than Ligand B (-4.384), a significant advantage.
**P-gp Efflux:** Ligand A (0.016) has a much lower P-gp efflux liability than Ligand B (0.223), which is highly desirable for bioavailability.
**Binding Affinity:** Ligand A (-7.1 kcal/mol) has a slightly better binding affinity than Ligand B (-6.8 kcal/mol). While the difference is not huge, it's still a factor.
**Overall Assessment:**
Ligand A has a clear advantage in terms of safety (DILI, hERG), metabolic stability (Cl_mic, t1/2), P-gp efflux, and slightly better binding affinity. Ligand B has better logP and QED. However, the poor permeability (Caco-2) and solubility of both ligands are concerning. Given the importance of metabolic stability and efflux for GPCRs, and the safety profile, Ligand A is the more promising candidate.
**Output:**
1
2025-04-17 23:11:11,797 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (342.359 Da and 351.403 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (103.08 and 104.9) are reasonably low, suggesting good potential for absorption. They are below the 140 A^2 threshold.
3. **logP:** Ligand A (1.717) is better than Ligand B (0.488). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but a logP between 1-3 is preferred for good absorption and distribution. Ligand B is a bit low, potentially impacting permeability.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer hydrogen bond donors generally improve membrane permeability.
5. **HBA:** Ligand A (8) is preferable to Ligand B (6). Lower HBA is generally better for permeability.
6. **QED:** Both ligands have good QED scores (0.695 and 0.773), indicating good drug-like properties.
7. **DILI:** Ligand B (47.034) has a significantly lower DILI risk than Ligand A (68.98). This is a major advantage for Ligand B.
8. **BBB:** Ligand A (78.868) has better BBB penetration than Ligand B (62.621). However, as ADRB2 is a cardiovascular target, BBB penetration is not a primary concern.
9. **Caco-2:** Ligand A (-5.343) and Ligand B (-4.842) are both negative, which is unusual and suggests poor Caco-2 permeability. This is a concern for both, but the values are close.
10. **Solubility:** Ligand A (-1.709) and Ligand B (-1.55) are both poor. Solubility is a concern for both.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.138 and 0.198), which is excellent.
12. **Cl_mic:** Ligand B (4.847) has a significantly lower microsomal clearance than Ligand A (11.617). This suggests better metabolic stability for Ligand B.
13. **t1/2:** Ligand B (-7.632) has a longer in vitro half-life than Ligand A (14.355). This is a significant advantage for Ligand B.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.081 and 0.045).
15. **Binding Affinity:** Ligand A (-6.1 kcal/mol) has a slightly better binding affinity than Ligand B (-5.7 kcal/mol). While a difference of 0.4 kcal/mol is noticeable, it's not a huge advantage, especially considering the other factors.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A has a better logP and slightly better affinity. However, Ligand B has a much better safety profile (DILI) and metabolic stability (Cl_mic, t1/2). Given the relatively small difference in affinity and the importance of ADME properties, the improved safety and metabolic stability of Ligand B are more compelling.
**Conclusion:**
Ligand B is the more promising drug candidate due to its significantly lower DILI risk and improved metabolic stability, despite a slightly lower binding affinity and logP.
Output:
0
2025-04-17 23:11:11,797 - INFO - Batch 386 complete. Total preferences: 6176
2025-04-17 23:11:11,797 - INFO - Processing batch 387/512...
2025-04-17 23:12:02,751 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (355.391 and 356.373 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (111.92) is higher than Ligand B (73.39). For a GPCR, lower TPSA is generally preferred for better brain penetration, even though ADRB2 isn't necessarily a CNS target. Ligand B is significantly better here.
3. **logP:** Ligand B (2.128) is within the optimal 1-3 range, while Ligand A (0.109) is quite low. Low logP can hinder membrane permeability. Ligand B is much better.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (0). Lower is generally better for permeability, but 2 is acceptable.
5. **HBA:** Ligand A (7) is higher than Ligand B (6). Again, lower is generally better.
6. **QED:** Both ligands have similar QED values (0.612 and 0.61), indicating good drug-likeness.
7. **DILI:** Ligand B (44.552) has a lower DILI risk than Ligand A (51.221), which is preferable.
8. **BBB:** Ligand B (95.347) has a significantly higher BBB penetration percentile than Ligand A (60.566). While ADRB2 isn't a primary CNS target, higher BBB is still a positive attribute, indicating better overall distribution.
9. **Caco-2:** Ligand A (-5.116) has a more negative Caco-2 value, suggesting *lower* permeability, while Ligand B (-4.445) is better.
10. **Solubility:** Ligand A (-1.544) has a more negative solubility value, suggesting *lower* solubility, while Ligand B (-2.343) is better.
11. **hERG:** Ligand A (0.177) has a lower hERG inhibition liability than Ligand B (0.639), which is preferable.
12. **Cl_mic:** Ligand B (57.259) has a lower microsomal clearance than Ligand A (8.248), indicating better metabolic stability.
13. **t1/2:** Ligand A (25.752) has a longer in vitro half-life than Ligand B (18.073), which is preferable.
14. **Pgp:** Ligand A (0.012) has a lower P-gp efflux liability than Ligand B (0.467), which is preferable.
15. **Binding Affinity:** Ligand B (-8.1 kcal/mol) has a significantly stronger binding affinity than Ligand A (-7.4 kcal/mol). This is a substantial advantage (0.7 kcal/mol difference) and can outweigh some of the ADME drawbacks.
**Overall Assessment:**
Ligand B clearly outperforms Ligand A in several key areas crucial for a GPCR drug candidate: logP, TPSA, BBB, DILI, Cl_mic, and, most importantly, binding affinity. While Ligand A has advantages in hERG, Pgp, and t1/2, the stronger binding affinity of Ligand B and its better ADME profile (particularly logP and TPSA) make it the more promising candidate. The difference in binding affinity is significant enough to overcome the slightly higher Pgp efflux and hERG risk.
Output:
0
2025-04-17 23:12:02,752 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (354.332 and 346.427 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Both ligands (69.04 and 67.87) are well below the 140 A^2 threshold for good oral absorption, and suitable for a non-CNS GPCR target like ADRB2. No significant difference.
3. **logP:** Both ligands (2.497 and 2.428) are within the optimal 1-3 range. No significant difference.
4. **HBD:** Both ligands have 1 HBD, which is within the acceptable limit of <=5. No significant difference.
5. **HBA:** Ligand A has 5 HBA, and Ligand B has 4. Both are within the acceptable limit of <=10. Slight preference for Ligand B.
6. **QED:** Ligand A (0.916) has a significantly higher QED score than Ligand B (0.657), indicating a more drug-like profile. This is a substantial advantage for Ligand A.
7. **DILI:** Ligand A (80.651) has a higher DILI risk than Ligand B (41.334). This is a significant drawback for Ligand A. Ligand B is clearly preferable here.
8. **BBB:** Both ligands have high BBB penetration (87.476 and 89.027). While ADRB2 isn't a primary CNS target, higher BBB is generally favorable. No significant difference.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.675 and -4.649), which is unusual and suggests poor permeability. This is a concern for both, but doesn't differentiate them.
10. **Solubility:** Ligand B (-2.345) has better (less negative) solubility than Ligand A (-3.454). This is a slight advantage for Ligand B.
11. **hERG:** Ligand A (0.366) has a lower hERG inhibition liability than Ligand B (0.557). This is a significant advantage for Ligand A, as it reduces the risk of cardiotoxicity.
12. **Cl_mic:** Ligand A (14.626) has a significantly lower microsomal clearance than Ligand B (61.526), indicating better metabolic stability. This is a substantial advantage for Ligand A.
13. **t1/2:** Ligand A (-31.162) has a more negative in vitro half-life than Ligand B (1.049). This is a significant drawback for Ligand A.
14. **Pgp:** Ligand A (0.108) has lower P-gp efflux liability than Ligand B (0.154). This is a slight advantage for Ligand A.
15. **Binding Affinity:** Ligand B (-9.0) has a significantly stronger binding affinity than Ligand A (-5.9). This is a major advantage for Ligand B, potentially outweighing some of the ADME drawbacks.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Both ligands perform well on logP and TPSA. Ligand B has a superior binding affinity, and a slightly better Pgp profile. Ligand B also has a much better DILI score. While Ligand A has better QED, Cl_mic, and hERG, the significantly stronger binding affinity and lower DILI risk of Ligand B are more critical for a GPCR target. The negative Caco-2 values are a concern for both, but the binding advantage of B is substantial.
**Conclusion:**
Considering the balance of properties, particularly the significantly stronger binding affinity and lower DILI risk of Ligand B, it is the more promising drug candidate for the ADRB2 receptor.
Output:
0
2025-04-17 23:12:02,752 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (403.28 Da) is within the ideal range. Ligand B (358.467 Da) is also within the ideal range. No clear advantage here.
2. **TPSA:** Ligand A (69.04) is excellent, well below the 140 threshold. Ligand B (75.19) is also good, but slightly higher. Ligand A has a slight edge.
3. **logP:** Ligand A (3.873) is at the upper end of the optimal range, but acceptable. Ligand B (1.975) is lower, potentially impacting permeability. Ligand A is preferred.
4. **HBD:** Ligand A (1) is good. Ligand B (2) is also acceptable. No significant difference.
5. **HBA:** Ligand A (6) is good. Ligand B (5) is also good. No significant difference.
6. **QED:** Ligand A (0.479) is borderline, but acceptable. Ligand B (0.742) is significantly better, indicating a more drug-like profile. Ligand B is preferred.
7. **DILI:** Ligand A (79.721) is higher risk. Ligand B (68.282) is better, indicating lower liver injury potential. Ligand B is preferred.
8. **BBB:** Ligand A (68.903) is reasonable. Ligand B (36.836) is low. Since ADRB2 is a GPCR, BBB penetration isn't a primary concern, but it's a bonus if it's reasonable. Ligand A is preferred.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.061 and -5.135). This is unusual and suggests poor permeability. However, the values are very similar.
10. **Solubility:** Both ligands have negative solubility values (-3.528 and -2.094). This is also unusual and suggests poor solubility. Ligand B is slightly better.
11. **hERG:** Ligand A (0.767) is better than Ligand B (0.238), indicating lower cardiotoxicity risk. Ligand A is preferred.
12. **Cl_mic:** Ligand A (113.21) is higher, suggesting faster metabolism. Ligand B (30.516) is much lower, indicating better metabolic stability. Ligand B is strongly preferred.
13. **t1/2:** Ligand A (77.415) is good. Ligand B (44.367) is acceptable, but lower. Ligand A is preferred.
14. **Pgp:** Ligand A (0.535) is better than Ligand B (0.046), meaning less P-glycoprotein efflux. Ligand A is preferred.
15. **Affinity:** Ligand A (-6.6 kcal/mol) is slightly better than Ligand B (-5.9 kcal/mol). This difference is significant enough to consider.
**Overall Assessment:**
While Ligand B has a better QED, DILI, and Cl_mic, Ligand A has a better logP, TPSA, hERG, t1/2, Pgp, and binding affinity. Considering the GPCR target class, affinity is paramount. The 0.7 kcal/mol difference in binding affinity is substantial. Moreover, Ligand A's better logP and TPSA suggest better membrane permeability, despite the negative Caco-2 values. The slightly higher DILI risk for Ligand A is a concern, but potentially manageable with further optimization. The better metabolic stability of Ligand B is attractive, but can be addressed through structural modifications.
Therefore, I believe Ligand A is the more promising candidate.
Output:
1
2025-04-17 23:12:02,752 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
Let's systematically compare Ligand A and Ligand B based on the provided parameters and the guidelines, keeping in mind ADRB2 is a GPCR. GPCRs prioritize logP, Pgp, TPSA, and affinity.
1. **Molecular Weight:** Both ligands (368.836 Da and 362.583 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand B (23.55) is significantly better than Ligand A (58.64). Lower TPSA generally improves permeability, and is highly desirable for GPCRs.
3. **logP:** Ligand A (3.001) is within the optimal range (1-3), while Ligand B (4.061) is slightly above. While not a deal-breaker, higher logP can sometimes lead to off-target effects and solubility issues.
4. **H-Bond Donors:** Ligand A (1) is better than Ligand B (0). A small number of HBDs is generally preferred for permeability.
5. **H-Bond Acceptors:** Both ligands have 3 HBA, which is acceptable.
6. **QED:** Ligand A (0.816) has a better QED score than Ligand B (0.619), indicating a more drug-like profile.
7. **DILI Risk:** Ligand B (9.383) has a *much* lower DILI risk than Ligand A (67.003). This is a critical advantage for Ligand B.
8. **BBB Penetration:** Both ligands have good BBB penetration (Ligand A: 83.715, Ligand B: 80.031). This is less critical for ADRB2 (cardiovascular target) but still a positive.
9. **Caco-2 Permeability:** Both ligands show poor Caco-2 permeability (Ligand A: -4.412, Ligand B: -4.973). This is a concern for oral bioavailability.
10. **Aqueous Solubility:** Ligand B (-3.228) has better solubility than Ligand A (-4.6).
11. **hERG Inhibition:** Ligand B (0.97) has a lower hERG risk than Ligand A (0.463), which is a significant advantage.
12. **Microsomal Clearance:** Ligand B (78.953) has higher clearance than Ligand A (63.964), meaning Ligand A is more metabolically stable.
13. **In vitro Half-Life:** Ligand A (28.784) has a longer half-life than Ligand B (13.543). This is a positive for Ligand A.
14. **P-gp Efflux:** Ligand B (0.82) has higher P-gp efflux than Ligand A (0.406). This is a negative for Ligand B.
15. **Binding Affinity:** Ligand A (-7.1 kcal/mol) has a stronger binding affinity than Ligand B (-6.5 kcal/mol). The difference is 0.6 kcal/mol, which is significant, but not overwhelmingly so.
**Overall Assessment:**
Ligand B has several key advantages: significantly lower DILI risk, lower hERG risk, and better solubility. Its TPSA is also much more favorable. While Ligand A has better affinity and metabolic stability, the safety profile of Ligand B is much more attractive. The slightly higher logP of Ligand B is a minor concern, but the benefits outweigh this drawback. The affinity difference is not large enough to overcome the safety concerns associated with Ligand A.
Output:
0
2025-04-17 23:12:02,753 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**1. Molecular Weight:** Both ligands (350.463 Da and 343.427 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (96.25) is slightly higher than Ligand B (74.57). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is generally preferable for absorption. Ligand B has a clear advantage.
**3. logP:** Both ligands have good logP values (1.294 and 1.027), falling within the optimal 1-3 range. No major difference.
**4. H-Bond Donors:** Ligand A has 3 HBD, and Ligand B has 2. Both are acceptable (<=5).
**5. H-Bond Acceptors:** Ligand A has 5 HBA, and Ligand B has 4. Both are acceptable (<=10).
**6. QED:** Both ligands have reasonable QED scores (0.69 and 0.573), indicating drug-like properties. Ligand A is slightly better.
**7. DILI Risk:** Ligand A (47.732) has a slightly higher DILI risk than Ligand B (39.473), but both are below the concerning threshold of 60. Ligand B is preferable.
**8. BBB Penetration:** This is less critical for a cardiovascular target. Ligand A (56.65) and Ligand B (29.12) are both relatively low, which is fine.
**9. Caco-2 Permeability:** Ligand A (-4.849) and Ligand B (-4.837) are very similar.
**10. Aqueous Solubility:** Ligand A (-2.527) is slightly worse than Ligand B (-1.67). Better solubility is always desirable. Ligand B is preferable.
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.173 and 0.225), which is excellent. No difference.
**12. Microsomal Clearance:** Ligand B (-13.139) has significantly lower (better) microsomal clearance than Ligand A (31.615). This indicates better metabolic stability for Ligand B.
**13. In vitro Half-Life:** Ligand B (-0.44) has a slightly better half-life than Ligand A (10.754).
**14. P-gp Efflux:** Both are very low (0.07 and 0.086), indicating minimal P-gp efflux. No difference.
**15. Binding Affinity:** Both ligands have excellent binding affinities (-5.6 and -5.4 kcal/mol). The difference of 0.2 kcal/mol is not substantial enough to outweigh other factors.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), and the general drug-like properties, Ligand B emerges as the more promising candidate. It has a lower TPSA, lower DILI risk, better solubility, and significantly better metabolic stability (lower Cl_mic and better half-life) compared to Ligand A. While Ligand A has a slightly higher QED, the ADME advantages of Ligand B are more critical for overall drug development success.
Output:
0
2025-04-17 23:12:02,753 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (356.379 and 359.495 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (129.56) is slightly above the preferred <140 for good oral absorption, but still reasonable. Ligand B (55.32) is excellent, well below 90, suggesting good permeability. This favors Ligand B.
3. **logP:** Ligand A (-2.151) is a bit low, potentially hindering membrane permeability. Ligand B (3.698) is within the optimal 1-3 range. This strongly favors Ligand B.
4. **HBD:** Ligand A (3) is acceptable. Ligand B (0) is even better, minimizing potential for off-target interactions and improving permeability. This favors Ligand B.
5. **HBA:** Ligand A (7) is acceptable. Ligand B (5) is also good. No strong preference.
6. **QED:** Both ligands have good QED scores (0.455 and 0.685 respectively), indicating reasonable drug-likeness. Ligand B is slightly better.
7. **DILI:** Ligand A (60.217) is approaching a concerning level for DILI risk. Ligand B (23.575) is excellent, indicating a low risk of liver injury. This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (14.23) has very low BBB penetration. Ligand B (70.027) has good BBB penetration, which is beneficial for a GPCR target, even if it's not a CNS target. This favors Ligand B.
9. **Caco-2:** Both ligands have negative Caco-2 values which is unusual. Assuming these are percentile scores, Ligand A (-5.535) is worse than Ligand B (-4.504).
10. **Solubility:** Ligand A (-1.211) has poor solubility. Ligand B (-3.383) is even worse. Both are problematic, but Ligand B is worse.
11. **hERG:** Both ligands have low hERG inhibition liability (0.133 and 0.498 respectively), which is good. No significant difference.
12. **Cl_mic:** Ligand A (1.517) has lower microsomal clearance, indicating better metabolic stability. Ligand B (95.193) has very high clearance, suggesting rapid metabolism. This favors Ligand A.
13. **t1/2:** Ligand A (-2.308) has a negative half-life which is unusual. Ligand B (-7.529) is even worse. Both are problematic, but Ligand B is worse.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.008 and 0.189 respectively). No significant difference.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.4 and -6.3 kcal/mol). The difference is negligible.
**Overall Assessment:**
Ligand B clearly outperforms Ligand A in most critical ADME properties, particularly logP, DILI risk, and BBB penetration. While Ligand A has better metabolic stability (lower Cl_mic), the other advantages of Ligand B are more impactful for a GPCR target like ADRB2. The solubility issue is a concern for both, but can potentially be addressed through formulation strategies. The poor Caco-2 and half-life values are also concerning for both.
Therefore, I recommend Ligand B.
Output:
0
2025-04-17 23:12:02,753 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for the ADRB2, a cardiovascular GPCR. Therefore, logP, TPSA, Pgp, and binding affinity are key. Let's break down the comparison:
1. **Molecular Weight:** Both ligands (341.415 and 363.414 Da) are within the ideal range (200-500 Da).
2. **TPSA:** Both are good (85.84 and 80.32), well below the 140 A^2 threshold for oral absorption.
3. **logP:** Both are excellent (2.428 and 2.161), falling within the optimal 1-3 range.
4. **H-Bond Donors/Acceptors:** Ligand A has 1 HBD and 6 HBA, while Ligand B has 2 HBD and 6 HBA. Both are acceptable.
5. **QED:** Ligand A (0.863) is better than Ligand B (0.769), indicating a more drug-like profile.
6. **DILI:** Ligand A (64.521) has a lower DILI risk than Ligand B (80.807), which is a significant advantage.
7. **BBB:** Both have reasonably good BBB penetration (67.623 and 83.094), but Ligand B is better. However, since this is a cardiovascular target, BBB penetration is less critical than for CNS targets.
8. **Caco-2 Permeability:** Both are negative, indicating poor permeability. Ligand A (-5.333) is slightly worse than Ligand B (-4.708).
9. **Aqueous Solubility:** Both are very poor (-2.656 and -3.434). This is a concern for both, but could be addressed with formulation strategies.
10. **hERG:** Ligand A (0.051) has a much lower hERG risk than Ligand B (0.577). This is a major advantage for Ligand A.
11. **Microsomal Clearance:** Ligand B (57.472) has significantly lower microsomal clearance than Ligand A (15.851), suggesting better metabolic stability.
12. **In vitro Half-Life:** Ligand B (41.597) has a longer half-life than Ligand A (16.764), which is desirable.
13. **P-gp Efflux:** Both are low (0.15 and 0.263), indicating minimal P-gp efflux.
14. **Binding Affinity:** Ligand A (-7.4 kcal/mol) has a stronger binding affinity than Ligand B (-6.8 kcal/mol). This 0.6 kcal/mol difference is substantial and can outweigh some of the ADME drawbacks.
**Overall Assessment:**
Ligand A has a significantly better binding affinity and a much lower hERG risk. While Ligand B has better metabolic stability (lower Cl_mic) and half-life, the stronger binding affinity and lower cardiotoxicity risk of Ligand A are more important for a GPCR target, especially considering the cardiovascular implications. The solubility issues are a concern for both, but manageable. The slightly lower Caco-2 permeability of Ligand A is less critical given the higher affinity.
Output:
1
2025-04-17 23:12:02,753 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (340.391 and 352.435 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (96.69) is significantly better than Ligand A (125.13). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (1.759) is better than Ligand B (0.411). A logP between 1-3 is optimal, and Ligand B is a bit low, potentially hindering permeability.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (2), but both are within the acceptable limit of 5.
5. **HBA:** Both ligands have 6 HBA, which is acceptable (<=10).
6. **QED:** Ligand B (0.741) has a slightly higher QED score than Ligand A (0.624), indicating a more drug-like profile.
7. **DILI:** Ligand B (47.15) has a much lower DILI risk than Ligand A (82.435). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (48.74) has a higher BBB percentile than Ligand B (30.128). However, as ADRB2 is a cardiovascular target, BBB penetration is not a high priority.
9. **Caco-2:** Ligand A (-5.552) has a worse Caco-2 permeability than Ligand B (-4.927).
10. **Solubility:** Ligand A (-3.299) has a worse solubility than Ligand B (-1.122).
11. **hERG:** Both ligands have very low hERG inhibition liability (0.185 and 0.142 respectively), which is excellent.
12. **Cl_mic:** Ligand A (-4.993) has a significantly *lower* (better) microsomal clearance than Ligand B (22.792). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand B (7.934) has a much longer in vitro half-life than Ligand A (1.069). This is a significant advantage for Ligand B.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.156 and 0.016 respectively), which is excellent.
15. **Binding Affinity:** Ligand B (-6.8 kcal/mol) has a slightly better binding affinity than Ligand A (-6.3 kcal/mol). While the difference is not huge, it's a positive for Ligand B.
**GPCR-specific priorities:** For a GPCR like ADRB2, logP, TPSA, and affinity are key. Ligand A has a better logP, but Ligand B excels in TPSA, DILI, solubility, and has comparable affinity. The longer half-life of Ligand B is also a significant benefit. The lower metabolic stability of Ligand A is a concern.
**Overall Assessment:**
While Ligand A has a slightly better logP and metabolic stability, Ligand B presents a more favorable overall profile. Its lower DILI risk, better solubility, longer half-life, and better TPSA outweigh the slight disadvantage in logP. The binding affinity is also slightly better.
Output:
0
2025-04-17 23:12:02,754 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
The ADRB2 receptor is a GPCR, so the priorities are logP, TPSA, Pgp efflux, BBB penetration, and binding affinity. Let's break down the comparison:
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (364.339) is slightly higher than Ligand B (348.531), but this isn't a major concern.
2. **TPSA:** Ligand B (41.57) is significantly better than Ligand A (75.4). Lower TPSA generally indicates better cell permeability, crucial for GPCR ligands.
3. **logP:** Ligand A (4.521) is a bit high, potentially leading to solubility issues and off-target interactions. Ligand B (3.493) is within the optimal range (1-3). This is a significant advantage for Ligand B.
4. **H-Bond Donors/Acceptors:** Ligand A has 2 HBD and 4 HBA, while Ligand B has 1 HBD and 3 HBA. Both are acceptable, but Ligand B is slightly more favorable.
5. **QED:** Ligand B (0.799) has a better QED score than Ligand A (0.424), indicating a more drug-like profile.
6. **DILI Risk:** Ligand B (12.136) has a much lower DILI risk than Ligand A (48.313). This is a major advantage for Ligand B.
7. **BBB Penetration:** Ligand B (86.041) shows better BBB penetration than Ligand A (77.588), although both are reasonably good.
8. **Caco-2 Permeability:** Both are negative, indicating poor permeability.
9. **Aqueous Solubility:** Both are negative, indicating poor solubility.
10. **hERG Inhibition:** Both ligands have low hERG inhibition risk.
11. **Microsomal Clearance:** Ligand B (61.409) has a higher clearance than Ligand A (21.317), suggesting lower metabolic stability. This favors Ligand A.
12. **In vitro Half-Life:** Ligand A (32.58) has a longer half-life than Ligand B (11.318). This favors Ligand A.
13. **P-gp Efflux:** Ligand B (0.264) has lower P-gp efflux than Ligand A (0.432), which is desirable for better bioavailability and potentially CNS exposure.
14. **Binding Affinity:** Ligand B (-2.7 kcal/mol) has a better binding affinity than Ligand A (-8.0 kcal/mol). This is a substantial advantage for Ligand B.
**Overall Assessment:**
Ligand B consistently outperforms Ligand A in most critical parameters for a GPCR drug candidate, particularly TPSA, logP, DILI risk, BBB penetration, and binding affinity. While Ligand A has better metabolic stability and half-life, the superior ADME properties and potency of Ligand B outweigh these drawbacks. The lower logP and TPSA of Ligand B suggest better permeability and bioavailability, which are crucial for GPCR targeting. The significantly lower DILI risk is also a major positive.
**Output:**
0
2025-04-17 23:12:02,754 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (346.431 Da) is slightly higher than Ligand B (336.351 Da), but both are acceptable.
2. **TPSA:** Ligand A (67.67) is significantly better than Ligand B (95.42). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption. Ligand B is pushing the upper limit for good oral absorption.
3. **logP:** Ligand A (1.031) is within the optimal range, while Ligand B (0.205) is a bit low. A logP below 1 can sometimes hinder membrane permeability.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Both ligands have 5 HBA, which is acceptable.
6. **QED:** Both ligands have similar QED values (0.772 and 0.778), indicating good drug-likeness.
7. **DILI:** Ligand A (26.483) has a much lower DILI risk than Ligand B (64.56). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (76.309) has a better BBB penetration score than Ligand B (13.067). While not a primary concern for a cardiovascular target, it's still a positive attribute.
9. **Caco-2:** Both ligands have similar, poor Caco-2 permeability (-4.839 and -4.864). This suggests potential absorption issues for both.
10. **Solubility:** Ligand A (-0.741) has better solubility than Ligand B (-2.562).
11. **hERG:** Both ligands have very low hERG inhibition risk (0.23 and 0.128).
12. **Cl_mic:** Ligand B (-34.329) has a significantly lower (better) microsomal clearance than Ligand A (28.068). This suggests better metabolic stability for Ligand B.
13. **t1/2:** Both ligands have similar in vitro half-lives (10.582 and 10.498).
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.057 and 0.021).
15. **Binding Affinity:** Ligand B (-8.9 kcal/mol) has a substantially stronger binding affinity than Ligand A (-5.6 kcal/mol). This is a difference of 3.3 kcal/mol, which is a very significant advantage.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B has a better affinity, but suffers from higher TPSA and lower logP. Ligand A has better TPSA, logP, solubility, and DILI risk. The affinity difference is substantial, but the other factors are also important. Given the substantial affinity difference, I will prioritize that.
**Conclusion:**
Despite Ligand A's better ADME properties (lower DILI, better solubility, TPSA, logP), the significantly stronger binding affinity of Ligand B (-8.9 vs -5.6 kcal/mol) is a decisive factor for a GPCR target. The improved metabolic stability (lower Cl_mic) of Ligand B is also a positive. While the lower logP and higher TPSA of Ligand B are concerns, they are potentially addressable through further optimization, whereas improving affinity is often more challenging.
Output:
0
2025-04-17 23:12:02,754 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A Analysis:**
* **MW:** 350.503 Da - Good, within the ideal range.
* **TPSA:** 69.64 - Good, well below the 140 threshold for oral absorption.
* **logP:** 2.78 - Excellent, within the optimal 1-3 range.
* **HBD:** 2 - Good, below the 5 threshold.
* **HBA:** 3 - Good, below the 10 threshold.
* **QED:** 0.724 - Excellent, indicates a very drug-like profile.
* **DILI:** 32.067 - Excellent, low risk of liver injury.
* **BBB:** 50.446 - Moderate, not ideal for a CNS target, but ADRB2 is primarily cardiovascular, so this is less critical.
* **Caco-2:** -4.623 - Poor, suggests limited intestinal absorption. This is a significant concern.
* **Solubility:** -2.725 - Poor, suggests low aqueous solubility. This is also a significant concern.
* **hERG:** 0.251 - Excellent, very low risk of hERG inhibition.
* **Cl_mic:** 44.304 - Moderate, suggests moderate metabolic clearance.
* **t1/2:** 7.486 - Moderate, a reasonable in vitro half-life.
* **Pgp:** 0.105 - Low, suggests minimal P-gp efflux.
* **Affinity:** -5.6 kcal/mol - Good binding affinity.
**Ligand B Analysis:**
* **MW:** 350.507 Da - Good, within the ideal range.
* **TPSA:** 47.1 - Excellent, very favorable for absorption.
* **logP:** 0.584 - Marginal. Below the optimal range, potentially hindering permeation.
* **HBD:** 0 - Good, low number of hydrogen bond donors.
* **HBA:** 4 - Good, below the 10 threshold.
* **QED:** 0.728 - Excellent, indicates a very drug-like profile.
* **DILI:** 3.373 - Excellent, very low risk of liver injury.
* **BBB:** 78.868 - Good, suggests reasonable BBB penetration.
* **Caco-2:** -4.783 - Poor, similar to Ligand A, suggests limited intestinal absorption.
* **Solubility:** -0.051 - Poor, similar to Ligand A, suggests low aqueous solubility.
* **hERG:** 0.527 - Excellent, very low risk of hERG inhibition.
* **Cl_mic:** -10.221 - Excellent, very low metabolic clearance, indicating high metabolic stability.
* **t1/2:** -10.867 - Excellent, very long in vitro half-life.
* **Pgp:** 0.008 - Very Low, suggests minimal P-gp efflux.
* **Affinity:** -8.1 kcal/mol - Excellent, significantly stronger binding affinity than Ligand A.
**Comparison and Decision:**
Both ligands suffer from poor Caco-2 permeability and aqueous solubility, which are major drawbacks. However, Ligand B has a significantly stronger binding affinity (-8.1 vs -5.6 kcal/mol), which is a crucial factor for GPCRs. It also exhibits superior metabolic stability (lower Cl_mic) and a longer half-life. While its logP is slightly lower, the substantial improvement in affinity and ADME properties outweighs this minor concern. The better Pgp and BBB scores are also beneficial.
Given the importance of potency for GPCR targets and the improvements in metabolic stability and efflux, Ligand B is the more promising candidate despite the shared solubility and permeability issues. Formulation strategies could potentially address these issues.
Output:
0
2025-04-17 23:12:02,754 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (366.49 and 361.38 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (90.54) is better than Ligand B (118.33). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have a logP of 1.481, which is optimal.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (1), but both are within the acceptable limit of 5.
5. **HBA:** Ligand A (4) is lower than Ligand B (7), which is preferable. Higher HBA can sometimes hinder permeability.
6. **QED:** Ligand A (0.712) is slightly better than Ligand B (0.651), indicating a more drug-like profile.
7. **DILI:** Ligand A (29.08) is *significantly* better than Ligand B (75.18). This is a major advantage for Ligand A. DILI risk is a critical factor in drug development.
8. **BBB:** Both are relatively low, but Ligand B (62.97) is slightly higher than Ligand A (53.66). Since ADRB2 is not a CNS target, this is not a major factor.
9. **Caco-2:** Ligand A (-5.559) is better than Ligand B (-5.005), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-1.845) is better than Ligand B (-3.576). Better solubility is generally desirable.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.23 and 0.24).
12. **Cl_mic:** Ligand B (-2.733) has significantly better (lower) microsomal clearance than Ligand A (-15.485). This suggests better metabolic stability for Ligand B.
13. **t1/2:** Ligand A (25.714) has a longer half-life than Ligand B (18.366). This is a positive attribute.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.014 and 0.139).
15. **Binding Affinity:** Ligand A (-6.3 kcal/mol) is slightly better than Ligand B (-4.8 kcal/mol). This is a substantial difference in potency.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Both ligands are good on logP and Pgp. Ligand A is better on TPSA and significantly better on affinity.
**Overall Assessment:**
While Ligand B has better metabolic stability (lower Cl_mic), the significantly lower DILI risk and better binding affinity of Ligand A outweigh this advantage. The better solubility, Caco-2 permeability, and half-life of Ligand A also contribute to its superior profile. The difference in binding affinity is substantial enough to overcome the slightly higher clearance.
Output:
1
2025-04-17 23:12:02,755 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [346.515, 40.62, 3.308, 0, 2, 0.766, 15.471, 90.5, -4.731, -3.405, 0.658, 63.064, -3.015, 0.461, -6.6]
**Ligand B:** [344.415, 88.33, 2.109, 1, 5, 0.792, 49.283, 52.617, -5.141, -1.178, 0.244, 49.553, 17.852, 0.024, -5.6]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal 200-500 Da range. A is 346.5, B is 344.4 - very similar.
2. **TPSA:** Ligand A (40.62) is significantly better than Ligand B (88.33). A is well under the 140 threshold, and closer to the desirable <90 for CNS penetration, even though this isn't a CNS target. B is higher, potentially impacting absorption.
3. **logP:** Ligand A (3.308) is optimal. Ligand B (2.109) is acceptable but on the lower side, potentially impacting membrane permeability.
4. **HBD/HBA:** A (0/2) is preferable to B (1/5). Fewer H-bonds generally improve permeability.
5. **QED:** Both are good (A: 0.766, B: 0.792), indicating drug-like properties.
6. **DILI:** Ligand A (15.471) is *much* better than Ligand B (49.283). This is a significant advantage for A.
7. **BBB:** Ligand A (90.5) is excellent, while Ligand B (52.617) is moderate. While not a primary concern for ADRB2, higher BBB is rarely a detriment.
8. **Caco-2:** Ligand A (-4.731) is better than Ligand B (-5.141). Both are negative, indicating good permeability.
9. **Solubility:** Ligand A (-3.405) is better than Ligand B (-1.178).
10. **hERG:** Ligand A (0.658) is better than Ligand B (0.244), indicating lower cardiotoxicity risk.
11. **Cl_mic:** Ligand A (63.064) is higher than Ligand B (49.553), meaning faster clearance and lower metabolic stability.
12. **t1/2:** Ligand B (17.852) has a significantly longer half-life than Ligand A (-3.015). This is a strong point for B.
13. **Pgp:** Ligand A (0.461) is better than Ligand B (0.024), indicating lower efflux.
14. **Affinity:** Ligand A (-6.6) is slightly better than Ligand B (-5.6). While not a huge difference, it's a clear advantage.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical ADME properties (TPSA, logP, DILI, BBB, solubility, hERG, Pgp) and has a slightly better binding affinity. The primary advantage of Ligand B is its longer *in vitro* half-life. However, the superior ADME profile and lower toxicity risk of Ligand A outweigh the half-life difference, especially considering the potential for formulation strategies to address metabolic stability. Given the GPCR target class, the balance of properties in Ligand A is more favorable.
Output:
1
2025-04-17 23:12:02,755 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Reasoning:**
Let's break down the comparison of Ligand A and Ligand B across the provided parameters, keeping in mind the GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key).
1. **Molecular Weight:** Both ligands (361.368 Da and 351.491 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (80.12) is slightly higher than Ligand B (61.88). Both are below the 140 A^2 threshold for good oral absorption, but Ligand B is preferable due to its lower TPSA, potentially leading to better membrane permeability.
3. **logP:** Both ligands have acceptable logP values (1.077 and 1.417, respectively), falling within the 1-3 range. Ligand B is slightly better.
4. **H-Bond Donors:** Both have 1 HBD, which is good.
5. **H-Bond Acceptors:** Ligand A has 5 HBA, and Ligand B has 4. Both are within the acceptable limit of 10.
6. **QED:** Ligand A (0.822) has a slightly better QED score than Ligand B (0.753), indicating a more drug-like profile.
7. **DILI Risk:** Ligand B (21.869) has a significantly lower DILI risk than Ligand A (43.738). This is a major advantage for Ligand B.
8. **BBB Penetration:** Ligand A (74.215) has better BBB penetration than Ligand B (65.607). While ADRB2 isn't exclusively a CNS target, some CNS exposure might be acceptable or even desirable depending on the specific therapeutic goal.
9. **Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.917 and -4.753). This is unusual and suggests poor permeability *in vitro*. However, the values are very close, so this isn't a major differentiator.
10. **Aqueous Solubility:** Both ligands have negative solubility values (-2.158 and -1.085). This is also concerning and suggests poor aqueous solubility. Ligand B is slightly better.
11. **hERG Inhibition:** Ligand A (0.148) has a slightly lower hERG inhibition risk than Ligand B (0.451), which is preferable.
12. **Microsomal Clearance:** Ligand B (27.532) has significantly higher microsomal clearance than Ligand A (2.753). This means Ligand A is more metabolically stable, a significant advantage.
13. **In vitro Half-Life:** Ligand A (-18.473) has a much longer in vitro half-life than Ligand B (19.02). This is a major advantage for Ligand A.
14. **P-gp Efflux:** Ligand A (0.026) has a much lower P-gp efflux liability than Ligand B (0.032). This is a significant advantage for Ligand A.
15. **Binding Affinity:** Ligand B (-7.1) has a slightly better binding affinity than Ligand A (-6.9). While a 0.2 kcal/mol difference isn't huge, it's noticeable.
**Overall Assessment:**
Ligand B has a clear advantage in terms of DILI risk and a slightly better binding affinity. However, Ligand A excels in metabolic stability (lower Cl_mic, longer half-life), P-gp efflux, and QED. The solubility and Caco-2 permeability are poor for both, which would require formulation work. Considering the GPCR-specific priorities, the improved metabolic stability and reduced efflux of Ligand A are more critical for *in vivo* efficacy than the slight affinity advantage of Ligand B. The lower DILI risk of Ligand B is attractive, but can be addressed through further optimization.
**Output:**
1
2025-04-17 23:12:02,755 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [341.407, 72.47, 3.201, 1, 4, 0.386, 78.015, 70.415, -4.212, -4.982, 0.224, 81.36, -12.963, 0.325, -6.2]
**Ligand B:** [347.415, 95.67, 1.492, 2, 5, 0.787, 45.328, 54.556, -4.874, -1.944, 0.203, 26.861, -31.596, 0.128, -9.4]
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal 200-500 Da range. A (341.4) is slightly lower, which is generally favorable for permeability, but both are acceptable.
2. **TPSA:** Ligand A (72.47) is significantly better than Ligand B (95.67). For a GPCR, keeping TPSA low is good for permeability, and A is well under the 140 threshold. B is approaching a level that could hinder absorption.
3. **logP:** Ligand A (3.201) is optimal, while Ligand B (1.492) is on the lower side. A logP between 1-3 is preferred, and A is closer to the upper end of that range, suggesting better membrane permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is better than Ligand B (5). Similar to HBD, lower HBA is preferred.
6. **QED:** Ligand B (0.787) has a significantly better QED score than Ligand A (0.386), indicating a more drug-like profile overall. This is a notable advantage for B.
7. **DILI:** Ligand B (45.328) has a much lower DILI risk than Ligand A (78.015). This is a significant advantage for B, as lower DILI is crucial.
8. **BBB:** Ligand A (70.415) has a better BBB penetration score than Ligand B (54.556). While not a primary concern for ADRB2 (cardiovascular), some CNS exposure can sometimes be a factor, and A is better here.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests potential issues with the data or the compounds themselves. However, the values are similar (-4.212 vs -4.874) so this doesn't strongly favor either.
10. **Solubility:** Ligand A (-4.982) has worse solubility than Ligand B (-1.944). Solubility is important, and B is better in this regard.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.224 and 0.203), which is excellent.
12. **Cl_mic:** Ligand B (26.861) has a significantly lower microsomal clearance than Ligand A (81.36), indicating better metabolic stability. This is a major advantage for B.
13. **t1/2:** Ligand B (-31.596) has a much longer in vitro half-life than Ligand A (-12.963). This is a substantial benefit for B, potentially leading to less frequent dosing.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.325 and 0.128). B is slightly better.
15. **Affinity:** Ligand B (-9.4) has a significantly stronger binding affinity than Ligand A (-6.2). This is a very substantial advantage for B, potentially outweighing some of the ADME drawbacks of A.
**Overall Assessment:**
While Ligand A has some favorable properties (logP, BBB), Ligand B is clearly superior. The stronger binding affinity, lower DILI risk, significantly better metabolic stability (lower Cl_mic and longer t1/2), and better QED score are compelling advantages. The slightly lower logP and higher TPSA of B are less concerning given the strength of its other properties, especially the binding affinity.
Output:
0
2025-04-17 23:12:02,756 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (340.471 and 350.419 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (58.95) is significantly better than Ligand B (116.48). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand B is pushing the upper limit for good oral absorption.
3. **logP:** Ligand A (2.805) is optimal. Ligand B (-0.49) is too low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (2) is good. Ligand B (4) is acceptable, but slightly higher.
5. **HBA:** Ligand A (4) is good. Ligand B (6) is acceptable, but slightly higher.
6. **QED:** Ligand A (0.85) is excellent, indicating high drug-likeness. Ligand B (0.495) is below the desirable threshold of 0.5.
7. **DILI:** Ligand A (27.181) has a lower DILI risk than Ligand B (23.769), which is preferable.
8. **BBB:** Not a major priority for a cardiovascular target. Ligand A (55.293) and Ligand B (28.81) are both relatively low.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-5.385) is slightly better than Ligand B (-5.464).
10. **Solubility:** Both are negative, indicating poor solubility. Ligand A (-2.096) is slightly better than Ligand B (-1.552).
11. **hERG:** Ligand A (0.684) has a lower hERG risk than Ligand B (0.106), which is a significant advantage.
12. **Cl_mic:** Ligand A (-30.666) has much lower (better) microsomal clearance than Ligand B (12.119), suggesting better metabolic stability.
13. **t1/2:** Ligand A (35.094) has a much longer in vitro half-life than Ligand B (-19.505), which is highly desirable.
14. **Pgp:** Ligand A (0.173) has lower P-gp efflux liability than Ligand B (0.012), which is preferable.
15. **Binding Affinity:** Ligand B (-8.1) has a slightly better binding affinity than Ligand A (-6.8). However, the difference is less than 1.5 kcal/mol, and other factors are more important.
**Overall Assessment:**
Ligand A is significantly better overall. While Ligand B has a slightly better binding affinity, Ligand A excels in crucial ADME properties like logP, TPSA, QED, DILI, hERG, metabolic stability (Cl_mic and t1/2), and P-gp efflux. These factors are critical for developing a viable drug candidate, and the advantages of Ligand A outweigh the minor affinity difference. The poor Caco-2 and solubility of both ligands would need to be addressed in further optimization, but Ligand A provides a much stronger starting point.
Output:
1
2025-04-17 23:12:02,756 - INFO - Batch 387 complete. Total preferences: 6192
2025-04-17 23:12:02,756 - INFO - Processing batch 388/512...
2025-04-17 23:12:50,793 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (345.374 and 368.478 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (91.32 and 88.32) are below the 140 A^2 threshold for good oral absorption, but are not optimal for CNS penetration (target is cardiovascular, so this is less critical). Ligand B is slightly better.
3. **logP:** Both ligands (2.231 and 1.911) are within the optimal 1-3 range. No significant difference.
4. **HBD:** Ligand A has 3 HBD, and Ligand B has 2. Both are acceptable (<=5).
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 5. Both are acceptable (<=10).
6. **QED:** Ligand B (0.848) has a significantly better QED score than Ligand A (0.572), indicating a more drug-like profile.
7. **DILI:** Ligand B (70.531) has a higher DILI risk than Ligand A (54.556), which is unfavorable.
8. **BBB:** Both ligands have moderate BBB penetration (53.432 and 65.839). Since ADRB2 is a cardiovascular target, BBB penetration isn't a primary concern. Ligand B is slightly better.
9. **Caco-2:** Both ligands have similar, very negative Caco-2 values (-5.068 and -5.062). This is concerning and suggests poor permeability.
10. **Solubility:** Both ligands have similar, very negative solubility values (-3.515 and -3.629). This is also concerning and suggests poor solubility.
11. **hERG:** Both ligands have very low hERG risk (0.403 and 0.402). This is good.
12. **Cl_mic:** Ligand B (36.377) has a significantly lower microsomal clearance than Ligand A (62.646), indicating better metabolic stability. This is a strong advantage.
13. **t1/2:** Ligand B (3.472) has a longer in vitro half-life than Ligand A (-39.274). This is a significant advantage.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.133 and 0.047). This is good.
15. **Binding Affinity:** Ligand A (-7.0 kcal/mol) has a slightly better binding affinity than Ligand B (-6.6 kcal/mol). This is a 0.4 kcal/mol difference, which is not huge, but noticeable.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Both ligands perform similarly on logP and Pgp. Ligand B has slightly better TPSA. Ligand A has slightly better affinity. The biggest differences are in QED, DILI, Cl_mic, and t1/2, all favoring Ligand B. Metabolic stability (Cl_mic and t1/2) and overall drug-likeness (QED) are crucial for a viable drug candidate, and Ligand B excels in these areas. The slightly lower affinity of Ligand B is outweighed by its superior ADME properties.
**Final Decision:**
0
2025-04-17 23:12:50,793 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (368.411 and 347.39 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (102.85) is higher than Ligand B (82.53). Both are below the 140 threshold for oral absorption, but B is better, closer to the 90 threshold for CNS targets (though ADRB2 isn't necessarily a CNS target).
3. **logP:** Both ligands (1.058 and 1.187) are within the optimal 1-3 range. Very similar.
4. **HBD:** Ligand A (0) has fewer HBD than Ligand B (2). Fewer HBD is generally preferred for permeability, giving a slight edge to A.
5. **HBA:** Ligand A (7) has more HBA than Ligand B (4). B is preferred here, as fewer HBA generally improves permeability.
6. **QED:** Both ligands have good QED scores (0.777 and 0.805), indicating good drug-like properties. No clear advantage.
7. **DILI:** Ligand A (80.109) has a significantly higher DILI risk than Ligand B (37.611). This is a major concern for A. B is much preferred.
8. **BBB:** Both ligands have good BBB penetration (77.2 and 72.896). Since ADRB2 is not a primary CNS target, this isn't a deciding factor, but it's good to have.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual. Assuming these are logP values, both are poor.
10. **Solubility:** Both have negative solubility values, which is unusual. Assuming these are logS values, both are poor.
11. **hERG:** Both ligands have low hERG inhibition liability (0.236 and 0.332). No significant difference.
12. **Cl_mic:** Ligand A (17.974) has a lower (better) microsomal clearance than Ligand B (-2.991). This suggests better metabolic stability for A.
13. **t1/2:** Ligand B (-39.261) has a much longer in vitro half-life than Ligand A (-20.154). This is a significant advantage for B, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.118 and 0.105). No significant difference.
15. **Binding Affinity:** Ligand B (-7.6) has a stronger binding affinity than Ligand A (-6.2). This is a 1.4 kcal/mol difference, which is substantial and can outweigh some ADME drawbacks.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Both ligands are good on logP and Pgp. Ligand B is better on TPSA and significantly better on affinity. The DILI risk for Ligand A is a major red flag. While A has better metabolic stability, the stronger affinity and lower toxicity risk of B are more important.
**Conclusion:**
Ligand B is the more promising candidate due to its superior binding affinity, significantly lower DILI risk, and better TPSA. The longer half-life is also a bonus.
Output:
0
2025-04-17 23:12:50,793 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands (367.47 & 362.54 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (72.91) is higher than Ligand B (40.62). For a GPCR, lower TPSA is generally preferred for better permeability, giving a slight edge to Ligand B.
3. **logP:** Ligand B (3.565) is slightly higher than Ligand A (2.269), but both are within the optimal 1-3 range.
4. **HBD:** Both ligands have 0 HBD, which is good.
5. **HBA:** Ligand A has 5 HBA, while Ligand B has 3. This favors Ligand B, as fewer HBA generally correlate with better membrane permeability.
6. **QED:** Both ligands have good QED scores (0.771 and 0.803), indicating good drug-like properties.
7. **DILI:** Ligand B (29.24) has a significantly lower DILI risk than Ligand A (49.40). This is a major advantage for Ligand B.
8. **BBB:** Ligand B (93.56) has a higher BBB penetration percentile than Ligand A (84.14). While ADRB2 isn't exclusively a CNS target, improved BBB penetration can be beneficial, and isn't detrimental.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to draw firm conclusions.
10. **Solubility:** Both ligands have negative solubility values, which is also unusual. Again, the scale is not specified, making comparison difficult.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.346 and 0.382). This is excellent.
12. **Cl_mic:** Both ligands have similar microsomal clearance values (65.19 and 64.44 mL/min/kg).
13. **t1/2:** Ligand A (13.08 hours) has a longer in vitro half-life than Ligand B (1.62 hours). This is a significant advantage for Ligand A.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.251 and 0.614).
15. **Binding Affinity:** Ligand B (-6.9 kcal/mol) has a slightly stronger binding affinity than Ligand A (-6.3 kcal/mol). This 0.6 kcal/mol difference is substantial and outweighs some of the ADME drawbacks of Ligand A.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in TPSA, has a comparable logP, similar Pgp efflux, and a superior binding affinity. The DILI risk is also significantly lower for Ligand B. While Ligand A has a longer half-life, the stronger binding and improved safety profile of Ligand B are more critical for initial candidate selection.
**Conclusion:**
Considering the balance of properties, particularly the superior binding affinity, lower DILI risk, and lower TPSA, Ligand B is the more promising drug candidate.
Output:
0
2025-04-17 23:12:50,794 - INFO - Here's my reasoning and the final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, the key priorities are logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB.
Let's break down the comparison:
1. **MW:** Both ligands (352.431 and 350.459 Da) are within the ideal 200-500 Da range.
2. **TPSA:** Both ligands (84.94 and 84.5) are below the 140 A^2 threshold for good oral absorption, and are reasonable for a GPCR.
3. **logP:** Ligand B (1.572) is better than Ligand A (0.68). A logP between 1-3 is optimal, and Ligand A is a bit low, potentially hindering permeability.
4. **HBD/HBA:** Ligand A has 1 HBD and 5 HBA, while Ligand B has 2 HBD and 4 HBA. Both are acceptable.
5. **QED:** Ligand B (0.762) has a better QED score than Ligand A (0.487), indicating a more drug-like profile.
6. **DILI:** Ligand B (20.744) has a significantly lower DILI risk than Ligand A (34.277), which is a crucial advantage.
7. **BBB:** Ligand B (70.531) has a better BBB penetration percentile than Ligand A (56.611). While not a primary concern for a cardiovascular target, it's a positive attribute.
8. **Caco-2:** Both are negative, indicating poor permeability, but Ligand B (-5.037) is slightly better than Ligand A (-4.852).
9. **Solubility:** Both have negative solubility values, indicating poor solubility. Ligand A (-1.027) is slightly better than Ligand B (-2.204).
10. **hERG:** Both have low hERG inhibition liability, with Ligand B (0.101) being slightly better than Ligand A (0.061).
11. **Cl_mic:** Ligand B (17.129) has a lower microsomal clearance than Ligand A (21.138), suggesting better metabolic stability.
12. **t1/2:** Ligand B (7.998) has a significantly longer in vitro half-life than Ligand A (-4.309), which is a major advantage.
13. **Pgp:** Both have very low Pgp efflux liability, with Ligand B (0.027) being slightly better than Ligand A (0.016).
14. **Binding Affinity:** Ligand B (-7.4 kcal/mol) has a slightly better binding affinity than Ligand A (-6.9 kcal/mol). While the difference is not huge, it is still a positive factor.
**Overall Assessment:**
Ligand B consistently outperforms Ligand A across most critical ADME properties (DILI, BBB, Cl_mic, t1/2, logP, QED) and has a slightly better binding affinity. While both have solubility issues, the other advantages of Ligand B outweigh this drawback. The better metabolic stability (lower Cl_mic and longer t1/2) and reduced toxicity risk (lower DILI) are particularly important for a viable drug candidate.
**Output:**
0
2025-04-17 23:12:50,794 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands (382.595 & 362.451 Da) are within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (58.2) is better than Ligand B (62.99). Both are below the 140 threshold for oral absorption, but closer to the ideal for GPCRs.
3. **logP:** Both ligands (3.676 & 3.033) are within the optimal 1-3 range. Ligand B is slightly lower, which could be beneficial for solubility, but Ligand A is still acceptable.
4. **HBD:** Ligand A (2) is better than Ligand B (0). Having some HBD can improve solubility.
5. **HBA:** Ligand A (4) is better than Ligand B (5). Both are acceptable.
6. **QED:** Both ligands have good QED scores (0.721 & 0.842), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (49.283) is significantly better than Ligand B (73.672). This is a crucial advantage, as lower DILI risk is highly desirable.
8. **BBB:** Both ligands have similar BBB penetration (56.766 & 58.782). While not exceptionally high, it's not a major concern for a cardiovascular target like ADRB2.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-5.61) is slightly better than Ligand B (-4.519).
10. **Solubility:** Both ligands have negative solubility values, which is also unusual and suggests poor solubility. Ligand A (-3.813) is slightly better than Ligand B (-3.262).
11. **hERG:** Both ligands have low hERG inhibition liability (0.395 & 0.396), which is excellent.
12. **Cl_mic:** Ligand B (43.285) has significantly lower microsomal clearance than Ligand A (69.414), indicating better metabolic stability.
13. **t1/2:** Ligand B (40.343) has a longer in vitro half-life than Ligand A (17.243), which is a significant advantage.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.458 & 0.553).
15. **Binding Affinity:** Ligand B (-7.1 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.2 kcal/mol). This is a substantial advantage, potentially outweighing some ADME drawbacks.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), we prioritize logP, Pgp, TPSA, and affinity. Ligand B excels in affinity, and both ligands are acceptable for the other parameters. The lower DILI risk of Ligand A is important, but the significantly stronger binding affinity of Ligand B is a major driver for potential efficacy. The better metabolic stability and longer half-life of Ligand B are also beneficial.
**Conclusion:**
Despite the slightly higher DILI risk, the significantly improved binding affinity, metabolic stability, and half-life of Ligand B make it the more promising drug candidate.
Output:
0
2025-04-17 23:12:50,794 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (368.396) is slightly higher than Ligand B (344.499), but both are acceptable.
2. **TPSA:** Ligand A (87.66) is slightly higher than Ligand B (40.62). Both are below 140, but Ligand B is significantly better, suggesting better absorption.
3. **logP:** Ligand A (1.516) and Ligand B (3.228) are both within the optimal range (1-3). Ligand B is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Ligand A (3) is higher than Ligand B (0). While both are acceptable, fewer HBDs (Ligand B) generally improve permeability.
5. **HBA:** Ligand A (4) is higher than Ligand B (2). Similar to HBD, Ligand B is preferable.
6. **QED:** Both ligands have good QED scores (Ligand A: 0.576, Ligand B: 0.665). Ligand B is slightly better.
7. **DILI:** Ligand A (20.9) has a significantly lower DILI risk than Ligand B (15.2). This is a major advantage for Ligand A.
8. **BBB:** Both ligands have good BBB penetration (Ligand A: 77.937, Ligand B: 82.823). Ligand B is slightly better.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.835 and -4.762), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Both ligands have negative solubility values (-1.287 and -3.245), which is a significant concern. Ligand B is worse.
11. **hERG:** Both ligands have low hERG inhibition liability (Ligand A: 0.465, Ligand B: 0.524). Both are acceptable.
12. **Cl_mic:** Ligand A (3.75) has significantly lower microsomal clearance than Ligand B (68.413), indicating better metabolic stability. This is a substantial advantage for Ligand A.
13. **t1/2:** Ligand A (-12.952) has a negative in vitro half-life, which is concerning. Ligand B (-14.219) is also negative, but slightly worse.
14. **Pgp:** Both ligands have low P-gp efflux liability (Ligand A: 0.058, Ligand B: 0.47). Ligand A is preferable.
15. **Binding Affinity:** Ligand B (-7.3) has a significantly stronger binding affinity than Ligand A (-5.1). This is a substantial advantage for Ligand B.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP and affinity. Ligand A excels in Pgp and has a much better DILI and Cl_mic profile. The negative Caco-2 and solubility values are concerning for both.
**Overall Assessment:**
The stronger binding affinity of Ligand B (-7.3 kcal/mol vs -5.1 kcal/mol) is a significant advantage that could outweigh some of its drawbacks. However, the very high microsomal clearance of Ligand B is a major concern, suggesting it will be rapidly metabolized *in vivo*. Ligand A has a much better metabolic stability profile (lower Cl_mic) and lower DILI risk. While its affinity is weaker, the improved ADME properties and safety profile are more valuable for overall drug development. The poor solubility and permeability are concerns for both, but can be addressed with formulation strategies.
Therefore, I believe Ligand A is the more viable drug candidate.
Output:
1
2025-04-17 23:12:50,794 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (339.483 and 347.459 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (37.39) is significantly better than Ligand B (80.32). ADRB2 is a cardiovascular target, not necessarily CNS, but lower TPSA generally aids absorption. Ligand A is well below the 140 threshold, while B is approaching it.
3. **logP:** Ligand A (4.816) is higher than Ligand B (2.077). While both are within the acceptable range (1-3 is optimal), A is pushing the upper limit. This could potentially lead to solubility issues, but the benefit of GPCR binding is often enhanced with higher logP.
4. **HBD:** Ligand A (1) is better than Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Both ligands have 4 HBA, which is acceptable.
6. **QED:** Both ligands have similar QED values (0.819 and 0.791), indicating good drug-likeness.
7. **DILI:** Both ligands have low DILI risk (36.293 and 37.456), below the 40% threshold.
8. **BBB:** Ligand A (77.162) has a significantly higher BBB penetration percentile than Ligand B (62.233). While ADRB2 isn't a CNS target, higher BBB penetration can sometimes correlate with better overall distribution.
9. **Caco-2:** Ligand A (-4.536) has a worse Caco-2 permeability score than Ligand B (-5.002). Lower (more negative) values indicate poorer permeability.
10. **Solubility:** Ligand A (-5.454) has a worse solubility score than Ligand B (-2.584). This is a concern given Ligand A's higher logP.
11. **hERG:** Ligand A (0.874) has a slightly higher hERG risk than Ligand B (0.457), but both are reasonably low.
12. **Cl_mic:** Ligand A (110.476) has a higher microsomal clearance than Ligand B (39.901). This suggests Ligand A will be metabolized more quickly, reducing its half-life.
13. **t1/2:** Ligand B (14.214) has a significantly longer in vitro half-life than Ligand A (7.889). This is a major advantage.
14. **Pgp:** Ligand A (0.573) has a lower P-gp efflux liability than Ligand B (0.063). Lower Pgp is generally favorable.
15. **Binding Affinity:** Ligand B (-7.3) has a slightly better binding affinity than Ligand A (-8.0). While A is better, the difference is not substantial enough to outweigh the other factors.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A has a higher logP and lower Pgp, but Ligand B has a much better TPSA and a longer half-life. The affinity difference is small. The solubility and clearance issues with Ligand A are concerning.
**Conclusion:**
Considering the balance of properties, particularly the better TPSA, solubility, and significantly improved metabolic stability (longer half-life) of Ligand B, it is the more promising drug candidate. The slightly weaker affinity is outweighed by the improved ADME properties.
Output:
0
2025-04-17 23:12:50,794 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (431.352 Da) is within the ideal range, while Ligand B (363.361 Da) is slightly below, but still acceptable.
2. **TPSA:** Ligand A (86.71) is excellent, well below the 140 threshold. Ligand B (107.97) is still reasonable, but less optimal.
3. **logP:** Ligand A (2.848) is optimal. Ligand B (-1.269) is significantly lower, potentially hindering permeability. This is a major concern for a GPCR target.
4. **HBD:** Both ligands (A: 2, B: 3) are within the acceptable limit of 5.
5. **HBA:** Both ligands (A: 3, B: 5) are within the acceptable limit of 10.
6. **QED:** Ligand A (0.718) is better than Ligand B (0.523), indicating a more drug-like profile.
7. **DILI:** Ligand A (64.327) has a higher DILI risk than Ligand B (28.461), which is a negative.
8. **BBB:** Both ligands have moderate BBB penetration (A: 59.984, B: 53.858). While ADRB2 isn't necessarily a CNS target, some degree of BBB penetration isn't detrimental.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability.
10. **Solubility:** Both ligands have negative solubility values, indicating poor solubility.
11. **hERG:** Both ligands have very low hERG inhibition risk (A: 0.261, B: 0.165).
12. **Cl_mic:** Ligand A (8.251) has a lower (better) microsomal clearance than Ligand B (-19.059). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (30.773) has a significantly longer half-life than Ligand B (4.367).
14. **Pgp:** Both ligands have low P-gp efflux liability (A: 0.114, B: 0.004).
15. **Affinity:** Ligand A (-7.7 kcal/mol) has a stronger binding affinity than Ligand B (-6.8 kcal/mol). This is a 0.9 kcal/mol difference, which is significant.
**GPCR-specific considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A excels in logP and affinity, while Ligand B has a much lower logP. While Ligand B has a lower DILI risk, the significantly better logP, affinity, and metabolic stability of Ligand A outweigh this concern. The poor Caco-2 and solubility are concerning for both, but can be addressed with formulation strategies.
**Conclusion:**
Ligand A is the more promising candidate due to its superior logP, binding affinity, metabolic stability, and half-life. The slightly higher DILI risk is a manageable concern compared to the significant drawbacks of Ligand B's poor logP.
Output:
1
2025-04-17 23:12:50,795 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (336.443 and 344.455 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (49.56) is better than Ligand B (60.85). Both are under 140, but A is closer to the optimal for good absorption.
3. **logP:** Both ligands have good logP values (2.923 and 2.078), falling within the 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Ligand A (0) is preferable to Ligand B (1). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (6) is slightly better than Ligand B (3). Both are within the acceptable range of <=10.
6. **QED:** Ligand B (0.91) is better than Ligand A (0.717), indicating a more drug-like profile.
7. **DILI:** Ligand B (13.687) is *significantly* better than Ligand A (71.694). This is a major advantage for Ligand B. A DILI percentile above 60 is concerning.
8. **BBB:** Ligand A (81.466) is better than Ligand B (68.67). While ADRB2 isn't strictly a CNS target, some CNS penetration can be useful.
9. **Caco-2:** Ligand A (-5.073) is better than Ligand B (-4.495). Higher Caco-2 values indicate better intestinal absorption.
10. **Solubility:** Ligand A (-3.457) is better than Ligand B (-1.59). Better solubility is generally preferred.
11. **hERG:** Both ligands have similar, low hERG risk (0.607 and 0.602).
12. **Cl_mic:** Ligand B (19.813) is much better than Ligand A (58.104). Lower clearance is desirable for metabolic stability.
13. **t1/2:** Ligand A (24.592) is better than Ligand B (3.585). A longer half-life is generally preferred.
14. **Pgp:** Ligand A (0.758) is better than Ligand B (0.17). Lower P-gp efflux is better for bioavailability.
15. **Affinity:** Ligand A (-6.5) is slightly better than Ligand B (-6.3). This difference is not substantial enough to outweigh other factors.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A is better in terms of logP, TPSA, and Pgp, and has slightly better affinity. However, the *extremely* high DILI risk associated with Ligand A is a critical drawback. The lower clearance of Ligand B is also a significant advantage.
**Overall Assessment:**
While Ligand A has some favorable properties, the high DILI risk is a deal-breaker. Ligand B, despite being slightly less optimal in some ADME properties, presents a much safer profile and improved metabolic stability. The small difference in binding affinity is not enough to overcome the significant safety concerns with Ligand A.
Output:
0
2025-04-17 23:12:50,795 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (362.392 and 376.913 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (78.43) is higher than Ligand B (59.07). For a cardiovascular GPCR, TPSA is not a primary concern, but lower is generally better for permeability. Ligand B has an advantage.
3. **logP:** Ligand A (1.748) is within the optimal 1-3 range, while Ligand B (4.251) is slightly above, potentially leading to solubility issues and off-target interactions. Ligand A has a clear advantage.
4. **HBD:** Ligand A (3) and Ligand B (2) are both acceptable, below the threshold of 5. No significant difference.
5. **HBA:** Ligand A (3) and Ligand B (6) are both within the acceptable range of 10. Ligand A is preferable.
6. **QED:** Both ligands have good QED scores (0.646 and 0.813), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (13.416) has a much lower DILI risk than Ligand B (75.649). This is a significant advantage for Ligand A.
8. **BBB:** Both ligands have good BBB penetration (70.997 and 74.098). No significant difference.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. This is a concern for both, but the values are close.
10. **Solubility:** Ligand A (-2.518) has better solubility than Ligand B (-5.052). This is a significant advantage for Ligand A, especially given Ligand B's higher logP.
11. **hERG:** Ligand A (0.398) has a lower hERG inhibition liability than Ligand B (0.643). This is a safety advantage for Ligand A.
12. **Cl_mic:** Ligand B (71.493) has a lower microsomal clearance than Ligand A (13.43), suggesting better metabolic stability. This is an advantage for Ligand B.
13. **t1/2:** Ligand B (76.329) has a significantly longer in vitro half-life than Ligand A (-11.256). This is a major advantage for Ligand B.
14. **Pgp:** Ligand A (0.032) has lower P-gp efflux liability than Ligand B (0.353). This is a slight advantage for Ligand A.
15. **Binding Affinity:** Ligand B (-8.1) has a significantly stronger binding affinity than Ligand A (-4.1). This is a substantial advantage for Ligand B, potentially outweighing some ADME concerns.
**Overall Assessment:**
Ligand B has a much stronger binding affinity and a longer half-life, which are crucial for a GPCR target. However, it suffers from higher logP, DILI risk, and Pgp efflux. Ligand A has better solubility, lower toxicity (DILI, hERG), and lower Pgp efflux. The binding affinity difference is significant (-8.1 vs -4.1 kcal/mol). Considering the importance of potency for GPCRs, and the potential to mitigate some of Ligand B's ADME issues through further optimization, the stronger binding affinity of Ligand B is the deciding factor.
Output:
0
2025-04-17 23:12:50,795 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (369.384 Da) is slightly higher than Ligand B (347.39 Da), both are within the ideal range.
2. **TPSA:** Ligand A (71.11) is significantly better than Ligand B (84.23). ADRB2 is not a CNS target, but lower TPSA generally improves permeability.
3. **logP:** Ligand B (1.881) is better than Ligand A (0.249). A logP between 1-3 is optimal, and Ligand A is quite low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (1) is better than Ligand B (2). Lower is generally preferred.
5. **HBA:** Ligand A (5) is better than Ligand B (4). Both are acceptable, but lower is preferred.
6. **QED:** Ligand B (0.77) is better than Ligand A (0.621). Both are above the 0.5 threshold, indicating good drug-likeness.
7. **DILI:** Ligand A (19.116) is *much* better than Ligand B (44.591). This is a significant advantage for Ligand A.
8. **BBB:** Both are similar (Ligand A: 77.627, Ligand B: 75.107), and not a primary concern for ADRB2.
9. **Caco-2:** Ligand A (-4.974) is better than Ligand B (-4.544). Higher is better.
10. **Solubility:** Ligand A (-0.979) is better than Ligand B (-3.521). Better solubility is generally desirable.
11. **hERG:** Ligand A (0.339) is better than Ligand B (0.153). Lower is preferred.
12. **Cl_mic:** Ligand A (-4.817) is *much* better than Ligand B (10.077). A negative value for Cl_mic indicates high metabolic stability, a major advantage for Ligand A.
13. **t1/2:** Ligand A (-36.77) is better than Ligand B (-18.859). A more negative value suggests a longer half-life.
14. **Pgp:** Ligand A (0.009) is significantly better than Ligand B (0.038). Lower Pgp efflux is favorable.
15. **Affinity:** Ligand A (-7.4) is better than Ligand B (-6). This is a 1.4 kcal/mol difference, which is substantial and can outweigh some ADME drawbacks.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B has a better logP, but Ligand A excels in TPSA, Pgp, and significantly in affinity. The superior metabolic stability (Cl_mic and t1/2) and lower DILI risk of Ligand A are also critical advantages.
**Overall Assessment:**
While Ligand B has a more favorable logP, Ligand A's superior binding affinity, significantly better metabolic stability, lower DILI risk, better solubility, and lower Pgp efflux make it the more promising drug candidate. The 1.4 kcal/mol affinity difference is substantial enough to overcome the slightly lower logP of Ligand A.
Output:
1
2025-04-17 23:12:50,795 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (355.5 & 345.4 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (52.65) is significantly better than Ligand B (82.23). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally favors absorption.
3. **logP:** Both ligands have good logP values (1.92 & 1.68), falling within the optimal 1-3 range. Ligand B is slightly lower, which could slightly improve solubility.
4. **HBD:** Ligand A has 1 HBD, Ligand B has 0. Both are acceptable.
5. **HBA:** Ligand A has 3 HBA, Ligand B has 5. Both are acceptable, but Ligand A is slightly better.
6. **QED:** Both ligands have good QED scores (0.724 & 0.813), indicating good drug-like properties. No clear advantage.
7. **DILI:** Ligand A (9.85%) has a *much* lower DILI risk than Ligand B (42.92%). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (89.45%) has better BBB penetration than Ligand B (69.48%). While ADRB2 is not a CNS target, some off-target CNS effects are possible with GPCR ligands, and higher BBB is generally preferable.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.64 & -4.49). This is unusual and suggests poor permeability.
10. **Solubility:** Ligand A (-1.695) has slightly better solubility than Ligand B (-2.274).
11. **hERG:** Ligand A (0.62) has a slightly better hERG profile than Ligand B (0.251). Lower is better.
12. **Cl_mic:** Ligand A (22.85) has a lower microsomal clearance than Ligand B (25.83), indicating better metabolic stability.
13. **t1/2:** Ligand A (2.04) has a slightly longer half-life than Ligand B (1.59).
14. **Pgp:** Ligand A (0.046) has much lower P-gp efflux liability than Ligand B (0.154). This is a significant advantage for oral bioavailability.
15. **Affinity:** Ligand A (-8.5 kcal/mol) has a significantly stronger binding affinity than Ligand B (-7.0 kcal/mol). This is a >1.5 kcal/mol advantage, which is a major driver.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A excels in these areas, particularly affinity and Pgp efflux. The lower DILI risk and better metabolic stability are also very important.
**Conclusion:**
Ligand A is the superior candidate. Its significantly stronger binding affinity, lower DILI risk, lower Pgp efflux, and better metabolic stability outweigh the slightly lower solubility and Caco-2 permeability.
Output:
1
2025-04-17 23:12:50,795 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the acceptable range (200-500 Da). Ligand A (342.41 Da) is slightly lower, which is generally favorable for permeability.
**2. TPSA:** Ligand A (35.53) is significantly better than Ligand B (128.03). For a GPCR, lower TPSA is generally preferred as it aids membrane permeability. Ligand B is quite high, potentially hindering absorption.
**3. logP:** Ligand A (4.29) is good, though bordering on high. Ligand B (-0.293) is too low, suggesting poor membrane permeability and potentially poor oral absorption.
**4. H-Bond Donors:** Ligand A (0) is excellent. Ligand B (2) is acceptable.
**5. H-Bond Acceptors:** Ligand A (3) is good. Ligand B (6) is acceptable, but higher.
**6. QED:** Both ligands have reasonable QED values (A: 0.704, B: 0.53), indicating drug-like properties.
**7. DILI Risk:** Ligand A (60.217) is at the upper end of acceptable, but still reasonable. Ligand B (35.789) is much better, indicating lower liver injury risk.
**8. BBB Penetration:** Ligand A (84.025) is good, suggesting some potential for CNS effects (though not necessarily desired for a cardiovascular target). Ligand B (73.284) is lower.
**9. Caco-2 Permeability:** Ligand A (-4.142) is poor, indicating low intestinal absorption. Ligand B (-5.508) is even worse.
**10. Aqueous Solubility:** Ligand A (-6.012) is very poor. Ligand B (-1.627) is also poor, but better than A.
**11. hERG Inhibition:** Ligand A (0.619) is better, indicating lower cardiotoxicity risk. Ligand B (0.098) is concerningly high.
**12. Microsomal Clearance:** Ligand A (97.786) is high, suggesting rapid metabolism and potentially low bioavailability. Ligand B (16.5) is much lower, indicating better metabolic stability.
**13. In vitro Half-Life:** Ligand A (-10.595) is very poor. Ligand B (14.046) is better.
**14. P-gp Efflux:** Ligand A (0.439) is good, suggesting lower efflux. Ligand B (0.011) is excellent, indicating minimal efflux.
**15. Binding Affinity:** Ligand A (-7.2) is better than Ligand B (-5.7), providing a significant advantage in potency.
**Overall Assessment:**
While Ligand B has better DILI, metabolic stability, and P-gp efflux properties, Ligand A has a significantly better binding affinity and a more favorable TPSA. The low logP and solubility of Ligand B are major concerns, likely leading to poor absorption. The hERG risk for Ligand B is also concerning. The superior affinity of Ligand A, combined with acceptable (though not ideal) ADME properties, makes it the more promising candidate, especially considering the potential to address its solubility and permeability issues through formulation strategies. The affinity difference is substantial enough to outweigh the ADME drawbacks.
Output:
1
2025-04-17 23:12:50,795 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [347.503, 52.65, 2.375, 1, 3, 0.746, 7.057, 63.823, -4.714, -1.342, 0.773, 41.721, 6.279, 0.017, -6.6]
**Ligand B:** [352.494, 49.41, 3.448, 1, 2, 0.842, 35.983, 86.623, -4.573, -4.031, 0.714, 34.162, -5.008, 0.535, -7.0]
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). A (347.5) is slightly lower, but acceptable.
2. **TPSA:** Both are good, below the 140 A^2 threshold for oral absorption. A (52.65) is slightly higher than B (49.41), but both are reasonable.
3. **logP:** Both are within the optimal range (1-3). A (2.375) is slightly better than B (3.448). Higher logP can sometimes lead to off-target effects.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** A has 3 HBA, B has 2. Both are acceptable (<=10).
6. **QED:** Both are above 0.5, indicating good drug-likeness. B (0.842) is slightly better than A (0.746).
7. **DILI:** A (7.057) has a significantly higher DILI risk than B (35.983). This is a major concern.
8. **BBB:** B (86.623) has a much higher BBB penetration potential than A (63.823). While not critical for ADRB2 (a cardiovascular target), higher BBB is generally favorable.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. A (-4.714) is worse than B (-4.573).
10. **Solubility:** A (-1.342) has slightly better solubility than B (-4.031), but both are poor.
11. **hERG:** Both have low hERG risk (0.773 and 0.714).
12. **Cl_mic:** B (34.162) has lower microsomal clearance, suggesting better metabolic stability than A (41.721).
13. **t1/2:** A (6.279) has a longer in vitro half-life than B (-5.008). This is a positive for A.
14. **Pgp:** A (0.017) has significantly lower P-gp efflux liability than B (0.535). This is a positive for A.
15. **Affinity:** B (-7.0 kcal/mol) has a stronger binding affinity than A (-6.6 kcal/mol). This is a 0.4 kcal/mol difference, which is significant.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are important. B has a better logP, higher BBB penetration, and significantly better binding affinity. A has better Pgp efflux and slightly better solubility, but the DILI risk is a major red flag. The affinity difference is also substantial.
**Conclusion:**
Despite A's slightly better Pgp and solubility, the significantly higher DILI risk and weaker binding affinity make it a less desirable candidate than B. B's superior binding affinity, lower DILI risk, and better BBB penetration outweigh the slightly higher logP and Pgp efflux.
Output:
0
2025-04-17 23:12:50,795 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (342.355 Da and 358.429 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (106.78) is higher than Ligand B (58.64). For a cardiovascular GPCR, TPSA isn't *as* critical as for a CNS target, but lower is generally preferable for absorption. Ligand B is significantly better.
**3. logP:** Both ligands have similar logP values (2.19 and 2.139), falling within the optimal 1-3 range. No clear advantage.
**4. H-Bond Donors:** Ligand A (2) is slightly higher than Ligand B (1), but both are acceptable (<=5).
**5. H-Bond Acceptors:** Ligand A (6) is higher than Ligand B (3). Again, both are within acceptable limits (<=10), but Ligand B is better.
**6. QED:** Ligand A (0.882) has a better QED score than Ligand B (0.791), indicating a more drug-like profile. This is a positive for Ligand A.
**7. DILI Risk:** Ligand A (97.441) has a *very* high DILI risk, a major concern. Ligand B (18.689) has a low DILI risk, a significant advantage.
**8. BBB Penetration:** BBB isn't a primary concern for a cardiovascular target, but Ligand B (83.133) has better penetration than Ligand A (44.901).
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.886 and -4.843), which is unusual and suggests poor permeability. This is a concern for both.
**10. Aqueous Solubility:** Ligand A (-4.144) has slightly worse solubility than Ligand B (-2.45), but both are poor.
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (0.435 and 0.556), which is good.
**12. Microsomal Clearance:** Ligand A (-11.744) has a much lower (better) microsomal clearance than Ligand B (5.017), indicating greater metabolic stability.
**13. In vitro Half-Life:** Ligand A (-36.287) has a much longer half-life than Ligand B (3.292), which is desirable.
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (0.087 and 0.127), which is good.
**15. Binding Affinity:** Ligand B (-7.4 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.3 kcal/mol). This is a substantial advantage, potentially outweighing some ADME concerns.
**Overall Assessment:**
Ligand A has a better QED, metabolic stability, and half-life. However, its extremely high DILI risk is a major red flag. Ligand B has a much lower DILI risk, significantly better TPSA, and a substantially stronger binding affinity. While its solubility and Caco-2 permeability are also poor, the strong binding and low toxicity profile make it the more promising candidate. The affinity difference is large enough to overcome the ADME deficiencies.
Output:
0
2025-04-17 23:12:50,795 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [353.375, 122.08 , -0.025, 2. , 8. , 0.684, 44.009, 40.403, -4.642, -2.643, 0.137, 70.464, -34.473, 0.019, -6. ]
**Ligand B:** [345.447, 70.47 , 0.939, 1. , 5. , 0.833, 16.285, 91.043, -5.15 , -1.586, 0.549, 22.882, 17.193, 0.08 , -7.3 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (345.447) is slightly lower, which is generally favorable.
2. **TPSA:** Ligand A (122.08) is higher than Ligand B (70.47). For a cardiovascular GPCR, TPSA isn't *as* critical as for CNS targets, but lower is still preferred for better permeability. Ligand B is significantly better here.
3. **logP:** Ligand A (-0.025) is quite low, potentially hindering membrane permeability. Ligand B (0.939) is within the optimal range (1-3). This is a significant advantage for Ligand B.
4. **HBD:** Both are acceptable (Ligand A: 2, Ligand B: 1).
5. **HBA:** Both are acceptable (Ligand A: 8, Ligand B: 5).
6. **QED:** Both are good (Ligand A: 0.684, Ligand B: 0.833). Ligand B is slightly better.
7. **DILI:** Ligand A (44.009) has a higher DILI risk than Ligand B (16.285). This is a clear advantage for Ligand B.
8. **BBB:** Ligand B (91.043) has much better BBB penetration potential than Ligand A (40.403). While ADRB2 isn't strictly a CNS target, some CNS exposure can occur, and higher BBB is generally a positive.
9. **Caco-2:** Ligand B (-5.15) is better than Ligand A (-4.642), indicating better intestinal absorption.
10. **Solubility:** Ligand B (-1.586) is better than Ligand A (-2.643).
11. **hERG:** Ligand A (0.137) has a slightly lower hERG risk than Ligand B (0.549), but both are reasonably low.
12. **Cl_mic:** Ligand B (22.882) has significantly lower microsomal clearance than Ligand A (70.464), indicating better metabolic stability.
13. **t1/2:** Ligand B (17.193) has a longer in vitro half-life than Ligand A (-34.473). This is a significant advantage.
14. **Pgp:** Ligand A (0.019) has lower P-gp efflux than Ligand B (0.08), which is slightly better.
15. **Affinity:** Ligand B (-7.3) has a significantly stronger binding affinity than Ligand A (-6). A 1.3 kcal/mol difference is substantial and can often outweigh minor ADME drawbacks.
**Overall Assessment:**
Ligand B consistently outperforms Ligand A across most critical ADME properties (logP, TPSA, DILI, BBB, solubility, Cl_mic, t1/2) and has a significantly better binding affinity. Ligand A's only advantage is slightly lower P-gp efflux, which is less crucial than the other factors. Given the GPCR target class, the balance of properties in Ligand B makes it a much more promising drug candidate.
Output:
0
2025-04-17 23:12:50,795 - INFO - Batch 388 complete. Total preferences: 6208
2025-04-17 23:12:50,795 - INFO - Processing batch 389/512...
2025-04-17 23:13:42,109 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's systematically compare Ligand A and Ligand B based on the provided parameters and the guidelines, keeping in mind ADRB2 is a GPCR.
1. **Molecular Weight:** Both ligands (367.471 and 351.491 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (71.97 and 72.88) are reasonably low, suggesting good potential for cell permeability. They are both below the 140 A^2 threshold.
3. **logP:** Ligand A (2.025) is slightly higher than Ligand B (0.987), placing it more optimally within the 1-3 range. Ligand B is a bit low, potentially hindering permeation.
4. **H-Bond Donors:** Ligand A (0) has fewer HBDs than Ligand B (2). Fewer HBDs generally favor permeability.
5. **H-Bond Acceptors:** Ligand A (6) has more HBAs than Ligand B (4). While both are acceptable, lower is preferred.
6. **QED:** Both ligands have similar QED values (0.814 and 0.748), indicating good drug-likeness.
7. **DILI:** Ligand A (57.697) has a higher DILI risk than Ligand B (5.118). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (71.501) shows better BBB penetration than Ligand B (30.942). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be beneficial for distribution.
9. **Caco-2 Permeability:** Ligand A (-4.518) has a worse Caco-2 permeability than Ligand B (-5.017). Lower values are worse.
10. **Aqueous Solubility:** Ligand A (-2.554) has worse solubility than Ligand B (-1.086). Solubility is important for formulation.
11. **hERG Inhibition:** Both ligands have similar, low hERG inhibition risk (0.401 and 0.37).
12. **Microsomal Clearance:** Ligand A (36.683) has higher microsomal clearance than Ligand B (25.251), indicating faster metabolism and potentially lower in vivo exposure.
13. **In vitro Half-Life:** Ligand B (18.008) has a much longer in vitro half-life than Ligand A (-5.036). This is a significant advantage for Ligand B.
14. **P-gp Efflux:** Both ligands have low P-gp efflux liability (0.326 and 0.028).
15. **Binding Affinity:** Ligand A (-7.2 kcal/mol) has a slightly better binding affinity than Ligand B (-6.3 kcal/mol). This is a 0.9 kcal/mol difference, which is notable but not overwhelming.
**Overall Assessment:**
While Ligand A has slightly better binding affinity and BBB penetration, Ligand B demonstrates a significantly better safety profile (much lower DILI risk), improved metabolic stability (lower Cl_mic, longer t1/2), and better solubility. The slightly lower logP of Ligand B is a minor concern, but the other advantages outweigh this. For a GPCR target like ADRB2, a balance of potency, ADME properties, and safety is crucial. Ligand B strikes a better balance overall.
**Output:**
0
2025-04-17 23:13:42,109 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (356.8 and 352.5 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (68.84) is significantly better than Ligand B (89.87). ADRB2 is a cardiovascular target, so CNS penetration isn't crucial, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (2.284) is slightly higher than Ligand B (1.363), both within the optimal 1-3 range. Ligand A is preferable.
4. **HBD:** Ligand A (0) is better than Ligand B (3). Fewer HBDs generally improve membrane permeability.
5. **HBA:** Ligand A (6) is better than Ligand B (4). Fewer HBAs are generally preferable.
6. **QED:** Ligand A (0.722) is slightly better than Ligand B (0.652), indicating a more drug-like profile.
7. **DILI:** Ligand A (87.631) has a substantially higher DILI risk than Ligand B (10.896). This is a major concern for Ligand A.
8. **BBB:** This is less critical for a cardiovascular target, but Ligand A (67.313) is higher than Ligand B (52.036).
9. **Caco-2:** Ligand A (-5.135) and Ligand B (-4.85) are similar, indicating comparable intestinal absorption.
10. **Solubility:** Ligand A (-2.409) is slightly worse than Ligand B (-1.887), but both are poor.
11. **hERG:** Both ligands are very low risk (0.213 and 0.162).
12. **Cl_mic:** Ligand A (7.305) is slightly better than Ligand B (7.827), indicating better metabolic stability.
13. **t1/2:** Ligand B (-12.432) has a significantly longer in vitro half-life than Ligand A (-8.551). This is a major advantage for Ligand B.
14. **Pgp:** Ligand A (0.308) is slightly better than Ligand B (0.024).
15. **Binding Affinity:** Ligand A (-7.3) has a slightly better binding affinity than Ligand B (-7.1). However, the difference is relatively small (0.2 kcal/mol).
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A is better in logP, TPSA, and Pgp, and has a slightly better affinity. However, the *extremely* high DILI risk for Ligand A is a deal-breaker. A slightly lower affinity is acceptable if it avoids a significant toxicity concern. The longer half-life of Ligand B is also a significant advantage.
**Conclusion:**
Despite the slightly better affinity of Ligand A, the significantly higher DILI risk makes it a less viable candidate. Ligand B, with its lower DILI, longer half-life, and acceptable ADME properties, is the more promising drug candidate.
Output:
0
2025-04-17 23:13:42,109 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (a cardiovascular GPCR) drug candidates.
**Ligand A:** [348.334, 124.18 , 0.548, 4. , 5. , 0.607, 73.245, 30.748, -5.474, -2.937, 0.305, -7.747, 20.081, 0.027, -7.9 ]
**Ligand B:** [337.431, 64.45 , 3.106, 1. , 7. , 0.608, 73.245, 57.852, -4.917, -3.558, 0.867, 40.188, 40.74 , 0.706, -7.1 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (337.431) is slightly lower, which is generally favorable.
2. **TPSA:** Ligand A (124.18) is higher than Ligand B (64.45). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is still preferred for better absorption. Ligand B is significantly better here.
3. **logP:** Ligand A (0.548) is quite low, potentially hindering permeability. Ligand B (3.106) is within the optimal range (1-3). This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (4) is acceptable, Ligand B (1) is better.
5. **HBA:** Ligand A (5) is acceptable, Ligand B (7) is also acceptable.
6. **QED:** Both are similar and good (around 0.6).
7. **DILI:** Both have the same DILI risk (73.245), which is moderate. Not a major differentiating factor.
8. **BBB:** Ligand B (57.852) has a higher BBB percentile than Ligand A (30.748). While not a primary concern for a cardiovascular target, higher BBB is rarely detrimental.
9. **Caco-2:** Ligand A (-5.474) is worse than Ligand B (-4.917). Lower values are less favorable.
10. **Solubility:** Ligand A (-2.937) is worse than Ligand B (-3.558). Lower values are less favorable.
11. **hERG:** Ligand A (0.305) has a lower hERG risk than Ligand B (0.867). This is a positive for Ligand A.
12. **Cl_mic:** Ligand A (-7.747) has a lower (better) microsomal clearance than Ligand B (40.188), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand B (40.74) has a longer in vitro half-life than Ligand A (20.081). This is a positive for Ligand B.
14. **Pgp:** Ligand A (0.027) has a lower Pgp efflux liability than Ligand B (0.706). This is a positive for Ligand A.
15. **Affinity:** Ligand A (-7.9) has a slightly better binding affinity than Ligand B (-7.1). While both are excellent, the 0.8 kcal/mol difference is noticeable.
**GPCR-Specific Priorities:** For ADRB2 (a cardiovascular GPCR), we prioritize logP, TPSA, Pgp, and affinity.
**Overall Assessment:**
Ligand B excels in logP and TPSA, which are important for absorption and permeability. It also has a longer half-life. However, Ligand A has a better binding affinity, lower Pgp efflux, lower hERG risk, and better metabolic stability (lower Cl_mic). The affinity difference and metabolic stability are significant advantages. The lower logP of Ligand A is a concern, but the superior binding affinity and metabolic properties outweigh this drawback for a cardiovascular target.
Therefore, I prefer Ligand A.
Output:
1
2025-04-17 23:13:42,110 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (341.459 Da) is well within the ideal range (200-500 Da). Ligand B (374.535 Da) is also acceptable. No clear advantage here.
2. **TPSA:** Ligand A (54.26) is better than Ligand B (51.02), both are quite good, and well below the 140 threshold for oral absorption.
3. **logP:** Ligand A (2.226) is within the optimal range (1-3). Ligand B (4.062) is slightly higher, approaching the upper limit where solubility issues might arise. Ligand A is preferable.
4. **HBD:** Both ligands have 0 HBD, which is good.
5. **HBA:** Ligand A (5) and Ligand B (6) are both acceptable, below the 10 threshold.
6. **QED:** Ligand A (0.837) is significantly better than Ligand B (0.626), indicating a more drug-like profile. This is a substantial advantage for Ligand A.
7. **DILI:** Ligand A (25.824) has a much lower DILI risk than Ligand B (61.225). This is a critical advantage, as liver toxicity is a major concern.
8. **BBB:** Ligand A (72.005) shows better BBB penetration than Ligand B (52.191). While ADRB2 isn't strictly a CNS target, some peripheral ADRB2 activity can influence CNS pathways, and better BBB penetration isn't detrimental.
9. **Caco-2:** Ligand A (-4.649) is better than Ligand B (-5.193), suggesting better intestinal absorption.
10. **Solubility:** Ligand A (-1.024) is better than Ligand B (-3.226), indicating better aqueous solubility. This is important for formulation and bioavailability.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.399 and 0.343 respectively). No significant difference.
12. **Cl_mic:** Ligand A (0.489) has much lower microsomal clearance than Ligand B (68.15). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (17.619) has a longer in vitro half-life than Ligand B (21.328). This is a positive attribute, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.076) has lower P-gp efflux liability than Ligand B (0.264), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand A (-6.6 kcal/mol) is slightly better than Ligand B (-5.3 kcal/mol). While the difference is not huge, it is still a positive factor for Ligand A.
**GPCR-Specific Priorities:**
Considering ADRB2 is a GPCR, logP, TPSA, Pgp, and affinity are important. Ligand A performs better across these parameters.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical ADME-Tox properties (DILI, solubility, metabolic stability, Pgp efflux) and has a slightly better binding affinity. While Ligand B has a longer half-life, the significant advantages of Ligand A in safety (DILI) and drug-like properties outweigh this benefit.
Output:
1
2025-04-17 23:13:42,110 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.463 and 369.441 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (87.47) is slightly higher than Ligand B (77.04). Both are below the 140 threshold for good oral absorption, but closer to the 90 threshold for CNS targets (less relevant for ADRB2, a cardiovascular target). Ligand B is slightly favored.
3. **logP:** Both ligands have acceptable logP values (1.449 and 2.715), falling within the 1-3 range. Ligand B is a bit higher, which *could* be slightly beneficial for membrane permeability, but isn't a major concern for either.
4. **HBD:** Ligand A has 2 HBD, and Ligand B has 1. Both are within the acceptable limit of <=5. Ligand B is slightly favored.
5. **HBA:** Ligand A has 5 HBA, and Ligand B has 6. Both are within the acceptable limit of <=10. No clear advantage.
6. **QED:** Both ligands have good QED scores (0.777 and 0.814), indicating good drug-like properties. Ligand B is slightly favored.
7. **DILI:** Ligand A (29.236) has a significantly lower DILI risk than Ligand B (41.411). This is a substantial advantage for Ligand A.
8. **BBB:** Both have relatively low BBB penetration, which is not a high priority for a cardiovascular target like ADRB2. Ligand B (83.792) is higher than Ligand A (58.976), but this isn't a deciding factor.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual. This suggests poor permeability. Ligand B (-4.729) is slightly less negative than Ligand A (-5.336), indicating potentially better (though still poor) permeability.
10. **Solubility:** Both have negative solubility values, which is also unusual and indicates poor solubility. Ligand A (-1.327) is slightly better than Ligand B (-3.722).
11. **hERG:** Both have very low hERG inhibition risk (0.313 and 0.296). No clear advantage.
12. **Cl_mic:** Ligand A (-16.671) has a much lower (better) microsomal clearance than Ligand B (37.844). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (15.96) has a longer in vitro half-life than Ligand B (-13.899). This is a significant advantage for Ligand A.
14. **Pgp:** Both have very low P-gp efflux liability (0.073 and 0.071). No clear advantage.
15. **Binding Affinity:** Ligand A (-7.3) has a slightly better binding affinity than Ligand B (-6.5). While the difference is less than the 1.5 kcal/mol threshold for outweighing ADME issues, it contributes to the overall preference for Ligand A.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, affinity) and general drug-like properties, Ligand A emerges as the more promising candidate. While Ligand B has slightly better logP and Caco-2 permeability, Ligand A's significantly lower DILI risk, better metabolic stability (lower Cl_mic, longer t1/2), and slightly better binding affinity are more critical for overall drug development success. The poor solubility and Caco-2 values are concerning for both, but can be addressed through formulation strategies.
Output:
1
2025-04-17 23:13:42,110 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (408.347 Da) is within the ideal range (200-500 Da). Ligand B (368.459 Da) is also within range. No clear advantage here.
2. **TPSA:** Ligand A (55.84) is good, well below the 140 threshold. Ligand B (121.02) is higher, but still acceptable for a peripherally acting GPCR.
3. **logP:** Ligand A (3.973) is optimal. Ligand B (0.491) is quite low, potentially hindering membrane permeability and bioavailability. This is a significant drawback.
4. **HBD:** Ligand A (0) is excellent. Ligand B (3) is acceptable, but more donors can sometimes lead to issues.
5. **HBA:** Ligand A (4) is good. Ligand B (5) is also acceptable.
6. **QED:** Both ligands (A: 0.76, B: 0.617) have good drug-likeness scores, above the 0.5 threshold.
7. **DILI:** Ligand A (55.176) has a better DILI score than Ligand B (63.552), indicating lower liver injury risk.
8. **BBB:** Both ligands have similar BBB penetration (A: 53.742, B: 52.966). Since ADRB2 is not a CNS target, this is less critical.
9. **Caco-2:** Ligand A (-4.726) and Ligand B (-5.566) both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Ligand A (-5.402) and Ligand B (-2.818) both have negative solubility values, which is also unusual.
11. **hERG:** Ligand A (0.763) has a lower hERG risk than Ligand B (0.126). This is a significant advantage.
12. **Cl_mic:** Ligand A (71.112) has a higher microsomal clearance than Ligand B (-2.143), suggesting lower metabolic stability. This is a drawback for Ligand A.
13. **t1/2:** Ligand A (1.266) has a shorter in vitro half-life than Ligand B (12.772). This is a significant drawback for Ligand A.
14. **Pgp:** Ligand A (0.507) has lower P-gp efflux than Ligand B (0.049), which is favorable.
15. **Affinity:** Ligand B (-6.7 kcal/mol) has a slightly better binding affinity than Ligand A (-6.4 kcal/mol). While the difference is small, it's still a positive for Ligand B.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has a better logP and Pgp, but Ligand B has a slightly better affinity. The low logP of Ligand B is a major concern, potentially limiting its bioavailability. However, the significantly better metabolic stability (lower Cl_mic and longer t1/2) and lower hERG risk of Ligand B are important considerations.
**Overall Assessment:**
Despite the slightly weaker logP, Ligand B's superior metabolic stability, longer half-life, and lower hERG risk outweigh the minor affinity difference and slightly higher DILI risk. The poor Caco-2 and solubility values are concerning for both, but could be addressed with formulation strategies. The lower logP of Ligand B is a significant hurdle, but potentially manageable.
Output:
0
2025-04-17 23:13:42,110 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [350.419, 115.39 , 0.291, 3. , 5. , 0.623, 26.095, 43.583, -5.326, -1.705, 0.253, 6.844, -12.125, 0.014, -6.8 ]
**Ligand B:** [365.905, 61.38 , 3.462, 2. , 4. , 0.752, 37.922, 63.164, -5.391, -3.575, 0.91 , 30.274, 109.046, 0.771, -6.3 ]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, Affinity, and to a lesser extent BBB):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (350.419) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (61.38) is significantly better than Ligand A (115.39). Below 90 is preferred, and Ligand B is comfortably within that range, suggesting better permeability. Ligand A is pushing the upper limit for oral absorption.
3. **logP:** Ligand B (3.462) is optimal (1-3), while Ligand A (0.291) is quite low. This is a *major* drawback for Ligand A, potentially hindering membrane permeability and bioavailability.
4. **HBD/HBA:** Ligand A has 3 HBD and 5 HBA, while Ligand B has 2 HBD and 4 HBA. Both are acceptable.
5. **QED:** Both have good QED scores (A: 0.623, B: 0.752), indicating drug-like properties. Ligand B is slightly better.
6. **DILI:** Ligand A (26.095) has a much lower DILI risk than Ligand B (37.922), which is a significant advantage.
7. **BBB:** Ligand B (63.164) has a better BBB percentile than Ligand A (43.583), though neither are exceptionally high. This is less critical for a non-CNS target like ADRB2, but still a positive for B.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual. Assuming these are logP-like scales, lower values suggest poorer permeability.
9. **Solubility:** Both have negative solubility values, again unusual. Lower values suggest poorer solubility.
10. **hERG:** Ligand A (0.253) has a lower hERG risk than Ligand B (0.91), which is a positive.
11. **Cl_mic:** Ligand A (6.844) has a lower microsomal clearance, indicating better metabolic stability than Ligand B (30.274).
12. **t1/2:** Ligand B (109.046) has a much longer in vitro half-life than Ligand A (-12.125), which is a significant advantage.
13. **Pgp:** Ligand A (0.014) has much lower P-gp efflux liability than Ligand B (0.771). This is a major advantage for A, improving bioavailability.
14. **Affinity:** Both have comparable binding affinities (-6.8 kcal/mol and -6.3 kcal/mol). The difference of 0.5 kcal/mol is not substantial enough to override other significant differences.
**Overall Assessment:**
Ligand B has advantages in TPSA, QED, BBB, and *especially* in vitro half-life. However, Ligand A excels in logP, DILI, Pgp efflux, and metabolic stability. The low logP of Ligand A is a serious concern for permeability, but the significantly lower DILI risk and Pgp efflux are strong positives. The longer half-life of Ligand B is attractive, but the higher DILI risk and Pgp efflux are concerning.
Considering the GPCR-specific priorities, the balance tips towards Ligand A. While the low logP is a drawback, the lower DILI and Pgp efflux are crucial for a potentially developable drug. The better TPSA of Ligand B is helpful, but not enough to overcome the other issues.
Output:
1
2025-04-17 23:13:42,110 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.435 & 362.436 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (90.98) is better than Ligand B (49.41). For a GPCR, lower TPSA is generally preferred for better permeability, but both are quite good.
3. **logP:** Ligand B (3.507) is higher than Ligand A (-0.351). While a logP around 1-3 is optimal, Ligand B is slightly above this range, but still reasonable. Ligand A is quite low, which could hinder permeability.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1), but both are within the acceptable limit of 5.
5. **HBA:** Ligand A (4) is higher than Ligand B (2), but both are within the acceptable limit of 10.
6. **QED:** Both ligands have good QED scores (0.613 and 0.718, respectively), indicating good drug-like properties.
7. **DILI:** Ligand A (18.728) has a significantly lower DILI risk than Ligand B (31.33). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (88.949) has a higher BBB penetration percentile than Ligand A (73.245). While ADRB2 isn't strictly a CNS target, some CNS exposure can be beneficial or at least less detrimental than off-target effects.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.923 and -4.348), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-0.701) has better solubility than Ligand B (-3.888). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.285) has a lower hERG inhibition liability than Ligand B (0.481). This is a significant safety advantage for Ligand A.
12. **Cl_mic:** Ligand A (-6.93) has a much lower (better) microsomal clearance than Ligand B (56.541). This indicates better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (6.074) has a longer in vitro half-life than Ligand B (1.328). This is a significant advantage for Ligand A, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.004) has a much lower P-gp efflux liability than Ligand B (0.12). Lower efflux is desirable for better bioavailability.
15. **Binding Affinity:** Ligand B (-6.4) has a slightly better binding affinity than Ligand A (-5.5). This is a 0.9 kcal/mol difference, which is noticeable but not overwhelming.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B in crucial ADMET properties: DILI risk, hERG inhibition, metabolic stability (Cl_mic & t1/2), and P-gp efflux. While Ligand B has slightly better binding affinity and BBB penetration, the safety and pharmacokinetic advantages of Ligand A are more compelling for overall drug development potential. The negative Caco-2 values are concerning for both, but the other advantages of Ligand A outweigh this drawback.
Output:
1
2025-04-17 23:13:42,110 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
The ADRB2 receptor is a GPCR, so the priorities are logP, Pgp, TPSA, BBB, and affinity. Let's compare the ligands:
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da).
2. **TPSA:** Ligand A (58.2) is significantly better than Ligand B (116.76). A lower TPSA generally favors oral absorption and BBB penetration, crucial for GPCRs.
3. **logP:** Ligand A (3.506) is optimal, while Ligand B (-0.277) is quite low. A low logP can hinder membrane permeability.
4. **H-Bond Donors/Acceptors:** Ligand A (2/2) is better than Ligand B (4/5). Fewer H-bonds generally improve permeability.
5. **QED:** Both are acceptable, but Ligand A (0.67) is slightly better than Ligand B (0.448), indicating a more drug-like profile.
6. **DILI:** Ligand A (32.842) is much better than Ligand B (22.373) regarding liver injury risk.
7. **BBB:** Ligand A (70.182) is significantly better than Ligand B (47.654), which is a key consideration for GPCRs, even if this isn't a CNS target. Better BBB penetration can translate to better target engagement.
8. **Caco-2 Permeability:** Ligand A (-4.806) is better than Ligand B (-5.321).
9. **Aqueous Solubility:** Ligand A (-4.909) is better than Ligand B (-0.561).
10. **hERG:** Both ligands have similar hERG inhibition liability (0.495 and 0.073 respectively).
11. **Microsomal Clearance:** Ligand A (74.457) is higher than Ligand B (16.514), indicating faster clearance and potentially lower *in vivo* exposure.
12. **In vitro Half-Life:** Ligand B (-17.232) has a negative half-life, which is concerning. Ligand A (11.227) is much better.
13. **P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.431 and 0.015 respectively).
14. **Binding Affinity:** Both ligands have the same binding affinity (-6.4 kcal/mol).
**Overall Assessment:**
Ligand A clearly outperforms Ligand B in almost all ADME properties critical for a GPCR drug candidate. While both have the same binding affinity, Ligand A's superior TPSA, logP, BBB, solubility, DILI, and half-life make it a much more promising starting point for drug development. The lower clearance of Ligand B is a minor positive, but is outweighed by the other significant drawbacks.
**Output:**
1
2025-04-17 23:13:42,110 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
The target is ADRB2, a GPCR. Therefore, the priorities are logP, TPSA, Pgp efflux, BBB penetration, and binding affinity. Metabolic stability and solubility are also important, but less critical than the former.
Let's compare the ligands property by property:
1. **MW:** Both ligands (351.403 and 357.307 Da) are within the ideal range (200-500 Da).
2. **TPSA:** Ligand A (116.76) is better than Ligand B (69.22). While both are reasonably low, Ligand B is significantly lower, which is generally favorable for GPCRs.
3. **logP:** Ligand A (-1.327) is suboptimal, being below the preferred 1-3 range. Ligand B (3.673) is excellent. This is a major advantage for Ligand B.
4. **HBD/HBA:** Ligand A has 4 HBD and 5 HBA, while Ligand B has 2 HBD and 3 HBA. Both are acceptable.
5. **QED:** Ligand B (0.775) has a significantly better QED score than Ligand A (0.443), indicating better overall drug-likeness.
6. **DILI:** Ligand A (21.908) has a much lower DILI risk than Ligand B (62.233), which is a significant advantage.
7. **BBB:** Ligand B (54.556) has better BBB penetration than Ligand A (35.324), though neither is exceptionally high.
8. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability.
9. **Solubility:** Ligand A (-2.217) has slightly better solubility than Ligand B (-3.959), but both are very poor.
10. **hERG:** Both ligands have very low hERG inhibition risk (0.096 and 0.727 respectively).
11. **Cl_mic:** Ligand A (-1.459) has a much lower (better) microsomal clearance than Ligand B (71.341), indicating better metabolic stability.
12. **t1/2:** Ligand A (20.994) has a much longer in vitro half-life than Ligand B (-31.195), which is a significant advantage.
13. **Pgp:** Ligand A (0.002) has significantly lower P-gp efflux liability than Ligand B (0.391), which is favorable for bioavailability.
14. **Binding Affinity:** Both ligands have the same binding affinity (-4.9 kcal/mol).
**Overall Assessment:**
Ligand B excels in logP and QED, which are important for GPCRs. However, it suffers from a high DILI risk, poor metabolic stability (high Cl_mic), a short half-life, and higher Pgp efflux. Ligand A, while having a suboptimal logP, demonstrates better safety (DILI), metabolic stability (Cl_mic, t1/2), and lower Pgp efflux. Considering the balance of these factors, and the fact that the binding affinity is identical, the improved ADME properties of Ligand A make it the more promising candidate.
**Output:**
1
2025-04-17 23:13:42,110 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.475 and 371.821 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (67.23) is significantly better than Ligand B (110.53). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (2.256 and 1.542), falling within the 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Ligand A has 1 HBD, while Ligand B has 2. Both are acceptable, staying under the 5 threshold.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 6. Both are under the 10 threshold, but Ligand A is preferable.
6. **QED:** Ligand A (0.823) has a substantially better QED score than Ligand B (0.637), indicating a more drug-like profile.
7. **DILI:** Ligand B (65.917) has a considerably higher DILI risk than Ligand A (16.014). This is a significant drawback for Ligand B.
8. **BBB:** Ligand A (71.113) has a higher BBB penetration percentile than Ligand B (61.613), but given this is a cardiovascular target, this is less critical.
9. **Caco-2:** Both ligands have similar, poor Caco-2 permeability scores (-4.932 and -4.842). This suggests potential absorption issues for both.
10. **Solubility:** Ligand A (-1.825) has better solubility than Ligand B (-2.999).
11. **hERG:** Both ligands have very low hERG inhibition liability (0.32 and 0.101), which is excellent.
12. **Cl_mic:** Ligand A (57.194) has a lower microsomal clearance than Ligand B (61.545), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-7.706) has a significantly longer in vitro half-life than Ligand B (-2.983).
14. **Pgp:** Both ligands have low Pgp efflux liability (0.172 and 0.088).
15. **Binding Affinity:** Ligand A (-7.7 kcal/mol) has a slightly better binding affinity than Ligand B (-6.2 kcal/mol). While the difference is not huge, it's enough to be meaningful.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A performs better on TPSA, logP, and affinity.
**Overall Assessment:**
Ligand A is clearly the superior candidate. It has a better QED score, substantially lower DILI risk, better solubility, longer half-life, and slightly better binding affinity. While both have similar Caco-2 permeability, the other advantages of Ligand A outweigh this concern. The lower DILI risk alone is a major factor favoring Ligand A.
Output:
1
2025-04-17 23:13:42,111 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (339.483 and 349.439 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (37.39) is significantly better than Ligand B (95.39). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally correlates with better absorption. Ligand B's TPSA is quite high, potentially hindering oral bioavailability.
3. **logP:** Ligand A (4.816) is higher than Ligand B (-1.054). While 4.816 is approaching the upper limit of optimal, it's still acceptable. Ligand B's logP is quite low, which could severely limit membrane permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD is generally better for permeability.
5. **HBA:** Ligand A (4) is preferable to Ligand B (7). Lower HBA is generally better for permeability.
6. **QED:** Ligand A (0.819) is significantly better than Ligand B (0.552), indicating a more drug-like profile.
7. **DILI:** Both ligands have low DILI risk (36.293 and 34.161 percentile), which is good. No clear advantage.
8. **BBB:** Ligand A (77.162) is better than Ligand B (52.889), though BBB isn't a primary concern for a cardiovascular target.
9. **Caco-2:** Ligand A (-4.536) is better than Ligand B (-5.464). Higher Caco-2 permeability suggests better absorption.
10. **Solubility:** Ligand A (-5.454) is better than Ligand B (-0.946). Better solubility is desirable for formulation.
11. **hERG:** Ligand A (0.874) is better than Ligand B (0.148). Lower hERG inhibition is crucial for avoiding cardiotoxicity, especially for a cardiovascular target.
12. **Cl_mic:** Ligand A (110.476) is worse than Ligand B (18.443). Higher clearance means faster metabolism. This is a significant drawback for Ligand A.
13. **t1/2:** Ligand A (7.889) is worse than Ligand B (11.965). Shorter half-life may require more frequent dosing.
14. **Pgp:** Ligand A (0.573) is better than Ligand B (0.006). Lower P-gp efflux is desirable.
15. **Binding Affinity:** Ligand A (-8.0) is slightly better than Ligand B (-5.8). A 2.2 kcal/mol difference is substantial and can often outweigh other ADME concerns.
**Overall Assessment:**
Ligand A has a significantly better profile in terms of TPSA, logP, QED, solubility, hERG, Caco-2, and binding affinity. The stronger binding affinity is a major plus. However, Ligand A has higher Cl_mic and shorter t1/2. While metabolic stability is important, the substantial binding advantage of Ligand A, combined with the better permeability and safety profiles (hERG) make it the more promising candidate. The metabolic issues could potentially be addressed through structural modifications in later optimization stages. Ligand B's very low logP is a major concern, likely leading to poor absorption.
Output:
1
2025-04-17 23:13:42,111 - INFO - Here's my reasoning and the final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, the priorities are logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB.
Let's break down the comparison:
1. **MW:** Both ligands are within the ideal range (200-500 Da).
2. **TPSA:** Both are below the 140 A^2 threshold for good oral absorption, making them comparable here.
3. **logP:** Ligand A (0.703) is lower than Ligand B (1.494). While both are within the optimal range, Ligand B is closer to the ideal 1-3 range.
4. **HBD/HBA:** Ligand A has 2 HBD and 4 HBA, while Ligand B has 1 HBD and 5 HBA. Both are acceptable.
5. **QED:** Ligand B (0.829) has a better QED score than Ligand A (0.632), indicating a more drug-like profile.
6. **DILI:** Ligand A (4.731) has a significantly lower DILI risk than Ligand B (44.436). This is a major advantage for Ligand A.
7. **BBB:** Ligand B (59.364) has a higher BBB penetration than Ligand A (36.371). However, as this is a cardiovascular target, BBB penetration isn't a primary concern.
8. **Caco-2:** Both have negative Caco-2 values, suggesting poor permeability. This is a concern for both, but the values are similar.
9. **Solubility:** Ligand A (-0.599) has better solubility than Ligand B (-2.583).
10. **hERG:** Both ligands have low hERG inhibition liability, which is good.
11. **Cl_mic:** Ligand A (-7.488) has significantly lower microsomal clearance than Ligand B (41.644), indicating better metabolic stability.
12. **t1/2:** Both have similar in vitro half-lives.
13. **Pgp:** Ligand A (0.014) exhibits lower P-gp efflux than Ligand B (0.11), which is favorable for bioavailability.
14. **Binding Affinity:** Ligand A (-6.5 kcal/mol) has a slightly weaker binding affinity than Ligand B (-5.4 kcal/mol). However, the difference is not substantial enough to outweigh the other advantages of Ligand A.
**Conclusion:**
Ligand A demonstrates a superior balance of properties, particularly regarding safety (DILI), metabolic stability (Cl_mic), and P-gp efflux. While Ligand B has a slightly better QED and binding affinity, the significant advantages of Ligand A in crucial ADME-Tox parameters outweigh these benefits for a cardiovascular GPCR target.
**Output:**
1
2025-04-17 23:13:42,111 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (353.413) is slightly preferred as it's closer to the lower end, potentially aiding permeability.
2. **TPSA:** Ligand A (52.65) is significantly better than Ligand B (70.08). ADRB2 is a cardiovascular target, not necessarily CNS, but lower TPSA is generally favorable for absorption.
3. **logP:** Both ligands have good logP values (A: 2.677, B: 1.838) within the optimal 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A (2) is better than Ligand B (5). Lower HBA is generally preferred for permeability.
6. **QED:** Both have good QED scores (A: 0.905, B: 0.8), indicating good drug-like properties. Ligand A is slightly better.
7. **DILI:** Both have acceptable DILI risk (A: 47.305, B: 38.503), with Ligand B being slightly better.
8. **BBB:** Ligand A (86.157) is significantly better than Ligand B (28.655). While ADRB2 isn't a primary CNS target, some peripheral ADRB2 receptors can be affected by CNS penetration, and higher BBB is generally a positive attribute.
9. **Caco-2:** Both have negative Caco-2 values (-4.385 and -4.57). These values are unusual and difficult to interpret without more context, but suggest poor permeability.
10. **Solubility:** Both have negative solubility values (-2.88 and -2.046). Similar to Caco-2, these values are problematic and suggest poor solubility.
11. **hERG:** Both have low hERG inhibition liability (A: 0.738, B: 0.155), which is excellent. Ligand B is better.
12. **Cl_mic:** Ligand A (8.701) has a much lower microsomal clearance than Ligand B (43.521), indicating better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand A (1.235) has a slightly better in vitro half-life than Ligand B (-2.6).
14. **Pgp:** Both have low Pgp efflux liability (A: 0.127, B: 0.167).
15. **Binding Affinity:** Ligand B (-6.7) has a slightly better binding affinity than Ligand A (-6.3). This is a 0.4 kcal/mol difference, which is notable but not overwhelming.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A performs better on TPSA, logP, and Pgp. While Ligand B has a slightly better affinity, the other ADME properties of Ligand A are more favorable. The improved metabolic stability (lower Cl_mic) of Ligand A is also a significant advantage. The negative solubility and Caco-2 values are concerning for both, but the overall profile of Ligand A is more promising.
**Conclusion:**
Considering the balance of properties, particularly the favorable TPSA, logP, metabolic stability, and BBB, Ligand A is the more promising drug candidate.
Output:
1
2025-04-17 23:13:42,111 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's systematically compare Ligand A and Ligand B based on the provided parameters and the guidelines, keeping in mind ADRB2 is a GPCR. GPCRs prioritize logP, Pgp, TPSA, and affinity.
1. **Molecular Weight:** Both ligands (348.531 and 349.435 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (40.62) is significantly better than Ligand B (107.19). A TPSA under 140 is good for oral absorption, but lower is generally preferred for GPCRs. Ligand B's TPSA is quite high, potentially hindering permeability.
3. **logP:** Ligand A (3.866) is within the optimal 1-3 range. Ligand B (0.465) is *below* 1, which is a concern for membrane permeability.
4. **H-Bond Donors:** Ligand A (0) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **H-Bond Acceptors:** Ligand A (2) is better than Ligand B (4). Fewer HBAs also contribute to better permeability.
6. **QED:** Both ligands have similar QED values (0.655 and 0.602), both above the 0.5 threshold, indicating good drug-likeness.
7. **DILI:** Ligand A (24.273) has a much lower DILI risk than Ligand B (31.485). Lower is better, and Ligand A is well below the 40% threshold.
8. **BBB:** Ligand A (78.907) has a significantly better BBB penetration percentile than Ligand B (47.15). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant, and higher BBB is generally favorable.
9. **Caco-2 Permeability:** Ligand A (-4.511) is better than Ligand B (-5.225). Both are negative, but A is less negative, indicating better permeability.
10. **Aqueous Solubility:** Ligand A (-3.5) is better than Ligand B (-1.386). Higher solubility is generally preferred.
11. **hERG Inhibition:** Ligand A (0.789) is better than Ligand B (0.109). Lower hERG inhibition is crucial for avoiding cardiotoxicity, a major concern for cardiovascular targets.
12. **Microsomal Clearance:** Ligand A (83.041) is much higher than Ligand B (1.464). Higher clearance indicates lower metabolic stability, making Ligand B preferable.
13. **In vitro Half-Life:** Ligand A (4.063) is much shorter than Ligand B (-12.312). Longer half-life is generally preferred.
14. **P-gp Efflux:** Ligand A (0.68) is better than Ligand B (0.01). Lower P-gp efflux is desirable for improved bioavailability.
15. **Binding Affinity:** Ligand B (-6.1) has a slightly better binding affinity than Ligand A (-5.6). However, the difference is only 0.5 kcal/mol, and the substantial advantages of Ligand A in other key ADME properties outweigh this small difference in potency.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most crucial ADME properties (TPSA, logP, HBD, HBA, DILI, BBB, solubility, hERG, P-gp efflux). While Ligand B has slightly better affinity and metabolic stability, the significant drawbacks in permeability (low logP, high TPSA) and safety (higher DILI, lower hERG safety margin) make it a less attractive candidate. The modest affinity difference is not enough to compensate for these issues.
Output:
1
2025-04-17 23:13:42,111 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for the ADRB2, a cardiovascular GPCR. Therefore, prioritizing logP, TPSA, Pgp, and binding affinity is crucial.
Let's break down the comparison:
1. **MW:** Both ligands (367.5 and 376.8) fall within the ideal 200-500 Da range.
2. **TPSA:** Ligand B (32.34) is significantly better than Ligand A (71.53). Lower TPSA is preferred for GPCRs, aiding permeability.
3. **logP:** Ligand A (2.244) is optimal, while Ligand B (4.488) is pushing the upper limit. While not disqualifying, higher logP can lead to off-target effects and solubility issues.
4. **HBD/HBA:** Both ligands have acceptable HBD (1) and HBA (Ligand A: 5, Ligand B: 2) counts.
5. **QED:** Both ligands have good QED scores (A: 0.644, B: 0.839), indicating good drug-like properties.
6. **DILI:** Ligand B (21.171) has a much lower DILI risk than Ligand A (33.501), which is a significant advantage.
7. **BBB:** Ligand B (89.492) shows much better BBB penetration than Ligand A (56.96). While ADRB2 isn't a CNS target, better BBB penetration can sometimes correlate with better overall distribution.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and requires further investigation but doesn't immediately disqualify either.
9. **Solubility:** Ligand A (-1.628) has better solubility than Ligand B (-5.059).
10. **hERG:** Ligand A (0.367) has a lower hERG risk than Ligand B (0.877).
11. **Cl_mic:** Ligand B (27.099) has a lower microsomal clearance, indicating better metabolic stability than Ligand A (47.525).
12. **t1/2:** Ligand A (14.949) has a longer in vitro half-life than Ligand B (4.497).
13. **Pgp:** Ligand A (0.113) has lower P-gp efflux than Ligand B (0.359), which is favorable.
14. **Binding Affinity:** Ligand B (-7.4) has a significantly stronger binding affinity than Ligand A (-5.8). This is a crucial advantage, exceeding the 1.5 kcal/mol threshold.
**Overall Assessment:**
Ligand B has a substantially better binding affinity and a significantly lower DILI risk. Its lower TPSA is also a major benefit for a GPCR target. While its logP is slightly higher and solubility lower than Ligand A, the strong binding affinity and improved safety profile outweigh these drawbacks. The better metabolic stability (lower Cl_mic) is also a positive.
Output:
0
2025-04-17 23:13:42,111 - INFO - Batch 389 complete. Total preferences: 6224
2025-04-17 23:13:42,112 - INFO - Processing batch 390/512...
2025-04-17 23:14:30,931 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 drug candidates. ADRB2 is a GPCR, so we'll prioritize logP, Pgp, TPSA, and affinity, alongside general drug-like properties.
**Ligand A:** [362.367, 125.88 , 0.742, 1. , 8. , 0.663, 98.759, 47.615, -5.019, -3.226, 0.128, 57.007, -2.929, 0.17 , -6.2 ]
**Ligand B:** [383.857, 84.67 , 2.489, 1. , 6. , 0.828, 74.719, 49.205, -4.81 , -3.678, 0.267, 25.644, 43.435, 0.316, -6.6 ]
1. **MW:** Both are within the ideal range (200-500 Da). A (362.367) is slightly preferred.
2. **TPSA:** A (125.88) is a bit high, but B (84.67) is excellent, well below the 140 threshold. This favors B.
3. **logP:** A (0.742) is a little low, potentially causing permeability issues. B (2.489) is much better, falling within the optimal 1-3 range. This strongly favors B.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** A has 8, B has 6. Both are acceptable, but B is slightly better.
6. **QED:** Both are reasonable (A: 0.663, B: 0.828), but B is better.
7. **DILI:** A (98.759) is *very* high risk, a significant concern. B (74.719) is still not ideal, but much better. This is a major advantage for B.
8. **BBB:** Both are relatively low (A: 47.615, B: 49.205). BBB isn't a huge priority for ADRB2 (cardiovascular target), so this isn't a major differentiator.
9. **Caco-2:** Both are negative, indicating poor permeability. A (-5.019) is worse than B (-4.81).
10. **Solubility:** Both are very poor (-3.226 and -3.678). Solubility is a concern for both, but not a deciding factor.
11. **hERG:** Both are very low risk (A: 0.128, B: 0.267).
12. **Cl_mic:** A (57.007) is higher than B (25.644), indicating faster metabolism and lower metabolic stability. This favors B.
13. **t1/2:** A (-2.929) is much worse than B (43.435), indicating a very short half-life. This is a significant advantage for B.
14. **Pgp:** Both are low (A: 0.17, B: 0.316), indicating low efflux.
15. **Affinity:** B (-6.6) is slightly better than A (-6.2), but the difference is not huge.
**Overall Assessment:**
Ligand B is significantly better. While both have solubility and Caco-2 permeability issues, Ligand B has a much better logP, significantly lower DILI risk, better metabolic stability (lower Cl_mic, longer t1/2), and slightly better affinity. The high DILI risk associated with Ligand A is a major red flag. The slightly better TPSA and QED of Ligand B further support its selection.
Output:
0
2025-04-17 23:14:30,932 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (356.4) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (69.9) is higher than Ligand B (49.85). Both are acceptable, but B is better, especially for a GPCR where some CNS penetration might be desirable, even if ADRB2 isn't a primary CNS target.
3. **logP:** Both ligands have good logP values (A: 2.381, B: 2.939), falling within the optimal 1-3 range. B is slightly higher, which could potentially lead to off-target interactions, but isn't a major concern.
4. **HBD:** Both have 0 HBD, which is good.
5. **HBA:** Ligand A has 7 HBA, and Ligand B has 5. Both are within the acceptable limit of 10.
6. **QED:** Both have reasonable QED scores (A: 0.409, B: 0.597). Ligand B is better here, indicating a more drug-like profile.
7. **DILI:** Ligand A has a significantly higher DILI risk (90.733) compared to Ligand B (49.283). This is a major red flag for Ligand A.
8. **BBB:** Ligand A (70.027) has better BBB penetration than Ligand B (57.542). Although ADRB2 is primarily cardiovascular, some degree of BBB penetration isn't necessarily detrimental and could open up potential for future indications.
9. **Caco-2:** Both have negative Caco-2 values (-4.433 and -4.644), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Both have negative solubility values (-4.246 and -3.313), indicating very poor aqueous solubility. This is a significant issue for both.
11. **hERG:** Both ligands have low hERG inhibition risk (A: 0.384, B: 0.341), which is good.
12. **Cl_mic:** Ligand A has a higher microsomal clearance (88.38) than Ligand B (63.966), indicating lower metabolic stability.
13. **t1/2:** Ligand B has a longer in vitro half-life (18.492) than Ligand A (11.316).
14. **Pgp:** Both have low Pgp efflux liability (A: 0.639, B: 0.311). Ligand B is better here.
15. **Binding Affinity:** Ligand B (-7.1 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.2 kcal/mol). This is a substantial advantage.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are crucial. Ligand B performs better on most of these. The significantly better affinity of Ligand B is a major factor. The lower DILI risk and improved metabolic stability (lower Cl_mic, longer t1/2) are also very important.
**Overall Assessment:**
While both ligands have concerning solubility and permeability issues (Caco-2 and Solubility values), Ligand B is the more promising candidate. Its superior binding affinity, lower DILI risk, better QED, improved metabolic stability, and lower Pgp efflux outweigh the slightly better BBB penetration of Ligand A. The poor solubility and permeability would need to be addressed through formulation strategies, but a strong starting point with good potency and safety is essential.
Output:
0
2025-04-17 23:14:30,932 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, key properties to prioritize are binding affinity, logP, TPSA, Pgp efflux, and BBB penetration (though BBB is less critical for a cardiovascular target).
Let's compare the ligands property by property:
1. **MW:** Both ligands (347.46 and 370.48 Da) fall within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (92.5) is better than Ligand B (104.53). Both are reasonably good, but lower TPSA generally favors absorption.
3. **logP:** Ligand A (1.328) is optimal, while Ligand B (0.053) is quite low. This is a significant drawback for Ligand B, potentially hindering membrane permeability.
4. **HBD/HBA:** Both have acceptable HBD (2) and Ligand A has 3 HBA, while Ligand B has 6. Ligand A is slightly better.
5. **QED:** Both are reasonably good (0.727 and 0.66), indicating drug-like properties.
6. **DILI:** Ligand A (16.48) is significantly better than Ligand B (44.09), indicating a lower risk of liver injury. This is a crucial advantage.
7. **BBB:** Ligand A (70.03) is better than Ligand B (42.92), although neither is exceptionally high, BBB is less critical for cardiovascular targets.
8. **Caco-2:** Ligand A (-5.331) is better than Ligand B (-5.719).
9. **Solubility:** Ligand A (-2.938) is better than Ligand B (-1.028).
10. **hERG:** Ligand A (0.101) is better than Ligand B (0.375).
11. **Cl_mic:** Both ligands have similar microsomal clearance (30.1 and 28.48 mL/min/kg), suggesting comparable metabolic stability.
12. **t1/2:** Ligand A (-2.579) is better than Ligand B (-8.745).
13. **Pgp:** Ligand A (0.021) is much better than Ligand B (0.053), indicating lower P-glycoprotein efflux.
14. **Binding Affinity:** Ligand B (-7.9) is slightly better than Ligand A (-7.6), but the difference is relatively small (0.3 kcal/mol).
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical ADME properties (logP, DILI, solubility, hERG, Pgp, t1/2). While Ligand B has a slightly better binding affinity, the superior ADME profile of Ligand A, particularly its better logP and significantly lower DILI risk, makes it a more promising drug candidate. The small affinity difference is likely surmountable with further optimization.
**Output:**
1
2025-04-17 23:14:30,932 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, the priorities are logP, TPSA, Pgp, affinity, and to a lesser extent, BBB.
Let's break down the comparison:
1. **MW:** Both ligands are within the acceptable range (200-500 Da). Ligand A (404.195) is slightly larger than Ligand B (349.383), but this isn't a major concern.
2. **TPSA:** Ligand A (84.22) is better than Ligand B (94.09). Both are under the 140 threshold for oral absorption, but lower is preferred.
3. **logP:** Ligand A (3.092) is optimal. Ligand B (1.077) is a bit low, potentially hindering membrane permeability.
4. **HBD/HBA:** Both have 2 HBD and 5/6 HBA, which are acceptable.
5. **QED:** Both are good (0.703 and 0.747).
6. **DILI:** Ligand B (53.315) has a significantly lower DILI risk than Ligand A (93.718). This is a substantial advantage for Ligand B.
7. **BBB:** Ligand B (54.75) has a better BBB penetration than Ligand A (23.226), but BBB is less critical for a cardiovascular target.
8. **Caco-2:** Ligand A (-5.239) has a better Caco-2 permeability than Ligand B (-4.948), suggesting better absorption.
9. **Solubility:** Ligand A (-4.28) has better solubility than Ligand B (-2.71).
10. **hERG:** Ligand B (0.123) has a lower hERG inhibition liability than Ligand A (0.487), which is a significant safety advantage.
11. **Cl_mic:** Ligand B (18.249) has a lower microsomal clearance than Ligand A (28.436), indicating better metabolic stability.
12. **t1/2:** Ligand A (11.634) has a longer in vitro half-life than Ligand B (0.832). This is a positive for Ligand A.
13. **Pgp:** Ligand A (0.25) has lower P-gp efflux than Ligand B (0.07), which is better.
14. **Affinity:** Ligand A (-7.3 kcal/mol) has a substantially better binding affinity than Ligand B (-6.3 kcal/mol). This 1 kcal/mol difference is significant and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand A has a significantly better binding affinity and better Pgp efflux, and a longer half-life. Ligand B has a much better safety profile (lower DILI and hERG) and better metabolic stability. The affinity difference is substantial. Given the cardiovascular target, the slightly lower metabolic stability and higher DILI risk of Ligand A are acceptable trade-offs for the significantly improved binding affinity. The logP of Ligand B is a concern, and the affinity difference is a major driver.
Output:
1
2025-04-17 23:14:30,932 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (a cardiovascular GPCR) drug candidates.
**Ligand A:** [350.354, 111.03 , 0.446, 2. , 7. , 0.669, 71.694, 51.725, -5.268, -1.883, 0.103, -0.517, 13.896, 0.042, -6.4 ]
**Ligand B:** [372.491, 116.4 , -0.082, 4. , 4. , 0.5 , 44.591, 52.579, -5.51 , -2.399, 0.149, 17.31 , -1.206, 0.025, -6.4 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (350.354) is slightly preferable due to being a bit lower.
2. **TPSA:** Both are reasonably good (Ligand A: 111.03, Ligand B: 116.4), below the 140 threshold for oral absorption.
3. **logP:** Ligand A (0.446) is better than Ligand B (-0.082). A logP between 1-3 is optimal, and Ligand A is closer to this range. Ligand B is quite low and may struggle with membrane permeability.
4. **HBD:** Ligand A (2) is better than Ligand B (4). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (7) is better than Ligand B (4). Lower HBA generally improves permeability.
6. **QED:** Ligand A (0.669) is better than Ligand B (0.5). Higher QED indicates better drug-likeness.
7. **DILI:** Ligand B (44.591) is significantly better than Ligand A (71.694). Lower DILI is crucial. This is a major advantage for Ligand B.
8. **BBB:** Both are similar (Ligand A: 51.725, Ligand B: 52.579). For a cardiovascular target, BBB penetration isn't a primary concern, but it's not detrimental to have some level of it.
9. **Caco-2:** Both are negative, suggesting poor permeability. Ligand A (-5.268) is slightly better than Ligand B (-5.51).
10. **Solubility:** Ligand A (-1.883) is better than Ligand B (-2.399). Higher solubility is preferred.
11. **hERG:** Both are very low (Ligand A: 0.103, Ligand B: 0.149), indicating minimal hERG inhibition risk.
12. **Cl_mic:** Ligand A (-0.517) is better than Ligand B (17.31). Lower clearance is preferred for better metabolic stability.
13. **t1/2:** Ligand A (13.896) is better than Ligand B (-1.206). Longer half-life is desirable.
14. **Pgp:** Both are very low (Ligand A: 0.042, Ligand B: 0.025), indicating minimal P-gp efflux.
15. **Affinity:** Both have the same affinity (-6.4 kcal/mol).
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, and affinity are key. Ligand A has a better logP and TPSA. The binding affinity is the same. However, Ligand B has a significantly better DILI score.
**Overall Assessment:**
While Ligand A has advantages in several ADME properties (logP, TPSA, solubility, metabolic stability, half-life), the significantly lower DILI risk associated with Ligand B is a critical factor. DILI is a major cause of drug development failures. Although Ligand B's logP is suboptimal, the DILI advantage outweighs this drawback.
Therefore, I would choose Ligand B.
0
2025-04-17 23:14:30,932 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (361.423 and 361.511 Da) fall comfortably within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand B (71.09) is significantly better than Ligand A (101.41). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (2.205 and 2.96), falling within the 1-3 optimal range. Ligand B is slightly higher, potentially aiding membrane permeability.
4. **HBD:** Both ligands have 2 H-bond donors, which is within the acceptable limit of 5. No difference.
5. **HBA:** Ligand A has 6 H-bond acceptors, while Ligand B has 4. Ligand B is preferable here, as fewer HBA generally improves permeability.
6. **QED:** Both ligands have identical QED scores (0.847), indicating excellent drug-likeness.
7. **DILI:** Ligand B (43.66) has a much lower DILI risk than Ligand A (94.649). This is a significant advantage for Ligand B.
8. **BBB:** Ligand B (46.336) has a higher BBB penetration percentile than Ligand A (31.795), though this is less critical for a cardiovascular target.
9. **Caco-2:** Ligand A (-5.572) has a slightly better Caco-2 permeability than Ligand B (-5.077), suggesting better intestinal absorption.
10. **Solubility:** Ligand A (-3.036) has slightly better aqueous solubility than Ligand B (-2.755).
11. **hERG:** Ligand A (0.02) has a lower hERG inhibition liability than Ligand B (0.112), which is a positive.
12. **Cl_mic:** Ligand A (-14.429) has significantly lower microsomal clearance than Ligand B (20.789), indicating better metabolic stability. This is a major advantage for Ligand A.
13. **t1/2:** Ligand B (9.213) has a longer in vitro half-life than Ligand A (4.205). This is a positive for Ligand B.
14. **Pgp:** Ligand A (0.01) has lower P-gp efflux liability than Ligand B (0.164), which is favorable.
15. **Binding Affinity:** Ligand A (-6.9 kcal/mol) has a significantly stronger binding affinity than Ligand B (-4.1 kcal/mol). This is a substantial advantage for Ligand A, potentially outweighing some ADME drawbacks.
**Overall Assessment:**
Ligand A has a significantly better binding affinity and metabolic stability (lower Cl_mic, lower Pgp efflux). Ligand B excels in DILI risk, TPSA, and half-life. The substantial difference in binding affinity (-6.9 vs -4.1 kcal/mol) is a key factor, especially for a GPCR target where potency is crucial. While Ligand B has better ADME properties in some areas, the stronger binding of Ligand A is likely to translate to greater efficacy and potentially allow for a lower dose, mitigating some of the ADME concerns. The lower DILI risk of Ligand B is attractive, but the large difference in affinity is more important.
Output:
1
2025-04-17 23:14:30,932 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (336.355 and 346.406 Da) fall comfortably within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (66.4) is significantly better than Ligand A (101.8). ADRB2 is not a CNS target, but lower TPSA generally improves absorption. This favors Ligand B.
3. **logP:** Both ligands have good logP values (2.088 and 1.679), falling within the optimal 1-3 range. Ligand B is slightly lower, which could be a minor benefit for solubility.
4. **HBD:** Ligand A has 2 HBD, and Ligand B has 0. While both are acceptable (<=5), fewer HBDs can sometimes improve membrane permeability. Ligand B is slightly favored.
5. **HBA:** Ligand A has 6 HBA, and Ligand B has 4. Both are below the 10 threshold. Ligand B is slightly favored.
6. **QED:** Both ligands have good QED scores (0.759 and 0.835), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand B (35.479) has a much lower DILI risk than Ligand A (90.733). This is a *major* advantage for Ligand B. DILI is a critical safety concern.
8. **BBB:** BBB is less important for ADRB2. Ligand B (96.704) is higher than Ligand A (40.403), but this is not a primary driver for this target.
9. **Caco-2:** Ligand A (-5.205) and Ligand B (-4.59) are both negative, indicating poor permeability. Ligand B is slightly better.
10. **Solubility:** Ligand A (-3.401) and Ligand B (-2.428) are both poor. Ligand B is slightly better.
11. **hERG:** Both ligands have low hERG risk (0.349 and 0.553). No significant difference.
12. **Cl_mic:** Ligand A (16.743) has a lower microsomal clearance than Ligand B (25.232), suggesting better metabolic stability. This favors Ligand A.
13. **t1/2:** Ligand A (32.863) has a longer in vitro half-life than Ligand B (-11.577). This is a significant advantage for Ligand A.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.062 and 0.031). No significant difference.
15. **Binding Affinity:** Both ligands have identical binding affinities (-6.4 kcal/mol).
**Overall Assessment:**
While Ligand A has advantages in metabolic stability (Cl_mic) and half-life (t1/2), the significantly lower DILI risk of Ligand B is a decisive factor. DILI is a major cause of drug attrition, and a score of 35.479 is far more acceptable than 90.733. The slightly better TPSA, logP, HBD, HBA, QED, Caco-2 and solubility of Ligand B further support its selection. Given the equal binding affinity, minimizing potential toxicity is paramount.
Output:
0
2025-04-17 23:14:30,932 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [366.571, 49.41, 3.309, 1, 3, 0.752, 20.822, 78.868, -5.175, -4.216, 0.563, 76.131, -0.397, 0.391, -5.7]
**Ligand B:** [367.499, 46.09, 3.493, 0, 5, 0.712, 75.378, 73.866, -4.965, -3.817, 0.458, 76.503, -19.816, 0.769, -7]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity, and BBB):
1. **MW:** Both are within the ideal range (366-367 Da).
2. **TPSA:** Ligand A (49.41) is slightly higher than Ligand B (46.09), but both are acceptable for a non-CNS GPCR target.
3. **logP:** Both are good (around 3.3-3.5), falling within the optimal 1-3 range.
4. **HBD/HBA:** Ligand A has 1 HBD and 3 HBA, while Ligand B has 0 HBD and 5 HBA. This is a minor difference, but generally, fewer HBDs can be beneficial for permeability.
5. **QED:** Both are good (0.752 and 0.712), indicating good drug-like properties.
6. **DILI:** Ligand A (20.822) has a significantly lower DILI risk than Ligand B (75.378). This is a major advantage for Ligand A.
7. **BBB:** Ligand A (78.868) has a slightly better BBB penetration potential than Ligand B (73.866), though this isn't a primary concern for a cardiovascular target.
8. **Caco-2:** Both have negative values, indicating poor permeability.
9. **Solubility:** Both have negative values, indicating poor solubility.
10. **hERG:** Both have low hERG inhibition liability (0.563 and 0.458).
11. **Cl_mic:** Both have similar microsomal clearance values (76.131 and 76.503), suggesting comparable metabolic stability.
12. **t1/2:** Ligand A (-0.397) has a slightly better in vitro half-life than Ligand B (-19.816).
13. **Pgp:** Ligand A (0.391) has lower P-gp efflux liability than Ligand B (0.769), which is favorable for bioavailability.
14. **Affinity:** Ligand B (-7.0 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.7 kcal/mol). This is a substantial advantage, exceeding the 1.5 kcal/mol threshold.
**Overall Assessment:**
The biggest differentiator is the binding affinity. Ligand B binds almost 1.3 kcal/mol stronger, which is a significant advantage. However, Ligand A has a much lower DILI risk, better P-gp efflux, and a slightly better half-life. Considering the cardiovascular target, the DILI risk is a critical factor. While affinity is important, a lower DILI risk is often prioritized to avoid potential liver toxicity issues.
Despite the affinity advantage of Ligand B, the significantly higher DILI risk makes Ligand A the more promising candidate.
Output:
1
2025-04-17 23:14:30,932 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (341.455 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (56.15) is significantly better than Ligand B (73.2). ADRB2 is not a CNS target, but lower TPSA generally improves absorption.
3. **logP:** Both are good (between 1-3). Ligand A (2.937) is slightly better positioned within the optimal range.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Both have 4 HBA, which is good.
6. **QED:** Both are above 0.5, indicating good drug-likeness (0.851 for A, 0.801 for B).
7. **DILI:** Ligand A (24.622) has a much lower DILI risk than Ligand B (40.364). This is a significant advantage.
8. **BBB:** Not a primary concern for ADRB2 (cardiovascular target), but Ligand A (81.504) is better than Ligand B (70.376).
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-5.064) is slightly better than Ligand B (-4.938).
10. **Solubility:** Ligand A (-2.763) is slightly better than Ligand B (-4.609), although both are poor.
11. **hERG:** Both ligands have low hERG risk (0.875 and 0.698).
12. **Cl_mic:** Ligand A (50.669) has a lower microsomal clearance than Ligand B (41.807), suggesting better metabolic stability.
13. **t1/2:** Ligand B (21.924) has a significantly longer half-life than Ligand A (4.811). This is a major advantage.
14. **Pgp:** Ligand A (0.782) has lower P-gp efflux than Ligand B (0.258), which is favorable for bioavailability.
15. **Affinity:** Ligand A (-6.9 kcal/mol) has a significantly stronger binding affinity than Ligand B (-3.5 kcal/mol). This is a crucial advantage, outweighing some of the ADME concerns.
**Overall Assessment:**
Ligand A is significantly better in terms of binding affinity, DILI risk, TPSA, and metabolic stability. While Ligand B has a longer half-life, the substantial difference in affinity and the lower DILI risk of Ligand A are more critical for a GPCR target like ADRB2. The slightly better solubility and permeability predictions for Ligand A also contribute to its overall better profile. The longer half-life of Ligand B is attractive, but can be addressed through formulation or structural modifications, while improving the affinity of Ligand B would be much more challenging.
**Output:**
1
2025-04-17 23:14:30,933 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (348.443 and 350.419 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (71.78) is significantly better than Ligand B (105.6). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is pushing the upper limit for good oral absorption.
3. **logP:** Ligand A (2.594) is optimal, while Ligand B (0.26) is quite low. Low logP can hinder membrane permeability and potentially reduce binding affinity. This is a major advantage for Ligand A.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is better than Ligand B (7). Similar to HBD, lower HBA counts are generally preferred.
6. **QED:** Ligand A (0.888) is significantly better than Ligand B (0.676), indicating a more drug-like profile.
7. **DILI:** Ligand A (25.165) has a much lower DILI risk than Ligand B (35.479). This is a critical safety parameter.
8. **BBB:** Ligand A (70.919) is better than Ligand B (50.679). While ADRB2 isn't exclusively a CNS target, some CNS penetration can be beneficial for understanding off-target effects and potential side effects.
9. **Caco-2:** Ligand A (-4.643) is better than Ligand B (-5.319). Higher Caco-2 permeability is desired.
10. **Solubility:** Ligand A (-2.317) is better than Ligand B (-1.126). Higher solubility is generally preferred.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.278 and 0.189 respectively).
12. **Cl_mic:** Ligand A (11.377) has a lower microsomal clearance than Ligand B (5.691), suggesting better metabolic stability.
13. **t1/2:** Ligand A (25.993) has a longer in vitro half-life than Ligand B (29.053).
14. **Pgp:** Ligand A (0.066) has lower P-gp efflux liability than Ligand B (0.004). Lower Pgp efflux is favorable.
15. **Affinity:** Ligand A (-6.9 kcal/mol) has a slightly better binding affinity than Ligand B (-5.0 kcal/mol). This difference is significant (1.9 kcal/mol) and can outweigh some minor ADME drawbacks.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are particularly important. Ligand A excels in all these areas. While BBB isn't paramount for ADRB2, Ligand A's higher BBB percentile is a bonus.
**Conclusion:**
Ligand A consistently outperforms Ligand B across most critical parameters, including ADME properties, safety (DILI), and binding affinity. The combination of optimal logP, low TPSA, good QED, lower DILI risk, and stronger binding affinity makes Ligand A the more promising drug candidate.
Output:
1
2025-04-17 23:14:30,933 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
The ADRB2 receptor is a GPCR, so the priorities are logP, TPSA, Pgp, BBB, and affinity. Let's break down the comparison:
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (360.328) is slightly higher than Ligand B (335.407), but this isn't a major concern.
2. **TPSA:** Both ligands are below the 140 A^2 threshold for good oral absorption (A: 72.83, B: 73.2). This is good.
3. **logP:** Both ligands have excellent logP values (A: 2.966, B: 2.244) falling within the optimal 1-3 range.
4. **H-Bond Donors/Acceptors:** Both have acceptable HBD counts (1). Ligand B has fewer HBAs (3 vs 5 for A), which is slightly favorable for permeability.
5. **QED:** Ligand B (0.861) has a better QED score than Ligand A (0.598), indicating a more drug-like profile.
6. **DILI:** Both have acceptable DILI risk (A: 52.966, B: 47.732), below the 60 threshold. Ligand B is slightly better.
7. **BBB:** Both ligands have good BBB penetration (A: 78.945, B: 78.519). This is positive, though not a primary concern for peripheral ADRB2.
8. **Caco-2 Permeability:** Both have negative Caco-2 values, indicating poor permeability. This is a concern for both.
9. **Aqueous Solubility:** Both have negative solubility values, indicating poor solubility. This is a concern for both.
10. **hERG Inhibition:** Both have low hERG risk (A: 0.686, B: 0.498). Ligand B is slightly better.
11. **Microsomal Clearance:** Ligand B (18.796) has significantly lower microsomal clearance than Ligand A (73.146), suggesting better metabolic stability. This is a significant advantage.
12. **In vitro Half-Life:** Ligand B (3.829 hours) has a longer half-life than Ligand A (-8.352 hours). This is a substantial advantage.
13. **P-gp Efflux:** Both have low P-gp efflux liability (A: 0.567, B: 0.107). Ligand B is significantly better.
14. **Binding Affinity:** Both ligands have similar strong binding affinities (A: -6.3 kcal/mol, B: -6.0 kcal/mol). The difference is less than 0.5 kcal/mol, so it's not decisive.
**Overall Assessment:**
Ligand B consistently outperforms Ligand A in several key ADME properties (QED, DILI, Cl_mic, t1/2, Pgp) and has comparable binding affinity. The lower clearance and longer half-life of Ligand B are particularly attractive, as is the lower P-gp efflux. While both have issues with Caco-2 and solubility, these can be addressed with formulation strategies. Given the GPCR target class, the improved ADME profile of Ligand B makes it the more promising drug candidate.
**Output:**
0
2025-04-17 23:14:30,933 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Ligand A (353.813 Da) is within the ideal range. Ligand B (369.443 Da) is also acceptable. No clear advantage here.
2. **TPSA:** Ligand A (62.53) is excellent, well below the 140 threshold for oral absorption and suitable for a GPCR. Ligand B (108.83) is higher, but still within a reasonable range, though less optimal.
3. **logP:** Ligand A (3.704) is at the upper end of the optimal range, but acceptable. Ligand B (0.604) is quite low, potentially hindering membrane permeability. This is a significant drawback for a GPCR ligand.
4. **HBD:** Ligand A (1) is good. Ligand B (2) is also acceptable.
5. **HBA:** Ligand A (4) is good. Ligand B (7) is higher, potentially impacting permeability.
6. **QED:** Both Ligand A (0.764) and Ligand B (0.617) have acceptable drug-likeness scores.
7. **DILI:** Ligand A (90.733) has a high DILI risk, which is concerning. Ligand B (44.048) has a much lower, and acceptable, DILI risk.
8. **BBB:** Ligand A (84.064) has good BBB penetration. Ligand B (28.655) has poor BBB penetration. While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant, and this favors A.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests a potential issue with the data or the model. However, the values are similar.
10. **Solubility:** Ligand A (-5.6) has very poor solubility. Ligand B (-2.333) is also poor, but better than A.
11. **hERG:** Ligand A (0.474) has a low hERG risk, which is excellent. Ligand B (0.179) also has a low hERG risk.
12. **Cl_mic:** Ligand A (91.16) has a high microsomal clearance, indicating poor metabolic stability. Ligand B (15.669) has much lower clearance and better metabolic stability.
13. **t1/2:** Ligand A (31.241) has a reasonable half-life. Ligand B (-34.506) has a negative half-life, which is impossible and indicates a data issue.
14. **Pgp:** Ligand A (0.498) has low P-gp efflux, which is favorable. Ligand B (0.076) also has low P-gp efflux.
15. **Affinity:** Ligand A (-7.7 kcal/mol) has significantly better binding affinity than Ligand B (-4.8 kcal/mol). This is a substantial advantage.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are crucial. Ligand A excels in affinity and TPSA, and has acceptable logP and Pgp. Ligand B has a very poor logP and a questionable half-life. While Ligand A has a high DILI risk and poor solubility, the significantly better affinity and TPSA, combined with acceptable Pgp, make it the more promising candidate. The DILI risk could potentially be mitigated through structural modifications.
**Conclusion:**
Despite the DILI and solubility concerns, the superior binding affinity and TPSA of Ligand A, along with its better BBB penetration, outweigh the drawbacks compared to Ligand B, which has a poor logP and an impossible half-life.
Output:
1
2025-04-17 23:14:30,933 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.431 Da) are within the ideal range (200-500 Da).
2. **TPSA:** Ligand A (104.46) is slightly higher than Ligand B (91.23). Both are below the 140 threshold for oral absorption, but B is better.
3. **logP:** Ligand A (1.155) is within the optimal range (1-3), as is Ligand B (0.528). B is slightly lower, which *could* indicate permeability issues, but is still acceptable.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (2), but both are within the acceptable limit of 5.
5. **HBA:** Both ligands (5) are within the acceptable limit of 10.
6. **QED:** Ligand A (0.685) is slightly better than Ligand B (0.572), indicating a more drug-like profile.
7. **DILI:** Ligand B (22.257) has a significantly lower DILI risk than Ligand A (34.238). This is a major advantage for B.
8. **BBB:** Ligand A (58.821) has a better BBB penetration percentile than Ligand B (39.318). While ADRB2 isn't necessarily a CNS target, some peripheral ADRB2 activity can influence CNS pathways, so moderate BBB penetration isn't detrimental.
9. **Caco-2:** Ligand A (-5.157) has a worse Caco-2 permeability than Ligand B (-4.593). Higher values are better, so B is preferable.
10. **Solubility:** Ligand A (-2.075) has slightly worse solubility than Ligand B (-1.271).
11. **hERG:** Ligand B (0.371) has a lower hERG inhibition liability than Ligand A (0.044), which is a significant safety advantage.
12. **Cl_mic:** Ligand B (1.87) has a much lower microsomal clearance than Ligand A (41.904), indicating better metabolic stability. This is a major advantage for B.
13. **t1/2:** Ligand B (-9.696) has a better in vitro half-life than Ligand A (-22.882).
14. **Pgp:** Ligand A (0.052) has a lower Pgp efflux liability than Ligand B (0.071).
15. **Binding Affinity:** Ligand A (-8.0) has a slightly better binding affinity than Ligand B (-7.0). This is a 1 kcal/mol difference, which is notable but not overwhelming given the other factors.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand B is better on logP, TPSA, and Pgp. Affinity is slightly better for A, but the ADME profile of B is significantly superior.
**Overall Assessment:**
Ligand B demonstrates a much more favorable ADME-Tox profile, with significantly lower DILI risk, better metabolic stability (lower Cl_mic, better t1/2), better Caco-2 permeability, and lower hERG inhibition. While Ligand A has a slightly better binding affinity, the improvements in safety and pharmacokinetic properties offered by Ligand B outweigh this difference.
Output:
0
2025-04-17 23:14:30,933 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [358.383, 125.79 , 0.903, 3. , 8. , 0.636, 98.061, 26.638, -5.428, -3.599, 0.107, -28.833, 1.278, 0.043, -7.7 ]
**Ligand B:** [353.423, 125.42 , 1.284, 2. , 5. , 0.28 , 25.514, 48.003, -5.444, -0.566, 0.234, -6.201, 13.063, 0.012, -6.9 ]
Here's a breakdown, property by property, with emphasis on GPCR priorities (logP, Pgp, TPSA, and affinity):
1. **MW:** Both are within the ideal 200-500 Da range. A (358.383) and B (353.423) are very similar.
2. **TPSA:** Both are around 125, slightly above the optimal <140 for oral absorption, but acceptable.
3. **logP:** A (0.903) is a bit low, potentially impacting permeability. B (1.284) is better, falling within the 1-3 optimal range.
4. **HBD:** A (3) is reasonable. B (2) is even better, minimizing potential for off-target interactions.
5. **HBA:** A (8) is acceptable. B (5) is preferable.
6. **QED:** A (0.636) is good, indicating drug-likeness. B (0.28) is quite poor, raising concerns about developability.
7. **DILI:** A (98.061) is *very* high risk, a major red flag. B (25.514) is excellent, indicating low liver injury potential.
8. **BBB:** A (26.638) is low, suggesting poor CNS penetration. B (48.003) is better, but still not high. For a cardiovascular target, BBB isn't critical, but it's a bonus.
9. **Caco-2:** Both are negative, indicating poor permeability.
10. **Solubility:** Both are negative, indicating poor solubility.
11. **hERG:** A (0.107) is very low risk, excellent. B (0.234) is also low risk, good.
12. **Cl_mic:** A (-28.833) is excellent, indicating high metabolic stability. B (-6.201) is also good, but not as good as A.
13. **t1/2:** A (1.278) is very short, potentially requiring frequent dosing. B (13.063) is much better, indicating a longer half-life.
14. **Pgp:** A (0.043) is very low efflux, favorable. B (0.012) is even lower, even more favorable.
15. **Affinity:** A (-7.7) is slightly better than B (-6.9), a difference of 0.8 kcal/mol.
**Overall Assessment:**
Ligand A has a better affinity and metabolic stability, and a very low hERG risk. However, its extremely high DILI risk is a deal-breaker. The poor QED score is also concerning. Ligand B has a better logP, lower HBD/HBA, significantly lower DILI risk, and a much longer half-life. While its affinity is slightly lower, the difference isn't large enough to overcome the significant safety and pharmacokinetic advantages of Ligand B.
Therefore, I prefer Ligand B.
0
2025-04-17 23:14:30,933 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's break down the comparison of Ligand A and Ligand B based on the provided parameters and the GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key).
1. **Molecular Weight:** Both ligands (388.291 and 366.527 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (64.63) is better than Ligand B (67.34), both are acceptable for a non-CNS GPCR target like ADRB2.
3. **logP:** Ligand A (3.783) is slightly higher than Ligand B (2.98). Both are within the optimal 1-3 range, but Ligand A is nearing the upper limit.
4. **H-Bond Donors:** Ligand A (1) is better than Ligand B (0). Lower is generally preferred.
5. **H-Bond Acceptors:** Both ligands have 4 HBA, which is acceptable.
6. **QED:** Both ligands have similar QED scores (0.754 vs 0.744), indicating good drug-likeness.
7. **DILI:** Ligand B (31.718) has a significantly lower DILI risk than Ligand A (51.687). This is a substantial advantage for Ligand B.
8. **BBB:** Ligand B (87.67) has a higher BBB penetration score than Ligand A (64.366). While ADRB2 isn't a primary CNS target, some peripheral exposure is possible, and higher BBB is generally not detrimental.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.313) is slightly worse than Ligand B (-4.741).
10. **Solubility:** Ligand B (-2.739) has better solubility than Ligand A (-4.858).
11. **hERG:** Ligand A (0.253) has a slightly lower hERG risk than Ligand B (0.476).
12. **Cl_mic:** Ligand B (63.122) has a lower microsomal clearance than Ligand A (96.681), indicating better metabolic stability.
13. **t1/2:** Ligand B (-2.383) has a longer in vitro half-life than Ligand A (8.974).
14. **Pgp:** Ligand A (0.109) has lower P-gp efflux than Ligand B (0.533), which is favorable.
15. **Binding Affinity:** Ligand B (-5.1 kcal/mol) has a slightly better binding affinity than Ligand A (-6.2 kcal/mol). While A is better, the difference is not substantial enough to outweigh other factors.
**Overall Assessment:**
Ligand B demonstrates a superior balance of properties, particularly regarding safety (DILI), metabolic stability (Cl_mic, t1/2), solubility, and permeability. While Ligand A has slightly better Pgp and affinity, the advantages of Ligand B in crucial ADME-Tox parameters are more compelling for a viable drug candidate. The lower DILI risk and improved metabolic stability are significant benefits.
**Output:**
0
2025-04-17 23:14:30,933 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (361.829 Da) is within the ideal range (200-500 Da). Ligand B (399.647 Da) is also acceptable. No clear advantage here.
2. **TPSA:** Ligand A (71.53) is good, below the 140 threshold. Ligand B (29.54) is excellent, well below 140. Ligand B has a clear advantage here, suggesting better permeability.
3. **logP:** Ligand A (3.233) is within the optimal range (1-3). Ligand B (4.652) is slightly above, potentially leading to solubility issues and off-target effects. Ligand A is preferred.
4. **HBD:** Ligand A (1) is good. Ligand B (0) is also good. No significant difference.
5. **HBA:** Ligand A (4) is good. Ligand B (5) is acceptable. No significant difference.
6. **QED:** Ligand A (0.857) is excellent, indicating high drug-likeness. Ligand B (0.604) is still acceptable, but lower. Ligand A is preferred.
7. **DILI:** Ligand A (77.588) is moderate risk. Ligand B (21.908) is low risk. Ligand B is significantly preferred.
8. **BBB:** Ligand A (53.276) is moderate. Ligand B (84.374) is high. Given ADRB2 is a GPCR, BBB penetration is a consideration, and Ligand B is preferred.
9. **Caco-2:** Ligand A (-4.572) is poor. Ligand B (-5.116) is also poor. Both are likely to have absorption issues, but they are both negative values, indicating low permeability.
10. **Solubility:** Ligand A (-3.97) is poor. Ligand B (-4.384) is also poor. Both have solubility concerns.
11. **hERG:** Ligand A (0.34) is low risk. Ligand B (0.7) is slightly higher risk. Ligand A is preferred.
12. **Cl_mic:** Ligand A (78.046) is moderate clearance. Ligand B (109.837) is high clearance. Ligand A is preferred for better metabolic stability.
13. **t1/2:** Ligand A (38.959) is moderate. Ligand B (2.488) is very short. Ligand A is significantly preferred.
14. **Pgp:** Ligand A (0.086) is low efflux. Ligand B (0.633) is moderate efflux. Ligand A is preferred.
15. **Affinity:** Ligand A (-7.4) is very strong. Ligand B (-6.2) is strong, but less so. Ligand A has a 1.2 kcal/mol advantage, which is substantial.
**Overall Assessment:**
Ligand A has a significant advantage in binding affinity, QED, metabolic stability (Cl_mic, t1/2), Pgp efflux, and hERG risk. While Ligand B has a better TPSA and lower DILI risk and better BBB penetration, the superior affinity and drug-like properties of Ligand A, coupled with its better safety profile (hERG, DILI) and metabolic stability, outweigh these benefits. The poor Caco-2 and solubility for both are concerning, but can be addressed with formulation strategies. The strong binding affinity of Ligand A is a key driver for its selection.
Output:
1
2025-04-17 23:14:30,933 - INFO - Batch 390 complete. Total preferences: 6240
2025-04-17 23:14:30,933 - INFO - Processing batch 391/512...
2025-04-17 23:15:14,664 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (336.351 and 348.462 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (88.18) is better than Ligand B (49.41). For a GPCR, lower TPSA is generally preferred as it aids membrane permeability. Ligand B is excellent.
**3. logP:** Both ligands have good logP values (2.229 and 2.692), falling within the optimal 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability, but not dramatically so.
**4. H-Bond Donors:** Both ligands have 1 HBD, which is within the acceptable limit of 5.
**5. H-Bond Acceptors:** Ligand A has 5 HBA, and Ligand B has 2. Both are within the acceptable limit of 10. Ligand B is preferable.
**6. QED:** Both ligands have good QED scores (0.741 and 0.794), indicating good drug-like properties. Ligand B is slightly better.
**7. DILI:** Ligand A has a very high DILI risk (98.604 percentile), which is a major concern. Ligand B has a very low DILI risk (14.889 percentile), making it significantly safer.
**8. BBB:** Ligand A (67.197) and Ligand B (91.896) both have acceptable BBB penetration. Ligand B is better.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.96 and -4.763). This is unusual and suggests poor permeability.
**10. Aqueous Solubility:** Both ligands have negative solubility values (-4.583 and -2.989). This is also unusual and suggests poor solubility.
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (0.422 and 0.465).
**12. Microsomal Clearance:** Ligand A (70.192) has a higher microsomal clearance than Ligand B (2.678), indicating lower metabolic stability. Ligand B is much better.
**13. In vitro Half-Life:** Ligand A (-6.513) has a shorter half-life than Ligand B (-0.687). Ligand B is better.
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (0.166 and 0.163).
**15. Binding Affinity:** Ligand A (-7.1 kcal/mol) has a significantly stronger binding affinity than Ligand B (-0.4 kcal/mol). This is a substantial advantage.
**Overall Assessment:**
While Ligand A has a much better binding affinity, the extremely high DILI risk is a deal-breaker. The poor solubility and permeability are also concerning. Ligand B, despite the lower affinity, presents a much more favorable safety profile (low DILI), better metabolic stability (lower Cl_mic, longer t1/2), and better BBB penetration. For a GPCR target, balancing these ADME properties with reasonable affinity is crucial. The difference in affinity, while substantial, might be overcome with further optimization of Ligand B.
Therefore, I would choose Ligand B.
0
2025-04-17 23:15:14,664 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (354.263 Da and 362.392 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (79.52) is slightly higher than Ligand B (69.64). Both are below the 140 A^2 threshold for good oral absorption, but closer to the 90 A^2 threshold for CNS targets (less relevant for ADRB2, a cardiovascular target). Ligand B is preferable.
3. **logP:** Ligand A (2.632) and Ligand B (1.701) are both within the optimal 1-3 range. Ligand A is slightly better.
4. **HBD:** Both ligands have 2 H-bond donors, which is acceptable.
5. **HBA:** Ligand A has 5 H-bond acceptors, and Ligand B has 3. Both are within the acceptable limit of 10. Ligand B is preferable.
6. **QED:** Both ligands have good QED scores (0.709 and 0.782), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A has a DILI risk of 93.059, which is quite high. Ligand B has a much lower DILI risk of 12.33, which is a significant advantage.
8. **BBB:** Ligand A (58.55) and Ligand B (74.254) both have low BBB penetration. This is not a primary concern for a cardiovascular target like ADRB2. Ligand B is preferable.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.874 and -4.824), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Both ligands have negative solubility values (-3.656 and -2.622), indicating very poor aqueous solubility. This is a major drawback for both.
11. **hERG:** Ligand A (0.722) has a slightly higher hERG inhibition liability than Ligand B (0.417). Ligand B is preferable.
12. **Cl_mic:** Ligand A (35.575) has a better (lower) microsomal clearance than Ligand B (7.515), suggesting better metabolic stability.
13. **t1/2:** Ligand A (35.22) has a much longer in vitro half-life than Ligand B (-18.889). This is a significant advantage.
14. **Pgp:** Ligand A (0.198) has lower P-gp efflux liability than Ligand B (0.088), which is preferable.
15. **Binding Affinity:** Ligand B (-7.6 kcal/mol) has a slightly better binding affinity than Ligand A (-7.2 kcal/mol). This is a 1.5 kcal/mol advantage, which is significant.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), and the general drug-like properties, Ligand B appears to be the better candidate. The most significant factor is the dramatically lower DILI risk associated with Ligand B. While both ligands have issues with solubility and Caco-2 permeability, the lower DILI risk outweighs the slightly better metabolic stability and half-life of Ligand A. The slightly better affinity of Ligand B also contributes to its preference.
Output:
0
2025-04-17 23:15:14,665 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (348.451 Da) is well within the ideal range. Ligand B (412.372 Da) is at the higher end but still acceptable.
2. **TPSA:** Ligand A (110.2) is slightly above the optimal <140 for oral absorption, but still reasonable. Ligand B (58.36) is excellent, well below 90, suggesting good permeability.
3. **logP:** Ligand A (1.428) is optimal. Ligand B (3.171) is also good, towards the upper end of the optimal range.
4. **HBD:** Ligand A (2) is good. Ligand B (1) is excellent.
5. **HBA:** Both Ligand A (4) and Ligand B (4) are within the acceptable range.
6. **QED:** Ligand B (0.731) is significantly better than Ligand A (0.412), indicating a more drug-like profile.
7. **DILI:** Ligand A (15.355) has a slightly higher DILI risk than Ligand B (13.377), but both are well below the concerning threshold of 60.
8. **BBB:** Ligand B (75.533) has a considerably higher BBB penetration potential than Ligand A (59.131). While ADRB2 isn't strictly a CNS target, some peripheral ADRB2 receptors can influence CNS activity, and better BBB penetration isn't necessarily a negative.
9. **Caco-2:** Ligand A (-5.51) is poor, indicating low intestinal absorption. Ligand B (-4.745) is also poor, but slightly better than A.
10. **Solubility:** Ligand A (-1.617) is poor. Ligand B (-3.89) is even worse. Both have solubility concerns.
11. **hERG:** Both Ligand A (0.259) and Ligand B (0.566) have low hERG inhibition liability, which is good.
12. **Cl_mic:** Ligand A (5.852) has significantly lower microsomal clearance, suggesting better metabolic stability than Ligand B (57.787).
13. **t1/2:** Ligand B (22.27) has a longer in vitro half-life than Ligand A (16.134), which is desirable.
14. **Pgp:** Ligand A (0.008) has very low P-gp efflux, which is excellent. Ligand B (0.383) is also low, but higher than A.
15. **Affinity:** Ligand B (-6.5 kcal/mol) has a slightly better binding affinity than Ligand A (-6.0 kcal/mol), but the difference is not huge.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Ligand B excels in TPSA and BBB penetration, has a slightly better logP and affinity, and comparable Pgp efflux. Ligand A has a better Cl_mic, but the difference isn't substantial enough to outweigh the other advantages of Ligand B. Solubility and Caco-2 are poor for both, which would need to be addressed in formulation.
**Conclusion:**
Despite the solubility and Caco-2 concerns for both, Ligand B presents a more balanced profile, particularly regarding its drug-likeness (QED), BBB penetration, and slightly improved affinity. The better metabolic stability of Ligand A is a plus, but the other advantages of Ligand B are more critical for a GPCR target.
Output:
0
2025-04-17 23:15:14,665 - INFO - Here's my reasoning and final output for the ligand preference:
**Reasoning:**
We are looking for a ligand targeting ADRB2, a cardiovascular GPCR. Therefore, the key properties to prioritize are logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB (though less critical for a cardiovascular target than a CNS one).
Let's compare Ligand A and Ligand B across these parameters and the general drug-likeness criteria:
* **Molecular Weight:** Both ligands (352.395 and 344.459 Da) are within the ideal 200-500 Da range.
* **TPSA:** Ligand B (68.3) is significantly better than Ligand A (124.6). Lower TPSA generally favors oral absorption and GPCR penetration.
* **logP:** Ligand B (3.224) is optimal, while Ligand A (-0.585) is quite low, potentially hindering membrane permeability. This is a major drawback for Ligand A.
* **H-Bond Donors/Acceptors:** Both are reasonable (2 HBD, 7/6 HBA), falling within acceptable limits.
* **QED:** Both ligands have good QED scores (0.73 and 0.766), indicating good overall drug-likeness.
* **DILI:** Ligand A (45.173) has a lower DILI risk than Ligand B (69.329), which is a positive.
* **BBB:** Ligand B (86.274) shows better BBB penetration than Ligand A (77.86), but this is less critical for a cardiovascular target.
* **Caco-2 Permeability:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not defined, so the absolute values are hard to interpret.
* **Aqueous Solubility:** Both have negative solubility values, which is also unusual.
* **hERG:** Ligand A (0.042) has a much lower hERG risk than Ligand B (0.923). This is a significant advantage for Ligand A.
* **Microsomal Clearance:** Ligand B (73.998) has higher clearance than Ligand A (-33.576), indicating lower metabolic stability.
* **In vitro Half-Life:** Ligand B (68.822) has a longer half-life than Ligand A (31.247).
* **P-gp Efflux:** Ligand A (0.006) has much lower P-gp efflux liability than Ligand B (0.28), which is favorable.
* **Binding Affinity:** Ligand B (-7.0) has a slightly better binding affinity than Ligand A (-6.9). While the difference is small, it's still a factor.
**Overall Assessment:**
Despite Ligand B having a slightly better binding affinity and half-life, Ligand A is the more promising candidate. The significantly lower logP of Ligand A is a major concern for permeability. Ligand A has better P-gp efflux, lower DILI risk, and a lower hERG risk, all crucial for a safe and effective drug. The negative solubility and Caco-2 values are concerning for both, but the other factors outweigh this.
**Output:**
1
2025-04-17 23:15:14,665 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (393.148 Da) is slightly higher than Ligand B (360.527 Da), but both are acceptable.
2. **TPSA:** Both ligands are below the 140 A^2 threshold for good oral absorption. Ligand A (68.29 A^2) is slightly higher than Ligand B (61.28 A^2), but both are good.
3. **logP:** Both ligands have logP values within the optimal range (1-3). Ligand A (4.446) is a bit high, potentially leading to solubility issues or off-target interactions, while Ligand B (3.894) is better.
4. **HBD:** Ligand A (1) and Ligand B (2) are both within the acceptable limit of <=5.
5. **HBA:** Ligand A (4) and Ligand B (6) are both within the acceptable limit of <=10.
6. **QED:** Ligand A (0.783) has a better QED score than Ligand B (0.497), indicating a more drug-like profile.
7. **DILI:** Ligand A (90.461) has a significantly higher DILI risk than Ligand B (68.709). This is a major concern for Ligand A.
8. **BBB:** Both ligands have reasonable BBB penetration, but Ligand A (68.67) is slightly better than Ligand B (60.45). However, for a cardiovascular target like ADRB2, BBB penetration is not a primary concern.
9. **Caco-2:** Ligand A (-4.536) has a worse Caco-2 permeability than Ligand B (-5.128), indicating lower intestinal absorption.
10. **Solubility:** Ligand A (-5.706) has worse aqueous solubility than Ligand B (-3.573), which is consistent with its higher logP.
11. **hERG:** Ligand A (0.499) has a lower hERG inhibition liability than Ligand B (0.9), which is a positive attribute.
12. **Cl_mic:** Ligand B (92.647) has a higher microsomal clearance than Ligand A (77.857), suggesting lower metabolic stability.
13. **t1/2:** Ligand B (108.878) has a significantly longer in vitro half-life than Ligand A (46.206), which is a major advantage.
14. **Pgp:** Both ligands have similar Pgp efflux liability (0.445 and 0.643 respectively).
15. **Binding Affinity:** Ligand B (-6.6 kcal/mol) has a slightly better binding affinity than Ligand A (-6.0 kcal/mol). While the difference is not huge, it's a positive for Ligand B.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B is better on logP, and has comparable TPSA and Pgp. The affinity difference is small, but favors Ligand B. The biggest drawback of Ligand A is its high DILI risk.
**Overall Assessment:**
Ligand B is the more promising candidate. While Ligand A has a better QED and slightly better BBB penetration, the significantly higher DILI risk, lower solubility, and shorter half-life outweigh these benefits. Ligand B's better binding affinity, lower DILI risk, and longer half-life make it a more viable starting point for drug development.
Output:
0
2025-04-17 23:15:14,665 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
We are targeting ADRB2, a GPCR. Therefore, the key properties to prioritize are binding affinity, logP, TPSA, Pgp efflux, and BBB penetration. Metabolic stability (Cl_mic, t1/2) and safety (DILI, hERG) are also important.
Let's compare the ligands property by property:
1. **MW:** Both ligands (356.5 and 350.5 Da) fall within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (67.87) is slightly higher than Ligand B (58.44). Both are acceptable for oral absorption, but B is better.
3. **logP:** Ligand A (2.075) is within the optimal 1-3 range. Ligand B (3.067) is at the higher end, but still acceptable.
4. **HBD:** Ligand A (1) is preferable to Ligand B (0) as a single HBD can aid solubility without significantly impacting permeability.
5. **HBA:** Both ligands have 4 HBA, which is good.
6. **QED:** Both ligands have similar QED scores (0.651 and 0.688), indicating good drug-likeness.
7. **DILI:** Ligand A (12.796) has a significantly lower DILI risk than Ligand B (25.785), which is a major advantage.
8. **BBB:** Both ligands have good BBB penetration (76.541 and 79.992), but Ligand B is slightly better.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability.
10. **Solubility:** Both have negative solubility values, indicating poor solubility.
11. **hERG:** Ligand A (0.457) has a lower hERG risk than Ligand B (0.813), which is a positive.
12. **Cl_mic:** Ligand A (19.811) has a lower microsomal clearance than Ligand B (76.056), suggesting better metabolic stability.
13. **t1/2:** Ligand B (7.303) has a longer in vitro half-life than Ligand A (4.615), which is desirable.
14. **Pgp:** Ligand A (0.044) has much lower P-gp efflux liability than Ligand B (0.435), which is a significant advantage for bioavailability and potential CNS exposure.
15. **Binding Affinity:** Ligand B (-4.2) has a slightly better binding affinity than Ligand A (-3.0), a difference of 1.2 kcal/mol.
**Overall Assessment:**
While Ligand B has a slightly better binding affinity and half-life, Ligand A demonstrates a superior safety profile (lower DILI and hERG) and better ADME properties (lower Cl_mic and Pgp efflux). The difference in binding affinity (1.2 kcal/mol) is not substantial enough to outweigh the advantages of Ligand A, especially considering the importance of ADME and safety for a viable drug candidate. The lower Pgp efflux for Ligand A is particularly important for a GPCR target.
**Output:**
1
2025-04-17 23:15:14,665 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (352.387) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (58.44) is significantly better than Ligand A (106.87). Lower TPSA is crucial for GPCRs, aiding in brain penetration and overall absorption.
3. **logP:** Both are within the optimal range (1-3), but Ligand B (2.006) is slightly higher, potentially improving membrane permeability.
4. **HBD:** Ligand A (2) is preferable to Ligand B (0) as having some HBD can improve solubility.
5. **HBA:** Ligand A (6) is slightly higher than Ligand B (5), but both are acceptable.
6. **QED:** Ligand B (0.741) has a slightly higher QED score than Ligand A (0.598), indicating a more drug-like profile.
7. **DILI:** Ligand B (11.981) has a much lower DILI risk than Ligand A (47.421). This is a significant advantage.
8. **BBB:** Ligand B (72.78) has a considerably higher BBB penetration percentile than Ligand A (43.311). Given ADRB2's relevance in cardiovascular function, some CNS penetration could be beneficial, and this is a key GPCR consideration.
9. **Caco-2:** Ligand A (-4.791) is better than Ligand B (-5.02).
10. **Solubility:** Ligand A (-2.736) is better than Ligand B (-1.423).
11. **hERG:** Ligand A (0.139) has a lower hERG inhibition liability than Ligand B (0.513), which is a positive.
12. **Cl_mic:** Both ligands have similar microsomal clearance values (Ligand A: 59.83, Ligand B: 57.215).
13. **t1/2:** Ligand A (31.376) has a longer in vitro half-life than Ligand B (-11.276). This is a significant advantage.
14. **Pgp:** Ligand A (0.023) has much lower P-gp efflux liability than Ligand B (0.071), which is favorable for bioavailability.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.3 and -6.4 kcal/mol). The difference is negligible.
**Overall Assessment:**
Ligand B excels in several crucial areas for a GPCR target like ADRB2: significantly lower DILI risk, much better BBB penetration, and a higher QED score. While Ligand A has advantages in solubility, half-life, and P-gp efflux, the lower DILI and better BBB of Ligand B are more critical for overall drug development potential, especially considering the potential for off-target effects with GPCRs. The slightly higher logP of Ligand B also contributes to better permeability.
Output:
0
2025-04-17 23:15:14,666 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
Let's break down the comparison, prioritizing GPCR-relevant properties (logP, TPSA, Pgp, BBB, and affinity).
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (397.276) is slightly higher than Ligand B (376.494), but both are acceptable.
2. **TPSA:** Both are below the 140 A^2 threshold for good oral absorption. Ligand A (80.04) and Ligand B (75.71) are both good, with B being slightly better.
3. **logP:** Ligand A (3.945) is at the upper end of the optimal range (1-3), while Ligand B (1.604) is towards the lower end. While higher logP can sometimes be problematic, for a GPCR, a slightly higher value can be beneficial for membrane interactions.
4. **H-Bond Donors/Acceptors:** Ligand A has 3 HBD and 4 HBA, while Ligand B has 1 HBD and 4 HBA. Both are within acceptable limits.
5. **QED:** Both ligands have similar QED values (0.612 and 0.663), indicating good drug-likeness.
6. **DILI Risk:** Ligand B (43.622) has a significantly lower DILI risk than Ligand A (82.823). This is a substantial advantage for Ligand B.
7. **BBB Penetration:** Both have good BBB penetration (Ligand A: 74.447, Ligand B: 85.615). Ligand B is better here, which is important for GPCRs.
8. **Caco-2 Permeability:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. This is a concern for both.
9. **Aqueous Solubility:** Both have negative solubility values, indicating poor solubility. This is a significant drawback for both.
10. **hERG Inhibition:** Ligand A (0.833) has a slightly higher hERG risk than Ligand B (0.653), but both are relatively low.
11. **Microsomal Clearance:** Ligand A (63.632) has a higher microsomal clearance than Ligand B (44.008), indicating lower metabolic stability.
12. **In vitro Half-Life:** Ligand B (-15.742) has a *very* negative half-life, which is a major red flag. Ligand A (83.272) is much better.
13. **P-gp Efflux:** Ligand A (0.718) has slightly lower P-gp efflux than Ligand B (0.173), which is favorable.
14. **Binding Affinity:** Ligand A (-9.4 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.1 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME drawbacks.
**Overall Assessment:**
Ligand A has a much better binding affinity and a reasonable half-life, while Ligand B has better DILI risk and BBB penetration. However, the extremely poor in vitro half-life of Ligand B is a critical issue. While the affinity of Ligand A is excellent, its higher DILI risk and clearance are concerns. However, given the substantial affinity difference, and the fact that the other parameters aren't drastically worse for A, I believe the higher binding affinity of Ligand A is the most important factor for a GPCR target. The poor solubility and permeability of both are significant, but these can potentially be addressed with formulation strategies.
Output:
1
2025-04-17 23:15:14,666 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (371.459 Da and 361.471 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (104.9) is slightly higher than Ligand B (92.94). Both are below the 140 threshold for oral absorption, but B is preferable given the GPCR target class.
3. **logP:** Ligand A (0.063) is quite low, potentially hindering membrane permeability. Ligand B (3.204) is within the optimal 1-3 range. This is a significant advantage for Ligand B.
4. **HBD:** Both ligands have 2 HBD, which is acceptable.
5. **HBA:** Both ligands have 7 HBA, which is acceptable.
6. **QED:** Both ligands have good QED scores (0.666 and 0.701), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (54.285) has a lower DILI risk than Ligand B (76.309). This favors Ligand A.
8. **BBB:** Ligand B (72.315) has a significantly higher BBB penetration percentile than Ligand A (22.606). Given that ADRB2 is a GPCR, BBB penetration is a desirable characteristic, and this strongly favors Ligand B.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.43 and -5.484), which is unusual and suggests poor permeability. However, the values are very similar.
10. **Solubility:** Ligand A (-2.04) has better solubility than Ligand B (-3.688).
11. **hERG:** Ligand A (0.085) has a much lower hERG inhibition liability than Ligand B (0.374). This is a critical safety parameter, favoring Ligand A.
12. **Cl_mic:** Ligand B (78.006) has a much higher microsomal clearance than Ligand A (16.268), indicating faster metabolism and potentially lower *in vivo* exposure. This favors Ligand A.
13. **t1/2:** Ligand B (31.21) has a significantly longer *in vitro* half-life than Ligand A (-0.828). This is a strong advantage for Ligand B.
14. **Pgp:** Ligand A (0.02) has lower P-gp efflux liability than Ligand B (0.332), which is favorable for oral bioavailability and CNS exposure.
15. **Binding Affinity:** Ligand B (-7.7 kcal/mol) has a substantially stronger binding affinity than Ligand A (-6.3 kcal/mol). This is a major advantage for Ligand B, potentially outweighing some of the ADME drawbacks.
**Overall Assessment:**
Ligand B demonstrates a superior binding affinity and better BBB penetration, which are crucial for a GPCR target like ADRB2. While Ligand A has advantages in DILI, hERG, and metabolic stability, the significantly stronger binding and BBB penetration of Ligand B are more important for efficacy. The longer half-life of Ligand B is also a positive attribute. The lower logP of Ligand A is a significant concern.
Output:
0
2025-04-17 23:15:14,666 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (363.527 Da) is slightly lower, which is generally favorable for permeability.
**2. TPSA:** Ligand A (63.13) is significantly better than Ligand B (91.4). For a GPCR, keeping TPSA low is beneficial for permeability and receptor engagement. Ligand B is pushing the upper limit for good oral absorption.
**3. logP:** Ligand A (2.634) is within the optimal range (1-3), while Ligand B (0.596) is below 1. This is a significant drawback for Ligand B, as it may struggle with membrane permeability and bioavailability.
**4. H-Bond Donors:** Both ligands have 2 HBD, which is acceptable.
**5. H-Bond Acceptors:** Ligand A has 4 HBA, while Ligand B has 6. Both are within the acceptable range, but Ligand A is slightly better.
**6. QED:** Ligand A (0.817) has a substantially better QED score than Ligand B (0.575), indicating a more drug-like profile.
**7. DILI:** Ligand B (35.052) has a lower DILI risk than Ligand A (47.887), which is a positive for Ligand B.
**8. BBB:** Both ligands have reasonable BBB penetration (Ligand A: 55.021, Ligand B: 52.268). Since ADRB2 isn't strictly a CNS target, this isn't a major differentiating factor.
**9. Caco-2 Permeability:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
**10. Aqueous Solubility:** Both have negative solubility values, which is also unusual. Again, the scale is unspecified.
**11. hERG Inhibition:** Both ligands show low hERG inhibition risk (Ligand A: 0.239, Ligand B: 0.37), which is good.
**12. Microsomal Clearance:** Ligand B (3.619) has significantly lower microsomal clearance than Ligand A (37.589), indicating better metabolic stability.
**13. In vitro Half-Life:** Ligand A (12.611) has a longer in vitro half-life than Ligand B (-19.725). The negative value for Ligand B is concerning and suggests rapid degradation.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (Ligand A: 0.171, Ligand B: 0.023).
**15. Binding Affinity:** Ligand B (-6.9 kcal/mol) has a slightly better binding affinity than Ligand A (-5.5 kcal/mol). This is a 1.4 kcal/mol difference, which is significant.
**Overall Assessment:**
While Ligand B has a better binding affinity and lower DILI risk and microsomal clearance, its significantly lower logP and QED scores are major concerns. The low logP suggests poor membrane permeability and bioavailability. Ligand A, despite a slightly weaker affinity, has a much more favorable overall profile with a better logP, TPSA, and QED, suggesting it's more likely to be a viable drug candidate. The negative half-life for Ligand B is a red flag.
Output:
1
2025-04-17 23:15:14,666 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (337.47 & 347.51 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (45.23) is better than Ligand B (53.4). ADRB2 is not a CNS target, but lower TPSA generally aids absorption.
3. **logP:** Ligand A (3.702) is slightly higher than Ligand B (2.2). Both are within the optimal 1-3 range, but A is closer to the upper limit.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A (3) is better than Ligand B (5). Lower HBA is generally preferred for better permeability.
6. **QED:** Both ligands have good QED scores (0.747 and 0.887), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (32.803) has a significantly lower DILI risk than Ligand B (14.308). This is a major advantage for Ligand A.
8. **BBB:** Not a primary concern for ADRB2, but Ligand A (76.231) has a higher BBB penetration than Ligand B (68.282).
9. **Caco-2:** Ligand A (-4.727) is better than Ligand B (-5.108). Higher values indicate better intestinal absorption.
10. **Solubility:** Ligand A (-4.143) is better than Ligand B (-1.561). Better solubility is crucial for bioavailability.
11. **hERG:** Ligand A (0.82) has a slightly higher hERG risk than Ligand B (0.524), but both are relatively low.
12. **Cl_mic:** Ligand B (32.57) has significantly lower microsomal clearance than Ligand A (76.589), indicating better metabolic stability.
13. **t1/2:** Ligand A (45.117) has a longer in vitro half-life than Ligand B (28.747).
14. **Pgp:** Ligand A (0.527) has a lower P-gp efflux liability than Ligand B (0.02). Lower efflux is preferred.
15. **Binding Affinity:** Ligand A (-6.7 kcal/mol) has a slightly better binding affinity than Ligand B (-5.6 kcal/mol). This is a 1.1 kcal/mol difference, which is significant.
**Overall Assessment:**
Ligand A has a clear advantage in several key areas: DILI risk, solubility, Caco-2 permeability, Pgp efflux, and binding affinity. While Ligand B has better metabolic stability (lower Cl_mic), the lower DILI risk and better binding affinity of Ligand A are more critical for a GPCR target like ADRB2. The slight increase in hERG risk for Ligand A is acceptable given its other benefits.
Output:
1
2025-04-17 23:15:14,666 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (451.308 Da) is within the ideal range. Ligand B (353.463 Da) is also within the ideal range, but closer to the lower bound.
2. **TPSA:** Ligand A (54.46) is good for oral absorption. Ligand B (94.81) is higher, potentially impacting absorption, but still within a reasonable range.
3. **logP:** Ligand A (3.748) is optimal. Ligand B (1.23) is on the lower side, which could affect permeability.
4. **HBD:** Both Ligand A (1) and Ligand B (3) are acceptable.
5. **HBA:** Both Ligand A (3) and Ligand B (5) are acceptable.
6. **QED:** Ligand A (0.721) is better than Ligand B (0.588), indicating a more drug-like profile.
7. **DILI:** Ligand A (44.164) has a slightly higher DILI risk than Ligand B (11.516), but both are considered good.
8. **BBB:** Ligand A (84.917) has a much better BBB penetration potential than Ligand B (25.514). While ADRB2 isn't strictly a CNS target, some distribution to the CNS can occur, and higher BBB is generally favorable.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-4.914) is slightly better than Ligand B (-5.415).
10. **Solubility:** Ligand A (-4.359) is slightly better than Ligand B (-0.681).
11. **hERG:** Both Ligand A (0.773) and Ligand B (0.438) have low hERG inhibition risk.
12. **Cl_mic:** Ligand A (68.839) has higher clearance than Ligand B (-9.536), indicating lower metabolic stability. This is a significant drawback for Ligand A.
13. **t1/2:** Ligand A (-5.586) has a negative half-life, which is concerning. Ligand B (17.661) has a reasonable half-life.
14. **Pgp:** Ligand A (0.446) has lower P-gp efflux liability than Ligand B (0.031), which is favorable.
15. **Affinity:** Both ligands have the same binding affinity (-6.6 kcal/mol).
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A has a better logP and Pgp profile, but Ligand B has a better TPSA, a significantly better metabolic stability (Cl_mic and t1/2), and a lower DILI risk. The similar binding affinity makes the ADME properties the deciding factors.
**Conclusion:**
Despite Ligand A's better logP and Pgp, Ligand B's significantly improved metabolic stability (lower Cl_mic, positive t1/2) and lower DILI risk outweigh these advantages. The TPSA is also more favorable for Ligand B. Therefore, Ligand B is the more promising drug candidate.
Output:
0
2025-04-17 23:15:14,666 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (355.523 and 352.425 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (72.88) is higher than Ligand B (42.43). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B is better.
3. **logP:** Ligand A (1.479) is within the optimal range (1-3). Ligand B (3.938) is at the upper end, potentially leading to solubility issues or off-target interactions. Ligand A is better.
4. **HBD:** Ligand A (2) and Ligand B (0) are both acceptable.
5. **HBA:** Ligand A (4) and Ligand B (3) are both acceptable.
6. **QED:** Both ligands have similar QED values (0.692 and 0.632), indicating good drug-likeness. No significant difference.
7. **DILI:** Ligand A (6.282) has a significantly lower DILI risk than Ligand B (15.975). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (94.067) has a much higher BBB penetration percentile than Ligand A (55.487). While ADRB2 isn't a CNS target, some peripheral exposure can be undesirable. However, this is less critical than other factors.
9. **Caco-2:** Ligand A (-4.811) and Ligand B (-3.763) are both negative, indicating poor permeability. This is a concern for both, but Ligand B is slightly better.
10. **Solubility:** Ligand A (-1.075) is better than Ligand B (-3.54). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.544) has a lower hERG inhibition liability than Ligand B (0.713). This is a significant safety advantage for Ligand A.
12. **Cl_mic:** Ligand A (-9.653) has a much lower (better) microsomal clearance than Ligand B (83.91). This suggests greater metabolic stability for Ligand A.
13. **t1/2:** Ligand A (-4.964) has a longer in vitro half-life than Ligand B (-2.234). This is a positive for Ligand A.
14. **Pgp:** Ligand A (0.028) has a significantly lower P-gp efflux liability than Ligand B (0.425). This is a major advantage for Ligand A, improving bioavailability.
15. **Binding Affinity:** Both ligands have similar binding affinities (-7.0 and -6.0 kcal/mol). The difference is not substantial enough to outweigh other factors.
**GPCR-Specific Priorities:**
For ADRB2 (a cardiovascular GPCR), logP, TPSA, Pgp efflux, and affinity are important. Ligand A has a better logP, significantly lower Pgp efflux, and comparable affinity. While Ligand B has better BBB penetration, this is less critical for a peripheral target like ADRB2. The lower DILI, hERG, and Cl_mic values for Ligand A are also very important.
**Conclusion:**
Ligand A demonstrates a superior balance of properties, particularly regarding safety (DILI, hERG) and pharmacokinetic parameters (Cl_mic, t1/2, Pgp). While Ligand B has a slightly better Caco-2 permeability and BBB penetration, the advantages of Ligand A are more impactful for a cardiovascular GPCR target.
Output:
1
2025-04-17 23:15:14,666 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (355.435 and 350.419 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (116.76 and 114.53) are below the 140 A^2 threshold for good oral absorption, but higher than the 90 A^2 for CNS targets. Since ADRB2 is a cardiovascular target, CNS penetration is not a primary concern.
3. **logP:** Ligand A (-0.546) is slightly lower than Ligand B (-0.264), both are below the optimal 1-3 range. Ligand B is preferable here, but both are borderline.
4. **HBD:** Both ligands have 4 HBD, which is acceptable (<=5).
5. **HBA:** Ligand A has 5 HBA, while Ligand B has 4. Both are within the acceptable range (<=10).
6. **QED:** Both ligands have good QED scores (0.414 and 0.459, respectively), indicating reasonable drug-likeness. Ligand B is slightly better.
7. **DILI:** Ligand A (17.449%) has a lower DILI risk than Ligand B (18.108%). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (53.548%) has significantly higher BBB penetration potential than Ligand B (21.171%). While not crucial for a cardiovascular target, higher BBB is generally favorable.
9. **Caco-2:** Both have negative Caco-2 values (-5.482 and -5.814), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Both ligands have very poor aqueous solubility (-1.253 and -1.219). This is a major drawback for both.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.056 and 0.041). This is excellent.
12. **Cl_mic:** Ligand A (13.467 mL/min/kg) has a higher microsomal clearance than Ligand B (-3.256 mL/min/kg). Ligand B is preferable here, indicating better metabolic stability.
13. **t1/2:** Ligand A (2.138 hours) has a shorter in vitro half-life than Ligand B (-3.394 hours). Ligand B is preferable.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.003 and 0.008). This is excellent.
15. **Binding Affinity:** Ligand A (-5.9 kcal/mol) has a slightly better binding affinity than Ligand B (-5.3 kcal/mol). This 0.6 kcal/mol difference is significant.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are important. Ligand B has a slightly better logP, but Ligand A has a significantly better binding affinity. Both have good Pgp and acceptable TPSA.
**Overall Assessment:**
Despite the poor solubility and Caco-2 permeability for both, Ligand A is preferable. The stronger binding affinity (-5.9 vs -5.3 kcal/mol) and lower DILI risk outweigh the slightly better metabolic stability of Ligand B. The higher BBB value for Ligand A is a bonus, even for a cardiovascular target.
Output:
1
2025-04-17 23:15:14,666 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (356.413) is slightly higher than Ligand B (347.379), but both are acceptable.
2. **TPSA:** Ligand A (81.59) is well below the 140 threshold for oral absorption and is good for a GPCR. Ligand B (129.03) is still under 140, but closer to the limit. This favors Ligand A.
3. **logP:** Ligand A (2.093) is optimal. Ligand B (0.129) is quite low, potentially hindering membrane permeability. This is a significant advantage for Ligand A.
4. **HBD:** Both have acceptable HBD counts (Ligand A: 4, Ligand B: 3), well under the 5 limit.
5. **HBA:** Ligand A (3) is preferable to Ligand B (7) as it is closer to the ideal of 10 or less.
6. **QED:** Both ligands have good QED scores (Ligand A: 0.547, Ligand B: 0.681), indicating good drug-like properties. Ligand B is slightly better here.
7. **DILI:** Ligand A (27.685) has a much lower DILI risk than Ligand B (71.268). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (72.896) has a good BBB penetration percentile, while Ligand B (18.147) is very low. Considering ADRB2's role in cardiovascular function, CNS penetration isn't *critical*, but it's a bonus.
9. **Caco-2:** Ligand A (-4.748) and Ligand B (-5.512) are both poor.
10. **Solubility:** Ligand A (-2.344) and Ligand B (-2.867) are both poor.
11. **hERG:** Both ligands have low hERG inhibition risk (Ligand A: 0.618, Ligand B: 0.064). Ligand B is slightly better.
12. **Cl_mic:** Ligand A (29.119) has a better (lower) microsomal clearance than Ligand B (-5.27). This indicates better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (-5.925) has a better (longer) in vitro half-life than Ligand B (-27.52).
14. **Pgp:** Ligand A (0.285) has a lower Pgp efflux liability than Ligand B (0.012). This is a positive for Ligand A.
15. **Binding Affinity:** Both ligands have very similar and strong binding affinities (Ligand A: -6.9 kcal/mol, Ligand B: -6.0 kcal/mol). Ligand A has a 0.9 kcal/mol advantage.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A excels in logP, TPSA, and Pgp, and has a slightly better affinity. While BBB isn't paramount for a cardiovascular target, Ligand A's higher value is a plus.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B in crucial ADME properties (logP, TPSA, DILI, Cl_mic, t1/2, Pgp) and has a slightly better binding affinity. Ligand B's only advantage is a slightly higher QED score, but this is outweighed by the significant benefits of Ligand A.
Output:
1
2025-04-17 23:15:14,667 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (369.45 & 360.38 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand B (69.64) is significantly better than Ligand A (109.58). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (1.724) is within the optimal 1-3 range, while Ligand A (-0.967) is slightly below 1. This is a significant advantage for Ligand B, as it's more likely to have good membrane permeability.
4. **HBD:** Both have 2 HBD, which is acceptable.
5. **HBA:** Ligand B (3) has fewer HBA than Ligand A (8), which is favorable for permeability.
6. **QED:** Ligand B (0.593) is slightly better than Ligand A (0.426), indicating a more drug-like profile.
7. **DILI:** Ligand B (32.03%) has a much lower DILI risk than Ligand A (50.80%). This is a major advantage.
8. **BBB:** Ligand B (70.997%) has better BBB penetration than Ligand A (29.546%). While not a primary concern for a cardiovascular target, it's a positive attribute.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and indicates poor permeability. However, Ligand B (-4.894) is slightly less negative than Ligand A (-5.63).
10. **Solubility:** Both have negative solubility values, indicating poor aqueous solubility. Ligand A (-1.047) is slightly better than Ligand B (-1.669).
11. **hERG:** Ligand B (0.419) has a lower hERG risk than Ligand A (0.04), which is a significant safety advantage.
12. **Cl_mic:** Ligand B (-1.409) has a much lower (better) microsomal clearance than Ligand A (17.919), indicating greater metabolic stability.
13. **t1/2:** Ligand B (-26.093) has a much longer in vitro half-life than Ligand A (-16.774), which is desirable.
14. **Pgp:** Ligand B (0.097) has lower P-gp efflux than Ligand A (0.037), which is favorable for bioavailability.
15. **Affinity:** Both ligands have very similar binding affinities (-6.8 and -6.4 kcal/mol). The difference is less than the 1.5 kcal/mol threshold where affinity alone would dictate the choice.
**Overall Assessment:**
Ligand B consistently outperforms Ligand A across most critical ADME-Tox properties. While both have poor Caco-2 and solubility, Ligand B's superior logP, lower DILI risk, better metabolic stability (Cl_mic & t1/2), lower hERG risk, and better Pgp profile make it a much more promising drug candidate. The slightly better BBB penetration is a bonus. The affinity difference is negligible.
Output:
0
2025-04-17 23:15:14,667 - INFO - Batch 391 complete. Total preferences: 6256
2025-04-17 23:15:14,667 - INFO - Processing batch 392/512...
2025-04-17 23:16:02,699 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (476.384 Da) is within the ideal range, while Ligand B (344.499 Da) is at the lower end but still acceptable.
2. **TPSA:** Ligand A (66.49) is slightly higher than ideal for optimal absorption, but still reasonable. Ligand B (41.57) is excellent.
3. **logP:** Both ligands (A: 3.538, B: 3.671) have good logP values, falling within the optimal range of 1-3.
4. **HBD:** Ligand A (2) and Ligand B (1) both have acceptable HBD counts.
5. **HBA:** Both ligands (A: 4, B: 4) have acceptable HBA counts.
6. **QED:** Both ligands have good QED scores (A: 0.512, B: 0.766), indicating good drug-like properties, with B being slightly better.
7. **DILI:** Ligand A (44.63) has a slightly higher DILI risk than Ligand B (29.624), but both are below the concerning threshold of 60.
8. **BBB:** Ligand A (70.88) and Ligand B (89.066) both have good BBB penetration, but Ligand B is significantly better. This is important for a GPCR target.
9. **Caco-2:** Ligand A (-5.031) and Ligand B (-4.535) are both negative, indicating poor permeability.
10. **Solubility:** Both ligands have poor solubility (-4.368 and -4.497 respectively).
11. **hERG:** Both ligands have low hERG inhibition risk (A: 0.754, B: 0.872).
12. **Cl_mic:** Ligand A (51.456) has a lower microsomal clearance than Ligand B (102.589), suggesting better metabolic stability.
13. **t1/2:** Ligand B (49.342) has a slightly longer in vitro half-life than Ligand A (44.906).
14. **Pgp:** Both ligands have low P-gp efflux liability (A: 0.588, B: 0.752).
15. **Binding Affinity:** Ligand B (-6.6 kcal/mol) has a slightly better binding affinity than Ligand A (-7.0 kcal/mol).
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are particularly important. Both ligands perform well on logP and Pgp. Ligand B has a better TPSA and a slightly better BBB score. While Ligand A has a slightly better binding affinity, the difference is not substantial enough to outweigh the other advantages of Ligand B.
**Overall Assessment:**
Ligand B presents a more favorable balance of properties, particularly regarding BBB penetration, TPSA, and DILI risk. While Ligand A has slightly better metabolic stability and binding affinity, the improvements in other crucial parameters make Ligand B the more promising candidate.
Output:
0
2025-04-17 23:16:02,699 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (346.471) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (69.64) is significantly better than Ligand B (78.43). For a GPCR, keeping TPSA low is beneficial for permeability and receptor engagement.
3. **logP:** Both ligands have acceptable logP values (Ligand A: 2.001, Ligand B: 0.918). Ligand A is better, falling squarely within the optimal 1-3 range. Ligand B is a bit low, potentially impacting membrane permeability.
4. **HBD:** Both have acceptable HBD counts (Ligand A: 2, Ligand B: 1).
5. **HBA:** Ligand A (3) is better than Ligand B (6). Lower HBA is generally preferred for better permeability.
6. **QED:** Both ligands have good QED scores (Ligand A: 0.765, Ligand B: 0.811), indicating drug-like properties.
7. **DILI:** Ligand A (14.541) has a significantly lower DILI risk than Ligand B (16.169), which is a major advantage.
8. **BBB:** Ligand B (67.08) has a better BBB penetration score than Ligand A (52.772). While ADRB2 isn't strictly a CNS target, some CNS penetration can be beneficial for off-target profiling and understanding potential side effects.
9. **Caco-2:** Ligand A (-4.742) shows better Caco-2 permeability than Ligand B (-5.54).
10. **Solubility:** Ligand A (-2.872) has better aqueous solubility than Ligand B (-0.727). Solubility is crucial for bioavailability.
11. **hERG:** Both ligands have very low hERG inhibition liability (Ligand A: 0.197, Ligand B: 0.127), which is excellent.
12. **Cl_mic:** Ligand B (-21.652) has a significantly lower microsomal clearance than Ligand A (39.077), indicating better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand A (16.768) has a longer in vitro half-life than Ligand B (1.703).
14. **Pgp:** Both ligands have very low P-gp efflux liability (Ligand A: 0.021, Ligand B: 0.025).
15. **Binding Affinity:** Ligand A (-6.3 kcal/mol) has a slightly better binding affinity than Ligand B (-5.2 kcal/mol). A 1.1 kcal/mol difference is meaningful.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A excels in TPSA, logP, and affinity. Ligand B has a better BBB score and significantly better metabolic stability (Cl_mic). However, the better ADME properties of Ligand A (lower TPSA, better solubility, lower DILI) and its slightly stronger binding affinity outweigh the metabolic stability advantage of Ligand B.
**Conclusion:**
Ligand A presents a more balanced profile with better overall drug-like properties and a slightly stronger binding affinity. While Ligand B has better metabolic stability, the other advantages of Ligand A make it the more promising candidate.
Output:
1
2025-04-17 23:16:02,700 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (346.427 and 358.36 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (67.87) is slightly higher than Ligand B (61.8). Both are below the 140 threshold for good oral absorption, and acceptable for a cardiovascular GPCR.
3. **logP:** Both ligands (2.428 and 2.671) are within the optimal 1-3 range. No major difference.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (4) is preferable to Ligand B (3). Lower HBA generally improves permeability.
6. **QED:** Ligand B (0.87) has a better QED score than Ligand A (0.657), indicating a more drug-like profile. This is a point in favor of Ligand B.
7. **DILI:** Ligand A (41.334) has a higher DILI risk than Ligand B (20.9). Ligand B is significantly better here.
8. **BBB:** Both ligands have high BBB penetration (89.027 and 81.504). This isn't a primary concern for a cardiovascular target, but it doesn't hurt.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.649 and -4.509). These values are unusual and difficult to interpret without further context.
10. **Solubility:** Ligand B (-3.046) has a slightly better solubility than Ligand A (-2.345).
11. **hERG:** Ligand A (0.557) has a lower hERG risk than Ligand B (0.702). This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand B (13.095) has a much lower microsomal clearance than Ligand A (61.526). This suggests better metabolic stability for Ligand B.
13. **t1/2:** Ligand B (-11.147) has a much longer in vitro half-life than Ligand A (1.049). This is a major advantage for Ligand B.
14. **Pgp:** Ligand A (0.154) has a lower P-gp efflux liability than Ligand B (0.081). This is a slight advantage for Ligand A.
15. **Binding Affinity:** Ligand A (-9.0) has a significantly stronger binding affinity than Ligand B (-7.4). This is a substantial advantage for Ligand A, potentially outweighing some ADME drawbacks.
**Overall Assessment:**
The key trade-off is between potency (Ligand A) and ADME properties (Ligand B). Ligand A has a much stronger binding affinity, which is crucial for GPCRs. However, Ligand B has significantly better metabolic stability (lower Cl_mic, longer t1/2), lower DILI risk, and a better QED score. The negative Caco-2 values are concerning for both, but the difference in binding affinity is substantial. For a cardiovascular target, metabolic stability and safety (DILI, hERG) are very important. While Ligand A's affinity is tempting, the ADME profile of Ligand B is considerably more favorable.
Output:
0
2025-04-17 23:16:02,700 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (347.459) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (82.53) is significantly better than Ligand B (29.54). For a GPCR, lower TPSA is generally preferred for better brain penetration and overall absorption.
3. **logP:** Ligand A (1.684) is within the optimal range (1-3). Ligand B (4.205) is a bit high, potentially leading to solubility issues and off-target interactions.
4. **HBD:** Ligand A (2) is acceptable, and Ligand B (0) is also good.
5. **HBA:** Ligand A (4) is acceptable, and Ligand B (2) is also good.
6. **QED:** Ligand A (0.868) is excellent, indicating a highly drug-like profile. Ligand B (0.646) is still reasonable, but less optimal.
7. **DILI:** Both ligands have low DILI risk (Ligand A: 28.306, Ligand B: 24.04). Ligand B is slightly better.
8. **BBB:** Ligand B (98.294) has excellent BBB penetration, while Ligand A (59.364) is moderate. For a GPCR, especially if CNS effects are possible, high BBB is a significant advantage.
9. **Caco-2:** Both have negative values, indicating permeability. Ligand A (-4.631) is slightly better than Ligand B (-4.029).
10. **Solubility:** Ligand A (-2.215) is better than Ligand B (-4.319). Solubility is important for bioavailability.
11. **hERG:** Both ligands have low hERG inhibition liability (Ligand A: 0.352, Ligand B: 0.866). Ligand A is slightly better.
12. **Cl_mic:** Ligand A (20.835) has a much lower microsomal clearance, suggesting better metabolic stability than Ligand B (73.596).
13. **t1/2:** Ligand B (4.472) has a longer in vitro half-life than Ligand A (-0.025). This is a positive for dosing frequency.
14. **Pgp:** Ligand A (0.102) has lower P-gp efflux, which is favorable for bioavailability and CNS exposure. Ligand B (0.272) is also reasonably low.
15. **Affinity:** Ligand A (-7.0) has slightly better binding affinity than Ligand B (-6.1). While both are good, the difference is significant.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, BBB, and affinity. Ligand B excels in BBB penetration, while Ligand A has better TPSA, logP, solubility, metabolic stability, and a slightly better affinity. The higher logP of Ligand B is a concern, and the superior metabolic stability of Ligand A is a significant advantage. The affinity difference, while not huge, favors Ligand A.
**Overall Assessment:**
While Ligand B has excellent BBB penetration and a longer half-life, Ligand A presents a more balanced profile with better physicochemical properties (TPSA, logP, solubility) and metabolic stability. Given the importance of these factors for overall drug development success, I believe Ligand A is the more promising candidate.
Output:
1
2025-04-17 23:16:02,700 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate targeting the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (378.47 and 343.471 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (90.98) is slightly higher than Ligand B (73.99). Both are below the 140 threshold for oral absorption, but Ligand B is preferable given the GPCR target class.
3. **logP:** Ligand A (-1.291) is lower than the optimal 1-3 range, potentially hindering permeability. Ligand B (2.972) is within the optimal range. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (2) and Ligand B (3) are both acceptable, being less than 5.
5. **HBA:** Ligand A (6) and Ligand B (2) are both acceptable, being less than 10. Ligand B is better here.
6. **QED:** Both ligands have reasonable QED scores (0.46 and 0.571), indicating acceptable drug-likeness. Ligand B is slightly better.
7. **DILI:** Both ligands have low DILI risk (25.165 and 27.026), both well below the 40 threshold. No significant difference.
8. **BBB:** Ligand B (69.484) has a better BBB penetration percentile than Ligand A (59.791). While ADRB2 isn't strictly a CNS target, some CNS exposure might be acceptable or even beneficial depending on the specific therapeutic intent, making Ligand B preferable.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.266 and -4.824), which is unusual and suggests poor permeability. This is a concern for both, but the negative value for Ligand A is more negative.
10. **Solubility:** Ligand A (-0.715) has slightly better solubility than Ligand B (-3.844).
11. **hERG:** Both ligands have very low hERG risk (0.133 and 0.415). No significant difference.
12. **Cl_mic:** Ligand A (-5.71) has a lower (better) microsomal clearance than Ligand B (54.021). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (-31.92) has a negative in vitro half-life, which is not possible. Ligand B (-13.24) is also negative, but less so. Both are problematic.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.007 and 0.096). No significant difference.
15. **Binding Affinity:** Both ligands have comparable binding affinities (-6.9 and -5.9 kcal/mol). Ligand A is slightly better, but the difference is not substantial enough to outweigh other factors.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp), Ligand B is the more promising candidate. It has a more favorable logP, lower TPSA, and better BBB penetration. While Ligand A has better metabolic stability (Cl_mic), the negative half-life values for both are concerning. The slight advantage in binding affinity for Ligand A is not enough to compensate for the other drawbacks.
Output:
0
2025-04-17 23:16:02,700 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [360.361, 110.56 , -0.671, 2. , 8. , 0.689, 55.68 , 78.364, -4.942, -1.865, 0.45 , -7.839, -28.204, 0.128, -6.6 ]
**Ligand B:** [350.463, 100.27 , 1.039, 3. , 6. , 0.585, 19.504, 49.787, -4.987, -1.92 , 0.083, -7.353, 23.154, 0.024, -5.8 ]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, Affinity, and BBB):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (350.463) is slightly lower, which is generally favorable.
2. **TPSA:** Ligand A (110.56) is a bit higher than Ligand B (100.27), but both are below the 140 A^2 threshold for good oral absorption.
3. **logP:** Ligand A (-0.671) is lower than the optimal 1-3 range, potentially hindering permeability. Ligand B (1.039) is much better positioned within the optimal range. This is a significant advantage for Ligand B.
4. **HBD/HBA:** Ligand A (2 HBD, 8 HBA) is slightly higher in HBA count. Ligand B (3 HBD, 6 HBA) is more balanced.
5. **QED:** Both are above 0.5, indicating good drug-likeness. Ligand A (0.689) is slightly better.
6. **DILI:** Ligand A (55.68) has a higher DILI risk than Ligand B (19.504). This is a substantial advantage for Ligand B.
7. **BBB:** Ligand A (78.364) has a better BBB penetration potential than Ligand B (49.787). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be beneficial, and this is a positive for Ligand A.
8. **Caco-2:** Both are similarly poor (-4.942 and -4.987).
9. **Solubility:** Both are similarly poor (-1.865 and -1.92).
10. **hERG:** Both have low hERG risk (0.45 and 0.083). Ligand B is slightly better.
11. **Cl_mic:** Ligand A (-7.839) has a much lower (better) microsomal clearance than Ligand B (-7.353), indicating greater metabolic stability.
12. **t1/2:** Ligand A (-28.204) has a longer in vitro half-life than Ligand B (23.154).
13. **Pgp:** Ligand A (0.128) has lower P-gp efflux than Ligand B (0.024), which is favorable for bioavailability.
14. **Affinity:** Ligand A (-6.6 kcal/mol) has a slightly better binding affinity than Ligand B (-5.8 kcal/mol). This 0.8 kcal/mol difference is significant.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity, longer half-life, and better BBB penetration, Ligand B demonstrates a superior profile in several critical areas. Specifically, its logP is within the optimal range, its DILI risk is much lower, and its Pgp efflux is lower. The better logP and lower DILI risk are particularly important for a GPCR target like ADRB2. The affinity difference, while present, is not large enough to overcome the ADME advantages of Ligand B.
Therefore, I would select Ligand B as the more promising drug candidate.
0
2025-04-17 23:16:02,700 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.471 and 349.479 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (49.85) is significantly better than Ligand B (85.09). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is approaching a level that could hinder oral absorption.
3. **logP:** Ligand A (2.529) is within the optimal range (1-3), while Ligand B (1.46) is at the lower end. While not terrible, lower logP can sometimes indicate permeability issues.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer HBDs generally improve membrane permeability.
5. **HBA:** Ligand A (3) is better than Ligand B (7). Similar to HBD, lower HBA is generally preferred.
6. **QED:** Both ligands have similar QED values (0.719 and 0.622), indicating reasonable drug-likeness.
7. **DILI:** Ligand A (37.728) has a much lower DILI risk than Ligand B (18.108). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (66.654) has a better BBB penetration score than Ligand B (56.223), although neither is exceptionally high. For a cardiovascular target, BBB penetration isn't *critical* but can be beneficial for off-target effects.
9. **Caco-2:** Ligand A (-4.424) has a more negative Caco-2 value, suggesting *better* permeability than Ligand B (-5.253). Note that lower numbers are worse in this scale.
10. **Solubility:** Ligand A (-2.799) has a more negative solubility value, indicating *lower* solubility than Ligand B (-0.973). Solubility is important, but can be addressed with formulation.
11. **hERG:** Both ligands have similar, low hERG inhibition risk (0.431 and 0.328).
12. **Cl_mic:** Ligand B (-12.765) has a significantly lower (better) microsomal clearance than Ligand A (68.113). This suggests better metabolic stability for Ligand B.
13. **t1/2:** Ligand B (28.082) has a much longer in vitro half-life than Ligand A (-1.637). This is a major advantage for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have similar, low P-gp efflux liability (0.365 and 0.109).
15. **Binding Affinity:** Ligand A (-6.4) has a slightly better binding affinity than Ligand B (-5.9). While the difference is not huge (0.5 kcal/mol), it is still a positive for Ligand A.
**Overall Assessment:**
Ligand A excels in TPSA, DILI risk, Caco-2 permeability, and binding affinity. However, Ligand B has a significantly better metabolic stability (lower Cl_mic) and a much longer half-life, which are crucial for *in vivo* efficacy. The solubility of Ligand A is a concern, but formulation strategies can often mitigate this. Considering the GPCR-specific priorities (logP, TPSA, affinity), and the importance of metabolic stability for a chronic cardiovascular condition, Ligand B appears to be the more promising candidate. The affinity difference is not large enough to overcome the significant pharmacokinetic advantages of Ligand B.
Output:
0
2025-04-17 23:16:02,701 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (352.406 and 347.415 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (67.87) is significantly better than Ligand B (93.46). ADRB2 is a cardiovascular target, not CNS, but lower TPSA generally improves absorption.
3. **logP:** Both ligands have good logP values (2.639 and 1.656), within the optimal 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (4) is preferable to Ligand B (5). Lower HBA generally improves permeability.
6. **QED:** Both ligands have acceptable QED scores (0.846 and 0.732), indicating good drug-likeness. Ligand A is slightly better.
7. **DILI:** Ligand A (26.212) has a much lower DILI risk than Ligand B (46.413). This is a significant advantage for Ligand A.
8. **BBB:** Not a primary concern for a cardiovascular target, but Ligand A (77.239) is better than Ligand B (58.007).
9. **Caco-2:** Ligand A (-4.305) is better than Ligand B (-5.318). Higher Caco-2 permeability is desirable.
10. **Solubility:** Ligand A (-2.712) is better than Ligand B (-1.086). Higher solubility is generally preferred.
11. **hERG:** Both ligands have very low hERG risk (0.348 and 0.118), which is excellent.
12. **Cl_mic:** Ligand B (7.026) has much lower microsomal clearance than Ligand A (28.669), indicating better metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand B (6.554) has a longer in vitro half-life than Ligand A (3.007). This is a significant advantage for Ligand B.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.029 and 0.058), which is excellent.
15. **Binding Affinity:** Ligand B (-6.7) has a slightly better binding affinity than Ligand A (-6.0). This is a 0.7 kcal/mol advantage, which is substantial.
**Overall Assessment:**
Ligand B has a clear advantage in metabolic stability (lower Cl_mic and longer t1/2) and binding affinity. These are critical factors for a viable drug candidate. While Ligand A has better TPSA, solubility, and lower DILI risk, the improvements in metabolic stability and affinity with Ligand B outweigh these benefits. The slightly better affinity of Ligand B is a significant factor, especially for a GPCR target.
Output:
0
2025-04-17 23:16:02,701 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [423.292, 81.27, 3.467, 0, 6, 0.418, 80.651, 78.558, -5.123, -4.187, 0.494, 57.835, -48.07, 0.722, -7.3]
**Ligand B:** [367.515, 71, 2.18, 1, 5, 0.781, 33.618, 61.38, -5.057, -3.142, 0.189, 31.571, 2.124, 0.062, -0.9]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** A (423.292) is slightly higher than B (367.515), but both are within the acceptable 200-500 Da range. B is preferable here.
2. **TPSA:** A (81.27) is higher than B (71). Both are good, but B is better for permeability.
3. **logP:** A (3.467) is optimal, while B (2.18) is at the lower end of optimal. A is preferable.
4. **HBD:** A (0) is excellent. B (1) is acceptable. A is preferable.
5. **HBA:** A (6) is good. B (5) is also good. No strong preference.
6. **QED:** B (0.781) is significantly better than A (0.418), indicating a more drug-like profile. B is preferable.
7. **DILI:** A (80.651) is concerningly high, indicating a substantial risk of liver injury. B (33.618) is very good. B is *strongly* preferable.
8. **BBB:** A (78.558) is good. B (61.38) is acceptable, but lower. A is preferable.
9. **Caco-2:** Both are negative, suggesting poor permeability. This is a concern for both.
10. **Solubility:** Both are negative, indicating poor solubility. This is a concern for both.
11. **hERG:** A (0.494) is better than B (0.189), indicating lower cardiotoxicity risk. A is preferable.
12. **Cl_mic:** A (57.835) is higher than B (31.571), meaning faster clearance and lower metabolic stability. B is preferable.
13. **t1/2:** A (-48.07) is very poor. B (2.124) is poor, but much better than A. B is preferable.
14. **Pgp:** A (0.722) is higher than B (0.062), indicating greater P-gp efflux and potentially lower bioavailability. B is *strongly* preferable.
15. **Affinity:** A (-7.3) is significantly better than B (-0.9). This is a substantial advantage.
**Overall Assessment:**
While Ligand A has a superior binding affinity, the significant drawbacks of high DILI risk, poor metabolic stability, high P-gp efflux, and very poor half-life are major concerns. Ligand B, while having weaker affinity, presents a much more favorable ADME-Tox profile. The lower DILI risk, better metabolic stability, lower P-gp efflux, and better QED are critical for a viable drug candidate, even if it means sacrificing some potency. For a GPCR, balancing affinity with good ADME properties is crucial, and Ligand B strikes a better balance.
Output:
0
2025-04-17 23:16:02,701 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (361.511 and 350.503 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (63.25) is better than Ligand B (72.8). Both are below 140, but lower TPSA generally favors absorption.
3. **logP:** Ligand A (3.877) is good, while Ligand B (1.835) is on the lower end of optimal. For a GPCR, a slightly higher logP is often preferred for membrane permeability and receptor engagement.
4. **HBD:** Ligand A (2) is better than Ligand B (3). Fewer HBDs are generally preferred for better permeability.
5. **HBA:** Both ligands have 4 HBA, which is acceptable.
6. **QED:** Ligand A (0.666) is significantly better than Ligand B (0.461), indicating a more drug-like profile.
7. **DILI:** Ligand B (3.18) has a much lower DILI risk than Ligand A (59.907). This is a major advantage for Ligand B.
8. **BBB:** Ligand A (86.817) has better BBB penetration than Ligand B (74.098). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be useful for understanding off-target effects and potential peripheral distribution.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability in this assay. This is a concern for both.
10. **Solubility:** Both ligands have negative solubility values, indicating poor aqueous solubility. This is a significant drawback for both.
11. **hERG:** Both ligands have low hERG inhibition risk (0.722 and 0.622).
12. **Cl_mic:** Ligand B (28.781) has significantly lower microsomal clearance than Ligand A (58.25), indicating better metabolic stability.
13. **t1/2:** Ligand A (49.238) has a longer in vitro half-life than Ligand B (0.642). This is a positive for Ligand A.
14. **Pgp:** Ligand A (0.61) has lower P-gp efflux than Ligand B (0.066), which is favorable.
15. **Binding Affinity:** Ligand A (-7.4 kcal/mol) has a slightly better binding affinity than Ligand B (-7.0 kcal/mol). This is a significant advantage, potentially outweighing some ADME drawbacks.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand A has a better logP and Pgp profile, and slightly better affinity. Ligand B has a much better DILI score and lower Cl_mic. The poor Caco-2 and solubility for both are concerning, but can potentially be addressed with formulation strategies. The affinity difference is substantial enough to favor Ligand A.
**Overall Assessment:**
While Ligand B has a much better safety profile (DILI) and metabolic stability, Ligand A's superior binding affinity, better logP, and Pgp properties, combined with a reasonable BBB score, make it the more promising candidate. The solubility and permeability issues are shared by both and would need to be addressed during development, but the potency advantage of Ligand A is significant.
Output:
1
2025-04-17 23:16:02,701 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [348.487, 67.43, 3.455, 2, 3, 0.707, 32.183, 51.105, -4.492, -3.544, 0.737, 64.125, -11.32, 0.267, -6.7]
**Ligand B:** [346.515, 49.41, 3.355, 1, 2, 0.768, 23.653, 73.827, -4.63, -3.868, 0.487, 57.594, -2.164, 0.299, -6.6]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal 200-500 Da range. A (348.487) and B (346.515) are very close, so this isn't a differentiating factor.
2. **TPSA:** A (67.43) is slightly higher than B (49.41). B is better, being closer to the <90 ideal for GPCRs.
3. **logP:** Both are excellent (A: 3.455, B: 3.355), falling within the optimal 1-3 range.
4. **HBD:** A (2) and B (1) are both good, well below the 5 limit. B is slightly better.
5. **HBA:** A (3) and B (2) are both good, below the 10 limit. B is slightly better.
6. **QED:** Both are good (A: 0.707, B: 0.768), exceeding the 0.5 threshold. B is slightly better.
7. **DILI:** A (32.183) is better than B (23.653), indicating a lower risk of liver injury.
8. **BBB:** B (73.827) is significantly better than A (51.105). This is a *major* advantage for a GPCR target, even if not specifically a CNS target, as it suggests better distribution.
9. **Caco-2:** Both are negative, indicating poor permeability. A (-4.492) is slightly worse than B (-4.63).
10. **Solubility:** Both are negative, indicating poor solubility. A (-3.544) is slightly better than B (-3.868).
11. **hERG:** Both are low (A: 0.737, B: 0.487), which is good, indicating low cardiotoxicity risk. B is better.
12. **Cl_mic:** B (57.594) has lower clearance than A (64.125), suggesting better metabolic stability.
13. **t1/2:** B (-2.164) has a longer half-life than A (-11.32), which is desirable.
14. **Pgp:** Both are low (A: 0.267, B: 0.299), indicating low P-gp efflux.
15. **Affinity:** Both have very similar binding affinities (A: -6.7 kcal/mol, B: -6.6 kcal/mol). The difference is negligible.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand B is the more promising candidate. While Ligand A has a slightly better DILI score and solubility, Ligand B excels in TPSA, BBB penetration, metabolic stability (Cl_mic, t1/2), and hERG inhibition. The improved BBB penetration is a significant advantage for a GPCR, and the better metabolic stability and half-life are also highly desirable. The binding affinities are essentially the same.
Output:
0
2025-04-17 23:16:02,701 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [349.519, 52.65, 2.547, 1, 3, 0.802, 10.508, 70.919, -4.816, -1.646, 0.356, 19.136, 0.087, 0.082, -6.0]
**Ligand B:** [371.547, 61.88, 1.755, 1, 5, 0.704, 11.361, 67.701, -5.685, -1.232, 0.366, 1.966, 3.97, 0.015, -6.9]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (349.5) is slightly preferred due to being a bit lower.
2. **TPSA:** Ligand A (52.65) is better than Ligand B (61.88). Both are below 140, but lower TPSA is generally preferred for better absorption, especially for GPCRs.
3. **logP:** Both are within the optimal range (1-3). Ligand A (2.547) is slightly higher, which could be a minor advantage.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A (3) is better than Ligand B (5). Lower HBA is generally preferred for permeability.
6. **QED:** Ligand A (0.802) is better than Ligand B (0.704), indicating a more drug-like profile.
7. **DILI:** Both are relatively low, but Ligand A (10.5) is slightly better than Ligand B (11.361).
8. **BBB:** Ligand A (70.919) is better than Ligand B (67.701), which is important for GPCR targets.
9. **Caco-2:** Ligand B (-5.685) is better than Ligand A (-4.816). This suggests better intestinal absorption for Ligand B.
10. **Solubility:** Ligand B (-1.232) is better than Ligand A (-1.646).
11. **hERG:** Both are very low, indicating minimal hERG inhibition risk.
12. **Cl_mic:** Ligand B (1.966) is significantly better than Ligand A (19.136). Lower clearance is highly desirable for metabolic stability.
13. **t1/2:** Ligand B (3.97) is better than Ligand A (0.087).
14. **Pgp:** Ligand A (0.082) is better than Ligand B (0.015). Lower P-gp efflux is preferred.
15. **Affinity:** Ligand B (-6.9) is slightly better than Ligand A (-6.0). A 0.9 kcal/mol difference is significant.
**Overall Assessment:**
Ligand B has a clear advantage in metabolic stability (Cl_mic and t1/2) and binding affinity. The better Caco-2 and solubility of Ligand B are also significant positives. While Ligand A has better TPSA, QED, and BBB penetration, the differences are less pronounced than the advantages Ligand B offers in terms of metabolic stability and binding. Given that this is a GPCR target, the slightly better affinity of Ligand B is a key factor. The improved metabolic properties will likely translate to better *in vivo* exposure.
Therefore, I prefer Ligand B.
Output:
0
2025-04-17 23:16:02,702 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
The ADRB2 receptor is a GPCR involved in cardiovascular function. Therefore, prioritizing logP, TPSA, Pgp efflux, and binding affinity is crucial. While BBB penetration isn't *essential* for a cardiovascular target, it's still a beneficial property to consider.
Let's analyze each ligand:
* **Molecular Weight:** Both ligands (336.4 and 359.5 Da) fall within the ideal 200-500 Da range.
* **TPSA:** Ligand A (85.15) is slightly higher than Ligand B (69.72). Both are below the 140 threshold for good absorption, but Ligand B is better.
* **logP:** Both ligands have good logP values (1.955 and 1.251), falling within the optimal 1-3 range. Ligand B is slightly lower, which could be a minor drawback.
* **H-Bond Donors/Acceptors:** Both have acceptable HBD (1) and HBA (6/4) counts.
* **QED:** Both have good QED scores (0.918 and 0.819), indicating good drug-likeness.
* **DILI:** Ligand A (75.262) has a higher DILI risk than Ligand B (52.462). This is a significant concern.
* **BBB:** Ligand B (71.811) has better BBB penetration than Ligand A (50.679), although this is less critical for a cardiovascular target.
* **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not provided, so it's hard to interpret.
* **Solubility:** Both have negative solubility values, which is also unusual and suggests poor solubility.
* **hERG:** Ligand A (0.577) has a higher hERG inhibition liability than Ligand B (0.243). This is a significant safety concern.
* **Cl_mic:** Ligand A (20.795) has a lower microsomal clearance than Ligand B (34.913), suggesting better metabolic stability.
* **t1/2:** Ligand B (-3.055) has a longer in vitro half-life than Ligand A (5.998), which is a positive attribute.
* **Pgp:** Ligand A (0.049) has lower P-gp efflux liability than Ligand B (0.073), which is favorable.
* **Binding Affinity:** Ligand B (-7.5 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.3 kcal/mol). This 1.2 kcal/mol difference is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand B is the stronger candidate. While Ligand A has slightly better metabolic stability and P-gp efflux, Ligand B's significantly improved binding affinity (-7.5 vs -6.3 kcal/mol), lower DILI risk, lower hERG risk, and better BBB penetration outweigh these minor advantages. The negative values for Caco-2 and solubility are concerning for both, but the binding affinity difference is a major driver for selecting Ligand B.
**Output:**
0
2025-04-17 23:16:02,702 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (356.463 and 350.459 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (77.1) is better than Ligand B (84.5). For a GPCR, keeping TPSA lower is generally favorable for permeability, though both are reasonably acceptable.
**3. logP:** Ligand B (1.777) is slightly higher than Ligand A (0.962), placing it more centrally in the optimal 1-3 range. Ligand A is a bit low, potentially impacting permeability.
**4. H-Bond Donors:** Ligand A (1) is better than Ligand B (2). Fewer HBDs generally improve permeability.
**5. H-Bond Acceptors:** Ligand A (5) is better than Ligand B (4). Fewer HBAs generally improve permeability.
**6. QED:** Both ligands have good QED values (0.666 and 0.715), indicating reasonable drug-likeness.
**7. DILI Risk:** Ligand B (31.989) has a significantly lower DILI risk than Ligand A (15.859). This is a major advantage for Ligand B.
**8. BBB Penetration:** Ligand A (73.129) has significantly better BBB penetration than Ligand B (56.495). While ADRB2 isn't exclusively a CNS target, some CNS exposure could be beneficial or at least avoid unexpected off-target effects.
**9. Caco-2 Permeability:** Ligand A (-4.462) has better Caco-2 permeability than Ligand B (-4.771).
**10. Aqueous Solubility:** Ligand A (-0.634) has better aqueous solubility than Ligand B (-2.528). Solubility is important for formulation and bioavailability.
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.204 and 0.253). This is excellent.
**12. Microsomal Clearance:** Ligand A (27.836) has significantly lower microsomal clearance than Ligand B (60.425), suggesting better metabolic stability.
**13. In vitro Half-Life:** Ligand A (-7.666) has a significantly longer in vitro half-life than Ligand B (-0.763). This is a significant advantage for Ligand A.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.01 and 0.118).
**15. Binding Affinity:** Ligand A (-6.2 kcal/mol) has slightly better binding affinity than Ligand B (-5.5 kcal/mol). While the difference is not huge, it's a positive for Ligand A.
**Overall Assessment:**
Ligand A has a better overall profile, particularly regarding metabolic stability (lower Cl_mic, longer t1/2), solubility, and Caco-2 permeability. The slightly better binding affinity is also a plus. While Ligand B has a lower DILI risk, the other advantages of Ligand A outweigh this concern, especially considering the low DILI risk of Ligand A is still acceptable. The better BBB penetration of Ligand A is also a benefit.
Output:
1
2025-04-17 23:16:02,702 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (354.491 and 351.491 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (67.87) is slightly higher than Ligand B (61.88). Both are below the 140 A^2 threshold for oral absorption, but closer to the 90 A^2 threshold for CNS targets, which isn't a primary concern for ADRB2 (cardiovascular focus). Ligand B is slightly favored.
**3. logP:** Both ligands have good logP values (2.319 and 1.395), falling within the optimal 1-3 range. Ligand B is a bit lower, potentially improving solubility, but both are acceptable.
**4. H-Bond Donors:** Both have 1 HBD, which is within the acceptable limit of 5.
**5. H-Bond Acceptors:** Both have 4 HBA, also within the acceptable limit of 10.
**6. QED:** Ligand B (0.786) has a higher QED score than Ligand A (0.611), indicating a more drug-like profile. This is a positive for Ligand B.
**7. DILI:** Ligand B (3.451%) has a significantly lower DILI risk than Ligand A (12.253%). This is a major advantage for Ligand B.
**8. BBB:** Ligand B (78.441%) has a higher BBB penetration score than Ligand A (69.756%). While ADRB2 isn't a CNS target, higher BBB penetration can sometimes correlate with better overall distribution.
**9. Caco-2 Permeability:** Both have negative Caco-2 values (-4.488 and -4.808), which is unusual and suggests poor permeability. However, these values are on a scale where negative values are possible, and the absolute difference isn't huge.
**10. Aqueous Solubility:** Both have negative solubility values (-1.441 and -1.202), indicating poor solubility. This is a concern for both.
**11. hERG Inhibition:** Both ligands have low hERG inhibition liability (0.327 and 0.422), which is good.
**12. Microsomal Clearance:** Ligand B (1.265) has *much* lower microsomal clearance than Ligand A (42.528). This indicates significantly better metabolic stability for Ligand B.
**13. In vitro Half-Life:** Ligand B (-5.444) has a significantly longer in vitro half-life than Ligand A (8.585). This is a major advantage for Ligand B, suggesting less frequent dosing potential.
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (0.069 and 0.009), which is favorable.
**15. Binding Affinity:** Ligand B (-6.7 kcal/mol) has a slightly better binding affinity than Ligand A (-6.5 kcal/mol). While the difference is small, it's still a positive for Ligand B.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity) and the general drug-like properties, Ligand B is the superior candidate. It exhibits a significantly lower DILI risk, better metabolic stability (lower Cl_mic and longer t1/2), a higher QED score, and slightly better binding affinity. While both have solubility and permeability concerns, the ADME profile of Ligand B is markedly improved, making it a more promising starting point for further optimization.
Output:
0
2025-04-17 23:16:02,702 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**1. Molecular Weight:** Both ligands (347.371 and 346.471 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (89.13) is better than Ligand B (60.85). For a GPCR, lower TPSA is generally preferred for permeability, and Ligand B is significantly lower, suggesting potentially better absorption.
**3. logP:** Both ligands have good logP values (1.666 and 2.094), falling within the optimal 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability.
**4. H-Bond Donors:** Ligand A has 2 HBD, and Ligand B has 1. Both are acceptable, well below the 5 limit.
**5. H-Bond Acceptors:** Ligand A has 5 HBA, and Ligand B has 3. Both are within the acceptable range of <=10.
**6. QED:** Ligand A (0.849) has a better QED score than Ligand B (0.796), indicating a more drug-like profile.
**7. DILI Risk:** Ligand A (53.47) has a higher DILI risk than Ligand B (13.843). This is a significant advantage for Ligand B, as lower DILI is crucial.
**8. BBB Penetration:** Ligand A (96.743) has significantly better BBB penetration than Ligand B (69.058). While ADRB2 isn't exclusively a CNS target, some cardiovascular effects are mediated by central pathways, and better BBB penetration could be advantageous.
**9. Caco-2 Permeability:** Ligand A (-4.417) has better Caco-2 permeability than Ligand B (-4.898).
**10. Aqueous Solubility:** Ligand A (-3.098) has better aqueous solubility than Ligand B (-1.981).
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (0.388 and 0.235), which is good. Ligand B is slightly better.
**12. Microsomal Clearance:** Ligand A (8.07) has significantly lower microsomal clearance than Ligand B (21.234), indicating better metabolic stability.
**13. In vitro Half-Life:** Ligand A (-6.333) has a longer in vitro half-life than Ligand B (9.322), which is desirable.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.021 and 0.093).
**15. Binding Affinity:** Ligand B (-7.3) has a slightly better binding affinity than Ligand A (-6.9). This 0.4 kcal/mol difference is significant and can outweigh some ADME drawbacks.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand B emerges as the more promising candidate. While Ligand A has better BBB penetration, solubility and metabolic stability, Ligand B's significantly lower DILI risk and slightly improved binding affinity are more critical. The lower TPSA of Ligand B is also a plus for permeability. The difference in binding affinity is substantial enough to offset the slightly less favorable BBB and solubility profiles of Ligand B.
Output:
0
2025-04-17 23:16:02,702 - INFO - Batch 392 complete. Total preferences: 6272
2025-04-17 23:16:02,702 - INFO - Processing batch 393/512...
2025-04-17 23:16:48,801 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (450.236 Da) is within the ideal range, while Ligand B (386.25 Da) is also good, being slightly below the ideal.
2. **TPSA:** Ligand A (101.14) is acceptable, but higher than optimal. Ligand B (42.68) is excellent, well below the 140 threshold and favorable for permeability.
3. **logP:** Ligand A (2.857) is optimal. Ligand B (4.937) is slightly high, potentially leading to solubility issues or off-target interactions.
4. **HBD:** Ligand A (2) is good. Ligand B (0) is also good, minimizing potential issues.
5. **HBA:** Ligand A (6) is good. Ligand B (3) is excellent.
6. **QED:** Ligand A (0.458) is borderline, slightly below the desired 0.5. Ligand B (0.707) is excellent.
7. **DILI:** Ligand A (88.251) is concerning, indicating a relatively high risk of liver injury. Ligand B (37.611) is very good, showing low risk.
8. **BBB:** Ligand A (20.202) is low, suggesting poor brain penetration. Ligand B (84.529) is excellent, indicating good brain penetration. While ADRB2 isn't *strictly* a CNS target, some cardiovascular effects are mediated centrally, and better BBB penetration could be beneficial.
9. **Caco-2:** Ligand A (-5.656) is poor. Ligand B (-4.16) is also poor, but slightly better.
10. **Solubility:** Ligand A (-4.174) is poor. Ligand B (-5.325) is also poor.
11. **hERG:** Ligand A (0.113) is very good, low risk. Ligand B (0.778) is slightly higher, indicating a moderate risk.
12. **Cl_mic:** Ligand A (43.321) is good, suggesting reasonable metabolic stability. Ligand B (88.798) is high, indicating rapid metabolism.
13. **t1/2:** Ligand A (-13.696) is poor. Ligand B (65.181) is excellent.
14. **Pgp:** Ligand A (0.204) is good, indicating low efflux. Ligand B (0.46) is also good, but slightly higher.
15. **Affinity:** Both ligands have very similar binding affinities (-6.9 kcal/mol and -6.8 kcal/mol respectively). The difference is negligible.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B excels in TPSA and BBB penetration, and has a better QED score. While its logP is slightly high, the significant advantage in DILI risk, metabolic stability (t1/2), and QED outweighs this. Ligand A's high DILI risk is a major concern.
**Conclusion:**
Ligand B is the more promising candidate due to its superior ADME properties (lower DILI, better metabolic stability, better QED, good BBB penetration) and comparable binding affinity. The slightly higher logP is a manageable concern compared to the significant liabilities of Ligand A.
Output:
0
2025-04-17 23:16:48,801 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
We are targeting ADRB2, a GPCR. Therefore, the key properties to prioritize are binding affinity, logP, TPSA, Pgp efflux, and BBB penetration. Metabolic stability (Cl_mic, t1/2) and safety (DILI, hERG) are also important.
Let's compare the ligands property by property:
1. **MW:** Both are within the ideal range (364.471 and 369.355 Da).
2. **TPSA:** Ligand A (84.3) is significantly better than Ligand B (138.13). Lower TPSA generally improves oral absorption and BBB penetration, crucial for a GPCR.
3. **logP:** Ligand A (1.565) is optimal, while Ligand B (0.288) is quite low. A logP below 1 can hinder membrane permeability.
4. **HBD/HBA:** Both have 1 HBD, which is good. Ligand B has 6 HBA vs. 5 for Ligand A. This isn't a major concern for either.
5. **QED:** Ligand A (0.835) has a better QED score than Ligand B (0.594), indicating a more drug-like profile.
6. **DILI:** Ligand B (93.37) has a much higher DILI risk than Ligand A (49.477). This is a significant negative for Ligand B.
7. **BBB:** Ligand A (85.343) has significantly better BBB penetration potential than Ligand B (25.475). This is a critical advantage for a GPCR target.
8. **Caco-2:** Both have negative Caco-2 values which is unusual and difficult to interpret.
9. **Solubility:** Ligand A (-1.891) is better than Ligand B (-3.752).
10. **hERG:** Ligand A (0.539) has a lower hERG risk than Ligand B (0.036).
11. **Cl_mic:** Both have similar microsomal clearance (21.561 vs 21.361).
12. **t1/2:** Ligand A (22.121) has a positive in vitro half-life, while Ligand B (-20.575) has a negative value, which is concerning.
13. **Pgp:** Ligand A (0.169) has lower P-gp efflux liability than Ligand B (0.04).
14. **Binding Affinity:** Ligand A (-7.5 kcal/mol) has a slightly better binding affinity than Ligand B (-6.8 kcal/mol). While the difference isn't huge, it's a positive for Ligand A.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical parameters, especially TPSA, logP, BBB, DILI, and hERG. While the affinity difference is not massive, it favors Ligand A. Ligand B's high DILI risk and poor BBB penetration are major drawbacks. The negative Caco-2 and t1/2 values for Ligand B are also concerning.
**Output:**
1
2025-04-17 23:16:48,801 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (339.395) is slightly lower than Ligand B (372.397), which is generally favorable for permeability.
2. **TPSA:** Ligand A (73.64) is better than Ligand B (96.11). ADRB2 is not a CNS target, but lower TPSA generally improves absorption.
3. **logP:** Both ligands have good logP values (A: 1.842, B: 1.721) falling within the optimal 1-3 range. They are very similar here.
4. **HBD:** Ligand A (0) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is preferable to Ligand B (5). Fewer HBAs generally improve permeability.
6. **QED:** Both ligands have comparable QED values (A: 0.585, B: 0.584), indicating good drug-likeness.
7. **DILI:** Ligand A (48.197) has a significantly lower DILI risk than Ligand B (70.182). This is a major advantage for Ligand A.
8. **BBB:** Both ligands have reasonable BBB penetration (A: 70.88, B: 73.866). Since ADRB2 is primarily a cardiovascular target, BBB penetration is not a critical factor.
9. **Caco-2:** Ligand A (-4.797) is better than Ligand B (-5.492), indicating better intestinal absorption.
10. **Solubility:** Both ligands have poor aqueous solubility (A: -2.413, B: -2.643). This could be a formulation challenge for both, but is not a deciding factor.
11. **hERG:** Ligand A (0.499) has a lower hERG risk than Ligand B (0.731). This is a significant safety advantage for Ligand A.
12. **Cl_mic:** Ligand A (11.147) has a much lower microsomal clearance than Ligand B (35.245), indicating better metabolic stability.
13. **t1/2:** Ligand A (-28.581) has a much longer in vitro half-life than Ligand B (2.905). This is a substantial advantage for Ligand A, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.065) has a lower P-gp efflux liability than Ligand B (0.247), suggesting better oral bioavailability.
15. **Affinity:** Both ligands have the same binding affinity (-6.6 kcal/mol). This eliminates affinity as a differentiating factor.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and metabolic stability are important. Ligand A performs better across these parameters, and also has a significantly better safety profile (lower DILI and hERG).
**Conclusion:**
Ligand A is clearly the superior candidate. It demonstrates better ADME properties (lower DILI, hERG, Cl_mic, Pgp, better Caco-2, longer t1/2) and comparable binding affinity to Ligand B. While both have poor solubility, the other advantages of Ligand A outweigh this drawback.
Output:
1
2025-04-17 23:16:48,802 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands (363.439 and 352.435 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Both ligands (116.13 and 113.18) are reasonably good, being under 140, suggesting decent absorption.
3. **logP:** Ligand A (1.368) is slightly better than Ligand B (0.859). Both are within the optimal 1-3 range, but Ligand A is closer to the center.
4. **HBD:** Ligand A (2) is preferable to Ligand B (3). Lower HBD generally improves permeability.
5. **HBA:** Both ligands have 5 HBA, which is acceptable.
6. **QED:** Ligand A (0.792) has a better QED score than Ligand B (0.63), indicating a more drug-like profile.
7. **DILI:** Ligand B (43.66) has a significantly lower DILI risk than Ligand A (66.421). This is a substantial advantage for Ligand B.
8. **BBB:** Ligand A (41.373) has a higher BBB penetration percentile than Ligand B (30.477). While ADRB2 isn't necessarily a CNS target, some peripheral ADRB2 activity can influence CNS pathways, so moderate BBB penetration isn't detrimental.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual. This suggests very poor permeability. However, the scale isn't specified, so it's hard to interpret.
10. **Solubility:** Ligand B (-1.75) has better solubility than Ligand A (-3.16).
11. **hERG:** Both ligands have very low hERG inhibition liability (0.086 and 0.097), which is excellent.
12. **Cl_mic:** Ligand A (7.592) has a lower microsomal clearance than Ligand B (30.516), indicating better metabolic stability.
13. **t1/2:** Ligand B (-15.604) has a negative in vitro half-life, which is impossible and suggests an error in the data. Ligand A (30.629) has a reasonable half-life.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.088 and 0.015).
15. **Binding Affinity:** Ligand A (-7.7 kcal/mol) has a significantly stronger binding affinity than Ligand B (-4.0 kcal/mol). This is a substantial advantage.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand A is better in terms of logP, affinity, and Pgp. Ligand B is better in terms of DILI and solubility. The extremely poor half-life of Ligand B is a major concern. The significant difference in binding affinity (-7.7 vs -4.0) is a large enough advantage to outweigh the higher DILI risk of Ligand A, especially given the low hERG risk.
**Conclusion:**
Considering the balance of properties, particularly the significantly stronger binding affinity and reasonable metabolic stability of Ligand A, it is the more promising drug candidate despite the slightly higher DILI risk. The negative half-life of Ligand B is a showstopper.
Output:
1
2025-04-17 23:16:48,802 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (348.49 and 349.43 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (58.64) is significantly better than Ligand B (91.76). ADRB2 is a cardiovascular target, not CNS, but lower TPSA generally improves absorption. Ligand A is well below the 140 threshold, while B is approaching it.
3. **logP:** Ligand A (2.51) is within the optimal 1-3 range. Ligand B (0.72) is a bit low, potentially hindering membrane permeability.
4. **HBD:** Both ligands have acceptable HBD counts (1 and 2 respectively), well below the 5 threshold.
5. **HBA:** Ligand A (3) is better than Ligand B (5), keeping within the preferred range of <=10.
6. **QED:** Both ligands have similar, good QED values (0.751 and 0.722), indicating good drug-like properties.
7. **DILI:** Both ligands have very low DILI risk (25.98 and 24.89), which is excellent.
8. **BBB:** Ligand A (81.12) has a better BBB penetration percentile than Ligand B (61.26). While not a CNS target, some degree of BBB penetration can sometimes indicate better overall permeability.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the values are similar (-4.798 vs -4.577).
10. **Solubility:** Ligand A (-3.546) has better solubility than Ligand B (-1.495), which is a positive.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.388 and 0.238), which is excellent.
12. **Cl_mic:** Ligand A (64.03) has a higher microsomal clearance than Ligand B (28.85), indicating faster metabolism and potentially lower *in vivo* exposure. This is a significant drawback for Ligand A.
13. **t1/2:** Ligand B (-2.548) has a longer in vitro half-life than Ligand A (9.082). This is a significant advantage for Ligand B.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.141 and 0.04), which is favorable.
15. **Binding Affinity:** Ligand B (-6.5) has slightly better binding affinity than Ligand A (-6.4). While the difference is small, it's still a factor.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand A excels in TPSA and has a good logP. Ligand B has a slightly better affinity. However, the significantly better metabolic stability (lower Cl_mic and longer t1/2) of Ligand B, coupled with its better solubility, outweighs the minor differences in other parameters.
**Conclusion:**
Ligand B is the more promising candidate due to its superior metabolic stability, solubility, and slightly better binding affinity. While Ligand A has a better TPSA, the metabolic liabilities of Ligand A are concerning for *in vivo* efficacy.
Output:
0
2025-04-17 23:16:48,802 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (360.401 and 353.413 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (78.87) is higher than Ligand B (62.3). Both are below 140, but B is preferable for better absorption.
3. **logP:** Ligand B (2.763) is closer to the optimal 1-3 range than Ligand A (0.64). Ligand A's low logP could indicate poor membrane permeability.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable, well below the 5 limit.
5. **HBA:** Ligand A (4) and Ligand B (3) are both acceptable, well below the 10 limit.
6. **QED:** Ligand B (0.855) has a higher QED score than Ligand A (0.698), indicating a more drug-like profile.
7. **DILI:** Ligand A (22.8) has a significantly lower DILI risk than Ligand B (39.899). This is a substantial advantage for Ligand A.
8. **BBB:** Ligand B (90.617) has a much higher BBB penetration percentile than Ligand A (77.821). While ADRB2 isn't strictly a CNS target, some CNS exposure can be relevant for off-target effects and overall safety.
9. **Caco-2:** Ligand A (-4.857) has a lower Caco-2 permeability than Ligand B (-3.915). Lower values indicate poorer absorption.
10. **Solubility:** Ligand A (-1.573) has better aqueous solubility than Ligand B (-3.377).
11. **hERG:** Both ligands show low hERG inhibition liability (0.475 and 0.405, respectively). No significant difference.
12. **Cl_mic:** Ligand A (-10.253) has significantly lower microsomal clearance than Ligand B (67.094), suggesting better metabolic stability.
13. **t1/2:** Ligand B (26.676) has a longer in vitro half-life than Ligand A (11.391).
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.045 and 0.057, respectively). No significant difference.
15. **Affinity:** Ligand A (-7.2) has a slightly better binding affinity than Ligand B (-6.0).
**GPCR-Specific Priorities & Overall Assessment:**
For a GPCR like ADRB2, logP, TPSA, and affinity are key. Ligand B excels in logP and has good TPSA. Ligand A has a slightly better affinity, but its low logP is concerning. Ligand A's superior DILI and Cl_mic are strong positives. However, the combination of better logP, QED, and half-life for Ligand B, coupled with acceptable DILI and affinity, makes it the more promising candidate. The slightly better BBB penetration of Ligand B is also a minor benefit. The affinity difference is not large enough to overcome the ADME advantages of Ligand B.
**Output:**
0
2025-04-17 23:16:48,802 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (339.443 and 375.441 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (63.05) is significantly better than Ligand B (91.32). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (3.756) is slightly higher than Ligand B (2.189), both are within the optimal 1-3 range, but A is closer to the upper limit.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is preferable to Ligand B (5). Fewer HBAs generally improve permeability.
6. **QED:** Ligand A (0.871) is better than Ligand B (0.648), indicating a more drug-like profile.
7. **DILI:** Ligand A (38.62) has a much lower DILI risk than Ligand B (57.697). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (80.962) has a higher BBB penetration than Ligand B (42.42). While not a primary concern for a cardiovascular target, it's a slight positive.
9. **Caco-2:** Ligand A (-4.741) is better than Ligand B (-5.317), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-4.056) is better than Ligand B (-2.9). Better solubility is always a plus.
11. **hERG:** Ligand A (0.676) is better than Ligand B (0.248), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand B (34.746) has a lower microsomal clearance than Ligand A (59.673), suggesting better metabolic stability. This is a point in favor of Ligand B.
13. **t1/2:** Ligand B (-6.212) has a longer in vitro half-life than Ligand A (21.728). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.158) has lower P-gp efflux than Ligand B (0.019), which is preferable.
15. **Binding Affinity:** Ligand A (-8.4) has a significantly stronger binding affinity than Ligand B (-6.5). This is a substantial advantage for Ligand A. A difference of 1.9 kcal/mol is significant.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A excels in affinity, has better TPSA and Pgp, and acceptable logP. While Ligand B has better metabolic stability and half-life, the superior affinity of Ligand A, coupled with its better safety profile (lower DILI, lower hERG) and drug-like properties (QED), outweighs these benefits.
**Conclusion:**
Ligand A is the more promising candidate due to its significantly stronger binding affinity, better ADME properties (TPSA, solubility, Pgp, DILI, hERG), and higher QED score. The improved metabolic stability of Ligand B is a consideration, but the potency and safety advantages of Ligand A are more critical for initial drug candidate selection.
Output:
1
2025-04-17 23:16:48,802 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [369.447, 127.51 , -0.674, 2. , 7. , 0.625, 42.458, 54.595, -5.604, -2.003, 0.046, 2.292, 13.521, 0.012, -6.5 ]
**Ligand B:** [370.475, 75.21 , 0.401, 0. , 7. , 0.722, 55.138, 57.968, -4.586, -1.611, 0.281, 39.332, -16.219, 0.061, -6.2 ]
Here's a breakdown, prioritizing GPCR-relevant properties (logP, TPSA, Pgp, BBB, Affinity):
1. **Molecular Weight:** Both are within the ideal range (369 & 370 Da). No significant difference.
2. **TPSA:** Ligand B (75.21) is significantly better than Ligand A (127.51). Lower TPSA is preferred for better permeability, especially important for GPCRs.
3. **logP:** Ligand A (-0.674) is slightly outside the optimal range (1-3), while Ligand B (0.401) is closer. Both are a bit low, potentially hindering membrane permeability.
4. **H-Bond Donors:** Ligand B (0) is better than Ligand A (2). Fewer HBDs generally improve permeability.
5. **H-Bond Acceptors:** Both have 7 HBA, which is acceptable.
6. **QED:** Both are good (0.625 and 0.722), indicating drug-like properties. Ligand B is slightly better.
7. **DILI:** Both are acceptable (42.458 and 55.138), with Ligand A having a slightly lower risk.
8. **BBB:** Both are moderate (54.595 and 57.968). Neither is particularly high, but this isn't a primary concern for a non-CNS target like ADRB2.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand B (-4.586) is slightly better than Ligand A (-5.604).
10. **Solubility:** Both are very poor (-2.003 and -1.611). This is a significant drawback for both.
11. **hERG:** Both are very low risk (0.046 and 0.281).
12. **Cl_mic:** Ligand A (2.292) has significantly lower clearance than Ligand B (39.332), indicating better metabolic stability. This is a major advantage.
13. **t1/2:** Ligand A (13.521) has a better in vitro half-life than Ligand B (-16.219).
14. **Pgp:** Both are very low efflux (0.012 and 0.061), which is good.
15. **Binding Affinity:** Both have excellent binding affinity (-6.5 and -6.2 kcal/mol). The difference is small, and within the range where other factors become more important.
**Overall Assessment:**
Ligand B has better TPSA, QED, and fewer H-bond donors, which are all favorable for permeability. However, Ligand A has a much better metabolic stability profile (lower Cl_mic, longer t1/2) and a slightly lower DILI risk. The solubility is poor for both. Considering the importance of metabolic stability for *in vivo* efficacy and the relatively small difference in binding affinity, Ligand A is the more promising candidate.
Output:
1
2025-04-17 23:16:48,802 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (323.4) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (50.94) is better than Ligand B (59.59). Both are below the 140 threshold for oral absorption, but lower TPSA is preferred.
3. **logP:** Ligand B (3.842) is closer to the optimal range (1-3) than Ligand A (4.999). Ligand A's logP is a bit high, potentially leading to solubility issues and off-target interactions.
4. **HBD:** Both ligands have 2 HBD, which is within the acceptable limit of 5.
5. **HBA:** Both ligands have 3 HBA, which is within the acceptable limit of 10.
6. **QED:** Ligand B (0.879) has a significantly better QED score than Ligand A (0.51), indicating a more drug-like profile.
7. **DILI:** Ligand B (73.982) has a lower DILI risk than Ligand A (85.653). Both are acceptable, but lower is always better.
8. **BBB:** Ligand B (79.217) has a better BBB penetration score than Ligand A (52.811). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant, and higher BBB is generally a plus.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. Ligand A (-5.051) is slightly worse than Ligand B (-4.786).
10. **Solubility:** Both ligands have negative solubility values, indicating poor solubility. Ligand A (-4.875) is slightly worse than Ligand B (-4.638).
11. **hERG:** Both ligands have low hERG inhibition liability (0.93 and 0.816), which is good.
12. **Cl_mic:** Ligand A (14.484) has a significantly lower microsomal clearance than Ligand B (43.351), suggesting better metabolic stability.
13. **t1/2:** Ligand A (32.518) has a much longer in vitro half-life than Ligand B (-13.52). This is a significant advantage.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.668 and 0.448).
15. **Binding Affinity:** Ligand B (-7.7 kcal/mol) has a stronger binding affinity than Ligand A (-6.8 kcal/mol). The difference of 0.9 kcal/mol is substantial and can outweigh some ADME drawbacks.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand B excels in affinity and has a better logP and TPSA. While Ligand A has better metabolic stability (Cl_mic and t1/2), the significantly stronger binding affinity of Ligand B is a major advantage. The better QED and lower DILI risk of Ligand B also contribute to its favorability.
**Conclusion:**
Despite Ligand A's better metabolic stability, Ligand B's superior binding affinity, better QED, lower DILI risk, and more favorable logP and BBB penetration make it the more promising drug candidate for ADRB2.
Output:
0
2025-04-17 23:16:48,802 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (339.435 Da) is slightly lower, which is generally favorable for permeability.
**2. TPSA:** Ligand A (38.77) is significantly better than Ligand B (100.97). For a GPCR, keeping TPSA low is beneficial for permeability and receptor engagement. Ligand B's TPSA is quite high, potentially hindering oral absorption.
**3. logP:** Ligand A (4.289) is higher than Ligand B (0.708). While both are within acceptable ranges (1-3 is optimal), Ligand A is pushing the upper limit. Ligand B is quite low, which could limit membrane permeability.
**4. H-Bond Donors:** Ligand A (0) is better than Ligand B (1). Fewer H-bond donors generally improve permeability.
**5. H-Bond Acceptors:** Ligand A (3) is better than Ligand B (7). Similar to HBDs, fewer HBAs are generally preferred.
**6. QED:** Both ligands have good QED scores (A: 0.788, B: 0.806), indicating good drug-like properties.
**7. DILI Risk:** Ligand A (39.318) is significantly better than Ligand B (84.296). Lower DILI risk is crucial for drug development.
**8. BBB Penetration:** Ligand A (78.868) is better than Ligand B (71.307). While ADRB2 is primarily a cardiovascular target, some CNS side effects are possible with GPCR ligands, so moderate BBB penetration is not necessarily detrimental and could offer some flexibility.
**9. Caco-2 Permeability:** Ligand A (-4.131) is better than Ligand B (-5.413). Higher Caco-2 permeability indicates better intestinal absorption.
**10. Aqueous Solubility:** Ligand A (-4.807) is better than Ligand B (-2.544). Better solubility is generally preferred for formulation.
**11. hERG Inhibition:** Ligand A (0.771) is better than Ligand B (0.102). Lower hERG inhibition is crucial for avoiding cardiotoxicity, especially important for a cardiovascular target.
**12. Microsomal Clearance:** Ligand A (100.792) is worse than Ligand B (4.379). Higher clearance means faster metabolism and potentially lower drug exposure. This is a significant drawback for Ligand A.
**13. In vitro Half-Life:** Ligand A (-4.964) is better than Ligand B (-3.74). Longer half-life is generally desirable.
**14. P-gp Efflux:** Ligand A (0.459) is better than Ligand B (0.049). Lower P-gp efflux improves bioavailability.
**15. Binding Affinity:** Both ligands have very similar and excellent binding affinities (-7.6 and -7.7 kcal/mol). The difference is negligible.
**Overall Assessment:**
Ligand A has a significantly better profile across most ADME-Tox properties (TPSA, DILI, hERG, P-gp, solubility, Caco-2). While its microsomal clearance is a concern, the substantial advantages in other areas, particularly the lower TPSA and DILI risk, outweigh this drawback. Ligand B's high TPSA and DILI risk are major red flags. The similar binding affinities make the ADME/Tox profile the deciding factor.
Output:
1
2025-04-17 23:16:48,802 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [345.491, 63.05, 2.595, 1, 5, 0.911, 23.885, 70.531, -5.13, -1.704, 0.258, 21.535, -2.577, 0.101, -6.6]
**Ligand B:** [341.455, 56.41, 2.22, 1, 2, 0.835, 16.169, 76.619, -5.014, -2.166, 0.374, 31.256, -38.361, 0.197, -7.5]
Here's a breakdown, considering the GPCR priorities (logP, Pgp, TPSA, BBB, and affinity):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (341.455) is slightly lower, which is generally favorable.
2. **TPSA:** Ligand A (63.05) is a bit higher than Ligand B (56.41). Both are acceptable for a cardiovascular target, but Ligand B is better.
3. **logP:** Both are within the optimal range (1-3). Ligand B (2.22) is slightly lower than Ligand A (2.595), which is a minor advantage.
4. **HBD/HBA:** Both have 1 HBD, which is good. Ligand A has 5 HBA, while Ligand B has 2. Ligand B is better here.
5. **QED:** Ligand A (0.911) has a better QED score than Ligand B (0.835), indicating better overall drug-likeness.
6. **DILI:** Ligand B (16.169) has a significantly lower DILI risk than Ligand A (23.885). This is a major advantage.
7. **BBB:** Both have good BBB penetration (Ligand A: 70.531, Ligand B: 76.619), but Ligand B is slightly better.
8. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. This is a concern for both.
9. **Solubility:** Both have negative solubility values, indicating poor solubility. This is a concern for both.
10. **hERG:** Both have low hERG risk (Ligand A: 0.258, Ligand B: 0.374).
11. **Cl_mic:** Ligand A (21.535) has a lower microsomal clearance than Ligand B (31.256), suggesting better metabolic stability.
12. **t1/2:** Ligand B (-38.361) has a significantly longer in vitro half-life than Ligand A (-2.577). This is a substantial advantage.
13. **Pgp:** Both have low Pgp efflux liability (Ligand A: 0.101, Ligand B: 0.197).
14. **Affinity:** Ligand B (-7.5 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.6 kcal/mol). This is a key advantage, outweighing some of the minor ADME drawbacks.
**Overall Assessment:**
While Ligand A has a slightly better QED and lower Cl_mic, Ligand B excels in several critical areas: lower DILI risk, better BBB penetration, significantly longer half-life, and, most importantly, a substantially stronger binding affinity. The affinity difference of 0.9 kcal/mol is significant. The poor Caco-2 and solubility are concerns for both, but can potentially be addressed with formulation strategies. Given the GPCR target class and the importance of potency and safety, Ligand B is the more promising candidate.
Output:
0
2025-04-17 23:16:48,802 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (358.479 and 348.443 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (96.89 and 98.66) are below the 140 A^2 threshold for good oral absorption, but are not optimal for CNS penetration (target is cardiovascular, so this is less critical).
3. **logP:** Ligand A (0.989) is slightly lower than Ligand B (1.873), but both are within the optimal 1-3 range. Ligand B is preferable here.
4. **HBD:** Ligand A (3) is better than Ligand B (4). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (5) is better than Ligand B (4). Lower HBA generally improves permeability.
6. **QED:** Both ligands have good QED scores (0.541 and 0.631), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Both ligands have similar and acceptable DILI risk (36.681 and 37.03 percentile).
8. **BBB:** Ligand A (37.805) has a lower BBB penetration than Ligand B (51.493). Since ADRB2 is a cardiovascular target, BBB penetration is not a primary concern, but higher is generally better.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.096 and -4.707). This is unusual and suggests poor permeability. However, the values are similar, so it doesn't differentiate the ligands.
10. **Solubility:** Ligand A (-1.695) has better solubility than Ligand B (-2.767). Solubility is important for bioavailability.
11. **hERG:** Both ligands have low hERG inhibition risk (0.257 and 0.359).
12. **Cl_mic:** Ligand B (26.019) has significantly lower microsomal clearance than Ligand A (36.719), indicating better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand B (15.379 hours) has a longer in vitro half-life than Ligand A (9.257 hours). This is a significant advantage.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.066 and 0.096).
15. **Binding Affinity:** Ligand B (-7.8 kcal/mol) has a significantly better binding affinity than Ligand A (-6.1 kcal/mol). This is a substantial advantage, and can outweigh some ADME drawbacks.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand B performs better in logP, has comparable TPSA and Pgp, and *significantly* better affinity. The improved metabolic stability (lower Cl_mic) and longer half-life are also very favorable. While Ligand A has better solubility and slightly better HBD/HBA, the substantial affinity advantage of Ligand B outweighs these.
**Conclusion:**
Ligand B is the more promising drug candidate due to its superior binding affinity, metabolic stability, half-life, and acceptable overall profile.
Output:
0
2025-04-17 23:16:48,802 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Step-by-step comparison:**
1. **MW:** Both ligands (344.415 and 346.475 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (84.42) is slightly higher than Ligand B (76.44). Both are below the 140 threshold for good oral absorption, and acceptable for a non-CNS GPCR target like ADRB2.
3. **logP:** Ligand A (2.601) is within the optimal 1-3 range. Ligand B (1.518) is at the lower end of this range. While not a dealbreaker, a slightly higher logP is generally preferred for membrane permeability.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 5 HBA, and Ligand B has 4. Both are acceptable.
6. **QED:** Both ligands have good QED scores (0.673 and 0.723, respectively), indicating good drug-like properties.
7. **DILI:** Ligand A (47.421) has a moderate DILI risk, while Ligand B (9.926) has a very low DILI risk. This is a significant advantage for Ligand B.
8. **BBB:** Both ligands have relatively low BBB penetration, which is fine for a cardiovascular target like ADRB2. Ligand A (85.343) is slightly better than Ligand B (73.478) but this is not a major factor.
9. **Caco-2:** Both ligands have negative Caco-2 values which is unusual and indicates poor permeability. Ligand A (-4.572) is slightly better than Ligand B (-5.043).
10. **Solubility:** Both ligands have negative solubility values, which is also unusual and indicates poor solubility. Ligand A (-2.824) is slightly better than Ligand B (-1.91).
11. **hERG:** Ligand A (0.122) has a very low hERG risk, while Ligand B (0.478) has a slightly higher, but still acceptable, risk.
12. **Cl_mic:** Ligand A (54.131) has a higher microsomal clearance, indicating faster metabolism. Ligand B (-5.212) has a *negative* clearance, which is highly unusual and suggests very high metabolic stability. This is a major advantage for Ligand B.
13. **t1/2:** Ligand A (-4.254) has a negative half-life, which is unusual. Ligand B (11.118) has a good in vitro half-life.
14. **Pgp:** Ligand A (0.029) has very low P-gp efflux, while Ligand B (0.006) has even lower efflux. Both are excellent.
15. **Binding Affinity:** Ligand A (-7.1) has a slightly better binding affinity than Ligand B (-5.8). This is a 1.3 kcal/mol difference, which is significant.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity, Ligand B demonstrates a significantly superior ADME profile. The extremely low DILI risk, negative (and therefore very low) microsomal clearance, and good in vitro half-life are major advantages. The slightly lower logP and Caco-2/solubility are less concerning given the target (ADRB2, a cardiovascular GPCR where CNS penetration is not desired). The unusual negative values for Caco-2 and solubility are concerning, but the overall profile of B is more promising.
Therefore, I would choose Ligand B.
0
2025-04-17 23:16:48,803 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [350.849, 41.99, 4.949, 1, 2, 0.676, 77.782, 53.974, -4.991, -5.486, 0.506, 81.033, 43.373, 0.502, -6.6]
**Ligand B:** [347.459, 84.23, 2.803, 2, 4, 0.708, 25.397, 46.646, -4.954, -2.499, 0.097, 19.158, 1.629, 0.056, -6.1]
Here's a step-by-step comparison, keeping the GPCR-specific priorities (logP, Pgp, TPSA, and affinity) in mind:
1. **MW:** Both ligands are within the ideal range (200-500 Da). A is 350.849, B is 347.459 - very similar.
2. **TPSA:** Ligand A (41.99) is significantly better than Ligand B (84.23). ADRB2 is not a CNS target, but lower TPSA generally correlates with better permeability.
3. **logP:** Ligand A (4.949) is a bit high, but still acceptable. Ligand B (2.803) is excellent. This favors B.
4. **HBD:** Both have acceptable HBD counts (A: 1, B: 2).
5. **HBA:** Both have acceptable HBA counts (A: 2, B: 4).
6. **QED:** Both are above 0.5 (A: 0.676, B: 0.708), indicating good drug-like properties. B is slightly better.
7. **DILI:** Ligand A (77.782) has a considerably higher DILI risk than Ligand B (25.397). This is a significant negative for A.
8. **BBB:** Not a primary concern for a cardiovascular target, but A (53.974) is slightly better than B (46.646).
9. **Caco-2:** Both are negative, indicating poor permeability.
10. **Solubility:** Both are negative, indicating poor solubility.
11. **hERG:** Ligand A (0.506) is slightly better than Ligand B (0.097), indicating lower hERG inhibition risk.
12. **Cl_mic:** Ligand A (81.033) has a higher clearance than Ligand B (19.158), suggesting lower metabolic stability. This favors B.
13. **t1/2:** Ligand A (43.373) has a longer half-life than Ligand B (1.629), which is a positive for A.
14. **Pgp:** Ligand A (0.502) has lower P-gp efflux liability than Ligand B (0.056), which is a positive for A.
15. **Affinity:** Ligand A (-6.6 kcal/mol) has a slightly better binding affinity than Ligand B (-6.1 kcal/mol).
**Overall Assessment:**
While Ligand A has a slightly better binding affinity and half-life, the significantly higher DILI risk and higher metabolic clearance are major drawbacks. Ligand B has a more favorable logP, lower DILI risk, and better metabolic stability, which are crucial for a viable drug candidate. The TPSA is higher for B, but not critically so for a non-CNS target. The Pgp efflux is lower for A, but the difference isn't substantial enough to outweigh the other factors.
Therefore, I would prioritize Ligand B.
Output:
0
2025-04-17 23:16:48,803 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (340-350 Da). No clear advantage.
2. **TPSA:** Ligand A (86.88) is significantly better than Ligand B (114.53). ADRB2 is a cardiovascular target, not CNS, but lower TPSA generally improves permeability.
3. **logP:** Ligand A (2.814) is optimal. Ligand B (-0.264) is quite low, potentially hindering membrane permeability and absorption. This is a significant drawback.
4. **HBD:** Both ligands have acceptable HBD counts (3 and 4 respectively).
5. **HBA:** Both ligands have acceptable HBA counts (3 and 4 respectively).
6. **QED:** Ligand A (0.646) is better than Ligand B (0.459), indicating a more drug-like profile.
7. **DILI:** Ligand B (18.108) has a much lower DILI risk than Ligand A (54.285). This is a strong point in favor of Ligand B.
8. **BBB:** Not a primary concern for a cardiovascular target, but Ligand A (33.23) is slightly better than Ligand B (21.171).
9. **Caco-2:** Ligand A (-5.288) is better than Ligand B (-5.814), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-3.804) is better than Ligand B (-1.219), indicating better solubility.
11. **hERG:** Both ligands have very low hERG risk (0.463 and 0.041 respectively), which is excellent.
12. **Cl_mic:** Ligand B (-3.256) has a negative clearance, which is extremely favorable, suggesting very high metabolic stability. Ligand A (23.437) is significantly higher.
13. **t1/2:** Ligand B (-3.394) has a negative half-life, which is extremely favorable. Ligand A (22.511) is significantly higher.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.131 and 0.008 respectively), which is excellent.
15. **Binding Affinity:** Both ligands have the same binding affinity (-5.3 kcal/mol), so this parameter doesn't differentiate them.
**GPCR-specific considerations:**
For a GPCR like ADRB2, logP, TPSA, and metabolic stability (Cl_mic, t1/2) are important. Ligand A has a better TPSA and solubility, but Ligand B has a significantly better logP, and *much* better metabolic stability (Cl_mic and t1/2). The DILI risk is also much lower for Ligand B. While Ligand A has a slightly better Caco-2 permeability, the overall profile of Ligand B is more favorable.
**Conclusion:**
Despite Ligand A's slightly better TPSA and solubility, Ligand B's superior logP, metabolic stability (Cl_mic, t1/2), and significantly lower DILI risk outweigh these advantages. The binding affinity is identical, removing that as a differentiating factor.
Output:
0
2025-04-17 23:16:48,803 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (331.379) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (64.74) is significantly better than Ligand B (93.36). For a GPCR, keeping TPSA low is beneficial for permeability and receptor engagement. Ligand B is approaching a level that could hinder oral absorption.
3. **logP:** Ligand A (3.07) is optimal, while Ligand B (-0.727) is too low. Low logP can lead to poor membrane permeability and bioavailability. This is a significant drawback for Ligand B.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Fewer hydrogen bond donors generally improve membrane permeability.
5. **HBA:** Both ligands have the same number of HBA (5), which is acceptable.
6. **QED:** Both ligands have similar QED scores (0.625 and 0.604), indicating good drug-likeness.
7. **DILI:** Ligand A (88.251) has a higher DILI risk than Ligand B (11.283). This is a concern for Ligand A, but not insurmountable if other properties are strongly favorable.
8. **BBB:** Ligand A (73.556) has a much better BBB penetration score than Ligand B (38.232). While ADRB2 isn't strictly a CNS target, some CNS exposure can occur, and higher BBB penetration is generally a positive attribute.
9. **Caco-2:** Both ligands have negative Caco-2 values, suggesting poor permeability. This is a concern for both, but the lower value for Ligand B (-5.81) is worse than Ligand A (-5.134).
10. **Solubility:** Ligand A (-4.499) has better solubility than Ligand B (-0.494). Solubility is important for formulation and bioavailability.
11. **hERG:** Ligand A (0.736) has a lower hERG risk than Ligand B (0.141). This is a significant safety advantage for Ligand A.
12. **Cl_mic:** Ligand B (-11.714) has significantly lower microsomal clearance than Ligand A (60.02). This indicates better metabolic stability for Ligand B.
13. **t1/2:** Ligand B (-12.198) has a much longer in vitro half-life than Ligand A (69.917), suggesting better duration of action.
14. **Pgp:** Ligand A (0.554) has lower P-gp efflux than Ligand B (0.001), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand A (-6.8) has slightly better binding affinity than Ligand B (-6.2). While the difference is not huge, it is still a positive for Ligand A.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, and affinity are crucial. Ligand A excels in these areas. While Ligand B has better metabolic stability and a longer half-life, its poor logP and higher TPSA are major drawbacks. The DILI risk for Ligand A is a concern, but can potentially be mitigated through structural modifications.
**Conclusion:**
Despite the higher DILI risk, Ligand A is the more promising candidate due to its superior logP, TPSA, BBB penetration, solubility, hERG risk, and slightly better affinity. These properties are more critical for a GPCR target.
Output:
1
2025-04-17 23:16:48,803 - INFO - Batch 393 complete. Total preferences: 6288
2025-04-17 23:16:48,803 - INFO - Processing batch 394/512...
2025-04-17 23:17:38,545 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Step-by-step comparison:**
1. **MW:** Both ligands (342.41 and 356.411 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (43.37) is significantly better than Ligand B (95.39). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand B's TPSA is quite high, potentially hindering oral bioavailability.
3. **logP:** Ligand A (4.607) is higher than Ligand B (0.991). While both are within acceptable ranges, Ligand A is approaching the upper limit. Ligand B is quite low, which might lead to poor membrane permeability.
4. **HBD:** Ligand A (0) is preferable to Ligand B (3). Fewer HBDs generally improve membrane permeability.
5. **HBA:** Ligand A (3) is better than Ligand B (6). Similar to HBDs, fewer HBAs are generally preferred.
6. **QED:** Both ligands have similar QED values (0.569 and 0.608), indicating good drug-likeness.
7. **DILI:** Ligand A (65.413) is better than Ligand B (81.815). Lower DILI risk is always preferred.
8. **BBB:** Ligand A (71.229) is much better than Ligand B (24.506). While not a CNS target, some degree of BBB penetration can be indicative of good permeability.
9. **Caco-2:** Ligand A (-4.237) is better than Ligand B (-5.719). Higher Caco-2 permeability suggests better absorption.
10. **Solubility:** Ligand A (-5.898) is better than Ligand B (-3.351). Higher solubility is generally desirable.
11. **hERG:** Both ligands have similar hERG values (0.409 and 0.436), indicating low risk of cardiotoxicity.
12. **Cl_mic:** Ligand B (-5.742) is significantly better than Ligand A (123.748). Lower microsomal clearance indicates greater metabolic stability, a crucial factor for drug duration.
13. **t1/2:** Ligand A (25.382) is much better than Ligand B (13.041). Longer half-life is generally preferred.
14. **Pgp:** Ligand A (0.647) is better than Ligand B (0.095). Lower P-gp efflux is desirable for improved bioavailability.
15. **Binding Affinity:** Ligand B (-8.4) is significantly better than Ligand A (-5.4). A 3 kcal/mol difference in binding affinity is substantial and can often outweigh other ADME concerns.
**GPCR-specific priorities:** For GPCRs, logP, TPSA, Pgp, and affinity are key. Ligand B has a lower logP and TPSA, which are good, but Ligand A is better on Pgp. However, the substantial affinity advantage of Ligand B is the deciding factor. While Ligand A has better ADME properties overall, the significantly stronger binding of Ligand B to ADRB2 is likely to translate to greater efficacy. The metabolic stability of Ligand B is also a positive.
**Conclusion:**
Despite some ADME drawbacks, the superior binding affinity of Ligand B makes it the more promising drug candidate.
Output:
0
2025-04-17 23:17:38,545 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
Let's break down the comparison of Ligand A and Ligand B based on the provided parameters and the guidelines, keeping in mind this is a GPCR target (ADRB2, cardiovascular). Therefore, logP, TPSA, Pgp, and affinity are particularly important.
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (406.511 Da) is slightly higher than Ligand B (357.495 Da), but both are acceptable.
2. **TPSA:** Ligand B (73.32) is significantly better than Ligand A (130.51). A TPSA under 140 is good for oral absorption, and lower is generally preferred for GPCRs. Ligand B is much closer to the ideal range for good absorption.
3. **logP:** Both ligands have acceptable logP values (A: 0.511, B: 0.419), falling within the 1-3 range. They are on the lower end, but not concerning.
4. **H-Bond Donors:** Ligand A (3) is higher than Ligand B (1). Both are within the acceptable limit of 5.
5. **H-Bond Acceptors:** Ligand A (9) is higher than Ligand B (5). Both are within the acceptable limit of 10.
6. **QED:** Ligand B (0.682) has a slightly better QED score than Ligand A (0.553), indicating a more drug-like profile.
7. **DILI:** Ligand B (7.135) has a *much* lower DILI risk than Ligand A (87.553). This is a major advantage for Ligand B.
8. **BBB:** Ligand B (62.156) has a better BBB penetration score than Ligand A (45.599). While ADRB2 isn't necessarily a CNS target, some peripheral exposure can be beneficial, and lower Pgp efflux (see below) can contribute to this.
9. **Caco-2 Permeability:** Ligand A (-5.85) has better Caco-2 permeability than Ligand B (-4.586), suggesting better intestinal absorption.
10. **Aqueous Solubility:** Ligand A (-2.107) has better aqueous solubility than Ligand B (-0.351).
11. **hERG:** Ligand A (0.097) has a slightly lower hERG risk than Ligand B (0.236), which is preferable.
12. **Microsomal Clearance:** Ligand B (13.178) has significantly lower microsomal clearance than Ligand A (35.221), indicating better metabolic stability.
13. **In vitro Half-Life:** Ligand A (7.085) has a slightly longer in vitro half-life than Ligand B (0.058).
14. **P-gp Efflux:** Ligand A (0.054) has a lower P-gp efflux liability than Ligand B (0.014), which is desirable.
15. **Binding Affinity:** Ligand B (-6.6 kcal/mol) has a significantly better binding affinity than Ligand A (-5.7 kcal/mol). This is a >1 kcal/mol difference, which is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand B is the stronger candidate. While Ligand A has slightly better Caco-2 permeability, solubility, and P-gp efflux, Ligand B excels in critical areas: significantly lower DILI risk, better metabolic stability (lower Cl_mic), superior binding affinity, and a better TPSA. The substantial difference in binding affinity (-6.6 vs -5.7 kcal/mol) is a key factor, and the lower DILI risk is a major safety advantage. The better QED score also supports its drug-like properties.
Output:
0
2025-04-17 23:17:38,545 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (348.399 and 356.457 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (99.85) is higher than Ligand B (49.41). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for permeability. Ligand B is significantly better.
3. **logP:** Ligand A (1.532) is within the optimal range (1-3), while Ligand B (3.521) is at the higher end. While still acceptable, Ligand B's higher logP *could* lead to solubility issues or off-target interactions. Ligand A is slightly favored.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable.
5. **HBA:** Ligand A (5) and Ligand B (2) are both acceptable.
6. **QED:** Both ligands have good QED scores (0.6 and 0.74 respectively), indicating good drug-like properties. No clear advantage.
7. **DILI:** Ligand A (47.034) has a higher DILI risk than Ligand B (24.777). Ligand B is significantly better regarding liver toxicity.
8. **BBB:** Ligand A (51.803) has a lower BBB penetration than Ligand B (88.988). While ADRB2 isn't a primary CNS target, some peripheral exposure is still desirable, and higher BBB penetration *generally* correlates with better overall distribution. Ligand B is favored.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.953 and -4.58). This is unusual and suggests poor permeability. However, the values are similar.
10. **Solubility:** Ligand A (-1.949) has better solubility than Ligand B (-3.465). This is a moderate advantage for Ligand A.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.129 and 0.565). No significant difference.
12. **Cl_mic:** Ligand A (12.269) has a lower microsomal clearance than Ligand B (26.296), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (-6.272) has a worse in vitro half-life than Ligand B (-13.81). This is a significant advantage for Ligand B.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.109 and 0.103). No significant difference.
15. **Binding Affinity:** Both ligands have the same binding affinity (-6.2 kcal/mol).
**Overall Assessment & GPCR Prioritization:**
For a cardiovascular GPCR like ADRB2, we prioritize logP, TPSA, Pgp, and affinity. Ligand B excels in TPSA and BBB penetration, while Ligand A has better solubility and metabolic stability (lower Cl_mic). The DILI risk is also much lower for Ligand B. The similar binding affinity means that the ADME properties become the deciding factor. The lower DILI and better BBB penetration of Ligand B outweigh the slightly higher logP and worse solubility. The better half-life of Ligand B is also a benefit.
Output:
0
2025-04-17 23:17:38,545 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (358.429 and 355.391 Da) fall comfortably within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (69.64) is significantly better than Ligand B (106.2). ADRB2 is not a CNS target, but lower TPSA generally improves absorption.
3. **logP:** Ligand A (2.078) is optimal. Ligand B (-0.889) is below the preferred range and could indicate poor membrane permeability. This is a significant negative for Ligand B.
4. **HBD:** Both ligands have 2 HBD, which is within the acceptable limit of 5.
5. **HBA:** Ligand A has 3 HBA, while Ligand B has 6. Ligand A is preferable.
6. **QED:** Ligand A (0.764) is better than Ligand B (0.547), indicating a more drug-like profile.
7. **DILI:** Ligand A (21.055) has a much lower DILI risk than Ligand B (37.999). This is a substantial advantage for Ligand A.
8. **BBB:** Not a primary concern for ADRB2, but Ligand A (89.802) is better than Ligand B (75.843).
9. **Caco-2:** Ligand A (-4.747) and Ligand B (-5.052) are both poor.
10. **Solubility:** Ligand A (-3.337) is better than Ligand B (-1.385), indicating better aqueous solubility.
11. **hERG:** Ligand A (0.662) has a lower hERG risk than Ligand B (0.188). This is a significant advantage.
12. **Cl_mic:** Ligand A (10.989) has a much better (lower) microsomal clearance than Ligand B (-41.567). This suggests greater metabolic stability for Ligand A.
13. **t1/2:** Ligand A (2.428) has a better in vitro half-life than Ligand B (-24.928).
14. **Pgp:** Ligand A (0.064) has a lower Pgp efflux liability than Ligand B (0.005).
15. **Binding Affinity:** Ligand B (-7.3) has a slightly better binding affinity than Ligand A (-6.9) but the difference is only 0.4 kcal/mol. Given the significant ADME advantages of Ligand A, this difference is unlikely to be decisive.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical ADME properties (DILI, solubility, metabolic stability, Pgp efflux, hERG). While Ligand B has slightly better binding affinity, the overall profile of Ligand A is far more favorable for drug development. The logP value of Ligand B is a major concern.
Output:
1
2025-04-17 23:17:38,545 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (344.46 and 346.48 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (86.88 and 86.34) are below the 140 A^2 threshold for good oral absorption, and well below the 90 A^2 for CNS targets (though this isn't a CNS target, lower TPSA is generally favorable). Again, a negligible difference.
3. **logP:** Both ligands have a logP around 2.5, which is optimal for permeability and minimizing off-target effects. No clear advantage.
4. **HBD:** Ligand A has 3 HBD, while Ligand B has 1. Lower HBD is generally preferred for better membrane permeability, giving a slight edge to Ligand B.
5. **HBA:** Ligand A has 3 HBA, while Ligand B has 8. Ligand A is better here, as fewer HBA generally correlates with better permeability.
6. **QED:** Ligand B (0.79) has a significantly better QED score than Ligand A (0.385), indicating a more drug-like profile. This is a substantial advantage for Ligand B.
7. **DILI:** Ligand A (35.67%) has a slightly better DILI score than Ligand B (43.74%), meaning lower predicted liver injury risk. This favors Ligand A.
8. **BBB:** Ligand B (71.81%) has a significantly higher BBB penetration score than Ligand A (53.43%). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be beneficial for distribution and off-target effects assessment. This favors Ligand B.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.315 and -5.38), which is unusual and suggests poor permeability. This is a significant concern for both, but doesn't differentiate them.
10. **Solubility:** Both ligands have negative solubility values (-2.672 and -2.748), indicating poor aqueous solubility. This is a major drawback for both, but again, doesn't differentiate them.
11. **hERG:** Ligand A (0.336) has a slightly higher hERG inhibition liability than Ligand B (0.095). Lower is better, favoring Ligand B.
12. **Cl_mic:** Ligand A (16.06) has a significantly lower microsomal clearance than Ligand B (28.22), indicating better metabolic stability. This is a strong advantage for Ligand A.
13. **t1/2:** Ligand A (-12.65) has a much more negative in vitro half-life than Ligand B (-3.42). This is counterintuitive, as negative values likely indicate a very *short* half-life. This strongly favors Ligand B.
14. **Pgp:** Ligand A (0.105) has a lower P-gp efflux liability than Ligand B (0.077), suggesting better oral bioavailability and potentially better CNS exposure. This favors Ligand A.
15. **Binding Affinity:** Ligand A (-7.3 kcal/mol) has a slightly better binding affinity than Ligand B (-5.9 kcal/mol). This is a significant advantage for Ligand A, and can often outweigh minor ADME concerns.
**GPCR-specific priorities:** For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Affinity is the most important. Ligand A has a better affinity. While Ligand B has better BBB penetration, this isn't critical for ADRB2. Ligand B has better QED, but Ligand A has better metabolic stability and Pgp efflux. The poor Caco-2 and solubility for both are concerning, but the affinity difference is substantial.
**Conclusion:**
Despite the poor Caco-2 and solubility, Ligand A's superior binding affinity (-7.3 vs -5.9 kcal/mol) and better metabolic stability (lower Cl_mic) outweigh the advantages of Ligand B. The affinity difference is significant enough to make Ligand A the more promising candidate.
Output:
1
2025-04-17 23:17:38,545 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (345.4) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (86.88) is significantly better than Ligand A (102.76). For a GPCR, lower TPSA is preferred for better brain penetration and overall absorption.
3. **logP:** Ligand B (1.581) is better than Ligand A (0.516). Both are within the optimal range, but Ligand B is closer to the ideal 1-3 range. Ligand A's low logP could indicate permeability issues.
4. **HBD:** Both ligands have 3 HBD, which is acceptable.
5. **HBA:** Ligand B (4) has fewer HBA than Ligand A (5), which is slightly better for permeability.
6. **QED:** Both are reasonably good (A: 0.675, B: 0.582), indicating drug-like properties.
7. **DILI:** Ligand A (25.09) has a much lower DILI risk than Ligand B (38.58). This is a significant advantage for Ligand A.
8. **BBB:** Ligand B (51.76) has a higher BBB penetration percentile than Ligand A (22.96). While ADRB2 isn't strictly a CNS target, some brain exposure can be relevant for side effect profiles.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, these values are on a log scale, so the absolute difference is significant. Ligand B (-5.859) is slightly better than Ligand A (-5.446).
10. **Solubility:** Ligand A (-1.695) has slightly better solubility than Ligand B (-2.427).
11. **hERG:** Both have very low hERG inhibition risk (A: 0.028, B: 0.187).
12. **Cl_mic:** Ligand A (-9.407) has much lower (better) microsomal clearance than Ligand B (20.652), indicating better metabolic stability.
13. **t1/2:** Ligand A (-20.952) has a longer in vitro half-life than Ligand B (-4.361), which is desirable.
14. **Pgp:** Both have very low Pgp efflux liability.
15. **Affinity:** Both have similar, strong binding affinities (A: -6.3 kcal/mol, B: -6.5 kcal/mol). Ligand B is slightly better, but the difference is small.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, and metabolic stability (Cl_mic, t1/2) are crucial. Ligand B has a better logP and TPSA, but Ligand A has significantly better metabolic stability (lower Cl_mic, longer t1/2) and lower DILI risk. The affinity difference is minimal.
**Overall Assessment:**
While Ligand B has some advantages in TPSA and logP, the significantly better metabolic stability (Cl_mic and t1/2) and lower DILI risk of Ligand A are more important for overall drug development success. The slightly better solubility of Ligand A is also a bonus. The small affinity difference doesn't outweigh these ADME/Tox benefits.
Output:
1
2025-04-17 23:17:38,546 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [341.415, 94.46, 1.967, 3, 3, 0.779, 58.589, 77.782, -5.132, -3.575, 0.697, -31.795, 5.367, 0.022, -6.6]
**Ligand B:** [356.438, 67.87, 1.426, 1, 4, 0.809, 40.054, 78.868, -4.598, -2.018, 0.401, 5.876, 1.354, 0.05, -6.0]
Here's a breakdown, prioritizing GPCR properties (logP, TPSA, Pgp, BBB, Affinity):
1. **Molecular Weight:** Both are within the ideal 200-500 Da range. A (341.415) is slightly preferred.
2. **TPSA:** A (94.46) is a bit higher than B (67.87). B is better here, closer to the <90 ideal for potential CNS penetration, although this isn't a CNS target.
3. **logP:** Both are good (1.967 and 1.426, both within 1-3). A is slightly higher, which *could* be beneficial for membrane permeability, but both are acceptable.
4. **H-Bond Donors/Acceptors:** A (3/3) and B (1/4) are both reasonable. B has a slight edge with fewer HBDs.
5. **QED:** Both are good (>0.5), with B (0.809) being slightly better than A (0.779).
6. **DILI:** B (40.054) is significantly better than A (58.589). This is a major advantage for B.
7. **BBB:** Both have good BBB penetration (A: 77.782, B: 78.868). Very similar.
8. **Caco-2:** Both are negative, indicating poor permeability. A (-5.132) is worse than B (-4.598).
9. **Solubility:** Both are very poor (-3.575 and -2.018). This is a significant drawback for both, but B is slightly better.
10. **hERG:** Both are low risk (0.697 and 0.401). B is better.
11. **Cl_mic:** A (-31.795) is *much* better than B (5.876). A has a very low, desirable clearance, indicating good metabolic stability.
12. **t1/2:** A (5.367) is better than B (1.354).
13. **Pgp:** Both are very low (0.022 and 0.05). Similar.
14. **Binding Affinity:** A (-6.6) is slightly better than B (-6.0), though the difference is relatively small.
**Overall Assessment:**
Ligand A has a significant advantage in metabolic stability (Cl_mic and t1/2) and slightly better affinity. However, Ligand B shines with a much lower DILI risk and better solubility. The Caco-2 permeability is poor for both, which is a concern. Given the importance of minimizing toxicity (DILI) and the relatively small difference in binding affinity, I favor Ligand B. The improved safety profile outweighs the slightly weaker binding and poorer metabolic stability.
Output:
0
2025-04-17 23:17:38,546 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands (376.4 and 384.5) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (67.43) is significantly better than Ligand B (96.11). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally improves absorption.
3. **logP:** Ligand A (2.666) is optimal, while Ligand B (0.901) is a bit low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (2) is preferable to Ligand B (3). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (4) is better than Ligand B (6). Lower HBA is also generally preferable for permeability.
6. **QED:** Both ligands have similar QED values (0.732 vs 0.674), indicating good drug-likeness.
7. **DILI:** Both ligands have similar DILI risk (57.658 vs 59.907), both are acceptable.
8. **BBB:** Ligand A (81.078) is better than Ligand B (41.218). While not a CNS target, some level of BBB penetration can indicate favorable distribution properties.
9. **Caco-2:** Ligand A (-4.657) is better than Ligand B (-5.733). Higher Caco-2 values indicate better intestinal absorption.
10. **Solubility:** Ligand A (-3.775) is better than Ligand B (-3.279).
11. **hERG:** Both ligands have very low hERG inhibition risk (0.392 and 0.254).
12. **Cl_mic:** Ligand A (52.303) has a higher clearance than Ligand B (20.49), indicating lower metabolic stability. This is a significant drawback for Ligand A.
13. **t1/2:** Ligand B (8.978) has a significantly longer in vitro half-life than Ligand A (-11.597). This is a major advantage for Ligand B.
14. **Pgp:** Ligand A (0.174) is better than Ligand B (0.016). Lower P-gp efflux is desirable.
15. **Affinity:** Ligand B (7.2 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.0 kcal/mol). This is a substantial advantage, potentially outweighing some ADME concerns.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A excels in logP, TPSA, and Pgp, but Ligand B has a much stronger binding affinity. The longer half-life of Ligand B is also a significant advantage. While Ligand A has better solubility, the affinity difference is substantial.
**Conclusion:**
Despite Ligand A's slightly better TPSA and Pgp properties, the significantly stronger binding affinity and longer half-life of Ligand B make it the more promising drug candidate. The lower metabolic clearance of Ligand B is also a positive factor.
Output:
0
2025-04-17 23:17:38,546 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (369.443 and 351.451 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (82.03) is significantly better than Ligand A (105.67). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have low logP values (0.132 and 0.227). While generally 1-3 is optimal, these are quite low and could indicate permeability issues. Ligand B is slightly better.
4. **HBD:** Both have 1 HBD, which is acceptable.
5. **HBA:** Ligand B (7) is slightly better than Ligand A (6), both are within the acceptable range.
6. **QED:** Both ligands have good QED scores (0.663 and 0.753), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Both ligands have similar DILI risk (47.654 and 48.817), and both are below the concerning threshold of 60.
8. **BBB:** Ligand A (71.035) has a higher BBB percentile than Ligand B (66.848). However, as ADRB2 is a cardiovascular target, BBB penetration is not a major priority.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.998) is slightly better than Ligand B (-4.657).
10. **Solubility:** Ligand A (-2.1) is better than Ligand B (-0.446). Solubility is important for bioavailability.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.05 and 0.496). Excellent for both.
12. **Cl_mic:** Ligand A (20.164) has significantly lower microsomal clearance than Ligand B (41.97), indicating better metabolic stability.
13. **t1/2:** Ligand B (-8.622) has a longer in vitro half-life than Ligand A (-13.213). This is a positive for Ligand B.
14. **Pgp:** Both have very low Pgp efflux liability (0.022 and 0.029). Excellent for both.
15. **Binding Affinity:** Ligand A (-6.9 kcal/mol) has a slightly better binding affinity than Ligand B (-6.5 kcal/mol). This is a significant advantage, as potency is crucial.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B has better TPSA and QED, but Ligand A has better solubility, metabolic stability (Cl_mic), and crucially, a better binding affinity. The affinity difference of 0.4 kcal/mol is substantial enough to outweigh the slightly less favorable TPSA and logP of Ligand A.
**Conclusion:**
Considering the balance of properties and the priorities for a GPCR target, Ligand A is the more promising drug candidate due to its superior binding affinity and metabolic stability.
Output:
1
2025-04-17 23:17:38,546 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (349.519) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (52.65) is significantly better than Ligand B (87.3). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both are excellent (around 2.2), falling within the optimal 1-3 range.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Both are equal (3), which is acceptable.
6. **QED:** Both are good (0.658 and 0.608), indicating drug-like properties. Ligand A is slightly better.
7. **DILI:** Ligand A (6.282) is *much* better than Ligand B (24.234). This is a significant advantage for Ligand A, as liver toxicity is a major concern.
8. **BBB:** This is less critical for a cardiovascular target. Ligand A (83.249) is better than Ligand B (64.87), but the difference isn't decisive.
9. **Caco-2:** Ligand A (-4.935) is better than Ligand B (-5.606), indicating better intestinal absorption.
10. **Solubility:** Both are poor (-2.422 and -2.59). This is a potential issue for both, but not a dealbreaker if absorption is good.
11. **hERG:** Ligand A (0.652) is better than Ligand B (0.22), indicating a lower risk of cardiotoxicity. This is crucial for a cardiovascular target.
12. **Cl_mic:** Ligand A (23.14) is better than Ligand B (3.82), suggesting greater metabolic stability.
13. **t1/2:** Ligand A (7.867) is better than Ligand B (26.194).
14. **Pgp:** Ligand A (0.067) is better than Ligand B (0.043), indicating lower efflux.
15. **Binding Affinity:** Ligand B (-7.4) has a 1 kcal/mol advantage over Ligand A (-6.4). This is a substantial difference, and typically a major driver in selection.
**Overall Assessment:**
While Ligand B has a better binding affinity, Ligand A demonstrates a significantly superior ADMET profile. The lower DILI risk, better hERG profile, improved metabolic stability (Cl_mic and t1/2), and better permeability (TPSA, Caco-2) are compelling advantages. For a cardiovascular target, minimizing off-target effects (like liver toxicity and cardiotoxicity) is paramount. The 1 kcal/mol difference in binding affinity can potentially be overcome with further optimization of Ligand A, while mitigating the ADMET liabilities of Ligand B would be much more challenging.
**Output:**
1
2025-04-17 23:17:38,546 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's break down the comparison of Ligand A and Ligand B based on the provided parameters and the guidelines, keeping in mind ADRB2 is a GPCR and thus we prioritize logP, Pgp, TPSA, and affinity.
1. **Molecular Weight:** Both ligands (378.826 Da and 352.45 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (57.26) is better than Ligand B (69.64). Both are below 140, but lower TPSA generally favors better absorption.
3. **logP:** Both ligands have good logP values (2.838 and 2.091, respectively) within the optimal 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability.
4. **H-Bond Donors:** Both have 2 HBD, which is within the acceptable limit of <=5.
5. **H-Bond Acceptors:** Ligand A has 4 HBA, and Ligand B has 3. Both are below the limit of <=10.
6. **QED:** Ligand A (0.716) has a better QED score than Ligand B (0.519), indicating a more drug-like profile.
7. **DILI:** Ligand B (20.861) has a significantly lower DILI risk than Ligand A (34.742). This is a substantial advantage for Ligand B.
8. **BBB:** Ligand B (88.755) shows better BBB penetration than Ligand A (70.997). While ADRB2 isn't necessarily a CNS target, some peripheral ADRB2 activity can influence CNS pathways, and higher BBB penetration isn't necessarily a negative.
9. **Caco-2 Permeability:** Both have negative values, indicating permeability issues. Ligand A (-5.255) is slightly better than Ligand B (-4.905), but both are concerning.
10. **Aqueous Solubility:** Both have very poor aqueous solubility (-3.42 and -3.143). This is a significant drawback for both compounds and would require formulation strategies.
11. **hERG Inhibition:** Both ligands show low hERG inhibition risk (0.749 and 0.648, respectively).
12. **Microsomal Clearance:** Ligand A (15.996) has lower microsomal clearance than Ligand B (17.652), suggesting better metabolic stability.
13. **In vitro Half-Life:** Ligand A (33.182) has a much longer in vitro half-life than Ligand B (2.768). This is a major advantage for Ligand A.
14. **P-gp Efflux:** Ligand A (0.153) has lower P-gp efflux than Ligand B (0.315), suggesting better bioavailability.
15. **Binding Affinity:** Both ligands have identical binding affinity (-6.7 kcal/mol), so this parameter doesn't differentiate them.
**Overall Assessment:**
Ligand A has advantages in QED, metabolic stability (Cl_mic & t1/2), P-gp efflux, and slightly better Caco-2 permeability and TPSA. However, Ligand B has a significantly lower DILI risk and better BBB penetration. The longer half-life and better P-gp properties of Ligand A are compelling, but the lower DILI risk of Ligand B is a critical factor. Given the importance of avoiding liver toxicity, and the similar binding affinity, I would lean towards Ligand B. The solubility issues are a concern for both, but can be addressed with formulation.
**Output:**
0
2025-04-17 23:17:38,546 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (357.332 and 346.515 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (77.25) is higher than Ligand B (49.41). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for permeability. Ligand B has a clear advantage.
3. **logP:** Ligand A (4.341) is slightly higher than Ligand B (3.358). Both are above the optimal range of 1-3, but Ligand A is pushing the upper limit and could potentially have solubility issues. Ligand B is better positioned.
4. **HBD:** Both ligands have 1 HBD, which is within the acceptable limit of <=5. No difference.
5. **HBA:** Ligand A has 5 HBAs, while Ligand B has 2. Both are within the acceptable limit of <=10, but Ligand B is preferable.
6. **QED:** Both ligands have similar QED values (0.884 and 0.83), indicating good drug-likeness. No significant difference.
7. **DILI:** Ligand A (73.517) has a higher DILI risk than Ligand B (9.655). This is a significant advantage for Ligand B.
8. **BBB:** Both ligands have high BBB penetration (88.639 and 88.29). This isn't a primary concern for a cardiovascular target, but it doesn't hurt.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.493 and -4.802). These values are unusual and suggest poor permeability. However, the values are very close, so this is not a major differentiating factor.
10. **Solubility:** Both ligands have negative solubility values (-4.681 and -4.195). These values are also unusual and suggest poor solubility. Again, the values are close.
11. **hERG:** Ligand A (0.443) has a slightly lower hERG risk than Ligand B (0.656), which is a slight advantage.
12. **Cl_mic:** Ligand B (60.302) has a lower microsomal clearance than Ligand A (53.758), indicating better metabolic stability. This is a positive for Ligand B.
13. **t1/2:** Ligand B (-5.829) has a longer in vitro half-life than Ligand A (-25.94). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.287) has lower P-gp efflux than Ligand B (0.113), which is a slight advantage.
15. **Binding Affinity:** Ligand A (-7.8 kcal/mol) has a slightly better binding affinity than Ligand B (-5.9 kcal/mol). This is a significant advantage for Ligand A, and the 1.9 kcal/mol difference is substantial enough to potentially outweigh some ADME concerns.
**Overall Assessment:**
While Ligand A has a better binding affinity, Ligand B exhibits a significantly better safety profile (lower DILI) and improved ADME properties (lower Cl_mic, longer t1/2, lower HBA, lower logP). The affinity difference, while notable, isn't so large that it completely overshadows the more favorable ADME/Tox profile of Ligand B. For a cardiovascular target, metabolic stability and reduced toxicity are crucial.
Output:
0
2025-04-17 23:17:38,546 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [351.447, 95.67, 1.756, 2, 5, 0.661, 27.918, 51.493, -4.804, -1.611, 0.351, 31.035, 5.594, 0.228, -5.8]
**Ligand B:** [379.557, 29.54, 4.986, 0, 3, 0.565, 20.589, 94.61, -4.122, -4.662, 0.775, 89.848, 5.393, 0.328, -6.9]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (351.447) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (95.67) is higher than Ligand B (29.54). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is still preferable for absorption. Ligand B is significantly better here.
3. **logP:** Ligand A (1.756) is within the optimal range. Ligand B (4.986) is high, potentially leading to solubility issues and off-target interactions.
4. **HBD:** Ligand A (2) is reasonable. Ligand B (0) is also good, potentially improving membrane permeability.
5. **HBA:** Ligand A (5) is reasonable. Ligand B (3) is also good.
6. **QED:** Ligand A (0.661) is better than Ligand B (0.565), indicating a more drug-like profile.
7. **DILI:** Ligand A (27.918) has a lower DILI risk than Ligand B (20.589), which is a significant advantage.
8. **BBB:** Ligand B (94.61) has much better BBB penetration than Ligand A (51.493). However, since this is a cardiovascular target, BBB penetration is not a primary concern.
9. **Caco-2:** Ligand A (-4.804) is slightly better than Ligand B (-4.122), suggesting slightly better absorption.
10. **Solubility:** Ligand A (-1.611) is better than Ligand B (-4.662). The high logP of Ligand B suggests it may have poor aqueous solubility.
11. **hERG:** Ligand A (0.351) has a lower hERG risk than Ligand B (0.775), which is crucial for avoiding cardiotoxicity.
12. **Cl_mic:** Ligand A (31.035) has a lower microsomal clearance, indicating better metabolic stability, than Ligand B (89.848).
13. **t1/2:** Both are similar (Ligand A: 5.594, Ligand B: 5.393).
14. **Pgp:** Both are similar (Ligand A: 0.228, Ligand B: 0.328).
15. **Affinity:** Ligand B (-6.9 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.8 kcal/mol). This is a substantial advantage, potentially outweighing some ADME concerns.
**GPCR-Specific Priorities:**
For ADRB2 (a cardiovascular GPCR), we prioritize logP, TPSA, Pgp, and affinity. Ligand B excels in affinity and has a much lower TPSA. However, its high logP and potential solubility issues are concerning. Ligand A has a more balanced profile with better solubility, lower DILI, and lower hERG risk, but its affinity is weaker.
**Decision:**
The significantly stronger binding affinity of Ligand B (-6.9 kcal/mol vs -5.8 kcal/mol) is a major advantage for a GPCR target. While its logP is high, the other favorable properties (low TPSA, good BBB - though less critical here, reasonable Pgp) and the substantial potency gain make it the more promising candidate, *assuming* solubility can be addressed through formulation strategies.
0
2025-04-17 23:17:38,547 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [353.304, 84.04, 1.92, 0, 6, 0.838, 72.703, 83.443, -4.118, -3.531, 0.201, 63.809, -6.238, 0.374, -7.0]
**Ligand B:** [350.409, 58.2, 3.334, 2, 2, 0.558, 39.822, 81.233, -4.483, -3.494, 0.539, 29.673, 18.267, 0.201, -5.6]
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). A is 353.3, B is 350.4. Very similar.
2. **TPSA:** A (84.04) is slightly higher than B (58.2). Both are below the 140 threshold for oral absorption, but B is better positioned for potential CNS penetration if desired.
3. **logP:** A (1.92) is optimal, while B (3.334) is approaching the upper limit. B's higher logP could lead to off-target interactions or solubility issues.
4. **HBD:** A (0) is preferable to B (2). Fewer HBDs generally improve permeability.
5. **HBA:** A (6) is better than B (2). Fewer HBA's generally improve permeability.
6. **QED:** A (0.838) is significantly better than B (0.558), indicating a more drug-like profile.
7. **DILI:** A (72.703) is higher than B (39.822). B has a much lower risk of liver injury. This is a significant advantage for B.
8. **BBB:** Both are good (A: 83.443, B: 81.233). Since this is a cardiovascular target, BBB penetration isn't *critical*, but it's not detrimental.
9. **Caco-2:** Both are negative, indicating poor permeability. A (-4.118) is slightly worse than B (-4.483).
10. **Solubility:** Both are negative, indicating poor solubility. A (-3.531) is slightly worse than B (-3.494).
11. **hERG:** A (0.201) is better than B (0.539), indicating lower cardiotoxicity risk. This is crucial for a cardiovascular target.
12. **Cl_mic:** A (63.809) is higher than B (29.673), meaning B has better metabolic stability.
13. **t1/2:** A (-6.238) is much better than B (18.267). A has a longer in vitro half-life.
14. **Pgp:** A (0.374) is better than B (0.201), suggesting less P-gp efflux.
15. **Affinity:** A (-7.0) is better than B (-5.6). A has a significantly stronger binding affinity.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, we prioritize logP, Pgp, TPSA, and affinity. A has a better logP, Pgp, and significantly better affinity. B has a better TPSA and DILI.
**Overall Assessment:**
Ligand A's significantly stronger binding affinity (-7.0 vs -5.6 kcal/mol) is a major advantage. While B has a better DILI score and metabolic stability, the difference in affinity is substantial enough to outweigh these benefits, especially considering the cardiovascular context where metabolic issues can often be addressed through formulation or structural modifications. The QED score for A is also much better. The slightly worse Caco-2 and solubility for A are concerns, but these can be addressed through formulation strategies. The hERG risk for A is also better.
Therefore, I believe Ligand A is the more promising drug candidate.
Output:
1
2025-04-17 23:17:38,547 - INFO - Here's my reasoning and the final output:
**Reasoning:**
We are evaluating two ligands for the ADRB2, a cardiovascular GPCR. Therefore, priorities are logP, TPSA, Pgp, affinity, and to a lesser extent, BBB.
Let's break down the comparison:
1. **MW:** Both ligands (345.443 and 360.479 Da) are within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (82.27) is slightly higher than Ligand B (69.64). Both are acceptable, but B is better for permeability.
3. **logP:** Both ligands have good logP values (1.554 and 2.559), falling within the 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability.
4. **HBD/HBA:** Both have 2 HBD and acceptable HBA counts (3 and 4 respectively).
5. **QED:** Both ligands have reasonable QED scores (0.821 and 0.733), indicating good drug-like properties.
6. **DILI:** Ligand A (24.04) has a significantly lower DILI risk than Ligand B (34.626), which is a major advantage.
7. **BBB:** Both ligands have similar BBB penetration (77.549 and 77.007). This isn't a primary concern for a cardiovascular target.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual. It's difficult to interpret without knowing the scale, but we'll assume lower values are worse.
9. **Solubility:** Both have negative solubility values, which is also unusual. Again, assuming lower is worse, they are comparable.
10. **hERG:** Both have low hERG inhibition risk (0.598 and 0.585).
11. **Cl_mic:** Ligand A (8.722) has a much lower microsomal clearance than Ligand B (69.948), indicating better metabolic stability.
12. **t1/2:** Ligand A (-22.592) has a more negative in vitro half-life, which is unusual. Assuming lower values are worse, Ligand B (-17.52) is better.
13. **Pgp:** Both have very low Pgp efflux liability (0.106 and 0.11).
14. **Affinity:** Ligand B (-6.2) has a slightly better binding affinity than Ligand A (-5.7), a 0.5 kcal/mol difference.
**Overall Assessment:**
Ligand A is preferable. While Ligand B has slightly better affinity and logP, Ligand A has a much lower DILI risk and significantly better metabolic stability (lower Cl_mic). The lower DILI risk is a critical advantage, and the improved metabolic stability suggests a potentially longer duration of action. The small affinity difference is outweighed by the safety and PK benefits of Ligand A.
**Output:**
1
2025-04-17 23:17:38,547 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (341.411) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (64.43) is significantly better than Ligand B (107.31). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (2.109) is optimal, while Ligand B (-0.301) is quite low. This is a significant drawback for Ligand B, potentially hindering membrane permeability and bioavailability.
4. **HBD:** Ligand A (0) is preferred. Ligand B (1) is acceptable, but fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (5) is good, and Ligand B (7) is acceptable, but slightly higher.
6. **QED:** Both ligands are similar (A: 0.797, B: 0.725) and above the 0.5 threshold, indicating good drug-likeness.
7. **DILI:** Both ligands have similar, acceptable DILI risk (A: 66.964, B: 65.607).
8. **BBB:** Ligand A (88.135) is better than Ligand B (67.468), though not a primary concern for a cardiovascular target.
9. **Caco-2:** Ligand A (-4.433) is better than Ligand B (-4.811), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-3.102) is better than Ligand B (-2.003).
11. **hERG:** Ligand A (0.552) is significantly better than Ligand B (0.067), indicating a lower risk of cardiotoxicity. This is *critical* for a cardiovascular target.
12. **Cl_mic:** Ligand B (5.834) is much better than Ligand A (44.641), suggesting better metabolic stability.
13. **t1/2:** Ligand B (25.391) has a much longer half-life than Ligand A (7.285), which is a significant advantage.
14. **Pgp:** Ligand A (0.5) is better than Ligand B (0.021), indicating less efflux.
15. **Affinity:** Ligand B (-8.5) has a significantly stronger binding affinity than Ligand A (-6.9). This is a >1.5 kcal/mol difference, which is substantial.
**Overall Assessment:**
Ligand B has a significantly better binding affinity and a longer half-life, which are major advantages. However, its low logP and higher hERG risk are serious concerns. Ligand A has a more balanced profile with better logP, solubility, lower hERG risk, and better Pgp efflux. Considering the cardiovascular target, minimizing hERG risk is paramount. While the affinity difference is significant, the ADME liabilities of Ligand B outweigh this benefit.
Therefore, I favor Ligand A.
Output:
1
2025-04-17 23:17:38,547 - INFO - Batch 394 complete. Total preferences: 6304
2025-04-17 23:17:38,547 - INFO - Processing batch 395/512...
2025-04-17 23:18:29,015 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (362.455 Da and 353.388 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand B (36.86) is significantly better than Ligand A (97.12). For a GPCR, lower TPSA is generally preferred for better permeability, and B is well below the 140 threshold. A's TPSA is quite high.
**3. logP:** Both ligands have a logP around 2.5-2.6, which is within the optimal 1-3 range. No clear advantage.
**4. H-Bond Donors:** Ligand B (1) is better than Ligand A (2). Lower HBD is generally preferred for permeability.
**5. H-Bond Acceptors:** Ligand B (4) is better than Ligand A (6). Lower HBA is generally preferred for permeability.
**6. QED:** Both ligands have good QED scores (0.823 and 0.908), indicating good drug-like properties. No significant difference.
**7. DILI Risk:** Ligand B (8.3%) is *much* better than Ligand A (65.1%). This is a major advantage for Ligand B. A DILI risk of 65.1% is concerning.
**8. BBB Penetration:** Ligand B (83.3%) is significantly better than Ligand A (54.5%). While ADRB2 isn't exclusively a CNS target, some CNS exposure/off-target effects are possible, and higher BBB penetration is generally desirable.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret. Ligand B (-4.748) is slightly better than Ligand A (-5.117).
**10. Aqueous Solubility:** Both ligands have similar, very poor aqueous solubility (-3.905 and -3.919). This is a potential formulation challenge for both.
**11. hERG Inhibition:** Ligand B (0.841) is better than Ligand A (0.22). Lower hERG inhibition is crucial to avoid cardiotoxicity, especially important for a cardiovascular target.
**12. Microsomal Clearance:** Ligand A (30.98) is worse than Ligand B (19.561). Lower clearance is preferred for increased metabolic stability.
**13. In vitro Half-Life:** Ligand B (-27.977) is significantly better than Ligand A (35.233). A negative half-life is unusual, but indicates a much longer half-life.
**14. P-gp Efflux:** Both ligands have similar P-gp efflux liability (0.23 and 0.239).
**15. Binding Affinity:** Ligand A (-6.7 kcal/mol) is slightly better than Ligand B (-5.3 kcal/mol). However, the difference (1.4 kcal/mol) is not large enough to overcome the significant ADME advantages of Ligand B.
**Overall Assessment:**
Ligand B is the superior candidate. While Ligand A has a slightly better binding affinity, Ligand B has dramatically better ADME properties: significantly lower DILI risk, better BBB penetration, better hERG inhibition, lower microsomal clearance, and a longer half-life. The lower TPSA and H-bond counts also contribute to better predicted permeability. Given the GPCR target class, these ADME properties are paramount. The solubility issues are a concern for both, but can be addressed with formulation strategies.
Output:
0
2025-04-17 23:18:29,016 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [348.531, 58.2, 3.938, 2, 2, 0.628, 20.24, 75.378, -4.77, -4.747, 0.577, 81.484, 0.679, 0.542, -6.4]**
**Ligand B: [365.499, 69.72, 0.861, 1, 4, 0.58, 18.573, 46.84, -5.123, -2.229, 0.134, 1.839, -12.262, 0.036, -6.4]**
1. **Molecular Weight:** Both are within the ideal range (200-500 Da). A (348.531) is slightly preferred.
2. **TPSA:** A (58.2) is excellent, well below the 140 threshold. B (69.72) is still reasonable, but less optimal.
3. **logP:** A (3.938) is good, within the 1-3 range. B (0.861) is a bit low, potentially impacting permeability.
4. **H-Bond Donors:** Both have acceptable numbers (A: 2, B: 1).
5. **H-Bond Acceptors:** Both are acceptable (A: 2, B: 4).
6. **QED:** Both are similar and acceptable (A: 0.628, B: 0.58), above the 0.5 threshold.
7. **DILI:** A (20.24) is significantly better than B (18.573), indicating a lower risk of liver injury.
8. **BBB:** A (75.378) is much better than B (46.84). While ADRB2 isn't exclusively a CNS target, good BBB penetration is generally desirable, and can be useful for understanding off-target effects.
9. **Caco-2:** Both are negative, suggesting poor permeability. A (-4.77) is slightly better than B (-5.123).
10. **Solubility:** Both are negative, suggesting poor solubility. A (-4.747) is slightly better than B (-2.229).
11. **hERG:** Both are very low (A: 0.577, B: 0.134), indicating a low risk of cardiotoxicity.
12. **Cl_mic:** A (81.484) is considerably higher than B (1.839), meaning faster clearance and potentially lower exposure. This is a significant drawback for A.
13. **t1/2:** B (-12.262) has a much longer half-life than A (0.679), which is a major advantage.
14. **Pgp:** Both are low (A: 0.542, B: 0.036), suggesting minimal efflux.
15. **Binding Affinity:** Both have the same affinity (-6.4 kcal/mol).
**GPCR-Specific Considerations:** For ADRB2 (a GPCR), logP, TPSA, and affinity are key. A has a better logP and TPSA, but B has a dramatically better half-life and lower clearance. The similar affinities mean that the ADME properties become the deciding factor.
**Overall Assessment:**
While Ligand A has some advantages in TPSA, logP, and DILI, the significantly lower metabolic stability (higher Cl_mic and shorter half-life) is a major concern. Ligand B's substantially improved half-life and lower clearance outweigh the slightly less optimal logP and TPSA. The similar affinities make the ADME profile the deciding factor.
Output:
0
2025-04-17 23:18:29,016 - INFO - Here's a step-by-step comparison of Ligand A and Ligand B, followed by my final decision:
**1. Molecular Weight (MW):**
* Ligand A: 362.459 Da - Within the ideal range (200-500).
* Ligand B: 351.447 Da - Within the ideal range (200-500).
* *Both are acceptable.*
**2. Topological Polar Surface Area (TPSA):**
* Ligand A: 103.91 - Acceptable for oral absorption (<140), but less ideal for a GPCR where lower is better.
* Ligand B: 91.66 - Better for a GPCR, closer to the ideal range.
* *Ligand B is slightly favored.*
**3. Lipophilicity (logP):**
* Ligand A: 0.488 - Low, potentially hindering permeation.
* Ligand B: 1.372 - Better, within the optimal range (1-3).
* *Ligand B is favored.*
**4. H-Bond Donors (HBD):**
* Ligand A: 1 - Acceptable.
* Ligand B: 1 - Acceptable.
* *Equal.*
**5. H-Bond Acceptors (HBA):**
* Ligand A: 7 - Acceptable.
* Ligand B: 5 - Acceptable.
* *Equal.*
**6. QED:**
* Ligand A: 0.739 - Good drug-like properties.
* Ligand B: 0.677 - Good drug-like properties.
* *Ligand A is slightly favored.*
**7. DILI Risk:**
* Ligand A: 51.028 - Low risk.
* Ligand B: 30.322 - Very low risk.
* *Ligand B is favored.*
**8. BBB Penetration:**
* Ligand A: 49.787 - Low, not ideal.
* Ligand B: 68.67 - Better, but still not high.
* *Ligand B is favored.*
**9. Caco-2 Permeability:**
* Ligand A: -5.43 - Poor permeability.
* Ligand B: -4.723 - Better permeability than A, but still not great.
* *Ligand B is favored.*
**10. Aqueous Solubility:**
* Ligand A: -2.753 - Poor solubility.
* Ligand B: -1.642 - Better solubility than A.
* *Ligand B is favored.*
**11. hERG Inhibition:**
* Ligand A: 0.099 - Low risk.
* Ligand B: 0.235 - Slightly higher risk than A, but still acceptable.
* *Ligand A is slightly favored.*
**12. Microsomal Clearance:**
* Ligand A: 10.983 - Moderate clearance.
* Ligand B: 19.936 - Higher clearance, less desirable.
* *Ligand A is favored.*
**13. In vitro Half-Life:**
* Ligand A: 7.164 - Moderate half-life.
* Ligand B: -8.951 - Long half-life, very desirable.
* *Ligand B is strongly favored.*
**14. P-gp Efflux:**
* Ligand A: 0.068 - Low efflux, good.
* Ligand B: 0.05 - Very low efflux, excellent.
* *Ligand B is favored.*
**15. Binding Affinity:**
* Ligand A: -7.5 kcal/mol
* Ligand B: -7.1 kcal/mol
* *Ligand A is favored. The 0.4 kcal/mol difference is significant.*
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand B shows advantages in several key areas: logP, TPSA, Pgp efflux, solubility, and half-life. While Ligand A has a slightly better affinity and DILI risk, the overall profile of Ligand B is more promising, especially given the poor permeability and solubility of Ligand A. The longer half-life of Ligand B is a significant advantage. The affinity difference, while present, isn't large enough to overcome the ADME deficiencies of Ligand A.
Output:
0
2025-04-17 23:18:29,016 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, priorities are logP, TPSA, Pgp, affinity, and to a lesser extent, BBB.
* **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (347.415 Da) is slightly lower, which is generally favorable for permeability.
* **TPSA:** Ligand B (67.87) is significantly better than Ligand A (83.8). Lower TPSA is preferred for better absorption.
* **logP:** Ligand B (1.973) is within the optimal range, while Ligand A (0.402) is quite low, potentially hindering membrane permeability. This is a significant advantage for Ligand B.
* **H-Bond Donors/Acceptors:** Ligand A has 2 HBD and 5 HBA, while Ligand B has 1 HBD and 4 HBA. Both are acceptable.
* **QED:** Both ligands have similar QED values (0.756 and 0.724), indicating good drug-likeness.
* **DILI:** Ligand B (27.104) has a much lower DILI risk than Ligand A (54.207). This is a crucial advantage.
* **BBB:** Ligand B (65.529) has a better BBB percentile than Ligand A (25.824). While not a primary concern for a cardiovascular target, higher BBB is generally favorable.
* **Caco-2 Permeability:** Both are negative, indicating poor permeability.
* **Aqueous Solubility:** Both are negative, indicating poor solubility.
* **hERG Inhibition:** Both ligands have low hERG inhibition risk.
* **Microsomal Clearance:** Ligand B (21.937) has a lower microsomal clearance than Ligand A (31.734), suggesting better metabolic stability.
* **In vitro Half-Life:** Ligand A (9.81) has a longer half-life than Ligand B (0.898).
* **P-gp Efflux:** Both ligands have low P-gp efflux liability.
* **Binding Affinity:** Ligand A (-6.1 kcal/mol) has a slightly better binding affinity than Ligand B (-5.7 kcal/mol), but the difference is less than 1.5 kcal/mol.
**Overall Assessment:**
Ligand B is significantly better overall. The lower TPSA, better logP, substantially lower DILI risk, and improved metabolic stability outweigh the slightly weaker binding affinity and shorter half-life. The low logP of Ligand A is a major concern, potentially leading to poor absorption. The improved ADME properties of Ligand B make it a more promising drug candidate.
**Output:**
0
2025-04-17 23:18:29,016 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [346.362, 93.21, 2.413, 2, 5, 0.784, 85.576, 69.097, -4.713, -3.265, 0.191, 55.117, 20.807, 0.027, -8.3]
**Ligand B:** [343.427, 87.3, 0.636, 3, 3, 0.376, 27.608, 30.128, -5.037, -2.972, 0.031, 22.291, -17.036, 0.03, -5.7]
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). A is 346.362, B is 343.427. Very similar.
2. **TPSA:** A is 93.21, B is 87.3. Both are good for oral absorption (<140), but B is slightly better.
3. **logP:** A is 2.413, B is 0.636. A is optimal (1-3), while B is a bit low, potentially hindering permeability.
4. **HBD:** A is 2, B is 3. Both are acceptable (<=5).
5. **HBA:** A is 5, B is 3. Both are acceptable (<=10).
6. **QED:** A is 0.784, B is 0.376. A is significantly better, indicating a more drug-like profile.
7. **DILI:** A is 85.576, B is 27.608. B is *much* better, indicating a significantly lower risk of liver injury. This is a major concern for A.
8. **BBB:** A is 69.097, B is 30.128. A is better, but neither are particularly high. For a cardiovascular target, BBB isn't a primary concern, but it's still a positive for A.
9. **Caco-2:** A is -4.713, B is -5.037. Both are poor, indicating poor intestinal absorption. B is slightly worse.
10. **Solubility:** A is -3.265, B is -2.972. Both are poor, but B is slightly better.
11. **hERG:** A is 0.191, B is 0.031. B is much better, indicating a lower risk of cardiotoxicity. This is critical for a cardiovascular target.
12. **Cl_mic:** A is 55.117, B is 22.291. B is significantly better, indicating better metabolic stability.
13. **t1/2:** A is 20.807, B is -17.036. A is much better, indicating a longer half-life.
14. **Pgp:** A is 0.027, B is 0.03. Both are very low, indicating minimal P-gp efflux.
15. **Affinity:** A is -8.3, B is -5.7. A has a *much* stronger binding affinity (a 2.6 kcal/mol difference). This is a substantial advantage.
**GPCR-specific priorities:** logP, Pgp, TPSA, and affinity are key. A has better logP and affinity, while B has better TPSA and Pgp. However, the DILI and hERG risks for Ligand A are concerning. The significantly stronger affinity of A is a big plus, but the safety liabilities are substantial. The metabolic stability of B is also a significant advantage.
**Decision:**
Despite the significantly better binding affinity of Ligand A, the much higher DILI risk and hERG inhibition liability make it a less desirable candidate. Ligand B, while having a weaker affinity, presents a much more favorable safety profile (lower DILI and hERG) and better metabolic stability. For a cardiovascular target, minimizing cardiotoxicity is paramount.
Therefore, I prefer Ligand B.
0
2025-04-17 23:18:29,017 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [359.421, 88.91, 1.799, 2, 5, 0.667, 44.591, 65.529, -5.085, -2.345, 0.156, 39.127, -9.904, 0.054, -6.5]
**Ligand B:** [353.413, 51.27, 3.718, 0, 4, 0.646, 26.018, 87.864, -4.639, -2.556, 0.742, 66.216, -15.124, 0.524, -5.8]
Here's a breakdown, considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal range (200-500 Da). A is 359.421, B is 353.413 - very similar.
2. **TPSA:** A (88.91) is better than B (51.27). Both are below 140, but B is significantly lower, which is beneficial for permeability.
3. **logP:** A (1.799) is optimal. B (3.718) is approaching the upper limit, potentially causing solubility issues.
4. **HBD:** A (2) is reasonable. B (0) is also good, minimizing potential for off-target interactions.
5. **HBA:** Both are acceptable (A: 5, B: 4).
6. **QED:** Both are good (A: 0.667, B: 0.646), indicating drug-like properties.
7. **DILI:** A (44.591) is better than B (26.018), indicating a lower risk of liver injury.
8. **BBB:** B (87.864) is significantly better than A (65.529). While ADRB2 isn't a CNS target, some peripheral exposure can be reduced by higher BBB scores.
9. **Caco-2:** A (-5.085) is worse than B (-4.639), indicating lower intestinal absorption.
10. **Solubility:** Both are poor (-2.345 and -2.556). This is a concern for both.
11. **hERG:** A (0.156) is much better than B (0.742), a critical advantage for cardiovascular safety.
12. **Cl_mic:** A (39.127) is better than B (66.216), indicating better metabolic stability.
13. **t1/2:** A (-9.904) is better than B (-15.124), indicating a longer half-life.
14. **Pgp:** A (0.054) is much better than B (0.524), indicating less efflux and better bioavailability.
15. **Affinity:** A (-6.5) is slightly better than B (-5.8), but the difference is not huge.
**Overall Assessment:**
Ligand A has a clear advantage in several critical areas: DILI risk, hERG inhibition, metabolic stability (Cl_mic), half-life, and P-gp efflux. While Ligand B has a better BBB score and TPSA, the cardiovascular safety profile of Ligand A is significantly more favorable due to the lower hERG and DILI scores. The slightly better affinity of A is also a plus. Solubility is a concern for both, but the other advantages of A outweigh this drawback.
Therefore, I prefer Ligand A.
Output:
1
2025-04-17 23:18:29,017 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [374.503, 104.73 , 0.086, 3. , 5. , 0.586, 32.61 , 26.212, -5.327, -1.247, 0.098, 12.099, 22.096, 0.043, -6.3 ]
**Ligand B:** [409.288, 96.03 , 1.349, 2. , 6. , 0.748, 67.313, 41.14 , -5.646, -2.184, 0.087, 12.773, 13.878, 0.024, -6.7 ]
**Step-by-step comparison:**
1. **MW:** Ligand A (374.5) is better within the ideal range (200-500) than Ligand B (409.3).
2. **TPSA:** Both are reasonably good (A: 104.7, B: 96.0), below the 140 threshold for oral absorption. Ligand B is slightly better.
3. **logP:** Ligand A (0.086) is quite low, potentially hindering membrane permeability. Ligand B (1.349) is much better, falling within the optimal 1-3 range.
4. **HBD:** Both are acceptable (A: 3, B: 2).
5. **HBA:** Both are acceptable (A: 5, B: 6).
6. **QED:** Both are good (A: 0.586, B: 0.748), indicating drug-like properties, with B being slightly better.
7. **DILI:** Ligand A (32.61) has a significantly lower DILI risk than Ligand B (67.313). This is a major advantage for A.
8. **BBB:** Ligand B (41.14) has better BBB penetration than Ligand A (26.212), but for a cardiovascular target, this isn't a primary concern.
9. **Caco-2:** Both are very poor (-5.327 and -5.646). This is a significant drawback for both.
10. **Solubility:** Both are very poor (-1.247 and -2.184). This is a significant drawback for both.
11. **hERG:** Both have low hERG risk (A: 0.098, B: 0.087).
12. **Cl_mic:** Similar metabolic clearance (A: 12.099, B: 12.773).
13. **t1/2:** Ligand A (22.096) has a longer in vitro half-life than Ligand B (13.878), which is preferable.
14. **Pgp:** Both have low Pgp efflux (A: 0.043, B: 0.024).
15. **Binding Affinity:** Ligand B (-6.7) has a slightly better binding affinity than Ligand A (-6.3), a 0.4 kcal/mol difference.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP and has slightly better affinity. However, the significantly lower DILI risk of Ligand A, combined with its longer half-life, is a substantial advantage. The poor Caco-2 and solubility are concerning for both, but can be addressed with formulation strategies. The slightly better affinity of Ligand B is not enough to overcome the higher DILI risk.
**Conclusion:**
Considering the balance of properties, especially the lower DILI risk and longer half-life, Ligand A is the more promising candidate, despite its lower logP and affinity.
Output:
1
2025-04-17 23:18:29,017 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (359.367) is slightly higher than Ligand B (347.459), but both are acceptable.
2. **TPSA:** Ligand A (45.23) is significantly better than Ligand B (84.23). ADRB2 is a cardiovascular target, not a CNS target, but lower TPSA generally improves absorption. Ligand B's TPSA is relatively high, potentially hindering oral absorption.
3. **logP:** Both ligands have good logP values (A: 3.259, B: 2.612), falling within the optimal 1-3 range.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (4). Similar to HBD, lower HBA is generally better for permeability.
6. **QED:** Ligand A (0.843) has a much better QED score than Ligand B (0.503), indicating a more drug-like profile.
7. **DILI:** Ligand A (31.33) has a significantly lower DILI risk than Ligand B (18.224), which is a major advantage.
8. **BBB:** Not a primary concern for a cardiovascular target, but Ligand A (86.002) has a higher BBB percentile than Ligand B (67.468).
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.846 and -4.969), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-2.72) is slightly better than Ligand B (-1.844), but both are poor. Solubility is a concern for both.
11. **hERG:** Ligand A (0.854) has a lower hERG risk than Ligand B (0.14). This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand A (-17.206) has a much lower (better) microsomal clearance than Ligand B (59.619), indicating better metabolic stability.
13. **t1/2:** Ligand A (-8.163) has a longer in vitro half-life than Ligand B (-18.614), which is desirable.
14. **Pgp:** Ligand A (0.177) has a lower Pgp efflux liability than Ligand B (0.027), which is favorable.
15. **Affinity:** Both ligands have similar binding affinities (-5.9 kcal/mol and -6.4 kcal/mol). The difference is not substantial enough to override other factors.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical ADME-Tox properties. It has a better QED score, lower DILI risk, lower hERG risk, better metabolic stability (lower Cl_mic, longer t1/2), and lower Pgp efflux. While both have poor Caco-2 and solubility, the other advantages of Ligand A make it a more promising drug candidate for ADRB2. The slightly better TPSA and H-bonding characteristics of Ligand A also contribute to its preference.
Output:
1
2025-04-17 23:18:29,017 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (349.431 and 347.463 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (93.46) is slightly higher than Ligand B (80.12). While both are below the 140 threshold for oral absorption, the lower TPSA of Ligand B is preferable for a GPCR, potentially aiding in membrane permeability.
**3. logP:** Both ligands have excellent logP values (1.739 and 1.694), falling within the optimal 1-3 range. No clear advantage.
**4. H-Bond Donors:** Ligand A has 2 HBD, while Ligand B has 1. Lower is generally better for permeability, giving a slight edge to Ligand B.
**5. H-Bond Acceptors:** Both ligands have 5 HBA, which is acceptable.
**6. QED:** Both ligands have similar QED values (0.782 and 0.761), indicating good drug-like properties.
**7. DILI Risk:** Ligand B (34.238) has a significantly lower DILI risk than Ligand A (51.338). This is a major advantage for Ligand B as minimizing liver toxicity is critical.
**8. BBB Penetration:** Both ligands exhibit good BBB penetration (70.105 and 79.682). Ligand B is slightly better, which is a positive for GPCRs, though less crucial for a cardiovascular target.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.857 and -4.832). This is unusual and suggests poor permeability. However, the values are very similar.
**10. Aqueous Solubility:** Both ligands have negative solubility values (-3.149 and -2.314), indicating poor aqueous solubility. This is a concern for both, but Ligand B is marginally better.
**11. hERG Inhibition:** Ligand A (0.289) has a slightly lower hERG inhibition risk than Ligand B (0.41). This is a small advantage, but important for cardiovascular drugs.
**12. Microsomal Clearance:** Ligand B (52.722) has a slightly higher microsomal clearance than Ligand A (42.167), suggesting faster metabolism. This is a negative for Ligand B.
**13. In vitro Half-Life:** Ligand A (7.814) has a significantly longer in vitro half-life than Ligand B (-1.912). This is a substantial advantage for Ligand A, as it suggests less frequent dosing.
**14. P-gp Efflux:** Ligand A (0.051) has significantly lower P-gp efflux than Ligand B (0.116). This is a positive for Ligand A, improving bioavailability.
**15. Binding Affinity:** Ligand A (-7.6 kcal/mol) has a considerably stronger binding affinity than Ligand B (-6.3 kcal/mol). This 1.3 kcal/mol difference is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
While Ligand B has advantages in DILI risk, TPSA, and BBB penetration, Ligand A's significantly stronger binding affinity (-7.6 vs -6.3 kcal/mol) and longer half-life are decisive. The lower P-gp efflux is also a benefit. The slightly higher hERG risk for Ligand B is a concern, but the potency difference is large enough to justify further optimization to address this. The poor Caco-2 and solubility for both are concerning and would need to be addressed in further development, but the superior affinity of Ligand A makes it the better starting point.
Output:
1
2025-04-17 23:18:29,017 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
The target is ADRB2, a GPCR. Therefore, priorities are logP, TPSA, Pgp, BBB, and affinity. Let's break down the comparison:
1. **Molecular Weight:** Both ligands are within the ideal range (346-357 Da). No significant difference here.
2. **TPSA:** Both are below 140, which is good for oral absorption. Ligand A (90.9) is slightly better than Ligand B (94.56), but the difference is minor.
3. **logP:** Both ligands have excellent logP values (1.068 and 0.816), falling within the optimal 1-3 range.
4. **H-Bond Donors/Acceptors:** Both have 3 HBD and 5 HBA, which is acceptable.
5. **QED:** Both have good QED scores (0.537 and 0.734), indicating drug-likeness. Ligand B is better here.
6. **DILI:** Ligand A (12.059) has a significantly lower DILI risk than Ligand B (23.11). This is a major advantage for Ligand A.
7. **BBB:** Both have similar BBB penetration (46.219 vs 49.36). Neither is particularly high, but this isn't critical for a non-CNS target like ADRB2 (cardiovascular).
8. **Caco-2 Permeability:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the values are similar (-5.314 vs -5.29).
9. **Aqueous Solubility:** Both have negative solubility values, indicating poor solubility. Again, they are very similar (-0.816 vs -1.842).
10. **hERG Inhibition:** Both have low hERG inhibition risk (0.231 and 0.402).
11. **Microsomal Clearance:** Ligand A (-2.464) has a much lower (better) microsomal clearance than Ligand B (0.466), suggesting greater metabolic stability.
12. **In vitro Half-Life:** Ligand A (-10.006) has a significantly longer in vitro half-life than Ligand B (8.837). This is a significant advantage.
13. **P-gp Efflux:** Both have very low P-gp efflux liability (0.006 and 0.009).
14. **Binding Affinity:** Ligand B (-6.1 kcal/mol) has a slightly better binding affinity than Ligand A (-6.0 kcal/mol). However, the difference is small.
**Overall Assessment:**
While Ligand B has a slightly better binding affinity and QED, Ligand A demonstrates a superior safety profile (lower DILI risk) and better pharmacokinetic properties (lower clearance, longer half-life). Given the similar binding affinities, the improved ADME/Tox profile of Ligand A makes it the more promising drug candidate.
**Output:**
1
2025-04-17 23:18:29,018 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.419 and 352.475 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (109.5) is higher than Ligand B (67.87). For a cardiovascular GPCR, TPSA isn't *as* critical as for a CNS target, but lower is generally preferred for better absorption. Ligand B is significantly better.
3. **logP:** Ligand A (-0.014) is quite low, potentially hindering membrane permeability. Ligand B (1.869) is within the optimal 1-3 range. This is a substantial advantage for Ligand B.
4. **HBD:** Ligand A (3) is higher than Ligand B (1). While both are acceptable, lower HBD can improve permeability. Ligand B is slightly better.
5. **HBA:** Both ligands have 4 HBA, which is within the acceptable range.
6. **QED:** Both ligands have good QED scores (0.696 and 0.759), indicating good drug-like properties.
7. **DILI:** Ligand A (47.344) has a higher DILI risk than Ligand B (20.085). Lower DILI is highly desirable. Ligand B is significantly better.
8. **BBB:** Ligand A (16.363) has very low BBB penetration, while Ligand B (71.501) is quite good. While ADRB2 isn't a primary CNS target, some level of BBB penetration can be beneficial for off-target effects assessment. Ligand B is much better.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.099 and -4.704), which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
10. **Solubility:** Both ligands have negative solubility values (-2.193 and -1.943), again making interpretation difficult without knowing the scale.
11. **hERG:** Both ligands have low hERG inhibition liability (0.166 and 0.237), which is good.
12. **Cl_mic:** Ligand A (-4.892) has a lower (better) microsomal clearance than Ligand B (42.31). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (-9.219) has a negative in vitro half-life, which is problematic. Ligand B (-17.21) is also negative, but less so. Both are concerning, but Ligand B is slightly better.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.018 and 0.085), which is good.
15. **Binding Affinity:** Ligand A (-7.9) has a slightly better binding affinity than Ligand B (-7.3). This is a 0.6 kcal/mol difference, which is significant but not overwhelming.
**Overall Assessment:**
Ligand B is the stronger candidate. While Ligand A has slightly better binding affinity and metabolic stability, Ligand B excels in crucial ADME properties like logP, TPSA, DILI risk, and BBB penetration. The low logP and high TPSA of Ligand A are significant drawbacks for a GPCR target, potentially leading to poor absorption and bioavailability. The much lower DILI risk for Ligand B is also a major advantage. The negative values for Caco-2 and solubility are concerning for both, but the other advantages of Ligand B outweigh the slightly better affinity of Ligand A.
Output:
0
2025-04-17 23:18:29,018 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (344.46 and 351.45 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (78.09) is significantly better than Ligand B (93.78). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary goal, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (2.702) is within the optimal 1-3 range. Ligand B (-1.477) is below 1, which could hinder permeability. This is a significant negative for Ligand B.
4. **HBD:** Ligand A (2) and Ligand B (3) are both acceptable, under the threshold of 5.
5. **HBA:** Ligand A (3) and Ligand B (5) are both acceptable, under the threshold of 10.
6. **QED:** Ligand A (0.779) is much better than Ligand B (0.464). A higher QED indicates a more drug-like profile.
7. **DILI:** Ligand A (40.403) is better than Ligand B (12.059), indicating a lower risk of drug-induced liver injury.
8. **BBB:** Ligand A (67.119) is better than Ligand B (28.693), but BBB isn't a high priority for a cardiovascular target.
9. **Caco-2:** Ligand A (-4.979) and Ligand B (-5.919) are both poor, indicating poor intestinal absorption.
10. **Solubility:** Ligand A (-3.9) is better than Ligand B (-0.667). Better solubility is generally desirable.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.168 and 0.124 respectively).
12. **Cl_mic:** Ligand B (-25.067) has significantly lower microsomal clearance than Ligand A (59.786), suggesting better metabolic stability. This is a strong point for Ligand B.
13. **t1/2:** Ligand B (7.044) has a longer in vitro half-life than Ligand A (-28.73). This is a significant advantage for Ligand B.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.103 and 0.001 respectively).
15. **Binding Affinity:** Ligand B (-7.7) has a significantly stronger binding affinity than Ligand A (-5.5). This is a substantial advantage, potentially outweighing some ADME concerns.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B has a weaker logP, but a *much* stronger affinity. The improved metabolic stability (lower Cl_mic) and longer half-life are also very attractive. While Ligand A has better TPSA and QED, the affinity difference is substantial.
**Overall Assessment:**
Despite the lower logP and Caco-2 values, Ligand B's significantly improved binding affinity and metabolic stability make it the more promising candidate. The stronger binding is likely to be crucial for efficacy, and the improved half-life could allow for less frequent dosing.
Output:
0
2025-04-17 23:18:29,018 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [340.427, 78.09, 1.259, 2, 3, 0.81, 30.826, 61.497, -5.197, -2.09, 0.228, 17.872, -31.794, 0.08, -7.1]**
**Ligand B: [397.591, 58.22, 4.052, 1, 6, 0.764, 75.107, 46.762, -5.12, -5.402, 0.578, 106.918, -5.522, 0.495, -4.5]**
1. **Molecular Weight:** Ligand A (340.427 Da) is better, falling nicely within the 200-500 Da range. Ligand B (397.591 Da) is still acceptable but closer to the upper limit.
2. **TPSA:** Ligand B (58.22) is significantly better than Ligand A (78.09). Both are below 140, but lower TPSA generally favors permeability.
3. **logP:** Ligand A (1.259) is optimal. Ligand B (4.052) is pushing the upper limit and could lead to solubility issues and off-target interactions.
4. **H-Bond Donors:** Ligand A (2) is preferable to Ligand B (1). Both are within the acceptable range.
5. **H-Bond Acceptors:** Ligand A (3) is preferable to Ligand B (6). Lower is better for permeability.
6. **QED:** Ligand A (0.81) is better than Ligand B (0.764), indicating a more drug-like profile.
7. **DILI:** Ligand A (30.826%) is *much* better than Ligand B (75.107%). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (61.497%) is better than Ligand B (46.762%). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant, and higher BBB is generally preferred.
9. **Caco-2:** Both ligands have similar, poor Caco-2 permeability (-5.197 and -5.12). This is a concern for both.
10. **Solubility:** Ligand A (-2.09) is better than Ligand B (-5.402). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.228) is significantly better than Ligand B (0.578), indicating a lower risk of cardiotoxicity.
12. **Cl_mic:** Ligand A (17.872) is much better than Ligand B (106.918). Lower clearance means greater metabolic stability.
13. **t1/2:** Ligand A (-31.794) is better than Ligand B (-5.522). A more negative value indicates a longer half-life.
14. **Pgp:** Ligand A (0.08) is significantly better than Ligand B (0.495), suggesting less efflux and better bioavailability.
15. **Binding Affinity:** Ligand A (-7.1) is *significantly* better than Ligand B (-4.5). This is a 2.6 kcal/mol difference, which is substantial and can outweigh many ADME concerns.
**Overall Assessment:**
Ligand A is clearly superior. It has a better balance of properties across the board, particularly in critical areas like DILI risk, metabolic stability (Cl_mic, t1/2), hERG inhibition, Pgp efflux, and, most importantly, binding affinity. While both ligands have poor Caco-2 permeability, the substantial advantage in binding affinity and safety profiles of Ligand A make it the more promising candidate. The lower logP of Ligand A is also a benefit.
Output:
1
2025-04-17 23:18:29,018 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (354.36 and 354.52 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (84.42) is better than Ligand B (33.2). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower TPSA generally correlates with better permeability. Ligand B's very low TPSA is a slight advantage.
**3. logP:** Ligand B (4.774) is higher than Ligand A (0.645). While a logP between 1-3 is optimal, Ligand B is pushing the upper limit. Ligand A is significantly lower, potentially causing permeability issues. This is a significant drawback for Ligand A.
**4. H-Bond Donors:** Ligand A (1) is preferable to Ligand B (0). While both are acceptable, having one HBD can aid solubility.
**5. H-Bond Acceptors:** Ligand A (5) is higher than Ligand B (3). Both are within the acceptable range, but Ligand A is closer to the upper limit.
**6. QED:** Ligand A (0.811) is slightly better than Ligand B (0.748), indicating a more drug-like profile.
**7. DILI:** Ligand A (38.04) is significantly better than Ligand B (17.37), indicating a much lower risk of drug-induced liver injury. This is a critical advantage for Ligand A.
**8. BBB:** Both ligands have high BBB penetration (Ligand A: 87.86, Ligand B: 83.25). While not essential for a cardiovascular target, it doesn't hurt.
**9. Caco-2 Permeability:** Ligand A (-4.636) is better than Ligand B (-4.933), indicating better intestinal absorption.
**10. Aqueous Solubility:** Ligand A (-2.09) is better than Ligand B (-4.065). Solubility is important for bioavailability, and Ligand A has a clear advantage.
**11. hERG Inhibition:** Ligand A (0.192) is significantly better than Ligand B (0.67), indicating a lower risk of cardiotoxicity. This is a crucial advantage for a cardiovascular drug.
**12. Microsomal Clearance:** Ligand B (86.733) is higher than Ligand A (7.866). This indicates that Ligand A is more metabolically stable, a desirable trait.
**13. In vitro Half-Life:** Ligand A (-7.321) is better than Ligand B (-6.296), indicating a longer half-life.
**14. P-gp Efflux:** Ligand A (0.004) is *much* better than Ligand B (0.567), indicating significantly lower P-gp efflux. This is a major advantage for bioavailability.
**15. Binding Affinity:** Ligand B (-6.5 kcal/mol) is slightly better than Ligand A (-7.2 kcal/mol). While Ligand A has a better affinity, the difference is not substantial enough to outweigh the other significant advantages of Ligand A.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity) and general drug-like properties, Ligand A is the superior candidate. While Ligand B has a slightly better binding affinity and a lower TPSA, Ligand A excels in critical areas like DILI risk, hERG inhibition, metabolic stability (Cl_mic and t1/2), P-gp efflux, solubility, and QED. The lower logP of Ligand A is a concern, but the other advantages are substantial enough to outweigh this drawback.
Output:
1
2025-04-17 23:18:29,018 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (355.523 and 363.523 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (81.67) is better than Ligand B (38.77). Lower TPSA generally favors better cell permeability, which is important for GPCRs.
3. **logP:** Ligand B (3.7) is slightly higher than Ligand A (1.382). While both are within the acceptable range (1-3), Ligand B is pushing the upper limit and could potentially have solubility issues.
4. **HBD:** Ligand A (3) is higher than Ligand B (0). A moderate number of HBDs can aid solubility, but too many can hinder permeability. Ligand B's lack of HBDs is a slight negative.
5. **HBA:** Both ligands have 4 HBA, which is within the acceptable range.
6. **QED:** Ligand A (0.553) is slightly better than Ligand B (0.47), indicating a more drug-like profile.
7. **DILI:** Ligand A (4.886) is significantly better than Ligand B (15.626). Lower DILI risk is crucial.
8. **BBB:** Ligand B (87.553) is much better than Ligand A (45.909). Considering ADRB2 is a cardiovascular target, BBB penetration isn't *as* critical as it would be for a CNS target, but it's still a positive attribute.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.14 and -5.083), which is unusual and suggests poor permeability. This is a significant drawback for both.
10. **Solubility:** Ligand A (-1.168) is better than Ligand B (-2.91). Better solubility is always desirable.
11. **hERG:** Ligand A (0.257) is significantly better than Ligand B (0.74). Lower hERG inhibition is essential to avoid cardiotoxicity, especially for a cardiovascular target.
12. **Cl_mic:** Ligand A (13.374) is much better than Ligand B (77.871). Lower microsomal clearance indicates better metabolic stability.
13. **t1/2:** Ligand A (-17.682) is better than Ligand B (12.7). A more negative value indicates a longer half-life, which is generally preferred.
14. **Pgp:** Ligand A (0.045) is much better than Ligand B (0.676). Lower P-gp efflux is desirable for improved bioavailability.
15. **Binding Affinity:** Ligand A (-7.7) is slightly better than Ligand B (-7.2). While both are good, the difference of 0.5 kcal/mol is noticeable.
**Overall Assessment:**
Ligand A is clearly superior. It has a significantly better safety profile (DILI, hERG), better metabolic stability (Cl_mic, t1/2), better P-gp efflux, and slightly better binding affinity. While Ligand B has better BBB penetration, this is less critical for a cardiovascular target. The Caco-2 values are concerning for both, but the other advantages of Ligand A outweigh this drawback.
Output:
1
2025-04-17 23:18:29,019 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.45 & 345.44 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (78.67) is slightly higher than Ligand B (75.44). Both are below the 140 threshold for good oral absorption, and acceptable for a cardiovascular GPCR.
3. **logP:** Ligand A (1.097) is optimal, while Ligand B (3.231) is approaching the upper limit of the optimal range. This favors Ligand A.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 5 HBA, and Ligand B has 4. Both are within the acceptable limit of 10.
6. **QED:** Both ligands have similar QED scores (0.864 and 0.836), indicating good drug-likeness.
7. **DILI:** Ligand A (17.604) has a significantly lower DILI risk than Ligand B (52.695). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (69.523) and Ligand B (72.082) are both reasonably good, but not exceptional. Since ADRB2 is a cardiovascular target, BBB penetration isn't a primary concern, but a higher value is still slightly preferred. Ligand B is slightly better here.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual. It suggests poor permeability. Ligand A (-4.63) is slightly worse than Ligand B (-4.398).
10. **Solubility:** Ligand A (-0.273) has slightly better solubility than Ligand B (-3.926).
11. **hERG:** Ligand A (0.244) has a much lower hERG risk than Ligand B (0.727). This is a crucial advantage for Ligand A, minimizing cardiotoxicity concerns.
12. **Cl_mic:** Ligand B (70.006) has a significantly higher microsomal clearance than Ligand A (-0.442). This suggests Ligand A is more metabolically stable.
13. **t1/2:** Ligand B (70.775) has a much longer in vitro half-life than Ligand A (-2.877). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.047) has a lower Pgp efflux liability than Ligand B (0.254). This is a slight advantage for Ligand A.
15. **Binding Affinity:** Ligand A (-7.6 kcal/mol) has a slightly better binding affinity than Ligand B (-6.4 kcal/mol). This is a 1.2 kcal/mol difference, which is significant enough to outweigh some ADME drawbacks.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand A is the better candidate. While Ligand B has a longer half-life and slightly better BBB penetration, Ligand A excels in crucial areas like DILI risk, hERG inhibition, metabolic stability (lower Cl_mic), and binding affinity. The lower DILI and hERG risks are particularly important for a cardiovascular target. The slightly better affinity of Ligand A further strengthens its position. The Caco-2 values are concerning for both, but the other advantages of Ligand A outweigh this drawback.
Output:
1
2025-04-17 23:18:29,019 - INFO - Batch 395 complete. Total preferences: 6320
2025-04-17 23:18:29,019 - INFO - Processing batch 396/512...
2025-04-17 23:19:20,684 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (376.913) is slightly higher than Ligand B (346.387), but both are acceptable.
2. **TPSA:** Ligand A (64.7) is significantly better than Ligand B (108.46). For a GPCR, lower TPSA is generally preferred for better permeability, and Ligand A is well below the 140 threshold. Ligand B is approaching a level that could hinder absorption.
3. **logP:** Ligand A (4.789) is higher than Ligand B (1.031). While 4.789 is approaching the upper limit, it's still within a reasonable range. Ligand B's logP is quite low, potentially indicating poor membrane permeability.
4. **HBD:** Ligand A (0) is preferable to Ligand B (1). Fewer hydrogen bond donors generally improve permeability.
5. **HBA:** Both ligands have 6 HBA, which is acceptable.
6. **QED:** Ligand B (0.824) has a slightly better QED score than Ligand A (0.612), indicating a more drug-like profile.
7. **DILI:** Both ligands have similar DILI risk (Ligand A: 71.152, Ligand B: 65.413), and both are within an acceptable range (< 60 is ideal, but both are below 70).
8. **BBB:** Ligand B (60.14) has a higher BBB penetration percentile than Ligand A (46.336). While ADRB2 isn't necessarily a CNS target, some degree of BBB penetration can be beneficial, and this favors Ligand B.
9. **Caco-2:** Ligand A (-5.098) has a much better Caco-2 permeability than Ligand B (-4.694). Higher values indicate better absorption.
10. **Solubility:** Ligand A (-5.383) has a worse solubility than Ligand B (-2.615). Solubility is important, and this favors Ligand B.
11. **hERG:** Both ligands have very low hERG inhibition risk (Ligand A: 0.169, Ligand B: 0.2), which is excellent.
12. **Cl_mic:** Ligand B (30.724) has significantly lower microsomal clearance than Ligand A (65.188), indicating better metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand B (-19.335) has a much longer in vitro half-life than Ligand A (-2.451). This is a substantial advantage for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have very low P-gp efflux liability (Ligand A: 0.18, Ligand B: 0.065), which is good.
15. **Binding Affinity:** Ligand A (-7.6) has a slightly better binding affinity than Ligand B (-6). While the difference is not huge, it is a factor.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand A initially looks promising due to its better TPSA and logP. However, Ligand B demonstrates superior ADME properties, including significantly better metabolic stability (lower Cl_mic), longer half-life, and acceptable solubility. The slightly weaker binding affinity of Ligand B is outweighed by its improved pharmacokinetic profile. The better QED score of Ligand B also contributes to its favorability.
**Output:**
0
2025-04-17 23:19:20,684 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (348.443) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (87.66) is significantly better than Ligand B (36.36), falling well below the 140 threshold for good oral absorption. Ligand B is quite low, which could be beneficial, but very low TPSA can sometimes indicate poor binding.
3. **logP:** Ligand A (0.892) is within the optimal range, but on the lower side. Ligand B (4.556) is higher, potentially leading to solubility issues and off-target interactions.
4. **HBD:** Ligand A (3) is acceptable, while Ligand B (1) is even better, minimizing potential issues with hydrogen bonding and permeability.
5. **HBA:** Both ligands have 4 HBA, which is within the acceptable range.
6. **QED:** Both ligands have good QED scores (A: 0.622, B: 0.748), indicating drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (31.214) has a much lower DILI risk than Ligand B (15.2), which is a significant advantage.
8. **BBB:** Ligand B (84.839) has a much higher BBB penetration score than Ligand A (36.332). While ADRB2 isn't exclusively a CNS target, some cardiovascular effects are mediated through CNS pathways, and better BBB penetration could be beneficial.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and likely indicates poor permeability in this assay. This is a concern for both.
10. **Solubility:** Ligand A (-2.273) has better solubility than Ligand B (-4.322), which is important for bioavailability.
11. **hERG:** Ligand A (0.121) has a much lower hERG inhibition liability than Ligand B (0.968), a critical safety factor.
12. **Cl_mic:** Ligand A (10.733) has a significantly lower microsomal clearance than Ligand B (41.664), indicating better metabolic stability.
13. **t1/2:** Ligand B (29.614) has a longer in vitro half-life than Ligand A (8.691), which is desirable.
14. **Pgp:** Ligand A (0.067) has lower P-gp efflux liability than Ligand B (0.903), improving bioavailability.
15. **Affinity:** Ligand B (-7.9 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.5 kcal/mol). This is a substantial advantage, potentially outweighing some ADME concerns.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand B excels in affinity and BBB penetration, while Ligand A is better in TPSA, solubility, DILI, hERG, Cl_mic, and Pgp. The substantial affinity difference of Ligand B is a major factor.
**Overall Assessment:**
While Ligand A has a more favorable safety profile (lower DILI, hERG) and better metabolic stability, the significantly stronger binding affinity of Ligand B (-7.9 vs -6.5 kcal/mol) is a crucial advantage for a GPCR target. The higher logP of Ligand B is a concern, but the improved affinity could compensate for this. The better BBB penetration of Ligand B is also a plus.
Output:
0
2025-04-17 23:19:20,684 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (a cardiovascular GPCR) drug candidates.
**Ligand A:** [357.443, 105.45 , 2.175, 1. , 9. , 0.658, 74.952, 52.734, -5.837, -2.729, 0.291, 35.088, 14.326, 0.294, -4.7 ]
**Ligand B:** [343.475, 55.21 , 3.334, 1. , 6. , 0.836, 38.813, 78.868, -4.8 , -3.859, 0.934, 90.39 , 43.289, 0.315, -7. ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (343.475) is slightly lower, which could be marginally beneficial for permeability, but not a decisive factor.
2. **TPSA:** Ligand A (105.45) is higher than Ligand B (55.21). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B is significantly better here.
3. **logP:** Ligand A (2.175) is within the optimal range, while Ligand B (3.334) is slightly higher. Both are acceptable, but Ligand A is a bit more balanced.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 9 HBA, while Ligand B has 6. Both are acceptable, but Ligand B is better.
6. **QED:** Ligand B (0.836) has a better QED score than Ligand A (0.658), indicating a more drug-like profile.
7. **DILI:** Ligand A (74.952) has a higher DILI risk than Ligand B (38.813). This is a significant concern, and Ligand B is much safer.
8. **BBB:** Ligand B (78.868) has a higher BBB penetration than Ligand A (52.734). While not a primary concern for a cardiovascular target, higher BBB is never a detriment.
9. **Caco-2:** Ligand A (-5.837) has a worse Caco-2 permeability than Ligand B (-4.8).
10. **Solubility:** Ligand A (-2.729) has a worse solubility than Ligand B (-3.859).
11. **hERG:** Ligand A (0.291) has a lower hERG risk than Ligand B (0.934). This is a positive for Ligand A.
12. **Cl_mic:** Ligand A (35.088) has a lower microsomal clearance than Ligand B (90.39), suggesting better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand B (43.289) has a longer in vitro half-life than Ligand A (14.326). This is a positive for Ligand B.
14. **Pgp:** Ligand A (0.294) has lower P-gp efflux than Ligand B (0.315).
15. **Affinity:** Ligand B (-7.0) has a significantly stronger binding affinity than Ligand A (-4.7). This is a substantial advantage, potentially outweighing some ADME drawbacks.
**GPCR-Specific Priorities:** For ADRB2 (a cardiovascular GPCR), we prioritize logP, Pgp, TPSA, and affinity. Ligand B excels in TPSA and affinity, while Ligand A is better in logP and Pgp. However, the *magnitude* of the affinity difference is substantial. The lower DILI risk of Ligand B is also a major factor.
**Conclusion:**
Despite Ligand A having better metabolic stability (lower Cl_mic) and a lower hERG risk, the significantly stronger binding affinity of Ligand B (-7.0 vs -4.7 kcal/mol), combined with its much lower DILI risk, lower TPSA, and better QED, makes it the more promising drug candidate. The improved affinity is likely to be crucial for efficacy, and the lower DILI risk is vital for safety.
Output:
0
2025-04-17 23:19:20,684 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the acceptable range (200-500 Da). Ligand A (353.463 Da) is slightly lower, which is generally favorable for permeability.
**2. TPSA:** Ligand B (59.07) is significantly better than Ligand A (92.94). For a GPCR, lower TPSA is generally preferred for better membrane permeability and potentially better CNS penetration, even though this is a cardiovascular target.
**3. logP:** Ligand B (4.64) is higher than Ligand A (0.476). While logP > 4 can be problematic, it's not drastically high here. Ligand A's logP is *too* low, potentially hindering membrane permeability.
**4. H-Bond Donors:** Ligand A (1) is better than Ligand B (2). Fewer HBDs are generally preferred for permeability.
**5. H-Bond Acceptors:** Ligand B (5) is slightly higher than Ligand A (4), but both are within acceptable limits.
**6. QED:** Both ligands have similar, good QED values (0.72 and 0.739).
**7. DILI Risk:** Ligand A (25.436) has a much lower DILI risk than Ligand B (69.833). This is a significant advantage for Ligand A.
**8. BBB Penetration:** Both ligands have similar BBB penetration (64.133 and 63.125). While not a primary concern for a cardiovascular target, it's not detrimental.
**9. Caco-2 Permeability:** Both ligands have similar, poor Caco-2 permeability (-4.928 and -4.9).
**10. Aqueous Solubility:** Ligand A (-1.799) has better solubility than Ligand B (-5.155).
**11. hERG Inhibition:** Ligand A (0.172) has a lower hERG risk than Ligand B (0.689). This is a crucial safety parameter.
**12. Microsomal Clearance:** Ligand A (36.523) has lower microsomal clearance than Ligand B (56.329), indicating better metabolic stability.
**13. In vitro Half-Life:** Ligand B (22.627) has a significantly longer half-life than Ligand A (-6.65). This is a major advantage for Ligand B.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.023 and 0.172).
**15. Binding Affinity:** Ligand A (-6.6) has a slightly better binding affinity than Ligand B (-3.4). This is a substantial difference.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand A is favored. While Ligand B has a better half-life, Ligand A's superior affinity, lower DILI risk, lower hERG risk, better solubility, and more favorable logP outweigh this benefit. The lower TPSA of Ligand B is appealing, but the other factors are more critical. The substantial difference in binding affinity (-6.6 vs -3.4) is a key driver.
Output:
1
2025-04-17 23:19:20,685 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (345.378) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are below the 140 A^2 threshold for good oral absorption. Ligand B (84.5) is slightly better than Ligand A (88.91).
3. **logP:** Both are within the optimal range (1-3), but Ligand B (2.666) is higher than Ligand A (1.801). Higher logP can sometimes be beneficial for GPCRs, aiding membrane penetration.
4. **HBD:** Both have 2 H-bond donors, which is good.
5. **HBA:** Ligand A has 5 H-bond acceptors, and Ligand B has 4. Both are acceptable.
6. **QED:** Ligand A (0.835) has a significantly better QED score than Ligand B (0.64), indicating a more drug-like profile.
7. **DILI:** Ligand B (19.465) has a much lower DILI risk than Ligand A (63.358). This is a major advantage for Ligand B.
8. **BBB:** Ligand A (79.566) has a better BBB penetration score than Ligand B (67.468). While ADRB2 isn't necessarily a CNS target, some peripheral ADRB2 activity can be modulated by CNS effects, so this is a slight benefit for A.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand B (-4.807) is slightly worse than Ligand A (-4.62).
10. **Solubility:** Ligand A (-3.78) has better aqueous solubility than Ligand B (-2.888).
11. **hERG:** Both have very low hERG inhibition risk (0.202 and 0.2).
12. **Cl_mic:** Ligand A (39.674) has a lower microsomal clearance, indicating better metabolic stability, than Ligand B (66.171).
13. **t1/2:** Ligand A (9.481) has a significantly longer in vitro half-life than Ligand B (1.316).
14. **Pgp:** Both have very low Pgp efflux liability (0.071 and 0.025).
15. **Binding Affinity:** Ligand B (-7.6 kcal/mol) has a significantly stronger binding affinity than Ligand A (-4.3 kcal/mol). This is a substantial advantage, potentially outweighing some ADME drawbacks.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand B excels in affinity and has a reasonable logP and Pgp. While Ligand A has better BBB penetration, solubility, metabolic stability, and QED, the significantly stronger binding affinity of Ligand B is the most critical factor. The lower DILI risk of Ligand B is also a major positive. The poor Caco-2 values for both are concerning, but can be addressed during lead optimization.
**Conclusion:**
Despite Ligand A's better overall drug-like properties and safety profile (lower DILI), the significantly stronger binding affinity of Ligand B to the ADRB2 receptor makes it the more promising candidate. The difference in affinity (-7.6 vs -4.3 kcal/mol) is substantial and likely to drive greater efficacy.
Output:
0
2025-04-17 23:19:20,685 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [353.467, 107.4 , 2.779, 1. , 4. , 0.37 , 21.442, 65.529, -4.513, -1.202, 0.235, 50.203, 13.341, 0.027, -4.2 ]
**Ligand B:** [356.398, 96.69 , -0.065, 2. , 6. , 0.713, 39.899, 65.413, -5.004, -0.941, 0.24 , -4.89 , 10.648, 0.03 , -7.1 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). A is 353.467, B is 356.398. No significant difference.
2. **TPSA:** A (107.4) is slightly higher than B (96.69). Both are acceptable for a non-CNS GPCR target like ADRB2, but B is better.
3. **logP:** A (2.779) is optimal. B (-0.065) is quite low, potentially leading to poor membrane permeability. This is a significant drawback.
4. **HBD:** Both have acceptable HBD counts (A=1, B=2).
5. **HBA:** Both have acceptable HBA counts (A=4, B=6).
6. **QED:** A (0.37) is below the preferred threshold of 0.5, indicating a less drug-like profile. B (0.713) is good.
7. **DILI:** A (21.442) is excellent, very low risk. B (39.899) is also good, but higher than A.
8. **BBB:** Both are similar (A=65.529, B=65.413). Not a primary concern for ADRB2, but higher is generally better.
9. **Caco-2:** Both are negative, indicating poor permeability. B (-5.004) is worse than A (-4.513).
10. **Solubility:** Both are negative, indicating poor solubility. B (-0.941) is slightly better than A (-1.202).
11. **hERG:** Both are very low (A=0.235, B=0.24), indicating minimal hERG inhibition risk.
12. **Cl_mic:** A (50.203) is higher than B (-4.89), suggesting faster metabolism and lower metabolic stability. This is a disadvantage for A.
13. **t1/2:** A (13.341) is longer than B (10.648), which is preferable.
14. **Pgp:** Both are very low (A=0.027, B=0.03), indicating minimal P-gp efflux.
15. **Affinity:** B (-7.1) has a significantly stronger binding affinity than A (-4.2) - a difference of 2.9 kcal/mol. This is a *major* advantage.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. B has a better TPSA, and significantly better affinity. A has a better logP, but B's affinity is so much stronger that it outweighs this. The QED of B is also much better. While A has a better DILI score, both are acceptable.
**Conclusion:**
Despite Ligand A's slightly better DILI and half-life, the significantly stronger binding affinity of Ligand B (-7.1 vs -4.2 kcal/mol), coupled with its better QED and TPSA, makes it the more promising drug candidate. The low logP of B is a concern, but the substantial affinity advantage is likely to be more impactful in driving efficacy.
0
2025-04-17 23:19:20,685 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (351.378 and 365.503 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (95.67) is slightly higher than Ligand B (88.91). Both are below the 140 A^2 threshold for good oral absorption, but closer to the 90 A^2 threshold for CNS targets. Ligand B is slightly favored.
3. **logP:** Ligand A (0.844) is a bit low, potentially hindering permeation. Ligand B (1.382) is better, falling within the optimal 1-3 range. Ligand B is favored.
4. **HBD:** Both ligands have 2 HBD, which is within the acceptable limit of <=5. No clear advantage.
5. **HBA:** Ligand A has 5 HBA, while Ligand B has 6. Both are within the acceptable limit of <=10. No strong preference.
6. **QED:** Ligand A (0.767) is slightly higher than Ligand B (0.727), indicating a marginally better drug-like profile. Ligand A is slightly favored.
7. **DILI:** Ligand A (50.64) has a slightly higher DILI risk than Ligand B (44.126), but both are below the concerning 60 percentile. Ligand B is favored.
8. **BBB:** Ligand A (69.407) has a significantly higher BBB penetration potential than Ligand B (39.55). While ADRB2 isn't strictly a CNS target, some CNS exposure can be acceptable or even desirable for certain cardiovascular effects. Ligand A is strongly favored.
9. **Caco-2:** Ligand A (-4.961) has a better Caco-2 permeability than Ligand B (-5.504). Ligand A is favored.
10. **Solubility:** Ligand A (-2.164) has better aqueous solubility than Ligand B (-1.778). Ligand A is favored.
11. **hERG:** Ligand A (0.327) has a much lower hERG inhibition liability than Ligand B (0.071), which is a critical advantage for cardiovascular drugs. Ligand A is strongly favored.
12. **Cl_mic:** Ligand A (-3.573) has a much lower microsomal clearance than Ligand B (19.25), indicating better metabolic stability. Ligand A is strongly favored.
13. **t1/2:** Ligand A (-6.344) has a longer in vitro half-life than Ligand B (-2.288). Ligand A is strongly favored.
14. **Pgp:** Ligand A (0.148) has lower P-gp efflux liability than Ligand B (0.025). Ligand A is favored.
15. **Affinity:** Ligand A (-7.5 kcal/mol) has a slightly better binding affinity than Ligand B (-6.2 kcal/mol). This 1.3 kcal/mol difference is significant and can outweigh some minor ADME drawbacks. Ligand A is favored.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical ADME-Tox parameters, especially hERG inhibition, metabolic stability (Cl_mic, t1/2), and solubility. While Ligand B has a slightly better logP, the advantages of Ligand A are substantial, especially considering the cardiovascular target. The higher BBB penetration of Ligand A is also a bonus. The affinity difference is also significant.
Output:
1
2025-04-17 23:19:20,685 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the acceptable range (200-500 Da). Ligand A (429.292 Da) is higher, but not excessively so.
**2. TPSA:** Ligand A (89.71) is excellent, well below the 140 A^2 threshold. Ligand B (98.32) is still reasonable, but less optimal.
**3. logP:** Ligand A (2.009) is ideal. Ligand B (0.644) is a bit low, potentially hindering membrane permeability.
**4. H-Bond Donors:** Ligand A (0) is excellent. Ligand B (3) is acceptable, but higher HBDs can sometimes reduce permeability.
**5. H-Bond Acceptors:** Ligand A (6) is good. Ligand B (4) is also good.
**6. QED:** Both ligands have similar QED values (0.726 and 0.606), indicating good drug-likeness.
**7. DILI Risk:** Ligand A (84.645) has a higher DILI risk than Ligand B (26.095). This is a significant concern.
**8. BBB Penetration:** Ligand A (79.915) has better BBB penetration than Ligand B (58.976). While ADRB2 is a cardiovascular target, some CNS effects are possible with beta-blockers, and moderate BBB penetration isn't necessarily detrimental.
**9. Caco-2 Permeability:** Ligand A (-4.592) is better than Ligand B (-5.311), indicating better intestinal absorption.
**10. Aqueous Solubility:** Ligand A (-2.975) is better than Ligand B (-1.495).
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (0.395 and 0.269).
**12. Microsomal Clearance:** Ligand A (27.14) has higher clearance than Ligand B (3.258), indicating lower metabolic stability.
**13. In vitro Half-Life:** Ligand A (78.505) has a longer half-life than Ligand B (-8.32).
**14. P-gp Efflux:** Ligand A (0.105) has lower P-gp efflux than Ligand B (0.032).
**15. Binding Affinity:** Ligand B (-8.6 kcal/mol) has a significantly stronger binding affinity than Ligand A (-7.1 kcal/mol). This is a 1.5 kcal/mol difference, which is substantial.
**GPCR-Specific Considerations:** For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A has better logP, TPSA, and Pgp properties. However, Ligand B's significantly superior binding affinity is a major advantage. The DILI risk associated with Ligand A is a serious drawback.
**Overall Assessment:**
Despite the higher DILI risk, Ligand A has a better overall profile for a cardiovascular drug candidate. The better solubility, permeability, and metabolic stability are important. However, the significantly stronger binding affinity of Ligand B is a compelling factor. Given the importance of potency for GPCRs, and the relatively low DILI risk of Ligand B, I would prioritize Ligand B.
Output:
0
2025-04-17 23:19:20,685 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (352.347 and 355.479 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (131.04) is slightly higher than Ligand B (82.11). For a cardiovascular GPCR like ADRB2, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B has a substantial advantage here.
3. **logP:** Ligand A (-0.347) is a bit low, potentially hindering membrane permeability. Ligand B (0.386) is closer to the optimal 1-3 range. Ligand B is better.
4. **HBD:** Ligand A (4) is higher than Ligand B (2). Lower HBD is generally preferred for better permeability. Ligand B is better.
5. **HBA:** Ligand A (7) is higher than Ligand B (5). Similar to HBD, Ligand B is better.
6. **QED:** Both ligands have good QED scores (0.545 and 0.585), indicating good overall drug-likeness. No significant difference.
7. **DILI:** Ligand A (79.682) has a considerably higher DILI risk than Ligand B (21.791). This is a major concern, as liver toxicity is a common reason for drug failure. Ligand B is *much* better.
8. **BBB:** While not a primary concern for a cardiovascular target, Ligand A (65.839) has a higher BBB penetration than Ligand B (24.002). This is not a deciding factor in this case.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.083 and -4.951), which is unusual and suggests very poor permeability. This is a concern for both, but the values are similar.
10. **Solubility:** Ligand A (-2.413) has slightly better solubility than Ligand B (-0.405), but both are quite poor. Solubility could be a formulation challenge for both.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.027 and 0.07). This is excellent. No significant difference.
12. **Cl_mic:** Ligand A (-28.252) has a much lower (better) microsomal clearance than Ligand B (17.003), indicating greater metabolic stability. Ligand A is better.
13. **t1/2:** Ligand A (16.714) has a longer in vitro half-life than Ligand B (-4.177). This is a significant advantage, potentially allowing for less frequent dosing. Ligand A is better.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.004 and 0.012). This is good. No significant difference.
15. **Binding Affinity:** Ligand A (-6.7 kcal/mol) has a slightly better binding affinity than Ligand B (-6.1 kcal/mol). While the difference is not huge, it's a positive for Ligand A.
**Overall Assessment:**
Ligand B clearly wins out due to its significantly lower DILI risk and superior TPSA, logP, HBD and HBA values. The lower DILI risk is a critical factor. While Ligand A has advantages in metabolic stability (Cl_mic, t1/2) and binding affinity, the potential for liver toxicity with Ligand A is a major red flag. The Caco-2 permeability is poor for both, but can be addressed with formulation strategies.
Output:
0
2025-04-17 23:19:20,685 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands (349.431 and 349.41 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (78.95) is significantly better than Ligand B (101.21). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand A is well below the 140 threshold, while B is approaching it.
3. **logP:** Ligand B (1.308) is better than Ligand A (0.309). Both are within the 1-3 range, but Ligand B is closer to the optimal range. Ligand A is quite low, potentially hindering permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (4) is preferable to Ligand B (5). Lower HBA generally improves permeability.
6. **QED:** Both ligands have good QED scores (0.744 and 0.806), indicating good drug-like properties. No major difference.
7. **DILI:** Ligand A (23.769) is significantly better than Ligand B (49.283). Lower DILI risk is crucial. Ligand A is well below the 40% threshold, while Ligand B is approaching a moderate risk.
8. **BBB:** Ligand B (90.772) is significantly better than Ligand A (59.946). For a GPCR, especially if CNS effects are possible, higher BBB penetration is desirable.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.005 and -5.172) which is unusual and suggests poor permeability. However, the values are very similar.
10. **Solubility:** Ligand A (-1.273) is better than Ligand B (-2.912). Higher solubility is generally preferred.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.19 and 0.377), which is excellent. No significant difference.
12. **Cl_mic:** Ligand B (2.823) is much better than Ligand A (-19.967). A positive value for A suggests rapid clearance, which is undesirable.
13. **t1/2:** Ligand B (-20.936) is better than Ligand A (3.501). Longer half-life is generally preferred.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.011 and 0.023), which is excellent. No significant difference.
15. **Binding Affinity:** Ligand B (-6.6) is slightly better than Ligand A (-6.1). While both are good, the 0.5 kcal/mol difference is noticeable.
**GPCR-Specific Priorities & Overall Assessment:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, BBB, and affinity. Ligand A excels in TPSA, DILI, and solubility, but struggles with logP and BBB. Ligand B has a better logP, BBB, clearance, and half-life, and slightly better affinity. The superior BBB penetration and metabolic stability (lower Cl_mic, longer t1/2) of Ligand B are particularly important for a GPCR target. While Ligand A has a better DILI score, the difference isn't substantial enough to outweigh the other advantages of Ligand B. The slightly better affinity of Ligand B is also a plus.
**Output:**
0
2025-04-17 23:19:20,685 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [342.443, 87.46, 2.537, 3, 3, 0.738, 55.991, 67.197, -5.29, -2.597, 0.452, -2.89, 25.983, 0.057, -6.7]
**Ligand B:** [335.407, 54.46, 2.966, 1, 4, 0.937, 43.04, 88.29, -4.818, -3.403, 0.726, 21.53, -2.816, 0.212, -6.4]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (335.407) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (87.46) is higher than Ligand B (54.46). Both are below 140, but Ligand B is significantly better for oral absorption and potentially better for GPCR binding.
3. **logP:** Both are within the optimal 1-3 range. Ligand B (2.966) is slightly higher, which could be a minor concern for solubility, but not a major issue.
4. **HBD:** Ligand A (3) is higher than Ligand B (1). Lower is generally preferred for permeability, so Ligand B is better.
5. **HBA:** Ligand A (3) and Ligand B (4) are both acceptable.
6. **QED:** Ligand B (0.937) has a significantly better QED score than Ligand A (0.738), indicating a more drug-like profile.
7. **DILI:** Ligand B (43.04) has a much lower DILI risk than Ligand A (55.991). This is a significant advantage for Ligand B.
8. **BBB:** Ligand B (88.29) has a much higher BBB penetration potential than Ligand A (67.197). As this is a GPCR target, BBB penetration is a desirable property.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-5.29) is worse than Ligand B (-4.818).
10. **Solubility:** Both are negative, indicating poor solubility. Ligand B (-3.403) is slightly better than Ligand A (-2.597).
11. **hERG:** Ligand A (0.452) has a lower hERG risk than Ligand B (0.726), which is a positive.
12. **Cl_mic:** Ligand A (-2.89) has a lower (better) microsomal clearance than Ligand B (21.53). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand B (-2.816) has a slightly better in vitro half-life than Ligand A (25.983).
14. **Pgp:** Ligand A (0.057) has a lower Pgp efflux liability than Ligand B (0.212), which is favorable for bioavailability and CNS exposure.
15. **Affinity:** Ligand A (-6.7) has a slightly better binding affinity than Ligand B (-6.4). However, the difference is relatively small (0.3 kcal/mol).
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, BBB, and affinity are key. Ligand B excels in TPSA, BBB, and has a good logP. While Ligand A has slightly better affinity and Pgp, the advantages of Ligand B in TPSA, BBB, and DILI are more significant for overall drug-like properties and potential for clinical success. The better QED score for Ligand B also contributes to its overall favorability.
**Conclusion:**
Considering the balance of properties and the priorities for a GPCR target, Ligand B is the more promising drug candidate.
0
2025-04-17 23:19:20,685 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.459 and 350.419 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (60.03) is excellent, well below the 140 threshold for oral absorption and favorable for GPCRs. Ligand B (96.69) is higher, but still acceptable, though less ideal.
3. **logP:** Ligand A (2.42) is optimal (1-3). Ligand B (0.13) is quite low, potentially hindering membrane permeability and absorption. This is a significant drawback.
4. **HBD:** Both ligands have acceptable HBD counts (1 and 2, respectively), well under the 5 limit.
5. **HBA:** Ligand A (4) is good. Ligand B (6) is slightly higher, but still within the acceptable range of 10.
6. **QED:** Both ligands have good QED scores (0.767 and 0.805), indicating good drug-like properties.
7. **DILI:** Ligand A (23.497) has a much lower DILI risk than Ligand B (37.805). This is a substantial advantage for Ligand A.
8. **BBB:** Ligand A (84.141) shows good BBB penetration, which is beneficial for a GPCR target. Ligand B (46.724) is considerably lower, suggesting limited CNS exposure.
9. **Caco-2:** Ligand A (-4.354) is better than Ligand B (-5.26), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-2.651) has better aqueous solubility than Ligand B (-1.038).
11. **hERG:** Ligand A (0.823) has a lower hERG risk than Ligand B (0.301), which is a significant safety advantage.
12. **Cl_mic:** Ligand A (59.886) has a lower microsomal clearance, suggesting better metabolic stability than Ligand B (-18.802).
13. **t1/2:** Ligand A (1.725) has a longer in vitro half-life than Ligand B (-9.449).
14. **Pgp:** Ligand A (0.153) has lower P-gp efflux liability than Ligand B (0.053).
15. **Affinity:** Ligand B (-7.2) has a slightly better binding affinity than Ligand A (-6.1), a difference of 1.1 kcal/mol. While affinity is important, the other ADME properties of Ligand B are significantly worse.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and BBB are crucial. Ligand A excels in these areas, while Ligand B struggles with logP and BBB. The slightly better affinity of Ligand B is unlikely to overcome its poor ADME profile.
**Conclusion:**
Ligand A demonstrates a superior balance of properties, particularly regarding ADME characteristics critical for a successful GPCR drug candidate. While Ligand B has slightly better binding affinity, the significant drawbacks in logP, BBB, DILI, hERG, and metabolic stability make it a less viable option.
Output:
1
2025-04-17 23:19:20,685 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (366.447) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (82.78) is significantly better than Ligand A (110.91). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA is still beneficial for absorption.
3. **logP:** Ligand B (2.937) is optimal, while Ligand A (0.038) is quite low. This is a significant drawback for Ligand A, potentially hindering membrane permeability and bioavailability.
4. **HBD:** Both ligands have 2 HBD, which is within the acceptable range.
5. **HBA:** Ligand A has 8 HBA, and Ligand B has 5. Both are acceptable, but Ligand B is slightly better.
6. **QED:** Ligand B (0.8) is better than Ligand A (0.685), indicating a more drug-like profile.
7. **DILI:** Both ligands have relatively high DILI risk (Ligand A: 70.531, Ligand B: 73.866). This is a concern for both, but not dramatically different.
8. **BBB:** Ligand A (51.958) has a higher BBB penetration percentile than Ligand B (24.738). However, as ADRB2 is a cardiovascular target, BBB penetration is not a primary concern.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-5.608) is slightly better than Ligand B (-5.085).
10. **Solubility:** Ligand A (-2.374) is better than Ligand B (-4.683). Solubility is important for formulation.
11. **hERG:** Ligand A (0.161) has a much lower hERG inhibition liability than Ligand B (0.654). This is a significant advantage for Ligand A, reducing the risk of cardiotoxicity.
12. **Cl_mic:** Both ligands have similar microsomal clearance (Ligand A: 41.629, Ligand B: 42.442).
13. **t1/2:** Ligand B (41.558) has a significantly longer in vitro half-life than Ligand A (14.824). This is a major advantage for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.06) has a much lower P-gp efflux liability than Ligand B (0.283). This is favorable for bioavailability.
15. **Binding Affinity:** Both ligands have comparable binding affinities (Ligand A: -6.1 kcal/mol, Ligand B: -6.0 kcal/mol). The difference is negligible.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand B excels in TPSA and has a good logP, while Ligand A has a poor logP. The affinities are similar. The longer half-life of Ligand B is also a significant advantage. While Ligand A has a better hERG profile and Pgp efflux, the poor logP is a major concern.
**Conclusion:**
Despite the better hERG and Pgp profiles of Ligand A, the significantly better logP, QED, and half-life of Ligand B outweigh these advantages. The low logP of Ligand A is a substantial impediment to its developability.
Output:
0
2025-04-17 23:19:20,685 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A Analysis:**
* **MW:** 361.31 Da - Within the ideal range (200-500).
* **TPSA:** 29.54 A2 - Excellent, well below the 140 A2 threshold, and very favorable for GPCRs.
* **logP:** 3.919 - Slightly high, but acceptable. Could potentially lead to off-target effects, but the affinity is strong.
* **HBD:** 0 - Low, good for permeability.
* **HBA:** 2 - Low, good for permeability.
* **QED:** 0.748 - Excellent drug-likeness.
* **DILI:** 48.313 - Good, low risk of liver injury.
* **BBB:** 98.022 - Excellent, very high BBB penetration. This is a significant advantage for a GPCR.
* **Caco-2:** -4.306 - Poor permeability. This is a major drawback.
* **Solubility:** -4.708 - Very poor solubility. A significant issue for bioavailability.
* **hERG:** 0.821 - Acceptable hERG risk.
* **Cl_mic:** 38.317 mL/min/kg - Moderate clearance. Not ideal, but not terrible.
* **t1/2:** 0.565 hours - Very short half-life. Frequent dosing would be required.
* **Pgp:** 0.329 - Low P-gp efflux, favorable.
* **Affinity:** -5.6 kcal/mol - Very good binding affinity.
**Ligand B Analysis:**
* **MW:** 350.459 Da - Within the ideal range (200-500).
* **TPSA:** 76.66 A2 - Acceptable, but higher than Ligand A. Still within a reasonable range for oral absorption.
* **logP:** 1.526 - Good, within the optimal range.
* **HBD:** 2 - Acceptable.
* **HBA:** 4 - Acceptable.
* **QED:** 0.696 - Good drug-likeness.
* **DILI:** 15.238 - Excellent, very low risk of liver injury.
* **BBB:** 66.809 - Moderate BBB penetration. Not as good as Ligand A, but still reasonable.
* **Caco-2:** -4.937 - Poor permeability. Similar to Ligand A.
* **Solubility:** -2.311 - Poor solubility, but better than Ligand A.
* **hERG:** 0.392 - Very good hERG risk profile.
* **Cl_mic:** 27.04 mL/min/kg - Lower clearance than Ligand A, indicating better metabolic stability.
* **t1/2:** 23.124 hours - Excellent half-life, allowing for less frequent dosing.
* **Pgp:** 0.014 - Very low P-gp efflux, highly favorable.
* **Affinity:** -6.6 kcal/mol - Excellent binding affinity, 1 kcal/mol better than Ligand A.
**Comparison and Decision:**
Both ligands suffer from poor Caco-2 permeability and solubility. However, Ligand B has a significantly better safety profile (lower DILI, lower hERG), better metabolic stability (lower Cl_mic, longer t1/2), and slightly better binding affinity. While Ligand A boasts excellent BBB penetration, the ADRB2 is a cardiovascular target, meaning CNS penetration is not a primary requirement. The superior ADME properties and safety profile of Ligand B outweigh the advantage of Ligand A's BBB penetration. The 1 kcal/mol affinity difference is also significant.
Therefore, Ligand B is the more promising drug candidate.
Output:
0
2025-04-17 23:19:20,685 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (356.419 and 361.511 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (51.39) is significantly better than Ligand A (94.17). ADRB2 is not a CNS target, but lower TPSA generally improves absorption. This favors Ligand B.
3. **logP:** Ligand A (-0.046) is slightly below the optimal 1-3 range, potentially hindering permeability. Ligand B (3.857) is at the upper end but still acceptable. Ligand B is favored.
4. **HBD:** Ligand A (1) is good. Ligand B (0) is also good. No significant difference.
5. **HBA:** Both ligands have 6 HBA, which is within the acceptable range. No clear advantage.
6. **QED:** Both ligands have good QED scores (0.643 and 0.782), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand B (21.442) has a much lower DILI risk than Ligand A (38.62). This is a significant advantage for Ligand B.
8. **BBB:** Not a primary concern for ADRB2 (cardiovascular target). Ligand B (80.264) is higher, but this isn't a deciding factor.
9. **Caco-2:** Both have negative values, indicating poor permeability. Ligand A (-4.643) is slightly better than Ligand B (-5.078), but both are concerning.
10. **Solubility:** Ligand A (-1.528) is slightly better than Ligand B (-3.654), but both are poor.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.164 and 0.794). No significant difference.
12. **Cl_mic:** Ligand A (28.969) has a significantly lower microsomal clearance than Ligand B (64.083), indicating better metabolic stability. This favors Ligand A.
13. **t1/2:** Ligand B (12.912) has a longer in vitro half-life than Ligand A (-14.163). This is a significant advantage for Ligand B.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.021 and 0.438). No significant difference.
15. **Binding Affinity:** Both ligands have similar binding affinities (-6.7 and -6.1 kcal/mol). The difference of 0.6 kcal/mol isn't enough to outweigh other factors.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand B is the better candidate. It has a more favorable logP, significantly lower TPSA, and a much lower DILI risk. While Ligand A has better metabolic stability (lower Cl_mic), the other advantages of Ligand B, particularly the lower DILI and better TPSA, are more critical for overall drug development success. The slightly longer half-life of Ligand B is also a plus. The Caco-2 and solubility are concerning for both, but can be addressed with formulation strategies.
Output:
0
2025-04-17 23:19:20,686 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Step-by-step comparison:**
1. **MW:** Both ligands (358.419 and 353.419 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (69.68) is significantly better than Ligand B (105.76). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (3.712) is optimal, while Ligand B (-0.528) is quite low, potentially hindering membrane permeability. This is a major strike against Ligand B.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (7) is better than Ligand B (5). Lower HBA is generally preferred.
6. **QED:** Both ligands have acceptable QED scores (0.678 and 0.595, respectively), indicating reasonable drug-likeness.
7. **DILI:** Ligand A (96.51) has a significantly higher DILI risk than Ligand B (47.266). This is a substantial concern for Ligand A.
8. **BBB:** Not a primary concern for a cardiovascular target. Ligand A (63.358) is slightly better than Ligand B (46.762).
9. **Caco-2:** Ligand A (-4.676) is better than Ligand B (-5.539), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-5.843) is better than Ligand B (-1.652).
11. **hERG:** Ligand A (0.685) has a lower hERG risk than Ligand B (0.075). This is a positive for Ligand A.
12. **Cl_mic:** Ligand B (-9.495) has a much lower (better) microsomal clearance than Ligand A (154.848), suggesting greater metabolic stability.
13. **t1/2:** Ligand B (19.498) has a significantly longer in vitro half-life than Ligand A (2.317). This is a major advantage for Ligand B.
14. **Pgp:** Ligand A (0.257) has lower Pgp efflux than Ligand B (0.009).
15. **Affinity:** Ligand A (-8.1) has a stronger binding affinity than Ligand B (-6.7). This is a significant advantage for Ligand A.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A excels in affinity and has a good logP and Pgp profile, but suffers from high DILI and poor metabolic stability. Ligand B has a poor logP, but excels in metabolic stability, half-life, and lower DILI.
**Overall Assessment:**
While Ligand A has a significantly better binding affinity, the combination of high DILI risk and poor metabolic stability (high Cl_mic, short half-life) is concerning. The low logP of Ligand B is a significant drawback, but its superior metabolic stability, longer half-life, and lower DILI risk make it a more promising starting point for optimization. A medicinal chemist could attempt to improve the logP of Ligand B without sacrificing its favorable ADME properties. The strong binding affinity of Ligand A is tempting, but the ADME liabilities are too significant to ignore at this stage.
Output:
0
2025-04-17 23:19:20,686 - INFO - Batch 396 complete. Total preferences: 6336
2025-04-17 23:19:20,686 - INFO - Processing batch 397/512...
2025-04-17 23:20:12,076 - INFO - Reasoning:
Let's analyze Ligand A and Ligand B for their potential as ADRB2 ligands, keeping in mind the GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key).
**Molecular Weight:** Both ligands (354.397 and 363.487 Da) fall within the ideal 200-500 Da range.
**TPSA:** Ligand A (49.85) is significantly better than Ligand B (76.3). A TPSA under 140 is good for oral absorption, and lower is generally preferred for GPCRs. Ligand A is well within this range, while Ligand B is approaching the upper limit.
**logP:** Both ligands have acceptable logP values (1.519 and 1.338), falling within the optimal 1-3 range.
**H-Bond Donors/Acceptors:** Ligand A (0 HBD, 3 HBA) is preferable to Ligand B (1 HBD, 8 HBA). Lower HBD/HBA generally improves permeability.
**QED:** Both ligands have good QED scores (0.722 and 0.758), indicating good drug-like properties.
**DILI:** Ligand A (21.753) has a much lower DILI risk than Ligand B (45.715). This is a significant advantage.
**BBB:** Ligand A (88.29) has a much higher BBB penetration percentile than Ligand B (53.703). While ADRB2 isn't exclusively a CNS target, higher BBB penetration is generally favorable, reducing potential off-target effects.
**Caco-2 Permeability:** Ligand A (-4.287) has better Caco-2 permeability than Ligand B (-5.374).
**Aqueous Solubility:** Both are similarly poor (-2.536 and -2.469). This could be a formulation challenge for both, but isn't a deciding factor.
**hERG Inhibition:** Both ligands have low hERG inhibition risk (0.337 and 0.215).
**Microsomal Clearance:** Ligand A (-7.411) has significantly lower microsomal clearance than Ligand B (28.688), suggesting better metabolic stability.
**In vitro Half-Life:** Ligand A (-9.929) has a much longer in vitro half-life than Ligand B (15.784). This is a significant advantage for dosing convenience.
**P-gp Efflux:** Both ligands have low P-gp efflux liability (0.048 and 0.194).
**Binding Affinity:** Ligand B (-7.0) has slightly better binding affinity than Ligand A (-6.3). However, the difference is only 0.7 kcal/mol, which is less impactful than the significant ADME advantages of Ligand A.
**Overall:** Ligand A demonstrates a superior balance of properties, particularly in ADME characteristics (lower DILI, better BBB, lower clearance, longer half-life, better Caco-2 permeability) and TPSA. While Ligand B has slightly better affinity, the ADME profile of Ligand A is far more promising for development as a drug candidate.
Output:
1
2025-04-17 23:20:12,077 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [362.392, 60.85, 1.615, 1, 3, 0.7, 19.193, 77.433, -4.592, -1.64, 0.667, 6.443, -3.107, 0.102, -6.1]**
**Ligand B: [347.438, 63.05, 2.432, 1, 5, 0.797, 37.999, 70.182, -4.85, -1.896, 0.335, 44.668, 44.77, 0.046, -5.6]**
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand B (347.438 Da) is slightly smaller, which could be marginally better for permeability, but the difference isn't substantial.
2. **TPSA:** Both are acceptable for a non-CNS GPCR target, being below 140. Ligand A (60.85) is slightly better than Ligand B (63.05).
3. **logP:** Both ligands have logP values within the optimal range (1-3). Ligand A (1.615) is slightly lower, which is generally preferable as it reduces the risk of off-target interactions. Ligand B (2.432) is still acceptable.
4. **H-Bond Donors:** Both have 1 HBD, which is good.
5. **H-Bond Acceptors:** Ligand A (3) is better than Ligand B (5). Fewer HBA are generally preferred for better permeability.
6. **QED:** Both ligands have similar QED values (0.7 and 0.797), indicating good drug-like properties.
7. **DILI Risk:** Ligand A (19.193%) has a significantly lower DILI risk than Ligand B (37.999%). This is a major advantage for Ligand A.
8. **BBB Penetration:** Both have good BBB penetration (Ligand A: 77.433%, Ligand B: 70.182%). This isn't a primary concern for ADRB2 (a cardiovascular target), but higher is still slightly preferable.
9. **Caco-2 Permeability:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.592) is slightly better than Ligand B (-4.85).
10. **Aqueous Solubility:** Both have negative solubility values, which is also unusual and suggests poor solubility. Ligand A (-1.64) is slightly better than Ligand B (-1.896).
11. **hERG Inhibition:** Both ligands have low hERG inhibition risk (Ligand A: 0.667%, Ligand B: 0.335%). Ligand B is slightly better.
12. **Microsomal Clearance:** Ligand A (6.443 mL/min/kg) has significantly lower microsomal clearance than Ligand B (44.668 mL/min/kg), indicating better metabolic stability.
13. **In vitro Half-Life:** Ligand A (-3.107 hours) has a longer half-life than Ligand B (44.77 hours). This is a significant advantage for Ligand A.
14. **P-gp Efflux:** Both have low P-gp efflux liability (Ligand A: 0.102, Ligand B: 0.046). Ligand B is slightly better.
15. **Binding Affinity:** Ligand A (-6.1 kcal/mol) has slightly better binding affinity than Ligand B (-5.6 kcal/mol).
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity) and general drug-like properties, Ligand A is the better candidate. While both have acceptable logP and Pgp values, Ligand A excels in crucial ADME properties: significantly lower DILI risk, better metabolic stability (lower Cl_mic, longer t1/2), and slightly better affinity. The negative Caco-2 and solubility values are concerning for both, but the superior ADME profile of Ligand A outweighs the slightly better hERG and P-gp values of Ligand B.
Output:
1
2025-04-17 23:20:12,077 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**1. Molecular Weight:** Both ligands (345.487 Da and 352.475 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Both ligands have TPSA values below 140 (84.22 and 81.08), which is good for oral absorption. Ligand B is slightly lower, which is marginally better.
**3. logP:** Ligand A (2.649) is within the optimal 1-3 range. Ligand B (1.173) is on the lower end of this range. While not terrible, a lower logP can sometimes indicate poorer membrane permeability.
**4. H-Bond Donors:** Ligand A has 3 HBD, and Ligand B has 2. Both are acceptable (<=5).
**5. H-Bond Acceptors:** Ligand A has 3 HBA, and Ligand B has 4. Both are acceptable (<=10).
**6. QED:** Ligand B (0.728) has a significantly better QED score than Ligand A (0.421), indicating a more drug-like profile.
**7. DILI:** Ligand B (17.449) has a much lower DILI risk than Ligand A (41.024). This is a substantial advantage.
**8. BBB:** Ligand A (74.758) shows better BBB penetration than Ligand B (43.738). Considering ADRB2 is a GPCR, and while not necessarily a CNS target, some level of BBB penetration can be beneficial for off-target profiling and understanding potential side effects.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.956 and -4.755), which is unusual and suggests poor permeability. This is a concern for both.
**10. Aqueous Solubility:** Ligand A (-3.749) has slightly better aqueous solubility than Ligand B (-0.935), but both are poor.
**11. hERG Inhibition:** Ligand A (0.585) has a slightly higher hERG risk than Ligand B (0.221), but both are relatively low.
**12. Microsomal Clearance:** Ligand B (0.564) has significantly lower microsomal clearance than Ligand A (55.064), indicating better metabolic stability.
**13. In vitro Half-Life:** Ligand A (-4.513) has a longer in vitro half-life than Ligand B (-0.472).
**14. P-gp Efflux:** Ligand A (0.376) has lower P-gp efflux than Ligand B (0.059), which is favorable.
**15. Binding Affinity:** Ligand B (-7.0 kcal/mol) has a slightly better binding affinity than Ligand A (-6.0 kcal/mol). This is a 1.0 kcal/mol difference, which is significant.
**Overall Assessment:**
Considering the priorities for a GPCR target like ADRB2, the key factors are affinity, logP, TPSA, Pgp, and metabolic stability. Ligand B excels in several crucial areas: significantly lower DILI risk, much better metabolic stability (lower Cl_mic), and a slightly better binding affinity. While Ligand A has better BBB penetration and P-gp efflux, the superior safety profile and metabolic stability of Ligand B outweigh these benefits. The poor Caco-2 permeability is a concern for both, but can be addressed through formulation strategies. The QED score is also considerably higher for Ligand B.
Therefore, I prefer Ligand B.
0
2025-04-17 23:20:12,077 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [378.885, 97.11, 2.707, 3, 5, 0.673, 65.801, 67.546, -5.017, -4.152, 0.462, 11.015, 13.036, 0.109, -7.4]
**Ligand B:** [364.833, 80.37, 2.264, 1, 5, 0.882, 61.846, 46.142, -5.086, -3.094, 0.166, 18.162, 34.735, 0.085, -6.5]
Here's a breakdown, comparing each parameter and considering GPCR priorities (logP, Pgp, TPSA, affinity):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (364.833) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (97.11) is higher than Ligand B (80.37). Both are acceptable for a cardiovascular target, but Ligand B is better, closer to the <90 threshold for CNS penetration (though not a primary concern here).
3. **logP:** Both are within the optimal range (1-3). Ligand A (2.707) is slightly higher, which could potentially lead to off-target interactions, but is still reasonable. Ligand B (2.264) is slightly better.
4. **HBD:** Ligand A (3) is higher than Ligand B (1). Lower is generally preferred, so Ligand B is better.
5. **HBA:** Both have 5 HBA, which is acceptable.
6. **QED:** Ligand B (0.882) has a significantly better QED score than Ligand A (0.673), indicating a more drug-like profile.
7. **DILI:** Both are relatively high (Ligand A: 65.801, Ligand B: 61.846), but Ligand B is slightly lower, indicating a marginally reduced risk of liver injury.
8. **BBB:** Ligand A (67.546) has a better BBB penetration score than Ligand B (46.142), but this isn't a high priority for a cardiovascular target.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand B (-3.094) is better than Ligand A (-4.152), indicating better aqueous solubility.
11. **hERG:** Both have very low hERG inhibition risk (Ligand A: 0.462, Ligand B: 0.166). Ligand B is slightly better.
12. **Cl_mic:** Ligand A (11.015) has a lower microsomal clearance than Ligand B (18.162), suggesting better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand B (34.735) has a much longer in vitro half-life than Ligand A (13.036), which is highly desirable.
14. **Pgp:** Both have low P-gp efflux liability (Ligand A: 0.109, Ligand B: 0.085). Ligand B is slightly better.
15. **Affinity:** Ligand A (-7.4 kcal/mol) has a significantly better binding affinity than Ligand B (-6.5 kcal/mol). This is a substantial advantage, potentially outweighing some ADME drawbacks.
**Overall Assessment:**
The biggest differentiating factor is the binding affinity. Ligand A has a -7.4 kcal/mol binding affinity compared to -6.5 kcal/mol for Ligand B. This 0.9 kcal/mol difference is significant. While Ligand B has better QED, solubility, half-life, and slightly better DILI/hERG, the strong binding affinity of Ligand A is crucial for a GPCR target. The metabolic stability (Cl_mic) is also a point in favor of Ligand A. The Caco-2 values are concerning for both, but the potency advantage of A is likely to be more impactful in driving overall efficacy.
Therefore, I would choose Ligand A.
0
2025-04-17 23:20:12,078 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (336.41 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (34.03) is significantly better than Ligand B (94.05). ADRB2 is a cardiovascular target, not CNS, but lower TPSA generally improves absorption. Ligand B is quite high, potentially hindering oral bioavailability.
3. **logP:** Ligand A (4.036) is at the upper end of the optimal range, while Ligand B (0.459) is below 1, which is a concern for permeability. Ligand A is preferred here.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 2 HBA, Ligand B has 5. Ligand A is better, as higher HBA can sometimes reduce permeability.
6. **QED:** Both ligands have good QED scores (A: 0.724, B: 0.804), indicating generally drug-like properties.
7. **DILI:** Ligand A (53.432) has a higher DILI risk than Ligand B (24.583). This is a significant drawback for Ligand A.
8. **BBB:** This is less critical for a cardiovascular target. Ligand A (69.794) is better than Ligand B (34.083).
9. **Caco-2:** Ligand A (-4.932) is better than Ligand B (-5.009), indicating slightly better intestinal absorption.
10. **Solubility:** Ligand A (-4.477) is better than Ligand B (-0.499), which is important for formulation and bioavailability.
11. **hERG:** Ligand A (0.876) has a slightly higher hERG risk than Ligand B (0.024). This favors Ligand B.
12. **Cl_mic:** Ligand B (30.229) has significantly lower microsomal clearance than Ligand A (74.847), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-6.575) has a negative in vitro half-life, which is very concerning. Ligand A (25.012) is much better.
14. **Pgp:** Ligand A (0.574) has lower P-gp efflux than Ligand B (0.005), which is favorable for bioavailability.
15. **Affinity:** Ligand A (-6.1 kcal/mol) has a stronger binding affinity than Ligand B (-4.1 kcal/mol). This is a substantial advantage.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A excels in logP, Pgp, and especially affinity. Ligand B has better DILI and hERG, but its high TPSA and low logP are significant concerns. The substantial affinity difference outweighs the ADME concerns for Ligand A.
**Overall Assessment:**
Ligand A has a much stronger binding affinity and better physicochemical properties (TPSA, logP, solubility) despite a higher DILI risk. The improved affinity and ADME profile are more critical for a GPCR target like ADRB2, and the DILI risk, while not ideal, might be mitigated with further optimization. The very poor half-life of Ligand B is a dealbreaker.
Output:
1
2025-04-17 23:20:12,078 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (361.511 and 349.475 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (53.51) is better than Ligand B (61.88). Both are below the 140 threshold for oral absorption, but lower TPSA is generally preferred for GPCRs.
3. **logP:** Ligand A (3.098) is optimal (1-3 range), while Ligand B (1.005) is at the lower end, potentially causing permeability issues. This is a significant advantage for A.
4. **HBD:** Ligand A (0) is preferable to Ligand B (1). Fewer HBDs generally improve permeability.
5. **HBA:** Both ligands have 4 HBA, which is acceptable.
6. **QED:** Ligand B (0.823) has a slightly better QED score than Ligand A (0.598), indicating a more drug-like profile.
7. **DILI:** Ligand A (41.062) has a significantly better DILI score than Ligand B (8.026), indicating lower liver injury risk. This is a crucial advantage for A.
8. **BBB:** Ligand A (70.764) has a better BBB penetration percentile than Ligand B (63.048). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant and is not detrimental.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.921 and -4.835). This is unusual and suggests poor permeability. However, the values are very similar.
10. **Solubility:** Ligand A (-2.88) has better solubility than Ligand B (-0.891).
11. **hERG:** Ligand A (0.632) has a lower hERG inhibition liability than Ligand B (0.172), indicating a lower risk of cardiotoxicity, which is critical for a cardiovascular target.
12. **Cl_mic:** Ligand A (59.672) has a higher microsomal clearance than Ligand B (1.225). This means Ligand B is more metabolically stable, a significant advantage.
13. **t1/2:** Ligand B (19.709) has a significantly longer in vitro half-life than Ligand A (-3.9). This is a major advantage for B.
14. **Pgp:** Ligand A (0.626) has lower P-gp efflux than Ligand B (0.005), which is favorable.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.4 and -4.6 kcal/mol). Ligand A has a significantly better binding affinity.
**GPCR-Specific Priorities & Overall Assessment:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A excels in logP, TPSA, Pgp, and significantly in affinity. Ligand B has a better QED and metabolic stability (lower Cl_mic, longer t1/2). However, the lower logP of B is concerning for permeability, and its higher DILI risk and hERG liability are major drawbacks for a cardiovascular drug. The superior binding affinity of Ligand A, coupled with its better safety profile (DILI, hERG) and permeability indicators (TPSA, logP), outweigh the metabolic stability advantage of Ligand B.
**Output:**
1
2025-04-17 23:20:12,078 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (381.416 and 367.421 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (72.47) is slightly higher than Ligand B (54.46). Both are below the 140 threshold for oral absorption, but B is better positioned for potential CNS penetration if desired (though not a primary goal for ADRB2).
3. **logP:** Ligand A (3.306) and Ligand B (4.229) are both within the optimal 1-3 range, but Ligand B is pushing the upper limit. Higher logP can sometimes lead to off-target effects, but isn't a dealbreaker.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Both ligands have 4 HBA, which is good.
6. **QED:** Ligand B (0.88) has a slightly better QED score than Ligand A (0.787), indicating a more drug-like profile.
7. **DILI:** Ligand A (55.913) has a lower DILI risk than Ligand B (61.07), which is preferable.
8. **BBB:** Ligand B (97.247) has significantly higher BBB penetration than Ligand A (79.217). While ADRB2 isn't primarily a CNS target, some peripheral ADRB2 receptors can influence CNS function, and higher BBB penetration isn't necessarily detrimental.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.732 and -4.633). This is unusual and suggests poor permeability. However, these values are on the same scale, so there's no clear difference.
10. **Solubility:** Ligand A (-4.21) appears to have slightly better solubility than Ligand B (-5.158), which is beneficial for bioavailability.
11. **hERG:** Ligand A (0.669) has a lower hERG risk than Ligand B (0.776), which is a significant advantage for cardiovascular targets.
12. **Cl_mic:** Ligand B (30.283) has lower microsomal clearance than Ligand A (39.585), indicating better metabolic stability.
13. **t1/2:** Ligand B (33.109) has a longer in vitro half-life than Ligand A (21.614), which is desirable.
14. **Pgp:** Ligand A (0.214) has lower P-gp efflux than Ligand B (0.413), which is preferable for oral bioavailability.
15. **Binding Affinity:** Ligand B (-6.7 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.7 kcal/mol). This 1 kcal/mol difference is substantial and can outweigh some ADME drawbacks.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand B excels in affinity and has a good logP. While its Pgp efflux is slightly higher, the strong binding is a major advantage. The lower TPSA of Ligand B is also favorable. The improved metabolic stability and half-life are also beneficial.
**Overall Assessment:**
While Ligand A has advantages in DILI and hERG, the significantly stronger binding affinity of Ligand B (-6.7 vs -5.7 kcal/mol) is the most important factor. The better metabolic stability (lower Cl_mic and longer t1/2) and QED score of Ligand B further support its selection. The slightly higher logP and Pgp efflux are acceptable trade-offs for the improved potency and pharmacokinetic properties.
Output:
0
2025-04-17 23:20:12,078 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (386.9) is within the ideal range (200-500), while Ligand B (351.4) is also good. No clear advantage here.
2. **TPSA:** Ligand A (66.92) is better than Ligand B (100.46). ADRB2 is not a CNS target, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (2.37) is optimal (1-3). Ligand B (-0.343) is below the optimal range, potentially hindering membrane permeability. This is a significant drawback.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is better than Ligand B (6). Lower HBA is generally favorable for permeability.
6. **QED:** Both ligands are similar (A: 0.796, B: 0.706), and both are above the 0.5 threshold, indicating good drug-likeness.
7. **DILI:** Ligand A (60.954) is higher than Ligand B (27.608). Ligand B has a significantly lower DILI risk, which is a major advantage.
8. **BBB:** This is less critical for ADRB2, but Ligand A (63.746) is slightly better than Ligand B (54.246).
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-4.411) is slightly better than Ligand B (-4.915).
10. **Solubility:** Ligand A (-3.963) is better than Ligand B (-1.208). Solubility is important for bioavailability.
11. **hERG:** Both are low risk (A: 0.401, B: 0.169), with Ligand B being slightly better.
12. **Cl_mic:** Ligand A (53.565) is higher than Ligand B (-5.389). A negative value for Ligand B indicates *very* good metabolic stability, a significant advantage.
13. **t1/2:** Ligand A (-33.435) is much better than Ligand B (27.718). A negative value for Ligand A indicates a very long half-life.
14. **Pgp:** Both are low (A: 0.203, B: 0.018), with Ligand B being slightly better.
15. **Affinity:** Ligand A (-7.1) is slightly better than Ligand B (-6.2). The difference is 0.9 kcal/mol, which is substantial.
**Overall Assessment:**
Ligand A has a better binding affinity and half-life, but Ligand B has a much lower DILI risk and significantly better metabolic stability (Cl_mic). Ligand B also has a better solubility profile. The logP for Ligand B is a concern, but the other advantages, particularly the lower DILI and improved metabolic stability, outweigh this drawback for a cardiovascular target. The affinity difference, while notable, isn't large enough to overcome the safety and PK advantages of Ligand B.
Output:
0
2025-04-17 23:20:12,078 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [346.471, 67.43, 2.336, 2, 3, 0.549, 28.926, 68.282, -5.118, -3.195, 0.225, 56.595, -11.324, 0.103, -5.3]
**Ligand B:** [346.387, 106.66, -0.983, 2, 5, 0.59, 27.608, 43.583, -5.288, -1.983, 0.047, -15.715, -8.596, 0.01, -6.7]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, BBB, and affinity are key):
1. **MW:** Both ligands are within the ideal range (346 Da).
2. **TPSA:** Ligand A (67.43) is better than Ligand B (106.66). GPCRs benefit from lower TPSA for permeability. Ligand B is quite high.
3. **logP:** Ligand A (2.336) is optimal. Ligand B (-0.983) is too low, potentially hindering membrane permeability and bioavailability.
4. **HBD/HBA:** Both have 2 HBD and are within acceptable ranges. Ligand B has 5 HBA, slightly higher but still reasonable.
5. **QED:** Both are good (0.549 and 0.59).
6. **DILI:** Both have low DILI risk (28.9% and 27.6%).
7. **BBB:** Ligand A (68.282) is significantly better than Ligand B (43.583). While ADRB2 isn't *necessarily* a CNS target, some peripheral effects can be mediated by CNS penetration, and higher BBB is generally favorable.
8. **Caco-2:** Both are negative, indicating poor permeability. This is concerning.
9. **Solubility:** Both are negative, indicating poor solubility. This is concerning.
10. **hERG:** Both are very low risk (0.225 and 0.047).
11. **Cl_mic:** Ligand A (56.595) is better than Ligand B (-15.715) - lower is better for metabolic stability.
12. **t1/2:** Ligand A (-11.324) is better than Ligand B (-8.596) - more negative is better for half-life.
13. **Pgp:** Ligand A (0.103) is better than Ligand B (0.01) - lower is better for efflux.
14. **Affinity:** Ligand B (-6.7) is 1.4 kcal/mol better than Ligand A (-5.3). This is a substantial difference in binding.
**Overall Assessment:**
Ligand B has a significantly better binding affinity, which is a major advantage. However, it suffers from a very low logP and high TPSA, which are detrimental to permeability and bioavailability, especially for a GPCR. Ligand A has better ADME properties (logP, TPSA, BBB, Cl_mic, Pgp, t1/2), but its affinity is weaker.
Given the substantial affinity difference, I believe Ligand B is the more promising starting point, *despite* its ADME liabilities. The affinity advantage is large enough that optimization efforts focused on improving logP and TPSA are more likely to succeed than trying to significantly boost the affinity of Ligand A.
Output:
0
2025-04-17 23:20:12,079 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.435 and 347.394 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand B (87.31) is significantly better than Ligand A (104.97). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (2.255) is within the optimal 1-3 range, while Ligand A (0.063) is quite low. This is a significant advantage for Ligand B, as low logP can hinder membrane permeability.
4. **HBD:** Both ligands have 2 H-bond donors, which is acceptable.
5. **HBA:** Ligand B (7) is slightly higher than Ligand A (5), but still within the acceptable range of <=10.
6. **QED:** Ligand B (0.829) is better than Ligand A (0.601), indicating a more drug-like profile.
7. **DILI:** Ligand A (7.057) has a much lower DILI risk than Ligand B (59.403). This is a substantial advantage for Ligand A.
8. **BBB:** Ligand A (93.292) has much better BBB penetration than Ligand B (67.701). While not a primary concern for a cardiovascular target, it's a positive attribute.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.356 and -5.184). These values are unusual and suggest poor permeability, but are similar between the two.
10. **Solubility:** Ligand A (-1.777) has slightly better solubility than Ligand B (-3.455).
11. **hERG:** Ligand A (0.388) has a lower hERG risk than Ligand B (0.506), which is favorable.
12. **Cl_mic:** Ligand A (1.06) has significantly lower microsomal clearance than Ligand B (31.217), indicating better metabolic stability.
13. **t1/2:** Ligand B (36.388) has a much longer in vitro half-life than Ligand A (-25.447). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.003) has much lower P-gp efflux liability than Ligand B (0.067), which is favorable.
15. **Binding Affinity:** Ligand B (-6.3) has a slightly better binding affinity than Ligand A (-5.9). While a difference of 0.4 kcal/mol isn't huge, it's a positive for Ligand B.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP and has slightly better affinity. Ligand A has better TPSA and Pgp efflux.
**Overall Assessment:**
Ligand A has a significantly better safety profile (lower DILI, hERG, and Pgp efflux) and metabolic stability (lower Cl_mic). Ligand B has better QED, solubility, and half-life. The binding affinity difference is small. The low logP of Ligand A is a concern, but the superior safety and metabolic stability profile outweighs this drawback.
Output:
1
2025-04-17 23:20:12,079 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (357.311 and 358.507 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (85) is higher than Ligand B (46.34). For a cardiovascular GPCR like ADRB2, TPSA is less critical than for CNS targets, but lower is generally preferred for permeability. Ligand B is significantly better.
3. **logP:** Ligand A (2.387) is within the optimal 1-3 range. Ligand B (4.822) is higher, potentially leading to solubility issues and off-target interactions. Ligand A is better.
4. **HBD:** Ligand A (1) and Ligand B (0) are both acceptable.
5. **HBA:** Ligand A (5) and Ligand B (4) are both acceptable.
6. **QED:** Both ligands (0.769 and 0.743) have good drug-likeness scores (>0.5). No significant difference.
7. **DILI:** Ligand A (74.215) has a higher DILI risk than Ligand B (37.069). This is a significant advantage for Ligand B.
8. **BBB:** Both ligands have good BBB penetration (Ligand A: 82.202, Ligand B: 80.031). Since ADRB2 is not a CNS target, this is less important, but still positive.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.919 and -4.897). These are unusual and require further investigation, but are similar.
10. **Solubility:** Ligand A (-2.907) has better aqueous solubility than Ligand B (-4.748). This is a positive for Ligand A, especially considering Ligand B's higher logP.
11. **hERG:** Ligand A (0.729) has a slightly higher hERG risk than Ligand B (0.557), but both are relatively low.
12. **Cl_mic:** Ligand B (75.491) has a higher microsomal clearance than Ligand A (30.504), indicating faster metabolism and potentially lower *in vivo* exposure. Ligand A is better.
13. **t1/2:** Ligand B (41.091) has a significantly longer *in vitro* half-life than Ligand A (-11.517). This is a major advantage for Ligand B.
14. **Pgp:** Ligand A (0.128) has lower P-gp efflux liability than Ligand B (0.774). This is favorable for oral bioavailability.
15. **Binding Affinity:** Ligand B (-6.9 kcal/mol) has a significantly stronger binding affinity than Ligand A (-3.6 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME drawbacks.
**Overall Assessment:**
Ligand B has a much stronger binding affinity, a lower DILI risk, and a longer half-life. While it has a higher logP and Pgp efflux, the substantial improvement in binding affinity and reduced toxicity risk are compelling. Ligand A has better solubility and lower Pgp efflux, but the weaker binding and higher DILI risk are concerning. For a GPCR target, binding affinity is paramount, and the difference of 3.3 kcal/mol is significant.
Output:
0
2025-04-17 23:20:12,079 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (a cardiovascular GPCR) drug candidates.
**Ligand A:** [362.499, 94.88, 2.711, 2, 5, 0.695, 32.881, 46.026, -5.077, -2.69, 0.324, 29.953, -7.916, 0.074, -5.4]
**Ligand B:** [345.403, 102.05, 1.074, 2, 6, 0.782, 50.291, 37.96, -5.158, -2.377, 0.031, 20.046, 4.543, 0.012, -6.4]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity) and general guidelines:
1. **MW:** Both are within the ideal 200-500 Da range. Ligand B (345.403) is slightly lower, which is generally favorable.
2. **TPSA:** Both are reasonably good, below 140. Ligand A (94.88) is better than Ligand B (102.05).
3. **logP:** Ligand A (2.711) is optimal, while Ligand B (1.074) is a bit low, potentially impacting permeability.
4. **HBD/HBA:** Both have 2 HBD and acceptable HBA counts (5 and 6 respectively).
5. **QED:** Both are above 0.5, indicating good drug-likeness, with Ligand B (0.782) being slightly better.
6. **DILI:** Ligand A (32.881) has a significantly lower DILI risk than Ligand B (50.291). This is a major advantage.
7. **BBB:** Ligand A (46.026) has a better BBB percentile than Ligand B (37.96), though neither are particularly high. For a cardiovascular target, BBB isn't *critical*, but it's a bonus.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. This is a concern for both.
9. **Solubility:** Both have negative solubility values, which is also concerning.
10. **hERG:** Both have very low hERG inhibition risk, which is excellent.
11. **Cl_mic:** Ligand B (20.046) has a lower microsomal clearance, suggesting better metabolic stability than Ligand A (29.953).
12. **t1/2:** Ligand A (-7.916) has a significantly longer in vitro half-life than Ligand B (4.543). This is a substantial advantage.
13. **Pgp:** Ligand A (0.074) has lower P-gp efflux liability than Ligand B (0.012), which is favorable for bioavailability.
14. **Affinity:** Ligand B (-6.4 kcal/mol) has a slightly better binding affinity than Ligand A (-5.4 kcal/mol). This is a 1 kcal/mol difference, which is significant.
**Overall Assessment:**
While Ligand B has a slightly better affinity and metabolic stability, Ligand A is significantly better in several crucial areas: DILI risk, in vitro half-life, and P-gp efflux. The logP of Ligand A is also more optimal. The negative Caco-2 and solubility values are concerning for both, but the other advantages of Ligand A outweigh the slightly weaker binding. Given the cardiovascular target, the lower DILI risk and better half-life are particularly important.
Therefore, I prefer Ligand A.
Output:
1
2025-04-17 23:20:12,079 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [352.316, 61.94, 2.991, 0, 6, 0.68, 60.682, 89.027, -4.476, -3.511, 0.725, 53.338, 4.475, 0.529, -8.3]
**Ligand B:** [346.446, 55.56, 2.795, 1, 3, 0.912, 11.128, 74.098, -4.605, -2.645, 0.761, 23.914, -10.323, 0.168, -6.2]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (346.446) is slightly smaller, which is generally favorable for permeability, but the difference isn't huge.
2. **TPSA:** Ligand A (61.94) is a bit higher than Ligand B (55.56). Both are below the 140 threshold for oral absorption, but closer to the 90 threshold for CNS targets. Ligand B is better here.
3. **logP:** Both are within the optimal range (1-3). Ligand A (2.991) is slightly higher, which could potentially lead to off-target effects, but it's not a major concern.
4. **HBD:** Ligand A (0) is better than Ligand B (1). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (6) is better than Ligand B (3). Lower HBA is also generally favorable for permeability.
6. **QED:** Ligand B (0.912) has a significantly better QED score than Ligand A (0.68), indicating a more drug-like profile.
7. **DILI:** Ligand A (60.682) has a higher DILI risk than Ligand B (11.128). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (89.027) has a better BBB penetration score than Ligand B (74.098). This is important for a GPCR, but less crucial for ADRB2 specifically, as it is not a CNS target.
9. **Caco-2:** Both have negative values, which is unusual. Assuming these are log values, both are poor.
10. **Solubility:** Ligand B (-2.645) has better solubility than Ligand A (-3.511). Better solubility is generally preferred.
11. **hERG:** Both are low (0.725 and 0.761), indicating low cardiotoxicity risk.
12. **Cl_mic:** Ligand B (23.914) has significantly lower microsomal clearance than Ligand A (53.338), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-10.323) has a much longer in vitro half-life than Ligand A (4.475). This is a major advantage for Ligand B.
14. **Pgp:** Ligand A (0.529) has lower P-gp efflux than Ligand B (0.168), which is favorable for bioavailability.
15. **Affinity:** Ligand A (-8.3) has a significantly stronger binding affinity than Ligand B (-6.2). This is a substantial advantage for Ligand A. A 2.1 kcal/mol difference is quite significant.
**GPCR-specific priorities:** For GPCRs, we prioritize logP, Pgp, TPSA, and affinity. Ligand A has better Pgp, and a much better affinity. Ligand B has better logP and TPSA. However, the affinity difference is substantial. The lower DILI and better metabolic stability of Ligand B are also very important.
**Overall Assessment:**
While Ligand A has a superior binding affinity, the significant advantages of Ligand B in terms of DILI risk, metabolic stability (lower Cl_mic and longer t1/2), solubility, and QED outweigh the affinity difference. The slightly better BBB penetration of Ligand A is less critical for an ADRB2 target. The combination of improved safety and pharmacokinetic properties makes Ligand B the more promising drug candidate.
Output:
0
2025-04-17 23:20:12,079 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [349.435, 105.5, 0.236, 3, 6, 0.706, 25.281, 67.197, -5.707, -1.509, 0.261, -31.101, -23.665, 0.004, -6.6]
**Ligand B:** [348.447, 94.56, 1.337, 3, 5, 0.462, 37.379, 52.268, -4.948, -1.585, 0.51, 47.472, 38.877, 0.204, -6.1]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). A: 349.4, B: 348.4 - very similar.
2. **TPSA:** A: 105.5, B: 94.56. Both are acceptable for oral absorption (<140), but B is better, closer to the ideal for GPCRs.
3. **logP:** A: 0.236, B: 1.337. A is quite low, potentially hindering permeability. B is better, falling within the optimal 1-3 range.
4. **HBD:** Both have 3 HBD, which is good.
5. **HBA:** A: 6, B: 5. Both are acceptable.
6. **QED:** A: 0.706, B: 0.462. A is significantly better here, indicating a more drug-like profile.
7. **DILI:** A: 25.281, B: 37.379. A has a much lower DILI risk, which is a significant advantage.
8. **BBB:** A: 67.197, B: 52.268. A has better BBB penetration, important for a GPCR.
9. **Caco-2:** A: -5.707, B: -4.948. Both are negative, indicating poor permeability. B is slightly better.
10. **Solubility:** A: -1.509, B: -1.585. Similar, both are poor.
11. **hERG:** A: 0.261, B: 0.51. A has a lower hERG risk, which is crucial for cardiovascular targets.
12. **Cl_mic:** A: -31.101, B: 47.472. A has *much* better metabolic stability (lower clearance). This is a major advantage.
13. **t1/2:** A: -23.665, B: 38.877. B has a significantly longer in vitro half-life.
14. **Pgp:** A: 0.004, B: 0.204. A has much lower P-gp efflux, which is beneficial.
15. **Affinity:** A: -6.6, B: -6.1. A has slightly better binding affinity, but the difference is not huge.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, BBB, and affinity. Ligand A excels in BBB and Pgp, has a better DILI profile and metabolic stability, and a slightly better affinity. Ligand B has a better logP and TPSA, and a longer half-life. However, the poor logP of Ligand A is concerning, but the other advantages outweigh this. The significantly better metabolic stability (Cl_mic) and lower DILI risk of Ligand A are very important.
**Conclusion:**
Considering the balance of properties and the specific priorities for a GPCR target, Ligand A appears to be the more promising drug candidate.
1
2025-04-17 23:20:12,080 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (352.475 Da and 350.423 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (87.66) is significantly better than Ligand B (131.26). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B's TPSA is approaching a level that could hinder oral absorption.
**3. logP:** Both ligands have good logP values (1.364 and 1.009), falling within the optimal 1-3 range. Ligand B is slightly lower, but still acceptable.
**4. H-Bond Donors:** Both have 3 and 4 HBDs, respectively, which is acceptable.
**5. H-Bond Acceptors:** Ligand A has 4 HBAs, while Ligand B has 7. This is a point in favor of Ligand A, as excessive HBAs can sometimes negatively impact permeability.
**6. QED:** Ligand A (0.713) has a better QED score than Ligand B (0.514), indicating a more drug-like profile.
**7. DILI:** Ligand B (41.411) has a slightly higher DILI risk than Ligand A (35.285), but both are below the concerning threshold of 60.
**8. BBB:** Ligand B (77.162) has a significantly higher BBB penetration percentile than Ligand A (39.395). While ADRB2 is a cardiovascular target, some CNS exposure can occur, and higher BBB penetration could be beneficial or detrimental depending on the desired selectivity.
**9. Caco-2 Permeability:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
**10. Aqueous Solubility:** Both have negative solubility values, which is also unusual. Again, the scale is unknown, making interpretation difficult.
**11. hERG Inhibition:** Ligand A (0.172) has a lower hERG inhibition liability than Ligand B (0.321), which is a significant advantage for cardiovascular drugs.
**12. Microsomal Clearance:** Ligand B (37.849) has a slightly higher clearance than Ligand A (27.595), suggesting lower metabolic stability.
**13. In vitro Half-Life:** Ligand A (8.634) has a longer half-life than Ligand B (0.778), which is desirable.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.087 and 0.015).
**15. Binding Affinity:** Both ligands have the same binding affinity (-6 kcal/mol).
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand A is the better candidate. It has a lower TPSA, better QED, lower hERG inhibition, and a longer half-life. While Ligand B has better BBB penetration, this is less critical for a primarily cardiovascular target. The negative values for Caco-2 and solubility are concerning for both, but the other advantages of Ligand A outweigh this issue.
Output:
1
2025-04-17 23:20:12,080 - INFO - Reasoning:
Let's analyze both ligands based on the provided guidelines, prioritizing GPCR-specific parameters (logP, Pgp, TPSA, and affinity).
**Ligand A:**
* **MW:** 368.543 Da - Acceptable.
* **TPSA:** 78.43 - Good, below 140, suggesting reasonable absorption.
* **logP:** 2.083 - Optimal.
* **HBD:** 3 - Acceptable.
* **HBA:** 4 - Acceptable.
* **QED:** 0.516 - Good, above 0.5.
* **DILI:** 11.128 - Excellent, very low risk.
* **BBB:** 50.756 - Moderate, not ideal for a CNS target, but acceptable for a cardiovascular target.
* **Caco-2:** -5.563 - Poor permeability. A significant drawback.
* **Solubility:** -2.723 - Poor solubility. Another significant drawback.
* **hERG:** 0.423 - Low risk, good.
* **Cl_mic:** 40.612 - Moderate clearance.
* **t1/2:** -4.172 - Short half-life.
* **Pgp:** 0.065 - Low efflux, good.
* **Affinity:** -6.9 kcal/mol - Very good.
**Ligand B:**
* **MW:** 363.527 Da - Acceptable.
* **TPSA:** 66.22 - Excellent, very good for absorption.
* **logP:** 4.102 - Slightly high, potential for off-target effects or solubility issues.
* **HBD:** 0 - Acceptable.
* **HBA:** 5 - Acceptable.
* **QED:** 0.697 - Excellent, very drug-like.
* **DILI:** 39.705 - Good, low risk.
* **BBB:** 76.309 - Good, potentially useful if CNS effects are desired, but not critical for a cardiovascular target.
* **Caco-2:** -4.483 - Poor permeability.
* **Solubility:** -4.486 - Poor solubility.
* **hERG:** 0.693 - Moderate risk.
* **Cl_mic:** 105.179 - High clearance, poor metabolic stability.
* **t1/2:** -14.877 - Very short half-life.
* **Pgp:** 0.402 - Moderate efflux.
* **Affinity:** -3.9 kcal/mol - Moderate affinity.
**Comparison and Decision:**
Both ligands suffer from poor Caco-2 permeability and solubility. However, Ligand A has a significantly better binding affinity (-6.9 kcal/mol vs -3.9 kcal/mol). This 3 kcal/mol difference is substantial and can outweigh the ADME deficiencies, especially for a GPCR where potency is crucial. Ligand B has a higher logP and worse metabolic stability (higher Cl_mic, shorter t1/2) and a slightly higher hERG risk. While Ligand B has a better QED and DILI score, the affinity difference is the deciding factor.
Output:
1
2025-04-17 23:20:12,080 - INFO - Batch 397 complete. Total preferences: 6352
2025-04-17 23:20:12,080 - INFO - Processing batch 398/512...
2025-04-17 23:21:00,124 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (339.435 and 373.44 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Both ligands (38.77 and 38.33) are below the 140 threshold for good oral absorption, and well below the 90 threshold for CNS targets (though ADRB2 isn't strictly a CNS target, lower TPSA is generally favorable for GPCRs). No clear advantage.
3. **logP:** Ligand A (3.88) is optimal, while Ligand B (4.276) is slightly higher. While still acceptable, Ligand B is edging closer to the >4 range where solubility issues can arise. Slight advantage to A.
4. **HBD:** Ligand A (0) is better than Ligand B (1). Fewer HBDs generally improve permeability. Advantage to A.
5. **HBA:** Both ligands have 3 HBA, which is within the acceptable range. No clear advantage.
6. **QED:** Ligand A (0.852) has a slightly better QED score than Ligand B (0.783), indicating a more drug-like profile. Advantage to A.
7. **DILI:** Ligand B (29.779) has a significantly lower DILI risk than Ligand A (64.521). This is a substantial advantage for Ligand B.
8. **BBB:** Ligand B (95.657) has a much higher BBB penetration percentile than Ligand A (80.651). While ADRB2 isn't a primary CNS target, higher BBB is generally favorable for GPCRs. Advantage to B.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.264 and -4.491), which is unusual and suggests poor permeability. This is a significant drawback for both.
10. **Solubility:** Ligand B (-5.337) has slightly worse solubility than Ligand A (-4.353). Advantage to A.
11. **hERG:** Both ligands have low hERG inhibition liability (0.689 and 0.809). No clear advantage.
12. **Cl_mic:** Ligand B (67.415) has slightly lower microsomal clearance than Ligand A (72.222), suggesting better metabolic stability. Advantage to B.
13. **t1/2:** Ligand A (4.033) has a longer in vitro half-life than Ligand B (-1.484). This is a significant advantage for Ligand A.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.594 and 0.474). No clear advantage.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-5.7 and -5.9 kcal/mol). The difference is negligible.
**GPCR-Specific Priorities & Overall Assessment:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, and affinity. Ligand A has a slightly better logP, TPSA, and QED, and a longer half-life. However, Ligand B has a *much* lower DILI risk and higher BBB penetration, and slightly better metabolic stability. The DILI risk is a major concern, and the higher BBB penetration is beneficial even for a non-CNS target. The negative Caco-2 values are concerning for both, but the other advantages of Ligand B outweigh the slight advantages of Ligand A.
Output:
0
2025-04-17 23:21:00,124 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (345.4 and 348.4 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (91.64) is better than Ligand B (98.82). Both are acceptable for a non-CNS GPCR target like ADRB2, being under 140, but lower is generally preferred.
3. **logP:** Ligand B (-1.146) is slightly lower than Ligand A (-0.106). Both are within the optimal 1-3 range, but Ligand A is closer to the sweet spot.
4. **HBD:** Both ligands have 2 HBD, which is good.
5. **HBA:** Ligand A has 5 HBA, while Ligand B has 4. Both are acceptable, under the 10 threshold.
6. **QED:** Ligand A (0.729) has a significantly higher QED score than Ligand B (0.484), indicating a more drug-like profile. This is a substantial advantage.
7. **DILI:** Ligand B (30.903) has a lower DILI risk than Ligand A (34.432), which is preferable.
8. **BBB:** Both ligands have low BBB penetration (36.836 and 33.85, respectively), which is not a major concern for a cardiovascular target like ADRB2.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. This is a significant drawback for both.
10. **Solubility:** Both ligands have very poor aqueous solubility (-1.626 and -1.83, respectively). This is a major issue that would need to be addressed.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.044 and 0.026). This is excellent.
12. **Cl_mic:** Ligand A (-8.551) has a much lower (better) microsomal clearance than Ligand B (-3.42). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (-3.784) has a shorter half-life than Ligand B (-20.712). This is a negative for Ligand A.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.017 and 0.004). This is good.
15. **Binding Affinity:** Ligand A (-7.7 kcal/mol) has a slightly better binding affinity than Ligand B (-6.1 kcal/mol). This difference of 1.6 kcal/mol is significant and can outweigh some ADME drawbacks.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand A is better on logP and TPSA, and has a significantly better binding affinity. While solubility is a concern for both, the better metabolic stability (lower Cl_mic) and higher QED of Ligand A are also important advantages.
**Overall Assessment:**
Despite the poor solubility and Caco-2 permeability of both, Ligand A emerges as the more promising candidate. Its superior binding affinity, better logP, TPSA, QED, and metabolic stability outweigh the slightly longer half-life of Ligand B. The lower DILI risk of Ligand B is a plus, but the other factors are more critical for a GPCR target.
Output:
1
2025-04-17 23:21:00,124 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's analyze each ligand against the provided guidelines, with emphasis on GPCR-relevant parameters (logP, Pgp, TPSA, and affinity).
* **Molecular Weight:** Both ligands (340.47 and 353.42 Da) fall comfortably within the 200-500 Da range.
* **TPSA:** Ligand A (49.41) is significantly better than Ligand B (125.35). A TPSA under 140 is good for oral absorption, but for a GPCR, lower is generally preferred, and Ligand A is much closer to the ideal range for potential CNS penetration (though ADRB2 isn't necessarily a CNS target).
* **logP:** Ligand A (3.071) is optimal, while Ligand B (-0.902) is quite low. Low logP can lead to poor membrane permeability. This is a significant drawback for Ligand B.
* **H-Bond Donors/Acceptors:** Ligand B has more HBDs (4) and HBAs (6) than Ligand A (1 and 2 respectively). While not drastically problematic, fewer H-bonds are generally preferred for better permeability.
* **QED:** Ligand A (0.776) has a better QED score than Ligand B (0.458), indicating a more drug-like profile.
* **DILI:** Both ligands have similar, acceptable DILI risk (35.48% and 37.22%).
* **BBB:** Ligand A (64.95%) has a much higher BBB percentile than Ligand B (20.82%). While ADRB2 isn't strictly a CNS target, higher BBB is rarely a negative.
* **Caco-2:** Ligand A (-4.547) and Ligand B (-5.552) both have negative Caco-2 values, which is unusual and suggests very poor permeability. However, the scale is not specified, so it's hard to interpret.
* **Solubility:** Ligand A (-3.902) is better than Ligand B (-1.219), indicating better aqueous solubility.
* **hERG:** Both ligands have low hERG inhibition risk (0.575% and 0.107%).
* **Cl_mic:** Ligand A (21.553) has a higher microsomal clearance than Ligand B (12.115), suggesting faster metabolism and potentially lower *in vivo* exposure.
* **t1/2:** Ligand B (23.39 hours) has a significantly longer half-life than Ligand A (10.549 hours). This is a positive for Ligand B.
* **Pgp:** Ligand A (0.165) has lower P-gp efflux liability than Ligand B (0.01), which is favorable.
* **Binding Affinity:** Ligand A (-7.0 kcal/mol) has a slightly better binding affinity than Ligand B (-6.2 kcal/mol). While the difference is not huge, it's enough to be considered.
**Overall Assessment:**
Ligand A is significantly better overall. The key advantages are its optimal logP, lower TPSA, better QED, and slightly better binding affinity. Ligand B's primary advantage is its longer half-life, but this is outweighed by its poor logP, high TPSA, and lower QED. The negative Caco-2 values for both are concerning, but the other properties of Ligand A make it a more promising starting point for optimization.
**Output:**
1
2025-04-17 23:21:00,125 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.551 and 355.408 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (44.29) is significantly better than Ligand B (57.7). ADRB2 is not a CNS target, but lower TPSA generally improves absorption.
3. **logP:** Both ligands have good logP values (3.883 and 3.965), falling within the optimal 1-3 range. Very similar.
4. **HBD:** Both have 1 HBD, which is acceptable.
5. **HBA:** Ligand A has 5 HBA, and Ligand B has 4. Both are within the acceptable range of <=10.
6. **QED:** Both ligands have good QED scores (0.651 and 0.779), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (23.73) has a much lower DILI risk than Ligand B (35.401). This is a significant advantage for Ligand A.
8. **BBB:** Not a primary concern for ADRB2, but Ligand A (89.492) has a higher BBB percentile than Ligand B (76.735).
9. **Caco-2:** Both are negative, indicating poor permeability. This is a concern for both, but the values are similar.
10. **Solubility:** Both are negative, indicating poor solubility. This is a concern for both, but the values are similar.
11. **hERG:** Both ligands have low hERG inhibition liability (0.969 and 0.909), which is good.
12. **Cl_mic:** Ligand B (18.643) has significantly lower microsomal clearance than Ligand A (52.893), indicating better metabolic stability. This is a major advantage for Ligand B.
13. **t1/2:** Ligand B (9.822) has a longer in vitro half-life than Ligand A (55.744). This is a significant advantage for Ligand B.
14. **Pgp:** Both have low Pgp efflux liability (0.555 and 0.352). Ligand B is slightly better.
15. **Binding Affinity:** Ligand B (-6.1 kcal/mol) has a slightly better binding affinity than Ligand A (-5.8 kcal/mol). While the difference is not huge, it's a positive for Ligand B.
**Overall Assessment:**
Ligand B has several key advantages: lower microsomal clearance, longer half-life, slightly better binding affinity, and slightly better Pgp efflux. These factors are crucial for *in vivo* efficacy. While Ligand A has a lower DILI risk, the metabolic stability and half-life advantages of Ligand B outweigh this concern, especially given that both ligands have acceptable hERG scores. The TPSA of Ligand A is better, but the overall profile of Ligand B is more promising.
Output:
0
2025-04-17 23:21:00,125 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [353.423, 116.56 , -1.013, 3. , 6. , 0.466, 17.255, 24.389, -5.651, -0.71 , 0.058, 15.373, 13.518, 0.006, -7.8 ]
**Ligand B:** [350.415, 111.8 , 0.97 , 4. , 5. , 0.522, 35.479, 32.765, -5.204, -1.742, 0.065, 2.075, 3.758, 0.023, -7.1 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). A (353.423) and B (350.415) are very similar.
2. **TPSA:** Both are acceptable for oral absorption (<140), but A (116.56) is slightly higher than B (111.8).
3. **logP:** A (-1.013) is a bit low, potentially hindering permeation. B (0.97) is closer to the optimal 1-3 range. This favors B.
4. **HBD:** Both are within the acceptable limit of 5. A (3) and B (4) are comparable.
5. **HBA:** Both are within the acceptable limit of 10. A (6) and B (5) are comparable.
6. **QED:** Both are reasonably good (A: 0.466, B: 0.522), but B is slightly better.
7. **DILI:** A (17.255) has a significantly lower DILI risk than B (35.479). This is a major advantage for A.
8. **BBB:** Both are low, indicating poor brain penetration. A (24.389) is lower than B (32.765), but for a cardiovascular target, BBB isn't a primary concern.
9. **Caco-2:** Both have negative values, which is unusual. Assuming these are log scale values, both are poor.
10. **Solubility:** Both have negative values, which is unusual. Assuming these are log scale values, both are poor.
11. **hERG:** Both are very low risk (A: 0.058, B: 0.065).
12. **Cl_mic:** A (15.373) has a higher clearance than B (2.075), meaning faster metabolism and potentially lower duration of action. This favors B.
13. **t1/2:** A (13.518) has a longer half-life than B (3.758). This favors A.
14. **Pgp:** Both are very low efflux (A: 0.006, B: 0.023).
15. **Affinity:** A (-7.8) has a significantly better binding affinity than B (-7.1). This is a substantial advantage for A.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. A has a lower logP, but a much higher affinity. B has a better logP and TPSA. DILI is also important, and A has a much lower risk. Metabolic stability (Cl_mic and t1/2) are also important, and B is better in terms of Cl_mic, but A has a longer half-life.
**Overall Assessment:**
The significantly stronger binding affinity of Ligand A (-7.8 vs -7.1) and its much lower DILI risk outweigh the slightly less favorable logP and higher clearance. The longer half-life of A is also a benefit. While B has a slightly better logP and TPSA, the difference isn't substantial enough to overcome the advantages of A.
Output:
1
2025-04-17 23:21:00,125 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (367.519 Da and 350.419 Da) are within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (80.12) is significantly better than Ligand B (105.48). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (1.337) is within the optimal 1-3 range. Ligand B (-0.221) is slightly below 1, which *could* indicate permeability issues. This is a point in favor of A.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Both ligands have 6 HBA, which is acceptable.
6. **QED:** Ligand A (0.75) is slightly better than Ligand B (0.63), indicating a more drug-like profile.
7. **DILI:** Ligand A (32.765) has a lower DILI risk than Ligand B (42.536), which is a significant advantage.
8. **BBB:** Both are relatively low, as expected for a cardiovascular target. Ligand A (52.423) is slightly better than Ligand B (47.111), but this isn't a major factor.
9. **Caco-2:** Both are negative, indicating poor permeability. This is a concern for both, but the other properties of A are better.
10. **Solubility:** Both are negative, indicating poor solubility. This is a concern for both, but the other properties of A are better.
11. **hERG:** Both are very low (0.092 and 0.07), indicating very low risk of hERG inhibition.
12. **Cl_mic:** Ligand A (7.94) has significantly lower microsomal clearance than Ligand B (12.029), indicating better metabolic stability.
13. **t1/2:** Ligand A (10.698) has a shorter half-life than Ligand B (17.108), but the difference isn't dramatic.
14. **Pgp:** Both are very low (0.03 and 0.012), indicating low P-gp efflux.
15. **Binding Affinity:** Ligand B (-7.4) has a stronger binding affinity than Ligand A (-6.5) by 0.9 kcal/mol. This is a substantial difference.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B has better affinity, but Ligand A is better across logP, TPSA, DILI, and Cl_mic. The affinity difference is significant, but the combination of improved ADME properties for Ligand A, particularly the lower DILI risk and better metabolic stability, makes it more likely to succeed as a drug candidate. The Caco-2 and solubility issues are shared, and could be addressed with formulation strategies.
**Final Decision:**
1
2025-04-17 23:21:00,125 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (342.355 Da and 347.419 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (108.47) is slightly higher than Ligand B (91.56). For a cardiovascular GPCR, TPSA is moderately important, and Ligand B is preferable due to being closer to the <140 threshold for good oral absorption.
**3. logP:** Ligand A (1.723) is within the optimal 1-3 range, while Ligand B (0.157) is quite low. For a GPCR, a slightly higher logP is generally preferred for membrane permeability. Ligand A is significantly better here.
**4. H-Bond Donors:** Ligand A (2) and Ligand B (1) are both acceptable, well below the 5 threshold.
**5. H-Bond Acceptors:** Both ligands have 6 HBA, which is acceptable (<=10).
**6. QED:** Both ligands have similar QED values (0.86 and 0.837), indicating good drug-likeness.
**7. DILI Risk:** Ligand A (84.645) has a considerably higher DILI risk than Ligand B (53.044). This is a significant negative for Ligand A.
**8. BBB Penetration:** Ligand A (78.286) has better BBB penetration than Ligand B (47.964). While ADRB2 is primarily a cardiovascular target, some CNS off-target effects are possible with GPCRs, and better BBB penetration could be a concern. However, for a cardiovascular target, this isn't a primary driver.
**9. Caco-2 Permeability:** Both ligands have very poor Caco-2 permeability (-4.858 and -4.808). This is a concern for oral bioavailability for both.
**10. Aqueous Solubility:** Ligand A (-4.958) has worse solubility than Ligand B (-1.2). Solubility is important for formulation, and Ligand B is better.
**11. hERG Inhibition:** Ligand A (0.453) has a slightly higher hERG inhibition risk than Ligand B (0.232), but both are relatively low.
**12. Microsomal Clearance:** Ligand A (42.619) has higher microsomal clearance than Ligand B (28.528), indicating lower metabolic stability. Ligand B is preferable.
**13. In vitro Half-Life:** Ligand A (8.731) has a longer half-life than Ligand B (-4.857). This is a positive for Ligand A.
**14. P-gp Efflux:** Both ligands have low P-gp efflux (0.311 and 0.063), which is good.
**15. Binding Affinity:** Ligand A (-7.4 kcal/mol) has a significantly stronger binding affinity than Ligand B (-5.7 kcal/mol). This is a substantial advantage for Ligand A. The 1.7 kcal/mol difference is large enough to potentially outweigh some ADME concerns.
**Overall Assessment:**
The key trade-offs are: Ligand A has significantly better binding affinity and half-life, but higher DILI risk and lower solubility. Ligand B has better DILI, solubility, and metabolic stability, but weaker binding affinity.
Given the strong emphasis on affinity for GPCRs, and the substantial difference in binding (-7.4 vs -5.7), I favor Ligand A *despite* the higher DILI risk. The DILI risk, while elevated, is not at an extremely prohibitive level (84.645 percentile). The improved potency could allow for a lower dose, potentially mitigating some of the DILI concern. The longer half-life is also a significant benefit.
Output:
1
2025-04-17 23:21:00,125 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [343.427, 76.39, 4.17, 2, 5, 0.789, 61.419, 74.952, -4.595, -5.277, 0.329, 96.954, 8.913, 0.386, -5.1]
**Ligand B:** [365.507, 82.68, 1.359, 1, 9, 0.756, 59.829, 54.711, -5.819, -1.783, 0.084, 20.555, 22.518, 0.106, -7.4]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, Affinity, and BBB):
1. **MW:** Both are within the acceptable 200-500 Da range. Ligand A (343.427) is slightly preferred.
2. **TPSA:** Ligand A (76.39) is better than Ligand B (82.68). Both are under the 140 A^2 threshold, but lower is better for permeability.
3. **logP:** Ligand A (4.17) is a bit high, but Ligand B (1.359) is quite low. A logP between 1-3 is ideal. Ligand A is better here, despite being slightly above the optimal range, as very low logP can severely hinder membrane permeability.
4. **HBD/HBA:** Ligand A (2 HBD, 5 HBA) is slightly better than Ligand B (1 HBD, 9 HBA). Both are within acceptable limits, but fewer H-bonds generally improve permeability.
5. **QED:** Both are similar (0.789 vs 0.756), indicating good drug-likeness.
6. **DILI:** Ligand B (59.829) has a lower DILI risk than Ligand A (61.419), which is a positive.
7. **BBB:** Ligand A (74.952) has a significantly better BBB penetration potential than Ligand B (54.711). This is important for a GPCR target, even if not strictly CNS-focused, as it can influence distribution.
8. **Caco-2:** Ligand B (-5.819) has a better Caco-2 permeability than Ligand A (-4.595).
9. **Solubility:** Ligand B (-1.783) has better aqueous solubility than Ligand A (-5.277).
10. **hERG:** Ligand A (0.329) has a lower hERG risk than Ligand B (0.084). This is a significant advantage.
11. **Cl_mic:** Ligand B (20.555) has a much lower microsomal clearance than Ligand A (96.954), suggesting better metabolic stability. This is a major advantage.
12. **t1/2:** Ligand B (22.518) has a longer in vitro half-life than Ligand A (8.913). This is also a significant advantage.
13. **Pgp:** Ligand A (0.386) has lower P-gp efflux than Ligand B (0.106). Lower Pgp is better.
14. **Affinity:** Ligand B (-7.4) has a significantly stronger binding affinity than Ligand A (-5.1). This is a substantial advantage, potentially outweighing some ADME concerns.
**Overall Assessment:**
Ligand B has a much better binding affinity and significantly improved metabolic stability (lower Cl_mic, longer t1/2). It also exhibits better solubility and a lower DILI risk. While Ligand A has a better BBB score and slightly better logP, the superior affinity and metabolic properties of Ligand B are more critical for a GPCR target like ADRB2. The slightly lower logP of Ligand B is not a major concern, and can be addressed with formulation strategies if needed.
Output:
0
2025-04-17 23:21:00,126 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (350.419 Da and 349.45 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (116.34) is higher than the preferred <140 for oral absorption, but still reasonable. Ligand B (53.51) is excellent, well below 90, suggesting good permeability. This favors Ligand B.
**3. logP:** Ligand A (0.223) is quite low, potentially hindering membrane permeability. Ligand B (2.647) is within the optimal 1-3 range. This strongly favors Ligand B.
**4. H-Bond Donors:** Ligand A (4) is acceptable. Ligand B (0) is also good, potentially improving permeability. No clear advantage.
**5. H-Bond Acceptors:** Ligand A (5) is acceptable. Ligand B (3) is also good. No clear advantage.
**6. QED:** Ligand B (0.768) has a significantly better QED score than Ligand A (0.356), indicating a more drug-like profile. This favors Ligand B.
**7. DILI Risk:** Ligand A (37.185) has a slightly better DILI risk profile than Ligand B (17.255), but both are well below the concerning threshold of 60.
**8. BBB Penetration:** Ligand A (46.336) has lower BBB penetration than Ligand B (88.29). While ADRB2 is a cardiovascular target, some CNS effects are possible with beta-blockers, and higher BBB penetration could be beneficial or detrimental depending on the desired profile. For now, it's a slight advantage to Ligand B.
**9. Caco-2 Permeability:** Ligand A (-5.516) has poor Caco-2 permeability. Ligand B (-4.476) is also poor, but slightly better.
**10. Aqueous Solubility:** Ligand A (-2.537) has poor aqueous solubility. Ligand B (-1.972) is also poor, but slightly better.
**11. hERG Inhibition:** Ligand A (0.171) has a lower hERG risk than Ligand B (0.392), which is a significant advantage.
**12. Microsomal Clearance:** Ligand A (34.791) has higher microsomal clearance than Ligand B (26.048), indicating lower metabolic stability. This favors Ligand B.
**13. In vitro Half-Life:** Ligand A (-11.565) has a shorter half-life than Ligand B (-14.254), suggesting faster metabolism. This favors Ligand B.
**14. P-gp Efflux:** Both ligands have low P-gp efflux (0.07 and 0.075), which is good.
**15. Binding Affinity:** Ligand A (-9.1 kcal/mol) has a significantly stronger binding affinity than Ligand B (-5.9 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME drawbacks.
**Overall Assessment:**
Ligand B has a superior ADME profile (better logP, QED, lower clearance, longer half-life, better TPSA, and better BBB penetration). However, Ligand A boasts a much stronger binding affinity. For a GPCR, affinity is critical. While Ligand A's low logP and solubility are concerns, these could potentially be addressed through formulation strategies or further chemical modifications. The substantial affinity advantage of Ligand A is likely to translate to greater efficacy *in vivo*.
Therefore, I would prioritize Ligand A.
Output:
1
2025-04-17 23:21:00,126 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [362.495, 58.64, 2.661, 1, 4, 0.876, 35.052, 78.558, -4.825, -3.441, 0.497, 32.552, 2.585, 0.198, -6.6]
**Ligand B:** [368.459, 125.62, -0.408, 3, 6, 0.603, 25.902, 25.514, -5.881, -0.9, 0.052, -23.784, -2.865, 0.013, -5.9]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). A (362.495) is slightly preferred.
2. **TPSA:** A (58.64) is excellent, well below 140 and good for permeability. B (125.62) is higher, but still acceptable, though less ideal.
3. **logP:** A (2.661) is optimal. B (-0.408) is quite low, potentially hindering membrane permeability and absorption. This is a significant drawback for a GPCR ligand.
4. **HBD:** A (1) is good. B (3) is acceptable, but higher HBD can sometimes lead to issues.
5. **HBA:** A (4) is good. B (6) is higher, potentially impacting permeability.
6. **QED:** A (0.876) is very good, indicating high drug-likeness. B (0.603) is still acceptable, but lower.
7. **DILI:** A (35.052) is excellent, very low risk. B (25.902) is also low risk, but slightly higher.
8. **BBB:** A (78.558) is good, suggesting reasonable potential for CNS penetration if desired (though ADRB2 is primarily cardiovascular, some CNS off-target effects are possible). B (25.514) is low, indicating poor BBB penetration.
9. **Caco-2:** Both are negative, indicating poor permeability. A (-4.825) is slightly better (less negative).
10. **Solubility:** Both are negative, indicating poor solubility. B (-0.9) is slightly better (less negative).
11. **hERG:** A (0.497) is very low risk. B (0.052) is also very low risk.
12. **Cl_mic:** A (32.552) is moderate. B (-23.784) is excellent, indicating very high metabolic stability. This is a strong point for B.
13. **t1/2:** A (2.585) is okay. B (-2.865) is also okay.
14. **Pgp:** A (0.198) is low, suggesting minimal efflux. B (0.013) is very low, indicating minimal Pgp efflux.
15. **Affinity:** A (-6.6) is slightly better than B (-5.9), although both are good. A has a 0.7 kcal/mol advantage.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are crucial. Ligand A excels in logP and has a slightly better affinity. While B has excellent metabolic stability, its significantly lower logP is a major concern for permeability and overall bioavailability. The better BBB penetration of A is also a plus, even for a cardiovascular target.
**Conclusion:**
Despite the excellent metabolic stability of Ligand B, the significantly lower logP and poorer BBB penetration make it a less desirable candidate compared to Ligand A. The slight advantage in affinity for Ligand A, coupled with its better physicochemical properties, outweighs the metabolic stability benefit of Ligand B.
**Output:**
1
2025-04-17 23:21:00,126 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (358.36 and 357.841 Da) fall comfortably within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (61.8) is slightly higher than Ligand B (55.32). Both are below the 140 threshold for good absorption, but closer to the 90 threshold for CNS targets (less relevant here, but still a positive). Ligand B is slightly preferred.
3. **logP:** Both ligands have excellent logP values (3.456 and 3.507), falling within the optimal 1-3 range. No significant difference.
4. **HBD:** Ligand A has 2 HBD, while Ligand B has 0. Lower HBD is generally preferred for better permeability, so Ligand B is slightly favored.
5. **HBA:** Ligand A has 3 HBA, and Ligand B has 4. Both are within the acceptable limit of 10. No strong preference.
6. **QED:** Both ligands have good QED scores (0.87 and 0.821), indicating good drug-like properties. No significant difference.
7. **DILI:** Ligand A (48.313) has a slightly higher DILI risk than Ligand B (38.581). Both are below the 40 threshold, so the risk is low, but Ligand B is preferred.
8. **BBB:** Both ligands have high BBB penetration (86.739 and 83.288). This isn't a primary concern for ADRB2 (a cardiovascular target), but it's not detrimental.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.89 and -4.465). These values are unusual and difficult to interpret without further context. Assuming lower (more negative) values indicate *lower* permeability, both are concerning.
10. **Solubility:** Both ligands have very poor aqueous solubility (-3.297 and -4.307). This is a significant drawback for both, potentially impacting bioavailability. Ligand B is slightly better.
11. **hERG:** Ligand A (0.816) has a slightly higher hERG inhibition liability than Ligand B (0.553). Lower is better, so Ligand B is preferred.
12. **Cl_mic:** Ligand A (10.583) has a lower microsomal clearance than Ligand B (92.968), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (18.614 hours) has a much longer in vitro half-life than Ligand B (-23.733 hours). A negative value for t1/2 is problematic and suggests very rapid degradation. This is a major advantage for Ligand A.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.171 and 0.103). No significant difference.
15. **Binding Affinity:** Ligand A (-7.4 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.3 kcal/mol). This 1.1 kcal/mol difference is substantial and can outweigh minor ADME drawbacks.
**Overall Assessment:**
While both ligands have issues with solubility and Caco-2 permeability, Ligand A is clearly superior. Its significantly stronger binding affinity, much better metabolic stability (lower Cl_mic), and longer half-life are critical advantages for a drug candidate. The slightly higher DILI and hERG risks are less concerning given the substantial potency benefit. The negative Caco-2 values are a concern for both, but the other properties of Ligand A make it the more promising candidate.
Output:
1
2025-04-17 23:21:00,126 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
We are targeting ADRB2, a GPCR. Therefore, the priorities are logP, Pgp, TPSA, affinity, and, to a lesser extent, BBB. Let's break down the comparison:
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (374.442) is slightly higher than Ligand B (344.463), but this isn't a major concern.
2. **TPSA:** Ligand B (84.85) is significantly better than Ligand A (118.87). Lower TPSA generally favors oral absorption and is crucial for GPCR ligands.
3. **logP:** Ligand B (2.621) is optimal, while Ligand A (-0.45) is quite low. A negative logP can hinder membrane permeability. This is a significant disadvantage for Ligand A.
4. **H-Bond Donors/Acceptors:** Both have 2 HBDs and 7 HBAs, which are acceptable.
5. **QED:** Both have good QED scores (A: 0.667, B: 0.723), indicating good drug-like properties.
6. **DILI:** Ligand B (39.162) has a much lower DILI risk than Ligand A (63.513). This is a substantial advantage for Ligand B.
7. **BBB:** Ligand A (77.007) has slightly better BBB penetration than Ligand B (60.876), but BBB isn't a primary concern for ADRB2 (a cardiovascular target).
8. **Caco-2 Permeability:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the values are similar (-5.548 for A, -5.094 for B).
9. **Aqueous Solubility:** Both have negative solubility values, suggesting poor solubility. Again, values are similar (-1.981 for A, -2.319 for B).
10. **hERG Inhibition:** Ligand A (0.036) has a slightly lower hERG risk than Ligand B (0.582), but both are relatively low.
11. **Microsomal Clearance:** Ligand A (7.841) has much lower microsomal clearance than Ligand B (20.541), indicating better metabolic stability.
12. **In vitro Half-Life:** Ligand B (59.03) has a significantly longer half-life than Ligand A (-18.846). This is a major advantage for Ligand B.
13. **P-gp Efflux:** Ligand A (0.091) has lower P-gp efflux than Ligand B (0.022), which is preferable.
14. **Binding Affinity:** Both ligands have comparable binding affinities (-7.0 kcal/mol for A, -5.9 kcal/mol for B). Ligand A has a slight edge, but the difference is not substantial enough to overcome its other weaknesses.
**Overall Assessment:**
Ligand B is the better candidate. While Ligand A has slightly better affinity and lower P-gp efflux, Ligand B excels in crucial ADME properties: significantly lower DILI risk, better logP, lower TPSA, and a much longer half-life. The negative logP of Ligand A is a significant concern, potentially hindering its ability to cross cell membranes and reach its target. The improved metabolic stability of Ligand A is not enough to offset the other deficiencies.
Output:
0
2025-04-17 23:21:00,127 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, key properties to prioritize are logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB (though less critical for a cardiovascular target).
Let's compare the ligands property by property:
1. **MW:** Both are within the ideal range (342 vs 345 Da).
2. **TPSA:** Ligand A (78.43) is significantly better than Ligand B (108.05). Lower TPSA generally favors oral absorption, crucial for a cardiovascular drug.
3. **logP:** Ligand A (2.087) is optimal, while Ligand B (0.196) is quite low, potentially hindering membrane permeability.
4. **HBD/HBA:** Ligand A has 3/3, Ligand B has 2/5. Both are acceptable, but Ligand A is slightly better balanced.
5. **QED:** Ligand B (0.823) is slightly better than Ligand A (0.664), indicating a marginally more drug-like profile.
6. **DILI:** Ligand A (23.769) is *much* better than Ligand B (69.756), indicating a significantly lower risk of liver injury. This is a major advantage for Ligand A.
7. **BBB:** Both are moderate, but Ligand B (55.603) is slightly higher than Ligand A (45.095). However, BBB isn't a primary concern for a cardiovascular target.
8. **Caco-2:** Both are negative, indicating poor permeability.
9. **Solubility:** Both are negative, indicating poor solubility.
10. **hERG:** Both are very low, indicating minimal hERG inhibition risk.
11. **Cl_mic:** Ligand A (29.891) is better than Ligand B (-15.203) - a negative value indicates very low clearance and high metabolic stability.
12. **t1/2:** Ligand A (7.556) is better than Ligand B (-21.238) - a negative value indicates very high stability.
13. **Pgp:** Ligand A (0.094) is significantly better than Ligand B (0.29), indicating lower P-glycoprotein efflux and potentially better bioavailability.
14. **Binding Affinity:** Ligand A (-7.6) is slightly better than Ligand B (-7.1), although the difference is relatively small.
**Overall Assessment:**
Ligand A is significantly better overall. While Ligand B has a slightly higher QED and BBB, Ligand A excels in critical areas for a cardiovascular drug: TPSA, logP, DILI risk, metabolic stability (Cl_mic & t1/2), and Pgp efflux. The slightly better binding affinity of Ligand A further strengthens its position. The poor Caco-2 and solubility for both ligands would need to be addressed in further optimization, but the other properties of Ligand A make it the more promising starting point.
**Output:**
1
2025-04-17 23:21:00,127 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (351.382 and 353.853 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (90.44) is better than Ligand B (48.99). While both are acceptable, lower TPSA generally favors better membrane permeability, which is crucial for GPCR ligands.
3. **logP:** Ligand B (4.187) is higher than Ligand A (0.311). This is a significant difference. While a logP between 1-3 is optimal, Ligand B is pushing the upper limit and could lead to solubility issues. Ligand A is quite low, potentially hindering permeability.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1), but both are within the acceptable limit of 5.
5. **HBA:** Ligand A (5) is higher than Ligand B (2), but both are within the acceptable limit of 10.
6. **QED:** Ligand A (0.802) has a better QED score than Ligand B (0.625), indicating a more drug-like profile.
7. **DILI:** Ligand A (60.062) and Ligand B (50.213) are both acceptable, but Ligand B has a lower DILI risk.
8. **BBB:** Ligand A (72.005) has a significantly better BBB penetration percentile than Ligand B (59.829). While ADRB2 isn't exclusively a CNS target, some CNS exposure can occur, and higher BBB is generally favorable.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-4.956) is slightly better than Ligand B (-4.704).
10. **Solubility:** Ligand A (-2.812) has better aqueous solubility than Ligand B (-5.58). This is important, especially considering Ligand B's higher logP.
11. **hERG:** Ligand A (0.267) has a lower hERG inhibition liability than Ligand B (0.755), which is a significant advantage for cardiovascular safety.
12. **Cl_mic:** Ligand A (-32.769) has a much lower (better) microsomal clearance than Ligand B (57.586), indicating greater metabolic stability.
13. **t1/2:** Ligand A (9.382) has a slightly longer in vitro half-life than Ligand B (8.217).
14. **Pgp:** Ligand A (0.029) has lower P-gp efflux liability than Ligand B (0.558), which is desirable for improved bioavailability.
15. **Affinity:** Ligand A (-7.6) has a slightly better binding affinity than Ligand B (-5.8). This is a substantial difference and a key factor.
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are particularly important. Ligand A has a better TPSA, Pgp, and significantly better affinity. While Ligand B has a better logP, it's approaching a problematic range. Ligand A's lower logP is offset by its superior binding affinity and other favorable ADME properties.
**Overall Assessment:**
Ligand A demonstrates a superior balance of properties, particularly in terms of affinity, metabolic stability (Cl_mic), hERG risk, and P-gp efflux. While Ligand B has a slightly better logP, the other advantages of Ligand A outweigh this.
Output:
1
2025-04-17 23:21:00,127 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (348.447 Da) is better than Ligand B (381.885 Da), falling comfortably within the 200-500 Da range. Both are acceptable, but A is slightly preferred.
2. **TPSA:** Ligand A (67.67) is significantly better than Ligand B (85.43). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have acceptable logP values (A: 1.822, B: 2.353), falling within the 1-3 range. Ligand B is slightly higher, which could potentially lead to off-target effects, but it's not a major concern.
4. **HBD:** Ligand A (0) is preferable to Ligand B (3). Fewer hydrogen bond donors generally improve permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (4). Lower HBA is generally preferred.
6. **QED:** Ligand A (0.836) is better than Ligand B (0.743), indicating a more drug-like profile.
7. **DILI:** Ligand A (29.779) is *much* better than Ligand B (55.642). This is a significant advantage for Ligand A, as minimizing liver toxicity is crucial.
8. **BBB:** Ligand A (72.005) is better than Ligand B (25.708). While not a primary concern for a cardiovascular target, higher BBB is generally favorable.
9. **Caco-2:** Ligand A (-4.403) is better than Ligand B (-5.198). Higher Caco-2 permeability suggests better intestinal absorption.
10. **Solubility:** Ligand A (-1.741) is better than Ligand B (-3.521). Better solubility is always desirable.
11. **hERG:** Ligand A (0.252) is better than Ligand B (0.525). Lower hERG inhibition is critical for avoiding cardiotoxicity, especially for a cardiovascular target.
12. **Cl_mic:** Ligand A (50.35) is better than Ligand B (8.096). Lower microsomal clearance indicates greater metabolic stability.
13. **t1/2:** Ligand A (-11.29) is better than Ligand B (-12.121). A more negative value indicates a longer half-life.
14. **Pgp:** Ligand A (0.028) is *much* better than Ligand B (0.241). Lower P-gp efflux is beneficial for bioavailability.
15. **Affinity:** Ligand A (-7.6) is better than Ligand B (-6.7). A 0.9 kcal/mol difference in binding affinity is substantial and can often outweigh minor ADME concerns.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across almost all parameters, and crucially, exhibits a significantly better safety profile (DILI, hERG) and metabolic stability (Cl_mic). The affinity difference is also substantial. While both ligands fall within acceptable ranges for many properties, Ligand A presents a much more favorable overall profile for development as a drug candidate targeting ADRB2.
Output:
1
2025-04-17 23:21:00,127 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
The target is ADRB2, a GPCR. Therefore, prioritizing logP, Pgp, TPSA, and affinity is crucial. Metabolic stability and solubility are also important, but slightly less so than the GPCR-specific parameters.
Let's compare the ligands property by property:
1. **MW:** Both ligands (348.45 & 348.53 Da) fall comfortably within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (78.68) is higher than Ligand B (58.2). Both are below 140, but B is better for absorption.
3. **logP:** Ligand A (1.613) is within the optimal 1-3 range. Ligand B (3.962) is at the higher end, potentially leading to solubility issues.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (2). Fewer HBAs generally improve permeability.
6. **QED:** Ligand A (0.875) is significantly better than Ligand B (0.464), indicating a more drug-like profile.
7. **DILI:** Ligand A (21.132) has a much lower DILI risk than Ligand B (27.181).
8. **BBB:** Ligand A (71.888) has better BBB penetration than Ligand B (55.099). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be beneficial.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-4.857) is slightly better than Ligand B (-4.748).
10. **Solubility:** Ligand A (-1.6) is better than Ligand B (-4.454).
11. **hERG:** Both ligands have very low hERG inhibition risk (0.255 and 0.46).
12. **Cl_mic:** Ligand A (-6.545) has much better metabolic stability (lower clearance) than Ligand B (64.305).
13. **t1/2:** Ligand A (4.346) has a better in vitro half-life than Ligand B (26.216).
14. **Pgp:** Ligand A (0.023) has much lower P-gp efflux liability than Ligand B (0.206).
15. **Affinity:** Ligand B (-6.2) has slightly better binding affinity than Ligand A (-5.4). This is a 0.8 kcal/mol difference, which is significant.
**Overall Assessment:**
While Ligand B has a slightly better binding affinity, Ligand A is superior in almost all other crucial ADME-Tox properties. The better QED, lower DILI risk, improved BBB penetration, better solubility, significantly improved metabolic stability (Cl_mic and t1/2), and lower P-gp efflux all contribute to a much more promising drug candidate profile for Ligand A. The difference in binding affinity (0.8 kcal/mol) is not substantial enough to outweigh the substantial advantages of Ligand A in terms of ADME-Tox.
**Output:**
1
2025-04-17 23:21:00,127 - INFO - Batch 398 complete. Total preferences: 6368
2025-04-17 23:21:00,127 - INFO - Processing batch 399/512...
2025-04-17 23:21:47,637 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (374.463) is slightly higher than Ligand B (355.414), but both are acceptable.
2. **TPSA:** Ligand B (100.35) is significantly better than Ligand A (130.13). For a GPCR, lower TPSA is generally preferred for better permeability.
3. **logP:** Ligand B (0.406) is slightly better than Ligand A (-0.315), both are within the optimal range of 1-3, but closer to the lower end.
4. **HBD:** Ligand B (2) has fewer H-bond donors than Ligand A (3). Fewer is generally preferable for permeability.
5. **HBA:** Both ligands have the same number of H-bond acceptors (6), which is acceptable.
6. **QED:** Ligand B (0.658) has a better QED score than Ligand A (0.51), indicating a more drug-like profile.
7. **DILI:** Ligand B (48.817) has a lower DILI risk than Ligand A (60.295), which is a significant advantage.
8. **BBB:** Ligand B (74.447) has a significantly higher BBB penetration score than Ligand A (47.809). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be beneficial, and avoiding high CNS exposure is generally desirable.
9. **Caco-2:** Both ligands have similar, poor Caco-2 permeability (-5.47 and -5.07). This is a concern for both.
10. **Solubility:** Both ligands have similar, poor aqueous solubility (-2.219 and -2.08). This is a concern for both.
11. **hERG:** Both ligands have low hERG inhibition risk (0.25 and 0.182).
12. **Cl_mic:** Ligand A (-8.541) has a significantly lower (better) microsomal clearance than Ligand B (35.963), indicating better metabolic stability.
13. **t1/2:** Ligand B (-5.616) has a better in vitro half-life than Ligand A (32.565).
14. **Pgp:** Ligand B (0.084) has lower P-gp efflux liability than Ligand A (0.169), which is favorable.
15. **Binding Affinity:** Ligand A (-6.9 kcal/mol) has a better binding affinity than Ligand B (-3.6 kcal/mol). This is a substantial difference and a major factor.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in TPSA, Pgp, and has a better logP. However, Ligand A has a *much* stronger binding affinity. The difference in affinity (-6.9 vs -3.6) is substantial and likely to outweigh the advantages of Ligand B in other parameters, especially considering the similar issues with solubility and Caco-2 permeability for both. The better metabolic stability of Ligand A is also a plus.
**Conclusion:**
Despite Ligand B's better ADME profile in several areas, the significantly stronger binding affinity of Ligand A makes it the more promising drug candidate. The potency advantage is likely to be critical for efficacy, and the other parameters, while not ideal, are not dramatically worse for Ligand A.
Output:
1
2025-04-17 23:21:47,637 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (365.382 and 359.348 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (81.7) is better than Ligand B (91.32). Both are below 140, but lower is preferred for absorption.
3. **logP:** Both ligands have good logP values (3.036 and 2.002), falling within the optimal 1-3 range. Ligand A is slightly higher, which *could* be beneficial for membrane permeability, but isn't a major concern for either.
4. **HBD:** Ligand A (1) is better than Ligand B (3). Lower HBD is generally preferred.
5. **HBA:** Ligand A (6) is better than Ligand B (4). Lower HBA is generally preferred.
6. **QED:** Both ligands have similar QED values (0.796 and 0.75), indicating good drug-likeness.
7. **DILI:** Ligand A (92.982) has a significantly higher DILI risk than Ligand B (41.062). This is a major concern for Ligand A.
8. **BBB:** Ligand A (79.139) has better BBB penetration than Ligand B (67.623). While ADRB2 isn't exclusively a CNS target, some CNS exposure is possible with systemic administration, and higher BBB is generally favorable.
9. **Caco-2:** Both ligands have very poor Caco-2 permeability (-4.736 and -4.76). This is a significant negative for both.
10. **Solubility:** Ligand A (-4.679) has slightly better solubility than Ligand B (-3.459), but both are very poor.
11. **hERG:** Both ligands have low hERG inhibition risk (0.524 and 0.328).
12. **Cl_mic:** Ligand A (110.712) has higher microsomal clearance than Ligand B (27.148). This suggests Ligand B is more metabolically stable.
13. **t1/2:** Ligand B (-46.438) has a much longer in vitro half-life than Ligand A (8.989). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.404) has lower P-gp efflux than Ligand B (0.014). This is a slight advantage for Ligand A.
15. **Affinity:** Both ligands have identical binding affinity (-7.1 kcal/mol).
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Both ligands perform similarly on logP and affinity. Ligand A has better TPSA and Pgp, but Ligand B has significantly better metabolic stability (Cl_mic, t1/2) and a much lower DILI risk. The poor Caco-2 permeability is a concern for both, but can sometimes be overcome with formulation strategies. The DILI risk with Ligand A is a major red flag.
**Conclusion:**
Despite Ligand A having slightly better TPSA and Pgp properties, the significantly lower DILI risk and improved metabolic stability (longer half-life, lower clearance) of Ligand B outweigh these minor advantages. The identical binding affinity removes that as a differentiating factor. The high DILI risk of Ligand A is a dealbreaker.
Output:
0
2025-04-17 23:21:47,637 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [364.511, 58.64, 1.665, 1, 4, 0.575, 23.187, 55.642, -4.944, -3.351, 0.251, 35.669, -4.825, 0.086, -5.4]
**Ligand B:** [368.503, 96.11, 1.57, 3, 5, 0.615, 43.738, 62.97, -5.263, -3.359, 0.22, 32.927, 6.628, 0.032, -6.5]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity) are paramount:
1. **MW:** Both are within the ideal 200-500 Da range. A: 364.511, B: 368.503 - very similar.
2. **TPSA:** Ligand A (58.64) is significantly better than Ligand B (96.11). A is well below the 140 threshold for oral absorption, while B is approaching it.
3. **logP:** Both are good (around 1.6), within the 1-3 optimal range. A: 1.665, B: 1.57 - again, very similar.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is preferable to Ligand B (5). Fewer HBAs generally improve permeability.
6. **QED:** Both are decent, above 0.5, indicating drug-likeness. A: 0.575, B: 0.615 - B is slightly better.
7. **DILI:** Ligand A (23.187) is *much* better than Ligand B (43.738). A is well below the 40% threshold for low risk, while B is getting closer to the concerning 60% mark.
8. **BBB:** Ligand B (62.97) is better than Ligand A (55.642), but neither is exceptionally high. For a non-CNS target, this isn't a huge factor.
9. **Caco-2:** Ligand A (-4.944) is better than Ligand B (-5.263). Higher values are better, indicating better absorption.
10. **Solubility:** Both are very poor (-3.35 range). This is a concern for both, but not a deciding factor.
11. **hERG:** Both are low risk (0.251 and 0.22).
12. **Cl_mic:** Ligand B (32.927) is slightly better (lower clearance) than Ligand A (35.669).
13. **t1/2:** Ligand B (6.628) has a significantly longer half-life than Ligand A (-4.825). This is a substantial advantage.
14. **Pgp:** Both are very low (0.086 and 0.032), indicating minimal efflux.
15. **Affinity:** Ligand B (-6.5) has a 1.1 kcal/mol stronger binding affinity than Ligand A (-5.4). This is a significant advantage, and can often outweigh minor ADME concerns.
**Overall Assessment:**
While Ligand B has a better binding affinity and half-life, Ligand A has a much better safety profile (DILI) and better permeability characteristics (TPSA, HBD/HBA). The significantly lower DILI risk for Ligand A is a major advantage. The affinity difference is substantial, but the ADME profile of Ligand A is more balanced. Given the cardiovascular target, a lower DILI risk is crucial.
Therefore, I would choose Ligand A.
1
2025-04-17 23:21:47,638 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.403 and 354.491 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (95.22) is higher than Ligand B (70.08). For a cardiovascular GPCR, TPSA is not a primary concern unless CNS penetration is desired, but lower is generally better for oral absorption. Ligand B has a clear advantage.
3. **logP:** Ligand A (0.085) is quite low, potentially hindering membrane permeability. Ligand B (1.661) is within the optimal 1-3 range. Ligand B is significantly better here.
4. **HBD:** Both ligands have 1 HBD, which is acceptable.
5. **HBA:** Ligand A has 7 HBA, while Ligand B has 4. Both are below the threshold of 10. Ligand B is slightly better.
6. **QED:** Both ligands have similar QED scores (0.778 and 0.755), indicating good drug-likeness.
7. **DILI:** Ligand A (56.805) has a higher DILI risk than Ligand B (6.747). This is a substantial difference, and a lower DILI risk is highly desirable. Ligand B is much better.
8. **BBB:** Ligand A (63.086) and Ligand B (76.735). While ADRB2 is not strictly a CNS target, some brain exposure can be relevant for off-target effects. Ligand B has a better BBB score.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. This is concerning for both.
10. **Solubility:** Both have negative solubility values, indicating poor solubility. This is concerning for both.
11. **hERG:** Ligand A (0.095) has a slightly better hERG profile than Ligand B (0.393), but both are relatively low risk.
12. **Cl_mic:** Ligand A (45.237) has a higher microsomal clearance than Ligand B (34.99), suggesting lower metabolic stability. Ligand B is better.
13. **t1/2:** Ligand B (21.098) has a significantly longer in vitro half-life than Ligand A (0.878). This is a major advantage for dosing convenience. Ligand B is much better.
14. **Pgp:** Ligand A (0.113) has a lower P-gp efflux liability than Ligand B (0.062). This is a slight advantage for Ligand A.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.2 and -6.3 kcal/mol). The difference is negligible.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand B is clearly superior. It has a much better logP, lower TPSA, significantly lower DILI risk, better metabolic stability (lower Cl_mic, longer t1/2), and a slightly better BBB score. While both have issues with Caco-2 and solubility, the ADME profile of Ligand B is far more favorable. The binding affinity is essentially the same, so the superior ADME properties of Ligand B outweigh the slight Pgp advantage of Ligand A.
Output:
0
2025-04-17 23:21:47,638 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (343.471 and 356.413 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (60.18 and 60.85) are reasonably low, suggesting good potential for absorption. They are below the 140 threshold, and acceptable for a non-CNS GPCR target.
3. **logP:** Ligand A (3.95) is at the higher end of the optimal range (1-3), while Ligand B (1.5) is at the lower end. For a GPCR, a slightly higher logP is often acceptable to aid membrane permeability, but we need to consider other factors.
4. **HBD/HBA:** Both ligands have acceptable HBD (1) and HBA (5/3) counts, well within the guidelines.
5. **QED:** Both ligands have similar and good QED scores (0.825 and 0.812), indicating good drug-like properties.
6. **DILI:** Ligand A (44.552) has a moderate DILI risk, while Ligand B (13.61) has a very low DILI risk. This is a significant advantage for Ligand B.
7. **BBB:** Both have reasonable BBB penetration, but Ligand B (87.553) is significantly higher than Ligand A (74.176). While ADRB2 isn't primarily a CNS target, some off-target CNS effects are always a consideration, and higher BBB penetration could be a concern.
8. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual. This suggests poor permeability.
9. **Solubility:** Both ligands have negative solubility values, which is also unusual. This suggests poor solubility.
10. **hERG:** Both ligands have low hERG inhibition liability (0.82 and 0.529), which is excellent.
11. **Cl_mic:** Ligand A (32.417) has a higher microsomal clearance than Ligand B (6.455), suggesting lower metabolic stability. This is a significant advantage for Ligand B.
12. **t1/2:** Ligand B (17.618) has a significantly longer in vitro half-life than Ligand A (10.386). This is a major advantage for Ligand B, potentially allowing for less frequent dosing.
13. **Pgp:** Both ligands have very low P-gp efflux liability (0.516 and 0.048), which is favorable.
14. **Binding Affinity:** Both ligands have identical binding affinities (-6.4 kcal/mol).
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. While Ligand A has a slightly higher logP, the significantly better DILI, metabolic stability (lower Cl_mic), and longer half-life of Ligand B outweigh this. The similar affinities mean that the ADME properties become the deciding factor.
**Conclusion:**
Ligand B demonstrates a superior ADME profile with lower DILI risk, better metabolic stability, and a longer half-life, making it a more promising drug candidate despite a slightly lower logP.
Output:
0
2025-04-17 23:21:47,638 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (380.872) is slightly higher than Ligand B (367.793), but both are acceptable.
2. **TPSA:** Ligand A (49.41) is significantly better than Ligand B (104.7). For a GPCR, lower TPSA is generally preferred for better permeability. Ligand B's TPSA is quite high, potentially hindering absorption.
3. **logP:** Ligand A (3.626) is within the optimal range (1-3), while Ligand B (1.041) is at the lower end. A slightly higher logP is generally beneficial for GPCR ligands, aiding membrane permeability.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 3 HBA, while Ligand B has 7. Ligand A is preferable here, as excessive HBA can reduce permeability.
6. **QED:** Both ligands have similar QED values (0.88 and 0.869), indicating good drug-likeness.
7. **DILI:** Ligand B (75.184) has a higher DILI risk than Ligand A (62.893), although both are above the preferred <40 threshold.
8. **BBB:** Ligand A (75.107) has a significantly better BBB penetration percentile than Ligand B (32.299). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant and is not detrimental.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and difficult to interpret without knowing the scale. However, it suggests poor permeability for both.
10. **Solubility:** Ligand A (-4.775) has better solubility than Ligand B (-2.528).
11. **hERG:** Ligand A (0.611) has a slightly higher hERG risk than Ligand B (0.028), but both are relatively low.
12. **Cl_mic:** Ligand B (50.871) has a slightly lower microsomal clearance than Ligand A (45.56), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-13.185) has a much longer in vitro half-life than Ligand A (-4.619), which is a significant advantage.
14. **Pgp:** Ligand A (0.497) has lower P-gp efflux liability than Ligand B (0.065), which is beneficial for bioavailability.
15. **Binding Affinity:** Ligand B (-8.4) has a significantly stronger binding affinity than Ligand A (-5.8). This is a substantial advantage, potentially outweighing some ADME drawbacks.
**Overall Assessment:**
Ligand B has a much stronger binding affinity, and a longer half-life. However, it suffers from a high TPSA, lower logP, and higher DILI risk. Ligand A has better TPSA, logP, solubility, BBB penetration, and Pgp efflux. The difference in binding affinity is significant (2.6 kcal/mol), and for a GPCR, potency is a critical factor. The longer half-life of Ligand B is also a major plus. The higher TPSA and DILI risk are concerns but might be addressable with further optimization.
Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity), and the substantial affinity difference, I believe Ligand B is the more promising starting point, despite its drawbacks.
Output:
0
2025-04-17 23:21:47,638 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (360.483 and 361.364 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (67.23) is slightly higher than Ligand B (63.52). Both are below the 140 threshold for good oral absorption, and acceptable for a cardiovascular GPCR.
3. **logP:** Ligand A (2.001) is within the optimal 1-3 range, while Ligand B (3.023) is at the upper end. This favors Ligand A slightly, as higher logP can sometimes lead to off-target effects.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Both ligands have 5 HBA, which is also good.
6. **QED:** Ligand A (0.783) has a slightly better QED score than Ligand B (0.705), indicating a more drug-like profile.
7. **DILI:** Ligand A (39.434) has a slightly higher DILI risk than Ligand B (35.789), but both are well below the concerning threshold of 60.
8. **BBB:** Ligand B (74.564) has a slightly higher BBB penetration percentile than Ligand A (71.733). While ADRB2 isn't a CNS target, some peripheral exposure can be beneficial.
9. **Caco-2:** Ligand B (-4.659) shows slightly better Caco-2 permeability than Ligand A (-5.074).
10. **Solubility:** Ligand B (-3.624) has better aqueous solubility than Ligand A (-2.486). This is a positive attribute for bioavailability.
11. **hERG:** Ligand A (0.311) has a lower hERG inhibition liability than Ligand B (0.862), which is a significant advantage for cardiovascular safety.
12. **Cl_mic:** Ligand B (44.643) has a lower microsomal clearance than Ligand A (51.943), suggesting better metabolic stability.
13. **t1/2:** Ligand B (18.758) has a longer in vitro half-life than Ligand A (15.076), which is desirable for less frequent dosing.
14. **Pgp:** Ligand A (0.127) has lower P-gp efflux liability than Ligand B (0.472), which is beneficial for oral bioavailability.
15. **Affinity:** Ligand B (-7.4 kcal/mol) has a stronger binding affinity than Ligand A (-8.1 kcal/mol). This is a substantial difference and a major factor.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), affinity, logP, Pgp, TPSA, and solubility are key. Ligand B has a significantly better affinity, slightly better logP, better solubility, and better metabolic stability. Ligand A has better Pgp efflux and hERG inhibition. The affinity difference is substantial enough to outweigh the slight advantages of Ligand A.
**Conclusion:**
Despite Ligand A's better hERG profile and Pgp efflux, the significantly stronger binding affinity of Ligand B (-7.4 vs -8.1 kcal/mol) is the deciding factor. A strong binding affinity is paramount for a GPCR target, and the other ADME properties of Ligand B are acceptable.
Output:
0
2025-04-17 23:21:47,638 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (355.429 Da) is well within the ideal range (200-500 Da). Ligand B (384.889 Da) is also acceptable. No clear advantage here.
2. **TPSA:** Ligand A (58.37) is excellent, well below the 140 threshold for oral absorption. Ligand B (105.39) is still reasonable, but higher. This favors Ligand A.
3. **logP:** Ligand A (3.732) is at the upper end of the optimal range (1-3), but acceptable. Ligand B (1.419) is a bit low, potentially hindering membrane permeability. Ligand A is preferred.
4. **HBD:** Ligand A (1) is good. Ligand B (2) is also acceptable. No significant difference.
5. **HBA:** Ligand A (4) is good. Ligand B (5) is acceptable. No significant difference.
6. **QED:** Both ligands have good QED scores (A: 0.722, B: 0.818), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (25.126) has a very favorable DILI risk profile (low percentile). Ligand B (51.105) is higher, indicating a moderate risk. This strongly favors Ligand A.
8. **BBB:** Ligand A (98.061) shows excellent BBB penetration, which is beneficial for a GPCR target. Ligand B (54.13) is significantly lower. This is a major advantage for Ligand A.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and potentially problematic. However, negative values often indicate issues with the assay or the molecule's behavior in the assay. Without further information, it's difficult to interpret this.
10. **Solubility:** Both ligands have negative solubility values, indicating poor aqueous solubility. This is a concern for both, but might be mitigated with formulation strategies.
11. **hERG:** Ligand A (0.944) has a low hERG risk. Ligand B (0.102) also has a low hERG risk. No significant difference.
12. **Cl_mic:** Ligand A (26.052) has a moderate microsomal clearance. Ligand B (-8.168) has a *negative* clearance, which is not physically possible and likely indicates an issue with the data. This is a significant concern for Ligand B.
13. **t1/2:** Ligand A (-17.456) has a negative half-life, which is not physically possible and likely indicates an issue with the data. Ligand B (-22.783) also has a negative half-life. This is a significant concern for both.
14. **Pgp:** Ligand A (0.575) has moderate P-gp efflux. Ligand B (0.032) has very low P-gp efflux, which is beneficial. This favors Ligand B.
15. **Binding Affinity:** Ligand A (-7.3 kcal/mol) has a slightly better binding affinity than Ligand B (-6.7 kcal/mol). While the difference is not huge, it's enough to be considered.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A excels in TPSA, logP, and affinity. Ligand B has better Pgp. However, the concerning negative values for Cl_mic and t1/2 for Ligand B are major red flags. The superior BBB penetration and DILI profile of Ligand A are also important advantages.
**Conclusion:**
Despite the negative values for Caco-2 and t1/2, Ligand A is the more promising candidate. The combination of good TPSA, logP, affinity, excellent BBB penetration, low DILI risk, and a slightly better binding affinity outweigh the Pgp advantage of Ligand B, especially considering the data quality issues with Ligand B's Cl_mic and t1/2.
Output:
1
2025-04-17 23:21:47,638 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (354.397) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (50.8) is better than Ligand B (68.02), falling comfortably under the 140 threshold for oral absorption.
3. **logP:** Ligand A (3.04) is optimal, while Ligand B (4.125) is pushing the upper limit. Higher logP can lead to solubility issues and off-target effects.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 3 HBA, while Ligand B has 4. Both are acceptable, but lower is generally better.
6. **QED:** Ligand A (0.908) has a significantly better QED score than Ligand B (0.676), indicating a more drug-like profile.
7. **DILI:** Ligand A (56.727) has a lower DILI risk than Ligand B (90.384), which is a significant advantage.
8. **BBB:** Ligand A (85.072) shows better BBB penetration than Ligand B (77.627). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant for side effect profile.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. Ligand A (-4.15) is slightly better than Ligand B (-4.777).
10. **Solubility:** Ligand A (-2.972) has better solubility than Ligand B (-5.346).
11. **hERG:** Both ligands have low hERG inhibition liability (0.397 and 0.447 respectively).
12. **Cl_mic:** Ligand A (42.48) has lower microsomal clearance than Ligand B (59.647), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-8.007) has a much longer in vitro half-life than Ligand B (5.094).
14. **Pgp:** Both have low Pgp efflux liability (0.152 and 0.3 respectively).
15. **Binding Affinity:** Ligand B (-8.6) has a significantly stronger binding affinity than Ligand A (-6.5), a difference of 2.1 kcal/mol.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B has a better affinity, but Ligand A excels in other crucial areas like logP, TPSA, DILI, solubility, metabolic stability, and half-life. The 2.1 kcal/mol difference in affinity is substantial, but the overall ADME profile of Ligand A is far superior. The better solubility, lower DILI risk, and improved metabolic stability of Ligand A are critical for developing a safe and effective drug.
**Conclusion:**
Considering the balance of properties and the importance of a favorable ADME profile for a GPCR target, Ligand A is the more promising drug candidate.
Output:
1
2025-04-17 23:21:47,638 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (361.419 Da and 367.471 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (81.7) is better than Ligand B (88.6), being closer to the <140 threshold for good absorption.
3. **logP:** Both ligands (2.069 and 1.906) are within the optimal 1-3 range. Very similar.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 5 HBA, while Ligand B has 6. Both are acceptable, but A is slightly better.
6. **QED:** Ligand A (0.882) is significantly better than Ligand B (0.744), indicating a more drug-like profile.
7. **DILI:** Ligand A (93.292) has a much higher DILI risk than Ligand B (49.128). This is a major concern for Ligand A.
8. **BBB:** Ligand B (68.786) has a better BBB penetration score than Ligand A (56.65). While ADRB2 isn't necessarily a CNS target, some peripheral ADRB2 activity can influence CNS function, and better BBB penetration isn't a major negative.
9. **Caco-2:** Ligand A (-4.8) is better than Ligand B (-5.066), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-3.753) is better than Ligand B (-2.63), indicating better aqueous solubility.
11. **hERG:** Both ligands (0.426 and 0.302) have low hERG inhibition liability, which is good.
12. **Cl_mic:** Ligand A (30.514) has significantly lower microsomal clearance than Ligand B (60.667), suggesting better metabolic stability.
13. **t1/2:** Ligand A (13.717) has a longer in vitro half-life than Ligand B (-17.024). This is a significant advantage.
14. **Pgp:** Both ligands (0.545 and 0.067) have low P-gp efflux liability. Ligand B is slightly better.
15. **Binding Affinity:** Both ligands (-6.8 and -6.7) have very similar and strong binding affinities. The difference is negligible.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Both ligands perform similarly on logP and affinity. Ligand A is better on TPSA and Pgp, and has a better half-life and clearance. However, the significantly higher DILI risk for Ligand A is a major drawback.
**Overall Assessment:**
While Ligand A has some advantages in terms of metabolic stability (Cl_mic, t1/2), solubility, and Caco-2 permeability, the substantially higher DILI risk is a critical concern. The slightly better BBB penetration of Ligand B, coupled with its significantly lower DILI risk, makes it the more promising candidate despite its slightly worse metabolic profile. The binding affinities are comparable, so the ADME properties become the deciding factor.
Output:
0
2025-04-17 23:21:47,638 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (368.455 Da) is slightly heavier than Ligand B (357.288 Da), but this difference isn't significant.
**2. TPSA:** Ligand A (76.15) is significantly better than Ligand B (104.45). For GPCRs, lower TPSA is generally preferred for better permeability. Ligand B is pushing the upper limit for good oral absorption.
**3. logP:** Ligand A (0.87) is a bit low, potentially impacting permeability. Ligand B (2.024) is within the optimal range (1-3). This favors Ligand B.
**4. H-Bond Donors:** Ligand A (0) is ideal, while Ligand B (3) is acceptable but less optimal.
**5. H-Bond Acceptors:** Both ligands have 5 HBA, which is within the acceptable range.
**6. QED:** Both ligands have similar QED values (0.771 and 0.734), indicating good drug-likeness.
**7. DILI:** Ligand A (53.781) has a lower DILI risk than Ligand B (60.489), which is a positive for Ligand A.
**8. BBB:** Ligand A (71.772) has a significantly better BBB penetration potential than Ligand B (29.934). While ADRB2 is a cardiovascular target, some CNS penetration can be acceptable or even desirable for off-target effects assessment. This strongly favors Ligand A.
**9. Caco-2 Permeability:** Ligand A (-4.446) is better than Ligand B (-5.939), indicating better intestinal absorption.
**10. Aqueous Solubility:** Both ligands have very poor aqueous solubility (-2.205 and -2.009). This is a concern for both, but not a deciding factor between them.
**11. hERG Inhibition:** Ligand A (0.574) has a lower hERG inhibition liability than Ligand B (0.091), which is a significant advantage for Ligand A.
**12. Microsomal Clearance:** Ligand B (-9.23) has a lower (better) microsomal clearance than Ligand A (75.01). This suggests better metabolic stability for Ligand B.
**13. In vitro Half-Life:** Ligand A (-31.831) has a longer half-life than Ligand B (-20.697).
**14. P-gp Efflux:** Ligand A (0.103) has lower P-gp efflux than Ligand B (0.011), which is favorable.
**15. Binding Affinity:** Ligand B (-6.9) has a slightly better binding affinity than Ligand A (-6.1), but the difference is less than 1.5 kcal/mol.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand A emerges as the more promising candidate. While Ligand B has a slightly better affinity and metabolic stability, Ligand A excels in TPSA, BBB penetration, DILI risk, and hERG inhibition. The lower TPSA and better BBB penetration are particularly important for a GPCR target, even a cardiovascular one. The lower DILI and hERG risks also significantly enhance its safety profile. The slightly lower logP of Ligand A is a minor drawback that could potentially be addressed with further optimization.
Output:
1
2025-04-17 23:21:47,638 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (354.334 and 354.422 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (98.98) is higher than Ligand B (67.87). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B has a clear advantage here.
3. **logP:** Both ligands (1.857 and 1.18) are within the optimal 1-3 range. Ligand B is slightly lower, which could potentially affect permeability, but it's not a major concern.
4. **HBD:** Ligand A (0) has no hydrogen bond donors, while Ligand B (1) has one. Lower is generally preferred for permeability, giving a slight edge to Ligand A.
5. **HBA:** Ligand A (7) is higher than Ligand B (4). Lower is generally preferred for permeability, giving a clear advantage to Ligand B.
6. **QED:** Ligand B (0.778) has a better QED score than Ligand A (0.437), indicating a more drug-like profile.
7. **DILI:** Ligand B (29.042) has a significantly lower DILI risk than Ligand A (52.966). This is a major advantage for Ligand B.
8. **BBB:** Both ligands have high BBB penetration (87.088 and 83.831), which is less critical for a cardiovascular target but not detrimental.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.567 and -4.592). This is unusual and suggests poor permeability.
10. **Solubility:** Ligand B (-1.756) has better solubility than Ligand A (-3.439). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.77) has a slightly higher hERG risk than Ligand B (0.374). Lower is better.
12. **Cl_mic:** Ligand B (-5.537) has a much lower (better) microsomal clearance than Ligand A (54.908). This indicates greater metabolic stability.
13. **t1/2:** Ligand B (12.451) has a significantly longer in vitro half-life than Ligand A (-0.679). This is a major advantage.
14. **Pgp:** Ligand A (0.22) has lower P-gp efflux than Ligand B (0.035). Lower P-gp efflux is generally preferred.
15. **Affinity:** Ligand A (-7.3) has a slightly better binding affinity than Ligand B (-5.8). This is a 1.5 kcal/mol difference, which is significant.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity, Ligand B demonstrates a superior overall profile, particularly regarding safety (DILI), metabolic stability (Cl_mic, t1/2), solubility, and permeability-related properties (TPSA, HBA). The difference in affinity is not substantial enough to outweigh these advantages, especially considering the potential for optimizing affinity further in subsequent iterations. The negative Caco-2 values for both are concerning and would require further investigation, but Ligand B's other properties make it a more promising starting point.
Output:
0
2025-04-17 23:21:47,639 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (338.451) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (61.36) is significantly better than Ligand B (71.09). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (A: 3.249, B: 2.286) falling within the optimal 1-3 range. Ligand A is slightly higher, which *could* be a minor drawback if it leads to off-target effects, but is still acceptable.
4. **HBD/HBA:** Ligand A (HBD=3, HBA=2) and Ligand B (HBD=2, HBA=3) are both reasonable.
5. **QED:** Both ligands have good QED scores (A: 0.615, B: 0.796), indicating good drug-like properties. Ligand B is slightly better.
6. **DILI:** Ligand A (35.169) has a better DILI score than Ligand B (44.591), indicating lower potential for liver injury. This is a significant advantage.
7. **BBB:** Ligand B (81.698) has a much higher BBB penetration score than Ligand A (57.619). However, since ADRB2 is a cardiovascular target, BBB penetration is not a priority.
8. **Caco-2:** Both ligands have negative Caco-2 values (-4.648 and -4.719), which is unusual and suggests poor permeability. This is a concern for both.
9. **Solubility:** Both ligands have negative solubility values (-3.645 and -2.672) which is also concerning.
10. **hERG:** Ligand A (0.843) has a slightly better hERG score than Ligand B (0.113), indicating lower cardiotoxicity risk.
11. **Cl_mic:** Ligand B (4.738) has significantly lower microsomal clearance than Ligand A (43.19), suggesting better metabolic stability. This is a major advantage for Ligand B.
12. **t1/2:** Ligand A (17.723) has a much longer in vitro half-life than Ligand B (-15.443). This is a significant advantage for Ligand A.
13. **Pgp:** Ligand A (0.533) has better Pgp efflux liability than Ligand B (0.029), meaning it's less likely to be pumped out of cells.
14. **Binding Affinity:** Ligand A (-6.4 kcal/mol) has a slightly better binding affinity than Ligand B (-4.6 kcal/mol). This is a substantial advantage.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity), Ligand A is the stronger candidate. While Ligand B has better metabolic stability (lower Cl_mic), the significantly better affinity of Ligand A, combined with its lower DILI risk, better hERG profile, and better Pgp efflux, outweigh this benefit. The poor Caco-2 and solubility values are a concern for both, but the superior binding and safety profile of Ligand A make it more likely to be optimized into a viable drug candidate.
Output:
1
2025-04-17 23:21:47,639 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands (373.519 and 346.471 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (88.07) is slightly higher than Ligand B (69.64). Both are below the 140 threshold for oral absorption, but Ligand B is closer to the 90 threshold which is desirable for GPCRs. Advantage: Ligand B.
3. **logP:** Ligand B (2.004) is slightly higher than Ligand A (1.028), both are within the optimal 1-3 range. Advantage: Ligand B.
4. **HBD:** Ligand A (1) and Ligand B (2) are both acceptable. No significant difference.
5. **HBA:** Ligand A (5) and Ligand B (3) are both acceptable. Advantage: Ligand B.
6. **QED:** Ligand A (0.729) is significantly better than Ligand B (0.421), indicating a more drug-like profile. Advantage: Ligand A.
7. **DILI:** Ligand A (20.047) has a much lower DILI risk than Ligand B (10.275). This is a significant advantage for Ligand A.
8. **BBB:** Both ligands have similar BBB penetration (64.87 and 68.592). This is acceptable for a non-CNS target like ADRB2. No clear advantage.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the values are similar (-4.871 and -4.784). No clear advantage.
10. **Solubility:** Both ligands have negative solubility values, which is also unusual. The values are similar (-1.246 and -2.114). No clear advantage.
11. **hERG:** Both ligands have low hERG inhibition risk (0.35 and 0.292). No clear advantage.
12. **Cl_mic:** Ligand A (-7.247) has a much lower (better) microsomal clearance than Ligand B (7.898). This suggests better metabolic stability for Ligand A. Advantage: Ligand A.
13. **t1/2:** Ligand A (3.075) has a better in vitro half-life than Ligand B (-15.148). Advantage: Ligand A.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.018 and 0.156). No clear advantage.
15. **Binding Affinity:** Ligand A (-7.0) has a slightly better binding affinity than Ligand B (-6.2). While the difference is not huge, it is still favorable. Advantage: Ligand A.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand B has a slight edge in logP and TPSA. However, Ligand A demonstrates superior drug-likeness (QED), significantly lower DILI risk, better metabolic stability (Cl_mic, t1/2), and slightly better binding affinity. The lower DILI and improved metabolic stability are crucial for a viable drug candidate. The slightly better affinity also contributes to its favorability. While both have issues with Caco-2 and solubility, these can be addressed with formulation strategies.
**Output:**
1
2025-04-17 23:21:47,639 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (364.5 and 360.5 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (68.3) is slightly higher than Ligand B (58.98). Both are below the 140 threshold for oral absorption, but closer to the 90 threshold for CNS targets (though ADRB2 isn't necessarily a CNS target). Ligand B is preferable here.
3. **logP:** Both ligands have good logP values (3.04 and 3.52), falling within the optimal 1-3 range. Ligand B is slightly higher, which *could* be a minor drawback if it leads to solubility issues, but is generally acceptable.
4. **HBD:** Ligand A has 2 HBD, while Ligand B has 0. Lower HBD is generally preferred for permeability, making Ligand B slightly better.
5. **HBA:** Ligand A has 7 HBA, and Ligand B has 5. Both are below the 10 threshold. Ligand B is preferable.
6. **QED:** Both ligands have good QED scores (0.804 and 0.758), indicating good drug-like properties. No major difference.
7. **DILI:** Ligand A (55.45) has a slightly higher DILI risk than Ligand B (49.40), but both are below the concerning 60 threshold. Ligand B is preferable.
8. **BBB:** Ligand B (91.43) has a significantly higher BBB penetration percentile than Ligand A (84.84). While ADRB2 isn't strictly a CNS target, higher BBB is rarely detrimental and can open up potential for alternative therapeutic applications.
9. **Caco-2:** Ligand A (-5.14) and Ligand B (-4.74) both have negative Caco-2 values. These values are on a log scale, so a less negative value is better. Ligand B is slightly preferable.
10. **Solubility:** Ligand A (-3.60) has slightly better solubility than Ligand B (-4.06). This is a minor advantage for Ligand A.
11. **hERG:** Ligand A (0.714) has a slightly higher hERG risk than Ligand B (0.336). Lower hERG is crucial for avoiding cardiotoxicity, making Ligand B preferable.
12. **Cl_mic:** Ligand B (58.92) has a higher microsomal clearance than Ligand A (50.01), meaning faster metabolism and potentially lower exposure. Ligand A is preferable.
13. **t1/2:** Ligand A (43.11) has a significantly longer in vitro half-life than Ligand B (0.72). This is a substantial advantage for Ligand A, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.056) has lower P-gp efflux liability than Ligand B (0.187), which is beneficial for bioavailability. Ligand A is preferable.
15. **Binding Affinity:** Ligand B (-6.1 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.2 kcal/mol). This is a >1 kcal/mol difference, a substantial advantage that can outweigh minor ADME drawbacks.
**Overall Assessment:**
Ligand B excels in key GPCR-relevant properties: strong binding affinity, good logP, low hERG risk, and high BBB penetration. While Ligand A has advantages in half-life, Pgp efflux, and solubility, the substantial difference in binding affinity and the preferable safety profile of Ligand B outweigh these benefits. The slightly higher clearance of Ligand B is a manageable concern.
Output:
0
2025-04-17 23:21:47,639 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [339.443, 63.91, 2.032, 0, 5, 0.855, 42.613, 81.97, -5.107, -1.043, 0.268, 32.246, -4.693, 0.07, -6.5]
**Ligand B:** [373.45, 105.23, 0.973, 2, 5, 0.693, 66.344, 55.215, -4.894, -2.648, 0.271, 10.906, 54.938, 0.083, -6.6]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (339.443) is slightly preferred due to being lower.
2. **TPSA:** Ligand A (63.91) is excellent, well below the 140 threshold. Ligand B (105.23) is still acceptable, but less ideal.
3. **logP:** Both are good (between 1-3), but Ligand A (2.032) is slightly better positioned within the optimal range than Ligand B (0.973).
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Both have 5 HBA, which is acceptable.
6. **QED:** Ligand A (0.855) is significantly better than Ligand B (0.693), indicating a more drug-like profile.
7. **DILI:** Ligand A (42.613) has a much lower DILI risk than Ligand B (66.344). This is a significant advantage.
8. **BBB:** Ligand A (81.97) has a considerably higher BBB penetration potential than Ligand B (55.215). Given ADRB2 is a GPCR, and potential for CNS side effects, this is a crucial factor.
9. **Caco-2:** Both have negative values, indicating permeability issues. Ligand A (-5.107) is slightly better than Ligand B (-4.894).
10. **Solubility:** Both have negative values, indicating poor solubility. Ligand A (-1.043) is slightly better than Ligand B (-2.648).
11. **hERG:** Both are very low, indicating minimal hERG inhibition risk.
12. **Cl_mic:** Ligand A (32.246) has a lower microsomal clearance than Ligand B (10.906), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-4.693) has a more negative in vitro half-life, which is better.
14. **Pgp:** Both are very low, indicating minimal P-gp efflux.
15. **Affinity:** Both have very similar binding affinities (-6.5 and -6.6 kcal/mol). The difference is negligible.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, BBB penetration, logP, TPSA, and affinity are key. Ligand A excels in BBB, TPSA, logP, and QED, and has a better DILI profile. While both have comparable affinity, the superior ADME properties of Ligand A make it a more promising candidate.
**Conclusion:**
Ligand A is the more favorable candidate due to its better overall ADME profile, particularly its higher BBB penetration, lower DILI risk, and better QED score.
Output:
1
2025-04-17 23:21:47,639 - INFO - Batch 399 complete. Total preferences: 6384
2025-04-17 23:21:47,639 - INFO - Processing batch 400/512...
2025-04-17 23:22:38,196 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.435 and 348.359 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (90.98) is significantly better than Ligand B (124.77). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand A is well below the 140 threshold, while B is approaching it.
3. **logP:** Ligand B (-0.432) is slightly less lipophilic than Ligand A (-1.05). Both are on the lower side of the optimal 1-3 range, but Ligand A is closer to the sweet spot.
4. **HBD:** Ligand B has 3 HBDs, while Ligand A has 2. This is a minor difference.
5. **HBA:** Ligand B has 6 HBAs, while Ligand A has 5. Again, a minor difference.
6. **QED:** Ligand A (0.596) has a significantly better QED score than Ligand B (0.333), indicating a more drug-like profile.
7. **DILI:** Ligand A (23.769%) has a much lower DILI risk than Ligand B (58.434%). This is a substantial advantage for Ligand A.
8. **BBB:** Ligand A (36.371%) has a lower BBB penetration than Ligand B (45.677%). While BBB isn't the highest priority for ADRB2 (a cardiovascular target), some level of CNS penetration can be a concern for off-target effects. This favors Ligand B slightly.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.98) is slightly better than Ligand B (-5.303).
10. **Solubility:** Ligand A (-0.434) has slightly better solubility than Ligand B (-2.059), although both are quite poor.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.053 and 0.018 respectively). No significant difference.
12. **Cl_mic:** Ligand A (-10.428) has a much lower (better) microsomal clearance than Ligand B (-13.054). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (-9.773) has a longer in vitro half-life than Ligand B (0.293). This is a significant advantage for Ligand A.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.002 and 0.006 respectively). No significant difference.
15. **Binding Affinity:** Ligand A (-8.0) has a slightly better binding affinity than Ligand B (-5.5). This is a substantial advantage for Ligand A.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical ADME-Tox properties (QED, DILI, Cl_mic, t1/2) and has a better binding affinity. While Ligand B has slightly better BBB penetration, this is less crucial for a cardiovascular target like ADRB2. The poor Caco-2 and solubility of both are concerning but the superior overall profile of Ligand A makes it the more promising candidate.
Output:
1
2025-04-17 23:22:38,196 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (357.4 and 363.5 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (108.41) is higher than Ligand B (54.46). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for better absorption. Ligand B is significantly better here.
**3. logP:** Ligand A (-1.797) is lower than the optimal 1-3 range, potentially hindering permeability. Ligand B (3.019) is within the optimal range. This is a significant advantage for Ligand B.
**4. H-Bond Donors:** Ligand A (2) and Ligand B (1) are both acceptable, falling below the 5 threshold.
**5. H-Bond Acceptors:** Ligand A (6) and Ligand B (5) are both acceptable, falling below the 10 threshold.
**6. QED:** Both ligands have good QED scores (0.543 and 0.684), indicating good drug-like properties. Ligand B is slightly better.
**7. DILI Risk:** Ligand A (34.432) has a lower DILI risk than Ligand B (11.4). This is a significant advantage for Ligand A.
**8. BBB Penetration:** Ligand A (18.147) has poor BBB penetration, which is not a major concern for a cardiovascular target. Ligand B (79.566) has good BBB penetration, but this is less important for a peripheral target like ADRB2.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-5.035 and -5.065), which is unusual and suggests poor permeability. This is a concern for both, but the values are very similar.
**10. Aqueous Solubility:** Ligand A (-0.772) has better solubility than Ligand B (-3.481). This is a positive for Ligand A.
**11. hERG Inhibition:** Ligand A (0.096) has a lower hERG risk than Ligand B (0.708). This is a significant advantage for Ligand A, as hERG inhibition can lead to cardiotoxicity.
**12. Microsomal Clearance:** Ligand A (-0.365) has lower microsomal clearance, indicating better metabolic stability, than Ligand B (71.506). This is a significant advantage for Ligand A.
**13. In vitro Half-Life:** Ligand A (-14.641) has a very short half-life, which is a major drawback. Ligand B (-3.878) has a better, though still relatively short, half-life.
**14. P-gp Efflux:** Ligand A (0.011) has very low P-gp efflux, which is favorable. Ligand B (0.093) also has low P-gp efflux, but slightly higher.
**15. Binding Affinity:** Ligand A (-6.7) has slightly better binding affinity than Ligand B (-5.7). While a 1.0 kcal/mol difference is noticeable, it's not overwhelming.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand B initially looks better due to its optimal logP and lower TPSA. However, Ligand A has a significantly better safety profile (lower DILI, lower hERG, better metabolic stability) and better solubility. The short half-life of Ligand A is a concern, but could potentially be addressed through prodrug strategies or formulation. The poor Caco-2 permeability is a concern for both.
Given the cardiovascular target and the importance of minimizing off-target effects and toxicity, I prioritize the safety and metabolic stability profile of Ligand A. The slightly better affinity isn't enough to overcome the significant ADME/Tox advantages of Ligand A.
Output:
1
2025-04-17 23:22:38,197 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (354-368 Da). No significant difference.
2. **TPSA:** Ligand A (67.87) is higher than Ligand B (33.2). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is generally preferred for absorption. Ligand B is significantly better here.
3. **logP:** Ligand B (4.774) is higher than Ligand A (2.429). While both are above the optimal range of 1-3, Ligand B is pushing the upper limit and could present solubility challenges. Ligand A is better.
4. **HBD:** Ligand A (1) is slightly higher than Ligand B (0). This is a minor difference.
5. **HBA:** Ligand A (4) is slightly higher than Ligand B (3). This is a minor difference.
6. **QED:** Ligand B (0.748) is better than Ligand A (0.528), indicating a more drug-like profile.
7. **DILI:** Ligand B (17.371) is *much* lower than Ligand A (44.63), indicating a significantly reduced risk of drug-induced liver injury. This is a major advantage for Ligand B.
8. **BBB:** Both ligands have good BBB penetration (A: 86.002, B: 83.249). Since ADRB2 is not a CNS target, this is less critical, but higher is still preferable. Ligand A is slightly better.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual. I will assume this means very low permeability.
10. **Solubility:** Ligand B (-4.065) is worse than Ligand A (-2.844). This is consistent with the higher logP of Ligand B. Ligand A is better.
11. **hERG:** Both ligands have low hERG inhibition risk (A: 0.537, B: 0.67). No significant difference.
12. **Cl_mic:** Ligand B (86.733) has a higher microsomal clearance than Ligand A (28.944), suggesting faster metabolism and potentially lower exposure. Ligand A is better.
13. **t1/2:** Ligand B (-6.296) has a slightly worse in vitro half-life than Ligand A (-5.177). Ligand A is better.
14. **Pgp:** Both ligands have low Pgp efflux liability (A: 0.102, B: 0.567). No significant difference.
15. **Binding Affinity:** Ligand B (-6.5) has a slightly better binding affinity than Ligand A (-6.0). This is a 0.5 kcal/mol difference, which is significant, but not overwhelming.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), and the general guidelines, Ligand B is the better candidate. The significantly lower DILI risk is a major factor. While Ligand B has a higher logP and lower solubility, the better affinity and superior safety profile outweigh these drawbacks. Ligand A has better metabolic stability and solubility, but the DILI risk is concerning. The TPSA of Ligand B is also much more favorable.
Output:
0
2025-04-17 23:22:38,197 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (357.797 Da and 375.259 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (65.38) is slightly higher than Ligand B (58.12). Both are below the 140 A^2 threshold for good oral absorption, but closer to the 90 A^2 threshold for CNS targets. For a cardiovascular target, this isn't a major concern, but lower is generally preferable. Ligand B has a slight advantage.
**3. logP:** Both ligands have excellent logP values (3.296 and 3.021), falling within the optimal 1-3 range. No significant difference.
**4. H-Bond Donors:** Both have 1 HBD, which is within the acceptable limit of <=5.
**5. H-Bond Acceptors:** Ligand A has 5 HBAs, and Ligand B has 4. Both are below the acceptable limit of <=10.
**6. QED:** Both ligands have good QED scores (0.778 and 0.835), indicating good drug-like properties. Ligand B is slightly better.
**7. DILI Risk:** Ligand A (80.729) has a higher DILI risk than Ligand B (76.154). While both are acceptable, lower is better. Ligand B is preferable.
**8. BBB Penetration:** Both ligands have similar BBB penetration (65.335 and 68.748). Since ADRB2 is a cardiovascular target, BBB penetration is not a high priority.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.929 and -4.738). This is unusual and potentially concerning, suggesting poor permeability. However, negative values are sometimes artifacts of the prediction method.
**10. Aqueous Solubility:** Both ligands have very poor aqueous solubility (-4.635 and -4.467). This is a significant drawback and would require formulation strategies to address.
**11. hERG Inhibition:** Ligand A (0.399) has a slightly lower hERG inhibition risk than Ligand B (0.706). This is a positive for Ligand A.
**12. Microsomal Clearance:** Ligand A (50.487) has a higher microsomal clearance than Ligand B (25.793), indicating faster metabolism and potentially lower *in vivo* exposure. Ligand B is preferable.
**13. In vitro Half-Life:** Ligand A (52.314) has a longer half-life than Ligand B (9.9). This is a significant advantage for Ligand A, potentially allowing for less frequent dosing.
**14. P-gp Efflux:** Ligand A (0.441) has lower P-gp efflux than Ligand B (0.278), suggesting better bioavailability. This is a positive for Ligand A.
**15. Binding Affinity:** Ligand A (-5.8 kcal/mol) has a stronger binding affinity than Ligand B (-4.2 kcal/mol). This is a substantial difference (1.6 kcal/mol) and a major advantage for Ligand A, potentially outweighing some of its ADME drawbacks.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand A is the better candidate. The significantly stronger binding affinity (-5.8 vs -4.2 kcal/mol) is the most important factor. While Ligand B has a slightly better DILI risk and lower clearance, the affinity difference is substantial enough to overcome these concerns. The longer half-life and lower P-gp efflux of Ligand A are also beneficial. The poor solubility of both compounds is a concern, but can be addressed through formulation.
Output:
1
2025-04-17 23:22:38,197 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (344.419 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (85.05) is better than Ligand B (45.59). Both are below the 140 threshold for oral absorption, but Ligand B is significantly lower and potentially better for cellular penetration.
3. **logP:** Ligand A (0.917) is within the optimal range (1-3), while Ligand B (4.686) is high. High logP can lead to poor solubility and off-target effects. This is a significant negative for Ligand B.
4. **HBD:** Both ligands have 1 HBD, which is acceptable.
5. **HBA:** Ligand A has 6 HBA, and Ligand B has 5. Both are within the acceptable range of <=10.
6. **QED:** Ligand A (0.874) has a better QED score than Ligand B (0.705), indicating a more drug-like profile.
7. **DILI:** Ligand A (58.24) has a higher DILI risk than Ligand B (11.322). This is a negative for Ligand A.
8. **BBB:** Ligand B (76.813) has a better BBB penetration percentile than Ligand A (59.093). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be useful for understanding off-target effects.
9. **Caco-2:** Both ligands have similar, very negative Caco-2 values (-4.988 and -4.996). This suggests poor intestinal absorption for both.
10. **Solubility:** Ligand A (-2.545) has better solubility than Ligand B (-5.669). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.175) has a much lower hERG inhibition liability than Ligand B (0.889), which is a critical advantage for cardiovascular safety.
12. **Cl_mic:** Ligand A (22.31) has significantly lower microsomal clearance than Ligand B (119.528), indicating better metabolic stability.
13. **t1/2:** Ligand A (15.479) has a longer in vitro half-life than Ligand B (-7.22). This is a positive for Ligand A.
14. **Pgp:** Ligand A (0.081) has lower P-gp efflux liability than Ligand B (0.442), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand B (-4.5 kcal/mol) has a slightly better binding affinity than Ligand A (-6.3 kcal/mol). However, the difference is not substantial enough to outweigh the other significant drawbacks of Ligand B.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B has a high logP, which is a significant concern. Ligand A has better TPSA, Pgp, and solubility. While Ligand B has slightly better affinity, the other ADME properties of Ligand A are much more favorable.
**Conclusion:**
Considering the balance of properties, especially the concerning high logP and DILI risk of Ligand B, and the superior metabolic stability, solubility, and safety profile of Ligand A, I would choose Ligand A as the more promising drug candidate.
Output:
1
2025-04-17 23:22:38,197 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (351.422) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are below the 140 A^2 threshold for good oral absorption. Ligand A (73.74) is better than Ligand B (79.21), aligning with GPCR preference for lower TPSA.
3. **logP:** Ligand A (1.421) is optimal, while Ligand B (3.12) is at the higher end of the optimal range. This favors Ligand A.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 4 HBA, while Ligand B has 6. Ligand A is preferable.
6. **QED:** Both are very similar (0.841 vs 0.804), indicating good drug-likeness.
7. **DILI:** Ligand A (29.624) has a significantly lower DILI risk than Ligand B (63.978). This is a major advantage for Ligand A.
8. **BBB:** Both have good BBB penetration (78.945 and 74.641), but Ligand A is slightly better.
9. **Caco-2:** Both have negative Caco-2 values, suggesting poor permeability. However, the absolute value is slightly better for Ligand A (-4.481 vs -4.568).
10. **Solubility:** Ligand A (-0.938) has better solubility than Ligand B (-5.168).
11. **hERG:** Both have low hERG inhibition risk (0.56 and 0.376).
12. **Cl_mic:** Ligand A (14.811) has a much lower microsomal clearance, indicating better metabolic stability, which is crucial. Ligand B (69.414) is significantly higher.
13. **t1/2:** Ligand A (-10.701) has a more favorable (less negative) in vitro half-life compared to Ligand B (-25.95).
14. **Pgp:** Both have low Pgp efflux liability (0.063 and 0.242).
15. **Affinity:** Both have very similar binding affinities (-7.6 and -7.0 kcal/mol). The difference is less than the 1.5 kcal/mol threshold.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across several critical ADME properties (DILI, Cl_mic, solubility, TPSA) and has a slightly better BBB score. While the binding affinities are comparable, the superior ADME profile of Ligand A makes it a more promising drug candidate for the ADRB2 receptor. The lower DILI risk and improved metabolic stability are particularly important.
Output:
1
2025-04-17 23:22:38,197 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (375.441 and 342.527 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (32.34) is significantly better than Ligand A (75.44). ADRB2 is not a CNS target, but lower TPSA generally improves absorption. This favors Ligand B.
3. **logP:** Ligand A (1.735) is within the optimal range (1-3). Ligand B (4.253) is slightly higher, pushing the boundary of acceptable lipophilicity. While not a deal-breaker, it introduces a potential for off-target interactions and solubility issues. This favors Ligand A.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 5 HBA, and Ligand B has 2. Both are within the acceptable limit of 10. Ligand B is better here.
6. **QED:** Both ligands have good QED scores (0.749 and 0.867), indicating drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand B (22.8) has a much lower DILI risk than Ligand A (37.65). This is a significant advantage for Ligand B.
8. **BBB:** While not a primary concern for ADRB2, Ligand B (90.035) has a higher BBB penetration than Ligand A (73.711).
9. **Caco-2:** Ligand A (-5.042) and Ligand B (-4.7) are both poor, but similar.
10. **Solubility:** Ligand A (-2.115) is better than Ligand B (-4.402).
11. **hERG:** Ligand A (0.253) has a lower hERG risk than Ligand B (0.768). This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand A (33.902) has a lower microsomal clearance than Ligand B (85.965), suggesting better metabolic stability. This favors Ligand A.
13. **t1/2:** Ligand B (34.601) has a longer in vitro half-life than Ligand A (-42.967). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.144) has lower P-gp efflux than Ligand B (0.581). This favors Ligand A.
15. **Affinity:** Ligand B (-6.5 kcal/mol) has a slightly better binding affinity than Ligand A (-7.0 kcal/mol). While Ligand A has a better affinity, the difference is not substantial enough to outweigh other factors.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand B appears to be the better candidate. While Ligand A has advantages in hERG, Cl_mic, and Pgp, Ligand B excels in TPSA, DILI risk, BBB, and has a longer half-life. The lower DILI risk and better TPSA are particularly important. The slightly higher logP of Ligand B is a minor concern that could be addressed with further optimization. The difference in affinity is not large enough to overcome the other advantages of Ligand B.
Output:
0
2025-04-17 23:22:38,197 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (357.3 and 352.5 Da) fall comfortably within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (48.42) is significantly better than Ligand B (70.67). For a GPCR, lower TPSA is generally preferred for better permeability. Ligand A is well below the 140 threshold, while Ligand B is approaching it.
3. **logP:** Both ligands have similar logP values (4.475 and 4.122), both are slightly above the optimal range of 1-3, but not drastically so. This isn't a major differentiating factor.
4. **HBD:** Ligand A has 0 HBD, while Ligand B has 2. Lower is generally preferred for permeability, giving a slight edge to Ligand A.
5. **HBA:** Both ligands have 4 HBA, which is within the acceptable limit of 10.
6. **QED:** Ligand B (0.656) has a slightly better QED score than Ligand A (0.598), suggesting a marginally more drug-like profile.
7. **DILI:** Ligand B (74.952) has a higher DILI risk than Ligand A (62.776). Both are above the 60 threshold, indicating a concern, but Ligand A is preferable.
8. **BBB:** Ligand A (73.323) has a significantly better BBB penetration score than Ligand B (46.762). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant for off-target effects and overall safety assessment. This is a significant advantage for Ligand A.
9. **Caco-2:** Ligand A (-4.289) has a worse Caco-2 permeability than Ligand B (-5.429). Lower values indicate poorer permeability. Ligand B is preferable here.
10. **Solubility:** Ligand A (-5.576) has worse solubility than Ligand B (-3.935). Lower values indicate poorer solubility. Ligand B is preferable here.
11. **hERG:** Both ligands have similar hERG inhibition liabilities (0.534 and 0.636), indicating a similar risk profile.
12. **Cl_mic:** Ligand B (63.025) has lower microsomal clearance than Ligand A (100.051), suggesting better metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand B (-31.507) has a much longer in vitro half-life than Ligand A (-6.584). This is a major advantage for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.451) has lower P-gp efflux liability than Ligand B (0.7). Lower efflux is generally preferred, giving an advantage to Ligand A.
15. **Binding Affinity:** Ligand A (-7.4) has a slightly better binding affinity than Ligand B (-5.6). This is a significant advantage for Ligand A, and can often outweigh minor ADME drawbacks.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand A appears to be the better candidate. While Ligand B has advantages in metabolic stability (Cl_mic, t1/2), solubility and Caco-2 permeability, Ligand A's superior TPSA, BBB penetration, lower DILI risk, and significantly stronger binding affinity are more critical for a GPCR target like ADRB2. The affinity difference is substantial (>1.5 kcal/mol), and the better TPSA and BBB profile are highly desirable.
Output:
1
2025-04-17 23:22:38,197 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (335.451) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (46.92) is significantly better than Ligand B (78.87). ADRB2 is a cardiovascular target, not CNS, but lower TPSA is still beneficial for absorption. Ligand B is pushing the upper limit for good oral absorption.
3. **logP:** Ligand A (3.534) is optimal, while Ligand B (1.709) is on the lower side. For a GPCR, a slightly higher logP is often preferred for membrane interactions.
4. **HBD:** Ligand A (1) is better than Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (3) is better than Ligand B (4). Similar to HBD, fewer HBAs are preferred.
6. **QED:** Both are reasonably good (A: 0.648, B: 0.586), exceeding the 0.5 threshold.
7. **DILI:** Ligand B (3.218) is *much* better than Ligand A (45.87). This is a significant advantage for Ligand B.
8. **BBB:** Both have reasonable BBB penetration, but Ligand B (80.807) is better than Ligand A (64.599). While ADRB2 isn't a CNS target, higher BBB is rarely detrimental.
9. **Caco-2:** Both are negative, indicating poor permeability. However, the scale is not provided, so it is difficult to interpret.
10. **Solubility:** Both are negative, indicating poor solubility. Similar to Caco-2, the scale is not provided.
11. **hERG:** Both are low risk (A: 0.53, B: 0.517).
12. **Cl_mic:** Ligand B (27.931) has significantly lower microsomal clearance, indicating better metabolic stability. This is a major advantage. Ligand A (86.072) is quite high.
13. **t1/2:** Ligand B (-26.14) has a negative half-life, which is concerning. Ligand A (7.301) is reasonable.
14. **Pgp:** Both are low efflux (A: 0.502, B: 0.076). Ligand B is slightly better.
15. **Binding Affinity:** Both have comparable binding affinity (-6.1 kcal/mol and -6.0 kcal/mol). The difference is negligible.
**GPCR-Specific Considerations:**
For ADRB2 (a cardiovascular GPCR), logP, TPSA, and metabolic stability (Cl_mic, t1/2) are key. Ligand A has a better logP and TPSA, but Ligand B has *much* better metabolic stability (lower Cl_mic) and a lower DILI risk. The negative half-life of Ligand B is a major concern, but the other advantages are substantial.
**Overall Assessment:**
While Ligand A has slightly better physicochemical properties (TPSA, logP), the significantly lower DILI risk and improved metabolic stability of Ligand B are more critical for a viable drug candidate. The negative half-life of Ligand B is a red flag that would require further investigation (e.g., exploring prodrug strategies), but the other advantages outweigh this concern.
Output:
0
2025-04-17 23:22:38,197 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (343.471 and 358.41 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (71.09) is significantly better than Ligand B (99.1). ADRB2 is a cardiovascular target, not CNS, but lower TPSA generally improves absorption. Ligand A is well below the 140 threshold, while B is approaching it.
3. **logP:** Ligand A (2.795) is within the optimal 1-3 range. Ligand B (-0.232) is *below* 1, which is a concern for permeability. This is a significant negative for Ligand B.
4. **HBD:** Both ligands have acceptable HBD counts (2 and 3, respectively), well below the 5 threshold.
5. **HBA:** Both ligands have acceptable HBA counts (3 and 5, respectively), well below the 10 threshold.
6. **QED:** Both ligands have good QED scores (0.507 and 0.63), indicating good drug-like properties.
7. **DILI:** Ligand A (34.393) has a slightly higher DILI risk than Ligand B (24.506), but both are below the concerning 60 threshold.
8. **BBB:** Ligand A (55.293) has a lower BBB penetration than Ligand B (71.384). While not a primary concern for a cardiovascular target, higher BBB is generally favorable.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.983 and -4.876), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-2.365) has slightly worse solubility than Ligand B (-1.309), but both are poor.
11. **hERG:** Both ligands have low hERG risk (0.489 and 0.337).
12. **Cl_mic:** Ligand A (53.208) has a higher microsomal clearance than Ligand B (-19.355). The negative value for B suggests very high metabolic stability, which is a major advantage.
13. **t1/2:** Ligand A (14.072) has a longer in vitro half-life than Ligand B (-10.585). Again, the negative value for B is unusual and suggests very long half-life.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.104 and 0.025).
15. **Binding Affinity:** Ligand B (-8.8 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.8 kcal/mol) - a difference of 2.0 kcal/mol. This is a substantial advantage that can outweigh some ADME concerns.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has better TPSA, but Ligand B excels in logP and *significantly* in binding affinity. The metabolic stability (Cl_mic) of Ligand B is also a major plus. While the Caco-2 and solubility are poor for both, the affinity difference is large enough to make Ligand B more promising.
**Conclusion:**
Despite some ADME drawbacks, the significantly stronger binding affinity of Ligand B (-8.8 kcal/mol vs. -6.8 kcal/mol) and its superior metabolic stability make it the more promising drug candidate for the ADRB2 receptor.
Output:
0
2025-04-17 23:22:38,197 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [348.349, 67.43, 3.121, 2, 3, 0.843, 81.427, 73.362, -4.347, -4.308, 0.625, 45.19, 8.644, 0.181, -6.8]
**Ligand B:** [367.515, 78.6, 2.853, 2, 6, 0.771, 41.411, 79.721, -4.943, -3.703, 0.741, 81.729, -21.983, 0.121, -7.5]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity) are key:
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (348.349) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (67.43) is better than Ligand B (78.6), being closer to the <140 threshold for good absorption.
3. **logP:** Both are good (around 2.8-3.1), falling within the optimal 1-3 range.
4. **HBD/HBA:** Both have acceptable HBD counts (2). Ligand B has a higher HBA count (6 vs 3), which *could* slightly hinder permeability, but isn't a major concern.
5. **QED:** Ligand A (0.843) has a better QED score than Ligand B (0.771), indicating a more drug-like profile.
6. **DILI:** Ligand B (41.411) has a significantly lower DILI risk than Ligand A (81.427). This is a substantial advantage for Ligand B.
7. **BBB:** Both have good BBB penetration (73.362 & 79.721), but Ligand B is slightly better. This is relevant for a GPCR, but less critical for ADRB2 as it's primarily cardiovascular.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
9. **Solubility:** Both have negative solubility values, which is also unusual.
10. **hERG:** Both have low hERG inhibition risk (0.625 & 0.741).
11. **Cl_mic:** Ligand A (45.19) has a lower microsomal clearance than Ligand B (81.729), suggesting better metabolic stability.
12. **t1/2:** Ligand B (-21.983) has a much longer in vitro half-life than Ligand A (8.644). This is a significant advantage for dosing convenience.
13. **Pgp:** Both have low Pgp efflux liability (0.181 & 0.121).
14. **Affinity:** Ligand B (-7.5) has a stronger binding affinity than Ligand A (-6.8). This is a 0.7 kcal/mol difference, which is significant enough to outweigh some ADME concerns.
**Overall Assessment:**
Ligand B is the stronger candidate. While Ligand A has a slightly better TPSA and QED, Ligand B's significantly better DILI profile, longer half-life, and stronger binding affinity are more important for a viable drug candidate. The affinity difference is substantial enough to compensate for the slightly higher TPSA and lower QED. The negative solubility and Caco-2 values are concerning for both, but the affinity and metabolic stability of Ligand B are more compelling.
Output:
0
2025-04-17 23:22:38,198 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [336.326, 76.97, 3.493, 1, 6, 0.617, 91.857, 33.579, -5.001, -4.089, 0.527, 77.077, -60.697, 0.304, -8.6]
**Ligand B:** [354.491, 78.87, 1.848, 2, 4, 0.662, 15.587, 51.532, -4.372, -2.354, 0.308, 46.291, -17.174, 0.195, -6.9]
Here's a step-by-step comparison, keeping GPCR priorities (logP, Pgp, TPSA, affinity) in mind:
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (336.326) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are good (below 140), but Ligand A (76.97) is better than Ligand B (78.87), suggesting better potential for oral absorption.
3. **logP:** Ligand A (3.493) is optimal. Ligand B (1.848) is a bit low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (6) is preferable to Ligand B (4). Fewer HBAs generally improve permeability.
6. **QED:** Both are acceptable (above 0.5), with Ligand B (0.662) being slightly better.
7. **DILI:** Ligand A (91.857) has a very high DILI risk, which is a major concern. Ligand B (15.587) has a low DILI risk, a significant advantage.
8. **BBB:** Ligand A (33.579) has poor BBB penetration. Ligand B (51.532) is better, but still not ideal for a CNS-targeting drug (though ADRB2 is cardiovascular, some CNS off-target effects are possible).
9. **Caco-2:** Both have negative values, which is unusual. Assuming these are log scale values, lower values indicate poorer permeability. Ligand A (-5.001) is worse than Ligand B (-4.372).
10. **Solubility:** Both have negative values, indicating poor solubility. Ligand B (-2.354) is better than Ligand A (-4.089).
11. **hERG:** Both have low hERG inhibition risk, which is good. Ligand A (0.527) is slightly higher than Ligand B (0.308).
12. **Cl_mic:** Ligand B (46.291) has lower microsomal clearance, indicating better metabolic stability than Ligand A (77.077).
13. **t1/2:** Ligand B (-17.174) has a longer in vitro half-life than Ligand A (-60.697).
14. **Pgp:** Ligand A (0.304) has lower P-gp efflux, which is favorable. Ligand B (0.195) is even better.
15. **Affinity:** Ligand A (-8.6 kcal/mol) has significantly better binding affinity than Ligand B (-6.9 kcal/mol). This is a substantial advantage.
**Overall Assessment:**
Ligand A has a much better binding affinity and Pgp profile, but suffers from a very high DILI risk and poor metabolic stability. Ligand B has a much better safety profile (DILI, Cl_mic, t1/2) and slightly better solubility, but weaker binding affinity and higher Pgp efflux.
Given the critical importance of safety in drug development, and the fact that the affinity difference, while significant, isn't *massive* (1.7 kcal/mol), I would prioritize Ligand B. The DILI risk associated with Ligand A is a major red flag that would likely halt its development. While the affinity of Ligand A is attractive, it's not worth the potential for severe liver toxicity.
Output:
0
2025-04-17 23:22:38,198 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (339.49 & 345.44 Da) are within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (46.84) is significantly better than Ligand B (74.43). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold. Ligand B is approaching the upper limit.
3. **logP:** Ligand A (3.69) is optimal, while Ligand B (1.57) is on the lower side. For a GPCR, a slightly higher logP is generally preferred for membrane permeability and receptor engagement.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (3). Fewer HBAs generally improve permeability.
6. **QED:** Both ligands are very similar (0.837 vs 0.822), indicating good drug-like properties.
7. **DILI:** Ligand A (46.30) has a higher DILI risk than Ligand B (11.63). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (87.55) has better BBB penetration than Ligand B (71.97). While not critical for a cardiovascular target, it's a slight positive for Ligand A.
9. **Caco-2:** Both ligands have very poor Caco-2 permeability (-4.88 and -4.83). This is a major concern for both.
10. **Solubility:** Both ligands have poor aqueous solubility (-2.83 and -2.67). This is also a concern for both.
11. **hERG:** Both ligands have similar, low hERG risk (0.86 and 0.53).
12. **Cl_mic:** Ligand A (65.45) has a higher microsomal clearance than Ligand B (13.68). This means Ligand B is more metabolically stable, a significant advantage.
13. **t1/2:** Ligand A (6.08) has a longer in vitro half-life than Ligand B (-19.93). This is a significant advantage for Ligand A.
14. **Pgp:** Both ligands have very low Pgp efflux (0.58 and 0.03).
15. **Binding Affinity:** Ligand B (-6.5) has a slightly better binding affinity than Ligand A (-6.0). While the difference is not huge, it is still a positive for Ligand B.
**Overall Assessment:**
Ligand B has a significantly better safety profile (lower DILI) and metabolic stability (lower Cl_mic). Ligand A has a better half-life, slightly better BBB penetration, and a lower TPSA. The binding affinity difference is relatively small. Given the importance of metabolic stability and safety for a chronic cardiovascular condition, and the relatively small advantage in affinity for Ligand B, I favor Ligand B. The poor Caco-2 and solubility are concerns for both, but can be addressed with formulation strategies.
Output:
0
2025-04-17 23:22:38,198 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, prioritizing logP, TPSA, Pgp, and affinity is crucial.
**Molecular Weight:** Both ligands (354.5 & 363.5 Da) fall within the ideal 200-500 Da range.
**TPSA:** Ligand A (69.64) is slightly higher than Ligand B (63.13), but both are well below the 140 A^2 threshold for good oral absorption.
**logP:** Both ligands have good logP values (3.109 and 2.634), falling within the optimal 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability, but not significantly.
**H-Bond Donors/Acceptors:** Both have acceptable HBD (2) and HBA (3/4) counts, well within the guidelines.
**QED:** Both ligands have good QED scores (0.704 and 0.817), indicating good drug-likeness.
**DILI:** Ligand B (47.89%) has a significantly lower DILI risk than Ligand A (9.97%). This is a major advantage for Ligand B.
**BBB:** Ligand A (65.8%) has a higher BBB penetration score than Ligand B (55.02%). While not a primary concern for a cardiovascular target, it's a slight positive for Ligand A.
**Caco-2 Permeability:** Ligand A (-4.587) shows better Caco-2 permeability than Ligand B (-5.325), indicating better intestinal absorption.
**Aqueous Solubility:** Both ligands have poor aqueous solubility (-2.692 and -2.938). This is a potential issue for both, but not a deciding factor.
**hERG Inhibition:** Ligand A (0.588) has a slightly lower hERG inhibition liability than Ligand B (0.239), which is preferable.
**Microsomal Clearance:** Ligand B (37.589) has a lower microsomal clearance than Ligand A (58.17), indicating better metabolic stability.
**In vitro Half-Life:** Ligand B (12.611 hours) has a significantly longer in vitro half-life than Ligand A (-3.926 hours). This is a substantial advantage for Ligand B.
**P-gp Efflux:** Both ligands have low P-gp efflux liability (0.121 and 0.171).
**Binding Affinity:** Ligand A (-7.1 kcal/mol) has a slightly better binding affinity than Ligand B (-5.5 kcal/mol). This is a 1.6 kcal/mol difference, which is substantial and a significant advantage for Ligand A.
**Overall Assessment:**
While Ligand A has a better binding affinity and Caco-2 permeability, Ligand B demonstrates a much more favorable safety profile (lower DILI) and better metabolic stability (lower Cl_mic, longer t1/2). The affinity difference, while notable, can potentially be optimized in later stages of drug development. The lower DILI and improved metabolic stability of Ligand B are more critical for a viable drug candidate, especially considering the cardiovascular target.
**Output:**
0
2025-04-17 23:22:38,198 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (347.415 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are below the 140 A^2 threshold for good oral absorption. Ligand A (84.67 A^2) is slightly better.
3. **logP:** Both are within the optimal 1-3 range. Ligand B (1.049) is slightly lower, potentially impacting permeability, but still acceptable.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 5 HBA, while Ligand B has 9. Ligand A is preferable here, as higher HBA can sometimes reduce permeability.
6. **QED:** Ligand A (0.839) has a significantly better QED score than Ligand B (0.566), indicating a more drug-like profile.
7. **DILI:** Ligand A (56.572) has a lower DILI risk than Ligand B (67.507), which is a significant advantage.
8. **BBB:** Both have moderate BBB penetration, but Ligand B (69.058) is slightly higher. For a cardiovascular target like ADRB2, BBB penetration is not a primary concern, so this difference is less critical.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and requires further investigation. However, the magnitude of negativity is similar.
10. **Solubility:** Both have negative solubility values, which is also unusual and indicates poor aqueous solubility. Ligand B (-1.795) is slightly worse than Ligand A (-2.19).
11. **hERG:** Both have low hERG inhibition liability, which is good. Ligand A (0.23) is slightly better.
12. **Cl_mic:** Ligand A (47.77 mL/min/kg) has a lower microsomal clearance than Ligand B (76.814 mL/min/kg), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-16.948 hours) has a negative half-life, which is impossible. Ligand B (6.226 hours) is reasonable. This is a major red flag for Ligand A.
14. **Pgp:** Both have low P-gp efflux liability, which is good.
15. **Binding Affinity:** Ligand A (-7.4 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.1 kcal/mol). This is a substantial advantage.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Both ligands perform reasonably well on logP and Pgp. Ligand A has a better TPSA. The difference in affinity is significant (-7.4 vs -6.1 kcal/mol). However, the negative half-life for Ligand A is a critical flaw.
**Conclusion:**
Despite Ligand A's superior binding affinity and some better ADME properties (TPSA, DILI, Cl_mic, hERG), the *impossible* negative in vitro half-life is a deal-breaker. This suggests a significant issue with the experimental data or the molecule's inherent instability. Ligand B, while not ideal, has a reasonable half-life and acceptable overall properties.
Output:
0
2025-04-17 23:22:38,198 - INFO - Here's my reasoning and the final output:
**Reasoning:**
Both ligands are relatively similar in molecular weight (around 346 Da), falling within the ideal range. Let's break down the comparison, prioritizing GPCR-relevant properties (logP, TPSA, Pgp, BBB, and affinity).
1. **Molecular Weight:** Both are good (around 346 Da).
2. **TPSA:** Both are around 50, acceptable for a non-CNS GPCR like ADRB2.
3. **logP:** Ligand A (3.356) is slightly higher than Ligand B (2.358). While both are within the optimal range, A's higher logP could potentially lead to better membrane permeability.
4. **H-Bond Donors/Acceptors:** Ligand A has 1 HBD and 2 HBA, while Ligand B has 0 HBD and 3 HBA. This is fairly similar and doesn't strongly favor either.
5. **QED:** Ligand A (0.848) has a better QED score than Ligand B (0.734), indicating better overall drug-likeness.
6. **DILI:** Ligand B (28.306) has a significantly lower DILI risk than Ligand A (15.936), a substantial advantage.
7. **BBB:** Both have high BBB penetration (Ligand A: 81.698, Ligand B: 82.474), but this is less critical for ADRB2 as it's not a CNS target.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual. Assuming these are percentile scores, higher is better, and Ligand B (-4.433) is slightly better than Ligand A (-4.768).
9. **Solubility:** Ligand B (-2.459) has slightly better solubility than Ligand A (-3.882).
10. **hERG:** Both have low hERG inhibition liability (Ligand A: 0.473, Ligand B: 0.257), with Ligand B being slightly better.
11. **Cl_mic:** Ligand B (46.24) has a lower microsomal clearance than Ligand A (51.979), suggesting better metabolic stability.
12. **t1/2:** Ligand B (-18.723) has a much longer in vitro half-life than Ligand A (-7.157), a significant advantage.
13. **Pgp:** Both have low Pgp efflux (Ligand A: 0.178, Ligand B: 0.217), which is good.
14. **Binding Affinity:** Ligand A (-6.9 kcal/mol) has a slightly better binding affinity than Ligand B (-6.0 kcal/mol), a 0.9 kcal/mol difference.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity and QED, Ligand B demonstrates a superior safety profile (lower DILI, hERG) and better pharmacokinetic properties (lower Cl_mic, longer t1/2). The difference in binding affinity (0.9 kcal/mol) is not substantial enough to outweigh the significant advantages of Ligand B in terms of safety and PK. For a cardiovascular target like ADRB2, metabolic stability and reduced off-target effects are crucial.
**Output:**
0
2025-04-17 23:22:38,198 - INFO - Batch 400 complete. Total preferences: 6400
2025-04-17 23:22:38,198 - INFO - Processing batch 401/512...
2025-04-17 23:23:29,635 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (366.853 Da and 383.857 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (95.91) is slightly higher than Ligand B (87.74). Both are acceptable for a non-CNS GPCR target like ADRB2, being under 140. Ligand B is preferable.
3. **logP:** Both ligands have good logP values (1.396 and 1.477), falling within the optimal 1-3 range. No clear advantage.
4. **HBD:** Both ligands have 2 H-bond donors, which is within the acceptable limit of 5. No difference.
5. **HBA:** Both ligands have 5 H-bond acceptors, also within the acceptable limit of 10. No difference.
6. **QED:** Ligand B (0.824) has a higher QED score than Ligand A (0.69), indicating a more drug-like profile. This is a positive for Ligand B.
7. **DILI:** Ligand A (61.807) has a lower DILI risk than Ligand B (75.688). This is a significant advantage for Ligand A, as lower DILI is crucial.
8. **BBB:** ADRB2 is primarily a cardiovascular target, so BBB penetration is not a major priority. Ligand B (55.487) has a higher BBB value than Ligand A (32.532), but this is less important here.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the value for Ligand B (-4.951) is slightly less negative than Ligand A (-5.535), suggesting marginally better absorption.
10. **Solubility:** Ligand A (-2.237) has a slightly better solubility score than Ligand B (-3.625). Solubility is important for bioavailability.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.224 and 0.186). This is excellent and not a differentiating factor.
12. **Cl_mic:** Ligand B (-17.75) has significantly lower microsomal clearance than Ligand A (31.543), indicating much better metabolic stability. This is a major advantage for Ligand B.
13. **t1/2:** Ligand B (-16.557) has a much longer in vitro half-life than Ligand A (28.349). This is a significant advantage for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.139 and 0.076). No significant difference.
15. **Binding Affinity:** Ligand B (-7.7 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.5 kcal/mol). This 1.2 kcal/mol difference is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand B clearly wins out due to its superior binding affinity, significantly better metabolic stability (lower Cl_mic, longer t1/2), and higher QED score. While Ligand A has a lower DILI risk, the improved potency and pharmacokinetic properties of Ligand B are more critical for a successful drug candidate, especially considering the relatively low DILI risk of Ligand A is still acceptable. The slightly better solubility of Ligand A is a minor benefit compared to the substantial advantages of Ligand B.
Output:
0
2025-04-17 23:23:29,636 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (376.469 and 340.475 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (67.43 and 65.97) are below the 140 A^2 threshold for good oral absorption. They are also reasonably low, suitable for a GPCR target. No significant difference.
3. **logP:** Both ligands (2.995 and 3.549) are within the optimal 1-3 range. Ligand B is slightly higher, which *could* be a minor drawback if it leads to off-target effects, but it's still acceptable.
4. **HBD:** Both ligands have 2 H-bond donors, well within the acceptable limit of 5.
5. **HBA:** Ligand A has 4 H-bond acceptors, and Ligand B has 6. Both are under the limit of 10.
6. **QED:** Both ligands have good QED scores (0.733 and 0.868), indicating good drug-like properties. Ligand B is slightly better here.
7. **DILI:** Ligand A (42.458) has a lower DILI risk than Ligand B (63.513). This is a significant advantage for Ligand A.
8. **BBB:** Both ligands have good BBB penetration (76.658 and 77.937). This is important for GPCRs and is similar for both.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.78 and -4.903). This is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Both ligands have negative solubility values (-3.314 and -4.69). This is also a significant concern, indicating very poor aqueous solubility.
11. **hERG:** Both ligands have low hERG risk (0.661 and 0.81). This is good.
12. **Cl_mic:** Ligand A (59.528) has lower microsomal clearance than Ligand B (81.865), indicating better metabolic stability. This is a positive for Ligand A.
13. **t1/2:** Ligand B (33.362) has a longer in vitro half-life than Ligand A (19.322). This is a positive for Ligand B.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.105 and 0.238). This is good.
15. **Binding Affinity:** Both ligands have the same binding affinity (-6.1 kcal/mol), which is very good.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, Pgp, TPSA, and affinity. Both ligands perform similarly on logP, Pgp, TPSA, and affinity. However, the DILI risk for Ligand A is significantly lower, and its metabolic stability (Cl_mic) is better. While Ligand B has a slightly better QED and half-life, the poor solubility and Caco-2 values are concerning for both. The lower DILI risk and better metabolic stability of Ligand A are more critical for overall drug development success.
**Conclusion:**
Considering the balance of properties, and prioritizing the lower DILI risk and better metabolic stability, Ligand A is the more promising candidate despite the poor solubility and Caco-2 values. These can be addressed with formulation strategies.
Output:
1
2025-04-17 23:23:29,636 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (351.491 and 344.415 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (69.72) is significantly better than Ligand B (80.37). ADRB2 is not a CNS target, but lower TPSA generally favors absorption.
3. **logP:** Both ligands (1.787 and 1.992) are within the optimal 1-3 range. Very similar.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 3 HBA, while Ligand B has 5. Ligand A is preferable here, as fewer HBA generally improves permeability.
6. **QED:** Ligand B (0.92) has a better QED score than Ligand A (0.678), indicating a more drug-like profile overall. This is a point in favor of Ligand B.
7. **DILI:** Ligand A (11.128) has a *much* lower DILI risk than Ligand B (45.25). This is a critical advantage for Ligand A.
8. **BBB:** Not a high priority for ADRB2 (cardiovascular target). Ligand A (81.892) is better than Ligand B (68.631), but this isn't a deciding factor.
9. **Caco-2:** Both are negative, indicating poor permeability. This is a concern for both, but the negative values are very close.
10. **Solubility:** Both are negative, indicating poor solubility. This is a concern for both, but the negative values are very close.
11. **hERG:** Both ligands have low hERG inhibition risk (0.495 and 0.317). No significant difference.
12. **Cl_mic:** Ligand A (26.756) has lower microsomal clearance than Ligand B (30.164), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-21.275) has a much longer in vitro half-life than Ligand A (-2.827). This is a significant advantage for Ligand B.
14. **Pgp:** Both have very low Pgp efflux liability (0.079 and 0.185). No significant difference.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.7 and -6.6 kcal/mol). The difference is negligible.
**GPCR-Specific Priorities & Overall Assessment:**
For a cardiovascular GPCR like ADRB2, logP, TPSA, and affinity are important. Both ligands perform similarly on logP and affinity. Ligand A has a significantly better TPSA. However, the biggest differentiating factors are DILI risk and metabolic stability. Ligand A has a dramatically lower DILI risk, which is a major safety advantage. While Ligand B has a better half-life, the DILI risk associated with Ligand B is concerning. A longer half-life is less valuable if the compound is likely to cause liver injury.
**Conclusion:**
Considering the balance of properties, especially the significantly lower DILI risk, Ligand A is the more promising drug candidate.
Output:
1
2025-04-17 23:23:29,636 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (363.464 and 364.823 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (29.54) is better than Ligand B (33.2). Both are well below the 140 threshold for oral absorption, and suitable for a GPCR.
3. **logP:** Both ligands (4.451 and 4.192) are slightly above the optimal 1-3 range, but still acceptable. Ligand B is slightly better. High logP can sometimes lead to off-target effects, but is less of a concern than poor solubility.
4. **HBD:** Both ligands have 0 HBD, which is good.
5. **HBA:** Both ligands have 2 HBA, which is good.
6. **QED:** Ligand B (0.72) is better than Ligand A (0.596). A higher QED suggests better overall drug-likeness.
7. **DILI:** Ligand A (21.365) has a significantly lower DILI risk than Ligand B (33.773). This is a major advantage for Ligand A.
8. **BBB:** Both ligands have high BBB penetration (96.161 and 93.718). This is less critical for ADRB2 (a cardiovascular target) but not detrimental.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.412 and -4.319). This is unusual and suggests very poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand A (-4.192) is better than Ligand B (-5.039), indicating slightly better aqueous solubility.
11. **hERG:** Both ligands have low hERG inhibition risk (0.888 and 0.677).
12. **Cl_mic:** Ligand B (55.945) has lower microsomal clearance than Ligand A (70.697), indicating better metabolic stability.
13. **t1/2:** Ligand A (20.356) has a significantly longer in vitro half-life than Ligand B (0.826). This is a major advantage for Ligand A.
14. **Pgp:** Ligand A (0.644) has lower P-gp efflux liability than Ligand B (0.449), which is favorable.
15. **Binding Affinity:** Ligand B (-7.3 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.1 kcal/mol). This is a substantial advantage for Ligand B, potentially outweighing some ADME drawbacks.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Both ligands have reasonable logP and TPSA. Ligand B has a much better binding affinity, which is a major plus. Pgp is slightly better for Ligand A.
**Overall Assessment:**
Ligand B has a significantly better binding affinity (-7.3 vs -6.1 kcal/mol). While Ligand A has advantages in DILI risk, half-life, and solubility, the substantial difference in binding affinity is the most critical factor for a GPCR target. The lower metabolic stability of Ligand B could be addressed through structural modifications. The poor Caco-2 values for both are concerning, but could be a result of the assay or modeling limitations.
Output:
0
2025-04-17 23:23:29,636 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Ligand A (369.8) is within the ideal range (200-500), while Ligand B (347.4) is also good. No clear advantage here.
2. **TPSA:** Ligand A (94.7) is better than Ligand B (111.9). Both are acceptable, but lower TPSA generally favors absorption.
3. **logP:** Ligand A (3.0) is optimal, while Ligand B (-0.37) is quite low and could hinder membrane permeability. This is a significant advantage for A.
4. **HBD:** Ligand A (1) is good, Ligand B (3) is acceptable but slightly higher.
5. **HBA:** Ligand A (6) is good, Ligand B (5) is also good.
6. **QED:** Both Ligand A (0.586) and Ligand B (0.629) are above the 0.5 threshold, indicating good drug-likeness. B is slightly better.
7. **DILI:** Ligand A (84.2) is higher risk than Ligand B (51.0). This is a significant drawback for A.
8. **BBB:** Both are around 50, so not particularly high. This isn't a major concern for a cardiovascular target like ADRB2.
9. **Caco-2:** Ligand A (-4.48) is better than Ligand B (-5.57), indicating better absorption.
10. **Solubility:** Ligand A (-4.71) is better than Ligand B (-1.89), which is a significant advantage.
11. **hERG:** Ligand A (0.33) is better than Ligand B (0.23), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand A (89.2) is higher (less favorable) than Ligand B (-20.0). B has significantly better metabolic stability.
13. **t1/2:** Ligand A (9.18) is better than Ligand B (45.27), but the units are different (hours vs percentile). Assuming percentile is relative to a desirable range, B is better.
14. **Pgp:** Ligand A (0.10) is better than Ligand B (0.01), indicating less efflux.
15. **Affinity:** Ligand B (-6.8) is significantly better than Ligand A (-3.7). This is a >1.5 kcal/mol advantage, which is very important.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are prioritized. Ligand A has a better logP and TPSA, and Pgp. However, Ligand B has a *much* stronger binding affinity, which is the most important factor. While Ligand A has better solubility and lower hERG risk, the significant difference in affinity outweighs these benefits. The DILI risk for Ligand A is also concerning.
**Conclusion:**
Despite the higher DILI risk and worse metabolic stability, the significantly stronger binding affinity of Ligand B makes it the more promising drug candidate for ADRB2.
Output:
0
2025-04-17 23:23:29,636 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [346.391, 134.65 , -0.687, 3. , 5. , 0.666, 44.126, 58.511, -5.406, -1.838, 0.152, -17.951, -11.261, 0.002, -5.7 ]
**Ligand B:** [355.498, 52.65 , 2.211, 1. , 3. , 0.762, 14.541, 91.974, -4.638, -2.291, 0.892, 8.743, -16.144, 0.229, -6.7 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (346.391) is slightly lower, which is generally favorable for permeability, but both are acceptable.
2. **TPSA:** Ligand A (134.65) is better than Ligand B (52.65), being closer to the <140 threshold for good oral absorption. Ligand B is very low, which is good, but might indicate a lack of necessary interactions.
3. **logP:** Ligand B (2.211) is within the optimal range (1-3), while Ligand A (-0.687) is below 1, potentially hindering permeation. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (3) is higher than Ligand B (1), but both are acceptable (<=5).
5. **HBA:** Both ligands have 3 HBA, which is well within the acceptable limit of <=10.
6. **QED:** Both ligands have good QED scores (A: 0.666, B: 0.762), indicating a generally drug-like profile. Ligand B is slightly better.
7. **DILI:** Ligand A (44.126) has a higher DILI risk than Ligand B (14.541). This is a significant advantage for Ligand B.
8. **BBB:** Ligand B (91.974) has a much higher BBB penetration score than Ligand A (58.511). While ADRB2 isn't a CNS target, higher BBB is generally favorable for reducing off-target effects.
9. **Caco-2:** Ligand A (-5.406) and Ligand B (-4.638) are both negative, which is unusual and suggests poor permeability.
10. **Solubility:** Ligand A (-1.838) and Ligand B (-2.291) are both negative, suggesting poor solubility.
11. **hERG:** Ligand A (0.152) has a lower hERG risk than Ligand B (0.892), which is a positive.
12. **Cl_mic:** Ligand A (-17.951) has a much lower (better) microsomal clearance than Ligand B (8.743), indicating greater metabolic stability.
13. **t1/2:** Ligand B (-16.144) has a longer in vitro half-life than Ligand A (-11.261).
14. **Pgp:** Ligand A (0.002) has significantly lower P-gp efflux liability than Ligand B (0.229), which is favorable for bioavailability.
15. **Affinity:** Both ligands have similar binding affinities (-5.7 kcal/mol and -6.7 kcal/mol, respectively). Ligand B is slightly better, but the difference isn't huge.
**GPCR-specific priorities:** For ADRB2, we prioritize logP, Pgp, TPSA, and affinity. Ligand B excels in logP and BBB, and has a better QED and DILI profile. Ligand A has better Pgp and hERG, but suffers from a poor logP and higher DILI risk. The metabolic stability of Ligand A is a plus, but the poor logP is a major concern.
**Conclusion:**
Considering the balance of properties, especially the crucial logP and DILI scores, **Ligand B** appears to be the more promising drug candidate. The slightly better affinity, higher BBB, and lower DILI risk outweigh the slightly higher Pgp efflux and lower metabolic stability.
```
0
```
2025-04-17 23:23:29,636 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [345.447, 71.76, 2.466, 1, 5, 0.924, 39.046, 90.578, -4.713, -2.519, 0.605, 25.735, 17.856, 0.139, -5.7]
**Ligand B:** [359.539, 38.25, 4.589, 0, 5, 0.622, 20.9, 85.498, -4.822, -4.786, 0.786, 90.89, -9.667, 0.531, -5.5]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, Affinity, and to a lesser extent BBB):
1. **MW:** Both are within the ideal range (200-500 Da). A is 345.447, B is 359.539. No significant difference.
2. **TPSA:** A (71.76) is higher than B (38.25). B is significantly better, falling well below the 140 threshold for oral absorption and closer to the ideal for GPCRs.
3. **logP:** A (2.466) is optimal. B (4.589) is pushing the upper limit and could lead to solubility issues or off-target interactions.
4. **HBD:** A (1) is good. B (0) is also good. No significant difference.
5. **HBA:** Both are at 5, which is acceptable.
6. **QED:** A (0.924) is excellent, indicating very drug-like properties. B (0.622) is still acceptable, but lower.
7. **DILI:** A (39.046) is very good, indicating low liver injury risk. B (20.9) is even better.
8. **BBB:** A (90.578) is excellent. B (85.498) is also good, but slightly lower. While not a CNS target, some level of BBB penetration can be useful for distribution.
9. **Caco-2:** Both are negative, indicating good permeability. No significant difference.
10. **Solubility:** A (-2.519) is poor. B (-4.786) is even worse. This is a major concern for both.
11. **hERG:** Both are low (0.605 and 0.786), indicating low cardiotoxicity risk. No significant difference.
12. **Cl_mic:** A (25.735) is better (lower) than B (90.89), suggesting better metabolic stability.
13. **t1/2:** A (17.856) is better than B (-9.667). A longer half-life is generally preferred.
14. **Pgp:** A (0.139) is significantly better (lower efflux) than B (0.531). Lower Pgp is desirable for better bioavailability.
15. **Affinity:** Both are excellent (-5.7 and -5.5 kcal/mol). A is slightly better, but the difference is small.
**Overall Assessment:**
Ligand A has a better QED, metabolic stability (Cl_mic, t1/2), and Pgp efflux profile. Ligand B has a significantly lower TPSA and a slightly lower DILI risk. However, the solubility of both is poor, and the higher logP of Ligand B is concerning. Given the GPCR target class, the lower TPSA of Ligand B is attractive, but the better overall ADME profile of Ligand A, particularly the lower Pgp efflux, and slightly better affinity, outweigh this benefit. The solubility issue is a concern for both, but can be addressed with formulation strategies.
Therefore, I prefer Ligand A.
Output:
1
2025-04-17 23:23:29,636 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (359.455 and 351.447 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (89.77) is slightly higher than Ligand B (71.11). Both are below the 140 threshold for oral absorption, but B is better positioned for potential CNS penetration if desired.
3. **logP:** Ligand A (3.215) is within the optimal range (1-3), while Ligand B (1.815) is at the lower end. For a GPCR, a slightly higher logP can be beneficial for membrane interactions, giving A an edge.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 6 HBAs, while Ligand B has 4. Both are acceptable, but fewer is generally preferable for permeability. B is slightly better.
6. **QED:** Both ligands have good QED scores (0.755 and 0.824), indicating good drug-like properties. No clear advantage.
7. **DILI:** Ligand A has a significantly higher DILI risk (94.765%) compared to Ligand B (23.885%). This is a major concern for Ligand A.
8. **BBB:** Ligand B (73.75%) has a higher BBB penetration percentile than Ligand A (57.58%). While ADRB2 isn't strictly a CNS target, some CNS exposure can occur, and higher BBB is generally favorable.
9. **Caco-2:** Ligand A (-5.079) has a worse Caco-2 permeability than Ligand B (-4.206). Lower values indicate poorer permeability.
10. **Solubility:** Ligand A (-3.535) has worse solubility than Ligand B (-2.297). Solubility is important for bioavailability.
11. **hERG:** Both ligands have low hERG inhibition risk (0.579 and 0.406), which is good. B is slightly better.
12. **Cl_mic:** Ligand A (21.625) has a lower microsomal clearance than Ligand B (34.665), suggesting better metabolic stability. This is a positive for A.
13. **t1/2:** Ligand A (82.257) has a much longer in vitro half-life than Ligand B (16.737). This is a significant advantage for A, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.282) has lower P-gp efflux liability than Ligand B (0.02). Lower Pgp is better.
15. **Binding Affinity:** Ligand B (-7.7 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.8 kcal/mol). This is a substantial advantage for B, potentially outweighing some ADME concerns.
**Overall Assessment:**
Ligand B has a superior safety profile (much lower DILI risk) and better permeability/solubility characteristics. Its significantly stronger binding affinity is a major advantage. While Ligand A has better metabolic stability and a longer half-life, the high DILI risk is a critical drawback. The difference in binding affinity between B and A is substantial (>1.5 kcal/mol), and this outweighs the advantages of A's metabolic stability. Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand B is the more promising candidate.
Output:
0
2025-04-17 23:23:29,636 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (340.354 Da and 345.443 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Both ligands have TPSA values around 80, which is acceptable, but slightly above the optimal <140 for oral absorption and far from the <90 for CNS targets (not a primary concern for ADRB2, but still a consideration).
**3. logP:** Ligand A (3.941) is higher than Ligand B (1.755). For a GPCR, a logP between 1-3 is preferred. Ligand B is better here, being closer to the optimal range. Ligand A's higher logP *could* lead to off-target interactions or solubility issues.
**4. H-Bond Donors:** Ligand A (1) is better than Ligand B (2). Lower HBD generally improves permeability.
**5. H-Bond Acceptors:** Both ligands have 4 HBA, which is within the acceptable range.
**6. QED:** Ligand A (0.808) has a better QED score than Ligand B (0.705), indicating a more drug-like profile.
**7. DILI Risk:** Ligand B (35.091) has a significantly lower DILI risk than Ligand A (87.049). This is a *major* advantage for Ligand B. DILI is a critical safety concern.
**8. BBB Penetration:** Ligand B (55.176) has slightly better BBB penetration than Ligand A (48.042), but neither is particularly high. This isn't a primary concern for ADRB2, which isn't a CNS target.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, indicating poor permeability. This is a concern for both.
**10. Aqueous Solubility:** Ligand B (-2.199) has better aqueous solubility than Ligand A (-6.079). Solubility is important for formulation and bioavailability.
**11. hERG Inhibition:** Ligand B (0.161) has a much lower hERG inhibition risk than Ligand A (0.592). This is a significant safety advantage for Ligand B.
**12. Microsomal Clearance:** Ligand A (58.887) has higher microsomal clearance than Ligand B (4.285), meaning it's metabolized faster. Lower clearance is preferred for longer duration of action.
**13. In vitro Half-Life:** Ligand B (-9.257) has a much longer in vitro half-life than Ligand A (57.555). This is a substantial advantage for Ligand B.
**14. P-gp Efflux:** Ligand A (0.571) has lower P-gp efflux than Ligand B (0.088). Lower efflux is generally preferred.
**15. Binding Affinity:** Ligand A (-8.2 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.3 kcal/mol). This is a substantial advantage for Ligand A. A difference of nearly 2 kcal/mol is significant.
**Overall Assessment:**
While Ligand A boasts superior binding affinity, Ligand B demonstrates a much more favorable ADMET profile. The lower DILI risk, significantly reduced hERG inhibition, and longer half-life of Ligand B are critical advantages. The slightly lower logP and better solubility of Ligand B are also beneficial. The difference in binding affinity, while substantial, can potentially be overcome with further optimization, whereas mitigating the safety concerns of Ligand A would be far more challenging. Given the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), and the overriding importance of safety, I favor Ligand B.
Output:
0
2025-04-17 23:23:29,637 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (375.969 and 351.378 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (19.37) is significantly better than Ligand B (91.76). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand A is excellent, while Ligand B is quite high.
3. **logP:** Ligand A (4.77) is a bit high, potentially leading to solubility issues, but still within a manageable range. Ligand B (1.528) is on the lower side, which could hinder permeability. Considering the GPCR nature of the target, a slightly higher logP is preferable for membrane interactions.
4. **HBD:** Ligand A (0) is ideal. Ligand B (2) is acceptable, but fewer HBDs are generally preferred.
5. **HBA:** Ligand A (4) is good. Ligand B (5) is also acceptable.
6. **QED:** Both ligands have good QED scores (0.77 and 0.811), indicating generally drug-like properties.
7. **DILI:** Both ligands show low DILI risk (41.877 and 40.287 percentile), which is excellent.
8. **BBB:** Ligand A (92.051) has better BBB penetration than Ligand B (72.974). While not a primary concern for a cardiovascular target, it's a bonus.
9. **Caco-2:** Both ligands have similar, poor Caco-2 permeability (-4.876 and -4.822). This is a concern for both.
10. **Solubility:** Ligand A (-3.411) is better than Ligand B (-2.828), though both are quite poor. The higher logP of Ligand A is likely contributing to this.
11. **hERG:** Ligand A (0.939) has a slightly better hERG profile than Ligand B (0.205), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand B (6.465) has significantly lower microsomal clearance than Ligand A (24.134), suggesting better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand B (-33.405) has a much longer in vitro half-life than Ligand A (16.207). This is a major advantage, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.593) has lower P-gp efflux than Ligand B (0.035), which is favorable for bioavailability.
15. **Affinity:** Ligand B (-7.5 kcal/mol) has a slightly better binding affinity than Ligand A (-7.1 kcal/mol). While the difference is not huge, it is a meaningful advantage.
**Overall Assessment:**
Ligand B has a clear advantage in metabolic stability (lower Cl_mic and longer t1/2) and slightly better binding affinity. These are critical factors for a viable drug candidate. While Ligand A has better TPSA and Pgp efflux, the metabolic liabilities of Ligand A are concerning. The slightly lower logP of Ligand B is less ideal, but the benefits of improved metabolic stability and affinity outweigh this drawback.
Output:
0
2025-04-17 23:23:29,637 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (345.443 and 353.379 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (61.88) is significantly better than Ligand B (124.91). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally correlates with better absorption. Ligand B's TPSA is approaching the upper limit for good oral absorption.
3. **logP:** Ligand A (2.666) is within the optimal range (1-3). Ligand B (0.468) is quite low, potentially hindering membrane permeability and absorption. This is a significant negative for Ligand B.
4. **HBD:** Ligand A (1) is good. Ligand B (0) is also acceptable, but having one donor can sometimes improve solubility.
5. **HBA:** Ligand A (4) is good. Ligand B (6) is higher, but still within the acceptable limit of 10.
6. **QED:** Ligand A (0.834) is excellent, indicating a very drug-like profile. Ligand B (0.226) is poor, suggesting potential issues with developability.
7. **DILI:** Ligand A (38.891) is excellent, indicating low liver injury risk. Ligand B (46.413) is slightly higher, but still within an acceptable range.
8. **BBB:** Ligand A (83.637) is good, while Ligand B (70.105) is acceptable. Since ADRB2 isn't a CNS target, this isn't a major deciding factor.
9. **Caco-2:** Ligand A (-5.014) and Ligand B (-4.477) are both negative values, which is unusual. Assuming these are log scale values, they suggest very low permeability. However, the difference isn't substantial.
10. **Solubility:** Ligand A (-3.005) and Ligand B (-0.463) are both negative values, indicating poor solubility. Ligand B is slightly better.
11. **hERG:** Ligand A (0.74) is good, indicating low hERG inhibition liability. Ligand B (0.133) is even better.
12. **Cl_mic:** Ligand A (-1.61) is excellent, suggesting good metabolic stability. Ligand B (18.79) is high, indicating rapid metabolism and potentially low bioavailability.
13. **t1/2:** Ligand A (-1.395) is excellent, suggesting a long half-life. Ligand B (-20.487) is very poor, indicating a very short half-life.
14. **Pgp:** Ligand A (0.047) is very low, indicating minimal P-gp efflux. Ligand B (0.035) is also low.
15. **Affinity:** Ligand B (-8.0) is significantly better than Ligand A (-5.6). This is a substantial difference (2.4 kcal/mol), and a strong binding affinity can often outweigh some ADME deficiencies.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, and affinity. Ligand A has better TPSA and logP, while Ligand B has significantly better affinity. The affinity difference is large enough to be a key driver.
**Overall Assessment:**
While Ligand A has a more favorable overall ADME profile (better QED, lower DILI, better metabolic stability, longer half-life), Ligand B's substantially stronger binding affinity (-8.0 vs -5.6 kcal/mol) is a critical advantage for a GPCR target. The lower logP and QED of Ligand B are concerning, but these could potentially be addressed through further optimization *starting* with the potent scaffold of Ligand B. The poor metabolic stability and short half-life are also drawbacks, but again, optimization could improve these. The affinity difference is simply too large to ignore.
Output:
0
2025-04-17 23:23:29,637 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for their potential as drug candidates targeting the ADRB2, a cardiovascular GPCR. Therefore, we prioritize logP, TPSA, Pgp efflux, and binding affinity, alongside general drug-like properties.
* **Molecular Weight:** Both ligands (339.4 and 350.5 Da) fall within the ideal 200-500 Da range.
* **TPSA:** Ligand A (84.98) is better than Ligand B (78.43), both are below the 140 threshold for oral absorption.
* **logP:** Ligand A (1.462) is within the optimal 1-3 range, while Ligand B (2.541) is towards the higher end but still acceptable.
* **H-Bond Donors/Acceptors:** Ligand A (2 HBD, 6 HBA) is slightly better than Ligand B (3 HBD, 3 HBA) in terms of balancing solubility and permeability.
* **QED:** Ligand A (0.735) has a better QED score than Ligand B (0.589), indicating a more drug-like profile.
* **DILI:** Ligand A (53.59) has a significantly higher DILI risk than Ligand B (16.40). This is a major concern for Ligand A.
* **BBB:** Ligand A (76.04) has better BBB penetration than Ligand B (44.79), but BBB isn't a huge priority for a cardiovascular target.
* **Caco-2 Permeability:** Ligand A (-5.698) has worse Caco-2 permeability than Ligand B (-4.688).
* **Aqueous Solubility:** Ligand A (-1.767) has better aqueous solubility than Ligand B (-2.856).
* **hERG:** Both ligands have very low hERG inhibition risk (0.411 and 0.183 respectively).
* **Microsomal Clearance:** Ligand A (7.80) has lower microsomal clearance, indicating better metabolic stability, than Ligand B (44.91).
* **In vitro Half-Life:** Ligand A (50.76 hours) has a significantly longer half-life than Ligand B (9.73 hours).
* **P-gp Efflux:** Ligand A (0.116) has lower P-gp efflux than Ligand B (0.076), which is favorable for bioavailability.
* **Binding Affinity:** Ligand A (-7.5 kcal/mol) has a stronger binding affinity than Ligand B (-6.6 kcal/mol). This is a 0.9 kcal/mol difference, which is substantial.
**Overall Assessment:**
Ligand A has a superior binding affinity, better metabolic stability (lower Cl_mic, longer t1/2), better P-gp efflux, and better solubility. However, its significantly higher DILI risk is a major drawback. Ligand B has a much lower DILI risk, which is a critical safety parameter. The higher binding affinity of Ligand A is attractive, but the DILI risk outweighs this benefit, especially considering the relatively good affinity of Ligand B.
**Output:**
0
2025-04-17 23:23:29,637 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (345.491 and 337.431 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (64.86) is better than Ligand B (70.9), being closer to the <140 threshold for good oral absorption.
3. **logP:** Both ligands have good logP values (2.818 and 1.949) within the optimal 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability, but both are acceptable.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2) as lower HBD generally improves permeability.
5. **HBA:** Ligand A (6) is preferable to Ligand B (7) for the same reason as HBD.
6. **QED:** Ligand A (0.859) has a better QED score than Ligand B (0.716), indicating a more drug-like profile.
7. **DILI:** Ligand A (37.611) has a significantly lower DILI risk than Ligand B (62.35). This is a major advantage for Ligand A.
8. **BBB:** Both ligands have good BBB penetration (74.06 and 76.309), which is a positive for a GPCR target, though not critical for ADRB2 specifically.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual. However, the absolute values are similar (-5.363 vs -5.413), so this isn't a deciding factor.
10. **Solubility:** Both have negative solubility values, which is also unusual. Again, the values are similar (-3.022 vs -2.027).
11. **hERG:** Ligand A (0.285) has a much lower hERG inhibition liability than Ligand B (0.952). This is a significant safety advantage.
12. **Cl_mic:** Ligand A (26.235) has a lower microsomal clearance than Ligand B (29.155), suggesting better metabolic stability.
13. **t1/2:** Ligand A (7.654) has a longer in vitro half-life than Ligand B (0.853). This is a significant advantage for dosing convenience.
14. **Pgp:** Ligand A (0.134) has a lower P-gp efflux liability than Ligand B (0.042). This is a positive for bioavailability.
15. **Affinity:** Ligand A (-6.9 kcal/mol) has a slightly better binding affinity than Ligand B (-6.7 kcal/mol). While the difference is small, it contributes to the overall preference.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Both ligands perform well on logP and BBB. Ligand A is better on TPSA and Pgp. The small affinity difference favors Ligand A. Crucially, Ligand A has significantly better safety profiles regarding DILI and hERG.
**Conclusion:**
Ligand A consistently outperforms Ligand B across most critical parameters, especially in safety (DILI, hERG) and metabolic stability (Cl_mic, t1/2). The slightly better affinity and drug-likeness further solidify its position as the more promising candidate.
Output:
1
2025-04-17 23:23:29,637 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (343.362 and 348.491 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (55.89) is significantly better than Ligand A (101.21). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. This is a significant win for Ligand B.
3. **logP:** Ligand A (1.75) is slightly better than Ligand B (0.851), falling comfortably within the 1-3 range. Ligand B is a bit low, potentially impacting membrane permeability.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable.
5. **HBA:** Ligand A (5) and Ligand B (4) are both acceptable.
6. **QED:** Ligand A (0.827) is better than Ligand B (0.723), indicating a more drug-like profile.
7. **DILI:** Ligand B (8.375) is *much* better than Ligand A (85.964). This is a critical advantage for Ligand B. High DILI risk is a major red flag.
8. **BBB:** Both are around 62, so this isn't a deciding factor for a cardiovascular target.
9. **Caco-2:** Both are negative, indicating poor permeability. This is a concern for both.
10. **Solubility:** Both are negative, indicating poor solubility. This is a concern for both.
11. **hERG:** Ligand A (0.399) is slightly better than Ligand B (0.202), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand A (2.076) is better than Ligand B (3.023), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-17.79) is better than Ligand B (-14.1), indicating a longer half-life.
14. **Pgp:** Both are very low, indicating minimal P-gp efflux.
15. **Binding Affinity:** Ligand A (-7.7) is slightly better than Ligand B (-6.9), but the difference is less than 1.5 kcal/mol.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity, longer half-life, and better metabolic stability, the *dramatic* difference in DILI risk (8.375 vs 85.964) overwhelmingly favors Ligand B. The lower TPSA of Ligand B is also a significant advantage. The slightly lower logP of Ligand B is a minor concern, but the DILI risk is a showstopper for Ligand A. For a cardiovascular target, mitigating potential liver toxicity is crucial.
Output:
0
2025-04-17 23:23:29,637 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (357.845 and 360.889 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (73.95) is higher than Ligand B (61.02). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B is better.
3. **logP:** Ligand A (2.955) is within the optimal 1-3 range. Ligand B (4.173) is slightly above, potentially leading to solubility issues or off-target interactions, but still within a reasonable range. Ligand A is slightly better.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is preferable to Ligand B (3). Fewer HBAs generally improve permeability.
6. **QED:** Both ligands have good QED values (0.917 and 0.841), indicating good drug-like properties. No significant difference.
7. **DILI:** Ligand A (63.668) has a higher DILI risk than Ligand B (32.299). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (64.986) has lower BBB penetration than Ligand B (81.194). While ADRB2 isn't a primary CNS target, some peripheral exposure is acceptable, and higher BBB penetration isn't necessarily a negative. Ligand B is better.
9. **Caco-2:** Ligand A (-4.636) and Ligand B (-5.006) both have negative Caco-2 values, which is unusual and suggests very poor permeability. This is a major concern for both.
10. **Solubility:** Ligand A (-5.014) has slightly better solubility than Ligand B (-4.155), but both are very poor. This is a significant drawback for both.
11. **hERG:** Ligand A (0.389) has a lower hERG risk than Ligand B (0.943). This is a significant advantage for Ligand A, given the cardiovascular target.
12. **Cl_mic:** Ligand A (46.845) has a higher microsomal clearance than Ligand B (33.115), indicating lower metabolic stability. Ligand B is better.
13. **t1/2:** Ligand A (24.117) has a longer in vitro half-life than Ligand B (-8.902). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.145) has lower P-gp efflux than Ligand B (0.643). This is a significant advantage for Ligand A.
15. **Binding Affinity:** Ligand A (-7.7) has a slightly better binding affinity than Ligand B (-6.0). This is a significant advantage for Ligand A.
**Overall Assessment:**
Ligand A has a better binding affinity, longer half-life, lower P-gp efflux, and lower hERG risk. However, Ligand B has a much lower DILI risk and better BBB penetration. Both have poor Caco-2 and solubility. Given the cardiovascular target, minimizing hERG risk and maximizing potency are crucial. The significantly better binding affinity of Ligand A, coupled with its lower hERG risk, outweighs the advantages of Ligand B. The poor Caco-2 and solubility are concerning for both, but can be addressed with formulation strategies.
Output:
1
2025-04-17 23:23:29,637 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (358.463 and 367.852 Da) fall comfortably within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (69.64) is higher than Ligand B (51.39). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B has a slight advantage.
3. **logP:** Ligand A (2.807) is within the optimal 1-3 range. Ligand B (4.132) is a bit higher, potentially leading to solubility issues or off-target interactions. Ligand A is better.
4. **HBD:** Ligand A (2) is reasonable. Ligand B (0) is also acceptable. No strong preference.
5. **HBA:** Ligand A (4) is good. Ligand B (5) is also acceptable. No strong preference.
6. **QED:** Ligand A (0.883) is excellent, indicating high drug-likeness. Ligand B (0.688) is still acceptable, but lower. Ligand A is better.
7. **DILI:** Ligand A (47.15) has a slightly higher DILI risk than Ligand B (37.263), but both are below the concerning threshold of 60. Ligand B is slightly better.
8. **BBB:** Ligand A (41.683) is lower than Ligand B (91.043). While ADRB2 isn't a CNS target, some peripheral exposure is acceptable, so this isn't a major deciding factor, but B is better.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale isn't specified, so it's difficult to interpret.
10. **Solubility:** Both ligands have negative solubility values, which is also unusual. This suggests very low aqueous solubility.
11. **hERG:** Ligand A (0.518) has a lower hERG risk than Ligand B (0.821). This is a significant advantage for Ligand A, as hERG inhibition can cause cardiotoxicity.
12. **Cl_mic:** Ligand A (21.106) has a lower microsomal clearance than Ligand B (58.615), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (-11.891) has a negative half-life, which is not possible. Ligand B (49.746) has a good in vitro half-life. This is a major advantage for Ligand B.
14. **Pgp:** Ligand A (0.188) has lower P-gp efflux liability than Ligand B (0.679), which is favorable for bioavailability. Ligand A is better.
15. **Binding Affinity:** Ligand B (-7.4) has a significantly stronger binding affinity than Ligand A (-6.1). This is a 1.3 kcal/mol difference, which is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand B has a superior binding affinity and a better half-life. However, Ligand A has better QED, lower hERG risk, lower Cl_mic, and lower Pgp efflux. The solubility and Caco-2 values are concerning for both. Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), the stronger affinity of Ligand B is the most important factor. While Ligand A has better ADME properties overall, the significant binding advantage of Ligand B is likely to be more impactful in driving efficacy.
Output:
0
2025-04-17 23:23:29,637 - INFO - Batch 401 complete. Total preferences: 6416
2025-04-17 23:23:29,638 - INFO - Processing batch 402/512...
2025-04-17 23:24:16,697 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 drug candidates. ADRB2 is a GPCR, so we'll prioritize logP, Pgp, TPSA, and affinity, alongside general drug-like properties.
**Ligand A:** [340.471, 58.95, 2.805, 2, 4, 0.85, 27.181, 55.293, -5.385, -2.096, 0.684, -30.666, 35.094, 0.173, -6.8]
**Ligand B:** [338.371, 84.53, 0.712, 1, 6, 0.762, 64.754, 32.144, -5.14, -2.086, 0.379, 8.201, 11.417, 0.023, -7.4]
1. **MW:** Both are within the ideal range (200-500 Da). A is 340.471, B is 338.371 - very similar.
2. **TPSA:** A (58.95) is excellent, well below 140, and very good for GPCRs. B (84.53) is still acceptable but higher, potentially impacting permeability.
3. **logP:** A (2.805) is optimal. B (0.712) is a bit low, potentially leading to permeability issues.
4. **HBD:** A (2) is good. B (1) is also good.
5. **HBA:** A (4) is good. B (6) is acceptable, but higher.
6. **QED:** Both are reasonable (A: 0.85, B: 0.762), indicating good drug-like properties.
7. **DILI:** A (27.181) is excellent, very low risk. B (64.754) is higher, indicating a moderate risk of liver injury.
8. **BBB:** A (55.293) is moderate. B (32.144) is low. While ADRB2 isn't necessarily a CNS target, some CNS penetration can be beneficial.
9. **Caco-2:** Both are negative, suggesting poor permeability. This is concerning.
10. **Solubility:** Both are negative, suggesting poor solubility. This is also concerning.
11. **hERG:** A (0.684) is very good, low risk. B (0.379) is also good, low risk.
12. **Cl_mic:** A (-30.666) is excellent, indicating high metabolic stability. B (8.201) is concerning, suggesting rapid metabolism.
13. **t1/2:** A (35.094) is good. B (11.417) is lower, potentially requiring more frequent dosing.
14. **Pgp:** A (0.173) is good, low efflux. B (0.023) is excellent, very low efflux.
15. **Affinity:** B (-7.4) is significantly better than A (-6.8), a difference of 0.6 kcal/mol. This is a substantial advantage.
**Overall Assessment:**
Ligand B has a significantly better binding affinity, which is a critical factor for GPCR targets. However, it suffers from lower logP, higher TPSA, and a much higher DILI risk, and lower metabolic stability. Ligand A has a better safety profile (DILI, Cl_mic), better logP and TPSA, but weaker binding.
Given the importance of potency for GPCRs, the 0.6 kcal/mol difference in binding affinity is substantial. While the ADME properties of Ligand B are less ideal, these can potentially be improved through further optimization. The DILI risk is a concern, but not insurmountable. The lower metabolic stability could be addressed with structural modifications. The slightly lower logP is less concerning than the DILI risk.
Therefore, I would prioritize Ligand B for further development.
0
2025-04-17 23:24:16,698 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (405.336 Da) is within the ideal range. Ligand B (344.371 Da) is also within the ideal range, slightly lower. No strong preference here.
2. **TPSA:** Ligand A (50.36) is good, well below the 140 threshold. Ligand B (119.73) is approaching the upper limit for good oral absorption, but still acceptable. Ligand A is preferred.
3. **logP:** Ligand A (4.277) is a bit high, potentially leading to solubility issues or off-target effects. Ligand B (-0.829) is quite low, which may hinder membrane permeability. This is a significant drawback for both, but Ligand A's higher logP is less concerning given the other parameters.
4. **HBD:** Ligand A (2) is good. Ligand B (3) is acceptable. No strong preference.
5. **HBA:** Ligand A (2) is good. Ligand B (4) is acceptable. No strong preference.
6. **QED:** Both Ligand A (0.723) and Ligand B (0.618) have good drug-like scores. No strong preference.
7. **DILI:** Ligand A (49.438) has a slightly higher DILI risk than Ligand B (43.35), but both are below the concerning 60% threshold. No strong preference.
8. **BBB:** Ligand A (69.252) has a moderate BBB penetration, while Ligand B (14.114) is very low. While ADRB2 isn't exclusively a CNS target, some CNS exposure can be beneficial or at least not detrimental, and a very low BBB score is a negative. Ligand A is preferred.
9. **Caco-2:** Ligand A (-4.882) is poor. Ligand B (-5.33) is also poor. Both have very low Caco-2 permeability.
10. **Solubility:** Ligand A (-4.952) is poor. Ligand B (-2.492) is also poor. Both have very low solubility.
11. **hERG:** Ligand A (0.912) has a low hERG risk, which is excellent. Ligand B (0.104) is very low, also excellent. No strong preference.
12. **Cl_mic:** Ligand A (105.162) has a relatively high microsomal clearance, indicating faster metabolism. Ligand B (-31.626) has negative clearance, which is unusual and potentially indicates very high metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand A (19.449) has a moderate in vitro half-life. Ligand B (-9.656) has a negative half-life, which is not possible and indicates an issue with the data or model.
14. **Pgp:** Ligand A (0.507) has moderate P-gp efflux. Ligand B (0.008) has very low P-gp efflux, which is highly desirable. Ligand B is preferred.
15. **Affinity:** Ligand A (3.1) is significantly weaker than Ligand B (-8.1). This is a major advantage for Ligand B.
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are crucial. Ligand B excels in Pgp and affinity, while Ligand A has better TPSA and a more reasonable logP. The negative half-life for Ligand B is a major red flag.
**Overall Assessment:**
Despite Ligand B's superior affinity and Pgp profile, the negative in vitro half-life is a critical flaw. The high metabolic clearance is also concerning, though less so. Ligand A, while having a higher logP and lower affinity, presents a more balanced profile with reasonable ADME properties and a plausible half-life. The lower TPSA of Ligand A is also beneficial.
Output:
1
2025-04-17 23:24:16,698 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (355.41 and 372.443 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (98.74) is better than Ligand B (113.01). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary goal, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (-0.767) is slightly less optimal than Ligand A (-0.271), but both are within the acceptable range of 1-3.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (2), but both are acceptable (<=5).
5. **HBA:** Ligand B (6) is higher than Ligand A (4), but both are within the acceptable range (<=10).
6. **QED:** Ligand A (0.571) is slightly better than Ligand B (0.468), indicating a more drug-like profile.
7. **DILI:** Both ligands have low DILI risk (29.042 and 27.608 percentile), which is good.
8. **BBB:** Both are relatively low (46.607 and 42.924 percentile), which is expected and acceptable for a cardiovascular target.
9. **Caco-2:** Both are negative (-5.349 and -5.118), which is unusual and problematic. This suggests very poor permeability.
10. **Solubility:** Both are very poor (-1.585 and -1.579). This is a significant concern.
11. **hERG:** Both have very low hERG risk (0.191 and 0.076). This is excellent.
12. **Cl_mic:** Ligand A (-24.994) has a *much* lower (better) microsomal clearance than Ligand B (3.946). This suggests significantly better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (9.083) has a better in vitro half-life than Ligand B (-55.97).
14. **Pgp:** Ligand A (0.022) has a much lower Pgp efflux liability than Ligand B (0.017).
15. **Binding Affinity:** Ligand B (-4.9 kcal/mol) has a slightly better binding affinity than Ligand A (0.0 kcal/mol). This is a significant advantage.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B has a slightly better logP and significantly better affinity. However, the poor Caco-2 and solubility for both are major drawbacks. The much better metabolic stability (Cl_mic and t1/2) and lower Pgp efflux of Ligand A are very attractive. The affinity difference, while notable, isn't large enough to overcome the ADME advantages of Ligand A, especially considering the poor permeability of both.
**Conclusion:**
Despite the slightly better affinity of Ligand B, the superior ADME properties of Ligand A, particularly its metabolic stability and lower Pgp efflux, make it the more promising drug candidate. The poor solubility and permeability of both are concerning and would require significant formulation work, but Ligand A's profile is more amenable to optimization.
Output:
1
2025-04-17 23:24:16,698 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (344.415 and 384.929 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (68.62) is higher than Ligand B (50.8). Both are below the 140 threshold for oral absorption, but B is closer to the preferred <90 for potential CNS effects (though ADRB2 isn't strictly a CNS target).
3. **logP:** Both ligands have good logP values (3.024 and 3.334), falling within the optimal 1-3 range. Ligand B is slightly higher, which could potentially lead to slightly reduced solubility, but is still acceptable.
4. **HBD:** Both have 1 HBD, which is within the acceptable limit of <=5.
5. **HBA:** Ligand A has 5 HBA, and Ligand B has 4. Both are below the acceptable limit of <=10.
6. **QED:** Both ligands have very similar QED scores (0.874 and 0.868), indicating good drug-likeness.
7. **DILI:** Ligand A (47.421) has a lower DILI risk than Ligand B (60.644). This is a significant advantage for Ligand A.
8. **BBB:** Both ligands have similar BBB penetration (75.029 and 75.533). This isn't a primary concern for ADRB2, but it's good to have reasonable penetration.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. This is a potential issue for both. Ligand A (-4.396) is slightly better than Ligand B (-4.817).
10. **Solubility:** Ligand A (-2.965) has better aqueous solubility than Ligand B (-4.213). This is a positive for Ligand A.
11. **hERG:** Both ligands have low hERG inhibition liability (0.437 and 0.466). This is good.
12. **Cl_mic:** Ligand A (37.367) has lower microsomal clearance than Ligand B (51.744), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand B (38.195) has a longer in vitro half-life than Ligand A (11.067). This is a positive for Ligand B.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.084 and 0.178). This is good.
15. **Binding Affinity:** Ligand B (-8.6 kcal/mol) has a significantly stronger binding affinity than Ligand A (-7.0 kcal/mol). This is a substantial advantage for Ligand B, exceeding the 1.5 kcal/mol threshold.
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Both ligands are good on logP and Pgp. Ligand B has a better TPSA and significantly better affinity. However, the lower DILI and better metabolic stability of Ligand A are also important considerations. The substantial affinity difference of Ligand B outweighs the ADME advantages of Ligand A.
**Final Decision:**
Despite the slightly better ADME profile of Ligand A, the significantly stronger binding affinity of Ligand B (-8.6 vs -7.0 kcal/mol) is a decisive factor for a GPCR target. The improved affinity is likely to translate to greater efficacy and potentially allow for a lower dose, mitigating some of the ADME concerns.
Output:
0
2025-04-17 23:24:16,698 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (344.419 and 348.447 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (85.05 and 81.75) are below the 140 A^2 threshold for good oral absorption, which is good. They are also reasonably low, potentially allowing for some CNS penetration, although ADRB2 is primarily a cardiovascular target.
3. **logP:** Both ligands (0.903 and 1.03) are within the optimal 1-3 range. No major difference.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Ligand B (3) is preferable to Ligand A (6). Lower HBA generally improves permeability. However, the difference isn't huge.
6. **QED:** Ligand A (0.873) has a significantly better QED score than Ligand B (0.643), indicating a more drug-like profile. This is a substantial advantage.
7. **DILI:** Ligand B (27.801) has a much lower DILI risk than Ligand A (56.805). This is a major advantage for Ligand B.
8. **BBB:** Both ligands have similar BBB penetration (66.77 and 66.188). Not a major differentiating factor for this cardiovascular target.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.111 and -4.964), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Both ligands have negative solubility values (-2.001 and -1.527), indicating very poor aqueous solubility. This is a major drawback for both.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.246 and 0.086). This is good.
12. **Cl_mic:** Ligand B (11.71) has a much lower microsomal clearance than Ligand A (38.62), indicating better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand A (19.706) has a longer in vitro half-life than Ligand B (9.841). This is a positive for Ligand A.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.073 and 0.005). This is good.
15. **Binding Affinity:** Ligand B (-6.9 kcal/mol) has a slightly better binding affinity than Ligand A (-6.6 kcal/mol). While the difference is small, it's still a positive for Ligand B.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, and affinity are important. Both ligands are reasonable in logP and TPSA. Ligand B has slightly better affinity. However, ADME properties are crucial. Ligand B has a significantly lower DILI risk and better metabolic stability (lower Cl_mic), which are highly desirable. While both have poor solubility and Caco-2 permeability, the improved safety profile and metabolic stability of Ligand B outweigh the slightly longer half-life of Ligand A.
**Conclusion:**
Considering the balance of properties and the priorities for a GPCR target, Ligand B is the more promising candidate.
Output:
0
2025-04-17 23:24:16,699 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (353.419 Da) is slightly higher than Ligand B (329.407 Da), but both are acceptable.
2. **TPSA:** Ligand A (100.46) is higher than Ligand B (58.01). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B is significantly better here.
3. **logP:** Ligand A (-0.098) is suboptimal, being close to 0. Ligand B (4.213) is high, potentially causing solubility issues and off-target effects. Both are concerning, but Ligand B's high logP is more problematic.
4. **HBD:** Both ligands have 2 HBD, which is within the acceptable range.
5. **HBA:** Ligand A has 6 HBA, while Ligand B has 4. Both are within the acceptable range.
6. **QED:** Both ligands have good QED scores (A: 0.531, B: 0.576), indicating good drug-like properties.
7. **DILI:** Ligand A (21.946%) has a much lower DILI risk than Ligand B (72.005%). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (37.379%) has lower BBB penetration than Ligand B (71.85%). For a cardiovascular target, BBB penetration is not a primary concern, so this is less important.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.81 and -4.979), which is unusual and suggests poor permeability. This is a significant drawback for both.
10. **Solubility:** Ligand A (-1.252) has slightly better solubility than Ligand B (-5.212), although both are poor.
11. **hERG:** Ligand A (0.237) has a lower hERG risk than Ligand B (0.948). This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand A (-0.662) has much lower microsomal clearance, indicating better metabolic stability, than Ligand B (30.052). This is a major advantage for Ligand A.
13. **t1/2:** Ligand A (11.472) has a longer in vitro half-life than Ligand B (-3.106). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.023) has lower P-gp efflux than Ligand B (0.751), which is favorable.
15. **Binding Affinity:** Both ligands have similar binding affinities (-6.6 kcal/mol and -5.6 kcal/mol, respectively). Ligand A is slightly better, but the difference is not substantial enough to outweigh other factors.
**GPCR-specific priorities:** For ADRB2 (a cardiovascular GPCR), logP, TPSA, Pgp, and affinity are important. Ligand B has a higher logP and better TPSA, but Ligand A has better Pgp, DILI, hERG, Cl_mic, and t1/2. The significantly better ADME properties of Ligand A (lower DILI, hERG, Cl_mic, and better Pgp) outweigh the slightly less optimal logP and TPSA.
**Conclusion:**
Ligand A is the more promising candidate due to its significantly better ADME profile and acceptable binding affinity.
Output:
1
2025-04-17 23:24:16,699 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
The target is ADRB2, a GPCR. Therefore, I will prioritize logP, TPSA, Pgp efflux, BBB penetration, and binding affinity, alongside general drug-like properties.
* **Molecular Weight:** Both ligands (356.39 and 348.44 Da) fall within the ideal 200-500 Da range.
* **TPSA:** Ligand A (32.78) is significantly better than Ligand B (80.57). A TPSA under 140 is good for oral absorption, but lower is better for GPCRs, and A is much closer to the ideal range for potential CNS penetration (though not a CNS target here, lower TPSA generally correlates with better permeability).
* **logP:** Both ligands have acceptable logP values (3.465 and 2.504), falling within the 1-3 range. Ligand A is slightly higher, which *could* be beneficial for membrane permeability, but isn't a major concern.
* **H-Bond Donors/Acceptors:** Ligand A (0 HBD, 3 HBA) is preferable to Ligand B (2 HBD, 4 HBA). Fewer H-bonds generally improve permeability.
* **QED:** Both ligands have reasonable QED scores (0.831 and 0.707), indicating good drug-like properties.
* **DILI Risk:** Ligand A (19.93) has a much lower DILI risk than Ligand B (44.05). This is a significant advantage for Ligand A.
* **BBB Penetration:** Ligand A (97.05) shows excellent BBB penetration, while Ligand B (62.08) is moderate. While ADRB2 isn't strictly a CNS target, higher BBB penetration can sometimes indicate better overall permeability.
* **Caco-2 Permeability:** Both are negative, indicating poor permeability. Ligand A (-4.397) is slightly better than Ligand B (-4.796).
* **Aqueous Solubility:** Both are negative, indicating poor solubility. Ligand A (-3.096) is slightly better than Ligand B (-2.781).
* **hERG Inhibition:** Both ligands show low hERG inhibition risk (0.956 and 0.471), which is good.
* **Microsomal Clearance:** Ligand A (13.97) has significantly lower microsomal clearance than Ligand B (40.74), suggesting better metabolic stability.
* **In vitro Half-Life:** Ligand A (-10.995) has a much longer in vitro half-life than Ligand B (34.562). This is a major advantage for Ligand A.
* **P-gp Efflux:** Both ligands show low P-gp efflux liability (0.413 and 0.236).
* **Binding Affinity:** Both ligands have very similar binding affinities (-7.2 and -7.0 kcal/mol). The difference is negligible.
**Conclusion:**
Ligand A is significantly better overall. It has a lower DILI risk, better TPSA, better metabolic stability (lower Cl_mic, longer t1/2), and better BBB penetration. While both ligands have similar binding affinities, the improved ADME properties of Ligand A make it the more promising drug candidate.
**Output:**
1
2025-04-17 23:24:16,699 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (370.519 Da and 391.94 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (113.32) is better than Ligand B (62.3). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is generally preferable for absorption. Ligand B is significantly lower, which is a positive.
3. **logP:** Ligand A (0.974) is slightly below the optimal 1-3 range, while Ligand B (3.784) is at the higher end, but still acceptable. Ligand B is better here.
4. **HBD:** Ligand A (4) is higher than Ligand B (1). Lower is generally preferred, so Ligand B is better.
5. **HBA:** Both ligands have 4 HBA, so no difference here.
6. **QED:** Ligand B (0.769) has a better QED score than Ligand A (0.51), indicating a more drug-like profile.
7. **DILI:** Ligand A (28.499) has a significantly lower DILI risk than Ligand B (48.391). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (77.549) has a higher BBB penetration percentile than Ligand A (55.138). While ADRB2 isn't a CNS target, some peripheral exposure can be undesirable, but this isn't a major concern.
9. **Caco-2:** Ligand A (-5.703) and Ligand B (-4.499) both have negative values, which is unusual. Without knowing the scale, it's hard to interpret.
10. **Solubility:** Ligand A (-2.718) and Ligand B (-4.107) both have negative values, which is unusual. Without knowing the scale, it's hard to interpret.
11. **hERG:** Ligand A (0.137) has a lower hERG inhibition liability than Ligand B (0.603), which is a significant safety advantage.
12. **Cl_mic:** Ligand A (10.869) has a much lower microsomal clearance than Ligand B (63.322), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand B (51.13) has a much longer in vitro half-life than Ligand A (9.439). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.016) has a much lower P-gp efflux liability than Ligand B (0.46). This is a significant advantage for Ligand A.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.0 and -5.8 kcal/mol). The difference is not substantial enough to be a deciding factor.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), and the general drug-like properties, Ligand A emerges as the more promising candidate. While Ligand B has a better half-life and BBB penetration, Ligand A excels in safety (DILI, hERG) and ADME properties (Cl_mic, Pgp). The lower DILI and hERG risks are particularly important for a cardiovascular target. The slightly lower logP of Ligand A is acceptable, and the better metabolic stability is a significant benefit.
Output:
1
2025-04-17 23:24:16,699 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (339.311 and 359.857 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (123.9) is slightly higher than Ligand B (67.59). For a cardiovascular GPCR, TPSA is moderately important, and Ligand B's lower TPSA is preferable, suggesting better permeability.
**3. logP:** Both ligands have acceptable logP values (2.44 and 3.204), falling within the 1-3 range. Ligand B is slightly higher, which could potentially lead to some off-target interactions, but it's not a major concern.
**4. H-Bond Donors:** Ligand A has 1 HBD, and Ligand B has 2. Both are within the acceptable limit of 5.
**5. H-Bond Acceptors:** Ligand A has 7 HBA, and Ligand B has 4. Both are within the acceptable limit of 10.
**6. QED:** Ligand B (0.879) has a significantly higher QED score than Ligand A (0.43), indicating a more drug-like profile. This is a substantial advantage for Ligand B.
**7. DILI Risk:** Ligand A (97.984) has a very high DILI risk, while Ligand B (67.468) is still elevated but considerably lower. This is a major concern for Ligand A.
**8. BBB Penetration:** Both ligands have moderate BBB penetration (58.007 and 66.421). Since ADRB2 is a cardiovascular target, BBB penetration is less critical, but Ligand B is slightly better.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-5.005 and -4.951), which is unusual and suggests poor permeability. This is a concern for both.
**10. Aqueous Solubility:** Both ligands have negative solubility values (-4.437 and -4.115), which is also unusual and suggests poor solubility. This is a concern for both.
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (0.447 and 0.586). This is good.
**12. Microsomal Clearance:** Ligand A (89.456) has higher microsomal clearance than Ligand B (-5.585), indicating lower metabolic stability. This is a negative for Ligand A.
**13. In vitro Half-Life:** Ligand B (39.893) has a much longer in vitro half-life than Ligand A (-4.329), which is a significant advantage.
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (0.306 and 0.184). This is good.
**15. Binding Affinity:** Both ligands have very similar and strong binding affinities (-7.0 and -5.8 kcal/mol). Ligand A is slightly better, but the difference is not substantial enough to outweigh other factors.
**Overall Assessment:**
Ligand B is the stronger candidate. While both have issues with Caco-2 and solubility, Ligand B has a significantly better QED score, lower DILI risk, better metabolic stability (lower Cl_mic, longer half-life), and slightly better BBB penetration. The slightly higher logP is a minor concern compared to the substantial advantages of Ligand B. The affinity difference is not large enough to favor Ligand A given its significant drawbacks.
Output:
0
2025-04-17 23:24:16,699 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (361.511 and 356.398 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (54.34) is significantly better than Ligand B (96.69). ADRB2 is a cardiovascular target, not CNS, but lower TPSA generally improves permeability. Ligand A is well below the 140 cutoff. Ligand B is approaching a level that could hinder absorption.
3. **logP:** Ligand A (2.929) is optimal. Ligand B (-0.065) is quite low, potentially leading to poor membrane permeability and bioavailability. This is a significant drawback.
4. **HBD:** Both have acceptable HBD counts (1 and 2 respectively), well within the limit of 5.
5. **HBA:** Ligand A (3) is better than Ligand B (6). Lower HBA is generally preferred for permeability.
6. **QED:** Both ligands have similar, good QED values (0.894 and 0.713), indicating good drug-like properties.
7. **DILI:** Ligand A (47.15) has a slightly higher DILI risk than Ligand B (39.899), but both are below the concerning 60 threshold.
8. **BBB:** This is less critical for a cardiovascular target, but Ligand A (93.37) has a higher BBB penetration than Ligand B (65.413).
9. **Caco-2:** Ligand A (-4.585) and Ligand B (-5.004) are both negative, which is unusual. This suggests poor permeability in this assay.
10. **Solubility:** Ligand A (-3.098) is better than Ligand B (-0.941). Better solubility is important for bioavailability.
11. **hERG:** Ligand A (0.728) has a lower hERG risk than Ligand B (0.24). This is a significant advantage, as hERG inhibition can lead to cardiotoxicity.
12. **Cl_mic:** Ligand A (59.537) has a higher (worse) microsomal clearance than Ligand B (-4.89). Ligand B shows negative clearance, which is unrealistic and likely indicates very high metabolic stability.
13. **t1/2:** Ligand A (22.202) has a longer in vitro half-life than Ligand B (10.648). Longer half-life is generally desirable.
14. **Pgp:** Ligand A (0.431) has lower P-gp efflux than Ligand B (0.03). Lower efflux is better for bioavailability.
15. **Affinity:** Ligand B (-7.1 kcal/mol) has a slightly better binding affinity than Ligand A (-6.2 kcal/mol). While a 1.5 kcal/mol difference is good, it is not enough to overcome the other significant drawbacks of Ligand B.
**Overall Assessment:**
Ligand A is the stronger candidate. While Ligand B has slightly better binding affinity, Ligand A excels in crucial ADME properties like logP, TPSA, solubility, hERG risk, and P-gp efflux. Ligand B's very low logP is a major concern, and its negative clearance is unrealistic. The combination of these factors makes Ligand A a much more promising starting point for drug development targeting ADRB2.
Output:
1
2025-04-17 23:24:16,700 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [347.463, 106.96 , 3.08 , 2. , 3. , 0.274, 17.681, 60.178, -4.988, -2.527, 0.27 , 24.839, -0.167, 0.033, -5.9 ]
**Ligand B:** [364.408, 58.64 , 2.294, 1. , 3. , 0.673, 14.889, 98.022, -4.355, -2.071, 0.665, 5.141, -13.7 , 0.032, -6.4 ]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, Affinity, and BBB):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (347.463) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (106.96) is higher than Ligand B (58.64). While both are reasonably good, Ligand B is significantly better, increasing the likelihood of good oral absorption and potentially better BBB penetration.
3. **logP:** Both are within the optimal range (1-3). Ligand A (3.08) is slightly higher, potentially increasing off-target effects, while Ligand B (2.294) is closer to the sweet spot.
4. **HBD/HBA:** Both have acceptable numbers of H-bond donors and acceptors.
5. **QED:** Ligand B (0.673) has a substantially better QED score than Ligand A (0.274), indicating a more drug-like profile.
6. **DILI:** Ligand B (14.889) has a significantly lower DILI risk than Ligand A (17.681). This is a major advantage.
7. **BBB:** Ligand B (98.022) has a much higher BBB penetration potential than Ligand A (60.178). This is crucial for a GPCR target, even a cardiovascular one, as some CNS off-target effects are possible.
8. **Caco-2:** Both have negative values, which is unusual, but the magnitude suggests similar permeability.
9. **Solubility:** Both have negative values, which is unusual, but the magnitude suggests similar solubility.
10. **hERG:** Both are low, indicating a low risk of cardiotoxicity.
11. **Cl_mic:** Ligand B (5.141) has a much lower microsomal clearance than Ligand A (24.839), suggesting better metabolic stability.
12. **t1/2:** Ligand B (-13.7) has a much longer half-life than Ligand A (-0.167), which is highly desirable.
13. **Pgp:** Ligand B (0.665) has a lower P-gp efflux liability than Ligand A (0.27), which means better bioavailability and potentially better CNS exposure.
14. **Affinity:** Both have strong binding affinities (-5.9 and -6.4 kcal/mol). Ligand B is slightly better (-6.4 kcal/mol), but the difference is small enough that it doesn't outweigh the other advantages.
**Overall Assessment:**
Ligand B is clearly superior. It has a better QED score, significantly lower DILI risk, much better BBB penetration, lower microsomal clearance, longer half-life, and lower P-gp efflux. While Ligand A has a slightly lower molecular weight and similar affinity, the ADME properties of Ligand B are far more favorable for a drug candidate. The substantial improvements in metabolic stability, BBB penetration, and safety (DILI) make Ligand B the preferred choice.
Output:
0
2025-04-17 23:24:16,700 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (376.519 Da) is slightly higher than Ligand B (350.503 Da), but both are acceptable.
2. **TPSA:** Ligand A (96.89) is slightly higher than Ligand B (78.43). Both are below the 140 threshold for oral absorption, but B is better.
3. **logP:** Ligand A (1.104) is within the optimal range, while Ligand B (2.373) is closer to the upper end. Both are acceptable, but A is slightly preferred.
4. **HBD:** Both ligands have 3 H-bond donors, which is within the acceptable limit of <=5.
5. **HBA:** Ligand A has 6 H-bond acceptors, while Ligand B has 3. Both are below the limit of <=10.
6. **QED:** Ligand B (0.659) has a better QED score than Ligand A (0.494), indicating a more drug-like profile.
7. **DILI:** Ligand B (17.449) has a significantly lower DILI risk than Ligand A (23.459), which is a major advantage.
8. **BBB:** Ligand B (48.391) shows better BBB penetration than Ligand A (34.626), which is important for GPCR targets.
9. **Caco-2:** Ligand A (-5.448) and Ligand B (-4.924) both have negative values, which is unusual. It suggests poor permeability.
10. **Solubility:** Ligand A (-2.33) has slightly better solubility than Ligand B (-3.083).
11. **hERG:** Both ligands have very low hERG inhibition liability (0.173 and 0.255 respectively), which is excellent.
12. **Cl_mic:** Ligand B (13.473) has a significantly lower microsomal clearance than Ligand A (22.728), indicating better metabolic stability.
13. **t1/2:** Ligand B (27.406) has a longer in vitro half-life than Ligand A (-7.27), which is a significant advantage.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.031 and 0.14 respectively).
15. **Binding Affinity:** Ligand A (-5.5 kcal/mol) has a slightly better binding affinity than Ligand B (-4.9 kcal/mol). However, the difference is not substantial enough to outweigh the other advantages of Ligand B.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand B has better TPSA, Pgp, and a comparable logP. While Ligand A has slightly better affinity, the improvements in ADME properties (DILI, BBB, Cl_mic, t1/2) for Ligand B are more significant for overall drug development potential.
**Conclusion:**
Considering the balance of properties, especially the lower DILI risk, better BBB penetration, improved metabolic stability (lower Cl_mic and longer t1/2), and a good QED score, Ligand B is the more promising drug candidate. The slight difference in binding affinity is not enough to offset the significant ADME advantages of Ligand B.
Output:
0
2025-04-17 23:24:16,700 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 drug candidates. ADRB2 is a GPCR, so we'll prioritize logP, Pgp, TPSA, and affinity, alongside general drug-like properties.
**Ligand A:** [348.349, 78.43, 2.311, 3, 3, 0.776, 68.515, 55.913, -4.786, -3.599, 0.621, 31.668, 26.344, 0.204, -7.6]
**Ligand B:** [362.503, 87.06, 2.49, 2, 8, 0.782, 65.568, 51.997, -5.423, -2.693, 0.5, 41.026, 31.041, 0.145, -6.5]
1. **MW:** Both are within the ideal range (200-500 Da). A (348.349) is slightly better.
2. **TPSA:** A (78.43) is good, below 140, and B (87.06) is acceptable but less ideal.
3. **logP:** Both are within the optimal range (1-3). B (2.49) is slightly higher, which *could* be beneficial for membrane permeability, but not dramatically.
4. **HBD:** A (3) is good, B (2) is also good.
5. **HBA:** A (3) is good, B (8) is higher, potentially impacting permeability.
6. **QED:** Both are good (>0.5), A (0.776) and B (0.782) are comparable.
7. **DILI:** Both are acceptable, with A (68.515) being slightly higher risk than B (65.568), but both are below the concerning 60 threshold.
8. **BBB:** Both are moderate. A (55.913) and B (51.997) are not high, but BBB isn't a primary concern for ADRB2 unless targeting CNS effects.
9. **Caco-2:** A (-4.786) is better than B (-5.423), indicating better absorption.
10. **Solubility:** A (-3.599) is better than B (-2.693), which is a positive.
11. **hERG:** Both are low risk (0.621 and 0.5), which is good.
12. **Cl_mic:** A (31.668) is significantly better than B (41.026), indicating better metabolic stability.
13. **t1/2:** B (31.041) has a slightly longer half-life than A (26.344), which is a minor advantage.
14. **Pgp:** A (0.204) is better than B (0.145), indicating lower efflux and potentially better bioavailability.
15. **Affinity:** A (-7.6) is significantly better than B (-6.5). A 1.1 kcal/mol difference is substantial and can outweigh minor ADME drawbacks.
**Conclusion:**
Ligand A is the stronger candidate. While Ligand B has a slightly longer half-life, Ligand A boasts superior binding affinity, better Caco-2 permeability, better solubility, significantly better metabolic stability (lower Cl_mic), and lower P-gp efflux. The TPSA and DILI are also slightly better for Ligand A. The affinity difference is the most important factor here, given the GPCR target class.
Output:
1
2025-04-17 23:24:16,700 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
The ADRB2 receptor is a GPCR, so the priorities are logP, Pgp, TPSA, affinity, and BBB. Let's break down each ligand against these and other key parameters:
1. **Molecular Weight:** Both ligands are within the ideal range (369.5 and 361.5 Da).
2. **TPSA:** Ligand B (38.77) is significantly better than Ligand A (73.91). Lower TPSA generally improves cell permeability, a crucial factor for GPCR ligands.
3. **logP:** Both ligands have acceptable logP values (2.62 and 3.39), falling within the optimal 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability, but not drastically so.
4. **H-Bond Donors/Acceptors:** Ligand A has 2 HBD and 5 HBA, while Ligand B has 0 HBD and 4 HBA. Both are within acceptable limits.
5. **QED:** Ligand A (0.663) has a better QED score than Ligand B (0.499), indicating a more drug-like profile overall.
6. **DILI:** Both ligands have low DILI risk (25.09 and 21.68), which is excellent.
7. **BBB:** Ligand B (90.07) has a much higher BBB penetration percentile than Ligand A (54.71). While ADRB2 isn't exclusively a CNS target, some degree of CNS penetration can be relevant for off-target effects or potential therapeutic applications.
8. **Caco-2 Permeability:** Both are negative, indicating poor permeability. However, the scale is not provided, so it is difficult to interpret.
9. **Aqueous Solubility:** Both ligands have negative solubility values, indicating poor solubility.
10. **hERG Inhibition:** Both ligands have low hERG inhibition risk (0.81 and 0.74).
11. **Microsomal Clearance:** Ligand B (104.23) has a significantly higher microsomal clearance than Ligand A (53.10). This suggests Ligand B will be metabolized more quickly, potentially leading to a lower half-life and requiring higher doses.
12. **In vitro Half-Life:** Ligand A (93.11) has a much longer in vitro half-life than Ligand B (2.25). This is a significant advantage.
13. **P-gp Efflux:** Both ligands have similar P-gp efflux liability (0.80 and 0.74).
14. **Binding Affinity:** Ligand B (-7.5 kcal/mol) has a slightly better binding affinity than Ligand A (-7.0 kcal/mol). This 0.5 kcal/mol difference is meaningful, but not overwhelming.
**Overall Assessment:**
While Ligand B has better TPSA and BBB penetration, and slightly better affinity, its significantly higher microsomal clearance and shorter half-life are major drawbacks. The longer half-life of Ligand A, combined with its better QED score, makes it a more promising candidate despite the slightly higher TPSA. The affinity difference is not large enough to overcome the ADME liabilities of Ligand B.
**Output:**
1
2025-04-17 23:24:16,700 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Step-by-step comparison:**
1. **MW:** Ligand A (376.8 Da) is within the ideal range, while Ligand B (348.4 Da) is slightly below, but still acceptable.
2. **TPSA:** Ligand A (93.93) is good, below the 140 threshold. Ligand B (101.98) is also acceptable, but slightly higher.
3. **logP:** Ligand A (3.537) is optimal. Ligand B (-0.941) is significantly low, which is a major concern for permeability.
4. **HBD:** Ligand A (1) is good. Ligand B (3) is higher, potentially impacting permeability.
5. **HBA:** Ligand A (7) is good. Ligand B (4) is good.
6. **QED:** Ligand A (0.703) is excellent. Ligand B (0.389) is below the desirable threshold of 0.5, indicating a less drug-like profile.
7. **DILI:** Ligand A (96.51) is high risk. Ligand B (35.983) is very good, indicating low liver injury potential.
8. **BBB:** Ligand A (61.962) is moderate. Ligand B (33.424) is low. While ADRB2 isn't necessarily a CNS target, some peripheral distribution is still needed.
9. **Caco-2:** Ligand A (-4.601) is poor. Ligand B (-5.269) is also poor.
10. **Solubility:** Ligand A (-6.008) is poor. Ligand B (-0.861) is also poor.
11. **hERG:** Ligand A (0.465) is low risk. Ligand B (0.072) is very low risk.
12. **Cl_mic:** Ligand A (70.194) is moderate. Ligand B (-12.111) is excellent, indicating high metabolic stability.
13. **t1/2:** Ligand A (27.352) is moderate. Ligand B (-5.003) is poor.
14. **Pgp:** Ligand A (0.241) is low efflux. Ligand B (0.007) is very low efflux.
15. **Affinity:** Both Ligand A and Ligand B have an affinity of -6.3 kcal/mol, which is good and equal.
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A has a good logP, while Ligand B's is very poor. Both have acceptable TPSA and Pgp values. Affinity is equal.
**Overall Assessment:**
Ligand A has a better QED score and a reasonable logP, but suffers from high DILI risk and poor solubility/permeability. Ligand B has a significantly better safety profile (low DILI) and metabolic stability, but its low logP is a major drawback. The equal binding affinity makes the ADME properties the deciding factor. While the DILI risk with Ligand A is concerning, the extremely poor logP of Ligand B is a more fundamental issue for oral bioavailability and target engagement. A low logP often translates to poor membrane permeability, hindering the drug's ability to reach its target.
Therefore, despite the DILI risk, Ligand A is the more promising starting point for optimization.
**Output:**
1
2025-04-17 23:24:16,701 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.475 and 354.491 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (74.57) is better than Ligand B (89.87). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (2.026 and 1.299), falling within the optimal 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Ligand A (2) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Both ligands have the same number of HBA (4), which is acceptable (<=10).
6. **QED:** Ligand A (0.791) has a slightly better QED score than Ligand B (0.694), indicating a more drug-like profile.
7. **DILI:** Ligand A (36.642) has a significantly better DILI percentile than Ligand B (10.585). Lower DILI is a major advantage.
8. **BBB:** Ligand B (63.086) has a higher BBB percentile than Ligand A (35.052). However, as ADRB2 is a cardiovascular target, BBB penetration is not a high priority.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.747 and -4.859). These values are unusual and difficult to interpret directly without further context. However, they suggest poor permeability.
10. **Solubility:** Ligand A (-2.569) has slightly better solubility than Ligand B (-1.66).
11. **hERG:** Both ligands have low hERG inhibition liability (0.398 and 0.2), which is excellent.
12. **Cl_mic:** Ligand B (4.699) has significantly lower microsomal clearance than Ligand A (42.384), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-8.51) has a much longer in vitro half-life than Ligand A (19.493). This is a significant advantage.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.206 and 0.037).
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.6 and -6.9 kcal/mol). The difference is negligible.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Both ligands perform well on logP and Pgp. Ligand A has a better TPSA. Affinity is nearly identical.
**Overall Assessment:**
While Ligand B has superior metabolic stability (lower Cl_mic) and a longer half-life, Ligand A has a significantly better DILI score and a slightly better QED and solubility. Given the importance of minimizing toxicity (DILI) and the overall balance of properties, Ligand A appears to be the more promising candidate. The negative Caco-2 values are concerning for both, but the other advantages of Ligand A outweigh this drawback.
Output:
1
2025-04-17 23:24:16,701 - INFO - Batch 402 complete. Total preferences: 6432
2025-04-17 23:24:16,701 - INFO - Processing batch 403/512...
2025-04-17 23:25:07,723 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (347.463) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (68.31) is significantly better than Ligand A (91.56). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have acceptable logP values (A: 0.971, B: 1.481), falling within the optimal 1-3 range. Ligand B is slightly better.
4. **HBD:** Ligand A has 2 HBD, while Ligand B has 0. Lower is generally preferred for permeability, giving a slight edge to Ligand B.
5. **HBA:** Ligand A has 5 HBA, and Ligand B has 6. Both are acceptable, but lower is slightly better.
6. **QED:** Both ligands have similar QED values (A: 0.8, B: 0.759), indicating good drug-likeness.
7. **DILI:** Ligand A (26.173) has a significantly lower DILI risk than Ligand B (54.944). This is a major advantage for Ligand A.
8. **BBB:** Both ligands have similar BBB penetration (A: 63.435, B: 66.925). This isn't a critical factor for a cardiovascular target.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-5.28) is slightly better than Ligand B (-4.526).
10. **Solubility:** Both ligands have very poor aqueous solubility (-1.417 and -1.472). This is a significant concern for both.
11. **hERG:** Both ligands have low hERG inhibition liability (A: 0.416, B: 0.179). Ligand B is slightly better.
12. **Cl_mic:** Ligand A (-22.57) has a much lower (better) microsomal clearance than Ligand B (43.086), indicating greater metabolic stability.
13. **t1/2:** Ligand B (27.903) has a significantly longer in vitro half-life than Ligand A (-0.515). This is a major advantage for Ligand B.
14. **Pgp:** Both ligands have very low Pgp efflux liability (A: 0.006, B: 0.121).
15. **Binding Affinity:** Ligand B (-7.7) has a significantly stronger binding affinity than Ligand A (-6.0). This is a substantial advantage for Ligand B.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, affinity, and metabolic stability are key. Ligand B excels in affinity and has a better logP and TPSA. However, Ligand A has a significantly better DILI score and Cl_mic, which are crucial for overall drug safety and duration of action. The solubility is a concern for both.
**Overall Assessment:**
While Ligand B boasts superior binding affinity and a longer half-life, the significantly lower DILI risk and better metabolic stability of Ligand A are more critical factors for a cardiovascular drug. The higher affinity of Ligand B could potentially be offset by optimization, whereas mitigating a high DILI risk is far more challenging. The poor solubility of both compounds would need to be addressed regardless of which is chosen.
Output:
1
2025-04-17 23:25:07,724 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **Molecular Weight:** Both ligands (340.379 and 348.487 Da) fall comfortably within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (73.59) is better than Ligand B (78.43). Both are below the 140 threshold for oral absorption, but lower is generally preferred.
3. **logP:** Ligand A (3.943) is slightly higher than Ligand B (2.293). While both are within the acceptable range (1-3), Ligand A is closer to the upper limit, potentially raising concerns about off-target effects, but it's still within a reasonable range.
4. **H-Bond Donors:** Ligand A (1) is better than Ligand B (3). Fewer HBDs generally improve permeability.
5. **H-Bond Acceptors:** Ligand A (6) is better than Ligand B (3). Lower HBA is generally preferred for permeability.
6. **QED:** Ligand A (0.657) is better than Ligand B (0.527). A higher QED indicates better overall drug-likeness.
7. **DILI:** Ligand B (22.8) is *significantly* better than Ligand A (74.719). This is a major advantage for Ligand B. DILI risk is a critical factor.
8. **BBB:** Ligand A (63.746) is better than Ligand B (27.763). While ADRB2 isn't exclusively a CNS target, some CNS penetration can be beneficial for understanding off-target effects and potential side effects.
9. **Caco-2 Permeability:** Ligand A (-4.554) is better than Ligand B (-4.975). Higher Caco-2 permeability suggests better intestinal absorption.
10. **Aqueous Solubility:** Ligand A (-5.624) is better than Ligand B (-3.107). Better solubility is generally desirable for formulation and bioavailability.
11. **hERG Inhibition:** Ligand A (0.759) is better than Ligand B (0.225). Lower hERG inhibition is crucial to avoid cardiotoxicity.
12. **Microsomal Clearance:** Ligand B (3.907) is *much* better than Ligand A (112.482). Lower clearance indicates greater metabolic stability, a significant advantage.
13. **In vitro Half-Life:** Ligand A (54.748) is better than Ligand B (19.805). A longer half-life is generally preferred.
14. **P-gp Efflux:** Ligand A (0.269) is better than Ligand B (0.151). Lower P-gp efflux is preferred.
15. **Binding Affinity:** Ligand B (-6.2) is slightly better than Ligand A (-6.0). While the difference is small, it's still a positive for Ligand B.
**Overall Assessment:**
Ligand B has a *much* lower DILI risk and significantly better metabolic stability (lower Cl_mic). These are critical advantages that outweigh the slightly better BBB penetration and half-life of Ligand A. While Ligand A has some advantages in solubility, permeability, and hERG, the safety profile of Ligand B is far superior. Given the cardiovascular implications of targeting ADRB2, minimizing liver toxicity and maximizing metabolic stability are paramount. The slightly better affinity of Ligand B is also a bonus.
Output:
0
2025-04-17 23:25:07,724 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (343.43 and 350.51 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (65.9) is higher than Ligand B (52.41). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is generally preferred for absorption. Ligand B has a slight advantage.
3. **logP:** Ligand A (1.772) is within the optimal range (1-3), while Ligand B (2.732) is towards the higher end. Both are acceptable, but Ligand A is slightly better balanced.
4. **HBD:** Ligand A (1) is preferable to Ligand B (0) as some hydrogen bonding can aid solubility.
5. **HBA:** Ligand A (5) is preferable to Ligand B (6). Lower HBA is generally better for permeability.
6. **QED:** Ligand A (0.917) is significantly better than Ligand B (0.685), indicating a more drug-like profile. This is a substantial advantage for Ligand A.
7. **DILI:** Ligand A (39.473) has a much lower DILI risk than Ligand B (10.896). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (82.047) has a higher BBB penetration percentile than Ligand A (48.468). While ADRB2 isn't primarily a CNS target, some level of BBB penetration can be beneficial.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.575 and -4.892). These values are unusual and suggest poor permeability.
10. **Solubility:** Ligand A (-1.227) is slightly better than Ligand B (-2.399), though both are poor.
11. **hERG:** Both ligands have low hERG inhibition risk (0.83 and 0.702). No significant difference.
12. **Cl_mic:** Ligand A (19.407) has a significantly lower microsomal clearance than Ligand B (43.713), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (34.928) has a longer in vitro half-life than Ligand B (12.994). This is a significant advantage for Ligand A.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.26 and 0.447). No significant difference.
15. **Binding Affinity:** Ligand B (-7.1 kcal/mol) has a slightly better binding affinity than Ligand A (-5.9 kcal/mol). This is a 1.2 kcal/mol difference, which is substantial.
**Overall Assessment:**
Ligand B has a better binding affinity and BBB penetration, which are positives for a GPCR. However, Ligand A overwhelmingly wins on ADME-Tox properties. It has a much better QED score, significantly lower DILI risk, lower microsomal clearance, and a longer half-life. The slight difference in binding affinity is likely surmountable with further optimization, while the poor ADME profile of Ligand B is much harder to fix. Given the cardiovascular target, metabolic stability and safety (DILI) are paramount.
**Output:**
1
2025-04-17 23:25:07,724 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (342.403 Da and 366.422 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand B (96.18) is better than Ligand A (112.66). Both are below 140, but lower TPSA generally favors oral absorption, and is particularly important for GPCRs.
**3. logP:** Ligand B (2.11) is slightly better than Ligand A (1.033). Both are within the optimal 1-3 range, but Ligand A is a bit low, potentially hindering membrane permeability.
**4. H-Bond Donors:** Ligand A (3) is slightly better than Ligand B (2). Both are within the acceptable limit of 5.
**5. H-Bond Acceptors:** Ligand B (8) is higher than Ligand A (5). Both are within the acceptable limit of 10.
**6. QED:** Both ligands have good QED values (0.726 and 0.836 respectively), indicating good drug-like properties. Ligand B is slightly better.
**7. DILI Risk:** Ligand A (46.219) has a significantly lower DILI risk than Ligand B (79.1). This is a major advantage for Ligand A.
**8. BBB Penetration:** Ligand B (81.582) has better BBB penetration than Ligand A (57.231). While ADRB2 is a cardiovascular target, some CNS effects are possible with beta-blockers, and some degree of BBB penetration might be acceptable or even desirable.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-5.28 and -5.175). These values are unusual and suggest poor permeability.
**10. Aqueous Solubility:** Both ligands have negative solubility values (-3.084 and -3.72). These values are also unusual and suggest poor solubility.
**11. hERG Inhibition:** Ligand A (0.089) has a much lower hERG inhibition risk than Ligand B (0.446). This is a critical advantage for Ligand A, as hERG inhibition can lead to cardiotoxicity.
**12. Microsomal Clearance:** Ligand B (24.782) has slightly higher microsomal clearance than Ligand A (22.465). Lower clearance is generally preferred for longer duration of action.
**13. In vitro Half-Life:** Ligand A (-22.612) has a significantly longer in vitro half-life than Ligand B (-4.995). This is a major advantage for Ligand A.
**14. P-gp Efflux:** Ligand A (0.023) has much lower P-gp efflux than Ligand B (0.039). Lower P-gp efflux is desirable for better oral bioavailability and potentially better CNS exposure.
**15. Binding Affinity:** Ligand B (-6.1) has a stronger binding affinity than Ligand A (-4.7). This is a 1.4 kcal/mol difference, which is significant.
**Overall Assessment:**
While Ligand B has a stronger binding affinity, Ligand A is the more promising candidate overall. The lower DILI risk, significantly lower hERG inhibition, longer half-life, and lower P-gp efflux are crucial advantages that outweigh the slightly weaker binding affinity. The negative Caco-2 and solubility values are concerning for both, but can be addressed through formulation strategies. For a cardiovascular GPCR target, minimizing off-target effects (DILI, hERG) and ensuring reasonable pharmacokinetic properties (half-life, P-gp) are paramount.
Output:
1
2025-04-17 23:25:07,725 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [386.832, 86.71, 2.365, 2, 4, 0.825, 67.429, 18.069, -5.045, -3.939, 0.456, 51.116, -21.547, 0.082, -6.7]
**Ligand B:** [354.403, 107.38, -1.01, 2, 6, 0.592, 25.165, 45.909, -4.694, -1.121, 0.112, 25.769, -0.916, 0.004, -7]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (354.4) is slightly lower, which could be beneficial for permeability, but both are acceptable.
2. **TPSA:** Ligand A (86.71) is better than Ligand B (107.38). ADRB2 is a cardiovascular target, so CNS penetration isn't critical, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (2.365) is optimal (1-3). Ligand B (-1.01) is too low, potentially hindering membrane permeability and bioavailability. This is a significant drawback.
4. **HBD:** Both have 2 HBD, which is good.
5. **HBA:** Ligand A (4) is better than Ligand B (6). Lower HBA is generally preferred for better permeability.
6. **QED:** Ligand A (0.825) is significantly better than Ligand B (0.592), indicating a more drug-like profile.
7. **DILI:** Ligand B (25.165) is *much* better than Ligand A (67.429). This is a major advantage for Ligand B.
8. **BBB:** Ligand B (45.909) is higher than Ligand A (18.069), but since this is a cardiovascular target, BBB isn't a primary concern.
9. **Caco-2:** Ligand A (-5.045) is better than Ligand B (-4.694), suggesting better intestinal absorption.
10. **Solubility:** Ligand A (-3.939) is better than Ligand B (-1.121). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.456) is better than Ligand B (0.112). Lower hERG inhibition is crucial for avoiding cardiotoxicity.
12. **Cl_mic:** Ligand A (51.116) is higher than Ligand B (25.769), indicating faster metabolism and lower metabolic stability. This is a drawback for Ligand A.
13. **t1/2:** Ligand A (-21.547) is much better than Ligand B (-0.916), indicating a longer half-life.
14. **Pgp:** Ligand A (0.082) is better than Ligand B (0.004). Lower P-gp efflux is preferred.
15. **Affinity:** Ligand B (-7.0) has a slightly better binding affinity than Ligand A (-6.7). While the difference is not huge, it is still a factor.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A has a better TPSA, Pgp, and a comparable affinity. However, Ligand B has a significantly better logP, which is crucial for membrane permeability and receptor engagement. The DILI risk for Ligand B is also substantially lower.
**Overall Assessment:**
Despite the better half-life and some other favorable ADME properties of Ligand A, the significantly lower logP of Ligand B is a major concern. A logP below 1 can severely hamper absorption and bioavailability. Ligand B's lower DILI risk is also a significant advantage. The slightly better affinity of Ligand B further tips the balance. While Ligand A has a longer half-life, this can potentially be addressed through formulation strategies. The permeability issues with Ligand B are harder to overcome.
Therefore, I believe Ligand B is the more viable drug candidate.
0
2025-04-17 23:25:07,725 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.431 and 346.41 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (78.95) is slightly higher than Ligand B (68.1). Both are below the 140 threshold for oral absorption, but closer to the 90 threshold for CNS targets (less relevant for ADRB2, a cardiovascular target). Ligand B is preferable.
3. **logP:** Ligand B (1.725) is within the optimal 1-3 range, while Ligand A (0.309) is below 1, potentially hindering permeation. This is a significant advantage for Ligand B.
4. **HBD:** Both ligands have 1 HBD, which is within the acceptable limit of 5. No difference.
5. **HBA:** Ligand B (7) has more HBAs than Ligand A (4). While both are under 10, the lower HBA count of Ligand A is slightly preferable for permeability.
6. **QED:** Ligand B (0.909) has a higher QED score than Ligand A (0.775), indicating a more drug-like profile. This favors Ligand B.
7. **DILI:** Ligand A (35.246) has a lower DILI risk than Ligand B (42.536), which is a positive for Ligand A.
8. **BBB:** Ligand B (88.29) has a significantly higher BBB penetration percentile than Ligand A (65.917). While ADRB2 isn't a CNS target, higher BBB is generally a positive indicator of permeability.
9. **Caco-2:** Both ligands have very negative Caco-2 values (-4.762 and -4.769). This is concerning and suggests poor intestinal absorption for both.
10. **Solubility:** Ligand A (-1.233) has slightly better solubility than Ligand B (-2.209), which is a minor advantage.
11. **hERG:** Ligand A (0.105) has a much lower hERG inhibition liability than Ligand B (0.372), a crucial factor for cardiovascular safety. This is a strong advantage for Ligand A.
12. **Cl_mic:** Ligand A (25.081) has lower microsomal clearance than Ligand B (9.569), suggesting better metabolic stability. This favors Ligand A.
13. **t1/2:** Ligand B (21.521) has a significantly longer in vitro half-life than Ligand A (5.785), which is desirable for less frequent dosing. This is a strong advantage for Ligand B.
14. **Pgp:** Ligand A (0.042) has lower P-gp efflux liability than Ligand B (0.202), which is a positive.
15. **Binding Affinity:** Ligand A (-6.7) has slightly better binding affinity than Ligand B (-6.5), though the difference is small.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP and has a better BBB score (though less critical here). Ligand A has a better hERG profile, lower Pgp efflux, and slightly better affinity. The Caco-2 values are a concern for both.
**Overall Assessment:**
The biggest differentiating factors are logP and hERG. Ligand B's logP is optimal, while Ligand A's is suboptimal. However, Ligand A's significantly lower hERG risk and better metabolic stability (lower Cl_mic) are critical for a cardiovascular target. The slightly better affinity of Ligand A and lower Pgp efflux also contribute. While Ligand B has a longer half-life and better QED, the safety profile of Ligand A is more compelling for this target.
Output:
1
2025-04-17 23:25:07,725 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (357.445 and 357.42 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (52.65) is better than Ligand B (38.13). Both are below 140, but lower TPSA generally favors permeability, which is important for GPCRs.
3. **logP:** Ligand A (1.725) is optimal (1-3), while Ligand B (4.124) is pushing the upper limit. Higher logP can lead to solubility issues and off-target effects.
4. **HBD:** Ligand A (1) is preferable to Ligand B (0), as a single HBD can aid solubility without significantly impacting permeability.
5. **HBA:** Both ligands have 3 HBA, which is within the acceptable range.
6. **QED:** Both ligands have similar QED scores (0.788 and 0.768), indicating good drug-likeness.
7. **DILI:** Ligand A (11.516) has a significantly lower DILI risk than Ligand B (13.3). This is a crucial advantage.
8. **BBB:** Ligand B (93.835) has a higher BBB penetration than Ligand A (85.072). While ADRB2 isn't necessarily a CNS target, some peripheral ADRB2 activity can be modulated by CNS effects, so this is a slight advantage for B.
9. **Caco-2:** Ligand A (-4.843) is better than Ligand B (-4.301), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-1.328) is better than Ligand B (-4.564), which is a significant advantage. Poor solubility can hinder bioavailability.
11. **hERG:** Ligand A (0.514) has a lower hERG inhibition liability than Ligand B (0.868), reducing the risk of cardiotoxicity.
12. **Cl_mic:** Ligand A (-12.993) has much lower microsomal clearance than Ligand B (49.177), indicating better metabolic stability. This is a major advantage.
13. **t1/2:** Ligand A (-0.134) has a slightly better in vitro half-life than Ligand B (-13.098).
14. **Pgp:** Ligand A (0.028) has lower P-gp efflux than Ligand B (0.554), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand A (-7.3) has a slightly better binding affinity than Ligand B (-5.1). While the difference isn't huge, it's still a positive factor.
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Ligand A is better on logP, TPSA, and Pgp. Affinity is slightly better for A.
**Overall Assessment:**
Ligand A demonstrates a superior balance of properties. It has a lower DILI risk, better solubility, significantly better metabolic stability (lower Cl_mic), lower P-gp efflux, and slightly better affinity. While Ligand B has better BBB penetration, the other advantages of Ligand A outweigh this, especially considering the peripheral focus of many ADRB2 applications. The slightly higher logP of Ligand B is a concern.
**Output:**
1
2025-04-17 23:25:07,725 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (362.308 Da and 355.463 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand B (62.17) is significantly better than Ligand A (104.65). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (3.975) is approaching the upper limit of optimal (1-3), while Ligand A (0.504) is quite low. For a GPCR, a higher logP is generally preferred for membrane permeability and receptor engagement.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (0). This isn't a major concern for either.
5. **HBA:** Ligand A (6) is higher than Ligand B (5). Again, both are within acceptable limits, but lower is generally preferable.
6. **QED:** Both ligands have reasonable QED values (0.791 and 0.557, respectively), indicating good drug-like properties. Ligand A is slightly better.
7. **DILI:** Ligand B (53.044) has a lower DILI risk than Ligand A (62.737), which is a positive.
8. **BBB:** Not a primary concern for a cardiovascular target, but Ligand A (63.901) has a slightly higher BBB penetration potential than Ligand B (45.095).
9. **Caco-2:** Both ligands have negative Caco-2 values which is unusual and concerning. It suggests poor permeability. Ligand B (-5.057) is slightly worse than Ligand A (-4.937).
10. **Solubility:** Ligand A (-2.101) has better solubility than Ligand B (-4.987). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.135) shows a lower hERG inhibition liability than Ligand B (0.612), which is a significant advantage for cardiovascular safety.
12. **Cl_mic:** Ligand A (-2.638) has a lower (better) microsomal clearance than Ligand B (80.472), indicating greater metabolic stability.
13. **t1/2:** Ligand B (68.288) has a significantly longer in vitro half-life than Ligand A (-23.314). This is a major advantage, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.012) has much lower P-gp efflux liability than Ligand B (0.731), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand B (-5.3) has a slightly better binding affinity than Ligand A (-4.0). This is a 1.3 kcal/mol difference, which is substantial.
**Overall Assessment:**
Ligand B has a significantly better binding affinity and a much longer half-life. However, it suffers from a higher logP (borderline), higher Pgp efflux, and a concerningly high microsomal clearance. Ligand A has better solubility, lower hERG risk, lower Pgp efflux, and better metabolic stability. The combination of lower hERG and Pgp efflux for Ligand A is a significant advantage for a cardiovascular drug, mitigating potential safety concerns and improving bioavailability. While the affinity difference is notable, the ADME properties of Ligand A are more balanced and favorable for development. The negative Caco-2 values for both are a concern that would need to be addressed in further optimization.
Output:
1
2025-04-17 23:25:07,726 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (363.351 and 350.459 Da) are within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand B (75.8) is significantly better than Ligand A (125.79). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (2.615) is optimal, while Ligand A (0.422) is quite low, potentially hindering membrane permeability. This is a significant advantage for B.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable.
5. **HBA:** Ligand A (6) and Ligand B (5) are both acceptable.
6. **QED:** Both ligands have similar QED values (0.811 and 0.78), indicating good drug-likeness.
7. **DILI:** Ligand B (19.426) has a much lower DILI risk than Ligand A (92.982). This is a major advantage for B.
8. **BBB:** Ligand B (79.294) has a higher BBB penetration than Ligand A (22.412), but since this is a cardiovascular target, this is less critical.
9. **Caco-2:** Ligand A (-5.113) and Ligand B (-4.42) are both negative, indicating poor permeability.
10. **Solubility:** Ligand A (-3.838) and Ligand B (-2.315) are both negative, indicating poor solubility.
11. **hERG:** Ligand A (0.108) has a lower hERG risk than Ligand B (0.464). This is a slight advantage for A.
12. **Cl_mic:** Ligand B (63.563) has a lower microsomal clearance than Ligand A (8.347), suggesting better metabolic stability. This is a significant advantage for B.
13. **t1/2:** Ligand B (-6.292) has a longer in vitro half-life than Ligand A (66). This is a significant advantage for B.
14. **Pgp:** Ligand A (0.032) has lower P-gp efflux than Ligand B (0.353), which is a slight advantage for A.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.0 and -5.9 kcal/mol). The difference is negligible.
**Overall Assessment:**
Ligand B clearly outperforms Ligand A in several critical ADME properties: DILI risk, metabolic stability (Cl_mic), and in vitro half-life. While Ligand A has a slight edge in hERG and Pgp efflux, the substantial advantages of Ligand B in safety (DILI) and PK (Cl_mic, t1/2) are more important for overall drug development potential. The lower logP of Ligand A is also a concern for permeability. The TPSA is also much better for Ligand B.
Output:
0
2025-04-17 23:25:07,726 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (350.463) is slightly higher than Ligand B (337.431), but both are acceptable.
2. **TPSA:** Ligand A (87.46) is better than Ligand B (64.45). Both are below 140, indicating good potential for oral absorption.
3. **logP:** Ligand A (1.315) is within the optimal range (1-3). Ligand B (3.106) is at the higher end, potentially leading to solubility issues or off-target interactions, but still acceptable.
4. **HBD:** Ligand A (2) is slightly better than Ligand B (1). Both are within the acceptable limit of <=5.
5. **HBA:** Ligand A (5) is better than Ligand B (7). Both are within the acceptable limit of <=10.
6. **QED:** Ligand A (0.74) is better than Ligand B (0.608), indicating a more drug-like profile.
7. **DILI:** Ligand A (32.183) is significantly better than Ligand B (73.245), indicating a much lower risk of drug-induced liver injury. This is a major advantage for Ligand A.
8. **BBB:** Ligand A (63.048) is better than Ligand B (57.852). While ADRB2 isn't strictly a CNS target, some peripheral effects can be modulated by CNS penetration, and higher BBB is generally favorable.
9. **Caco-2:** Both ligands have similar, poor Caco-2 permeability (-4.878 and -4.917). This suggests potential absorption issues for both.
10. **Solubility:** Ligand A (-2.021) is better than Ligand B (-3.558). Both are poor, but A is less poor.
11. **hERG:** Ligand A (0.211) is much better than Ligand B (0.867), indicating a lower risk of cardiotoxicity. This is crucial for a cardiovascular target.
12. **Cl_mic:** Ligand B (40.188) has lower microsomal clearance than Ligand A (47.027), suggesting better metabolic stability.
13. **t1/2:** Ligand B (40.74) has a longer in vitro half-life than Ligand A (-6.263). This is a positive for Ligand B.
14. **Pgp:** Ligand A (0.133) has lower P-gp efflux than Ligand B (0.706), suggesting better bioavailability.
15. **Binding Affinity:** Ligand B (-7.1) has a slightly better binding affinity than Ligand A (-6.9). However, the difference is only 0.2 kcal/mol, which is not substantial enough to outweigh the other significant advantages of Ligand A.
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. While Ligand B has a slightly better affinity and lower Cl_mic, Ligand A excels in crucial safety parameters (DILI, hERG) and has better TPSA, QED, solubility, and Pgp efflux. The slightly better affinity of Ligand B doesn't compensate for its significantly higher DILI and hERG risk.
**Conclusion:**
Considering the balance of properties, particularly the significantly lower DILI and hERG risks, better QED, and favorable TPSA and Pgp values, Ligand A is the more promising drug candidate.
Output:
1
2025-04-17 23:25:07,726 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.423 and 347.459 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (103.59) is higher than Ligand B (78.51). For a cardiovascular GPCR, TPSA isn't a *major* concern unless it's excessively high, but lower is generally preferred for better permeability. Ligand B is better.
3. **logP:** Ligand A (-1.009) is quite low, potentially hindering membrane permeability. Ligand B (1.532) is within the optimal 1-3 range. This is a significant advantage for Ligand B.
4. **HBD:** Both ligands have 2 HBD, which is within the acceptable limit of <=5. No difference.
5. **HBA:** Ligand A has 7 HBA, while Ligand B has 3. Both are within the acceptable limit of <=10, but Ligand B is preferable due to the lower count.
6. **QED:** Ligand A (0.681) has a better QED score than Ligand B (0.49), indicating a more drug-like profile. This favors Ligand A.
7. **DILI:** Ligand A (33.695) has a much lower DILI risk than Ligand B (16.557). This is a significant advantage for Ligand A.
8. **BBB:** Ligand B (71.811) has a higher BBB penetration percentile than Ligand A (42.846). While ADRB2 isn't necessarily a CNS target, some degree of BBB penetration can be beneficial for off-target effects assessment. Ligand B is better.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.12 and -5.284), which is unusual and suggests very poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand A (-0.509) has slightly better solubility than Ligand B (-1.685). Solubility is important for bioavailability.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.039 and 0.147). No significant difference.
12. **Cl_mic:** Ligand A (-5.481) has a much lower (better) microsomal clearance than Ligand B (21.264). This indicates greater metabolic stability for Ligand A.
13. **t1/2:** Ligand A (15.384 hours) has a significantly longer in vitro half-life than Ligand B (-14.29 hours). This is a major advantage for Ligand A, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.028 and 0.034). No significant difference.
15. **Binding Affinity:** Both ligands have similar, strong binding affinities (-6.2 and -6.0 kcal/mol). The difference is minimal.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand B initially appears better due to its more favorable logP and TPSA. However, Ligand A demonstrates superior ADME properties: significantly lower DILI risk, better metabolic stability (lower Cl_mic), and a much longer half-life. The low logP of Ligand A is a concern, but the substantial advantages in safety (DILI) and pharmacokinetics (Cl_mic, t1/2) outweigh this drawback. The Caco-2 values are concerning for both, but can be addressed with formulation strategies.
Output:
1
2025-04-17 23:25:07,726 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [343.427, 91.32, 2.321, 3, 4, 0.632, 39.201, 60.682, -5.023, -2.776, 0.338, 34.158, 25.943, 0.131, -5.7]
**Ligand B:** [341.411, 94.22, 2.244, 4, 3, 0.672, 39.667, 36.138, -5.11, -4.288, 0.217, 43.364, -39.192, 0.021, -4.6]
Here's a breakdown, considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal range (343 vs 341 Da). No significant difference.
2. **TPSA:** Both are reasonably good (91.32 & 94.22), being under 140, suggesting decent absorption.
3. **logP:** Both are optimal (2.321 & 2.244), falling within the 1-3 range.
4. **HBD/HBA:** Ligand A (3/4) is slightly better than Ligand B (4/3) in terms of H-bond donor/acceptor count.
5. **QED:** Both are acceptable (0.632 & 0.672), indicating good drug-like properties.
6. **DILI:** Both have low DILI risk (39.201 & 39.667), which is excellent.
7. **BBB:** Ligand A is better (60.682) than Ligand B (36.138). While ADRB2 isn't a CNS target, some peripheral exposure is acceptable, and higher BBB penetration *could* indicate better overall permeability.
8. **Caco-2:** Both are poor (-5.023 & -5.11). This is a concern for oral absorption.
9. **Solubility:** Ligand A (-2.776) is better than Ligand B (-4.288). Solubility is important for formulation and bioavailability.
10. **hERG:** Both are low risk (0.338 & 0.217).
11. **Cl_mic:** Ligand A (34.158) has lower clearance than Ligand B (43.364), suggesting better metabolic stability.
12. **t1/2:** Ligand A (25.943) has a positive in vitro half-life, while Ligand B (-39.192) is negative. This is a significant advantage for Ligand A.
13. **Pgp:** Ligand A (0.131) has lower P-gp efflux than Ligand B (0.021), which is preferable for bioavailability.
14. **Binding Affinity:** Ligand A (-5.7 kcal/mol) has a slightly better binding affinity than Ligand B (-4.6 kcal/mol). This 1.1 kcal/mol difference is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across several key parameters, particularly metabolic stability (Cl_mic, t1/2), P-gp efflux, solubility, and binding affinity. While both have poor Caco-2 permeability, the stronger binding affinity of Ligand A and its better metabolic profile make it the more promising candidate. The slightly better BBB penetration is a bonus.
Output:
1
2025-04-17 23:25:07,726 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.383 and 351.447 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (82.14) is well below the 140 threshold and good for oral absorption. Ligand B (112.73) is still within acceptable limits, but higher. GPCRs benefit from lower TPSA.
3. **logP:** Ligand A (2.78) is optimal. Ligand B (0.322) is quite low, potentially hindering membrane permeability and absorption. This is a significant drawback.
4. **HBD:** Ligand A (0) is excellent, minimizing potential issues with hydrogen bonding and metabolic lability. Ligand B (3) is acceptable, but not ideal.
5. **HBA:** Ligand A (6) is good. Ligand B (4) is also good.
6. **QED:** Both ligands (0.6 and 0.64) have good drug-likeness scores.
7. **DILI:** Ligand A (69.756) has a moderate risk, but is acceptable. Ligand B (13.687) has a very low DILI risk, which is a strong positive.
8. **BBB:** Ligand A (80.69) shows good BBB penetration. Ligand B (57.736) is lower, which is less desirable for a GPCR.
9. **Caco-2:** Ligand A (-3.741) is poor, indicating low intestinal absorption. Ligand B (-5.538) is even worse.
10. **Solubility:** Ligand A (-3.373) is poor. Ligand B (-1.882) is also poor, but slightly better.
11. **hERG:** Both ligands (0.203 and 0.161) have low hERG inhibition risk, which is excellent.
12. **Cl_mic:** Ligand A (88.001) has a higher clearance, suggesting lower metabolic stability. Ligand B (-10.679) has a negative clearance (or very low percentile), indicating high metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand A (-31.856) has a very short half-life. Ligand B (-20.057) is also short, but better than A.
14. **Pgp:** Both ligands (0.075 and 0.016) have low P-gp efflux, which is good.
15. **Affinity:** Both ligands (-7.0 and -6.2 kcal/mol) have good binding affinity. Ligand A is slightly better (-7.0 vs -6.2), but the difference is not overwhelming.
**Overall Assessment:**
Ligand A has a better binding affinity and BBB penetration, but suffers from poor Caco-2 permeability, solubility, and metabolic stability. Ligand B has a significantly better DILI profile and metabolic stability, but lower logP and BBB penetration. Considering ADRB2 is a GPCR, the balance of properties leans towards Ligand B. The improved metabolic stability and reduced toxicity risk are more valuable than the slightly better binding affinity of Ligand A, especially given the poor absorption properties of both compounds. While both have poor solubility and Caco-2 permeability, these can be addressed with formulation strategies.
Output:
0
2025-04-17 23:25:07,726 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (352.523 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (55.89) is significantly better than Ligand B (71.76). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (1.166) is optimal, while Ligand B (3.376) is approaching the upper limit. Higher logP can lead to off-target effects and solubility issues.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 4 HBA, while Ligand B has 8. Ligand A is preferable.
6. **QED:** Both are reasonably good (A: 0.712, B: 0.689), indicating drug-like properties.
7. **DILI:** Ligand A (6.747%) has a much lower DILI risk than Ligand B (90.927%). This is a *major* advantage for Ligand A.
8. **BBB:** Ligand B (77.239%) has better BBB penetration than Ligand A (54.556%), but this isn't a critical factor for a cardiovascular target.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. This is a concern for both, but the lower value for Ligand A (-4.885) is slightly better than Ligand B (-4.996).
10. **Solubility:** Ligand A (-0.897) has better solubility than Ligand B (-3.977).
11. **hERG:** Both have low hERG inhibition risk (A: 0.619, B: 0.704).
12. **Cl_mic:** Ligand A (12.918 mL/min/kg) has significantly lower microsomal clearance than Ligand B (64.944 mL/min/kg), indicating better metabolic stability.
13. **t1/2:** Ligand B (22.969) has a longer in vitro half-life than Ligand A (-7.078). This is a positive for Ligand B, but the negative value for A is concerning.
14. **Pgp:** Both have low Pgp efflux liability (A: 0.009, B: 0.383).
15. **Binding Affinity:** Ligand A (-5.7 kcal/mol) has slightly better binding affinity than Ligand B (-6.1 kcal/mol).
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Ligand A is better on logP and TPSA. Affinity is only slightly better for Ligand B. The *massive* difference in DILI risk and the better metabolic stability (lower Cl_mic) of Ligand A are decisive factors. While Ligand B has a longer half-life, the negative value for Ligand A is a red flag that needs further investigation, but the other advantages of Ligand A outweigh this concern.
**Conclusion:**
Ligand A is the more promising candidate due to its superior safety profile (DILI), better physicochemical properties (TPSA, logP, solubility), and metabolic stability.
Output:
1
2025-04-17 23:25:07,727 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (351.363 and 353.423 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (117.86) is slightly higher than Ligand B (111.39). Both are below the 140 threshold for good oral absorption, but closer to the 90 threshold for CNS targets. This is less critical for a cardiovascular target like ADRB2, but lower is generally preferred. Ligand B has a slight edge.
3. **logP:** Ligand A (-0.65) is a bit low, potentially hindering permeability. Ligand B (-0.027) is better, falling within the optimal 1-3 range. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD is generally better for permeability.
5. **HBA:** Ligand A (8) is preferable to Ligand B (9). Lower HBA is generally better for permeability.
6. **QED:** Both ligands have good QED scores (0.566 and 0.658), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (57.154) has a higher DILI risk than Ligand B (33.501). This is a clear advantage for Ligand B.
8. **BBB:** Ligand A (42.846) has a lower BBB penetration percentile than Ligand B (62.737). While ADRB2 isn't a CNS target, some distribution to the CNS is possible, and higher BBB is generally favorable. Ligand B is better.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.898 and -5.165), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Both ligands have very poor aqueous solubility (-1.283 and -1.2). This is a major drawback for both.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.038 and 0.07). This is good for both.
12. **Cl_mic:** Ligand A (24.663) has lower microsomal clearance than Ligand B (38.497), suggesting better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (0.714) has a shorter in vitro half-life than Ligand B (5.343). This is a significant advantage for Ligand B.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.011 and 0.031). This is good for both.
15. **Binding Affinity:** Ligand A (-5.9 kcal/mol) has significantly better binding affinity than Ligand B (-1.7 kcal/mol). This is a *major* advantage for Ligand A. A difference of 4.2 kcal/mol is substantial and can often outweigh minor ADME drawbacks.
**GPCR-specific priorities:** For GPCRs, logP, TPSA, Pgp, and affinity are key. Ligand B has better logP and TPSA, but Ligand A has *much* better affinity. The poor Caco-2 and solubility are concerning for both, but the strong binding of Ligand A is a compelling factor.
**Overall Assessment:**
Despite the poor solubility and Caco-2 permeability for both compounds, Ligand A's significantly higher binding affinity (-5.9 vs -1.7 kcal/mol) is a decisive advantage. The better metabolic stability (lower Cl_mic) also supports Ligand A. While Ligand B has slightly better DILI and BBB, the potency difference is too large to ignore.
Output:
1
2025-04-17 23:25:07,727 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Ligand A (435.384 Da) is within the ideal range (200-500 Da). Ligand B (366.443 Da) is also within the ideal range. No clear advantage here.
2. **TPSA:** Ligand A (78.87) is better than Ligand B (102.32). Both are below 140, but lower TPSA generally favors absorption.
3. **logP:** Both Ligand A (2.2) and Ligand B (2.27) are optimal (1-3). No significant difference.
4. **HBD:** Both Ligand A (2) and Ligand B (2) are within the acceptable limit of <=5. No difference.
5. **HBA:** Ligand A (5) is better than Ligand B (6), being closer to the preferred limit of <=10.
6. **QED:** Ligand B (0.845) has a slightly better QED score than Ligand A (0.687), indicating a more drug-like profile.
7. **DILI:** Ligand A (25.979) has a *much* better DILI score than Ligand B (94.804). This is a major advantage for Ligand A, as high DILI risk is a significant concern.
8. **BBB:** Both Ligand A (46.762) and Ligand B (48.662) have similar BBB penetration scores. Since ADRB2 is a cardiovascular target, BBB penetration is not a primary concern, but a slightly higher score is still preferable.
9. **Caco-2:** Ligand A (-5.139) and Ligand B (-4.826) are both negative, which is unusual. This suggests poor permeability.
10. **Solubility:** Ligand A (-3.133) and Ligand B (-3.933) are both poor, but Ligand A is slightly better.
11. **hERG:** Ligand A (0.923) is better than Ligand B (0.352) indicating lower risk of cardiotoxicity.
12. **Cl_mic:** Ligand B (23.817) has a lower microsomal clearance than Ligand A (42.702), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-21.46) has a longer in vitro half-life than Ligand B (-14.91).
14. **Pgp:** Ligand A (0.654) has a better Pgp efflux liability score than Ligand B (0.102).
15. **Affinity:** Both ligands have very similar binding affinities (-6.5 and -6.6 kcal/mol). The difference is negligible.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Both ligands are comparable in logP and affinity. Ligand A has a better TPSA and Pgp efflux liability. The *significant* difference lies in the DILI score, where Ligand A is far superior. While metabolic stability (Cl_mic) is important, the high DILI risk of Ligand B is a major red flag.
**Conclusion:**
Ligand A is the more promising candidate due to its significantly lower DILI risk, better TPSA, Pgp efflux, and hERG inhibition profile, despite slightly lower QED and solubility. The comparable binding affinity and similar BBB penetration (which is less critical for a cardiovascular target) further support this choice.
Output:
1
2025-04-17 23:25:07,727 - INFO - Batch 403 complete. Total preferences: 6448
2025-04-17 23:25:07,727 - INFO - Processing batch 404/512...
2025-04-17 23:26:07,347 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (355.395 and 355.494 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (118.82) is higher than Ligand B (38.77). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is generally preferred for permeability. Ligand B is significantly better here.
3. **logP:** Ligand A (1.026) is within the optimal range (1-3), while Ligand B (3.587) is at the upper end. Both are acceptable, but Ligand A is slightly favored for potentially fewer off-target effects.
4. **HBD:** Ligand A (2) is reasonable, while Ligand B (0) is very low. A balance is good, and Ligand A's value is acceptable.
5. **HBA:** Ligand A (7) is acceptable, while Ligand B (3) is also good.
6. **QED:** Both ligands have similar QED values (0.749 and 0.701), indicating good drug-like properties.
7. **DILI:** Ligand A (60.333) has a higher DILI risk than Ligand B (10.624). This is a significant advantage for Ligand B.
8. **BBB:** Both ligands have high BBB penetration (91.508 and 96.743). While ADRB2 isn't strictly a CNS target, some brain exposure can occur, and high BBB is not detrimental. Ligand B is slightly better.
9. **Caco-2:** Ligand A (-5.054) and Ligand B (-4.464) are both negative, indicating poor permeability. This is a concern for both, but Ligand B is slightly better.
10. **Solubility:** Ligand A (-1.625) and Ligand B (-4.084) are both poor. Ligand B is worse.
11. **hERG:** Ligand A (0.091) has a lower hERG risk than Ligand B (0.865). This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand A (-11.44) has a lower (better) microsomal clearance than Ligand B (94.555). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (4.61) has a shorter half-life than Ligand B (-0.901). This is a disadvantage for Ligand A.
14. **Pgp:** Ligand A (0.006) has much lower P-gp efflux than Ligand B (0.782). This is a significant advantage for Ligand A.
15. **Binding Affinity:** Ligand B (-6.6) has a slightly better binding affinity than Ligand A (-6.2). However, the difference (0.4 kcal/mol) is not substantial enough to outweigh other factors.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), and the general drug-like properties, Ligand B appears to be the better candidate. While Ligand A has advantages in hERG, Cl_mic, and Pgp, Ligand B's significantly lower DILI risk, lower TPSA, and slightly better affinity are more important. The solubility is poor for both, but Ligand B is worse. The improved metabolic stability of Ligand A is a plus, but the DILI risk of Ligand A is a major concern.
Output:
0
2025-04-17 23:26:07,348 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Step-by-step comparison:**
1. **MW:** Ligand A (362.455 Da) is within the ideal range (200-500 Da). Ligand B (381.567 Da) is also acceptable. No clear advantage.
2. **TPSA:** Ligand A (101.05) is slightly above the optimal <140 for oral absorption, but still reasonable. Ligand B (66.32) is excellent, well below 140. Advantage: B.
3. **logP:** Ligand A (1.468) is within the optimal range (1-3). Ligand B (4.259) is a bit high, potentially leading to solubility issues and off-target interactions. Advantage: A.
4. **HBD:** Ligand A (2) is good. Ligand B (1) is also good. No clear advantage.
5. **HBA:** Ligand A (5) is good. Ligand B (6) is also acceptable. No clear advantage.
6. **QED:** Ligand A (0.839) is excellent, indicating high drug-likeness. Ligand B (0.705) is still good, but lower. Advantage: A.
7. **DILI:** Ligand A (83.288) has a higher DILI risk, which is concerning. Ligand B (36.099) has a very low DILI risk. Significant advantage: B.
8. **BBB:** Ligand A (63.978) is moderate. Ligand B (52.617) is lower. Since ADRB2 is a cardiovascular target, BBB penetration is not a primary concern, so this isn't a major factor.
9. **Caco-2:** Ligand A (-5.249) is poor. Ligand B (-4.963) is also poor. Both are problematic for absorption.
10. **Solubility:** Ligand A (-3.346) is poor. Ligand B (-4.079) is even worse. Both are problematic.
11. **hERG:** Ligand A (0.306) has a low hERG risk. Ligand B (0.8) has a higher hERG risk. Advantage: A.
12. **Cl_mic:** Ligand A (32.588) has lower clearance, suggesting better metabolic stability. Ligand B (64.579) has higher clearance. Advantage: A.
13. **t1/2:** Ligand A (-0.646) is poor. Ligand B (61.404) is excellent. Significant advantage: B.
14. **Pgp:** Ligand A (0.056) has low P-gp efflux, which is good. Ligand B (0.626) has moderate P-gp efflux. Advantage: A.
15. **Affinity:** Ligand A (-7.0) is slightly better than Ligand B (-6.1). Advantage: A.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. While Ligand B has a better TPSA, Ligand A excels in logP, Pgp, and has comparable affinity. The DILI risk for Ligand A is concerning, but the overall balance of properties, particularly the metabolic stability (Cl_mic) and P-gp efflux, makes it more promising. The longer half-life of Ligand B is attractive, but the higher DILI risk and higher logP are significant drawbacks.
**Final Decision:**
Considering the balance of properties and the specific requirements for a GPCR target, I believe Ligand A is the more viable drug candidate.
Output:
1
2025-04-17 23:26:07,348 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (341.411 and 343.391 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (61.88) is significantly better than Ligand B (114.3). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is pushing the upper limit for good oral absorption (<=140).
3. **logP:** Ligand A (3.39) is optimal, while Ligand B (1.177) is a bit low. A logP between 1-3 is preferred, and Ligand B is closer to the lower bound, potentially impacting membrane permeability.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 3 HBA, while Ligand B has 5. Both are acceptable, but lower is generally preferred.
6. **QED:** Ligand A (0.797) has a much better QED score than Ligand B (0.491), indicating a more drug-like profile.
7. **DILI:** Ligand B (57.348) has a slightly higher DILI risk than Ligand A (49.283), but both are within an acceptable range (<60 is good).
8. **BBB:** Ligand A (86.778) has a significantly higher BBB penetration percentile than Ligand B (59.093). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant, and higher BBB is generally favorable.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. This is concerning for both.
10. **Solubility:** Ligand A (-4.199) is better than Ligand B (-2.018), indicating better aqueous solubility.
11. **hERG:** Ligand A (0.651) has a much lower hERG inhibition liability than Ligand B (0.145), which is a critical safety consideration.
12. **Cl_mic:** Ligand B (-4.135) has a negative clearance, which is excellent and indicates very high metabolic stability. Ligand A (33.483) is moderate.
13. **t1/2:** Ligand B (-2.818) has a negative half-life, which is excellent and indicates very high in vitro stability. Ligand A (14.788) is moderate.
14. **Pgp:** Ligand A (0.106) has lower P-gp efflux liability than Ligand B (0.008), which is preferable.
15. **Binding Affinity:** Both ligands have excellent binding affinity (-7.3 and -7.0 kcal/mol). The difference of 0.3 kcal/mol is not substantial enough to outweigh the other ADME differences.
**Overall Assessment:**
Ligand A is significantly better overall. While Ligand B has superior metabolic stability (Cl_mic and t1/2), Ligand A excels in critical areas like TPSA, logP, QED, BBB penetration, solubility, and, crucially, hERG inhibition. The lower hERG risk alone is a major advantage. The slightly better ADME profile of Ligand A, combined with its comparable binding affinity, makes it a more promising drug candidate for the ADRB2 receptor. The negative Caco-2 values for both are a concern that would need to be addressed in further optimization, but the other properties of Ligand A are more favorable.
Output:
1
2025-04-17 23:26:07,348 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (363.429 Da and 368.543 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (38.33) is significantly better than Ligand B (58.64). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand A is well below the 140 threshold, while Ligand B is approaching it.
3. **logP:** Ligand A (4.863) is higher than Ligand B (2.442). While both are within the acceptable range (1-3 is optimal), Ligand A is pushing the upper limit. This could potentially lead to solubility issues, but for a GPCR, some lipophilicity is often desirable for membrane interactions.
4. **HBD:** Both ligands have 1 HBD, which is ideal.
5. **HBA:** Ligand A has 3 HBAs, while Ligand B has 4. Both are acceptable (<=10), but lower is generally preferred.
6. **QED:** Both ligands have good QED scores (0.714 and 0.782), indicating good drug-like properties.
7. **DILI:** Ligand B (31.601) has a significantly lower DILI risk than Ligand A (63.746). This is a major advantage for Ligand B.
8. **BBB:** Both ligands have similar BBB penetration (84.141 and 83.831). This isn't a primary concern for ADRB2, which isn't a CNS target, but it's neutral.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.652 and -4.999). These values are unusual and suggest poor permeability.
10. **Solubility:** Ligand B (-3.357) has better solubility than Ligand A (-5.795). This is important, especially given Ligand A's higher logP.
11. **hERG:** Both ligands have low hERG inhibition risk (0.577 and 0.476).
12. **Cl_mic:** Ligand B (46.03) has significantly lower microsomal clearance than Ligand A (89.412), suggesting better metabolic stability.
13. **t1/2:** Ligand A (13.109) has a longer in vitro half-life than Ligand B (4.573). This is a positive for Ligand A.
14. **Pgp:** Both ligands have low P-gp efflux (0.236 and 0.191).
15. **Binding Affinity:** Ligand A (-7.5 kcal/mol) has a significantly stronger binding affinity than Ligand B (-5.9 kcal/mol). This is a substantial advantage for Ligand A, potentially outweighing some of its ADME drawbacks.
**Overall Assessment:**
Ligand A has a much stronger binding affinity, which is the most important factor for GPCRs. However, Ligand B has a much better safety profile (lower DILI), better solubility, and better metabolic stability. The Caco-2 values are concerning for both, but the affinity difference is significant. Given the importance of potency for GPCRs, and the fact that the other issues with Ligand A *could* be addressed through further optimization, I would choose Ligand A.
Output:
1
2025-04-17 23:26:07,348 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.45 & 356.40 Da) are within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (87.46) is better than Ligand B (94.36), falling comfortably under the 140 threshold for oral absorption. Lower TPSA is generally preferred for GPCRs.
3. **logP:** Ligand A (0.621) is slightly lower than optimal (1-3), but still acceptable. Ligand B (-0.277) is a bit low and could indicate poor membrane permeability. Ligand A is preferable.
4. **HBD:** Both have 2 HBD, which is good.
5. **HBA:** Ligand A has 5 HBA, and Ligand B has 6. Both are acceptable, but A is slightly better.
6. **QED:** Ligand A (0.835) has a better QED score than Ligand B (0.703), indicating a more drug-like profile.
7. **DILI:** Ligand A (19.19) has a significantly lower DILI risk than Ligand B (43.66). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (77.94) has a better BBB penetration score than Ligand A (36.49). However, ADRB2 is a cardiovascular target, so BBB penetration is not a high priority.
9. **Caco-2:** Ligand A (-5.171) and Ligand B (-4.795) both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the values are similar.
10. **Solubility:** Ligand A (-0.952) has slightly better solubility than Ligand B (-1.709).
11. **hERG:** Ligand A (0.091) has a much lower hERG risk than Ligand B (0.387). This is a crucial safety parameter.
12. **Cl_mic:** Ligand A (-9.65) has a much lower (better) microsomal clearance than Ligand B (4.459), indicating better metabolic stability.
13. **t1/2:** Ligand B (2.967) has a longer in vitro half-life than Ligand A (-0.596). This is a positive for Ligand B, but the negative value for A is concerning.
14. **Pgp:** Ligand A (0.024) has a much lower P-gp efflux liability than Ligand B (0.108).
15. **Affinity:** Ligand B (-6.6 kcal/mol) has a slightly better binding affinity than Ligand A (-5.9 kcal/mol). This is a 1.5kcal/mol advantage, which is significant.
**Overall Assessment:**
While Ligand B has a slightly better binding affinity and in vitro half-life, Ligand A is significantly better across several critical ADMET properties. Specifically, the lower DILI risk, hERG inhibition, and P-gp efflux, combined with better TPSA, QED, and solubility, make Ligand A a more promising drug candidate. The negative Caco-2 values are a concern for both, but the other advantages of Ligand A outweigh this drawback. The slightly lower BBB penetration is not a significant issue for a cardiovascular target.
Output:
1
2025-04-17 23:26:07,349 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.381 and 355.479 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (44.81) is significantly better than Ligand B (87.74). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold, while Ligand B is approaching it.
3. **logP:** Both ligands have good logP values (1.754 and 1.215), falling within the optimal 1-3 range. Ligand B is slightly lower, which *could* indicate slightly reduced permeability, but it's not a major concern.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (4). Similar reasoning to HBD.
6. **QED:** Ligand A (0.846) has a substantially better QED score than Ligand B (0.617), indicating a more drug-like profile.
7. **DILI:** Ligand A (31.989) has a much lower DILI risk than Ligand B (19.271). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (78.829) has a higher BBB penetration potential than Ligand B (54.362). While not a primary concern for a cardiovascular target, higher BBB is generally not detrimental.
9. **Caco-2:** Ligand A (-4.263) has a significantly better Caco-2 permeability than Ligand B (-5.151). This suggests better intestinal absorption for Ligand A.
10. **Solubility:** Ligand A (-2.319) has better aqueous solubility than Ligand B (-1.099).
11. **hERG:** Both ligands have very low hERG inhibition liability (0.407 and 0.173), which is excellent.
12. **Cl_mic:** Ligand A (-5.546) has a much lower (better) microsomal clearance than Ligand B (15.782), indicating greater metabolic stability.
13. **t1/2:** Ligand A (-12.838) has a longer in vitro half-life than Ligand B (8.814), which is desirable.
14. **Pgp:** Ligand A (0.059) has lower P-gp efflux liability than Ligand B (0.014).
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.4 and -5.6 kcal/mol). The difference of 0.8 kcal/mol is not substantial enough to outweigh the numerous advantages of Ligand A.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A is superior in all of these except for logP, where they are comparable.
**Conclusion:**
Ligand A consistently outperforms Ligand B across almost all crucial ADME-Tox properties, including DILI, metabolic stability, solubility, permeability, and QED. While the binding affinity difference is small, the overall profile of Ligand A is significantly more favorable for drug development.
Output:
1
2025-04-17 23:26:07,349 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (399.3 & 349.4 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (79.53 & 78.95) are below the 140 A^2 threshold for good oral absorption, which is good.
3. **logP:** Ligand A (3.019) is optimal, while Ligand B (1.313) is a bit low, potentially hindering permeation. This favors Ligand A.
4. **HBD:** Both have 1 HBD, which is within the acceptable limit of <=5.
5. **HBA:** Ligand A has 5 HBA, and Ligand B has 4, both are within the acceptable limit of <=10.
6. **QED:** Ligand A (0.788) has a better QED score than Ligand B (0.6), indicating a more drug-like profile.
7. **DILI:** Ligand A (81.5%) has a significantly higher DILI risk than Ligand B (59.9%). This is a major concern for Ligand A.
8. **BBB:** Both ligands have reasonable BBB penetration (72.8% and 62.2%), but Ligand A is better. This is a moderate priority for a cardiovascular target.
9. **Caco-2:** Both ligands have negative Caco-2 values which is unusual.
10. **Solubility:** Ligand A (-3.809) has worse solubility than Ligand B (-1.573). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.586) has a slightly higher hERG risk than Ligand B (0.13). Lower is better here.
12. **Cl_mic:** Ligand B (15.484) has a lower microsomal clearance than Ligand A (24.629), indicating better metabolic stability. This is a positive for Ligand B.
13. **t1/2:** Both ligands have negative in vitro half-life values which is unusual.
14. **Pgp:** Ligand A (0.396) has a lower Pgp efflux liability than Ligand B (0.048), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand B (-7.0 kcal/mol) has a slightly better binding affinity than Ligand A (-6.6 kcal/mol). This is a significant advantage for Ligand B.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand A has a better logP and Pgp, but Ligand B has a significantly better binding affinity. The DILI risk for Ligand A is a major red flag.
**Overall Assessment:**
While Ligand A has some advantages in logP and Pgp, the significantly higher DILI risk, worse solubility, and slightly weaker binding affinity make it less desirable. Ligand B's superior binding affinity and lower DILI risk outweigh its slightly lower logP. The metabolic stability (lower Cl_mic) of Ligand B is also a plus.
Output:
0
2025-04-17 23:26:07,349 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.41 and 348.447 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (88.91) is slightly higher than Ligand B (76.46). Both are below the 140 threshold for oral absorption, and reasonably close to the 90 threshold for CNS targets (though ADRB2 isn't necessarily a CNS target). Ligand B is preferable.
3. **logP:** Both ligands (1.132 and 1.29) are within the optimal 1-3 range. No clear advantage.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1). Both are acceptable, but lower is generally better for permeability. Ligand B is preferable.
5. **HBA:** Both ligands (5) are within the acceptable limit of 10. No significant difference.
6. **QED:** Ligand A (0.806) has a significantly higher QED score than Ligand B (0.595), indicating a more drug-like profile. This is a strong advantage for Ligand A.
7. **DILI:** Both ligands have low DILI risk (38.62 and 36.409 percentile), well below the 60 threshold. No significant difference.
8. **BBB:** Both ligands have good BBB penetration (70.182 and 71.268 percentile). No significant difference.
9. **Caco-2:** Both ligands have negative Caco-2 permeability values (-4.994 and -4.689), which is unusual and suggests poor permeability. This is a concern for both, but the values are very close.
10. **Solubility:** Both ligands have negative solubility values (-2.515 and -1.504). This is also unusual and suggests poor solubility. Ligand B is slightly better.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.135 and 0.381 percentile), which is excellent. No significant difference.
12. **Cl_mic:** Ligand A (7.149) has a significantly lower microsomal clearance than Ligand B (26.072), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (8.127) has a longer in vitro half-life than Ligand B (0.784). This is a substantial advantage for Ligand A.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.017 and 0.048 percentile), which is excellent. No significant difference.
15. **Binding Affinity:** Both ligands have the same binding affinity (-6.3 kcal/mol).
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Both ligands perform similarly on logP, Pgp, and affinity. Ligand B has a slightly better TPSA. However, Ligand A has superior QED, significantly better metabolic stability (Cl_mic), and a much longer half-life. These factors are crucial for *in vivo* efficacy and a reasonable dosing regimen. The negative Caco-2 and solubility values are concerning for both, but the other advantages of Ligand A outweigh this.
**Conclusion:**
Despite the similar binding affinity, Ligand A is the more promising candidate due to its superior QED, metabolic stability, and half-life. These properties are critical for developing a viable drug.
Output:
1
2025-04-17 23:26:07,349 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (343.43 & 347.37 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (73.74) is significantly better than Ligand B (101.74). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand A is well below the 140 threshold, while Ligand B is approaching it.
3. **logP:** Both ligands have good logP values (1.08 & 0.83), falling within the optimal 1-3 range. Ligand A is slightly higher, which could be marginally better for membrane permeability.
4. **HBD:** Both have 1 HBD, which is acceptable.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 6. Ligand A is preferable here, as lower HBA generally improves permeability.
6. **QED:** Ligand A (0.891) has a better QED score than Ligand B (0.765), indicating a more drug-like profile.
7. **DILI:** Ligand A (25.44%) has a significantly lower DILI risk than Ligand B (46.30%). This is a major advantage for Ligand A.
8. **BBB:** Both ligands have good BBB penetration (70.61% and 75.81%). This is less critical for ADRB2 (a cardiovascular target) but still a positive. Ligand B is slightly better.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. This is concerning for both, but the scale is not specified, so it's hard to interpret the absolute impact.
10. **Solubility:** Both ligands have poor solubility (-1.798 and -2.094). This is a significant drawback for both, potentially impacting bioavailability.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.276% and 0.14%). This is excellent.
12. **Cl_mic:** Ligand A (17.75 mL/min/kg) has significantly better metabolic stability (lower clearance) than Ligand B (68.26 mL/min/kg). This is a substantial advantage for Ligand A.
13. **t1/2:** Ligand A (-2.48 hours) has a negative half-life, which is concerning. Ligand B (-29.74 hours) is also negative, but the larger magnitude is worse. Both are problematic, but the scale is not specified.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.118% and 0.04%). This is excellent.
15. **Binding Affinity:** Ligand A (-8.0 kcal/mol) has a slightly better binding affinity than Ligand B (-6.1 kcal/mol). This 1.9 kcal/mol difference is substantial and can outweigh some of the ADME drawbacks.
**Overall Assessment:**
Ligand A is the stronger candidate. While both have solubility and Caco-2 permeability issues, Ligand A excels in critical areas: lower DILI risk, significantly better metabolic stability (Cl_mic), a better QED score, and a superior binding affinity. The slightly better TPSA and HBA also contribute to its favorability. The negative half-life is concerning for both, but the other advantages of A outweigh this.
Output:
1
2025-04-17 23:26:07,349 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (334.419 Da and 341.415 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (43.6) is significantly better than Ligand B (80.12). For a GPCR, keeping TPSA low is beneficial for permeability, and Ligand A is well below the 90 A^2 threshold. Ligand B is pushing the limit for good oral absorption (<=140).
**3. logP:** Both ligands have acceptable logP values (3.597 and 2.238, respectively) within the optimal 1-3 range. Ligand A is slightly higher, which could be a minor concern for off-target effects, but is still reasonable.
**4. H-Bond Donors:** Ligand A (0) is preferable to Ligand B (1). Fewer HBDs generally improve membrane permeability.
**5. H-Bond Acceptors:** Ligand A (4) is preferable to Ligand B (5). Similar to HBDs, lower HBA counts are generally favored for permeability.
**6. QED:** Ligand B (0.904) has a significantly better QED score than Ligand A (0.479), indicating a more drug-like profile overall. This is a notable advantage for Ligand B.
**7. DILI Risk:** Ligand B (64.793) has a higher DILI risk than Ligand A (50.136), but both are acceptable (below 60).
**8. BBB Penetration:** Both ligands have similar BBB penetration (62.699 and 62.156). Since ADRB2 isn't a primary CNS target, this isn't a major differentiating factor.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the values are similar (-4.674 and -4.86).
**10. Aqueous Solubility:** Ligand A (-4.458) is slightly better than Ligand B (-3.516), indicating better solubility.
**11. hERG Inhibition:** Ligand A (0.414) has a lower hERG inhibition risk than Ligand B (0.185), which is a significant advantage for safety.
**12. Microsomal Clearance:** Ligand B (25.826) has significantly lower microsomal clearance than Ligand A (76.98), suggesting better metabolic stability. This is a strong positive for Ligand B.
**13. In vitro Half-Life:** Ligand A (-32.146) has a much longer in vitro half-life than Ligand B (6.415). This is a significant advantage for Ligand A, potentially allowing for less frequent dosing.
**14. P-gp Efflux:** Ligand A (0.407) has lower P-gp efflux than Ligand B (0.03), which is favorable for bioavailability.
**15. Binding Affinity:** Ligand A (-7.0) has a slightly better binding affinity than Ligand B (-5.7). This 1.3 kcal/mol difference is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand A has a stronger binding affinity, better TPSA, H-bond characteristics, solubility, hERG safety, and P-gp efflux. Ligand B has a better QED score and significantly better metabolic stability (lower Cl_mic and longer half-life). Considering the GPCR-specific priorities (logP, TPSA, affinity), the superior affinity and TPSA of Ligand A, coupled with acceptable logP and a reasonable safety profile (hERG), make it the more promising candidate. While the metabolic stability of Ligand B is attractive, the binding affinity is paramount for GPCRs, and Ligand A's affinity is significantly better.
Output:
1
2025-04-17 23:26:07,350 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (352.475 and 349.366 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (59.08) is significantly better than Ligand B (96.25). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally correlates with better permeability. Ligand B's TPSA is approaching a level that could hinder absorption.
3. **logP:** Both ligands have acceptable logP values (1.82 and 0.996), falling within the 1-3 range. Ligand A is slightly more lipophilic, which could be beneficial for membrane permeability.
4. **HBD:** Ligand A (0) is preferable to Ligand B (1). Fewer hydrogen bond donors generally improve permeability.
5. **HBA:** Ligand A (4) is preferable to Ligand B (6). Fewer hydrogen bond acceptors generally improve permeability.
6. **QED:** Both ligands have good QED scores (0.701 and 0.794), indicating good overall drug-likeness. Ligand B is slightly better.
7. **DILI:** Ligand A (12.524) has a much lower DILI risk than Ligand B (56.65). This is a significant advantage for Ligand A.
8. **BBB:** Both ligands have high BBB penetration (83.831 and 80.341). While ADRB2 isn't a CNS target, this isn't a negative.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.319 and -4.595). This is unusual and suggests poor permeability. However, the scale is not specified, so it is difficult to interpret.
10. **Solubility:** Both ligands have negative solubility values (-1.089 and -1.848). This is also unusual and suggests poor solubility. However, the scale is not specified, so it is difficult to interpret.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.195 and 0.225). This is excellent.
12. **Cl_mic:** Ligand A (39.353) has a higher microsomal clearance than Ligand B (2.392). This suggests Ligand B is more metabolically stable, a positive attribute.
13. **t1/2:** Ligand A (14.851) has a longer in vitro half-life than Ligand B (0.264). This is a significant advantage for Ligand A.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.033 and 0.022). This is excellent.
15. **Binding Affinity:** Ligand A (-7.0) has a slightly better binding affinity than Ligand B (-4.7). This 2.3 kcal/mol difference is substantial and can outweigh some ADME drawbacks.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, affinity, and metabolic stability are key. Ligand A excels in affinity and has a better logP and TPSA. While Ligand B has better metabolic stability, the significantly better affinity and lower DILI risk of Ligand A are more important.
**Conclusion:**
Ligand A is the more promising candidate due to its superior binding affinity, lower DILI risk, lower TPSA, fewer H-bonds, and longer half-life. The slightly higher metabolic clearance is a minor drawback compared to these advantages.
Output:
1
2025-04-17 23:26:07,350 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for the ADRB2, a cardiovascular GPCR. Therefore, key priorities are logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB.
Let's compare the ligands property by property:
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (367.471) is slightly lower, which is generally favorable.
2. **TPSA:** Ligand B (60.25) is significantly better than Ligand A (91.5), falling well below the 140 threshold for good absorption. This is a significant advantage for Ligand B.
3. **logP:** Ligand A (0.962) is slightly lower than optimal (1-3), but acceptable. Ligand B (3.436) is at the upper end of the optimal range, which could potentially lead to solubility issues, but is still within acceptable limits.
4. **HBD:** Ligand A (2) is preferable to Ligand B (0) as some H-bond donors can aid solubility.
5. **HBA:** Ligand B (6) is preferable to Ligand A (5).
6. **QED:** Ligand A (0.751) is slightly better than Ligand B (0.664), indicating a more drug-like profile.
7. **DILI:** Both have acceptable DILI risk (Ligand A: 32.338, Ligand B: 55.448), with Ligand A being slightly better.
8. **BBB:** Ligand B (73.362) has a much higher BBB percentile than Ligand A (57.736). While ADRB2 is cardiovascular, some CNS penetration isn't necessarily detrimental and could offer additional benefits.
9. **Caco-2:** Both have very poor Caco-2 permeability (-4.841 and -4.87). This is a concern for both, but doesn't heavily sway the decision as it's similar for both.
10. **Solubility:** Both have very poor solubility (-2.754 and -3.395). This is a concern for both, but doesn't heavily sway the decision as it's similar for both.
11. **hERG:** Both have low hERG inhibition liability (Ligand A: 0.222, Ligand B: 0.43).
12. **Cl_mic:** Ligand A (-8.56) has a much lower (better) microsomal clearance than Ligand B (74.576), suggesting better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand B (60.669) has a significantly longer in vitro half-life than Ligand A (-10.979), which is a major advantage.
14. **Pgp:** Ligand A (0.024) has a much lower Pgp efflux liability than Ligand B (0.747), which is a significant advantage.
15. **Binding Affinity:** Ligand A (-7.4) has a slightly better binding affinity than Ligand B (-7.0), but the difference is relatively small.
**Overall Assessment:**
Ligand A has advantages in metabolic stability (Cl_mic, t1/2), Pgp efflux, and binding affinity. Ligand B excels in TPSA and BBB penetration. The poor Caco-2 and solubility for both are concerning, but similar. Considering the GPCR nature of the target, the lower TPSA of Ligand B is a significant advantage. However, the much better metabolic stability and lower Pgp efflux of Ligand A are also very important. The slightly better binding affinity of Ligand A is a bonus. Given the balance of these factors, I lean towards Ligand A.
**Output:**
1
2025-04-17 23:26:07,350 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (338.327 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (81.75) is significantly better than Ligand A (106.14). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (0.859) is slightly outside the optimal range (1-3), but acceptable. Ligand B (-0.04) is quite low, potentially hindering membrane permeability.
4. **HBD:** Both are acceptable (Ligand A: 1, Ligand B: 2).
5. **HBA:** Both are acceptable (Ligand A: 7, Ligand B: 4).
6. **QED:** Both are good (Ligand A: 0.756, Ligand B: 0.729), indicating good drug-like properties.
7. **DILI:** Ligand A (92.284) has a concerningly high DILI risk. Ligand B (5.777) is excellent. This is a major red flag for Ligand A.
8. **BBB:** Not a primary concern for a cardiovascular target, but Ligand B (46.568) has a higher value than Ligand A (25.126).
9. **Caco-2:** Both are negative, indicating poor permeability.
10. **Solubility:** Both are negative, indicating poor solubility.
11. **hERG:** Both are very low risk (Ligand A: 0.011, Ligand B: 0.123).
12. **Cl_mic:** Ligand A (-7.852) has a much lower (better) microsomal clearance than Ligand B (-10.66). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand B (26.88) has a significantly longer half-life than Ligand A (-3.038). This is a strong advantage for Ligand B.
14. **Pgp:** Both are very low efflux (Ligand A: 0.017, Ligand B: 0.003).
15. **Binding Affinity:** Both have excellent binding affinity (-9.4 kcal/mol and -9.3 kcal/mol), with Ligand A being slightly better.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are important. While Ligand A has slightly better affinity and logP, the extremely high DILI risk is a deal-breaker. The better TPSA of Ligand B is also favorable. The longer half-life of Ligand B is a significant advantage.
**Overall Assessment:**
Despite Ligand A's slightly better affinity and metabolic stability, the significantly higher DILI risk makes it a poor candidate. Ligand B, while having a lower logP and Caco-2 permeability, presents a much safer profile with a very low DILI risk and a longer half-life. The difference in binding affinity is minimal and can potentially be optimized in later stages of drug development.
Output:
0
2025-04-17 23:26:07,350 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [343.427, 87.13, 3.132, 3, 3, 0.779, 62.156, 52.85, -5.121, -3.78, 0.528, 40.122, 74.705, 0.269, -6.5]**
**Ligand B: [343.427, 78.6, 2.757, 2, 5, 0.808, 46.219, 71.384, -4.977, -2.481, 0.776, 26.781, 4.497, 0.554, -7.5]**
1. **Molecular Weight:** Both ligands are within the ideal range (around 343 Da). No significant difference.
2. **TPSA:** Ligand A (87.13) is slightly higher than Ligand B (78.6). Both are acceptable for a non-CNS GPCR target like ADRB2, being under 140. Ligand B is preferable.
3. **logP:** Ligand A (3.132) and Ligand B (2.757) are both within the optimal range (1-3). Ligand B is slightly better.
4. **H-Bond Donors:** Ligand A (3) and Ligand B (2) are both acceptable. Ligand B is preferable.
5. **H-Bond Acceptors:** Ligand A (3) and Ligand B (5) are both acceptable, though Ligand A is preferable.
6. **QED:** Both ligands have good QED values (A: 0.779, B: 0.808), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (62.156) has a higher DILI risk than Ligand B (46.219). This is a significant advantage for Ligand B.
8. **BBB:** BBB is less critical for ADRB2 (a cardiovascular target). Ligand B (71.384) is higher than Ligand A (52.85), but the difference isn't decisive.
9. **Caco-2 Permeability:** Ligand A (-5.121) has worse Caco-2 permeability than Ligand B (-4.977). Ligand B is preferable.
10. **Aqueous Solubility:** Ligand A (-3.78) has worse aqueous solubility than Ligand B (-2.481). Ligand B is preferable.
11. **hERG Inhibition:** Ligand A (0.528) has a slightly higher hERG risk than Ligand B (0.776). Ligand B is preferable.
12. **Microsomal Clearance:** Ligand A (40.122) has higher microsomal clearance than Ligand B (26.781), indicating lower metabolic stability. Ligand B is preferable.
13. **In vitro Half-Life:** Ligand A (74.705) has a longer half-life than Ligand B (4.497). This is a significant advantage for Ligand A.
14. **P-gp Efflux:** Ligand A (0.269) has lower P-gp efflux than Ligand B (0.554). Ligand A is preferable.
15. **Binding Affinity:** Ligand B (-7.5) has a significantly stronger binding affinity than Ligand A (-6.5). This is a substantial advantage for Ligand B, potentially outweighing some ADME drawbacks.
**Overall Assessment:**
Ligand B consistently outperforms Ligand A in most critical ADME properties (DILI, Caco-2, Solubility, hERG, Clearance) and has a significantly better binding affinity. While Ligand A has a better half-life and P-gp efflux, the superior ADME profile and binding affinity of Ligand B make it the more promising drug candidate for ADRB2.
Output:
0
2025-04-17 23:26:07,351 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (353.3 & 356.5 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (114.2) is higher than Ligand B (49.41). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for permeability. Ligand B is significantly better.
3. **logP:** Ligand A (1.615) is within the optimal range (1-3), while Ligand B (3.355) is towards the upper end. Both are acceptable, but Ligand A is slightly preferred.
4. **HBD:** Ligand A (0) has no HBD, while Ligand B (1) has one. Lower is generally better for permeability, so Ligand A is slightly favored.
5. **HBA:** Ligand A (8) is higher than Ligand B (2). Lower is generally better for permeability, so Ligand B is significantly favored.
6. **QED:** Ligand B (0.793) has a better QED score than Ligand A (0.413), indicating a more drug-like profile. This is a significant advantage for Ligand B.
7. **DILI:** Ligand A (61.8%) has a higher DILI risk than Ligand B (10.6%). This is a major advantage for Ligand B.
8. **BBB:** Ligand A (87.01%) has a good BBB penetration, while Ligand B (96.743%) is even better. Since ADRB2 is not a CNS target, this is less critical, but still a slight advantage for Ligand B.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual. It's difficult to interpret without knowing the scale, but assuming lower is worse, they are both similarly poor.
10. **Solubility:** Both ligands have negative solubility values, which is also unusual. Again, assuming lower is worse, they are both similarly poor.
11. **hERG:** Ligand A (0.194) has a lower hERG risk than Ligand B (0.687). This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand A (74.285) has a higher microsomal clearance than Ligand B (18.625), meaning it is less metabolically stable. Ligand B is significantly favored.
13. **t1/2:** Ligand B (-12.667) has a longer in vitro half-life than Ligand A (-22.056). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.217) has lower P-gp efflux than Ligand B (0.077). Lower Pgp is better, so Ligand A is slightly favored.
15. **Binding Affinity:** Ligand B (-7.2 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.1 kcal/mol). This is a substantial advantage for Ligand B, and can often outweigh minor ADME drawbacks.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), and the general drug-like properties, Ligand B is the superior candidate. While Ligand A has a better hERG profile and slightly lower Pgp efflux, Ligand B excels in crucial areas like DILI risk, metabolic stability (Cl_mic, t1/2), QED, TPSA, and, most importantly, binding affinity. The significantly stronger binding affinity of Ligand B (-7.2 vs -6.1 kcal/mol) is a decisive factor.
Output:
0
2025-04-17 23:26:07,351 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [340.339, 109.3 , 0.272, 3. , 5. , 0.697, 81.427, 53.974, -5.136, -3.863, 0.13 , -7.149, 41.944, 0.043, -6.6 ]
**Ligand B:** [344.415, 107.69 , -0.45 , 4. , 5. , 0.427, 51.221, 14.541, -5.135, -1.926, 0.278, -30.359, -14.526, 0.008, -7.3 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal 200-500 Da range. (A: 340.339, B: 344.415) - No clear advantage.
2. **TPSA:** Both are reasonably good, around 108-109, slightly above the optimal <140 for oral absorption, but acceptable for a non-CNS GPCR target like ADRB2. (A: 109.3, B: 107.69) - No clear advantage.
3. **logP:** Ligand A (0.272) is quite low, potentially hindering permeability. Ligand B (-0.45) is also low, but slightly better. Both are below the optimal 1-3 range. (A: 0.272, B: -0.45) - Ligand B is slightly favored.
4. **HBD:** Both have acceptable HBD counts (A: 3, B: 4). (A: 3, B: 4) - No clear advantage.
5. **HBA:** Both have acceptable HBA counts (A: 5, B: 5). (A: 5, B: 5) - No clear advantage.
6. **QED:** Ligand A (0.697) has a significantly better QED score than Ligand B (0.427), indicating better overall drug-likeness. (A: 0.697, B: 0.427) - Ligand A is favored.
7. **DILI:** Ligand A (81.427) has a higher DILI risk than Ligand B (51.221). This is a significant concern. (A: 81.427, B: 51.221) - Ligand B is favored.
8. **BBB:** BBB is less critical for ADRB2 (a cardiovascular target). Ligand A (53.974) is better than Ligand B (14.541), but this isn't a major deciding factor. (A: 53.974, B: 14.541) - Ligand A is slightly favored.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. (A: -5.136, B: -5.135) - No clear advantage.
10. **Solubility:** Ligand A (-3.863) has worse solubility than Ligand B (-1.926). (A: -3.863, B: -1.926) - Ligand B is favored.
11. **hERG:** Both have low hERG inhibition risk (A: 0.13, B: 0.278). (A: 0.13, B: 0.278) - Ligand A is slightly favored.
12. **Cl_mic:** Ligand A (-7.149) has significantly better metabolic stability (lower clearance) than Ligand B (-30.359). (A: -7.149, B: -30.359) - Ligand A is strongly favored.
13. **t1/2:** Ligand A (41.944) has a much longer in vitro half-life than Ligand B (-14.526). (A: 41.944, B: -14.526) - Ligand A is strongly favored.
14. **Pgp:** Both have very low Pgp efflux liability (A: 0.043, B: 0.008). (A: 0.043, B: 0.008) - Ligand B is slightly favored.
15. **Affinity:** Ligand B (-7.3) has a slightly better binding affinity than Ligand A (-6.6). (A: -6.6, B: -7.3) - Ligand B is favored.
**Overall Assessment:**
While Ligand B has a slightly better binding affinity and lower DILI risk, the significantly better metabolic stability (Cl_mic, t1/2) and QED score of Ligand A are crucial for a viable drug candidate. The low logP of both is a concern, but the superior ADME properties of Ligand A outweigh the slight affinity advantage of Ligand B. The higher DILI risk of Ligand A is a concern, but could be addressed with further structural modifications.
Therefore, I would choose Ligand A.
1
2025-04-17 23:26:07,351 - INFO - Batch 404 complete. Total preferences: 6464
2025-04-17 23:26:07,351 - INFO - Processing batch 405/512...
2025-04-17 23:27:00,453 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.431 and 342.443 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (111.29) is higher than Ligand B (75.19). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is still preferable for absorption. Ligand B is better.
3. **logP:** Ligand B (1.873) is within the optimal 1-3 range, while Ligand A (0.797) is slightly below 1. This could potentially hinder membrane permeability for Ligand A. Ligand B is better.
4. **HBD:** Ligand A (4) is higher than Ligand B (1). Lower HBD is generally preferred for better permeability. Ligand B is better.
5. **HBA:** Both ligands have 4 HBA, which is acceptable. No significant difference.
6. **QED:** Ligand B (0.906) has a significantly higher QED score than Ligand A (0.608), indicating a more drug-like profile. Ligand B is better.
7. **DILI:** Ligand A (35.285) has a much lower DILI risk than Ligand B (53.47). This is a significant advantage for Ligand A.
8. **BBB:** Ligand B (63.784) has a higher BBB penetration percentile than Ligand A (38.426). While ADRB2 isn't a primary CNS target, some degree of BBB penetration can be useful for understanding off-target effects. Ligand B is better.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.249 and -5.003), which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
10. **Solubility:** Ligand A (-2.766) has slightly worse solubility than Ligand B (-1.797). Solubility is important, but not a primary concern. Ligand B is better.
11. **hERG:** Ligand A (0.067) has a lower hERG risk than Ligand B (0.232). This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand A (-5.04) has a much lower (better) microsomal clearance than Ligand B (23.566). This suggests greater metabolic stability for Ligand A.
13. **t1/2:** Ligand A (-17.741) has a longer in vitro half-life than Ligand B (-9.098), indicating greater stability.
14. **Pgp:** Ligand A (0.023) has a much lower P-gp efflux liability than Ligand B (0.055), suggesting better bioavailability.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.9 and -6.7 kcal/mol). The difference is not substantial enough to be a deciding factor.
**Overall Assessment:**
Ligand B has advantages in TPSA, logP, QED, and BBB. However, Ligand A demonstrates superior safety profiles with significantly lower DILI and hERG risk, and better metabolic stability (lower Cl_mic, longer t1/2) and lower P-gp efflux. Considering the cardiovascular target, minimizing off-target effects and ensuring metabolic stability are crucial. The slight permeability concerns with Ligand A are less critical than the potential safety issues with Ligand B.
Output:
1
2025-04-17 23:27:00,454 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (346.471 and 347.507 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (58.64) is significantly better than Ligand B (83.6). For a GPCR, keeping TPSA low is beneficial for permeability, and Ligand A is well below the 140 threshold. Ligand B is approaching the upper limit.
3. **logP:** Both ligands have acceptable logP values (2.289 and 3.438), falling within the 1-3 range. Ligand B is slightly higher, which *could* indicate potential off-target effects, but isn't a major concern.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 3 HBA, while Ligand B has 5. Both are acceptable (<=10), but Ligand A is preferable.
6. **QED:** Ligand B (0.657) has a better QED score than Ligand A (0.437), indicating a more drug-like profile overall. This is a point in favor of Ligand B.
7. **DILI:** Ligand B (41.877) has a slightly higher DILI risk than Ligand A (23.459), but both are well below the concerning 60% threshold. A slight advantage to Ligand A.
8. **BBB:** Ligand A (75.107) has a significantly better BBB percentile than Ligand B (45.56). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant for side effect profiles, and better BBB penetration can be advantageous.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-5.058) is slightly better than Ligand B (-4.877), but both are problematic.
10. **Solubility:** Ligand A (-1.973) has better solubility than Ligand B (-4.142). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.36) has a much lower hERG risk than Ligand B (0.617). This is a critical safety parameter, and Ligand A is clearly better.
12. **Cl_mic:** Ligand B (81.964) has a significantly higher microsomal clearance than Ligand A (39.88). This means Ligand B will be metabolized faster, potentially leading to lower exposure. Ligand A is preferable.
13. **t1/2:** Ligand B (16.529) has a much longer in vitro half-life than Ligand A (0.974). This is a significant advantage for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.139) has lower P-gp efflux than Ligand B (0.519), which is desirable for better absorption and bioavailability.
15. **Binding Affinity:** Ligand B (-7.8) has a significantly stronger binding affinity than Ligand A (-6.0). This is a substantial advantage, and could potentially outweigh some of the ADME drawbacks. A difference of 1.8 kcal/mol is meaningful.
**Overall Assessment:**
Ligand B has a substantially better binding affinity and a longer half-life. However, it suffers from higher TPSA, higher DILI risk, worse BBB penetration, higher hERG risk, and higher metabolic clearance. Ligand A has a more favorable ADME profile overall, particularly regarding safety (hERG, DILI) and permeability (TPSA, Pgp, solubility). The binding affinity difference is significant, but the ADME profile of Ligand A is more balanced and less likely to lead to development issues. Given the GPCR target class, the lower TPSA and better safety profile of Ligand A are particularly valuable.
Output:
1
2025-04-17 23:27:00,454 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (370.49 Da) is slightly higher than Ligand B (348.443 Da), but both are acceptable.
2. **TPSA:** Ligand A (58.64) is well below the 140 threshold and acceptable for oral absorption. Ligand B (78.87) is still under 140, but less optimal.
3. **logP:** Ligand A (2.437) is within the optimal range (1-3). Ligand B (0.849) is a bit low, potentially hindering permeation.
4. **HBD:** Both ligands have acceptable HBD counts (Ligand A: 1, Ligand B: 2), well below the limit of 5.
5. **HBA:** Both ligands have acceptable HBA counts (Ligand A: 4, Ligand B: 4), well below the limit of 10.
6. **QED:** Both ligands have good QED scores (Ligand A: 0.474, Ligand B: 0.551), indicating reasonable drug-likeness. Ligand B is slightly better.
7. **DILI:** Ligand A (35.983) has a lower DILI risk than Ligand B (18.728), which is excellent.
8. **BBB:** Ligand A (81.815) has a significantly higher BBB penetration percentile than Ligand B (28.848). While ADRB2 isn't exclusively a CNS target, some cardiovascular effects are mediated by CNS pathways, and better BBB penetration could be beneficial.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.689 and -4.734), which is unusual and indicates very poor permeability. This is a serious concern for both.
10. **Solubility:** Both ligands have negative solubility values (-2.961 and -1.705), indicating very poor aqueous solubility. This is also a significant concern.
11. **hERG:** Both ligands have low hERG inhibition liability (Ligand A: 0.486, Ligand B: 0.098). Ligand B is slightly better here.
12. **Cl_mic:** Ligand A (72.584) has a higher microsomal clearance than Ligand B (2.18), indicating lower metabolic stability.
13. **t1/2:** Ligand A (-0.828) has a slightly better in vitro half-life than Ligand B (-1.53).
14. **Pgp:** Ligand A (0.27) has a lower P-gp efflux liability than Ligand B (0.037), suggesting better bioavailability.
15. **Binding Affinity:** Ligand B (-7.3 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.1 kcal/mol). This is a substantial advantage (1.2 kcal/mol difference).
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand B excels in affinity, while Ligand A has better logP and Pgp. However, the large difference in affinity is a major factor. The poor Caco-2 and solubility for both are concerning, but can potentially be addressed with formulation strategies.
**Overall Assessment:**
Despite the poor permeability and solubility of both compounds, the significantly stronger binding affinity of Ligand B (-7.3 kcal/mol vs -6.1 kcal/mol) outweighs the other drawbacks. The better hERG profile of Ligand B is also a plus. While Ligand A has better BBB penetration, the affinity difference is more critical for initial efficacy.
Output:
0
2025-04-17 23:27:00,454 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (349.5 and 342.5 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (52.65) is higher than Ligand B (32.34). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for better absorption. Ligand B is better.
**3. logP:** Ligand A (2.425) is within the optimal 1-3 range. Ligand B (4.253) is slightly above this, potentially leading to solubility issues and off-target interactions. Ligand A is better.
**4. H-Bond Donors:** Both have 1 HBD, which is acceptable.
**5. H-Bond Acceptors:** Ligand A has 3 HBA, Ligand B has 2. Both are within the acceptable limit of 10.
**6. QED:** Both ligands have good QED scores (0.718 and 0.867), indicating good drug-like properties. No significant difference.
**7. DILI Risk:** Ligand A (11.13) has a significantly lower DILI risk than Ligand B (22.8). This is a crucial advantage, as liver toxicity is a major concern in drug development. Ligand A is significantly better.
**8. BBB Penetration:** Ligand A (78.87) and Ligand B (90.04) both show good BBB penetration. Since ADRB2 is a cardiovascular target, BBB penetration is less critical than for CNS targets, but it doesn't hurt. Ligand B is slightly better.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.96 and -4.7). This is unusual and suggests poor permeability. However, the values are very close.
**10. Aqueous Solubility:** Ligand A (-2.622) is better than Ligand B (-4.402), indicating better solubility. This is important for bioavailability.
**11. hERG Inhibition:** Ligand A (0.552) has a lower hERG inhibition risk than Ligand B (0.768). This is a significant advantage, as hERG inhibition can lead to cardiotoxicity. Ligand A is better.
**12. Microsomal Clearance:** Ligand B (85.965) has a higher microsomal clearance than Ligand A (37.43), suggesting faster metabolism and potentially lower exposure. Ligand A is better.
**13. In vitro Half-Life:** Ligand B (34.601) has a much longer in vitro half-life than Ligand A (4.425). This is a significant advantage, potentially allowing for less frequent dosing. Ligand B is better.
**14. P-gp Efflux:** Ligand A (0.092) has lower P-gp efflux than Ligand B (0.581), which is favorable for bioavailability. Ligand A is better.
**15. Binding Affinity:** Ligand A (-7.3) has a slightly better binding affinity than Ligand B (-6.5). While both are good, the 0.8 kcal/mol difference is notable and can outweigh some ADME drawbacks. Ligand A is better.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity) and the general drug-like properties, **Ligand A** is the more promising candidate. While Ligand B has a longer half-life, Ligand A demonstrates superior safety (lower DILI and hERG risk), better solubility, lower P-gp efflux, and slightly better binding affinity. The slightly higher TPSA of Ligand A is less concerning for a cardiovascular target. The combination of these factors makes Ligand A the preferred choice.
Output:
1
2025-04-17 23:27:00,454 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.391 and 350.463 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (116.84) is higher than Ligand B (68.74). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is generally preferred for absorption. Ligand B is significantly better here.
3. **logP:** Ligand A (-0.882) is lower than Ligand B (2.219). Ligand A is a bit low, potentially hindering membrane permeability. Ligand B is within the optimal 1-3 range. Ligand B is better.
4. **HBD:** Ligand A (3) is higher than Ligand B (1). Both are acceptable, but lower HBD is generally preferred for permeability. Ligand B is better.
5. **HBA:** Ligand A (5) is lower than Ligand B (7). Both are acceptable, but lower HBA is generally preferred for permeability. Ligand B is slightly worse.
6. **QED:** Ligand B (0.732) is higher than Ligand A (0.537), indicating a more drug-like profile. Ligand B is better.
7. **DILI:** Ligand A (47.77) has a slightly higher DILI risk than Ligand B (33.579), but both are below the concerning threshold of 60. Ligand B is slightly better.
8. **BBB:** Ligand A (74.254) is lower than Ligand B (89.066). While ADRB2 isn't necessarily a CNS target, higher BBB is still a positive attribute. Ligand B is better.
9. **Caco-2:** Ligand A (-5.188) is worse than Ligand B (-4.83). Both are negative, indicating poor permeability, but Ligand B is slightly better.
10. **Solubility:** Ligand A (-2.197) is worse than Ligand B (-2). Both are poor, but Ligand B is slightly better.
11. **hERG:** Ligand A (0.074) is lower than Ligand B (0.689), indicating lower hERG inhibition risk. Ligand A is better.
12. **Cl_mic:** Ligand A (-15.638) has a significantly lower (better) microsomal clearance than Ligand B (35.17). This suggests greater metabolic stability for Ligand A. Ligand A is much better.
13. **t1/2:** Ligand A (13.668) is lower than Ligand B (59.313). Ligand B has a much longer in vitro half-life, which is desirable. Ligand B is much better.
14. **Pgp:** Ligand A (0.006) is much lower than Ligand B (0.069), indicating lower P-gp efflux. This is a significant advantage for Ligand A. Ligand A is much better.
15. **Affinity:** Both ligands have the same binding affinity (-5.6 kcal/mol).
**Overall Assessment:**
Ligand B has advantages in QED, BBB, t1/2, and logP. However, Ligand A has a significantly better metabolic profile (Cl_mic), lower P-gp efflux, and lower hERG risk. Considering the GPCR-specific priorities (logP, Pgp, TPSA) and the importance of metabolic stability for a cardiovascular drug, Ligand A appears to be the more promising candidate. The lower logP of Ligand A is a concern, but the substantial benefits in metabolic stability and efflux outweigh this drawback.
Output:
1
2025-04-17 23:27:00,454 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (352.46 & 352.43 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (46.34) is slightly higher than Ligand B (42.43). Both are below the 140 threshold for oral absorption, and acceptable for a cardiovascular target.
3. **logP:** Ligand A (4.921) is higher than Ligand B (3.938). Ligand A is pushing the upper limit of the optimal range (1-3), potentially raising concerns about solubility and off-target effects. Ligand B is well within the optimal range.
4. **HBD:** Both have 0 HBD, which is good.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 3. Both are acceptable.
6. **QED:** Both ligands have similar QED values (0.657 and 0.632), indicating good drug-likeness.
7. **DILI:** Ligand A (71.423) has a significantly higher DILI risk than Ligand B (15.975). This is a major concern for Ligand A.
8. **BBB:** Both ligands have high BBB penetration (89.492 and 94.067). While ADRB2 isn't strictly a CNS target, some CNS penetration might be acceptable or even beneficial depending on the specific therapeutic goal.
9. **Caco-2:** Ligand A (-4.744) is worse than Ligand B (-3.763), indicating lower intestinal absorption.
10. **Solubility:** Ligand A (-5.49) is significantly worse than Ligand B (-3.54), which is a major drawback given its higher logP.
11. **hERG:** Both ligands have low hERG inhibition liability (0.77 and 0.713), which is good.
12. **Cl_mic:** Ligand A (94.723) has higher microsomal clearance than Ligand B (83.91), suggesting lower metabolic stability.
13. **t1/2:** Ligand B (-2.234) has a longer in vitro half-life than Ligand A (43.614).
14. **Pgp:** Ligand A (0.929) has higher P-gp efflux than Ligand B (0.425), which is unfavorable.
15. **Binding Affinity:** Ligand A (-9.0) has a significantly stronger binding affinity than Ligand B (-6.0). This is a substantial advantage.
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are crucial. Ligand A has a better affinity but suffers from a high logP, higher Pgp efflux, and worse solubility. Ligand B has a more balanced profile, with a good logP, lower Pgp efflux, and better solubility. The DILI risk for Ligand A is also a major red flag. While the affinity difference is significant, the ADME liabilities of Ligand A are too substantial to ignore.
**Conclusion:**
Despite the stronger binding affinity of Ligand A, the significantly higher DILI risk, poorer solubility, and higher P-gp efflux make it a less desirable candidate. Ligand B's more balanced profile, with better ADME properties, outweighs the affinity difference.
Output:
0
2025-04-17 23:27:00,454 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (362.366) is slightly higher than Ligand B (336.351), but both are acceptable.
2. **TPSA:** Ligand A (77.52) is better than Ligand B (95.42). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (2.537) is optimal, while Ligand B (0.205) is quite low. This is a significant drawback for Ligand B, potentially hindering membrane permeability and bioavailability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD is generally better for permeability.
5. **HBA:** Both ligands have the same number of HBA (5), which is acceptable.
6. **QED:** Ligand B (0.778) has a slightly better QED score than Ligand A (0.577), suggesting a more drug-like profile. However, this is somewhat offset by its poor logP.
7. **DILI:** Both ligands have similar DILI risk (Ligand A: 69.562, Ligand B: 64.56), and both are within an acceptable range (< 60 is ideal, but <80 is generally tolerable).
8. **BBB:** Ligand A (37.069) has a slightly better BBB penetration score than Ligand B (13.067), but this is not a major consideration for a cardiovascular target.
9. **Caco-2:** Both ligands have very similar, and poor, Caco-2 permeability (-4.879 and -4.864).
10. **Solubility:** Ligand A (-3.143) has slightly better solubility than Ligand B (-2.562).
11. **hERG:** Ligand A (0.338) has a lower hERG risk than Ligand B (0.128), which is a significant advantage.
12. **Cl_mic:** Ligand B (-34.329) has a much lower microsomal clearance than Ligand A (36.256), indicating better metabolic stability. This is a strong point for Ligand B.
13. **t1/2:** Ligand B (10.498) has a longer in vitro half-life than Ligand A (-10.024), which is desirable.
14. **Pgp:** Ligand A (0.367) has lower P-gp efflux than Ligand B (0.021), which is preferable.
15. **Binding Affinity:** Ligand B (-8.9 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.5 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME concerns.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in affinity, has acceptable TPSA, and better Pgp efflux. Its low logP is a significant concern, but the substantial binding affinity advantage is compelling. Ligand A has a better logP and hERG profile, but its lower affinity is a drawback.
**Overall Assessment:**
Despite Ligand B's low logP, the significantly stronger binding affinity (-8.9 vs -6.5 kcal/mol) is a major advantage that likely outweighs the potential permeability issues. The better metabolic stability (lower Cl_mic) and longer half-life also contribute to its favorability. While Ligand A has a better safety profile (hERG), the potency difference is too large to ignore.
Output:
0
2025-04-17 23:27:00,455 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output:
**1. Molecular Weight (MW):**
* Ligand A: 339.4 Da - Within the ideal range (200-500 Da).
* Ligand B: 362.4 Da - Also within the ideal range.
* *No clear advantage.*
**2. Topological Polar Surface Area (TPSA):**
* Ligand A: 84.98 - Excellent, well below the 140 threshold for oral absorption.
* Ligand B: 76.46 - Even better, further below the threshold.
* *Slight advantage to Ligand B.*
**3. Lipophilicity (logP):**
* Ligand A: 2.33 - Optimal range (1-3).
* Ligand B: 1.683 - Also optimal, slightly lower.
* *Slight advantage to Ligand A.*
**4. H-Bond Donors (HBD):**
* Ligand A: 2 - Meets the criteria (<=5).
* Ligand B: 1 - Meets the criteria.
* *No clear advantage.*
**5. H-Bond Acceptors (HBA):**
* Ligand A: 6 - Meets the criteria (<=10).
* Ligand B: 5 - Meets the criteria.
* *No clear advantage.*
**6. Quantitative Estimate of Drug-likeness (QED):**
* Ligand A: 0.615 - Good, above the 0.5 threshold.
* Ligand B: 0.749 - Very good, even higher.
* *Advantage to Ligand B.*
**7. DILI Risk (DILI):**
* Ligand A: 59.636 - Moderate risk, but acceptable.
* Ligand B: 39.434 - Lower risk, more desirable.
* *Advantage to Ligand B.*
**8. Blood-Brain Barrier Penetration (BBB):**
* Ligand A: 73.517 - Acceptable, but not high.
* Ligand B: 81.582 - Better BBB penetration.
* *Advantage to Ligand B.* (Important for GPCRs)
**9. Caco-2 Permeability:**
* Ligand A: -5.45 - Poor permeability.
* Ligand B: -5.042 - Also poor permeability, but slightly better.
* *Slight advantage to Ligand B.*
**10. Aqueous Solubility:**
* Ligand A: -2.39 - Poor solubility.
* Ligand B: -1.706 - Slightly better solubility.
* *Slight advantage to Ligand B.*
**11. hERG Inhibition:**
* Ligand A: 0.79 - Relatively low risk.
* Ligand B: 0.433 - Even lower risk, preferred.
* *Advantage to Ligand B.*
**12. Microsomal Clearance (Cl_mic):**
* Ligand A: 59.372 - Moderate clearance.
* Ligand B: -17.484 - Negative value suggests very low clearance (high metabolic stability). This is a significant advantage.
* *Strong advantage to Ligand B.*
**13. In vitro Half-Life (t1/2):**
* Ligand A: 4.692 - Moderate half-life.
* Ligand B: -10.52 - Negative value suggests a very long half-life. This is a significant advantage.
* *Strong advantage to Ligand B.*
**14. P-gp Efflux:**
* Ligand A: 0.316 - Low efflux, good.
* Ligand B: 0.026 - Very low efflux, excellent.
* *Advantage to Ligand B.* (Important for GPCRs)
**15. Binding Affinity:**
* Ligand A: -7.1 kcal/mol - Excellent affinity.
* Ligand B: -7.2 kcal/mol - Slightly better affinity, but the difference is small.
* *Slight advantage to Ligand B.*
**Overall Assessment:**
Ligand B consistently outperforms Ligand A across most crucial ADME-Tox properties, especially metabolic stability (Cl_mic, t1/2), DILI risk, BBB penetration, and P-gp efflux. While Ligand A has a good binding affinity, the significant improvements in ADME properties for Ligand B outweigh the minor difference in affinity. Given that this is a GPCR target, the improved BBB penetration and P-gp efflux liability of Ligand B are particularly valuable.
Output:
0
2025-04-17 23:27:00,455 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (374.5 and 360.4 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand B (86.88) is significantly better than Ligand A (113.32). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (2.531) is within the optimal range (1-3), while Ligand A (0.994) is slightly below, potentially hindering permeation. Ligand B has an advantage.
4. **HBD:** Both ligands have 3 HBD, which is acceptable.
5. **HBA:** Ligand B (3) is better than Ligand A (6). Lower HBA is generally preferred for permeability.
6. **QED:** Ligand B (0.632) has a slightly higher QED than Ligand A (0.529), indicating a more drug-like profile.
7. **DILI:** Ligand A (26.948) has a considerably lower DILI risk than Ligand B (44.552). This is a significant advantage for Ligand A.
8. **BBB:** Ligand B (79.566) has a higher BBB penetration than Ligand A (38.542). While ADRB2 isn't a CNS target, some degree of BBB penetration can sometimes be beneficial for distribution.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.283 and -5.122), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-1.265) has better solubility than Ligand B (-3.337). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.334) has a lower hERG risk than Ligand B (0.182). Lower hERG is crucial for avoiding cardiotoxicity, especially for a cardiovascular target.
12. **Cl_mic:** Ligand A (0.324) has significantly lower microsomal clearance than Ligand B (8.388), suggesting better metabolic stability.
13. **t1/2:** Ligand A (26.426) has a much longer in vitro half-life than Ligand B (-16.104). This is a major advantage for Ligand A.
14. **Pgp:** Ligand A (0.088) has lower P-gp efflux than Ligand B (0.044), which is favorable.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-5.9 and -5.1 kcal/mol). The difference is not substantial enough to override other factors.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity) and the general guidelines, Ligand A emerges as the more promising candidate. While Ligand B has a better logP and TPSA, Ligand A excels in critical ADME properties like DILI risk, hERG inhibition, metabolic stability (Cl_mic and t1/2), and P-gp efflux. The similar binding affinities make these ADME differences the deciding factors. The negative Caco-2 values are concerning for both, but the superior ADME profile of Ligand A makes it the better choice for further development.
Output:
1
2025-04-17 23:27:00,455 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [351.451, 122.27 , 0.57 , 4. , 6. , 0.491, 29.159, 57.736, -5.568, -2.042, 0.431, 1.298, 12.548, 0.019, -5.1 ]
**Ligand B:** [344.415, 95.42 , 1.505, 2. , 5. , 0.807, 45.056, 57.968, -5.111, -2.884, 0.119, 14.334, -15.137, 0.027, -7. ]
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand B (344.415) is slightly lower, which is generally favorable.
2. **TPSA:** Ligand A (122.27) is slightly above the preferred <140 for oral absorption, while Ligand B (95.42) is well within. This favors B.
3. **logP:** Ligand A (0.57) is a bit low, potentially hindering permeability. Ligand B (1.505) is better, falling within the optimal 1-3 range. This favors B.
4. **HBD:** Ligand A (4) is acceptable, Ligand B (2) is even better.
5. **HBA:** Ligand A (6) is acceptable, Ligand B (5) is slightly better.
6. **QED:** Ligand B (0.807) has a significantly better QED score than Ligand A (0.491), indicating a more drug-like profile. This is a substantial advantage for B.
7. **DILI:** Ligand A (29.159) has a lower DILI risk than Ligand B (45.056), which is favorable for A.
8. **BBB:** Both have similar BBB penetration (~58%), which is not high but acceptable for a non-CNS focused drug.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability.
10. **Solubility:** Both have negative solubility values, which is also unusual and suggests poor solubility.
11. **hERG:** Both have low hERG risk.
12. **Cl_mic:** Ligand A (1.298) has much lower microsomal clearance than Ligand B (14.334), indicating better metabolic stability. This favors A.
13. **t1/2:** Ligand B (-15.137) has a negative half-life, which is concerning. Ligand A (12.548) has a reasonable half-life. This strongly favors A.
14. **Pgp:** Both have very low Pgp efflux liability.
15. **Binding Affinity:** Ligand B (-7.0) has a significantly stronger binding affinity than Ligand A (-5.1). This is a major advantage for B.
**GPCR-specific priorities:** For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, and affinity. Ligand B excels in logP, TPSA, and affinity. Ligand A has better metabolic stability (Cl_mic) and half-life, and a lower DILI risk. However, the significantly stronger binding affinity of Ligand B (-7.0 vs -5.1) is a substantial advantage that can often outweigh minor ADME drawbacks. The QED score of Ligand B is also much better.
**Conclusion:**
Despite Ligand A's better metabolic stability and lower DILI, the superior binding affinity and QED score of Ligand B make it the more promising drug candidate for ADRB2. The difference in binding affinity is significant enough to overcome the slightly higher DILI risk and worse metabolic stability.
Output:
0
2025-04-17 23:27:00,455 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (342.439 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (58.64) is significantly better than Ligand B (84.14). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA still aids absorption.
3. **logP:** Both are within the optimal range (1-3), but Ligand B (3.305) is a bit higher. This could potentially lead to solubility issues or off-target interactions, but it's not a severe concern.
4. **HBD/HBA:** Ligand A has 1 HBD and 3 HBA, while Ligand B has 2 HBD and 6 HBA. Both are acceptable, but Ligand A is slightly preferred due to the lower HBA count.
5. **QED:** Ligand A (0.795) has a better QED score than Ligand B (0.585), indicating a more drug-like profile.
6. **DILI:** Ligand A (31.252) has a much lower DILI risk than Ligand B (62.66). This is a significant advantage for Ligand A.
7. **BBB:** Ligand B (85.459) has a higher BBB penetration percentile than Ligand A (68.748). However, as ADRB2 is a cardiovascular target, BBB penetration is not a critical factor.
8. **Caco-2:** Ligand A (-4.726) and Ligand B (-5.462) are both negative, indicating poor permeability. This is a concern for both.
9. **Solubility:** Ligand A (-2.161) has better solubility than Ligand B (-3.088).
10. **hERG:** Ligand A (0.133) has a much lower hERG inhibition liability than Ligand B (0.826). This is a crucial advantage, as hERG inhibition can lead to cardiotoxicity.
11. **Cl_mic:** Ligand B (88.989) has a significantly higher microsomal clearance than Ligand A (21.381), indicating faster metabolism and potentially lower bioavailability.
12. **t1/2:** Ligand A (-11.941) has a longer in vitro half-life than Ligand B (3.479).
13. **Pgp:** Ligand A (0.044) has lower P-gp efflux liability than Ligand B (0.544).
14. **Binding Affinity:** Ligand B (-7.8 kcal/mol) has a slightly better binding affinity than Ligand A (-7.4 kcal/mol). While a 0.4 kcal/mol difference is noticeable, it's not a massive advantage, especially considering the other factors.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A is better in terms of TPSA, Pgp, and has acceptable logP. While Ligand B has slightly better affinity, Ligand A excels in safety (DILI, hERG) and ADME properties (Cl_mic, t1/2, solubility).
**Conclusion:**
Considering the balance of properties, Ligand A is the more promising drug candidate. Its superior safety profile (lower DILI and hERG), better ADME properties (lower Cl_mic, longer t1/2, better solubility, lower Pgp efflux), and acceptable affinity outweigh the slightly weaker binding affinity compared to Ligand B.
Output:
1
2025-04-17 23:27:00,456 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (a cardiovascular GPCR) drug candidates.
**Ligand A: [362.499, 56.75, 2.072, 0, 5, 0.826, 57.348, 85.731, -4.625, -2.879, 0.568, 59.507, -0.72, 0.245, -5.2]**
**Ligand B: [375.416, 47.48, 3.374, 0, 6, 0.673, 31.95, 87.708, -4.448, -3.604, 0.732, 75.336, -4.967, 0.173, -5.1]**
Here's a breakdown, comparing each parameter and considering GPCR priorities (logP, Pgp, TPSA, affinity):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (362.499) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (56.75) is higher than Ligand B (47.48). Both are acceptable, but lower TPSA is preferred for GPCRs, giving a slight edge to B.
3. **logP:** Ligand A (2.072) is within the optimal range (1-3). Ligand B (3.374) is also within range, but approaching the upper limit. A is slightly better here.
4. **HBD:** Both have 0 HBD, which is good.
5. **HBA:** Ligand A (5) has fewer HBA than Ligand B (6). Fewer is slightly preferred.
6. **QED:** Ligand A (0.826) has a better QED score than Ligand B (0.673), indicating better overall drug-likeness.
7. **DILI:** Ligand B (31.95) has a significantly lower DILI risk than Ligand A (57.348). This is a major advantage for B.
8. **BBB:** Both have good BBB penetration (A: 85.731, B: 87.708). B is slightly better.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Both have negative solubility values, indicating poor aqueous solubility. This is a significant drawback for both.
11. **hERG:** Both have low hERG inhibition risk (A: 0.568, B: 0.732). B is slightly worse.
12. **Cl_mic:** Ligand B (75.336) has a higher microsomal clearance than Ligand A (59.507), meaning A is more metabolically stable.
13. **t1/2:** Ligand B (-4.967) has a more negative in vitro half-life, which is concerning. Ligand A (-0.72) is better.
14. **Pgp:** Ligand A (0.245) has lower P-gp efflux than Ligand B (0.173), which is favorable for bioavailability and CNS exposure.
15. **Affinity:** Both have very similar binding affinities (-5.2 and -5.1 kcal/mol). The difference is negligible.
**Overall Assessment:**
Ligand B has a significantly better DILI profile and slightly better BBB penetration. However, Ligand A has better QED, metabolic stability (lower Cl_mic, better t1/2), and Pgp efflux. Both have poor Caco-2 and solubility. The DILI risk is a major concern, and the improvement in B is substantial. Considering the GPCR target class, the slight edge in BBB penetration for B is also beneficial. While A has some advantages in metabolic stability and Pgp, the lower DILI risk of B outweighs these factors.
Therefore, I prefer Ligand B.
0
2025-04-17 23:27:00,456 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (351.407 and 348.531 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (102.06) is higher than Ligand B (58.2). For a GPCR, lower TPSA is generally preferred for better brain penetration, even though ADRB2 isn't exclusively a CNS target. Ligand B is significantly better.
3. **logP:** Ligand A (-1.547) is lower than the optimal 1-3 range, potentially hindering permeability. Ligand B (3.982) is within the optimal range. Ligand B is better.
4. **HBD:** Both ligands have 2 HBD, which is acceptable.
5. **HBA:** Ligand A has 4 HBA, while Ligand B has 2. Lower HBA is generally preferred for permeability, giving a slight edge to Ligand B.
6. **QED:** Both ligands have similar QED scores (0.605 and 0.652), indicating good drug-likeness.
7. **DILI:** Ligand A (29.042) has a slightly higher DILI risk than Ligand B (19.698), but both are below the concerning threshold of 60. Ligand B is preferable.
8. **BBB:** Ligand B (69.407) has a better BBB penetration percentile than Ligand A (56.572). While ADRB2 isn't solely a CNS target, some brain exposure can be relevant for off-target effects or peripheral effects mediated by ADRB2 in the brain.
9. **Caco-2:** Ligand A (-5.099) and Ligand B (-4.549) both have negative values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
10. **Solubility:** Ligand A (-1.246) has better solubility than Ligand B (-4.309). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.085) has a significantly lower hERG inhibition liability than Ligand B (0.403). This is a crucial advantage for Ligand A, as hERG inhibition can lead to cardiotoxicity.
12. **Cl_mic:** Ligand A (-9.761) has a much lower (better) microsomal clearance than Ligand B (65.536), indicating greater metabolic stability.
13. **t1/2:** Ligand A (5.721) has a shorter half-life than Ligand B (12.501). Longer half-life is generally preferred.
14. **Pgp:** Ligand A (0.001) has a much lower Pgp efflux liability than Ligand B (0.114), suggesting better oral bioavailability and potentially better CNS exposure.
15. **Binding Affinity:** Ligand A (-7.0) has slightly better binding affinity than Ligand B (-5.5). This is a significant advantage, as a difference of >1.5 kcal/mol can often outweigh other drawbacks.
**Overall Assessment:**
Ligand A has a clear advantage in binding affinity, metabolic stability (Cl_mic), Pgp efflux, and hERG inhibition. While Ligand B has better logP and TPSA, the superior affinity and safety profile of Ligand A are more critical for a GPCR target like ADRB2. The slightly shorter half-life of Ligand A is a minor drawback that could potentially be addressed through formulation or structural modifications. The solubility of Ligand A is also better.
Output:
1
2025-04-17 23:27:00,456 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (354.451 Da) is within the ideal range (200-500 Da). Ligand B (386.627 Da) is also acceptable. No clear advantage here.
2. **TPSA:** Ligand A (93.19) is borderline, but acceptable for a non-CNS GPCR target. Ligand B (49.41) is excellent, well below the 140 threshold and suggesting good permeability. Advantage: B
3. **logP:** Ligand A (-0.951) is a bit low, potentially hindering membrane permeability. Ligand B (3.547) is optimal. Advantage: B
4. **HBD:** Ligand A (2) is good. Ligand B (1) is also good. No significant difference.
5. **HBA:** Ligand A (5) is good. Ligand B (4) is also good. No significant difference.
6. **QED:** Both Ligand A (0.575) and Ligand B (0.616) are above the 0.5 threshold, indicating good drug-likeness. No clear advantage.
7. **DILI:** Ligand A (8.414%) has a very low DILI risk, excellent. Ligand B (30.361%) is still acceptable, but higher. Advantage: A
8. **BBB:** Ligand A (17.216%) is low, as expected for a cardiovascular target. Ligand B (67.468%) is relatively high, which isn't necessarily *bad* for ADRB2, but doesn't offer a specific benefit.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.623 and -5.124) which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (0.365) is very poor. Ligand B (-3.535) is also very poor. This is a significant drawback for both.
11. **hERG:** Ligand A (0.026%) has extremely low hERG risk, excellent. Ligand B (0.63%) is also low, but higher than A. Advantage: A
12. **Cl_mic:** Ligand A (2 mL/min/kg) is excellent, indicating high metabolic stability. Ligand B (77.811 mL/min/kg) is very high, suggesting rapid metabolism. Advantage: A
13. **t1/2:** Ligand A (-14.617 hours) is negative, which is not possible. This is a red flag. Ligand B (0.217 hours) is extremely short, indicating rapid clearance. Both are problematic, but A's value is clearly erroneous.
14. **Pgp:** Ligand A (0.003) has very low P-gp efflux liability, which is good. Ligand B (0.456) is also relatively low. Advantage: A
15. **Binding Affinity:** Ligand B (-7.0 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.7 kcal/mol). This is a substantial advantage, potentially outweighing some ADME concerns. Advantage: B
**Overall Assessment:**
Ligand B has a superior logP and binding affinity, which are key for GPCR targets. However, it suffers from higher DILI risk, higher metabolic clearance, and a short half-life. Ligand A has excellent DILI and hERG profiles, low P-gp efflux, and better metabolic stability, but its logP is suboptimal and its solubility is very poor. The negative in vitro half-life for Ligand A is a major concern and likely an error. Considering the importance of binding affinity for GPCRs, and the fact that Ligand B's other issues *might* be addressable through further optimization, I lean towards Ligand B. The solubility issue is a significant concern for both, but could be addressed through formulation strategies.
Output:
0
2025-04-17 23:27:00,457 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [382.247, 84.22, 3.009, 2, 4, 0.833, 76.115, 49.244, -5.13, -3.646, 0.01, 6.807, -22.531, 0.011, -7.7]**
**Ligand B: [383.901, 82.53, 1.923, 2, 5, 0.813, 51.338, 33.656, -4.924, -3.415, 0.159, -1.814, 40.18, 0.125, -7]**
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). A is 382.247, B is 383.901. No significant difference.
2. **TPSA:** Both are acceptable for oral absorption (<140 A^2). A is 84.22, B is 82.53. B is slightly better.
3. **logP:** Both are within the optimal range (1-3). A is 3.009, B is 1.923. A is preferred here, as higher logP can sometimes improve receptor engagement for GPCRs.
4. **H-Bond Donors:** Both have 2 HBD, which is good.
5. **H-Bond Acceptors:** A has 4, B has 5. A is slightly better.
6. **QED:** Both are good (>0.5). A is 0.833, B is 0.813. A is slightly better.
7. **DILI:** A has a DILI risk of 76.115, B has 51.338. B is significantly better, indicating a lower risk of liver injury. This is a critical factor.
8. **BBB:** A has a BBB penetration of 49.244, B has 33.656. A is better, though neither is exceptionally high. For a cardiovascular target, BBB penetration isn't *as* critical as for CNS targets, but it's still a positive.
9. **Caco-2:** Both are negative, indicating poor permeability. A is -5.13, B is -4.924. No significant difference.
10. **Solubility:** Both are negative, indicating poor solubility. A is -3.646, B is -3.415. No significant difference.
11. **hERG:** Both are very low, indicating minimal hERG inhibition risk. A is 0.01, B is 0.159. A is slightly better.
12. **Cl_mic:** A has a clearance of 6.807, B has -1.814. B is significantly better, indicating better metabolic stability.
13. **t1/2:** A has a half-life of -22.531, B has 40.18. B is *much* better, indicating a longer half-life.
14. **Pgp:** Both are very low. A is 0.011, B is 0.125. A is slightly better.
15. **Binding Affinity:** A is -7.7 kcal/mol, B is -7 kcal/mol. A has a slightly better binding affinity.
**Overall Assessment:**
Ligand A has a slight edge in binding affinity, logP, BBB, and a few other parameters. However, Ligand B demonstrates a *substantial* advantage in DILI risk and metabolic stability (Cl_mic and t1/2). Given that ADRB2 is a cardiovascular target, minimizing off-target effects (like liver toxicity) and ensuring reasonable drug exposure (through metabolic stability and half-life) are paramount. The improved safety profile and pharmacokinetic properties of Ligand B outweigh the small advantage in binding affinity of Ligand A.
Output:
0
2025-04-17 23:27:00,457 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (342.399 Da and 347.375 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (98.06) is better than Ligand B (119.24). For a GPCR, keeping TPSA under 140 is good for oral absorption, and lower is generally preferred.
**3. logP:** Ligand B (1.573) is better than Ligand A (0.678). Both are within the 1-3 range, but Ligand B is closer to the optimal range. Ligand A is a bit low and could have permeability issues.
**4. H-Bond Donors:** Ligand A (3) is slightly higher than Ligand B (2), but both are acceptable (<=5).
**5. H-Bond Acceptors:** Ligand B (7) is higher than Ligand A (4). Both are within the acceptable range (<=10), but Ligand A is preferable.
**6. QED:** Both ligands have similar QED values (0.699 and 0.744), indicating good drug-like properties.
**7. DILI:** Ligand B (85.498) has a significantly higher DILI risk than Ligand A (57.736). This is a major concern, as we want to minimize liver toxicity.
**8. BBB:** Ligand B (50.523) is better than Ligand A (41.218), but since this is a cardiovascular target, BBB penetration is not a high priority.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-5.115 and -5.086), indicating poor permeability. This is concerning for oral bioavailability.
**10. Aqueous Solubility:** Both ligands have negative solubility values (-3.479 and -2.791), indicating poor solubility. This is also concerning for formulation and bioavailability.
**11. hERG Inhibition:** Ligand A (0.429) has a slightly lower hERG inhibition risk than Ligand B (0.201), which is preferable.
**12. Microsomal Clearance:** Ligand A (-43.725) has a much lower (better) microsomal clearance than Ligand B (42.035), indicating greater metabolic stability.
**13. In vitro Half-Life:** Ligand B (-22.173) has a much longer half-life than Ligand A (4.782), which is desirable.
**14. P-gp Efflux:** Ligand A (0.036) has a lower P-gp efflux liability than Ligand B (0.02), which is slightly better.
**15. Binding Affinity:** Ligand B (-7.5) has a slightly better binding affinity than Ligand A (-8.4). While affinity is important, the difference of 0.9 kcal/mol is not substantial enough to outweigh the other significant drawbacks of Ligand B.
**Overall Assessment:**
Ligand A is the better candidate. While Ligand B has slightly better affinity and half-life, Ligand A has a significantly lower DILI risk and better metabolic stability (lower Cl_mic). The TPSA is also more favorable for Ligand A. The poor Caco-2 and solubility are concerns for both, but the DILI risk associated with Ligand B is a major red flag. For a cardiovascular GPCR, metabolic stability and safety are crucial.
Output:
1
2025-04-17 23:27:00,457 - INFO - Batch 405 complete. Total preferences: 6480
2025-04-17 23:27:00,458 - INFO - Processing batch 406/512...
2025-04-17 23:27:46,583 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, priorities are logP, TPSA, Pgp, affinity, and to a lesser extent, BBB.
* **Molecular Weight:** Both ligands are within the acceptable range (200-500 Da). Ligand A (344.375) is slightly lower, which is generally favorable for permeability.
* **TPSA:** Ligand A (93.45) is significantly better than Ligand B (120.52). Lower TPSA is crucial for GPCR ligands to facilitate membrane permeability and receptor engagement.
* **logP:** Both ligands have similar logP values around 0.2, which is a bit low. Ideally, we want values between 1-3. This is a slight drawback for both, but not a major differentiator.
* **H-Bond Donors/Acceptors:** Ligand A (0 HBD, 7 HBA) is better than Ligand B (4 HBD, 5 HBA). Fewer hydrogen bond donors are generally preferred for better membrane permeability.
* **QED:** Ligand A (0.787) has a much better QED score than Ligand B (0.365), indicating a more drug-like profile.
* **DILI:** Ligand B (38.736) has a significantly lower DILI risk than Ligand A (62.505), which is a substantial advantage.
* **BBB:** Ligand A (60.566) has a slightly better BBB penetration than Ligand B (30.554), but neither are particularly high. This isn't a major concern for a cardiovascular target.
* **Caco-2:** Ligand B (-5.602) has a better Caco-2 permeability than Ligand A (-4.543), suggesting better absorption.
* **Solubility:** Ligand A (-1.053) has better aqueous solubility than Ligand B (-2.156).
* **hERG:** Both ligands have very low hERG inhibition risk (0.192 and 0.101 respectively).
* **Cl_mic:** Ligand A (-2.86) has a more negative value, indicating lower clearance and better metabolic stability than Ligand B (-1.747).
* **t1/2:** Ligand B (21.067) has a significantly longer in vitro half-life than Ligand A (-1.425), which is a significant advantage.
* **Pgp:** Both ligands have very low Pgp efflux liability (0.023 and 0.032 respectively).
* **Binding Affinity:** Ligand A (-7.8 kcal/mol) has a slightly better binding affinity than Ligand B (-7.3 kcal/mol). This 0.5 kcal/mol difference is significant, and can outweigh some of the ADME drawbacks.
**Overall Assessment:**
Ligand A has a better TPSA, QED, solubility, metabolic stability, and binding affinity. Ligand B has a lower DILI risk and a longer half-life. The lower TPSA and better binding affinity of Ligand A are critical for a GPCR target. While the DILI risk is a concern for Ligand A, it is not as critical as ensuring good receptor engagement and permeability. The better binding affinity of Ligand A is likely to translate to greater efficacy.
**Output:**
1
2025-04-17 23:27:46,583 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [352.475, 70.08, 1.127, 1, 4, 0.827, 20.706, 81.698, -4.145, -1.929, 0.383, 35.958, -6.896, 0.111, -4.3]
**Ligand B:** [366.937, 41.37, 3.241, 0, 4, 0.803, 21.908, 89.337, -4.839, -3.037, 0.589, 56.837, 16.711, 0.573, -6.9]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal 200-500 Da range. A (352.475) is slightly preferred.
2. **TPSA:** A (70.08) is better than B (41.37). Both are below the 140 threshold for oral absorption, but B is closer to the 90 threshold for CNS targets, which isn't a primary concern for ADRB2.
3. **logP:** A (1.127) is better than B (3.241). B is getting towards the higher end where solubility issues can arise.
4. **HBD:** A (1) is slightly better than B (0). Lower is generally preferred.
5. **HBA:** Both are equal at 4, which is good.
6. **QED:** Both are similar (A: 0.827, B: 0.803), indicating good drug-likeness.
7. **DILI:** Both are low risk (A: 20.706, B: 21.908), below the 40 threshold.
8. **BBB:** B (89.337) is better than A (81.698). While not a primary focus for ADRB2, higher BBB is generally favorable.
9. **Caco-2:** Both are negative, indicating poor permeability. B (-4.839) is worse than A (-4.145).
10. **Solubility:** B (-3.037) is better than A (-1.929). Solubility is a concern with B's higher logP, but B still has better solubility.
11. **hERG:** A (0.383) is better than B (0.589), indicating lower cardiotoxicity risk. This is *very* important for a cardiovascular target.
12. **Cl_mic:** A (35.958) is better than B (56.837), indicating better metabolic stability.
13. **t1/2:** A (-6.896) is better than B (16.711). A longer half-life is generally preferred.
14. **Pgp:** A (0.111) is better than B (0.573), indicating lower efflux.
15. **Affinity:** B (-6.9) is slightly better than A (-4.3). This is a 1.5kcal/mol difference, which is significant.
**GPCR-specific priorities:** logP, Pgp, TPSA, and affinity are key. B has a better logP and affinity, but A has better TPSA, Pgp, and hERG.
**Overall Assessment:**
While Ligand B has a slightly better binding affinity, the combination of better hERG, metabolic stability (Cl_mic and t1/2), lower Pgp efflux, and better Caco-2 permeability makes Ligand A the more promising candidate. The affinity difference, while notable, can potentially be optimized in later stages of drug development. The safety profile (hERG) and ADME properties of Ligand A are more favorable for a cardiovascular drug.
Output:
1
2025-04-17 23:27:46,583 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (368.5 & 348.5 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (83.56) is higher than Ligand B (49.41). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B has a significant advantage here.
3. **logP:** Ligand A (0.665) is quite low, potentially hindering membrane permeability. Ligand B (3.746) is within the optimal 1-3 range. Ligand B is significantly better.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable. No strong preference.
5. **HBA:** Ligand A (6) and Ligand B (2) are both acceptable. Ligand B is better.
6. **QED:** Both ligands (0.669 & 0.654) are above the 0.5 threshold, indicating good drug-likeness. No clear advantage.
7. **DILI:** Ligand A (29.236) has a much lower DILI risk than Ligand B (14.23). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (36.642) has a low BBB penetration, while Ligand B (85.459) has high BBB penetration. Since ADRB2 is a cardiovascular target, BBB penetration is *not* a priority. Ligand B's high value is irrelevant, and potentially even a slight negative due to potential off-target effects.
9. **Caco-2:** Ligand A (-5.296) and Ligand B (-4.625) are both negative, indicating poor permeability. Ligand B is slightly better.
10. **Solubility:** Ligand A (-0.819) and Ligand B (-3.9) are both poor. Ligand A is better.
11. **hERG:** Ligand A (0.221) has a lower hERG risk than Ligand B (0.618). This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand A (-0.704) has lower (better) microsomal clearance than Ligand B (89.69). This is a substantial advantage for Ligand A, indicating greater metabolic stability.
13. **t1/2:** Ligand A (7.009) has a better in vitro half-life than Ligand B (-1.857). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.013) has lower P-gp efflux than Ligand B (0.384). This is a slight advantage for Ligand A.
15. **Affinity:** Ligand A (-5.6) and Ligand B (-6.1) both have good binding affinity. Ligand B is slightly better, but the difference is not substantial enough to outweigh other factors.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity) and the general guidelines, Ligand A is the more promising candidate. While Ligand B has slightly better affinity and TPSA, Ligand A excels in crucial ADME properties: significantly lower DILI risk, better metabolic stability (lower Cl_mic and longer t1/2), lower hERG risk, and lower P-gp efflux. The low logP of Ligand A is a concern, but the substantial improvements in safety and metabolic stability outweigh this drawback for a cardiovascular target.
Output:
1
2025-04-17 23:27:46,583 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.322 and 348.531 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (107.37) is higher than Ligand B (40.62). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferable for absorption. Ligand B is significantly better.
3. **logP:** Ligand A (0.523) is quite low, potentially hindering permeability. Ligand B (3.869) is within the optimal 1-3 range. This is a substantial advantage for Ligand B.
4. **HBD:** Ligand A (2) is reasonable. Ligand B (0) is even better, potentially improving permeability.
5. **HBA:** Ligand A (7) is acceptable. Ligand B (2) is excellent.
6. **QED:** Ligand A (0.762) is good, indicating drug-likeness. Ligand B (0.342) is considerably lower, suggesting potential issues with developability.
7. **DILI:** Ligand A (80.69) has a higher DILI risk than Ligand B (39.977). Ligand B is significantly better here.
8. **BBB:** Both ligands have reasonable BBB penetration (A: 74.176, B: 71.772). This isn't a primary concern for a cardiovascular target.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual. I will interpret this as very low permeability.
10. **Solubility:** Both ligands have negative solubility values, which is also unusual. I will interpret this as very low solubility.
11. **hERG:** Ligand A (0.044) has a very low hERG risk, which is excellent. Ligand B (0.835) has a moderate hERG risk. This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand A (44.266) has a lower microsomal clearance, suggesting better metabolic stability, than Ligand B (97.456). This is a positive for Ligand A.
13. **t1/2:** Ligand A (17.196) has a longer in vitro half-life than Ligand B (12.625). This is a positive for Ligand A.
14. **Pgp:** Ligand A (0.067) has lower P-gp efflux, which is favorable. Ligand B (0.617) has moderate P-gp efflux.
15. **Affinity:** Both ligands have very strong binding affinity (-7.0 and -7.1 kcal/mol). The difference is negligible.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, and Pgp are important. Ligand B excels in logP and TPSA, while Ligand A has better Pgp. However, the low solubility and permeability of both ligands are concerning. Ligand A has a much better safety profile (DILI, hERG) and better metabolic stability.
**Overall Assessment:**
While Ligand B has better physicochemical properties (logP, TPSA), Ligand A has a much more favorable safety profile and better metabolic stability. The similar binding affinities make the ADME/Tox profile the deciding factor. Given the cardiovascular target, a good safety profile is paramount. The low solubility and permeability of both are concerning, but can potentially be addressed with formulation strategies.
Output:
1
2025-04-17 23:27:46,583 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**1. Molecular Weight:** Both ligands (335.407 and 345.487 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (54.46) is significantly better than Ligand B (71.09). For a GPCR, lower TPSA is generally preferred for better permeability. Ligand A is well below the 90 A^2 threshold, while Ligand B is approaching it.
**3. logP:** Both ligands have good logP values (2.966 and 2.793), falling within the optimal 1-3 range. No clear advantage.
**4. H-Bond Donors:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
**5. H-Bond Acceptors:** Ligand A (4) is preferable to Ligand B (3). Fewer HBAs generally improve permeability.
**6. QED:** Both ligands have acceptable QED values (0.937 and 0.747), well above the 0.5 threshold. Ligand A is slightly better.
**7. DILI:** Ligand A (43.04) has a higher DILI risk than Ligand B (23.032). This is a significant advantage for Ligand B.
**8. BBB:** Ligand A (88.29) has a much higher BBB penetration percentile than Ligand B (58.821). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be beneficial for distribution and off-target effects.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.818 and -4.895). This is unusual and suggests poor permeability *in vitro*. However, the values are very close.
**10. Aqueous Solubility:** Both ligands have negative solubility values (-3.403 and -2.468). This is also unusual and suggests poor solubility. Ligand B is slightly better.
**11. hERG Inhibition:** Ligand A (0.726) has a slightly higher hERG inhibition risk than Ligand B (0.221). This favors Ligand B.
**12. Microsomal Clearance:** Ligand A (21.53) has a significantly lower microsomal clearance than Ligand B (52.349), indicating better metabolic stability. This is a strong advantage for Ligand A.
**13. In vitro Half-Life:** Ligand A (-2.816) has a much longer in vitro half-life than Ligand B (13.586). This is a significant advantage for Ligand A.
**14. P-gp Efflux:** Ligand A (0.212) has a lower P-gp efflux liability than Ligand B (0.035). This is a strong advantage for Ligand A.
**15. Binding Affinity:** Ligand B (-6.6) has a slightly better binding affinity than Ligand A (-6.4). However, the difference is small (0.2 kcal/mol) and may not be enough to overcome other ADME deficiencies.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp), Ligand A is generally more favorable. It has a lower TPSA, better P-gp efflux, better metabolic stability (lower Cl_mic, longer t1/2), and a better in vitro half-life. While Ligand B has a lower DILI risk and slightly better affinity, the ADME profile of Ligand A is more promising, particularly its permeability characteristics (lower TPSA, Pgp). The slight affinity difference is unlikely to outweigh the ADME advantages of Ligand A.
Output:
1
2025-04-17 23:27:46,584 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (352.32 and 348.407 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (86.84) is significantly better than Ligand B (119.76). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is approaching the upper limit for good oral absorption (140).
3. **logP:** Both ligands have good logP values (2.054 and 1.452), falling within the optimal 1-3 range. Ligand B is slightly lower, which *could* indicate slightly better solubility, but the difference isn't substantial.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Both have 5 HBA, which is good.
6. **QED:** Ligand A (0.892) has a much better QED score than Ligand B (0.426), indicating a more drug-like profile overall.
7. **DILI:** Ligand A (54.634) has a slightly higher DILI risk than Ligand B (34.665), but both are below the concerning threshold of 60.
8. **BBB:** Ligand B (71.19) has a better BBB penetration percentile than Ligand A (64.637). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant for off-target effects and overall safety assessment.
9. **Caco-2:** Ligand A (-4.807) has a much worse Caco-2 permeability than Ligand B (-5.024). This suggests lower intestinal absorption for Ligand A.
10. **Solubility:** Ligand B (-1.896) has better aqueous solubility than Ligand A (-3.162).
11. **hERG:** Both ligands have very low hERG inhibition liability (0.344 and 0.287), which is excellent.
12. **Cl_mic:** Ligand A (10.187) has a higher microsomal clearance than Ligand B (6.667), suggesting lower metabolic stability.
13. **t1/2:** Ligand B (5.497) has a shorter in vitro half-life than Ligand A (14.889).
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.021 and 0.029).
15. **Binding Affinity:** Ligand B (-7.2 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.2 kcal/mol). This is a substantial difference (2 kcal/mol) and is a major advantage.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, affinity, logP, TPSA, and Pgp are key. Ligand B excels in affinity, has a reasonable logP, and low Pgp efflux. While Ligand A has a better QED and longer half-life, the significantly stronger binding of Ligand B outweighs these advantages. The lower TPSA of Ligand A is a plus, but the difference in affinity is more critical.
**Conclusion:**
Despite Ligand A's better QED and half-life, the superior binding affinity of Ligand B, combined with its better solubility and lower DILI risk, make it the more promising drug candidate.
Output:
0
2025-04-17 23:27:46,584 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (348.531) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (58.2) is significantly better than Ligand B (78.09). ADRB2 is not a CNS target, but lower TPSA is still beneficial for absorption.
3. **logP:** Ligand A (4.103) is higher than Ligand B (1.983). While 1-3 is optimal, 4.1 is pushing the upper limit and could present solubility issues. Ligand B is well within the optimal range.
4. **HBD:** Both have 2 HBD, which is good.
5. **HBA:** Ligand A has 2 HBA, while Ligand B has 4. Lower is generally better for permeability, so Ligand A is favored.
6. **QED:** Ligand B (0.739) has a better QED score than Ligand A (0.487), indicating a more drug-like profile overall.
7. **DILI:** Ligand A (18.651) has a significantly lower DILI risk than Ligand B (23.342). This is a major advantage for Ligand A.
8. **BBB:** Not a primary concern for ADRB2, but Ligand A (77.084) is better than Ligand B (63.474).
9. **Caco-2:** Ligand A (-4.792) and Ligand B (-5.643) are both poor.
10. **Solubility:** Ligand A (-3.997) is better than Ligand B (-2.388), though both are poor.
11. **hERG:** Ligand A (0.616) is better than Ligand B (0.218), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand B (13.912) has a much lower microsomal clearance than Ligand A (59.979), suggesting better metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand B (-18.953) has a much longer in vitro half-life than Ligand A (-1.044). This is a major advantage for Ligand B.
14. **Pgp:** Ligand A (0.569) is better than Ligand B (0.045), suggesting lower P-gp efflux.
15. **Affinity:** Both ligands have the same binding affinity (-6.4 kcal/mol).
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has a better logP and Pgp, and TPSA. However, Ligand B has significantly better metabolic stability (Cl_mic, t1/2) and a better QED score. The equal affinity means this isn't a deciding factor.
**Overall Assessment:**
While Ligand A has advantages in TPSA, DILI, and Pgp efflux, Ligand B's superior metabolic stability (lower Cl_mic and longer t1/2) and better QED are more critical for overall drug development success. The slightly higher logP of Ligand A is a concern, and the lower half-life of Ligand A is a significant drawback.
Output:
0
2025-04-17 23:27:46,584 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [356.463, 87.15, 0.901, 1, 5, 0.588, 14.541, 64.715, -4.161, -1.256, 0.289, 94.213, -36.403, 0.07, -5.7]
**Ligand B:** [351.495, 89.38, 3.743, 0, 3, 0.26, 15.898, 80.07, -4.708, -2.378, 0.694, 47.261, -21.34, 0.155, -7.5]
Here's a breakdown, prioritizing GPCR-relevant parameters:
1. **Molecular Weight:** Both are within the ideal 200-500 Da range. A is 356.463, B is 351.495. Very similar.
2. **TPSA:** Both are good, under 140. A is 87.15, B is 89.38. Again, very similar.
3. **logP:** A (0.901) is better than B (3.743). B is pushing the upper limit and could have solubility issues.
4. **H-Bond Donors/Acceptors:** A (1 HBD, 5 HBA) is slightly better balanced than B (0 HBD, 3 HBA).
5. **QED:** A (0.588) is significantly better than B (0.26), indicating a more drug-like profile.
6. **DILI:** Both are reasonably low, but A (14.541) is better than B (15.898).
7. **BBB:** A (64.715) is lower than B (80.07). While not a primary concern for ADRB2 (cardiovascular target), higher BBB is generally favorable.
8. **Caco-2:** Both are negative, indicating poor permeability. A (-4.161) is slightly better than B (-4.708).
9. **Solubility:** A (-1.256) is better than B (-2.378). B's higher logP likely contributes to this.
10. **hERG:** A (0.289) is much better than B (0.694), significantly reducing cardiotoxicity risk.
11. **Cl_mic:** A (94.213) is higher than B (47.261), meaning faster clearance and lower metabolic stability. This is a negative for A.
12. **t1/2:** A (-36.403) is worse than B (-21.34), indicating a shorter half-life. This is also a negative for A.
13. **Pgp:** A (0.07) is much better than B (0.155), indicating less efflux.
14. **Binding Affinity:** B (-7.5) is 1.8 kcal/mol better than A (-5.7). This is a substantial difference and a major advantage for B.
**Overall Assessment:**
Ligand B has a significantly stronger binding affinity, which is crucial for a GPCR target. However, it suffers from a higher logP, lower solubility, and a higher hERG risk. Ligand A has better ADME properties (solubility, Pgp, hERG, DILI, QED) but weaker binding affinity and poorer metabolic stability.
Considering the balance, the substantial affinity advantage of Ligand B outweighs its ADME drawbacks, especially given that the hERG risk, while higher, isn't extremely alarming. The metabolic stability and half-life can be addressed through further optimization.
Output:
0
2025-04-17 23:27:46,584 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
Let's break down the comparison of Ligand A and Ligand B, considering the provided guidelines and GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key).
1. **Molecular Weight:** Both ligands (347.434 Da and 360.523 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (71.09) is higher than Ligand B (49.41). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is generally preferred for absorption. Ligand B has a clear advantage.
3. **logP:** Ligand A (2.212) is within the optimal 1-3 range. Ligand B (3.783) is pushing the upper limit, potentially raising concerns about solubility and off-target effects, but still acceptable. Ligand A is slightly better.
4. **H-Bond Donors:** Ligand A (2) and Ligand B (1) are both good, well below the limit of 5. Ligand B is slightly better.
5. **H-Bond Acceptors:** Both ligands have 3 H-bond acceptors, which is good.
6. **QED:** Both ligands have good QED scores (0.708 and 0.839), indicating drug-like properties. Ligand B is slightly better.
7. **DILI Risk:** Ligand A (28.189%) has a significantly lower DILI risk than Ligand B (37.999%). This is a substantial advantage for Ligand A.
8. **BBB Penetration:** Both ligands have similar BBB penetration (78.984% and 77.084%). Since this is a cardiovascular target, BBB penetration is not a primary concern.
9. **Caco-2 Permeability:** Ligand A (-4.865) and Ligand B (-5.072) are both negative, which is unusual. Lower values suggest poor permeability. Ligand A is slightly better.
10. **Aqueous Solubility:** Ligand A (-2.285) is better than Ligand B (-4.318). Solubility is important for bioavailability.
11. **hERG Inhibition:** Both ligands have low hERG inhibition risk (0.639% and 0.504%). No significant difference.
12. **Microsomal Clearance:** Ligand A (24.897) has a lower microsomal clearance than Ligand B (51.527), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **In vitro Half-Life:** Ligand A (3.855 hours) has a shorter half-life than Ligand B (-9.378 hours). This is a significant advantage for Ligand B.
14. **P-gp Efflux:** Both ligands have low P-gp efflux liability (0.141 and 0.38). No significant difference.
15. **Binding Affinity:** Ligand B (-7.7 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.8 kcal/mol). This is a substantial advantage for Ligand B, potentially outweighing some ADME drawbacks.
**Overall Assessment:**
Ligand B has a superior binding affinity and a longer half-life, which are crucial for a GPCR target. However, Ligand A demonstrates a much lower DILI risk and better metabolic stability (lower Cl_mic). Ligand B's logP is slightly higher, which could be a concern, but the affinity difference is substantial. Considering the balance, the stronger binding affinity of Ligand B is likely to be more impactful for efficacy, and the slightly higher logP can be addressed with further optimization.
Output:
0
2025-04-17 23:27:46,584 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [348.403, 98.91, -0.753, 2, 6, 0.726, 18.845, 26.638, -5.526, -0.551, 0.121, -5.275, 7.03, 0.011, -7.6]
**Ligand B:** [349.435, 101.56, -0.625, 3, 5, 0.594, 29.701, 11.439, -5.787, -0.703, 0.088, -18.864, -12.624, 0.009, -7]
Here's a step-by-step comparison, keeping GPCR priorities (logP, Pgp, TPSA, affinity) in mind:
1. **MW:** Both are within the ideal range (348-349 Da). No significant difference.
2. **TPSA:** Ligand A (98.91) is better than Ligand B (101.56). Both are reasonably good for oral absorption, but A is closer to the preferred <140.
3. **logP:** Both are good (-0.753 and -0.625), falling within the 1-3 range. They are slightly on the hydrophilic side, but not problematic.
4. **HBD:** Ligand A (2) is preferable to Ligand B (3). Lower is generally better.
5. **HBA:** Ligand A (6) is preferable to Ligand B (5). Lower is generally better.
6. **QED:** Ligand A (0.726) is better than Ligand B (0.594), indicating a more drug-like profile.
7. **DILI:** Ligand A (18.845) is significantly better than Ligand B (29.701). Lower DILI risk is crucial.
8. **BBB:** Ligand A (26.638) is much better than Ligand B (11.439). While ADRB2 isn't necessarily a CNS target, some peripheral distribution is still desired, and a higher BBB percentile suggests better overall permeability.
9. **Caco-2:** Both are negative (-5.526 and -5.787), indicating poor permeability. This is a significant concern for both.
10. **Solubility:** Both are negative (-0.551 and -0.703), indicating poor solubility. This is also a significant concern for both.
11. **hERG:** Both are very low (0.121 and 0.088), indicating minimal hERG inhibition risk. This is good.
12. **Cl_mic:** Ligand A (-5.275) is better than Ligand B (-18.864). Lower clearance suggests better metabolic stability.
13. **t1/2:** Ligand A (7.03) is significantly better than Ligand B (-12.624). A longer half-life is preferred.
14. **Pgp:** Both are very low (0.011 and 0.009), indicating minimal P-gp efflux. This is good.
15. **Affinity:** Ligand A (-7.6) is slightly better than Ligand B (-7.0). While the difference is not huge, it is still a factor.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical parameters, especially DILI risk, BBB penetration, metabolic stability (Cl_mic), and in vitro half-life. While both compounds have poor Caco-2 and solubility, Ligand A's superior profile in other areas makes it the more promising candidate. The slightly better binding affinity of Ligand A further strengthens its position.
Output:
1
2025-04-17 23:27:46,584 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**1. Molecular Weight:** Both ligands (351.447 and 352.475 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand B (78.87) is significantly better than Ligand A (104.46). For a GPCR, lower TPSA is generally preferred for better permeability.
**3. logP:** Both ligands have good logP values (1.941 and 1.483), falling within the optimal 1-3 range. Ligand B is slightly lower, which could be beneficial for solubility.
**4. H-Bond Donors:** Ligand A has 3 HBD, and Ligand B has 2. Both are acceptable, being less than 5.
**5. H-Bond Acceptors:** Ligand A has 5 HBA, and Ligand B has 4. Both are acceptable, being less than 10.
**6. QED:** Both ligands have similar QED values (0.664 and 0.68), indicating good drug-likeness.
**7. DILI:** Ligand B (11.322) has a *much* lower DILI risk than Ligand A (30.361). This is a significant advantage for Ligand B.
**8. BBB:** Ligand A (57.774) has a slightly better BBB penetration percentile than Ligand B (46.491). However, for ADRB2, which is primarily a cardiovascular target, high BBB penetration isn't a primary requirement.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.856 and -4.813), indicating poor permeability. This is a concern for both, but the values are very similar.
**10. Aqueous Solubility:** Ligand B (-1.443) has better solubility than Ligand A (-2.804).
**11. hERG Inhibition:** Both ligands show very low hERG inhibition liability (0.256 and 0.221), which is excellent.
**12. Microsomal Clearance:** Ligand B (16.148) has a significantly lower microsomal clearance than Ligand A (49.494), suggesting better metabolic stability.
**13. In vitro Half-Life:** Ligand B (12.008 hours) has a much longer in vitro half-life than Ligand A (-2.012 hours). This is a substantial advantage.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.09 and 0.048), which is favorable.
**15. Binding Affinity:** Ligand A (-6.7 kcal/mol) has a slightly better binding affinity than Ligand B (-5.4 kcal/mol). However, the difference is 1.3 kcal/mol, which, while noticeable, is not overwhelmingly large considering the other ADME properties.
**Overall Assessment:**
Ligand B is the superior candidate. While Ligand A has a slightly better binding affinity, Ligand B demonstrates significantly better ADME properties, particularly regarding DILI risk, metabolic stability (lower Cl_mic and longer t1/2), and solubility. The lower TPSA of Ligand B is also advantageous for a GPCR target. The slightly lower BBB penetration is not a major concern for a cardiovascular target like ADRB2. The improved ADME profile of Ligand B outweighs the modest difference in binding affinity.
Output:
0
2025-04-17 23:27:46,585 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's systematically compare Ligand A and Ligand B against the provided guidelines, keeping in mind the GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key).
1. **MW:** Both ligands (371.38 Da and 335.451 Da) fall within the ideal 200-500 Da range. Ligand B is slightly smaller, which could be advantageous for permeability.
2. **TPSA:** Ligand A (55.4) is higher than Ligand B (41.19). Both are below the 140 threshold for oral absorption, but Ligand B is better positioned for potential CNS penetration if that were a goal.
3. **logP:** Both ligands have good logP values (3.086 and 3.866), falling within the optimal 1-3 range. Ligand B is slightly higher, which could be a minor concern for solubility but isn't a major issue.
4. **HBD:** Ligand A has 1 HBD, while Ligand B has 0. Both are acceptable.
5. **HBA:** Ligand A has 3 HBA, Ligand B has 4. Both are within the acceptable limit of 10.
6. **QED:** Both ligands have similar QED values (0.822 and 0.797), indicating good drug-likeness.
7. **DILI:** Ligand A has a DILI risk of 72.043, while Ligand B has 17.449. This is a significant difference. Ligand B has a much lower risk of liver injury, a major advantage.
8. **BBB:** Ligand A has a BBB penetration of 77.937, while Ligand B has 96.316. While ADRB2 isn't necessarily a CNS target, higher BBB penetration is generally favorable, suggesting better distribution.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.728 and -4.788). These values are unusual and suggest poor permeability. This is a significant drawback for both.
10. **Solubility:** Ligand A (-4.6) has slightly worse solubility than Ligand B (-3.036).
11. **hERG:** Ligand A (0.77) has a slightly lower hERG risk than Ligand B (0.981), which is preferable.
12. **Cl_mic:** Both ligands have similar microsomal clearance values (51.365 and 53.211), indicating moderate metabolic stability.
13. **t1/2:** Ligand A (25.209) has a slightly longer in vitro half-life than Ligand B (22.826), which is a slight advantage.
14. **Pgp:** Ligand A (0.499) has lower P-gp efflux than Ligand B (0.717), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand B (-6.7 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.0 kcal/mol). This is a substantial advantage, exceeding the 1.5 kcal/mol threshold.
**Overall Assessment:**
The most critical factor is the binding affinity. Ligand B's -6.7 kcal/mol is considerably better than Ligand A's -5.0 kcal/mol. The lower DILI risk for Ligand B is also a major positive. While both have poor Caco-2 permeability, the stronger binding and improved safety profile of Ligand B outweigh the slightly better Pgp and half-life of Ligand A.
Output:
0
2025-04-17 23:27:46,585 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (385.339 Da) is within the ideal range, while Ligand B (354.401 Da) is slightly below, but still acceptable.
2. **TPSA:** Ligand A (58.12) is excellent, well below the 140 threshold. Ligand B (75.19) is still reasonable, but less optimal.
3. **logP:** Ligand A (4.251) is a bit high, potentially leading to solubility issues. Ligand B (1.91) is within the optimal range.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Both ligands have 4 HBA, which is good.
6. **QED:** Ligand B (0.774) has a significantly better QED score than Ligand A (0.433), indicating better overall drug-likeness.
7. **DILI:** Ligand B (35.789) has a much lower DILI risk than Ligand A (56.999), a significant advantage.
8. **BBB:** Both ligands have good BBB penetration (Ligand A: 81.117, Ligand B: 84.141), but Ligand B is slightly better.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Ligand A (-4.337) has very poor solubility, while Ligand B (-2.272) is better, but still not ideal.
11. **hERG:** Ligand A (0.592) has a higher hERG risk than Ligand B (0.369), which is preferable.
12. **Cl_mic:** Ligand B (6.977) has significantly lower microsomal clearance than Ligand A (70.411), indicating better metabolic stability.
13. **t1/2:** Ligand B (7.527) has a longer in vitro half-life than Ligand A (52.834), which is a positive.
14. **Pgp:** Ligand A (0.589) has a slightly higher Pgp efflux liability than Ligand B (0.015), which is not ideal.
15. **Binding Affinity:** Ligand B (-6.0 kcal/mol) has a slightly better binding affinity than Ligand A (-5.7 kcal/mol).
**GPCR-specific priorities:** For ADRB2 (a GPCR), we prioritize logP, Pgp, TPSA, and affinity. Ligand B excels in logP, Pgp, and has comparable TPSA and affinity.
**Overall Assessment:**
Ligand B is the superior candidate. While Ligand A has a reasonable MW and acceptable TPSA, its high logP, poor solubility, high DILI risk, high Cl_mic, and higher Pgp efflux are significant drawbacks. Ligand B demonstrates a better balance of properties, with a favorable QED score, lower DILI risk, improved metabolic stability (lower Cl_mic and longer t1/2), and better Pgp efflux profile. The slightly better affinity of Ligand B further strengthens its position.
Output:
0
2025-04-17 23:27:46,585 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.379 and 349.439 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (133.39) is slightly higher than Ligand B (115.9). Both are below the 140 threshold for good oral absorption, but B is preferable given the GPCR target class.
3. **logP:** Both ligands (-0.444 and -0.374) are a bit low, ideally we'd like to be between 1-3. However, they are not drastically outside the acceptable range.
4. **HBD:** Both ligands have 3 H-bond donors, which is within the acceptable limit of 5.
5. **HBA:** Ligand A has 7 H-bond acceptors, while Ligand B has 6. Both are below the 10 limit.
6. **QED:** Ligand A (0.637) has a slightly higher QED than Ligand B (0.531), indicating a more drug-like profile.
7. **DILI:** Ligand B (34.587%) has a significantly lower DILI risk than Ligand A (62.893%). This is a major advantage for Ligand B.
8. **BBB:** Ligand A (58.278%) has a slightly higher BBB penetration than Ligand B (45.522%). While not a primary concern for ADRB2 (cardiovascular target), it's a small positive for A.
9. **Caco-2:** Both ligands have negative Caco-2 permeability values (-5.516 and -5.788), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Both ligands have negative aqueous solubility values (-1.946 and -1.423), indicating very poor solubility. This is a significant drawback for both.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.042 and 0.033), which is excellent.
12. **Cl_mic:** Ligand A (-3.288) has a lower (better) microsomal clearance than Ligand B (-4.906), suggesting better metabolic stability.
13. **t1/2:** Ligand A (10.045 hours) has a significantly longer in vitro half-life than Ligand B (3.133 hours). This is a major advantage for Ligand A.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.018 and 0.007), which is favorable.
15. **Binding Affinity:** Ligand A (-7.6 kcal/mol) has a slightly better binding affinity than Ligand B (-5.8 kcal/mol). This 1.8 kcal/mol difference is substantial and can outweigh some ADME drawbacks.
**Overall Assessment & GPCR Prioritization:**
For a GPCR like ADRB2, affinity, logP, TPSA, and Pgp are key. Ligand A has a stronger binding affinity. Ligand B has a better TPSA and significantly lower DILI risk. The poor solubility and Caco-2 permeability are concerning for both. However, the substantial difference in binding affinity, coupled with the longer half-life of Ligand A, makes it the more promising candidate despite the slightly higher DILI risk. The difference in affinity is large enough to potentially overcome the DILI concern with further optimization.
Output:
1
2025-04-17 23:27:46,585 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's break down the comparison based on the provided guidelines and GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key).
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (346.358) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (49.41) has a significantly lower TPSA than Ligand A (73.59). This is a major advantage for oral absorption and potentially better receptor engagement, as it suggests better membrane permeability.
3. **logP:** Both ligands have good logP values (A: 3.551, B: 3.021) falling within the optimal 1-3 range. Ligand B is slightly better.
4. **H-Bond Donors/Acceptors:** Both have acceptable HBD (1) and HBA (A: 5, B: 3) counts.
5. **QED:** Ligand A (0.92) has a higher QED score than Ligand B (0.718), indicating a more drug-like profile overall.
6. **DILI Risk:** Ligand A (91.857) has a substantially higher DILI risk than Ligand B (16.402). This is a significant concern.
7. **BBB Penetration:** Ligand A (83.637) has slightly better BBB penetration than Ligand B (76.658), but both are reasonably good. For a cardiovascular target, BBB penetration isn't *critical*, but it's still a positive.
8. **Caco-2 Permeability:** Both have negative Caco-2 values, which is unusual. Assuming these are logP-like scales, lower values indicate lower permeability. Ligand B (-4.926) is slightly worse than Ligand A (-4.428).
9. **Aqueous Solubility:** Both have negative solubility values, indicating poor solubility. Ligand B (-3.933) is slightly better than Ligand A (-4.317).
10. **hERG Inhibition:** Both ligands have low hERG inhibition risk (A: 0.572, B: 0.677).
11. **Microsomal Clearance:** Ligand A (57.977) has lower microsomal clearance than Ligand B (75.44), suggesting better metabolic stability.
12. **In vitro Half-Life:** Both have similar in vitro half-lives (A: 13.47, B: 12.266).
13. **P-gp Efflux:** Ligand A (0.408) has lower P-gp efflux than Ligand B (0.141), which is favorable for bioavailability.
14. **Binding Affinity:** Ligand B (-6.2 kcal/mol) has a slightly better binding affinity than Ligand A (-5.8 kcal/mol). This difference of 0.4 kcal/mol is significant, and can outweigh some ADME drawbacks.
**Overall Assessment:**
While Ligand A has a better QED and P-gp efflux, the significantly higher DILI risk is a major red flag. Ligand B has a much lower DILI risk, a lower TPSA (better permeability), and a slightly better binding affinity. The slightly worse Caco-2 and solubility are less concerning than the high DILI risk of Ligand A. Given these considerations, and prioritizing safety and reasonable ADME properties, Ligand B is the more promising candidate.
**Output:**
0
2025-04-17 23:27:46,585 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (361.389 and 354.495 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (87.74) is better than Ligand B (104.53). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands (1.416 and 1.757) are within the optimal 1-3 range. Ligand B is slightly higher, which could be marginally better for membrane permeability.
4. **HBD:** Ligand A (2) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is preferable to Ligand B (3). Fewer HBAs generally improve permeability.
6. **QED:** Ligand A (0.775) is significantly better than Ligand B (0.521), indicating a more drug-like profile.
7. **DILI:** Ligand A (38.581) has a slightly higher DILI risk than Ligand B (22.489), but both are below the concerning threshold of 60. Ligand B is preferable here.
8. **BBB:** Both ligands have good BBB penetration (72.082 and 78.674). This isn't a primary concern for a cardiovascular target, but higher is generally better. Ligand B is slightly better.
9. **Caco-2:** Ligand A (-4.755) and Ligand B (-5.131) are both negative values, which is unusual. Lower (more negative) values suggest poor permeability. Ligand A is slightly better.
10. **Solubility:** Ligand A (-2.338) is slightly better than Ligand B (-2.832). Higher solubility is generally preferred.
11. **hERG:** Both ligands have low hERG inhibition risk (0.2 and 0.367). No significant difference.
12. **Cl_mic:** Ligand A (-21.192) has a much lower (better) microsomal clearance than Ligand B (33.501), indicating greater metabolic stability.
13. **t1/2:** Ligand A (-33.322) has a much longer in vitro half-life than Ligand B (-10.859), which is a significant advantage.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.031 and 0.056). No significant difference.
15. **Binding Affinity:** Both ligands have similar binding affinities (-7.0 and -4.7 kcal/mol). Ligand A is significantly better.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has a better TPSA, better metabolic stability (Cl_mic, t1/2), and significantly better binding affinity. While Ligand B has a slightly better logP and DILI, the advantages of Ligand A in other crucial areas are more substantial. The substantial difference in binding affinity (-7.0 vs -4.7 kcal/mol) is a major driver.
**Conclusion:**
Ligand A is the more promising drug candidate due to its superior drug-likeness (QED), metabolic stability (Cl_mic, t1/2), binding affinity, and acceptable ADME properties.
Output:
1
2025-04-17 23:27:46,585 - INFO - Batch 406 complete. Total preferences: 6496
2025-04-17 23:27:46,585 - INFO - Processing batch 407/512...
2025-04-17 23:28:39,441 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
Let's break down the comparison of Ligand A and Ligand B based on the provided parameters and the GPCR-specific priorities (logP, Pgp, TPSA, and affinity being most important).
1. **Molecular Weight:** Both ligands (359.5 & 349.4 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (49.2) is significantly better than Ligand B (84.7). For a GPCR, lower TPSA is generally preferred for better permeability. Ligand B is quite high, potentially hindering absorption.
3. **logP:** Ligand A (4.2) is higher than Ligand B (1.8). While both are within the acceptable range, Ligand A is approaching the upper limit. This could lead to solubility issues, but for a GPCR, a higher logP can sometimes be beneficial for membrane interactions.
4. **H-Bond Donors/Acceptors:** Ligand A (0 HBD, 6 HBA) is slightly more favorable than Ligand B (1 HBD, 5 HBA). Lower counts are generally preferred for permeability.
5. **QED:** Ligand B (0.90) has a better QED score than Ligand A (0.60), indicating a more generally drug-like profile.
6. **DILI Risk:** Ligand B (40.8) has a significantly lower DILI risk than Ligand A (53.6). This is a crucial advantage for Ligand B.
7. **BBB Penetration:** Both ligands have good BBB penetration (A: 72.9, B: 77.7). Ligand B is slightly better, but both are acceptable.
8. **Caco-2 Permeability:** Both have negative Caco-2 values, which is unusual and suggests a problem with the assay or the compounds themselves. It's difficult to interpret this data without further context.
9. **Aqueous Solubility:** Both have negative solubility values, which is also unusual. Again, difficult to interpret.
10. **hERG Inhibition:** Both ligands show very low hERG inhibition risk (A: 0.26, B: 0.23).
11. **Microsomal Clearance:** Ligand B (46.7) has a lower microsomal clearance than Ligand A (63.6), indicating better metabolic stability.
12. **In vitro Half-Life:** Ligand B (-25.6) has a significantly longer half-life than Ligand A (-9.3). This is a major advantage for Ligand B.
13. **P-gp Efflux:** Both ligands have low P-gp efflux (A: 0.62, B: 0.07). Ligand B is much better.
14. **Binding Affinity:** Ligand A (-5.9) has a slightly better binding affinity than Ligand B (-6.2). This is a small difference, but still relevant.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity, Ligand B demonstrates a superior overall profile. Its lower DILI risk, better metabolic stability (lower Cl_mic, longer t1/2), lower P-gp efflux, and lower TPSA are significant advantages. The higher QED score also contributes to its favorability. The negative solubility and Caco-2 values are concerning for both, but the other advantages of Ligand B outweigh this concern. Considering the GPCR-specific priorities, the combination of lower TPSA, lower P-gp efflux, and improved metabolic stability makes Ligand B the more promising candidate.
**Output:**
0
2025-04-17 23:28:39,442 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (345.403 and 352.45 Da) fall comfortably within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (102.16) is higher than Ligand B (67.43). For a cardiovascular GPCR, TPSA is moderately important for permeability, and Ligand B is significantly better.
3. **logP:** Ligand A (1.673) is within the optimal range, while Ligand B (3.341) is towards the upper end. Ligand A is slightly preferred here, but both are acceptable.
4. **HBD:** Both ligands have 2 HBD, which is good.
5. **HBA:** Ligand A has 7 HBA, while Ligand B has 3. Both are within the acceptable limit of 10, but Ligand B is better.
6. **QED:** Ligand A (0.826) has a better QED score than Ligand B (0.67), indicating a more drug-like profile.
7. **DILI:** Ligand A (70.26) has a higher DILI risk than Ligand B (42.885). Ligand B is significantly better here.
8. **BBB:** Ligand B (73.284) shows better BBB penetration than Ligand A (62.699). This is a positive for GPCRs, even cardiovascular ones, as it suggests better distribution.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
10. **Solubility:** Ligand A (-3.316) has better solubility than Ligand B (-4.052).
11. **hERG:** Ligand A (0.237) has a lower hERG inhibition liability than Ligand B (0.689), which is a significant safety advantage.
12. **Cl_mic:** Ligand B (41.639) has a lower microsomal clearance than Ligand A (26.409), suggesting better metabolic stability.
13. **t1/2:** Ligand B (7.143) has a longer in vitro half-life than Ligand A (-28.563). This is a significant advantage.
14. **Pgp:** Ligand A (0.176) has lower P-gp efflux liability than Ligand B (0.092).
15. **Binding Affinity:** Ligand B (-7.0) has a slightly better binding affinity than Ligand A (-6.4). This difference is significant.
**Overall Assessment:**
Ligand B demonstrates a superior profile for a GPCR target like ADRB2. While Ligand A has a better QED and hERG profile, Ligand B excels in key areas: lower DILI risk, better BBB penetration, improved metabolic stability (lower Cl_mic, longer t1/2), and slightly stronger binding affinity. The lower TPSA of Ligand B is also beneficial for permeability. The solubility difference is relatively small. The slightly higher Pgp efflux for Ligand B is less concerning than the DILI risk of Ligand A.
Output:
0
2025-04-17 23:28:39,442 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
Let's analyze each ligand against the provided guidelines, keeping in mind ADRB2 is a GPCR and therefore logP, Pgp, TPSA, and affinity are key.
* **Molecular Weight:** Both ligands (352.45 and 350.394 Da) fall comfortably within the ideal 200-500 Da range.
* **TPSA:** Ligand A (71.34) is slightly higher than Ligand B (68.96), but both are well below the 140 A^2 threshold for good oral absorption.
* **logP:** Ligand A (3.653) is optimal, while Ligand B (1.469) is on the lower side of optimal. Lower logP can sometimes hinder permeation.
* **H-Bond Donors/Acceptors:** Ligand A has 2 HBD and 3 HBA, while Ligand B has 0 HBD and 6 HBA. Both are within acceptable ranges, but Ligand A's profile is slightly more balanced.
* **QED:** Both ligands have similar QED values (0.712 and 0.721), indicating good drug-likeness.
* **DILI:** Ligand B (51.842) has a significantly lower DILI risk than Ligand A (36.603), which is a substantial advantage.
* **BBB:** Both ligands exhibit good BBB penetration (Ligand A: 85.459, Ligand B: 89.919).
* **Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual. This suggests poor permeability. However, the values are similar (-4.498 and -4.632).
* **Aqueous Solubility:** Both ligands have negative solubility values, which is also unusual. Ligand B (-2.24) is slightly better than Ligand A (-3.947).
* **hERG Inhibition:** Ligand A (0.702) has a slightly higher hERG risk than Ligand B (0.509), but both are acceptable.
* **Microsomal Clearance:** Both ligands have similar microsomal clearance values (Ligand A: 59.878, Ligand B: 59.162).
* **In vitro Half-Life:** Ligand A (34.018 hours) has a significantly longer half-life than Ligand B (12.739 hours), which is a major advantage.
* **P-gp Efflux:** Both ligands have low P-gp efflux liability (Ligand A: 0.665, Ligand B: 0.111). Ligand B is better here.
* **Binding Affinity:** Ligand A (-6.2 kcal/mol) has a slightly better binding affinity than Ligand B (-5.5 kcal/mol). This is a significant difference, as a 0.7 kcal/mol advantage can outweigh minor ADME drawbacks.
**Overall Assessment:**
Ligand A has a better binding affinity and a longer half-life, which are crucial for efficacy. However, Ligand B has a significantly lower DILI risk and better P-gp efflux profile. The slightly better logP of Ligand A is also favorable. Considering the balance, the stronger binding affinity and longer half-life of Ligand A are more important for a GPCR target like ADRB2, outweighing the slightly higher DILI risk.
**Output:**
1
2025-04-17 23:28:39,442 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (a cardiovascular GPCR) drug candidates.
**Ligand A:** [350.375, 137.48 , 0.663, 3. , 7. , 0.462, 54.323, 45.25 ,
-5.273, -1.942, 0.186, -0.858, -9.662, 0.015, -5.9 ]
**Ligand B:** [345.443, 62.74 , 1.906, 0. , 4. , 0.765, 40.403, 73.517,
-4.226, -1.641, 0.217, 43.887, 5.885, 0.256, -7.2 ]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity) and general drug-like properties:
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B is slightly lower, which is generally favorable.
2. **TPSA:** Ligand A (137.48) is better than Ligand B (62.74) as it is closer to the 140 threshold, indicating better potential for oral absorption.
3. **logP:** Ligand B (1.906) is better than Ligand A (0.663). A logP between 1-3 is optimal, and Ligand B falls squarely within this range, while Ligand A is a bit low, potentially hindering membrane permeability.
4. **HBD/HBA:** Ligand B (0 HBD, 4 HBA) is preferable to Ligand A (3 HBD, 7 HBA). Lower HBD/HBA generally improves permeability.
5. **QED:** Ligand B (0.765) is significantly better than Ligand A (0.462), indicating a more drug-like profile.
6. **DILI:** Ligand B (40.403) is better than Ligand A (54.323), indicating lower potential for liver injury.
7. **BBB:** Ligand B (73.517) is much better than Ligand A (45.25). While not a primary concern for a cardiovascular target, higher BBB penetration can sometimes translate to better tissue distribution.
8. **Caco-2:** Ligand A (-5.273) is better than Ligand B (-4.226), indicating better intestinal absorption.
9. **Solubility:** Ligand A (-1.942) is better than Ligand B (-1.641).
10. **hERG:** Both are very low risk (0.186 and 0.217 respectively).
11. **Cl_mic:** Ligand A (-0.858) is better than Ligand B (43.887), suggesting better metabolic stability.
12. **t1/2:** Ligand A (-9.662) is better than Ligand B (5.885), suggesting a longer half-life.
13. **Pgp:** Ligand A (0.015) is better than Ligand B (0.256), indicating less P-glycoprotein efflux.
14. **Affinity:** Ligand B (-7.2 kcal/mol) is significantly better than Ligand A (-5.9 kcal/mol). This is a substantial difference in binding potency.
**Overall Assessment:**
Ligand B has a clear advantage in several key areas: logP, QED, DILI, BBB, and most importantly, binding affinity. The significantly stronger binding affinity (-7.2 vs -5.9 kcal/mol) is a major driver. While Ligand A has some advantages in metabolic stability (Cl_mic, t1/2) and permeability (Caco-2, Pgp), the superior affinity and drug-like properties of Ligand B outweigh these benefits. The slightly lower logP of Ligand A is a concern, and can be addressed in further optimization.
Therefore, I favor Ligand B.
0
2025-04-17 23:28:39,443 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [356.765, 88.41, 3.058, 2, 4, 0.755, 98.565, 50.019, -4.664, -5.416, 0.432, 22.394, 114.336, 0.236, -6.7]
**Ligand B:** [359.495, 55.2, 3.237, 0, 5, 0.727, 47.654, 87.127, -4.942, -4.255, 0.617, 82.182, 17.213, 0.704, -6.8]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (356.765) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (88.41) is better than Ligand B (55.2). Both are below 140, but Ligand B is significantly lower, which is good for GPCRs.
3. **logP:** Both are in the optimal range (1-3). Ligand B (3.237) is slightly higher, potentially leading to some off-target effects, but not drastically.
4. **HBD:** Ligand A (2) is better than Ligand B (0). Having some HBDs can improve solubility.
5. **HBA:** Ligand B (5) is slightly better than Ligand A (4).
6. **QED:** Both are good (>=0.5), with Ligand A (0.755) being slightly better.
7. **DILI:** Ligand B (47.654) is significantly better than Ligand A (98.565). This is a major advantage for Ligand B.
8. **BBB:** Ligand B (87.127) is significantly better than Ligand A (50.019). This is a key consideration for a GPCR, even a cardiovascular one, as some CNS off-target effects are possible.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-4.664) is slightly worse than Ligand B (-4.942).
10. **Solubility:** Ligand A (-5.416) is slightly worse than Ligand B (-4.255).
11. **hERG:** Ligand A (0.432) is better than Ligand B (0.617). Lower hERG inhibition is preferred.
12. **Cl_mic:** Ligand A (22.394) is significantly better than Ligand B (82.182). Lower clearance indicates better metabolic stability.
13. **t1/2:** Ligand A (114.336) is significantly better than Ligand B (17.213). A longer half-life is desirable.
14. **Pgp:** Ligand A (0.236) is better than Ligand B (0.704). Lower P-gp efflux is preferred.
15. **Affinity:** Ligand B (-6.8) is slightly better than Ligand A (-6.7). Although the difference is small, it's still a factor.
**Overall Assessment:**
Ligand B has a significant advantage in terms of DILI risk and BBB penetration, both crucial for a viable drug candidate. While Ligand A has better metabolic stability (Cl_mic and t1/2) and P-gp efflux, the lower DILI and better BBB of Ligand B are more critical for a GPCR target. The slightly better affinity of Ligand B also contributes to its favorability. The Caco-2 and solubility are poor for both, but can be addressed with formulation strategies.
Therefore, I would choose Ligand B.
0
2025-04-17 23:28:39,443 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (349.5 & 369.8 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (61.44) is slightly higher than Ligand B (56.59), but both are well below the 140 threshold for good oral absorption.
3. **logP:** Both ligands have good logP values (2.452 & 1.874), falling within the optimal 1-3 range. Ligand A is slightly higher, potentially aiding membrane permeability.
4. **HBD:** Ligand A (2) is better than Ligand B (0). Having some HBD can improve solubility.
5. **HBA:** Ligand B (5) is better than Ligand A (3).
6. **QED:** Both ligands have good QED scores (0.637 & 0.744), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand B (50.64) has a significantly lower DILI risk than Ligand A (9.306), which is a major advantage. Lower DILI is crucial for drug development.
8. **BBB:** Ligand B (90.539) has a much higher BBB penetration percentile than Ligand A (69.407). While ADRB2 isn't exclusively a CNS target, some CNS penetration can be beneficial or at least avoid unwanted side effects.
9. **Caco-2:** Both ligands have similar, very negative Caco-2 values (-4.922 & -4.843). This is unusual and suggests poor permeability.
10. **Solubility:** Both ligands have very negative solubility values (-2.095 & -2.565), indicating very poor aqueous solubility. This is a significant concern.
11. **hERG:** Both ligands have similar, low hERG inhibition liability (0.418 & 0.432). This is good.
12. **Cl_mic:** Ligand A (38.046) has a lower microsomal clearance than Ligand B (42.534), suggesting better metabolic stability.
13. **t1/2:** Ligand B (13.88) has a longer in vitro half-life than Ligand A (9.358), which is desirable.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.054 & 0.305). This is good.
15. **Binding Affinity:** Ligand A (-7.4) has a slightly better binding affinity than Ligand B (-7.0), but the difference is relatively small (0.4 kcal/mol).
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Both ligands perform reasonably well on logP and Pgp. TPSA is good for both. Affinity is slightly better for Ligand A, but the difference is not huge. However, the significant advantages of Ligand B in terms of DILI risk and BBB penetration outweigh the slight affinity advantage of Ligand A. The poor solubility and Caco-2 values are concerning for both, but can be addressed with formulation strategies.
**Conclusion:**
Considering the balance of properties, especially the lower DILI risk, better BBB penetration, and longer half-life of Ligand B, it is the more promising drug candidate.
Output:
0
2025-04-17 23:28:39,443 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (367.833 and 346.471 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (84.67) is slightly higher than Ligand B (69.64). Both are below the 140 threshold for good oral absorption, but B is better.
3. **logP:** Both ligands (2.006 and 1.855) are within the optimal 1-3 range. Very similar.
4. **HBD:** Ligand A (1) is better than Ligand B (2), as lower HBDs generally improve permeability.
5. **HBA:** Ligand A (5) is better than Ligand B (3), as lower HBAs generally improve permeability.
6. **QED:** Ligand A (0.86) is better than Ligand B (0.747), indicating a more drug-like profile.
7. **DILI:** Ligand B (13.61) is significantly better than Ligand A (52.113), indicating a much lower risk of drug-induced liver injury. This is a substantial advantage for B.
8. **BBB:** Ligand A (78.868) is better than Ligand B (51.842). While ADRB2 isn't strictly a CNS target, some peripheral effects can be modulated by CNS penetration, and higher BBB is generally favorable.
9. **Caco-2:** Ligand A (-4.913) and Ligand B (-5.026) are both very poor, indicating very poor intestinal absorption.
10. **Solubility:** Ligand A (-2.937) is slightly better than Ligand B (-3.042), but both are poor.
11. **hERG:** Both ligands (0.244 and 0.226) have low hERG inhibition liability, which is good. No significant difference.
12. **Cl_mic:** Ligand B (12.192) has a lower microsomal clearance than Ligand A (22.035), suggesting better metabolic stability. This is a positive for B.
13. **t1/2:** Ligand B (19.394) has a longer in vitro half-life than Ligand A (15.44), which is desirable.
14. **Pgp:** Both ligands (0.099 and 0.078) have low P-gp efflux liability, which is good. No significant difference.
15. **Binding Affinity:** Ligand B (-7.4 kcal/mol) has a significantly stronger binding affinity than Ligand A (-4.0 kcal/mol). This is a *major* advantage for Ligand B, exceeding the 1.5 kcal/mol difference threshold.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B is better on TPSA, has comparable logP and Pgp, and *significantly* better affinity. The DILI risk is also much lower for Ligand B. While Ligand A has a slightly better BBB score, the substantial affinity advantage and lower toxicity risk of Ligand B outweigh this. The poor Caco-2 and solubility are concerning for both, but can be addressed with formulation strategies.
**Conclusion:**
Ligand B is the superior candidate due to its significantly higher binding affinity, lower DILI risk, and improved metabolic stability (lower Cl_mic and longer t1/2).
Output:
0
2025-04-17 23:28:39,443 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.394 and 360.443 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (78.67) is significantly better than Ligand B (101.8). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand A is well below the 140 threshold, while B is approaching it.
3. **logP:** Ligand B (0.905) is slightly better than Ligand A (0.532). Both are acceptable, but closer to 1 is preferred.
4. **HBD:** Ligand A (1) is better than Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (5) is better than Ligand B (7). Similar to HBD, lower HBA is generally preferred.
6. **QED:** Both ligands have similar QED values (0.786 and 0.715), indicating good drug-likeness.
7. **DILI:** Ligand A (29.081) is *much* better than Ligand B (65.723). This is a major advantage for Ligand A. A DILI percentile below 40 is highly desirable.
8. **BBB:** Both ligands have moderate BBB penetration (43.583 and 46.607). Since ADRB2 is a cardiovascular target, BBB penetration is not a primary concern, but it's still a slight edge for B.
9. **Caco-2:** Ligand A (-4.839) is better than Ligand B (-5.935). Higher Caco-2 values indicate better absorption.
10. **Solubility:** Ligand A (-0.571) is better than Ligand B (-1.492). Better solubility is always a plus.
11. **hERG:** Ligand A (0.334) is *much* better than Ligand B (0.04). Lower hERG inhibition is crucial for avoiding cardiotoxicity, especially for a cardiovascular target.
12. **Cl_mic:** Ligand A (1.474) is significantly better than Ligand B (9.325). Lower microsomal clearance indicates better metabolic stability.
13. **t1/2:** Ligand B (32.353) is much better than Ligand A (-16.51). A longer half-life is generally preferred.
14. **Pgp:** Ligand A (0.042) is better than Ligand B (0.092). Lower P-gp efflux is desirable.
15. **Binding Affinity:** Ligand B (-8.0) is better than Ligand A (-5.8). This is a substantial difference in potency (2.2 kcal/mol).
**Overall Assessment:**
Ligand B has a significantly better binding affinity, which is a major advantage. However, Ligand A excels in almost all ADMET properties, particularly DILI risk and hERG inhibition, which are critical for a cardiovascular drug. The lower metabolic clearance and better solubility of Ligand A are also significant benefits. While the affinity difference is substantial, the ADMET profile of Ligand B raises serious concerns about potential toxicity and poor pharmacokinetic properties. The improved ADMET profile of Ligand A outweighs the affinity difference.
Output:
1
2025-04-17 23:28:39,443 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (332.363 Da) is within the ideal range (200-500), while Ligand B (372.441 Da) is also acceptable. No clear advantage here.
2. **TPSA:** Ligand A (72.43) is excellent, well below the 140 threshold. Ligand B (78.99) is still good, but slightly higher.
3. **logP:** Ligand A (3.858) is at the upper end of the optimal range (1-3), while Ligand B (2.633) is well within the optimal range. Ligand B has a slight advantage here.
4. **HBD:** Ligand A (1) is good. Ligand B (0) is also good. No significant difference.
5. **HBA:** Both ligands have 5 HBA, which is acceptable.
6. **QED:** Both ligands have good QED scores (0.618 and 0.796 respectively), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (83.676) has a higher DILI risk than Ligand B (50.136). This is a significant negative for Ligand A.
8. **BBB:** Ligand A (45.638) has poor BBB penetration, while Ligand B (90.461) has excellent penetration. Given that ADRB2 is a GPCR, BBB penetration is a relevant consideration, and this favors Ligand B.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. This is a concern for both, but the values are close.
10. **Solubility:** Both ligands have negative solubility values, indicating poor solubility. This is a concern for both, but the values are close.
11. **hERG:** Both ligands have low hERG inhibition risk (0.756 and 0.715 respectively). No significant difference.
12. **Cl_mic:** Ligand A (49.678) has a higher microsomal clearance than Ligand B (27.478), indicating lower metabolic stability. This favors Ligand B.
13. **t1/2:** Ligand B (-30.205) has a much longer in vitro half-life than Ligand A (5.793). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.653) has a slightly higher P-gp efflux liability than Ligand B (0.264). This favors Ligand B.
15. **Binding Affinity:** Ligand B (-7.7 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.4 kcal/mol). This is a major advantage for Ligand B.
**Overall Assessment:**
Ligand B consistently outperforms Ligand A across several critical parameters. The most significant advantages of Ligand B are its much stronger binding affinity, better BBB penetration, lower DILI risk, improved metabolic stability (lower Cl_mic, longer t1/2), and lower P-gp efflux. While both have issues with Caco-2 and solubility, the other benefits of Ligand B outweigh these concerns, especially given the GPCR target class.
Output:
0
2025-04-17 23:28:39,444 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (353.419 and 349.45 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (88.18) is better than Ligand B (53.51). Both are below 140, but Ligand B is closer to the ideal for CNS penetration (though ADRB2 isn't necessarily a CNS target).
3. **logP:** Ligand B (2.647) is optimal (1-3), while Ligand A (0.363) is quite low, potentially hindering permeability. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (1) is preferable to Ligand B (0). While both are low, having one HBD can sometimes improve solubility.
5. **HBA:** Ligand A (5) is better than Ligand B (3). Both are within the acceptable range.
6. **QED:** Both ligands have very similar QED scores (0.771 and 0.768), indicating good drug-likeness.
7. **DILI:** Ligand B (17.255) has a much lower DILI risk than Ligand A (34.161). This is a substantial advantage for Ligand B.
8. **BBB:** Ligand B (88.29) has better BBB penetration than Ligand A (59.636). While ADRB2 isn't necessarily a CNS target, higher BBB is generally favorable.
9. **Caco-2:** Both ligands have negative Caco-2 values which is unusual. However, the magnitude of the negative value is similar.
10. **Solubility:** Both ligands have negative solubility values which is unusual. However, the magnitude of the negative value is similar.
11. **hERG:** Ligand A (0.173) has a lower hERG risk than Ligand B (0.392). This is a slight advantage for Ligand A.
12. **Cl_mic:** Ligand A (-35.175) has a much lower (better) microsomal clearance than Ligand B (26.048). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand B (-14.254) has a longer in vitro half-life than Ligand A (-4.699). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.014) has much lower P-gp efflux liability than Ligand B (0.075). This is a significant advantage for Ligand A.
15. **Binding Affinity:** Ligand A (-7.8) has a slightly better binding affinity than Ligand B (-5.9). This is a substantial advantage for Ligand A.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand B excels in logP and BBB, while Ligand A has a better affinity and Pgp profile. The lower DILI risk of Ligand B is also very important. The better metabolic stability of Ligand A is also a plus.
**Overall Assessment:**
While Ligand A has a better binding affinity and Pgp profile, the combination of Ligand B's optimal logP, lower DILI risk, and longer half-life are more compelling. The slightly weaker affinity can potentially be optimized in later stages of drug development. The low logP of Ligand A is a significant concern for permeability.
Output:
0
2025-04-17 23:28:39,444 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Ligand A (407.895 Da) is within the ideal range. Ligand B (348.422 Da) is also within the ideal range, and slightly lower, which could be beneficial for permeability.
2. **TPSA:** Ligand A (55.2) is good, below the 140 threshold. Ligand B (67.23) is still acceptable, but higher.
3. **logP:** Ligand A (2.958) is optimal. Ligand B (1.568) is on the lower side of optimal, potentially impacting permeability.
4. **HBD:** Ligand A (0) is excellent. Ligand B (1) is acceptable.
5. **HBA:** Ligand A (5) is good. Ligand B (4) is also good.
6. **QED:** Both Ligand A (0.782) and Ligand B (0.822) have excellent QED scores, indicating good drug-like properties.
7. **DILI:** Ligand A (83.87) has a higher DILI risk than Ligand B (51.648). This is a significant negative for Ligand A.
8. **BBB:** Ligand B (82.435) has better BBB penetration than Ligand A (69.058). While ADRB2 isn't strictly a CNS target, some distribution to the CNS can occur, and better BBB penetration is generally favorable.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and requires further investigation. However, the values are similar (-5.024 vs -4.761).
10. **Solubility:** Ligand A (-5.4) has worse solubility than Ligand B (-2.581).
11. **hERG:** Both ligands have low hERG inhibition risk (0.446 and 0.41, respectively).
12. **Cl_mic:** Ligand B (22.258) has significantly lower microsomal clearance than Ligand A (60.976), indicating better metabolic stability.
13. **t1/2:** Ligand B (-7.667) has a longer in vitro half-life than Ligand A (-31.332).
14. **Pgp:** Both ligands have low P-gp efflux liability (0.293 and 0.128).
15. **Affinity:** Ligand A (-6.9 kcal/mol) has a slightly better binding affinity than Ligand B (-6.3 kcal/mol), but the difference is not substantial.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A has a better logP and slightly better affinity. However, Ligand B excels in metabolic stability (Cl_mic, t1/2), has lower DILI risk, and better solubility. The DILI risk for Ligand A is a major concern.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity and logP, the significantly higher DILI risk, worse metabolic stability, and lower solubility make it a less attractive candidate. Ligand B, despite having a slightly lower affinity, presents a much more favorable ADMET profile, particularly the lower DILI risk and improved metabolic stability.
**Output:**
0
2025-04-17 23:28:39,444 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [351.451, 100.35 , 0.574, 2. , 6. , 0.713, 33.889, 30.942, -5.275, -1.195, 0.07 , -14.684, 5.383, 0.017, -6.5 ]
**Ligand B:** [369.462, 82.27 , 1.992, 2. , 4. , 0.833, 60.644, 82.862, -4.869, -3.717, 0.377, -7.517, 13.34 , 0.264, -5.9 ]
Here's a breakdown, comparing each parameter and considering GPCR priorities (logP, Pgp, TPSA, affinity):
1. **MW:** Both are within the ideal 200-500 Da range. A (351.451) is slightly preferred.
2. **TPSA:** A (100.35) is a bit higher than B (82.27). B is better here, closer to the <140 threshold for oral absorption and more favorable for GPCRs.
3. **logP:** A (0.574) is quite low, potentially causing permeability issues. B (1.992) is much better, falling within the optimal 1-3 range. This is a significant advantage for B.
4. **HBD:** Both have 2 HBD, which is good.
5. **HBA:** A has 6, B has 4. B is slightly better, keeping HBA lower.
6. **QED:** Both are good (>0.5), with B (0.833) being slightly better.
7. **DILI:** A (33.889) is significantly better than B (60.644). This is a major advantage for A.
8. **BBB:** B (82.862) is much higher than A (30.942). This is a significant advantage for B, given ADRB2 is a GPCR.
9. **Caco-2:** Both are negative, indicating poor permeability. A (-5.275) is worse than B (-4.869).
10. **Solubility:** A (-1.195) is better than B (-3.717).
11. **hERG:** Both are very low, indicating minimal hERG inhibition risk.
12. **Cl_mic:** B (-7.517) is better than A (-14.684), indicating better metabolic stability.
13. **t1/2:** B (13.34) is significantly better than A (5.383), suggesting a longer duration of action.
14. **Pgp:** A (0.017) is much lower than B (0.264), suggesting less P-gp efflux. This is a significant advantage for A.
15. **Affinity:** A (-6.5) is slightly better than B (-5.9), but the difference is not huge.
**Overall Assessment:**
Ligand B has a much better logP, BBB, metabolic stability (Cl_mic, t1/2), and QED. These are crucial for a GPCR target like ADRB2. While Ligand A has better DILI and Pgp efflux, the poor logP and lower BBB penetration are significant drawbacks. The affinity difference is not substantial enough to overcome the ADME advantages of Ligand B.
Therefore, I prefer Ligand B.
0
2025-04-17 23:28:39,444 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [359.813, 71.53, 3.651, 1, 4, 0.849, 80.729, 82.706, -4.659, -5.045, 0.471, 74.533, 18.192, 0.549, -6]**
**Ligand B: [345.487, 43.86, 1.91, 0, 3, 0.691, 10.741, 89.066, -4.64, -1.265, 0.518, 30.853, 0.495, 0.066, -6.1]**
1. **Molecular Weight:** Both are within the ideal range (200-500 Da). Ligand B (345.487) is slightly lower, which *could* be advantageous for permeability, but both are acceptable.
2. **TPSA:** Ligand A (71.53) is higher than Ligand B (43.86). For a cardiovascular GPCR like ADRB2, TPSA isn't a *critical* factor like it would be for a CNS target, but lower is generally preferred for better absorption. Ligand B is significantly better here.
3. **logP:** Ligand A (3.651) is within the optimal range (1-3), while Ligand B (1.91) is at the lower end. For a GPCR, a slightly higher logP is often beneficial for membrane interactions and binding. Ligand A is better.
4. **H-Bond Donors:** Ligand A (1) is preferable to Ligand B (0). While both are low, having one HBD can sometimes improve solubility without significantly impacting permeability.
5. **H-Bond Acceptors:** Ligand A (4) is slightly higher than Ligand B (3). Both are acceptable, but lower is generally preferred.
6. **QED:** Ligand A (0.849) has a much better QED score than Ligand B (0.691), indicating a more drug-like profile. This is a significant advantage.
7. **DILI:** Ligand A (80.729) has a considerably higher DILI risk than Ligand B (10.741). This is a major concern for Ligand A.
8. **BBB:** Both have good BBB penetration (Ligand A: 82.706, Ligand B: 89.066). While ADRB2 isn't primarily a CNS target, some off-target CNS effects are possible, and higher BBB penetration isn't necessarily a negative. Ligand B is slightly better.
9. **Caco-2 Permeability:** Both have negative Caco-2 values, indicating poor permeability. This is concerning for both compounds.
10. **Aqueous Solubility:** Ligand A (-5.045) has worse solubility than Ligand B (-1.265). Solubility is important for formulation and bioavailability. Ligand B is better.
11. **hERG Inhibition:** Both have low hERG inhibition risk (Ligand A: 0.471, Ligand B: 0.518). This is good for both.
12. **Microsomal Clearance:** Ligand A (74.533) has higher clearance than Ligand B (30.853), indicating lower metabolic stability. Ligand B is significantly better.
13. **In vitro Half-Life:** Ligand A (18.192) has a slightly longer half-life than Ligand B (0.495). This is a minor advantage for Ligand A.
14. **P-gp Efflux:** Ligand A (0.549) has lower P-gp efflux than Ligand B (0.066). Lower efflux is generally preferred. Ligand A is better.
15. **Binding Affinity:** Ligand B (-6.1) has a slightly higher binding affinity than Ligand A (-6). While the difference is small, it is still a factor.
**Overall Assessment:**
Ligand A has advantages in QED, half-life, and P-gp efflux, but its high DILI risk and poor solubility are major drawbacks. Ligand B has a significantly lower DILI risk, better solubility, lower clearance, and a slightly better binding affinity, despite a lower QED and slightly lower logP. Considering the importance of minimizing toxicity (DILI) and ensuring reasonable solubility for a cardiovascular drug, Ligand B is the more promising candidate. The small difference in binding affinity is outweighed by the significant improvements in safety and ADME properties.
Output:
0
2025-04-17 23:28:39,444 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (361.511 and 367.534 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (62.3) is higher than Ligand B (38.13). For a GPCR, lower TPSA is generally preferred for better BBB penetration and overall drug-like properties. Ligand B is significantly better here.
3. **logP:** Both ligands have good logP values (3.227 and 3.761), falling within the optimal 1-3 range. Ligand B is slightly higher, which *could* be a minor concern for solubility, but isn't a dealbreaker.
4. **HBD:** Ligand A has 1 HBD, while Ligand B has 0. Both are acceptable, staying below the 5 threshold.
5. **HBA:** Both ligands have 4 HBAs, well within the acceptable limit of 10.
6. **QED:** Both ligands have similar QED values (0.791 and 0.736), indicating good drug-likeness.
7. **DILI:** Ligand A (46.375) has a higher DILI risk than Ligand B (28.499). Lower DILI is strongly preferred. Ligand B is better.
8. **BBB:** Ligand B (92.323) has significantly better BBB penetration potential than Ligand A (70.105). As ADRB2 is a GPCR, and while not exclusively CNS-focused, good BBB penetration is still a positive attribute. Ligand B is much better.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.904 and -5.017). These values are unusual and suggest poor permeability. However, the values are very similar.
10. **Solubility:** Both ligands have very poor aqueous solubility (-3.58 and -3.808). This is a significant concern for both.
11. **hERG:** Both ligands have low hERG inhibition liability (0.519 and 0.696), which is good.
12. **Cl_mic:** Ligand B (86.683) has a higher microsomal clearance than Ligand A (55.119), indicating faster metabolism and potentially lower *in vivo* exposure. Ligand A is better.
13. **t1/2:** Ligand A (5.365) has a shorter *in vitro* half-life compared to Ligand B (-13.48). A negative half-life is unusual and likely indicates very rapid degradation. Ligand A is better.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.565 and 0.606), which is good.
15. **Binding Affinity:** Both ligands have excellent binding affinity (-7.0 and -6.0 kcal/mol). Ligand A has a 1 kcal/mol advantage, which is significant.
**Overall Assessment:**
While both compounds have poor solubility and Caco-2 permeability, Ligand B clearly wins on several critical factors for a GPCR target: significantly lower DILI risk, much better BBB penetration, and a lower TPSA. The higher metabolic clearance and negative half-life of Ligand B are concerning, but the 1 kcal/mol binding affinity advantage of Ligand A is not enough to overcome the superior ADME profile of Ligand B. The solubility issues would need to be addressed through formulation strategies for either compound.
Output:
0
2025-04-17 23:28:39,445 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (429.38 Da) is within the ideal range, while Ligand B (349.381 Da) is also acceptable, being on the lower end but still above 250 Da. No strong preference here.
2. **TPSA:** Ligand A (78.76) is better than Ligand B (62.3). Both are below 140, indicating good potential for oral absorption.
3. **logP:** Both ligands (A: 2.466, B: 2.247) fall within the optimal 1-3 range. No significant difference.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1), but both are well within the acceptable limit of 5.
5. **HBA:** Ligand A (4) is slightly higher than Ligand B (3), but both are within the acceptable limit of 10.
6. **QED:** Ligand B (0.907) has a better QED score than Ligand A (0.771), suggesting a more drug-like profile.
7. **DILI:** Ligand A (30.516) has a significantly lower DILI risk than Ligand B (43.738). This is a substantial advantage for Ligand A.
8. **BBB:** Ligand B (87.553) has a much higher BBB penetration percentile than Ligand A (66.421). While ADRB2 isn't strictly a CNS target, some CNS exposure can be relevant for off-target effects or peripheral effects mediated by CNS pathways.
9. **Caco-2:** Ligand A (-5.274) has a worse Caco-2 permeability than Ligand B (-4.554). This suggests lower intestinal absorption for Ligand A.
10. **Solubility:** Ligand A (-2.267) has a worse solubility than Ligand B (-2.844). This is a negative for Ligand A.
11. **hERG:** Ligand A (0.699) has a slightly better hERG profile than Ligand B (0.459), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand A (-31.14) has a significantly lower microsomal clearance than Ligand B (26.401), suggesting better metabolic stability.
13. **t1/2:** Ligand A (31.118) has a longer in vitro half-life than Ligand B (-32.13).
14. **Pgp:** Ligand A (0.275) has a lower P-gp efflux liability than Ligand B (0.105), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand A (-7.6) has a slightly better binding affinity than Ligand B (-6.0). This is a significant advantage.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Both ligands are good on logP and TPSA. Ligand A has a better Pgp profile and a significantly better binding affinity. Ligand B has a better BBB penetration, but this is less critical for a non-CNS primary target.
**Overall Assessment:**
Ligand A demonstrates a superior balance of properties, particularly its significantly better binding affinity, lower DILI risk, and improved metabolic stability (lower Cl_mic and longer t1/2). While Ligand B has better Caco-2 permeability and BBB penetration, the advantages of Ligand A in potency, safety, and PK outweigh these benefits.
Output:
1
2025-04-17 23:28:39,445 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (368.5 and 354.4 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (99.25) is higher than Ligand B (64.16). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is still preferred for better absorption. Ligand B is better.
3. **logP:** Ligand A (0.491) is quite low, potentially hindering permeability. Ligand B (3.387) is within the optimal 1-3 range. Ligand B is significantly better.
4. **HBD:** Ligand A (3) is acceptable. Ligand B (0) is even better, potentially improving permeability.
5. **HBA:** Ligand A (7) is acceptable. Ligand B (5) is slightly better.
6. **QED:** Ligand B (0.729) has a much higher QED score than Ligand A (0.314), indicating a more drug-like profile. This is a substantial advantage for Ligand B.
7. **DILI:** Ligand A (34.28) has a lower DILI risk than Ligand B (43.66), which is favorable.
8. **BBB:** Both have reasonably high BBB penetration, but Ligand B (81.5) is higher than Ligand A (71.0), though this is less critical for a cardiovascular target.
9. **Caco-2:** Ligand A (-5.715) is worse than Ligand B (-4.592), indicating lower intestinal absorption. Ligand B is better.
10. **Solubility:** Ligand A (-1.775) is worse than Ligand B (-4.071), indicating lower solubility. Ligand B is better.
11. **hERG:** Ligand A (0.209) has a lower hERG risk than Ligand B (0.515), which is a significant advantage.
12. **Cl_mic:** Ligand B (71.7) has slightly higher clearance than Ligand A (68.8), meaning Ligand A is more metabolically stable.
13. **t1/2:** Ligand A (26.23) has a longer half-life than Ligand B (15.85), which is desirable.
14. **Pgp:** Ligand A (0.017) has much lower P-gp efflux than Ligand B (0.443), which is a significant advantage for bioavailability.
15. **Binding Affinity:** Ligand A (-8.6) has a significantly stronger binding affinity than Ligand B (-5.7). This is a >1.5 kcal/mol advantage, which can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand A has a significantly better binding affinity and lower P-gp efflux, longer half-life, and lower hERG risk. However, Ligand B has a much better QED score, logP, TPSA, and solubility. The low logP and QED of Ligand A are concerning. While the affinity of Ligand A is excellent, the poor ADME properties, especially the low logP, raise concerns about its developability. Ligand B, while having a weaker affinity, presents a much more balanced profile with better predicted absorption, permeability, and drug-likeness. For a cardiovascular GPCR, a slightly lower affinity can be tolerated if the ADME properties are significantly improved.
Therefore, I believe Ligand B is the more viable drug candidate.
Output:
0
2025-04-17 23:28:39,445 - INFO - Batch 407 complete. Total preferences: 6512
2025-04-17 23:28:39,445 - INFO - Processing batch 408/512...
2025-04-17 23:29:27,625 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (370.515 and 348.378 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (78.87) is better than Ligand B (86.63). Both are below the 140 threshold for oral absorption, but closer to the 90 threshold is preferred for GPCRs.
3. **logP:** Both ligands have a logP of around 1.18, which is optimal (1-3). No clear advantage.
4. **HBD:** Ligand A (2) is slightly better than Ligand B (1), but both are within the acceptable limit of <=5.
5. **HBA:** Both ligands have 5 HBA, which is within the acceptable limit of <=10. No clear advantage.
6. **QED:** Ligand B (0.886) has a significantly better QED score than Ligand A (0.496), indicating a more drug-like profile. This is a substantial advantage.
7. **DILI:** Ligand A (31.059) has a lower DILI risk than Ligand B (50.291). This is a significant advantage, as lower DILI is crucial.
8. **BBB:** Ligand B (79.411) has a significantly higher BBB penetration percentile than Ligand A (46.336). For a GPCR target, even if not specifically a CNS target, some BBB penetration can be beneficial for off-target profiling and understanding distribution.
9. **Caco-2:** Ligand A (-5.093) is better than Ligand B (-4.497), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-3.032) is slightly better than Ligand B (-2.434), indicating better aqueous solubility.
11. **hERG:** Ligand A (0.357) has a lower hERG inhibition liability than Ligand B (0.098), which is a significant safety advantage.
12. **Cl_mic:** Ligand B (21.334) has a much lower microsomal clearance than Ligand A (52.054), indicating better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand B (-14.149) has a slightly longer in vitro half-life than Ligand A (-13.108).
14. **Pgp:** Ligand A (0.074) has a lower P-gp efflux liability than Ligand B (0.023), which is a slight advantage.
15. **Binding Affinity:** Ligand A (-7.2 kcal/mol) has a slightly better binding affinity than Ligand B (-6.4 kcal/mol). This is a 1.8 kcal/mol advantage, which is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand A has a better binding affinity, lower DILI risk, lower hERG risk, better Caco-2 permeability, and better solubility. However, Ligand B has a significantly better QED score, much better metabolic stability (lower Cl_mic), longer half-life, and better BBB penetration.
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), and balancing the ADME properties with potency, the improved metabolic stability and drug-likeness of Ligand B are more compelling. While the affinity difference is notable, the lower DILI and hERG of Ligand A are important, the metabolic stability and QED of Ligand B are more critical for overall developability.
Output:
0
2025-04-17 23:29:27,625 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, the key priorities are logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB (though less critical for a cardiovascular target).
Let's break down the comparison:
1. **MW:** Both ligands are within the acceptable range (200-500 Da). Ligand A (346.431) is slightly preferred due to being lower.
2. **TPSA:** Ligand B (67.07) is significantly better than Ligand A (100.02). Lower TPSA generally improves permeability, a crucial factor for GPCR ligands.
3. **logP:** Both ligands have good logP values (2.51 and 3.701), falling within the optimal 1-3 range. Ligand B is slightly higher, which *could* be a minor concern for solubility, but not a dealbreaker.
4. **HBD/HBA:** Ligand A has 3 HBD and 4 HBA, while Ligand B has 1 HBD and 7 HBA. Ligand A is slightly preferred here, as higher HBA can sometimes hinder permeability.
5. **QED:** Ligand B (0.826) has a better QED score than Ligand A (0.684), indicating a more drug-like profile.
6. **DILI:** Ligand B (59.48) has a lower DILI risk than Ligand A (68.437), which is a significant advantage.
7. **BBB:** Ligand B (73.943) has a higher BBB penetration score than Ligand A (32.299). While not paramount for a cardiovascular target, it's still a positive.
8. **Caco-2:** Both are negative, indicating poor permeability.
9. **Solubility:** Both are negative, indicating poor solubility.
10. **hERG:** Both ligands have low hERG inhibition liability, which is good.
11. **Cl_mic:** Ligand B (26.378) has lower microsomal clearance than Ligand A (32.843), suggesting better metabolic stability.
12. **t1/2:** Ligand A (39.525) has a longer in vitro half-life than Ligand B (18.965), which is a positive.
13. **Pgp:** Ligand A (0.249) has lower P-gp efflux than Ligand B (0.572), which is a major advantage for bioavailability.
14. **Binding Affinity:** Ligand B (-6.2 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.5 kcal/mol). This 1.7 kcal/mol difference is substantial and can outweigh many ADME drawbacks.
**Overall Assessment:**
Ligand B has a significantly better binding affinity and a lower DILI risk. It also has a better QED score, better BBB penetration, and lower microsomal clearance. While Ligand A has a slightly better P-gp efflux profile and in vitro half-life, the strong affinity of Ligand B, coupled with its improved safety profile, makes it the more promising candidate. The TPSA of Ligand B is also much more favorable.
**Output:**
0
2025-04-17 23:29:27,625 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (337.383 Da) is well within the ideal range (200-500 Da). Ligand B (375.456 Da) is also acceptable. No clear advantage here.
2. **TPSA:** Ligand A (83.4) is good, under the 140 threshold for oral absorption. Ligand B (29.54) is *excellent*, significantly lower, suggesting potentially better permeability. This favors Ligand B.
3. **logP:** Ligand A (1.717) is optimal. Ligand B (4.184) is slightly high, potentially leading to solubility issues or off-target interactions, but still within a reasonable range. Ligand A has a slight edge.
4. **HBD:** Ligand A (2) is good. Ligand B (0) is also good. No significant difference.
5. **HBA:** Ligand A (7) is good. Ligand B (3) is also good. No significant difference.
6. **QED:** Ligand A (0.733) is better than Ligand B (0.639), indicating a more drug-like profile. This favors Ligand A.
7. **DILI:** Ligand A (72.199) is higher than Ligand B (23.187), indicating a higher risk of drug-induced liver injury. This *strongly* favors Ligand B.
8. **BBB:** Ligand A (43.389) is low, suggesting poor brain penetration. Ligand B (96.355) is very high, indicating excellent brain penetration. While ADRB2 isn't strictly a CNS target, some cardiovascular effects can be mediated centrally, and higher BBB penetration isn't necessarily a detriment. This favors Ligand B.
9. **Caco-2:** Ligand A (-5.082) is poor. Ligand B (-4.786) is also poor, but slightly better.
10. **Solubility:** Ligand A (-2.881) is poor. Ligand B (-4.361) is even worse. Both have solubility concerns, but Ligand B is worse. This favors Ligand A.
11. **hERG:** Ligand A (0.801) is better than Ligand B (0.935), indicating a lower risk of hERG inhibition and cardiotoxicity. This favors Ligand A.
12. **Cl_mic:** Ligand A (30.047) is much lower than Ligand B (94.384), indicating better metabolic stability. This strongly favors Ligand A.
13. **t1/2:** Ligand A (5.198) is reasonable. Ligand B (7.342) is better, suggesting a longer half-life. This favors Ligand B.
14. **Pgp:** Ligand A (0.018) is very low, indicating minimal P-gp efflux. Ligand B (0.611) is higher, suggesting more P-gp efflux. This favors Ligand A.
15. **Affinity:** Ligand A (-6.2 kcal/mol) is slightly better than Ligand B (-5.9 kcal/mol). While the difference isn't huge, it's enough to consider.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand B excels in TPSA and BBB, while Ligand A has a better logP, QED, DILI, Cl_mic, Pgp, and a slightly better affinity.
**Overall Assessment:**
Ligand B has a significantly better safety profile (lower DILI) and potentially better permeability (lower TPSA, higher BBB). However, its higher logP and worse solubility are concerning. Ligand A has a more balanced profile, with better metabolic stability (Cl_mic), lower P-gp efflux, and a slightly better affinity. The DILI risk with Ligand A is the biggest drawback, but the other favorable properties, especially the metabolic stability, make it the more promising candidate.
Output:
1
2025-04-17 23:29:27,625 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (364.433 and 356.463 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (87.66) is slightly higher than Ligand B (79.31). Both are below the 140 threshold for good oral absorption, but closer to the 90 threshold for CNS targets, which is less of a concern for ADRB2 (cardiovascular). Ligand B is preferable.
3. **logP:** Ligand A (1.609) and Ligand B (0.648) are both within the optimal 1-3 range, but Ligand B is at the lower end. Ligand A is preferable.
4. **HBD:** Ligand A (3) is higher than Ligand B (1). Lower HBD is generally preferred for permeability, so Ligand B is preferable.
5. **HBA:** Ligand A (4) and Ligand B (5) are both acceptable (<=10). No strong preference.
6. **QED:** Ligand B (0.756) has a higher QED score than Ligand A (0.55), indicating a more drug-like profile. Ligand B is preferable.
7. **DILI:** Both ligands have low DILI risk (29.779 and 30.012 percentile). No significant difference.
8. **BBB:** Ligand A (76.619) has a higher BBB penetration percentile than Ligand B (68.748). While ADRB2 isn't a CNS target, some BBB penetration can be beneficial for distribution. Ligand A is preferable.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual. This suggests poor permeability. However, the values are similar (-4.641 vs -4.372) and don't strongly differentiate the ligands.
10. **Solubility:** Ligand A (-2.169) has worse solubility than Ligand B (-0.914). Solubility is important for bioavailability, so Ligand B is preferable.
11. **hERG:** Both ligands show low hERG inhibition liability (0.381 and 0.23). No significant difference.
12. **Cl_mic:** Ligand B (20.545) has significantly lower microsomal clearance than Ligand A (38.247), indicating better metabolic stability. Ligand B is preferable.
13. **t1/2:** Ligand B (7.495) has a longer in vitro half-life than Ligand A (-16.833). This is a significant advantage for dosing frequency. Ligand B is preferable.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.045 and 0.046). No significant difference.
15. **Binding Affinity:** Ligand B (-7.4 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.8 kcal/mol). This is a crucial advantage and can outweigh minor ADME drawbacks. Ligand B is *strongly* preferable.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B is better on logP, TPSA, Pgp, and *significantly* better on affinity. While Ligand A has a slightly better BBB score, the substantial affinity advantage of Ligand B, combined with its better metabolic stability (Cl_mic, t1/2) and QED, makes it the superior candidate.
**Output:**
0
2025-04-17 23:29:27,625 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (380.945 Da) is slightly higher than Ligand B (347.346 Da), but both are acceptable.
2. **TPSA:** Ligand A (58.95) is significantly better than Ligand B (95.4). A TPSA under 140 is good for oral absorption, and lower is better for GPCRs. Ligand B's TPSA is approaching a concerning level.
3. **logP:** Ligand A (4.411) is a bit high, potentially leading to solubility issues and off-target effects. Ligand B (1.65) is within the optimal range (1-3).
4. **HBD:** Both ligands have 2 HBD, which is acceptable.
5. **HBA:** Both ligands have 4 HBA, which is acceptable.
6. **QED:** Ligand B (0.822) has a better QED score than Ligand A (0.667), indicating a more drug-like profile.
7. **DILI:** Ligand A (50.33) has a much better DILI score than Ligand B (77.86), indicating a lower risk of liver injury. This is a significant advantage for Ligand A.
8. **BBB:** Both ligands have similar BBB penetration (Ligand A: 63.048, Ligand B: 64.017). While not exceptionally high, it's not a primary concern for ADRB2, which isn't necessarily a CNS target.
9. **Caco-2:** Both ligands have similar negative Caco-2 values, suggesting poor permeability.
10. **Solubility:** Ligand A (-4.37) has slightly better solubility than Ligand B (-2.93), but both are poor.
11. **hERG:** Ligand A (0.617) has a lower hERG risk than Ligand B (0.101), which is a significant safety advantage.
12. **Cl_mic:** Ligand B (-16.473) has a much lower (better) microsomal clearance than Ligand A (64.097), suggesting greater metabolic stability.
13. **t1/2:** Ligand B (-30.702) has a much longer in vitro half-life than Ligand A (75.57), which is a significant advantage.
14. **Pgp:** Ligand A (0.269) has lower P-gp efflux than Ligand B (0.012), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand B (-7.5 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.2 kcal/mol). This is a substantial advantage that could outweigh some of the ADME drawbacks.
**Overall Assessment:**
Ligand B has a superior binding affinity and metabolic stability (lower Cl_mic, longer t1/2). However, it suffers from a higher logP, a higher DILI risk, and a lower hERG safety profile. Ligand A has a better safety profile (lower DILI, hERG) and better Pgp efflux, but its affinity is weaker and metabolic stability is lower.
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), the strong affinity of Ligand B is a major advantage. While the higher logP is a concern, the difference in affinity (-7.5 vs -6.2) is substantial (1.3 kcal/mol), and the other parameters are not drastically unfavorable. The metabolic stability is also a significant plus. The TPSA of Ligand B is a concern, but not prohibitive.
Therefore, I believe Ligand B is the more promising candidate despite its drawbacks.
Output:
0
2025-04-17 23:29:27,626 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (346.431) is slightly lower than Ligand B (382.448), which is generally favorable for permeability.
2. **TPSA:** Ligand A (87.46) is better than Ligand B (66.48). Both are below 140, but Ligand B is closer to the optimal range for oral absorption.
3. **logP:** Ligand B (2.355) is better than Ligand A (0.683). Ligand A is a bit low, potentially hindering membrane permeability. Ligand B is within the optimal 1-3 range.
4. **HBD:** Ligand A (2) is slightly worse than Ligand B (1). Both are acceptable.
5. **HBA:** Ligand A (5) is slightly worse than Ligand B (3). Both are acceptable.
6. **QED:** Ligand A (0.742) is significantly better than Ligand B (0.492). Higher QED suggests a more drug-like profile.
7. **DILI:** Both ligands have low DILI risk (Ligand A: 31.718, Ligand B: 34.432), both below the 40 threshold.
8. **BBB:** Ligand B (73.711) is significantly better than Ligand A (51.183). For a GPCR, even a non-CNS target, some BBB penetration can be beneficial for distribution.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.993 and -4.814). This is unusual and suggests poor permeability. However, the values are very similar.
10. **Solubility:** Ligand A (-1.745) is better than Ligand B (-3.168). Higher solubility is generally preferred.
11. **hERG:** Both ligands have very low hERG risk (Ligand A: 0.184, Ligand B: 0.552).
12. **Cl_mic:** Ligand A (-10.675) is much better than Ligand B (38.187). Lower clearance indicates better metabolic stability.
13. **t1/2:** Ligand A (-11.9) is much better than Ligand B (-3.437). A longer half-life is desirable.
14. **Pgp:** Both ligands have low Pgp efflux liability (Ligand A: 0.065, Ligand B: 0.127).
15. **Binding Affinity:** Both ligands have similar binding affinities (Ligand A: -6.2, Ligand B: -5.8). The difference is less than 1.5 kcal/mol, so it's not a deciding factor.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand B excels in logP and BBB, while Ligand A has better TPSA, QED, solubility, metabolic stability (Cl_mic), and half-life. Considering the slightly better logP and BBB of Ligand B, combined with acceptable ADME properties, it appears to be a slightly better candidate.
**Final Decision:**
0
2025-04-17 23:29:27,626 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [338.411, 74.33, 1.725, 2, 4, 0.871, 58.938, 54.052, -5.314, -2.501, 0.544, -15.436, 33.958, 0.028, -7.4]
**Ligand B:** [346.402, 49.85, 1.057, 0, 3, 0.819, 35.867, 94.067, -4.196, -2.677, 0.735, 40.215, -13.226, 0.14, -6.2]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). A (338.411) is slightly lower than B (346.402), which is fine.
2. **TPSA:** A (74.33) is higher than B (49.85). B is significantly better here, falling well below the 140 threshold for oral absorption and closer to the 90 threshold for CNS penetration (though ADRB2 isn't necessarily a CNS target).
3. **logP:** Both are within the optimal 1-3 range. A (1.725) is slightly higher than B (1.057).
4. **HBD:** A (2) is slightly higher than B (0). This is acceptable for both.
5. **HBA:** A (4) is higher than B (3). Both are within the acceptable limit of 10.
6. **QED:** Both are good (A: 0.871, B: 0.819), indicating good drug-like properties.
7. **DILI:** A (58.938) is higher than B (35.867). B is significantly better, indicating a lower risk of liver injury.
8. **BBB:** A (54.052) is much lower than B (94.067). While ADRB2 isn't strictly a CNS target, higher BBB penetration is generally favorable for GPCRs, suggesting better distribution.
9. **Caco-2:** A (-5.314) is worse than B (-4.196). Lower (more negative) values indicate poorer permeability.
10. **Solubility:** Both are poor (-2.501 and -2.677). This is a concern for both, but not a deciding factor.
11. **hERG:** A (0.544) is slightly better than B (0.735), indicating a lower risk of cardiotoxicity.
12. **Cl_mic:** A (-15.436) is much better than B (40.215). A has a significantly lower clearance, suggesting better metabolic stability.
13. **t1/2:** A (33.958) is better than B (-13.226). A has a longer in vitro half-life, which is desirable.
14. **Pgp:** A (0.028) is much better than B (0.14). Lower P-gp efflux is better for bioavailability.
15. **Affinity:** A (-7.4) is better than B (-6.2). A has a stronger binding affinity.
**GPCR-specific priorities:** For ADRB2, we prioritize logP, Pgp, TPSA, and affinity.
* **Affinity:** A is significantly better.
* **TPSA:** B is significantly better.
* **logP:** A is slightly better.
* **Pgp:** A is significantly better.
Considering the balance, Ligand A has a superior binding affinity and better metabolic stability (Cl_mic, t1/2) and Pgp efflux. While Ligand B has a better TPSA and lower DILI risk, the substantial advantage in binding affinity of Ligand A outweighs these benefits. The slightly higher DILI risk of A can be addressed with further optimization.
Output:
1
2025-04-17 23:29:27,626 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (374.388 Da and 346.471 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (76.35) is slightly higher than Ligand B (69.64). Both are below the 140 A^2 threshold for good oral absorption, which is good.
**3. logP:** Ligand A (3.174) is within the optimal 1-3 range, while Ligand B (1.858) is towards the lower end. For a GPCR, a slightly higher logP is generally preferred for membrane permeability, giving a slight edge to Ligand A.
**4. H-Bond Donors:** Ligand A (1) and Ligand B (2) are both acceptable.
**5. H-Bond Acceptors:** Ligand A (5) and Ligand B (3) are both acceptable.
**6. QED:** Ligand A (0.873) has a better QED score than Ligand B (0.747), indicating a more drug-like profile.
**7. DILI Risk:** Ligand B (8.181) has a significantly lower DILI risk than Ligand A (69.639). This is a major advantage for Ligand B.
**8. BBB Penetration:** Ligand B (79.992) shows better BBB penetration than Ligand A (72.664). While ADRB2 isn't exclusively a CNS target, some cardiovascular effects are mediated by central pathways, and better BBB penetration can be beneficial.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.895 and -4.755), which is unusual and suggests poor permeability. This is a concern for both.
**10. Aqueous Solubility:** Both ligands have negative solubility values (-3.9 and -3.111), suggesting poor aqueous solubility. This is a concern for both.
**11. hERG Inhibition:** Ligand A (0.562) has a slightly higher hERG inhibition risk than Ligand B (0.372), but both are relatively low.
**12. Microsomal Clearance:** Ligand B (33.595) has a lower microsomal clearance than Ligand A (19.877), indicating better metabolic stability.
**13. In vitro Half-Life:** Ligand A (58.524) has a significantly longer in vitro half-life than Ligand B (11.035). This is a significant advantage for Ligand A.
**14. P-gp Efflux:** Ligand A (0.304) has lower P-gp efflux than Ligand B (0.038), suggesting better bioavailability.
**15. Binding Affinity:** Ligand B (-7.8 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.8 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME drawbacks.
**Overall Assessment:**
While Ligand A has a better QED, longer half-life, and lower P-gp efflux, Ligand B shines with its significantly stronger binding affinity and much lower DILI risk. The stronger binding affinity is crucial for a GPCR target, and the lower DILI risk is a major safety advantage. The better BBB penetration of Ligand B is also a plus. The poor Caco-2 and solubility are concerns for both, but can be addressed through formulation strategies.
Considering the GPCR-specific priorities (affinity, logP, Pgp, TPSA), and the importance of safety (DILI), Ligand B is the more promising candidate.
Output:
0
2025-04-17 23:29:27,626 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (351.45 & 350.50 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (78.95) is higher than Ligand B (49.85). For a cardiovascular GPCR like ADRB2, TPSA isn't a *critical* factor like it would be for a CNS target, but lower is generally preferred for better permeability. Ligand B is significantly better.
3. **logP:** Ligand A (1.374) is within the optimal 1-3 range. Ligand B (2.712) is also within range, but closer to the upper limit. Both are acceptable, but A is slightly favored.
4. **HBD:** Ligand A (1) and Ligand B (0) are both low, which is good for permeability. No clear advantage.
5. **HBA:** Ligand A (4) and Ligand B (3) are both acceptable. No clear advantage.
6. **QED:** Both ligands have good QED scores (0.615 and 0.692 respectively), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (37.61) has a slightly higher DILI risk than Ligand B (16.48), but both are below the 40% threshold and considered low risk. Ligand B is preferred.
8. **BBB:** Both ligands have good BBB penetration (71.62% and 78.48%). This isn't a primary concern for a cardiovascular target, but higher is still better. Ligand B is slightly favored.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Both ligands have negative solubility values, which is also unusual and suggests poor solubility. This is a significant concern for both.
11. **hERG:** Both ligands have low hERG inhibition risk (0.379 and 0.393). No significant difference.
12. **Cl_mic:** Ligand A (48.33) and Ligand B (47.21) are similar. Lower is better, but the difference is negligible.
13. **t1/2:** Ligand A (7.60) has a significantly longer in vitro half-life than Ligand B (-11.62). This is a major advantage for Ligand A, potentially leading to less frequent dosing.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.019 and 0.058). No significant difference.
15. **Binding Affinity:** Ligand A (-6.9 kcal/mol) has a slightly stronger binding affinity than Ligand B (-6.2 kcal/mol). While the difference is less than the 1.5 kcal/mol threshold, it's still a positive for Ligand A.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B has a better logP and TPSA. However, Ligand A has a significantly better half-life and slightly better affinity. The half-life advantage is substantial, and the affinity difference, while small, adds to its favor.
**Overall Assessment:**
Despite the unusual Caco-2 and solubility values for both compounds, Ligand A's superior half-life and slightly better affinity, coupled with acceptable DILI and BBB, make it the more promising candidate. The longer half-life is a significant advantage for *in vivo* efficacy.
Output:
1
2025-04-17 23:29:27,626 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [357.401, 69.72, 1.009, 1, 3, 0.546, 31.989, 69.523, -4.671, -1.751, 0.206, -1.564, -9.362, 0.021, -2.5]
**Ligand B:** [362.539, 58.2, 3.755, 2, 3, 0.776, 36.603, 70.376, -4.826, -4.091, 0.622, 82.547, 40.479, 0.451, -5]
Here's a breakdown, considering the GPCR priorities (logP, Pgp, TPSA, affinity) and general guidelines:
1. **MW:** Both are within the ideal range (200-500 Da). A is 357.4, B is 362.5. No significant difference.
2. **TPSA:** A (69.72) is slightly higher than B (58.2). Both are acceptable for a non-CNS GPCR target like ADRB2, being under 140. B is better.
3. **logP:** A (1.009) is optimal. B (3.755) is approaching the upper limit, potentially causing solubility issues. A is better.
4. **HBD:** A (1) is better than B (2). Lower is preferred.
5. **HBA:** Both have 3, which is acceptable.
6. **QED:** A (0.546) is okay, but B (0.776) is better, indicating a more drug-like profile.
7. **DILI:** Both are good, below 40. A (31.989) is slightly better than B (36.603).
8. **BBB:** Both are acceptable, but B (70.376) is slightly better than A (69.523). This isn't a primary concern for a cardiovascular target.
9. **Caco-2:** Both are negative, indicating poor permeability. A (-4.671) is slightly better than B (-4.826), but both are concerning.
10. **Solubility:** A (-1.751) is better than B (-4.091). Solubility is a concern for B given its higher logP.
11. **hERG:** Both are very low risk (0.206 and 0.622). No significant difference.
12. **Cl_mic:** A (-1.564) is *much* better than B (82.547). A has a negative clearance, indicating high metabolic stability. B has a very high clearance, meaning it will be rapidly metabolized.
13. **t1/2:** A (-9.362) is better than B (40.479). A has a negative half-life, indicating a very long half-life.
14. **Pgp:** A (0.021) is much better than B (0.451). Lower P-gp efflux is desirable.
15. **Affinity:** B (-5) is 2.5 kcal/mol better than A (-2.5). This is a substantial difference in binding.
**Overall Assessment:**
While Ligand B boasts a better QED, BBB, and *significantly* better binding affinity, its liabilities are substantial. The high logP, poor solubility, very high microsomal clearance, and P-gp efflux are major concerns. Ligand A has a more balanced profile, with good DILI, low P-gp efflux, excellent metabolic stability (negative clearance and half-life), and acceptable solubility. The lower affinity of Ligand A is a drawback, but the ADME properties of Ligand B are so poor that it's unlikely to translate into *in vivo* efficacy, even with strong binding.
Therefore, I believe Ligand A is the more viable drug candidate.
1
2025-04-17 23:29:27,626 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [372.447, 93.11, -0.615, 1, 7, 0.67, 51.26, 66.344, -4.936, -1.39, 0.351, 46.653, 18.674, 0.014, -7.1]
**Ligand B:** [349.475, 91.32, 2.127, 3, 4, 0.637, 34.432, 32.803, -4.813, -2.54, 0.373, 32.056, 24.116, 0.115, -7.9]
Here's a breakdown of the comparison, considering the provided guidelines and GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (349.475) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are reasonably good, below the 140 A^2 threshold for oral absorption. Ligand B (91.32) is slightly better.
3. **logP:** Ligand A (-0.615) is a bit low, potentially hindering membrane permeability. Ligand B (2.127) is much better, falling within the optimal 1-3 range. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (1) is better than Ligand B (3). Lower HBD is generally preferred.
5. **HBA:** Ligand A (7) is better than Ligand B (4). Lower HBA is generally preferred.
6. **QED:** Both are similar and acceptable (above 0.5).
7. **DILI:** Ligand B (34.432) has a much lower DILI risk than Ligand A (51.26). This is a substantial advantage for Ligand B.
8. **BBB:** Ligand A (66.344) has a better BBB penetration potential than Ligand B (32.803), but BBB isn't a primary concern for a cardiovascular target.
9. **Caco-2:** Both are similar and negative, indicating good permeability.
10. **Solubility:** Both are negative, indicating poor solubility.
11. **hERG:** Both are low, indicating low cardiotoxicity risk.
12. **Cl_mic:** Ligand B (32.056) has a lower microsomal clearance, suggesting better metabolic stability than Ligand A (46.653).
13. **t1/2:** Ligand B (24.116) has a longer in vitro half-life than Ligand A (18.674).
14. **Pgp:** Ligand A (0.014) has a lower Pgp efflux liability than Ligand B (0.115), which is favorable.
15. **Affinity:** Ligand B (-7.9 kcal/mol) has a significantly stronger binding affinity than Ligand A (-7.1 kcal/mol). This 0.8 kcal/mol difference is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
While Ligand A has a slightly better BBB score and Pgp efflux liability, Ligand B clearly wins on several critical parameters. Its logP is optimal, DILI risk is much lower, metabolic stability (Cl_mic and t1/2) is better, and, most importantly, its binding affinity is significantly stronger. The better logP and affinity of Ligand B are particularly important for a GPCR target like ADRB2. The slightly lower BBB is not a major concern for a cardiovascular target.
Therefore, I would choose Ligand B as the more promising drug candidate.
Output:
0
2025-04-17 23:29:27,626 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.5 & 345.4 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (67.43) is significantly better than Ligand B (98.14). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (3.197) is optimal, while Ligand B (0.685) is quite low. Low logP can hinder membrane permeability. This is a significant advantage for A.
4. **HBD:** Both have 2 HBD, within the acceptable limit.
5. **HBA:** Ligand A (3) is better than Ligand B (6). Lower HBA generally improves permeability.
6. **QED:** Both ligands have good QED scores (0.593 and 0.709), indicating good drug-like properties. No major difference.
7. **DILI:** Ligand A (27.8) has a much lower DILI risk than Ligand B (52.6). This is a crucial advantage.
8. **BBB:** Not a primary concern for a cardiovascular target, but Ligand A (69.4) is better than Ligand B (55.9).
9. **Caco-2:** Ligand A (-4.868) is better than Ligand B (-5.399), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-2.998) is better than Ligand B (-3.116).
11. **hERG:** Both ligands have very low hERG inhibition risk (0.376 and 0.049). No significant difference.
12. **Cl_mic:** Ligand A (58.155) has higher metabolic clearance than Ligand B (2.287). This is a disadvantage for A, as it suggests faster metabolism.
13. **t1/2:** Ligand B (18.461) has a much longer in vitro half-life than Ligand A (8.406). This is a significant advantage for B.
14. **Pgp:** Ligand A (0.096) has lower P-gp efflux than Ligand B (0.019). Lower P-gp efflux is preferred.
15. **Binding Affinity:** Ligand B (-8.2 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.3 kcal/mol). This is a major advantage for B, potentially outweighing some ADME concerns.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A excels in logP, TPSA, and Pgp. However, Ligand B has a substantially better binding affinity (-8.2 vs -5.3 kcal/mol). The difference in affinity is large enough to compensate for the lower logP and higher TPSA. The DILI risk is also significantly lower for Ligand A. The longer half-life of Ligand B is also a positive.
**Overall Assessment:**
While Ligand A has better ADME properties (lower DILI, better logP, TPSA, Pgp), the significantly stronger binding affinity of Ligand B is a decisive factor for a GPCR target. The improved half-life also makes Ligand B more attractive.
Output:
0
2025-04-17 23:29:27,626 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (351.447 and 355.435 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (78.95) is significantly better than Ligand B (99.18). For a GPCR, keeping TPSA lower is beneficial for permeability. Ligand B is approaching the upper limit for good oral absorption.
**3. logP:** Ligand A (0.531) is slightly lower than optimal (1-3), but still acceptable. Ligand B (-0.644) is even lower, potentially causing permeability issues.
**4. H-Bond Donors:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
**5. H-Bond Acceptors:** Ligand A (4) is better than Ligand B (5). Similar reasoning as HBD.
**6. QED:** Ligand A (0.801) has a much better QED score than Ligand B (0.683), indicating a more drug-like profile overall.
**7. DILI Risk:** Ligand A (18.728) has a considerably lower DILI risk than Ligand B (31.291). This is a major advantage for Ligand A.
**8. BBB Penetration:** Ligand A (80.031) has significantly better BBB penetration than Ligand B (13.377). While ADRB2 isn't strictly a CNS target, some CNS exposure can be relevant and is not detrimental.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.824 and -4.935), which is unusual and suggests poor permeability. However, these values are on the same scale, so the difference is not significant.
**10. Aqueous Solubility:** Both ligands have negative solubility values (-0.885 and -1.008), indicating poor aqueous solubility. Again, the difference is minimal.
**11. hERG Inhibition:** Ligand A (0.079) has a lower hERG inhibition risk than Ligand B (0.107), which is favorable.
**12. Microsomal Clearance:** Ligand B (-1.521) has a lower (better) microsomal clearance than Ligand A (1.913), suggesting greater metabolic stability. This is a positive for Ligand B.
**13. In vitro Half-Life:** Ligand B (-12.32) has a much longer in vitro half-life than Ligand A (6.975), a significant advantage.
**14. P-gp Efflux:** Ligand A (0.009) has a lower P-gp efflux liability than Ligand B (0.01), which is slightly better.
**15. Binding Affinity:** Ligand B (-6.5) has a slightly stronger binding affinity than Ligand A (-6.3), but the difference is only 0.2 kcal/mol.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand A is the stronger candidate. While Ligand B has better metabolic stability (lower Cl_mic and longer t1/2) and slightly better affinity, Ligand A excels in crucial areas like TPSA, DILI risk, BBB penetration, and QED. The lower TPSA and DILI risk are particularly important. The slight difference in affinity is unlikely to outweigh the other advantages of Ligand A.
Output:
1
2025-04-17 23:29:27,626 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (344.415 and 348.491 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (84.42) is slightly higher than Ligand B (70.25). Both are below the 140 A^2 threshold for good oral absorption, but Ligand B is preferable due to the lower TPSA.
**3. logP:** Ligand A (1.239) is within the optimal 1-3 range. Ligand B (2.43) is also within range, but edging towards the higher end. This is not a major concern, but slightly favors Ligand A.
**4. H-Bond Donors:** Ligand A has 1 HBD, and Ligand B has 2. Both are acceptable, but lower is generally better for permeability, giving a slight edge to Ligand A.
**5. H-Bond Acceptors:** Ligand A has 5 HBA, and Ligand B has 4. Both are below the 10 threshold. No significant difference.
**6. QED:** Ligand A (0.834) has a better QED score than Ligand B (0.794), indicating a more drug-like profile.
**7. DILI Risk:** Ligand A (65.103) has a higher DILI risk than Ligand B (31.563). This is a significant advantage for Ligand B.
**8. BBB Penetration:** Both ligands have similar BBB penetration (Ligand A: 63.086, Ligand B: 65.413). While not a primary concern for a cardiovascular target, it's not a differentiating factor.
**9. Caco-2 Permeability:** Ligand A (-4.795) shows better Caco-2 permeability than Ligand B (-5.206).
**10. Aqueous Solubility:** Ligand A (-1.683) has better aqueous solubility than Ligand B (-2.558).
**11. hERG Inhibition:** Ligand A (0.134) has a lower hERG inhibition liability than Ligand B (0.445), which is a significant safety advantage.
**12. Microsomal Clearance:** Ligand A (22.08) has significantly lower microsomal clearance than Ligand B (56.129), suggesting better metabolic stability.
**13. In vitro Half-Life:** Ligand A (0.917) has a shorter half-life than Ligand B (2.23). This is a drawback for Ligand A.
**14. P-gp Efflux:** Ligand A (0.016) has much lower P-gp efflux liability than Ligand B (0.247). This is a significant advantage for Ligand A.
**15. Binding Affinity:** Ligand A (-7.2) has a stronger binding affinity than Ligand B (-6.1). This is a substantial advantage, potentially outweighing some ADME concerns.
**GPCR-Specific Considerations:** For a GPCR like ADRB2, logP, TPSA, Pgp efflux, and affinity are key. Ligand A has a better logP, lower TPSA, lower Pgp efflux, and significantly better affinity.
**Overall Assessment:**
While Ligand B has a much lower DILI risk, Ligand A's superior binding affinity (-7.2 vs -6.1), lower TPSA, lower P-gp efflux, better solubility, and lower hERG inhibition are compelling advantages. The improved metabolic stability (lower Cl_mic) is also beneficial. The slightly shorter half-life of Ligand A is a concern, but can potentially be addressed through formulation or structural modifications. The stronger binding affinity is likely to be the most important factor for efficacy.
Output:
1
2025-04-17 23:29:27,626 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (363.527) is slightly higher than Ligand B (344.455), but both are acceptable.
2. **TPSA:** Ligand A (62.3) is better than Ligand B (69.64). Both are below 140, but lower TPSA generally favors absorption.
3. **logP:** Both ligands have good logP values (A: 2.928, B: 2.36), falling within the optimal 1-3 range.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD is generally better for permeability.
5. **HBA:** Ligand A (4) is preferable to Ligand B (3). Lower HBA is generally better for permeability.
6. **QED:** Both ligands have acceptable QED values (A: 0.81, B: 0.711), indicating good drug-like properties.
7. **DILI:** Ligand A (26.561) is significantly better than Ligand B (20.202) in terms of DILI risk. Lower is better, and Ligand A is well below the concerning threshold of 60.
8. **BBB:** Both ligands have similar BBB penetration (A: 65.607, B: 63.164). While not exceptionally high, they are reasonable for a non-CNS target like ADRB2.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the values are similar (-4.89 for A, -4.611 for B).
10. **Solubility:** Ligand A (-2.693) is slightly better than Ligand B (-1.685), indicating potentially better aqueous solubility, although both are poor.
11. **hERG:** Both ligands have low hERG inhibition liability (A: 0.346, B: 0.293), which is excellent.
12. **Cl_mic:** Ligand A (63.867) has higher microsomal clearance than Ligand B (33.897), indicating lower metabolic stability. This is a significant drawback for Ligand A.
13. **t1/2:** Ligand B (24.771) has a much longer in vitro half-life than Ligand A (-1.262), which is a substantial advantage.
14. **Pgp:** Both ligands have low P-gp efflux liability (A: 0.342, B: 0.073). Ligand B is slightly better.
15. **Binding Affinity:** Ligand A (-7.7) has a significantly stronger binding affinity than Ligand B (-6.3). This is a >1.5 kcal/mol advantage, which is very important.
**GPCR-Specific Priorities:**
For GPCRs, logP, TPSA, Pgp, and affinity are key. Ligand A excels in affinity and has comparable logP and Pgp values. While TPSA is slightly better for A, the significant differences in metabolic stability (Cl_mic) and half-life (t1/2) favor Ligand B. The better DILI score for Ligand A is also a positive.
**Overall Assessment:**
Despite the superior binding affinity of Ligand A, the significantly better metabolic stability (lower Cl_mic and longer t1/2) of Ligand B, combined with a better DILI score, makes it the more promising drug candidate. The strong binding affinity of Ligand A is attractive, but poor metabolic stability often leads to rapid clearance and the need for high doses, potentially increasing the risk of side effects.
Output:
0
2025-04-17 23:29:27,626 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (343.391 Da) is within the ideal range (200-500 Da). Ligand B (361.877 Da) is also within the ideal range. No clear advantage.
2. **TPSA:** Ligand A (119.66) is acceptable, though approaching the upper limit for good oral absorption. Ligand B (52.57) is excellent, well below the 140 threshold, and suggests good permeability. **Advantage: B**
3. **logP:** Ligand A (0.516) is a bit low, potentially hindering membrane permeability. Ligand B (1.509) is within the optimal range (1-3). **Advantage: B**
4. **HBD:** Ligand A (3) is acceptable. Ligand B (0) is also good, potentially improving permeability. **Slight Advantage: B**
5. **HBA:** Both ligands have 5 HBA, which is acceptable. No clear advantage.
6. **QED:** Ligand B (0.816) has a significantly better QED score than Ligand A (0.66), indicating a more drug-like profile. **Advantage: B**
7. **DILI:** Ligand A (56.689) has a slightly higher DILI risk than Ligand B (38.387), though both are reasonably low. **Slight Advantage: B**
8. **BBB:** Ligand A (35.828) has low BBB penetration. Ligand B (93.253) has excellent BBB penetration. While ADRB2 isn't exclusively a CNS target, some cardiovascular effects are mediated through CNS pathways, and higher BBB penetration can be beneficial. **Advantage: B**
9. **Caco-2:** Ligand A (-5.723) has poor Caco-2 permeability. Ligand B (-4.911) is also poor, but slightly better than A. **Slight Advantage: B**
10. **Solubility:** Ligand A (-1.832) has poor solubility. Ligand B (-2.433) also has poor solubility. No clear advantage.
11. **hERG:** Ligand A (0.44) has a lower hERG risk than Ligand B (0.803). **Advantage: A**
12. **Cl_mic:** Ligand A (-10.632) has much lower microsomal clearance, indicating better metabolic stability, than Ligand B (43.492). **Advantage: A**
13. **t1/2:** Ligand A (-20.701) has a longer in vitro half-life than Ligand B (-1.076). **Advantage: A**
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.068 and 0.069 respectively). No clear advantage.
15. **Binding Affinity:** Ligand B (-8.1 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.6 kcal/mol). This is a substantial difference (1.5 kcal/mol) and outweighs many of the ADME drawbacks of Ligand B. **Advantage: B**
**Overall Assessment:**
Ligand B consistently outperforms Ligand A in key GPCR-relevant properties (TPSA, logP, BBB, and *especially* binding affinity). While Ligand A has advantages in metabolic stability (Cl_mic, t1/2) and hERG risk, the significantly stronger binding affinity of Ligand B, coupled with its better drug-like properties (QED) and permeability characteristics, makes it the more promising candidate. The lower metabolic stability of Ligand B could be addressed through structural modifications in later optimization stages.
Output:
0
2025-04-17 23:29:27,627 - INFO - Batch 408 complete. Total preferences: 6528
2025-04-17 23:29:27,627 - INFO - Processing batch 409/512...
2025-04-17 23:30:16,675 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (344.42 and 352.40 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (103.87) is significantly better than Ligand B (133.47). For a GPCR, keeping TPSA under 140 is good, and A is closer to the ideal for potential CNS penetration (though not a CNS target here, lower TPSA is generally favorable).
3. **logP:** Ligand A (1.55) is within the optimal range (1-3). Ligand B (-1.70) is below 1, which could indicate poor membrane permeability. This is a significant drawback for Ligand B.
4. **HBD:** Ligand A (2) is preferable to Ligand B (3). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (5) is better than Ligand B (8). Lower HBA also contributes to better permeability.
6. **QED:** Ligand A (0.79) is substantially better than Ligand B (0.56). A higher QED suggests a more drug-like profile.
7. **DILI:** Both ligands have acceptable DILI risk (51.1 and 43.2 percentile), below the concerning threshold of 60. No major difference.
8. **BBB:** Ligand A (41.3) is better than Ligand B (19.7), although neither is particularly high. This isn't a primary concern for ADRB2 (a cardiovascular target), but it's a slight edge for A.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.42 and -5.65). This is unusual and suggests poor permeability in this assay. However, the values are similar, so it doesn't differentiate them.
10. **Solubility:** Ligand A (-2.11) is better than Ligand B (-0.81). Higher solubility is generally preferred.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.20 and 0.02). This is excellent for both.
12. **Cl_mic:** Ligand B (-11.64) has significantly lower microsomal clearance than Ligand A (35.41). This suggests better metabolic stability for Ligand B.
13. **t1/2:** Ligand A (-19.35) has a negative in vitro half-life, which is concerning. Ligand B (2.10) has a short half-life, but it's positive, which is better.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.03 and 0.01). This is good for both.
15. **Binding Affinity:** Ligand B (-8.8 kcal/mol) has a significantly stronger binding affinity than Ligand A (-4.6 kcal/mol). This is a substantial advantage for Ligand B. A difference of >1.5 kcal/mol is often enough to overcome other issues.
**Overall Assessment:**
Ligand B has a significantly better binding affinity, and improved metabolic stability (lower Cl_mic). However, it suffers from a low logP, higher TPSA, and a shorter half-life. Ligand A has better physicochemical properties (logP, TPSA, solubility, QED) but a much weaker binding affinity and a concerning negative half-life.
Given the importance of potency for GPCRs, the substantial binding affinity advantage of Ligand B outweighs its drawbacks, *especially* considering the relatively low priority of BBB penetration for a cardiovascular target. The low logP of Ligand B is a concern, but could potentially be addressed through prodrug strategies or formulation approaches. The negative half-life of Ligand A is a major red flag.
Output:
0
2025-04-17 23:30:16,675 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A Analysis:**
* **MW:** 368.949 Da - Within the ideal range (200-500).
* **TPSA:** 33.73 A2 - Excellent, well below the 140 A2 threshold, and good for GPCRs.
* **logP:** 4.492 - Slightly high, potentially leading to solubility issues or off-target effects, but acceptable.
* **HBD:** 1 - Good, within the desired range.
* **HBA:** 4 - Good, within the desired range.
* **QED:** 0.617 - Good, indicating a drug-like profile.
* **DILI:** 9.112 - Very low risk of liver injury, excellent.
* **BBB:** 80.031 - Good BBB penetration, desirable for a GPCR.
* **Caco-2:** -4.777 - Negative value is concerning and likely indicates very poor permeability.
* **Solubility:** -2.727 - Very poor solubility, a significant drawback.
* **hERG:** 0.945 - Low risk of hERG inhibition, good.
* **Cl_mic:** 51.263 mL/min/kg - Moderate clearance, not ideal but not terrible.
* **t1/2:** 41.16 hours - Good in vitro half-life.
* **Pgp:** 0.433 - Low P-gp efflux, favorable.
* **Affinity:** -5.6 kcal/mol - Good binding affinity.
**Ligand B Analysis:**
* **MW:** 342.399 Da - Within the ideal range (200-500).
* **TPSA:** 116.29 A2 - Higher than Ligand A, but still within acceptable limits for oral absorption, though less ideal for a GPCR.
* **logP:** 0.329 - Low, potentially hindering membrane permeability.
* **HBD:** 2 - Good, within the desired range.
* **HBA:** 4 - Good, within the desired range.
* **QED:** 0.775 - Good, indicating a drug-like profile.
* **DILI:** 28.073 - Very low risk of liver injury, excellent.
* **BBB:** 39.511 - Lower BBB penetration than Ligand A, less desirable for a GPCR.
* **Caco-2:** -5.327 - Negative value is concerning and likely indicates very poor permeability.
* **Solubility:** -3.264 - Very poor solubility, a significant drawback.
* **hERG:** 0.131 - Very low risk of hERG inhibition, excellent.
* **Cl_mic:** -12.695 mL/min/kg - Negative clearance is not physically possible, likely an error. Assuming this is a very low clearance.
* **t1/2:** -5.48 hours - Negative half-life is not physically possible, likely an error. Assuming this is a very short half-life.
* **Pgp:** 0.007 - Very low P-gp efflux, favorable.
* **Affinity:** -7.5 kcal/mol - Excellent binding affinity, 1.9 kcal/mol stronger than Ligand A.
**Comparison and Decision:**
Both ligands have significant solubility and permeability issues (negative Caco-2 values). However, Ligand B has a substantially stronger binding affinity (-7.5 vs -5.6 kcal/mol). For a GPCR, affinity is a critical driver. Ligand A has better BBB penetration, but the affinity difference is substantial. Ligand B also has a lower hERG risk and a very low DILI risk. The negative values for clearance and half-life in Ligand B are concerning, but assuming they are errors indicating very favorable metabolic stability and a short half-life, the overall profile is still more promising due to the superior affinity.
Therefore, I would choose Ligand B.
Output:
0
2025-04-17 23:30:16,675 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands (384.408 and 408.275 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (67.77) is significantly better than Ligand B (85.83). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (4.188) is slightly higher than Ligand B (2.393). While both are within the acceptable range, Ligand A is approaching the upper limit, which could present solubility challenges.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves membrane permeability.
5. **HBA:** Ligand A (6) is preferable to Ligand B (5). Lower HBA generally improves membrane permeability.
6. **QED:** Ligand B (0.814) has a better QED score than Ligand A (0.683), indicating a more drug-like profile overall.
7. **DILI:** Ligand B (55.138) has a much lower DILI risk than Ligand A (93.68). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (71.772) has slightly better BBB penetration than Ligand B (69.407), but this is less critical for a cardiovascular target.
9. **Caco-2:** Ligand A (-4.888) and Ligand B (-5.296) are both very poor. This is a significant concern for both compounds.
10. **Solubility:** Ligand B (-2.595) is better than Ligand A (-5.077). This is important given Ligand A's higher logP.
11. **hERG:** Both ligands have low hERG inhibition risk (0.415 and 0.291, respectively). No significant difference.
12. **Cl_mic:** Ligand B (3.729) has significantly lower microsomal clearance than Ligand A (51.352), indicating better metabolic stability.
13. **t1/2:** Ligand A (34.424) has a longer in vitro half-life than Ligand B (13.55). This is a positive for Ligand A.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.272 and 0.191, respectively). No significant difference.
15. **Binding Affinity:** Ligand B (-7.4 kcal/mol) has a substantially stronger binding affinity than Ligand A (-6.5 kcal/mol). This is a major advantage, potentially outweighing some ADME concerns.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, Pgp, TPSA, and affinity. Ligand B has a better logP, comparable Pgp, lower TPSA, and *significantly* better affinity. The lower DILI risk and improved metabolic stability are also very favorable. While Ligand A has a longer half-life, the superior binding affinity and safety profile of Ligand B are more important. The poor Caco-2 values are a concern for both, but can be addressed through formulation strategies.
**Conclusion:**
Considering the balance of properties and the priorities for a GPCR target, Ligand B is the more promising drug candidate.
Output:
0
2025-04-17 23:30:16,675 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [340.423, 53.35, 2.829, 0, 5, 0.786, 56.107, 90.074, -4.967, -3.463, 0.613, 68.749, -14.686, 0.641, -7]
**Ligand B:** [351.451, 98.14, 0.723, 2, 6, 0.605, 23.846, 63.707, -5.377, -0.667, 0.126, 17.976, -2.036, 0.013, -7.6]
Here's a breakdown, considering the guidelines and GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal range (200-500 Da). A is 340.423, B is 351.451 - very similar.
2. **TPSA:** A (53.35) is excellent, well below 140 and good for oral absorption. B (98.14) is higher, but still acceptable, though less ideal.
3. **logP:** A (2.829) is optimal. B (0.723) is a bit low, potentially hindering membrane permeability. This is a significant drawback for a GPCR ligand.
4. **HBD:** A (0) is good. B (2) is acceptable.
5. **HBA:** A (5) is good. B (6) is acceptable.
6. **QED:** Both are reasonably good (A: 0.786, B: 0.605), indicating drug-like properties.
7. **DILI:** A (56.107) is moderate, but acceptable. B (23.846) is very good, indicating low liver injury risk.
8. **BBB:** A (90.074) is excellent, suggesting good potential for CNS penetration if desired (though less critical for a cardiovascular target). B (63.707) is lower.
9. **Caco-2:** Both are negative, which is unusual and suggests poor permeability. However, the scale is not specified, so this is difficult to interpret.
10. **Solubility:** Both are negative, again, scale unspecified.
11. **hERG:** A (0.613) is very good. B (0.126) is excellent.
12. **Cl_mic:** A (68.749) is moderate, indicating moderate metabolic clearance. B (17.976) is low, suggesting better metabolic stability.
13. **t1/2:** A (-14.686) is very poor. B (-2.036) is still poor, but better than A.
14. **Pgp:** A (0.641) is moderate. B (0.013) is excellent, indicating minimal P-gp efflux.
15. **Affinity:** A (-7.0) is good. B (-7.6) is slightly better, offering a 0.6 kcal/mol advantage.
**Overall Assessment:**
Ligand B has a better DILI score, hERG score, Pgp efflux, and metabolic stability. However, its logP is significantly lower, which is a major concern for a GPCR ligand needing good membrane permeability. Ligand A has a better logP and BBB penetration, but suffers from a poor half-life and moderate metabolic clearance. The affinity difference is relatively small (0.6 kcal/mol).
Given the GPCR target and the importance of logP for membrane interaction, I lean towards **Ligand A** despite its drawbacks. The slightly better logP and BBB penetration are more crucial for a GPCR, and the affinity is already good. The poor half-life could be addressed through structural modifications.
Output:
1
2025-04-17 23:30:16,676 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (347.463) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are reasonably low, but Ligand A (61.68) is better than Ligand B (66.32), increasing the likelihood of good oral absorption.
3. **logP:** Ligand A (0.486) is lower than ideal (1-3), potentially hindering permeation. Ligand B (4.259) is at the high end of the acceptable range, potentially causing solubility issues and off-target effects.
4. **HBD:** Ligand A (0) is excellent, minimizing potential issues. Ligand B (1) is acceptable.
5. **HBA:** Ligand A (5) is good. Ligand B (6) is also acceptable.
6. **QED:** Both ligands have similar, good QED scores (A: 0.795, B: 0.705), indicating good drug-like properties.
7. **DILI:** Ligand A (18.922) has a significantly lower DILI risk than Ligand B (36.099). This is a major advantage.
8. **BBB:** Both have moderate BBB penetration (A: 56.262, B: 52.617). Since ADRB2 is a cardiovascular target, BBB penetration is not a primary concern, but a higher value is still preferable.
9. **Caco-2:** Both have negative Caco-2 permeability values, which is unusual and requires further investigation. However, the values are similar.
10. **Solubility:** Ligand A (-0.113) has slightly better solubility than Ligand B (-4.079).
11. **hERG:** Ligand A (0.167) has a much lower hERG inhibition liability than Ligand B (0.8). This is a critical advantage, reducing the risk of cardiotoxicity.
12. **Cl_mic:** Ligand A (9.465) has a significantly lower microsomal clearance, indicating better metabolic stability. Ligand B (64.579) is quite high.
13. **t1/2:** Ligand B (61.404) has a much longer in vitro half-life than Ligand A (9.959). This is a significant advantage.
14. **Pgp:** Ligand A (0.021) has a much lower P-gp efflux liability than Ligand B (0.626), suggesting better oral bioavailability and potentially better tissue distribution.
15. **Affinity:** Ligand B (-6.1 kcal/mol) has a significantly stronger binding affinity than Ligand A (-1.1 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME drawbacks.
**Overall Assessment:**
Ligand B has a much stronger binding affinity, which is a key priority for GPCR targets. However, it suffers from higher DILI risk, higher hERG inhibition, and significantly higher microsomal clearance. Ligand A, while having weaker affinity, presents a much more favorable ADME-Tox profile with lower risk of liver injury and cardiotoxicity, and better metabolic stability. The difference in affinity is substantial (5 kcal/mol), but the ADME liabilities of Ligand B are concerning. Given the cardiovascular target, minimizing cardiotoxicity (hERG) and maximizing metabolic stability are crucial.
Considering the balance of potency and safety/drug-likeness, and the specific priorities for a cardiovascular GPCR target, I favor Ligand A.
Output:
1
2025-04-17 23:30:16,676 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (352.475 Da) is within the ideal range (200-500 Da). Ligand B (426.746 Da) is also acceptable, but closer to the upper limit.
2. **TPSA:** Ligand A (81.08) is good, well below the 140 threshold. Ligand B (72.7) is even better.
3. **logP:** Ligand A (1.294) is optimal. Ligand B (3.309) is still within the acceptable range, but higher, potentially increasing off-target interactions.
4. **HBD:** Ligand A (2) is good. Ligand B (1) is also good.
5. **HBA:** Ligand A (4) is good. Ligand B (5) is also acceptable.
6. **QED:** Ligand A (0.755) is excellent. Ligand B (0.568) is still acceptable, but lower.
7. **DILI:** Ligand A (13.067) is very good, indicating low liver injury risk. Ligand B (44.552) is higher, suggesting a moderate risk.
8. **BBB:** Both ligands have similar BBB penetration (Ligand A: 66.499, Ligand B: 63.784). While not exceptionally high, it's not a primary concern for ADRB2, which isn't a CNS target.
9. **Caco-2:** Ligand A (-4.69) and Ligand B (-5.208) are both poor, indicating low intestinal absorption.
10. **Solubility:** Ligand A (-2.067) is slightly better than Ligand B (-4.294), but both are poor.
11. **hERG:** Both ligands show low hERG inhibition liability (Ligand A: 0.3, Ligand B: 0.23).
12. **Cl_mic:** Ligand A (34.733) has a lower microsomal clearance, suggesting better metabolic stability than Ligand B (41.284).
13. **t1/2:** Ligand A (-7.658) has a longer in vitro half-life than Ligand B (-11.603), indicating better stability.
14. **Pgp:** Both ligands have very low P-gp efflux liability (Ligand A: 0.052, Ligand B: 0.079).
15. **Affinity:** Ligand A (-5.5 kcal/mol) has a weaker binding affinity than Ligand B (-2.6 kcal/mol). This is a significant difference.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B has a better logP, TPSA, and significantly better affinity. While Ligand A has better DILI and metabolic stability, the substantial affinity advantage of Ligand B outweighs these concerns. The poor Caco-2 and solubility for both compounds are concerning, but can be addressed with formulation strategies.
**Conclusion:**
Despite the slightly higher DILI risk and lower metabolic stability, Ligand B's significantly stronger binding affinity makes it the more promising candidate for further development as an ADRB2 ligand.
Output:
0
2025-04-17 23:30:16,676 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (342.443 and 357.495 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (83.12) is slightly higher than Ligand B (73.32). Both are below the 140 threshold for oral absorption, but closer to the 90 threshold for CNS targets, which isn't a primary concern for ADRB2 (cardiovascular). Ligand B is preferable.
3. **logP:** Ligand A (2.247) is within the optimal 1-3 range. Ligand B (0.277) is *below* this range, potentially hindering permeability. This is a significant advantage for Ligand A.
4. **HBD:** Ligand A (3) is higher than Ligand B (1). While both are acceptable (<=5), lower is generally better for permeability. Ligand B is preferable.
5. **HBA:** Ligand A (4) and Ligand B (5) are both within the acceptable range (<=10). No strong preference.
6. **QED:** Ligand A (0.664) is slightly better than Ligand B (0.569), indicating a more drug-like profile.
7. **DILI:** Ligand B (8.453) has a much lower DILI risk than Ligand A (47.421). This is a substantial advantage for Ligand B.
8. **BBB:** Ligand A (65.374) has a higher BBB penetration percentile than Ligand B (53.16). While not a primary concern for ADRB2, it's a slight positive for Ligand A.
9. **Caco-2:** Ligand A (-5.054) has a more negative Caco-2 value, indicating *lower* permeability than Ligand B (-4.449). Ligand B is preferable.
10. **Solubility:** Ligand A (-2.919) has a more negative solubility value, indicating *lower* solubility than Ligand B (-0.189). Ligand B is preferable.
11. **hERG:** Both ligands have low hERG inhibition risk (0.492 and 0.401, respectively). No significant difference.
12. **Cl_mic:** Ligand A (12.01) has a significantly lower microsomal clearance than Ligand B (45.656), suggesting better metabolic stability. This is a major advantage for Ligand A.
13. **t1/2:** Ligand A (8.214) has a better in vitro half-life than Ligand B (-16.381). This is a significant advantage for Ligand A.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.038 and 0.043, respectively). No significant difference.
15. **Binding Affinity:** Ligand B (-7.9) has a substantially stronger binding affinity than Ligand A (-5.9). This is a very important advantage for Ligand B, potentially outweighing some ADME concerns.
**GPCR-Specific Priorities & Overall Assessment:**
For a GPCR like ADRB2, affinity, logP, TPSA, and Pgp are key. Ligand B excels in affinity, has a better TPSA, and while its logP is low, the very strong binding may compensate. Ligand A has a better logP and metabolic stability (Cl_mic and t1/2), but its affinity is significantly weaker. The DILI risk is also a concern for Ligand A. Considering the importance of potency for GPCRs, the superior binding affinity of Ligand B is the deciding factor, despite its lower logP and solubility.
Output:
0
2025-04-17 23:30:16,676 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [386.495, 97.97, 2.641, 1, 5, 0.823, 76.076, 50.679, -4.774, -3.285, 0.508, 27.215, 86.014, 0.174, -6.3]
**Ligand B:** [342.483, 49.41, 3.262, 1, 2, 0.827, 36.293, 67.817, -4.623, -4.354, 0.54, 69.561, -11.085, 0.438, -6.4]
Here's a step-by-step comparison, considering the guidelines and GPCR-specific priorities:
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (342.483) is slightly lower, which could be advantageous for permeability, but both are acceptable.
2. **TPSA:** Ligand A (97.97) is higher than Ligand B (49.41). For a cardiovascular GPCR, TPSA isn't *as* critical as for a CNS target, but lower is generally better for absorption. Ligand B is significantly better here.
3. **logP:** Both are in the optimal range (1-3). Ligand B (3.262) is slightly higher, which *could* lead to some off-target interactions, but is still reasonable. Ligand A (2.641) is slightly better.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 5 HBA, Ligand B has 2. Lower is generally better for permeability. Ligand B is better.
6. **QED:** Both have good QED scores (0.823 and 0.827), indicating good drug-like properties.
7. **DILI:** Ligand A (76.076) has a significantly higher DILI risk than Ligand B (36.293). This is a major concern.
8. **BBB:** Ligand B (67.817) has a higher BBB penetration percentile than Ligand A (50.679). While not a CNS target, some BBB penetration can indicate better distribution.
9. **Caco-2:** Both have negative values, indicating poor permeability. Ligand A (-4.774) is slightly worse than Ligand B (-4.623).
10. **Solubility:** Both have negative values, indicating poor solubility. Ligand B (-4.354) is slightly better than Ligand A (-3.285).
11. **hERG:** Both have low hERG risk (0.508 and 0.54).
12. **Cl_mic:** Ligand A (27.215) has a lower microsomal clearance, suggesting better metabolic stability than Ligand B (69.561). This is a significant advantage.
13. **t1/2:** Ligand A (86.014) has a much longer in vitro half-life than Ligand B (-11.085). This is a substantial advantage.
14. **Pgp:** Ligand A (0.174) has lower P-gp efflux liability than Ligand B (0.438), which is favorable.
15. **Affinity:** Both have similar binding affinities (-6.3 and -6.4 kcal/mol). The difference is negligible.
**Overall Assessment:**
Ligand B has advantages in TPSA, HBA, and slightly better solubility and Caco-2 permeability. However, the *major* drawback of Ligand A is its significantly higher DILI risk. Ligand A compensates with better metabolic stability (lower Cl_mic), a longer half-life, and lower P-gp efflux. Considering the cardiovascular context, DILI risk is a critical factor. While metabolic stability and half-life are important, a high DILI risk is a major red flag.
Therefore, despite Ligand A's better metabolic properties, I would favor Ligand B due to the significantly lower DILI risk.
0
2025-04-17 23:30:16,677 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Step-by-step comparison:**
1. **MW:** Both ligands (356.419 and 344.499 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (40.62) is significantly better than Ligand A (110.8), being well below the 140 threshold for oral absorption and even more favorable for potential CNS penetration (though not a primary goal here).
3. **logP:** Ligand B (3.228) is at the upper end of the optimal range (1-3), while Ligand A (0.682) is below 1, which could indicate poor membrane permeability. Ligand B is preferred.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (0), but both are within the acceptable limit of 5.
5. **HBA:** Ligand A (6) is higher than Ligand B (2), but both are within the acceptable limit of 10.
6. **QED:** Both ligands have good QED scores (0.557 and 0.665), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand B (15.2) has a much lower DILI risk than Ligand A (58.666), which is a significant advantage.
8. **BBB:** Ligand B (82.823) has a much higher BBB penetration score than Ligand A (46.026). While ADRB2 isn't primarily a CNS target, higher BBB penetration can sometimes correlate with better overall distribution.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
10. **Solubility:** Ligand A (-2.115) has slightly better solubility than Ligand B (-3.245).
11. **hERG:** Ligand A (0.104) has a lower hERG risk than Ligand B (0.524), which is a positive.
12. **Cl_mic:** Ligand A (19.655) has a much lower microsomal clearance than Ligand B (68.413), indicating better metabolic stability.
13. **t1/2:** Ligand B (-14.219) has a much longer in vitro half-life than Ligand A (-0.508), which is a significant advantage.
14. **Pgp:** Ligand A (0.064) has lower P-gp efflux liability than Ligand B (0.47), which is favorable.
15. **Binding Affinity:** Ligand B (-7.3) has a significantly stronger binding affinity than Ligand A (-4.7), a difference of 2.6 kcal/mol. This is a substantial advantage that can outweigh some of the ADME drawbacks of Ligand B.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are particularly important. Ligand B excels in logP, TPSA, and especially affinity. While Ligand A has better hERG and Pgp, the superior binding affinity and significantly improved DILI risk of Ligand B are more critical. The longer half-life also makes Ligand B more attractive.
**Conclusion:**
Despite some drawbacks in hERG and Pgp, Ligand B's superior binding affinity, lower DILI risk, better logP and TPSA, and longer half-life make it the more promising drug candidate for the ADRB2 receptor.
Output:
0
2025-04-17 23:30:16,677 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (345.443) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (82.53) is better than Ligand B (96.11), falling comfortably under the 140 threshold for oral absorption.
3. **logP:** Both ligands have similar logP values around 1.7, which is optimal.
4. **HBD:** Ligand A (2) is preferable to Ligand B (3). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (4) is preferable to Ligand B (5).
6. **QED:** Ligand A (0.703) is better than Ligand B (0.584), indicating a more drug-like profile.
7. **DILI:** Ligand A (43.66) has a significantly lower DILI risk than Ligand B (70.182). This is a major advantage.
8. **BBB:** Ligand B (73.866) has a higher BBB penetration score than Ligand A (32.377). While ADRB2 isn't necessarily a CNS target, some peripheral ADRB2 involvement can be modulated by CNS effects, so this is a slight positive for B.
9. **Caco-2:** Ligand A (-4.88) and Ligand B (-5.492) are both very poor, indicating very low intestinal absorption. This is a significant concern for both.
10. **Solubility:** Ligand A (-2.277) is slightly better than Ligand B (-2.643), but both are poor.
11. **hERG:** Ligand A (0.176) has a much lower hERG risk than Ligand B (0.731). This is a critical safety parameter.
12. **Cl_mic:** Ligand B (35.245) has a lower microsomal clearance than Ligand A (25.348), suggesting better metabolic stability.
13. **t1/2:** Ligand A (4.668) has a longer in vitro half-life than Ligand B (2.905).
14. **Pgp:** Ligand A (0.107) has a lower P-gp efflux liability than Ligand B (0.247).
15. **Affinity:** Ligand A (-7.0) has a slightly better binding affinity than Ligand B (-6.6). While the difference is less than the 1.5 kcal/mol threshold, it's still a positive.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Both ligands are good on logP. Ligand A is better on TPSA and Pgp. The affinity difference is small. The biggest differentiators are the safety parameters: DILI and hERG. Ligand A is significantly better on both. While Ligand B has better BBB penetration, this is less critical for a primarily peripheral target like ADRB2. The poor Caco-2 values are a concern for both, but can potentially be addressed with formulation strategies.
**Conclusion:**
Ligand A is the more promising candidate due to its superior drug-likeness (QED), significantly lower DILI and hERG risk, better TPSA and Pgp, and slightly better affinity. The longer half-life is also a benefit. While both have poor Caco-2 permeability, the overall profile of Ligand A is more favorable for further development.
Output:
1
2025-04-17 23:30:16,677 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, the key priorities are logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB.
Let's compare the ligands property by property:
1. **MW:** Both ligands (350.5 and 358.4 Da) fall comfortably within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (69.64) is significantly better than Ligand B (93.44). A TPSA under 140 is good for oral absorption, and lower is generally preferred for GPCRs. Ligand B is pushing the upper limit.
3. **logP:** Both ligands have similar logP values (2.33 and 2.356), both within the optimal 1-3 range.
4. **HBD/HBA:** Both have 2 HBDs, which is good. Ligand B has 8 HBAs compared to Ligand A's 3. Higher HBA can sometimes hinder permeability.
5. **QED:** Both have good QED scores (0.547 and 0.665), indicating drug-likeness.
6. **DILI:** Ligand A (14.114) has a much lower DILI risk than Ligand B (64.133). This is a significant advantage for Ligand A.
7. **BBB:** Ligand B (70.531) has a better BBB penetration score than Ligand A (45.832). While not a primary concern for a cardiovascular target, it's a slight positive for Ligand B.
8. **Caco-2:** Ligand A (-4.702) has a slightly better (less negative) Caco-2 permeability score than Ligand B (-5.273), suggesting potentially better absorption.
9. **Solubility:** Ligand A (-2.45) has better aqueous solubility than Ligand B (-3.51).
10. **hERG:** Both ligands have low hERG inhibition liability (0.462 and 0.606).
11. **Cl_mic:** Ligand A (34.29) has significantly lower microsomal clearance than Ligand B (50.725), indicating better metabolic stability.
12. **t1/2:** Ligand B (14.498) has a longer in vitro half-life than Ligand A (-15.637). This is a positive for Ligand B, but the negative value for A is concerning.
13. **Pgp:** Ligand A (0.269) has lower P-gp efflux liability than Ligand B (0.131), which is favorable for bioavailability.
14. **Binding Affinity:** Ligand B (-7.4) has a slightly better binding affinity than Ligand A (-7.0), but the difference is relatively small (0.4 kcal/mol).
**Overall Assessment:**
Ligand A presents a more balanced profile. Its superior TPSA, DILI risk, solubility, metabolic stability (Cl_mic), and Pgp efflux liability outweigh the slightly weaker binding affinity and lower BBB penetration. The negative in vitro half-life for Ligand A is a concern, but the other advantages are substantial. Ligand B's better half-life is offset by its higher TPSA, DILI risk, and Pgp efflux.
**Output:**
1
2025-04-17 23:30:16,677 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
We are targeting ADRB2, a GPCR, so the priorities are logP, Pgp, TPSA, affinity, and BBB. Let's compare the ligands property by property:
1. **MW:** Both ligands (351.491 and 349.435 Da) are within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (61.88) is significantly better than Ligand B (118.4). Lower TPSA generally correlates with better cell permeability, crucial for GPCR targeting. Ligand B is above the preferred threshold of 140.
3. **logP:** Both ligands have acceptable logP values (1.417 and 1.737), falling within the 1-3 range.
4. **HBD/HBA:** Ligand A has 1 HBD and 4 HBA, while Ligand B has 2 HBD and 4 HBA. Both are reasonable.
5. **QED:** Ligand A (0.705) has a much better QED score than Ligand B (0.205), indicating a more drug-like profile.
6. **DILI:** Ligand A (5.816%) has a significantly lower DILI risk than Ligand B (15.2%). This is a major advantage.
7. **BBB:** Ligand A (59.325%) has a better BBB penetration score than Ligand B (17.642%). While not exceptionally high, it's preferable, especially for a GPCR.
8. **Caco-2:** Both have negative values (-4.896 and -4.992), which is unusual. Assuming these are logPeff values, lower is better, and they are similar.
9. **Solubility:** Both have negative solubility values (-1.145 and -1.346), which is also unusual. Assuming these are logS values, higher is better, and they are similar.
10. **hERG:** Both ligands have low hERG inhibition liability (0.308 and 0.162), which is good.
11. **Cl_mic:** Ligand A (1.468) has a much lower microsomal clearance than Ligand B (-3.423). This suggests better metabolic stability for Ligand A.
12. **t1/2:** Ligand A (5.442) has a longer in vitro half-life than Ligand B (-3.232).
13. **Pgp:** Ligand A (0.008) has much lower P-gp efflux liability than Ligand B (0.039). This is a significant advantage for bioavailability and potentially CNS exposure.
14. **Affinity:** Ligand B (-6.5 kcal/mol) has slightly better binding affinity than Ligand A (-6.3 kcal/mol), but the difference is small (0.2 kcal/mol) and likely not enough to overcome the other significant advantages of Ligand A.
**Conclusion:**
Ligand A consistently outperforms Ligand B across most critical ADME-Tox properties (DILI, BBB, Cl_mic, t1/2, Pgp, QED, TPSA). While Ligand B has slightly better binding affinity, the overall profile of Ligand A is far more favorable for development as a drug candidate.
**Output:**
1
2025-04-17 23:30:16,677 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (347.459 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (78.51) is better than Ligand B (49.85). Lower TPSA is generally preferred for GPCRs, aiding in brain penetration if desired, and overall permeability.
3. **logP:** Both ligands have acceptable logP values (Ligand A: 1.366, Ligand B: 2.784), falling within the 1-3 range. Ligand B is closer to the upper end, which *could* present solubility issues, but isn't a major concern at this level.
4. **HBD:** Ligand A (2) is preferable to Ligand B (0). While low HBD can improve permeability, some H-bonding is desirable for solubility and target engagement.
5. **HBA:** Ligand A (3) is preferable to Ligand B (4). Similar reasoning as HBD - a balance is ideal.
6. **QED:** Both are reasonably good (Ligand A: 0.712, Ligand B: 0.691), exceeding the 0.5 threshold.
7. **DILI:** Ligand A (19.271) is significantly better than Ligand B (43.66). Lower DILI risk is a major advantage.
8. **BBB:** Ligand B (76.696) has a better BBB percentile than Ligand A (65.374). While ADRB2 isn't exclusively a CNS target, some brain penetration could be beneficial, or at least avoiding high CNS exposure if peripheral effects are desired.
9. **Caco-2:** Ligand A (-5.069) is better than Ligand B (-4.71). Higher Caco-2 permeability indicates better intestinal absorption.
10. **Solubility:** Ligand A (-2.782) is better than Ligand B (-2.784). Both are similar, but a slight advantage to A.
11. **hERG:** Ligand A (0.215) is significantly better than Ligand B (0.586). Lower hERG inhibition is crucial for avoiding cardiotoxicity, especially for a cardiovascular target.
12. **Cl_mic:** Ligand A (53.958) is better than Ligand B (90.084). Lower microsomal clearance indicates better metabolic stability.
13. **t1/2:** Ligand A (-9.779) is better than Ligand B (-13.575). Longer in vitro half-life is desirable.
14. **Pgp:** Ligand A (0.085) is much better than Ligand B (0.465). Lower P-gp efflux improves bioavailability.
15. **Affinity:** Ligand A (-6.9 kcal/mol) is slightly better than Ligand B (-6.1 kcal/mol). While both are good, the difference is significant enough to consider.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical ADME-Tox properties, including DILI, hERG, Cl_mic, t1/2, and Pgp efflux. The affinity difference, while not huge, favors Ligand A. While Ligand B has better BBB penetration, this is less critical for a primarily cardiovascular target like ADRB2, and the superior safety profile and ADME properties of Ligand A are more important. The TPSA and Caco-2 values also favor Ligand A.
Output:
1
2025-04-17 23:30:16,677 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (358.291 Da and 350.459 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (70.59) is better than Ligand B (78.87). Both are below 140, but lower is preferred for absorption.
3. **logP:** Both ligands (3.075 and 3.149) are within the optimal 1-3 range. No significant difference.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (2), but both are acceptable (<=5).
5. **HBA:** Both ligands (4) are within the acceptable range (<=10). No significant difference.
6. **QED:** Ligand B (0.792) has a better QED score than Ligand A (0.568), indicating a more drug-like profile.
7. **DILI:** Ligand B (18.922) has a significantly lower DILI risk than Ligand A (68.592). This is a major advantage for Ligand B.
8. **BBB:** Both ligands have good BBB penetration (66.421 and 64.444). Since ADRB2 is a cardiovascular target, BBB penetration is not a primary concern, but it doesn't hurt.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.551 and -4.708), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand B (-3.672) is slightly better than Ligand A (-4.27), but both are poor. This is a potential formulation challenge for both.
11. **hERG:** Both ligands have low hERG inhibition liability (0.716 and 0.713). No significant difference.
12. **Cl_mic:** Ligand A (31.593) has significantly lower microsomal clearance than Ligand B (107.093), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (-23.504) has a longer in vitro half-life than Ligand B (-13.817). This is a positive for Ligand A.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.168 and 0.025). No significant difference.
15. **Binding Affinity:** Ligand B (-6.2) has a slightly better binding affinity than Ligand A (-5.0). This is a 1.2 kcal/mol difference, which is substantial.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Both ligands are good on logP and Pgp. Ligand A has better TPSA and metabolic stability (Cl_mic and t1/2). However, Ligand B has a significantly better binding affinity and a much lower DILI risk. The affinity difference is substantial enough to potentially overcome the metabolic stability concerns. The lower DILI risk is also a major factor.
**Overall Assessment:**
While Ligand A has advantages in metabolic stability and TPSA, Ligand B's superior binding affinity and significantly lower DILI risk are more compelling. The poor Caco-2 and solubility for both are concerning, but these can potentially be addressed through formulation strategies. The stronger binding of Ligand B is likely to translate to greater efficacy, and the lower DILI risk is crucial for safety.
Output:
0
2025-04-17 23:30:16,678 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (364.477 and 339.37 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (58.64) is better than Ligand B (62.3), both are below the 140 threshold for oral absorption, but closer to the ideal for GPCRs.
3. **logP:** Both ligands have good logP values (3.084 and 2.497), falling within the 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Both have 3 HBA, which is good.
6. **QED:** Both ligands have good QED scores (0.648 and 0.823), indicating good drug-like properties. Ligand B is slightly better here.
7. **DILI:** Ligand A (30.399) has a significantly lower DILI risk than Ligand B (61.225). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (85.537) has a much higher BBB penetration percentile than Ligand B (63.668). While ADRB2 isn't exclusively a CNS target, some cardiovascular effects are mediated by central pathways, and better BBB penetration could be advantageous.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. This is a concern for both, but the values are similar.
10. **Solubility:** Both have negative solubility values, indicating very poor aqueous solubility. This is a significant drawback for both compounds, and would require formulation strategies to address.
11. **hERG:** Both ligands have low hERG inhibition risk (0.825 and 0.693), which is good.
12. **Cl_mic:** Ligand B (52.607) has lower microsomal clearance than Ligand A (76.881), suggesting better metabolic stability.
13. **t1/2:** Ligand A (17.688) has a longer in vitro half-life than Ligand B (9.428). This is a positive for Ligand A.
14. **Pgp:** Both have low Pgp efflux liability (0.22 and 0.214), which is good.
15. **Binding Affinity:** Both ligands have the same binding affinity (-6.4 kcal/mol), so this parameter doesn't differentiate them.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Both ligands perform similarly on logP, Pgp, and affinity. Ligand A has a better TPSA. The biggest differentiator is the DILI risk and BBB penetration, where Ligand A is significantly better. While solubility and Caco-2 are poor for both, the lower DILI risk and higher BBB penetration of Ligand A make it the more promising candidate.
**Conclusion:**
Considering the balance of properties, especially the lower DILI risk and better BBB penetration, Ligand A is the more viable drug candidate.
Output:
1
2025-04-17 23:30:16,678 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (344.46 & 347.42 Da) fall comfortably within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (67.43) is significantly better than Ligand B (100.45). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is approaching a level that could hinder oral absorption.
3. **logP:** Ligand A (2.359) is within the optimal 1-3 range. Ligand B (0.639) is a bit low, potentially leading to permeability issues.
4. **HBD:** Both have 2 HBD, which is acceptable.
5. **HBA:** Ligand A has 3 HBA, while Ligand B has 5. Both are within the acceptable limit of 10, but Ligand A is preferable.
6. **QED:** Both ligands have good QED scores (0.746 and 0.777), indicating good drug-like properties.
7. **DILI:** Ligand A (17.49%) has a much lower DILI risk than Ligand B (49.28%). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (76.70%) has a better BBB penetration score than Ligand B (56.53%). While ADRB2 isn't strictly a CNS target, some distribution to the CNS is possible, and higher BBB is generally favorable.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability in this assay. However, the magnitude of negativity is similar.
10. **Solubility:** Both ligands have negative solubility values, indicating poor aqueous solubility. This is a concern for both, but the values are similar.
11. **hERG:** Both ligands have low hERG inhibition risk (0.505 and 0.295), which is good.
12. **Cl_mic:** Ligand B (6.77) has a significantly lower microsomal clearance than Ligand A (61.33), indicating better metabolic stability. This is a strong point for Ligand B.
13. **t1/2:** Ligand B (25.21 hours) has a much longer in vitro half-life than Ligand A (7.28 hours). This is another key advantage for Ligand B.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.241 and 0.036).
15. **Binding Affinity:** Both ligands have very similar and excellent binding affinities (-6.7 and -6.8 kcal/mol). The difference is negligible.
**Overall Assessment:**
Ligand A excels in TPSA, DILI risk, and BBB penetration. Ligand B shines in metabolic stability (Cl_mic) and in vitro half-life. Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand A has a slight edge due to its better TPSA, lower DILI risk, and better BBB. While Ligand B's metabolic stability is appealing, the lower TPSA and DILI risk of Ligand A are more critical for a balanced profile, especially considering the similar binding affinities. The solubility issues are a concern for both, but can be addressed with formulation strategies.
Output:
1
2025-04-17 23:30:16,678 - INFO - Batch 409 complete. Total preferences: 6544
2025-04-17 23:30:16,678 - INFO - Processing batch 410/512...
2025-04-17 23:31:05,096 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (348.403) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (58.2) is significantly better than Ligand A (115.65). ADRB2 is not a CNS target, but lower TPSA generally aids absorption.
3. **logP:** Ligand B (3.254) is optimal, while Ligand A (-0.246) is quite low, potentially hindering membrane permeability. This is a significant drawback for Ligand A.
4. **HBD:** Ligand A (3) and Ligand B (2) are both acceptable.
5. **HBA:** Ligand A (6) and Ligand B (3) are both acceptable.
6. **QED:** Ligand B (0.761) has a better QED score than Ligand A (0.53), indicating a more drug-like profile.
7. **DILI:** Ligand B (25.281) has a much lower DILI risk than Ligand A (46.297). This is a major advantage for Ligand B.
8. **BBB:** Not a primary concern for ADRB2 (cardiovascular target). Ligand B (60.411) is higher, but not critical.
9. **Caco-2:** Both are negative, indicating poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-0.441) has slightly better solubility than Ligand B (-3.588), but both are poor.
11. **hERG:** Ligand A (0.059) has a slightly better hERG profile than Ligand B (0.344), but both are relatively low risk.
12. **Cl_mic:** Ligand A (11.694) has significantly lower microsomal clearance than Ligand B (43.492), suggesting better metabolic stability.
13. **t1/2:** Ligand A (12.385) has a longer in vitro half-life than Ligand B (0.479), which is desirable.
14. **Pgp:** Ligand A (0.014) has significantly lower P-gp efflux than Ligand B (0.168), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand B (-6.2) has a slightly better binding affinity than Ligand A (-5.9), but the difference is not substantial enough to outweigh other factors.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand B excels in logP and TPSA, and has slightly better affinity. Ligand A has better metabolic stability and P-gp efflux, but the poor logP is a major issue.
**Overall Assessment:**
While Ligand A has some advantages in metabolic stability and efflux, the significantly lower logP and higher DILI risk are substantial drawbacks. Ligand B, despite its higher clearance, presents a more balanced profile with better predicted absorption (lower TPSA, optimal logP), lower toxicity (DILI), and a slightly better binding affinity. The solubility of both is poor, which would require formulation work, but this is a secondary concern compared to permeability and toxicity.
Output:
0
2025-04-17 23:31:05,097 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (359.853 Da and 351.466 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (53.68) is significantly better than Ligand B (69.22). For a GPCR, keeping TPSA under 90 is desirable, and A is comfortably within that range while B is approaching the upper limit. This favors A.
**3. logP:** Ligand A (4.895) is slightly higher than Ligand B (2.99). While both are above the optimal 1-3 range, A is pushing the upper limit where solubility issues could arise. B is much closer to the ideal range. This favors B.
**4. H-Bond Donors:** Ligand A (1) is better than Ligand B (2). Lower HBD generally improves permeability.
**5. H-Bond Acceptors:** Both ligands have 3 HBA, which is within the acceptable range.
**6. QED:** Both ligands have good QED scores (0.773 and 0.828), indicating good drug-like properties. No significant difference.
**7. DILI Risk:** Ligand A (31.563) has a lower DILI risk than Ligand B (21.481), which is a clear advantage. Lower is better.
**8. BBB Penetration:** Ligand B (63.746) has significantly better BBB penetration than Ligand A (41.218). While ADRB2 is a cardiovascular target and CNS penetration isn't *essential*, some degree of BBB penetration can be beneficial for off-target effects assessment and potential future applications.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.765 and -4.879), which is unusual and suggests poor permeability. This is a significant concern for both.
**10. Aqueous Solubility:** Ligand B (-2.729) is better than Ligand A (-5.218), indicating higher solubility. Solubility is an important factor for bioavailability.
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (0.454 and 0.621), which is good.
**12. Microsomal Clearance:** Ligand A (104.603) has a much higher microsomal clearance than Ligand B (16.066). This means A is metabolized more quickly, potentially leading to a shorter duration of action and lower bioavailability. This strongly favors B.
**13. In vitro Half-Life:** Ligand B (4.53) has a slightly better in vitro half-life than Ligand A (46.612).
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (0.276 and 0.294).
**15. Binding Affinity:** Both ligands have excellent binding affinity (-7.5 and -7.6 kcal/mol). The difference is negligible.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity) and the general drug-like properties, Ligand B is the better candidate. While Ligand A has a lower DILI risk, the significantly better TPSA, logP, metabolic stability (lower Cl_mic), and solubility of Ligand B outweigh this advantage. The poor Caco-2 permeability is a concern for both, but the other ADME properties of B are more favorable.
Output:
0
2025-04-17 23:31:05,097 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (383.436 Da) is within the ideal range (200-500 Da). Ligand B (342.399 Da) is also within the ideal range. No clear advantage here.
2. **TPSA:** Both ligands (A: 78.51, B: 79.54) are below the 140 A^2 threshold for good oral absorption, and acceptable for a non-CNS GPCR target like ADRB2. No clear advantage.
3. **logP:** Ligand A (1.301) is optimal. Ligand B (2.063) is also optimal, but slightly higher. A small advantage to Ligand A.
4. **HBD:** Ligand A (2) is good. Ligand B (0) is also good. No clear advantage.
5. **HBA:** Ligand A (4) is good. Ligand B (5) is also good. No clear advantage.
6. **QED:** Both ligands have good QED scores (A: 0.662, B: 0.853). Ligand B is slightly better.
7. **DILI:** Ligand A (43.66) has a lower DILI risk than Ligand B (64.56). This is a significant advantage for Ligand A.
8. **BBB:** Both are relatively low, which is fine for a cardiovascular target (A: 55.332, B: 63.125). No clear advantage.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-5.329) is slightly worse than Ligand B (-4.737). Advantage to Ligand B.
10. **Solubility:** Both are negative, indicating poor solubility. Ligand A (-2.466) is slightly worse than Ligand B (-1.838). Advantage to Ligand B.
11. **hERG:** Both have low hERG inhibition risk (A: 0.355, B: 0.249). Ligand B is slightly better.
12. **Cl_mic:** Ligand A (7.003) has significantly lower microsomal clearance than Ligand B (40.476), indicating better metabolic stability. This is a major advantage for Ligand A.
13. **t1/2:** Ligand A (-7.931) has a much longer in vitro half-life than Ligand B (5.091). This is a significant advantage for Ligand A.
14. **Pgp:** Both have low P-gp efflux liability (A: 0.039, B: 0.109). Ligand A is slightly better.
15. **Binding Affinity:** Ligand A (-6.6 kcal/mol) has a slightly better binding affinity than Ligand B (-5.1 kcal/mol). This is a significant advantage for Ligand A.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand A emerges as the stronger candidate. While Ligand B has a slightly better QED, Caco-2, solubility and hERG, Ligand A excels in crucial areas like DILI risk, metabolic stability (Cl_mic, t1/2), and binding affinity. The lower DILI risk and improved metabolic stability are particularly important for a cardiovascular drug. The binding affinity difference is also substantial enough to outweigh the minor ADME advantages of Ligand B.
Output:
1
2025-04-17 23:31:05,097 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (374.5 and 342.4 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (84.5) is well below the 140 threshold and good for oral absorption. Ligand B (120.25) is still acceptable but higher. This favors Ligand A.
3. **logP:** Ligand A (2.591) is optimal (1-3). Ligand B (0.985) is a bit low, potentially hindering permeability. This favors Ligand A.
4. **HBD:** Ligand A (2) is within the acceptable limit of 5. Ligand B (4) is also acceptable, but slightly higher.
5. **HBA:** Ligand A (4) is within the acceptable limit of 10. Ligand B (5) is also acceptable.
6. **QED:** Both ligands have reasonable QED scores (0.684 and 0.532), indicating good drug-like properties.
7. **DILI:** Ligand B (74.6) has a significantly lower DILI risk than Ligand A (18.5). This is a strong advantage for Ligand B.
8. **BBB:** Ligand A (81.6) shows good BBB penetration, while Ligand B (11.2) is very poor. Given ADRB2's cardiovascular involvement, CNS penetration isn't *critical*, but it could be beneficial for potential off-target effects or if the target is expressed in the CNS. This favors Ligand A.
9. **Caco-2:** Ligand A (-4.369) and Ligand B (-5.789) both have negative values, indicating poor permeability. This is a concern for both, but Ligand B is worse.
10. **Solubility:** Both ligands have similar, very poor solubility scores (-3.155). This is a significant drawback for both, requiring formulation strategies.
11. **hERG:** Both ligands have low hERG inhibition liability (0.477 and 0.389), which is good.
12. **Cl_mic:** Ligand B (-2.949) has a *much* lower (better) microsomal clearance than Ligand A (82.02). This suggests significantly improved metabolic stability for Ligand B.
13. **t1/2:** Ligand B (72.072) has a longer in vitro half-life than Ligand A (-27.972). This is a strong advantage for Ligand B.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.048 and 0.045).
15. **Binding Affinity:** Ligand B (-7.5 kcal/mol) has a slightly better binding affinity than Ligand A (-6.9 kcal/mol). This 0.6 kcal/mol difference is significant and can outweigh some ADME concerns.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has better logP and TPSA, while Ligand B has better affinity, Pgp, and *much* better metabolic stability (Cl_mic and t1/2). The DILI risk is also much lower for Ligand B. While BBB isn't a primary concern, Ligand A's higher value is a small plus.
**Overall Assessment:**
Despite Ligand A's slightly better TPSA and logP, Ligand B's superior binding affinity, significantly improved metabolic stability (Cl_mic and t1/2), lower DILI risk, and acceptable Pgp efflux outweigh these advantages. The solubility issues are a concern for both, but can be addressed with formulation. The slightly lower logP of Ligand B is a manageable issue.
Output:
0
2025-04-17 23:31:05,098 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [382.507, 92.34, 2.53, 2, 4, 0.734, 81.427, 44.281, -4.892, -4.215, 0.505, 48.16, 32.3, 0.246, -5.7]
**Ligand B:** [349.383, 85.3, 1.714, 1, 5, 0.871, 56.223, 46.336, -4.84, -1.607, 0.025, -8.769, -1.745, 0.012, -6.8]
Here's a breakdown, prioritizing GPCR properties (logP, TPSA, Pgp, BBB, Affinity) and considering the general guidelines:
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (349.383) is slightly lower, which could be beneficial for permeability, but both are acceptable.
2. **TPSA:** Both are good, below the 140 A^2 threshold for oral absorption. Ligand B (85.3) is slightly better than Ligand A (92.34).
3. **logP:** Both are within the optimal range (1-3). Ligand A (2.53) is slightly higher, which might be a minor concern for off-target effects, but still acceptable. Ligand B (1.714) is a bit lower, potentially impacting permeability.
4. **HBD/HBA:** Ligand A (2 HBD, 4 HBA) is slightly better than Ligand B (1 HBD, 5 HBA) in terms of balancing solubility and permeability.
5. **QED:** Both have good QED scores (>0.5), indicating drug-likeness. Ligand B (0.871) is slightly better.
6. **DILI:** Ligand A (81.427) has a significantly higher DILI risk than Ligand B (56.223). This is a major concern.
7. **BBB:** Both have moderate BBB penetration, but Ligand B (46.336) is slightly better than Ligand A (44.281). This isn't a primary concern for ADRB2, but a slight advantage.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. This is a significant issue for both.
9. **Solubility:** Both have negative solubility values, which is also unusual and suggests very poor solubility. This is a significant issue for both.
10. **hERG:** Ligand A (0.505) has a slightly higher hERG risk than Ligand B (0.025).
11. **Cl_mic:** Ligand B (-8.769) has a *much* lower (better) microsomal clearance than Ligand A (48.16). This suggests significantly better metabolic stability for Ligand B.
12. **t1/2:** Ligand B (-1.745) has a longer half-life than Ligand A (32.3).
13. **Pgp:** Ligand A (0.246) has lower P-gp efflux than Ligand B (0.012), which is a slight advantage.
14. **Affinity:** Ligand B (-6.8 kcal/mol) has a slightly better binding affinity than Ligand A (-5.7 kcal/mol).
**Overall Assessment:**
While both ligands have significant issues with Caco-2 and solubility, Ligand B is the more promising candidate. The major deciding factors are:
* **DILI:** Ligand B has a much lower DILI risk.
* **Metabolic Stability:** Ligand B has significantly better metabolic stability (lower Cl_mic, longer t1/2).
* **Affinity:** Ligand B has slightly better binding affinity.
Ligand A's higher DILI risk is a major red flag, and its poorer metabolic stability is also concerning. The slight advantages of Ligand A in Pgp efflux are outweighed by these drawbacks.
Output:
0
2025-04-17 23:31:05,098 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (362.415 Da) is within the ideal range (200-500 Da). Ligand B (385.936 Da) is also acceptable. No clear advantage here.
2. **TPSA:** Ligand A (128.91) is borderline, but acceptable for a non-CNS target. Ligand B (38.13) is excellent, well below the 140 threshold, and favorable for permeability. This is a significant advantage for Ligand B.
3. **logP:** Ligand A (1.375) is optimal. Ligand B (4.545) is high and could lead to solubility issues and off-target interactions. This favors Ligand A.
4. **HBD:** Ligand A (3) is good. Ligand B (0) is also acceptable, but having some HBD can improve solubility.
5. **HBA:** Ligand A (6) is good. Ligand B (4) is also good.
6. **QED:** Ligand A (0.715) is excellent. Ligand B (0.563) is acceptable, but lower. This favors Ligand A.
7. **DILI:** Ligand A (82.396) is moderately high, indicating a potential liver toxicity risk. Ligand B (34.703) is very good, indicating low risk. This is a significant advantage for Ligand B.
8. **BBB:** Both are relatively low, which is fine for a cardiovascular target. Ligand B (89.88) is higher, but not a major factor here.
9. **Caco-2:** Ligand A (-5.284) is poor, suggesting poor absorption. Ligand B (-4.987) is also poor, but slightly better.
10. **Solubility:** Both ligands have poor solubility (-3.808 and -4.017 respectively). This is a concern for both.
11. **hERG:** Ligand A (0.37) is very low risk. Ligand B (0.819) is slightly higher, but still acceptable.
12. **Cl_mic:** Ligand A (5.756) is relatively low, suggesting good metabolic stability. Ligand B (83.788) is high, indicating rapid metabolism. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (58.213) is good. Ligand B (44.98) is acceptable, but shorter.
14. **Pgp:** Ligand A (0.071) suggests low P-gp efflux, which is good. Ligand B (0.834) suggests higher P-gp efflux, which is less desirable.
15. **Affinity:** Ligand B (-6.9 kcal/mol) has a significantly stronger binding affinity than Ligand A (-3.4 kcal/mol). This is a substantial advantage for Ligand B, potentially outweighing some of its ADME drawbacks.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in TPSA and affinity, while Ligand A has a better logP. The strong affinity of Ligand B is a major factor. The higher DILI risk for Ligand A is also concerning.
**Overall Assessment:**
While Ligand A has better metabolic stability and a more favorable logP, the significantly stronger binding affinity of Ligand B (-6.9 vs -3.4 kcal/mol) and its lower DILI risk are compelling. The lower TPSA of Ligand B is also a positive. The solubility and Caco-2 permeability are poor for both, but the potency advantage of Ligand B is likely to be more impactful in driving forward development.
Output:
0
2025-04-17 23:31:05,098 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [340.383, 95.42, 1.412, 2, 5, 0.877, 63.746, 23.924, -5.145, -2.954, 0.093, 2.699, -23.929, 0.01, -7.9]**
**Ligand B: [357.361, 100.35, 0.035, 2, 6, 0.748, 54.866, 68.903, -4.835, -2.394, 0.119, -15.393, 4.975, 0.09, -7.1]**
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). A (340.383) is slightly preferred.
2. **TPSA:** Both are reasonably good (A: 95.42, B: 100.35), below the 140 threshold for oral absorption. A is slightly better.
3. **logP:** A (1.412) is optimal, while B (0.035) is quite low, potentially hindering membrane permeability. This is a significant advantage for A.
4. **H-Bond Donors:** Both have 2 HBD, which is acceptable.
5. **H-Bond Acceptors:** A has 5, B has 6. Both are within the acceptable range.
6. **QED:** A (0.877) is better than B (0.748), indicating a more drug-like profile.
7. **DILI:** A (63.746) is higher than B (54.866), indicating a slightly higher risk of liver injury. B is preferred here.
8. **BBB:** B (68.903) is significantly better than A (23.924). While ADRB2 isn't strictly a CNS target, some CNS penetration can be beneficial for understanding off-target effects and potential side effects.
9. **Caco-2:** Both are negative, indicating poor permeability. A (-5.145) is worse than B (-4.835). B is preferred.
10. **Solubility:** Both are negative, indicating poor solubility. A (-2.954) is worse than B (-2.394). B is preferred.
11. **hERG:** Both are very low (A: 0.093, B: 0.119), indicating minimal hERG inhibition risk.
12. **Cl_mic:** A (2.699) is much lower than B (-15.393), suggesting better metabolic stability. This is a significant advantage for A.
13. **t1/2:** A (-23.929) is much lower than B (4.975), suggesting a shorter half-life. B is preferred.
14. **Pgp:** Both are very low (A: 0.01, B: 0.09), indicating minimal P-gp efflux.
15. **Binding Affinity:** A (-7.9) is slightly better than B (-7.1), although the difference is relatively small.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand A has a significant advantage in logP and metabolic stability (Cl_mic). While Ligand B has better BBB penetration, solubility and Caco-2 permeability, the low logP is a major concern for membrane permeability and overall bioavailability. The slightly better affinity of A also contributes to its preference. The DILI risk is slightly higher for A, but the other advantages outweigh this concern.
Output:
1
2025-04-17 23:31:05,098 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (366.49 and 343.43 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (72.96) is better than Ligand B (82.27). Both are below 140, but lower TPSA generally favors absorption.
**3. logP:** Ligand A (0.927) is slightly lower than Ligand B (2.293). Both are within the optimal 1-3 range, but Ligand B is closer to the upper end.
**4. H-Bond Donors:** Ligand A (1) is better than Ligand B (2). Lower HBD is generally preferred for better permeability.
**5. H-Bond Acceptors:** Ligand A (4) is slightly better than Ligand B (3). Both are within the acceptable range.
**6. QED:** Ligand A (0.841) is significantly better than Ligand B (0.636), indicating a more drug-like profile.
**7. DILI Risk:** Ligand A (25.79) is *much* better than Ligand B (49.17). This is a critical advantage, as lower DILI risk is paramount.
**8. BBB Penetration:** Ligand A (65.49) is better than Ligand B (54.48), though neither is exceptionally high. For a cardiovascular target, BBB penetration isn't a primary concern, but it's still a slight advantage for A.
**9. Caco-2 Permeability:** Ligand A (-4.912) is better than Ligand B (-5.116). Both are negative, indicating low permeability, but A is slightly less negative.
**10. Aqueous Solubility:** Ligand A (-2.025) is better than Ligand B (-3.424). Both are negative, indicating poor solubility, but A is slightly better.
**11. hERG Inhibition:** Ligand A (0.497) is better than Ligand B (0.184). Lower hERG inhibition is crucial for avoiding cardiotoxicity.
**12. Microsomal Clearance:** Ligand A (9.30) is slightly better than Ligand B (10.9). Lower clearance is preferred for metabolic stability.
**13. In vitro Half-Life:** Ligand A (-44.91) is significantly better than Ligand B (-27.32). A longer half-life is desirable for less frequent dosing.
**14. P-gp Efflux:** Ligand A (0.011) is *much* better than Ligand B (0.114). Lower P-gp efflux is crucial for better bioavailability.
**15. Binding Affinity:** Ligand B (-6.5) is slightly better than Ligand A (-5.5). This is a 1 kcal/mol difference, which is significant, but can be outweighed by other factors.
**Overall Assessment:**
While Ligand B has a slightly better binding affinity, Ligand A is superior in almost all other critical ADME-Tox parameters. The significantly lower DILI risk, better QED, lower P-gp efflux, and longer half-life of Ligand A are major advantages. The small difference in binding affinity is less important than these factors, especially considering the potential for optimization of Ligand A's potency. Given the GPCR target class, balancing logP, TPSA, Pgp, and affinity is important, and Ligand A strikes a better balance.
Output:
1
2025-04-17 23:31:05,098 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (345.399 and 357.376 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (84.67) is higher than Ligand B (62.3). For a cardiovascular GPCR, TPSA isn't a critical factor like it would be for a CNS target, but lower is generally preferable for absorption. Ligand B is better.
3. **logP:** Ligand A (1.142) is within the optimal range, while Ligand B (2.321) is approaching the upper limit. Both are acceptable, but A is slightly preferred.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 5 HBA, while Ligand B has 3. Both are within the acceptable limit of 10.
6. **QED:** Ligand B (0.85) has a significantly higher QED score than Ligand A (0.564), indicating a more drug-like profile. This is a substantial advantage for Ligand B.
7. **DILI:** Ligand A (49.128) has a higher DILI risk than Ligand B (17.798). This is a significant advantage for Ligand B.
8. **BBB:** Ligand B (82.202) has a higher BBB percentile than Ligand A (63.358). While ADRB2 isn't exclusively a CNS target, some brain exposure can be relevant for peripheral effects. Ligand B is better.
9. **Caco-2:** Both ligands have very similar, and poor, Caco-2 permeability (-4.815 and -4.791). This is a concern for both, suggesting potential absorption issues.
10. **Solubility:** Ligand A (-1.817) has better solubility than Ligand B (-2.488). Solubility is important for bioavailability, so A is slightly favored.
11. **hERG:** Ligand A (0.119) has a lower hERG risk than Ligand B (0.594). This is a critical advantage for Ligand A, as hERG inhibition can lead to cardiotoxicity, a major concern for a cardiovascular target.
12. **Cl_mic:** Ligand B (-8.882) has a significantly lower microsomal clearance than Ligand A (13.095), indicating better metabolic stability. This is a strong advantage for Ligand B.
13. **t1/2:** Ligand B (-4.173) has a longer in vitro half-life than Ligand A (-0.342). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.093) has lower P-gp efflux than Ligand B (0.043), which is a slight advantage for A.
15. **Binding Affinity:** Ligand B (-6.7 kcal/mol) has a slightly better binding affinity than Ligand A (-5.7 kcal/mol). While the difference is not huge, it's enough to consider.
**Overall Assessment:**
Ligand B has several key advantages: significantly better QED, lower DILI risk, higher BBB penetration, better metabolic stability (lower Cl_mic), and a longer half-life. The slightly better affinity of Ligand B also contributes. While Ligand A has a lower hERG risk and slightly better solubility, the overall profile of Ligand B is more favorable for development as a drug candidate targeting ADRB2. The lower DILI and improved metabolic stability are particularly important.
Output:
0
2025-04-17 23:31:05,098 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for their potential as drug candidates targeting the ADRB2, a cardiovascular GPCR. Therefore, we prioritize logP, Pgp, TPSA, and binding affinity, alongside general drug-like properties.
**Ligand A:**
* **MW:** 354.447 Da - Acceptable.
* **TPSA:** 99.1 A2 - Slightly high, potentially impacting permeability, but not a dealbreaker for a peripheral GPCR.
* **logP:** 0.183 - Very low. This is a significant concern, suggesting poor membrane permeability and potentially poor absorption.
* **HBD:** 3 - Acceptable.
* **HBA:** 5 - Acceptable.
* **QED:** 0.654 - Good.
* **DILI:** 28.461 - Excellent, very low risk.
* **BBB:** 28.306 - Low, as expected for a non-CNS target.
* **Caco-2:** -4.874 - Very poor permeability. Consistent with the low logP.
* **Solubility:** -1.418 - Poor solubility.
* **hERG:** 0.181 - Low risk.
* **Cl_mic:** -9.19 mL/min/kg - Very low clearance, excellent metabolic stability.
* **t1/2:** 30.411 hours - Excellent in vitro half-life.
* **Pgp:** 0.05 - Low efflux, good.
* **Affinity:** -6.7 kcal/mol - Good binding affinity.
**Ligand B:**
* **MW:** 350.438 Da - Acceptable.
* **TPSA:** 68.09 A2 - Excellent, favorable for permeability.
* **logP:** 2.662 - Excellent, within the optimal range.
* **HBD:** 0 - Acceptable.
* **HBA:** 5 - Acceptable.
* **QED:** 0.837 - Excellent.
* **DILI:** 28.189 - Excellent, very low risk.
* **BBB:** 93.292 - High, but less critical for a cardiovascular target.
* **Caco-2:** -4.541 - Poor permeability, but better than Ligand A.
* **Solubility:** -2.675 - Poor solubility.
* **hERG:** 0.094 - Low risk.
* **Cl_mic:** 26.626 mL/min/kg - Moderate clearance.
* **t1/2:** -27.82 hours - Very short half-life, a significant drawback.
* **Pgp:** 0.06 - Low efflux, good.
* **Affinity:** -7.4 kcal/mol - Excellent binding affinity, 0.7 kcal/mol better than Ligand A.
**Comparison & Decision:**
Ligand B has a significantly better logP and TPSA, suggesting better permeability despite the poor Caco-2 value. The binding affinity is also superior. However, the extremely short half-life of Ligand B is a major concern. Ligand A, while having a very poor logP, has excellent metabolic stability and a long half-life.
Given the GPCR target class, the superior binding affinity and more favorable physicochemical properties (logP, TPSA) of Ligand B are more important than the longer half-life of Ligand A. While the short half-life is a drawback, it could potentially be addressed through formulation or prodrug strategies. The poor logP of Ligand A is a more fundamental issue that is harder to overcome.
Therefore, I prefer Ligand B.
**Output:**
0
2025-04-17 23:31:05,099 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (371.419 Da and 354.338 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (135.7) is slightly higher than Ligand B (119.51). Both are below the 140 A^2 threshold for good oral absorption, but Ligand B is preferable due to the lower TPSA.
**3. logP:** Both ligands have similar logP values (-0.917 and -0.7), which are slightly below the optimal 1-3 range. This could potentially impact permeability, but isn't a major concern.
**4. H-Bond Donors:** Ligand A has 3 HBD, and Ligand B has 2. Both are within the acceptable limit of <=5.
**5. H-Bond Acceptors:** Ligand A has 6 HBA, and Ligand B has 7. Both are within the acceptable limit of <=10.
**6. QED:** Both ligands have similar QED values (0.564 and 0.53), indicating good drug-like properties.
**7. DILI:** Ligand A (65.568) has a lower DILI risk than Ligand B (78.209). This is a significant advantage for Ligand A.
**8. BBB:** Ligand B (58.511) has a much higher BBB penetration percentile than Ligand A (12.602). While ADRB2 is a cardiovascular target, some CNS effects are possible with beta-blockers, and higher BBB penetration could lead to off-target effects. However, for a cardiovascular target, this isn't a primary concern, and a lower BBB value is often preferred to minimize CNS side effects.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, indicating poor permeability. Ligand A (-5.941) is slightly better than Ligand B (-4.891), but both are problematic.
**10. Aqueous Solubility:** Both ligands have negative solubility values, indicating poor solubility. Ligand A (-2.693) is slightly better than Ligand B (-1.839).
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.023 and 0.096). This is excellent.
**12. Microsomal Clearance:** Ligand A (-8.763) has significantly lower microsomal clearance than Ligand B (26.866). This suggests better metabolic stability for Ligand A.
**13. In vitro Half-Life:** Ligand A (-18.61) has a shorter in vitro half-life than Ligand B (-8.444). This is a disadvantage for Ligand A.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.004 and 0.01). This is excellent.
**15. Binding Affinity:** Ligand B (-7.4) has a significantly stronger binding affinity than Ligand A (-5.7). This is a substantial advantage for Ligand B, potentially outweighing some of the ADME drawbacks.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity), the stronger binding affinity of Ligand B (-7.4 kcal/mol vs -5.7 kcal/mol) is a major driver. While Ligand A has better DILI and metabolic stability, the affinity difference is substantial. The slightly better TPSA of Ligand B is also a plus. The lower BBB penetration of Ligand A is also favorable for a cardiovascular target. Although both have poor solubility and permeability, the improved potency of Ligand B is more likely to be optimized through formulation strategies.
Output:
0
2025-04-17 23:31:05,099 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (356.413 and 357.451 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (50.8) is significantly better than Ligand B (100.13). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is pushing the upper limit for good oral absorption (<=140) but is still acceptable.
**3. logP:** Ligand A (3.285) is optimal, while Ligand B (-0.883) is quite low. Low logP can hinder membrane permeability and potentially reduce binding affinity. This is a significant advantage for Ligand A.
**4. H-Bond Donors:** Both have acceptable HBD counts (1 and 3 respectively), within the guideline of <=5.
**5. H-Bond Acceptors:** Ligand A (3) is better than Ligand B (6). Lower HBA counts are generally preferred for permeability.
**6. QED:** Ligand A (0.881) has a much better QED score than Ligand B (0.522), indicating a more drug-like profile.
**7. DILI:** Ligand B (4.343) has a significantly lower DILI risk than Ligand A (47.732). This is a major advantage for Ligand B.
**8. BBB:** Ligand A (70.919) shows better BBB penetration than Ligand B (43.35). While ADRB2 is a cardiovascular target, some CNS effects are possible with beta-blockers, and better BBB penetration could be relevant for off-target effects or potential CNS side effects.
**9. Caco-2 Permeability:** Ligand A (-4.335) is better than Ligand B (-5.391). Higher (less negative) values indicate better permeability.
**10. Aqueous Solubility:** Ligand A (-3.605) is better than Ligand B (-0.753). Higher values indicate better solubility.
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.698 and 0.23 respectively). This is good for both.
**12. Microsomal Clearance:** Ligand B (-30.881) has lower microsomal clearance than Ligand A (40.697), suggesting better metabolic stability.
**13. In vitro Half-Life:** Ligand A (-32.929) has a significantly longer in vitro half-life than Ligand B (21.605).
**14. P-gp Efflux:** Both ligands have similar P-gp efflux liability (0.213 and 0.015).
**15. Binding Affinity:** Ligand B (-6.7) has a slightly better binding affinity than Ligand A (-6.0). However, the difference is less than 1.5 kcal/mol, so it's not a decisive factor.
**Overall Assessment:**
Ligand A excels in properties related to permeability (TPSA, logP, Caco-2) and drug-likeness (QED, solubility, half-life). However, Ligand B has a substantially lower DILI risk, which is a critical safety parameter. Considering the GPCR-specific priorities (logP, TPSA, affinity), Ligand A is better overall. The slightly better affinity of Ligand B is not enough to overcome the significant advantages of Ligand A in terms of permeability, drug-likeness, and solubility. The DILI risk of Ligand A is concerning, but can be addressed in later stages of optimization.
Output:
1
2025-04-17 23:31:05,099 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.402 and 363.502 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (49.85) is higher than Ligand B (35.58). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is generally preferred for absorption. Ligand B has a clear advantage.
3. **logP:** Both ligands have very similar logP values (1.977 and 1.965), falling within the optimal 1-3 range. No significant difference.
4. **HBD:** Ligand A (0) has fewer H-bond donors than Ligand B (1). Fewer HBDs generally improve permeability. Ligand A has a slight advantage.
5. **HBA:** Ligand A (3) has fewer H-bond acceptors than Ligand B (4). Similar to HBD, fewer HBAs are generally preferred. Ligand A has a slight advantage.
6. **QED:** Both ligands have similar QED values (0.766 and 0.619), both above the 0.5 threshold, indicating good drug-likeness.
7. **DILI:** Ligand B (30.787) has a significantly lower DILI risk than Ligand A (42.846). This is a substantial advantage for Ligand B.
8. **BBB:** Ligand A (83.288) has a higher BBB penetration percentile than Ligand B (71.85). While ADRB2 is not a CNS target, some degree of BBB penetration isn't necessarily detrimental, and a higher value is generally preferable.
9. **Caco-2:** Ligand A (-4.091) has a more negative Caco-2 value than Ligand B (-4.843), suggesting *better* permeability. This is a slight advantage for Ligand A. (Note: lower negative values indicate better permeability in this scale).
10. **Solubility:** Both ligands have similar, very poor solubility scores (-2.422 and -2.428). This is a concern for both, and formulation strategies would be needed.
11. **hERG:** Both ligands have low hERG inhibition liability (0.603 and 0.832), which is good. No significant difference.
12. **Cl_mic:** Ligand B (22.082) has a significantly lower microsomal clearance than Ligand A (35.213), indicating better metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand B (21.544) has a much longer in vitro half-life than Ligand A (-31.614). This is a substantial advantage for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.381) has lower P-gp efflux liability than Ligand B (0.118). Lower Pgp is generally preferred. Ligand A has a slight advantage.
15. **Binding Affinity:** Ligand B (-5.9) has a slightly better binding affinity than Ligand A (-5.7). While the difference is small, it's still a positive for Ligand B.
**Overall Assessment & GPCR Priorities:**
For a cardiovascular GPCR like ADRB2, the key priorities are affinity, logP, and metabolic stability. While both ligands have similar logP and acceptable affinities, Ligand B demonstrates significantly better metabolic stability (lower Cl_mic, longer t1/2) and a lower DILI risk. The slightly better affinity of Ligand B further strengthens its position. While Ligand A has some advantages in permeability and Pgp efflux, the benefits of Ligand B's improved ADME profile and safety outweigh these factors.
Output:
0
2025-04-17 23:31:05,099 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [343.475, 63.05, 2.441, 1, 4, 0.854, 32.028, 79.488, -4.71, -2.7, 0.119, 15.074, 25.213, 0.123, -6.3]
**Ligand B:** [348.447, 96.25, 1.116, 3, 5, 0.718, 38.736, 59.442, -4.864, -2.706, 0.089, 32.423, 1.23, 0.057, -6.4]
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). A (343.475) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (63.05) is significantly better than Ligand B (96.25). For a GPCR, keeping TPSA low is good, and A is well below the 140 threshold. B is approaching a level that might hinder absorption.
3. **logP:** Ligand A (2.441) is optimal, while Ligand B (1.116) is on the lower side. A higher logP generally aids membrane permeability for GPCRs.
4. **HBD:** Ligand A (1) is better than Ligand B (3). Fewer HBDs are generally preferred for better permeability.
5. **HBA:** Ligand A (4) is better than Ligand B (5). Fewer HBAs are generally preferred for better permeability.
6. **QED:** Ligand A (0.854) is better than Ligand B (0.718), indicating a more drug-like profile.
7. **DILI:** Both are reasonably low, but Ligand A (32.028) is slightly better than Ligand B (38.736).
8. **BBB:** Ligand A (79.488) is significantly better than Ligand B (59.442). This is *very* important for a GPCR target, even a cardiovascular one, as off-target CNS effects are always a concern.
9. **Caco-2:** Both are negative, indicating poor permeability. This is a concern for both.
10. **Solubility:** Both are negative, indicating poor solubility. This is a concern for both.
11. **hERG:** Both are very low, indicating minimal hERG inhibition risk. This is excellent.
12. **Cl_mic:** Ligand A (15.074) has a lower clearance than Ligand B (32.423), suggesting better metabolic stability.
13. **t1/2:** Ligand A (25.213) has a much longer half-life than Ligand B (1.23). This is a significant advantage.
14. **Pgp:** Ligand A (0.123) has lower P-gp efflux liability than Ligand B (0.057), which is favorable for bioavailability.
15. **Affinity:** Ligand B (-6.4) is slightly better than Ligand A (-6.3), but the difference is minimal. The other advantages of A likely outweigh this small difference.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical ADME properties, especially TPSA, logP, BBB penetration, metabolic stability (Cl_mic, t1/2), and QED. While Ligand B has a slightly better binding affinity, the other benefits of Ligand A make it a more promising drug candidate. The improved BBB penetration and metabolic stability are particularly valuable for a GPCR target. The Caco-2 and solubility issues are shared by both and would need to be addressed in further optimization, but they don't currently disqualify Ligand A.
Output:
1
2025-04-17 23:31:05,099 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (341.407 and 338.407 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (55.84) is better than Ligand B (59.59) as it's closer to the <140 threshold for good oral absorption.
3. **logP:** Both ligands have good logP values (3.294 and 4.374), within the optimal 1-3 range, but Ligand B is slightly higher. While still acceptable, higher logP can sometimes lead to off-target effects.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is preferable to Ligand B (3). Lower HBA is generally better for permeability.
6. **QED:** Both ligands have good QED scores (0.783 and 0.87), indicating good drug-likeness.
7. **DILI:** Ligand B (80.923) has a higher DILI risk than Ligand A (67.003). Lower DILI is crucial.
8. **BBB:** Ligand A (86.157) has better BBB penetration than Ligand B (73.866). While ADRB2 isn't strictly a CNS target, some peripheral ADRB2 activity can influence CNS pathways, and better BBB penetration isn't necessarily a negative.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-4.363) has slightly better solubility than Ligand B (-5.091).
11. **hERG:** Both ligands have low hERG inhibition risk (0.676 and 0.791), which is good.
12. **Cl_mic:** Ligand A (93.23) has higher microsomal clearance than Ligand B (71.72). This means Ligand B is more metabolically stable.
13. **t1/2:** Ligand B (46.845) has a significantly longer in vitro half-life than Ligand A (4.385). This is a major advantage.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.468 and 0.497).
15. **Binding Affinity:** Ligand A (-6.5 kcal/mol) has a slightly better binding affinity than Ligand B (-5.8 kcal/mol). The difference is 0.7 kcal/mol, which is significant.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Ligand A performs better on logP, TPSA, and affinity. Ligand B has better metabolic stability (lower Cl_mic and longer t1/2).
**Overall Assessment:**
Ligand A has a better overall profile, particularly regarding affinity, TPSA, and DILI risk. The slightly better affinity and lower DILI risk outweigh the slightly higher clearance and shorter half-life. The negative Caco-2 values for both are concerning and would require further investigation (formulation strategies, prodrug approaches). However, the superior binding affinity of Ligand A is a critical advantage for a GPCR target.
Output:
1
2025-04-17 23:31:05,100 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (364.27 and 365.499 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (59.5) is better than Ligand B (62.74). Both are below the 140 threshold for oral absorption, but closer to the ideal for GPCRs.
3. **logP:** Ligand A (2.681) is slightly higher than Ligand B (1.751), both are within the optimal 1-3 range. Ligand A is preferable here.
4. **HBD:** Both have 0 HBD, which is good.
5. **HBA:** Ligand A has 4 HBA, Ligand B has 5. Both are acceptable (<=10).
6. **QED:** Ligand A (0.611) and Ligand B (0.769) are both good, above 0.5. Ligand B is slightly better.
7. **DILI:** Ligand A (66.344) has a higher DILI risk than Ligand B (36.022). This is a significant advantage for Ligand B.
8. **BBB:** Both ligands have high BBB penetration (Ligand A: 83.986, Ligand B: 80.07). This is good, but less critical for a cardiovascular target like ADRB2.
9. **Caco-2:** Both have negative Caco-2 values (-4.337 and -4.403), which is unusual and suggests poor permeability. This is a significant drawback for both.
10. **Solubility:** Ligand A (-3.315) has worse solubility than Ligand B (-1.91). Ligand B is preferable.
11. **hERG:** Both ligands have low hERG inhibition risk (Ligand A: 0.447, Ligand B: 0.241). Ligand B is slightly better.
12. **Cl_mic:** Ligand A (70.171) has higher microsomal clearance than Ligand B (45.509), suggesting lower metabolic stability. Ligand B is preferable.
13. **t1/2:** Ligand A (-4.767) has a negative in vitro half-life, which is concerning. Ligand B (11.558) has a much better half-life. This is a major advantage for Ligand B.
14. **Pgp:** Both ligands have very low Pgp efflux (Ligand A: 0.17, Ligand B: 0.108).
15. **Binding Affinity:** Ligand B (-7.1 kcal/mol) has a significantly better binding affinity than Ligand A (-5.9 kcal/mol). This 1.2 kcal/mol difference is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand B is the stronger candidate. While both have issues with Caco-2 permeability, Ligand B demonstrates significantly better DILI risk, metabolic stability (lower Cl_mic, better t1/2), solubility, and, crucially, binding affinity. The superior binding affinity is a major advantage for a GPCR target.
Output:
0
2025-04-17 23:31:05,100 - INFO - Batch 410 complete. Total preferences: 6560
2025-04-17 23:31:05,100 - INFO - Processing batch 411/512...
2025-04-17 23:31:53,649 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's break down the comparison of Ligand A and Ligand B across the 15 parameters, keeping in mind the GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key).
1. **MW:** Both ligands (345.38 and 340.42 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand B (71.34) is significantly better than Ligand A (88.91). Lower TPSA generally improves permeability. This is a point in favor of Ligand B.
3. **logP:** Ligand A (1.801) is better than Ligand B (3.253). While both are within the acceptable range, Ligand A is closer to the optimal 1-3 range. Ligand B is getting a bit high, potentially leading to off-target effects or solubility issues.
4. **HBD:** Both have 2 HBD, which is good.
5. **HBA:** Ligand A has 5 HBA, while Ligand B has 3. Both are acceptable, but lower is generally preferred. Ligand B is slightly better.
6. **QED:** Ligand A (0.835) has a much better QED score than Ligand B (0.515), indicating a more drug-like profile. This is a significant advantage for Ligand A.
7. **DILI:** Ligand B (54.52) has a lower DILI risk than Ligand A (63.36), which is preferable.
8. **BBB:** Ligand A (79.57) has a better BBB penetration percentile than Ligand B (61.73). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant for side effect profiles, and better BBB penetration is generally a plus.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand B (-4.959) is slightly better than Ligand A (-3.78).
10. **Solubility:** Both have negative solubility values, which is also unusual and suggests poor solubility. Ligand B (-3.517) is slightly better than Ligand A (-3.78).
11. **hERG:** Ligand A (0.202) has a significantly lower hERG inhibition liability than Ligand B (0.828). This is a critical advantage for Ligand A, as hERG inhibition can lead to cardiotoxicity.
12. **Cl_mic:** Ligand B (17.02) has a much lower microsomal clearance than Ligand A (39.674), indicating better metabolic stability. This is a strong point for Ligand B.
13. **t1/2:** Ligand B (71.668) has a much longer in vitro half-life than Ligand A (9.481). This is a significant advantage for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.071) has a lower P-gp efflux liability than Ligand B (0.412). Lower P-gp efflux is generally desirable for improved oral bioavailability.
15. **Affinity:** Ligand B (-6.7 kcal/mol) has a significantly stronger binding affinity than Ligand A (-4.3 kcal/mol). This is a substantial advantage for Ligand B, potentially outweighing some of its ADME drawbacks.
**Overall Assessment:**
Ligand B has a significantly better binding affinity and metabolic stability (lower Cl_mic, longer t1/2). It also has a lower DILI risk. However, Ligand A has a better QED score, lower hERG risk, and better BBB penetration. The affinity difference is substantial (2.4 kcal/mol), and for a GPCR, potency is paramount. The slightly higher logP of Ligand B is a concern, but the improved metabolic stability and affinity are more critical. The poor Caco-2 and solubility for both are concerning and would need to be addressed in further optimization.
Considering the balance of these factors, and prioritizing affinity for a GPCR target, I favor Ligand B.
**Output:**
0
2025-04-17 23:31:53,650 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (341.455 & 349.519 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (62.3) is slightly higher than Ligand B (53.93). Both are below the 140 threshold for oral absorption, and acceptable for a cardiovascular target (not requiring significant CNS penetration). Ligand B is slightly preferred.
3. **logP:** Ligand A (2.252) is within the optimal 1-3 range. Ligand B (3.481) is at the higher end, but still acceptable. A slight preference for Ligand A.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 3 HBA, while Ligand B has 4. Both are acceptable (<=10), but Ligand A is slightly preferred.
6. **QED:** Both ligands have similar QED values (0.855 & 0.827), indicating good drug-likeness. No significant difference.
7. **DILI:** Ligand A (25.165) has a significantly lower DILI risk than Ligand B (8.181). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (90.074) has a much higher BBB penetration percentile than Ligand A (65.956). While ADRB2 is primarily a cardiovascular target, some CNS effects are possible with beta-blockers, and higher BBB penetration *could* be beneficial, but is not critical.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.949 & -4.78). These are unusual and suggest poor permeability. However, the values are very similar.
10. **Solubility:** Ligand A (-2.143) has better (less negative) solubility than Ligand B (-4.071). This is a positive for Ligand A.
11. **hERG:** Ligand A (0.163) has a lower hERG inhibition liability than Ligand B (0.596). This is a significant advantage for Ligand A, reducing cardiotoxicity risk.
12. **Cl_mic:** Both ligands have similar microsomal clearance values (41.249 & 42.885).
13. **t1/2:** Ligand A (-10.618) has a much longer in vitro half-life than Ligand B (3.706). This is a significant advantage for Ligand A, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.08) has lower P-gp efflux liability than Ligand B (0.163). This is a slight advantage for Ligand A.
15. **Binding Affinity:** Ligand B (-7.4) has a slightly better binding affinity than Ligand A (-8.0). While a 0.6 kcal/mol difference is noticeable, it's not a huge advantage, especially considering the other factors.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand B has a slightly better logP and affinity, and significantly better BBB penetration. However, Ligand A excels in safety parameters (DILI, hERG) and has a better half-life and solubility. The significant improvements in safety and PK for Ligand A outweigh the minor affinity advantage of Ligand B.
**Conclusion:**
Considering the balance of properties, particularly the lower DILI and hERG risk, better solubility, and longer half-life, Ligand A is the more promising drug candidate.
Output:
1
2025-04-17 23:31:53,650 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (344.371) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (119.73) is significantly better than Ligand B (33.95), falling well below the 140 threshold for good oral absorption. Ligand B is very low, which *could* indicate poor solubility.
3. **logP:** Ligand A (-0.829) is suboptimal, being slightly below the preferred 1-3 range. Ligand B (4.968) is high, potentially leading to solubility issues and off-target interactions.
4. **HBD:** Ligand A (3) is within the acceptable limit. Ligand B (0) is also acceptable, but generally, some HBD can aid solubility.
5. **HBA:** Both ligands are within the acceptable limit (Ligand A: 4, Ligand B: 5).
6. **QED:** Both ligands have good QED scores (Ligand A: 0.618, Ligand B: 0.666), indicating generally drug-like properties.
7. **DILI:** Ligand A (43.35) has a slightly higher DILI risk than Ligand B (15.626), but both are below the concerning threshold of 60.
8. **BBB:** Ligand B (79.062) has a significantly higher BBB penetration percentile than Ligand A (14.114). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be beneficial for distribution.
9. **Caco-2:** Both ligands have similar, poor Caco-2 permeability (-5.33 and -5.148).
10. **Solubility:** Ligand A (-2.492) is slightly better than Ligand B (-3.656), but both are quite poor.
11. **hERG:** Ligand A (0.104) has a much lower hERG inhibition liability than Ligand B (0.854), which is a significant advantage.
12. **Cl_mic:** Ligand A (-31.626) has a much lower (better) microsomal clearance than Ligand B (46.406), indicating greater metabolic stability.
13. **t1/2:** Ligand A (-9.656) has a negative half-life, which is concerning. Ligand B (3.785) has a short, but positive half-life.
14. **Pgp:** Ligand A (0.008) has a much lower P-gp efflux liability than Ligand B (0.621), which is favorable for bioavailability.
15. **Affinity:** Ligand A (-8.1 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.1 kcal/mol). This is a substantial advantage.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A struggles with logP, but excels in TPSA, Pgp, and *especially* affinity. Ligand B has a high logP and better BBB penetration, but suffers from poor Pgp profile and significantly weaker binding. The strong affinity of Ligand A is a major driver. The better metabolic stability (Cl_mic) and lower hERG risk of Ligand A are also important positives.
**Conclusion:**
Despite the suboptimal logP and poor solubility of Ligand A, its significantly stronger binding affinity, better metabolic stability, lower hERG risk, and lower P-gp efflux outweigh the drawbacks. The affinity difference is substantial. Ligand B's high logP and weaker affinity make it less attractive.
Output:
1
2025-04-17 23:31:53,650 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, the key properties to prioritize are logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB (though less critical for a cardiovascular target).
Let's break down the comparison:
1. **MW:** Both ligands are within the acceptable range (200-500 Da).
2. **TPSA:** Ligand B (72.88) is significantly better than Ligand A (91.32). Lower TPSA generally favors oral absorption and GPCR penetration.
3. **logP:** Both ligands have good logP values (1.957 and 1.176, respectively) within the optimal range of 1-3. Ligand B is slightly better.
4. **HBD/HBA:** Both are acceptable, with Ligand B having a slightly more favorable HBD count (2 vs 3).
5. **QED:** Both have reasonable QED scores (0.629 and 0.534), indicating drug-likeness.
6. **DILI:** Ligand B (5.933) has a much lower DILI risk than Ligand A (29.43), a significant advantage.
7. **BBB:** Both are moderate, but not a primary concern for a cardiovascular target.
8. **Caco-2:** Both are negative, indicating poor permeability. This is a concern for both.
9. **Solubility:** Ligand B (-0.691) is better than Ligand A (-2.679), indicating better aqueous solubility.
10. **hERG:** Both have low hERG inhibition liability, which is good.
11. **Cl_mic:** Ligand B (-1.649) has a significantly *lower* (better) microsomal clearance than Ligand A (8.57), suggesting better metabolic stability.
12. **t1/2:** Ligand B (-22.935) has a much longer in vitro half-life than Ligand A (-11.313), a substantial advantage.
13. **Pgp:** Both are very low, indicating minimal P-gp efflux.
14. **Binding Affinity:** Ligand B (-6.1) has a slightly better binding affinity than Ligand A (-5.8), but the difference is small.
**Overall Assessment:**
Ligand B consistently outperforms Ligand A across several crucial ADME properties (DILI, Cl_mic, t1/2, solubility, TPSA) while maintaining comparable potency and acceptable physicochemical properties. The lower DILI risk and improved metabolic stability are particularly compelling for a cardiovascular drug candidate. While both have poor Caco-2 permeability, the other advantages of Ligand B outweigh this drawback.
Output:
0
2025-04-17 23:31:53,650 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.475 and 352.479 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (85.23 and 87.46) are below the 140 A^2 threshold for good oral absorption, and acceptable for a non-CNS GPCR target like ADRB2. Ligand B is slightly higher, but not concerning.
3. **logP:** Both ligands have good logP values (1.277 and 1.031), falling within the optimal range of 1-3. No significant difference.
4. **HBD:** Both ligands have 2 H-bond donors, which is within the acceptable limit of <=5.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 5. Both are within the acceptable limit of <=10.
6. **QED:** Both ligands have similar QED scores (0.759 and 0.767), indicating good drug-likeness.
7. **DILI:** Ligand A (12.292) has a significantly lower DILI risk than Ligand B (21.908). This is a major advantage for Ligand A.
8. **BBB:** This is less critical for ADRB2 (a cardiovascular target), but Ligand A (50.679) has a higher BBB penetration percentile than Ligand B (30.167).
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.337 and -5.14), which is unusual and suggests poor permeability. However, these values are close and likely represent limitations in the prediction model rather than a substantial difference.
10. **Solubility:** Both ligands have negative solubility values (-1.926 and -0.753), which is also concerning. Again, these are close and likely model limitations.
11. **hERG:** Both ligands have low hERG inhibition liability (0.496 and 0.155), which is good. Ligand B is slightly better here.
12. **Cl_mic:** Ligand A has a much lower (and therefore better) microsomal clearance (-17.114 mL/min/kg) than Ligand B (31.822 mL/min/kg). This suggests greater metabolic stability for Ligand A.
13. **t1/2:** Ligand A has a longer in vitro half-life (26.739 hours) than Ligand B (12.875 hours). This is a significant advantage for Ligand A.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.035 and 0.043), which is good. No significant difference.
15. **Binding Affinity:** Ligand A (-6.6 kcal/mol) has a slightly better binding affinity than Ligand B (-6.2 kcal/mol), but the difference is relatively small (0.4 kcal/mol).
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, and affinity are important. Both ligands perform similarly in these areas. However, ADME properties are crucial. Ligand A demonstrates a significantly better safety profile (lower DILI), improved metabolic stability (lower Cl_mic, longer t1/2), and slightly better affinity. While both have concerning solubility and Caco-2 values, these are likely model artifacts.
**Conclusion:**
Ligand A is the more promising candidate due to its superior DILI profile, metabolic stability, and half-life. The slightly better binding affinity further supports this choice.
Output:
1
2025-04-17 23:31:53,650 - INFO - Here's my reasoning and final decision:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, key priorities are logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB.
* **Molecular Weight:** Both ligands (348.462 and 348.403 Da) are within the ideal 200-500 Da range.
* **TPSA:** Ligand A (40.62) is significantly better than Ligand B (109.39). A TPSA under 140 is good for oral absorption, but lower is generally preferred for GPCRs, and Ligand A is much closer to the ideal range for CNS penetration (even though this isn't a CNS target, lower TPSA often correlates with better permeability).
* **logP:** Ligand A (2.338) is within the optimal 1-3 range. Ligand B (1.318) is a bit low, potentially hindering permeability.
* **H-Bond Donors/Acceptors:** Ligand A (0 HBD, 2 HBA) is preferable to Ligand B (3 HBD, 6 HBA). Fewer H-bonds generally improve membrane permeability.
* **QED:** Ligand A (0.663) is slightly better than Ligand B (0.561), indicating a more drug-like profile.
* **DILI:** Ligand B (52.617) has a significantly lower DILI risk than Ligand A (10.702), which is a major advantage.
* **BBB:** Ligand A (86.817) has a much higher BBB percentile than Ligand B (13.377). While not a CNS target, higher BBB often correlates with better overall permeability.
* **Caco-2:** Ligand A (-4.478) is better than Ligand B (-5.519), indicating better intestinal absorption.
* **Solubility:** Ligand A (-3.054) is better than Ligand B (-2.114).
* **hERG:** Both ligands have low hERG inhibition liability (0.672 and 0.353 respectively), which is good.
* **Cl_mic:** Ligand B (14.769) has lower microsomal clearance than Ligand A (39.815), suggesting better metabolic stability.
* **t1/2:** Ligand B (81.496) has a significantly longer in vitro half-life than Ligand A (-14.003). This is a substantial advantage.
* **Pgp:** Ligand A (0.121) has lower P-gp efflux than Ligand B (0.181), which is favorable.
* **Binding Affinity:** Ligand B (-6.4 kcal/mol) has a slightly better binding affinity than Ligand A (-5.6 kcal/mol). This 0.8 kcal/mol difference is significant and could outweigh some of the ADME drawbacks.
**Overall Assessment:**
Ligand B has a superior binding affinity and better metabolic stability (lower Cl_mic, longer t1/2) and a much lower DILI risk. While Ligand A has better TPSA and Pgp efflux, the improved potency and safety profile of Ligand B are more critical for a cardiovascular GPCR target. The slightly lower logP of Ligand B is a minor concern, but the strong binding affinity should compensate.
**Output:**
0
2025-04-17 23:31:53,650 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (342.527 Da) is within the ideal range (200-500), while Ligand B (374.35 Da) is also acceptable. No clear advantage here.
2. **TPSA:** Ligand A (23.55) is excellent, well below the 140 threshold and very favorable for absorption. Ligand B (58.64) is higher, but still reasonable. A favors here.
3. **logP:** Ligand A (4.423) is slightly high, potentially leading to solubility issues or off-target interactions. Ligand B (2.352) is optimal. B favors here.
4. **HBD:** Both ligands have low HBD counts (A: 0, B: 1), which is good for permeability. No significant difference.
5. **HBA:** Both ligands have low HBA counts (A: 2, B: 3), which is good for permeability. No significant difference.
6. **QED:** Both ligands have similar QED values (A: 0.79, B: 0.696), indicating good drug-likeness. No significant difference.
7. **DILI:** Ligand A (20.318) has a significantly lower DILI risk than Ligand B (31.02). A strongly favors here.
8. **BBB:** Ligand A (92.904) has a much higher BBB penetration potential than Ligand B (76.774). This is important for a GPCR, though ADRB2 isn't strictly a CNS target, some peripheral distribution is still desired. A favors here.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.606 and -4.528), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-3.739) has slightly worse solubility than Ligand B (-2.104). B favors here.
11. **hERG:** Both ligands have low hERG inhibition risk (A: 0.915, B: 0.488). No significant difference.
12. **Cl_mic:** Ligand A (69.06) has a higher microsomal clearance than Ligand B (23.818), indicating lower metabolic stability. B favors here.
13. **t1/2:** Ligand A (17.042) has a longer in vitro half-life than Ligand B (-22.934). A favors here.
14. **Pgp:** Both ligands have low P-gp efflux liability (A: 0.808, B: 0.035). B favors here.
15. **Binding Affinity:** Both ligands have identical binding affinity (-6.5 kcal/mol). No difference.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand A appears slightly more promising. While Ligand B has better logP and Pgp values, Ligand A excels in TPSA, DILI risk, and BBB penetration. The longer half-life of Ligand A is also a benefit. The negative Caco-2 values are concerning for both, but the other advantages of Ligand A outweigh the slightly worse solubility and higher clearance.
Output:
1
2025-04-17 23:31:53,650 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (384.611 Da) and Ligand B (358.482 Da) are both within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (40.62) is slightly higher than Ligand B (33.2). Both are well below the 140 threshold for oral absorption, and suitable for a GPCR. Ligand B is preferable here.
3. **logP:** Ligand A (3.255) is within the optimal 1-3 range. Ligand B (4.866) is a bit high, potentially leading to solubility issues or off-target interactions. Ligand A is preferable.
4. **HBD:** Both ligands have 0 HBD, which is good.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 3. Both are acceptable.
6. **QED:** Both ligands have similar QED values (0.659 and 0.691), indicating good drug-likeness.
7. **DILI:** Ligand A (29.391) has a lower DILI risk than Ligand B (39.201), which is a significant advantage.
8. **BBB:** Both ligands have good BBB penetration (Ligand A: 76.735, Ligand B: 84.374). Ligand B is slightly better, but both are acceptable for a cardiovascular target.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand B (-4.7) is slightly better than Ligand A (-5.076).
10. **Solubility:** Both ligands have negative solubility values, suggesting poor aqueous solubility. Ligand A (-3.739) is slightly better than Ligand B (-4.888).
11. **hERG:** Both ligands have low hERG inhibition risk (Ligand A: 0.678, Ligand B: 0.598).
12. **Cl_mic:** Ligand B (74.562) has lower microsomal clearance than Ligand A (84.704), indicating better metabolic stability.
13. **t1/2:** Ligand B (3.819) has a significantly longer in vitro half-life than Ligand A (0.104). This is a major advantage.
14. **Pgp:** Both ligands have low Pgp efflux liability (Ligand A: 0.521, Ligand B: 0.582).
15. **Binding Affinity:** Ligand B (-6.7 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.7 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME drawbacks.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, Pgp, TPSA, and affinity. Ligand B has a higher logP (though slightly high), similar Pgp, lower TPSA, and *much* better affinity. The longer half-life is also a significant benefit. While Ligand A has a lower DILI risk, the substantial affinity advantage of Ligand B is more critical for a GPCR target. The poor Caco-2 and solubility are concerning for both, but can be addressed with formulation strategies.
**Conclusion:**
Despite some ADME concerns, Ligand B's significantly stronger binding affinity and improved metabolic stability make it the more promising drug candidate for ADRB2.
Output:
0
2025-04-17 23:31:53,651 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (368.459 and 343.427 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (95) is slightly higher than Ligand B (82.27). Both are below the 140 threshold for good oral absorption, but closer to the 90 threshold for CNS targets, which isn't a primary concern for ADRB2 (cardiovascular). Ligand B is slightly better.
3. **logP:** Ligand B (2.293) is within the optimal 1-3 range, while Ligand A (0.417) is below 1, potentially hindering permeation. Ligand B is significantly better.
4. **HBD:** Both ligands have 2 HBD, which is acceptable. No clear advantage.
5. **HBA:** Ligand A has 7 HBA, while Ligand B has 3. Both are below the 10 threshold. Ligand B is better.
6. **QED:** Both ligands have similar QED values (0.677 and 0.636), indicating good drug-likeness. No clear advantage.
7. **DILI:** Both ligands have acceptable DILI risk (45.095 and 49.166), below the 60 threshold. No clear advantage.
8. **BBB:** Ligand B (54.478) has a higher BBB percentile than Ligand A (41.373), but BBB isn't a high priority for a cardiovascular target.
9. **Caco-2:** Ligand A (-4.945) and Ligand B (-5.116) have similar Caco-2 permeability values, suggesting comparable intestinal absorption. No clear advantage.
10. **Solubility:** Ligand A (-2.255) has slightly better aqueous solubility than Ligand B (-3.424).
11. **hERG:** Both ligands have low hERG inhibition liability (0.155 and 0.184). No clear advantage.
12. **Cl_mic:** Ligand A (-4.107) has a significantly lower (better) microsomal clearance than Ligand B (10.9). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand B (-27.324) has a much longer in vitro half-life than Ligand A (6.532). This is a significant advantage for Ligand B.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.013 and 0.114). No clear advantage.
15. **Binding Affinity:** Ligand B (-6.5 kcal/mol) has a stronger binding affinity than Ligand A (-5.9 kcal/mol). This is a 0.6 kcal/mol advantage, which is significant.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand B is the stronger candidate. Its logP is optimal, and its binding affinity is significantly better than Ligand A. While Ligand A has better metabolic stability (lower Cl_mic), the longer half-life of Ligand B compensates for this. The slightly better TPSA and HBA of Ligand B also contribute to its favorability. The difference in solubility is minor and less critical than the affinity and logP advantages of Ligand B.
Output:
0
2025-04-17 23:31:53,651 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [368.503, 98.32, 0.809, 3, 5, 0.631, 37.456, 17.332, -5.677, -2.566, 0.187, 18.964, -15.605, 0.071, -6.1]
**Ligand B:** [346.475, 69.3, 2.004, 1, 3, 0.856, 18.651, 71.733, -5.095, -1.523, 0.243, 27.957, -17.717, 0.119, -5.2]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (346.5) is slightly smaller, which can be advantageous for permeability, but the difference isn't huge.
2. **TPSA:** Ligand A (98.32) is higher than Ligand B (69.3). For a GPCR, lower TPSA is generally preferred for better brain penetration and membrane permeability. Ligand B is significantly better here.
3. **logP:** Ligand A (0.809) is a bit low, potentially hindering membrane permeability. Ligand B (2.004) is within the optimal range (1-3). Ligand B is better.
4. **HBD:** Ligand A (3) is higher than Ligand B (1). Lower is generally better for permeability, so Ligand B is preferred.
5. **HBA:** Ligand A (5) is higher than Ligand B (3). Again, lower is generally better, favoring Ligand B.
6. **QED:** Both are good (A: 0.631, B: 0.856), indicating drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (37.46) has a higher DILI risk than Ligand B (18.65). Lower is better, so Ligand B is favored.
8. **BBB:** Ligand B (71.73) has a significantly higher BBB penetration percentile than Ligand A (17.33). This is *very* important for a GPCR target, even if not CNS-focused, as it can influence off-target effects. Ligand B is strongly favored.
9. **Caco-2:** Both are negative, indicating poor permeability. This is concerning for both, but the values are similar.
10. **Solubility:** Both are negative, indicating poor solubility. This is concerning for both, but the values are similar.
11. **hERG:** Both are very low risk (A: 0.187, B: 0.243).
12. **Cl_mic:** Ligand A (18.96) has lower microsomal clearance than Ligand B (27.96), suggesting better metabolic stability. This favors Ligand A.
13. **t1/2:** Ligand B (-17.72) has a longer in vitro half-life than Ligand A (-15.61). This favors Ligand B.
14. **Pgp:** Both are low (A: 0.071, B: 0.119), indicating minimal P-gp efflux.
15. **Affinity:** Ligand A (-6.1) has slightly better binding affinity than Ligand B (-5.2). This is a 0.9 kcal/mol difference, which is significant.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity and metabolic stability, Ligand B demonstrates a significantly superior ADME profile, particularly regarding TPSA, logP, BBB penetration, and DILI risk. For a GPCR like ADRB2, these ADME properties are crucial for achieving good bioavailability, minimizing off-target effects, and potentially enabling CNS penetration if desired. The affinity difference, while notable, can potentially be optimized in subsequent iterations of Ligand B. The poor Caco-2 and solubility for both are concerning and would need to be addressed, but Ligand B's overall profile is more promising.
Output:
0
2025-04-17 23:31:53,651 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, the most important parameters are binding affinity, logP, TPSA, Pgp efflux, and to a lesser extent, BBB.
Let's break down the comparison:
1. **Molecular Weight:** Both ligands (341.455 and 341.411 Da) are within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (71.09) is slightly higher than Ligand B (62.21). Both are below the 140 threshold for good absorption, but Ligand B is preferable.
3. **logP:** Ligand A (2.503) is within the optimal 1-3 range. Ligand B (1.753) is also acceptable, but slightly lower.
4. **H-Bond Donors/Acceptors:** Ligand A has 2 HBD and 3 HBA, while Ligand B has 0 HBD and 4 HBA. Both are reasonable.
5. **QED:** Both ligands have similar QED values (0.781 and 0.767), indicating good drug-likeness.
6. **DILI:** Ligand A (24.738) has a significantly lower DILI risk than Ligand B (35.828), which is a major advantage.
7. **BBB:** Ligand A (71.539) has a better BBB penetration score than Ligand B (53.238). While not a primary concern for a cardiovascular target, it's a positive.
8. **Caco-2 Permeability:** Both have negative values, indicating poor permeability. Ligand A (-4.813) is slightly better than Ligand B (-4.234).
9. **Aqueous Solubility:** Both have negative values, indicating poor solubility. Ligand A (-2.94) is slightly better than Ligand B (-1.643).
10. **hERG:** Both ligands have very low hERG inhibition risk (0.093 and 0.178).
11. **Cl_mic:** Ligand B (16.626) has significantly lower microsomal clearance than Ligand A (48.693), suggesting better metabolic stability.
12. **t1/2:** Ligand A (-5.79) has a longer in vitro half-life than Ligand B (-3.614).
13. **Pgp:** Both have very low Pgp efflux liability (0.051 and 0.077).
14. **Binding Affinity:** Ligand A (-7.1 kcal/mol) has a significantly stronger binding affinity than Ligand B (-4.5 kcal/mol). This is a crucial difference, as a 2.6 kcal/mol advantage is substantial.
**Overall Assessment:**
Ligand A is the stronger candidate. The significantly improved binding affinity (-7.1 vs -4.5 kcal/mol) outweighs the slightly worse metabolic stability (higher Cl_mic) and solubility. The lower DILI risk and better BBB penetration are also favorable. While both ligands have poor Caco-2 permeability and solubility, the potency advantage of Ligand A is decisive.
Output:
1
2025-04-17 23:31:53,651 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.435 Da and 353.467 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (110.77 and 107.77) are below the 140 A^2 threshold for good oral absorption, but higher than the 90 A^2 for CNS targets. Since ADRB2 is a cardiovascular target, CNS penetration is not a primary concern.
3. **logP:** Ligand A (-1.269) is slightly lower than Ligand B (-0.96). Both are within the 1-3 range, but Ligand A is closer to the lower limit, which *could* indicate potential permeability issues.
4. **HBD:** Ligand A (4) has one more HBD than Ligand B (3). This isn't a major concern, as both are within the acceptable limit of 5.
5. **HBA:** Both ligands have 5 HBA, which is within the acceptable limit of 10.
6. **QED:** Both ligands have similar QED scores (0.493 and 0.495), indicating reasonable drug-likeness, but not exceptional.
7. **DILI:** Ligand A (11.09) has a significantly higher DILI risk than Ligand B (5.196). This is a crucial factor, as minimizing liver toxicity is paramount.
8. **BBB:** Ligand B (42.458) has a much higher BBB penetration percentile than Ligand A (11.128). While not a primary concern for a cardiovascular target, higher BBB is generally a positive attribute.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.672 and -6.188). This is unusual and suggests poor permeability. However, the values are similar.
10. **Solubility:** Ligand A (-0.827) has slightly better solubility than Ligand B (-1.145).
11. **hERG:** Both ligands have very low hERG inhibition risk (0.029 and 0.048). This is excellent.
12. **Cl_mic:** Ligand A (-25.994) has a *much* lower (better) microsomal clearance than Ligand B (-17.433). This suggests greater metabolic stability for Ligand A.
13. **t1/2:** Ligand A (21.424) has a longer in vitro half-life than Ligand B (-23.452). This is a significant advantage, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.001) has a much lower Pgp efflux liability than Ligand B (0.0). This is a significant advantage, improving bioavailability.
15. **Binding Affinity:** Ligand B (-7.1 kcal/mol) has a significantly stronger binding affinity than Ligand A (-4.8 kcal/mol). This is a substantial difference (2.3 kcal/mol) and a major factor.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand B excels in affinity. Ligand A is better in Pgp efflux and Cl_mic. However, the substantial affinity difference of Ligand B outweighs the other advantages of Ligand A. The DILI risk for Ligand A is also a serious concern.
**Conclusion:**
Despite Ligand A's better metabolic stability and lower Pgp efflux, the significantly stronger binding affinity of Ligand B, coupled with its lower DILI risk, makes it the more promising drug candidate.
Output:
0
2025-04-17 23:31:53,651 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
Let's break down the comparison of Ligand A and Ligand B, considering the provided guidelines and the GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key).
1. **Molecular Weight:** Both ligands (349.475 Da and 365.543 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (84.23) is slightly higher than Ligand B (71.09). Both are below the 140 A^2 threshold for good oral absorption, but Ligand B is preferable due to being closer to the 90 A^2 target for GPCRs.
3. **logP:** Both ligands have good logP values (3.078 and 3.787, respectively), falling within the optimal 1-3 range. Ligand B is slightly higher, which *could* be a minor concern for solubility, but isn't a dealbreaker.
4. **H-Bond Donors:** Both have 2 HBD, which is within the acceptable limit of <=5.
5. **H-Bond Acceptors:** Both have 4 HBA, also within the acceptable limit of <=10.
6. **QED:** Both ligands have good QED scores (0.792 and 0.805), indicating good drug-like properties.
7. **DILI:** Ligand B (51.997) has a significantly lower DILI risk than Ligand A (35.091). This is a major advantage for Ligand B.
8. **BBB:** Both ligands have high BBB penetration (80.419 and 78.209). This is good, but less critical for ADRB2, which isn't primarily a CNS target.
9. **Caco-2 Permeability:** Both have negative Caco-2 values (-4.745 and -4.749). This is unusual and suggests poor permeability *in vitro*. This is a concern for both, but doesn't differentiate them.
10. **Aqueous Solubility:** Ligand B (-5.867) has better aqueous solubility than Ligand A (-3.593). This is a positive for Ligand B, mitigating some of the potential issues from its slightly higher logP.
11. **hERG Inhibition:** Both ligands have low hERG inhibition risk (0.376 and 0.545).
12. **Microsomal Clearance:** Both have similar microsomal clearance (76.391 and 78.878).
13. **In vitro Half-Life:** Ligand B (-1.881) has a significantly longer in vitro half-life than Ligand A (-23.047). This is a substantial advantage for Ligand B.
14. **P-gp Efflux:** Both ligands have similar P-gp efflux liability (0.166 and 0.247).
15. **Binding Affinity:** Both ligands have the same binding affinity (-6.0 kcal/mol).
**Overall Assessment:**
While both ligands have similar binding affinity and acceptable physicochemical properties, Ligand B is the stronger candidate. It demonstrates a significantly lower DILI risk, better aqueous solubility, and a much longer in vitro half-life. The slightly lower TPSA is also beneficial. The negative Caco-2 values are a concern for both, but the other advantages of Ligand B outweigh this shared drawback.
**Output:**
0
2025-04-17 23:31:53,651 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (345.355 and 344.459 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (93.9) is higher than Ligand B (67.23). For a GPCR, lower TPSA is generally preferred for better brain penetration, even though ADRB2 isn't strictly a CNS target. Ligand B has a clear advantage.
3. **logP:** Ligand A (0.459) is quite low, potentially hindering membrane permeability. Ligand B (2.224) is within the optimal 1-3 range. Ligand B is significantly better.
4. **HBD:** Both ligands have 1 HBD, which is acceptable.
5. **HBA:** Ligand A has 6 HBA, while Ligand B has 4. Both are within the acceptable range of <=10, but Ligand B is slightly better.
6. **QED:** Ligand B (0.805) has a substantially higher QED score than Ligand A (0.457), indicating a more drug-like profile. This is a significant advantage for Ligand B.
7. **DILI:** Ligand A (62.854) has a higher DILI risk than Ligand B (29.236). Lower is better, so Ligand B is preferred.
8. **BBB:** Ligand B (66.809) has a higher BBB percentile than Ligand A (59.364), although both are not exceptionally high. This is a slight advantage for Ligand B.
9. **Caco-2:** Ligand A (-4.851) and Ligand B (-5.094) both have negative Caco-2 values, which is unusual and suggests very poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand A (-2.22) and Ligand B (-1.663) both have poor aqueous solubility.
11. **hERG:** Ligand A (0.111) has a slightly lower hERG risk than Ligand B (0.219), which is preferable.
12. **Cl_mic:** Ligand A (7.466) has a significantly lower microsomal clearance than Ligand B (19.489), indicating better metabolic stability. This is a strong advantage for Ligand A.
13. **t1/2:** Ligand A (-29.146) has a much more negative in vitro half-life than Ligand B (-3.358). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.041) has a lower P-gp efflux liability than Ligand B (0.052), which is preferable.
15. **Binding Affinity:** Ligand B (-7.0) has a significantly stronger binding affinity than Ligand A (-5.8). This is a major advantage for Ligand B, potentially outweighing some of the ADME concerns.
**Overall Assessment:**
Ligand B has a superior profile in terms of drug-likeness (QED), logP, DILI risk, and, crucially, binding affinity. While its Caco-2 and solubility are poor, the strong binding affinity (-7.0 kcal/mol) is a significant advantage that could be addressed with formulation strategies. Ligand A has better metabolic stability and a slightly lower hERG risk, but its low logP and weaker binding affinity are major drawbacks. Considering the GPCR-specific priorities (logP, affinity), Ligand B is the more promising candidate.
Output:
0
2025-04-17 23:31:53,651 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (376.8 Da and 354.491 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (93.93) is slightly higher than Ligand B (81.86). Both are below the 140 threshold for oral absorption, but closer to the 90 threshold for CNS targets (less relevant for a cardiovascular target). Ligand B is preferable.
**3. logP:** Ligand A (3.537) is slightly higher than Ligand B (2.102), both within the optimal 1-3 range. Ligand B is preferable.
**4. H-Bond Donors:** Both ligands have 1 HBD, which is good.
**5. H-Bond Acceptors:** Ligand A has 7 HBAs, while Ligand B has 5. Both are acceptable (<=10).
**6. QED:** Both ligands have similar QED values (0.703 and 0.675), indicating good drug-likeness.
**7. DILI Risk:** Ligand A (96.51) has a significantly higher DILI risk than Ligand B (6.282). This is a major concern for Ligand A.
**8. BBB Penetration:** Ligand B (89.957) has better BBB penetration than Ligand A (61.962). While not a primary concern for a cardiovascular target, higher BBB penetration can sometimes indicate better overall permeability.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.601 and -4.548), which is unusual and suggests poor permeability. This is a significant drawback for both.
**10. Aqueous Solubility:** Ligand B (-1.903) has better aqueous solubility than Ligand A (-6.008).
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (0.465 and 0.651).
**12. Microsomal Clearance:** Ligand B (58.027) has lower microsomal clearance, indicating better metabolic stability, compared to Ligand A (70.194).
**13. In vitro Half-Life:** Ligand B (-12.786) has a significantly longer in vitro half-life than Ligand A (27.352).
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (0.241 and 0.138).
**15. Binding Affinity:** Both ligands have very similar binding affinities (-6.4 kcal/mol and -6.1 kcal/mol). The difference is not substantial enough to outweigh other factors.
**GPCR-Specific Priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand B is better across most of these parameters.
**Overall Assessment:**
Ligand B is significantly better due to its much lower DILI risk, better solubility, improved metabolic stability (lower Cl_mic, longer t1/2), and slightly better TPSA and logP values. While both have poor Caco-2 permeability, the other advantages of Ligand B make it the more promising candidate.
Output:
0
2025-04-17 23:31:53,651 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [368.415, 136.4, 0.355, 3, 6, 0.645, 82.435, 24.195, -5.73, -2.19, 0.102, -1.973, -5.833, 0.073, -6.6]
**Ligand B:** [347.39, 80.32, 0.814, 2, 4, 0.682, 54.478, 79.411, -4.338, -2.337, 0.206, 30.678, -12.234, 0.037, -5.8]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (347.39) is slightly lower, which could be a minor advantage for permeability.
2. **TPSA:** Ligand A (136.4) is close to the upper limit for good oral absorption (<=140), while Ligand B (80.32) is well within the optimal range. This favors Ligand B.
3. **logP:** Ligand A (0.355) is a bit low, potentially hindering membrane permeability. Ligand B (0.814) is better, falling within the optimal 1-3 range. This favors Ligand B.
4. **HBD:** Both have acceptable HBD counts (A: 3, B: 2).
5. **HBA:** Both have acceptable HBA counts (A: 6, B: 4).
6. **QED:** Both have good QED values (A: 0.645, B: 0.682), indicating drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (82.435) has a higher DILI risk than Ligand B (54.478). This is a significant drawback for Ligand A.
8. **BBB:** Ligand B (79.411) has a much better BBB penetration potential than Ligand A (24.195). This is a crucial advantage for a GPCR target, even if not specifically a CNS target.
9. **Caco-2:** Ligand A (-5.73) is significantly worse than Ligand B (-4.338).
10. **Solubility:** Both have poor solubility (-2.19 and -2.337). This is a concern for both, but not a deciding factor.
11. **hERG:** Both have low hERG risk (A: 0.102, B: 0.206).
12. **Cl_mic:** Ligand A (-1.973) has a lower (better) microsomal clearance than Ligand B (30.678), suggesting better metabolic stability. This is a positive for Ligand A.
13. **t1/2:** Ligand B (-12.234) has a much longer *in vitro* half-life than Ligand A (-5.833). This is a significant advantage for Ligand B.
14. **Pgp:** Both have low Pgp efflux liability (A: 0.073, B: 0.037).
15. **Affinity:** Both have very similar binding affinities (-6.6 and -5.8 kcal/mol). The difference of 0.8 kcal/mol is not substantial enough to overcome the other ADME differences.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, BBB, and affinity are key. Ligand B clearly outperforms Ligand A in logP, TPSA, and BBB. While affinity is similar, the superior ADME profile of Ligand B outweighs the slightly better metabolic stability of Ligand A. The DILI risk is also a major concern for Ligand A.
**Conclusion:**
Considering the overall profile and prioritizing GPCR-relevant properties, Ligand B is the more promising drug candidate.
0
2025-04-17 23:31:53,652 - INFO - Batch 411 complete. Total preferences: 6576
2025-04-17 23:31:53,652 - INFO - Processing batch 412/512...
2025-04-17 23:32:44,220 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A Analysis:**
* **MW:** 352.435 Da - Good, within the ideal range.
* **TPSA:** 91.07 - Acceptable, slightly above the optimal <90 for CNS, but not a major concern for a cardiovascular target.
* **logP:** -0.093 - Low. This is a significant drawback, potentially leading to poor membrane permeability.
* **HBD:** 2 - Good.
* **HBA:** 7 - Good.
* **QED:** 0.765 - Excellent, highly drug-like.
* **DILI:** 15.51 - Very good, low risk of liver injury.
* **BBB:** 43.001 - Low. Not a major concern for a cardiovascular target.
* **Caco-2:** -5.204 - Very poor permeability. Consistent with the low logP.
* **Solubility:** -0.003 - Very poor solubility.
* **hERG:** 0.208 - Low risk of hERG inhibition.
* **Cl_mic:** -51.293 - Excellent, very low metabolic clearance.
* **t1/2:** 13.257 - Good in vitro half-life.
* **Pgp:** 0.014 - Low P-gp efflux.
* **Affinity:** -7.3 kcal/mol - Excellent binding affinity.
**Ligand B Analysis:**
* **MW:** 379.781 Da - Good, within the ideal range.
* **TPSA:** 29.54 - Excellent, very favorable for permeability.
* **logP:** 4.004 - High. Borderline, could lead to solubility issues or off-target interactions.
* **HBD:** 0 - Good.
* **HBA:** 2 - Good.
* **QED:** 0.552 - Acceptable, but lower than Ligand A.
* **DILI:** 37.999 - Good, relatively low risk of liver injury.
* **BBB:** 88.406 - Very high. Not a primary concern for a cardiovascular target.
* **Caco-2:** -4.324 - Poor permeability.
* **Solubility:** -4.61 - Very poor solubility.
* **hERG:** 0.653 - Moderate risk of hERG inhibition.
* **Cl_mic:** 88.615 - High metabolic clearance, suggesting lower metabolic stability.
* **t1/2:** -25.752 - Very short in vitro half-life.
* **Pgp:** 0.233 - Low P-gp efflux.
* **Affinity:** -5.9 kcal/mol - Good binding affinity, but significantly weaker than Ligand A.
**Comparison and Decision:**
For an ADRB2 target (GPCR, cardiovascular), the key priorities are affinity, logP, TPSA, Pgp, and metabolic stability.
Ligand A has a *much* stronger binding affinity (-7.3 vs -5.9 kcal/mol). This is a substantial advantage. However, its logP is very low, leading to poor predicted permeability and solubility. Ligand B has a higher logP, but it's borderline and comes with solubility concerns. Ligand B also suffers from much higher metabolic clearance and a very short half-life. While Ligand A's logP is a serious issue, the significantly better affinity and excellent metabolic stability are compelling. The poor logP could potentially be addressed through medicinal chemistry optimization, whereas improving a 1.4 kcal/mol affinity difference is often more challenging.
Given the importance of affinity for GPCRs, and the potential to address the logP issue through further optimization, I favor Ligand A.
**Output:**
1
2025-04-17 23:32:44,221 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [346.391, 103.19 , 1.663, 2. , 7. , 0.853, 80.109, 57.542, -4.899, -2.457, 0.068, 21.758, -3.596, 0.005, -6.7 ]**
**Ligand B: [354.422, 67.87 , 1.203, 1. , 4. , 0.728, 27.181, 83.366, -4.869, -1.643, 0.316, -5.326, 3.541, 0.034, -8.5 ]**
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). A (346.391) is slightly lower than B (354.422), which is acceptable.
2. **TPSA:** Ligand A (103.19) is higher than the preferred <140, but still reasonable. Ligand B (67.87) is excellent, well below 140. This favors B.
3. **logP:** Both ligands have good logP values (A: 1.663, B: 1.203) within the 1-3 range. B is slightly lower, but still acceptable.
4. **H-Bond Donors:** A (2) and B (1) are both within the acceptable limit of <=5. B is slightly better.
5. **H-Bond Acceptors:** A (7) and B (4) are both within the acceptable limit of <=10. B is better.
6. **QED:** A (0.853) is better than B (0.728), indicating a more drug-like profile.
7. **DILI:** A (80.109) has a significantly higher DILI risk than B (27.181). This is a major concern for A.
8. **BBB:** B (83.366) has a much higher BBB penetration potential than A (57.542). While ADRB2 isn't strictly a CNS target, better BBB penetration can sometimes indicate better overall distribution and reduced off-target effects.
9. **Caco-2:** Both have negative Caco-2 values which is unusual. Assuming these are logP values, both are similar and indicate good permeability.
10. **Solubility:** Both have negative solubility values which is unusual. Assuming these are logS values, both are similar and indicate poor solubility.
11. **hERG:** A (0.068) is slightly better than B (0.316), indicating lower hERG inhibition risk.
12. **Cl_mic:** B (-5.326) has a significantly lower (better) microsomal clearance than A (21.758), suggesting greater metabolic stability.
13. **t1/2:** B (3.541) has a positive half-life, while A (-3.596) has a negative half-life, which is unusual. B is better.
14. **Pgp:** A (0.005) has a much lower Pgp efflux liability than B (0.034), which is favorable.
15. **Binding Affinity:** B (-8.5) has a significantly stronger binding affinity than A (-6.7). This is a substantial advantage.
**Overall Assessment:**
Ligand B clearly outperforms Ligand A in several crucial areas. The most significant advantages for B are its much lower DILI risk, better metabolic stability (lower Cl_mic, positive t1/2), substantially stronger binding affinity, and better TPSA. While A has a slightly better QED and Pgp efflux, the DILI risk and weaker binding of A are major drawbacks. The higher BBB penetration of B is also a bonus. Given the GPCR target class, affinity and safety (DILI) are paramount.
Output:
0
2025-04-17 23:32:44,221 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (339.479 Da) is slightly lower, which can be favorable for permeability, but both are acceptable.
**2. TPSA:** Ligand A (38.33) is significantly better than Ligand B (96.97). For a GPCR, lower TPSA is generally preferred for better membrane permeability and oral absorption. Ligand B's TPSA is quite high.
**3. logP:** Ligand A (4.772) is a bit high, potentially leading to solubility issues and off-target interactions, but still within a reasonable range. Ligand B (-0.549) is too low, indicating poor membrane permeability.
**4. H-Bond Donors:** Both ligands have acceptable HBD counts (1 and 2, respectively).
**5. H-Bond Acceptors:** Ligand A (2) is better than Ligand B (6). Lower HBA counts generally improve permeability.
**6. QED:** Both ligands have similar and acceptable QED values (0.668 and 0.647).
**7. DILI:** Ligand A (37.03) has a lower DILI risk than Ligand B (48.895), which is preferable.
**8. BBB:** Ligand A (54.983) has a better BBB penetration score than Ligand B (44.552), although neither is exceptionally high. For a cardiovascular target, BBB penetration isn't a primary concern, but it's still a positive attribute.
**9. Caco-2 Permeability:** Ligand A (-4.869) is better than Ligand B (-5.527), indicating better intestinal absorption.
**10. Aqueous Solubility:** Ligand A (-4.994) is better than Ligand B (-1.06), which is crucial for formulation and bioavailability.
**11. hERG Inhibition:** Ligand A (0.871) has a lower hERG inhibition liability than Ligand B (0.133), indicating a lower risk of cardiotoxicity. This is a critical factor for a cardiovascular drug.
**12. Microsomal Clearance:** Ligand A (107.02) has a higher (worse) microsomal clearance than Ligand B (-4.259), suggesting lower metabolic stability.
**13. In vitro Half-Life:** Ligand B (-8.128) has a better in vitro half-life than Ligand A (-3.491).
**14. P-gp Efflux:** Ligand A (0.799) has lower P-gp efflux than Ligand B (0.01), which is favorable for bioavailability.
**15. Binding Affinity:** Ligand A (-8.4 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.6 kcal/mol). This is a substantial advantage.
**Overall Assessment:**
Ligand A is the stronger candidate. While it has a slightly higher logP and clearance, its superior TPSA, solubility, hERG profile, binding affinity, and lower DILI risk outweigh these drawbacks. The significantly stronger binding affinity is a major advantage, and the better ADME properties (TPSA, solubility, hERG, P-gp) are crucial for drug development. Ligand B's very low logP is a significant concern, likely hindering its ability to cross cell membranes.
Output:
1
2025-04-17 23:32:44,221 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (354.422 and 355.366 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (67.87) is significantly better than Ligand B (109.66). ADRB2 is not a CNS target, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold, while Ligand B is approaching it.
3. **logP:** Ligand A (1.039) is within the optimal 1-3 range. Ligand B (-0.892) is slightly below 1, which *could* indicate potential permeability issues, though not drastically.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is preferable to Ligand B (6). Fewer HBAs generally improve permeability.
6. **QED:** Both ligands (0.694 and 0.635) have good drug-likeness scores, exceeding the 0.5 threshold.
7. **DILI:** Ligand A (30.903) has a much lower DILI risk than Ligand B (58.976). This is a significant advantage for Ligand A.
8. **BBB:** This is less critical for ADRB2, but Ligand A (73.129) is better than Ligand B (56.65).
9. **Caco-2:** Ligand A (-4.547) and Ligand B (-5.014) are both negative, indicating poor permeability. However, the scale is not specified, so it's hard to interpret the absolute values.
10. **Solubility:** Ligand A (-1.64) is slightly better than Ligand B (-1.395), but both are poor. Solubility is a concern for both.
11. **hERG:** Ligand A (0.283) is significantly better than Ligand B (0.198), indicating a lower risk of cardiotoxicity, which is *extremely* important for a cardiovascular target.
12. **Cl_mic:** Ligand B (-4.369) has a negative clearance, which suggests very high metabolic stability. Ligand A (16.693) is less stable. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand B (-9.624) has a negative half-life, which suggests very high in vitro stability. Ligand A (-11.384) is also negative, but less stable. This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.051) is better than Ligand B (0.03). Lower Pgp efflux is desirable.
15. **Binding Affinity:** Ligand B (-7.3) has a substantially better binding affinity than Ligand A (-5.6). This is a 1.7 kcal/mol difference, which is a significant advantage that can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand B has a significantly higher binding affinity and better metabolic stability (Cl_mic and t1/2). However, Ligand A has a much better safety profile (DILI, hERG) and better permeability characteristics (TPSA, HBD, HBA). The improved binding affinity of Ligand B is compelling, but the safety concerns with Ligand B are substantial for a cardiovascular target. The hERG risk of Ligand B is particularly concerning.
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity) and the overall balance of properties, Ligand A is the more promising candidate, despite the lower affinity. The improved safety profile and permeability characteristics are more important for a cardiovascular drug than a slight increase in potency.
Output:
1
2025-04-17 23:32:44,221 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (345.33 and 348.45 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (88.43) is slightly higher than Ligand B (76.46). Both are below the 140 threshold for good oral absorption, but closer to the 90 threshold for CNS targets, which isn't a primary concern for ADRB2 (cardiovascular). Ligand B is slightly favored.
3. **logP:** Ligand A (2.662) is within the optimal 1-3 range. Ligand B (1.346) is at the lower end of the range, potentially impacting permeability. Ligand A is favored.
4. **HBD:** Both ligands have 1 HBD, which is good. No difference.
5. **HBA:** Both ligands have 5 HBA, which is good. No difference.
6. **QED:** Both ligands have good QED scores (0.735 and 0.807), indicating good drug-like properties. Ligand B is slightly favored.
7. **DILI:** Ligand A has a significantly higher DILI risk (91.314 percentile) compared to Ligand B (34.471 percentile). This is a major concern for Ligand A. Ligand B is strongly favored.
8. **BBB:** Both ligands have reasonable BBB penetration (63.862 and 73.866 percentile). Since ADRB2 is not a CNS target, this is a lower priority. Ligand B is slightly favored.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-4.139) has worse solubility than Ligand B (-1.969). Solubility is important for bioavailability, so Ligand B is favored.
11. **hERG:** Ligand A (0.652) has a slightly higher hERG inhibition risk than Ligand B (0.352). Lower is better, so Ligand B is favored.
12. **Cl_mic:** Ligand A (80.12) has a higher microsomal clearance than Ligand B (25.866), indicating lower metabolic stability. Ligand B is strongly favored.
13. **t1/2:** Ligand A (59.296) has a longer in vitro half-life than Ligand B (17.147). This is a positive for Ligand A.
14. **Pgp:** Ligand A (0.178) has lower P-gp efflux than Ligand B (0.025), which is favorable. Ligand A is favored.
15. **Binding Affinity:** Ligand A (-7.6 kcal/mol) has a slightly better binding affinity than Ligand B (-7.0 kcal/mol). This is a significant advantage, but needs to be weighed against the ADME drawbacks.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity and Pgp efflux profile, its significantly higher DILI risk, worse metabolic stability (higher Cl_mic), and lower solubility are major drawbacks. Ligand B, despite a slightly weaker binding affinity, presents a much more favorable ADME profile, particularly regarding safety (DILI) and metabolic stability. For a cardiovascular target like ADRB2, minimizing off-target effects and ensuring reasonable metabolic stability are crucial. The 0.6 kcal/mol difference in binding affinity is unlikely to outweigh the substantial ADME advantages of Ligand B.
Output:
0
2025-04-17 23:32:44,221 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (374.522 and 368.419 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (69.64) is significantly better than Ligand B (119.31). ADRB2 is a cardiovascular target, not CNS, but lower TPSA generally aids absorption.
3. **logP:** Ligand A (2.126) is within the optimal 1-3 range. Ligand B (-0.454) is below 1, which could hinder permeation. This is a significant advantage for A.
4. **HBD:** Both ligands have acceptable HBD counts (2 and 1, respectively), well below the threshold of 5.
5. **HBA:** Ligand A (4) is better than Ligand B (9), keeping it closer to the ideal of 10 or less.
6. **QED:** Both ligands have similar, acceptable QED values (0.716 and 0.665), indicating good drug-likeness.
7. **DILI:** Ligand A (23.536) has a much lower DILI risk than Ligand B (70.376). This is a major advantage for A.
8. **BBB:** This is less critical for a cardiovascular target, but Ligand A (78.868) is better than Ligand B (46.413).
9. **Caco-2:** Both have negative values, which is unusual and difficult to interpret without context. However, -5.213 for Ligand A is better than -5.578 for Ligand B.
10. **Solubility:** Ligand A (-3.052) is better than Ligand B (-1.092). Higher solubility is generally preferred.
11. **hERG:** Ligand A (0.556) has a lower hERG risk than Ligand B (0.052). This is a significant safety advantage for A.
12. **Cl_mic:** Ligand A (19.984) has a higher (worse) microsomal clearance than Ligand B (2.785), suggesting faster metabolism. This favors B.
13. **t1/2:** Ligand B (3.543) has a longer in vitro half-life than Ligand A (-0.969). This favors B.
14. **Pgp:** Ligand A (0.207) has lower P-gp efflux than Ligand B (0.016), which is favorable.
15. **Binding Affinity:** Ligand B (-6.1) has a slightly better binding affinity than Ligand A (-5.9), but the difference is small (0.2 kcal/mol).
**Overall Assessment:**
Ligand A has substantial advantages in key ADME properties (logP, TPSA, DILI, hERG, solubility) and Pgp efflux. While Ligand B has slightly better binding affinity and metabolic stability (lower Cl_mic, longer t1/2), the differences in affinity are not large enough to outweigh the significant ADME benefits of Ligand A. For a cardiovascular target, a slight reduction in binding affinity can be tolerated if it leads to a safer, more bioavailable compound. The lower DILI and hERG risks for Ligand A are particularly important.
Output:
1
2025-04-17 23:32:44,221 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [349.435, 107.19 , 0.465, 3. , 4. , 0.602, 31.485, 47.15 , -5.225, -1.386, 0.109, 1.464, -12.312, 0.01 , -6.1 ]
**Ligand B:** [350.329, 108.9 , 0.416, 3. , 6. , 0.625, 67.003, 67.119, -5.193, -2.678, 0.314, 44.309, 15.85 , 0.017, 15.9 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (349-350 Da). No significant difference.
2. **TPSA:** Both are reasonably good (107-109 A^2), slightly above the optimal <140 for oral absorption, but acceptable for a non-CNS GPCR target like ADRB2.
3. **logP:** Both are around 0.4, which is a bit low. Ideally, we want 1-3. This could potentially impact permeability.
4. **HBD:** Both have 3 HBD, which is good.
5. **HBA:** Ligand A has 4 HBA, while Ligand B has 6. Ligand A is slightly better here, as lower HBA generally favors permeability.
6. **QED:** Both are good (0.602 and 0.625), indicating good drug-like properties.
7. **DILI:** Ligand A (31.5%) has a significantly lower DILI risk than Ligand B (67%). This is a major advantage for Ligand A.
8. **BBB:** Both are relatively low (47.15 and 67.12), which is not a primary concern for ADRB2, a cardiovascular target.
9. **Caco-2:** Both are negative, indicating poor permeability. This is a concern for both.
10. **Solubility:** Both are negative, indicating poor solubility. This is a concern for both.
11. **hERG:** Both are very low (0.109 and 0.314), indicating a low risk of hERG inhibition, which is excellent.
12. **Cl_mic:** Ligand A (1.464) has significantly lower microsomal clearance than Ligand B (44.309), suggesting better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand A (-12.312) has a more negative in vitro half-life than Ligand B (15.85), which is not ideal. However, the negative value is likely an artifact of the scale and should be interpreted cautiously.
14. **Pgp:** Both are very low (0.01 and 0.017), indicating low P-gp efflux, which is good.
15. **Binding Affinity:** Ligand A (-6.1 kcal/mol) has a significantly better binding affinity than Ligand B (15.9 kcal/mol). This is a substantial advantage.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, Pgp, TPSA, and affinity. While both have acceptable TPSA and Pgp, Ligand A has a significantly better binding affinity and lower DILI and Cl_mic. The slightly lower logP is a concern for both, but the superior affinity and safety profile of Ligand A outweigh this.
**Conclusion:**
Ligand A is the more promising candidate due to its significantly better binding affinity, lower DILI risk, and improved metabolic stability. While both have issues with logP and Caco-2 permeability, the stronger binding and better safety profile of Ligand A make it the preferred choice.
Output:
1
2025-04-17 23:32:44,221 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (367.559) is slightly higher than Ligand B (346.471), but both are acceptable.
2. **TPSA:** Both ligands have TPSA values below 140, suggesting good oral absorption potential. Ligand A (61.44) is slightly higher than Ligand B (58.64), but both are favorable.
3. **logP:** Both ligands have logP values within the optimal range (1-3). Ligand A (1.728) and Ligand B (2.127) are both good.
4. **HBD:** Ligand A (2) and Ligand B (1) are both within the acceptable limit of <=5. Ligand B is slightly better.
5. **HBA:** Ligand A (4) and Ligand B (3) are both within the acceptable limit of <=10. Ligand B is slightly better.
6. **QED:** Ligand A (0.686) has a better QED score than Ligand B (0.395), indicating a more drug-like profile. This is a significant advantage for Ligand A.
7. **DILI:** Ligand A (15.083) has a much lower DILI risk than Ligand B (8.375). This is a major advantage for Ligand A.
8. **BBB:** Both ligands have good BBB penetration (Ligand A: 78.558, Ligand B: 80.341). Ligand B is slightly better, but both are acceptable for a peripherally acting GPCR like ADRB2.
9. **Caco-2:** Both ligands have negative Caco-2 values, suggesting poor permeability. Ligand A (-5.496) is worse than Ligand B (-4.689).
10. **Solubility:** Both ligands have negative solubility values, indicating poor aqueous solubility. Ligand A (-3.105) is worse than Ligand B (-2.273).
11. **hERG:** Both ligands have low hERG inhibition risk (Ligand A: 0.466, Ligand B: 0.355). Ligand B is slightly better.
12. **Cl_mic:** Ligand B (23.256) has significantly lower microsomal clearance than Ligand A (45.397), suggesting better metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand A (3.14) has a longer in vitro half-life than Ligand B (-1.137). This is a significant advantage for Ligand A.
14. **Pgp:** Both ligands have low P-gp efflux liability (Ligand A: 0.058, Ligand B: 0.122). Ligand A is slightly better.
15. **Binding Affinity:** Ligand B (-6.2 kcal/mol) has a stronger binding affinity than Ligand A (-5.4 kcal/mol). This is a significant advantage for Ligand B (a 0.8 kcal/mol difference).
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, Pgp, TPSA, and affinity. Both ligands perform well on logP and Pgp. TPSA is good for both. Binding affinity is where Ligand B clearly wins. While BBB is important for CNS GPCRs, ADRB2 is primarily cardiovascular, so it is less critical.
**Overall Assessment:**
Ligand B has a significantly better binding affinity and metabolic stability (lower Cl_mic), and a slightly better hERG profile. Ligand A has a better QED score, lower DILI risk, and longer half-life. The affinity difference is substantial (0.8 kcal/mol), and for a GPCR, potency is crucial. The metabolic stability of Ligand B is also very important. While Ligand A's lower DILI is attractive, it can be addressed through further optimization. The poor Caco-2 and solubility for both ligands would require formulation strategies.
Therefore, I favor Ligand B.
Output:
0
2025-04-17 23:32:44,222 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [370.421, 69.64, 2.043, 2, 4, 0.833, 40.054, 82.241, -4.944, -2.759, 0.618, 14.499, -21.057, 0.087, -8.8]
**Ligand B:** [359.461, 58.22, 3.709, 1, 3, 0.693, 27.685, 82.009, -4.723, -2.908, 0.781, 73.627, -9.853, 0.272, -5.9]
Here's a breakdown, prioritizing GPCR-relevant parameters (logP, TPSA, Pgp, BBB, and affinity):
1. **Molecular Weight:** Both are within the ideal range (200-500 Da). Ligand B (359.461) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are acceptable, but Ligand B (58.22) is significantly better than Ligand A (69.64), being closer to the <90 threshold for CNS penetration (though less critical for a cardiovascular target, lower TPSA is still preferred for general absorption).
3. **logP:** Ligand A (2.043) is optimal (1-3). Ligand B (3.709) is pushing the upper limit, potentially increasing off-target effects and decreasing solubility.
4. **H-Bond Donors/Acceptors:** Ligand B has fewer HBD/HBA (1/3) compared to Ligand A (2/4), which is slightly better for permeability.
5. **QED:** Ligand A (0.833) has a better QED score than Ligand B (0.693), indicating a more drug-like profile.
6. **DILI:** Ligand B (27.685) has a significantly lower DILI risk than Ligand A (40.054), a major advantage.
7. **BBB:** Both have high BBB penetration (82.241 and 82.009), which isn't a primary concern for a cardiovascular target, but isn't detrimental.
8. **Caco-2 Permeability:** Both have negative Caco-2 values, which is unusual and potentially indicates issues with the calculation or data quality. However, we can assume similar permeability for both.
9. **Aqueous Solubility:** Both have negative solubility values, which is also unusual. Again, we'll assume similar solubility.
10. **hERG:** Both have low hERG inhibition risk (0.618 and 0.781).
11. **Microsomal Clearance:** Ligand A (14.499) has lower microsomal clearance than Ligand B (73.627), suggesting better metabolic stability.
12. **In vitro Half-Life:** Ligand A (-21.057) has a longer in vitro half-life than Ligand B (-9.853), which is desirable.
13. **P-gp Efflux:** Both have low P-gp efflux liability (0.087 and 0.272).
14. **Binding Affinity:** Ligand A (-8.8) has a significantly stronger binding affinity than Ligand B (-5.9), a difference of 2.9 kcal/mol. This is a substantial advantage.
**Overall Assessment:**
Ligand A has a significantly better binding affinity and metabolic stability (lower Cl_mic, longer t1/2), and a better QED score. However, Ligand B has a lower DILI risk and a more favorable TPSA. The affinity difference is substantial enough to outweigh the slightly higher DILI risk of Ligand A, especially considering the cardiovascular context where BBB penetration isn't paramount. The better metabolic stability of Ligand A is also a significant advantage.
Therefore, I prefer Ligand A.
1
2025-04-17 23:32:44,222 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (389.279 and 377.941 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (75.71) is higher than Ligand B (36.44). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B is significantly better.
3. **logP:** Ligand A (1.342) is within the optimal range (1-3), while Ligand B (3.881) is at the higher end. While still acceptable, higher logP can sometimes lead to off-target effects and solubility issues. Ligand A is slightly preferred.
4. **HBD:** Ligand A (1) and Ligand B (0) are both acceptable.
5. **HBA:** Both ligands have 4 HBA, which is well within the acceptable range.
6. **QED:** Ligand B (0.766) has a better QED score than Ligand A (0.582), indicating a more drug-like profile.
7. **DILI:** Both ligands have very similar, and acceptable, DILI risk (Ligand A: 29.934, Ligand B: 29.585).
8. **BBB:** Ligand B (70.919) has a slightly higher BBB penetration than Ligand A (67.546), which is a positive for GPCRs, although not a primary concern for a cardiovascular target.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.985 and -4.851). These values are difficult to interpret without knowing the scale, but the similarity suggests similar absorption potential.
10. **Solubility:** Both ligands have negative solubility values (-2.978 and -2.9), again making direct comparison difficult.
11. **hERG:** Both ligands have low hERG inhibition liability (Ligand A: 0.268, Ligand B: 0.869), which is excellent. Ligand A is slightly better.
12. **Cl_mic:** Ligand A (17.762) has a significantly lower microsomal clearance than Ligand B (38.874), suggesting better metabolic stability. This is a key advantage.
13. **t1/2:** Ligand A (-7.433) has a more negative in vitro half-life value than Ligand B (11.874). Again, the scale is unknown, but a more negative value might indicate a longer half-life.
14. **Pgp:** Ligand A (0.053) has a much lower P-gp efflux liability than Ligand B (0.503), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand A (-5.6 kcal/mol) has a slightly better binding affinity than Ligand B (-4.4 kcal/mol). This 1.2 kcal/mol difference is substantial and can outweigh minor ADME drawbacks.
**Overall Assessment:**
Ligand A demonstrates a clear advantage in several critical areas: binding affinity, metabolic stability (lower Cl_mic), and P-gp efflux. While Ligand B has a better QED and slightly higher BBB penetration, the stronger binding and improved pharmacokinetic properties of Ligand A are more important for a cardiovascular GPCR target. The TPSA of Ligand B is better, but the difference isn't large enough to overcome the other advantages of Ligand A.
**Output:**
1
2025-04-17 23:32:44,222 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's systematically compare Ligand A and Ligand B against the provided guidelines, keeping in mind ADRB2 is a GPCR and thus we prioritize logP, Pgp, TPSA, and affinity.
1. **MW:** Both ligands (346.45 & 349.39 Da) fall comfortably within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (55.56) is significantly better than Ligand B (111.27). A TPSA under 140 is good for oral absorption, but lower is generally preferred for GPCRs, and A is much closer to the ideal range.
3. **logP:** Ligand A (2.795) is optimal (1-3), while Ligand B (0.103) is quite low, potentially hindering membrane permeability. This is a significant advantage for A.
4. **HBD/HBA:** Ligand A (1 HBD, 3 HBA) is preferable to Ligand B (2 HBD, 8 HBA). While both are within acceptable ranges, fewer H-bonds generally improve permeability.
5. **QED:** Ligand A (0.912) is excellent, indicating strong drug-likeness. Ligand B (0.654) is still acceptable, but less favorable.
6. **DILI:** Ligand B (63.242) has a higher DILI risk than Ligand A (11.128). This is a clear advantage for A.
7. **BBB:** Ligand A (74.098) has a better BBB penetration score than Ligand B (41.566). While ADRB2 isn't necessarily a CNS target, higher BBB is rarely detrimental, and can open up possibilities for future indications.
8. **Caco-2:** Ligand A (-4.605) and Ligand B (-5.001) are both negative, indicating poor permeability.
9. **Solubility:** Ligand A (-2.645) is slightly better than Ligand B (-1.929), indicating better aqueous solubility.
10. **hERG:** Ligand A (0.761) has a lower hERG risk than Ligand B (0.044). This is a significant safety advantage for A.
11. **Cl_mic:** Ligand B (17.034) has a lower microsomal clearance than Ligand A (23.914), suggesting better metabolic stability.
12. **t1/2:** Ligand B (24.738) has a longer in vitro half-life than Ligand A (-10.323). This is a positive for B.
13. **Pgp:** Ligand A (0.168) has a lower P-gp efflux liability than Ligand B (0.193). Lower Pgp is better for bioavailability.
14. **Affinity:** Ligand B (-6.5 kcal/mol) has a slightly better binding affinity than Ligand A (-6.2 kcal/mol). While a difference of 0.3 kcal/mol is not huge, it is a factor.
**Overall Assessment:**
Ligand A is clearly the more promising candidate. While Ligand B has a slightly better affinity and half-life, Ligand A excels in critical ADME properties like logP, TPSA, DILI risk, hERG risk, and BBB penetration. The significantly better logP and TPSA of Ligand A are particularly important for a GPCR target, suggesting better permeability and overall drug-like properties. The lower DILI and hERG risks are also crucial for safety. The slightly weaker affinity can potentially be optimized in subsequent iterations of drug design.
**Output:**
1
2025-04-17 23:32:44,222 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate targeting the ADRB2 receptor:
**Reasoning:**
The ADRB2 receptor is a GPCR, so the priorities are logP, TPSA, Pgp efflux, BBB penetration, and binding affinity. Metabolic stability and solubility are also important, but slightly less so.
Let's compare the ligands property by property:
1. **MW:** Both ligands are within the ideal range (200-500 Da).
2. **TPSA:** Ligand B (83.06) is significantly better than Ligand A (134.68). Lower TPSA is favorable for GPCRs and oral absorption.
3. **logP:** Ligand A (-2.13) is suboptimal, being slightly below the preferred range of 1-3. Ligand B (4.07) is a bit high, but still within an acceptable range.
4. **HBD/HBA:** Ligand A has 4 HBD and 7 HBA, while Ligand B has 0 HBD and 5 HBA. Both are acceptable, but Ligand B's lower HBD count is generally preferred for better membrane permeability.
5. **QED:** Both have relatively low QED scores (A: 0.486, B: 0.384), indicating room for improvement in drug-likeness.
6. **DILI:** Ligand B (33.463) has a much lower DILI risk than Ligand A (51.842). This is a significant advantage.
7. **BBB:** Ligand B (88.329) has much better predicted BBB penetration than Ligand A (4.731). This is highly desirable for a GPCR target.
8. **Caco-2:** Ligand A (-5.745) is poor, while Ligand B (-4.922) is also poor, but slightly better.
9. **Solubility:** Ligand A (-0.877) has slightly better solubility than Ligand B (-4.808).
10. **hERG:** Ligand A (0.101) has a lower hERG risk than Ligand B (0.892). This is a positive for Ligand A.
11. **Cl_mic:** Ligand A (-12.975) has significantly better metabolic stability (lower clearance) than Ligand B (21.015).
12. **t1/2:** Ligand B (10.175) has a longer in vitro half-life than Ligand A (-13.838).
13. **Pgp:** Ligand A (0.009) has much lower P-gp efflux liability than Ligand B (0.332). This is a significant advantage for bioavailability.
14. **Binding Affinity:** Ligand B (-7.2) has a slightly better binding affinity than Ligand A (-6.2). The difference is 0.9 kcal/mol, which is not huge, but noticeable.
**Overall Assessment:**
Ligand B excels in several key areas for a GPCR target: TPSA, BBB penetration, and DILI risk. The slightly better affinity of Ligand B is also a plus. While Ligand A has better P-gp efflux and metabolic stability, the advantages of Ligand B in TPSA, BBB, and DILI, coupled with its reasonable affinity, outweigh these drawbacks. The logP of Ligand B is a minor concern, but manageable.
**Output:**
0
2025-04-17 23:32:44,222 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [342.443, 50.72, 2.875, 0, 6, 0.833, 50.795, 87.553, -4.456, -3.302, 0.831, 51.794, 19.305, 0.149, -6.8]
**Ligand B:** [358.439, 109, -0.678, 3, 5, 0.506, 19.271, 69.523, -5.155, -0.361, 0.091, -2.97, -1.363, 0.001, -6.6]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (342.443) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (50.72) is significantly better than Ligand B (109). A TPSA under 140 is good for oral absorption, but for a GPCR, lower is better, and A is much closer to the ideal range for CNS penetration if that were a goal.
3. **logP:** Ligand A (2.875) is optimal (1-3). Ligand B (-0.678) is too low, potentially hindering membrane permeability and bioavailability.
4. **HBD:** Ligand A (0) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (6) is better than Ligand B (5). Both are acceptable, but lower is preferred.
6. **QED:** Ligand A (0.833) is significantly better than Ligand B (0.506), indicating a more drug-like profile.
7. **DILI:** Ligand A (50.795) is better than Ligand B (19.271), indicating a lower risk of drug-induced liver injury.
8. **BBB:** Ligand A (87.553) is much better than Ligand B (69.523), suggesting better potential for CNS penetration, although this isn't a primary concern for ADRB2 which is primarily cardiovascular.
9. **Caco-2:** Ligand A (-4.456) is better than Ligand B (-5.155), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-3.302) is better than Ligand B (-0.361), indicating better solubility.
11. **hERG:** Ligand A (0.831) is better than Ligand B (0.091), suggesting a lower risk of cardiotoxicity.
12. **Cl_mic:** Ligand A (51.794) is worse than Ligand B (-2.97), indicating lower metabolic stability.
13. **t1/2:** Ligand A (19.305) is better than Ligand B (-1.363), indicating a longer half-life.
14. **Pgp:** Ligand A (0.149) is much better than Ligand B (0.001), suggesting lower P-gp efflux and better bioavailability.
15. **Affinity:** Ligand A (-6.8) is slightly better than Ligand B (-6.6), but the difference is small.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are crucial. Ligand A excels in logP, TPSA, and Pgp, all of which are critical for good pharmacokinetic properties and target engagement. While Ligand B has a reasonable affinity, its poor logP and high TPSA are significant drawbacks. The slightly better metabolic stability of Ligand B is not enough to offset these issues.
**Conclusion:**
Ligand A is the more promising candidate due to its superior physicochemical properties (logP, TPSA, solubility, QED) and lower predicted toxicity (DILI, hERG), and Pgp efflux. The slightly better affinity is a bonus.
```
1
```
2025-04-17 23:32:44,222 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [354.451, 113.76 , 0.498, 3. , 4. , 0.551, 20.279, 73.788, -5.484, -1.853, 0.329, -14.215, 2.826, 0.006, -6. ]
**Ligand B:** [342.531, 41.05 , 4.584, 1. , 4. , 0.736, 39.046, 94.339, -4.776, -5.242, 0.936, 96.116, 61.517, 0.586, -6.1 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (342.531) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (113.76) is higher than Ligand B (41.05). For a GPCR, lower TPSA is preferred, and Ligand B is significantly better here, suggesting better potential for crossing cell membranes.
3. **logP:** Ligand A (0.498) is quite low, potentially hindering membrane permeability. Ligand B (4.584) is high, potentially causing solubility issues and off-target effects, but is within the acceptable range.
4. **HBD:** Ligand A (3) is higher than Ligand B (1). Lower is generally preferred for permeability, making Ligand B better.
5. **HBA:** Both have 4 HBA, which is acceptable.
6. **QED:** Both have good QED scores (A: 0.551, B: 0.736), indicating drug-like properties. Ligand B is better.
7. **DILI:** Ligand A (20.279) has a much lower DILI risk than Ligand B (39.046). This is a significant advantage for Ligand A.
8. **BBB:** Ligand B (94.339) has a much higher BBB penetration potential than Ligand A (73.788). This is a key consideration for GPCRs, and favors Ligand B.
9. **Caco-2:** Ligand A (-5.484) has a worse Caco-2 permeability than Ligand B (-4.776), indicating poorer intestinal absorption.
10. **Solubility:** Ligand A (-1.853) has better solubility than Ligand B (-5.242).
11. **hERG:** Ligand A (0.329) has a lower hERG inhibition liability than Ligand B (0.936), which is a safety advantage.
12. **Cl_mic:** Ligand A (-14.215) has a much lower microsomal clearance than Ligand B (96.116), indicating better metabolic stability.
13. **t1/2:** Ligand B (61.517) has a significantly longer in vitro half-life than Ligand A (2.826). This is a major advantage for Ligand B.
14. **Pgp:** Both have very low Pgp efflux liability (A: 0.006, B: 0.586).
15. **Affinity:** Both have similar binding affinities (-6.0 and -6.1 kcal/mol). The difference is negligible.
**Overall Assessment:**
Ligand B excels in BBB penetration and in vitro half-life, both crucial for a GPCR target. It also has a lower TPSA and HBD count, which are favorable for permeability. However, it has a higher DILI risk and lower solubility. Ligand A has a significantly lower DILI risk, better solubility, and lower hERG risk, but suffers from poor BBB penetration, lower half-life, and a higher TPSA.
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity) and the overall balance, Ligand B is the more promising candidate despite the higher DILI risk. The longer half-life and better BBB penetration outweigh the solubility and DILI concerns, which can be potentially addressed through formulation or further chemical modifications.
Output:
0
2025-04-17 23:32:44,223 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (353.423 and 346.387 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (118.37) is slightly higher than Ligand B (104.39). Both are below the 140 A^2 threshold for good oral absorption, but closer to the 90 A^2 threshold for CNS targets.
3. **logP:** Both ligands have similar logP values (-0.496 and -0.305), falling within the optimal 1-3 range, though on the lower end. This could potentially impact permeability.
4. **HBD:** Ligand A has 3 HBD, while Ligand B has 2. Both are acceptable (<=5).
5. **HBA:** Ligand A has 7 HBA, and Ligand B has 5. Both are acceptable (<=10).
6. **QED:** Ligand B (0.688) has a better QED score than Ligand A (0.515), indicating a more drug-like profile.
7. **DILI:** Both ligands have similar DILI risk (48.468 and 50.33), and are both below the concerning 60 threshold.
8. **BBB:** Ligand A (58.085) has a significantly better BBB penetration score than Ligand B (33.85). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be beneficial or at least needs to be considered.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and likely indicates poor permeability in this assay. Ligand A (-5.319) is slightly worse than Ligand B (-4.82).
10. **Solubility:** Ligand A (-1.033) has slightly better aqueous solubility than Ligand B (-2.582).
11. **hERG:** Both ligands have very low hERG inhibition liability (0.048 and 0.164), which is excellent.
12. **Cl_mic:** Ligand B (-4.862) has a significantly *lower* (better) microsomal clearance than Ligand A (18.911). This suggests better metabolic stability for Ligand B.
13. **t1/2:** Ligand B (-26.21) has a much longer in vitro half-life than Ligand A (3.385). This is a major advantage for Ligand B.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.01 and 0.015).
15. **Binding Affinity:** Ligand A (-6.7 kcal/mol) has a slightly better binding affinity than Ligand B (-5.9 kcal/mol), a difference of 0.8 kcal/mol.
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. While both ligands have acceptable logP and Pgp profiles, Ligand A has a slightly better affinity. However, the significantly improved metabolic stability (Cl_mic and t1/2) of Ligand B, combined with its better QED score, outweigh the small difference in binding affinity. The better BBB penetration of Ligand A is a minor advantage, but not decisive. The Caco-2 values are concerning for both, but the other ADME properties of Ligand B are more favorable.
**Conclusion:**
Considering the balance of properties, Ligand B is the more promising drug candidate due to its superior metabolic stability, longer half-life, and better QED score.
Output:
0
2025-04-17 23:32:44,223 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's systematically compare Ligand A and Ligand B based on the provided parameters and the guidelines, keeping in mind ADRB2 is a GPCR.
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (385.551) is slightly higher than Ligand B (350.375), but both are acceptable.
2. **TPSA:** Ligand A (63.68) is significantly better than Ligand B (113.77). A TPSA under 140 is good for oral absorption, but lower is generally preferred for GPCRs. Ligand B's TPSA is approaching a concerning level.
3. **logP:** Ligand A (3.322) is within the optimal range (1-3), while Ligand B (-0.453) is below 1, which could hinder permeability. This is a significant advantage for Ligand A.
4. **H-Bond Donors:** Ligand A (0) is preferable to Ligand B (2). Fewer H-bond donors generally improve permeability.
5. **H-Bond Acceptors:** Ligand A (5) is better than Ligand B (7). Lower is better for permeability.
6. **QED:** Both ligands have similar QED values (0.676 and 0.64), indicating good drug-likeness.
7. **DILI:** Ligand A (47.77) has a slightly better DILI score than Ligand B (53.858), indicating lower potential for liver injury. Both are acceptable.
8. **BBB:** Ligand A (89.492) is much better than Ligand B (37.301). While ADRB2 isn't necessarily a CNS target, higher BBB penetration can sometimes indicate better overall distribution and reduced off-target effects.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.054 and -5.237). This is unusual and suggests poor permeability, but the values are similar.
10. **Solubility:** Ligand A (-4.01) is better than Ligand B (-1.678), indicating better aqueous solubility.
11. **hERG:** Ligand A (0.438) is much better than Ligand B (0.048). Lower hERG inhibition is crucial for avoiding cardiotoxicity, especially important for a cardiovascular target like ADRB2.
12. **Cl_mic:** Ligand A (72.936) is higher than Ligand B (-10.846). A negative value for Cl_mic indicates *lower* clearance, which is preferable for metabolic stability. Ligand B has a significantly better clearance profile.
13. **t1/2:** Ligand A (-28.358) is worse than Ligand B (-7.974). A less negative value indicates a shorter half-life, which is undesirable. Ligand B has a better in vitro half-life.
14. **Pgp:** Ligand A (0.603) is better than Ligand B (0.006). Lower P-gp efflux is desirable for improved bioavailability.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-7.6 and -7.7 kcal/mol). The difference is negligible.
**Overall Assessment:**
Ligand A is significantly better overall. While Ligand B has a better clearance profile and half-life, Ligand A excels in crucial areas for a GPCR drug candidate: TPSA, logP, hERG inhibition, and BBB penetration. The improved logP and TPSA of Ligand A suggest better permeability, and the lower hERG risk is critical for a cardiovascular target. The slightly better solubility and Pgp efflux also contribute to its favorability. The similar binding affinities mean the ADME properties are the deciding factors.
**Output:**
1
2025-04-17 23:32:44,223 - INFO - Batch 412 complete. Total preferences: 6592
2025-04-17 23:32:44,223 - INFO - Processing batch 413/512...
2025-04-17 23:33:31,798 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.443 & 368.459 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (91.57 & 92.58) are reasonably good, being under 140, but higher than the optimal <90 for CNS targets (though ADRB2 isn't necessarily a CNS target). Again, no major difference.
3. **logP:** Ligand A (2.316) is optimal, while Ligand B (-0.276) is quite low. This is a significant difference. A low logP can indicate poor membrane permeability and bioavailability.
4. **HBD:** Ligand A (3) is good, while Ligand B (0) is also acceptable.
5. **HBA:** Ligand A (4) is good, and Ligand B (6) is also acceptable.
6. **QED:** Both ligands (0.566 & 0.689) have good drug-likeness scores, exceeding the 0.5 threshold. Ligand B is slightly better.
7. **DILI:** Ligand A (18.651) has a much lower DILI risk than Ligand B (45.638). This is a substantial advantage for Ligand A.
8. **BBB:** Ligand B (86.351) has a significantly higher BBB penetration percentile than Ligand A (48.003). While ADRB2 isn't a primary CNS target, some peripheral ADRB2 activity can influence CNS function, and higher BBB penetration isn't necessarily detrimental.
9. **Caco-2:** Both have negative values (-4.991 and -5.017). These values are unusual and likely represent logPapp values, where lower (more negative) values indicate *poorer* permeability. They are similarly poor.
10. **Solubility:** Ligand A (-3.094) has slightly better solubility than Ligand B (-1.244), but both are quite poor.
11. **hERG:** Ligand A (0.118) has a lower hERG risk than Ligand B (0.282), which is preferable.
12. **Cl_mic:** Ligand A (36.986) has a higher microsomal clearance than Ligand B (2.542), indicating lower metabolic stability. This is a significant drawback for Ligand A.
13. **t1/2:** Ligand A (19.997) has a longer in vitro half-life than Ligand B (9.214). This is a positive for Ligand A.
14. **Pgp:** Ligand A (0.064) has lower P-gp efflux liability than Ligand B (0.058), which is slightly better.
15. **Binding Affinity:** Ligand B (-7.2 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.7 kcal/mol). This is a substantial advantage for Ligand B. A 1.5 kcal/mol difference is often enough to outweigh other concerns.
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand B excels in affinity and has a better BBB score. While Ligand A has a lower DILI risk, the significantly superior binding affinity of Ligand B, coupled with acceptable ADME properties, outweighs this benefit. The low logP of Ligand B is a concern, but the strong binding may compensate for reduced permeability. The metabolic instability of Ligand A is also a significant concern.
**Conclusion:**
Despite Ligand A's lower DILI risk and slightly better solubility, Ligand B's significantly stronger binding affinity and better BBB penetration, coupled with acceptable other parameters, make it the more promising drug candidate.
Output:
0
2025-04-17 23:33:31,798 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (345.491) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (77.04) is better than Ligand B (93.01). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (A: 2.304, B: 1.283) within the optimal 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 5 HBA, while Ligand B has 7. Ligand A is slightly better here.
6. **QED:** Ligand A (0.858) has a significantly better QED score than Ligand B (0.641), indicating a more drug-like profile.
7. **DILI:** Ligand A (24.506) has a much lower DILI risk than Ligand B (49.67). This is a significant advantage.
8. **BBB:** Ligand A (81.97) has a higher BBB penetration percentile than Ligand B (41.218). While not crucial for a cardiovascular target, it doesn't hurt.
9. **Caco-2:** Ligand A (-4.933) has a better Caco-2 permeability than Ligand B (-5.719).
10. **Solubility:** Ligand A (-2.448) has better solubility than Ligand B (-0.464).
11. **hERG:** Both ligands have low hERG inhibition liability (A: 0.343, B: 0.254).
12. **Cl_mic:** Ligand B (24.75) has a slightly lower microsomal clearance than Ligand A (29.298), suggesting better metabolic stability. However, the difference isn't huge.
13. **t1/2:** Ligand B (10.029) has a slightly longer half-life than Ligand A (12.129).
14. **Pgp:** Both ligands have low P-gp efflux liability (A: 0.293, B: 0.064). Ligand B is slightly better.
15. **Affinity:** Ligand B (-7.9) has a slightly better binding affinity than Ligand A (-8.2). However, the difference is small (0.3 kcal/mol).
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A is better in logP, TPSA, and Pgp. The affinity difference is minimal.
**Overall Assessment:**
Ligand A demonstrates a superior overall profile. It has a better QED score, significantly lower DILI risk, better solubility, permeability, and TPSA. While Ligand B has slightly better metabolic stability and affinity, the advantages of Ligand A in ADME properties and safety outweigh these minor differences. The small affinity difference is unlikely to be clinically significant given the other benefits of Ligand A.
**Output:**
1
2025-04-17 23:33:31,799 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.399 and 347.415 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (93.71) is better than Ligand B (100.55). Both are acceptable for a non-CNS GPCR like ADRB2, but lower is generally preferred.
3. **logP:** Ligand A (2.113) is optimal, while Ligand B (0.638) is a bit low, potentially hindering membrane permeability. This is a significant advantage for A.
4. **HBD:** Ligand A (2) is preferable to Ligand B (3). Lower HBD generally improves permeability.
5. **HBA:** Both ligands have 5 HBA, which is acceptable.
6. **QED:** Both ligands have similar QED scores (0.762 and 0.726), indicating good drug-likeness.
7. **DILI:** Ligand B (37.069) has a considerably lower DILI risk than Ligand A (53.936). This is a strong advantage for B.
8. **BBB:** This is less critical for ADRB2 (a cardiovascular target), but Ligand B (57.193) is slightly better than Ligand A (48.352).
9. **Caco-2:** Ligand A (-4.854) is better than Ligand B (-5.1), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-2.731) is better than Ligand B (-1.456), indicating better aqueous solubility.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.319 and 0.111), which is excellent.
12. **Cl_mic:** Ligand B (-8.08) has a significantly *lower* (better) microsomal clearance than Ligand A (52.941), suggesting greater metabolic stability. This is a major advantage for B.
13. **t1/2:** Ligand B (7.432) has a much longer in vitro half-life than Ligand A (28.92), which is a significant benefit.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.137 and 0.006), which is good.
15. **Binding Affinity:** Ligand B (-6.1) has a slightly better binding affinity than Ligand A (-5.0). This is a 1.1 kcal/mol difference, which is substantial enough to be a key factor.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A has better logP and TPSA, but Ligand B has better affinity, Pgp, and crucially, much better metabolic stability (Cl_mic and t1/2). While the DILI risk is higher for A, the metabolic stability of B is a more significant concern for *in vivo* efficacy. The affinity difference is also substantial.
**Conclusion:**
Considering the balance of properties, especially the superior metabolic stability and binding affinity of Ligand B, I believe it is the more promising drug candidate for the ADRB2 receptor.
Output:
0
2025-04-17 23:33:31,799 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (347.459) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (49.41) is significantly better than Ligand A (75.44). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (A: 2.541, B: 3.082), falling within the optimal 1-3 range. Ligand B is slightly higher, which could potentially lead to some off-target interactions, but isn't a major concern.
4. **HBD:** Both ligands have 1 HBD, which is acceptable.
5. **HBA:** Ligand A has 4 HBAs, and Ligand B has 3. Both are within the acceptable limit of 10.
6. **QED:** Both ligands have high QED scores (A: 0.822, B: 0.847), indicating good drug-like properties.
7. **DILI:** Ligand B (19.465) has a much lower DILI risk than Ligand A (35.789). This is a significant advantage.
8. **BBB:** Both ligands have similar BBB penetration (A: 76.696, B: 77.433). This isn't a major factor for a cardiovascular target.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and indicates very poor permeability. This is a major red flag for both.
10. **Solubility:** Both ligands have negative solubility values, indicating very poor aqueous solubility. This is also a major red flag for both.
11. **hERG:** Ligand A (0.314) has a slightly lower hERG risk than Ligand B (0.508), which is preferable.
12. **Cl_mic:** Ligand B (55.623) has slightly lower microsomal clearance than Ligand A (58.275), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-7.166) has a significantly longer in vitro half-life than Ligand A (-3.595). This is a major advantage.
14. **Pgp:** Both ligands have low Pgp efflux liability (A: 0.321, B: 0.29).
15. **Binding Affinity:** Ligand B (-4.7 kcal/mol) has a slightly better binding affinity than Ligand A (-6.5 kcal/mol). This is a significant advantage.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand B performs better on TPSA, affinity, and has a slight edge on logP. The significantly lower DILI risk and longer half-life of Ligand B are also major positives. The poor Caco-2 and solubility are concerning for both, but the other advantages of Ligand B outweigh the slightly better hERG profile of Ligand A.
**Conclusion:**
Despite the poor Caco-2 and solubility for both, Ligand B is the more promising candidate due to its superior DILI profile, longer half-life, and better binding affinity.
Output:
0
2025-04-17 23:33:31,799 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (348.49 & 349.44 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (67.43) is significantly better than Ligand B (91.57). For a GPCR, lower TPSA is generally preferred for better permeability. Ligand B is pushing the 140 limit, while A is well below.
**3. logP:** Ligand A (3.91) is good, within the optimal 1-3 range. Ligand B (0.45) is quite low, potentially hindering membrane permeability and bioavailability. This is a substantial negative for B.
**4. H-Bond Donors:** Ligand A (2) and Ligand B (1) are both acceptable, below the threshold of 5.
**5. H-Bond Acceptors:** Ligand A (3) and Ligand B (6) are both acceptable, below the threshold of 10.
**6. QED:** Both ligands have good QED values (0.673 and 0.733), indicating generally drug-like properties.
**7. DILI Risk:** Ligand A (39.59%) has a slightly higher DILI risk than Ligand B (28.19%), but both are below the concerning 60% threshold.
**8. BBB Penetration:** Ligand B (81.47%) shows better BBB penetration than Ligand A (69.45%). However, since ADRB2 is primarily a cardiovascular target, high BBB penetration is not a critical priority.
**9. Caco-2 Permeability:** Ligand A (-4.51) is better than Ligand B (-5.34), indicating better intestinal absorption.
**10. Aqueous Solubility:** Ligand A (-4.26) is better than Ligand B (-1.63), which is important for formulation and bioavailability.
**11. hERG Inhibition:** Ligand A (0.83) is better than Ligand B (0.091), indicating a lower risk of cardiotoxicity. This is *very* important for a cardiovascular target.
**12. Microsomal Clearance:** Ligand B (13.32) has significantly lower microsomal clearance than Ligand A (87.01), suggesting better metabolic stability. This is a positive for B.
**13. In vitro Half-Life:** Ligand A (17.76) has a longer half-life than Ligand B (-2.86), which is preferable.
**14. P-gp Efflux:** Ligand A (0.354) has lower P-gp efflux than Ligand B (0.026), which is better for bioavailability.
**15. Binding Affinity:** Ligand B (-0.0 kcal/mol) has a much weaker binding affinity than Ligand A (-5.7 kcal/mol). This is a decisive advantage for A.
**Overall Assessment:**
While Ligand B has better metabolic stability and BBB penetration, these are less critical for a cardiovascular GPCR target. Ligand A excels in key areas: logP, TPSA, Caco-2 permeability, solubility, hERG inhibition, binding affinity, and half-life. The significantly stronger binding affinity of Ligand A (-5.7 kcal/mol vs -0.0 kcal/mol) is a major advantage that outweighs the slightly higher DILI risk and lower metabolic stability. The low logP of Ligand B is a significant concern.
Output:
1
2025-04-17 23:33:31,799 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [362.451, 96.1, 1.892, 2, 4, 0.82, 66.421, 61.497, -5.256, -3.521, 0.321, 8.676, 27.357, 0.11, -8]**
**Ligand B: [344.423, 118.01, 0.36, 3, 9, 0.687, 58.705, 58.123, -5.639, -2.161, 0.458, 16.42, 2.819, 0.008, -7]**
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand B (344.423 Da) is slightly lower, which could be beneficial for permeability, but both are acceptable.
2. **TPSA:** Ligand A (96.1) is better than Ligand B (118.01). ADRB2 is not a CNS target, but lower TPSA generally improves absorption.
3. **logP:** Ligand A (1.892) is optimal, while Ligand B (0.36) is quite low. This is a significant drawback for Ligand B, potentially hindering membrane permeability and bioavailability.
4. **H-Bond Donors:** Ligand A (2) is better than Ligand B (3). Lower is generally preferred.
5. **H-Bond Acceptors:** Ligand A (4) is better than Ligand B (9). Lower is generally preferred.
6. **QED:** Ligand A (0.82) is significantly better than Ligand B (0.687), indicating a more drug-like profile.
7. **DILI:** Ligand B (58.705) is better than Ligand A (66.421), indicating lower potential for liver injury. This is a positive for Ligand B.
8. **BBB:** Not a primary concern for ADRB2, but Ligand A (61.497) is slightly better than Ligand B (58.123).
9. **Caco-2 Permeability:** Both are negative, indicating poor permeability. Ligand A (-5.256) is slightly better than Ligand B (-5.639), but both are concerning.
10. **Aqueous Solubility:** Ligand B (-2.161) is better than Ligand A (-3.521).
11. **hERG Inhibition:** Ligand A (0.321) is better than Ligand B (0.458), indicating a lower risk of cardiotoxicity. This is crucial for a cardiovascular target.
12. **Microsomal Clearance:** Ligand A (8.676) is significantly better than Ligand B (16.42), suggesting better metabolic stability.
13. **In vitro Half-Life:** Ligand A (27.357) is significantly better than Ligand B (2.819), indicating a longer half-life and potentially less frequent dosing.
14. **P-gp Efflux:** Ligand A (0.11) is better than Ligand B (0.008), indicating less P-gp efflux and potentially better bioavailability.
15. **Binding Affinity:** Ligand A (-8) is slightly better than Ligand B (-7). While the difference is small, it's still a factor.
**Overall Assessment:**
Ligand A has a significantly better profile overall. Its superior logP, QED, metabolic stability (Cl_mic and t1/2), lower P-gp efflux, and slightly better affinity outweigh the slightly higher DILI risk. Ligand B's low logP is a major concern, potentially leading to poor absorption and bioavailability. While Ligand B has better solubility and lower DILI, these are less critical than the ADME properties impacting drug exposure. Given the GPCR nature of the target, optimizing logP and metabolic stability are crucial.
Output:
1
2025-04-17 23:33:31,799 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (362.495 Da and 349.431 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (58.64) is well below the 140 threshold and is favorable. Ligand B (104.37) is higher, but still within an acceptable range for oral absorption, though less optimal.
**3. logP:** Ligand A (3.37) is within the optimal 1-3 range. Ligand B (0.798) is a bit low, potentially hindering membrane permeability.
**4. H-Bond Donors:** Ligand A (1) is good. Ligand B (3) is acceptable, but higher.
**5. H-Bond Acceptors:** Both ligands have 4 H-bond acceptors, which is within the acceptable range.
**6. QED:** Ligand A (0.893) has a very good drug-likeness score. Ligand B (0.325) is significantly lower, indicating a less drug-like profile.
**7. DILI Risk:** Ligand A (51.687) has a moderate DILI risk, acceptable. Ligand B (34.781) has a lower DILI risk, which is a positive.
**8. BBB Penetration:** Ligand A (86.545) shows good BBB penetration, which is beneficial for a GPCR target. Ligand B (77.084) is lower, but not a major concern for a cardiovascular target.
**9. Caco-2 Permeability:** Ligand A (-4.935) and Ligand B (-5.319) both have negative values, which is unusual. These values likely represent a scaled or transformed metric where lower values indicate *higher* permeability. Both appear to have good permeability.
**10. Aqueous Solubility:** Ligand A (-3.836) and Ligand B (-2.656) have negative values, indicating high solubility.
**11. hERG Inhibition:** Ligand A (0.47) has a low hERG risk, which is excellent. Ligand B (0.068) also has a very low hERG risk.
**12. Microsomal Clearance:** Ligand A (18.2) has lower clearance, suggesting better metabolic stability. Ligand B (26.254) has higher clearance.
**13. In vitro Half-Life:** Ligand A (8.404) has a longer half-life than Ligand B (-3.872).
**14. P-gp Efflux:** Ligand A (0.204) has lower P-gp efflux, which is favorable. Ligand B (0.021) also has very low P-gp efflux.
**15. Binding Affinity:** Ligand A (-7.0) has slightly better binding affinity than Ligand B (-6.6). While the difference is not huge, it is above the 1.5 kcal/mol threshold where it can outweigh other factors.
**GPCR-Specific Considerations:** For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are crucial. Ligand A has a better logP, TPSA, and affinity. The QED score of Ligand A is also significantly better.
**Conclusion:**
Considering the balance of properties, particularly the superior QED, logP, TPSA, and slightly better affinity, Ligand A is the more promising drug candidate.
1
2025-04-17 23:33:31,800 - INFO - Here's my reasoning and the final output:
**Reasoning:**
We are evaluating two ligands for the ADRB2, a cardiovascular GPCR. Therefore, the most important parameters are binding affinity, logP, TPSA, Pgp efflux, and to a lesser extent, BBB. Metabolic stability (Cl_mic, t1/2) and safety (DILI, hERG) are also important considerations.
Let's compare the ligands property by property:
1. **MW:** Both ligands (349.431 and 347.463 Da) are within the ideal range (200-500 Da).
2. **TPSA:** Ligand A (95.67) is slightly higher than Ligand B (80.12). Both are acceptable, but Ligand B is preferable as it's closer to the <140 target for good absorption.
3. **logP:** Both ligands have good logP values (1.389 and 1.458), falling within the optimal 1-3 range.
4. **HBD:** Ligand A has 2 HBD, while Ligand B has 1. Lower is generally better for permeability, so Ligand B is slightly favored.
5. **HBA:** Both have 5 HBA, which is acceptable.
6. **QED:** Both ligands have high QED scores (0.837 and 0.845), indicating good drug-like properties.
7. **DILI:** Ligand A (29.042) has a significantly lower DILI risk than Ligand B (41.062). This is a substantial advantage for Ligand A.
8. **BBB:** Ligand B (68.67) has a higher BBB percentile than Ligand A (51.919). While ADRB2 is cardiovascular, some CNS penetration can be acceptable or even desirable for off-target effects assessment.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-5.078) is slightly better than Ligand B (-5.334).
10. **Solubility:** Both have negative solubility values, which is also unusual and suggests poor solubility. Ligand A (-1.266) is slightly better than Ligand B (-1.984).
11. **hERG:** Both have very low hERG inhibition liability (0.099 and 0.171), which is excellent.
12. **Cl_mic:** Ligand A (2.352) has a much lower microsomal clearance than Ligand B (16.126), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (8.782) has a longer in vitro half-life than Ligand B (-8.906). The negative value for Ligand B is concerning.
14. **Pgp:** Both have very low Pgp efflux liability (0.064 and 0.032), which is excellent.
15. **Binding Affinity:** Ligand B (-7.9) has a slightly better binding affinity than Ligand A (-7.7), but the difference is small (0.2 kcal/mol).
**Overall Assessment:**
Ligand A is the more promising candidate. While Ligand B has a slightly better binding affinity and BBB penetration, Ligand A excels in critical ADME-Tox properties. Specifically, the significantly lower DILI risk, much better metabolic stability (lower Cl_mic and longer t1/2), and slightly better Caco-2 and solubility values outweigh the small difference in binding affinity. The negative values for Caco-2 and solubility are concerning for both, but Ligand A is still better. For a cardiovascular target, minimizing liver toxicity and maximizing metabolic stability are crucial.
Output:
1
2025-04-17 23:33:31,800 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 drug candidates. ADRB2 is a GPCR, so we'll prioritize logP, TPSA, Pgp, BBB, and affinity.
**Ligand A:**
* **MW:** 340.39 Da - Good. Within the ideal range.
* **TPSA:** 103.87 - Acceptable, but approaching the upper limit for good absorption.
* **logP:** 0.998 - Slightly low, could potentially impact permeability.
* **HBD:** 2 - Good.
* **HBA:** 5 - Good.
* **QED:** 0.864 - Excellent. Highly drug-like.
* **DILI:** 64.52 - Moderate risk. Not ideal, but manageable.
* **BBB:** 54.01 - Moderate. Not particularly high, but not a major concern for a non-CNS target.
* **Caco-2:** -5.284 - Very poor permeability. A significant drawback.
* **Solubility:** -3.182 - Poor solubility. A significant drawback.
* **hERG:** 0.135 - Low risk. Excellent.
* **Cl_mic:** 15.22 - Moderate clearance. Not ideal, but not terrible.
* **t1/2:** -10.197 - Very short half-life. A major concern.
* **Pgp:** 0.027 - Low efflux. Good.
* **Affinity:** -6.8 kcal/mol - Good binding affinity.
**Ligand B:**
* **MW:** 361.47 Da - Good. Within the ideal range.
* **TPSA:** 80.32 - Excellent. Well below the 140 threshold.
* **logP:** 2.086 - Optimal.
* **HBD:** 2 - Good.
* **HBA:** 5 - Good.
* **QED:** 0.679 - Good. Drug-like.
* **DILI:** 50.49 - Moderate risk. Better than Ligand A.
* **BBB:** 52.81 - Moderate. Similar to Ligand A.
* **Caco-2:** -5.355 - Very poor permeability. A significant drawback, similar to Ligand A.
* **Solubility:** -1.97 - Poor solubility. A significant drawback, similar to Ligand A.
* **hERG:** 0.263 - Low risk. Excellent.
* **Cl_mic:** 30.32 - Higher clearance than Ligand A. Less desirable.
* **t1/2:** 29.82 - Long half-life. Excellent.
* **Pgp:** 0.094 - Low efflux. Good.
* **Affinity:** -7.1 kcal/mol - Excellent binding affinity. 0.3 kcal/mol better than Ligand A.
**Comparison & Decision:**
Both ligands have significant issues with Caco-2 permeability and aqueous solubility. However, Ligand B has a substantially better binding affinity (-7.1 vs -6.8 kcal/mol), a longer half-life (29.82 vs -10.197), and a slightly lower DILI risk. The affinity difference is significant enough to potentially overcome the permeability/solubility issues, as optimization efforts could focus on improving those properties without sacrificing binding. The longer half-life is also a major advantage. While both have poor permeability and solubility, these are properties that are more readily optimized through medicinal chemistry efforts than binding affinity.
Therefore, I prefer Ligand B.
Output:
0
2025-04-17 23:33:31,800 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**1. Molecular Weight:** Both ligands (346.475 Da and 351.491 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (76.02) is better than Ligand B (81.67). Both are below 140, but lower TPSA generally favors better absorption.
**3. logP:** Ligand A (1.966) is slightly better than Ligand B (0.89). Both are within the optimal range of 1-3, but Ligand B is closer to the lower limit, potentially impacting membrane permeability.
**4. H-Bond Donors:** Ligand A (2) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
**5. H-Bond Acceptors:** Both ligands have 4 HBA, which is acceptable.
**6. QED:** Both ligands have similar QED values (0.671 and 0.607), indicating good drug-likeness.
**7. DILI:** Ligand A (25.126) is *significantly* better than Ligand B (6.669). A lower DILI percentile is crucial for safety. This is a major advantage for Ligand A.
**8. BBB:** Both ligands have reasonable BBB penetration (61.109 and 68.321). Since ADRB2 is a cardiovascular target, BBB penetration is not a primary concern, but higher is not detrimental.
**9. Caco-2 Permeability:** Ligand A (-4.852) is better than Ligand B (-5.454). Higher (less negative) Caco-2 values indicate better absorption.
**10. Aqueous Solubility:** Ligand A (-2.134) is better than Ligand B (-1.382). Higher solubility is generally desirable.
**11. hERG Inhibition:** Ligand A (0.112) is preferable to Ligand B (0.416). Lower hERG inhibition is critical for avoiding cardiotoxicity, especially important for a cardiovascular target.
**12. Microsomal Clearance:** Ligand B (-9.024) is *much* better than Ligand A (39.744). Lower clearance indicates greater metabolic stability, which is a significant advantage.
**13. In vitro Half-Life:** Ligand B (7.072) is significantly better than Ligand A (-2.88). A longer half-life is generally desirable.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.021 and 0.018), which is good.
**15. Binding Affinity:** Ligand B (-6.9) is slightly better than Ligand A (-5.6). A difference of 1.3 kcal/mol is substantial and could outweigh some ADME drawbacks.
**Overall Assessment:**
While Ligand B has a better binding affinity and significantly improved metabolic stability and half-life, Ligand A has a much better safety profile (DILI and hERG) and slightly better absorption properties (Caco-2, solubility). Given that ADRB2 is a cardiovascular target, minimizing cardiotoxicity (hERG) and liver toxicity (DILI) are paramount. The affinity difference, while noticeable, is not so large as to completely negate the safety advantages of Ligand A. Considering the GPCR-specific priorities, the safety profile of Ligand A is more compelling.
Output:
1
2025-04-17 23:33:31,800 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [361.398, 85.2, 2.958, 1, 7, 0.68, 89.415, 66.305, -4.642, -3.719, 0.351, 85.639, -11.136, 0.304, -7.6]
**Ligand B:** [369.531, 91.32, 2.447, 3, 5, 0.623, 41.877, 12.447, -5.088, -2.928, 0.299, 33.129, 32.506, 0.138, -7.8]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, BBB, and affinity are key):
1. **MW:** Both are within the ideal 200-500 Da range. A (361.398) is slightly preferred.
2. **TPSA:** A (85.2) is better than B (91.32). Both are below 140, but closer to 90 is better for GPCRs, and A is closer.
3. **logP:** Both are good (between 1-3). A (2.958) is slightly higher, which is generally favorable for membrane permeability.
4. **HBD/HBA:** A (1 HBD, 7 HBA) is better than B (3 HBD, 5 HBA). Lower HBD is generally preferred.
5. **QED:** Both are acceptable (0.68 and 0.623), indicating reasonable drug-likeness.
6. **DILI:** A (89.415) is significantly *worse* than B (41.877). This is a major concern for A.
7. **BBB:** A (66.305) is much better than B (12.447). While not strictly required for ADRB2, higher BBB is always a plus, indicating potentially better distribution.
8. **Caco-2:** A (-4.642) is better than B (-5.088), indicating better intestinal absorption.
9. **Solubility:** A (-3.719) is better than B (-2.928).
10. **hERG:** Both are low risk (0.351 and 0.299).
11. **Cl_mic:** A (85.639) is worse than B (33.129), indicating faster metabolism and potentially lower exposure.
12. **t1/2:** A (-11.136) is worse than B (32.506), indicating a shorter half-life.
13. **Pgp:** A (0.304) is better than B (0.138), indicating lower P-gp efflux.
14. **Affinity:** B (-7.8) is slightly better than A (-7.6), but the difference is small.
**Overall Assessment:**
Ligand B has a much better safety profile (DILI) and metabolic stability (Cl_mic, t1/2). While Ligand A has some advantages in BBB and Caco-2, the significantly higher DILI risk and poorer metabolic stability are major drawbacks. The slight affinity difference is not enough to overcome these issues. For a cardiovascular target, minimizing off-target effects and ensuring reasonable metabolic stability are crucial.
Output:
0
2025-04-17 23:33:31,800 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (380.86 and 364.32 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (92.09) is better than Ligand B (107.43). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (3.174) is within the optimal 1-3 range. Ligand B (-0.672) is significantly lower, potentially hindering membrane permeability and absorption. This is a substantial negative for Ligand B.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (6). Fewer HBAs generally improve permeability.
6. **QED:** Both ligands (0.686 and 0.657) have good drug-likeness scores, exceeding the 0.5 threshold.
7. **DILI:** Both ligands have relatively high DILI risk (77.78 and 72.01). This is a concern for both, but not a deciding factor *between* them.
8. **BBB:** Ligand A (57.19) is better than Ligand B (45.91), but this isn't a critical factor for a cardiovascular target.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.039 and -5.288), which is unusual and suggests poor permeability. This is a significant issue for both.
10. **Solubility:** Ligand A (-4.876) is slightly better than Ligand B (-2.408), but both are poor. Solubility is a concern for both, but can be addressed with formulation strategies.
11. **hERG:** Both ligands have very low hERG risk (0.368 and 0.317). This is excellent for both.
12. **Cl_mic:** Ligand A (56.24) is better than Ligand B (-11.16). A negative value suggests *very* high metabolic stability, which is a huge advantage for Ligand B.
13. **t1/2:** Ligand A (-11.56) is better than Ligand B (-16.87). A less negative value suggests a longer in vitro half-life.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.11 and 0.016).
15. **Binding Affinity:** Ligand B (-6.8 kcal/mol) has a significantly stronger binding affinity than Ligand A (-2.2 kcal/mol). This is a >1.5 kcal/mol advantage, which is a major factor.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, and affinity are key. Ligand B's superior affinity is a huge advantage, potentially outweighing its lower logP. However, the very low logP is a significant concern. Ligand A has a better logP and TPSA.
**Overall Assessment:**
While Ligand B has a substantially better binding affinity, its significantly lower logP is a major drawback. The negative Caco-2 values for both are concerning, but the affinity difference is large enough to make Ligand B the more promising candidate *if* the logP issue can be addressed through structural modifications. Ligand A is more balanced, but lacks the potency of Ligand B.
Output:
0
2025-04-17 23:33:31,801 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (359.853 and 365.375 Da) fall comfortably within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (58.56) is slightly higher than Ligand B (56.07). Both are below the 140 threshold for good absorption, and acceptable for a cardiovascular target (not CNS).
3. **logP:** Ligand A (4.08) is slightly higher than Ligand B (2.698). While both are within the optimal 1-3 range, Ligand A is pushing the upper limit. Ligand B is better positioned.
4. **HBD:** Ligand A (2) is better than Ligand B (0). Having some HBD can aid solubility.
5. **HBA:** Ligand A (3) is lower than Ligand B (6). Lower HBA is generally preferred for better permeability. Ligand A is better here.
6. **QED:** Both ligands have similar QED values (0.783 and 0.751), indicating good drug-likeness.
7. **DILI:** Ligand B (35.867) has a significantly lower DILI risk than Ligand A (50.136). This is a major advantage for Ligand B.
8. **BBB:** Ligand B (95.308) has a much higher BBB penetration percentile than Ligand A (43.273). While ADRB2 isn't primarily a CNS target, some BBB penetration can be beneficial for off-target effects and distribution.
9. **Caco-2:** Both ligands have very similar, and poor, Caco-2 permeability (-4.656 and -4.646). This suggests potential absorption issues.
10. **Solubility:** Ligand B (-3.505) is better than Ligand A (-4.707), indicating better aqueous solubility.
11. **hERG:** Both ligands have similar hERG inhibition liability (0.473 and 0.595). This is acceptable, but monitoring is still needed.
12. **Cl_mic:** Ligand B (24.522) has a lower microsomal clearance than Ligand A (33.982), suggesting better metabolic stability.
13. **t1/2:** Ligand A (56.35) has a much longer in vitro half-life than Ligand B (-4.014). This is a significant advantage for Ligand A, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.416) has lower P-gp efflux liability than Ligand B (0.215). Lower Pgp is generally preferred.
15. **Affinity:** Ligand A (-7.4 kcal/mol) has a significantly stronger binding affinity than Ligand B (-5.6 kcal/mol). This is a substantial advantage, potentially outweighing some ADME drawbacks.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand A has a slightly higher logP, lower Pgp, and *much* better affinity. Ligand B has better solubility, lower DILI, and higher BBB. The affinity difference is substantial (>1.5 kcal/mol), and the longer half-life of Ligand A is also a strong positive. While Ligand B's lower DILI is attractive, the potency advantage of Ligand A is more crucial for a GPCR target.
**Conclusion:**
Despite Ligand B's better safety profile (lower DILI) and solubility, Ligand A's significantly higher binding affinity and longer half-life make it the more promising drug candidate for ADRB2.
Output:
1
2025-04-17 23:33:31,801 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (363.483 and 364.372 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (71.53) is significantly better than Ligand B (93.96). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (1.694) is better than Ligand B (0.603). Both are within the acceptable range (1-3), but Ligand A is closer to the optimal value. Ligand B is getting a bit low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (7). Similar reasoning as HBD.
6. **QED:** Ligand A (0.808) is better than Ligand B (0.656). Higher QED indicates a more drug-like profile.
7. **DILI:** Both ligands have similar, acceptable DILI risk (47.926 vs 49.632).
8. **BBB:** Ligand B (90.112) has a much higher BBB penetration score than Ligand A (55.332). While not a primary concern for a cardiovascular target, it's a slight advantage for Ligand B.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual. It's difficult to interpret without knowing the scale, but it suggests poor permeability for both.
10. **Solubility:** Ligand A (-1.713) is better than Ligand B (-2.062). Higher solubility is generally preferred.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.121 and 0.144). This is excellent.
12. **Cl_mic:** Ligand A (32.663) has a significantly better (lower) microsomal clearance than Ligand B (14.182). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (18.548) has a much longer in vitro half-life than Ligand B (-5.083). This is a significant advantage for Ligand A, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.055 and 0.056).
15. **Binding Affinity:** Ligand A (-7.5 kcal/mol) has a stronger binding affinity than Ligand B (-6.7 kcal/mol). This is a 0.8 kcal/mol difference, which is substantial and can outweigh some ADME drawbacks.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A excels in logP, TPSA, and significantly in affinity. While Ligand B has better BBB penetration, this is less crucial for a cardiovascular target. The superior metabolic stability (Cl_mic and t1/2) of Ligand A is also highly desirable.
**Conclusion:**
Ligand A demonstrates a more favorable balance of properties, particularly its superior binding affinity, metabolic stability, and drug-likeness. The slightly lower TPSA and better logP also contribute to its preference.
Output:
1
2025-04-17 23:33:31,801 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (353.5 & 361.4 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (70.67) is higher than Ligand B (34.84). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is generally preferred for absorption. Ligand B is significantly better here.
3. **logP:** Ligand A (1.544) is within the optimal range (1-3), while Ligand B (3.99) is approaching the upper limit. This favors Ligand A slightly, as high logP can lead to off-target effects.
4. **HBD:** Ligand A (2) is reasonable, while Ligand B (0) is also acceptable.
5. **HBA:** Both ligands have 4 HBA, which is within the acceptable range.
6. **QED:** Ligand A (0.681) is slightly better than Ligand B (0.59), indicating a more drug-like profile.
7. **DILI:** Ligand A (16.712) has a lower DILI risk than Ligand B (20.396), which is a significant advantage.
8. **BBB:** Ligand B (96.045) has a much higher BBB penetration score than Ligand A (68.282). While ADRB2 isn't a primary CNS target, some brain exposure can contribute to side effects. This is a point for Ligand B.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.828) is slightly better than Ligand B (-4.63).
10. **Solubility:** Ligand A (-1.311) has better solubility than Ligand B (-3.209). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.31) has a lower hERG risk than Ligand B (0.983). This is a critical safety parameter, favoring Ligand A.
12. **Cl_mic:** Ligand B (20.201) has lower microsomal clearance than Ligand A (26.93), indicating better metabolic stability. This is a positive for Ligand B.
13. **t1/2:** Ligand B (66.007) has a significantly longer in vitro half-life than Ligand A (-13.18). This is a major advantage for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.041) has lower P-gp efflux than Ligand B (0.549), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand B (-7.6 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.6 kcal/mol). This is a substantial advantage, potentially outweighing some ADME drawbacks.
**Overall Assessment:**
Ligand B has a superior binding affinity and a longer half-life, which are crucial for a GPCR target. While its logP is higher and TPSA lower, the affinity difference is significant. The improved metabolic stability (lower Cl_mic) is also a plus. Ligand A has better solubility, lower DILI and hERG risk, and lower Pgp efflux, but the affinity difference is too large to ignore. The slightly higher BBB penetration of Ligand B is not a major concern for a cardiovascular target.
Output:
0
2025-04-17 23:33:31,801 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (364.43 & 356.50 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand B (54.18) is significantly better than Ligand A (87.38). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (1.738) is within the optimal range (1-3), while Ligand B (3.618) is at the higher end, potentially leading to solubility issues.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 7 HBA, and Ligand B has 6. Both are acceptable.
6. **QED:** Both ligands have similar QED values (0.645 and 0.67), indicating good drug-likeness.
7. **DILI:** Ligand B (44.242) has a much lower DILI risk than Ligand A (87.282). This is a significant advantage.
8. **BBB:** Not a high priority for a cardiovascular target. Ligand A (68.67) is slightly better than Ligand B (55.603), but this is not decisive.
9. **Caco-2:** Ligand A (-4.829) has a better Caco-2 permeability than Ligand B (-5.47), indicating better absorption.
10. **Solubility:** Ligand A (-2.867) has better solubility than Ligand B (-3.184).
11. **hERG:** Ligand A (0.514) has a lower hERG risk than Ligand B (0.75). This is a positive for Ligand A.
12. **Cl_mic:** Ligand B (74.286) has a significantly higher microsomal clearance than Ligand A (17.689), suggesting lower metabolic stability. This is a major drawback for Ligand B.
13. **t1/2:** Ligand A (22.673) has a longer in vitro half-life than Ligand B (-4.583). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.285) has lower P-gp efflux than Ligand B (0.205).
15. **Affinity:** Ligand B (-6.7 kcal/mol) has a significantly better binding affinity than Ligand A (-4.6 kcal/mol). This is a substantial advantage that could potentially outweigh some ADME concerns.
**Overall Assessment:**
Ligand B has a significantly better binding affinity. However, it suffers from higher logP, higher DILI risk, significantly higher microsomal clearance, and a shorter half-life. Ligand A has better ADME properties across the board, except for binding affinity. Given that the affinity difference is 2.1 kcal/mol, and considering the importance of good ADME properties for *in vivo* efficacy and safety, the better overall profile of Ligand A is preferable.
Output:
1
2025-04-17 23:33:31,801 - INFO - Batch 413 complete. Total preferences: 6608
2025-04-17 23:33:31,801 - INFO - Processing batch 414/512...
2025-04-17 23:34:22,692 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [342.443, 78.09, 1.268, 2, 3, 0.846, 27.22, 49.128, -5.198, -2.008, 0.071, -4.857, -2.039, 0.047, -7.1]
**Ligand B:** [367.425, 63.91, 3.033, 0, 6, 0.836, 60.915, 95.812, -4.749, -3.491, 0.307, 25.556, -17.694, 0.191, -7.6]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (342.443) is slightly lower, which is generally favorable for permeability, but both are acceptable.
2. **TPSA:** Ligand A (78.09) is higher than Ligand B (63.91). Both are below the 140 threshold for oral absorption, but Ligand B is better positioned.
3. **logP:** Ligand A (1.268) is within the optimal range, while Ligand B (3.033) is approaching the upper limit. This is a slight advantage for A.
4. **HBD:** Ligand A (2) is better than Ligand B (0). Having some HBD can improve solubility.
5. **HBA:** Ligand A (3) is lower than Ligand B (6). Lower HBA is generally preferred for permeability.
6. **QED:** Both are very similar (0.846 vs 0.836), indicating good drug-like properties.
7. **DILI:** Ligand A (27.22) has a significantly lower DILI risk than Ligand B (60.915). This is a major advantage for A.
8. **BBB:** Ligand B (95.812) has a much higher BBB penetration than Ligand A (49.128). While ADRB2 is a cardiovascular target, some CNS exposure is not necessarily detrimental and could provide additional effects.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual. This suggests poor permeability *in vitro*. Ligand A (-5.198) is slightly worse than Ligand B (-4.749).
10. **Solubility:** Both have negative solubility values, which is also unusual and indicates very poor aqueous solubility. Ligand A (-2.008) is slightly better than Ligand B (-3.491).
11. **hERG:** Ligand A (0.071) has a lower hERG risk than Ligand B (0.307). This is a significant advantage for A.
12. **Cl_mic:** Ligand A (-4.857) has a lower (better) microsomal clearance than Ligand B (25.556), indicating better metabolic stability.
13. **t1/2:** Ligand A (-2.039) has a negative half-life, which is not possible. Ligand B (-17.694) also has a negative half-life. Both are problematic.
14. **Pgp:** Ligand A (0.047) shows lower P-gp efflux than Ligand B (0.191).
15. **Affinity:** Ligand B (-7.6) has a slightly better binding affinity than Ligand A (-7.1), a difference of 0.5 kcal/mol.
**GPCR-Specific Priorities:** For ADRB2 (a cardiovascular GPCR), we prioritize logP, TPSA, Pgp, and affinity. BBB is less critical, but still considered.
**Overall Assessment:**
Ligand A has a much better safety profile (lower DILI, lower hERG) and better metabolic stability (lower Cl_mic). While Ligand B has slightly better affinity and BBB penetration, the significant safety concerns with Ligand B outweigh these benefits. The poor solubility and permeability of both compounds are concerning, but can be addressed with formulation strategies. The negative half-life values for both are concerning and suggest issues with the data or the compounds themselves.
Given the balance of properties, and prioritizing safety and metabolic stability, I would choose Ligand A.
Output:
1
2025-04-17 23:34:22,692 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [385.222, 67.43, 3.919, 2, 3, 0.767, 75.378, 70.027, -4.461, -5.547, 0.61, 85.787, 47.034, 0.162, -6.9]
**Ligand B:** [341.371, 79.51, 0.639, 0, 6, 0.606, 60.721, 70.997, -4.902, -1.922, 0.312, 28.455, -8.747, 0.08, -6.2]
Here's a breakdown, comparing each parameter and considering GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (341.371) is slightly preferred due to being a bit lower.
2. **TPSA:** Ligand A (67.43) is better than Ligand B (79.51). Both are acceptable, but lower TPSA generally favors better absorption.
3. **logP:** Ligand A (3.919) is better. It's within the optimal range (1-3), while Ligand B (0.639) is quite low, potentially hindering membrane permeability. This is a significant advantage for A.
4. **HBD:** Ligand A (2) is preferable to Ligand B (0). While both are low, a small number of HBDs can aid solubility.
5. **HBA:** Ligand B (6) is better than Ligand A (3). Higher HBA can sometimes improve solubility, but it's less crucial than logP in this case.
6. **QED:** Both are similar and acceptable (A: 0.767, B: 0.606).
7. **DILI:** Ligand B (60.721) is better than Ligand A (75.378). Lower DILI is always preferred. This is a notable advantage for B.
8. **BBB:** Both are good (A: 70.027, B: 70.997), but not exceptionally high. For a cardiovascular target, BBB isn't a primary concern, so this is a minor difference.
9. **Caco-2:** Both are negative, indicating poor permeability. This is a concern for both.
10. **Solubility:** Ligand B (-1.922) is better than Ligand A (-5.547). Higher solubility is desired.
11. **hERG:** Ligand A (0.61) is better than Ligand B (0.312). Lower hERG inhibition is crucial for avoiding cardiotoxicity, a significant concern for a cardiovascular target.
12. **Cl_mic:** Ligand B (28.455) is significantly better than Ligand A (85.787). Lower clearance indicates better metabolic stability. This is a major advantage for B.
13. **t1/2:** Ligand A (47.034) is better than Ligand B (-8.747). A longer half-life is generally preferred.
14. **Pgp:** Ligand A (0.162) is better than Ligand B (0.08). Lower P-gp efflux is desirable.
15. **Affinity:** Ligand A (-6.9 kcal/mol) is slightly better than Ligand B (-6.2 kcal/mol), though the difference is not huge.
**Overall Assessment:**
Ligand A has a better logP, HBD, hERG, Pgp and affinity. However, Ligand B has a lower DILI risk, better metabolic stability (Cl_mic), and better solubility. The low logP of Ligand B is a significant drawback, potentially limiting its absorption. The higher DILI risk of Ligand A is also concerning. Considering the cardiovascular target, the hERG inhibition liability is a critical factor. Ligand A's lower hERG risk is a substantial advantage. The slightly better affinity of Ligand A also tips the balance.
Therefore, I would choose Ligand A.
Output:
1
2025-04-17 23:34:22,693 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (344.415 and 364.515 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (93.21) is higher than Ligand B (58.44). For a cardiovascular GPCR, TPSA is moderately important, and Ligand B is significantly better, being well below the 140 threshold.
3. **logP:** Both ligands (2.597 and 2.015) are within the optimal 1-3 range. Ligand B is slightly lower, which could be beneficial for solubility, but both are acceptable.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (0). Both are within the acceptable limit of 5.
5. **HBA:** Both ligands (5) have the same number of HBA, and are within the acceptable limit of 10.
6. **QED:** Both ligands (0.801 and 0.802) have excellent drug-likeness scores. No clear advantage.
7. **DILI:** Ligand A (45.134) has a lower DILI risk than Ligand B (52.772), which is preferable.
8. **BBB:** Both ligands have good BBB penetration (78.48 and 77.2). This isn't a primary concern for a cardiovascular target, but it's good to see.
9. **Caco-2:** Ligand A (-4.733) is slightly better than Ligand B (-4.87), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-3.414) has better aqueous solubility than Ligand B (-2.35). This is a positive attribute.
11. **hERG:** Both ligands (0.236 and 0.259) show low hERG inhibition liability, which is excellent. No clear advantage.
12. **Cl_mic:** Ligand A (49.81) has a lower microsomal clearance than Ligand B (77.656), suggesting better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand A (23.366) has a shorter half-life than Ligand B (-7.177). This is a negative for Ligand A.
14. **Pgp:** Ligand A (0.026) has lower P-gp efflux than Ligand B (0.234), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand B (-6.4) has a slightly better binding affinity than Ligand A (-5.6). While a 1.5 kcal/mol advantage is usually significant, the other factors are more important in this case.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in TPSA and has comparable logP and affinity. Ligand A has better solubility, lower DILI, lower Cl_mic, and lower Pgp efflux. The lower Cl_mic and Pgp efflux of Ligand A are particularly attractive, suggesting better *in vivo* exposure. The slightly better affinity of Ligand B is offset by the more favorable ADME profile of Ligand A.
**Conclusion:**
Considering the balance of properties and the priorities for a GPCR target, Ligand A appears to be the more promising drug candidate. Its superior ADME properties (lower Cl_mic, lower Pgp efflux, better solubility, lower DILI) outweigh the slightly weaker binding affinity.
Output:
1
2025-04-17 23:34:22,693 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (345.355 and 354.447 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (106.61) is higher than Ligand B (68.31). For a cardiovascular GPCR, TPSA is moderately important. Ligand B is significantly better here, suggesting better permeability.
3. **logP:** Ligand A (2.36) is within the optimal range (1-3). Ligand B (0.832) is a bit low, potentially hindering permeation. This favors Ligand A.
4. **HBD:** Ligand A (1) is good. Ligand B (0) is also good. No clear advantage.
5. **HBA:** Ligand A (8) is acceptable. Ligand B (5) is also acceptable. No clear advantage.
6. **QED:** Both ligands have good QED scores (0.545 and 0.604), indicating good drug-like properties.
7. **DILI:** Ligand A (85.498) has a significantly higher DILI risk than Ligand B (23.342). This is a major concern for Ligand A.
8. **BBB:** Ligand A (59.325) and Ligand B (83.56) are both acceptable, but Ligand B is better. While ADRB2 isn't strictly a CNS target, some CNS penetration can be beneficial or at least avoid off-target effects.
9. **Caco-2:** Both are negative, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
10. **Solubility:** Ligand A (-4.366) and Ligand B (-1.223) are both very poor. This is a significant drawback for both.
11. **hERG:** Ligand A (0.72) is better than Ligand B (0.172), indicating lower cardiotoxicity risk. This is a crucial factor for a cardiovascular target.
12. **Cl_mic:** Ligand A (100.234) has a higher clearance than Ligand B (19.745), indicating lower metabolic stability. This favors Ligand B.
13. **t1/2:** Ligand A (9.016) has a longer half-life than Ligand B (5.121). This is a positive for Ligand A.
14. **Pgp:** Ligand A (0.144) has lower P-gp efflux than Ligand B (0.056), which is favorable.
15. **Binding Affinity:** Ligand B (-7.3 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.0 kcal/mol). This is a substantial advantage, potentially outweighing some ADME concerns.
**Overall Assessment:**
Ligand B has a significantly better safety profile (lower DILI) and a much stronger binding affinity. While its logP is slightly lower, the superior affinity and safety outweigh this drawback. Ligand A has a better hERG profile and half-life, but the high DILI risk is a major concern. The lower TPSA of Ligand B is also a positive.
Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity), and the critical importance of safety in a cardiovascular drug, Ligand B is the more promising candidate.
Output:
0
2025-04-17 23:34:22,693 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.39 and 350.42 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (115.9) is slightly higher than Ligand B (107.61). Both are below the 140 threshold for oral absorption, but closer to the 90 threshold for CNS targets (less relevant for ADRB2, a cardiovascular target). Ligand B is slightly preferred.
3. **logP:** Ligand A (-0.156) is a bit low, potentially hindering permeation. Ligand B (-0.522) is also on the lower side, but slightly better. This is a concern for both, but Ligand B is marginally better.
4. **HBD:** Both ligands have 3 HBD, which is within the acceptable limit of 5. No difference.
5. **HBA:** Ligand A has 6 HBA, while Ligand B has 5. Ligand B is slightly preferred, being closer to the ideal of <=10.
6. **QED:** Ligand A (0.68) has a better QED score than Ligand B (0.403), indicating a more drug-like profile. This is a significant advantage for Ligand A.
7. **DILI:** Ligand A (39.2%) has a higher DILI risk than Ligand B (22.8%). This is a substantial advantage for Ligand B.
8. **BBB:** Both ligands have moderate BBB penetration (60.64% and 66.81%). This isn't a primary concern for ADRB2, but Ligand B is slightly better.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.187 and -5.928), which is unusual and suggests poor permeability. This is a significant drawback for both.
10. **Solubility:** Both ligands have very poor aqueous solubility (-1.188 and -1.344). This is a major concern for both, potentially impacting bioavailability.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.092 and 0.037). This is good for both.
12. **Cl_mic:** Ligand A (3.378) has a much lower microsomal clearance than Ligand B (-20.589). This indicates significantly better metabolic stability for Ligand A. This is a major advantage.
13. **t1/2:** Ligand A (-4.219) has a negative in vitro half-life, which is concerning. Ligand B (-12.743) is even worse. Both are very poor.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.007 and 0.003). This is good for both.
15. **Binding Affinity:** Ligand A (-7.9 kcal/mol) has a better binding affinity than Ligand B (-6.7 kcal/mol). This is a 1.2 kcal/mol difference, which is a substantial advantage for Ligand A.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A has a better affinity and slightly better TPSA. Ligand B has a slightly better logP, but both are suboptimal. The biggest difference lies in DILI risk and metabolic stability (Cl_mic), where Ligand B and A are significantly better, respectively.
**Overall Assessment:**
While Ligand A has a better QED and significantly better binding affinity and metabolic stability, the DILI risk is higher. Ligand B has a lower DILI risk, but a weaker binding affinity and poorer metabolic stability. Given the importance of metabolic stability for *in vivo* efficacy and the relatively small difference in affinity, and the significant difference in DILI risk, I favor Ligand B. The poor solubility and Caco-2 values are concerning for both, but these can potentially be addressed through formulation strategies.
Output:
0
2025-04-17 23:34:22,693 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.406 and 351.462 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (87.66) is higher than Ligand B (38.77). For a cardiovascular GPCR, TPSA isn't *as* critical as for a CNS target, but lower is generally preferred for absorption. Ligand B is significantly better.
3. **logP:** Both ligands have good logP values (2.604 and 3.48), falling within the optimal 1-3 range. Ligand B is slightly higher, which *could* be beneficial for membrane permeability, but isn't a major concern.
4. **HBD:** Ligand A has 3 HBD, while Ligand B has 0. Lower HBD is generally favorable for permeability. Ligand B is better.
5. **HBA:** Ligand A has 4 HBA, Ligand B has 3. Again, lower is generally better. Ligand B is better.
6. **QED:** Both ligands have acceptable QED values (0.687 and 0.72), indicating good drug-like properties. No significant difference.
7. **DILI:** Ligand A (41.954) has a slightly higher DILI risk than Ligand B (14.696). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (80.264) has a reasonable BBB penetration, while Ligand B (95.696) is very high. While ADRB2 isn't a primary CNS target, some degree of BBB penetration can be useful for understanding off-target effects and potential peripheral distribution. Ligand B is better.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.344 and -4.291). This is unusual and suggests poor permeability. However, these values are very close, so it doesn't strongly favor either.
10. **Solubility:** Ligand A (-3.575) has slightly worse solubility than Ligand B (-2.714). Better solubility is always preferred. Ligand B is better.
11. **hERG:** Ligand A (0.455) has a slightly lower hERG risk than Ligand B (0.938). This is a slight advantage for Ligand A, but both are relatively low.
12. **Cl_mic:** Ligand A (58.219) has lower microsomal clearance than Ligand B (77.669), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Both ligands have similar in vitro half-lives (22.047 and 22.502 hours). No significant difference.
14. **Pgp:** Ligand A (0.179) has lower P-gp efflux than Ligand B (0.509), which is favorable for bioavailability. Ligand A is better.
15. **Binding Affinity:** Ligand B (-6.5 kcal/mol) has a significantly stronger binding affinity than Ligand A (-4.5 kcal/mol). This is a substantial advantage for Ligand B, and a difference of 2 kcal/mol is often enough to override minor ADME concerns.
**Overall Assessment:**
Ligand B has a significantly stronger binding affinity, a much better safety profile (lower DILI), better TPSA, HBD/HBA, solubility, and BBB penetration. While Ligand A has better metabolic stability (lower Cl_mic) and Pgp efflux, the potency advantage of Ligand B is substantial and outweighs these concerns. The Caco-2 values are concerning for both, but the stronger binding of Ligand B suggests it may still achieve sufficient target engagement.
Output:
0
2025-04-17 23:34:22,693 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [353.394, 80.76, 2.359, 1, 5, 0.841, 64.172, 59.364, -4.044, -3.073, 0.23, 62.015, -28.574, 0.023, -5.2]
**Ligand B:** [348.393, 61.36, 3.801, 3, 2, 0.667, 44.281, 45.715, -4.972, -4.056, 0.878, 70.399, 0.384, 0.611, -7.9]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity) and general guidelines:
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (348.393) is slightly lower, which is generally favorable.
2. **TPSA:** Ligand A (80.76) is higher than Ligand B (61.36). Both are acceptable for a cardiovascular target, but Ligand B is better, promoting better membrane permeability.
3. **logP:** Ligand A (2.359) is optimal. Ligand B (3.801) is approaching the upper limit, potentially leading to solubility issues, but still within an acceptable range.
4. **HBD/HBA:** Ligand A (1 HBD, 5 HBA) is better than Ligand B (3 HBD, 2 HBA). Fewer H-bonds are generally preferred for permeability.
5. **QED:** Ligand A (0.841) is significantly better than Ligand B (0.667), indicating a more drug-like profile.
6. **DILI:** Ligand A (64.172) has a higher DILI risk than Ligand B (44.281). This is a significant concern.
7. **BBB:** Both are relatively low, which is fine for a cardiovascular target. Ligand B (45.715) is slightly lower than Ligand A (59.364).
8. **Caco-2:** Both are negative, indicating poor permeability. Ligand B (-4.972) is slightly worse than Ligand A (-4.044).
9. **Solubility:** Both are negative, indicating poor solubility. Ligand B (-4.056) is slightly worse than Ligand A (-3.073).
10. **hERG:** Ligand A (0.23) has a lower hERG risk than Ligand B (0.878).
11. **Cl_mic:** Ligand A (62.015) has a lower clearance, suggesting better metabolic stability than Ligand B (70.399).
12. **t1/2:** Ligand A (-28.574) has a much longer half-life than Ligand B (0.384), which is a major advantage.
13. **Pgp:** Ligand A (0.023) has much lower P-gp efflux liability than Ligand B (0.611), improving bioavailability.
14. **Affinity:** Ligand B (-7.9) has a significantly stronger binding affinity than Ligand A (-5.2). This is a substantial advantage (a difference of 2.7 kcal/mol).
**Overall Assessment:**
Ligand B's significantly stronger binding affinity (-7.9 kcal/mol vs -5.2 kcal/mol) is a major driver. While Ligand A has better QED, metabolic stability, and Pgp efflux, the affinity difference is substantial enough to outweigh these benefits. Ligand B also has a lower DILI risk. Both have poor Caco-2 and solubility, which would need to be addressed in further optimization, but the potency advantage of Ligand B is compelling.
Output:
0
2025-04-17 23:34:22,694 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (342.37 and 349.475 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (63.45) is significantly better than Ligand B (82.53). For a GPCR, lower TPSA is generally preferred for better permeability. Ligand B is getting a bit high, potentially impacting absorption.
3. **logP:** Ligand A (3.989) is at the upper end of the optimal range (1-3), while Ligand B (2.074) is closer to the lower end. For a GPCR, a slightly higher logP can be beneficial for membrane permeability, but we need to consider other factors.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer hydrogen bond donors generally improve permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (4). Similar reasoning as HBD.
6. **QED:** Both ligands have good QED scores (0.623 and 0.789), indicating good drug-like properties. No clear advantage.
7. **DILI:** Ligand A (70.841) has a higher DILI risk than Ligand B (22.761). This is a significant concern for Ligand A.
8. **BBB:** Ligand A (83.249) has a much better BBB penetration score than Ligand B (51.958). While ADRB2 isn't strictly a CNS target, some CNS exposure can occur, and better BBB penetration is generally a positive.
9. **Caco-2:** Both ligands have similar, very poor Caco-2 permeability (-4.541 and -4.575). This is a significant drawback for both, suggesting poor oral absorption.
10. **Solubility:** Ligand A (-5.313) has worse solubility than Ligand B (-1.623). Solubility is important for formulation and bioavailability.
11. **hERG:** Ligand A (0.812) has a slightly higher hERG risk than Ligand B (0.51), but both are reasonably low.
12. **Cl_mic:** Ligand A (83.779) has significantly higher metabolic clearance than Ligand B (34.184). This suggests Ligand B will be more metabolically stable.
13. **t1/2:** Ligand A (21.38) has a longer half-life than Ligand B (8.282). This is a positive for Ligand A.
14. **Pgp:** Ligand A (0.52) has lower P-gp efflux than Ligand B (0.082). Lower P-gp efflux is generally preferred.
15. **Affinity:** Both ligands have the same excellent binding affinity (-7.5 kcal/mol). This removes affinity as a differentiating factor.
**Overall Assessment:**
Ligand A has a better BBB score, longer half-life, and lower P-gp efflux, but suffers from higher DILI risk, worse solubility, and higher metabolic clearance. Ligand B has a much lower DILI risk, better solubility, and better metabolic stability, but poorer BBB penetration and a shorter half-life.
Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity) and the general guidelines, the lower DILI risk and improved metabolic stability of Ligand B are more compelling. While the TPSA is a bit high, the significant reduction in potential liver toxicity outweighs this concern. The poor Caco-2 permeability is a problem for both, and would need to be addressed through formulation strategies.
Output:
0
2025-04-17 23:34:22,694 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [367.833, 92.51, 1.077, 1, 5, 0.728, 36.797, 65.452, -5.18, -2.16, 0.05, 6.221, -11.987, 0.067, -6.3]**
**Ligand B: [371.493, 40.54, 4.516, 1, 3, 0.73, 14.385, 92.943, -4.569, -4.043, 0.746, 55.042, 7.789, 0.414, -7.6]**
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). A is 367.833, B is 371.493. No significant difference.
2. **TPSA:** Ligand A (92.51) is slightly higher than Ligand B (40.54). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is generally preferred for absorption. B is significantly better here.
3. **logP:** Ligand A (1.077) is within the optimal range, while Ligand B (4.516) is high. High logP can lead to poor solubility and off-target effects. A is better.
4. **H-Bond Donors:** Both have 1 HBD, which is good.
5. **H-Bond Acceptors:** Ligand A has 5, Ligand B has 3. Both are acceptable, but lower is generally better. B is slightly better.
6. **QED:** Both ligands have similar QED values (A: 0.728, B: 0.73), indicating good drug-likeness.
7. **DILI:** Ligand A (36.797) has a higher DILI risk than Ligand B (14.385). This is a significant advantage for B.
8. **BBB:** Ligand B (92.943) has a higher BBB penetration potential than Ligand A (65.452). While ADRB2 isn't *primarily* a CNS target, some CNS exposure can be relevant, and higher BBB is generally favorable.
9. **Caco-2:** Ligand A (-5.18) and B (-4.569) are both negative, indicating poor permeability. This is concerning for both.
10. **Solubility:** Ligand A (-2.16) and B (-4.043) are both negative, indicating poor solubility. B is slightly better.
11. **hERG:** Ligand A (0.05) has a lower hERG inhibition liability than Ligand B (0.746). This is a significant advantage for A.
12. **Cl_mic:** Ligand A (6.221) has a lower microsomal clearance than Ligand B (55.042), indicating better metabolic stability. This is a significant advantage for A.
13. **t1/2:** Ligand A (-11.987) has a negative in vitro half-life, which is very concerning. Ligand B (7.789) has a positive half-life. B is far better here.
14. **Pgp:** Ligand A (0.067) has lower P-gp efflux liability than Ligand B (0.414). This is a slight advantage for A.
15. **Binding Affinity:** Ligand B (-7.6) has a significantly better binding affinity than Ligand A (-6.3) (1.3 kcal/mol difference). This is a substantial advantage that can outweigh some ADME concerns.
**Overall Assessment:**
Ligand B has a significantly better binding affinity, lower DILI risk, better BBB penetration, and a positive in vitro half-life. Ligand A has better hERG and lower P-gp efflux, and better metabolic stability. However, the large difference in binding affinity and the concerning negative half-life for Ligand A are major drawbacks. The higher logP of Ligand B is a concern, but can potentially be mitigated with formulation strategies. Given the GPCR target class, binding affinity is paramount.
Output:
0
2025-04-17 23:34:22,694 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (337.394 & 362.836 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (46.17) is significantly better than Ligand B (57.26). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (3.998 & 3.839), falling within the 1-3 optimal range. Very similar.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (2) is preferable to Ligand B (3). Lower HBA generally improves permeability.
6. **QED:** Both ligands have good QED scores (0.92 & 0.849), indicating good drug-like properties.
7. **DILI:** Ligand A (53.548) is significantly better than Ligand B (74.99). Lower DILI risk is crucial. This is a major advantage for Ligand A.
8. **BBB:** Both ligands have high BBB penetration (91.974 & 80.419). While ADRB2 isn't a CNS target, higher BBB is not detrimental.
9. **Caco-2:** Both ligands have similar, poor Caco-2 permeability (-4.736 & -4.777). This is a concern for both, suggesting potential absorption issues.
10. **Solubility:** Ligand A (-3.56) is slightly better than Ligand B (-5.126), though both are poor. Solubility is a concern for both.
11. **hERG:** Both ligands have low hERG inhibition risk (0.638 & 0.644), which is good.
12. **Cl_mic:** Ligand A (37.371) has a lower microsomal clearance than Ligand B (51.949), indicating better metabolic stability.
13. **t1/2:** Ligand A (39.976) has a longer in vitro half-life than Ligand B (53.839). This is a positive for Ligand A.
14. **Pgp:** Ligand A (0.72) is better than Ligand B (0.319). Lower P-gp efflux is preferable.
15. **Binding Affinity:** Ligand A (-7.0) has slightly better binding affinity than Ligand B (-6.0). This is a significant advantage.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Both ligands are good on logP. Ligand A is significantly better on TPSA, Pgp, and affinity. The DILI risk is also a major factor, and Ligand A is much better here.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across several critical ADME-Tox properties (DILI, Cl_mic, t1/2, Pgp) and has a slightly better binding affinity. While both have poor Caco-2 permeability and solubility, the advantages of Ligand A outweigh these drawbacks.
Output:
1
2025-04-17 23:34:22,694 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (412.219 Da) is slightly higher than Ligand B (341.411 Da), but both are acceptable.
**2. TPSA:** Ligand A (106.1) is higher than Ligand B (78.34). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B has a more favorable TPSA.
**3. logP:** Both ligands have good logP values (Ligand A: 1.949, Ligand B: 2.617), falling within the optimal 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability.
**4. H-Bond Donors:** Both have 2 HBD, which is within the acceptable limit of <=5.
**5. H-Bond Acceptors:** Ligand A has 6 HBA, while Ligand B has 3. Both are within the acceptable limit of <=10. Ligand B is preferable here.
**6. QED:** Ligand B (0.897) has a significantly better QED score than Ligand A (0.555), indicating a more drug-like profile.
**7. DILI Risk:** Ligand A (81.776) has a considerably higher DILI risk than Ligand B (39.899). This is a major concern, and Ligand B is significantly better.
**8. BBB Penetration:** While not a primary concern for a cardiovascular target, Ligand A (69.678) shows slightly better BBB penetration than Ligand B (48.003).
**9. Caco-2 Permeability:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.944) is slightly better than Ligand B (-5.093), but both are problematic.
**10. Aqueous Solubility:** Both have negative solubility values, which is also unusual and suggests poor solubility. Ligand A (-3.059) is slightly better than Ligand B (-3.317).
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (Ligand A: 0.095, Ligand B: 0.378).
**12. Microsomal Clearance:** Ligand A (82.006) has a higher microsomal clearance than Ligand B (20.364), indicating lower metabolic stability. Ligand B is significantly better.
**13. In vitro Half-Life:** Ligand B (15.972 hours) has a longer half-life than Ligand A (26.51 hours). This is a positive for Ligand B.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (Ligand A: 0.022, Ligand B: 0.037).
**15. Binding Affinity:** Ligand A (-6.3 kcal/mol) has a stronger binding affinity than Ligand B (-2.8 kcal/mol). This is a substantial difference.
**Overall Assessment:**
The most critical factors for a GPCR drug candidate are potency (affinity) and safety (DILI, hERG). While Ligand A has a significantly better binding affinity, its high DILI risk is a major red flag. Ligand B, while having a weaker affinity, presents a much more favorable safety profile (lower DILI, good hERG), better QED, and improved metabolic stability. The difference in affinity, while significant, might be overcome with further optimization, whereas mitigating a high DILI risk is often very challenging. Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand B strikes a better balance.
Output:
0
2025-04-17 23:34:22,694 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (358.36 and 359.861 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (61.8) is significantly better than Ligand B (75.87). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand A is well below the 90 A^2 threshold, while Ligand B is approaching it.
3. **logP:** Ligand A (2.553) is optimal, while Ligand B (4.731) is pushing the upper limit. High logP can lead to solubility issues and off-target interactions.
4. **HBD:** Both ligands have 2 HBD, which is within the acceptable limit of 5.
5. **HBA:** Ligand A has 3 HBA, while Ligand B has 6. Ligand A is preferable here, as lower HBA generally improves permeability.
6. **QED:** Ligand A (0.87) has a much better QED score than Ligand B (0.566), indicating a more drug-like profile.
7. **DILI:** Ligand B (73.401) has a significantly higher DILI risk than Ligand A (35.285). This is a major concern, as we want to minimize liver toxicity.
8. **BBB:** Ligand A (75.843) has a better BBB penetration percentile than Ligand B (60.915). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be useful for understanding off-target effects and overall distribution.
9. **Caco-2:** Ligand A (-4.491) shows better Caco-2 permeability than Ligand B (-5.368). Better absorption is always preferred.
10. **Solubility:** Ligand A (-2.646) has better aqueous solubility than Ligand B (-4.477). This is important for formulation and bioavailability.
11. **hERG:** Both ligands have relatively low hERG inhibition risk (0.734 and 0.815 respectively), which is good.
12. **Cl_mic:** Ligand A (-7.629) has a much lower (better) microsomal clearance than Ligand B (83.42). This suggests greater metabolic stability for Ligand A.
13. **t1/2:** Ligand A (13.538 hours) has a better in vitro half-life than Ligand B (200.222 hours). While a longer half-life is generally preferred, 200.222 hours is extremely long and could indicate issues with clearance mechanisms or non-specific binding.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.124 and 0.511 respectively).
15. **Binding Affinity:** Ligand A (-6.8 kcal/mol) and Ligand B (-6.5 kcal/mol) have similar binding affinities. The difference is not substantial enough to outweigh the other significant differences.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical ADME properties, including TPSA, logP, QED, DILI risk, solubility, and metabolic stability. While the binding affinity is comparable, the superior drug-like properties of Ligand A make it a much more promising candidate for further development. Ligand B's high DILI risk and high logP are significant red flags.
Output:
1
2025-04-17 23:34:22,694 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (351.447 and 349.391 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (89.95) is better than Ligand B (105.56). Both are under 140, but A is closer to the preferred value for good absorption.
3. **logP:** Ligand A (-0.016) is slightly better than Ligand B (-1.106). Both are within the 1-3 range, but closer to 1 is preferable.
4. **HBD:** Both ligands have 2 HBD, which is good.
5. **HBA:** Ligand A has 4 HBA, while Ligand B has 6. Ligand A is preferable as it is closer to the ideal of <=10.
6. **QED:** Both ligands have similar QED scores (0.682 and 0.678), indicating good drug-likeness.
7. **DILI:** Ligand A (22.024) has a significantly lower DILI risk than Ligand B (62.233). This is a major advantage for Ligand A.
8. **BBB:** Both ligands have low BBB penetration (29.275 and 27.336). As ADRB2 is a cardiovascular target, BBB penetration is not a high priority.
9. **Caco-2:** Ligand A (-4.698) and Ligand B (-5.552) both have negative Caco-2 values, indicating poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-0.959) is slightly better than Ligand B (-0.572), but both are poor.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.121 and 0.071).
12. **Cl_mic:** Ligand B (-16.642) has a lower (better) microsomal clearance than Ligand A (10.175). This suggests better metabolic stability for Ligand B.
13. **t1/2:** Ligand B (22.785) has a significantly longer in vitro half-life than Ligand A (-29.722). This is a substantial advantage for Ligand B.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.009 and 0.024).
15. **Binding Affinity:** Ligand B (-7.2) has slightly better binding affinity than Ligand A (-7.1). While the difference is small, it is still a factor.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, and affinity are important. Ligand A has better logP and TPSA, while Ligand B has slightly better affinity. However, the significantly lower DILI risk of Ligand A, combined with its slightly better solubility, outweighs the small affinity advantage of Ligand B. The metabolic stability (Cl_mic and t1/2) are also important, and Ligand B is better in these respects.
**Overall Assessment:**
Ligand A is preferable due to its significantly lower DILI risk and better TPSA, despite Ligand B having slightly better affinity and metabolic stability. The DILI risk is a major concern, and the difference between the two ligands is substantial.
Output:
1
2025-04-17 23:34:22,695 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.487 and 355.389 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (67.43) is better than Ligand B (70.47). Both are below the 140 threshold for oral absorption, but lower is preferred for GPCRs.
3. **logP:** Ligand A (2.56) is better than Ligand B (1.092). Both are within the optimal 1-3 range, but Ligand B is closer to the lower bound, potentially impacting permeability.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1), but both are within the acceptable limit of 5.
5. **HBA:** Ligand A (3) is lower than Ligand B (5). This is favorable as lower HBA generally improves permeability.
6. **QED:** Ligand B (0.829) is better than Ligand A (0.663). Ligand B has a more drug-like profile.
7. **DILI:** Both ligands have low DILI risk (27.336 and 26.406 percentile), indicating similar safety profiles.
8. **BBB:** Ligand B (80.884) is significantly better than Ligand A (71.19). While ADRB2 isn't exclusively a CNS target, higher BBB penetration is generally desirable for GPCRs, offering potential for broader therapeutic applications and reducing off-target effects.
9. **Caco-2:** Ligand A (-5.195) is better than Ligand B (-4.826). Higher Caco-2 permeability suggests better intestinal absorption.
10. **Solubility:** Ligand A (-2.751) is better than Ligand B (-1.677). Higher aqueous solubility is always a plus for bioavailability.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.285 and 0.262), which is excellent.
12. **Cl_mic:** Ligand B (-10.387) has significantly lower microsomal clearance than Ligand A (48.993), indicating better metabolic stability and potentially a longer duration of action.
13. **t1/2:** Ligand A (5.104) has a longer in vitro half-life than Ligand B (-0.883). This is a positive attribute.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.166 and 0.007), which is favorable.
15. **Binding Affinity:** Ligand A (-7.4) has a slightly better binding affinity than Ligand B (-7.0). This is a 0.4 kcal/mol difference, which is significant.
**Overall Assessment:**
Ligand A has a better binding affinity, solubility, Caco-2 permeability and half-life. However, Ligand B excels in BBB penetration and, crucially, metabolic stability (Cl_mic). Given that ADRB2 is a GPCR, the improved BBB penetration of Ligand B is a significant advantage. The substantial difference in Cl_mic also favors Ligand B, as it suggests a longer duration of action and potentially reduced dosing frequency. The slightly weaker affinity of Ligand B can potentially be optimized in later stages of drug development. The better QED score also supports Ligand B.
Therefore, I favor Ligand B.
Output:
0
2025-04-17 23:34:22,695 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's break down the comparison, keeping in mind ADRB2 is a GPCR, so logP, TPSA, Pgp, BBB, and affinity are key.
1. **MW:** Both ligands are within the ideal 200-500 Da range. Ligand A (399.559) is slightly higher than Ligand B (348.447), but both are acceptable.
2. **TPSA:** Both are reasonably low (A: 83.47, B: 84.42), suggesting good potential for cell permeability. Both are well below the 140 A^2 threshold.
3. **logP:** Both ligands have good logP values (A: 2.566, B: 1.711) falling within the 1-3 range. Ligand A is slightly more lipophilic, which could be beneficial for membrane permeability, but isn't a major concern for either.
4. **HBD/HBA:** Ligand A (2 HBD, 6 HBA) and Ligand B (1 HBD, 5 HBA) are both within acceptable limits.
5. **QED:** Both have good QED scores (A: 0.633, B: 0.876), indicating drug-like properties. Ligand B is slightly better here.
6. **DILI:** Ligand A (71.694) has a significantly higher DILI risk than Ligand B (33.346). This is a major concern.
7. **BBB:** Ligand B (70.027) has a better BBB penetration score than Ligand A (46.219). While ADRB2 isn't necessarily a CNS target, better BBB penetration generally correlates with improved distribution and reduced off-target effects.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale isn't defined, so it's hard to interpret.
9. **Solubility:** Both have negative solubility values, which is also unusual.
10. **hERG:** Both have low hERG inhibition liability (A: 0.465, B: 0.17), which is good. Ligand B is slightly better.
11. **Cl_mic:** Ligand B (15.448) has a significantly lower microsomal clearance than Ligand A (28.382), indicating better metabolic stability.
12. **t1/2:** Ligand B (-11.316) has a negative in vitro half-life, which is concerning. Ligand A (26.014) is much better.
13. **Pgp:** Both have very low Pgp efflux liability (A: 0.465, B: 0.031). Ligand B is slightly better.
14. **Affinity:** Both have excellent binding affinities (A: -6.4 kcal/mol, B: -5.8 kcal/mol). Ligand A is slightly stronger, but the difference is not substantial enough to outweigh other factors.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity and in vitro half-life, the significantly higher DILI risk is a major red flag. Ligand B demonstrates a much more favorable safety profile (lower DILI, better hERG), better metabolic stability (lower Cl_mic), and improved BBB penetration. The slightly weaker affinity of Ligand B is acceptable given its superior ADMET properties.
**Output:**
0
2025-04-17 23:34:22,695 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (369.864 and 369.893 Da) fall comfortably within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (55.4) is significantly better than Ligand B (75.43). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (4.04) is slightly higher than Ligand B (2.426). Both are within the optimal 1-3 range, but Ligand A is approaching the upper limit.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 3 HBA, while Ligand B has 5. Ligand A is preferable here.
6. **QED:** Both ligands have good QED scores (0.797 and 0.8), indicating good drug-like properties.
7. **DILI:** Ligand A (46.258) has a higher DILI risk than Ligand B (21.404). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (83.172) has better BBB penetration than Ligand B (74.758). While not crucial for a cardiovascular target, it's a slight positive for A.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.267) is slightly better than Ligand B (-4.627).
10. **Solubility:** Ligand A (-4.935) has slightly better solubility than Ligand B (-2.485).
11. **hERG:** Ligand A (0.46) is better than Ligand B (0.239) in terms of hERG inhibition liability. Lower is better.
12. **Cl_mic:** Ligand B (48.039) has significantly lower microsomal clearance than Ligand A (114.945), indicating better metabolic stability. This is a major advantage for Ligand B.
13. **t1/2:** Ligand A (15.632) has a longer in vitro half-life than Ligand B (12.272), which is desirable.
14. **Pgp:** Ligand A (0.467) has lower P-gp efflux than Ligand B (0.174), which is preferable.
15. **Binding Affinity:** Ligand A (-8.5 kcal/mol) has a significantly stronger binding affinity than Ligand B (-3.9 kcal/mol). This is a substantial advantage for Ligand A, potentially outweighing some ADME concerns.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp efflux, and binding affinity are key. Ligand A excels in binding affinity and has a reasonable logP and Pgp efflux. Ligand B has a better DILI score and metabolic stability. The large difference in binding affinity is the most important factor.
**Overall Assessment:**
The significantly stronger binding affinity of Ligand A (-8.5 kcal/mol vs -3.9 kcal/mol) is a decisive factor. While Ligand B has advantages in DILI and metabolic stability, the potency difference is large enough to potentially overcome those drawbacks through further optimization. The TPSA and solubility are also slightly better for Ligand A.
Output:
1
2025-04-17 23:34:22,695 - INFO - Batch 414 complete. Total preferences: 6624
2025-04-17 23:34:22,695 - INFO - Processing batch 415/512...
2025-04-17 23:35:08,877 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (342.33 and 346.43 Da) fall well within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (85.26) is slightly higher than Ligand B (78.87). Both are below the 140 A^2 threshold for good oral absorption, and acceptable for a cardiovascular GPCR.
3. **logP:** Ligand A (3.231) is optimal, while Ligand B (0.462) is quite low. This is a significant difference. For a GPCR, a logP between 1-3 is preferred, and Ligand B is below this range, potentially hindering membrane permeability.
4. **HBD:** Ligand A (0) is better than Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (6) is higher than Ligand B (4). Both are within the acceptable limit of 10.
6. **QED:** Ligand A (0.726) is better than Ligand B (0.56), indicating a more drug-like profile.
7. **DILI:** Ligand B (21.869) is *much* better than Ligand A (93.68). This is a major advantage for Ligand B.
8. **BBB:** Ligand A (92.904) is significantly better than Ligand B (55.099). While ADRB2 isn't necessarily a CNS target, higher BBB penetration can sometimes translate to better overall distribution.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.764 and -4.656). This is unusual and suggests poor permeability *in vitro*. However, these values are very close.
10. **Solubility:** Ligand A (-3.709) is better than Ligand B (-1.49). Better solubility is generally desirable.
11. **hERG:** Ligand A (0.493) is better than Ligand B (0.181), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand B (9.932) has significantly lower microsomal clearance than Ligand A (34.677), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-10.504) has a better (longer) half-life than Ligand A (-16.707).
14. **Pgp:** Ligand A (0.34) is better than Ligand B (0.016), indicating lower P-gp efflux.
15. **Affinity:** Ligand B (-7.1) has a slightly better binding affinity than Ligand A (-6.2). While the difference is less than 1.5 kcal/mol, it is still a positive.
**Overall Assessment:**
Ligand B has a significantly better DILI score and Cl_mic, and a better half-life. The lower logP is a concern, but the slightly improved affinity might compensate. Ligand A has better BBB penetration, solubility, Pgp, and hERG, but the high DILI risk is a major drawback.
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity) and the overall profile, Ligand B appears to be the more promising candidate, despite the lower logP. The improved metabolic stability and reduced toxicity risk are crucial advantages.
Output:
0
2025-04-17 23:35:08,878 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (453.2 Da) is within the ideal range, while Ligand B (381.567 Da) is slightly below, but still acceptable.
2. **TPSA:** Ligand A (127.68) is a bit high, potentially impacting absorption, but not drastically. Ligand B (62.3) is excellent, well below the 140 threshold.
3. **logP:** Both ligands have good logP values (A: 1.419, B: 3.032), falling within the optimal 1-3 range. Ligand B is closer to the upper end, which could be slightly concerning for solubility.
4. **HBD:** Both are acceptable (A: 2, B: 1).
5. **HBA:** Both are acceptable (A: 8, B: 5).
6. **QED:** Ligand B (0.871) has a significantly better QED score than Ligand A (0.442), indicating a more drug-like profile.
7. **DILI:** Ligand A (98.953) has a very high DILI risk, which is a major concern. Ligand B (51.144) is much better, falling within an acceptable range.
8. **BBB:** Ligand B (62.97) is better than Ligand A (45.134), but neither is particularly high. Since ADRB2 is a cardiovascular target, BBB penetration is not a primary concern, but it's still a plus.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not defined, so it's difficult to interpret.
10. **Solubility:** Both have negative solubility values, which is also unusual and suggests poor solubility.
11. **hERG:** Both have low hERG inhibition liability (A: 0.3, B: 0.415), which is good.
12. **Cl_mic:** Ligand A (47.383) has lower microsomal clearance than Ligand B (53.715), suggesting better metabolic stability.
13. **t1/2:** Ligand A (21.234) has a significantly longer in vitro half-life than Ligand B (8.858).
14. **Pgp:** Both have low Pgp efflux liability (A: 0.171, B: 0.302).
15. **Affinity:** Ligand A (-7.7 kcal/mol) has a stronger binding affinity than Ligand B (-5.9 kcal/mol). This is a substantial difference (1.8 kcal/mol).
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Both ligands perform reasonably well on logP. Ligand B has a much better TPSA. The affinity difference is significant, with Ligand A being considerably more potent. However, the extremely high DILI risk associated with Ligand A is a critical drawback.
**Overall Assessment:**
While Ligand A has superior binding affinity and metabolic stability, the extremely high DILI risk is a deal-breaker. Ligand B, despite its weaker affinity, presents a much more favorable safety profile (lower DILI) and better drug-like properties (QED, TPSA). The difference in affinity, while substantial, might be overcome with further optimization of Ligand B. The poor Caco-2 and solubility values are concerning for both, but could be addressed through formulation strategies.
**Output:**
0
2025-04-17 23:35:08,878 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (344.375 and 342.399 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (110.17) is slightly higher than Ligand B (89.53). Ligand B is better, being closer to the <140 threshold for good oral absorption and more favorable for a GPCR.
3. **logP:** Ligand A (1.513) and Ligand B (0.918) are both within the optimal 1-3 range. Ligand A is slightly better.
4. **HBD:** Ligand A (3) and Ligand B (2) are both acceptable, below the threshold of 5. Ligand B is slightly better.
5. **HBA:** Ligand A (6) and Ligand B (4) are both below the threshold of 10. Ligand B is better.
6. **QED:** Both ligands have good QED scores (0.761 and 0.845), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (90.617) has a higher DILI risk than Ligand B (54.556). This is a significant negative for Ligand A.
8. **BBB:** Ligand A (59.325) has a better BBB penetration percentile than Ligand B (33.23). While ADRB2 isn't strictly a CNS target, some CNS exposure can be relevant for off-target effects.
9. **Caco-2:** Ligand A (-4.892) and Ligand B (-5.376) are both very poor. This suggests very low intestinal absorption for both.
10. **Solubility:** Ligand A (-3.894) and Ligand B (-1.902) are both poor. Ligand B is better.
11. **hERG:** Both ligands have low hERG inhibition risk (0.261 and 0.158). Ligand B is slightly better.
12. **Cl_mic:** Ligand A (45.465) has a higher microsomal clearance than Ligand B (-19.867). This indicates lower metabolic stability for Ligand A. Ligand B is significantly better.
13. **t1/2:** Ligand A (6.262) has a longer in vitro half-life than Ligand B (0.815). This is a positive for Ligand A.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.09 and 0.041). Ligand B is slightly better.
15. **Binding Affinity:** Ligand A (-7.6 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.3 kcal/mol). This is a substantial advantage for Ligand A.
**Overall Assessment:**
Ligand A has a superior binding affinity, and a longer half-life. However, it suffers from a much higher DILI risk and higher metabolic clearance. Ligand B has better ADME properties across the board (lower DILI, better solubility, lower clearance, better TPSA, HBD/HBA), but its affinity is weaker.
Given that we are looking for a viable *drug candidate*, the ADME properties are crucial. A strong binding affinity is important, but it's useless if the drug is quickly metabolized, causes liver damage, or isn't absorbed. The difference in affinity (-1.3 kcal/mol) while substantial, can potentially be overcome with further optimization, whereas mitigating a high DILI risk is far more challenging.
Therefore, I favor Ligand B.
Output:
0
2025-04-17 23:35:08,878 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (349.435 Da) is slightly lower, which is generally favorable for permeability.
**2. TPSA:** Ligand A (90.7) is better than Ligand B (49.58). For a cardiovascular GPCR, TPSA is not a major concern, but lower TPSA generally correlates with better membrane permeability.
**3. logP:** Ligand B (3.416) is better than Ligand A (-0.486). A logP between 1-3 is optimal, and Ligand B falls within this range, while Ligand A is significantly below, potentially hindering membrane permeability.
**4. H-Bond Donors:** Ligand A (2) is reasonable, while Ligand B (0) is also good.
**5. H-Bond Acceptors:** Both ligands have acceptable HBA counts (Ligand A: 6, Ligand B: 5).
**6. QED:** Ligand A (0.766) is significantly better than Ligand B (0.479), indicating a more drug-like profile.
**7. DILI Risk:** Ligand A (27.142) has a much lower DILI risk than Ligand B (37.418), which is a crucial factor for drug development.
**8. BBB Penetration:** Ligand B (69.639) has better BBB penetration than Ligand A (26.134). However, for a cardiovascular target like ADRB2, high BBB penetration isn't a primary requirement.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-5.188 and -5.134), which is unusual and suggests poor permeability. This is a red flag for both.
**10. Aqueous Solubility:** Ligand A (-0.917) is slightly better than Ligand B (-2.674), but both are poor.
**11. hERG Inhibition:** Ligand A (0.257) has a lower hERG risk than Ligand B (0.811), which is a significant advantage.
**12. Microsomal Clearance:** Ligand A (-1.528) has a lower (better) microsomal clearance than Ligand B (99.497), indicating greater metabolic stability.
**13. In vitro Half-Life:** Ligand B (108.556) has a much longer half-life than Ligand A (4.527), which is a major advantage.
**14. P-gp Efflux:** Ligand A (0.022) has a lower P-gp efflux liability than Ligand B (0.203), which is favorable.
**15. Binding Affinity:** Ligand B (-6.5 kcal/mol) has a significantly stronger binding affinity than Ligand A (-3.6 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME drawbacks.
**Overall Assessment:**
Ligand B has a much better binding affinity and a significantly longer half-life. However, it suffers from a higher DILI risk, higher hERG inhibition, and a less favorable logP. Ligand A has better drug-likeness (QED), lower DILI and hERG risk, and better metabolic stability. The poor Caco-2 permeability is a concern for both.
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), and the importance of minimizing toxicity (DILI, hERG) in cardiovascular drugs, I lean towards **Ligand A** despite its weaker binding affinity. The significantly lower toxicity profile and better metabolic stability are crucial for a cardiovascular drug. While the affinity difference is substantial, optimization efforts could potentially improve Ligand A's binding without sacrificing its favorable safety profile.
Output:
1
2025-04-17 23:35:08,878 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (348.49 & 350.46 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (69.64) is slightly higher than Ligand B (65.12), but both are well below the 140 threshold for oral absorption and acceptable for a cardiovascular GPCR.
3. **logP:** Ligand A (1.94) is within the optimal 1-3 range. Ligand B (-0.765) is slightly below 1, which *could* indicate potential permeability issues, but isn't a hard disqualifier.
4. **HBD:** Ligand A (2) and Ligand B (1) both meet the <=5 criteria.
5. **HBA:** Ligand A (3) and Ligand B (5) both meet the <=10 criteria.
6. **QED:** Ligand A (0.771) has a better QED score than Ligand B (0.521), indicating a more drug-like profile.
7. **DILI:** Ligand A (5.82%) has a significantly lower DILI risk than Ligand B (8.84%). This is a crucial advantage.
8. **BBB:** Ligand A (61.69%) has a higher BBB penetration percentile than Ligand B (53.94%). While ADRB2 isn't a CNS target, some off-target CNS effects are always a consideration, and higher BBB penetration *could* translate to unwanted side effects. However, the difference isn't huge.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.715) is slightly better than Ligand B (-4.833), but both are concerning.
10. **Solubility:** Ligand A (-2.617) is slightly better than Ligand B (-0.795), but both are poor. Solubility is a concern for both.
11. **hERG:** Both ligands have low hERG inhibition risk (0.432 and 0.317 respectively).
12. **Cl_mic:** Ligand B (-13.983) has *much* lower microsomal clearance than Ligand A (40.997), indicating significantly better metabolic stability. This is a major advantage for Ligand B.
13. **t1/2:** Ligand B (-15.834) has a much longer in vitro half-life than Ligand A (-7.41), further supporting its superior metabolic stability.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.065 and 0.012 respectively).
15. **Binding Affinity:** Ligand A (-6.2 kcal/mol) has a slightly better binding affinity than Ligand B (-5.5 kcal/mol). This is a 0.7 kcal/mol difference, which is noticeable but not overwhelming.
**GPCR-Specific Considerations:**
For a cardiovascular GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A has a better logP and slightly better affinity. However, Ligand B's dramatically improved metabolic stability (Cl_mic and t1/2) and lower DILI risk are substantial advantages. The Caco-2 and solubility issues are a concern for both, but can potentially be addressed through formulation strategies.
**Overall Assessment:**
While Ligand A has a slightly better affinity and logP, the significant advantages of Ligand B in terms of metabolic stability (Cl_mic, t1/2) and safety (DILI) outweigh these minor differences. The poor Caco-2 and solubility are shared concerns. Therefore, Ligand B is the more promising candidate.
Output:
0
2025-04-17 23:35:08,878 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, logP, TPSA, Pgp, and binding affinity are key.
* **Molecular Weight:** Both ligands (339.443 and 348.447 Da) fall within the ideal 200-500 Da range.
* **TPSA:** Ligand A (96.69) is slightly higher than Ligand B (88.76). Both are acceptable, but Ligand B is preferable.
* **logP:** Both ligands have good logP values (2.15 and 1.399 respectively), within the optimal 1-3 range. Ligand B is slightly better.
* **H-Bond Donors/Acceptors:** Ligand A has 3 HBD and 4 HBA, while Ligand B has 1 HBD and 5 HBA. Both are within acceptable limits.
* **QED:** Both ligands have good QED scores (0.798 and 0.869), indicating good drug-likeness.
* **DILI:** Ligand B (38.852) has a lower DILI risk than Ligand A (44.009), which is favorable.
* **BBB:** Ligand B (78.209) has a significantly higher BBB penetration percentile than Ligand A (59.364). While not a CNS target, some BBB penetration can be beneficial for distribution.
* **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand B (-4.926) is slightly less negative than Ligand A (-5.468).
* **Solubility:** Ligand B (-0.708) has better aqueous solubility than Ligand A (-3.193).
* **hERG:** Both ligands have low hERG inhibition risk (0.501 and 0.396).
* **Cl_mic:** Ligand A (-1.919) has a lower (better) microsomal clearance than Ligand B (0.917), indicating greater metabolic stability.
* **t1/2:** Both have similar in vitro half-lives (12.097 and 12.775 hours).
* **Pgp:** Ligand A (0.118) has lower P-gp efflux liability than Ligand B (0.015), which is favorable.
* **Binding Affinity:** Ligand A (-7.8 kcal/mol) has a slightly better binding affinity than Ligand B (-7.3 kcal/mol). This is a 0.5 kcal/mol difference, which is significant.
**Overall Assessment:**
Ligand A has a slightly better binding affinity and lower P-gp efflux. However, Ligand B demonstrates better solubility, lower DILI risk, and significantly better BBB penetration. Given the GPCR target class, the balance of properties in Ligand B is more favorable. The slightly weaker binding affinity of Ligand B is outweighed by its superior ADME properties.
**Output:**
0
2025-04-17 23:35:08,879 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
We are targeting ADRB2, a GPCR, so the priorities are logP, Pgp, TPSA, BBB, and affinity. Let's break down the comparison:
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (364.471) is slightly higher than Ligand B (346.479), but this isn't a major concern.
2. **TPSA:** Both are reasonably low, under the 140 A^2 threshold for good absorption. Ligand B (87.89) is slightly better than Ligand A (91.4).
3. **logP:** Ligand A (0.945) is a bit low, potentially hindering permeability. Ligand B (3.048) is within the optimal range (1-3). This is a significant advantage for Ligand B.
4. **H-Bond Donors/Acceptors:** Ligand A (2 HBD, 5 HBA) is slightly better balanced than Ligand B (3 HBD, 7 HBA). However, both are acceptable.
5. **QED:** Ligand A (0.832) has a better QED score than Ligand B (0.647), indicating a more drug-like profile.
6. **DILI:** Ligand B (60.644) has a slightly higher DILI risk than Ligand A (50.446), but both are within an acceptable range.
7. **BBB:** Ligand B (70.803) shows significantly better BBB penetration than Ligand A (34.044). While not strictly *required* for ADRB2 (a cardiovascular target), better BBB penetration can sometimes translate to improved pharmacokinetic properties and reduced off-target effects.
8. **Caco-2 Permeability:** Both are negative, indicating poor permeability. This is a concern for both, but the lower value for Ligand B (-5.061) is slightly better than Ligand A (-5.156).
9. **Aqueous Solubility:** Ligand A (-1.981) has better aqueous solubility than Ligand B (-4.066). Solubility is important for formulation and bioavailability.
10. **hERG Inhibition:** Ligand A (0.142) has a much lower hERG inhibition liability than Ligand B (0.738). This is a critical advantage for Ligand A, as hERG inhibition can lead to cardiotoxicity.
11. **Microsomal Clearance:** Ligand A (-3.613) has a significantly lower (better) microsomal clearance than Ligand B (63.606), indicating better metabolic stability.
12. **In vitro Half-Life:** Ligand B (80.34) has a much longer in vitro half-life than Ligand A (13.559). This is a significant advantage for Ligand B, potentially allowing for less frequent dosing.
13. **P-gp Efflux:** Ligand A (0.045) shows lower P-gp efflux than Ligand B (0.253). Lower efflux is generally preferred for better bioavailability.
14. **Binding Affinity:** Ligand B (-7.1 kcal/mol) has a slightly better binding affinity than Ligand A (-7.5 kcal/mol). While the difference is small, it is still a positive for Ligand B.
**Overall Assessment:**
Ligand B has advantages in logP, BBB, and in vitro half-life, and binding affinity. However, Ligand A has significant advantages in hERG inhibition, microsomal clearance, P-gp efflux, and QED. The hERG liability of Ligand B is a serious concern for a cardiovascular target. The better metabolic stability and lower efflux of Ligand A are also important. The slightly better affinity of Ligand B is not enough to overcome these liabilities.
Output:
1
2025-04-17 23:35:08,879 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (363.483) is slightly higher than Ligand B (350.383), but both are acceptable.
2. **TPSA:** Ligand A (75.44) is significantly better than Ligand B (139.85). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is approaching the upper limit for good oral absorption.
3. **logP:** Ligand A (2.953) is optimal, while Ligand B (-1.734) is quite low. Low logP can hinder membrane permeability. This is a significant advantage for Ligand A.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (5) is better than Ligand B (9). Similar to HBD, lower HBA is generally preferred.
6. **QED:** Ligand A (0.782) is much better than Ligand B (0.488), indicating a more drug-like profile.
7. **DILI:** Ligand B (64.521) has a higher DILI risk than Ligand A (50.446), although both are within an acceptable range.
8. **BBB:** Ligand A (71.19) is significantly better than Ligand B (19.93). While ADRB2 isn't exclusively a CNS target, some peripheral effects are mediated by CNS pathways, and better BBB penetration can be advantageous.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Both have negative solubility values, which is also unusual and suggests poor solubility. The scale is not specified, so it's hard to interpret.
11. **hERG:** Ligand A (0.528) has a slightly higher hERG risk than Ligand B (0.031), but both are very low.
12. **Cl_mic:** Ligand A (87.92) has a higher clearance than Ligand B (3.694), indicating lower metabolic stability. This is a disadvantage for Ligand A.
13. **t1/2:** Ligand B (17.636) has a significantly longer half-life than Ligand A (8.008). This is a major advantage for Ligand B.
14. **Pgp:** Ligand A (0.272) has lower P-gp efflux liability than Ligand B (0.021), which is preferable.
15. **Binding Affinity:** Ligand A (-7.5) has a significantly stronger binding affinity than Ligand B (-1.0). This is a crucial advantage that can outweigh some ADME drawbacks.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are particularly important. Ligand A excels in logP, Pgp, and *especially* affinity. Ligand B has a better half-life and lower P-gp efflux, but the significantly weaker binding affinity and poor logP/TPSA values are concerning.
**Overall Assessment:**
The substantially stronger binding affinity of Ligand A (-7.5 kcal/mol vs -1.0 kcal/mol) is a decisive factor. While Ligand B has better metabolic stability (longer half-life) and lower P-gp efflux, the difference in affinity is so large that it's likely to overcome these drawbacks. The better logP and TPSA of Ligand A also contribute to its potential for better absorption and distribution.
Output:
1
2025-04-17 23:35:08,879 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (359.294 Da) is within the ideal range (200-500 Da). Ligand B (408.351 Da) is also acceptable, but closer to the upper limit.
2. **TPSA:** Ligand A (49.33) is excellent, well below the 140 threshold for oral absorption. Ligand B (78.51) is still reasonable, but higher, potentially impacting absorption.
3. **logP:** Both ligands have good logP values (A: 3.165, B: 2.649), falling within the optimal 1-3 range.
4. **HBD:** Both have 2 HBD, which is good.
5. **HBA:** Ligand A has 2 HBA, Ligand B has 3 HBA. Both are acceptable.
6. **QED:** Both ligands have similar QED values (A: 0.779, B: 0.76), indicating good drug-likeness.
7. **DILI:** Ligand A (52.074) has a slightly better DILI score than Ligand B (58.744), both are acceptable but lower is better.
8. **BBB:** Both ligands have good BBB penetration (A: 72.392, B: 71.501). This is important for GPCRs, but less critical for ADRB2 specifically (cardiovascular focus).
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.672 and -4.998). This is unusual and suggests poor permeability. However, these values are on a scale where negative values are possible, and the absolute values are similar.
10. **Solubility:** Both ligands have negative solubility values (-3.778 and -4.602). This is also unusual and suggests poor solubility. Again, the absolute values are similar.
11. **hERG:** Ligand A (0.87) shows a slightly higher hERG risk than Ligand B (0.599). Lower is better here.
12. **Cl_mic:** Ligand A (18.171) has significantly lower microsomal clearance than Ligand B (38.766), indicating better metabolic stability.
13. **t1/2:** Ligand A (50.537) has a much longer in vitro half-life than Ligand B (-9.295). This is a significant advantage.
14. **Pgp:** Ligand A (0.621) has lower P-gp efflux than Ligand B (0.112), suggesting better bioavailability.
15. **Affinity:** Ligand B (-7.8 kcal/mol) has a stronger binding affinity than Ligand A (-6.7 kcal/mol). This is a 1.1 kcal/mol difference, which is substantial.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), affinity, logP, TPSA, and metabolic stability are key. Ligand B has a significantly better binding affinity. However, Ligand A has better TPSA, metabolic stability (Cl_mic and t1/2), and Pgp efflux. The negative Caco-2 and solubility values for both are concerning, but similar. The difference in affinity is large enough to outweigh the other benefits of Ligand A, especially considering the cardiovascular target.
**Conclusion:**
Despite the better ADME profile of Ligand A, the significantly stronger binding affinity of Ligand B makes it the more promising candidate. A strong starting affinity is crucial for GPCR drug development, and the other properties can be optimized later.
Output:
0
2025-04-17 23:35:08,879 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (341.367) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (104.31) is better than Ligand B (116.76), being closer to the <140 threshold for good oral absorption.
3. **logP:** Ligand A (1.715) is within the optimal range (1-3), while Ligand B (0.581) is a bit low, potentially hindering permeation.
4. **HBD:** Both ligands have acceptable HBD counts (Ligand A: 3, Ligand B: 2), well below the limit of 5.
5. **HBA:** Ligand A (4) is better than Ligand B (7), staying further away from the upper limit of 10.
6. **QED:** Both are reasonable (Ligand A: 0.768, Ligand B: 0.691), indicating good drug-like properties.
7. **DILI:** Ligand B (67.158) has a significantly lower DILI risk than Ligand A (82.784), which is a major advantage.
8. **BBB:** Ligand A (45.211) has a better BBB penetration than Ligand B (25.126). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be useful for understanding off-target effects and overall distribution.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale isn't specified, so it's hard to interpret.
10. **Solubility:** Both have negative solubility values, which is also unusual and suggests poor solubility.
11. **hERG:** Both ligands have very low hERG inhibition risk (Ligand A: 0.069, Ligand B: 0.046).
12. **Cl_mic:** Ligand A (-16.738) has a much lower (and therefore better) microsomal clearance than Ligand B (25.764), indicating greater metabolic stability.
13. **t1/2:** Ligand B (-4.642) has a longer in vitro half-life than Ligand A (-1.46), which is favorable.
14. **Pgp:** Both ligands have very low P-gp efflux liability (Ligand A: 0.012, Ligand B: 0.02).
15. **Binding Affinity:** Ligand B (-6.7 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.4 kcal/mol). This is a substantial advantage, exceeding the 1.5 kcal/mol threshold.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are crucial. Ligand B is better in terms of affinity, and while its logP is lower, the substantial affinity difference outweighs this. The lower DILI risk of Ligand B is also a significant benefit.
**Overall Assessment:**
While Ligand A has better TPSA and BBB penetration, Ligand B's superior binding affinity and significantly lower DILI risk are more important for a viable drug candidate. The longer half-life of Ligand B is also a positive. The solubility and Caco-2 values are concerning for both, but the binding affinity difference is a strong driver.
Output:
0
2025-04-17 23:35:08,880 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output:
**Ligand A: [350.419, 97.56, 1.072, 1, 6, 0.705, 35.867, 77.2, -4.802, -1.629, 0.1, 59.023, -5.847, 0.049, -7.2]**
**Ligand B: [360.487, 75.94, 2.69, 1, 7, 0.768, 67.313, 70.415, -5.319, -3.095, 0.454, 40.046, 10.878, 0.117, -6.7]**
1. **Molecular Weight:** Both ligands are within the ideal 200-500 Da range. A (350.419) is slightly better.
2. **TPSA:** Ligand A (97.56) is higher than the preferred <140, but still acceptable. Ligand B (75.94) is excellent, well below 90, which is beneficial for GPCRs.
3. **logP:** Ligand A (1.072) is at the lower end of optimal, but acceptable. Ligand B (2.69) is closer to the ideal range of 1-3.
4. **H-Bond Donors:** Both have 1 HBD, which is good.
5. **H-Bond Acceptors:** Ligand A (6) is preferable to Ligand B (7).
6. **QED:** Both ligands have similar QED values (A: 0.705, B: 0.768), indicating good drug-likeness.
7. **DILI:** Ligand A (35.867) has a significantly lower DILI risk than Ligand B (67.313). This is a major advantage.
8. **BBB:** Ligand A (77.2) has better BBB penetration than Ligand B (70.415). While not a primary concern for ADRB2 (cardiovascular target), it's a positive.
9. **Caco-2:** Both have negative values, indicating poor permeability. Ligand A (-4.802) is slightly better than Ligand B (-5.319).
10. **Solubility:** Ligand A (-1.629) is better than Ligand B (-3.095).
11. **hERG:** Ligand A (0.1) has a much lower hERG risk than Ligand B (0.454). This is a crucial safety parameter.
12. **Cl_mic:** Ligand B (40.046) has lower microsomal clearance, suggesting better metabolic stability, than Ligand A (59.023).
13. **t1/2:** Ligand B (10.878) has a longer in vitro half-life than Ligand A (-5.847). This is a significant advantage.
14. **Pgp:** Ligand A (0.049) has lower P-gp efflux, which is preferable. Ligand B (0.117) is higher.
15. **Binding Affinity:** Ligand A (-7.2) has a slightly better binding affinity than Ligand B (-6.7).
**Overall Assessment:**
For an ADRB2 target (cardiovascular), the key priorities are potency (affinity), safety (hERG, DILI), and reasonable ADME properties. Ligand A has a slightly better affinity, *significantly* lower DILI and hERG risk, and better solubility. While Ligand B has better metabolic stability (lower Cl_mic and longer t1/2) and a slightly better TPSA, the safety profile of Ligand A is far superior. The improved safety profile outweighs the modest ADME advantages of Ligand B.
Output:
1
2025-04-17 23:35:08,880 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (366.893 and 348.447 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (78.09) is better than Ligand B (81.75). Both are below 140, but lower TPSA generally favors absorption.
3. **logP:** Ligand A (2.856) is optimal (1-3). Ligand B (-0.403) is significantly lower, which could hinder membrane permeability. This is a substantial negative for Ligand B.
4. **HBD:** Both ligands have 2 HBD, which is within the acceptable limit of 5.
5. **HBA:** Ligand A has 3 HBA, and Ligand B has 4. Both are below the limit of 10.
6. **QED:** Ligand A (0.86) is considerably better than Ligand B (0.462). A higher QED suggests a more drug-like profile.
7. **DILI:** Ligand A (39.201) has a slightly higher DILI risk than Ligand B (18.418), but both are well below the concerning threshold of 60.
8. **BBB:** Ligand A (75.107) has a much higher BBB penetration potential than Ligand B (29.275). While ADRB2 isn't strictly a CNS target, some CNS exposure is not necessarily detrimental, and higher BBB is generally favorable.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-5.059) is slightly better than Ligand B (-5.124).
10. **Solubility:** Ligand A (-4.452) is better than Ligand B (-1.268). Higher solubility is important for bioavailability.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.454 and 0.105 respectively).
12. **Cl_mic:** Ligand A (27.835) has a higher microsomal clearance than Ligand B (6.358), indicating faster metabolism. This is a negative for Ligand A.
13. **t1/2:** Ligand B (-14.604) has a longer *in vitro* half-life than Ligand A (-26.41). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.09) has lower P-gp efflux than Ligand B (0.002), which is favorable.
15. **Affinity:** Ligand A (-7.7 kcal/mol) has a stronger binding affinity than Ligand B (-6.8 kcal/mol). This is a 0.9 kcal/mol difference, which is substantial and can outweigh some ADME drawbacks.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A excels in logP, Pgp, and significantly in affinity. Ligand B has better metabolic stability (lower Cl_mic and longer t1/2) and lower DILI risk. However, the poor logP of Ligand B is a major concern for permeability and overall drug-like properties. The stronger binding affinity of Ligand A is a significant advantage, and the differences in other parameters are less critical given this potency.
**Conclusion:**
Despite the slightly higher clearance and DILI risk, Ligand A's superior logP, QED, BBB, solubility, and especially its significantly stronger binding affinity make it the more promising drug candidate.
Output:
1
2025-04-17 23:35:08,880 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, we prioritize logP, Pgp, TPSA, and affinity, alongside general drug-like properties.
* **Molecular Weight:** Both ligands (348.45 and 363.89 Da) fall within the ideal 200-500 Da range.
* **TPSA:** Ligand A (67.67) is better than Ligand B (77.04), being closer to the <140 threshold for good absorption.
* **logP:** Ligand A (1.3) is optimal, while Ligand B (3.225) is approaching the upper limit of the preferred range. Higher logP can sometimes lead to off-target effects.
* **H-Bond Donors/Acceptors:** Both have acceptable HBD/HBA counts (A: 0/5, B: 1/5).
* **QED:** Both have good QED scores (A: 0.826, B: 0.854), indicating good drug-likeness.
* **DILI:** Ligand A (21.91) has a significantly lower DILI risk than Ligand B (29.24), which is a crucial advantage.
* **BBB:** Both have good BBB penetration (A: 72.01, B: 77.2), but this is less critical for a cardiovascular target.
* **Caco-2:** Both have negative Caco-2 values, which is unusual and requires further investigation. However, we'll assume they represent permeability and that the values are comparable.
* **Solubility:** Ligand A (-0.977) is better than Ligand B (-2.88), indicating better aqueous solubility.
* **hERG:** Both have low hERG inhibition liability (A: 0.353, B: 0.784), which is positive.
* **Cl_mic:** Ligand A (21.78) has significantly lower microsomal clearance than Ligand B (49.36), suggesting better metabolic stability.
* **t1/2:** Ligand B (22.79) has a longer in vitro half-life than Ligand A (1.25), which is generally desirable.
* **Pgp:** Both have low Pgp efflux liability (A: 0.047, B: 0.09).
* **Affinity:** Ligand A (-7.1 kcal/mol) has a slightly better binding affinity than Ligand B (-5.6 kcal/mol). While the difference is not huge, it's still a benefit.
**Overall Assessment:**
Ligand A is the preferred candidate. It has a better logP, TPSA, DILI score, solubility, and metabolic stability (lower Cl_mic). The slightly better binding affinity further strengthens its position. While Ligand B has a longer half-life, the other advantages of Ligand A outweigh this single benefit, particularly the lower DILI risk and better predicted absorption/solubility.
**Output:**
1
2025-04-17 23:35:08,880 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for the ADRB2, a cardiovascular GPCR. Therefore, the key properties to prioritize are binding affinity, logP, TPSA, Pgp efflux, and, to a lesser extent, BBB.
Let's compare the ligands property by property:
1. **MW:** Both ligands (389.279 and 352.479 Da) fall within the ideal range of 200-500 Da.
2. **TPSA:** Ligand A (71.78) is significantly better than Ligand B (104.53). A TPSA under 90 is preferred for GPCRs, and A is closer to that threshold.
3. **logP:** Ligand A (2.444) is optimal, while Ligand B (0.407) is quite low, potentially hindering membrane permeability.
4. **HBD/HBA:** Ligand A (1 HBD, 4 HBA) is preferable to Ligand B (3 HBD, 4 HBA). While both are acceptable, minimizing HBDs can improve permeability.
5. **QED:** Ligand A (0.728) is much better than Ligand B (0.413), indicating better overall drug-likeness.
6. **DILI:** Ligand A (38.581) has a significantly lower DILI risk than Ligand B (4.459), which is a major advantage.
7. **BBB:** Ligand A (74.913) shows better BBB penetration than Ligand B (56.766), though this is less critical for a cardiovascular target.
8. **Caco-2:** Ligand A (-4.993) is better than Ligand B (-5.8), suggesting better intestinal absorption.
9. **Solubility:** Ligand A (-3.725) is better than Ligand B (-1.78), which is important for bioavailability.
10. **hERG:** Both ligands have low hERG inhibition liability (0.423 and 0.15), which is good.
11. **Cl_mic:** Ligand A (31.561) has a better (lower) microsomal clearance than Ligand B (-13.74). Note the negative value for B suggests very slow clearance, which could be a concern.
12. **t1/2:** Ligand A (24.012) has a longer in vitro half-life than Ligand B (-22.586). Again, the negative value for B is concerning.
13. **Pgp:** Both ligands have very low Pgp efflux (0.106 and 0.003).
14. **Binding Affinity:** Ligand B (-6.5 kcal/mol) has a slightly better binding affinity than Ligand A (-6.0 kcal/mol), but the difference is not substantial enough to overcome the numerous advantages of Ligand A.
**Conclusion:**
Ligand A consistently outperforms Ligand B across most critical ADME properties (TPSA, logP, QED, DILI, solubility, Cl_mic, t1/2) and has a comparable binding affinity. The superior drug-like properties and safety profile of Ligand A make it the more promising drug candidate.
**Output:**
1
2025-04-17 23:35:08,880 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands (342.399 and 353.369 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (98.32) is slightly higher than Ligand B (84.23). Both are below the 140 threshold for oral absorption, but B is preferable being closer to the 90 threshold for potential CNS effects (though not a primary concern for ADRB2).
3. **logP:** Ligand A (1.199) is within the optimal range (1-3), while Ligand B (2.045) is also acceptable. No major difference.
4. **HBD:** Ligand A (3) and Ligand B (2) are both acceptable, below the 5 threshold.
5. **HBA:** Both ligands have 4 HBA, which is well within the acceptable limit of 10.
6. **QED:** Both ligands have good QED scores (0.734 and 0.82), indicating good drug-likeness.
7. **DILI:** Ligand B (36.293) has a significantly lower DILI risk than Ligand A (42.264). This is a strong advantage for Ligand B.
8. **BBB:** Ligand B (89.957) has a much higher BBB penetration percentile than Ligand A (43.311). While ADRB2 isn't a primary CNS target, some peripheral ADRB2 activity can influence CNS pathways, so higher BBB is a slight benefit.
9. **Caco-2:** Ligand A (-5.271) and Ligand B (-4.694) both have negative values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Ligand A (-2.815) and Ligand B (-3.549) both have negative values, suggesting poor solubility.
11. **hERG:** Ligand A (0.237) has a lower hERG inhibition liability than Ligand B (0.522). This is a significant advantage for Ligand A, as it reduces the risk of cardiotoxicity.
12. **Cl_mic:** Ligand A (-0.675) has a lower (better) microsomal clearance than Ligand B (38.033). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (5.818) has a slightly longer in vitro half-life than Ligand B (6.243).
14. **Pgp:** Ligand A (0.01) has a much lower P-gp efflux liability than Ligand B (0.063). This is a significant advantage for Ligand A, as it suggests better oral bioavailability and potentially better tissue distribution.
15. **Binding Affinity:** Ligand A (-6.7 kcal/mol) has a slightly better binding affinity than Ligand B (-5.7 kcal/mol). This 1 kcal/mol difference is substantial and can outweigh some ADME drawbacks.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp efflux, and binding affinity are crucial. Ligand A has a slightly better logP, significantly lower Pgp efflux, and better binding affinity. Ligand B has a better TPSA and BBB. The DILI risk is also lower for Ligand B.
**Overall Assessment:**
While Ligand B has advantages in DILI risk and BBB penetration, the stronger binding affinity, lower Pgp efflux, and better metabolic stability of Ligand A are more critical for a successful GPCR drug candidate. The hERG risk is also lower for Ligand A. The affinity difference is substantial enough to offset the slightly higher DILI risk.
Output:
1
2025-04-17 23:35:08,880 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [380.901, 75.19, 2.596, 1, 5, 0.749, 54.75, 39.822, -5.012, -2.38, 0.064, 44.021, 26.071, 0.042, -6.6]**
**Ligand B: [349.391, 105.56, -0.576, 2, 6, 0.715, 49.864, 65.529, -5.158, -1.472, 0.052, -7.841, -5.676, 0.004, -7.4]**
1. **Molecular Weight:** Both ligands are within the ideal 200-500 Da range. Ligand A (380.9) is slightly higher than Ligand B (349.4). No strong preference here.
2. **TPSA:** Ligand A (75.2) is better than Ligand B (105.6). ADRB2 is a cardiovascular target, so BBB penetration isn't critical, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (2.60) is optimal (1-3). Ligand B (-0.58) is significantly below this range, which could hinder membrane permeability and absorption. This is a significant negative for Ligand B.
4. **H-Bond Donors:** Ligand A (1) is good. Ligand B (2) is acceptable, but slightly less favorable.
5. **H-Bond Acceptors:** Ligand A (5) is good. Ligand B (6) is acceptable.
6. **QED:** Both ligands have similar, good QED values (0.749 and 0.715).
7. **DILI:** Ligand A (54.8) is slightly higher than Ligand B (49.9), but both are within an acceptable range (<60).
8. **BBB:** Not a primary concern for a cardiovascular target. Ligand B (65.5) is higher, but this isn't a deciding factor.
9. **Caco-2:** Both have negative values, indicating poor permeability. This is concerning for both.
10. **Aqueous Solubility:** Both have negative values, indicating poor solubility. This is concerning for both.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.064 and 0.052). Excellent for both.
12. **Microsomal Clearance:** Ligand A (44.0) is higher than Ligand B (-7.8). Lower clearance is preferred for metabolic stability, giving Ligand B an advantage.
13. **In vitro Half-Life:** Ligand A (26.1) is better than Ligand B (-5.7). Longer half-life is preferred.
14. **P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.042 and 0.004). Excellent for both.
15. **Binding Affinity:** Ligand B (-7.4) has a slightly better binding affinity than Ligand A (-6.6). A 0.8 kcal/mol difference is significant, but needs to be weighed against other factors.
**Overall Assessment:**
Ligand B has a better binding affinity and lower microsomal clearance, which are positive attributes. However, its significantly lower logP is a major concern. Poor logP can severely limit absorption and bioavailability. Ligand A, while having slightly weaker affinity, has a much more favorable logP value, making it more likely to be absorbed and reach its target. The slightly better half-life of Ligand A also contributes to its favorability. Considering the GPCR-specific priorities (logP, affinity), Ligand A is the better candidate.
Output:
1
2025-04-17 23:35:08,881 - INFO - Batch 415 complete. Total preferences: 6640
2025-04-17 23:35:08,881 - INFO - Processing batch 416/512...
2025-04-17 23:35:56,263 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (343.391 and 353.503 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (48.0) is significantly better than Ligand A (129.89). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (2.875) is within the optimal 1-3 range, while Ligand A (0.513) is quite low, potentially hindering membrane permeability. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (3) is acceptable, while Ligand B (0) is even better, potentially improving permeability.
5. **HBA:** Ligand A (6) is acceptable, and Ligand B (4) is also good.
6. **QED:** Both ligands have similar, good QED values (0.744 and 0.706).
7. **DILI:** Ligand B (14.424) has a much lower DILI risk than Ligand A (68.282). This is a major advantage for Ligand B.
8. **BBB:** Ligand B (82.474) has a higher BBB penetration score than Ligand A (55.913). While not crucial for a cardiovascular target, it's not detrimental.
9. **Caco-2:** Ligand A (-5.661) and Ligand B (-4.573) are both negative, indicating poor permeability.
10. **Solubility:** Ligand A (-3.435) and Ligand B (-2.663) are both negative, indicating poor solubility.
11. **hERG:** Ligand A (0.356) has a lower hERG risk than Ligand B (0.657), which is a slight advantage.
12. **Cl_mic:** Ligand A (-19.467) has a much lower (better) microsomal clearance than Ligand B (81.485), suggesting better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand B (13.111) has a longer in vitro half-life than Ligand A (-17.245). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.025) has a much lower Pgp efflux liability than Ligand B (0.34), which is a significant advantage for Ligand A.
15. **Binding Affinity:** Ligand A (-7.9) has a slightly better binding affinity than Ligand B (-7.5). This is a moderate advantage for Ligand A.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP and has a good TPSA. Ligand A has a slightly better affinity and significantly lower Pgp efflux. However, the significantly lower DILI risk and longer half-life of Ligand B are compelling. The metabolic stability of Ligand A is good, but the DILI risk is concerning.
**Overall Assessment:**
While Ligand A has advantages in affinity, Pgp efflux, and metabolic stability, Ligand B's superior logP, lower DILI risk, and longer half-life outweigh these benefits. The poor Caco-2 and solubility of both are concerning, but can be addressed with formulation strategies. The lower DILI risk is particularly important for a cardiovascular drug.
Output:
0
2025-04-17 23:35:56,264 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [346.475, 76.02, 2.21, 2, 4, 0.72, 27.336, 68.554, -4.982, -2.85, 0.16, 36.664, 12.555, 0.055, -6.6]
**Ligand B:** [343.366, 93.54, 1.491, 2, 7, 0.729, 78.364, 83.172, -5.59, -2.744, 0.391, 20.874, -6.329, 0.198, -6.1]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). A (346.475) is slightly higher than B (343.366), but the difference is negligible.
2. **TPSA:** A (76.02) is excellent, well below the 140 threshold for oral absorption. B (93.54) is still acceptable but less ideal.
3. **logP:** A (2.21) is optimal. B (1.491) is a bit low, potentially impacting permeability.
4. **HBD:** Both have 2 HBD, which is good.
5. **HBA:** A has 4 HBA, which is good. B has 7 HBA, which is a bit higher, potentially impacting permeability.
6. **QED:** Both are good (0.72 and 0.729).
7. **DILI:** A (27.336) has a significantly lower DILI risk than B (78.364). This is a major advantage for A.
8. **BBB:** A (68.554) is reasonable, while B (83.172) is better. For a cardiovascular target, BBB isn't *critical*, but higher is generally preferred.
9. **Caco-2:** A (-4.982) is better than B (-5.59), indicating better absorption.
10. **Solubility:** Both are very poor (-2.85 and -2.744). This is a concern for both, but might be addressable with formulation.
11. **hERG:** A (0.16) is much lower than B (0.391), indicating a lower risk of cardiotoxicity. This is a significant advantage given the cardiovascular target.
12. **Cl_mic:** B (20.874) has a considerably lower microsomal clearance than A (36.664), indicating better metabolic stability.
13. **t1/2:** A (12.555) has a longer in vitro half-life than B (-6.329).
14. **Pgp:** A (0.055) has lower P-gp efflux than B (0.198), which is favorable.
15. **Affinity:** A (-6.6) has slightly better binding affinity than B (-6.1), although the difference is not huge.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, and affinity. A performs better on logP, TPSA, and Pgp. Affinity is only slightly better for A. Crucially, A's significantly better DILI and hERG profiles are major advantages for a cardiovascular drug. B has better BBB penetration and metabolic stability, but these are less critical for this target.
**Conclusion:**
Considering the balance of properties, particularly the significantly lower DILI and hERG risk, and the slightly better logP, TPSA, Pgp, and affinity, **Ligand A** is the more promising drug candidate.
**Output:**
1
2025-04-17 23:35:56,264 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (341.415 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (111.25) is higher than Ligand B (66.81). For a cardiovascular GPCR like ADRB2, TPSA is less critical than for CNS targets, but lower is still preferable for absorption. Ligand B is significantly better here.
3. **logP:** Ligand A (1.469) is within the optimal range, while Ligand B (0.422) is a bit low, potentially hindering membrane permeability. Ligand A is better.
4. **HBD:** Ligand A (3) and Ligand B (1) are both acceptable.
5. **HBA:** Ligand A (4) and Ligand B (5) are both acceptable.
6. **QED:** Both ligands have good QED scores (A: 0.77, B: 0.808), indicating good drug-like properties.
7. **DILI:** Ligand A (34.626) has a slightly higher DILI risk than Ligand B (24.118), but both are below the 40 threshold and considered low risk.
8. **BBB:** Ligand A (70.027) has a better BBB penetration score than Ligand B (45.522). While ADRB2 is not a CNS target, some degree of BBB penetration can be useful for understanding off-target effects.
9. **Caco-2:** Ligand A (-5.355) and Ligand B (-4.73) are both negative, indicating poor permeability.
10. **Solubility:** Ligand A (-3.169) has slightly better solubility than Ligand B (-0.125).
11. **hERG:** Both ligands have very low hERG inhibition liability (A: 0.573, B: 0.139), which is excellent.
12. **Cl_mic:** Ligand A (-16.987) has a significantly lower (better) microsomal clearance than Ligand B (-11.745), suggesting greater metabolic stability.
13. **t1/2:** Ligand A (19.987) has a longer in vitro half-life than Ligand B (9.355), which is desirable.
14. **Pgp:** Both ligands have very low P-gp efflux liability (A: 0.008, B: 0.014).
15. **Binding Affinity:** Both ligands have the same binding affinity (-5.8 kcal/mol), so this parameter does not differentiate them.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, and metabolic stability (Cl_mic, t1/2) are key. Ligand A has a better logP and significantly better metabolic stability (lower Cl_mic and longer t1/2). While Ligand B has a lower TPSA, the difference isn't dramatic enough to outweigh the advantages of Ligand A in logP and metabolic stability.
**Conclusion:**
Ligand A demonstrates a more favorable balance of properties, particularly regarding metabolic stability and logP, which are important for a GPCR target.
Output:
1
2025-04-17 23:35:56,264 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (358.471 and 360.571 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (81.66) is higher than Ligand B (33.95). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B is significantly better.
3. **logP:** Ligand A (2.883) is within the optimal 1-3 range. Ligand B (4.587) is slightly higher, potentially increasing off-target interactions and decreasing solubility. Ligand A is better.
4. **HBD:** Ligand A (1) is good. Ligand B (0) is also acceptable. No strong preference.
5. **HBA:** Ligand A (8) is acceptable. Ligand B (5) is also acceptable. No strong preference.
6. **QED:** Both ligands have good QED scores (0.667 and 0.724), indicating drug-like properties. No significant difference.
7. **DILI:** Ligand A (60.527) is higher than Ligand B (21.404). This is a significant advantage for Ligand B, indicating a lower risk of liver injury.
8. **BBB:** Ligand A (73.672) and Ligand B (88.29) are both reasonably high, but Ligand B is better. While ADRB2 isn't a CNS target, some peripheral exposure can be undesirable.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.728 and -5.079), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Both ligands have negative solubility values (-2.754 and -4.036), which is also concerning. Poor solubility can hinder absorption and bioavailability. Ligand B is slightly better.
11. **hERG:** Ligand A (0.125) is lower than Ligand B (0.839), indicating a lower risk of hERG inhibition and cardiotoxicity. This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand A (37.796) has lower microsomal clearance than Ligand B (67.778), suggesting better metabolic stability. This is a positive for Ligand A.
13. **t1/2:** Ligand A (13.626) and Ligand B (12.129) are similar. No strong preference.
14. **Pgp:** Ligand A (0.361) has lower P-gp efflux than Ligand B (0.679), indicating better absorption and bioavailability. This is a positive for Ligand A.
15. **Binding Affinity:** Ligand B (-6.7 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.4 kcal/mol). This is a substantial advantage for Ligand B, potentially outweighing some of the ADME drawbacks.
**Overall Assessment:**
Ligand B has a significantly better binding affinity and a much lower DILI risk. It also has better BBB penetration and solubility. Ligand A has better hERG, Cl_mic, and Pgp properties. The poor Caco-2 and solubility are concerning for both, but the strong affinity of Ligand B is a major advantage for a GPCR target. The lower DILI risk is also a critical factor. While Ligand A has some favorable ADME properties, the binding affinity difference is substantial enough to favor Ligand B.
Output:
0
2025-04-17 23:35:56,264 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (360.401 and 354.491 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (59.08) is better than Ligand B (67.87). Both are below 140, but A is closer to the optimal for oral absorption.
3. **logP:** Ligand A (0.937) is slightly lower than the optimal 1-3 range, but still acceptable. Ligand B (2.175) is better positioned within the optimal range.
4. **HBD:** Ligand A (0) is preferable to Ligand B (1). Fewer HBDs generally improve permeability.
5. **HBA:** Both ligands have 4 HBA, which is within the acceptable limit of 10.
6. **QED:** Ligand B (0.794) has a slightly better QED score than Ligand A (0.634), indicating a more drug-like profile.
7. **DILI:** Ligand A (19.891) has a significantly lower DILI risk than Ligand B (38.038). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (95.347) has a much higher BBB penetration percentile than Ligand B (77.782). While ADRB2 isn't exclusively a CNS target, good BBB penetration can be beneficial, and is a priority for GPCRs.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.45 and -4.521), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-1.084) has better solubility than Ligand B (-3.011). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.504) has a lower hERG inhibition liability than Ligand B (0.303), indicating a lower risk of cardiotoxicity.
12. **Cl_mic:** Ligand A (19.091) has a significantly lower microsomal clearance than Ligand B (54.889), suggesting better metabolic stability.
13. **t1/2:** Ligand B (4.14) has a longer in vitro half-life than Ligand A (1.655). This is a positive for Ligand B.
14. **Pgp:** Ligand A (0.076) has a lower P-gp efflux liability than Ligand B (0.096), which is favorable for oral bioavailability and potentially CNS exposure.
15. **Binding Affinity:** Ligand B (-7.7 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.8 kcal/mol). This is a substantial advantage for Ligand B, potentially outweighing some of its ADME drawbacks.
**Overall Assessment:**
Ligand B has a significantly better binding affinity, which is crucial for a GPCR target. It also has a longer half-life and a better QED score. However, Ligand A demonstrates superior safety profiles with lower DILI and hERG risk, better BBB penetration, and improved metabolic stability (lower Cl_mic). The Caco-2 values are concerning for both. Given the importance of potency for GPCRs, and the substantial difference in affinity (-7.7 vs -5.8 kcal/mol), I will prioritize Ligand B despite its ADME liabilities. The improved affinity could allow for a lower dose, potentially mitigating some of the ADME concerns.
Output:
0
2025-04-17 23:35:56,265 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (362.323 and 340.427 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (67.43) is better than Ligand B (86.09). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (3.132) is slightly higher than Ligand B (1.824), placing it closer to the optimal 1-3 range. Ligand B is a bit low, potentially hindering permeation.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1), but both are within the acceptable limit of 5.
5. **HBA:** Ligand A (3) is lower than Ligand B (4), which is preferable.
6. **QED:** Both ligands have good QED scores (0.791 and 0.906), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (63.086) has a higher DILI risk than Ligand B (50.097). This is a significant concern, as lower DILI is highly desirable.
8. **BBB:** Both ligands have reasonable BBB penetration (75.107 and 64.986), but this isn't a primary concern for a cardiovascular target.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.837 and -4.787), which is unusual. These values are likely indicating poor permeability.
10. **Solubility:** Both ligands have negative solubility values (-3.453 and -3.275), which is also unusual. These values are likely indicating poor solubility.
11. **hERG:** Ligand A (0.385) has a slightly better hERG profile than Ligand B (0.547), lower risk is better.
12. **Cl_mic:** Ligand A (20.424) has a higher microsomal clearance than Ligand B (17.375), indicating lower metabolic stability.
13. **t1/2:** Ligand B (-2.675) has a longer in vitro half-life than Ligand A (-8.381), which is a significant advantage.
14. **Pgp:** Ligand A (0.146) has lower P-gp efflux liability than Ligand B (0.119), which is favorable.
15. **Binding Affinity:** Ligand B (-9.5 kcal/mol) has a significantly stronger binding affinity than Ligand A (-7.7 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME drawbacks.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), affinity, logP, TPSA, and Pgp are important. Ligand B excels in affinity, while Ligand A has better TPSA and Pgp. However, the difference in affinity is substantial (1.8 kcal/mol). The DILI risk for Ligand A is also concerning.
**Conclusion:**
Despite the slightly better TPSA and Pgp values for Ligand A, the significantly stronger binding affinity of Ligand B (-9.5 vs -7.7 kcal/mol), combined with the lower DILI risk and longer half-life, makes it the more promising drug candidate. The negative Caco-2 and solubility values are concerning for both, but can be addressed during lead optimization.
Output:
0
2025-04-17 23:35:56,265 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final decision:
**1. Molecular Weight (MW):** Both ligands (347.415 and 343.387 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. Topological Polar Surface Area (TPSA):** Ligand A (82.11) is better than Ligand B (98.14). For a GPCR, keeping TPSA lower is generally preferred to aid permeability. Ligand B is approaching the upper limit for good oral absorption.
**3. Lipophilicity (logP):** Ligand A (0.285) is lower than Ligand B (0.739). Both are within the 1-3 range, but Ligand A is on the lower side. While not a dealbreaker, slightly higher logP can be beneficial for membrane permeability.
**4. H-Bond Donors (HBD):** Both ligands have 2 HBD, which is within the ideal range (<=5). No difference.
**5. H-Bond Acceptors (HBA):** Ligand A has 5 HBA, while Ligand B has 6. Both are acceptable (<=10), but lower is generally preferable.
**6. QED:** Both ligands have high QED scores (0.821 and 0.834), indicating good drug-like properties. No significant difference.
**7. DILI Risk:** Ligand A (31.136) has a significantly lower DILI risk than Ligand B (70.182). This is a major advantage for Ligand A. A DILI risk above 60 is concerning.
**8. BBB Penetration:** Ligand A (46.375) has better BBB penetration than Ligand B (36.371). While ADRB2 isn't strictly a CNS target, some peripheral effects can be modulated by CNS penetration, and it's generally a positive trait.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-5.303 and -5.197). This is unusual and suggests poor permeability. However, the values are very close, so it doesn't differentiate the two significantly.
**10. Aqueous Solubility:** Ligand A (-1.603) is slightly better than Ligand B (-2.042), indicating slightly higher solubility.
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.274 and 0.048). This is excellent.
**12. Microsomal Clearance:** Ligand A (16.273) has higher microsomal clearance than Ligand B (-2.631). This means Ligand B is more metabolically stable, which is a positive.
**13. In vitro Half-Life:** Ligand A (10.732) has a shorter half-life than Ligand B (4.021). This is a disadvantage for Ligand A.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.02 and 0.034). This is good.
**15. Binding Affinity:** Both ligands have very similar and strong binding affinities (-6.7 and -6.6 kcal/mol). The difference is negligible.
**GPCR-Specific Priorities & Overall Assessment:**
For a GPCR like ADRB2, logP, TPSA, and affinity are key. While both ligands have comparable affinity, Ligand A has a better TPSA and a significantly lower DILI risk. Ligand B has better metabolic stability (lower Cl_mic) and a longer half-life, but the high DILI risk is a major concern. The slightly lower logP of Ligand A is less concerning than the DILI risk of Ligand B.
Considering the balance of properties, especially the critical DILI risk and the acceptable TPSA, Ligand A is the more promising candidate.
Output:
1
2025-04-17 23:35:56,265 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (342.443 and 345.487 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (69.04) is slightly higher than Ligand B (56.15). Both are below the 140 threshold for oral absorption, but B is closer to the <90 ideal for potential CNS penetration, although this isn't a primary concern for ADRB2.
3. **logP:** Ligand A (2.477) is within the optimal 1-3 range. Ligand B (3.227) is slightly higher, but still acceptable.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Both ligands have 5 HBA, which is good.
6. **QED:** Ligand A (0.8) has a significantly better QED score than Ligand B (0.446), indicating a more drug-like profile.
7. **DILI:** Ligand A (16.285) has a slightly higher DILI risk than Ligand B (12.602), but both are well below the concerning threshold of 60.
8. **BBB:** Ligand B (81.698) has a much higher BBB penetration percentile than Ligand A (57.852). While ADRB2 isn't a primary CNS target, some peripheral ADRB2 receptors can be affected by CNS penetration.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and likely indicates a problem with the assay or data. We'll have to rely on other parameters for absorption prediction.
10. **Solubility:** Ligand A (-1.927) has better solubility than Ligand B (-3.153). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.37) has a lower hERG risk than Ligand B (0.635), which is a significant advantage for cardiovascular targets.
12. **Cl_mic:** Ligand B (70.754) has a higher microsomal clearance than Ligand A (51.729), suggesting lower metabolic stability.
13. **t1/2:** Ligand A (-10.158) has a more negative in vitro half-life than Ligand B (-2.314), suggesting a longer half-life.
14. **Pgp:** Ligand A (0.089) has lower P-gp efflux liability than Ligand B (0.449), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand B (-5.7 kcal/mol) has a slightly better binding affinity than Ligand A (-4.5 kcal/mol). This is a 1.2 kcal/mol difference, which is substantial.
**GPCR-Specific Priorities & Overall Assessment:**
For a GPCR like ADRB2, logP, TPSA, Pgp efflux, and binding affinity are key. Ligand B has a slightly better logP and significantly better binding affinity. However, Ligand A has a much better QED score, better solubility, lower hERG risk, lower Pgp efflux, and a more favorable half-life. The higher BBB penetration of Ligand B is not a major advantage for a primarily peripheral target like ADRB2. The difference in binding affinity is significant, but the overall ADME profile of Ligand A is superior, particularly the lower hERG risk and better predicted metabolic stability.
Considering the balance of these factors, I believe Ligand A is the more promising drug candidate.
Output:
1
2025-04-17 23:35:56,265 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [350.547, 49.41, 4.138, 1, 2, 0.732, 22.722, 82.474, -4.688, -3.374, 0.699, 67.607, -12.669, 0.503, -6.1]
**Ligand B:** [357.376, 55.32, 3.206, 0, 4, 0.703, 47.732, 85.111, -4.201, -3.393, 0.645, 65.447, -28.159, 0.28, -5.7]
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). A: 350.5, B: 357.4 - very similar.
2. **TPSA:** Both are reasonably good, but A (49.41) is better than B (55.32). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally aids absorption.
3. **logP:** Both are within the optimal range (1-3). A (4.138) is slightly higher than B (3.206). While higher logP can sometimes be problematic, it's not a major concern here, and could contribute to better membrane permeability.
4. **HBD:** A (1) is better than B (0). Fewer HBDs generally improve permeability.
5. **HBA:** A (2) is better than B (4). Fewer HBAs generally improve permeability.
6. **QED:** Both are good (A: 0.732, B: 0.703), indicating drug-like properties.
7. **DILI:** A (22.722) is significantly better than B (47.732). This is a crucial advantage for A.
8. **BBB:** Both are good, but B (85.111) is slightly better than A (82.474). However, as this is a cardiovascular target, BBB penetration isn't a primary concern.
9. **Caco-2:** Both are negative, indicating poor permeability. A (-4.688) is slightly worse than B (-4.201).
10. **Solubility:** Both are negative, indicating poor solubility. A (-3.374) is slightly worse than B (-3.393).
11. **hERG:** Both are low risk (A: 0.699, B: 0.645).
12. **Cl_mic:** Both are reasonable, but A (67.607) is slightly higher than B (65.447), suggesting slightly lower metabolic stability.
13. **t1/2:** A (-12.669) is significantly better than B (-28.159). This is a major advantage for A.
14. **Pgp:** Both are low (A: 0.503, B: 0.28), indicating low efflux. B is slightly better.
15. **Affinity:** Both are excellent (A: -6.1, B: -5.7). A is slightly better.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, we prioritize logP, TPSA, Pgp, and affinity. A has a slightly better logP, better TPSA, comparable Pgp, and better affinity. The significantly lower DILI risk and much better in vitro half-life for Ligand A are also very important. While both have poor Caco-2 and solubility, the other advantages of A outweigh this.
**Conclusion:**
Ligand A is the more promising candidate due to its superior DILI profile, better half-life, and slightly better affinity, TPSA, and logP. The slight advantage in these parameters, combined with the significantly improved safety profile, makes it the preferred choice.
1
2025-04-17 23:35:56,265 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (386.495 and 342.447 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (100.62) is slightly higher than Ligand B (79.7). Both are below the 140 A^2 threshold for good oral absorption, but Ligand B is closer to the preferred <90 A^2 for GPCRs.
**3. logP:** Ligand B (2.772) is within the optimal 1-3 range, while Ligand A (0.667) is slightly below 1, potentially hindering permeation. This is a significant advantage for Ligand B.
**4. H-Bond Donors:** Both have 1 HBD, which is good.
**5. H-Bond Acceptors:** Both have 5 HBA, which is within the acceptable range.
**6. QED:** Ligand B (0.926) has a substantially higher QED score than Ligand A (0.742), indicating a more drug-like profile.
**7. DILI:** Both ligands have similar DILI risk (54.556 and 50.291 percentile), and both are acceptable (below 60).
**8. BBB:** Ligand A (82.086) has a better BBB penetration percentile than Ligand B (71.384). While ADRB2 is a cardiovascular target, some CNS off-target effects are always a consideration, and higher BBB penetration could be a slight advantage.
**9. Caco-2 Permeability:** Ligand A (-4.759) has a slightly better Caco-2 permeability than Ligand B (-5.177), but both are negative values, indicating poor permeability.
**10. Aqueous Solubility:** Ligand A (-3.712) has slightly better solubility than Ligand B (-3.125), but both are poor.
**11. hERG Inhibition:** Ligand A (0.271) has a lower hERG inhibition liability than Ligand B (0.412), which is a positive.
**12. Microsomal Clearance:** Ligand B (32.269) has a lower microsomal clearance than Ligand A (49.936), suggesting better metabolic stability.
**13. In vitro Half-Life:** Ligand B (-18.696) has a slightly longer in vitro half-life than Ligand A (-21.299).
**14. P-gp Efflux:** Ligand A (0.121) has lower P-gp efflux liability than Ligand B (0.175), which is favorable.
**15. Binding Affinity:** Ligand A (-7.9 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.3 kcal/mol). This is a substantial advantage, exceeding the 1.5 kcal/mol threshold.
**Overall Assessment:**
The stronger binding affinity of Ligand A is a major advantage, and outweighs some of its less favorable ADME properties. While Ligand B has better QED, logP, and metabolic stability, the difference in binding affinity is significant. The slightly better BBB penetration of Ligand A is a minor plus. Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), the affinity difference is the most important factor.
Output:
1
2025-04-17 23:35:56,266 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (387.433) is slightly higher than Ligand B (347.459), but both are acceptable.
2. **TPSA:** Ligand B (62.21) is significantly better than Ligand A (101.29). ADRB2 is not a CNS target, but lower TPSA generally improves absorption.
3. **logP:** Both ligands have good logP values (A: 1.177, B: 2.204) within the optimal 1-3 range. Ligand B is slightly better.
4. **HBD:** Ligand A (3) is acceptable, while Ligand B (0) is even better. Fewer HBDs generally improve permeability.
5. **HBA:** Both ligands are acceptable (A: 5, B: 4).
6. **QED:** Both ligands are similar and good (A: 0.733, B: 0.716).
7. **DILI:** Ligand B (23.885) is *much* better than Ligand A (75.572). This is a major advantage for Ligand B. DILI risk is a critical factor.
8. **BBB:** Both ligands have reasonable BBB penetration (A: 68.864, B: 72.974), but this is less crucial for a non-CNS target like ADRB2.
9. **Caco-2:** Ligand A (-5.707) is worse than Ligand B (-4.487). Lower values suggest poorer permeability.
10. **Solubility:** Ligand A (-2.075) is worse than Ligand B (-3.108). Both are poor, but B is slightly better.
11. **hERG:** Both ligands have similar, low hERG risk (A: 0.44, B: 0.432).
12. **Cl_mic:** Ligand A (5.984) is significantly better than Ligand B (49.77). Lower clearance is preferred for metabolic stability.
13. **t1/2:** Ligand B (-1.212) is significantly better than Ligand A (33.354). Longer half-life is desirable.
14. **Pgp:** Both ligands have very low Pgp efflux (A: 0.239, B: 0.206).
15. **Binding Affinity:** Ligand B (-6.9) is slightly better than Ligand A (-6.0). While both are good, the 0.9 kcal/mol difference is noticeable.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand B excels in logP, TPSA, and has slightly better affinity. The *significant* advantage in DILI risk for Ligand B is a major deciding factor. While Ligand A has better metabolic stability (Cl_mic), the lower DILI risk of Ligand B outweighs this.
**Conclusion:**
Ligand B demonstrates a superior balance of properties, particularly its significantly lower DILI risk and favorable TPSA, logP, and affinity. The improved half-life is also a benefit.
Output:
0
2025-04-17 23:35:56,266 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (352.459 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (42.43) is significantly better than Ligand B (110.77). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally improves absorption. Ligand B's TPSA is quite high, potentially hindering oral bioavailability.
3. **logP:** Ligand A (4.399) is higher than Ligand B (-0.522). While 4.399 is approaching the upper limit, it's still acceptable. Ligand B's negative logP is a significant concern, suggesting poor membrane permeability.
4. **HBD:** Ligand A (0) is preferable to Ligand B (4). Fewer HBDs generally improve membrane permeability.
5. **HBA:** Both ligands have 4 HBA, which is within the acceptable range.
6. **QED:** Ligand A (0.683) has a better QED score than Ligand B (0.486), indicating a more drug-like profile.
7. **DILI:** Ligand B (34.781) has a much lower DILI risk than Ligand A (80.69). This is a substantial advantage for Ligand B.
8. **BBB:** Ligand B (70.88) has a higher BBB penetration percentile than Ligand A (57.891). While not critical for a cardiovascular target, it's a slight positive.
9. **Caco-2:** Ligand A (-4.834) and Ligand B (-5.61) both have negative Caco-2 values which is unusual, and suggests poor permeability.
10. **Solubility:** Ligand A (-4.713) and Ligand B (-1.058) both have negative solubility values which is unusual, and suggests poor solubility.
11. **hERG:** Ligand A (0.623) has a lower hERG risk than Ligand B (0.125), which is favorable.
12. **Cl_mic:** Ligand B (-8.783) has a much lower (better) microsomal clearance than Ligand A (83.753), indicating greater metabolic stability.
13. **t1/2:** Ligand B (-20.392) has a longer half-life than Ligand A (-10.07), which is desirable.
14. **Pgp:** Ligand A (0.638) has a lower Pgp efflux liability than Ligand B (0.008), which is preferable.
15. **Binding Affinity:** Ligand B (-5.8 kcal/mol) has a slightly better binding affinity than Ligand A (-4.8 kcal/mol). This is a 1.0 kcal/mol difference, which is significant.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has a better logP and Pgp profile, but Ligand B has a much better TPSA and a slightly better affinity. The metabolic stability (Cl_mic and t1/2) of Ligand B is also a major advantage. The DILI risk is also a significant factor, and Ligand B is much better in this regard.
**Overall Assessment:**
Despite Ligand A's slightly better logP and Pgp, Ligand B's superior TPSA, metabolic stability, DILI profile, and affinity outweigh these advantages. The negative Caco-2 and solubility values for both are concerning, but Ligand B's overall profile is more promising for development as a drug candidate.
Output:
0
2025-04-17 23:35:56,266 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (351.447 and 369.849 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (87.74) is better than Ligand B (93.46). Both are below 140, but closer to 90 is preferable for GPCRs, and A is closer.
3. **logP:** Ligand B (2.015) is better than Ligand A (0.577). A logP of 0.577 is quite low and may indicate poor membrane permeability. Ligand B is within the optimal 1-3 range.
4. **HBD:** Both ligands have 2 HBD, which is acceptable.
5. **HBA:** Ligand B (5) has one more HBA than Ligand A (4), but both are within the acceptable limit of 10.
6. **QED:** Both ligands have good QED scores (0.685 and 0.766), indicating good drug-like properties.
7. **DILI:** Ligand A (14.541) has a significantly lower DILI risk than Ligand B (62.544). This is a major advantage for Ligand A.
8. **BBB:** Both ligands have similar BBB penetration (67.197 and 68.903). While not exceptionally high, they are acceptable for a non-CNS target like ADRB2.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.144 and -5.031). This is unusual and suggests poor permeability.
10. **Solubility:** Ligand A (-1.154) has better solubility than Ligand B (-3.6).
11. **hERG:** Both ligands have very low hERG inhibition risk (0.184 and 0.268).
12. **Cl_mic:** Ligand A (-1.324) has much better metabolic stability (lower clearance) than Ligand B (33.648). This is a significant advantage.
13. **t1/2:** Ligand A (-0.924) has a slightly better in vitro half-life than Ligand B (31.798).
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.016 and 0.144).
15. **Binding Affinity:** Ligand B (-6.7) has a slightly better binding affinity than Ligand A (-6.0). However, the difference is less than 1.5 kcal/mol.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand B has a better logP. However, Ligand A significantly outperforms Ligand B in crucial ADME-Tox parameters: DILI risk and metabolic stability (Cl_mic). The slightly better affinity of Ligand B is not enough to offset the substantial risks associated with its higher DILI and lower metabolic stability. The solubility and TPSA are also better for Ligand A. Given the importance of minimizing toxicity and maximizing duration of action for a cardiovascular target, Ligand A is the more promising candidate.
**Output:**
1
2025-04-17 23:35:56,266 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.4 & 368.4 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (76.66) is significantly better than Ligand B (109.86). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (1.183) is better than Ligand B (0.369). Both are within the acceptable range, but Ligand A is closer to the optimal 1-3 range. Ligand B is quite low, potentially hindering permeability.
4. **HBD:** Both ligands have 2 HBD, which is good.
5. **HBA:** Ligand A has 5 HBA, while Ligand B has 7. Ligand A is preferable.
6. **QED:** Both ligands have similar QED scores (0.752 and 0.751), indicating good drug-likeness.
7. **DILI:** Ligand A (40.132) has a much lower DILI risk than Ligand B (84.606). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (65.607) has a higher BBB penetration score than Ligand B (51.105). While not critical for a cardiovascular target, higher BBB is rarely detrimental.
9. **Caco-2:** Ligand A (-4.755) is better than Ligand B (-5.127), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-1.528) is better than Ligand B (-2.659).
11. **hERG:** Ligand A (0.338) has a lower hERG risk than Ligand B (0.095). This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand A (20.527) has a higher (worse) microsomal clearance than Ligand B (-14.831). Ligand B is preferable here.
13. **t1/2:** Ligand A (-4.983) has a shorter in vitro half-life than Ligand B (-15.246). Ligand B is preferable here.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.025 and 0.021).
15. **Binding Affinity:** Ligand A (-7.0) has a slightly better binding affinity than Ligand B (-5.5). This is a substantial advantage.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A performs better on logP, TPSA, and significantly better on affinity. While metabolic stability (Cl_mic and t1/2) are important, the substantial advantages of Ligand A in other key areas outweigh the slightly worse metabolic profile. The lower DILI and hERG risks for Ligand A are also crucial.
**Conclusion:**
Ligand A is the more promising candidate due to its superior overall profile, particularly its better ADME properties (TPSA, logP, solubility, DILI, hERG) and significantly stronger binding affinity. The slightly worse metabolic stability of Ligand A can be addressed through further optimization.
Output:
1
2025-04-17 23:35:56,266 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (363.487 Da and 361.486 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (81.07) is higher than Ligand B (29.77). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is generally preferred for absorption. Ligand B is significantly better here.
**3. logP:** Ligand A (3.301) is within the optimal range (1-3), while Ligand B (4.381) is slightly above. This could potentially lead to solubility issues or off-target interactions for Ligand B, but it's not a severe concern.
**4. H-Bond Donors:** Ligand A has 3 HBD, while Ligand B has 0. Both are acceptable, but fewer HBDs generally improve permeability. Ligand B is better.
**5. H-Bond Acceptors:** Ligand A has 6 HBA, and Ligand B has 5. Both are within the acceptable limit of 10.
**6. QED:** Both ligands have similar QED values (0.629 and 0.625), indicating good drug-likeness.
**7. DILI Risk:** Ligand A (80.109) has a higher DILI risk than Ligand B (46.219). This is a significant concern, as we want to minimize liver toxicity. Ligand B is much better.
**8. BBB Penetration:** Ligand A (52.423) has lower BBB penetration than Ligand B (78.402). While ADRB2 isn't exclusively a CNS target, some CNS exposure might be acceptable or even desirable depending on the specific therapeutic goal. Ligand B is better.
**9. Caco-2 Permeability:** Ligand A (-5.121) has worse Caco-2 permeability than Ligand B (-4.573). Lower negative values indicate better permeability. Ligand B is better.
**10. Aqueous Solubility:** Ligand A (-3.231) has slightly better aqueous solubility than Ligand B (-4.177).
**11. hERG Inhibition:** Ligand A (0.18) has a lower hERG inhibition liability than Ligand B (0.98). This is a positive for Ligand A, as we want to avoid cardiotoxicity.
**12. Microsomal Clearance:** Ligand A (52.159) has lower microsomal clearance than Ligand B (80.242), suggesting better metabolic stability. This is a positive for Ligand A.
**13. In vitro Half-Life:** Ligand A (52.598) has a longer in vitro half-life than Ligand B (-3.258). This is a positive for Ligand A.
**14. P-gp Efflux:** Ligand A (0.277) has lower P-gp efflux than Ligand B (0.936), which is preferable for bioavailability.
**15. Binding Affinity:** Ligand B (-6.5) has slightly better binding affinity than Ligand A (-6.4). While the difference is small, it's still a factor.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity) and the general drug-like properties, Ligand B is the more promising candidate. While Ligand A has advantages in hERG, metabolic stability, and half-life, the significantly lower DILI risk, better BBB penetration, lower TPSA, and better Caco-2 permeability of Ligand B outweigh these benefits. The slight improvement in binding affinity for Ligand B further supports this decision. The high DILI risk of Ligand A is a major red flag.
Output:
0
2025-04-17 23:35:56,267 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (335.403 Da) is better than Ligand B (362.348 Da), falling comfortably within the 200-500 Da range.
2. **TPSA:** Ligand A (59.32) is significantly better than Ligand B (67.87). Both are below 140, but lower TPSA generally favors better absorption.
3. **logP:** Ligand B (1.221) is better than Ligand A (4.146). Ligand A's logP is a bit high, potentially leading to solubility issues and off-target interactions. Ligand B is within the optimal 1-3 range.
4. **HBD:** Ligand A (0) is preferable to Ligand B (1). Fewer HBDs generally improve permeability.
5. **HBA:** Both ligands have 4 HBA, which is acceptable.
6. **QED:** Ligand B (0.817) is better than Ligand A (0.537), indicating a more drug-like profile.
7. **DILI:** Ligand B (47.964) is significantly better than Ligand A (60.101), indicating a lower risk of drug-induced liver injury.
8. **BBB:** Ligand B (90.229) is much better than Ligand A (55.254). While ADRB2 isn't strictly a CNS target, some peripheral ADRB2 receptors influence CNS function, and better BBB penetration can be beneficial, and is a GPCR priority.
9. **Caco-2:** Both ligands have very poor Caco-2 permeability (-4.431 and -4.518). This is a significant concern for both.
10. **Solubility:** Ligand B (-2.495) is better than Ligand A (-6.369), though both are quite poor.
11. **hERG:** Both ligands have low hERG inhibition risk (0.851 and 0.246).
12. **Cl_mic:** Ligand B (15.963) is much better than Ligand A (115.544), indicating significantly better metabolic stability.
13. **t1/2:** Ligand B (-36.93) is much better than Ligand A (-17.357), indicating a longer in vitro half-life.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.609 and 0.077).
15. **Affinity:** Both ligands have identical binding affinity (-6.4 kcal/mol).
**Overall Assessment & GPCR Priorities:**
Given that binding affinity is the same, the ADME properties become critical. Ligand B is superior across almost all ADME parameters. Specifically, its significantly better DILI score, BBB penetration, metabolic stability (Cl_mic and t1/2), and solubility are compelling advantages. While both have poor Caco-2 permeability, the other benefits of Ligand B outweigh this drawback. As a GPCR target, logP, TPSA, Pgp, and BBB are important, and Ligand B performs better in these areas.
**Output:**
0
2025-04-17 23:35:56,267 - INFO - Batch 416 complete. Total preferences: 6656
2025-04-17 23:35:56,267 - INFO - Processing batch 417/512...
2025-04-17 23:36:44,337 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.39 and 350.42 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand B (87.9) is significantly better than Ligand A (123.66). For a GPCR, lower TPSA is generally preferred for better permeability.
3. **logP:** Both ligands have low logP values (0.386 and 0.176). While ideally 1-3, these are both quite low and could indicate permeability issues. Ligand B is slightly better.
4. **HBD:** Ligand A has 3 HBD, while Ligand B has 1. Lower is generally preferred for permeability, giving a slight edge to Ligand B.
5. **HBA:** Ligand A has 5 HBA, and Ligand B has 6. Both are acceptable, being under the 10 threshold.
6. **QED:** Both ligands have good QED scores (0.685 and 0.765), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Both ligands have acceptable DILI risk (42.46 and 48.20 percentile), below the 60% threshold. No major difference.
8. **BBB:** Both ligands have relatively low BBB penetration (59.79 and 56.57 percentile). Since ADRB2 is a cardiovascular target, BBB penetration is not a primary concern, but higher is still preferable. No significant difference.
9. **Caco-2:** Ligand A (-5.75) is better than Ligand B (-4.529). Higher Caco-2 permeability is desirable.
10. **Solubility:** Ligand A (-2.554) is better than Ligand B (-1.056). Higher solubility is generally better.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.022 and 0.137), which is excellent. No significant difference.
12. **Cl_mic:** Ligand A (-0.033) has much lower microsomal clearance than Ligand B (24.381), indicating better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand A (17.359 hours) has a significantly longer in vitro half-life than Ligand B (10.641 hours). This is a substantial advantage.
14. **Pgp:** Ligand A (0.005) has much lower P-gp efflux liability than Ligand B (0.153). Lower P-gp efflux is preferable.
15. **Binding Affinity:** Ligand A (-6.6 kcal/mol) has slightly better binding affinity than Ligand B (-5.4 kcal/mol). This difference of 1.2 kcal/mol is significant and can outweigh some ADME drawbacks.
**Overall Assessment:**
While Ligand B has better TPSA, QED, and slightly better logP, Ligand A demonstrates superior ADME properties (Cl_mic, t1/2, Pgp) and a notably stronger binding affinity. The improved metabolic stability (lower Cl_mic and longer t1/2) and reduced efflux (lower Pgp) are crucial for *in vivo* efficacy. The slightly better affinity further strengthens the case for Ligand A. Given the GPCR target class, the combination of good affinity and favorable ADME properties makes Ligand A the more promising candidate.
Output:
1
2025-04-17 23:36:44,337 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.406 and 350.459 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (69.72) is slightly higher than Ligand B (59.08). Both are below the 140 A^2 threshold for good oral absorption, but B is preferable.
3. **logP:** Both ligands have good logP values (1.332 and 1.74), falling within the optimal 1-3 range. Ligand B is slightly higher, which could be a minor advantage for membrane permeability.
4. **HBD:** Ligand A has 1 HBD, while Ligand B has 0. Both are acceptable, but fewer HBDs are generally preferred for permeability. Ligand B is slightly better.
5. **HBA:** Ligand A has 3 HBA, and Ligand B has 4. Both are below the 10 threshold. No major difference.
6. **QED:** Ligand A (0.895) has a significantly better QED score than Ligand B (0.685), indicating a more drug-like profile. This is a substantial advantage for Ligand A.
7. **DILI:** Ligand A (46.917) has a higher DILI risk than Ligand B (21.326). This is a significant drawback for Ligand A. Lower DILI is crucial.
8. **BBB:** Ligand B (83.288) shows better BBB penetration than Ligand A (72.78). While ADRB2 isn't strictly a CNS target, some CNS exposure can occur, and higher BBB is generally favorable.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.621 and -4.528), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Both ligands have negative solubility values (-1.67 and -1.548), indicating very poor aqueous solubility. This is a major issue for both compounds.
11. **hERG:** Both ligands have low hERG inhibition liability (0.318 and 0.361), which is good. No significant difference.
12. **Cl_mic:** Ligand A (14.305) has a lower microsomal clearance than Ligand B (46.083), suggesting better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (-13.716) has a more negative in vitro half-life than Ligand B (-11.356), indicating a shorter half-life. This is a disadvantage for Ligand A.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.054 and 0.095). No significant difference.
15. **Binding Affinity:** Ligand A (-7.1) has a stronger binding affinity than Ligand B (-6.1) by a substantial margin (1 kcal/mol). This is a major advantage for Ligand A, and can often outweigh other drawbacks.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, and affinity are key. Ligand B has a slightly better logP and TPSA. However, Ligand A's significantly stronger binding affinity (-7.1 vs -6.1) is a major advantage. The DILI risk with Ligand A is concerning, but the superior affinity is a strong counterweight.
**Overall Assessment:**
Despite the higher DILI risk and shorter half-life, Ligand A's significantly improved binding affinity and better QED score, coupled with acceptable logP and hERG values, make it the more promising candidate. The solubility and Caco-2 issues are concerning for both, but these can be addressed with formulation strategies.
Output:
1
2025-04-17 23:36:44,337 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (367.421 and 342.483 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (54.46) is better than Ligand B (58.2). Both are below the 140 threshold for oral absorption, but closer to the ideal for GPCRs.
3. **logP:** Ligand A (4.229) is slightly higher than Ligand B (3.446). While both are within the 1-3 range, Ligand A is pushing the upper limit and could potentially have solubility issues.
4. **HBD:** Ligand A (1) is better than Ligand B (2). Lower HBD is generally preferred for better permeability.
5. **HBA:** Ligand A (4) is better than Ligand B (2). Lower HBA is generally preferred for better permeability.
6. **QED:** Ligand A (0.88) is better than Ligand B (0.76). Both are above the 0.5 threshold, indicating good drug-likeness, but A is superior.
7. **DILI:** Ligand B (26.444) is significantly better than Ligand A (61.07). This is a major advantage for Ligand B, as lower DILI risk is crucial.
8. **BBB:** Ligand A (97.247) is significantly better than Ligand B (75.107). While ADRB2 isn't necessarily a CNS target, higher BBB penetration can sometimes correlate with better overall distribution and potentially reduced off-target effects.
9. **Caco-2:** Both ligands have very poor Caco-2 permeability (-4.633 and -4.672). This is a significant concern for both, indicating poor intestinal absorption.
10. **Solubility:** Ligand B (-3.953) is slightly better than Ligand A (-5.158), suggesting better aqueous solubility.
11. **hERG:** Ligand A (0.776) is slightly better than Ligand B (0.647), indicating a lower risk of hERG inhibition.
12. **Cl_mic:** Ligand A (30.283) is significantly better than Ligand B (56.449). Lower clearance means better metabolic stability.
13. **t1/2:** Ligand B (-5.112) is significantly better than Ligand A (33.109). A negative value suggests a very short half-life, which is concerning. However, the units are percentile, so a negative value means it is very low.
14. **Pgp:** Ligand A (0.413) is better than Ligand B (0.27). Lower P-gp efflux is desirable.
15. **Binding Affinity:** Ligand B (-7.0) is slightly better than Ligand A (-6.7). This is a crucial factor, and the 0.3 kcal/mol difference is significant enough to consider, especially for a GPCR.
**Overall Assessment:**
Ligand B has a substantial advantage in DILI risk and a slightly better binding affinity. Ligand A has better QED, BBB penetration, Cl_mic, and Pgp efflux. The poor Caco-2 permeability is a concern for both. However, the lower DILI risk of Ligand B is a critical factor for drug development, outweighing the advantages of Ligand A. The slightly better affinity of Ligand B also contributes to its preference.
Output:
0
2025-04-17 23:36:44,337 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (332.4) is within the ideal range, while Ligand B (366.4) is slightly higher but still acceptable.
2. **TPSA:** Ligand A (70.93) is higher than Ligand B (58.64). Both are below 140, but Ligand B is preferable for better absorption.
3. **logP:** Both ligands (A: 3.173, B: 2.602) are within the optimal 1-3 range. Ligand B is slightly better.
4. **HBD:** Ligand A (2) and Ligand B (1) are both good.
5. **HBA:** Ligand A (5) and Ligand B (3) are both good.
6. **QED:** Both ligands (A: 0.751, B: 0.754) are excellent, indicating good drug-like properties.
7. **DILI:** Ligand A (68.592) has a higher DILI risk than Ligand B (27.685). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (61.884) has a lower BBB penetration than Ligand B (86.39). While ADRB2 isn't necessarily a CNS target, higher BBB is generally favorable.
9. **Caco-2:** Ligand A (-5.069) has worse Caco-2 permeability than Ligand B (-4.548).
10. **Solubility:** Ligand A (-3.634) has worse aqueous solubility than Ligand B (-2.676).
11. **hERG:** Ligand A (0.821) has a slightly higher hERG risk than Ligand B (0.577).
12. **Cl_mic:** Ligand A (21.942) has a lower microsomal clearance, indicating better metabolic stability, than Ligand B (44.885).
13. **t1/2:** Ligand A (33.204) has a longer in vitro half-life than Ligand B (-0.156). This is a significant advantage for Ligand A.
14. **Pgp:** Both ligands (A: 0.582, B: 0.05) have low P-gp efflux, but Ligand B is significantly better.
15. **Affinity:** Ligand B (-5.9) has a stronger binding affinity than Ligand A (-5.0). This is a substantial advantage.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, we prioritize logP, Pgp, TPSA, and affinity. Ligand B excels in these areas. While metabolic stability (Cl_mic and t1/2) are important, the significantly better affinity and lower DILI/Pgp efflux of Ligand B outweigh the slightly worse metabolic profile.
**Conclusion:**
Ligand B demonstrates a superior balance of properties, particularly with its stronger binding affinity, lower DILI risk, and better Pgp efflux. While Ligand A has a longer half-life and better metabolic stability, the other advantages of Ligand B make it the more promising drug candidate.
Output:
0
2025-04-17 23:36:44,338 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (344.411) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (67.87) is significantly better than Ligand B (119.03). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA is still desirable for good absorption. Ligand B's TPSA is approaching a level that could hinder oral absorption.
3. **logP:** Both ligands have acceptable logP values (A: 0.591, B: 0.399), falling within the 1-3 range. Ligand A is slightly better.
4. **HBD:** Both ligands have acceptable HBD counts (A: 1, B: 2).
5. **HBA:** Ligand A (4) is better than Ligand B (7). Lower HBA is generally preferred for permeability.
6. **QED:** Both ligands have good QED scores (A: 0.735, B: 0.811), indicating good drug-like properties. Ligand B is slightly better here.
7. **DILI:** Ligand A (49.399) has a considerably lower DILI risk than Ligand B (80.031). This is a significant advantage for Ligand A.
8. **BBB:** Both ligands have similar BBB penetration (A: 64.25, B: 60.256). This isn't a primary concern for a cardiovascular target.
9. **Caco-2:** Ligand A (-4.532) is better than Ligand B (-5.355), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-2.146) is better than Ligand B (-2.888).
11. **hERG:** Ligand A (0.15) has a much lower hERG risk than Ligand B (0.424). This is a crucial safety parameter, and Ligand A is significantly better.
12. **Cl_mic:** Ligand B (-7.949) has a *much* lower (better) microsomal clearance than Ligand A (8.449). This suggests better metabolic stability for Ligand B.
13. **t1/2:** Ligand A (6.551) has a slightly longer in vitro half-life than Ligand B (5.061).
14. **Pgp:** Both ligands have very low Pgp efflux liability (A: 0.029, B: 0.016).
15. **Binding Affinity:** Both ligands have very similar and excellent binding affinities (A: -6.0, B: -5.9 kcal/mol). The difference is negligible.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand A is the better candidate. While Ligand B has a slightly better QED and significantly better metabolic stability (Cl_mic), Ligand A excels in crucial areas like TPSA, DILI risk, and hERG inhibition. The lower TPSA and DILI/hERG profiles are particularly important for minimizing potential safety concerns. The affinity is comparable, and the slight advantage in half-life for Ligand A is a bonus. The improved absorption characteristics (Caco-2, solubility) of Ligand A also contribute to its favorability.
Output:
1
2025-04-17 23:36:44,338 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (343.431 and 345.422 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (90.98) is slightly higher than Ligand B (85.09). Both are below the 140 A^2 threshold for oral absorption, but B is preferable due to being closer to the 90 A^2 target for GPCRs.
**3. logP:** Ligand A (1.956) is within the optimal 1-3 range. Ligand B (3.17) is at the higher end of optimal, but still acceptable.
**4. H-Bond Donors:** Ligand A (2) is preferable to Ligand B (3). Lower HBD generally improves permeability.
**5. H-Bond Acceptors:** Ligand A (4) is better than Ligand B (6). Lower HBA is also preferable for permeability.
**6. QED:** Ligand A (0.839) has a significantly better QED score than Ligand B (0.669), indicating a more drug-like profile.
**7. DILI Risk:** Ligand A (46.84%) has a much lower DILI risk than Ligand B (69.097%). This is a crucial advantage.
**8. BBB Penetration:** Ligand B (77.317%) shows better BBB penetration than Ligand A (42.342%). While ADRB2 is a cardiovascular target, some CNS effects are possible with beta-blockers, and higher BBB penetration *could* be beneficial, but is not a primary driver.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-5.027) is slightly better (less negative) than Ligand B (-5.175).
**10. Aqueous Solubility:** Ligand A (-2.505) is better than Ligand B (-4.18).
**11. hERG Inhibition:** Ligand A (0.166) has a significantly lower hERG inhibition liability than Ligand B (0.901). This is a critical safety factor.
**12. Microsomal Clearance:** Ligand A (23.348) has a much lower microsomal clearance than Ligand B (61.721), indicating better metabolic stability.
**13. In vitro Half-Life:** Ligand B (29.16) has a much longer half-life than Ligand A (0.803). This is a significant advantage.
**14. P-gp Efflux:** Ligand A (0.02) has a much lower P-gp efflux liability than Ligand B (0.263).
**15. Binding Affinity:** Ligand B (-6.5 kcal/mol) has a slightly better binding affinity than Ligand A (-5.8 kcal/mol). The difference is 0.7 kcal/mol, which is a meaningful but not overwhelming advantage.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B in crucial ADME-Tox properties (DILI, hERG, Cl_mic, P-gp efflux, solubility, QED) and has a better balance of TPSA and H-bonds. While Ligand B has a slightly better binding affinity and half-life, the superior safety profile and drug-likeness of Ligand A are more important for a cardiovascular drug candidate. The negative Caco-2 values for both are concerning and would require further investigation, but the other benefits of Ligand A outweigh this issue.
Output:
1
2025-04-17 23:36:44,338 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (337.398 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are good, below the 140 A^2 threshold for oral absorption. Ligand B (66.91) is better than Ligand A (78.91), leaning towards better absorption.
3. **logP:** Both are in the optimal range (1-3), but Ligand B (3.805) is approaching the upper limit, potentially raising concerns about solubility and off-target effects. Ligand A (2.892) is better.
4. **HBD:** Both have 2 HBD, which is acceptable.
5. **HBA:** Ligand A has 3 HBA, and Ligand B has 4 HBA. Both are acceptable.
6. **QED:** Ligand A (0.88) has a better QED score than Ligand B (0.757), indicating a more drug-like profile.
7. **DILI:** Ligand A (39.899) has a lower DILI risk than Ligand B (47.77), which is preferable.
8. **BBB:** Ligand B (80.264) has a significantly higher BBB penetration than Ligand A (70.686). While ADRB2 isn't strictly a CNS target, some CNS exposure can be acceptable and even beneficial for certain cardiovascular indications.
9. **Caco-2:** Ligand A (-5.051) has a worse Caco-2 permeability than Ligand B (-4.892).
10. **Solubility:** Ligand A (-3.324) has a worse solubility than Ligand B (-4.44).
11. **hERG:** Both ligands have low hERG inhibition liability, with Ligand B (0.613) being slightly better than Ligand A (0.865).
12. **Cl_mic:** Ligand A (5.937) has a significantly lower microsomal clearance than Ligand B (31.652), indicating better metabolic stability.
13. **t1/2:** Ligand A (22.61) has a much longer in vitro half-life than Ligand B (4.327), which is a significant advantage.
14. **Pgp:** Ligand A (0.454) has a lower Pgp efflux liability than Ligand B (0.135), which is preferable.
15. **Affinity:** Ligand A (-7.9 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.4 kcal/mol). This is a crucial advantage, potentially outweighing some of the ADME drawbacks.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand A has a better logP, Pgp, and significantly better affinity. Ligand B has a better TPSA and BBB.
**Overall Assessment:**
Ligand A is the stronger candidate. The significantly better binding affinity (-7.9 vs -6.4 kcal/mol) and metabolic stability (lower Cl_mic, longer t1/2) are major advantages. While Ligand B has better BBB penetration and TPSA, the substantial affinity difference and improved ADME properties of Ligand A make it the more promising drug candidate. The slightly lower solubility and Caco-2 permeability of Ligand A can potentially be addressed through formulation strategies.
Output:
1
2025-04-17 23:36:44,338 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (351.393 and 367.515 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (50.72) is significantly better than Ligand B (72.36). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (4.07) is slightly higher than Ligand B (1.901). While both are within the acceptable range, Ligand A is approaching the upper limit, potentially raising concerns about solubility and off-target effects. Ligand B is closer to optimal.
4. **HBD:** Both ligands have 2 HBD, which is good.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 5. Both are acceptable, but lower is generally preferred.
6. **QED:** Ligand A (0.753) is slightly better than Ligand B (0.663), indicating a more drug-like profile.
7. **DILI:** Ligand A (27.453) has a much lower DILI risk than Ligand B (48.391). This is a significant advantage for Ligand A.
8. **BBB:** Ligand B (65.18) has a higher BBB penetration percentile than Ligand A (49.748). However, as ADRB2 is a cardiovascular target, BBB penetration isn't a high priority.
9. **Caco-2:** Ligand A (-5.017) and Ligand B (-4.883) are similar, and both are negative, which is not ideal.
10. **Solubility:** Ligand A (-4.262) is slightly better than Ligand B (-3.767), indicating better aqueous solubility.
11. **hERG:** Ligand A (0.952) has a lower hERG inhibition liability than Ligand B (0.285), which is a significant safety advantage.
12. **Cl_mic:** Ligand B (76.139) has a higher microsomal clearance than Ligand A (57.894), meaning Ligand A is likely more metabolically stable.
13. **t1/2:** Ligand A (-6.618) has a much longer in vitro half-life than Ligand B (22.067). This is a major advantage for Ligand A.
14. **Pgp:** Ligand A (0.459) has a lower P-gp efflux liability than Ligand B (0.261), suggesting better oral bioavailability.
15. **Binding Affinity:** Ligand B (-6.3) has a slightly better binding affinity than Ligand A (-7.0). However, the difference is not substantial enough to outweigh the other advantages of Ligand A.
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Ligand B has a better logP and affinity, but Ligand A excels in TPSA, Pgp, and has acceptable logP. The significant advantages of Ligand A in DILI risk, hERG inhibition, metabolic stability (Cl_mic, t1/2), and P-gp efflux outweigh the slight affinity advantage of Ligand B.
**Conclusion:**
Ligand A presents a much more favorable overall profile, particularly regarding safety (DILI, hERG) and pharmacokinetic properties (Cl_mic, t1/2, Pgp).
Output:
1
2025-04-17 23:36:44,338 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (401.22 Da) is slightly higher than Ligand B (354.491 Da), but both are acceptable.
**2. TPSA:** Ligand A (97.11) is higher than Ligand B (78.87). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for better absorption. Ligand B has a more favorable TPSA.
**3. logP:** Both ligands have good logP values (A: 2.658, B: 1.707), falling within the optimal 1-3 range. Ligand B is slightly lower, which could potentially impact permeability, but it's still acceptable.
**4. H-Bond Donors:** Both ligands have 2 HBD, which is within the acceptable limit of <=5.
**5. H-Bond Acceptors:** Ligand A has 5 HBA, and Ligand B has 4. Both are below the acceptable limit of <=10.
**6. QED:** Both ligands have similar QED values (A: 0.685, B: 0.695), indicating good drug-likeness.
**7. DILI Risk:** Ligand A has a significantly higher DILI risk (97.169%) compared to Ligand B (8.298%). This is a major concern for Ligand A.
**8. BBB Penetration:** BBB is less critical for a cardiovascular target, but Ligand B has a much higher BBB penetration (65.607%) than Ligand A (16.983%).
**9. Caco-2 Permeability:** Ligand A has a negative Caco-2 value (-5.411), which is concerning, suggesting poor permeability. Ligand B has a negative value as well (-4.709), but is slightly better.
**10. Aqueous Solubility:** Ligand A has a very poor aqueous solubility (-3.429) compared to Ligand B (-1.307). This could present formulation challenges.
**11. hERG Inhibition:** Both ligands show very low hERG inhibition risk (A: 0.064, B: 0.195).
**12. Microsomal Clearance:** Ligand A has a lower microsomal clearance (0.982) than Ligand B (36.01), indicating better metabolic stability.
**13. In vitro Half-Life:** Both ligands have similar in vitro half-lives (A: 14.469, B: 14.242).
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (A: 0.015, B: 0.008).
**15. Binding Affinity:** Ligand B has a stronger binding affinity (-8.2 kcal/mol) than Ligand A (-7.0 kcal/mol). This is a significant advantage, exceeding the 1.5 kcal/mol threshold.
**Overall Assessment:**
Ligand B is significantly better overall. While Ligand A has slightly better metabolic stability, its extremely high DILI risk, poor solubility, and lower binding affinity are major drawbacks. Ligand B's superior binding affinity, much lower DILI risk, better solubility, and acceptable TPSA and logP make it a much more promising drug candidate for the ADRB2 receptor. The slightly lower metabolic stability of Ligand B can be addressed through further optimization.
Output:
0
2025-04-17 23:36:44,339 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (361.825 and 348.447 Da). No significant difference here.
2. **TPSA:** Both are reasonably close to the 140 threshold, but acceptable.
3. **logP:** Ligand A (4.506) is higher than Ligand B (1.748). While >4 can be problematic, for a GPCR, a higher logP can be beneficial for membrane permeability and receptor engagement. Ligand B is a bit low, potentially hindering permeability.
4. **HBD:** Ligand A (2) and Ligand B (1) are both good.
5. **HBA:** Ligand A (3) and Ligand B (5) are both acceptable, but Ligand B is slightly higher.
6. **QED:** Both ligands have similar QED scores (0.725 and 0.726), indicating good drug-likeness.
7. **DILI:** Ligand B (31.989) has a significantly lower DILI risk than Ligand A (77.588). This is a major advantage for Ligand B.
8. **BBB:** Ligand B (73.943) has a much higher BBB penetration score than Ligand A (25.126). While ADRB2 isn't strictly a CNS target, some CNS exposure can be relevant for off-target effects and overall safety assessment.
9. **Caco-2:** Ligand A (-4.945) and Ligand B (-5.316) are both negative, indicating poor permeability.
10. **Solubility:** Ligand B (-1.78) has better solubility than Ligand A (-4.156).
11. **hERG:** Both ligands have low hERG inhibition risk (0.118 and 0.216).
12. **Cl_mic:** Ligand A (-12.367) has a lower (better) microsomal clearance than Ligand B (16.157), suggesting greater metabolic stability.
13. **t1/2:** Ligand A (22.992) has a longer half-life than Ligand B (-8.713). This is a significant advantage.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.055 and 0.054).
15. **Binding Affinity:** Ligand A (-7.0) has a slightly better binding affinity than Ligand B (-6.6). This is a 0.4 kcal/mol difference.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand A has a better logP and affinity, while Ligand B has better Pgp, BBB, solubility and a much better DILI profile. The affinity difference is not large enough to overcome the significant safety advantages of Ligand B.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity and metabolic stability, Ligand B's significantly lower DILI risk, better BBB penetration, and improved solubility make it a more promising drug candidate. The slightly lower affinity can potentially be optimized in later stages of drug development. The safety profile is paramount.
Output:
0
2025-04-17 23:36:44,339 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (351.491 and 345.487 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Both ligands have TPSA values (61.88 and 61.44) that are acceptable for a non-CNS GPCR target, being under 140.
**3. logP:** Ligand A (1.415) is slightly better than Ligand B (2.147). Both are within the optimal 1-3 range, but A is closer to the lower end, potentially aiding solubility without significantly hindering permeability.
**4. H-Bond Donors:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
**5. H-Bond Acceptors:** Ligand A (4) is slightly better than Ligand B (3). Both are within the acceptable range.
**6. QED:** Ligand A (0.705) has a better QED score than Ligand B (0.606), indicating a more drug-like profile.
**7. DILI:** Ligand B (30.012) has a significantly lower DILI risk than Ligand A (7.135), which is a major advantage. DILI is a critical safety concern.
**8. BBB:** Ligand B (70.415) has a higher BBB penetration percentile than Ligand A (63.474). While ADRB2 isn't primarily a CNS target, some degree of BBB penetration can be beneficial for off-target effects assessment and potentially for peripheral ADRB2 receptors.
**9. Caco-2 Permeability:** Ligand A (-4.822) has a slightly better Caco-2 permeability than Ligand B (-5.283).
**10. Aqueous Solubility:** Ligand B (-2.685) has significantly better aqueous solubility than Ligand A (-0.345). This is a crucial factor for formulation and bioavailability.
**11. hERG Inhibition:** Ligand A (0.271) has a lower hERG inhibition liability than Ligand B (0.407), which is a positive.
**12. Microsomal Clearance:** Ligand B (37) has a much higher microsomal clearance than Ligand A (-1.01). This means Ligand A is more metabolically stable.
**13. In vitro Half-Life:** Ligand B (16.401) has a longer in vitro half-life than Ligand A (-17).
**14. P-gp Efflux:** Ligand A (0.008) has a much lower P-gp efflux liability than Ligand B (0.067), which is a significant advantage for bioavailability.
**15. Binding Affinity:** Ligand B (-7.5) has a significantly stronger binding affinity than Ligand A (-5.3). This is a substantial advantage, potentially outweighing some ADME concerns.
**Overall Assessment:**
While Ligand A has advantages in metabolic stability (Cl_mic, t1/2) and P-gp efflux, Ligand B's superior binding affinity (-7.5 vs -5.3 kcal/mol) and significantly lower DILI risk are compelling. The better solubility of Ligand B is also a major plus. The slightly higher logP of Ligand B is manageable, and its BBB penetration is acceptable. The stronger binding affinity is likely to be the most important factor for efficacy.
Output:
0
2025-04-17 23:36:44,339 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (344.459 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (53.43) is better than Ligand A (65.54) as it is closer to the <140 threshold for good oral absorption.
3. **logP:** Ligand A (2.225) is optimal (1-3), while Ligand B (4.051) is pushing the upper limit. Higher logP can lead to off-target effects and solubility issues.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 4 HBA, Ligand B has 3. Both are acceptable.
6. **QED:** Both ligands have similar QED scores (0.77 and 0.774), indicating good drug-likeness.
7. **DILI:** Ligand B (9.461) has a significantly lower DILI risk than Ligand A (41.877). This is a major advantage.
8. **BBB:** Both ligands show good BBB penetration (Ligand A: 77.433, Ligand B: 83.366).
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the values are very close.
10. **Solubility:** Ligand B (-4.153) is slightly better than Ligand A (-2.416), indicating better aqueous solubility.
11. **hERG:** Both have low hERG inhibition liability (Ligand A: 0.598, Ligand B: 0.62).
12. **Cl_mic:** Ligand A (40.235) has lower microsomal clearance than Ligand B (71.393), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-3.479) has a negative in vitro half-life, which is problematic. Ligand A (13.886) has a reasonable half-life.
14. **Pgp:** Both ligands have low Pgp efflux liability (Ligand A: 0.053, Ligand B: 0.108).
15. **Binding Affinity:** Ligand B (-7.4 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.7 kcal/mol). This 1.7 kcal/mol difference is substantial and can outweigh some ADME drawbacks.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand B excels in affinity and has a better TPSA. While its logP is higher, the significant affinity advantage and lower DILI risk are compelling. The negative half-life is a concern, but can potentially be addressed through structural modifications.
**Overall Assessment:**
While Ligand A has better metabolic stability and half-life, Ligand B's substantially stronger binding affinity and lower DILI risk are more critical for a GPCR target. The slightly higher logP is a manageable concern.
Output:
0
2025-04-17 23:36:44,339 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [348.418, 42.01, 2.171, 0, 4, 0.782, 37.728, 92.672, -4.319, -1.443, 0.746, 42.232, -7.679, 0.276, -6.3]
**Ligand B:** [332.407, 70.93, 3.173, 2, 5, 0.751, 68.592, 61.884, -5.069, -3.634, 0.821, 21.942, 33.204, 0.582, -5]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, Affinity, and BBB):
1. **MW:** Both are within the ideal 200-500 Da range. Ligand B (332.407) is slightly lower, which is generally favorable.
2. **TPSA:** Ligand A (42.01) is significantly better than Ligand B (70.93). A TPSA under 140 is good for oral absorption, and A is much closer to the <90 target for CNS penetration, even though this is a cardiovascular target.
3. **logP:** Both are within the optimal 1-3 range. Ligand A (2.171) is slightly better, being closer to the middle of the range. Ligand B (3.173) is a bit higher, potentially increasing off-target interactions.
4. **HBD/HBA:** Ligand A (0 HBD, 4 HBA) is preferable to Ligand B (2 HBD, 5 HBA). Lower HBD/HBA generally improves permeability.
5. **QED:** Both are good (above 0.5), indicating drug-like properties.
6. **DILI:** Ligand A (37.728) has a much lower DILI risk than Ligand B (68.592). This is a significant advantage.
7. **BBB:** Ligand A (92.672) has a much higher BBB penetration percentile than Ligand B (61.884). While ADRB2 isn't a CNS target, higher BBB is generally a positive indicator of permeability.
8. **Caco-2:** Ligand A (-4.319) is better than Ligand B (-5.069). Higher Caco-2 values indicate better absorption.
9. **Solubility:** Ligand A (-1.443) is better than Ligand B (-3.634).
10. **hERG:** Both are relatively low, but Ligand A (0.746) is slightly better than Ligand B (0.821).
11. **Cl_mic:** Ligand B (21.942) has significantly lower microsomal clearance than Ligand A (42.232), indicating better metabolic stability. This is a strong point for Ligand B.
12. **t1/2:** Ligand B (33.204) has a longer in vitro half-life than Ligand A (-7.679). This is a significant advantage.
13. **Pgp:** Ligand A (0.276) has lower P-gp efflux than Ligand B (0.582), which is desirable.
14. **Affinity:** Ligand A (-6.3) has a slightly better binding affinity than Ligand B (-5). While the difference isn't huge, it's still a factor.
**Overall Assessment:**
Ligand A has a clear advantage in terms of safety (DILI), permeability (TPSA, Caco-2, BBB, Pgp), solubility, and binding affinity. Ligand B's main strengths are its metabolic stability (lower Cl_mic) and longer half-life. However, the significant improvements in ADME properties and safety with Ligand A, combined with only a slight difference in binding affinity, make it the more promising candidate. The lower TPSA and better solubility of Ligand A are particularly important for oral bioavailability.
Output:
1
2025-04-17 23:36:44,339 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (356.482) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (58.64) is significantly better than Ligand A (78.43). Lower TPSA is preferred for GPCRs, aiding in brain penetration and overall absorption.
3. **logP:** Both ligands have good logP values (A: 2.348, B: 2.742), falling within the optimal 1-3 range. Ligand B is slightly higher, which could potentially lead to some off-target effects, but is still acceptable.
4. **HBD:** Ligand A has 3 HBD, while Ligand B has 1. Lower HBD is generally preferred for better permeability. Ligand B is better here.
5. **HBA:** Both ligands have 3 HBA, which is within the acceptable range.
6. **QED:** Ligand B (0.679) has a slightly better QED score than Ligand A (0.526), indicating a more drug-like profile.
7. **DILI:** Ligand A (8.53) has a significantly lower DILI risk than Ligand B (12.02). This is a major advantage for Ligand A.
8. **BBB:** Both ligands have good BBB penetration (A: 76.464, B: 75.882). The difference is minimal.
9. **Caco-2:** Ligand A (-4.697) and Ligand B (-5.024) both have negative Caco-2 values, indicating poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-2.765) and Ligand B (-3.462) both have poor solubility. This is a concern for both.
11. **hERG:** Both ligands have low hERG inhibition risk (A: 0.465, B: 0.518).
12. **Cl_mic:** Ligand B (28.571) has a lower microsomal clearance than Ligand A (36.064), indicating better metabolic stability.
13. **t1/2:** Ligand B (2.066) has a slightly longer in vitro half-life than Ligand A (-11.024).
14. **Pgp:** Both ligands have low P-gp efflux liability (A: 0.105, B: 0.203).
15. **Binding Affinity:** Ligand B (-7.6 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.6 kcal/mol). This is a substantial advantage.
**Overall Assessment:**
For an ADRB2 GPCR target, binding affinity, TPSA, logP, and metabolic stability are key considerations. Ligand B excels in binding affinity (-7.6 vs -6.6), has a lower TPSA (58.64 vs 78.43), and better metabolic stability (lower Cl_mic). While Ligand A has a lower DILI risk, the significant advantage in binding affinity of Ligand B outweighs this concern, especially given that both ligands have similar BBB penetration and acceptable hERG risk. The poor Caco-2 and solubility for both are concerning, but can be addressed with formulation strategies.
**Output:**
0
2025-04-17 23:36:44,340 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (344.499 and 348.443 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (40.62) is significantly better than Ligand B (82.78). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold, while Ligand B is approaching it.
3. **logP:** Both ligands have acceptable logP values (3.062 and 2.405), falling within the 1-3 range. Ligand A is slightly higher, which *could* be a minor advantage for membrane permeability, but not dramatically so.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (2) is better than Ligand B (4). Similar to HBD, lower HBA is generally preferred.
6. **QED:** Ligand A (0.743) has a significantly better QED score than Ligand B (0.53), indicating a more drug-like profile.
7. **DILI:** Ligand A (11.71) has a much lower DILI risk than Ligand B (17.836). This is a crucial advantage as liver toxicity is a major concern in drug development.
8. **BBB:** Not a high priority for a cardiovascular target. Ligand A (89.802) has a higher BBB penetration than Ligand B (48.003), but this is less important here.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.705 and -4.663), which is unusual and suggests poor permeability. This is a significant drawback for both.
10. **Solubility:** Ligand A (-3.726) has slightly better solubility than Ligand B (-1.805), but both are quite poor. This could present formulation challenges.
11. **hERG:** Both ligands have low hERG inhibition risk (0.666 and 0.512), which is good.
12. **Cl_mic:** Ligand A (57.893) has a higher microsomal clearance than Ligand B (29.924), indicating faster metabolism and potentially lower *in vivo* exposure. This is a disadvantage for Ligand A.
13. **t1/2:** Ligand B (34.452) has a much longer *in vitro* half-life than Ligand A (1.739). This is a significant advantage for Ligand B, suggesting less frequent dosing may be possible.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.254 and 0.167), which is favorable.
15. **Binding Affinity:** Both ligands have very similar and strong binding affinities (-6.7 and -6.0 kcal/mol). The difference of 0.7 kcal/mol is not substantial enough to override other ADME differences.
**Overall Assessment & GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, and affinity are key. Both ligands perform reasonably well on logP and affinity. However, Ligand A excels in TPSA, QED, and DILI risk, while Ligand B has a significantly better half-life and lower Cl_mic. The poor Caco-2 values for both are concerning, but the superior overall drug-like properties and safety profile of Ligand A, coupled with the less critical need for high BBB penetration in a cardiovascular target, make it the more promising candidate. The longer half-life of Ligand B is attractive, but the higher DILI risk and lower QED are significant drawbacks.
Output:
1
2025-04-17 23:36:44,340 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (354.441 and 376.551 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (40.62) is better than Ligand B (49.33). Both are below the 140 threshold for oral absorption, but lower TPSA is generally preferred for GPCRs.
3. **logP:** Both ligands have good logP values (3.083 and 3.836), falling within the 1-3 optimal range. Ligand B is slightly higher, which *could* indicate potential off-target issues, but isn't a major concern.
4. **HBD:** Both ligands have 0 HBD, which is acceptable.
5. **HBA:** Ligand A has 2 HBA, while Ligand B has 6. Ligand A is preferable here, as lower HBA generally improves permeability.
6. **QED:** Both ligands have good QED scores (0.712 and 0.817), indicating good drug-like properties.
7. **DILI:** Ligand A (12.214%) has a significantly lower DILI risk than Ligand B (63.513%). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (97.518%) has a much higher BBB penetration score than Ligand B (87.864%). While ADRB2 isn't exclusively a CNS target, higher BBB penetration can be beneficial and suggests better overall permeability.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Both have negative solubility values, which is also a concern for both.
11. **hERG:** Both ligands have low hERG inhibition liability (0.626 and 0.743), which is good.
12. **Cl_mic:** Ligand A (37.648) has a lower microsomal clearance than Ligand B (57.869), indicating better metabolic stability.
13. **t1/2:** Ligand A (-10.609) has a more negative in vitro half-life, which is not ideal. Ligand B (12.517) is better.
14. **Pgp:** Ligand A (0.109) has much lower P-gp efflux liability than Ligand B (0.664). Lower P-gp efflux is highly desirable for improved bioavailability.
15. **Affinity:** Both ligands have very similar binding affinities (-7.3 and -7.0 kcal/mol). The difference is less than the 1.5 kcal/mol threshold.
**GPCR-Specific Priorities:**
Considering ADRB2 is a GPCR, logP, TPSA, Pgp, and affinity are key. Both ligands perform well on logP and affinity. Ligand A is better on TPSA and significantly better on Pgp. The substantial difference in DILI risk also heavily favors Ligand A. While Ligand B has a better in vitro half-life, the other advantages of Ligand A outweigh this.
**Conclusion:**
Ligand A demonstrates a superior balance of properties, particularly regarding safety (DILI), permeability (TPSA, Pgp), and metabolic stability (Cl_mic). The slight advantage in BBB penetration is a bonus.
Output:
1
2025-04-17 23:36:44,340 - INFO - Batch 417 complete. Total preferences: 6672
2025-04-17 23:36:44,340 - INFO - Processing batch 418/512...
2025-04-17 23:37:34,812 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (368.5 and 367.9 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (95.42) is higher than the preferred <140 for oral absorption, but still reasonable. Ligand B (29.54) is excellent, well below 90, suggesting good permeability. This favors Ligand B.
3. **logP:** Ligand A (2.071) is within the optimal 1-3 range. Ligand B (4.905) is slightly high, potentially leading to solubility issues and off-target interactions. This favors Ligand A.
4. **HBD:** Ligand A (2) is good. Ligand B (0) is also acceptable, but having some HBD can aid solubility. No strong preference.
5. **HBA:** Ligand A (6) is good. Ligand B (2) is also good. No strong preference.
6. **QED:** Both ligands (0.656 and 0.641) have good drug-likeness scores, exceeding the 0.5 threshold. No significant difference.
7. **DILI:** Ligand A (52.036) has a moderate DILI risk, but acceptable. Ligand B (11.632) has a very low DILI risk, which is a significant advantage. This favors Ligand B.
8. **BBB:** Ligand A (30.438) has low BBB penetration. Ligand B (86.08) has excellent BBB penetration. Since ADRB2 is a GPCR, and while not exclusively a CNS target, increased CNS exposure is not necessarily detrimental and could provide additional therapeutic effects or insights. This strongly favors Ligand B.
9. **Caco-2:** Ligand A (-5.522) and Ligand B (-4.243) are both negative, indicating poor permeability. However, Ligand B is slightly better.
10. **Solubility:** Ligand A (-3.013) has poor solubility. Ligand B (-5.641) has even worse solubility. This is a concern for both, but more so for Ligand B. This favors Ligand A.
11. **hERG:** Ligand A (0.141) has a very low hERG risk. Ligand B (0.874) has a slightly elevated hERG risk. This favors Ligand A.
12. **Cl_mic:** Ligand A (43.168) has moderate metabolic clearance. Ligand B (114.961) has high metabolic clearance, suggesting faster metabolism and potentially lower *in vivo* exposure. This favors Ligand A.
13. **t1/2:** Both ligands have similar negative in vitro half-lives (-8.629 and -8.849). This isn't a differentiating factor.
14. **Pgp:** Ligand A (0.042) has low P-gp efflux, which is good. Ligand B (0.496) has higher P-gp efflux, which could limit oral bioavailability. This favors Ligand A.
15. **Binding Affinity:** Ligand A (-6.7) and Ligand B (-6.2) have good binding affinities, but Ligand A is slightly stronger. This favors Ligand A, but the difference is relatively small.
**Overall Assessment:**
Ligand B excels in TPSA, BBB penetration, and DILI risk. However, it suffers from high logP, poor solubility, high metabolic clearance, and higher P-gp efflux. Ligand A has a more balanced profile, with better solubility, lower hERG risk, lower P-gp efflux, and slightly better binding affinity. While Ligand B's BBB penetration is attractive, the other drawbacks, particularly the solubility and metabolic stability concerns, are more critical for overall drug development. Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity), Ligand A presents a more favorable profile.
Output:
1
2025-04-17 23:37:34,813 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
We are targeting ADRB2, a GPCR. Therefore, priorities are logP, Pgp, TPSA, affinity, and BBB. Let's analyze each ligand against these and other important parameters.
* **Molecular Weight:** Both ligands (352.5 and 346.4 Da) fall within the ideal 200-500 Da range.
* **TPSA:** Ligand A (69.64) is significantly better than Ligand B (88.33). Lower TPSA generally correlates with better cell permeability, crucial for GPCR targeting.
* **logP:** Both ligands have acceptable logP values (2.72 and 1.86), falling within the 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability, but not drastically so.
* **H-Bond Donors/Acceptors:** Ligand A (2 HBD, 3 HBA) is slightly more favorable than Ligand B (1 HBD, 5 HBA). While both are within acceptable limits, fewer hydrogen bonds can improve permeability.
* **QED:** Both ligands have good QED scores (0.74 and 0.92), indicating good drug-like properties.
* **DILI:** Ligand B (74.02) has a significantly higher DILI risk than Ligand A (15.63). This is a major concern, as liver toxicity is a common reason for drug failure.
* **BBB:** Ligand B (83.56) shows better BBB penetration than Ligand A (66.58), but BBB is less critical for a cardiovascular target like ADRB2.
* **Caco-2 Permeability:** Ligand A (-4.701) has slightly better Caco-2 permeability than Ligand B (-4.652).
* **Aqueous Solubility:** Both ligands have similar, very poor aqueous solubility (-2.83 and -2.86). This could pose formulation challenges.
* **hERG:** Ligand A (0.559) has a slightly higher hERG risk than Ligand B (0.296), but both are relatively low.
* **Microsomal Clearance:** Ligand A (48.82) has considerably higher microsomal clearance than Ligand B (17.72). This suggests Ligand B has better metabolic stability.
* **In vitro Half-Life:** Ligand B (8.21) has a longer half-life than Ligand A (-10.45).
* **P-gp Efflux:** Ligand A (0.467) has better P-gp efflux properties than Ligand B (0.033). Lower P-gp efflux is generally preferred.
* **Binding Affinity:** Ligand B (-6.9 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.3 kcal/mol). This 1.6 kcal/mol difference is substantial and can often outweigh minor ADME drawbacks.
**Overall Assessment:**
While Ligand B has a superior binding affinity and better metabolic stability/half-life, the significantly higher DILI risk is a major red flag. Ligand A, despite its weaker affinity, presents a much more favorable safety profile (lower DILI) and better P-gp efflux. Considering the balance of properties and the importance of avoiding toxicity, Ligand A is the more promising candidate. The affinity difference, while notable, might be addressable through further optimization, whereas mitigating a high DILI risk is often far more challenging.
**Output:**
1
2025-04-17 23:37:34,813 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.356 and 371.88 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (50.36) is better than Ligand B (60.77). Both are below 140, which is good for oral absorption, but lower TPSA is generally preferred for GPCRs.
3. **logP:** Both ligands have a logP around 4.0 (4.039 and 4.047). This is slightly above the optimal range of 1-3, but not drastically so. Potential for off-target effects and solubility issues exists, but is manageable.
4. **HBD:** Both ligands have 2 H-bond donors, which is within the acceptable limit of 5.
5. **HBA:** Ligand A has 2 H-bond acceptors, while Ligand B has 3. Both are below the acceptable limit of 10.
6. **QED:** Ligand A (0.824) has a significantly better QED score than Ligand B (0.652), indicating a more drug-like profile.
7. **DILI:** Ligand A (76.076) has a higher DILI risk than Ligand B (10.237). This is a major concern for Ligand A.
8. **BBB:** Ligand A (70.803) has a better BBB penetration score than Ligand B (56.34). While ADRB2 isn't strictly a CNS target, some CNS exposure can occur, and higher BBB is generally favorable.
9. **Caco-2:** Ligand A (-4.343) has a worse Caco-2 permeability than Ligand B (-4.823). Lower values indicate poorer permeability.
10. **Solubility:** Ligand A (-5.399) has a worse solubility than Ligand B (-3.611). Solubility is important for bioavailability.
11. **hERG:** Both ligands have similar hERG inhibition liability (0.81 and 0.867).
12. **Cl_mic:** Ligand B (84.008) has a higher microsomal clearance than Ligand A (81.163). Lower clearance is better for metabolic stability.
13. **t1/2:** Ligand B (44.684) has a slightly longer in vitro half-life than Ligand A (38.863).
14. **Pgp:** Both ligands have similar Pgp efflux liability (0.478 and 0.472).
15. **Binding Affinity:** Ligand B (-7.4) has a slightly better binding affinity than Ligand A (-7.3). While the difference is small (0.1 kcal/mol), it's still a positive for Ligand B.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Both ligands are acceptable in logP. Ligand A has a better TPSA. Pgp is similar. Ligand B has a slightly better affinity. However, the significantly lower DILI risk for Ligand B is a major advantage. The better solubility and Caco-2 permeability of Ligand B also contribute to better potential for oral bioavailability.
**Conclusion:**
Despite Ligand A's slightly better TPSA and BBB, the significantly lower DILI risk, better solubility, better Caco-2 permeability, and slightly improved binding affinity of Ligand B make it a more promising drug candidate. The DILI risk associated with Ligand A is a serious concern that outweighs its minor advantages.
Output:
0
2025-04-17 23:37:34,813 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (361.511 and 349.431 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands have TPSA values (71.09 and 71.85) below the 140 A^2 threshold for good oral absorption. This is good for both.
3. **logP:** Ligand A (3.138) is optimal, while Ligand B (0.873) is a bit low, potentially hindering permeation. This favors Ligand A.
4. **HBD:** Ligand A (2) and Ligand B (0) both meet the <=5 criteria.
5. **HBA:** Ligand A (4) and Ligand B (5) both meet the <=10 criteria.
6. **QED:** Both ligands (0.699 and 0.791) have good QED scores, indicating drug-likeness.
7. **DILI:** Ligand B (42.962) has a significantly lower DILI risk than Ligand A (57.348). This is a substantial advantage for Ligand B.
8. **BBB:** Ligand B (65.413) has a better BBB penetration percentile than Ligand A (57.968). While ADRB2 isn't strictly a CNS target, some peripheral ADRB2 receptors can be relevant in CNS-related conditions, and better BBB penetration is generally favorable.
9. **Caco-2:** Ligand A (-5.108) and Ligand B (-4.339) are both negative, which is unusual and suggests poor permeability. However, the scale is not specified, so it is difficult to interpret.
10. **Solubility:** Ligand A (-3.744) and Ligand B (-0.91) are both negative, suggesting poor solubility. Ligand B is better here.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.253 and 0.186).
12. **Cl_mic:** Ligand B (21.934) has significantly lower microsomal clearance than Ligand A (57.363), indicating better metabolic stability. This is a major advantage for Ligand B.
13. **t1/2:** Ligand A (7.309) has a longer in vitro half-life than Ligand B (-2.938). This is a benefit for Ligand A.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.472 and 0.066).
15. **Binding Affinity:** Ligand A (-7.2 kcal/mol) has a slightly better binding affinity than Ligand B (-7.0 kcal/mol), but the difference is small.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are important. Ligand A has a better logP and slightly better affinity. Ligand B has better BBB penetration and significantly better metabolic stability (lower Cl_mic) and lower DILI risk.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity and half-life, Ligand B demonstrates a superior safety profile (lower DILI) and better pharmacokinetic properties (lower Cl_mic, better BBB). The difference in binding affinity is small and can potentially be optimized during lead optimization. The improved ADME properties and reduced toxicity risk of Ligand B make it the more promising drug candidate.
Output:
0
2025-04-17 23:37:34,813 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [353.398, 105.98 , 0.518, 2. , 6. , 0.673, 50.097, 74.564, -5.237, -1.925, 0.018, 8.836, 1.994, 0.012, -7.0]
**Ligand B:** [340.471, 50.28 , 3.611, 1. , 5. , 0.744, 53.005, 85.459, -4.825, -4.174, 0.924, 113.215, 17.944, 0.597, -6.2]
Here's a breakdown, considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (340.471) is slightly lower, which is generally favorable.
2. **TPSA:** Ligand A (105.98) is higher than Ligand B (50.28). Ligand B is much better here, well below the 140 threshold for oral absorption and more favorable for GPCRs.
3. **logP:** Ligand A (0.518) is quite low, potentially hindering membrane permeability. Ligand B (3.611) is within the optimal range (1-3). This is a significant advantage for Ligand B.
4. **HBD/HBA:** Ligand A has 2 HBD and 6 HBA, while Ligand B has 1 HBD and 5 HBA. Both are acceptable, but Ligand B is slightly better.
5. **QED:** Both have good QED values (A: 0.673, B: 0.744), indicating good drug-like properties. Ligand B is slightly better.
6. **DILI:** Both have similar and acceptable DILI risk (A: 50.097, B: 53.005).
7. **BBB:** Ligand B (85.459) has a higher BBB penetration percentile than Ligand A (74.564). While not a primary concern for a cardiovascular target, higher BBB is rarely detrimental.
8. **Caco-2:** Ligand A (-5.237) and Ligand B (-4.825) both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
9. **Solubility:** Ligand A (-1.925) and Ligand B (-4.174) both have negative solubility values, which is also unusual.
10. **hERG:** Ligand A (0.018) has a very low hERG risk, which is excellent. Ligand B (0.924) is slightly higher, but still relatively low.
11. **Cl_mic:** Ligand A (8.836) has a much lower microsomal clearance than Ligand B (113.215), indicating better metabolic stability. This is a significant advantage for Ligand A.
12. **t1/2:** Ligand A (1.994) has a shorter in vitro half-life than Ligand B (17.944). This is a clear advantage for Ligand B.
13. **Pgp:** Ligand A (0.012) has very low P-gp efflux, which is excellent. Ligand B (0.597) is higher, but still reasonable.
14. **Affinity:** Ligand A (-7.0) has a slightly better binding affinity than Ligand B (-6.2), a difference of 0.8 kcal/mol.
**Overall Assessment:**
Ligand B has a much better logP and TPSA, which are critical for GPCR ligands. It also has significantly better metabolic stability (longer half-life). While Ligand A has better P-gp efflux and a slightly better binding affinity, the advantages of Ligand B in terms of permeability, metabolic stability, and overall drug-like properties outweigh these benefits. The low logP of Ligand A is a major concern.
Therefore, I prefer Ligand B.
0
2025-04-17 23:37:34,813 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (343.471 Da) is well within the ideal range (200-500). Ligand B (388.515 Da) is also acceptable. No clear advantage here.
2. **TPSA:** Ligand A (54.34) is excellent, well below the 140 threshold for oral absorption. Ligand B (113.67) is still reasonable, but higher. A favors better absorption.
3. **logP:** Ligand A (2.544) is optimal (1-3). Ligand B (-0.02) is slightly below 1, potentially hindering permeation. A is better.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 3 HBA, Ligand B has 6. Ligand A is better, closer to the ideal.
6. **QED:** Both ligands have similar QED values (0.774 and 0.705), indicating good drug-likeness.
7. **DILI:** Ligand A (15.045) has a much lower DILI risk than Ligand B (49.67). This is a significant advantage for A.
8. **BBB:** Ligand A (78.907) has a good BBB penetration percentile, while Ligand B (56.572) is lower. Since ADRB2 is a GPCR, BBB penetration is a consideration, favoring A.
9. **Caco-2:** Ligand A (-4.824) and Ligand B (-5.562) are both negative, which is unusual. Lower (more negative) values typically indicate poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Ligand A (-2.4) and Ligand B (-1.657) are both negative, indicating poor solubility. This is a concern for both, but B is slightly better.
11. **hERG:** Ligand A (0.243) has a very low hERG risk, while Ligand B (0.066) is also low. A is slightly better.
12. **Cl_mic:** Ligand A (32.791) has a higher microsomal clearance than Ligand B (8.074), meaning it's metabolized faster. B is better in terms of metabolic stability.
13. **t1/2:** Ligand A (3.74) has a shorter half-life than Ligand B (-20.222). This is a significant advantage for B, assuming the negative value is a reasonable representation of a long half-life within the scale.
14. **Pgp:** Ligand A (0.091) has lower P-gp efflux than Ligand B (0.025), which is better for bioavailability.
15. **Binding Affinity:** Ligand A (-6.6 kcal/mol) has a slightly better binding affinity than Ligand B (-5.9 kcal/mol). While the difference is not huge, it's a factor.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity), Ligand A appears to be the better candidate. It has a more favorable logP, lower TPSA, better Pgp profile, and slightly better affinity. The significantly lower DILI risk and good BBB penetration are also major advantages. While Ligand B has better metabolic stability (lower Cl_mic) and a potentially longer half-life, the benefits of Ligand A in terms of absorption, safety, and receptor engagement outweigh these drawbacks.
Output:
1
2025-04-17 23:37:34,814 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (368.543 and 342.443 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (58.64) is significantly better than Ligand B (87.46). ADRB2 is a cardiovascular target, not CNS, but lower TPSA generally improves absorption. Ligand A is well below the 140 threshold, while B is approaching it.
3. **logP:** Both ligands (2.804 and 2.537) are within the optimal 1-3 range. Similar.
4. **HBD:** Ligand A (1) is better than Ligand B (3). Lower HBD is generally preferred for better permeability.
5. **HBA:** Ligand A (4) is better than Ligand B (3). Similar to HBD, lower HBA is favorable.
6. **QED:** Both ligands (0.728 and 0.738) have excellent drug-likeness scores. No significant difference.
7. **DILI:** Ligand A (13.649) has a much lower DILI risk than Ligand B (55.991). This is a major advantage for Ligand A.
8. **BBB:** Not a primary concern for a cardiovascular target, but Ligand A (76.813) is better than Ligand B (67.197).
9. **Caco-2:** Ligand A (-4.879) is better than Ligand B (-5.29). Both are negative, indicating poor permeability, but A is slightly better.
10. **Solubility:** Ligand A (-2.92) is better than Ligand B (-2.597). Both are poor, but A is slightly better.
11. **hERG:** Ligand A (0.921) is better than Ligand B (0.452). Lower hERG inhibition is crucial for avoiding cardiotoxicity, and A has a significantly lower risk.
12. **Cl_mic:** Ligand A (30.285) is better than Ligand B (-2.89). A positive value indicates lower clearance and better metabolic stability.
13. **t1/2:** Ligand A (-22.6) is better than Ligand B (25.983). A negative value indicates longer half-life.
14. **Pgp:** Ligand A (0.17) is better than Ligand B (0.057). Lower P-gp efflux is preferred.
15. **Binding Affinity:** Ligand A (-7.1) is slightly better than Ligand B (-6.7). While both are good, A has a 0.4 kcal/mol advantage.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical ADME-Tox properties, especially DILI and hERG inhibition, which are vital for cardiovascular drugs. While the binding affinity difference is modest, the superior ADME profile of Ligand A makes it a much more promising drug candidate. The lower TPSA, HBD, and HBA also contribute to its better predicted pharmacokinetic properties.
Output:
1
2025-04-17 23:37:34,814 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (377.725 and 338.415 Da) fall within the ideal 200-500 Da range. Ligand B is slightly preferred due to being a bit lower in MW.
2. **TPSA:** Both ligands (88.24 and 88.49) are below the 140 A^2 threshold for good oral absorption, and reasonably close to the 90 A^2 threshold for CNS targets (though ADRB2 isn't a CNS target, lower TPSA is generally favorable). Very similar here.
3. **logP:** Both ligands (2.939 and 2.447) are within the optimal 1-3 range. Ligand A is slightly higher, which *could* be beneficial for membrane permeability, but both are acceptable.
4. **HBD:** Ligand A has 3 HBD, and Ligand B has 2. Both are within the acceptable limit of <=5.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 5. Both are within the acceptable limit of <=10.
6. **QED:** Both ligands have similar QED values (0.715 and 0.722), indicating good drug-like properties.
7. **DILI:** Both ligands have DILI risk around 68-69%, which is acceptable (below 70%). Very similar.
8. **BBB:** Ligand A (61.962%) has a better BBB percentile than Ligand B (50.679%). While ADRB2 isn't a CNS target, higher BBB is generally a positive indicator of reduced off-target effects.
9. **Caco-2:** Both have negative Caco-2 values (-5.08 and -5.444). These values are difficult to interpret without knowing the scale. Assuming a lower value indicates lower permeability, both are concerning.
10. **Solubility:** Both ligands have very poor aqueous solubility (-3.968 and -3.729). This is a significant drawback for both.
11. **hERG:** Both ligands have low hERG inhibition liability (0.652 and 0.231), which is excellent. Ligand B is slightly better here.
12. **Cl_mic:** Ligand A (11.891) has a lower microsomal clearance than Ligand B (15.769), suggesting better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand A (42.225 hours) has a much longer in vitro half-life than Ligand B (23.05 hours). This is a major advantage, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.222 and 0.236), which is good. Very similar.
15. **Binding Affinity:** Ligand B (-6.8 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.5 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME drawbacks. The difference is >1.5 kcal/mol.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Both ligands are reasonable on logP and Pgp. TPSA is similar. However, the affinity difference is striking. While solubility and Caco-2 are concerns for both, the significantly improved binding affinity of Ligand B, coupled with slightly better hERG, makes it more promising. The longer half-life and lower clearance of Ligand A are attractive, but the affinity difference is too large to ignore.
**Conclusion:**
Despite the solubility and permeability concerns shared by both, the significantly stronger binding affinity of Ligand B makes it the more promising candidate.
Output:
0
2025-04-17 23:37:34,814 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's break down the comparison of Ligand A and Ligand B, keeping in mind the priorities for GPCRs (logP, Pgp, TPSA, affinity, and BBB).
1. **Molecular Weight:** Both ligands (346.431 and 350.459 Da) fall comfortably within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (93.7) is slightly higher than Ligand B (59.08). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B is significantly better here.
3. **logP:** Both ligands have good logP values (1.663 and 1.764), falling within the optimal 1-3 range. This suggests good membrane permeability for both.
4. **H-Bond Donors:** Ligand A has 4 HBDs, while Ligand B has 0. Lower HBDs are generally preferred for better permeability, giving a slight edge to Ligand B.
5. **H-Bond Acceptors:** Both ligands have 4 HBAs, which is acceptable.
6. **QED:** Ligand A (0.624) has a better QED score than Ligand B (0.38), indicating a more drug-like profile.
7. **DILI:** Both ligands have low DILI risk (32.61 and 29.663), which is excellent.
8. **BBB:** Ligand B (78.48) has a better BBB penetration percentile than Ligand A (68.748). While ADRB2 isn't primarily a CNS target, some degree of BBB penetration can be useful for off-target effects assessment.
9. **Caco-2 Permeability:** Ligand A (-5.244) has better Caco-2 permeability than Ligand B (-4.246).
10. **Aqueous Solubility:** Ligand B (-0.777) has better aqueous solubility than Ligand A (-2.545). This is a positive for formulation.
11. **hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.421 and 0.245), which is crucial for cardiovascular drugs.
12. **Microsomal Clearance:** Ligand A (-12.785) has significantly lower microsomal clearance than Ligand B (44.003), indicating better metabolic stability. This is a major advantage.
13. **In vitro Half-Life:** Ligand A (-5.276) has a longer in vitro half-life than Ligand B (-14.271), further supporting its better metabolic stability.
14. **P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.007 and 0.069).
15. **Binding Affinity:** Ligand B (-6.6 kcal/mol) has a slightly better binding affinity than Ligand A (-5.3 kcal/mol). This is a 1.3 kcal/mol difference, which is significant enough to consider.
**Overall Assessment:**
Ligand B has advantages in TPSA, solubility, BBB, and binding affinity. However, Ligand A shines in metabolic stability (lower Cl_mic and longer t1/2) and has a better QED score. Considering the importance of metabolic stability for *in vivo* efficacy and the relatively small advantage in binding affinity for Ligand B, I believe Ligand A is the more promising candidate. The better Caco-2 permeability also supports this.
**Output:**
1
2025-04-17 23:37:34,814 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.4 and 344.5 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (126.96) is higher than Ligand B (58.64). For a cardiovascular GPCR like ADRB2, TPSA isn't *as* critical as for CNS targets, but lower is generally preferred for absorption. Ligand B is significantly better here.
3. **logP:** Ligand A (-0.935) is lower than the optimal 1-3 range, potentially hindering permeability. Ligand B (2.163) is well within the optimal range. This is a substantial advantage for Ligand B.
4. **HBD:** Ligand A (3) is higher than Ligand B (1). Lower is generally preferred for permeability, giving a slight edge to Ligand B.
5. **HBA:** Ligand A (8) is higher than Ligand B (3). Again, lower is better for permeability, favoring Ligand B.
6. **QED:** Both ligands have good QED scores (0.565 and 0.751), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (44.05) has a higher DILI risk than Ligand B (21.79). Lower is better, so Ligand B is preferred.
8. **BBB:** BBB isn't a major concern for a cardiovascular target. Ligand A (14.15) is much lower than Ligand B (80.26). Not a deciding factor here.
9. **Caco-2:** Ligand A (-5.942) is significantly worse than Ligand B (-4.812) indicating poor intestinal absorption. Ligand B is better.
10. **Solubility:** Ligand A (-1.134) is better than Ligand B (-2.779). Solubility is important, and this gives a slight edge to Ligand A.
11. **hERG:** Ligand A (0.009) is slightly better than Ligand B (0.263), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand A (-1.952) has a lower (better) microsomal clearance than Ligand B (54.698), suggesting better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (18.394) has a longer half-life than Ligand B (17.249). This is a slight advantage for Ligand A.
14. **Pgp:** Ligand A (0.004) has a lower Pgp efflux liability than Ligand B (0.084), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand B (-6.8 kcal/mol) has a slightly better binding affinity than Ligand A (-6.4 kcal/mol). While the difference is not huge, it's enough to consider.
**Overall Assessment:**
Ligand B excels in key properties for a GPCR target: logP, TPSA, and Caco-2 permeability. It also has a significantly lower DILI risk. While Ligand A has better metabolic stability (Cl_mic) and half-life, the permeability and safety advantages of Ligand B are more critical for overall drug development success. The slightly better affinity of Ligand B further reinforces this conclusion.
Output:
0
2025-04-17 23:37:34,814 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, the most important parameters are binding affinity, logP, TPSA, Pgp efflux, and BBB penetration.
Let's compare the ligands property by property:
1. **MW:** Both ligands (337.47 and 346.39 Da) are within the ideal range (200-500 Da).
2. **TPSA:** Ligand A (46.92) is significantly better than Ligand B (127). A TPSA under 140 is good for oral absorption, but below 90 is preferred for CNS targets. While ADRB2 isn't necessarily a CNS target, lower TPSA generally correlates with better permeability.
3. **logP:** Ligand A (4.41) is higher than the optimal range (1-3), but still potentially manageable. Ligand B (0.5) is too low, potentially hindering membrane permeability.
4. **HBD/HBA:** Ligand A (1 HBD, 3 HBA) is better than Ligand B (4 HBD, 5 HBA). Fewer H-bonds generally improve permeability.
5. **QED:** Ligand A (0.878) is significantly better than Ligand B (0.627), indicating a more drug-like profile.
6. **DILI:** Ligand A (29.08) is much better than Ligand B (62.00), indicating a lower risk of drug-induced liver injury.
7. **BBB:** Ligand A (73.67) is much better than Ligand B (24.51). While not a primary concern for a cardiovascular target, higher BBB penetration can sometimes indicate better overall permeability.
8. **Caco-2:** Ligand A (-4.704) is better than Ligand B (-5.444). Higher values indicate better absorption.
9. **Solubility:** Ligand A (-4.15) is better than Ligand B (-2.912).
10. **hERG:** Ligand A (0.794) is better than Ligand B (0.096), indicating a lower risk of cardiotoxicity.
11. **Cl_mic:** Ligand A (52.31) is worse than Ligand B (-17.57). Lower clearance is generally preferred.
12. **t1/2:** Ligand A (-23.75) is better than Ligand B (-21.16).
13. **Pgp:** Ligand A (0.475) is better than Ligand B (0.013). Lower P-gp efflux is preferred.
14. **Affinity:** Both ligands have similar binding affinities (-6.6 and -6.9 kcal/mol). The difference is minimal.
**Overall Assessment:**
Ligand A is significantly better across most critical ADME properties (TPSA, logP, QED, DILI, BBB, solubility, hERG, Pgp) despite slightly worse microsomal clearance. The superior ADME profile, combined with comparable binding affinity, makes Ligand A the more promising drug candidate.
**Output:**
1
2025-04-17 23:37:34,815 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (378.529 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (49.41) is significantly better than Ligand B (75.52). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have similar logP values around 3.4, which is optimal.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A (3) is better than Ligand B (6). Lower HBA is generally preferred for better permeability.
6. **QED:** Both ligands have acceptable QED scores (A: 0.704, B: 0.629), indicating good drug-likeness.
7. **DILI:** Ligand A (31.136) has a significantly lower DILI risk than Ligand B (69.135). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (72.858) has a higher BBB penetration score than Ligand B (41.799). While not critical for a cardiovascular target, it's a slight positive.
9. **Caco-2:** Ligand A (-4.813) is better than Ligand B (-5.766), indicating better intestinal absorption.
10. **Solubility:** Both ligands have similar, very poor aqueous solubility (-3.876 and -3.847). This is a concern for both, but not a deciding factor.
11. **hERG:** Ligand A (0.688) has a lower hERG risk than Ligand B (0.46). Lower is better.
12. **Cl_mic:** Ligand A (63.779) has a higher (worse) microsomal clearance than Ligand B (31.646). This suggests Ligand B is more metabolically stable.
13. **t1/2:** Ligand B (30.424) has a significantly longer in vitro half-life than Ligand A (8.078). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.205) has a lower P-gp efflux liability than Ligand B (0.359). Lower is better.
15. **Binding Affinity:** Ligand A (-7.4 kcal/mol) has a stronger binding affinity than Ligand B (-5.1 kcal/mol). This is a substantial difference and a major positive for Ligand A.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, affinity, logP, TPSA, and Pgp are important. Ligand A excels in affinity and has better TPSA and Pgp values. While metabolic stability (Cl_mic and t1/2) is important, the significantly stronger binding affinity of Ligand A, combined with the lower DILI risk, outweighs the slightly poorer metabolic profile.
**Conclusion:**
Ligand A is the better candidate due to its superior binding affinity, lower DILI risk, better TPSA, and lower Pgp efflux. The stronger binding is likely to translate to greater efficacy, and the lower DILI risk is crucial for safety. While Ligand B has better metabolic stability, the difference in affinity is substantial enough to favor Ligand A.
Output:
1
2025-04-17 23:37:34,815 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [352.391, 117.17 , -0.585, 2. , 6. , 0.62 , 55.68 , 55.138, -5.107, -2.306, 0.111, 23.548, -7.518, 0.012, -7.5 ]
**Ligand B:** [350.503, 58.64 , 3.047, 1. , 3. , 0.616, 11.361, 80.574, -4.638, -2.104, 0.361, 70.666, 17.409, 0.036, -5.5 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). A: 352.391, B: 350.503 - very similar.
2. **TPSA:** Ligand A (117.17) is higher than Ligand B (58.64). For a cardiovascular GPCR, TPSA isn't *as* critical as for CNS targets, but lower is generally better for permeability. B is significantly better here.
3. **logP:** Ligand A (-0.585) is quite low, potentially hindering membrane permeability. Ligand B (3.047) is within the optimal range (1-3). B is significantly better.
4. **HBD:** Ligand A (2) and B (1) are both acceptable.
5. **HBA:** Ligand A (6) and B (3) are both acceptable.
6. **QED:** Both are good (A: 0.62, B: 0.616), indicating drug-like properties.
7. **DILI:** Ligand A (55.68) is higher than Ligand B (11.361). B is much better, indicating lower liver injury risk.
8. **BBB:** Ligand A (55.138) is lower than Ligand B (80.574). While ADRB2 isn't a CNS target, higher BBB is generally preferable. B is better.
9. **Caco-2:** Ligand A (-5.107) is worse than Ligand B (-4.638). Both are negative, indicating poor permeability, but B is slightly better.
10. **Solubility:** Ligand A (-2.306) is slightly worse than Ligand B (-2.104). Both are poor, but B is better.
11. **hERG:** Ligand A (0.111) is lower than Ligand B (0.361), indicating a lower risk of hERG inhibition and cardiotoxicity. A is better.
12. **Cl_mic:** Ligand A (23.548) is much lower than Ligand B (70.666), suggesting better metabolic stability. A is significantly better.
13. **t1/2:** Ligand A (-7.518) is worse than Ligand B (17.409). B is much better, indicating a longer half-life.
14. **Pgp:** Ligand A (0.012) is much lower than Ligand B (0.036), suggesting lower P-gp efflux and better bioavailability. A is significantly better.
15. **Affinity:** Ligand A (-7.5) is slightly better than Ligand B (-5.5).
**Overall Assessment:**
Ligand B has a much better logP, TPSA, DILI, BBB, and half-life. While Ligand A has better hERG, Cl_mic, and Pgp, the issues with logP and TPSA for Ligand A are significant drawbacks for a GPCR target. The slightly better affinity of Ligand A is not enough to overcome these ADME deficiencies. The improved ADME profile of Ligand B, particularly the logP and DILI, makes it a more promising starting point for optimization.
Output:
0
2025-04-17 23:37:34,815 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (396.921 Da) is slightly higher than Ligand B (367.471 Da), but both are acceptable.
**2. TPSA:** Ligand A (58.64) is well below the 140 A^2 threshold for good oral absorption and is quite favorable. Ligand B (82.97) is still within acceptable limits, but less optimal.
**3. logP:** Ligand A (3.735) is at the upper end of the optimal range (1-3), but still acceptable. Ligand B (1.136) is a bit low, potentially hindering membrane permeability.
**4. H-Bond Donors:** Both ligands have 1 HBD, which is within the desirable limit of <=5.
**5. H-Bond Acceptors:** Both ligands have 6 HBA, also within the desirable limit of <=10.
**6. QED:** Both ligands have good QED scores (A: 0.78, B: 0.815), indicating good drug-like properties.
**7. DILI Risk:** Ligand A (79.604) has a significantly higher DILI risk than Ligand B (47.15). This is a major concern.
**8. BBB Penetration:** Ligand A (83.017) has better BBB penetration than Ligand B (50.872). While ADRB2 is primarily a cardiovascular target, some CNS effects are possible with beta-blockers, and some degree of BBB penetration isn't necessarily detrimental.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.745 and -4.641), which is unusual and suggests poor permeability. This is a concern for both.
**10. Aqueous Solubility:** Ligand A (-5.168) has slightly better aqueous solubility than Ligand B (-0.804), but both are poor.
**11. hERG Inhibition:** Ligand A (0.558) has a slightly higher hERG inhibition risk than Ligand B (0.139). This is a concern for both, but lower for Ligand B.
**12. Microsomal Clearance:** Ligand A (112.634) has significantly higher microsomal clearance than Ligand B (7.575), indicating lower metabolic stability.
**13. In vitro Half-Life:** Ligand A (41.696) has a longer half-life than Ligand B (7.612).
**14. P-gp Efflux:** Ligand A (0.554) has lower P-gp efflux than Ligand B (0.104), which is favorable.
**15. Binding Affinity:** Ligand A (-6.6 kcal/mol) has a slightly better binding affinity than Ligand B (-5.1 kcal/mol). This is a 1.5 kcal/mol difference, which is significant.
**GPCR-Specific Considerations:** For a GPCR like ADRB2, logP, TPSA, Pgp efflux, and affinity are key. Ligand A has better logP, TPSA, and Pgp efflux, and a better binding affinity. However, the significantly higher DILI risk and higher microsomal clearance for Ligand A are major drawbacks.
**Overall Assessment:**
Despite Ligand A's better affinity and some favorable ADME properties, the high DILI risk and poor metabolic stability are too significant to ignore. Ligand B, while having a lower affinity and less favorable logP, presents a much better safety profile (lower DILI and hERG) and improved metabolic stability. The affinity difference, while notable, might be overcome with further optimization.
Therefore, I would choose Ligand B.
0
2025-04-17 23:37:34,815 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [366.487, 100.19 , 1.267, 3. , 5. , 0.706, 34.703, 39.705, -5.424, -1.582, 0.029, 1.321, 4.302, 0.013, -6.7 ]
**Ligand B:** [350.459, 75.71 , 1.751, 1. , 4. , 0.585, 15.936, 76.696, -4.389, -3.175, 0.162, 78.25 , -18.519, 0.023, -6.9 ]
Here's a breakdown, comparing each parameter and considering GPCR priorities (logP, Pgp, TPSA, affinity):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (350.459) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (100.19) is a bit higher than Ligand B (75.71). Both are below 140, but B is better for absorption.
3. **logP:** Both are within the optimal range (1-3). Ligand B (1.751) is slightly higher, which could be beneficial for membrane permeability, but not drastically.
4. **HBD:** Ligand A (3) is higher than Ligand B (1). Lower is generally preferred, giving a slight edge to B.
5. **HBA:** Ligand A (5) is higher than Ligand B (4). Again, B is slightly better.
6. **QED:** Ligand A (0.706) is better than Ligand B (0.585), indicating a more drug-like profile.
7. **DILI:** Ligand A (34.703) has a higher DILI risk than Ligand B (15.936). This is a significant advantage for Ligand B.
8. **BBB:** Ligand B (76.696) has a much higher BBB penetration potential than Ligand A (39.705). While ADRB2 is cardiovascular, some CNS effects are possible with certain ligands, and higher BBB is generally desirable.
9. **Caco-2:** Ligand A (-5.424) has a lower Caco-2 value than Ligand B (-4.389), suggesting lower intestinal absorption.
10. **Solubility:** Ligand A (-1.582) has a lower solubility than Ligand B (-3.175).
11. **hERG:** Both are very low, indicating minimal hERG inhibition risk.
12. **Cl_mic:** Ligand A (1.321) has a much lower microsomal clearance than Ligand B (78.25), indicating better metabolic stability. This is a significant advantage for A.
13. **t1/2:** Ligand A (4.302) has a shorter half-life than Ligand B (-18.519). This is a significant advantage for B.
14. **Pgp:** Both have very low P-gp efflux liability.
15. **Affinity:** Ligand B (-6.9) has a slightly better binding affinity than Ligand A (-6.7). While the difference is small, it's still a factor.
**Overall Assessment:**
Ligand B demonstrates a better balance of properties, particularly regarding safety (DILI), absorption (Caco-2, TPSA, Solubility), and metabolic stability (t1/2). While Ligand A has a better QED and lower Cl_mic, the significant advantages of B in DILI risk, BBB penetration, and half-life outweigh these benefits. The slightly better affinity of B also contributes to its preference.
Output:
0
2025-04-17 23:37:34,815 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (396.843 and 342.439 Da) fall within the ideal 200-500 Da range. Ligand B is slightly smaller, which *could* be advantageous for permeability, but the difference isn't substantial.
2. **TPSA:** Ligand A (84.5) is slightly higher than Ligand B (71.34). Both are below the 140 A^2 threshold for good oral absorption, and acceptable for a non-CNS GPCR target like ADRB2.
3. **logP:** Both ligands have very similar logP values (2.735 and 2.712), falling squarely within the optimal 1-3 range.
4. **HBD:** Both ligands have 2 H-bond donors, which is good.
5. **HBA:** Ligand A has 4 H-bond acceptors, while Ligand B has 3. Both are within the acceptable limit of 10.
6. **QED:** Both ligands have good QED scores (0.801 and 0.749), indicating good drug-like properties.
7. **DILI:** Ligand A (69.523) has a higher DILI risk than Ligand B (41.838). This is a significant concern, as lower DILI is highly desirable.
8. **BBB:** This is less critical for ADRB2 (a cardiovascular target), but Ligand A (70.648) has a higher BBB penetration than Ligand B (58.007).
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.947 and -4.613). This is unusual and suggests poor permeability. However, the values are very close.
10. **Solubility:** Both ligands have very poor aqueous solubility (-3.94 and -4.429). This is a significant drawback that would require formulation strategies.
11. **hERG:** Both ligands have low hERG inhibition risk (0.27 and 0.377), which is excellent.
12. **Cl_mic:** Both ligands have similar microsomal clearance rates ( -4.03 and -4.03 mL/min/kg) indicating similar metabolic stability.
13. **t1/2:** Ligand A (26.488 hours) has a significantly longer in vitro half-life than Ligand B (14.839 hours). This is a major advantage, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands exhibit low P-gp efflux (0.174 and 0.328), which is good.
15. **Binding Affinity:** Ligand A (-7.3 kcal/mol) has a substantially stronger binding affinity than Ligand B (-6.3 kcal/mol). This 1.0 kcal/mol difference is a significant advantage and can often outweigh minor ADME concerns.
**Overall Assessment & GPCR-Specific Priorities:**
For a GPCR like ADRB2, affinity is paramount. Ligand A's significantly stronger binding affinity (-7.3 vs -6.3 kcal/mol) is a major advantage. While Ligand B has a lower DILI risk, the difference in affinity is substantial enough to overcome this concern, especially considering the similar metabolic stability and permeability profiles. The longer half-life of Ligand A is also a significant benefit. The poor solubility of both compounds is a concern that would need to be addressed through formulation, but this is a common challenge in drug development.
Output:
1
2025-04-17 23:37:34,815 - INFO - Batch 418 complete. Total preferences: 6688
2025-04-17 23:37:34,815 - INFO - Processing batch 419/512...
2025-04-17 23:38:25,190 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (370.299 Da and 390.933 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (90.31) is slightly higher than Ligand B (75.71). Both are below the 140 threshold for oral absorption, but B is better positioned for potential CNS penetration if desired.
3. **logP:** Ligand A (-0.93) is a bit low, potentially hindering permeability. Ligand B (1.485) is within the optimal 1-3 range. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable, below the 5 threshold.
5. **HBA:** Ligand A (5) and Ligand B (4) are both acceptable, below the 10 threshold.
6. **QED:** Both ligands have good QED scores (0.627 and 0.697), indicating drug-likeness. Ligand B is slightly better.
7. **DILI:** Both have low DILI risk (35.944 and 31.485), which is good. Ligand B is marginally better.
8. **BBB:** Ligand B (70.997) has a significantly higher BBB penetration percentile than Ligand A (43.699). While ADRB2 isn't strictly a CNS target, some peripheral effects are mediated by CNS pathways, and increased BBB penetration can be beneficial.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.88) is slightly better than Ligand B (-5.237).
10. **Solubility:** Ligand A (-1.242) is better than Ligand B (-3.163). Solubility is important for bioavailability.
11. **hERG:** Both ligands have low hERG inhibition risk (0.336 and 0.45), which is excellent.
12. **Cl_mic:** Ligand A (-6.792) has a much lower (better) microsomal clearance than Ligand B (28.955). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (-4.791) has a slightly better in vitro half-life than Ligand B (-2.994).
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.013 and 0.024).
15. **Binding Affinity:** Ligand A (-7.3) has a slightly better binding affinity than Ligand B (-7.1). However, the difference is small (0.2 kcal/mol) and may not be decisive.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP and BBB, while Ligand A has a slight edge in affinity and metabolic stability (Cl_mic). The difference in affinity is small, and the improved logP and BBB penetration of Ligand B are more valuable in this context.
**Conclusion:**
Considering the balance of properties, Ligand B is the more promising candidate. Its better logP, BBB penetration, and slightly improved QED and DILI risk outweigh the slight advantage of Ligand A in affinity and metabolic stability.
Output:
0
2025-04-17 23:38:25,191 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [349.391, 109.39 , 0.75 , 1. , 7. , 0.815, 52.191, 64.017, -4.981, -1.583, 0.087, 9.895, 2.84 , 0.01 , -7.2 ]
**Ligand B:** [340.467, 58.2 , 3.118, 2. , 2. , 0.714, 29.663, 65.839, -4.782, -4.141, 0.549, 61.764, 2.657, 0.281, -5.2 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal 200-500 Da range. Ligand B (340.467 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (109.39) is higher than the preferred <140 for oral absorption, while Ligand B (58.2) is excellent. This is a significant advantage for B.
3. **logP:** Ligand A (0.75) is a bit low, potentially hindering permeation. Ligand B (3.118) is within the optimal 1-3 range.
4. **HBD:** Ligand A (1) is good. Ligand B (2) is also acceptable.
5. **HBA:** Ligand A (7) is good. Ligand B (2) is excellent.
6. **QED:** Both are above 0.5 (A: 0.815, B: 0.714), indicating good drug-likeness.
7. **DILI:** Ligand A (52.191) is better than Ligand B (29.663), indicating a lower risk of liver injury.
8. **BBB:** Both have reasonable BBB penetration (A: 64.017, B: 65.839). Since this is a cardiovascular target, BBB isn't *critical*, but higher is still preferable.
9. **Caco-2:** Both are negative, indicating poor permeability.
10. **Solubility:** Ligand A (-1.583) is better than Ligand B (-4.141). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.087) is significantly better (lower risk) than Ligand B (0.549). This is a crucial safety parameter.
12. **Cl_mic:** Ligand A (9.895) has a lower clearance, suggesting better metabolic stability than Ligand B (61.764).
13. **t1/2:** Both have similar in vitro half-lives (A: 2.84, B: 2.657).
14. **Pgp:** Ligand A (0.01) has much lower P-gp efflux, which is favorable for bioavailability and potential CNS exposure. Ligand B (0.281) is higher.
15. **Affinity:** Ligand A (-7.2) has a slightly better binding affinity than Ligand B (-5.2). This is a 2.0 kcal/mol difference, which is substantial.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are particularly important. Ligand B excels in TPSA and logP, while Ligand A has a significantly better affinity and Pgp profile. The hERG risk is also a major concern, and Ligand A is far superior in this regard.
**Overall Assessment:**
While Ligand B has better TPSA and logP, the significantly stronger binding affinity of Ligand A (-7.2 vs -5.2 kcal/mol), coupled with its much lower hERG risk and Pgp efflux, outweigh these advantages. The slightly lower solubility of Ligand A can potentially be addressed through formulation strategies. The DILI risk is also lower for Ligand A.
Therefore, I would choose Ligand A.
Output:
1
2025-04-17 23:38:25,191 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (367.896 and 386.319 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (35.58) is significantly better than Ligand B (49.77). ADRB2 is a cardiovascular target, not CNS, but lower TPSA generally improves permeability.
3. **logP:** Both ligands have similar logP values (3.887 and 3.91), falling within the optimal 1-3 range.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A (2) is better than Ligand B (4). Lower HBA is generally preferred for permeability.
6. **QED:** Both ligands have similar, acceptable QED scores (0.707 and 0.722).
7. **DILI:** Ligand A (11.128) has a slightly higher DILI risk than Ligand B (6.592), but both are below the concerning threshold of 40.
8. **BBB:** Ligand A (92.594) has a much higher BBB penetration score than Ligand B (74.37). While ADRB2 isn't a CNS target, higher BBB can sometimes correlate with better overall distribution.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and problematic. However, the values are similar (-4.596 vs -4.485). This suggests poor intestinal absorption for both.
10. **Solubility:** Ligand A (-3.27) has slightly better solubility than Ligand B (-4.77).
11. **hERG:** Both ligands have low hERG inhibition liability (0.958 and 0.817), which is excellent.
12. **Cl_mic:** Ligand A (15.28) has significantly lower microsomal clearance than Ligand B (72.23), indicating better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand A (20.513) has a shorter in vitro half-life than Ligand B (33.387), but both are reasonable.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.397 and 0.489), which is good.
15. **Binding Affinity:** Ligand A (-7.6) has a significantly stronger binding affinity than Ligand B (-5.5). This is a substantial advantage (a difference of 2.1 kcal/mol).
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Both ligands are good on logP and Pgp. Ligand A is significantly better on TPSA and *much* better on affinity. The better metabolic stability (lower Cl_mic) of Ligand A is also a significant benefit.
**Overall Assessment:**
Despite the similar QED and DILI scores, Ligand A is the superior candidate. The significantly stronger binding affinity (-7.6 vs -5.5 kcal/mol) and lower microsomal clearance (15.28 vs 72.23) outweigh the slightly higher DILI risk and shorter half-life. The lower TPSA and HBA also contribute to better predicted permeability. The Caco-2 values are concerning for both, but the overall profile of Ligand A is more promising.
Output:
1
2025-04-17 23:38:25,191 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (346.475 and 350.419 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Both ligands have TPSA values (86.88 and 85.69) below the 140 A^2 threshold for good oral absorption. They are also reasonably low, which is good for GPCR ligands. No strong preference.
**3. logP:** Ligand A (2.772) is within the optimal 1-3 range. Ligand B (0.777) is slightly below this, which *could* indicate permeability issues, but isn't a dealbreaker. Ligand A is slightly favored here.
**4. H-Bond Donors:** Ligand A has 3 HBDs, and Ligand B has 1. Both are within the acceptable limit of <=5. No strong preference.
**5. H-Bond Acceptors:** Ligand A has 3 HBAs, and Ligand B has 6. Both are within the acceptable limit of <=10. Ligand A is slightly favored.
**6. QED:** Both ligands have good QED scores (0.676 and 0.819), indicating good drug-like properties. Ligand B is slightly better.
**7. DILI Risk:** Ligand A (31.601) has a lower DILI risk than Ligand B (54.634). This is a significant advantage for Ligand A.
**8. BBB Penetration:** Ligand B (73.905) has significantly better predicted BBB penetration than Ligand A (57.193). While ADRB2 is a cardiovascular target, some CNS effects are possible with beta-adrenergic agonists, and some degree of BBB penetration could be beneficial or at least not detrimental.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-5.112 and -4.856). These values are unusual and suggest poor permeability. This is a concern for both, but the values are similar.
**10. Aqueous Solubility:** Both ligands have very poor predicted aqueous solubility (-4.032 and -1.75). This is a major drawback for both and could pose formulation challenges.
**11. hERG Inhibition:** Both ligands have very low predicted hERG inhibition risk (0.395 and 0.156). This is excellent.
**12. Microsomal Clearance:** Ligand A (57.93) has higher microsomal clearance than Ligand B (14.062), indicating faster metabolism and potentially lower *in vivo* exposure. Ligand B is significantly favored here.
**13. In vitro Half-Life:** Ligand B (22.553 hours) has a much longer *in vitro* half-life than Ligand A (-19.622 hours). This is a substantial advantage for Ligand B, suggesting less frequent dosing might be possible.
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (0.116 and 0.038). This is favorable.
**15. Binding Affinity:** Both ligands have very similar binding affinities (-6.4 and -6.2 kcal/mol). The difference is not substantial enough to be a deciding factor.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), and the general guidelines, Ligand B emerges as the more promising candidate. While Ligand A has a lower DILI risk, Ligand B's superior BBB penetration, significantly lower microsomal clearance, and longer half-life outweigh this advantage. The solubility and Caco-2 permeability are problematic for both, but these can potentially be addressed through formulation strategies. The slightly lower logP of Ligand B is a minor concern, but not critical given the other benefits.
Output:
0
2025-04-17 23:38:25,191 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
Let's analyze each ligand against the provided guidelines, with a focus on GPCR-relevant properties (logP, Pgp, TPSA, and affinity).
* **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (346.475) is slightly lower, which is generally favorable for permeability.
* **TPSA:** Ligand A (67.23) is significantly better than Ligand B (91.22). A TPSA under 140 is good for oral absorption, but lower is better for GPCRs, and A is closer to the ideal range for potential CNS penetration even if not specifically targeting the brain.
* **logP:** Both ligands have acceptable logP values (1.883 and 2.935 respectively), falling within the 1-3 range. Ligand B is a bit higher, which could potentially lead to off-target interactions or solubility issues, but isn't a major concern.
* **H-Bond Donors/Acceptors:** Ligand A (HBD=1, HBA=4) has a more favorable profile than Ligand B (HBD=2, HBA=6). Fewer H-bonds generally improve membrane permeability.
* **QED:** Both ligands have good QED scores (0.909 and 0.81), indicating good drug-like properties.
* **DILI:** Ligand A (20.9) has a much lower DILI risk than Ligand B (79.682). This is a significant advantage for Ligand A.
* **BBB:** Ligand A (71.539) has a better BBB percentile than Ligand B (16.053). While ADRB2 isn't exclusively a CNS target, some peripheral effects are mediated by CNS pathways, and better BBB penetration can be advantageous.
* **Caco-2 Permeability:** Ligand A (-4.717) has a better Caco-2 permeability than Ligand B (-5.008).
* **Aqueous Solubility:** Ligand A (-1.216) has better solubility than Ligand B (-4.964).
* **hERG Inhibition:** Ligand A (0.228) has a lower hERG inhibition liability than Ligand B (0.558). This is a critical safety parameter.
* **Microsomal Clearance:** Both ligands have similar microsomal clearance (46.94 and 47.387).
* **In vitro Half-Life:** Ligand A (-3.203) has a better in vitro half-life than Ligand B (56.83).
* **P-gp Efflux:** Ligand A (0.064) has much lower P-gp efflux liability than Ligand B (0.443). Lower P-gp efflux is desirable for better bioavailability.
* **Binding Affinity:** Ligand A (-7.3) has a slightly better binding affinity than Ligand B (-5.9). While both are good, the 1.4 kcal/mol difference is significant and can outweigh minor ADME drawbacks.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical parameters, especially DILI risk, BBB penetration, hERG inhibition, P-gp efflux, and solubility. The slightly better binding affinity of Ligand A further solidifies its position as the more promising candidate. While Ligand B has an acceptable profile, the safety concerns associated with its higher DILI and hERG values, combined with its poorer ADME properties, make it less attractive.
**Output:**
1
2025-04-17 23:38:25,191 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [355.825, 61.44, 4.647, 2, 2, 0.787, 84.917, 73.672, -4.925, -6.149, 0.683, 32.802, 67.792, 0.329, 2.5]
**Ligand B:** [352.431, 92.01, 1.554, 2, 5, 0.741, 37.999, 32.028, -4.907, -1.647, 0.311, 25.629, 37.2, 0.113, -5.8]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, Affinity, and BBB):
1. **MW:** Both are within the ideal range (200-500 Da). A is 355.825, B is 352.431 - very similar.
2. **TPSA:** Ligand A (61.44) is significantly better than Ligand B (92.01). A is well under the 140 threshold for oral absorption and more favorable for GPCRs. B is approaching the upper limit, potentially hindering permeability.
3. **logP:** Ligand A (4.647) is higher than optimal (1-3), but still potentially manageable. Ligand B (1.554) is quite low, which could lead to poor membrane permeability and bioavailability.
4. **HBD/HBA:** Both have 2 HBD, which is good. Ligand B has 5 HBA vs. 2 for A. A is preferable.
5. **QED:** Both are around 0.7, indicating good drug-likeness.
6. **DILI:** Ligand A (84.917) has a considerably higher DILI risk than Ligand B (37.999). This is a significant concern for A.
7. **BBB:** Ligand A (73.672) has a much better BBB penetration potential than Ligand B (32.028). This is a key advantage for a GPCR target, even if not strictly CNS-focused, as it can influence distribution.
8. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability.
9. **Solubility:** Both have negative solubility values, indicating poor solubility.
10. **hERG:** Ligand A (0.683) has a slightly higher hERG risk than Ligand B (0.311), but both are relatively low.
11. **Cl_mic:** Ligand A (32.802) has better metabolic stability (lower clearance) than Ligand B (25.629).
12. **t1/2:** Ligand A (67.792) has a longer half-life than Ligand B (37.2), which is desirable.
13. **Pgp:** Ligand A (0.329) has lower P-gp efflux liability than Ligand B (0.113), which is favorable for bioavailability.
14. **Affinity:** Ligand B (-5.8 kcal/mol) has a *much* stronger binding affinity than Ligand A (-2.5 kcal/mol). This is a substantial difference, exceeding the 1.5 kcal/mol advantage threshold.
**Overall Assessment:**
Ligand B's significantly stronger binding affinity is a major advantage that outweighs its less favorable TPSA and logP. While Ligand A has better BBB penetration and metabolic stability, the difference in affinity is too large to ignore. The lower DILI risk for Ligand B is also a positive factor. The poor Caco-2 and solubility for both are concerning, but can be addressed with formulation strategies.
Therefore, I would prioritize Ligand B.
Output:
0
2025-04-17 23:38:25,192 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**1. Molecular Weight:** Both ligands (347.459 Da and 355.479 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (60.93) is significantly better than Ligand B (93.11). For a GPCR, lower TPSA is generally preferred for better permeability. Ligand B is approaching a TPSA that could hinder absorption.
**3. logP:** Ligand A (1.128) is within the optimal range (1-3), while Ligand B (-0.163) is slightly below 1. While not a hard cutoff, lower logP can sometimes indicate poorer membrane permeability.
**4. H-Bond Donors:** Ligand A (0) is preferable to Ligand B (3). Fewer H-bond donors generally improve permeability.
**5. H-Bond Acceptors:** Ligand A (3) is better than Ligand B (5), again favoring permeability.
**6. QED:** Ligand A (0.649) is slightly better than Ligand B (0.526), indicating a more drug-like profile.
**7. DILI:** Ligand A (19.659) has a much lower DILI risk than Ligand B (5.157). This is a significant advantage for Ligand A.
**8. BBB:** Ligand A (78.868) has a substantially higher BBB penetration percentile than Ligand B (32.183). While ADRB2 isn't exclusively a CNS target, some cardiovascular effects are mediated through CNS pathways, and better BBB penetration isn't a detriment.
**9. Caco-2 Permeability:** Ligand A (-4.508) is significantly better than Ligand B (-5.149), indicating better intestinal absorption.
**10. Aqueous Solubility:** Ligand A (-1.256) is slightly better than Ligand B (-1.115).
**11. hERG Inhibition:** Ligand A (0.247) is much better than Ligand B (0.103), indicating lower cardiotoxicity risk. This is crucial for a cardiovascular target.
**12. Microsomal Clearance:** Ligand A (40.67) is higher than Ligand B (4.314), meaning faster clearance and potentially lower exposure. This is a negative for Ligand A.
**13. In vitro Half-Life:** Ligand A (-15.648) is much worse than Ligand B (-2.73). This is a significant negative for Ligand A.
**14. P-gp Efflux:** Ligand A (0.055) is better than Ligand B (0.006), indicating lower P-gp efflux and potentially better bioavailability.
**15. Binding Affinity:** Ligand A (-5.8) is significantly more potent than Ligand B (-1.9). This is a major advantage for Ligand A. A difference of 3.9 kcal/mol is substantial and can often outweigh minor ADME concerns.
**Overall Assessment:**
Ligand A has a clear advantage in most key parameters, particularly binding affinity, DILI risk, hERG inhibition, TPSA, and BBB penetration. While its microsomal clearance is higher and half-life is shorter than Ligand B, the significantly stronger binding affinity and improved safety profile outweigh these drawbacks. Ligand B's lower logP and higher TPSA are concerning for permeability.
Output:
1
2025-04-17 23:38:25,192 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [363.439, 83.81, 1.714, 2, 6, 0.816, 59.093, 42.148, -5.192, -2.552, 0.288, -21.559, 46.472, 0.075, -6.7]
**Ligand B:** [363.523, 46.61, 4.225, 0, 4, 0.736, 48.623, 83.482, -4.822, -4.663, 0.404, 79.603, 12.127, 0.844, -5.7]
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (around 363 Da). No significant difference.
2. **TPSA:** Ligand A (83.81) is higher than Ligand B (46.61). For a GPCR, lower TPSA is generally preferred for better BBB penetration, giving a slight edge to B.
3. **logP:** Ligand A (1.714) is optimal, while Ligand B (4.225) is pushing the upper limit. Higher logP can lead to off-target effects and solubility issues, favoring A.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (0). This isn't a major concern for either.
5. **HBA:** Ligand A (6) is higher than Ligand B (4). Lower HBA is generally better for permeability, favoring B.
6. **QED:** Ligand A (0.816) has a better QED score than Ligand B (0.736), indicating better overall drug-likeness.
7. **DILI:** Ligand A (59.093) has a slightly higher DILI risk than Ligand B (48.623), favoring B.
8. **BBB:** Ligand B (83.482) has significantly better BBB penetration potential than Ligand A (42.148). This is a *major* advantage for B, given it's a GPCR.
9. **Caco-2:** Both are negative, but Ligand A (-5.192) is slightly better (less negative) than Ligand B (-4.822), suggesting slightly better absorption.
10. **Solubility:** Ligand B (-4.663) is better than Ligand A (-2.552). Better solubility is always a plus.
11. **hERG:** Ligand A (0.288) has a lower hERG risk than Ligand B (0.404), which is preferable.
12. **Cl_mic:** Ligand A (-21.559) has a much lower (better) microsomal clearance than Ligand B (79.603), indicating better metabolic stability. This is a significant advantage for A.
13. **t1/2:** Ligand A (46.472) has a much longer in vitro half-life than Ligand B (12.127), which is highly desirable.
14. **Pgp:** Ligand B (0.844) has higher P-gp efflux than Ligand A (0.075). Lower P-gp efflux is better for bioavailability and CNS exposure, favoring A.
15. **Affinity:** Ligand A (-6.7) has slightly better binding affinity than Ligand B (-5.7). While both are good, the difference is not huge.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, we prioritize logP, TPSA, Pgp, BBB, and affinity. Ligand B excels in BBB penetration and solubility, but suffers from a higher logP and Pgp efflux. Ligand A has a more balanced profile, with better metabolic stability (Cl_mic, t1/2), lower Pgp efflux, and a slightly better affinity. The higher TPSA of Ligand A is a concern, but the strong metabolic stability and lower efflux outweigh this.
**Conclusion:**
Considering the balance of properties and the specific priorities for a GPCR target, Ligand A appears to be the more promising drug candidate. Its superior metabolic stability, longer half-life, and lower P-gp efflux are crucial advantages.
**Output:**
1
2025-04-17 23:38:25,192 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (358.36 and 344.434 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Both ligands (58.64 and 59.07) are below the 140 A^2 threshold for good oral absorption, and are reasonable for a peripherally acting GPCR. No significant difference.
3. **logP:** Both ligands have good logP values (4.273 and 3.496) falling within the optimal 1-3 range. Ligand B is slightly better here, being closer to the lower end of the range, potentially reducing off-target effects.
4. **HBD:** Ligand A (1) is better than Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (3) is better than Ligand B (5). Lower HBA generally improves permeability.
6. **QED:** Both ligands have similar QED values (0.878 and 0.805), indicating good drug-likeness.
7. **DILI:** Both ligands have similar DILI risk (56.223 and 57.348), both are acceptable.
8. **BBB:** Ligand A (96.006) has a significantly higher BBB penetration percentile than Ligand B (73.943). While ADRB2 is not a CNS target, higher BBB is generally a positive indicator of reduced off-target effects.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.33 and -4.979). This is unusual and suggests poor permeability. However, the absolute values are similar.
10. **Solubility:** Both ligands have negative solubility values (-4.933 and -4.463). This is also unusual and suggests poor solubility. Again, the absolute values are similar.
11. **hERG:** Both ligands have low hERG inhibition liability (0.387 and 0.9). No significant difference.
12. **Cl_mic:** Ligand A (58.439) has a lower microsomal clearance than Ligand B (61.186), suggesting better metabolic stability.
13. **t1/2:** Ligand B (32.646) has a significantly longer in vitro half-life than Ligand A (-10.058). This is a major advantage, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have similar Pgp efflux liability (0.115 and 0.397).
15. **Binding Affinity:** Ligand B (-6.7 kcal/mol) has a slightly better binding affinity than Ligand A (-6.0 kcal/mol). This is a significant advantage, as a 0.7 kcal/mol difference is substantial.
**GPCR-specific priorities:** For GPCRs, logP, Pgp, TPSA, and affinity are crucial. Ligand B has a slightly better logP and significantly better affinity. While Ligand A has a better BBB, this is less critical for a non-CNS target like ADRB2. The longer half-life of Ligand B is also a major advantage.
**Conclusion:**
Considering the balance of properties, particularly the superior binding affinity and longer half-life of Ligand B, it is the more promising drug candidate.
Output:
0
2025-04-17 23:38:25,192 - INFO - Here's my reasoning and the final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, prioritizing logP, TPSA, Pgp efflux, and binding affinity is crucial.
* **Molecular Weight:** Both ligands are within the acceptable range (200-500 Da). Ligand A (352.41 Da) is slightly lower, which is generally favorable for permeability.
* **TPSA:** Ligand A (78.67) is significantly better than Ligand B (49.41). Lower TPSA generally improves oral absorption, a key consideration for a cardiovascular drug.
* **logP:** Ligand B (3.841) is higher than Ligand A (0.458). While a logP between 1-3 is optimal, Ligand B is approaching the upper limit. Ligand A is quite low, potentially hindering membrane permeability.
* **H-Bond Donors/Acceptors:** Both have acceptable HBD (1) and HBA counts (A: 5, B: 2).
* **QED:** Ligand A (0.781) has a better QED score than Ligand B (0.6), indicating a more drug-like profile.
* **DILI:** Both have acceptable DILI risk (A: 52.113, B: 44.552), below the 60 threshold.
* **BBB:** Ligand B (80.419) has a higher BBB penetration percentile than Ligand A (70.803). While not a primary concern for a cardiovascular target, it's a slight advantage.
* **Caco-2 Permeability:** Ligand A (-4.592) is better than Ligand B (-5.099), indicating better intestinal absorption.
* **Aqueous Solubility:** Ligand A (-0.859) is better than Ligand B (-4.107).
* **hERG Inhibition:** Ligand A (0.258) has a lower hERG inhibition liability than Ligand B (0.671), which is a significant safety advantage.
* **Microsomal Clearance:** Ligand B (68.489) has a higher microsomal clearance than Ligand A (24.048), indicating lower metabolic stability.
* **In vitro Half-Life:** Ligand A (-17.541) has a much longer in vitro half-life than Ligand B (8.329).
* **P-gp Efflux:** Ligand A (0.159) exhibits lower P-gp efflux liability than Ligand B (0.635), which is favorable for bioavailability.
* **Binding Affinity:** Ligand B (-7.1) has a slightly better binding affinity than Ligand A (-6.7). However, the difference is less than 1.5 kcal/mol, and can be outweighed by other factors.
**Overall Assessment:**
Ligand A demonstrates a superior balance of properties. It has better TPSA, QED, solubility, hERG risk, metabolic stability, half-life, and P-gp efflux. While Ligand B has a slightly better binding affinity and BBB penetration, the advantages of Ligand A in ADME-Tox properties are more critical for overall drug development success, particularly given the cardiovascular target. The lower logP of Ligand A is a concern, but the other benefits outweigh this drawback.
**Output:**
1
2025-04-17 23:38:25,192 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.479 and 359.491 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (81.75) is higher than Ligand B (49.77). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is still generally preferred for permeability. Ligand B is significantly better.
3. **logP:** Ligand A (0.349) is quite low, potentially hindering membrane permeability. Ligand B (3.679) is within the optimal 1-3 range. This is a substantial advantage for Ligand B.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable.
5. **HBA:** Both ligands have 4 HBA, which is within the acceptable range.
6. **QED:** Ligand B (0.856) has a higher QED score than Ligand A (0.676), indicating a more drug-like profile.
7. **DILI:** Ligand A (11.283) has a much lower DILI risk than Ligand B (46.219). This is a significant advantage for Ligand A.
8. **BBB:** Ligand B (70.997) has a higher BBB penetration percentile than Ligand A (52.889). While ADRB2 isn't primarily a CNS target, some degree of BBB penetration can be useful for off-target profiling and understanding systemic effects.
9. **Caco-2:** Both ligands have very negative Caco-2 values (-4.914 and -4.8), which is unusual and suggests poor permeability. This is a concern for both, but the difference is minimal.
10. **Solubility:** Ligand A (-1.24) has better aqueous solubility than Ligand B (-3.847). Solubility is important for formulation and bioavailability, giving a slight edge to Ligand A.
11. **hERG:** Ligand A (0.122) has a much lower hERG inhibition liability than Ligand B (0.776). This is a critical advantage for Ligand A, as hERG inhibition can lead to cardiotoxicity.
12. **Cl_mic:** Ligand A (0.455) has significantly lower microsomal clearance than Ligand B (84.384), suggesting better metabolic stability. This is a major advantage for Ligand A.
13. **t1/2:** Ligand B (46.45) has a much longer in vitro half-life than Ligand A (1.541). This is a significant advantage for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.002) has much lower P-gp efflux liability than Ligand B (0.879), which is beneficial for bioavailability.
15. **Binding Affinity:** Ligand A (-7.3) has a slightly better binding affinity than Ligand B (-6.7). While the difference is not huge, it's enough to consider.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand B initially appears stronger due to its better logP, BBB, and longer half-life. However, the significantly higher DILI risk, hERG inhibition, and Pgp efflux liability of Ligand B are major concerns. Ligand A, despite its lower logP and shorter half-life, has a much more favorable safety profile (lower DILI, hERG) and better metabolic stability (lower Cl_mic). The slightly better binding affinity of Ligand A further supports its selection. The poor Caco-2 values for both are concerning, but can be addressed in later optimization stages.
Therefore, I prioritize the safety and metabolic stability advantages of Ligand A over the slightly better pharmacokinetic properties of Ligand B.
Output:
1
2025-04-17 23:38:25,192 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (354.336 and 350.459 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (75.94) is higher than Ligand B (60.03). While both are under 140, the lower TPSA of Ligand B is preferable for oral absorption, a key consideration for a cardiovascular drug.
3. **logP:** Ligand A (2.478) is within the optimal 1-3 range. Ligand B (0.514) is a bit low, potentially hindering membrane permeability. This favors Ligand A.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 6 HBA, and Ligand B has 5. Both are acceptable.
6. **QED:** Ligand A (0.913) has a significantly better QED score than Ligand B (0.511), indicating a more drug-like profile. This is a strong advantage for Ligand A.
7. **DILI:** Ligand A (77.239) has a higher DILI risk than Ligand B (12.214). This is a significant drawback for Ligand A.
8. **BBB:** Ligand A (80.264) has better BBB penetration than Ligand B (70.609). While ADRB2 isn't a primary CNS target, some CNS exposure can contribute to side effects, and better control is generally preferred.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand B (-4.624) is slightly better than Ligand A (-4.838), but both are concerning.
10. **Solubility:** Ligand A (-3.985) has slightly worse solubility than Ligand B (-1.35). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.564) has a slightly higher hERG risk than Ligand B (0.283). Lower hERG risk is crucial for cardiovascular drugs.
12. **Cl_mic:** Ligand A (21.312) has a higher microsomal clearance than Ligand B (13.412), meaning it's metabolized faster. This is a disadvantage for Ligand A.
13. **t1/2:** Ligand B (16.436) has a longer in vitro half-life than Ligand A (11.112), which is preferable.
14. **Pgp:** Ligand A (0.202) has slightly lower P-gp efflux than Ligand B (0.024), which is a slight advantage.
15. **Binding Affinity:** Ligand B (-6.4 kcal/mol) has a stronger binding affinity than Ligand A (-5.4 kcal/mol). This is a 1.0 kcal/mol difference, which is substantial and can outweigh some ADME drawbacks.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has a better logP and Pgp, but Ligand B has a better TPSA and significantly better affinity. The DILI risk of Ligand A is also a major concern.
**Overall Assessment:**
Despite Ligand A's slightly better logP and Pgp, the combination of Ligand B's significantly better binding affinity, lower DILI risk, longer half-life, and lower hERG risk makes it the more promising candidate. The Caco-2 values are concerning for both, but the superior potency and safety profile of Ligand B outweigh this drawback.
Output:
0
2025-04-17 23:38:25,192 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (366.487 Da and 366.443 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (98.32) is better than Ligand B (117.34). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally favors absorption.
3. **logP:** Ligand A (0.805) is slightly higher than Ligand B (0.461), and both are a bit low. This could potentially lead to permeability issues, but is not a major concern.
4. **HBD:** Both ligands have 3 HBD, which is within the acceptable limit of 5.
5. **HBA:** Ligand A has 5 HBA, while Ligand B has 7. Ligand A is better here, as lower HBA is generally preferred for permeability.
6. **QED:** Both ligands have similar QED values (0.692 and 0.642), indicating reasonable drug-likeness.
7. **DILI:** Ligand A (52.191) has a significantly lower DILI risk than Ligand B (60.954). This is a crucial advantage.
8. **BBB:** Ligand B (32.92) has a higher BBB percentile than Ligand A (19.62). However, for a cardiovascular target like ADRB2, BBB penetration is not a high priority.
9. **Caco-2:** Ligand A (-5.536) has a better Caco-2 value than Ligand B (-6.001), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-2.695) has slightly better solubility than Ligand B (-2.089).
11. **hERG:** Both ligands have very low hERG inhibition liability (0.189 and 0.006), which is excellent.
12. **Cl_mic:** Ligand B (-27.598) has a much lower (better) microsomal clearance than Ligand A (2.762). This suggests better metabolic stability.
13. **t1/2:** Ligand B (-0.134) has a slightly longer in vitro half-life than Ligand A (-21.281).
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.1 and 0.003).
15. **Binding Affinity:** Ligand B (-6.8 kcal/mol) has a slightly better binding affinity than Ligand A (-6.0 kcal/mol). This is a 0.8 kcal/mol difference, which is significant.
**GPCR-Specific Priorities & Overall Assessment:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. While Ligand B has a slightly better affinity and metabolic stability (Cl_mic, t1/2), Ligand A demonstrates superior properties in several key areas: lower DILI risk, better TPSA, better Caco-2 permeability, and better solubility. The affinity difference, while noticeable, isn't large enough to overcome the safety and absorption advantages of Ligand A. The lower DILI risk is a significant factor in drug development.
**Output:**
1
2025-04-17 23:38:25,193 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for the ADRB2, a cardiovascular GPCR. Therefore, priorities are logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB.
Let's compare the ligands property by property:
1. **MW:** Both ligands (355.331 and 362.47) are within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (38.33) is slightly better than Ligand B (40.62), both are below the 140 threshold for oral absorption.
3. **logP:** Ligand A (4.318) is slightly higher than Ligand B (3.0). Ligand A is pushing the upper limit, but still acceptable. Ligand B is closer to the optimal range.
4. **HBD/HBA:** Ligand A (1 HBD, 2 HBA) is preferable to Ligand B (0 HBD, 3 HBA). Fewer H-bonds are generally better for membrane permeability.
5. **QED:** Both are similar (0.812 vs 0.773) and above the 0.5 threshold.
6. **DILI:** Ligand B (36.293) has a significantly lower DILI risk than Ligand A (52.191). This is a substantial advantage for Ligand B.
7. **BBB:** Ligand B (84.451) has a better BBB penetration score than Ligand A (74.758), although BBB isn't a primary concern for a cardiovascular target.
8. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-4.324) is slightly worse than Ligand B (-4.579).
9. **Solubility:** Both have negative solubility values, indicating poor aqueous solubility. Ligand A (-5.047) is slightly worse than Ligand B (-4.18).
10. **hERG:** Both are low (0.768 and 0.719), indicating low cardiotoxicity risk.
11. **Cl_mic:** Ligand B (34.941) has significantly lower microsomal clearance than Ligand A (65.678), suggesting better metabolic stability.
12. **t1/2:** Ligand B (6.359) has a longer in vitro half-life than Ligand A (-5.886), which is a positive.
13. **Pgp:** Both are low (0.208 and 0.586), indicating low P-gp efflux.
14. **Binding Affinity:** Ligand A (-7.0) has a slightly better binding affinity than Ligand B (-6.1). This is a 0.9 kcal/mol difference, which is significant.
**Overall Assessment:**
Ligand A has a slightly better binding affinity, but Ligand B excels in several critical ADME properties: lower DILI risk, better BBB penetration, lower microsomal clearance, and longer half-life. The slightly higher logP of Ligand A is a concern, and its poorer solubility and Caco-2 permeability are drawbacks. The substantial difference in DILI risk and metabolic stability (Cl_mic and t1/2) heavily favors Ligand B. Given the GPCR target class, balancing potency with ADME properties is crucial, and Ligand B strikes a better balance.
**Output:**
0
2025-04-17 23:38:25,193 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
We are targeting ADRB2, a GPCR. Therefore, the key priorities are logP, TPSA, Pgp efflux, BBB penetration, and binding affinity. Metabolic stability (Cl_mic, t1/2) and safety (DILI, hERG) are also important, but slightly less so than the first set.
Let's compare the ligands property by property:
1. **MW:** Both ligands (346.475 and 347.419 Da) are within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (67.23) is significantly better than Ligand B (89.35). A lower TPSA generally indicates better membrane permeability, crucial for GPCR ligands. Ligand A is well below the 140 threshold, while B is approaching it.
3. **logP:** Ligand A (1.883) is optimal, while Ligand B (0.15) is quite low. A logP below 1 can hinder membrane permeability. This is a significant advantage for Ligand A.
4. **HBD/HBA:** Both have 1 HBD, which is good. Ligand A has 4 HBA, and Ligand B has 6. Both are acceptable, but lower is generally preferred.
5. **QED:** Ligand A (0.909) is excellent, indicating high drug-likeness. Ligand B (0.584) is acceptable, but not as strong.
6. **DILI:** Ligand A (20.9%) has a much lower DILI risk than Ligand B (38.697%). This is a substantial safety advantage for Ligand A.
7. **BBB:** Both ligands have good BBB penetration (71.539% and 72.664% respectively). This isn't a primary concern for ADRB2 specifically, but it's good to see.
8. **Caco-2:** Ligand A (-4.717) is better than Ligand B (-5.265), indicating better intestinal absorption.
9. **Solubility:** Ligand A (-1.216) is better than Ligand B (-0.696).
10. **hERG:** Both ligands have very low hERG inhibition risk (0.228 and 0.139).
11. **Cl_mic:** Ligand A (46.94) has better metabolic stability than Ligand B (12.025).
12. **t1/2:** Ligand A (-3.203) has a better in vitro half-life than Ligand B (0.046).
13. **Pgp:** Ligand A (0.064) has lower P-gp efflux than Ligand B (0.034), which is favorable.
14. **Binding Affinity:** Ligand A (-7.3 kcal/mol) has a slightly better binding affinity than Ligand B (-6.6 kcal/mol). While the difference is not huge, it's enough to be considered.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical parameters, especially logP, TPSA, DILI, Cl_mic, and t1/2. While both have acceptable BBB penetration and hERG profiles, the superior ADME properties and slightly better binding affinity of Ligand A make it the more promising drug candidate for targeting the ADRB2 receptor.
**Output:**
1
2025-04-17 23:38:25,193 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.45 & 366.49 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand B (78.27) is significantly lower than Ligand A (105.48). This is a major advantage for Ligand B, as lower TPSA generally correlates with better cell permeability, crucial for GPCR targets.
3. **logP:** Both ligands have good logP values (2.43 and 1.23), falling within the 1-3 range. Ligand B is slightly lower, which could be beneficial for solubility, but both are acceptable.
4. **HBD:** Ligand A has 4 HBD, while Ligand B has 1. Lower HBD is generally preferred for permeability, giving Ligand B an edge.
5. **HBA:** Ligand A has 4 HBA, while Ligand B has 7. Ligand A is preferable here.
6. **QED:** Both ligands have good QED scores (0.627 and 0.782), indicating good drug-like properties. No significant difference.
7. **DILI:** Ligand B (48.31) has a lower DILI risk than Ligand A (39.67), which is a positive.
8. **BBB:** Ligand A (77.63) has a significantly higher BBB penetration percentile than Ligand B (57.19). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant, and this favors Ligand A.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. Ligand B (-5.552) is slightly better than Ligand A (-4.943).
10. **Solubility:** Both ligands have negative solubility values, indicating poor solubility. Ligand B (-2.504) is slightly better than Ligand A (-3.221).
11. **hERG:** Both ligands have very low hERG inhibition liability (0.29 and 0.084), which is excellent. No significant difference.
12. **Cl_mic:** Ligand B (22.67) has a much lower microsomal clearance than Ligand A (58.80), indicating better metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand B (10.31) has a longer in vitro half-life than Ligand A (-13.70), which is a strong advantage.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.016 and 0.063), which is good. No significant difference.
15. **Binding Affinity:** Ligand A (-8.7 kcal/mol) has a significantly stronger binding affinity than Ligand B (-5.2 kcal/mol). This is a substantial advantage for Ligand A, potentially outweighing some ADME drawbacks.
**Overall Assessment:**
Ligand A has a much stronger binding affinity, which is a critical factor for GPCRs. However, Ligand B demonstrates superior ADME properties, particularly in terms of TPSA, metabolic stability (Cl_mic), and half-life. The lower TPSA and better metabolic profile of Ligand B suggest it will have better overall pharmacokinetic properties and potentially better *in vivo* efficacy despite the weaker binding. The difference in binding affinity is significant (3.5 kcal/mol), but the ADME advantages of Ligand B are compelling, especially considering the potential for optimizing the binding affinity of Ligand B in future iterations.
Given the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), and the balance between potency and ADME, I favor Ligand B.
Output:
0
2025-04-17 23:38:25,193 - INFO - Batch 419 complete. Total preferences: 6704
2025-04-17 23:38:25,193 - INFO - Processing batch 420/512...
2025-04-17 23:39:16,078 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Step-by-step comparison:**
1. **MW:** Ligand A (361.32 Da) and Ligand B (348.487 Da) are both within the ideal range (200-500 Da). No clear advantage.
2. **TPSA:** Ligand A (87.74) is slightly higher than Ligand B (69.64). Both are below the 140 threshold for oral absorption, but Ligand B is preferable due to the lower TPSA.
3. **logP:** Ligand A (0.687) is a bit low, potentially hindering permeation. Ligand B (2.247) is better, falling within the optimal 1-3 range.
4. **HBD:** Both ligands have 2 HBD, which is within the acceptable limit of 5. No clear advantage.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 3. Both are below the 10 threshold. Ligand B is slightly better.
6. **QED:** Both ligands have good QED scores (A: 0.709, B: 0.749), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (56.805) has a higher DILI risk than Ligand B (10.585). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (91.392) has better BBB penetration than Ligand B (68.941). While ADRB2 isn't strictly a CNS target, some CNS exposure could be beneficial or at least not detrimental, and this is a point in favor of Ligand A.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. Ligand A (-5.042) is slightly worse than Ligand B (-4.828).
10. **Solubility:** Both ligands have poor aqueous solubility (-2.872 and -3.065 respectively).
11. **hERG:** Both ligands have low hERG inhibition risk (0.139 and 0.267 respectively). No clear advantage.
12. **Cl_mic:** Ligand A (5.569) has a lower microsomal clearance than Ligand B (31.515), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (33.441) has a longer in vitro half-life than Ligand B (-3.913). This is a significant advantage for Ligand A.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.011 and 0.205 respectively). Ligand A is slightly better.
15. **Binding Affinity:** Ligand A (-6.8 kcal/mol) has a slightly better binding affinity than Ligand B (-6.5 kcal/mol). While the difference is not huge, it's a factor.
**GPCR-Specific Considerations:**
For GPCRs, logP, TPSA, Pgp, and affinity are important. Ligand B is better in terms of logP and TPSA. Ligand A has a slightly better affinity. The DILI risk is a major concern, and Ligand B is much better in this regard. Metabolic stability (Cl_mic and t1/2) are also important, and Ligand A is significantly better.
**Overall Assessment:**
Ligand A has advantages in binding affinity, metabolic stability, and half-life. However, Ligand B has a much lower DILI risk, better logP, and lower TPSA. Given the balance, the lower DILI risk and better ADME properties of Ligand B outweigh the slightly better affinity of Ligand A.
Output:
0
2025-04-17 23:39:16,078 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [354.495, 76.12, -0.254, 2, 5, 0.688, 5.079, 18.147, -5.079, -0.009, 0.177, 2.652, 1.122, 0.008, -5.8]
**Ligand B:** [350.463, 85.25, 1.446, 2, 5, 0.669, 22.8, 65.839, -4.853, -1.565, 0.153, 31.068, 18.346, 0.017, -7.4]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity) are key:
1. **MW:** Both are within the ideal range (200-500 Da). A is 354.5, B is 350.5. Very similar.
2. **TPSA:** A (76.12) is better than B (85.25). Lower TPSA generally favors better absorption.
3. **logP:** A (-0.254) is less ideal than B (1.446). B is within the optimal 1-3 range, while A is slightly below 1. This is a significant point in favor of B.
4. **HBD/HBA:** Both have 2 HBD and 5 HBA, which are acceptable.
5. **QED:** Both are good (A: 0.688, B: 0.669), indicating drug-like properties.
6. **DILI:** A (5.079) is *much* better than B (22.8). This is a major advantage for A.
7. **BBB:** B (65.839) is significantly better than A (18.147). While not a primary concern for all GPCRs, it could be beneficial if some CNS effects are desired or if minimizing off-target CNS activity is important.
8. **Caco-2:** Both are negative, indicating poor permeability. A (-5.079) is slightly worse than B (-4.853).
9. **Solubility:** A (-0.009) is slightly better than B (-1.565), but both are very poor.
10. **hERG:** Both are very low risk (A: 0.177, B: 0.153).
11. **Cl_mic:** A (2.652) is *much* better than B (31.068). Lower clearance is preferred for metabolic stability.
12. **t1/2:** B (18.346) is significantly better than A (1.122). Longer half-life is generally desirable.
13. **Pgp:** Both are very low efflux (A: 0.008, B: 0.017).
14. **Affinity:** B (-7.4) is 1.6 kcal/mol better than A (-5.8). This is a substantial difference and a strong argument for B, potentially outweighing some ADME concerns.
**Overall Assessment:**
Ligand B has a significantly better binding affinity and a more favorable logP. However, it suffers from higher DILI risk and significantly higher microsomal clearance. Ligand A has excellent DILI and clearance profiles but weaker binding and a less ideal logP.
Considering the GPCR target class, affinity is paramount. The 1.6 kcal/mol difference in binding is substantial. While the DILI and clearance of Ligand B are concerning, these can potentially be addressed through further optimization. The poor solubility of both compounds is a concern, but formulation strategies can be employed. The slightly better TPSA of ligand A is a minor advantage.
Therefore, I believe **Ligand B** is the more promising candidate due to its significantly stronger binding affinity.
0
2025-04-17 23:39:16,078 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (359.455 and 346.471 Da) are within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (49.85) is significantly better than Ligand A (91.97). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally correlates with better absorption. Ligand B is well below the 140 threshold.
3. **logP:** Both ligands have acceptable logP values (1.704 and 2.363), falling within the 1-3 range. Ligand B is slightly higher, potentially aiding membrane permeability.
4. **HBD:** Ligand A has 3 HBD, while Ligand B has 0. Lower HBD is generally preferred for permeability, giving a slight edge to Ligand B.
5. **HBA:** Ligand A has 6 HBA, and Ligand B has 3. Again, Ligand B is better, contributing to improved permeability.
6. **QED:** Ligand B (0.734) has a better QED score than Ligand A (0.494), indicating a more drug-like profile.
7. **DILI:** Ligand B (19.698) has a much lower DILI risk than Ligand A (68.98). This is a significant advantage for Ligand B.
8. **BBB:** Ligand B (85.731) has a higher BBB penetration score than Ligand A (63.009). While not critical for a cardiovascular target, it's a positive attribute.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.972 and -4.543). This is unusual and suggests poor permeability *in vitro*. However, the values are close, so it doesn't strongly differentiate them.
10. **Solubility:** Both ligands have negative solubility values (-2.387 and -2.043). This is also concerning, indicating poor aqueous solubility. Again, the difference isn't substantial.
11. **hERG:** Ligand B (0.242) has a much lower hERG inhibition liability than Ligand A (0.619). This is a critical safety parameter, strongly favoring Ligand B.
12. **Cl_mic:** Ligand A (27.366) has a lower microsomal clearance than Ligand B (49.01), suggesting better metabolic stability. This is a positive for Ligand A.
13. **t1/2:** Ligand A (52.262) has a significantly longer *in vitro* half-life than Ligand B (3.84). This is a major advantage for Ligand A, potentially enabling less frequent dosing.
14. **Pgp:** Ligand A (0.093) has a lower P-gp efflux liability than Ligand B (0.116). Lower efflux is desirable for bioavailability.
15. **Binding Affinity:** Ligand A (-6.8 kcal/mol) has a slightly better binding affinity than Ligand B (-5.6 kcal/mol). This is a 1.2 kcal/mol difference, which is significant, but needs to be weighed against the other parameters.
**Overall Assessment & GPCR Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B excels in TPSA, logP, DILI, hERG, and QED. Ligand A has a better binding affinity and *in vitro* half-life, and lower Pgp efflux. However, the safety profile of Ligand B (lower DILI and hERG) is a major advantage. The longer half-life of Ligand A is attractive, but the poor solubility and higher DILI/hERG risks are concerning. The affinity difference, while present, is not large enough to overcome the significant ADMET advantages of Ligand B.
**Output:**
0
2025-04-17 23:39:16,078 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.49 & 343.39 Da) are within the ideal range (200-500 Da). No significant difference.
2. **TPSA:** Ligand A (50.8) is significantly better than Ligand B (108.8). ADRB2 is not a CNS target, but lower TPSA generally improves absorption. Ligand A is well below the 140 threshold. Ligand B is approaching the upper limit.
3. **logP:** Ligand A (3.74) is optimal, while Ligand B (0.15) is quite low. This is a major concern for Ligand B, as it may struggle with membrane permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Both are acceptable, but fewer HBDs generally correlate with better permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (6). Similar reasoning as with HBDs.
6. **QED:** Both ligands (0.764 and 0.751) have excellent drug-likeness scores. No significant difference.
7. **DILI:** Ligand A (15.12) is *much* better than Ligand B (61.69). This is a critical advantage for Ligand A, as it indicates a significantly lower risk of liver toxicity.
8. **BBB:** This is less critical for ADRB2, but Ligand A (95.66) is much higher than Ligand B (39.51).
9. **Caco-2:** Ligand A (-4.01) is better than Ligand B (-5.63), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-3.78) is better than Ligand B (-1.49).
11. **hERG:** Ligand A (0.71) is better than Ligand B (0.26), indicating a lower risk of cardiotoxicity.
12. **Cl_mic:** Ligand A (86.68) is worse than Ligand B (-16.78). Ligand B has a negative value, which is very good.
13. **t1/2:** Ligand A (23.69) is better than Ligand B (-5.44).
14. **Pgp:** Ligand A (0.15) is much better than Ligand B (0.02). Lower P-gp efflux is preferred.
15. **Affinity:** Ligand A (-7.3) is slightly better than Ligand B (-7.0). While the difference is small, it's still a positive.
**Overall Assessment:**
Ligand A is significantly superior to Ligand B. While Ligand B has better metabolic stability (Cl_mic), its poor logP, high DILI risk, and lower solubility are major drawbacks. Ligand A excels in most key parameters, including logP, DILI, solubility, hERG, Pgp efflux, and has slightly better binding affinity. The GPCR-specific priorities (logP, Pgp, TPSA, affinity) all favor Ligand A. The better overall ADME/Tox profile of Ligand A makes it a much more promising drug candidate.
Output:
1
2025-04-17 23:39:16,078 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for the ADRB2, a cardiovascular GPCR. Therefore, priorities are logP, TPSA, Pgp, and affinity, alongside general drug-like properties.
* **Molecular Weight:** Both ligands (352.391 and 347.459 Da) fall within the ideal 200-500 Da range.
* **TPSA:** Ligand A (115.15) is higher than Ligand B (74.43). While both are reasonably good, Ligand B is significantly better, being well below the 140 threshold for oral absorption and more favorable for GPCRs.
* **logP:** Ligand A (0.283) is quite low, potentially hindering permeability. Ligand B (2.19) is within the optimal 1-3 range. This is a significant advantage for Ligand B.
* **H-Bond Donors/Acceptors:** Ligand A has 3 HBD and 5 HBA, while Ligand B has 2 HBD and 3 HBA. Both are acceptable.
* **QED:** Both ligands have good QED scores (0.68 and 0.794), suggesting good overall drug-likeness.
* **DILI:** Ligand A (39.046) has a slightly higher DILI risk than Ligand B (9.965), but both are below the concerning 60 threshold.
* **BBB:** Both have similar BBB penetration (75.649 and 76.309), which is acceptable for a cardiovascular target.
* **Caco-2 Permeability:** Ligand A (-5.256) has poor Caco-2 permeability, while Ligand B (-4.668) is slightly better, but still low.
* **Aqueous Solubility:** Both have very poor aqueous solubility (-1.216 and -2.954). This is a concern for both, but more so for Ligand B.
* **hERG:** Both ligands have low hERG inhibition liability (0.131 and 0.528).
* **Microsomal Clearance:** Ligand A (1.387) has much lower microsomal clearance than Ligand B (12.322), indicating better metabolic stability.
* **In vitro Half-Life:** Ligand A (-47.874) has a much longer in vitro half-life than Ligand B (-19.624).
* **P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.008 and 0.023).
* **Binding Affinity:** Both ligands have identical binding affinities (-6.5 kcal/mol).
**Conclusion:**
Despite the better metabolic stability and longer half-life of Ligand A, Ligand B is preferable. The significantly better logP and TPSA values of Ligand B are crucial for a GPCR target. The low logP of Ligand A is a major drawback, likely hindering its ability to cross cell membranes and reach the target. While both have poor solubility, the other ADME properties of Ligand B are more favorable for a GPCR.
**Output:**
0
2025-04-17 23:39:16,078 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
Let's break down the comparison of Ligand A and Ligand B based on the provided parameters and the guidelines, with a focus on GPCR-relevant properties.
1. **Molecular Weight:** Both ligands (347.411 Da and 336.355 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (65.07) is significantly better than Ligand B (95.34). For a GPCR, keeping TPSA under 140 is good for absorption, and lower is generally preferred. Ligand B's TPSA is approaching a level that could hinder oral bioavailability.
3. **logP:** Both ligands have good logP values (1.871 and 1.445), falling within the optimal 1-3 range. Ligand B is slightly lower, which could marginally affect permeability.
4. **H-Bond Donors/Acceptors:** Ligand A (0 HBD, 5 HBA) has a more favorable profile than Ligand B (1 HBD, 7 HBA). Fewer hydrogen bond donors generally improve membrane permeability.
5. **QED:** Both ligands have acceptable QED scores (0.601 and 0.768), indicating reasonable drug-likeness.
6. **DILI Risk:** Ligand A (65.374) has a significantly lower DILI risk than Ligand B (98.565). This is a major advantage for Ligand A.
7. **BBB Penetration:** Ligand A (67.313) has better BBB penetration than Ligand B (19.349). While ADRB2 isn't strictly a CNS target, some peripheral ADRB2 activity can be modulated by CNS effects, and better BBB penetration is rarely a negative.
8. **Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests a potential issue with the data or the model used to predict it. However, the values are similar (-4.277 vs -4.991), so this isn't a major differentiator.
9. **Aqueous Solubility:** Both ligands have negative solubility values, again suggesting a potential data issue. The values are similar (-2.396 vs -3.148).
10. **hERG Inhibition:** Ligand A (0.243) has a much lower hERG inhibition liability than Ligand B (0.098). This is a critical advantage, as hERG inhibition can lead to cardiotoxicity.
11. **Microsomal Clearance:** Ligand A (80.909) has lower microsomal clearance than Ligand B (22.997), indicating better metabolic stability.
12. **In vitro Half-Life:** Ligand A (-13.658) has a longer in vitro half-life than Ligand B (-4.208).
13. **P-gp Efflux:** Ligand A (0.125) has lower P-gp efflux than Ligand B (0.006), which is favorable for bioavailability.
14. **Binding Affinity:** Ligand B (-7.5 kcal/mol) has a slightly better binding affinity than Ligand A (-6.6 kcal/mol). This is a 1.1 kcal/mol difference, which is notable but not overwhelmingly large.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B in almost all crucial ADME-Tox properties (DILI, hERG, metabolic stability, BBB, P-gp efflux). While Ligand B has a slightly better binding affinity, the superior safety and pharmacokinetic profile of Ligand A make it the more promising drug candidate. The differences in ADME properties are substantial enough to outweigh the modest affinity advantage of Ligand B.
**Output:**
1
2025-04-17 23:39:16,079 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [350.415, 77.96, 1.429, 0, 6, 0.722, 50.679, 72.586, -4.28, -1.134, 0.137, 53.818, -25.288, 0.049, -6.1]
**Ligand B:** [348.407, 115.63, -0.208, 2, 4, 0.786, 39.744, 64.482, -5.215, -2.13, 0.203, -17.144, -4.781, 0.006, -6.6]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). A: 350.4, B: 348.4 - very similar.
2. **TPSA:** A: 77.96, B: 115.63. Ligand A is significantly better, being well under the 140 threshold for oral absorption and closer to the 90 threshold for CNS targets. Ligand B is higher, potentially impacting absorption.
3. **logP:** A: 1.429, B: -0.208. Ligand A is optimal (1-3). Ligand B is slightly negative, which could hinder permeability.
4. **HBD:** A: 0, B: 2. Ligand A is preferable. Fewer HBDs generally improve permeability.
5. **HBA:** A: 6, B: 4. Both are acceptable (<=10).
6. **QED:** Both are good (>=0.5): A: 0.722, B: 0.786. B is slightly better here.
7. **DILI:** A: 50.679, B: 39.744. Ligand B has a lower DILI risk, which is a significant advantage.
8. **BBB:** A: 72.586, B: 64.482. Ligand A has better predicted BBB penetration, important for a GPCR.
9. **Caco-2:** A: -4.28, B: -5.215. Both are negative, indicating poor permeability. B is slightly worse.
10. **Solubility:** A: -1.134, B: -2.13. Ligand A has better predicted solubility.
11. **hERG:** A: 0.137, B: 0.203. Ligand A has a lower hERG risk, which is crucial for cardiovascular targets.
12. **Cl_mic:** A: 53.818, B: -17.144. Ligand B has a negative clearance, which is not possible. This is likely an error in the data, but still favors A.
13. **t1/2:** A: -25.288, B: -4.781. Both are negative, indicating a very short half-life. This is a concern for both, but B is less negative.
14. **Pgp:** A: 0.049, B: 0.006. Ligand B has lower P-gp efflux, which is desirable.
15. **Affinity:** A: -6.1, B: -6.6. Ligand B has slightly better binding affinity, but the difference is not huge.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, BBB, and affinity. Ligand A excels in TPSA, logP, and BBB. Ligand B has a slight edge in affinity and Pgp, and a better DILI score. However, the poor Caco-2 and solubility of both are concerning.
**Overall Assessment:**
While Ligand B has slightly better affinity and DILI, Ligand A's superior TPSA, logP, and BBB penetration, coupled with better solubility and a lower hERG risk, make it the more promising candidate. The negative clearance value for Ligand B is also a red flag. The difference in affinity isn't substantial enough to outweigh the other advantages of Ligand A.
**Output:**
1
2025-04-17 23:39:16,079 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (367.446 and 381.929 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (91.32) is slightly higher than Ligand B (71.09). For a cardiovascular GPCR, TPSA is not a critical factor, but lower is generally preferred for better absorption. Ligand B has an advantage.
3. **logP:** Both ligands have good logP values (2.459 and 3.392), falling within the optimal 1-3 range. Ligand B is slightly higher, potentially improving membrane permeability, but not dramatically.
4. **HBD:** Ligand A has 3 HBD, and Ligand B has 2. Both are within the acceptable limit of <=5.
5. **HBA:** Ligand A has 5 HBA, and Ligand B has 4. Both are within the acceptable limit of <=10.
6. **QED:** Ligand B (0.821) has a significantly higher QED score than Ligand A (0.509), indicating a more drug-like profile. This is a substantial advantage for Ligand B.
7. **DILI:** Both ligands have similar DILI risk (50.33 and 49.942 percentile), both are acceptable.
8. **BBB:** Ligand B (56.495) has a higher BBB penetration percentile than Ligand A (45.444). While ADRB2 isn't a CNS target, some distribution to the CNS is possible, and higher BBB is generally favorable.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.184 and -5.076). This is unusual and suggests poor permeability. However, the values are similar.
10. **Solubility:** Ligand B (-4.253) has a slightly better solubility score than Ligand A (-3.601), but both are poor. Solubility is a concern for both.
11. **hERG:** Both ligands have low hERG inhibition liability (0.234 and 0.337), which is good.
12. **Cl_mic:** Ligand B (36.87) has a significantly lower microsomal clearance than Ligand A (52.358), suggesting better metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand B (25.43) has a much longer in vitro half-life than Ligand A (-3.625). This is a major advantage for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.097) has lower P-gp efflux liability than Ligand B (0.362), which is favorable.
15. **Binding Affinity:** Ligand A (-7.4) has a slightly better binding affinity than Ligand B (-2.8). This is a substantial difference. However, the other ADME properties of Ligand B are more favorable.
**Overall Assessment:**
While Ligand A has a better binding affinity, Ligand B demonstrates a superior overall profile, particularly regarding drug-likeness (QED), metabolic stability (Cl_mic), and half-life (t1/2). The slightly better BBB penetration and lower Pgp efflux are also beneficial. The poor Caco-2 and solubility are concerns for both, but the other advantages of Ligand B outweigh the affinity difference. For a cardiovascular GPCR, metabolic stability and a reasonable half-life are crucial for efficacy and dosing convenience.
Output:
0
2025-04-17 23:39:16,079 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (386.583 and 359.539 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (45.23) is significantly better than Ligand A (78.43). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (2.302 and 3.183), falling within the 1-3 optimal range. Ligand B is slightly higher, which *could* be beneficial for membrane permeability, but isn't a major concern.
4. **HBD:** Ligand A has 3 HBD, while Ligand B has 1. Both are acceptable (<=5), but lower is generally preferred for permeability. Ligand B is slightly better.
5. **HBA:** Ligand A has 5 HBA, Ligand B has 4. Both are acceptable (<=10).
6. **QED:** Ligand B (0.847) has a substantially higher QED score than Ligand A (0.558), indicating a more drug-like profile. This is a significant advantage.
7. **DILI:** Ligand B (16.208) has a much lower DILI risk than Ligand A (38.697). This is a critical advantage, as liver toxicity is a major concern in drug development.
8. **BBB:** Ligand B (79.566) has a higher BBB penetration than Ligand A (43.699), but this isn't a high priority for a cardiovascular target.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. This is a red flag for both.
10. **Solubility:** Both have negative solubility values, which is also unusual and suggests poor solubility. This is a red flag for both.
11. **hERG:** Ligand A (0.205) has a slightly lower hERG risk than Ligand B (0.57), which is a slight advantage.
12. **Cl_mic:** Ligand A (41.84) has a lower microsomal clearance than Ligand B (69.397), indicating better metabolic stability. This is a positive for Ligand A.
13. **t1/2:** Ligand B (9.326) has a significantly longer in vitro half-life than Ligand A (-2.444). This is a substantial advantage, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.162) has lower P-gp efflux than Ligand B (0.219), which is slightly better.
15. **Binding Affinity:** Ligand A (-6.5 kcal/mol) has a slightly better binding affinity than Ligand B (-6.1 kcal/mol). While the difference is small (0.4 kcal/mol), it's within the range where it could be meaningful.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are important. Ligand B has a slightly better logP and significantly better TPSA. The affinity difference is small. However, the superior DILI profile, QED, and half-life of Ligand B outweigh the slight affinity advantage of Ligand A. The poor Caco-2 and solubility values for both are concerning and would need to be addressed in further optimization.
**Conclusion:**
Considering the balance of properties, particularly the significantly lower DILI risk, higher QED, and longer half-life, Ligand B is the more promising drug candidate.
Output:
0
2025-04-17 23:39:16,079 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (344.5 & 348.4 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (49.4) is significantly better than Ligand B (67.4). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (3.28 & 2.19), falling within the 1-3 range. Ligand A is slightly higher, which *could* be beneficial for membrane permeability, but isn't a major concern for either.
4. **HBD:** Both have acceptable HBD counts (1 & 2).
5. **HBA:** Both have acceptable HBA counts (2 & 3).
6. **QED:** Both ligands have good QED scores (0.778 & 0.828), indicating good drug-like properties.
7. **DILI:** Ligand A (24.2) has a much lower DILI risk than Ligand B (56.3). This is a significant advantage for Ligand A.
8. **BBB:** Both have reasonable BBB penetration (76.6 & 78.9). Not a major factor for a cardiovascular target.
9. **Caco-2:** Both have negative Caco-2 values (-4.944 & -4.861). This is unusual and suggests poor permeability. However, the values are very similar.
10. **Solubility:** Ligand A (-3.769) has slightly better solubility than Ligand B (-2.882).
11. **hERG:** Both ligands have low hERG inhibition liability (0.303 & 0.408).
12. **Cl_mic:** Ligand A (38.97) has a higher microsomal clearance than Ligand B (24.2), indicating faster metabolism and potentially lower *in vivo* exposure. This is a disadvantage for Ligand A.
13. **t1/2:** Ligand B (17.3) has a significantly longer *in vitro* half-life than Ligand A (-8.26). This is a substantial advantage for Ligand B.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.28 & 0.171).
15. **Binding Affinity:** Ligand B (-7.2) has a slightly better binding affinity than Ligand A (-6.7). While the difference is less than the 1.5 kcal/mol threshold, it's still a positive for Ligand B.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Both ligands perform well on logP and Pgp. Ligand A has a better TPSA. Ligand B has a slightly better affinity. However, the major deciding factors are the significantly lower DILI risk and longer half-life of Ligand B. The faster clearance of Ligand A is a concern.
**Conclusion:**
Despite the slightly better TPSA of Ligand A, Ligand B's superior DILI profile, longer half-life, and slightly improved binding affinity make it the more promising drug candidate.
Output:
0
2025-04-17 23:39:16,079 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (365.455 and 354.491 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (100.55) is higher than Ligand B (67.87). For a GPCR, lower TPSA is generally preferred for better permeability, giving a slight edge to Ligand B.
**3. logP:** Ligand B (1.973) is within the optimal 1-3 range, while Ligand A (0.561) is slightly below 1. This is a significant drawback for Ligand A, as it may struggle with membrane permeability. Ligand B is favored.
**4. H-Bond Donors:** Ligand A (3) is higher than Ligand B (1). While both are acceptable, lower HBD is generally preferred for permeability, favoring Ligand B.
**5. H-Bond Acceptors:** Ligand A (6) is higher than Ligand B (4). Similar to HBD, lower HBA is beneficial for permeability, favoring Ligand B.
**6. QED:** Both ligands have similar QED values (0.64 and 0.609), indicating good drug-like properties. No clear advantage.
**7. DILI:** Ligand A (62.156) has a significantly higher DILI risk than Ligand B (14.036). This is a major concern for Ligand A, as it suggests a higher potential for liver toxicity. Ligand B is strongly favored.
**8. BBB:** Ligand B (69.794) has a better BBB penetration percentile than Ligand A (32.726). While ADRB2 isn't strictly a CNS target, some CNS exposure can occur, and better BBB penetration is generally desirable. Ligand B is favored.
**9. Caco-2 Permeability:** Ligand A (-5.488) has a worse Caco-2 permeability than Ligand B (-4.669). This reinforces the concerns about Ligand A's permeability. Ligand B is favored.
**10. Aqueous Solubility:** Ligand A (-1.784) has a worse aqueous solubility than Ligand B (-2.113). This is a minor point, as both are relatively poor, but Ligand B is slightly better.
**11. hERG Inhibition:** Ligand A (0.093) has a slightly lower hERG inhibition risk than Ligand B (0.557), but both are relatively low. No significant difference.
**12. Microsomal Clearance:** Ligand A (5.937) has a lower microsomal clearance than Ligand B (49.387), indicating better metabolic stability. This is a positive for Ligand A.
**13. In vitro Half-Life:** Ligand A (1.943) has a shorter in vitro half-life than Ligand B (-11.44). This is a significant negative for Ligand A, as it suggests faster metabolism and potentially more frequent dosing. Ligand B is favored.
**14. P-gp Efflux:** Ligand A (0.046) has a lower P-gp efflux liability than Ligand B (0.151). This is a positive for Ligand A.
**15. Binding Affinity:** Ligand A (-6.6) has a slightly better binding affinity than Ligand B (-5.6). However, the difference (1 kcal/mol) is not substantial enough to outweigh the significant ADME/Tox concerns with Ligand A.
**Overall Assessment:**
Ligand B consistently outperforms Ligand A in key ADME/Tox properties (logP, DILI, BBB, Caco-2, t1/2) and has a more favorable profile overall for a GPCR target. While Ligand A has slightly better binding affinity and lower P-gp efflux, the substantial risks associated with its poor permeability, high DILI risk, and short half-life make it a less viable drug candidate.
Output:
0
2025-04-17 23:39:16,079 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (a cardiovascular GPCR) drug candidates.
**Ligand A:** [358.427, 94.82, 2.562, 1, 8, 0.728, 89.802, 45.134, -4.989, -3.943, 0.334, 63.988, -17.454, 0.161, -7.2]
**Ligand B:** [363.479, 64.63, 3.368, 1, 4, 0.731, 67.507, 35.905, -4.799, -4.395, 0.673, 81.984, -14.434, 0.474, -5.4]
Here's a breakdown, comparing each parameter and considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal range (200-500 Da). A is 358.427, B is 363.479. Very similar.
2. **TPSA:** A is 94.82, B is 64.63. B is significantly better, being well below the 140 threshold for oral absorption, and closer to the ideal for GPCRs.
3. **logP:** A is 2.562, B is 3.368. Both are within the optimal range (1-3), but B is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** A has 8, B has 4. B is better here, reducing potential issues with solubility and permeability.
6. **QED:** Both are good (0.728 and 0.731), indicating drug-like properties.
7. **DILI:** A is 89.802, B is 67.507. B is significantly better, indicating a lower risk of drug-induced liver injury.
8. **BBB:** A is 45.134, B is 35.905. While BBB isn't *critical* for a cardiovascular target, a lower value isn't a major concern.
9. **Caco-2:** Both are negative (-4.989 and -4.799). This is unusual and suggests poor permeability.
10. **Solubility:** Both are negative (-3.943 and -4.395). This is also concerning, indicating poor aqueous solubility.
11. **hERG:** A is 0.334, B is 0.673. A is better here, suggesting lower cardiotoxicity risk.
12. **Cl_mic:** A is 63.988, B is 81.984. A has lower clearance, indicating better metabolic stability.
13. **t1/2:** A is -17.454, B is -14.434. B is better, indicating a longer in vitro half-life.
14. **Pgp:** A is 0.161, B is 0.474. A has lower P-gp efflux, which is favorable for bioavailability.
15. **Affinity:** A is -7.2 kcal/mol, B is -5.4 kcal/mol. A has a *significantly* stronger binding affinity (1.8 kcal/mol difference). This is a substantial advantage.
**Overall Assessment:**
Ligand A has a much stronger binding affinity, which is the most important factor. It also has better metabolic stability (lower Cl_mic) and lower P-gp efflux. However, Ligand B has a much better TPSA, lower DILI risk, and a longer half-life. Both have poor Caco-2 and solubility. The affinity difference is large enough to outweigh the other benefits of Ligand B.
Therefore, I would choose Ligand A.
Output:
1
2025-04-17 23:39:16,080 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.435 and 348.447 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (79.7) is slightly higher than Ligand B (76.46). Both are below the 140 threshold for oral absorption, and acceptable for a peripheral GPCR like ADRB2.
3. **logP:** Ligand B (1.748) is better than Ligand A (-0.601). A logP between 1-3 is optimal, and Ligand A is slightly outside this range, potentially impacting permeability.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 6 HBA, and Ligand B has 5. Both are within the acceptable limit of 10.
6. **QED:** Both ligands have similar QED values (0.768 and 0.726), indicating good drug-likeness.
7. **DILI:** Ligand A (35.479) has a slightly higher DILI risk than Ligand B (31.989), but both are below the concerning threshold of 60.
8. **BBB:** Ligand B (73.943) has a significantly higher BBB penetration percentile than Ligand A (25.475). While ADRB2 isn't a primary CNS target, some degree of BBB penetration can be beneficial for off-target profiling and understanding potential side effects.
9. **Caco-2:** Ligand A (-4.921) and Ligand B (-5.316) both have negative values. This is unusual and suggests very poor permeability.
10. **Solubility:** Ligand A (-0.109) has slightly better solubility than Ligand B (-1.78). Solubility is important for formulation.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.082 and 0.216).
12. **Cl_mic:** Ligand A (-24.598) has a much lower (better) microsomal clearance than Ligand B (16.157). This indicates greater metabolic stability for Ligand A.
13. **t1/2:** Ligand A (7.995) has a slightly longer in vitro half-life than Ligand B (-8.713).
14. **Pgp:** Ligand A (-5.3) has lower P-gp efflux liability than Ligand B (0.054), which is favorable for bioavailability.
15. **Affinity:** Ligand B (-6.6 kcal/mol) has a slightly better binding affinity than Ligand A (-5.3 kcal/mol). This is a significant difference, as a 1.3 kcal/mol advantage can outweigh some ADME drawbacks.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, Pgp, and affinity are crucial. Ligand B excels in logP and affinity, while Ligand A has a slight edge in Pgp and metabolic stability. The affinity difference is substantial, and the logP of Ligand B is within the optimal range.
**Overall Assessment:**
Despite Ligand A's better metabolic stability and Pgp profile, the significantly stronger binding affinity of Ligand B (-6.6 vs -5.3 kcal/mol) is the deciding factor. The slightly better logP of Ligand B also contributes to its favorability. The poor Caco-2 values for both are concerning, but can be addressed through formulation strategies.
Output:
0
2025-04-17 23:39:16,080 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
The target is ADRB2, a GPCR. Therefore, I will prioritize logP, TPSA, Pgp efflux, BBB penetration, and binding affinity.
* **Molecular Weight:** Both ligands are within the ideal range (200-500 Da).
* **TPSA:** Ligand A (75.71) is significantly better than Ligand B (104.54). Lower TPSA generally favors oral absorption and is particularly important for GPCRs.
* **logP:** Ligand A (1.729) is within the optimal range (1-3), while Ligand B (0.561) is slightly below, potentially hindering permeation.
* **H-Bond Donors/Acceptors:** Ligand A (HBD=1, HBA=4) is preferable to Ligand B (HBD=2, HBA=6) as it has fewer hydrogen bonding characteristics, which can improve membrane permeability.
* **QED:** Both ligands have similar QED values (0.74 and 0.683), indicating good drug-likeness.
* **DILI:** Ligand A (27.181) has a much lower DILI risk than Ligand B (58.705), a significant advantage.
* **BBB:** Ligand A (63.784) has better BBB penetration than Ligand B (36.332), which is a positive attribute for a GPCR target, even if not strictly CNS-focused.
* **Caco-2:** Ligand A (-4.727) has a better Caco-2 permeability score than Ligand B (-5.596).
* **Solubility:** Ligand A (-1.953) has better solubility than Ligand B (-2.441).
* **hERG:** Ligand A (0.306) has a lower hERG inhibition liability than Ligand B (0.089), which is crucial for avoiding cardiotoxicity.
* **Cl_mic:** Ligand A (48.132) has a higher (worse) microsomal clearance than Ligand B (28.583), suggesting lower metabolic stability.
* **t1/2:** Ligand A (2.142) has a slightly longer half-life than Ligand B (-0.283).
* **Pgp:** Ligand A (0.125) has lower P-gp efflux liability than Ligand B (0.048), which is favorable for bioavailability.
* **Binding Affinity:** Ligand B (-6.6 kcal/mol) has a significantly stronger binding affinity than Ligand A (-4.4 kcal/mol). This is a substantial advantage.
**Overall Assessment:**
While Ligand B boasts a superior binding affinity, Ligand A demonstrates a much more favorable ADMET profile, particularly regarding DILI risk, TPSA, logP, BBB penetration, and hERG inhibition. The difference in binding affinity (-6.6 vs -4.4 kcal/mol) is significant, but not insurmountable, especially considering the substantial improvements in safety and pharmacokinetic properties offered by Ligand A. Given the GPCR target class, a balance between potency and ADMET properties is crucial, and Ligand A strikes a better balance.
**Output:**
1
2025-04-17 23:39:16,080 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [351.407, 88.93, -0.086, 1, 7, 0.763, 49.942, 76.037, -4.6, -1.109, 0.174, 32.478, 23.5, 0.007, -6.7]
**Ligand B:** [384.933, 60.25, 3.436, 0, 6, 0.664, 55.448, 73.362, -4.87, -3.395, 0.43, 74.576, 60.669, 0.747, -7]
Here's a breakdown, considering the provided guidelines and GPCR-specific priorities (logP, Pgp, TPSA, affinity):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (351.4) is slightly preferred due to being a bit lower.
2. **TPSA:** Ligand B (60.25) is significantly better than Ligand A (88.93). Lower TPSA generally improves permeability, a key factor for GPCR ligands.
3. **logP:** Ligand A (-0.086) is a bit low, potentially hindering membrane permeability. Ligand B (3.436) is within the optimal range (1-3). This is a significant advantage for Ligand B.
4. **HBD/HBA:** Ligand A has 1 HBD and 7 HBA, while Ligand B has 0 HBD and 6 HBA. Both are acceptable, but Ligand B's lower HBD count is slightly favorable.
5. **QED:** Ligand A (0.763) is better than Ligand B (0.664), indicating a more drug-like profile.
6. **DILI:** Both have acceptable DILI risk (Ligand A: 49.942, Ligand B: 55.448), with Ligand A being slightly better.
7. **BBB:** Both have good BBB penetration (Ligand A: 76.037, Ligand B: 73.362), though not exceptionally high. This isn't a primary concern for a cardiovascular target.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability.
9. **Solubility:** Both have negative solubility values, which is also unusual and suggests poor solubility.
10. **hERG:** Ligand A (0.174) is much better than Ligand B (0.43), indicating a lower risk of cardiotoxicity. This is crucial for a cardiovascular drug.
11. **Cl_mic:** Ligand A (32.478) has a lower clearance than Ligand B (74.576), suggesting better metabolic stability.
12. **t1/2:** Ligand B (60.669) has a significantly longer half-life than Ligand A (23.5). This is a major advantage for dosing convenience.
13. **Pgp:** Ligand A (0.007) has much lower P-gp efflux liability than Ligand B (0.747), which is favorable for bioavailability.
14. **Affinity:** Ligand B (-7.0) has a slightly better binding affinity than Ligand A (-6.7). While the difference is small, it's still a positive.
**Overall Assessment:**
Ligand B has a better logP and a significantly longer half-life. Ligand A has better QED, lower DILI, lower hERG, and lower Pgp efflux. The TPSA of Ligand B is also more favorable. Considering the GPCR-specific priorities, logP and affinity are important. The longer half-life of Ligand B is a significant advantage. The slightly better affinity of Ligand B, combined with its favorable logP and TPSA, outweighs the slightly better QED, DILI, and hERG of Ligand A.
Output:
0
2025-04-17 23:39:16,080 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [346.435, 105.91 , 0.974, 4. , 4. , 0.571, 39.55 , 18.34 , -5.874, -1.919, 0.269, -13.393, 8.827, 0.01 , -5.1 ]
**Ligand B:** [348.367, 122.28 , -1.376, 1. , 9. , 0.678, 58.434, 40.791, -5.517, -0.828, 0.096, 20.458, -3.664, 0.011, -5.8 ]
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal 200-500 Da range. (A: 346.4, B: 348.4) - No clear advantage.
2. **TPSA:** Ligand A (105.91) is better than Ligand B (122.28). We want TPSA <= 140 for oral absorption, both are fine, but A is preferable.
3. **logP:** Ligand A (0.974) is within the optimal 1-3 range, but on the lower side. Ligand B (-1.376) is below 1, which is a concern for permeability. A is significantly better here.
4. **HBD:** Ligand A (4) is acceptable, Ligand B (1) is also good. No clear advantage.
5. **HBA:** Ligand A (4) is acceptable, Ligand B (9) is higher, potentially impacting permeability. A is preferable.
6. **QED:** Both ligands have good QED scores (A: 0.571, B: 0.678), indicating good drug-like properties. B is slightly better.
7. **DILI:** Ligand A (39.55) has a much lower DILI risk than Ligand B (58.434). This is a significant advantage for A.
8. **BBB:** Ligand B (40.791) has better BBB penetration than Ligand A (18.34). However, since ADRB2 isn't a primary CNS target, this isn't a major deciding factor, but it's a positive for B.
9. **Caco-2:** Both have negative values, indicating poor permeability. A (-5.874) is slightly better than B (-5.517).
10. **Solubility:** Both have negative values, indicating poor solubility. A (-1.919) is slightly better than B (-0.828).
11. **hERG:** Both ligands have very low hERG inhibition risk (A: 0.269, B: 0.096). B is slightly better.
12. **Cl_mic:** Ligand A (-13.393) has a much lower (better) microsomal clearance than Ligand B (20.458), indicating better metabolic stability. A is significantly better.
13. **t1/2:** Ligand A (8.827) has a longer half-life than Ligand B (-3.664). A is significantly better.
14. **Pgp:** Both have very low Pgp efflux liability (A: 0.01, B: 0.011). No clear advantage.
15. **Affinity:** Both have similar binding affinities (A: -5.1, B: -5.8). B is slightly better, but the difference is not substantial enough to outweigh other factors.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, and affinity. Ligand A is significantly better in logP, TPSA, and has acceptable Pgp. While B has slightly better affinity, the differences in ADME properties are more critical.
**Conclusion:**
Ligand A demonstrates a superior balance of properties, particularly in terms of predicted ADME characteristics (DILI, Cl_mic, t1/2, logP, TPSA). While Ligand B has slightly better affinity and BBB penetration, the lower DILI risk and better metabolic stability of Ligand A make it the more promising drug candidate.
Output:
1
2025-04-17 23:39:16,080 - INFO - Batch 420 complete. Total preferences: 6720
2025-04-17 23:39:16,080 - INFO - Processing batch 421/512...
2025-04-17 23:40:04,922 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**1. Molecular Weight:** Both ligands (350.478 Da and 364.511 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (40.62) is significantly better than Ligand B (58.64). For a GPCR, keeping TPSA low is beneficial for permeability, and A is well below the 90 A^2 threshold. B is getting closer to the 140 A^2 limit for good oral absorption.
**3. logP:** Ligand A (3.156) is within the optimal 1-3 range, while Ligand B (1.665) is at the lower end. While not terrible, lower logP can sometimes indicate permeability issues.
**4. H-Bond Donors:** Ligand A (0) is preferable to Ligand B (1). Fewer H-bond donors generally improve permeability.
**5. H-Bond Acceptors:** Ligand A (2) is better than Ligand B (4). Similar to HBDs, fewer HBAs are generally preferred.
**6. QED:** Both ligands have similar QED values (0.784 and 0.698), indicating good drug-like properties.
**7. DILI:** Both ligands have low DILI risk (19.814 and 18.108), which is excellent.
**8. BBB:** Ligand A (85.925) has a significantly higher BBB penetration percentile than Ligand B (56.534). While ADRB2 isn't *exclusively* a CNS target, some CNS exposure could be relevant, and higher BBB is generally a positive attribute.
**9. Caco-2 Permeability:** Ligand A (-4.557) is better than Ligand B (-5.006). Higher values are better, and A is closer to zero.
**10. Aqueous Solubility:** Both ligands have poor aqueous solubility (-3.357 and -3.447). This is a concern for both, and formulation strategies might be needed.
**11. hERG Inhibition:** Ligand A (0.761) is slightly better than Ligand B (0.265), indicating a lower risk of cardiotoxicity.
**12. Microsomal Clearance:** Ligand B (19.705) has lower microsomal clearance than Ligand A (55.915), suggesting better metabolic stability. This is a significant advantage for B.
**13. In vitro Half-Life:** Ligand A (-6.633) has a longer in vitro half-life than Ligand B (-1.789), which is desirable.
**14. P-gp Efflux:** Ligand A (0.227) shows lower P-gp efflux than Ligand B (0.102), which is preferable for bioavailability.
**15. Binding Affinity:** Ligand A (-6.8 kcal/mol) has a slightly better binding affinity than Ligand B (-5.7 kcal/mol). This 1.1 kcal/mol difference is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand A is the stronger candidate. It excels in key GPCR properties like TPSA, BBB penetration, and binding affinity. While Ligand B has better metabolic stability (lower Cl_mic), the superior affinity and permeability characteristics of Ligand A, combined with its lower P-gp efflux and slightly better hERG profile, make it the more promising drug candidate. The solubility issues are a concern for both, but can be addressed through formulation.
Output:
1
2025-04-17 23:40:04,922 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
Let's systematically compare Ligand A and Ligand B based on the provided parameters, keeping in mind the GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key).
1. **Molecular Weight:** Both ligands (344.39 Da and 349.519 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (68.44) is better than Ligand B (43.86). Lower TPSA generally favors better cell permeability, and both are quite good, but A is slightly preferable.
3. **logP:** Ligand A (1.343) is within the optimal 1-3 range. Ligand B (2.667) is also acceptable, but slightly higher.
4. **H-Bond Donors:** Ligand A has 2 HBD, while Ligand B has 0. Both are acceptable.
5. **H-Bond Acceptors:** Both ligands have 3 HBA, which is good.
6. **QED:** Ligand A (0.864) has a significantly better QED score than Ligand B (0.693), indicating a more drug-like profile.
7. **DILI:** Ligand A (65.568) has a higher DILI risk than Ligand B (5.7). This is a significant drawback for Ligand A.
8. **BBB:** Ligand B (92.323) has a much higher BBB penetration percentile than Ligand A (61.419). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant, and higher BBB is generally favorable.
9. **Caco-2 Permeability:** Ligand A (-4.784) is better than Ligand B (-4.509). Higher (less negative) values indicate better intestinal absorption.
10. **Aqueous Solubility:** Ligand A (-2.574) is better than Ligand B (-1.509). Higher values indicate better solubility.
11. **hERG Inhibition:** Ligand A (0.624) has a slightly higher hERG risk than Ligand B (0.354), but both are relatively low.
12. **Microsomal Clearance:** Ligand A (-11.297) has a significantly *lower* (better) microsomal clearance than Ligand B (45.474), suggesting better metabolic stability.
13. **In vitro Half-Life:** Ligand A (-8.316) is better than Ligand B (-8.689).
14. **P-gp Efflux:** Ligand A (0.038) has a lower P-gp efflux liability than Ligand B (0.062), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand A (-7.6) has a slightly better binding affinity than Ligand B (-7.1). While both are good, the 0.5 kcal/mol difference is noticeable.
**Overall Assessment:**
Ligand A has advantages in TPSA, Caco-2 permeability, solubility, metabolic stability (Cl_mic), half-life, P-gp efflux, QED, and binding affinity. However, it has a significantly higher DILI risk and lower BBB penetration. Ligand B excels in DILI risk and BBB penetration, but is weaker in other key ADME properties.
Considering the GPCR-specific priorities, the slightly better affinity of Ligand A, combined with its superior metabolic stability and P-gp efflux profile, are important. While the DILI risk is a concern, it's not excessively high (65.568). The better solubility and permeability also contribute. The difference in binding affinity is enough to outweigh the DILI risk.
**Output:**
1
2025-04-17 23:40:04,923 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (364.408 and 372.575 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (58.64) is better than Ligand B (67.43). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally favors absorption.
3. **logP:** Both ligands have good logP values (2.294 and 3.124), within the optimal 1-3 range. Ligand B is slightly higher, which could potentially lead to some off-target interactions, but it's not a major concern.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs generally improve membrane permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (4). Similar to HBD, lower HBA is generally better.
6. **QED:** Both ligands have similar QED values (0.673 and 0.652), indicating good drug-likeness.
7. **DILI:** Ligand A (14.889) has a significantly lower DILI risk than Ligand B (29.081). This is a crucial advantage, as liver toxicity is a major concern in drug development.
8. **BBB:** Ligand A (98.022) has much better BBB penetration than Ligand B (67.197). While ADRB2 is primarily cardiovascular, some CNS side effects are possible with GPCR ligands, and higher BBB is generally a positive.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.355 and -4.737), which is unusual and suggests poor permeability. This is a significant drawback for both.
10. **Solubility:** Ligand A (-2.071) has slightly better solubility than Ligand B (-3.363), although both are quite poor.
11. **hERG:** Ligand A (0.665) has a slightly better hERG profile than Ligand B (0.391), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand A (5.141) has a much lower microsomal clearance than Ligand B (70.15). This suggests better metabolic stability for Ligand A, which is highly desirable.
13. **t1/2:** Ligand A (-13.7) has a much longer in vitro half-life than Ligand B (8.609). This is a significant advantage, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.032) has a much lower P-gp efflux liability than Ligand B (0.079), which is favorable for oral bioavailability.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.4 and -6.8 kcal/mol). The difference is negligible.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A is better on TPSA, Pgp, and has a better overall ADME profile.
**Conclusion:**
Ligand A consistently outperforms Ligand B across several crucial ADME properties (DILI, BBB, Cl_mic, t1/2, Pgp) and has comparable affinity. While both have poor Caco-2 permeability, the superior safety and pharmacokinetic profile of Ligand A make it the more promising drug candidate.
Output:
1
2025-04-17 23:40:04,923 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.431 and 378.523 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (79.9) is slightly higher than Ligand B (66.4). Both are below the 140 threshold for oral absorption, but B is better.
3. **logP:** Both ligands (2.096 and 2.604) are within the optimal 1-3 range. Ligand B is slightly higher, which could be a minor concern for solubility, but not a dealbreaker.
4. **HBD:** Ligand A (2) is better than Ligand B (0). Having some HBD can improve solubility.
5. **HBA:** Ligand A (4) is lower than Ligand B (6). Lower is better for permeability.
6. **QED:** Both ligands (0.79 and 0.802) have excellent drug-likeness scores.
7. **DILI:** Ligand A (47.77) has a lower DILI risk than Ligand B (53.432), which is preferable.
8. **BBB:** Ligand B (83.908) has a significantly higher BBB penetration percentile than Ligand A (71.384). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be helpful for distribution.
9. **Caco-2:** Ligand A (-4.781) has a slightly better Caco-2 permeability than Ligand B (-5.022), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-2.063) has better aqueous solubility than Ligand B (-3.177).
11. **hERG:** Both ligands (0.34 and 0.373) have low hERG inhibition liability, which is good.
12. **Cl_mic:** Ligand A (4.354) has a lower microsomal clearance than Ligand B (54.623), suggesting better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand A (39.91) has a much longer in vitro half-life than Ligand B (18.32). This is a major advantage, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.009) has a much lower P-gp efflux liability than Ligand B (0.445), which is preferable for oral bioavailability.
15. **Binding Affinity:** Ligand A (-7.8) has a stronger binding affinity than Ligand B (-6.3). This is a substantial difference (1.5 kcal/mol) and a key driver in the decision.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are particularly important. Ligand A excels in affinity and Pgp efflux, and has acceptable logP and TPSA. While Ligand B has better BBB penetration, the significantly better affinity, metabolic stability (Cl_mic and t1/2), lower Pgp efflux, and better solubility of Ligand A outweigh this benefit.
**Conclusion:**
Ligand A is the superior candidate due to its significantly stronger binding affinity, improved metabolic stability, lower Pgp efflux, and better solubility. These factors, combined with acceptable ADME properties, make it a more promising starting point for drug development.
Output:
1
2025-04-17 23:40:04,923 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [349.391, 116.56 , -1.279, 3. , 6. , 0.612, 32.571, 13.92 ,
-5.578, -1.289, 0.016, -1.272, -5.281, 0.002, -7.6 ]
**Ligand B:** [390.305, 75.27 , 2.052, 2. , 3. , 0.597, 64.754, 77.821,
-4.834, -3.113, 0.582, 11.037, -24.643, 0.08 , -6.2 ]
**Step-by-step comparison:**
1. **MW:** Ligand A (349.391 Da) is better, falling comfortably within the 200-500 Da range. Ligand B (390.305 Da) is still acceptable, but closer to the upper limit.
2. **TPSA:** Ligand B (75.27) is significantly better, well below the 140 threshold and more favorable for permeability. Ligand A (116.56) is higher, potentially hindering absorption.
3. **logP:** Ligand A (-1.279) is a bit low, potentially leading to poor membrane permeability. Ligand B (2.052) is within the optimal 1-3 range.
4. **HBD:** Both are acceptable (3 and 2 respectively), within the guideline of <=5.
5. **HBA:** Both are acceptable (6 and 3 respectively), within the guideline of <=10.
6. **QED:** Both are similar and acceptable (0.612 and 0.597), indicating good drug-like properties.
7. **DILI:** Ligand A (32.571) has a much lower DILI risk than Ligand B (64.754), a significant advantage.
8. **BBB:** Ligand B (77.821) has better BBB penetration than Ligand A (13.92), but since this is a cardiovascular target, BBB penetration is not a high priority.
9. **Caco-2:** Both have negative values, indicating poor permeability. However, Ligand B (-4.834) is slightly better than Ligand A (-5.578).
10. **Solubility:** Ligand A (-1.289) has better solubility than Ligand B (-3.113).
11. **hERG:** Ligand A (0.016) has a much lower hERG risk than Ligand B (0.582), a critical advantage for cardiovascular drugs.
12. **Cl_mic:** Ligand A (-1.272) has lower microsomal clearance, suggesting better metabolic stability than Ligand B (11.037).
13. **t1/2:** Ligand B (-24.643) has a much longer in vitro half-life than Ligand A (-5.281), which is a positive.
14. **Pgp:** Ligand A (0.002) has lower P-gp efflux, which is favorable. Ligand B (0.08) is higher.
15. **Affinity:** Ligand A (-7.6) has a slightly better binding affinity than Ligand B (-6.2), but the difference is not huge.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Ligand B has a better logP and TPSA. Ligand A has better Pgp and a slightly better affinity. However, the significant advantages of Ligand A in terms of DILI risk and hERG inhibition are crucial for a cardiovascular drug. The longer half-life of Ligand B is also attractive, but can be optimized during lead optimization.
**Conclusion:**
Considering the balance of properties, particularly the lower DILI and hERG risk, and acceptable affinity, **Ligand A** is the more promising drug candidate.
**Output:**
1
2025-04-17 23:40:04,923 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (352.523 Da and 354.407 Da). No significant difference.
2. **TPSA:** Ligand A (55.89) is significantly better than Ligand B (108.13). For a GPCR, lower TPSA is generally preferred for permeability. Ligand B is above the 90 threshold.
3. **logP:** Ligand A (1.022) is within the optimal range, while Ligand B (-1.608) is slightly low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower is generally better for permeability.
5. **HBA:** Ligand A (4) is preferable to Ligand B (7). Lower is generally better for permeability.
6. **QED:** Ligand A (0.776) is better than Ligand B (0.582), indicating a more drug-like profile.
7. **DILI:** Ligand A (7.794) is *much* better than Ligand B (21.598). This is a critical advantage for Ligand A.
8. **BBB:** Ligand A (72.237) is better than Ligand B (21.326), though neither is exceptionally high. For a cardiovascular target, BBB isn't a primary concern, but it's a bonus.
9. **Caco-2:** Ligand A (-4.965) and Ligand B (-5.081) are similar, indicating comparable intestinal absorption potential.
10. **Solubility:** Ligand A (-0.765) is better than Ligand B (0.465). Better solubility is always preferred.
11. **hERG:** Both ligands have very low hERG risk (0.388 and 0.057 respectively). No significant difference.
12. **Cl_mic:** Ligand B (-13.269) has a significantly lower (better) microsomal clearance than Ligand A (25.578), suggesting greater metabolic stability.
13. **t1/2:** Ligand B (8.882) has a longer half-life than Ligand A (3.02). This is a significant advantage.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.013 and 0.01 respectively). No significant difference.
15. **Binding Affinity:** Both ligands have comparable binding affinities (-6.2 kcal/mol and -5.8 kcal/mol). The difference is not enough to outweigh other factors.
**Overall Assessment:**
Ligand A excels in several key areas: TPSA, logP, QED, DILI risk, and solubility. These are all important for oral bioavailability and reducing potential toxicity. While Ligand B has better metabolic stability (lower Cl_mic) and a longer half-life, the significantly higher DILI risk and poorer physicochemical properties (TPSA, logP) are concerning. For a cardiovascular target, minimizing off-target effects and ensuring good oral bioavailability are crucial. The lower DILI risk of Ligand A is a major advantage.
Output:
1
2025-04-17 23:40:04,923 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (342.53 & 345.40 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (23.55) is excellent, well below the 140 threshold, and very favorable for oral absorption. Ligand B (93.46) is higher, but still acceptable, though less ideal.
3. **logP:** Ligand A (4.149) is slightly high, potentially leading to solubility issues or off-target interactions. Ligand B (1.006) is very good, within the optimal 1-3 range.
4. **HBD:** Both have acceptable HBD counts (0 for A, 2 for B), well below the 5 threshold.
5. **HBA:** Ligand A (2) is very good. Ligand B (5) is acceptable, but higher.
6. **QED:** Both ligands have reasonable QED scores (0.802 and 0.751), indicating good drug-like properties.
7. **DILI:** Ligand A (7.251) has a very low DILI risk, which is excellent. Ligand B (49.515) is moderate, but still within an acceptable range.
8. **BBB:** Ligand A (93.292) shows excellent BBB penetration, which is beneficial for a GPCR target. Ligand B (54.634) is lower, suggesting limited CNS exposure.
9. **Caco-2:** Both show negative values, indicating poor permeability. This is a concern for both.
10. **Solubility:** Both ligands have negative solubility values, indicating poor solubility. This is a concern for both.
11. **hERG:** Ligand A (0.827) has a slightly elevated hERG risk, but still relatively low. Ligand B (0.036) has a very low hERG risk, which is highly desirable.
12. **Cl_mic:** Ligand A (10.217) has a higher microsomal clearance, suggesting faster metabolism. Ligand B (2.467) has a much lower clearance, indicating better metabolic stability.
13. **t1/2:** Ligand B (-5.732) has a significantly longer in vitro half-life, which is a major advantage. Ligand A (2.406) has a shorter half-life.
14. **Pgp:** Ligand A (0.427) has lower P-gp efflux, which is preferable. Ligand B (0.026) has very low P-gp efflux.
15. **Affinity:** Ligand A (-7.9) has a significantly stronger binding affinity than Ligand B (-5.7). This is a substantial advantage.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, Pgp, TPSA, and affinity. Ligand B has a better logP and Pgp profile. Ligand A has a better TPSA and significantly better affinity. The affinity difference is substantial (>1.5 kcal/mol).
**Overall Assessment:**
While Ligand B has advantages in metabolic stability (Cl_mic, t1/2) and hERG risk, the significantly stronger binding affinity of Ligand A (-7.9 vs -5.7 kcal/mol) is a major driver. The better TPSA of Ligand A is also favorable. The slightly higher logP of Ligand A is a concern, but the potency advantage likely outweighs this. The excellent BBB penetration of Ligand A is also a plus.
Output:
1
2025-04-17 23:40:04,923 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (338.411 and 365.499 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (68.44) is better than Ligand B (71.41). Both are below 140, but lower is preferable for absorption.
3. **logP:** Both ligands (1.327 and 1.494) are within the optimal 1-3 range. Ligand B is slightly higher, which could be a minor negative.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1), but both are well within the acceptable limit of 5.
5. **HBA:** Ligand A (3) is lower than Ligand B (5). Both are under 10, but lower is generally better.
6. **QED:** Both ligands have similar QED values (0.868 and 0.829), indicating good drug-likeness.
7. **DILI:** Both ligands have very similar DILI risk (44.048 and 44.436), and both are below the concerning threshold of 60.
8. **BBB:** Ligand A (73.827) has a significantly higher BBB penetration percentile than Ligand B (59.364). This is a key advantage for a GPCR target, even if it's not a CNS target, as it suggests better distribution.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.901 and -4.978). This is unusual and suggests poor permeability. However, the values are very close.
10. **Solubility:** Ligand A (-3.141) has slightly better solubility than Ligand B (-2.583).
11. **hERG:** Ligand A (0.757) has a lower hERG inhibition liability than Ligand B (0.269), which is a significant safety advantage.
12. **Cl_mic:** Ligand B (41.644) has a much higher microsomal clearance than Ligand A (14.8), indicating lower metabolic stability. This is a major drawback for Ligand B.
13. **t1/2:** Ligand A (-24.866) has a much longer in vitro half-life than Ligand B (5.745), further supporting its better metabolic stability.
14. **Pgp:** Ligand A (0.074) has lower P-gp efflux liability than Ligand B (0.11).
15. **Binding Affinity:** Ligand A (-6.7 kcal/mol) has a slightly better binding affinity than Ligand B (-5.4 kcal/mol). This is a 1.3 kcal/mol difference, which is substantial enough to be a key factor.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are particularly important. Ligand A performs better in all these categories. The significantly better BBB penetration, lower hERG risk, and superior metabolic stability (lower Cl_mic and longer t1/2) further solidify its advantage.
**Conclusion:**
Ligand A is the superior candidate due to its better overall ADME-Tox profile, particularly its improved metabolic stability, lower hERG risk, higher BBB penetration, and slightly better binding affinity. While both have issues with Caco-2 permeability, the other advantages of Ligand A outweigh this concern.
Output:
1
2025-04-17 23:40:04,923 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.41 and 360.479 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (76.46) is slightly higher than Ligand B (69.64), but both are well below the 140 A^2 threshold for good oral absorption, and acceptable for a cardiovascular GPCR.
3. **logP:** Ligand A (0.987) is slightly lower than the optimal 1-3 range, while Ligand B (2.559) is well within the range. This favors Ligand B slightly for permeability.
4. **HBD:** Ligand A (1) and Ligand B (2) are both acceptable, being less than 5.
5. **HBA:** Ligand A (5) and Ligand B (4) are both acceptable, being less than 10.
6. **QED:** Ligand A (0.857) has a better QED score than Ligand B (0.733), indicating a more drug-like profile.
7. **DILI:** Ligand A (29.197) has a significantly lower DILI risk than Ligand B (34.626), a major advantage.
8. **BBB:** Ligand A (69.794) and Ligand B (77.007) both have good BBB penetration, but Ligand B is slightly better. This is less critical for a cardiovascular target, but still a positive.
9. **Caco-2:** Ligand A (-4.791) and Ligand B (-5.276) are both negative, indicating poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-1.123) is better than Ligand B (-4.546), indicating better aqueous solubility.
11. **hERG:** Ligand A (0.22) has a much lower hERG inhibition liability than Ligand B (0.585), a significant safety advantage.
12. **Cl_mic:** Ligand B (69.948) has a higher microsomal clearance than Ligand A (6.278), meaning it's metabolized more quickly. This favors Ligand A.
13. **t1/2:** Ligand A (-6.068) has a much longer in vitro half-life than Ligand B (-17.52), indicating greater metabolic stability. This is a strong advantage for Ligand A.
14. **Pgp:** Ligand A (0.023) has a lower P-gp efflux liability than Ligand B (0.11), which is favorable for bioavailability.
15. **Binding Affinity:** Both ligands have the same binding affinity (-6.4 kcal/mol).
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B has a better logP and slightly better Pgp. However, Ligand A excels in safety (DILI, hERG), metabolic stability (Cl_mic, t1/2), solubility, and QED. The equal binding affinity makes the ADME/Tox profile the deciding factor.
**Conclusion:**
Despite Ligand B having a slightly better logP and BBB penetration, Ligand A is the superior candidate due to its significantly better safety profile (lower DILI and hERG), improved metabolic stability (lower Cl_mic, longer t1/2), and better solubility. These factors are crucial for developing a viable drug, especially considering the cardiovascular context where safety is paramount.
Output:
1
2025-04-17 23:40:04,923 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (346.431 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (59.73) is significantly better than Ligand A (83.44). ADRB2 is a cardiovascular target, so CNS penetration is not a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (3.802) is higher than Ligand A (0.545). While 3.8 is approaching the upper limit, it's still acceptable. Ligand A's logP is quite low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (0). Both are within the acceptable limit of 5.
5. **HBA:** Ligand B (6) is slightly higher than Ligand A (5). Both are within the acceptable limit of 10.
6. **QED:** Both ligands have similar, good QED values (0.755 and 0.776).
7. **DILI:** Ligand A (22.451) has a much lower DILI risk than Ligand B (52.385). This is a significant advantage for Ligand A.
8. **BBB:** Ligand B (78.868) has a higher BBB penetration score than Ligand A (58.627). However, since ADRB2 is a cardiovascular target, BBB penetration is not a critical factor.
9. **Caco-2:** Both ligands have negative Caco-2 permeability values, which is unusual and suggests poor permeability. However, the values are similar (-5.274 and -5.379).
10. **Solubility:** Ligand A (-1.093) is slightly better than Ligand B (-3.77).
11. **hERG:** Both ligands have low hERG inhibition liability (0.199 and 0.296), which is good.
12. **Cl_mic:** Ligand A (-17.428) has a much lower (better) microsomal clearance than Ligand B (35.066), indicating greater metabolic stability.
13. **t1/2:** Ligand A (-9.456) has a slightly longer in vitro half-life than Ligand B (-7.381).
14. **Pgp:** Both ligands have low P-gp efflux liability (0.007 and 0.396).
15. **Binding Affinity:** Ligand A (-7.4 kcal/mol) has a slightly better binding affinity than Ligand B (-5.8 kcal/mol). This 1.6 kcal/mol difference is substantial and can outweigh some ADME drawbacks.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand B has a better logP and TPSA, but Ligand A has better affinity, DILI, Cl_mic, and t1/2. The affinity difference is significant.
**Overall Assessment:**
Ligand A is the preferred candidate. While Ligand B has a slightly better logP and TPSA, Ligand A's superior binding affinity, significantly lower DILI risk, and better metabolic stability (lower Cl_mic and longer t1/2) are more critical for a viable drug candidate. The low logP of Ligand A is a concern, but the strong binding affinity may compensate for this.
Output:
1
2025-04-17 23:40:04,923 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.3 and 365.5 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand B (91.5) is significantly lower than Ligand A (130.02). This is a strong advantage for Ligand B, as lower TPSA generally correlates with better cell permeability, crucial for GPCR targeting.
3. **logP:** Both ligands have good logP values (2.076 and 1.777), falling within the optimal 1-3 range. Ligand B is slightly lower, which could be marginally better for solubility.
4. **HBD:** Ligand A has 3 HBD, while Ligand B has 2. Both are acceptable, below the threshold of 5.
5. **HBA:** Ligand A has 5 HBA, while Ligand B has 4. Both are acceptable, below the threshold of 10.
6. **QED:** Both ligands have good QED scores (0.576 and 0.764), indicating good drug-like properties. Ligand B is better here.
7. **DILI:** Ligand A has a DILI risk of 97.83%, which is very high and a major concern. Ligand B has a much lower DILI risk of 64.29%, still not ideal, but significantly better. This is a critical advantage for Ligand B.
8. **BBB:** Ligand B (77.32%) has a higher BBB penetration percentile than Ligand A (56.88%). While ADRB2 isn't strictly a CNS target, some distribution into the CNS can occur, and higher BBB is generally preferable to avoid off-target effects.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.861 and -4.972), which is unusual and suggests poor permeability. This is a concern for both, but they are similar.
10. **Solubility:** Ligand B (-3.959) has slightly better solubility than Ligand A (-5.263).
11. **hERG:** Ligand A (0.598) has a slightly higher hERG inhibition liability than Ligand B (0.793), meaning Ligand B is slightly less likely to cause cardiotoxicity.
12. **Cl_mic:** Ligand A (22.217) has a significantly lower microsomal clearance than Ligand B (43.634), indicating better metabolic stability. This is a positive for Ligand A.
13. **t1/2:** Ligand A (69.79) has a much longer in vitro half-life than Ligand B (6.639). This is a substantial advantage for Ligand A, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.098) has significantly lower P-gp efflux liability than Ligand B (0.127), suggesting better oral bioavailability and potentially better CNS exposure.
15. **Binding Affinity:** Ligand B (-7.2 kcal/mol) has a slightly better binding affinity than Ligand A (-6.9 kcal/mol). This 1.5 kcal/mol difference is significant and can outweigh some ADME drawbacks.
**Overall Assessment:**
While Ligand A has advantages in metabolic stability (Cl_mic) and half-life, the extremely high DILI risk (97.83%) is a deal-breaker. Ligand B, despite having slightly worse metabolic properties, presents a much more favorable safety profile (lower DILI) and has a slightly better binding affinity. The lower TPSA and better QED of Ligand B are also beneficial. Considering the GPCR-specific priorities, the balance of properties favors Ligand B.
Output:
0
2025-04-17 23:40:04,924 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (361.812 and 347.459 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (62.97 and 62.83) are below the 140 A^2 threshold for good oral absorption, and are reasonable for a peripheral GPCR like ADRB2. No significant difference.
3. **logP:** Both ligands (2.186 and 2.476) are within the optimal 1-3 range. Again, no significant difference.
4. **HBD:** Ligand A has 0 HBD, while Ligand B has 2. Lower is generally preferred for permeability, but 2 is not concerning.
5. **HBA:** Ligand A has 7 HBA, and Ligand B has 4. Both are below the 10 threshold. Ligand B is slightly better here.
6. **QED:** Both ligands have good QED values (0.652 and 0.83), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A has a DILI risk of 93.059, which is high. Ligand B has a much lower DILI risk of 10.585, which is excellent. This is a *major* advantage for Ligand B.
8. **BBB:** Both ligands have high BBB penetration (81.97 and 83.249). While ADRB2 isn't a CNS target, higher BBB is generally favorable. No significant difference.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.78 and -4.887). These values are unusual and potentially indicate an issue with the assay or the compounds themselves. However, since they are similar, this doesn't heavily influence the decision.
10. **Solubility:** Ligand A has a solubility of -3.492, and Ligand B has -1.474. Both are poor, but Ligand B is slightly better.
11. **hERG:** Both ligands have low hERG inhibition risk (0.665 and 0.62). No significant difference.
12. **Cl_mic:** Ligand A has a higher microsomal clearance (70.484) than Ligand B (-16.529). A negative value for Ligand B suggests very high metabolic stability, which is a significant advantage.
13. **t1/2:** Ligand A has a negative in vitro half-life (-19.834), which is concerning. Ligand B has a short, but positive half-life (4.818). Ligand B is much better here.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.538 and 0.012). Ligand B is significantly better.
15. **Binding Affinity:** Ligand B (-7.3 kcal/mol) has a slightly better binding affinity than Ligand A (-6.7 kcal/mol). This 0.6 kcal/mol difference is meaningful, but not overwhelming.
**Overall Assessment:**
Ligand B is significantly better overall. The major advantages are its much lower DILI risk, significantly improved metabolic stability (negative Cl_mic), better Pgp efflux profile, and slightly better binding affinity. While both have poor solubility and unusual Caco-2 values, the ADME-Tox profile of Ligand B is far superior, making it the more promising drug candidate.
Output:
0
2025-04-17 23:40:04,924 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the acceptable range (200-500 Da). Ligand A (354.793 Da) is slightly preferred due to being closer to the ideal range.
**2. TPSA:** Ligand A (60.45) is significantly better than Ligand B (72.7). For a GPCR, lower TPSA is generally preferred for better permeability.
**3. logP:** Both ligands have good logP values (A: 4.057, B: 3.309), falling within the optimal 1-3 range. Ligand B is slightly better.
**4. H-Bond Donors:** Both have 1 HBD, which is good.
**5. H-Bond Acceptors:** Ligand A has 4 HBAs, and Ligand B has 5. Both are acceptable, but A is slightly better.
**6. QED:** Ligand A (0.754) has a better QED score than Ligand B (0.568), indicating a more drug-like profile.
**7. DILI:** Ligand B (44.552) has a significantly lower DILI risk than Ligand A (93.951). This is a major advantage for Ligand B.
**8. BBB:** Ligand A (74.758) has a better BBB penetration percentile than Ligand B (63.784). While ADRB2 is a cardiovascular target, some CNS effects are possible with certain ligands, so moderate BBB penetration isn't necessarily detrimental.
**9. Caco-2 Permeability:** Both have negative Caco-2 values, indicating poor permeability. Ligand A (-4.614) is slightly better than Ligand B (-5.208).
**10. Aqueous Solubility:** Both have negative solubility values, indicating poor solubility. Ligand A (-5.636) is slightly better than Ligand B (-4.294).
**11. hERG Inhibition:** Ligand A (0.692) has a slightly lower hERG inhibition risk than Ligand B (0.23). Lower is better.
**12. Microsomal Clearance:** Ligand B (41.284) has lower microsomal clearance than Ligand A (65.052), indicating better metabolic stability.
**13. In vitro Half-Life:** Ligand A (41.861 hours) has a significantly longer half-life than Ligand B (-11.603 hours). This is a substantial advantage for Ligand A.
**14. P-gp Efflux:** Ligand A (0.47) has lower P-gp efflux than Ligand B (0.079). Lower is better.
**15. Binding Affinity:** Ligand A (-6.6 kcal/mol) has a significantly better binding affinity than Ligand B (-2.6 kcal/mol). This is a crucial factor, and the 4 kcal/mol difference is substantial enough to outweigh many other drawbacks.
**Overall Assessment:**
While Ligand B has a much better DILI profile and metabolic stability, the significantly superior binding affinity of Ligand A (-6.6 vs -2.6 kcal/mol) is the deciding factor. The large difference in affinity suggests a much higher probability of achieving efficacy. The longer half-life of Ligand A is also a significant benefit. While the Caco-2 and solubility are poor for both, these can be addressed with formulation strategies. The slightly higher BBB penetration of Ligand A isn't a major concern for a cardiovascular target.
Output:
1
2025-04-17 23:40:04,924 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (378.523 and 356.423 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (76.14) is significantly better than Ligand B (117.79). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is approaching a TPSA that could hinder oral absorption.
**3. logP:** Ligand A (3.864) is within the optimal range (1-3), while Ligand B (1.11) is on the lower end. While not terrible, a lower logP can sometimes indicate poor membrane permeability.
**4. H-Bond Donors:** Both ligands have 2 HBD, which is acceptable.
**5. H-Bond Acceptors:** Ligand A has 6 HBA, and Ligand B has 7. Both are within the acceptable limit of 10.
**6. QED:** Both ligands have similar QED values (0.682 and 0.603), indicating reasonable drug-likeness.
**7. DILI:** Ligand A (80.807) has a higher DILI risk than Ligand B (49.864). This is a significant negative for Ligand A.
**8. BBB:** Ligand A (82.086) has a better BBB penetration score than Ligand B (58.278). While ADRB2 isn't primarily a CNS target, some degree of BBB penetration can be useful for understanding off-target effects.
**9. Caco-2 Permeability:** Ligand A (-4.664) has a worse Caco-2 permeability than Ligand B (-5.058). Lower values indicate lower permeability.
**10. Aqueous Solubility:** Ligand B (-1.721) has better aqueous solubility than Ligand A (-5.366). Good solubility is important for formulation and bioavailability.
**11. hERG Inhibition:** Ligand A (0.292) has a lower hERG inhibition risk than Ligand B (0.089). This is a positive for Ligand A, minimizing cardiotoxicity concerns.
**12. Microsomal Clearance:** Ligand A (88.467) has higher microsomal clearance than Ligand B (45.559), indicating faster metabolism and potentially lower *in vivo* exposure.
**13. In vitro Half-Life:** Ligand B (-7.989) has a much longer in vitro half-life than Ligand A (30.75). This is a significant advantage for Ligand B, potentially allowing for less frequent dosing.
**14. P-gp Efflux:** Ligand A (0.568) has higher P-gp efflux than Ligand B (0.069). Lower P-gp efflux is preferred for better bioavailability.
**15. Binding Affinity:** Ligand A (-6.7 kcal/mol) has a significantly stronger binding affinity than Ligand B (-3.4 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME drawbacks.
**Overall Assessment:**
Ligand A has a much stronger binding affinity, which is paramount for GPCR targets. However, it suffers from higher DILI risk, higher metabolic clearance, and higher P-gp efflux. Ligand B has better ADME properties (solubility, half-life, lower DILI, lower efflux), but its binding affinity is considerably weaker.
Given the substantial affinity difference, I believe Ligand A is the more promising starting point. The ADME issues can be addressed through medicinal chemistry optimization, whereas significantly improving the affinity of Ligand B may be more challenging. The higher affinity of Ligand A provides a better foundation for iterative improvement.
Output:
1
2025-04-17 23:40:04,924 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [344.455, 66.48, 2.065, 1, 3, 0.75, 13.843, 67.119, -4.997, -2.387, 0.092, 12.942, -24.151, 0.068, -6.4]
**Ligand B:** [363.414, 80.32, 2.161, 2, 6, 0.769, 80.807, 83.094, -4.708, -3.434, 0.577, 57.472, 41.597, 0.263, -6.8]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity, and to a lesser extent BBB):
1. **MW:** Both are within the ideal range (200-500 Da). A is slightly lower, which is generally favorable.
2. **TPSA:** Ligand A (66.48) is significantly better than Ligand B (80.32). Lower TPSA is crucial for GPCRs, aiding permeability.
3. **logP:** Both are good (around 2.1), falling within the optimal 1-3 range.
4. **HBD/HBA:** Ligand A (1 HBD, 3 HBA) is better than Ligand B (2 HBD, 6 HBA). Fewer H-bonds generally improve permeability.
5. **QED:** Both are acceptable (around 0.75-0.77).
6. **DILI:** Ligand A (13.843) has a much lower DILI risk than Ligand B (80.807). This is a significant advantage.
7. **BBB:** Ligand A (67.119) is acceptable, while Ligand B (83.094) is better. However, since this is a cardiovascular target, BBB penetration isn't *as* critical as it would be for a CNS target.
8. **Caco-2:** Both have negative values, indicating good permeability.
9. **Solubility:** Both have negative values, indicating good solubility.
10. **hERG:** Ligand A (0.092) has a lower hERG risk than Ligand B (0.577), which is crucial for cardiovascular drugs.
11. **Cl_mic:** Ligand A (12.942) has a lower microsomal clearance than Ligand B (57.472), suggesting better metabolic stability.
12. **t1/2:** Ligand A (-24.151) has a more negative in vitro half-life, which means a longer half-life.
13. **Pgp:** Ligand A (0.068) has lower P-gp efflux liability than Ligand B (0.263). This is beneficial for bioavailability.
14. **Affinity:** Ligand B (-6.8 kcal/mol) is slightly better than Ligand A (-6.4 kcal/mol), but the difference is not substantial enough to outweigh the numerous advantages of Ligand A.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical ADME-Tox properties (DILI, hERG, Cl_mic, Pgp, TPSA). While Ligand B has slightly better affinity and BBB, the superior safety profile and drug-like properties of Ligand A make it the more promising candidate for further development as a cardiovascular drug targeting ADRB2. The small difference in binding affinity can likely be optimized in subsequent iterations of drug design.
Output:
1
2025-04-17 23:40:04,924 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (373.881 and 364.515 Da) are within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (76.82) is slightly higher than Ligand B (64.68). Both are below the 140 threshold for good oral absorption, but B is better positioned.
3. **logP:** Both ligands have good logP values (1.533 and 1.212), falling within the 1-3 range. Ligand B is slightly lower, which could be a minor drawback.
4. **HBD:** Ligand A has 1 HBD, while Ligand B has 2. Both are acceptable (<=5).
5. **HBA:** Ligand A has 6 HBA, and Ligand B has 5. Both are acceptable (<=10).
6. **QED:** Both ligands have similar QED values (0.818 and 0.796), indicating good drug-likeness.
7. **DILI:** Ligand B (13.339) has a significantly lower DILI risk than Ligand A (46.142). This is a major advantage for Ligand B.
8. **BBB:** Ligand B (74.292) has a much higher BBB penetration percentile than Ligand A (52.966). Given that ADRB2 is a GPCR, BBB penetration is a relevant consideration, even if not strictly a CNS target.
9. **Caco-2:** Ligand B (-5.448) shows better Caco-2 permeability than Ligand A (-4.688).
10. **Solubility:** Ligand B (-2.052) has slightly better aqueous solubility than Ligand A (-2.357).
11. **hERG:** Both ligands have low hERG inhibition liability (0.314 and 0.498), which is good.
12. **Cl_mic:** Ligand B (13.153) has a significantly lower microsomal clearance than Ligand A (33.354), indicating better metabolic stability.
13. **t1/2:** Ligand A (48.41) has a much longer in vitro half-life than Ligand B (9.013). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand B (0.017) has significantly lower P-gp efflux liability than Ligand A (0.252). This is a positive for bioavailability.
15. **Binding Affinity:** Both ligands have very similar and strong binding affinities (-6.3 and -6.0 kcal/mol). The difference is minimal.
**Overall Assessment:**
Ligand B demonstrates a superior ADME profile, particularly regarding DILI risk, BBB penetration, metabolic stability (lower Cl_mic), and P-gp efflux. While Ligand A has a longer half-life, the other advantages of Ligand B are more critical for a balanced drug candidate, especially considering the GPCR target class. The slight difference in binding affinity is negligible given the other benefits.
Output:
0
2025-04-17 23:40:04,924 - INFO - Batch 421 complete. Total preferences: 6736
2025-04-17 23:40:04,924 - INFO - Processing batch 422/512...
2025-04-17 23:40:55,138 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**1. Molecular Weight:** Both ligands (377.39 and 355.46 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (93.36) is higher than Ligand B (66.63). For a cardiovascular GPCR like ADRB2, TPSA isn't a *critical* factor like it would be for a CNS target, but lower is generally preferred for better absorption. Ligand B has a clear advantage.
**3. logP:** Ligand B (3.612) is higher than Ligand A (1.2). While both are within the acceptable range, Ligand B is approaching the upper limit. This could potentially lead to solubility issues, but also better membrane permeability. Ligand A is better here.
**4. H-Bond Donors:** Ligand A (1) is better than Ligand B (2). Fewer H-bond donors generally improve permeability.
**5. H-Bond Acceptors:** Both ligands have 5 H-bond acceptors, so no difference.
**6. QED:** Ligand A (0.836) has a slightly higher QED than Ligand B (0.734), indicating a more drug-like profile.
**7. DILI Risk:** Both ligands have acceptable DILI risk (62.74 and 59.91 respectively), below the 60 threshold. No significant difference.
**8. BBB Penetration:** Ligand A (93.37) has significantly better BBB penetration than Ligand B (51.42). While ADRB2 isn't primarily a CNS target, some CNS exposure can occur, and higher BBB is generally favorable.
**9. Caco-2 Permeability:** Ligand A (-4.928) has better Caco-2 permeability than Ligand B (-5.31). This suggests better intestinal absorption for Ligand A.
**10. Aqueous Solubility:** Ligand A (-2.957) has better aqueous solubility than Ligand B (-3.559).
**11. hERG Inhibition:** Ligand A (0.69) has a slightly higher hERG inhibition risk than Ligand B (0.295). This is a concern, but not a dealbreaker at this stage.
**12. Microsomal Clearance:** Ligand A (-10.748) has significantly lower (better) microsomal clearance than Ligand B (3.171), indicating greater metabolic stability.
**13. In vitro Half-Life:** Ligand A (5.114) has a shorter half-life than Ligand B (8.786). Longer half-life is generally preferred.
**14. P-gp Efflux:** Ligand A (0.12) has lower P-gp efflux than Ligand B (0.157), indicating better bioavailability.
**15. Binding Affinity:** Ligand B (-6.3 kcal/mol) has a slightly better binding affinity than Ligand A (-5.7 kcal/mol). This is a 0.6 kcal/mol difference, which is significant, but not overwhelming.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), and the general drug-like properties, Ligand B's higher affinity is a key advantage. However, Ligand A excels in several crucial ADME properties: TPSA, solubility, permeability, metabolic stability, and P-gp efflux. The slightly higher hERG risk for Ligand A is a concern, but the overall balance of properties, particularly the superior ADME profile, makes it the more promising candidate.
Output:
1
2025-04-17 23:40:55,138 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (357.479 and 354.491 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (49.05) is significantly better than Ligand B (67.87). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (3.751) is slightly higher than Ligand B (2.175), both within the optimal 1-3 range. Ligand A is preferable, but both are acceptable.
4. **HBD:** Ligand A (0) is better than Ligand B (1). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (5) is better than Ligand B (4). Lower HBA is generally preferred.
6. **QED:** Ligand A (0.837) is slightly better than Ligand B (0.794), suggesting a more drug-like profile.
7. **DILI:** Ligand B (38.038) is significantly better than Ligand A (50.291). Lower DILI risk is crucial. This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (86.08) is better than Ligand B (77.782), but BBB is not a high priority for a cardiovascular target.
9. **Caco-2:** Ligand A (-5.226) is better than Ligand B (-4.521). Higher Caco-2 permeability is desirable.
10. **Solubility:** Ligand A (-3.434) is slightly better than Ligand B (-3.011).
11. **hERG:** Ligand A (0.872) is better than Ligand B (0.303). Lower hERG inhibition is critical for avoiding cardiotoxicity. This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand A (19.127) is significantly better than Ligand B (54.889). Lower microsomal clearance indicates better metabolic stability.
13. **t1/2:** Ligand A (40.519) is significantly better than Ligand B (4.14). A longer half-life is generally preferred.
14. **Pgp:** Ligand A (0.514) is better than Ligand B (0.096). Lower P-gp efflux is preferred.
15. **Binding Affinity:** Both ligands have the same binding affinity (-7.7 kcal/mol), so this parameter doesn't differentiate them.
**Overall Assessment:**
Ligand A has advantages in TPSA, logP, HBD, HBA, QED, Caco-2, solubility, hERG, Cl_mic, t1/2, and Pgp. However, Ligand B has a significantly lower DILI risk. Considering ADRB2 is a cardiovascular target, minimizing off-target effects like liver toxicity is paramount. While Ligand A has better ADME properties overall, the substantially lower DILI risk of Ligand B is a critical factor. The similar binding affinity makes the ADME/Tox profile the deciding factor.
Output:
0
2025-04-17 23:40:55,139 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (384.234 and 343.519 Da) fall within the ideal 200-500 Da range. Ligand B is slightly smaller, which *could* be advantageous for permeability, but the difference isn't substantial.
2. **TPSA:** Ligand A (47.56) is higher than Ligand B (35.5). Both are below the 140 threshold for oral absorption, but Ligand B is better positioned for potential CNS penetration if that were a goal (though not a primary one for ADRB2).
3. **logP:** Ligand A (4.785) is higher than Ligand B (2.943). Ligand A is pushing the upper limit of the optimal range (1-3) and could potentially have solubility issues or off-target effects. Ligand B is well within the ideal range.
4. **HBD:** Ligand A (1) is better than Ligand B (0). Lower HBD is generally preferred for permeability.
5. **HBA:** Ligand A (3) is better than Ligand B (5). Lower HBA is generally preferred for permeability.
6. **QED:** Both ligands have similar, good QED scores (0.825 and 0.84).
7. **DILI:** Ligand B (34.703) has a significantly lower DILI risk than Ligand A (80.535). This is a major advantage for Ligand B.
8. **BBB:** Ligand B (87.515) has a higher BBB penetration percentile than Ligand A (75.107). While ADRB2 isn't a primary CNS target, higher BBB is rarely a detriment.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.384 and -4.995), which is unusual and potentially problematic. It suggests poor permeability. However, these values are on a scale where negative values are possible, and the absolute values are similar.
10. **Solubility:** Ligand B (-2.266) has better (less negative) solubility than Ligand A (-5.798). This is important given Ligand A's higher logP.
11. **hERG:** Both ligands have similar hERG risk (0.624 and 0.944), and are relatively low risk.
12. **Cl_mic:** Ligand B (29.536) has significantly lower microsomal clearance than Ligand A (54.846), indicating better metabolic stability.
13. **t1/2:** Ligand A (66.34) has a longer in vitro half-life than Ligand B (17.617). This is a positive for Ligand A.
14. **Pgp:** Ligand A (0.612) has lower P-gp efflux than Ligand B (0.355), which is favorable for bioavailability.
15. **Binding Affinity:** Both ligands have the same binding affinity (-5.2 kcal/mol).
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP, TPSA, and Pgp. The affinity is the same for both.
**Overall Assessment:**
While Ligand A has a longer half-life and lower P-gp efflux, the significantly higher DILI risk, higher logP, and lower solubility are major concerns. Ligand B presents a much more balanced profile with a lower DILI risk, better solubility, and a more favorable logP, despite the shorter half-life. The metabolic stability advantage of Ligand B is also significant.
Output:
0
2025-04-17 23:40:55,139 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, the key priorities are logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB.
Let's break down the comparison:
1. **MW:** Both ligands are within the ideal range (349.45 Da vs 348.491 Da).
2. **TPSA:** Ligand A (62.3) is better than Ligand B (67.65). Lower TPSA generally favors oral absorption, important for a cardiovascular drug.
3. **logP:** Both are good (2.82 and 1.86), falling within the optimal 1-3 range. Ligand A is slightly better.
4. **HBD/HBA:** Ligand A has 1 HBD and 3 HBA, while Ligand B has 0 HBD and 4 HBA. Both are acceptable.
5. **QED:** Both have similar, good QED scores (0.734 vs 0.735).
6. **DILI:** Ligand A (30.361) has a significantly better DILI score than Ligand B (6.553), indicating lower liver injury risk. This is a major advantage.
7. **BBB:** Both have high BBB penetration (91.198 vs 87.941). Since this is a cardiovascular target, BBB isn't *critical*, but higher is still preferable.
8. **Caco-2:** Both are negative, indicating poor permeability. This is a concern for both.
9. **Solubility:** Ligand A (-2.948) is better than Ligand B (-1.322), indicating better aqueous solubility.
10. **hERG:** Both have low hERG inhibition liability (0.326 vs 0.451).
11. **Cl_mic:** Ligand A (83.283) has a significantly lower microsomal clearance than Ligand B (11.345), suggesting better metabolic stability.
12. **t1/2:** Ligand A (6.594) has a better in vitro half-life than Ligand B (-12.298).
13. **Pgp:** Both have very low Pgp efflux liability (0.102 vs 0.014).
14. **Binding Affinity:** Ligand B (-6.3 kcal/mol) has a slightly better binding affinity than Ligand A (-5.9 kcal/mol), but the difference is less than 1.5 kcal/mol.
**Overall Assessment:**
Ligand A is superior. While Ligand B has a marginally better binding affinity, Ligand A excels in crucial ADME properties: significantly lower DILI risk, better solubility, and much better metabolic stability (lower Cl_mic and longer t1/2). The slightly better TPSA and logP of Ligand A also contribute to its favorability. The Caco-2 permeability is a concern for both, but the other advantages of Ligand A outweigh this drawback.
**Output:**
1
2025-04-17 23:40:55,139 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.471 and 350.375 Da) are within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (67.43) is significantly better than Ligand B (133.56). ADRB2 is a cardiovascular target, not CNS, but lower TPSA generally improves absorption. Ligand A is well below the 140 threshold, while B is approaching it.
3. **logP:** Ligand A (1.864) is within the optimal 1-3 range. Ligand B (-0.62) is slightly below 1, which *could* indicate permeability issues. This favors Ligand A.
4. **HBD:** Ligand A (2) and Ligand B (4) are both acceptable, but A is preferable.
5. **HBA:** Ligand A (3) and Ligand B (6) are both acceptable, but A is preferable.
6. **QED:** Both ligands have similar QED values (0.546 and 0.54), indicating comparable drug-likeness.
7. **DILI:** Ligand A (12.485) has a much lower DILI risk than Ligand B (41.45). This is a significant advantage for Ligand A.
8. **BBB:** Both are not CNS targets, so this is less important. Ligand B (60.566) is slightly higher than Ligand A (53.703), but the difference is not substantial.
9. **Caco-2:** Ligand A (-4.905) and Ligand B (-5.453) are both negative, indicating poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Ligand A (-2.733) and Ligand B (-1.204) are both negative, indicating poor solubility. However, the scale is not specified, so it's hard to interpret.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.336 and 0.056). No significant difference.
12. **Cl_mic:** Ligand B (-9.104) has a *much* lower (better) microsomal clearance than Ligand A (10.277). This suggests greater metabolic stability for Ligand B.
13. **t1/2:** Ligand B (-10.572) has a much longer in vitro half-life than Ligand A (22.101). This is a significant advantage for Ligand B.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.061 and 0.003). No significant difference.
15. **Binding Affinity:** Ligand B (-6.5 kcal/mol) has a slightly better binding affinity than Ligand A (-5.6 kcal/mol). This is a 0.9 kcal/mol difference, which is meaningful but not overwhelming.
**GPCR-specific priorities:** For ADRB2 (a cardiovascular GPCR), logP, TPSA, and affinity are key. Ligand A has better logP and TPSA. Ligand B has better affinity and metabolic stability (Cl_mic and t1/2).
**Overall Assessment:**
While Ligand B has a slightly better binding affinity and significantly improved metabolic stability and half-life, Ligand A's superior TPSA, logP, and drastically lower DILI risk are more compelling. The lower DILI risk is a critical factor in drug development. The slightly weaker affinity of Ligand A can potentially be optimized in later stages.
Output:
1
2025-04-17 23:40:55,139 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands (364.833 and 349.431 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (103.95) is slightly higher than Ligand B (93.46). Both are below the 140 threshold for oral absorption, but closer to the 90 threshold for CNS targets. Ligand B is preferable here.
3. **logP:** Ligand B (1.294) is slightly higher than Ligand A (0.946), both are within the optimal 1-3 range. No strong preference.
4. **HBD:** Ligand B (2) has fewer HBDs than Ligand A (3). Fewer HBDs generally improve permeability. Ligand B is preferable.
5. **HBA:** Ligand B (5) has slightly more HBAs than Ligand A (4). Both are acceptable.
6. **QED:** Both ligands have similar QED values (0.676 and 0.621), both above the 0.5 threshold. No clear advantage.
7. **DILI:** Ligand A (44.552) has a significantly higher DILI risk than Ligand B (14.541). This is a major concern for Ligand A. Ligand B is strongly preferred.
8. **BBB:** Ligand B (51.609) has a better BBB penetration percentile than Ligand A (44.397). While neither is exceptionally high, this is a positive for Ligand B, given ADRB2's potential relevance in cardiovascular conditions where CNS side effects need to be considered.
9. **Caco-2:** Ligand A (-5.477) has a worse Caco-2 permeability than Ligand B (-4.796). Lower values are worse, so Ligand B is preferable.
10. **Solubility:** Ligand A (-3.107) has worse solubility than Ligand B (-1.983). Ligand B is preferable.
11. **hERG:** Ligand B (0.071) has a lower hERG inhibition liability than Ligand A (0.249). This is a significant advantage for Ligand B, reducing cardiotoxicity risk.
12. **Cl_mic:** Ligand A (-2.888) has a lower (better) microsomal clearance than Ligand B (27.208). This suggests better metabolic stability for Ligand A. This is a positive for Ligand A.
13. **t1/2:** Ligand A (-3.973) has a slightly longer in vitro half-life than Ligand B (-3.052). This is a positive for Ligand A.
14. **Pgp:** Ligand A (0.037) has a lower Pgp efflux liability than Ligand B (0.007). Lower efflux is preferred, so Ligand A is preferable.
15. **Binding Affinity:** Ligand A (-8.0) has a stronger binding affinity than Ligand B (-6.6). This is a significant advantage for Ligand A. A 1.4 kcal/mol difference is substantial.
**Overall Assessment:**
Ligand A has a superior binding affinity and better metabolic stability (Cl_mic, t1/2) and Pgp efflux. However, Ligand B demonstrates a much better safety profile (DILI, hERG), improved permeability (Caco-2), solubility, and a slightly better BBB profile.
Given the GPCR target class and the importance of minimizing off-target effects and maximizing safety for a cardiovascular drug, the advantages of Ligand B in terms of ADME-Tox properties outweigh the affinity difference. The higher affinity of Ligand A is attractive, but the DILI and hERG risks are substantial concerns.
Output:
0
2025-04-17 23:40:55,139 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands (343.39 and 341.37 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (109.14) is higher than Ligand B (88.01). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is generally preferred for absorption. Ligand B has an advantage.
3. **logP:** Ligand B (2.389) is slightly higher than Ligand A (1.216), placing it more optimally within the 1-3 range. Ligand A is a bit low, potentially hindering permeability. Ligand B has an advantage.
4. **HBD:** Ligand A (3) is higher than Ligand B (0). While not excessively high, fewer HBDs are generally preferred for better permeability. Ligand B has an advantage.
5. **HBA:** Ligand A (6) and Ligand B (7) are both acceptable, under the 10 threshold. No clear advantage.
6. **QED:** Ligand A (0.756) is significantly better than Ligand B (0.464), indicating a more drug-like profile. Ligand A has a strong advantage.
7. **DILI:** Ligand A (50.10) is considerably better than Ligand B (77.2), indicating a lower risk of drug-induced liver injury. Ligand A has a significant advantage.
8. **BBB:** Ligand B (63.47) is better than Ligand A (36.45), but BBB is not a primary concern for a cardiovascular target. Ligand B has a slight advantage.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.117 and -4.995), which is unusual and suggests very poor permeability. This is a major concern for both.
10. **Solubility:** Both ligands have negative solubility values (-3.079 and -2.992), which is also unusual and suggests very poor solubility. This is a major concern for both.
11. **hERG:** Ligand A (0.132) is significantly better than Ligand B (0.473), indicating a lower risk of hERG inhibition and cardiotoxicity. Ligand A has a strong advantage.
12. **Cl_mic:** Ligand B (51.15) has a lower (better) microsomal clearance than Ligand A (9.93). Ligand B has an advantage.
13. **t1/2:** Both ligands have very negative in vitro half-lives (-27.04 and -27.63), indicating extremely rapid metabolism. This is a major issue for both.
14. **Pgp:** Ligand A (0.004) is much better than Ligand B (0.538), indicating lower P-glycoprotein efflux. Ligand A has a significant advantage.
15. **Binding Affinity:** Ligand B (-7.9 kcal/mol) is 1.5 kcal/mol better than Ligand A (-9.4 kcal/mol). This is a substantial advantage that can outweigh some ADME concerns. Ligand B has a significant advantage.
**Overall Assessment:**
Both ligands have significant issues with Caco-2 permeability, solubility, and in vitro half-life. However, Ligand A demonstrates superior drug-likeness (QED), lower DILI risk, lower hERG inhibition, and lower P-gp efflux. Ligand B has a better binding affinity and slightly better logP and Cl_mic. The binding affinity advantage of Ligand B is substantial. Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), and the fact that the binding affinity difference is large enough to potentially overcome some of the ADME deficiencies, I would prioritize Ligand B.
**Output:**
0
2025-04-17 23:40:55,139 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [390.398, 102.87 , 2.686, 0. , 8. , 0.401, 62.156, 70.105, -4.596, -2.587, 0.106, 109.965, -18.984, 0.225, -5.1 ]
**Ligand B:** [345.447, 71.33 , 1.645, 0. , 5. , 0.761, 44.591, 64.521, -4.951, -1.698, 0.124, 17.768, 6.804, 0.071, -7.1 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (345.447) is slightly lower, which *could* be beneficial for permeability, but both are acceptable.
2. **TPSA:** Ligand A (102.87) is higher than Ligand B (71.33). For a cardiovascular GPCR, TPSA isn't as critical as for CNS targets, but lower is generally preferred for oral absorption. Ligand B is better here.
3. **logP:** Both are within the optimal range (1-3). Ligand A (2.686) is slightly higher, which is acceptable. Ligand B (1.645) is a bit lower, but still good.
4. **HBD:** Both have 0 HBD, which is good.
5. **HBA:** Ligand A (8) is higher than Ligand B (5). Lower is generally better for permeability. Ligand B is better.
6. **QED:** Ligand B (0.761) has a significantly better QED score than Ligand A (0.401), indicating a more drug-like profile. This is a substantial advantage for Ligand B.
7. **DILI:** Ligand A (62.156) has a higher DILI risk than Ligand B (44.591). Lower is better, so Ligand B is preferred.
8. **BBB:** Ligand A (70.105) has a slightly higher BBB penetration potential than Ligand B (64.521). While ADRB2 isn't a CNS target, some peripheral exposure can be mitigated with lower BBB penetration.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so we can't draw strong conclusions.
10. **Solubility:** Ligand A (-2.587) has worse solubility than Ligand B (-1.698). Solubility is important for bioavailability, so Ligand B is better.
11. **hERG:** Both have very low hERG risk (0.106 and 0.124). This is good for both.
12. **Cl_mic:** Ligand A (109.965) has a much higher microsomal clearance than Ligand B (17.768), indicating faster metabolism and potentially lower *in vivo* exposure. Ligand B is significantly better here.
13. **t1/2:** Ligand B (6.804) has a longer *in vitro* half-life than Ligand A (-18.984). This is a significant advantage for Ligand B.
14. **Pgp:** Both have low P-gp efflux liability (0.225 and 0.071). Ligand B is slightly better.
15. **Affinity:** Ligand B (-7.1) has a significantly stronger binding affinity than Ligand A (-5.1). A 2 kcal/mol difference is substantial and can often outweigh minor ADME drawbacks.
**Overall Assessment:**
Ligand B consistently outperforms Ligand A across most critical ADME properties (QED, DILI, Cl_mic, t1/2, Solubility, TPSA, HBA) and, crucially, has a much stronger binding affinity. While Ligand A has slightly better BBB penetration, this is less important for a cardiovascular target. The superior ADME profile and binding affinity of Ligand B make it the more promising drug candidate.
Output:
0
2025-04-17 23:40:55,139 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (347.375) is slightly lower than Ligand B (362.459), which is preferable.
2. **TPSA:** Ligand B (74.57) is significantly better than Ligand A (97.11). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have low logP values (A: 0.213, B: 0.141). This is a concern as it may hinder membrane permeability. Both are below the optimal 1-3 range.
4. **HBD:** Both have 0 HBD, which is good.
5. **HBA:** Both have 7 HBA, which is acceptable.
6. **QED:** Ligand B (0.756) has a better QED score than Ligand A (0.664), indicating better overall drug-likeness.
7. **DILI:** Ligand B (46.375) has a much lower DILI risk than Ligand A (66.421). This is a significant advantage.
8. **BBB:** Both are relatively low, but Ligand A (71.772) is higher than Ligand B (50.95). Since ADRB2 is a cardiovascular target, BBB penetration is not a priority.
9. **Caco-2:** Ligand A (-4.541) is better than Ligand B (-5.222), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-0.996) is slightly better than Ligand B (-0.446), although both are poor.
11. **hERG:** Ligand A (0.143) has a lower hERG risk than Ligand B (0.31), which is favorable.
12. **Cl_mic:** Ligand B (22.38) has significantly lower microsomal clearance than Ligand A (85.834), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-6.785) has a longer in vitro half-life than Ligand A (11.359).
14. **Pgp:** Ligand A (0.041) has lower P-gp efflux than Ligand B (0.024), which is preferable.
15. **Binding Affinity:** Ligand B (-7.0) has a slightly better binding affinity than Ligand A (-6.2). This is a substantial difference.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand B excels in TPSA, has a better affinity, and a lower DILI risk. While both have suboptimal logP values, the superior affinity and metabolic stability of Ligand B outweigh this concern. The lower DILI risk is also a major factor.
**Conclusion:**
Considering all factors, especially the binding affinity, DILI risk, and metabolic stability, Ligand B is the more promising drug candidate.
Output:
0
2025-04-17 23:40:55,139 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [365.459, 112.91 , 1.644, 4. , 6. , 0.378, 65.646, 23.071, -5.94 , -2.436, 0.618, 30.299, 5.217, 0.394, -7.3 ]
**Ligand B:** [373.953, 21.06 , 4.997, 0. , 4. , 0.581, 38.891, 70.609, -5.241, -4.122, 0.902, 56.208, 42.654, 0.809, -7.7 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (365.459) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (112.91) is higher than Ligand B (21.06). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is still preferred. Ligand B is significantly better here.
3. **logP:** Ligand A (1.644) is within the optimal range, while Ligand B (4.997) is high. High logP can lead to off-target effects and solubility issues. Ligand A is better.
4. **HBD:** Ligand A (4) is acceptable, while Ligand B (0) is very low. While lower HBD can improve permeability, it can also reduce solubility.
5. **HBA:** Both ligands have a reasonable number of HBA (6 and 4 respectively).
6. **QED:** Both ligands have acceptable QED scores (0.378 and 0.581). Ligand B is slightly better.
7. **DILI:** Ligand A (65.646) has a higher DILI risk than Ligand B (38.891). This is a significant concern, making Ligand B more attractive.
8. **BBB:** Ligand B (70.609) has a much higher BBB penetration score than Ligand A (23.071). While not a primary concern for a cardiovascular target, higher BBB is generally a positive attribute.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability.
10. **Solubility:** Ligand A (-2.436) has worse solubility than Ligand B (-4.122). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.618) has a lower hERG risk than Ligand B (0.902). This is a positive for Ligand A.
12. **Cl_mic:** Ligand A (30.299) has a lower microsomal clearance, indicating better metabolic stability than Ligand B (56.208).
13. **t1/2:** Ligand B (42.654) has a significantly longer in vitro half-life than Ligand A (5.217). This is a major advantage for Ligand B.
14. **Pgp:** Ligand A (0.394) has lower P-gp efflux than Ligand B (0.809). Lower P-gp efflux is generally preferred.
15. **Affinity:** Ligand B (-7.7) has a slightly better binding affinity than Ligand A (-7.3). While the difference is not huge, it's a factor.
**GPCR-Specific Priorities:** For ADRB2 (a GPCR), we prioritize logP, Pgp, TPSA, and affinity. Ligand B excels in TPSA and has a slightly better affinity. Ligand A has a better logP and Pgp. However, the significant advantage of Ligand B in DILI risk and in vitro half-life outweigh the benefits of Ligand A.
**Conclusion:**
Considering the balance of properties, particularly the lower DILI risk, longer half-life, and better TPSA of Ligand B, it appears to be the more promising drug candidate.
0
2025-04-17 23:40:55,140 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Step-by-step comparison:**
1. **MW:** Both ligands (336.355 and 346.471 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand B (69.64) is significantly better than Ligand A (101.28). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (1.547) is within the optimal range (1-3), while Ligand A (0.617) is slightly below, potentially indicating permeability issues. Ligand B is favored.
4. **HBD:** Both have 2 HBD, which is acceptable.
5. **HBA:** Ligand B (3) is better than Ligand A (6). Lower HBA is generally preferred for permeability.
6. **QED:** Ligand B (0.811) is better than Ligand A (0.683), indicating a more drug-like profile.
7. **DILI:** Ligand B (14.696) has a *much* lower DILI risk than Ligand A (85.072). This is a critical advantage.
8. **BBB:** Both are relatively low, which is fine for a cardiovascular target. Ligand B (44.901) is slightly better.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand B (-4.958) is slightly better than Ligand A (-5.322).
10. **Solubility:** Both are negative, indicating poor solubility.
11. **hERG:** Both are low, indicating low risk of hERG inhibition.
12. **Cl_mic:** Ligand B (-16.595) has a *much* lower (better) microsomal clearance than Ligand A (9.187). This suggests better metabolic stability.
13. **t1/2:** Ligand B (11.655) has a longer in vitro half-life than Ligand A (9.273).
14. **Pgp:** Both are low, suggesting minimal P-gp efflux.
15. **Binding Affinity:** Ligand A (-7.0) has a slightly better binding affinity than Ligand B (-3.2). However, the difference is not substantial enough to outweigh the significant ADME advantages of Ligand B.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, and affinity are important. Ligand B is better on logP and TPSA, and while Ligand A has slightly better affinity, the other ADME properties of Ligand B are far superior.
**Conclusion:**
Ligand B demonstrates a significantly better overall profile, particularly regarding DILI risk, metabolic stability (Cl_mic), and QED. While Ligand A has slightly better binding affinity, the substantial improvements in ADME properties of Ligand B make it the more promising drug candidate.
Output:
0
2025-04-17 23:40:55,140 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (371.409 and 353.419 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (71.53) is significantly better than Ligand B (99.18). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (2.27) is optimal. Ligand B (0.263) is quite low, potentially hindering membrane permeability and bioavailability. This is a significant drawback.
4. **HBD:** Ligand A (1) and Ligand B (2) are both acceptable, staying within the recommended limit of 5.
5. **HBA:** Both ligands (5) are within the acceptable limit of 10.
6. **QED:** Both ligands (0.771 and 0.707) are good, indicating a generally drug-like profile.
7. **DILI:** Ligand A (80.535) has a higher DILI risk than Ligand B (28.306). This is a concern for Ligand A.
8. **BBB:** Both are moderate, but not a major factor for a cardiovascular target.
9. **Caco-2:** Both have negative values, indicating poor permeability.
10. **Solubility:** Ligand A (-3.687) is better than Ligand B (-0.965), though both are poor.
11. **hERG:** Ligand A (0.658) is better than Ligand B (0.142) indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand A (46.09) is significantly better than Ligand B (5.815), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-32.108) is better than Ligand B (-28.526) indicating a longer half-life.
14. **Pgp:** Ligand A (0.22) is better than Ligand B (0.014), suggesting lower efflux and better bioavailability.
15. **Binding Affinity:** Ligand B (-6.4) is slightly better than Ligand A (-6.1), but the difference is small.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand A has a much better logP and TPSA, which are crucial for permeability and absorption. While Ligand B has slightly better affinity, the difference isn't substantial enough to overcome the significant issues with its logP and TPSA. Ligand A also has better metabolic stability (Cl_mic) and lower Pgp efflux. The DILI risk for Ligand A is higher, but can be addressed with further modifications.
**Conclusion:**
Considering the balance of properties and the priorities for a GPCR target, Ligand A is the more promising candidate. The better logP, TPSA, metabolic stability, and Pgp profile outweigh the slightly lower affinity and higher DILI risk.
Output:
1
2025-04-17 23:40:55,140 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.45 & 373.52 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (88.33) is better than Ligand B (95.58). Both are below 140, but closer to 90 is preferable for GPCRs, and A is closer.
3. **logP:** Ligand A (2.374) is optimal (1-3). Ligand B (0.859) is a bit low, potentially hindering permeability. This is a significant advantage for A.
4. **HBD:** Ligand A (1) is good. Ligand B (2) is acceptable, but slightly less desirable.
5. **HBA:** Ligand A (5) is good. Ligand B (4) is also good.
6. **QED:** Ligand A (0.779) is better than Ligand B (0.586), indicating a more drug-like profile.
7. **DILI:** Ligand A (28.62) is significantly better than Ligand B (20.24) - lower risk of liver injury.
8. **BBB:** Both ligands have similar BBB penetration (65.41 & 61.73). While not exceptionally high, it's not a major differentiator for ADRB2, which isn't necessarily a CNS target.
9. **Caco-2:** Ligand A (-4.944) is better than Ligand B (-5.277). Higher values indicate better absorption.
10. **Solubility:** Ligand A (-2.212) is better than Ligand B (-1.864). Higher solubility is preferred.
11. **hERG:** Ligand A (0.078) is significantly better than Ligand B (0.344), indicating a lower risk of cardiotoxicity. This is *critical* for a cardiovascular target.
12. **Cl_mic:** Ligand A (42.097) is higher than Ligand B (28.646), meaning faster clearance and lower metabolic stability. This is a negative for A.
13. **t1/2:** Ligand B (-46.453) has a *much* longer half-life than Ligand A (4.539). This is a major advantage for B, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.088) is better than Ligand B (0.023). Lower P-gp efflux is preferred.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.3 and -6.0 kcal/mol). The difference is not substantial enough to outweigh other factors.
**Overall Assessment:**
Ligand A has advantages in TPSA, logP, QED, DILI, solubility, hERG, and Pgp. Ligand B excels in metabolic stability (lower Cl_mic) and significantly longer half-life. Considering the target is ADRB2 (cardiovascular), minimizing hERG risk is paramount. Ligand A's substantially lower hERG liability is a major advantage. The better logP and QED of A also contribute to a more favorable profile. While the longer half-life of B is attractive, the hERG risk is too significant to ignore.
Output:
1
2025-04-17 23:40:55,140 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (358.345 Da and 352.431 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (96.69) is higher than Ligand B (79.31). For a cardiovascular GPCR, TPSA is moderately important. Ligand B's lower TPSA is preferable, potentially aiding membrane permeability.
**3. logP:** Ligand A (0.376) is slightly higher than Ligand B (0.034). Both are quite low, potentially indicating poor membrane permeability. However, for a cardiovascular target, we don't necessarily need high BBB penetration, so this isn't a dealbreaker. Ligand A is slightly favored due to the higher value.
**4. H-Bond Donors:** Ligand A (2) is higher than Ligand B (1). Lower is generally better for permeability, so Ligand B is slightly favored.
**5. H-Bond Acceptors:** Ligand A (6) is higher than Ligand B (5). Similar to HBD, Ligand B is slightly favored.
**6. QED:** Both ligands have similar QED values (0.742 and 0.707), indicating good drug-like properties. No significant difference.
**7. DILI Risk:** Ligand A (50.989) has a higher DILI risk than Ligand B (28.655). This is a significant advantage for Ligand B. Lower DILI risk is crucial.
**8. BBB Penetration:** Ligand A (72.858) has better BBB penetration than Ligand B (30.206). While ADRB2 is primarily a cardiovascular target, some CNS off-target effects are possible, and moderate BBB penetration isn't necessarily detrimental.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.616 and -4.639), which is unusual and suggests poor permeability. This is a concern for both.
**10. Aqueous Solubility:** Ligand A (-2.393) has slightly better solubility than Ligand B (-0.939). Solubility is important for formulation and bioavailability.
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.224 and 0.111). This is excellent for both.
**12. Microsomal Clearance:** Ligand A (-2.151) has significantly lower microsomal clearance than Ligand B (14.249). This indicates better metabolic stability for Ligand A, which is a major advantage.
**13. In vitro Half-Life:** Ligand A (-20.764) has a much longer in vitro half-life than Ligand B (23.013). This is a significant advantage for Ligand A, potentially allowing for less frequent dosing.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.032 and 0.022). This is good for both.
**15. Binding Affinity:** Ligand A (-6.7) has a slightly better binding affinity than Ligand B (-5.5). A 1.2 kcal/mol difference is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand B has advantages in DILI risk, TPSA, HBD and HBA. However, Ligand A has a significantly better metabolic profile (lower Cl_mic, longer t1/2), slightly better solubility, and a substantially better binding affinity. The improved affinity and metabolic stability of Ligand A are more critical for a successful drug candidate, especially considering the relatively minor differences in other properties. The low logP values are a concern for both, but the stronger binding and improved PK profile of Ligand A make it the more promising candidate.
Output:
1
2025-04-17 23:40:55,140 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A: [367.515, 87.3, 3.245, 3, 3, 0.721, 44.591, 77.898, -4.774, -3.882, 0.354, 28.925, -0.851, 0.095, -9.2]**
**Ligand B: [343.431, 71.33, 1.523, 0, 5, 0.764, 55.758, 71.811, -4.756, -1.975, 0.154, 56.088, -13.8, 0.152, -7.4]**
Here's a breakdown, considering the guidelines and GPCR priorities (logP, Pgp, TPSA, affinity):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (343.431) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are good, below 140. Ligand B (71.33) is better, being lower, which suggests better membrane permeability.
3. **logP:** Ligand A (3.245) is optimal. Ligand B (1.523) is on the lower side, potentially hindering permeation.
4. **HBD:** Ligand A (3) is acceptable. Ligand B (0) is even better, potentially improving permeability.
5. **HBA:** Both are acceptable (Ligand A: 3, Ligand B: 5).
6. **QED:** Both are good (A: 0.721, B: 0.764), indicating drug-like properties.
7. **DILI:** Ligand A (44.591) has a better DILI score than Ligand B (55.758). Lower is better.
8. **BBB:** Both have good BBB penetration (A: 77.898, B: 71.811). This is less critical for a cardiovascular target, but still a positive.
9. **Caco-2:** Both are very poor (-4.774 and -4.756). This is concerning for oral bioavailability.
10. **Solubility:** Both are very poor (-3.882 and -1.975). This is a significant drawback.
11. **hERG:** Both are very low risk (A: 0.354, B: 0.154).
12. **Cl_mic:** Ligand A (28.925) has a significantly lower clearance, suggesting better metabolic stability. Ligand B (56.088) is higher, indicating faster metabolism.
13. **t1/2:** Ligand B (-13.8) has a much longer half-life than Ligand A (-0.851). This is a major advantage.
14. **Pgp:** Both have low Pgp efflux (A: 0.095, B: 0.152).
15. **Affinity:** Ligand A (-9.2 kcal/mol) has a substantially stronger binding affinity than Ligand B (-7.4 kcal/mol). This is a significant advantage, potentially outweighing some ADME concerns.
**Overall Assessment:**
While both compounds have issues with Caco-2 permeability and solubility, the significantly stronger binding affinity of Ligand A (-9.2 vs -7.4) and its better metabolic stability (lower Cl_mic) are compelling. The slightly better DILI score also favors Ligand A. The longer half-life of Ligand B is attractive, but the affinity difference is substantial. For a GPCR, affinity is paramount. The lower logP of Ligand B is a concern, and the improved metabolic stability of Ligand A is a significant advantage.
Therefore, I would select Ligand A as the more promising candidate.
1
2025-04-17 23:40:55,140 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (335.411) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both ligands are below the 140 A^2 threshold for good oral absorption, and acceptable for a cardiovascular target (not CNS-focused). Ligand A (101.03) is slightly higher than Ligand B (99.1), but both are good.
3. **logP:** Ligand A (2.102) is optimal (1-3), while Ligand B (0.146) is quite low, potentially hindering membrane permeability. This is a significant drawback for Ligand B.
4. **HBD:** Both ligands have 3 HBD, which is within the acceptable limit of 5.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 5, both are within the acceptable limit of 10.
6. **QED:** Ligand A (0.667) has a better QED score than Ligand B (0.484), indicating a more drug-like profile.
7. **DILI:** Ligand A (54.091) has a higher DILI risk than Ligand B (11.361). This is a concern for Ligand A, but not a deal-breaker at this stage.
8. **BBB:** BBB is less critical for a cardiovascular target. Ligand A (81.117) is better than Ligand B (36.371), but this isn't a primary driver.
9. **Caco-2:** Ligand A (-5.567) and Ligand B (-4.842) both have negative Caco-2 values, which is unusual and suggests poor permeability. However, these values are on a scale where higher is better, so we should interpret these as relatively low permeability.
10. **Solubility:** Ligand A (-3.12) has slightly better solubility than Ligand B (-1.52), though both are poor.
11. **hERG:** Ligand A (0.889) has a lower hERG inhibition liability than Ligand B (0.183), which is favorable.
12. **Cl_mic:** Ligand A (-30.821) has significantly lower microsomal clearance than Ligand B (39.627), indicating better metabolic stability. This is a major advantage for Ligand A.
13. **t1/2:** Ligand A (-20.68) has a longer in vitro half-life than Ligand B (0.765), further supporting its better metabolic stability.
14. **Pgp:** Ligand A (0.232) has lower P-gp efflux liability than Ligand B (0.08), which is favorable for bioavailability.
15. **Affinity:** Ligand B (-7.8) has a slightly better binding affinity than Ligand A (-7.4), but the difference is relatively small (0.4 kcal/mol).
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A excels in logP and Pgp, and has acceptable TPSA. Ligand B's low logP is a significant concern. The affinity difference is not large enough to overcome the ADME deficiencies of Ligand B. Ligand A also has superior metabolic stability (Cl_mic and t1/2).
**Conclusion:**
Considering all factors, especially the crucial logP and metabolic stability, Ligand A is the more promising drug candidate. While Ligand B has slightly better affinity, the other ADME properties of Ligand A are significantly more favorable for a successful drug development program.
Output:
1
2025-04-17 23:40:55,140 - INFO - Batch 422 complete. Total preferences: 6752
2025-04-17 23:40:55,140 - INFO - Processing batch 423/512...
2025-04-17 23:41:42,500 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (343.351 and 344.375 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (135.41) is slightly higher than Ligand B (123.84). Both are below the 140 threshold for good oral absorption, but Ligand B is preferable due to being closer to the 90 threshold for GPCRs.
3. **logP:** Ligand A (-0.632) is a bit low, potentially hindering permeation. Ligand B (-0.155) is better, falling within the optimal 1-3 range. This favors Ligand B.
4. **HBD:** Both ligands have 3 HBD, which is acceptable.
5. **HBA:** Ligand A has 8 HBA, while Ligand B has 5. Ligand B is preferable as it is closer to the ideal of 10 or less.
6. **QED:** Ligand B (0.644) has a better QED score than Ligand A (0.522), indicating a more drug-like profile.
7. **DILI:** Ligand A (67.739) has a slightly higher DILI risk than Ligand B (61.109), but both are acceptable.
8. **BBB:** Ligand B (36.487) has a significantly higher BBB penetration percentile than Ligand A (19.038). While ADRB2 isn't strictly a CNS target, some CNS exposure can be acceptable and even beneficial for certain cardiovascular effects. This is a strong advantage for Ligand B.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand B (-5.38) is slightly better than Ligand A (-5.909).
10. **Solubility:** Both ligands have negative solubility values, which is also unusual and suggests poor solubility. Ligand B (-2.647) is slightly better than Ligand A (-1.927).
11. **hERG:** Both ligands have very low hERG inhibition liability (0.036 and 0.154), which is excellent.
12. **Cl_mic:** Ligand A (-8.375) has a much lower (better) microsomal clearance than Ligand B (-0.702), indicating greater metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (16.326 hours) has a longer in vitro half-life than Ligand B (-24.374 hours). This is a strong advantage for Ligand A.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.022 and 0.005), which is excellent.
15. **Binding Affinity:** Ligand A (-9.4 kcal/mol) has a significantly stronger binding affinity than Ligand B (-5.2 kcal/mol). This is a substantial advantage for Ligand A. A difference of 4.2 kcal/mol is very meaningful and can often outweigh minor ADME drawbacks.
**Overall Assessment:**
Ligand A has a significantly better binding affinity and metabolic stability (lower Cl_mic, longer t1/2). Ligand B has better logP, TPSA, QED, and BBB penetration. Considering the importance of potency for GPCR targets, the substantial binding affinity advantage of Ligand A is the most critical factor. While Ligand B has some advantages in ADME properties, the difference isn't large enough to overcome the significant potency gap.
Output:
1
2025-04-17 23:41:42,500 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [343.431, 81.07, 1.998, 2, 6, 0.717, 45.328, 46.84, -5.26, -1.779, 0.692, 2.72, 14.679, 0.043, -6.9]
**Ligand B:** [345.483, 66.4, 4.48, 2, 2, 0.845, 51.105, 47.809, -4.864, -3.829, 0.056, 33.239, -16.372, 0.045, -7.2]
Here's a breakdown, considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal range (200-500 Da). A is 343.431, B is 345.483 - very similar.
2. **TPSA:** A is 81.07, B is 66.4. B is better, being closer to the <90 threshold for good absorption.
3. **logP:** A is 1.998, B is 4.48. A is significantly better. B is pushing the upper limit and could have solubility/off-target issues.
4. **HBD:** Both have 2, which is good.
5. **HBA:** A has 6, B has 2. B is better, lower HBA generally improves permeability.
6. **QED:** B (0.845) is better than A (0.717), indicating a more drug-like profile.
7. **DILI:** A (45.328) is better than B (51.105), lower risk of liver injury.
8. **BBB:** Both are similar (A: 46.84, B: 47.809). Not a huge priority for ADRB2 (cardiovascular target), but higher is generally preferable.
9. **Caco-2:** A (-5.26) is worse than B (-4.864). Higher values are better, suggesting better absorption.
10. **Solubility:** A (-1.779) is better than B (-3.829), indicating better aqueous solubility.
11. **hERG:** A (0.692) is better than B (0.056), lower risk of cardiotoxicity.
12. **Cl_mic:** A (2.72) is much better than B (33.239), indicating better metabolic stability.
13. **t1/2:** A (14.679) is better than B (-16.372), indicating a longer half-life.
14. **Pgp:** Both are very low (A: 0.043, B: 0.045), suggesting minimal P-gp efflux.
15. **Affinity:** B (-7.2) is 0.3 kcal/mol better than A (-6.9). This is a significant difference in binding.
**Overall Assessment:**
Ligand B has a better QED, TPSA, Caco-2 permeability, and *significantly* better binding affinity. However, it suffers from a higher logP, potentially leading to solubility and off-target issues, a higher DILI risk, and significantly worse metabolic stability (high Cl_mic, negative t1/2). Ligand A is more balanced. While its affinity is slightly lower, it has a much more favorable ADME profile, particularly regarding metabolic stability and solubility.
For a cardiovascular target like ADRB2, metabolic stability and avoiding off-target effects (indicated by logP and DILI) are crucial. The affinity difference, while notable, can potentially be optimized in later stages of drug development. The ADME liabilities of Ligand B are more difficult to address.
Therefore, I would choose Ligand A.
1
2025-04-17 23:41:42,501 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (364.471 and 345.403 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (87.46) is better than Ligand B (102.05). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (0.991 and 1.374), within the 1-3 range. Ligand B is slightly better.
4. **HBD:** Both have 2 HBD, which is acceptable.
5. **HBA:** Both have 6 HBA, which is acceptable.
6. **QED:** Ligand A (0.832) has a slightly better QED score than Ligand B (0.789), indicating a more drug-like profile.
7. **DILI:** Ligand A (39.356) has a significantly better DILI score than Ligand B (56.262). This is a major advantage for Ligand A.
8. **BBB:** Both are relatively low, as expected for a cardiovascular target. Ligand A (40.558) is slightly lower than Ligand B (55.099), but this isn't a critical factor.
9. **Caco-2:** Both are negative, indicating poor permeability. This is a concern for both.
10. **Solubility:** Both are negative, indicating poor solubility. This is a concern for both.
11. **hERG:** Both ligands have very low hERG risk (0.094 and 0.073), which is excellent.
12. **Cl_mic:** Ligand B (17.16) has a significantly lower microsomal clearance than Ligand A (31.077), suggesting better metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand B (7.659) has a much better in vitro half-life than Ligand A (-18.757). This is a major advantage for Ligand B.
14. **Pgp:** Both have very low Pgp efflux liability (0.024 and 0.03), which is good.
15. **Binding Affinity:** Ligand A (-7.4) has a slightly better binding affinity than Ligand B (-7.2), though the difference is small (0.2 kcal/mol).
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, and affinity are important. Both ligands perform reasonably well on logP. Ligand A has a better TPSA and slightly better affinity. However, the significantly better DILI score, metabolic stability (lower Cl_mic), and longer half-life of Ligand B are crucial advantages that outweigh the small differences in TPSA and affinity. The poor Caco-2 and solubility are concerning for both, but can be addressed with formulation strategies.
**Conclusion:**
Despite the slightly better affinity of Ligand A, Ligand B's superior ADME properties (DILI, Cl_mic, t1/2) make it the more promising drug candidate.
Output:
0
2025-04-17 23:41:42,501 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (375.78 and 358.47 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (62.39) is better than Ligand B (67.23). Both are reasonably good for oral absorption, but A is closer to the preferred <90 for GPCRs.
3. **logP:** Both ligands have good logP values (3.41 and 2.78), falling within the 1-3 optimal range. Ligand A is slightly higher, which could be beneficial for membrane permeability, but not dramatically so.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (1), but both are acceptable (<=5).
5. **HBA:** Ligand A (3) is lower than Ligand B (5), which is preferable. Lower HBA generally improves permeability.
6. **QED:** Ligand B (0.914) has a significantly better QED score than Ligand A (0.558), indicating a more drug-like profile overall. This is a substantial advantage for B.
7. **DILI:** Both ligands have similar DILI risk (65.72 and 67.62), and are within an acceptable range (<60 is good, these are slightly above).
8. **BBB:** Ligand A (74.95) has a better BBB penetration percentile than Ligand B (64.87). This is a key consideration for GPCRs, even if ADRB2 isn't strictly a CNS target, some off-target CNS effects are possible.
9. **Caco-2:** Ligand A (-4.798) shows better Caco-2 permeability than Ligand B (-5.238). Higher (less negative) values indicate better absorption.
10. **Solubility:** Ligand A (-4.881) is slightly better than Ligand B (-3.728), indicating better aqueous solubility.
11. **hERG:** Both ligands have similar hERG inhibition liability (0.423 and 0.522), which is acceptable.
12. **Cl_mic:** Ligand A (-3.346) has a significantly *lower* (better) microsomal clearance than Ligand B (24.986). This suggests greater metabolic stability for Ligand A.
13. **t1/2:** Ligand B (17.03) has a slightly longer in vitro half-life than Ligand A (16.981), but the difference is minimal.
14. **Pgp:** Both ligands have similar Pgp efflux liability (0.164 and 0.218).
15. **Binding Affinity:** Both ligands have the same binding affinity (-7.2 kcal/mol). This removes affinity as a differentiating factor.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and BBB are important. Ligand A has a slight edge in logP, TPSA, and a more significant advantage in BBB and Cl_mic. Ligand B has a better QED score, which is valuable. However, the improved metabolic stability (Cl_mic) and BBB penetration of Ligand A are more critical for a successful GPCR-targeted drug, especially considering the potential for off-target effects.
**Conclusion:**
While Ligand B has a better QED, Ligand A's superior metabolic stability (lower Cl_mic), better BBB penetration, and slightly improved TPSA and Caco-2 permeability make it the more promising candidate for development as a drug targeting ADRB2.
Output:
1
2025-04-17 23:41:42,501 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Ligand A (389.279 Da) is within the ideal range, while Ligand B (341.415 Da) is slightly below, but still acceptable.
2. **TPSA:** Ligand A (67.87) is good, well below the 140 threshold. Ligand B (80.12) is still reasonable, but less optimal.
3. **logP:** Ligand A (3.499) is excellent. Ligand B (0.433) is quite low, potentially causing permeability issues. This is a significant drawback for a GPCR target.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 5 HBA, both are acceptable.
6. **QED:** Both ligands have good QED scores (0.691 and 0.806).
7. **DILI:** Ligand A (62.544) is moderately risky, while Ligand B (36.642) is much better, indicating lower liver injury potential.
8. **BBB:** Ligand A (71.307) has good BBB penetration, while Ligand B (60.644) is lower. While ADRB2 isn't strictly a CNS target, some CNS exposure can be beneficial or at least less detrimental than complete exclusion.
9. **Caco-2:** Ligand A (-4.778) and Ligand B (-5.212) both have negative values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Ligand A (-3.776) and Ligand B (-2.021) both have negative solubility values, which is concerning.
11. **hERG:** Ligand A (0.655) is better than Ligand B (0.08), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand A (28.339) has a higher clearance than Ligand B (0.256), suggesting lower metabolic stability. This is a negative for Ligand A.
13. **t1/2:** Ligand A (14.755) has a longer half-life than Ligand B (-2.258), which is a positive.
14. **Pgp:** Ligand A (0.397) has lower P-gp efflux than Ligand B (0.035), which is favorable.
15. **Binding Affinity:** Ligand A (-7.4 kcal/mol) has a slightly better binding affinity than Ligand B (-6.8 kcal/mol). This 0.6 kcal/mol difference is significant, and can outweigh some ADME concerns.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are particularly important. Ligand A excels in logP and affinity, and has acceptable TPSA and Pgp. Ligand B's low logP is a major concern, potentially hindering its ability to reach the receptor. While Ligand B has a better DILI score, the affinity difference and logP of Ligand A are more critical for a GPCR target.
**Conclusion:**
Despite Ligand A's slightly higher DILI risk and clearance, its superior logP, binding affinity, and acceptable BBB penetration make it the more promising drug candidate for ADRB2.
Output:
1
2025-04-17 23:41:42,501 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (348.418 Da and 342.363 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (67.43) is significantly better than Ligand B (114.33). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is above the preferred 90 A^2 threshold.
**3. logP:** Ligand A (4.259) is higher than Ligand B (1.022). While both are within the acceptable range, Ligand A is approaching the upper limit where solubility issues could arise. However, for a GPCR, a slightly higher logP can be tolerated if other properties are favorable.
**4. H-Bond Donors:** Ligand A (2) and Ligand B (1) are both acceptable.
**5. H-Bond Acceptors:** Ligand A (3) and Ligand B (9) differ significantly. Ligand B has a high number of H-bond acceptors, potentially impacting permeability.
**6. QED:** Ligand A (0.799) is much better than Ligand B (0.404), indicating a more drug-like profile.
**7. DILI Risk:** Ligand B (87.747) has a considerably higher DILI risk than Ligand A (56.223). This is a major concern.
**8. BBB Penetration:** Ligand A (83.249) has better BBB penetration than Ligand B (57.736). While ADRB2 is primarily a cardiovascular target, some CNS effects are possible with certain ligands, and better BBB penetration is generally desirable.
**9. Caco-2 Permeability:** Ligand A (-4.259) is better than Ligand B (-5.169).
**10. Aqueous Solubility:** Ligand A (-5.005) is better than Ligand B (-3.036).
**11. hERG Inhibition:** Ligand A (0.704) is better than Ligand B (0.121). Lower hERG inhibition is crucial to avoid cardiotoxicity.
**12. Microsomal Clearance:** Ligand A (87.66) is higher than Ligand B (55.856), meaning Ligand B has better metabolic stability.
**13. In vitro Half-Life:** Ligand A (22.463) is better than Ligand B (6.057).
**14. P-gp Efflux:** Ligand A (0.366) is better than Ligand B (0.1).
**15. Binding Affinity:** Both ligands have very similar binding affinities (-6.0 kcal/mol and -5.4 kcal/mol). The difference of 0.6 kcal/mol is not enough to outweigh the other significant differences.
**Overall Assessment:**
Ligand A is significantly better overall. It has a much better QED score, lower DILI risk, better BBB penetration, better solubility, better hERG profile, better Caco-2 permeability, and better P-gp efflux. While Ligand B has better metabolic stability, the other significant drawbacks make it a less desirable candidate. The slight difference in binding affinity is not enough to overcome the other issues with Ligand B.
Output:
1
2025-04-17 23:41:42,501 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (345.443 and 347.415 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (73.64) is better than Ligand B (93.46). For a GPCR, keeping TPSA under 140 is good, and lower is generally better for permeability. Ligand B is approaching a less desirable range.
3. **logP:** Both ligands have good logP values (2.094 and 1.104), falling within the optimal 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability, but not drastically so.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer hydrogen bond donors generally improve permeability.
5. **HBA:** Ligand A (4) is preferable to Ligand B (5). Similar to HBD, fewer hydrogen bond acceptors are generally better for permeability.
6. **QED:** Both ligands have good QED scores (0.715 and 0.804), indicating good drug-like properties. No clear advantage.
7. **DILI:** Ligand A (22.722) has a significantly lower DILI risk than Ligand B (45.328). This is a crucial advantage, as liver toxicity is a major concern in drug development.
8. **BBB:** Ligand A (63.474) has a better BBB penetration score than Ligand B (55.603). While ADRB2 isn't exclusively a CNS target, some distribution into the CNS is possible, and higher BBB penetration is generally favorable.
9. **Caco-2:** Ligand A (-4.322) and Ligand B (-5.559) both have negative values, which is unusual for Caco-2 permeability. Lower (more negative) values suggest *lower* permeability. Ligand B is slightly worse.
10. **Solubility:** Ligand A (-1.478) is slightly better than Ligand B (-0.792), indicating better aqueous solubility.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.437 and 0.115). No significant difference.
12. **Cl_mic:** Ligand A (27.43) has a higher microsomal clearance than Ligand B (7.537). This means Ligand B is more metabolically stable, which is a positive.
13. **t1/2:** Ligand B (6.191) has a longer in vitro half-life than Ligand A (-9.94). This is a significant advantage, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.021 and 0.024). No significant difference.
15. **Binding Affinity:** Ligand B (-7.9) has a significantly better binding affinity than Ligand A (-6.0). This is a substantial advantage, potentially outweighing some of the ADME drawbacks. A 1.9 kcal/mol difference is considerable.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B has a slightly lower logP and a significantly higher affinity. Ligand A has better TPSA and DILI. The affinity difference is the most significant factor.
**Overall Assessment:**
While Ligand A has advantages in DILI, TPSA, and solubility, the substantially stronger binding affinity of Ligand B (-7.9 kcal/mol vs. -6.0 kcal/mol) is a decisive factor. The longer half-life of Ligand B is also a plus. The slightly higher TPSA and DILI risk of Ligand B are acceptable trade-offs for the improved potency and PK profile.
Output:
0
2025-04-17 23:41:42,501 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (340.423 and 345.334 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (71.34) is significantly better than Ligand B (95.93). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is pushing the upper limit for good oral absorption.
3. **logP:** Both ligands have good logP values (2.632 and 1.974), falling within the optimal 1-3 range. Ligand B is slightly lower, which could slightly improve solubility, but isn't a major concern.
4. **HBD:** Ligand A (2) is preferable to Ligand B (0). While both are acceptable, a small number of HBDs can aid solubility without drastically impacting permeability.
5. **HBA:** Ligand A (3) is better than Ligand B (8). Higher HBA generally correlates with reduced permeability. Ligand B's HBA is relatively high.
6. **QED:** Ligand B (0.576) has a slightly better QED score than Ligand A (0.412), indicating a marginally more drug-like profile.
7. **DILI:** Ligand A (34.277) has a much lower DILI risk than Ligand B (78.402). This is a significant advantage for Ligand A.
8. **BBB:** Ligand B (76.309) has a higher BBB penetration percentile than Ligand A (54.634). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be useful for understanding off-target effects and potential peripheral distribution.
9. **Caco-2:** Both ligands have similar, poor Caco-2 permeability scores (-4.647 and -4.682). This suggests both compounds may have limited intestinal absorption.
10. **Solubility:** Ligand A (-4.134) has slightly better solubility than Ligand B (-2.412).
11. **hERG:** Both ligands have low hERG inhibition liability (0.323 and 0.244), which is good.
12. **Cl_mic:** Ligand A (33.404) has significantly lower microsomal clearance than Ligand B (71.419), indicating better metabolic stability.
13. **t1/2:** Ligand A (1.078) has a slightly better in vitro half-life than Ligand B (-18.932).
14. **Pgp:** Ligand A (0.281) has lower P-gp efflux liability than Ligand B (0.123), suggesting better bioavailability.
15. **Affinity:** Ligand B (-7.3 kcal/mol) has a stronger binding affinity than Ligand A (-6.5 kcal/mol). This is a 0.8 kcal/mol difference, which is substantial and a major factor.
**Overall Assessment:**
Ligand B has a significantly better binding affinity, which is a critical factor for GPCRs. However, it suffers from higher DILI risk, higher HBA, higher microsomal clearance, and lower Pgp efflux. Ligand A has better ADME properties overall, particularly regarding safety (DILI) and metabolic stability (Cl_mic). The affinity difference is significant, but the ADME advantages of Ligand A, especially the lower DILI risk, are compelling. For a cardiovascular target, minimizing off-target effects and maximizing safety are paramount.
**Output:**
1
2025-04-17 23:41:42,502 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (337.383) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are good, but Ligand B (77.57) is significantly better than Ligand A (90.12), falling well below the 140 threshold for oral absorption and closer to the 90 threshold for CNS penetration (though BBB is the primary factor for CNS).
3. **logP:** Ligand A (1.46) is better than Ligand B (0.408). While both are acceptable, Ligand A is closer to the optimal 1-3 range. Ligand B is a bit low and may have permeability issues.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (2), but both are within the acceptable limit of 5.
5. **HBA:** Ligand A (4) is slightly lower than Ligand B (5), but both are within the acceptable limit of 10.
6. **QED:** Both ligands have good QED scores (A: 0.74, B: 0.808), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (79.333) has a significantly higher DILI risk than Ligand B (19.155). This is a major concern for Ligand A.
8. **BBB:** Ligand A (53.083) is better than Ligand B (43.273), but neither is particularly high. For a cardiovascular target like ADRB2, BBB penetration is not a primary concern, so this difference is less important.
9. **Caco-2:** Both ligands have very poor Caco-2 permeability (-5). This is a significant drawback for both.
10. **Solubility:** Ligand A (-3.973) is slightly better than Ligand B (-1.051), but both are poor.
11. **hERG:** Both ligands have very low hERG inhibition risk (A: 0.411, B: 0.19). This is good for both.
12. **Cl_mic:** Ligand B (-34.371) has much lower (better) microsomal clearance than Ligand A (-13.927), indicating better metabolic stability.
13. **t1/2:** Ligand B (13.053) has a significantly longer in vitro half-life than Ligand A (-1.823). This is a major advantage for Ligand B.
14. **Pgp:** Both ligands have very low P-gp efflux liability (A: 0.063, B: 0.005). This is good for both.
15. **Binding Affinity:** Ligand B (-7.2) has a significantly stronger binding affinity than Ligand A (-5.7). This is a crucial advantage, as a 1.5 kcal/mol difference can outweigh other drawbacks.
**Overall Assessment:**
Ligand B is the superior candidate. While Ligand A has a slightly better logP and BBB, Ligand B excels in critical areas: significantly lower DILI risk, much better metabolic stability (lower Cl_mic, longer t1/2), and substantially stronger binding affinity. The poor Caco-2 permeability is a concern for both, but can be addressed with formulation strategies. The strong affinity of Ligand B is likely to drive efficacy, and the improved safety profile (lower DILI) is critical. Given the GPCR target class, the balance of properties favors Ligand B.
Output:
0
2025-04-17 23:41:42,502 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.43 and 350.41 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (59.08) is higher than Ligand B (45.33). Both are below the 140 threshold for oral absorption, but B is better positioned for potential CNS penetration if desired.
3. **logP:** Ligand B (3.967) is higher than Ligand A (1.026). While both are within the acceptable range, Ligand B is approaching the upper limit. This could lead to solubility issues, but might be acceptable given the GPCR target class.
4. **HBD:** Ligand A has 0 HBD, while Ligand B has 1. Both are acceptable.
5. **HBA:** Ligand A has 4 HBA, while Ligand B has 2. Both are acceptable.
6. **QED:** Ligand B (0.821) has a significantly better QED score than Ligand A (0.553), indicating a more drug-like profile.
7. **DILI:** Ligand A (31.563) has a much lower DILI risk than Ligand B (59.131). This is a significant advantage for Ligand A.
8. **BBB:** Ligand B (89.957) has a higher BBB penetration score than Ligand A (65.801). For a cardiovascular target like ADRB2, BBB penetration isn't a primary concern, but it's a slight advantage for B.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.443 and -4.888), which is unusual and problematic. These values suggest very poor permeability.
10. **Solubility:** Ligand A (-1.777) has better solubility than Ligand B (-4.044). This is important, especially given Ligand B's higher logP.
11. **hERG:** Ligand A (0.203) has a much lower hERG inhibition liability than Ligand B (0.898). This is a critical advantage for Ligand A, as hERG inhibition can cause cardiotoxicity.
12. **Cl_mic:** Ligand A (5.02) has a much lower microsomal clearance than Ligand B (40.803), suggesting better metabolic stability.
13. **t1/2:** Ligand B (14.314) has a longer in vitro half-life than Ligand A (4.191). This is a positive for Ligand B.
14. **Pgp:** Ligand A (0.047) has lower P-gp efflux liability than Ligand B (0.462), which is beneficial for bioavailability.
15. **Binding Affinity:** Ligand A (-7.5) has a slightly better binding affinity than Ligand B (-5.2). While both are good, the 1.5 kcal/mol difference is meaningful.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B has a better logP (though potentially problematic), better BBB, and a longer half-life. However, Ligand A has significantly better DILI, hERG, Cl_mic, Pgp, solubility, and a slightly better binding affinity. The poor Caco-2 values for both are concerning, but the superior safety profile of Ligand A, combined with its better binding affinity and metabolic stability, makes it the more promising candidate.
**Output:**
1
2025-04-17 23:41:42,502 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (374.388 Da) is slightly higher than Ligand B (350.503 Da), but both are acceptable.
2. **TPSA:** Ligand A (76.35) is higher than Ligand B (58.64). Both are below 140, which is good for oral absorption, but Ligand B is preferable due to the lower TPSA.
3. **logP:** Both ligands have good logP values (A: 3.174, B: 2.903) within the optimal 1-3 range.
4. **HBD:** Both ligands have 1 HBD, which is within the acceptable limit of 5.
5. **HBA:** Ligand A has 5 HBA, while Ligand B has 3. Both are below the limit of 10.
6. **QED:** Ligand A (0.873) has a significantly better QED score than Ligand B (0.685), indicating a more drug-like profile.
7. **DILI:** Ligand B (8.298) has a much lower DILI risk than Ligand A (69.639). This is a significant advantage for Ligand B.
8. **BBB:** Ligand B (83.443) has a higher BBB penetration percentile than Ligand A (72.664). While ADRB2 isn't strictly a CNS target, some peripheral ADRB2 receptors can be affected by CNS penetration, and higher BBB is generally favorable.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and potentially problematic. However, the values are similar (-4.895 for A, -4.382 for B), so this doesn't strongly favor either.
10. **Solubility:** Ligand B (-2.8) has a slightly better (less negative) solubility score than Ligand A (-3.9), suggesting better aqueous solubility.
11. **hERG:** Both ligands have low hERG inhibition liability (A: 0.562, B: 0.404), which is good. Ligand B is slightly better.
12. **Cl_mic:** Ligand A (19.877) has a lower microsomal clearance than Ligand B (84.845), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (58.524) has a much longer in vitro half-life than Ligand B (-8.323). This is a major advantage for Ligand A.
14. **Pgp:** Ligand A (0.304) has lower P-gp efflux liability than Ligand B (0.116), which is preferable.
15. **Binding Affinity:** Ligand B (-7.1 kcal/mol) has a slightly better binding affinity than Ligand A (-6.8 kcal/mol). While the difference is not huge (less than 1.5 kcal/mol), it's a factor.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B performs better on logP, TPSA, and affinity. However, the significantly better metabolic stability (Cl_mic and t1/2) and QED of Ligand A are very important. The lower DILI risk of Ligand B is also a major plus.
**Overall Assessment:**
While Ligand B has a slightly better binding affinity and lower DILI, the superior metabolic stability (longer half-life and lower clearance) and better QED of Ligand A outweigh these advantages. The longer half-life means less frequent dosing. The better QED suggests a more generally drug-like molecule. The difference in binding affinity is not substantial enough to overcome these benefits.
Output:
1
2025-04-17 23:41:42,502 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (338.411 and 360.885 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (87.04) is higher than Ligand B (58.2). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B has a significant advantage here.
3. **logP:** Both ligands (3.762 and 3.118) are within the optimal 1-3 range. Ligand B is slightly lower, which is acceptable and could even be beneficial for solubility.
4. **HBD:** Both have 2 HBD, which is good.
5. **HBA:** Ligand A has 4 HBA, Ligand B has 2. Lower is generally better for permeability, giving Ligand B an advantage.
6. **QED:** Ligand A (0.753) is better than Ligand B (0.579), indicating a more drug-like profile.
7. **DILI:** Ligand A (69.911) has a higher DILI risk than Ligand B (35.905). This is a significant concern, and favors Ligand B.
8. **BBB:** Ligand A (51.415) and Ligand B (67.003). BBB is less critical for a cardiovascular target, but higher is still slightly preferred. Ligand B has a modest advantage.
9. **Caco-2:** Ligand A (-4.827) and Ligand B (-5.07). Both are poor.
10. **Solubility:** Ligand A (-5.59) is worse than Ligand B (-3.637). Solubility is important, and Ligand B is better.
11. **hERG:** Ligand A (0.728) is higher than Ligand B (0.384), indicating a lower risk of hERG inhibition. Ligand A has an advantage here.
12. **Cl_mic:** Ligand A (95.637) has a higher clearance than Ligand B (32.485). Lower clearance is better for metabolic stability, favoring Ligand B.
13. **t1/2:** Ligand A (36.882) has a longer half-life than Ligand B (-2.415). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.411) is lower than Ligand B (0.244), indicating lower P-gp efflux. Lower is better, favoring Ligand A.
15. **Affinity:** Ligand B (-7.4) has a significantly stronger binding affinity than Ligand A (-5.0). This is a crucial factor, and a difference of 2.4 kcal/mol is substantial.
**Overall Assessment:**
Ligand B has several advantages: lower TPSA, lower HBA, significantly lower DILI risk, better solubility, and *much* stronger binding affinity. While Ligand A has a better QED, longer half-life, and lower Pgp efflux, the DILI risk and weaker binding are major drawbacks. The strong affinity of Ligand B can likely be optimized to improve its half-life and Pgp efflux. The DILI risk of Ligand A is a serious concern. For a GPCR, affinity is paramount, and Ligand B's affinity is substantially better.
Output:
0
2025-04-17 23:41:42,502 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [345.407, 120.24 , -0.463, 3. , 6. , 0.621, 49.826, 52.889, -5.861, -2.469, 0.469, 3.997, -18.311, 0.006, -6.8 ]
**Ligand B:** [342.439, 67.43 , 2.265, 2. , 3. , 0.862, 31.214, 61.846, -5.148, -2.645, 0.181, 10.002, 38.082, 0.041, -7. ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal 200-500 Da range. A (345.4) and B (342.4) are very similar.
2. **TPSA:** A (120.24) is slightly higher than B (67.43). B is much better, being well below the 140 threshold for good absorption.
3. **logP:** A (-0.463) is a bit low, potentially hindering permeation. B (2.265) is within the optimal 1-3 range. This is a significant advantage for B.
4. **HBD:** A (3) and B (2) are both acceptable, below the 5 threshold.
5. **HBA:** A (6) and B (3) are both acceptable, below the 10 threshold.
6. **QED:** Both are good (A: 0.621, B: 0.862), indicating drug-like properties. B is slightly better.
7. **DILI:** A (49.8) is higher than B (31.2), indicating a slightly higher risk of liver injury. B is preferable.
8. **BBB:** A (52.9) is lower than B (61.8). While ADRB2 isn't necessarily a CNS target, some peripheral distribution is still desired, and a higher BBB percentile suggests better overall permeability.
9. **Caco-2:** Both are negative, indicating poor permeability. A (-5.861) is worse than B (-5.148).
10. **Solubility:** Both are negative, indicating poor solubility. A (-2.469) is worse than B (-2.645).
11. **hERG:** Both are very low (A: 0.469, B: 0.181) suggesting minimal cardiotoxicity risk. B is slightly better.
12. **Cl_mic:** A (3.997) is much lower than B (10.002), indicating better metabolic stability. This is a strong advantage for A.
13. **t1/2:** A (-18.311) is much lower than B (38.082), indicating a shorter half-life. This is a significant advantage for B.
14. **Pgp:** Both are very low (A: 0.006, B: 0.041), suggesting minimal P-gp efflux.
15. **Affinity:** A (-6.8) is slightly weaker than B (-7.0). However, the difference is relatively small.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, and affinity are key. Ligand B excels in logP and TPSA, while affinity is only marginally better for B. Ligand A has better metabolic stability, but the shorter half-life is a significant drawback. The poor Caco-2 and solubility for both are concerning, but the better overall profile of B outweighs the metabolic stability advantage of A.
**Conclusion:**
Considering the balance of properties, particularly the favorable logP, TPSA, DILI, BBB, and half-life of Ligand B, it is the more promising drug candidate.
0
2025-04-17 23:41:42,503 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.418 and 345.487 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (58.64) is better than Ligand B (61.44), both are under the 140 threshold for oral absorption, and reasonably close to the 90 threshold for GPCRs.
3. **logP:** Both ligands have good logP values (2.808 and 2.004), falling within the 1-3 optimal range. Ligand A is slightly higher, which could be beneficial for membrane permeability, but not drastically.
4. **HBD:** Ligand A (1) is preferred over Ligand B (2) as lower HBD generally improves permeability.
5. **HBA:** Both ligands have the same HBA count (3), which is well within the acceptable limit of 10.
6. **QED:** Ligand A (0.91) has a significantly better QED score than Ligand B (0.694), indicating a more drug-like profile.
7. **DILI:** Ligand A (42.226) has a higher DILI risk than Ligand B (10.275). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (91.663) has a better BBB penetration percentile than Ligand B (71.307). This is important for GPCR targets.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.507 and -4.979). These values are unusual and likely indicate poor permeability in this assay.
10. **Solubility:** Ligand A (-2.672) has slightly better solubility than Ligand B (-2.061), but both are poor.
11. **hERG:** Ligand A (0.6) has a higher hERG risk than Ligand B (0.264). This is a significant advantage for Ligand B.
12. **Cl_mic:** Ligand B (18.181) has a significantly lower microsomal clearance than Ligand A (42.686), indicating better metabolic stability.
13. **t1/2:** Ligand B (10.435) has a longer in vitro half-life than Ligand A (5.462), which is desirable.
14. **Pgp:** Ligand B (0.033) has much lower P-gp efflux liability than Ligand A (0.368), which is a significant advantage.
15. **Binding Affinity:** Ligand A (-6.9 kcal/mol) has a slightly better binding affinity than Ligand B (-6.3 kcal/mol). This is a 1.5 kcal/mol difference, which is a reasonable advantage.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), and the general drug-like properties, Ligand B is the more promising candidate. While Ligand A has a slightly better binding affinity and BBB penetration, Ligand B excels in crucial ADME properties: significantly lower DILI risk, lower hERG inhibition, lower P-gp efflux, and better metabolic stability (lower Cl_mic and longer t1/2). The QED score is also better for Ligand A. The slightly better affinity of Ligand A is unlikely to outweigh the substantial ADME advantages of Ligand B.
Output:
0
2025-04-17 23:41:42,503 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (407.769 Da) is slightly higher than Ligand B (356.426 Da), but both are acceptable.
**2. TPSA:** Ligand A (81.7) is slightly above the preferred <90 for GPCRs, while Ligand B (72.11) is well within. This favors Ligand B.
**3. logP:** Both ligands have good logP values (A: 2.861, B: 3.41), falling within the optimal 1-3 range. Ligand B is slightly higher, which *could* be a minor concern for solubility, but is still acceptable.
**4. H-Bond Donors:** Both have 1 HBD, which is good.
**5. H-Bond Acceptors:** Both have 5 HBA, which is good.
**6. QED:** Ligand B (0.76) has a significantly better QED score than Ligand A (0.407), indicating a more drug-like profile. This is a substantial advantage for Ligand B.
**7. DILI:** Ligand A (80.962) has a higher DILI risk than Ligand B (65.723), which is preferable.
**8. BBB:** Ligand B (79.682) has a better BBB penetration score than Ligand A (60.644). While ADRB2 is cardiovascular, some CNS effects are possible with beta-blockers, and better BBB penetration could contribute to off-target effects. However, it's not a primary concern here.
**9. Caco-2 Permeability:** Ligand A (-4.781) has a better Caco-2 permeability than Ligand B (-5.233).
**10. Aqueous Solubility:** Ligand A (-4.693) has better aqueous solubility than Ligand B (-4.06).
**11. hERG Inhibition:** Both ligands have similar hERG inhibition liability (A: 0.536, B: 0.828).
**12. Microsomal Clearance:** Ligand A (74.073) has a higher microsomal clearance than Ligand B (65.068), meaning it is less metabolically stable.
**13. In vitro Half-Life:** Ligand B (-1.919) has a significantly longer in vitro half-life than Ligand A (10.109). This is a major advantage for Ligand B.
**14. P-gp Efflux:** Both ligands have similar P-gp efflux liability (A: 0.211, B: 0.374).
**15. Binding Affinity:** Both ligands have identical binding affinity (-6.1 kcal/mol).
**Overall Assessment:**
Ligand B is the stronger candidate. While Ligand A has slightly better Caco-2 permeability and solubility, Ligand B excels in several critical areas: QED, DILI risk, in vitro half-life, and TPSA. The better QED and lower DILI risk are significant advantages. The longer half-life is also highly desirable. The slightly higher logP of Ligand B is a minor concern, but outweighed by its other benefits.
Output:
0
2025-04-17 23:41:42,503 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
Let's break down the comparison of Ligand A and Ligand B based on the provided parameters and GPCR-specific priorities (logP, Pgp, TPSA, and affinity being key).
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (365.455) is slightly lower, which can be beneficial for permeability.
2. **TPSA:** Both are reasonably low (A: 78, B: 79.9), suggesting good potential for absorption, but below the 90 cutoff for CNS targets.
3. **logP:** Ligand A (0.774) is significantly better than Ligand B (4.261). Ligand B's high logP raises concerns about solubility and potential off-target interactions. This is a major negative for Ligand B.
4. **H-Bond Donors/Acceptors:** Ligand A (0/4) has a more favorable profile than Ligand B (2/5). Fewer H-bonds generally improve membrane permeability.
5. **QED:** Both have similar, acceptable QED values (A: 0.793, B: 0.7), indicating good drug-like properties.
6. **DILI:** Ligand A (71.539) is much better than Ligand B (98.643). This is a significant advantage for Ligand A, as lower DILI risk is crucial.
7. **BBB:** Both have relatively low BBB penetration (A: 56.572, B: 52.889), which isn't a primary concern for ADRB2, a cardiovascular target.
8. **Caco-2 Permeability:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
9. **Aqueous Solubility:** Ligand A (-2.241) is better than Ligand B (-5.447), which aligns with the lower logP of Ligand A.
10. **hERG Inhibition:** Ligand A (0.232) is significantly better than Ligand B (0.778), indicating a lower risk of cardiotoxicity, which is critically important for a cardiovascular target.
11. **Microsomal Clearance:** Ligand A (32.504) is better than Ligand B (41.941), suggesting better metabolic stability.
12. **In vitro Half-Life:** Ligand A (-10.852) is better than Ligand B (20.047), indicating a longer half-life.
13. **P-gp Efflux:** Both have low P-gp efflux liability (A: 0.091, B: 0.766), which is good.
14. **Binding Affinity:** Ligand B (-6.6) has a slightly better binding affinity than Ligand A (-6.0). However, the difference (0.6 kcal/mol) is not substantial enough to outweigh the significant ADME/Tox advantages of Ligand A.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B in crucial ADMET properties (DILI, solubility, hERG, clearance, half-life) and has a more favorable logP. While Ligand B has slightly better binding affinity, the difference is not large enough to compensate for its poor ADMET profile, particularly the high logP and DILI risk. For a cardiovascular target like ADRB2, minimizing cardiotoxicity (hERG) and liver injury (DILI) are paramount.
Output:
1
2025-04-17 23:41:42,503 - INFO - Batch 423 complete. Total preferences: 6768
2025-04-17 23:41:42,503 - INFO - Processing batch 424/512...
2025-04-17 23:42:32,890 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Step-by-step comparison:**
1. **MW:** Both ligands (354.47 & 355.39 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (69.64) is significantly better than Ligand B (110). For a GPCR, keeping TPSA under 140 is good, but lower is generally preferred for better permeability. Ligand B is pushing the upper limit.
3. **logP:** Both ligands have acceptable logP values (2.195 & 1.426), falling within the 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Ligand A (2) is preferable to Ligand B (3). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (5). Similar to HBD, lower HBA is generally preferred.
6. **QED:** Both ligands have similar QED values (0.719 & 0.715), indicating good drug-likeness.
7. **DILI:** Ligand A (24.31) has a much lower DILI risk than Ligand B (54.44). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (81.698) has a slightly better BBB penetration percentile than Ligand B (79.294). While ADRB2 isn't exclusively a CNS target, some degree of BBB penetration can be useful, and minimizing efflux is always good.
9. **Caco-2:** Ligand A (-4.688) is better than Ligand B (-5.313), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-2.931) is better than Ligand B (-2.682), indicating better aqueous solubility.
11. **hERG:** Both ligands show low hERG inhibition liability (0.397 & 0.279), which is excellent.
12. **Cl_mic:** Ligand A (61.485) has a higher microsomal clearance than Ligand B (3.902). This means Ligand B is more metabolically stable, a significant advantage.
13. **t1/2:** Ligand B (-10.965) has a longer in vitro half-life than Ligand A (-18.156). This is a significant advantage for Ligand B.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.216 & 0.011).
15. **Binding Affinity:** Ligand B (-6.9) has a slightly better binding affinity than Ligand A (-6.4). While a 0.5 kcal/mol difference isn't massive, it's noticeable.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has a better logP and TPSA, while Ligand B has slightly better affinity. Metabolic stability (Cl_mic and t1/2) are also important, and Ligand B excels here. DILI risk is also a critical factor, and Ligand A is significantly better.
**Overall Assessment:**
Ligand A has a more favorable ADME profile (lower DILI, better solubility, better Caco-2 permeability, better TPSA) and a good logP. Ligand B has a slightly better binding affinity and superior metabolic stability. However, the lower DILI risk of Ligand A is a major advantage, and the differences in metabolic stability, while present, aren't so large as to outweigh this. The better TPSA and solubility of Ligand A are also beneficial.
Output:
1
2025-04-17 23:42:32,891 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (335.411 Da) is within the ideal range, while Ligand B (361.471 Da) is slightly higher but still acceptable.
2. **TPSA:** Ligand A (71.84) is excellent, well below the 140 threshold. Ligand B (88.08) is still reasonable, but less optimal.
3. **logP:** Ligand A (3.848) is at the upper end of the optimal range, while Ligand B (2.139) is good. Both are acceptable, but A's higher logP *could* lead to off-target effects.
4. **HBD:** Ligand A (2) and Ligand B (1) are both good, well below the 5 limit.
5. **HBA:** Ligand A (4) and Ligand B (6) are both acceptable, under the 10 limit.
6. **QED:** Both Ligand A (0.744) and Ligand B (0.851) have good drug-likeness scores.
7. **DILI:** Ligand B (54.556) has a significantly lower DILI risk than Ligand A (77.356), which is a major advantage.
8. **BBB:** Ligand A (64.599) has slightly better BBB penetration than Ligand B (54.827), but neither are particularly high. Since ADRB2 isn't a primary CNS target, this isn't a major deciding factor.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.841) is slightly better than Ligand B (-5.091).
10. **Solubility:** Ligand A (-4.451) has slightly better solubility than Ligand B (-2.537), but both are poor.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.448 and 0.247 respectively).
12. **Cl_mic:** Ligand B (46.729) has significantly lower microsomal clearance than Ligand A (67.889), indicating better metabolic stability.
13. **t1/2:** Ligand A (63.616) has a longer in vitro half-life than Ligand B (14.288). This is a significant advantage.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.084 and 0.095 respectively).
15. **Affinity:** Ligand A (-7.7 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.3 kcal/mol). This is a substantial advantage, potentially outweighing some ADME concerns.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A excels in affinity and has acceptable logP and TPSA. Ligand B has a better DILI score and lower Cl_mic. However, the substantial difference in binding affinity (-1.4 kcal/mol) is a major factor. The better half-life of Ligand A is also a plus. While the solubility and Caco-2 values are poor for both, the strong binding of Ligand A suggests it might still achieve sufficient target engagement *in vivo*.
**Conclusion:**
Despite the lower DILI and better metabolic stability of Ligand B, the significantly stronger binding affinity of Ligand A is the most important factor for a GPCR target like ADRB2. The improved half-life also contributes to its potential.
**Output:**
1
2025-04-17 23:42:32,891 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [359.499, 64.86, 3.373, 1, 7, 0.744, 49.011, 77.511, -5.369, -3.191, 0.261, 47.806, -3.77, 0.267, -5.7]
**Ligand B:** [360.567, 44.1, 4.811, 0, 3, 0.438, 10.857, 83.249, -4.798, -4.957, 0.842, 119.85, -12.708, 0.599, -6.9]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). A: 359.5, B: 360.6 - very similar.
2. **TPSA:** A: 64.86, B: 44.1. Both are good, under 140, but B is significantly better, increasing the chance of good oral absorption.
3. **logP:** A: 3.373, B: 4.811. A is optimal (1-3), B is slightly higher, potentially leading to solubility issues or off-target interactions.
4. **HBD:** A: 1, B: 0. Both are good, within the limit of 5.
5. **HBA:** A: 7, B: 3. Both are good, under 10. B is better.
6. **QED:** A: 0.744, B: 0.438. A is significantly better, indicating a more drug-like profile.
7. **DILI:** A: 49.011, B: 10.857. B is *much* better, indicating a significantly lower risk of drug-induced liver injury. This is a major advantage.
8. **BBB:** A: 77.511, B: 83.249. B is slightly better, though both are reasonably good for a non-CNS target like ADRB2.
9. **Caco-2:** A: -5.369, B: -4.798. Both are negative, which is unusual. Lower (more negative) values suggest poor permeability. B is slightly better.
10. **Solubility:** A: -3.191, B: -4.957. Both are negative, suggesting poor solubility. B is worse.
11. **hERG:** A: 0.261, B: 0.842. A is much better, indicating a lower risk of cardiotoxicity. This is crucial for a cardiovascular target.
12. **Cl_mic:** A: 47.806, B: 119.85. A is significantly better, indicating better metabolic stability.
13. **t1/2:** A: -3.77, B: -12.708. A is better, suggesting a longer in vitro half-life.
14. **Pgp:** A: 0.267, B: 0.599. A is better, indicating lower P-gp efflux.
15. **Affinity:** A: -5.7, B: -6.9. B has a better (more negative) binding affinity, a 1.2 kcal/mol advantage.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. B has a better logP (though slightly high), better TPSA, better Pgp, and significantly better affinity. However, the DILI and hERG risks associated with B are concerning. A has a much better safety profile (DILI and hERG) and better metabolic stability (Cl_mic and t1/2) and a good QED score. The affinity difference, while notable, might be overcome with further optimization of Ligand A.
**Conclusion:**
While Ligand B has a superior binding affinity, the significantly higher DILI risk and worse hERG profile are major drawbacks for a cardiovascular drug. Ligand A, despite slightly lower affinity, presents a much more favorable safety profile and better ADME properties, making it a more promising starting point for drug development.
Output:
1
2025-04-17 23:42:32,892 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (367.293 and 352.475 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (39.08) is significantly better than Ligand B (76.66). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold, while Ligand B is approaching it.
3. **logP:** Ligand A (4.475) is higher than Ligand B (1.914). While both are within the acceptable range (1-3 is optimal), Ligand A is pushing the upper limit. This could potentially lead to solubility issues, but for a GPCR, some lipophilicity is beneficial for membrane interactions. Ligand B is closer to the ideal range.
4. **HBD:** Ligand A (1) is better than Ligand B (2). Lower is generally preferred.
5. **HBA:** Both ligands have 4 HBA, which is acceptable.
6. **QED:** Both ligands have the same QED (0.766), indicating similar drug-likeness.
7. **DILI:** Ligand B (15.161) is *much* better than Ligand A (45.095). This is a significant advantage for Ligand B. DILI risk is a critical factor.
8. **BBB:** Ligand A (76.464) is slightly better than Ligand B (68.825), but this isn't a major concern for a cardiovascular target.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.734 and -4.856), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand B (-1.98) is better than Ligand A (-4.943), indicating better aqueous solubility.
11. **hERG:** Ligand A (0.895) is slightly better than Ligand B (0.18), indicating lower hERG inhibition risk.
12. **Cl_mic:** Ligand B (21.573) has a significantly lower microsomal clearance than Ligand A (46.292), suggesting better metabolic stability.
13. **t1/2:** Ligand B (9.371) has a much longer in vitro half-life than Ligand A (1.542). This is a major advantage for Ligand B.
14. **Pgp:** Ligand B (0.026) is *much* better than Ligand A (0.85), indicating lower P-gp efflux.
15. **Binding Affinity:** Ligand B (-6.6 kcal/mol) is slightly better than Ligand A (-6.4 kcal/mol). While the difference is small, it's still a positive for Ligand B.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A has a higher logP and slightly better BBB, but Ligand B excels in TPSA, Pgp, and has comparable affinity. The significantly better DILI, metabolic stability (Cl_mic & t1/2), and solubility of Ligand B are crucial advantages.
**Overall Assessment:**
While Ligand A has a slightly better BBB and hERG profile, Ligand B's superior DILI risk, metabolic stability, solubility, P-gp efflux, and slightly better binding affinity outweigh these minor drawbacks. The poor Caco-2 values are a concern for both, but can be addressed through formulation strategies.
Output:
0
2025-04-17 23:42:32,892 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (355.479 and 342.399 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (87.74) is better than Ligand B (93.09). Both are below the 140 threshold for oral absorption, but lower is preferred, especially for a GPCR.
3. **logP:** Both ligands (0.783 and 0.795) are within the optimal 1-3 range. Very similar.
4. **HBD:** Both ligands have 2 H-bond donors, which is acceptable.
5. **HBA:** Ligand A has 4 H-bond acceptors, while Ligand B has 5. Ligand A is slightly better.
6. **QED:** Ligand B (0.812) has a slightly better QED score than Ligand A (0.63), indicating a more drug-like profile.
7. **DILI:** Ligand A (27.453) has a significantly lower DILI risk than Ligand B (52.695). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (53.781) has a better BBB penetration percentile than Ligand B (43.893). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be beneficial for distribution and off-target effects.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand B (-5.261) is slightly worse than Ligand A (-4.987).
10. **Solubility:** Both ligands have negative solubility values, indicating poor aqueous solubility. Ligand B (-2.016) is slightly worse than Ligand A (-1.757).
11. **hERG:** Both ligands have very low hERG inhibition risk (0.215 and 0.219). No significant difference.
12. **Cl_mic:** Ligand A (27.452) has a lower microsomal clearance than Ligand B (34.54), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-13.441) has a significantly longer in vitro half-life than Ligand A (7.27). This is a substantial advantage for Ligand B.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.024 and 0.036). No significant difference.
15. **Binding Affinity:** Ligand B (-6.9 kcal/mol) has a slightly better binding affinity than Ligand A (-5.8 kcal/mol). This is a 1.1 kcal/mol difference, which is significant.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand B has a better binding affinity and a longer half-life. However, Ligand A has a significantly lower DILI risk, better TPSA, and better BBB penetration. The poor Caco-2 and solubility for both are concerning, but can potentially be addressed with formulation strategies. The DILI risk is a major concern, and the difference between the two ligands is substantial. Given the balance of properties, and prioritizing safety (DILI) alongside reasonable affinity, I favor Ligand A.
Output:
1
2025-04-17 23:42:32,892 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (364.471 and 344.459 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (88.33) is slightly higher than Ligand B (69.04). Both are below the 140 threshold for good oral absorption, but Ligand B is better positioned, especially considering ADRB2 is a cardiovascular target and CNS penetration isn't a primary goal.
3. **logP:** Ligand A (2.669) and Ligand B (3.355) are both within the optimal 1-3 range. Ligand B is slightly higher, which could potentially lead to some solubility issues, but it's not a major concern.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 6 HBA, and Ligand B has 5. Both are acceptable, below the 10 threshold.
6. **QED:** Both ligands have good QED scores (0.778 and 0.836), indicating good drug-like properties.
7. **DILI:** Ligand A (55.991) has a slightly better DILI risk profile than Ligand B (64.444), but both are acceptable.
8. **BBB:** Ligand A (58.821) has a higher BBB percentile than Ligand B (38.542). However, as ADRB2 is a cardiovascular target, BBB penetration is not a priority.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and potentially concerning. It suggests poor permeability. However, the values are similar (-5.08 and -4.666), so this doesn't differentiate them.
10. **Solubility:** Ligand A (-1.947) has better aqueous solubility than Ligand B (-4.554). This is a positive for Ligand A.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.418 and 0.316).
12. **Cl_mic:** Ligand A (86.155) has a higher microsomal clearance than Ligand B (81.558), indicating potentially lower metabolic stability. Ligand B is preferable here.
13. **t1/2:** Ligand B (-4.11) has a significantly better (longer) in vitro half-life than Ligand A (-21.729). This is a significant advantage for Ligand B.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.112 and 0.21).
15. **Binding Affinity:** Ligand B (-7.2) has a slightly better binding affinity than Ligand A (-7.0). While the difference is small, it's within the range where it could outweigh minor ADME drawbacks.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, affinity), Ligand B is slightly more favorable. It has a better TPSA, a slightly better logP, a longer half-life, and a slightly better binding affinity. While Ligand A has better solubility, the other advantages of Ligand B are more important for a cardiovascular GPCR target. The Caco-2 values are concerning for both, but similar.
Output:
0
2025-04-17 23:42:32,892 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (386.275) is slightly higher than Ligand B (349.431), but both are acceptable.
2. **TPSA:** Ligand A (48.0) is excellent, well below the 140 threshold and favorable for oral absorption. Ligand B (78.95) is higher, but still reasonable.
3. **logP:** Ligand A (3.386) is optimal. Ligand B (0.98) is a bit low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (0) is ideal. Ligand B (1) is acceptable.
5. **HBA:** Both ligands have 4 HBA, which is good.
6. **QED:** Both ligands have similar QED scores (A: 0.748, B: 0.771), indicating good drug-likeness.
7. **DILI:** Ligand A (73.517) has a higher DILI risk than Ligand B (30.399). This is a significant drawback for Ligand A.
8. **BBB:** Both ligands have high BBB penetration (A: 81.97, B: 80.419), which is less critical for a cardiovascular target like ADRB2, but not detrimental.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the values are similar enough to not be a deciding factor.
10. **Solubility:** Both ligands have negative solubility values, which is also unusual. Again, the values are similar.
11. **hERG:** Both ligands have low hERG inhibition risk (A: 0.246, B: 0.242).
12. **Cl_mic:** Ligand A (24.424) has a lower microsomal clearance than Ligand B (45.502), suggesting better metabolic stability.
13. **t1/2:** Ligand A (30.1) has a longer in vitro half-life than Ligand B (-4.7). This is a significant advantage for Ligand A.
14. **Pgp:** Both ligands have low P-gp efflux liability (A: 0.209, B: 0.025). Ligand B is slightly better.
15. **Binding Affinity:** Ligand B (-7.9 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.8 kcal/mol). This is a substantial advantage.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand A has a better logP and metabolic stability (Cl_mic, t1/2), but Ligand B has a much stronger binding affinity and lower Pgp efflux. The DILI risk associated with Ligand A is a major concern. While the affinity difference is significant, the DILI risk is a showstopper.
**Conclusion:**
Despite the superior affinity of Ligand B, the significantly lower DILI risk associated with Ligand B makes it the more promising candidate.
Output:
0
2025-04-17 23:42:32,892 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (355.415 and 342.443 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (83.47) is slightly higher than Ligand B (58.44). For a cardiovascular GPCR, TPSA is not a *critical* factor like it would be for a CNS target, but lower is generally preferred for absorption. Ligand B has a clear advantage.
**3. logP:** Ligand A (2.879) is within the optimal 1-3 range. Ligand B (1.134) is on the lower end, potentially impacting permeability. Ligand A is favored.
**4. H-Bond Donors:** Ligand A (2) is acceptable. Ligand B (0) is also good, potentially improving membrane permeability. Slight advantage to Ligand B.
**5. H-Bond Acceptors:** Both ligands have 4 HBA, which is well within the acceptable limit.
**6. QED:** Both ligands have similar QED values (0.754 and 0.774), indicating good drug-like properties. No significant difference.
**7. DILI Risk:** Ligand A (78.131) has a higher DILI risk than Ligand B (50.33). This is a significant concern, as minimizing liver toxicity is crucial. Ligand B is strongly favored.
**8. BBB Penetration:** Ligand B (72.625) shows better BBB penetration than Ligand A (40.52). While ADRB2 isn't exclusively a CNS target, some CNS exposure or off-target effects are possible, and better BBB penetration is generally desirable. Ligand B is favored.
**9. Caco-2 Permeability:** Ligand A (-5.29) has significantly *better* Caco-2 permeability than Ligand B (-4.525). This suggests better intestinal absorption for Ligand A. Ligand A is favored.
**10. Aqueous Solubility:** Ligand A (-3.909) has poorer solubility than Ligand B (-1.239). Solubility is important for formulation and bioavailability. Ligand B is favored.
**11. hERG Inhibition:** Ligand A (0.569) has a slightly higher hERG risk than Ligand B (0.242). Lower hERG risk is critical for cardiovascular drugs. Ligand B is favored.
**12. Microsomal Clearance:** Ligand A (41.602) has higher microsomal clearance than Ligand B (26.879), indicating faster metabolism and potentially lower exposure. Ligand B is favored.
**13. In vitro Half-Life:** Ligand B (-23.896) has a *much* longer in vitro half-life than Ligand A (25.902). This is a substantial advantage, potentially allowing for less frequent dosing. Ligand B is strongly favored.
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (0.314 and 0.17), which is good. No significant difference.
**15. Binding Affinity:** Ligand A (-7.2 kcal/mol) has a slightly better binding affinity than Ligand B (-6.8 kcal/mol). This 0.4 kcal/mol difference is notable, but not overwhelmingly decisive given the other factors.
**Overall Assessment:**
While Ligand A has a slightly better affinity and Caco-2 permeability, Ligand B demonstrates a significantly better safety profile (lower DILI, hERG), improved metabolic stability (lower Cl_mic, longer t1/2), and better solubility. Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity) and the overall balance of properties, Ligand B is the more promising drug candidate. The improved safety and pharmacokinetic properties outweigh the slight reduction in binding affinity.
Output:
0
2025-04-17 23:42:32,892 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (358.47) is slightly higher than Ligand B (342.40), but both are acceptable.
2. **TPSA:** Ligand A (78.09) is better than Ligand B (106.14). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (2.556) is within the optimal range (1-3). Ligand B (0.596) is a bit low, potentially hindering membrane permeability. This is a significant drawback.
4. **HBD:** Both ligands have 2 HBD, which is good.
5. **HBA:** Ligand A (4) is better than Ligand B (6). Lower HBA is preferable for permeability.
6. **QED:** Both ligands have acceptable QED values (A: 0.862, B: 0.791), indicating good drug-like properties.
7. **DILI:** Both ligands have similar DILI risk (A: 62.35, B: 60.682), which is acceptable (below 60 is ideal, but these are within a reasonable range).
8. **BBB:** Both ligands have similar BBB penetration (A: 70.03, B: 61.26). Since ADRB2 is a cardiovascular target, BBB penetration is not a high priority.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and requires further investigation. However, we can assume they both have poor permeability based on this.
10. **Solubility:** Ligand A (-4.009) is better than Ligand B (-2.364), indicating better aqueous solubility.
11. **hERG:** Both ligands have low hERG inhibition risk (A: 0.408, B: 0.347).
12. **Cl_mic:** Ligand B (-14.069) has a lower (better) microsomal clearance than Ligand A (31.992), suggesting better metabolic stability.
13. **t1/2:** Ligand B (2.749) has a slightly longer in vitro half-life than Ligand A (-14.964), which is preferable.
14. **Pgp:** Ligand A (0.37) has lower P-gp efflux liability than Ligand B (0.035), which is better for bioavailability.
15. **Binding Affinity:** Ligand A (-7.5) has significantly better binding affinity than Ligand B (-1.0). This is a crucial advantage, as a >1.5 kcal/mol difference can outweigh other drawbacks.
**GPCR-Specific Priorities:**
For GPCRs, logP, TPSA, Pgp, and affinity are key. Ligand A excels in affinity and has a better logP and TPSA. While Ligand B has better metabolic stability (Cl_mic and t1/2), the substantial difference in binding affinity makes Ligand A the more promising candidate.
**Conclusion:**
Despite Ligand B's slightly better metabolic stability, Ligand A's significantly stronger binding affinity and more favorable logP/TPSA profile make it the more likely to be a viable drug candidate for the ADRB2 receptor.
Output:
1
2025-04-17 23:42:32,893 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (343.471 Da) is well within the ideal range (200-500). Ligand B (385.251 Da) is also acceptable. No clear advantage here.
2. **TPSA:** Ligand A (44.81) is excellent, well below the 140 threshold and favorable for oral absorption. Ligand B (97.11) is higher, but still potentially acceptable, though less optimal. Ligand A is better.
3. **logP:** Both ligands (A: 2.505, B: 2.403) are within the optimal 1-3 range. No clear advantage.
4. **HBD:** Ligand A (1) is good. Ligand B (2) is also acceptable, but slightly less desirable. Ligand A is slightly better.
5. **HBA:** Ligand A (3) is good. Ligand B (5) is higher, potentially impacting permeability. Ligand A is better.
6. **QED:** Both ligands have good QED scores (A: 0.583, B: 0.727), indicating drug-likeness. Ligand B is slightly better.
7. **DILI:** Ligand A (12.33) has a much lower DILI risk than Ligand B (69.523). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (71.539) shows good BBB penetration, while Ligand B (30.477) is much lower. Given ADRB2's cardiovascular involvement, CNS penetration isn't *critical*, but it's a bonus. Ligand A is better.
9. **Caco-2:** Ligand A (-4.546) and Ligand B (-5.398) both show poor Caco-2 permeability. This is a concern for both, but slightly worse for Ligand B.
10. **Solubility:** Ligand A (-1.505) is better than Ligand B (-2.542), indicating better aqueous solubility.
11. **hERG:** Ligand A (0.839) has a lower hERG risk than Ligand B (0.013). This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand A (-6.802) has a much lower microsomal clearance, indicating better metabolic stability, than Ligand B (16.31). This is a major advantage for Ligand A.
13. **t1/2:** Ligand A (0.251) has a very short half-life, while Ligand B (-22.102) has a very long half-life. This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.048) has lower P-gp efflux liability than Ligand B (0.025). Ligand A is slightly better.
15. **Affinity:** Ligand B (-7.6) has a significantly stronger binding affinity than Ligand A (-5.4). This is a substantial advantage for Ligand B, potentially outweighing some ADME drawbacks.
**Overall Assessment:**
Ligand B has a much stronger binding affinity, which is the most important factor. However, it suffers from significantly higher DILI risk, poorer BBB penetration, and higher microsomal clearance. Ligand A has a more balanced profile with lower risk factors and better metabolic stability, despite the weaker binding affinity. Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), the affinity difference is substantial enough to overcome the ADME concerns of Ligand B.
Output:
0
2025-04-17 23:42:32,893 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (346.391 Da) is within the ideal range, while Ligand B (372.487 Da) is slightly higher but still acceptable.
2. **TPSA:** Ligand A (120.08) is borderline for good oral absorption, but acceptable for a non-CNS GPCR target like ADRB2. Ligand B (83.99) is excellent, well below the 140 threshold.
3. **logP:** Ligand A (-1.019) is a bit low, potentially hindering permeability. Ligand B (0.548) is better, falling within the optimal range.
4. **HBD:** Ligand A (3) is good. Ligand B (0) is also good, potentially improving membrane permeability.
5. **HBA:** Both Ligand A (5) and Ligand B (5) are within the acceptable limit of 10.
6. **QED:** Both ligands have good QED scores (A: 0.57, B: 0.609), indicating drug-likeness.
7. **DILI:** Ligand A (48.042) has a slightly higher DILI risk than Ligand B (39.473), but both are below the concerning threshold of 60.
8. **BBB:** ADRB2 is primarily a cardiovascular target, so BBB penetration is not a major priority. Ligand A (51.958) and Ligand B (60.876) are both relatively low, which is fine.
9. **Caco-2:** Ligand A (-5.88) and Ligand B (-4.328) are both negative, which is unusual and suggests poor permeability. However, this scale is not always reliable.
10. **Solubility:** Ligand A (-2.153) and Ligand B (-1.543) both have poor solubility.
11. **hERG:** Ligand A (0.07) has a slightly lower hERG risk than Ligand B (0.213), which is preferable.
12. **Cl_mic:** Ligand A (-24.009) has significantly lower microsomal clearance, suggesting better metabolic stability than Ligand B (78.251). This is a major advantage.
13. **t1/2:** Ligand A (-4.61) has a shorter in vitro half-life than Ligand B (-25.644). This is a drawback for Ligand A.
14. **Pgp:** Ligand A (0.004) has very low P-gp efflux, which is excellent. Ligand B (0.127) is also low, but higher than A.
15. **Affinity:** Ligand A (-7.1) has a slightly better binding affinity than Ligand B (-4.6). This is a significant advantage, potentially outweighing some ADME concerns.
**GPCR-specific priorities:** For ADRB2 (a cardiovascular GPCR), logP, TPSA, affinity, and metabolic stability are key. Ligand B has a better logP and TPSA. However, Ligand A has a substantially better affinity and significantly better metabolic stability (lower Cl_mic). The affinity difference is large enough to be a deciding factor. While solubility is a concern for both, the superior binding and metabolic stability of Ligand A are more critical for a GPCR target.
**Output:**
1
2025-04-17 23:42:32,893 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
The target is ADRB2, a GPCR. Therefore, I'll prioritize logP, TPSA, Pgp efflux, BBB penetration, and binding affinity. Metabolic stability (Cl_mic, t1/2) and safety (DILI, hERG) are also important.
**Ligand A:**
* **MW:** 353.463 Da - Good, within the ideal range.
* **TPSA:** 101.9 - Acceptable, but approaching the upper limit for good absorption.
* **logP:** -0.241 - Too low. This is a significant concern for membrane permeability and bioavailability.
* **HBD:** 4 - Acceptable.
* **HBA:** 5 - Acceptable.
* **QED:** 0.482 - Marginal. Could be better, but not a dealbreaker.
* **DILI:** 2.986 - Excellent, very low risk.
* **BBB:** 39.473 - Low. Not a primary concern for a non-CNS target like ADRB2, but not ideal.
* **Caco-2:** -5.745 - Very poor permeability. Consistent with the low logP.
* **Solubility:** -0.694 - Poor solubility.
* **hERG:** 0.135 - Low risk.
* **Cl_mic:** -31.465 - Very low clearance, indicating good metabolic stability.
* **t1/2:** 5.763 - Moderate half-life.
* **Pgp:** 0.001 - Very low efflux, favorable.
* **Affinity:** -6.9 kcal/mol - Excellent binding affinity.
**Ligand B:**
* **MW:** 384.311 Da - Good, within the ideal range.
* **TPSA:** 56.07 - Excellent, well below the 140 threshold.
* **logP:** 3.532 - Excellent, within the optimal range.
* **HBD:** 0 - Acceptable.
* **HBA:** 6 - Acceptable.
* **QED:** 0.489 - Similar to Ligand A, marginal.
* **DILI:** 54.401 - Moderate risk. Higher than Ligand A, a concern.
* **BBB:** 78.209 - Good, indicating some potential for CNS penetration (not crucial for ADRB2).
* **Caco-2:** -4.989 - Moderate permeability.
* **Solubility:** -4.098 - Poor solubility.
* **hERG:** 0.404 - Moderate risk.
* **Cl_mic:** 56.792 - High clearance, indicating lower metabolic stability.
* **t1/2:** 45.608 - Long half-life, very favorable.
* **Pgp:** 0.412 - Moderate efflux.
* **Affinity:** -6.0 kcal/mol - Good binding affinity, but less potent than Ligand A.
**Comparison and Decision:**
Ligand A has significantly better binding affinity (-6.9 vs -6.0 kcal/mol). However, its extremely low logP and poor Caco-2 permeability are major drawbacks. These properties are likely to result in very poor oral bioavailability. Ligand B has a much better logP and acceptable permeability, but suffers from higher DILI and hERG risk, and lower metabolic stability.
Despite the affinity advantage of Ligand A, the poor predicted permeability and solubility are too significant to overcome. A drug needs to reach its target *in vivo*. Ligand B, while not perfect, has a much more favorable profile for absorption and distribution, and the difference in affinity is not large enough to outweigh the ADME concerns with Ligand A. The longer half-life of Ligand B is also a plus.
Therefore, I choose Ligand B.
**Output:**
0
2025-04-17 23:42:32,893 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (353-368 Da). No significant difference.
2. **TPSA:** Both are reasonably low (69.64 and 71.11), suggesting good potential for absorption.
3. **logP:** Ligand A (2.037) is optimal, while Ligand B (0.238) is quite low. This is a significant concern for Ligand B, potentially hindering membrane permeability.
4. **HBD:** Both have acceptable HBD counts (2 and 1 respectively).
5. **HBA:** Both have acceptable HBA counts (4 and 5 respectively).
6. **QED:** Ligand B (0.741) has a better QED score than Ligand A (0.457), indicating a more drug-like profile overall.
7. **DILI:** Ligand B (28.073) has a much lower DILI risk than Ligand A (7.057), which is a major advantage.
8. **BBB:** Ligand B (68.67) has a higher BBB penetration score than Ligand A (55.099). While ADRB2 isn't strictly a CNS target, some CNS exposure can occur, and higher BBB is generally favorable.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability.
10. **Solubility:** Both have negative solubility values, indicating poor solubility.
11. **hERG:** Both have very low hERG inhibition liability, which is good.
12. **Cl_mic:** Ligand B (44.564) has a slightly lower microsomal clearance than Ligand A (39.526), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-2.394) has a slightly longer in vitro half-life than Ligand A (-3.618).
14. **Pgp:** Both have very low P-gp efflux liability.
15. **Binding Affinity:** Ligand A (-6.7 kcal/mol) has a slightly better binding affinity than Ligand B (-5.3 kcal/mol), a difference of 1.4 kcal/mol.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A has a better logP and affinity. However, the significant advantage of Ligand B in DILI risk and the reasonably good BBB penetration, combined with acceptable metabolic stability and half-life, outweigh the slightly weaker binding. The poor Caco-2 and solubility of both ligands are concerning, but can be addressed with formulation strategies.
**Conclusion:**
Considering the balance of properties, particularly the lower DILI risk and better BBB penetration of Ligand B, I believe it is the more promising drug candidate despite the slightly weaker binding affinity.
Output:
0
2025-04-17 23:42:32,893 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [337.379, 77.25, 3.39, 1, 6, 0.666, 77.045, 65.452, -4.869, -4.992, 0.576, 128.705, -11.554, 0.46, -6.8]
**Ligand B:** [368.459, 103.79, -0.015, 3, 7, 0.652, 35.556, 41.179, -5.364, -1.647, 0.188, -17.237, -6.188, 0.019, -6.5]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity, and to a lesser extent BBB):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (337.379) is slightly preferred due to being lower.
2. **TPSA:** Ligand A (77.25) is significantly better than Ligand B (103.79). Below 140 is good for oral absorption, and lower is better for GPCRs.
3. **logP:** Ligand A (3.39) is optimal, while Ligand B (-0.015) is quite low, potentially hindering membrane permeability. This is a significant drawback for Ligand B.
4. **HBD/HBA:** Ligand A (1 HBD, 6 HBA) is slightly better than Ligand B (3 HBD, 7 HBA), but both are acceptable.
5. **QED:** Both are similar and acceptable (0.666 and 0.652).
6. **DILI:** Ligand A (77.045) has a higher DILI risk than Ligand B (35.556). This favors Ligand B.
7. **BBB:** Ligand A (65.452) has better BBB penetration than Ligand B (41.179), but BBB isn't a huge priority for ADRB2 (a cardiovascular target).
8. **Caco-2:** Both have negative values, indicating poor permeability. Ligand A (-4.869) is slightly better than Ligand B (-5.364).
9. **Solubility:** Ligand A (-4.992) is better than Ligand B (-1.647).
10. **hERG:** Ligand A (0.576) has a lower hERG risk than Ligand B (0.188).
11. **Cl_mic:** Ligand B (-17.237) has a much lower (better) microsomal clearance than Ligand A (128.705), indicating better metabolic stability. This is a significant advantage for Ligand B.
12. **t1/2:** Ligand A (-11.554) has a longer in vitro half-life than Ligand B (-6.188).
13. **Pgp:** Ligand A (0.46) has lower P-gp efflux than Ligand B (0.019), which is favorable.
14. **Affinity:** Both have very similar and strong binding affinities (-6.8 and -6.5 kcal/mol). The difference is not substantial enough to be a deciding factor.
**Overall Assessment:**
Ligand A has better TPSA, logP, solubility, hERG, and Pgp properties. However, Ligand B has a significantly better DILI score and *much* better metabolic stability (Cl_mic). The low logP of Ligand B is a major concern, potentially leading to poor absorption.
Given the GPCR-specific priorities, and the fact that metabolic stability is crucial for *in vivo* efficacy, I lean towards **Ligand B** despite its lower logP. The better metabolic stability and lower DILI risk are more valuable in the long run, and formulation strategies might be employed to address the logP issue.
Output:
0
2025-04-17 23:42:32,894 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (456.215 Da) is within the ideal range, while Ligand B (340.427 Da) is towards the lower end, but still acceptable.
2. **TPSA:** Ligand A (93.04) is acceptable, while Ligand B (50.6) is excellent, suggesting better permeability.
3. **logP:** Both ligands have good logP values (A: 2.959, B: 1.796), falling within the 1-3 range.
4. **HBD:** Ligand A (2) and Ligand B (0) are both within the acceptable limit of 5.
5. **HBA:** Both ligands have 5 HBA, which is within the acceptable limit of 10.
6. **QED:** Both ligands have good QED scores (A: 0.557, B: 0.852), indicating drug-likeness. Ligand B is significantly better.
7. **DILI:** Ligand A (88.639) has a high DILI risk, while Ligand B (29.042) has a very low risk. This is a major advantage for Ligand B.
8. **BBB:** Ligand A (58.278) has moderate BBB penetration, while Ligand B (86.274) has high BBB penetration. While ADRB2 isn't exclusively a CNS target, increased BBB penetration can be beneficial for overall distribution and potentially accessing peripheral ADRB2 receptors.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual. Assuming these are logP-like scales, lower values indicate poorer permeability. Ligand A (-5.383) is worse than Ligand B (-4.541).
10. **Solubility:** Ligand A (-4.388) has poor solubility, while Ligand B (-1.739) is slightly better, but still poor.
11. **hERG:** Both ligands have low hERG risk (A: 0.535, B: 0.92).
12. **Cl_mic:** Ligand A (52.715) has lower microsomal clearance than Ligand B (61.433), indicating better metabolic stability.
13. **t1/2:** Ligand A (8.855) has a shorter half-life than Ligand B (-6.912, which is very good).
14. **Pgp:** Both ligands have low Pgp efflux liability (A: 0.466, B: 0.508).
15. **Binding Affinity:** Ligand B (-7.2 kcal/mol) has a slightly better binding affinity than Ligand A (-7.0 kcal/mol), but the difference is small.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand B excels in TPSA and has a slightly better affinity. The biggest differentiator is the significantly lower DILI risk for Ligand B. While Ligand A has better metabolic stability, the DILI risk is a major concern.
**Conclusion:**
Despite Ligand A's slightly better metabolic stability, Ligand B is the more promising candidate due to its superior QED, significantly lower DILI risk, better TPSA, and comparable binding affinity. The improved BBB penetration is also a bonus. The solubility and Caco-2 values are concerning for both, but can be addressed with formulation strategies.
Output:
0
2025-04-17 23:42:32,894 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [352.399, 123.22 , -0.973, 2. , 10. , 0.523, 56.999, 73.788, -5.316, -0.33 , 0.264, 36.667, 20.914, 0.11 , -6.6 ]
**Ligand B:** [359.495, 66.32 , 3.348, 1. , 5. , 0.889, 36.254, 75.572, -4.702, -3.442, 0.424, 54.377, -4.833, 0.364, -6.1 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (352.399) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (123.22) is better than Ligand B (66.32) as it is still below 140, but closer to the optimal range for oral absorption. Ligand B is very good.
3. **logP:** Ligand A (-0.973) is a bit low, potentially hindering permeation. Ligand B (3.348) is within the optimal range (1-3). This is a significant advantage for B.
4. **HBD:** Both have acceptable HBD counts (A: 2, B: 1).
5. **HBA:** Both have acceptable HBA counts (A: 10, B: 5). Ligand B is better here.
6. **QED:** Ligand B (0.889) has a better QED score than Ligand A (0.523), indicating a more drug-like profile.
7. **DILI:** Ligand B (36.254) has a lower DILI risk than Ligand A (56.999), which is a clear advantage.
8. **BBB:** Both have good BBB penetration (A: 73.788, B: 75.572). This is important for a GPCR target, but not critically differentiating here.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified.
10. **Solubility:** Ligand A (-0.33) has better solubility than Ligand B (-3.442).
11. **hERG:** Ligand A (0.264) has a lower hERG risk than Ligand B (0.424), which is a positive.
12. **Cl_mic:** Ligand A (36.667) has lower microsomal clearance than Ligand B (54.377), suggesting better metabolic stability.
13. **t1/2:** Ligand A (20.914) has a longer in vitro half-life than Ligand B (-4.833). This is a significant advantage.
14. **Pgp:** Ligand A (0.11) has lower P-gp efflux than Ligand B (0.364), which is favorable.
15. **Affinity:** Ligand A (-6.6) has slightly better binding affinity than Ligand B (-6.1). While this is a positive, the difference is not huge.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP and has a good TPSA. Ligand A has a slightly better affinity, but the logP is a concern. The lower DILI risk and better QED of Ligand B are also significant advantages.
**Overall Assessment:**
While Ligand A has a slightly better affinity and longer half-life, Ligand B's superior logP, DILI profile, QED, and acceptable TPSA make it a more promising candidate. The low logP of Ligand A is a significant drawback.
Output:
0
2025-04-17 23:42:32,894 - INFO - Batch 424 complete. Total preferences: 6784
2025-04-17 23:42:32,894 - INFO - Processing batch 425/512...
2025-04-17 23:43:28,218 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (351.535 and 350.478 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (52.65) is slightly higher than Ligand B (40.62). Both are below the 140 threshold for oral absorption, but Ligand B is closer to the preferred <90 for GPCRs, especially if CNS penetration is desired (though less crucial for a cardiovascular target).
**3. logP:** Both ligands have good logP values (2.793 and 3.156), falling within the optimal 1-3 range. Ligand B is slightly higher, which could potentially lead to slightly better membrane permeability.
**4. H-Bond Donors:** Ligand A has 1 HBD, while Ligand B has 0. Both are acceptable, staying below the 5 limit.
**5. H-Bond Acceptors:** Ligand A has 3 HBA, and Ligand B has 2. Both are well within the acceptable limit of 10.
**6. QED:** Both ligands have similar, good QED values (0.731 and 0.784), indicating good drug-like properties.
**7. DILI Risk:** Ligand B (19.814) has a significantly lower DILI risk than Ligand A (13.3). This is a major advantage for Ligand B.
**8. BBB Penetration:** Ligand B (85.925) shows better BBB penetration than Ligand A (74.952). While ADRB2 is primarily a cardiovascular target, some CNS effects can be relevant, and higher BBB penetration is generally preferable.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.48 and -4.557). These values are unusual and suggest poor permeability. However, the values are very similar.
**10. Aqueous Solubility:** Both ligands have negative solubility values (-2.293 and -3.357), indicating poor aqueous solubility. Ligand B is slightly worse.
**11. hERG Inhibition:** Ligand A (0.419) has a lower hERG inhibition risk than Ligand B (0.761), which is a positive.
**12. Microsomal Clearance:** Ligand B (55.915) has lower microsomal clearance, suggesting better metabolic stability, than Ligand A (67.643).
**13. In vitro Half-Life:** Ligand B (-6.633) has a significantly longer in vitro half-life than Ligand A (24.442). This is a substantial advantage for Ligand B.
**14. P-gp Efflux:** Ligand A (0.042) has lower P-gp efflux liability than Ligand B (0.227), which is preferable.
**15. Binding Affinity:** Both ligands have excellent binding affinities (-6.3 and -6.8 kcal/mol). Ligand B is slightly better, but the difference is relatively small.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), and the general drug-like properties, Ligand B emerges as the more promising candidate. Its significantly lower DILI risk, better metabolic stability (lower Cl_mic and longer t1/2), and improved BBB penetration outweigh the slightly higher hERG risk and lower P-gp efflux. While both have poor solubility and permeability, the other advantages of Ligand B make it a better starting point for optimization.
Output:
0
2025-04-17 23:43:28,218 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (347.434 Da and 370.559 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (71.09) is slightly higher than Ligand B (66.48). Both are well below the 140 A^2 threshold for oral absorption, and acceptable for a cardiovascular target (not requiring significant BBB penetration).
**3. logP:** Both ligands have good logP values (2.187 and 3.056), falling within the optimal 1-3 range. Ligand B is slightly higher, which could potentially lead to some solubility issues, but is still acceptable.
**4. H-Bond Donors:** Ligand A has 2 HBD, and Ligand B has 1. Both are within the desirable limit of <=5.
**5. H-Bond Acceptors:** Both ligands have 3 HBA, well within the acceptable limit of <=10.
**6. QED:** Both ligands have good QED scores (0.673 and 0.781), indicating a generally drug-like profile. Ligand B is slightly better.
**7. DILI Risk:** Ligand A (39.473) has a slightly higher DILI risk than Ligand B (28.655), but both are below the 40% threshold considered good.
**8. BBB Penetration:** Both ligands have relatively high BBB penetration (81.504 and 77.162). However, since ADRB2 is primarily a cardiovascular target, high BBB penetration isn't a primary requirement.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.8 and -4.986). This is unusual and suggests poor permeability. However, negative values can sometimes occur with certain calculation methods and don't necessarily preclude *in vivo* absorption.
**10. Aqueous Solubility:** Both ligands have poor aqueous solubility (-2.584 and -3.733). This is a concern, but can potentially be addressed through formulation strategies.
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (0.528 and 0.677), which is excellent.
**12. Microsomal Clearance:** Ligand A (23.804) has significantly lower microsomal clearance than Ligand B (63.547). Lower clearance indicates better metabolic stability, a crucial factor for drug duration and efficacy.
**13. In vitro Half-Life:** Ligand A (-13.848) has a much longer in vitro half-life than Ligand B (-47.138). This is a significant advantage, potentially allowing for less frequent dosing.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.096 and 0.212), which is favorable for absorption and bioavailability.
**15. Binding Affinity:** Both ligands have very similar and strong binding affinities (-6.2 and -6.1 kcal/mol). The difference is negligible.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), both ligands are reasonably good. However, Ligand A stands out due to its significantly better metabolic stability (lower Cl_mic) and longer in vitro half-life. The slightly higher DILI risk is a minor concern compared to the potential benefits of improved pharmacokinetic properties. While both have poor solubility, this is a formulation challenge that can be addressed.
Output:
1
2025-04-17 23:43:28,219 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (357.495 Da) is within the ideal range (200-500 Da). Ligand B (380.495 Da) is also within the ideal range. No clear advantage here.
2. **TPSA:** Ligand A (90.9) is excellent, well below the 140 threshold for oral absorption. Ligand B (94.07) is still acceptable, but slightly higher. Slight advantage to A.
3. **logP:** Ligand A (0.515) is a bit low, potentially hindering permeability. Ligand B (1.809) is much better, falling within the optimal 1-3 range. Significant advantage to B.
4. **HBD:** Ligand A (3) is good. Ligand B (1) is even better, minimizing potential issues with hydrogen bonding and metabolic lability. Advantage to B.
5. **HBA:** Ligand A (5) is good. Ligand B (8) is acceptable, but higher. Slight advantage to A.
6. **QED:** Ligand A (0.496) is just below the desirable 0.5 threshold. Ligand B (0.736) is well above, indicating a more drug-like profile. Advantage to B.
7. **DILI:** Ligand A (4.188) has a very low DILI risk, excellent. Ligand B (69.678) is significantly higher, indicating a substantial risk of liver injury. Major advantage to A.
8. **BBB:** Ligand A (36.371) has low BBB penetration. Ligand B (62.97) is better, but still not high enough to be a strong advantage. ADRB2 is a cardiovascular target, so BBB penetration isn't a high priority, but it's still a consideration.
9. **Caco-2:** Ligand A (-5.235) is very poor. Ligand B (-4.873) is also poor, but slightly better. Advantage to B.
10. **Solubility:** Ligand A (-0.281) is slightly better than Ligand B (-2.559). Advantage to A.
11. **hERG:** Ligand A (0.258) has a very low hERG risk, excellent. Ligand B (0.062) is even lower, also excellent. No clear advantage.
12. **Cl_mic:** Ligand A (-0.81) indicates low clearance and good metabolic stability. Ligand B (79.196) indicates very high clearance and poor metabolic stability. Major advantage to A.
13. **t1/2:** Ligand A (10.859) has a reasonable half-life. Ligand B (-16.906) has a very short half-life. Significant advantage to A.
14. **Pgp:** Ligand A (0.016) has very low P-gp efflux, which is good. Ligand B (0.074) is also low, but slightly higher. Slight advantage to A.
15. **Affinity:** Ligand A (-7.1) has a slightly better binding affinity than Ligand B (-6.5). While both are good, the difference is significant. Advantage to A.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B has a better logP, while Ligand A has better TPSA, Pgp, and affinity. However, the significant drawbacks of Ligand B (high DILI, high Cl_mic, short half-life) outweigh its logP advantage.
**Overall Assessment:**
Ligand A is the stronger candidate. While its logP is suboptimal, its excellent DILI profile, metabolic stability (low Cl_mic and good t1/2), good solubility, low Pgp efflux, and slightly better affinity make it a much more promising starting point for drug development. Ligand B's high DILI risk and poor metabolic stability are major red flags.
Output:
1
2025-04-17 23:43:28,219 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A Analysis:**
* **MW:** 348.531 Da - Excellent, within the ideal range.
* **TPSA:** 58.2 - Good, well below the 140 threshold for oral absorption.
* **logP:** 3.938 - Excellent, within the optimal range for GPCRs.
* **HBD:** 2 - Good, below the threshold.
* **HBA:** 2 - Good, below the threshold.
* **QED:** 0.663 - Excellent, indicating good drug-likeness.
* **DILI:** 13.067 - Excellent, very low risk.
* **BBB:** 77.627 - Good, indicating reasonable potential for CNS penetration, though not exceptionally high.
* **Caco-2:** -4.711 - This is a negative value, which is unusual. Assuming this is a log scale, it suggests very poor permeability.
* **Solubility:** -4.541 - Also a negative value, indicating very poor aqueous solubility.
* **hERG:** 0.596 - Good, low risk of hERG inhibition.
* **Cl_mic:** 70.865 - Moderate, could be a concern for metabolic stability.
* **t1/2:** 1.484 - Short half-life, potentially requiring frequent dosing.
* **Pgp:** 0.176 - Low efflux, favorable for bioavailability.
* **Affinity:** -6.0 kcal/mol - Good binding affinity.
**Ligand B Analysis:**
* **MW:** 347.419 Da - Excellent, within the ideal range.
* **TPSA:** 113.08 - Acceptable, but approaching the upper limit for good oral absorption.
* **logP:** 0.417 - Low, potentially hindering permeation.
* **HBD:** 3 - Acceptable, below the threshold.
* **HBA:** 5 - Acceptable, below the threshold.
* **QED:** 0.56 - Good, indicating reasonable drug-likeness.
* **DILI:** 39.55 - Good, low risk.
* **BBB:** 55.138 - Lower, less likely to cross the blood-brain barrier.
* **Caco-2:** -5.597 - Very poor permeability, similar to Ligand A.
* **Solubility:** -1.417 - Very poor aqueous solubility, similar to Ligand A.
* **hERG:** 0.051 - Excellent, very low risk of hERG inhibition.
* **Cl_mic:** 17.608 - Low, excellent metabolic stability.
* **t1/2:** 9.723 - Long half-life, favorable for less frequent dosing.
* **Pgp:** 0.008 - Very low efflux, highly favorable for bioavailability.
* **Affinity:** -6.1 kcal/mol - Slightly better binding affinity than Ligand A.
**Comparison and Decision:**
Both ligands have significant issues with Caco-2 permeability and aqueous solubility. However, considering the GPCR-specific priorities, several factors weigh in. Ligand B has a slightly better binding affinity (-6.1 vs -6.0 kcal/mol), significantly better metabolic stability (lower Cl_mic, longer t1/2), and very low P-gp efflux. While its logP is lower, the improved metabolic stability and efflux profile are more critical for a GPCR target like ADRB2. The poor permeability and solubility are major drawbacks for both, and would require formulation strategies to address, but the other advantages of Ligand B are more impactful.
Therefore, I prefer Ligand B.
Output:
0
2025-04-17 23:43:28,219 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's systematically compare Ligand A and Ligand B based on the provided parameters and the guidelines, keeping in mind that ADRB2 is a GPCR, so logP, Pgp, TPSA, and affinity are particularly important.
1. **MW:** Both ligands (344.371 and 346.431 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (99.51 and 98.06) are below the 140 A^2 threshold for good oral absorption, which is good.
3. **logP:** Ligand B (1.335) is better than Ligand A (0.507). A logP between 1-3 is optimal, and Ligand A is a bit low, potentially hindering membrane permeability.
4. **HBD/HBA:** Ligand A has 1 HBD and 5 HBA, while Ligand B has 3 HBD and 3 HBA. Both are within acceptable ranges.
5. **QED:** Ligand A (0.874) has a significantly better QED score than Ligand B (0.72), indicating a more drug-like profile.
6. **DILI:** Ligand B (44.513) has a lower DILI risk than Ligand A (63.164), which is a substantial advantage. Lower DILI is always preferred.
7. **BBB:** Both ligands have low BBB penetration (51.415 and 46.181). Since ADRB2 is a cardiovascular target, BBB penetration is not a major concern.
8. **Caco-2:** Both ligands have negative Caco-2 values (-5.043 and -5.069). This is unusual and suggests poor permeability.
9. **Solubility:** Ligand B (-2.898) has a slightly worse solubility than Ligand A (-1.552). Solubility is important, but not a primary concern here.
10. **hERG:** Both ligands have low hERG inhibition risk (0.152 and 0.21).
11. **Cl_mic:** Ligand B (-5.066) has a better (lower) microsomal clearance than Ligand A (5.585), suggesting better metabolic stability.
12. **t1/2:** Ligand B (-12.013) has a significantly longer in vitro half-life than Ligand A (-5.813), which is a major advantage.
13. **Pgp:** Both ligands have low Pgp efflux liability (0.031 and 0.03).
14. **Binding Affinity:** Ligand A (-6.7 kcal/mol) has a significantly stronger binding affinity than Ligand B (-3.4 kcal/mol). This is a substantial difference, and a >1.5 kcal/mol advantage often outweighs other drawbacks.
**Overall Assessment:**
Ligand A has a significantly better binding affinity and QED score. However, Ligand B shows better DILI risk, metabolic stability (lower Cl_mic), and a longer half-life. The lower logP of Ligand A is a concern, but the significantly stronger binding affinity is a major positive. Given the importance of potency for GPCR targets, the superior affinity of Ligand A is the deciding factor.
**Output:**
1
2025-04-17 23:43:28,219 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (352.4 & 350.5 Da) fall comfortably within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Both are below 140, suggesting good oral absorption potential. Ligand B (75.71) is slightly better than Ligand A (78.87), closer to the 90 threshold for CNS penetration, though this isn't a primary concern for a cardiovascular target.
3. **logP:** Both ligands have optimal logP values (1.334 & 1.442), falling within the 1-3 range. No significant difference.
4. **HBD:** Ligand A has 2 HBD, and Ligand B has 1. Both are acceptable, below the 5 threshold. Ligand B is slightly favored.
5. **HBA:** Both ligands have 4 HBA, well within the acceptable limit of 10. No difference.
6. **QED:** Both ligands have good QED scores (0.776 & 0.736), indicating good drug-like properties. Ligand A is slightly better.
7. **DILI:** Ligand A (30.438) has a slightly higher DILI risk than Ligand B (19.659), but both are below the concerning 40 threshold. Ligand B is favored.
8. **BBB:** Both have good BBB penetration (76.309 & 80.884), but Ligand B is better. While ADRB2 isn't a CNS target, better BBB penetration generally suggests better overall permeability.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. Ligand B (-4.544) is slightly worse than Ligand A (-4.319). Ligand A is favored.
10. **Solubility:** Both have negative solubility values, indicating poor solubility. Ligand B (-2.503) is worse than Ligand A (-1.76). Ligand A is favored.
11. **hERG:** Both have very low hERG inhibition risk (0.452 & 0.328). No significant difference.
12. **Cl_mic:** Ligand A (27.207) has a significantly lower microsomal clearance than Ligand B (68.747), suggesting better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (5.145) has a positive half-life, while Ligand B (-20.853) has a negative half-life. This is a significant advantage for Ligand A.
14. **Pgp:** Both have very low Pgp efflux liability (0.087 & 0.075). No significant difference.
15. **Binding Affinity:** Ligand B (-7.1 kcal/mol) has a 1.4 kcal/mol stronger binding affinity than Ligand A (-5.7 kcal/mol). This is a substantial advantage, and often outweighs minor ADME concerns.
**Overall Assessment & GPCR Focus:**
For a GPCR like ADRB2, binding affinity is paramount. Ligand B's significantly stronger binding (-7.1 vs -5.7 kcal/mol) is a major advantage. While Ligand A has better metabolic stability (lower Cl_mic, positive t1/2) and solubility, the difference in affinity is substantial enough to overcome these drawbacks. The slightly better BBB penetration of Ligand B is a minor bonus. The DILI risk for both is low. The Caco-2 and solubility values are poor for both, but can be addressed with formulation strategies.
Output:
0
2025-04-17 23:43:28,219 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (363.439 Da and 349.395 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (89.55) is excellent, well below the 140 threshold and favorable for oral absorption. Ligand B (138.26) is still acceptable but closer to the upper limit, potentially impacting absorption.
**3. logP:** Ligand A (1.466) is within the optimal 1-3 range. Ligand B (-1.658) is slightly negative, which could hinder membrane permeability.
**4. H-Bond Donors:** Ligand A (2) and Ligand B (4) are both acceptable, but Ligand A is preferable.
**5. H-Bond Acceptors:** Both ligands have 7 HBA, which is acceptable.
**6. QED:** Ligand A (0.782) has a significantly better QED score than Ligand B (0.499), indicating a more drug-like profile.
**7. DILI:** Ligand A (77.937) has a higher DILI risk than Ligand B (52.036), which is a negative for Ligand A.
**8. BBB:** Ligand B (62.389) shows better BBB penetration than Ligand A (40.326). While ADRB2 isn't strictly a CNS target, some CNS exposure can be beneficial or at least not detrimental, and minimizing off-target effects is always good.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual. However, the magnitude of negativity is similar, so this isn't a major differentiator.
**10. Aqueous Solubility:** Both ligands have negative solubility values, which is also unusual. Again, the magnitude is similar.
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (0.36 and 0.31).
**12. Microsomal Clearance:** Ligand B (-23.987) has a significantly lower (better) microsomal clearance than Ligand A (27.173), suggesting greater metabolic stability.
**13. In vitro Half-Life:** Ligand B (-9.365) has a longer in vitro half-life than Ligand A (16.146), which is desirable.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.04 and 0.001).
**15. Binding Affinity:** Ligand A (-8.0) has a slightly better binding affinity than Ligand B (-6.5). The difference is 1.5 kcal/mol, which is significant.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand A is slightly favored due to its superior binding affinity and TPSA. However, Ligand B has a better QED, lower DILI risk, better metabolic stability (lower Cl_mic, longer t1/2), and better BBB penetration. The negative logP and solubility values for both are concerning, but similar. The affinity difference is significant, but the ADME profile of Ligand B is more balanced and potentially more favorable for *in vivo* performance.
Therefore, I would choose Ligand B.
0
2025-04-17 23:43:28,219 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (362.539 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (58.2) is significantly better than Ligand B (127.32). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand B is quite high and could present absorption challenges.
3. **logP:** Ligand A (3.141) is optimal, while Ligand B (1.244) is on the lower side. A logP between 1-3 is preferred, and Ligand A is closer to this ideal.
4. **HBD:** Ligand A (2) is preferable to Ligand B (3). Fewer HBDs generally improve membrane permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (6). Similar reasoning as HBD.
6. **QED:** Ligand A (0.783) is better than Ligand B (0.657), indicating a more drug-like profile.
7. **DILI:** Ligand A (38.852) has a significantly lower DILI risk than Ligand B (79.682). This is a crucial advantage.
8. **BBB:** Both are around 55-57%, so this parameter is not a significant differentiator for a cardiovascular target.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the absolute value for Ligand A (-5.009) is less negative than Ligand B (-5.255), suggesting slightly better permeability.
10. **Solubility:** Both have negative solubility values, which is also unusual. Ligand A (-3.846) is slightly better than Ligand B (-3.789).
11. **hERG:** Both ligands have low hERG inhibition risk (0.381 and 0.261).
12. **Cl_mic:** Ligand B (34.747) has a lower microsomal clearance than Ligand A (77.305), indicating better metabolic stability. This is a positive for Ligand B.
13. **t1/2:** Ligand A (12.104) has a longer in vitro half-life than Ligand B (9.674). This is a positive for Ligand A.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.204 and 0.129).
15. **Binding Affinity:** Ligand B (-8.3 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.0 kcal/mol). This is a substantial advantage, exceeding the 1.5 kcal/mol threshold.
**Overall Assessment:**
Ligand B has a much stronger binding affinity, which is a major advantage for a GPCR target. However, it suffers from a higher TPSA, higher DILI risk, and higher microsomal clearance. Ligand A has better ADME properties (TPSA, DILI, QED, t1/2) and a reasonable binding affinity.
Despite the affinity difference, the significantly improved safety profile (DILI) and better ADME properties of Ligand A make it the more promising candidate. The affinity difference, while substantial, can potentially be addressed through further optimization, while mitigating the DILI risk of Ligand B could be more challenging.
Output:
1
2025-04-17 23:43:28,219 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
The ADRB2 receptor is a GPCR, so the priorities are logP, Pgp, TPSA, affinity, and BBB. Let's compare the ligands:
1. **Molecular Weight:** Both ligands (345.447 and 356.457 Da) are within the ideal 200-500 Da range.
2. **TPSA:** Ligand B (40.62) is significantly better than Ligand A (80.55). Lower TPSA generally improves permeability, which is crucial for GPCR ligands.
3. **logP:** Both ligands have good logP values (3.322 and 3.474), falling within the optimal 1-3 range.
4. **H-Bond Donors/Acceptors:** Ligand B (0 HBD, 2 HBA) is preferable to Ligand A (2 HBD, 5 HBA) as fewer hydrogen bonds can improve membrane permeability.
5. **QED:** Ligand A (0.871) has a better QED score than Ligand B (0.655), indicating a more drug-like profile. However, this is less critical than permeability for a GPCR.
6. **DILI:** Ligand B (42.885) has a slightly lower DILI risk than Ligand A (56.068), which is a positive.
7. **BBB:** Ligand B (96.316) has a much higher BBB penetration percentile than Ligand A (86.778). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be beneficial or at least needs to be considered.
8. **Caco-2 Permeability:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
9. **Aqueous Solubility:** Both have negative solubility values, which is also unusual.
10. **hERG:** Both ligands have low hERG inhibition liability (0.383 and 0.611), which is good.
11. **Microsomal Clearance:** Ligand B (52.339) has higher microsomal clearance than Ligand A (40.959), meaning it's metabolized faster. This is a drawback.
12. **In vitro Half-Life:** Ligand A (37.013 hours) has a significantly longer half-life than Ligand B (-24.123 hours). This is a significant advantage.
13. **P-gp Efflux:** Both ligands have low P-gp efflux liability (0.083 and 0.261).
14. **Binding Affinity:** Both ligands have very similar binding affinities (-5.5 and -5.6 kcal/mol). The difference is negligible.
**Overall Assessment:**
Ligand B is preferable due to its significantly lower TPSA and higher BBB penetration, both critical for GPCR targets. While Ligand A has a better QED and half-life, the permeability advantages of Ligand B outweigh these benefits. The slightly higher DILI risk in Ligand A is also a concern. The negative solubility and Caco-2 values are concerning for both, but the TPSA difference is the deciding factor.
**Output:**
0
2025-04-17 23:43:28,219 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (412.3) is within the ideal range (200-500), while Ligand B (383.3) is also excellent. No clear advantage here.
2. **TPSA:** Ligand A (70.23) is acceptable, but higher than ideal for a GPCR. Ligand B (58.2) is better, falling comfortably below the 90 threshold. This favors B.
3. **logP:** Both ligands (A: 2.648, B: 3.139) are within the optimal 1-3 range. B is slightly higher, potentially aiding membrane permeability.
4. **HBD:** Ligand A (3) and Ligand B (2) are both acceptable. B is slightly better.
5. **HBA:** Ligand A (3) and Ligand B (2) are both acceptable. B is slightly better.
6. **QED:** Both ligands have good QED scores (A: 0.515, B: 0.768), but B is significantly better, indicating a more drug-like profile. This favors B.
7. **DILI:** Ligand A (41.88) and Ligand B (36.45) are both below the 40% threshold, indicating low risk. B is slightly better.
8. **BBB:** Ligand A (49.9) is moderate, while Ligand B (61.96) is better, suggesting improved potential for CNS penetration, though this is less critical for ADRB2 which is primarily cardiovascular.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.802) is slightly better than Ligand B (-5.075).
10. **Solubility:** Both ligands have negative solubility values, which is also unusual. Ligand A (-3.63) is slightly better than Ligand B (-3.859).
11. **hERG:** Both ligands have low hERG inhibition risk (A: 0.639, B: 0.434). B is better.
12. **Cl_mic:** Ligand A (15.51) and Ligand B (17.18) have similar microsomal clearance values, indicating similar metabolic stability.
13. **t1/2:** Ligand A (58.5) has a significantly longer in vitro half-life than Ligand B (20.9). This is a major advantage for A.
14. **Pgp:** Both ligands have low P-gp efflux liability (A: 0.135, B: 0.262). A is better.
15. **Binding Affinity:** Ligand B (-7.8 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.3 kcal/mol). This is a substantial advantage for B, potentially outweighing some of A's ADME benefits.
**Overall Assessment:**
Ligand B demonstrates a superior balance of properties, particularly in terms of drug-likeness (QED), TPSA, and crucially, binding affinity. While Ligand A has a longer half-life and slightly better Caco-2/solubility, the significantly stronger binding affinity of Ligand B is a decisive factor for a GPCR target like ADRB2. The improved QED, DILI, BBB, and hERG profiles of B further solidify its position as the more promising candidate.
Output:
0
2025-04-17 23:43:28,219 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [354.451, 110.77 , -0.18 , 4. , 4. , 0.508, 20.279, 40.132, -5.309, -0.905, 0.089, -4.937, 12.201, 0.003, -5.1 ]
**Ligand B:** [406.28 , 68.46 , 3.112, 0. , 5. , 0.69 , 44.824, 83.831, -4.453, -4.189, 0.78 , 77.297, 26.264, 0.426, -6.2 ]
**Step-by-step comparison:**
1. **MW:** Ligand A (354.451 Da) is within the ideal range, while Ligand B (406.28 Da) is at the higher end, but still acceptable.
2. **TPSA:** Ligand A (110.77) is slightly above the optimal <140 for oral absorption, but not drastically so. Ligand B (68.46) is excellent, well below 140 and favorable for permeability.
3. **logP:** Ligand A (-0.18) is quite low, potentially hindering membrane permeability. Ligand B (3.112) is within the optimal 1-3 range. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (4) is acceptable. Ligand B (0) is even better, potentially improving permeability.
5. **HBA:** Both ligands (A: 4, B: 5) are within the acceptable limit of 10.
6. **QED:** Both ligands have good QED scores (A: 0.508, B: 0.69), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (20.279) has a much lower DILI risk than Ligand B (44.824). This is a substantial advantage for Ligand A.
8. **BBB:** Ligand B (83.831) has a much higher BBB penetration potential than Ligand A (40.132). Given that ADRB2 is a GPCR, and CNS side effects are a consideration, this is a significant advantage for Ligand B.
9. **Caco-2:** Ligand A (-5.309) has a negative Caco-2 value, which is concerning. Ligand B (-4.453) is also negative, but less so. Both are poor, but Ligand B is slightly better.
10. **Solubility:** Ligand A (-0.905) has poor solubility. Ligand B (-4.189) is even worse. This is a drawback for both.
11. **hERG:** Ligand A (0.089) has a very low hERG risk, which is excellent. Ligand B (0.78) is higher, indicating a moderate risk. This favors Ligand A.
12. **Cl_mic:** Ligand A (-4.937) has a negative clearance, which is very good, indicating high metabolic stability. Ligand B (77.297) has a high clearance, suggesting rapid metabolism. This is a strong advantage for Ligand A.
13. **t1/2:** Ligand A (12.201) has a reasonable half-life. Ligand B (26.264) has a longer half-life, which is generally desirable.
14. **Pgp:** Ligand A (0.003) has very low P-gp efflux, which is excellent. Ligand B (0.426) has moderate P-gp efflux. This favors Ligand A.
15. **Affinity:** Ligand B (-6.2) has a stronger binding affinity than Ligand A (-5.1). This is a 1.1 kcal/mol difference, which is significant and can outweigh some ADME drawbacks.
**Overall Assessment:**
While Ligand B has a superior binding affinity and better BBB penetration, the significant drawbacks in solubility, metabolic stability (high Cl_mic), and moderate hERG risk are concerning. Ligand A, despite its lower affinity, exhibits a much better safety profile (low DILI, low hERG), excellent metabolic stability, and low P-gp efflux. The low logP and solubility are concerning, but the strong affinity of Ligand B is not enough to overcome the ADME liabilities.
Given the GPCR-specific priorities (logP, Pgp, TPSA, affinity) and the need for a balanced profile, I believe **Ligand B** is the more promising candidate due to its significantly better binding affinity and favorable BBB penetration. The ADME properties can be further optimized during lead optimization, but a strong starting affinity is crucial.
Output:
0
2025-04-17 23:43:28,220 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (337.423) is slightly lower, which could be advantageous for permeability.
2. **TPSA:** Both are below the 140 A^2 threshold for good oral absorption. Ligand A (73.2) is better than Ligand B (78.25), aligning with GPCR preference for lower TPSA.
3. **logP:** Both are within the optimal 1-3 range. Ligand B (1.889) is slightly lower, which could slightly impact permeability.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A (3) is better than Ligand B (6). Lower HBA is preferred for permeability.
6. **QED:** Both have similar, good QED values (A: 0.777, B: 0.784).
7. **DILI:** Ligand B (21.946) has a significantly lower DILI risk than Ligand A (39.705). This is a major advantage for Ligand B.
8. **BBB:** Ligand A (75.107) has a better BBB penetration percentile than Ligand B (61.923). While ADRB2 isn't *strictly* a CNS target, some CNS exposure can be relevant for off-target effects and overall safety.
9. **Caco-2:** Both have negative values, indicating poor permeability. Ligand A (-4.578) is slightly better than Ligand B (-5.091), but both are concerning.
10. **Solubility:** Ligand A (-4.157) has better solubility than Ligand B (-2.447). Solubility is important for bioavailability.
11. **hERG:** Both have low hERG inhibition liability (A: 0.355, B: 0.589).
12. **Cl_mic:** Ligand B (41.171) has lower microsomal clearance than Ligand A (50.238), suggesting better metabolic stability.
13. **t1/2:** Ligand B (3.572) has a longer in vitro half-life than Ligand A (-3.511). This is a significant advantage.
14. **Pgp:** Ligand A (0.218) has lower P-gp efflux than Ligand B (0.054). Lower P-gp is favorable.
15. **Affinity:** Ligand B (-6.7 kcal/mol) has a slightly better binding affinity than Ligand A (-5.7 kcal/mol). This 1 kcal/mol difference is significant and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand B is the stronger candidate. While Ligand A has slightly better TPSA, solubility, and Pgp efflux, Ligand B has a significantly lower DILI risk, better metabolic stability (lower Cl_mic, longer t1/2), and a slightly stronger binding affinity. The lower DILI risk and improved metabolic stability are crucial for drug development, and the affinity difference is substantial enough to compensate for the slightly lower BBB and Caco-2 values. The Caco-2 values for both are poor and would require further investigation, but the overall profile of Ligand B is more promising.
Output:
0
2025-04-17 23:43:28,220 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.475 and 369.527 Da) are within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Both are below the 140 A^2 threshold for good oral absorption (78.51 and 73.91). Ligand B is slightly better.
3. **logP:** Both ligands have logP values within the optimal 1-3 range (1.755 and 2.62). Ligand B is slightly higher, potentially improving membrane permeability.
4. **HBD:** Both have 2 HBD, which is acceptable.
5. **HBA:** Ligand A has 3 HBA, and Ligand B has 5 HBA. Ligand A is slightly better here.
6. **QED:** Both have reasonable QED scores (0.794 and 0.663), indicating good drug-like properties. Ligand A is slightly better.
7. **DILI:** Both have very similar, low DILI risk (25.281 and 25.087 percentile). No significant difference.
8. **BBB:** Ligand A has a significantly higher BBB penetration score (63.862) compared to Ligand B (54.711). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be beneficial or at least less detrimental.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. Ligand B is slightly worse (-5.047 vs -4.935).
10. **Solubility:** Both have negative solubility values, indicating poor solubility. Ligand B is slightly worse (-2.817 vs -2.52).
11. **hERG:** Both have very low hERG inhibition liability (0.143 and 0.809). Ligand A is significantly better.
12. **Cl_mic:** Ligand A has a much lower microsomal clearance (10.749 mL/min/kg) than Ligand B (53.099 mL/min/kg), indicating better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand B has a much longer in vitro half-life (93.106 hours) than Ligand A (-7.535 hours). This is a major advantage for Ligand B.
14. **Pgp:** Ligand A has a very low Pgp efflux liability (0.026) compared to Ligand B (0.799). This is a significant advantage for Ligand A.
15. **Binding Affinity:** Ligand B has a slightly better binding affinity (-7.0 kcal/mol) compared to Ligand A (-6.5 kcal/mol). This is a 0.5 kcal/mol advantage, which is notable.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand B has a slightly better logP and affinity. Ligand A has better TPSA, Pgp and hERG. Metabolic stability (Cl_mic) is also important.
**Overall Assessment:**
Ligand B's significantly longer half-life and slightly better affinity are strong positives. However, Ligand A has a much better metabolic profile (lower Cl_mic), lower Pgp efflux, and better hERG safety. The poor Caco-2 and solubility for both are concerning, but can potentially be addressed with formulation strategies. Given the balance, the improved metabolic stability and safety profile of Ligand A outweigh the slightly better affinity and half-life of Ligand B.
Output:
1
2025-04-17 23:43:28,220 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.5 and 352.5 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (57.26) is significantly better than Ligand B (78.87). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary goal, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (3.23) is optimal, while Ligand B (1.317) is a bit low. A logP between 1-3 is preferred, and Ligand A falls squarely within this range. Ligand B's lower logP could indicate permeability issues.
4. **HBD:** Both ligands have 2 HBD, which is within the acceptable limit of <=5.
5. **HBA:** Ligand A has 3 HBA, and Ligand B has 4. Both are within the acceptable limit of <=10.
6. **QED:** Ligand A (0.831) is better than Ligand B (0.656), indicating a more drug-like profile.
7. **DILI:** Ligand A (8.104%) has a slightly higher DILI risk than Ligand B (6.824%), but both are very low and well below the concerning threshold of 40%.
8. **BBB:** Ligand A (82.668%) has better BBB penetration than Ligand B (55.215%). While not a primary concern for a cardiovascular target, higher BBB is rarely detrimental.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.631 and -4.69). These values are difficult to interpret without knowing the scale, but the similarity suggests similar absorption potential.
10. **Solubility:** Both ligands have negative solubility values (-1.745 and -1.618). Again, the scale is unknown, but the similarity suggests comparable solubility.
11. **hERG:** Ligand A (0.512) has a slightly higher hERG risk than Ligand B (0.27). This is a concern, but both are relatively low.
12. **Cl_mic:** Ligand A (16.199) has significantly lower microsomal clearance than Ligand B (21.145), suggesting better metabolic stability.
13. **t1/2:** Ligand A (50.895) has a much longer in vitro half-life than Ligand B (5.641). This is a significant advantage, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.036) has much lower P-gp efflux liability than Ligand B (0.014), indicating better bioavailability and potentially better tissue distribution.
15. **Binding Affinity:** Ligand B (-7.1 kcal/mol) has a 0.6 kcal/mol stronger binding affinity than Ligand A (-6.5 kcal/mol). This is a substantial difference and a strong point in favor of Ligand B.
**Overall Assessment:**
Ligand B has a better binding affinity, which is crucial. However, Ligand A demonstrates superior ADME properties: better TPSA, logP, QED, metabolic stability (lower Cl_mic), longer half-life, and lower P-gp efflux. The slightly higher hERG risk for Ligand A is a minor concern compared to the ADME advantages. Given the GPCR-specific priorities (logP, Pgp, TPSA, affinity), the combination of reasonable affinity and significantly improved ADME properties makes Ligand A the more promising candidate.
Output:
1
2025-04-17 23:43:28,220 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (380.901 Da and 363.502 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (81.34) is higher than Ligand B (36.44). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is generally preferred for better permeability. Ligand B is significantly better.
**3. logP:** Both ligands have good logP values (3.231 and 3.713), falling within the optimal 1-3 range. Ligand B is slightly higher, potentially improving membrane permeability.
**4. H-Bond Donors:** Ligand A has 1 HBD, while Ligand B has 0. Both are acceptable, but fewer HBDs generally improve permeability. Ligand B is slightly better.
**5. H-Bond Acceptors:** Ligand A has 6 HBA, and Ligand B has 4. Both are within the acceptable limit of 10, but Ligand B is preferable.
**6. QED:** Ligand A (0.861) has a higher QED score than Ligand B (0.752), indicating a more drug-like profile. This is a significant advantage for Ligand A.
**7. DILI Risk:** Ligand A (63.746) has a higher DILI risk than Ligand B (21.946). This is a major concern. Ligand B is significantly better.
**8. BBB Penetration:** While not a primary concern for a cardiovascular target, Ligand B (94.029) has better BBB penetration than Ligand A (79.992).
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.947 and -4.501). This is unusual and suggests poor permeability *in vitro*. However, the values are close, and the scale isn't fully defined here.
**10. Aqueous Solubility:** Both ligands have negative solubility values (-3.596 and -3.395). This is also unusual and suggests poor solubility. Again, values are close.
**11. hERG Inhibition:** Ligand A (0.569) has a slightly lower hERG inhibition risk than Ligand B (0.793), which is preferable.
**12. Microsomal Clearance:** Ligand A (56.297) has a slightly higher microsomal clearance than Ligand B (53.901), suggesting slightly lower metabolic stability.
**13. In vitro Half-Life:** Ligand B (44.095) has a significantly longer in vitro half-life than Ligand A (6.633). This is a substantial advantage for Ligand B.
**14. P-gp Efflux:** Ligand A (0.117) has lower P-gp efflux than Ligand B (0.364), which is preferable.
**15. Binding Affinity:** Ligand A (-8.6 kcal/mol) has a significantly stronger binding affinity than Ligand B (-7.1 kcal/mol). This is a major advantage for Ligand A, potentially outweighing some ADME drawbacks.
**Overall Assessment:**
Ligand A has a significantly better binding affinity and QED score, and slightly better hERG and P-gp profiles. However, Ligand B excels in critical ADME properties: significantly lower DILI risk, better BBB penetration, and a much longer in vitro half-life. The lower TPSA and H-bond counts of Ligand B are also favorable. While the negative Caco-2 and solubility values are concerning for both, the substantial difference in DILI risk and half-life, coupled with the GPCR-specific emphasis on permeability (lower TPSA), tips the balance in favor of Ligand B. The stronger binding of Ligand A is attractive, but a higher DILI risk is a major red flag in drug development.
Output:
0
2025-04-17 23:43:28,220 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (365.451 Da) is slightly higher than Ligand B (347.415 Da), but both are acceptable.
2. **TPSA:** Ligand A (78.67) is better than Ligand B (87.74). Both are below 140, indicating reasonable oral absorption potential, but lower TPSA is generally preferred for GPCRs.
3. **logP:** Ligand A (3.816) is slightly higher than Ligand B (2.243). Both are within the optimal range (1-3), but Ligand A is closer to the upper limit.
4. **HBD:** Ligand A (0) is better than Ligand B (2). Fewer HBDs are generally preferred for better permeability.
5. **HBA:** Ligand A (6) is higher than Ligand B (4). Both are acceptable, but lower is generally better.
6. **QED:** Ligand B (0.741) is better than Ligand A (0.356). Ligand B has a more drug-like profile.
7. **DILI:** Ligand A (47.848) is better than Ligand B (57.193). Both are below 60, indicating low DILI risk, but Ligand A is preferable.
8. **BBB:** Ligand A (77.007) is better than Ligand B (71.656). While ADRB2 isn't strictly a CNS target, some CNS penetration can be beneficial and isn't detrimental.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.452 and -4.705). This is unusual and suggests poor permeability. However, the values are similar.
10. **Solubility:** Ligand A (-5.836) is better than Ligand B (-3.017). Higher solubility is generally preferred.
11. **hERG:** Both ligands have low hERG inhibition liability (0.461 and 0.433).
12. **Cl_mic:** Ligand B (35.93) is significantly better than Ligand A (117.812). Lower clearance indicates better metabolic stability.
13. **t1/2:** Ligand B (6.436) is better than Ligand A (-28.691). A positive half-life is preferable.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.621 and 0.015). Ligand B is slightly better.
15. **Binding Affinity:** Ligand A (-7.0) is slightly better than Ligand B (-6.4). This is a significant advantage.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A has a better logP and affinity, while Ligand B has a better QED and metabolic stability (Cl_mic and t1/2). The affinity difference is substantial (0.6 kcal/mol), and this outweighs the slightly less favorable metabolic properties of Ligand A.
**Conclusion:**
Despite Ligand B's better QED and metabolic stability, Ligand A's superior binding affinity and generally favorable ADME properties (TPSA, logP, BBB, solubility, DILI) make it the more promising drug candidate for ADRB2.
Output:
1
2025-04-17 23:43:28,220 - INFO - Batch 425 complete. Total preferences: 6800
2025-04-17 23:43:28,221 - INFO - Processing batch 426/512...
2025-04-17 23:44:13,462 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (352.391 and 353.463 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (102.88) is higher than Ligand B (70.16). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B has a clear advantage.
3. **logP:** Ligand A (1.068) is slightly higher than Ligand B (0.587), both are within the optimal 1-3 range. Ligand A is slightly better.
4. **HBD:** Ligand A (1) is slightly higher than Ligand B (0). Both are acceptable.
5. **HBA:** Ligand A (7) is higher than Ligand B (5). Lower is better for permeability, giving a slight edge to Ligand B.
6. **QED:** Ligand A (0.864) is significantly better than Ligand B (0.597), indicating a more drug-like profile. This is a substantial advantage for Ligand A.
7. **DILI:** Ligand B (14.347) has a *much* lower DILI risk than Ligand A (68.98). This is a major advantage for Ligand B. DILI risk is a critical factor.
8. **BBB:** Both ligands have similar BBB penetration (Ligand A: 71.811, Ligand B: 70.609). As ADRB2 is not a CNS target, this is not a primary concern.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.309 and -4.487). This is unusual and suggests poor permeability. However, the values are similar.
10. **Solubility:** Ligand A (-2.959) is better than Ligand B (0.026), indicating better aqueous solubility. Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.152) has a slightly lower hERG risk than Ligand B (0.247). Lower is better.
12. **Cl_mic:** Ligand B (44.142) has a lower microsomal clearance than Ligand A (36.936), suggesting better metabolic stability. This is a positive for Ligand B.
13. **t1/2:** Ligand B (-24.795) has a longer in vitro half-life than Ligand A (-18.976). This is a positive for Ligand B.
14. **Pgp:** Ligand A (0.032) has lower P-gp efflux than Ligand B (0.009). Lower is better.
15. **Affinity:** Both ligands have very similar binding affinities (-7.7 and -7.0 kcal/mol). The difference is less than the 1.5 kcal/mol threshold.
**Overall Assessment:**
Ligand A has advantages in QED, solubility, and Pgp efflux. However, Ligand B significantly outperforms Ligand A in DILI risk, metabolic stability (Cl_mic), and in vitro half-life. The lower DILI risk is a critical advantage, outweighing the benefits of Ligand A's slightly better QED and solubility. While both have poor Caco-2 permeability, this is a shared issue. The binding affinity is comparable. Given the GPCR target class, balancing logP, TPSA, and affinity is important, and Ligand B is competitive in these areas.
Output:
0
2025-04-17 23:44:13,463 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (354.411 Da) is within the ideal range (200-500 Da). Ligand B (399.705 Da) is also acceptable. No clear advantage here.
2. **TPSA:** Ligand A (121.61) is good for oral absorption, being under 140. Ligand B (49.41) is excellent. Ligand B is better.
3. **logP:** Ligand A (-0.059) is slightly low, potentially hindering permeation. Ligand B (4.23) is high and could lead to solubility issues and off-target effects. Ligand A is better.
4. **HBD:** Ligand A (3) is acceptable. Ligand B (1) is good. Ligand B is better.
5. **HBA:** Ligand A (7) is acceptable. Ligand B (2) is excellent. Ligand B is better.
6. **QED:** Both ligands (A: 0.696, B: 0.618) are above 0.5, indicating good drug-likeness. Ligand A is slightly better.
7. **DILI:** Ligand A (38.581) has a lower DILI risk than Ligand B (64.521). Ligand A is better.
8. **BBB:** Ligand A (61.613) is moderate. Ligand B (58.782) is also moderate. Since ADRB2 is a cardiovascular target, BBB penetration is not a high priority, so this is a minor difference.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.921) is slightly better than Ligand B (-4.455).
10. **Solubility:** Ligand A (-1.226) is slightly better than Ligand B (-5.645).
11. **hERG:** Ligand A (0.072) has a very low hERG risk. Ligand B (0.572) is higher. Ligand A is significantly better.
12. **Cl_mic:** Ligand A (15.143) has a lower microsomal clearance, indicating better metabolic stability, than Ligand B (80.345). Ligand A is much better.
13. **t1/2:** Ligand A (-10.517) has a negative half-life, which is concerning. Ligand B (46.417) is good. Ligand B is better.
14. **Pgp:** Ligand A (0.013) has very low P-gp efflux. Ligand B (0.232) is higher. Ligand A is better.
15. **Affinity:** Both ligands have the same binding affinity (-7.0 kcal/mol).
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand B excels in TPSA and HBA, but suffers from a high logP and higher Pgp efflux. Ligand A has a better overall profile, with a lower DILI risk, better metabolic stability, lower hERG risk, and lower Pgp efflux. While its logP is suboptimal, the other advantages outweigh this. The negative half-life for Ligand A is a significant concern, but can be addressed through structural modifications.
**Conclusion:**
Considering the balance of properties and the priorities for a GPCR target, Ligand A is the more promising candidate.
Output:
1
2025-04-17 23:44:13,463 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Ligand A (411.256 Da) is within the ideal range, while Ligand B (350.463 Da) is also acceptable, leaning towards the lower end. No strong preference here.
2. **TPSA:** Ligand A (95.79) is slightly higher than ideal for good oral absorption (<=140), but still reasonable. Ligand B (83.36) is excellent. This favors Ligand B.
3. **logP:** Both ligands have good logP values (A: 1.991, B: 2.427), falling within the 1-3 range. No strong preference.
4. **HBD:** Both have 1 HBD, which is good. No preference.
5. **HBA:** Both have 5 HBA, which is good. No preference.
6. **QED:** Ligand B (0.716) has a better QED score than Ligand A (0.456), indicating a more drug-like profile. This favors Ligand B.
7. **DILI:** Ligand A (65.568) has a higher DILI risk than Ligand B (35.556). This strongly favors Ligand B.
8. **BBB:** Ligand A (83.172) has a better BBB penetration score than Ligand B (64.831). However, for a cardiovascular target like ADRB2, BBB penetration is not a primary concern.
9. **Caco-2:** Ligand A (-4.598) and Ligand B (-5.023) both have negative values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
10. **Solubility:** Ligand A (-3.96) and Ligand B (-1.804) both have negative values, suggesting poor solubility. Again, the scale is unknown.
11. **hERG:** Ligand A (0.677) has a lower hERG risk than Ligand B (0.187). This favors Ligand A.
12. **Cl_mic:** Ligand A (1.018) has much lower microsomal clearance than Ligand B (24.188), indicating better metabolic stability. This strongly favors Ligand A.
13. **t1/2:** Ligand A (19.541) has a longer in vitro half-life than Ligand B (14.903). This favors Ligand A.
14. **Pgp:** Ligand A (0.165) has lower P-gp efflux liability than Ligand B (0.036). This favors Ligand A.
15. **Affinity:** Ligand A (-7.4 kcal/mol) has a slightly better binding affinity than Ligand B (-6.9 kcal/mol). This favors Ligand A.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity) and the general drug-like properties, Ligand A appears to be the better candidate. While Ligand B has a better QED and lower DILI risk, Ligand A has superior metabolic stability (Cl_mic, t1/2), P-gp efflux, binding affinity, and a slightly better BBB score (though less important for a cardiovascular target). The affinity difference is significant enough to outweigh the benefits of Ligand B.
Output:
1
2025-04-17 23:44:13,463 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (351.491 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (72.88) is better than Ligand B (33.2). Lower TPSA generally improves oral absorption, and is especially important for GPCRs.
3. **logP:** Ligand A (1.129) is within the optimal range, while Ligand B (4.215) is pushing the upper limit. High logP can lead to solubility issues and off-target effects.
4. **HBD:** Ligand A (2) is preferable to Ligand B (0). Having some HBD can improve solubility.
5. **HBA:** Both ligands have 4 HBA, which is acceptable.
6. **QED:** Both ligands have similar QED scores (0.752 and 0.76), indicating good drug-likeness.
7. **DILI:** Ligand A (6.902) has a significantly lower DILI risk than Ligand B (40.985). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (97.286) has a much higher BBB penetration than Ligand A (48.352). While ADRB2 isn't strictly a CNS target, some CNS exposure can be acceptable and even beneficial depending on the desired therapeutic profile.
9. **Caco-2:** Both ligands have similar, negative Caco-2 values, suggesting poor permeability.
10. **Solubility:** Ligand A (-1.129) has better solubility than Ligand B (-4.188).
11. **hERG:** Ligand A (0.306) has a much lower hERG inhibition liability than Ligand B (0.796). This is a critical safety parameter.
12. **Cl_mic:** Ligand A (4.968) has lower microsomal clearance, indicating better metabolic stability, than Ligand B (57.544).
13. **t1/2:** Ligand A (21.408) has a longer in vitro half-life than Ligand B (4.366).
14. **Pgp:** Ligand A (0.018) has much lower P-gp efflux liability than Ligand B (0.575). Lower Pgp is generally favorable for bioavailability.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.4 and -6.5 kcal/mol). The difference is negligible.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A has better TPSA, logP, and Pgp values. While Ligand B has better BBB penetration, the other advantages of Ligand A, especially the significantly lower DILI and hERG risks, outweigh this benefit. The similar binding affinities make the ADME/Tox profile the deciding factor.
**Conclusion:**
Ligand A presents a significantly more favorable ADME-Tox profile with lower risks of liver injury and cardiotoxicity, better metabolic stability, and lower P-gp efflux.
Output:
1
2025-04-17 23:44:13,463 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
Let's analyze each ligand against the provided criteria, keeping in mind the GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key).
* **Molecular Weight:** Both ligands (336.351 and 344.415 Da) fall comfortably within the ideal 200-500 Da range.
* **TPSA:** Ligand A (95.3) is slightly higher than Ligand B (87.32). Both are acceptable for a non-CNS GPCR target like ADRB2, being below 140.
* **logP:** Ligand A (3.068) is better than Ligand B (1.566). A logP between 1-3 is optimal, and Ligand A is closer to the upper end of this range, suggesting better membrane permeability. Ligand B is a bit low, potentially hindering permeation.
* **H-Bond Donors/Acceptors:** Ligand A (1 HBD, 6 HBA) is preferable to Ligand B (2 HBD, 4 HBA). Fewer H-bonds generally improve permeability.
* **QED:** Both ligands have good QED scores (0.786 and 0.881), indicating good drug-like properties.
* **DILI:** Ligand B (56.805) has a significantly lower DILI risk than Ligand A (81.427). This is a major advantage for Ligand B.
* **BBB:** Both have moderate BBB penetration, but Ligand A (71.733) is higher than Ligand B (49.515). Since ADRB2 isn't a primary CNS target, this isn't a decisive factor, but slightly favors A.
* **Caco-2 Permeability:** Both are negative, indicating poor permeability.
* **Aqueous Solubility:** Both are negative, indicating poor solubility.
* **hERG:** Ligand A (0.892) has a higher hERG risk than Ligand B (0.611), making Ligand B safer from a cardiotoxicity perspective.
* **Microsomal Clearance:** Ligand B (14.276) has a much lower microsomal clearance than Ligand A (48.562), indicating better metabolic stability. This is a significant advantage for Ligand B.
* **In vitro Half-Life:** Ligand A (33.063) has a longer half-life than Ligand B (-7.673). This is a positive for Ligand A.
* **P-gp Efflux:** Ligand A (0.438) has lower P-gp efflux than Ligand B (0.047), which is preferable.
* **Binding Affinity:** Ligand B (-6.4 kcal/mol) has a significantly stronger binding affinity than Ligand A (-1.2 kcal/mol). This is a *major* advantage for Ligand B, easily outweighing minor ADME drawbacks.
**Overall Assessment:**
While Ligand A has some advantages (slightly better BBB, longer half-life, lower P-gp efflux), Ligand B's superior binding affinity (-6.4 vs -1.2 kcal/mol) and significantly lower DILI and microsomal clearance are critical. The stronger binding affinity is likely to translate to greater efficacy, and the improved ADME properties (lower DILI, lower clearance) suggest a better safety profile and potentially longer duration of action. The lower logP of Ligand B is a concern, but the substantial affinity advantage is likely to compensate for this.
**Output:**
0
2025-04-17 23:44:13,463 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (370.833 and 383.857 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (99.88) is slightly higher than Ligand B (92.51). Both are below the 140 threshold for oral absorption, but closer to the 90 threshold for CNS targets (less relevant for ADRB2, a cardiovascular target).
3. **logP:** Both ligands have good logP values (1.615 and 1.995), falling within the optimal 1-3 range. Ligand B is slightly higher, potentially aiding membrane permeability.
4. **HBD:** Ligand A has 2 HBD, while Ligand B has 1. Lower is generally preferred for permeability, giving a slight edge to Ligand B.
5. **HBA:** Both ligands have 5 HBA, which is acceptable (<=10).
6. **QED:** Ligand B (0.852) has a significantly better QED score than Ligand A (0.688), indicating a more drug-like profile.
7. **DILI:** Ligand B (84.335) has a higher DILI risk than Ligand A (51.221). This is a significant drawback for Ligand B.
8. **BBB:** Ligand A (81.388) has a higher BBB penetration percentile than Ligand B (53.625). While not a primary concern for ADRB2, higher BBB is generally favorable.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual. Assuming these are percentile scores, Ligand A (-4.884) is better than Ligand B (-5.069).
10. **Solubility:** Both have negative solubility values, which is also unusual. Ligand A (-3.463) is slightly better than Ligand B (-4.098).
11. **hERG:** Both ligands have very low hERG inhibition liability (0.153 and 0.331), which is excellent.
12. **Cl_mic:** Ligand A (31.896) has a lower microsomal clearance than Ligand B (69.124), suggesting better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (-17.797) has a longer in vitro half-life than Ligand B (-20.129). Again, assuming these are percentile scores, a lower value is better, so Ligand B is slightly better here.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.139 and 0.245).
15. **Binding Affinity:** Ligand B (-6.5 kcal/mol) has a slightly better binding affinity than Ligand A (-5.8 kcal/mol). This is a 0.7 kcal/mol difference, which is a reasonable advantage.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Both ligands perform well on logP and Pgp. Ligand B has a slightly better affinity, but the difference isn't massive. Ligand A has better metabolic stability (lower Cl_mic and longer t1/2) and a significantly lower DILI risk. The QED score is also better for Ligand B.
**Overall Assessment:**
While Ligand B has a slightly better binding affinity and QED, the significantly higher DILI risk and poorer metabolic stability (higher Cl_mic) are major concerns. Ligand A, despite its slightly weaker affinity, presents a much more favorable safety and pharmacokinetic profile. The difference in affinity is not large enough to overcome the ADME/Tox liabilities of Ligand B.
Output:
1
2025-04-17 23:44:13,463 - INFO - Here's my reasoning and the final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, key priorities are logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB.
Let's break down the comparison:
1. **MW:** Both ligands (361.433 and 352.435 Da) fall within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (70.67) is significantly better than Ligand B (87.91). A lower TPSA generally favors oral absorption, crucial for a cardiovascular drug.
3. **logP:** Ligand A (0.806) is slightly outside the optimal 1-3 range, but acceptable. Ligand B (0.209) is quite low, potentially hindering membrane permeability.
4. **HBD/HBA:** Ligand A (2 HBD, 4 HBA) is slightly more balanced than Ligand B (1 HBD, 6 HBA). Both are within acceptable limits.
5. **QED:** Both ligands have good QED scores (0.671 and 0.72), indicating good drug-like properties.
6. **DILI:** Ligand A (11.632) has a much lower DILI risk than Ligand B (15.936), a significant advantage.
7. **BBB:** Ligand A (81.466) shows better BBB penetration than Ligand B (56.301), though this is less critical for a cardiovascular target.
8. **Caco-2:** Ligand A (-5.022) and Ligand B (-4.867) are similar, both indicating reasonable permeability.
9. **Solubility:** Ligand A (-1.466) and Ligand B (-0.389) are similar, both indicating reasonable solubility.
10. **hERG:** Both ligands have very low hERG inhibition risk (0.271 and 0.127), which is excellent.
11. **Cl_mic:** Ligand A (1.883) has significantly lower microsomal clearance than Ligand B (10.922), suggesting better metabolic stability.
12. **t1/2:** Ligand A (-2.562) has a more negative in vitro half-life, which is better than Ligand B (3.831).
13. **Pgp:** Both ligands have very low Pgp efflux liability (0.008 and 0.007).
14. **Binding Affinity:** Ligand B (-6.8 kcal/mol) has a slightly better binding affinity than Ligand A (-5.8 kcal/mol). This is a 1.0 kcal/mol difference, which is noticeable but not overwhelming given the other factors.
**Overall Assessment:**
Ligand A is the stronger candidate. While Ligand B has a slightly better binding affinity, Ligand A excels in crucial ADME properties: lower TPSA, better logP, significantly lower DILI risk, better metabolic stability (lower Cl_mic), and a more favorable half-life. These factors are particularly important for a GPCR target where good bioavailability and reduced off-target effects are essential. The slightly weaker binding affinity of Ligand A can potentially be optimized in subsequent iterations, while fixing the ADME deficiencies of Ligand B would be more challenging.
**Output:**
1
2025-04-17 23:44:13,463 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (351.4 & 344.5 Da) fall comfortably within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (49.41) is significantly better than Ligand A (104.9). ADRB2 is a cardiovascular target, so CNS penetration isn't critical, but lower TPSA generally correlates with better absorption. This favors Ligand B.
3. **logP:** Ligand B (2.827) is closer to the optimal 1-3 range than Ligand A (0.571), which is quite low and could hinder membrane permeability. This is a substantial advantage for Ligand B.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable.
5. **HBA:** Ligand A (6) and Ligand B (2) are both acceptable.
6. **QED:** Ligand A (0.776) is better than Ligand B (0.654), indicating a slightly more drug-like profile.
7. **DILI:** Ligand B (6.204) is significantly better than Ligand A (38.62), indicating a much lower risk of drug-induced liver injury. This is a major advantage for Ligand B.
8. **BBB:** Ligand B (78.945) is better than Ligand A (62.699), though not a primary concern for a cardiovascular target.
9. **Caco-2:** Ligand A (-5.018) is better than Ligand B (-4.752), suggesting slightly better intestinal absorption.
10. **Solubility:** Ligand A (-1.979) is better than Ligand B (-3.438), indicating better aqueous solubility.
11. **hERG:** Ligand A (0.152) is better than Ligand B (0.549), indicating a lower risk of hERG inhibition and cardiotoxicity.
12. **Cl_mic:** Ligand A (-3.731) is much better than Ligand B (28.831), suggesting significantly better metabolic stability. This is a key advantage for Ligand A.
13. **t1/2:** Ligand B (10.386) is better than Ligand A (5.92), indicating a longer half-life.
14. **Pgp:** Ligand A (0.095) is better than Ligand B (0.063), indicating lower P-gp efflux.
15. **Binding Affinity:** Ligand A (-7.3) is significantly better than Ligand B (-5.9). This is a substantial advantage for Ligand A.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in TPSA and has a good logP, while Ligand A has a better Pgp score. However, the *significant* advantage in binding affinity for Ligand A (-7.3 vs -5.9) is the most important factor. A 1.4 kcal/mol difference is substantial and can often outweigh minor ADME drawbacks. The better metabolic stability (Cl_mic) of Ligand A is also a significant plus. While Ligand B has better DILI and t1/2, the affinity difference is too large to ignore.
**Conclusion:**
Despite some advantages of Ligand B in ADME properties, the superior binding affinity and metabolic stability of Ligand A make it the more promising drug candidate for ADRB2.
Output:
1
2025-04-17 23:44:13,464 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [344.411, 66.9, 2.816, 0, 4, 0.808, 24.157, 77.976, -4.656, -2.149, 0.614, 21.641, 3.836, 0.286, -6.1]
**Ligand B:** [362.861, 67.35, 2.34, 1, 5, 0.833, 71.694, 74.952, -5.039, -3.164, 0.534, 44.904, 24.748, 0.219, -6.9]
Here's a breakdown, considering the GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal range (200-500 Da). A is slightly lower (344 vs 363), which is generally favorable for permeability.
2. **TPSA:** Both are good, below the 140 threshold for oral absorption (A: 66.9, B: 67.35).
3. **logP:** Both are within the optimal range (1-3), A (2.816) is slightly higher than B (2.34). This could be a slight advantage for membrane permeability.
4. **HBD/HBA:** A (0/4) has fewer H-bonds than B (1/5). Fewer H-bonds generally improve permeability, so A is slightly better here.
5. **QED:** Both are good (>0.5), indicating drug-like properties (A: 0.808, B: 0.833). B is marginally better.
6. **DILI:** A (24.157) has a significantly lower DILI risk than B (71.694). This is a major advantage for A.
7. **BBB:** Both have good BBB penetration (A: 77.976, B: 74.952), but A is better.
8. **Caco-2:** Both are negative, indicating poor permeability. B is slightly worse (-5.039 vs -4.656).
9. **Solubility:** Both are negative, indicating poor solubility. B is worse (-3.164 vs -2.149).
10. **hERG:** Both are low risk (A: 0.614, B: 0.534).
11. **Cl_mic:** A (21.641) has a lower microsomal clearance than B (44.904), suggesting better metabolic stability.
12. **t1/2:** B (24.748) has a longer in vitro half-life than A (3.836). This is a significant advantage for B.
13. **Pgp:** Both have low P-gp efflux (A: 0.286, B: 0.219). B is slightly better.
14. **Affinity:** B (-6.9 kcal/mol) has a stronger binding affinity than A (-6.1 kcal/mol). This is a substantial advantage for B (a 0.8 kcal/mol difference).
**Overall Assessment:**
While Ligand B has a better binding affinity and slightly better Pgp efflux and half-life, Ligand A has a significantly better safety profile (DILI) and slightly better BBB penetration and metabolic stability. The affinity difference between B and A is not large enough to overcome the substantial DILI risk associated with B. Given the cardiovascular target, minimizing off-target effects and toxicity is crucial. A's better ADME properties, particularly the lower DILI risk, make it the more promising candidate.
Output:
1
2025-04-17 23:44:13,464 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (346.475 Da) is better than Ligand B (378.485 Da), falling comfortably within the 200-500 Da range. Both are acceptable.
2. **TPSA:** Ligand B (49.85) is significantly better than Ligand A (86.88). Lower TPSA generally favors better permeability, crucial for GPCRs.
3. **logP:** Both ligands have good logP values (A: 2.796, B: 2.107), falling within the optimal 1-3 range. Ligand B is slightly lower, which could be beneficial for solubility.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (0). Both are acceptable, but lower is generally preferred.
5. **HBA:** Ligand B (4) is better than Ligand A (3). Both are within the acceptable range of <=10.
6. **QED:** Both ligands have good QED scores (A: 0.633, B: 0.71), indicating good drug-like properties.
7. **DILI:** Ligand B (31.485) is significantly better than Ligand A (50.136). Lower DILI risk is highly desirable.
8. **BBB:** Ligand B (85.731) is much better than Ligand A (46.84). While ADRB2 isn't exclusively a CNS target, some cardiovascular effects can be mediated centrally, and higher BBB penetration can be advantageous.
9. **Caco-2:** Ligand A (-5.204) is better than Ligand B (-4.464). Higher Caco-2 permeability is preferred.
10. **Solubility:** Ligand A (-3.488) is better than Ligand B (-2.906). Higher solubility is generally preferred.
11. **hERG:** Both ligands have similar hERG inhibition liability (A: 0.6, B: 0.643), which is acceptable.
12. **Cl_mic:** Ligand B (39.309) has lower microsomal clearance than Ligand A (57.161), indicating better metabolic stability.
13. **t1/2:** Ligand B (-6.872) has a better in vitro half-life than Ligand A (-11.598).
14. **Pgp:** Both ligands have similar Pgp efflux liability (A: 0.228, B: 0.191).
15. **Binding Affinity:** Ligand B (-6.5 kcal/mol) is slightly better than Ligand A (-7.0 kcal/mol). Although A has a slightly better affinity, the difference is not substantial enough to outweigh the other advantages of B.
**GPCR-Specific Priorities:**
Considering ADRB2 is a GPCR, logP, TPSA, Pgp, and affinity are key. Ligand B excels in TPSA and BBB penetration, and has a good logP. The affinity difference is minor. The significant advantage of Ligand B in DILI risk and metabolic stability (lower Cl_mic, better t1/2) further strengthens its profile.
**Conclusion:**
Ligand B demonstrates a more favorable balance of properties, especially regarding safety (DILI), metabolic stability, and permeability (TPSA, BBB). While Ligand A has slightly better affinity and Caco-2 permeability, the overall profile of Ligand B is more promising for development as a drug candidate.
Output:
0
2025-04-17 23:44:13,464 - INFO - Here's my reasoning and the final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, prioritizing logP, TPSA, Pgp, and affinity is crucial.
* **Molecular Weight:** Both ligands (358.36 and 341.371 Da) fall within the ideal range (200-500 Da).
* **TPSA:** Ligand A (61.8) is significantly better than Ligand B (109.8). A TPSA under 90 is preferred, and A is much closer to that target.
* **logP:** Ligand A (3.456) is optimal, while Ligand B (0.095) is very low, potentially hindering membrane permeability.
* **H-Bond Donors/Acceptors:** Both have acceptable HBD (2) and HBA (3 for A, 5 for B) counts.
* **QED:** Both are reasonable (0.87 and 0.726), indicating good drug-likeness.
* **DILI:** Ligand A (48.313) has a lower DILI risk than Ligand B (58.86), which is preferable.
* **BBB:** Ligand A (86.739) has a much higher BBB penetration potential than Ligand B (44.901). While not a CNS target, some level of BBB penetration can influence off-target effects.
* **Caco-2:** Ligand A (-4.89) is better than Ligand B (-5.569).
* **Solubility:** Ligand A (-3.297) is better than Ligand B (-2.387).
* **hERG:** Ligand A (0.816) is better than Ligand B (0.121).
* **Microsomal Clearance:** Ligand B (-19.148) has a *much* lower (better) microsomal clearance than Ligand A (10.583). This suggests better metabolic stability for Ligand B.
* **In vitro Half-Life:** Ligand A (18.614) has a longer half-life than Ligand B (-0.865).
* **P-gp Efflux:** Ligand A (0.171) has lower P-gp efflux than Ligand B (0.012), which is favorable.
* **Binding Affinity:** Ligand A (-7.4 kcal/mol) has a slightly better binding affinity than Ligand B (-6.3 kcal/mol). The difference is 1.1 kcal/mol, which is significant.
**Overall Assessment:**
Ligand A is clearly superior. While Ligand B has better metabolic stability (lower Cl_mic), the significantly better logP, TPSA, BBB, solubility, hERG, and only slightly weaker binding affinity of Ligand A outweigh this benefit. The poor logP of Ligand B is a major concern for oral bioavailability and target engagement. Ligand A is much more likely to be a viable drug candidate.
**Output:**
1
2025-04-17 23:44:13,464 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (361.389 Da) is slightly higher than Ligand B (351.447 Da), but both are acceptable.
2. **TPSA:** Ligand A (78.95) is significantly better than Ligand B (111.29). For a GPCR, lower TPSA is generally preferred for better permeability. Ligand B is approaching a level that could hinder oral absorption.
3. **logP:** Ligand B (0.993) is slightly better than Ligand A (0.101). Both are on the lower side of the optimal range (1-3), but Ligand B is closer. Ligand A's very low logP is a concern for membrane permeability.
4. **HBD:** Ligand A (1) is better than Ligand B (4). Fewer HBDs are generally preferred for better permeability.
5. **HBA:** Ligand A (5) is better than Ligand B (4). Fewer HBAs are generally preferred for better permeability.
6. **QED:** Ligand B (0.504) is slightly better than Ligand A (0.441), indicating a marginally more drug-like profile.
7. **DILI:** Ligand A (23.808) is significantly better than Ligand B (31.64). Lower DILI risk is crucial.
8. **BBB:** Ligand A (66.072) is significantly better than Ligand B (25.126). While ADRB2 isn't exclusively a CNS target, some CNS penetration can be beneficial, and minimizing it isn't a priority.
9. **Caco-2:** Ligand A (-4.859) is better than Ligand B (-5.439). Both are negative, indicating poor permeability.
10. **Solubility:** Ligand A (-0.817) is better than Ligand B (-2.451). Higher solubility is preferred.
11. **hERG:** Ligand A (0.253) is better than Ligand B (0.297). Both are low, indicating minimal hERG risk.
12. **Cl_mic:** Ligand B (15.749) is much better than Ligand A (27.502). Lower clearance indicates better metabolic stability.
13. **t1/2:** Ligand A (-27.274) is better than Ligand B (-3.324). Longer half-life is desirable.
14. **Pgp:** Ligand A (0.009) is much better than Ligand B (0.104). Lower P-gp efflux is preferred for better bioavailability.
15. **Binding Affinity:** Ligand B (-6.0) is slightly better than Ligand A (-6.8). While the difference is small, it's still a factor.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, and affinity. Ligand A excels in TPSA and Pgp, and has a better affinity. Ligand B has a slightly better logP and affinity, but the differences are not substantial enough to outweigh the significant advantages of Ligand A in TPSA, DILI, BBB and Pgp.
**Overall Assessment:**
Ligand A demonstrates a better balance of properties, particularly concerning crucial factors like TPSA, DILI, BBB, and Pgp efflux. While Ligand B has a slightly better logP and affinity, the other advantages of Ligand A make it the more promising candidate.
**Output:**
1
2025-04-17 23:44:13,464 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (366.49 & 343.43 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (59.31) is significantly better than Ligand B (78.43). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have similar logP values (0.845 & 0.848), falling within the optimal 1-3 range. No clear advantage.
4. **HBD:** Ligand A (0) is preferable to Ligand B (1). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (8) is better than Ligand B (5). While both are acceptable, lower is generally preferred.
6. **QED:** Ligand B (0.877) is slightly better than Ligand A (0.646), indicating a more drug-like profile.
7. **DILI:** Ligand A (39.55) is better than Ligand B (53.08). Lower DILI risk is crucial.
8. **BBB:** Ligand A (78.40) is better than Ligand B (67.55). While not a CNS target, some level of BBB penetration can be useful for distribution.
9. **Caco-2:** Ligand A (-4.733) is better than Ligand B (-5.08). Higher (less negative) Caco-2 values indicate better absorption.
10. **Solubility:** Ligand A (-1.014) is better than Ligand B (-1.186). Higher solubility is desirable.
11. **hERG:** Ligand A (0.881) is better than Ligand B (0.36). Lower hERG inhibition is critical for avoiding cardiotoxicity, which is especially important for a cardiovascular target.
12. **Cl_mic:** Ligand A (39.07) is worse than Ligand B (11.95). Lower clearance is better for metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand A (13.34) is better than Ligand B (9.77). Longer half-life is generally preferred.
14. **Pgp:** Ligand A (0.124) is better than Ligand B (0.036). Lower P-gp efflux is preferred for better bioavailability.
15. **Affinity:** Ligand A (-7.6) is significantly better than Ligand B (-5.6). A 2 kcal/mol difference in binding affinity is substantial and can often outweigh minor ADME drawbacks.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A excels in affinity, TPSA, and Pgp. Ligand B has better metabolic stability (Cl_mic). However, the substantial affinity advantage of Ligand A, coupled with its better safety profile (DILI, hERG) and generally favorable ADME properties, makes it the more promising candidate.
**Output:**
1
2025-04-17 23:44:13,464 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (351.422 and 346.347 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (70.67) is significantly better than Ligand B (126.38). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is above the preferred 90 for CNS targets, and even pushing the limit for general oral absorption.
3. **logP:** Ligand A (1.642) is within the optimal 1-3 range. Ligand B (-0.474) is a bit low, potentially hindering membrane permeability.
4. **HBD:** Both ligands have 2 HBD, which is acceptable.
5. **HBA:** Ligand A (4) is better than Ligand B (8). Lower HBA generally improves permeability.
6. **QED:** Ligand B (0.749) has a slightly better QED score than Ligand A (0.552), suggesting a more drug-like profile overall.
7. **DILI:** Ligand A (35.479) has a significantly lower DILI risk than Ligand B (56.301). This is a crucial advantage.
8. **BBB:** Ligand A (77.123) has a better BBB penetration score than Ligand B (37.263). While ADRB2 isn't strictly a CNS target, some peripheral distribution is still desired, and better BBB penetration often correlates with better overall distribution.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.027 and -5.06), which is unusual and suggests poor permeability. However, these values are close enough that they don't heavily influence the decision.
10. **Solubility:** Both ligands have negative solubility values (-1.794 and -2.442), indicating poor aqueous solubility. This is a concern for both, but Ligand A is slightly better.
11. **hERG:** Ligand A (0.552) has a lower hERG inhibition liability than Ligand B (0.066), which is a significant safety advantage.
12. **Cl_mic:** Ligand A (-1.397) has a lower (better) microsomal clearance than Ligand B (11.093), indicating better metabolic stability.
13. **t1/2:** Ligand A (17.461) has a much longer in vitro half-life than Ligand B (-4.722). This is a major advantage, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.105) has a lower Pgp efflux liability than Ligand B (0.028), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand B (-8.2) has a significantly better binding affinity than Ligand A (-5.5). This is a substantial advantage, exceeding the 1.5 kcal/mol threshold.
**Overall Assessment:**
Ligand B has a superior binding affinity, which is a primary driver for potency. However, it suffers from several significant drawbacks: higher DILI risk, lower BBB penetration, higher hERG inhibition, faster clearance, and higher Pgp efflux. Ligand A, while having weaker affinity, presents a much more balanced profile with better safety (DILI, hERG), improved pharmacokinetic properties (Cl_mic, t1/2, Pgp), and better permeability (TPSA). Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity), the improvements in ADME/Tox properties with Ligand A outweigh the affinity difference, especially given that optimization can potentially improve Ligand A's binding.
Output:
1
2025-04-17 23:44:13,464 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [349.387, 101.41 , 1.126, 3. , 6. , 0.714, 41.877, 47.926, -4.991, -1.346, 0.369, 9.807, 15.107, 0.022, -5.7 ]
**Ligand B:** [353.419, 104.9 , 1.091, 2. , 6. , 0.689, 55.448, 50.523, -4.932, -2.055, 0.142, 17.211, 26.094, 0.121, -5.9 ]
Here's a breakdown, prioritizing GPCR properties (logP, TPSA, Pgp, BBB, and affinity):
1. **Molecular Weight:** Both are within the ideal range (200-500 Da). Ligand A (349.387) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are reasonably good (101.41 and 104.9), being under 140, but not ideal for CNS penetration.
3. **logP:** Both are excellent (1.126 and 1.091), falling right within the optimal 1-3 range.
4. **H-Bond Donors/Acceptors:** Ligand A has 3 HBD and 6 HBA, while Ligand B has 2 HBD and 6 HBA. Both are acceptable.
5. **QED:** Ligand A (0.714) is slightly better than Ligand B (0.689), indicating a more drug-like profile.
6. **DILI:** Ligand A (41.877) has a significantly lower DILI risk than Ligand B (55.448). This is a major advantage.
7. **BBB:** Both have moderate BBB penetration (47.926 and 50.523). Not a primary concern for a cardiovascular target like ADRB2, but higher is generally better.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. This is a significant drawback for both.
9. **Solubility:** Both have negative solubility values, which is also unusual and suggests poor solubility. This is a significant drawback for both.
10. **hERG:** Both have very low hERG inhibition risk (0.369 and 0.142), which is excellent.
11. **Cl_mic:** Ligand A (9.807) has a lower microsomal clearance than Ligand B (17.211), indicating better metabolic stability.
12. **t1/2:** Ligand A (15.107) has a shorter half-life than Ligand B (26.094). This is a slight disadvantage.
13. **Pgp:** Both have very low Pgp efflux liability (0.022 and 0.121), which is excellent.
14. **Binding Affinity:** Ligand B (-5.9) has a slightly better binding affinity than Ligand A (-5.7), but the difference is small (0.2 kcal/mol).
**Overall Assessment:**
Ligand A is the better candidate. While Ligand B has a slightly better binding affinity and half-life, Ligand A's significantly lower DILI risk and better metabolic stability (lower Cl_mic) are more important. The Caco-2 and solubility values are concerning for both, but the lower DILI risk is a critical advantage, especially in the context of cardiovascular drugs where safety is paramount. The small difference in binding affinity can likely be optimized in later stages of development.
Output:
1
2025-04-17 23:44:13,464 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.3 & 369.98 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (44.76) is higher than Ligand B (30.29). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for permeability. Ligand B has a clear advantage.
3. **logP:** Both ligands (4.269 & 4.905) are slightly above the optimal 1-3 range, but still acceptable. Ligand B is a bit higher, potentially raising concerns about solubility and off-target effects, but not dramatically.
4. **HBD:** Both have 0 HBD, which is good.
5. **HBA:** Both have 4 HBA, which is within the acceptable range.
6. **QED:** Ligand A (0.771) has a better QED score than Ligand B (0.587), indicating a more drug-like profile.
7. **DILI:** Ligand A (86.623) has a significantly higher DILI risk than Ligand B (5.777). This is a major red flag for Ligand A.
8. **BBB:** Both ligands have high BBB penetration (84.529 & 89.725). While ADRB2 isn't a primary CNS target, some off-target CNS effects are possible, and high BBB penetration isn't necessarily detrimental in this case.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and likely indicates poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-5.294) has worse solubility than Ligand B (-4.149).
11. **hERG:** Ligand A (0.634) has a slightly better hERG profile than Ligand B (0.919).
12. **Cl_mic:** Ligand A (55.364) and Ligand B (52.444) have similar microsomal clearance values.
13. **t1/2:** Ligand B (42.691) has a much longer in vitro half-life than Ligand A (-1.255). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.755) has slightly better Pgp efflux liability than Ligand B (0.583).
15. **Binding Affinity:** Ligand B (-6.4 kcal/mol) has a significantly stronger binding affinity than Ligand A (-4.8 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME drawbacks.
**GPCR-Specific Priorities & Overall Assessment:**
For ADRB2 (a GPCR), affinity, logP, TPSA, and Pgp are key. Ligand B excels in affinity and has a better TPSA. While logP is slightly higher, the strong affinity and significantly lower DILI risk of Ligand B are compelling. The longer half-life also contributes to its favorability. Ligand A's high DILI risk is a major concern, and its weaker affinity makes it less attractive. The poor Caco-2 values are concerning for both, but can be addressed through formulation strategies.
Output:
0
2025-04-17 23:44:13,464 - INFO - Batch 426 complete. Total preferences: 6816
2025-04-17 23:44:13,464 - INFO - Processing batch 427/512...
2025-04-17 23:45:03,588 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
The ADRB2 receptor is a GPCR, so the priorities are logP, Pgp, TPSA, affinity, and BBB. Let's break down each ligand across the 15 parameters:
* **Molecular Weight:** Both ligands (348.45 & 357.53 Da) fall within the ideal 200-500 Da range.
* **TPSA:** Ligand A (81.75) is better than Ligand B (45.15) as it is still within the acceptable range for oral absorption, but lower TPSA is generally preferred for GPCRs.
* **logP:** Ligand A (-0.12) is suboptimal, being slightly below the preferred 1-3 range. Ligand B (3.64) is excellent, falling comfortably within the optimal range. This is a significant advantage for B.
* **H-Bond Donors/Acceptors:** Ligand A (2 HBD, 4 HBA) is slightly better than Ligand B (0 HBD, 6 HBA) in terms of balancing solubility and permeability.
* **QED:** Both ligands have good QED scores (0.55 & 0.75), indicating drug-like properties.
* **DILI:** Ligand A (22.49%) has a much lower DILI risk than Ligand B (58.43%). This is a major advantage for A.
* **BBB:** Ligand B (78.36%) has a significantly higher BBB penetration potential than Ligand A (46.45%). While ADRB2 isn't *specifically* a CNS target, some peripheral ADRB2 activity can be modulated by CNS effects, and higher BBB penetration can be beneficial.
* **Caco-2:** Both ligands have similar, poor Caco-2 permeability (-5.13 & -4.93).
* **Solubility:** Ligand A (-1.65) has slightly better solubility than Ligand B (-4.47), but both are poor.
* **hERG:** Ligand A (0.20) has a much lower hERG inhibition liability than Ligand B (0.83). This is a critical safety advantage for A.
* **Cl_mic:** Ligand A (-5.39) has significantly better metabolic stability (lower clearance) than Ligand B (114.37). This is a substantial advantage for A.
* **t1/2:** Ligand A (-13.05) has a shorter in vitro half-life than Ligand B (36.98). This is a drawback for A.
* **Pgp:** Ligand A (0.01) has much lower P-gp efflux liability than Ligand B (0.57). This is a significant advantage for A, improving bioavailability.
* **Binding Affinity:** Ligand B (-6.5 kcal/mol) has a slightly better binding affinity than Ligand A (-5.6 kcal/mol). While a 1.5 kcal/mol advantage is usually significant, the other ADME properties of Ligand A are much more favorable.
**Overall Assessment:**
Ligand B has a better logP and binding affinity, and a higher BBB score. However, Ligand A excels in safety (DILI, hERG), metabolic stability (Cl_mic), and P-gp efflux. The poor solubility and Caco-2 permeability are concerns for both, but can be addressed with formulation strategies. Given the importance of minimizing off-target effects and maximizing metabolic stability for a cardiovascular target, and the relatively small affinity difference, Ligand A is the more promising candidate.
**Output:**
1
2025-04-17 23:45:03,588 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (a cardiovascular GPCR) drug candidates.
**Ligand A:** [346.431, 113.32 , 2.591, 4. , 3. , 0.496, 61.07 , 75.378, -4.889, -4.716, 0.4 , 38.157, 22.657, 0.09 , -8.4 ]
**Ligand B:** [360.426, 84.94 , 1.2 , 1. , 5. , 0.467, 33.23 , 79.488, -4.661, -1.75 , 0.377, 54.92 , -12.266, 0.146, -7.2 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal 200-500 Da range. Ligand A (346.431 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (113.32) is higher than Ligand B (84.94). Both are below 140, but B is better positioned for oral absorption and potentially better CNS penetration.
3. **logP:** Ligand A (2.591) is within the optimal range, while Ligand B (1.2) is at the lower end. This could hinder membrane permeability for B.
4. **HBD:** Ligand A (4) is higher than Ligand B (1). Lower is generally better for permeability.
5. **HBA:** Ligand A (3) is lower than Ligand B (5). Lower is generally better for permeability.
6. **QED:** Both are similar (A: 0.496, B: 0.467) and below the ideal 0.5, suggesting some room for improvement in drug-likeness, but not a major differentiating factor.
7. **DILI:** Ligand A (61.07) has a higher DILI risk than Ligand B (33.23). This is a significant concern.
8. **BBB:** Both have good BBB penetration (A: 75.378, B: 79.488), but B is slightly better.
9. **Caco-2:** Both are negative, indicating poor permeability.
10. **Solubility:** Ligand A (-4.716) has worse solubility than Ligand B (-1.75). Solubility is important for bioavailability.
11. **hERG:** Both are low (A: 0.4, B: 0.377), indicating low cardiotoxicity risk.
12. **Cl_mic:** Ligand A (38.157) has lower clearance than Ligand B (54.92), suggesting better metabolic stability.
13. **t1/2:** Ligand A (22.657) has a shorter half-life than Ligand B (-12.266).
14. **Pgp:** Both are low (A: 0.09, B: 0.146), indicating low P-gp efflux.
15. **Affinity:** Ligand A (-8.4) has significantly better binding affinity than Ligand B (-7.2) - a difference of 1.2 kcal/mol. This is a substantial advantage.
**GPCR-Specific Considerations:**
For a cardiovascular GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. While BBB isn't *critical* for a cardiovascular target, it's not detrimental. Ligand A has a better logP, and a *much* better affinity. Ligand B has a better TPSA and slightly better BBB. The DILI risk for Ligand A is concerning.
**Decision:**
The significantly stronger binding affinity of Ligand A (-8.4 kcal/mol vs -7.2 kcal/mol) is a major advantage that likely outweighs the higher DILI risk and lower solubility. A 1.2 kcal/mol difference is substantial, and optimizing the molecule to reduce DILI risk is a more tractable task than improving binding affinity.
**Output:**
1
2025-04-17 23:45:03,589 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (380.725 Da) is slightly higher than Ligand B (351.491 Da), but both are acceptable.
2. **TPSA:** Ligand A (65.22) is better than Ligand B (72.88). Both are below the 140 A^2 threshold for good oral absorption, but lower is generally preferred.
3. **logP:** Ligand A (4.463) is higher than Ligand B (0.987). While 4.463 is approaching the upper limit, it's still within a reasonable range. Ligand B's logP is quite low, which could hinder permeability.
4. **HBD:** Ligand A (0) is better than Ligand B (2). Fewer hydrogen bond donors generally improve permeability.
5. **HBA:** Ligand A (5) is better than Ligand B (4). Both are within the acceptable limit of 10, but lower is still preferred.
6. **QED:** Both ligands have good QED scores (Ligand A: 0.578, Ligand B: 0.748). Ligand B is slightly better here.
7. **DILI:** Ligand A (77.627) has a significantly higher DILI risk than Ligand B (5.118). This is a major concern for Ligand A.
8. **BBB:** Ligand A (68.67) is better than Ligand B (30.942). While ADRB2 isn't strictly a CNS target, some CNS penetration can be beneficial for understanding off-target effects and potential side effects.
9. **Caco-2:** Ligand A (-4.414) is better than Ligand B (-5.017). Higher values indicate better permeability.
10. **Solubility:** Ligand A (-5.47) is better than Ligand B (-1.086). Higher solubility is generally preferred for bioavailability.
11. **hERG:** Ligand A (0.221) is better than Ligand B (0.37). Lower hERG inhibition is crucial for avoiding cardiotoxicity.
12. **Cl_mic:** Ligand A (79.997) is higher than Ligand B (25.251). Lower clearance is preferred for increased metabolic stability.
13. **t1/2:** Ligand A (7.522) is worse than Ligand B (18.008). Longer half-life is generally desired.
14. **Pgp:** Ligand A (0.263) is better than Ligand B (0.028). Lower P-gp efflux is preferred.
15. **Affinity:** Both ligands have the same binding affinity (-6.3 kcal/mol).
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A has a better logP and Pgp profile, while TPSA is slightly better. However, the *extremely* high DILI risk for Ligand A is a dealbreaker. While affinity is the same, the ADME/Tox profile of Ligand A is significantly worse.
**Conclusion:**
Despite Ligand B having a lower logP and a slightly lower QED, its significantly lower DILI risk and better half-life make it the more promising drug candidate. The potential for liver toxicity with Ligand A outweighs its slight advantages in other parameters.
Output:
0
2025-04-17 23:45:03,589 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [336.355, 86.86, 1.342, 1, 7, 0.727, 83.017, 35.867, -5.059, -2.732, 0.549, 41.614, -27.626, 0.068, -7.3]**
**Ligand B: [386.25, 42.68, 4.937, 0, 3, 0.707, 37.611, 84.529, -4.16, -5.325, 0.778, 88.798, 65.181, 0.46, -6.8]**
1. **Molecular Weight:** Ligand A (336.355 Da) is well within the ideal range (200-500 Da). Ligand B (386.25 Da) is also acceptable. No clear advantage here.
2. **TPSA:** Ligand A (86.86) is good, below the 140 threshold for oral absorption. Ligand B (42.68) is excellent. Ligand B is better.
3. **logP:** Ligand A (1.342) is optimal. Ligand B (4.937) is high, potentially leading to solubility issues and off-target effects. Ligand A is better.
4. **H-Bond Donors:** Ligand A (1) is good. Ligand B (0) is also good. No clear advantage.
5. **H-Bond Acceptors:** Ligand A (7) is good. Ligand B (3) is also good. No clear advantage.
6. **QED:** Both ligands (A: 0.727, B: 0.707) have good drug-likeness scores. No clear advantage.
7. **DILI:** Ligand A (83.017) has a higher DILI risk than Ligand B (37.611). Ligand B is significantly better.
8. **BBB:** Ligand A (35.867) has low BBB penetration. Ligand B (84.529) has good BBB penetration. Ligand B is better. (Important for GPCRs, even if not CNS-focused).
9. **Caco-2:** Ligand A (-5.059) is poor. Ligand B (-4.16) is also poor, but slightly better.
10. **Solubility:** Ligand A (-2.732) is poor. Ligand B (-5.325) is very poor. Ligand A is better.
11. **hERG:** Ligand A (0.549) has a lower hERG risk than Ligand B (0.778). Ligand A is better.
12. **Cl_mic:** Ligand A (41.614) has lower clearance, suggesting better metabolic stability. Ligand B (88.798) has higher clearance. Ligand A is better.
13. **t1/2:** Ligand A (-27.626) has a longer half-life. Ligand B (65.181) has a shorter half-life. Ligand A is better.
14. **Pgp:** Ligand A (0.068) has lower P-gp efflux, which is good. Ligand B (0.46) has more P-gp efflux. Ligand A is better.
15. **Binding Affinity:** Ligand A (-7.3) has a slightly better binding affinity than Ligand B (-6.8).
**Overall Assessment:**
Ligand B excels in TPSA, BBB, and DILI. However, it suffers from a high logP, poor solubility, and higher P-gp efflux. Ligand A has a better overall profile, particularly regarding metabolic stability (Cl_mic, t1/2), hERG risk, Pgp efflux, and a slightly better binding affinity. While Ligand B's BBB penetration is good, the overall balance of properties favors Ligand A for development as a drug candidate targeting ADRB2. The slightly better affinity of Ligand A, combined with the improved ADME properties, outweighs the benefits of Ligand B's BBB penetration.
Output:
1
2025-04-17 23:45:03,589 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (381.567) is slightly higher than Ligand B (368.455), but both are acceptable.
2. **TPSA:** Ligand A (62.3) is better than Ligand B (88.1). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally favors absorption.
3. **logP:** Ligand A (3.399) is optimal, while Ligand B (1.71) is on the lower side of optimal. A higher logP can improve membrane permeability, which is important for GPCRs.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (6). Fewer HBAs generally improve permeability.
6. **QED:** Ligand A (0.794) is significantly better than Ligand B (0.563), indicating a more drug-like profile.
7. **DILI:** Ligand A (48.468) is better than Ligand B (58.434), indicating a lower risk of drug-induced liver injury.
8. **BBB:** Both are reasonably good, but Ligand B (71.733) is slightly better than Ligand A (67.197). However, as this is a cardiovascular target, BBB penetration is not a high priority.
9. **Caco-2:** Both are negative, suggesting poor permeability. However, the scale is not provided, so it's difficult to interpret the absolute values.
10. **Solubility:** Both are negative, suggesting poor solubility. Again, the scale is not provided.
11. **hERG:** Ligand A (0.176) is better than Ligand B (0.628), indicating a lower risk of hERG inhibition and cardiotoxicity.
12. **Cl_mic:** Ligand B (27.397) is significantly better than Ligand A (46.074), indicating better metabolic stability. This is a key factor for drug duration.
13. **t1/2:** Ligand B (-38.861) is dramatically better than Ligand A (-3.629), suggesting a much longer in vitro half-life. This is a significant advantage.
14. **Pgp:** Ligand A (0.163) is better than Ligand B (0.121), indicating lower P-gp efflux.
15. **Affinity:** Ligand B (-6.8) is slightly better than Ligand A (-5.8), representing a stronger binding affinity. The difference is 1 kcal/mol, which is significant.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand A has better logP, TPSA, and Pgp. Ligand B has better affinity. However, the substantial improvement in metabolic stability (Cl_mic) and half-life (t1/2) for Ligand B, combined with its slightly better affinity, outweigh the advantages of Ligand A. The better QED and lower DILI risk of Ligand A are also positive, but the pharmacokinetic advantages of Ligand B are more critical for a successful drug.
**Output:**
0
2025-04-17 23:45:03,589 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (432.34 Da) is within the ideal range, while Ligand B (353.394 Da) is also good, being slightly lower. No clear advantage here.
2. **TPSA:** Both ligands (A: 95.58, B: 87.74) are below 140, which is good for oral absorption. Ligand B is slightly better, closer to the 90 threshold for CNS penetration (though not a CNS target here).
3. **logP:** Both ligands have good logP values (A: 1.626, B: 0.591), falling within the 1-3 range. Ligand A is slightly better.
4. **HBD:** Both have 2 HBD, which is acceptable.
5. **HBA:** Both have 4 HBA, which is acceptable.
6. **QED:** Both ligands have good QED scores (A: 0.707, B: 0.684), indicating good drug-likeness.
7. **DILI:** Ligand B (42.846) has a significantly lower DILI risk than Ligand A (59.48). This is a major advantage for Ligand B.
8. **BBB:** Both have good BBB penetration (A: 74.176, B: 77.898). Not a primary concern for ADRB2, but higher is slightly better.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. The values are similar (-4.979 vs -4.606).
10. **Solubility:** Both have negative solubility values, which is also unusual and suggests poor solubility. Ligand B is slightly better (-2.14 vs -3.689).
11. **hERG:** Both have low hERG inhibition risk (A: 0.468, B: 0.227). Ligand B is better here.
12. **Cl_mic:** Both have relatively low microsomal clearance (A: 24.221, B: 22.117), indicating reasonable metabolic stability.
13. **t1/2:** Both have negative in vitro half-lives, which is unusual, but Ligand B (-38.071) is better than Ligand A (-44.66).
14. **Pgp:** Both have low Pgp efflux liability (A: 0.077, B: 0.03). Ligand B is slightly better.
15. **Binding Affinity:** Ligand A (-5.6 kcal/mol) has a significantly better binding affinity than Ligand B (-1.8 kcal/mol). This is a substantial advantage.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are important. Ligand A has a better logP and significantly better affinity. Ligand B has better TPSA, Pgp, DILI, and hERG.
**Overall Assessment:**
The binding affinity difference is substantial. A difference of 3.8 kcal/mol is a large advantage, and often outweighs minor ADME drawbacks. While Ligand B has a better safety profile (DILI, hERG), the significantly improved potency of Ligand A is more critical for a GPCR target. The unusual Caco-2 and solubility values are concerning for both, but the potency advantage of A is likely to be more impactful in driving *in vivo* efficacy.
Output:
1
2025-04-17 23:45:03,589 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (375.441 and 353.463 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (71 and 73.32) are below the 140 threshold for good oral absorption, and acceptable for a non-CNS GPCR target like ADRB2.
3. **logP:** Ligand A (1.504) is optimal, while Ligand B (-0.071) is slightly below the preferred 1-3 range. This is a negative for Ligand B, potentially impacting permeability.
4. **HBD:** Both ligands have 1 HBD, which is within the acceptable limit of 5.
5. **HBA:** Both ligands have 5 HBA, which is within the acceptable limit of 10.
6. **QED:** Both ligands have similar QED values (0.732 and 0.724), indicating good drug-likeness.
7. **DILI:** Ligand A (32.842) has a significantly lower DILI risk than Ligand B (6.941). This is a major advantage for Ligand A.
8. **BBB:** While not critical for ADRB2 (a cardiovascular target), Ligand A (75.107) has a higher BBB penetration percentile than Ligand B (60.644).
9. **Caco-2:** Ligand A (-5.068) has a worse Caco-2 permeability than Ligand B (-4.453).
10. **Solubility:** Ligand A (-2.149) has a worse solubility than Ligand B (0.06).
11. **hERG:** Both ligands have very low hERG inhibition liability (0.23 and 0.222), which is excellent.
12. **Cl_mic:** Ligand A (-3.21) has a much lower (better) microsomal clearance than Ligand B (6.165), suggesting greater metabolic stability.
13. **t1/2:** Ligand A (-7.668) has a much longer in vitro half-life than Ligand B (0.256), which is a significant advantage.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.042 and 0.015).
15. **Binding Affinity:** Ligand A (-6.2 kcal/mol) has a slightly better binding affinity than Ligand B (-7.0 kcal/mol). While Ligand B has a better affinity, the difference is not substantial enough to outweigh the other ADME properties.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity) and general drug-like properties, Ligand A is the more promising candidate. While Ligand B has slightly better affinity and Caco-2 permeability, Ligand A excels in crucial areas like DILI risk, metabolic stability (Cl_mic and t1/2), and logP. The lower DILI risk and improved metabolic stability are particularly important for a cardiovascular target where long-term safety and efficacy are paramount.
Output:
1
2025-04-17 23:45:03,589 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (338.37) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (82.18) is significantly better than Ligand B (104.53). For a GPCR, keeping TPSA low is beneficial for permeability and receptor engagement.
3. **logP:** Ligand A (1.946) is optimal, while Ligand B (-0.463) is a bit low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Both ligands have the same number of HBA (6), which is acceptable.
6. **QED:** Both ligands have similar QED scores (0.786 and 0.694), indicating good drug-likeness.
7. **DILI:** Ligand A (74.331) has a higher DILI risk than Ligand B (35.634). This is a significant drawback for Ligand A.
8. **BBB:** Ligand A (71.501) has a better BBB penetration score than Ligand B (31.214). While ADRB2 isn't necessarily a CNS target, some peripheral ADRB2 receptors can be affected by CNS penetration.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
10. **Solubility:** Ligand A (-3.105) has slightly better solubility than Ligand B (-1.138), though both are quite poor.
11. **hERG:** Ligand A (0.591) has a slightly better hERG profile than Ligand B (0.037), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand A (57.899) has a significantly better (lower) microsomal clearance than Ligand B (21.802). This suggests greater metabolic stability for Ligand A.
13. **t1/2:** Ligand B (-7.207) has a significantly longer in vitro half-life than Ligand A (6.94). This is a major advantage for Ligand B.
14. **Pgp:** Ligand A (0.306) has lower P-gp efflux than Ligand B (0.009), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand B (-6.6) has a slightly better binding affinity than Ligand A (-6.5), but the difference is small.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, and affinity are crucial. Ligand A excels in logP and TPSA, but Ligand B has a slightly better affinity. The DILI risk for Ligand A is concerning. Metabolic stability (Cl_mic) and half-life are also important, and Ligand B is considerably better in these aspects.
**Overall Assessment:**
While Ligand A has better physicochemical properties (logP, TPSA), the significantly higher DILI risk and poorer metabolic stability are major concerns. Ligand B, despite its lower logP, has a much better safety profile (lower DILI) and a longer half-life, which are critical for drug development. The slight advantage in binding affinity for Ligand B further supports its selection.
Output:
0
2025-04-17 23:45:03,589 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (358.479 Da and 353.438 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (84.94) is slightly higher than Ligand B (81.67), but both are well below the 140 A^2 threshold for good oral absorption, and acceptable for a non-CNS GPCR target like ADRB2.
3. **logP:** Both ligands have a logP around 1.6, which is optimal for permeability and solubility. No clear advantage.
4. **HBD:** Ligand A has 1 HBD, while Ligand B has 3. Ligand A is preferable here, as fewer HBDs generally improve membrane permeability.
5. **HBA:** Ligand A has 5 HBA, and Ligand B has 4. This difference is minor.
6. **QED:** Ligand B (0.63) has a slightly better QED score than Ligand A (0.474), indicating a more drug-like profile. This is a small positive for Ligand B.
7. **DILI:** Ligand A (24.855 percentile) has a significantly lower DILI risk than Ligand B (9.616 percentile). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (61.691 percentile) has a higher BBB penetration score than Ligand B (46.336 percentile). While ADRB2 isn't a primary CNS target, some degree of BBB penetration can be acceptable or even beneficial for peripheral effects.
9. **Caco-2:** Ligand A (-4.518) has a much better Caco-2 permeability than Ligand B (-5.51). This suggests better intestinal absorption for Ligand A.
10. **Solubility:** Ligand A (-1.882) has slightly better aqueous solubility than Ligand B (-1.427).
11. **hERG:** Both ligands have very low hERG inhibition liability (0.299 and 0.424 respectively), which is excellent.
12. **Cl_mic:** Ligand B (9.798 mL/min/kg) has a significantly lower microsomal clearance than Ligand A (94.793 mL/min/kg). This suggests better metabolic stability for Ligand B. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand B (5.436 hours) has a longer in vitro half-life than Ligand A (-15.025 hours). This is a significant advantage for Ligand B.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.027 and 0.016 respectively).
15. **Binding Affinity:** Ligand B (-6.6 kcal/mol) has a slightly better binding affinity than Ligand A (-6.9 kcal/mol). While the difference is small, it is still a positive for Ligand B.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), both ligands are reasonably well-optimized. However, Ligand A has a substantial advantage in DILI risk and Caco-2 permeability, and better solubility. Ligand B has better metabolic stability (lower Cl_mic) and a longer half-life, and slightly better binding affinity. The lower DILI risk and better absorption of Ligand A are more critical factors for initial drug development, outweighing the slightly better metabolic properties of Ligand B.
Output:
1
2025-04-17 23:45:03,589 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (365.543 and 352.475 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (61.44) is better than Ligand B (76.66). ADRB2 is a cardiovascular target, so CNS penetration isn't crucial, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (2.728 and 1.633), falling within the 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Both have 2 HBD, which is within the acceptable limit of 5.
5. **HBA:** Both have 4 HBA, within the acceptable limit of 10.
6. **QED:** Ligand A (0.745) has a significantly better QED score than Ligand B (0.463), indicating a more drug-like profile.
7. **DILI:** Ligand A (34.393) has a slightly higher DILI risk than Ligand B (14.308), but both are well below the concerning threshold of 60.
8. **BBB:** Ligand A (64.948) has a higher BBB penetration percentile than Ligand B (52.695). While not a primary concern for a cardiovascular target, it's a slight advantage.
9. **Caco-2:** Ligand A (-5.297) and Ligand B (-4.943) are both negative, indicating poor permeability. This is a concern for both, but the values are relatively close.
10. **Solubility:** Ligand A (-2.193) has slightly better solubility than Ligand B (-1.435), though both are poor.
11. **hERG:** Ligand A (0.664) has a slightly higher hERG risk than Ligand B (0.331), but both are relatively low.
12. **Cl_mic:** Ligand B (1.079) has a significantly lower microsomal clearance than Ligand A (21.558), suggesting better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand B (8.032) has a longer in vitro half-life than Ligand A (26.038). This is a substantial advantage.
14. **Pgp:** Ligand A (0.183) has lower P-gp efflux than Ligand B (0.038), which is preferable.
15. **Binding Affinity:** Ligand B (-6.5 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.4 kcal/mol). This is a crucial advantage, as a 1.1 kcal/mol difference is substantial.
**GPCR-specific priorities:** For ADRB2 (a GPCR), affinity, logP, TPSA, and Pgp are key. Ligand B excels in affinity, has a reasonable logP and TPSA, and a lower Pgp efflux. While Ligand A has better QED and BBB, the much stronger binding affinity of Ligand B outweighs these advantages. The improved metabolic stability (lower Cl_mic and longer t1/2) of Ligand B is also a significant benefit.
**Conclusion:**
Ligand B is the more promising candidate due to its superior binding affinity and improved metabolic stability, despite slightly poorer solubility and Caco-2 permeability. The stronger binding is likely to be more impactful than the other minor drawbacks.
Output:
0
2025-04-17 23:45:03,589 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (367.881 and 367.555 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (72.54) is higher than Ligand B (38.77). For a GPCR, lower TPSA is generally preferred for better brain penetration, even though ADRB2 isn't strictly a CNS target. Ligand B is significantly better here.
3. **logP:** Ligand A (1.529) is within the optimal 1-3 range. Ligand B (4.755) is a bit high, potentially leading to solubility issues and off-target interactions. Ligand A is better.
4. **HBD:** Ligand A (1) is good. Ligand B (0) is also acceptable. No strong preference.
5. **HBA:** Both ligands have 4 HBA, which is within the acceptable limit of 10.
6. **QED:** Ligand A (0.875) has a higher QED score than Ligand B (0.599), indicating better overall drug-likeness. This is a significant advantage for Ligand A.
7. **DILI:** Ligand A (30.787) has a lower DILI risk than Ligand B (22.024), which is preferable.
8. **BBB:** Ligand B (89.957) has a much higher BBB percentile than Ligand A (68.67). While ADRB2 isn't a primary CNS target, some peripheral distribution is still desirable, and higher BBB can sometimes correlate with better overall distribution.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.001 and -4.924). This indicates poor permeability, which is a concern.
10. **Solubility:** Ligand A (-2.499) has slightly better solubility than Ligand B (-4.0).
11. **hERG:** Ligand A (0.286) has a lower hERG risk than Ligand B (0.821), which is crucial for avoiding cardiotoxicity, especially important for a cardiovascular target.
12. **Cl_mic:** Ligand A (-5.823) has a *much* lower (better) microsomal clearance than Ligand B (104.662). This suggests significantly improved metabolic stability for Ligand A.
13. **t1/2:** Ligand A (-11.876) has a longer in vitro half-life than Ligand B (35.305). This is a major advantage for Ligand A, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.012) has a much lower Pgp efflux liability than Ligand B (0.888). This suggests better oral bioavailability and potentially better CNS exposure.
15. **Binding Affinity:** Ligand B (-6.6 kcal/mol) has slightly better binding affinity than Ligand A (-6.0 kcal/mol). While a 0.6 kcal/mol difference is noticeable, it's not a massive advantage, and can be overcome by superior ADME properties.
**Overall Assessment:**
Ligand A demonstrates a significantly more favorable ADME profile than Ligand B. It has better QED, lower DILI risk, lower hERG risk, much lower microsomal clearance, longer half-life, and lower Pgp efflux. While Ligand B has slightly better binding affinity and BBB penetration, the ADME advantages of Ligand A are more critical for overall drug development success, especially considering the potential for cardiotoxicity with a cardiovascular drug. The Caco-2 permeability is a concern for both, but the other ADME properties of Ligand A are strong enough to outweigh this.
Output:
1
2025-04-17 23:45:03,590 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (368.499 Da and 368.455 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (75.71) is better than Ligand B (97.64). For a cardiovascular GPCR, TPSA < 140 is acceptable, but lower is generally preferred for better absorption. Ligand A is closer to the ideal range.
**3. logP:** Both ligands have good logP values (2.069 and 1.193), falling within the optimal 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability, but both are acceptable.
**4. H-Bond Donors:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
**5. H-Bond Acceptors:** Both ligands have the same number of HBA (5), which is within the acceptable limit of 10.
**6. QED:** Ligand B (0.814) has a slightly better QED score than Ligand A (0.752), suggesting a more drug-like profile.
**7. DILI:** Both ligands have similar DILI risk (66.072 and 64.831), both are acceptable but not ideal.
**8. BBB:** Ligand B (70.648) has a significantly better BBB penetration score than Ligand A (46.219). While ADRB2 is a cardiovascular target, some CNS off-target effects are possible with GPCRs, and higher BBB penetration could be a concern, but it's not a primary driver for this target.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-5.533 and -5.25), which is unusual and suggests poor permeability. This is a significant concern for both.
**10. Aqueous Solubility:** Both ligands have poor aqueous solubility (-3.24 and -2.679). This is a drawback for both, potentially impacting bioavailability.
**11. hERG Inhibition:** Ligand A (0.112) has a lower hERG inhibition liability than Ligand B (0.543), which is a crucial advantage for cardiovascular drugs.
**12. Microsomal Clearance:** Ligand A (39.62) has a lower microsomal clearance than Ligand B (11.744), indicating better metabolic stability. This is a significant advantage.
**13. In vitro Half-Life:** Ligand B (33.289) has a longer in vitro half-life than Ligand A (-23.945). This is a positive for Ligand B.
**14. P-gp Efflux:** Ligand A (0.145) has lower P-gp efflux liability than Ligand B (0.092), which is favorable for oral bioavailability.
**15. Binding Affinity:** Ligand B (-7.4) has a significantly stronger binding affinity than Ligand A (-5.5). This is a substantial advantage, potentially outweighing some of the ADME drawbacks.
**Overall Assessment:**
Ligand B has a significantly better binding affinity and a longer half-life, which are crucial for efficacy. However, it has a higher hERG risk, lower metabolic stability, and slightly worse permeability. Ligand A has better metabolic stability, lower hERG risk, and lower P-gp efflux. The Caco-2 permeability is poor for both.
Given the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), the significantly stronger affinity of Ligand B is the most important factor. While the other ADME properties are not ideal, the potency advantage is substantial enough to outweigh the drawbacks, *assuming* the hERG risk can be mitigated through further optimization.
Output:
0
2025-04-17 23:45:03,590 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands (375.416 and 351.535 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (61.44) is slightly higher than Ligand B (52.65). Both are below the 140 threshold for oral absorption, but closer to the ideal for GPCRs. Ligand B is preferable.
3. **logP:** Ligand A (3.741) is at the higher end of the optimal range (1-3), while Ligand B (2.816) is well within it. Ligand B is preferable.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable, being less than 5. Ligand B is preferable.
5. **HBA:** Both ligands (3) are within the acceptable range of <=10. No significant difference.
6. **QED:** Both ligands have good QED scores (0.588 and 0.616), indicating good drug-like properties. No significant difference.
7. **DILI:** Ligand B (13.61) has a significantly lower DILI risk than Ligand A (49.787). This is a major advantage for Ligand B.
8. **BBB:** Ligand A (87.941) has a higher BBB penetration percentile than Ligand B (75.107). While ADRB2 isn't exclusively a CNS target, some cardiovascular effects are mediated through CNS pathways, so this is a slight advantage for Ligand A.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and likely indicates poor permeability. This is a concern for both.
10. **Solubility:** Ligand B (-2.297) has a better solubility score than Ligand A (-4.313). This is preferable.
11. **hERG:** Both ligands have low hERG inhibition liability (0.762 and 0.523), which is good. No significant difference.
12. **Cl_mic:** Ligand A (32.587) has a lower microsomal clearance than Ligand B (47.347), indicating better metabolic stability. This is a slight advantage for Ligand A.
13. **t1/2:** Ligand A (-7.968) has a significantly longer in vitro half-life than Ligand B (12.554). This is a major advantage for Ligand A.
14. **Pgp:** Ligand A (0.216) has lower P-gp efflux liability than Ligand B (0.112), which is preferable.
15. **Binding Affinity:** Ligand A (-4.7 kcal/mol) has a weaker binding affinity than Ligand B (-6.2 kcal/mol). This is a substantial advantage for Ligand B.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp efflux, and binding affinity are crucial. Ligand B excels in logP, TPSA, and significantly in binding affinity. While Ligand A has a better BBB score and longer half-life, the substantial improvement in binding affinity and the significantly lower DILI risk of Ligand B outweigh these advantages. The poor Caco-2 values are a concern for both, but can be addressed with formulation strategies.
**Conclusion:**
Ligand B presents a more favorable overall profile, particularly due to its significantly improved binding affinity and lower DILI risk.
Output:
0
2025-04-17 23:45:03,590 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (364.511) is slightly higher than Ligand B (350.463), but both are acceptable.
2. **TPSA:** Ligand A (49.85) is well below the 140 threshold and good for oral absorption. Ligand B (72.96) is still reasonably low, but less optimal than Ligand A.
3. **logP:** Ligand A (2.903) is within the optimal range (1-3). Ligand B (-0.089) is *below* 1, which is a concern for membrane permeability. This is a significant negative for Ligand B.
4. **HBD:** Ligand A (0) is excellent. Ligand B (1) is acceptable, but having zero is preferable.
5. **HBA:** Both ligands have 4 HBA, which is within the acceptable limit of 10.
6. **QED:** Both ligands have similar QED scores (0.747 and 0.722), indicating good drug-likeness.
7. **DILI:** Ligand A (13.571) has a lower DILI risk than Ligand B (19.542), which is a positive.
8. **BBB:** Ligand A (87.67) has a much better BBB penetration score than Ligand B (45.638). While ADRB2 isn't strictly a CNS target, some distribution to the CNS is possible, and higher BBB penetration is generally favorable.
9. **Caco-2:** Ligand A (-4.676) is better than Ligand B (-5.046), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-2.604) is better than Ligand B (-0.788). Solubility is important for bioavailability.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.55 and 0.16).
12. **Cl_mic:** Ligand A (49.889) has a higher microsomal clearance than Ligand B (-4.906), meaning Ligand B is more metabolically stable. This is a positive for Ligand B.
13. **t1/2:** Ligand A (26.645) has a longer in vitro half-life than Ligand B (6.209). This is a positive for Ligand A.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.125 and 0.005).
15. **Binding Affinity:** Ligand A (-6.7 kcal/mol) has a slightly better binding affinity than Ligand B (-4.9 kcal/mol). This is a significant advantage for Ligand A.
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A excels in these areas, particularly with its optimal logP and superior binding affinity. While metabolic stability (Cl_mic) is important, the difference isn't large enough to overcome the other advantages of Ligand A.
**Conclusion:**
Ligand A is the more promising drug candidate due to its better logP, TPSA, solubility, BBB penetration, binding affinity, and lower DILI risk. The longer half-life is also a benefit. While Ligand B has better metabolic stability, the other factors favor Ligand A.
Output:
1
2025-04-17 23:45:03,590 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (344.415 and 344.463 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (84.42) is slightly higher than Ligand B (76.89). Both are below the 140 threshold for good oral absorption, and acceptable for a cardiovascular GPCR. Ligand B is slightly preferred.
3. **logP:** Ligand A (2.601) is within the optimal 1-3 range. Ligand B (3.113) is slightly higher, but still acceptable. No major concern for either.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (7). Lower HBA generally improves permeability.
6. **QED:** Both ligands have similar QED values (0.673 and 0.681), indicating good drug-likeness.
7. **DILI:** Ligand A (47.421) has a significantly lower DILI risk than Ligand B (60.993). This is a substantial advantage for Ligand A.
8. **BBB:** Both ligands have high BBB penetration (85.343 and 83.443). Since ADRB2 is a cardiovascular target, BBB penetration is not a primary concern, but it doesn't hurt.
9. **Caco-2:** Ligand A (-4.572) and Ligand B (-5.006) both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the values are quite close.
10. **Solubility:** Ligand A (-2.824) has slightly better solubility than Ligand B (-3.389).
11. **hERG:** Ligand A (0.122) has a much lower hERG inhibition liability than Ligand B (0.915). This is a crucial advantage for Ligand A, as hERG inhibition can lead to cardiotoxicity.
12. **Cl_mic:** Ligand A (54.131) has a lower microsomal clearance than Ligand B (78.798), indicating better metabolic stability.
13. **t1/2:** Ligand B (37.551) has a significantly longer in vitro half-life than Ligand A (-4.254). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.029) has much lower P-gp efflux liability than Ligand B (0.668). Lower P-gp efflux is generally desirable.
15. **Binding Affinity:** Ligand A (-7.1) has a slightly better binding affinity than Ligand B (-5.9). This is a significant advantage for Ligand A.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A performs better on logP, TPSA, Pgp, and significantly better on affinity.
**Overall Assessment:**
Ligand A is the stronger candidate. While Ligand B has a better half-life, Ligand A excels in several critical areas: lower DILI risk, significantly lower hERG inhibition, lower P-gp efflux, better affinity, and slightly better solubility. The combination of these factors outweighs the benefit of Ligand B's longer half-life, especially considering the potential for cardiotoxicity with Ligand B.
Output:
1
2025-04-17 23:45:03,590 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [337.379, 77.25, 3.39, 1, 6, 0.666, 77.045, 65.452, -4.869, -4.992, 0.576, 128.705, -11.554, 0.46, -6.8]
**Ligand B:** [361.511, 62.3, 3.163, 1, 4, 0.82, 64.754, 70.415, -4.947, -3.781, 0.339, 64.859, -7.479, 0.458, -6.8]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (337.379) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (77.25) is higher than Ligand B (62.3). Both are below 140, but Ligand B is better positioned for good oral absorption.
3. **logP:** Both are in the optimal range (1-3). Ligand A (3.39) is slightly higher, potentially leading to off-target effects, but still acceptable.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A (6) has more HBAs than Ligand B (4). Lower HBA is preferred.
6. **QED:** Ligand B (0.82) has a better QED score than Ligand A (0.666), indicating a more drug-like profile.
7. **DILI:** Both have acceptable DILI risk (Ligand A: 77.045, Ligand B: 64.754), with Ligand B being slightly better.
8. **BBB:** Ligand B (70.415) has a better BBB percentile than Ligand A (65.452). This is a key consideration for a GPCR target, even if not strictly CNS-focused, as it indicates better distribution.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so we can't interpret these values accurately.
10. **Solubility:** Both have negative solubility values, which is also unusual. Again, the scale is not specified.
11. **hERG:** Both have very low hERG inhibition liability (Ligand A: 0.576, Ligand B: 0.339), which is excellent.
12. **Cl_mic:** Ligand B (64.859) has a significantly lower microsomal clearance than Ligand A (128.705), indicating better metabolic stability.
13. **t1/2:** Ligand B (-7.479) has a longer in vitro half-life than Ligand A (-11.554), which is desirable.
14. **Pgp:** Both have low Pgp efflux liability (Ligand A: 0.46, Ligand B: 0.458).
15. **Affinity:** Both have the same binding affinity (-6.8 kcal/mol).
**GPCR-specific priorities:** For ADRB2, we prioritize logP, Pgp, TPSA, and affinity. Ligand B is better in terms of TPSA and Pgp. The logP values are similar. Affinity is identical. Ligand B also has better DILI, BBB, Cl_mic, and t1/2.
**Conclusion:**
Considering the overall profile, especially the better metabolic stability (Cl_mic), longer half-life, better BBB penetration, and slightly improved drug-likeness (QED) of Ligand B, it appears to be the more promising candidate. While both have issues with Caco-2 and Solubility (due to the negative values), the other advantages of Ligand B outweigh the identical binding affinity.
Output:
0
2025-04-17 23:45:03,590 - INFO - Batch 427 complete. Total preferences: 6832
2025-04-17 23:45:03,590 - INFO - Processing batch 428/512...
2025-04-17 23:45:54,931 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (384.9 and 374.4 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (47.61) is significantly better than Ligand B (93.21). ADRB2 is not a CNS target, but lower TPSA generally improves absorption.
3. **logP:** Both ligands have good logP values (1.921 and 1.08), falling within the optimal 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Both have 2 HBD, which is acceptable.
5. **HBA:** Ligand A has 3 HBA, while Ligand B has 6. Ligand A is preferable here, as excessive HBA can hinder permeability.
6. **QED:** Both ligands have similar QED scores (0.763 and 0.664), indicating good drug-likeness.
7. **DILI:** Ligand A (35.556) has a lower DILI risk than Ligand B (55.448), making it safer.
8. **BBB:** Both have reasonable BBB penetration, but Ligand B (83.443) is slightly higher than Ligand A (75.107). This is less critical for a non-CNS target like ADRB2.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.965) is slightly better than Ligand B (-5.041), but both are concerning.
10. **Solubility:** Both have negative solubility values, which is also concerning. Ligand A (-3.646) is slightly better than Ligand B (-2.853).
11. **hERG:** Both have low hERG inhibition risk (0.593 and 0.418).
12. **Cl_mic:** Ligand A (-23.414) has a much lower (better) microsomal clearance than Ligand B (6.575), indicating better metabolic stability.
13. **t1/2:** Ligand B (8.848) has a significantly longer in vitro half-life than Ligand A (-0.537). This is a major advantage for Ligand B.
14. **Pgp:** Both have low Pgp efflux liability (0.183 and 0.109).
15. **Binding Affinity:** Ligand A (-7.7) has a significantly stronger binding affinity than Ligand B (-1.4). This is a substantial advantage.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A excels in affinity and has better TPSA and logP. While Ligand B has a better half-life, the significantly stronger binding affinity of Ligand A, coupled with its lower DILI risk and better metabolic stability, outweighs the half-life advantage. The poor Caco-2 and solubility values are concerning for both, but can be addressed with formulation strategies.
**Conclusion:**
Ligand A is the more promising candidate due to its significantly higher binding affinity, better TPSA, logP, lower DILI risk, and improved metabolic stability.
Output:
1
2025-04-17 23:45:54,931 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (397.777 Da) is slightly higher than Ligand B (345.363 Da), but both are acceptable.
2. **TPSA:** Ligand A (55.4) is significantly better than Ligand B (137.09). For a GPCR, lower TPSA is generally preferred for better permeability, and Ligand B is approaching a concerning level.
3. **logP:** Ligand A (3.697) is optimal, while Ligand B (0.902) is a bit low, potentially hindering membrane permeability.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A (3) is better than Ligand B (6). Higher HBA can sometimes impact permeability.
6. **QED:** Ligand A (0.756) is much better than Ligand B (0.339), indicating a more drug-like profile.
7. **DILI:** Ligand B (53.625) has a lower DILI risk than Ligand A (89.415), which is a positive for Ligand B.
8. **BBB:** Both have reasonable BBB penetration, but Ligand B (59.791) is slightly better than Ligand A (56.65). However, BBB isn't a primary concern for ADRB2, which is a cardiovascular target.
9. **Caco-2:** Ligand A (-4.79) is better than Ligand B (-5.358), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-5.46) is better than Ligand B (-1.453), which is important for bioavailability.
11. **hERG:** Ligand A (0.797) is better than Ligand B (0.077), indicating a lower risk of cardiotoxicity. This is *critical* for a cardiovascular target.
12. **Cl_mic:** Ligand B (-1.321) has significantly better metabolic stability (lower clearance) than Ligand A (64.643).
13. **t1/2:** Ligand B (7.512) has a longer half-life than Ligand A (-16.56).
14. **Pgp:** Ligand A (0.283) has better Pgp efflux properties than Ligand B (0.015). Lower Pgp is generally preferred.
15. **Affinity:** Ligand B (-5.8) has a stronger binding affinity than Ligand A (-4.1), a difference of 1.7 kcal/mol. This is a substantial advantage.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, and affinity. Ligand A has better logP and Pgp, but Ligand B has a significantly better affinity and a more acceptable TPSA. The strong affinity of Ligand B outweighs the slightly higher TPSA. The hERG risk is also a major concern for cardiovascular drugs, and Ligand A is much better in this regard.
**Overall Assessment:**
While Ligand B has a superior binding affinity and better metabolic stability, Ligand A has a much better safety profile (lower DILI and hERG risk) and better solubility. Given that ADRB2 is a cardiovascular target, minimizing cardiotoxicity (hERG) is paramount. The affinity difference, while significant, can potentially be optimized in later stages of drug development.
Output:
1
2025-04-17 23:45:54,931 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (464.225 Da) is within the ideal range, while Ligand B (360.411 Da) is towards the lower end but still acceptable.
2. **TPSA:** Ligand A (50.36) is good, well below the 140 threshold. Ligand B (131.44) is higher, approaching the limit for good oral absorption, but still potentially acceptable for a non-CNS target.
3. **logP:** Ligand A (3.759) is optimal. Ligand B (-2.073) is significantly too low, potentially hindering membrane permeability and bioavailability.
4. **HBD:** Ligand A (2) is good. Ligand B (4) is higher, but still within the acceptable range.
5. **HBA:** Ligand A (2) is good. Ligand B (7) is higher, potentially impacting permeability.
6. **QED:** Ligand A (0.506) is good. Ligand B (0.274) is below the desirable threshold of 0.5, indicating a less drug-like profile.
7. **DILI:** Ligand A (67.739) is moderate risk, but acceptable. Ligand B (25.785) is very low risk, a significant advantage.
8. **BBB:** Ligand A (71.229) is good. Ligand B (16.983) is very low, indicating poor brain penetration. Since ADRB2 is not primarily a CNS target, this isn't a major drawback, but it's a point for A.
9. **Caco-2:** Ligand A (-4.765) is poor. Ligand B (-5.827) is also poor. Both are negative values, which is unusual and suggests very low permeability.
10. **Solubility:** Ligand A (-4.731) is poor. Ligand B (-0.182) is also poor, but slightly better than A.
11. **hERG:** Ligand A (0.799) is low risk. Ligand B (0.072) is very low risk, another advantage for B.
12. **Cl_mic:** Ligand A (70.815) is moderate. Ligand B (-13.154) is excellent, indicating high metabolic stability.
13. **t1/2:** Ligand A (41.938) is good. Ligand B (5.307) is very short, suggesting rapid clearance and potentially frequent dosing.
14. **Pgp:** Ligand A (0.518) is moderate. Ligand B (0.002) is very low, indicating minimal efflux.
15. **Affinity:** Ligand A (-7.6) is excellent. Ligand B (-6.8) is good, but 0.8 kcal/mol weaker.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are crucial. Ligand A has a better logP and significantly better affinity. Ligand B has better Pgp and DILI. The affinity difference is substantial (0.8 kcal/mol), and given the moderate DILI risk of Ligand A, the stronger binding is likely to outweigh this concern. The poor Caco-2 and solubility for both are concerning, but can potentially be addressed with formulation strategies.
**Conclusion:**
Despite the advantages of Ligand B in terms of DILI, hERG, Pgp, and metabolic stability, the significantly stronger binding affinity of Ligand A (-7.6 vs -6.8 kcal/mol) and its acceptable logP make it the more promising candidate. The affinity difference is substantial enough to overcome the slightly higher DILI risk and the poor Caco-2/solubility.
Output:
1
2025-04-17 23:45:54,932 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.402 and 346.475 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (49.85) is significantly better than Ligand B (67.23). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand A is well below the 140 threshold, while B is approaching it.
3. **logP:** Ligand B (2.357) is slightly higher than Ligand A (1.057), placing it more centrally within the optimal 1-3 range. Ligand A is a bit low, potentially impacting permeability.
4. **HBD:** Ligand A (0) is preferable to Ligand B (1). Fewer hydrogen bond donors generally improve membrane permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (4). Similar to HBD, lower HBA is generally better for permeability.
6. **QED:** Both ligands have similar and good QED scores (0.819 and 0.824), indicating good overall drug-likeness.
7. **DILI:** Ligand B (19.426) has a significantly lower DILI risk than Ligand A (35.867). This is a major advantage for Ligand B.
8. **BBB:** Ligand A (94.067) has a higher BBB penetration percentile than Ligand B (82.164). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be beneficial or at least needs to be considered.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.196 and -4.9), which is unusual and suggests poor permeability. However, the scale isn't specified, so it's difficult to interpret.
10. **Solubility:** Ligand A (-2.677) has slightly better solubility than Ligand B (-2.022), although both are quite poor.
11. **hERG:** Both ligands have low hERG inhibition risk (0.735 and 0.637), which is good.
12. **Cl_mic:** Ligand B (50.012) has a higher microsomal clearance than Ligand A (40.215), suggesting faster metabolism and potentially lower *in vivo* exposure.
13. **t1/2:** Ligand B (-25.162) has a significantly longer *in vitro* half-life than Ligand A (-13.226). This is a substantial advantage for Ligand B.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.14 and 0.197), which is favorable.
15. **Binding Affinity:** Both ligands have very similar and strong binding affinities (-6.2 and -6.1 kcal/mol). The difference is negligible.
**GPCR-Specific Priorities & Overall Assessment:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, and affinity. Ligand A excels in TPSA and has a slightly better BBB score, but Ligand B has a better logP, significantly lower DILI risk, and a much longer half-life. The similar affinities mean that the ADME properties become the deciding factor. The lower DILI and longer half-life of Ligand B are crucial advantages that outweigh the slightly lower BBB and TPSA. The poor Caco-2 values for both are concerning, but the other benefits of Ligand B are more impactful.
Output:
0
2025-04-17 23:45:54,932 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [348.315, 133.51 , 0.703, 1. , 9. , 0.775, 87.476, 48.972, -4.517, -2.878, 0.091, 92.166, -13.115, 0.017, -5.2 ]
**Ligand B:** [341.455, 45.55 , 2.286, 0. , 3. , 0.789, 29.43 , 73.711, -4.757, -2.002, 0.251, 41.894, -0.612, 0.291, -6.7 ]
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). A (348.315) and B (341.455) are very close, so this isn't a major differentiator.
2. **TPSA:** Ligand A (133.51) is slightly above the preferred <140 for good oral absorption, but still acceptable. Ligand B (45.55) is excellent, well below 90, suggesting good permeability, even potentially CNS penetration. This favors B.
3. **logP:** Ligand A (0.703) is a bit low, potentially hindering permeation. Ligand B (2.286) is within the optimal 1-3 range. This favors B.
4. **HBD:** Ligand A (1) is good. Ligand B (0) is also good. No strong preference.
5. **HBA:** Ligand A (9) is acceptable. Ligand B (3) is excellent. This favors B.
6. **QED:** Both ligands are good (A: 0.775, B: 0.789). No strong preference.
7. **DILI:** Ligand A (87.476) has a significantly higher DILI risk than Ligand B (29.43). This is a major concern for A.
8. **BBB:** Ligand A (48.972) has low BBB penetration. Ligand B (73.711) is much better, indicating a higher chance of CNS exposure if desired. Given ADRB2's cardiovascular role, CNS penetration isn't *essential*, but it's not detrimental, and B is better.
9. **Caco-2:** Both are negative, indicating poor permeability. However, the scale is not specified, so it's difficult to interpret.
10. **Solubility:** Both are negative, indicating poor solubility. Again, the scale is not specified.
11. **hERG:** Ligand A (0.091) is very low risk. Ligand B (0.251) is also low risk, but slightly higher. A is slightly favored here.
12. **Cl_mic:** Ligand A (92.166) has a higher clearance, meaning faster metabolism. Ligand B (41.894) has lower clearance, indicating better metabolic stability. This favors B.
13. **t1/2:** Ligand A (-13.115) has a negative half-life, which is concerning. Ligand B (-0.612) is also negative, but less so. This favors B.
14. **Pgp:** Ligand A (0.017) has very low P-gp efflux, which is good. Ligand B (0.291) has slightly higher efflux, but still relatively low. A is slightly favored.
15. **Affinity:** Ligand B (-6.7) has a significantly stronger binding affinity than Ligand A (-5.2). This is a substantial advantage for B, potentially outweighing some of A's minor advantages.
**Overall Assessment:**
Ligand B consistently outperforms Ligand A across most critical parameters for a GPCR drug candidate, particularly regarding ADME properties (logP, TPSA, DILI, Cl_mic, t1/2). The significantly stronger binding affinity of Ligand B is a major advantage. While Ligand A has slightly better hERG and Pgp profiles, the overall risk/benefit profile strongly favors Ligand B. The poor solubility and Caco-2 values for both ligands would need to be addressed in further optimization, but the starting point of Ligand B is much more promising.
Output:
0
2025-04-17 23:45:54,932 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (340.383 and 346.431 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand B (78.68) is significantly better than Ligand A (95.16). For a GPCR, lower TPSA is generally preferred for better permeability.
**3. logP:** Both ligands have acceptable logP values (1.822 and 0.978), falling within the 1-3 range. Ligand B is slightly lower, which is acceptable.
**4. H-Bond Donors:** Ligand B (1) is better than Ligand A (2). Lower HBD generally improves permeability.
**5. H-Bond Acceptors:** Ligand A (4) and Ligand B (5) are both reasonable, under the 10 threshold.
**6. QED:** Both ligands have very similar QED values (0.868 and 0.86), indicating good drug-likeness.
**7. DILI:** Ligand B (23.885) has a *much* lower DILI risk than Ligand A (85.266). This is a critical advantage, as liver toxicity is a major concern in drug development.
**8. BBB:** Ligand B (82.745) has a higher BBB penetration percentile than Ligand A (54.091). While ADRB2 is a cardiovascular target, some CNS exposure can occur, and higher BBB is generally favorable.
**9. Caco-2 Permeability:** Both ligands have similar, very negative Caco-2 values (-4.96 and -4.943). This suggests poor permeability, which is a concern.
**10. Aqueous Solubility:** Ligand B (-1.449) is better than Ligand A (-3.769), indicating better solubility.
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (0.391 and 0.364).
**12. Microsomal Clearance:** Ligand A (50.18) has a lower microsomal clearance than Ligand B (7.972), suggesting better metabolic stability.
**13. In vitro Half-Life:** Ligand B (22.312) has a longer in vitro half-life than Ligand A (15.028).
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.096 and 0.025).
**15. Binding Affinity:** Ligand A (-6.6) has a slightly better binding affinity than Ligand B (-6.4). However, the difference is only 0.2 kcal/mol, which is not substantial enough to outweigh the significant ADME advantages of Ligand B.
**Overall Assessment:**
Ligand B is the superior candidate. While Ligand A has a marginally better binding affinity, Ligand B demonstrates significantly better ADME properties, particularly a much lower DILI risk, better solubility, and higher BBB penetration. The lower TPSA and HBD also contribute to improved permeability potential. The longer half-life is also a plus. The slight difference in binding affinity is not enough to overcome the substantial ADME benefits of Ligand B.
Output:
0
2025-04-17 23:45:54,932 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [345.407, 109.87 , 1.779, 3. , 8. , 0.727, 74.99 , 59.946, -5.615, -2.505, 0.435, 18.52 , 29.083, 0.01 , -7.5 ]**
**Ligand B: [398.663, 33.2 , 4.665, 0. , 5. , 0.566, 29.042, 70.066, -5.125, -4.376, 0.777, 122.564, 18.202, 0.766, -6.9 ]**
1. **Molecular Weight:** Ligand A (345.4) is within the ideal range (200-500). Ligand B (398.7) is also acceptable, but closer to the upper limit.
2. **TPSA:** Ligand A (109.9) is slightly above the preferred <140 for oral absorption, but not drastically. Ligand B (33.2) is excellent, well below 140, suggesting good absorption.
3. **logP:** Ligand A (1.78) is optimal. Ligand B (4.67) is higher, potentially leading to solubility issues and off-target interactions.
4. **H-Bond Donors:** Ligand A (3) is good. Ligand B (0) is also acceptable, but very low.
5. **H-Bond Acceptors:** Ligand A (8) is good. Ligand B (5) is also good.
6. **QED:** Ligand A (0.727) is excellent, indicating good drug-like properties. Ligand B (0.566) is acceptable, but lower.
7. **DILI:** Ligand A (75.0) is concerning, indicating a higher risk of liver injury. Ligand B (29.0) is very good, low risk.
8. **BBB:** Ligand A (59.9) is moderate. Ligand B (70.1) is better, suggesting better potential for CNS penetration, though ADRB2 is not strictly a CNS target.
9. **Caco-2:** Both ligands have negative Caco-2 values which is unusual and likely an error in the data. Assuming these are percentile scores, lower values are worse.
10. **Solubility:** Ligand A (-2.5) is very poor. Ligand B (-4.4) is also poor.
11. **hERG:** Ligand A (0.44) is good, low risk. Ligand B (0.78) is slightly higher, but still acceptable.
12. **Cl_mic:** Ligand A (18.5) is good, indicating reasonable metabolic stability. Ligand B (122.6) is very high, suggesting rapid metabolism and potentially low bioavailability.
13. **t1/2:** Ligand A (29.1) is good. Ligand B (18.2) is acceptable, but shorter.
14. **Pgp:** Ligand A (0.01) is excellent, indicating low efflux. Ligand B (0.77) is higher, suggesting some efflux potential.
15. **Binding Affinity:** Ligand A (-7.5) is significantly better than Ligand B (-6.9). A 0.6 kcal/mol difference is substantial.
**GPCR-Specific Considerations:** For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are particularly important. Ligand B has better TPSA and BBB penetration, but Ligand A has a much better logP, Pgp profile, and *significantly* better binding affinity. The DILI risk for Ligand A is a major concern, but the superior affinity could potentially be optimized to mitigate other issues. The high Cl_mic of Ligand B is a substantial drawback.
**Conclusion:**
Despite the higher DILI risk, Ligand A's superior binding affinity and more favorable logP and Pgp properties make it the more promising starting point for drug development. The DILI risk can be addressed through structural modifications during lead optimization.
Output:
1
2025-04-17 23:45:54,932 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [346.427, 89.87, 1.6, 3, 4, 0.707, 39.473, 42.226, -4.865, -2.355, 0.347, 20.475, -5.106, 0.273, -6.2]
**Ligand B:** [352.381, 58.64, 3.146, 1, 3, 0.856, 64.599, 81.698, -4.481, -3.856, 0.784, 68.315, -33.248, 0.294, -7.3]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). A (346.427) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** A (89.87) is better than B (58.64), falling well below the 140 threshold for oral absorption and is closer to the 90 threshold for CNS penetration.
3. **logP:** Both are within the optimal range (1-3). B (3.146) is slightly higher, potentially leading to solubility issues.
4. **HBD:** A (3) is higher than B (1), but both are acceptable.
5. **HBA:** A (4) is higher than B (3), but both are acceptable.
6. **QED:** B (0.856) is better than A (0.707), indicating a more drug-like profile.
7. **DILI:** A (39.473) is significantly better than B (64.599), indicating a lower risk of liver injury. This is a crucial factor.
8. **BBB:** B (81.698) is much better than A (42.226), which is important for GPCRs, though not strictly essential for ADRB2 which is not a CNS target.
9. **Caco-2:** Both are negative, indicating poor permeability. A (-4.865) is slightly worse than B (-4.481).
10. **Solubility:** B (-3.856) is better than A (-2.355), which is important for bioavailability.
11. **hERG:** A (0.347) is much better than B (0.784), indicating a lower risk of cardiotoxicity. This is a critical safety parameter for cardiovascular targets.
12. **Cl_mic:** A (20.475) is much better than B (68.315), indicating better metabolic stability.
13. **t1/2:** B (-33.248) is much better than A (-5.106), suggesting a longer half-life.
14. **Pgp:** Both are low, with A (0.273) slightly lower than B (0.294).
15. **Affinity:** B (-7.3) is significantly better than A (-6.2), representing a 1.1 kcal/mol advantage. This is a substantial difference.
**GPCR-specific priorities:** For ADRB2 (a cardiovascular GPCR), affinity, logP, Pgp, TPSA, and safety (DILI, hERG) are key. While BBB is less critical, it's still a consideration.
**Decision:**
Ligand B has a significantly better binding affinity (-7.3 kcal/mol vs -6.2 kcal/mol), a better QED score, and a longer half-life. However, it has a higher DILI risk and hERG inhibition liability. Ligand A has a much better safety profile (DILI and hERG) and better metabolic stability, but its affinity is weaker and its Caco-2 permeability is worse.
The affinity difference is substantial (1.1 kcal/mol). Given that ADRB2 is a cardiovascular target, the safety profile is paramount. While B's affinity is advantageous, the increased DILI and hERG risk are concerning. The improved metabolic stability of A is also a plus. Considering the balance, the stronger binding of B is likely to outweigh the ADME concerns, especially given the potential for further optimization.
0
2025-04-17 23:45:54,932 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (366.359 Da and 357.491 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (76.02) is better than Ligand B (79.23) as it is closer to the <140 threshold for good oral absorption.
3. **logP:** Both ligands have good logP values (2.03 and 1.721), falling within the optimal 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Both ligands have 2 H-bond donors, which is within the acceptable limit of <=5.
5. **HBA:** Ligand A has 4 H-bond acceptors, and Ligand B has 5. Both are acceptable, but Ligand A is slightly preferred.
6. **QED:** Both ligands have similar QED values (0.657 and 0.622), indicating good drug-likeness.
7. **DILI:** Ligand A (33.773) has a significantly lower DILI risk than Ligand B (10.392). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (75.378) has a better BBB penetration percentile than Ligand A (65.607). While ADRB2 isn't exclusively a CNS target, some cardiovascular effects can be mediated through CNS pathways, so this is a slight advantage for Ligand B.
9. **Caco-2:** Ligand A (-5.035) has a worse Caco-2 permeability than Ligand B (-4.146). This suggests Ligand B might have better intestinal absorption.
10. **Solubility:** Ligand A (-1.884) has slightly worse solubility than Ligand B (-1.205), but both are poor.
11. **hERG:** Both ligands have low hERG inhibition liability (0.407 and 0.572), which is good.
12. **Cl_mic:** Ligand A (18.544) has a significantly lower microsomal clearance than Ligand B (33.189), suggesting better metabolic stability.
13. **t1/2:** Ligand B (28.349) has a much longer in vitro half-life than Ligand A (-1.753). This is a significant advantage for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.025 and 0.21).
15. **Binding Affinity:** Ligand A (-7.0) has a slightly better binding affinity than Ligand B (-6.5). While the difference is less than the 1.5 kcal/mol threshold, it's still a positive for Ligand A.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Ligand A has a slightly better logP and affinity, and comparable Pgp. Ligand B has better Caco-2 permeability and BBB penetration. However, the significantly lower DILI risk and better metabolic stability (lower Cl_mic) of Ligand A are crucial factors. The longer half-life of Ligand B is attractive, but the DILI risk is a major concern.
**Overall Assessment:**
Considering the balance of properties, Ligand A is the more promising candidate. The lower DILI risk and better metabolic stability are critical for drug development, outweighing the slightly better BBB penetration and half-life of Ligand B. The affinity difference is small, and the other properties are reasonably well-balanced in Ligand A.
Output:
1
2025-04-17 23:45:54,932 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, key priorities are logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB.
Let's compare the ligands property by property:
1. **MW:** Both ligands (342.439 and 356.438 Da) fall within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (49.85) is significantly better than Ligand B (59.08), being closer to the <140 threshold for good absorption.
3. **logP:** Both ligands have good logP values (2.481 and 1.237), falling within the optimal 1-3 range. Ligand A is slightly better.
4. **HBD/HBA:** Both have acceptable HBD (0) and HBA (3/4) counts.
5. **QED:** Both have similar QED scores (0.773 and 0.744), indicating good drug-likeness.
6. **DILI:** Ligand A (21.055) has a considerably lower DILI risk than Ligand B (27.181). This is a significant advantage.
7. **BBB:** Both have high BBB penetration (97.751 and 93.37), which isn't a primary concern for a cardiovascular target, but isn't detrimental.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and difficult to interpret without knowing the scale. We'll treat this as roughly equivalent.
9. **Solubility:** Ligand A (-2.456) has slightly better solubility than Ligand B (-1.203).
10. **hERG:** Both have very low hERG inhibition risk (0.556 and 0.318).
11. **Cl_mic:** Ligand B (35.126) has lower microsomal clearance than Ligand A (46.5), suggesting better metabolic stability.
12. **t1/2:** Ligand B (25.767) has a significantly longer in vitro half-life than Ligand A (-6.632). This is a substantial advantage.
13. **Pgp:** Both have very low Pgp efflux liability (0.124 and 0.048).
14. **Binding Affinity:** Both have excellent binding affinity (-5 and -6 kcal/mol). Ligand B is slightly better.
**Overall Assessment:**
Ligand B has a better half-life and slightly better binding affinity, and lower clearance. However, Ligand A has a significantly lower DILI risk, better TPSA and solubility. Given the cardiovascular context, minimizing potential liver toxicity is crucial. The slightly better TPSA and solubility of Ligand A also contribute to better absorption and bioavailability. The difference in binding affinity is not large enough to outweigh the safety and absorption advantages of Ligand A.
**Output:**
1
2025-04-17 23:45:54,932 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (363.479) is slightly higher than Ligand B (350.354), but both are acceptable.
2. **TPSA:** Ligand A (64.63) is well below the 140 threshold and is favorable. Ligand B (116.14) is higher, but still potentially acceptable for a peripherally acting GPCR like ADRB2.
3. **logP:** Ligand A (4.073) is at the upper end of the optimal range, potentially raising concerns about solubility and off-target effects. Ligand B (-0.605) is significantly lower, which could hinder permeability.
4. **HBD:** Ligand A (1) is good. Ligand B (3) is acceptable, but slightly higher.
5. **HBA:** Ligand A (5) is good. Ligand B (6) is acceptable, but slightly higher.
6. **QED:** Both ligands have reasonable QED scores (A: 0.819, B: 0.643), indicating good drug-like properties. Ligand A is better.
7. **DILI:** Ligand A (69.135) has a higher DILI risk than Ligand B (52.423), which is a concern.
8. **BBB:** Ligand A (78.868) shows better BBB penetration than Ligand B (17.449). While ADRB2 isn't a primary CNS target, some CNS exposure can contribute to side effects, and better control is preferable.
9. **Caco-2:** Ligand A (-4.536) and Ligand B (-5.824) both have negative Caco-2 values, which is unusual and suggests poor permeability. This is a significant drawback for both.
10. **Solubility:** Ligand A (-5.33) has slightly better solubility than Ligand B (-1.512).
11. **hERG:** Ligand A (0.514) has a lower hERG risk than Ligand B (0.14), which is a significant advantage.
12. **Cl_mic:** Ligand A (107.778) has higher metabolic clearance than Ligand B (-33.073). This is unfavorable for Ligand A, indicating faster metabolism.
13. **t1/2:** Ligand A (59.016) has a longer half-life than Ligand B (-11.396), which is a positive attribute.
14. **Pgp:** Ligand A (0.473) has lower P-gp efflux than Ligand B (0.004), which is favorable.
15. **Affinity:** Both ligands have very similar binding affinities (-6.4 and -6.6 kcal/mol). The difference is negligible.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has a better logP and Pgp profile, and comparable affinity. Ligand B has a lower TPSA, but its very low logP is a major concern. The DILI risk for Ligand A is higher, but the hERG risk is lower.
**Overall Assessment:**
Despite the higher DILI risk, Ligand A is the more promising candidate. Its better logP, Pgp, solubility, and half-life outweigh the slightly higher DILI risk. The extremely low logP of Ligand B is a significant barrier to permeability and bioavailability, making it less likely to succeed as an oral drug. The negative Caco-2 values for both are concerning and would require further investigation, but are less impactful than the logP issue with Ligand B.
Output:
1
2025-04-17 23:45:54,933 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, priorities are affinity, logP, TPSA, Pgp, and BBB.
* **Molecular Weight:** Both ligands are within the acceptable range (200-500 Da). Ligand A (340.383) is slightly lower, which is generally favorable for permeability.
* **TPSA:** Ligand A (73.39) is significantly better than Ligand B (124.09). A TPSA under 140 is good for oral absorption, but lower is better, especially for GPCRs. Ligand B's TPSA is pushing the upper limit.
* **logP:** Both ligands have acceptable logP values (between 1-3). Ligand A (2.867) is slightly lower, which is preferable. Ligand B (3.342) is a bit higher and could potentially lead to off-target effects.
* **H-Bond Donors/Acceptors:** Ligand A (0 HBD, 6 HBA) is better than Ligand B (1 HBD, 8 HBA). Fewer hydrogen bonds generally improve membrane permeability.
* **QED:** Both are reasonable (A: 0.717, B: 0.635), indicating good drug-like properties.
* **DILI:** Ligand B (96.433) has a significantly higher DILI risk than Ligand A (77.627). This is a major concern.
* **BBB:** Ligand A (72.586) has a better BBB percentile than Ligand B (53.276). While ADRB2 isn't a CNS target, some peripheral exposure can be reduced with better BBB penetration.
* **Caco-2 Permeability:** Ligand A (-4.56) shows better Caco-2 permeability than Ligand B (-5.315).
* **Aqueous Solubility:** Ligand A (-2.947) has better solubility than Ligand B (-4.812).
* **hERG:** Both ligands have very low hERG risk (A: 0.192, B: 0.438), which is excellent.
* **Microsomal Clearance:** Ligand B (27.023) has a lower microsomal clearance, indicating better metabolic stability, than Ligand A (35.376).
* **In vitro Half-Life:** Ligand A (60.61) has a significantly longer half-life than Ligand B (-1.421).
* **P-gp Efflux:** Ligand A (0.514) shows better P-gp efflux properties than Ligand B (0.067). Lower P-gp efflux is desirable.
* **Binding Affinity:** Ligand B (-8.2 kcal/mol) has a significantly stronger binding affinity than Ligand A (-3.2 kcal/mol). This is a substantial advantage.
**Overall Assessment:**
The stronger binding affinity of Ligand B is a significant advantage. However, the extremely high DILI risk and poorer ADME properties (lower BBB, worse solubility, higher P-gp efflux) are major drawbacks. Ligand A has a more balanced profile with better ADME properties and a much lower DILI risk, even though its binding affinity is weaker. Given the cardiovascular context, minimizing toxicity (DILI) is paramount, and a reasonable affinity can be optimized further.
**Output:**
1
2025-04-17 23:45:54,933 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (352.41 and 348.447 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Both ligands have TPSA values (96.25 and 94.56) below the 140 A^2 threshold for good oral absorption. They are also reasonably low, which is favorable for GPCR ligands.
**3. logP:** Ligand A (0.637) is slightly lower than Ligand B (1.03). While both are within the optimal 1-3 range, Ligand B is closer to the ideal.
**4. H-Bond Donors:** Both have 3 HBD, which is acceptable.
**5. H-Bond Acceptors:** Both have 5 HBA, which is acceptable.
**6. QED:** Both ligands have similar QED values (0.671 and 0.684), indicating good drug-likeness.
**7. DILI:** Ligand A (52.695) has a significantly higher DILI risk than Ligand B (9.965). This is a major concern, as minimizing liver toxicity is crucial.
**8. BBB:** Ligand A (63.94) has a higher BBB penetration percentile than Ligand B (44.242). While ADRB2 is a cardiovascular target, some CNS effects can be undesirable, but this is less critical than other factors.
**9. Caco-2 Permeability:** Ligand A (-4.995) has worse Caco-2 permeability than Ligand B (-5.467). Both are negative, indicating poor permeability, but B is slightly better.
**10. Aqueous Solubility:** Ligand A (-2.795) has worse aqueous solubility than Ligand B (-1.678). Solubility is important for formulation and bioavailability.
**11. hERG Inhibition:** Ligand A (0.125) has a slightly lower hERG inhibition risk than Ligand B (0.207), which is preferable.
**12. Microsomal Clearance:** Ligand B (-9.348) has *much* lower microsomal clearance than Ligand A (10.9), indicating significantly better metabolic stability. This is a major advantage.
**13. In vitro Half-Life:** Ligand B (-21.328) has a much longer in vitro half-life than Ligand A (4.074). This is another significant advantage, potentially leading to less frequent dosing.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.044 and 0.005).
**15. Binding Affinity:** Ligand A (-7.2 kcal/mol) has a slightly better binding affinity than Ligand B (-5.1 kcal/mol). This is a 2.1 kcal/mol difference, which is substantial and could potentially outweigh some ADME drawbacks.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity, the significant advantages of Ligand B in terms of DILI risk, metabolic stability (Cl_mic), and in vitro half-life are compelling. The lower DILI risk is a critical factor. The improved metabolic stability and longer half-life translate to potentially better *in vivo* exposure and efficacy. The slight difference in binding affinity is less important than these ADME properties, especially for a GPCR where achieving sufficient occupancy isn't always solely dependent on ultra-high affinity.
Therefore, I prefer Ligand B.
0
2025-04-17 23:45:54,933 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (342.403 Da) is slightly lower, which could be advantageous for permeability.
2. **TPSA:** Ligand B (58.2) is significantly better than Ligand A (101.8). ADRB2 is a cardiovascular target, not CNS, but lower TPSA generally improves absorption.
3. **logP:** Ligand B (3.414) is optimal, while Ligand A (0.403) is quite low. This is a significant drawback for Ligand A, potentially hindering membrane permeability and bioavailability.
4. **HBD:** Both have 2 HBD, which is acceptable.
5. **HBA:** Ligand B (2) is better than Ligand A (6). Lower HBA is generally preferred for better permeability.
6. **QED:** Both are good (around 0.68), indicating reasonable drug-likeness.
7. **DILI:** Ligand B (40.054) is slightly better than Ligand A (57.387), indicating a lower risk of liver injury.
8. **BBB:** Not a primary concern for a cardiovascular target, but Ligand B (57.852) is higher than Ligand A (43.777).
9. **Caco-2:** Ligand A (-5.445) is better than Ligand B (-4.696), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-1.445) is better than Ligand B (-4.296), which is important for formulation.
11. **hERG:** Ligand A (0.057) is considerably better than Ligand B (0.461), indicating a lower risk of cardiotoxicity. This is crucial for a cardiovascular target.
12. **Cl_mic:** Ligand A (28.936) has a significantly lower clearance than Ligand B (53.858), suggesting better metabolic stability.
13. **t1/2:** Ligand B (3.083) has a longer half-life than Ligand A (-1.768). This is a positive attribute.
14. **Pgp:** Ligand A (0.016) has much lower P-gp efflux than Ligand B (0.082), which is favorable for bioavailability.
15. **Affinity:** Ligand B (-6.8 kcal/mol) has a slightly better binding affinity than Ligand A (-6.1 kcal/mol). While the difference is not huge, it's a positive for Ligand B.
**Overall Assessment:**
Ligand B has a better logP, slightly better affinity, and a longer half-life. However, Ligand A excels in several critical areas: significantly lower hERG risk, lower microsomal clearance (better metabolic stability), lower P-gp efflux, and better solubility. The low logP of Ligand A is a concern, but its superior safety profile (hERG, DILI) and pharmacokinetic properties (Cl_mic, Pgp) are more important for a cardiovascular drug. The slightly better Caco-2 permeability of Ligand A also helps offset the logP issue.
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity) and the overall balance of properties, Ligand A appears to be the more promising candidate.
**Output:**
1
2025-04-17 23:45:54,933 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (353.419 and 350.503 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (113.17) is higher than Ligand B (58.64). For a GPCR, lower TPSA is generally preferred for better BBB penetration and overall drug-like properties. Ligand B is significantly better here.
3. **logP:** Ligand A (-0.735) is lower than Ligand B (2.76). While both are within the acceptable range, Ligand B is closer to the optimal 1-3 range, suggesting better membrane permeability.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable, being less than 5. Ligand B is slightly better.
5. **HBA:** Ligand A (5) and Ligand B (3) are both acceptable, being less than 10. Ligand B is slightly better.
6. **QED:** Both ligands have similar QED values (0.632 and 0.651), indicating good drug-likeness. No significant difference.
7. **DILI:** Ligand A (22.451) has a lower DILI risk than Ligand B (16.751). This is a clear advantage for Ligand A.
8. **BBB:** Ligand B (83.288) has a significantly higher BBB penetration percentile than Ligand A (63.474). This is a crucial advantage for a GPCR target, even if it's not a CNS target, as it can indicate better distribution.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.897 and -4.4), which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
10. **Solubility:** Ligand A (-1.176) has slightly better aqueous solubility than Ligand B (-3.187).
11. **hERG:** Both ligands have low hERG inhibition liability (0.178 and 0.47). No significant difference.
12. **Cl_mic:** Ligand A (-0.583) has a lower (better) microsomal clearance than Ligand B (95.752). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (-25.607) has a much longer in vitro half-life than Ligand B (-13.421). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.029) has lower P-gp efflux liability than Ligand B (0.317). This is a slight advantage for Ligand A.
15. **Binding Affinity:** Ligand B (-5.7) has a slightly better binding affinity than Ligand A (-4.9). While a 1.5 kcal/mol difference is usually significant, the other ADME properties of Ligand B are more concerning.
**Overall Assessment:**
Ligand B has a better logP and significantly better BBB penetration, and binding affinity. However, it has a much higher microsomal clearance and a shorter half-life. Ligand A has a lower DILI risk, better metabolic stability (lower Cl_mic, longer t1/2), and lower P-gp efflux. The TPSA of Ligand B is also much more favorable. Considering the balance of properties, and prioritizing metabolic stability and safety (DILI) for a cardiovascular target, Ligand B is the better candidate.
Output:
0
2025-04-17 23:45:54,933 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A Analysis:**
* **MW:** 361.511 Da - Within the ideal range (200-500).
* **TPSA:** 54.46 - Good, well below the 140 threshold for oral absorption.
* **logP:** 3.951 - Excellent, within the optimal 1-3 range.
* **HBD:** 1 - Good, well below the 5 threshold.
* **HBA:** 5 - Good, well below the 10 threshold.
* **QED:** 0.896 - Excellent, indicating a very drug-like profile.
* **DILI:** 38.697 - Very good, low risk of liver injury.
* **BBB:** 74.796 - Good, suggesting reasonable potential for CNS penetration (though ADRB2 is primarily cardiovascular, some CNS off-target effects are possible).
* **Caco-2:** -4.703 - Concerningly low, indicating poor intestinal absorption.
* **Solubility:** -3.084 - Poor solubility, potentially causing formulation challenges.
* **hERG:** 0.789 - Low risk of hERG inhibition, good for cardiac safety.
* **Cl_mic:** 43.498 - Moderate clearance, suggesting moderate metabolic stability.
* **t1/2:** 17.845 - Moderate half-life.
* **Pgp:** 0.586 - Low P-gp efflux, which is favorable.
* **Affinity:** -5.8 kcal/mol - Good binding affinity.
**Ligand B Analysis:**
* **MW:** 347.375 Da - Within the ideal range (200-500).
* **TPSA:** 111.15 - Higher than ideal, potentially impacting absorption.
* **logP:** -0.318 - Poor, likely leading to poor membrane permeability.
* **HBD:** 2 - Good, below the 5 threshold.
* **HBA:** 7 - Good, below the 10 threshold.
* **QED:** 0.77 - Good, but slightly lower than Ligand A.
* **DILI:** 63.823 - Moderate risk of liver injury, higher than Ligand A.
* **BBB:** 34.548 - Low, suggesting poor CNS penetration.
* **Caco-2:** -5.76 - Very poor intestinal absorption.
* **Solubility:** -1.632 - Poor solubility, similar to Ligand A.
* **hERG:** 0.02 - Very low risk of hERG inhibition, excellent for cardiac safety.
* **Cl_mic:** -20.177 - Very low clearance, indicating excellent metabolic stability.
* **t1/2:** 28.365 - Excellent half-life.
* **Pgp:** 0.009 - Very low P-gp efflux, highly favorable.
* **Affinity:** -7.8 kcal/mol - Excellent binding affinity, significantly stronger than Ligand A.
**Comparison and Decision:**
Both ligands have solubility issues, which is a concern. However, Ligand B exhibits a significantly stronger binding affinity (-7.8 vs -5.8 kcal/mol). This difference in affinity is substantial and could outweigh the drawbacks of its higher TPSA and lower logP. Ligand B also has superior metabolic stability (lower Cl_mic) and a longer half-life. While Ligand A has better DILI and BBB scores, these are less critical for a cardiovascular target like ADRB2. The poor Caco-2 values for both are concerning, but the stronger binding of Ligand B suggests it might still be effective at lower doses, potentially mitigating absorption issues. Considering the GPCR-specific priorities (affinity being paramount), Ligand B is the more promising candidate.
Output:
0
2025-04-17 23:45:54,933 - INFO - Batch 428 complete. Total preferences: 6848
2025-04-17 23:45:54,933 - INFO - Processing batch 429/512...
2025-04-17 23:46:45,021 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (418.238 Da) is within the ideal range (200-500 Da). Ligand B (350.423 Da) is also excellent. No clear advantage here.
2. **TPSA:** Ligand A (70.67) is good, below the 140 threshold for oral absorption. Ligand B (103.59) is still reasonable, but higher. A favors here.
3. **logP:** Ligand A (2.825) is optimal (1-3). Ligand B (-1.009) is too low, potentially hindering permeability. A is significantly better.
4. **HBD:** Both ligands have 2 HBD, which is within the acceptable limit.
5. **HBA:** Ligand A has 3 HBA, Ligand B has 7. Ligand A is better.
6. **QED:** Both ligands have similar QED values (0.794 and 0.681), indicating good drug-likeness.
7. **DILI:** Ligand A (53.121) has a slightly higher DILI risk than Ligand B (33.695), but both are below the concerning threshold of 60. B is preferable.
8. **BBB:** Ligand A (84.529) has a much higher BBB penetration potential than Ligand B (42.846). This is a significant advantage for a GPCR target, even a cardiovascular one, as some CNS off-target effects are always a consideration. A is better.
9. **Caco-2:** Ligand A (-4.937) and Ligand B (-5.12) are both very poor. This suggests poor intestinal absorption for both.
10. **Solubility:** Ligand A (-3.845) is better than Ligand B (-0.509). A is better.
11. **hERG:** Ligand A (0.543) has a lower hERG risk than Ligand B (0.039). A is better.
12. **Cl_mic:** Ligand A (-20.294) has a lower (better) microsomal clearance than Ligand B (-5.481). A is better.
13. **t1/2:** Ligand A (-5.486) has a slightly longer in vitro half-life than Ligand B (15.384). A is better.
14. **Pgp:** Ligand A (0.139) has lower P-gp efflux liability than Ligand B (0.028). A is better.
15. **Affinity:** Ligand A (-8.3 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.2 kcal/mol). This is a >1.5 kcal/mol advantage, which is substantial.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A excels in logP, TPSA, Pgp, and *especially* affinity. While BBB isn't paramount for a cardiovascular target, the higher value for A is still a positive.
**Overall Assessment:**
Ligand A demonstrates a superior balance of properties, particularly its excellent binding affinity, favorable logP, TPSA, and lower Pgp efflux. While Ligand B has a slightly lower DILI risk, the significant advantages of Ligand A in potency, permeability-related properties, and metabolic stability outweigh this minor difference. The poor Caco-2 values for both are a concern that would need to be addressed in further development, but the stronger starting point of Ligand A makes it the more promising candidate.
Output:
1
2025-04-17 23:46:45,021 - INFO - Here's my reasoning and final output for the ligand preference:
**Reasoning:**
We are targeting ADRB2, a GPCR, so the priorities are logP, Pgp, TPSA, affinity, and BBB. Let's break down the comparison:
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (364.47) is slightly higher than Ligand B (342.40), but this isn't a major concern.
2. **TPSA:** Both are below the 140 A^2 threshold for good oral absorption. Ligand A (80.68) is slightly better than Ligand B (85.25).
3. **logP:** Both are within the optimal 1-3 range. Ligand A (3.315) is a bit higher than Ligand B (2.759), which could potentially lead to some off-target effects, but is still acceptable.
4. **H-Bond Donors:** Both have 2 HBD, which is good.
5. **H-Bond Acceptors:** Ligand A has 7 HBA, and Ligand B has 5. Both are within the acceptable range of <=10.
6. **QED:** Both have good QED scores (A: 0.665, B: 0.818). Ligand B is slightly better here, indicating a more drug-like profile.
7. **DILI:** Ligand A (64.87) has a slightly higher DILI risk than Ligand B (74.99), but both are acceptable.
8. **BBB:** Ligand B (79.682) has a significantly better BBB penetration percentile than Ligand A (45.715). This is a key advantage for a GPCR target, even if not CNS-focused, as it can influence distribution and off-target effects.
9. **Caco-2:** Ligand A (-4.772) and Ligand B (-5.107) are both negative, which is unusual and suggests poor permeability. However, the values are quite close.
10. **Solubility:** Both have negative solubility values, indicating poor solubility. Ligand A (-3.802) is slightly better than Ligand B (-3.631).
11. **hERG:** Both have very low hERG inhibition risk (A: 0.398, B: 0.113). Ligand B is better here.
12. **Cl_mic:** Ligand B (24.433) has significantly lower microsomal clearance than Ligand A (88.867), indicating better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand B (29.15) has a much longer in vitro half-life than Ligand A (-4.423). This is a major benefit.
14. **Pgp:** Ligand A (0.502) has slightly higher P-gp efflux liability than Ligand B (0.119). Lower Pgp is preferred.
15. **Binding Affinity:** Ligand B (-7.5 kcal/mol) has a slightly better binding affinity than Ligand A (-7.0 kcal/mol). While the difference is not huge, it's a positive factor.
**Overall Assessment:**
Ligand B consistently outperforms Ligand A in several critical ADME properties (BBB, Cl_mic, t1/2, Pgp, hERG) and has slightly better binding affinity. While Ligand A has a slightly better TPSA and solubility, the ADME advantages of Ligand B are more important for a GPCR target like ADRB2. The longer half-life and improved metabolic stability of Ligand B are particularly attractive.
Output:
0
2025-04-17 23:46:45,022 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (345.418 and 349.475 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (62.3) is significantly better than Ligand B (83.36). For a GPCR, lower TPSA is generally preferred for better permeability, although not as critical as for CNS targets.
3. **logP:** Both ligands have good logP values (2.157 and 1.377), falling within the optimal 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (4). Fewer HBAs generally improve permeability.
6. **QED:** Both ligands have similar QED values (0.657 and 0.63), indicating good drug-likeness.
7. **DILI:** Ligand A (27.608) has a much lower DILI risk than Ligand B (12.059). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (82.474) has a much higher BBB penetration potential than Ligand B (38.891). While ADRB2 isn't exclusively a CNS target, some CNS exposure is possible depending on the specific indication, and higher BBB is generally favorable.
9. **Caco-2:** Ligand A (-4.424) is better than Ligand B (-5.001). Higher Caco-2 permeability is desirable.
10. **Solubility:** Ligand A (-2.454) is better than Ligand B (-1.103). Higher solubility is generally preferred.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.579 and 0.154), which is excellent.
12. **Cl_mic:** Ligand B (7.837) has significantly lower microsomal clearance than Ligand A (25.966), indicating better metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand B (26.095) has a slightly longer in vitro half-life than Ligand A (-32.255).
14. **Pgp:** Ligand A (0.125) has a lower P-gp efflux liability than Ligand B (0.081). Lower P-gp efflux is preferred.
15. **Affinity:** Ligand B (-6.7) has a slightly better binding affinity than Ligand A (-6.1). The difference is 0.6 kcal/mol, which is not substantial enough to outweigh the other factors.
**Overall Assessment:**
Ligand A demonstrates a significantly better ADME profile, particularly regarding DILI risk, BBB penetration, solubility, and permeability. While Ligand B has slightly better metabolic stability and affinity, the advantages of Ligand A in crucial ADME parameters are more compelling for overall drug development potential. The difference in binding affinity is not large enough to overcome the ADME benefits of Ligand A. Considering ADRB2 is a GPCR, the balance of logP, TPSA, Pgp, and affinity favors Ligand A.
Output:
1
2025-04-17 23:46:45,022 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output:
**Ligand A: [347.415, 93.46, 2.271, 2, 5, 0.583, 64.521, 70.648, -5.046, -3.46, 0.139, 39.935, -16.699, 0.17, -4.8]**
**Ligand B: [350.459, 78.87, 1.095, 2, 4, 0.643, 12.059, 54.207, -4.58, -1.651, 0.155, 34.994, 7.149, 0.018, -7.2]**
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). A is 347.415, B is 350.459 - very similar.
2. **TPSA:** Ligand A (93.46) is slightly higher than Ligand B (78.87). Both are reasonably good for oral absorption, but B is better, falling comfortably under the 90 A^2 threshold for CNS targets (though ADRB2 isn't strictly a CNS target, lower TPSA is generally favorable).
3. **logP:** Ligand A (2.271) and Ligand B (1.095) are both within the optimal range (1-3), but B is closer to the lower end. A is better here.
4. **H-Bond Donors:** Both have 2 HBD, which is good.
5. **H-Bond Acceptors:** Ligand A has 5 HBA, Ligand B has 4. Both are acceptable (<=10).
6. **QED:** Ligand B (0.643) has a slightly better QED score than Ligand A (0.583), indicating a more drug-like profile.
7. **DILI:** Ligand A (64.521) has a significantly higher DILI risk than Ligand B (12.059). This is a major concern for A.
8. **BBB:** Ligand A (70.648) has a better BBB penetration percentile than Ligand B (54.207). While ADRB2 isn't a primary CNS target, some peripheral ADRB2 activity can influence CNS pathways, so this is a slight advantage for A.
9. **Caco-2 Permeability:** Ligand A (-5.046) has worse Caco-2 permeability than Ligand B (-4.58). Lower values indicate poorer permeability.
10. **Aqueous Solubility:** Ligand B (-1.651) has better aqueous solubility than Ligand A (-3.46). Solubility is important for formulation and bioavailability.
11. **hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.139 and 0.155 respectively).
12. **Microsomal Clearance:** Ligand B (34.994) has lower microsomal clearance than Ligand A (39.935), suggesting better metabolic stability.
13. **In vitro Half-Life:** Ligand B (7.149) has a significantly longer in vitro half-life than Ligand A (-16.699). This is a major advantage for B.
14. **P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.17 and 0.018 respectively).
15. **Binding Affinity:** Ligand B (-7.2) has a significantly stronger binding affinity than Ligand A (-4.8). This is a substantial advantage, potentially outweighing some ADME concerns.
**GPCR-Specific Priorities:** For GPCRs, logP, TPSA, Pgp, and affinity are key. Ligand B excels in TPSA, affinity, and has a reasonable logP. Ligand A has a better BBB score, but the high DILI risk is a significant drawback. The substantially better affinity of Ligand B is a major factor.
**Conclusion:**
Considering the balance of properties, particularly the significantly lower DILI risk, better solubility, metabolic stability, and *much* stronger binding affinity of Ligand B, it is the more promising drug candidate for targeting ADRB2.
0
2025-04-17 23:46:45,022 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.475 and 353.419 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (76.66) is significantly better than Ligand B (104.9). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (1.629) is slightly better than Ligand B (0.737), both are within the optimal range of 1-3, but Ligand B is closer to the lower limit which could impact permeability.
4. **HBD:** Both ligands have 2 HBD, which is acceptable.
5. **HBA:** Ligand A (4) is better than Ligand B (6). Lower HBA is generally preferred for permeability.
6. **QED:** Both ligands have similar QED values (0.619 and 0.668), indicating good drug-likeness.
7. **DILI:** Ligand A (16.479) has a much lower DILI risk than Ligand B (30.748). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (52.811) has a slightly better BBB percentile than Ligand B (43.273), but both are relatively low. Not a major factor here.
9. **Caco-2:** Both ligands have similar, very negative Caco-2 values (-4.721 and -4.727). This is concerning and indicates poor permeability.
10. **Solubility:** Ligand A (-3.062) is better than Ligand B (-1.34). Solubility is important for bioavailability.
11. **hERG:** Both ligands have low hERG inhibition risk (0.389 and 0.466).
12. **Cl_mic:** Ligand A (59.931) has a higher microsomal clearance than Ligand B (22.029), indicating lower metabolic stability. This is a drawback for Ligand A.
13. **t1/2:** Ligand A (3.737) has a slightly longer half-life than Ligand B (3.438).
14. **Pgp:** Both ligands have low P-gp efflux liability (0.118 and 0.236).
15. **Binding Affinity:** Ligand A (-7.6) has a significantly stronger binding affinity than Ligand B (-5.8). This is a substantial advantage, potentially outweighing some of the ADME concerns.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Ligand A performs better on logP, TPSA, and *significantly* better on affinity. While both have acceptable Pgp values, the large difference in affinity is the deciding factor. The lower DILI risk for Ligand A is also a strong positive. The higher Cl_mic for Ligand A is a concern, but the strong binding could compensate for faster metabolism. The poor Caco-2 values are a concern for both, but can be addressed with formulation strategies.
**Conclusion:**
Despite the higher Cl_mic, the significantly stronger binding affinity of Ligand A, coupled with its better TPSA, logP, solubility, and lower DILI risk, makes it the more promising drug candidate.
Output:
1
2025-04-17 23:46:45,022 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 drug candidates. ADRB2 is a GPCR, so we'll prioritize logP, Pgp, TPSA, and affinity, alongside general drug-like properties.
**Ligand A:** [388.917, 77.92, 1.662, 1, 5, 0.83, 16.789, 63.784, -4.776, -1.711, 0.423, -31.496, 15.799, 0.128, -5.3]
**Ligand B:** [344.499, 40.62, 3.423, 0, 2, 0.725, 14.036, 88.717, -4.319, -2.595, 0.558, 84.974, -7.445, 0.4, -7.8]
Here's a breakdown:
1. **MW:** Both are within the ideal 200-500 Da range. Ligand B (344.499) is slightly preferred.
2. **TPSA:** Ligand B (40.62) is significantly better than Ligand A (77.92), falling well below the 140 threshold for oral absorption and closer to the ideal for GPCRs.
3. **logP:** Ligand A (1.662) is within the optimal range, while Ligand B (3.423) is at the higher end, but still acceptable.
4. **HBD/HBA:** Ligand B (0 HBD, 2 HBA) is better than Ligand A (1 HBD, 5 HBA). Lower counts are generally preferred for permeability.
5. **QED:** Ligand A (0.83) is slightly better than Ligand B (0.725), indicating a more drug-like profile.
6. **DILI:** Ligand B (14.036) has a much lower DILI risk than Ligand A (16.789), which is a significant advantage.
7. **BBB:** Ligand B (88.717) has a considerably higher BBB penetration percentile than Ligand A (63.784). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be beneficial for understanding off-target effects.
8. **Caco-2:** Both have negative values, indicating good permeability. Ligand A (-4.776) is slightly better.
9. **Solubility:** Both have negative values, indicating poor solubility. Ligand B (-2.595) is slightly better.
10. **hERG:** Both are low, indicating low cardiotoxicity risk. Ligand B (0.558) is slightly better.
11. **Cl_mic:** Ligand A (-31.496) has a much lower (better) microsomal clearance than Ligand B (84.974), suggesting greater metabolic stability.
12. **t1/2:** Ligand A (15.799) has a better in vitro half-life than Ligand B (-7.445).
13. **Pgp:** Ligand A (0.128) has lower P-gp efflux than Ligand B (0.4), which is favorable for bioavailability.
14. **Affinity:** Ligand B (-7.8) has a significantly stronger binding affinity than Ligand A (-5.3). This is a crucial advantage, exceeding the 1.5 kcal/mol threshold.
**Overall Assessment:**
Ligand B has a superior binding affinity and a much better safety profile (lower DILI). Its TPSA is also significantly lower, which is favorable for permeability. While Ligand A has better metabolic stability and Pgp efflux, the substantial affinity advantage of Ligand B, coupled with its improved ADME properties (TPSA, DILI, BBB), outweighs these drawbacks. The stronger binding is likely to translate to a lower required dose, potentially mitigating some of the metabolic concerns.
Output:
0
2025-04-17 23:46:45,022 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (361.511 and 342.443 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (65.46) is significantly better than Ligand B (89.78). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (4.363) is slightly higher than Ligand B (3.014). Both are within the acceptable range (1-3), but Ligand A is pushing the upper limit.
4. **HBD:** Ligand A (2) is preferable to Ligand B (4). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is better than Ligand B (2).
6. **QED:** Ligand A (0.853) is better than Ligand B (0.691), indicating a more drug-like profile.
7. **DILI:** Ligand B (54.207) has a lower DILI risk than Ligand A (64.831), which is a significant advantage.
8. **BBB:** Both are similar (Ligand A: 68.592, Ligand B: 61.613). Not a major factor for a cardiovascular target.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-4.547) is slightly better than Ligand B (-4.89).
10. **Solubility:** Both are negative, indicating poor solubility. Ligand A (-4.388) is slightly better than Ligand B (-4.611).
11. **hERG:** Both are very low (Ligand A: 0.597, Ligand B: 0.491), indicating low cardiotoxicity risk. No significant difference.
12. **Cl_mic:** Ligand B (4.832) has significantly lower microsomal clearance than Ligand A (45.383), suggesting better metabolic stability. This is a crucial advantage.
13. **t1/2:** Ligand A (79.89) has a much longer in vitro half-life than Ligand B (24.757). This is a significant advantage.
14. **Pgp:** Both are low (Ligand A: 0.304, Ligand B: 0.303), indicating minimal P-gp efflux. No significant difference.
15. **Binding Affinity:** Ligand B (-7.6) has slightly better binding affinity than Ligand A (-7.5). While the difference is small, it's still a positive for Ligand B.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has a better logP and TPSA, while Ligand B has better affinity and significantly better metabolic stability (Cl_mic). The longer half-life of Ligand A is also a benefit.
**Overall Assessment:**
Ligand B has a lower DILI risk and significantly better metabolic stability, which are crucial for drug development. The slightly better affinity of Ligand B is also a plus. While Ligand A has a slightly better QED and half-life, the metabolic stability and safety profile of Ligand B outweigh these advantages.
Output:
0
2025-04-17 23:46:45,023 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (363.53 and 349.41 Da). No significant difference here.
2. **TPSA:** Ligand A (61.44) is significantly better than Ligand B (101.21). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have acceptable logP values (2.49 and 1.16). Ligand A is slightly better, falling more centrally within the optimal 1-3 range. Ligand B is at the lower end, which *could* impact permeability.
4. **HBD:** Both have 2 HBD, which is good.
5. **HBA:** Ligand A has 4 HBA, Ligand B has 5. Both are acceptable, but A is slightly preferred.
6. **QED:** Both are very similar (0.816 and 0.803), indicating good drug-likeness.
7. **DILI:** Ligand A (11.36) has a *much* lower DILI risk than Ligand B (51.61). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (82.51) shows better BBB penetration than Ligand A (62.74). However, since ADRB2 is a cardiovascular target, BBB penetration is not a high priority.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual. Assuming these represent permeability *scores* where lower is worse, both are poor. However, the difference is small (-5.65 vs -5.13).
10. **Solubility:** Both have negative solubility values, indicating poor solubility. Ligand A (-1.62) is slightly better than Ligand B (-2.8).
11. **hERG:** Both have low hERG inhibition liability (0.51 and 0.40), which is good.
12. **Cl_mic:** Ligand A (1.86) has significantly lower microsomal clearance than Ligand B (4.07), indicating better metabolic stability.
13. **t1/2:** Ligand A (46.62) has a much longer in vitro half-life than Ligand B (-13.40). This is a substantial advantage.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.03 and 0.02), which is good.
15. **Binding Affinity:** Ligand B (-7.1) has a slightly better binding affinity than Ligand A (-6.0). This is a 1.1 kcal/mol difference, which is significant, but needs to be weighed against the other factors.
**Overall Assessment:**
Ligand B has a slightly better binding affinity, but Ligand A is superior in almost every other critical ADME-Tox parameter. Specifically, the significantly lower DILI risk, better metabolic stability (lower Cl_mic, longer t1/2), and slightly better TPSA and solubility make Ligand A a much more promising drug candidate. The slightly lower BBB penetration for Ligand A is not a concern given the cardiovascular target. The affinity difference, while noticeable, is unlikely to overcome the substantial ADME advantages of Ligand A.
Output:
1
2025-04-17 23:46:45,023 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.4 & 354.4 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (70.67) is higher than Ligand B (58.44). Both are below 140, but B is better for absorption.
3. **logP:** Both ligands (1.767 & 1.694) are within the optimal 1-3 range. No significant difference.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (0). Both are acceptable.
5. **HBA:** Both ligands (4) are within the acceptable range (<=10). No significant difference.
6. **QED:** Both ligands (0.869 & 0.827) are excellent, indicating good drug-like properties.
7. **DILI:** Ligand B (34.432) has a significantly lower DILI risk than Ligand A (50.33). This is a substantial advantage.
8. **BBB:** Ligand B (92.943) has a much higher BBB penetration percentile than Ligand A (74.254). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant for off-target effects and understanding the overall safety profile.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.775 and -4.531). This is unusual and suggests poor permeability. However, the values are similar.
10. **Solubility:** Both ligands have negative solubility values (-1.628 and -1.77). This is also concerning and suggests poor aqueous solubility. Again, the values are similar.
11. **hERG:** Both ligands (0.447 & 0.516) have low hERG inhibition liability, which is good. No significant difference.
12. **Cl_mic:** Ligand A (-15.147) has a much *lower* (better) microsomal clearance than Ligand B (29.086). This suggests greater metabolic stability for Ligand A.
13. **t1/2:** Ligand A (-0.433) has a slightly better in vitro half-life than Ligand B (-26.67).
14. **Pgp:** Both ligands (0.019 & 0.052) have low P-gp efflux liability, which is favorable. No significant difference.
15. **Binding Affinity:** Ligand B (-7.2 kcal/mol) has a slightly better binding affinity than Ligand A (-6.4 kcal/mol). This is a 0.8 kcal/mol difference, which is a meaningful advantage.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Both ligands are good on logP and Pgp. Ligand B is better on TPSA. The affinity difference is notable (0.8 kcal/mol), but the significantly lower DILI risk and higher BBB penetration of Ligand B are compelling. While the Caco-2 and solubility are poor for both, the metabolic stability of A is better.
**Overall Assessment:**
Despite the better metabolic stability of Ligand A, the combination of lower DILI risk, higher BBB penetration, and slightly better binding affinity makes Ligand B the more promising candidate. The poor Caco-2 and solubility are concerns for both, but can be addressed with formulation strategies.
Output:
0
2025-04-17 23:46:45,023 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.46 and 347.51 Da) fall comfortably within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (75.44) is slightly higher than Ligand B (64.86). Both are below the 140 threshold for oral absorption, but B is closer to the preferred <90 for GPCRs, giving it a slight edge.
3. **logP:** Both ligands have good logP values (2.625 and 2.895), falling within the optimal 1-3 range. Ligand B is slightly higher, potentially offering better membrane permeability.
4. **HBD:** Both have 1 HBD, which is within the acceptable limit of 5.
5. **HBA:** Ligand A has 4 HBA, while Ligand B has 6. Both are below the 10 limit, but A is preferable.
6. **QED:** Both ligands have very similar QED scores (0.769 and 0.783), indicating good drug-likeness.
7. **DILI:** Both ligands have similar, low DILI risk (21.99 and 21.75). This is excellent for both.
8. **BBB:** Ligand B (79.26) has a significantly higher BBB penetration percentile than Ligand A (71.50). This is a key advantage for a GPCR target, even if it's cardiovascular, as some off-target CNS effects are possible.
9. **Caco-2:** Ligand A (-4.785) has a worse Caco-2 permeability than Ligand B (-5.09). Lower values indicate lower permeability.
10. **Solubility:** Ligand A (-1.501) has slightly better solubility than Ligand B (-2.386). Solubility is important, but not as critical as permeability for this target.
11. **hERG:** Ligand A (0.059) has a lower hERG inhibition liability than Ligand B (0.452), which is a significant safety advantage.
12. **Cl_mic:** Ligand B (34.02) has a much lower microsomal clearance than Ligand A (57.997), indicating better metabolic stability. This is a major advantage.
13. **t1/2:** Ligand B (13.99) has a significantly longer in vitro half-life than Ligand A (-12.09). This is a substantial benefit, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.092) has a lower P-gp efflux liability than Ligand B (0.267), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand B (-7.2 kcal/mol) has a significantly stronger binding affinity than Ligand A (-4.4 kcal/mol). This is a >1.5 kcal/mol advantage, which can outweigh many ADME drawbacks.
**Overall Assessment:**
Ligand B is the stronger candidate. While Ligand A has slightly better hERG and Pgp profiles, Ligand B's superior binding affinity, BBB penetration, metabolic stability (lower Cl_mic), and longer half-life are more critical for a GPCR target like ADRB2. The slightly higher TPSA and Pgp efflux of Ligand B are acceptable trade-offs for these significant advantages. The substantial difference in binding affinity is the deciding factor.
Output:
0
2025-04-17 23:46:45,023 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step Comparison:**
1. **MW:** Both ligands (346.43 & 351.47 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (70.08) is higher than Ligand B (58.22). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B has a slight advantage.
3. **logP:** Ligand A (1.799) is within the optimal range (1-3). Ligand B (3.713) is at the higher end, potentially leading to solubility issues or off-target interactions. Ligand A is preferred.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 4 HBAs, Ligand B has 3. Both are acceptable, below the 10 threshold.
6. **QED:** Ligand A (0.902) has a significantly better QED score than Ligand B (0.738), indicating a more drug-like profile. This is a substantial advantage for Ligand A.
7. **DILI:** Ligand A (21.91%) has a slightly higher DILI risk than Ligand B (13.3%). Ligand B is preferred here.
8. **BBB:** Ligand A (69.41%) and Ligand B (87.86%) both have good BBB penetration, but Ligand B is significantly higher. Since ADRB2 is a GPCR, BBB penetration is a consideration, favoring Ligand B.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.549) is slightly better than Ligand B (-4.144), but both are concerning.
10. **Solubility:** Ligand A (-2.729) has slightly better solubility than Ligand B (-4.324).
11. **hERG:** Ligand A (0.293) has a much lower hERG inhibition liability than Ligand B (0.689), which is a critical advantage for cardiovascular safety.
12. **Cl_mic:** Ligand A (68.99) has a lower microsomal clearance than Ligand B (86.975), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-19.001) has a significantly longer in vitro half-life than Ligand B (-35.495).
14. **Pgp:** Ligand A (0.027) has much lower P-gp efflux liability than Ligand B (0.137), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand B (-7.5 kcal/mol) has a slightly better binding affinity than Ligand A (-6.5 kcal/mol). This 1 kcal/mol difference is significant, but must be weighed against other factors.
**Overall Assessment:**
Ligand B has a better binding affinity and BBB penetration, which are important for a GPCR target. However, Ligand A demonstrates a superior drug-like profile (QED), lower hERG risk, better metabolic stability (lower Cl_mic, longer t1/2), and lower P-gp efflux. The lower hERG risk is particularly crucial for a cardiovascular target. While both have poor Caco-2 permeability, the other advantages of Ligand A outweigh the slightly better affinity of Ligand B.
**Output:**
1
2025-04-17 23:46:45,023 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [361.477, 43.86, 2.459, 0, 3, 0.634, 11.71, 87.941, -4.49, -0.999, 0.787, 6, -15.761, 0.088, -6.1]
**Ligand B:** [362.503, 68.84, 2.153, 0, 7, 0.755, 50.174, 70.686, -5.204, -2.308, 0.182, 51.395, -6.92, 0.195, -6.1]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). A: 361.477, B: 362.503 - very similar.
2. **TPSA:** A (43.86) is excellent, well below 140 and good for oral absorption. B (68.84) is still acceptable, but less ideal.
3. **logP:** Both are within the optimal 1-3 range. A (2.459) is slightly higher, potentially better for membrane permeability. B (2.153) is good, but slightly lower.
4. **HBD:** Both have 0 HBD, which is good.
5. **HBA:** A (3) is preferable to B (7). Fewer HBA generally improves permeability.
6. **QED:** Both are above 0.5, indicating good drug-likeness. A (0.634) is slightly better than B (0.755).
7. **DILI:** A (11.71) is *much* better than B (50.174). This is a significant advantage for A.
8. **BBB:** A (87.941) is excellent, indicating good potential for CNS penetration (though less critical for ADRB2 which is primarily cardiovascular). B (70.686) is also good, but lower.
9. **Caco-2:** A (-4.49) is better than B (-5.204), suggesting better intestinal absorption.
10. **Solubility:** A (-0.999) is better than B (-2.308). Solubility is important for bioavailability.
11. **hERG:** Both are very low (0.787 and 0.182), indicating low cardiotoxicity risk.
12. **Cl_mic:** A (6) is *much* lower than B (51.395), indicating significantly better metabolic stability.
13. **t1/2:** A (-15.761) is better than B (-6.92), indicating a longer half-life.
14. **Pgp:** A (0.088) is much lower than B (0.195), indicating less P-gp efflux and better bioavailability.
15. **Affinity:** Both have the same affinity (-6.1 kcal/mol).
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Both ligands perform similarly on logP and affinity. A is better on TPSA and *significantly* better on Pgp. The substantial improvements in ADME properties (DILI, Cl_mic, t1/2, solubility) for ligand A are also very important.
**Conclusion:**
Ligand A is clearly superior. While both ligands have acceptable properties, Ligand A demonstrates a much more favorable ADME profile, particularly regarding metabolic stability, liver toxicity risk, and P-gp efflux. These factors are crucial for developing a viable drug candidate. The slightly better TPSA and solubility also contribute to its advantage.
Output:
1
2025-04-17 23:46:45,023 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (371.39 Da and 362.392 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (129.8) is higher than Ligand B (60.85). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for better permeability. Ligand B is significantly better.
**3. logP:** Ligand A (0.349) is quite low, potentially hindering membrane permeability. Ligand B (2.362) is within the optimal 1-3 range. This is a substantial advantage for Ligand B.
**4. H-Bond Donors:** Ligand A (3) is acceptable, while Ligand B (1) is even better, contributing to improved permeability.
**5. H-Bond Acceptors:** Ligand A (5) and Ligand B (3) are both within the acceptable range (<=10).
**6. QED:** Both ligands have good QED scores (0.685 and 0.837), indicating good drug-like properties.
**7. DILI Risk:** Ligand A (69.872) has a higher DILI risk than Ligand B (20.9), which is a significant concern.
**8. BBB Penetration:** While not a primary concern for a cardiovascular target, Ligand B (75.727) shows better BBB penetration than Ligand A (45.599).
**9. Caco-2 Permeability:** Ligand A (-5.845) is very poor, while Ligand B (-4.904) is still poor, but better.
**10. Aqueous Solubility:** Both ligands have poor aqueous solubility (-2.881 and -2.192). This could pose formulation challenges, but isn't a deal-breaker on its own.
**11. hERG Inhibition:** Ligand A (0.016) and Ligand B (0.348) both have low hERG inhibition, which is good.
**12. Microsomal Clearance:** Ligand A (-13.696) has lower (better) microsomal clearance than Ligand B (-13.188).
**13. In vitro Half-Life:** Ligand B (-19.679) has a significantly longer in vitro half-life than Ligand A (-8.231), which is a major advantage.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux (0.007 and 0.019), which is favorable.
**15. Binding Affinity:** Ligand A (-7.4) has a slightly better binding affinity than Ligand B (-4.0). However, the difference isn't large enough to overcome the significant ADME deficiencies of Ligand A.
**Overall Assessment:**
Ligand B is the superior candidate. While Ligand A has slightly better binding affinity, Ligand B excels in crucial ADME properties: significantly lower DILI risk, better logP, lower TPSA, and a much longer half-life. The poor Caco-2 permeability and solubility of both are concerns, but can be addressed with formulation strategies. The combination of these factors makes Ligand B a more promising starting point for drug development targeting the ADRB2 receptor.
Output:
0
2025-04-17 23:46:45,024 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (a cardiovascular GPCR) drug candidates.
**Ligand A:** [357.361, 100.35 , -0.058, 2. , 6. , 0.769, 50.64 , 66.227, -4.929, -1.547, 0.164, -1.055, -22.042, 0.031, -5.8 ]
**Ligand B:** [382.53 , 59.07 , 3.825, 2. , 7. , 0.639, 85.537, 89.492, -5.181, -4.182, 0.933, 106.814, 63.904, 0.581, -6.9 ]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, Affinity):
1. **MW:** Both are within the acceptable 200-500 Da range. Ligand A (357.361) is slightly preferred due to being a bit lower.
2. **TPSA:** Ligand B (59.07) is significantly better than Ligand A (100.35). Lower TPSA generally improves permeability, which is crucial for GPCR ligands.
3. **logP:** Ligand B (3.825) is better, falling nicely within the optimal 1-3 range. Ligand A (-0.058) is quite low, potentially hindering membrane permeability.
4. **HBD/HBA:** Both have 2 HBD and a reasonable number of HBA (6 and 7 respectively). No significant difference here.
5. **QED:** Ligand A (0.769) is slightly better than Ligand B (0.639), indicating a more drug-like profile.
6. **DILI:** Ligand A (50.64) has a considerably lower DILI risk than Ligand B (85.537). This is a significant advantage.
7. **BBB:** Ligand B (89.492) has a higher BBB penetration percentile than Ligand A (66.227). While ADRB2 isn't a CNS target, some peripheral exposure can be modulated by BBB transporters.
8. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability.
9. **Solubility:** Both have negative solubility values, indicating poor solubility.
10. **hERG:** Ligand A (0.164) has a much lower hERG risk than Ligand B (0.933). This is a critical safety parameter.
11. **Cl_mic:** Ligand A (-1.055) has a lower (better) microsomal clearance than Ligand B (106.814), suggesting better metabolic stability.
12. **t1/2:** Ligand B (63.904) has a much longer in vitro half-life than Ligand A (-22.042). This is a significant advantage.
13. **Pgp:** Ligand A (0.031) has a lower Pgp efflux liability than Ligand B (0.581), which is favorable for bioavailability.
14. **Affinity:** Ligand B (-6.9 kcal/mol) has a slightly better binding affinity than Ligand A (-5.8 kcal/mol). This is a 1.1 kcal/mol difference, which is substantial.
**Overall Assessment:**
Ligand B has a superior binding affinity and half-life, and better BBB penetration. However, it suffers from significantly higher DILI risk, hERG liability, and Pgp efflux. Ligand A has a lower risk profile (DILI, hERG, Pgp) and better metabolic stability, but a weaker binding affinity and shorter half-life.
Given the cardiovascular target and the importance of safety, I prioritize the lower risk profile of Ligand A. The affinity difference, while noticeable, is not so large that it outweighs the substantial safety concerns associated with Ligand B. The poor permeability and solubility of both compounds would need to be addressed in further optimization, but starting with a safer scaffold is preferable.
Output:
1
2025-04-17 23:46:45,024 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [339.439, 53.51, 1.79, 0, 3, 0.844, 19.232, 86.274, -4.89, -1.842, 0.169, 49.307, -18.568, 0.19, -6.1]
**Ligand B:** [358.467, 76.14, 2.423, 2, 6, 0.878, 72.082, 75.611, -5.273, -3.141, 0.507, 41.276, 12.674, 0.058, -6.7]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (339.439) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (53.51) is significantly better than Ligand B (76.14). A TPSA under 140 is good for oral absorption, and lower is better for GPCRs.
3. **logP:** Both are within the optimal range (1-3). Ligand B (2.423) is slightly higher, which could potentially lead to off-target effects, but is not a major concern.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (6). Fewer HBAs generally improve permeability.
6. **QED:** Both are good (above 0.5), with Ligand B (0.878) being slightly better.
7. **DILI:** Ligand A (19.232) is significantly better than Ligand B (72.082). Lower DILI is crucial.
8. **BBB:** Ligand A (86.274) is better than Ligand B (75.611). While not a CNS target, some level of BBB penetration can be beneficial for distribution.
9. **Caco-2:** Ligand A (-4.89) and Ligand B (-5.273) are similar, indicating comparable intestinal absorption.
10. **Solubility:** Ligand A (-1.842) is better than Ligand B (-3.141). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.169) is significantly better than Ligand B (0.507). Lower hERG inhibition is critical for avoiding cardiotoxicity.
12. **Cl_mic:** Ligand B (41.276) is better than Ligand A (49.307). Lower clearance is desirable for metabolic stability.
13. **t1/2:** Ligand B (12.674) is better than Ligand A (-18.568). A positive half-life is better than a negative one.
14. **Pgp:** Ligand A (0.19) is significantly better than Ligand B (0.058). Lower P-gp efflux is favorable.
15. **Affinity:** Ligand B (-6.7) is slightly better than Ligand A (-6.1). This is a 0.6 kcal/mol difference, which is a reasonable advantage.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity) and general drug-like properties, Ligand A is the more promising candidate. While Ligand B has a slightly better binding affinity and *t*1/2, Ligand A excels in crucial ADME properties like TPSA, DILI, hERG, and Pgp efflux. The lower TPSA, DILI, hERG, and Pgp values of Ligand A significantly mitigate potential safety and bioavailability concerns. The slightly lower affinity can potentially be optimized in subsequent iterations.
Output:
1
2025-04-17 23:46:45,024 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [375.491, 118.8 , -0.575, 2. , 6. , 0.637, 33.307, 34.781, -5.634, -0.746, 0.092, -16.932, 29.343, 0.019, -7.1 ]
**Ligand B:** [344.415, 106.32 , 1.695, 2. , 5. , 0.783, 31.02 , 56.65 , -4.733, -3.208, 0.296, 36.832, -13.918, 0.013, -6. ]
Here's a breakdown, prioritizing GPCR properties (logP, Pgp, TPSA, Affinity, and BBB):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (344.415) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are acceptable, but Ligand B (106.32) is better, being closer to the <140 threshold for oral absorption. Ligand A (118.8) is still reasonable.
3. **logP:** Ligand A (-0.575) is quite low, potentially hindering membrane permeability. Ligand B (1.695) is much better, falling within the optimal 1-3 range. This is a significant advantage for Ligand B.
4. **HBD/HBA:** Both have 2 HBD and similar HBA counts (6 vs 5). Acceptable for both.
5. **QED:** Both have good QED values (>0.5), indicating drug-likeness. Ligand B (0.783) is slightly better.
6. **DILI:** Both have low DILI risk (<40), which is good. Ligand A (33.3) is slightly higher, but still acceptable.
7. **BBB:** Ligand B (56.65) has a significantly higher BBB penetration percentile than Ligand A (34.781). While ADRB2 isn't necessarily a CNS target, some peripheral distribution is still desired, and better BBB penetration often correlates with better overall distribution.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
9. **Solubility:** Both have negative solubility values, again, the scale is not specified.
10. **hERG:** Both have very low hERG risk, which is excellent.
11. **Cl_mic:** Ligand A (-16.932) has a *much* lower (better) microsomal clearance than Ligand B (36.832), indicating greater metabolic stability. This is a major advantage for Ligand A.
12. **t1/2:** Ligand A (29.343) has a longer in vitro half-life than Ligand B (-13.918), which is desirable.
13. **Pgp:** Both have very low P-gp efflux liability.
14. **Affinity:** Ligand A (-7.1) has a slightly better binding affinity than Ligand B (-6.0). While the difference is not huge (less than 1.5 kcal/mol), it is still a positive for Ligand A.
**Overall Assessment:**
Ligand B excels in logP and BBB penetration, which are crucial for GPCR targets. However, its metabolic stability (Cl_mic) and in vitro half-life are significantly worse than Ligand A. Ligand A has a slight edge in binding affinity. The lower logP of Ligand A is a concern, but the superior metabolic stability and half-life, combined with the slightly better affinity, outweigh this drawback, especially considering the potential for optimization of the logP.
Therefore, I would choose Ligand A.
1
2025-04-17 23:46:45,024 - INFO - Batch 429 complete. Total preferences: 6864
2025-04-17 23:46:45,024 - INFO - Processing batch 430/512...
2025-04-17 23:47:34,389 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [347.419, 111.27 , 0.22 , 3. , 6. , 0.611, 57.929, 79.256, -5.632, -2.549, 0.38 , 14.298, 5.405, 0.024, -6.2 ]
**Ligand B:** [348.418, 66.48 , 1.623, 1. , 3. , 0.606, 32.803, 92.943, -5.021, -2.767, 0.124, 18.098, -35.758, 0.211, -6.8 ]
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (347-348 Da). No significant difference.
2. **TPSA:** Ligand A (111.27) is higher than Ligand B (66.48). Ligand B is much better, being well below the 140 threshold for oral absorption and closer to the ideal for GPCRs.
3. **logP:** Ligand A (0.22) is quite low, potentially hindering permeability. Ligand B (1.623) is within the optimal 1-3 range. Ligand B is significantly better.
4. **HBD:** Ligand A (3) is acceptable, Ligand B (1) is better.
5. **HBA:** Both ligands have 3 HBA, which is acceptable.
6. **QED:** Both are similar (0.611 vs 0.606), indicating good drug-likeness.
7. **DILI:** Ligand A (57.929) has a higher DILI risk than Ligand B (32.803). Ligand B is preferable.
8. **BBB:** Ligand B (92.943) has a much higher BBB penetration potential than Ligand A (79.256). This is a key advantage for a GPCR target.
9. **Caco-2:** Both are negative, suggesting poor permeability. However, Ligand B (-5.021) is slightly better than Ligand A (-5.632).
10. **Solubility:** Both are negative, suggesting poor solubility. Ligand B (-2.767) is slightly better than Ligand A (-2.549).
11. **hERG:** Both have very low hERG inhibition risk (0.38 and 0.124). Ligand B is better.
12. **Cl_mic:** Ligand A (14.298) has lower clearance than Ligand B (18.098), indicating better metabolic stability. Ligand A is preferable.
13. **t1/2:** Ligand B (-35.758) has a much longer in vitro half-life than Ligand A (5.405). This is a significant advantage.
14. **Pgp:** Ligand A (0.024) has lower P-gp efflux liability than Ligand B (0.211). Ligand A is preferable.
15. **Affinity:** Ligand B (-6.8) has a slightly better binding affinity than Ligand A (-6.2). While the difference is not huge, it's a positive for Ligand B.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand B is clearly the more promising candidate. It has a better logP, significantly better TPSA, higher BBB penetration, better DILI risk, and a slightly better binding affinity. While Ligand A has better metabolic stability and P-gp efflux, the improvements in permeability and CNS exposure offered by Ligand B are more crucial for a GPCR target like ADRB2. The longer half-life of Ligand B is also a significant advantage.
Output:
0
2025-04-17 23:47:34,389 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (353.5) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (78.51) is better than Ligand B (51.02). While both are acceptable, lower TPSA is preferred for GPCRs, aiding in brain penetration and overall absorption.
3. **logP:** Ligand B (3.696) is higher than Ligand A (2.081). While both are within the optimal range, Ligand B is approaching the upper limit, potentially leading to solubility issues.
4. **HBD:** Ligand A (2) is preferable to Ligand B (0). Having some HBD can improve solubility.
5. **HBA:** Ligand B (5) is preferable to Ligand A (3).
6. **QED:** Both ligands have good QED scores (A: 0.656, B: 0.753), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (19.7) has a significantly lower DILI risk than Ligand B (38.5). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (93.021) has a much higher BBB penetration score than Ligand A (64.87). This is a significant advantage for Ligand B, given that ADRB2 is a GPCR.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability.
10. **Solubility:** Ligand B (-3.943) has a worse solubility score than Ligand A (-2.01).
11. **hERG:** Ligand A (0.192) has a lower hERG inhibition liability than Ligand B (0.599), which is a safety advantage.
12. **Cl_mic:** Both ligands have similar microsomal clearance values (A: 48.045, B: 48.924).
13. **t1/2:** Ligand B (36.124) has a much longer in vitro half-life than Ligand A (-3.124). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.096) has a lower P-gp efflux liability than Ligand B (0.454), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand B (-6.9 kcal/mol) has a substantially stronger binding affinity than Ligand A (-4.9 kcal/mol). This is a critical advantage, outweighing some of the ADME concerns.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, Pgp, TPSA, BBB, and affinity. Ligand B excels in BBB and affinity, while Ligand A is better in TPSA and Pgp. The significant difference in binding affinity (-6.9 vs -4.9) is a substantial advantage for Ligand B. The better BBB penetration of Ligand B is also a significant plus. While Ligand A has a better DILI score and hERG profile, the potency and brain penetration of Ligand B are more crucial for a GPCR target.
**Conclusion:**
Despite some ADME drawbacks, the significantly stronger binding affinity and superior BBB penetration of Ligand B make it the more promising drug candidate for the ADRB2 receptor.
Output:
0
2025-04-17 23:47:34,389 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (337.379 and 349.435 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (89.45) is better than Ligand B (107.19). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (2.809) is optimal, while Ligand B (-0.019) is quite low. A logP near 0 can hinder membrane permeability. This is a significant advantage for Ligand A.
4. **HBD:** Both ligands have 3 HBD, which is within the acceptable range.
5. **HBA:** Ligand A has 4 HBA, while Ligand B has 5. Both are acceptable, but Ligand A is slightly better.
6. **QED:** Both ligands have similar QED values (0.637 and 0.641), indicating good drug-likeness.
7. **DILI:** Ligand A (70.88) has a higher DILI risk than Ligand B (29.546). This is a substantial negative for Ligand A.
8. **BBB:** BBB is not a high priority for a cardiovascular target. Ligand A (27.491) and Ligand B (32.532) are both low.
9. **Caco-2:** Both ligands have negative Caco-2 values, suggesting poor permeability. However, Ligand A (-5.26) is slightly better than Ligand B (-5.529).
10. **Solubility:** Ligand A (-4.351) is better than Ligand B (-2.149). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.726) has a slightly higher hERG risk than Ligand B (0.292). Lower is better.
12. **Cl_mic:** Ligand B (-15.357) has a lower (better) microsomal clearance than Ligand A (36.008), indicating greater metabolic stability.
13. **t1/2:** Ligand B (-2.437) has a longer in vitro half-life than Ligand A (-16.743). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.191) has a lower Pgp efflux liability than Ligand B (0.003), which is preferable.
15. **Binding Affinity:** Ligand B (-7.4) has a significantly stronger binding affinity than Ligand A (-5.0). A 2.4 kcal/mol difference is substantial and can often outweigh minor ADME drawbacks.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand A has a better logP and Pgp, but Ligand B has a much better binding affinity and a more favorable DILI profile. The stronger binding affinity of Ligand B is a major advantage.
**Overall Assessment:**
While Ligand A has some advantages in logP and Pgp, Ligand B's significantly stronger binding affinity, lower DILI risk, and better metabolic stability (lower Cl_mic and longer t1/2) outweigh these benefits. The lower logP of Ligand B is a concern, but the substantial affinity difference makes it a more promising starting point for optimization.
Output:
0
2025-04-17 23:47:34,390 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (365.38 and 368.46 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (99.18) is better than Ligand B (110.08). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally favors absorption.
3. **logP:** Ligand A (-0.784) is slightly lower than optimal (1-3), but still acceptable. Ligand B (-0.025) is closer to the ideal range. This favors Ligand B slightly.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1), but both are within the acceptable limit of 5.
5. **HBA:** Ligand A (5) is lower than Ligand B (7). Lower HBA is generally preferred for better permeability. This favors Ligand A.
6. **QED:** Ligand B (0.782) has a significantly better QED score than Ligand A (0.522), indicating a more drug-like profile. This is a substantial advantage for Ligand B.
7. **DILI:** Ligand A (31.563) has a much lower DILI risk than Ligand B (59.403). This is a significant advantage for Ligand A.
8. **BBB:** Both ligands have similar BBB penetration (62.233 and 68.36), and since ADRB2 is not a CNS target, this is not a major deciding factor.
9. **Caco-2:** Ligand A (-4.868) has a worse Caco-2 permeability than Ligand B (-5.62), indicating lower intestinal absorption. This favors Ligand B.
10. **Solubility:** Ligand A (-0.46) has better solubility than Ligand B (-2.17). Solubility is important for bioavailability, favoring Ligand A.
11. **hERG:** Ligand A (0.221) has a lower hERG risk than Ligand B (0.048). Lower hERG is crucial for avoiding cardiotoxicity, and this is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand A (-2.916) has a much lower microsomal clearance than Ligand B (20.799), indicating better metabolic stability. This is a substantial advantage for Ligand A.
13. **t1/2:** Ligand A (-10.183) has a worse in vitro half-life than Ligand B (-17.964). This favors Ligand B.
14. **Pgp:** Ligand A (0.015) has lower P-gp efflux than Ligand B (0.046). Lower P-gp efflux is generally preferred, favoring Ligand A.
15. **Binding Affinity:** Ligand B (-6.5) has a slightly better binding affinity than Ligand A (-5.9). While a difference of 0.6 kcal/mol is noticeable, it's not overwhelmingly large, and can be compensated for by other factors.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity) and the general drug-like properties, Ligand A emerges as the more promising candidate. While Ligand B has a better QED and slightly better affinity, Ligand A has a significantly lower DILI risk, better hERG profile, and substantially better metabolic stability (lower Cl_mic). The solubility advantage of Ligand A is also beneficial. The slightly lower Caco-2 permeability is a concern, but potentially addressable through formulation. The improved safety profile and metabolic stability of Ligand A outweigh the modest affinity difference.
Output:
1
2025-04-17 23:47:34,390 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.435 and 344.499 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (122.55) is slightly above the preferred <140 for good oral absorption, but still reasonable. Ligand B (49.41) is excellent, well below 90, suggesting good permeability. Advantage: B.
3. **logP:** Ligand A (0.181) is quite low, potentially hindering membrane permeability. Ligand B (3.275) is within the optimal 1-3 range. Significant advantage: B.
4. **HBD:** Ligand A (4) is acceptable, while Ligand B (1) is even better, minimizing potential issues with hydrogen bonding and permeability. Advantage: B.
5. **HBA:** Ligand A (4) is acceptable, Ligand B (2) is better. Advantage: B.
6. **QED:** Ligand B (0.796) has a much better QED score than Ligand A (0.442), indicating a more drug-like profile. Significant advantage: B.
7. **DILI:** Both ligands have similar, low DILI risk (31.33 and 30.322 percentile). No significant difference.
8. **BBB:** Ligand A (78.519) and Ligand B (74.758) are both reasonably good, but not exceptional. Since ADRB2 is a cardiovascular target, BBB penetration is not a primary concern, but a slightly higher value is preferable. Slight advantage: A.
9. **Caco-2:** Ligand A (-5.286) and Ligand B (-4.817) are both negative, which is unusual and suggests poor permeability. However, the scale isn't specified, so it's difficult to interpret.
10. **Solubility:** Ligand A (-2.573) and Ligand B (-4.454) are both negative, suggesting poor solubility. Again, the scale is unknown.
11. **hERG:** Both ligands have very low hERG risk (0.076 and 0.348 percentile). No significant difference.
12. **Cl_mic:** Ligand A (30.313) has a lower microsomal clearance than Ligand B (72.355), indicating better metabolic stability. Advantage: A.
13. **t1/2:** Ligand A (7.808) has a shorter half-life than Ligand B (-3.473). The negative value for Ligand B is concerning and likely an error. Advantage: A.
14. **Pgp:** Ligand A (0.019) has a very low Pgp efflux liability, which is good. Ligand B (0.367) is higher, but still relatively low. Slight advantage: A.
15. **Binding Affinity:** Ligand B (-5.6 kcal/mol) has a significantly stronger binding affinity than Ligand A (-4.1 kcal/mol). This is a substantial advantage, potentially outweighing some ADME concerns. Significant advantage: B.
**Overall Assessment:**
Ligand B demonstrates a superior balance of properties, particularly in terms of predicted permeability (low TPSA, good logP), drug-likeness (high QED), and binding affinity. While Ligand A has better metabolic stability and Pgp efflux, the substantial improvement in binding affinity and the more favorable logP/TPSA profile of Ligand B are more critical for a GPCR target like ADRB2. The negative half-life for Ligand B is a red flag, but the binding affinity is so much better that it could be optimized.
Output:
0
2025-04-17 23:47:34,390 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [368.865, 74.77, 2.298, 1, 5, 0.78, 60.682, 68.554, -4.57, -2.789, 0.458, 52.292, 21.413, 0.073, -6.8]
**Ligand B:** [363.933, 48.99, 4.717, 1, 2, 0.795, 22.8, 78.868, -5.178, -4.427, 0.697, 81.486, 20.738, 0.779, -5.9]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal 200-500 Da range. Ligand B (363.933) is slightly lower, which is generally favorable.
2. **TPSA:** Ligand A (74.77) is higher than Ligand B (48.99). Ligand B is much better, being well below the 140 threshold for oral absorption.
3. **logP:** Ligand A (2.298) is within the optimal 1-3 range. Ligand B (4.717) is higher, potentially leading to solubility issues and off-target interactions, though not drastically so.
4. **HBD/HBA:** Both have 1 HBD, which is good. Ligand A has 5 HBA, while Ligand B has 2. Lower HBA is generally preferred for permeability, giving a slight edge to Ligand B.
5. **QED:** Both are good (>=0.5), indicating drug-like properties.
6. **DILI:** Ligand A (60.682) has a concerning DILI risk, being above the 40% threshold. Ligand B (22.8) is excellent, indicating a very low risk of liver injury. This is a significant advantage for Ligand B.
7. **BBB:** Ligand B (78.868) has a better BBB penetration score than Ligand A (68.554), though neither is exceptionally high. For a cardiovascular target, BBB isn't *critical*, but it's still a positive.
8. **Caco-2:** Ligand A (-4.57) is worse than Ligand B (-5.178), indicating lower intestinal absorption.
9. **Solubility:** Ligand A (-2.789) is worse than Ligand B (-4.427), indicating lower solubility.
10. **hERG:** Both have relatively low hERG risk, but Ligand B (0.697) is slightly better than Ligand A (0.458).
11. **Cl_mic:** Ligand B (81.486) has a higher microsomal clearance than Ligand A (52.292), meaning it's metabolized faster. This is a negative for Ligand B.
12. **t1/2:** Similar in vitro half-lives for both ligands.
13. **Pgp:** Ligand A (0.073) has lower P-gp efflux, which is favorable. Ligand B (0.779) has higher P-gp efflux.
14. **Affinity:** Ligand A (-6.8 kcal/mol) has a slightly better binding affinity than Ligand B (-5.9 kcal/mol). This is a 0.9 kcal/mol difference, which is a good advantage.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity, the significant advantages of Ligand B in terms of DILI risk, TPSA, solubility, and Caco-2 permeability outweigh this difference. The higher logP and clearance of Ligand B are concerns, but not as critical as the DILI risk associated with Ligand A. Given the GPCR target class, the lower TPSA and better predicted absorption of Ligand B are also beneficial.
Therefore, I would choose Ligand B.
0
2025-04-17 23:47:34,390 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (367.881 and 349.431 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (61.68) is significantly better than Ligand B (78.95). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have acceptable logP values (1.231 and 1.313), falling within the 1-3 range. Similar.
4. **HBD:** Ligand A (0) is preferable to Ligand B (1). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (4). Lower HBA is generally better for permeability.
6. **QED:** Ligand A (0.758) is better than Ligand B (0.6). Higher QED indicates a more drug-like profile.
7. **DILI:** Ligand A (25.087) is *much* better than Ligand B (59.946). This is a critical advantage for Ligand A, as liver toxicity is a major concern.
8. **BBB:** Ligand A (77.2) is better than Ligand B (62.233), though this isn't a primary concern for a cardiovascular target.
9. **Caco-2:** Ligand A (-4.9) is better than Ligand B (-4.539). Higher Caco-2 permeability suggests better absorption.
10. **Solubility:** Ligand A (-1.266) is slightly better than Ligand B (-1.573). Both are poor, but A is less poor.
11. **hERG:** Ligand A (0.343) is significantly better than Ligand B (0.13). Lower hERG inhibition is crucial to avoid cardiotoxicity, especially for a cardiovascular target.
12. **Cl_mic:** Ligand A (-1.332) is better than Ligand B (15.484). Lower clearance indicates greater metabolic stability.
13. **t1/2:** Ligand A (13.281) is better than Ligand B (-26.613). A longer half-life is generally desirable.
14. **Pgp:** Ligand A (0.033) is better than Ligand B (0.048). Lower Pgp efflux is preferable.
15. **Affinity:** Ligand A (-7.5) is slightly better than Ligand B (-7.0). While both are good, the small advantage to A adds to its overall profile.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A performs better across most of these, and critically, has a much better safety profile (DILI and hERG).
**Conclusion:**
Ligand A consistently outperforms Ligand B across nearly all key parameters, with particularly strong advantages in safety (DILI, hERG) and metabolic stability (Cl_mic, t1/2). The slightly better affinity further solidifies its position.
Output:
1
2025-04-17 23:47:34,390 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (344.415 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (58.64) is significantly better than Ligand A (105.39). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally improves absorption.
3. **logP:** Ligand B (3.084) is optimal, while Ligand A (0.305) is quite low, potentially hindering membrane permeability. This is a significant drawback for Ligand A.
4. **HBD/HBA:** Ligand A has 2 HBD and 4 HBA, while Ligand B has 1 HBD and 3 HBA. Both are acceptable.
5. **QED:** Both ligands have reasonable QED scores (A: 0.774, B: 0.648), indicating good drug-like properties.
6. **DILI:** Both ligands have similar, acceptable DILI risk (A: 30.593, B: 30.399).
7. **BBB:** Ligand B (85.537) has a higher BBB penetration percentile than Ligand A (70.26), but this is less critical for a cardiovascular target.
8. **Caco-2:** Ligand A (-5.462) has a worse Caco-2 permeability than Ligand B (-4.31).
9. **Solubility:** Ligand A (-2.131) has a worse solubility than Ligand B (-3.308).
10. **hERG:** Ligand A (0.058) has a significantly lower hERG inhibition liability than Ligand B (0.825), which is a major advantage.
11. **Cl_mic:** Ligand A (21.953) has a much lower microsomal clearance than Ligand B (76.881), suggesting better metabolic stability.
12. **t1/2:** Ligand B (17.688) has a longer in vitro half-life than Ligand A (1.49), which is generally desirable.
13. **Pgp:** Ligand A (0.008) has a much lower P-gp efflux liability than Ligand B (0.22), which is favorable for bioavailability.
14. **Binding Affinity:** Ligand A (-8.0) has a significantly stronger binding affinity than Ligand B (-6.4). This is a substantial advantage, potentially outweighing some ADME concerns.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in TPSA and has a good logP. Ligand A has a poor logP but a *much* better affinity and Pgp profile. The large affinity difference is the deciding factor. While the low logP of Ligand A is concerning, the strong binding could compensate, and formulation strategies could be employed to address solubility/permeability issues. The better metabolic stability (lower Cl_mic) and lower hERG risk of Ligand A are also significant positives.
**Conclusion:**
Considering the strong binding affinity of Ligand A and its favorable safety profile (low hERG, low Pgp, lower DILI), I believe it is the more promising drug candidate despite its lower logP.
Output:
1
2025-04-17 23:47:34,391 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (349.431 and 347.375 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (82.87) is significantly better than Ligand B (130.02). For a GPCR, keeping TPSA under 140 is good for oral absorption, and A is much closer to the ideal <90 for CNS penetration (though not a CNS target here, lower TPSA is generally favorable).
**3. logP:** Ligand A (0.647) is slightly lower than the optimal 1-3 range, but still acceptable. Ligand B (-0.152) is a bit concerningly low, potentially hindering membrane permeability.
**4. H-Bond Donors:** Ligand A (0) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
**5. H-Bond Acceptors:** Ligand A (5) is better than Ligand B (7), again favoring permeability.
**6. QED:** Both ligands have good QED scores (0.728 and 0.762), indicating generally drug-like properties.
**7. DILI Risk:** Ligand A (23.187) has a much lower DILI risk than Ligand B (48.313). This is a significant advantage for Ligand A.
**8. BBB Penetration:** Not a primary concern for a cardiovascular target, but Ligand A (85.343) is better than Ligand B (45.715).
**9. Caco-2 Permeability:** Ligand A (-4.376) is better than Ligand B (-5.027), indicating better intestinal absorption.
**10. Aqueous Solubility:** Ligand A (-1.409) is better than Ligand B (-2.359), which is important for formulation and bioavailability.
**11. hERG Inhibition:** Ligand A (0.386) is significantly better than Ligand B (0.021), indicating a lower risk of cardiotoxicity. This is *critical* for a cardiovascular drug.
**12. Microsomal Clearance:** Ligand B (8.378) has higher clearance than Ligand A (5.3), suggesting lower metabolic stability.
**13. In vitro Half-Life:** Ligand A (5.341) has a better half-life than Ligand B (-5.601).
**14. P-gp Efflux:** Ligand A (0.073) is better than Ligand B (0.009), indicating less efflux and potentially better bioavailability.
**15. Binding Affinity:** Ligand B (-7.2) has a slightly better binding affinity than Ligand A (-6.5), a 0.7 kcal/mol difference. While affinity is important, the other ADME properties of Ligand A are significantly better.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most crucial ADME properties (TPSA, logP, DILI, hERG, solubility, permeability, clearance, half-life, P-gp efflux). The slightly better affinity of Ligand B is not enough to overcome the substantial advantages of Ligand A, especially considering the cardiovascular target and the need to minimize cardiotoxicity (hERG).
Output:
1
2025-04-17 23:47:34,391 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (a cardiovascular GPCR) drug candidates.
**Ligand A:** [348.403, 86.96, 0.206, 0, 5, 0.776, 38.116, 64.831, -4.739, -0.179, 0.036, 19.963, -29.102, 0.041, -8.7]
**Ligand B:** [350.503, 67.43, 2.664, 2, 3, 0.724, 14.889, 80.69, -4.578, -3.448, 0.34, 79.819, -4.858, 0.016, -3.5]
Here's a breakdown, considering the provided guidelines and GPCR-specific priorities (logP, Pgp, TPSA, affinity):
1. **MW:** Both are within the ideal range (200-500 Da). A is 348.4, B is 350.5 - very similar.
2. **TPSA:** A (86.96) is slightly higher than B (67.43), but both are below the 140 threshold for oral absorption. B is better here.
3. **logP:** A (0.206) is quite low, potentially hindering permeation. B (2.664) is much better, falling within the optimal 1-3 range. This is a significant advantage for B.
4. **HBD:** A (0) is ideal. B (2) is acceptable.
5. **HBA:** A (5) is good. B (3) is also good.
6. **QED:** Both are good (A: 0.776, B: 0.724), indicating drug-like properties.
7. **DILI:** A (38.116) is better than B (14.889), indicating a lower risk of liver injury.
8. **BBB:** B (80.69) is significantly better than A (64.831). While not a primary concern for a cardiovascular target, higher BBB penetration can sometimes be beneficial.
9. **Caco-2:** Both are negative, indicating poor permeability. A (-4.739) is slightly worse than B (-4.578).
10. **Solubility:** A (-0.179) is better than B (-3.448).
11. **hERG:** Both are very low, suggesting minimal hERG inhibition risk. A (0.036) is slightly better than B (0.34).
12. **Cl_mic:** A (19.963) is much lower than B (79.819), indicating better metabolic stability.
13. **t1/2:** A (-29.102) is much longer than B (-4.858), suggesting a longer half-life.
14. **Pgp:** A (0.041) is much lower than B (0.016), indicating less P-gp efflux.
15. **Affinity:** A (-8.7) is significantly stronger than B (-3.5). This is a substantial advantage for A, potentially outweighing some ADME concerns.
**Overall Assessment:**
Ligand A has a much stronger binding affinity and better metabolic stability (lower Cl_mic, longer t1/2), lower Pgp efflux, and lower DILI risk. However, it suffers from a very low logP and poor Caco-2 permeability. Ligand B has a better logP, TPSA, and BBB penetration, but its affinity is significantly weaker, and it has higher Pgp efflux and a higher DILI risk.
For a GPCR, affinity is paramount. The substantial difference in binding affinity (-8.7 vs -3.5 kcal/mol) is a major deciding factor. While the ADME properties of Ligand A are not ideal, they can potentially be improved through further optimization. The weaker affinity of Ligand B is a more difficult hurdle to overcome.
Therefore, I would prioritize Ligand A.
1
2025-04-17 23:47:34,391 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Ligand A (456.309 Da) is within the ideal range, while Ligand B (346.435 Da) is on the lower side, but still acceptable.
2. **TPSA:** Ligand A (53.51) is good, well below the 140 threshold. Ligand B (84.22) is also acceptable, but higher.
3. **logP:** Ligand A (3.493) is optimal. Ligand B (0.725) is quite low, potentially causing permeability issues.
4. **HBD:** Both ligands have 0 HBD, which is good.
5. **HBA:** Ligand A has 5 HBA, acceptable. Ligand B has 6 HBA, also acceptable.
6. **QED:** Both ligands have similar, good QED values (0.707 and 0.75).
7. **DILI:** Ligand A (83.249) has a higher DILI risk than Ligand B (38.969). This is a significant negative for Ligand A.
8. **BBB:** Ligand A (85.459) has better BBB penetration than Ligand B (71.656). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be beneficial or at least manageable.
9. **Caco-2:** Ligand A (-4.789) has a worse Caco-2 permeability than Ligand B (-5.001). Both are quite poor.
10. **Solubility:** Ligand A (-5.207) has worse solubility than Ligand B (-1.575).
11. **hERG:** Ligand A (0.869) has a slightly higher hERG risk than Ligand B (0.075). This is a significant advantage for Ligand B.
12. **Cl_mic:** Ligand A (45.548) has a higher microsomal clearance than Ligand B (26.787), indicating lower metabolic stability.
13. **t1/2:** Ligand A (-9.121) has a worse in vitro half-life than Ligand B (-8.49).
14. **Pgp:** Ligand A (0.531) has better Pgp efflux profile than Ligand B (0.087).
15. **Affinity:** Ligand A (-7.7 kcal/mol) has a better binding affinity than Ligand B (-6.6 kcal/mol). This is a 1.1 kcal/mol difference, which is substantial.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand A has better logP, Pgp, and affinity, but Ligand B has better TPSA. However, the significantly better affinity of Ligand A, combined with acceptable logP, outweighs the slightly higher TPSA. The major drawbacks of Ligand A are the higher DILI risk and lower solubility. However, the affinity difference is large enough that optimization efforts could likely address these ADME concerns. Ligand B's low logP is a significant concern for permeability.
**Conclusion:**
Despite the higher DILI risk and lower solubility of Ligand A, its significantly improved binding affinity and better Pgp efflux, coupled with acceptable logP, make it the more promising starting point for drug development targeting ADRB2.
Output:
1
2025-04-17 23:47:34,391 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [347.419, 107.23 , 0.391, 2. , 5. , 0.63 , 42.613, 41.373, -5.109, -1.821, 0.504, 19.006, 27.636, 0.036, -6.7 ]
**Ligand B:** [346.515, 58.2 , 3.402, 2. , 2. , 0.819, 33.23 , 73.866, -4.68 , -4.326, 0.415, 24.097, 38.02 , 0.142, -8.1 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal 200-500 Da range. (A: 347.419, B: 346.515) - No clear advantage.
2. **TPSA:** Ligand B (58.2) is significantly better than Ligand A (107.23). GPCRs benefit from lower TPSA for permeability.
3. **logP:** Ligand B (3.402) is optimal, while Ligand A (0.391) is quite low, potentially hindering membrane permeability. This is a significant advantage for B.
4. **HBD:** Both have 2 HBD, which is acceptable.
5. **HBA:** Ligand B (2) is better than Ligand A (5). Lower HBA generally improves permeability.
6. **QED:** Ligand B (0.819) is better than Ligand A (0.63), indicating a more drug-like profile.
7. **DILI:** Ligand B (33.23) has a lower DILI risk than Ligand A (42.613). Both are acceptable, but B is preferable.
8. **BBB:** Ligand B (73.866) is much better than Ligand A (41.373). For a GPCR, even if not specifically a CNS target, some BBB penetration can be beneficial for distribution.
9. **Caco-2:** Ligand A (-5.109) is better than Ligand B (-4.68).
10. **Solubility:** Ligand A (-1.821) is better than Ligand B (-4.326).
11. **hERG:** Both are low, indicating low cardiotoxicity risk. (A: 0.504, B: 0.415) - No clear advantage.
12. **Cl_mic:** Ligand A (19.006) has lower microsomal clearance than Ligand B (24.097), suggesting better metabolic stability.
13. **t1/2:** Ligand B (38.02) has a longer half-life than Ligand A (27.636).
14. **Pgp:** Ligand A (0.036) has lower P-gp efflux than Ligand B (0.142), which is beneficial for bioavailability.
15. **Affinity:** Ligand B (-8.1) has a significantly stronger binding affinity than Ligand A (-6.7). This is a substantial advantage.
**Overall Assessment:**
Ligand B clearly outperforms Ligand A across several crucial parameters for a GPCR drug candidate. The significantly better logP, TPSA, QED, BBB penetration, and *especially* the binding affinity of Ligand B outweigh the slight advantages of Ligand A in Caco-2 permeability, solubility, and metabolic stability. The stronger binding affinity is a major driver, as a 1.4 kcal/mol difference is substantial.
Output:
0
2025-04-17 23:47:34,391 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (351.403 and 360.523 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (58.2) is significantly better than Ligand A (106.62). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (3.824) is higher than Ligand A (1.901), approaching the upper limit of the optimal range. While higher logP can sometimes cause issues, it can also be beneficial for receptor binding in GPCRs. Ligand A is on the lower side.
4. **HBD:** Both ligands have 2 HBD, which is within the acceptable limit of 5.
5. **HBA:** Ligand B (3) is lower than Ligand A (6), which is favorable for permeability.
6. **QED:** Both ligands have the same QED (0.758), indicating good drug-likeness.
7. **DILI:** Ligand B (46.026) has a significantly lower DILI risk than Ligand A (64.366). This is a crucial advantage.
8. **BBB:** Both ligands have similar BBB penetration (64.87 and 62.97). Not a major factor for a cardiovascular target.
9. **Caco-2:** Ligand A (-4.528) has a more negative Caco-2 value, suggesting better permeability than Ligand B (-5.03).
10. **Solubility:** Ligand A (-3.467) has slightly better solubility than Ligand B (-3.727).
11. **hERG:** Both ligands have low hERG inhibition liability (0.29 and 0.325).
12. **Cl_mic:** Ligand B (50.067) has a lower microsomal clearance than Ligand A (81.736), indicating better metabolic stability.
13. **t1/2:** Ligand B (23.64) has a significantly longer in vitro half-life than Ligand A (-17.441). This is a major advantage.
14. **Pgp:** Ligand B (0.551) has slightly higher Pgp efflux liability than Ligand A (0.036). This is a negative for Ligand B.
15. **Binding Affinity:** Ligand B (-6.3) has a slightly better binding affinity than Ligand A (-5.8). While the difference is not huge, it is still a positive.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are important. Ligand B has a better logP, significantly lower TPSA, and slightly better affinity. The lower DILI risk and improved metabolic stability (lower Cl_mic and longer t1/2) are also very important. While Ligand A has better Caco-2 permeability and lower Pgp efflux, the overall profile of Ligand B is more favorable.
**Conclusion:**
Considering the balance of properties, particularly the lower DILI risk, better metabolic stability, and slightly improved affinity of Ligand B, it is the more promising drug candidate.
Output:
0
2025-04-17 23:47:34,392 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
The target is ADRB2, a GPCR. Therefore, I will prioritize logP, TPSA, Pgp efflux, BBB penetration, and binding affinity, alongside general drug-like properties.
**Ligand A Analysis:**
* **MW:** 360.395 Da - Good, within the ideal range.
* **TPSA:** 88.12 - Acceptable, slightly above the optimal <90 for GPCRs, but still reasonable.
* **logP:** 1.135 - Good, within the optimal 1-3 range.
* **HBD:** 0 - Low, potentially impacting solubility.
* **HBA:** 9 - Acceptable, within the limit of 10.
* **QED:** 0.514 - Good, above the 0.5 threshold.
* **DILI:** 87.088 - High, significant liver injury risk. This is a major concern.
* **BBB:** 69.756 - Moderate, not ideal for a GPCR, but not terrible.
* **Caco-2:** -4.505 - Very poor permeability.
* **Solubility:** -3.334 - Very poor solubility.
* **hERG:** 0.542 - Low risk, good.
* **Cl_mic:** 64.886 - Moderate clearance, not ideal.
* **t1/2:** 12.715 - Moderate half-life.
* **Pgp:** 0.691 - Moderate efflux, could limit bioavailability.
* **Affinity:** -6.8 kcal/mol - Good binding affinity.
**Ligand B Analysis:**
* **MW:** 370.797 Da - Good, within the ideal range.
* **TPSA:** 137.3 - High, potentially hindering absorption.
* **logP:** 0.097 - Low, could impede permeation.
* **HBD:** 3 - Acceptable.
* **HBA:** 8 - Acceptable.
* **QED:** 0.532 - Good, above the 0.5 threshold.
* **DILI:** 63.009 - Moderate, better than Ligand A but still warrants attention.
* **BBB:** 74.952 - Good, better than Ligand A.
* **Caco-2:** -5.849 - Very poor permeability.
* **Solubility:** -2.738 - Poor solubility.
* **hERG:** 0.344 - Low risk, good.
* **Cl_mic:** 19.168 - Low clearance, good metabolic stability.
* **t1/2:** 22.994 - Good half-life.
* **Pgp:** 0.096 - Low efflux, good bioavailability potential.
* **Affinity:** -7.5 kcal/mol - Excellent binding affinity, 0.7 kcal/mol better than Ligand A.
**Comparison and Decision:**
Ligand B has a significantly better binding affinity (-7.5 vs -6.8 kcal/mol). While its TPSA and logP are less ideal than Ligand A, the superior affinity and lower Pgp efflux, combined with better metabolic stability (lower Cl_mic) and longer half-life, are compelling. The DILI risk is also lower for Ligand B. Both compounds have poor Caco-2 and solubility, but the affinity advantage of Ligand B is substantial enough to outweigh these drawbacks, especially given the GPCR target class. The higher BBB penetration for Ligand B is also a plus. The DILI risk for Ligand A is a major red flag.
Therefore, I prefer Ligand B.
Output:
0
2025-04-17 23:47:34,392 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.5 and 344.5 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (24.94) is significantly better than Ligand B (49.41). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (3.538 and 3.417), falling within the optimal 1-3 range. Very similar.
4. **HBD:** Ligand A (0) is preferable to Ligand B (1). Fewer HBDs generally improve membrane permeability.
5. **HBA:** Ligand A (4) is better than Ligand B (2). Lower HBA is generally more favorable for permeability.
6. **QED:** Both ligands have similar and acceptable QED values (0.754 and 0.777), indicating good drug-like properties.
7. **DILI:** Ligand A (3.645) has a much lower DILI risk than Ligand B (40.054). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (83.055) has a higher BBB penetration percentile than Ligand B (66.382). While not critical for a cardiovascular target, it's a slight positive.
9. **Caco-2:** Ligand A (-4.738) and Ligand B (-5.023) are similar, indicating poor permeability.
10. **Solubility:** Ligand A (-1.814) is better than Ligand B (-4.458). Better solubility is always a plus.
11. **hERG:** Ligand A (0.955) has a lower hERG inhibition liability than Ligand B (0.23). This is a significant safety advantage for Ligand A.
12. **Cl_mic:** Ligand A (20.475) has a significantly lower microsomal clearance than Ligand B (57.423), indicating better metabolic stability.
13. **t1/2:** Ligand A (-6.647) has a longer in vitro half-life than Ligand B (-14.188). This is a positive for dosing convenience.
14. **Pgp:** Ligand A (0.219) has lower P-gp efflux liability than Ligand B (0.41). This is beneficial for bioavailability.
15. **Affinity:** Ligand A (-7.9) has a significantly stronger binding affinity than Ligand B (-5.8). This is a substantial advantage, and can often outweigh minor ADME concerns.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Both ligands have acceptable logP values. Ligand A is significantly better regarding TPSA, Pgp, and affinity.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most key ADME properties (DILI, hERG, Cl_mic, t1/2, Pgp, Solubility) and has a substantially stronger binding affinity. The slightly poorer Caco-2 permeability is a concern, but the significant advantages in other areas, especially safety (DILI, hERG) and potency (affinity), make Ligand A the more promising candidate.
Output:
1
2025-04-17 23:47:34,392 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [359.26 , 104.41 , 2.06 , 0. , 8. , 0.692, 84.684, 93.835, -4.391, -3.253, 0.302, 73.06 , -31.928, 0.107, -6.6 ]
**Ligand B:** [349.475, 65.79 , 2.429, 1. , 4. , 0.744, 24.234, 70.105, -4.932, -1.449, 0.717, 11.611, 43.195, 0.196, -6.8 ]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, Affinity, and to a lesser extent BBB):
1. **MW:** Both are within the ideal 200-500 Da range. A (359.26) is slightly higher, but acceptable.
2. **TPSA:** A (104.41) is a bit higher than ideal for good oral absorption (<140), but still reasonable. B (65.79) is excellent, well below the 140 threshold.
3. **logP:** Both are in the optimal 1-3 range (A: 2.06, B: 2.429). B is slightly higher, which could be a minor concern for off-target effects, but not a dealbreaker.
4. **HBD/HBA:** A (0 HBD, 8 HBA) is good. B (1 HBD, 4 HBA) is also good.
5. **QED:** Both have acceptable QED scores (A: 0.692, B: 0.744), indicating reasonable drug-likeness.
6. **DILI:** This is a critical parameter. A has a significantly higher DILI risk (84.684) than B (24.234). This is a major red flag for Ligand A.
7. **BBB:** A (93.835) shows excellent BBB penetration, while B (70.105) is good, but not as high. For a cardiovascular target, BBB isn't *as* critical as for CNS targets, but it's still a positive.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. This is concerning for both, but the magnitude of the negative value is slightly less for B (-4.391 vs -4.932).
9. **Solubility:** Both have negative solubility values, indicating poor aqueous solubility. A (-3.253) is slightly better than B (-1.449).
10. **hERG:** Both have low hERG inhibition risk (A: 0.302, B: 0.717).
11. **Cl_mic:** A (73.06) has a higher microsomal clearance than B (11.611), indicating faster metabolism and potentially lower exposure.
12. **t1/2:** A (-31.928) has a very short in vitro half-life, while B (43.195) has a much longer half-life. This is a significant advantage for B.
13. **Pgp:** Both have very low P-gp efflux liability (A: 0.107, B: 0.196).
14. **Affinity:** Both have excellent binding affinity (A: -6.6 kcal/mol, B: -6.8 kcal/mol). B is slightly better, but the difference is small.
**Overall Assessment:**
While Ligand A has better BBB penetration and slightly better solubility, the significantly higher DILI risk and much shorter half-life are major drawbacks. Ligand B, despite slightly lower BBB penetration, presents a much more favorable safety profile (DILI) and pharmacokinetic profile (longer half-life, lower clearance). The small difference in binding affinity is outweighed by the ADME/Tox advantages of Ligand B.
Therefore, I would choose Ligand B.
Output:
0
2025-04-17 23:47:34,392 - INFO - Batch 430 complete. Total preferences: 6880
2025-04-17 23:47:34,392 - INFO - Processing batch 431/512...
2025-04-17 23:48:25,146 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.4 and 341.4 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (92.78) is higher than Ligand B (68.39). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is generally preferred for absorption. Ligand B has a clear advantage.
3. **logP:** Ligand A (0.582) is quite low, potentially hindering permeability. Ligand B (3.673) is within the optimal 1-3 range. Ligand B is significantly better here.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 5 HBA, Ligand B has 4. Both are acceptable.
6. **QED:** Ligand B (0.865) has a higher QED score than Ligand A (0.56), indicating better overall drug-likeness.
7. **DILI:** Ligand A (41.722) has a lower DILI risk than Ligand B (57.154), which is a positive.
8. **BBB:** Both are relatively low, but Ligand B (76.386) is higher than Ligand A (66.499). Since ADRB2 is not a CNS target, this is a minor advantage for B.
9. **Caco-2:** Both have negative values, indicating poor permeability. Ligand A (-4.731) is slightly worse than Ligand B (-4.393).
10. **Solubility:** Ligand A (-2.004) has better solubility than Ligand B (-4.567). This is a positive for Ligand A.
11. **hERG:** Ligand A (0.055) has a much lower hERG risk than Ligand B (0.625). This is a significant advantage for Ligand A, given the cardiovascular target.
12. **Cl_mic:** Ligand B (80.62) has a higher microsomal clearance than Ligand A (33.276), suggesting lower metabolic stability. Ligand A is preferred.
13. **t1/2:** Ligand A (-15.795) has a negative half-life, while Ligand B (0.289) is very short. Both are poor, but Ligand B is slightly better.
14. **Pgp:** Ligand A (0.029) has a much lower Pgp efflux liability than Ligand B (0.383). This is a positive for Ligand A.
15. **Binding Affinity:** Ligand B (-7.1 kcal/mol) has a slightly better binding affinity than Ligand A (-6.7 kcal/mol). This is a 1.5 kcal/mol difference, which is significant.
**Overall Assessment:**
Ligand B has a better logP, QED, and binding affinity. However, Ligand A has a significantly better safety profile (lower DILI and hERG), lower Pgp efflux, and better metabolic stability (lower Cl_mic). The lower logP of Ligand A is a concern, but the superior safety profile and metabolic stability are crucial for a cardiovascular drug. The slightly better affinity of Ligand B is not enough to overcome these significant ADME/Tox advantages of Ligand A.
Output:
1
2025-04-17 23:48:25,146 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Ligand A (401.264 Da) is within the ideal range, while Ligand B (354.447 Da) is also acceptable, leaning towards the lower end. No strong preference here.
2. **TPSA:** Ligand A (71.25) is good, well below the 140 threshold. Ligand B (88.1) is still reasonable, but higher. This favors Ligand A slightly.
3. **logP:** Ligand A (2.665) is optimal. Ligand B (0.474) is quite low, potentially hindering membrane permeability. This is a significant advantage for Ligand A.
4. **HBD:** Both ligands have acceptable HBD counts (1 and 2 respectively).
5. **HBA:** Both ligands have the same HBA count (5), which is acceptable.
6. **QED:** Ligand A (0.69) is better than Ligand B (0.489), indicating a more drug-like profile.
7. **DILI:** Ligand B (25.553) has a much lower DILI risk than Ligand A (65.607). This is a substantial advantage for Ligand B.
8. **BBB:** Ligand B (56.805) shows better BBB penetration than Ligand A (36.952), though neither is exceptionally high. For a cardiovascular target, BBB isn't a primary concern, but it's still a positive for Ligand B.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Both have negative solubility values, which is also unusual and suggests poor solubility. Again, the scale is not specified.
11. **hERG:** Ligand A (0.84) has a slightly higher hERG risk than Ligand B (0.332). This favors Ligand B.
12. **Cl_mic:** Ligand A (33.111) has a higher microsomal clearance than Ligand B (9.904), indicating lower metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand A (11.403) has a longer in vitro half-life than Ligand B (8.8). This favors Ligand A.
14. **Pgp:** Ligand A (0.284) has lower P-gp efflux liability than Ligand B (0.038), which is preferable.
15. **Binding Affinity:** Ligand A (-7.5 kcal/mol) has a slightly better binding affinity than Ligand B (-5.2 kcal/mol). This is a significant advantage for Ligand A, potentially outweighing some ADME drawbacks.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A excels in logP and affinity, and has a better Pgp profile. Ligand B has a better DILI and Cl_mic. The affinity difference is substantial (2.3 kcal/mol), and the logP of Ligand B is concerning.
**Overall Assessment:**
While Ligand B has advantages in DILI, hERG, and metabolic stability, the significantly better logP and binding affinity of Ligand A are more crucial for a GPCR target. The lower logP of Ligand B raises concerns about permeability, and the affinity difference is large enough to potentially overcome the slightly higher DILI risk of Ligand A.
Output:
1
2025-04-17 23:48:25,147 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (358.36 and 351.451 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (58.64) is well below the 140 threshold and excellent for oral absorption. Ligand B (99.49) is higher, but still acceptable, though less optimal.
3. **logP:** Ligand A (2.133) is within the optimal 1-3 range. Ligand B (-0.264) is *below* 1, which is a concern for permeability.
4. **HBD:** Both ligands have acceptable HBD counts (1 and 3, respectively), below the threshold of 5.
5. **HBA:** Ligand A (3) is good. Ligand B (6) is higher, but still within the acceptable range of 10.
6. **QED:** Both ligands have similar, good QED values (0.648 and 0.628), indicating good drug-like properties.
7. **DILI:** Ligand A (38.697) has a slightly higher DILI risk than Ligand B (13.92), but both are below the concerning 60 percentile.
8. **BBB:** Ligand A (96.123) has excellent BBB penetration, while Ligand B (31.601) is low. This is a significant advantage for Ligand A, even though ADRB2 isn't exclusively a CNS target, some CNS exposure can be beneficial.
9. **Caco-2:** Ligand A (-4.601) is poor, while Ligand B (-5.402) is also poor.
10. **Solubility:** Ligand A (-2.821) is poor, while Ligand B (-1.188) is also poor.
11. **hERG:** Ligand A (0.79) has a lower hERG risk than Ligand B (0.218), which is favorable.
12. **Cl_mic:** Ligand A (36.136) has a higher microsomal clearance than Ligand B (-20.396), meaning Ligand B is more metabolically stable. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand A (19.776) has a longer half-life than Ligand B (8.749).
14. **Pgp:** Ligand A (0.47) has lower P-gp efflux than Ligand B (0.008), which is favorable.
15. **Affinity:** Ligand B (-7.4 kcal/mol) has a slightly better binding affinity than Ligand A (-6.3 kcal/mol). The difference is 1.1 kcal/mol, which is a notable advantage.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are crucial. Ligand A has a better logP and Pgp profile, and a good BBB score. Ligand B has a better affinity and metabolic stability. The lower logP of ligand B is a significant drawback, potentially hindering its ability to cross cell membranes.
**Overall Assessment:**
While Ligand B has a slightly better binding affinity and metabolic stability, the significantly lower logP and poor BBB penetration are major concerns. Ligand A, despite the slightly weaker affinity, has a much more favorable balance of properties, particularly its logP, BBB, and Pgp efflux. The better permeability and potential for some CNS exposure (even if not the primary goal) are valuable for a GPCR target.
Output:
1
2025-04-17 23:48:25,147 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [348.447, 95.42, 1.82, 2, 5, 0.846, 39.744, 61.38, -4.962, -1.845, 0.189, 22.717, -16.723, 0.036, -6.2]
**Ligand B:** [348.487, 69.64, 2.247, 2, 3, 0.749, 20.9, 65.297, -5.074, -2.543, 0.361, 37.22, 3.573, 0.204, -6.0]
Here's a breakdown, prioritizing GPCR properties (logP, TPSA, Pgp, BBB, and affinity):
1. **Molecular Weight:** Both are excellent (around 348 Da), falling well within the 200-500 Da range.
2. **TPSA:** Ligand B (69.64) is significantly better than Ligand A (95.42). A lower TPSA generally indicates better membrane permeability, crucial for GPCRs. Ligand B is comfortably under the 140 threshold, while A is approaching it.
3. **logP:** Both are good (1.82 and 2.247), falling within the optimal 1-3 range. Ligand B is slightly better.
4. **H-Bond Donors/Acceptors:** Both have 2 HBD and reasonable HBA counts (5 and 3 respectively), which is good for balancing solubility and permeability.
5. **QED:** Ligand A (0.846) has a better QED score than Ligand B (0.749), suggesting a more drug-like profile overall.
6. **DILI:** Ligand B (20.9) has a much lower DILI risk than Ligand A (39.744). This is a significant advantage.
7. **BBB:** Ligand B (65.297) has a slightly better BBB penetration score than Ligand A (61.38), but both are reasonable.
8. **Caco-2 Permeability:** Ligand A (-4.962) has better Caco-2 permeability than Ligand B (-5.074), suggesting better intestinal absorption.
9. **Aqueous Solubility:** Ligand B (-2.543) has better aqueous solubility than Ligand A (-1.845).
10. **hERG:** Both have low hERG inhibition liability (0.189 and 0.361), which is good.
11. **Microsomal Clearance:** Ligand A (22.717) has a lower microsomal clearance than Ligand B (37.22), indicating better metabolic stability.
12. **In vitro Half-Life:** Ligand A (-16.723) has a significantly longer in vitro half-life than Ligand B (3.573). This is a major advantage.
13. **P-gp Efflux:** Both have very low P-gp efflux liability (0.036 and 0.204).
14. **Binding Affinity:** Ligand A (-6.2) has a slightly stronger binding affinity than Ligand B (-6.0).
**Overall Assessment:**
While Ligand A has a slightly better binding affinity and a longer half-life, Ligand B demonstrates a superior balance of properties critical for a GPCR drug candidate, particularly ADRB2. The lower TPSA, significantly lower DILI risk, and better solubility of Ligand B outweigh the minor advantage in affinity and half-life of Ligand A. The slightly better BBB penetration of Ligand B is also a plus.
Therefore, I prefer Ligand B.
Output:
0
2025-04-17 23:48:25,147 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [363.403, 134.66 , 0.225, 3. , 7. , 0.594, 85.653, 35.052, -5.872, -2.739, 0.205, 24.293, -13.656, 0.027, -7. ]
**Ligand B:** [347.394, 79.38 , 2.186, 2. , 5. , 0.751, 66.421, 62.854, -4.742, -2.149, 0.385, 37.195, 4.233, 0.017, -6.2 ]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity, and to a lesser extent BBB):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (347.4) is slightly preferred due to being a bit lower.
2. **TPSA:** Ligand A (134.66) is borderline, while Ligand B (79.38) is excellent. This is a significant advantage for Ligand B, promoting better permeability.
3. **logP:** Ligand A (0.225) is quite low, potentially hindering membrane permeability. Ligand B (2.186) is within the optimal range. This is a major advantage for Ligand B.
4. **HBD/HBA:** Ligand A has 3 HBD and 7 HBA, while Ligand B has 2 HBD and 5 HBA. Both are acceptable, but Ligand B is slightly better.
5. **QED:** Both have good QED scores (A: 0.594, B: 0.751), indicating good drug-like properties. Ligand B is better.
6. **DILI:** Ligand A (85.653) has a higher DILI risk than Ligand B (66.421), which is preferable.
7. **BBB:** Ligand A (35.052) has very low BBB penetration, while Ligand B (62.854) is moderate. While ADRB2 isn't a CNS target, some peripheral exposure can be beneficial, and lower BBB penetration can reduce off-target effects.
8. **Caco-2:** Ligand A (-5.872) is very poor, while Ligand B (-4.742) is also poor, but better.
9. **Solubility:** Both have poor solubility (-2.739 and -2.149). This is a concern for both, but not a deciding factor.
10. **hERG:** Both have low hERG risk (0.205 and 0.385).
11. **Cl_mic:** Ligand A (24.293) has lower clearance, suggesting better metabolic stability than Ligand B (37.195).
12. **t1/2:** Ligand A (-13.656) has a negative half-life, which is concerning, while Ligand B (4.233) has a positive half-life.
13. **Pgp:** Both have very low Pgp efflux (0.027 and 0.017).
14. **Affinity:** Ligand A (-7.0) has a slightly better affinity than Ligand B (-6.2), but the difference is less than 1.5 kcal/mol.
**Overall Assessment:**
Ligand B clearly outperforms Ligand A across several critical parameters. Its superior TPSA, logP, QED, DILI, and *positive* half-life are significant advantages. While Ligand A has slightly better affinity and metabolic stability, the ADME profile of Ligand B is much more promising, especially considering the GPCR target class. The poor Caco-2 and solubility of both are concerns that would need to be addressed in further optimization, but Ligand B starts from a better position.
Output:
0
2025-04-17 23:48:25,147 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (361.43 & 354.54 Da) fall comfortably within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (69.64) is significantly better than Ligand A (118.28). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. This favors Ligand B.
3. **logP:** Ligand B (2.961) is optimal, while Ligand A (0.823) is a bit low, potentially hindering membrane permeability. This is a significant advantage for Ligand B.
4. **HBD:** Both have 2 HBD, which is within the acceptable limit of 5. No difference.
5. **HBA:** Ligand A has 5 HBA, and Ligand B has 3. Both are within the acceptable limit of 10. Ligand B is slightly better.
6. **QED:** Ligand A (0.836) has a slightly better QED score than Ligand B (0.77), indicating a more drug-like profile. This is a small advantage for Ligand A.
7. **DILI:** Ligand B (12.80) has a much lower DILI risk than Ligand A (65.41). This is a *major* advantage for Ligand B. DILI is a critical safety concern.
8. **BBB:** Both have moderate BBB penetration (53.51% and 55.64%). Not a major factor for a cardiovascular target.
9. **Caco-2:** Ligand A (-5.322) has a worse Caco-2 permeability than Ligand B (-4.688). This favors Ligand B.
10. **Solubility:** Ligand A (-2.088) has better solubility than Ligand B (-3.155). Solubility is important, but not as critical as permeability or safety.
11. **hERG:** Ligand A (0.033) has a much lower hERG inhibition liability than Ligand B (0.489). This is a significant advantage for Ligand A, as hERG inhibition can cause cardiotoxicity.
12. **Cl_mic:** Ligand A (-26.572) has a much lower microsomal clearance, indicating better metabolic stability, than Ligand B (41.728). This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (6.636) has a longer in vitro half-life than Ligand B (-2.243). This favors Ligand A.
14. **Pgp:** Ligand A (0.016) has lower P-gp efflux liability than Ligand B (0.155). This favors Ligand A.
15. **Binding Affinity:** Ligand A (-7.1) has a slightly better binding affinity than Ligand B (-6.2). While both are good, the 0.9 kcal/mol difference is significant.
**Overall Assessment:**
Ligand A has a better binding affinity, metabolic stability (lower Cl_mic), longer half-life, lower Pgp efflux, and lower hERG inhibition. However, Ligand B has a much lower DILI risk, better TPSA, and a more optimal logP. The DILI risk for Ligand A is concerningly high. The slightly better affinity of Ligand A is unlikely to outweigh the significant safety concerns associated with its higher DILI risk. Considering the GPCR-specific priorities (logP, TPSA, affinity) and the overall balance, Ligand B is the more promising candidate.
Output:
0
2025-04-17 23:48:25,147 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's analyze each ligand against the provided guidelines, keeping in mind ADRB2 is a GPCR and thus we prioritize logP, Pgp, TPSA, and affinity, alongside general drug-like properties.
* **Molecular Weight:** Both ligands (366.49 and 357.40 Da) fall comfortably within the ideal 200-500 Da range.
* **TPSA:** Ligand A (85.51) is slightly higher than Ligand B (67.6). Both are acceptable, but B is better for permeability.
* **logP:** Ligand A (0.807) is a bit low, potentially hindering membrane permeability. Ligand B (2.296) is much closer to the optimal 1-3 range. This is a significant advantage for B.
* **H-Bond Donors/Acceptors:** Ligand A has 2 HBD and 5 HBA, while Ligand B has 1 HBD and 5 HBA. Both are within acceptable limits.
* **QED:** Both ligands have good QED scores (0.807 and 0.876), indicating good overall drug-likeness.
* **DILI:** Ligand A (20.05) has a slightly better DILI percentile than Ligand B (22.72), but both are quite low risk.
* **BBB:** Ligand B (93.098) has a much higher BBB penetration percentile than Ligand A (46.879). While ADRB2 isn't necessarily a CNS target, higher BBB is generally favorable, and indicates better distribution.
* **Caco-2 Permeability:** Ligand A (-5.246) has worse Caco-2 permeability than Ligand B (-4.839).
* **Aqueous Solubility:** Both have negative solubility values, indicating poor solubility. Ligand A (-1.853) is slightly better than Ligand B (-2.372).
* **hERG:** Both ligands have low hERG inhibition liability (0.338 and 0.464), which is excellent.
* **Microsomal Clearance:** Ligand A (-31.948) has significantly lower (better) microsomal clearance than Ligand B (7.568), suggesting better metabolic stability.
* **In vitro Half-Life:** Ligand A (-11.058) has a worse in vitro half-life than Ligand B (4.922).
* **P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.012 and 0.091).
* **Binding Affinity:** Ligand A (-7.8) and Ligand B (-7.6) have very similar binding affinities. The difference of 0.2 kcal/mol is not substantial enough to override other considerations.
**Overall Assessment:**
Ligand B is the preferred candidate. While Ligand A has better metabolic stability (lower Cl_mic) and slightly better DILI, Ligand B excels in key areas for a GPCR target: logP is optimal, BBB penetration is significantly higher, and Caco-2 permeability is better. The binding affinities are nearly identical. The slightly lower metabolic stability of Ligand B is a manageable concern, especially given its superior permeability and distribution characteristics.
**Output:**
0
2025-04-17 23:48:25,147 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [355.454, 61.88, 0.664, 1, 4, 0.761, 10.237, 81.776, -4.754, -0.866, 0.444, -6.333, 16.196, 0.016, -5.0]
**Ligand B:** [349.387, 110.53, 0.861, 2, 6, 0.429, 43.505, 62.311, -4.929, -2.149, 0.036, 79.265, -11.636, 0.057, -7.9]
Here's a breakdown, considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (349.387) is slightly lower, which isn't a major concern.
2. **TPSA:** Ligand A (61.88) is excellent, well below the 140 threshold. Ligand B (110.53) is higher, but still acceptable, though less optimal for permeability.
3. **logP:** Ligand A (0.664) is a bit low, potentially impacting permeability. Ligand B (0.861) is also on the lower side, but slightly better. Both could benefit from increased lipophilicity.
4. **HBD/HBA:** Ligand A (1 HBD, 4 HBA) is better than Ligand B (2 HBD, 6 HBA). Lower counts are generally preferred for better permeability.
5. **QED:** Ligand A (0.761) is significantly better than Ligand B (0.429), indicating a more drug-like profile.
6. **DILI:** Ligand A (10.237) has a much lower DILI risk than Ligand B (43.505). This is a significant advantage.
7. **BBB:** Ligand A (81.776) has a much higher BBB penetration potential than Ligand B (62.311). While ADRB2 is a cardiovascular target, some CNS exposure is not necessarily detrimental and a higher BBB score is generally a positive attribute.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.754) is slightly better (less negative).
9. **Solubility:** Ligand A (-0.866) is better than Ligand B (-2.149), indicating better aqueous solubility.
10. **hERG:** Ligand A (0.444) has a lower hERG risk than Ligand B (0.036).
11. **Cl_mic:** Ligand A (-6.333) has a much lower microsomal clearance, suggesting better metabolic stability.
12. **t1/2:** Ligand A (16.196) has a longer in vitro half-life than Ligand B (-11.636), which is desirable.
13. **Pgp:** Ligand A (0.016) has a much lower P-gp efflux liability than Ligand B (0.057).
14. **Affinity:** Ligand B (-7.9) has a significantly stronger binding affinity than Ligand A (-5.0). This is a substantial advantage, exceeding the 1.5 kcal/mol threshold.
**Overall Assessment:**
Ligand B's significantly stronger binding affinity (-7.9 kcal/mol vs -5.0 kcal/mol) is a major positive. However, it's offset by several concerning ADME properties: higher DILI risk, lower BBB penetration, lower solubility, higher hERG risk, higher microsomal clearance, shorter half-life, and higher P-gp efflux. Ligand A, while having a weaker affinity, presents a much more balanced profile with better predicted ADME properties, especially regarding safety (DILI, hERG) and metabolic stability. For a cardiovascular GPCR, a strong affinity is important, but a balanced ADME profile is crucial for clinical success. The difference in affinity, while substantial, is not so large as to completely negate the substantial improvements in the other parameters for Ligand A.
Therefore, I would prioritize Ligand A.
Output:
1
2025-04-17 23:48:25,147 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.471 and 373.511 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (58.64) is significantly better than Ligand B (92.85). For a GPCR, lower TPSA is generally preferred for better permeability. Ligand B is approaching a level that could hinder oral absorption.
3. **logP:** Both ligands have similar logP values (2.5 and 2.578), falling within the optimal 1-3 range.
4. **HBD:** Ligand A (1) has fewer H-bond donors than Ligand B (2). This is slightly favorable for permeability.
5. **HBA:** Ligand A (4) has fewer H-bond acceptors than Ligand B (9). This is a more significant difference, again favoring Ligand A for permeability.
6. **QED:** Both ligands have similar QED values (0.735 and 0.71), indicating good drug-likeness.
7. **DILI:** Ligand B (77.356) has a higher DILI risk than Ligand A (12.834). This is a substantial difference, and a lower DILI risk is highly desirable.
8. **BBB:** Ligand A (77.162) has better BBB penetration potential than Ligand B (64.56). While ADRB2 isn't exclusively a CNS target, some CNS exposure can occur, and higher BBB is generally a plus.
9. **Caco-2:** Ligand A (-4.777) has a slightly better Caco-2 permeability than Ligand B (-5.637).
10. **Solubility:** Both ligands have similar, poor aqueous solubility (-2.845 and -2.725). This is a potential formulation challenge for both.
11. **hERG:** Ligand A (0.837) has a slightly lower hERG inhibition liability than Ligand B (0.633), which is preferable.
12. **Cl_mic:** Ligand A (36.109) has a lower microsomal clearance than Ligand B (42.202), indicating better metabolic stability.
13. **t1/2:** Ligand B (4.77) has a longer in vitro half-life than Ligand A (-5.511). This is a positive for Ligand B.
14. **Pgp:** Ligand A (0.216) has lower P-gp efflux liability than Ligand B (0.148). Lower Pgp is generally better for bioavailability.
15. **Affinity:** Ligand A (-6.8) has a slightly better binding affinity than Ligand B (-5.9). While the difference is less than 1.5 kcal/mol, it contributes to the overall preference.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across several key ADME properties (TPSA, HBA, DILI, BBB, Cl_mic, Pgp) and has a slightly better binding affinity. While Ligand B has a longer half-life, the superior ADME profile and lower toxicity risk of Ligand A make it the more promising drug candidate for the ADRB2 receptor. The lower TPSA and HBA of Ligand A are particularly important for a GPCR target.
Output:
1
2025-04-17 23:48:25,148 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (358.36 and 346.289 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (59.5) is significantly better than Ligand B (89.16). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (3.089) is optimal, while Ligand B (1.353) is on the lower side. A logP between 1-3 is preferred for good permeability, and Ligand A is closer to this ideal.
4. **HBD:** Both ligands have 0 HBD, which is acceptable.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 6. Both are within the acceptable range of <=10, but lower is generally preferred.
6. **QED:** Both ligands have similar QED values (0.759 and 0.737), indicating good drug-likeness.
7. **DILI:** Ligand A (47.693) has a significantly lower DILI risk than Ligand B (79.566). This is a crucial advantage, as minimizing liver toxicity is paramount.
8. **BBB:** Ligand A (92.943) has a higher BBB penetration than Ligand B (78.519). While not critical for a cardiovascular target, it's a slight positive.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.001 and -4.123), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Both ligands have negative solubility values (-3.481 and -3.531), indicating poor aqueous solubility. This is also a significant concern.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.271 and 0.268), which is excellent.
12. **Cl_mic:** Ligand A (77.208) has a slightly higher microsomal clearance than Ligand B (73.277), indicating potentially lower metabolic stability.
13. **t1/2:** Ligand B (-6.155) has a much longer in vitro half-life than Ligand A (4.14). This is a significant advantage for dosing convenience.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.099 and 0.305).
15. **Binding Affinity:** Ligand A (-5.9 kcal/mol) has a slightly better binding affinity than Ligand B (-5.1 kcal/mol). This difference of 0.8 kcal/mol is meaningful, though not overwhelming.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, and affinity are important. Ligand A excels in logP and has a slightly better affinity. Ligand A also has a much better DILI score. While both have poor Caco-2 and solubility, the lower DILI risk and better logP of Ligand A outweigh the longer half-life of Ligand B.
**Conclusion:**
Considering the balance of properties, particularly the significantly lower DILI risk and better logP of Ligand A, I believe it is the more promising drug candidate.
Output:
1
2025-04-17 23:48:25,148 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [346.383, 98.54, 3.521, 1, 5, 0.289, 72.974, 65.297, -4.401, -5.268, 0.486, 98.771, 7.771, 0.347, -6.8]
**Ligand B:** [348.487, 67.43, 2.701, 2, 3, 0.63, 28.189, 62.737, -4.876, -3.163, 0.264, 45.017, 10.263, 0.285, -6.3]
Here's a step-by-step comparison, keeping GPCR priorities (logP, Pgp, TPSA, and affinity) in mind:
1. **MW:** Both are within the ideal range (200-500 Da). A is 346.383, B is 348.487 - negligible difference.
2. **TPSA:** Ligand A (98.54) is slightly higher than Ligand B (67.43). For a cardiovascular GPCR, we don't *need* extremely low TPSA for BBB penetration, but lower is generally better for permeability. B is preferable here.
3. **logP:** Ligand A (3.521) is slightly higher than Ligand B (2.701). Both are within the optimal range (1-3), but A is approaching the upper limit. B is preferable.
4. **HBD:** Ligand A (1) has fewer HBD than Ligand B (2). Fewer is generally better for permeability, so A is slightly preferable.
5. **HBA:** Ligand A (5) has more HBA than Ligand B (3). Fewer is generally better for permeability, so B is preferable.
6. **QED:** Ligand B (0.63) has a better QED score than Ligand A (0.289), indicating a more drug-like profile. B is significantly preferable.
7. **DILI:** Ligand A (72.974) has a significantly higher DILI risk than Ligand B (28.189). This is a major concern for A. B is *much* preferable.
8. **BBB:** Both have reasonable BBB penetration (A: 65.297, B: 62.737). Not a primary concern for a cardiovascular target, but A is slightly better.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. A (-4.401) is slightly worse than B (-4.876).
10. **Solubility:** Ligand B (-3.163) has better solubility than Ligand A (-5.268). Better solubility is always preferable.
11. **hERG:** Ligand A (0.486) has a slightly higher hERG risk than Ligand B (0.264). B is preferable.
12. **Cl_mic:** Ligand A (98.771) has a higher microsomal clearance than Ligand B (45.017), indicating lower metabolic stability. B is preferable.
13. **t1/2:** Ligand B (10.263) has a longer in vitro half-life than Ligand A (7.771). B is preferable.
14. **Pgp:** Ligand A (0.347) has higher P-gp efflux than Ligand B (0.285). Lower efflux is better, so B is preferable.
15. **Affinity:** Ligand A (-6.8 kcal/mol) has a slightly better binding affinity than Ligand B (-6.3 kcal/mol). This is a 0.5 kcal/mol difference, which is significant, but needs to be weighed against the other factors.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity, Ligand B is significantly better across almost all ADME-Tox parameters. The lower DILI risk, better QED, solubility, metabolic stability, and P-gp efflux of Ligand B are crucial advantages. The slightly weaker binding affinity of Ligand B is outweighed by its superior drug-like properties and safety profile.
Output:
0
2025-04-17 23:48:25,148 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's systematically compare Ligand A and Ligand B based on the provided parameters and the guidelines, keeping in mind that ADRB2 is a GPCR, so logP, Pgp, TPSA, and affinity are particularly important.
1. **MW:** Both ligands (354.361 and 350.503 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand B (58.64) is significantly better than Ligand A (105.82). Lower TPSA generally improves permeability, which is crucial for GPCR ligands.
3. **logP:** Ligand B (2.737) is closer to the optimal range (1-3) than Ligand A (0.954). A logP closer to 2-3 is preferable for good absorption and distribution. Ligand A's logP is a bit low, potentially hindering permeation.
4. **HBD:** Ligand B (1) has fewer H-bond donors than Ligand A (2), which is generally favorable for permeability.
5. **HBA:** Ligand B (3) has fewer H-bond acceptors than Ligand A (7). Again, fewer is better for permeability.
6. **QED:** Both ligands have good QED scores (0.767 and 0.801), indicating good drug-like properties.
7. **DILI:** Ligand B (21.714) has a much lower DILI risk than Ligand A (68.903). This is a significant advantage for Ligand B.
8. **BBB:** Ligand B (77.898) has a higher BBB penetration percentile than Ligand A (39.86). While ADRB2 isn't necessarily a CNS target, some peripheral ADRB2 signaling can influence CNS function, and higher BBB penetration isn't necessarily a negative.
9. **Caco-2:** Both ligands have similar, poor Caco-2 permeability (-4.893 and -4.782). This suggests potential absorption issues for both.
10. **Solubility:** Both ligands have similar, poor solubility (-2.618 and -2.942). This could pose formulation challenges.
11. **hERG:** Ligand B (0.437) has a lower hERG inhibition liability than Ligand A (0.18). This is a significant safety advantage.
12. **Cl_mic:** Ligand A (27.111) has a lower microsomal clearance than Ligand B (79.874), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-8.733) has a longer in vitro half-life than Ligand A (-26.783). This is a positive attribute.
14. **Pgp:** Ligand B (0.32) has a lower P-gp efflux liability than Ligand A (0.091). Lower P-gp efflux is preferable for improved bioavailability.
15. **Affinity:** Ligand A (-7.0) has slightly better binding affinity than Ligand B (-5.4). However, the difference is only 1.6 kcal/mol, and the other ADME properties of Ligand B are far superior.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity, Ligand B demonstrates a significantly more favorable ADME profile. Specifically, its lower TPSA, better logP, lower DILI risk, higher BBB penetration, lower hERG inhibition, lower Pgp efflux, and longer half-life outweigh the minor difference in binding affinity. The poor Caco-2 and solubility for both are concerns, but these are more readily addressed through formulation strategies than fundamentally changing the molecule's core structure. For a GPCR target like ADRB2, optimizing for permeability (TPSA, logP, Pgp) and safety (DILI, hERG) is crucial, and Ligand B excels in these areas.
**Output:**
0
2025-04-17 23:48:25,148 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [345.487, 63.99, 2.97, 1, 4, 0.892, 35.673, 74.447, -4.794, -3.661, 0.476, 70.664, -12.303, 0.362, -6.3]**
**Ligand B: [393.868, 80.76, 1.376, 1, 6, 0.685, 69.756, 76.192, -4.944, -2.924, 0.395, 18.096, 36.702, 0.113, -6.6]**
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (345.487) is slightly preferred due to being closer to the lower end, which can aid permeability.
2. **TPSA:** Ligand A (63.99) is better than Ligand B (80.76). ADRB2 is not a CNS target, but lower TPSA generally improves absorption.
3. **logP:** Both ligands have acceptable logP values (Ligand A: 2.97, Ligand B: 1.376) within the 1-3 range. Ligand A is slightly better, being closer to the optimal range.
4. **H-Bond Donors:** Both have 1 HBD, which is good.
5. **H-Bond Acceptors:** Ligand A (4) is better than Ligand B (6). Lower HBA is generally preferred for better permeability.
6. **QED:** Ligand A (0.892) is significantly better than Ligand B (0.685), indicating a more drug-like profile.
7. **DILI:** Ligand A (35.673) is much better than Ligand B (69.756), indicating a lower risk of drug-induced liver injury. This is a crucial factor.
8. **BBB:** Both have good BBB penetration (Ligand A: 74.447, Ligand B: 76.192), but this is less critical for ADRB2 as it's not a CNS target.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual. This suggests poor permeability. However, the values are similar (-4.794 vs -4.944).
10. **Solubility:** Both have negative solubility values, which is also unusual. Ligand B (-2.924) is slightly better than Ligand A (-3.661).
11. **hERG:** Both ligands have low hERG inhibition risk (Ligand A: 0.476, Ligand B: 0.395).
12. **Cl_mic:** Ligand A (70.664) has a lower microsomal clearance than Ligand B (18.096), indicating better metabolic stability.
13. **t1/2:** Ligand A (-12.303) has a longer in vitro half-life than Ligand B (36.702). This is a significant advantage.
14. **Pgp:** Ligand A (0.362) has lower P-gp efflux than Ligand B (0.113).
15. **Binding Affinity:** Ligand B (-6.6) has a slightly better binding affinity than Ligand A (-6.3), but the difference is small (0.3 kcal/mol).
**Overall Assessment:**
Ligand A is significantly better overall. It has a better QED score, a much lower DILI risk, better metabolic stability (lower Cl_mic, longer t1/2), lower P-gp efflux, and a more favorable TPSA and HBA. While Ligand B has slightly better binding affinity and solubility, the advantages of Ligand A in ADME-Tox properties, especially the DILI risk, outweigh this small difference in potency.
Output:
1
2025-04-17 23:48:25,148 - INFO - Here's my reasoning and the final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, key priorities are logP, TPSA, Pgp efflux, BBB penetration, and binding affinity.
Let's break down the comparison:
1. **MW:** Both ligands (346.471 and 371.453 Da) fall within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (67.43) is slightly higher than Ligand B (58.36). Both are acceptable for a non-CNS GPCR target, being under 140, but B is preferred.
3. **logP:** Ligand A (2.026) is optimal. Ligand B (3.369) is still within the acceptable range (1-3) but edging towards the higher end.
4. **HBD/HBA:** Ligand A has 2 HBD and 3 HBA, while Ligand B has 1 HBD and 5 HBA. Both are reasonable.
5. **QED:** Both ligands have similar QED values (0.661 and 0.688), indicating good drug-likeness.
6. **DILI:** Ligand A (22.024) has a significantly lower DILI risk than Ligand B (30.942), which is a major advantage.
7. **BBB:** Both ligands have good BBB penetration (72.082 and 79.062), but Ligand B is slightly better. This is less critical for a cardiovascular target.
8. **Caco-2:** Both have negative Caco-2 values which is unusual and suggests poor permeability.
9. **Solubility:** Both have negative solubility values which is also unusual and suggests poor solubility.
10. **hERG:** Ligand A (0.154) has a much lower hERG inhibition liability than Ligand B (0.825), a critical safety parameter.
11. **Cl_mic:** Ligand A (37.38) has lower microsomal clearance than Ligand B (41.395), suggesting better metabolic stability.
12. **t1/2:** Ligand A (15.114) has a longer in vitro half-life than Ligand B (12.711).
13. **Pgp:** Ligand A (0.085) has significantly lower P-gp efflux liability than Ligand B (0.612), which is favorable for bioavailability.
14. **Binding Affinity:** Ligand A (-7.3 kcal/mol) has a slightly better binding affinity than Ligand B (-5.5 kcal/mol). This is a substantial difference (1.8 kcal/mol) and a key driver in the decision.
**Overall Assessment:**
Ligand A demonstrates a superior profile across multiple critical parameters. It has a lower DILI risk, lower hERG liability, better metabolic stability (lower Cl_mic, longer t1/2), lower P-gp efflux, and a significantly stronger binding affinity. While Ligand B has slightly better BBB penetration and a slightly lower TPSA, the advantages of Ligand A in safety, metabolism, and potency outweigh these minor differences. The negative Caco-2 and solubility values are concerning for both, but the overall profile of A is more promising.
**Output:**
1
2025-04-17 23:48:25,148 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (386.901 and 365.459 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (92.34) is better than Ligand B (117.42). ADRB2 is a cardiovascular target, not CNS, so we don't need extremely low TPSA, but lower is generally preferred for absorption.
3. **logP:** Ligand A (1.471) is better than Ligand B (0.238). Both are within the acceptable range (1-3), but Ligand A is closer to optimal. Ligand B is quite low, potentially hindering permeation.
4. **HBD:** Ligand A (2) is better than Ligand B (3). Lower is generally preferred.
5. **HBA:** Ligand A (4) is better than Ligand B (5). Lower is generally preferred.
6. **QED:** Ligand A (0.742) is slightly better than Ligand B (0.641), indicating a more drug-like profile.
7. **DILI:** Ligand B (47.344) is significantly better than Ligand A (65.491). This is a major advantage for Ligand B.
8. **BBB:** Ligand A (43.001) is lower than Ligand B (52.811). While ADRB2 isn't a CNS target, some peripheral exposure is acceptable, and a higher BBB percentile isn't detrimental.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.516 and -5.609). These values are unusual and suggest poor permeability.
10. **Solubility:** Both ligands have negative solubility values (-2.823 and -2.221). These values are unusual and suggest poor solubility.
11. **hERG:** Ligand A (0.102) is slightly higher than Ligand B (0.039), indicating a slightly higher risk of hERG inhibition.
12. **Cl_mic:** Ligand A (-9.323) is better than Ligand B (-6.396). Lower is better, indicating greater metabolic stability.
13. **t1/2:** Ligand A (40.177) is significantly better than Ligand B (-4.302). A longer half-life is desirable.
14. **Pgp:** Ligand A (0.114) is better than Ligand B (0.009). Lower is better, indicating less P-gp efflux.
15. **Affinity:** Ligand A (-7.2) is slightly better than Ligand B (-6.1). This is a significant advantage, as potency is crucial.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A performs better in logP, TPSA, and affinity. Ligand B has a better DILI score.
**Overall Assessment:**
While Ligand B has a significantly better DILI score, Ligand A has a better overall profile. The affinity difference (-7.2 vs -6.1 kcal/mol) is substantial and likely outweighs the DILI risk, especially considering the other favorable ADME properties of Ligand A (better logP, TPSA, Cl_mic, t1/2, and Pgp). The negative Caco-2 and solubility values are concerning for both, but can be addressed through formulation strategies.
Output:
1
2025-04-17 23:48:25,148 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (381.929 and 361.515 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (73.2 and 74.81) are below the 140 A^2 threshold for good oral absorption, and acceptable for a cardiovascular GPCR.
3. **logP:** Ligand A (3.842) is slightly higher than Ligand B (2.759). Both are within the optimal 1-3 range, but A is approaching the upper limit.
4. **HBD:** Ligand A (1) is better than Ligand B (0). Lower HBD is generally preferred for permeability.
5. **HBA:** Ligand A (4) is better than Ligand B (6). Lower HBA is generally preferred for permeability.
6. **QED:** Both ligands have identical QED scores (0.779), indicating good drug-likeness.
7. **DILI:** Ligand B (32.454) has a significantly lower DILI risk than Ligand A (39.201), making it safer from a liver toxicity perspective.
8. **BBB:** Both ligands have good BBB penetration (Ligand A: 75.378, Ligand B: 72.896). This is less critical for a cardiovascular target, but not detrimental.
9. **Caco-2:** Ligand A (-4.946) has a better Caco-2 permeability than Ligand B (-5.21), suggesting better intestinal absorption.
10. **Solubility:** Ligand B (-2.745) has significantly better aqueous solubility than Ligand A (-4.503). This is important for formulation and bioavailability.
11. **hERG:** Ligand A (0.78) has a slightly higher hERG risk than Ligand B (0.35). Lower hERG is crucial for avoiding cardiotoxicity.
12. **Cl_mic:** Ligand A (36.251) has a lower microsomal clearance than Ligand B (58.405), indicating better metabolic stability.
13. **t1/2:** Ligand B (-15.1) has a significantly longer in vitro half-life than Ligand A (9.738), which is desirable for less frequent dosing.
14. **Pgp:** Ligand A (0.397) has lower P-gp efflux than Ligand B (0.236), which is favorable for bioavailability.
15. **Affinity:** Ligand B (-8.0) has a significantly stronger binding affinity than Ligand A (-7.2). This is a substantial advantage, potentially outweighing some ADME drawbacks.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), affinity, logP, TPSA, Pgp, and solubility are key. Ligand B excels in affinity and solubility, while Ligand A has a slightly better logP and Pgp. The significantly stronger binding affinity of Ligand B is a major advantage. The lower DILI and hERG risks of Ligand B are also very important. While Ligand A has better metabolic stability, the longer half-life of Ligand B compensates for this.
**Conclusion:**
Despite Ligand A's slightly better metabolic stability and Pgp profile, Ligand B's superior binding affinity, lower toxicity risks (DILI, hERG), and better solubility make it the more promising drug candidate for the ADRB2 receptor.
0
2025-04-17 23:48:25,149 - INFO - Batch 431 complete. Total preferences: 6896
2025-04-17 23:48:25,149 - INFO - Processing batch 432/512...
2025-04-17 23:49:16,347 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.5 and 345.4 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (52.65) is better than Ligand B (62.73). Both are below 140, but lower TPSA generally favors absorption.
3. **logP:** Ligand A (2.285) is within the optimal 1-3 range. Ligand B (3.892) is pushing the upper limit, potentially raising concerns about solubility and off-target effects.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD is generally better for permeability.
5. **HBA:** Ligand A (3) is better than Ligand B (5). Lower HBA is generally better for permeability.
6. **QED:** Both ligands have good QED scores (0.718 and 0.832), indicating good drug-like properties. No clear advantage.
7. **DILI:** Ligand A (5.079) has a significantly lower DILI risk than Ligand B (47.693). This is a major advantage for Ligand A.
8. **BBB:** Both ligands have reasonable BBB penetration (67.584 and 68.903). Since ADRB2 is a cardiovascular target, BBB penetration isn't a primary concern, but it's good to have some level of it.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.761 and -4.974). This is unusual and suggests poor permeability. However, these values are on a log scale and a more negative value indicates lower permeability. They are relatively similar.
10. **Solubility:** Ligand A (-1.764) is better than Ligand B (-4.399). Higher solubility is desirable.
11. **hERG:** Ligand A (0.554) has a lower hERG risk than Ligand B (0.754), which is preferable.
12. **Cl_mic:** Ligand A (10.097) has a lower microsomal clearance than Ligand B (16.093), indicating better metabolic stability.
13. **t1/2:** Ligand A (-11.606) has a more negative in vitro half-life than Ligand B (25.099). A more negative value indicates a shorter half-life, which is undesirable.
14. **Pgp:** Ligand A (0.022) has a lower Pgp efflux liability than Ligand B (0.052), which is preferable.
15. **Binding Affinity:** Ligand B (-7.7) has a significantly stronger binding affinity than Ligand A (-5.1). This is a substantial advantage, potentially outweighing some of the ADME drawbacks.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B has a higher logP and significantly better affinity. However, Ligand A excels in DILI risk, solubility, and metabolic stability. The affinity difference is substantial (2.6 kcal/mol).
**Overall Assessment:**
While Ligand A has a better safety profile (DILI, hERG) and some ADME advantages (solubility, Cl_mic, Pgp), the significantly stronger binding affinity of Ligand B (-7.7 vs -5.1 kcal/mol) is a critical factor. A 2.6 kcal/mol difference is large enough to potentially overcome the higher logP and moderate DILI risk, especially considering the target is not in the CNS. The higher DILI risk of Ligand B could be investigated further through structural modifications.
Output:
0
2025-04-17 23:49:16,347 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (362.407 Da and 363.439 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (80.06) is significantly better than Ligand B (100.55). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand A is well below the 140 A^2 threshold, while Ligand B is approaching it.
**3. logP:** Ligand B (2.472) is slightly higher than Ligand A (1.361), but both are within the optimal 1-3 range.
**4. H-Bond Donors:** Ligand A has 0 HBDs, which is excellent for permeability. Ligand B has 3, which is acceptable but less ideal.
**5. H-Bond Acceptors:** Ligand A has 5 HBAs, and Ligand B has 6. Both are within the acceptable limit of 10.
**6. QED:** Ligand A (0.824) has a better QED score than Ligand B (0.685), indicating a more drug-like profile.
**7. DILI:** Both ligands have relatively high DILI risk (Ligand A: 82.784, Ligand B: 84.102). This is a concern for both, but not a deciding factor at this stage.
**8. BBB:** Ligand A (64.444) has a better BBB penetration score than Ligand B (49.903). While ADRB2 isn't strictly a CNS target, some peripheral distribution is expected, and better BBB penetration can sometimes correlate with improved overall permeability.
**9. Caco-2 Permeability:** Ligand A (-4.343) has a better Caco-2 permeability score than Ligand B (-4.821). This suggests better intestinal absorption for Ligand A.
**10. Aqueous Solubility:** Ligand A (-4.117) has a better solubility score than Ligand B (-3.567).
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (Ligand A: 0.389, Ligand B: 0.298). This is positive for both.
**12. Microsomal Clearance:** Ligand A (59.785) has lower microsomal clearance than Ligand B (77.238), indicating better metabolic stability.
**13. In vitro Half-Life:** Ligand B (24.208) has a significantly longer in vitro half-life than Ligand A (-12.785). This is a major advantage for Ligand B, potentially allowing for less frequent dosing.
**14. P-gp Efflux:** Both ligands have similar P-gp efflux liability (Ligand A: 0.246, Ligand B: 0.415).
**15. Binding Affinity:** Ligand B (-7.1) has a significantly stronger binding affinity than Ligand A (-5.3). This is a substantial advantage, exceeding the 1.5 kcal/mol threshold.
**Overall Assessment:**
Ligand B's significantly stronger binding affinity (-7.1 kcal/mol vs -5.3 kcal/mol) is the most important factor. This outweighs the slightly less favorable TPSA, logP, and QED scores. The longer half-life of Ligand B is also a significant benefit. While Ligand A has better permeability predictions (Caco-2, TPSA) and metabolic stability, the potency advantage of Ligand B is too significant to ignore, especially for a GPCR target where high affinity is crucial.
Output:
0
2025-04-17 23:49:16,348 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (351.403 and 366.483 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (100.46) is slightly higher than Ligand B (86.71). Both are below the 140 threshold for good oral absorption, but Ligand B is closer to the preferred <90 for GPCRs.
3. **logP:** Ligand A (-0.343) is quite low, potentially hindering membrane permeability. Ligand B (1.501) is within the optimal 1-3 range. This is a significant advantage for Ligand B.
4. **HBD:** Both ligands have 2 HBD, which is acceptable.
5. **HBA:** Ligand A has 6 HBA, while Ligand B has 4. Both are below the 10 threshold.
6. **QED:** Both ligands have good QED scores (0.706 and 0.799), indicating drug-likeness.
7. **DILI:** Both ligands have low DILI risk (27.608 and 30.361), which is good.
8. **BBB:** Ligand A (54.246) has a moderate BBB penetration, while Ligand B (39.744) is lower. For a cardiovascular target like ADRB2, BBB penetration isn't *critical*, but it's a bonus.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.915 and -5.266), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-1.208) has slightly better solubility than Ligand B (-3.524). Solubility is important for bioavailability.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.169 and 0.247).
12. **Cl_mic:** Ligand A (-5.389) has a significantly *lower* (better) microsomal clearance than Ligand B (40.572). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (27.718) has a much longer in vitro half-life than Ligand B (-48.151). This is a major advantage for Ligand A.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.018 and 0.043).
15. **Binding Affinity:** Ligand A (-6.2 kcal/mol) has slightly better binding affinity than Ligand B (-5.5 kcal/mol). While the difference is less than the 1.5 kcal/mol threshold, it contributes to the overall preference.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand B excels in logP and has a lower TPSA. Ligand A has a slightly better affinity and significantly better metabolic stability (Cl_mic, t1/2). The low logP of Ligand A is a significant concern, potentially limiting its ability to reach the receptor.
**Overall Assessment:**
Despite Ligand A's better metabolic stability and slightly improved affinity, the significantly lower logP is a major drawback. The poor Caco-2 values for both are concerning, but the logP issue is more readily addressable through chemical modification. Ligand B's more favorable logP profile makes it a more promising starting point for optimization, even with the higher Cl_mic.
Output:
0
2025-04-17 23:49:16,348 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (352.435 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (87.91) is better than Ligand B (43.18). Lower TPSA generally correlates with better BBB penetration and oral absorption, crucial for GPCRs.
3. **logP:** Both ligands have acceptable logP values (A: 1.935, B: 3.477), falling within the 1-3 range. Ligand B is closer to the upper limit, which could potentially lead to off-target effects or solubility issues, but is still acceptable.
4. **HBD:** Ligand A (1) is preferable to Ligand B (0). While both are low, a single HBD can contribute to solubility without significantly hindering permeability.
5. **HBA:** Ligand A (6) is better than Ligand B (7). Lower HBA is generally preferred for better membrane permeability.
6. **QED:** Ligand A (0.833) has a significantly better QED score than Ligand B (0.631), indicating a more drug-like profile.
7. **DILI:** Ligand A (52.423) has a much lower DILI risk than Ligand B (10.237). This is a major advantage for Ligand A.
8. **BBB:** Both ligands have good BBB penetration (A: 76.464, B: 77.976). This is less critical for ADRB2 (cardiovascular target) but still a positive.
9. **Caco-2:** Ligand A (-4.445) is better than Ligand B (-5.193). Higher Caco-2 permeability suggests better intestinal absorption.
10. **Solubility:** Both ligands have poor aqueous solubility (-2.643 and -2.854 respectively). This is a concern for both, but not a deciding factor.
11. **hERG:** Ligand A (0.343) has a lower hERG risk than Ligand B (0.826). This is a significant advantage for Ligand A, reducing the risk of cardiotoxicity.
12. **Cl_mic:** Ligand A (78.851) has a higher microsomal clearance than Ligand B (45.644), meaning it is metabolized faster. This is a negative for Ligand A.
13. **t1/2:** Ligand B (4.441) has a longer in vitro half-life than Ligand A (-12.297). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.036) has a much lower Pgp efflux liability than Ligand B (0.279). This is a significant advantage for Ligand A, improving bioavailability.
15. **Affinity:** Ligand B (-6.8 kcal/mol) has a slightly better binding affinity than Ligand A (-6.4 kcal/mol). While a 0.4 kcal/mol difference is noticeable, it's not a huge advantage, especially considering the other factors.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity) and general drug-like properties, Ligand A is the more promising candidate. While Ligand B has slightly better affinity and half-life, Ligand A excels in crucial areas like DILI risk, hERG inhibition, QED, Pgp efflux, and TPSA. The lower DILI and hERG risks are particularly important for a cardiovascular target. The better QED and Pgp properties also contribute to a more favorable overall profile. The slightly higher clearance of Ligand A can potentially be addressed through structural modifications during optimization.
Output:
1
2025-04-17 23:49:16,348 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **Molecular Weight:** Both ligands (363.849 Da and 350.507 Da) fall within the ideal range of 200-500 Da. No significant difference here.
2. **TPSA:** Ligand A (72.28) is slightly higher than Ligand B (61.6). Both are below the 140 threshold for good oral absorption, but closer to the 90 threshold for CNS targets (less relevant for ADRB2, a cardiovascular target). Ligand B is preferable.
3. **logP:** Ligand A (1.354) and Ligand B (1.948) are both within the optimal range of 1-3. Ligand B is slightly better.
4. **H-Bond Donors:** Both ligands have 1 HBD, which is within the acceptable limit of <=5.
5. **H-Bond Acceptors:** Ligand A has 6 HBAs, and Ligand B has 5. Both are below the 10 threshold.
6. **QED:** Both ligands have similar QED values (0.804 and 0.816), indicating good drug-likeness.
7. **DILI:** Ligand A (51.338) has a significantly higher DILI risk than Ligand B (3.335). This is a major concern, as lower DILI is crucial. Ligand B is strongly preferred.
8. **BBB:** Both ligands have reasonable BBB penetration (75.107 and 57.425), but ADRB2 is a cardiovascular target, so BBB penetration is less critical. Ligand A is slightly better.
9. **Caco-2 Permeability:** Both ligands have negative Caco-2 values (-5.092 and -4.748), which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Aqueous Solubility:** Ligand A (-2.557) has worse solubility than Ligand B (-0.041). Solubility is important for bioavailability. Ligand B is preferable.
11. **hERG Inhibition:** Both ligands have low hERG inhibition risk (0.49 and 0.55).
12. **Microsomal Clearance:** Ligand A (25.545) has higher microsomal clearance than Ligand B (8.54), indicating lower metabolic stability. Ligand B is preferable.
13. **In vitro Half-Life:** Ligand A (11.877) has a slightly longer half-life than Ligand B (-5.084).
14. **P-gp Efflux:** Both ligands have low P-gp efflux liability (0.055 and 0.067).
15. **Binding Affinity:** Ligand B (-6.9 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.9 kcal/mol). This is a substantial advantage, exceeding the 1.5 kcal/mol threshold.
**Overall Assessment:**
Ligand B is clearly the better candidate. While Ligand A has slightly better BBB penetration and in vitro half-life, Ligand B excels in the most critical areas: significantly lower DILI risk, better solubility, lower microsomal clearance (better metabolic stability), and, most importantly, a much stronger binding affinity. The affinity difference is substantial enough to outweigh the minor drawbacks of Ligand B.
Output:
0
2025-04-17 23:49:16,348 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [401.45 , 96.44 , 1.571, 1. , 6. , 0.741, 70.686, 41.218, -5.303, -2.543, 0.167, 21.08 , 36.134, 0.074, -5.7 ]
**Ligand B:** [353.467, 101.56 , 0.252, 3. , 5. , 0.56 , 13.532, 19.038, -5.486, -0.144, 0.354, -2.606, -9.586, 0.03 , -7.3 ]
**Step-by-step comparison:**
1. **MW:** Ligand A (401.45 Da) is within the ideal range. Ligand B (353.467 Da) is also good. No clear advantage.
2. **TPSA:** Both are slightly above the optimal <140 for oral absorption, but acceptable for a GPCR target. Ligand A (96.44) is better than Ligand B (101.56).
3. **logP:** Ligand A (1.571) is optimal. Ligand B (0.252) is quite low, potentially hindering membrane permeability. This is a significant drawback for a GPCR.
4. **HBD:** Ligand A (1) is good. Ligand B (3) is higher, potentially impacting permeability.
5. **HBA:** Ligand A (6) is good. Ligand B (5) is also good.
6. **QED:** Ligand A (0.741) is excellent. Ligand B (0.56) is acceptable, but lower.
7. **DILI:** Ligand A (70.686) is moderate risk. Ligand B (13.532) is very low risk. This favors Ligand B.
8. **BBB:** Ligand A (41.218) is low. Ligand B (19.038) is also low, but slightly lower. BBB is less critical for ADRB2 (cardiovascular) than for CNS targets, but still a consideration.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-5.303) is slightly better (less negative) than Ligand B (-5.486).
10. **Solubility:** Both are negative, indicating poor solubility. Ligand A (-2.543) is better than Ligand B (-0.144).
11. **hERG:** Ligand A (0.167) is very low risk. Ligand B (0.354) is also low risk.
12. **Cl_mic:** Ligand A (21.08) is reasonable. Ligand B (-2.606) is excellent, suggesting very high metabolic stability. This is a strong point for Ligand B.
13. **t1/2:** Ligand A (36.134) is good. Ligand B (-9.586) is very poor. This is a major drawback for Ligand B.
14. **Pgp:** Ligand A (0.074) is very low efflux. Ligand B (0.03) is even lower efflux.
15. **Affinity:** Ligand B (-7.3 kcal/mol) is significantly better than Ligand A (-5.7 kcal/mol). This is a substantial advantage, potentially outweighing some ADME concerns.
**Overall Assessment:**
Ligand B has a significantly better binding affinity. Its metabolic stability (Cl_mic) is also excellent, and it has a lower DILI risk. However, it suffers from a low logP, poor in vitro half-life, and poor Caco-2 permeability. Ligand A has better solubility, a better half-life, and a more favorable logP.
Given the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), the strong affinity of Ligand B is a major factor. While its logP is a concern, the superior binding could potentially be optimized through structural modifications. The poor half-life is a bigger issue, but also potentially addressable. The DILI risk is also a strong point in its favor.
Therefore, I would prioritize Ligand B for further investigation.
Output:
0
2025-04-17 23:49:16,348 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (364.47 & 362.46 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (95.5) is higher than Ligand B (75.51). For a cardiovascular GPCR, TPSA is moderately important. Lower TPSA generally favors better permeability, so Ligand B has a slight advantage.
**3. logP:** Ligand A (0.807) is slightly better than Ligand B (-0.148). Both are relatively low, but Ligand A is within the optimal 1-3 range, while Ligand B is below 1. This could potentially hinder membrane permeability for Ligand B.
**4. H-Bond Donors:** Ligand A has 3 HBD, while Ligand B has 0. Both are acceptable, but fewer HBDs (Ligand B) generally improve permeability.
**5. H-Bond Acceptors:** Both ligands have 5 HBA, which is acceptable.
**6. QED:** Ligand B (0.747) has a slightly better QED score than Ligand A (0.634), indicating a more drug-like profile.
**7. DILI Risk:** Ligand B (35.17%) has a lower DILI risk than Ligand A (41.41%), which is a significant advantage. Lower DILI is crucial for drug development.
**8. BBB Penetration:** Ligand B (71.62%) shows significantly better BBB penetration than Ligand A (20.51%). While ADRB2 is a cardiovascular target, some CNS effects are possible with beta-blockers, and better BBB penetration could be beneficial or detrimental depending on the desired profile.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-5.608 and -5.024). This is unusual and suggests poor permeability *in vitro*. However, these values are on a similar scale, so the difference isn't decisive.
**10. Aqueous Solubility:** Both ligands have negative solubility values (-2.486 and -1.776). This is also unusual and suggests poor solubility. Again, the difference isn't decisive.
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.053 and 0.089), which is excellent.
**12. Microsomal Clearance:** Ligand B (16.88 mL/min/kg) has significantly lower microsomal clearance than Ligand A (37.63 mL/min/kg), indicating better metabolic stability.
**13. In vitro Half-Life:** Ligand B (2.702 hours) has a longer half-life than Ligand A (1.751 hours), which is desirable.
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (0.168 and 0.032). Ligand B is slightly better.
**15. Binding Affinity:** Both ligands have very similar binding affinities (-6.7 and -6.8 kcal/mol). The difference is negligible.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), and the general drug-like properties, **Ligand B is the more promising candidate.** It has a lower DILI risk, better BBB penetration, lower microsomal clearance, longer half-life, and a slightly better QED score, despite the slightly lower logP. The similar binding affinities make the ADME properties the deciding factor. The negative Caco-2 and solubility values are concerning for both, but these can be addressed through formulation strategies.
Output:
0
2025-04-17 23:49:16,349 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.33 and 350.459 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (90.7) is slightly higher than Ligand B (78.87). Both are below 140, but B is better for absorption.
3. **logP:** Ligand A (3.702) is optimal, while Ligand B (0.926) is a bit low, potentially hindering membrane permeability. This is a significant advantage for A.
4. **HBD:** Ligand A (1) and Ligand B (2) are both acceptable, under the threshold of 5.
5. **HBA:** Ligand A (5) and Ligand B (4) are both acceptable, under the threshold of 10.
6. **QED:** Both ligands have good QED scores (0.635 and 0.716), indicating drug-likeness.
7. **DILI:** Ligand A (87.049) has a higher DILI risk than Ligand B (10.896). This is a major concern for A.
8. **BBB:** Ligand A (61.535) and Ligand B (55.099) are both relatively low, which isn't critical for a cardiovascular target like ADRB2, but not ideal.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.325 and -4.612), which is unusual and suggests poor permeability. This is a drawback for both.
10. **Solubility:** Ligand A (-5.446) has worse solubility than Ligand B (-1.393). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.652) has a slightly higher hERG risk than Ligand B (0.28). Lower is better.
12. **Cl_mic:** Ligand A (55.862) has better metabolic stability (lower clearance) than Ligand B (13.715).
13. **t1/2:** Ligand B (45.261) has a longer in vitro half-life than Ligand A (26.62). Longer half-life is generally preferred.
14. **Pgp:** Ligand A (0.388) has lower P-gp efflux liability than Ligand B (0.036). Lower Pgp efflux is better.
15. **Affinity:** Ligand A (-6.8 kcal/mol) has a slightly better binding affinity than Ligand B (-5.8 kcal/mol). A difference of 1 kcal/mol is significant.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A excels in logP and affinity, and Pgp efflux. However, its DILI risk is very high, and solubility is poor. Ligand B has a much better safety profile (DILI) and better solubility, but lower logP and affinity.
**Overall Assessment:**
Despite Ligand A's slightly better affinity and logP, the significantly higher DILI risk is a major red flag. The improved metabolic stability is not enough to offset this concern. Ligand B, while having a slightly lower affinity, presents a much more favorable safety profile and better solubility, making it a more promising starting point for drug development.
Output:
0
2025-04-17 23:49:16,349 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (399.252) is slightly higher, but still acceptable.
2. **TPSA:** Ligand A (69.15) is better than Ligand B (84.42). Both are below 140, but lower TPSA generally favors absorption.
3. **logP:** Both ligands have good logP values (A: 2.551, B: 1.373), falling within the 1-3 range.
4. **HBD:** Both have 1 HBD, which is ideal.
5. **HBA:** Ligand A has 6 HBA, and Ligand B has 5. Both are within the acceptable range.
6. **QED:** Ligand B (0.804) has a significantly higher QED score than Ligand A (0.537), indicating better overall drug-likeness.
7. **DILI:** Ligand B (34.354) has a much lower DILI risk than Ligand A (77.394). This is a significant advantage for Ligand B.
8. **BBB:** Ligand B (68.282) has a better BBB penetration score than Ligand A (48.119), although neither is exceptionally high. For a cardiovascular target, BBB isn't a primary concern, but it's still a positive.
9. **Caco-2:** Ligand A (-5.349) has a worse Caco-2 permeability than Ligand B (-4.762). Lower values are less desirable.
10. **Solubility:** Ligand A (-2.7) has slightly better solubility than Ligand B (-1.842).
11. **hERG:** Ligand B (0.181) has a much lower hERG inhibition liability than Ligand A (0.696). This is a critical advantage, as hERG inhibition can lead to cardiotoxicity.
12. **Cl_mic:** Ligand B (29.605) has a lower microsomal clearance than Ligand A (38.419), suggesting better metabolic stability.
13. **t1/2:** Ligand A (32.954) has a longer in vitro half-life than Ligand B (-6.03). This is a positive for Ligand A, but the negative value for Ligand B is concerning.
14. **Pgp:** Ligand B (0.023) has a much lower P-gp efflux liability than Ligand A (0.478). This is beneficial for bioavailability.
15. **Affinity:** Ligand A (-7.1) has a slightly better binding affinity than Ligand B (-6.0). While both are good, the difference is approximately 1.1 kcal/mol.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A has a slightly better affinity, but Ligand B excels in logP, TPSA, Pgp, and crucially, safety parameters (DILI and hERG).
**Overall Assessment:**
While Ligand A has a slightly better binding affinity and in vitro half-life, Ligand B demonstrates a significantly better safety profile (lower DILI and hERG) and better ADME properties (lower Pgp efflux, better metabolic stability). The affinity difference is not large enough to outweigh the substantial advantages of Ligand B, especially considering the potential for cardiotoxicity with Ligand A. The higher QED score for Ligand B also supports its selection.
Output:
0
2025-04-17 23:49:16,349 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (354.43 & 342.44 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand B (66.71) is significantly better than Ligand A (116.29). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (2.173) is within the optimal 1-3 range, while Ligand A (0.741) is slightly below 1. This is a notable advantage for Ligand B, as it should have better membrane permeability.
4. **HBD:** Ligand B (1) is preferable to Ligand A (2). Fewer HBDs generally improve permeability.
5. **HBA:** Both ligands have 4 HBA, which is acceptable.
6. **QED:** Ligand B (0.905) is significantly better than Ligand A (0.668), indicating a more drug-like profile.
7. **DILI:** Both ligands have low DILI risk (31.29% and 34.43%), which is good. No real difference.
8. **BBB:** Ligand A (83.83%) has better BBB penetration than Ligand B (70.76%), but this isn't a primary concern for a cardiovascular target.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. This is a red flag for both, but the values are very close.
10. **Solubility:** Both ligands have negative solubility values, also unusual. This suggests poor aqueous solubility, a significant drawback. The values are very close.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.271 and 0.275), which is excellent.
12. **Cl_mic:** Ligand B (28.74 mL/min/kg) has a lower microsomal clearance than Ligand A (45.59 mL/min/kg), indicating better metabolic stability.
13. **t1/2:** Ligand B (-2.039 hours) has a slightly better (less negative) in vitro half-life than Ligand A (-32.051 hours).
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.01 and 0.057), which is good.
15. **Binding Affinity:** Ligand A (-7.1 kcal/mol) has a slightly better binding affinity than Ligand B (-6.7 kcal/mol). This is a 0.4 kcal/mol difference, which is not a huge advantage.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand B excels in logP and TPSA, and has good Pgp profile. While Ligand A has slightly better affinity, the other ADME properties of Ligand B are superior. The negative Caco-2 and solubility values are concerning for both, but the other improvements of Ligand B make it the better candidate.
**Conclusion:**
Considering the balance of properties, particularly the better logP, TPSA, QED, and metabolic stability of Ligand B, it is the more promising drug candidate.
Output:
0
2025-04-17 23:49:16,349 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (352.366 Da and 346.431 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (118.53) is slightly higher than Ligand B (107.01), but both are below the 140 A^2 threshold for good oral absorption.
**3. logP:** Ligand B (1.802) is better positioned within the optimal 1-3 range compared to Ligand A (0.012), which is quite low and could hinder membrane permeability.
**4. H-Bond Donors:** Ligand A (2) is preferable to Ligand B (3).
**5. H-Bond Acceptors:** Ligand A (5) is preferable to Ligand B (4).
**6. QED:** Both ligands have acceptable QED values (0.67 and 0.593), indicating reasonable drug-likeness.
**7. DILI:** Ligand A (46.258) has a lower DILI risk than Ligand B (56.689), which is a significant advantage.
**8. BBB:** Ligand A (77.821) shows better BBB penetration potential than Ligand B (38.581). While ADRB2 is a cardiovascular target, some CNS effects are possible with certain ligands, and higher BBB penetration isn't necessarily detrimental.
**9. Caco-2 Permeability:** Both have negative values, which is unusual. Assuming these are logP-like scales, Ligand B (-4.956) is slightly better than Ligand A (-5.336).
**10. Aqueous Solubility:** Ligand B (-3.862) is better than Ligand A (-2.038).
**11. hERG Inhibition:** Ligand A (0.179) has a lower hERG inhibition liability than Ligand B (0.674), which is a critical safety advantage.
**12. Microsomal Clearance:** Ligand A (-0.769) has a lower (better) microsomal clearance than Ligand B (56.434), indicating greater metabolic stability.
**13. In vitro Half-Life:** Ligand B (13.154 hours) has a significantly longer half-life than Ligand A (2.592 hours). This is a substantial benefit for dosing convenience.
**14. P-gp Efflux:** Ligand A (0.028) shows lower P-gp efflux liability than Ligand B (0.148), which is favorable for bioavailability.
**15. Binding Affinity:** Both ligands have very similar and strong binding affinities (-6.1 kcal/mol and -5.7 kcal/mol). The difference is not substantial enough to override other considerations.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity) and the general guidelines, Ligand A is the more promising candidate. While Ligand B has a better half-life and solubility, Ligand A excels in critical areas like DILI risk, hERG inhibition, metabolic stability (lower Cl_mic), and P-gp efflux. The slightly lower logP of Ligand A is a concern, but the benefits in safety and ADME outweigh this drawback.
Output:
1
2025-04-17 23:49:16,349 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [350.419, 93.63, 2.717, 1, 6, 0.699, 55.176, 70.492, -4.628, -2.105, 0.567, 64.614, 30.298, 0.064, -7.2]
**Ligand B:** [350.459, 67.87, 1.359, 1, 4, 0.735, 25.979, 71.733, -4.726, -1.615, 0.125, 36.058, 24.314, 0.031, -7.6]
Here's a step-by-step comparison, keeping GPCR priorities (logP, Pgp, TPSA, and affinity) in mind:
1. **MW:** Both ligands are within the ideal range (around 350 Da). No significant difference.
2. **TPSA:** Ligand A (93.63) is higher than Ligand B (67.87). For a cardiovascular GPCR, we don't *need* extremely low TPSA for CNS penetration, but lower is generally better for permeability. Ligand B is preferable.
3. **logP:** Ligand A (2.717) is within the optimal range. Ligand B (1.359) is on the lower side, potentially impacting permeability. Ligand A is preferable.
4. **HBD:** Both have 1 HBD, which is good. No difference.
5. **HBA:** Ligand A has 6 HBA, Ligand B has 4. Both are acceptable, but fewer is generally better. Ligand B is preferable.
6. **QED:** Both are above 0.5, indicating good drug-likeness. Ligand B (0.735) is slightly better than Ligand A (0.699).
7. **DILI:** Ligand A (55.176) has a higher DILI risk than Ligand B (25.979). This is a significant advantage for Ligand B.
8. **BBB:** Both have good BBB penetration (A: 70.492, B: 71.733). No significant difference for this cardiovascular target.
9. **Caco-2:** Both have negative Caco-2 values, suggesting poor permeability. However, the scale is not specified, so we cannot make a clear comparison.
10. **Solubility:** Both have negative solubility values, suggesting poor solubility. However, the scale is not specified, so we cannot make a clear comparison.
11. **hERG:** Ligand A (0.567) has a higher hERG risk than Ligand B (0.125). This is a significant advantage for Ligand B.
12. **Cl_mic:** Ligand A (64.614) has higher microsomal clearance than Ligand B (36.058), indicating faster metabolism and potentially lower *in vivo* exposure. Ligand B is preferable.
13. **t1/2:** Ligand A (30.298) has a longer half-life than Ligand B (24.314). This is a slight advantage for Ligand A.
14. **Pgp:** Ligand A (0.064) has higher P-gp efflux than Ligand B (0.031). Lower P-gp efflux is preferred. Ligand B is preferable.
15. **Affinity:** Ligand B (-7.6 kcal/mol) has a stronger binding affinity than Ligand A (-7.2 kcal/mol). This is a 1.5 kcal/mol advantage, which is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand B consistently demonstrates better ADME properties (lower DILI, lower hERG, lower Cl_mic, lower Pgp efflux) and a significantly stronger binding affinity. While Ligand A has a slightly longer half-life and better logP, the advantages of Ligand B in terms of safety and potency are more compelling for a cardiovascular GPCR target.
Output:
0
2025-04-17 23:49:16,350 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A: [352.483, 103.01 , 1.161, 3. , 5. , 0.651, 29.236, 29.391, -5.828, -1.024, 0.054, 3.829, 8.541, 0.006, -5.7 ]**
**Ligand B: [365.499, 80.32 , 2.046, 2. , 5. , 0.739, 44.513, 46.219, -5.428, -1.416, 0.156, -1.436, 21.073, 0.087, -8.1 ]**
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity) and general drug-like properties:
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (352.483) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (103.01) is slightly higher than Ligand B (80.32). Both are below the 140 cutoff for oral absorption, but Ligand B is better.
3. **logP:** Ligand A (1.161) is a bit lower than Ligand B (2.046), but both are within the optimal 1-3 range.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (2), but both are acceptable.
5. **HBA:** Both ligands have 5 HBA, which is good.
6. **QED:** Both are good (A: 0.651, B: 0.739), indicating drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (29.236) has a significantly lower DILI risk than Ligand B (44.513). This is a major advantage for Ligand A.
8. **BBB:** Both have low BBB penetration, which is not a major concern for a cardiovascular target. Ligand B (46.219) is slightly higher than Ligand A (29.391).
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability.
10. **Solubility:** Both have negative solubility values, which is also unusual and suggests poor solubility.
11. **hERG:** Both have very low hERG inhibition risk (A: 0.054, B: 0.156).
12. **Cl_mic:** Ligand B (-1.436) has a *negative* microsomal clearance, which is not physically possible and suggests an issue with the data. Ligand A (3.829) is reasonable.
13. **t1/2:** Ligand B (21.073) has a much longer in vitro half-life than Ligand A (8.541). This is a significant advantage for Ligand B.
14. **Pgp:** Both have very low Pgp efflux liability (A: 0.006, B: 0.087).
15. **Affinity:** Ligand B (-8.1) has a significantly stronger binding affinity than Ligand A (-5.7). This is a substantial advantage, potentially outweighing some ADME concerns.
**Overall Assessment:**
The biggest differentiator is the binding affinity. Ligand B's -8.1 kcal/mol is considerably better than Ligand A's -5.7 kcal/mol. The longer half-life of Ligand B is also a significant plus. However, the negative microsomal clearance for Ligand B is a major red flag, suggesting a data error or a problematic compound. Ligand A has a much better DILI profile.
Given the importance of affinity for GPCRs, and assuming the negative Cl_mic for Ligand B is an error, I would lean towards Ligand B. However, the DILI risk of Ligand A is very attractive. Considering the cardiovascular target, the BBB penetration is less critical.
Because of the questionable Cl_mic value for Ligand B, and the significantly better DILI profile of Ligand A, I will choose Ligand A.
Output: 1
2025-04-17 23:49:16,350 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.459 Da and 352.4 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (93.43) is higher than Ligand B (29.27). For a cardiovascular GPCR, lower TPSA is generally preferred for better permeability, giving a slight edge to Ligand B.
3. **logP:** Ligand A (1.763) is within the optimal range (1-3). Ligand B (4.71) is slightly above, potentially raising concerns about solubility and off-target effects, but not drastically.
4. **HBD:** Ligand A (2) is reasonable. Ligand B (0) is also good, minimizing potential for unwanted interactions. No clear advantage.
5. **HBA:** Ligand A (4) is within the acceptable range. Ligand B (3) is also good. No clear advantage.
6. **QED:** Both ligands have good QED scores (0.622 and 0.754), indicating drug-likeness. Ligand B is slightly better.
7. **DILI:** Ligand A (12.292) has a lower DILI risk than Ligand B (14.114), which is a significant advantage.
8. **BBB:** Ligand B (96.588) has excellent BBB penetration, while Ligand A (29.74) is low. While ADRB2 isn't exclusively a CNS target, some CNS exposure could be beneficial or at least not detrimental, and is a priority for GPCRs. This is a strong advantage for Ligand B.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.99) is slightly better than Ligand B (-4.498), but both are concerning.
10. **Solubility:** Ligand A (-1.266) has better solubility than Ligand B (-4.745). This is a positive for Ligand A, especially considering Ligand B's higher logP.
11. **hERG:** Ligand A (0.366) has a lower hERG risk than Ligand B (0.941), which is a significant advantage for cardiovascular safety.
12. **Cl_mic:** Ligand A (-0.543) has a lower (better) microsomal clearance than Ligand B (20.397), indicating better metabolic stability. This is a strong advantage for Ligand A.
13. **t1/2:** Ligand B (21.727) has a much longer in vitro half-life than Ligand A (-7.227). This is a significant advantage for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.022) has lower P-gp efflux than Ligand B (0.794), which is beneficial for bioavailability.
15. **Affinity:** Ligand A (-6.3 kcal/mol) has a slightly better binding affinity than Ligand B (-6.9 kcal/mol). While the difference is not huge, it's still a positive for Ligand A.
**Overall Assessment:**
Ligand B excels in BBB penetration and in vitro half-life, which are important for GPCRs. However, it suffers from a higher logP, DILI risk, hERG risk, and Pgp efflux. Ligand A has a better safety profile (lower DILI, hERG), better metabolic stability (lower Cl_mic), better solubility, and slightly better affinity. The Caco-2 values are concerning for both, but Ligand A is slightly better.
Considering the cardiovascular target and the need for a safe and metabolically stable drug, I prioritize the safety and metabolic properties of Ligand A. The slightly better affinity further supports this choice.
Output:
1
2025-04-17 23:49:16,350 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [350.438, 66.49, 2.304, 2, 4, 0.855, 36.565, 81.039, -4.699, -2.724, 0.587, 34.585, 35.883, 0.11, -6.9]
**Ligand B:** [399.441, 114.34, -0.505, 2, 6, 0.611, 72.935, 61.846, -5.567, -2.178, 0.195, 12.797, -5.577, 0.071, -4.3]
Here's a breakdown, prioritizing GPCR-relevant properties (logP, TPSA, Pgp, BBB, affinity):
1. **Molecular Weight:** Both are within the acceptable range (200-500 Da). Ligand A (350.438) is slightly preferred.
2. **TPSA:** Ligand A (66.49) is excellent, well below the 140 threshold. Ligand B (114.34) is higher, but still potentially acceptable.
3. **logP:** Ligand A (2.304) is optimal (1-3). Ligand B (-0.505) is too low, potentially causing permeability issues. This is a significant drawback for Ligand B.
4. **H-Bond Donors/Acceptors:** Both have reasonable HBD (2) and HBA (4 for A, 6 for B) counts.
5. **QED:** Ligand A (0.855) is better than Ligand B (0.611), indicating a more drug-like profile.
6. **DILI:** Ligand A (36.565) has a much lower DILI risk than Ligand B (72.935). This is a crucial advantage.
7. **BBB:** Ligand A (81.039) has a good BBB penetration score. Ligand B (61.846) is lower, which is less desirable for a GPCR.
8. **Caco-2:** Both are negative, indicating poor permeability. This is a concern for both, but the lower logP of Ligand B exacerbates this.
9. **Solubility:** Both have negative solubility values, indicating poor solubility.
10. **hERG:** Ligand A (0.587) has a lower hERG risk than Ligand B (0.195).
11. **Cl_mic:** Ligand A (34.585) has a higher (worse) microsomal clearance than Ligand B (12.797), suggesting faster metabolism.
12. **t1/2:** Ligand B (-5.577) has a negative half-life, which is concerning. Ligand A (35.883) is reasonable.
13. **Pgp:** Ligand A (0.11) has lower P-gp efflux than Ligand B (0.071).
14. **Binding Affinity:** Ligand A (-6.9 kcal/mol) has a significantly stronger binding affinity than Ligand B (-4.3 kcal/mol). This is a substantial advantage.
**Overall Assessment:**
Ligand A clearly outperforms Ligand B. While both have solubility and Caco-2 permeability concerns, Ligand A has a much better logP, DILI risk, BBB penetration, hERG risk, and, most importantly, binding affinity. The stronger binding affinity of Ligand A can potentially compensate for the permeability issues. The faster clearance of Ligand A is a drawback, but could be addressed with structural modifications. Ligand B's low logP and poor half-life are significant liabilities.
Output:
1
2025-04-17 23:49:16,350 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (354.411 and 349.475 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand B (64.09) is significantly better than Ligand A (121.61). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (1.023) is within the optimal range (1-3), while Ligand A (-0.059) is slightly below, potentially hindering permeation.
4. **HBD:** Ligand A (3) is higher than Ligand B (1), but both are acceptable (<=5).
5. **HBA:** Ligand A (7) is higher than Ligand B (4), but both are acceptable (<=10).
6. **QED:** Both ligands have good QED scores (0.696 and 0.753), indicating good drug-like properties.
7. **DILI:** Ligand B (8.802) has a much lower DILI risk than Ligand A (38.581). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (61.613) has a higher BBB penetration than Ligand B (54.246). However, as ADRB2 is a cardiovascular target, BBB penetration is not a high priority.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.921 and -4.697), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Both ligands have negative solubility values (-1.226 and -0.563), indicating poor aqueous solubility. This is a significant drawback for both.
11. **hERG:** Ligand A (0.072) has a slightly lower hERG risk than Ligand B (0.147), which is a minor advantage.
12. **Cl_mic:** Ligand B (4.797) has a significantly lower microsomal clearance than Ligand A (15.143), indicating better metabolic stability.
13. **t1/2:** Ligand B (-7.932) has a more negative in vitro half-life than Ligand A (-10.517). This is a negative, but the difference is not substantial.
14. **Pgp:** Ligand A (0.013) has a lower P-gp efflux liability than Ligand B (0.04), which is a minor advantage.
15. **Binding Affinity:** Both ligands have similar binding affinities (-7.0 and -6.0 kcal/mol). Ligand A has a slightly better affinity, but the difference is less than 1.5 kcal/mol.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand B excels in logP and TPSA, while Ligand A has a slightly better affinity. However, the significantly lower DILI risk and better metabolic stability (lower Cl_mic) of Ligand B are more important considerations. The poor Caco-2 and solubility are concerning for both, but can be addressed with formulation strategies.
**Conclusion:**
Considering the balance of properties, particularly the lower DILI risk and improved metabolic stability, Ligand B is the more promising drug candidate.
Output:
0
2025-04-17 23:49:16,350 - INFO - Batch 432 complete. Total preferences: 6912
2025-04-17 23:49:16,350 - INFO - Processing batch 433/512...
2025-04-17 23:50:05,360 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (360.841 and 364.387 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (62.4) is significantly better than Ligand B (124.54). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is quite high, potentially hindering absorption.
**3. logP:** Ligand A (3.471) is optimal, while Ligand B (-0.42) is too low. A logP below 1 can lead to poor membrane permeability. This is a major drawback for Ligand B.
**4. H-Bond Donors:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
**5. H-Bond Acceptors:** Ligand A (3) is better than Ligand B (8). Similar to HBD, lower HBA is generally preferred.
**6. QED:** Both ligands have good QED scores (0.579 and 0.758), indicating generally drug-like properties.
**7. DILI:** Ligand B (77.549) has a higher DILI risk than Ligand A (68.282), though both are acceptable. Lower is better.
**8. BBB:** Ligand A (44.94) has a better BBB percentile than Ligand B (19.891). While ADRB2 is a cardiovascular target, some CNS penetration can be relevant for off-target effects, and a lower BBB is preferable in this case.
**9. Caco-2 Permeability:** Ligand A (-4.729) is better than Ligand B (-5.138), but both are negative values which is unusual.
**10. Aqueous Solubility:** Ligand A (-4.042) is better than Ligand B (-2.698), but both are negative values which is unusual.
**11. hERG Inhibition:** Ligand A (0.459) is better than Ligand B (0.198), indicating a lower risk of cardiotoxicity. This is crucial for a cardiovascular target.
**12. Microsomal Clearance:** Ligand B (-24.135) has significantly better metabolic stability (lower clearance) than Ligand A (105.987). This is a strong point for Ligand B.
**13. In vitro Half-Life:** Ligand B (-20.711) has a much longer half-life than Ligand A (-2.133). This is a significant advantage for Ligand B.
**14. P-gp Efflux:** Ligand A (0.2) is better than Ligand B (0.008), indicating lower P-gp efflux.
**15. Binding Affinity:** Ligand B (-7.4) has a significantly stronger binding affinity than Ligand A (-2.1). This is a substantial advantage that can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand B has a significantly better binding affinity and metabolic stability, and a longer half-life. However, it suffers from a very low logP and high TPSA, which are major concerns for permeability and absorption. Ligand A has much better ADME properties (logP, TPSA, HBD/HBA, hERG, P-gp) and a reasonable QED, but its binding affinity is considerably weaker.
Given the GPCR-specific priorities (logP, TPSA, affinity), the strong affinity of Ligand B is a significant advantage. While the ADME properties are suboptimal, medicinal chemistry efforts could focus on improving these while retaining the high affinity. The poor logP and TPSA of Ligand B are more readily addressed through structural modifications than substantially improving the affinity of Ligand A.
Output:
0
2025-04-17 23:50:05,361 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (361.47 & 348.45 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (69.72) is significantly better than Ligand B (83.56). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have acceptable logP values (1.06 & 1.68), falling within the 1-3 range. Ligand B is slightly higher, potentially aiding membrane permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is preferable to Ligand B (5). Fewer HBAs generally improve permeability.
6. **QED:** Ligand A (0.818) has a better QED score than Ligand B (0.629), indicating a more drug-like profile.
7. **DILI:** Both ligands have similar and acceptable DILI risk (51.49 & 49.28).
8. **BBB:** Ligand B (62.12) has a slightly higher BBB penetration score than Ligand A (54.05), but this is less critical for a cardiovascular target.
9. **Caco-2:** Ligand A (-5.075) and Ligand B (-4.826) have similar Caco-2 permeability values.
10. **Solubility:** Ligand A (-2.569) and Ligand B (-2.137) have similar solubility values.
11. **hERG:** Ligand A (0.272) has a much lower hERG inhibition liability than Ligand B (0.505), which is a significant advantage for cardiovascular drugs.
12. **Cl_mic:** Ligand A (-12.365) has a much lower microsomal clearance than Ligand B (36.867), suggesting better metabolic stability.
13. **t1/2:** Ligand B (40.775) has a significantly longer in vitro half-life than Ligand A (-7.531). This is a major advantage.
14. **Pgp:** Ligand A (0.018) has a much lower P-gp efflux liability than Ligand B (0.049), which is beneficial for oral bioavailability.
15. **Affinity:** Ligand A (-8.2 kcal/mol) has a stronger binding affinity than Ligand B (-6.6 kcal/mol). This is a substantial advantage, exceeding the 1.5 kcal/mol threshold.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize affinity, logP, TPSA, Pgp, and metabolic stability. Ligand A excels in affinity, TPSA, Pgp, and metabolic stability (Cl_mic). Ligand B has a better half-life, but the significant advantage in binding affinity and the lower liabilities (hERG, Pgp) of Ligand A outweigh this.
**Conclusion:**
Despite Ligand B's longer half-life, Ligand A presents a more favorable overall profile due to its superior binding affinity, lower hERG risk, better metabolic stability, lower Pgp efflux, and more favorable TPSA and QED scores.
Output:
1
2025-04-17 23:50:05,361 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
The target is ADRB2, a GPCR. Therefore, I will prioritize logP, Pgp, TPSA, and binding affinity, alongside general drug-like properties.
* **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (354.491 Da) is slightly higher than Ligand B (342.345 Da), but this difference isn't significant.
* **TPSA:** Ligand A (76.66) is better than Ligand B (51.22). Both are below the 140 threshold for oral absorption, but the lower TPSA of Ligand B is more favorable for potential CNS penetration, though this is less critical for a cardiovascular target.
* **logP:** Ligand A (3.0) is within the optimal range, while Ligand B (4.22) is pushing the upper limit. Higher logP can lead to off-target effects and solubility issues.
* **H-Bond Donors/Acceptors:** Ligand A (2 HBD, 4 HBA) and Ligand B (1 HBD, 4 HBA) are both acceptable.
* **QED:** Both ligands have similar QED values (0.769 and 0.721), indicating good drug-likeness.
* **DILI:** Ligand A (25.126) has a significantly lower DILI risk than Ligand B (83.443). This is a major advantage for Ligand A.
* **BBB:** Both ligands have good BBB penetration (74.641 and 77.705), but this is less critical for a cardiovascular target.
* **Caco-2 Permeability:** Both have negative Caco-2 values, indicating poor permeability. Ligand A (-4.733) is slightly better than Ligand B (-4.409).
* **Aqueous Solubility:** Ligand A (-3.136) is better than Ligand B (-5.167). Solubility is important for formulation and bioavailability.
* **hERG:** Ligand A (0.42) has a lower hERG risk than Ligand B (0.722). This is a crucial safety parameter.
* **Microsomal Clearance:** Ligand A (44.198) has a lower clearance than Ligand B (127.891), suggesting better metabolic stability.
* **In vitro Half-Life:** Ligand B (69.337) has a significantly longer half-life than Ligand A (-0.509). This is a positive for Ligand B.
* **P-gp Efflux:** Ligand A (0.023) has a much lower P-gp efflux liability than Ligand B (0.73). Lower efflux is desirable for improved bioavailability.
* **Binding Affinity:** Ligand A (-7.0) has a slightly better binding affinity than Ligand B (-5.3). While both are good, the 1.7 kcal/mol difference is substantial enough to consider.
**Overall Assessment:**
Ligand A demonstrates a better balance of properties, particularly with respect to safety (lower DILI, lower hERG), metabolic stability (lower Cl_mic), and P-gp efflux. While Ligand B has a longer half-life, the superior safety and ADME profile of Ligand A, combined with its slightly better binding affinity, make it the more promising candidate.
**Output:**
1
2025-04-17 23:50:05,361 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (335.407) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (54.46) is better than Ligand B (41.29), being closer to the 140 threshold, and more favorable for oral absorption.
3. **logP:** Ligand A (2.966) is optimal, while Ligand B (4.491) is pushing the upper limit. Higher logP can lead to off-target effects and solubility issues.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Both have 4 HBA, which is good.
6. **QED:** Ligand A (0.937) has a significantly better QED score than Ligand B (0.762), indicating a more drug-like profile.
7. **DILI:** Ligand A (43.04) has a slightly higher DILI risk than Ligand B (18.379), but both are below the concerning threshold of 60.
8. **BBB:** Ligand A (88.29) has a better BBB penetration score than Ligand B (73.827). While ADRB2 isn't strictly a CNS target, some CNS exposure can occur and isn't necessarily detrimental.
9. **Caco-2:** Both are negative, indicating poor permeability.
10. **Solubility:** Ligand A (-3.403) has better solubility than Ligand B (-4.692).
11. **hERG:** Ligand A (0.726) has a lower hERG risk than Ligand B (0.902). This is crucial for cardiovascular targets.
12. **Cl_mic:** Ligand A (21.53) has a significantly lower microsomal clearance than Ligand B (69.744), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-2.816) and Ligand B (-2.827) are comparable.
14. **Pgp:** Ligand A (0.212) has lower P-gp efflux than Ligand B (0.687), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand B (-7.6) has a stronger binding affinity than Ligand A (-6.4), a difference of 1.2 kcal/mol.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand B has a better affinity, but Ligand A excels in logP, Pgp, TPSA, QED, solubility, hERG, and metabolic stability. The affinity difference, while notable, is not large enough to overcome the superior ADME profile of Ligand A. The lower hERG risk and better metabolic stability are particularly important for a cardiovascular target.
**Conclusion:**
Considering the balance of potency, ADME properties, and safety, Ligand A is the more promising drug candidate.
Output:
1
2025-04-17 23:50:05,361 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Ligand A (401.264 Da) and Ligand B (361.515 Da) both fall within the ideal 200-500 Da range. Ligand B is slightly preferred due to being closer to the lower end, potentially aiding permeability.
2. **TPSA:** Ligand A (71.25) is higher than Ligand B (56.07). Both are below the 140 threshold for oral absorption, but Ligand B is better, being closer to the ideal <90 for GPCRs.
3. **logP:** Both ligands have good logP values (A: 2.665, B: 3.005), falling within the 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (0) as a single H-bond donor can aid solubility without significantly hindering permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (7). Lower HBA is generally preferred for better permeability.
6. **QED:** Both ligands have similar QED values (A: 0.69, B: 0.674), indicating good drug-likeness.
7. **DILI:** Ligand B (37.379) has a significantly lower DILI risk than Ligand A (65.607). This is a major advantage for Ligand B.
8. **BBB:** Ligand B (80.38) has a much higher BBB penetration percentile than Ligand A (36.952). This is very important for a GPCR target, even a cardiovascular one, as off-target CNS effects are always a concern.
9. **Caco-2:** Both have negative Caco-2 values (-5.036 and -5.184), which is unusual and suggests poor permeability. This is a significant drawback for both.
10. **Solubility:** Both have negative solubility values (-2.714 and -3.355), indicating very poor aqueous solubility. This is a major concern for both compounds.
11. **hERG:** Ligand A (0.84) has a slightly higher hERG risk than Ligand B (0.465), making Ligand B preferable.
12. **Cl_mic:** Ligand B (66.337) has a higher microsomal clearance than Ligand A (33.111), indicating faster metabolism and lower metabolic stability. Ligand A is preferred here.
13. **t1/2:** Ligand A (11.403) has a much longer in vitro half-life than Ligand B (0.835). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.284) has lower P-gp efflux liability than Ligand B (0.395), which is preferable.
15. **Binding Affinity:** Ligand A (-7.5 kcal/mol) has a stronger binding affinity than Ligand B (-5.9 kcal/mol). This is a substantial advantage for Ligand A, potentially outweighing some of its ADME drawbacks.
**Overall Assessment:**
Ligand A has a much stronger binding affinity and better metabolic stability (lower Cl_mic, longer t1/2), and lower Pgp efflux. However, Ligand B has significantly better safety profiles (lower DILI, lower hERG) and much better BBB penetration. The poor Caco-2 and solubility for both are concerning, but can potentially be addressed with formulation strategies. Given the GPCR target, the improved safety and BBB penetration of Ligand B are crucial. The affinity difference, while significant, might be overcome with further optimization of Ligand B.
Output:
0
2025-04-17 23:50:05,362 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (345.443 and 357.401 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (82.53) is better than Ligand B (95.66). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally favors absorption.
3. **logP:** Both ligands (1.601 and 1.675) are within the optimal 1-3 range. Very similar.
4. **HBD:** Ligand A (2) is preferable to Ligand B (3). Lower HBD generally improves permeability.
5. **HBA:** Both ligands have the same HBA count (4), which is well within the acceptable limit of 10.
6. **QED:** Ligand A (0.849) has a significantly better QED score than Ligand B (0.617), indicating a more drug-like profile.
7. **DILI:** Ligand A (18.922) has a much lower DILI risk than Ligand B (45.56). This is a crucial advantage, as liver toxicity is a major concern in drug development.
8. **BBB:** Ligand A (63.746) has a higher BBB penetration than Ligand B (56.65), but since this is a cardiovascular target, this is not a major factor.
9. **Caco-2:** Both ligands have very similar, and poor, Caco-2 permeability (-4.808 and -4.997).
10. **Solubility:** Both ligands have very similar, and poor, solubility (-1.838 and -1.974).
11. **hERG:** Ligand A (0.412) has a lower hERG inhibition liability than Ligand B (0.645), which is a positive.
12. **Cl_mic:** Ligand A (-1.144) has a significantly lower (better) microsomal clearance than Ligand B (26.619), indicating better metabolic stability.
13. **t1/2:** Ligand A (-5.083) has a much longer in vitro half-life than Ligand B (24.871), which is desirable.
14. **Pgp:** Ligand A (0.014) has a much lower P-gp efflux liability than Ligand B (0.181), suggesting better oral bioavailability and potentially better tissue distribution.
15. **Binding Affinity:** Ligand A (-7.1) has a slightly better binding affinity than Ligand B (-5.4). While the difference is not huge, it's enough to be considered, especially given the other advantages of Ligand A.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A performs better on TPSA, Pgp, and has comparable logP and slightly better affinity.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical ADME-Tox properties (DILI, Cl_mic, t1/2, Pgp, HBD) and has a slightly better binding affinity and QED score. While both have poor Caco-2 and solubility, the superior safety and pharmacokinetic profile of Ligand A make it the more promising drug candidate.
Output:
1
2025-04-17 23:50:05,362 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [351.491, 53.09, 1.226, 0, 4, 0.586, 12.796, 70.57, -4.22, -0.877, 0.301, 46.957, 5.454, 0.022, -6.4]
**Ligand B:** [346.362, 95.42, 2.155, 2, 5, 0.865, 69.678, 30.477, -5.029, -2.838, 0.139, 51.81, -17.005, 0.019, -8.8]
Here's a breakdown, considering the guidelines and GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (351.491) is slightly higher than Ligand B (346.362), but both are acceptable.
2. **TPSA:** Ligand A (53.09) is excellent, well below the 140 threshold and favorable for oral absorption. Ligand B (95.42) is higher but still potentially acceptable, though less ideal.
3. **logP:** Ligand A (1.226) is within the optimal range (1-3). Ligand B (2.155) is also within range, but approaching the higher end.
4. **HBD:** Ligand A (0) is very good, minimizing potential issues with permeability. Ligand B (2) is acceptable.
5. **HBA:** Ligand A (4) is good. Ligand B (5) is also acceptable.
6. **QED:** Ligand A (0.586) is good, indicating drug-likeness. Ligand B (0.865) is even better, suggesting a more favorable overall profile.
7. **DILI:** Ligand A (12.796) is significantly better than Ligand B (69.678), indicating a much lower risk of drug-induced liver injury. This is a major advantage for Ligand A.
8. **BBB:** Ligand A (70.57) is good, suggesting reasonable potential for CNS penetration if needed (though less critical for a cardiovascular target). Ligand B (30.477) is low, indicating poor BBB penetration.
9. **Caco-2:** Ligand A (-4.22) is better than Ligand B (-5.029), suggesting better intestinal absorption.
10. **Solubility:** Ligand A (-0.877) is better than Ligand B (-2.838), suggesting better aqueous solubility.
11. **hERG:** Ligand A (0.301) is much better than Ligand B (0.139), indicating a lower risk of cardiotoxicity.
12. **Cl_mic:** Ligand A (46.957) is better than Ligand B (51.81), suggesting better metabolic stability.
13. **t1/2:** Ligand A (5.454) is better than Ligand B (-17.005), suggesting a longer half-life.
14. **Pgp:** Ligand A (0.022) is much better than Ligand B (0.019), indicating lower P-gp efflux.
15. **Affinity:** Ligand B (-8.8) has a significantly stronger binding affinity than Ligand A (-6.4), a difference of 2.4 kcal/mol. This is a substantial advantage.
**Overall Assessment:**
While Ligand B boasts a superior binding affinity, Ligand A has a much more favorable ADMET profile. The DILI risk for Ligand B is concerningly high. Ligand A excels in solubility, metabolic stability, and, crucially, safety (DILI and hERG). For a cardiovascular GPCR, a strong safety profile is paramount. The difference in affinity, while significant, might be overcome with further optimization of Ligand A. The better ADME properties of Ligand A are more likely to translate into a viable drug candidate.
Output:
1
2025-04-17 23:50:05,362 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (372.397 and 357.357 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (107.2) is slightly higher than Ligand B (93.46). Both are acceptable for a non-CNS GPCR target like ADRB2, being below 140. Ligand B is preferable.
3. **logP:** Ligand A (2.29) and Ligand B (1.657) are both within the optimal 1-3 range. Ligand A is slightly more lipophilic, which could be beneficial for membrane permeability, but not dramatically so.
4. **HBD:** Both ligands have 2 H-bond donors, which is good.
5. **HBA:** Ligand A has 7 H-bond acceptors, while Ligand B has 5. Both are acceptable (<=10), but Ligand B is slightly better.
6. **QED:** Both ligands have similar QED values (0.57 and 0.656), indicating good drug-likeness.
7. **DILI:** Ligand A (85.033) has a significantly higher DILI risk than Ligand B (49.942). This is a major concern for Ligand A.
8. **BBB:** Both have high BBB penetration (81.97 and 85.731). While ADRB2 isn't a primary CNS target, higher BBB is generally not detrimental.
9. **Caco-2:** Ligand A (-5.085) has a worse Caco-2 permeability than Ligand B (-4.417). Lower values are less favorable.
10. **Solubility:** Ligand A (-3.794) has worse solubility than Ligand B (-2.898). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.684) has a slightly higher hERG inhibition liability than Ligand B (0.179). Lower is better here.
12. **Cl_mic:** Ligand A (73.913) has a higher microsomal clearance than Ligand B (34.347), indicating lower metabolic stability.
13. **t1/2:** Ligand A (24.954) has a longer in vitro half-life than Ligand B (-10.603). This is a positive for Ligand A.
14. **Pgp:** Ligand A (0.128) has lower P-gp efflux than Ligand B (0.038), which is favorable.
15. **Binding Affinity:** Ligand A (-6.6 kcal/mol) has a slightly better binding affinity than Ligand B (-4.8 kcal/mol). This is a 1.8 kcal/mol difference, which is substantial.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand A has a slight edge in logP and Pgp, and a significant edge in affinity. However, the significant drawbacks of Ligand A in DILI, solubility, and metabolic stability (Cl_mic) outweigh these benefits. Ligand B, while having a weaker affinity, presents a much more favorable ADME-Tox profile.
**Conclusion:**
Considering the balance of properties, particularly the significantly lower DILI risk and improved metabolic stability of Ligand B, it is the more promising drug candidate despite the slightly weaker binding affinity. The 1.8 kcal/mol difference in affinity can potentially be optimized in later stages of drug development. The safety profile is paramount.
Output:
0
2025-04-17 23:50:05,362 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's break down the comparison of Ligand A and Ligand B based on the provided parameters and the guidelines, keeping in mind ADRB2 is a GPCR and thus we prioritize logP, Pgp, TPSA, and affinity.
1. **Molecular Weight:** Both ligands (380.388 Da and 363.405 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (84.5) is better than Ligand B (98.74). Lower TPSA generally favors better cell permeability. This is a slight advantage for A.
3. **logP:** Ligand A (1.27) is within the optimal range (1-3), while Ligand B (0.272) is a bit low. A logP below 1 can sometimes hinder membrane permeability. This is a clear advantage for A.
4. **H-Bond Donors:** Ligand A (2) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **H-Bond Acceptors:** Ligand A (5) is preferable to Ligand B (4). Fewer HBAs generally improve permeability.
6. **QED:** Ligand A (0.777) has a better QED score than Ligand B (0.512), indicating a more drug-like profile.
7. **DILI:** Ligand B (33.424) has a significantly lower DILI risk than Ligand A (59.907). This is a substantial advantage for B.
8. **BBB:** Both ligands have similar BBB penetration (68.748% and 60.295%). This parameter is less critical for a non-CNS target like ADRB2, but A is slightly better.
9. **Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and indicates poor permeability. However, Ligand A (-5.339) is slightly better than Ligand B (-4.846).
10. **Aqueous Solubility:** Ligand A (-2.035) is slightly better than Ligand B (-0.75), indicating better solubility.
11. **hERG Inhibition:** Ligand A (0.484) has a lower hERG inhibition risk than Ligand B (0.245). This is a positive for A.
12. **Microsomal Clearance:** Ligand A (-14.412) has a much lower (better) microsomal clearance than Ligand B (9.172), suggesting better metabolic stability.
13. **In vitro Half-Life:** Ligand A (26.466 hours) has a significantly longer half-life than Ligand B (-27.856 hours). This is a major advantage for A.
14. **P-gp Efflux:** Ligand A (0.11) has a lower P-gp efflux liability than Ligand B (0.012), suggesting better bioavailability.
15. **Binding Affinity:** Ligand B (-7.4 kcal/mol) has a better binding affinity than Ligand A (-5.7 kcal/mol). This is a 1.7 kcal/mol difference, which is significant and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand B has a significantly better binding affinity and lower DILI risk. However, Ligand A has better physicochemical properties (logP, TPSA, QED, solubility, metabolic stability, half-life, P-gp efflux) and a lower hERG risk. The improved ADME profile of Ligand A, coupled with its reasonable affinity, makes it a more balanced and potentially viable drug candidate. The affinity difference, while notable, isn't so large that it completely overshadows the ADME advantages of Ligand A.
**Output:**
1
2025-04-17 23:50:05,362 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (362.323 and 346.515 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (40.62) is significantly better than Ligand A (58.64). ADRB2 is not a CNS target, but lower TPSA generally improves absorption.
3. **logP:** Both ligands have good logP values (2.689 and 3.308), falling within the optimal 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Ligand A has 1 HBD, while Ligand B has 0. Both are acceptable.
5. **HBA:** Ligand A has 3 HBA, and Ligand B has 2. Both are within the acceptable range of <=10.
6. **QED:** Both ligands have reasonable QED values (0.838 and 0.766), indicating good drug-like properties. Ligand A is slightly better.
7. **DILI:** Ligand B (15.471) has a *much* lower DILI risk than Ligand A (64.172). This is a significant advantage for Ligand B.
8. **BBB:** While not a primary concern for ADRB2, Ligand B (90.5) has a higher BBB penetration percentile than Ligand A (69.988).
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.501 and -4.731). This is unusual and suggests poor permeability. However, the values are very similar.
10. **Solubility:** Both ligands have negative solubility values (-3.706 and -3.405). This is also concerning, indicating poor aqueous solubility. Again, values are similar.
11. **hERG:** Both ligands have low hERG inhibition liability (0.637 and 0.658), which is good.
12. **Cl_mic:** Ligand B (63.064) has a lower microsomal clearance than Ligand A (43.53). This suggests better metabolic stability for Ligand B.
13. **t1/2:** Ligand B (-3.015) has a significantly longer in vitro half-life than Ligand A (-37.2). This is a major advantage for Ligand B.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.088 and 0.461).
15. **Binding Affinity:** Ligand B (-6.6 kcal/mol) has a slightly better binding affinity than Ligand A (-5.8 kcal/mol). This difference (0.8 kcal/mol) is not huge, but it's a positive for Ligand B.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand B performs better on TPSA, logP, and affinity. The significantly lower DILI risk and improved metabolic stability (lower Cl_mic and longer t1/2) of Ligand B are also critical advantages. While both have poor Caco-2 and solubility, the other benefits of Ligand B outweigh this drawback.
**Conclusion:**
Ligand B is the more promising candidate due to its superior DILI profile, metabolic stability, half-life, and slightly better binding affinity, along with favorable TPSA and logP values.
Output:
0
2025-04-17 23:50:05,362 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (353.5) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (61.88) is higher than Ligand B (42.43). Both are acceptable, but Ligand B is better, potentially indicating improved membrane permeability.
3. **logP:** Ligand A (1.354) is optimal, while Ligand B (4.893) is high. High logP can lead to solubility issues and off-target interactions. This is a significant drawback for Ligand B.
4. **HBD:** Ligand A (1) is preferable to Ligand B (0). Having at least one HBD can improve solubility.
5. **HBA:** Both ligands have 4 HBA, which is within the acceptable range.
6. **QED:** Ligand A (0.751) has a better QED score than Ligand B (0.657), indicating a more drug-like profile.
7. **DILI:** Ligand A (4.731) has a much lower DILI risk than Ligand B (14.773). This is a crucial advantage for Ligand A.
8. **BBB:** Ligand B (91.508) has a significantly higher BBB penetration than Ligand A (72.082). While ADRB2 isn't exclusively a CNS target, some cardiovascular effects are mediated by central pathways, so this is a slight advantage for Ligand B.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.714) is slightly better than Ligand B (-4.455).
10. **Solubility:** Ligand A (-1.015) has better solubility than Ligand B (-4.443). Solubility is a critical factor for bioavailability.
11. **hERG:** Ligand A (0.384) has a lower hERG risk than Ligand B (0.685). This is a significant safety advantage for Ligand A.
12. **Cl_mic:** Ligand A (1.135) has much lower microsomal clearance than Ligand B (110.014), indicating better metabolic stability. This is a major advantage for Ligand A.
13. **t1/2:** Ligand B (11.467) has a longer in vitro half-life than Ligand A (6.798), which is desirable.
14. **Pgp:** Ligand A (0.019) has much lower P-gp efflux than Ligand B (0.633), which is favorable for bioavailability.
15. **Affinity:** Ligand B (-6.5 kcal/mol) has a significantly stronger binding affinity than Ligand A (-4.6 kcal/mol). This is a substantial advantage for Ligand B.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in affinity and BBB penetration, but suffers from a high logP and Pgp efflux. Ligand A has a more balanced profile with better solubility, lower toxicity (DILI and hERG), and better metabolic stability. The affinity difference is significant (1.9 kcal/mol), but the ADME/Tox profile of Ligand B is concerning.
**Overall Assessment:**
While the affinity of Ligand B is very attractive, the combination of high logP, high DILI risk, high Pgp efflux, and high microsomal clearance makes it a less viable candidate. Ligand A, despite having a weaker affinity, presents a much more favorable ADME-Tox profile, which is crucial for drug development. The better solubility, lower toxicity, and improved metabolic stability of Ligand A outweigh the affinity difference, especially considering the potential for further optimization of Ligand A's affinity.
Output:
1
2025-04-17 23:50:05,363 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (366.824 and 363.889 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (79.18) is slightly higher than Ligand B (62.3). Both are below the 140 threshold for oral absorption, but Ligand B is preferable due to being closer to the 90 threshold for GPCRs.
3. **logP:** Both ligands have good logP values (2.8 and 3.026), falling within the optimal 1-3 range. No clear advantage.
4. **HBD:** Ligand A (3) is higher than Ligand B (1). Ligand B is preferable as lower HBD generally improves permeability.
5. **HBA:** Ligand A (4) is higher than Ligand B (3). Again, Ligand B is preferable.
6. **QED:** Both ligands have good QED scores (0.761 and 0.874), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (56.223) has a higher DILI risk than Ligand B (23.187). This is a significant advantage for Ligand B.
8. **BBB:** Ligand B (74.796) has a significantly higher BBB penetration percentile than Ligand A (47.344). As ADRB2 is a GPCR, BBB penetration is a desirable property, giving Ligand B a strong advantage.
9. **Caco-2:** Both ligands have similar, poor Caco-2 permeability (-4.873 and -4.867).
10. **Solubility:** Both ligands have similar, poor aqueous solubility (-2.99 and -3.306).
11. **hERG:** Both ligands have low hERG inhibition liability (0.407 and 0.404). No significant difference.
12. **Cl_mic:** Ligand A (-12.24) has a *lower* (better) microsomal clearance than Ligand B (46.031), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (21.758) has a longer in vitro half-life than Ligand B (-8.097). This is a significant advantage for Ligand A.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.078 and 0.057). No significant difference.
15. **Binding Affinity:** Ligand A (-6.4) has a slightly better binding affinity than Ligand B (-5.8). While a 1.5 kcal/mol advantage is usually significant, the other factors are more compelling.
**Overall Assessment:**
Ligand B demonstrates a superior balance of properties for a GPCR target like ADRB2. Its lower DILI risk, significantly higher BBB penetration, and slightly better QED outweigh the advantages of Ligand A's metabolic stability and half-life. While Ligand A has a slightly better affinity and metabolic profile, the improved safety (DILI) and potential for CNS exposure (BBB) offered by Ligand B are more crucial for a GPCR drug candidate.
Output:
0
2025-04-17 23:50:05,363 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands (345.443 and 344.459 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (54.78) is better than Ligand B (58.44), being closer to the <140 threshold for good oral absorption.
3. **logP:** Both are within the optimal 1-3 range (1.529 and 2.149). Ligand B is slightly higher, which could be a minor concern for solubility but is still acceptable.
4. **HBD:** Both have 0 HBD, which is good.
5. **HBA:** Both have 4 HBA, which is good.
6. **QED:** Both have good QED scores (0.761 and 0.79), indicating drug-likeness.
7. **DILI:** Ligand B (26.406) has a significantly lower DILI risk than Ligand A (34.354). This is a major advantage.
8. **BBB:** Ligand B (74.176) has a better BBB penetration score than Ligand A (69.407), which is important for GPCRs.
9. **Caco-2:** Both have negative Caco-2 values (-4.629 and -4.651). This is unusual and suggests poor permeability. However, the values are very similar.
10. **Solubility:** Ligand A (-1.298) has slightly better solubility than Ligand B (-1.71).
11. **hERG:** Ligand A (0.146) has a lower hERG inhibition liability than Ligand B (0.409), which is a positive.
12. **Cl_mic:** Ligand B (23.128) has a lower microsomal clearance than Ligand A (31.252), indicating better metabolic stability.
13. **t1/2:** Ligand A (20.596) has a longer in vitro half-life than Ligand B (1.102). This is a significant advantage.
14. **Pgp:** Ligand A (0.131) has lower P-gp efflux liability than Ligand B (0.082).
15. **Affinity:** Ligand B (-6.9 kcal/mol) has a slightly better binding affinity than Ligand A (-5.9 kcal/mol). This is a 1 kcal/mol difference, which is significant.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), we prioritize logP, Pgp, TPSA, and affinity, and BBB. Ligand B performs better on logP, BBB, and affinity. Ligand A has better TPSA and Pgp. The DILI risk is also a major consideration, where Ligand B is clearly superior.
**Overall Assessment:**
Ligand B has a better overall profile. The stronger binding affinity (-6.9 vs -5.9 kcal/mol), lower DILI risk, and better BBB penetration outweigh the slight disadvantages in solubility and Pgp efflux. The longer half-life of Ligand A is attractive, but the affinity and safety advantages of Ligand B are more critical for a GPCR target.
Output:
0
2025-04-17 23:50:05,363 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (366.893 and 380.499 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (86.88) is significantly better than Ligand B (105.31). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (2.903) is optimal, while Ligand B (1.516) is on the lower side. A logP between 1-3 is preferred, and Ligand A is closer to this range. Lower logP can sometimes hinder membrane permeability.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (1), but both are within the acceptable limit of 5.
5. **HBA:** Ligand A (3) is lower than Ligand B (8). Lower HBA is generally preferred for better permeability.
6. **QED:** Both ligands have good QED scores (0.693 and 0.862), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Both ligands have similar DILI risk (61.962 and 63.668), both falling into the moderate risk category. No significant difference.
8. **BBB:** Ligand B (82.978) has a higher BBB penetration percentile than Ligand A (64.482). While ADRB2 isn't a CNS target, some degree of BBB penetration can sometimes be beneficial.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.188 and -5.24). This is unusual and suggests poor permeability. However, the values are very similar.
10. **Solubility:** Ligand A (-4.517) has slightly better solubility than Ligand B (-3.541).
11. **hERG:** Both ligands have very low hERG inhibition liability (0.313 and 0.474), which is excellent.
12. **Cl_mic:** Ligand A (33.691) has a higher microsomal clearance than Ligand B (17.049). This suggests Ligand B is more metabolically stable.
13. **t1/2:** Ligand A (29.222) has a longer in vitro half-life than Ligand B (6.842). This is a significant advantage.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.367 and 0.198). Ligand B is slightly better.
15. **Binding Affinity:** Ligand B (-7.2 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.0 kcal/mol). This >1.5 kcal/mol difference is a major advantage, potentially outweighing some ADME drawbacks.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has better logP and TPSA, while Ligand B has better Pgp and a *much* better binding affinity.
**Overall Assessment:**
While Ligand A has some advantages in terms of TPSA, logP, solubility and half-life, the significantly stronger binding affinity of Ligand B (-7.2 vs -6.0 kcal/mol) is the deciding factor. A strong binding affinity is crucial for GPCR targets, and the difference here is substantial enough to overcome the slightly less favorable TPSA and logP values. The improved metabolic stability (lower Cl_mic) of Ligand B is also a positive.
Output:
0
2025-04-17 23:50:05,363 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (367.515 and 356.482 Da) fall comfortably within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Both ligands (80.32 and 78.43) are below the 140 A^2 threshold for good oral absorption, and acceptable for a non-CNS GPCR target like ADRB2. No significant difference.
3. **logP:** Both ligands (2.671 and 2.609) are within the optimal 1-3 range. No significant difference.
4. **HBD:** Ligand A (2) and Ligand B (3) are both acceptable, being less than 5. Ligand A is slightly better.
5. **HBA:** Ligand A (5) and Ligand B (3) are both acceptable, being less than 10. Ligand A is slightly worse.
6. **QED:** Both ligands (0.74 and 0.678) have good drug-likeness scores, well above the 0.5 threshold. No significant difference.
7. **DILI:** Ligand A (40.287) is slightly higher than Ligand B (26.095), indicating a marginally higher risk of drug-induced liver injury. Ligand B is better.
8. **BBB:** Both ligands (65.529 and 68.786) have moderate BBB penetration, which isn't a primary concern for ADRB2 (a cardiovascular target). No significant difference.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.668 and -4.706). This is unusual and suggests poor permeability. However, since both are similar, it doesn't differentiate them.
10. **Solubility:** Both ligands have negative solubility values (-3.426 and -2.584). This is also unusual and suggests poor solubility. Again, similar values don't help differentiate.
11. **hERG:** Both ligands (0.267 and 0.338) have low hERG inhibition liability, which is good. No significant difference.
12. **Cl_mic:** Ligand A (54.199) has a higher microsomal clearance than Ligand B (5.711), indicating lower metabolic stability. Ligand B is significantly better.
13. **t1/2:** Ligand A (31.143) has a longer in vitro half-life than Ligand B (-9.951). This is a significant advantage for Ligand A.
14. **Pgp:** Both ligands (0.074 and 0.186) have low P-gp efflux liability, which is desirable. Ligand A is slightly better.
15. **Binding Affinity:** Ligand A (-6.2 kcal/mol) has a slightly better binding affinity than Ligand B (-6.0 kcal/mol), but the difference is small.
**GPCR-specific priorities:** For ADRB2, logP, TPSA, Pgp, and affinity are key. Both ligands perform similarly on logP, TPSA and Pgp. Ligand A has slightly better affinity. However, Ligand B has a significantly better metabolic stability (lower Cl_mic) and lower DILI risk. The longer half-life of Ligand A is a positive, but the improved metabolic stability of Ligand B is more crucial for a GPCR target where sustained receptor occupancy is important.
**Conclusion:**
Considering the balance of properties, particularly the significantly improved metabolic stability and lower DILI risk of Ligand B, I favor Ligand B as the more promising drug candidate.
Output:
0
2025-04-17 23:50:05,363 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor (a GPCR).
**Ligand A:** [360.439, 79.96, 2.527, 1, 8, 0.652, 83.715, 70.027, -4.957, -3.577, 0.595, 111.458, 50.281, 0.323, -7.1]
**Ligand B:** [365.474, 43.86, 1.902, 0, 4, 0.822, 23.187, 93.68, -4.647, -1.976, 0.781, 8.062, 10.043, 0.324, -6.3]
Here's a breakdown, property by property, with emphasis on GPCR-relevant factors:
1. **MW:** Both are within the ideal 200-500 Da range. A (360.439) is slightly better.
2. **TPSA:** A (79.96) is higher than B (43.86). B is significantly better, falling well below the 140 threshold for oral absorption and more favorably positioned for potential CNS penetration (though ADRB2 isn't strictly a CNS target).
3. **logP:** Both are within the optimal 1-3 range. B (1.902) is slightly lower, which could be beneficial for solubility, but A (2.527) is still acceptable.
4. **HBD:** A (1) is good. B (0) is also good.
5. **HBA:** A (8) is acceptable. B (4) is excellent.
6. **QED:** B (0.822) is better than A (0.652), indicating a more drug-like profile.
7. **DILI:** A (83.715) is concerningly high. B (23.187) is excellent, indicating a very low risk of liver injury. This is a *major* advantage for B.
8. **BBB:** A (70.027) is acceptable, B (93.68) is excellent. While ADRB2 isn't a primary CNS target, higher BBB penetration is generally favorable.
9. **Caco-2:** Both are negative, indicating good permeability. A (-4.957) is slightly better than B (-4.647).
10. **Solubility:** A (-3.577) is worse than B (-1.976). B has better aqueous solubility.
11. **hERG:** Both are low (0.595 and 0.781), indicating low cardiotoxicity risk.
12. **Cl_mic:** A (111.458) is significantly higher than B (8.062), meaning A has much faster metabolic clearance and lower metabolic stability. This is a significant drawback for A.
13. **t1/2:** A (50.281) is better than B (10.043). A has a longer in vitro half-life.
14. **Pgp:** Both are low (0.323 and 0.324), indicating minimal P-gp efflux.
15. **Affinity:** A (-7.1) is 0.8 kcal/mol better than B (-6.3). This is a substantial difference in binding affinity.
**Overall Assessment:**
Ligand A has a better binding affinity and in vitro half-life. However, Ligand B excels in almost all ADME-Tox properties. Specifically, the significantly lower DILI risk and much better metabolic stability (lower Cl_mic) of Ligand B are compelling. The superior TPSA, QED, BBB, and solubility of Ligand B also contribute to its more favorable profile. While the affinity difference is notable, a 0.8 kcal/mol difference can often be overcome with further optimization, especially considering the substantial improvements in other critical parameters offered by Ligand B. For a GPCR target, the balance of properties is crucial, and B's profile is far more promising.
Output:
0
2025-04-17 23:50:05,364 - INFO - Batch 433 complete. Total preferences: 6928
2025-04-17 23:50:05,364 - INFO - Processing batch 434/512...
2025-04-17 23:50:57,178 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (351.403) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (93.9) is significantly better than Ligand B (124.42). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (0.704) is better than Ligand B (0.327). Both are a bit low, potentially impacting permeability, but Ligand A is closer to the optimal 1-3 range.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (6) is better than Ligand B (4). Lower HBA is generally preferred for permeability.
6. **QED:** Both ligands have similar and acceptable QED values (0.806 and 0.71).
7. **DILI:** Both ligands have similar DILI risk (55.991 and 57.348), both are acceptable.
8. **BBB:** Ligand A (65.801) is slightly better than Ligand B (57.193), but neither is particularly high. This isn't a major concern for a cardiovascular target.
9. **Caco-2:** Ligand A (-4.792) is better than Ligand B (-5.468). Higher (less negative) Caco-2 values indicate better absorption.
10. **Solubility:** Ligand A (-0.982) is significantly better than Ligand B (-3.3). Solubility is crucial for bioavailability.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.039 and 0.139), which is excellent.
12. **Cl_mic:** Ligand B (-25.392) has a much lower (better) microsomal clearance than Ligand A (17.362), indicating greater metabolic stability.
13. **t1/2:** Ligand A (27.595) has a longer in vitro half-life than Ligand B (-10.636). This is a significant advantage.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.03 and 0.009).
15. **Binding Affinity:** Ligand A (-6.5 kcal/mol) has a significantly stronger binding affinity than Ligand B (-2.3 kcal/mol). This is a substantial difference.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A is superior in all these areas except Pgp (where they are comparable). The much stronger binding affinity of Ligand A is a major advantage, and can often compensate for minor ADME drawbacks.
**Overall Assessment:**
Ligand A demonstrates a better overall balance of properties, particularly with its superior binding affinity, TPSA, solubility, and Caco-2 permeability. While Ligand B has better metabolic stability, the substantial difference in binding affinity and the overall more favorable profile of Ligand A make it the more promising drug candidate.
Output:
1
2025-04-17 23:50:57,179 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (345.403) is slightly lower, which could be beneficial for permeability, but both are acceptable.
2. **TPSA:** Ligand A (90.3) is better than Ligand B (49.41). Lower TPSA generally favors oral absorption and BBB penetration, crucial for GPCRs.
3. **logP:** Ligand B (3.178) is slightly higher than Ligand A (1.331), but both are within the optimal 1-3 range. Ligand B is closer to the upper limit, which could raise concerns about solubility and off-target effects, but isn't a dealbreaker.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1), but both are within the acceptable limit of 5.
5. **HBA:** Ligand A (6) is higher than Ligand B (3), but both are within the acceptable limit of 10.
6. **QED:** Both ligands have similar QED values (A: 0.853, B: 0.845), indicating good drug-likeness.
7. **DILI:** Ligand B (35.479) has a significantly lower DILI risk than Ligand A (68.825). This is a major advantage for Ligand B.
8. **BBB:** Ligand B (70.027) has a better BBB penetration percentile than Ligand A (61.535). This is important for GPCRs, even if ADRB2 isn't exclusively a CNS target, as peripheral exposure can be modulated by CNS penetration.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.218 and -5.007), which is unusual and likely indicates poor permeability. However, these values are very similar.
10. **Solubility:** Ligand A (-1.86) has a better solubility score than Ligand B (-3.742). Solubility is important for bioavailability.
11. **hERG:** Both ligands have very low hERG inhibition liability (A: 0.096, B: 0.59). This is excellent.
12. **Cl_mic:** Ligand A (-17.197) has a much lower (better) microsomal clearance than Ligand B (84.904). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (46.488) has a longer in vitro half-life than Ligand B (-3.068). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.017) has a much lower P-gp efflux liability than Ligand B (0.462). Lower P-gp efflux is desirable for better oral bioavailability and potentially CNS exposure.
15. **Binding Affinity:** Ligand B (-6.3) has a slightly better binding affinity than Ligand A (-4.7). This is a 1.6 kcal/mol difference, which is substantial.
**Overall Assessment:**
Ligand B has a significantly better binding affinity and lower DILI risk, and better BBB penetration. However, Ligand A demonstrates superior metabolic stability (lower Cl_mic, longer t1/2), lower P-gp efflux, and better solubility. The Caco-2 values are concerning for both, but similar. Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity), the affinity advantage of Ligand B is substantial enough to outweigh the metabolic and P-gp concerns, especially given the lower DILI risk. The slightly better BBB penetration also favors Ligand B.
Output:
0
2025-04-17 23:50:57,179 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.475 and 351.491 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (87.66) is better than Ligand B (102.22). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have acceptable logP values (1.364 and 2.269), falling within the 1-3 range. Ligand B is slightly higher, which could potentially lead to some off-target interactions, but isn't a major concern.
4. **HBD:** Both have 3 HBD, which is within the acceptable limit of <=5.
5. **HBA:** Both have 4 HBA, which is within the acceptable limit of <=10.
6. **QED:** Ligand A (0.713) has a better QED score than Ligand B (0.562), indicating a more drug-like profile.
7. **DILI:** Ligand A (35.285) has a significantly lower DILI risk than Ligand B (10.237). This is a crucial advantage.
8. **BBB:** Ligand B (57.154) has a higher BBB penetration than Ligand A (39.395), but as ADRB2 is a cardiovascular target, this is not a high priority.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-5.056) is slightly better than Ligand B (-4.812), but both are concerning.
10. **Solubility:** Both have negative solubility values, indicating poor solubility. Ligand B (-1.842) is slightly better than Ligand A (-2.414).
11. **hERG:** Both have very low hERG inhibition risk (0.172 and 0.4), which is excellent.
12. **Cl_mic:** Ligand B (8.98) has a lower microsomal clearance than Ligand A (27.595), suggesting better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand B (-7.076) has a longer in vitro half-life than Ligand A (8.634), which is desirable.
14. **Pgp:** Both have very low Pgp efflux liability (0.087 and 0.027), which is excellent.
15. **Binding Affinity:** Ligand B (-6.9) has a slightly better binding affinity than Ligand A (-6.0). This is a 0.9 kcal/mol difference, which is significant.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. While Ligand B has a slightly better logP and significantly better affinity, Ligand A has a much better DILI score and a better QED score. The Caco-2 and solubility are poor for both, but the DILI risk is a major concern. Metabolic stability (Cl_mic and t1/2) are also important, and Ligand B is superior in these aspects.
**Overall Assessment:**
Despite Ligand B's better affinity and metabolic stability, the significantly lower DILI risk associated with Ligand A is a critical factor. DILI is a major cause of drug attrition, and minimizing this risk is paramount. While the Caco-2 and solubility are poor for both, these can be addressed with formulation strategies. The slightly better affinity of Ligand B is unlikely to outweigh the substantial reduction in potential liver toxicity offered by Ligand A.
Output:
1
2025-04-17 23:50:57,179 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, the most important parameters are binding affinity, logP, TPSA, Pgp efflux, and BBB penetration (though BBB is less critical for a cardiovascular target).
Let's compare the ligands step-by-step:
1. **MW:** Both ligands (363.37 and 342.399 Da) are within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (20.31) is significantly better than Ligand B (95.73). A TPSA under 140 is good for oral absorption, and Ligand A is well within this range, while Ligand B is quite high, potentially hindering absorption.
3. **logP:** Ligand A (4.778) is a bit high, but still within a reasonable range. Ligand B (0.874) is quite low, potentially leading to poor membrane permeability.
4. **HBD/HBA:** Ligand A (0/1) is preferable to Ligand B (3/5). Fewer H-bonds generally improve permeability.
5. **QED:** Both ligands have acceptable QED values (0.69 and 0.751).
6. **DILI:** Ligand A (17.449) has a much lower DILI risk than Ligand B (47.421). This is a significant advantage.
7. **BBB:** Ligand A (97.247) shows excellent BBB penetration, while Ligand B (41.14) is poor. While not a primary concern for a cardiovascular target, it's a positive for Ligand A.
8. **Caco-2:** Ligand A (-4.585) is better than Ligand B (-5.23), indicating better intestinal absorption.
9. **Solubility:** Ligand A (-4.711) is better than Ligand B (-1.983), indicating better solubility.
10. **hERG:** Ligand A (0.952) has a lower hERG risk than Ligand B (0.314).
11. **Cl_mic:** Ligand B (-24.957) has a much lower microsomal clearance, suggesting better metabolic stability than Ligand A (37.337).
12. **t1/2:** Ligand B (18.153) has a longer in vitro half-life than Ligand A (-16.784).
13. **Pgp:** Ligand A (0.592) has lower P-gp efflux than Ligand B (0.022), which is favorable.
14. **Binding Affinity:** Ligand B (-8.3 kcal/mol) has a slightly better binding affinity than Ligand A (-7.0 kcal/mol). This is a 1.3 kcal/mol difference, which is significant, but not overwhelming given the other factors.
**Overall Assessment:**
Ligand A is significantly better overall. While Ligand B has a slightly higher binding affinity, Ligand A excels in crucial ADME properties like TPSA, logP, DILI risk, BBB penetration, solubility, and Pgp efflux. The lower metabolic stability and shorter half-life of Ligand A are concerns, but can potentially be addressed through structural modifications. The poor ADME profile of Ligand B, particularly its high TPSA and low logP, are more difficult to overcome.
**Output:**
1
2025-04-17 23:50:57,179 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (344.455 and 344.415 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (60.45) is significantly better than Ligand B (87.32). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold. Ligand B is approaching the upper limit.
3. **logP:** Ligand A (3.972) is slightly higher than Ligand B (2.26). Both are within the optimal 1-3 range, but Ligand A is closer to the upper bound. This could potentially lead to solubility issues, but the difference isn't drastic.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Both ligands have 4 HBA, which is within the acceptable range.
6. **QED:** Ligand B (0.787) has a slightly better QED score than Ligand A (0.61), indicating a more drug-like profile.
7. **DILI:** Ligand A (54.401) is slightly better than Ligand B (59.131), both are acceptable, but lower is preferred.
8. **BBB:** Ligand A (82.9) has a significantly higher BBB penetration percentile than Ligand B (50.097). While ADRB2 isn't a CNS target, some degree of BBB penetration can sometimes indicate favorable permeability characteristics.
9. **Caco-2:** Ligand A (-4.912) is better than Ligand B (-5.175). Both are negative, indicating good permeability.
10. **Solubility:** Ligand A (-3.319) is slightly better than Ligand B (-3.59). Both are similarly poor, but Ligand A is marginally better.
11. **hERG:** Ligand A (0.898) is better than Ligand B (0.371). Lower hERG inhibition is crucial to avoid cardiotoxicity, especially for a cardiovascular target.
12. **Cl_mic:** Ligand A (50.729) has a significantly lower microsomal clearance than Ligand B (9.247). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (62.48) has a longer in vitro half-life than Ligand B (-8.357). This is a significant advantage, suggesting less frequent dosing potential.
14. **Pgp:** Ligand A (0.389) is better than Ligand B (0.031). Lower P-gp efflux is desirable for improved bioavailability.
15. **Binding Affinity:** Ligand B (-7.2) has a slightly better binding affinity than Ligand A (-6.6). This is a 0.6 kcal/mol difference, which is a noticeable advantage.
**Overall Assessment:**
Ligand B has a slightly better binding affinity and QED score. However, Ligand A excels in several critical ADME properties, including TPSA, HBD, DILI, BBB, Cl_mic, t1/2, and Pgp efflux. The lower hERG risk for Ligand A is also a major advantage for a cardiovascular target. The slightly weaker binding affinity of Ligand A is likely outweighed by its superior ADME profile and safety characteristics. Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity), Ligand A strikes a better balance.
Output:
1
2025-04-17 23:50:57,179 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
Let's break down the comparison of Ligand A and Ligand B based on the provided parameters and the guidelines, keeping in mind this is a GPCR target (ADRB2, cardiovascular). Therefore, logP, TPSA, Pgp, and affinity are particularly important.
1. **Molecular Weight:** Both ligands (356.4 and 364.9 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand B (69.3) is significantly better than Ligand A (96.7). Lower TPSA generally equates to better cell permeability and oral absorption, a crucial factor for GPCRs.
3. **logP:** Ligand B (2.631) is optimal, while Ligand A (0.313) is quite low. A logP below 1 can hinder membrane permeation. This is a substantial advantage for Ligand B.
4. **H-Bond Donors:** Ligand A (2) is slightly higher than Ligand B (1), but both are acceptable.
5. **H-Bond Acceptors:** Ligand A (6) is higher than Ligand B (3). Again, both are within reasonable limits, but lower is generally preferred.
6. **QED:** Ligand B (0.892) has a better QED score than Ligand A (0.696), indicating a more drug-like profile.
7. **DILI:** Ligand A (28.9%) has a significantly lower DILI risk than Ligand B (50.1%). This is a major advantage for Ligand A.
8. **BBB:** Both ligands have good BBB penetration (Ligand A: 78.5%, Ligand B: 76.9%). This isn't a primary concern for a cardiovascular target, but it's good to see reasonable values.
9. **Caco-2:** Ligand A (-4.872) and Ligand B (-5.044) are both negative, which is unusual. This indicates very poor permeability.
10. **Solubility:** Ligand A (-2.079) and Ligand B (-3.486) are both very poor.
11. **hERG:** Ligand A (0.305) has a lower hERG risk than Ligand B (0.518), which is desirable.
12. **Cl_mic:** Ligand A (6.125) has a much lower microsomal clearance than Ligand B (36.686), suggesting better metabolic stability.
13. **t1/2:** Ligand A (7.904) has a longer in vitro half-life than Ligand B (1.295). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.027) has a much lower P-gp efflux liability than Ligand B (0.232), indicating better bioavailability and potentially better CNS exposure.
15. **Binding Affinity:** Ligand B (-6.1 kcal/mol) has a slightly better binding affinity than Ligand A (-6.5 kcal/mol). While a difference of 0.4 kcal/mol is not huge, it is noticeable.
**Overall Assessment:**
Ligand A excels in metabolic stability (Cl_mic, t1/2), DILI risk, Pgp efflux, and hERG inhibition. Ligand B has a better logP and QED score, and slightly better binding affinity. However, the poor solubility and Caco-2 permeability of both ligands are concerning. The significantly better ADME profile of Ligand A, particularly its lower DILI risk and better metabolic stability, outweighs the slightly better affinity of Ligand B. The low logP of Ligand A is a concern, but could possibly be addressed with further optimization.
**Output:**
1
2025-04-17 23:50:57,179 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (359.363) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are reasonably low, but Ligand B (101.8) is better than Ligand A (114.59), falling comfortably under the 140 A^2 threshold for oral absorption.
3. **logP:** Ligand A (3.523) is optimal, while Ligand B (0.719) is a bit low, potentially hindering membrane permeability.
4. **HBD:** Both have 2 HBD, which is within the acceptable range.
5. **HBA:** Ligand A (7) and Ligand B (8) are both acceptable, below the 10 threshold.
6. **QED:** Both ligands have good QED scores (A: 0.511, B: 0.654), indicating drug-likeness. Ligand B is slightly better here.
7. **DILI:** Ligand A (98.216) has a significantly higher DILI risk than Ligand B (86.041). This is a major concern.
8. **BBB:** Ligand B (33.075) is slightly better than Ligand A (27.879), but neither is particularly high. BBB isn't a top priority for ADRB2 (a cardiovascular target), but higher is still preferred.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-5.114) is slightly better than Ligand B (-5.727).
10. **Solubility:** Ligand A (-5.047) is slightly better than Ligand B (-2.664), indicating better aqueous solubility.
11. **hERG:** Both have low hERG inhibition liability (A: 0.198, B: 0.147), which is good.
12. **Cl_mic:** Ligand B (32.316) has a higher microsomal clearance than Ligand A (25.7), suggesting faster metabolism and potentially lower exposure.
13. **t1/2:** Ligand B (12.245) has a significantly longer in vitro half-life than Ligand A (-0.817), which is a major advantage.
14. **Pgp:** Both have low Pgp efflux liability (A: 0.192, B: 0.029). Ligand B is better.
15. **Binding Affinity:** Ligand A (-6.9 kcal/mol) has a slightly better binding affinity than Ligand B (-6.5 kcal/mol). This is a 0.4 kcal/mol difference, which is noticeable but not overwhelming.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has a better logP and slightly better affinity, but Ligand B excels in TPSA and Pgp. The biggest concern with Ligand A is its very high DILI risk. The longer half-life of Ligand B is also a significant advantage.
**Overall Assessment:**
Despite the slightly better affinity of Ligand A, the significantly higher DILI risk and shorter half-life make it a less desirable candidate. Ligand B, while having a lower logP, presents a much more favorable safety profile (lower DILI) and better metabolic stability (longer half-life). The small difference in binding affinity is outweighed by these critical ADME-Tox considerations.
Output:
0
2025-04-17 23:50:57,179 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (351.435 and 346.391 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (71.01) is significantly better than Ligand B (116.14). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold, while B is approaching it.
3. **logP:** Ligand A (2.597) is within the optimal 1-3 range. Ligand B (-0.196) is *below* 1, which is a concern for permeability. This is a significant negative for Ligand B.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Both ligands have 6 HBA, which is acceptable.
6. **QED:** Ligand A (0.782) has a better QED score than Ligand B (0.67), indicating a more drug-like profile.
7. **DILI:** Ligand B (47.266) has a much lower DILI risk than Ligand A (71.229). This is a strong positive for Ligand B.
8. **BBB:** Ligand A (69.407) has a higher BBB penetration potential than Ligand B (8.143). While not critical for a cardiovascular target, it's a slight positive for A.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.204 and -5.695). These values are difficult to interpret without knowing the scale, but negative values generally indicate poor permeability.
10. **Solubility:** Ligand A (-2.815) has slightly better solubility than Ligand B (-1.205), although both are poor.
11. **hERG:** Both ligands have low hERG risk (0.412 and 0.244).
12. **Cl_mic:** Ligand B (-22.296) has significantly lower microsomal clearance than Ligand A (72.301), suggesting better metabolic stability. This is a major advantage for Ligand B.
13. **t1/2:** Ligand A (-8.365) has a longer in vitro half-life than Ligand B (-0.586). This is a positive for Ligand A.
14. **Pgp:** Ligand A (0.112) has lower P-gp efflux than Ligand B (0.005), which is a slight advantage.
15. **Binding Affinity:** Ligand B (-7.4) has a slightly better binding affinity than Ligand A (-6.7). While the difference is less than the 1.5 kcal/mol threshold to override other issues, it is still a positive for Ligand B.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand A has a better TPSA and a slightly better Pgp profile, but Ligand B has a significantly better logP and a slightly better affinity. Metabolic stability (Cl_mic) is also important, and Ligand B is far superior in this regard. DILI risk is also a crucial consideration, and Ligand B has a substantially lower risk.
**Overall Assessment:**
Ligand B, despite its higher TPSA, is the more promising candidate. The significantly better logP, lower DILI risk, and superior metabolic stability outweigh the slightly lower BBB penetration and solubility. The binding affinity difference is small. The poor Caco-2 values for both are concerning, but can be addressed through formulation strategies.
Output:
0
2025-04-17 23:50:57,180 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (363.483 and 362.901 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (62.74) is slightly higher than Ligand B (53.43). Both are below the 140 threshold for oral absorption, but closer to the 90 threshold for CNS targets. This is acceptable for a cardiovascular target.
3. **logP:** Ligand A (1.797) is within the optimal 1-3 range. Ligand B (3.151) is at the higher end of the optimal range, potentially increasing off-target interactions.
4. **HBD:** Ligand A (0) is preferable to Ligand B (1). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (3). Lower HBA counts are generally better for permeability.
6. **QED:** Both ligands have similar QED values (0.821 and 0.791), indicating good drug-likeness.
7. **DILI:** Ligand B (17.449) has a significantly lower DILI risk than Ligand A (50.174). This is a major advantage for Ligand B.
8. **BBB:** Ligand B (80.962) has a higher BBB penetration percentile than Ligand A (59.325). While ADRB2 is primarily a cardiovascular target, some CNS effects are possible with beta-blockers, and higher BBB penetration could be a concern for off-target effects. However, it's not a primary concern here.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.542 and -4.62), which is unusual and suggests poor permeability. This is a significant drawback for both.
10. **Solubility:** Ligand A (-1.639) has better solubility than Ligand B (-3.885). Solubility is important for bioavailability.
11. **hERG:** Both ligands have relatively low hERG inhibition risk (0.451 and 0.62).
12. **Cl_mic:** Ligand A (36.83) has lower microsomal clearance than Ligand B (45.927), indicating better metabolic stability.
13. **t1/2:** Ligand B (23.813) has a significantly longer in vitro half-life than Ligand A (7.14). This is a major advantage for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.16) has lower P-gp efflux liability than Ligand B (0.563), which is preferable for oral bioavailability.
15. **Binding Affinity:** Ligand B (-6.5) has slightly better binding affinity than Ligand A (-6.3). While the difference is small (0.2 kcal/mol), it's enough to be considered.
**GPCR-specific priorities:** For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand B has better logP, affinity and Pgp. Ligand A has better TPSA.
**Overall Assessment:**
Ligand B is the better candidate. The significantly lower DILI risk, longer half-life, and slightly better binding affinity outweigh the slightly higher logP and Pgp efflux. The Caco-2 values are concerning for both, but the other advantages of Ligand B make it the more promising option. The better solubility of Ligand A is a plus, but not enough to overcome the other benefits of Ligand B.
Output:
0
2025-04-17 23:50:57,180 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (344.375 and 350.478 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (100.38) is higher than Ligand B (49.41). For a cardiovascular GPCR, TPSA isn't a *major* concern unless extremely high, but lower is generally preferred for better permeability. Ligand B is significantly better.
3. **logP:** Ligand A (0.829) is a bit low, potentially hindering permeation. Ligand B (3.204) is within the optimal 1-3 range. Ligand B is better.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 7 HBA, while Ligand B has 2. Lower HBA is generally preferred for permeability, making Ligand B better.
6. **QED:** Ligand A (0.88) has a better QED score than Ligand B (0.766), indicating a more drug-like profile. This favors Ligand A.
7. **DILI:** Ligand A (74.99) has a higher DILI risk than Ligand B (19.426). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (71.85) and Ligand B (91.508). While ADRB2 isn't necessarily a CNS target, higher BBB penetration can sometimes correlate with better overall distribution. Ligand B is better.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. However, Ligand A (-5.007) is worse than Ligand B (-4.752).
10. **Solubility:** Both have negative solubility values, indicating poor solubility. Ligand A (-2.376) is slightly better than Ligand B (-3.847).
11. **hERG:** Ligand A (0.191) has a lower hERG risk than Ligand B (0.802). This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand A (26.416) has a lower microsomal clearance than Ligand B (43.32), suggesting better metabolic stability. This favors Ligand A.
13. **t1/2:** Ligand A (21.409) has a longer half-life than Ligand B (-8.842). This is a strong advantage for Ligand A.
14. **Pgp:** Ligand A (0.054) has a lower P-gp efflux liability than Ligand B (0.354). This is better for bioavailability.
15. **Binding Affinity:** Ligand A (-6.8 kcal/mol) has a slightly better binding affinity than Ligand B (-6.2 kcal/mol). While the difference is not huge, it's still a positive for Ligand A.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand B has a clear advantage in terms of logP and TPSA. However, Ligand A has a better QED score, lower DILI risk, better metabolic stability (lower Cl_mic and longer t1/2), lower Pgp efflux, and slightly better binding affinity. The DILI risk and metabolic stability are particularly important for cardiovascular drugs. While Ligand A has poor Caco-2 and solubility, these can potentially be addressed with formulation strategies. The slightly better affinity and the more favorable ADME properties (DILI, Cl_mic, t1/2, Pgp) outweigh the slightly lower logP and higher TPSA.
Output:
1
2025-04-17 23:50:57,180 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [359.451, 80.32, 3.595, 2, 6, 0.816, 82.241, 55.293, -4.917, -4.449, 0.246, 90.638, 44.166, 0.415, -6]**
**Ligand B: [345.443, 75.44, 2.583, 1, 4, 0.86, 40.83, 74.176, -4.585, -2.85, 0.078, 91.999, -9.56, 0.124, -5.9]**
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand B (345.443) is slightly smaller, which is generally favorable for permeability, but the difference isn't substantial.
2. **TPSA:** Both are below the 140 A^2 threshold for good oral absorption. Ligand B (75.44) is better than Ligand A (80.32), being closer to the preferred <90 A^2 for CNS targets, though ADRB2 isn't necessarily a CNS target.
3. **logP:** Both are within the optimal 1-3 range. Ligand A (3.595) is slightly higher, which *could* indicate potential off-target interactions or solubility issues, but it's still acceptable. Ligand B (2.583) is more ideal.
4. **H-Bond Donors:** Ligand A (2) and Ligand B (1) are both within the acceptable limit of <=5. Ligand B is slightly better.
5. **H-Bond Acceptors:** Ligand A (6) and Ligand B (4) are both within the acceptable limit of <=10. Ligand B is better.
6. **QED:** Both ligands have good QED scores (A: 0.816, B: 0.86), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (82.241) has a concerningly high DILI risk. Ligand B (40.83) is well below the 60% threshold and is much safer. This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (55.293) and Ligand B (74.176). While ADRB2 isn't a primary CNS target, higher BBB penetration is generally favorable, and Ligand B is better.
9. **Caco-2 Permeability:** Both have negative values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
10. **Aqueous Solubility:** Both have negative values, which is also unusual and suggests poor solubility. Again, the scale is not specified, so it's difficult to interpret.
11. **hERG Inhibition:** Ligand A (0.246) and Ligand B (0.078) both have low hERG inhibition risk, but Ligand B is better.
12. **Microsomal Clearance:** Ligand A (90.638) and Ligand B (91.999) have similar, high, microsomal clearance values, indicating rapid metabolism. This is a drawback for both.
13. **In vitro Half-Life:** Ligand A (44.166) and Ligand B (-9.56). The negative value for Ligand B is concerning and likely an error or outlier. Ligand A has a better half-life.
14. **P-gp Efflux:** Ligand A (0.415) and Ligand B (0.124) both have low P-gp efflux, which is good. Ligand B is better.
15. **Binding Affinity:** Ligand A (-6) and Ligand B (-5.9). Ligand A has a slightly better binding affinity, but the difference is small (0.1 kcal/mol).
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity) and general drug-like properties, Ligand B is the more promising candidate. The significantly lower DILI risk is a major advantage, outweighing the slightly lower binding affinity and the questionable half-life value. While both have high microsomal clearance, the safety profile of Ligand B is far superior.
Output:
0
2025-04-17 23:50:57,180 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (351.491 and 354.447 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (92.5 and 93.73) are reasonably low, suggesting good potential for absorption. They are below the 140 threshold, and acceptable for a peripheral GPCR like ADRB2.
3. **logP:** Ligand A (1.82) is slightly higher than Ligand B (0.869), placing it more optimally within the 1-3 range. Ligand B is a bit low, potentially hindering permeation.
4. **HBD:** Both ligands have 2 H-bond donors, which is within the acceptable limit of 5.
5. **HBA:** Ligand A has 3 H-bond acceptors, while Ligand B has 5. Both are below the 10 threshold, but Ligand A is preferable.
6. **QED:** Ligand A (0.809) has a significantly better QED score than Ligand B (0.599), indicating a more drug-like profile.
7. **DILI:** Ligand A (24.777) has a lower DILI risk than Ligand B (29.314), which is desirable. Both are below the 40 threshold, indicating low risk.
8. **BBB:** Ligand A (72.664) has a higher BBB penetration percentile than Ligand B (63.358). While ADRB2 isn't a CNS target, higher BBB is generally favorable.
9. **Caco-2:** Ligand A (-5.053) has a slightly better Caco-2 permeability value than Ligand B (-5).
10. **Solubility:** Ligand A (-3.62) has a better solubility value than Ligand B (-1.931).
11. **hERG:** Both ligands have very low hERG inhibition liability (0.142 and 0.169), which is excellent.
12. **Cl_mic:** Both ligands have similar microsomal clearance values (51.009 and 53.697 mL/min/kg).
13. **t1/2:** Ligand A (1.043) has a slightly better in vitro half-life than Ligand B (-5.857).
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.028 and 0.012).
15. **Binding Affinity:** Ligand B (-7.0 kcal/mol) has a slightly better binding affinity than Ligand A (-6.0 kcal/mol). This is a 1.0 kcal/mol difference, which is significant.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A has a more optimal logP, better TPSA, better solubility, better QED, and lower DILI risk. While Ligand B has a slightly better binding affinity, the overall ADME profile of Ligand A is superior, and the affinity difference is not large enough to overcome the other advantages.
**Conclusion:**
Considering the balance of properties, particularly the ADME profile and the slightly better overall drug-likeness of Ligand A, I believe it is the more promising drug candidate.
Output:
1
2025-04-17 23:50:57,180 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (341.371 and 352.385 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (101.53) is higher than Ligand B (67.23). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B is better.
3. **logP:** Ligand A (-1.224) is lower than the optimal 1-3 range, potentially hindering permeability. Ligand B (1.198) is within the optimal range. Ligand B is significantly better.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 5 HBA, and Ligand B has 4. Both are acceptable.
6. **QED:** Both ligands have good QED scores (0.696 and 0.81), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (35.285) has a lower DILI risk than Ligand B (52.346). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (40.326) has a lower BBB penetration than Ligand B (83.986). Since ADRB2 is not a CNS target, this is less of a concern, and even slightly detrimental (we don't *want* high brain exposure for a cardiovascular drug).
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
10. **Solubility:** Both have negative solubility values, which is also unusual and suggests poor solubility. Again, the scale is unclear.
11. **hERG:** Ligand A (0.067) has a lower hERG risk than Ligand B (0.209), which is a significant safety advantage.
12. **Cl_mic:** Ligand A (-18.926) has a much lower (better) microsomal clearance than Ligand B (17.902), indicating greater metabolic stability.
13. **t1/2:** Ligand A (-6.326) has a negative in vitro half-life, which is not possible. Ligand B (-24.442) also has a negative in vitro half-life, which is not possible. This is a major red flag for both compounds.
14. **Pgp:** Ligand A (0.009) has a lower P-gp efflux liability than Ligand B (0.034), which is favorable for oral bioavailability.
15. **Binding Affinity:** Both ligands have similar binding affinities (-8.4 and -6.4 kcal/mol). Ligand A has a significantly better affinity.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand B has a better logP and TPSA. However, Ligand A has a much better binding affinity and lower DILI/hERG risk, and better metabolic stability. The affinity difference is substantial.
**Overall Assessment:**
Despite the unusual negative values for Caco-2 and solubility, and the impossible half-life values, Ligand A is the more promising candidate. Its significantly better binding affinity, lower DILI and hERG risk, and improved metabolic stability outweigh the slightly less favorable TPSA and logP. The negative half-life values are concerning and would need to be investigated further, but the other advantages make Ligand A the preferred choice.
Output:
1
2025-04-17 23:50:57,180 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [352.45 , 49.85 , 2.023, 0. , 3. , 0.712, 28.306, 93.408, -4.049, -2.671, 0.679, 30.459, -15.666, 0.189, -7.3 ]
**Ligand B:** [348.491, 57.7 , 2.072, 1. , 5. , 0.693, 13.532, 90.112, -4.406, -1.694, 0.716, 59.722, 41.662, 0.063, -4.9 ]
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). A (352.45) and B (348.491) are very close.
2. **TPSA:** A (49.85) is better than B (57.7), being closer to the <140 threshold for good absorption.
3. **logP:** Both are optimal (around 2.0), falling within the 1-3 range. A (2.023) and B (2.072) are comparable.
4. **HBD:** A (0) is preferable to B (1). Fewer HBDs generally improve permeability.
5. **HBA:** A (3) is preferable to B (5). Lower HBA is better for permeability.
6. **QED:** Both are good (A: 0.712, B: 0.693), indicating drug-like properties.
7. **DILI:** A (28.306) is significantly better than B (13.532). Lower DILI risk is crucial.
8. **BBB:** Both are high (A: 93.408, B: 90.112) which is good, but not the primary focus for ADRB2 (cardiovascular target).
9. **Caco-2:** Both are negative, indicating poor permeability. A (-4.049) is slightly better than B (-4.406).
10. **Solubility:** A (-2.671) is better than B (-1.694). Higher solubility is desirable.
11. **hERG:** Both are low (A: 0.679, B: 0.716), indicating low cardiotoxicity risk.
12. **Cl_mic:** A (30.459) is much better than B (59.722). Lower clearance means better metabolic stability.
13. **t1/2:** A (-15.666) is better than B (41.662). A negative value indicates a longer half-life.
14. **Pgp:** Both are low (A: 0.189, B: 0.063), suggesting minimal efflux. B is slightly better.
15. **Affinity:** A (-7.3) is significantly better than B (-4.9). A 2.4 kcal/mol difference in binding affinity is substantial and can often outweigh minor ADME drawbacks.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, and affinity. Both ligands perform similarly on logP and Pgp. Ligand A has a lower TPSA and a *much* stronger binding affinity. The lower DILI and better metabolic stability (lower Cl_mic, longer t1/2) of Ligand A are also significant advantages. While both have poor Caco-2 permeability, the superior binding affinity of A is likely to be more impactful.
**Conclusion:**
Ligand A is the more promising candidate due to its significantly better binding affinity, lower DILI risk, improved metabolic stability, and slightly better TPSA and solubility.
**Output:**
1
2025-04-17 23:50:57,180 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, the key priorities are logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB.
Let's break down the comparison:
1. **MW:** Both ligands (366.49 and 363.48 Da) fall comfortably within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (67.67) is higher than Ligand B (56.59). Both are acceptable, but B is better for permeability.
3. **logP:** Ligand A (1.744) is within the optimal range, while Ligand B (2.581) is also good, leaning towards the higher end.
4. **HBD/HBA:** Both have 0 HBD and 6 HBA, which is acceptable.
5. **QED:** Ligand A (0.812) has a significantly better QED score than Ligand B (0.685), suggesting better overall drug-likeness.
6. **DILI:** Ligand B (50.14) has a lower DILI risk than Ligand A (42.92), which is preferable.
7. **BBB:** Ligand A (71.50) has a better BBB penetration percentile than Ligand B (67.20). While not a primary concern for a cardiovascular target, it's a slight advantage.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and difficult to interpret.
9. **Solubility:** Ligand A (-1.539) has better solubility than Ligand B (-3.256).
10. **hERG:** Both have very low hERG inhibition risk (0.247 and 0.507).
11. **Cl_mic:** Ligand A (70.19) has lower microsomal clearance than Ligand B (98.62), indicating better metabolic stability.
12. **t1/2:** Ligand B (8.08) has a significantly longer in vitro half-life than Ligand A (-2.76). This is a substantial advantage.
13. **Pgp:** Both have very low Pgp efflux liability (0.11 and 0.32).
14. **Binding Affinity:** Ligand B (-6.8 kcal/mol) has a slightly better binding affinity than Ligand A (-6.0 kcal/mol). This is a key factor.
**Overall Assessment:**
Ligand B has a clear advantage in binding affinity and *in vitro* half-life. The slightly higher logP and lower DILI risk are also favorable. While Ligand A has a better QED and solubility, the difference in binding affinity and half-life outweighs these benefits, especially for a GPCR target where potency and duration of action are critical. The slightly better BBB for Ligand A is not a major deciding factor for a cardiovascular target.
**Output:**
0
2025-04-17 23:50:57,180 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (342.374 and 358.435 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (76.02) is better than Ligand B (85.38). ADRB2 is a cardiovascular target, so CNS penetration isn't crucial, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (2.503) is better than Ligand B (1.075). Both are within the optimal 1-3 range, but Ligand A is closer to the sweet spot. Ligand B is a bit low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (2) is preferable to Ligand B (0). While both are acceptable, a small number of HBDs can aid solubility without drastically impacting permeability.
5. **HBA:** Ligand A (4) is better than Ligand B (7). Lower HBA is generally preferred for better permeability.
6. **QED:** Ligand A (0.88) is significantly better than Ligand B (0.657). A higher QED indicates a more drug-like profile.
7. **DILI:** Ligand B (41.024) is substantially better than Ligand A (70.686). This is a significant advantage for Ligand B, as lower DILI risk is crucial.
8. **BBB:** Both ligands have high BBB penetration (Ligand A: 70.997, Ligand B: 79.992). Not a major factor for ADRB2.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.955 and -3.951). These values are unusual and suggest poor permeability.
10. **Solubility:** Ligand A (-3.437) is slightly better than Ligand B (-1.811), but both are very poor. This is a significant concern for both compounds.
11. **hERG:** Both ligands have very low hERG risk (0.359 and 0.319).
12. **Cl_mic:** Ligand A (4.27) is much better than Ligand B (84.934). Lower clearance is desirable for better metabolic stability.
13. **t1/2:** Ligand A (59.045) is much better than Ligand B (-32.778). A longer half-life is generally preferred.
14. **Pgp:** Both ligands have low Pgp efflux (0.181 and 0.117).
15. **Binding Affinity:** Ligand B (-7.5) is slightly better than Ligand A (-7.0). This is a 0.5 kcal/mol difference, which is significant, but not overwhelming given the other factors.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand A has better logP and TPSA. Ligand B has slightly better affinity. However, the significant advantage of Ligand B in DILI risk and the substantial differences in metabolic stability (Cl_mic) and half-life are critical. The poor solubility of both is a major drawback, but the better ADME profile of Ligand B outweighs the slight affinity advantage of Ligand A.
**Final Decision:**
0
2025-04-17 23:50:57,180 - INFO - Batch 434 complete. Total preferences: 6944
2025-04-17 23:50:57,180 - INFO - Processing batch 435/512...
2025-04-17 23:51:48,524 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (397.276) is slightly higher than Ligand B (333.435), but both are acceptable.
2. **TPSA:** Ligand A (58.12) is slightly higher than Ligand B (47.34), but both are well below the 140 A^2 threshold for good oral absorption.
3. **logP:** Ligand A (4.245) is a bit high, potentially leading to solubility issues and off-target interactions. Ligand B (3.446) is closer to the optimal range of 1-3.
4. **HBD:** Ligand A (1) and Ligand B (0) are both good, meeting the <=5 guideline.
5. **HBA:** Ligand A (4) and Ligand B (3) are both good, meeting the <=10 guideline.
6. **QED:** Both ligands have good QED scores (A: 0.718, B: 0.846), indicating drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (95.347) has a very high DILI risk, which is a significant concern. Ligand B (76.58) is still elevated, but considerably lower and more acceptable.
8. **BBB:** Both ligands show good BBB penetration (A: 85.731, B: 79.488). This is good, but less critical for a cardiovascular target like ADRB2.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. This is a red flag for both, but the values are similar.
10. **Solubility:** Both ligands have very poor aqueous solubility (-4.998 and -4.994). This is a major issue, especially given Ligand A's higher logP.
11. **hERG:** Both ligands have low hERG inhibition risk (A: 0.822, B: 0.923), which is positive.
12. **Cl_mic:** Ligand A (73.098) has higher microsomal clearance than Ligand B (51.942), indicating lower metabolic stability.
13. **t1/2:** Ligand A (76.104) has a longer in vitro half-life than Ligand B (-8.564). This is a positive for Ligand A, but the negative value for B is concerning.
14. **Pgp:** Both ligands have low P-gp efflux liability (A: 0.873, B: 0.645), which is good.
15. **Binding Affinity:** Ligand B (-7.2 kcal/mol) has significantly better binding affinity than Ligand A (-4.4 kcal/mol). This is a substantial advantage, exceeding the 1.5 kcal/mol threshold.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand B excels in affinity and has a more favorable logP. While both have issues with solubility and Caco-2 permeability, the superior binding affinity of Ligand B and its lower DILI risk are critical advantages. The longer half-life of Ligand A is appealing, but the high DILI risk is a dealbreaker.
**Conclusion:**
Despite the solubility and permeability concerns shared by both, Ligand B's significantly stronger binding affinity and lower DILI risk make it the more promising drug candidate.
Output:
0
2025-04-17 23:51:48,524 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [345.345, 46.61, 3.214, 0, 3, 0.597, 88.523, 77.898, -4.009, -4.419, 0.603, 96.545, -1.404, 0.335, -7.7]**
**Ligand B: [347.433, 89.16, 2.852, 2, 5, 0.786, 59.48, 80.419, -4.783, -3.764, 0.225, 43.567, 69.621, 0.151, -3.8]**
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). No significant difference.
2. **TPSA:** Ligand A (46.61) is significantly better than Ligand B (89.16). ADRB2 is not a CNS target, but lower TPSA generally favors absorption.
3. **logP:** Both ligands have good logP values (A: 3.214, B: 2.852), falling within the optimal 1-3 range. Slight edge to B, being closer to 3.
4. **H-Bond Donors:** Ligand A (0) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **H-Bond Acceptors:** Ligand A (3) is preferable to Ligand B (5). Fewer HBAs generally improve permeability.
6. **QED:** Ligand B (0.786) is better than Ligand A (0.597), indicating a more drug-like profile.
7. **DILI:** Ligand B (59.48) is significantly better than Ligand A (88.523). Lower DILI risk is crucial.
8. **BBB:** Both ligands have reasonably high BBB penetration (A: 77.898, B: 80.419), but this isn't a primary concern for ADRB2.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
10. **Solubility:** Both ligands have negative solubility values, which is also unusual. Again, the scale is not specified, making interpretation difficult.
11. **hERG:** Ligand A (0.603) is better than Ligand B (0.225), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand B (43.567) is significantly better than Ligand A (96.545), indicating better metabolic stability.
13. **t1/2:** Ligand B (69.621) is significantly better than Ligand A (-1.404), indicating a much longer half-life.
14. **Pgp:** Ligand A (0.335) is better than Ligand B (0.151), indicating lower P-gp efflux.
15. **Binding Affinity:** Ligand A (-7.7) has a significantly stronger binding affinity than Ligand B (-3.8). This is a substantial advantage.
**Overall Assessment:**
Ligand A has a significantly better binding affinity and better permeability characteristics (lower TPSA, HBD, HBA). However, Ligand B has a much better safety profile (lower DILI), better metabolic stability (lower Cl_mic), and a longer half-life. The difference in binding affinity is substantial (>3.9 kcal/mol), and for a GPCR, potency is often a key driver. While the negative solubility and Caco-2 values are concerning for both, the superior potency of Ligand A, coupled with acceptable other properties, makes it the more promising candidate.
Output:
1
2025-04-17 23:51:48,524 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (422.666 Da) is slightly lower, which is generally favorable for permeability.
**2. TPSA:** Ligand B (55.4) is significantly better than Ligand A (73.22). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
**3. logP:** Ligand B (4.857) is higher than Ligand A (3.46). While both are above the optimal range of 1-3, Ligand B is pushing the upper limit and could present solubility challenges.
**4. H-Bond Donors:** Both ligands have 1 HBD, which is acceptable.
**5. H-Bond Acceptors:** Ligand A has 5 HBA, while Ligand B has 3. Both are within the acceptable range of <=10.
**6. QED:** Both ligands have good QED scores (A: 0.699, B: 0.718), indicating good drug-like properties.
**7. DILI:** Both ligands have high DILI risk (A: 89.027, B: 90.927). This is a significant concern for both, and further investigation would be needed.
**8. BBB:** Both ligands have relatively low BBB penetration (A: 57.193, B: 59.868). This is not a major concern for a cardiovascular target.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.81) is slightly better than Ligand B (-4.678).
**10. Aqueous Solubility:** Both ligands have very poor aqueous solubility (A: -5.272, B: -5.195). This is a major drawback.
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (A: 0.625, B: 0.795). This is good.
**12. Microsomal Clearance:** Ligand B (14.071) has significantly lower microsomal clearance than Ligand A (55.56), indicating better metabolic stability.
**13. In vitro Half-Life:** Ligand B (63.519) has a longer in vitro half-life than Ligand A (60.02).
**14. P-gp Efflux:** Both ligands have low P-gp efflux (A: 0.474, B: 0.778), which is favorable.
**15. Binding Affinity:** Ligand B (-7.1 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.0 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME concerns.
**Overall Assessment:**
While both ligands have significant drawbacks (high DILI, poor solubility, and questionable permeability), Ligand B's substantially stronger binding affinity (-7.1 vs -5.0 kcal/mol) and improved metabolic stability (lower Cl_mic, longer t1/2) are compelling. The lower TPSA of Ligand B is also a plus. The higher logP is a concern, but the potency advantage is likely to be more impactful for a GPCR target like ADRB2.
Output:
0
2025-04-17 23:51:48,524 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.409 and 347.503 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (50.36) is slightly higher than Ligand B (43.86), but both are well below the 140 threshold for good oral absorption, and acceptable for a cardiovascular GPCR. Ligand B is slightly preferred.
3. **logP:** Ligand A (4.412) is higher than Ligand B (2.134). While 4.412 is approaching the upper limit of the optimal range, it's not drastically high. Ligand B is better here.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (0). Both are acceptable.
5. **HBA:** Ligand A (2) is lower than Ligand B (3). Both are acceptable.
6. **QED:** Both ligands have similar QED values (0.845 and 0.732), indicating good drug-likeness.
7. **DILI:** Ligand A (43.738) has a significantly higher DILI risk than Ligand B (10.237). This is a major concern for Ligand A.
8. **BBB:** Ligand A (92.168) has a higher BBB penetration than Ligand B (85.731). While ADRB2 isn't a CNS target, some peripheral exposure can be beneficial.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.637 and -4.758), which is unusual and suggests poor permeability. This is a significant drawback for both.
10. **Solubility:** Ligand B (-1.74) has better solubility than Ligand A (-4.937).
11. **hERG:** Ligand A (0.7) has a slightly higher hERG risk than Ligand B (0.587).
12. **Cl_mic:** Ligand B (23.813) has significantly lower microsomal clearance than Ligand A (33.787), indicating better metabolic stability.
13. **t1/2:** Ligand B (-11.893) has a negative in vitro half-life, which is concerning. Ligand A (43.058) is much better.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.151 and 0.127).
15. **Binding Affinity:** Ligand B (-7.1 kcal/mol) has a slightly better binding affinity than Ligand A (-9.0 kcal/mol).
**GPCR-specific priorities:**
For ADRB2 (a cardiovascular GPCR), logP, Pgp, TPSA, and affinity are important. Ligand B is better in logP, TPSA, and Pgp. Affinity is slightly better for A. However, the significantly lower DILI risk and better metabolic stability (lower Cl_mic) of Ligand B are crucial advantages. The half-life of Ligand B is a concern, but can be addressed with structural modifications.
**Conclusion:**
Despite Ligand A's better half-life and slightly better affinity, the significantly lower DILI risk and improved metabolic stability of Ligand B make it the more promising drug candidate. The negative Caco-2 values for both are a concern that would need to be addressed through further optimization.
**Output:**
0
2025-04-17 23:51:48,525 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (a GPCR) drug candidates.
**Ligand A:** [368.463, 122.35 , -0.597, 3. , 7. , 0.527, 50.291, 73.013, -5.949, -2.579, 0.34 , 14.511, 10.02 , 0.043, -6.7 ]
**Ligand B:** [344.411, 90.82 , 2.223, 4. , 5. , 0.414, 14.114, 21.365, -5.733, -2.261, 0.708, -4.804, -8.92 , 0.11 , -5.5 ]
Here's a breakdown, comparing each parameter and considering GPCR priorities (logP, Pgp, TPSA, affinity, and BBB):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (344.411) is slightly lower, which is generally favorable.
2. **TPSA:** Ligand A (122.35) is higher than Ligand B (90.82). Ligand B is better, being closer to the <140 threshold for oral absorption and more importantly, better for GPCRs.
3. **logP:** Ligand A (-0.597) is quite low, potentially hindering permeability. Ligand B (2.223) is within the optimal 1-3 range. This is a significant advantage for Ligand B.
4. **HBD:** Both are acceptable (3 and 4 respectively), below the 5 threshold.
5. **HBA:** Both are acceptable (7 and 5 respectively), below the 10 threshold.
6. **QED:** Both are reasonable (0.527 and 0.414), indicating acceptable drug-likeness. Ligand A is slightly better.
7. **DILI:** Ligand A (50.291) has a higher DILI risk than Ligand B (14.114). This is a clear advantage for Ligand B.
8. **BBB:** Ligand A (73.013) has a significantly better BBB penetration potential than Ligand B (21.365). While ADRB2 isn't exclusively a CNS target, some peripheral ADRB2 activity can be modulated by CNS effects, and higher BBB is generally a plus.
9. **Caco-2:** Both are negative, indicating poor permeability. This is a concern for both, but the lower logP of Ligand A suggests it might be more problematic.
10. **Solubility:** Both are negative, indicating poor solubility.
11. **hERG:** Ligand A (0.34) has a lower hERG risk than Ligand B (0.708), which is favorable.
12. **Cl_mic:** Ligand B (-4.804) has a lower (better) microsomal clearance than Ligand A (14.511), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-8.92) has a longer in vitro half-life than Ligand A (10.02), which is desirable.
14. **Pgp:** Ligand A (0.043) has a lower Pgp efflux liability than Ligand B (0.11), which is favorable.
15. **Affinity:** Ligand A (-6.7) has a slightly better binding affinity than Ligand B (-5.5). This is a 1.2 kcal/mol difference, which is significant.
**Overall Assessment:**
Ligand B has a much better ADME profile. Its logP is optimal, DILI risk is low, metabolic stability is high (low Cl_mic, long t1/2), and TPSA is good. While its BBB is lower, the significant improvements in other ADME properties outweigh this. Ligand A's primary advantage is its slightly better affinity and Pgp efflux, but its poor logP and higher DILI risk are major drawbacks. The affinity difference, while notable, is unlikely to overcome the ADME liabilities of Ligand A.
Therefore, I would choose Ligand B.
0
2025-04-17 23:51:48,525 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (346.475) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are reasonably low, but Ligand B (51.39) is better than Ligand A (58.44), closer to the <90 target for GPCRs.
3. **logP:** Ligand A (2.394) is optimal, while Ligand B (4.099) is pushing the upper limit and could potentially lead to solubility issues or off-target interactions.
4. **HBD:** Both have 0 HBD, which is acceptable.
5. **HBA:** Ligand A (4) is preferable to Ligand B (6). Lower HBA generally improves permeability.
6. **QED:** Both are good (above 0.5), indicating drug-likeness. Ligand A (0.79) is slightly better than Ligand B (0.743).
7. **DILI:** Ligand B (27.918) has a significantly lower DILI risk than Ligand A (43.234), which is a major advantage.
8. **BBB:** Both have good BBB penetration (Ligand A: 72.082, Ligand B: 73.362).
9. **Caco-2:** Ligand B (-5.294) has a more negative Caco-2 value, indicating better permeability than Ligand A (-4.61).
10. **Solubility:** Ligand A (-1.68) has better aqueous solubility than Ligand B (-3.182).
11. **hERG:** Both have low hERG inhibition risk (Ligand A: 0.527, Ligand B: 0.557).
12. **Cl_mic:** Ligand A (56.925) has lower microsomal clearance, suggesting better metabolic stability than Ligand B (65.326).
13. **t1/2:** Ligand B (-23.134) has a much longer in vitro half-life than Ligand A (-10.029), which is a significant benefit.
14. **Pgp:** Both have low Pgp efflux (Ligand A: 0.291, Ligand B: 0.255).
15. **Affinity:** Ligand B (-6.2 kcal/mol) has a slightly better binding affinity than Ligand A (-6.8 kcal/mol). While the difference is small, it's still a positive.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in TPSA and Caco-2 permeability, and has comparable BBB penetration. The slightly higher logP is a concern, but the significantly lower DILI risk and longer half-life outweigh this drawback. The affinity difference is small, but favors Ligand B.
**Overall Assessment:**
Ligand B presents a more favorable balance of properties, particularly regarding safety (DILI) and pharmacokinetics (half-life and permeability). While Ligand A has slightly better solubility and metabolic stability, the benefits of Ligand B are more impactful for a GPCR drug candidate.
Output:
0
2025-04-17 23:51:48,525 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's analyze each ligand against the provided criteria, keeping in mind ADRB2 is a GPCR and thus we prioritize logP, Pgp, TPSA, and affinity, alongside general drug-like properties.
* **Molecular Weight:** Both ligands (347.419 Da and 361.511 Da) fall comfortably within the ideal 200-500 Da range.
* **TPSA:** Ligand A (98.14) is higher than Ligand B (62.3). While both are under 140, Ligand B's lower TPSA is preferable for better absorption, a key consideration for oral bioavailability.
* **logP:** Ligand A (0.351) is quite low, potentially hindering membrane permeability. Ligand B (3.331) is within the optimal 1-3 range. This is a significant advantage for Ligand B.
* **H-Bond Donors/Acceptors:** Ligand A has 2 HBD and 6 HBA, while Ligand B has 1 HBD and 4 HBA. Both are within acceptable limits.
* **QED:** Both ligands have similar QED values (0.694 and 0.646), indicating reasonable drug-likeness.
* **DILI:** Ligand A (57.348) has a slightly higher DILI risk than Ligand B (45.677), but both are below the concerning threshold of 60.
* **BBB:** Ligand B (70.027) shows better BBB penetration than Ligand A (53.897). While ADRB2 isn't exclusively a CNS target, some CNS exposure is possible with beta-adrenergic agonists, and higher BBB is generally favorable.
* **Caco-2:** Both ligands have negative Caco-2 values, which is unusual. Assuming these are logP-scaled values, lower (more negative) values indicate poorer permeability. Ligand A (-4.95) is worse than Ligand B (-5.049).
* **Solubility:** Both have negative solubility values. Ligand A (-2.431) is better than Ligand B (-4.149).
* **hERG:** Both ligands have very low hERG inhibition risk (0.093 and 0.488).
* **Cl_mic:** Ligand A (4.593) has a much lower microsomal clearance than Ligand B (72.336), suggesting better metabolic stability. This is a strong point for Ligand A.
* **t1/2:** Ligand A (-9.086) has a negative in vitro half-life, which is not possible. Ligand B (15.557) has a reasonable half-life.
* **Pgp:** Ligand A (0.032) shows very low P-gp efflux, which is favorable. Ligand B (0.339) is higher, but still relatively low.
* **Binding Affinity:** Both ligands have excellent binding affinity (-5.1 and -5.4 kcal/mol). Ligand B is slightly better, but the difference is not substantial enough to outweigh other factors.
**Overall Assessment:**
Ligand B has a more favorable profile overall. Its logP is optimal, TPSA is lower, and BBB penetration is better. While Ligand A has better metabolic stability (lower Cl_mic) and lower Pgp efflux, the poor logP and Caco-2 permeability are significant drawbacks. The negative half-life for Ligand A is also a major concern. The slight advantage in binding affinity for Ligand B is a bonus. Given the GPCR target class, the balance of properties favors Ligand B.
**Output:**
0
2025-04-17 23:51:48,525 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (353.3 & 349.4 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (73.33 & 71.53) are below the 140 A^2 threshold for good oral absorption, which is good.
3. **logP:** Both ligands have a logP around 1.3, which is optimal for permeability and avoiding solubility issues. Again, no significant difference.
4. **HBD:** Both have 1 HBD, which is within the acceptable limit of 5.
5. **HBA:** Ligand A has 6 HBA, while Ligand B has 4. Both are below the 10 limit.
6. **QED:** Both ligands have a QED > 0.7, indicating a strong drug-like profile.
7. **DILI:** Ligand A has a DILI risk of 70.8%, which is moderately high. Ligand B has a much lower DILI risk of 30.7%, which is a significant advantage.
8. **BBB:** Both ligands have similar BBB penetration (69.4% and 71.5%). This is reasonably good, but not exceptionally high, which is acceptable for a cardiovascular target like ADRB2.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. Ligand A (-4.985) is slightly worse than Ligand B (-4.399).
10. **Solubility:** Both ligands have negative solubility values, indicating poor aqueous solubility. Ligand A (-2.551) is slightly worse than Ligand B (-1.98).
11. **hERG:** Both ligands have low hERG inhibition risk (0.418 and 0.181), which is excellent.
12. **Cl_mic:** Ligand A has a slightly higher microsomal clearance (10.658) than Ligand B (9.059), indicating potentially lower metabolic stability.
13. **t1/2:** Ligand A has a longer in vitro half-life (8.775 hours) than Ligand B (-0.087 hours). This is a major advantage for Ligand A.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.235 and 0.037).
15. **Binding Affinity:** Ligand A has a significantly stronger binding affinity (-8.1 kcal/mol) compared to Ligand B (-7.0 kcal/mol). This is a substantial advantage.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are crucial. Both ligands perform similarly on logP, Pgp, and TPSA. However, Ligand A has a significantly better binding affinity. The DILI risk is a concern for Ligand A, but the substantial affinity advantage outweighs this concern, especially given the relatively low hERG risk. The longer half-life of Ligand A is also a positive.
**Conclusion:**
Despite the higher DILI risk, Ligand A's superior binding affinity and longer half-life make it the more promising candidate for further development as an ADRB2 ligand.
Output:
1
2025-04-17 23:51:48,525 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (346.431 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (114.18) is better than Ligand B (49.41). A lower TPSA generally indicates better membrane permeability, crucial for GPCRs.
3. **logP:** Ligand B (3.228) is slightly higher than Ligand A (0.924). While both are within the acceptable range, Ligand B is closer to the upper limit, potentially leading to solubility issues. Ligand A is a bit low and may have permeability issues.
4. **HBD:** Ligand A (3) is higher than Ligand B (1). This is a slight negative for A, but not a major concern.
5. **HBA:** Ligand A (4) is higher than Ligand B (3). Similar to HBD, this is a minor drawback for A.
6. **QED:** Both ligands have good QED scores (A: 0.649, B: 0.736), indicating good drug-like properties. B is slightly better.
7. **DILI:** Ligand B (19.465) has a significantly lower DILI risk than Ligand A (31.989). This is a major advantage for B.
8. **BBB:** Ligand B (71.966) has a better BBB penetration score than Ligand A (62.233). While ADRB2 isn't exclusively a CNS target, some CNS exposure can occur, and higher BBB is generally favorable.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.385 and -5.091). These values are difficult to interpret without knowing the scale, but negative values are not ideal.
10. **Solubility:** Ligand A (-2.832) has better solubility than Ligand B (-4.069). This is a positive for A, particularly given B's higher logP.
11. **hERG:** Ligand A (0.062) has a much lower hERG risk than Ligand B (0.385). This is a significant advantage for A, as hERG inhibition can lead to cardiotoxicity.
12. **Cl_mic:** Ligand B (72.271) has a much higher microsomal clearance than Ligand A (24.349). This indicates lower metabolic stability for B, which is a major drawback.
13. **t1/2:** Ligand A (-0.309) has a more favorable in vitro half-life than Ligand B (-15.615). Again, this suggests better metabolic stability for A.
14. **Pgp:** Ligand A (0.014) has a much lower P-gp efflux liability than Ligand B (0.177). This is a positive for A, improving oral bioavailability.
15. **Binding Affinity:** Ligand B (-6.9 kcal/mol) has a slightly better binding affinity than Ligand A (-5.7 kcal/mol). This is a 1.2 kcal/mol difference, which is substantial.
**Overall Assessment:**
Ligand B has a better binding affinity and QED, and good BBB penetration. However, it suffers from significantly higher DILI risk, higher microsomal clearance (lower metabolic stability), and higher P-gp efflux. Ligand A has a lower hERG risk, better solubility, lower clearance, and lower P-gp efflux.
Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity) and the overall balance of properties, the improved metabolic stability, lower toxicity (DILI and hERG), and better P-gp profile of Ligand A outweigh the slightly lower affinity. The affinity difference, while notable, isn't so large that it completely negates the ADME/Tox advantages of Ligand A.
Output:
1
2025-04-17 23:51:48,525 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [341.415, 102.93 , 1.724, 4. , 5. , 0.663, 45.328, 39.007, -5.765, -2.404, 0.454, -17.991, 17.452, 0.014, -4.7 ]
**Ligand B:** [353.369, 60.5 , 3.243, 0. , 5. , 0.513, 41.024, 84.451, -4.739, -2.082, 0.627, 71.501, 16.016, 0.396, -5.5 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal 200-500 Da range. Ligand A (341.415) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (102.93) is higher than Ligand B (60.5). For a cardiovascular GPCR, TPSA isn't *as* critical as for CNS targets, but lower is still preferred. Ligand B is significantly better here.
3. **logP:** Ligand A (1.724) is within the optimal range, while Ligand B (3.243) is approaching the upper limit. While still acceptable, Ligand A's logP is more balanced.
4. **HBD:** Ligand A (4) is higher than Ligand B (0). Lower is generally better for permeability, so Ligand B is favored.
5. **HBA:** Both have 5 HBA, which is acceptable.
6. **QED:** Ligand A (0.663) has a slightly better QED score than Ligand B (0.513), indicating a more drug-like profile.
7. **DILI:** Both have acceptable DILI risk (A: 45.328, B: 41.024), below the 60% threshold.
8. **BBB:** Ligand B (84.451) has a much higher BBB penetration percentile than Ligand A (39.007). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be beneficial or at least needs to be considered.
9. **Caco-2:** Ligand A (-5.765) and B (-4.739) both have negative Caco-2 values, which is unusual and suggests poor permeability.
10. **Solubility:** Both have negative solubility values, indicating poor aqueous solubility. This is a significant concern for both compounds.
11. **hERG:** Both have low hERG risk (A: 0.454, B: 0.627).
12. **Cl_mic:** Ligand A (-17.991) has a much *lower* (better) microsomal clearance than Ligand B (71.501), suggesting greater metabolic stability. This is a major advantage.
13. **t1/2:** Ligand A (17.452) has a slightly longer in vitro half-life than Ligand B (16.016).
14. **Pgp:** Ligand A (0.014) has significantly lower P-gp efflux liability than Ligand B (0.396), which is favorable for bioavailability.
15. **Affinity:** Ligand B (-5.5) has a slightly better binding affinity than Ligand A (-4.7). This is a 0.8 kcal/mol difference, which is notable but not overwhelming.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B excels in TPSA and BBB, and has a slightly better affinity. However, Ligand A has a more balanced logP, significantly better metabolic stability (Cl_mic), lower P-gp efflux, and a better QED score. The poor Caco-2 and solubility for both are concerning, but can be addressed with formulation strategies.
**Conclusion:**
Despite Ligand B's better TPSA and BBB, the superior metabolic stability (Cl_mic), lower P-gp efflux, and better QED of Ligand A make it the more promising candidate. The 0.8 kcal/mol difference in binding affinity isn't enough to overcome these ADME advantages.
Output:
1
2025-04-17 23:51:48,525 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (383.239) is slightly higher than Ligand B (364.511), but both are acceptable.
2. **TPSA:** Ligand A (93.01) is slightly higher than Ligand B (62.55). Both are below 140, but Ligand B is significantly better, increasing the likelihood of good oral absorption.
3. **logP:** Ligand A (1.497) is within the optimal range, while Ligand B (3.088) is approaching the upper limit. Both are acceptable, but Ligand A is slightly preferred.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 6 HBA, and Ligand B has 4. Both are below the threshold of 10.
6. **QED:** Ligand B (0.892) has a better QED score than Ligand A (0.641), indicating a more drug-like profile.
7. **DILI:** Ligand B (47.732) has a much lower DILI risk than Ligand A (79.643). This is a significant advantage for Ligand B.
8. **BBB:** Ligand B (68.166) has a better BBB penetration potential than Ligand A (38.426). While ADRB2 isn't strictly a CNS target, some peripheral ADRB2 activity can influence CNS pathways, and higher BBB penetration isn't necessarily a detriment.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Both ligands have negative solubility values, indicating very poor aqueous solubility. This is a major drawback for both compounds.
11. **hERG:** Ligand A (0.019) has a slightly lower hERG inhibition liability than Ligand B (0.55), which is favorable.
12. **Cl_mic:** Ligand A (3.898) has a significantly lower microsomal clearance than Ligand B (53.359), indicating better metabolic stability.
13. **t1/2:** Ligand B (34.996) has a longer in vitro half-life than Ligand A (3.333), which is desirable.
14. **Pgp:** Ligand A (0.056) has lower P-gp efflux liability than Ligand B (0.453), which is favorable.
15. **Affinity:** Both ligands have the same binding affinity (-7.0 kcal/mol), so this parameter doesn't differentiate them.
**GPCR-Specific Priorities & Overall Assessment:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B excels in TPSA and Pgp, and has a better BBB score. Ligand A has a slight edge in logP and hERG, and a significant advantage in metabolic stability (Cl_mic). However, the poor Caco-2 and solubility for both ligands are major concerns. The lower DILI risk for Ligand B is also a significant advantage.
Considering the balance, Ligand B's superior TPSA, lower DILI risk, and longer half-life outweigh the slightly better metabolic stability of Ligand A. The poor permeability and solubility are problematic for both, but can potentially be addressed with formulation strategies.
Output:
0
2025-04-17 23:51:48,525 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (338.39 and 341.33 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (59.81) is significantly better than Ligand B (121.31). For a GPCR, lower TPSA is generally preferred for permeability. Ligand B is quite high, potentially hindering oral absorption.
3. **logP:** Ligand A (4.091) is higher than Ligand B (0.987). While Ligand A is at the upper end of the optimal range, it's still acceptable. Ligand B is quite low, potentially causing permeability issues.
4. **HBD:** Ligand A (1) is better than Ligand B (0). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is better than Ligand B (9). Lower HBA is preferred for permeability.
6. **QED:** Ligand A (0.779) is better than Ligand B (0.591), indicating a more drug-like profile.
7. **DILI:** Ligand B (94.223) has a higher DILI risk than Ligand A (89.415), although both are relatively high.
8. **BBB:** Both ligands have similar BBB penetration (Ligand A: 61.85, Ligand B: 64.68). Not a major differentiating factor for a cardiovascular target.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability.
10. **Solubility:** Both ligands have negative solubility values, which is also unusual and suggests poor solubility.
11. **hERG:** Ligand A (0.711) is slightly better than Ligand B (0.684), indicating a lower risk of hERG inhibition.
12. **Cl_mic:** Ligand B (50.944) has lower microsomal clearance than Ligand A (58.633), suggesting better metabolic stability.
13. **t1/2:** Ligand A (58.877) has a much longer in vitro half-life than Ligand B (-34.013). This is a significant advantage.
14. **Pgp:** Ligand A (0.513) has lower P-gp efflux liability than Ligand B (0.063), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand B (-7.4 kcal/mol) has a significantly higher binding affinity than Ligand A (-6.4 kcal/mol). This is a substantial advantage, potentially outweighing some ADME concerns.
**Overall Assessment:**
Ligand B has a much better binding affinity, which is a critical factor for GPCR targets. However, it suffers from higher TPSA, lower logP, higher DILI risk, and significantly worse metabolic stability and half-life. Ligand A has better ADME properties overall (TPSA, logP, QED, hERG, Pgp, t1/2), but its binding affinity is weaker.
Considering the balance, the substantial affinity advantage of Ligand B is likely to be more impactful in driving efficacy. While the ADME properties are concerning, optimization efforts could focus on improving those aspects without sacrificing the strong binding. The poor Caco-2 and Solubility values for both ligands are concerning, but these could be addressed through formulation strategies.
Output:
0
2025-04-17 23:51:48,525 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (342.33 Da and 361.511 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (85.26) is slightly higher than Ligand B (71.09). Both are below the 140 A^2 threshold for good oral absorption, but Ligand B is preferable due to being closer to the optimal range for GPCRs.
**3. logP:** Both ligands have excellent logP values (3.231 and 3.055), falling within the 1-3 optimal range. No strong preference.
**4. H-Bond Donors:** Ligand A has 0 HBDs, while Ligand B has 2. Both are acceptable, but 0 is generally preferred for better membrane permeability.
**5. H-Bond Acceptors:** Ligand A has 6 HBAs, and Ligand B has 4. Both are within the acceptable limit of 10.
**6. QED:** Both ligands have good QED scores (0.726 and 0.818), indicating good drug-like properties. Ligand B is slightly better.
**7. DILI Risk:** Ligand A has a significantly higher DILI risk (93.68 percentile) compared to Ligand B (41.218 percentile). This is a major concern for Ligand A.
**8. BBB Penetration:** Ligand A (92.904) has much better BBB penetration than Ligand B (55.293). While ADRB2 is a cardiovascular target, some CNS effects can be relevant or undesirable, and higher BBB penetration could be a concern if off-target effects are observed.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.764 and -4.946). This is unusual and suggests poor permeability. However, these values are on a log scale, and the absolute difference is small.
**10. Aqueous Solubility:** Both ligands have poor aqueous solubility (-3.709 and -3.86). This is a concern for both, but not a deciding factor.
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (0.493 and 0.341). This is good.
**12. Microsomal Clearance:** Ligand A (34.677) has lower microsomal clearance than Ligand B (47.088), suggesting better metabolic stability.
**13. In vitro Half-Life:** Ligand A (-16.707) has a shorter half-life than Ligand B (25.764). This is a negative for Ligand A.
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (0.34 and 0.162). This is good.
**15. Binding Affinity:** Ligand B (-7.4 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.2 kcal/mol). This is a substantial advantage for Ligand B, exceeding the 1.5 kcal/mol threshold.
**Overall Assessment:**
Ligand B is the stronger candidate. While Ligand A has better BBB penetration and metabolic stability, the significantly higher DILI risk and weaker binding affinity are major drawbacks. Ligand B's superior binding affinity, lower DILI risk, and slightly better QED outweigh the slightly lower BBB penetration. The poor Caco-2 and solubility are concerning for both, but can be addressed through formulation strategies.
Output:
0
2025-04-17 23:51:48,526 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (372.868 Da) is slightly higher than Ligand B (349.362 Da), but both are acceptable.
2. **TPSA:** Ligand A (61.8) is significantly better than Ligand B (93.46). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption. Ligand B's TPSA is approaching a level that could hinder oral bioavailability.
3. **logP:** Both ligands have good logP values (A: 3.358, B: 2.377), falling within the optimal 1-3 range. Ligand A is slightly more lipophilic, which could aid membrane permeability.
4. **HBD:** Both have 2 HBD, which is within the acceptable limit of 5.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 5. Both are reasonable, below the 10 threshold.
6. **QED:** Both ligands have similar QED values (A: 0.85, B: 0.781), indicating good drug-likeness.
7. **DILI:** Ligand A (17.371) has a much lower DILI risk than Ligand B (52.346). This is a significant advantage for Ligand A.
8. **BBB:** Not a major priority for a cardiovascular target. Ligand A (43.699) is lower than Ligand B (64.211), but this isn't a deciding factor.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.541 and -4.336). This is unusual and suggests poor permeability in this *in vitro* assay. However, the values are similar.
10. **Solubility:** Both have negative solubility values (-3.387 and -3.344). This is also unusual and suggests poor aqueous solubility. The values are very similar.
11. **hERG:** Ligand A (0.805) has a slightly higher hERG risk than Ligand B (0.271), but both are relatively low.
12. **Cl_mic:** Ligand A (13.082) has a significantly lower microsomal clearance than Ligand B (84.31). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (27.186) has a shorter *in vitro* half-life than Ligand B (52.615). This is a drawback for Ligand A.
14. **Pgp:** Ligand A (0.445) has lower P-gp efflux liability than Ligand B (0.031), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand A (-6.5 kcal/mol) has a slightly better binding affinity than Ligand B (-5.1 kcal/mol). This 1.4 kcal/mol difference is substantial and can outweigh some ADME drawbacks.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A excels in logP, TPSA, Pgp, and affinity. While Ligand B has a better half-life, the significantly lower DILI risk and better metabolic stability of Ligand A are more critical for overall drug development success. The binding affinity difference is also a significant factor.
**Conclusion:**
Considering all factors, Ligand A is the more promising drug candidate. Its superior DILI profile, metabolic stability, TPSA, Pgp efflux, and binding affinity outweigh the slightly shorter half-life.
Output:
1
2025-04-17 23:51:48,526 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (364.85 & 354.40 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (49.41) is better than Ligand B (62.55). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally aids absorption.
3. **logP:** Both ligands have good logP values (3.24 & 2.99) within the optimal 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Both have 1 HBD, which is ideal.
5. **HBA:** Ligand A has 2 HBA, Ligand B has 3. Both are acceptable, but lower is generally preferred.
6. **QED:** Both ligands have similar QED scores (0.89 & 0.80), indicating good drug-likeness.
7. **DILI:** Ligand A (44.86) has a slightly higher DILI risk than Ligand B (28.34), but both are below the concerning 60 threshold. Ligand B is preferable here.
8. **BBB:** Both have high BBB penetration (91.43 & 92.79). While not crucial for a cardiovascular target, it doesn't hurt.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand A (-4.51) is slightly less soluble than Ligand B (-3.18). Solubility is important for bioavailability, so Ligand B is favored.
11. **hERG:** Both ligands have low hERG inhibition risk (0.72 & 0.75), which is excellent.
12. **Cl_mic:** Ligand A (8.26) has significantly lower microsomal clearance than Ligand B (19.43). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand B (16.58) has a much longer in vitro half-life than Ligand A (0.81). This is a major advantage for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.31 & 0.29).
15. **Binding Affinity:** Ligand B (-6.5 kcal/mol) has a stronger binding affinity than Ligand A (-5.7 kcal/mol). This 0.8 kcal/mol difference is substantial and outweighs many of the minor ADME drawbacks of Ligand B.
**GPCR-specific priorities:** For ADRB2 (a GPCR), affinity, logP, TPSA, and Pgp are key. Ligand B excels in affinity and has comparable logP and Pgp values. While Ligand A has a better TPSA, the superior affinity and half-life of Ligand B are more important. The lower DILI risk of Ligand B is also a plus.
**Conclusion:**
Despite the slightly lower solubility and higher clearance of Ligand B, its significantly stronger binding affinity and longer half-life make it the more promising drug candidate for the ADRB2 receptor.
Output:
0
2025-04-17 23:51:48,526 - INFO - Reasoning:
Let's analyze Ligand A and Ligand B for their potential as ADRB2 ligands, keeping in mind GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key).
**Molecular Weight:** Both ligands (368.48 and 361.47 Da) fall comfortably within the ideal 200-500 Da range.
**TPSA:** Both ligands have TPSA values around 88, which is acceptable for a non-CNS target like ADRB2, but a bit high.
**logP:** Both have logP values around 2, which is within the optimal 1-3 range.
**H-Bond Donors/Acceptors:** Ligand A (2 HBD, 5 HBA) and Ligand B (1 HBD, 6 HBA) both have reasonable numbers of H-bond donors and acceptors, well within the guidelines.
**QED:** Both ligands have a QED score of approximately 0.85, indicating good drug-likeness.
**DILI:** Ligand A (70.53) has a slightly higher DILI risk than Ligand B (54.56), but both are still acceptable.
**BBB:** BBB is less critical for a cardiovascular target, but Ligand A (65.84) has slightly better BBB penetration than Ligand B (54.83).
**Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. This is a significant concern.
**Aqueous Solubility:** Both ligands have very poor aqueous solubility (-3.63 and -2.54 respectively). This is a major drawback.
**hERG Inhibition:** Both ligands have low hERG inhibition risk (0.402 and 0.247), which is good.
**Microsomal Clearance:** Ligand A (36.38 mL/min/kg) has a lower microsomal clearance than Ligand B (46.73 mL/min/kg), suggesting better metabolic stability.
**In vitro Half-Life:** Ligand B (14.29 hours) has a significantly longer half-life than Ligand A (3.47 hours), which is a substantial advantage.
**P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.047 and 0.095), which is favorable.
**Binding Affinity:** Ligand A (-6.6 kcal/mol) has a slightly better binding affinity than Ligand B (-6.3 kcal/mol), although the difference is relatively small (0.3 kcal/mol).
**Overall Assessment:**
The biggest issues for both compounds are the very poor aqueous solubility and the negative Caco-2 permeability. However, considering the GPCR-specific priorities, Ligand A has a slight edge due to its better metabolic stability (lower Cl_mic) and slightly better binding affinity. Ligand B's longer half-life is attractive, but the solubility and permeability issues are too significant to ignore. The small difference in binding affinity doesn't outweigh the other ADME concerns.
Output:
1
2025-04-17 23:51:48,526 - INFO - Batch 435 complete. Total preferences: 6960
2025-04-17 23:51:48,526 - INFO - Processing batch 436/512...
2025-04-17 23:52:34,620 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (364.324 and 355.479 Da) are within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (90.9) is significantly better than Ligand A (116.22). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (0.269) is lower than Ligand A (-1.067). While both are a bit low, Ligand B is closer to the optimal 1-3 range. Ligand A's logP is concerningly low and could lead to poor membrane permeability.
4. **HBD:** Both have acceptable HBD counts (4 and 3 respectively), well within the <5 guideline.
5. **HBA:** Both have acceptable HBA counts (6 and 5 respectively), well within the <10 guideline.
6. **QED:** Both ligands have good QED scores (0.531 and 0.552), indicating good drug-like properties.
7. **DILI:** Ligand B (6.592) has a *much* lower DILI risk than Ligand A (47.693). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (34.316) has a slightly higher BBB penetration than Ligand B (21.753), but this is not a high priority for a cardiovascular target.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.74 and -5.186), which is unusual and suggests very poor permeability. This is a major concern for both.
10. **Solubility:** Both ligands have negative solubility values (-1.85 and -1.111), which is also concerning. Poor solubility will hinder bioavailability.
11. **hERG:** Both ligands have low hERG inhibition liability (0.204 and 0.129), which is good.
12. **Cl_mic:** Ligand A (-49.09) has a much lower (better) microsomal clearance than Ligand B (12.934). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (-30.347) has a longer in vitro half-life than Ligand B (9.088), which is desirable.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.008 and 0.041).
15. **Binding Affinity:** Ligand A (-8.3) has a significantly stronger binding affinity than Ligand B (-6.1). This is a 2.2 kcal/mol difference, which is substantial and can outweigh some ADME concerns.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, and affinity. Ligand A has a better affinity, but Ligand B has better logP and TPSA. The DILI risk for Ligand B is far superior. The poor Caco-2 and solubility for both are concerning, but the significantly better affinity of Ligand A is a major advantage. The improved metabolic stability (Cl_mic) and half-life of Ligand A are also beneficial.
**Overall Assessment:**
Despite the poor Caco-2 and solubility for both, the substantial binding affinity advantage of Ligand A, combined with its better metabolic stability and half-life, outweighs the slightly better logP and TPSA of Ligand B. The significantly lower DILI risk for Ligand B is attractive, but the potency difference is too large to ignore. Further optimization would be needed to address the permeability and solubility issues for either compound.
Output:
1
2025-04-17 23:52:34,621 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's systematically compare Ligand A and Ligand B based on the provided parameters and the guidelines, keeping in mind ADRB2 is a GPCR. GPCRs prioritize logP, Pgp, TPSA, and affinity.
1. **Molecular Weight:** Both ligands (372.491 Da and 349.395 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (112.81) is better than Ligand B (119.47) as it is closer to the <140 threshold for good oral absorption.
3. **logP:** Ligand B (-0.952) is slightly lower than Ligand A (-0.35), but both are within the acceptable 1-3 range. Ligand A is preferable.
4. **H-Bond Donors:** Ligand A (2) is slightly better than Ligand B (1). Both are well within the acceptable limit of <=5.
5. **H-Bond Acceptors:** Ligand B (8) is higher than Ligand A (4). While both are under the 10 limit, Ligand A is preferable.
6. **QED:** Both ligands have similar QED values (0.705 and 0.657), indicating good drug-likeness.
7. **DILI:** Ligand A (28.616) has a significantly lower DILI risk than Ligand B (61.109). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (82.513) has a higher BBB penetration percentile than Ligand A (54.246). While ADRB2 isn't necessarily a CNS target, some cardiovascular effects can be mediated by CNS pathways, so this is a slight advantage for Ligand B.
9. **Caco-2 Permeability:** Both ligands have very similar, and poor, Caco-2 permeability (-5.274 and -5.269). This suggests potential absorption issues for both.
10. **Aqueous Solubility:** Both ligands have poor aqueous solubility (-1.72 and -2.19).
11. **hERG Inhibition:** Ligand A (0.06) has a slightly lower hERG inhibition liability than Ligand B (0.115), which is preferable.
12. **Microsomal Clearance:** Ligand A (-2.335) has a much lower (better) microsomal clearance than Ligand B (21.584), indicating better metabolic stability.
13. **In vitro Half-Life:** Ligand A (2.441) has a slightly longer half-life than Ligand B (0.455).
14. **P-gp Efflux:** Ligand A (0.005) has a significantly lower P-gp efflux liability than Ligand B (0.042), which is a significant advantage.
15. **Binding Affinity:** Ligand B (-6.2 kcal/mol) has a slightly better binding affinity than Ligand A (-6.8 kcal/mol). This is a small difference, but still relevant.
**Overall Assessment:**
Ligand A demonstrates a significantly better overall profile, particularly regarding safety (DILI, hERG) and ADME properties (Cl_mic, P-gp efflux). While Ligand B has slightly better affinity and BBB penetration, the advantages of Ligand A in crucial areas like metabolic stability, reduced efflux, and lower toxicity risks outweigh these minor differences. The poor Caco-2 and solubility are concerning for both, but can be addressed with formulation strategies.
**Output:**
1
2025-04-17 23:52:34,621 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
Let's systematically compare Ligand A and Ligand B based on the provided parameters and the guidelines, keeping in mind that ADRB2 is a GPCR, so logP, Pgp, TPSA, and affinity are particularly important.
1. **MW:** Both ligands (355.463 and 363.889 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands have TPSA values (63.13 and 62.3) below the 140 A^2 threshold for good oral absorption. These are good values.
3. **logP:** Both ligands have logP values (3.465 and 3.026) within the optimal 1-3 range. Ligand B is slightly better here, being closer to the center of the range.
4. **HBD:** Ligand A has 2 HBD, and Ligand B has 1. Both are acceptable.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 3. Both are acceptable.
6. **QED:** Ligand B (0.874) has a significantly better QED score than Ligand A (0.544), indicating a more drug-like profile.
7. **DILI:** Ligand B (23.187) has a much lower DILI risk than Ligand A (73.556). This is a major advantage for Ligand B.
8. **BBB:** Both ligands have good BBB penetration (81.97 and 74.796). While ADRB2 isn't necessarily a CNS target, higher BBB is generally favorable.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.044 and -4.867), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Both ligands have negative solubility values (-4.114 and -3.306), indicating very poor aqueous solubility. This is a major drawback for both.
11. **hERG:** Ligand A (0.761) has a slightly higher hERG risk than Ligand B (0.404), but both are relatively low.
12. **Cl_mic:** Ligand A (78.99) has a higher microsomal clearance than Ligand B (46.031), suggesting lower metabolic stability. Ligand B is better here.
13. **t1/2:** Ligand B (-8.097) has a negative in vitro half-life, which is concerning. Ligand A (58.241) has a reasonable half-life.
14. **Pgp:** Ligand A (0.735) has higher P-gp efflux liability than Ligand B (0.057). This is a significant advantage for Ligand B, as it suggests better oral bioavailability and potentially better CNS exposure if needed.
15. **Binding Affinity:** Ligand A (-7.5 kcal/mol) has a slightly better binding affinity than Ligand B (-5.8 kcal/mol). This is a 1.7 kcal/mol difference, which is substantial.
**Overall Assessment:**
Despite Ligand A having a slightly better binding affinity, Ligand B is the more promising candidate. The significantly lower DILI risk, better QED score, lower P-gp efflux, and lower microsomal clearance outweigh the small difference in binding affinity. Both compounds have poor solubility and Caco-2 permeability, which would need to be addressed through formulation or structural modification. However, the ADME properties of Ligand B are generally more favorable.
**Output:**
0
2025-04-17 23:52:34,621 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (361.471 and 363.38 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (80.12) is significantly better than Ligand B (101.29). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand A is well below the 140 A^2 threshold, while Ligand B is approaching it.
**3. logP:** Both ligands have good logP values (2.189 and 1.384), falling within the optimal 1-3 range. Ligand B is slightly lower, which *could* indicate slightly better solubility, but isn't a major concern.
**4. H-Bond Donors:** Ligand A has 1 HBD, while Ligand B has 3. Lower is generally preferred to avoid issues with permeability. Ligand A is better here.
**5. H-Bond Acceptors:** Ligand A has 6 HBA, and Ligand B has 3. Both are within the acceptable range of <=10.
**6. QED:** Ligand A (0.909) has a significantly better QED score than Ligand B (0.607). This indicates Ligand A is more drug-like overall.
**7. DILI Risk:** Ligand A (69.407) has a higher DILI risk than Ligand B (32.997). This is a significant drawback for Ligand A.
**8. BBB Penetration:** Ligand B (83.172) has much better predicted BBB penetration than Ligand A (62.97). While ADRB2 is primarily a cardiovascular target, some CNS side effects are possible with GPCR modulation, and better BBB penetration could contribute to this.
**9. Caco-2 Permeability:** Ligand A (-4.875) has better Caco-2 permeability than Ligand B (-5.341). This suggests better intestinal absorption for Ligand A.
**10. Aqueous Solubility:** Ligand A (-2.137) has better aqueous solubility than Ligand B (-3.426).
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (0.171 and 0.28). No major difference here.
**12. Microsomal Clearance:** Ligand B (20.074) has lower microsomal clearance than Ligand A (28.799), suggesting better metabolic stability.
**13. In vitro Half-Life:** Ligand A (34.867) has a longer in vitro half-life than Ligand B (13.78). This is a positive for Ligand A.
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (0.159 and 0.046). No major difference here.
**15. Binding Affinity:** Ligand B (-8.7 kcal/mol) has significantly stronger binding affinity than Ligand A (-5.5 kcal/mol). This is a substantial advantage, exceeding the 1.5 kcal/mol threshold where it can outweigh other drawbacks.
**Overall Assessment:**
While Ligand A has better QED, solubility, Caco-2 permeability, and half-life, Ligand B's *much* stronger binding affinity (-8.7 vs -5.5 kcal/mol) and significantly lower DILI risk are decisive. The better BBB penetration and metabolic stability of Ligand B are also beneficial. The slightly higher TPSA of Ligand B is a minor concern compared to the other advantages. For a GPCR, potency is paramount, and the difference in affinity is substantial.
Output:
0
2025-04-17 23:52:34,621 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 drug candidates. ADRB2 is a GPCR, so we'll prioritize logP, Pgp, TPSA, and affinity, alongside general drug-like properties.
**Ligand A:** [408.208, 110.64 , 1.741, 2. , 7. , 0.742, 90.927, 53.393, -5.195, -3.388, 0.113, 60.205, 13.287, 0.098, -7.1 ]
**Ligand B:** [341.415, 88.91 , 1.135, 2. , 5. , 0.824, 35.634, 61.846, -5.068, -1.794, 0.218, 18.337, -20.294, 0.018, -7.4 ]
1. **MW:** A (408.2) is within the ideal range, B (341.4) is also good, slightly lower.
2. **TPSA:** A (110.6) is acceptable, but pushing the limit for good oral absorption. B (88.9) is excellent.
3. **logP:** Both A (1.74) and B (1.14) are within the optimal range.
4. **HBD:** Both have 2 HBD, which is good.
5. **HBA:** A has 7, B has 5. Both are acceptable.
6. **QED:** Both are good (A: 0.74, B: 0.82).
7. **DILI:** A (90.9) is concerningly high risk. B (35.6) is very good. This is a significant advantage for B.
8. **BBB:** A (53.4) is moderate. B (61.8) is better, but not exceptionally high. For a cardiovascular target, BBB isn't *critical*, but a higher value is still preferable.
9. **Caco-2:** Both are negative, indicating poor permeability. This is a concern for both.
10. **Solubility:** Both are negative, indicating poor solubility. This is a concern for both.
11. **hERG:** Both are very low risk (A: 0.11, B: 0.22).
12. **Cl_mic:** A (60.2) is moderate. B (18.3) is significantly better (lower = more stable).
13. **t1/2:** A (13.3) is okay. B (-20.3) is very poor, indicating rapid metabolism. This is a major drawback for B.
14. **Pgp:** Both are very low efflux (A: 0.098, B: 0.018).
15. **Affinity:** B (-7.4) is 0.3 kcal/mol stronger than A (-7.1). While a 0.3 kcal/mol difference isn't massive, it's noticeable, and can be a deciding factor.
**Overall Assessment:**
Ligand B has a much better safety profile (DILI) and metabolic stability (Cl_mic). It also has a slightly better affinity and TPSA. However, its *extremely* short in vitro half-life is a major concern. Ligand A has a higher DILI risk and moderate metabolic stability, but a reasonable half-life.
Given the GPCR target, affinity is crucial. The 0.3 kcal/mol difference in affinity, coupled with the significantly improved DILI and Cl_mic, initially favors Ligand B. However, the extremely poor half-life of Ligand B is a showstopper. While formulation strategies *might* address this, it represents a significant hurdle. Ligand A, while not perfect, presents a more balanced profile, with acceptable metabolic stability and a reasonable half-life.
Therefore, I would choose Ligand A.
1
2025-04-17 23:52:34,621 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
The target is ADRB2, a GPCR. Therefore, the priorities are logP, TPSA, Pgp efflux, BBB penetration, and binding affinity.
Let's compare the ligands property by property:
1. **MW:** Both ligands (352.431 & 349.475 Da) are within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (84.94) is better than Ligand B (61.88) as it is still below 140 and closer to the ideal for oral absorption.
3. **logP:** Both ligands have acceptable logP values (1.004 & 1.169), falling within the 1-3 range. Ligand B is slightly better.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 5 HBA, Ligand B has 4. Both are acceptable.
6. **QED:** Both ligands have good QED scores (0.746 & 0.809), indicating good drug-likeness. Ligand B is slightly better.
7. **DILI:** Ligand A (41.838) has a slightly higher DILI risk than Ligand B (23.575), but both are below the concerning threshold of 60.
8. **BBB:** Ligand B (65.839) has better BBB penetration than Ligand A (54.634). This is a positive for a GPCR target.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual. I'll assume these are percentile scores and higher is better. Both are similar.
10. **Solubility:** Both have negative solubility values, which is unusual. I'll assume these are percentile scores and higher is better. Ligand B is slightly better.
11. **hERG:** Both have low hERG inhibition liability (0.112 & 0.252).
12. **Cl_mic:** Ligand B (7.298) has significantly lower microsomal clearance than Ligand A (19.806), indicating better metabolic stability.
13. **t1/2:** Ligand A (17.56) has a slightly longer in vitro half-life than Ligand B (15.755).
14. **Pgp:** Both have very low Pgp efflux liability (0.027 & 0.064).
15. **Affinity:** Ligand B (-8.0 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.9 kcal/mol). This is a >1.5 kcal/mol difference, which is a substantial advantage.
**Conclusion:**
While Ligand A has slightly better TPSA and in vitro half-life, Ligand B demonstrates superior characteristics in the most critical areas for a GPCR target: significantly better binding affinity, better BBB penetration, and lower microsomal clearance. The slightly better QED and lower DILI risk also contribute to its favorability. The difference in binding affinity is large enough to outweigh the minor drawbacks of Ligand B.
Output:
0
2025-04-17 23:52:34,621 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (354.451 and 360.42 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (99.77) is higher than Ligand B (58.2). For a cardiovascular GPCR, TPSA isn't a *major* concern unless it's excessively high, but lower is generally preferred for permeability. Ligand B is better here.
3. **logP:** Both ligands have good logP values (1.906 and 3.022), falling within the optimal 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (2). Both are acceptable.
5. **HBA:** Ligand A (4) is higher than Ligand B (2). Lower is generally better for permeability, so Ligand B is favored.
6. **QED:** Both ligands have similar and acceptable QED values (0.657 and 0.664).
7. **DILI:** Ligand B (30.632) has a significantly lower DILI risk than Ligand A (47.421). This is a substantial advantage for Ligand B.
8. **BBB:** Ligand B (83.908) has a higher BBB penetration percentile than Ligand A (70.997). While ADRB2 isn't primarily a CNS target, some degree of BBB penetration can be useful for understanding off-target effects and overall distribution.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.449 and -4.628). These values are difficult to interpret without knowing the scale, but the fact they are negative suggests poor permeability.
10. **Solubility:** Both ligands have negative solubility values (-3.347 and -4.411). Similar to Caco-2, these are hard to interpret, but suggest poor solubility.
11. **hERG:** Ligand A (0.198) has a slightly higher hERG inhibition liability than Ligand B (0.561). Lower is better, favoring Ligand B.
12. **Cl_mic:** Ligand B (29.289) has a lower microsomal clearance than Ligand A (40.431), indicating better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand B (17.374) has a much longer in vitro half-life than Ligand A (4.393). This is a major advantage, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.021) has a lower P-gp efflux liability than Ligand B (0.117). Lower Pgp is generally better, favoring Ligand A.
15. **Binding Affinity:** Ligand B (-6.7 kcal/mol) has a slightly stronger binding affinity than Ligand A (-5.6 kcal/mol). This 1.1 kcal/mol difference is significant and can outweigh some of the ADME drawbacks of Ligand A.
**Overall Assessment:**
Ligand B consistently outperforms Ligand A in most critical ADME properties (DILI, BBB, Cl_mic, t1/2) and has a slightly better binding affinity. While Ligand A has a lower Pgp efflux liability, the benefits of Ligand B's improved metabolic stability, reduced toxicity, and longer half-life are more important for a viable drug candidate targeting a cardiovascular GPCR like ADRB2. The TPSA and logP values for both are acceptable.
Output:
0
2025-04-17 23:52:34,621 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (358.785 Da and 368.499 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (91.08) is slightly higher than Ligand B (87.66). Both are below the 140 A^2 threshold for good oral absorption, but closer to the 90 A^2 limit for CNS targets (less relevant here, but still a positive). Ligand B is marginally better.
**3. logP:** Ligand A (2.53) is within the optimal 1-3 range. Ligand B (1.398) is at the lower end of this range. While not problematic, a slightly higher logP is generally preferred for GPCR ligands to facilitate membrane permeability. Ligand A is better.
**4. H-Bond Donors:** Ligand A (2) is preferable to Ligand B (3). Lower HBD generally improves permeability.
**5. H-Bond Acceptors:** Ligand A (4) is preferable to Ligand B (5) for the same reason as HBD.
**6. QED:** Both ligands have similar QED values (0.689 and 0.647), indicating good drug-like properties. No clear advantage.
**7. DILI Risk:** Ligand A (98.178) has a significantly higher DILI risk than Ligand B (35.595). This is a major concern for Ligand A.
**8. BBB Penetration:** Ligand A (50.523) has slightly better BBB penetration than Ligand B (40.403), but this isn't a primary concern for a cardiovascular target.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-5.015 and -5.288). This is unusual and suggests poor permeability. However, these values are on a log scale, and the difference is small.
**10. Aqueous Solubility:** Ligand A (-4.715) has slightly worse solubility than Ligand B (-1.953). Solubility is important for bioavailability. Ligand B is better.
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.382 and 0.266). This is excellent.
**12. Microsomal Clearance:** Ligand A (76.546) has higher microsomal clearance than Ligand B (34.074), indicating lower metabolic stability. Ligand B is better.
**13. In vitro Half-Life:** Ligand A (23.013) has a slightly longer half-life than Ligand B (29.749). This is a minor advantage.
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (0.313 and 0.105). This is good.
**15. Binding Affinity:** Ligand A (-7.4 kcal/mol) has a significantly stronger binding affinity than Ligand B (-5.7 kcal/mol). This is a substantial advantage, potentially outweighing some ADME concerns.
**Overall Assessment:**
While Ligand A has a superior binding affinity, its significantly higher DILI risk is a major red flag. The slightly better metabolic stability of Ligand B, coupled with its lower DILI risk and acceptable logP/TPSA, makes it the more promising candidate despite the weaker binding. The difference in binding affinity, while substantial, might be overcome with further optimization of Ligand B. The DILI risk of Ligand A is too high to ignore at this stage.
Output:
0
2025-04-17 23:52:34,621 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.45 & 352.52 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (98.32) is higher than Ligand B (58.64). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B is better.
3. **logP:** Ligand B (3.125) is slightly higher than Ligand A (1.161). Both are within the optimal 1-3 range, but Ligand B is closer to the upper limit. This could potentially lead to some solubility issues, but is still acceptable.
4. **HBD:** Ligand A (3) is higher than Ligand B (1). Lower is generally better for permeability, so Ligand B has an advantage.
5. **HBA:** Ligand A (4) is higher than Ligand B (3). Similar to HBD, Ligand B is preferred.
6. **QED:** Both ligands have similar QED values (0.718 vs 0.73), indicating good drug-likeness. No clear advantage.
7. **DILI:** Ligand A (21.753) has a slightly lower DILI risk than Ligand B (19.698), which is favorable.
8. **BBB:** Ligand B (71.772) has a significantly higher BBB penetration percentile than Ligand A (36.642). While ADRB2 isn't a primary CNS target, some level of BBB penetration can be beneficial for off-target effects and distribution.
9. **Caco-2:** Ligand A (-5.152) has a more negative Caco-2 value, suggesting *lower* permeability than Ligand B (-4.215). This is a negative for Ligand A.
10. **Solubility:** Ligand A (-1.572) has a slightly better solubility score than Ligand B (-2.967).
11. **hERG:** Both ligands have very low hERG inhibition risk (0.222 and 0.403 respectively). No significant difference.
12. **Cl_mic:** Ligand A (-15.661) has a *much* lower (better) microsomal clearance than Ligand B (83.219). This indicates significantly improved metabolic stability for Ligand A.
13. **t1/2:** Ligand A (-24.013) has a more negative in vitro half-life, suggesting a shorter half-life than Ligand B (2.6). This is a negative for Ligand A.
14. **Pgp:** Ligand A (0.012) has a much lower Pgp efflux liability than Ligand B (0.209). This is a significant advantage for Ligand A, improving bioavailability.
15. **Binding Affinity:** Ligand A (-6.7) has a slightly better binding affinity than Ligand B (-6.1). While the difference is not huge, it's still a positive for Ligand A.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand A and B are relatively close. However, Ligand A demonstrates superior metabolic stability (Cl_mic) and P-gp efflux liability, which are crucial for *in vivo* exposure. The slightly better binding affinity of Ligand A further strengthens its profile. While Ligand B has better TPSA and BBB penetration, these are less critical for a cardiovascular target. The Caco-2 and t1/2 values are less favorable for Ligand A, but the benefits of metabolic stability and reduced efflux outweigh these drawbacks.
Output:
1
2025-04-17 23:52:34,621 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.341 and 364.364 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (70.08) is significantly better than Ligand A (86.94). Lower TPSA generally favors better cell permeability, crucial for GPCRs.
3. **logP:** Both ligands have reasonable logP values (0.54 and 0.784), falling within the 1-3 range. Ligand B is slightly better.
4. **HBD:** Ligand A has 2 HBD, and Ligand B has 1. Both are acceptable, but lower is often preferred for permeability. Ligand B is slightly better.
5. **HBA:** Ligand A has 5 HBA, and Ligand B has 4. Both are within the acceptable range (<=10). Ligand B is slightly better.
6. **QED:** Both ligands have similar QED values (0.822 and 0.786), indicating good drug-likeness.
7. **DILI:** Ligand B (32.028) has a much lower DILI risk than Ligand A (55.991). This is a significant advantage for Ligand B.
8. **BBB:** Ligand B (77.084) has a considerably higher BBB penetration percentile than Ligand A (42.807). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant, and higher BBB is generally favorable.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.896 and -4.362). This is unusual and suggests poor permeability. However, the values are similar.
10. **Solubility:** Both ligands have similar, very poor solubility values (-1.961 and -1.871). This is a concern for both.
11. **hERG:** Both ligands have low hERG inhibition liability (0.657 and 0.461), which is good. Ligand B is slightly better.
12. **Cl_mic:** Ligand A (-22.819) has a much lower (better) microsomal clearance than Ligand B (26.982). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand B (-33.995) has a significantly longer in vitro half-life than Ligand A (11.33). This is a major advantage for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.012 and 0.021). This is good.
15. **Binding Affinity:** Both ligands have the same binding affinity (-7.3 kcal/mol). This eliminates affinity as a differentiating factor.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, TPSA, logP, Pgp, and affinity are key. Ligand B excels in TPSA, logP, Pgp, and has a significantly better BBB score. While both have similar affinity, Ligand B's superior ADME properties, particularly the lower DILI risk and longer half-life, outweigh Ligand A's slightly better metabolic stability. The poor solubility is a concern for both, but can be addressed with formulation strategies.
**Conclusion:**
Ligand B is the more promising drug candidate due to its superior ADME profile, lower toxicity risk, and better predicted permeability, despite similar binding affinity.
Output:
0
2025-04-17 23:52:34,622 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.471 and 344.419 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (60.85) is significantly better than Ligand B (101.06). For a GPCR, lower TPSA is generally preferred for better permeability, and Ligand A is well below the 140 threshold. Ligand B is approaching a level that could hinder absorption.
3. **logP:** Ligand A (2.404) is within the optimal range (1-3), while Ligand B (1.355) is at the lower end. While not a dealbreaker, a slightly higher logP is often beneficial for GPCR ligands to facilitate membrane interactions.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (7). Similar to HBD, fewer HBAs are generally better for permeability.
6. **QED:** Both ligands have similar QED values (0.72 and 0.631), indicating good drug-like properties.
7. **DILI:** Ligand A (34.82) has a significantly lower DILI risk than Ligand B (45.638). This is a substantial advantage for Ligand A.
8. **BBB:** Ligand A (71.811) has a higher BBB penetration percentile than Ligand B (52.036). While ADRB2 isn't exclusively a CNS target, some cardiovascular effects are mediated by central pathways, and better BBB penetration isn't detrimental.
9. **Caco-2:** Ligand A (-4.704) has a better Caco-2 permeability than Ligand B (-5.301), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-2.57) has better aqueous solubility than Ligand B (-1.917).
11. **hERG:** Both ligands have very low hERG inhibition liability (0.35 and 0.236), which is excellent.
12. **Cl_mic:** Ligand A (60.893) has a lower microsomal clearance than Ligand B (31.899), suggesting better metabolic stability.
13. **t1/2:** Ligand A (18.721) has a shorter in vitro half-life than Ligand B (24.668), but the difference isn't huge.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.183 and 0.006).
15. **Binding Affinity:** Ligand A (-7.9) has a significantly stronger binding affinity than Ligand B (-5.5). This difference of 2.4 kcal/mol is substantial and can often outweigh minor ADME drawbacks.
**GPCR-Specific Priorities:**
Considering ADRB2 is a GPCR, logP, TPSA, Pgp, and affinity are key. Ligand A excels in these areas, particularly with its superior TPSA, logP, and significantly stronger binding affinity.
**Conclusion:**
Ligand A demonstrates a more favorable balance of properties, particularly regarding permeability (TPSA, logP, Caco-2), metabolic stability (Cl_mic), safety (DILI, hERG), and, crucially, binding affinity. The 2.4 kcal/mol difference in binding affinity is a major advantage.
Output:
1
2025-04-17 23:52:34,622 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (373.45 and 349.41 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand B (88.91) is significantly better than Ligand A (118.36). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have acceptable logP values (0.775 and 1.132, respectively), falling within the 1-3 range. Ligand B is slightly better.
4. **HBD:** Ligand A has 3 HBD, and Ligand B has 2. Both are acceptable.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 5. Both are acceptable.
6. **QED:** Ligand B (0.806) has a better QED score than Ligand A (0.592), indicating a more drug-like profile.
7. **DILI:** Ligand B (38.62%) has a lower DILI risk than Ligand A (50.989%), which is a significant advantage.
8. **BBB:** Ligand B (70.182%) has a higher BBB penetration than Ligand A (59.054%). While not critical for a cardiovascular target, it's a slight positive.
9. **Caco-2:** Both have negative values, indicating permeability issues. Ligand B (-4.994) is slightly better than Ligand A (-5.57).
10. **Solubility:** Both have negative solubility values, indicating poor solubility. Ligand B (-2.515) is slightly better than Ligand A (-2.073).
11. **hERG:** Both ligands have very low hERG inhibition risk (0.31 and 0.135, respectively). Ligand B is better.
12. **Cl_mic:** Ligand A (3.691) has a lower microsomal clearance than Ligand B (7.149), suggesting better metabolic stability. This is a key advantage.
13. **t1/2:** Ligand B (8.127) has a significantly longer in vitro half-life than Ligand A (-20.503). This is a substantial advantage.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.091 and 0.017, respectively). Ligand B is better.
15. **Binding Affinity:** Ligand B (-6.3 kcal/mol) has a slightly better binding affinity than Ligand A (-5.9 kcal/mol). While the difference is not huge, it's a positive.
**GPCR-Specific Priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand B performs better on all these fronts, and also has a significantly better QED, DILI, BBB, and t1/2. While Ligand A has better metabolic stability (Cl_mic), the overall profile of Ligand B is superior.
**Conclusion:**
Considering the balance of properties, Ligand B is the more promising drug candidate.
Output:
0
2025-04-17 23:52:34,622 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.5 & 353.4 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (49.85) is significantly better than Ligand B (104.9). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is quite high, potentially hindering absorption.
3. **logP:** Ligand A (2.974) is optimal, while Ligand B (0.515) is quite low. Low logP can lead to poor membrane permeability. This is a substantial advantage for Ligand A.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (3) is better than Ligand B (6). Lower HBA also favors permeability.
6. **QED:** Both ligands are similar (0.766 vs 0.74), indicating good drug-likeness.
7. **DILI:** Ligand A (21.869) has a substantially lower DILI risk than Ligand B (27.065), indicating better predicted safety.
8. **BBB:** Ligand A (86.739) has a much higher BBB penetration percentile than Ligand B (49.011). While ADRB2 isn't *strictly* a CNS target, some CNS exposure can occur, and higher BBB is generally favorable.
9. **Caco-2:** Ligand A (-4.261) and Ligand B (-4.596) are similar, suggesting comparable intestinal absorption potential.
10. **Solubility:** Ligand A (-3.052) is better than Ligand B (-1.5). Better solubility is always a plus.
11. **hERG:** Ligand A (0.549) is better than Ligand B (0.255), indicating a lower risk of cardiotoxicity.
12. **Cl_mic:** Ligand A (50.534) has a higher clearance than Ligand B (35.09), meaning Ligand B is more metabolically stable. This is a point in favor of Ligand B.
13. **t1/2:** Ligand A (-19.864) has a longer half-life than Ligand B (-6.659). This is a significant advantage for Ligand A, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have the same Pgp efflux liability (0.547 vs 0.012).
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.0 vs -6.1 kcal/mol). The difference is negligible.
**Overall Assessment:**
Ligand A clearly outperforms Ligand B across most critical ADME properties, especially TPSA, logP, DILI, BBB, solubility, and hERG. While Ligand B has better metabolic stability (lower Cl_mic), the other advantages of Ligand A, particularly its superior permeability characteristics and safety profile, outweigh this single benefit. For a GPCR like ADRB2, optimizing permeability and minimizing off-target effects (like hERG inhibition) are crucial.
Output:
1
2025-04-17 23:52:34,622 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [345.418, 47.36, 4.121, 0, 4, 0.837, 62.466, 89.066, -4.022, -4.672, 0.483, 107.304, -13.557, 0.573, -6.1]
**Ligand B:** [378.372, 86.71, 1.824, 2, 4, 0.837, 50.64, 66.615, -5.113, -3.975, 0.794, 21.673, -22.245, 0.08, -7.4]
**Step-by-step comparison:**
1. **MW:** Both are within the acceptable range (200-500 Da). Ligand A (345.418) is slightly preferred.
2. **TPSA:** Ligand A (47.36) is excellent, well below the 140 threshold. Ligand B (86.71) is still reasonable but less optimal.
3. **logP:** Ligand A (4.121) is at the upper end of the optimal range, potentially causing solubility issues. Ligand B (1.824) is a bit low, potentially impacting permeability.
4. **HBD:** Ligand A (0) is excellent. Ligand B (2) is acceptable.
5. **HBA:** Both ligands have 4 HBA, which is good.
6. **QED:** Both have identical QED scores (0.837), indicating good drug-likeness.
7. **DILI:** Ligand B (50.64) has a significantly lower DILI risk than Ligand A (62.466), which is a major advantage.
8. **BBB:** Ligand A (89.066) shows better BBB penetration than Ligand B (66.615). This is important for a GPCR, but less critical for ADRB2 specifically (cardiovascular target).
9. **Caco-2:** Ligand B (-5.113) has better Caco-2 permeability than Ligand A (-4.022).
10. **Solubility:** Ligand B (-3.975) has better solubility than Ligand A (-4.672).
11. **hERG:** Ligand A (0.483) has a lower hERG risk than Ligand B (0.794).
12. **Cl_mic:** Ligand B (21.673) has a much lower microsomal clearance, indicating better metabolic stability, than Ligand A (107.304).
13. **t1/2:** Ligand B (-22.245) has a significantly longer in vitro half-life than Ligand A (-13.557).
14. **Pgp:** Ligand A (0.573) has lower P-gp efflux than Ligand B (0.08), which is good.
15. **Affinity:** Ligand B (-7.4) has a significantly stronger binding affinity than Ligand A (-6.1). This is a substantial advantage.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, we prioritize logP, TPSA, Pgp, and affinity. Ligand B has a better logP, better Caco-2 permeability, and a significantly higher binding affinity. While Ligand A has better BBB penetration, the cardiovascular target doesn't necessitate high CNS exposure. The lower DILI and improved metabolic stability of Ligand B are also very attractive.
**Conclusion:**
Despite Ligand A's slightly better MW and lower Pgp efflux, Ligand B's superior binding affinity, lower DILI risk, better metabolic stability, and improved solubility outweigh these advantages. The stronger binding affinity is a critical factor.
Output:
0
2025-04-17 23:52:34,622 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (422.71 Da) is within the ideal range, while Ligand B (349.45 Da) is towards the lower end but still acceptable.
2. **TPSA:** Both ligands (A: 55.63, B: 52.65) are below 140, which is good for oral absorption, and reasonably low for a GPCR.
3. **logP:** Ligand A (4.856) is a bit high, potentially leading to solubility issues or off-target effects. Ligand B (2.166) is within the optimal range.
4. **HBD:** Both have 1 HBD, which is acceptable.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 3. Both are within the acceptable range.
6. **QED:** Both ligands have good QED scores (A: 0.577, B: 0.783), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (72.392) has a higher DILI risk than Ligand B (11.826). This is a significant concern for Ligand A.
8. **BBB:** Ligand A (60.411) has moderate BBB penetration, while Ligand B (90.772) has very good BBB penetration. For a cardiovascular GPCR, BBB isn't *critical*, but higher is generally preferable for potential off-target effects.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it is hard to interpret.
10. **Solubility:** Both have negative solubility values, which is also unusual and suggests poor solubility.
11. **hERG:** Both ligands have low hERG inhibition risk (A: 0.848, B: 0.872).
12. **Cl_mic:** Ligand A (80.234) has a higher microsomal clearance than Ligand B (19.347), indicating lower metabolic stability.
13. **t1/2:** Ligand A (67.196) has a longer half-life than Ligand B (-5.173). This is a positive for Ligand A.
14. **Pgp:** Both ligands have low P-gp efflux liability (A: 0.869, B: 0.054). Ligand B is significantly lower, which is favorable.
15. **Affinity:** Ligand B (-6.4 kcal/mol) has a significantly stronger binding affinity than Ligand A (-4.6 kcal/mol) - a difference of 1.8 kcal/mol. This is a substantial advantage.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand B excels in these areas. While BBB isn't paramount for a cardiovascular target, Ligand B's higher value is still a plus. The significant difference in affinity and the lower DILI risk of Ligand B outweigh the longer half-life of Ligand A.
**Conclusion:**
Ligand B is the more promising drug candidate due to its superior binding affinity, lower DILI risk, better logP, and lower P-gp efflux.
Output:
0
2025-04-17 23:52:34,622 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (353.375 and 370.387 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (58.64) is significantly better than Ligand A (114.04). ADRB2 is not a CNS target, but lower TPSA generally improves absorption. This is a point for Ligand B.
3. **logP:** Ligand B (2.448) is within the optimal 1-3 range, while Ligand A (-0.453) is below 1, which could hinder permeation. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1), but both are acceptable (<=5).
5. **HBA:** Ligand A (6) is higher than Ligand B (3), but both are acceptable (<=10).
6. **QED:** Both ligands have reasonably good QED scores (0.625 and 0.527, respectively), exceeding the 0.5 threshold.
7. **DILI:** Ligand B (23.963) has a much lower DILI risk than Ligand A (34.471). This is a substantial advantage for Ligand B.
8. **BBB:** Not a primary concern for ADRB2 (cardiovascular target), but Ligand B (94.261) is higher than Ligand A (76.696).
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.889 and -4.484). This is unusual and suggests poor permeability. However, the values are similar.
10. **Solubility:** Both ligands have negative solubility values (-1.331 and -2.383). This is also concerning, indicating poor aqueous solubility. Ligand B is slightly worse.
11. **hERG:** Ligand A (0.056) has a slightly lower hERG risk than Ligand B (0.83), which is preferable.
12. **Cl_mic:** Ligand B (12.499) has a lower microsomal clearance than Ligand A (17.885), indicating better metabolic stability. This is a positive for Ligand B.
13. **t1/2:** Ligand A (-23.167) has a more negative in vitro half-life than Ligand B (-15.408). This suggests a shorter half-life for Ligand A, which is less desirable.
14. **Pgp:** Ligand A (0.005) has a much lower P-gp efflux liability than Ligand B (0.12), which is a benefit.
15. **Binding Affinity:** Both ligands have similar binding affinities (-5.5 and -5.0 kcal/mol). The difference is not substantial enough to outweigh other factors.
**Overall Assessment:**
Ligand B clearly outperforms Ligand A in several crucial ADME properties, including logP, DILI, and Cl_mic. While Ligand A has a slightly better hERG profile and Pgp efflux, the benefits of Ligand B's improved pharmacokinetic properties and safety profile are more significant for overall drug development potential. The poor Caco-2 and solubility values are concerning for both, but can be addressed with formulation strategies.
Output:
0
2025-04-17 23:52:34,622 - INFO - Batch 436 complete. Total preferences: 6976
2025-04-17 23:52:34,622 - INFO - Processing batch 437/512...
2025-04-17 23:53:24,660 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (354.422 and 358.404 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (78.87) is higher than Ligand B (58.2). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is generally preferred for absorption. Ligand B has a clear advantage.
3. **logP:** Ligand A (1.633) is within the optimal range (1-3). Ligand B (3.363) is at the higher end, potentially raising concerns about solubility and off-target effects, but still acceptable.
4. **HBD:** Both ligands have 2 HBD, which is good.
5. **HBA:** Ligand A has 4 HBA, while Ligand B has 2. Lower HBA is generally favorable for permeability, giving Ligand B an edge.
6. **QED:** Both ligands have similar QED values (0.711 and 0.749), indicating good drug-likeness.
7. **DILI:** Both ligands have acceptable DILI risk (45.095 and 43.117), below the 60% threshold. No significant difference.
8. **BBB:** Ligand A (85.653) shows significantly better BBB penetration than Ligand B (71.035). While ADRB2 isn't a CNS target, some degree of BBB penetration can be useful for understanding off-target effects.
9. **Caco-2:** Ligand A (-5.064) has a worse Caco-2 permeability than Ligand B (-4.593), indicating potentially lower intestinal absorption. Ligand B is better.
10. **Solubility:** Ligand A (-2.857) has better aqueous solubility than Ligand B (-3.974). Solubility is important, and this is a point in favor of Ligand A.
11. **hERG:** Both ligands have low hERG inhibition risk (0.425 and 0.684), which is excellent.
12. **Cl_mic:** Ligand A (-2.837) has a lower (better) microsomal clearance than Ligand B (12.98). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand B (30.659) has a significantly longer in vitro half-life than Ligand A (3.094). This is a major advantage for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.12) has lower P-gp efflux than Ligand B (0.06). Lower P-gp efflux is generally desirable for improved bioavailability.
15. **Binding Affinity:** Ligand B (-7.2 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.2 kcal/mol). This 1.0 kcal/mol difference is substantial and can often outweigh minor ADME drawbacks.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP, TPSA, and *especially* affinity. While Ligand A has better solubility and metabolic stability, the significantly stronger binding of Ligand B is the most important factor. The longer half-life of Ligand B is also a significant benefit.
**Conclusion:**
Despite Ligand A's better solubility and metabolic stability, the superior binding affinity and longer half-life of Ligand B make it the more promising drug candidate for the ADRB2 receptor.
0
2025-04-17 23:53:24,660 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.475 and 372.531 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (76.02 and 75.71) are below the 140 A^2 threshold for good oral absorption, and acceptable for a cardiovascular GPCR. Very similar.
3. **logP:** Both ligands have good logP values (2.246 and 1.76), falling within the optimal 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability, but not dramatically.
4. **HBD:** Ligand A has 2 HBD, and Ligand B has 1. Both are within the acceptable limit of <=5.
5. **HBA:** Both ligands have 4 HBA, well within the acceptable limit of <=10.
6. **QED:** Ligand A (0.776) has a slightly better QED score than Ligand B (0.626), indicating a more drug-like profile.
7. **DILI:** Both ligands have acceptable DILI risk (43.466 and 45.095 percentile), below the concerning threshold of 60.
8. **BBB:** Ligand A (70.997) has a better BBB penetration percentile than Ligand B (65.103). While ADRB2 isn't a CNS target, some peripheral exposure can be minimized with lower BBB penetration.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.691 and -4.321), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Both ligands have negative solubility values (-3.544 and -3.351), indicating very poor aqueous solubility. This is a major drawback for both.
11. **hERG:** Ligand A (0.114) has a much lower hERG inhibition liability than Ligand B (0.522), which is a significant advantage regarding cardiotoxicity risk.
12. **Cl_mic:** Ligand B (69.66) has a slightly higher microsomal clearance than Ligand A (64.073), suggesting slightly lower metabolic stability.
13. **t1/2:** Ligand B (-62.767) has a much more negative in vitro half-life than Ligand A (-2.67), indicating significantly shorter half-life and faster metabolism.
14. **Pgp:** Ligand A (0.244) has a lower P-gp efflux liability than Ligand B (0.08), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand A (-7.9 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.3 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME drawbacks.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), affinity, logP, TPSA, and Pgp efflux are important. Ligand A excels in affinity and has a better Pgp profile. While both have similar logP and TPSA, the significantly stronger binding affinity of Ligand A is a major driver. The poor Caco-2 and solubility are concerning for both, but can be addressed with formulation strategies. The lower hERG risk for Ligand A is also a critical advantage for a cardiovascular target.
**Conclusion:**
Despite the shared issues with Caco-2 and solubility, Ligand A's superior binding affinity, lower hERG risk, better Pgp profile, and longer half-life make it the more promising drug candidate.
Output:
1
2025-04-17 23:53:24,660 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (335.363) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are reasonably low, but Ligand A (88.19) is better than Ligand B (93.99), being closer to the <140 threshold for good absorption and more favorable for GPCRs.
3. **logP:** Both are in the optimal range (1-3), but Ligand B (4.25) is approaching the upper limit, potentially raising concerns about solubility and off-target effects. Ligand A (3.584) is better.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Both have 5 HBA, which is good.
6. **QED:** Ligand A (0.666) has a better QED score than Ligand B (0.483), indicating better overall drug-likeness.
7. **DILI:** Ligand B (50.291) has a significantly lower DILI risk than Ligand A (67.003), which is a major advantage.
8. **BBB:** Ligand A (82.319) has a better BBB penetration score than Ligand B (69.833). While ADRB2 isn't strictly a CNS target, some CNS exposure can be beneficial or at least less detrimental than complete exclusion.
9. **Caco-2:** Ligand A (-4.853) has a higher Caco-2 permeability than Ligand B (-5.185), suggesting better intestinal absorption.
10. **Solubility:** Ligand B (-3.387) has better aqueous solubility than Ligand A (-6.178). This is a significant advantage, especially given Ligand A's higher logP.
11. **hERG:** Ligand A (0.856) has a slightly lower hERG inhibition liability than Ligand B (0.298), which is preferable.
12. **Cl_mic:** Both have similar microsomal clearance values (Ligand A: 37.399, Ligand B: 35.748).
13. **t1/2:** Ligand A (17.044) has a significantly longer in vitro half-life than Ligand B (1.907), which is a major advantage for dosing convenience.
14. **Pgp:** Ligand B (0.185) has a lower P-gp efflux liability than Ligand A (0.396), which is beneficial for bioavailability.
15. **Binding Affinity:** Ligand B (-6.4) has a slightly better binding affinity than Ligand A (-6.8). This is a 0.4 kcal/mol difference, which is not substantial enough to outweigh other factors.
**Overall Assessment:**
Ligand A has advantages in QED, BBB, Caco-2 permeability, hERG, and especially half-life. However, Ligand B has a much lower DILI risk and better solubility, and slightly better affinity. Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity), and the importance of minimizing toxicity (DILI), Ligand B appears to be the more promising candidate. The slightly better affinity of Ligand B, combined with the significantly lower DILI risk and improved solubility, outweighs the advantages of Ligand A.
Output:
0
2025-04-17 23:53:24,660 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 drug candidates. ADRB2 is a GPCR, so we'll prioritize logP, Pgp, TPSA, and affinity, alongside general drug-like properties.
**Ligand A:**
* **MW:** 369.447 Da - Acceptable.
* **TPSA:** 116.68 - A bit high, potentially impacting permeability, but not a dealbreaker.
* **logP:** -1.259 - Too low. This is a significant concern for membrane permeability and bioavailability.
* **HBD:** 3 - Acceptable.
* **HBA:** 8 - Acceptable.
* **QED:** 0.52 - Good, drug-like.
* **DILI:** 63.397 - Moderate risk, but not alarming.
* **BBB:** 26.561 - Very low. Not a major concern for a non-CNS target like ADRB2, but indicates poor overall permeability.
* **Caco-2:** -5.61 - Very poor permeability. Consistent with the low logP and BBB.
* **Solubility:** -1.857 - Poor solubility.
* **hERG:** 0.089 - Low risk.
* **Cl_mic:** 7.26 - Moderate clearance.
* **t1/2:** -20.59 - Very short half-life.
* **Pgp:** 0.003 - Low efflux, good.
* **Affinity:** -4.5 kcal/mol - Reasonable, but not exceptional.
**Ligand B:**
* **MW:** 358.41 Da - Acceptable.
* **TPSA:** 77.1 - Excellent, well within the desired range.
* **logP:** 0.765 - Acceptable, though on the lower side of optimal.
* **HBD:** 1 - Acceptable.
* **HBA:** 5 - Acceptable.
* **QED:** 0.693 - Very good, highly drug-like.
* **DILI:** 30.283 - Low risk.
* **BBB:** 94.261 - Very high, suggesting good permeability.
* **Caco-2:** -4.579 - Good permeability.
* **Solubility:** -1.458 - Acceptable solubility.
* **hERG:** 0.268 - Low risk.
* **Cl_mic:** 8.796 - Moderate clearance.
* **t1/2:** 7.743 - Moderate half-life.
* **Pgp:** 0.033 - Low efflux, good.
* **Affinity:** -5.7 kcal/mol - Significantly better affinity than Ligand A.
**Comparison and Decision:**
Ligand B is clearly the superior candidate. While Ligand A has low Pgp efflux, its extremely low logP, poor Caco-2 permeability, and short half-life are major drawbacks. The affinity of Ligand A is also weaker. Ligand B excels in key areas: TPSA, BBB, Caco-2, solubility, and, crucially, binding affinity. The slightly higher clearance of Ligand B is less concerning than the permeability issues of Ligand A. The improved affinity of Ligand B (-5.7 kcal/mol vs -4.5 kcal/mol) is a substantial advantage that outweighs any minor ADME concerns.
0
2025-04-17 23:53:24,660 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (361.873 and 371.459 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (56.15) is significantly better than Ligand B (102.69). For a GPCR, lower TPSA is generally preferred for better permeability, and Ligand A is well below the 140 threshold. Ligand B is approaching the upper limit.
3. **logP:** Ligand A (3.851) is good, within the optimal 1-3 range. Ligand B (1.52) is on the lower side, potentially hindering membrane permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (4) is better than Ligand B (7). Again, lower HBA is generally favored for permeability.
6. **QED:** Ligand A (0.814) is significantly better than Ligand B (0.501), indicating a more drug-like profile.
7. **DILI:** Ligand B (78.17) has a higher DILI risk than Ligand A (50.523). Ligand A is well within the acceptable range, while Ligand B is approaching a concerning level.
8. **BBB:** Ligand A (82.668) has better predicted BBB penetration than Ligand B (72.78). While ADRB2 isn't exclusively a CNS target, some degree of BBB penetration can be beneficial for understanding off-target effects and potential peripheral distribution.
9. **Caco-2:** Ligand A (-4.519) and Ligand B (-5.473) both have negative values, which is unusual and suggests poor permeability in this scale. However, the scale is not specified, so it's difficult to interpret.
10. **Solubility:** Ligand A (-4.772) and Ligand B (-3.279) both have negative values, suggesting poor solubility. Again, the scale is not specified.
11. **hERG:** Both ligands have low hERG inhibition risk (0.575 and 0.364, respectively), which is good.
12. **Cl_mic:** Ligand A (87.716) has higher microsomal clearance than Ligand B (41.525), indicating faster metabolism and potentially lower *in vivo* exposure. This is a drawback for Ligand A.
13. **t1/2:** Ligand B (16.516) has a significantly longer *in vitro* half-life than Ligand A (1.752). This is a substantial advantage for Ligand B.
14. **Pgp:** Ligand A (0.347) has lower P-gp efflux liability than Ligand B (0.125), which is favorable.
15. **Binding Affinity:** Ligand B (-7.1 kcal/mol) has a slightly better binding affinity than Ligand A (-6.6 kcal/mol). The difference is 0.5 kcal/mol, which is significant, but not overwhelming.
**Overall Assessment:**
Ligand A has a superior profile in terms of drug-likeness (QED), TPSA, logP, HBD/HBA, and DILI risk. Ligand B has a better binding affinity and a significantly longer half-life. However, the ADME properties of Ligand A are generally more favorable, especially considering the importance of permeability for GPCRs. The higher clearance of Ligand A is a concern, but the other advantages outweigh this drawback.
Therefore, I prefer Ligand A.
Output:
1
2025-04-17 23:53:24,660 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (343.383 and 347.459 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (87.68) is slightly higher than Ligand B (72.88). Both are below the 140 A^2 threshold for good oral absorption, but B is preferable given the GPCR target class.
3. **logP:** Ligand A (1.15) is better than Ligand B (0.515). Both are within the optimal 1-3 range, but A is closer to the ideal.
4. **HBD:** Both ligands have 2 H-bond donors, which is good.
5. **HBA:** Ligand A has 5 H-bond acceptors, while Ligand B has 4. Both are acceptable (<=10).
6. **QED:** Ligand A (0.869) has a significantly higher QED score than Ligand B (0.711), indicating better overall drug-likeness.
7. **DILI:** Ligand B (6.398) has a much lower DILI risk than Ligand A (54.827). This is a major advantage for Ligand B.
8. **BBB:** Ligand A (28.693) has a very low BBB penetration percentile, while Ligand B (19.387) is also low, but higher than A. While ADRB2 isn't strictly a CNS target, some peripheral exposure is still desirable, and minimizing CNS side effects is always a plus.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.057 and -5.178), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand A (-2.596) has slightly better solubility than Ligand B (-1.042), but both are quite poor.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.289 and 0.106). This is good.
12. **Cl_mic:** Ligand A (-12.896) has a lower (better) microsomal clearance than Ligand B (-6.374). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (19.649 hours) has a significantly longer in vitro half-life than Ligand B (-5.98 hours). This is a major advantage for Ligand A.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.045 and 0.018). This is good.
15. **Binding Affinity:** Ligand A (-7.2 kcal/mol) has a slightly better binding affinity than Ligand B (-5.3 kcal/mol). This is a significant advantage for Ligand A.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, and affinity are important. Ligand A has a better logP and affinity. While both have suboptimal TPSA values, Ligand B is better. However, the DILI risk for Ligand A is unacceptably high.
**Overall Assessment:**
Despite Ligand A's superior affinity, half-life, and metabolic stability, the significantly higher DILI risk is a major red flag. Ligand B, while having a slightly lower affinity, presents a much more favorable safety profile (DILI) and a better TPSA. The difference in affinity isn't large enough to overcome the DILI concern.
Output:
0
2025-04-17 23:53:24,661 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [345.443, 71.41, 1.851, 1, 4, 0.8, 36.448, 65.839, -4.892, -2.701, 0.191, 4.61, -3.258, 0.127, -5.1]**
**Ligand B: [388.339, 61.44, 2.376, 2, 3, 0.562, 13.416, 55.176, -5.265, -2.096, 0.234, -3.51, 21.733, 0.049, -8.4]**
**1. Molecular Weight (MW):** Ligand A (345.443 Da) is within the ideal range (200-500 Da). Ligand B (388.339 Da) is also acceptable. No clear advantage.
**2. TPSA:** Ligand A (71.41) is better than Ligand B (61.44) as it is closer to the 140 A^2 threshold.
**3. logP:** Both ligands have good logP values (A: 1.851, B: 2.376), falling within the optimal 1-3 range. Ligand B is slightly higher, which could potentially lead to off-target effects, but it's not a major concern.
**4. H-Bond Donors (HBD):** Both ligands have acceptable HBD counts (A: 1, B: 2).
**5. H-Bond Acceptors (HBA):** Both ligands have acceptable HBA counts (A: 4, B: 3).
**6. QED:** Ligand A (0.8) has a significantly better QED score than Ligand B (0.562), indicating a more drug-like profile.
**7. DILI:** Ligand A (36.448) has a much lower DILI risk than Ligand B (13.416), which is a significant advantage.
**8. BBB:** Ligand A (65.839) has a better BBB penetration percentile than Ligand B (55.176), although neither are exceptionally high. This is relevant as ADRB2 is a GPCR.
**9. Caco-2 Permeability:** Ligand A (-4.892) and Ligand B (-5.265) both have negative values, which is unusual. Lower values suggest poor permeability.
**10. Aqueous Solubility:** Both ligands have poor aqueous solubility (-2.701 and -2.096 respectively).
**11. hERG:** Both ligands have low hERG inhibition liability (A: 0.191, B: 0.234).
**12. Microsomal Clearance:** Ligand A (4.61) has a lower microsomal clearance than Ligand B (-3.51), suggesting better metabolic stability.
**13. In vitro Half-Life:** Ligand A (-3.258) has a longer in vitro half-life than Ligand B (21.733).
**14. P-gp Efflux:** Ligand A (0.127) has lower P-gp efflux liability than Ligand B (0.049), which is favorable.
**15. Binding Affinity:** Ligand B (-8.4 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.1 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME drawbacks.
**Overall Assessment:**
Ligand B has a much stronger binding affinity, which is a critical factor for GPCR targets. However, it suffers from a higher DILI risk, lower QED, and worse metabolic stability. Ligand A has a better overall ADME profile, particularly regarding safety (DILI) and drug-likeness (QED), but its affinity is considerably weaker.
Considering the ADRB2 target is a GPCR, and the affinity difference is substantial (3.3 kcal/mol), I believe the stronger binding of Ligand B is the most important factor. While the ADME properties of Ligand B are less ideal, they may be addressable through further optimization. The strong binding provides a better starting point for optimization.
Output:
0
2025-04-17 23:53:24,661 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
The ADRB2 receptor is a GPCR, so the priorities are logP, TPSA, Pgp efflux, BBB penetration, and binding affinity. Let's analyze each ligand against these and other important parameters.
* **Molecular Weight:** Both ligands (353.5 and 356.3 Da) fall within the ideal 200-500 Da range.
* **TPSA:** Ligand A (72.88) is significantly better than Ligand B (131.59). A TPSA under 140 is good for oral absorption, but lower is preferred for GPCRs, and A is much closer to the ideal range.
* **logP:** Ligand A (1.234) is within the optimal 1-3 range. Ligand B (0.564) is slightly below 1, which could indicate potential permeability issues.
* **H-Bond Donors/Acceptors:** Ligand A (2 HBD, 4 HBA) is slightly more balanced than Ligand B (1 HBD, 8 HBA). High HBA can sometimes hinder permeability.
* **QED:** Both ligands have good QED scores (0.62 and 0.844), indicating good drug-like properties.
* **DILI Risk:** Ligand A (3.335 percentile) has a much lower DILI risk than Ligand B (87.01 percentile). This is a significant advantage for Ligand A.
* **BBB Penetration:** Ligand B (80.419 percentile) shows better BBB penetration than Ligand A (47.15 percentile). However, for a cardiovascular target like ADRB2, strong BBB penetration isn't *essential*.
* **Caco-2 Permeability:** Both ligands have similar, poor Caco-2 permeability (-4.84 and -4.898). This suggests potential absorption challenges for both.
* **Aqueous Solubility:** Both have poor aqueous solubility (-0.984 and -3.058).
* **hERG Inhibition:** Ligand A (0.188) has a much lower hERG risk than Ligand B (0.359). This is a critical safety parameter.
* **Microsomal Clearance:** Ligand A (16.14 mL/min/kg) has significantly lower clearance than Ligand B (33.042 mL/min/kg), indicating better metabolic stability.
* **In vitro Half-Life:** Ligand A (-6.721 hours) has a better half-life than Ligand B (-50.854 hours).
* **P-gp Efflux:** Ligand A (0.023) has lower P-gp efflux than Ligand B (0.034), which is favorable for bioavailability.
* **Binding Affinity:** Ligand B (-7.2 kcal/mol) has a slightly better binding affinity than Ligand A (-5.6 kcal/mol). This is a 1.6 kcal/mol difference, which is significant.
**Overall Assessment:**
While Ligand B has a slightly better binding affinity, Ligand A is clearly superior in terms of safety (DILI, hERG), metabolic stability (Cl_mic, t1/2), and TPSA. The slightly better BBB penetration of Ligand B is less important for a cardiovascular target. The lower logP of Ligand B is also a concern. The combination of favorable ADME properties and acceptable binding affinity makes Ligand A the more promising drug candidate.
**Output:**
1
2025-04-17 23:53:24,661 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.459 Da and 364.417 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (66.65) is slightly higher than Ligand B (53.33). Both are below the 140 threshold for oral absorption, but B is better.
3. **logP:** Ligand B (4.123) is slightly higher than Ligand A (3.217). Both are above the optimal 1-3 range, but B is pushing the upper limit and could present solubility challenges.
4. **HBD:** Both have 0 HBD, which is good.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 5. Both are acceptable, below the 10 threshold.
6. **QED:** Both ligands have similar QED values (0.677 and 0.661), indicating good drug-likeness.
7. **DILI:** Ligand A (33.23) has a significantly lower DILI risk than Ligand B (47.654). This is a substantial advantage for Ligand A.
8. **BBB:** Both have high BBB penetration (89.531 and 80.574). This is good, but not a primary driver for ADRB2 (a cardiovascular target).
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-3.1) has better solubility than Ligand B (-4.462).
11. **hERG:** Ligand A (0.28) has a much lower hERG inhibition liability than Ligand B (0.885). This is a critical advantage for Ligand A, minimizing cardiotoxicity risk.
12. **Cl_mic:** Ligand A (81.081) has lower microsomal clearance than Ligand B (105.97), indicating better metabolic stability.
13. **t1/2:** Ligand B (5.715) has a longer in vitro half-life than Ligand A (3.482), which is a positive.
14. **Pgp:** Ligand A (0.299) has lower P-gp efflux liability than Ligand B (0.361), suggesting better bioavailability.
15. **Binding Affinity:** Ligand B (-6.8) has a slightly better binding affinity than Ligand A (-6.4). This is a 0.4 kcal/mol difference, which is not substantial enough to overcome other significant drawbacks.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. While Ligand B has a slightly better logP and affinity, Ligand A is better in other crucial areas.
**Overall Assessment:**
Ligand A demonstrates a significantly better safety profile (lower DILI and hERG) and better ADME properties (solubility, metabolic stability, Pgp efflux). While Ligand B has a slightly better affinity and half-life, the differences are not large enough to outweigh the advantages of Ligand A. The slightly better affinity of Ligand B is not enough to overcome the higher DILI and hERG risk.
Output:
1
2025-04-17 23:53:24,661 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.49 and 349.43 Da) fall well within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (67.43) is significantly better than Ligand B (111.29). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is pushing the upper limit for good oral absorption.
3. **logP:** Ligand A (2.73) is optimal, while Ligand B (0.86) is slightly low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (2) is preferable to Ligand B (4). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (4). Fewer HBAs generally improve permeability.
6. **QED:** Both ligands have good QED values (0.597 and 0.61), indicating drug-like properties.
7. **DILI:** Ligand A (22.10) has a much lower DILI risk than Ligand B (32.18). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (78.79) shows better BBB penetration than Ligand B (39.40). While ADRB2 isn't necessarily a CNS target, some peripheral ADRB2 receptors can be affected by CNS penetration.
9. **Caco-2:** Ligand A (-4.576) is better than Ligand B (-5.124). Higher values indicate better intestinal absorption.
10. **Solubility:** Ligand A (-3.153) is better than Ligand B (-2.425).
11. **hERG:** Ligand A (0.298) is better than Ligand B (0.088). Lower hERG inhibition is crucial for avoiding cardiotoxicity, especially important for a cardiovascular target.
12. **Cl_mic:** Ligand A (81.39) has a higher clearance than Ligand B (-0.072). Ligand B has a negative clearance, which is not possible. This is a major red flag for Ligand B.
13. **t1/2:** Ligand A (3.98) is better than Ligand B (-42.61). Ligand B has a negative half-life, which is not possible.
14. **Pgp:** Ligand A (0.22) is better than Ligand B (0.016). Lower P-gp efflux is preferred.
15. **Binding Affinity:** Both ligands have comparable binding affinities (-6.5 and -6.6 kcal/mol).
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical ADME-Tox parameters. Ligand A has a better TPSA, logP, HBD/HBA counts, DILI risk, BBB penetration, solubility, hERG inhibition, and Pgp efflux. Ligand B has impossible values for Cl_mic and t1/2, making it an unviable candidate. While both have similar binding affinities, the superior ADME profile of Ligand A makes it the much more promising drug candidate.
Output:
1
2025-04-17 23:53:24,661 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**1. Molecular Weight:** Both ligands (352.387 Da and 348.487 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (112.24) is higher than Ligand B (54.71). For a GPCR like ADRB2, lower TPSA is generally preferred for better permeability, giving a slight edge to Ligand B.
**3. logP:** Ligand A (-0.252) is quite low, potentially hindering membrane permeability. Ligand B (3.517) is within the optimal 1-3 range. This is a significant advantage for Ligand B.
**4. H-Bond Donors:** Ligand A (3) is higher than Ligand B (1). While both are within the acceptable limit of 5, lower HBDs are generally preferred for better permeability, favoring Ligand B.
**5. H-Bond Acceptors:** Ligand A (6) is higher than Ligand B (4). Similar to HBDs, lower HBA is slightly preferred, favoring Ligand B.
**6. QED:** Both ligands have good QED scores (0.651 and 0.781), indicating good drug-like properties. No clear advantage.
**7. DILI:** Ligand A (43.466) has a lower DILI risk than Ligand B (8.375). This is a significant advantage for Ligand A.
**8. BBB:** Ligand B (78.79) has a much higher BBB penetration percentile than Ligand A (31.912). While ADRB2 isn't exclusively a CNS target, some CNS exposure could be beneficial or at least not detrimental, giving an advantage to Ligand B.
**9. Caco-2 Permeability:** Ligand A (-5.168) has a negative Caco-2 value, which is concerning. Ligand B (-4.844) is also negative, but less so. Both are poor, but Ligand B is slightly better.
**10. Aqueous Solubility:** Ligand A (-0.871) has slightly better solubility than Ligand B (-2.516). This is a minor advantage for Ligand A.
**11. hERG Inhibition:** Ligand A (0.177) has a lower hERG inhibition liability than Ligand B (0.505). This is a significant advantage for Ligand A, as it reduces the risk of cardiotoxicity.
**12. Microsomal Clearance:** Ligand A (-4.787) has a lower (better) microsomal clearance than Ligand B (50.548). This suggests better metabolic stability for Ligand A.
**13. In vitro Half-Life:** Ligand B (59.319) has a significantly longer in vitro half-life than Ligand A (33.864). This is a substantial advantage for Ligand B, potentially allowing for less frequent dosing.
**14. P-gp Efflux:** Ligand A (0.035) has lower P-gp efflux than Ligand B (0.098). This is a slight advantage for Ligand A.
**15. Binding Affinity:** Ligand A (-7.0) and Ligand B (-6.5) have very similar binding affinities. The 0.5 kcal/mol difference is not enough to outweigh other significant differences.
**Overall Assessment:**
Ligand B excels in logP, BBB, and half-life, which are important for a GPCR target. However, it has concerningly high P-gp efflux and a higher DILI risk. Ligand A has a better safety profile (lower DILI, hERG, and P-gp) and better metabolic stability. While its logP and TPSA are less ideal, the safety and metabolic stability advantages are crucial for a viable drug candidate.
Considering the balance of properties, especially the safety profile and metabolic stability, I favor Ligand A.
Output:
1
2025-04-17 23:53:24,661 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [368.371, 69.64, 1.794, 2, 3, 0.507, 16.053, 94.029, -5.079, -2.444, 0.78, 17.961, -6.157, 0.135, -6.6]**
**Ligand B: [357.397, 48, 3.003, 0, 4, 0.682, 36.177, 90.035, -4.455, -2.793, 0.816, 75.647, 4.092, 0.375, -7.2]**
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (368.371) is slightly higher than Ligand B (357.397), but both are acceptable.
2. **TPSA:** Ligand A (69.64) is higher than Ligand B (48). Both are below the 140 A^2 threshold for oral absorption, but Ligand B is significantly better, indicating potentially better permeability.
3. **logP:** Both ligands have good logP values (A: 1.794, B: 3.003), falling within the 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability, but also raises a slight concern for off-target effects.
4. **H-Bond Donors:** Ligand A (2) is better than Ligand B (0). Having some H-bond donors can improve solubility.
5. **H-Bond Acceptors:** Ligand A (3) is lower than Ligand B (4). Lower is generally preferred for permeability.
6. **QED:** Ligand B (0.682) has a slightly better QED score than Ligand A (0.507), suggesting a more drug-like profile.
7. **DILI:** Ligand A (16.053) has a much lower DILI risk than Ligand B (36.177). This is a significant advantage for Ligand A.
8. **BBB:** Both ligands have excellent BBB penetration (A: 94.029, B: 90.035). This is a positive for both, given ADRB2 is a GPCR.
9. **Caco-2:** Ligand A (-5.079) is worse than Ligand B (-4.455). Lower values indicate poorer permeability.
10. **Aqueous Solubility:** Ligand A (-2.444) is slightly better than Ligand B (-2.793), but both are poor.
11. **hERG:** Both ligands have low hERG inhibition risk (A: 0.78, B: 0.816).
12. **Cl_mic:** Ligand A (17.961) has a much lower microsomal clearance than Ligand B (75.647), indicating better metabolic stability.
13. **t1/2:** Ligand A (-6.157) has a longer in vitro half-life than Ligand B (4.092).
14. **Pgp:** Ligand A (0.135) has lower P-gp efflux liability than Ligand B (0.375), which is favorable.
15. **Binding Affinity:** Ligand B (-7.2) has a significantly stronger binding affinity than Ligand A (-6.6). This is a 0.6 kcal/mol difference, which is substantial.
**Overall Assessment:**
Ligand B has a superior binding affinity, a slightly better QED, and better Caco-2 permeability. However, Ligand A exhibits a much lower DILI risk, significantly better metabolic stability (lower Cl_mic, longer t1/2), and lower P-gp efflux. Considering ADRB2 is a GPCR, BBB penetration is important (both are good). The stronger binding affinity of Ligand B is a major advantage, and outweighs the slightly poorer ADME properties.
Output:
0
2025-04-17 23:53:24,661 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (354.39 and 355.47 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand B (63.91) is significantly better than Ligand A (88.35). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (3.665) is closer to the optimal 1-3 range than Ligand A (4.255), which is pushing the upper limit and could present solubility issues.
4. **HBD:** Ligand B (0) is preferable to Ligand A (2). Fewer HBDs generally improve membrane permeability.
5. **HBA:** Both ligands have 6 HBA, which is acceptable.
6. **QED:** Ligand B (0.7) is better than Ligand A (0.535), indicating a more drug-like profile.
7. **DILI:** Ligand B (76.464) is significantly better than Ligand A (93.602). Lower DILI risk is crucial.
8. **BBB:** While not a primary concern for a cardiovascular target, Ligand B (73.711) has a higher BBB percentile than Ligand A (30.748).
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
10. **Solubility:** Ligand B (-3.47) is better than Ligand A (-5.053), suggesting better aqueous solubility.
11. **hERG:** Both ligands have low hERG inhibition liability (0.553 and 0.397), which is good.
12. **Cl_mic:** Ligand B (62.597) has significantly lower microsomal clearance than Ligand A (107.514), indicating better metabolic stability.
13. **t1/2:** Ligand B (34.516) has a much longer in vitro half-life than Ligand A (-35.631). This is a major advantage.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.571 and 0.545).
15. **Binding Affinity:** Ligand B (-7.6) has a significantly stronger binding affinity than Ligand A (-4.6). This is a substantial advantage, potentially outweighing some minor ADME concerns.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in all these areas. While BBB isn't critical for a cardiovascular target, Ligand B also performs better.
**Overall Assessment:**
Ligand B consistently outperforms Ligand A across most crucial parameters, including DILI risk, metabolic stability, solubility, and, most importantly, binding affinity. The stronger binding affinity of Ligand B is a significant advantage that outweighs the slightly higher logP.
Output:
0
2025-04-17 23:53:24,661 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (341.455 and 344.455 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (60.18) is better than Ligand B (69.64). Both are below 140, but lower TPSA generally favors absorption.
3. **logP:** Ligand B (1.828) is significantly better than Ligand A (4.585). Ligand A is pushing the upper limit and could lead to solubility issues and off-target interactions. Ligand B is within the optimal 1-3 range.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (3). Fewer HBAs generally improve permeability.
6. **QED:** Ligand A (0.833) is better than Ligand B (0.774), indicating a more drug-like profile.
7. **DILI:** Ligand B (11.632) is *much* better than Ligand A (47.421). This is a major advantage for Ligand B. A DILI percentile below 40 is highly desirable.
8. **BBB:** Ligand A (82.474) is significantly better than Ligand B (40.403). While ADRB2 isn't necessarily a CNS target, higher BBB penetration can sometimes indicate better overall permeability and distribution.
9. **Caco-2:** Both are very poor (-4.906 and -4.911). This is a concern for both, indicating poor intestinal absorption.
10. **Solubility:** Ligand B (-2.07) is better than Ligand A (-4.662), though both are quite poor.
11. **hERG:** Ligand A (0.47) is slightly better than Ligand B (0.342), but both are low risk.
12. **Cl_mic:** Ligand B (14.621) is much better than Ligand A (63.826). Lower clearance is preferred for metabolic stability.
13. **t1/2:** Ligand B (-15.173) is much better than Ligand A (6.224). A negative value suggests a very long half-life.
14. **Pgp:** Ligand A (0.501) is slightly better than Ligand B (0.144), indicating less efflux.
15. **Affinity:** Ligand A (-7.2) is significantly better than Ligand B (-4.9). This is a substantial 2.3 kcal/mol difference, which is a major advantage.
**GPCR-Specific Priorities & Overall Assessment:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A has a much better affinity, which is a huge advantage. However, Ligand B excels in critical ADME properties: DILI risk, metabolic stability (Cl_mic, t1/2), and logP. The poor Caco-2 permeability is a concern for both, but the significantly better safety profile (DILI) and metabolic stability of Ligand B, coupled with its more favorable logP, outweigh the affinity difference. While the affinity difference is substantial, a well-optimized molecule based on Ligand B's scaffold could potentially achieve comparable binding with further modifications. The high DILI risk associated with Ligand A is a major red flag.
**Output:**
0
2025-04-17 23:53:24,661 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
The target is ADRB2, a GPCR. Therefore, I'll prioritize logP, TPSA, Pgp efflux, BBB penetration, and binding affinity, followed by general drug-like properties.
* **Molecular Weight:** Both ligands (348.451 and 364.471 Da) are within the ideal range (200-500 Da).
* **TPSA:** Ligand B (88.33) is significantly better than Ligand A (106.14). Lower TPSA generally improves cell permeability, crucial for GPCR targeting.
* **logP:** Both ligands have acceptable logP values (0.944 and 1.03), falling within the 1-3 range.
* **H-Bond Donors/Acceptors:** Ligand B has 1 HBD and 6 HBA, while Ligand A has 2 HBD and 6 HBA. Both are within acceptable limits.
* **QED:** Ligand A (0.824) has a better QED score than Ligand B (0.574), indicating a more drug-like profile.
* **DILI:** Both ligands have low DILI risk (45.328 and 41.295), which is good.
* **BBB:** Ligand A (86.739) has significantly better BBB penetration than Ligand B (68.282). While not a CNS target, some degree of BBB penetration can influence off-target effects and distribution.
* **Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests a potential issue with the experimental setup or data quality. However, the values are comparable.
* **Aqueous Solubility:** Both ligands have negative solubility values, which is also unusual.
* **hERG:** Both ligands have very low hERG inhibition risk (0.306 and 0.151).
* **Microsomal Clearance:** Both ligands have similar microsomal clearance values (22.184 and 23.719), indicating comparable metabolic stability.
* **In vitro Half-Life:** Ligand B (-4.686) has a slightly better (less negative) in vitro half-life than Ligand A (-25.558), suggesting better stability.
* **P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.026 and 0.056), which is favorable.
* **Binding Affinity:** Ligand B (-7.0 kcal/mol) has a significantly better binding affinity than Ligand A (-5.4 kcal/mol). This is a substantial difference (>1.5 kcal/mol) and a major advantage.
**Overall Assessment:**
Ligand B's superior binding affinity (-7.0 kcal/mol vs -5.4 kcal/mol) is the most critical factor. This outweighs the slightly better QED and BBB penetration of Ligand A. The lower TPSA of Ligand B is also a positive attribute for a GPCR ligand. While both have some unusual solubility and Caco-2 values, the binding affinity difference is decisive.
**Output:**
0
2025-04-17 23:53:24,661 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [339.359, 101.88 , 1.027, 1. , 8. , 0.744, 96.704, 75.727, -4.859, -3.854, 0.536, 50.33 , -32.073, 0.141, -6.8 ]
**Ligand B:** [340.471, 49.64 , 3.022, 1. , 4. , 0.931, 14.773, 84.917, -5.054, -2.684, 0.825, 40.419, -10.388, 0.272, -7.2 ]
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). A is 339.359, B is 340.471 - very similar.
2. **TPSA:** Ligand A (101.88) is higher than Ligand B (49.64). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for better permeability. B is significantly better here.
3. **logP:** Ligand A (1.027) is within the optimal range, but on the lower side. Ligand B (3.022) is also within the optimal range and closer to the ideal. B is better.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 8 HBA, while Ligand B has 4. Lower HBA is generally preferred for permeability, so B is better.
6. **QED:** Ligand B (0.931) has a significantly better QED score than Ligand A (0.744), indicating a more drug-like profile.
7. **DILI:** Ligand A (96.704) has a very high DILI risk, a major concern. Ligand B (14.773) has a very low DILI risk, a significant advantage.
8. **BBB:** Both have reasonable BBB penetration, but Ligand B (84.917) is better than Ligand A (75.727). While not a CNS target, some BBB penetration can be beneficial for distribution.
9. **Caco-2:** Ligand A (-4.859) and Ligand B (-5.054) are both very poor. This is a major drawback for both.
10. **Solubility:** Ligand B (-2.684) has better solubility than Ligand A (-3.854).
11. **hERG:** Ligand A (0.536) has a lower hERG risk than Ligand B (0.825). This is a slight advantage for A.
12. **Cl_mic:** Ligand B (40.419) has a lower microsomal clearance than Ligand A (50.33), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-10.388) has a longer in vitro half-life than Ligand A (-32.073), which is a significant advantage.
14. **Pgp:** Ligand A (0.141) has lower P-gp efflux than Ligand B (0.272), which is a slight advantage for A.
15. **Affinity:** Ligand B (-7.2) has a slightly better binding affinity than Ligand A (-6.8). While the difference is not huge, it's enough to consider.
**Overall Assessment:**
Ligand B is significantly better overall. The major deciding factor is the drastically lower DILI risk. It also has better QED, logP, TPSA, solubility, metabolic stability, and half-life. Although Ligand A has a slightly lower hERG risk and Pgp efflux, the DILI risk associated with Ligand A is too high to ignore. The slightly better affinity of Ligand B further solidifies its preference. The poor Caco-2 values for both are a concern, but can be addressed with formulation strategies.
Output:
0
2025-04-17 23:53:24,662 - INFO - Batch 437 complete. Total preferences: 6992
2025-04-17 23:53:24,662 - INFO - Processing batch 438/512...
2025-04-17 23:54:12,928 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (354.491 Da and 361.389 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (67.87) is well below the 140 A^2 threshold for good oral absorption, and comfortably within a reasonable range for a GPCR. Ligand B (87.74) is higher, but still acceptable.
**3. logP:** Ligand A (2.114) is optimal (1-3). Ligand B (0.149) is quite low, potentially leading to poor membrane permeability. This is a significant drawback.
**4. H-Bond Donors:** Both ligands have acceptable HBD counts (1 and 2 respectively), well below the 5 limit.
**5. H-Bond Acceptors:** Both ligands have acceptable HBA counts (4), well below the 10 limit.
**6. QED:** Ligand A (0.76) has a much better QED score than Ligand B (0.428), indicating a more drug-like profile.
**7. DILI Risk:** Ligand A (20.9) has a significantly lower DILI risk than Ligand B (33.695). This is a crucial advantage for a cardiovascular drug.
**8. BBB Penetration:** Both ligands show reasonable BBB penetration, but Ligand B (87.476) is better than Ligand A (73.943). However, for a cardiovascular target, BBB penetration is less critical than for CNS targets.
**9. Caco-2 Permeability:** Ligand A (-4.205) is better than Ligand B (-5.186), indicating better intestinal absorption.
**10. Aqueous Solubility:** Ligand A (-1.781) is better than Ligand B (-1.428).
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (0.29 and 0.402 respectively).
**12. Microsomal Clearance:** Ligand A (43.502) has a higher clearance than Ligand B (-1.101), suggesting lower metabolic stability. This is a disadvantage for Ligand A.
**13. In vitro Half-Life:** Ligand B (-9.479) has a longer half-life than Ligand A (-18.679). This is a significant advantage for Ligand B.
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (0.023 and 0.025 respectively).
**15. Binding Affinity:** Ligand A (-7.3) has a slightly better binding affinity than Ligand B (-6.0). However, the difference is not substantial enough to outweigh other concerns.
**GPCR-Specific Priorities:** For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Ligand A has a better logP and slightly better affinity. However, Ligand B has better BBB penetration and a much longer half-life. The low logP of Ligand B is a major concern, potentially hindering its ability to reach the receptor. The lower DILI risk of Ligand A is also a significant benefit.
**Conclusion:**
Considering all factors, particularly the problematic low logP and higher DILI risk of Ligand B, and the better overall drug-like properties of Ligand A, I favor Ligand A. While Ligand B has a longer half-life, the potential for poor absorption and increased toxicity associated with Ligand B are too significant to ignore.
Output:
1
2025-04-17 23:54:12,929 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [372.69 , 93.21 , 2.732, 2. , 5. , 0.791, 99.147, 70.919, -4.852, -4.407, 0.261, 16.876, 35.083, 0.187, -6.1 ]
**Ligand B:** [352.475, 89.87 , 1.053, 3. , 4. , 0.609, 22.722, 58.938, -5.011, -3.066, 0.486, 42.078, 45.248, 0.031, -6.3 ]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, Affinity, and BBB):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (352.475) is slightly lower, which is generally favorable.
2. **TPSA:** Both are acceptable, below 140. Ligand B (89.87) is slightly better, closer to the optimal range for GPCRs.
3. **logP:** Ligand A (2.732) is better than Ligand B (1.053). A logP between 1-3 is ideal, and Ligand A falls comfortably within that range, while Ligand B is at the lower end, potentially impacting permeability.
4. **HBD/HBA:** Ligand A (2/5) is slightly better than Ligand B (3/4). Both are within acceptable limits.
5. **QED:** Ligand A (0.791) is better than Ligand B (0.609), indicating a more drug-like profile.
6. **DILI:** Ligand A (99.147) is *very* high risk. Ligand B (22.722) is excellent, indicating low potential for liver injury. This is a major concern for Ligand A.
7. **BBB:** Ligand A (70.919) is good, while Ligand B (58.938) is moderate. While not a CNS target, some level of BBB penetration can influence distribution.
8. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-4.852) is slightly worse than Ligand B (-5.011).
9. **Solubility:** Both are negative, indicating poor solubility. Ligand A (-4.407) is slightly better than Ligand B (-3.066).
10. **hERG:** Both are low risk (0.261 and 0.486).
11. **Cl_mic:** Ligand A (16.876) has significantly lower clearance than Ligand B (42.078), suggesting better metabolic stability.
12. **t1/2:** Ligand B (45.248) has a longer half-life than Ligand A (35.083).
13. **Pgp:** Ligand A (0.187) has lower P-gp efflux than Ligand B (0.031), which is favorable for bioavailability.
14. **Affinity:** Both have excellent binding affinity (-6.1 and -6.3 kcal/mol). Ligand B is slightly better (-6.3 kcal/mol), but the difference is small.
**Overall Assessment:**
Ligand A has a better logP, QED, Pgp, and Cl_mic. However, its *extremely* high DILI risk is a critical flaw. Ligand B has a better safety profile (DILI) and a slightly longer half-life and better affinity, but suffers from a lower logP and Caco-2 permeability.
Given the severe DILI risk associated with Ligand A, and the importance of safety in drug development, I would prioritize Ligand B despite its slightly less optimal physicochemical properties. The affinity difference is minimal, and the DILI risk is a showstopper for Ligand A.
Output:
0
2025-04-17 23:54:12,929 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Ligand A (368.415 Da) is within the ideal range (200-500 Da). Ligand B (338.455 Da) is also within the ideal range. No clear advantage here.
2. **TPSA:** Ligand A (116.88) is slightly above the preferred <140 for oral absorption, but acceptable. Ligand B (70.07) is excellent, well below 140 and suggesting good absorption. **Advantage: B**
3. **logP:** Ligand A (1.029) is within the optimal range (1-3). Ligand B (3.727) is at the higher end of the optimal range, potentially raising concerns about solubility and off-target effects, but still acceptable. **Advantage: A**
4. **HBD:** Ligand A (1) is good. Ligand B (3) is acceptable, but higher HBD can sometimes impact permeability. **Advantage: A**
5. **HBA:** Ligand A (7) is good. Ligand B (5) is also good. No significant difference.
6. **QED:** Ligand A (0.627) is good, indicating a drug-like profile. Ligand B (0.53) is still acceptable, but slightly lower. **Advantage: A**
7. **DILI:** Both Ligand A (55.293) and Ligand B (56.727) have similar DILI risk, both being acceptable (<60). No clear advantage.
8. **BBB:** Ligand A (65.025) is moderate. Ligand B (80.031) is better, indicating potentially improved CNS penetration. While ADRB2 isn't *primarily* a CNS target, some CNS exposure can be relevant for side effect profiles. **Advantage: B**
9. **Caco-2:** Ligand A (-4.848) is poor. Ligand B (-5.051) is also poor. Both have very low Caco-2 permeability. **Advantage: None**
10. **Solubility:** Ligand A (-2.406) is poor. Ligand B (-4.03) is worse. Both have poor solubility. **Advantage: A**
11. **hERG:** Ligand A (0.076) is very low risk. Ligand B (0.919) is higher risk, though not dramatically so. **Advantage: A**
12. **Cl_mic:** Ligand A (7.569) is lower, indicating better metabolic stability. Ligand B (69.218) is much higher, suggesting rapid metabolism. **Advantage: A**
13. **t1/2:** Ligand A (2.578) is shorter. Ligand B (34.465) is significantly longer, which is desirable. **Advantage: B**
14. **Pgp:** Ligand A (0.022) is very low efflux, indicating good bioavailability. Ligand B (0.409) is higher efflux, potentially reducing bioavailability. **Advantage: A**
15. **Binding Affinity:** Ligand B (-7.9 kcal/mol) is significantly stronger than Ligand A (-6.1 kcal/mol). This is a substantial difference in potency. **Advantage: B**
**Overall Assessment:**
Ligand B has a significantly stronger binding affinity, which is a critical factor for GPCR targets. It also has better BBB penetration and a longer half-life. However, it suffers from higher logP, poorer solubility, and higher Pgp efflux. Ligand A has better ADME properties (solubility, metabolic stability, Pgp efflux, hERG), but its affinity is considerably weaker.
Considering the ADRB2 target (a cardiovascular GPCR), potency is paramount. The 1.8 kcal/mol difference in binding affinity is substantial enough to outweigh the ADME drawbacks of Ligand B, *provided* those drawbacks can be addressed through further optimization. The poor Caco-2 and solubility of both compounds are concerning and would need to be improved, but the potency advantage of B is a strong starting point.
Output:
0
2025-04-17 23:54:12,929 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (344.415 and 361.877 Da) are within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (84.42) is better than Ligand B (64.86), both are below the 140 threshold for oral absorption, and acceptable for a cardiovascular target.
3. **logP:** Ligand A (1.706) is optimal, while Ligand B (3.805) is approaching the upper limit. This favors Ligand A.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 5 HBA, and Ligand B has 6. Both are acceptable, but A is slightly preferred.
6. **QED:** Both ligands have very similar QED scores (0.899 and 0.897), indicating good drug-likeness.
7. **DILI:** Both ligands have similar DILI risk (63.125 and 62.35), which is acceptable (below 60 is preferred, but these are close enough).
8. **BBB:** Ligand B (83.986) has significantly better BBB penetration than Ligand A (67.895). While ADRB2 isn't a CNS target, some distribution to the CNS is possible and might be beneficial or detrimental depending on the specific therapeutic goal.
9. **Caco-2:** Ligand B (-5.152) shows better Caco-2 permeability than Ligand A (-4.692). This suggests better intestinal absorption for Ligand B.
10. **Solubility:** Ligand A (-3.116) has better aqueous solubility than Ligand B (-4.556). This is a positive for formulation and bioavailability.
11. **hERG:** Both ligands have low hERG inhibition liability (0.196 and 0.261), which is excellent.
12. **Cl_mic:** Ligand A (32.254) has lower microsomal clearance than Ligand B (45.11), indicating better metabolic stability.
13. **t1/2:** Ligand B (7.162) has a longer in vitro half-life than Ligand A (-19.331). This is a significant advantage for dosing frequency.
14. **Pgp:** Ligand A (0.13) has lower P-gp efflux liability than Ligand B (0.459), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand B (-6.8 kcal/mol) has a slightly better binding affinity than Ligand A (-6.1 kcal/mol). This is a 0.7 kcal/mol difference, which is significant enough to consider.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand A has a better logP and Pgp profile, while Ligand B has better Caco-2 permeability and a slightly better binding affinity. The difference in affinity is substantial enough to outweigh the slightly less ideal logP of Ligand B. The longer half-life of Ligand B is also a significant benefit.
**Overall Assessment:**
While Ligand A has some advantages in solubility and metabolic stability, Ligand B's superior binding affinity, Caco-2 permeability, and half-life are more critical for a GPCR target like ADRB2. The slightly higher logP is manageable.
Output:
0
2025-04-17 23:54:12,929 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (345.4 and 348.3 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (115.99) is slightly higher than Ligand B (108.56). Both are below the 140 threshold for good oral absorption, but closer to the 90 threshold for CNS targets (less relevant for ADRB2, a cardiovascular target). Ligand B is slightly preferred.
3. **logP:** Ligand A (1.26) and Ligand B (0.953) are both within the optimal 1-3 range. No strong preference.
4. **HBD:** Ligand A (1) has fewer HBDs than Ligand B (2). Fewer HBDs are generally preferred for permeability, so Ligand A is slightly favored.
5. **HBA:** Ligand A (5) has fewer HBAs than Ligand B (6). Similar to HBD, Ligand A is slightly favored.
6. **QED:** Ligand B (0.852) has a significantly higher QED score than Ligand A (0.475), indicating a more drug-like profile. This is a substantial advantage for Ligand B.
7. **DILI:** Ligand A (47.693) has a lower DILI risk than Ligand B (65.413). This is a clear advantage for Ligand A.
8. **BBB:** Both ligands have relatively low BBB penetration (Ligand A: 56.883, Ligand B: 60.178). This isn't a major concern for a cardiovascular target like ADRB2.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-5.148) is slightly better than Ligand B (-4.99), but both are problematic.
10. **Solubility:** Both ligands have very poor solubility scores (Ligand A: -1.598, Ligand B: -2.691). This is a significant drawback for both.
11. **hERG:** Both ligands have low hERG inhibition risk (Ligand A: 0.162, Ligand B: 0.096). Ligand B is slightly preferred.
12. **Cl_mic:** Ligand A (9.08) has a lower microsomal clearance than Ligand B (7.418), suggesting better metabolic stability. This is a positive for Ligand A.
13. **t1/2:** Ligand A (1.01) has a significantly shorter in vitro half-life than Ligand B (-46.646). This is a major drawback for Ligand A. The negative value for Ligand B is unusual and suggests very high stability.
14. **Pgp:** Both ligands have very low Pgp efflux liability (Ligand A: 0.012, Ligand B: 0.018). No significant difference.
15. **Binding Affinity:** Ligand B (-7.1 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.6 kcal/mol). This 0.5 kcal/mol difference is substantial and outweighs many of the minor ADME drawbacks.
**Overall Assessment:**
Ligand B has a significantly better binding affinity and a much higher QED score, indicating a more drug-like profile. While Ligand A has a lower DILI risk and better metabolic stability, the superior affinity and QED of Ligand B are more critical for a GPCR target. The poor solubility and Caco-2 values are concerns for both, but can be addressed through formulation strategies. The longer half-life of Ligand B is also a significant advantage.
Output:
0
2025-04-17 23:54:12,930 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.479 and 350.503 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (78.43) is higher than Ligand B (58.64). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B is better.
3. **logP:** Ligand A (1.482) is within the optimal range (1-3), while Ligand B (2.757) is towards the higher end. Both are acceptable, but A is slightly more balanced.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 5 HBA, while Ligand B has 3. Both are within the acceptable limit of 10.
6. **QED:** Both ligands have similar QED values (0.769 and 0.718), indicating good drug-likeness.
7. **DILI:** Ligand A (24.855) has a significantly lower DILI risk than Ligand B (13.532). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (84.064) has a much higher BBB penetration percentile than Ligand A (57.736). While ADRB2 isn't a primary CNS target, some CNS exposure is possible, and higher BBB is generally favorable.
9. **Caco-2:** Ligand A (-5.023) has a worse Caco-2 permeability than Ligand B (-4.454). This suggests Ligand B might have better intestinal absorption.
10. **Solubility:** Ligand A (-0.595) has better aqueous solubility than Ligand B (-2.928). Solubility is important for formulation and bioavailability.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.199 and 0.343). No significant difference.
12. **Cl_mic:** Ligand A (18.348) has a lower microsomal clearance than Ligand B (52.385). This indicates better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (13.361) has a longer in vitro half-life than Ligand B (-15.253). This is a significant advantage for Ligand A.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.01 and 0.093). No significant difference.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.3 and -6.4 kcal/mol). The difference is negligible.
**GPCR-specific priorities:** For ADRB2 (a cardiovascular GPCR), logP, TPSA, Pgp, and affinity are important. While BBB isn't as critical as for CNS GPCRs, it's still a consideration.
**Overall Assessment:**
Ligand A excels in safety (DILI), metabolic stability (Cl_mic, t1/2), and solubility. Ligand B has better Caco-2 permeability and BBB penetration. However, the significantly lower DILI risk and improved metabolic stability of Ligand A are more crucial for a cardiovascular drug candidate, outweighing the slightly better permeability and BBB of Ligand B. The binding affinity is essentially the same.
Output:
1
2025-04-17 23:54:12,930 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.519 Da and 349.475 Da) are within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Both ligands (60.85 and 61.88) are below the 140 A^2 threshold for good oral absorption, and acceptable for a cardiovascular GPCR. Similar.
3. **logP:** Ligand A (2.525) is better than Ligand B (1.005). ADRB2 is not a CNS target, but a logP between 1-3 is preferred for good balance of permeability and solubility. Ligand B is a bit low, potentially hindering membrane permeability.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 3 HBA, Ligand B has 4. Both are acceptable, but fewer is generally better.
6. **QED:** Both ligands have similar QED scores (0.846 and 0.823), indicating good drug-likeness.
7. **DILI:** Ligand A (14.308) has a significantly higher DILI risk than Ligand B (8.026). This is a major concern for Ligand A.
8. **BBB:** Both have similar BBB penetration (64.327 and 63.048), which isn't a primary concern for a cardiovascular target.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual. However, the magnitude is similar.
10. **Solubility:** Ligand A (-2.386) has slightly better solubility than Ligand B (-0.891).
11. **hERG:** Both have very low hERG inhibition risk (0.467 and 0.172).
12. **Cl_mic:** Ligand A (46.033) has a higher microsomal clearance than Ligand B (1.225), indicating lower metabolic stability. This is a significant disadvantage for Ligand A.
13. **t1/2:** Ligand B (19.709) has a much longer in vitro half-life than Ligand A (-18.875). This is a substantial advantage for Ligand B.
14. **Pgp:** Both have low Pgp efflux liability (0.274 and 0.005).
15. **Binding Affinity:** Both ligands have very similar binding affinities (-5.5 and -4.6 kcal/mol). The difference is not substantial enough to outweigh other factors.
**Overall Assessment:**
Ligand B is the better candidate. While Ligand A has slightly better solubility, Ligand B has a significantly lower DILI risk, much better metabolic stability (lower Cl_mic and longer t1/2), and a more favorable logP. The binding affinity difference is minimal. The lower DILI and improved metabolic properties of Ligand B are crucial for a viable drug candidate.
Output:
0
2025-04-17 23:54:12,930 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (363.374 Da) and Ligand B (344.411 Da) both fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (109.0) is higher than Ligand B (75.71). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B has a significant advantage here.
3. **logP:** Ligand A (2.487) is within the optimal 1-3 range. Ligand B (0.504) is slightly low, potentially hindering membrane permeability. Ligand A is better.
4. **HBD:** Ligand A (3) and Ligand B (1) are both acceptable. Ligand B is slightly better.
5. **HBA:** Ligand A (5) and Ligand B (4) are both acceptable. Ligand B is slightly better.
6. **QED:** Both Ligand A (0.617) and Ligand B (0.712) are good, exceeding the 0.5 threshold. Ligand B is slightly better.
7. **DILI:** Ligand A (98.759) has a very high DILI risk, which is a major concern. Ligand B (27.414) has a low DILI risk, a significant advantage.
8. **BBB:** Both are relatively low, but Ligand B (52.036) is higher than Ligand A (40.52). Not a primary concern for a cardiovascular target, but still slightly favors Ligand B.
9. **Caco-2:** Ligand A (-4.911) and Ligand B (-4.684) are both negative, indicating poor permeability. No clear advantage.
10. **Solubility:** Ligand A (-4.365) and Ligand B (-1.642) are both poor. Ligand B is better.
11. **hERG:** Ligand A (0.723) and Ligand B (0.038) are both low, indicating low risk of hERG inhibition. Ligand B is significantly better.
12. **Cl_mic:** Ligand A (27.904) is higher than Ligand B (-0.7). Lower is better for metabolic stability. Ligand B is much better.
13. **t1/2:** Ligand A (49.551) is better than Ligand B (-8.408). Ligand A has a longer in vitro half-life.
14. **Pgp:** Ligand A (0.097) is better than Ligand B (0.017). Lower Pgp efflux is better. Ligand A is better.
15. **Binding Affinity:** Ligand A (-5.8 kcal/mol) is slightly better than Ligand B (-6.0 kcal/mol).
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has a better logP and Pgp, and comparable affinity. However, Ligand B has a significantly better TPSA, and critically, a *much* lower DILI risk and better metabolic stability (Cl_mic). The high DILI risk of Ligand A is a major red flag.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity and Pgp profile, the extremely high DILI risk and poorer metabolic stability are deal-breakers. Ligand B, despite a slightly lower logP and affinity, presents a much more favorable safety and pharmacokinetic profile. The difference in affinity is not large enough to overcome the significant ADME/Tox advantages of Ligand B.
Output:
0
2025-04-17 23:54:12,930 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (337.379 and 344.419 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands have a TPSA of approximately 84, well below the 140 A^2 threshold for good oral absorption. This is good for both.
3. **logP:** Ligand A (2.294) is optimal, while Ligand B (0.2) is quite low, potentially hindering membrane permeability. This is a significant advantage for Ligand A.
4. **HBD:** Ligand A has 2 HBD, which is acceptable. Ligand B has 0, which is also fine, but doesn't contribute to solubility.
5. **HBA:** Ligand A has 4 HBA, within the acceptable range. Ligand B has 6, also within range.
6. **QED:** Both ligands have similar QED values (0.676 and 0.689), indicating good drug-likeness.
7. **DILI:** Ligand A (73.052 percentile) has a higher DILI risk than Ligand B (31.059 percentile). This is a clear advantage for Ligand B.
8. **BBB:** Ligand A (37.65 percentile) has a low BBB penetration, while Ligand B (76.309 percentile) has good BBB penetration. Since ADRB2 is a GPCR, BBB penetration is a consideration, favoring Ligand B.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.112 and -4.918), which is unusual and suggests poor permeability. However, these values are on a scale where negative values are possible, and the absolute values are similar.
10. **Solubility:** Ligand A (-4.528) has slightly worse solubility than Ligand B (-1.225). This favors Ligand B.
11. **hERG:** Ligand A (0.765) has a slightly higher hERG risk than Ligand B (0.045). This is a significant advantage for Ligand B.
12. **Cl_mic:** Ligand A (40.948 mL/min/kg) has a higher microsomal clearance than Ligand B (1.89 mL/min/kg), indicating lower metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand A (-12.358 hours) has a negative half-life, which is concerning. Ligand B (-1.227 hours) is also low, but less problematic than a negative value.
14. **Pgp:** Ligand A (0.563) has a lower P-gp efflux liability than Ligand B (0.02). This is a slight advantage for Ligand A.
15. **Binding Affinity:** Ligand A (-6.3 kcal/mol) has a slightly better binding affinity than Ligand B (-5.6 kcal/mol). While a difference of 0.7 kcal/mol is not huge, it's noticeable.
**Overall Assessment:**
Ligand B demonstrates a superior ADMET profile. It has a significantly lower DILI risk, better BBB penetration, better solubility, lower hERG risk, and much better metabolic stability (lower Cl_mic and a more reasonable t1/2). While Ligand A has a slightly better binding affinity and Pgp profile, the ADMET advantages of Ligand B are more critical for overall drug development success, especially considering the GPCR target class. The low logP of Ligand B is a concern, but the other advantages outweigh this drawback.
Output:
0
2025-04-17 23:54:12,930 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (338.327) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are below the 140 A^2 threshold for good oral absorption, but Ligand A (114.94) is better than Ligand B (119.24).
3. **logP:** Ligand A (0.853) is within the optimal range (1-3), but on the lower side. Ligand B (-1.551) is below 1, which could indicate poor membrane permeability. This is a significant drawback.
4. **HBD:** Both ligands have acceptable HBD counts (Ligand A: 2, Ligand B: 1), well below the 5 threshold.
5. **HBA:** Both ligands have acceptable HBA counts (Ligand A: 7, Ligand B: 6), below the 10 threshold.
6. **QED:** Ligand A (0.729) has a better QED score than Ligand B (0.453), indicating a more drug-like profile.
7. **DILI:** Ligand B (44.552) has a significantly lower DILI risk than Ligand A (87.98), which is a major advantage.
8. **BBB:** Ligand B (79.062) shows better BBB penetration than Ligand A (49.244). While ADRB2 isn't exclusively a CNS target, some peripheral ADRB2 activity can be modulated by CNS effects, and higher BBB penetration is rarely a detriment.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-5.365) is slightly worse than Ligand B (-4.985).
10. **Solubility:** Ligand A (-3.96) has slightly better solubility than Ligand B (-1.527).
11. **hERG:** Both ligands have very low hERG inhibition risk (Ligand A: 0.214, Ligand B: 0.171).
12. **Cl_mic:** Ligand A (1.094) has significantly lower microsomal clearance than Ligand B (2.993), indicating better metabolic stability.
13. **t1/2:** Ligand A (62.675) has a much longer in vitro half-life than Ligand B (-34.976), which is a substantial benefit.
14. **Pgp:** Both ligands have low P-gp efflux liability (Ligand A: 0.049, Ligand B: 0.026).
15. **Affinity:** Ligand A (-7.5 kcal/mol) has a slightly better binding affinity than Ligand B (-6.8 kcal/mol), but the difference is not overwhelmingly large.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A has a better TPSA, and comparable Pgp. However, Ligand B has a better BBB score and a significantly lower DILI risk. The logP of Ligand B is a concern, but the difference in affinity isn't large enough to overcome the better safety profile and potential for CNS effects (even if not the primary target). The metabolic stability and half-life of Ligand A are very attractive, but the DILI risk is concerning.
**Conclusion:**
Despite the slightly better affinity and metabolic stability of Ligand A, the significantly lower DILI risk and better BBB penetration of Ligand B make it the more promising drug candidate. The poor logP of Ligand B could potentially be addressed through further medicinal chemistry optimization.
Output:
0
2025-04-17 23:54:12,931 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (351.324 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (42.16) is significantly better than Ligand A (59.42). ADRB2 is not a CNS target, but lower TPSA generally improves absorption.
3. **logP:** Both ligands have logP values within the optimal range (1-3), but Ligand B (4.94) is pushing the upper limit. Ligand A (3.945) is better.
4. **HBD:** Ligand A (1) is preferable to Ligand B (0). While both are acceptable, a single HBD can aid solubility.
5. **HBA:** Ligand A (4) is preferable to Ligand B (5). Lower HBA is generally better for permeability.
6. **QED:** Ligand A (0.851) is significantly better than Ligand B (0.412), indicating a more drug-like profile.
7. **DILI:** Ligand B (52.385) is better than Ligand A (62.893), indicating a lower risk of drug-induced liver injury. This is a significant advantage for Ligand B.
8. **BBB:** Not a primary concern for ADRB2 (cardiovascular target). Ligand A (83.288) is slightly better than Ligand B (78.247).
9. **Caco-2:** Ligand A (-4.52) is better than Ligand B (-5.564), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-4.049) is better than Ligand B (-3.335), indicating better aqueous solubility.
11. **hERG:** Ligand A (0.313) is better than Ligand B (0.961), indicating lower hERG inhibition liability and thus lower cardiotoxicity risk.
12. **Cl_mic:** Ligand A (28.576) is significantly better than Ligand B (75.562), indicating better metabolic stability.
13. **t1/2:** Ligand B (154.008) is *much* better than Ligand A (-4.556). This is a major advantage for Ligand B.
14. **Pgp:** Ligand A (0.617) is better than Ligand B (0.817), indicating lower P-gp efflux.
15. **Binding Affinity:** Ligand B (-6.9 kcal/mol) is significantly better than Ligand A (-5.3 kcal/mol). This is a substantial advantage, potentially outweighing some ADME concerns.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, Pgp, TPSA, and affinity. Ligand B has a higher logP (though borderline), better affinity, and a slightly worse Pgp. Ligand A has better TPSA. The large difference in binding affinity is the most important factor.
**Overall Assessment:**
Ligand B has a significantly stronger binding affinity (-6.9 vs -5.3 kcal/mol) and a much longer in vitro half-life (154.008 vs -4.556). While Ligand B has a higher logP and slightly worse DILI and Pgp, the substantial improvement in affinity and half-life are critical for a GPCR target. The better DILI score for Ligand B is also a positive. The other parameters are either comparable or favor Ligand A, but the affinity and half-life differences are decisive.
Output:
0
2025-04-17 23:54:12,931 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (360.336 and 368.455 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (87.32) is better than Ligand B (101.57). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally favors absorption.
3. **logP:** Ligand A (1.152) is better than Ligand B (0.109). Both are within the acceptable range (1-3), but Ligand A is closer to the optimal range, while Ligand B is quite low, potentially hindering membrane permeability.
4. **HBD:** Both ligands have 2 HBD, which is within the acceptable limit of <=5.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 5. Both are within the acceptable limit of <=10.
6. **QED:** Ligand A (0.843) is significantly better than Ligand B (0.633). A higher QED suggests a more drug-like profile.
7. **DILI:** Ligand B (44.009) is significantly better than Ligand A (65.917). Lower DILI is crucial, and Ligand B is well below the 60% risk threshold. Ligand A is approaching a concerning level.
8. **BBB:** Both ligands have reasonable BBB penetration (Ligand A: 67.158, Ligand B: 60.915), but this isn't a major priority for a cardiovascular target.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.933 and -5.352). This is unusual and suggests poor permeability. However, the values are similar.
10. **Solubility:** Ligand A (-3.015) is better than Ligand B (-1.96). Higher solubility is preferred.
11. **hERG:** Ligand A (0.387) is better than Ligand B (0.032). Lower hERG inhibition is critical for avoiding cardiotoxicity, and Ligand B is very close to zero, indicating potential issues.
12. **Cl_mic:** Ligand A (5.221) is *much* better than Ligand B (15.208). Lower microsomal clearance indicates better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand B (-8.113) is better than Ligand A (-5.054). A longer half-life is generally desirable.
14. **Pgp:** Ligand A (0.018) is better than Ligand B (0.04). Lower P-gp efflux is preferred.
15. **Binding Affinity:** Ligand A (-7.5) is significantly better than Ligand B (-3.4). A difference of 4.1 kcal/mol is substantial and can outweigh many ADME drawbacks.
**Overall Assessment:**
Ligand A has a significantly stronger binding affinity, a better QED score, lower DILI risk, better metabolic stability (lower Cl_mic), and lower Pgp efflux. While Ligand B has a better half-life and slightly lower hERG risk, the substantial advantage in binding affinity and the concerning DILI and Cl_mic values for Ligand B make Ligand A the more promising candidate. The lower logP of Ligand B is also a concern. For a GPCR, affinity is paramount, and Ligand A's advantage is substantial.
Output:
1
2025-04-17 23:54:12,931 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
Let's systematically compare Ligand A and Ligand B based on the provided parameters, keeping in mind the GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key).
1. **Molecular Weight:** Both ligands (374.566 and 346.475 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (58.2) is slightly higher than Ligand B (50.72). Both are below the 140 threshold for oral absorption, which is good.
3. **logP:** Ligand A (3.553) is slightly higher than Ligand B (2.406), both are within the optimal 1-3 range, but Ligand A is approaching the upper limit.
4. **H-Bond Donors:** Ligand A (2) is better than Ligand B (0). A small number of HBDs are generally preferred for permeability.
5. **H-Bond Acceptors:** Ligand B (6) has more HBA than Ligand A (3). Lower HBA is generally preferred for better permeability.
6. **QED:** Both ligands have good QED scores (0.683 and 0.82), indicating good overall drug-likeness.
7. **DILI:** Ligand B (37.263) has a significantly lower DILI risk than Ligand A (18.108). This is a major advantage for Ligand B.
8. **BBB:** Ligand B (86.933) shows better BBB penetration than Ligand A (76.541). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant for off-target effects or potential therapeutic benefits.
9. **Caco-2 Permeability:** Ligand A (-5.077) has a more negative Caco-2 value, indicating better permeability than Ligand B (-4.479).
10. **Aqueous Solubility:** Ligand A (-4.254) has a slightly better solubility than Ligand B (-3.167).
11. **hERG Inhibition:** Both ligands show low hERG inhibition liability (0.711 and 0.734), which is good.
12. **Microsomal Clearance:** Ligand B (54.799) has a lower microsomal clearance than Ligand A (74.34), suggesting better metabolic stability.
13. **In vitro Half-Life:** Ligand A (17.586) has a longer half-life than Ligand B (8.271).
14. **P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.131 and 0.105).
15. **Binding Affinity:** Ligand B (-6.8 kcal/mol) has a slightly better binding affinity than Ligand A (-6.0 kcal/mol). The difference is 0.8 kcal/mol, which is significant.
**Overall Assessment:**
Ligand B is the preferred candidate. While Ligand A has slightly better Caco-2 permeability and in vitro half-life, Ligand B excels in crucial areas: significantly lower DILI risk, better BBB penetration, better metabolic stability (lower Cl_mic), and slightly better binding affinity. The combination of these factors, particularly the lower DILI risk, makes Ligand B the more promising drug candidate for development.
**Output:**
0
2025-04-17 23:54:12,931 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (386.361 and 363.38 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (41.13) is significantly better than Ligand B (84.23). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is quite high, potentially hindering absorption.
**3. logP:** Ligand A (4.416) is a bit high, but still within a manageable range. Ligand B (2.696) is excellent. While higher logP can sometimes be tolerated, it can also lead to off-target effects.
**4. H-Bond Donors:** Both have 2 HBD, which is good.
**5. H-Bond Acceptors:** Ligand A has 2 HBA, while Ligand B has 4. Both are acceptable, but lower is generally preferred.
**6. QED:** Both ligands have similar QED values (0.753 and 0.744), indicating good drug-likeness.
**7. DILI Risk:** Ligand A (53.625) has a slightly lower DILI risk than Ligand B (58.511), but both are reasonably acceptable.
**8. BBB Penetration:** Ligand A (80.264) has better BBB penetration than Ligand B (74.06). While ADRB2 is primarily cardiovascular, some CNS side effects are possible with GPCR modulation, so some BBB penetration is not necessarily detrimental.
**9. Caco-2 Permeability:** Ligand A (-5.148) has worse Caco-2 permeability than Ligand B (-4.775). However, the difference is small and both are negative, suggesting poor permeability.
**10. Aqueous Solubility:** Ligand A (-4.495) has slightly worse solubility than Ligand B (-3.047). Solubility is important, but can often be addressed with formulation strategies.
**11. hERG Inhibition:** Ligand A (0.692) has a slightly higher hERG risk than Ligand B (0.452), but both are relatively low.
**12. Microsomal Clearance:** Ligand B (52.705) has lower microsomal clearance than Ligand A (23.535), indicating better metabolic stability. This is a significant advantage.
**13. In vitro Half-Life:** Ligand B (-9.508) has a much longer in vitro half-life than Ligand A (2.367). This is a substantial benefit, potentially leading to less frequent dosing.
**14. P-gp Efflux:** Ligand A (0.229) has lower P-gp efflux than Ligand B (0.157), which is favorable for bioavailability.
**15. Binding Affinity:** Ligand A (-7.1) has a significantly stronger binding affinity than Ligand B (-6.6). This is a 1.5 kcal/mol difference, which is enough to outweigh some of the ADME drawbacks of Ligand A.
**Overall Assessment:**
Ligand A has a superior binding affinity, better BBB penetration, and lower DILI risk. However, Ligand B has significantly better metabolic stability (lower Cl_mic, longer t1/2) and a more favorable logP. The TPSA of Ligand B is a major concern, potentially hindering absorption. Considering the GPCR-specific priorities (logP, TPSA, affinity), and the importance of metabolic stability for cardiovascular drugs, the stronger affinity of Ligand A is compelling. The slightly higher TPSA is a concern, but the difference in binding affinity is substantial.
Output:
1
2025-04-17 23:54:12,931 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's systematically compare Ligand A and Ligand B based on the provided parameters and the guidelines, keeping in mind that ADRB2 is a GPCR, so logP, Pgp, TPSA, and affinity are key.
1. **MW:** Both ligands (352.475 and 349.475 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (78.87) is slightly higher than Ligand B (69.72). Both are below the 140 A^2 threshold for good oral absorption, but B is preferable.
3. **logP:** Both ligands have good logP values (1.458 and 1.707) within the optimal 1-3 range. B is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Ligand A has 2 HBD, while Ligand B has 1. Lower is generally better for permeability, so B is slightly favored.
5. **HBA:** Ligand A has 4 HBA, while Ligand B has 3. Again, B is slightly favored.
6. **QED:** Both ligands have reasonable QED scores (0.727 and 0.678), indicating good drug-like properties. A is slightly better.
7. **DILI:** Ligand A (8.414%) has a significantly lower DILI risk than Ligand B (12.796%). This is a major advantage for Ligand A.
8. **BBB:** Both ligands show relatively low BBB penetration (60.838% and 69.407%). This isn't a primary concern for ADRB2 (a cardiovascular target), but higher is still better, giving a slight edge to B.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.65 and -4.634), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Both ligands have very poor aqueous solubility (-2.089 and -1.248). This is a significant drawback for both and could pose formulation challenges.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.24 and 0.115), which is excellent. B is slightly better.
12. **Cl_mic:** Ligand A has a lower microsomal clearance (7.892) than Ligand B (39.203), indicating better metabolic stability. This is a significant advantage for A.
13. **t1/2:** Ligand A has a negative in vitro half-life (-1.021), which is unusual and concerning. Ligand B has a positive half-life (3.408), a clear advantage.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.078 and 0.014), which is good. B is slightly better.
15. **Binding Affinity:** Ligand B (-7.1 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.1 kcal/mol). This 2 kcal/mol difference is substantial and can often outweigh minor ADME drawbacks.
**Overall Assessment:**
Ligand B has a significantly stronger binding affinity, which is the most crucial factor for a GPCR target. It also has slightly better logP, Pgp, and hERG profiles. While its DILI risk is higher, the substantial affinity advantage outweighs this concern. The poor solubility and Caco-2 values are problematic for both, but can potentially be addressed with formulation strategies. Ligand A's better metabolic stability is appealing, but the weaker affinity is a major drawback.
Output:
0
2025-04-17 23:54:12,932 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (365.455 and 352.475 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (66.92) is significantly better than Ligand A (93.97). ADRB2 is not a CNS target, but lower TPSA generally improves absorption.
3. **logP:** Ligand B (2.239) is optimal, while Ligand A (0.399) is quite low, potentially hindering membrane permeability. This is a significant negative for Ligand A.
4. **HBD:** Ligand A (2) is preferable to Ligand B (0), as some H-bond donors can aid solubility.
5. **HBA:** Ligand A (6) is slightly higher than Ligand B (4), but both are within acceptable limits.
6. **QED:** Ligand A (0.791) is much better than Ligand B (0.471), indicating a more drug-like profile.
7. **DILI:** Ligand B (19.504) has a much lower DILI risk than Ligand A (46.995). This is a substantial advantage for Ligand B.
8. **BBB:** Not a primary concern for ADRB2 (cardiovascular target), but Ligand B (75.107) has a higher BBB percentile than Ligand A (31.756).
9. **Caco-2:** Ligand A (-5.073) and Ligand B (-4.293) are both negative, indicating poor permeability.
10. **Solubility:** Both are very poor (-1.856 and -1.982). Solubility is a concern for both.
11. **hERG:** Both ligands have low hERG risk (0.24 and 0.328).
12. **Cl_mic:** Ligand A (5.741) has a much lower microsomal clearance than Ligand B (85.586), suggesting better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand B (-15.672) has a negative half-life, which is concerning. Ligand A (3.492) is reasonable.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.047 and 0.063).
15. **Binding Affinity:** Ligand A (-7.1) has a slightly better binding affinity than Ligand B (-6.7), but the difference is not huge (0.4 kcal/mol).
**Overall Assessment:**
Ligand A has better affinity and metabolic stability (lower Cl_mic). However, Ligand B has a much better logP, lower DILI risk, and a more favorable BBB profile (though BBB is less critical here). The poor logP of Ligand A is a major concern, potentially leading to poor absorption. The negative half-life of Ligand B is a significant drawback, but the other factors favor Ligand B. Considering the balance, and prioritizing logP and safety (DILI) for a cardiovascular target, Ligand B appears to be the more promising candidate.
Output:
0
2025-04-17 23:54:12,932 - INFO - Batch 438 complete. Total preferences: 7008
2025-04-17 23:54:12,932 - INFO - Processing batch 439/512...
2025-04-17 23:55:04,509 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.4 and 356.4 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (83.22) is better than Ligand B (93.21). Both are below 140, but lower TPSA generally favors absorption.
3. **logP:** Ligand A (2.048) is better than Ligand B (1.076). Both are within the optimal 1-3 range, but B is closer to the lower bound, which could potentially hinder permeation.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (2), but both are within the acceptable limit of 5.
5. **HBA:** Ligand B (5) is higher than Ligand A (3). Both are within the acceptable limit of 10.
6. **QED:** Both ligands have similar QED values (0.704 and 0.727), indicating good drug-likeness.
7. **DILI:** Ligand A (51.26) is better than Ligand B (55.021), both are acceptable, but lower is preferred.
8. **BBB:** Both ligands have good BBB penetration (79.294 and 80.729). This is less critical for ADRB2 (a cardiovascular target) but doesn't hurt.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.695 and -4.661). This is unusual and suggests poor permeability. However, the values are very close.
10. **Solubility:** Ligand A (-3.195) is better than Ligand B (-2.1). Higher solubility is generally preferred.
11. **hERG:** Ligand A (0.419) is better than Ligand B (0.13). Lower hERG inhibition is crucial for avoiding cardiotoxicity, especially targeting a cardiovascular receptor.
12. **Cl_mic:** Ligand A (20.783) is better than Ligand B (25.465). Lower microsomal clearance suggests better metabolic stability.
13. **t1/2:** Ligand B (-42.727) is significantly better than Ligand A (13.63). A negative value for t1/2 is unusual and suggests a very long half-life, which is highly desirable.
14. **Pgp:** Ligand A (0.071) is better than Ligand B (0.024). Lower P-gp efflux is preferred.
15. **Binding Affinity:** Ligand B (-7.6) is significantly better than Ligand A (-6.0). A 1.6 kcal/mol difference in binding affinity is substantial and can often outweigh minor ADME drawbacks.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are particularly important. Ligand A has better logP, TPSA, and Pgp. However, Ligand B's substantially superior binding affinity (-7.6 vs -6.0 kcal/mol) is a major advantage. The longer half-life of Ligand B is also a significant positive. The slightly worse solubility and DILI risk of Ligand B are less concerning given the strong affinity and metabolic stability.
**Conclusion:**
Despite some slightly better ADME properties for Ligand A, the significantly stronger binding affinity and longer half-life of Ligand B make it the more promising drug candidate for ADRB2.
Output:
0
2025-04-17 23:55:04,510 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (351.466 and 349.406 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (61.44) is significantly better than Ligand B (87.3). For a GPCR, lower TPSA is generally preferred for better permeability. Ligand B is approaching a level that could hinder oral absorption.
3. **logP:** Both ligands have good logP values (1.623 and 1.884), falling within the optimal 1-3 range. Ligand B is slightly higher, but not concerningly so.
4. **HBD:** Ligand A (2) is preferable to Ligand B (3). Lower HBD generally improves permeability.
5. **HBA:** Both ligands have the same number of HBA (3), which is acceptable.
6. **QED:** Both ligands have similar, good QED values (0.621 and 0.657), indicating good drug-like properties.
7. **DILI:** Ligand A (10.392) has a significantly lower DILI risk than Ligand B (51.648). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (70.105) has a better BBB penetration percentile than Ligand B (66.809). While ADRB2 isn't exclusively a CNS target, some CNS exposure can occur, and higher BBB is generally favorable.
9. **Caco-2:** Ligand A (-4.854) and Ligand B (-5.124) are similar and both indicate good permeability.
10. **Solubility:** Ligand A (-1.949) is slightly better than Ligand B (-2.749), but both are poor.
11. **hERG:** Ligand A (0.523) has a lower hERG risk than Ligand B (0.344), which is a significant advantage.
12. **Cl_mic:** Ligand A (-11.043) has a significantly lower (better) microsomal clearance than Ligand B (4.126), indicating better metabolic stability.
13. **t1/2:** Ligand A (9.509) has a shorter in vitro half-life than Ligand B (22.121). This is a drawback for Ligand A.
14. **Pgp:** Ligand A (0.028) has a much lower P-gp efflux liability than Ligand B (0.118), which is a significant advantage for bioavailability.
15. **Binding Affinity:** Ligand B (-8.9 kcal/mol) has a stronger binding affinity than Ligand A (-6.8 kcal/mol). This is a substantial difference (2.1 kcal/mol), and is a significant factor.
**Overall Assessment:**
Ligand B has a substantially better binding affinity, which is a key driver for potency. However, Ligand A is superior in almost all ADME-Tox properties, particularly DILI risk, hERG inhibition, metabolic stability (Cl_mic), and P-gp efflux. The lower DILI and hERG risks are crucial for safety. The better TPSA and BBB are also beneficial. The longer half-life of Ligand B is a plus, but can be addressed through structural modifications.
Given the GPCR target class, balancing potency with ADME properties is critical. While the affinity difference is substantial, the safety and pharmacokinetic advantages of Ligand A are compelling. I believe the affinity of Ligand A is still within a reasonable range for a starting point, and the ADME profile offers a much more favorable path to clinical development.
Output:
1
2025-04-17 23:55:04,510 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (387.311 Da) is slightly higher than Ligand B (366.571 Da), but both are acceptable.
2. **TPSA:** Ligand B (40.62) is significantly better than Ligand A (68.7). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (A: 2.69, B: 3.404), falling within the optimal 1-3 range. Ligand B is slightly higher, potentially increasing permeability.
4. **HBD:** Ligand A has 2 HBD, and Ligand B has 0. Both are within the acceptable limit of 5.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 3. Both are within the acceptable limit of 10.
6. **QED:** Both ligands have similar QED values (A: 0.78, B: 0.648), indicating good drug-likeness.
7. **DILI:** Ligand B (13.843) has a much lower DILI risk than Ligand A (19.969). This is a significant advantage.
8. **BBB:** Ligand B (92.478) has a much higher BBB penetration percentile than Ligand A (47.848). While not critical for a cardiovascular target, higher BBB is rarely a detriment.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.105 and -5.079). This is unusual and suggests poor permeability in this *in vitro* assay.
10. **Solubility:** Both ligands have negative solubility values (-2.193 and -3.232). This is also unusual and suggests poor aqueous solubility.
11. **hERG:** Both ligands have low hERG inhibition liability (A: 0.623, B: 0.804), which is good.
12. **Cl_mic:** Ligand A (-21.954) has a much lower (better) microsomal clearance than Ligand B (61.336). This indicates greater metabolic stability.
13. **t1/2:** Ligand A (74.584) has a significantly longer *in vitro* half-life than Ligand B (-2.335). This is a substantial advantage.
14. **Pgp:** Both ligands have low Pgp efflux liability (A: 0.061, B: 0.497).
15. **Binding Affinity:** Both ligands have the same binding affinity (-6.8 kcal/mol).
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B is better on logP and TPSA. Ligand A is better on metabolic stability (Cl_mic) and half-life. However, the significantly lower DILI risk for Ligand B is a major factor.
**Overall Assessment:**
While Ligand A has advantages in metabolic stability and half-life, the lower DILI risk and better TPSA of Ligand B are more compelling. The binding affinity is identical, so these factors become decisive. The poor Caco-2 and solubility values are concerning for both, but can be addressed with formulation strategies. The lower DILI risk is a critical safety consideration.
Output:
0
2025-04-17 23:55:04,510 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (379.5 and 374.5 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (43.86) is significantly better than Ligand B (76.02). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 cutoff. Ligand B is approaching a level that could hinder absorption.
3. **logP:** Both ligands have similar logP values (2.164 and 2.229), falling within the optimal 1-3 range.
4. **HBD:** Ligand A has 0 HBD, while Ligand B has 2. Lower is generally preferred for permeability, so Ligand A is slightly better.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 5. Again, Ligand A is slightly better.
6. **QED:** Ligand B (0.732) has a better QED score than Ligand A (0.584), indicating a more drug-like profile. This is a point in favor of Ligand B.
7. **DILI:** Ligand A (11.594) has a much lower DILI risk than Ligand B (54.866). This is a *major* advantage for Ligand A. DILI is a critical safety concern.
8. **BBB:** Ligand A (86.817) has a higher BBB penetration percentile than Ligand B (70.027). While not crucial for a cardiovascular target, higher BBB is generally not detrimental.
9. **Caco-2:** Ligand A (-4.685) and Ligand B (-5.063) are both very poor. This is concerning for both, suggesting poor intestinal absorption.
10. **Solubility:** Ligand A (-1.215) has slightly better solubility than Ligand B (-2.915).
11. **hERG:** Both ligands have very low hERG inhibition risk (0.471 and 0.325). This is excellent for both.
12. **Cl_mic:** Ligand B (14.718) has a lower microsomal clearance than Ligand A (16.726), suggesting better metabolic stability. This is a point in favor of Ligand B.
13. **t1/2:** Ligand B (-8.007) has a longer in vitro half-life than Ligand A (-12). This is a significant advantage for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.021 and 0.061).
15. **Binding Affinity:** Ligand B (-7.6) has a slightly better binding affinity than Ligand A (-6.3). This is a 1.3 kcal/mol difference, which is significant and could potentially outweigh some ADME drawbacks.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Both ligands are good on logP. Ligand A is significantly better on TPSA. Ligand B has a slightly better affinity. However, the *significant* difference in DILI risk heavily favors Ligand A. A safer profile is paramount, especially in cardiovascular drug development.
**Conclusion:**
While Ligand B has a slightly better affinity and half-life, the substantially lower DILI risk associated with Ligand A makes it the more promising drug candidate. The TPSA advantage of Ligand A also supports better absorption.
Output:
1
2025-04-17 23:55:04,510 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.5 and 348.5 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (43.86) is better than Ligand B (49.85). Both are below 140, but lower TPSA is generally preferred for better absorption.
3. **logP:** Both ligands have good logP values (2.275 and 2.895), falling within the optimal 1-3 range. Ligand B is slightly higher, which *could* be a minor concern for solubility, but isn't a dealbreaker.
4. **HBD:** Both ligands have 0 HBD, which is good.
5. **HBA:** Both ligands have 3 HBA, which is good.
6. **QED:** Ligand A (0.717) has a significantly better QED score than Ligand B (0.475). This suggests Ligand A is more generally "drug-like."
7. **DILI:** Ligand A (5.777) has a much lower DILI risk than Ligand B (17.836). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (92.827) has a higher BBB penetration percentile than Ligand A (81). While ADRB2 isn't strictly a CNS target, some CNS exposure can be relevant for off-target effects or peripheral effects mediated by CNS pathways.
9. **Caco-2:** Both are negative values, indicating permeability. No clear advantage.
10. **Solubility:** Both have negative solubility values. No clear advantage.
11. **hERG:** Both ligands have low hERG risk (0.582 and 0.678), which is good.
12. **Cl_mic:** Ligand A (23.524) has a significantly lower microsomal clearance than Ligand B (63.647), indicating better metabolic stability.
13. **t1/2:** Ligand A (22.791) has a longer in vitro half-life than Ligand B (-8.118). This is a significant advantage.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.052 and 0.458). No clear advantage.
15. **Binding Affinity:** Ligand B (-5.9 kcal/mol) has a slightly better binding affinity than Ligand A (-4.8 kcal/mol). This is a 1.1 kcal/mol difference, which is notable but not overwhelming.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Both ligands perform well on logP and Pgp. Ligand B has a slightly better affinity, but Ligand A has a better TPSA. The significant advantages of Ligand A in QED, DILI risk, metabolic stability (Cl_mic), and half-life outweigh the modest affinity difference.
**Conclusion:**
Ligand A presents a more balanced and favorable profile overall, with significantly better predicted safety (DILI) and pharmacokinetic properties (Cl_mic, t1/2, QED) than Ligand B. The slightly weaker binding affinity is a reasonable trade-off for these improvements.
Output:
1
2025-04-17 23:55:04,510 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (347.459 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (84.23) is better than Ligand B (99.93), falling comfortably under the 140 threshold for good oral absorption.
3. **logP:** Both ligands have acceptable logP values (A: 2.803, B: 1.787) within the 1-3 range. Ligand A is slightly higher, which could potentially lead to off-target effects, but is still within a reasonable range.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1), but both are well within the acceptable limit of 5.
5. **HBA:** Ligand A (4) is lower than Ligand B (5), which is preferable.
6. **QED:** Both ligands have good QED scores (A: 0.708, B: 0.747), indicating good drug-like properties.
7. **DILI:** Ligand A (25.397) has a significantly lower DILI risk than Ligand B (52.617). This is a major advantage for Ligand A.
8. **BBB:** Both ligands have similar BBB penetration (A: 46.646, B: 46.607). While not exceptionally high, it's not a primary concern for ADRB2, which isn't a CNS target.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.954 and -4.665), which is unusual and suggests poor permeability. This is a significant drawback for both.
10. **Solubility:** Both ligands have negative solubility values (-2.499 and -2.325), indicating very poor aqueous solubility. This is a major concern for both.
11. **hERG:** Both ligands have low hERG inhibition risk (A: 0.097, B: 0.181).
12. **Cl_mic:** Ligand A (19.158) has a lower microsomal clearance than Ligand B (24.079), suggesting better metabolic stability.
13. **t1/2:** Ligand B (20.442) has a significantly longer in vitro half-life than Ligand A (1.629). This is a substantial advantage for Ligand B.
14. **Pgp:** Both ligands have low P-gp efflux liability (A: 0.056, B: 0.211).
15. **Binding Affinity:** Both ligands have the same binding affinity (-6.1 kcal/mol).
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. While both ligands have similar affinity and Pgp values, Ligand A has a better logP and TPSA. The significantly lower DILI risk and better metabolic stability (lower Cl_mic) of Ligand A are also crucial advantages. The longer half-life of Ligand B is attractive, but the higher DILI risk and worse ADME properties overall are concerning. The poor Caco-2 and solubility for both are problematic, but can potentially be addressed with formulation strategies.
**Conclusion:**
Despite the longer half-life of Ligand B, the significantly lower DILI risk, better TPSA, and improved metabolic stability of Ligand A make it the more promising drug candidate.
**Output:**
1
2025-04-17 23:55:04,510 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (367.833 and 346.427 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Both ligands have TPSA values (78.95 and 73.99) below the 140 A^2 threshold for good oral absorption. They are also reasonably low, which is beneficial for GPCR ligands. Ligand B is slightly better.
**3. logP:** Both ligands have logP values (1.291 and 1.456) within the optimal 1-3 range. No significant difference.
**4. H-Bond Donors:** Both have 1 HBD, which is acceptable.
**5. H-Bond Acceptors:** Both have 4 HBA, also acceptable.
**6. QED:** Ligand A (0.813) has a slightly higher QED than Ligand B (0.759), indicating a more drug-like profile.
**7. DILI:** Ligand B (21.946) has a significantly lower DILI risk than Ligand A (76.89). This is a major advantage for Ligand B.
**8. BBB:** Ligand A (70.299) has a slightly higher BBB penetration percentile than Ligand B (62.195). While ADRB2 is a cardiovascular target, some CNS effects are possible with beta-blockers, and some brain exposure might be acceptable or even desirable for certain therapeutic strategies.
**9. Caco-2 Permeability:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand B (-4.638) is slightly worse than Ligand A (-4.483).
**10. Aqueous Solubility:** Ligand B (-1.092) has better aqueous solubility than Ligand A (-3.17). This is a positive for bioavailability.
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.273 and 0.222).
**12. Microsomal Clearance:** Both have similar microsomal clearance values (27.408 and 26.736 mL/min/kg).
**13. In vitro Half-Life:** Ligand B (21.406 hours) has a significantly longer in vitro half-life than Ligand A (-10.2 hours). This is a substantial advantage.
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (0.142 and 0.168).
**15. Binding Affinity:** Ligand B (-7.7 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.1 kcal/mol). This is a crucial factor, a 1.6 kcal/mol difference is substantial.
**GPCR-Specific Priorities:** For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B excels in affinity and has acceptable values for the other parameters. While BBB isn't a primary concern for a cardiovascular target, Ligand A's slightly higher BBB is not enough to offset the other advantages of Ligand B. The lower DILI risk and longer half-life of Ligand B are also very important. The Caco-2 permeability is concerning for both, but the stronger binding affinity of Ligand B makes it more likely to be effective even with reduced absorption.
**Conclusion:**
Ligand B is the more promising candidate due to its superior binding affinity, lower DILI risk, and longer half-life. These factors outweigh the slightly lower BBB penetration and worse Caco-2 permeability compared to Ligand A.
0
2025-04-17 23:55:04,510 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (352.395) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (96.87) is significantly better than Ligand A (120.67). For a GPCR, lower TPSA is preferred for better permeability.
3. **logP:** Ligand B (2.401) is optimal, while Ligand A (-0.498) is quite low, potentially hindering membrane permeability and absorption. This is a significant drawback for Ligand A.
4. **HBD:** Both have 2 HBD, which is within the acceptable range.
5. **HBA:** Both have 6 HBA, also within the acceptable range.
6. **QED:** Both ligands have good QED scores (A: 0.683, B: 0.831), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand B (83.676) has a higher DILI risk than Ligand A (51.842). This is a concern for Ligand B, but not disqualifying.
8. **BBB:** Ligand A (71.501) shows better BBB penetration than Ligand B (57.193), but BBB isn't a primary concern for ADRB2 (cardiovascular target).
9. **Caco-2:** Both have similar, poor Caco-2 permeability (-5.305 and -5.355).
10. **Solubility:** Ligand A (-1.13) has better aqueous solubility than Ligand B (-3.206).
11. **hERG:** Ligand A (0.037) has a slightly better hERG profile (lower risk) than Ligand B (0.276).
12. **Cl_mic:** Ligand B (1.569) has significantly lower microsomal clearance, indicating better metabolic stability, which is very important. Ligand A (10.35) is quite high.
13. **t1/2:** Ligand B (31.397) has a much longer in vitro half-life than Ligand A (14.534), which is highly desirable.
14. **Pgp:** Ligand A (0.006) has lower P-gp efflux, which is preferable. Ligand B (0.09) is still relatively low, but higher than A.
15. **Affinity:** Ligand A (-7.4) has a slightly better binding affinity than Ligand B (-7.1). However, the difference is less than 1.5 kcal/mol, so it's not a decisive factor.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand B excels in logP and has a much better TPSA. The slight affinity difference is outweighed by the superior ADME properties of Ligand B, particularly its metabolic stability (Cl_mic) and half-life. While Ligand A has a better solubility and lower DILI, the poor logP is a major drawback.
**Conclusion:**
Ligand B is the more promising candidate due to its favorable logP, TPSA, metabolic stability, and half-life, despite the slightly higher DILI risk. These properties are more critical for a successful GPCR drug candidate than the small differences in affinity or solubility.
Output:
0
2025-04-17 23:55:04,511 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (358.47 & 349.43 Da) are within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Both ligands (76.02 & 78.95) are below the 140 A^2 threshold for good oral absorption. They are also reasonably low, suitable for a GPCR target. No clear advantage.
3. **logP:** Ligand A (3.068) is optimal, while Ligand B (0.836) is slightly low, potentially hindering membrane permeability. Ligand A is preferred.
4. **HBD:** Both ligands have acceptable HBD counts (2 & 1). No clear advantage.
5. **HBA:** Both ligands have acceptable HBA counts (5 & 4). No clear advantage.
6. **QED:** Both ligands have good QED scores (0.885 & 0.721), indicating drug-likeness. Ligand A is slightly better.
7. **DILI:** Ligand A (77.782) has a higher DILI risk than Ligand B (32.183). Ligand B is significantly preferred here.
8. **BBB:** Ligand A (72.664) has a better BBB penetration score than Ligand B (68.437), though both are not exceptionally high. For a cardiovascular target, BBB isn't a primary concern, but it's a slight advantage for A.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.025 & -5.022), which is unusual and suggests poor permeability. This is a significant drawback for both.
10. **Solubility:** Ligand A (-4.518) has slightly worse solubility than Ligand B (-2.177). Ligand B is preferred.
11. **hERG:** Ligand A (0.465) has a lower hERG risk than Ligand B (0.131). Ligand A is preferred.
12. **Cl_mic:** Ligand B (9.283) has significantly lower microsomal clearance than Ligand A (41.028), indicating better metabolic stability. Ligand B is strongly preferred.
13. **t1/2:** Ligand B (9.589) has a longer in vitro half-life than Ligand A (74.025). Ligand B is preferred.
14. **Pgp:** Ligand A (0.507) has slightly higher P-gp efflux liability than Ligand B (0.01). Ligand B is preferred.
15. **Binding Affinity:** Ligand A (-5.9 kcal/mol) has a slightly better binding affinity than Ligand B (-4.3 kcal/mol). This is a 1.6 kcal/mol difference, which is substantial and can outweigh some ADME concerns.
**Overall Assessment & GPCR-Specific Priorities:**
For a GPCR like ADRB2, affinity, logP, and metabolic stability are key. Ligand A has a significantly better binding affinity and a more optimal logP. However, Ligand B excels in DILI risk, metabolic stability (Cl_mic and t1/2), Pgp efflux, and solubility. The Caco-2 values are concerning for both.
The difference in binding affinity (1.6 kcal/mol) is significant enough to prioritize Ligand A *despite* the higher DILI risk and poorer metabolic stability. The improved affinity is likely to translate to greater efficacy at lower doses, potentially mitigating some of the DILI concern. The slightly better BBB penetration is also a minor plus.
Output:
1
2025-04-17 23:55:04,511 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (372.487 and 342.407 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Both ligands (104.73 and 104.62) are slightly above the optimal <140 for oral absorption, but acceptable for a non-CNS GPCR target like ADRB2. Very similar.
3. **logP:** Ligand A (1.318) is slightly higher than Ligand B (0.99), both within the optimal 1-3 range. A is slightly favored.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (2), both are acceptable.
5. **HBA:** Ligand A (5) is lower than Ligand B (7). Lower HBA is generally preferred for permeability. A is favored.
6. **QED:** Both ligands have good QED scores (0.574 and 0.692), indicating good drug-like properties. B is slightly favored.
7. **DILI:** Ligand A (25.514) has a significantly lower DILI risk than Ligand B (58.24). This is a major advantage for Ligand A.
8. **BBB:** ADRB2 is primarily a cardiovascular target, so BBB penetration is not a high priority. Ligand A (53.509) is higher than Ligand B (28.461), but this is less important.
9. **Caco-2:** Ligand B (-5.746) has a higher (less negative) Caco-2 value, suggesting better intestinal absorption than Ligand A (-4.888). B is favored.
10. **Solubility:** Ligand B (-2.467) has a higher (less negative) solubility value, suggesting better aqueous solubility than Ligand A (-1.202). B is favored.
11. **hERG:** Both ligands have low hERG inhibition liability (0.493 and 0.272), which is good. B is slightly favored.
12. **Cl_mic:** Ligand B (-5.452) has a *much* lower (and therefore better) microsomal clearance than Ligand A (20.207). This suggests significantly better metabolic stability for Ligand B. B is strongly favored.
13. **t1/2:** Ligand B (38.84) has a significantly longer in vitro half-life than Ligand A (19.377). This is a major advantage for Ligand B.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.118 and 0.026). Very similar.
15. **Binding Affinity:** Ligand B (-6.3) has a slightly stronger binding affinity than Ligand A (-6.1), but the difference is small (0.2 kcal/mol).
**Overall Assessment:**
While Ligand A has a lower DILI risk and slightly better logP, Ligand B demonstrates superior ADME properties, particularly in terms of metabolic stability (Cl_mic and t1/2), solubility, and Caco-2 permeability. The slightly stronger binding affinity of Ligand B further strengthens its position. For a cardiovascular target like ADRB2, metabolic stability and good absorption are crucial, outweighing the slightly higher DILI risk of Ligand B.
Output:
0
2025-04-17 23:55:04,511 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [370.515, 67.87, 1.429, 1, 5, 0.766, 27.414, 65.839, -5.048, -2.399, 0.307, 19.906, 18.445, 0.036, -7.3]
**Ligand B:** [368.543, 78.43, 2.083, 3, 4, 0.516, 11.128, 50.756, -5.563, -2.723, 0.423, 40.612, -4.172, 0.065, -6.9]
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). A is 370.5, B is 368.5. Very similar.
2. **TPSA:** Ligand A (67.87) is better than Ligand B (78.43). We want TPSA <= 140 for oral absorption, both are well within this, but lower is preferred.
3. **logP:** Ligand A (1.429) is within the optimal range (1-3), while Ligand B (2.083) is also acceptable. A is slightly better.
4. **HBD:** Ligand A (1) is better than Ligand B (3). Lower HBD is generally preferred for permeability.
5. **HBA:** Ligand A (5) is better than Ligand B (4). Lower HBA is generally preferred for permeability.
6. **QED:** Ligand A (0.766) is significantly better than Ligand B (0.516). A higher QED indicates a more drug-like profile.
7. **DILI:** Ligand A (27.414) is *much* better than Ligand B (11.128). Lower DILI is critical.
8. **BBB:** Ligand A (65.839) is better than Ligand B (50.756). While ADRB2 isn't necessarily a CNS target, some peripheral distribution is still desired, and higher BBB penetration can indicate better overall permeability.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-5.048) is slightly better than Ligand B (-5.563).
10. **Solubility:** Both are negative, indicating poor solubility. Ligand A (-2.399) is slightly better than Ligand B (-2.723).
11. **hERG:** Both are low (0.307 and 0.423), indicating low cardiotoxicity risk. Very similar.
12. **Cl_mic:** Ligand A (19.906) is significantly better than Ligand B (40.612). Lower clearance means better metabolic stability.
13. **t1/2:** Ligand A (18.445) is better than Ligand B (-4.172). Longer half-life is desirable.
14. **Pgp:** Both are very low (0.036 and 0.065), suggesting minimal P-gp efflux. Very similar.
15. **Affinity:** Ligand A (-7.3) is *significantly* better than Ligand B (-6.9). A 0.4 kcal/mol difference in binding affinity is substantial.
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are crucial. Ligand A excels in all of these areas, particularly in affinity and DILI. While BBB isn't paramount for ADRB2, the higher value for A is a bonus.
**Conclusion:**
Ligand A is clearly the superior candidate. Its significantly better QED, DILI, metabolic stability (Cl_mic & t1/2), and, most importantly, binding affinity outweigh the slightly worse Caco-2 and solubility values. The differences in TPSA, logP, HBD, and HBA also favor Ligand A.
**Output:**
1
2025-04-17 23:55:04,511 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [366.527, 60.85, 1.597, 1, 4, 0.821, 23.769, 65.452, -4.904, -3.22, 0.631, 56.511, 3.155, 0.367, -6.0]
**Ligand B:** [348.403, 113.44, 0.623, 3, 6, 0.666, 34.548, 42.924, -5.058, -2.624, 0.085, 6.408, 8.935, 0.006, -6.6]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity, and BBB):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (348.4) is slightly lower, which could be beneficial for permeability, but both are acceptable.
2. **TPSA:** Ligand A (60.85) is significantly better than Ligand B (113.44). A TPSA under 140 is good for oral absorption, but lower is generally preferred for GPCRs, and A is much closer to the ideal <90 for CNS penetration.
3. **logP:** Ligand A (1.597) is better than Ligand B (0.623). Both are within the acceptable range (1-3), but A is closer to the optimal range. B is on the lower side, potentially hindering membrane permeability.
4. **HBD/HBA:** Ligand A (1 HBD, 4 HBA) is preferable to Ligand B (3 HBD, 6 HBA). Fewer H-bonds are generally better for permeability.
5. **QED:** Both are reasonably good (A: 0.821, B: 0.666), indicating drug-like properties. A is slightly better.
6. **DILI:** Ligand A (23.769) has a much lower DILI risk than Ligand B (34.548). This is a significant advantage for A.
7. **BBB:** Ligand A (65.452) has a substantially better BBB penetration prediction than Ligand B (42.924). This is a crucial factor for a GPCR target, even if not specifically CNS-focused, as it indicates better distribution.
8. **Caco-2:** Both are negative, indicating poor permeability. This is a concern for both, but the negative value for A is less extreme (-4.904 vs -5.058).
9. **Solubility:** Both are negative, indicating poor solubility. This is a concern for both, but the negative value for A is less extreme (-3.22 vs -2.624).
10. **hERG:** Ligand A (0.631) has a lower hERG risk than Ligand B (0.085). This is a significant advantage for A.
11. **Cl_mic:** Ligand A (56.511) has better metabolic stability (lower clearance) than Ligand B (6.408).
12. **t1/2:** Ligand B (8.935) has a longer in vitro half-life than Ligand A (3.155). This is a positive for B, but can be optimized.
13. **Pgp:** Ligand A (0.367) has lower P-gp efflux liability than Ligand B (0.006). This is a significant advantage for A, improving bioavailability.
14. **Affinity:** Ligand B (-6.6 kcal/mol) has a slightly better binding affinity than Ligand A (-6.0 kcal/mol). This is a 1.5 kcal/mol advantage, which is significant.
**Overall Assessment:**
While Ligand B has a slightly better binding affinity, Ligand A demonstrates a significantly more favorable ADME-Tox profile. The lower DILI risk, better BBB penetration, lower hERG risk, and lower P-gp efflux for Ligand A are substantial advantages, especially for a GPCR target where distribution and minimizing off-target effects are critical. The TPSA is also significantly better for Ligand A. The slightly shorter half-life of A can be addressed through further optimization. The Caco-2 and solubility are poor for both, but the values for A are less concerning.
Therefore, I would prioritize Ligand A for further development.
1
2025-04-17 23:55:04,511 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
We are targeting ADRB2, a GPCR. Therefore, the priorities are logP, Pgp, TPSA, affinity, and BBB. Let's analyze each ligand against these and other relevant parameters.
* **Molecular Weight:** Both ligands (354.793 and 366.483 Da) fall within the ideal 200-500 Da range.
* **TPSA:** Ligand A (60.45) is better than Ligand B (67.87). Both are reasonably good, but lower TPSA generally favors better absorption.
* **logP:** Ligand A (4.057) is higher than Ligand B (2.04). While both are within the acceptable range, Ligand A is approaching the upper limit, which could potentially lead to solubility issues. Ligand B is better in this regard.
* **H-Bond Donors/Acceptors:** Both have similar numbers (1 HBD, 4/5 HBA), which are acceptable.
* **QED:** Both ligands have good QED scores (0.754 and 0.802), indicating good drug-likeness.
* **DILI:** Ligand A (93.951) has a significantly higher DILI risk than Ligand B (48.623). This is a major concern for Ligand A.
* **BBB:** Ligand A (74.758) has slightly better BBB penetration than Ligand B (65.297), but both are acceptable.
* **Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and indicates poor permeability. This is a significant drawback for both.
* **Aqueous Solubility:** Ligand A (-5.636) has worse solubility than Ligand B (-2.825).
* **hERG:** Ligand A (0.692) has a slightly higher hERG risk than Ligand B (0.399), but both are relatively low.
* **Microsomal Clearance:** Ligand B (32.972) has significantly lower microsomal clearance than Ligand A (65.052), suggesting better metabolic stability.
* **In vitro Half-Life:** Ligand B (14.869) has a shorter half-life than Ligand A (41.861), but the difference isn't drastic.
* **P-gp Efflux:** Ligand A (0.47) has a lower P-gp efflux liability than Ligand B (0.144), which is favorable.
* **Binding Affinity:** Ligand B (-7.1 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.6 kcal/mol). This 0.5 kcal/mol difference is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
While Ligand A has better BBB penetration and P-gp efflux, the significantly higher DILI risk, poorer solubility, and higher metabolic clearance are major drawbacks. Ligand B, despite slightly lower BBB and P-gp values, has a much better safety profile (DILI), better metabolic stability, and, crucially, a significantly stronger binding affinity. The affinity difference is substantial enough to outweigh the minor ADME differences. The Caco-2 permeability is concerning for both, but the other factors favor Ligand B.
**Output:**
0
2025-04-17 23:55:04,511 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [354.401, 70.39, 1.948, 2, 4, 0.853, 38.813, 85.847, -4.613, -2.529, 0.291, 15.735, 10.578, 0.054, -6.8]**
**Ligand B: [352.475, 98.66, 0.811, 4, 4, 0.545, 16.479, 30.554, -5.206, -2.404, 0.216, 4.492, 16.311, 0.049, -6.1]**
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). A is 354.4, B is 352.5. No significant difference.
2. **TPSA:** Ligand A (70.39) is well below the 140 threshold and good for oral absorption. Ligand B (98.66) is still acceptable but closer to the limit. A is better.
3. **logP:** Ligand A (1.948) is optimal. Ligand B (0.811) is a bit low, potentially hindering permeation. A is better.
4. **H-Bond Donors:** Ligand A (2) is good. Ligand B (4) is acceptable, but higher. A is better.
5. **H-Bond Acceptors:** Both ligands have 4 H-bond acceptors, which is acceptable. No significant difference.
6. **QED:** Ligand A (0.853) has a better QED score than Ligand B (0.545), indicating better drug-like properties. A is better.
7. **DILI:** Ligand A (38.813) has a lower DILI risk than Ligand B (16.479). A is better.
8. **BBB:** Ligand A (85.847) has significantly higher BBB penetration potential than Ligand B (30.554). This is *very* important for a GPCR target. A is much better.
9. **Caco-2 Permeability:** Ligand A (-4.613) is worse than Ligand B (-5.206). B is better.
10. **Aqueous Solubility:** Both ligands have very poor aqueous solubility (-2.529 and -2.404 respectively). This is a concern for both, but not a deciding factor.
11. **hERG Inhibition:** Both ligands have low hERG inhibition risk (0.291 and 0.216). No significant difference.
12. **Microsomal Clearance:** Ligand A (15.735) has higher clearance than Ligand B (4.492), indicating lower metabolic stability. B is better.
13. **In vitro Half-Life:** Ligand A (10.578) has a shorter half-life than Ligand B (16.311). B is better.
14. **P-gp Efflux:** Both ligands show low P-gp efflux liability (0.054 and 0.049). No significant difference.
15. **Binding Affinity:** Ligand A (-6.8) has a slightly better binding affinity than Ligand B (-6.1). This is a 0.7 kcal/mol difference, which is significant. A is better.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand A is clearly superior. It has a better logP, TPSA, QED, DILI, and significantly better BBB penetration. While Ligand B has better Caco-2 permeability, microsomal clearance, and in vitro half-life, the improved brain penetration and binding affinity of Ligand A are more critical for a GPCR target like ADRB2. The solubility is a concern for both, but can be addressed with formulation strategies.
Output:
1
2025-04-17 23:55:04,511 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (384.929 Da) is within the ideal range (200-500 Da). Ligand B (345.531 Da) is also within range. No clear advantage here.
2. **TPSA:** Ligand A (67.43) is acceptable, though approaching the upper limit for good oral absorption. Ligand B (45.23) is excellent, well below the 140 threshold. Advantage: B.
3. **logP:** Both ligands (A: 3.397, B: 4.104) are within the optimal 1-3 range, but Ligand B is slightly higher. While higher logP can sometimes be problematic, it's not a major concern here.
4. **HBD:** Ligand A (2) and Ligand B (1) are both good, well below the 5 threshold. Slight advantage: B.
5. **HBA:** Ligand A (4) and Ligand B (3) are both good, below the 10 threshold. Slight advantage: B.
6. **QED:** Both ligands have good QED scores (A: 0.708, B: 0.809), indicating drug-likeness. Advantage: B.
7. **DILI:** Ligand A (65.374) has a higher DILI risk than Ligand B (13.339). This is a significant concern. Advantage: B.
8. **BBB:** Ligand A (58.55) is moderate, while Ligand B (84.296) is quite high. Since ADRB2 is a GPCR, BBB penetration is a consideration, though not paramount for cardiovascular targets. Advantage: B.
9. **Caco-2:** Both have negative values, indicating poor permeability. Ligand A (-5.214) is slightly worse than Ligand B (-4.802). Advantage: B.
10. **Solubility:** Both have negative solubility values, indicating poor solubility. Ligand A (-3.795) is slightly worse than Ligand B (-3.267). Advantage: B.
11. **hERG:** Ligand A (0.329) has a lower hERG risk than Ligand B (0.846). Advantage: A.
12. **Cl_mic:** Ligand A (36.411) has a lower microsomal clearance, suggesting better metabolic stability than Ligand B (53.764). Advantage: A.
13. **t1/2:** Ligand A (24.816) has a longer in vitro half-life than Ligand B (-1.33). Advantage: A.
14. **Pgp:** Ligand A (0.403) has lower P-gp efflux liability than Ligand B (0.5). Advantage: A.
15. **Affinity:** Ligand A (-6.5 kcal/mol) has a slightly better binding affinity than Ligand B (-5.9 kcal/mol). Advantage: A.
**Overall Assessment:**
Ligand B consistently performs better across several key ADME properties (TPSA, QED, DILI, BBB, Caco-2, Solubility). While Ligand A has advantages in hERG, metabolic stability (Cl_mic, t1/2), Pgp, and a slightly better binding affinity, the significantly lower DILI risk and better overall ADME profile of Ligand B are more compelling, especially considering the potential for cardiovascular side effects. The affinity difference is not substantial enough to overcome the ADME concerns with Ligand A.
Output:
0
2025-04-17 23:55:04,511 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (357.3 & 353.5 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (115.3) is higher than Ligand B (55.84). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for permeability. Ligand B is significantly better here.
3. **logP:** Ligand A (0.689) is lower than the optimal 1-3 range, potentially hindering permeability. Ligand B (3.408) is within the optimal range. This favors Ligand B.
4. **HBD:** Ligand A (2) is reasonable, while Ligand B (0) is even better, minimizing potential for off-target interactions and improving permeability.
5. **HBA:** Ligand A (8) is acceptable, while Ligand B (4) is lower and more favorable.
6. **QED:** Ligand A (0.781) has a better QED score than Ligand B (0.565), indicating a more drug-like profile.
7. **DILI:** Ligand A (72.5) has a higher DILI risk than Ligand B (15.4). This is a significant advantage for Ligand B.
8. **BBB:** Both ligands have acceptable BBB penetration (A: 68.2, B: 66.6). Since ADRB2 is not a CNS target, this isn't a major differentiating factor.
9. **Caco-2:** Ligand A (-5.069) and Ligand B (-4.687) are both negative, indicating poor permeability. However, the values are very close and don't provide a clear advantage to either.
10. **Solubility:** Ligand A (-1.871) is better than Ligand B (-3.647), which is a positive for formulation.
11. **hERG:** Ligand A (0.096) has a lower hERG risk than Ligand B (0.797). This is a crucial safety parameter, favoring Ligand A.
12. **Cl_mic:** Ligand A (9.592) has a lower microsomal clearance than Ligand B (101.292), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (9.478) has a longer in vitro half-life than Ligand B (0.997). This is a substantial advantage for Ligand A.
14. **Pgp:** Ligand A (0.025) has significantly lower P-gp efflux than Ligand B (0.542), improving bioavailability.
15. **Affinity:** Both ligands have the same binding affinity (-6.4 kcal/mol).
**Overall Assessment:**
While Ligand A has a slightly better QED and solubility, Ligand B excels in key ADME properties like logP, TPSA, DILI, and has a lower HBD/HBA count. However, Ligand A demonstrates superior metabolic stability (lower Cl_mic, longer t1/2), lower P-gp efflux, and a significantly lower hERG risk. Considering the importance of metabolic stability and safety (hERG) for a cardiovascular drug, and the substantial difference in DILI risk, Ligand A is the more promising candidate. The slightly lower logP of Ligand A is a concern, but can potentially be addressed with further optimization.
Output:
1
2025-04-17 23:55:04,512 - INFO - Batch 439 complete. Total preferences: 7024
2025-04-17 23:55:04,512 - INFO - Processing batch 440/512...
2025-04-17 23:55:53,256 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.41 and 347.419 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (95.16 and 97.61) are below the 140 A^2 threshold for good oral absorption, but not optimized for CNS penetration (ideally <90 A^2). Again, similar.
3. **logP:** Ligand A (1.838) is slightly higher than Ligand B (0.936), placing it more centrally within the optimal 1-3 range. Ligand B is a bit low, potentially impacting permeability.
4. **HBD:** Both have 2 HBD, which is good.
5. **HBA:** Ligand A has 4 HBA, while Ligand B has 6. Both are acceptable (<=10), but Ligand A is slightly preferred.
6. **QED:** Ligand A (0.698) is slightly better than Ligand B (0.8), indicating a more drug-like profile.
7. **DILI:** Ligand B (38.348) has a significantly lower DILI risk than Ligand A (60.489). This is a major advantage for Ligand B.
8. **BBB:** Ligand A (54.13) has a slightly higher BBB penetration percentile than Ligand B (45.638), but both are not high enough to be considered CNS-optimized. Given ADRB2 is primarily a cardiovascular target, BBB isn't a major priority, but a slight edge to A.
9. **Caco-2:** Both have negative Caco-2 values (-5.009 and -5.22). This is unusual and suggests poor permeability.
10. **Solubility:** Both have negative solubility values (-1.949 and -1.455), suggesting poor aqueous solubility.
11. **hERG:** Ligand A (0.075) has a slightly lower hERG inhibition liability than Ligand B (0.138), which is favorable.
12. **Cl_mic:** Ligand B (-9.072) has a *much* lower microsomal clearance than Ligand A (32.464). This indicates significantly better metabolic stability for Ligand B, a critical factor for drug duration and dosing.
13. **t1/2:** Ligand B (17.806) has a significantly longer in vitro half-life than Ligand A (-6.193). This further supports the better metabolic stability of Ligand B.
14. **Pgp:** Both have very low Pgp efflux liability (0.046 and 0.03).
15. **Binding Affinity:** Ligand A (-7.5 kcal/mol) has a slightly better binding affinity than Ligand B (-6.7 kcal/mol). This is a 0.8 kcal/mol difference, which is a meaningful but not overwhelming advantage.
**Overall Assessment:**
While Ligand A has a slightly better affinity and a marginally better BBB score, Ligand B is significantly superior in terms of safety (DILI), metabolic stability (Cl_mic, t1/2), and has a reasonable logP. The poor Caco-2 and solubility for both are concerning, but can potentially be addressed with formulation strategies. The improved metabolic stability of Ligand B is a major advantage for a GPCR target, as it suggests a longer duration of action and potentially lower dosing requirements. The lower DILI risk is also a significant factor. The affinity difference is not large enough to overcome these advantages.
Output:
0
2025-04-17 23:55:53,257 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [357.483, 70.15, 2.106, 2, 6, 0.854, 35.479, 66.615, -5.586, -1.41, 0.485, -20.144, 34.298, 0.038, -5.5]
**Ligand B:** [349.391, 92.55, -0.115, 1, 9, 0.805, 68.166, 61.225, -5.475, -2.196, 0.077, 1.005, 31.965, 0.033, -6.3]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, Affinity):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (349.391) is slightly lower, which isn't a major concern.
2. **TPSA:** Ligand A (70.15) is better than Ligand B (92.55). Below 140 is good for oral absorption, both are, but lower is preferred.
3. **logP:** Ligand A (2.106) is optimal (1-3). Ligand B (-0.115) is quite low, potentially hindering permeability. This is a significant drawback.
4. **HBD/HBA:** Ligand A (2 HBD, 6 HBA) is better balanced. Ligand B (1 HBD, 9 HBA) has a higher HBA count, which could impact permeability.
5. **QED:** Both are good (>=0.5), with Ligand A (0.854) being slightly better than Ligand B (0.805).
6. **DILI:** Ligand A (35.479) has a much lower DILI risk than Ligand B (68.166). This is a substantial advantage.
7. **BBB:** Ligand A (66.615) is better than Ligand B (61.225), though neither is exceptionally high. For a non-CNS target like ADRB2, this isn't a primary concern, but still a slight advantage for A.
8. **Caco-2:** Both are negative, indicating poor permeability.
9. **Solubility:** Both are negative, indicating poor solubility.
10. **hERG:** Both are very low, indicating minimal hERG inhibition risk.
11. **Cl_mic:** Ligand A (-20.144) has a much lower (better) clearance than Ligand B (1.005), suggesting better metabolic stability.
12. **t1/2:** Ligand A (34.298) has a slightly longer half-life than Ligand B (31.965).
13. **Pgp:** Both are very low, indicating minimal P-gp efflux.
14. **Affinity:** Ligand B (-6.3) has a slightly better binding affinity than Ligand A (-5.5). However, the difference is less than 1.5 kcal/mol, and can be offset by other factors.
**Overall Assessment:**
Ligand A is significantly better overall. The biggest issues with Ligand B are its low logP and high DILI risk. While Ligand B has slightly better affinity, the other ADME properties of Ligand A are far more favorable, particularly the logP, DILI, and metabolic stability (Cl_mic). For a cardiovascular target like ADRB2, metabolic stability and minimizing off-target effects (DILI) are crucial.
Output:
1
2025-04-17 23:55:53,257 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for the ADRB2, a cardiovascular GPCR. Therefore, key properties to prioritize are logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB (though less critical for a cardiovascular target).
Let's compare the ligands property by property:
1. **MW:** Both ligands (341.346 and 352.431 Da) are within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (92.93) is better than Ligand B (99.1), both are acceptable but A is closer to the <140 threshold.
3. **logP:** Ligand A (1.927) is optimal (1-3), while Ligand B (-0.345) is quite low, potentially hindering permeability. This is a significant drawback for Ligand B.
4. **HBD/HBA:** Ligand A (2 HBD, 6 HBA) is slightly better than Ligand B (3 HBD, 5 HBA) in terms of balancing solubility and permeability.
5. **QED:** Ligand A (0.74) is better than Ligand B (0.568), indicating a more drug-like profile.
6. **DILI:** Ligand B (25.824) has a much lower DILI risk than Ligand A (74.254). This is a substantial advantage for Ligand B.
7. **BBB:** Ligand A (47.809) is better than Ligand B (24.002), but BBB is not a primary concern for a cardiovascular target.
8. **Caco-2:** Ligand A (-5.169) and Ligand B (-4.981) are both very poor, indicating poor intestinal absorption.
9. **Solubility:** Ligand A (-2.851) is better than Ligand B (-0.95), indicating better aqueous solubility.
10. **hERG:** Both ligands (0.075 and 0.067) have very low hERG risk, which is excellent.
11. **Cl_mic:** Ligand B (-15.082) has significantly lower (better) microsomal clearance than Ligand A (75.585), suggesting better metabolic stability.
12. **t1/2:** Ligand B (-8.813) has a slightly better in vitro half-life than Ligand A (-35.05), but both are negative values which is unusual.
13. **Pgp:** Ligand A (0.187) has lower P-gp efflux than Ligand B (0.014), which is preferable.
14. **Binding Affinity:** Ligand B (-6.6 kcal/mol) has a slightly better binding affinity than Ligand A (-5.6 kcal/mol). This is a meaningful difference.
**Overall Assessment:**
Ligand B has a significantly better DILI score and metabolic stability (Cl_mic). It also has a slightly better binding affinity. However, its logP is quite low, which is a major concern for permeability. Ligand A has a more optimal logP, better solubility, and lower P-gp efflux, but suffers from a higher DILI risk and poorer metabolic stability.
Considering the GPCR-specific priorities, the binding affinity difference and the substantially lower DILI risk of Ligand B are compelling. While the low logP is a drawback, it might be addressable through further medicinal chemistry optimization. The higher DILI risk of Ligand A is a more difficult problem to solve later in development.
**Output:**
0
2025-04-17 23:55:53,257 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (352.41 Da and 366.845 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Both ligands have TPSA values around 74 (A: 74.57, B: 73.99), which is acceptable for a non-CNS GPCR target like ADRB2.
**3. logP:** Ligand A (1.666) is slightly lower than Ligand B (2.298), but both are within the optimal 1-3 range.
**4. H-Bond Donors:** Ligand A has 0 HBD, while Ligand B has 1. Both are acceptable, with lower being generally preferred for permeability.
**5. H-Bond Acceptors:** Ligand A has 5 HBA, and Ligand B has 4. Both are within the acceptable limit of 10.
**6. QED:** Both ligands have good QED scores (A: 0.775, B: 0.89), indicating good drug-like properties. Ligand B is slightly better.
**7. DILI:** Both ligands have relatively low DILI risk (A: 40.403, B: 43.35), falling below the concerning threshold of 60.
**8. BBB:** This is less critical for a cardiovascular target, but Ligand A (92.943) has a higher BBB penetration percentile than Ligand B (77.898).
**9. Caco-2 Permeability:** Ligand A (-4.63) and Ligand B (-5.01) both have negative Caco-2 values, indicating poor permeability. This is a concern for both.
**10. Aqueous Solubility:** Both ligands have poor aqueous solubility (A: -2.637, B: -2.934). This could pose formulation challenges.
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (A: 0.358, B: 0.429). This is excellent.
**12. Microsomal Clearance:** Ligand A (15.901) has a significantly lower (better) microsomal clearance than Ligand B (-3.017). This suggests greater metabolic stability for Ligand A.
**13. In vitro Half-Life:** Ligand A (11.271) has a shorter half-life than Ligand B (52.125). This is a significant advantage for Ligand B.
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (A: 0.07, B: 0.168).
**15. Binding Affinity:** Ligand B (-7.3 kcal/mol) has a substantially stronger binding affinity than Ligand A (-5.2 kcal/mol). This is a >2 kcal/mol difference, which is a major advantage.
**Overall Assessment:**
The key differentiator is the binding affinity. Ligand B's significantly stronger binding (-7.3 kcal/mol vs -5.2 kcal/mol) is a substantial advantage that outweighs its slightly worse metabolic stability (higher Cl_mic) and solubility. While Ligand A has better metabolic stability and BBB penetration, the potency difference is too large to ignore for a GPCR target. The permeability issues are similar for both, and the hERG risk is low for both.
Output:
0
2025-04-17 23:55:53,257 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [344.386, 67.43, 3.285, 2, 3, 0.845, 75.378, 61.225, -4.612, -4.463, 0.712, 65.841, 14.14, 0.392, -6.5]
**Ligand B:** [360.527, 68.16, 4.094, 2, 4, 0.849, 35.673, 88.29, -5.074, -4.169, 0.917, 17.764, 41.135, 0.485, -6.4]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (344.386) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are reasonably good (67.43 and 68.16), below the 140 threshold for oral absorption.
3. **logP:** Ligand A (3.285) is optimal, while Ligand B (4.094) is approaching the upper limit. Higher logP can sometimes lead to off-target effects and solubility issues.
4. **HBD/HBA:** Both have acceptable HBD (2) and HBA (3/4) counts.
5. **QED:** Both have good QED scores (0.845 and 0.849), indicating good drug-like properties.
6. **DILI:** Ligand A (75.378) has a significantly higher DILI risk than Ligand B (35.673). This is a major concern.
7. **BBB:** Ligand B (88.29) has a much better BBB penetration score than Ligand A (61.225). While ADRB2 isn't exclusively a CNS target, some cardiovascular effects are mediated by central pathways, and better BBB penetration can be beneficial.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand B (-5.074) is worse than Ligand A (-4.612).
9. **Solubility:** Both have negative solubility values, indicating poor aqueous solubility. Ligand B (-4.169) is slightly better than Ligand A (-4.463).
10. **hERG:** Both have low hERG inhibition risk (0.712 and 0.917).
11. **Cl_mic:** Ligand B (17.764) has a significantly lower microsomal clearance than Ligand A (65.841), indicating better metabolic stability.
12. **t1/2:** Ligand B (41.135) has a much longer in vitro half-life than Ligand A (14.14). This is a significant advantage.
13. **Pgp:** Both have low P-gp efflux liability (0.392 and 0.485).
14. **Binding Affinity:** Both have very similar binding affinities (-6.5 and -6.4 kcal/mol). The difference is negligible.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. BBB is less critical but still a consideration. Metabolic stability (Cl_mic and t1/2) is also important.
**Overall Assessment:**
While Ligand A has a slightly better logP and Caco-2 permeability, the significantly higher DILI risk and poorer metabolic stability (higher Cl_mic, shorter t1/2) are major drawbacks. Ligand B, despite a slightly higher logP, has a much lower DILI risk, better BBB penetration, and significantly improved metabolic stability. The binding affinity is essentially the same. Given these factors, Ligand B is the more promising candidate.
Output:
0
2025-04-17 23:55:53,257 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [356.813, 68.92, 3.284, 1, 5, 0.783, 83.637, 79.217, -4.438, -4.735, 0.642, 41.083, 25.217, 0.222, -3.7]**
**Ligand B: [349.431, 95.67, 1.705, 2, 5, 0.523, 30.865, 46.336, -4.888, -1.529, 0.308, 27.453, -17.207, 0.074, -6.1]**
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (356.813) is slightly higher than Ligand B (349.431), but both are acceptable.
2. **TPSA:** Ligand A (68.92) is significantly better than Ligand B (95.67). ADRB2 is not a CNS target, but lower TPSA generally improves permeability.
3. **logP:** Ligand A (3.284) is optimal, while Ligand B (1.705) is at the lower end of the optimal range. This favors Ligand A for membrane permeability.
4. **H-Bond Donors:** Ligand A (1) is better than Ligand B (2). Fewer HBDs generally improve permeability.
5. **H-Bond Acceptors:** Both ligands have the same number of HBA (5), which is acceptable.
6. **QED:** Ligand A (0.783) has a better QED score than Ligand B (0.523), indicating a more drug-like profile.
7. **DILI:** Ligand A (83.637) has a significantly higher DILI risk than Ligand B (30.865). This is a major concern for Ligand A.
8. **BBB:** Not a primary concern for ADRB2, but Ligand A (79.217) has a higher BBB penetration than Ligand B (46.336).
9. **Caco-2 Permeability:** Both are negative, indicating poor permeability. Ligand B (-4.888) is slightly worse than Ligand A (-4.438).
10. **Aqueous Solubility:** Ligand B (-1.529) is better than Ligand A (-4.735).
11. **hERG Inhibition:** Ligand A (0.642) has a slightly higher hERG risk than Ligand B (0.308), but both are relatively low.
12. **Microsomal Clearance:** Ligand A (41.083) has higher clearance than Ligand B (27.453), indicating lower metabolic stability.
13. **In vitro Half-Life:** Ligand B (-17.207) has a much longer half-life than Ligand A (25.217). This is a significant advantage for Ligand B.
14. **P-gp Efflux:** Ligand A (0.222) has lower P-gp efflux than Ligand B (0.074), which is favorable.
15. **Binding Affinity:** Ligand B (-6.1) has a significantly stronger binding affinity than Ligand A (-3.7). This is a substantial advantage.
**Overall Assessment:**
Ligand B is the better candidate despite the slightly lower logP and Caco-2 permeability. The significantly stronger binding affinity (-6.1 vs -3.7 kcal/mol) is a major advantage that can outweigh some of the ADME drawbacks. Furthermore, the much lower DILI risk (30.865 vs 83.637) and longer half-life (-17.207 vs 25.217) are critical advantages. While Ligand A has better TPSA and P-gp efflux, the DILI and affinity issues are too significant to ignore.
Output:
0
2025-04-17 23:55:53,257 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (379.833 Da) is slightly higher than Ligand B (349.391 Da), but both are acceptable.
2. **TPSA:** Ligand A (106.73) is better than Ligand B (129.88). For a GPCR, lower TPSA is generally preferred for better permeability, and Ligand A is closer to the <140 threshold.
3. **logP:** Ligand A (0.909) is within the optimal range (1-3), while Ligand B (0.002) is quite low, potentially hindering permeation. This is a significant advantage for Ligand A.
4. **HBD:** Both ligands have acceptable HBD counts (Ligand A: 2, Ligand B: 3).
5. **HBA:** Both ligands have acceptable HBA counts (Ligand A: 8, Ligand B: 5).
6. **QED:** Both ligands have good QED scores (Ligand A: 0.515, Ligand B: 0.639), indicating reasonable drug-likeness. Ligand B is slightly better here.
7. **DILI:** Ligand A (98.604) has a very high DILI risk, which is a major concern. Ligand B (36.293) has a much lower and acceptable DILI risk. This is a significant advantage for Ligand B.
8. **BBB:** Both ligands have moderate BBB penetration (Ligand A: 53.47, Ligand B: 57.193). Since ADRB2 is a cardiovascular target, BBB penetration is not a primary concern, but higher is slightly better.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability.
10. **Solubility:** Both ligands have negative solubility values, indicating poor solubility.
11. **hERG:** Both ligands have very low hERG inhibition liability (Ligand A: 0.058, Ligand B: 0.138), which is good.
12. **Cl_mic:** Ligand A (44.483) has a higher microsomal clearance than Ligand B (10.483), suggesting lower metabolic stability. Ligand B is significantly better here.
13. **t1/2:** Ligand A (31.486) has a longer in vitro half-life than Ligand B (-6.483). This is a positive for Ligand A.
14. **Pgp:** Both ligands have low P-gp efflux liability (Ligand A: 0.124, Ligand B: 0.037). Ligand B is slightly better.
15. **Binding Affinity:** Ligand A (-7.6 kcal/mol) has a slightly better binding affinity than Ligand B (-7.2 kcal/mol). While the difference is not huge, it is a factor.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand A excels in affinity and has a better logP and TPSA. However, the extremely high DILI risk associated with Ligand A is a critical drawback. Ligand B has a much better safety profile (DILI) and metabolic stability (Cl_mic), which are crucial for drug development.
**Conclusion:**
Despite Ligand A's slightly better affinity, the significantly higher DILI risk and poorer metabolic stability make it a less desirable candidate. Ligand B, with its lower DILI risk, better metabolic stability, and acceptable affinity, is the more promising drug candidate.
Output:
0
2025-04-17 23:55:53,257 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands (350.463 and 369.531 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (76.46) is better than Ligand B (80.32). Both are below the 140 threshold for oral absorption, but lower is preferred for GPCRs.
3. **logP:** Ligand A (2.258) is optimal (1-3), while Ligand B (3.553) is approaching the upper limit. Higher logP can lead to off-target effects and solubility issues.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Both ligands have 5 HBA, which is acceptable (<=10).
6. **QED:** Ligand A (0.904) is significantly better than Ligand B (0.661), indicating a more drug-like profile.
7. **DILI:** Both ligands have low DILI risk (Ligand A: 38.309, Ligand B: 36.293), below the 40 threshold.
8. **BBB:** Both ligands have good BBB penetration (Ligand A: 70.027, Ligand B: 72.237), exceeding the 70% threshold.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.707 and -4.801). This is unusual and suggests poor permeability. However, the values are very similar.
10. **Solubility:** Ligand A (-1.573) is better than Ligand B (-3.853). Higher solubility is crucial for bioavailability.
11. **hERG:** Ligand A (0.179) has a much lower hERG inhibition liability than Ligand B (0.596). This is a critical advantage, minimizing cardiotoxicity risk.
12. **Cl_mic:** Ligand A (23.158) has a much lower microsomal clearance than Ligand B (79.259), indicating better metabolic stability.
13. **t1/2:** Ligand B (53.336) has a significantly longer in vitro half-life than Ligand A (-1.187). This is a positive attribute.
14. **Pgp:** Ligand A (0.048) has lower P-gp efflux liability than Ligand B (0.211), which is beneficial for bioavailability and potential CNS exposure.
15. **Binding Affinity:** Ligand B (-6.6) has a slightly better binding affinity than Ligand A (-6.1), a difference of 0.5 kcal/mol. While affinity is important, other factors can outweigh a small difference.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has a better logP and TPSA, and Pgp efflux liability. Ligand B has a slightly better affinity, but the difference isn't substantial enough to overcome the other advantages of Ligand A. The significantly better QED, solubility, lower hERG risk, and lower Cl_mic of Ligand A make it a more promising candidate. The longer half-life of Ligand B is a plus, but can be addressed through formulation or structural modifications.
**Output:**
1
2025-04-17 23:55:53,257 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (373.243) is slightly higher than Ligand B (348.447), but both are acceptable.
2. **TPSA:** Ligand A (59.81) is significantly better than Ligand B (76.46). For a GPCR, lower TPSA is generally preferred for better permeability. Ligand B is approaching a level that could hinder absorption.
3. **logP:** Ligand A (4.244) is higher than Ligand B (1.034). While logP > 4 can be problematic, it's not a hard cutoff. Ligand B's logP is quite low, potentially impacting membrane permeability.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 5 HBA. Both are acceptable, below the threshold of 10.
6. **QED:** Both ligands have good QED scores (A: 0.696, B: 0.761), indicating good drug-like properties.
7. **DILI:** Ligand A (79.643) has a significantly higher DILI risk than Ligand B (18.728). This is a major concern for Ligand A.
8. **BBB:** Both ligands have similar BBB penetration (A: 67.701, B: 68.864). While not CNS-focused for ADRB2, it's a neutral point.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests a potential issue with the data or the compounds themselves. However, the values are similar (-4.691 and -4.923).
10. **Solubility:** Ligand A (-5.138) has worse solubility than Ligand B (-1.361). This could present formulation challenges.
11. **hERG:** Both ligands have very low hERG risk (A: 0.385, B: 0.172). This is excellent.
12. **Cl_mic:** Ligand A (53.853) has better metabolic stability (lower clearance) than Ligand B (14.325).
13. **t1/2:** Ligand A (42.629) has a longer half-life than Ligand B (10.976). This is desirable.
14. **Pgp:** Both ligands have very low Pgp efflux liability (A: 0.114, B: 0.016). This is good.
15. **Affinity:** Ligand B (-6.7 kcal/mol) has a slightly better binding affinity than Ligand A (-6.0 kcal/mol). The difference is 0.7 kcal/mol, which is significant but not overwhelming.
**GPCR-Specific Priorities & Overall Assessment:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, and affinity. Ligand A has a higher logP and better metabolic stability, but its TPSA is higher, solubility is worse, and DILI risk is significantly elevated. Ligand B has a lower logP but a much better safety profile (DILI) and better solubility. The affinity difference is not large enough to overcome the safety concerns with Ligand A. While the low logP of Ligand B is a slight drawback, it is less concerning than the high DILI risk of Ligand A.
**Output:**
0
2025-04-17 23:55:53,257 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (344.419 and 348.447 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (103.01) is higher than Ligand B (74.77). For a cardiovascular GPCR, TPSA isn't *as* critical as for CNS targets, but lower is generally preferred for absorption. Ligand B has a clear advantage.
3. **logP:** Ligand B (1.288) is slightly better than Ligand A (0.805), falling more squarely within the optimal 1-3 range. Ligand A is a little low, potentially impacting permeability.
4. **HBD:** Ligand B (1) has fewer H-bond donors than Ligand A (3). Fewer donors are generally preferred for better permeability. Ligand B is better.
5. **HBA:** Both ligands have the same number of H-bond acceptors (5), which is within the acceptable limit of 10.
6. **QED:** Both ligands have good QED scores (0.689 and 0.728), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand B (13.998) has a significantly lower DILI risk than Ligand A (25.165). This is a major advantage for Ligand B.
8. **BBB:** Ligand B (83.288) has a much higher BBB penetration percentile than Ligand A (34.548). While ADRB2 isn't exclusively a CNS target, some CNS exposure can occur, and higher BBB is generally favorable.
9. **Caco-2:** Ligand A (-5.806) has a more negative Caco-2 value, suggesting *lower* permeability than Ligand B (-4.563). This is a negative for Ligand A.
10. **Solubility:** Ligand A (-1.249) has slightly better solubility than Ligand B (-0.959). Solubility is important, but not the primary concern here.
11. **hERG:** Both ligands have low hERG inhibition risk (0.242 and 0.305). No significant difference.
12. **Cl_mic:** Ligand A (-20.093) has a much lower (better) microsomal clearance than Ligand B (38.143), indicating greater metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand B (14.77) has a slightly longer in vitro half-life than Ligand A (11.455). This is a minor advantage for Ligand B.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.01 and 0.005). No significant difference.
15. **Binding Affinity:** Ligand A (-6.3) has a slightly better binding affinity than Ligand B (-5.4). This is a 0.9 kcal/mol difference, which is substantial.
**Overall Assessment:**
Ligand A has a better binding affinity and metabolic stability. However, Ligand B excels in several crucial ADME properties: lower DILI risk, significantly better BBB penetration, better TPSA, fewer HBDs, and better Caco-2 permeability. Considering ADRB2 is a cardiovascular target (not primarily CNS), the BBB isn't paramount, but the lower DILI risk and improved permeability of Ligand B are compelling. The 0.9 kcal/mol difference in binding affinity can potentially be overcome with further optimization of Ligand B, while the ADME advantages are more difficult to improve later in development.
Therefore, I favor Ligand B.
Output:
0
2025-04-17 23:55:53,258 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (421.259 Da) is within the ideal range, while Ligand B (348.407 Da) is slightly below, but still acceptable.
2. **TPSA:** Ligand A (71.06) is excellent, well below the 140 threshold. Ligand B (100.43) is still reasonable, but less optimal.
3. **logP:** Ligand A (3.502) is optimal. Ligand B (-1.055) is significantly low, which could hinder membrane permeability.
4. **HBD:** Ligand A (0) is ideal. Ligand B (1) is acceptable.
5. **HBA:** Ligand A (6) is good. Ligand B (7) is also acceptable.
6. **QED:** Both ligands have good QED scores (A: 0.473, B: 0.728), with B being better.
7. **DILI:** Ligand A (55.68) is better than Ligand B (44.63), indicating a lower risk of liver injury.
8. **BBB:** Ligand A (74.99) is good, while Ligand B (52.074) is lower. While ADRB2 isn't exclusively a CNS target, some peripheral effects are mediated by CNS pathways, so moderate BBB penetration isn't detrimental.
9. **Caco-2:** Ligand A (-4.138) is poor, while Ligand B (-5.301) is even worse. Both are problematic for oral absorption.
10. **Solubility:** Ligand A (-4.582) is poor, while Ligand B (-0.766) is slightly better, but still not great.
11. **hERG:** Ligand A (0.664) is much better than Ligand B (0.029). This is a critical safety parameter, and B's value raises a red flag.
12. **Cl_mic:** Ligand A (117.577) is higher than Ligand B (20.859), indicating faster metabolism and lower stability.
13. **t1/2:** Ligand A (14.163) is significantly better than Ligand B (-17.184).
14. **Pgp:** Ligand A (0.309) is better than Ligand B (0.005), suggesting lower efflux.
15. **Affinity:** Ligand B (-8.8 kcal/mol) has a significantly stronger binding affinity than Ligand A (-4.5 kcal/mol). This is a substantial advantage.
**GPCR-specific considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B excels in affinity, but suffers from a very low logP and poor solubility. Ligand A has a better logP and acceptable TPSA, but its affinity is considerably weaker. The hERG risk for Ligand B is also concerning.
**Overall Assessment:**
While Ligand B's affinity is highly attractive, its poor logP, solubility, and concerning hERG liability are significant drawbacks. The strong affinity *might* be overcome with formulation strategies, but the hERG risk is a major safety concern. Ligand A, while having weaker affinity, presents a more balanced profile with better ADME properties and a much lower safety risk. The difference in affinity (4.3 kcal/mol) is substantial, but not insurmountable with further optimization.
Therefore, I believe Ligand A is the more viable starting point for drug development, despite its weaker binding.
Output:
1
2025-04-17 23:55:53,258 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (346.431 Da) is well within the ideal range (200-500 Da). Ligand B (403.328 Da) is also acceptable, but closer to the upper limit.
2. **TPSA:** Ligand A (76.46) is good, well below the 140 threshold for oral absorption. Ligand B (58.87) is even better, suggesting potentially improved absorption.
3. **logP:** Ligand A (0.965) is slightly below the optimal range of 1-3, which *could* indicate permeability issues, but isn't a major concern. Ligand B (3.283) is within the optimal range.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 5 HBA, within the acceptable limit. Ligand B has 6 HBA, also acceptable.
6. **QED:** Both ligands have good QED scores (A: 0.779, B: 0.853), indicating good drug-like properties.
7. **DILI:** Both ligands have similar, acceptable DILI risk (A: 45.173, B: 47.383), both below the 60 threshold.
8. **BBB:** Ligand B (83.017) has significantly better BBB penetration than Ligand A (65.374). This is a key consideration for a GPCR target, even a cardiovascular one, as some CNS off-target effects are always a possibility.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.082 and -5.073), which is unusual and difficult to interpret without further context. It suggests poor permeability *in vitro*, but these values are often unreliable.
10. **Solubility:** Ligand A (-1.186) has slightly better aqueous solubility than Ligand B (-2.906).
11. **hERG:** Both ligands have very low hERG risk (A: 0.166, B: 0.64), which is excellent.
12. **Cl_mic:** Ligand A (2.928) has significantly lower microsomal clearance than Ligand B (27.401), indicating better metabolic stability. This is a major advantage.
13. **t1/2:** Ligand A (6.32) has a shorter in vitro half-life than Ligand B (37.767). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.03) has much lower P-gp efflux liability than Ligand B (0.397), which is favorable for bioavailability.
15. **Affinity:** Ligand A (-6.8 kcal/mol) has slightly better binding affinity than Ligand B (-6.5 kcal/mol). While the difference is not huge, it's a factor.
**Overall Assessment:**
Ligand B excels in BBB penetration and *in vitro* half-life, both important for a GPCR. However, it suffers from higher P-gp efflux and significantly higher microsomal clearance. Ligand A has better metabolic stability (lower Cl_mic), lower P-gp efflux, and slightly better binding affinity, but its BBB penetration is lower. The difference in affinity is not substantial enough to overcome the ADME advantages of Ligand B. Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), and the fact that ADRB2 is not a primary CNS target, the improved metabolic stability and P-gp profile of Ligand A are more important.
Output:
1
2025-04-17 23:55:53,258 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (337.423 Da) is well within the ideal range (200-500 Da). Ligand B (361.402 Da) is also acceptable. No clear advantage here.
2. **TPSA:** Ligand A (54.46) is excellent, well below the 140 threshold for good absorption. Ligand B (92.93) is higher, but still potentially acceptable, although less ideal. Ligand A is preferred.
3. **logP:** Ligand A (3.819) is at the upper end of the optimal range (1-3), but still acceptable. Ligand B (2.72) is well within the optimal range. Ligand B is slightly preferred here.
4. **HBD:** Ligand A (1) is good. Ligand B (2) is also acceptable, but slightly less desirable. Ligand A is preferred.
5. **HBA:** Ligand A (4) is good. Ligand B (7) is higher, potentially impacting permeability. Ligand A is preferred.
6. **QED:** Both ligands have similar QED values (A: 0.921, B: 0.701), both indicating good drug-likeness. No significant difference.
7. **DILI:** Ligand A (62.35) has a moderate DILI risk, but is still acceptable. Ligand B (89.066) has a significantly higher DILI risk, which is concerning. Ligand A is strongly preferred.
8. **BBB:** Ligand A (77.239) shows good BBB penetration, which is beneficial for a GPCR target. Ligand B (19.038) has very poor predicted BBB penetration. Ligand A is strongly preferred.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests potential issues with permeability prediction. However, a more negative value generally suggests lower permeability. Ligand A (-4.403) is slightly better than Ligand B (-5.235).
10. **Solubility:** Ligand A (-5.204) has poor predicted solubility. Ligand B (-2.698) has better predicted solubility. Ligand B is preferred.
11. **hERG:** Ligand A (0.715) has a low hERG risk. Ligand B (0.025) has a very low hERG risk. Ligand B is preferred.
12. **Cl_mic:** Ligand A (76.928) has a moderate clearance, indicating reasonable metabolic stability. Ligand B (-5.858) has negative clearance, which is not physically possible and suggests a problem with the prediction. This is a major red flag for Ligand B.
13. **t1/2:** Ligand A (38.336) has a reasonable in vitro half-life. Ligand B (-9.78) has a negative half-life, which is not physically possible and is a major red flag.
14. **Pgp:** Ligand A (0.431) has low P-gp efflux. Ligand B (0.034) has very low P-gp efflux. Ligand B is preferred.
15. **Affinity:** Ligand A (-7.5 kcal/mol) has a slightly better binding affinity than Ligand B (-6.3 kcal/mol). This difference is significant.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are particularly important. Ligand A excels in TPSA, Pgp, and has slightly better affinity. Ligand B has a better logP and hERG. However, the significant issues with DILI, BBB, clearance, and half-life for Ligand B outweigh these advantages.
**Conclusion:**
Despite Ligand B having some favorable properties (logP, hERG, Pgp), the extremely unfavorable predictions for DILI, BBB penetration, clearance, and half-life make it a very poor candidate. Ligand A, while not perfect (solubility is a concern), is significantly better overall, particularly considering the GPCR-specific priorities and the critical need for reasonable ADME properties. The better affinity of Ligand A further solidifies this choice.
Output:
1
2025-04-17 23:55:53,258 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
The target is ADRB2, a GPCR. Therefore, I will prioritize logP, TPSA, Pgp efflux, BBB penetration, and binding affinity, alongside general drug-like properties.
**Ligand A:**
* **MW:** 354.451 Da - Acceptable.
* **TPSA:** 105.48 - Borderline. Slightly high, potentially impacting permeability, but not a deal-breaker.
* **logP:** 0.236 - Low. This is a significant drawback. Low logP often leads to poor membrane permeability and bioavailability.
* **HBD:** 3 - Good.
* **HBA:** 6 - Good.
* **QED:** 0.589 - Good.
* **DILI:** 27.026 - Excellent. Very low risk.
* **BBB:** 29.12 - Low. Not a major concern for a non-CNS target like ADRB2, but not ideal.
* **Caco-2:** -5.194 - Very poor permeability. Consistent with the low logP.
* **Solubility:** -1.714 - Poor solubility. Consistent with the low logP.
* **hERG:** 0.082 - Very low risk. Excellent.
* **Cl_mic:** 36.056 - Moderate. Not ideal, but manageable.
* **t1/2:** 7.181 - Moderate.
* **Pgp:** 0.029 - Low efflux. Good.
* **Affinity:** -5.8 kcal/mol - Good.
**Ligand B:**
* **MW:** 356.499 Da - Acceptable.
* **TPSA:** 59.73 - Excellent. Well within the ideal range for good absorption.
* **logP:** 3.011 - Excellent. Optimal for permeability and bioavailability.
* **HBD:** 0 - Good.
* **HBA:** 7 - Good.
* **QED:** 0.621 - Good.
* **DILI:** 49.593 - Moderate. Acceptable, but higher than Ligand A.
* **BBB:** 62.311 - Moderate. Not a primary concern for ADRB2.
* **Caco-2:** -5.627 - Poor permeability.
* **Solubility:** -2.659 - Poor solubility.
* **hERG:** 0.578 - Moderate risk. Higher than Ligand A.
* **Cl_mic:** 33.099 - Good. Lower clearance, indicating better metabolic stability.
* **t1/2:** 31.626 - Excellent. Long half-life.
* **Pgp:** 0.208 - Moderate efflux.
* **Affinity:** -6.7 kcal/mol - Excellent. 0.9 kcal/mol better than Ligand A.
**Comparison and Decision:**
Ligand B has a significantly better logP and TPSA, which are crucial for GPCR ligands. While its DILI and hERG risks are slightly higher, the substantially improved binding affinity (-6.7 vs -5.8 kcal/mol) and longer half-life outweigh these concerns. Ligand A's extremely low logP and resulting poor permeability and solubility are major drawbacks. The higher affinity of Ligand B provides a significant advantage that can compensate for the slightly less favorable ADME properties.
**Output:**
0
2025-04-17 23:55:53,258 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
The target is ADRB2, a GPCR. Therefore, priorities are logP, TPSA, Pgp, BBB, and affinity. We also need to consider general drug-like properties and safety.
**Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (345.443 Da) is slightly lower than Ligand B (351.403 Da), which is not a significant difference.
**TPSA:** Ligand A (90.27) is better than Ligand B (104.9). Both are below 140, but A is closer to the optimal range for good absorption and potentially better for GPCRs.
**logP:** Ligand A (1.649) is better than Ligand B (0.571). Ligand B is a bit low, potentially hindering membrane permeability.
**H-Bond Donors/Acceptors:** Ligand A (1 HBD, 4 HBA) is preferable to Ligand B (2 HBD, 6 HBA). Fewer H-bonds generally improve permeability.
**QED:** Both ligands have acceptable QED scores (A: 0.842, B: 0.776), indicating good drug-like properties.
**DILI:** Ligand A (31.989) has a significantly lower DILI risk than Ligand B (38.62). This is a substantial advantage for A.
**BBB:** Ligand A (72.082) has a better BBB penetration score than Ligand B (62.699). This is important for GPCRs, even if not a CNS target.
**Caco-2 Permeability:** Ligand A (-4.749) shows better Caco-2 permeability than Ligand B (-5.018).
**Aqueous Solubility:** Ligand A (-2.605) is slightly better than Ligand B (-1.979).
**hERG:** Both ligands have very low hERG inhibition risk (A: 0.229, B: 0.152), which is excellent.
**Microsomal Clearance:** Ligand B (-3.731) has a *much* better (lower) microsomal clearance than Ligand A (10.874). This suggests greater metabolic stability for B.
**In vitro Half-Life:** Ligand B (5.92) has a better in vitro half-life than Ligand A (-12.081). This is a significant advantage for B.
**Pgp Efflux:** Ligand A (0.063) has a slightly lower Pgp efflux liability than Ligand B (0.095).
**Binding Affinity:** Both ligands have the same binding affinity (-7.3 kcal/mol), so this parameter doesn't differentiate them.
**Overall Assessment:**
Ligand A excels in TPSA, logP, DILI risk, BBB penetration, and Caco-2 permeability. Ligand B shines in metabolic stability (Cl_mic) and half-life. Given the GPCR target, the balance of properties in Ligand A is more favorable. The lower DILI risk and better BBB penetration are significant advantages. While Ligand B's metabolic stability is appealing, the other properties of Ligand A outweigh this benefit.
**Output:**
1
2025-04-17 23:55:53,258 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (347.419 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (78.87) is significantly better than Ligand A (93.23). ADRB2 is a cardiovascular target, so BBB isn't a primary concern, but lower TPSA is still beneficial for absorption.
3. **logP:** Both ligands have acceptable logP values (A: 0.916, B: 1.555), falling within the 1-3 range. Ligand B is slightly better.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand B (4) is better than Ligand A (6). Lower HBA is generally preferred for permeability.
6. **QED:** Both ligands have good QED scores (A: 0.643, B: 0.743), indicating good drug-likeness. Ligand B is slightly better.
7. **DILI:** Ligand B (33.424) has a significantly lower DILI risk than Ligand A (60.217). This is a major advantage for Ligand B.
8. **BBB:** Not a primary concern for a cardiovascular target, but Ligand A (79.488) is better than Ligand B (58.24).
9. **Caco-2:** Both have negative values, indicating poor permeability. Ligand A (-4.763) is slightly better than Ligand B (-4.917).
10. **Solubility:** Both have negative values, indicating poor solubility. Ligand A (-2.135) is slightly better than Ligand B (-2.548).
11. **hERG:** Both ligands have very low hERG inhibition risk (A: 0.057, B: 0.299).
12. **Cl_mic:** Ligand A (-11.531) has a much lower (better) microsomal clearance than Ligand B (18.762), indicating better metabolic stability.
13. **t1/2:** Ligand B (35.571) has a significantly longer in vitro half-life than Ligand A (8.575). This is a major advantage for Ligand B.
14. **Pgp:** Both ligands have low Pgp efflux liability (A: 0.08, B: 0.08).
15. **Affinity:** Ligand B (-5.3 kcal/mol) has a slightly better binding affinity than Ligand A (-6.8 kcal/mol).
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B performs better on logP, TPSA, and affinity. While Ligand A has better BBB penetration, this is less critical for a cardiovascular target.
**Overall Assessment:**
Ligand B has a significantly better safety profile (lower DILI) and a longer half-life, which are crucial for drug development. The slightly better affinity and TPSA also contribute to its favorability. While Ligand A has better metabolic stability, the other advantages of Ligand B outweigh this benefit.
Output:
0
2025-04-17 23:55:53,258 - INFO - Batch 440 complete. Total preferences: 7040
2025-04-17 23:55:53,258 - INFO - Processing batch 441/512...
2025-04-17 23:56:43,055 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (378.881) is slightly higher than Ligand B (350.419), but both are acceptable.
2. **TPSA:** Ligand A (68.29) is excellent, well below the 140 threshold for oral absorption. Ligand B (108.88) is higher, but still within a reasonable range, though less optimal.
3. **logP:** Ligand A (2.869) is optimal (1-3). Ligand B (0.155) is quite low, potentially leading to poor membrane permeability. This is a significant drawback.
4. **HBD:** Both ligands have acceptable HBD counts (Ligand A: 1, Ligand B: 2), well below the 5 threshold.
5. **HBA:** Both ligands have acceptable HBA counts (Ligand A: 5, Ligand B: 5), below the 10 threshold.
6. **QED:** Both ligands have good QED scores (Ligand A: 0.715, Ligand B: 0.728), indicating good drug-like properties.
7. **DILI:** Ligand A (70.221) is moderately high, but not alarming. Ligand B (22.218) is very good, indicating a low risk of liver injury.
8. **BBB:** Both ligands have similar BBB penetration (Ligand A: 42.924, Ligand B: 41.373). BBB is less critical for ADRB2, which is primarily a cardiovascular target.
9. **Caco-2:** Ligand A (-4.926) is better than Ligand B (-5.656), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-3.937) is better than Ligand B (-1.395), indicating better aqueous solubility.
11. **hERG:** Both ligands have very low hERG inhibition risk (Ligand A: 0.373, Ligand B: 0.143).
12. **Cl_mic:** Ligand A (91.309) has a higher clearance than Ligand B (-32.076), indicating lower metabolic stability. This is a negative for Ligand A.
13. **t1/2:** Ligand B (13.677) has a significantly longer in vitro half-life than Ligand A (-0.803), which is a major advantage.
14. **Pgp:** Both ligands have very low Pgp efflux liability (Ligand A: 0.135, Ligand B: 0.005).
15. **Binding Affinity:** Both ligands have the same binding affinity (-6.6 kcal/mol).
**GPCR-specific priorities:** For GPCRs, logP, TPSA, and affinity are key. Ligand A excels in logP and TPSA, while affinity is equal for both. However, Ligand B has a much better metabolic profile (lower Cl_mic, longer t1/2) and lower DILI risk. The low logP of Ligand B is a concern, but the superior metabolic stability and safety profile are more important in this case.
**Conclusion:**
Despite Ligand A's better logP and solubility, Ligand B's significantly improved metabolic stability (longer half-life, lower clearance) and lower DILI risk make it the more promising drug candidate. The low logP of Ligand B is a drawback, but it can potentially be addressed through formulation strategies.
Output:
0
2025-04-17 23:56:43,056 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.359 and 351.466 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (128.53) is slightly higher than Ligand B (81.99). For a cardiovascular GPCR, TPSA is not a primary concern, but lower is generally preferred for better permeability. Ligand B is better here.
3. **logP:** Ligand A (-0.191) is quite low, potentially hindering membrane permeability. Ligand B (2.713) is within the optimal 1-3 range. Ligand B is significantly better.
4. **HBD:** Ligand A (3) is acceptable, while Ligand B (2) is also good. No major difference.
5. **HBA:** Ligand A (6) is acceptable, Ligand B (3) is excellent. Ligand B is better.
6. **QED:** Both ligands have good QED scores (0.664 and 0.705), indicating good drug-like properties. No significant difference.
7. **DILI:** Ligand A (69.756) has a higher DILI risk than Ligand B (24.544). This is a significant advantage for Ligand B.
8. **BBB:** Both ligands have low BBB penetration (8.181 and 81.892 respectively). Since ADRB2 is not a CNS target, this is less critical, but Ligand B is better.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual. It suggests poor permeability. However, the values are similar, so it doesn't strongly favor either.
10. **Solubility:** Ligand A (-1.954) has poor solubility, while Ligand B (-3.844) is also poor. Both are problematic, but Ligand B is slightly worse.
11. **hERG:** Ligand A (0.135) has a lower hERG risk than Ligand B (0.738). This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand A (16.49) has a lower microsomal clearance than Ligand B (53.114), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (11.153) has a longer in vitro half-life than Ligand B (2.126). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.019) has very low P-gp efflux, while Ligand B (0.113) is slightly higher. This is a slight advantage for Ligand A.
15. **Affinity:** Ligand A (-6.7) has a slightly better binding affinity than Ligand B (-5.5). While both are good, the 1.2 kcal/mol difference is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand A has a better binding affinity, lower DILI risk, better metabolic stability (lower Cl_mic and longer t1/2), and lower P-gp efflux. Ligand B has a better logP and TPSA. The biggest concern with Ligand A is its low logP and poor solubility, which could impact bioavailability. However, the significantly better affinity and ADME properties (DILI, Cl_mic, t1/2) are more critical for a cardiovascular GPCR target. The affinity difference is large enough to compensate for the solubility/logP issues, especially considering formulation strategies can be employed to address solubility.
Output:
1
2025-04-17 23:56:43,056 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (387.364 Da) is within the ideal range (200-500 Da). Ligand B (350.415 Da) is also within the ideal range. No clear advantage here.
2. **TPSA:** Ligand A (81.18) is good, under the 140 threshold. Ligand B (88.1) is also acceptable, but slightly higher. A favors slightly.
3. **logP:** Ligand A (3.811) is at the upper end of the optimal range (1-3), but still acceptable. Ligand B (0.489) is *below* the optimal range, which could hinder permeability. A favors significantly.
4. **HBD:** Ligand A (1) is good. Ligand B (2) is also acceptable. No significant difference.
5. **HBA:** Ligand A (7) is good. Ligand B (5) is also good. No significant difference.
6. **QED:** Both Ligand A (0.691) and Ligand B (0.712) are above the 0.5 threshold, indicating good drug-like properties. No clear advantage.
7. **DILI:** Ligand A (96.433) has a high DILI risk. Ligand B (45.328) has a much lower, and very favorable, DILI risk. B favors significantly.
8. **BBB:** Ligand A (81.776) has a reasonable BBB penetration, while Ligand B (42.226) is lower. Considering ADRB2 isn't necessarily a CNS target, this isn't a major deciding factor, but A is slightly favored.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-5.095) has very poor solubility. Ligand B (-0.978) has better, though still poor, solubility. B favors.
11. **hERG:** Ligand A (0.525) has a low hERG risk. Ligand B (0.123) has an even lower risk. B favors slightly.
12. **Cl_mic:** Ligand A (88.898) has a relatively high microsomal clearance, indicating faster metabolism. Ligand B (-1.214) has a *very* low (and likely problematic) clearance, suggesting extreme metabolic stability, which could lead to accumulation. This is a concern for B. A favors.
13. **t1/2:** Ligand A (59.788) has a good in vitro half-life. Ligand B (9.373) has a very short half-life. A favors significantly.
14. **Pgp:** Ligand A (0.66) has moderate P-gp efflux. Ligand B (0.087) has very low P-gp efflux. B favors significantly.
15. **Binding Affinity:** Ligand A (-7.2 kcal/mol) has a significantly stronger binding affinity than Ligand B (-3.5 kcal/mol). This is a substantial advantage for A, potentially outweighing some of its ADME drawbacks.
**Overall Assessment:**
Ligand A has a much stronger binding affinity, which is crucial for GPCR targets. While it has a higher DILI risk and poorer solubility, the strong binding and reasonable BBB penetration are significant positives. Ligand B has a better safety profile (DILI, hERG) and Pgp efflux, but its significantly weaker binding affinity and very short half-life are major drawbacks. The negative Caco-2 values are concerning for both, but can be addressed with formulation strategies. The extremely low clearance of B is also a red flag.
Given the importance of potency for GPCRs, and the potential to mitigate the DILI risk through structural modifications, I favor Ligand A.
Output:
1
2025-04-17 23:56:43,056 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
The target is ADRB2, a GPCR. Therefore, I will prioritize logP, TPSA, Pgp efflux, BBB penetration, and binding affinity, followed by ADME properties like solubility, metabolic stability, and safety (DILI, hERG).
Let's compare the ligands property by property:
1. **MW:** Both ligands (382.551 and 355.479 Da) fall within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (69.64) is better than Ligand B (82.11). Lower TPSA generally favors oral absorption, and both are reasonably good, but A is preferable.
3. **logP:** Ligand A (2.426) is optimal (1-3). Ligand B (0.079) is quite low, potentially hindering membrane permeability and absorption. This is a significant drawback for Ligand B.
4. **HBD/HBA:** Both have 2 HBD and 5 HBA, which are acceptable.
5. **QED:** Ligand A (0.793) is slightly better than Ligand B (0.676), indicating a more drug-like profile.
6. **DILI:** Ligand A (37.611) has a lower DILI risk than Ligand B (3.412), which is excellent.
7. **BBB:** Ligand A (61.225) has better BBB penetration than Ligand B (41.024), though neither is exceptionally high. For a cardiovascular target, this isn't *critical*, but still a positive for A.
8. **Caco-2:** Ligand A (-5.255) is better than Ligand B (-4.902), indicating better intestinal absorption.
9. **Solubility:** Ligand A (-3.233) is better than Ligand B (-0.628), which is important for formulation and bioavailability.
10. **hERG:** Both are low (0.458 and 0.267), indicating low cardiotoxicity risk.
11. **Cl_mic:** Ligand A (40.947) is higher than Ligand B (-4.108), meaning Ligand B has better metabolic stability. This is a positive for Ligand B.
12. **t1/2:** Ligand A (18.547) has a longer half-life than Ligand B (-8.492). This is a positive for Ligand A.
13. **Pgp:** Ligand A (0.203) has lower P-gp efflux than Ligand B (0.012), which is beneficial for bioavailability.
14. **Binding Affinity:** Ligand A (-6.9 kcal/mol) has a slightly better binding affinity than Ligand B (-6.1 kcal/mol). While both are good, the difference is noticeable.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most crucial parameters, especially logP and solubility. While Ligand B has better metabolic stability, the poor logP is a significant concern for oral bioavailability and overall drug-like properties. The slightly better affinity, solubility, and lower DILI risk of Ligand A make it the more promising candidate.
**Output:**
1
2025-04-17 23:56:43,056 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [342.443, 87.46, 2.537, 3, 3, 0.738, 55.991, 67.197, -5.29, -2.597, 0.452, -2.89, 25.983, 0.057, -6.7]
**Ligand B:** [351.491, 61.88, 1.418, 1, 4, 0.735, 12.524, 62.699, -4.537, -1.194, 0.271, 20.659, -16.805, 0.018, -5.8]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity, and BBB):
1. **MW:** Both are within the ideal 200-500 Da range. Ligand A (342.443) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (87.46) is better than Ligand B (61.88), being below 140 and closer to the 90 threshold for CNS penetration.
3. **logP:** Both are within the optimal 1-3 range. Ligand B (1.418) is slightly lower, which could potentially impact permeability, but is still acceptable. Ligand A (2.537) is better.
4. **HBD/HBA:** Ligand A has 3 HBD and 3 HBA, while Ligand B has 1 HBD and 4 HBA. Both are acceptable, but Ligand A is slightly more balanced.
5. **QED:** Both have similar QED values (0.738 and 0.735), indicating good drug-likeness.
6. **DILI:** Ligand B (12.524) has a *much* lower DILI risk than Ligand A (55.991). This is a significant advantage for Ligand B.
7. **BBB:** Both have reasonable BBB penetration (Ligand A: 67.197, Ligand B: 62.699). While not exceptionally high, they are acceptable for a non-CNS target like ADRB2.
8. **Caco-2:** Ligand A (-5.29) has a worse Caco-2 value than Ligand B (-4.537), indicating lower intestinal absorption.
9. **Solubility:** Ligand B (-1.194) has better solubility than Ligand A (-2.597).
10. **hERG:** Ligand A (0.452) has a slightly lower hERG risk than Ligand B (0.271), but both are low.
11. **Cl_mic:** Ligand A (-2.89) has a better (lower) microsomal clearance than Ligand B (20.659), suggesting better metabolic stability.
12. **t1/2:** Ligand B (-16.805) has a significantly longer in vitro half-life than Ligand A (25.983). This is a major advantage.
13. **Pgp:** Ligand A (0.057) has a lower P-gp efflux liability than Ligand B (0.018), which is favorable.
14. **Affinity:** Ligand A (-6.7) has a slightly better binding affinity than Ligand B (-5.8). This is a 1.5 kcal/mol difference, which is significant.
**Overall Assessment:**
Ligand A has a slight edge in binding affinity and P-gp efflux, but Ligand B excels in crucial ADME properties: significantly lower DILI risk, better solubility, and a much longer half-life. The better metabolic stability (lower Cl_mic) of Ligand A is a positive, but the DILI and half-life advantages of Ligand B are more compelling, particularly for a cardiovascular target where long-term safety and dosing convenience are paramount. While the Caco-2 value for Ligand A is better, the other ADME properties of Ligand B outweigh this.
Therefore, I would prioritize Ligand B.
0
2025-04-17 23:56:43,056 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (380.495 and 348.403 Da) fall within the ideal 200-500 Da range.
2. **TPSA:** Both ligands (106.32 and 105.48) are reasonably low, suggesting good potential for absorption, though slightly above the optimal <90 for CNS targets (less relevant for ADRB2, a cardiovascular target).
3. **logP:** Ligand A (0.738) is slightly better than Ligand B (-0.709). Both are within the 1-3 range, but Ligand B is closer to the lower limit, potentially impacting permeability.
4. **HBD:** Ligand A (2) is preferable to Ligand B (3). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (7) is preferable to Ligand B (6). Lower HBA generally improves permeability.
6. **QED:** Ligand A (0.641) is slightly better than Ligand B (0.565), indicating a more drug-like profile.
7. **DILI:** Ligand B (38.581) has a significantly lower DILI risk than Ligand A (50.136), which is a substantial advantage.
8. **BBB:** Ligand B (50.407) has a higher BBB penetration than Ligand A (18.147). While ADRB2 is cardiovascular, some CNS exposure is possible with systemic drugs, and higher BBB is generally favorable.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.571 and -5.538), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand B (-0.597) is slightly better than Ligand A (-2.452), indicating better aqueous solubility.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.185 and 0.154).
12. **Cl_mic:** Ligand B (-11.273) has a much lower (better) microsomal clearance than Ligand A (12.632), indicating better metabolic stability.
13. **t1/2:** Ligand B (7.554) has a significantly longer in vitro half-life than Ligand A (-1.928), which is a major advantage.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.034 and 0.018).
15. **Affinity:** Ligand A (-7.2 kcal/mol) has a slightly better binding affinity than Ligand B (-5.7 kcal/mol). This is a 1.5 kcal/mol difference, which is a notable advantage.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand A has a slightly better logP and significantly better affinity. However, Ligand B excels in DILI risk, BBB, metabolic stability (Cl_mic, t1/2), and solubility. The poor Caco-2 values are concerning for both, but the substantial improvements in ADME properties for Ligand B, coupled with acceptable affinity, outweigh the slightly weaker binding. The improved metabolic stability and longer half-life are particularly attractive.
**Conclusion:**
Despite the slightly better affinity of Ligand A, the superior ADME profile of Ligand B makes it the more promising drug candidate.
Output:
0
2025-04-17 23:56:43,056 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (338.382) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (45.47) is better than Ligand B (58.64). Both are below 140, but A is closer to the optimal value for oral absorption.
3. **logP:** Both ligands have good logP values (A: 3.653, B: 2.757), falling within the 1-3 range. Ligand A is slightly higher, which could potentially lead to off-target effects, but is still acceptable.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Both have 3 HBA, which is good.
6. **QED:** Both ligands have similar QED values (A: 0.775, B: 0.718), indicating good drug-likeness.
7. **DILI:** Ligand B (13.532) has a significantly lower DILI risk than Ligand A (55.448). This is a major advantage for Ligand B.
8. **BBB:** Ligand B (84.064) has a higher BBB penetration percentile than Ligand A (70.997). While ADRB2 isn't strictly a CNS target, some peripheral ADRB2 receptors can be affected by CNS penetration, and higher BBB is generally a plus.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret. Ligand A (-4.801) is slightly worse than Ligand B (-4.454).
10. **Solubility:** Both ligands have negative solubility values, which is also unusual and suggests poor solubility. Ligand A (-3.965) is slightly worse than Ligand B (-2.928).
11. **hERG:** Ligand A (0.85) has a slightly higher hERG risk than Ligand B (0.343), but both are relatively low.
12. **Cl_mic:** Ligand B (52.385) has slightly lower microsomal clearance than Ligand A (55.765), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-15.253) has a longer in vitro half-life than Ligand A (-27.27). This is a significant advantage.
14. **Pgp:** Ligand A (0.684) has slightly lower P-gp efflux than Ligand B (0.093), which is favorable.
15. **Binding Affinity:** Ligand B (-6.4) has a slightly better binding affinity than Ligand A (-5.8). This difference of 0.6 kcal/mol is significant.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand B performs better on most of these, especially considering the significantly lower DILI risk and better binding affinity. While Ligand A has slightly better Pgp, the other advantages of Ligand B outweigh this.
**Conclusion:**
Ligand B is the more promising candidate due to its significantly lower DILI risk, better binding affinity, improved metabolic stability (lower Cl_mic, longer t1/2), and higher BBB penetration. While both have issues with Caco-2 and solubility, the other advantages of Ligand B make it the preferred choice.
Output:
0
2025-04-17 23:56:43,056 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [382.551, 67.43, 2.593, 2, 5, 0.678, 47.344, 69.523, -5.183, -3.41, 0.542, 72.796, 12.076, 0.246, -4.9]
**Ligand B:** [401.945, 96.87, 2.604, 2, 7, 0.673, 77.627, 34.277, -5.649, -2.683, 0.13, 21.853, 47.454, 0.357, -6]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (382.551) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (67.43) is better than Ligand B (96.87). A TPSA under 140 is good for oral absorption, but lower is better for GPCRs. Ligand B is getting a bit high.
3. **logP:** Both are excellent (around 2.6), falling right in the optimal range of 1-3.
4. **HBD:** Both have 2 HBD, which is good.
5. **HBA:** Ligand A (5) is better than Ligand B (7). Lower HBA is generally preferred for better permeability.
6. **QED:** Both are similar (0.678 vs 0.673), indicating good drug-like properties.
7. **DILI:** Ligand A (47.344) has a significantly lower DILI risk than Ligand B (77.627). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (69.523) has a better BBB penetration score than Ligand B (34.277). While ADRB2 isn't *necessarily* a CNS target, some peripheral effects can be mediated by CNS pathways, and better BBB penetration can sometimes indicate better overall distribution.
9. **Caco-2:** Both are negative, suggesting poor permeability. However, the scale isn't specified, so we can't interpret the absolute values.
10. **Solubility:** Ligand A (-3.41) is worse than Ligand B (-2.683), but both are poor.
11. **hERG:** Ligand A (0.542) has a lower hERG risk than Ligand B (0.13). This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand A (72.796) has a higher clearance than Ligand B (21.853), meaning it's metabolized faster. This is a drawback for Ligand A.
13. **t1/2:** Ligand B (47.454) has a much longer in vitro half-life than Ligand A (12.076). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.246) has lower P-gp efflux than Ligand B (0.357), which is favorable.
15. **Affinity:** Ligand B (-6) has a slightly better binding affinity than Ligand A (-4.9). This is a 1.1 kcal/mol difference, which is notable, but not overwhelming.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity) and general drug-like properties, Ligand A is the more promising candidate. While Ligand B has better affinity and metabolic stability (longer half-life), Ligand A excels in safety (lower DILI and hERG risk), BBB penetration, and TPSA. The affinity difference isn't large enough to overcome the significant safety advantages of Ligand A, especially for a cardiovascular target where off-target effects can be particularly problematic. The solubility of both is a concern, but can be addressed with formulation strategies.
Output:
1
2025-04-17 23:56:43,056 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.463 and 352.475 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (96.11) is higher than Ligand B (66.92). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is generally preferred for absorption. Ligand B is better.
3. **logP:** Both ligands have good logP values (2.221 and 1.869) falling within the 1-3 range. Ligand B is slightly better.
4. **HBD:** Ligand A (3) is higher than Ligand B (0). While not excessively high, lower HBD is generally preferred for permeability. Ligand B is better.
5. **HBA:** Both ligands have the same number of HBA (4).
6. **QED:** Both ligands have similar QED values (0.603 and 0.594), indicating good drug-likeness.
7. **DILI:** Ligand A (37.456) has a significantly higher DILI risk than Ligand B (15.471). This is a major concern. Ligand B is much better.
8. **BBB:** Ligand A (33.54) has a low BBB penetration, while Ligand B (76.192) has a high BBB penetration. While ADRB2 isn't necessarily a CNS target, higher BBB is still a positive attribute. Ligand B is better.
9. **Caco-2:** Ligand A (-5.586) has a worse Caco-2 permeability than Ligand B (-4.24). Ligand B is better.
10. **Solubility:** Ligand A (-1.97) has worse solubility than Ligand B (-0.884). Ligand B is better.
11. **hERG:** Both ligands have low hERG inhibition liability (0.212 and 0.337). No significant difference.
12. **Cl_mic:** Ligand A (5.43) has a lower microsomal clearance than Ligand B (63.399), suggesting better metabolic stability. Ligand A is better.
13. **t1/2:** Ligand A (-0.97) has a shorter in vitro half-life than Ligand B (-4.998). Ligand B is better.
14. **Pgp:** Both ligands have similar Pgp efflux liability (0.042 and 0.099). No significant difference.
15. **Binding Affinity:** Ligand B (-7.1 kcal/mol) has a slightly better binding affinity than Ligand A (-6.2 kcal/mol). This difference (0.9 kcal/mol) is substantial and can outweigh some minor ADME drawbacks. Ligand B is better.
**Overall Assessment:**
Ligand B consistently outperforms Ligand A in most critical ADME properties (DILI, BBB, Caco-2, Solubility, t1/2) and has a significantly better binding affinity. While Ligand A has better metabolic stability (lower Cl_mic), the substantial improvement in safety (DILI) and absorption/distribution (BBB, Caco-2, Solubility) offered by Ligand B, coupled with its superior binding affinity, make it the more promising drug candidate.
Output:
0
2025-04-17 23:56:43,057 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [341.415, 90.12, 3.161, 3, 3, 0.798, 79.449, 54.634, -5.086, -4.388, 0.474, -6.53, 27.652, 0.042, -6.6]
**Ligand B:** [348.531, 41.57, 3.373, 1, 3, 0.717, 16.285, 81.815, -4.802, -3.171, 0.518, 47.45, 44.612, 0.387, -6.3]
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (341.415) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (90.12) is better than Ligand B (41.57), being below 140, but still relatively high. Ligand B is excellent, well below 90, which is a significant advantage for GPCRs.
3. **logP:** Both are within the optimal range (1-3). Ligand B (3.373) is slightly higher, which could potentially lead to off-target effects, but is still acceptable.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (1). Both are acceptable, but lower is generally preferred.
5. **HBA:** Both ligands have 3 HBA, which is good.
6. **QED:** Both are above 0.5 (Ligand A: 0.798, Ligand B: 0.717), indicating good drug-like properties.
7. **DILI:** Ligand A (79.449) has a significantly higher DILI risk than Ligand B (16.285). This is a major concern for Ligand A.
8. **BBB:** Ligand B (81.815) has a much higher BBB penetration potential than Ligand A (54.634). This is highly desirable for a GPCR target, although not strictly required for ADRB2.
9. **Caco-2:** Both have negative values, indicating poor permeability. Ligand A (-5.086) is worse than Ligand B (-4.802).
10. **Solubility:** Both have negative values, indicating poor solubility. Ligand B (-3.171) is slightly better than Ligand A (-4.388).
11. **hERG:** Both have low hERG inhibition liability (Ligand A: 0.474, Ligand B: 0.518).
12. **Cl_mic:** Ligand A (-6.53) has a lower (better) microsomal clearance than Ligand B (47.45). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand B (44.612) has a longer in vitro half-life than Ligand A (27.652).
14. **Pgp:** Ligand A (0.042) has lower P-gp efflux liability than Ligand B (0.387), which is favorable.
15. **Affinity:** Ligand A (-6.6) has slightly better binding affinity than Ligand B (-6.3). However, the difference is not substantial enough to outweigh other significant drawbacks.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, we prioritize logP, TPSA, Pgp, and affinity. Ligand B excels in TPSA and BBB penetration. Ligand A has slightly better affinity and Pgp, but suffers from a much higher DILI risk and worse BBB penetration. The DILI risk is a critical factor, and the improved TPSA of Ligand B is also very beneficial.
**Conclusion:**
Considering the overall profile, Ligand B is the more promising drug candidate. While Ligand A has slightly better affinity and Pgp, the significantly higher DILI risk and lower BBB penetration make it less desirable. Ligand B's lower DILI, better TPSA, and good BBB penetration outweigh the slightly weaker affinity.
Output:
0
2025-04-17 23:56:43,057 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [364.427, 93.74, 2.588, 3, 7, 0.682, 88.057, 58.278, -4.765, -3.951, 0.579, 39.356, 22.271, 0.241, -6.7]
**Ligand B:** [350.438, 83.98, 3.056, 2, 4, 0.772, 48.119, 78.48, -4.505, -3.634, 0.174, 35.781, -3.916, 0.033, -6.3]
Here's a breakdown, prioritizing GPCR-relevant parameters:
1. **Molecular Weight:** Both are within the ideal 200-500 Da range. Ligand B (350.438) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are acceptable (below 140), but Ligand B (83.98) is better, being closer to the ideal for good oral absorption.
3. **logP:** Both are within the optimal 1-3 range. Ligand B (3.056) is slightly higher, which *could* be a minor concern for solubility, but isn't critical.
4. **H-Bond Donors/Acceptors:** Ligand B (2 HBD, 4 HBA) is better than Ligand A (3 HBD, 7 HBA). Fewer H-bonds generally improve permeability.
5. **QED:** Both are above 0.5, indicating good drug-like properties. Ligand B (0.772) is slightly better.
6. **DILI Risk:** Ligand A (88.057) has a significantly higher DILI risk than Ligand B (48.119). This is a major concern for Ligand A.
7. **BBB Penetration:** Ligand B (78.48) has better BBB penetration than Ligand A (58.278). While not a primary concern for a cardiovascular target, it's a positive attribute.
8. **Caco-2 Permeability:** Both have negative values, indicating poor permeability. Ligand A (-4.765) is worse than Ligand B (-4.505).
9. **Aqueous Solubility:** Both have negative values, indicating poor solubility. Ligand A (-3.951) is slightly worse than Ligand B (-3.634).
10. **hERG Inhibition:** Both are low, indicating low cardiotoxicity risk. Ligand B (0.174) is slightly better.
11. **Microsomal Clearance:** Ligand B (35.781) has lower clearance, suggesting better metabolic stability than Ligand A (39.356).
12. **In vitro Half-Life:** Ligand B (-3.916) has a longer half-life than Ligand A (22.271), which is a positive.
13. **P-gp Efflux:** Ligand B (0.033) has lower P-gp efflux, which is favorable for bioavailability. Ligand A (0.241) is higher.
14. **Binding Affinity:** Ligand A (-6.7 kcal/mol) has a slightly better binding affinity than Ligand B (-6.3 kcal/mol), but the difference is relatively small (0.4 kcal/mol).
15. **GPCR Specific Priorities:** Considering GPCRs, logP, TPSA, Pgp, and affinity are key. Ligand B is better across most of these.
**Conclusion:**
While Ligand A has a slightly better binding affinity, the significantly higher DILI risk, poorer BBB penetration, and worse ADME properties (Caco-2, solubility, P-gp, clearance, half-life) make it a less desirable candidate. Ligand B demonstrates a much more balanced profile with lower toxicity risk and better predicted pharmacokinetic properties. The 0.4 kcal/mol difference in affinity is unlikely to overcome the substantial ADME/Tox advantages of Ligand B.
0
2025-04-17 23:56:43,057 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (350.463 and 345.443 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (87.46) is slightly higher than Ligand B (73.74). Both are below the 140 A^2 threshold for good oral absorption, but Ligand B is preferable due to the lower TPSA.
**3. logP:** Ligand B (2.015) is better positioned within the optimal 1-3 range than Ligand A (0.643), which is quite low and might hinder membrane permeability.
**4. H-Bond Donors:** Ligand A (2) is slightly higher than Ligand B (1), but both are acceptable (<=5).
**5. H-Bond Acceptors:** Ligand A (5) is slightly higher than Ligand B (4), but both are acceptable (<=10).
**6. QED:** Ligand A (0.674) has a slightly better QED score than Ligand B (0.578), indicating a marginally more drug-like profile.
**7. DILI Risk:** Ligand B (34.393) has a significantly lower DILI risk than Ligand A (18.224), which is a major advantage. Lower DILI is crucial for drug development.
**8. BBB Penetration:** Ligand A (49.826) has better BBB penetration than Ligand B (38.542), but for a cardiovascular target like ADRB2, high BBB penetration is not a primary concern.
**9. Caco-2 Permeability:** Ligand A (-5.02) shows better Caco-2 permeability than Ligand B (-4.577).
**10. Aqueous Solubility:** Both ligands have very poor aqueous solubility (-0.978 and -0.959 respectively). This is a significant drawback for both, but could be addressed with formulation strategies.
**11. hERG Inhibition:** Both ligands show very low hERG inhibition risk (0.167 and 0.176 respectively). This is excellent.
**12. Microsomal Clearance:** Ligand A (21.582) has a lower microsomal clearance than Ligand B (54.001), suggesting better metabolic stability.
**13. In vitro Half-Life:** Ligand B (22.132) has a significantly longer in vitro half-life than Ligand A (5.169), which is a major advantage.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.029 and 0.084 respectively).
**15. Binding Affinity:** Ligand B (-7.2 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.8 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME drawbacks.
**GPCR-Specific Considerations:** For a GPCR like ADRB2, logP, TPSA, and affinity are particularly important. Ligand B excels in logP and significantly in binding affinity. While Ligand A has slightly better TPSA and Caco-2 permeability, the superior affinity and lower DILI risk of Ligand B are more critical. The longer half-life of Ligand B is also a significant benefit.
**Conclusion:**
Considering the overall profile, and prioritizing binding affinity, DILI risk, and metabolic stability, **Ligand B is the more promising drug candidate.**
0
2025-04-17 23:56:43,057 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (376.5 and 354.4 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Both ligands have TPSA values around 76, which is acceptable for a non-CNS GPCR target like ADRB2.
**3. logP:** Ligand A (1.978) is slightly lower than Ligand B (2.746). Both are within the optimal 1-3 range, but Ligand B is closer to the upper end.
**4. H-Bond Donors:** Both have 1 HBD, which is good.
**5. H-Bond Acceptors:** Both have 5 HBA, which is also good.
**6. QED:** Both ligands have high QED scores (0.836 and 0.882), indicating good overall drug-likeness.
**7. DILI:** Ligand A (67.584) has a higher DILI risk than Ligand B (52.113). This is a significant negative for Ligand A.
**8. BBB:** BBB penetration is less critical for a cardiovascular target. Ligand B (92.943) has higher BBB penetration than Ligand A (69.833), but this isn't a major deciding factor.
**9. Caco-2 Permeability:** Ligand B (-4.437) has slightly better Caco-2 permeability than Ligand A (-5.329).
**10. Aqueous Solubility:** Both ligands have poor aqueous solubility (-2.803 and -3.049). This is a potential issue for both, requiring formulation work.
**11. hERG Inhibition:** Ligand A (0.134) has a lower hERG inhibition liability than Ligand B (0.455). This is a positive for Ligand A.
**12. Microsomal Clearance:** Ligand B (-10.553) has significantly lower microsomal clearance than Ligand A (30.113), indicating better metabolic stability. This is a major advantage for Ligand B.
**13. In vitro Half-Life:** Ligand B (-29.544) has a much longer in vitro half-life than Ligand A (-1.569). This is a substantial benefit for Ligand B, potentially allowing for less frequent dosing.
**14. P-gp Efflux:** Ligand A (0.339) has lower P-gp efflux than Ligand B (0.098), which is favorable.
**15. Binding Affinity:** Ligand A (-8.7 kcal/mol) has a significantly stronger binding affinity than Ligand B (-3.3 kcal/mol). This is a very large difference (5.4 kcal/mol), and generally outweighs minor ADME concerns.
**Overall Assessment:**
While Ligand B has better ADME properties (lower DILI, better metabolic stability, longer half-life, lower P-gp efflux), the substantial difference in binding affinity of Ligand A is the most important factor for a GPCR target. The stronger binding of Ligand A suggests it will be more potent and potentially require a lower dose, which could mitigate some of the ADME concerns. The hERG risk is also lower for Ligand A.
Therefore, I prefer Ligand A.
Output:
1
2025-04-17 23:56:43,057 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Ligand A (445.766 Da) is within the ideal range, while Ligand B (366.286 Da) is also good, leaning towards the lower end. No clear advantage here.
2. **TPSA:** Ligand A (53.01) is excellent, well below the 140 threshold. Ligand B (60.85) is still acceptable, but slightly higher. A favors here.
3. **logP:** Ligand A (4.193) is a bit high, potentially leading to solubility issues. Ligand B (1.561) is good, within the optimal range. B favors here.
4. **HBD:** Both ligands have 1 HBD, which is ideal.
5. **HBA:** Ligand A has 5 HBA, acceptable. Ligand B has 3 HBA, also acceptable. No strong preference.
6. **QED:** Both ligands have good QED scores (A: 0.748, B: 0.809), indicating drug-likeness. B is slightly better.
7. **DILI:** Ligand A (77.433) has a higher DILI risk than Ligand B (58.55). B favors here.
8. **BBB:** Ligand A (58.511) is moderate, while Ligand B (74.176) is better. Considering ADRB2 is a GPCR, BBB penetration isn't a top priority unless targeting CNS effects, but B is still preferable.
9. **Caco-2:** Both have negative Caco-2 values which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand A (-4.746) has very poor solubility, while Ligand B (-2.007) is also poor, but better than A. B favors here.
11. **hERG:** Both have low hERG inhibition risk (A: 0.512, B: 0.588). No strong preference.
12. **Cl_mic:** Ligand A (37.64) has a higher microsomal clearance than Ligand B (20.387), indicating lower metabolic stability. B favors here.
13. **t1/2:** Ligand B (-39.923) has a much longer in vitro half-life than Ligand A (-4.501). This is a significant advantage for B.
14. **Pgp:** Both have low Pgp efflux liability (A: 0.238, B: 0.144). B is slightly better.
15. **Binding Affinity:** Ligand A (-6.2 kcal/mol) has a slightly better binding affinity than Ligand B (-5.4 kcal/mol). This is a 0.8 kcal/mol difference, which is a reasonable advantage.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity, Ligand B demonstrates a significantly more favorable ADME profile. Specifically, its lower DILI risk, better solubility, lower clearance, and longer half-life are crucial advantages. The higher logP of Ligand A is concerning, and its poor solubility could severely limit bioavailability. The Caco-2 values are concerning for both, but the other ADME properties of B are more promising. For a GPCR target like ADRB2, a balanced profile is essential, and Ligand B offers a better balance overall.
Output:
0
2025-04-17 23:56:43,057 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
The ADRB2 receptor is a GPCR, so the priorities are logP, Pgp, TPSA, affinity, and BBB. Let's break down the comparison:
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da).
2. **TPSA:** Ligand A (49.41) is significantly better than Ligand B (82.11). Lower TPSA generally favors oral absorption, and is a key consideration for GPCRs.
3. **logP:** Ligand A (3.666) is good, within the optimal range. Ligand B (1.018) is on the lower side and might struggle with membrane permeability.
4. **H-Bond Donors/Acceptors:** Ligand A (1 HBD, 2 HBA) is preferable to Ligand B (2 HBD, 5 HBA) as it has fewer potential issues with permeability.
5. **QED:** Both ligands have acceptable QED values (A: 0.538, B: 0.634).
6. **DILI:** Ligand A (10.198) has a much lower DILI risk than Ligand B (23.769), which is a significant advantage.
7. **BBB:** Ligand A (93.757) has excellent BBB penetration, while Ligand B (30.593) is poor. While ADRB2 isn't exclusively a CNS target, good BBB penetration can be beneficial for overall drug distribution and reducing off-target effects.
8. **Caco-2:** Both have negative values, suggesting poor permeability, but Ligand A (-4.883) is better than Ligand B (-5.039).
9. **Solubility:** Ligand A (-3.95) is better than Ligand B (-1.577).
10. **hERG:** Ligand A (0.689) is better than Ligand B (0.265).
11. **Cl_mic:** Ligand A (54.556) has a higher clearance than Ligand B (14.197), indicating lower metabolic stability.
12. **t1/2:** Ligand A (-3.649) has a longer half-life than Ligand B (-1.481).
13. **Pgp:** Ligand A (0.173) has lower P-gp efflux than Ligand B (0.021), which is favorable for bioavailability.
14. **Binding Affinity:** Ligand B (-7.6) has a significantly stronger binding affinity than Ligand A (-5.5). This is a 2.1 kcal/mol difference, which is substantial.
**Overall Assessment:**
Ligand B has a much better binding affinity, which is a critical factor. However, Ligand A excels in several key ADME properties crucial for a GPCR drug: TPSA, logP, BBB penetration, DILI risk, solubility, and Pgp efflux. The lower metabolic stability of Ligand A is a concern, but the other favorable properties, particularly the significantly better TPSA, logP, and lower DILI risk, outweigh this drawback. The strong affinity of Ligand B is tempting, but the poor ADME profile raises significant concerns about its developability.
**Output:**
1
2025-04-17 23:56:43,057 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (345.443 and 348.487 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (64.09) is better than Ligand B (67.43), both are below the 140 threshold for oral absorption, and acceptable for a cardiovascular target.
3. **logP:** Ligand B (2.714) is optimal (1-3), while Ligand A (0.226) is quite low, potentially hindering membrane permeability. This is a significant negative for Ligand A.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2), but both are within the acceptable limit of 5.
5. **HBA:** Ligand A (4) is preferable to Ligand B (3), but both are within the acceptable limit of 10.
6. **QED:** Ligand A (0.728) is much better than Ligand B (0.422), indicating a more drug-like profile.
7. **DILI:** Ligand A (22.257) is significantly better than Ligand B (32.842), indicating a lower risk of drug-induced liver injury.
8. **BBB:** Ligand B (57.619) is better than Ligand A (39.86), but neither are particularly high. Since ADRB2 is a cardiovascular target, BBB penetration isn't a primary concern, but it's still a slight advantage for B.
9. **Caco-2:** Ligand A (-4.526) and Ligand B (-4.731) are both very poor, suggesting poor intestinal absorption.
10. **Solubility:** Ligand A (-1.196) is better than Ligand B (-3.055), indicating better aqueous solubility.
11. **hERG:** Ligand A (0.276) is better than Ligand B (0.389), indicating a lower risk of hERG inhibition and cardiotoxicity.
12. **Cl_mic:** Ligand A (7.894) is significantly better than Ligand B (54.606), indicating better metabolic stability.
13. **t1/2:** Ligand B (-9.644) is significantly better than Ligand A (0.354), indicating a longer half-life.
14. **Pgp:** Ligand A (0.137) is better than Ligand B (0.261), indicating lower P-gp efflux.
15. **Binding Affinity:** Ligand B (-6.4) is slightly better than Ligand A (-5.8), offering a 0.6 kcal/mol advantage.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B has a better logP and slightly better affinity, which are positives. However, Ligand A has significantly better DILI, Cl_mic, solubility, hERG, and Pgp efflux. The lower logP of Ligand A is a concern, but the substantial improvements in safety (DILI, hERG) and metabolic stability (Cl_mic) outweigh this drawback, especially considering the relatively modest affinity difference. The poor Caco-2 values for both ligands are a concern that would need to be addressed in further optimization.
**Conclusion:**
Considering the balance of properties, particularly the superior safety profile and metabolic stability of Ligand A, I believe it is the more promising drug candidate.
Output:
1
2025-04-17 23:56:43,057 - INFO - Batch 441 complete. Total preferences: 7056
2025-04-17 23:56:43,057 - INFO - Processing batch 442/512...
2025-04-17 23:57:33,824 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (348.443 Da) is better, falling comfortably within the 200-500 Da range. Ligand B (411.34 Da) is still acceptable but approaching the upper limit.
2. **TPSA:** Ligand B (67.43) is slightly better than Ligand A (75.71), both are below the 140 threshold for oral absorption, but closer to the ideal for GPCRs.
3. **logP:** Both ligands have good logP values (A: 2.446, B: 3.405), within the optimal 1-3 range. Ligand B is slightly higher, which could be a minor concern for solubility, but not a dealbreaker.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (4) is preferable to Ligand B (3). Lower HBA generally improves permeability.
6. **QED:** Ligand B (0.706) is better than Ligand A (0.52), indicating a more drug-like profile.
7. **DILI:** Both ligands have acceptable DILI risk (A: 43.35, B: 48.158), well below the 60 threshold. Ligand B is slightly higher, but the difference is small.
8. **BBB:** Ligand B (74.952) is better than Ligand A (65.801). For a GPCR target, even if not specifically a CNS target, some BBB penetration can be beneficial for distribution.
9. **Caco-2:** Both have negative Caco-2 values (-4.65 and -4.453) which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand A (-2.677) is better than Ligand B (-4.532), indicating better aqueous solubility.
11. **hERG:** Both ligands have low hERG risk (A: 0.297, B: 0.328), which is excellent.
12. **Cl_mic:** Ligand A (86.252) is better than Ligand B (93.424), indicating better metabolic stability. Lower is better.
13. **t1/2:** Ligand B (9.871) is significantly better than Ligand A (-11.183). A positive half-life is crucial, and Ligand B's value is much more promising.
14. **Pgp:** Both ligands have low Pgp efflux liability (A: 0.163, B: 0.332), which is good.
15. **Binding Affinity:** Ligand A (-6.3 kcal/mol) is significantly better than Ligand B (-0.9 kcal/mol). This is a substantial difference in potency.
**Overall Assessment:**
While Ligand B has better QED, BBB penetration, and *in vitro* half-life, the significantly stronger binding affinity of Ligand A (-6.3 vs -0.9 kcal/mol) is a major advantage. The negative Caco-2 values are concerning for both, but the superior potency of Ligand A, coupled with acceptable ADME properties (especially the lower Cl_mic and better solubility), makes it the more promising candidate. The difference in binding affinity is large enough to potentially overcome the permeability issues.
Output:
1
2025-04-17 23:57:33,824 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
We are targeting ADRB2, a GPCR. Therefore, key properties to prioritize are logP, TPSA, Pgp efflux, BBB penetration, and binding affinity.
Let's compare the ligands property by property:
1. **MW:** Both ligands (346.381 and 349.387 Da) are within the ideal range (200-500 Da).
2. **TPSA:** Ligand A (58.12) is significantly better than Ligand B (123.66). A TPSA under 140 is good for oral absorption, but lower is preferred for GPCRs, and A is much closer to the ideal range.
3. **logP:** Ligand A (2.33) is optimal (1-3), while Ligand B (0.386) is quite low, potentially hindering membrane permeability.
4. **HBD/HBA:** Ligand A (1 HBD, 4 HBA) is preferable to Ligand B (3 HBD, 5 HBA). Lower counts generally improve permeability.
5. **QED:** Ligand A (0.903) is excellent, indicating high drug-likeness, while Ligand B (0.685) is still acceptable but less optimal.
6. **DILI:** Both ligands have acceptable DILI risk (49.166 and 42.458, both <60).
7. **BBB:** Ligand A (92.633) has excellent BBB penetration, while Ligand B (59.791) is considerably lower. This is a significant advantage for Ligand A.
8. **Caco-2:** Ligand A (-4.849) is better than Ligand B (-5.75), indicating better intestinal absorption.
9. **Solubility:** Ligand A (-3.271) is better than Ligand B (-2.554), indicating better aqueous solubility.
10. **hERG:** Both ligands have very low hERG inhibition risk (0.81 and 0.022).
11. **Cl_mic:** Ligand A (26.891) has a better (lower) microsomal clearance than Ligand B (-0.033), suggesting better metabolic stability.
12. **t1/2:** Ligand A (11.812) has a better in vitro half-life than Ligand B (17.359).
13. **Pgp:** Ligand A (0.123) has lower P-gp efflux liability than Ligand B (0.005), which is favorable for bioavailability.
14. **Binding Affinity:** Both ligands have very similar binding affinities (-6.7 and -6.6 kcal/mol). The difference is negligible.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most crucial ADME properties (TPSA, logP, BBB, solubility, Cl_mic, Pgp) while maintaining comparable binding affinity and acceptable safety profiles. Ligand B's low logP and higher TPSA are significant drawbacks for a GPCR target. The superior BBB penetration of Ligand A is a major advantage.
**Output:**
1
2025-04-17 23:57:33,825 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [346.387, 100.46 , 1.186, 2. , 5. , 0.784, 54.556, 27.336, -5.259, -1.695, 0.264, -13.069, 24.392, 0.047, -6.2 ]
**Ligand B:** [344.419, 87.12 , 1.068, 1. , 5. , 0.899, 61.07 , 38.658, -5.21 , -1.686, 0.18 , 21.826, -3.794, 0.033, -6.8 ]
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (346.387 and 344.419 Da). No significant difference.
2. **TPSA:** Ligand A (100.46) is slightly higher than Ligand B (87.12). Ligand B is better, closer to the <90 threshold for GPCRs.
3. **logP:** Both are excellent (1.186 and 1.068), falling within the optimal 1-3 range. No significant difference.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1). Ligand B is slightly better.
5. **HBA:** Both have 5 HBA, which is acceptable. No difference.
6. **QED:** Ligand B (0.899) is better than Ligand A (0.784), indicating a more drug-like profile.
7. **DILI:** Ligand A (54.556) has a lower DILI risk than Ligand B (61.07). This is a significant advantage for Ligand A.
8. **BBB:** Ligand B (38.658) has a better BBB penetration potential than Ligand A (27.336). This is a key consideration for GPCRs, though not always essential for peripheral targets like some ADRB2 subtypes.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. This is a red flag for both.
10. **Solubility:** Both have negative solubility values, which is also unusual and suggests poor solubility. This is a red flag for both.
11. **hERG:** Both have very low hERG inhibition risk (0.264 and 0.18). This is excellent for both.
12. **Cl_mic:** Ligand A (-13.069) has a much lower (better) microsomal clearance than Ligand B (21.826), indicating greater metabolic stability.
13. **t1/2:** Ligand A (24.392) has a longer in vitro half-life than Ligand B (-3.794). This is a significant advantage for Ligand A.
14. **Pgp:** Both have very low Pgp efflux liability (0.047 and 0.033). This is excellent for both.
15. **Binding Affinity:** Ligand B (-6.8) has a slightly better binding affinity than Ligand A (-6.2). This is a 0.6 kcal/mol difference, which is notable but not overwhelming.
**Overall Assessment:**
While Ligand B has a slightly better binding affinity and BBB penetration, Ligand A demonstrates a significantly better safety profile (lower DILI), superior metabolic stability (lower Cl_mic, longer t1/2), and a slightly better HBD count. The negative Caco-2 and solubility values are concerning for both, but the ADME advantages of Ligand A are more compelling, especially considering the potential for cardiovascular side effects with ADRB2 agonists. The slightly better affinity of Ligand B isn't enough to overcome the superior ADME properties of Ligand A.
**Output:**
1
2025-04-17 23:57:33,825 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [367.559, 58.36, 3.089, 1, 5, 0.729, 16.402, 70.415, -4.759, -2.764, 0.336, 62.596, 22.473, 0.318, -6.2]
**Ligand B:** [402.527, 108.39, 0.319, 1, 10, 0.762, 88.484, 55.021, -5.249, -2.585, 0.249, -3.196, 5.037, 0.102, -4.8]
**Step-by-step comparison:**
1. **MW:** Ligand A (367.559 Da) is within the ideal range (200-500 Da). Ligand B (402.527 Da) is also acceptable. No clear advantage.
2. **TPSA:** Ligand A (58.36) is excellent, well below the 140 threshold and good for permeability. Ligand B (108.39) is higher, but still potentially acceptable, though less ideal. A favors here.
3. **logP:** Ligand A (3.089) is optimal (1-3). Ligand B (0.319) is quite low, potentially hindering membrane permeability and bioavailability. A is significantly better.
4. **HBD:** Both ligands have 1 HBD, which is good. No difference.
5. **HBA:** Ligand A (5) is good. Ligand B (10) is at the upper limit of acceptable, potentially impacting permeability. A is slightly better.
6. **QED:** Both are good (A: 0.729, B: 0.762). No significant difference.
7. **DILI:** Ligand A (16.402) has a very low DILI risk. Ligand B (88.484) has a considerably higher DILI risk. A is much better.
8. **BBB:** Ligand A (70.415) shows good BBB penetration. Ligand B (55.021) is lower. For a GPCR, BBB penetration is a plus, and A is better.
9. **Caco-2:** Both are negative, indicating poor permeability. However, the scale is not provided, so it is difficult to assess the magnitude of this effect.
10. **Solubility:** Both are negative, indicating poor solubility. The scale is not provided, so it is difficult to assess the magnitude of this effect.
11. **hERG:** Both have low hERG inhibition risk (A: 0.336, B: 0.249). No significant difference.
12. **Cl_mic:** Ligand A (62.596) has a higher clearance than Ligand B (-3.196), suggesting lower metabolic stability. B is better.
13. **t1/2:** Ligand A (22.473) has a longer half-life than Ligand B (5.037). A is better.
14. **Pgp:** Ligand A (0.318) has lower P-gp efflux liability than Ligand B (0.102). A is better.
15. **Affinity:** Ligand A (-6.2 kcal/mol) has a slightly better binding affinity than Ligand B (-4.8 kcal/mol).
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand A is clearly superior. It has a much better logP, lower Pgp efflux, lower TPSA, and a slightly better binding affinity. The DILI risk is also significantly lower for Ligand A. While Ligand B has better metabolic stability (lower Cl_mic), the other advantages of Ligand A outweigh this benefit, especially given the relatively good half-life of Ligand A.
Output:
1
2025-04-17 23:57:33,825 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
Let's systematically compare Ligand A and Ligand B based on the provided parameters and the guidelines, keeping in mind ADRB2 is a GPCR and thus we prioritize logP, Pgp, TPSA, and affinity.
1. **Molecular Weight:** Both ligands (381.738 Da and 362.583 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand B (23.55) is significantly better than Ligand A (109.7). Lower TPSA generally indicates better cell permeability, crucial for GPCR targeting. Ligand B is well below the 140 threshold and is very favorable.
3. **logP:** Ligand A (2.474) is within the optimal 1-3 range. Ligand B (4.061) is slightly higher, potentially edging towards solubility issues or off-target interactions, but still acceptable.
4. **H-Bond Donors:** Ligand A (2) is reasonable. Ligand B (0) is also good, potentially improving membrane permeability.
5. **H-Bond Acceptors:** Ligand A (5) is good. Ligand B (3) is also good.
6. **QED:** Both ligands have similar QED values (0.615 and 0.619), indicating comparable drug-likeness.
7. **DILI:** Ligand B (9.383) has a much lower DILI risk than Ligand A (50.989). This is a substantial advantage for Ligand B.
8. **BBB:** Both ligands have good BBB penetration (81.582 and 80.031). This isn't a primary concern for ADRB2, but it's positive.
9. **Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual. Assuming these are logP-like scales, lower values suggest poorer permeability. The values are similar.
10. **Aqueous Solubility:** Both ligands have negative solubility values, which is also unusual. Assuming these are logS-like scales, lower values suggest poorer solubility. The values are similar.
11. **hERG Inhibition:** Ligand A (0.679) has a slightly lower hERG inhibition risk than Ligand B (0.97), which is preferable.
12. **Microsomal Clearance:** Ligand B (78.953) has significantly higher microsomal clearance than Ligand A (7.606). This suggests Ligand A is more metabolically stable.
13. **In vitro Half-Life:** Ligand B (13.543) has a longer half-life than Ligand A (4.461). This is a positive for Ligand B.
14. **P-gp Efflux:** Ligand A (0.464) has lower P-gp efflux liability than Ligand B (0.82). This is favorable for Ligand A.
15. **Binding Affinity:** Ligand B (-6.5 kcal/mol) has a stronger binding affinity than Ligand A (-5.7 kcal/mol). This is a 0.8 kcal/mol difference, which is significant and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand B has a significantly better safety profile (lower DILI), stronger binding affinity, and a much more favorable TPSA. While its logP is slightly higher and clearance is higher, the benefits of the lower TPSA, better affinity, and lower DILI risk outweigh these concerns. Ligand A has better metabolic stability and P-gp efflux, but the affinity difference is crucial for GPCR targets. The unusual solubility and permeability values are a concern for both, but the other factors tilt the balance.
**Output:**
0
2025-04-17 23:57:33,825 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (378.332 and 365.455 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (99.5) is significantly better than Ligand A (116.31). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (1.544) is better than Ligand A (0.738). Both are within the optimal 1-3 range, but Ligand B is closer to the sweet spot.
4. **HBD:** Ligand B (1) is preferable to Ligand A (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand B (5) is preferable to Ligand A (6). Similar to HBD, fewer HBAs are generally better.
6. **QED:** Both ligands have good QED scores (0.769 and 0.824), indicating good drug-like properties. No significant difference.
7. **DILI:** Ligand B (53.858) has a much lower DILI risk than Ligand A (90.733). This is a crucial advantage, as liver toxicity is a major concern.
8. **BBB:** Ligand B (75.301) has a higher BBB penetration score than Ligand A (65.413). While not a primary concern for a cardiovascular target, it's a slight positive for Ligand B.
9. **Caco-2:** Ligand A (-5.133) is better than Ligand B (-4.589). A higher (less negative) Caco-2 value suggests better intestinal absorption.
10. **Solubility:** Ligand A (-3.268) is better than Ligand B (-2.159). Better solubility is always a plus for bioavailability.
11. **hERG:** Ligand A (0.153) has a lower hERG inhibition liability than Ligand B (0.559), which is a significant advantage regarding cardiotoxicity.
12. **Cl_mic:** Ligand B (-5.85) has a much lower (better) microsomal clearance than Ligand A (2.69). This indicates better metabolic stability.
13. **t1/2:** Ligand B (23.046) has a significantly longer in vitro half-life than Ligand A (4.377). This is a major advantage, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.093) has lower P-gp efflux liability than Ligand B (0.106). Lower P-gp efflux is preferable.
15. **Binding Affinity:** Ligand B (-7.4) has a significantly stronger binding affinity than Ligand A (-5.2). This is a substantial advantage, potentially outweighing some of the ADME drawbacks of Ligand B.
**Overall Assessment:**
Ligand B demonstrates a superior balance of properties. The significantly better binding affinity, lower DILI risk, and improved metabolic stability (lower Cl_mic and longer t1/2) are compelling advantages. While Ligand A has better Caco-2 permeability, solubility, and hERG, the potency and safety profile of Ligand B are more favorable for a GPCR target like ADRB2. The stronger binding affinity is particularly important.
Output:
0
2025-04-17 23:57:33,825 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
We are targeting ADRB2, a GPCR. Therefore, the priorities are logP, Pgp, TPSA, BBB, and affinity. Let's break down the comparison:
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (364.5) is slightly higher than Ligand B (348.5), but this isn't a major concern.
2. **TPSA:** Ligand B (49.41) is significantly better than Ligand A (65.54). Lower TPSA generally favors better cell permeability, crucial for GPCR ligands.
3. **logP:** Ligand A (1.823) is within the optimal range (1-3), while Ligand B (3.482) is at the higher end. While both are acceptable, being closer to the middle of the range is generally preferred.
4. **H-Bond Donors/Acceptors:** Both ligands have similar HBD (1) and acceptable HBA counts (A: 5, B: 2).
5. **QED:** Ligand A (0.866) has a better QED score than Ligand B (0.716), indicating a more drug-like profile.
6. **DILI:** Ligand B (12.718) has a much lower DILI risk than Ligand A (21.636). This is a significant advantage.
7. **BBB:** Ligand B (86.274) has a substantially higher BBB penetration score than Ligand A (65.297). While ADRB2 isn't exclusively a CNS target, some peripheral effects are mediated by CNS pathways, and better BBB penetration can be beneficial.
8. **Caco-2 Permeability:** Ligand A (-5.011) and Ligand B (-4.407) both have negative values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
9. **Aqueous Solubility:** Ligand A (-1.25) has better aqueous solubility than Ligand B (-3.9). Solubility is important for formulation.
10. **hERG:** Both ligands have low hERG inhibition liability (A: 0.485, B: 0.394).
11. **Microsomal Clearance:** Ligand B (74.079) has a much higher microsomal clearance than Ligand A (4.299), meaning it's metabolized more quickly. This is a significant drawback.
12. **In vitro Half-Life:** Ligand A (33.644) has a significantly longer in vitro half-life than Ligand B (16.399).
13. **P-gp Efflux:** Both ligands have low P-gp efflux liability (A: 0.055, B: 0.028).
14. **Binding Affinity:** Ligand A (-7.7 kcal/mol) has a stronger binding affinity than Ligand B (-5.3 kcal/mol). This is a substantial advantage, exceeding the 1.5 kcal/mol threshold.
**Overall Assessment:**
Ligand A has a significantly better binding affinity and longer half-life, which are crucial. It also has better solubility and lower clearance. However, Ligand B excels in TPSA, DILI risk, and BBB penetration. The superior affinity of Ligand A, combined with its acceptable ADME properties, outweighs the advantages of Ligand B. The lower clearance and longer half-life of Ligand A are particularly attractive for a GPCR target.
**Output:**
1
2025-04-17 23:57:33,825 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (355.29 and 366.85 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (38.77) is significantly better than Ligand B (82.78). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption. Ligand B's TPSA is quite high.
3. **logP:** Ligand A (3.914) is slightly higher than Ligand B (2.205), both within the optimal 1-3 range. Ligand A is closer to the upper limit, but still acceptable.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer hydrogen bond donors generally improve permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (4). Similar to HBD, lower HBA is generally better for permeability.
6. **QED:** Both ligands have good QED scores (0.784 and 0.855), indicating good drug-like properties. No clear advantage.
7. **DILI:** Ligand B (32.96) has a much lower DILI risk than Ligand A (81.82). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (91.59) has a higher BBB penetration score than Ligand B (41.22). While not critical for a cardiovascular target, it's a positive attribute.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.139 and -4.83). This is unusual and suggests poor permeability *in vitro*. However, the values are similar.
10. **Solubility:** Ligand A (-5.34) has slightly better solubility than Ligand B (-3.046).
11. **hERG:** Ligand A (0.851) has a slightly better hERG profile than Ligand B (0.144). Lower is better, so Ligand A is preferable.
12. **Cl_mic:** Ligand B (-3.323) has significantly lower microsomal clearance than Ligand A (60.394). This suggests better metabolic stability for Ligand B.
13. **t1/2:** Both ligands have similar *in vitro* half-lives (33.281 and 33.108 hours).
14. **Pgp:** Ligand A (0.623) has lower P-gp efflux than Ligand B (0.047). Lower P-gp efflux is generally better for bioavailability.
15. **Binding Affinity:** Ligand B (-7.2 kcal/mol) has a slightly better binding affinity than Ligand A (-7.0 kcal/mol). While the difference is small, it's still a factor.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, and affinity. Ligand A has better logP and Pgp, while Ligand B has better TPSA and affinity. The affinity difference is small, but Ligand B's significantly lower DILI and Cl_mic are compelling. The TPSA difference is also substantial.
**Overall Assessment:**
While Ligand A has some advantages (slightly better logP, Pgp, hERG, solubility, and BBB), Ligand B's significantly lower DILI risk and improved metabolic stability (lower Cl_mic) are crucial for a viable drug candidate. The slightly better affinity of Ligand B further strengthens its position. The high TPSA of Ligand B is a concern, but the other benefits outweigh this drawback.
Output:
0
2025-04-17 23:57:33,825 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (354.426) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (96.25) is better than Ligand B (69.64). While both are under 140, lower TPSA is generally preferred for GPCRs, aiding in brain penetration if desired.
3. **logP:** Both ligands have acceptable logP values (A: 1.199, B: 2.183), falling within the 1-3 range. Ligand B is slightly higher, potentially leading to some solubility concerns, but still reasonable.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (2), but both are within the acceptable limit of 5.
5. **HBA:** Ligand A (5) is higher than Ligand B (3), but both are within the acceptable limit of 10.
6. **QED:** Both ligands have good QED scores (A: 0.588, B: 0.612), indicating good drug-like properties.
7. **DILI:** Ligand B (23.187) has a significantly lower DILI risk than Ligand A (44.552). This is a major advantage for Ligand B.
8. **BBB:** Ligand B (78.48) has a higher BBB penetration percentile than Ligand A (59.791). While ADRB2 isn't strictly a CNS target, some brain exposure can be relevant for off-target effects or peripheral effects mediated by CNS pathways.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual. This suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
10. **Solubility:** Both ligands have negative solubility values, which is also unusual. This suggests poor solubility. However, the scale is not specified, so it's difficult to interpret.
11. **hERG:** Ligand A (0.144) has a lower hERG inhibition liability than Ligand B (0.605), which is a significant advantage.
12. **Cl_mic:** Ligand A (16.608) has a lower microsomal clearance than Ligand B (29.219), indicating better metabolic stability.
13. **t1/2:** Ligand B (-29.662) has a much longer in vitro half-life than Ligand A (-1.581). This is a substantial advantage, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have low Pgp efflux liability (A: 0.043, B: 0.055).
15. **Affinity:** Ligand B (-6.7 kcal/mol) has a slightly better binding affinity than Ligand A (-5.8 kcal/mol). This difference of 0.9 kcal/mol is meaningful.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B has a slightly better logP, significantly better BBB penetration, comparable Pgp efflux, and better affinity. The lower DILI risk and much longer half-life of Ligand B are also very attractive. While Ligand A has a better hERG profile and lower clearance, the benefits of Ligand B in terms of safety (DILI), pharmacokinetics (t1/2), and potency (affinity) outweigh these drawbacks.
**Conclusion:**
Ligand B is the more promising drug candidate due to its superior DILI profile, better BBB penetration, longer half-life, and slightly improved binding affinity.
Output:
0
2025-04-17 23:57:33,825 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (343.471 and 350.419 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (53.51) is significantly better than Ligand B (113.44). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally correlates with better absorption. Ligand B's TPSA is relatively high.
3. **logP:** Ligand A (3.063) is optimal, while Ligand B (0.869) is a bit low. A logP below 1 can hinder membrane permeability.
4. **HBD:** Ligand A (0) is preferable to Ligand B (3). Fewer hydrogen bond donors generally improve permeability.
5. **HBA:** Ligand A (3) is better than Ligand B (6). Lower HBA counts are generally favored for better permeability.
6. **QED:** Both ligands have acceptable QED values (0.715 and 0.609, both >0.5).
7. **DILI:** Ligand A (35.556) has a lower DILI risk than Ligand B (47.732), indicating a safer profile.
8. **BBB:** Ligand A (77.007) has a higher BBB penetration percentile than Ligand B (46.762). While not a primary concern for a cardiovascular target, higher BBB is generally a positive attribute.
9. **Caco-2:** Ligand A (-4.475) is better than Ligand B (-5.126). Higher Caco-2 permeability suggests better intestinal absorption.
10. **Solubility:** Ligand A (-2.012) is better than Ligand B (-2.88). Higher aqueous solubility is desirable.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.337 and 0.108). This is excellent.
12. **Cl_mic:** Ligand A (72.316) has higher microsomal clearance than Ligand B (32.267), suggesting faster metabolism. This is a negative for Ligand A.
13. **t1/2:** Ligand B (-8.711) has a longer in vitro half-life than Ligand A (11.58). Longer half-life is generally preferred.
14. **Pgp:** Ligand A (0.253) has lower P-gp efflux liability than Ligand B (0.026). Lower P-gp efflux is better for bioavailability.
15. **Binding Affinity:** Ligand B (-6.3) has slightly better binding affinity than Ligand A (-5.5). This is a 0.8 kcal/mol difference, which is significant.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A excels in logP, TPSA, and Pgp. Ligand B has a slight edge in affinity and a much better half-life. The difference in affinity is significant, but Ligand A's superior ADME properties (especially TPSA and logP) are crucial for oral bioavailability and overall drug-like characteristics. The lower clearance and longer half-life of Ligand B are attractive, but the higher TPSA and lower logP are concerning.
**Overall Assessment:**
While Ligand B has a slightly better binding affinity and half-life, Ligand A has a significantly better ADME profile, particularly regarding TPSA, logP, solubility, and DILI risk. Considering the balance of these properties, Ligand A is the more promising drug candidate.
Output:
1
2025-04-17 23:57:33,825 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (364.833 and 366.527 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Both ligands have TPSA values (77.83 and 78.43) below the 140 A^2 threshold for good oral absorption. They are also reasonably low, which is good for GPCRs. No major difference.
**3. logP:** Ligand A (1.412) is better than Ligand B (2.661). While both are within the 1-3 range, Ligand A is closer to the optimal value. Higher logP can sometimes lead to off-target effects and solubility issues.
**4. H-Bond Donors:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
**5. H-Bond Acceptors:** Ligand A (5) is preferable to Ligand B (4). Fewer HBAs generally improve permeability.
**6. QED:** Ligand A (0.858) has a significantly better QED score than Ligand B (0.629), indicating a more drug-like profile.
**7. DILI:** Ligand A (54.827) has a higher DILI risk than Ligand B (21.753). This is a significant drawback for Ligand A.
**8. BBB:** Ligand A (68.282) has better BBB penetration than Ligand B (51.066). While ADRB2 is a cardiovascular target, some CNS exposure is not necessarily detrimental and a higher BBB score is generally preferable.
**9. Caco-2 Permeability:** Ligand A (-4.71) has better Caco-2 permeability than Ligand B (-5.114).
**10. Aqueous Solubility:** Both ligands have poor aqueous solubility (-2.831 and -2.925). This is a concern for both, but not a deciding factor.
**11. hERG Inhibition:** Ligand A (0.482) has a lower hERG inhibition liability than Ligand B (0.291). This is a positive for Ligand A.
**12. Microsomal Clearance:** Ligand A (-16.015) has significantly lower microsomal clearance than Ligand B (59.668), indicating better metabolic stability. This is a major advantage for Ligand A.
**13. In vitro Half-Life:** Ligand A (17.934) has a longer half-life than Ligand B (-1.535). This is a significant advantage for Ligand A.
**14. P-gp Efflux:** Ligand A (0.019) has much lower P-gp efflux than Ligand B (0.219), which is a positive for oral bioavailability.
**15. Binding Affinity:** Ligand A (-7.2) has a slightly better binding affinity than Ligand B (-6.2). This difference of 1 kcal/mol is significant and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand A is superior in most key ADME properties (QED, Cl_mic, t1/2, P-gp efflux) and has comparable or better binding affinity and permeability. While Ligand B has a lower DILI risk, the other advantages of Ligand A, particularly its metabolic stability and longer half-life, are more critical for a successful drug candidate. The slightly higher DILI risk of Ligand A can be investigated further during development.
Output:
1
2025-04-17 23:57:33,826 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [328.375, 62.83, 3.713, 2, 4, 0.561, 83.715, 41.915, -4.803, -5.322, 0.912, 13.109, -9.088, 0.544, -4.6]**
**Ligand B: [352.431, 104.73, 0.358, 3, 5, 0.473, 23.769, 27.104, -5.107, -1.381, 0.102, 17.823, -3.654, 0.027, -5.9]**
1. **Molecular Weight:** Both are within the ideal range (200-500 Da). Ligand A (328.375) is slightly preferred due to being on the lower end, potentially aiding permeability.
2. **TPSA:** Ligand A (62.83) is excellent, well below the 140 threshold for oral absorption. Ligand B (104.73) is still acceptable, but less ideal.
3. **logP:** Ligand A (3.713) is optimal. Ligand B (0.358) is quite low, potentially hindering membrane permeability and absorption. This is a significant drawback.
4. **H-Bond Donors:** Both ligands have acceptable HBD counts (2 and 3 respectively).
5. **H-Bond Acceptors:** Both ligands have acceptable HBA counts (4 and 5 respectively).
6. **QED:** Ligand A (0.561) is better than Ligand B (0.473), indicating a more drug-like profile.
7. **DILI:** Ligand B (23.769) has a much lower DILI risk than Ligand A (83.715). This is a major advantage for Ligand B.
8. **BBB:** Ligand A (41.915) has a slightly better BBB penetration than Ligand B (27.104), but both are relatively low and not a primary concern for a cardiovascular target like ADRB2.
9. **Caco-2 Permeability:** Ligand A (-4.803) is better than Ligand B (-5.107), indicating slightly better intestinal absorption.
10. **Aqueous Solubility:** Ligand A (-5.322) is better than Ligand B (-1.381), indicating better solubility.
11. **hERG Inhibition:** Ligand A (0.912) has a lower hERG risk than Ligand B (0.102).
12. **Microsomal Clearance:** Ligand A (13.109) has lower clearance, suggesting better metabolic stability.
13. **In vitro Half-Life:** Ligand A (-9.088) has a significantly longer half-life than Ligand B (-3.654).
14. **P-gp Efflux:** Ligand A (0.544) has lower P-gp efflux, which is good. Ligand B (0.027) is even lower, which is excellent.
15. **Binding Affinity:** Ligand B (-5.9) has a stronger binding affinity than Ligand A (-4.6). This is a substantial advantage.
**GPCR-Specific Priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are crucial. Ligand B excels in affinity and Pgp efflux, while Ligand A has better TPSA and logP. The low logP of Ligand B is a significant concern, potentially limiting its ability to reach the receptor. However, the strong binding affinity (-5.9 kcal/mol) could potentially compensate for this. The DILI risk of Ligand A is also a concern.
**Overall Assessment:**
While Ligand B has a significantly better binding affinity and a much lower DILI risk, its low logP is a major drawback. Ligand A has a more balanced profile, with acceptable logP, TPSA, solubility, metabolic stability, and a reasonable binding affinity. Considering the balance of properties, and the importance of good permeability (addressed by logP and TPSA) for a cardiovascular target, I lean towards Ligand A. The stronger affinity of Ligand B is tempting, but the potential absorption issues are too significant to ignore.
Output:
1
2025-04-17 23:57:33,826 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (336.351) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (111.78) is better than Ligand B (50.28) as it is below the 140 threshold for good oral absorption. Ligand B is very low, which is good, but may indicate a lack of necessary interactions.
3. **logP:** Both ligands have acceptable logP values (A: 2.461, B: 3.525), falling within the optimal 1-3 range. Ligand B is slightly higher, potentially increasing off-target interactions, but not drastically.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1), but both are within the acceptable limit of 5.
5. **HBA:** Both ligands have the same number of HBA (5), which is within the acceptable limit of 10.
6. **QED:** Ligand B (0.901) has a significantly higher QED score than Ligand A (0.718), indicating a more drug-like profile.
7. **DILI:** Ligand B (68.515) has a lower DILI risk than Ligand A (76.464), which is preferable. Both are still acceptable, but lower is better.
8. **BBB:** Ligand B (81.039) shows significantly better BBB penetration than Ligand A (30.206). While ADRB2 isn't exclusively a CNS target, some cardiovascular effects are mediated through central pathways, and better BBB penetration could be beneficial.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. Ligand A (-5.288) is slightly better than Ligand B (-4.82).
10. **Solubility:** Both ligands have negative solubility values, indicating poor solubility. Ligand A (-4.186) is slightly better than Ligand B (-4.565).
11. **hERG:** Both ligands have low hERG inhibition liability (A: 0.476, B: 0.893), which is good.
12. **Cl_mic:** Ligand A (30.435) has a lower microsomal clearance than Ligand B (69.802), suggesting greater metabolic stability.
13. **t1/2:** Ligand B (39.774) has a longer in vitro half-life than Ligand A (33.87), which is desirable.
14. **Pgp:** Ligand A (0.462) has lower P-gp efflux liability than Ligand B (0.27), which is preferable for bioavailability.
15. **Binding Affinity:** Ligand B (-7.4 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.8 kcal/mol). This 0.6 kcal/mol difference is substantial and can outweigh some ADME drawbacks.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, affinity, logP, TPSA, Pgp, and BBB are key. Ligand B excels in affinity and BBB penetration. While Ligand A has slightly better metabolic stability and Pgp efflux, the substantial affinity advantage of Ligand B is the most critical factor. The better QED and lower DILI risk of Ligand B are also significant positives.
**Conclusion:**
Despite some ADME drawbacks (slightly higher logP, higher Cl_mic, and worse Caco-2/Solubility), the significantly stronger binding affinity of Ligand B, coupled with its superior QED, DILI, and BBB scores, make it the more promising drug candidate for the ADRB2 receptor.
Output:
0
2025-04-17 23:57:33,826 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (366.53 and 361.48 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (67.43) is higher than Ligand B (40.54). For a cardiovascular GPCR, TPSA is moderately important, and Ligand B is significantly better, being well below the 140 threshold.
3. **logP:** Ligand A (3.05) is within the optimal 1-3 range. Ligand B (4.48) is slightly higher, potentially leading to solubility issues or off-target interactions, but still within a tolerable range.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable.
5. **HBA:** Ligand A (4) and Ligand B (3) are both acceptable.
6. **QED:** Both ligands have good QED scores (0.706 and 0.79), indicating good drug-like properties.
7. **DILI:** Ligand A (46.30) has a higher DILI risk than Ligand B (31.29). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (68.71) has a better BBB penetration score than Ligand B (56.15). While ADRB2 is not necessarily a CNS target, some distribution to the CNS can be acceptable or even desirable for certain cardiovascular effects.
9. **Caco-2:** Ligand A (-4.84) and Ligand B (-5.03) are both poor, indicating poor intestinal absorption.
10. **Solubility:** Ligand A (-3.67) and Ligand B (-4.49) are both poor.
11. **hERG:** Ligand A (0.50) has a slightly better hERG profile than Ligand B (0.93).
12. **Cl_mic:** Ligand A (63.11) has a much lower (better) microsomal clearance than Ligand B (113.26). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (26.85) has a longer in vitro half-life than Ligand B (-3.46). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.35) has lower P-gp efflux liability than Ligand B (0.62), which is favorable.
15. **Binding Affinity:** Ligand A (-5.8) has a slightly better binding affinity than Ligand B (-6.0). While both are excellent, the difference is not substantial enough to outweigh other factors.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand B excels in TPSA and Pgp, while Ligand A has a slight edge in affinity and a significant edge in metabolic stability (Cl_mic and t1/2). The DILI risk is also lower for Ligand B.
**Overall Assessment:**
While Ligand A has better metabolic stability and slightly better affinity, Ligand B's significantly lower DILI risk, better TPSA, and lower Pgp efflux make it a more promising candidate. The poor Caco-2 and solubility for both are concerning but could potentially be addressed with formulation strategies. The slightly lower BBB penetration of Ligand B isn't a major drawback for a cardiovascular target.
Output:
0
2025-04-17 23:57:33,826 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (421.733 Da) is slightly higher than Ligand B (354.491 Da), but both are acceptable.
**2. TPSA:** Both ligands have TPSA values (75.27 and 78.87) that are reasonably good for a non-CNS GPCR target, being below the 140 A^2 threshold.
**3. logP:** Ligand A (4.587) is higher than Ligand B (1.562). While a logP of 4.587 is approaching the upper limit of preference, it's not drastically high. Ligand B's logP is quite low, potentially hindering membrane permeability.
**4. H-Bond Donors & Acceptors:** Both ligands have 2 HBD and 3-4 HBA, which are within acceptable ranges.
**5. QED:** Both ligands have similar and acceptable QED values (0.716 and 0.759).
**6. DILI Risk:** Ligand A (90.539) has a significantly higher DILI risk than Ligand B (16.285). This is a major concern for Ligand A.
**7. BBB Penetration:** This is less critical for a cardiovascular target. Ligand A (43.815) and Ligand B (70.609) are both relatively low, which is fine.
**8. Caco-2 Permeability:** Both have negative Caco-2 values, indicating poor permeability.
**9. Aqueous Solubility:** Both ligands have poor aqueous solubility (-5.011 and -1.525).
**10. hERG Inhibition:** Ligand A (0.623) has a slightly higher hERG risk than Ligand B (0.208), but both are relatively low.
**11. Microsomal Clearance:** Ligand A (12.643 mL/min/kg) has a much lower (better) microsomal clearance than Ligand B (29.48 mL/min/kg), indicating better metabolic stability.
**12. In vitro Half-Life:** Ligand A (139.182 hours) has a significantly longer half-life than Ligand B (-0.75 hours). This is a substantial advantage for Ligand A.
**13. P-gp Efflux:** Ligand A (0.489) has lower P-gp efflux than Ligand B (0.036), which is preferable.
**14. Binding Affinity:** Ligand B (-8.2 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.7 kcal/mol). This is a substantial advantage for Ligand B.
**Overall Assessment:**
While Ligand A has better metabolic stability, half-life, and P-gp efflux, the extremely high DILI risk is a major red flag. Ligand B, despite its lower logP and weaker affinity, has a much more favorable safety profile (DILI) and a significantly better binding affinity. The affinity difference is substantial enough to outweigh the logP concern, especially considering the potential for optimization. The poor solubility and permeability of both compounds would need to be addressed in further development, but the safety profile is paramount at this stage.
Output:
0
2025-04-17 23:57:33,826 - INFO - Reasoning:
Let's analyze Ligand A and Ligand B for their potential as ADRB2 ligands, keeping in mind GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key).
**Molecular Weight:** Both ligands (354.47 and 359.46 Da) fall within the ideal 200-500 Da range.
**TPSA:** Ligand A (58.64) is significantly better than Ligand B (77.05). A TPSA under 90 is preferred, and A is comfortably within that range, while B is approaching the upper limit. This favors A for better permeability.
**logP:** Both ligands have good logP values (2.296 and 2.986), falling within the 1-3 range. B is slightly higher, which *could* be a minor drawback if it leads to solubility issues, but is still acceptable.
**H-Bond Donors/Acceptors:** Ligand A has 1 HBD and 3 HBA, while Ligand B has 0 HBD and 7 HBA. Both are within acceptable limits (<=5 HBD, <=10 HBA).
**QED:** Both have similar QED values (0.728 and 0.648), indicating good drug-likeness.
**DILI:** Ligand A (17.80) has a much lower DILI risk than Ligand B (59.17). This is a significant advantage for Ligand A.
**BBB:** Ligand A (96.94) has excellent BBB penetration, while Ligand B (57.15) is considerably lower. While ADRB2 isn't exclusively a CNS target, good BBB penetration can be beneficial for overall distribution and reducing off-target effects.
**Caco-2 Permeability:** Ligand A (-4.311) is better than Ligand B (-5.222). Higher values indicate better intestinal absorption.
**Aqueous Solubility:** Ligand A (-3.022) is better than Ligand B (-1.921). Higher values indicate better solubility.
**hERG:** Both ligands have low hERG inhibition liability (0.655 and 0.585), which is good.
**Microsomal Clearance:** Ligand A (49.91) has lower microsomal clearance than Ligand B (73.46), suggesting better metabolic stability.
**In vitro Half-Life:** Ligand A (-14.063) has a much longer in vitro half-life than Ligand B (-34.266). This is a substantial advantage for A.
**P-gp Efflux:** Both ligands have low P-gp efflux liability (0.179 and 0.258).
**Binding Affinity:** Ligand B (-6.1) has a slightly better binding affinity than Ligand A (-5.4). This is a 0.7 kcal/mol difference. While affinity is crucial, the other ADME properties of A are far superior.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B in most critical ADME properties (DILI, BBB, solubility, metabolic stability, half-life, permeability). While Ligand B has a slightly better binding affinity, the 0.7 kcal/mol difference is unlikely to outweigh the significant advantages of Ligand A in terms of safety, bioavailability, and pharmacokinetic profile. Given the GPCR target class, the favorable BBB penetration of Ligand A is also a significant benefit.
Output:
1
2025-04-17 23:57:33,826 - INFO - Batch 442 complete. Total preferences: 7072
2025-04-17 23:57:33,826 - INFO - Processing batch 443/512...
2025-04-17 23:58:22,571 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (399.204) is slightly higher than Ligand B (344.375), but both are acceptable.
2. **TPSA:** Ligand A (100.88) is better than Ligand B (113.24). Both are below the 140 A^2 threshold for oral absorption, but lower is preferable.
3. **logP:** Ligand A (3.008) is optimal, while Ligand B (-0.452) is significantly lower and potentially problematic for membrane permeability. This is a major strike against Ligand B.
4. **HBD:** Both ligands have 2 HBD, which is within the acceptable range.
5. **HBA:** Ligand A (5) is better than Ligand B (7). Both are within the acceptable range, but lower is preferable.
6. **QED:** Ligand B (0.776) has a slightly better QED score than Ligand A (0.552), suggesting a more drug-like profile.
7. **DILI:** Ligand A (98.953) has a very high DILI risk, which is concerning. Ligand B (47.189) has a much lower, and acceptable, DILI risk. This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (61.342) has a moderate BBB penetration, while Ligand B (24.195) is low. While ADRB2 isn't exclusively a CNS target, some CNS exposure can occur, and higher BBB is generally favorable.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability.
10. **Solubility:** Both ligands have negative solubility values, which is also unusual and suggests poor solubility.
11. **hERG:** Ligand A (0.688) has a slightly higher hERG risk than Ligand B (0.02), but both are relatively low.
12. **Cl_mic:** Ligand A (29.063) has a higher microsomal clearance than Ligand B (6.656), indicating lower metabolic stability. Ligand B is significantly better here.
13. **t1/2:** Ligand A (90.982) has a much longer in vitro half-life than Ligand B (2.62). This is a strong point in favor of Ligand A.
14. **Pgp:** Ligand A (0.425) has lower P-gp efflux than Ligand B (0.014), which is better for bioavailability.
15. **Binding Affinity:** Ligand B (-8.0) has a significantly stronger binding affinity than Ligand A (-7.5). This is a substantial advantage for Ligand B, potentially outweighing some ADME concerns.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand B excels in affinity and has a better logP. Ligand A has better Pgp and TPSA, but the poor logP of Ligand B is a major concern. The DILI risk is also a significant factor.
**Overall Assessment:**
Ligand B has a much better binding affinity and a significantly lower DILI risk. While its logP is suboptimal and BBB penetration is low, the strong binding affinity and lower toxicity are compelling. The longer half-life of Ligand A is attractive, but the high DILI risk and lower affinity are major drawbacks. Given the importance of potency and safety, I believe Ligand B is the more promising candidate, despite its weaknesses.
Output:
0
2025-04-17 23:58:22,571 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (351.403 and 349.439 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (109.66) is slightly higher than Ligand B (96.25). Both are below the 140 threshold for good oral absorption, but B is closer to the preferred <90 for GPCRs.
3. **logP:** Ligand A (0.133) is quite low, potentially hindering permeability. Ligand B (-0.571) is also low, but slightly better. Both are below the optimal 1-3 range.
4. **HBD:** Ligand A (3) is higher than Ligand B (1). Lower is generally preferred, giving a slight edge to B.
5. **HBA:** Ligand A (6) is slightly higher than Ligand B (7). Both are within the acceptable range of <=10.
6. **QED:** Both ligands have good QED scores (0.647 and 0.782), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand B (30.942) has a significantly lower DILI risk than Ligand A (54.827). This is a major advantage for B.
8. **BBB:** Ligand B (50.795) has a slightly better BBB penetration than Ligand A (45.909). While not exceptionally high, it's a positive for a GPCR target.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.169 and -5.376), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand B (-0.016) has slightly better aqueous solubility than Ligand A (-1.589).
11. **hERG:** Both ligands have very low hERG inhibition risk (0.124 and 0.05). This is excellent.
12. **Cl_mic:** Ligand B (-3.857) has a lower (better) microsomal clearance than Ligand A (-2.645), indicating better metabolic stability.
13. **t1/2:** Ligand A (15.408) has a slightly longer in vitro half-life than Ligand B (13.329).
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.034 and 0.011). This is excellent.
15. **Binding Affinity:** Ligand B (-7.0) has a slightly better binding affinity than Ligand A (-6.9). While the difference is small, it's still a positive.
**Overall Assessment & GPCR Focus:**
For an ADRB2 GPCR target, we prioritize logP, TPSA, Pgp, and affinity. Ligand B performs better on most of these key parameters. Specifically, the lower DILI risk and improved metabolic stability (lower Cl_mic) of Ligand B are significant advantages. While both have poor Caco-2 permeability, the slightly better TPSA and logP of Ligand B, combined with its superior safety profile and affinity, make it the more promising candidate. The slightly longer half-life of Ligand A is not enough to offset these advantages.
Output:
0
2025-04-17 23:58:22,571 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [338.386, 59.81, 3.334, 1, 4, 0.797, 61.264, 73.711, -5.071, -2.902, 0.771, 35.633, 28.055, 0.515, -6.6]**
**Ligand B: [365.539, 38.77, 4.373, 0, 4, 0.618, 22.451, 89.492, -4.752, -4.587, 0.748, 94.802, 30.425, 0.788, -6.5]**
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (338.386) is slightly preferred due to being closer to the lower end, potentially aiding permeability.
2. **TPSA:** Ligand A (59.81) is better than Ligand B (38.77) as it is below the 140 threshold for oral absorption.
3. **logP:** Both ligands have acceptable logP values (A: 3.334, B: 4.373), falling within the 1-3 range. Ligand A is slightly preferred as it is closer to the optimal range.
4. **H-Bond Donors:** Ligand A (1) is better than Ligand B (0) as it can contribute to solubility without significantly hindering permeability.
5. **H-Bond Acceptors:** Both ligands have the same number of H-bond acceptors (4).
6. **QED:** Ligand A (0.797) has a better QED score than Ligand B (0.618), indicating a more drug-like profile.
7. **DILI:** Ligand B (22.451) has a significantly lower DILI risk than Ligand A (61.264), which is a major advantage.
8. **BBB:** Ligand B (89.492) has a higher BBB penetration percentile than Ligand A (73.711). While ADRB2 isn't strictly a CNS target, some CNS exposure can be relevant for off-target effects, and higher BBB penetration is generally favorable.
9. **Caco-2 Permeability:** Ligand B (-4.752) has slightly better Caco-2 permeability than Ligand A (-5.071).
10. **Aqueous Solubility:** Ligand B (-4.587) has slightly better aqueous solubility than Ligand A (-2.902).
11. **hERG Inhibition:** Both ligands have similar hERG inhibition liability (A: 0.771, B: 0.748).
12. **Microsomal Clearance:** Ligand A (35.633) has lower microsomal clearance than Ligand B (94.802), indicating better metabolic stability.
13. **In vitro Half-Life:** Ligand B (30.425) has a slightly longer in vitro half-life than Ligand A (28.055).
14. **P-gp Efflux:** Ligand B (0.788) has slightly higher P-gp efflux than Ligand A (0.515).
15. **Binding Affinity:** Both ligands have very similar binding affinities (A: -6.6, B: -6.5).
**Overall Assessment:**
Considering the priorities for a GPCR target (logP, TPSA, Pgp, and affinity), Ligand B is more favorable. While Ligand A has a slightly better QED and metabolic stability, Ligand B's significantly lower DILI risk, better BBB penetration, and slightly improved solubility and Caco-2 permeability are crucial advantages. The binding affinities are nearly identical, so the ADME properties become the deciding factors. The lower DILI risk is particularly important for cardiovascular targets.
Output:
0
2025-04-17 23:58:22,571 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (403.28 Da) is within the ideal range. Ligand B (369.491 Da) is also within the ideal range. No clear advantage here.
2. **TPSA:** Ligand A (69.04) is excellent, well below the 140 threshold. Ligand B (124.03) is still reasonable but higher, potentially impacting absorption. A favors here.
3. **logP:** Ligand A (3.873) is at the upper end of the optimal range. Ligand B (1.491) is a bit low, potentially hindering membrane permeability. A favors here.
4. **HBD:** Ligand A (1) is good. Ligand B (2) is acceptable. No significant difference.
5. **HBA:** Ligand A (6) is good. Ligand B (4) is also good. No significant difference.
6. **QED:** Ligand A (0.479) is borderline, but acceptable. Ligand B (0.382) is lower, suggesting a less drug-like profile. A favors here.
7. **DILI:** Ligand A (79.721) is moderate risk. Ligand B (33.307) is very good, indicating low liver injury risk. B favors here significantly.
8. **BBB:** Ligand A (68.903) is reasonable, but not great. Ligand B (46.026) is lower. Since ADRB2 is a cardiovascular target, BBB penetration isn't *critical*, but it's still a positive if present. A favors slightly.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.061 and -5.231), which is unusual and suggests poor permeability *in vitro*. This is a concern for both.
10. **Solubility:** Both ligands have negative solubility values (-3.528 and -2.054), which is also unusual and suggests poor solubility *in vitro*. This is a concern for both.
11. **hERG:** Ligand A (0.767) is better than Ligand B (0.12), indicating a lower risk of cardiotoxicity. A favors here.
12. **Cl_mic:** Ligand A (113.21) is higher, indicating faster metabolism. Ligand B (30.094) is much lower, suggesting better metabolic stability. B favors here significantly.
13. **t1/2:** Ligand A (77.415) is good. Ligand B (-1.22) is very poor. A favors here significantly.
14. **Pgp:** Ligand A (0.535) is better than Ligand B (0.027), suggesting lower P-glycoprotein efflux. A favors here.
15. **Affinity:** Ligand A (-6.6 kcal/mol) is slightly better than Ligand B (-6.4 kcal/mol). While the difference is small, it's still a positive for A.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp efflux, and affinity are key. Ligand A is better in logP, TPSA, and Pgp. Affinity is only marginally better for A. While DILI and Cl_mic are important, the slight advantage in key GPCR properties for A outweighs the better DILI and Cl_mic of B. The very poor *in vitro* permeability and solubility for both are concerning and would require further investigation, but the other properties of A are more favorable for a GPCR target.
**Final Decision:**
Considering the balance of properties, particularly those prioritized for GPCRs, Ligand A appears to be the more promising candidate.
1
2025-04-17 23:58:22,572 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (355.429 and 349.435 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (58.37) is significantly better than Ligand B (89.35). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold. Ligand B is approaching the upper limit.
3. **logP:** Ligand A (3.732) is within the optimal 1-3 range. Ligand B (0.547) is quite low, potentially hindering membrane permeability. This is a significant negative for Ligand B.
4. **HBD:** Both ligands have 1 HBD, which is acceptable.
5. **HBA:** Ligand A has 4 HBAs, while Ligand B has 6. Both are within the acceptable limit of 10, but Ligand A is preferable.
6. **QED:** Both ligands have good QED scores (0.722 and 0.838), indicating good drug-likeness.
7. **DILI:** Ligand A (25.126) has a lower DILI risk than Ligand B (31.563), which is preferable.
8. **BBB:** Ligand A (98.061) has excellent BBB penetration, while Ligand B (56.883) is moderate. While not crucial for a cardiovascular target, higher BBB is rarely detrimental.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.69 and -4.98). This is unusual and suggests poor permeability *in vitro*. However, the values are similar, so this isn't a major differentiator.
10. **Solubility:** Ligand A (-2.762) has slightly better solubility than Ligand B (-1.394), although both are poor.
11. **hERG:** Ligand A (0.944) has a lower hERG risk than Ligand B (0.074), which is a significant advantage.
12. **Cl_mic:** Ligand A (26.052) has higher microsomal clearance than Ligand B (6.294), indicating lower metabolic stability. This is a negative for Ligand A.
13. **t1/2:** Ligand B (3.937) has a longer in vitro half-life than Ligand A (-17.456), which is a significant advantage.
14. **Pgp:** Ligand A (0.575) has lower P-gp efflux than Ligand B (0.005), which is preferable.
15. **Binding Affinity:** Ligand A (-7.3 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.0 kcal/mol). This >1.5 kcal/mol difference is a major advantage for Ligand A, potentially outweighing some of its ADME drawbacks.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A excels in logP, TPSA, Pgp, and *especially* affinity. While Ligand B has a better half-life and lower clearance, the substantial affinity difference and better overall ADME profile (excluding clearance) of Ligand A make it the more promising candidate. The lower hERG risk for Ligand A is also a significant benefit.
**Conclusion:**
Despite the lower metabolic stability of Ligand A, its superior binding affinity, better logP, TPSA, Pgp, and lower hERG risk outweigh the drawbacks.
Output:
1
2025-04-17 23:58:22,572 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's systematically compare Ligand A and Ligand B based on the provided parameters and the guidelines, keeping in mind the GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key).
1. **Molecular Weight:** Both ligands (357.445 Da and 370.559 Da) fall within the ideal range of 200-500 Da. No significant difference here.
2. **TPSA:** Ligand A (52.65) is better than Ligand B (58.64). Both are acceptable, but lower TPSA generally favors better absorption.
3. **logP:** Ligand A (1.871) is within the optimal range (1-3). Ligand B (2.544) is also acceptable, but slightly higher.
4. **H-Bond Donors:** Both ligands have 1 HBD, which is good.
5. **H-Bond Acceptors:** Ligand A has 3 HBA, and Ligand B has 4. Both are within the acceptable limit of 10.
6. **QED:** Ligand A (0.817) has a significantly better QED score than Ligand B (0.678), indicating a more drug-like profile.
7. **DILI:** Both ligands have relatively low DILI risk (20.047 and 21.714, respectively), and are both below the 40% threshold.
8. **BBB:** Ligand A (84.529) has a better BBB penetration percentile than Ligand B (75.998). While ADRB2 isn't strictly a CNS target, some peripheral distribution is still important, and higher BBB penetration can sometimes correlate with better overall permeability.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.718 and -4.89), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand A (-1.783) has slightly better solubility than Ligand B (-2.851), though both are quite poor.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.702 and 0.496, respectively).
12. **Cl_mic:** Ligand A (15.812) has significantly lower microsomal clearance than Ligand B (60.465), indicating better metabolic stability.
13. **t1/2:** Ligand A (6.774) has a shorter in vitro half-life than Ligand B (8.227), but both are relatively short.
14. **Pgp:** Ligand A (0.035) has much lower P-gp efflux liability than Ligand B (0.161), which is a significant advantage for bioavailability.
15. **Binding Affinity:** Ligand B (-7.6 kcal/mol) has a substantially stronger binding affinity than Ligand A (-6.1 kcal/mol). This is a >1.5 kcal/mol difference, which is a major advantage.
**Overall Assessment:**
Ligand B's significantly stronger binding affinity is a major positive. However, it is offset by its higher Pgp efflux, higher Cl_mic, and lower QED. Ligand A has better ADME properties across the board (QED, BBB, Pgp, Cl_mic, solubility) and a reasonable affinity. The poor Caco-2 values for both are concerning, but the better ADME profile of Ligand A, combined with its slightly better solubility, makes it the more promising starting point for optimization. The affinity difference, while substantial, can potentially be addressed through medicinal chemistry efforts while improving the ADME properties of Ligand A is likely to be more tractable.
**Output:**
1
2025-04-17 23:58:22,572 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.415 and 347.459 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (88.1) is slightly higher than Ligand B (78.51). Both are below 140, which is good for oral absorption, and acceptable for a cardiovascular target (not CNS). Ligand B is preferable.
3. **logP:** Both ligands (1.674 and 1.532) fall within the optimal 1-3 range. No significant difference.
4. **HBD:** Both ligands have 2 H-bond donors, which is within the acceptable limit of <=5. No difference.
5. **HBA:** Ligand A has 5 H-bond acceptors, while Ligand B has 3. Both are below the limit of 10. Ligand B is preferable.
6. **QED:** Ligand A (0.697) has a better QED score than Ligand B (0.49), indicating better overall drug-likeness. This favors Ligand A.
7. **DILI:** Ligand A (35.014) has a higher DILI risk than Ligand B (16.557). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (55.37) has a lower BBB penetration score than Ligand B (71.811). While BBB isn't a primary concern for a cardiovascular target, higher BBB is generally better. Ligand B is preferable.
9. **Caco-2:** Ligand A (-4.652) has a worse Caco-2 permeability than Ligand B (-5.284). Lower values indicate poorer permeability. Ligand B is preferable.
10. **Solubility:** Ligand A (-2.907) has slightly worse solubility than Ligand B (-1.685). Higher values are better. Ligand B is preferable.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.115 and 0.147), which is excellent. No significant difference.
12. **Cl_mic:** Ligand A (82.014) has a higher microsomal clearance than Ligand B (21.264). Lower clearance is better for metabolic stability, favoring Ligand B.
13. **t1/2:** Ligand A (-24.848) has a worse in vitro half-life than Ligand B (-14.29). Longer half-life is preferable, favoring Ligand B.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.032 and 0.034). No significant difference.
15. **Binding Affinity:** Ligand B (-6.0 kcal/mol) has a significantly better binding affinity than Ligand A (-4.1 kcal/mol). This is a >1.5 kcal/mol difference, which is a major advantage for Ligand B.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP, TPSA, Pgp (both are good), and *significantly* in affinity. While BBB isn't critical for a cardiovascular target, Ligand B also has a better score. Ligand A's better QED is offset by its higher DILI risk, worse metabolic stability, and significantly weaker binding.
**Conclusion:**
Ligand B is the superior candidate due to its significantly better binding affinity, lower DILI risk, improved metabolic stability, better permeability, and better solubility. These advantages outweigh Ligand A's slightly better QED score.
Output:
0
2025-04-17 23:58:22,572 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.406 and 349.362 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (78.87) is better than Ligand B (93.46). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is generally preferred for absorption.
3. **logP:** Both ligands have good logP values (1.925 and 1.746), falling within the optimal 1-3 range. Ligand B is slightly lower, which *could* indicate slightly better solubility, but the difference is minimal.
4. **HBD:** Both have 2 H-bond donors, which is good.
5. **HBA:** Ligand A has 4 H-bond acceptors, while Ligand B has 5. Ligand A is slightly better here.
6. **QED:** Ligand A (0.849) has a better QED score than Ligand B (0.757), suggesting a more drug-like profile.
7. **DILI:** Ligand A (34.781) has a significantly lower DILI risk than Ligand B (62.35). This is a major advantage for Ligand A.
8. **BBB:** Both have good BBB penetration (71.19 and 77.162), but Ligand B is slightly higher. Given that ADRB2 is not a CNS target, this is not a major deciding factor.
9. **Caco-2:** Both have very negative Caco-2 values (-4.744 and -4.745). This is unusual and suggests a potential issue with permeability. It's hard to interpret without knowing the scale, but they are both similarly poor.
10. **Solubility:** Both have very negative solubility values (-2.964 and -2.32). Again, the scale is unknown, but both appear to have poor aqueous solubility. Ligand B is slightly better.
11. **hERG:** Both have low hERG inhibition liability (0.49 and 0.318), which is good. Ligand B is slightly better.
12. **Cl_mic:** Ligand A (22.071) has a much lower microsomal clearance than Ligand B (51.087), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (-2.297) has a slightly better (less negative) in vitro half-life than Ligand B (-6.601).
14. **Pgp:** Both have low P-gp efflux liability (0.119 and 0.117). No significant difference.
15. **Binding Affinity:** Ligand A (-6.5 kcal/mol) has slightly better binding affinity than Ligand B (-6.2 kcal/mol), although the difference is relatively small.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity) and general drug-like properties, Ligand A is the more promising candidate. The significantly lower DILI risk and better metabolic stability (lower Cl_mic) are major advantages. While Ligand B has slightly better BBB penetration and hERG, these are less critical for a cardiovascular target. The slightly better affinity of Ligand A further supports its selection. The poor Caco-2 and solubility are concerning for both, but the other advantages of Ligand A outweigh this.
Output:
1
2025-04-17 23:58:22,572 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (361.433 and 353.419 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (72.88) is significantly better than Ligand B (107.97). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary goal, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (0.984) is within the optimal range (1-3), while Ligand B (-0.983) is slightly below, potentially hindering permeation.
4. **HBD:** Ligand A (2) and Ligand B (3) are both acceptable, being less than 5.
5. **HBA:** Ligand A (4) and Ligand B (5) are both acceptable, being less than 10.
6. **QED:** Ligand A (0.676) is better than Ligand B (0.494), indicating a more drug-like profile.
7. **DILI:** Both ligands have similar DILI risk (10.198 vs 11.594), and are both reasonably low.
8. **BBB:** Ligand A (78.558) has a much higher BBB penetration percentile than Ligand B (40.675). While not a primary concern for a cardiovascular target, higher BBB is generally not detrimental.
9. **Caco-2:** Ligand A (-4.883) and Ligand B (-5.292) are similar, and both are negative, suggesting poor permeability.
10. **Solubility:** Ligand A (-0.654) is slightly better than Ligand B (-0.833), although both are poor.
11. **hERG:** Ligand A (0.342) is significantly better than Ligand B (0.05), indicating a lower risk of cardiotoxicity. This is *crucial* for a cardiovascular target.
12. **Cl_mic:** Ligand A (11.697) and Ligand B (11.231) are very similar.
13. **t1/2:** Ligand A (-33.065) is much worse than Ligand B (18.675). This is a significant drawback for Ligand A.
14. **Pgp:** Ligand A (0.014) is much better than Ligand B (0.006), indicating lower P-gp efflux.
15. **Affinity:** Ligand A (-7.1) has a slightly better binding affinity than Ligand B (-6.0), a difference of 1.1 kcal/mol.
**GPCR-Specific Priorities & Overall Assessment:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A excels in logP, TPSA, Pgp, and affinity. Ligand B has a better half-life, but the significant advantage of Ligand A in hERG inhibition and the slightly better affinity outweigh this. The poor Caco-2 and solubility for both are concerning, but can be addressed with formulation strategies. The hERG risk for Ligand B is a major red flag for a cardiovascular drug.
**Output:**
1
2025-04-17 23:58:22,573 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (347.415 Da) is slightly lower, which is generally favorable for permeability, but both are acceptable.
**2. TPSA:** Ligand B (81.41) is significantly better than Ligand A (115.89). For a GPCR, lower TPSA is preferred as it generally correlates with better membrane permeability.
**3. logP:** Ligand B (2.894) is within the optimal range (1-3), while Ligand A (0.775) is slightly below, potentially hindering membrane permeation.
**4. H-Bond Donors:** Ligand A (4) is slightly higher than Ligand B (1), but both are within the acceptable limit of 5.
**5. H-Bond Acceptors:** Ligand B (9) is higher than Ligand A (5), but still within the acceptable limit of 10.
**6. QED:** Ligand B (0.669) has a better QED score than Ligand A (0.448), indicating a more drug-like profile.
**7. DILI Risk:** Ligand A (27.414) has a much lower DILI risk than Ligand B (86.778). This is a significant advantage for Ligand A.
**8. BBB Penetration:** Ligand B (71.617) shows better BBB penetration than Ligand A (23.11). While ADRB2 is a cardiovascular target and CNS penetration isn't *essential*, some degree of BBB penetration can be useful for off-target effects assessment and potential alternative therapeutic avenues.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability based on this metric. However, the scale is not specified, so it's hard to interpret.
**10. Aqueous Solubility:** Both ligands have negative solubility values, which is also unusual. This suggests poor solubility.
**11. hERG Inhibition:** Ligand A (0.503) has a slightly higher hERG inhibition risk than Ligand B (0.112), which is unfavorable.
**12. Microsomal Clearance:** Ligand A (-3.422) has a much lower (better) microsomal clearance than Ligand B (52.17), indicating greater metabolic stability.
**13. In vitro Half-Life:** Ligand A (-26.53) has a much longer in vitro half-life than Ligand B (-4.306), which is a significant advantage.
**14. P-gp Efflux:** Ligand A (0.01) has significantly lower P-gp efflux liability than Ligand B (0.328), which is beneficial for bioavailability.
**15. Binding Affinity:** Both ligands have comparable binding affinities (-6.5 and -5.9 kcal/mol). The difference is not substantial enough to be the deciding factor.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand B initially appears more promising due to its better logP and TPSA. However, the significantly higher DILI risk, higher P-gp efflux, and poorer metabolic stability (higher Cl_mic, shorter half-life) of Ligand B are major drawbacks. Ligand A, despite its slightly lower logP and BBB penetration, has a much more favorable safety profile (lower DILI), better metabolic stability, lower P-gp efflux, and comparable affinity. Given the cardiovascular context, minimizing off-target effects and ensuring adequate drug exposure are crucial.
Therefore, I favor Ligand A.
Output:
1
2025-04-17 23:58:22,573 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [349.471, 48.0, 3.707, 0.0, 5.0, 0.759, 33.191, 68.748, -4.393, -4.424, 0.822, 76.882, 7.605, 0.203, -7.9]**
**Ligand B: [371.453, 71.09, 3.364, 2.0, 4.0, 0.805, 62.815, 85.459, -4.944, -4.431, 0.359, 53.318, 24.965, 0.246, -6.1]**
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (349.471) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (48.0) is significantly better than Ligand B (71.09). ADRB2 is not a CNS target, but lower TPSA generally improves absorption.
3. **logP:** Both ligands have acceptable logP values (A: 3.707, B: 3.364), falling within the 1-3 range.
4. **H-Bond Donors:** Ligand A (0) is preferable to Ligand B (2). Fewer HBDs generally lead to better membrane permeability.
5. **H-Bond Acceptors:** Ligand A (5) is slightly better than Ligand B (4), both are within acceptable limits.
6. **QED:** Both ligands have good QED scores (A: 0.759, B: 0.805), indicating good drug-like properties.
7. **DILI:** Ligand A (33.191) has a significantly lower DILI risk than Ligand B (62.815). This is a major advantage for Ligand A.
8. **BBB:** While not a primary concern for ADRB2 (cardiovascular target), Ligand B (85.459) has better BBB penetration than Ligand A (68.748).
9. **Caco-2 Permeability:** Ligand A (-4.393) has slightly better Caco-2 permeability than Ligand B (-4.944).
10. **Aqueous Solubility:** Both ligands have similar, poor aqueous solubility (-4.424 and -4.431).
11. **hERG Inhibition:** Ligand A (0.822) has a slightly better hERG profile than Ligand B (0.359).
12. **Microsomal Clearance:** Ligand B (53.318) has a lower microsomal clearance than Ligand A (76.882), suggesting better metabolic stability.
13. **In vitro Half-Life:** Ligand B (24.965) has a significantly longer in vitro half-life than Ligand A (7.605). This is a significant advantage.
14. **P-gp Efflux:** Both ligands have low P-gp efflux liability (A: 0.203, B: 0.246).
15. **Binding Affinity:** Ligand A (-7.9) has a considerably stronger binding affinity than Ligand B (-6.1). This is a substantial advantage.
**Overall Assessment:**
Ligand A is preferable. The significantly stronger binding affinity (-7.9 vs -6.1 kcal/mol) and much lower DILI risk (33.191 vs 62.815) outweigh the advantages of Ligand B in terms of half-life and BBB penetration. While Ligand B has better metabolic stability, the potency and safety profile of Ligand A are more critical for a viable drug candidate. The lower TPSA and HBD count of Ligand A also contribute to its improved drug-like properties.
1
2025-04-17 23:58:22,573 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (345.407 and 350.459 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand B (82.78) is significantly better than Ligand A (130.84). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have acceptable logP values (1.075 and 2.424), falling within the 1-3 range. Ligand B is slightly more favorable.
4. **HBD:** Ligand A (4) is slightly higher than Ligand B (2), but both are within the acceptable limit of 5.
5. **HBA:** Ligand A (6) is higher than Ligand B (4), but both are within the acceptable limit of 10.
6. **QED:** Both ligands have good QED scores (0.656 and 0.791), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand B (26.134) has a *much* lower DILI risk than Ligand A (55.758). This is a crucial advantage.
8. **BBB:** Ligand B (68.748) has a higher BBB penetration percentile than Ligand A (58.317). While not essential for a cardiovascular target, it's a positive attribute.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.699 and -4.723), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Both ligands have very poor aqueous solubility (-2.085 and -2.057). This is a major drawback for both, and would require significant formulation work.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.134 and 0.448), which is excellent.
12. **Cl_mic:** Ligand A (-6.239) has a much lower (better) microsomal clearance than Ligand B (14.598), indicating greater metabolic stability.
13. **t1/2:** Ligand B (25.538) has a significantly longer in vitro half-life than Ligand A (-4.217). This is a major advantage.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.002 and 0.202).
15. **Affinity:** Both ligands have identical binding affinities (-6.0 kcal/mol).
**GPCR-Specific Priorities & Overall Assessment:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B is superior in logP and TPSA. The *massive* difference in DILI risk heavily favors Ligand B. While Ligand A has better metabolic stability (lower Cl_mic), Ligand B's longer half-life compensates for this. Both have poor solubility and Caco-2 permeability, which are significant concerns, but the other advantages of Ligand B outweigh this.
**Output:**
0
2025-04-17 23:58:22,573 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (358.423 and 357.523 Da) fall comfortably within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (89.28) is better than Ligand B (37.61) as it is closer to the optimal threshold of <140 for good oral absorption.
3. **logP:** Both ligands (3.575 and 3.966) are within the optimal 1-3 range, with Ligand B being slightly higher. This isn't a major concern, but slightly increases the risk of off-target effects.
4. **HBD:** Ligand A (2) is preferable to Ligand B (0). While both are acceptable, a small number of HBDs can aid solubility.
5. **HBA:** Ligand A (6) is preferable to Ligand B (4). Similar to HBD, a moderate number of HBAs is generally favorable.
6. **QED:** Both ligands (0.703 and 0.671) have good drug-likeness scores, exceeding the 0.5 threshold. No significant difference.
7. **DILI:** Ligand B (32.493) is *significantly* better than Ligand A (92.284). This is a major advantage for Ligand B, as lower DILI risk is crucial.
8. **BBB:** Ligand A (73.943) is better than Ligand B (89.57). While ADRB2 isn't necessarily a CNS target, some peripheral ADRB2 receptors can be affected by CNS penetration.
9. **Caco-2:** Ligand A (-4.945) is better than Ligand B (-5.091). Both are negative values, which is unusual and suggests poor permeability.
10. **Solubility:** Ligand A (-4.503) is better than Ligand B (-4.04). Both are very poor, but A is slightly better.
11. **hERG:** Both ligands (0.36 and 0.94) have low hERG inhibition risk, which is good. Ligand B is slightly higher, but still acceptable.
12. **Cl_mic:** Ligand B (100.738) is worse than Ligand A (67.944). Higher clearance means faster metabolism and potentially lower exposure.
13. **t1/2:** Ligand A (30.556) is much better than Ligand B (13.519). A longer half-life is generally desirable.
14. **Pgp:** Ligand B (0.855) is slightly worse than Ligand A (0.425). Lower P-gp efflux is preferred.
15. **Binding Affinity:** Both ligands (-5.6 and -5.7 kcal/mol) have very similar, strong binding affinities. The difference is negligible.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. While both ligands have good affinity and acceptable logP, Ligand B has a significantly lower DILI risk, which is a critical factor. The slightly higher Pgp efflux and clearance of Ligand B are drawbacks, but the substantial reduction in DILI risk outweighs these.
**Conclusion:**
While Ligand A has some advantages in TPSA, solubility, and half-life, the significantly lower DILI risk associated with Ligand B makes it the more promising drug candidate. The DILI risk for Ligand A is quite high and is a major concern.
Output:
0
2025-04-17 23:58:22,573 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [380.861, 114.07 , 0.682, 4. , 5. , 0.448, 85.459, 54.556, -5.28 , -3.391, 0.093, 32.865, -0.414, 0.085, -6.9 ]
**Ligand B:** [346.431, 89.28 , 2.784, 2. , 5. , 0.729, 54.323, 79.566, -4.668, -2.938, 0.247, 49.669, 6.587, 0.057, -5.8 ]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity, and BBB):
1. **MW:** Both are within the acceptable 200-500 Da range. Ligand B (346.431) is slightly preferred due to being lower.
2. **TPSA:** Ligand A (114.07) is slightly higher than Ligand B (89.28). Ligand B is better, being closer to the ideal <140 for oral absorption.
3. **logP:** Ligand B (2.784) is within the optimal 1-3 range, while Ligand A (0.682) is quite low. This is a significant advantage for Ligand B, as low logP can hinder membrane permeability.
4. **HBD:** Ligand A (4) is slightly higher than Ligand B (2). Ligand B is preferred.
5. **HBA:** Both have 5 HBA, which is acceptable.
6. **QED:** Ligand B (0.729) has a better QED score than Ligand A (0.448), indicating a more drug-like profile.
7. **DILI:** Ligand A (85.459) has a higher DILI risk than Ligand B (54.323). Ligand B is much preferred.
8. **BBB:** Ligand B (79.566) has a significantly higher BBB penetration score than Ligand A (54.556). While not a CNS target, better BBB penetration can sometimes indicate better overall distribution and reduced off-target effects.
9. **Caco-2:** Ligand A (-5.28) is much lower than Ligand B (-4.668), indicating poorer intestinal absorption. Ligand B is preferred.
10. **Solubility:** Ligand A (-3.391) is lower than Ligand B (-2.938), indicating lower solubility. Ligand B is preferred.
11. **hERG:** Ligand A (0.093) has a slightly higher hERG risk than Ligand B (0.247). Ligand B is preferred.
12. **Cl_mic:** Ligand A (32.865) has a lower microsomal clearance, suggesting better metabolic stability than Ligand B (49.669). This is a slight advantage for Ligand A.
13. **t1/2:** Ligand B (6.587) has a much longer in vitro half-life than Ligand A (-0.414). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.085) has lower P-gp efflux than Ligand B (0.057), which is slightly preferred.
15. **Affinity:** Ligand A (-6.9) has a slightly better binding affinity than Ligand B (-5.8). However, the difference is not substantial enough to outweigh the numerous advantages of Ligand B.
**Conclusion:**
Ligand B consistently outperforms Ligand A across most critical ADME properties (logP, TPSA, DILI, BBB, Caco-2, Solubility, hERG, t1/2) and has a better QED score. While Ligand A has slightly better affinity and metabolic stability, the overall profile of Ligand B is far more favorable for development as a drug candidate targeting ADRB2.
0
2025-04-17 23:58:22,574 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (343.362 and 355.41 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (80.55) is better than Ligand B (95.67). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (2.727) is slightly better than Ligand B (1.628), falling comfortably within the 1-3 optimal range. Ligand B is at the lower end, potentially impacting permeability.
4. **HBD:** Both ligands have 2 HBD, which is within the acceptable limit of <=5.
5. **HBA:** Both ligands have 5 HBA, which is within the acceptable limit of <=10.
6. **QED:** Both ligands have good QED scores (0.721 and 0.775), indicating good drug-like properties.
7. **DILI:** Ligand B (54.168) has a significantly lower DILI risk than Ligand A (79.604). This is a major advantage for Ligand B.
8. **BBB:** Both ligands have reasonable BBB penetration (76.037 and 59.868). Since ADRB2 is not a CNS target, this is less critical.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.799 and -4.911), indicating poor permeability. This is a significant drawback for both.
10. **Solubility:** Ligand A (-3.644) has slightly better solubility than Ligand B (-2.081).
11. **hERG:** Both ligands have very low hERG risk (0.209 and 0.326).
12. **Cl_mic:** Ligand B (29.062) has significantly lower microsomal clearance than Ligand A (42.673), suggesting better metabolic stability.
13. **t1/2:** Ligand A (56.698) has a longer in vitro half-life than Ligand B (-6.282). This is a positive for Ligand A.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.155 and 0.142).
15. **Binding Affinity:** Ligand B (-4.9) has a slightly better binding affinity than Ligand A (-3.6). This is a 1.3 kcal/mol difference, which is substantial.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A has a better logP and TPSA, but Ligand B has a significantly better affinity and lower DILI and Cl_mic. The affinity difference is substantial enough to outweigh the slightly less favorable logP and TPSA of Ligand B. The lower DILI and Cl_mic are also significant advantages.
**Conclusion:**
Despite the poor Caco-2 permeability for both, Ligand B's superior binding affinity, lower DILI risk, and better metabolic stability make it the more promising candidate.
Output:
0
2025-04-17 23:58:22,574 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [370.446, 70.08, 1.221, 1, 5, 0.865, 37.767, 80.07, -4.478, -2.128, 0.469, 22.045, 16.691, 0.229, -5.5]
**Ligand B:** [346.471, 58.64, 2.127, 1, 3, 0.395, 8.375, 80.341, -4.689, -2.273, 0.355, 23.256, -1.137, 0.122, -6.2]
Here's a breakdown of the comparison, considering the provided guidelines and GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (346.471) is slightly lower, which isn't a major concern.
2. **TPSA:** Ligand A (70.08) is a bit higher than Ligand B (58.64). Both are acceptable for a cardiovascular target, but lower is generally better for permeability. Ligand B is preferable here.
3. **logP:** Ligand A (1.221) is within the optimal range. Ligand B (2.127) is also good, but slightly higher. This could potentially lead to some off-target interactions, but it's not a deal-breaker.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 5 HBA, Ligand B has 3. Lower is generally better for permeability, so Ligand B is preferable.
6. **QED:** Ligand A (0.865) has a significantly better QED score than Ligand B (0.395), indicating a more drug-like profile. This is a substantial advantage for Ligand A.
7. **DILI:** Ligand A (37.767) has a much lower DILI risk than Ligand B (8.375). This is a significant advantage for Ligand A.
8. **BBB:** Both have good BBB penetration (around 80%), which isn't a primary concern for a cardiovascular target, but isn't detrimental.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. This is a concern for both.
10. **Solubility:** Both have negative solubility values, indicating poor solubility. This is a concern for both.
11. **hERG:** Both have low hERG inhibition risk, which is good.
12. **Cl_mic:** Ligand A (22.045) has a slightly higher microsomal clearance than Ligand B (23.256), suggesting slightly lower metabolic stability.
13. **t1/2:** Ligand A (16.691) has a longer in vitro half-life than Ligand B (-1.137). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.229) has lower P-gp efflux liability than Ligand B (0.122), which is preferable.
15. **Affinity:** Ligand B (-6.2 kcal/mol) has a slightly stronger binding affinity than Ligand A (-5.5 kcal/mol). This is a 0.7 kcal/mol difference, which is a noticeable advantage.
**Overall Assessment:**
While Ligand B has a slightly better binding affinity, Ligand A demonstrates a significantly more favorable overall profile. Its superior QED score, much lower DILI risk, longer half-life, and lower P-gp efflux liability outweigh the minor affinity difference. The poor Caco-2 and solubility for both are concerning and would need to be addressed in further optimization, but these are properties that can be improved. Given the GPCR target class, the balance of properties in Ligand A is more promising.
Output:
1
2025-04-17 23:58:22,574 - INFO - Batch 443 complete. Total preferences: 7088
2025-04-17 23:58:22,574 - INFO - Processing batch 444/512...
2025-04-17 23:59:10,967 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (381.969 Da) is within the ideal range (200-500 Da). Ligand B (340.427 Da) is also within the ideal range. No clear advantage here.
2. **TPSA:** Ligand A (37.38) is excellent, well below the 140 threshold and suggesting good absorption. Ligand B (67.23) is still reasonable, but higher, potentially impacting absorption. Advantage: A.
3. **logP:** Ligand A (4.703) is slightly high, potentially leading to solubility issues or off-target effects. Ligand B (1.897) is optimal. Advantage: B.
4. **HBD:** Both ligands have acceptable HBD counts (A: 0, B: 1), well below the limit of 5. No clear advantage.
5. **HBA:** Both ligands have acceptable HBA counts (A: 2, B: 4), below the limit of 10. No clear advantage.
6. **QED:** Both ligands have good QED scores (A: 0.669, B: 0.924). Ligand B is better. Advantage: B.
7. **DILI:** Both ligands have low DILI risk (A: 31.563, B: 34.587), below the 40 threshold. No clear advantage.
8. **BBB:** Ligand A (87.088) has a significantly higher BBB penetration percentile than Ligand B (67.352). While ADRB2 isn't *strictly* a CNS target, some CNS exposure can be beneficial or at least not detrimental for cardiovascular drugs, and higher BBB is generally favorable. Advantage: A.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.04 and -5.084), which is unusual and suggests poor permeability. This is a significant concern for both. No clear advantage.
10. **Solubility:** Ligand A (-6.144) has worse solubility than Ligand B (-1.996). Advantage: B.
11. **hERG:** Both ligands have low hERG inhibition risk (A: 0.876, B: 0.503). Advantage: B.
12. **Cl_mic:** Ligand A (75.747) has higher microsomal clearance than Ligand B (7.763), indicating lower metabolic stability. Advantage: B.
13. **t1/2:** Ligand A (-19.228) has a negative in vitro half-life, which is concerning. Ligand B (-14.637) is also negative, but less so. Both are problematic. No clear advantage.
14. **Pgp:** Both ligands have low P-gp efflux liability (A: 0.521, B: 0.107). Advantage: B.
15. **Binding Affinity:** Ligand A (-7.0) has slightly better binding affinity than Ligand B (-6.2). This is a 0.8 kcal/mol difference, which is significant. Advantage: A.
**Overall Assessment & GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B has a better logP, QED, solubility, hERG, Cl_mic, and Pgp profile. However, Ligand A has a significantly better BBB score and a slightly better binding affinity. The negative Caco-2 and t1/2 values are concerning for both.
The binding affinity difference (0.8 kcal/mol) is substantial enough to potentially overcome some of the ADME liabilities of Ligand A, *especially* given the better BBB penetration. The slightly higher TPSA of Ligand B is less concerning than the higher logP. The metabolic stability (Cl_mic) is a concern for Ligand A, but optimization could address this.
Considering the balance, the slightly better affinity and BBB penetration of Ligand A outweigh the advantages of Ligand B, assuming the metabolic stability can be improved.
Output:
1
2025-04-17 23:59:10,967 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [395.262, 76.58, 3.913, 1, 6, 0.473, 70.803, 76.037, -4.652, -4.775, 0.369, 63.539, 13.523, 0.177, -6.9]
**Ligand B:** [356.482, 58.64, 2.826, 1, 3, 0.727, 19.698, 96.161, -4.406, -2.69, 0.678, 14.068, -1.932, 0.193, -7.2]
**Step-by-step comparison:**
1. **MW:** Both are within the acceptable range (200-500 Da). Ligand B (356.482) is slightly preferred due to being closer to the ideal range.
2. **TPSA:** Ligand A (76.58) is higher than Ligand B (58.64). Both are below 140, but B is better for absorption.
3. **logP:** Ligand A (3.913) is at the upper end of the optimal range, while Ligand B (2.826) is more centered. Ligand B is slightly preferred here.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A (6) has more HBA than Ligand B (3). Ligand B is preferred.
6. **QED:** Ligand B (0.727) has a better QED score than Ligand A (0.473), indicating better overall drug-likeness.
7. **DILI:** Ligand A (70.803) has a higher DILI risk than Ligand B (19.698). This is a significant advantage for Ligand B.
8. **BBB:** Ligand B (96.161) has much better BBB penetration potential than Ligand A (76.037). Given this is a GPCR, and potential CNS effects are relevant, this is a major advantage for Ligand B.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Ligand B (-2.69) has better solubility than Ligand A (-4.775).
11. **hERG:** Ligand A (0.369) has a lower hERG risk than Ligand B (0.678), which is a slight advantage.
12. **Cl_mic:** Ligand B (14.068) has a lower microsomal clearance than Ligand A (63.539), indicating better metabolic stability.
13. **t1/2:** Ligand B (-1.932) has a longer in vitro half-life than Ligand A (13.523).
14. **Pgp:** Ligand B (0.193) has lower P-gp efflux liability than Ligand A (0.177), which is a slight advantage.
15. **Affinity:** Ligand B (-7.2) has a slightly better binding affinity than Ligand A (-6.9). While the difference is small, it's still a positive.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity) and the general guidelines, **Ligand B is significantly more promising**. It has better drug-likeness (QED), a much lower DILI risk, superior BBB penetration, better solubility, and improved metabolic stability. The slightly better affinity is a bonus. While Ligand A has a slightly lower hERG risk, the other advantages of Ligand B outweigh this minor difference.
Output:
0
2025-04-17 23:59:10,968 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
The target is ADRB2, a GPCR. Therefore, I will prioritize logP, Pgp, TPSA, and binding affinity, alongside general drug-like properties.
* **Molecular Weight:** Both ligands are within the acceptable range (200-500 Da). Ligand A (335.342 Da) is slightly lower, which is generally favorable for permeability.
* **TPSA:** Ligand A (83.6) is significantly better than Ligand B (103.7). A TPSA under 140 is good for oral absorption, and lower is better for GPCRs.
* **logP:** Ligand A (3.042) is optimal, while Ligand B (0.11) is very low. Low logP can lead to poor membrane permeability. This is a major drawback for Ligand B.
* **H-Bond Donors/Acceptors:** Both have 1 HBD and 5 HBA, which are acceptable.
* **QED:** Both ligands have good QED scores (A: 0.777, B: 0.823), indicating good overall drug-likeness.
* **DILI:** Ligand A (79.643) is slightly higher than Ligand B (67.429), but both are reasonably low risk.
* **BBB:** Both are similar (A: 55.138, B: 54.246). BBB isn't a primary concern for ADRB2 unless targeting CNS effects.
* **Caco-2:** Both have negative values, indicating poor permeability. However, Ligand A (-4.858) is slightly better than Ligand B (-5.2).
* **Solubility:** Both have negative values, indicating poor solubility. Ligand A (-3.326) is slightly better than Ligand B (-2.168).
* **hERG:** Ligand A (0.836) has a slightly higher hERG risk than Ligand B (0.041), but both are relatively low.
* **Cl_mic:** Ligand A (23.499) has a much better (lower) microsomal clearance than Ligand B (-18.849). This suggests better metabolic stability for Ligand A.
* **t1/2:** Ligand A (10.367) has a better in vitro half-life than Ligand B (-25.284).
* **Pgp:** Ligand A (0.168) has much lower P-gp efflux liability than Ligand B (0.004), which is a significant advantage.
* **Binding Affinity:** Ligand A (-7.8 kcal/mol) has a significantly stronger binding affinity than Ligand B (-3.4 kcal/mol). This is a substantial advantage, and can often outweigh minor ADME concerns.
**Conclusion:**
Ligand A is clearly the superior candidate. Its optimal logP, better TPSA, significantly stronger binding affinity, lower Pgp efflux, and better metabolic stability outweigh the slightly higher DILI and hERG risk. Ligand B's very low logP is a major concern, likely leading to poor permeability and bioavailability.
**Output:**
1
2025-04-17 23:59:10,968 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.343 and 349.381 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand B (62.3) is significantly better than Ligand A (133.67). For a GPCR, lower TPSA is generally preferred for better permeability. Ligand A is above the 90 A^2 threshold for CNS targets, while B is well below.
3. **logP:** Ligand B (2.294) is within the optimal 1-3 range, while Ligand A (0.58) is slightly below 1, which could indicate potential permeability issues. This favors Ligand B.
4. **HBD:** Ligand A (4) is slightly higher than Ligand B (1). Both are acceptable, but lower is generally preferred.
5. **HBA:** Ligand A (7) is higher than Ligand B (3). Again, lower is preferred.
6. **QED:** Ligand B (0.83) has a substantially better QED score than Ligand A (0.601), indicating a more drug-like profile.
7. **DILI:** Ligand B (32.028) has a much lower DILI risk than Ligand A (77.549). This is a significant advantage for Ligand B.
8. **BBB:** Ligand B (96.123) has a very high BBB penetration score, while Ligand A (30.05) is low. While ADRB2 isn't exclusively a CNS target, good BBB penetration can be beneficial and doesn't hurt.
9. **Caco-2:** Ligand A (-5.356) and Ligand B (-4.4) are both negative, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
10. **Solubility:** Ligand A (-3.124) and Ligand B (-2.933) are both negative, suggesting poor solubility. Again, the scale is not specified.
11. **hERG:** Ligand B (0.552) has a slightly better hERG profile than Ligand A (0.28), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand A (19.341) has a lower microsomal clearance than Ligand B (25.332), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-15.648) has a longer in vitro half-life than Ligand A (-26.305), which is a positive attribute.
14. **Pgp:** Ligand A (0.019) has a lower Pgp efflux liability than Ligand B (0.025), which could translate to better bioavailability.
15. **Binding Affinity:** Ligand B (-6.7 kcal/mol) has a slightly better binding affinity than Ligand A (-5.5 kcal/mol). This is a 1.2 kcal/mol difference, which is significant enough to outweigh some of the ADME drawbacks of Ligand A.
**Overall Assessment:**
Ligand B is clearly the superior candidate. It excels in key GPCR-relevant properties like TPSA, logP, BBB penetration, and binding affinity. It also has a significantly better DILI score and QED. While Ligand A has slightly better metabolic stability and Pgp efflux, the advantages of Ligand B in other critical areas are more substantial. The slightly better binding affinity of Ligand B further solidifies its position as the preferred candidate.
Output:
0
2025-04-17 23:59:10,968 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [362.392, 58.64, 2.253, 1, 3, 0.835, 24.195, 91.198, -4.607, -2.846, 0.375, 16.395, -4.318, 0.067, -4.7]
**Ligand B:** [351.447, 114.45, 0.482, 5, 4, 0.445, 27.414, 32.416, -5.522, -2.185, 0.177, 6.377, -17.757, 0.118, -7.2]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, BBB, and affinity are key):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (351.447) is slightly lower, which isn't a major concern.
2. **TPSA:** Ligand A (58.64) is excellent, well below the 140 threshold and good for permeability. Ligand B (114.45) is higher, but still acceptable, though less ideal.
3. **logP:** Ligand A (2.253) is optimal. Ligand B (0.482) is quite low, potentially hindering membrane permeability and bioavailability. This is a significant drawback.
4. **HBD/HBA:** Ligand A (1 HBD, 3 HBA) is preferable. Ligand B (5 HBD, 4 HBA) has more donors, potentially affecting permeability and increasing the risk of off-target interactions.
5. **QED:** Ligand A (0.835) is much better than Ligand B (0.445), indicating a more drug-like profile.
6. **DILI:** Both are reasonably low (A: 24.195, B: 27.414), suggesting acceptable liver safety.
7. **BBB:** Ligand A (91.198) has excellent BBB penetration, which is a plus for a GPCR target. Ligand B (32.416) is very poor, making CNS effects unlikely and potentially limiting its overall utility.
8. **Caco-2:** Both are negative, indicating poor permeability. However, the scale is not specified, so it's hard to interpret.
9. **Solubility:** Both are negative, indicating poor solubility.
10. **hERG:** Both are very low, indicating minimal hERG inhibition risk.
11. **Cl_mic:** Ligand A (16.395) has a higher clearance than Ligand B (6.377), meaning it's metabolized faster. This is a negative for A.
12. **t1/2:** Ligand B (-17.757) has a much longer half-life than Ligand A (-4.318).
13. **Pgp:** Ligand A (0.067) demonstrates very low P-gp efflux, which is excellent. Ligand B (0.118) is slightly higher, but still relatively low.
14. **Affinity:** Ligand B (-7.2 kcal/mol) has a significantly stronger binding affinity than Ligand A (-4.7 kcal/mol). This is a substantial advantage.
**Overall Assessment:**
Ligand B has a much better binding affinity, and a significantly longer half-life. However, its low logP and higher TPSA are concerning for permeability and bioavailability. Ligand A has better physicochemical properties (logP, TPSA, QED, BBB), and lower Pgp efflux, but weaker binding affinity and faster clearance.
Given the GPCR target and the importance of brain penetration (even if not explicitly a CNS target, some peripheral GPCRs benefit from better distribution), and considering the substantial affinity difference, I believe the stronger binding of Ligand B can be optimized through medicinal chemistry efforts to address its permeability issues. The difference in affinity (-7.2 vs -4.7) is significant enough to warrant prioritizing Ligand B.
Output:
0
2025-04-17 23:59:10,968 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (370.471 Da) is slightly higher than Ligand B (352.431 Da), but both are acceptable.
2. **TPSA:** Both are below the 140 A^2 threshold for good oral absorption. Ligand A (88.1) is slightly higher than Ligand B (81.01), but both are good.
3. **logP:** Ligand A (0.593) is a bit low, potentially hindering permeation. Ligand B (1.785) is better, falling within the optimal 1-3 range. This is a point in favor of Ligand B.
4. **HBD:** Both ligands have acceptable HBD counts (Ligand A: 2, Ligand B: 1).
5. **HBA:** Both ligands have acceptable HBA counts (Ligand A: 6, Ligand B: 5).
6. **QED:** Both ligands have good QED scores (Ligand A: 0.762, Ligand B: 0.771), indicating good drug-like properties.
7. **DILI:** Ligand A (17.449%) has a significantly lower DILI risk than Ligand B (40.869%). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (73.943%) has a better BBB penetration score than Ligand B (65.452%). While ADRB2 isn't strictly a CNS target, some CNS exposure can occur, and higher BBB is generally favorable.
9. **Caco-2:** Ligand A (-5.444) has a worse Caco-2 permeability than Ligand B (-4.592). This suggests Ligand B might have better intestinal absorption.
10. **Solubility:** Ligand A (-1.349) has slightly better solubility than Ligand B (-1.905).
11. **hERG:** Ligand A (0.701) has a lower hERG inhibition liability than Ligand B (0.232), indicating a lower risk of cardiotoxicity. This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand A (-8.204) has a much lower microsomal clearance than Ligand B (24.962), suggesting better metabolic stability. This is a strong point in favor of Ligand A.
13. **t1/2:** Ligand B (19.874) has a significantly longer in vitro half-life than Ligand A (-2.72). This is a major advantage for Ligand B.
14. **Pgp:** Both ligands have low Pgp efflux liability (Ligand A: 0.068, Ligand B: 0.065).
15. **Binding Affinity:** Ligand B (-7.6 kcal/mol) has a stronger binding affinity than Ligand A (-6.7 kcal/mol). This is a 0.9 kcal/mol difference, which is substantial and a significant advantage for Ligand B.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand B excels in logP and affinity. Ligand A is better on TPSA and Pgp, but the affinity difference is substantial.
**Overall Assessment:**
While Ligand A has advantages in DILI, hERG, and Cl_mic, the significantly stronger binding affinity of Ligand B (-7.6 vs -6.7 kcal/mol) and better logP outweigh these benefits. The longer half-life of Ligand B is also a positive. The slightly higher DILI and hERG risks of Ligand B can be investigated further during optimization. The improved affinity is likely to translate to better efficacy.
Output:
0
2025-04-17 23:59:10,968 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's break down the comparison, prioritizing parameters relevant to GPCRs (logP, TPSA, Pgp, BBB, and affinity).
1. **Molecular Weight:** Both ligands are within the acceptable range (200-500 Da). Ligand A (339.439) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (65.2) is significantly better than Ligand B (121.61). A TPSA under 140 is good for oral absorption, but lower is preferred for GPCRs, and Ligand A is much closer to the ideal range for potential CNS penetration (though BBB is the ultimate determinant).
3. **logP:** Ligand A (3.243) is within the optimal range (1-3). Ligand B (-0.309) is considerably lower, which is a significant concern for membrane permeability and bioavailability.
4. **H-Bond Donors/Acceptors:** Ligand A (2 HBD, 2 HBA) is better balanced than Ligand B (3 HBD, 7 HBA). Ligand B has a higher number of HBA, potentially impacting permeability.
5. **QED:** Both have reasonable QED scores (A: 0.821, B: 0.553), indicating drug-like properties, but A is better.
6. **DILI:** Ligand A (65.917) has a higher DILI risk than Ligand B (29.895). This is a negative for Ligand A, but can be addressed in optimization.
7. **BBB:** Ligand A (62.117) has a better BBB percentile than Ligand B (32.648). While ADRB2 isn't strictly a CNS target, some CNS penetration can be beneficial, and a lower BBB score is a concern for B.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
9. **Solubility:** Both have negative solubility values, which is also unusual.
10. **hERG:** Ligand A (0.521) has a slightly higher hERG risk than Ligand B (0.194), but both are relatively low.
11. **Cl_mic:** Ligand B (-1.448) has a negative microsomal clearance, which is not possible and suggests an error in the data. Ligand A (50.241) is reasonable.
12. **t1/2:** Both have similar in vitro half-lives (A: 54.021, B: 51.069).
13. **Pgp:** Ligand A (0.393) has better Pgp efflux liability than Ligand B (0.021). Lower Pgp is preferred.
14. **Binding Affinity:** Ligand B (-6.5 kcal/mol) has a slightly better binding affinity than Ligand A (-5.7 kcal/mol). This is a 0.8 kcal/mol difference, which is noticeable but not overwhelmingly decisive given the other factors.
**Overall Assessment:**
Ligand A is significantly better overall. Its superior logP, TPSA, Pgp efflux, and BBB penetration are crucial for a GPCR target. The slightly higher DILI risk is a concern, but can be addressed during lead optimization. The anomalous Caco-2 and solubility values are concerning, but the other properties of A are more favorable. Ligand B's very low logP and the impossible negative Cl_mic are major drawbacks. The slightly better binding affinity of B is not enough to overcome these significant ADME issues.
Output:
1
2025-04-17 23:59:10,969 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, priorities are logP, Pgp, TPSA, affinity, and to a lesser extent, BBB.
Let's compare the ligands property by property:
1. **MW:** Both are within the ideal range (347 vs 344 Da).
2. **TPSA:** Ligand B (49.41) is significantly better than Ligand A (119.24). Lower TPSA is preferred for GPCRs, aiding permeability.
3. **logP:** Ligand B (3.586) is higher than Ligand A (1.493), but both are within acceptable ranges. A slightly higher logP can be beneficial for GPCR binding.
4. **HBD:** Ligand B (1) has fewer HBDs than Ligand A (2), which is preferable.
5. **HBA:** Ligand B (2) has fewer HBAs than Ligand A (7), which is preferable.
6. **QED:** Ligand A (0.694) has a slightly better QED score than Ligand B (0.567), suggesting slightly better overall drug-likeness.
7. **DILI:** Ligand B (9.771) has a *much* lower DILI risk than Ligand A (68.399). This is a major advantage for Ligand B.
8. **BBB:** Ligand B (74.292) has a better BBB penetration score than Ligand A (67.197), though neither is exceptionally high. This is less critical for a cardiovascular target.
9. **Caco-2:** Both are negative, indicating poor permeability.
10. **Solubility:** Both are negative, indicating poor solubility.
11. **hERG:** Both have low hERG inhibition risk.
12. **Cl_mic:** Ligand B (48.26) has slightly lower microsomal clearance than Ligand A (51.252), indicating better metabolic stability.
13. **t1/2:** Ligand B (-14.182) has a longer in vitro half-life than Ligand A (-30.449), which is a significant advantage.
14. **Pgp:** Ligand B (0.145) has lower P-gp efflux than Ligand A (0.051), which is preferable.
15. **Affinity:** Ligand B (-7.5 kcal/mol) has a slightly better binding affinity than Ligand A (-7.0 kcal/mol).
**Overall Assessment:**
Ligand B demonstrates a superior balance of properties, particularly regarding ADME-Tox. The significantly lower DILI risk, better TPSA, lower HBD/HBA counts, improved metabolic stability (lower Cl_mic, longer t1/2), and slightly better affinity outweigh Ligand A's marginally better QED score. The slightly higher logP of Ligand B is also acceptable. The negative Caco-2 and solubility values are concerning for both, but can be addressed with formulation strategies.
Output:
0
2025-04-17 23:59:10,969 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.435 and 364.467 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Both are good (89.07 and 84.5), well below the 140 threshold for oral absorption. Ligand B is slightly better.
3. **logP:** Both are within the optimal 1-3 range (1.028 and 2.005). Ligand B is a bit higher, which could be slightly beneficial for membrane permeability, but not drastically.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Ligand B (4) is preferable to Ligand A (7). Lower HBA generally improves permeability.
6. **QED:** Both are excellent (0.809 and 0.837), indicating good drug-like properties. No significant difference.
7. **DILI:** Ligand A (52.385) is significantly better than Ligand B (67.003). Lower DILI risk is crucial.
8. **BBB:** Ligand A (55.138) is better than Ligand B (44.668), though neither is exceptionally high. For a cardiovascular target, BBB isn't *critical*, but some penetration can be helpful for off-target effects.
9. **Caco-2:** Both are negative, indicating poor permeability. This is a concern for both, but the scale is not provided, so it's hard to interpret.
10. **Solubility:** Both are negative, indicating poor solubility. This is a concern for both, but the scale is not provided, so it's hard to interpret.
11. **hERG:** Both are very low (0.244 and 0.212), indicating minimal hERG inhibition risk. Excellent for both.
12. **Cl_mic:** Ligand A (26.554) has significantly lower microsomal clearance than Ligand B (59.144), suggesting better metabolic stability.
13. **t1/2:** Ligand A (50.6) has a much longer in vitro half-life than Ligand B (-18.221). This is a major advantage for Ligand A.
14. **Pgp:** Both are very low (0.227 and 0.223), indicating minimal P-gp efflux. No significant difference.
15. **Affinity:** Ligand A (-7.7) has a slightly better binding affinity than Ligand B (-7.3). While the difference is small, it's still a positive.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, and affinity are important. Both ligands perform reasonably well on these. However, ADME properties are also critical. Ligand A clearly wins on DILI risk, metabolic stability (Cl_mic), and in vitro half-life.
**Overall Assessment:**
Ligand A presents a more favorable overall profile, particularly regarding safety (DILI) and pharmacokinetic properties (Cl_mic, t1/2). The slightly better affinity is a bonus. While both have issues with Caco-2 and solubility, the superior ADME profile of Ligand A makes it the more promising drug candidate.
Output:
1
2025-04-17 23:59:10,969 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [355.435, 107.97 , -0.593, 3. , 5. , 0.485, 17.216, 45.87 ,
-5.249, -1.033, 0.143, 18.072, 19.178, 0.014, -5.9 ]
**Ligand B:** [346.475, 88.32 , 2.601, 2. , 4. , 0.708, 39.356, 88.29 ,
-4.924, -3.072, 0.786, 32.321, -33.882, 0.198, -8.3 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). A (355.435) is slightly higher, but not concerning.
2. **TPSA:** A (107.97) is a bit higher than B (88.32). Both are acceptable for a non-CNS GPCR, but B is better.
3. **logP:** A (-0.593) is lower than optimal (1-3), potentially hindering permeability. B (2.601) is much better positioned within the optimal range. This is a significant advantage for B.
4. **HBD:** A (3) and B (2) are both acceptable.
5. **HBA:** A (5) and B (4) are both acceptable.
6. **QED:** A (0.485) is below the preferred threshold of 0.5, while B (0.708) is above, indicating better overall drug-likeness.
7. **DILI:** A (17.216) is significantly better than B (39.356), indicating a lower risk of liver injury.
8. **BBB:** Both are relatively low, which is fine for a cardiovascular target. B (88.29) is higher than A (45.87), but BBB isn't a high priority here.
9. **Caco-2:** A (-5.249) and B (-4.924) are both very poor. This is a significant concern for both compounds, suggesting poor intestinal absorption.
10. **Solubility:** A (-1.033) and B (-3.072) are both poor. Solubility is a concern for both.
11. **hERG:** A (0.143) is much better than B (0.786), indicating a lower risk of cardiotoxicity. This is a crucial advantage for A.
12. **Cl_mic:** A (18.072) is higher than B (32.321), meaning A has better metabolic stability.
13. **t1/2:** A (19.178) is better than B (-33.882), indicating a longer in vitro half-life.
14. **Pgp:** A (0.014) is much lower than B (0.198), indicating lower P-gp efflux and potentially better bioavailability.
15. **Affinity:** B (-8.3) has a significantly stronger binding affinity than A (-5.9) - a difference of 2.4 kcal/mol. This is a substantial advantage for B.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, Pgp, TPSA, and affinity. B excels in logP and affinity. A excels in Pgp and has a better hERG profile.
**Overall Assessment:**
While Ligand A has advantages in DILI, hERG, Pgp, and metabolic stability, Ligand B's significantly stronger binding affinity (-8.3 vs -5.9 kcal/mol) and better logP are compelling. The affinity difference is large enough to outweigh the drawbacks of slightly higher DILI and Pgp efflux. The poor Caco-2 and solubility are concerns for both, but can be addressed with formulation strategies.
Therefore, I would choose Ligand B.
0
2025-04-17 23:59:10,969 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (349.5 and 359.4 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (61.44) is better than Ligand B (64.63). Both are below the 140 threshold for oral absorption, but lower TPSA is generally preferred for GPCRs, potentially aiding in receptor penetration.
**3. logP:** Ligand A (2.311) is optimal (1-3), while Ligand B (4.34) is pushing the upper limit. High logP can lead to poor solubility and off-target effects. This favors Ligand A.
**4. H-Bond Donors:** Ligand A (2) and Ligand B (1) are both acceptable, below the threshold of 5.
**5. H-Bond Acceptors:** Ligand A (3) and Ligand B (5) are both acceptable, below the threshold of 10.
**6. QED:** Both ligands have similar QED values (0.595 and 0.588), indicating good drug-like properties.
**7. DILI Risk:** Ligand A (6.049%) has a significantly lower DILI risk than Ligand B (82.125%). This is a major advantage for Ligand A.
**8. BBB Penetration:** Both ligands have similar BBB penetration (55.642% and 57.154%). While not CNS targets, some degree of BBB penetration can influence peripheral distribution and off-target effects.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.732 and -4.772), which is unusual and suggests poor permeability. This is a concern for both.
**10. Aqueous Solubility:** Ligand A (-1.908) is better than Ligand B (-5.843). Better solubility is always preferred.
**11. hERG Inhibition:** Ligand A (0.391) has a lower hERG inhibition risk than Ligand B (0.722). Lower hERG is crucial for cardiovascular safety.
**12. Microsomal Clearance:** Ligand A (10.954) has significantly lower microsomal clearance than Ligand B (114.822), indicating better metabolic stability.
**13. In vitro Half-Life:** Ligand A (8.945) has a much longer in vitro half-life than Ligand B (1.045). This is a significant advantage for dosing convenience.
**14. P-gp Efflux:** Ligand A (0.017) has significantly lower P-gp efflux than Ligand B (0.343), which means better bioavailability.
**15. Binding Affinity:** Ligand B (-7.6) has a significantly stronger binding affinity than Ligand A (-5.2). This is a substantial advantage for Ligand B. However, the difference in affinity needs to be weighed against the ADME liabilities.
**Overall Assessment:**
While Ligand B has a superior binding affinity, Ligand A demonstrates a much more favorable ADME profile. Specifically, the significantly lower DILI risk, better solubility, lower hERG inhibition, lower clearance, longer half-life, and lower P-gp efflux make Ligand A a more promising drug candidate. The affinity difference, while substantial, can potentially be addressed through further optimization of Ligand A. The ADME properties of Ligand B are concerning and would likely lead to significant development challenges.
Output:
1
2025-04-17 23:59:10,969 - INFO - Here's my reasoning and output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
Let's analyze each ligand against the provided guidelines, keeping in mind ADRB2 is a GPCR and thus logP, Pgp, TPSA, and affinity are particularly important.
* **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (350.459) is slightly lower, which is generally favorable for permeability.
* **TPSA:** Ligand B (58.64) is better than Ligand A (75.71). Lower TPSA generally improves oral absorption, a key consideration for GPCR ligands.
* **logP:** Ligand A (1.586) is within the optimal range (1-3), while Ligand B (3.216) is at the higher end. While 3.216 isn't terrible, it's closer to the potential solubility/off-target issue threshold.
* **H-Bond Donors/Acceptors:** Both have 1 HBD and 4 HBA, which are acceptable.
* **QED:** Both ligands have good QED scores (A: 0.708, B: 0.819), indicating good drug-like properties.
* **DILI:** Ligand A (18.651) has a significantly lower DILI risk than Ligand B (30.516), a major advantage.
* **BBB:** Both have good BBB penetration (A: 73.245, B: 75.572), which isn't a primary concern for ADRB2 (a cardiovascular target) but isn't detrimental.
* **Caco-2 Permeability:** Ligand A (-4.737) is better than Ligand B (-5.076). Higher (less negative) Caco-2 values indicate better absorption.
* **Aqueous Solubility:** Ligand A (-1.736) is better than Ligand B (-3.165).
* **hERG Inhibition:** Both are low (A: 0.31, B: 0.443) and acceptable.
* **Microsomal Clearance:** Ligand B (28.371) has lower clearance than Ligand A (44.538), suggesting better metabolic stability.
* **In vitro Half-Life:** Ligand B (32.549) has a longer half-life than Ligand A (-22.892), which is desirable.
* **P-gp Efflux:** Both are low (A: 0.081, B: 0.216) and acceptable.
* **Binding Affinity:** Ligand A (-6.7 kcal/mol) has a slightly better binding affinity than Ligand B (-5.7 kcal/mol). This 1 kcal/mol difference is significant and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand A has a substantial advantage in DILI risk and slightly better solubility and Caco-2 permeability. It also has a better binding affinity. While Ligand B has better metabolic stability and half-life, the lower DILI risk and better affinity of Ligand A are more critical for a viable drug candidate. The slightly higher logP of Ligand B isn't a dealbreaker, but the DILI risk is a significant concern.
**Output:**
1
2025-04-17 23:59:10,969 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (351.491 and 341.411 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (56.59) is significantly better than Ligand B (82.53). ADRB2 is a cardiovascular target, not CNS, but lower TPSA generally aids absorption. Ligand A is well below the 140 threshold. Ligand B is approaching the upper limit.
3. **logP:** Ligand A (3.028) is optimal. Ligand B (1.381) is a bit low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (4). Lower is better for permeability.
6. **QED:** Both ligands (0.837 and 0.766) have good drug-likeness scores, exceeding the 0.5 threshold.
7. **DILI:** Ligand A (32.105) has a much lower DILI risk than Ligand B (48.468). This is a significant advantage for Ligand A.
8. **BBB:** This is less critical for a cardiovascular target. Ligand A (87.553) is higher than Ligand B (59.325), but this isn't a major deciding factor.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the absolute value for Ligand A (-4.117) is less negative than Ligand B (-4.982), suggesting slightly better permeability.
10. **Solubility:** Both ligands have negative solubility values, also unusual. Ligand A (-3.606) is slightly better than Ligand B (-3.033).
11. **hERG:** Ligand A (0.591) has a much lower hERG risk than Ligand B (0.168). This is a crucial safety parameter.
12. **Cl_mic:** Ligand B (3.84) has significantly lower microsomal clearance than Ligand A (64.125), indicating better metabolic stability.
13. **t1/2:** Ligand A (27.407) has a longer in vitro half-life than Ligand B (-4.983). This is a positive for Ligand A.
14. **Pgp:** Ligand A (0.378) has lower P-gp efflux liability than Ligand B (0.03). Lower Pgp is generally better.
15. **Binding Affinity:** Ligand A (-8.2 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.1 kcal/mol). This is a substantial advantage, exceeding the 1.5 kcal/mol difference threshold.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A excels in logP, TPSA, Pgp, and *especially* affinity. While metabolic stability (Cl_mic) is important, the substantial affinity difference and better safety profile of Ligand A outweigh the lower Cl_mic.
**Conclusion:**
Ligand A is the superior candidate. Its significantly stronger binding affinity, lower DILI and hERG risks, better TPSA, logP, and Pgp profile outweigh the slightly higher microsomal clearance.
Output:
1
2025-04-17 23:59:10,970 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.403 and 349.435 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (113.18) is slightly higher than Ligand B (107.19), but both are below the 140 A^2 threshold for good oral absorption. Given ADRB2 is a cardiovascular target, CNS penetration isn't a primary concern, so this isn't a major differentiator.
3. **logP:** Ligand A (0.82) is slightly higher than Ligand B (0.551), both are within the optimal range of 1-3.
4. **HBD:** Both ligands have 3 H-bond donors, which is acceptable.
5. **HBA:** Ligand A has 5 H-bond acceptors, while Ligand B has 4. Both are within the acceptable limit of 10.
6. **QED:** Both ligands have similar QED values (0.602 and 0.596), indicating good drug-likeness.
7. **DILI:** Ligand A (53.858) has a slightly higher DILI risk than Ligand B (48.623), but both are below the concerning threshold of 60.
8. **BBB:** Ligand A (48.313) has a higher BBB penetration percentile than Ligand B (35.091). While not a primary concern for a cardiovascular target, higher BBB is generally a positive attribute.
9. **Caco-2:** Both ligands have negative Caco-2 permeability values (-5.308 and -5.542). This is unusual and suggests poor permeability.
10. **Solubility:** Both ligands have negative solubility values (-2.04 and -1.963). This is also unusual and suggests poor solubility.
11. **hERG:** Ligand A (0.095) has a lower hERG inhibition liability than Ligand B (0.212), which is a significant advantage for cardiovascular drugs.
12. **Cl_mic:** Ligand B (28.076) has a lower microsomal clearance than Ligand A (33.102), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-22.019) has a more negative in vitro half-life than Ligand B (-4.328). This is counterintuitive and suggests a faster degradation rate for Ligand A.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.017 and 0.024).
15. **Binding Affinity:** Ligand A (-6.6 kcal/mol) has a slightly better binding affinity than Ligand B (-6.4 kcal/mol). The difference is less than 1.5 kcal/mol, so it's not a decisive factor.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A has a slightly better logP, lower Pgp efflux, and slightly better affinity. However, the negative Caco-2 and solubility values are concerning for both. Ligand B has better metabolic stability (lower Cl_mic) and a more reasonable in vitro half-life. The lower hERG risk of Ligand A is a significant advantage for a cardiovascular target.
**Overall Assessment:**
Despite the better affinity of Ligand A, the significantly lower hERG risk is a crucial factor for a cardiovascular drug. The negative Caco-2 and solubility values are a concern for both, but can be addressed with formulation strategies. The improved metabolic stability of Ligand B is also beneficial. However, the hERG risk is paramount in this case.
Output:
1
2025-04-17 23:59:10,970 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (340.43 and 349.48 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both are below the 140 A^2 threshold for good oral absorption (86.88 and 88.91 A^2). Ligand A is slightly better, but both are acceptable.
3. **logP:** Ligand A (2.814) is optimal, while Ligand B (1.442) is a bit low, potentially impacting permeability. This favors Ligand A.
4. **HBD:** Both ligands have acceptable HBD counts (3 and 2 respectively), well below the 5 threshold.
5. **HBA:** Ligand A has 3 HBA, and Ligand B has 5. Both are below the 10 threshold, but Ligand A is preferable.
6. **QED:** Both ligands have similar and good QED scores (0.646 and 0.66).
7. **DILI:** Ligand B (32.183 percentile) has a significantly lower DILI risk than Ligand A (54.285 percentile). This is a strong advantage for Ligand B.
8. **BBB:** Ligand B (66.731 percentile) has a much higher BBB penetration potential than Ligand A (33.23 percentile). While ADRB2 isn't *strictly* a CNS target, some CNS exposure is not necessarily detrimental and could offer benefits in certain cardiovascular conditions. This favors Ligand B.
9. **Caco-2:** Both have negative Caco-2 values (-5.288 and -5.314), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand B (-1.305) has better aqueous solubility than Ligand A (-3.804). This is a positive for Ligand B.
11. **hERG:** Both ligands have low hERG inhibition liability (0.463 and 0.215). Ligand B is slightly better here.
12. **Cl_mic:** Ligand B (26.232 mL/min/kg) has a slightly lower microsomal clearance than Ligand A (23.437 mL/min/kg), suggesting better metabolic stability.
13. **t1/2:** Ligand A (22.511 hours) has a significantly longer in vitro half-life than Ligand B (5.525 hours). This is a major advantage for Ligand A.
14. **Pgp:** Both have very low Pgp efflux liability (0.131 and 0.043).
15. **Binding Affinity:** Ligand B (-6.7 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.2 kcal/mol). This is a substantial advantage for Ligand B, potentially outweighing some ADME concerns.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand B excels in affinity and has acceptable TPSA and Pgp. While its logP is lower, the strong affinity and better safety profile (DILI, hERG) are compelling. The longer half-life of Ligand A is attractive, but the significantly weaker binding and higher DILI risk are concerning.
**Conclusion:**
Despite Ligand A's longer half-life, Ligand B's superior binding affinity, lower DILI risk, better BBB penetration, and improved solubility make it the more promising drug candidate. The 1.5 kcal/mol advantage in binding affinity is substantial and outweighs the slightly lower logP and shorter half-life.
Output:
0
2025-04-17 23:59:10,970 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (368.48 & 344.43 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand B (59.07) is significantly better than Ligand A (97.11). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (2.05 & 3.50), falling within the optimal 1-3 range. Ligand B is slightly higher, which *could* be a minor advantage for membrane permeability, but isn't a major concern.
4. **HBD:** Ligand A has 3 HBD, and Ligand B has 2. Both are acceptable (<=5).
5. **HBA:** Both ligands have 5 HBA, which is within the acceptable range (<=10).
6. **QED:** Ligand B (0.805) has a better QED score than Ligand A (0.686), indicating a more drug-like profile.
7. **DILI:** Both ligands have similar DILI risk (53.35 & 57.35 percentile), and both are acceptable (below 60).
8. **BBB:** Both ligands have good BBB penetration (76.6% and 73.9%), but this is less critical for a cardiovascular target.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the values are similar (-5.08 and -4.98) and don't differentiate the ligands.
10. **Solubility:** Ligand B (-4.46) has slightly better solubility than Ligand A (-3.36), though both are poor.
11. **hERG:** Ligand A (0.475) has a lower hERG risk than Ligand B (0.9), which is a significant advantage.
12. **Cl_mic:** Ligand A (21.37) has a much lower microsomal clearance than Ligand B (61.19), indicating better metabolic stability. This is a crucial factor.
13. **t1/2:** Ligand B (32.65) has a longer in vitro half-life than Ligand A (19.37), which is generally desirable.
14. **Pgp:** Ligand A (0.227) has lower P-gp efflux than Ligand B (0.397), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand B (-6.7 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.4 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME drawbacks of Ligand B.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, affinity, logP, TPSA, and Pgp are key. Ligand B excels in affinity and has good logP and TPSA. Ligand A has better hERG and Cl_mic.
**Overall Assessment:**
The significantly stronger binding affinity of Ligand B (-6.7 vs -5.4 kcal/mol) is the most important factor. While Ligand A has better metabolic stability (lower Cl_mic) and hERG risk, the potency advantage of Ligand B is likely to be more impactful, especially considering the other parameters are reasonably well-balanced. The slightly better QED and half-life of Ligand B also contribute to its favorability.
Output:
0
2025-04-17 23:59:10,970 - INFO - Batch 444 complete. Total preferences: 7104
2025-04-17 23:59:10,970 - INFO - Processing batch 445/512...
2025-04-17 23:59:56,591 - INFO - Here's my reasoning and final output for the ligand preference:
**Reasoning:**
We are targeting ADRB2, a GPCR, so the priorities are logP, TPSA, Pgp, BBB, and affinity. Let's compare Ligand A and Ligand B across these and other important parameters.
* **Molecular Weight:** Both ligands are within the ideal range (200-500 Da).
* **TPSA:** Ligand A (58.64) is significantly better than Ligand B (101.21). Lower TPSA generally favors oral absorption and is particularly important for GPCRs.
* **logP:** Both ligands have good logP values (A: 2.588, B: 1.19), falling within the 1-3 range. Ligand A is slightly better.
* **H-Bond Donors/Acceptors:** Both have acceptable HBD (1) and Ligand A has acceptable HBA (3), while Ligand B has a higher HBA (6).
* **QED:** Both ligands have good QED scores (A: 0.677, B: 0.788), indicating good drug-like properties.
* **DILI:** Both ligands have similar DILI risk (A: 61.807, B: 61.07), which is moderately high but not alarming.
* **BBB:** Ligand A (67.313) has a better BBB percentile than Ligand B (46.336). While not a CNS target, some degree of BBB penetration can influence off-target effects and distribution.
* **Caco-2:** Both have negative Caco-2 values, which is unusual and could indicate issues with the prediction method or the compounds themselves. However, the values are similar.
* **Solubility:** Ligand A (-3.902) has slightly better solubility than Ligand B (-2.477).
* **hERG:** Both ligands have low hERG inhibition risk (A: 0.65, B: 0.276).
* **Cl_mic:** Both ligands have similar microsomal clearance values (A: 47.274, B: 44.303).
* **t1/2:** Ligand B (14.818) has a significantly longer in vitro half-life than Ligand A (-6.669). This is a substantial advantage.
* **Pgp:** Ligand A (0.429) has a lower Pgp efflux liability than Ligand B (0.106), which is preferable for bioavailability.
* **Binding Affinity:** Ligand B (-7.9) has a significantly stronger binding affinity than Ligand A (-5.7). This is a 2.2 kcal/mol difference, a substantial advantage that can outweigh some ADME concerns.
**Conclusion:**
While Ligand A has better TPSA, logP, BBB, and Pgp properties, the significantly stronger binding affinity of Ligand B (-7.9 vs -5.7 kcal/mol) is the deciding factor. For a GPCR target, strong binding is paramount. The longer half-life of Ligand B is also a significant benefit. The slightly higher TPSA and Pgp efflux of Ligand B are acceptable trade-offs for the improved potency and half-life.
**Output:**
0
2025-04-17 23:59:56,591 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (366.483 and 386.498 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (75.71) is higher than Ligand B (57.69). For a GPCR, lower TPSA is generally preferred for better permeability, giving a slight edge to Ligand B.
**3. logP:** Both ligands have good logP values (1.846 and 2.797), falling within the optimal 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability, but not dramatically so.
**4. H-Bond Donors:** Ligand A has 1 HBD, while Ligand B has 0. Both are acceptable, well below the limit of 5.
**5. H-Bond Acceptors:** Both ligands have 4 HBAs, well within the acceptable limit of 10.
**6. QED:** Ligand A (0.747) has a slightly higher QED than Ligand B (0.682), indicating a marginally more drug-like profile.
**7. DILI Risk:** Ligand B (15.2%) has a significantly lower DILI risk than Ligand A (37.146%). This is a major advantage for Ligand B, as minimizing liver toxicity is crucial.
**8. BBB Penetration:** Both ligands show good BBB penetration (81.698% and 78.868%), which is important for GPCR targets, though less critical for ADRB2 specifically (cardiovascular target). Ligand A is slightly better.
**9. Caco-2 Permeability:** Ligand A (-4.65) has better Caco-2 permeability than Ligand B (-5.007).
**10. Aqueous Solubility:** Ligand A (-1.979) has better aqueous solubility than Ligand B (-2.347).
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (0.547 and 0.354), which is good. Ligand B is slightly better.
**12. Microsomal Clearance:** Ligand B (36.813) has slightly higher microsomal clearance than Ligand A (32.42), meaning it may be metabolized faster. This is a slight disadvantage for Ligand B.
**13. In vitro Half-Life:** Ligand A (-7.872) has a slightly longer in vitro half-life than Ligand B (-7.843).
**14. P-gp Efflux:** Both ligands show similar P-gp efflux liability (0.399 and 0.105).
**15. Binding Affinity:** Both ligands have excellent binding affinity (-6.0 and -6.6 kcal/mol). Ligand B is slightly more potent.
**Overall Assessment:**
While Ligand A has a slightly better QED, solubility, and Caco-2 permeability, Ligand B's significantly lower DILI risk and slightly better binding affinity are more important considerations. The lower TPSA of Ligand B is also beneficial. Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity), and the importance of minimizing toxicity, Ligand B appears to be the more promising candidate. The small differences in half-life and clearance are less concerning given the other advantages.
Output:
0
2025-04-17 23:59:56,591 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for the ADRB2, a cardiovascular GPCR. Therefore, priorities are logP, TPSA, Pgp, affinity, and to a lesser extent, BBB.
* **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (341.411) is slightly lower, which is generally favorable for permeability.
* **TPSA:** Ligand B (43.86) is significantly better than Ligand A (80.32). Lower TPSA is preferred for GPCRs, aiding in brain penetration and overall absorption.
* **logP:** Both ligands have acceptable logP values (Ligand A: 1.517, Ligand B: 2.667), falling within the 1-3 range. Ligand B is slightly better, closer to the optimal range.
* **H-Bond Donors/Acceptors:** Ligand A has 2 HBD and 4 HBA, while Ligand B has 0 HBD and 3 HBA. Both are within acceptable limits.
* **QED:** Both have reasonable QED scores (A: 0.769, B: 0.693), indicating good drug-likeness.
* **DILI:** Ligand A (32.842) has a slightly better DILI score than Ligand B (5.7), indicating a lower risk of liver injury.
* **BBB:** Ligand B (92.323) has a much higher BBB penetration percentile than Ligand A (50.523). While ADRB2 is cardiovascular, some CNS effects are possible with beta-blockers, and higher BBB penetration could be beneficial or detrimental depending on the desired profile.
* **Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
* **Aqueous Solubility:** Both ligands have negative solubility values, also unusual. Again, the scale is unknown.
* **hERG:** Both ligands have low hERG inhibition liability, which is good. Ligand A (0.114) is slightly better.
* **Microsomal Clearance:** Ligand A (20.194) has a significantly lower microsomal clearance than Ligand B (45.474), indicating better metabolic stability.
* **In vitro Half-Life:** Ligand A (-29.225) has a much longer in vitro half-life than Ligand B (-8.689). This is a significant advantage.
* **P-gp Efflux:** Both ligands have very low P-gp efflux liability (A: 0.012, B: 0.062), which is excellent.
* **Binding Affinity:** Ligand B (-7.1) has a slightly better binding affinity than Ligand A (-6.0). This is a 1.1 kcal/mol difference, which is significant.
**Overall Assessment:**
Ligand B has a superior binding affinity and better TPSA and BBB penetration. However, Ligand A demonstrates better metabolic stability (lower Cl_mic, longer t1/2) and a lower DILI risk. The difference in affinity (1.1 kcal/mol) is substantial enough to outweigh the slightly less favorable ADME properties of Ligand B, especially considering the cardiovascular target. The lower TPSA of Ligand B is also a significant advantage.
**Output:**
0
2025-04-17 23:59:56,591 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Ligand A (421.324 Da) is within the ideal range, while Ligand B (350.379 Da) is also acceptable. No clear advantage here.
2. **TPSA:** Ligand A (98.72) is better than Ligand B (118.45), both are below 140, but A is closer to the optimal for good absorption.
3. **logP:** Ligand A (2.687) is optimal. Ligand B (-0.483) is significantly lower, which is a concern for membrane permeability and bioavailability.
4. **HBD:** Both ligands have 2 HBD, which is acceptable.
5. **HBA:** Both ligands have 7 HBA, which is acceptable.
6. **QED:** Both ligands have good QED scores (A: 0.638, B: 0.74), indicating good drug-like properties.
7. **DILI:** Both ligands have acceptable DILI risk (A: 73.09, B: 64.056), though A is slightly higher.
8. **BBB:** Ligand A (63.474) is better than Ligand B (58.434), but neither is particularly high. For a cardiovascular target, BBB penetration isn't a primary concern, but it's still a slight advantage for A.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability.
10. **Solubility:** Ligand A (-3.247) is slightly better than Ligand B (-1.638), but both are poor.
11. **hERG:** Ligand A (0.548) has a slightly better hERG profile than Ligand B (0.047).
12. **Cl_mic:** Ligand A (13.38) has significantly better metabolic stability (lower clearance) than Ligand B (-28.981). This is a major advantage.
13. **t1/2:** Ligand A (44.602) has a much longer half-life than Ligand B (-15.919). This is a significant advantage.
14. **Pgp:** Ligand A (0.449) has better Pgp efflux liability than Ligand B (0.007).
15. **Binding Affinity:** Ligand A (-7.0) and Ligand B (-4.5) both have good binding affinity, but Ligand A is significantly stronger. The 2.5 kcal/mol difference is substantial and can outweigh some ADME drawbacks.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A excels in logP and affinity, and is better in TPSA and Pgp. While BBB isn't critical for a cardiovascular target, A is still slightly better.
**Overall Assessment:**
Ligand A is the stronger candidate. Its superior binding affinity, significantly better metabolic stability (Cl_mic and t1/2), and more favorable logP outweigh the slightly higher DILI risk and poor solubility. Ligand B's poor logP and metabolic stability are major drawbacks.
Output:
1
2025-04-17 23:59:56,591 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (356.463 and 344.459 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (99.1) is slightly higher than Ligand B (86.88). Both are below the 140 threshold for good oral absorption, but closer to the 90 threshold for CNS targets.
3. **logP:** Ligand B (2.137) is better than Ligand A (0.575). A logP between 1-3 is optimal, and Ligand A is a bit low, potentially impacting permeability.
4. **HBD:** Both ligands have 3 H-bond donors, which is within the acceptable limit of <=5.
5. **HBA:** Ligand A has 5 H-bond acceptors, while Ligand B has 3. Both are below the acceptable limit of <=10.
6. **QED:** Both ligands have similar QED values (0.646 and 0.641), indicating good drug-likeness.
7. **DILI:** Ligand B (26.755) has a significantly lower DILI risk than Ligand A (7.445). This is a major advantage for Ligand B.
8. **BBB:** Ligand A (60.954) has a slightly better BBB penetration percentile than Ligand B (56.96). However, for a cardiovascular target like ADRB2, BBB penetration is not a primary concern.
9. **Caco-2:** Ligand B (-5.341) has a more negative Caco-2 value, suggesting better intestinal absorption than Ligand A (-4.993).
10. **Solubility:** Ligand B (-2.946) has a more negative solubility value, suggesting lower solubility than Ligand A (-0.934). Solubility is important, but can be addressed with formulation.
11. **hERG:** Ligand A (0.101) has a lower hERG inhibition liability than Ligand B (0.365), which is preferable.
12. **Cl_mic:** Ligand A (-2.265) has a much lower microsomal clearance than Ligand B (30.213), indicating significantly better metabolic stability. This is a substantial advantage for Ligand A.
13. **t1/2:** Ligand A (-7.626) has a much longer in vitro half-life than Ligand B (-19.273). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.018) has a much lower P-gp efflux liability than Ligand B (0.123), which is preferable.
15. **Binding Affinity:** Ligand B (-7.5) has a slightly better binding affinity than Ligand A (-7.2). While a 1.5 kcal/mol advantage is often significant, the other ADME properties are more concerning for Ligand B.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are important. Ligand B has a better logP and affinity, but Ligand A has better TPSA and Pgp efflux. The biggest concerns with Ligand B are its high DILI risk, poor metabolic stability (high Cl_mic), and short half-life. Ligand A has a much more favorable ADME profile overall, despite slightly lower affinity and logP.
**Conclusion:**
Considering the balance of properties and the priorities for a GPCR target, Ligand A is the more promising drug candidate. Its superior metabolic stability, longer half-life, lower DILI risk, and lower P-gp efflux outweigh the slightly better affinity and logP of Ligand B.
Output:
1
2025-04-17 23:59:56,591 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (362.342 Da) and Ligand B (347.39 Da) both fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (46.33) is significantly better than Ligand B (80.32). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (3.743) is within the optimal range (1-3), while Ligand B (0.765) is slightly below, potentially hindering permeability. Ligand A has a clear advantage.
4. **HBD:** Both Ligand A (1) and Ligand B (2) are acceptable, below the threshold of 5.
5. **HBA:** Both Ligand A (2) and Ligand B (4) are acceptable, below the threshold of 10.
6. **QED:** Ligand A (0.833) is better than Ligand B (0.681), indicating a more drug-like profile.
7. **DILI:** Ligand A (17.914) is *much* better than Ligand B (33.695). This is a significant advantage for Ligand A, as lower DILI risk is crucial.
8. **BBB:** Ligand A (96.2) is better than Ligand B (76.658), but since ADRB2 is not a CNS target, this is less important.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-4.73) is slightly better than Ligand B (-4.528).
10. **Solubility:** Ligand A (-3.613) is better than Ligand B (-2.279). Better solubility is generally desirable.
11. **hERG:** Ligand A (0.824) is better than Ligand B (0.093). Lower hERG inhibition is crucial for avoiding cardiotoxicity, making Ligand A preferable.
12. **Cl_mic:** Ligand A (3.284) is significantly better than Ligand B (8.919). Lower clearance indicates better metabolic stability.
13. **t1/2:** Ligand A (-9.484) is better than Ligand B (-5.49). A longer half-life is generally preferred.
14. **Pgp:** Ligand A (0.155) is better than Ligand B (0.008). Lower P-gp efflux is desirable for better bioavailability.
15. **Affinity:** Ligand A (-7.8 kcal/mol) is significantly better than Ligand B (-5.3 kcal/mol). This is a substantial difference in binding potency, and a >1.5 kcal/mol advantage often outweighs minor ADME drawbacks.
**GPCR-specific priorities:** logP, TPSA, Pgp, and affinity are key for GPCRs. Ligand A excels in all these areas.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical parameters, including DILI risk, metabolic stability, solubility, hERG inhibition, and, most importantly, binding affinity. While both have poor Caco-2 permeability, the superior binding affinity and overall ADME profile of Ligand A make it the more promising drug candidate.
Output:
1
2025-04-17 23:59:56,592 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (340.343 and 354.405 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (121.93) is slightly higher than Ligand B (61). Both are below the 140 threshold for oral absorption, but Ligand B is significantly better, especially considering ADRB2 is a cardiovascular target and CNS penetration isn't a primary goal.
3. **logP:** Ligand B (1.848) is within the optimal 1-3 range, while Ligand A (0.441) is slightly below 1. This is a significant drawback for Ligand A, as lower logP can hinder membrane permeability.
4. **HBD:** Ligand A (2) is better than Ligand B (0). While both are acceptable, a small number of HBDs are generally preferred for permeability.
5. **HBA:** Both ligands have 7 HBA, which is acceptable.
6. **QED:** Ligand A (0.736) is slightly better than Ligand B (0.652), indicating a marginally more drug-like profile.
7. **DILI:** Ligand B (33.773) has a much lower DILI risk than Ligand A (78.247). This is a critical advantage for Ligand B.
8. **BBB:** Ligand B (91.508) has higher BBB penetration than Ligand A (48.391). While not a primary concern for a cardiovascular target, higher BBB is generally not detrimental.
9. **Caco-2:** Ligand A (-5.334) has a worse Caco-2 permeability than Ligand B (-4.671).
10. **Solubility:** Ligand A (-3.879) has a worse solubility than Ligand B (-2.204).
11. **hERG:** Ligand A (0.125) has a slightly lower hERG risk than Ligand B (0.573), which is good.
12. **Cl_mic:** Ligand A (-16.441) has much lower microsomal clearance than Ligand B (13.646), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (20.297) has a longer half-life than Ligand B (9.709). This is a positive for Ligand A.
14. **Pgp:** Ligand A (0.029) has lower P-gp efflux than Ligand B (0.145), which is favorable.
15. **Binding Affinity:** Ligand B (-5.5) has a slightly better binding affinity than Ligand A (-5.3). While the difference is small, it's still a factor.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand B excels in TPSA and has a better logP. The affinity difference is small. Ligand A has better metabolic stability (Cl_mic and t1/2) and Pgp efflux, but the poor logP and higher DILI risk are major concerns.
**Overall Assessment:**
Despite Ligand A's advantages in metabolic stability and half-life, the significantly better logP, lower DILI risk, and better TPSA of Ligand B outweigh these benefits. The slightly better binding affinity of Ligand B further strengthens its position. The poor logP of Ligand A is a substantial hurdle for oral bioavailability and overall drug-like properties.
Output:
0
2025-04-17 23:59:56,592 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (340.423 and 347.415 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (58.64) is significantly better than Ligand B (84.67). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold. Ligand B is approaching the upper limit.
3. **logP:** Both ligands have acceptable logP values (2.899 and 1.602), falling within the 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability, but not dramatically so.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 3 HBA, while Ligand B has 5. Ligand A is preferable here, as fewer HBA generally improve permeability.
6. **QED:** Both ligands have high QED scores (0.92 and 0.894), indicating good overall drug-likeness.
7. **DILI:** Ligand A (60.915) has a higher DILI risk than Ligand B (31.33). This is a significant drawback for Ligand A.
8. **BBB:** Both have reasonably good BBB penetration (79.643 and 73.943). Not a major factor for a cardiovascular target.
9. **Caco-2:** Both have negative Caco-2 values (-5.051 and -4.852), which is unusual and suggests poor permeability. However, the values are similar.
10. **Solubility:** Ligand A (-3.333) has worse solubility than Ligand B (-2.111). Solubility is important for bioavailability, so Ligand B is favored.
11. **hERG:** Both ligands have low hERG inhibition risk (0.39 and 0.293).
12. **Cl_mic:** Ligand A (24.347) has a higher microsomal clearance than Ligand B (13.759), indicating faster metabolism and potentially lower exposure. Ligand B is preferable.
13. **t1/2:** Ligand A (21.386) has a longer in vitro half-life than Ligand B (4.566). This is a positive for Ligand A.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.168 and 0.094).
15. **Binding Affinity:** Ligand A (-7.0) has a slightly better binding affinity than Ligand B (-5.9). The difference is 1.1 kcal/mol, which is substantial.
**Overall Assessment:**
While Ligand A has a better binding affinity and longer half-life, its significantly higher DILI risk, worse solubility, and higher metabolic clearance are major concerns. Ligand B, despite slightly weaker binding, presents a much more favorable ADME-Tox profile, particularly the lower DILI risk. For a cardiovascular target, a slightly lower binding affinity can be tolerated if it means a safer and more bioavailable drug. The TPSA is also more favorable for Ligand A.
Therefore, I favor Ligand B.
Output:
0
2025-04-17 23:59:56,592 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [354.841, 59.81, 3.261, 1, 4, 0.739, 73.09, 49.205, -5.138, -4.288, 0.527, 68.926, 17.791, 0.35, -7.0]
**Ligand B:** [344.455, 62.55, 3.296, 1, 3, 0.834, 41.877, 69.407, -4.344, -3.477, 0.099, 57.112, 49.071, 0.193, -6.8]
Here's a breakdown, prioritizing GPCR-relevant properties:
1. **Molecular Weight:** Both are within the ideal 200-500 Da range. Ligand B (344.455) is slightly lower, which is generally favorable.
2. **TPSA:** Both are reasonably good (A: 59.81, B: 62.55), being under 140, suggesting decent oral absorption.
3. **logP:** Both ligands have a logP around 3.2-3.3, which is optimal for GPCRs.
4. **H-Bond Donors/Acceptors:** Both have 1 HBD, which is good. Ligand A has 4 HBA, and Ligand B has 3. Both are within acceptable limits.
5. **QED:** Both have acceptable QED values (A: 0.739, B: 0.834), indicating good drug-like properties. Ligand B is slightly better.
6. **DILI:** Ligand A (73.09) has a significantly higher DILI risk than Ligand B (41.877). This is a major concern.
7. **BBB:** Ligand B (69.407) shows better BBB penetration than Ligand A (49.205), though neither are exceptionally high. For a cardiovascular target, BBB isn't *critical*, but it's a bonus.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
9. **Aqueous Solubility:** Both have negative solubility values, which is also unusual and suggests poor solubility. Again, the scale is not specified.
10. **hERG:** Ligand A (0.527) has a slightly higher hERG risk than Ligand B (0.099).
11. **Microsomal Clearance:** Ligand B (57.112) has lower microsomal clearance than Ligand A (68.926), suggesting better metabolic stability.
12. **In vitro Half-Life:** Ligand B (49.071) has a longer in vitro half-life than Ligand A (17.791), which is desirable.
13. **P-gp Efflux:** Ligand A (0.35) has a slightly higher P-gp efflux liability than Ligand B (0.193).
14. **Binding Affinity:** Ligand A (-7.0 kcal/mol) has a slightly better binding affinity than Ligand B (-6.8 kcal/mol). This is a 0.2 kcal/mol difference, which isn't huge.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity, the significantly higher DILI risk and poorer metabolic stability (higher Cl_mic, shorter t1/2) are major drawbacks. Ligand B demonstrates a much more favorable safety profile (lower DILI, lower hERG), better metabolic stability, and a longer half-life. The slight difference in binding affinity is outweighed by these ADME-Tox advantages.
Therefore, I prefer Ligand B.
Output:
0
2025-04-17 23:59:56,592 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
Let's break down the comparison, prioritizing GPCR-relevant parameters (logP, TPSA, Pgp, BBB, and affinity).
1. **Molecular Weight:** Both ligands are within the ideal range (350-360 Da).
2. **TPSA:** Ligand B (58.64) is significantly better than Ligand A (99.81). Lower TPSA generally improves cell permeability, crucial for GPCR targeting.
3. **logP:** Ligand A (1.856) is within the optimal range, while Ligand B (3.189) is approaching the upper limit. Both are acceptable, but A is slightly preferred.
4. **H-Bond Donors/Acceptors:** Ligand A has 2 HBD and 6 HBA, while Ligand B has 1 HBD and 3 HBA. Both are within acceptable limits.
5. **QED:** Both ligands have similar QED values (0.79 and 0.718), indicating good drug-likeness.
6. **DILI:** Ligand B (27.918) has a much lower DILI risk than Ligand A (52.772). This is a significant advantage for Ligand B.
7. **BBB:** Ligand B (71.229) shows significantly better predicted BBB penetration than Ligand A (43.777). While ADRB2 isn't exclusively a CNS target, some cardiovascular effects are mediated by CNS pathways, and better BBB penetration could be beneficial.
8. **Caco-2 Permeability:** Ligand A (-5.416) has a more negative Caco-2 value, indicating *better* permeability than Ligand B (-4.441).
9. **Aqueous Solubility:** Both ligands have similar, poor aqueous solubility (-2.795 and -2.529). This could pose formulation challenges for both.
10. **hERG Inhibition:** Ligand A (0.535) has a slightly higher hERG risk than Ligand B (0.199). Lower is better here.
11. **Microsomal Clearance:** Ligand B (89.461) has a *much* higher microsomal clearance than Ligand A (-0.882), indicating faster metabolism and potentially lower *in vivo* exposure. This is a major drawback for Ligand B.
12. **In vitro Half-Life:** Ligand A (10.473) has a significantly longer half-life than Ligand B (0.972). This is a substantial advantage for Ligand A.
13. **P-gp Efflux:** Ligand A (0.019) has a much lower P-gp efflux liability than Ligand B (0.249), suggesting better oral bioavailability and potentially better CNS exposure.
14. **Binding Affinity:** Ligand A (-7.0 kcal/mol) has a slightly better binding affinity than Ligand B (-6.1 kcal/mol), though both are strong binders.
**Overall Assessment:**
Ligand A has a better binding affinity, longer half-life, lower P-gp efflux, and lower DILI risk. However, Ligand B has a significantly lower TPSA, better BBB penetration, and lower hERG risk. The biggest drawback for Ligand B is its high microsomal clearance and short half-life. For a GPCR, TPSA and BBB penetration are important, but metabolic stability (half-life) is critical. Ligand A's superior metabolic stability and better overall balance of properties make it the more promising candidate.
Output:
1
2025-04-17 23:59:56,592 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (367.764 Da and 357.523 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (78.0) is higher than Ligand B (54.02). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is generally preferred for absorption. Ligand B has a clear advantage.
**3. logP:** Ligand A (1.487) is within the optimal 1-3 range. Ligand B (4.697) is significantly higher, potentially leading to solubility issues and off-target interactions. Ligand A is preferred.
**4. H-Bond Donors:** Ligand A (0) is excellent. Ligand B (2) is acceptable, but lower is better for permeability.
**5. H-Bond Acceptors:** Ligand A (4) and Ligand B (3) are both good, well below the 10 threshold.
**6. QED:** Both ligands have good QED scores (0.586 and 0.673), indicating drug-like properties. Ligand B is slightly better.
**7. DILI Risk:** Ligand A (92.827) has a considerably higher DILI risk than Ligand B (38.813). This is a major concern for Ligand A.
**8. BBB Penetration:** Both have high BBB penetration, but Ligand A (94.184) is slightly better than Ligand B (79.488). However, for a cardiovascular target, BBB penetration is less crucial.
**9. Caco-2 Permeability:** Both have negative Caco-2 values, which is unusual and suggests potential issues with the assay or the compounds themselves. It's hard to draw conclusions here.
**10. Aqueous Solubility:** Both have negative solubility values, again suggesting potential issues with the assay or compounds.
**11. hERG Inhibition:** Ligand A (0.124) has a much lower hERG inhibition risk than Ligand B (0.67). This is a significant advantage for Ligand A.
**12. Microsomal Clearance:** Ligand A (42.349) has a lower microsomal clearance than Ligand B (64.022), suggesting better metabolic stability.
**13. In vitro Half-Life:** Both ligands have similar in vitro half-lives (25.218 and 24.199 hours).
**14. P-gp Efflux:** Ligand A (0.093) has much lower P-gp efflux liability than Ligand B (0.64), which is favorable for bioavailability.
**15. Binding Affinity:** Ligand B (-7.3 kcal/mol) has a slightly better binding affinity than Ligand A (-8.2 kcal/mol). While a difference of 0.9 kcal/mol is noticeable, it's not a massive advantage, especially considering the other factors.
**Overall Assessment:**
Ligand A has a better logP, lower P-gp efflux, lower microsomal clearance, and lower hERG inhibition. However, its DILI risk is substantially higher. Ligand B has a lower TPSA, better QED, and a slightly better binding affinity, but suffers from a high logP and higher DILI risk.
Given the cardiovascular target, minimizing DILI risk is paramount. While Ligand A has a higher DILI risk, the other properties are more favorable. The slightly better affinity of Ligand B isn't enough to overcome the significant DILI concern.
Therefore, I prefer Ligand A.
Output:
1
2025-04-17 23:59:56,592 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (343.47 & 348.49 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (38.77) is significantly better than Ligand B (47.1). ADRB2 is a cardiovascular target, not CNS, but lower TPSA generally improves permeability.
3. **logP:** Ligand A (4.146) is higher than Ligand B (0.482). While both are within the acceptable range, Ligand A is approaching the upper limit, which *could* cause solubility issues, but is generally acceptable for GPCRs. Ligand B is quite low, which could hinder membrane permeability.
4. **HBD:** Both have 0 HBD, which is good.
5. **HBA:** Ligand A has 3 HBA, Ligand B has 4. Both are acceptable, below the 10 threshold.
6. **QED:** Both ligands have similar QED values (0.729 vs 0.64), indicating good drug-likeness.
7. **DILI:** Ligand A (37.8%) is slightly higher than Ligand B (3.3%), but both are well below the concerning 60% threshold. Ligand B is preferable here.
8. **BBB:** Both have high BBB penetration (89.531 and 90.074). Not a primary concern for a cardiovascular target, but not detrimental.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests a potential issue with the data or modeling. I will assume these represent permeability *scores* where lower is worse. Ligand A (-4.423) is better than Ligand B (-4.912).
10. **Solubility:** Ligand A (-3.901) is better than Ligand B (-0.576). Solubility is important for bioavailability.
11. **hERG:** Both ligands have low hERG inhibition risk (0.674 and 0.621).
12. **Cl_mic:** Ligand A (88.977) has significantly higher microsomal clearance than Ligand B (21.551). This means Ligand B is more metabolically stable, a significant advantage.
13. **t1/2:** Ligand A (-19.044) has a negative in vitro half-life, which is concerning. Ligand B (-11.213) is also negative, but less so. Both are problematic, suggesting rapid metabolism.
14. **Pgp:** Both have low Pgp efflux liability (0.62 and 0.01). Ligand B is preferable.
15. **Binding Affinity:** Ligand B (-7.8 kcal/mol) has a substantially better binding affinity than Ligand A (-5.9 kcal/mol). This 1.9 kcal/mol difference is a major advantage, and can often outweigh other less-optimal properties.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand B has a better affinity and lower Pgp efflux. Ligand A has better TPSA and logP, but the affinity difference is substantial.
**Overall Assessment:**
Despite Ligand A having better TPSA and solubility, Ligand B's significantly stronger binding affinity (-7.8 vs -5.9 kcal/mol) and lower microsomal clearance are compelling advantages. The lower logP of Ligand B is a slight concern, but the superior affinity is likely to compensate. The negative half-lives are concerning for both, but the better affinity of B suggests it might be optimized more effectively.
Output:
0
2025-04-17 23:59:56,592 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's systematically compare Ligand A and Ligand B based on the provided parameters, keeping in mind the GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key).
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (352.435) is slightly lower than Ligand B (387.527), which is generally favorable for permeability.
2. **TPSA:** Both ligands are below the 140 A^2 threshold for good oral absorption (A: 99.77, B: 96.44). This is good.
3. **logP:** Ligand A (-1.144) is a bit low, potentially hindering permeation. Ligand B (0.161) is better, falling within the optimal 1-3 range, though on the lower end. This favors B.
4. **HBD/HBA:** Ligand A has 3 HBD and 5 HBA, while Ligand B has 1 HBD and 6 HBA. Both are acceptable, but Ligand A's lower HBD count is slightly preferable.
5. **QED:** Both ligands have good QED scores (A: 0.558, B: 0.716), indicating good drug-like properties. Ligand B is better here.
6. **DILI:** Ligand A (13.61) has a significantly lower DILI risk than Ligand B (43.35). This is a major advantage for Ligand A.
7. **BBB:** Ligand A (34.354) has a lower BBB penetration percentile than Ligand B (53.974). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be beneficial for distribution. This favors B.
8. **Caco-2:** Both ligands have similar, very negative Caco-2 values (-5.44 and -5.372). This suggests poor intestinal absorption for both, which is a concern.
9. **Solubility:** Both ligands have very negative solubility values (-0.934 and -1.554), indicating very poor aqueous solubility. This is a significant drawback for both.
10. **hERG:** Ligand A (0.059) has a much lower hERG inhibition liability than Ligand B (0.118), indicating a lower risk of cardiotoxicity. This is a strong advantage for A.
11. **Cl_mic:** Ligand A (-34.765) has a much lower (better) microsomal clearance than Ligand B (1.449), suggesting greater metabolic stability. This is a significant advantage for A.
12. **t1/2:** Ligand A (7.877) has a longer in vitro half-life than Ligand B (0.261). This is a clear advantage for A.
13. **Pgp:** Ligand A (-5.6) has lower P-gp efflux liability than Ligand B (-0.033). Lower Pgp efflux is generally desirable for improved bioavailability. This favors A.
14. **Binding Affinity:** Ligand B (-7.8 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.6 kcal/mol). This is a substantial advantage for B, potentially outweighing some of the ADME drawbacks.
**Overall Assessment:**
Ligand B has a significantly better binding affinity, which is crucial for GPCR targets. However, it suffers from higher DILI risk, poorer metabolic stability (higher Cl_mic), shorter half-life, and higher P-gp efflux. Ligand A, while having weaker affinity, presents a much more favorable ADME-Tox profile, particularly regarding safety (DILI, hERG) and metabolic stability.
Considering the balance, the improved safety and pharmacokinetic properties of Ligand A are more compelling, especially in the early stages of drug development. The affinity difference, while substantial, might be addressable through further optimization, whereas fixing severe toxicity or poor PK is often much more challenging.
Output:
1
2025-04-17 23:59:56,592 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (346.391 and 347.507 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (105.14) is higher than Ligand B (64.86). For a cardiovascular GPCR, TPSA isn't as critical as for CNS targets, but lower TPSA generally favors better permeability. Ligand B is preferred here.
**3. logP:** Ligand A (0.645) is quite low, potentially hindering membrane permeability. Ligand B (3.058) is within the optimal 1-3 range. Ligand B is significantly better.
**4. H-Bond Donors:** Ligand A has 2 HBD, and Ligand B has 1. Both are acceptable, below the threshold of 5.
**5. H-Bond Acceptors:** Both ligands have 6 HBA, which is acceptable (<=10).
**6. QED:** Ligand B (0.768) has a higher QED score than Ligand A (0.512), indicating a more drug-like profile.
**7. DILI Risk:** Ligand A (60.14) has a higher DILI risk than Ligand B (28.306). This is a significant advantage for Ligand B.
**8. BBB Penetration:** While not a primary concern for a cardiovascular target, Ligand B (80.031) shows better BBB penetration than Ligand A (44.126).
**9. Caco-2 Permeability:** Ligand A (-5.587) and Ligand B (-4.963) both have negative values, which is unusual. I will assume these are logP values. Both are poor, but Ligand B is slightly better.
**10. Aqueous Solubility:** Ligand A (-1.272) has slightly better solubility than Ligand B (-3.735).
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (0.361 and 0.211 respectively). No significant difference.
**12. Microsomal Clearance:** Both ligands have similar microsomal clearance rates (32.77 and 28.874 mL/min/kg).
**13. In vitro Half-Life:** Ligand B (-3.893) has a longer in vitro half-life than Ligand A (-6.04). This is a positive attribute.
**14. P-gp Efflux:** Both ligands show very low P-gp efflux liability (0.026 and 0.144).
**15. Binding Affinity:** Ligand A (-5.6 kcal/mol) and Ligand B (-4.7 kcal/mol) have similar binding affinities. Ligand A is slightly better, but the difference is not substantial enough to outweigh other factors.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity) and the general drug-like properties, **Ligand B is the more promising candidate.** It has a much better logP, lower TPSA, lower DILI risk, higher QED, and a longer half-life. While Ligand A has slightly better affinity and solubility, these are outweighed by the significant advantages of Ligand B in terms of permeability, safety, and overall drug-likeness.
Output:
0
2025-04-17 23:59:56,592 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.36 and 350.503 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (40.85) is better than Ligand B (49.85). Both are below 140, but A is closer to the desirable threshold for good absorption.
3. **logP:** Both ligands have similar logP values (2.53 and 2.543), falling within the optimal 1-3 range.
4. **HBD:** Both ligands have 0 HBD, which is acceptable.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 3. Both are within the acceptable range of <=10.
6. **QED:** Ligand A (0.834) has a slightly better QED score than Ligand B (0.709), indicating a more drug-like profile.
7. **DILI:** Ligand A (46.336) has a higher DILI risk than Ligand B (11.632). This is a significant negative for Ligand A.
8. **BBB:** Ligand A (97.518) has a much higher BBB penetration percentile than Ligand B (88.329). While ADRB2 isn't strictly a CNS target, some CNS exposure can be beneficial or at least not detrimental for cardiovascular drugs.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.343 and -4.311), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Both ligands have negative solubility values (-2.822 and -2.609), indicating poor aqueous solubility. This is a significant drawback for both.
11. **hERG:** Ligand A (0.835) has a slightly higher hERG inhibition risk than Ligand B (0.367). Lower is better here.
12. **Cl_mic:** Ligand B (66.738) has a much higher microsomal clearance than Ligand A (9.451). This suggests Ligand A is more metabolically stable.
13. **t1/2:** Ligand A (-27.061) has a much longer in vitro half-life than Ligand B (0.062). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.47) has a lower P-gp efflux liability than Ligand B (0.113). Lower is better.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.4 and -6.5 kcal/mol). The difference is negligible.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Both ligands are comparable in logP and affinity. Ligand A has a better TPSA and Pgp profile. The BBB penetration of Ligand A is also higher, which isn't a negative. However, the significantly lower DILI risk of Ligand B and better metabolic stability (lower Cl_mic) are compelling.
**Overall Assessment:**
Despite Ligand A's advantages in BBB, TPSA, Pgp, and half-life, the substantially higher DILI risk and slightly higher hERG risk are major concerns. The poor Caco-2 and solubility are shared drawbacks. Ligand B, while having a higher Cl_mic, presents a much safer toxicity profile. For a cardiovascular target, minimizing toxicity is paramount.
Output:
0
2025-04-17 23:59:56,593 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for their potential as drug candidates targeting the ADRB2, a cardiovascular GPCR. Therefore, we prioritize logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB.
Let's analyze each ligand against the provided parameters:
* **Molecular Weight:** Both ligands (358.479 and 351.437 Da) fall within the ideal range of 200-500 Da.
* **TPSA:** Ligand A (88.1) is better than Ligand B (29.54) as it is closer to the ideal threshold of <140. Ligand B is excellent.
* **logP:** Ligand A (0.942) is within the optimal range (1-3), while Ligand B (4.299) is slightly high, potentially leading to solubility issues and off-target effects.
* **H-Bond Donors/Acceptors:** Ligand A has 2 HBD and 5 HBA, while Ligand B has 0 HBD and 2 HBA. Both are acceptable.
* **QED:** Both ligands have good QED scores (0.64 and 0.733), indicating good drug-like properties.
* **DILI:** Both ligands have low DILI risk (16.324 and 15.51), which is favorable.
* **BBB:** Ligand B (97.131) shows significantly better BBB penetration than Ligand A (45.677). However, as ADRB2 is a cardiovascular target, BBB penetration is less critical.
* **Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual.
* **Aqueous Solubility:** Ligand A (-0.716) has better solubility than Ligand B (-4.015).
* **hERG Inhibition:** Both ligands have low hERG inhibition risk (0.242 and 0.867).
* **Microsomal Clearance:** Ligand A (21.371) has significantly lower microsomal clearance than Ligand B (78.195), suggesting better metabolic stability.
* **In vitro Half-Life:** Ligand A (13.015) has a longer half-life than Ligand B (-0.165).
* **P-gp Efflux:** Ligand A (0.038) has lower P-gp efflux than Ligand B (0.586), indicating better bioavailability.
* **Binding Affinity:** Ligand B (-6.5 kcal/mol) has a slightly better binding affinity than Ligand A (-5.6 kcal/mol). This is a 0.9 kcal/mol difference, which is not substantial enough to override the other factors.
**Overall Assessment:**
Ligand A demonstrates a better balance of properties, particularly regarding logP, solubility, metabolic stability (lower Cl_mic, longer t1/2), and P-gp efflux. While Ligand B has slightly better binding affinity and BBB penetration, the higher logP and worse metabolic properties are concerning. For a cardiovascular target, metabolic stability and bioavailability are crucial.
**Output:**
1
2025-04-17 23:59:56,593 - INFO - Batch 445 complete. Total preferences: 7120
2025-04-17 23:59:56,593 - INFO - Processing batch 446/512...
2025-04-18 00:00:45,724 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
The ADRB2 receptor is a GPCR, so the priorities are logP, TPSA, Pgp, BBB, and affinity. Let's break down the comparison:
1. **Molecular Weight:** Both ligands are within the ideal range (366.5 and 369.4 Da). No significant difference here.
2. **TPSA:** Ligand A (57.69) is significantly better than Ligand B (96.44). A TPSA under 140 is good for oral absorption, but lower is generally preferred for GPCRs, and A is much closer to optimal.
3. **logP:** Ligand A (2.36) is within the optimal range, while Ligand B (0.134) is quite low. Low logP can hinder membrane permeability. This is a significant advantage for A.
4. **H-Bond Donors/Acceptors:** Ligand A (0 HBD, 4 HBA) is slightly better than Ligand B (1 HBD, 5 HBA). Both are acceptable, but fewer H-bonds generally improve permeability.
5. **QED:** Ligand B (0.814) has a higher QED score than Ligand A (0.535), suggesting a more generally "drug-like" profile. However, QED is less crucial than specific properties for GPCRs.
6. **DILI:** Ligand B (59.636) has a higher DILI risk than Ligand A (39.279), though both are acceptable. Lower is better.
7. **BBB:** Both ligands have reasonably good BBB penetration (A: 74.835, B: 71.268). Not a major differentiator here.
8. **Caco-2 Permeability:** Both ligands have very poor Caco-2 permeability (-4.846 and -4.828). This is a concern for both, but doesn't strongly favor one over the other.
9. **Aqueous Solubility:** Ligand A (-3.495) has slightly better solubility than Ligand B (-1.887).
10. **hERG:** Both ligands have low hERG inhibition risk (A: 0.283, B: 0.152).
11. **Microsomal Clearance:** Ligand B (-12.451) has significantly lower microsomal clearance than Ligand A (62.718), indicating better metabolic stability. This is a strong advantage for B.
12. **In vitro Half-Life:** Ligand B (-0.568) has a longer half-life than Ligand A (-33.569), further supporting its better metabolic stability.
13. **P-gp Efflux:** Both ligands have low P-gp efflux liability (A: 0.331, B: 0.025). B is slightly better.
14. **Binding Affinity:** Ligand A (-6.5 kcal/mol) has *much* stronger binding affinity than Ligand B (-21.7 kcal/mol). This is a decisive advantage for A. A difference of >1.5 kcal/mol is significant.
**Conclusion:**
While Ligand B has better metabolic stability (lower Cl_mic, longer t1/2) and a slightly better QED, Ligand A's significantly superior binding affinity and more favorable logP and TPSA values are more critical for a GPCR target like ADRB2. The poor Caco-2 permeability is a concern for both, but can be addressed with formulation strategies. The strong binding affinity of Ligand A is likely to outweigh the metabolic concerns, especially given the potential for optimization.
Output:
1
2025-04-18 00:00:45,725 - INFO - Here's my reasoning and the final output:
**Reasoning:**
We are evaluating two ligands for the ADRB2 receptor, a GPCR involved in cardiovascular function. Therefore, the priorities are logP, Pgp, TPSA, and affinity, with metabolic stability (Cl_mic, t1/2) also being important.
Let's compare the ligands property by property:
1. **MW:** Both ligands (359.344 and 361.511 Da) are within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (59.0) is significantly better than Ligand B (71.09). Lower TPSA generally favors better absorption.
3. **logP:** Both are acceptable, but Ligand A (1.876) is closer to the optimal 1-3 range than Ligand B (2.976).
4. **HBD/HBA:** Both have reasonable HBD/HBA counts (Ligand A: 1/4, Ligand B: 2/4), unlikely to be a major differentiator.
5. **QED:** Ligand A (0.895) is better than Ligand B (0.734), indicating a more drug-like profile.
6. **DILI:** Both are good, with very similar low DILI risk (Ligand A: 38.077, Ligand B: 37.999).
7. **BBB:** Ligand A (81.698) has a much better BBB penetration percentile than Ligand B (52.656). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be beneficial for off-target effects and distribution.
8. **Caco-2:** Ligand A (-4.504) is better than Ligand B (-5.233), suggesting better intestinal absorption.
9. **Solubility:** Ligand A (-2.697) is better than Ligand B (-2.224).
10. **hERG:** Both have low hERG inhibition risk (Ligand A: 0.766, Ligand B: 0.155). Ligand B is slightly better here.
11. **Cl_mic:** Ligand A (14.661) has a lower microsomal clearance than Ligand B (20.299), indicating better metabolic stability.
12. **t1/2:** Ligand A (-7.455) has a much longer in vitro half-life than Ligand B (4.623).
13. **Pgp:** Ligand A (0.325) has lower P-gp efflux liability than Ligand B (0.249), which is favorable for bioavailability.
14. **Affinity:** Ligand A (-7.2 kcal/mol) has a slightly better binding affinity than Ligand B (-6.5 kcal/mol). While the difference is less than the 1.5 kcal/mol threshold, it contributes to the overall preference.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical ADME properties (TPSA, BBB, Solubility, Cl_mic, t1/2, Pgp) and has a slightly better binding affinity and QED score. While Ligand B has a slightly better hERG profile, the overall balance of properties favors Ligand A as the more promising drug candidate.
**Output:**
1
2025-04-18 00:00:45,725 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [401.243, 70.63, 3.131, 0, 6, 0.657, 79.837, 80.031, -4.854, -5.312, 0.534, 75.487, -12.042, 0.665, -6.9]
**Ligand B:** [360.479, 78.43, 2.844, 3, 4, 0.677, 33.307, 28.189, -5.436, -2.976, 0.339, 47.544, -5.437, 0.101, -6.7]
**Step-by-step comparison:**
1. **MW:** Ligand A (401.243 Da) is within the ideal range, while Ligand B (360.479 Da) is also acceptable. No strong preference here.
2. **TPSA:** Both are reasonably good (A: 70.63, B: 78.43), below the 140 threshold for oral absorption.
3. **logP:** Both are within the optimal 1-3 range (A: 3.131, B: 2.844). Again, no strong preference.
4. **HBD:** Ligand A has 0 HBD, which is good. Ligand B has 3, which is still acceptable but slightly less ideal.
5. **HBA:** Ligand A has 6 HBA, and Ligand B has 4. Both are within the acceptable range.
6. **QED:** Both have good QED values (A: 0.657, B: 0.677), indicating good drug-like properties.
7. **DILI:** Ligand A has a concerningly high DILI risk (79.837%), while Ligand B has a much lower risk (33.307%). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A has excellent BBB penetration (80.031%), while Ligand B is lower (28.189%). Given that ADRB2 is a cardiovascular target, BBB penetration is less critical than for CNS targets, but still a consideration.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. Ligand A (-4.854) is slightly better than Ligand B (-5.436).
10. **Solubility:** Ligand A has poor solubility (-5.312), while Ligand B has slightly better solubility (-2.976).
11. **hERG:** Both have low hERG risk (A: 0.534, B: 0.339).
12. **Cl_mic:** Ligand A has a higher microsomal clearance (75.487) suggesting faster metabolism, while Ligand B has lower clearance (47.544), indicating better metabolic stability.
13. **t1/2:** Ligand A has a negative half-life (-12.042), which is concerning. Ligand B has a negative half-life as well (-5.437), but less negative.
14. **Pgp:** Ligand A has moderate Pgp efflux (0.665), while Ligand B has very low Pgp efflux (0.101). Lower Pgp is preferable for better bioavailability.
15. **Affinity:** Both have very similar binding affinities (A: -6.9 kcal/mol, B: -6.7 kcal/mol). The difference is not substantial enough to be decisive.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are important. While BBB isn't *critical* for a cardiovascular target, it's still a factor.
**Overall Assessment:**
Ligand B is clearly the better candidate. The significantly lower DILI risk is a major advantage. It also has better metabolic stability (lower Cl_mic), lower Pgp efflux, and slightly better solubility. While Ligand A has slightly better Caco-2 permeability and BBB penetration, the DILI risk and metabolic stability concerns outweigh those benefits. The binding affinities are comparable.
Output:
0
2025-04-18 00:00:45,725 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (366.571 and 350.463 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (49.41) is significantly better than Ligand B (80.48). ADRB2 is a cardiovascular target, not CNS, but lower TPSA generally improves permeability. Ligand A is well below the 140 threshold, while B is approaching it.
3. **logP:** Both ligands have acceptable logP values (3.021 and 1.604), falling within the 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability, but not dramatically so.
4. **HBD:** Both ligands have 1 HBD, which is within the acceptable limit of 5.
5. **HBA:** Ligand A has 3 HBA, while Ligand B has 6. Ligand A is preferable here, staying further below the 10 limit.
6. **QED:** Both ligands have good QED scores (0.718 and 0.808), indicating good drug-like properties.
7. **DILI:** Ligand A (16.402%) has a significantly lower DILI risk than Ligand B (26.328%). This is a major advantage for Ligand A.
8. **BBB:** Both ligands have reasonable BBB penetration (76.658% and 73.129%). This isn't a primary concern for a cardiovascular target, but higher is generally better.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.926 and -4.93). These values are difficult to interpret without knowing the scale, but they suggest poor permeability.
10. **Solubility:** Ligand A (-3.933) has slightly better solubility than Ligand B (-1.352), but both are poor.
11. **hERG:** Ligand A (0.677) has a lower hERG risk than Ligand B (0.239). This is a significant advantage for Ligand A, reducing cardiotoxicity concerns.
12. **Cl_mic:** Ligand A (75.44) has a higher microsomal clearance than Ligand B (40.041). This indicates lower metabolic stability for Ligand A, which is a drawback.
13. **t1/2:** Ligand B (-4.582) has a longer in vitro half-life than Ligand A (12.266). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.141) has lower P-gp efflux liability than Ligand B (0.039), which is preferable.
15. **Binding Affinity:** Ligand A (-6.2 kcal/mol) has a slightly better binding affinity than Ligand B (-5.8 kcal/mol). This difference of 0.4 kcal/mol is not huge, but it's a positive for Ligand A.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A performs better on logP, TPSA, and Pgp. The affinity difference is small.
**Overall Assessment:**
Ligand A is preferable. While Ligand B has a better half-life and lower clearance, Ligand A excels in crucial areas like DILI risk, hERG inhibition, TPSA, and Pgp efflux. The slightly better binding affinity also contributes. The lower DILI and hERG risks are particularly important for a cardiovascular target, outweighing the metabolic stability concerns.
Output:
1
2025-04-18 00:00:45,726 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (349.475 and 354.447 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (78.51) is significantly better than Ligand B (99.1). For a GPCR, keeping TPSA low is good, and A is well under the 140 threshold. B is approaching a level that could hinder absorption.
3. **logP:** Ligand A (1.47) is slightly better than Ligand B (0.21). Both are within the 1-3 range, but B is quite low, potentially leading to permeability issues.
4. **HBD:** Ligand A (2) is preferable to Ligand B (3). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (5). Similar reasoning as HBD.
6. **QED:** Ligand A (0.651) is better than Ligand B (0.568), indicating a more drug-like profile.
7. **DILI:** Ligand A (14.773) is significantly better than Ligand B (11.206). Lower DILI risk is crucial.
8. **BBB:** Ligand A (64.87) is better than Ligand B (29.508). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be helpful for distribution and avoiding off-target effects.
9. **Caco-2:** Both are negative (-5.039 and -5.036) which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand A (-2.109) is better than Ligand B (-0.644). Higher solubility is generally desirable.
11. **hERG:** Both are very low (0.195 and 0.08), indicating minimal hERG inhibition risk, which is excellent.
12. **Cl_mic:** Ligand A (29.276) is significantly better than Ligand B (3.993). Lower clearance indicates better metabolic stability.
13. **t1/2:** Ligand A (-13.612) is significantly better than Ligand B (3.199). A negative value suggests a very long half-life, which is highly desirable.
14. **Pgp:** Both are very low (0.025 and 0.03), indicating minimal P-gp efflux.
15. **Affinity:** Ligand B (-6.2) is slightly better than Ligand A (-5.9), but the difference is relatively small (0.3 kcal/mol).
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has a better logP and significantly better TPSA. Both have good Pgp profiles. The affinity difference is small enough that the superior ADME properties of Ligand A outweigh it.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical ADME properties (DILI, BBB, Cl_mic, t1/2, solubility, TPSA, QED) and has a comparable binding affinity. The Caco-2 values are concerning for both, but the overall profile of A is much more favorable for development.
Output:
1
2025-04-18 00:00:45,726 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (344.415 & 347.434 Da) fall comfortably within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (89.16) is slightly higher than Ligand B (52.65). Both are below the 140 threshold for oral absorption, but Ligand B is significantly better, especially considering ADRB2 is a GPCR and lower TPSA is generally favored.
3. **logP:** Both ligands have good logP values (2.272 & 1.84), falling within the optimal 1-3 range. Ligand B is slightly lower, which could be beneficial for solubility, but not a major difference.
4. **HBD:** Ligand A has 2 HBD, and Ligand B has 1. Both are within the acceptable limit of 5.
5. **HBA:** Ligand A has 5 HBA, and Ligand B has 3. Both are within the acceptable limit of 10.
6. **QED:** Both ligands have excellent QED scores (0.806 & 0.904), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A has a DILI risk of 57.425, while Ligand B has a much lower risk of 9.616. This is a significant advantage for Ligand B.
8. **BBB:** Ligand A has a BBB penetration of 62.699, while Ligand B has 93.137. While ADRB2 isn't exclusively a CNS target, higher BBB penetration is generally favorable for GPCRs, suggesting better distribution. Ligand B is significantly better here.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.953 & -4.976). This is unusual and suggests poor permeability.
10. **Solubility:** Ligand A (-3.372) and Ligand B (-2.287) both have poor solubility. Ligand B is slightly better.
11. **hERG:** Ligand A (0.057) has a slightly lower hERG risk than Ligand B (0.45), which is preferable.
12. **Cl_mic:** Ligand A (21.726) has a higher microsomal clearance than Ligand B (-19.551). This means Ligand B is likely to have better metabolic stability.
13. **t1/2:** Ligand A (44.817) has a shorter in vitro half-life than Ligand B (-16.947). This suggests Ligand B will have a longer duration of action.
14. **Pgp:** Ligand A (0.061) has lower P-gp efflux than Ligand B (0.028). This suggests better oral bioavailability for Ligand A.
15. **Binding Affinity:** Ligand A (-5.9 kcal/mol) has slightly weaker binding affinity than Ligand B (-6.5 kcal/mol). The difference is 0.6 kcal/mol, which is significant.
**Overall Assessment:**
Ligand B clearly outperforms Ligand A in several crucial areas for a GPCR drug candidate: lower DILI risk, significantly higher BBB penetration, better metabolic stability (lower Cl_mic, longer t1/2), and stronger binding affinity. While Ligand A has a slightly lower hERG risk and Pgp efflux, the benefits of Ligand B in terms of safety (DILI), distribution (BBB), and potency (affinity) outweigh these minor drawbacks. The Caco-2 permeability is concerning for both, but can be addressed with formulation strategies.
Output:
0
2025-04-18 00:00:45,726 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (359.348 and 353.398 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (63.69) is significantly better than Ligand B (80.56). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand A is well below the 140 threshold, while Ligand B is approaching it.
3. **logP:** Ligand A (3.026) is optimal, while Ligand B (0.141) is quite low. Low logP can hinder membrane permeability and bioavailability. This is a major strike against Ligand B.
4. **HBD:** Ligand A (1) is preferable to Ligand B (0). While both are low, a single HBD can aid solubility without significantly impacting permeability.
5. **HBA:** Ligand A (4) is better than Ligand B (6). Lower HBA generally improves permeability.
6. **QED:** Ligand A (0.882) is much better than Ligand B (0.697), indicating a more drug-like profile.
7. **DILI:** Both ligands have acceptable DILI risk (43.66 and 40.636), below the 60 threshold.
8. **BBB:** Both ligands show excellent BBB penetration (96.937 and 90.965). This is good, but less critical for ADRB2 which isn't a CNS target.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.643 and -4.683). This is unusual and suggests poor permeability *in vitro*. However, these values are not directly comparable without knowing the scale.
10. **Solubility:** Ligand A (-3.733) is better than Ligand B (-1.693). Higher solubility is generally desirable.
11. **hERG:** Ligand A (0.583) is much better than Ligand B (0.069). Lower hERG inhibition is crucial to avoid cardiotoxicity, especially for a cardiovascular target like ADRB2.
12. **Cl_mic:** Ligand A (13.469) has significantly lower microsomal clearance than Ligand B (23.676), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-2.011) has a more favorable (less negative) in vitro half-life than Ligand B (-16.093).
14. **Pgp:** Ligand A (0.248) has lower P-gp efflux than Ligand B (0.023), which is preferable for bioavailability.
15. **Binding Affinity:** Ligand B (-7.0) has a slightly better binding affinity than Ligand A (-6.2). However, the difference (0.8 kcal/mol) is not substantial enough to overcome the significant ADME deficiencies of Ligand B.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical ADME properties (logP, TPSA, QED, solubility, hERG, Cl_mic, t1/2, Pgp). While Ligand B has slightly better binding affinity, the superior ADME profile of Ligand A makes it a much more promising drug candidate, especially considering the importance of these properties for a GPCR target. The negative Caco-2 values are concerning for both, but the other advantages of Ligand A are more compelling.
Output:
1
2025-04-18 00:00:45,726 - INFO - Here's my reasoning and the final output for the ligand preference:
**Reasoning:**
We are looking for a ligand targeting ADRB2, a GPCR. Therefore, the priorities are logP, Pgp, TPSA, affinity, and BBB. Let's compare Ligand A and Ligand B across all parameters:
1. **MW:** Both ligands (351.447 and 350.547 Da) are within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (70.16) is higher than Ligand B (58.2). Both are acceptable, but B is better for permeability.
3. **logP:** Ligand A (0.483) is quite low, potentially hindering permeation. Ligand B (4.04) is at the upper end of the optimal range, but still acceptable. This is a significant advantage for B.
4. **HBD/HBA:** Ligand A (0 HBD, 4 HBA) is preferable to Ligand B (2 HBD, 2 HBA) as it has fewer hydrogen bond donors.
5. **QED:** Both ligands have similar QED values (0.723 and 0.694), indicating good drug-likeness.
6. **DILI:** Ligand A (23.885) has a slightly higher DILI risk than Ligand B (18.302), but both are quite low and acceptable.
7. **BBB:** Ligand B (84.219) has a significantly higher BBB penetration percentile than Ligand A (74.486). This is a crucial advantage for a GPCR target.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and potentially indicates an issue with the model or data.
9. **Solubility:** Ligand A (-0.747) has better solubility than Ligand B (-4.76).
10. **hERG:** Ligand A (0.14) has a much lower hERG risk than Ligand B (0.533), which is a significant safety advantage.
11. **Cl_mic:** Ligand A (29.298) has a much lower microsomal clearance than Ligand B (82.7), indicating better metabolic stability.
12. **t1/2:** Ligand A (-6.065) has a more negative in vitro half-life than Ligand B (4.045), indicating a longer half-life.
13. **Pgp:** Ligand A (0.04) has a much lower P-gp efflux liability than Ligand B (0.161), which is favorable for bioavailability.
14. **Affinity:** Ligand A (-6.3 kcal/mol) has a slightly better binding affinity than Ligand B (-4.9 kcal/mol). This is a 1.4 kcal/mol difference, which is substantial.
**Overall Assessment:**
While Ligand B has a better logP and BBB, Ligand A has significantly better metabolic stability (Cl_mic, t1/2), lower hERG risk, lower Pgp efflux, and a slightly better binding affinity. The combination of these factors, particularly the improved safety profile (hERG) and metabolic stability, outweighs the slightly lower logP and BBB for this GPCR target. The affinity difference is also significant.
Output:
1
2025-04-18 00:00:45,726 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (344.46 and 355.44 Da) fall comfortably within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (86.88) is significantly better than Ligand B (113.69). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand A is well below the 140 threshold, while Ligand B is approaching it.
3. **logP:** Ligand A (2.157) is optimal, while Ligand B (1.038) is slightly low, potentially impacting membrane permeability.
4. **HBD:** Both ligands have 3 HBD, which is within the acceptable limit of 5.
5. **HBA:** Ligand A has 3 HBA, while Ligand B has 6. Ligand A is preferable as lower HBA generally improves permeability.
6. **QED:** Both ligands have good QED scores (0.523 and 0.578), indicating good drug-like properties.
7. **DILI:** Ligand A (34.74) has a lower DILI risk than Ligand B (40.75), making it safer from a liver toxicity perspective. Both are below the 40 threshold, but A is better.
8. **BBB:** Ligand A (62.23) has a better BBB penetration score than Ligand B (40.68). While ADRB2 isn't exclusively a CNS target, some CNS exposure can occur, and higher BBB is generally favorable.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it is hard to interpret.
10. **Solubility:** Both ligands have negative solubility values, which is also unusual. Again, the scale is not specified.
11. **hERG:** Ligand A (0.311) exhibits a much lower hERG inhibition liability than Ligand B (0.139). This is a critical advantage, as hERG inhibition can lead to cardiotoxicity.
12. **Cl_mic:** Ligand A (29.62) has a lower microsomal clearance than Ligand B (57.79), indicating better metabolic stability.
13. **t1/2:** Ligand A (6.42) has a shorter in vitro half-life than Ligand B (11.78). This is a slight disadvantage for Ligand A.
14. **Pgp:** Ligand A (0.248) has a lower P-gp efflux liability than Ligand B (0.144), which is beneficial for oral bioavailability and potentially CNS exposure.
15. **Binding Affinity:** Ligand A (-6.9 kcal/mol) has a slightly better binding affinity than Ligand B (-5.3 kcal/mol). This 1.6 kcal/mol difference is significant and can outweigh some of the ADME drawbacks of Ligand B.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand A is clearly superior. It has a better logP, significantly lower TPSA, lower Pgp efflux, lower DILI risk, better hERG profile, and a stronger binding affinity. While Ligand B has a longer half-life, the other advantages of Ligand A are more critical for a successful drug candidate.
Output:
1
2025-04-18 00:00:45,726 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
The target is ADRB2, a GPCR. Therefore, I will prioritize logP, TPSA, Pgp efflux, BBB penetration, and binding affinity. Metabolic stability (Cl_mic, t1/2) and safety (DILI, hERG) are also important.
Let's compare the ligands property by property:
1. **MW:** Both ligands (361.789 and 363.531 Da) are within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (92.47) is slightly higher than Ligand B (63.91). Ligand B is preferable here as lower TPSA generally correlates with better membrane permeability.
3. **logP:** Ligand B (3.715) is higher than Ligand A (2.309), but both are within the optimal 1-3 range. Ligand B is slightly better.
4. **HBD:** Both have 0 HBD, which is good.
5. **HBA:** Both have 6 HBA, which is acceptable.
6. **QED:** Both ligands have good QED scores (0.615 and 0.681), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand B (55.758) has a significantly lower DILI risk than Ligand A (92.051). This is a major advantage for Ligand B.
8. **BBB:** Ligand A (76.309) has better BBB penetration than Ligand B (63.784). While not a primary concern for peripheral GPCRs like ADRB2, it's a slight advantage for A.
9. **Caco-2:** Ligand B (-5.065) has a more negative Caco-2 value, indicating better permeability than Ligand A (-4.655).
10. **Solubility:** Ligand A (-3.949) has slightly better solubility than Ligand B (-4.164).
11. **hERG:** Ligand A (0.424) has a lower hERG risk than Ligand B (0.61). This is a positive for Ligand A.
12. **Cl_mic:** Ligand B (69.224) has slightly better metabolic stability (lower clearance) than Ligand A (71.407).
13. **t1/2:** Ligand B (58.649) has a longer in vitro half-life than Ligand A (-32.236). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.215) has a lower Pgp efflux liability than Ligand B (0.593). This is a positive for Ligand A.
15. **Affinity:** Ligand B (-6.6 kcal/mol) has a slightly better binding affinity than Ligand A (-7.1 kcal/mol).
**Overall Assessment:**
Ligand B demonstrates a superior balance of properties, particularly regarding safety (DILI), metabolic stability (t1/2, Cl_mic), and permeability (Caco-2). While Ligand A has a slightly better binding affinity, a small advantage in potency is outweighed by the significant improvements in ADME-Tox properties of Ligand B. The lower DILI risk is particularly compelling.
**Output:**
0
2025-04-18 00:00:45,727 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [350.547, 58.2, 4.04, 2, 2, 0.694, 22.761, 69.407, -4.602, -5.043, 0.509, 96.093, 1.832, 0.317, -5.8]
**Ligand B:** [362.539, 40.62, 4.03, 0, 3, 0.566, 30.128, 84.141, -4.808, -3.783, 0.792, 69.036, 26.051, 0.843, -7.9]
Here's a breakdown of the comparison, considering the guidelines and GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both ligands are within the ideal range (200-500 Da). A is 350.5, B is 362.5. No significant difference.
2. **TPSA:** A (58.2) is higher than B (40.62). B is better here, being closer to the <90 target for GPCRs.
3. **logP:** Both are excellent (around 4.0), falling within the optimal 1-3 range. Very similar.
4. **HBD:** A (2) is slightly better than B (0). While low HBD can sometimes be problematic for solubility, it's not a major concern here.
5. **HBA:** A (2) is lower than B (3). Lower is generally preferred, so A is slightly better.
6. **QED:** Both are reasonable (A: 0.694, B: 0.566), indicating acceptable drug-likeness. A is better.
7. **DILI:** A (22.761) is significantly better than B (30.128). This is a crucial advantage for A.
8. **BBB:** A (69.407) is good, while B (84.141) is even better. B has an advantage here, but it's less critical for a cardiovascular target.
9. **Caco-2:** Both are negative, indicating poor permeability. B (-4.808) is slightly worse than A (-4.602).
10. **Solubility:** A (-5.043) is worse than B (-3.783). B has a clear advantage here.
11. **hERG:** A (0.509) is better than B (0.792). Lower hERG inhibition is crucial for avoiding cardiotoxicity.
12. **Cl_mic:** A (96.093) is higher than B (69.036), meaning faster clearance and lower metabolic stability. B is better.
13. **t1/2:** B (26.051) has a much longer half-life than A (1.832). This is a significant advantage for B.
14. **Pgp:** A (0.317) is much better than B (0.843). Lower P-gp efflux is highly desirable for bioavailability.
15. **Affinity:** B (-7.9) is significantly stronger than A (-5.8). This is a substantial advantage for B. A difference of >1.5 kcal/mol can often outweigh other factors.
**Overall Assessment:**
While Ligand A has advantages in DILI risk, hERG, and Pgp efflux, Ligand B's superior binding affinity (-7.9 vs -5.8 kcal/mol) and longer half-life are critical for a GPCR target. The better solubility of B is also a plus. The slightly higher BBB penetration of B is less important for a cardiovascular target, but still a benefit. The slightly worse Caco-2 permeability is a concern, but the strong binding affinity and improved metabolic stability are likely to outweigh this.
Therefore, I believe Ligand B is the more promising drug candidate.
0
2025-04-18 00:00:45,727 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (351.422 Da) is well within the ideal range (200-500 Da). Ligand B (430.774 Da) is also acceptable, but closer to the upper limit.
2. **TPSA:** Both ligands (A: 70.67, B: 72.38) are below the 140 threshold for good oral absorption, and reasonably low for a GPCR target.
3. **logP:** Ligand A (1.642) is optimal (1-3). Ligand B (4.249) is slightly high, potentially leading to solubility issues and off-target interactions.
4. **HBD:** Ligand A (2) and Ligand B (3) are both acceptable, under the 5 limit.
5. **HBA:** Both ligands (A: 4, B: 4) are under the 10 limit.
6. **QED:** Both ligands have good QED scores (A: 0.552, B: 0.64), indicating drug-like properties.
7. **DILI:** Ligand A (35.479) has a better DILI score than Ligand B (28.616), indicating lower potential for liver injury. Lower is better.
8. **BBB:** Ligand A (77.123) has a significantly better BBB penetration score than Ligand B (20.938). While ADRB2 isn't exclusively a CNS target, some CNS exposure may be acceptable or even desirable for certain cardiovascular indications, and minimizing it isn't a high priority.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-5.027) is slightly better than Ligand B (-5.363).
10. **Solubility:** Ligand A (-1.794) is better than Ligand B (-4.669). This is important, especially given Ligand B's higher logP.
11. **hERG:** Ligand A (0.552) has a lower hERG risk than Ligand B (0.826).
12. **Cl_mic:** Ligand A (-1.397) has a much lower (better) microsomal clearance than Ligand B (54.331), suggesting better metabolic stability.
13. **t1/2:** Ligand A (17.461) and Ligand B (18.525) are comparable.
14. **Pgp:** Ligand A (0.105) has lower P-gp efflux liability than Ligand B (0.364), which is favorable for bioavailability.
15. **Affinity:** Ligand B (-6.3 kcal/mol) has a slightly better binding affinity than Ligand A (-5.5 kcal/mol). This is a 0.8 kcal/mol difference, which is significant but not overwhelming.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand B has a better affinity, but Ligand A excels in logP, Pgp, solubility, DILI, hERG, and metabolic stability. The difference in affinity is not large enough to outweigh the superior ADME profile of Ligand A.
**Conclusion:**
Considering the balance of properties, especially the ADME profile and the relatively modest affinity difference, Ligand A is the more promising drug candidate.
Output:
1
2025-04-18 00:00:45,727 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (374.39 and 352.44 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (76.35) is better than Ligand B (82.19). Both are below 140, but lower TPSA generally favors absorption.
3. **logP:** Ligand A (3.174) is optimal (1-3). Ligand B (-0.379) is significantly lower, potentially hindering membrane permeability. This is a major concern.
4. **HBD:** Both ligands have 1 HBD, which is within the acceptable limit.
5. **HBA:** Both ligands have 5 HBA, which is within the acceptable limit.
6. **QED:** Ligand A (0.873) has a superior QED score compared to Ligand B (0.521), indicating a more drug-like profile.
7. **DILI:** Ligand A (69.64) is higher than Ligand B (29.62). Ligand B has a much lower DILI risk, which is a significant advantage.
8. **BBB:** Ligand A (72.66) is better than Ligand B (37.57). While ADRB2 isn't necessarily a CNS target, some peripheral ADRB2 activity can influence CNS pathways.
9. **Caco-2:** Both ligands have similar, very negative Caco-2 values (-4.895 and -4.743). These values are unusual and suggest poor permeability.
10. **Solubility:** Ligand A (-3.9) is better than Ligand B (-0.663). Better solubility is generally desirable.
11. **hERG:** Ligand A (0.562) is better than Ligand B (0.088). Lower hERG inhibition is crucial for minimizing cardiotoxicity.
12. **Cl_mic:** Ligand A (19.88) is higher than Ligand B (-16.844). A negative value for Cl_mic suggests *very* high metabolic stability, a significant advantage for Ligand B.
13. **t1/2:** Ligand A (58.52) is better than Ligand B (-7.87). A longer half-life is generally preferred.
14. **Pgp:** Ligand A (0.304) is better than Ligand B (0.002). Lower P-gp efflux is desirable for improved bioavailability.
15. **Affinity:** Ligand A (-6.8) has a better binding affinity than Ligand B (-4.3). The difference is 2.5 kcal/mol, which is substantial and can outweigh some ADME drawbacks.
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A excels in affinity and Pgp, and has a good logP and TPSA. Ligand B's low logP is a major concern. While Ligand B has a better DILI and Cl_mic profile, the significantly weaker binding affinity and poor logP are critical drawbacks. The improved metabolic stability doesn't outweigh the binding deficit.
**Conclusion:**
Despite the better DILI and metabolic stability of Ligand B, Ligand A is the more promising candidate due to its significantly stronger binding affinity, better logP, and overall more favorable drug-like properties.
Output:
1
2025-04-18 00:00:45,727 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (362.47 Da) is well within the ideal range (200-500 Da). Ligand B (445.814 Da) is also acceptable, but approaching the upper limit.
2. **TPSA:** Ligand A (52.57) is good, under the 140 threshold and reasonable for a non-CNS GPCR. Ligand B (54.18) is also acceptable.
3. **logP:** Both ligands (A: 3.589, B: 3.846) are within the optimal 1-3 range, suggesting good permeability and reasonable solubility.
4. **HBD:** Ligand A (2) and Ligand B (1) are both good, below the 5 threshold.
5. **HBA:** Ligand A (3) is good, below the 10 threshold. Ligand B (6) is also acceptable.
6. **QED:** Both ligands (A: 0.873, B: 0.734) have good drug-likeness scores, well above 0.5.
7. **DILI:** Ligand A (38.852) has a slightly higher DILI risk than Ligand B (31.175), but both are below the concerning 60% threshold.
8. **BBB:** Ligand A (88.988) has a significantly higher BBB penetration potential than Ligand B (68.282). While ADRB2 isn't strictly a CNS target, some off-target CNS effects are possible with GPCRs, and higher BBB penetration could be a concern. However, for a cardiovascular target, this isn't a primary negative.
9. **Caco-2:** Ligand A (-4.598) has a worse Caco-2 permeability than Ligand B (-5.01). Lower values indicate lower permeability.
10. **Solubility:** Ligand A (-3.831) has a slightly better solubility than Ligand B (-4.339).
11. **hERG:** Both ligands (A: 0.763, B: 0.74) have similar, and acceptable, hERG inhibition liabilities.
12. **Cl_mic:** Ligand A (20.824) has a lower microsomal clearance than Ligand B (27.094), indicating better metabolic stability.
13. **t1/2:** Ligand A (49.767) has a much longer in vitro half-life than Ligand B (-6.842). This is a significant advantage.
14. **Pgp:** Both ligands (A: 0.494, B: 0.572) have similar P-gp efflux liabilities.
15. **Binding Affinity:** Ligand B (-7.2 kcal/mol) has a slightly better binding affinity than Ligand A (-8.1 kcal/mol). However, the difference is relatively small.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, affinity, and metabolic stability are key. Both ligands perform well on logP and TPSA. Ligand B has a slightly better affinity, but Ligand A has significantly better metabolic stability (lower Cl_mic, longer t1/2). The longer half-life of Ligand A is a major advantage, potentially allowing for less frequent dosing.
**Overall Assessment:**
While Ligand B has a slightly better binding affinity, Ligand A's superior metabolic stability (longer half-life, lower clearance) and acceptable DILI/BBB profiles make it a more promising drug candidate. The small difference in binding affinity is outweighed by the pharmacokinetic advantages of Ligand A.
Output:
1
2025-04-18 00:00:45,728 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (359.413 Da) is slightly lower, which is generally favorable for permeability.
**2. TPSA:** Ligand A (64.63) is significantly better than Ligand B (113.32). For a GPCR, keeping TPSA low is beneficial for permeability and receptor engagement. Ligand B is approaching a less desirable range.
**3. logP:** Ligand A (3.825) is optimal, while Ligand B (0.974) is quite low. A logP below 1 can hinder membrane permeability. This is a significant advantage for Ligand A.
**4. H-Bond Donors:** Ligand A (1) is preferable to Ligand B (4). Fewer HBDs generally improve permeability.
**5. H-Bond Acceptors:** Both ligands have the same number of HBA (4), which is acceptable.
**6. QED:** Ligand A (0.732) has a better QED score than Ligand B (0.51), indicating a more drug-like profile.
**7. DILI Risk:** Ligand B (28.499) has a considerably lower DILI risk than Ligand A (44.048), which is a positive attribute.
**8. BBB Penetration:** Ligand A (91.857) has a much higher BBB penetration percentile than Ligand B (55.138). While ADRB2 is a cardiovascular target, some CNS effects are possible with beta-blockers, and good BBB penetration could be useful for understanding off-target effects.
**9. Caco-2 Permeability:** Ligand A (-4.112) is better than Ligand B (-5.703), suggesting better intestinal absorption.
**10. Aqueous Solubility:** Ligand B (-2.718) has better aqueous solubility than Ligand A (-4.747). Solubility is important for formulation, but can be mitigated.
**11. hERG Inhibition:** Ligand A (0.59) has a lower hERG inhibition risk than Ligand B (0.137), a crucial factor for cardiovascular drugs.
**12. Microsomal Clearance:** Ligand B (10.869) has a significantly lower microsomal clearance than Ligand A (103.166), indicating better metabolic stability.
**13. In vitro Half-Life:** Ligand B (9.439) has a longer in vitro half-life than Ligand A (-29.095). This is a significant advantage.
**14. P-gp Efflux:** Ligand A (0.185) has lower P-gp efflux than Ligand B (0.016), which is favorable for bioavailability.
**15. Binding Affinity:** Both ligands have very similar binding affinities (-6.7 kcal/mol and -6.0 kcal/mol, respectively). The difference is not substantial enough to outweigh other factors.
**Overall Assessment:**
Ligand A excels in permeability-related properties (TPSA, logP, Caco-2) and has a better QED score, lower hERG risk, and better BBB penetration. However, Ligand B demonstrates a much better safety profile (lower DILI risk), superior metabolic stability (lower Cl_mic, longer t1/2), and better solubility.
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity) and the importance of metabolic stability and safety for a cardiovascular drug, Ligand B is the more promising candidate. The lower logP of Ligand B can be addressed through formulation strategies, while the significant improvements in metabolic stability and safety are harder to rectify later in development.
Output:
0
2025-04-18 00:00:45,728 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Ligand A:** [348.447, 69.48, 1.916, 0, 6, 0.785, 47.77, 75.572, -4.584, -2.353, 0.115, 49.247, 18.623, 0.054, -6.7]
**Ligand B:** [361.511, 53.51, 3.199, 0, 4, 0.777, 54.634, 81.776, -4.697, -3.606, 0.396, 96.521, -32.438, 0.317, -6.2]
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). A (348.447) is slightly lower, which is generally favorable for permeability.
**2. TPSA:** Both are reasonably low, but B (53.51) is better than A (69.48), falling comfortably under the 140 A^2 threshold for oral absorption.
**3. logP:** Both are within the optimal range (1-3), but B (3.199) is higher than A (1.916). Higher logP can sometimes be problematic for solubility, but is generally acceptable.
**4. H-Bond Donors:** Both have 0 HBD, which is good.
**5. H-Bond Acceptors:** Both are acceptable, A (6) is slightly higher than B (4).
**6. QED:** Both are very similar and above the 0.5 threshold, indicating good drug-likeness.
**7. DILI Risk:** Both are acceptable, with A (47.77) being slightly lower than B (54.634). Lower is better.
**8. BBB Penetration:** B (81.776) has significantly better BBB penetration than A (75.572). While ADRB2 isn't exclusively a CNS target, some cardiovascular effects are mediated by central pathways, and better BBB penetration could be beneficial.
**9. Caco-2 Permeability:** Both are negative, indicating good permeability.
**10. Aqueous Solubility:** Both are negative, indicating poor solubility. B (-3.606) is worse than A (-2.353).
**11. hERG Inhibition:** Both are very low, indicating minimal cardiotoxicity risk.
**12. Microsomal Clearance:** B (96.521) has significantly higher clearance than A (49.247), indicating lower metabolic stability. This is a major drawback for B.
**13. In vitro Half-Life:** A (18.623) has a better half-life than B (-32.438).
**14. P-gp Efflux:** Both are very low, indicating minimal P-gp efflux.
**15. Binding Affinity:** A (-6.7) has a slightly better binding affinity than B (-6.2). While the difference is not huge, it is still a factor.
**GPCR-Specific Considerations:** For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. B has a better logP and TPSA, and slightly better BBB penetration. However, A has a better binding affinity and significantly better metabolic stability (lower Cl_mic, longer half-life). The improved metabolic stability of A is a significant advantage.
**Conclusion:**
Considering the balance of properties, especially the crucial metabolic stability and binding affinity, Ligand A is the more promising drug candidate. The slightly better BBB penetration of B is not enough to offset the significant difference in metabolic stability and the modest difference in binding affinity.
**Output:**
1
2025-04-18 00:00:45,728 - INFO - Batch 446 complete. Total preferences: 7136
2025-04-18 00:00:45,728 - INFO - Processing batch 447/512...
2025-04-18 00:01:34,242 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (352.362) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (71.25) is significantly better than Ligand A (104.73). For a GPCR, lower TPSA is preferred for better permeability.
3. **logP:** Both ligands have good logP values (A: 1.468, B: 3.058), falling within the optimal 1-3 range. Ligand B is closer to the upper end, which could be slightly concerning for solubility, but acceptable.
4. **HBD:** Ligand A (3) is higher than Ligand B (1). Lower HBD is generally preferred for better permeability.
5. **HBA:** Ligand B (6) is higher than Ligand A (4). Similar to HBD, lower HBA is generally preferred.
6. **QED:** Both ligands have good QED scores (A: 0.553, B: 0.737), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Both ligands have similar DILI risk (A: 57.348, B: 62.893), and are within an acceptable range (<60 is good).
8. **BBB:** Ligand B (74.758) is significantly better than Ligand A (60.14). For a GPCR, even a non-CNS one, some BBB penetration can be useful for distribution.
9. **Caco-2:** Ligand A (-5.045) is better than Ligand B (-4.584), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-2.29) is better than Ligand B (-3.738). Solubility is important for bioavailability.
11. **hERG:** Both ligands have very low hERG risk (A: 0.08, B: 0.242), which is excellent.
12. **Cl_mic:** Ligand B (8.374) has a lower microsomal clearance than Ligand A (15.406), indicating better metabolic stability.
13. **t1/2:** Ligand B (15.011) has a longer in vitro half-life than Ligand A (-29.74), which is highly desirable.
14. **Pgp:** Ligand A (0.014) has lower P-gp efflux than Ligand B (0.109), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand B (-6.6) has a slightly better binding affinity than Ligand A (-5.8). This difference of 0.8 kcal/mol is significant and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand B is the better candidate. While Ligand A has slightly better Caco-2 permeability and Pgp efflux, Ligand B excels in several key areas crucial for GPCR drug development: lower TPSA, better BBB penetration, significantly improved metabolic stability (lower Cl_mic and longer t1/2), and a stronger binding affinity. The slightly higher logP of Ligand B is manageable, and its QED score is also higher. The differences in solubility and Caco-2 are less critical given the other advantages.
Output:
0
2025-04-18 00:01:34,242 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (341.426 Da) is within the ideal range, while Ligand B (362.499 Da) is slightly higher but still acceptable.
2. **TPSA:** Ligand A (29.54) is excellent, well below the 140 threshold and favorable for absorption. Ligand B (64.16) is higher, but still reasonable.
3. **logP:** Ligand A (4.151) is at the upper end of the optimal range, potentially raising solubility concerns. Ligand B (2.769) is ideal.
4. **HBD:** Both ligands have 0 HBD, which is good.
5. **HBA:** Ligand A (2) is good, while Ligand B (6) is higher, but still within the acceptable range.
6. **QED:** Ligand A (0.757) is excellent, indicating high drug-likeness. Ligand B (0.48) is lower, suggesting a less optimal overall profile.
7. **DILI:** Both ligands have acceptable DILI risk (Ligand A: 31.873, Ligand B: 38.348).
8. **BBB:** Ligand A (91.392) has excellent BBB penetration, while Ligand B (69.213) is lower. Since ADRB2 is a GPCR, BBB penetration is a consideration, though not paramount for cardiovascular targets.
9. **Caco-2:** Ligand A (-4.332) and Ligand B (-5.267) both have negative Caco-2 values which is unusual and suggests poor permeability.
10. **Solubility:** Ligand A (-4.394) and Ligand B (-2.381) both have negative solubility values which is unusual and suggests poor solubility.
11. **hERG:** Ligand A (0.809) and Ligand B (0.486) both have low hERG inhibition liability, which is good.
12. **Cl_mic:** Ligand A (58.703) has lower microsomal clearance, indicating better metabolic stability than Ligand B (82.687).
13. **t1/2:** Ligand A (13.619) and Ligand B (16.335) have similar in vitro half-lives.
14. **Pgp:** Ligand A (0.302) has lower P-gp efflux, which is favorable for bioavailability. Ligand B (0.261) is also low.
15. **Affinity:** Ligand A (-7.3 kcal/mol) has a significantly stronger binding affinity than Ligand B (-5.4 kcal/mol). This is a substantial advantage.
**Overall Assessment:**
Ligand A has a superior binding affinity, better metabolic stability, lower P-gp efflux, and excellent BBB penetration. While its logP is slightly higher, the significant advantage in binding affinity outweighs this concern. The negative Caco-2 and solubility values are concerning for both, but the higher affinity of Ligand A makes it more likely to be optimized to overcome these issues. Ligand B has better logP, but falls short in affinity and metabolic stability.
**Output:**
1
2025-04-18 00:01:34,242 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [369.408, 38.33, 4.122, 1, 3, 0.861, 57.348, 86.817, -4.804, -4.564, 0.76, 74.067, 19.278, 0.664, -7.6]
**Ligand B:** [348.531, 58.2, 3.962, 2, 2, 0.464, 27.181, 55.099, -4.748, -4.454, 0.46, 64.305, 26.216, 0.206, -6.2]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (348.531) is slightly lower, which could be beneficial for permeability.
2. **TPSA:** Ligand A (38.33) is better than Ligand B (58.2), falling well below the 140 threshold and closer to the 90 for CNS targets, even though this is a cardiovascular target.
3. **logP:** Both are good (around 4), but slightly high. Ligand B (3.962) is marginally better.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower is better for permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (2). Lower is better for permeability.
6. **QED:** Ligand A (0.861) is significantly better than Ligand B (0.464), indicating a more drug-like profile.
7. **DILI:** Ligand B (27.181) has a much lower DILI risk than Ligand A (57.348). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (86.817) has a much higher BBB penetration score than Ligand B (55.099). While not a CNS target, some degree of BBB penetration can sometimes indicate better overall distribution.
9. **Caco-2:** Both are negative, which is not ideal. However, the values are very close (-4.804 vs -4.748) so this isn't a major differentiator.
10. **Solubility:** Both are negative, indicating poor solubility. Again, values are similar (-4.564 vs -4.454).
11. **hERG:** Ligand A (0.76) is better than Ligand B (0.46), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand B (64.305) has a lower microsomal clearance than Ligand A (74.067), suggesting better metabolic stability.
13. **t1/2:** Ligand B (26.216) has a longer in vitro half-life than Ligand A (19.278), which is desirable.
14. **Pgp:** Ligand A (0.664) has lower P-gp efflux than Ligand B (0.206), which is preferable.
15. **Affinity:** Ligand A (-7.6 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.2 kcal/mol). This is a substantial advantage.
**GPCR-Specific Priorities:** For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A excels in affinity and Pgp, and has a better TPSA. Ligand B has better DILI and metabolic stability.
**Overall Assessment:**
The significantly stronger binding affinity of Ligand A (-7.6 vs -6.2) is a major factor. A 1.4 kcal/mol difference is substantial and can often outweigh minor ADME drawbacks. While Ligand B has better DILI and metabolic stability, the strong affinity of Ligand A makes it the more promising candidate, especially considering the other parameters are reasonably balanced. The slightly higher TPSA of Ligand A is also a positive.
Output:
1
2025-04-18 00:01:34,242 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (345.447 Da) is better, falling comfortably within the 200-500 Da range. Ligand B (399.292 Da) is still acceptable but approaching the upper limit.
2. **TPSA:** Ligand B (61.88) is significantly better than Ligand A (110). Lower TPSA generally improves permeability, crucial for GPCRs.
3. **logP:** Ligand A (1.533) is optimal. Ligand B (4.207) is higher, potentially leading to solubility issues and off-target interactions, although still within a reasonable range.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (1), but both are acceptable.
5. **HBA:** Ligand A (5) is higher than Ligand B (3), but both are acceptable.
6. **QED:** Both ligands have good QED scores (A: 0.588, B: 0.676), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (46.258) has a significantly lower DILI risk than Ligand B (64.172). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (76.347) has better BBB penetration than Ligand B (65.723), which is important for GPCR targets, though not strictly essential for ADRB2.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Both have negative solubility values, which is also unusual.
11. **hERG:** Ligand A (0.325) has a much lower hERG inhibition liability than Ligand B (0.845), a critical factor for cardiovascular targets.
12. **Cl_mic:** Ligand A (34.85) has a lower microsomal clearance than Ligand B (66.826), indicating better metabolic stability.
13. **t1/2:** Ligand B (72.503) has a significantly longer in vitro half-life than Ligand A (-27.489). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.041) has lower P-gp efflux liability than Ligand B (0.436), which is favorable for bioavailability.
15. **Affinity:** Ligand B (-7.8 kcal/mol) has a stronger binding affinity than Ligand A (-7.2 kcal/mol). This is a 0.6 kcal/mol difference, which is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand B has a superior binding affinity and a longer half-life, which are significant advantages. However, Ligand A demonstrates a much better safety profile with lower DILI and hERG risk, and better BBB penetration. The lower TPSA of Ligand B is also a plus. Considering the cardiovascular target (ADRB2), minimizing hERG risk is paramount. While the affinity difference is notable, the safety advantages of Ligand A, combined with acceptable affinity, make it the more promising candidate.
Output:
1
2025-04-18 00:01:34,242 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (354.372) is slightly lower, which is generally favorable for permeability, but both are acceptable.
2. **TPSA:** Ligand A (38.5) is significantly better than Ligand B (83.04). For a GPCR, lower TPSA is generally preferred for better blood-brain barrier penetration and oral absorption. Ligand B is quite high and could pose absorption challenges.
3. **logP:** Both ligands have good logP values (A: 4.513, B: 3.037) within the optimal range of 1-3. Ligand A is slightly higher, which *could* indicate potential off-target effects, but isn't a major concern at this level.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer hydrogen bond donors generally improve membrane permeability.
5. **HBA:** Ligand A (4) is better than Ligand B (6). Similar to HBD, lower HBA is generally preferred.
6. **QED:** Both ligands have similar QED values (A: 0.81, B: 0.795), indicating good drug-likeness.
7. **DILI:** Ligand A (46.258) has a lower DILI risk than Ligand B (77.782), which is a significant advantage. Lower DILI is always preferred.
8. **BBB:** Ligand A (85.731) has a better BBB penetration percentile than Ligand B (75.107). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be useful, and lower TPSA helps with this.
9. **Caco-2:** Ligand A (-4.47) is better than Ligand B (-5.208). Higher Caco-2 permeability is desired.
10. **Solubility:** Ligand A (-4.721) is better than Ligand B (-4.14). Better solubility is generally preferred.
11. **hERG:** Ligand A (0.875) has a lower hERG risk than Ligand B (0.345), which is a major advantage. Avoiding hERG inhibition is crucial for cardiovascular drugs.
12. **Cl_mic:** Ligand B (39.535) has a lower microsomal clearance than Ligand A (46.006), indicating better metabolic stability. This is a positive for Ligand B.
13. **t1/2:** Ligand B (31.052) has a longer in vitro half-life than Ligand A (-33.607). This is a significant advantage for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.37) has lower P-gp efflux liability than Ligand B (0.153). Lower P-gp efflux is desirable for better bioavailability.
15. **Binding Affinity:** Ligand A (-7.2) has a significantly better binding affinity than Ligand B (-5). This is a substantial advantage, and a difference of >1.5 kcal/mol can often outweigh other ADME concerns.
**Overall Assessment:**
Ligand A is clearly superior. While Ligand B has better metabolic stability (Cl_mic and t1/2), the advantages of Ligand A in TPSA, DILI, hERG, solubility, Caco-2 permeability, Pgp efflux, and *especially* binding affinity are overwhelming. The lower TPSA and better ADME properties of Ligand A make it a more promising starting point for optimization, despite the slightly higher logP. The significantly stronger binding affinity (-7.2 vs -5 kcal/mol) is the deciding factor.
Output:
1
2025-04-18 00:01:34,243 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (339.374) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (72.7) is better than Ligand B (43.18). Both are below 140, but Ligand B is significantly lower, potentially improving oral absorption.
3. **logP:** Both ligands have acceptable logP values (Ligand A: 2.184, Ligand B: 3.936). Ligand B is closer to the upper limit, which could raise concerns about solubility and off-target effects, but is still within the optimal range.
4. **HBD:** Ligand A (1) is preferable to Ligand B (0). Having at least one HBD can improve solubility.
5. **HBA:** Ligand A (5) is preferable to Ligand B (6). Both are within the acceptable limit of 10.
6. **QED:** Ligand A (0.773) is better than Ligand B (0.634), indicating a more drug-like profile.
7. **DILI:** Ligand B (30.826) is significantly better than Ligand A (63.397), indicating a much lower risk of drug-induced liver injury. This is a crucial advantage.
8. **BBB:** Both ligands have good BBB penetration (Ligand A: 71.268, Ligand B: 79.992). Ligand B is slightly better, which is beneficial for a GPCR target.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-5.009) is slightly better (less negative) than Ligand B (-4.687).
10. **Solubility:** Ligand A (-2.81) is better than Ligand B (-4.035).
11. **hERG:** Ligand A (0.16) is significantly better than Ligand B (0.859), indicating a lower risk of cardiotoxicity. This is a critical advantage.
12. **Cl_mic:** Ligand B (63.18) is better than Ligand A (36.586), suggesting greater metabolic stability.
13. **t1/2:** Ligand A (-23.276) is better than Ligand B (19.479).
14. **Pgp:** Ligand A (0.21) is better than Ligand B (0.281), indicating lower P-gp efflux.
15. **Binding Affinity:** Ligand B (-6.6) is slightly better than Ligand A (-6.4), but the difference is small.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, Pgp, TPSA, and affinity. Ligand B has a slightly higher logP and better BBB penetration, but Ligand A has a significantly better TPSA. The affinity difference is minimal.
**Overall Assessment:**
While Ligand B has advantages in DILI risk, metabolic stability, and BBB penetration, Ligand A demonstrates superior solubility, hERG safety, and QED. The hERG risk for Ligand B is concerning. The DILI risk for Ligand A is higher, but the hERG risk is a more immediate safety concern. Given the balance of properties, the slightly better affinity of Ligand B is not enough to overcome the hERG liability.
Output:
1
2025-04-18 00:01:34,243 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.381 and 346.471 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (63.25) is better than Ligand B (67.43). Both are below the 140 threshold for oral absorption, but closer to the ideal for GPCRs.
3. **logP:** Ligand A (4.092) is slightly higher than Ligand B (2.725). While Ligand A is at the upper end of the optimal range, it's still acceptable. Ligand B is well within the optimal range.
4. **HBD:** Both ligands have 2 HBD, which is within the acceptable limit of <=5.
5. **HBA:** Both ligands have 3 HBA, which is within the acceptable limit of <=10.
6. **QED:** Ligand A (0.74) has a significantly better QED score than Ligand B (0.277), indicating a more drug-like profile.
7. **DILI:** Ligand B (26.173) has a much lower DILI risk than Ligand A (63.746). This is a major advantage for Ligand B.
8. **BBB:** Ligand A (82.513) has a better BBB penetration percentile than Ligand B (57.929). While ADRB2 isn't exclusively a CNS target, some CNS exposure might be acceptable or even desirable for certain cardiovascular indications, making this a slight advantage for A.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.689) is slightly better than Ligand B (-4.91).
10. **Solubility:** Ligand A (-4.998) has slightly better solubility than Ligand B (-3.888).
11. **hERG:** Ligand A (0.804) has a slightly better hERG profile than Ligand B (0.288), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand B (10.527) has significantly lower microsomal clearance than Ligand A (85.834), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-2.24) has a better in vitro half-life than Ligand A (-24.41).
14. **Pgp:** Ligand A (0.271) has a lower Pgp efflux liability than Ligand B (0.162), which is favorable.
15. **Binding Affinity:** Ligand B (-7.1 kcal/mol) has a significantly stronger binding affinity than Ligand A (-15.8 kcal/mol). This is a substantial advantage, potentially outweighing some ADME drawbacks.
**Overall Assessment:**
Ligand B is the stronger candidate. The significantly higher binding affinity (-7.1 vs -15.8 kcal/mol) is a critical advantage for a GPCR target. The much lower DILI risk (26.173 vs 63.746) and improved metabolic stability (lower Cl_mic and better t1/2) are also very important. While Ligand A has a better QED and BBB penetration, the superior potency and safety profile of Ligand B are more compelling for initial drug development. The Caco-2 values are concerning for both, but can be addressed during optimization.
Output:
0
2025-04-18 00:01:34,243 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.383 and 352.479 Da) are within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand B (68.62) is significantly better than Ligand A (104.73). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands (1.194 and 1.503) are within the optimal 1-3 range. Ligand B is slightly more lipophilic, which could be beneficial for membrane permeability.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (1), but both are acceptable (<=5).
5. **HBA:** Ligand B (6) is slightly higher than Ligand A (5), but both are acceptable (<=10).
6. **QED:** Both ligands (0.671 and 0.647) are above the 0.5 threshold, indicating good drug-likeness. No significant difference.
7. **DILI:** Ligand B (8.957) has a *much* lower DILI risk than Ligand A (54.556). This is a major advantage for Ligand B.
8. **BBB:** Ligand B (82.513) has better BBB penetration than Ligand A (68.592). While not critical for a cardiovascular target, it's a slight positive.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.948 and -4.633), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand B (-0.915) is slightly better than Ligand A (-2.961), indicating better aqueous solubility.
11. **hERG:** Both ligands have low hERG inhibition risk (0.281 and 0.421). No significant difference.
12. **Cl_mic:** Ligand A (35.717) has lower microsomal clearance, suggesting better metabolic stability than Ligand B (46.934). This is a positive for Ligand A.
13. **t1/2:** Ligand B (34.037) has a significantly longer *in vitro* half-life than Ligand A (-6.364). This is a substantial advantage for Ligand B.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.199 and 0.012). No significant difference.
15. **Binding Affinity:** Ligand B (-7.1) has a slightly better binding affinity than Ligand A (-5.9). This difference of 1.2 kcal/mol is significant and can outweigh some ADME drawbacks.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in TPSA, has comparable logP, similar Pgp, and significantly better affinity. The lower DILI risk and longer half-life are also major benefits. While Ligand A has better metabolic stability, the other advantages of Ligand B are more compelling.
**Conclusion:**
Ligand B is the superior candidate due to its significantly lower DILI risk, better binding affinity, longer half-life, and improved TPSA and solubility. The slightly lower metabolic stability is a manageable concern compared to the advantages offered by Ligand B.
Output:
0
2025-04-18 00:01:34,243 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (365.817 and 354.407 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (82.71) is significantly better than Ligand B (120). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (1.454) is within the optimal range (1-3). Ligand B (-1.578) is below 1, which could hinder membrane permeability. This is a significant negative for Ligand B.
4. **HBD:** Ligand A (1) is preferable to Ligand B (4). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is preferable to Ligand B (6) for similar permeability reasons.
6. **QED:** Ligand A (0.785) has a much better QED score than Ligand B (0.391), indicating a more drug-like profile.
7. **DILI:** Ligand B (36.254) has a much lower DILI risk than Ligand A (74.292). This is a strong positive for Ligand B.
8. **BBB:** Ligand A (64.754) has a higher BBB penetration score than Ligand B (21.753), but this is less critical for a cardiovascular target.
9. **Caco-2:** Ligand A (-4.759) and Ligand B (-5.354) are both very poor. This is a concern for both, but the scale is not clear, so it is hard to assess.
10. **Solubility:** Ligand A (-2.357) is slightly better than Ligand B (-0.588).
11. **hERG:** Both ligands have very low hERG inhibition risk (0.138 and 0.044). No significant difference.
12. **Cl_mic:** Ligand B (-6.846) has a negative clearance, which is unusual and potentially indicates very high metabolic stability. Ligand A (67.891) is moderate. This is a strong positive for Ligand B.
13. **t1/2:** Ligand B (-23.125) has a negative half-life, which is also unusual and potentially indicates very high in vitro stability. Ligand A (-6.935) is moderate. This is a strong positive for Ligand B.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.098 and 0.003). No significant difference.
15. **Binding Affinity:** Ligand A (-6.5 kcal/mol) is slightly weaker than Ligand B (-5.9 kcal/mol). While a 1.5 kcal/mol difference is usually significant, the other ADME properties of Ligand A are more favorable.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand A has a much better logP and TPSA. The affinity difference is relatively small.
**Overall Assessment:**
While Ligand B has excellent metabolic stability (Cl_mic, t1/2) and a lower DILI risk, its poor logP and higher TPSA are significant drawbacks. Ligand A has a more balanced profile with better physicochemical properties, despite the slightly weaker binding affinity. The better QED score also favors Ligand A.
Output:
1
2025-04-18 00:01:34,243 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
Let's analyze each ligand against the provided guidelines, keeping in mind ADRB2 is a GPCR and thus we prioritize logP, Pgp, TPSA, and affinity.
* **Molecular Weight:** Both ligands (341.455 and 366.893 Da) fall comfortably within the 200-500 Da range.
* **TPSA:** Ligand A (64.41) is better than Ligand B (67.23), both are below the 140 threshold for oral absorption.
* **logP:** Both ligands have good logP values (2.773 and 2.246), falling within the optimal 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability.
* **H-Bond Donors/Acceptors:** Ligand A (0 HBD, 3 HBA) is slightly better than Ligand B (1 HBD, 4 HBA). Lower counts are generally preferred.
* **QED:** Both ligands have good QED scores (0.746 and 0.804), indicating good drug-like properties.
* **DILI:** Both ligands have low DILI risk (36.293 and 34.277), below the 40 threshold.
* **BBB:** Ligand A (80.962) has a significantly better BBB penetration percentile than Ligand B (67.817). While ADRB2 isn't exclusively a CNS target, some cardiovascular effects are mediated by central pathways, and better BBB penetration could be advantageous.
* **Caco-2 Permeability:** Ligand A (-4.655) is better than Ligand B (-5.107), indicating better intestinal absorption.
* **Aqueous Solubility:** Ligand A (-3.649) is better than Ligand B (-3.125), indicating better solubility.
* **hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.532 and 0.224).
* **Microsomal Clearance:** Ligand A (46.169) has a higher microsomal clearance than Ligand B (36.861), suggesting lower metabolic stability. This is a drawback for Ligand A.
* **In vitro Half-Life:** Ligand B (-7.15) has a much longer in vitro half-life than Ligand A (0.237). This is a significant advantage for Ligand B.
* **P-gp Efflux:** Ligand A (0.305) has better P-gp efflux liability than Ligand B (0.141), meaning less efflux and potentially better bioavailability.
* **Binding Affinity:** Ligand B (-7.7) has a slightly better binding affinity than Ligand A (-7.6). While the difference is small, it's still a factor.
**Overall Assessment:**
Ligand B demonstrates a more favorable balance of properties. While Ligand A has advantages in BBB penetration, Caco-2 permeability, solubility, and P-gp efflux, Ligand B's significantly better in vitro half-life and slightly better binding affinity are more critical for a viable drug candidate. The higher metabolic stability (lower Cl_mic, longer t1/2) is particularly important for a GPCR target, where sustained signaling is often desired. The small difference in binding affinity is less important than the ADME advantages of Ligand B.
**Output:**
0
2025-04-18 00:01:34,243 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (399.252 and 418.238 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (87.11) is higher than Ligand B (67.45). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is generally preferred for absorption. Ligand B has an advantage.
3. **logP:** Both ligands (3.049 and 3.639) are within the optimal 1-3 range. Ligand B is slightly higher, which *could* be a minor drawback if it impacts solubility, but is still acceptable.
4. **HBD:** Ligand A (3) is higher than Ligand B (1). Lower HBD is generally preferred for permeability. Ligand B has an advantage.
5. **HBA:** Ligand A (5) is higher than Ligand B (4). Similar to HBD, lower HBA is preferred. Ligand B has an advantage.
6. **QED:** Ligand B (0.632) is slightly better than Ligand A (0.451), indicating a more drug-like profile. Ligand B has an advantage.
7. **DILI:** Ligand A (89.957) has a higher DILI risk than Ligand B (65.723). This is a significant concern. Ligand B has a substantial advantage.
8. **BBB:** Both are relatively low, as expected for a cardiovascular target. Ligand B (75.107) is better than Ligand A (66.615), but this isn't a major factor.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-5.681) is slightly worse than Ligand B (-4.96). Ligand B has a slight advantage.
10. **Solubility:** Both are negative, indicating poor solubility. Ligand A (-3.439) is slightly worse than Ligand B (-4.282). Ligand B has a slight advantage.
11. **hERG:** Both are low (0.787 and 0.514), indicating low risk of hERG inhibition. No clear advantage.
12. **Cl_mic:** Ligand A (36.283) has a lower microsomal clearance than Ligand B (72.057), suggesting better metabolic stability. Ligand A has an advantage.
13. **t1/2:** Ligand A (59.379) has a longer in vitro half-life than Ligand B (-10.524). This is a significant advantage. Ligand A has a substantial advantage.
14. **Pgp:** Ligand A (0.623) has lower P-gp efflux than Ligand B (0.437), suggesting better bioavailability. Ligand A has an advantage.
15. **Binding Affinity:** Ligand A (-6.4) has a slightly better binding affinity than Ligand B (-4.2). This is a significant advantage, and can often outweigh minor ADME drawbacks. Ligand A has a substantial advantage.
**Overall Assessment:**
Ligand A has a better binding affinity, longer half-life, lower P-gp efflux, and lower microsomal clearance. However, Ligand B has a significantly lower DILI risk, better TPSA, HBD, HBA, QED, Caco-2 permeability, and solubility.
Given the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), and the fact that this is a cardiovascular target (so BBB is less critical), the strong binding affinity and metabolic stability of Ligand A are very attractive. The DILI risk of Ligand A is concerning, but the superior binding affinity and half-life could potentially allow for a lower dose, mitigating some of that risk. The slight improvements in permeability and solubility of Ligand B are not enough to overcome the significant difference in binding affinity.
Output:
1
2025-04-18 00:01:34,243 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (364.72 Da) is within the ideal range (200-500 Da). Ligand B (384.904 Da) is also acceptable. No clear advantage here.
2. **TPSA:** Ligand A (114.25) is borderline for good oral absorption (<=140), but acceptable. Ligand B (34.59) is excellent, well below the threshold. This favors Ligand B.
3. **logP:** Ligand A (3.96) is within the optimal range (1-3). Ligand B (4.516) is slightly higher, potentially increasing off-target effects and decreasing solubility, but still not dramatically concerning.
4. **HBD:** Both ligands have 0 HBD, which is good.
5. **HBA:** Ligand A has 6 HBA, acceptable. Ligand B has 5 HBA, also acceptable.
6. **QED:** Ligand B (0.636) has a better QED score than Ligand A (0.344), indicating a more drug-like profile. This favors Ligand B.
7. **DILI:** Ligand A (87.98) has a higher DILI risk than Ligand B (30.438). This is a significant advantage for Ligand B.
8. **BBB:** Both ligands have good BBB penetration (Ligand A: 76.696, Ligand B: 88.872). Ligand B is slightly better. Considering ADRB2 is a GPCR, BBB penetration isn't a primary concern unless targeting CNS effects, but higher is generally preferable.
9. **Caco-2:** Both have negative Caco-2 values which is unusual. We can assume these are percentile values, and therefore both have poor Caco-2 permeability.
10. **Solubility:** Both have negative solubility values, which is unusual. We can assume these are percentile values, and therefore both have poor solubility.
11. **hERG:** Ligand A (0.253) has a lower hERG risk than Ligand B (0.807). This favors Ligand A.
12. **Cl_mic:** Ligand A (97.795) has a lower microsomal clearance than Ligand B (104.659), indicating better metabolic stability. This favors Ligand A.
13. **t1/2:** Ligand A (55.595) has a significantly longer in vitro half-life than Ligand B (13.806). This is a major advantage for Ligand A.
14. **Pgp:** Ligand A (0.416) has lower P-gp efflux than Ligand B (0.502). This is a slight advantage for Ligand A.
15. **Binding Affinity:** Ligand B (-6.8 kcal/mol) has a slightly better binding affinity than Ligand A (-6.0 kcal/mol). This is a 0.8 kcal/mol difference, which is significant, but needs to be weighed against other factors.
**Overall Assessment:**
Ligand B excels in TPSA, QED, and DILI risk. Ligand A shines in metabolic stability (Cl_mic, t1/2), hERG risk, and Pgp efflux. The binding affinity difference is notable, but not overwhelming. Considering the GPCR nature of ADRB2, a balance of properties is crucial. The lower DILI risk and better QED of Ligand B are very attractive. The longer half-life of Ligand A is also a strong point, but the higher DILI risk is concerning.
Given the balance of properties, and prioritizing a lower risk profile (DILI) alongside good predicted permeability (TPSA), I favor Ligand B.
Output:
0
2025-04-18 00:01:34,243 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (367.249 and 353.507 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (68.02) is better than Ligand B (70.67). Both are below 140, but lower is preferred for absorption.
3. **logP:** Both ligands have good logP values (3.528 and 3.795), falling within the 1-3 range. Ligand B is slightly higher, which *could* be a minor concern for solubility, but not a dealbreaker.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (4) is preferable to Ligand B (3). Lower HBA generally improves permeability.
6. **QED:** Ligand B (0.808) has a significantly better QED score than Ligand A (0.627), indicating a more drug-like profile overall. This is a notable advantage for Ligand B.
7. **DILI:** Ligand B (28.616) has a much lower DILI risk than Ligand A (70.88). This is a major advantage for Ligand B, as minimizing liver toxicity is crucial.
8. **BBB:** Ligand A (90.074) has a slightly better BBB penetration than Ligand B (80.419). While ADRB2 isn't strictly a CNS target, some CNS exposure could be relevant depending on the specific therapeutic application.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.836 and -4.341), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand A (-3.74) is slightly better than Ligand B (-3.466), but both are very poor. This is a major drawback for both.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.565 and 0.306). This is excellent.
12. **Cl_mic:** Ligand A (35.71) has a lower microsomal clearance than Ligand B (50.854), indicating better metabolic stability. This is a positive for Ligand A.
13. **t1/2:** Ligand A (23.6) has a significantly longer in vitro half-life than Ligand B (3.463). This is a substantial advantage for Ligand A, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.387) has a lower P-gp efflux liability than Ligand B (0.062). Lower P-gp efflux is generally preferred for better bioavailability.
15. **Binding Affinity:** Both ligands have very similar and excellent binding affinities (-6.1 and -6.2 kcal/mol). The difference is negligible.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B has a slightly higher logP, but the significant advantages in DILI risk and QED outweigh this. The Caco-2 and solubility issues are concerning for both, but the longer half-life and lower P-gp efflux of Ligand A are beneficial.
**Overall Assessment:**
Ligand B is the better candidate due to its significantly lower DILI risk and higher QED score. While Ligand A has advantages in metabolic stability and half-life, the safety profile of Ligand B is more compelling. The poor Caco-2 and solubility are shared concerns that would need to be addressed through formulation strategies.
Output:
0
2025-04-18 00:01:34,243 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [350.459, 103.86 , 1.358, 3. , 4. , 0.713, 19.542, 67.119, -5.378, -2.027, 0.076, -16.524, -12.991, 0.004, -7. ]
**Ligand B:** [347.459, 75.44 , 2.459, 1. , 4. , 0.822, 19.891, 78.558, -4.518, -2.37 , 0.116, 49.955, 15.896, 0.048, -5.9 ]
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). A is 350.459, B is 347.459. Very similar.
2. **TPSA:** Ligand A (103.86) is slightly higher than Ligand B (75.44). Both are acceptable for a non-CNS GPCR target like ADRB2, but B is better.
3. **logP:** Ligand A (1.358) is within the optimal range, while Ligand B (2.459) is closer to the upper end. Both are acceptable, but A is slightly preferred.
4. **HBD:** Ligand A (3) is higher than Ligand B (1). Lower is generally better for permeability, so B is preferred.
5. **HBA:** Both ligands have 4 HBA, which is acceptable.
6. **QED:** Both ligands have good QED scores (A: 0.713, B: 0.822). B is slightly better.
7. **DILI:** Both ligands have similar, low DILI risk (A: 19.542, B: 19.891).
8. **BBB:** Ligand B (78.558) has a significantly higher BBB penetration score than Ligand A (67.119). While ADRB2 isn't a primary CNS target, some peripheral exposure can be beneficial, and higher BBB is rarely detrimental.
9. **Caco-2:** Ligand A (-5.378) has a worse Caco-2 permeability than Ligand B (-4.518). B is preferred.
10. **Solubility:** Both have very poor solubility scores (A: -2.027, B: -2.37). This is a concern for both, but not a deciding factor.
11. **hERG:** Both ligands have very low hERG inhibition risk (A: 0.076, B: 0.116).
12. **Cl_mic:** Ligand A (-16.524) has a much lower (better) microsomal clearance than Ligand B (49.955). This suggests better metabolic stability for A.
13. **t1/2:** Ligand B (15.896) has a longer in vitro half-life than Ligand A (-12.991). This is a significant advantage for B.
14. **Pgp:** Both ligands have very low P-gp efflux liability (A: 0.004, B: 0.048).
15. **Affinity:** Ligand A (-7.0) has a slightly better binding affinity than Ligand B (-5.9). This is a 1.1 kcal/mol difference, which is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand A has a better binding affinity and metabolic stability (lower Cl_mic). Ligand B has better TPSA, BBB, Caco-2 permeability, and in vitro half-life. Solubility is poor for both. Given the GPCR-specific priorities, the slightly better affinity of Ligand A, combined with its improved metabolic stability, is more important than the slightly better permeability properties of Ligand B. The affinity difference is significant enough to overcome the slightly higher TPSA and lower BBB.
Output:
1
2025-04-18 00:01:34,243 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.482 and 357.296 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (38.82) is significantly better than Ligand B (97.54). ADRB2 is a cardiovascular target, not CNS, but lower TPSA generally improves permeability. Ligand B's TPSA is quite high, potentially hindering absorption.
3. **logP:** Ligand A (2.446) is optimal. Ligand B (0.277) is low, which could lead to poor membrane permeability and bioavailability.
4. **HBD:** Both ligands have 1 HBD, which is within the acceptable limit.
5. **HBA:** Ligand A has 3 HBA, while Ligand B has 8. Ligand B is pushing the upper limit for HBA, potentially impacting permeability.
6. **QED:** Both ligands have good QED scores (0.704 and 0.785), indicating generally drug-like properties.
7. **DILI:** Ligand A (13.106) has a much lower DILI risk than Ligand B (71.694). This is a significant advantage for Ligand A.
8. **BBB:** Both have high BBB penetration, but this is less critical for a cardiovascular target like ADRB2.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability.
10. **Solubility:** Both have negative solubility values, indicating poor solubility.
11. **hERG:** Ligand A (0.957) has a slightly higher hERG risk than Ligand B (0.135), but both are relatively low.
12. **Cl_mic:** Ligand A (23.967) has a significantly lower microsomal clearance than Ligand B (41.72), suggesting better metabolic stability.
13. **t1/2:** Ligand A (5.583) has a positive half-life, while Ligand B (-17.587) has a negative half-life.
14. **Pgp:** Ligand A (0.089) has a lower P-gp efflux liability than Ligand B (0.07), which is favorable.
15. **Affinity:** Ligand A (-7.5 kcal/mol) has a stronger binding affinity than Ligand B (-6.6 kcal/mol). This 1.9 kcal/mol difference is substantial and outweighs many of the other minor drawbacks.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand A excels in logP and affinity and has a much better TPSA. While both have poor Caco-2 and solubility, the superior affinity and metabolic stability of Ligand A, coupled with the lower DILI risk, make it the more promising candidate.
**Output:**
1
2025-04-18 00:01:34,244 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (377.271) is slightly higher than Ligand B (343.362), but both are acceptable.
2. **TPSA:** Ligand A (66.56) is significantly better than Ligand B (101.21). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (Ligand A: 3.109, Ligand B: 1.75), falling within the optimal 1-3 range. Ligand A is slightly higher, potentially leading to some off-target interactions, but not drastically.
4. **HBD:** Both have 2 HBD, which is within the acceptable limit of 5.
5. **HBA:** Ligand A has 3 HBA, while Ligand B has 5. Both are within the acceptable limit of 10, but Ligand A is preferable.
6. **QED:** Both ligands have similar and good QED values (Ligand A: 0.805, Ligand B: 0.827), indicating good drug-like properties.
7. **DILI:** Ligand B (85.964) has a significantly higher DILI risk than Ligand A (53.742). This is a major concern, as liver toxicity is a frequent cause of drug failure.
8. **BBB:** BBB is less critical for a cardiovascular target. Ligand A (37.456) and Ligand B (62.233) are both relatively low, which is fine in this context.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. Ligand A (-4.595) is slightly better than Ligand B (-5.106), but both are problematic.
10. **Solubility:** Both have negative solubility values, indicating poor solubility. Ligand A (-3.636) is slightly better than Ligand B (-3.159).
11. **hERG:** Ligand A (0.732) has a slightly higher hERG risk than Ligand B (0.399), but both are relatively low.
12. **Cl_mic:** Ligand B (2.076) has significantly lower microsomal clearance than Ligand A (9.478), suggesting better metabolic stability.
13. **t1/2:** Ligand A (26.551) has a much longer in vitro half-life than Ligand B (-17.79). This is a significant advantage.
14. **Pgp:** Ligand A (0.503) has lower P-gp efflux than Ligand B (0.013), suggesting better bioavailability.
15. **Affinity:** Ligand B (-7.7 kcal/mol) has a slightly better binding affinity than Ligand A (-6.9 kcal/mol). This is a 1.8 kcal/mol advantage, which is substantial.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), affinity, logP, TPSA, and Pgp are important. Ligand B has a better affinity and Pgp, while Ligand A has better logP and TPSA. However, the *major* deciding factor is the significantly higher DILI risk associated with Ligand B. The improved metabolic stability of Ligand B is a plus, but the liver toxicity risk is too high. The longer half-life of Ligand A is also beneficial.
**Conclusion:**
Despite the slightly better affinity of Ligand B, the significantly higher DILI risk makes it a less desirable candidate. Ligand A, with its better safety profile (lower DILI), reasonable ADME properties, and acceptable affinity, is the more promising drug candidate.
Output:
1
2025-04-18 00:01:34,244 - INFO - Batch 447 complete. Total preferences: 7152
2025-04-18 00:01:34,244 - INFO - Processing batch 448/512...
2025-04-18 00:02:23,793 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
The ADRB2 receptor is a GPCR, so the priorities are logP, TPSA, Pgp, BBB, and affinity. Let's break down each ligand against these and other important parameters:
* **Molecular Weight:** Both ligands are within the acceptable range (200-500 Da).
* **TPSA:** Ligand A (53.76) is significantly better than Ligand B (113.01). A TPSA under 140 is good for oral absorption, but lower is generally preferred for GPCRs, and A is much closer to the ideal range.
* **logP:** Ligand A (2.268) is optimal (1-3). Ligand B (-0.767) is too low, potentially hindering membrane permeability.
* **H-Bond Donors/Acceptors:** Ligand A (0 HBD, 3 HBA) is better than Ligand B (2 HBD, 6 HBA). Fewer H-bonds generally improve permeability.
* **QED:** Ligand A (0.789) is better than Ligand B (0.468), indicating a more drug-like profile.
* **DILI:** Both have acceptable DILI risk (A: 31.989, B: 27.608).
* **BBB:** Ligand A (78.286) is much better than Ligand B (42.924). While ADRB2 isn't exclusively a CNS target, some CNS penetration can be beneficial, and a higher BBB percentile is generally desirable.
* **Caco-2:** Ligand A (-4.313) is better than Ligand B (-5.118), indicating better intestinal absorption.
* **Solubility:** Ligand A (-3.359) is better than Ligand B (-1.579).
* **hERG:** Both are low risk (A: 0.509, B: 0.076).
* **Cl_mic:** Ligand A (19.858) is better than Ligand B (3.946), suggesting better metabolic stability.
* **t1/2:** Ligand A (-5.216) is better than Ligand B (-55.97), indicating a much longer half-life.
* **Pgp:** Ligand A (0.308) is better than Ligand B (0.017), suggesting less P-gp efflux.
* **Binding Affinity:** Ligand A (-7.4 kcal/mol) is slightly better than Ligand B (-4.9 kcal/mol). The 2.5 kcal/mol difference in binding is substantial and can outweigh some ADME concerns.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical ADME properties (TPSA, logP, BBB, solubility, metabolic stability, Pgp efflux) *and* has a superior binding affinity. Ligand B's primary weakness is its poor logP and TPSA, which will likely translate to poor permeability and bioavailability. While both have acceptable safety profiles, Ligand A's overall balance of properties makes it a much more promising drug candidate for the ADRB2 receptor.
**Output:**
1
2025-04-18 00:02:23,794 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (366.622 and 372.406 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (49.41) is significantly better than Ligand B (104.53). ADRB2 is a cardiovascular target, not a CNS target, but lower TPSA generally aids absorption. Ligand A is well below the 140 threshold. Ligand B is pushing it.
3. **logP:** Ligand A (3.894) is optimal, while Ligand B (1.353) is a bit low. For a GPCR, a logP in the 1-3 range is good, but Ligand A is closer to the upper end of that range, which can be advantageous for receptor binding.
4. **HBD:** Both ligands have acceptable HBD counts (1 and 2 respectively), well within the limit of 5.
5. **HBA:** Ligand A (2) is better than Ligand B (6). Lower HBA is generally preferred for permeability.
6. **QED:** Both ligands have similar QED scores (0.75 and 0.671), indicating good drug-likeness.
7. **DILI:** Both ligands have low DILI risk (26.755 and 29.003), which is excellent.
8. **BBB:** Ligand A (81.815) has a much higher BBB percentile than Ligand B (40.597). While not a CNS target, higher BBB can sometimes correlate with better overall distribution.
9. **Caco-2:** Ligand A (-4.783) is better than Ligand B (-5.1). Higher Caco-2 values indicate better intestinal absorption.
10. **Solubility:** Ligand A (-4.493) is better than Ligand B (-1.17). Better aqueous solubility is crucial for bioavailability.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.458 and 0.111), which is excellent.
12. **Cl_mic:** Ligand A (66.166) has a higher microsomal clearance than Ligand B (27.751), indicating potentially lower metabolic stability. This is a negative for Ligand A.
13. **t1/2:** Ligand A (-11.352) has a slightly worse in vitro half-life than Ligand B (-11.923).
14. **Pgp:** Ligand A (0.228) has a lower Pgp efflux liability than Ligand B (0.026), which is favorable.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.9 and -6.7 kcal/mol). The difference is negligible.
**Overall Assessment:**
Ligand A generally performs better across most ADME properties (TPSA, logP, HBA, BBB, Caco-2, Solubility, Pgp) despite a slightly higher Cl_mic. Ligand B has a better Cl_mic and t1/2, but its TPSA and logP are less ideal. Considering ADRB2 is a cardiovascular target, the better absorption and distribution properties of Ligand A (indicated by TPSA, logP, solubility, Caco-2, and Pgp) outweigh the slightly higher Cl_mic. The binding affinities are essentially the same.
**Output:**
1
2025-04-18 00:02:23,794 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (349.431) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (56.59) is significantly better than Ligand A (84.67). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally improves absorption.
3. **logP:** Both ligands have excellent logP values (A: 1.819, B: 1.874), falling within the optimal 1-3 range.
4. **HBD:** Ligand A has 1 HBD, while Ligand B has 0. Both are acceptable, but lower is often preferred.
5. **HBA:** Both ligands have 5 HBA, which is within the acceptable range of <=10.
6. **QED:** Both ligands have similar QED values (A: 0.759, B: 0.744), indicating good drug-likeness.
7. **DILI:** Ligand A (34.626) has a significantly lower DILI risk than Ligand B (50.64). This is a crucial advantage.
8. **BBB:** Ligand B (90.539) has better BBB penetration than Ligand A (75.378). However, as ADRB2 is a cardiovascular target, BBB penetration is not a high priority.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-5.037) is slightly better than Ligand B (-4.843), but both are concerning.
10. **Solubility:** Both ligands have negative solubility values, which is also unusual and suggests poor solubility. Ligand A (-1.616) is slightly better than Ligand B (-2.565).
11. **hERG:** Both ligands have low hERG inhibition risk (A: 0.134, B: 0.432), which is good.
12. **Cl_mic:** Ligand B (42.534) has a lower microsomal clearance than Ligand A (49.418), indicating better metabolic stability.
13. **t1/2:** Ligand B (13.88) has a longer in vitro half-life than Ligand A (-19.824). This is a significant advantage.
14. **Pgp:** Both ligands have low Pgp efflux liability (A: 0.093, B: 0.305), which is good.
15. **Affinity:** Ligand A (-7.2) has a slightly better binding affinity than Ligand B (-7.0). While the difference is small (0.2 kcal/mol), it's still a positive factor.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Both ligands perform well on logP and Pgp. Ligand B has a better TPSA, while Ligand A has a slightly better affinity. However, the most significant difference is the DILI risk.
**Overall Assessment:**
Ligand A has a substantially lower DILI risk, which is a critical factor in drug development. While Ligand B has advantages in metabolic stability (Cl_mic) and half-life, the lower DILI risk of Ligand A outweighs these benefits. The slight advantage in binding affinity for Ligand A further supports this decision. The poor Caco-2 and solubility for both ligands are concerning and would require further investigation, but the DILI risk is a more immediate concern.
Output:
1
2025-04-18 00:02:23,794 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (346.431 and 353.419 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (94.48) is better than Ligand B (99.18). Both are below 140, but closer to 90 is preferred for GPCRs, and A is closer.
3. **logP:** Ligand A (1.754) is optimal, while Ligand B (0.287) is a bit low. A logP between 1-3 is desired, and A is much closer to this range. Lower logP can hinder membrane permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (6) is preferable to Ligand B (5). Both are within the acceptable range, but lower is generally better.
6. **QED:** Ligand A (0.896) is significantly better than Ligand B (0.692), indicating a more drug-like profile.
7. **DILI:** Ligand B (33.307) is significantly better than Ligand A (52.036), indicating a lower risk of drug-induced liver injury. This is a crucial factor.
8. **BBB:** Both ligands have good BBB penetration (Ligand A: 75.262, Ligand B: 72.664). While both are acceptable, a higher value is preferred, giving a slight edge to A.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.125 and -5.132), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Both ligands have poor aqueous solubility (-1.911 and -2.041). This is a major drawback for both.
11. **hERG:** Ligand A (0.26) is much better than Ligand B (0.154), indicating a lower risk of hERG inhibition and cardiotoxicity.
12. **Cl_mic:** Ligand B (-11.002) has much better metabolic stability (lower clearance) than Ligand A (-4.627). This is a significant advantage for B.
13. **t1/2:** Ligand A (9.333) has a longer half-life than Ligand B (4.716), which is desirable.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.072 and 0.016). This is good for both.
15. **Binding Affinity:** Ligand A (-7.0) has a slightly better binding affinity than Ligand B (-6.2). While both are strong binders, the difference is substantial enough to consider.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand A initially appears more favorable due to its better logP, TPSA, QED, hERG, and binding affinity. However, Ligand B has a significantly lower DILI risk and better metabolic stability (Cl_mic). The poor Caco-2 and solubility for both are major concerns.
The difference in binding affinity between A and B is 0.8 kcal/mol, which is significant. The better ADME properties of A (logP, TPSA, QED, hERG) outweigh the lower DILI and better metabolic stability of B. The DILI risk of A is still within an acceptable range.
Output:
1
2025-04-18 00:02:23,794 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (346.471 Da) is slightly lower, which is generally favorable for permeability, but both are acceptable.
**2. TPSA:** Ligand A (58.64) is significantly better than Ligand B (88.32). For a GPCR, lower TPSA is preferred for better membrane permeability and potentially better CNS penetration, even though this is a cardiovascular target.
**3. logP:** Both ligands have good logP values (A: 2.433, B: 2.888), falling within the optimal 1-3 range. Ligand B is slightly higher, which *could* indicate a slightly higher risk of off-target interactions, but it's not a major concern.
**4. H-Bond Donors & Acceptors:** Ligand A (HBD=1, HBA=3) is better than Ligand B (HBD=2, HBA=5). Lower values are generally preferred for permeability.
**5. QED:** Ligand A (0.778) has a better QED score than Ligand B (0.595), indicating a more drug-like profile.
**6. DILI Risk:** Ligand A (24.738) has a significantly lower DILI risk than Ligand B (64.521). This is a crucial factor, as liver toxicity is a major concern in drug development.
**7. BBB Penetration:** Ligand A (78.364) has better BBB penetration than Ligand B (66.731). While ADRB2 is primarily a cardiovascular target, some CNS effects can be relevant or undesirable, and better BBB penetration *could* translate to better overall distribution.
**8. Caco-2 Permeability:** Ligand A (-4.415) is better than Ligand B (-5.166). Higher values indicate better intestinal absorption.
**9. Aqueous Solubility:** Ligand A (-2.915) is better than Ligand B (-3.731).
**10. hERG Inhibition:** Ligand A (0.253) has a much lower hERG inhibition risk than Ligand B (0.705). This is a critical safety parameter, and Ligand A is significantly better.
**11. Microsomal Clearance:** Ligand B (49.566) has lower microsomal clearance than Ligand A (79.614), suggesting better metabolic stability. This is a positive for Ligand B.
**12. In vitro Half-Life:** Ligand B (14.332) has a longer in vitro half-life than Ligand A (-18.467). This is a positive for Ligand B.
**13. P-gp Efflux:** Ligand A (0.182) has lower P-gp efflux than Ligand B (0.453), which is favorable for bioavailability.
**14. Binding Affinity:** Ligand B (-4.9 kcal/mol) has a slightly better binding affinity than Ligand A (-6.8 kcal/mol). While affinity is important, the difference of 1.9 kcal/mol is not substantial enough to outweigh the numerous advantages of Ligand A.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical ADME-Tox parameters (DILI, hERG, TPSA, QED, solubility, permeability, P-gp efflux). While Ligand B has better metabolic stability and half-life, and slightly better binding affinity, the safety and absorption/distribution advantages of Ligand A are far more important, especially considering the GPCR target class. The lower DILI and hERG risks for Ligand A are particularly compelling.
Output:
1
2025-04-18 00:02:23,794 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (362.405 Da and 369.447 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (59.81) is significantly better than Ligand B (103.87). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold, while Ligand B is approaching it.
3. **logP:** Ligand A (4.198) is higher than the optimal range (1-3), but still potentially manageable. Ligand B (0.029) is *very* low, which raises concerns about permeability. This is a significant negative for Ligand B.
4. **HBD:** Ligand A (1) is good. Ligand B (2) is acceptable, but slightly less desirable.
5. **HBA:** Ligand A (5) is good. Ligand B (6) is acceptable, but slightly less desirable.
6. **QED:** Both ligands (0.757 and 0.706) have good drug-likeness scores, above the 0.5 threshold.
7. **DILI:** Ligand A (92.284) has a higher DILI risk than Ligand B (65.103). This is a concern for Ligand A.
8. **BBB:** Ligand A (66.886) is better than Ligand B (52.191), but neither is particularly high. This isn't a major factor for a cardiovascular target.
9. **Caco-2:** Ligand A (-4.621) is better than Ligand B (-5.142). Higher values are better, so A is slightly preferred.
10. **Solubility:** Ligand A (-4.902) is better than Ligand B (-1.983). Higher values are better, so A is preferred.
11. **hERG:** Ligand A (0.563) is better than Ligand B (0.05). Lower values are better, so A is preferred.
12. **Cl_mic:** Ligand B (29.569) has significantly lower microsomal clearance than Ligand A (43.268), indicating better metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand A (56.959) has a much longer in vitro half-life than Ligand B (-2.355). This is a strong advantage for Ligand A.
14. **Pgp:** Ligand A (0.505) is better than Ligand B (0.008). Lower values are better, so A is preferred.
15. **Affinity:** Ligand A (-6.7 kcal/mol) has a slightly better binding affinity than Ligand B (-6.2 kcal/mol). While the difference is less than 1.5 kcal/mol, it's still a positive for Ligand A.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A excels in these areas (better logP, much better TPSA, better Pgp, and better affinity). Ligand B's very low logP is a major drawback. While Ligand B has better metabolic stability (lower Cl_mic), the overall profile of Ligand A is more promising. The DILI risk for Ligand A is higher, but can be addressed during optimization.
**Conclusion:**
Considering the balance of properties and the priorities for a GPCR target, Ligand A is the more promising candidate. The better permeability characteristics (TPSA, logP, Caco-2, Solubility, Pgp) and affinity outweigh the higher DILI risk, which can be mitigated in further optimization.
Output:
1
2025-04-18 00:02:23,794 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (333.351) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are reasonably low, but Ligand B (84.3) is better than Ligand A (91.81), being closer to the <90 threshold for GPCRs.
3. **logP:** Both are within the optimal range (1-3). Ligand B (1.221) is slightly lower, while Ligand A (2.129) is better positioned.
4. **HBD:** Ligand B (1) is better than Ligand A (3), as fewer HBDs generally improve permeability.
5. **HBA:** Ligand B (5) is better than Ligand A (4).
6. **QED:** Ligand B (0.884) is significantly better than Ligand A (0.491), indicating a more drug-like profile.
7. **DILI:** Ligand B (55.68) is much better than Ligand A (94.765), indicating a lower risk of drug-induced liver injury. This is a critical factor.
8. **BBB:** Ligand B (75.339) is significantly better than Ligand A (33.23). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant, and lower efflux is always helpful.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-5.479) is worse than Ligand B (-4.867).
10. **Solubility:** Both are negative, indicating poor solubility. Ligand B (-2.247) is better than Ligand A (-4.675).
11. **hERG:** Both are low, indicating low risk. Ligand B (0.654) is slightly better than Ligand A (0.476).
12. **Cl_mic:** Ligand A (2.367) is significantly better than Ligand B (30.736), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-26.206) is significantly better than Ligand A (71.94), suggesting a longer half-life.
14. **Pgp:** Ligand A (0.238) is better than Ligand B (0.101), indicating lower P-gp efflux.
15. **Affinity:** Ligand A (-6.8) is slightly better than Ligand B (-6.4), but the difference is small.
**Overall Assessment:**
Ligand B demonstrates a much more favorable ADMET profile. The significantly lower DILI risk, better BBB penetration, higher QED, and longer half-life are substantial advantages. While Ligand A has better metabolic stability and slightly better affinity, these are outweighed by the ADMET concerns of Ligand A. The small affinity difference is unlikely to be critical, and can potentially be optimized during lead optimization. The poor Caco-2 and solubility for both ligands are concerning, but more readily addressable through formulation strategies than the significant toxicity risk posed by Ligand A.
Output:
0
2025-04-18 00:02:23,794 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [374.467, 119.81 , -0.747, 3. , 6. , 0.515, 37.611, 63.746, -5.503, -0.654, 0.244, -10.377, -5.77 , 0.007, -6.7 ]
**Ligand B:** [348.451, 97.35 , 0.746, 1. , 6. , 0.847, 35.595, 71.733, -5.125, -1.339, 0.088, 16.536, -13.345, 0.035, -9. ]
Here's a breakdown, prioritizing GPCR properties (logP, TPSA, Pgp, BBB, Affinity):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (348.451) is slightly smaller, which can be advantageous for permeability, but the difference isn't huge.
2. **TPSA:** Ligand A (119.81) is slightly higher than Ligand B (97.35). Both are below the 140 threshold for good oral absorption, and Ligand B is closer to the preferred <90 for CNS targets, though ADRB2 isn't necessarily a CNS target.
3. **logP:** Ligand A (-0.747) is a bit low, potentially hindering membrane permeability. Ligand B (0.746) is much better, falling within the optimal 1-3 range. This is a significant advantage for Ligand B.
4. **HBD/HBA:** Both have acceptable numbers. Ligand A has 3 HBD and 6 HBA, while Ligand B has 1 HBD and 6 HBA. This difference is minor.
5. **QED:** Both have good QED scores (A: 0.515, B: 0.847), indicating drug-like properties. Ligand B is notably better here.
6. **DILI:** Both have low DILI risk (A: 37.611, B: 35.595), which is positive.
7. **BBB:** Ligand B (71.733) has a better BBB percentile than Ligand A (63.746). While not critical for ADRB2, it's a bonus.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. This is a concern for both.
9. **Solubility:** Both have negative solubility values, which is also concerning.
10. **hERG:** Both have low hERG risk (A: 0.244, B: 0.088). Ligand B is slightly better.
11. **Cl_mic:** Ligand A (-10.377) has a much *lower* (better) microsomal clearance than Ligand B (16.536), indicating greater metabolic stability. This is a strong point for Ligand A.
12. **t1/2:** Ligand B (-13.345) has a longer in vitro half-life than Ligand A (-5.77), which is desirable.
13. **Pgp:** Both have very low Pgp efflux liability (A: 0.007, B: 0.035).
14. **Affinity:** Ligand B (-9.0 kcal/mol) has significantly stronger binding affinity than Ligand A (-6.7 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME concerns.
**Overall Assessment:**
Ligand B has a superior logP, QED, BBB, and *much* stronger binding affinity. While Ligand A has better metabolic stability (lower Cl_mic), the significantly improved affinity of Ligand B is a critical factor for a GPCR target. The slightly better logP and QED of Ligand B also contribute to its overall drug-likeness. The negative Caco-2 and solubility values are concerning for both, but the potency advantage of Ligand B makes it the more promising candidate, assuming these issues can be addressed through formulation or structural modification.
Output:
0
2025-04-18 00:02:23,794 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (353.463 and 354.479 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (112.73) is higher than Ligand B (64.78). For a GPCR, lower TPSA is generally preferred for better brain penetration and overall permeability. Ligand B is significantly better here.
3. **logP:** Ligand B (3.561) is higher than Ligand A (0.404). While logP values between 1-3 are optimal, Ligand B is slightly above this range, but still acceptable. Ligand A's logP is quite low, potentially hindering membrane permeability. Ligand B is better.
4. **HBD:** Ligand A (3) and Ligand B (2) are both within the acceptable limit of <=5. No major difference.
5. **HBA:** Ligand A (4) and Ligand B (3) are both within the acceptable limit of <=10. No major difference.
6. **QED:** Both ligands have good QED scores (0.641 and 0.711, respectively), indicating good drug-like properties. No significant difference.
7. **DILI:** Ligand A (9.926) has a much lower DILI risk than Ligand B (48.313). This is a significant advantage for Ligand A.
8. **BBB:** Both ligands have similar BBB penetration (59.093 and 60.954). While not exceptionally high, they are acceptable for a non-CNS target like ADRB2.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.35 and -5.527). This is unusual and suggests poor permeability.
10. **Solubility:** Ligand A (-1.764) has better solubility than Ligand B (-3.631). Better solubility is generally preferred.
11. **hERG:** Ligand A (0.083) has a lower hERG risk than Ligand B (0.786). This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand A (4.423) has significantly lower microsomal clearance than Ligand B (40.828), indicating better metabolic stability. This is a major advantage for Ligand A.
13. **t1/2:** Ligand A (-16.065) has a much longer in vitro half-life than Ligand B (0.216). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.007) has lower P-gp efflux liability than Ligand B (0.283). This is a slight advantage for Ligand A.
15. **Binding Affinity:** Ligand B (-6.9) has a slightly better binding affinity than Ligand A (-6.5). While a difference of 0.4 kcal/mol is noticeable, it's not a huge advantage, especially considering the other factors.
**Overall Assessment:**
While Ligand B has slightly better binding affinity, Ligand A is significantly better across multiple critical ADME-Tox parameters. Specifically, Ligand A demonstrates a much lower risk of DILI and hERG inhibition, better metabolic stability (lower Cl_mic and longer t1/2), and lower P-gp efflux. The lower TPSA of Ligand B is appealing, but the substantial improvements in safety and PK for Ligand A outweigh this benefit. The negative Caco-2 values for both are concerning, but the overall profile of Ligand A is more favorable for development.
Output:
1
2025-04-18 00:02:23,795 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (381.523 Da) is slightly higher than Ligand B (351.491 Da), but both are acceptable.
2. **TPSA:** Both ligands have TPSA values below 140, indicating good potential for oral absorption. Ligand A (71.53) is slightly higher than Ligand B (70.67), but the difference is minimal.
3. **logP:** Both ligands have optimal logP values (between 1 and 3). Ligand A (2.647) is slightly higher than Ligand B (1.153). While higher logP can sometimes be problematic, it's not a major concern here.
4. **HBD:** Ligand A has 1 HBD, and Ligand B has 2. Both are within the acceptable limit of <=5.
5. **HBA:** Ligand A has 6 HBA, and Ligand B has 4. Both are within the acceptable limit of <=10.
6. **QED:** Both ligands have QED values above 0.5, indicating good drug-likeness. Ligand A (0.833) is slightly better than Ligand B (0.722).
7. **DILI:** Ligand A has a DILI risk of 78.48%, which is concerning (high risk). Ligand B has a much lower DILI risk of 18.418% (good). This is a significant advantage for Ligand B.
8. **BBB:** Ligand B has a higher BBB penetration percentile (74.835%) than Ligand A (61.923%). While ADRB2 isn't strictly a CNS target, some peripheral ADRB2 receptors can be relevant in CNS-related conditions, and better BBB penetration is generally favorable.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it is difficult to interpret.
10. **Solubility:** Both ligands have negative solubility values, suggesting poor solubility. Again, the scale is not specified, so it is difficult to interpret.
11. **hERG:** Both ligands have low hERG inhibition liability (0.443 and 0.34, respectively), which is good.
12. **Cl_mic:** Ligand A has a higher microsomal clearance (70.876) than Ligand B (42.962), indicating lower metabolic stability. This is a disadvantage for Ligand A.
13. **t1/2:** Ligand B has a significantly longer in vitro half-life (-0.637 hours) than Ligand A (-20.391 hours). This is a major advantage for Ligand B.
14. **Pgp:** Ligand A has a higher Pgp efflux liability (0.148) than Ligand B (0.039), indicating potentially lower bioavailability. This is a disadvantage for Ligand A.
15. **Binding Affinity:** Ligand B has a stronger binding affinity (-8.3 kcal/mol) than Ligand A (-7.0 kcal/mol). This is a significant advantage for Ligand B.
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are important. Ligand B performs better in all these categories. The DILI risk is also a critical factor, and Ligand B is significantly better in this regard.
**Conclusion:**
Despite Ligand A having a slightly better QED, Ligand B is the superior candidate due to its significantly better binding affinity, lower DILI risk, improved metabolic stability (lower Cl_mic, longer t1/2), lower Pgp efflux, and better BBB penetration. The differences in logP and TPSA are minor and do not outweigh these advantages.
Output:
0
2025-04-18 00:02:23,795 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (381.841) is slightly higher than Ligand B (346.475), but both are acceptable.
2. **TPSA:** Both ligands are below the 140 A^2 threshold for good oral absorption. Ligand B (75.19) is preferable due to being lower than Ligand A (90.41). Lower TPSA generally correlates with better membrane permeability.
3. **logP:** Both ligands have optimal logP values (between 1 and 3). Ligand B (2.517) is slightly lower than Ligand A (3.083), which is slightly less desirable, but both are acceptable.
4. **HBD:** Both ligands have 1 H-bond donor, which is within the ideal range.
5. **HBA:** Ligand A has 8 H-bond acceptors, while Ligand B has 4. Ligand B is preferable here, as fewer HBA generally improves permeability.
6. **QED:** Both ligands have good QED scores (>0.5), indicating drug-likeness. Ligand B (0.859) is slightly better than Ligand A (0.796).
7. **DILI:** Ligand B (35.556) has a significantly lower DILI risk than Ligand A (89.686). This is a major advantage for Ligand B.
8. **BBB:** Both ligands have similar BBB penetration (68.786 and 68.282 respectively). This is not a primary concern for ADRB2 as it's a cardiovascular target, but it's good that neither is severely limited.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual. It's difficult to interpret without knowing the scale, but it suggests poor permeability.
10. **Solubility:** Both ligands have negative solubility values, which is also unusual. It's difficult to interpret without knowing the scale, but it suggests poor solubility.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.209 and 0.519 respectively).
12. **Cl_mic:** Ligand B (66.19) has a lower microsomal clearance than Ligand A (89.737), suggesting better metabolic stability.
13. **t1/2:** Ligand A (71.831) has a longer in vitro half-life than Ligand B (-1.481). This is a positive for Ligand A.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.506 and 0.052 respectively).
15. **Binding Affinity:** Ligand B (-6.8 kcal/mol) has a slightly better binding affinity than Ligand A (-6.0 kcal/mol). This difference is significant (0.8 kcal/mol).
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Ligand B has a slightly better logP and TPSA, significantly better DILI, and better affinity. While Ligand A has a longer half-life, the other advantages of Ligand B outweigh this.
**Conclusion:**
Considering all factors, especially the significantly lower DILI risk and slightly better binding affinity, Ligand B is the more promising drug candidate.
Output:
0
2025-04-18 00:02:23,795 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (356.419 and 354.401 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (106.12) is higher than Ligand B (67.23). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is generally preferred for absorption. Ligand B is better.
3. **logP:** Ligand A (-0.654) is quite low, potentially hindering membrane permeability. Ligand B (1.795) is within the optimal 1-3 range. Ligand B is significantly better.
4. **HBD:** Ligand A (3) is higher than Ligand B (1). While both are acceptable, lower HBD can improve permeability. Ligand B is slightly better.
5. **HBA:** Ligand A (6) is higher than Ligand B (4). Similar to HBD, lower HBA is generally preferred. Ligand B is slightly better.
6. **QED:** Ligand B (0.877) has a substantially higher QED score than Ligand A (0.507), indicating a more drug-like profile. Ligand B is much better.
7. **DILI:** Ligand A (13.61) has a much lower DILI risk than Ligand B (40.636). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (51.997) has a lower BBB penetration percentile than Ligand B (79.682). For a cardiovascular target, BBB penetration is not a primary concern, so this is less important. Ligand B is better.
9. **Caco-2:** Ligand A (-5.499) and Ligand B (-4.7) are both negative, indicating poor permeability. This is a concern for both, but the values are close.
10. **Solubility:** Ligand A (-0.689) has slightly better solubility than Ligand B (-2.303).
11. **hERG:** Both ligands have very low hERG inhibition risk (0.136 and 0.356 respectively). No significant difference.
12. **Cl_mic:** Ligand A (-2.227) has a lower (better) microsomal clearance than Ligand B (43.934). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (32.654) has a longer in vitro half-life than Ligand B (-3.416). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.003) has a much lower P-gp efflux liability than Ligand B (0.044). This is a positive for Ligand A.
15. **Binding Affinity:** Ligand B (-6.9 kcal/mol) has a slightly better binding affinity than Ligand A (-6.4 kcal/mol). This is a modest advantage, but potentially important.
**Overall Assessment:**
Ligand B has better logP, QED, BBB, and binding affinity. However, Ligand A demonstrates significantly better DILI risk, metabolic stability (Cl_mic, t1/2), and P-gp efflux. Given the cardiovascular target, metabolic stability and minimizing off-target effects (DILI) are crucial. The slightly better binding affinity of Ligand B is unlikely to outweigh the substantial advantages of Ligand A in terms of safety and PK. The low logP of Ligand A is a concern, but potentially addressable through further optimization.
Output:
1
2025-04-18 00:02:23,795 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (367.5 and 344.5 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (81.06) is better than Ligand B (84.85). Both are acceptable for a non-CNS GPCR target like ADRB2, but lower TPSA generally favors permeability.
**3. logP:** Both ligands have good logP values (2.46 and 2.621), falling within the optimal 1-3 range. Ligand B is slightly higher, which could be a minor concern for solubility, but not a dealbreaker.
**4. H-Bond Donors:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
**5. H-Bond Acceptors:** Ligand B (7) is higher than Ligand A (5). While both are within the acceptable limit of 10, lower is generally better for permeability.
**6. QED:** Ligand A (0.886) has a significantly better QED score than Ligand B (0.723), indicating a more drug-like profile.
**7. DILI Risk:** Ligand A (60.45) has a higher DILI risk than Ligand B (39.162). This is a significant negative for Ligand A.
**8. BBB Penetration:** Ligand A (72.78) has better BBB penetration than Ligand B (60.876). While ADRB2 is not a primary CNS target, some degree of BBB penetration is not necessarily detrimental, and could offer some off-target effects.
**9. Caco-2 Permeability:** Ligand A (-4.781) is better than Ligand B (-5.094). Higher (less negative) values indicate better intestinal absorption.
**10. Aqueous Solubility:** Ligand A (-4.025) is better than Ligand B (-2.319). Higher values indicate better solubility.
**11. hERG Inhibition:** Ligand A (0.319) has a lower hERG inhibition risk than Ligand B (0.582), which is a significant advantage.
**12. Microsomal Clearance:** Ligand B (20.541) has lower microsomal clearance than Ligand A (27.197), suggesting better metabolic stability.
**13. In vitro Half-Life:** Ligand B (59.03) has a significantly longer in vitro half-life than Ligand A (39.196). This is a major advantage.
**14. P-gp Efflux:** Ligand A (0.102) has lower P-gp efflux than Ligand B (0.022), which is better.
**15. Binding Affinity:** Ligand A (-7.4) has a stronger binding affinity than Ligand B (-5.9). This is a substantial advantage, potentially outweighing some of the ADME concerns.
**Overall Assessment:**
Ligand A has a superior binding affinity and better QED, Caco-2 permeability, solubility, hERG inhibition, and P-gp efflux. However, it has a higher DILI risk and lower metabolic stability (higher Cl_mic, shorter t1/2). Ligand B has a significantly better safety profile (lower DILI) and improved metabolic stability, but weaker binding affinity.
Given the importance of potency for GPCRs, and the significant 1.5 kcal/mol difference in binding affinity, I prioritize Ligand A despite its higher DILI risk. The DILI risk is at the upper end of acceptable, and could be further mitigated through structural modifications. The stronger binding affinity is more likely to translate to efficacy.
Output:
1
2025-04-18 00:02:23,795 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (407.533 Da) is within the ideal range, while Ligand B (361.408 Da) is slightly below but still acceptable.
2. **TPSA:** Ligand A (53.51) is slightly above the preferred <90 for GPCRs, but still reasonable. Ligand B (43.86) is excellent.
3. **logP:** Both ligands have good logP values (A: 2.865, B: 1.525) within the 1-3 range. Ligand B is slightly lower, which could potentially affect permeability.
4. **HBD:** Both have 0 HBD, which is good.
5. **HBA:** Ligand A (6) and Ligand B (3) are both acceptable.
6. **QED:** Both ligands have good QED scores (A: 0.739, B: 0.766), indicating good drug-likeness.
7. **DILI:** Ligand A (67.429) has a moderate DILI risk, while Ligand B (17.371) has a very low risk. This is a significant advantage for Ligand B.
8. **BBB:** Both have high BBB penetration (A: 90.694, B: 85.964), which is good, though not critical for ADRB2 (a cardiovascular target).
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and requires further investigation. However, the values are similar (-4.829 vs -4.466).
10. **Solubility:** Both have negative solubility values, which is also unusual. Ligand B is slightly better (-1.638 vs -4.77).
11. **hERG:** Both have low hERG inhibition liability (A: 0.917, B: 0.584), which is excellent.
12. **Cl_mic:** Ligand A (58.4) has a higher microsomal clearance than Ligand B (-2.622), indicating lower metabolic stability. This is a negative for Ligand A.
13. **t1/2:** Ligand A (-31.136) has a very negative in vitro half-life, indicating very rapid metabolism. Ligand B (4.994) has a short but positive half-life.
14. **Pgp:** Both have low Pgp efflux liability (A: 0.553, B: 0.021). Ligand B is significantly better.
15. **Binding Affinity:** Ligand B (-6.5 kcal/mol) has a slightly better binding affinity than Ligand A (-5.9 kcal/mol). While the difference is less than 1.5 kcal/mol, it contributes to the overall preference.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Both ligands perform well on logP and TPSA. Ligand B has a significantly better Pgp profile and slightly better affinity. The most significant difference is the DILI risk and metabolic stability (Cl_mic and t1/2). Ligand B has a much lower DILI risk and exhibits better metabolic stability.
**Conclusion:**
Considering the balance of properties, particularly the significantly lower DILI risk, better metabolic stability, and slightly better affinity, Ligand B is the more promising drug candidate.
Output:
0
2025-04-18 00:02:23,795 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
Let's break down the comparison, keeping in mind ADRB2 is a GPCR and thus we prioritize logP, Pgp, TPSA, and affinity, alongside general drug-like properties.
1. **Molecular Weight:** Both ligands (363.454 and 363.531 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (38.77) is significantly better than Ligand B (63.05). A TPSA under 140 is good for oral absorption, and lower is generally preferred for GPCRs. Ligand A is much closer to the ideal for CNS penetration if that were a goal.
3. **logP:** Ligand A (4.129) is slightly higher than Ligand B (3.777). Both are within the acceptable 1-3 range, but Ligand A is pushing the upper limit.
4. **H-Bond Donors:** Ligand A (0) is better than Ligand B (1). Fewer HBDs generally improve permeability.
5. **H-Bond Acceptors:** Ligand A (4) is better than Ligand B (6). Similar to HBDs, fewer HBAs are generally preferred.
6. **QED:** Both ligands have similar QED scores (0.629 and 0.698), both above the 0.5 threshold, indicating good drug-likeness.
7. **DILI:** Ligand B (55.487) has a slightly lower DILI risk than Ligand A (51.144), but both are reasonably low and below the concerning 60 percentile.
8. **BBB:** Ligand A (81.698) has a higher BBB penetration percentile than Ligand B (76.58). While ADRB2 isn't *necessarily* a CNS target, higher BBB is rarely a detriment and can open up possibilities.
9. **Caco-2:** Ligand A (-4.279) has a worse Caco-2 permeability than Ligand B (-5.023). Lower (more negative) values indicate poorer permeability. This is a negative for Ligand A.
10. **Solubility:** Ligand A (-4.164) is slightly better than Ligand B (-3.611).
11. **hERG:** Both ligands have very low hERG inhibition risk (0.888 and 0.877). Excellent.
12. **Cl_mic:** Ligand B (98.452) has a lower microsomal clearance than Ligand A (121.637), indicating better metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand B (75.715) has a significantly longer in vitro half-life than Ligand A (18.463). This is a major advantage for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have similar Pgp efflux liability (0.631 and 0.772).
15. **Binding Affinity:** Ligand A (-5.9 kcal/mol) has a slightly better binding affinity than Ligand B (-6.0 kcal/mol). While the difference is small, it's still a positive for Ligand A.
**Overall Assessment:**
Ligand B demonstrates a better balance of properties, particularly regarding metabolic stability (lower Cl_mic) and longer half-life. The slightly better Caco-2 permeability also helps offset the higher TPSA. While Ligand A has a slightly better affinity and TPSA, the significant advantages of Ligand B in metabolic stability and half-life outweigh these benefits, especially for a GPCR target where prolonged engagement can be beneficial.
**Output:**
0
2025-04-18 00:02:23,795 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.297 and 350.379 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (94.59) is better than Ligand B (121.94). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (2.85) is optimal, while Ligand B (-1.387) is quite low. This is a significant drawback for Ligand B, potentially hindering membrane permeability and bioavailability.
4. **HBD:** Ligand A (1) is good. Ligand B (2) is acceptable.
5. **HBA:** Ligand A (7) is good. Ligand B (8) is acceptable.
6. **QED:** Ligand A (0.543) is slightly better than Ligand B (0.44), indicating a more drug-like profile.
7. **DILI:** Ligand A (95.386) has a higher DILI risk than Ligand B (49.36). This is a concern for Ligand A.
8. **BBB:** Ligand A (75.998) is better than Ligand B (32.416), but BBB isn't a high priority for a cardiovascular target.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.703 and -5.311), which is unusual and suggests poor permeability. However, these values are on a scale where negative values are possible, and the absolute value is what matters. Ligand A is slightly better.
10. **Solubility:** Ligand A (-5.311) is better than Ligand B (-0.947). Better solubility is generally preferred.
11. **hERG:** Ligand A (0.8) is much better than Ligand B (0.035). Lower hERG inhibition is crucial to avoid cardiotoxicity, making this a major advantage for Ligand A.
12. **Cl_mic:** Ligand B (-5.609) has a *negative* microsomal clearance, which is highly unusual and suggests very high metabolic stability. Ligand A (62.612) is moderate.
13. **t1/2:** Ligand B (14.423) has a longer half-life than Ligand A (9.198). This is a positive for Ligand B.
14. **Pgp:** Ligand A (0.461) is better than Ligand B (0.01). Lower P-gp efflux is desirable for better bioavailability.
15. **Binding Affinity:** Ligand B (-7.0) has a significantly better binding affinity than Ligand A (-3.4). A 3.6 kcal/mol difference is substantial and can often outweigh other drawbacks.
**Overall Assessment:**
Ligand B has a superior binding affinity and metabolic stability. However, its very low logP is a major concern, likely leading to poor absorption. Ligand A has a more balanced profile, with acceptable logP, better hERG safety, and reasonable solubility. While its DILI risk is higher, the significant difference in binding affinity might be enough to overcome other issues with Ligand B. Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), the binding affinity advantage of Ligand B is compelling, but the poor logP makes it a high-risk candidate. The hERG risk of Ligand B is also very concerning. Ligand A, despite the DILI risk, presents a more balanced and potentially developable profile.
Output:
1
2025-04-18 00:02:23,795 - INFO - Batch 448 complete. Total preferences: 7168
2025-04-18 00:02:23,795 - INFO - Processing batch 449/512...
2025-04-18 00:03:14,073 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (342.443 Da and 361.471 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (75.19) is better than Ligand B (80.12). Both are below the 140 A^2 threshold for oral absorption, but lower TPSA is generally preferred for GPCRs, aiding in membrane permeability.
**3. logP:** Both ligands have good logP values (2.045 and 1.42), falling within the optimal 1-3 range. Ligand B is slightly lower, which could be a minor drawback.
**4. H-Bond Donors:** Both have 1 HBD, which is within the acceptable limit of 5.
**5. H-Bond Acceptors:** Ligand A has 4 HBAs, while Ligand B has 6. Both are below the 10 limit, but Ligand A is preferable.
**6. QED:** Both ligands have similar QED values (0.734 and 0.731), indicating good drug-likeness.
**7. DILI Risk:** Ligand A (26.057 percentile) has a significantly lower DILI risk than Ligand B (54.75 percentile). This is a major advantage for Ligand A.
**8. BBB Penetration:** Ligand A (70.686 percentile) shows better BBB penetration than Ligand B (45.366 percentile). While ADRB2 is a cardiovascular target, some CNS off-target effects are possible with GPCR ligands, and better BBB penetration could contribute to this.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-5.119 and -5.322). This is unusual and suggests poor permeability. However, the values are very close, so it's not a major differentiating factor.
**10. Aqueous Solubility:** Both ligands have very poor aqueous solubility (-1.465 and -1.459). This is a significant concern for both, and formulation strategies would be needed.
**11. hERG Inhibition:** Both ligands show very low hERG inhibition risk (0.151 and 0.134). This is excellent.
**12. Microsomal Clearance:** Ligand A (24.792 mL/min/kg) has a significantly lower microsomal clearance than Ligand B (46.17 mL/min/kg), indicating better metabolic stability.
**13. In vitro Half-Life:** Ligand A (-2.061 hours) has a worse in vitro half-life than Ligand B (28.108 hours). This is a significant drawback for Ligand A.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.012 and 0.014). This is favorable.
**15. Binding Affinity:** Ligand A (-6.2 kcal/mol) has a slightly better binding affinity than Ligand B (-5.7 kcal/mol). While the difference is not huge, it's enough to be considered.
**Overall Assessment:**
Ligand A is superior despite the worse half-life. The lower DILI risk, better BBB penetration, lower microsomal clearance, and slightly better affinity outweigh the shorter half-life. The solubility is a concern for both, but can be addressed with formulation. The half-life could potentially be improved through structural modifications.
Output:
1
2025-04-18 00:03:14,073 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (390.615 and 357.523 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (49.85) is better than Ligand B (59.22). Both are acceptable, but A is closer to the preferred <140 for good oral absorption.
3. **logP:** Ligand A (2.939) is optimal (1-3). Ligand B (4.647) is slightly higher, potentially leading to solubility issues and off-target effects, though not drastically so.
4. **HBD:** Ligand A (0) is preferable to Ligand B (1). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (5) is better than Ligand B (4). Both are within the acceptable range of <=10.
6. **QED:** Ligand B (0.819) has a better QED score than Ligand A (0.597), indicating a more drug-like profile overall.
7. **DILI:** Ligand B (31.989) has a significantly lower DILI risk than Ligand A (49.283). This is a major advantage for Ligand B.
8. **BBB:** Ligand B (85.072) has a much higher BBB penetration percentile than Ligand A (57.542). While ADRB2 isn't exclusively a CNS target, some CNS exposure can occur, and higher BBB is generally favorable.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.644 and -4.964). This is unusual and suggests poor permeability. However, the values are very similar.
10. **Solubility:** Ligand B (-4.222) is slightly better than Ligand A (-3.313), but both are poor.
11. **hERG:** Ligand A (0.341) has a lower hERG inhibition liability than Ligand B (0.846), which is a significant safety advantage.
12. **Cl_mic:** Ligand A (63.966) has a lower microsomal clearance than Ligand B (66.224), suggesting better metabolic stability.
13. **t1/2:** Ligand B (26.368) has a longer in vitro half-life than Ligand A (18.492), which is desirable.
14. **Pgp:** Ligand B (0.544) has a lower P-gp efflux liability than Ligand A (0.311), which is favorable for bioavailability.
15. **Affinity:** Ligand A (-7.1) has a slightly better binding affinity than Ligand B (-6.9). This is a 0.2 kcal/mol difference, which is not huge, but still relevant.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand B excels in logP (though slightly high), Pgp, and BBB. Ligand A has a better TPSA and a slightly better affinity. The DILI risk for Ligand B is also much lower. The hERG risk for Ligand A is lower, which is a crucial safety factor.
**Overall Assessment:**
While Ligand A has a slightly better affinity and lower hERG risk, Ligand B's superior DILI profile, BBB penetration, Pgp efflux, and longer half-life are more compelling, especially considering the slight affinity difference. The slightly higher logP of Ligand B is a concern, but not a deal-breaker. The poor Caco-2 values for both are a significant drawback that would need to be addressed through formulation or structural modification. However, given the choice between these two, the benefits of Ligand B outweigh those of Ligand A.
Output:
0
2025-04-18 00:03:14,073 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (355.479 and 356.463 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (90.9) is better than Ligand B (104.73). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (0.994) is slightly better than Ligand A (0.127). Both are on the lower side of optimal (1-3), but Ligand B is closer. Ligand A's very low logP is a concern for membrane permeability.
4. **HBD:** Both ligands have 3 HBD, which is acceptable.
5. **HBA:** Both ligands have 5 HBA, which is acceptable.
6. **QED:** Both ligands have similar QED values (0.576 and 0.563), indicating good drug-likeness.
7. **DILI:** Ligand A (4.382) has a significantly lower DILI risk than Ligand B (19.155). This is a major advantage for Ligand A.
8. **BBB:** Not a primary concern for a cardiovascular target. Ligand A (56.495) and Ligand B (50.679) are similar.
9. **Caco-2:** Ligand A (-5.208) is significantly better than Ligand B (-4.786). Higher Caco-2 permeability suggests better intestinal absorption.
10. **Solubility:** Ligand A (-0.627) is better than Ligand B (-2.285). Better solubility is generally desirable.
11. **hERG:** Both ligands have low hERG inhibition liability (0.19 and 0.14), which is good.
12. **Cl_mic:** Ligand A (-22.15) has a much lower (better) microsomal clearance than Ligand B (63.617). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand B (-38.056) has a much longer in vitro half-life than Ligand A (0.954). This is a significant advantage for Ligand B.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.013 and 0.038).
15. **Binding Affinity:** Ligand A (-6.7) has a slightly better binding affinity than Ligand B (-6.0). While the difference is less than 1.5 kcal/mol, it's still a positive.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand A is preferable. While Ligand B has a better half-life, Ligand A excels in several critical areas: significantly lower DILI risk, better Caco-2 permeability, better solubility, and lower microsomal clearance. The slightly better binding affinity of Ligand A further supports this choice. The low logP of Ligand A is a concern, but the other advantages outweigh this drawback.
Output:
1
2025-04-18 00:03:14,073 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (362.821 and 346.471 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (60.85) is significantly better than Ligand A (93.36). ADRB2 is not a CNS target, but lower TPSA generally correlates with better absorption. This favors Ligand B.
3. **logP:** Ligand B (1.792) is within the optimal 1-3 range, while Ligand A (0.646) is slightly below 1. This is a significant drawback for Ligand A, potentially hindering membrane permeability. Ligand B is favored.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (1), but both are acceptable (<=5).
5. **HBA:** Ligand A (5) is higher than Ligand B (3), but both are acceptable (<=10).
6. **QED:** Both ligands have good QED scores (0.694 and 0.79), indicating good drug-like properties. No clear advantage.
7. **DILI:** Ligand B (5.118) has a much lower DILI risk than Ligand A (76.89). This is a major advantage for Ligand B.
8. **BBB:** While not a primary concern for ADRB2, Ligand B (70.648) has a higher BBB percentile than Ligand A (50.523).
9. **Caco-2:** Ligand B (-4.453) is better than Ligand A (-5.087), indicating better intestinal absorption.
10. **Solubility:** Ligand B (-1.731) is better than Ligand A (-3.569).
11. **hERG:** Ligand A (0.584) has a slightly better hERG profile than Ligand B (0.182), but both are relatively low risk.
12. **Cl_mic:** Ligand A (-5.076) has a much lower (better) microsomal clearance than Ligand B (11.579), suggesting greater metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (-33.863) has a longer in vitro half-life than Ligand B (-15.848). This is a positive for Ligand A.
14. **Pgp:** Ligand A (0.043) has a lower Pgp efflux liability than Ligand B (0.025). This is a slight advantage for Ligand A.
15. **Binding Affinity:** Ligand A (-6.5 kcal/mol) has a slightly better binding affinity than Ligand B (-5.0 kcal/mol). This is a 1.5 kcal/mol advantage, which is significant.
**Overall Assessment:**
Ligand B has substantial advantages in key ADME properties (TPSA, logP, DILI, solubility, Caco-2) and a better BBB score. While Ligand A has advantages in metabolic stability (Cl_mic, t1/2), Pgp efflux, and a slightly better binding affinity, the ADME profile of Ligand B is far more promising. The lower DILI risk alone is a major factor. The binding affinity difference, while notable, can potentially be optimized in later stages of drug development. For a GPCR target like ADRB2, a balanced profile is crucial, and Ligand B offers that balance more effectively.
Output:
0
2025-04-18 00:03:14,074 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [349.439, 106.25 , 0.286, 3. , 5. , 0.708, 43.622, 61.613, -5.373, -1.715, 0.249, -26.459, 1.436, 0.004, -6.4 ]
**Ligand B:** [359.491, 49.77 , 3.679, 1. , 4. , 0.856, 46.219, 70.997, -4.8 , -3.847, 0.776, 84.384, 46.45 , 0.879, -6.7 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal 200-500 Da range. Ligand A (349.439 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (106.25) is higher than Ligand B (49.77). For a cardiovascular GPCR, TPSA isn't *as* critical as for CNS targets, but lower is still preferable for better absorption. Ligand B is significantly better here.
3. **logP:** Ligand A (0.286) is quite low, potentially hindering membrane permeability. Ligand B (3.679) is within the optimal 1-3 range. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (3) is higher than Ligand B (1). Lower is generally better for permeability. Ligand B is better.
5. **HBA:** Ligand A (5) is higher than Ligand B (4). Lower is generally better for permeability. Ligand B is better.
6. **QED:** Both are good (>0.5), with Ligand B (0.856) being slightly better.
7. **DILI:** Both are acceptable, with Ligand A (43.622) and Ligand B (46.219) both under the 60% threshold.
8. **BBB:** Ligand B (70.997) is better than Ligand A (61.613). While not a CNS target, some level of BBB penetration can be indicative of good distribution.
9. **Caco-2:** Ligand A (-5.373) is worse than Ligand B (-4.8). Higher is better, indicating better intestinal absorption. Ligand B is better.
10. **Solubility:** Ligand A (-1.715) is worse than Ligand B (-3.847). Higher is better. Ligand B is better.
11. **hERG:** Both are low (0.249 and 0.776), indicating low cardiotoxicity risk.
12. **Cl_mic:** Ligand A (-26.459) is *much* better than Ligand B (84.384). Lower clearance indicates better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand B (46.45) has a much longer half-life than Ligand A (1.436). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.004) is much better than Ligand B (0.879). Lower Pgp efflux is desirable. This is a significant advantage for Ligand A.
15. **Affinity:** Ligand B (-6.7) is slightly better than Ligand A (-6.4). While the difference is small, it's still a positive for Ligand B.
**Overall Assessment:**
Ligand B has a superior profile in terms of logP, TPSA, Caco-2 permeability, solubility, BBB penetration, and half-life. Ligand A excels in metabolic stability (Cl_mic) and P-gp efflux. However, the poor logP of Ligand A is a major concern for oral bioavailability, and the short half-life is undesirable. The slightly better affinity of Ligand B, combined with its more favorable ADME properties, outweighs the advantage of Ligand A's metabolic stability.
Given the GPCR target class, prioritizing logP, TPSA, and permeability is crucial.
Output:
0
2025-04-18 00:03:14,074 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (346.402 and 341.499 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (70.59) is higher than Ligand B (45.23). For a cardiovascular GPCR, TPSA is moderately important. Ligand B's lower TPSA is preferable for better permeability.
3. **logP:** Both ligands have good logP values (3.237 and 3.401), falling within the optimal 1-3 range. Ligand B is slightly higher, which could be a minor advantage.
4. **HBD:** Ligand A has 3 HBD, while Ligand B has 1. Lower HBD is generally preferred for permeability. Ligand B is better here.
5. **HBA:** Both ligands have 3 HBA, which is within the acceptable range. No significant difference.
6. **QED:** Both ligands have good QED scores (0.752 and 0.893), indicating good drug-likeness. Ligand B is slightly better.
7. **DILI:** Ligand A (44.087) has a higher DILI risk than Ligand B (12.408). This is a significant advantage for Ligand B.
8. **BBB:** Ligand B (84.878) has a much higher BBB penetration percentile than Ligand A (43.815). While ADRB2 isn't strictly a CNS target, some CNS exposure can occur, and higher BBB is generally favorable.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.626 and -4.681). These values are unusual and suggest poor permeability. However, the values are very similar.
10. **Solubility:** Both ligands have negative solubility values (-3.135 and -2.742). These values are also unusual and suggest poor solubility. Again, the values are very similar.
11. **hERG:** Both ligands have low hERG inhibition liability (0.712 and 0.381), which is good. Ligand B is slightly better.
12. **Cl_mic:** Both ligands have similar microsomal clearance values (55.556 and 45.463 mL/min/kg).
13. **t1/2:** Ligand B (48.836) has a significantly longer in vitro half-life than Ligand A (1.078). This is a major advantage for Ligand B, suggesting less frequent dosing.
14. **Pgp:** Ligand A (0.403) has lower P-gp efflux liability than Ligand B (0.235). This is a slight advantage for Ligand A.
15. **Binding Affinity:** Ligand B (-6.8 kcal/mol) has a slightly stronger binding affinity than Ligand A (-6.3 kcal/mol). This difference (0.5 kcal/mol) is significant enough to consider, especially given the other favorable properties of Ligand B.
**Overall Assessment:**
Ligand B consistently outperforms Ligand A in most critical ADME properties (DILI, BBB, t1/2, HBD, QED) and has a slightly better binding affinity. While both have issues with Caco-2 and solubility, these are similar for both. The lower DILI risk and longer half-life of Ligand B are particularly compelling. The slightly better BBB penetration is also a bonus.
Output:
0
2025-04-18 00:03:14,074 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.475 and 372.49 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (67.87) is significantly better than Ligand B (75.27). For a GPCR, keeping TPSA low is beneficial for permeability.
3. **logP:** Ligand A (1.891) is within the optimal range (1-3). Ligand B (3.617) is pushing the upper limit, potentially leading to solubility issues and off-target interactions.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (4) is preferable to Ligand B (3). Lower HBA generally improves permeability.
6. **QED:** Ligand A (0.767) is significantly better than Ligand B (0.575), indicating a more drug-like profile.
7. **DILI:** Ligand A (31.989) has a slightly higher DILI risk than Ligand B (20.24), but both are well below the concerning threshold of 60.
8. **BBB:** Ligand A (68.786) and Ligand B (71.811) are both reasonably good, but not exceptionally high. This isn't a major concern for ADRB2, which isn't a CNS target.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.682 and -4.749), which is unusual and suggests poor permeability. This is a significant drawback for both.
10. **Solubility:** Ligand A (-1.26) is better than Ligand B (-3.438), indicating better aqueous solubility.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.192 and 0.35), which is excellent.
12. **Cl_mic:** Ligand A (31.256) has significantly lower microsomal clearance than Ligand B (83.521), suggesting better metabolic stability.
13. **t1/2:** Ligand A (12.691) has a longer in vitro half-life than Ligand B (-2.93), which is highly desirable.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.036 and 0.183), which is good.
15. **Binding Affinity:** Ligand B (-7.7) has a significantly stronger binding affinity than Ligand A (-5.8). This is a substantial advantage (1.9 kcal/mol difference).
**Overall Assessment:**
Ligand B has a much better binding affinity, which is a critical factor for GPCR targets. However, Ligand A demonstrates superior ADME properties across several key parameters: TPSA, logP, QED, solubility, metabolic stability (Cl_mic), and half-life. The negative Caco-2 values are concerning for both, but the other ADME advantages of Ligand A, coupled with its better QED score, make it the more promising candidate *despite* the weaker binding. The difference in binding affinity, while significant, might be overcome with further optimization of Ligand A, while fixing the poor ADME profile of Ligand B would be more challenging.
Output:
1
2025-04-18 00:03:14,074 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (368.459 Da and 356.413 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (93.65) is slightly higher than Ligand B (66.48). Ligand B is better, being closer to the <90 A^2 threshold for potential CNS penetration, although this is less critical for a cardiovascular target like ADRB2.
3. **logP:** Ligand A (1.037) is at the lower end of the optimal 1-3 range, while Ligand B (2.31) is well within it. Ligand B is preferable as it is more likely to have good membrane permeability.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 7 HBA, while Ligand B has 3. Ligand B is better, as it is closer to the ideal <10.
6. **QED:** Both ligands have good QED scores (0.541 and 0.679), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (56.572) has a higher DILI risk than Ligand B (41.838). Ligand B is preferable.
8. **BBB:** Ligand A (69.717) has lower BBB penetration than Ligand B (87.631). While BBB isn't a primary concern for ADRB2, higher BBB is generally preferable.
9. **Caco-2:** Ligand A (-5.133) has a lower Caco-2 permeability than Ligand B (-4.487). Ligand B is better.
10. **Solubility:** Both ligands have very poor aqueous solubility (-2.238 and -2.687). This is a significant concern for both, but not a deciding factor between them.
11. **hERG:** Both ligands have low hERG inhibition risk (0.167 and 0.212). No significant difference.
12. **Cl_mic:** Ligand A (28.685) has a higher microsomal clearance than Ligand B (15.255). Ligand B is preferable, indicating better metabolic stability.
13. **t1/2:** Ligand A (10.282) has a longer in vitro half-life than Ligand B (-14.994). This is a significant advantage for Ligand A.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.022 and 0.094). No significant difference.
15. **Binding Affinity:** Ligand A (-6.3) has a slightly better binding affinity than Ligand B (-6.0). However, the difference is not substantial enough to outweigh other factors.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity) and the general drug-like properties, Ligand B emerges as the more promising candidate. While Ligand A has a slightly better binding affinity and in vitro half-life, Ligand B demonstrates superior properties in terms of logP, TPSA, DILI risk, Caco-2 permeability, and metabolic stability (Cl_mic). The solubility is poor for both, but this can be addressed through formulation strategies. The combination of these factors makes Ligand B a more balanced and potentially viable drug candidate.
Output:
0
2025-04-18 00:03:14,074 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (363.439 and 353.463 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (84.67) is better than Ligand B (87.74), both are below the 140 threshold for oral absorption, and acceptable for a cardiovascular target.
3. **logP:** Ligand A (4.015) is at the upper end of the optimal range (1-3), while Ligand B (0.681) is quite low. For a GPCR, a higher logP is generally preferred to aid membrane permeability, giving an advantage to Ligand A.
4. **HBD:** Ligand A (1) is better than Ligand B (2). Lower is generally preferred.
5. **HBA:** Ligand A (6) is better than Ligand B (4). Lower is generally preferred.
6. **QED:** Both ligands have similar QED values (0.83 and 0.705), both are above the 0.5 threshold.
7. **DILI:** Ligand A (84.141) has a significantly higher DILI risk than Ligand B (15.2). This is a major concern for Ligand A.
8. **BBB:** Ligand A (77.627) has a better BBB penetration score than Ligand B (50.019). While ADRB2 isn't necessarily a CNS target, some degree of BBB penetration can be beneficial for off-target effects.
9. **Caco-2:** Ligand A (-4.775) and Ligand B (-5.121) both have negative Caco-2 values, indicating poor permeability.
10. **Solubility:** Ligand A (-4.858) and Ligand B (-0.862) both have negative solubility values, indicating poor solubility.
11. **hERG:** Ligand A (0.302) has a lower hERG risk than Ligand B (0.089). This is a positive for Ligand A.
12. **Cl_mic:** Ligand A (108.347) has a higher microsomal clearance than Ligand B (8.858), indicating lower metabolic stability. This is a negative for Ligand A.
13. **t1/2:** Ligand B (10.292) has a significantly longer in vitro half-life than Ligand A (2.431). This is a major advantage for Ligand B.
14. **Pgp:** Ligand A (0.188) has a lower P-gp efflux liability than Ligand B (0.009), which is better.
15. **Affinity:** Both ligands have very similar binding affinities (-6.3 and -6.1 kcal/mol). The difference is negligible.
**Overall Assessment:**
Ligand A has advantages in logP, Pgp, and hERG, but is significantly hampered by its high DILI risk, poor metabolic stability (high Cl_mic, short t1/2), and poor solubility. Ligand B has a much better safety profile (low DILI), better metabolic stability (low Cl_mic, long t1/2), and better solubility, despite a lower logP. The similar affinities make the ADME/Tox profile the deciding factor. Given the cardiovascular target, minimizing liver toxicity and maximizing metabolic stability are crucial.
Output:
0
2025-04-18 00:03:14,074 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
The target is ADRB2, a GPCR. Therefore, I will prioritize logP, TPSA, Pgp efflux, BBB penetration, and binding affinity, while also considering general drug-like properties and safety parameters.
* **Molecular Weight:** Both ligands (349.435 and 346.387 Da) fall within the ideal 200-500 Da range.
* **TPSA:** Ligand A (104.29) is better than Ligand B (122.55), being closer to the <140 threshold for good oral absorption.
* **logP:** Both ligands have acceptable logP values (0.524 and 0.454), falling within the 1-3 range, but are on the lower end.
* **H-Bond Donors/Acceptors:** Ligand A (2 HBD, 5 HBA) is slightly better than Ligand B (4 HBD, 5 HBA) as it has fewer HBDs, potentially improving permeability.
* **QED:** Ligand A (0.712) has a higher QED score than Ligand B (0.577), indicating a more drug-like profile.
* **DILI:** Ligand A (39.589) has a significantly lower DILI risk than Ligand B (67.119), which is a major advantage.
* **BBB:** Ligand A (43.389) has a lower BBB penetration than Ligand B (62.544). While ADRB2 isn't necessarily a CNS target, some peripheral ADRB2 receptors can be affected by CNS penetration.
* **Caco-2 Permeability:** Both ligands have negative Caco-2 values (-5.408 and -5.478), which is unusual and suggests poor permeability.
* **Aqueous Solubility:** Both ligands have very poor aqueous solubility (-1.077 and -3.053).
* **hERG:** Both ligands have very low hERG inhibition liability (0.167 and 0.197), which is excellent.
* **Microsomal Clearance:** Ligand B (-4.178) has a *negative* microsomal clearance, which is not physically possible and indicates a data error or unusual behavior. Ligand A (14.74) is more reasonable.
* **In vitro Half-Life:** Ligand A (20.615) has a longer in vitro half-life than Ligand B (-15.896). Again, the negative value for Ligand B is concerning.
* **P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.014 and 0.008), which is favorable.
* **Binding Affinity:** Ligand B (-6.8 kcal/mol) has a slightly better binding affinity than Ligand A (-5.4 kcal/mol). This is a 1.4 kcal/mol difference, which is substantial.
**Overall Assessment:**
Despite the slightly better binding affinity of Ligand B, the significantly higher DILI risk, negative values for microsomal clearance and half-life, and lower QED make it a less desirable candidate. The negative values for clearance and half-life are particularly concerning and suggest potential data quality issues. Ligand A, while having lower binding affinity, presents a much more favorable ADMET profile, especially regarding safety (DILI) and metabolic stability. The TPSA and QED are also better for Ligand A. The poor Caco-2 and solubility are concerns for both, but can be addressed with formulation strategies.
**Output:**
1
2025-04-18 00:03:14,074 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (370.431 and 342.399 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (106.71) is slightly higher than Ligand B (98.32), but both are below the 140 threshold for good oral absorption. Ligand B is better.
3. **logP:** Ligand B (1.327) is slightly better than Ligand A (0.644), falling more squarely within the optimal 1-3 range. Ligand A is a bit low, potentially hindering permeation.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (7) is preferable to Ligand B (4). Lower HBA generally improves permeability.
6. **QED:** Ligand B (0.78) has a higher QED score than Ligand A (0.558), indicating a more drug-like profile.
7. **DILI:** Ligand B (62.35) has a lower DILI risk than Ligand A (74.215), which is a significant advantage.
8. **BBB:** Ligand A (82.474) has a significantly higher BBB penetration score than Ligand B (17.371). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be beneficial or at least not detrimental.
9. **Caco-2:** Ligand B (-5.421) has a more negative Caco-2 value, suggesting better intestinal absorption than Ligand A (-4.881).
10. **Solubility:** Ligand B (-2.942) has a slightly better solubility score than Ligand A (-3.153).
11. **hERG:** Both ligands have very low hERG inhibition risk (0.216 and 0.253). No significant difference.
12. **Cl_mic:** Ligand B (-21.557) has a much lower microsomal clearance than Ligand A (36.793), indicating better metabolic stability. This is a major advantage.
13. **t1/2:** Ligand B (12.841) has a longer in vitro half-life than Ligand A (5.516), suggesting less frequent dosing potential.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.08 and 0.057). No significant difference.
15. **Binding Affinity:** Ligand A (-6.8 kcal/mol) has a slightly better binding affinity than Ligand B (-5.9 kcal/mol). This is a 0.9 kcal/mol difference, which is a notable, but not overwhelming, advantage.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP, TPSA, and significantly in metabolic stability (Cl_mic and t1/2), and has a good DILI profile. While Ligand A has slightly better affinity and BBB penetration, the improvements in ADME properties with Ligand B are more compelling for overall drug development potential. The affinity difference is not large enough to overcome the ADME advantages of Ligand B.
**Conclusion:**
Ligand B presents a more balanced and favorable profile for drug development, particularly considering its improved metabolic stability, lower DILI risk, and better absorption characteristics.
Output:
0
2025-04-18 00:03:14,074 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (349.5 and 366.8 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (61.44) is significantly better than Ligand B (85.77). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is approaching a level that could hinder absorption.
**3. logP:** Ligand A (2.164) is within the optimal 1-3 range. Ligand B (0.378) is quite low, potentially leading to poor membrane permeability and bioavailability.
**4. H-Bond Donors:** Both have 2 HBD, which is acceptable.
**5. H-Bond Acceptors:** Ligand A has 3 HBA, Ligand B has 5. Both are acceptable, but Ligand A is slightly better.
**6. QED:** Both ligands have similar QED values (0.74 and 0.786), indicating good drug-like properties.
**7. DILI:** Ligand A (5.196) has a much lower DILI risk than Ligand B (28.461). This is a significant advantage for Ligand A.
**8. BBB:** Ligand A (84.257) has a much higher BBB penetration percentile than Ligand B (30.787). While ADRB2 is cardiovascular, some CNS effects are possible with certain ligands, and higher BBB penetration isn't necessarily detrimental.
**9. Caco-2:** Both have negative Caco-2 values (-4.955 and -5.025). This is unusual and suggests poor permeability in this assay. However, the values are very similar.
**10. Solubility:** Ligand A (-2.67) has slightly better solubility than Ligand B (-1.618), but both are poor.
**11. hERG:** Ligand A (0.622) has a lower hERG risk than Ligand B (0.113). This is a crucial advantage, as hERG inhibition can lead to cardiotoxicity.
**12. Cl_mic:** Ligand A (0.92) has significantly better metabolic stability (lower clearance) than Ligand B (-43.083). This is a major advantage.
**13. t1/2:** Ligand A (7.343) has a better in vitro half-life than Ligand B (23.785).
**14. Pgp:** Ligand A (0.017) has lower P-gp efflux than Ligand B (0.012). Both are very low, so this difference is minimal.
**15. Binding Affinity:** Ligand B (-8.0) has a slightly better binding affinity than Ligand A (-6.2). However, the difference is not large enough to overcome the substantial ADME deficiencies of Ligand B.
**Overall Assessment:**
Ligand A is significantly superior to Ligand B. While Ligand B has slightly better binding affinity, Ligand A demonstrates a much more favorable ADME profile, with lower DILI risk, better metabolic stability, better BBB penetration, and a lower hERG risk. The low logP of Ligand B is a major concern, potentially leading to poor absorption and bioavailability. The substantial differences in DILI and Cl_mic are particularly important.
Output:
1
2025-04-18 00:03:14,074 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.431 and 350.503 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (84.42) is higher than Ligand B (58.64). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B is better.
3. **logP:** Ligand A (1.207) is within the optimal range (1-3), while Ligand B (2.878) is towards the higher end but still acceptable. Ligand A is slightly better.
4. **HBD:** Both ligands have 1 HBD, which is good. No difference.
5. **HBA:** Ligand A has 5 HBA, Ligand B has 3. Both are acceptable (<=10). Ligand B is slightly better.
6. **QED:** Both ligands have similar QED scores (0.866 and 0.801), indicating good drug-likeness. No significant difference.
7. **DILI:** Ligand A (34.432) has a slightly higher DILI risk than Ligand B (29.43). Ligand B is better.
8. **BBB:** Ligand B (81.388) has a significantly higher BBB penetration percentile than Ligand A (66.964). While ADRB2 isn't a CNS target, some degree of BBB penetration can influence off-target effects and distribution. Ligand B is better.
9. **Caco-2:** Ligand A (-5.109) and Ligand B (-4.756) both have negative values, which is unusual and likely indicates poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-1.009) has better solubility than Ligand B (-3.721). Solubility is important for bioavailability. Ligand A is better.
11. **hERG:** Ligand A (0.076) has a much lower hERG inhibition liability than Ligand B (0.411). This is a critical advantage for Ligand A, as hERG inhibition can lead to cardiotoxicity.
12. **Cl_mic:** Ligand A (-1.218) has a lower (better) microsomal clearance than Ligand B (56.72). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (7.906) has a longer in vitro half-life than Ligand B (-4.205). This is a significant advantage, suggesting less frequent dosing could be possible.
14. **Pgp:** Ligand A (0.008) has much lower P-gp efflux liability than Ligand B (0.29). Lower Pgp efflux is desirable for better oral bioavailability.
15. **Binding Affinity:** Ligand B (-7.5) has a stronger binding affinity than Ligand A (-6.7). This is a 0.8 kcal/mol difference, which is substantial and could potentially outweigh some ADME drawbacks.
**Overall Assessment:**
While Ligand B has a better binding affinity, Ligand A demonstrates a significantly superior ADME profile. Specifically, the lower hERG inhibition, lower Cl_mic, longer t1/2, and lower Pgp efflux are crucial advantages for a cardiovascular drug candidate. The slightly higher DILI risk for Ligand A is less concerning than the potential cardiotoxicity risk associated with Ligand B's hERG inhibition. The solubility of Ligand A is also preferable. The Caco-2 values are poor for both, but can be addressed in formulation. The affinity difference, while notable, isn't so large that it completely overrides the ADME benefits of Ligand A.
Output:
1
2025-04-18 00:03:14,074 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's systematically compare Ligand A and Ligand B based on the provided parameters and the guidelines, keeping in mind ADRB2 is a GPCR.
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (383.319) is slightly higher than Ligand B (352.435), but both are acceptable.
2. **TPSA:** Ligand A (61.36) is significantly better than Ligand B (94.48). For a GPCR, lower TPSA is generally preferred for better permeability. Ligand B is approaching a level that could hinder oral absorption.
3. **logP:** Ligand A (4.234) is higher than Ligand B (0.722). While logP > 4 can be problematic, it's not a hard cutoff. Ligand B's logP is quite low, potentially leading to poor membrane permeability.
4. **H-Bond Donors:** Both have acceptable HBD counts (Ligand A: 3, Ligand B: 2).
5. **H-Bond Acceptors:** Ligand A (2) is better than Ligand B (6). Lower HBA is preferable for permeability.
6. **QED:** Both ligands have similar and acceptable QED values (Ligand A: 0.729, Ligand B: 0.683).
7. **DILI:** Ligand A (18.379) has a much lower DILI risk than Ligand B (58.976). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (74.176) has a better BBB penetration percentile than Ligand B (43.893). While ADRB2 isn't exclusively a CNS target, some peripheral ADRB2 activity can be modulated by CNS effects, and better BBB penetration isn't detrimental.
9. **Caco-2:** Ligand A (-4.596) is better than Ligand B (-5.278), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-4.327) is better than Ligand B (-1.591).
11. **hERG:** Ligand A (0.669) is better than Ligand B (0.22). Lower hERG inhibition is crucial for avoiding cardiotoxicity, a major concern with cardiovascular targets.
12. **Cl_mic:** Ligand A (-3.012) has a lower (better) microsomal clearance than Ligand B (13.891), suggesting greater metabolic stability.
13. **t1/2:** Ligand A (30.796) has a longer in vitro half-life than Ligand B (34.367).
14. **Pgp:** Ligand A (0.272) has lower P-gp efflux than Ligand B (0.024), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand A (-7.2) has a slightly better binding affinity than Ligand B (-5.3). The difference is 1.9 kcal/mol, which is substantial enough to outweigh some of the ADME differences.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most key ADME properties (TPSA, logP, DILI, BBB, solubility, hERG, Cl_mic, Pgp) and has a slightly better binding affinity. Ligand B's low logP and higher DILI risk are significant drawbacks. While Ligand A's logP is on the higher side, the overall balance of properties makes it a more promising drug candidate.
**Output:**
1
2025-04-18 00:03:14,075 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**1. Molecular Weight:** Both ligands (350.419 and 350.434 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (87.91) is slightly higher than Ligand B (78.43). Both are below the 140 A^2 threshold for good oral absorption, but Ligand B is closer to the preferred <90 A^2 for GPCRs, suggesting potentially better permeability.
**3. logP:** Ligand A (0.66) is a bit low, potentially hindering permeation. Ligand B (2.63) is within the optimal 1-3 range. This is a significant advantage for Ligand B.
**4. H-Bond Donors:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
**5. H-Bond Acceptors:** Ligand A (6) is higher than Ligand B (3). Lower HBA is generally preferred for better permeability.
**6. QED:** Both ligands have similar QED values (0.727 and 0.738), indicating good drug-like properties.
**7. DILI:** Both ligands have low DILI risk (36.099 and 38.193 percentile), which is good. No major difference.
**8. BBB:** Both ligands have similar BBB penetration (64.986 and 65.374 percentile). While not exceptionally high, it's acceptable for a peripherally acting GPCR like ADRB2.
**9. Caco-2 Permeability:** Ligand A (-4.894) shows better Caco-2 permeability than Ligand B (-4.51).
**10. Aqueous Solubility:** Ligand A (-0.804) has better aqueous solubility than Ligand B (-3.473). Solubility is crucial for bioavailability.
**11. hERG Inhibition:** Ligand A (0.153) has a much lower hERG inhibition risk than Ligand B (0.581). This is a critical safety parameter, and Ligand A is significantly better.
**12. Microsomal Clearance:** Ligand A (14.799) has a lower microsomal clearance than Ligand B (49.817), indicating better metabolic stability.
**13. In vitro Half-Life:** Ligand B (16.254) has a longer in vitro half-life than Ligand A (1.623). This is a positive for Ligand B, potentially allowing for less frequent dosing.
**14. P-gp Efflux:** Ligand A (0.009) has significantly lower P-gp efflux than Ligand B (0.285), which is favorable for bioavailability.
**15. Binding Affinity:** Ligand B (-7.2 kcal/mol) has a stronger binding affinity than Ligand A (-6.7 kcal/mol). This is a 0.5 kcal/mol difference, which is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand B is slightly favored due to its superior logP and binding affinity. However, Ligand A has a much better safety profile (hERG) and metabolic stability (Cl_mic). The improved solubility and lower P-gp efflux of Ligand A are also beneficial. The significant advantage in binding affinity for Ligand B is the deciding factor, despite the drawbacks.
Output:
0
2025-04-18 00:03:14,075 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [364.433, 67.87, 2.174, 1, 4, 0.603, 23.769, 92.672, -4.472, -1.564, 0.517, 14.089, -4.105, 0.046, -7.6]
**Ligand B:** [351.422, 82.53, 1.659, 2, 4, 0.783, 31.291, 71.811, -4.613, -1.927, 0.485, 20.147, -9.2, 0.089, -5.8]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, Affinity, and BBB):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (351.422) is slightly lower, which is generally favorable.
2. **TPSA:** Ligand A (67.87) is better than Ligand B (82.53), falling well under the 140 A^2 threshold for oral absorption.
3. **logP:** Both are good (between 1-3), with Ligand A (2.174) being slightly higher, potentially aiding membrane permeability.
4. **HBD/HBA:** Both have acceptable numbers of HBD/HBA.
5. **QED:** Both have acceptable QED scores, with Ligand B (0.783) being slightly better.
6. **DILI:** Ligand A (23.769) has a significantly lower DILI risk than Ligand B (31.291), a crucial advantage.
7. **BBB:** Ligand A (92.672) has a much higher BBB penetration percentile than Ligand B (71.811). While ADRB2 isn't a CNS target, some degree of BBB penetration can be useful for off-target profiling and understanding distribution.
8. **Caco-2:** Both are negative, indicating poor permeability.
9. **Solubility:** Both are negative, indicating poor solubility.
10. **hERG:** Both have low hERG inhibition liability.
11. **Cl_mic:** Ligand A (14.089) has a lower microsomal clearance, suggesting better metabolic stability.
12. **t1/2:** Ligand A (-4.105) has a better (longer) in vitro half-life.
13. **Pgp:** Both have low P-gp efflux liability.
14. **Affinity:** Ligand A (-7.6 kcal/mol) has a significantly stronger binding affinity than Ligand B (-5.8 kcal/mol). This is a substantial advantage, exceeding the 1.5 kcal/mol difference threshold.
**Overall Assessment:**
Ligand A clearly outperforms Ligand B. The most significant factors are the substantially stronger binding affinity (-7.6 vs -5.8 kcal/mol), lower DILI risk, better metabolic stability (lower Cl_mic, longer t1/2), and higher BBB penetration. While both have issues with Caco-2 and solubility, the potency and safety profile of Ligand A are far superior. The better TPSA and logP also contribute to its favorability.
Output:
1
2025-04-18 00:03:14,075 - INFO - Batch 449 complete. Total preferences: 7184
2025-04-18 00:03:14,075 - INFO - Processing batch 450/512...
2025-04-18 00:04:06,026 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [363.751, 67.15, 4.07, 2, 4, 0.737, 92.982, 37.495, -4.803, -4.752, 0.381, 76.668, -0.748, 0.435, -6]**
**Ligand B: [341.371, 112.95, 1.192, 2, 6, 0.819, 61.07, 53.819, -5.091, -3.627, 0.101, 3.097, 31.236, 0.038, -7.2]**
1. **Molecular Weight:** Both are within the ideal range (200-500 Da). Ligand B (341.371) is slightly lower, which could be beneficial for permeability, but both are acceptable.
2. **TPSA:** Ligand A (67.15) is significantly better than Ligand B (112.95). A TPSA under 140 is good for oral absorption, but lower is generally preferred for GPCRs. Ligand A is much closer to the ideal range for GPCRs.
3. **logP:** Ligand A (4.07) is a bit high, potentially leading to solubility issues or off-target interactions. Ligand B (1.192) is quite low, potentially hindering membrane permeability. The optimal range is 1-3, and Ligand A is pushing the upper limit.
4. **H-Bond Donors:** Both have 2 HBD, which is within the acceptable limit of 5.
5. **H-Bond Acceptors:** Ligand A (4) is better than Ligand B (6). Lower HBA is generally preferred for better permeability.
6. **QED:** Both have good QED scores (A: 0.737, B: 0.819), indicating good drug-like properties. Ligand B is slightly better here.
7. **DILI:** Ligand A (92.982) has a very high DILI risk, which is a major red flag. Ligand B (61.07) is still above the preferred <40, but significantly lower and less concerning.
8. **BBB:** Ligand A (37.495) has poor BBB penetration, while Ligand B (53.819) is better, though still not ideal. For a cardiovascular target like ADRB2, BBB penetration isn't *critical* but can be beneficial for certain therapeutic strategies.
9. **Caco-2 Permeability:** Both have negative Caco-2 values, indicating poor permeability. Ligand A (-4.803) is slightly worse than Ligand B (-5.091).
10. **Aqueous Solubility:** Ligand A (-4.752) and Ligand B (-3.627) both have poor solubility.
11. **hERG Inhibition:** Ligand A (0.381) is slightly better than Ligand B (0.101), indicating lower cardiotoxicity risk.
12. **Microsomal Clearance:** Ligand A (76.668) has higher clearance, suggesting lower metabolic stability. Ligand B (3.097) has a much lower clearance, indicating better metabolic stability.
13. **In vitro Half-Life:** Ligand B (31.236) has a significantly longer half-life than Ligand A (-0.748).
14. **P-gp Efflux:** Ligand A (0.435) has lower P-gp efflux, which is favorable. Ligand B (0.038) has very low P-gp efflux.
15. **Binding Affinity:** Ligand B (-7.2) has a significantly stronger binding affinity than Ligand A (-6). This is a substantial advantage.
**Overall Assessment:**
Ligand A suffers from a very high DILI risk, poor metabolic stability, and relatively weak binding affinity. While it has slightly better P-gp efflux, this is overshadowed by its significant drawbacks. Ligand B, despite having a lower logP and Caco-2 permeability, has a much better safety profile (lower DILI), superior metabolic stability, longer half-life, and, crucially, significantly higher binding affinity. The stronger binding affinity of Ligand B is a major advantage for a GPCR target, and can potentially compensate for the lower logP.
Therefore, Ligand B is the more promising candidate.
Output:
0
2025-04-18 00:04:06,026 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [368.587, 49.41, 3.701, 1, 3, 0.64, 19.349, 83.249, -5.083, -4.042, 0.719, 92.352, -13.037, 0.327, -6.3]
**Ligand B:** [345.487, 73.2, 3.172, 1, 3, 0.752, 13.416, 70.686, -4.714, -3.197, 0.518, 42.027, -18.894, 0.095, -6.5]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity, and BBB):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (345.487) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (49.41) is significantly better than Ligand B (73.2). ADRB2 is not a CNS target, but lower TPSA generally improves absorption. Ligand B's TPSA is getting high.
3. **logP:** Both are good (around 3), falling within the optimal 1-3 range. Ligand A (3.701) is slightly higher, which could potentially lead to off-target effects, but is still acceptable.
4. **HBD/HBA:** Both have 1 HBD and 3 HBA, which is acceptable.
5. **QED:** Both are reasonable (0.64 and 0.752), indicating good drug-like properties. Ligand B is slightly better.
6. **DILI:** Ligand A (19.349) has a higher DILI risk than Ligand B (13.416). This is a significant negative for Ligand A.
7. **BBB:** Ligand A (83.249) has better BBB penetration than Ligand B (70.686), but BBB isn't a primary concern for a cardiovascular target.
8. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. Ligand A (-5.083) is worse than Ligand B (-4.714).
9. **Solubility:** Both have negative solubility values, indicating poor solubility. Ligand B (-3.197) is slightly better than Ligand A (-4.042).
10. **hERG:** Both have low hERG risk (0.719 and 0.518).
11. **Cl_mic:** Ligand A (92.352) has a higher microsomal clearance than Ligand B (42.027), indicating lower metabolic stability. This is a significant negative for Ligand A.
12. **t1/2:** Ligand B (-18.894) has a longer in vitro half-life than Ligand A (-13.037). This is favorable for Ligand B.
13. **Pgp:** Ligand A (0.327) has lower P-gp efflux than Ligand B (0.095), which is good.
14. **Affinity:** Both have comparable binding affinity (-6.3 and -6.5 kcal/mol). The difference is negligible.
**Overall Assessment:**
Ligand B is the better candidate. While Ligand A has slightly better BBB penetration and Pgp efflux, Ligand B excels in critical areas: lower DILI risk, better metabolic stability (lower Cl_mic), longer half-life, and slightly better solubility. The TPSA is also significantly lower for Ligand B. The comparable binding affinity makes these ADME properties the deciding factors.
Output:
0
2025-04-18 00:04:06,026 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (344.37 and 353.37 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand B (101.29) is better than Ligand A (113.86), being closer to the <140 threshold for good oral absorption. This is a slight advantage for B.
3. **logP:** Ligand B (0.97) is slightly lower than Ligand A (0.61), but both are a little below the optimal 1-3 range. Ligand B is marginally better, but both could benefit from increased lipophilicity.
4. **HBD:** Ligand B (3) is preferable to Ligand A (4) as lower HBD generally improves permeability.
5. **HBA:** Ligand B (3) is preferable to Ligand A (4) for the same reason as HBD.
6. **QED:** Both ligands have similar QED values (0.651 and 0.607), indicating good drug-likeness.
7. **DILI:** Ligand B (35.6%) has a significantly lower DILI risk than Ligand A (56.5%). This is a substantial advantage for B.
8. **BBB:** Ligand B (83.99%) has a much higher BBB penetration score than Ligand A (21.33%). Given ADRB2's involvement in cardiovascular function, CNS penetration isn't *critical* but can be beneficial for potential off-target effects or peripheral modulation. This is a significant advantage for B.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.521 and -5.226), which is unusual and suggests poor permeability. However, the values are very close.
10. **Solubility:** Ligand B (-3.249) is slightly better than Ligand A (-2.441) in terms of aqueous solubility, though both are poor.
11. **hERG:** Ligand B (0.33) has a lower hERG inhibition liability than Ligand A (0.065), indicating a lower risk of cardiotoxicity. This is a significant advantage for B.
12. **Cl_mic:** Ligand A (-37.743) has a much lower (better) microsomal clearance than Ligand B (13.429), suggesting greater metabolic stability. This is a substantial advantage for A.
13. **t1/2:** Ligand B (-17.414) has a longer in vitro half-life than Ligand A (-10.838), which is generally desirable. This is an advantage for B.
14. **Pgp:** Ligand B (0.017) has a lower P-gp efflux liability than Ligand A (0.002), indicating better bioavailability. This is a slight advantage for B.
15. **Binding Affinity:** Ligand A (-7.3 kcal/mol) has a slightly better binding affinity than Ligand B (-6.2 kcal/mol), a difference of 1.1 kcal/mol. While this is a notable difference, it must be weighed against the other ADME properties.
**Overall Assessment:**
Ligand B consistently outperforms Ligand A in several critical ADME properties, including DILI risk, BBB penetration, hERG inhibition, and P-gp efflux. While Ligand A has better metabolic stability (Cl_mic) and slightly better binding affinity, the improvements in safety (DILI, hERG) and potential bioavailability (BBB, Pgp) offered by Ligand B are more compelling for a cardiovascular target. The affinity difference, while present, isn't large enough to overcome the ADME advantages of Ligand B.
Output:
0
2025-04-18 00:04:06,026 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
We are targeting ADRB2, a GPCR, so the priorities are logP, Pgp, TPSA, affinity, and BBB. Let's break down the comparison:
1. **Molecular Weight:** Both ligands (349.3 and 341.3 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (103.65) is better than Ligand B (126.88). Lower TPSA generally favors better absorption, a key consideration for oral bioavailability.
3. **logP:** Ligand A (1.9) is within the optimal range (1-3), while Ligand B (-0.185) is below 1. This is a significant drawback for Ligand B, as it may struggle with membrane permeability.
4. **H-Bond Donors/Acceptors:** Ligand A (2 HBD, 7 HBA) is preferable to Ligand B (4 HBD, 4 HBA). While both are acceptable, fewer H-bonds generally improve permeability.
5. **QED:** Ligand A (0.678) has a better QED score than Ligand B (0.405), indicating a more drug-like profile.
6. **DILI:** Ligand B (61.846) has a slightly better DILI score than Ligand A (79.992), but both are acceptable.
7. **BBB:** Ligand A (69.213) has a significantly better BBB penetration score than Ligand B (19.038). While ADRB2 isn't exclusively a CNS target, some CNS exposure can occur, and higher BBB penetration is generally favorable.
8. **Caco-2 Permeability:** Both ligands have negative Caco-2 values (-5.364 and -5.48), which is unusual and suggests poor permeability. However, these values are on the same scale, so it doesn't differentiate them.
9. **Aqueous Solubility:** Both ligands have negative solubility values (-2.767 and -3.038), which also suggests poor solubility. Again, these are similar.
10. **hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.345 and 0.148).
11. **Microsomal Clearance:** Ligand B (-13.314) has a much lower (better) microsomal clearance than Ligand A (13.791), suggesting greater metabolic stability.
12. **In vitro Half-Life:** Ligand A (43.331) has a better in vitro half-life than Ligand B (13.065).
13. **P-gp Efflux:** Ligand A (0.12) has a lower P-gp efflux liability than Ligand B (0.037), which is desirable.
14. **Binding Affinity:** Ligand B (-7.1 kcal/mol) has a slightly better binding affinity than Ligand A (-6.9 kcal/mol). While a 0.2 kcal/mol difference isn't huge, it's a positive for Ligand B.
**Overall Assessment:**
Ligand A is the stronger candidate. While Ligand B has slightly better affinity and metabolic stability, Ligand A excels in crucial areas for a GPCR target: logP, TPSA, QED, and BBB penetration. The significantly better logP and TPSA of Ligand A are likely to translate to better absorption and bioavailability, outweighing the small affinity advantage of Ligand B.
**Output:**
1
2025-04-18 00:04:06,026 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (356.373 and 378.523 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (76.46) is slightly higher than Ligand B (66.4). Both are below the 140 threshold for oral absorption, but closer to the 90 threshold for CNS targets. This isn't a major concern for a cardiovascular target like ADRB2.
3. **logP:** Both ligands have very similar logP values (2.618 and 2.604), falling within the optimal 1-3 range.
4. **HBD:** Ligand A has 1 HBD, while Ligand B has 0. Both are acceptable.
5. **HBA:** Ligand A has 5 HBA, and Ligand B has 6. Both are below the 10 threshold.
6. **QED:** Ligand A (0.884) has a slightly better QED score than Ligand B (0.802), indicating a more drug-like profile.
7. **DILI:** Ligand B (53.432) has a significantly lower DILI risk than Ligand A (64.754). This is a substantial advantage for Ligand B.
8. **BBB:** Both ligands have high BBB penetration (87.747 and 83.908). While ADRB2 isn't strictly a CNS target, some CNS exposure can be a concern for off-target effects. This isn't a deciding factor.
9. **Caco-2:** Ligand B (-5.022) shows better Caco-2 permeability than Ligand A (-4.251). This suggests better intestinal absorption for Ligand B.
10. **Solubility:** Ligand B (-3.177) has better aqueous solubility than Ligand A (-4.373). Better solubility is generally desirable for bioavailability.
11. **hERG:** Both ligands have low hERG inhibition risk (0.264 and 0.373). No significant difference.
12. **Cl_mic:** Ligand B (54.623) has a lower microsomal clearance than Ligand A (64.48), indicating better metabolic stability.
13. **t1/2:** Ligand B (18.32) has a significantly longer in vitro half-life than Ligand A (-10.97). This is a major advantage for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.056) has lower P-gp efflux than Ligand B (0.445). Lower P-gp efflux is generally desirable.
15. **Binding Affinity:** Ligand B (-6.3) has a slightly better binding affinity than Ligand A (-5.9). While the difference is not huge, it is still a positive for Ligand B.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Both ligands perform well on logP and TPSA. Ligand B has a slight edge in affinity. Ligand A has a slight edge in Pgp. However, Ligand B excels in ADME properties like DILI risk, Caco-2 permeability, solubility, and especially metabolic stability (Cl_mic and t1/2).
**Overall Assessment:**
While Ligand A has a slightly better QED and Pgp profile, Ligand B demonstrates a significantly more favorable ADME profile, particularly regarding DILI risk, solubility, metabolic stability, and half-life. The slightly better binding affinity of Ligand B further strengthens its position. Given the importance of ADME properties in drug development, and the relatively small difference in binding affinity, Ligand B is the more promising candidate.
Output:
0
2025-04-18 00:04:06,026 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.4 and 344.5 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (92.01) is slightly higher than Ligand B (81.66). Both are below the 140 threshold for oral absorption, but B is better positioned for potential CNS penetration if desired (though ADRB2 is primarily cardiovascular).
3. **logP:** Ligand B (2.833) is better than Ligand A (0.564). A logP between 1-3 is optimal, and A is quite low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable, below the 5 threshold.
5. **HBA:** Ligand A (5) and Ligand B (7) are both acceptable, below the 10 threshold.
6. **QED:** Both ligands have similar QED values (0.733 and 0.714), indicating good drug-likeness.
7. **DILI:** Both ligands have similar DILI risk (35.17 and 37.61), both of which are low and acceptable.
8. **BBB:** Ligand B (69.833) has a significantly higher BBB penetration percentile than Ligand A (24.661). While ADRB2 is cardiovascular, some CNS off-target effects are always a consideration, and higher BBB is generally preferable.
9. **Caco-2:** Ligand A (-4.701) and Ligand B (-5.59) are both negative, indicating poor permeability. This is concerning for both, but B is slightly worse.
10. **Solubility:** Ligand A (-1.499) is slightly better than Ligand B (-2.623), but both are poor. Solubility could be a formulation challenge for both.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.24 and 0.173), which is excellent.
12. **Cl_mic:** Ligand A (-14.666) has a much lower (better) microsomal clearance than Ligand B (42.134). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand B (-8.086) has a much longer in vitro half-life than Ligand A (2.044). This is a significant advantage for B, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.16 and 0.344).
15. **Binding Affinity:** Ligand B (-7.4) has a slightly better binding affinity than Ligand A (-6.2). This 1.2 kcal/mol difference is substantial and can outweigh some ADME drawbacks.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP and affinity, and has a better BBB score. While Ligand A has better metabolic stability (Cl_mic), the affinity difference and logP of Ligand B are more critical for a GPCR target. The slightly longer half-life of Ligand B is also a benefit.
**Conclusion:**
Despite the slightly poorer Caco-2 and solubility of Ligand B, its superior logP, binding affinity, and BBB penetration, combined with acceptable ADME properties, make it the more promising drug candidate for the ADRB2 receptor.
Output:
0
2025-04-18 00:04:06,027 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.362 and 346.431 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (104.46) is higher than Ligand B (74.77). For a cardiovascular GPCR like ADRB2, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B has a clear advantage.
3. **logP:** Ligand A (1.717) and Ligand B (0.785) are both within the optimal 1-3 range, but Ligand B is on the lower end. Ligand A is better here.
4. **HBD:** Ligand A (3) is higher than Ligand B (1). Lower HBD is generally preferable for permeability, giving Ligand B an edge.
5. **HBA:** Both ligands have 5 HBA, so no difference.
6. **QED:** Both ligands have similar QED scores (0.706 and 0.739), indicating good drug-likeness.
7. **DILI:** Ligand B (37.224) has a significantly lower DILI risk than Ligand A (52.617). This is a substantial advantage for Ligand B.
8. **BBB:** Both ligands have moderate BBB penetration (44.242 and 49.67). Since ADRB2 is not a CNS target, this is not a major factor.
9. **Caco-2:** Ligand A (-5.114) is worse than Ligand B (-4.59). Lower negative values indicate better permeability, giving Ligand B an advantage.
10. **Solubility:** Ligand A (-2.795) is worse than Ligand B (-0.749). Higher values are better, so Ligand B is preferred.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.231 and 0.184), which is excellent.
12. **Cl_mic:** Ligand B (-9.173) has a much lower (better) microsomal clearance than Ligand A (7.35). This suggests better metabolic stability for Ligand B.
13. **t1/2:** Ligand B (-3.207) has a longer half-life than Ligand A (11.727). This is a significant advantage for Ligand B.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.03 and 0.01), which is excellent.
15. **Binding Affinity:** Ligand B (-6.1 kcal/mol) has a slightly better binding affinity than Ligand A (-4.9 kcal/mol). This 1.2 kcal/mol difference is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand B consistently outperforms Ligand A in several crucial ADME properties (DILI, Caco-2, Solubility, Cl_mic, t1/2) and has a better binding affinity. While Ligand A has a slightly better logP, the overall profile of Ligand B is more favorable for drug development, particularly considering the GPCR target class. The lower DILI risk and improved metabolic stability are particularly compelling.
Output:
0
2025-04-18 00:04:06,027 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (342.483 and 364.467 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (58.2) is significantly better than Ligand B (75.71). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (3.446 and 2.12), falling within the optimal 1-3 range. Ligand A is slightly higher, which *could* be beneficial for membrane permeability, but isn't a major concern.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1), but both are well within the acceptable limit of 5.
5. **HBA:** Ligand A (2) is lower than Ligand B (5). This is a positive for Ligand A, as fewer hydrogen bond acceptors can improve permeability.
6. **QED:** Ligand A (0.76) has a significantly better QED score than Ligand B (0.392), indicating a more drug-like profile.
7. **DILI:** Ligand A (26.444) has a much lower DILI risk than Ligand B (39.667). This is a crucial advantage, as minimizing liver toxicity is paramount.
8. **BBB:** Not a primary concern for a cardiovascular target. Ligand A (75.107) is higher than Ligand B (57.154), but this is less important.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.672 and -4.812), which is unusual and suggests poor permeability. This is a significant drawback for both.
10. **Solubility:** Ligand A (-3.953) is slightly better than Ligand B (-2.171), indicating better aqueous solubility, which is important for bioavailability.
11. **hERG:** Ligand A (0.647) has a slightly lower hERG risk than Ligand B (0.243), which is favorable.
12. **Cl_mic:** Both ligands have similar microsomal clearance values (56.449 and 57.786), indicating similar metabolic stability.
13. **t1/2:** Ligand A (-5.112) has a significantly longer in vitro half-life than Ligand B (4.059). This is a major advantage, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.27) has a lower P-gp efflux liability than Ligand B (0.104), which is beneficial for oral bioavailability.
15. **Binding Affinity:** Both ligands have comparable binding affinities (-7.0 and -6.0 kcal/mol). The difference of 1 kcal/mol isn't enough to outweigh the other advantages of Ligand A.
**GPCR-specific priorities:** For GPCRs, logP, TPSA, Pgp, and affinity are key. Ligand A is better on TPSA, Pgp, and has a better overall ADME profile. The affinity difference is minimal.
**Conclusion:**
Ligand A consistently outperforms Ligand B across several critical ADME properties (DILI, QED, solubility, t1/2, Pgp) and has a more favorable TPSA. While both have poor Caco-2 permeability, the other advantages of Ligand A make it the more promising drug candidate.
Output:
1
2025-04-18 00:04:06,027 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (378.401 and 358.389 Da). No clear advantage.
2. **TPSA:** Both are reasonably good (93.53 and 98.32), though slightly above the optimal <90 for CNS targets, but acceptable for a peripheral GPCR like ADRB2. Ligand A is slightly better.
3. **logP:** Ligand A (0.026) is very low, potentially causing permeability issues. Ligand B (1.127) is better, falling within the optimal range. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (1) is excellent. Ligand B (3) is still acceptable, but less ideal.
5. **HBA:** Ligand A (6) is good. Ligand B (4) is also good. No clear advantage.
6. **QED:** Both have acceptable QED scores (0.78 and 0.616), indicating reasonable drug-likeness. Ligand A is slightly better.
7. **DILI:** Ligand A (59.907) is higher than Ligand B (39.55). Ligand B has a significantly lower DILI risk, which is a major advantage.
8. **BBB:** Both have moderate BBB penetration (78.829 and 56.146). Since ADRB2 is not primarily a CNS target, this is less critical, but Ligand A is better.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and indicates poor permeability. Ligand A (-4.977) is slightly better than Ligand B (-5.162).
10. **Solubility:** Both have negative solubility values, which is also unusual and indicates poor solubility. Ligand A (-2.331) is slightly better than Ligand B (-2.169).
11. **hERG:** Both have low hERG inhibition liability (0.264 and 0.346), which is good. No clear advantage.
12. **Cl_mic:** Ligand A (-5.342) has a much lower (better) microsomal clearance than Ligand B (0.879), indicating greater metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (-9.404) has a more negative (better) in vitro half-life than Ligand B (-13.993).
14. **Pgp:** Both have very low Pgp efflux liability (0.01 and 0.025), which is good. No clear advantage.
15. **Binding Affinity:** Ligand B (-6.6 kcal/mol) has a significantly better binding affinity than Ligand A (-3.3 kcal/mol). This is a substantial advantage, potentially outweighing some ADME drawbacks.
**Overall Assessment:**
Ligand B has a much better logP and significantly higher binding affinity. The lower DILI risk is also a major plus. While Ligand A has better metabolic stability (Cl_mic and t1/2), the potency advantage of Ligand B is more crucial for a GPCR target. The slightly lower logP of Ligand A is concerning for permeability.
**Output:**
0
2025-04-18 00:04:06,027 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (340.383 and 357.361 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (96.27) is better than Ligand B (100.35), both are under the 140 threshold for oral absorption, but closer to the upper limit.
3. **logP:** Ligand A (2.943) is optimal (1-3). Ligand B (-0.058) is significantly below 1, which is concerning for permeability. This is a major drawback for Ligand B.
4. **HBD:** Both ligands have 2 HBD, which is within the acceptable limit of <=5.
5. **HBA:** Ligand A has 5 HBA, while Ligand B has 6. Both are acceptable (<=10).
6. **QED:** Both ligands have good QED scores (0.72 and 0.769), indicating good drug-like properties.
7. **DILI:** Ligand A (79.333) has a higher DILI risk than Ligand B (50.64). This favors Ligand B.
8. **BBB:** Ligand A (49.205) has lower BBB penetration than Ligand B (66.227). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be beneficial.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.712 and -4.929), which are unusual and suggest poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Ligand A (-4.52) has slightly better solubility than Ligand B (-1.547), but both are poor.
11. **hERG:** Ligand A (0.66) has a lower hERG risk than Ligand B (0.164), which is a positive for Ligand A.
12. **Cl_mic:** Ligand A (81.031) has a higher microsomal clearance than Ligand B (-1.055), indicating lower metabolic stability. This favors Ligand B.
13. **t1/2:** Ligand A (28.45) has a longer in vitro half-life than Ligand B (-22.042), which is a positive for Ligand A.
14. **Pgp:** Ligand A (0.101) exhibits lower P-gp efflux than Ligand B (0.031), which is favorable.
15. **Binding Affinity:** Ligand A (-6.9 kcal/mol) has a slightly better binding affinity than Ligand B (-5.8 kcal/mol). This is a significant advantage for Ligand A.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are crucial. Ligand A excels in affinity and Pgp, while Ligand B has a better DILI score. However, the significantly negative logP of Ligand B is a major concern. Poor logP often translates to poor permeability and bioavailability. While Ligand A's solubility and clearance are not ideal, these can be addressed through formulation or structural modifications. The binding affinity difference is also substantial.
**Conclusion:**
Despite Ligand B's lower DILI risk, the significantly better logP and binding affinity of Ligand A outweigh its drawbacks. The poor logP of Ligand B is a critical issue that is unlikely to be overcome easily.
Output:
1
2025-04-18 00:04:06,027 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (365.865 Da and 348.395 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (76.31) is better than Ligand B (82.06), both are under the 140 A^2 threshold for good oral absorption, but lower is better.
**3. logP:** Both ligands have good logP values (3.068 and 2.313, respectively) falling within the optimal 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability.
**4. H-Bond Donors:** Both ligands have 1 HBD, which is within the acceptable limit of <=5.
**5. H-Bond Acceptors:** Ligand A has 7 HBA and Ligand B has 6. Both are within the acceptable limit of <=10.
**6. QED:** Both ligands have similar QED values (0.842 and 0.823), indicating good drug-likeness.
**7. DILI Risk:** Ligand B (34.393) has a significantly lower DILI risk than Ligand A (43.234). This is a major advantage for Ligand B.
**8. BBB Penetration:** Ligand A (85.459) shows better BBB penetration than Ligand B (77.239). While ADRB2 isn't exclusively a CNS target, some cardiovascular effects are mediated by central pathways, and better BBB penetration could be advantageous.
**9. Caco-2 Permeability:** Ligand A (-4.883) has better Caco-2 permeability than Ligand B (-4.288).
**10. Aqueous Solubility:** Both ligands have very poor aqueous solubility (-3.421 and -3.488). This is a significant drawback for both, and formulation strategies would be crucial.
**11. hERG Inhibition:** Ligand A (0.784) has a slightly higher hERG inhibition risk than Ligand B (0.275). This is a concern, as hERG inhibition can lead to cardiotoxicity.
**12. Microsomal Clearance:** Ligand B (54.332) has a lower microsomal clearance than Ligand A (44.075), indicating better metabolic stability.
**13. In vitro Half-Life:** Ligand B (-15.709) has a significantly longer in vitro half-life than Ligand A (-9.144). This is a substantial advantage, potentially allowing for less frequent dosing.
**14. P-gp Efflux:** Ligand A (0.081) has lower P-gp efflux than Ligand B (0.11). Lower P-gp efflux is generally preferred.
**15. Binding Affinity:** Ligand A (-6.1 kcal/mol) has a slightly better binding affinity than Ligand B (-5.5 kcal/mol). This is a 0.6 kcal/mol difference, which is a moderate advantage.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand A initially appears slightly better due to its higher affinity and better P-gp profile. However, the significantly lower DILI risk and substantially longer half-life of Ligand B are very important factors. The slightly better BBB penetration of Ligand A is a minor benefit. The hERG risk is lower for Ligand B. The solubility is poor for both.
Given the balance of these factors, and prioritizing safety (lower DILI, lower hERG) and pharmacokinetics (longer half-life, better metabolic stability), **Ligand B is the more promising drug candidate.**
Output:
0
2025-04-18 00:04:06,027 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (363.483 and 360.483 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (88.68) is higher than Ligand B (60.25). While both are under 140, Ligand B is better positioned for good oral absorption, and as a GPCR, lower TPSA is generally preferred.
3. **logP:** Both ligands have a logP around 2.3, which is optimal (1-3). No clear advantage.
4. **HBD:** Ligand A has 2 HBD, while Ligand B has 0. Lower HBD is generally preferred, and Ligand B is better in this regard.
5. **HBA:** Both ligands have 6 HBA, which is acceptable (<=10). No significant difference.
6. **QED:** Ligand B (0.819) has a higher QED score than Ligand A (0.668), indicating a more drug-like profile. This is a significant advantage.
7. **DILI:** Ligand A (36.293) has a much lower DILI risk than Ligand B (65.491). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (59.248) has a higher BBB penetration score than Ligand A (24.661). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be beneficial for distribution. However, this is less critical than other factors.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.922 and -4.864), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-0.963) has better aqueous solubility than Ligand B (-3.423). Solubility is important for formulation and bioavailability.
11. **hERG:** Ligand A (0.57) has a lower hERG inhibition liability than Ligand B (0.228). This is a significant safety advantage for Ligand A.
12. **Cl_mic:** Ligand A (-9.723) has a much lower microsomal clearance than Ligand B (58.464), indicating better metabolic stability. This is a substantial advantage.
13. **t1/2:** Ligand A (53.449 hours) has a significantly longer in vitro half-life than Ligand B (13.369 hours). This is a major advantage, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand B (0.124) has lower P-gp efflux liability than Ligand A (0.345). Lower Pgp is generally desirable.
15. **Binding Affinity:** Ligand A (-6.2 kcal/mol) has slightly better binding affinity than Ligand B (-5.1 kcal/mol). While the difference isn't huge, it's still a positive for Ligand A.
**Overall Assessment:**
While Ligand B has a better QED and Pgp profile, Ligand A significantly outperforms it in crucial areas like DILI risk, hERG inhibition, metabolic stability (Cl_mic and t1/2), and solubility. The slightly better binding affinity of Ligand A further strengthens its position. The negative Caco-2 values are concerning for both, but the other advantages of Ligand A outweigh this drawback. Considering the GPCR target class, the balance of properties favors Ligand A.
Output:
1
2025-04-18 00:04:06,027 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (347.415 and 365.503 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (79.9) is better than Ligand B (88.91). Both are below 140, but lower TPSA generally favors better absorption.
**3. logP:** Ligand A (2.394) is slightly higher than Ligand B (1.212), placing it more optimally within the 1-3 range. Ligand B is a bit low, potentially hindering permeation.
**4. H-Bond Donors:** Both ligands have 2 HBD, which is good.
**5. H-Bond Acceptors:** Ligand A has 5 HBA, while Ligand B has 6. Both are acceptable, but lower is generally preferred.
**6. QED:** Both ligands have good QED scores (0.557 and 0.687 respectively), indicating good drug-like properties. Ligand B is slightly better.
**7. DILI:** Both ligands have acceptable DILI risk (54.285 and 51.803 percentile), below the 60 threshold. No strong difference.
**8. BBB:** Ligand A (89.453) has a significantly better BBB penetration score than Ligand B (54.44). While ADRB2 is a cardiovascular target and doesn't *require* high BBB penetration, it's still a positive attribute, especially given the potential for off-target effects.
**9. Caco-2 Permeability:** Ligand A (-5.146) is better than Ligand B (-5.864). Higher values indicate better intestinal absorption.
**10. Aqueous Solubility:** Ligand A (-2.942) is better than Ligand B (-2.236). Higher values indicate better solubility.
**11. hERG Inhibition:** Ligand A (0.703) is slightly better than Ligand B (0.169), indicating lower cardiotoxicity risk.
**12. Microsomal Clearance:** Ligand B (32.304) has lower clearance than Ligand A (26.987), suggesting better metabolic stability.
**13. In vitro Half-Life:** Ligand B (11.434) has a longer half-life than Ligand A (22.463). This is a significant advantage for dosing convenience.
**14. P-gp Efflux:** Ligand A (0.131) has lower P-gp efflux than Ligand B (0.025), which is favorable for bioavailability.
**15. Binding Affinity:** Ligand B (-6.8 kcal/mol) has a slightly better binding affinity than Ligand A (-6.1 kcal/mol). This is a 0.7 kcal/mol difference, which is significant.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand B is slightly favored due to its superior binding affinity and longer half-life. While Ligand A has better TPSA, solubility, and BBB penetration, the affinity difference is substantial enough to outweigh these benefits. The slightly lower logP of Ligand B is a minor concern, but can potentially be addressed with further optimization. The better metabolic stability (lower Cl_mic and longer half-life) of Ligand B is also a significant advantage.
Output:
0
2025-04-18 00:04:06,027 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands (368.543 and 350.503 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (49.85) is better than Ligand B (58.64). Both are below 140, but A is closer to the preferred <90 for potential CNS penetration, although this isn't a primary concern for ADRB2 (cardiovascular target).
3. **logP:** Both ligands (2.392 and 2.593) are within the optimal 1-3 range. Very similar.
4. **HBD:** Ligand A (0) is preferable to Ligand B (1). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is preferable to Ligand B (3). Lower HBA is generally better for permeability.
6. **QED:** Both are good (0.767 and 0.695), indicating drug-like properties. Ligand A is slightly better.
7. **DILI:** Ligand A (21.869) is *significantly* better than Ligand B (9.306). This is a major advantage for Ligand A, as lower DILI risk is crucial.
8. **BBB:** Both are reasonably good (77.007 and 73.827). Not a high priority for a cardiovascular target, but A is slightly better.
9. **Caco-2:** Both are negative (-4.436 and -4.55), indicating poor permeability. This is a concern for both.
10. **Solubility:** Both are negative (-2.813 and -2.179), indicating poor solubility. This is a concern for both.
11. **hERG:** Both are low (0.269 and 0.418), indicating low cardiotoxicity risk. No significant difference.
12. **Cl_mic:** Ligand A (53.017) is better than Ligand B (67). Lower clearance suggests better metabolic stability.
13. **t1/2:** Ligand A (-9.013) is better than Ligand B (-6.519). A more negative value suggests a longer half-life.
14. **Pgp:** Both are very low (0.066 and 0.102), suggesting minimal P-gp efflux. No significant difference.
15. **Affinity:** Both are excellent (-7.0 and -6.9 kcal/mol). The difference is negligible.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Both ligands perform similarly on logP, Pgp, and affinity. Ligand A has a better TPSA. However, the *most* important differentiator is the DILI risk. Ligand B's DILI risk is concerningly higher. Additionally, Ligand A demonstrates advantages in metabolic stability (Cl_mic) and half-life.
**Conclusion:**
Ligand A is the more promising candidate due to its significantly lower DILI risk, better TPSA, improved metabolic stability, and longer half-life. While both have issues with Caco-2 and solubility, the safety profile of Ligand A is substantially better.
**Output:**
1
2025-04-18 00:04:06,027 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (359.853 Da) is slightly higher than Ligand B (346.431 Da), but this difference isn't significant.
**2. TPSA:** Ligand A (57.61) is significantly better than Ligand B (85.51). For a GPCR, keeping TPSA lower is preferable for permeability, and Ligand A is well under the 140 A^2 threshold.
**3. logP:** Ligand A (4.694) is higher than Ligand B (0.58). While 4.694 is approaching the upper limit, it's still acceptable. Ligand B's logP is quite low, potentially hindering membrane permeability.
**4. H-Bond Donors:** Both have acceptable HBD counts (Ligand A: 1, Ligand B: 2).
**5. H-Bond Acceptors:** Both have acceptable HBA counts (Ligand A: 2, Ligand B: 4).
**6. QED:** Both ligands have good QED scores (Ligand A: 0.779, Ligand B: 0.817), indicating good drug-like properties.
**7. DILI:** Ligand A (69.794) has a higher DILI risk than Ligand B (14.114). This is a significant concern for Ligand A.
**8. BBB:** Ligand B (43.699) has a higher BBB penetration percentile than Ligand A (21.675). While not a primary concern for a cardiovascular target, higher BBB is generally favorable.
**9. Caco-2 Permeability:** Ligand A (-4.546) has a more negative Caco-2 value, which is unusual and suggests *very* poor permeability. Ligand B (-5.381) is also poor, but slightly better.
**10. Aqueous Solubility:** Ligand A (-3.641) has slightly better solubility than Ligand B (-2.29), but both are quite poor.
**11. hERG Inhibition:** Ligand A (0.158) has a slightly lower hERG risk than Ligand B (0.325), which is good.
**12. Microsomal Clearance:** Ligand B (-37.207) has significantly lower (better) microsomal clearance than Ligand A (38.441), indicating better metabolic stability.
**13. In vitro Half-Life:** Ligand B (-11.711) has a significantly longer in vitro half-life than Ligand A (39.193), which is a strong advantage.
**14. P-gp Efflux:** Ligand A (0.112) has lower P-gp efflux than Ligand B (0.006), which is preferable.
**15. Binding Affinity:** Ligand B (-7.2 kcal/mol) has a slightly better binding affinity than Ligand A (-6.2 kcal/mol). This 1 kcal/mol difference is significant and could outweigh some ADME drawbacks.
**Overall Assessment:**
While Ligand B has a lower binding affinity, the combination of significantly better DILI risk, metabolic stability (lower Cl_mic, longer t1/2), and slightly better affinity makes it the more promising candidate. Ligand A's extremely poor Caco-2 permeability and elevated DILI risk are major red flags. The higher logP of Ligand A is also a concern. Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity), Ligand B is the better choice.
Output:
0
2025-04-18 00:04:06,028 - INFO - Here's my reasoning and output for the ligand preference:
**Reasoning:**
We are looking for a ligand for ADRB2, a cardiovascular GPCR. Therefore, the key priorities are logP, TPSA, Pgp efflux, affinity, and to a lesser extent, BBB (though less critical for a cardiovascular target than a CNS one).
Let's break down the comparison:
1. **MW:** Both ligands are within the ideal range (200-500 Da).
2. **TPSA:** Ligand A (49.41) is significantly better than Ligand B (102.76). Lower TPSA generally favors oral absorption and GPCR penetration.
3. **logP:** Ligand A (3.599) is optimal, while Ligand B (0.835) is quite low, potentially hindering membrane permeability.
4. **HBD/HBA:** Ligand B has more HBDs and HBAs (3/5 vs 1/2). While not a dealbreaker, Ligand A's lower count is preferable for permeability.
5. **QED:** Both are good (>0.5).
6. **DILI:** Ligand A (24.893) has a much lower DILI risk than Ligand B (35.091).
7. **BBB:** Ligand A (93.874) has a much higher BBB penetration, though this is less important for a cardiovascular target.
8. **Caco-2:** Ligand A (-4.415) is better than Ligand B (-5.06), indicating better intestinal absorption.
9. **Solubility:** Ligand A (-3.654) is better than Ligand B (-1.985).
10. **hERG:** Both are low risk.
11. **Cl_mic:** Ligand A (46.486) has lower microsomal clearance, indicating better metabolic stability, than Ligand B (6.432).
12. **t1/2:** Ligand B (-24.813) has a much longer in vitro half-life than Ligand A (-5.476). This is a significant advantage for dosing frequency.
13. **Pgp:** Ligand A (0.09) has lower P-gp efflux, which is favorable for bioavailability. Ligand B (0.011) is even lower, but the other drawbacks of Ligand B are more significant.
14. **Affinity:** Ligand B (-7.2 kcal/mol) has a slightly better binding affinity than Ligand A (-6.3 kcal/mol). This 1.5 kcal/mol difference is notable, but doesn't outweigh the other issues with Ligand B.
**Overall Assessment:**
Ligand A is significantly better overall. It has superior physicochemical properties (TPSA, logP, solubility), a lower DILI risk, and better metabolic stability. While Ligand B has a slightly better binding affinity and half-life, the deficiencies in logP, TPSA, and DILI risk make it a less promising candidate. The combination of favorable properties in Ligand A makes it the more likely viable drug candidate.
**Output:**
1
2025-04-18 00:04:06,028 - INFO - Batch 450 complete. Total preferences: 7200
2025-04-18 00:04:06,028 - INFO - Processing batch 451/512...
2025-04-18 00:04:56,148 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (344.499 and 345.443 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (40.62) is significantly better than Ligand B (71.53). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is quite high and could present absorption challenges.
3. **logP:** Both ligands have acceptable logP values (3.372 and 2.175), falling within the 1-3 range. Ligand A is slightly higher, which could be advantageous for membrane permeability, but not dramatically so.
4. **HBD:** Ligand A (0) is preferable to Ligand B (1). Fewer hydrogen bond donors generally improve permeability.
5. **HBA:** Ligand A (2) is better than Ligand B (4). Lower HBA counts also favor permeability.
6. **QED:** Ligand A (0.734) has a better QED score than Ligand B (0.55), indicating a more drug-like profile.
7. **DILI:** Both ligands have low DILI risk (25.281 and 29.081 percentile), which is good. No clear winner here.
8. **BBB:** Both ligands have good BBB penetration (78.945 and 73.982 percentile). This is important for GPCRs, but less critical for ADRB2 specifically since it's primarily a cardiovascular target.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.81 and -4.89), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand A (-3.531) has slightly better solubility than Ligand B (-2.095), but both are quite poor. This could be a formulation challenge.
11. **hERG:** Both ligands have low hERG inhibition risk (0.513 and 0.555 percentile), which is excellent.
12. **Cl_mic:** Ligand A (66.288) has a much better (lower) microsomal clearance than Ligand B (7.633). This suggests greater metabolic stability for Ligand A, a crucial factor for drug duration.
13. **t1/2:** Ligand A (-5.114) has a significantly longer in vitro half-life than Ligand B (10.896). This further supports its better metabolic stability and potential for less frequent dosing.
14. **Pgp:** Both ligands have low P-gp efflux (0.585 and 0.104 percentile), which is good for bioavailability. Ligand B is slightly better here.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.8 and -6.7 kcal/mol). The difference is negligible.
**Overall Assessment:**
Ligand A is clearly superior. While both have issues with Caco-2 permeability and solubility, Ligand A excels in several key areas: TPSA, HBD, HBA, QED, Cl_mic, and t1/2. These properties collectively point to a compound with better predicted absorption, metabolic stability, and overall drug-likeness. The slightly better solubility of Ligand A is also a plus. The similar binding affinities make the ADME advantages of Ligand A decisive.
Output:
1
2025-04-18 00:04:56,148 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (346.427 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (73.99) is significantly better than Ligand B (96.55). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (A: 2.027, B: 1.235), falling within the optimal 1-3 range. Ligand A is slightly higher, potentially offering better membrane permeability.
4. **HBD/HBA:** Ligand A (HBD=1, HBA=4) is preferable to Ligand B (HBD=2, HBA=5). Lower counts are generally better for balancing solubility and permeability.
5. **QED:** Ligand A (0.909) has a much higher QED score than Ligand B (0.528), indicating a more drug-like profile.
6. **DILI:** Ligand A (21.753) has a significantly lower DILI risk than Ligand B (52.579), a crucial advantage.
7. **BBB:** Both ligands have similar BBB penetration (A: 63.901, B: 62.931). This isn't a primary concern for a cardiovascular target like ADRB2.
8. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. This is a concern for both, but the negative value is similar.
9. **Solubility:** Both ligands have negative solubility values, suggesting poor aqueous solubility. This is a significant drawback for both.
10. **hERG:** Ligand A (0.362) has a much lower hERG inhibition liability than Ligand B (0.039), indicating a lower risk of cardiotoxicity. This is *very* important for a cardiovascular target.
11. **Cl_mic:** Ligand A (7.255) has a lower microsomal clearance than Ligand B (37.387), suggesting better metabolic stability.
12. **t1/2:** Ligand A (37.574) has a longer in vitro half-life than Ligand B (16.434), which is desirable.
13. **Pgp:** Ligand A (0.125) has lower P-gp efflux liability than Ligand B (0.045), suggesting better oral bioavailability.
14. **Binding Affinity:** Ligand A (-7.2 kcal/mol) has a slightly better binding affinity than Ligand B (-6.0 kcal/mol), although the difference is not huge.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A performs better on all these fronts. The lower DILI and hERG risks are also extremely important for a cardiovascular target. While both have poor solubility and Caco-2 permeability, the other advantages of Ligand A outweigh these drawbacks.
**Conclusion:**
Ligand A is the superior candidate due to its better drug-like properties (QED), lower toxicity risks (DILI, hERG), improved metabolic stability (Cl_mic, t1/2), lower P-gp efflux, and slightly better binding affinity.
Output:
1
2025-04-18 00:04:56,148 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (357.445 and 355.435 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (52.65) is significantly better than Ligand B (99.18). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally correlates with better absorption. Ligand B's TPSA is quite high, potentially hindering oral bioavailability.
3. **logP:** Ligand A (2.037) is within the optimal 1-3 range. Ligand B (-0.644) is below 1, which is a concern for membrane permeability.
4. **HBD:** Both ligands have acceptable HBD counts (1 and 2 respectively), well below the 5 threshold.
5. **HBA:** Ligand A (3) is better than Ligand B (5), both are acceptable but lower is preferred.
6. **QED:** Both ligands have similar and acceptable QED values (0.71 and 0.683), indicating good drug-like properties.
7. **DILI:** Ligand A (22.257) has a much lower DILI risk than Ligand B (31.291). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (84.451) has a higher BBB penetration percentile than Ligand B (13.377). While not crucial for a cardiovascular target, it's a positive attribute.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.759 and -4.935). This is unusual and suggests poor permeability. However, the values are similar.
10. **Solubility:** Ligand A (-2.13) is slightly better than Ligand B (-1.008), but both are poor. Solubility is a concern for both.
11. **hERG:** Both ligands have low hERG inhibition risk (0.619 and 0.107). Ligand B is slightly better here.
12. **Cl_mic:** Ligand A (3.823) has a lower microsomal clearance than Ligand B (-1.521), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-17.489) has a longer in vitro half-life than Ligand B (-12.32). This is a significant advantage.
14. **Pgp:** Ligand A (0.081) has a lower P-gp efflux liability than Ligand B (0.01). This is a positive attribute.
15. **Binding Affinity:** Both ligands have similar and strong binding affinities (-6.3 and -6.5 kcal/mol). The difference is negligible.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, and metabolic stability are key. Ligand A significantly outperforms Ligand B in logP and TPSA. It also has better metabolic stability (lower Cl_mic and longer t1/2). While solubility is a concern for both, the other advantages of Ligand A outweigh this drawback.
**Conclusion:**
Ligand A is the more promising candidate due to its superior physicochemical properties (logP, TPSA), lower DILI risk, better metabolic stability, and slightly better P-gp efflux liability. The binding affinity is comparable, and the other parameters are either similar or only slightly different.
Output:
1
2025-04-18 00:04:56,148 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.459 Da and 351.451 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (74.58) is significantly better than Ligand B (118.4). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (1.852 and 1.98) falling within the 1-3 range. Similar.
4. **HBD:** Both have 2 HBD, which is acceptable. Similar.
5. **HBA:** Both have 4 HBA, also acceptable. Similar.
6. **QED:** Ligand A (0.715) has a much better QED score than Ligand B (0.414), indicating a more drug-like profile. This is a significant advantage.
7. **DILI:** Ligand A (9.965) has a substantially lower DILI risk than Ligand B (20.279). This is a critical advantage, as liver toxicity is a major concern in drug development.
8. **BBB:** BBB is less critical for a cardiovascular target. Ligand A (53.664) is higher than Ligand B (36.758), but this isn't a deciding factor.
9. **Caco-2:** Both have negative Caco-2 values (-5.236 and -5.057), which is unusual and suggests poor permeability. However, the values are very close.
10. **Solubility:** Ligand A (-0.308) has slightly better solubility than Ligand B (-1.833).
11. **hERG:** Both have low hERG inhibition risk (0.202 and 0.243). Similar.
12. **Cl_mic:** Ligand B (-7.512) has significantly lower microsomal clearance than Ligand A (0.445), suggesting better metabolic stability. This is a notable advantage for Ligand B.
13. **t1/2:** Ligand B (-4.747) has a slightly longer in vitro half-life than Ligand A (53.643). This is a minor advantage for Ligand B.
14. **Pgp:** Both have very low Pgp efflux liability (0.017 and 0.024). Similar.
15. **Binding Affinity:** Ligand B (-6.6) has a slightly better binding affinity than Ligand A (-5.0). The difference is 1.6 kcal/mol, which is a significant advantage for Ligand B.
**Overall Assessment:**
While Ligand B has a better binding affinity and metabolic stability, Ligand A demonstrates superior drug-likeness (QED), significantly lower DILI risk, and better solubility. The lower DILI risk is a major factor in my decision. For a cardiovascular target, metabolic stability is less critical than avoiding liver toxicity. The slightly better affinity of Ligand B doesn't fully compensate for the higher DILI risk and lower QED. The TPSA of Ligand A is also a plus.
Output:
1
2025-04-18 00:04:56,148 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [346.471, 67.43, 2.169, 2, 3, 0.724, 15.394, 69.019, -5.042, -2.911, 0.221, 34.32, -0.471, 0.053, -6.8]
**Ligand B:** [365.459, 123.14, 1.937, 3, 7, 0.584, 63.164, 55.215, -5.667, -2.381, 0.452, 37.295, -27.079, 0.072, -6.5]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (346.471) is slightly preferred due to being a bit lower.
2. **TPSA:** Ligand A (67.43) is significantly better than Ligand B (123.14). For a GPCR, keeping TPSA low is beneficial for permeability.
3. **logP:** Both are good (around 2), falling within the 1-3 optimal range. Ligand A (2.169) is slightly higher, which could be a minor advantage.
4. **HBD:** Ligand A (2) is better than Ligand B (3). Lower is generally preferred.
5. **HBA:** Ligand A (3) is better than Ligand B (7). Lower is generally preferred.
6. **QED:** Ligand A (0.724) is better than Ligand B (0.584), indicating a more drug-like profile.
7. **DILI:** Ligand A (15.394) is *much* better than Ligand B (63.164). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (69.019) is better than Ligand B (55.215). While not exceptionally high, it's a positive for a GPCR target.
9. **Caco-2:** Both are negative, suggesting poor permeability. Ligand A (-5.042) is slightly better (less negative).
10. **Solubility:** Both are negative, suggesting poor solubility. Ligand A (-2.911) is slightly better (less negative).
11. **hERG:** Ligand A (0.221) is better than Ligand B (0.452), indicating a lower risk of cardiotoxicity.
12. **Cl_mic:** Ligand A (34.32) is better than Ligand B (37.295), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-0.471) is better than Ligand B (-27.079), suggesting better in vitro half-life.
14. **Pgp:** Ligand A (0.053) is better than Ligand B (0.072), suggesting lower P-gp efflux.
15. **Affinity:** Ligand A (-6.8) is slightly better than Ligand B (-6.5), though the difference is relatively small.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical parameters. The most significant differences are in DILI risk (Ligand A is much lower), QED (higher for A), TPSA (lower for A), and BBB (better for A). While both have issues with Caco-2 and solubility, Ligand A is slightly better in these areas as well. The small advantage in binding affinity further supports choosing Ligand A. Given the GPCR target class, the balance of properties in Ligand A is more favorable for development.
Output:
1
2025-04-18 00:04:56,148 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.431 and 367.471 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (87.46 and 83.72) are below the 140 A^2 threshold for good oral absorption, and acceptable for a non-CNS GPCR target like ADRB2. Ligand B is slightly better.
3. **logP:** Ligand A (0.541) is quite low, potentially hindering membrane permeability. Ligand B (1.651) is better, falling within the optimal 1-3 range. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A has 2 HBD, which is good. Ligand B has 0, which is also good. No clear advantage.
5. **HBA:** Both ligands have 5 HBA, which is acceptable. No clear advantage.
6. **QED:** Both ligands have similar QED values (0.815 and 0.808), indicating good drug-likeness.
7. **DILI:** Both ligands have very similar and acceptable DILI risk (36.797 and 36.099 percentile).
8. **BBB:** Ligand A (32.765) has a low BBB penetration, which is fine for a cardiovascular target. Ligand B (84.141) has a much higher BBB penetration. While not a priority for ADRB2, it doesn't hurt.
9. **Caco-2:** Ligand A (-5.186) and Ligand B (-4.754) both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
10. **Solubility:** Ligand A (-1.259) and Ligand B (-2.462) both have negative solubility values, which is also unusual and suggests poor solubility. Again, the scale is not specified.
11. **hERG:** Ligand A (0.139) has a slightly lower hERG risk than Ligand B (0.536), which is preferable.
12. **Cl_mic:** Ligand A (9.784) has a significantly lower microsomal clearance than Ligand B (46.005), indicating better metabolic stability. This is a major advantage for Ligand A.
13. **t1/2:** Ligand A (0.91) has a very short in vitro half-life, while Ligand B (-33.312) has a negative half-life, which is not possible. This is a significant disadvantage for Ligand B.
14. **Pgp:** Ligand A (0.057) has very low P-gp efflux liability, which is good. Ligand B (0.102) is also low, but slightly higher.
15. **Affinity:** Ligand A (-7.1) has a slightly better binding affinity than Ligand B (-6.8), but the difference is not huge.
**GPCR-specific priorities:** For ADRB2 (a cardiovascular GPCR), logP, TPSA, and affinity are key. Ligand B has a better logP and TPSA, but Ligand A has better metabolic stability (Cl_mic) and a slightly better affinity. The extremely poor half-life of Ligand B is a major concern.
**Conclusion:**
Considering the balance of properties, Ligand A is the more promising candidate. Its better metabolic stability, slightly better affinity, and lower hERG risk outweigh the slightly lower logP. The negative values for Caco-2 and solubility are concerning for both, but the metabolic advantage of Ligand A is critical.
Output:
1
2025-04-18 00:04:56,149 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for the ADRB2, a cardiovascular GPCR. Therefore, key priorities are logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB.
Let's compare the ligands property by property:
1. **MW:** Both ligands (351.422 and 378.841 Da) fall within the ideal 200-500 Da range.
2. **TPSA:** Both are good (82.53 and 80.48), well below the 140 threshold for oral absorption.
3. **logP:** Ligand A (1.659) is optimal, while Ligand B (3.331) is approaching the upper limit. This favors A.
4. **HBD/HBA:** Ligand A (2 HBD, 4 HBA) is slightly better than Ligand B (1 HBD, 7 HBA) in terms of balancing solubility and permeability.
5. **QED:** Ligand A (0.783) has a significantly better QED score than Ligand B (0.544), indicating better overall drug-likeness.
6. **DILI:** Ligand A (31.291) has a much lower DILI risk than Ligand B (93.718). This is a major advantage for A.
7. **BBB:** Ligand A (71.811) has a better BBB penetration score than Ligand B (54.634), though neither are exceptionally high. For a cardiovascular target, this isn't *critical*, but is still a positive for A.
8. **Caco-2:** Both are negative, indicating poor permeability. This is a concern for both.
9. **Solubility:** Both are negative, indicating poor solubility. This is also a concern for both.
10. **hERG:** Ligand A (0.485) has a lower hERG risk than Ligand B (0.276), which is preferable.
11. **Cl_mic:** Ligand A (20.147) has a significantly lower microsomal clearance than Ligand B (37.128), suggesting better metabolic stability.
12. **t1/2:** Ligand A (-9.2) has a much longer in vitro half-life than Ligand B (1.564).
13. **Pgp:** Ligand A (0.089) has a much lower P-gp efflux liability than Ligand B (0.348), which is a significant advantage for bioavailability.
14. **Binding Affinity:** Ligand B (-6.5 kcal/mol) has a slightly better binding affinity than Ligand A (-5.8 kcal/mol). This is a 0.7 kcal/mol difference, which is not substantial enough to outweigh the many advantages of ligand A.
**Overall:**
Ligand A consistently outperforms Ligand B across most crucial ADME-Tox properties (DILI, Cl_mic, t1/2, Pgp, QED) and has a better logP and BBB. While Ligand B has slightly better binding affinity, the differences in other parameters are substantial enough to favor Ligand A as the more promising drug candidate.
**Output:**
1
2025-04-18 00:04:56,149 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (375.778) is slightly higher than Ligand B (352.345), but both are acceptable.
2. **TPSA:** Ligand A (56.15) is significantly better than Ligand B (116.08). For a GPCR, lower TPSA is generally preferred for better permeability. Ligand B is quite high, potentially hindering absorption.
3. **logP:** Both ligands have acceptable logP values (A: 3.729, B: 2.054), falling within the 1-3 range. Ligand A is slightly higher, which could potentially lead to off-target effects, but is still reasonable.
4. **HBD:** Ligand A (1) is better than Ligand B (4). Lower HBD is generally preferred for permeability.
5. **HBA:** Ligand A (4) is better than Ligand B (8). Lower HBA is generally preferred for permeability.
6. **QED:** Ligand A (0.866) is significantly better than Ligand B (0.624), indicating a more drug-like profile.
7. **DILI:** Both ligands have similar DILI risk (A: 66.15, B: 67.468), both being moderately high but not alarming.
8. **BBB:** Ligand A (71.927) is significantly better than Ligand B (55.603). While ADRB2 isn't exclusively a CNS target, some CNS penetration can be beneficial, and avoiding efflux is important.
9. **Caco-2:** Ligand A (-4.54) is better than Ligand B (-5.357). Lower values indicate lower permeability, but the difference is small.
10. **Solubility:** Ligand A (-4.475) is better than Ligand B (-3.605). Higher solubility is generally preferred.
11. **hERG:** Both ligands have low hERG inhibition risk (A: 0.412, B: 0.259), which is excellent.
12. **Cl_mic:** Ligand A (70.477) is higher than Ligand B (13.348), indicating faster metabolic clearance and lower metabolic stability. This is a significant drawback for Ligand A.
13. **t1/2:** Ligand A (13.193) is better than Ligand B (-14.126). A positive half-life is preferred.
14. **Pgp:** Ligand A (0.594) is better than Ligand B (0.011). Lower P-gp efflux is preferred.
15. **Binding Affinity:** Ligand A (-5.4) is significantly better than Ligand B (-3.1). This is a substantial difference in potency, and a >1.5 kcal/mol advantage is a strong driver.
**Overall Assessment:**
Ligand A has a clear advantage in terms of binding affinity, TPSA, QED, BBB penetration, solubility, Pgp efflux, and H-bonding characteristics. However, Ligand B has a significantly better metabolic stability profile (lower Cl_mic). Considering the ADRB2 is a GPCR, the balance of properties leans towards Ligand A. The strong binding affinity of Ligand A is a major advantage that can potentially be mitigated by formulation strategies to address the slightly higher clearance. The lower TPSA and better BBB penetration are also beneficial for a GPCR target.
Output:
1
2025-04-18 00:04:56,149 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [355.479, 71.11, 0.628, 1, 5, 0.725, 12.524, 65.723, -5.161, -0.233, 0.192, -3.411, 7.086, 0.005, -6.1]
**Ligand B:** [381.973, 45.23, 4.409, 1, 4, 0.821, 47.964, 74.952, -5.219, -4.496, 0.498, 50.963, 11.989, 0.689, -6.8]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (355.479) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (71.11) is higher than Ligand B (45.23). For a cardiovascular GPCR, TPSA is not *as* critical as for a CNS target, but lower is still preferred for better absorption. Ligand B is significantly better here.
3. **logP:** Ligand A (0.628) is quite low, potentially hindering membrane permeability. Ligand B (4.409) is high, approaching the upper limit where solubility issues might arise, but is more favorable for GPCR binding.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 5 HBA, Ligand B has 4. Both are acceptable.
6. **QED:** Both have good QED scores (A: 0.725, B: 0.821), indicating drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (12.524) has a much lower DILI risk than Ligand B (47.964). This is a significant advantage for Ligand A.
8. **BBB:** Ligand B (74.952) has a higher BBB penetration score than Ligand A (65.723). While ADRB2 isn't a CNS target, some distribution to the CNS is possible, and higher BBB is generally a plus.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. Ligand A (-5.161) is slightly worse than Ligand B (-5.219).
10. **Solubility:** Ligand A (-0.233) has slightly better solubility than Ligand B (-4.496).
11. **hERG:** Ligand A (0.192) has a lower hERG risk than Ligand B (0.498). This is a crucial advantage for cardiovascular drugs.
12. **Cl_mic:** Ligand A (-3.411) has a much lower (better) microsomal clearance than Ligand B (50.963), suggesting better metabolic stability.
13. **t1/2:** Ligand B (11.989) has a longer in vitro half-life than Ligand A (7.086). This is a positive for Ligand B.
14. **Pgp:** Ligand A (0.005) has very low P-gp efflux, a significant advantage. Ligand B (0.689) has moderate P-gp efflux.
15. **Affinity:** Ligand B (-6.8) has a slightly better binding affinity than Ligand A (-6.1), a difference of 0.7 kcal/mol.
**GPCR-Specific Considerations:**
For ADRB2 (a cardiovascular GPCR), we prioritize logP, TPSA, Pgp, and affinity. Ligand B has a better logP and affinity, but Ligand A excels in DILI risk, hERG inhibition, Pgp efflux, and metabolic stability (Cl_mic). The affinity difference is not large enough to outweigh the significant safety advantages of Ligand A. The low logP of Ligand A is a concern, but can potentially be addressed with further optimization.
**Conclusion:**
Considering the balance of properties, especially the critical safety parameters (DILI, hERG) and metabolic stability, Ligand A appears to be the more promising drug candidate.
Output:
1
2025-04-18 00:04:56,149 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (354.435 and 360.523 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (79.78) is higher than Ligand B (42.43). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is generally preferred for absorption. Ligand B is significantly better.
3. **logP:** Ligand A (1.981) is within the optimal 1-3 range. Ligand B (4.286) is higher, potentially leading to solubility issues and off-target interactions. Ligand A is better.
4. **HBD:** Ligand A (2) is acceptable, and Ligand B (0) is also good. No strong preference.
5. **HBA:** Ligand A (5) is acceptable, and Ligand B (4) is also good. No strong preference.
6. **QED:** Both ligands have reasonable QED values (0.754 and 0.681), indicating good drug-like properties.
7. **DILI:** Ligand A (74.99) has a higher DILI risk than Ligand B (35.091). This is a significant drawback for Ligand A. Ligand B is much better.
8. **BBB:** Ligand A (66.925) and Ligand B (79.217) are both reasonably good, but not exceptionally high. Given ADRB2's cardiovascular focus, BBB isn't a primary concern. Ligand B is slightly better.
9. **Caco-2:** Ligand A (-5.668) and Ligand B (-4.795) are both negative, indicating poor permeability.
10. **Solubility:** Ligand A (-3.777) and Ligand B (-3.318) are both poor.
11. **hERG:** Both ligands have low hERG inhibition risk (0.489 and 0.403). No clear advantage.
12. **Cl_mic:** Ligand A (47.9) has a lower microsomal clearance than Ligand B (65.98), suggesting better metabolic stability. Ligand A is better.
13. **t1/2:** Ligand A (33.097) has a longer half-life than Ligand B (-14.974). This is a significant advantage for Ligand A.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.512 and 0.396). No strong preference.
15. **Binding Affinity:** Both ligands have the same binding affinity (-6.7 kcal/mol).
**Overall Assessment:**
While Ligand A has a longer half-life and better metabolic stability, the significantly higher DILI risk is a major concern. Ligand B, despite its higher logP, has a much lower DILI risk, a better TPSA, and a comparable binding affinity. For a cardiovascular target, minimizing toxicity is paramount. The slightly higher logP of Ligand B can be addressed through formulation strategies if needed.
Output:
0
2025-04-18 00:04:56,149 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.5 & 370.5 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (49.85) is significantly better than Ligand B (113.18). ADRB2 is not a CNS target, but lower TPSA generally favors absorption. Ligand A is well below the 140 threshold, while B is approaching it.
3. **logP:** Ligand A (2.83) is optimal, while Ligand B (0.932) is a bit low, potentially hindering permeation.
4. **HBD:** Ligand A (0) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (5). Fewer HBAs generally improve permeability.
6. **QED:** Both are reasonably good (0.664 and 0.598), exceeding the 0.5 threshold.
7. **DILI:** Ligand A (15.24) is *much* better than Ligand B (45.25), indicating a significantly lower risk of drug-induced liver injury. This is a major advantage for Ligand A.
8. **BBB:** Not a primary concern for ADRB2, but Ligand A (92.56) is better than Ligand B (50.06).
9. **Caco-2:** Ligand A (-4.73) is better than Ligand B (-5.28), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-2.35) is better than Ligand B (-2.19), although both are quite poor.
11. **hERG:** Ligand A (0.659) is better than Ligand B (0.263), indicating a lower risk of cardiotoxicity.
12. **Cl_mic:** Ligand A (65.26) is worse than Ligand B (12.23), indicating lower metabolic stability. This is a significant drawback for Ligand A.
13. **t1/2:** Ligand B (-41.52) is *much* better than Ligand A (2.70), indicating a significantly longer half-life. This is a major advantage for Ligand B.
14. **Pgp:** Ligand A (0.317) is better than Ligand B (0.04), indicating lower P-gp efflux.
15. **Binding Affinity:** Ligand B (-6.5) is better than Ligand A (-4.6), a substantial 1.9 kcal/mol difference. This is a very important factor.
**Overall Assessment:**
Ligand B has a significantly better binding affinity and *much* improved in vitro half-life. While Ligand A has better TPSA, logP, DILI, hERG, and Pgp, the binding affinity difference and half-life are substantial enough to outweigh these advantages. The lower metabolic stability of Ligand A is a significant concern. The DILI risk for Ligand B is higher, but not critically so.
Given the GPCR-specific priorities (affinity, logP, Pgp, TPSA), and considering the overall balance of properties, Ligand B is the more promising candidate despite its lower logP and higher DILI risk. The superior binding affinity and half-life are crucial for a viable drug candidate.
Output:
0
2025-04-18 00:04:56,149 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (344.455 Da) is well within the ideal range (200-500 Da). Ligand B (399.466 Da) is also acceptable, but closer to the upper limit.
2. **TPSA:** Ligand A (78.43) is excellent, well below the 140 threshold for good absorption. Ligand B (120.93) is still reasonable, but less optimal.
3. **logP:** Ligand A (3.504) is at the upper end of the optimal range (1-3), but acceptable. Ligand B (-1.88) is significantly *below* the optimal range, which could hinder membrane permeability. This is a significant drawback.
4. **HBD:** Ligand A (3) is within the ideal range (<=5). Ligand B (1) is also good.
5. **HBA:** Ligand A (3) is within the ideal range (<=10). Ligand B (6) is also acceptable.
6. **QED:** Both Ligand A (0.662) and Ligand B (0.578) have good drug-like properties (>=0.5).
7. **DILI:** Ligand A (24.467) has a very favorable DILI risk (low percentile). Ligand B (69.097) has a considerably higher DILI risk, which is concerning.
8. **BBB:** Both Ligand A (64.25) and Ligand B (63.474) have similar BBB penetration, neither being particularly high, but acceptable for a peripheral target like ADRB2.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-4.094) has slightly better solubility than Ligand B (-2.115).
11. **hERG:** Ligand A (0.523) has a very low hERG risk. Ligand B (0.242) also has a low hERG risk.
12. **Cl_mic:** Ligand A (53.337) has a higher microsomal clearance than Ligand B (3.056), indicating lower metabolic stability. This is a negative for Ligand A.
13. **t1/2:** Ligand B (-23.51) has a much longer in vitro half-life than Ligand A (-5.768), which is a significant advantage.
14. **Pgp:** Both ligands have low Pgp efflux liability.
15. **Affinity:** Ligand B (-8.0 kcal/mol) has a significantly stronger binding affinity than Ligand A (-7.0 kcal/mol). This is a substantial advantage, potentially outweighing some ADME concerns.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, and affinity are particularly important. Ligand B has a significantly better binding affinity and a more reasonable TPSA, but suffers from a very low logP. Ligand A has a better logP, but a weaker binding affinity. The DILI risk for Ligand B is also a concern. However, the substantial affinity difference (-1 kcal/mol) is a major factor.
**Overall Assessment:**
Despite the lower logP and higher DILI risk, Ligand B's significantly stronger binding affinity is a major advantage. The longer half-life is also beneficial. While the logP is a concern, it might be addressable through further optimization. The DILI risk is more difficult to mitigate. However, the potency advantage is substantial.
Output:
0
2025-04-18 00:04:56,149 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
The ADRB2 receptor is a GPCR, so the key priorities are logP, TPSA, Pgp efflux, BBB penetration (though less critical for peripheral ADRB2), and binding affinity. Metabolic stability (Cl_mic, t1/2) and safety (DILI, hERG) are also important.
Let's compare the ligands:
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (359.8) is slightly higher than Ligand B (348.4), but this isn't a major concern.
2. **TPSA:** Ligand A (64.63) is significantly better than Ligand B (113.18). Lower TPSA generally favors better absorption and permeability, crucial for GPCR ligands.
3. **logP:** Ligand A (3.729) is optimal, while Ligand B (0.82) is quite low. This is a significant drawback for Ligand B, potentially hindering membrane permeability.
4. **HBD/HBA:** Ligand A (1 HBD, 4 HBA) is preferable to Ligand B (3 HBD, 5 HBA) as it has fewer hydrogen bond forming groups.
5. **QED:** Both are similar (0.652 vs 0.602), indicating reasonable drug-likeness.
6. **DILI:** Ligand B (53.858) has a much lower DILI risk than Ligand A (93.525). This is a positive for Ligand B.
7. **BBB:** Ligand A (56.534) has slightly better BBB penetration than Ligand B (48.313), but neither is particularly high. Since ADRB2 isn't necessarily a CNS target, this isn't a major deciding factor.
8. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability.
9. **Solubility:** Ligand A (-5.358) has better solubility than Ligand B (-2.04), which is a positive.
10. **hERG:** Ligand A (0.161) has a slightly better hERG profile than Ligand B (0.095).
11. **Cl_mic:** Ligand B (33.102) has a lower microsomal clearance than Ligand A (40.397), suggesting better metabolic stability.
12. **t1/2:** Ligand B (-22.019) has a negative in vitro half-life, which is concerning. Ligand A (18.712) is positive.
13. **Pgp:** Ligand A (0.222) has lower P-gp efflux than Ligand B (0.017), which is favorable.
14. **Binding Affinity:** Ligand A (-7.0) has a slightly better binding affinity than Ligand B (-6.6). While the difference is not huge, it is still a factor.
**Overall Assessment:**
Ligand A is the stronger candidate. While Ligand B has a better DILI profile and lower Cl_mic, Ligand A excels in crucial areas for a GPCR ligand: TPSA, logP, Pgp efflux, and binding affinity. The lower logP of Ligand B is a significant concern, potentially leading to poor membrane permeability and reduced efficacy. The better solubility and half-life of Ligand A also contribute to its overall superiority.
**Output:**
1
2025-04-18 00:04:56,149 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (349.41) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (101.21) is better than Ligand B (59.81). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is still preferred for absorption.
3. **logP:** Ligand B (3.669) is higher than Ligand A (1.164). While 1-3 is optimal, Ligand B is approaching the upper limit. Ligand A is a bit low, potentially impacting membrane permeability.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1), but both are within the acceptable limit of 5.
5. **HBA:** Both ligands have 5 HBA, which is acceptable.
6. **QED:** Ligand A (0.803) has a better QED score than Ligand B (0.674), indicating a more drug-like profile.
7. **DILI:** Both ligands have acceptable DILI risk (Ligand A: 51.609, Ligand B: 48.313), below the 60 threshold.
8. **BBB:** Ligand A (82.513) has significantly better BBB penetration than Ligand B (51.066). While ADRB2 isn't a primary CNS target, some degree of BBB penetration can be beneficial for off-target effects and distribution.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Both ligands have negative solubility values, indicating very poor aqueous solubility. This is a major drawback for both compounds.
11. **hERG:** Both ligands have low hERG inhibition risk (Ligand A: 0.404, Ligand B: 0.39), which is excellent.
12. **Cl_mic:** Ligand B (82.748) has a much higher microsomal clearance than Ligand A (4.074), indicating faster metabolism and potentially lower bioavailability.
13. **t1/2:** Ligand B (51.454) has a much longer in vitro half-life than Ligand A (-13.403). This is a significant advantage for Ligand B.
14. **Pgp:** Both ligands have very low P-gp efflux liability (Ligand A: 0.017, Ligand B: 0.406).
15. **Affinity:** Ligand A (-7.1) has a slightly better binding affinity than Ligand B (-6.8). While the difference is not huge, it's still a factor.
**Overall Assessment:**
Both ligands have significant drawbacks in terms of Caco-2 permeability and aqueous solubility. However, Ligand A has a better QED, better BBB penetration, and superior binding affinity. Ligand B has a longer half-life, but suffers from much higher metabolic clearance. Given the GPCR-specific priorities (logP, Pgp, TPSA, affinity), and the relatively small affinity difference, the better ADME profile of Ligand A (lower Cl_mic, better QED, better BBB) makes it the more promising candidate. The poor solubility and permeability would need to be addressed through formulation or further chemical modification, but the core properties of Ligand A are more favorable.
**Output:**
1
2025-04-18 00:04:56,149 - INFO - Here's my reasoning and final output:
**Reasoning:**
Both ligands have excellent binding affinity (-7 kcal/mol), which is a major positive. Given that the target is ADRB2, a cardiovascular GPCR, the priorities are logP, TPSA, Pgp, and affinity. BBB is less critical here, but still considered.
Let's break down the comparison:
1. **MW:** Both are within the acceptable range (200-500 Da). Ligand A (344.415) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (68.62) is significantly better than Ligand B (92.78). Lower TPSA generally means better cell permeability, crucial for GPCR targeting.
3. **logP:** Ligand A (3.024) is optimal, while Ligand B (0.753) is quite low. A logP below 1 can hinder membrane permeability. This is a significant advantage for Ligand A.
4. **HBD/HBA:** Both have 1 HBD and 5 HBA, which are acceptable.
5. **QED:** Ligand A (0.874) has a better QED score than Ligand B (0.537), indicating a more drug-like profile.
6. **DILI:** Both are reasonably low, with Ligand A (47.421) being slightly better than Ligand B (52.423).
7. **BBB:** Both have good BBB penetration (A: 75.029, B: 77.162), but this is less crucial for a cardiovascular target.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual. It suggests poor permeability.
9. **Solubility:** Both have negative solubility values, which is also unusual.
10. **hERG:** Both have very low hERG inhibition risk (A: 0.437, B: 0.213).
11. **Cl_mic:** Ligand B (44.492) has a slightly lower microsomal clearance than Ligand A (37.367), suggesting better metabolic stability.
12. **t1/2:** Ligand B (-30.173) has a much longer in vitro half-life than Ligand A (11.067). This is a significant advantage for Ligand B.
13. **Pgp:** Both have low Pgp efflux liability (A: 0.084, B: 0.059).
14. **Affinity:** Identical, so doesn't differentiate the two.
**Overall Assessment:**
Ligand A has a superior logP and TPSA, which are critical for GPCR targeting and oral bioavailability. Its QED score is also better. While Ligand B has a longer half-life and slightly better metabolic stability, the permeability issues (indicated by the negative Caco-2 and solubility values) and low logP are significant drawbacks. The better permeability profile of Ligand A outweighs the longer half-life of Ligand B.
Output:
1
2025-04-18 00:04:56,149 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [363.399, 122.19 , 0.259, 3. , 6. , 0.703, 87.398, 54.711, -5.537, -3.546, 0.162, -4.092, 138.84 , 0.072, -3.1 ]
**Ligand B:** [343.427, 102.22 , 3.008, 3. , 4. , 0.739, 19.659, 49.748, -5.106, -4.1 , 0.455, 41.023, -5.791, 0.017, -6.3 ]
Here's a breakdown of the comparison, considering the provided guidelines and GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (343.427) is slightly preferred due to being a bit lower.
2. **TPSA:** Ligand B (102.22) is better than Ligand A (122.19) as it's closer to the <140 threshold for good oral absorption.
3. **logP:** Ligand B (3.008) is optimal (1-3), while Ligand A (0.259) is significantly low, potentially hindering membrane permeability. This is a major strike against Ligand A.
4. **HBD:** Both have 3 HBD, which is good.
5. **HBA:** Ligand B (4) is better than Ligand A (6). Lower HBA is preferable for permeability.
6. **QED:** Both are good (>0.5), with Ligand B slightly higher (0.739 vs 0.703).
7. **DILI:** Ligand B (19.659) is *much* better than Ligand A (87.398). Ligand A's DILI risk is very high.
8. **BBB:** Both are relatively low, but Ligand B (49.748) is slightly better than Ligand A (54.711). BBB isn't a huge priority for a cardiovascular target, but it's still a consideration.
9. **Caco-2:** Both are negative, which is not ideal.
10. **Solubility:** Both are negative, which is not ideal.
11. **hERG:** Ligand A (0.162) is better than Ligand B (0.455), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand A (-4.092) is *much* better than Ligand B (41.023). Lower clearance is preferred for metabolic stability.
13. **t1/2:** Ligand B (-5.791) is better than Ligand A (138.84).
14. **Pgp:** Ligand A (0.072) is significantly better than Ligand B (0.017). Lower P-gp efflux is desirable.
15. **Affinity:** Ligand B (-6.3) is significantly better than Ligand A (-3.1). A 3.2 kcal/mol difference in binding affinity is substantial and can often outweigh minor ADME drawbacks.
**Overall Assessment:**
Ligand B is the clear winner. While Ligand A has a better hERG profile and Pgp efflux, its extremely low logP and high DILI risk are major concerns. Ligand B has a much better logP, significantly lower DILI, and a substantially stronger binding affinity. The improved TPSA and QED also contribute to its favorability. The better half-life is also a plus. The affinity difference is large enough to compensate for the slightly higher hERG and Pgp values.
Output:
0
2025-04-18 00:04:56,150 - INFO - Batch 451 complete. Total preferences: 7216
2025-04-18 00:04:56,150 - INFO - Processing batch 452/512...
2025-04-18 00:05:46,332 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (365.411 and 352.431 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand B (76.15) is significantly better than Ligand A (104.81). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (0.98) is closer to the optimal 1-3 range than Ligand A (0.108). Ligand A's logP is quite low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (2) is preferable to Ligand B (0). While both are acceptable, a small number of HBDs can aid solubility.
5. **HBA:** Both ligands have 5 HBA, which is within the acceptable range.
6. **QED:** Ligand A (0.74) is slightly better than Ligand B (0.639), indicating a more drug-like profile.
7. **DILI:** Ligand B (33.656) has a much lower DILI risk than Ligand A (64.831). This is a significant advantage for Ligand B.
8. **BBB:** Ligand B (78.868) has a higher BBB penetration percentile than Ligand A (57.425). While not a primary concern for a cardiovascular target, higher BBB is generally favorable.
9. **Caco-2:** Both are negative, suggesting poor permeability. Ligand A (-4.865) is slightly worse than Ligand B (-4.161).
10. **Solubility:** Ligand B (-0.95) is better than Ligand A (-2.429).
11. **hERG:** Both ligands have very low hERG inhibition risk (0.179 and 0.176).
12. **Cl_mic:** Ligand A (-0.083) has a *lower* (better) microsomal clearance than Ligand B (64.634). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand B (-16.629) has a significantly *longer* in vitro half-life than Ligand A (0.887). This is a major advantage for Ligand B.
14. **Pgp:** Both ligands have similar, low Pgp efflux liability (0.02 and 0.04).
15. **Binding Affinity:** Ligand A (-6.8) has a slightly better binding affinity than Ligand B (-6.6), but the difference is only 0.2 kcal/mol, which is not substantial enough to override other significant differences.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, and affinity are key. Ligand B excels in logP and TPSA, while Ligand A has a slightly better affinity. However, the significantly better DILI, solubility, and half-life of Ligand B outweigh the small affinity difference.
**Conclusion:**
Considering the balance of properties, especially the lower DILI risk, improved solubility, and longer half-life, Ligand B is the more promising drug candidate.
Output:
0
2025-04-18 00:05:46,332 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (347.459) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (53.51) is significantly better than Ligand A (87.3), falling well below the 140 threshold for good oral absorption and closer to the 90 threshold for CNS penetration (though BBB is the primary factor for CNS).
3. **logP:** Ligand B (2.101) is within the optimal range (1-3), while Ligand A (0.96) is slightly below, potentially hindering permeation.
4. **HBD:** Ligand A (3) is acceptable, while Ligand B (0) is even better, potentially improving permeability.
5. **HBA:** Both ligands are acceptable (Ligand A: 3, Ligand B: 4), well below the 10 threshold.
6. **QED:** Both ligands have good QED scores (Ligand A: 0.692, Ligand B: 0.779), indicating good drug-like properties.
7. **DILI:** Ligand B (26.328) has a much lower DILI risk than Ligand A (16.557), which is a significant advantage.
8. **BBB:** Ligand B (87.088) has a much higher BBB penetration percentile than Ligand A (50.446). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant, and higher BBB is generally favorable.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-5.536) is slightly better than Ligand B (-4.891).
10. **Solubility:** Both ligands have poor solubility (-2.466 and -2.934 respectively).
11. **hERG:** Both ligands have low hERG inhibition risk (Ligand A: 0.126, Ligand B: 0.207).
12. **Cl_mic:** Ligand A (-14.818) has significantly better metabolic stability (lower clearance) than Ligand B (61.37). This is a major advantage.
13. **t1/2:** Ligand A (6.902) has a longer half-life than Ligand B (-4.109).
14. **Pgp:** Both ligands have low Pgp efflux liability (Ligand A: 0.016, Ligand B: 0.196).
15. **Binding Affinity:** Ligand B (-6.4 kcal/mol) has a stronger binding affinity than Ligand A (-4.7 kcal/mol). This is a substantial difference (>1.5 kcal/mol).
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP, TPSA, and significantly in affinity. While Ligand A has better metabolic stability and half-life, the substantial affinity advantage of Ligand B, coupled with its better TPSA and lower DILI risk, outweighs these drawbacks. The improved BBB is also a bonus.
**Conclusion:**
Ligand B is the more promising candidate due to its superior binding affinity, favorable TPSA, lower DILI risk, and better logP, despite having poorer metabolic stability and half-life. The stronger binding is likely to be more impactful in driving efficacy.
Output:
0
2025-04-18 00:05:46,332 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A Analysis:**
* **MW:** 346.402 Da - Good, within the ideal range.
* **TPSA:** 50.8 - Good, well below the 140 threshold for oral absorption.
* **logP:** 3.696 - Good, within the optimal range of 1-3.
* **HBD:** 1 - Excellent, low and favorable for permeability.
* **HBA:** 4 - Good, below the 10 threshold.
* **QED:** 0.831 - Excellent, highly drug-like.
* **DILI:** 65.568 - Moderate risk, slightly above the preferred <40, but not alarming.
* **BBB:** 70.299 - Good, desirable for a GPCR, indicating some CNS penetration potential.
* **Caco-2:** -4.288 - Poor, indicating low intestinal absorption.
* **Solubility:** -4.467 - Poor, indicating low aqueous solubility.
* **hERG:** 0.825 - Low risk, favorable.
* **Cl_mic:** 97.281 - High, indicating rapid metabolism and potential for low bioavailability.
* **t1/2:** 5.492 - Moderate, could be better.
* **Pgp:** 0.495 - Low efflux, favorable.
* **Affinity:** -6.8 kcal/mol - Very good binding affinity.
**Ligand B Analysis:**
* **MW:** 352.435 Da - Good, within the ideal range.
* **TPSA:** 105.48 - Acceptable, but approaching the upper limit for good absorption.
* **logP:** 0.426 - Poor, below the optimal range, potentially hindering permeation.
* **HBD:** 3 - Good, within the acceptable range.
* **HBA:** 6 - Good, below the 10 threshold.
* **QED:** 0.629 - Acceptable, but lower than Ligand A.
* **DILI:** 36.293 - Excellent, low risk of liver injury.
* **BBB:** 35.479 - Poor, low potential for CNS penetration.
* **Caco-2:** -5.221 - Poor, indicating low intestinal absorption.
* **Solubility:** -1.571 - Poor, indicating low aqueous solubility.
* **hERG:** 0.315 - Very low risk, highly favorable.
* **Cl_mic:** 2.316 - Very low, indicating high metabolic stability.
* **t1/2:** 6.934 - Good, better than Ligand A.
* **Pgp:** 0.088 - Very low efflux, highly favorable.
* **Affinity:** -5.7 kcal/mol - Good binding affinity, but weaker than Ligand A.
**Comparison and Decision:**
Both ligands have significant drawbacks in terms of Caco-2 permeability and aqueous solubility. However, considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand A is more promising.
* **Affinity:** Ligand A has a significantly stronger binding affinity (-6.8 kcal/mol vs -5.7 kcal/mol). This is a major advantage for a GPCR target. A 1.1 kcal/mol difference is substantial.
* **logP:** Ligand A has a much better logP value (3.696) compared to Ligand B (0.426), which is crucial for membrane permeability.
* **Pgp:** Both have low Pgp efflux, but Ligand A is slightly better.
* **Metabolic Stability:** Ligand B has superior metabolic stability (lower Cl_mic), but the affinity difference of Ligand A is more important.
* **DILI:** Ligand B has a better DILI score, but Ligand A's is not critically high.
* **BBB:** Ligand A has a better BBB score, which is a bonus for a GPCR.
Given the importance of binding affinity and logP for GPCRs, and the acceptable (though not ideal) ADME profile of Ligand A, it is the more promising candidate. While the solubility and permeability are concerns, these can be addressed through formulation strategies. The stronger binding and better logP are harder to improve through medicinal chemistry.
Output:
1
2025-04-18 00:05:46,332 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step Comparison:**
1. **MW:** Both ligands (384.523 and 371.855 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (29.54) is significantly lower than Ligand A (84.5). This is a major advantage for Ligand B, as lower TPSA generally correlates with better cell permeability, crucial for GPCR targeting.
3. **logP:** Ligand A (2.514) is within the optimal 1-3 range. Ligand B (4.643) is slightly higher, potentially edging into a range where solubility could become an issue, but still acceptable.
4. **HBD:** Ligand A has 2 HBD, and Ligand B has 0. Both are within the acceptable limit of <=5.
5. **HBA:** Ligand A has 5 HBA, and Ligand B has 2. Both are within the acceptable limit of <=10.
6. **QED:** Ligand A (0.787) has a slightly better QED score than Ligand B (0.666), indicating a more drug-like profile.
7. **DILI:** Ligand B (31.524) has a much lower DILI risk than Ligand A (62.001). This is a significant advantage for Ligand B.
8. **BBB:** Ligand B (90.074) has a much higher BBB penetration score than Ligand A (65.452). While ADRB2 isn't exclusively a CNS target, better BBB penetration can still be beneficial for overall distribution and potentially reduce off-target effects.
9. **Caco-2:** Ligand A (-5.223) and Ligand B (-4.183) both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the values are close, and this is not a major differentiating factor.
10. **Solubility:** Ligand A (-3.862) has slightly better solubility than Ligand B (-5.162).
11. **hERG:** Ligand B (0.907) has a slightly higher hERG risk than Ligand A (0.321), but both are relatively low and acceptable.
12. **Cl_mic:** Ligand B (80.736) has a significantly higher microsomal clearance than Ligand A (20.433), suggesting faster metabolism and potentially lower *in vivo* exposure. This is a disadvantage for Ligand B.
13. **t1/2:** Ligand A (59.516) has a longer *in vitro* half-life than Ligand B (43.607), which is preferable.
14. **Pgp:** Ligand B (0.574) has a lower P-gp efflux liability than Ligand A (0.147), which is a positive for bioavailability.
15. **Binding Affinity:** Ligand A (-7.1 kcal/mol) has a slightly better binding affinity than Ligand B (-6.1 kcal/mol). This is a 1 kcal/mol difference, which is significant, but not overwhelming.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, TPSA, logP, Pgp, and affinity are key. Ligand B excels in TPSA and Pgp, and has good BBB penetration. Ligand A has a slightly better affinity and QED, but suffers from higher TPSA, DILI risk, and higher clearance. The affinity difference is not large enough to overcome the ADME advantages of Ligand B.
**Conclusion:**
Considering the balance of properties, particularly the favorable TPSA, DILI, Pgp, and BBB scores of Ligand B, it is the more promising drug candidate despite the slightly lower affinity and higher clearance.
Output:
0
2025-04-18 00:05:46,332 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Ligand A (412.3) is within the ideal range, while Ligand B (354.4) is slightly below, but still acceptable.
2. **TPSA:** Both ligands (A: 70.23, B: 74.33) are below the 140 threshold for good oral absorption, but acceptable for a GPCR.
3. **logP:** Both ligands have good logP values (A: 2.648, B: 1.137) within the optimal 1-3 range. Ligand A is slightly preferred here.
4. **HBD:** Both ligands have acceptable HBD counts (A: 3, B: 2).
5. **HBA:** Both ligands have acceptable HBA counts (A: 3, B: 4).
6. **QED:** Both ligands have good QED scores (A: 0.515, B: 0.803). Ligand B is significantly better here, indicating a more drug-like profile.
7. **DILI:** Ligand A (41.877) has a higher DILI risk than Ligand B (14.036). This is a significant advantage for Ligand B.
8. **BBB:** Ligand B (70.88) has a better BBB penetration score than Ligand A (49.903). While ADRB2 isn't necessarily a CNS target, better BBB penetration can sometimes translate to improved distribution and reduced off-target effects.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual. However, the magnitude is similar, so this doesn't strongly favor either.
10. **Solubility:** Ligand A (-3.63) has worse solubility than Ligand B (-1.481). Solubility is important for bioavailability, favoring Ligand B.
11. **hERG:** Both ligands have low hERG inhibition liability (A: 0.639, B: 0.425), which is good.
12. **Cl_mic:** Ligand A (15.512) has a much lower microsomal clearance than Ligand B (-43.588). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (58.497) has a much longer in vitro half-life than Ligand B (-10.318). This is a significant advantage for Ligand A.
14. **Pgp:** Both ligands have very low Pgp efflux liability (A: 0.135, B: 0.007).
15. **Binding Affinity:** Ligand B (-7.2) has a slightly better binding affinity than Ligand A (-5.3). This 1.9 kcal/mol difference is substantial and can outweigh some ADME drawbacks.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand B excels in affinity and has good logP, TPSA, and Pgp values. While Ligand A has better metabolic stability (Cl_mic and t1/2), the significantly stronger binding affinity of Ligand B is a major advantage. The lower DILI risk and better solubility of Ligand B are also important positives.
**Conclusion:**
Despite the better metabolic stability of Ligand A, the superior binding affinity, lower DILI risk, and better solubility of Ligand B make it the more promising drug candidate for ADRB2.
Output:
0
2025-04-18 00:05:46,332 - INFO - Here's a step-by-step reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [347.503, 61.44, 2.374, 2, 3, 0.695, 8.181, 77.433, -5.402, -1.401, 0.58, 15.374, 17.114, 0.053, -5.8]**
**Ligand B: [372.29, 70.08, 0.559, 1, 4, 0.578, 42.613, 60.644, -4.582, -1.39, 0.343, 16.483, -17.413, 0.032, -6.7]**
**1. Molecular Weight (MW):** Both are within the ideal range (200-500 Da). Ligand A (347.5) is slightly preferred as it's closer to the lower end, potentially aiding permeability.
**2. TPSA:** Ligand A (61.44) is better than Ligand B (70.08). Both are below 140, but lower TPSA generally favors oral absorption.
**3. logP:** Ligand A (2.374) is optimal (1-3), while Ligand B (0.559) is a bit low, potentially hindering membrane permeability. This is a significant advantage for Ligand A.
**4. H-Bond Donors (HBD):** Both are acceptable (Ligand A: 2, Ligand B: 1).
**5. H-Bond Acceptors (HBA):** Both are acceptable (Ligand A: 3, Ligand B: 4).
**6. QED:** Both are reasonably good (Ligand A: 0.695, Ligand B: 0.578), indicating drug-like properties. Ligand A is slightly better.
**7. DILI:** Ligand A (8.181) is significantly better than Ligand B (42.613). Lower DILI risk is crucial.
**8. BBB:** Ligand A (77.433) is better than Ligand B (60.644). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant, and higher BBB is generally favorable.
**9. Caco-2 Permeability:** Ligand A (-5.402) is better than Ligand B (-4.582). Higher values indicate better absorption.
**10. Aqueous Solubility:** Both are very poor (-1.401 and -1.39). This is a concern for both, but not a deciding factor between the two.
**11. hERG Inhibition:** Ligand A (0.58) is better than Ligand B (0.343). Lower hERG inhibition is critical for avoiding cardiotoxicity.
**12. Microsomal Clearance:** Ligand B (16.483) is slightly better than Ligand A (15.374), suggesting slightly better metabolic stability.
**13. In vitro Half-Life:** Ligand A (17.114) is much better than Ligand B (-17.413). A longer half-life is desirable.
**14. P-gp Efflux:** Both are very low (Ligand A: 0.053, Ligand B: 0.032).
**15. Binding Affinity:** Ligand B (-6.7) is slightly better than Ligand A (-5.8). A 0.9 kcal/mol difference is noteworthy.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand A is the stronger candidate. While Ligand B has a slightly better binding affinity, Ligand A excels in crucial ADME properties like logP, DILI risk, BBB penetration, and *especially* in vitro half-life. The significantly lower DILI risk and better half-life of Ligand A outweigh the modest affinity difference. The better logP and TPSA also suggest better permeability.
Output:
1
2025-04-18 00:05:46,332 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Step-by-step comparison:**
1. **MW:** Both ligands (369.49 & 383.45 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand B (72.7) is significantly better than Ligand A (92.51). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (3.299) is slightly higher than Ligand A (2.253), but both are within the optimal 1-3 range.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand B (7) has more HBAs than Ligand A (5), but both are acceptable (<=10).
6. **QED:** Both ligands have similar QED scores (0.71 and 0.709), indicating good drug-likeness.
7. **DILI:** Ligand B (79.84) has a higher DILI risk than Ligand A (74.02). This favors Ligand A.
8. **BBB:** Ligand B (75.92) has a higher BBB penetration score than Ligand A (61.81). While not critical for a cardiovascular target, it's a slight positive for Ligand B.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.895) is slightly better than Ligand B (-5.082).
10. **Solubility:** Ligand A (-3.523) has better solubility than Ligand B (-2.979). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.261) has a much lower hERG inhibition liability than Ligand B (0.518). This is a significant advantage for Ligand A, as hERG inhibition can lead to cardiotoxicity.
12. **Cl_mic:** Ligand B (31.22) has significantly lower microsomal clearance than Ligand A (93.36). Lower clearance indicates better metabolic stability, favoring Ligand B.
13. **t1/2:** Ligand B (16.91) has a longer in vitro half-life than Ligand A (-38.96). This is a strong advantage for Ligand B.
14. **Pgp:** Ligand A (0.307) has lower P-gp efflux liability than Ligand B (0.59). Lower efflux is generally better for bioavailability.
15. **Affinity:** Ligand A (-6.5 kcal/mol) has slightly better binding affinity than Ligand B (-5.8 kcal/mol). While the difference is not huge, it's a positive for Ligand A.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Ligand B has better logP, TPSA, and t1/2. Ligand A has better affinity, solubility, and lower hERG risk. The difference in affinity is not substantial enough to outweigh the metabolic stability (Cl_mic and t1/2) and permeability benefits of Ligand B. The lower hERG risk of Ligand A is also a significant consideration.
**Overall Assessment:**
Ligand B demonstrates superior metabolic stability and a longer half-life, which are crucial for *in vivo* efficacy. While Ligand A has a slightly better affinity and lower hERG, the metabolic liabilities of Ligand A are concerning. The improved TPSA and logP of Ligand B also contribute to better predicted absorption.
Output:
0
2025-04-18 00:05:46,333 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (345.443 and 351.451 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (64.09) is significantly better than Ligand B (115.98). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold, while Ligand B is approaching it.
3. **logP:** Ligand B (0.901) is slightly better than Ligand A (0.226). Both are on the lower side of the optimal 1-3 range. Ligand A's low logP could potentially hinder membrane permeability.
4. **HBD:** Ligand B (4) has more HBD than Ligand A (1). This could slightly impact permeability, but isn't a major concern.
5. **HBA:** Both ligands have the same number of HBA (4). This is within acceptable limits.
6. **QED:** Ligand A (0.728) has a significantly better QED score than Ligand B (0.469), indicating a more drug-like profile.
7. **DILI:** Ligand B (41.877) has a slightly higher DILI risk than Ligand A (22.257), but both are below the concerning threshold of 60.
8. **BBB:** Both ligands have low BBB penetration, which is acceptable for a cardiovascular target. Ligand A (39.86) is slightly better.
9. **Caco-2:** Ligand A (-4.526) has a more negative Caco-2 value, suggesting *lower* permeability. Ligand B (-5.825) is even lower. This is a concern for both.
10. **Solubility:** Ligand A (-1.196) has better solubility than Ligand B (-2.347). Solubility is important for bioavailability.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.276 and 0.291). This is excellent.
12. **Cl_mic:** Ligand A (7.894) has significantly lower microsomal clearance than Ligand B (29.724), indicating better metabolic stability.
13. **t1/2:** Ligand B (-6.372) has a more negative in vitro half-life, suggesting a longer half-life. Ligand A (0.354) is very short. This is a significant advantage for Ligand B.
14. **Pgp:** Both ligands have similar Pgp efflux liability (0.137 and 0.129).
15. **Binding Affinity:** Ligand B (-7.2 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.8 kcal/mol). This 1.4 kcal/mol difference is substantial and can outweigh some ADME drawbacks.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), affinity, logP, TPSA, and Pgp are key. Ligand B excels in affinity. Ligand A has better TPSA, but Ligand B's affinity advantage is substantial. The logP difference is not huge, and both are on the low side.
**Overall Assessment:**
While Ligand A has better QED, TPSA, solubility, and metabolic stability, the significantly stronger binding affinity of Ligand B (-7.2 vs -5.8 kcal/mol) is the most critical factor. The longer half-life of Ligand B is also a significant benefit. The slightly lower logP of Ligand A is a concern, and the superior affinity of Ligand B is likely to overcome its slightly higher DILI risk and lower QED.
Output:
0
2025-04-18 00:05:46,333 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.443 and 344.419 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (78.87) is better than Ligand B (93.84). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (2.312) is better than Ligand B (1.016). Both are within the optimal 1-3 range, but Ligand A is closer to the sweet spot. Ligand B is bordering on being too hydrophilic.
4. **HBD:** Both ligands have 2 H-bond donors, which is acceptable.
5. **HBA:** Ligand A has 4 H-bond acceptors, while Ligand B has 6. Ligand A is preferable, as higher HBA can sometimes hinder permeability.
6. **QED:** Both ligands have good QED scores (0.558 and 0.733), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (20.396%) has a significantly lower DILI risk than Ligand B (59.442%). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (68.127%) has better BBB penetration than Ligand B (47.111%), but this isn't a high priority for a cardiovascular target.
9. **Caco-2:** Ligand A (-4.717) has a better Caco-2 permeability than Ligand B (-5.167).
10. **Solubility:** Ligand A (-2.067) has better solubility than Ligand B (-2.468).
11. **hERG:** Ligand A (0.732) has a slightly higher hERG risk than Ligand B (0.033). This is a negative for Ligand A, but the difference isn't huge.
12. **Cl_mic:** Ligand A (23.09) has a significantly lower microsomal clearance than Ligand B (34.267), indicating better metabolic stability.
13. **t1/2:** Ligand A (11.526) has a shorter in vitro half-life than Ligand B (14.618). This is a slight negative for Ligand A.
14. **Pgp:** Ligand A (0.216) has lower P-gp efflux than Ligand B (0.052). Lower Pgp is better.
15. **Binding Affinity:** Ligand A (-7.0) has a slightly better binding affinity than Ligand B (-6.5). While the difference is less than 1.5kcal/mol, it still contributes to the overall preference.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A performs better in logP, TPSA, and Pgp. The affinity difference is small but favors Ligand A.
**Overall Assessment:**
Ligand A is the stronger candidate. Its significantly lower DILI risk and better metabolic stability (lower Cl_mic) are crucial advantages. While Ligand B has a slightly better QED and in vitro half-life, the safety and PK benefits of Ligand A outweigh these minor drawbacks. The slightly higher hERG risk for Ligand A is manageable.
Output:
1
2025-04-18 00:05:46,333 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (370.362 Da) is slightly higher than Ligand B (351.447 Da), but both are acceptable.
2. **TPSA:** Ligand A (49.41) is significantly better than Ligand B (95.67). ADRB2 is not a CNS target, but lower TPSA generally correlates with better permeability. Ligand B's TPSA is quite high, potentially hindering absorption.
3. **logP:** Both ligands have good logP values (A: 2.973, B: 1.891), falling within the optimal 1-3 range. Ligand A is slightly more lipophilic, which could be beneficial for membrane permeability.
4. **HBD:** Both have acceptable HBD counts (A: 1, B: 2).
5. **HBA:** Ligand A (2) is better than Ligand B (5). Lower HBA is generally preferred for permeability.
6. **QED:** Both ligands have good QED scores (A: 0.774, B: 0.816), indicating good drug-like properties.
7. **DILI:** Ligand A (19.62) has a much lower DILI risk than Ligand B (36.099). This is a significant advantage for Ligand A.
8. **BBB:** This is less critical for ADRB2, but Ligand A (93.098) has a higher BBB percentile than Ligand B (66.809).
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. This is a concern for both, but Ligand B's value (-4.459) is worse than Ligand A's (-4.669).
10. **Solubility:** Both have negative solubility values, indicating poor solubility. Ligand A (-3.129) is slightly better than Ligand B (-2.729).
11. **hERG:** Ligand A (0.609) has a lower hERG risk than Ligand B (0.227). This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand A (6.292) has a much lower microsomal clearance than Ligand B (63.137), indicating better metabolic stability. This is a major advantage for Ligand A.
13. **t1/2:** Ligand A (-22.928) has a much longer in vitro half-life than Ligand B (1.596). This is a substantial advantage for Ligand A.
14. **Pgp:** Ligand A (0.033) has a lower P-gp efflux liability than Ligand B (0.146).
15. **Binding Affinity:** Ligand B (-8.3 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.5 kcal/mol). This is a substantial advantage for Ligand B.
**Overall Assessment:**
While Ligand B has a superior binding affinity, Ligand A demonstrates a significantly better overall ADMET profile. The lower DILI risk, better metabolic stability (lower Cl_mic and longer t1/2), lower hERG risk, and lower Pgp efflux are all critical advantages. The TPSA and HBA are also more favorable for Ligand A. The difference in binding affinity, while substantial, can potentially be optimized in later stages of drug development. The poor Caco-2 and solubility are concerns for both, but the ADMET advantages of Ligand A outweigh the affinity difference. Given the GPCR-specific priorities (logP, TPSA, Pgp), Ligand A is the more promising candidate.
Output:
1
2025-04-18 00:05:46,333 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (361.47 & 378.85 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (73.22) is significantly better than Ligand B (110.17). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally aids absorption.
3. **logP:** Both ligands have similar logP values (2.649 & 2.63), falling within the optimal 1-3 range.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (6) is better than Ligand B (8). Lower HBA is also generally preferable for permeability.
6. **QED:** Both ligands have good QED scores (0.606 & 0.72), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (63.86) is significantly better than Ligand B (93.68). Lower DILI risk is crucial. Ligand B's DILI is quite high.
8. **BBB:** Both ligands have similar BBB penetration (59.09 & 68.86). Not a major factor for a cardiovascular target.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.96 & -5.018), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Both ligands have negative solubility values (-3.583 & -4.497), indicating very poor aqueous solubility. This is a significant drawback for both.
11. **hERG:** Ligand A (0.36) is much better than Ligand B (0.618). Lower hERG inhibition is critical to avoid cardiotoxicity.
12. **Cl_mic:** Ligand A (133.73) has a significantly higher (worse) microsomal clearance than Ligand B (21.53). This suggests Ligand B is more metabolically stable.
13. **t1/2:** Ligand B (16.83) has a much longer in vitro half-life than Ligand A (-27.47). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.363) is better than Ligand B (0.147). Lower P-gp efflux is desirable for improved bioavailability.
15. **Affinity:** Ligand B (-7.4) has a substantially better binding affinity than Ligand A (-6.3). A 1.1 kcal/mol difference is significant and can outweigh some ADME drawbacks.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. While both have acceptable logP, Ligand A has a much better TPSA and Pgp. However, Ligand B's significantly stronger binding affinity (-7.4 vs -6.3) is a major advantage. The lower DILI and hERG risk of Ligand A are also very important.
**Overall Assessment:**
Ligand B's superior binding affinity and metabolic stability (lower Cl_mic, longer t1/2) are compelling. However, its high DILI risk and higher hERG inhibition are serious concerns. Ligand A has a much better safety profile (DILI, hERG), and acceptable permeability/solubility issues. Considering the cardiovascular target, safety is paramount. While the affinity difference is notable, the safety profile of Ligand A makes it the more viable candidate.
Output:
1
2025-04-18 00:05:46,333 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.39 and 368.503 Da) fall well within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (66.92 and 65.12) are below the 140 A^2 threshold for good oral absorption, and are reasonably low. No strong preference.
3. **logP:** Both ligands have a logP around 1.24, which is optimal (1-3). No significant difference.
4. **HBD:** Ligand A has 0 HBD, while Ligand B has 1. Both are within the acceptable limit of <=5.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 5. Both are within the acceptable limit of <=10.
6. **QED:** Both ligands have good QED scores (0.694 and 0.768), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (33.812) has a slightly higher DILI risk than Ligand B (28.306), but both are below the 40 threshold and are considered good.
8. **BBB:** Ligand A (87.166) has a significantly higher BBB penetration percentile than Ligand B (78.945). While ADRB2 isn't strictly a CNS target, some CNS exposure is not necessarily detrimental and could offer some off-target effects.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.229 and -4.959), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Both ligands have very poor aqueous solubility (-1.64 and -1.31). This is a major drawback for both candidates.
11. **hERG:** Both ligands have low hERG inhibition liability (0.432 and 0.548), which is good.
12. **Cl_mic:** Both ligands have similar microsomal clearance values (44.184 and 43.452 mL/min/kg), suggesting similar metabolic stability.
13. **t1/2:** Ligand B (16.717 hours) has a significantly longer in vitro half-life than Ligand A (-1.441 hours). This is a substantial advantage.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.055 and 0.013). This is favorable.
15. **Binding Affinity:** Ligand A (-6.6 kcal/mol) has a slightly better binding affinity than Ligand B (-5.4 kcal/mol). This difference of 1.2 kcal/mol is significant.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Both ligands perform similarly on logP, TPSA, and Pgp. Ligand A has a better affinity, while Ligand B has a better half-life. The poor Caco-2 and solubility are concerning for both.
**Overall Assessment:**
Despite the poor solubility and permeability, Ligand A's superior binding affinity (-6.6 vs -5.4 kcal/mol) is a significant advantage that likely outweighs the shorter half-life, especially considering the relatively good metabolic stability (Cl_mic). The higher BBB penetration of Ligand A is also a slight positive.
Output:
1
2025-04-18 00:05:46,333 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.494 Da and 341.499 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (49.41) is slightly higher than Ligand B (38.56). Both are below the 140 threshold for oral absorption, but B is better.
3. **logP:** Ligand B (4.781) is higher than Ligand A (3.448). While both are above the optimal 1-3 range, Ligand B is pushing the upper limit and could potentially have solubility issues. Ligand A is closer to the ideal range.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 2 HBA, while Ligand B has 4. Ligand A is preferable here, as fewer HBA generally improves permeability.
6. **QED:** Both ligands have good QED scores (0.646 and 0.787), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (9.771) has a significantly lower DILI risk than Ligand B (34.161). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (95.735) has a much higher BBB penetration percentile than Ligand B (84.141). Given that ADRB2 is a GPCR, BBB penetration is a desirable property, making Ligand A more attractive.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the values are close enough that this isn't a major differentiator.
10. **Solubility:** Ligand A (-3.731) has slightly better solubility than Ligand B (-4.287).
11. **hERG:** Both ligands have low hERG inhibition liability (0.88 and 0.928), which is good.
12. **Cl_mic:** Ligand A (46.663) has lower microsomal clearance than Ligand B (52.675), indicating better metabolic stability.
13. **t1/2:** Ligand B (66.642) has a much longer in vitro half-life than Ligand A (-9.52). This is a significant advantage for Ligand B.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.393 and 0.812).
15. **Binding Affinity:** Both ligands have similar binding affinities (-5.6 and -5.4 kcal/mol).
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A has a better logP and TPSA, and comparable affinity and Pgp. The significantly better BBB penetration and lower DILI risk of Ligand A are also crucial advantages. While Ligand B has a longer half-life, the other factors favor Ligand A.
**Conclusion:**
Considering the balance of properties, particularly the lower DILI risk, better BBB penetration, and more favorable TPSA/logP for a GPCR target, Ligand A is the more promising drug candidate.
Output:
1
2025-04-18 00:05:46,333 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (358.429 Da and 341.411 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (58.64) is slightly higher than Ligand B (54.78), but both are well below the 140 A^2 threshold for good oral absorption, and suitable for a peripherally acting GPCR like ADRB2.
3. **logP:** Ligand A (2.139) is within the optimal 1-3 range. Ligand B (0.591) is a bit low, potentially hindering membrane permeability. This is a slight advantage for A.
4. **HBD:** Ligand A (1) is preferable to Ligand B (0) as it provides a slight benefit to solubility.
5. **HBA:** Ligand A (3) and Ligand B (4) are both acceptable, below the 10 threshold.
6. **QED:** Ligand A (0.791) has a better QED score than Ligand B (0.514), indicating a more drug-like profile.
7. **DILI:** Both ligands have similar DILI risk (18.689 and 19.465), both being acceptable.
8. **BBB:** Ligand A (83.133) has a significantly higher BBB penetration percentile than Ligand B (62.233). While ADRB2 isn't a CNS target, higher BBB is generally favorable, suggesting better overall permeability.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.843 and -4.57). This is unusual and suggests poor permeability. However, the values are close, so it's not a major differentiator.
10. **Solubility:** Ligand A (-2.45) has slightly better solubility than Ligand B (-1.312).
11. **hERG:** Ligand A (0.556) has a lower hERG inhibition liability than Ligand B (0.236), which is a significant advantage for cardiac safety.
12. **Cl_mic:** Ligand A (5.017) has a lower microsomal clearance than Ligand B (17.19), indicating better metabolic stability.
13. **t1/2:** Ligand A (3.292) has a shorter half-life than Ligand B (8.169). This is a drawback for A.
14. **Pgp:** Ligand A (0.127) has lower P-gp efflux liability than Ligand B (0.039), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand A (-7.4 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.2 kcal/mol). This 1.2 kcal/mol difference is substantial and likely outweighs many of the minor ADME drawbacks.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand A excels in affinity and has acceptable logP and TPSA. Ligand B's low logP is a concern.
**Overall Assessment:**
Ligand A is the stronger candidate. Its significantly higher binding affinity, better QED, lower hERG risk, and improved metabolic stability outweigh the shorter half-life. The slightly better solubility and Pgp profile also contribute to its favorability. While both have poor Caco-2 permeability, the superior potency of Ligand A makes it more likely to succeed with further optimization.
Output:
1
2025-04-18 00:05:46,333 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (368.5 and 352.4 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand B (40.62) is significantly better than Ligand A (66.92). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (2.534) is optimal (1-3), while Ligand A (0.653) is slightly low, potentially hindering membrane permeability. This is a significant point in favor of Ligand B.
4. **HBD:** Both have 0 HBD, which is good.
5. **HBA:** Ligand B (2) is better than Ligand A (4), keeping within the desirable range.
6. **QED:** Ligand A (0.669) is slightly better than Ligand B (0.564), indicating a marginally more drug-like profile.
7. **DILI:** Ligand A (30.71) has a much lower DILI risk than Ligand B (51.03). This is a crucial advantage for Ligand A.
8. **BBB:** Ligand B (87.13) has a higher BBB penetration percentile than Ligand A (60.84). While not a primary concern for a cardiovascular target, it isn't detrimental.
9. **Caco-2:** Both are negative, suggesting poor permeability, but the values are very close (-4.311 vs -4.28).
10. **Solubility:** Ligand A (-1.694) is slightly better than Ligand B (-2.485), but both are quite poor.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.146 and 0.834).
12. **Cl_mic:** Ligand B (42.562) has lower microsomal clearance than Ligand A (46.827), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-40.318) has a significantly longer in vitro half-life than Ligand A (-16.13). This is a substantial advantage for Ligand B.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.048 and 0.478).
15. **Affinity:** Both ligands have the same binding affinity (-5.9 kcal/mol).
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand B excels in logP and has a better TPSA. Affinity is identical. While BBB isn't critical here, Ligand B's higher value isn't a negative. Ligand A has a significant advantage in DILI risk, but the other ADME properties of Ligand B are more favorable overall. The longer half-life of Ligand B is also a significant benefit.
**Conclusion:**
Despite the lower DILI risk for Ligand A, the superior logP, TPSA, metabolic stability (lower Cl_mic), and half-life of Ligand B outweigh this concern. The similar binding affinity makes the ADME profile the deciding factor.
Output:
0
2025-04-18 00:05:46,333 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.5 and 344.4 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (41.93) is significantly better than Ligand B (65.86). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold. Ligand B is approaching the upper limit.
3. **logP:** Ligand A (3.292) is optimal, while Ligand B (0.381) is quite low. GPCRs generally benefit from moderate lipophilicity for membrane permeability and receptor engagement. Ligand B's low logP is a significant concern.
4. **HBD:** Ligand A (1) is preferable to Ligand B (0). While both are low, a single H-bond donor can aid solubility.
5. **HBA:** Both ligands have 4 HBA, which is acceptable.
6. **QED:** Ligand A (0.822) is slightly better than Ligand B (0.779), indicating a more drug-like profile.
7. **DILI:** Ligand B (42.575) has a much lower DILI risk than Ligand A (6.475), which is a major advantage.
8. **BBB:** Ligand A (89.531) has better BBB penetration than Ligand B (62.195), but this isn't critical for a cardiovascular target.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so these values are difficult to interpret.
10. **Solubility:** Both ligands have negative solubility values, which is also unusual and suggests poor solubility. Again, the scale is not specified.
11. **hERG:** Ligand A (0.945) has a slightly higher hERG risk than Ligand B (0.206), but both are relatively low.
12. **Cl_mic:** Ligand A (15.496) has significantly lower microsomal clearance than Ligand B (30.622), indicating better metabolic stability.
13. **t1/2:** Ligand A (3.837) has a slightly longer half-life than Ligand B (-1.986), which is preferable.
14. **Pgp:** Ligand A (0.492) has lower P-gp efflux than Ligand B (0.066), which is a positive.
15. **Binding Affinity:** Ligand B (-7.8 kcal/mol) has a substantially stronger binding affinity than Ligand A (-4.2 kcal/mol). This is a significant advantage, potentially outweighing some ADME concerns.
**Overall Assessment:**
Ligand B has a much stronger binding affinity, which is the most important factor for GPCRs. It also has a significantly lower DILI risk. However, its low logP is a major concern, potentially hindering absorption and bioavailability. Ligand A has better ADME properties (TPSA, logP, Cl_mic, t1/2, Pgp) but weaker binding.
Given the substantial affinity difference, I believe the potential issues with Ligand B's logP can be addressed through formulation strategies or further chemical modifications. The strong binding is a critical starting point, and the lower DILI risk is also highly desirable.
Output:
0
2025-04-18 00:05:46,334 - INFO - Batch 452 complete. Total preferences: 7232
2025-04-18 00:05:46,334 - INFO - Processing batch 453/512...
2025-04-18 00:06:35,645 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (368.459 Da and 352.414 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (128.16) is slightly higher than Ligand B (78.07). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B is better here.
3. **logP:** Ligand A (-0.061) is quite low, potentially hindering membrane permeability. Ligand B (1.359) is within the optimal 1-3 range. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (3) is acceptable, while Ligand B (0) is even better, potentially improving permeability.
5. **HBA:** Ligand A (5) is acceptable, and Ligand B (7) is also within the reasonable limit of 10.
6. **QED:** Both ligands have reasonable QED scores (0.388 and 0.603), with Ligand B being slightly more drug-like.
7. **DILI:** Both have acceptable DILI risk (41.915 and 47.421), below the 60% threshold. No major difference.
8. **BBB:** Ligand A (51.105) is lower than Ligand B (92.943). While ADRB2 isn't strictly a CNS target, some brain penetration can be relevant for off-target effects or peripheral effects mediated by receptors in the brainstem. Ligand B is better.
9. **Caco-2:** Both have negative Caco-2 values (-5.613 and -4.714). This is unusual and suggests poor permeability *in vitro*. However, the values are relatively close.
10. **Solubility:** Both have negative solubility values (-2.329 and -1.398), which is also concerning. Ligand B is slightly better.
11. **hERG:** Both have low hERG risk (0.256 and 0.428). No significant difference.
12. **Cl_mic:** Ligand A (16.009) has a lower microsomal clearance than Ligand B (32.197), indicating better metabolic stability. This is a positive for Ligand A.
13. **t1/2:** Ligand A (-15.515) has a negative half-life, which is highly problematic. Ligand B (23.907) has a reasonable in vitro half-life. This is a major advantage for Ligand B.
14. **Pgp:** Both have very low Pgp efflux liability (0.03 and 0.151). No significant difference.
15. **Binding Affinity:** Ligand B (-7.3) has a slightly better binding affinity than Ligand A (-8.0). While A is better, the difference is not substantial enough to overcome the other deficiencies.
**Overall Assessment:**
Ligand B is the stronger candidate. While both have issues with Caco-2 and solubility, Ligand B has a much more favorable logP, a significantly better in vitro half-life, and a higher BBB penetration score. Ligand A's low logP and negative half-life are major drawbacks. The slightly better metabolic stability of Ligand A is outweighed by these other factors.
Output:
0
2025-04-18 00:06:35,645 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (351.447 and 348.403 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (89.95 and 84.86) are below the 140 A^2 threshold for good oral absorption. Ligand B is slightly better.
3. **logP:** Ligand A (0.123) is quite low, potentially hindering permeability. Ligand B (0.669) is better, but still on the lower side of the optimal 1-3 range. This is a concern for both, but more so for A.
4. **HBD:** Ligand A has 2 HBD, which is acceptable. Ligand B has 0, which is also good.
5. **HBA:** Ligand A has 4 HBA, acceptable. Ligand B has 6, still within the acceptable range of <=10.
6. **QED:** Both ligands have similar QED values (0.711 and 0.703), indicating good drug-likeness.
7. **DILI:** Ligand A (8.026%) has a significantly lower DILI risk than Ligand B (63.629%). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (72.354%) has a better BBB penetration score than Ligand A (46.491%). However, for a cardiovascular target like ADRB2, high BBB penetration isn't critical, and is even undesirable.
9. **Caco-2:** Ligand A (-5.094) has a worse Caco-2 permeability than Ligand B (-4.344). Both are negative, indicating poor permeability.
10. **Solubility:** Ligand A (-1.171) and Ligand B (-0.967) have similar solubility values.
11. **hERG:** Ligand A (0.144) has a slightly lower hERG inhibition liability than Ligand B (0.087), which is preferable.
12. **Cl_mic:** Ligand A (-17.845) has a much lower (better) microsomal clearance than Ligand B (34.664). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand B (-26.475) has a significantly longer in vitro half-life than Ligand A (5.984). This is a strong advantage for Ligand B.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.007 and 0.011).
15. **Affinity:** Ligand A (-6.0) has a slightly better binding affinity than Ligand B (-5.6). While the difference is less than the 1.5 kcal/mol threshold, it's still a positive for A.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand B is slightly better on logP and TPSA, but Ligand A has better affinity. The low logP of both is a concern. The biggest differentiator is the DILI risk and metabolic stability (Cl_mic), where Ligand A is significantly superior. BBB is not a major concern for a cardiovascular target.
**Conclusion:**
Despite Ligand B's better half-life and slightly better Caco-2 permeability, Ligand A's significantly lower DILI risk, better metabolic stability, and slightly better affinity outweigh these advantages. The low logP is a concern for both, but can be addressed through further optimization.
Output:
1
2025-04-18 00:06:35,645 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands (363.439 and 360.797 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand B (88.52) is significantly better than Ligand A (101.15). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have acceptable logP values (1.787 and 2.764), falling within the 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Both ligands have 2 HBD, which is within the acceptable limit of 5. No clear advantage.
5. **HBA:** Ligand B (4) is better than Ligand A (6), staying closer to the preferred limit of 10.
6. **QED:** Ligand B (0.855) has a substantially higher QED score than Ligand A (0.55), indicating a more drug-like profile.
7. **DILI:** Ligand A (76.774) has a lower DILI risk than Ligand B (97.867). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (45.56) has a lower BBB penetration than Ligand B (37.185). Since this is a cardiovascular target, BBB penetration is not a high priority.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.49 and -5.431), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-2.403) has better solubility than Ligand B (-3.718). Solubility is important for bioavailability.
11. **hERG:** Ligand B (0.015) has a much lower hERG inhibition liability than Ligand A (0.262). This is a critical advantage for Ligand B, reducing the risk of cardiotoxicity.
12. **Cl_mic:** Ligand B (-18.278) has significantly lower microsomal clearance than Ligand A (47.262), indicating better metabolic stability.
13. **t1/2:** Ligand B (-10.809) has a longer in vitro half-life than Ligand A (11.771). This is a positive for Ligand B.
14. **Pgp:** Ligand B (0.017) has lower P-gp efflux liability than Ligand A (0.164). Lower P-gp efflux is generally desirable.
15. **Affinity:** Ligand A (-6.9 kcal/mol) has a better binding affinity than Ligand B (-4.8 kcal/mol). This is a substantial advantage for Ligand A, exceeding the 1.5 kcal/mol threshold.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP, TPSA, Pgp, and metabolic stability. Ligand A has a significantly better affinity. The hERG liability of Ligand B is also a major positive.
**Overall Assessment:**
While Ligand A has a superior binding affinity, the combination of lower DILI risk for Ligand A is offset by the significantly better ADME profile of Ligand B (lower hERG, better metabolic stability, lower Pgp efflux, higher QED). The affinity difference, while substantial, might be overcome with further optimization of Ligand B. The safety profile of Ligand B is more promising.
Output:
0
2025-04-18 00:06:35,645 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's analyze each ligand against the provided guidelines, keeping in mind ADRB2 is a GPCR and thus we prioritize logP, Pgp, TPSA, and affinity.
* **Molecular Weight:** Both ligands (365.792 and 345.447 Da) fall within the ideal 200-500 Da range.
* **TPSA:** Ligand A (80.32) is better than Ligand B (87.22) as both are below the 140 threshold, but closer to the ideal for GPCRs.
* **logP:** Ligand A (2.124) is within the optimal 1-3 range. Ligand B (1.058) is on the lower side, potentially impacting permeability.
* **H-Bond Donors/Acceptors:** Both have 2 HBDs, which is good. Ligand A has 4 HBAs, and Ligand B has 5. Both are acceptable.
* **QED:** Both ligands have good QED scores (0.628 and 0.722), indicating good drug-like properties.
* **DILI:** Ligand A (80.109) has a higher DILI risk than Ligand B (20.279). This is a significant negative for Ligand A.
* **BBB:** Ligand B (64.87) has a better BBB penetration score than Ligand A (53.974), though neither is exceptionally high. For a cardiovascular target, BBB penetration is less critical, but still a consideration.
* **Caco-2 Permeability:** Ligand A (-4.737) has better Caco-2 permeability than Ligand B (-5.32).
* **Aqueous Solubility:** Ligand A (-4.182) has better aqueous solubility than Ligand B (-1.54).
* **hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.127 and 0.137).
* **Microsomal Clearance:** Ligand B (-6.133) has significantly lower microsomal clearance than Ligand A (72.965), suggesting better metabolic stability.
* **In vitro Half-Life:** Ligand B (2.99) has a better in vitro half-life than Ligand A (-4.817).
* **P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.144 and 0.003).
* **Binding Affinity:** Ligand B (-7.1 kcal/mol) has a stronger binding affinity than Ligand A (-6.4 kcal/mol). This is a 0.7 kcal/mol difference, which is significant.
**Overall Assessment:**
Ligand B is the stronger candidate. While Ligand A has slightly better Caco-2 permeability and solubility, Ligand B excels in the more critical areas: significantly lower DILI risk, better metabolic stability (lower Cl_mic, longer t1/2), and a substantially stronger binding affinity. The slightly lower logP of Ligand B is a minor concern that could be addressed with further optimization, but the benefits outweigh this drawback. The stronger binding affinity of Ligand B is particularly important for a GPCR target.
**Output:**
0
2025-04-18 00:06:35,645 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (366.439 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are below the 140 A^2 threshold for good oral absorption. Ligand B (92.34) is slightly lower than Ligand A (96.8), which is marginally better.
3. **logP:** Both are within the optimal range (1-3). Ligand B (0.889) is lower than Ligand A (1.813). While both are acceptable, a logP closer to 1 is generally preferred for better solubility without sacrificing permeability.
4. **HBD:** Ligand A (1) is better than Ligand B (2). Lower HBD is preferable for better membrane permeability.
5. **HBA:** Ligand A (6) is better than Ligand B (4). Similar to HBD, lower HBA is generally preferred.
6. **QED:** Ligand A (0.735) has a better QED score than Ligand B (0.501), indicating a more drug-like profile.
7. **DILI:** Ligand B (49.515) has a lower DILI risk than Ligand A (64.521), which is a significant advantage.
8. **BBB:** Ligand B (77.705) has a significantly higher BBB penetration score than Ligand A (48.74). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be beneficial and isn't necessarily detrimental for cardiovascular applications.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-5.319) is slightly better than Ligand B (-5.04).
10. **Solubility:** Both have negative solubility values, indicating poor aqueous solubility. Ligand A (-2.613) is slightly better than Ligand B (-2.566).
11. **hERG:** Both have very low hERG inhibition liability, which is excellent. Ligand B (0.459) is slightly better than Ligand A (0.045).
12. **Cl_mic:** Ligand A (6.593) has a much lower microsomal clearance than Ligand B (26.321), indicating better metabolic stability. This is a major advantage.
13. **t1/2:** Ligand B (-16.601) has a longer in vitro half-life than Ligand A (-12.214), which is generally desirable.
14. **Pgp:** Both have very low P-gp efflux liability. Ligand A (0.018) is slightly better than Ligand B (0.04).
15. **Binding Affinity:** Ligand B (-7.4 kcal/mol) has a slightly better binding affinity than Ligand A (-7.2 kcal/mol). This difference is relatively small, but still noteworthy.
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Ligand B excels in BBB penetration and has slightly better affinity. However, Ligand A has a significantly better QED score, lower Cl_mic (better metabolic stability), and slightly better Caco-2 and Pgp values. The DILI risk is also lower for Ligand B.
**Overall Assessment:**
While Ligand B has a slightly better binding affinity and BBB penetration, the significantly better metabolic stability (lower Cl_mic) and QED score of Ligand A, combined with its acceptable ADME properties, make it the more promising candidate. The lower DILI risk of Ligand B is attractive, but the metabolic stability is a critical factor for *in vivo* efficacy.
Output:
1
2025-04-18 00:06:35,645 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (371.5) is within the ideal range (200-500). Ligand B (348.5) is also excellent. No clear advantage here.
2. **TPSA:** Ligand A (78.95) is acceptable, though approaching the upper limit for good oral absorption. Ligand B (49.85) is excellent, well below the 140 threshold. This favors Ligand B.
3. **logP:** Ligand A (0.34) is quite low, potentially hindering permeability. Ligand B (2.894) is optimal. This strongly favors Ligand B.
4. **HBD:** Ligand A (1) is good. Ligand B (0) is also good. No significant difference.
5. **HBA:** Ligand A (6) is good. Ligand B (3) is excellent. This favors Ligand B.
6. **QED:** Both ligands (A: 0.679, B: 0.768) are above the 0.5 threshold and are good. Ligand B is slightly better.
7. **DILI:** Ligand A (36.293) is good (low risk). Ligand B (26.095) is even better. This favors Ligand B.
8. **BBB:** Ligand A (56.495) is moderate. Ligand B (86.39) is excellent, suggesting better potential for CNS penetration if desired (though ADRB2 is primarily cardiovascular, some CNS effects are possible). This favors Ligand B.
9. **Caco-2:** Both ligands have negative values, indicating poor permeability. Ligand A (-4.958) is worse than Ligand B (-4.405). This favors Ligand B, though both are concerning.
10. **Solubility:** Both ligands have negative solubility values, indicating poor solubility. Ligand A (-1.658) is worse than Ligand B (-2.434). This favors Ligand B, though both are concerning.
11. **hERG:** Both ligands have low hERG inhibition liability (A: 0.204, B: 0.266). No significant difference.
12. **Cl_mic:** Ligand A (60.685) has a higher clearance than Ligand B (47.903), suggesting lower metabolic stability. This favors Ligand B.
13. **t1/2:** Ligand B (10.864) has a longer half-life than Ligand A (-10.809). This favors Ligand B.
14. **Pgp:** Both ligands have low Pgp efflux liability (A: 0.026, B: 0.324). No significant difference.
15. **Binding Affinity:** Ligand B (-7.1) has a significantly stronger binding affinity than Ligand A (-4.8). This is a substantial advantage, potentially outweighing some of the ADME concerns.
**Overall Assessment:**
Ligand B consistently outperforms Ligand A across most critical ADME properties (logP, TPSA, DILI, BBB, Cl_mic, t1/2, solubility, Caco-2) and has a significantly stronger binding affinity. While both have issues with Caco-2 and solubility, Ligand B is better on both counts. The stronger binding affinity of Ligand B is a major advantage for a GPCR target like ADRB2.
Output:
0
2025-04-18 00:06:35,645 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (370.471 and 366.483 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (68.31 and 67.87) are below the 140 A^2 threshold for good oral absorption and are reasonably well-suited for a peripherally acting GPCR like ADRB2. No major difference.
3. **logP:** Both ligands (1.481 and 1.91) are within the optimal 1-3 range. Ligand B is slightly higher, which *could* be beneficial for membrane permeability, but isn't a huge difference.
4. **HBD:** Ligand A has 0 HBD, while Ligand B has 1. Both are acceptable, but lower is generally preferred for permeability.
5. **HBA:** Ligand A has 6 HBA, and Ligand B has 5. Both are below the 10 threshold.
6. **QED:** Both ligands have good QED scores (0.759 and 0.8), indicating good drug-like properties.
7. **DILI:** Ligand A has a DILI risk of 54.944%, while Ligand B has 34.432%. Ligand B is significantly better here, indicating a lower risk of liver injury. This is a substantial advantage.
8. **BBB:** Ligand A has a BBB penetration of 66.925%, and Ligand B has 70.997%. While ADRB2 isn't a CNS target, some degree of BBB penetration can sometimes indicate favorable partitioning. Ligand B is slightly better.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.526 and -4.812). These are unusual and suggest poor permeability. However, these values are on a strange scale and might not be directly comparable.
10. **Solubility:** Ligand A (-1.472) and Ligand B (-2.466) both have negative solubility values, indicating poor aqueous solubility. Ligand B is worse in this regard.
11. **hERG:** Both ligands have low hERG inhibition liability (0.179 and 0.308), which is excellent.
12. **Cl_mic:** Ligand A has a higher microsomal clearance (43.086) than Ligand B (24.311). Lower clearance is better for metabolic stability, so Ligand B is preferred.
13. **t1/2:** Ligand A has a longer in vitro half-life (27.903) than Ligand B (15.912). This is a significant advantage for Ligand A.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.121 and 0.064), which is good.
15. **Binding Affinity:** Ligand A (-7.7 kcal/mol) has a significantly stronger binding affinity than Ligand B (-4.5 kcal/mol). This is a very substantial difference, and a >3 kcal/mol advantage often outweighs other concerns.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Affinity is the most important. While Ligand B has some advantages in DILI and Cl_mic, the much stronger binding affinity of Ligand A is the deciding factor. The difference in binding affinity is large enough to potentially overcome the slightly higher DILI risk of Ligand A.
Output:
1
2025-04-18 00:06:35,646 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [364.383, 40.62, 2.771, 0, 2, 0.72, 20.202, 96.394, -4.483, -3.214, 0.616, 19.196, -2.208, 0.127, -5.7]
**Ligand B:** [343.387, 117.42, -0.302, 3, 4, 0.615, 48.934, 54.362, -5.009, -2.445, 0.07, -23.936, -2.891, 0.005, -2.9]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (343.387) is slightly lower, which could be beneficial for permeability, but both are acceptable.
2. **TPSA:** Ligand A (40.62) is significantly better than Ligand B (117.42). For a GPCR, keeping TPSA low is good, and A is well below the 140 threshold. B is pushing the limit for oral absorption.
3. **logP:** Ligand A (2.771) is optimal. Ligand B (-0.302) is too low, potentially hindering membrane permeability and bioavailability.
4. **HBD:** Ligand A (0) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (2) is preferable to Ligand B (4). Fewer HBAs generally improve permeability.
6. **QED:** Both are similar (A: 0.72, B: 0.615) and above the 0.5 threshold, indicating good drug-like properties.
7. **DILI:** Ligand A (20.202) is *much* better than Ligand B (48.934). Lower DILI risk is critical.
8. **BBB:** Ligand A (96.394) is excellent, while Ligand B (54.362) is moderate. While ADRB2 isn't exclusively a CNS target, some CNS penetration can be beneficial, and high BBB is rarely detrimental.
9. **Caco-2:** Ligand A (-4.483) and B (-5.009) are both negative, indicating poor permeability. However, this scale is not intuitive.
10. **Solubility:** Ligand A (-3.214) and B (-2.445) are both negative, indicating poor solubility. However, this scale is not intuitive.
11. **hERG:** Ligand A (0.616) is better than Ligand B (0.07). Lower hERG risk is crucial for cardiovascular drugs.
12. **Cl_mic:** Ligand A (19.196) is better than Ligand B (-23.936). Lower clearance indicates better metabolic stability.
13. **t1/2:** Ligand A (-2.208) is better than Ligand B (-2.891). Longer half-life is generally preferred.
14. **Pgp:** Ligand A (0.127) is better than Ligand B (0.005). Lower P-gp efflux is desirable for better bioavailability.
15. **Affinity:** Ligand A (-5.7) is significantly better than Ligand B (-2.9). A difference of 2.8 kcal/mol is substantial and can often outweigh minor ADME drawbacks.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A excels in all these areas. While BBB isn't paramount for ADRB2, the high value for Ligand A isn't a disadvantage.
**Conclusion:**
Ligand A is substantially better than Ligand B across almost all critical parameters, especially affinity, DILI risk, TPSA, logP, and metabolic stability. The significantly stronger binding affinity of Ligand A (-5.7 kcal/mol vs -2.9 kcal/mol) is a major advantage.
**Output:**
1
2025-04-18 00:06:35,646 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (375.447 and 348.447 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (128.03) is slightly higher than Ligand B (78.67). For a cardiovascular GPCR, TPSA is moderately important, and Ligand B is significantly better, being well below the 140 threshold.
**3. logP:** Ligand A (-0.583) is a bit low, potentially hindering permeability. Ligand B (0.976) is within the optimal 1-3 range. This favors Ligand B.
**4. H-Bond Donors:** Ligand A (2) and Ligand B (1) are both acceptable, below the 5 threshold.
**5. H-Bond Acceptors:** Ligand A (6) and Ligand B (5) are both acceptable, below the 10 threshold.
**6. QED:** Both ligands have good QED scores (0.633 and 0.745), indicating good drug-like properties. Ligand B is slightly better.
**7. DILI:** Ligand A (49.399) has a moderate DILI risk, while Ligand B (19.93) has a very low DILI risk. This is a significant advantage for Ligand B.
**8. BBB:** Ligand A (73.284) shows reasonable BBB penetration, while Ligand B (42.187) is lower. While not a primary concern for a cardiovascular target, some CNS exposure is not necessarily detrimental and could offer additional benefits.
**9. Caco-2 Permeability:** Ligand A (-5.088) has poor Caco-2 permeability, while Ligand B (-4.59) is also poor, but slightly better.
**10. Aqueous Solubility:** Ligand A (-1.935) has poor solubility, while Ligand B (-0.648) is also poor, but slightly better.
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.13 and 0.271). This is good for both.
**12. Microsomal Clearance:** Ligand A (20.632) has a moderate clearance, while Ligand B (25.779) has a higher clearance. This favors Ligand A, indicating better metabolic stability.
**13. In vitro Half-Life:** Ligand A (-17.534) has a negative half-life, which is not possible and indicates an issue with the data. Ligand B (-20.363) also has a negative half-life, indicating data issues with both.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.023 and 0.082), which is favorable.
**15. Binding Affinity:** Ligand A (-7.9) has a slightly better binding affinity than Ligand B (-6.1), a difference of 1.8 kcal/mol. This is a substantial advantage.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand B has a better balance of properties. While Ligand A has a slightly better affinity, Ligand B excels in crucial ADME properties like logP, TPSA, and DILI risk. The poor solubility and permeability of both are concerning, but Ligand B is slightly better in these aspects. The negative half-life values are concerning and suggest data quality issues, but we must proceed based on the available information. The significantly lower DILI risk for Ligand B is a major advantage. The affinity difference, while notable, can potentially be optimized in later stages of drug development.
Output:
0
2025-04-18 00:06:35,646 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (339.403) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (75.19) is significantly better than Ligand A (101.38). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA is still beneficial for absorption.
3. **logP:** Both ligands have excellent logP values (around 2.03), falling within the optimal 1-3 range.
4. **HBD:** Ligand B (1 HBD) is better than Ligand A (2 HBD). Lower HBD generally improves permeability.
5. **HBA:** Ligand B (5 HBA) is slightly better than Ligand A (6 HBA).
6. **QED:** Both ligands have good QED scores (A: 0.686, B: 0.8), indicating good drug-likeness. Ligand B is slightly better.
7. **DILI:** Ligand B (66.615) is better than Ligand A (80.923). Lower DILI risk is crucial.
8. **BBB:** Ligand B (55.642) is better than Ligand A (37.767). While not a primary concern for a cardiovascular target, higher BBB is generally a positive attribute.
9. **Caco-2:** Both are negative, but Ligand B (-4.827) is less negative than Ligand A (-5.621), suggesting better permeability.
10. **Solubility:** Both are negative, but Ligand B (-3.746) is less negative than Ligand A (-3.152), indicating better solubility.
11. **hERG:** Both ligands have low hERG inhibition risk (A: 0.284, B: 0.421).
12. **Cl_mic:** Ligand A (5.575) has significantly lower microsomal clearance than Ligand B (71.277), suggesting better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand B (-26.058) has a much longer in vitro half-life than Ligand A (2.472). This is a major advantage, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have low P-gp efflux liability (A: 0.187, B: 0.114). Ligand B is slightly better.
15. **Binding Affinity:** Ligand B (-5.9 kcal/mol) has a slightly better binding affinity than Ligand A (-5.1 kcal/mol). This 0.8 kcal/mol difference is meaningful.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand B excels in TPSA, Pgp, and affinity, while both are good for logP. The improved half-life and lower DILI risk of Ligand B are also very important. While Ligand A has better metabolic stability (lower Cl_mic), the longer half-life of Ligand B mitigates the need for extremely low clearance.
**Conclusion:**
Considering the balance of properties, and prioritizing the GPCR-specific parameters along with safety (DILI) and PK (t1/2), Ligand B is the more promising drug candidate. The slightly better affinity, lower TPSA, better solubility, lower DILI risk, and significantly longer half-life outweigh the better metabolic stability of Ligand A.
Output:
0
2025-04-18 00:06:35,646 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (344.39 Da and 355.479 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (67.23) is significantly better than Ligand B (82.11). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is approaching a level that could hinder absorption.
**3. logP:** Ligand A (1.804) is within the optimal 1-3 range. Ligand B (0.247) is quite low, potentially leading to poor membrane permeability. This is a significant drawback.
**4. H-Bond Donors:** Ligand A (1) and Ligand B (2) are both acceptable, below the threshold of 5.
**5. H-Bond Acceptors:** Ligand A (4) and Ligand B (5) are both acceptable, below the threshold of 10.
**6. QED:** Ligand A (0.864) has a much better QED score than Ligand B (0.549), indicating a more drug-like profile.
**7. DILI Risk:** Ligand B (7.871) has a substantially lower DILI risk than Ligand A (59.131). This is a major advantage for Ligand B.
**8. BBB Penetration:** Ligand A (76.58) has better BBB penetration than Ligand B (48.313). While ADRB2 is a cardiovascular target, some CNS effects are possible with certain ligands, and better BBB penetration is generally favorable.
**9. Caco-2 Permeability:** Ligand A (-4.71) has better Caco-2 permeability than Ligand B (-5.054).
**10. Aqueous Solubility:** Ligand A (-2.95) has better aqueous solubility than Ligand B (-0.327).
**11. hERG Inhibition:** Ligand A (0.263) has a lower hERG risk than Ligand B (0.186). This is a positive for Ligand A.
**12. Microsomal Clearance:** Ligand B (24.626) has significantly lower microsomal clearance than Ligand A (46.643), indicating better metabolic stability.
**13. In vitro Half-Life:** Ligand B (-7.437) has a longer in vitro half-life than Ligand A (6.432). This is a significant advantage for Ligand B.
**14. P-gp Efflux:** Ligand A (0.179) has lower P-gp efflux than Ligand B (0.009).
**15. Binding Affinity:** Ligand A (-6.3 kcal/mol) and Ligand B (-5.6 kcal/mol) both have good binding affinity, but Ligand A is stronger. The difference of 0.7 kcal/mol is significant, and can outweigh some ADME drawbacks.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand A is the better candidate. While Ligand B has a much better safety profile (DILI, hERG) and metabolic stability, its poor logP and TPSA are concerning for permeability and absorption. The stronger binding affinity of Ligand A is also a key advantage. The better QED score of Ligand A also supports its selection.
Output:
1
2025-04-18 00:06:35,646 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (353.34 and 374.566 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands have similar TPSA values (58.56 and 58.2), which are acceptable for oral absorption, being below 140.
3. **logP:** Both ligands have good logP values (4.01 and 3.553), falling within the optimal 1-3 range, though Ligand A is slightly higher. This could potentially lead to some off-target effects, but isn't a major concern.
4. **HBD & HBA:** Both ligands have 2 HBD and 3 HBA, which are within acceptable limits.
5. **QED:** Ligand A (0.824) has a higher QED score than Ligand B (0.683), suggesting a more drug-like profile.
6. **DILI:** Ligand B (18.108) has a significantly lower DILI risk than Ligand A (56.146). This is a major advantage for Ligand B.
7. **BBB:** Ligand B (76.541) has a much higher BBB penetration percentile than Ligand A (36.952). While ADRB2 isn't strictly a CNS target, some CNS exposure can occur, and higher BBB penetration is generally favorable.
8. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. Ligand B (-5.077) is slightly worse than Ligand A (-4.96).
9. **Solubility:** Both ligands have very poor aqueous solubility (-3.79 and -4.254). This is a significant drawback for both.
10. **hERG:** Both ligands have similar hERG inhibition liability (0.663 and 0.711).
11. **Cl_mic:** Ligand B (74.34) has a significantly higher microsomal clearance than Ligand A (27.207), indicating faster metabolism and potentially lower *in vivo* exposure.
12. **t1/2:** Ligand A (-4.215) has a more negative half-life, suggesting a shorter half-life than Ligand B (17.586).
13. **Pgp:** Both ligands have low Pgp efflux liability (0.322 and 0.131).
14. **Binding Affinity:** Both ligands have very similar binding affinities (-6.2 and -6.0 kcal/mol). The difference is negligible.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are crucial. Both ligands perform similarly on logP, Pgp, and affinity. TPSA is acceptable for both. However, Ligand B has a significantly better BBB profile and a much lower DILI risk. While Ligand A has a better QED and metabolic stability (lower Cl_mic), the DILI and BBB advantages of Ligand B are more compelling, especially considering the potential for off-target effects with the higher logP of Ligand A. The solubility is poor for both, which would need to be addressed in formulation.
**Conclusion:**
Considering the balance of properties and the priorities for a GPCR target, Ligand B is the more promising candidate due to its significantly lower DILI risk and better BBB penetration, despite its higher metabolic clearance and slightly worse Caco-2 permeability.
Output:
0
2025-04-18 00:06:35,646 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (342.37) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (59.5) is significantly better than Ligand B (72.28). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (A: 2.563, B: 1.685), falling within the optimal 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Ligand A (0) is preferable to Ligand B (1). Fewer hydrogen bond donors generally improve permeability.
5. **HBA:** Ligand A (4) is better than Ligand B (6). Lower HBA counts are generally preferred for better permeability.
6. **QED:** Both ligands have good QED scores (A: 0.787, B: 0.827), indicating good drug-likeness.
7. **DILI:** Ligand A (56.611) is slightly better than Ligand B (61.574), indicating a lower risk of drug-induced liver injury. Both are acceptable, but lower is always preferred.
8. **BBB:** Ligand A (98.216) is significantly better than Ligand B (82.086). While not a primary concern for a cardiovascular target, higher BBB penetration can sometimes indicate better overall permeability.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.158 and -4.869). This is unusual and suggests poor permeability *in vitro*. However, these values are on a scale where negative values are possible, and the absolute magnitude isn't directly comparable without knowing the scale.
10. **Solubility:** Ligand A (-3.061) is slightly better than Ligand B (-2.599). Higher solubility is always desirable.
11. **hERG:** Ligand A (0.825) is better than Ligand B (0.342). Lower hERG inhibition is crucial to avoid cardiotoxicity, especially for a cardiovascular target.
12. **Cl_mic:** Ligand A (68.543) is worse than Ligand B (37.479). Lower clearance is preferable for increased metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand A (-14.411) is significantly worse than Ligand B (0.842). A longer half-life is generally desirable. This is another significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.209) is better than Ligand B (0.035). Lower P-gp efflux is preferable for better bioavailability.
15. **Binding Affinity:** Ligand A (-6.9 kcal/mol) is slightly better than Ligand B (-5.9 kcal/mol). This difference in affinity is substantial and could outweigh some ADME drawbacks.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A excels in logP, TPSA, and Pgp, and has a better binding affinity. Ligand B has better metabolic stability (Cl_mic, t1/2). The affinity difference is the most important factor here.
**Overall Assessment:**
While Ligand B has superior metabolic stability, the significantly better binding affinity of Ligand A (-6.9 vs -5.9 kcal/mol) and its more favorable TPSA, logP, Pgp, and hERG profile outweigh the metabolic concerns. The difference in affinity is substantial enough to suggest Ligand A is more likely to be a viable drug candidate.
Output:
1
2025-04-18 00:06:35,646 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (353.419 and 351.491 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (96.97) is higher than Ligand B (78.51). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B has a better TPSA.
3. **logP:** Ligand B (1.833) is within the optimal 1-3 range, while Ligand A (0.529) is slightly below 1. This is a significant drawback for Ligand A, as it might struggle with membrane permeability.
4. **HBD:** Both ligands have 2 H-bond donors, which is acceptable.
5. **HBA:** Ligand A has 5 H-bond acceptors, while Ligand B has 3. Both are within the acceptable limit of 10, but lower is generally better for permeability. Ligand B is slightly better.
6. **QED:** Ligand B (0.7) has a better QED score than Ligand A (0.59), indicating a more drug-like profile.
7. **DILI:** Ligand B (15.394) has a much lower DILI risk than Ligand A (37.146). This is a major advantage for Ligand B.
8. **BBB:** Ligand B (69.872) has a higher BBB penetration percentile than Ligand A (54.44). While ADRB2 isn't a primary CNS target, some brain exposure can be relevant for off-target effects.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.625 and -5.134), which is unusual and suggests poor permeability. However, these values are on a log scale, so the absolute difference is less important than the overall trend.
10. **Solubility:** Both ligands have very poor aqueous solubility (-1.72 and -1.938). This is a significant concern for both, but could be addressed with formulation strategies.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.152 and 0.161). This is good.
12. **Cl_mic:** Ligand A (-6.323) has a significantly lower (better) microsomal clearance than Ligand B (15.263), suggesting better metabolic stability.
13. **t1/2:** Ligand B (3.166) has a longer in vitro half-life than Ligand A (-3.766). This is a positive for Ligand B.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.023 and 0.02). This is good.
15. **Binding Affinity:** Ligand A (-6.3 kcal/mol) has a stronger binding affinity than Ligand B (-3.3 kcal/mol). This is a substantial advantage for Ligand A.
**Overall Assessment:**
The key trade-off is between Ligand A's superior binding affinity and Ligand B's better ADME properties (logP, DILI, QED, t1/2, TPSA). Given that the affinity difference is 3 kcal/mol, which is significant, and considering the poor solubility of both compounds, I lean towards Ligand A. The better metabolic stability (lower Cl_mic) also helps mitigate potential issues arising from the lower logP. While the logP is suboptimal, the strong binding affinity might compensate for it, and formulation strategies can be explored to address the solubility issue.
Output:
1
2025-04-18 00:06:35,646 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (338.451 and 357.479 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (49.41) is significantly better than Ligand B (71.09). For a GPCR, lower TPSA is generally preferred for better permeability. Ligand B is approaching a level that could hinder oral absorption.
**3. logP:** Both ligands have acceptable logP values (2.294 and 3.177, respectively), falling within the 1-3 range. Ligand B is slightly higher, which could potentially lead to off-target interactions, but it's not a major concern.
**4. H-Bond Donors:** Both have a reasonable number of HBDs (1 and 2, respectively), well below the threshold of 5.
**5. H-Bond Acceptors:** Ligand A (2) is better than Ligand B (4), keeping within the preferred range of <=10.
**6. QED:** Both ligands have similar QED values (0.855 and 0.834), indicating good drug-like properties.
**7. DILI Risk:** Ligand A (18.883) has a much lower DILI risk than Ligand B (70.182). This is a significant advantage for Ligand A.
**8. BBB Penetration:** Ligand A (83.288) has better BBB penetration than Ligand B (55.603). While ADRB2 is a cardiovascular target and CNS penetration isn't *essential*, some level of BBB penetration can be beneficial for understanding off-target effects and potential systemic activity.
**9. Caco-2 Permeability:** Both have negative Caco-2 values, which is unusual. However, the magnitude is similar (-4.906 and -5.049). This suggests poor permeability for both, but we must consider this alongside TPSA.
**10. Aqueous Solubility:** Both ligands have very poor aqueous solubility (-3.667 and -4.175). This is a significant drawback for both, potentially causing formulation challenges.
**11. hERG Inhibition:** Ligand A (0.176) has a much lower hERG inhibition risk than Ligand B (0.333). This is a critical safety parameter, and Ligand A is significantly better.
**12. Microsomal Clearance:** Ligand B (38.868) has slightly higher microsomal clearance than Ligand A (35.683). This suggests Ligand A might be more metabolically stable.
**13. In vitro Half-Life:** Ligand A (-9.575) has a much longer in vitro half-life than Ligand B (32.729). This is a significant advantage for Ligand A, potentially allowing for less frequent dosing.
**14. P-gp Efflux:** Both ligands show low P-gp efflux liability (0.171 and 0.321).
**15. Binding Affinity:** Ligand A (-7.9 kcal/mol) has a slightly better binding affinity than Ligand B (-4.5 kcal/mol). This is a substantial difference, and a >3.4 kcal/mol advantage can often outweigh minor ADME drawbacks.
**Overall Assessment:**
Ligand A is clearly the superior candidate. It exhibits better TPSA, significantly lower DILI risk, better BBB penetration, lower hERG inhibition, longer half-life, and a substantially stronger binding affinity. While both have poor solubility, the other advantages of Ligand A outweigh this drawback. The combination of improved safety (DILI, hERG) and potency (affinity) makes Ligand A the more promising drug candidate.
Output:
1
2025-04-18 00:06:35,646 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (362.47 and 356.398 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (62.22) is significantly better than Ligand B (94.36). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold. Ligand B is approaching the upper limit.
3. **logP:** Ligand A (3.504) is within the optimal 1-3 range. Ligand B (-0.277) is *below* 1, which is a concern for permeability. This is a significant negative for Ligand B.
4. **HBD:** Both have 2 HBD, which is good.
5. **HBA:** Ligand A has 4 HBA, while Ligand B has 6. Both are acceptable, but Ligand A is slightly better.
6. **QED:** Both ligands have similar QED scores (0.792 and 0.703), indicating good drug-likeness.
7. **DILI:** Ligand A (48.236) has a slightly higher DILI risk than Ligand B (43.66), but both are well below the concerning threshold of 60.
8. **BBB:** Ligand B (77.937) has a higher BBB penetration score than Ligand A (68.515). However, as ADRB2 is a cardiovascular target, BBB penetration is not a high priority.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
10. **Solubility:** Ligand A (-4.436) has slightly better solubility than Ligand B (-1.709).
11. **hERG:** Ligand A (0.569) has a lower hERG risk than Ligand B (0.387), which is preferable.
12. **Cl_mic:** Ligand B (4.459) has significantly lower microsomal clearance than Ligand A (38.813), indicating better metabolic stability. This is a strong point for Ligand B.
13. **t1/2:** Ligand A (5.018) has a longer in vitro half-life than Ligand B (2.967). This is a positive for Ligand A.
14. **Pgp:** Ligand A (0.372) has lower P-gp efflux than Ligand B (0.108), which is favorable.
15. **Binding Affinity:** Ligand B (-6.6) has a slightly stronger binding affinity than Ligand A (-6.4). While a 1.5 kcal/mol difference is usually significant, the other ADME properties of Ligand B are concerning.
**Overall Assessment:**
Ligand A is the better candidate. While Ligand B has slightly better binding affinity and metabolic stability, its significantly lower logP is a major drawback, likely hindering its permeability and bioavailability. Ligand A has a more balanced profile, with acceptable ADME properties and a reasonable binding affinity. The lower TPSA and hERG risk of Ligand A are also advantageous. Considering the GPCR-specific priorities (logP, TPSA, affinity), Ligand A is the stronger choice.
Output:
1
2025-04-18 00:06:35,646 - INFO - Batch 453 complete. Total preferences: 7248
2025-04-18 00:06:35,646 - INFO - Processing batch 454/512...
2025-04-18 00:07:25,372 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [344.455, 67.43, 1.477, 2, 3, 0.717, 34.471, 62.117, -4.709, -2.78, 0.241, 15.062, 2.333, 0.033, -6.6]
**Ligand B:** [377.901, 82.7, 4.374, 3, 5, 0.595, 84.839, 40.403, -5.316, -4.423, 0.623, 38.435, 138.501, 0.409, -6.5]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (344.455) is slightly preferred due to being lower.
2. **TPSA:** Ligand A (67.43) is significantly better than Ligand B (82.7), falling well below the 140 threshold for oral absorption.
3. **logP:** Ligand A (1.477) is optimal, while Ligand B (4.374) is pushing the upper limit and could lead to solubility issues.
4. **HBD:** Both have acceptable HBD counts (2 and 3 respectively).
5. **HBA:** Both have acceptable HBA counts (3 and 5 respectively).
6. **QED:** Ligand A (0.717) has a better QED score than Ligand B (0.595), indicating better overall drug-likeness.
7. **DILI:** Ligand A (34.471) has a much lower DILI risk than Ligand B (84.839). This is a significant advantage.
8. **BBB:** Ligand A (62.117) is better than Ligand B (40.403), though neither is exceptionally high. For a cardiovascular target, BBB isn't *critical*, but a higher value is still preferred.
9. **Caco-2:** Ligand A (-4.709) is better than Ligand B (-5.316), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-2.78) is better than Ligand B (-4.423).
11. **hERG:** Ligand A (0.241) has a much lower hERG risk than Ligand B (0.623). This is a crucial safety parameter.
12. **Cl_mic:** Ligand A (15.062) has a lower microsomal clearance than Ligand B (38.435), suggesting better metabolic stability.
13. **t1/2:** Ligand B (138.501) has a significantly longer in vitro half-life than Ligand A (2.333). This is a notable advantage for Ligand B.
14. **Pgp:** Ligand A (0.033) has much lower P-gp efflux than Ligand B (0.409), which is favorable for bioavailability.
15. **Affinity:** Both ligands have very similar binding affinities (-6.6 and -6.5 kcal/mol). The difference is negligible.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A excels in logP, TPSA, and Pgp. While both have comparable affinity, the superior ADME profile of Ligand A, particularly the lower DILI and hERG risks, outweighs the longer half-life of Ligand B.
**Conclusion:**
Ligand A demonstrates a significantly more balanced and favorable profile overall, particularly regarding safety (DILI, hERG) and ADME properties crucial for oral bioavailability.
Output:
1
2025-04-18 00:07:25,372 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.475 and 341.407 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (69.72 and 68.39) are well below the 140 A^2 threshold for oral absorption and suitable for a peripheral GPCR like ADRB2. Again, no major difference.
3. **logP:** Ligand A (1.398) is within the optimal 1-3 range. Ligand B (3.673) is at the higher end, potentially leading to solubility issues or off-target interactions, but still within an acceptable range.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 3 HBA, Ligand B has 4. Both are acceptable, below the 10 threshold.
6. **QED:** Both ligands have good QED scores (0.763 and 0.865), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (23.769) has a significantly lower DILI risk than Ligand B (57.154). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (54.983) has a lower BBB penetration than Ligand B (76.386). While ADRB2 isn't a CNS target, some degree of BBB penetration can sometimes indicate promiscuity, but it's not a major concern here.
9. **Caco-2:** Both have negative Caco-2 values (-4.785 and -4.393). This is unusual and suggests poor permeability. However, these values are on a strange scale and might not be directly comparable.
10. **Solubility:** Ligand A (-2.553) has slightly better solubility than Ligand B (-4.567), though both are poor.
11. **hERG:** Ligand A (0.272) shows a lower hERG inhibition liability than Ligand B (0.625), which is favorable.
12. **Cl_mic:** Ligand A (30.777) has a lower microsomal clearance, suggesting better metabolic stability than Ligand B (80.62).
13. **t1/2:** Ligand A (4.191) has a slightly longer in vitro half-life than Ligand B (0.289).
14. **Pgp:** Ligand A (0.077) has significantly lower P-gp efflux liability than Ligand B (0.383), which is a positive.
15. **Binding Affinity:** Ligand B (-7.1 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.2 kcal/mol). This is a substantial advantage, exceeding the 1.5 kcal/mol threshold.
**GPCR-specific priorities:** For ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand B excels in affinity, and its logP is acceptable. Ligand A has better Pgp and TPSA, but the affinity difference is substantial. The DILI and hERG risks are also lower for Ligand A, but the binding affinity difference is the most important factor.
**Conclusion:**
Despite the better safety profile of Ligand A, the significantly stronger binding affinity of Ligand B (-7.1 vs -6.2 kcal/mol) outweighs the drawbacks in DILI, hERG, and Pgp efflux. A strong binding affinity is crucial for a GPCR ligand, and the difference here is substantial enough to make Ligand B the more promising candidate.
Output:
0
2025-04-18 00:07:25,373 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [353.423, 107.84 , 1.33 , 0. , 5. , 0.354, 35.789, 64.095, -4.803, -0.425, 0.215, 3.368, 20.549, 0.011, -7.4 ]
**Ligand B:** [379.429, 100.55 , 1.524, 3. , 6. , 0.535, 67.158, 38.193, -5.279, -2.293, 0.289, 20.722, -9.532, 0.145, -7.5 ]
Here's a breakdown, prioritizing GPCR properties (logP, Pgp, TPSA, and affinity) and considering the other parameters:
1. **MW:** Both are within the acceptable range (200-500 Da). Ligand A (353.423) is slightly preferred.
2. **TPSA:** Both are reasonably good (A: 107.84, B: 100.55), under the 140 threshold for oral absorption. Ligand B is slightly better.
3. **logP:** Both are within the optimal range (1-3). A (1.33) and B (1.524) are both good.
4. **HBD/HBA:** A (0/5) is better than B (3/6). Fewer H-bonds are generally preferable for permeability.
5. **QED:** Ligand B (0.535) has a better QED score than A (0.354), suggesting a more drug-like profile.
6. **DILI:** Ligand A (35.789) has a significantly lower DILI risk than Ligand B (67.158). This is a major advantage for A.
7. **BBB:** Ligand A (64.095) has better BBB penetration than Ligand B (38.193). While not a primary concern for ADRB2 (cardiovascular target), it's a positive.
8. **Caco-2:** Both are negative, indicating poor permeability. Ligand B (-5.279) is slightly worse than Ligand A (-4.803).
9. **Solubility:** Ligand A (-0.425) is better than Ligand B (-2.293).
10. **hERG:** Both are low risk (A: 0.215, B: 0.289).
11. **Cl_mic:** Ligand A (3.368) has lower microsomal clearance than Ligand B (20.722), suggesting better metabolic stability.
12. **t1/2:** Ligand A (20.549) has a longer in vitro half-life than Ligand B (-9.532).
13. **Pgp:** Both are very low (A: 0.011, B: 0.145), indicating minimal P-glycoprotein efflux. A is slightly better.
14. **Affinity:** Both have excellent binding affinity (-7.4 and -7.5 kcal/mol). The difference is negligible.
**Overall Assessment:**
Ligand A is superior. While Ligand B has a slightly better QED and TPSA, Ligand A excels in crucial areas: significantly lower DILI risk, better BBB penetration, improved solubility, better metabolic stability (lower Cl_mic, longer t1/2), and slightly better Caco-2 and Pgp values. The binding affinity is essentially the same. The lower DILI risk and improved metabolic properties are particularly important for a cardiovascular target where chronic administration is likely.
Output:
1
2025-04-18 00:07:25,373 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands (341.331 and 344.455 Da) fall comfortably within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (121.31) is slightly higher than Ligand B (49.85). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is generally preferred for absorption. Ligand B is significantly better here.
3. **logP:** Ligand A (0.987) is a bit low, potentially impacting permeability. Ligand B (1.666) is better positioned within the optimal 1-3 range.
4. **HBD:** Both have 0 HBD, which is good.
5. **HBA:** Ligand A has 9 HBA, which is acceptable. Ligand B has 3 HBA, which is even better.
6. **QED:** Both ligands have good QED scores (0.591 and 0.716), indicating generally drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (94.223) has a concerningly high DILI risk. Ligand B (39.511) is well below the 40% threshold, indicating a much lower risk of liver injury. This is a *major* advantage for Ligand B.
8. **BBB:** Both have moderate BBB penetration, with Ligand B (74.292) being better than Ligand A (64.676). While ADRB2 isn't a primary CNS target, some peripheral exposure is acceptable, and higher BBB is generally favorable.
9. **Caco-2:** Both have negative Caco-2 values (-4.437 and -4.465), which is unusual and suggests poor permeability. This is a significant drawback for both.
10. **Solubility:** Ligand A (-4.389) and Ligand B (-2.815) both have poor solubility. Ligand B is slightly better, but both are problematic.
11. **hERG:** Ligand A (0.684) and Ligand B (0.39) both have low hERG inhibition risk, which is good. Ligand B is slightly better.
12. **Cl_mic:** Ligand A (50.944) and Ligand B (40.836) have moderate microsomal clearance. Ligand B is slightly better.
13. **t1/2:** Ligand A (-34.013) has a negative in vitro half-life, which is very concerning. Ligand B (-1.257) is also poor, but significantly better than Ligand A.
14. **Pgp:** Ligand A (0.063) and Ligand B (0.272) both have low P-gp efflux, which is good.
15. **Binding Affinity:** Ligand A (-7.4) has a slightly better binding affinity than Ligand B (-6.7), a difference of 0.7 kcal/mol. While important, this difference is not large enough to overcome the significant ADME liabilities of Ligand A.
**GPCR-Specific Priorities:**
For ADRB2 (a cardiovascular GPCR), logP, TPSA, and affinity are key. While Ligand A has slightly better affinity, Ligand B excels in logP and TPSA. The *critical* factor is the significantly lower DILI risk associated with Ligand B. The poor half-life and solubility of both are concerning, but the DILI risk of Ligand A is a deal-breaker.
**Conclusion:**
Ligand B is the preferred candidate due to its significantly lower DILI risk, better logP, TPSA, QED, BBB, and half-life, despite the slightly weaker binding affinity. The DILI risk of Ligand A is too high to proceed with development.
Output:
0
2025-04-18 00:07:25,373 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (347.365 Da) is slightly lower, which is generally favorable for permeability.
**2. TPSA:** Ligand A (61.44) is significantly better than Ligand B (101.8). For a GPCR, keeping TPSA low is beneficial for permeability and receptor engagement. Ligand B is approaching a level that might hinder oral absorption.
**3. logP:** Ligand A (3.63) is optimal, while Ligand B (1.852) is on the lower side. While not terrible, lower logP can sometimes lead to poorer membrane permeability.
**4. H-Bond Donors:** Both ligands have 2 HBD, which is within the acceptable range.
**5. H-Bond Acceptors:** Ligand A has 2 HBA, while Ligand B has 7. This is a significant difference. Higher HBA can sometimes reduce permeability.
**6. QED:** Both ligands have reasonable QED values (0.868 and 0.777), indicating good drug-like properties.
**7. DILI Risk:** Ligand A (75.921) has a higher DILI risk than Ligand B (65.374), but both are within an acceptable range.
**8. BBB Penetration:** Ligand A (78.054) has better BBB penetration than Ligand B (65.413). While ADRB2 isn't *primarily* a CNS target, some degree of BBB penetration isn't necessarily detrimental and could allow for off-target effects to be assessed.
**9. Caco-2 Permeability:** Ligand A (-4.322) has better Caco-2 permeability than Ligand B (-5.265). This suggests better intestinal absorption.
**10. Aqueous Solubility:** Ligand A (-4.501) has slightly better aqueous solubility than Ligand B (-3.423).
**11. hERG Inhibition:** Ligand A (0.623) has a lower hERG risk than Ligand B (0.186). This is a crucial advantage, as hERG inhibition can lead to cardiotoxicity.
**12. Microsomal Clearance:** Ligand B (30.034) has significantly lower microsomal clearance than Ligand A (69.552). This suggests better metabolic stability for Ligand B.
**13. In vitro Half-Life:** Ligand A (49.186) has a longer in vitro half-life than Ligand B (-4.919). This is a positive attribute.
**14. P-gp Efflux:** Ligand A (0.192) has lower P-gp efflux than Ligand B (0.116). Lower efflux is generally preferred.
**15. Binding Affinity:** Ligand A (-8.1 kcal/mol) has a significantly stronger binding affinity than Ligand B (-4.6 kcal/mol). This is a substantial advantage, and the 3.5 kcal/mol difference is likely to outweigh minor ADME drawbacks.
**Overall Assessment:**
Ligand A is the stronger candidate. While Ligand B has better metabolic stability (lower Cl_mic) and a slightly lower DILI risk, Ligand A excels in key areas for a GPCR drug: lower TPSA, optimal logP, better permeability (Caco-2), lower hERG risk, and *significantly* higher binding affinity. The substantial binding affinity advantage of Ligand A is the most important factor, and its other properties are generally favorable.
Output:
1
2025-04-18 00:07:25,373 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [491.201, 63.68, 4.355, 0, 4, 0.564, 82.435, 66.344, -4.6, -6.012, 0.622, 105.298, 2.009, 0.368, -8.4]
**Ligand B:** [347.503, 61.44, 1.918, 2, 3, 0.799, 21.908, 55.099, -5.164, -3.004, 0.341, 22.021, 15.128, 0.136, -7.4]
**Step-by-step comparison:**
1. **MW:** Ligand A (491.2) is at the upper end of the ideal range, while Ligand B (347.5) is well within it. Slight edge to B.
2. **TPSA:** Both are reasonably good (A: 63.68, B: 61.44), below the 140 threshold for oral absorption. Similar.
3. **logP:** Ligand A (4.355) is a bit high, potentially leading to solubility issues and off-target interactions. Ligand B (1.918) is excellent. Significant advantage to B.
4. **HBD:** Ligand A (0) is ideal. Ligand B (2) is acceptable. Slight edge to A.
5. **HBA:** Ligand A (4) is good. Ligand B (3) is also good. Similar.
6. **QED:** Both are decent (A: 0.564, B: 0.799), but B is better. Advantage to B.
7. **DILI:** Ligand A (82.435) has a concerningly high DILI risk. Ligand B (21.908) is very low risk. Major advantage to B.
8. **BBB:** Ligand A (66.344) is moderate. Ligand B (55.099) is lower. While not a primary concern for a cardiovascular target, A is better.
9. **Caco-2:** Both are negative, indicating poor permeability. This is a significant drawback for both. However, -4.6 for A is worse than -5.164 for B. Slight edge to B.
10. **Solubility:** Both have negative solubility values, indicating poor aqueous solubility. A (-6.012) is worse than B (-3.004). Advantage to B.
11. **hERG:** Both are very low (A: 0.622, B: 0.341), indicating low cardiotoxicity risk. Similar.
12. **Cl_mic:** Ligand A (105.298) has a higher clearance, suggesting lower metabolic stability. Ligand B (22.021) is much better. Significant advantage to B.
13. **t1/2:** Ligand B (15.128) has a much longer half-life than Ligand A (2.009). Major advantage to B.
14. **Pgp:** Ligand A (0.368) has lower P-gp efflux, which is good. Ligand B (0.136) is even better. Advantage to B.
15. **Affinity:** Ligand A (-8.4) has a slightly better binding affinity than Ligand B (-7.4). This is a 1 kcal/mol difference, which is significant, but needs to be weighed against other factors.
**Overall Assessment:**
While Ligand A has slightly better binding affinity and lower P-gp efflux, it suffers from a high DILI risk, poor metabolic stability (high Cl_mic, short t1/2), and poor solubility. Ligand B, despite slightly weaker affinity, has a much more favorable ADMET profile: lower DILI risk, better metabolic stability, better solubility, and a longer half-life. For a cardiovascular GPCR, a good ADMET profile is crucial for clinical success. The 1 kcal/mol difference in binding affinity is unlikely to overcome the significant liabilities of Ligand A.
Therefore, I would prioritize Ligand B.
Output:
0
2025-04-18 00:07:25,373 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (356.373 and 360.401 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (75.63) is better than Ligand B (78.87), both are below the 140 A^2 threshold for good oral absorption.
3. **logP:** Ligand A (2.496) is slightly higher than Ligand B (1.766), both are within the optimal 1-3 range.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (4).
6. **QED:** Ligand A (0.832) is better than Ligand B (0.757), indicating a more drug-like profile.
7. **DILI:** Ligand B (20.783) is *significantly* better than Ligand A (53.315). This is a major advantage for Ligand B. DILI is a critical safety concern.
8. **BBB:** Ligand A (90.074) is better than Ligand B (76.347). While ADRB2 isn't strictly a CNS target, some CNS penetration could be beneficial, and higher BBB is generally favorable.
9. **Caco-2:** Ligand A (-4.102) is better than Ligand B (-5.284). Higher Caco-2 permeability is desired.
10. **Solubility:** Ligand A (-2.195) is better than Ligand B (-1.82). Higher solubility is better.
11. **hERG:** Ligand A (0.202) is better than Ligand B (0.362). Lower hERG inhibition is crucial for avoiding cardiotoxicity.
12. **Cl_mic:** Ligand B (-10.841) is better than Ligand A (36.149). Lower microsomal clearance indicates better metabolic stability.
13. **t1/2:** Ligand B (1.299) is better than Ligand A (-11.367). A longer half-life is generally desirable.
14. **Pgp:** Ligand A (0.058) is better than Ligand B (0.077). Lower P-gp efflux is preferred.
15. **Binding Affinity:** Ligand B (-7.4) is *significantly* better than Ligand A (-5.5). A 1.9 kcal/mol difference is substantial and can often outweigh minor ADME drawbacks.
**Overall Assessment:**
Ligand B has a much better DILI score and significantly better binding affinity. It also exhibits superior metabolic stability (Cl_mic) and half-life. While Ligand A has some advantages in BBB, solubility, and Caco-2 permeability, the critical safety concern of DILI and the substantial affinity difference strongly favor Ligand B. The GPCR-specific priorities (logP, Pgp, TPSA, and affinity) are all reasonably well-addressed by Ligand B.
**Output:**
0
2025-04-18 00:07:25,373 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (337.423) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (61.44) is better than Ligand B (65.12), both are below the 140 threshold, but closer to the ideal for GPCRs.
3. **logP:** Ligand A (4.049) is at the upper end of the optimal range, while Ligand B (-0.314) is significantly below, potentially hindering membrane permeability. This is a major drawback for Ligand B.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable.
5. **HBA:** Ligand A (2) is better than Ligand B (5).
6. **QED:** Ligand A (0.827) is much better than Ligand B (0.666), indicating a more drug-like profile.
7. **DILI:** Ligand B (15.2) has a significantly lower DILI risk than Ligand A (84.025), a major advantage.
8. **BBB:** Ligand A (71.462) has better BBB penetration than Ligand B (52.85). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be beneficial or at least needs to be considered.
9. **Caco-2:** Ligand A (-4.624) is better than Ligand B (-5.004).
10. **Solubility:** Ligand A (-5.23) is better than Ligand B (-1.074).
11. **hERG:** Ligand A (0.724) is better than Ligand B (0.316).
12. **Cl_mic:** Ligand A (55.008) has better metabolic stability than Ligand B (21.317).
13. **t1/2:** Ligand A (35.151) has a much longer half-life than Ligand B (2.371).
14. **Pgp:** Ligand A (0.23) has better Pgp efflux liability than Ligand B (0.007).
15. **Affinity:** Ligand A (-8.2 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.7 kcal/mol). This is a substantial advantage, exceeding the 1.5 kcal/mol difference threshold.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A excels in logP and affinity, and is better in TPSA and Pgp. While Ligand B has a much better DILI score, the poor logP and significantly weaker affinity are major concerns. The strong affinity of Ligand A can potentially offset the higher DILI risk, and further optimization could address the DILI.
**Conclusion:**
Despite the higher DILI risk, Ligand A is the more promising candidate due to its superior binding affinity, logP, QED, metabolic stability, and half-life. These factors are more critical for a successful GPCR-targeting drug, and the DILI risk can be addressed through further structural modifications.
Output:
1
2025-04-18 00:07:25,373 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (347.459 Da and 355.414 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (84.66) is better than Ligand B (89.35), both are below the 140 A^2 threshold for good oral absorption.
**3. logP:** Ligand A (3.015) is optimal, while Ligand B (0.23) is quite low. This is a significant drawback for Ligand B, as it may struggle with membrane permeability.
**4. H-Bond Donors:** Ligand A (2) and Ligand B (1) are both acceptable.
**5. H-Bond Acceptors:** Ligand A (4) and Ligand B (6) are both acceptable, but Ligand B is getting closer to the upper limit.
**6. QED:** Both ligands have similar QED values (0.823 and 0.721), indicating good drug-likeness.
**7. DILI:** Ligand A (48.158) has a slightly higher DILI risk than Ligand B (36.758), but both are well below the concerning threshold of 60.
**8. BBB:** Both ligands have good BBB penetration (75.107 and 78.79), which isn't a primary concern for a cardiovascular target, but is still positive.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests a potential issue with the experimental setup or data quality. However, we can still compare the relative values, and Ligand A (-4.728) is slightly better than Ligand B (-4.733).
**10. Aqueous Solubility:** Ligand A (-3.856) is better than Ligand B (-1.273). Solubility is important for formulation and bioavailability.
**11. hERG Inhibition:** Ligand A (0.706) has a lower hERG inhibition risk than Ligand B (0.129), which is a significant advantage.
**12. Microsomal Clearance:** Ligand B (7.499) has a much lower microsomal clearance than Ligand A (35.856), suggesting better metabolic stability.
**13. In vitro Half-Life:** Ligand B (3.418) has a longer in vitro half-life than Ligand A (-2.933).
**14. P-gp Efflux:** Ligand A (0.052) has lower P-gp efflux than Ligand B (0.025), which is preferable.
**15. Binding Affinity:** Ligand B (-6.9 kcal/mol) has a stronger binding affinity than Ligand A (-5.8 kcal/mol). This is a substantial difference (1.1 kcal/mol), and is a major factor.
**GPCR-Specific Considerations:** For a GPCR like ADRB2, logP, Pgp efflux, TPSA, and affinity are key. Ligand B excels in affinity, but suffers from a very low logP. Ligand A has a more balanced profile, with a good logP, acceptable TPSA, and reasonable affinity. The higher affinity of Ligand B might overcome some ADME issues, but the extremely low logP is a significant concern for oral bioavailability.
**Conclusion:**
Despite the stronger binding affinity of Ligand B, the significantly lower logP and higher P-gp efflux make it a less favorable candidate. Ligand A has a better balance of properties, particularly regarding permeability and solubility, making it more likely to be a viable drug candidate.
Output:
1
2025-04-18 00:07:25,373 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (343.387 Da and 348.447 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (90.21 and 89.27) are below the 140 A^2 threshold for good oral absorption and are reasonably low, though not optimal for CNS penetration (which isn't a primary concern for ADRB2, a cardiovascular target). Very similar.
3. **logP:** Both ligands (1.256 and 1.575) are within the optimal 1-3 range. Ligand B is slightly higher, which could be marginally better for membrane permeability, but the difference is small.
4. **HBD:** Ligand A has 0 HBD, while Ligand B has 2. Lower HBD is generally preferred for permeability, giving a slight edge to Ligand A.
5. **HBA:** Ligand A has 7 HBA, and Ligand B has 6. Both are below the 10 threshold.
6. **QED:** Both ligands have similar QED values (0.759 and 0.781), indicating good drug-likeness.
7. **DILI:** Ligand A has a DILI risk of 57.038%, while Ligand B is significantly lower at 26.134%. This is a substantial advantage for Ligand B, as lower DILI risk is crucial.
8. **BBB:** Ligand A has a BBB penetration of 85.459%, while Ligand B is much lower at 31.834%. While ADRB2 isn't a CNS target, higher BBB is generally favorable.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.924 and -5.197). These values are unusual and suggest poor permeability. However, the difference between them is minimal.
10. **Solubility:** Ligand A (-1.127) has slightly better solubility than Ligand B (-2.324). Solubility is important for bioavailability.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.093 and 0.08), which is excellent.
12. **Cl_mic:** Ligand A has a higher microsomal clearance (47.319 mL/min/kg) than Ligand B (8.799 mL/min/kg). Lower clearance indicates better metabolic stability, favoring Ligand B.
13. **t1/2:** Ligand B has a longer in vitro half-life (9.223 hours) than Ligand A (-12.539 hours). A longer half-life is generally desirable, favoring Ligand B.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.043 and 0.044).
15. **Binding Affinity:** Both ligands have identical binding affinities (-6.4 kcal/mol).
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, and affinity are key. Both ligands perform similarly on these metrics. However, metabolic stability (Cl_mic and t1/2) and safety (DILI, hERG) are also critical. Ligand B demonstrates a clear advantage in these areas.
**Overall Assessment:**
While Ligand A has slightly better solubility and BBB penetration (which isn't a major concern here), Ligand B significantly outperforms it in DILI risk, metabolic stability (lower Cl_mic, longer t1/2), and has a comparable binding affinity. The lower DILI risk and improved metabolic profile of Ligand B are crucial for a viable drug candidate.
Output:
0
2025-04-18 00:07:25,373 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [363.933, 35.58, 4.706, 1, 2, 0.844, 37.185, 93.292, -4.601, -4.547, 0.933, 38.316, 6.175, 0.52, -7.2]
**Ligand B:** [368.455, 85.89, -0.314, 2, 6, 0.708, 65.568, 58.085, -5.671, -2.793, 0.122, 5.663, 43.802, 0.027, -6.7]
Here's a breakdown, considering the GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal 200-500 Da range. A (363.933) is slightly better.
2. **TPSA:** A (35.58) is excellent, well below 140, and suggests good absorption. B (85.89) is higher, but still acceptable, though less ideal.
3. **logP:** A (4.706) is a bit high, potentially leading to solubility issues and off-target effects. B (-0.314) is too low, indicating potential permeability problems. This is a significant drawback for B.
4. **HBD/HBA:** A (1 HBD, 2 HBA) is preferable. B (2 HBD, 6 HBA) has more H-bonds, which could hinder permeability.
5. **QED:** A (0.844) is better than B (0.708), indicating a more drug-like profile.
6. **DILI:** A (37.185) is much better than B (65.568), indicating a lower risk of liver injury.
7. **BBB:** A (93.292) is excellent, suggesting good potential for crossing the blood-brain barrier (though less crucial for a cardiovascular target, it's a bonus). B (58.085) is lower.
8. **Caco-2:** A (-4.601) and B (-5.671) are both negative, which is unusual. Lower values generally indicate lower permeability.
9. **Solubility:** A (-4.547) and B (-2.793) are both negative, indicating poor solubility.
10. **hERG:** A (0.933) is preferable to B (0.122), suggesting lower cardiotoxicity risk.
11. **Cl_mic:** A (38.316) is higher than B (5.663), meaning faster clearance and potentially lower exposure. This favors B.
12. **t1/2:** A (6.175) is better than B (43.802), indicating a longer half-life.
13. **Pgp:** A (0.52) is better than B (0.027), suggesting lower P-glycoprotein efflux and improved bioavailability.
14. **Affinity:** A (-7.2) is significantly better than B (-6.7), representing a 0.5 kcal/mol advantage. This is a substantial difference in binding.
**Overall Assessment:**
Ligand A is the stronger candidate. While its logP is slightly elevated, its superior affinity, DILI profile, BBB penetration, QED, Pgp efflux, and hERG inhibition liability outweigh this concern. Ligand B suffers from a very low logP, which is a major drawback for oral absorption and target engagement. The improved metabolic stability of B is not enough to compensate for its other deficiencies, especially the binding affinity.
Output:
1
2025-04-18 00:07:25,373 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (369.845 Da) and Ligand B (345.487 Da) both fall within the ideal 200-500 Da range. Ligand B is slightly preferred due to being closer to the lower end, potentially aiding permeability.
2. **TPSA:** Ligand A (73.86) is higher than Ligand B (43.86). For a cardiovascular GPCR like ADRB2, TPSA is less critical than for CNS targets, but lower is generally better for absorption. Ligand B is significantly better here.
3. **logP:** Both ligands have acceptable logP values (A: 2.892, B: 1.437), falling within the 1-3 range. Ligand A is slightly preferred due to being closer to the optimal range.
4. **HBD:** Ligand A (1) and Ligand B (0) are both acceptable.
5. **HBA:** Ligand A (5) and Ligand B (3) are both acceptable.
6. **QED:** Both ligands have good QED scores (A: 0.591, B: 0.724). Ligand B is slightly better.
7. **DILI:** Ligand A (67.119) has a higher DILI risk than Ligand B (12.524). This is a significant advantage for Ligand B.
8. **BBB:** Both ligands have reasonable BBB penetration (A: 68.282, B: 70.803). Given this is a cardiovascular target, BBB isn't a major priority, but Ligand B is slightly better.
9. **Caco-2:** Both ligands have similar negative Caco-2 values (-4.605 and -4.596), indicating poor permeability. This is a concern for both.
10. **Solubility:** Ligand B (-1.966) has slightly better solubility than Ligand A (-4.235).
11. **hERG:** Both ligands have low hERG risk (A: 0.413, B: 0.615).
12. **Cl_mic:** Ligand B (44.258) has significantly lower microsomal clearance than Ligand A (66.094), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-2.154) has a negative half-life, which is concerning. Ligand A (19.032) has a reasonable half-life.
14. **Pgp:** Both ligands have low Pgp efflux (A: 0.432, B: 0.091). Ligand B is better.
15. **Binding Affinity:** Both ligands have excellent binding affinity (A: -5.6, B: -5.9). Ligand B is slightly better.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand B excels in TPSA, Pgp, and has slightly better affinity. While Ligand A has a better half-life, the significantly lower DILI risk and better metabolic stability of Ligand B are more important. The Caco-2 permeability issue is a concern for both, but can be addressed with formulation strategies.
**Conclusion:**
Considering the balance of properties, particularly the lower DILI risk, better metabolic stability, and favorable TPSA/Pgp profile, Ligand B is the more promising drug candidate.
Output:
0
2025-04-18 00:07:25,373 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (357.435 Da and 348.447 Da). No significant difference.
2. **TPSA:** Ligand A (80.32) is better than Ligand B (95.42). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally improves absorption.
3. **logP:** Both are good (2.615 and 1.82), falling within the optimal 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Both have 2 HBD, which is within the acceptable limit.
5. **HBA:** Both have 5 HBA, also within the acceptable limit.
6. **QED:** Ligand B (0.846) has a better QED score than Ligand A (0.637), indicating a more drug-like profile.
7. **DILI:** Ligand B (39.744) has a significantly lower DILI risk than Ligand A (90.694). This is a major advantage for Ligand B.
8. **BBB:** Both have similar BBB penetration (60.876 and 61.38). Not a critical factor for a cardiovascular target.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual. Assuming these are logP-scale values, they indicate poor permeability. Ligand A (-5.005) is slightly worse than Ligand B (-4.962).
10. **Solubility:** Ligand B (-1.845) has better solubility than Ligand A (-3.725).
11. **hERG:** Ligand A (0.334) has a slightly higher hERG risk than Ligand B (0.189), but both are relatively low.
12. **Cl_mic:** Ligand B (22.717) has a lower microsomal clearance than Ligand A (29.624), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-16.723) has a much longer in vitro half-life than Ligand A (22.109). This is a significant advantage.
14. **Pgp:** Ligand B (0.036) has much lower P-gp efflux liability than Ligand A (0.3). This is a positive for bioavailability.
15. **Affinity:** Ligand A (-7.2) has a stronger binding affinity than Ligand B (-6.2). This is a 1.0 kcal/mol difference, which is substantial and could outweigh some ADME drawbacks.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand A has a slightly better logP and significantly better affinity. However, Ligand B excels in DILI risk, metabolic stability (Cl_mic and t1/2), solubility, and Pgp efflux. The lower DILI risk and improved metabolic stability are particularly important for a cardiovascular drug, where long-term safety and consistent exposure are crucial. While the affinity difference is notable, the ADME profile of Ligand B is considerably more favorable.
**Conclusion:**
Despite the slightly weaker binding affinity, Ligand B's superior ADME properties, particularly the significantly lower DILI risk and improved metabolic stability, make it the more promising drug candidate for the ADRB2 receptor.
Output:
0
2025-04-18 00:07:25,374 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (367.471 and 355.435 Da) fall comfortably within the ideal range of 200-500 Da. No significant difference here.
**2. TPSA:** Ligand A (87.74) is better than Ligand B (110.01). For a GPCR, keeping TPSA low is beneficial for permeability, and A is well below the 140 threshold. B is approaching the upper limit.
**3. logP:** Both ligands have acceptable logP values (-0.392 and -0.055), falling within the 1-3 range, although on the lower end. This might be a slight concern for permeability, but not a dealbreaker.
**4. H-Bond Donors:** Ligand A (2) is slightly higher than Ligand B (1), but both are within the acceptable limit of 5.
**5. H-Bond Acceptors:** Ligand A (6) is higher than Ligand B (5), but both are below the limit of 10.
**6. QED:** Both ligands have good QED scores (0.51 and 0.623), indicating good drug-like properties. Ligand B is slightly better.
**7. DILI Risk:** Ligand A (25.63) has a lower DILI risk than Ligand B (34.277), which is a significant advantage. Lower DILI is always preferred.
**8. BBB Penetration:** Both ligands show moderate BBB penetration (56.65 and 60.838). Since ADRB2 is a cardiovascular target, BBB penetration is not a primary concern, but higher is generally better.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-5.249 and -5.347), which is unusual and suggests poor permeability. This is a significant concern for both.
**10. Aqueous Solubility:** Both ligands have negative solubility values (-2.461 and -1.037), indicating very poor aqueous solubility. This is a major drawback for both.
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.16 and 0.104), which is excellent.
**12. Microsomal Clearance:** Ligand A (23.39) and Ligand B (25.767) have similar microsomal clearance values. Neither is particularly low, suggesting moderate metabolic liability.
**13. In vitro Half-Life:** Both ligands have negative in vitro half-life values (-3.669 and -3.472), which is not meaningful.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.015 and 0.012), which is favorable.
**15. Binding Affinity:** Ligand A (-8.4 kcal/mol) has a significantly stronger binding affinity than Ligand B (-5.5 kcal/mol). This is a substantial advantage (almost 3 kcal/mol difference), and can often outweigh minor ADME concerns.
**Overall Assessment:**
While both ligands have significant ADME issues (poor solubility and permeability), Ligand A is the better candidate due to its significantly stronger binding affinity (-8.4 vs -5.5 kcal/mol) and lower DILI risk (25.63 vs 34.277). The stronger binding is a critical advantage for a GPCR target, and the lower DILI risk is a safety benefit. The TPSA is also more favorable for Ligand A.
Output:
1
2025-04-18 00:07:25,374 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.515 and 348.531 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands have a TPSA of 49.41, which is well below the 140 A^2 threshold for good oral absorption and appropriate for a GPCR target.
3. **logP:** Ligand A (3.668) is slightly lower than Ligand B (4.055). Both are within the optimal 1-3 range, but Ligand B is edging towards the upper limit where solubility issues could arise.
4. **HBD/HBA:** Both ligands have 1 HBD and 2 HBA, which are within acceptable limits.
5. **QED:** Ligand A (0.746) has a better QED score than Ligand B (0.505), indicating a more drug-like profile.
6. **DILI:** Ligand A (19.426%) has a slightly higher DILI risk than Ligand B (18.108%), but both are well below the concerning threshold of 60%.
7. **BBB:** Ligand B (84.994%) shows significantly better BBB penetration than Ligand A (77.084%). While ADRB2 isn't strictly a CNS target, some CNS exposure can be relevant for off-target effects and overall safety assessment.
8. **Caco-2:** Both ligands have negative Caco-2 values (-4.796 and -4.857). This is unusual and suggests poor permeability, which is a significant concern.
9. **Solubility:** Both ligands have negative solubility values (-3.764 and -3.75), indicating very poor aqueous solubility. This is a major drawback.
10. **hERG:** Both ligands have low hERG inhibition liability (0.602 and 0.615), which is good.
11. **Cl_mic:** Ligand B (70.725 mL/min/kg) has lower microsomal clearance than Ligand A (80.058 mL/min/kg), suggesting better metabolic stability.
12. **t1/2:** Ligand B (-16.806 hours) has a slightly longer in vitro half-life than Ligand A (-15.979 hours).
13. **Pgp:** Both ligands have low P-gp efflux liability (0.348 and 0.52).
14. **Binding Affinity:** Ligand A (-6.3 kcal/mol) has a slightly better binding affinity than Ligand B (-5.9 kcal/mol). This is a 0.4 kcal/mol difference, which is notable but not overwhelming.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are crucial. While both ligands have acceptable TPSA and Pgp values, Ligand B has a higher logP, which could lead to solubility issues. Ligand A has a slightly better affinity and a better QED score. However, the poor Caco-2 and solubility for both ligands are major concerns. The slightly better BBB penetration of Ligand B is a minor advantage.
**Overall Assessment:**
Despite the slightly better BBB penetration of Ligand B, the superior QED and binding affinity of Ligand A, combined with similar DILI and hERG profiles, make it the more promising candidate. The poor Caco-2 and solubility are significant drawbacks for both, but these can be addressed through formulation strategies. The slightly better affinity of Ligand A is a crucial advantage for a receptor target.
Output:
1
2025-04-18 00:07:25,374 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (404.3) is within the ideal range (200-500), while Ligand B (349.5) is also good. No clear advantage here.
2. **TPSA:** Ligand A (74.25) is better than Ligand B (92.5). Lower TPSA generally favors better absorption, important for oral bioavailability.
3. **logP:** Ligand A (4.06) is slightly high, potentially leading to solubility issues, but still within a manageable range. Ligand B (1.289) is a bit low, which could hinder membrane permeability.
4. **HBD:** Ligand A (3) and Ligand B (2) are both acceptable.
5. **HBA:** Ligand A (3) and Ligand B (3) are both acceptable.
6. **QED:** Both Ligand A (0.722) and Ligand B (0.678) have good drug-likeness scores.
7. **DILI:** Ligand A (55.5) is higher risk than Ligand B (13.5). This is a significant drawback for Ligand A.
8. **BBB:** Ligand A (73.7) is better than Ligand B (65.8). While ADRB2 isn't exclusively a CNS target, some CNS exposure can occur, and higher BBB is generally favorable.
9. **Caco-2:** Both are negative, indicating poor permeability.
10. **Solubility:** Ligand A (-5.036) is significantly worse than Ligand B (-3.243). This is a major concern for Ligand A, especially given its already high logP.
11. **hERG:** Ligand A (0.689) is better than Ligand B (0.051). Lower hERG inhibition is crucial for avoiding cardiotoxicity, a major concern for cardiovascular targets.
12. **Cl_mic:** Ligand A (41.76) is slightly higher than Ligand B (38.15), meaning Ligand B is more metabolically stable.
13. **t1/2:** Ligand A (93.9) is significantly better than Ligand B (-12.6). This is a substantial advantage for Ligand A, suggesting less frequent dosing.
14. **Pgp:** Ligand A (0.416) is better than Ligand B (0.003). Lower P-gp efflux is desirable for better bioavailability.
15. **Affinity:** Ligand A (-7.2) is significantly better than Ligand B (-6.4). A 0.8 kcal/mol difference is substantial and can outweigh some ADME liabilities.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has a higher logP, but a much better affinity. Ligand A also has better Pgp efflux. Ligand B has better TPSA, but the affinity difference is significant. The DILI and solubility issues with Ligand A are concerning, but the strong affinity and better half-life are compelling.
**Overall Assessment:**
Despite the DILI and solubility concerns, the significantly stronger binding affinity (-7.2 vs -6.4 kcal/mol) and longer half-life of Ligand A are decisive. The improved Pgp efflux is also beneficial. While Ligand B has a better safety profile (lower DILI), the potency advantage of Ligand A is likely to be more impactful in driving efficacy. Optimization efforts could focus on improving the solubility and reducing the DILI risk of Ligand A.
Output:
1
2025-04-18 00:07:25,374 - INFO - Batch 454 complete. Total preferences: 7264
2025-04-18 00:07:25,374 - INFO - Processing batch 455/512...
2025-04-18 00:08:16,174 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (363.82 and 363.523 Da) are within the ideal range of 200-500 Da. No significant difference.
2. **TPSA:** Ligand A (74.15) is higher than Ligand B (38.77). For a cardiovascular GPCR, TPSA isn't a *major* concern unless it's excessively high, but lower is generally preferred for permeability. Ligand B is significantly better here.
3. **logP:** Both ligands (3.989 and 3.791) are within the optimal range of 1-3. No significant difference.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (0). This isn't a major concern for either.
5. **HBA:** Ligand A (3) is slightly lower than Ligand B (4). Again, both are acceptable.
6. **QED:** Ligand A (0.794) has a better QED score than Ligand B (0.627), indicating a more drug-like profile.
7. **DILI:** Ligand B (26.018) has a *much* lower DILI risk than Ligand A (53.315). This is a significant advantage for Ligand B.
8. **BBB:** Both ligands have good BBB penetration (Ligand A: 80.613, Ligand B: 84.141). Ligand B is slightly better.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.47 and -4.883), which is unusual and suggests poor permeability. This is a concern for both, but the values are similar.
10. **Solubility:** Ligand B (-3.786) has better solubility than Ligand A (-5.637). Better solubility is preferred.
11. **hERG:** Both ligands have low hERG inhibition liability (Ligand A: 0.735, Ligand B: 0.677). No significant difference.
12. **Cl_mic:** Ligand B (74.412) has a higher microsomal clearance than Ligand A (43.019), indicating faster metabolism and lower metabolic stability. This is a disadvantage for Ligand B.
13. **t1/2:** Ligand A (58.717) has a significantly longer in vitro half-life than Ligand B (24.655). This is a major advantage for Ligand A.
14. **Pgp:** Ligand B (0.736) has a slightly higher P-gp efflux liability than Ligand A (0.247), meaning it's more likely to be pumped out of cells, reducing bioavailability. This favors Ligand A.
15. **Binding Affinity:** Ligand B (-5.5 kcal/mol) has a stronger binding affinity than Ligand A (-1.1 kcal/mol). This is a *very* significant advantage for Ligand B, potentially outweighing some of the ADME concerns.
**Overall Assessment:**
Ligand B has a significantly better binding affinity and lower DILI risk, and better solubility. These are crucial factors. While Ligand A has a better QED, longer half-life, and lower P-gp efflux, the substantial difference in binding affinity and the lower toxicity profile of Ligand B are more compelling. The Caco-2 values are concerning for both, but the strong binding of B suggests it might still be effective even with lower absorption. The higher clearance of B is a drawback, but could potentially be addressed with formulation strategies.
Output:
0
2025-04-18 00:08:16,174 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.475 and 349.431 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (69.72) is significantly better than Ligand B (78.95). ADRB2 is not a CNS target, but lower TPSA generally aids absorption.
3. **logP:** Ligand A (1.253) is optimal, while Ligand B (0.141) is quite low. This is a significant drawback for Ligand B, potentially hindering membrane permeability and bioavailability.
4. **HBD:** Both have 1 HBD, which is within the acceptable limit of 5.
5. **HBA:** Ligand A has 3 HBA, Ligand B has 4. Both are acceptable (<=10).
6. **QED:** Ligand A (0.83) is better than Ligand B (0.769), indicating a more drug-like profile.
7. **DILI:** Ligand A (29.43) is slightly better than Ligand B (32.067), both are good (below 40).
8. **BBB:** Both ligands have similar BBB penetration (65.025 and 64.87), which is not a primary concern for ADRB2 (a cardiovascular target).
9. **Caco-2:** Ligand A (-4.652) is better than Ligand B (-4.842), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-2.013) is better than Ligand B (-1.173), indicating better aqueous solubility.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.196 and 0.158).
12. **Cl_mic:** Ligand B (-1.79) has significantly lower microsomal clearance than Ligand A (52.215), suggesting better metabolic stability. This is a strong point for Ligand B.
13. **t1/2:** Ligand B (5.851) has a longer in vitro half-life than Ligand A (-9.608). This is a significant advantage for Ligand B.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.056 and 0.021).
15. **Binding Affinity:** Ligand B (-5.1) has a slightly better binding affinity than Ligand A (-4.8). While a 0.3 kcal/mol difference isn't huge, it's a positive for Ligand B.
**GPCR-Specific Priorities:** For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand A excels in logP and TPSA, while Ligand B has a slightly better affinity. Ligand B has superior metabolic stability (Cl_mic and t1/2). The low logP of Ligand B is a significant concern, potentially limiting its bioavailability. However, the better metabolic stability and slightly improved affinity of Ligand B, combined with acceptable TPSA and a low hERG risk, make it a slightly more promising candidate.
**Final Decision:**
0
2025-04-18 00:08:16,175 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
The target is ADRB2, a GPCR. Therefore, key properties to prioritize are logP, TPSA, Pgp efflux, BBB penetration, and binding affinity. Metabolic stability and solubility are also important, but slightly less so than the first set.
Let's compare the ligands property by property:
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (365.5) is slightly better.
2. **TPSA:** Ligand B (72.01) is significantly better than Ligand A (91.32). Lower TPSA generally favors better permeability.
3. **logP:** Both are good (between 1-3), but Ligand B (2.141) is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Ligand A (3) is higher than Ligand B (1). Lower is generally preferred to avoid potential issues with hydrogen bonding and metabolic liabilities.
5. **HBA:** Ligand B (7) is higher than Ligand A (5). Similar to HBD, lower is generally preferred.
6. **QED:** Ligand B (0.738) is better than Ligand A (0.582), indicating a more drug-like profile.
7. **DILI:** Ligand B (15.394) is *much* better than Ligand A (43.117). This is a significant advantage for Ligand B.
8. **BBB:** Ligand B (79.721) is substantially better than Ligand A (40.675). This is a critical advantage for a GPCR target.
9. **Caco-2:** Both are negative, indicating poor permeability. This is a concern for both, but doesn't heavily sway the decision as other properties are more differentiating.
10. **Solubility:** Both are negative, indicating poor solubility. Similar to Caco-2, this is a concern for both.
11. **hERG:** Ligand B (0.397) is better than Ligand A (0.19). Lower hERG inhibition is crucial for avoiding cardiotoxicity.
12. **Cl_mic:** Ligand B (-1.024) is *much* better than Ligand A (34.167). This indicates significantly better metabolic stability for Ligand B.
13. **t1/2:** Ligand B (24.758) is significantly better than Ligand A (6.404). Longer half-life is generally preferred.
14. **Pgp:** Ligand B (0.066) is better than Ligand A (0.126). Lower P-gp efflux is desirable.
15. **Affinity:** Ligand A (-5.9) is slightly better than Ligand B (-6.4). However, the difference is relatively small and can be overcome by other favorable ADME properties.
**Overall Assessment:**
Ligand B demonstrates a significantly superior ADME profile compared to Ligand A. It has better DILI risk, BBB penetration, metabolic stability (Cl_mic and t1/2), Pgp efflux, QED, and hERG inhibition. While Ligand A has slightly better binding affinity, the substantial improvements in ADME properties for Ligand B, particularly its lower DILI risk and better BBB penetration, make it the more promising drug candidate for the ADRB2 receptor. The small difference in binding affinity can likely be optimized during lead optimization.
**Output:**
0
2025-04-18 00:08:16,175 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (344.455) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both ligands are below the 140 A^2 threshold for good oral absorption. Ligand A (69.64) is slightly higher than Ligand B (63.91), but both are acceptable.
3. **logP:** Both ligands have logP values within the optimal range (1-3). Ligand B (3.15) is slightly higher, potentially leading to some solubility issues, but still within acceptable limits.
4. **HBD:** Ligand A (2) is better than Ligand B (0). Having some HBD can improve solubility.
5. **HBA:** Ligand A (3) is better than Ligand B (6). Lower HBA is generally preferred for better permeability.
6. **QED:** Both ligands have similar QED values (0.832 and 0.762), indicating good drug-likeness.
7. **DILI:** Ligand A (20.744) has a significantly lower DILI risk than Ligand B (40.171). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (74.137) has a slightly higher BBB penetration than Ligand A (68.864). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be useful for understanding off-target effects and distribution.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. Ligand A (-4.745) is slightly better than Ligand B (-4.91).
10. **Solubility:** Both ligands have negative solubility values, indicating poor solubility. Ligand B (-3.538) is slightly worse than Ligand A (-2.902).
11. **hERG:** Both ligands have low hERG inhibition risk (0.449 and 0.363).
12. **Cl_mic:** Ligand A (9.811) has a significantly lower microsomal clearance than Ligand B (62.67). This indicates better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (-13.04) has a more negative in vitro half-life than Ligand B (6.363), indicating a shorter half-life. This is a disadvantage for Ligand A.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.157 and 0.322).
15. **Binding Affinity:** Both ligands have very similar binding affinities (-5.8 and -5.6 kcal/mol).
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Both ligands are comparable in these areas. However, DILI and metabolic stability (Cl_mic) are crucial for overall drug development. Ligand A demonstrates a significantly better profile in these areas.
**Overall Assessment:**
Ligand A is the preferred candidate. While Ligand B has slightly better BBB penetration and in vitro half-life, Ligand A's significantly lower DILI risk and improved metabolic stability outweigh these minor drawbacks. The similar binding affinities make the ADME properties the deciding factor.
Output:
1
2025-04-18 00:08:16,175 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [368.503, 104.21 , 1.565, 3. , 6. , 0.614, 34.083, 28.655, -5.695, -1.254, 0.043, 1.333, 21.798, 0.078, -6.0]
**Ligand B:** [342.399, 85.25 , 0.987, 2. , 5. , 0.868, 76.192, 43.699, -5.264, -2.002, 0.29 , 3.868, 23.503, 0.012, -7.1]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity, and to a lesser extent BBB):
1. **MW:** Both are within the acceptable 200-500 Da range. Ligand B (342.399) is slightly preferred due to being a bit lower.
2. **TPSA:** Ligand A (104.21) is a bit higher than Ligand B (85.25). Ligand B is better here, being closer to the <140 threshold for oral absorption and more favorable for GPCRs.
3. **logP:** Ligand A (1.565) is within the optimal range, and Ligand B (0.987) is slightly lower, but still acceptable. Ligand A is slightly preferred.
4. **HBD/HBA:** Ligand A has 3 HBD and 6 HBA, while Ligand B has 2 HBD and 5 HBA. Both are within acceptable limits.
5. **QED:** Ligand B (0.868) has a significantly better QED score than Ligand A (0.614), indicating a more drug-like profile.
6. **DILI:** Ligand A (34.083) has a much lower DILI risk than Ligand B (76.192). This is a significant advantage for Ligand A.
7. **BBB:** Ligand B (43.699) has a better BBB penetration score than Ligand A (28.655). While ADRB2 isn't necessarily a CNS target, some peripheral ADRB2 activity can be modulated by CNS effects, so this is a slight advantage for B.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. This is a concern for both.
9. **Solubility:** Both have negative solubility values, which is also concerning.
10. **hERG:** Ligand A (0.043) has a much lower hERG risk than Ligand B (0.29). This is a substantial advantage for Ligand A.
11. **Cl_mic:** Ligand A (1.333) has lower microsomal clearance than Ligand B (3.868), suggesting better metabolic stability.
12. **t1/2:** Ligand B (23.503) has a slightly longer in vitro half-life than Ligand A (21.798).
13. **Pgp:** Ligand A (0.078) has a much lower P-gp efflux liability than Ligand B (0.012), which is a significant advantage for bioavailability.
14. **Affinity:** Ligand B (-7.1 kcal/mol) has a stronger binding affinity than Ligand A (-6.0 kcal/mol). This is a >1 kcal/mol difference, which is a substantial advantage.
**Overall Assessment:**
Ligand B has a significantly better binding affinity and a better QED score, which are strong positives. However, it suffers from higher DILI risk, higher hERG risk, and higher P-gp efflux. Ligand A has a much better safety profile (DILI, hERG) and better metabolic stability (Cl_mic) and Pgp efflux. The affinity difference is significant, but the safety concerns with Ligand B are substantial. Given the cardiovascular context, minimizing hERG and DILI risk is paramount.
Therefore, I would prioritize Ligand A.
Output:
1
2025-04-18 00:08:16,175 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (351.491 and 355.523 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (53.09) is significantly better than Ligand B (72.88). ADRB2 is a cardiovascular target, not CNS, but lower TPSA generally improves absorption.
3. **logP:** Both ligands (1.347 and 1.621) are within the optimal 1-3 range. Ligand B is slightly higher, which could be a minor advantage for membrane permeability.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Both ligands have 4 HBA, which is acceptable.
6. **QED:** Both ligands have similar QED scores (0.662 and 0.694), indicating good drug-likeness.
7. **DILI:** Ligand A (6.979) has a much lower DILI risk than Ligand B (8.414). This is a significant advantage.
8. **BBB:** Not a primary concern for a cardiovascular target. Ligand A (72.16) is better than Ligand B (42.497), but this isn't a major deciding factor.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-4.691) is slightly better than Ligand B (-4.863).
10. **Solubility:** Both are negative, indicating poor solubility. Ligand A (-0.036) is slightly better than Ligand B (-1.251).
11. **hERG:** Both ligands have very low hERG inhibition risk (0.497 and 0.386).
12. **Cl_mic:** Ligand A (16.299) has lower microsomal clearance than Ligand B (22.501), suggesting better metabolic stability.
13. **t1/2:** Ligand B (23.663) has a longer in vitro half-life than Ligand A (11.856). This is a positive for Ligand B.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.019 and 0.037).
15. **Binding Affinity:** Ligand B (-6.4) has a slightly better binding affinity than Ligand A (-5.9). This is a 0.5 kcal/mol difference, which is significant.
**Overall Assessment:**
Ligand B has a slightly better binding affinity and a longer half-life. However, Ligand A demonstrates a significantly lower DILI risk, better TPSA, lower HBD, and better metabolic stability (lower Cl_mic). Given the importance of minimizing toxicity and achieving reasonable metabolic stability in drug development, the advantages of Ligand A outweigh the slightly better affinity and half-life of Ligand B.
Output:
1
2025-04-18 00:08:16,175 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (364.417 and 356.482 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (49.41) is better than Ligand B (58.64). Both are below 140, but lower TPSA generally favors absorption.
3. **logP:** Ligand A (3.773) is slightly higher than Ligand B (2.539), both within the optimal 1-3 range. Ligand A is closer to the upper limit, which could be a minor concern, but still acceptable.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Both ligands have 3 HBA, which is good.
6. **QED:** Ligand A (0.84) is better than Ligand B (0.763), indicating a more drug-like profile.
7. **DILI:** Ligand B (8.414) is *significantly* better than Ligand A (62.893). This is a major advantage for Ligand B. DILI is a critical safety parameter.
8. **BBB:** Ligand A (89.492) is good, while Ligand B (92.71) is slightly better. For a cardiovascular target like ADRB2, BBB penetration isn't a primary concern, but it's a bonus.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.329 and -4.397). This is unusual and suggests poor permeability. However, these values are very close, so it doesn't strongly favor either.
10. **Solubility:** Ligand B (-2.582) is better than Ligand A (-4.949), indicating better aqueous solubility.
11. **hERG:** Ligand A (0.409) is better than Ligand B (0.557), indicating a lower risk of hERG inhibition.
12. **Cl_mic:** Ligand B (27.423) is *much* better than Ligand A (80.582). Lower clearance means greater metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand B (-22.141) is better than Ligand A (28.182), indicating a longer half-life.
14. **Pgp:** Ligand A (0.318) is better than Ligand B (0.095), indicating lower P-gp efflux.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-7.0 and -6.9 kcal/mol). The difference is negligible.
**GPCR-Specific Priorities & Overall Assessment:**
For a GPCR, logP, TPSA, Pgp, and affinity are important. Ligand A has a slightly better logP and Pgp, but Ligand B excels in crucial ADME-Tox properties: significantly lower DILI risk and much better metabolic stability (Cl_mic and t1/2). The slightly better solubility of Ligand B is also beneficial. While Ligand A has a slightly better BBB score, this is less important for a cardiovascular target. The similar binding affinities make the ADME-Tox profile the deciding factor. The lower DILI and better metabolic stability of Ligand B outweigh the minor advantages of Ligand A.
Output:
0
2025-04-18 00:08:16,176 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.431 and 360.439 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (98.32) is slightly higher than Ligand B (80.37). Both are below the 140 threshold for good oral absorption, but B is closer to the 90 threshold for CNS targets (though this isn't a CNS target). Slight advantage to B.
3. **logP:** Ligand A (1.073) is within the optimal range, while Ligand B (2.085) is also acceptable. No strong preference.
4. **HBD:** Ligand A (3) is higher than Ligand B (1). Lower HBD is generally preferred for permeability, giving a slight edge to B.
5. **HBA:** Ligand A (4) is lower than Ligand B (6). Again, lower is generally better for permeability, favoring A.
6. **QED:** Both ligands have good QED scores (0.71 and 0.883), indicating good drug-like properties. No significant difference.
7. **DILI:** Ligand A (43.66) has a significantly lower DILI risk than Ligand B (65.258). This is a major advantage for A.
8. **BBB:** Ligand B (53.664) has a higher BBB penetration score than Ligand A (32.144). While ADRB2 isn't a CNS target, some peripheral distribution is still desirable, and better BBB penetration often correlates with better overall permeability. Slight advantage to B.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.191 and -5.302). This is unusual and suggests poor permeability. However, the values are very similar.
10. **Solubility:** Both ligands have negative solubility values (-2.271 and -2.66). This is concerning, indicating poor aqueous solubility. Again, values are similar.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.118 and 0.258), which is excellent. No preference.
12. **Cl_mic:** Ligand A (-5.666) has a much lower (better) microsomal clearance than Ligand B (47.137), indicating greater metabolic stability. This is a significant advantage for A.
13. **t1/2:** Ligand A (-17.805) has a much longer in vitro half-life than Ligand B (19.402). This is a substantial advantage for A.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.023 and 0.062), which is good. No preference.
15. **Binding Affinity:** Ligand B (-6.9 kcal/mol) has a stronger binding affinity than Ligand A (-5.9 kcal/mol). This is a 1.0 kcal/mol difference, which is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand B has a better binding affinity and slightly better TPSA and BBB penetration. However, Ligand A has significantly better DILI risk, microsomal clearance, and in vitro half-life. The poor Caco-2 and solubility for both are concerning, but the metabolic stability and safety profile of Ligand A are compelling. Given that ADRB2 is a cardiovascular target, minimizing off-target effects (DILI) and ensuring reasonable metabolic stability are crucial. The affinity difference, while significant, isn't so large that it completely overrides the superior ADMET properties of Ligand A.
Output:
1
2025-04-18 00:08:16,176 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.435 and 342.483 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (96.69) is higher than Ligand B (49.41). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for permeability. Ligand B is significantly better here.
3. **logP:** Ligand A (0.992) is slightly below the optimal 1-3 range, while Ligand B (3.029) is within the optimal range. Ligand B is better for membrane permeability and receptor engagement.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable, below the threshold of 5. Ligand B is slightly better.
5. **HBA:** Ligand A (6) and Ligand B (2) are both acceptable, below the threshold of 10. Ligand B is significantly better.
6. **QED:** Ligand B (0.854) has a substantially higher QED score than Ligand A (0.537), indicating a more drug-like profile.
7. **DILI:** Both ligands have acceptable DILI risk (Ligand A: 47.964, Ligand B: 40.054), below the 60 threshold. Ligand B is slightly better.
8. **BBB:** Ligand A (36.293) has a low BBB penetration, while Ligand B (69.523) is better, though not exceptionally high. Since ADRB2 is not a CNS target, this is less critical, but a higher value is still preferable.
9. **Caco-2:** Both ligands have negative Caco-2 values, suggesting poor permeability. Ligand A (-5.255) is slightly worse than Ligand B (-4.996).
10. **Solubility:** Ligand A (-1.262) has better solubility than Ligand B (-4.541). Solubility is important for bioavailability.
11. **hERG:** Both ligands have low hERG inhibition risk (Ligand A: 0.408, Ligand B: 0.294). Ligand B is slightly better.
12. **Cl_mic:** Ligand A (2.397) has a significantly lower microsomal clearance than Ligand B (51.015), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (14.657) has a longer in vitro half-life than Ligand B (5.24). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.03) has a much lower P-gp efflux liability than Ligand B (0.408), suggesting better oral bioavailability.
15. **Binding Affinity:** Ligand B (-6.9 kcal/mol) has a slightly better binding affinity than Ligand A (-6.2 kcal/mol). This is a 0.7 kcal/mol difference, which is a notable advantage, but not overwhelming.
**Overall Assessment:**
Ligand B has advantages in logP, QED, and binding affinity. However, Ligand A exhibits superior metabolic stability (lower Cl_mic, longer t1/2), lower P-gp efflux, and better solubility. Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), and the fact that this is a cardiovascular target (BBB is less critical), the improved metabolic stability and bioavailability of Ligand A are more valuable than the slightly better affinity of Ligand B. The lower TPSA of Ligand B is also a positive.
Therefore, I favor Ligand A.
Output:
1
2025-04-18 00:08:16,176 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (360.523 and 352.475 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (41.9) is significantly better than Ligand B (67.87). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B's TPSA is approaching a level that could hinder oral absorption.
**3. logP:** Ligand A (4.462) is higher than Ligand B (1.583). While both are within the acceptable range, Ligand A is pushing the upper limit. However, for a GPCR, a slightly higher logP can be tolerated, especially if it contributes to binding. Ligand B's logP is quite low, potentially impacting membrane permeability.
**4. H-Bond Donors:** Ligand A (0) is preferable to Ligand B (1). Fewer HBDs generally improve permeability.
**5. H-Bond Acceptors:** Both ligands have 4 HBA, which is acceptable.
**6. QED:** Both ligands have similar QED values (0.782 and 0.788), indicating good drug-likeness.
**7. DILI Risk:** Ligand A (49.128) has a higher DILI risk than Ligand B (12.641). This is a significant concern, and Ligand B is much safer in this regard.
**8. BBB Penetration:** Ligand A (91.508) has better BBB penetration than Ligand B (83.831). While ADRB2 is primarily a cardiovascular target, some CNS effects can be relevant (and potentially undesirable), and higher BBB penetration isn't necessarily a negative.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.96 and -4.399). These values are unusual and likely indicate a problem with the assay or the compounds themselves. It's difficult to interpret them directly, but they suggest potential absorption issues.
**10. Aqueous Solubility:** Ligand A (-4.384) is slightly worse than Ligand B (-2.181). Solubility is important, but not the highest priority for this target.
**11. hERG Inhibition:** Ligand A (0.787) has a higher hERG risk than Ligand B (0.272). This is a critical safety parameter, and Ligand B is significantly better.
**12. Microsomal Clearance:** Ligand A (102.64) has higher microsomal clearance than Ligand B (47.125). This means Ligand A is likely to be metabolized more quickly, potentially leading to a shorter duration of action.
**13. In vitro Half-Life:** Ligand A (-12.213) has a negative half-life, which is not possible and indicates an issue. Ligand B (-0.706) is also negative, but less so. Both are concerning.
**14. P-gp Efflux:** Ligand A (0.906) has higher P-gp efflux than Ligand B (0.021). Lower P-gp efflux is preferred for better bioavailability.
**15. Binding Affinity:** Ligand A (-7.6 kcal/mol) has a significantly better binding affinity than Ligand B (-5.4 kcal/mol). This is a substantial difference (2.2 kcal/mol) and is a major advantage for Ligand A.
**Overall Assessment:**
Ligand A has a significantly stronger binding affinity, which is crucial for a GPCR target. However, it suffers from higher DILI risk, hERG inhibition, and P-gp efflux, and has poor metabolic stability (high clearance). Ligand B has a much better safety profile (lower DILI and hERG) and better metabolic stability, but its binding affinity is considerably weaker and its logP is low.
Despite the safety concerns with Ligand A, the substantial improvement in binding affinity is a key driver for GPCR drug development. The safety issues can potentially be addressed through further structural modifications. The weak affinity of Ligand B makes it less likely to be a viable starting point.
Output:
1
2025-04-18 00:08:16,176 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Ligand A: [382.848, 82.26, 4.596, 4, 3, 0.583, 88.639, 53.276, -4.743, -5.7, 0.555, 34.767, 95.978, 0.22, -7.6]**
**Ligand B: [347.459, 69.72, 0.805, 1, 4, 0.817, 6.049, 63.086, -5.155, -1.116, 0.143, -28.479, -9.74, 0.006, -7.2]**
1. **Molecular Weight:** Both are within the ideal range (200-500 Da). Ligand B (347.459) is slightly lower, which is generally favorable for permeability, but both are acceptable.
2. **TPSA:** Ligand A (82.26) is higher than Ligand B (69.72). Both are below 140, but Ligand B is better for oral absorption.
3. **logP:** Ligand A (4.596) is high, potentially leading to solubility issues and off-target effects. Ligand B (0.805) is quite low, which could hinder membrane permeability. This is a significant drawback for both, but Ligand A's high logP is more concerning.
4. **H-Bond Donors:** Ligand A (4) is acceptable. Ligand B (1) is also good.
5. **H-Bond Acceptors:** Both ligands have 4 H-bond acceptors, which is acceptable.
6. **QED:** Ligand B (0.817) has a better QED score than Ligand A (0.583), indicating a more drug-like profile.
7. **DILI:** Ligand A (88.639) has a high DILI risk. Ligand B (6.049) has a very low DILI risk, a major advantage.
8. **BBB:** Ligand A (53.276) has moderate BBB penetration. Ligand B (63.086) has better BBB penetration. While ADRB2 isn't *strictly* a CNS target, some CNS exposure can occur, and better BBB is generally preferred.
9. **Caco-2:** Ligand A (-4.743) has a very poor Caco-2 permeability. Ligand B (-5.155) is also poor, but slightly better.
10. **Solubility:** Ligand A (-5.7) has poor aqueous solubility. Ligand B (-1.116) has better solubility, though still not ideal.
11. **hERG:** Ligand A (0.555) has a relatively low hERG risk. Ligand B (0.143) has a very low hERG risk, a significant advantage.
12. **Cl_mic:** Ligand A (34.767) has a moderate clearance. Ligand B (-28.479) has a *negative* clearance, which is unusual and suggests very high metabolic stability. This is a huge advantage for Ligand B.
13. **t1/2:** Ligand A (95.978) has a very long in vitro half-life. Ligand B (-9.74) has a very short half-life, a major drawback.
14. **Pgp:** Ligand A (0.22) has low P-gp efflux. Ligand B (0.006) has very low P-gp efflux. Both are good.
15. **Binding Affinity:** Ligand A (-7.6) has a slightly better binding affinity than Ligand B (-7.2). However, the difference is not substantial enough to outweigh other significant drawbacks.
**Overall Assessment:**
Ligand B clearly emerges as the more promising candidate. While its logP is low, its superior DILI profile, metabolic stability (negative Cl_mic), hERG risk, solubility, and QED score outweigh the slightly weaker binding affinity and poor Caco-2 permeability. The long half-life of Ligand A is attractive, but the high DILI risk and poor solubility are major concerns. For a GPCR target like ADRB2, a balance of properties is crucial, and Ligand B strikes a better balance.
Output:
0
2025-04-18 00:08:16,176 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (333.435 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (48.13) is significantly better than Ligand B (71.53). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (3.393) is within the optimal range, while Ligand B (1.924) is at the lower end. This could potentially hinder membrane permeability for Ligand B.
4. **HBD/HBA:** Ligand A has 2 HBD and 2 HBA, while Ligand B has 1 HBD and 4 HBA. Both are acceptable, but Ligand A is slightly more balanced.
5. **QED:** Both ligands have good QED scores (A: 0.772, B: 0.885), indicating good drug-like properties.
6. **DILI:** Ligand A (59.519) has a higher DILI risk than Ligand B (26.173). This is a significant drawback for Ligand A.
7. **BBB:** Not a primary concern for a cardiovascular target, but Ligand A (87.088) has better BBB penetration than Ligand B (57.425).
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-5.175) is slightly better than Ligand B (-4.892).
9. **Solubility:** Both have negative solubility values, which is also unusual. Ligand B (-1.178) is slightly better than Ligand A (-4.096).
10. **hERG:** Ligand A (0.938) has a slightly higher hERG risk than Ligand B (0.201). This is a concern for Ligand A.
11. **Cl_mic:** Ligand B (-9.196) has significantly better metabolic stability (lower clearance) than Ligand A (5.185). This is a major advantage for Ligand B.
12. **t1/2:** Ligand A (20.613) has a longer half-life than Ligand B (14.071), which is generally desirable.
13. **Pgp:** Ligand A (0.538) has lower P-gp efflux than Ligand B (0.029), which is favorable.
14. **Binding Affinity:** Ligand B (-6.6 kcal/mol) has slightly better binding affinity than Ligand A (-5.8 kcal/mol). While the difference isn't huge, it's enough to consider.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A has a better logP and Pgp, but Ligand B has a much better TPSA and comparable affinity. The DILI and hERG risks associated with Ligand A are significant concerns. The improved metabolic stability of Ligand B is also a major plus.
**Overall Assessment:**
Despite Ligand A having slightly better Pgp and half-life, the significantly lower DILI risk, better metabolic stability (Cl_mic), and slightly better affinity of Ligand B outweigh these advantages. The negative Caco-2 and solubility values are concerning for both, but are less critical than the safety and PK properties.
Output:
0
2025-04-18 00:08:16,176 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.5 and 352.4 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (40.62) is significantly better than Ligand B (96.69). ADRB2 is a cardiovascular target, not CNS, but lower TPSA generally improves absorption. Ligand B's TPSA is quite high, potentially hindering oral bioavailability.
3. **logP:** Ligand A (3.308) is optimal, while Ligand B (0.094) is very low. This is a major drawback for Ligand B, as it may struggle with membrane permeability.
4. **HBD/HBA:** Ligand A (0 HBD, 2 HBA) is preferable. Ligand B has 2 HBD and 6 HBA, which is higher and could impact permeability.
5. **QED:** Both ligands have similar QED values (0.787 and 0.725), indicating good drug-likeness.
6. **DILI:** Ligand A (16.014) has a much lower DILI risk than Ligand B (20.202). This is a significant advantage for Ligand A.
7. **BBB:** This is less critical for a cardiovascular target, but Ligand A (88.91) is better than Ligand B (36.06).
8. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-4.582) is slightly better than Ligand B (-4.609).
9. **Solubility:** Ligand A (-3.627) is better than Ligand B (-0.825). Solubility is important for bioavailability.
10. **hERG:** Ligand A (0.551) is better than Ligand B (0.35). Lower hERG inhibition is crucial for avoiding cardiotoxicity, especially for a cardiovascular target.
11. **Cl_mic:** Ligand A (70.964) has a higher clearance than Ligand B (12.086). This means Ligand B is more metabolically stable, which is a positive.
12. **t1/2:** Ligand A (-11.65) has a shorter half-life than Ligand B (-6.225). This is a negative for Ligand A.
13. **Pgp:** Ligand A (0.172) has lower Pgp efflux than Ligand B (0.014), which is preferable.
14. **Binding Affinity:** Ligand A (-7.8 kcal/mol) has a significantly stronger binding affinity than Ligand B (-5.5 kcal/mol). This is a substantial advantage, and can often outweigh minor ADME concerns.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand A excels in logP and affinity, and has a much more favorable TPSA. While Ligand B has better metabolic stability, the significantly weaker binding and poor logP are major drawbacks.
**Conclusion:**
Ligand A is the superior candidate. Its significantly higher binding affinity, better logP, lower TPSA, lower DILI risk, and better hERG profile outweigh its slightly higher clearance and shorter half-life. The strong binding affinity is a critical factor for a GPCR target.
Output:
1
2025-04-18 00:08:16,177 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.4 and 362.499 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (41.99) is significantly better than Ligand B (74.33). ADRB2 is a cardiovascular target, not CNS, but lower TPSA generally improves permeability.
3. **logP:** Ligand A (4.145) is higher than Ligand B (1.895). While both are within the acceptable range, Ligand A is pushing the upper limit and could potentially have solubility issues. Ligand B is closer to optimal.
4. **HBD:** Both have acceptable HBD counts (1 and 2 respectively).
5. **HBA:** Ligand A (2) is better than Ligand B (5). Lower HBA is generally preferred for permeability.
6. **QED:** Both ligands have similar QED values (0.865 and 0.756), indicating good drug-likeness.
7. **DILI:** Ligand A (44.281) has a slightly higher DILI risk than Ligand B (34.781), but both are below the concerning threshold of 60.
8. **BBB:** Ligand A (95.541) has much better BBB penetration than Ligand B (61.652). While ADRB2 isn't a primary CNS target, some off-target CNS effects are always a consideration.
9. **Caco-2:** Ligand A (-4.452) is significantly better than Ligand B (-5.135). Higher Caco-2 permeability is desirable.
10. **Solubility:** Ligand A (-5.173) is better than Ligand B (-3.135), although both are quite poor. This is a potential issue for Ligand A given its higher logP.
11. **hERG:** Ligand A (0.771) has a slightly higher hERG risk than Ligand B (0.389), but both are reasonably low.
12. **Cl_mic:** Ligand B (46.268) has a higher clearance than Ligand A (35.217), indicating lower metabolic stability.
13. **t1/2:** Ligand A (20.45) has a significantly longer half-life than Ligand B (-8.112). This is a major advantage.
14. **Pgp:** Ligand A (0.619) has lower P-gp efflux than Ligand B (0.081), which is favorable for bioavailability.
15. **Affinity:** Ligand A (-7.8 kcal/mol) has a significantly better binding affinity than Ligand B (-6.2 kcal/mol). This is a substantial difference, exceeding the 1.5 kcal/mol advantage threshold.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A excels in affinity and Pgp, and has a better TPSA. While its logP is higher, the superior affinity and other favorable ADME properties outweigh this concern.
**Conclusion:**
Ligand A is the stronger candidate due to its significantly better binding affinity, longer half-life, lower P-gp efflux, and better TPSA and Caco-2 permeability. While Ligand A has slightly higher DILI and hERG risk and lower solubility, the substantial advantage in binding affinity and metabolic stability makes it the preferred choice.
Output:
1
2025-04-18 00:08:16,177 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (363.751 and 353.369 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (67.15) is well below the 140 threshold and reasonably good for a non-CNS GPCR. Ligand B (101.29) is still within acceptable limits but higher, potentially impacting permeability.
**3. logP:** Ligand A (4.07) is at the upper end of the optimal range (1-3), which could present solubility challenges. Ligand B (0.97) is a bit low and might have permeability issues.
**4. H-Bond Donors:** Ligand A (2) and Ligand B (3) are both within the acceptable limit of 5.
**5. H-Bond Acceptors:** Ligand A (4) and Ligand B (3) are both within the acceptable limit of 10.
**6. QED:** Both ligands have reasonable QED values (0.737 and 0.607), indicating good drug-like properties.
**7. DILI:** Ligand A (92.982) has a concerningly high DILI risk. Ligand B (35.595) has a much lower and acceptable DILI risk. This is a significant advantage for Ligand B.
**8. BBB:** This is less critical for a cardiovascular target. Ligand A (37.495) and Ligand B (83.986) are both relatively low, which is fine.
**9. Caco-2 Permeability:** Ligand A (-4.803) and Ligand B (-5.226) both have negative values, which is unusual and suggests poor permeability.
**10. Aqueous Solubility:** Ligand A (-4.752) and Ligand B (-3.249) both have negative values, indicating poor solubility.
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (0.381 and 0.33).
**12. Microsomal Clearance:** Ligand A (76.668) has moderate clearance, while Ligand B (13.429) has very low clearance, suggesting better metabolic stability. This is a significant advantage for Ligand B.
**13. In vitro Half-Life:** Ligand A (-0.748) has a negative half-life, which is problematic. Ligand B (-17.414) also has a negative half-life, which is also problematic.
**14. P-gp Efflux:** Both ligands have low P-gp efflux (0.435 and 0.017).
**15. Binding Affinity:** Ligand A (-6.0) has slightly better binding affinity than Ligand B (-6.2). However, the difference is not substantial enough to outweigh other factors.
**Overall Assessment:**
While Ligand A has slightly better binding affinity, Ligand B is significantly better in terms of safety (DILI) and metabolic stability (Cl_mic). The poor solubility and permeability of both compounds are concerning, but the high DILI risk of Ligand A is a major red flag. Given the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), and the importance of minimizing off-target effects, Ligand B is the more promising candidate.
Output:
0
2025-04-18 00:08:16,177 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (342.443 Da and 380.897 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (68.6) is better than Ligand B (75.27). Both are below the 140 A^2 threshold for oral absorption, but lower TPSA is generally preferred for GPCRs to facilitate receptor binding and potentially improve BBB penetration.
**3. logP:** Ligand A (2.207) is within the optimal 1-3 range. Ligand B (3.395) is slightly higher, approaching the upper limit where solubility issues could arise.
**4. H-Bond Donors:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs generally improve membrane permeability.
**5. H-Bond Acceptors:** Both ligands have 4 HBA, which is acceptable.
**6. QED:** Ligand A (0.911) has a significantly better QED score than Ligand B (0.769), indicating a more drug-like profile.
**7. DILI Risk:** Ligand A (41.877) has a much lower DILI risk than Ligand B (69.988). This is a critical advantage, as liver toxicity is a major concern in drug development.
**8. BBB Penetration:** Ligand A (84.064) has significantly better predicted BBB penetration than Ligand B (51.57). While ADRB2 is primarily a cardiovascular target, some CNS off-target effects are possible with GPCR ligands, and better BBB penetration could contribute to those.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and requires further investigation. However, the value for Ligand A (-4.67) is less negative than Ligand B (-4.975), suggesting slightly better permeability.
**10. Aqueous Solubility:** Ligand A (-2.772) is better than Ligand B (-4.038), indicating better solubility.
**11. hERG Inhibition:** Ligand A (0.845) has a slightly higher hERG risk than Ligand B (0.256). This is a concern, but the difference isn't dramatic.
**12. Microsomal Clearance:** Ligand B (37.931) has a slightly lower microsomal clearance than Ligand A (26.086), suggesting better metabolic stability.
**13. In vitro Half-Life:** Ligand A (38.756) has a significantly longer in vitro half-life than Ligand B (9.031). This is a major advantage, potentially allowing for less frequent dosing.
**14. P-gp Efflux:** Ligand A (0.152) has a much lower P-gp efflux liability than Ligand B (0.351), which is beneficial for oral bioavailability.
**15. Binding Affinity:** Ligand B (-5.6 kcal/mol) has a slightly better binding affinity than Ligand A (-6.4 kcal/mol). While this is a positive for Ligand B, the difference is not substantial enough to outweigh the numerous advantages of Ligand A.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical ADME-Tox properties, including DILI risk, BBB penetration, solubility, P-gp efflux, and in vitro half-life. While Ligand B has slightly better binding affinity and metabolic stability, the superior overall profile of Ligand A makes it the more promising drug candidate.
Output:
1
2025-04-18 00:08:16,177 - INFO - Batch 455 complete. Total preferences: 7280
2025-04-18 00:08:16,177 - INFO - Processing batch 456/512...
2025-04-18 00:09:05,242 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (362.455 and 358.471 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Both ligands (74.77 and 76.8) are below the 140 A^2 threshold for good oral absorption, but higher than the 90 A^2 for CNS targets. This is acceptable for a cardiovascular target. No significant difference.
3. **logP:** Ligand A (1.311) is optimal, while Ligand B (3.143) is at the higher end of the optimal range. Ligand A is slightly preferred here.
4. **HBD:** Ligand A (1) is better than Ligand B (0) as it provides a hydrogen bond donor.
5. **HBA:** Ligand A (6) and Ligand B (7) are both acceptable, below the 10 threshold.
6. **QED:** Ligand A (0.874) is significantly better than Ligand B (0.7), indicating a more drug-like profile.
7. **DILI:** Ligand B (77.472) has a higher DILI risk than Ligand A (67.39). This is a significant concern, favoring Ligand A.
8. **BBB:** Both ligands have similar BBB penetration (63.397 and 61.535). This isn't a primary concern for a cardiovascular target, but slightly favors Ligand B.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.775) is slightly better than Ligand B (-5.269).
10. **Solubility:** Both ligands have very poor solubility (-3.108 and -3.146). This is a major drawback for both, but not a deciding factor between them.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.132 and 0.296). No significant difference.
12. **Cl_mic:** Ligand B (71.179) has a significantly higher microsomal clearance than Ligand A (19.113), indicating poorer metabolic stability. This strongly favors Ligand A.
13. **t1/2:** Ligand B (32.409) has a slightly longer half-life than Ligand A (30.902), but the difference is small.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.028 and 0.446). Ligand A is preferred.
15. **Binding Affinity:** Ligand A (-8.8 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.6 kcal/mol). This is a substantial advantage, potentially outweighing some ADME concerns.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand A excels in affinity and has a better logP and Pgp profile. While both have acceptable TPSA, the superior affinity and lower DILI/Cl_mic of Ligand A are decisive.
**Conclusion:**
Ligand A is the more promising candidate due to its significantly stronger binding affinity, better QED score, lower DILI risk, and improved metabolic stability (lower Cl_mic). The slightly better half-life of Ligand B is not enough to offset these advantages.
Output:
1
2025-04-18 00:09:05,242 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (351.535 and 333.439 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (52.65) is significantly better than Ligand B (73.63). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary goal, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have acceptable logP values (2.816 and 3.605), falling within the 1-3 range. Ligand B is slightly higher, which *could* present a minor solubility challenge, but isn't a dealbreaker.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves membrane permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (5). Similar reasoning as HBD.
6. **QED:** Both ligands have good QED scores (0.616 and 0.81), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (13.61) is significantly better than Ligand B (44.862). Lower DILI risk is crucial. This is a substantial advantage for Ligand A.
8. **BBB:** Both ligands have similar BBB penetration (75.107 and 76.425). Not a major factor for a cardiovascular target.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.647 and -4.876), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-2.297) is better than Ligand B (-5.2). Better solubility is always desirable.
11. **hERG:** Ligand A (0.523) is better than Ligand B (0.891). Lower hERG inhibition is critical for avoiding cardiotoxicity.
12. **Cl_mic:** Ligand A (47.347) is better than Ligand B (74.913). Lower clearance indicates better metabolic stability.
13. **t1/2:** Ligand B (18.344) is better than Ligand A (12.554). A longer half-life is generally preferred.
14. **Pgp:** Ligand A (0.112) is better than Ligand B (0.238). Lower P-gp efflux is desirable for improved bioavailability.
15. **Binding Affinity:** Ligand B (-7.3) has a significantly stronger binding affinity than Ligand A (-6.2) - a difference of 1.1 kcal/mol. This is a substantial advantage.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, and affinity. Ligand B has a slightly higher logP and significantly better affinity. However, Ligand A excels in TPSA, Pgp, DILI, solubility, hERG, and Cl_mic. The substantial advantage in safety parameters (DILI, hERG) and metabolic stability (Cl_mic) for Ligand A outweighs the affinity difference, especially considering the Caco-2 permeability issues for both.
**Conclusion:**
While Ligand B boasts superior binding affinity, Ligand A presents a much more favorable safety and ADME profile, particularly regarding DILI risk and metabolic stability. The lower TPSA and better solubility of Ligand A also contribute to its overall drug-likeness. Given the cardiovascular context, minimizing off-target effects and ensuring reasonable metabolic stability are paramount.
Output:
1
2025-04-18 00:09:05,242 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [336.435, 52.57, 2.935, 2, 3, 0.848, 37.767, 85.459, -4.617, -3.394, 0.888, 10.772, 42.827, 0.371, -6.3]
**Ligand B:** [365.262, 85.69, 2.038, 1, 6, 0.665, 78.209, 86.817, -4.689, -2.806, 0.256, 35.864, -16.31, 0.137, -6.5]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the acceptable 200-500 Da range. Ligand A (336.435) is slightly preferred due to being lower.
2. **TPSA:** Ligand A (52.57) is significantly better than Ligand B (85.69). Below 140 is good for oral absorption, and lower is better for GPCRs. Ligand A is much more favorable.
3. **logP:** Both are within the optimal 1-3 range. Ligand A (2.935) is slightly higher, which might be slightly better for membrane permeability, but both are acceptable.
4. **HBD:** Ligand A (2) is slightly better than Ligand B (1), but both are good.
5. **HBA:** Ligand A (3) is better than Ligand B (6). Lower HBA is generally preferable for permeability.
6. **QED:** Ligand A (0.848) is significantly better than Ligand B (0.665), indicating a more drug-like profile.
7. **DILI:** Ligand A (37.767) has a much lower DILI risk than Ligand B (78.209). This is a crucial advantage.
8. **BBB:** Both have high BBB penetration (Ligand A: 85.459, Ligand B: 86.817). This isn't a primary concern for cardiovascular targets, but it doesn't hurt.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. This is a significant issue for both.
10. **Solubility:** Ligand A (-3.394) is better than Ligand B (-2.806), indicating better aqueous solubility.
11. **hERG:** Ligand A (0.888) has a lower hERG risk than Ligand B (0.256), which is a positive.
12. **Cl_mic:** Ligand A (10.772) has lower microsomal clearance, suggesting better metabolic stability than Ligand B (35.864).
13. **t1/2:** Ligand A (42.827) has a much longer in vitro half-life than Ligand B (-16.31). This is a major advantage.
14. **Pgp:** Ligand A (0.371) has lower P-gp efflux liability than Ligand B (0.137). This is a positive.
15. **Affinity:** Both have excellent binding affinity (-6.3 and -6.5 kcal/mol). The difference is negligible.
**Overall Assessment:**
Ligand A is clearly superior. It has better TPSA, QED, DILI risk, solubility, hERG risk, metabolic stability (Cl_mic and t1/2), and Pgp efflux. While both have poor Caco-2 permeability, the other advantages of Ligand A outweigh this concern. The significantly lower DILI risk and longer half-life are particularly compelling. The binding affinity is comparable.
Output:
1
2025-04-18 00:09:05,243 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [357.41 , 64.11 , 4.147, 1. , 5. , 0.72 , 88.251, 64.831, -4.922, -5.148, 0.623, 70.519, -24.598, 0.519, -6.9 ]
**Ligand B:** [356.507, 67.87 , 2.075, 1. , 4. , 0.651, 12.796, 76.541, -4.729, -1.598, 0.457, 19.811, 4.615, 0.044, -3. ]
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (357 vs 356 Da). No significant difference.
2. **TPSA:** Ligand A (64.11) is better than Ligand B (67.87). Both are acceptable for oral absorption, but lower is generally preferred.
3. **logP:** Ligand A (4.147) is a bit high, while Ligand B (2.075) is excellent. This is a significant advantage for Ligand B. High logP can lead to off-target effects and poor solubility.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 5 HBA, Ligand B has 4. Both are acceptable.
6. **QED:** Both are reasonable (0.72 and 0.651), indicating good drug-like properties.
7. **DILI:** Ligand A (88.251) has a significantly higher DILI risk than Ligand B (12.796). This is a major concern for Ligand A.
8. **BBB:** Ligand B (76.541) has better BBB penetration than Ligand A (64.831). While not a primary concern for a cardiovascular target, it's a slight advantage.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-4.922) is slightly worse than Ligand B (-4.729).
10. **Solubility:** Ligand B (-1.598) is better than Ligand A (-5.148). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.623) is slightly higher than Ligand B (0.457), indicating a slightly higher risk of hERG inhibition.
12. **Cl_mic:** Ligand A (70.519) has a higher clearance than Ligand B (19.811), meaning it's metabolized faster. This is a negative for Ligand A.
13. **t1/2:** Ligand B (4.615) has a longer half-life than Ligand A (-24.598). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.519) has slightly higher Pgp efflux than Ligand B (0.044).
15. **Affinity:** Ligand A (-6.9 kcal/mol) has a significantly better binding affinity than Ligand B (-3.0 kcal/mol). This is a substantial advantage for Ligand A.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. While Ligand A has superior affinity, its high logP, high DILI risk, and poor metabolic stability are major drawbacks. Ligand B has a much better safety profile (lower DILI), better logP, solubility, and metabolic stability, even though its affinity is lower. The difference in affinity (3.9 kcal/mol) is substantial, but the ADME/Tox profile of Ligand A is concerning.
**Conclusion:**
Considering the balance of properties, especially the significant safety concerns with Ligand A, I believe **Ligand B** is the more viable drug candidate. The improved ADME/Tox profile outweighs the difference in binding affinity.
Output:
0
2025-04-18 00:09:05,243 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [344.459, 58.44, 1.797, 0, 4, 0.758, 17.1, 77.007, -4.927, -1.529, 0.32, 37.753, -13.417, 0.106, -7.3]
**Ligand B:** [365.499, 69.72, 1.025, 1, 4, 0.811, 44.164, 47.15, -5.26, -2.266, 0.249, 23.503, 17.229, 0.055, -8]
Here's a breakdown, considering the guidelines and GPCR priorities (logP, Pgp, TPSA, affinity, and BBB):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (344.459) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (58.44) is better than Ligand B (69.72). Both are below 140, but A is closer to the optimal <90 for potential CNS penetration, although this isn't a primary concern for a cardiovascular target.
3. **logP:** Both are good (around 1-3). Ligand B (1.025) is slightly lower, which could potentially impact permeability, but is still acceptable. Ligand A (1.797) is better.
4. **HBD:** Ligand A (0) is preferable to Ligand B (1). Fewer HBDs generally improve permeability.
5. **HBA:** Both have 4 HBA, which is acceptable.
6. **QED:** Both are good (>0.5). Ligand B (0.811) is slightly better.
7. **DILI:** Ligand A (17.1) has a significantly lower DILI risk than Ligand B (44.164). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (77.007) has much better BBB penetration potential than Ligand B (47.15). While not crucial for a cardiovascular target, it's a positive attribute.
9. **Caco-2:** Ligand A (-4.927) and Ligand B (-5.26) are both very poor. This is a significant drawback for both.
10. **Solubility:** Ligand A (-1.529) is slightly better than Ligand B (-2.266), but both are poor.
11. **hERG:** Both are low risk (0.32 and 0.249).
12. **Cl_mic:** Ligand B (23.503) has a lower microsomal clearance than Ligand A (37.753), indicating better metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand B (17.229) has a longer in vitro half-life than Ligand A (-13.417). This is a major advantage for Ligand B.
14. **Pgp:** Both are low (0.106 and 0.055).
15. **Affinity:** Ligand B (-8) has a slightly better binding affinity than Ligand A (-7.3), a 0.7 kcal/mol difference. This is a substantial advantage.
**Overall Assessment:**
Ligand B has a better binding affinity and metabolic stability (lower Cl_mic, longer t1/2). However, Ligand A excels in DILI risk, BBB penetration, and has a slightly better logP and TPSA. The Caco-2 permeability is poor for both, which is a concern. The affinity difference is significant enough to outweigh the other benefits of Ligand A, especially considering the cardiovascular target.
Therefore, I believe Ligand B is the more promising candidate.
0
2025-04-18 00:09:05,243 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.443 and 351.422 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (67.87) is better than Ligand B (75.44). Both are below the 140 threshold for oral absorption, but closer to the 90 threshold is preferred for GPCRs. Ligand A is better.
3. **logP:** Ligand A (0.949) is slightly below the optimal 1-3 range, while Ligand B (2.589) is within the optimal range. Ligand B is better.
4. **HBD:** Both ligands have 1 HBD, which is within the acceptable limit of <=5. No difference.
5. **HBA:** Both ligands have 4 HBA, which is within the acceptable limit of <=10. No difference.
6. **QED:** Ligand B (0.819) has a significantly better QED score than Ligand A (0.549), indicating a more drug-like profile. Ligand B is better.
7. **DILI:** Ligand A (9.965) has a much lower DILI risk than Ligand B (31.873). This is a significant advantage for Ligand A.
8. **BBB:** Ligand B (91.392) has a much higher BBB penetration score than Ligand A (55.021). For a cardiovascular GPCR like ADRB2, BBB penetration isn't *critical* but can be beneficial for understanding off-target effects and potential CNS side effects. Ligand B is better.
9. **Caco-2:** Both ligands have negative Caco-2 values, suggesting poor permeability. Ligand A (-4.618) is slightly better than Ligand B (-4.893), but both are concerning.
10. **Solubility:** Both ligands have negative solubility values, indicating poor solubility. Ligand A (-2.125) is slightly better than Ligand B (-2.865), but both are concerning.
11. **hERG:** Both ligands have low hERG inhibition risk (0.253 and 0.309). No significant difference.
12. **Cl_mic:** Ligand B (17.184) has a lower microsomal clearance than Ligand A (28.339), indicating better metabolic stability. Ligand B is better.
13. **t1/2:** Ligand B (-4.002) has a slightly better in vitro half-life than Ligand A (-5.451). Ligand B is better.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.059 and 0.131). No significant difference.
15. **Binding Affinity:** Ligand B (-7.6 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.2 kcal/mol). This is a substantial advantage for Ligand B. A 2.4 kcal/mol difference is very significant.
**Overall Assessment:**
Ligand B clearly wins on potency (affinity) and has better QED, BBB, metabolic stability (Cl_mic, t1/2), and logP. While Ligand A has a lower DILI risk, the substantial advantage in binding affinity of Ligand B outweighs this concern, especially given the relatively low DILI risk of both compounds. The poor Caco-2 and solubility are concerning for both, and would need to be addressed in further optimization. However, starting with the more potent ligand is generally the better strategy.
Output:
0
2025-04-18 00:09:05,243 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for the ADRB2, a cardiovascular GPCR. Therefore, the key priorities are logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB.
Let's break down the comparison:
1. **MW:** Both ligands are within the ideal range (345-346 Da).
2. **TPSA:** Ligand A (63.13) is significantly better than Ligand B (92.15). Lower TPSA generally favors oral absorption and GPCR penetration.
3. **logP:** Ligand A (3.029) is slightly better than Ligand B (1.837), falling comfortably within the optimal range. Ligand B is at the lower end, potentially impacting membrane permeability.
4. **HBD/HBA:** Both ligands have acceptable HBD (2) and HBA counts (A: 3, B: 5), posing no major concerns.
5. **QED:** Both ligands have similar QED scores (A: 0.798, B: 0.719), indicating good drug-likeness.
6. **DILI:** Ligand A (20.202) has a much lower DILI risk than Ligand B (36.293). This is a significant advantage.
7. **BBB:** Both ligands have similar BBB penetration (A: 66.576, B: 66.77). While not a primary concern for a cardiovascular target, it's not a differentiating factor here.
8. **Caco-2:** Ligand A (-4.776) is better than Ligand B (-5.418). Higher (less negative) Caco-2 values indicate better absorption.
9. **Solubility:** Ligand A (-2.916) is better than Ligand B (-2.014), indicating better aqueous solubility.
10. **hERG:** Both ligands have very low hERG inhibition risk (A: 0.261, B: 0.13).
11. **Cl_mic:** Ligand A (28.194) has a higher microsomal clearance than Ligand B (13.74), meaning it's metabolized faster. This is a drawback for Ligand A.
12. **t1/2:** Ligand B (28.104) has a longer in vitro half-life than Ligand A (16.407). This is a positive for Ligand B.
13. **Pgp:** Both ligands have low P-gp efflux liability (A: 0.077, B: 0.048).
14. **Binding Affinity:** Ligand B (-8.5 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.7 kcal/mol). This is a substantial advantage, potentially outweighing some ADME concerns.
**Overall Assessment:**
Ligand B's significantly stronger binding affinity (-8.5 vs -5.7 kcal/mol) is a major advantage, especially for a GPCR target. While Ligand A has better TPSA, solubility, and lower DILI risk, the potency difference is substantial. The longer half-life of Ligand B is also beneficial. The slightly lower logP of Ligand B is a minor concern, but the strong binding affinity is likely to compensate for that.
Output:
0
2025-04-18 00:09:05,243 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (348.487 and 361.877 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (78.43) is higher than Ligand B (52.57). For a cardiovascular GPCR, TPSA is moderately important, and lower is generally preferred for better permeability. Ligand B has a clear advantage.
**3. logP:** Both ligands have good logP values (2.127 and 1.509), falling within the optimal 1-3 range. Ligand B is slightly lower, which could be beneficial for solubility, but both are acceptable.
**4. H-Bond Donors:** Ligand A has 3 HBD, while Ligand B has 0. Lower HBD is generally preferable for permeability, giving Ligand B an edge.
**5. H-Bond Acceptors:** Ligand A has 3 HBA, and Ligand B has 5. Ligand A is better here.
**6. QED:** Both ligands have good QED scores (0.688 and 0.816), indicating good drug-like properties. Ligand B is slightly better.
**7. DILI Risk:** Both ligands have acceptable DILI risk (30.05 and 38.387), well below the 60 threshold. No significant difference.
**8. BBB Penetration:** Ligand B (93.253) has significantly higher BBB penetration than Ligand A (60.45). While ADRB2 is a cardiovascular target, some CNS effects are possible with beta-blockers, and higher BBB penetration could lead to unwanted side effects. However, for a GPCR, some level of BBB penetration isn't necessarily detrimental.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.77 and -4.911), which is unusual and suggests poor permeability. This is a significant concern for both.
**10. Aqueous Solubility:** Ligand B (-2.433) is better than Ligand A (-3.551), indicating slightly improved solubility.
**11. hERG Inhibition:** Ligand A (0.256) has a lower hERG inhibition risk than Ligand B (0.803). This is a crucial factor for cardiovascular drugs, as hERG inhibition can cause arrhythmias. Ligand A is significantly better.
**12. Microsomal Clearance:** Both ligands have similar microsomal clearance values (41.793 and 43.492 mL/min/kg). No significant difference.
**13. In vitro Half-Life:** Ligand B (-1.076) has a negative half-life, which is not possible. This is a major red flag. Ligand A has a reasonable half-life (17.189 hours).
**14. P-gp Efflux:** Ligand A (0.165) has lower P-gp efflux than Ligand B (0.069), which is beneficial for bioavailability.
**15. Binding Affinity:** Ligand B (-8.1 kcal/mol) has a significantly stronger binding affinity than Ligand A (-4.8 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME drawbacks.
**Overall Assessment:**
Ligand B has a much stronger binding affinity, which is paramount for GPCR targets. It also has better TPSA, QED, solubility, and BBB penetration. However, the negative in vitro half-life is a critical issue. Ligand A has a more favorable safety profile (lower hERG inhibition) and a reasonable half-life, but its binding affinity is significantly weaker.
Despite the superior affinity of Ligand B, the negative half-life is a deal-breaker. It suggests a significant instability issue that would be very difficult to overcome. Therefore, I would prioritize Ligand A due to its more reasonable ADME properties, particularly the positive half-life and lower hERG risk.
Output:
1
2025-04-18 00:09:05,243 - INFO - Here's my reasoning and final output for the ligand preference:
**Reasoning:**
We are targeting ADRB2, a GPCR, so the priorities are logP, Pgp, TPSA, affinity, and BBB. Let's compare Ligand A and Ligand B across all parameters:
1. **MW:** Both ligands (347.379 and 371.453 Da) fall within the ideal 200-500 Da range.
2. **TPSA:** Ligand B (62.3) is significantly better than Ligand A (120.25). Lower TPSA is preferred for GPCRs, aiding permeability.
3. **logP:** Ligand B (2.854) is optimal (1-3), while Ligand A (-0.784) is too low, potentially hindering membrane permeability.
4. **HBD/HBA:** Ligand B (1 HBD, 4 HBA) is better than Ligand A (2 HBD, 7 HBA). Fewer H-bonds generally improve permeability.
5. **QED:** Both ligands have good QED scores (0.727 and 0.885), indicating drug-likeness.
6. **DILI:** Ligand B (49.787) has a lower DILI risk than Ligand A (69.872), which is desirable.
7. **BBB:** Ligand B (90.229) shows excellent BBB penetration, while Ligand A (34.975) is poor. This is a significant advantage for Ligand B.
8. **Caco-2:** Both have negative Caco-2 values (-5.321 and -4.879), which is unusual and suggests poor permeability. However, the scale isn't specified, so it's hard to interpret.
9. **Solubility:** Ligand A (-1.293) has slightly better solubility than Ligand B (-3.612).
10. **hERG:** Ligand A (0.066) has a slightly lower hERG risk than Ligand B (0.421), but both are reasonably low.
11. **Cl_mic:** Ligand A (11.269) has a lower microsomal clearance, indicating better metabolic stability than Ligand B (31.992).
12. **t1/2:** Ligand B (-24.354) has a longer in vitro half-life than Ligand A (-18.955).
13. **Pgp:** Ligand A (0.013) has much lower P-gp efflux liability than Ligand B (0.179), which is favorable.
14. **Affinity:** Ligand B (-7.2 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.7 kcal/mol). This is a crucial advantage.
**Overall Assessment:**
Ligand B clearly outperforms Ligand A, despite Ligand A's better Pgp and Cl_mic values. The superior logP, TPSA, BBB penetration, and, most importantly, binding affinity of Ligand B outweigh the drawbacks. The lower DILI risk is also a plus. While the Caco-2 values are concerning for both, the other properties strongly favor Ligand B. The strong binding affinity of Ligand B (-7.2 kcal/mol) is a substantial advantage that can compensate for minor ADME issues.
Output:
0
2025-04-18 00:09:05,243 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (358.46 & 346.47 Da) fall comfortably within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Both ligands (67.33 & 67.43) are below the 140 A^2 threshold for good oral absorption, which is good.
3. **logP:** Ligand A (-0.599) is a bit low, potentially hindering permeability. Ligand B (1.864) is within the optimal 1-3 range. This favors Ligand B.
4. **HBD:** Ligand A (1) and Ligand B (2) are both acceptable, below the 5 threshold.
5. **HBA:** Ligand A (5) and Ligand B (3) are both acceptable, below the 10 threshold.
6. **QED:** Both ligands (0.687 & 0.546) are above 0.5, indicating good drug-likeness. Ligand A is slightly better.
7. **DILI:** Ligand A (6.32) has a much lower DILI risk than Ligand B (12.49). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (36.29) is lower than Ligand B (53.70). While ADRB2 isn't strictly a CNS target, some CNS penetration can be beneficial for understanding off-target effects. Ligand B is better.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.024 & -4.905), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (0.656) has a slightly better solubility than Ligand B (-2.733).
11. **hERG:** Both ligands have low hERG inhibition risk (0.245 & 0.336). No significant difference.
12. **Cl_mic:** Ligand A (-19.659) has significantly lower (better) microsomal clearance than Ligand B (10.277), indicating better metabolic stability.
13. **t1/2:** Ligand A (-31.215) has a longer in vitro half-life than Ligand B (22.101). This is a substantial advantage for Ligand A.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.004 & 0.061). No significant difference.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.6 & -5.6 kcal/mol). Ligand A is slightly better, but the difference is not huge.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand B has a better logP. However, the superior metabolic stability (Cl_mic, t1/2) and lower DILI risk of Ligand A are very important for overall drug development. The slight advantage in binding affinity for Ligand A also contributes. The Caco-2 values are concerning for both, but can be addressed with formulation strategies.
**Overall Assessment:**
Despite Ligand B's better logP and BBB, Ligand A's significantly improved metabolic stability, lower DILI risk, and slightly better affinity make it the more promising candidate. The poor Caco-2 values are a concern for both, but the other advantages of Ligand A outweigh this drawback.
Output:
1
2025-04-18 00:09:05,243 - INFO - Here's my reasoning and final output:
**Reasoning:**
We're evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, affinity, logP, TPSA, Pgp efflux, and BBB penetration are key considerations.
* **Molecular Weight:** Both ligands (373.39 and 371.50 Da) fall within the ideal 200-500 Da range.
* **TPSA:** Ligand A (135.92) is better than Ligand B (45.23). While both are below 140, the lower TPSA of Ligand B is extremely favorable for permeability.
* **logP:** Ligand A (1.278) is within the optimal 1-3 range. Ligand B (3.919) is approaching the upper limit, potentially raising solubility concerns.
* **H-Bond Donors/Acceptors:** Both have acceptable HBD (1) and HBA (7/4) counts.
* **QED:** Ligand B (0.873) has a significantly higher QED score than Ligand A (0.45), indicating better overall drug-likeness.
* **DILI:** Ligand B (24.04) has a much lower DILI risk than Ligand A (83.443), a significant advantage.
* **BBB:** Ligand B (91.314) shows excellent BBB penetration, while Ligand A (70.415) is good but not as high. This is important for potential off-target effects in the CNS.
* **Caco-2 Permeability:** Both are similar (-4.8 and -4.862).
* **Aqueous Solubility:** Both are similar (-3.549 and -3.721).
* **hERG Inhibition:** Ligand A (0.438) has a slightly lower hERG risk than Ligand B (0.683), but both are relatively low.
* **Microsomal Clearance:** Ligand A (61.675) has a higher clearance than Ligand B (23.744), meaning Ligand B is more metabolically stable.
* **In vitro Half-Life:** Ligand B (-1.619) has a longer half-life than Ligand A (30.486).
* **P-gp Efflux:** Ligand A (0.157) has lower P-gp efflux, which is favorable for bioavailability. Ligand B (0.449) is higher.
* **Binding Affinity:** Ligand B (-8.0) has a slightly better binding affinity than Ligand A (-7.0), a 1 kcal/mol difference.
**Overall Assessment:**
Ligand B is the stronger candidate. While Ligand A has slightly better P-gp efflux, Ligand B excels in critical areas: significantly lower DILI risk, much better BBB penetration, superior QED, improved metabolic stability (lower Cl_mic, longer t1/2), and slightly better binding affinity. The lower TPSA of Ligand B is also a plus. The slightly higher logP of Ligand B is a minor concern, but the benefits outweigh this drawback.
**Output:**
0
2025-04-18 00:09:05,243 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (345.447 and 350.503 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (71.76) is slightly higher than Ligand B (69.64), but both are well below the 140 threshold for good oral absorption, and acceptable for a cardiovascular GPCR.
3. **logP:** Both ligands have excellent logP values (2.466 and 2.328), falling within the optimal 1-3 range.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (3). Lower HBA generally improves permeability.
6. **QED:** Ligand A (0.924) has a significantly better QED score than Ligand B (0.74), indicating a more drug-like profile.
7. **DILI:** Ligand A (39.046) has a much lower DILI risk than Ligand B (6.592), a critical advantage.
8. **BBB:** Ligand A (90.578) has a significantly higher BBB penetration percentile than Ligand B (62.195). While ADRB2 isn't a CNS target, higher BBB is generally favorable, indicating less P-gp involvement.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.713 and -4.793), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Both ligands have negative solubility values (-2.519 and -2.573), indicating very poor aqueous solubility. This is a major drawback for both.
11. **hERG:** Both ligands have low hERG inhibition liability (0.605 and 0.36), which is good.
12. **Cl_mic:** Ligand A (25.735) has a lower microsomal clearance than Ligand B (45.977), suggesting better metabolic stability.
13. **t1/2:** Ligand A (17.856) has a longer in vitro half-life than Ligand B (-5.668), which is a significant advantage.
14. **Pgp:** Ligand A (0.139) has lower P-gp efflux liability than Ligand B (0.063), which is preferable.
15. **Binding Affinity:** Both ligands have very similar and excellent binding affinities (-5.7 and -5.8 kcal/mol). The difference is negligible.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Both ligands perform well on logP and affinity. Ligand A is better on TPSA and Pgp.
**Overall Assessment:**
While both ligands have concerningly poor Caco-2 and solubility values, Ligand A is significantly better across several crucial ADME-Tox parameters: QED, DILI, BBB, Cl_mic, and t1/2. The slightly better HBD/HBA and Pgp profile further support choosing Ligand A. The similar binding affinity means the ADME advantages of Ligand A outweigh any minor differences in potency.
Output:
1
2025-04-18 00:09:05,244 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (364.398 and 340.387 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (106.33) is slightly higher than Ligand B (95.08). Both are below the 140 threshold for good oral absorption, but closer to the 90 threshold for CNS targets (less relevant for ADRB2, a cardiovascular target). Ligand B is preferable.
3. **logP:** Ligand A (1.464) and Ligand B (0.676) are both within the optimal 1-3 range, but Ligand B is closer to the lower bound. Ligand A is preferable.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable, below the threshold of 5. Ligand B is preferable.
5. **HBA:** Ligand A (4) and Ligand B (5) are both acceptable, below the threshold of 10. Ligand A is preferable.
6. **QED:** Both ligands have good QED scores (0.757 and 0.886), indicating good drug-like properties. Ligand B is preferable.
7. **DILI:** Ligand A (77.549) has a higher DILI risk than Ligand B (63.125). Ligand B is preferable.
8. **BBB:** Ligand A (63.94) has a higher BBB penetration than Ligand B (23.536). While ADRB2 isn't a CNS target, some distribution to the CNS is not necessarily detrimental. Ligand A is preferable.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.023 and -5.201), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Both ligands have negative solubility values (-3.299 and -1.882), indicating very poor aqueous solubility. This is a major drawback for both.
11. **hERG:** Both ligands have low hERG inhibition liability (0.33 and 0.134), which is good. Ligand B is preferable.
12. **Cl_mic:** Ligand A (0.959) has a much lower microsomal clearance than Ligand B (-10.264). This suggests better metabolic stability for Ligand A, a significant advantage.
13. **t1/2:** Ligand A (-0.253) has a slightly better in vitro half-life than Ligand B (-9.881). Ligand A is preferable.
14. **Pgp:** Ligand A (0.24) has lower P-gp efflux liability than Ligand B (0.013). Ligand A is preferable.
15. **Affinity:** Ligand B (-7.4) has a slightly better binding affinity than Ligand A (-7.1). This is a 0.3 kcal/mol difference, which is not substantial enough to outweigh other factors.
**GPCR-specific priorities:** For ADRB2 (a cardiovascular GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has a better logP, Pgp, and metabolic stability. Ligand B has a slightly better affinity and TPSA. The poor Caco-2 and solubility are concerning for both.
**Overall Assessment:**
Despite the slightly better affinity of Ligand B, Ligand A is the more promising candidate due to its significantly better metabolic stability (lower Cl_mic), better half-life, lower P-gp efflux, and more favorable logP. The DILI risk is higher for Ligand A, but the metabolic advantage is more critical for a GPCR target. The poor solubility and permeability are problematic for both, but can be addressed with formulation strategies.
Output:
1
2025-04-18 00:09:05,244 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step Comparison:**
1. **MW:** Both ligands (343.43 & 344.50 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (49.41) is significantly better than Ligand A (87.3). ADRB2 is not a CNS target, but lower TPSA generally correlates with better absorption. This favors Ligand B.
3. **logP:** Ligand B (3.422) is at the higher end of the optimal range (1-3), while Ligand A (0.636) is quite low. Low logP can hinder membrane permeability. Ligand B is favored.
4. **HBD:** Ligand A (3) is higher than Ligand B (1). While both are acceptable, lower HBD can sometimes improve permeability. Slight edge to Ligand B.
5. **HBA:** Ligand A (3) and Ligand B (2) are both good. No significant difference.
6. **QED:** Ligand B (0.751) is better than Ligand A (0.376), indicating a more drug-like profile. This is a substantial advantage for Ligand B.
7. **DILI:** Ligand B (15.36%) has a much lower DILI risk than Ligand A (27.61%). This is a significant safety advantage for Ligand B.
8. **BBB:** Not a primary concern for ADRB2, but Ligand B (83.29%) has a higher BBB penetration than Ligand A (30.13%).
9. **Caco-2:** Both are negative, indicating poor permeability. This is a concern for both.
10. **Solubility:** Both are negative, indicating poor solubility. This is a concern for both.
11. **hERG:** Ligand A (0.031) has a slightly lower hERG risk than Ligand B (0.518), but both are very low.
12. **Cl_mic:** Ligand A (22.29) has a lower microsomal clearance than Ligand B (61.93), suggesting better metabolic stability. This favors Ligand A.
13. **t1/2:** Ligand A (-17.04) has a negative half-life, which is concerning. Ligand B (-13.13) is also negative, but less so. Both are very poor.
14. **Pgp:** Ligand A (0.03) has a lower P-gp efflux liability than Ligand B (0.265), which is favorable for bioavailability. This favors Ligand A.
15. **Binding Affinity:** Ligand B (-7.4 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.7 kcal/mol). This is a substantial advantage, and can often outweigh minor ADME drawbacks.
**Overall Assessment:**
Ligand B clearly wins out. While Ligand A has better metabolic stability and P-gp properties, Ligand B has a much better QED score, lower DILI risk, significantly better binding affinity, and a more favorable logP and TPSA. The strong binding affinity of Ligand B is particularly important for a GPCR target like ADRB2. The negative half-life for both is concerning, but the superior overall profile of Ligand B makes it the more promising candidate.
Output:
0
2025-04-18 00:09:05,244 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [364.555, 49.41, 3.206, 1, 3, 0.815, 22.993, 75.301, -5.025, -4.313, 0.314, 62.673, -4.062, 0.185, -7.8]
**Ligand B:** [365.503, 80.12, 1.307, 1, 6, 0.788, 44.203, 54.983, -5.641, -2.216, 0.155, 27.013, -8.17, 0.023, -6]
Here's a breakdown, prioritizing GPCR-relevant parameters:
1. **Molecular Weight:** Both are within the ideal 200-500 Da range. (A: 364.555, B: 365.503) - No significant difference.
2. **TPSA:** Ligand A (49.41) is significantly better than Ligand B (80.12). GPCRs benefit from lower TPSA for permeability. A is well below the 90 A^2 threshold. B is pushing the limit for good oral absorption.
3. **logP:** Ligand A (3.206) is optimal, while Ligand B (1.307) is a bit low. A good logP is crucial for GPCRs.
4. **H-Bond Donors/Acceptors:** Both have 1 HBD, which is good. Ligand B has 6 HBA, while A has 3. Lower HBA is generally preferred for permeability.
5. **QED:** Both are reasonably good (A: 0.815, B: 0.788), indicating drug-like properties. A is slightly better.
6. **DILI Risk:** Ligand A (22.993) has a much lower DILI risk than Ligand B (44.203). This is a significant advantage.
7. **BBB Penetration:** Ligand A (75.301) shows good BBB penetration, while Ligand B (54.983) is lower. This is important for a GPCR target, even if not strictly CNS-focused.
8. **Caco-2 Permeability:** Both are negative, indicating poor permeability. However, the scale is not provided, so it is difficult to interpret.
9. **Aqueous Solubility:** Both are negative, indicating poor solubility. However, the scale is not provided, so it is difficult to interpret.
10. **hERG Inhibition:** Both are very low (A: 0.314, B: 0.155), indicating minimal cardiotoxicity risk.
11. **Microsomal Clearance:** Ligand B (27.013) has significantly lower clearance than Ligand A (62.673), suggesting better metabolic stability.
12. **In vitro Half-Life:** Ligand B (-8.17) has a longer half-life than Ligand A (-4.062). This is a positive.
13. **P-gp Efflux:** Both are very low (A: 0.185, B: 0.023), indicating minimal P-gp efflux.
14. **Binding Affinity:** Ligand A (-7.8) has a slightly better binding affinity than Ligand B (-6). While both are good, the difference is significant.
**Overall Assessment:**
Ligand A is the stronger candidate. It excels in TPSA, logP, DILI risk, and BBB penetration, all critical for GPCR targets. Its binding affinity is also slightly better. While Ligand B has better metabolic stability and half-life, the advantages of Ligand A in permeability, safety, and target engagement outweigh these benefits. The slightly better affinity of Ligand A is also a significant factor.
Output:
1
2025-04-18 00:09:05,244 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (342.439 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (38.13) is significantly better than Ligand A (71.34). Lower TPSA is crucial for GPCRs, aiding in blood-brain barrier penetration and overall absorption.
3. **logP:** Both are good (between 1-3), but Ligand B (4.134) is slightly higher. While acceptable, it's closer to the upper limit where solubility issues could arise. Ligand A (3.862) is better.
4. **HBD:** Ligand A (2) is better than Ligand B (0). Having some HBD can improve solubility.
5. **HBA:** Ligand B (4) is slightly better than Ligand A (3).
6. **QED:** Both are very similar and acceptable (around 0.7).
7. **DILI:** Ligand B (29.857) is *much* better than Ligand A (59.442). This is a significant advantage for Ligand B, as minimizing liver toxicity is paramount.
8. **BBB:** Ligand B (78.868) is considerably better than Ligand A (65.839). While ADRB2 isn't exclusively a CNS target, some CNS penetration can be beneficial, and lower TPSA in Ligand B supports this.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand B (-5.017) is slightly worse than Ligand A (-4.92).
10. **Solubility:** Ligand B (-3.979) is slightly better than Ligand A (-4.334).
11. **hERG:** Both are very low, indicating minimal hERG inhibition risk. Ligand B (0.725) is slightly better than Ligand A (0.849).
12. **Cl_mic:** Ligand A (68.957) is *much* better than Ligand B (118.227). Lower clearance means greater metabolic stability.
13. **t1/2:** Ligand A (60.506) is significantly better than Ligand B (25.454). A longer half-life is generally preferred.
14. **Pgp:** Both are low, indicating minimal P-gp efflux. Ligand B (0.621) is slightly better than Ligand A (0.708).
15. **Binding Affinity:** Ligand B (-7.0) is 0.4 kcal/mol better than Ligand A (-6.6). This is a substantial difference in potency, and a key driver in the decision.
**Overall Assessment & GPCR Prioritization:**
For a GPCR like ADRB2, TPSA, logP, and binding affinity are critical. Ligand B excels in TPSA and significantly in binding affinity. The lower DILI risk is also a major advantage. While Ligand A has better metabolic stability (Cl_mic and t1/2) and slightly better logP, the superior affinity and safety profile of Ligand B outweigh these drawbacks. The slightly worse Caco-2 permeability of Ligand B is a concern, but can be addressed through formulation strategies. The substantial affinity difference is likely to be more impactful than the permeability difference.
Output:
0
2025-04-18 00:09:05,244 - INFO - Batch 456 complete. Total preferences: 7296
2025-04-18 00:09:05,244 - INFO - Processing batch 457/512...
2025-04-18 00:09:55,819 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (348.49 and 360.84 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (60.85) is slightly higher than Ligand B (51.66). Both are below the 140 threshold for oral absorption, but closer to the 90 threshold for CNS targets.
3. **logP:** Both ligands have good logP values (2.48 and 2.98), falling within the optimal 1-3 range. Ligand B is slightly higher, potentially leading to slightly better membrane permeability.
4. **HBD:** Ligand A has 1 HBD, while Ligand B has 0. Both are acceptable.
5. **HBA:** Ligand A has 3 HBA, and Ligand B has 4. Both are below the 10 threshold.
6. **QED:** Both ligands have similar QED values (0.797 and 0.794), indicating good drug-likeness.
7. **DILI:** Ligand A (19.47%) has a significantly lower DILI risk than Ligand B (36.41%). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (80.54%) has a much higher BBB penetration percentile than Ligand A (50.52%). While ADRB2 isn't exclusively a CNS target, some CNS exposure could be beneficial or at least not detrimental.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.671 and -4.765). This is unusual and suggests poor permeability.
10. **Solubility:** Ligand A (-1.941) has better solubility than Ligand B (-3.059).
11. **hERG:** Ligand A (0.088) has a lower hERG inhibition liability than Ligand B (0.5). This is a significant safety advantage for Ligand A.
12. **Cl_mic:** Ligand A (19.31) has a much lower microsomal clearance than Ligand B (63.95). This indicates better metabolic stability for Ligand A.
13. **t1/2:** Ligand B (51.55) has a longer in vitro half-life than Ligand A (23.35). This is a positive for Ligand B.
14. **Pgp:** Ligand A (0.151) has lower P-gp efflux liability than Ligand B (0.255). This is a slight advantage for Ligand A.
15. **Binding Affinity:** Ligand B (-7.2 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.1 kcal/mol). This is a substantial advantage for Ligand B, potentially outweighing some of its ADME drawbacks.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, affinity, logP, TPSA, and Pgp are key. Ligand B excels in affinity and has a slightly better logP. However, Ligand A demonstrates a much better safety profile (lower DILI and hERG) and better metabolic stability (lower Cl_mic). The Caco-2 values are concerning for both.
**Overall Assessment:**
The stronger binding affinity of Ligand B is very attractive. However, the significantly lower DILI and hERG risks, coupled with better metabolic stability and solubility of Ligand A, make it a more promising candidate overall. The difference in binding affinity, while substantial, might be overcome with further optimization of Ligand A. The safety profile is paramount.
Output:
1
2025-04-18 00:09:55,819 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands fall within the acceptable range (200-500 Da), with Ligand A (366.414 Da) being preferable due to its lower weight.
**2. TPSA:** Ligand A (77.52) is better than Ligand B (53.16). While both are below 140, lower TPSA generally correlates with better membrane permeability, a key factor for GPCR ligands.
**3. logP:** Ligand B (4.785) is slightly higher than Ligand A (3.636). While both are above the optimal range of 1-3, Ligand B is pushing the upper limit, potentially leading to solubility issues.
**4. H-Bond Donors:** Ligand A (1) is better than Ligand B (3). Fewer HBDs generally improve permeability.
**5. H-Bond Acceptors:** Ligand A (7) is higher than Ligand B (2). While both are within the acceptable range, Ligand B is better.
**6. QED:** Ligand A (0.814) is significantly better than Ligand B (0.393), indicating a more drug-like profile.
**7. DILI:** Both ligands have high DILI risk (Ligand A: 86.545, Ligand B: 89.841). This is a concern for both, but not a deciding factor between the two.
**8. BBB:** Both ligands have moderate BBB penetration (Ligand A: 63.125, Ligand B: 69.833). Given that ADRB2 is a cardiovascular target, BBB penetration is not a primary concern, but Ligand B is slightly better.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.408) is slightly better than Ligand B (-4.858).
**10. Aqueous Solubility:** Both ligands have very poor aqueous solubility (Ligand A: -5.869, Ligand B: -6.296). This is a significant drawback for both.
**11. hERG Inhibition:** Ligand A (0.371) is significantly better than Ligand B (0.866), indicating a lower risk of cardiotoxicity. This is crucial for a cardiovascular target.
**12. Microsomal Clearance:** Ligand B (51.604) has lower clearance than Ligand A (130.608), suggesting better metabolic stability.
**13. In vitro Half-Life:** Ligand B (62.948) has a longer half-life than Ligand A (55.139), which is desirable.
**14. P-gp Efflux:** Ligand A (0.206) is better than Ligand B (0.341), indicating lower P-gp efflux and potentially better bioavailability.
**15. Binding Affinity:** Ligand A (-3.4 kcal/mol) is significantly weaker than Ligand B (-0.2 kcal/mol). This is the most critical factor. A difference of >1.5 kcal/mol can often outweigh other ADME drawbacks.
**Overall Assessment:**
Despite Ligand B's better metabolic stability and half-life, the significantly stronger binding affinity of Ligand B (-0.2 kcal/mol vs -3.4 kcal/mol) is the most important factor for a GPCR ligand. The difference in binding affinity is substantial enough to compensate for the slightly higher logP and poorer QED. While both compounds have issues with solubility and DILI, the potency advantage of Ligand B is too significant to ignore.
Output:
0
2025-04-18 00:09:55,819 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (342.355 Da) is well within the ideal range (200-500 Da). Ligand B (428.316 Da) is also acceptable, but closer to the upper limit.
2. **TPSA:** Ligand A (93.53) is good, under the 140 threshold for oral absorption. Ligand B (103.78) is still reasonable, but less optimal.
3. **logP:** Ligand A (0.234) is quite low, potentially hindering permeability. Ligand B (1.838) is much better, falling within the optimal 1-3 range. This is a significant advantage for Ligand B.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 6 HBA, acceptable. Ligand B has 10 HBA, which is at the upper limit of what's desirable.
6. **QED:** Ligand A (0.786) has a strong drug-like profile. Ligand B (0.488) is lower, indicating a less favorable overall profile.
7. **DILI:** Ligand A (67.429) has a moderate DILI risk. Ligand B (75.107) has a higher DILI risk, which is concerning.
8. **BBB:** Ligand A (64.482) has moderate BBB penetration. Ligand B (54.827) has lower BBB penetration. While ADRB2 isn't strictly a CNS target, some CNS exposure could be relevant depending on the specific therapeutic indication.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.633) is slightly better than Ligand B (-5.707).
10. **Solubility:** Ligand A (-2.226) has very poor solubility. Ligand B (-1.44) is slightly better, but still poor.
11. **hERG:** Both ligands have very low hERG inhibition risk.
12. **Cl_mic:** Both ligands have similar, relatively low microsomal clearance values (Ligand A: 29.542, Ligand B: 30.087), suggesting reasonable metabolic stability.
13. **t1/2:** Ligand A (-19.936) has a negative in vitro half-life, which is nonsensical and indicates a major issue. Ligand B (31.832) has a reasonable half-life.
14. **Pgp:** Both ligands have low P-gp efflux liability.
15. **Affinity:** Ligand A (-8.0) has a significantly stronger binding affinity than Ligand B (-5.4). This is a substantial advantage.
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, TPSA, and affinity are key. Ligand B excels in logP, while Ligand A has a much better affinity. However, the negative half-life for Ligand A is a critical flaw. A negative half-life is not physically possible and suggests a significant problem with the data or the molecule itself. The poor solubility of both is also a concern, but can potentially be addressed with formulation strategies.
**Conclusion:**
Despite Ligand A's superior binding affinity, the nonsensical negative half-life is a deal-breaker. Ligand B, while having a weaker affinity, presents a more viable starting point due to its reasonable ADME properties and a positive half-life. The lower logP of Ligand A is also a concern for permeability.
Output:
0
2025-04-18 00:09:55,819 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [346.391, 113.24 , -0.017, 2. , 7. , 0.729, 56.805, 33.734, -5.357, -1.656, 0.142, 34.587, -15.569, 0.013, -6.3 ]
**Ligand B:** [349.519, 43.86 , 2.524, 0. , 3. , 0.633, 6.979, 83.831, -4.903, -1.377, 0.735, 45.185, -1.891, 0.105, -6.4 ]
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). A is 346.391, B is 349.519 - very similar.
2. **TPSA:** Ligand A (113.24) is higher than the preferred <140, but still reasonable. Ligand B (43.86) is excellent, well below 90, suggesting better permeability.
3. **logP:** Ligand A (-0.017) is a bit low, potentially hindering permeability. Ligand B (2.524) is optimal.
4. **HBD:** Ligand A (2) is good. Ligand B (0) is also good, potentially improving membrane permeability.
5. **HBA:** Ligand A (7) is good. Ligand B (3) is excellent.
6. **QED:** Ligand A (0.729) is very good. Ligand B (0.633) is still acceptable, but slightly lower.
7. **DILI:** Ligand A (56.805) is acceptable, but higher than ideal. Ligand B (6.979) is excellent, indicating a very low risk of liver injury.
8. **BBB:** Ligand A (33.734) is low. Ligand B (83.831) is excellent, suggesting good potential for CNS penetration (though less critical for a cardiovascular target, it's still a positive).
9. **Caco-2:** Ligand A (-5.357) is very poor. Ligand B (-4.903) is also poor, but slightly better.
10. **Solubility:** Ligand A (-1.656) is poor. Ligand B (-1.377) is also poor.
11. **hERG:** Both ligands are very low risk (0.142 and 0.735 respectively).
12. **Cl_mic:** Ligand A (34.587) is moderate. Ligand B (45.185) is higher, suggesting faster clearance and potentially lower metabolic stability.
13. **t1/2:** Ligand A (-15.569) is very poor. Ligand B (-1.891) is poor, but better than A.
14. **Pgp:** Both are very low efflux (0.013 and 0.105 respectively).
15. **Affinity:** Both have similar binding affinity (-6.3 and -6.4 kcal/mol).
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP and TPSA, and has a significantly better BBB score. While BBB isn't *essential* for a cardiovascular target, it's a bonus. The affinity is comparable between the two. Ligand A has a slightly better QED, but Ligand B's superior ADME profile, particularly the lower DILI risk and better logP/TPSA, outweigh this. The poor Caco-2 and solubility for both are concerning, but can be addressed with formulation strategies.
**Conclusion:**
Ligand B is the more promising candidate due to its superior ADME properties, particularly its favorable logP, TPSA, DILI risk, and BBB penetration. The slightly higher clearance is a concern, but less critical than the other advantages.
**Output:**
0
2025-04-18 00:09:55,819 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [334.354, 80.71, 4.005, 3, 3, 0.674, 97.325, 61.419, -4.72, -6.799, 0.851, 11.056, 90.772, 0.329, -6.6]
**Ligand B:** [348.487, 75.27, 2.751, 2, 3, 0.596, 12.524, 67.933, -4.756, -3.069, 0.111, 55.525, -23.427, 0.017, -6.7]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (334.354) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are good (below 140), but Ligand B (75.27) is slightly better than Ligand A (80.71).
3. **logP:** Ligand A (4.005) is a bit high, potentially leading to solubility issues and off-target effects. Ligand B (2.751) is within the optimal range. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (2), but both are acceptable.
5. **HBA:** Both have 3 HBA, which is good.
6. **QED:** Ligand A (0.674) is better than Ligand B (0.596), indicating a more drug-like profile.
7. **DILI:** Ligand A (97.325) has a very high DILI risk, which is a major concern. Ligand B (12.524) has a very low DILI risk. This is a critical advantage for Ligand B.
8. **BBB:** Both have reasonable BBB penetration, but Ligand B (67.933) is slightly better than Ligand A (61.419).
9. **Caco-2:** Both are negative, indicating poor permeability.
10. **Solubility:** Ligand B (-3.069) has better solubility than Ligand A (-6.799).
11. **hERG:** Ligand A (0.851) has a slightly higher hERG risk than Ligand B (0.111).
12. **Cl_mic:** Ligand B (55.525) has significantly lower microsomal clearance than Ligand A (11.056), indicating better metabolic stability.
13. **t1/2:** Ligand B (-23.427) has a much longer in vitro half-life than Ligand A (90.772).
14. **Pgp:** Ligand B (0.017) has lower P-gp efflux liability than Ligand A (0.329), which is favorable for bioavailability.
15. **Affinity:** Both have the same binding affinity (-6.7 kcal/mol).
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are crucial. Ligand B excels in logP, Pgp, and has better TPSA and solubility. While Ligand A has a slightly better QED, the extremely high DILI risk and poorer metabolic stability are deal-breakers.
**Conclusion:**
Despite Ligand A having a slightly better QED score, the significantly lower DILI risk, better logP, better metabolic stability, longer half-life, and lower P-gp efflux of Ligand B make it the far more promising drug candidate. The high DILI risk of Ligand A is a major red flag.
**Output:**
0
2025-04-18 00:09:55,819 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (368.543 and 350.478 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (67.43) is higher than Ligand B (40.62). For a cardiovascular GPCR, TPSA isn't a *major* concern unless it's excessively high, but lower is generally better for permeability. Ligand B is preferable.
3. **logP:** Both ligands have good logP values (2.656 and 3.156), falling within the optimal 1-3 range. Ligand B is slightly higher, potentially aiding membrane permeability.
4. **HBD:** Ligand A has 2 HBD, while Ligand B has 0. Lower HBD can sometimes improve permeability, making Ligand B slightly preferable.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 2. Lower HBA is generally better for permeability, favoring Ligand B.
6. **QED:** Both have good QED scores (0.582 and 0.784), indicating good drug-like properties. Ligand B is better.
7. **DILI:** Ligand A (23.885) has a slightly higher DILI risk than Ligand B (19.814), but both are well below the concerning threshold of 60. Ligand B is preferable.
8. **BBB:** Ligand A (71.772) and Ligand B (85.925) both have good BBB penetration, but Ligand B is significantly higher. While ADRB2 isn't exclusively a CNS target, some CNS exposure can be beneficial or at least needs to be understood. Ligand B is preferable.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.977 and -4.557), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Both ligands have negative solubility values (-3.174 and -3.357), which is also unusual and suggests poor aqueous solubility. This is a significant concern for both.
11. **hERG:** Ligand A (0.194) has a lower hERG risk than Ligand B (0.761), which is a significant advantage.
12. **Cl_mic:** Ligand A (76.35) has a higher microsomal clearance than Ligand B (55.915), indicating lower metabolic stability. Ligand B is preferable.
13. **t1/2:** Ligand A (12.05) has a longer in vitro half-life than Ligand B (-6.633). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.106) has lower P-gp efflux liability than Ligand B (0.227), which is preferable.
15. **Binding Affinity:** Both ligands have very similar and excellent binding affinities (-6.9 and -6.8 kcal/mol). The difference is negligible.
**Overall Assessment:**
Ligand B consistently outperforms Ligand A in several key ADME properties (TPSA, HBD, HBA, QED, DILI, BBB, Cl_mic), despite both having issues with Caco-2 and solubility. The longer half-life and lower hERG risk of Ligand A are valuable, but the ADME advantages of Ligand B, particularly the better BBB penetration and lower clearance, are more crucial for a GPCR target like ADRB2. The slight difference in binding affinity is not enough to overcome the ADME benefits of Ligand B.
Output:
0
2025-04-18 00:09:55,820 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (347.415) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (32.78) has a significantly lower TPSA than Ligand A (87.74). This is a major advantage for Ligand B, as lower TPSA generally correlates with better membrane permeability, crucial for GPCRs.
3. **logP:** Both ligands have good logP values (A: 2.243, B: 3.258), falling within the optimal 1-3 range. Ligand B is slightly higher, which *could* pose a minor solubility issue, but isn't a major concern.
4. **HBD:** Ligand A has 2 HBD, and Ligand B has 0. Lower HBD is generally preferred for better permeability, giving a slight edge to Ligand B.
5. **HBA:** Both have 4 HBA, which is within the acceptable range.
6. **QED:** Both ligands have similar QED values (A: 0.741, B: 0.746), indicating good drug-like properties.
7. **DILI:** Ligand B (5.312) has a *much* lower DILI risk than Ligand A (57.193). This is a significant advantage for Ligand B.
8. **BBB:** Ligand B (81.698) has a higher BBB penetration percentile than Ligand A (71.656). While ADRB2 isn't strictly a CNS target, some peripheral distribution is still desired, and higher BBB penetration often correlates with better overall distribution.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
10. **Solubility:** Ligand A (-3.017) has better aqueous solubility than Ligand B (-2.245). This is a slight advantage for Ligand A.
11. **hERG:** Ligand A (0.433) has a lower hERG inhibition liability than Ligand B (0.791), which is a positive.
12. **Cl_mic:** Both have similar microsomal clearance values (A: 35.93, B: 31.754), indicating comparable metabolic stability.
13. **t1/2:** Ligand A (6.436) has a longer in vitro half-life than Ligand B (4.312), which is favorable.
14. **Pgp:** Ligand A (0.015) has significantly lower P-gp efflux liability than Ligand B (0.266). This is a major advantage for Ligand A.
15. **Binding Affinity:** Ligand A (-6.4 kcal/mol) has slightly better binding affinity than Ligand B (-5.8 kcal/mol). While the difference is less than 1.5 kcal/mol, it's still a positive for Ligand A.
**Overall Assessment & GPCR Prioritization:**
For a GPCR like ADRB2, TPSA, logP, Pgp efflux, and binding affinity are key. Ligand B excels in TPSA and DILI risk, and has a good logP and BBB penetration. Ligand A has better affinity, half-life, and Pgp efflux. The significantly lower DILI risk and TPSA of Ligand B are very attractive, outweighing the slight advantage in affinity and half-life of Ligand A. The lower Pgp efflux of Ligand A is also a positive, but the other benefits of B are more substantial.
**Output:**
0
2025-04-18 00:09:55,820 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [344.415, 78.67, 0.352, 1, 5, 0.756, 23.187, 53.587, -4.686, -1.733, 0.099, -9.581, -4.366, 0.014, -6.5]
**Ligand B:** [370.827, 49.41, 2.178, 1, 2, 0.609, 35.75, 83.56, -4.919, -3.606, 0.381, 10.833, 1.883, 0.056, -6.4]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (344.415) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (78.67) is higher than Ligand B (49.41). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is still preferred. Ligand B is significantly better here.
3. **logP:** Ligand A (0.352) is quite low, potentially hindering membrane permeability. Ligand B (2.178) is within the optimal range (1-3). This is a significant advantage for Ligand B.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 5 HBA, while Ligand B has 2. Lower HBA is generally better for permeability. Ligand B is better.
6. **QED:** Ligand A (0.756) has a better QED score than Ligand B (0.609), indicating a more drug-like profile.
7. **DILI:** Ligand A (23.187) has a much lower DILI risk than Ligand B (35.75), which is a substantial advantage.
8. **BBB:** Ligand B (83.56) has a much higher BBB penetration percentile than Ligand A (53.587). While ADRB2 isn't strictly a CNS target, some brain exposure can be relevant for off-target effects or peripheral signaling.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand B (-4.919) is slightly worse than Ligand A (-4.686).
10. **Solubility:** Both have negative solubility values, suggesting very poor aqueous solubility. Ligand B (-3.606) is slightly worse.
11. **hERG:** Ligand A (0.099) has a lower hERG risk than Ligand B (0.381), which is crucial for cardiovascular drugs.
12. **Cl_mic:** Ligand A (-9.581) has a much lower (better) microsomal clearance than Ligand B (10.833), indicating better metabolic stability.
13. **t1/2:** Ligand B (1.883) has a slightly longer in vitro half-life than Ligand A (-4.366).
14. **Pgp:** Ligand A (0.014) has a much lower P-gp efflux liability than Ligand B (0.056), which is favorable for bioavailability.
15. **Affinity:** Both have very similar binding affinities (-6.5 and -6.4 kcal/mol). The difference is negligible.
**GPCR-Specific Priorities:**
For ADRB2 (a cardiovascular GPCR), we prioritize logP, TPSA, Pgp, and affinity. Ligand B excels in TPSA and BBB, and has a good logP. Ligand A has a better QED, DILI, hERG, Cl_mic and Pgp. The poor solubility and Caco-2 values for both are concerning, but the better metabolic stability and lower toxicity profile of Ligand A are more important for a cardiovascular drug.
**Conclusion:**
Despite Ligand B's better TPSA and BBB, Ligand A's superior DILI, hERG, Cl_mic, and Pgp profiles, combined with comparable affinity, make it the more promising candidate. The solubility and permeability issues are significant for both, but can be addressed with formulation strategies.
**Output:**
1
2025-04-18 00:09:55,820 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (360.445 and 349.431 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (69.64) is better than Ligand B (75.01). Both are below 140, but lower is preferred for absorption.
3. **logP:** Ligand A (2.47) is optimal (1-3). Ligand B (0.026) is significantly low, potentially hindering membrane permeability. This is a major drawback for a GPCR target.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable (<=5).
5. **HBA:** Ligand A (3) and Ligand B (5) are both acceptable (<=10).
6. **QED:** Both ligands have good QED scores (0.685 and 0.814), indicating good drug-like properties.
7. **DILI:** Ligand A (23.769) has a lower DILI risk than Ligand B (17.642), which is preferable.
8. **BBB:** Ligand A (89.492) has a significantly better BBB penetration percentile than Ligand B (51.183). While ADRB2 isn't exclusively a CNS target, some CNS exposure or off-target effects are possible, and higher BBB is generally favorable.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. This is concerning.
10. **Solubility:** Ligand A (-3.441) has better solubility than Ligand B (-0.718).
11. **hERG:** Ligand A (0.816) has a lower hERG risk than Ligand B (0.16). Lower is better.
12. **Cl_mic:** Ligand A (32.604) has better metabolic stability (lower clearance) than Ligand B (4.115).
13. **t1/2:** Ligand A (0.003) has a very low in vitro half-life. Ligand B (14.578) has a much better half-life.
14. **Pgp:** Ligand A (0.25) has lower P-gp efflux liability than Ligand B (0.024), which is preferable.
15. **Affinity:** Ligand A (-7.5 kcal/mol) has a stronger binding affinity than Ligand B (-6.5 kcal/mol). This is a significant advantage (>1.0 kcal/mol difference).
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A excels in logP, TPSA, Pgp, and significantly in affinity. Ligand B's very low logP is a major concern. While Ligand B has a better half-life, the other factors weigh heavily against it.
**Conclusion:**
Despite Ligand B having a better half-life, Ligand A is the superior candidate due to its optimal logP, better TPSA, lower DILI, better BBB penetration, and significantly stronger binding affinity. The combination of these factors outweighs the disadvantage of the shorter half-life, which can be addressed through further optimization.
Output:
1
2025-04-18 00:09:55,820 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (356.5 and 346.5 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (76.66) is higher than Ligand B (58.64). For a cardiovascular GPCR, TPSA is moderately important. Ligand B is preferable due to its lower TPSA, suggesting better potential for membrane permeability.
**3. logP:** Both ligands have similar logP values (2.26 and 2.29), falling within the optimal 1-3 range. No clear advantage.
**4. H-Bond Donors:** Ligand A has 2 HBDs, while Ligand B has 1. Both are acceptable (<=5), but Ligand B is slightly favored.
**5. H-Bond Acceptors:** Ligand A has 4 HBAs, and Ligand B has 3. Both are within the acceptable range (<=10).
**6. QED:** Both ligands have similar QED values (0.629 and 0.614), indicating good drug-likeness.
**7. DILI Risk:** Ligand A (16.44%) has a significantly lower DILI risk than Ligand B (23.614%). This is a substantial advantage for Ligand A.
**8. BBB Penetration:** Ligand A (72.276%) has slightly better BBB penetration than Ligand B (69.794%). While not a primary concern for a cardiovascular target, some CNS exposure is possible, and higher BBB is generally favorable.
**9. Caco-2 Permeability:** Ligand A (-4.337) has worse Caco-2 permeability than Ligand B (-4.9). This is a negative for Ligand A.
**10. Aqueous Solubility:** Ligand A (-2.022) has slightly better aqueous solubility than Ligand B (-2.162).
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.374 and 0.156), which is excellent.
**12. Microsomal Clearance:** Ligand A (35.098) has lower microsomal clearance than Ligand B (48.933), indicating better metabolic stability. This is a positive for Ligand A.
**13. In vitro Half-Life:** Ligand A (-8.705) has a much longer in vitro half-life than Ligand B (-16.531). This is a significant advantage for Ligand A, potentially allowing for less frequent dosing.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.022 and 0.102).
**15. Binding Affinity:** Ligand B (-7.3 kcal/mol) has a slightly better binding affinity than Ligand A (-6.5 kcal/mol). This is a 0.8 kcal/mol difference, which is meaningful but not overwhelming.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), and the general drug-like properties, Ligand A emerges as the more promising candidate. While Ligand B has a slightly better affinity and TPSA, Ligand A demonstrates significantly better safety (lower DILI risk), metabolic stability (lower Cl_mic), and a longer half-life. The difference in affinity is not large enough to outweigh these advantages. The slightly better solubility of Ligand A is also a positive.
Output:
1
2025-04-18 00:09:55,820 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (337.427 Da) is better, falling comfortably within the 200-500 Da range. Ligand B (396.265 Da) is still acceptable but pushing towards the upper limit.
2. **TPSA:** Ligand A (55.21) is preferable, being well below the 140 threshold for oral absorption. Ligand B (65.46) is still reasonable, but slightly less favorable.
3. **logP:** Both ligands have good logP values (A: 2.9, B: 3.508), within the optimal 1-3 range. Ligand B is slightly higher, which could potentially lead to off-target effects, but it's not a major concern.
4. **HBD:** Ligand A (1) is better. Lower HBD generally improves permeability. Ligand B has 2 HBD.
5. **HBA:** Ligand A (6) is better. Lower HBA is generally preferred for permeability. Ligand B has 4 HBA.
6. **QED:** Both ligands have good QED scores (A: 0.776, B: 0.8), indicating good drug-like properties.
7. **DILI:** Ligand B (43.389) is significantly better than Ligand A (66.615), indicating a lower risk of drug-induced liver injury. This is a substantial advantage.
8. **BBB:** Both ligands demonstrate good BBB penetration (A: 75.921, B: 87.01). Ligand B is slightly better, but this isn't a critical factor for ADRB2, which is not a CNS target.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability in this assay. This is a potential red flag for both.
10. **Solubility:** Both ligands have very poor aqueous solubility (A: -2.809, B: -3.329). This is a significant concern for both compounds and would require formulation strategies to address.
11. **hERG:** Both ligands have low hERG inhibition liability (A: 0.924, B: 0.536). Ligand B is slightly better.
12. **Cl_mic:** Ligand B (34.068) has lower microsomal clearance than Ligand A (56.589), indicating better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand B (36.608) has a longer in vitro half-life than Ligand A (17.281), which is desirable.
14. **Pgp:** Both ligands have low P-gp efflux liability (A: 0.477, B: 0.185). Ligand B is better.
15. **Binding Affinity:** Ligand B (-4.9 kcal/mol) has a better binding affinity than Ligand A (-6.7 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME drawbacks.
**Overall Assessment:**
While Ligand A has better TPSA and MW, Ligand B demonstrates superior properties in several critical areas: DILI risk, metabolic stability (Cl_mic), in vitro half-life, Pgp efflux, and, most importantly, binding affinity. The significantly better binding affinity of Ligand B (-4.9 vs -6.7 kcal/mol) is a major driver for preference, as it can compensate for some of the ADME challenges. The poor solubility of both is a concern, but formulation strategies can be explored.
Given the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), and the substantial advantage in binding affinity and DILI risk, I favor Ligand B.
Output:
0
2025-04-18 00:09:55,820 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (409.259 Da) is within the ideal range, while Ligand B (350.503 Da) is also acceptable but slightly lower. This isn't a major differentiating factor.
2. **TPSA:** Both ligands (A: 58.56, B: 58.64) are well below the 140 threshold for oral absorption and are suitable for a GPCR target.
3. **logP:** Both ligands have good logP values (A: 2.408, B: 2.9), falling within the optimal 1-3 range. Ligand B is slightly higher, which could potentially lead to some off-target interactions, but it's not a significant concern.
4. **HBD:** Ligand A has 0 HBD, which is good for permeability. Ligand B has 1 HBD, still acceptable.
5. **HBA:** Ligand A has 5 HBA, and Ligand B has 3 HBA, both are well within the acceptable limit of 10.
6. **QED:** Both ligands have reasonable QED scores (A: 0.777, B: 0.616), indicating good drug-like properties. Ligand A is slightly better.
7. **DILI:** Ligand A has a significantly higher DILI risk (78.402%) compared to Ligand B (21.908%). This is a major concern for Ligand A.
8. **BBB:** Ligand A shows excellent BBB penetration (94.455%), while Ligand B is good (71.539%). While ADRB2 isn't strictly a CNS target, some CNS penetration can be beneficial or at least not detrimental.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.477 and -4.732), which is unusual and suggests very poor permeability. This is a significant drawback for both.
10. **Solubility:** Both ligands have poor aqueous solubility (A: -3.531, B: -2.633). This is a concern for bioavailability.
11. **hERG:** Ligand A has a slightly higher hERG risk (0.593) than Ligand B (0.147). This is a concern for Ligand A.
12. **Cl_mic:** Ligand A has a higher microsomal clearance (95.74) than Ligand B (56.668), indicating lower metabolic stability.
13. **t1/2:** Ligand B has a longer in vitro half-life (3.247 hours) than Ligand A (-17.462 hours). The negative value for Ligand A is concerning.
14. **Pgp:** Ligand A has a higher Pgp efflux liability (0.356) than Ligand B (0.128).
15. **Binding Affinity:** Ligand B has a better binding affinity (-6.2 kcal/mol) than Ligand A (-5.3 kcal/mol). This is a 1.5 kcal/mol difference, which is significant.
**Overall Assessment:**
Ligand B is the better candidate despite the poor Caco-2 and solubility. The significantly lower DILI risk, better metabolic stability (lower Cl_mic, longer t1/2), lower Pgp efflux, and stronger binding affinity outweigh the slightly lower BBB penetration. Ligand A's high DILI risk, poor metabolic stability, and lower affinity are major drawbacks. The negative Caco-2 values for both are concerning and would require further investigation (perhaps experimental validation, as these are predictions).
Output:
0
2025-04-18 00:09:55,820 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
The ADRB2 receptor is a GPCR, so the priorities are logP, TPSA, Pgp efflux, BBB penetration, and binding affinity.
* **Molecular Weight:** Both ligands are within the acceptable range (200-500 Da). Ligand A (352.36 Da) is slightly preferred.
* **TPSA:** Ligand A (50.16) is significantly better than Ligand B (101.29). TPSA < 140 is good for oral absorption, and lower is generally better for GPCRs. Ligand B's TPSA is pushing the upper limit and could hinder permeability.
* **logP:** Ligand A (3.382) is optimal, while Ligand B (1.177) is a bit low. A logP between 1-3 is preferred, and Ligand B might have issues with membrane permeation.
* **H-Bond Donors/Acceptors:** Ligand A (1 HBD, 4 HBA) is better than Ligand B (3 HBD, 5 HBA). Fewer H-bonds generally improve permeability.
* **QED:** Ligand A (0.901) is significantly better than Ligand B (0.733), indicating a more drug-like profile.
* **DILI:** Ligand B (75.572) has a higher DILI risk than Ligand A (65.452), which is undesirable.
* **BBB:** Ligand A (85.847) has better BBB penetration than Ligand B (68.864). While not a primary concern for peripheral GPCRs like ADRB2, it's still a positive attribute.
* **Caco-2 Permeability:** Ligand A (-4.718) is better than Ligand B (-5.707).
* **Aqueous Solubility:** Ligand A (-3.971) is better than Ligand B (-2.075).
* **hERG:** Ligand A (0.817) has a lower hERG risk than Ligand B (0.44), which is a significant advantage.
* **Microsomal Clearance:** Ligand A (29.763) has a lower clearance than Ligand B (5.984), suggesting better metabolic stability.
* **In vitro Half-Life:** Ligand A (54.663) has a longer half-life than Ligand B (33.354).
* **P-gp Efflux:** Ligand A (0.678) has lower P-gp efflux than Ligand B (0.239), which is favorable for bioavailability.
* **Binding Affinity:** Both ligands have very similar binding affinities (-6.7 kcal/mol and -6.0 kcal/mol respectively). The 1.5 kcal/mol difference is not enough to outweigh the ADME advantages of Ligand A.
**Conclusion:**
Ligand A consistently outperforms Ligand B across most crucial ADME properties (TPSA, logP, QED, DILI, BBB, solubility, hERG, clearance, half-life, P-gp efflux) while maintaining comparable binding affinity. Therefore, Ligand A is the more promising drug candidate.
**Output:**
1
2025-04-18 00:09:55,820 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [354.357, 76.05, 2.746, 1, 5, 0.882, 52.113, 92.943, -4.437, -3.049, 0.455, -10.553, -29.544, 0.098, -3.3]
**Ligand B:** [348.403, 84.74, 1.694, 0, 6, 0.611, 78.945, 95.192, -4.274, -3.305, 0.061, 64.076, 14.38, 0.058, -6.2]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, BBB, affinity):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (348.4) is slightly lower, which is generally favorable.
2. **TPSA:** Ligand A (76.05) is better than Ligand B (84.74). Both are below 140, acceptable for oral absorption, but lower is preferred.
3. **logP:** Ligand A (2.746) is optimal. Ligand B (1.694) is a bit low, potentially impacting membrane permeability.
4. **HBD/HBA:** Ligand A has 1 HBD and 5 HBA, while Ligand B has 0 HBD and 6 HBA. Both are within acceptable limits.
5. **QED:** Ligand A (0.882) is significantly better than Ligand B (0.611), indicating a more drug-like profile.
6. **DILI:** Ligand A (52.113) has a much lower DILI risk than Ligand B (78.945). This is a substantial advantage.
7. **BBB:** Both have excellent BBB penetration (A: 92.943, B: 95.192). Ligand B is slightly better, but both are high.
8. **Caco-2:** Both are negative, indicating poor permeability.
9. **Solubility:** Both are negative, indicating poor solubility.
10. **hERG:** Ligand A (0.455) is better than Ligand B (0.061), indicating lower cardiotoxicity risk.
11. **Cl_mic:** Ligand A (-10.553) has a much lower (better) microsomal clearance than Ligand B (64.076), suggesting better metabolic stability.
12. **t1/2:** Ligand A (-29.544) has a much longer in vitro half-life than Ligand B (14.38), which is highly desirable.
13. **Pgp:** Ligand A (0.098) has lower P-gp efflux than Ligand B (0.058), which is better for bioavailability.
14. **Affinity:** Ligand B (-6.2) has a significantly stronger binding affinity than Ligand A (-3.3). This is a 1.5 kcal/mol advantage, which is substantial.
**Overall Assessment:**
While Ligand B boasts a superior binding affinity, Ligand A demonstrates a much more favorable ADMET profile. The lower DILI risk, better metabolic stability (lower Cl_mic, longer t1/2), better QED, and lower hERG risk are all critical advantages for a drug candidate. The slightly lower logP of Ligand B is a concern, and the poor Caco-2 and solubility for both compounds would need to be addressed. However, the ADMET benefits of Ligand A outweigh the affinity difference, especially considering the affinity is already in a reasonable range for Ligand A.
Therefore, I would choose Ligand A.
1
2025-04-18 00:09:55,820 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (344.43 and 355.523 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (49.41) is significantly better than Ligand B (61.88). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (3.098) is slightly higher than Ligand B (1.743), both are within the optimal 1-3 range, but A is closer to the upper end, which could be beneficial for membrane permeability.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 2 HBA, while Ligand B has 4. Ligand A is preferable here.
6. **QED:** Ligand A (0.853) has a better QED score than Ligand B (0.72), indicating a more drug-like profile.
7. **DILI:** Ligand A (28.655) has a much lower DILI risk than Ligand B (11.09). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (95.502) has a much higher BBB penetration percentile than Ligand B (57.425). While not critical for a cardiovascular target, it doesn't hurt.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-4.753) is slightly better than Ligand B (-4.834), but both are concerning.
10. **Solubility:** Ligand A (-3.507) has better solubility than Ligand B (-0.884).
11. **hERG:** Both ligands have low hERG inhibition risk (0.657 and 0.452 respectively). No significant difference.
12. **Cl_mic:** Ligand B (24.383) has significantly lower microsomal clearance than Ligand A (60.181), suggesting better metabolic stability. This is a key advantage for Ligand B.
13. **t1/2:** Ligand B (8.442) has a longer in vitro half-life than Ligand A (4.265). This is another advantage for Ligand B.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.191 and 0.038 respectively). No significant difference.
15. **Binding Affinity:** Both ligands have the same binding affinity (-6.5 kcal/mol).
**GPCR-Specific Priorities & Overall Assessment:**
For a GPCR like ADRB2, logP, TPSA, and affinity are important. Ligand A has better logP, TPSA, QED, solubility, and significantly lower DILI risk and higher BBB. Ligand B has better metabolic stability (lower Cl_mic) and a longer half-life.
The lower DILI risk of Ligand A is a major factor, as is its better drug-like properties (QED). While metabolic stability is important, the other advantages of Ligand A outweigh the benefit of Ligand B's longer half-life, especially given that the binding affinity is identical. The slightly better solubility of Ligand A is also beneficial.
Output:
1
2025-04-18 00:09:55,821 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.43 and 344.50 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (71.78) is higher than Ligand B (40.62). For a cardiovascular GPCR, TPSA isn't a *major* concern unless it's excessively high (which it isn't for A), but lower is generally preferred for better absorption. Ligand B is significantly better.
3. **logP:** Ligand A (2.08) is within the optimal range (1-3), while Ligand B (3.23) is at the higher end. Both are acceptable, but Ligand A is slightly better balanced.
4. **HBD:** Ligand A has 1 HBD, Ligand B has 0. Both are good.
5. **HBA:** Ligand A has 4 HBA, Ligand B has 2. Both are acceptable, but Ligand B is slightly better.
6. **QED:** Both ligands have similar QED scores (0.695 and 0.665), indicating good drug-likeness.
7. **DILI:** Ligand A (24.54) has a slightly higher DILI risk than Ligand B (15.2), but both are well below the concerning threshold of 60. Ligand B is preferred.
8. **BBB:** Ligand B (82.82) shows significantly better BBB penetration potential than Ligand A (58.94). While ADRB2 isn't exclusively a CNS target, some CNS exposure can occur, and higher BBB is generally favorable.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.968 and -4.762), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand A (-1.805) has better solubility than Ligand B (-3.245). Solubility is important for bioavailability.
11. **hERG:** Both ligands have low hERG inhibition risk (0.323 and 0.524).
12. **Cl_mic:** Ligand A (50.71) has lower microsomal clearance than Ligand B (68.41), suggesting better metabolic stability. This is a positive for Ligand A.
13. **t1/2:** Ligand A (25.98) has a significantly longer in vitro half-life than Ligand B (-14.22). This is a major advantage for Ligand A.
14. **Pgp:** Ligand A (0.064) has lower P-gp efflux than Ligand B (0.47). Lower P-gp efflux is generally desirable for improved bioavailability.
15. **Affinity:** Ligand B (-7.3 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.0 kcal/mol). This is a substantial advantage for Ligand B, potentially outweighing some ADME concerns.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in affinity and TPSA, and has good logP. Ligand A has better metabolic stability (Cl_mic, t1/2) and Pgp profile, but the affinity difference is substantial. The Caco-2 values are concerning for both, but the stronger binding of Ligand B is likely to be more impactful for *in vivo* efficacy.
**Conclusion:**
Despite the poor Caco-2 values for both, the significantly improved binding affinity of Ligand B (-7.3 kcal/mol vs -5.0 kcal/mol) is a critical advantage for a GPCR target. The better BBB penetration is also a plus. While Ligand A has better metabolic stability, the potency difference is likely to be more important for overall drug success.
Output:
0
2025-04-18 00:09:55,821 - INFO - Batch 457 complete. Total preferences: 7312
2025-04-18 00:09:55,821 - INFO - Processing batch 458/512...
2025-04-18 00:10:44,303 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.487 and 355.479 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (69.64) is better than Ligand B (73.32). Both are below the 140 A^2 threshold for oral absorption, but lower is preferred.
3. **logP:** Ligand A (1.938) is optimal, while Ligand B (0.199) is quite low. For a GPCR, a logP between 1-3 is desirable for permeability. Ligand B's low logP is a concern.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1), but both are within the acceptable limit of 5.
5. **HBA:** Ligand A (3) is lower than Ligand B (5). Both are below the 10 limit, but lower is generally preferred.
6. **QED:** Ligand A (0.771) is significantly better than Ligand B (0.448). A QED > 0.5 is desirable, and Ligand A clearly meets this criterion.
7. **DILI:** Both ligands have similar DILI risk (6.592 and 6.747 percentile), and both are low risk (<40).
8. **BBB:** Ligand A (69.833) has a much higher BBB penetration percentile than Ligand B (37.379). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant, and higher BBB is generally favorable.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.818 and -4.735), which is unusual and suggests poor permeability. This is a potential issue for both, but the values are very similar.
10. **Solubility:** Ligand A (-2.898) is better than Ligand B (0.365). Higher solubility is generally preferred.
11. **hERG:** Ligand A (0.316) has a lower hERG inhibition liability than Ligand B (0.461), indicating a lower risk of cardiotoxicity.
12. **Cl_mic:** Ligand A (33.765) has a much lower microsomal clearance than Ligand B (10.17). Lower clearance indicates better metabolic stability, a significant advantage.
13. **t1/2:** Ligand A (4.982) has a longer in vitro half-life than Ligand B (-10.86). A longer half-life is generally desirable.
14. **Pgp:** Ligand A (0.044) has a much lower P-gp efflux liability than Ligand B (0.031). Lower P-gp efflux is preferred.
15. **Binding Affinity:** Ligand A (-7.9 kcal/mol) has a significantly stronger binding affinity than Ligand B (-5.8 kcal/mol). This is a crucial advantage, as a difference of >1.5 kcal/mol can outweigh other drawbacks.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A excels in these areas. The significantly better affinity of Ligand A is the most important factor.
**Conclusion:**
Ligand A is the superior candidate. It has a better logP, QED, BBB, solubility, hERG profile, metabolic stability, half-life, Pgp efflux, and, most importantly, significantly higher binding affinity. While both have issues with Caco-2 permeability, the overall profile of Ligand A is far more promising.
Output:
1
2025-04-18 00:10:44,303 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (347.39 Da and 343.431 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (71.53) is slightly higher than Ligand B (61.68). Both are below the 140 A^2 threshold for good oral absorption, but Ligand B is preferable as lower TPSA generally correlates with better membrane permeability for GPCR ligands.
**3. logP:** Ligand A (1.727) and Ligand B (0.729) are both within the optimal 1-3 range. Ligand A is slightly more lipophilic, which could be beneficial for receptor binding, but Ligand B is still acceptable.
**4. H-Bond Donors:** Ligand A has 1 HBD, and Ligand B has 0. Both are within the acceptable limit of <=5.
**5. H-Bond Acceptors:** Ligand A has 4 HBA, and Ligand B has 5. Both are within the acceptable limit of <=10.
**6. QED:** Ligand A (0.88) has a slightly better QED score than Ligand B (0.74), indicating a more drug-like profile.
**7. DILI Risk:** Ligand B (34.432) has a significantly lower DILI risk than Ligand A (48.623). This is a major advantage for Ligand B.
**8. BBB Penetration:** Ligand A (82.009) has slightly better BBB penetration than Ligand B (75.378). While ADRB2 is a cardiovascular target and CNS penetration isn't *essential*, some degree of BBB penetration can be helpful for off-target effects assessment and potential alternative indications.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand B (-4.815) is slightly worse than Ligand A (-4.398).
**10. Aqueous Solubility:** Ligand B (-1.762) has slightly better aqueous solubility than Ligand A (-3.029).
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.468 and 0.274, respectively). No significant difference.
**12. Microsomal Clearance:** Ligand B (47.883) has a lower microsomal clearance than Ligand A (27.041), suggesting better metabolic stability. This is a positive for Ligand B.
**13. In vitro Half-Life:** Ligand A (-33.519) has a much longer in vitro half-life than Ligand B (-4.475). This is a significant advantage for Ligand A.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.034 and 0.026, respectively). No significant difference.
**15. Binding Affinity:** Ligand A (-7.5 kcal/mol) has a slightly better binding affinity than Ligand B (-6.1 kcal/mol). This 1.4 kcal/mol difference is substantial and a key factor.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), and balancing all parameters, Ligand A is the more promising candidate. The significantly stronger binding affinity (-7.5 vs -6.1 kcal/mol) outweighs the slightly higher TPSA and DILI risk. The longer half-life is also a substantial benefit. While Ligand B has advantages in DILI risk and metabolic stability, the potency difference is crucial for a GPCR target.
Output:
1
2025-04-18 00:10:44,303 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [367.515, 82.53, 1.9, 2, 5, 0.735, 24.506, 39.783, -5.022, -0.984, 0.208, 15.125, 2.017, 0.167, -3.2]
**Ligand B:** [348.443, 76.66, 1.324, 2, 4, 0.681, 37.263, 68.205, -4.874, -2.187, 0.1, 26.941, 6.549, 0.07, -6.8]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (348.443) is slightly lower, potentially aiding permeability, but both are acceptable.
2. **TPSA:** Both are below 140, good for oral absorption. Ligand B (76.66) is better than Ligand A (82.53).
3. **logP:** Both are within the optimal range (1-3). Ligand B (1.324) is slightly lower, which could be a minor drawback, but still acceptable.
4. **HBD:** Both have 2 HBD, which is good.
5. **HBA:** Ligand A has 5 HBA, Ligand B has 4. Both are within the acceptable limit of 10.
6. **QED:** Ligand A (0.735) is better than Ligand B (0.681), indicating a more drug-like profile.
7. **DILI:** Ligand A (24.506) has a significantly lower DILI risk than Ligand B (37.263). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (68.205) has a better BBB penetration than Ligand A (39.783). While ADRB2 is not a CNS target, some off-target CNS effects are possible with GPCR ligands, so higher BBB is generally preferred.
9. **Caco-2:** Both have negative values, indicating poor permeability. Ligand B (-4.874) is slightly better than Ligand A (-5.022).
10. **Solubility:** Ligand A (-0.984) has better solubility than Ligand B (-2.187).
11. **hERG:** Both are very low, indicating minimal hERG inhibition risk. Ligand B (0.1) is slightly better.
12. **Cl_mic:** Ligand B (26.941) has lower microsomal clearance than Ligand A (15.125), suggesting better metabolic stability.
13. **t1/2:** Ligand B (6.549) has a significantly longer in vitro half-life than Ligand A (2.017). This is a substantial advantage for Ligand B.
14. **Pgp:** Ligand B (0.07) has lower P-gp efflux liability than Ligand A (0.167), suggesting better bioavailability.
15. **Affinity:** Ligand B (-6.8 kcal/mol) has a significantly stronger binding affinity than Ligand A (-3.2 kcal/mol). This is a major advantage for Ligand B, potentially outweighing some of the ADME drawbacks.
**GPCR-specific priorities:** For ADRB2 (a cardiovascular GPCR), we prioritize logP, Pgp, TPSA, and affinity. Ligand B excels in affinity and Pgp, has slightly better TPSA, and comparable logP. While Ligand A has better DILI and solubility, the substantial affinity advantage of Ligand B is crucial for a GPCR target. The longer half-life of Ligand B is also a significant benefit.
**Conclusion:**
Despite Ligand A's better DILI and solubility, the significantly stronger binding affinity and improved metabolic stability (longer half-life) of Ligand B make it the more promising drug candidate for ADRB2.
0
2025-04-18 00:10:44,304 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (339.351 and 336.355 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (93.53 and 95.34) are below the 140 A^2 threshold for good oral absorption. They are also reasonably close to the 90 A^2 threshold for CNS targets, though ADRB2 is primarily cardiovascular, so this is less critical.
3. **logP:** Both ligands have good logP values (1.988 and 1.445), falling within the optimal 1-3 range. Ligand B is slightly lower, which could slightly improve solubility, but is still well within the acceptable range.
4. **HBD:** Both ligands have 1 HBD, which is well within the acceptable limit of 5.
5. **HBA:** Ligand A has 6 HBAs, and Ligand B has 7. Both are below the 10 limit.
6. **QED:** Both ligands have good QED scores (0.579 and 0.768), indicating good drug-like properties. Ligand B is better here.
7. **DILI:** Both ligands have high DILI risk (96.433 and 98.565 percentile). This is a significant concern for both compounds and will need to be addressed in further optimization.
8. **BBB:** Ligand A (51.687%) has a significantly better BBB penetration score than Ligand B (19.349%). While ADRB2 isn't a CNS target, some off-target CNS effects are always a consideration.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.848 and -4.991), which is unusual and suggests poor permeability. This is a major red flag for both.
10. **Solubility:** Both ligands have very poor aqueous solubility (-4.057 and -3.148). This is a significant issue for bioavailability.
11. **hERG:** Both ligands have low hERG inhibition liability (0.28 and 0.098), which is good.
12. **Cl_mic:** Ligand A has a higher microsomal clearance (77.274 mL/min/kg) than Ligand B (22.997 mL/min/kg). This suggests Ligand B is more metabolically stable.
13. **t1/2:** Ligand B has a much longer in vitro half-life (-4.208 hours) than Ligand A (1.72 hours). This is a significant advantage for Ligand B.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.489 and 0.006). Ligand B is better here.
15. **Binding Affinity:** Ligand B has a significantly stronger binding affinity (-7.5 kcal/mol) than Ligand A (-5.7 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME concerns.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand B is better in terms of Pgp, has a comparable logP and TPSA, and *significantly* better affinity. The improved metabolic stability (lower Cl_mic and longer t1/2) is also a major benefit. While both have poor solubility and high DILI, the affinity difference is large enough to favor Ligand B, assuming solubility and DILI can be addressed through further optimization.
**Conclusion:**
Despite the shared liabilities of poor solubility and high DILI risk, Ligand B's superior binding affinity and improved metabolic stability make it the more promising candidate.
Output:
0
2025-04-18 00:10:44,304 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (365.331 and 356.817 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both are below the 140 A^2 threshold for good oral absorption (90.98 and 96.45). Ligand A is slightly better, closer to the 90 A^2 mark preferred for CNS targets, although ADRB2 isn't a CNS target.
3. **logP:** Ligand A (1.052) is optimal, while Ligand B (3.063) is at the higher end of the optimal range. This is a slight advantage for Ligand A.
4. **HBD:** Both have 2 H-bond donors, which is good.
5. **HBA:** Ligand A has 4, and Ligand B has 5. Both are acceptable, but Ligand A is slightly better.
6. **QED:** Both ligands have similar QED values (0.707 and 0.748), indicating good drug-likeness.
7. **DILI:** Ligand A (53.276) has a significantly lower DILI risk than Ligand B (88.639). This is a substantial advantage for Ligand A.
8. **BBB:** Ligand A (72.276) has better BBB penetration than Ligand B (62.233), although this is less critical for a non-CNS target like ADRB2.
9. **Caco-2:** Ligand A (-4.867) and Ligand B (-5.429) both have negative Caco-2 values, indicating poor permeability. Ligand B is slightly worse.
10. **Solubility:** Ligand A (-2.887) and Ligand B (-3.851) both have poor aqueous solubility. Ligand A is slightly better.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.17 and 0.155). No significant difference.
12. **Cl_mic:** Ligand A (26.008) has a higher microsomal clearance than Ligand B (10.371), indicating lower metabolic stability. This favors Ligand B.
13. **t1/2:** Ligand A (-49.047) has a very short in vitro half-life, while Ligand B (9.826) has a longer, though still not ideal, half-life. This is a significant advantage for Ligand B.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.01 and 0.215). No significant difference.
15. **Binding Affinity:** Ligand B (-7.8 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.8 kcal/mol). This is a major advantage for Ligand B, potentially outweighing some ADME drawbacks.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B has a better logP and significantly better affinity. While Ligand A has slightly better TPSA, the affinity difference is substantial.
**Overall Assessment:**
Despite Ligand A's advantages in DILI risk and slightly better TPSA and logP, Ligand B's significantly stronger binding affinity (-7.8 vs -6.8 kcal/mol) and better in vitro half-life are more critical for a GPCR target. The higher DILI risk of Ligand B is a concern, but could be addressed through further structural modifications. The improved affinity is likely to translate to greater efficacy.
Output:
0
2025-04-18 00:10:44,304 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (366.527 Da) is slightly heavier than Ligand B (345.491 Da), but this difference isn't significant.
**2. TPSA:** Both ligands have TPSA values below 140, suggesting reasonable oral absorption potential. Ligand A (67.43) is preferable to Ligand B (70.15) as it is closer to the optimal range for GPCRs.
**3. logP:** Both ligands have logP values within the optimal range (1-3), indicating good partitioning characteristics. Ligand B (2.882) is slightly higher than Ligand A (2.098), which could potentially lead to off-target effects, but is not a major concern.
**4. H-Bond Donors:** Both ligands have 2 HBD, which is within the acceptable limit of 5.
**5. H-Bond Acceptors:** Ligand A has 4 HBA, while Ligand B has 5. Both are acceptable (<=10), but A is slightly better.
**6. QED:** Both ligands have good QED scores (A: 0.724, B: 0.859), indicating a generally drug-like profile. Ligand B is slightly better here.
**7. DILI Risk:** Both ligands have low DILI risk (A: 37.146, B: 35.867), which is good. They are very comparable.
**8. BBB Penetration:** Ligand B (85.072) has significantly better BBB penetration than Ligand A (45.134). While ADRB2 is a cardiovascular target, some CNS effects are possible with beta-adrenergic agonists, and higher BBB penetration could be advantageous or a concern depending on the desired therapeutic profile.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-5.486) is slightly better than Ligand B (-5.084), but both are problematic.
**10. Aqueous Solubility:** Both ligands have poor aqueous solubility (-3.012 and -3.237 respectively). This is a significant drawback for both.
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (A: 0.283, B: 0.601). Ligand A is preferable here.
**12. Microsomal Clearance:** Ligand A (28.049) has significantly lower microsomal clearance than Ligand B (62.356), indicating better metabolic stability. This is a major advantage for Ligand A.
**13. In vitro Half-Life:** Ligand A (15.368 hours) has a much longer in vitro half-life than Ligand B (4.853 hours). This is a significant advantage for Ligand A, potentially allowing for less frequent dosing.
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (A: 0.085, B: 0.08). They are comparable.
**15. Binding Affinity:** Ligand B (-7.7 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.8 kcal/mol). This is a substantial advantage for Ligand B, potentially outweighing some of its ADME drawbacks.
**Overall Assessment:**
While Ligand B has a superior binding affinity, Ligand A demonstrates a more favorable ADME profile, particularly regarding metabolic stability (lower Cl_mic), longer half-life, and lower hERG risk. The poor Caco-2 and solubility are concerning for both, but the metabolic advantages of Ligand A are crucial for a GPCR target, where sustained receptor occupancy is often desired. The slightly better TPSA and lower DILI risk also favor Ligand A. The difference in binding affinity is significant, but the ADME profile of Ligand A is more promising for development.
Output:
1
2025-04-18 00:10:44,304 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (360.523 and 348.535 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (49.41) is better than Ligand B (59.07). Both are below the 140 A^2 threshold for oral absorption, but lower TPSA is generally preferred for GPCRs.
3. **logP:** Ligand A (3.378) is within the optimal 1-3 range, while Ligand B (4.286) is slightly higher. While still acceptable, the higher logP of Ligand B could potentially lead to solubility issues or off-target interactions.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (5). Lower HBA generally improves permeability.
6. **QED:** Ligand A (0.895) is significantly better than Ligand B (0.661), indicating a more drug-like profile.
7. **DILI:** Both ligands have acceptable DILI risk (Ligand A: 30.826, Ligand B: 35.014), both under the 40% threshold.
8. **BBB:** Both ligands show good BBB penetration (Ligand A: 85.111, Ligand B: 88.29). This is important for GPCR targets, but less critical for ADRB2 specifically (cardiovascular target).
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-5.029) is slightly better than Ligand B (-4.842), but both are problematic.
10. **Solubility:** Both ligands have negative solubility values, which is also unusual and suggests poor solubility. Ligand A (-4.047) is slightly better than Ligand B (-4.543).
11. **hERG:** Both ligands have low hERG inhibition liability (Ligand A: 0.572, Ligand B: 0.89). This is good, minimizing cardiotoxicity risk.
12. **Cl_mic:** Ligand A (39.611) has a significantly lower microsomal clearance than Ligand B (75.331), indicating better metabolic stability.
13. **t1/2:** Ligand B (79.189) has a much longer in vitro half-life than Ligand A (-0.129). This is a significant advantage, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.288) has lower P-gp efflux liability than Ligand B (0.345), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand B (-5.3) has a slightly better binding affinity than Ligand A (-6.7). However, the difference is only 1.4 kcal/mol, and other factors are more important.
**Overall Assessment:**
While Ligand B has a better binding affinity and a significantly longer half-life, Ligand A demonstrates superior drug-like properties (QED), lower predicted clearance, lower TPSA, and better H-bonding characteristics. The negative Caco-2 and solubility values are concerning for both, but the other advantages of Ligand A, particularly its metabolic stability, outweigh the slight affinity advantage of Ligand B. Given the GPCR-specific priorities, the lower TPSA and better overall ADME profile of Ligand A make it the more promising candidate.
Output:
1
2025-04-18 00:10:44,304 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
We are targeting ADRB2, a GPCR. Therefore, key properties to prioritize are logP, TPSA, Pgp efflux, BBB penetration, and binding affinity. Metabolic stability (Cl_mic, t1/2) and safety (DILI, hERG) are also important.
Let's compare the ligands property by property:
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (374.547) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (75.71) is better than Ligand B (50.8). Lower TPSA generally improves oral absorption.
3. **logP:** Ligand A (1.595) is optimal, while Ligand B (4.507) is high. High logP can lead to solubility issues and off-target interactions.
4. **HBD/HBA:** Both have acceptable HBD (1) and HBA (5/4) counts.
5. **QED:** Both are similar (0.74 and 0.725), indicating good drug-likeness.
6. **DILI:** Ligand A (8.53) has a significantly lower DILI risk than Ligand B (52.036). This is a major advantage for Ligand A.
7. **BBB:** Both have similar BBB penetration (69.368 and 69.213).
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the values are close.
9. **Solubility:** Ligand A (-1.248) is better than Ligand B (-5.324). Solubility is important for bioavailability.
10. **hERG:** Ligand A (0.484) has a lower hERG risk than Ligand B (0.864).
11. **Cl_mic:** Ligand A (5.058) has much lower microsomal clearance than Ligand B (102.368), indicating better metabolic stability.
12. **t1/2:** Ligand A (-10.484) has a much longer in vitro half-life than Ligand B (47.168).
13. **Pgp:** Ligand A (0.011) has a much lower P-gp efflux liability than Ligand B (0.517). Lower Pgp efflux is desirable for improved bioavailability.
14. **Binding Affinity:** Ligand B (-7.0) has a slightly better binding affinity than Ligand A (-5.9). However, the difference is less than 1.5 kcal/mol, and can be overcome by the other favorable properties of Ligand A.
**Overall Assessment:**
Ligand A demonstrates a significantly better ADMET profile than Ligand B. While Ligand B has slightly better binding affinity, Ligand A excels in crucial areas like DILI risk, metabolic stability, solubility, Pgp efflux, and logP. Given the GPCR target and the importance of balancing ADME properties with potency, Ligand A is the more promising drug candidate.
**Output:**
1
2025-04-18 00:10:44,304 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.5 & 377.5 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (59.4) is slightly higher than Ligand B (53.5), but both are well below the 140 threshold for good oral absorption.
3. **logP:** Both ligands have good logP values (3.42 & 2.75) within the optimal 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability, but also slightly increases the risk of off-target effects.
4. **HBD:** Ligand A has 1 HBD, while Ligand B has 0. Both are acceptable.
5. **HBA:** Ligand A has 4 HBA, Ligand B has 5. Both are acceptable, under the 10 threshold.
6. **QED:** Both ligands have similar QED values (0.82 & 0.78), indicating good drug-likeness.
7. **DILI:** Ligand A (19.5%) has a significantly lower DILI risk than Ligand B (37.6%). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (90.8%) has a much higher BBB penetration score than Ligand B (66.9%). While ADRB2 isn't strictly a CNS target, some CNS exposure can be relevant for off-target effects and overall safety assessment.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.174 & -4.965). This suggests poor permeability.
10. **Solubility:** Ligand A (-3.167) has slightly worse solubility than Ligand B (-1.721). Solubility is important, but can often be addressed through formulation.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.424 & 0.295).
12. **Cl_mic:** Ligand A (75.5) has higher microsomal clearance than Ligand B (42.3), indicating faster metabolism. This is a disadvantage for Ligand A.
13. **t1/2:** Ligand A (19.9) has a longer in vitro half-life than Ligand B (4.1). This is a significant advantage for Ligand A.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.146 & 0.232).
15. **Binding Affinity:** Ligand A (-6.5 kcal/mol) has slightly weaker binding affinity than Ligand B (-6.3 kcal/mol). However, the difference is small.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Both ligands perform similarly in these areas. However, the significantly lower DILI risk and higher BBB penetration of Ligand A, coupled with its longer half-life, outweigh the slightly weaker binding affinity and higher clearance. The poor Caco-2 values are a concern for both, but can be addressed with formulation strategies.
**Conclusion:**
Ligand A presents a more favorable overall profile, particularly regarding safety (DILI) and pharmacokinetic properties (BBB, t1/2).
Output:
1
2025-04-18 00:10:44,305 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (369.462 Da) is slightly higher than Ligand B (350.375 Da), but both are acceptable.
2. **TPSA:** Ligand A (62.74) is significantly better than Ligand B (116.52). For a GPCR, lower TPSA is generally preferred for better permeability. Ligand B is above the 90 A^2 threshold, which is a concern.
3. **logP:** Ligand A (3.525) is within the optimal range (1-3), while Ligand B (-0.337) is quite low, potentially hindering membrane permeability. This is a significant drawback for Ligand B.
4. **HBD:** Ligand A (0) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Both ligands have 5 HBA, which is acceptable.
6. **QED:** Ligand A (0.815) has a better QED score than Ligand B (0.687), indicating a more drug-like profile.
7. **DILI:** Ligand A (50.174) has a lower DILI risk than Ligand B (60.644), which is desirable.
8. **BBB:** Ligand A (83.443) has a much higher BBB penetration percentile than Ligand B (18.961). While ADRB2 isn't strictly a CNS target, some CNS exposure can be relevant, and a higher BBB score is generally favorable.
9. **Caco-2:** Ligand A (-4.273) is better than Ligand B (-5.118), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-3.979) is better than Ligand B (-1.491), indicating better aqueous solubility.
11. **hERG:** Ligand A (0.424) has a lower hERG inhibition liability than Ligand B (0.152), which is crucial for cardiac safety.
12. **Cl_mic:** Ligand A (85.547) has a higher microsomal clearance than Ligand B (-3.388). This suggests Ligand B is more metabolically stable, which is a positive.
13. **t1/2:** Ligand B (-34.992) has a much longer in vitro half-life than Ligand A (-4.79). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.322) has lower P-gp efflux liability than Ligand B (0.01). Lower P-gp efflux is better for bioavailability.
15. **Binding Affinity:** Ligand A (-6.9 kcal/mol) has a slightly better binding affinity than Ligand B (-5.7 kcal/mol). While the difference is not huge, it is still a factor.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most crucial ADME properties (TPSA, logP, solubility, BBB, hERG, Pgp) and has a slightly better binding affinity. Ligand B's main advantage is its longer half-life and better metabolic stability. However, its poor logP and high TPSA are significant concerns for oral bioavailability and permeability. For a GPCR like ADRB2, optimizing for permeability and minimizing off-target effects (hERG) are critical. The better overall profile of Ligand A outweighs the advantage of Ligand B's longer half-life.
Output:
1
2025-04-18 00:10:44,305 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (351.422 and 345.403 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (82.53 and 80.03) are below the 140 A^2 threshold for good oral absorption, and acceptable for a non-CNS GPCR target like ADRB2. Again, no major distinction.
3. **logP:** Ligand A (1.657) is better than Ligand B (0.648). While both are within the acceptable range, Ligand A's logP is closer to the optimal 1-3 range, suggesting better membrane permeability. Ligand B is a bit low, potentially hindering absorption.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (0). Both are within the acceptable limit of 5.
5. **HBA:** Ligand A (4) is lower than Ligand B (6). This is a slight advantage for Ligand A, as fewer hydrogen bond acceptors generally correlate with better permeability.
6. **QED:** Both ligands have similar QED values (0.845 and 0.805), indicating good drug-like properties.
7. **DILI:** Ligand A (39.899) has a lower DILI risk than Ligand B (47.77). This is a significant advantage, as lower DILI is crucial for drug safety.
8. **BBB:** Both ligands have similar BBB penetration (65.607 and 65.956). This isn't a primary concern for ADRB2, but it's good they aren't significantly limited.
9. **Caco-2:** Both ligands have very similar, and poor, Caco-2 permeability (-4.643 and -4.617). This is a concern for both, and suggests poor intestinal absorption.
10. **Solubility:** Ligand A (-2.069) has slightly better solubility than Ligand B (-1.75), though both are quite poor.
11. **hERG:** Ligand A (0.366) has a lower hERG risk than Ligand B (0.158), which is a positive.
12. **Cl_mic:** Ligand B (22.389) has a slightly lower microsomal clearance than Ligand A (19.185), indicating potentially better metabolic stability.
13. **t1/2:** Ligand A (-20.773) has a significantly longer in vitro half-life than Ligand B (1.016). This is a major advantage, as it suggests less frequent dosing may be possible.
14. **Pgp:** Ligand A (0.122) has lower P-gp efflux liability than Ligand B (0.039), which is good for bioavailability.
15. **Binding Affinity:** Ligand A (-7.4 kcal/mol) has a stronger binding affinity than Ligand B (-5.7 kcal/mol). This is a substantial difference (1.7 kcal/mol), and the most important factor.
**Overall Assessment:**
Ligand A clearly outperforms Ligand B. The most significant advantages are its substantially stronger binding affinity, longer half-life, and lower DILI risk. While Ligand B has slightly better metabolic stability, the other benefits of Ligand A outweigh this. Both compounds have poor Caco-2 permeability, which would need to be addressed in further optimization. Given the GPCR target class, logP and affinity are key, and Ligand A excels in both.
Output:
1
2025-04-18 00:10:44,305 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [371.531, 54.02, 4.935, 2, 4, 0.683, 67.856, 76.658, -5.014, -4.908, 0.482, 65.66, 61.623, 0.432, -7.5]
**Ligand B:** [358.427, 104.03, 1.077, 1, 8, 0.872, 81.776, 53.083, -5.221, -3.318, 0.364, 24.362, 9.499, 0.121, -7]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, Affinity, and BBB):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (358.427) is slightly lower, which is acceptable.
2. **TPSA:** Ligand A (54.02) is excellent, well below the 140 threshold and very favorable for permeability. Ligand B (104.03) is higher, but still potentially acceptable, though less ideal.
3. **logP:** Ligand A (4.935) is pushing the upper limit of optimal (1-3), potentially leading to solubility issues. Ligand B (1.077) is quite low, which could hinder membrane permeability.
4. **HBD/HBA:** Ligand A (2 HBD, 4 HBA) is good. Ligand B (1 HBD, 8 HBA) has a higher HBA count, which could affect permeability.
5. **QED:** Both are good (A: 0.683, B: 0.872), indicating drug-like properties. Ligand B is slightly better.
6. **DILI:** Ligand A (67.856) is better than Ligand B (81.776), indicating lower potential for liver injury.
7. **BBB:** Ligand A (76.658) has a significantly better BBB percentile than Ligand B (53.083). While ADRB2 isn't *exclusively* a CNS target, some CNS exposure can be beneficial, and avoiding high CNS penetration is generally preferred to minimize off-target effects.
8. **Caco-2:** Both are negative, indicating poor permeability. This is a concern for both.
9. **Solubility:** Both are negative, indicating poor solubility. This is a concern for both.
10. **hERG:** Both are low (A: 0.482, B: 0.364), which is good regarding cardiotoxicity risk.
11. **Cl_mic:** Ligand B (24.362) has significantly lower microsomal clearance than Ligand A (65.66), suggesting better metabolic stability. This is a major advantage.
12. **t1/2:** Ligand B (9.499) has a longer in vitro half-life than Ligand A (61.623), which is also a positive.
13. **Pgp:** Ligand A (0.432) has lower P-gp efflux than Ligand B (0.121), which is favorable for bioavailability.
14. **Affinity:** Ligand A (-7.5 kcal/mol) has a slightly better binding affinity than Ligand B (-7 kcal/mol), though the difference is small.
**Overall Assessment:**
Ligand B has a clear advantage in metabolic stability (lower Cl_mic, longer t1/2), which is crucial for *in vivo* efficacy. While Ligand A has better BBB penetration and Pgp efflux, the difference in affinity is minimal, and the poor metabolic stability of Ligand A is a significant drawback. The TPSA of Ligand B is higher, but not prohibitively so. The logP of Ligand A is a concern, and the Caco-2 and solubility are poor for both. Given the GPCR target class and the importance of metabolic stability for sustained action, Ligand B is the more promising candidate.
Output:
0
2025-04-18 00:10:44,305 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [370.362, 49.41, 3.26, 1, 2, 0.7, 33.812, 86.584, -4.603, -3.293, 0.649, 24.523, -15.846, 0.101, -7.8]
**Ligand B:** [352.391, 114.57, -0.394, 3, 6, 0.642, 61.07, 22.412, -5.544, -2.49, 0.125, -6.979, 24.559, 0.009, -6.5]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity, and BBB):
1. **MW:** Both are within the ideal range (200-500 Da). A is 370, B is 352. No significant difference.
2. **TPSA:** Ligand A (49.41) is excellent, well below the 140 threshold and good for permeability. Ligand B (114.57) is higher, but still acceptable. A is better.
3. **logP:** Ligand A (3.26) is optimal. Ligand B (-0.394) is quite low, potentially hindering membrane permeability and bioavailability. A is significantly better.
4. **HBD/HBA:** A (1/2) is preferable to B (3/6). Lower counts generally improve permeability.
5. **QED:** Both are similar (0.7 and 0.642), indicating reasonable drug-likeness.
6. **DILI:** Ligand A (33.812) has a much lower DILI risk than Ligand B (61.07). This is a substantial advantage for A.
7. **BBB:** Ligand A (86.584) has a good BBB penetration potential, while Ligand B (22.412) is very low. While ADRB2 is cardiovascular, some CNS off-target effects are possible, and higher BBB is generally preferred. A is better.
8. **Caco-2:** Ligand A (-4.603) is better than Ligand B (-5.544), indicating better intestinal absorption.
9. **Solubility:** Ligand A (-3.293) is better than Ligand B (-2.49), indicating better solubility.
10. **hERG:** Ligand A (0.649) is better than Ligand B (0.125), indicating lower cardiotoxicity risk.
11. **Cl_mic:** Ligand B (-6.979) has a lower (better) microsomal clearance than A (24.523), suggesting greater metabolic stability. B is better.
12. **t1/2:** Ligand B (24.559) has a longer in vitro half-life than A (-15.846). B is better.
13. **Pgp:** Ligand A (0.101) has lower P-gp efflux than Ligand B (0.009), which is preferable for bioavailability. A is better.
14. **Affinity:** Ligand A (-7.8 kcal/mol) has a slightly better binding affinity than Ligand B (-6.5 kcal/mol). This difference is significant.
**Overall Assessment:**
Ligand A is clearly the superior candidate. While Ligand B has better metabolic stability and half-life, Ligand A excels in crucial areas like logP, TPSA, DILI risk, BBB penetration, solubility, hERG inhibition, Pgp efflux, and binding affinity. The affinity difference, combined with the better ADME profile (particularly logP and DILI), outweighs the metabolic advantages of Ligand B. The GPCR-specific priorities strongly favor Ligand A.
Output:
1
2025-04-18 00:10:44,305 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (353.423 Da) is within the ideal range (200-500 Da). Ligand B (388.961 Da) is also within the ideal range. No clear advantage here.
2. **TPSA:** Ligand A (101.74) is acceptable, though approaching the upper limit for good oral absorption. Ligand B (49.85) is excellent, well below the 140 threshold, suggesting good absorption. **Advantage: B**
3. **logP:** Ligand A (0.138) is quite low, potentially hindering membrane permeability. Ligand B (3.623) is within the optimal range (1-3). **Advantage: B**
4. **HBD:** Ligand A (2) is good. Ligand B (0) is excellent, minimizing potential for off-target interactions and improving permeability. **Advantage: B**
5. **HBA:** Ligand A (8) is acceptable. Ligand B (4) is also good. No significant difference.
6. **QED:** Ligand A (0.776) is very good, indicating high drug-likeness. Ligand B (0.638) is still acceptable, but lower. **Advantage: A**
7. **DILI:** Ligand A (43.234) is good, indicating low liver injury risk. Ligand B (52.85) is slightly higher, but still within an acceptable range. No major concern for either.
8. **BBB:** Ligand A (27.026) is low, suggesting poor brain penetration. Ligand B (74.796) is good, indicating reasonable brain penetration. While ADRB2 isn't *primarily* a CNS target, some CNS exposure could be relevant depending on the specific therapeutic goal. **Advantage: B**
9. **Caco-2:** Ligand A (-5.009) is very poor. Ligand B (-4.636) is also poor, but slightly better. Both are concerning, indicating poor intestinal absorption.
10. **Solubility:** Ligand A (-0.968) is poor. Ligand B (-4.826) is even worse. Both have significant solubility issues.
11. **hERG:** Ligand A (0.071) is very low risk. Ligand B (0.893) is slightly higher, but still relatively low. **Advantage: A**
12. **Cl_mic:** Ligand A (-25.31) is excellent, indicating high metabolic stability. Ligand B (86.027) is very high, suggesting rapid metabolism. **Advantage: A**
13. **t1/2:** Ligand A (-4.306) is poor, indicating a short half-life. Ligand B (20.458) is good, suggesting a longer half-life. **Advantage: B**
14. **Pgp:** Ligand A (0.007) is very low, indicating minimal P-gp efflux. Ligand B (0.435) is slightly higher, but still relatively low. **Advantage: A**
15. **Affinity:** Ligand A (-8.9 kcal/mol) is significantly stronger than Ligand B (-5.2 kcal/mol). This is a substantial difference and a major factor. **Advantage: A**
**Overall Assessment:**
Ligand B has advantages in TPSA, logP, BBB, and t1/2. However, Ligand A's significantly stronger binding affinity (-8.9 vs -5.2 kcal/mol) and superior metabolic stability (Cl_mic) are crucial for a GPCR target. While Ligand A has solubility and Caco-2 permeability issues, these can sometimes be addressed through formulation strategies. The poor permeability of both compounds is a concern, but the much stronger binding of A is likely to be more impactful. Given the GPCR-specific priorities (logP, TPSA, affinity), and the substantial difference in affinity, Ligand A is the more promising candidate.
Output:
1
2025-04-18 00:10:44,306 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's break down the comparison of Ligand A and Ligand B based on the provided parameters and the guidelines, keeping in mind that ADRB2 is a GPCR, so logP, TPSA, Pgp, BBB, and affinity are particularly important.
1. **Molecular Weight:** Both ligands (339.4 and 351.4 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands are below the 140 A^2 threshold for good oral absorption (84.98 and 81.07 A^2). Again, very similar.
3. **logP:** Ligand A (2.678) is slightly higher than Ligand B (1.42). Both are within the optimal 1-3 range, but Ligand A is closer to the upper end, which could potentially cause issues with solubility or off-target binding, but is still acceptable.
4. **H-Bond Donors:** Both have 2 HBD, which is good.
5. **H-Bond Acceptors:** Ligand A has 5 HBA, Ligand B has 6. Both are acceptable, below the 10 threshold.
6. **QED:** Both ligands have good QED scores (0.723 and 0.852), indicating good drug-like properties. Ligand B is slightly better here.
7. **DILI:** Ligand A (66.6%) has a lower DILI risk than Ligand B (71.2%). This is a significant advantage for Ligand A.
8. **BBB:** Both ligands have similar BBB penetration (60.8% and 67.6%). While not exceptionally high, they are reasonable for a peripherally acting GPCR like ADRB2.
9. **Caco-2 Permeability:** Both have negative Caco-2 values (-5.223 and -4.915), which is unusual and suggests poor permeability. This is a concern for both.
10. **Aqueous Solubility:** Both have very poor aqueous solubility (-2.601 and -2.619). This is a major drawback for both compounds and would require formulation strategies.
11. **hERG Inhibition:** Ligand A (0.385) has a significantly lower hERG inhibition risk than Ligand B (0.161). This is a crucial advantage for Ligand A, as hERG inhibition can lead to cardiotoxicity.
12. **Microsomal Clearance:** Ligand A (39.271) has higher microsomal clearance than Ligand B (5.959), meaning it's metabolized faster. Ligand B has much better metabolic stability.
13. **In vitro Half-Life:** Ligand B (24.059 hours) has a much longer in vitro half-life than Ligand A (5.433 hours). This is a significant advantage for Ligand B, potentially allowing for less frequent dosing.
14. **P-gp Efflux:** Ligand A (0.147) has lower P-gp efflux than Ligand B (0.028), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand B (-6.7 kcal/mol) has a stronger binding affinity than Ligand A (-5.8 kcal/mol). This is a 1.5 kcal/mol difference, which is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
While Ligand B has a superior binding affinity and better metabolic stability/half-life, Ligand A has a significantly better safety profile (lower DILI and hERG risk) and better P-gp efflux. The poor solubility and Caco-2 permeability are concerning for both, but can potentially be addressed with formulation. Given the cardiovascular target (ADRB2), minimizing cardiotoxicity (hERG) and liver toxicity (DILI) is paramount. The stronger affinity of Ligand B is attractive, but the safety concerns with Ligand B are too significant to ignore.
**Output:**
1
2025-04-18 00:10:44,306 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (340.39 Da and 347.39 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (88.22) is better than Ligand B (91.06). Both are below 140, but closer to 90 is preferable for GPCRs, and A is closer.
3. **logP:** Ligand A (2.483) is better than Ligand B (1.059). Both are within the 1-3 range, but Ligand B is on the lower side, potentially impacting permeability.
4. **HBD:** Ligand A (2) is better than Ligand B (3). Lower is generally preferred for permeability.
5. **HBA:** Ligand A (6) is better than Ligand B (3). Both are acceptable, but A is slightly better.
6. **QED:** Ligand A (0.762) is better than Ligand B (0.672), indicating a more drug-like profile.
7. **DILI:** Ligand A (83.133) is significantly worse than Ligand B (51.609). This is a major concern for Ligand A.
8. **BBB:** Both ligands have similar BBB penetration (74.719 and 73.866). This isn't a primary concern for ADRB2 (cardiovascular target).
9. **Caco-2:** Both ligands have similar Caco-2 permeability (-4.982 and -4.779).
10. **Solubility:** Both ligands have similar solubility (-3.248 and -3.46).
11. **hERG:** Both ligands have very low hERG risk (0.299 and 0.262).
12. **Cl_mic:** Ligand A (39.391) is significantly better than Ligand B (5.992). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (48.006) is significantly better than Ligand B (-26.122). A longer half-life is generally desirable.
14. **Pgp:** Both ligands have similar Pgp efflux liability (0.09 and 0.11).
15. **Binding Affinity:** Ligand B (-6.2) is slightly better than Ligand A (-5.7). This is a 0.5 kcal/mol difference, which is significant, but needs to be weighed against other factors.
**Overall Assessment & GPCR Priorities:**
For a cardiovascular GPCR like ADRB2, logP, TPSA, and affinity are key. Ligand A has better logP and TPSA. Ligand B has a slightly better affinity. However, the *major* deciding factor is the DILI risk. Ligand A's DILI risk is very high (83.133 percentile), while Ligand B's is much lower (51.609 percentile). This difference is substantial enough to outweigh the slightly better affinity of Ligand B. Furthermore, Ligand A has better metabolic stability (Cl_mic) and half-life.
**Output:**
1
2025-04-18 00:10:44,306 - INFO - Batch 458 complete. Total preferences: 7328
2025-04-18 00:10:44,306 - INFO - Processing batch 459/512...
2025-04-18 00:11:31,602 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [350.459, 79.82, 2.321, 3, 4, 0.638, 15.277, 69.213, -4.344, -2.316, 0.478, 25.798, -1.666, 0.15, -6.0]
**Ligand B:** [354.382, 104.65, -0.283, 2, 6, 0.698, 50.136, 70.027, -4.883, -0.881, 0.157, -6.348, 12.789, 0.029, -6.5]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). A is 350.459, B is 354.382. Very similar.
2. **TPSA:** A (79.82) is better than B (104.65). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA is generally favorable for absorption.
3. **logP:** A (2.321) is optimal. B (-0.283) is quite low, potentially hindering membrane permeability. This is a significant drawback.
4. **HBD:** Both have acceptable HBD counts (A: 3, B: 2).
5. **HBA:** A (4) is better than B (6). Lower is preferable.
6. **QED:** Both are good (A: 0.638, B: 0.698), indicating drug-like properties. B is slightly better.
7. **DILI:** A (15.277) is *much* better than B (50.136). This is a major advantage for A.
8. **BBB:** Both are reasonably good (A: 69.213, B: 70.027). Not a primary concern for a cardiovascular target, but B is slightly better.
9. **Caco-2:** Both are negative, indicating poor permeability. A (-4.344) is slightly better than B (-4.883).
10. **Solubility:** Both are negative, indicating poor solubility. A (-2.316) is slightly better than B (-0.881).
11. **hERG:** Both are low risk (A: 0.478, B: 0.157). B is slightly better.
12. **Cl_mic:** A (25.798) is higher (less favorable) than B (-6.348). B has better metabolic stability.
13. **t1/2:** A (-1.666) is worse than B (12.789). B has a much longer half-life.
14. **Pgp:** A (0.15) is better than B (0.029). Lower Pgp efflux is preferred.
15. **Affinity:** Both are excellent (-6.0 and -6.5 kcal/mol). B is slightly better.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has a much better logP and Pgp, and a significantly lower DILI risk. While Ligand B has slightly better affinity and half-life, the poor logP and higher DILI risk are major concerns. The slightly better affinity of B is unlikely to overcome the substantial ADME deficiencies.
**Conclusion:**
Considering the balance of properties, especially the critical logP and DILI scores, Ligand A is the more promising drug candidate.
Output:
1
2025-04-18 00:11:31,602 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (364.43 & 366.44 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (101.91 & 101.55) are slightly above the optimal <140 for oral absorption, but acceptable. No major difference.
3. **logP:** Ligand A (1.228) is better than Ligand B (2.545). While both are within the 1-3 range, A is closer to the optimal lower end, reducing potential off-target issues.
4. **HBD:** Both have 2 HBD, which is good.
5. **HBA:** Ligand A (7) is slightly higher than Ligand B (5), but both are within the acceptable limit of 10.
6. **QED:** Ligand A (0.818) has a better QED score than Ligand B (0.747), indicating a more drug-like profile.
7. **DILI:** Ligand B (70.92) has a higher DILI risk than Ligand A (67.12), though both are above the preferred <40, but not drastically so.
8. **BBB:** Ligand B (52.46) has a slightly higher BBB penetration than Ligand A (45.56), but for a cardiovascular target, BBB penetration is not a primary concern.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand B (-4.902) is slightly worse than Ligand A (-4.738).
10. **Solubility:** Both have negative solubility values, indicating very poor aqueous solubility. Ligand A (-2.623) is slightly better than Ligand B (-2.983).
11. **hERG:** Both have very low hERG inhibition liability (0.141 & 0.266), which is excellent.
12. **Cl_mic:** Ligand A (5.723) has a significantly lower microsomal clearance than Ligand B (43.868), suggesting better metabolic stability. This is a major advantage.
13. **t1/2:** Ligand A (28.168) has a longer in vitro half-life than Ligand B (22.532), further supporting better metabolic stability.
14. **Pgp:** Both have low P-gp efflux liability (0.092 & 0.15).
15. **Binding Affinity:** Ligand B (-7.0) has a slightly better binding affinity than Ligand A (-6.8), a difference of 0.2 kcal/mol.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B has a slightly better logP and affinity, but Ligand A is better in terms of QED, DILI, and significantly better in terms of metabolic stability (Cl_mic and t1/2). The difference in affinity (0.2 kcal/mol) is not substantial enough to outweigh the clear advantages of Ligand A in ADME properties, particularly metabolic stability. Poor Caco-2 and solubility are concerning for both, but can be addressed with formulation strategies.
**Conclusion:**
Considering the balance of properties, Ligand A is the more promising drug candidate due to its superior QED, lower DILI risk, and significantly improved metabolic stability. While Ligand B has slightly better affinity, the ADME advantages of Ligand A are more critical for overall drug development success.
Output:
1
2025-04-18 00:11:31,603 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (344.39 and 350.43 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (79.18) is significantly better than Ligand B (130.32). For a GPCR, keeping TPSA under 140 is good, but lower is generally preferred for better permeability. Ligand B is approaching a level that could hinder absorption.
3. **logP:** Ligand A (2.121) is within the optimal 1-3 range. Ligand B (-0.723) is below 1, which could lead to poor membrane permeability. This is a significant drawback for Ligand B.
4. **HBD:** Ligand A (3) and Ligand B (4) are both acceptable, being less than 5.
5. **HBA:** Ligand A (5) is better than Ligand B (9). Lower HBA is generally preferred for permeability.
6. **QED:** Ligand A (0.797) has a much better QED score than Ligand B (0.525), indicating a more drug-like profile.
7. **DILI:** Ligand A (72.082) is higher than Ligand B (37.611), indicating a higher risk of drug-induced liver injury. This favors Ligand B.
8. **BBB:** Both ligands have good BBB penetration (Ligand A: 70.648, Ligand B: 72.392). This isn't a major differentiating factor for ADRB2, which isn't a CNS target.
9. **Caco-2:** Both have negative values, indicating poor permeability. However, Ligand A (-5.086) is slightly better than Ligand B (-5.753).
10. **Solubility:** Ligand A (-3.469) is better than Ligand B (-1.912). Better solubility is generally desirable.
11. **hERG:** Ligand A (0.643) is better than Ligand B (0.228), indicating a lower risk of hERG inhibition and cardiotoxicity.
12. **Cl_mic:** Ligand A (5.589) has a lower microsomal clearance than Ligand B (7.025), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-1.889) has a longer in vitro half-life than Ligand B (1.857).
14. **Pgp:** Ligand A (0.151) has lower P-gp efflux than Ligand B (0.001), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand B (-5.6) has a slightly better binding affinity than Ligand A (-4.6), a difference of 1.0 kcal/mol. While affinity is crucial, the other ADME properties must be considered.
**Overall Assessment:**
Ligand A has a significantly better profile overall. While Ligand B has slightly better affinity and lower DILI risk, Ligand A excels in crucial properties like TPSA, logP, QED, solubility, hERG, metabolic stability, and P-gp efflux. The lower logP of Ligand B is a major concern for permeability, and its higher TPSA and HBA are also unfavorable. The affinity difference, while present, is likely outweighed by the superior ADME properties of Ligand A. For a cardiovascular target like ADRB2, metabolic stability and avoiding cardiotoxicity (hERG) are particularly important, and Ligand A performs better in both areas.
Output:
1
2025-04-18 00:11:31,603 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's systematically compare Ligand A and Ligand B based on the provided parameters, keeping in mind the GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key).
1. **MW:** Both ligands (356.482 and 344.419 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (78.43) is significantly better than Ligand B (104.7). A TPSA under 140 is good for oral absorption, and lower is generally preferred for GPCRs. Ligand B is pushing the upper limit.
3. **logP:** Ligand A (2.609) is optimal, while Ligand B (1.162) is a bit low. Lower logP can hinder membrane permeability.
4. **HBD/HBA:** Both have 3 HBD and similar HBA counts (3 vs 5). This is acceptable for both.
5. **QED:** Both ligands have good QED scores (0.678 and 0.701), indicating good drug-like properties.
6. **DILI:** Ligand A (26.095) has a much lower DILI risk than Ligand B (51.144). This is a significant advantage for Ligand A.
7. **BBB:** Ligand A (68.786) has a better BBB penetration score than Ligand B (36.72). While ADRB2 isn't exclusively a CNS target, some CNS exposure can occur, and higher BBB is generally favorable.
8. **Caco-2:** Ligand A (-4.706) has a better Caco-2 permeability score than Ligand B (-5.607).
9. **Solubility:** Ligand A (-2.584) has better aqueous solubility than Ligand B (-1.917).
10. **hERG:** Both ligands have similar hERG inhibition liabilities (0.338 and 0.454), which are relatively low and acceptable.
11. **Cl_mic:** Ligand B (-7.928) has a significantly *lower* (better) microsomal clearance than Ligand A (5.711). This suggests better metabolic stability for Ligand B.
12. **t1/2:** Ligand B (-17.662) has a much longer in vitro half-life than Ligand A (-9.951). This is a major advantage for Ligand B.
13. **Pgp:** Both ligands have very low Pgp efflux liability (0.186 and 0.036).
14. **Binding Affinity:** Both ligands have excellent binding affinity (-6.0 and -7.0 kcal/mol). Ligand B is slightly better, but the difference is not huge.
**Overall Assessment:**
Ligand A excels in several key areas: TPSA, logP, DILI risk, BBB penetration, solubility, and Caco-2 permeability. These are all important for a good ADME profile and oral bioavailability. Ligand B shines in metabolic stability (Cl_mic) and half-life, and has a slightly better binding affinity.
However, the lower DILI risk and better overall ADME profile of Ligand A, combined with its acceptable binding affinity, make it the more promising candidate. The improved TPSA and logP are particularly important for a GPCR target. While the longer half-life of Ligand B is attractive, the higher DILI risk is a significant concern.
Output:
1
2025-04-18 00:11:31,603 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [340.387, 97.87, 1.973, 2, 6, 0.74, 75.029, 79.721, -5.206, -2.395, 0.169, 24.817, 12.024, 0.121, -6.4]
**Ligand B:** [349.431, 114.43, 1.395, 3, 4, 0.658, 40.403, 65.297, -5.216, -3.371, 0.136, 30.491, 3.405, 0.038, -6.2]
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (340.387) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (97.87) is better than Ligand B (114.43). Both are below 140, but lower TPSA is preferred for GPCRs.
3. **logP:** Both ligands have good logP values (A: 1.973, B: 1.395) within the optimal 1-3 range. Ligand A is slightly higher, which could be a minor advantage.
4. **HBD:** Ligand A (2) is better than Ligand B (3). Lower HBD is generally preferred for better permeability.
5. **HBA:** Ligand A (6) is better than Ligand B (4). Lower HBA is generally preferred for better permeability.
6. **QED:** Ligand A (0.74) is slightly better than Ligand B (0.658), indicating a more drug-like profile.
7. **DILI:** Ligand B (40.403) is significantly better than Ligand A (75.029). This is a major advantage for Ligand B. DILI is a critical safety concern.
8. **BBB:** Ligand A (79.721) is better than Ligand B (65.297). While not a primary concern for ADRB2 (cardiovascular), higher BBB is still a positive attribute.
9. **Caco-2:** Both are very poor (-5.206 and -5.216). This is a significant drawback for both, indicating poor intestinal absorption.
10. **Solubility:** Ligand A (-2.395) is better than Ligand B (-3.371). Better solubility is always preferred.
11. **hERG:** Both are very low (A: 0.169, B: 0.136), indicating low hERG inhibition risk.
12. **Cl_mic:** Ligand A (24.817) is better than Ligand B (30.491), indicating better metabolic stability.
13. **t1/2:** Ligand A (12.024) is significantly better than Ligand B (3.405). A longer half-life is desirable.
14. **Pgp:** Ligand A (0.121) is better than Ligand B (0.038), indicating lower P-gp efflux.
15. **Affinity:** Ligand A (-6.4) is slightly better than Ligand B (-6.2), but the difference is small.
**Overall Assessment:**
Ligand A has advantages in TPSA, QED, solubility, metabolic stability, half-life, and Pgp efflux. However, Ligand B has a *much* lower DILI risk, which is a critical factor in drug development. The small difference in binding affinity is unlikely to outweigh the significant safety advantage of Ligand B. Both compounds have poor Caco-2 permeability, which would need to be addressed through formulation or structural modification. Given the GPCR target class, a balance of properties is needed, and the lower DILI risk of Ligand B is paramount.
Output:
0
2025-04-18 00:11:31,603 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [347.256, 74.43, 3.205, 0, 7, 0.564, 99.069, 92.284, -4.196, -5.326, 0.546, 69.362, -24.336, 0.384, -6.8]
**Ligand B:** [356.413, 58.64, 1.815, 1, 3, 0.533, 25.553, 89.376, -4.414, -2.237, 0.571, 26.547, -21.711, 0.123, -5.4]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, Affinity, and BBB):
1. **MW:** Both are within the ideal 200-500 Da range. A (347.256) is slightly preferred.
2. **TPSA:** A (74.43) is higher than B (58.64). B is better here, closer to the <90 for CNS targets, though ADRB2 isn't necessarily a CNS target.
3. **logP:** A (3.205) is optimal, while B (1.815) is on the lower side, potentially impacting permeability. A is favored.
4. **HBD/HBA:** A (0/7) and B (1/3) are both acceptable.
5. **QED:** Both are good (A: 0.564, B: 0.533), indicating drug-like properties.
6. **DILI:** A (99.069) is *very* high risk, a major concern. B (25.553) is excellent, well below the 40% threshold. This is a significant advantage for B.
7. **BBB:** A (92.284) is excellent, B (89.376) is also good, but A is slightly better.
8. **Caco-2:** Both are negative, indicating poor permeability.
9. **Solubility:** Both are negative, indicating poor solubility.
10. **hERG:** Both are low risk (A: 0.546, B: 0.571).
11. **Cl_mic:** A (69.362) is higher than B (26.547), meaning faster clearance and lower metabolic stability. B is favored.
12. **t1/2:** A (-24.336) and B (-21.711) are both negative, indicating short half-life.
13. **Pgp:** A (0.384) is better than B (0.123), indicating lower efflux. A is favored.
14. **Affinity:** A (-6.8 kcal/mol) is significantly better than B (-5.4 kcal/mol) - a 1.4 kcal/mol difference. This is a substantial advantage.
**Overall Assessment:**
Ligand A has a superior binding affinity and better Pgp properties. However, its extremely high DILI risk is a major red flag. Ligand B has a much better safety profile (DILI) and metabolic stability (Cl_mic), but weaker binding affinity and lower logP.
Given the GPCR target class, and balancing potency with safety and ADME properties, the significantly lower DILI risk of Ligand B outweighs the affinity difference. While the affinity of A is attractive, the high DILI risk makes it a less viable candidate. The slightly lower logP of B can be addressed with further optimization.
Output:
0
2025-04-18 00:11:31,603 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (418.332 Da) is within the ideal range. Ligand B (340.431 Da) is also within the ideal range, and slightly lower which could be beneficial for permeability.
2. **TPSA:** Both ligands (A: 82.45, B: 85.94) are below the 140 threshold for good oral absorption, and acceptable for a cardiovascular GPCR.
3. **logP:** Both ligands have good logP values (A: 2.848, B: 1.908), falling within the 1-3 range. Ligand B is slightly lower, which might slightly improve solubility but could potentially reduce membrane permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3) as lower HBD generally improves permeability.
5. **HBA:** Both are acceptable (A: 6, B: 5), below the 10 threshold.
6. **QED:** Both ligands have similar and good QED values (A: 0.719, B: 0.724).
7. **DILI:** Ligand A (55.797) has a lower DILI risk than Ligand B (65.374), which is a significant advantage.
8. **BBB:** Ligand B (73.672) has a better BBB penetration percentile than Ligand A (49.864). While ADRB2 isn't a CNS target, some off-target CNS effects are always a consideration.
9. **Caco-2:** Ligand A (-4.93) has a better Caco-2 permeability than Ligand B (-5.346), suggesting better absorption.
10. **Solubility:** Both ligands have poor aqueous solubility (-3.021 and -3.068 respectively). This is a concern for both.
11. **hERG:** Ligand A (0.128) has a much lower hERG inhibition liability than Ligand B (0.771). This is a critical advantage, as hERG inhibition can lead to cardiotoxicity.
12. **Cl_mic:** Ligand B (40.076) has significantly lower microsomal clearance than Ligand A (90.473), indicating better metabolic stability.
13. **t1/2:** Ligand A (9.497) has a slightly longer in vitro half-life than Ligand B (8.353).
14. **Pgp:** Ligand A (0.082) has lower P-gp efflux liability than Ligand B (0.071), suggesting better bioavailability.
15. **Binding Affinity:** Ligand A (-7.3 kcal/mol) has a significantly stronger binding affinity than Ligand B (-5.3 kcal/mol). This 1.9 kcal/mol difference is substantial and can often outweigh minor ADME drawbacks.
**Overall Assessment:**
While Ligand B has better BBB penetration and metabolic stability, Ligand A is superior due to its significantly stronger binding affinity, lower DILI risk, and much lower hERG inhibition liability. The stronger binding affinity is a major advantage for a GPCR target. The lower hERG risk is crucial for a cardiovascular target. The slightly longer half-life and better Caco-2 permeability also contribute to its favorability. The solubility is a concern for both, but can be addressed with formulation strategies.
Output:
1
2025-04-18 00:11:31,604 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (344.46 & 367.56 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (76.44) is slightly higher than Ligand B (61.44). Both are below the 140 threshold for oral absorption, but B is better positioned for potential CNS penetration if desired.
3. **logP:** Ligand B (1.872) is better than Ligand A (0.841). Both are within the 1-3 range, but A is a bit low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower is generally better, balancing solubility and permeability.
5. **HBA:** Both ligands have 4 HBA, which is acceptable.
6. **QED:** Both ligands have similar QED values (0.802 and 0.779), indicating good drug-likeness.
7. **DILI:** Ligand B (6.204) has a slightly better DILI profile than Ligand A (5.894), both are low risk.
8. **BBB:** Ligand A (71.229) has a better BBB penetration percentile than Ligand B (66.344). While ADRB2 isn't necessarily a CNS target, some peripheral ADRB2 activity can influence CNS function, so this is a slight advantage for A.
9. **Caco-2:** Ligand A (-4.937) has a worse Caco-2 permeability than Ligand B (-5.557). Both are negative, indicating poor permeability, but B is slightly better.
10. **Solubility:** Ligand A (-2.072) has slightly better solubility than Ligand B (-1.865).
11. **hERG:** Ligand A (0.511) has a slightly better hERG profile than Ligand B (0.385), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand B (-7.97) has significantly better metabolic stability (lower clearance) than Ligand A (-16.258). This is a crucial advantage for *in vivo* efficacy.
13. **t1/2:** Ligand B (3.475) has a longer *in vitro* half-life than Ligand A (9.108). This is also a significant advantage.
14. **Pgp:** Ligand A (0.004) has a slightly better Pgp efflux profile than Ligand B (0.011).
15. **Binding Affinity:** Ligand B (-8.0) has a significantly stronger binding affinity than Ligand A (-5.0). This is a substantial advantage that can outweigh some ADME drawbacks.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP and significantly in binding affinity. While Ligand A has a slightly better BBB score, the improved metabolic stability (Cl_mic and t1/2) and binding affinity of Ligand B are more critical for overall drug development success. The slightly lower Caco-2 permeability of B is a concern, but can be addressed with formulation strategies.
**Conclusion:**
Ligand B is the more promising candidate due to its superior binding affinity and metabolic stability. The stronger binding is likely to translate to greater efficacy, and the improved metabolic profile will lead to better *in vivo* exposure.
Output:
0
2025-04-18 00:11:31,604 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands are within the ideal 200-500 Da range (A: 446.18, B: 350.50).
**2. TPSA:** Ligand A (57.26) is slightly higher than Ligand B (43.82), but both are well below the 140 threshold for oral absorption.
**3. logP:** Both ligands have good logP values (A: 4.61, B: 3.38), falling within the 1-3 range. Ligand A is a bit higher, which *could* potentially lead to off-target effects, but not dramatically.
**4. H-Bond Donors:** Ligand A has 2 HBD, and Ligand B has 0. Both are within the acceptable limit of 5.
**5. H-Bond Acceptors:** Ligand A has 3 HBA, and Ligand B has 5. Both are below the 10 limit.
**6. QED:** Both ligands have similar QED values (A: 0.682, B: 0.647), indicating good drug-likeness.
**7. DILI Risk:** Ligand A has a DILI risk of 63.94%, which is moderately high. Ligand B has a much lower DILI risk of 9.112%, a significant advantage.
**8. BBB Penetration:** Both ligands show good BBB penetration (A: 74.29, B: 81.04), which is a positive for a GPCR target, though not strictly essential for ADRB2 which is primarily cardiovascular.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.824 and -4.537). This is unusual and suggests poor permeability. However, these values are on a log scale and the absolute value is more important. Both are similar and suggest a permeability issue.
**10. Aqueous Solubility:** Both ligands have very poor aqueous solubility (A: -5.639, B: -2.72). This is a major concern for bioavailability.
**11. hERG Inhibition:** Both ligands show low hERG inhibition risk (A: 0.828, B: 0.859).
**12. Microsomal Clearance:** Ligand A has a higher microsomal clearance (82.16) than Ligand B (76.23), indicating faster metabolism and potentially lower exposure.
**13. In vitro Half-Life:** Ligand B has a significantly longer in vitro half-life ( -6.066 hours) than Ligand A (124.28 hours). This is a substantial advantage.
**14. P-gp Efflux:** Both ligands show low P-gp efflux liability (A: 0.368, B: 0.181).
**15. Binding Affinity:** Ligand B has a significantly better binding affinity (-5.9 kcal/mol) than Ligand A (0.0 kcal/mol). This is a very large difference and likely outweighs many of the other drawbacks.
**Overall Assessment:**
While both ligands have issues with solubility and Caco-2 permeability, Ligand B is clearly superior. The significantly better binding affinity (-5.9 vs 0.0 kcal/mol) is a major advantage for a GPCR target. The lower DILI risk, longer half-life, and slightly better P-gp efflux profile further support choosing Ligand B. The higher logP of Ligand A is a slight concern, but the dramatic difference in binding affinity outweighs this.
Output:
0
2025-04-18 00:11:31,604 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (353.5 and 363.8 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (72.88 and 72.28) are below the 140 A^2 threshold for good oral absorption, which is good.
3. **logP:** Both ligands have acceptable logP values (1.256 and 1.824), falling within the 1-3 range. Ligand B is slightly higher, potentially aiding membrane permeability.
4. **HBD:** Ligand A has 2 HBD, and Ligand B has 1. Both are within the acceptable limit of <=5.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 6. Both are within the acceptable limit of <=10.
6. **QED:** Ligand B (0.877) has a significantly higher QED score than Ligand A (0.644), indicating a more drug-like profile.
7. **DILI:** Ligand A (5.235) has a much lower DILI risk than Ligand B (76.076). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (57.193) has a higher BBB penetration score than Ligand A (33.036). While ADRB2 isn't strictly a CNS target, some CNS exposure can be a consequence of systemic administration, and higher BBB is generally favorable.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.887 and -4.64). These values are unusual and suggest poor permeability.
10. **Solubility:** Ligand A (-0.367) has slightly better aqueous solubility than Ligand B (-3.04).
11. **hERG:** Both ligands have low hERG inhibition liability (0.189 and 0.241), which is good.
12. **Cl_mic:** Ligand A (12.261) has a lower microsomal clearance than Ligand B (29.134), suggesting better metabolic stability.
13. **t1/2:** Ligand A (3.284) has a slightly longer in vitro half-life than Ligand B (0.493).
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.015 and 0.08).
15. **Binding Affinity:** Ligand B (-7.0) has a significantly stronger binding affinity than Ligand A (-5.1). This is a substantial advantage.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand B is better in logP and significantly better in affinity. Both are good on Pgp and TPSA. However, the extremely high DILI risk for Ligand B is a major concern. While affinity is important, a high risk of liver injury is a significant drawback. Ligand A has a much better safety profile (DILI) and acceptable affinity.
**Conclusion:**
Despite Ligand B's superior binding affinity, the drastically higher DILI risk and poorer metabolic stability make it a less desirable candidate. Ligand A, while having slightly weaker affinity, presents a much more favorable safety profile and better metabolic stability. Therefore, I would choose Ligand A.
Output:
1
2025-04-18 00:11:31,604 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (356.4) is within the ideal range (200-500), while Ligand B (380.9) is also acceptable. No clear advantage.
2. **TPSA:** Ligand A (82.29) is better than Ligand B (67.23). Both are below 140, but lower TPSA generally favors permeability, which is important for GPCRs.
3. **logP:** Ligand A (3.465) is slightly higher than Ligand B (2.756), both are within the optimal range of 1-3.
4. **HBD:** Ligand A (0) is preferred over Ligand B (1). Fewer HBDs generally improve membrane permeability.
5. **HBA:** Ligand A (7) is slightly higher than Ligand B (5). Both are acceptable, but lower is generally better.
6. **QED:** Ligand B (0.867) is better than Ligand A (0.603), indicating a more drug-like profile.
7. **DILI:** Ligand B (59.093) is significantly better than Ligand A (87.049). Lower DILI is crucial.
8. **BBB:** Both ligands have similar BBB penetration (Ligand A: 59.597, Ligand B: 61.419). This isn't a primary concern for ADRB2 (cardiovascular target).
9. **Caco-2:** Both have negative values, indicating poor permeability. Ligand A (-4.857) is slightly better than Ligand B (-5.072).
10. **Solubility:** Ligand A (-4.158) is slightly better than Ligand B (-3.147).
11. **hERG:** Ligand A (0.153) is much better than Ligand B (0.682). Lower hERG risk is critical for cardiovascular drugs.
12. **Cl_mic:** Ligand B (36.902) has significantly lower microsomal clearance than Ligand A (107.701), indicating better metabolic stability.
13. **t1/2:** Ligand B (-8.993) has a longer in vitro half-life than Ligand A (-23.587).
14. **Pgp:** Ligand A (0.65) is better than Ligand B (0.471), indicating lower P-gp efflux.
15. **Affinity:** Ligand A (-7.0) is slightly better than Ligand B (-2.9). This is a substantial difference in binding strength.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has a slightly better logP and Pgp, and a significantly better affinity. However, Ligand B excels in DILI, Cl_mic, and t1/2, all of which are important for overall drug development. The large difference in binding affinity for Ligand A is a significant advantage.
**Overall Assessment:**
Despite Ligand B's better QED, DILI, and metabolic stability, the significantly stronger binding affinity of Ligand A (-7.0 kcal/mol vs -2.9 kcal/mol) is a decisive factor. A >4 kcal/mol difference in affinity can often outweigh minor ADME drawbacks, and the hERG risk for Ligand A is also much lower.
Output:
1
2025-04-18 00:11:31,604 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's systematically compare Ligand A and Ligand B based on the provided parameters and the guidelines, keeping in mind ADRB2 is a GPCR.
1. **Molecular Weight:** Both ligands (362.392 Da and 370.479 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (60.85) is significantly better than Ligand B (129.13). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is approaching the upper limit for good oral absorption.
3. **logP:** Ligand A (1.939) is within the optimal 1-3 range. Ligand B (0.184) is quite low, potentially hindering membrane permeability. This is a significant drawback for Ligand B.
4. **H-Bond Donors:** Ligand A (1) is preferable to Ligand B (4). Fewer HBDs generally improve permeability.
5. **H-Bond Acceptors:** Ligand A (3) is preferable to Ligand B (8). Similar to HBDs, lower HBA counts are generally better for permeability.
6. **QED:** Ligand A (0.813) is much better than Ligand B (0.453). A higher QED suggests a more drug-like profile.
7. **DILI Risk:** Ligand A (18.612) has a much lower DILI risk than Ligand B (61.574). This is a crucial safety parameter.
8. **BBB Penetration:** Ligand A (78.829) shows good BBB penetration, while Ligand B (49.787) is considerably lower. While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant, and better BBB penetration is generally favorable.
9. **Caco-2 Permeability:** Ligand A (-4.629) is better than Ligand B (-5.527), indicating better intestinal absorption.
10. **Aqueous Solubility:** Both are similarly poor (-3.01 and -2.908). This could pose formulation challenges for both, but isn't a deciding factor.
11. **hERG Inhibition:** Ligand A (0.465) has a lower hERG risk than Ligand B (0.666). This is a positive for Ligand A from a safety perspective.
12. **Microsomal Clearance:** Ligand A (24.409) has a lower Cl_mic than Ligand B (37.753), suggesting better metabolic stability.
13. **In vitro Half-Life:** Ligand A (-7.798) has a significantly longer half-life than Ligand B (-21.538). This is a major advantage for Ligand A, potentially allowing for less frequent dosing.
14. **P-gp Efflux:** Ligand A (0.161) has lower P-gp efflux than Ligand B (0.012). Lower efflux is generally better for bioavailability.
15. **Binding Affinity:** Both ligands have comparable binding affinities (-7.0 kcal/mol and -6.5 kcal/mol). The difference of 0.5 kcal/mol is not substantial enough to outweigh the numerous advantages of Ligand A.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical ADME-Tox properties. It has a better drug-like profile (QED), lower toxicity risk (DILI), better permeability (TPSA, logP, Caco-2), improved metabolic stability (Cl_mic, t1/2), and comparable binding affinity. Ligand B's low logP and high DILI risk are significant concerns.
Output:
1
2025-04-18 00:11:31,605 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
The ADRB2 receptor is a GPCR, so the priorities are logP, Pgp, TPSA, and affinity, with BBB being less critical for a cardiovascular target. Let's break down the comparison:
1. **Molecular Weight:** Both ligands are within the acceptable 200-500 Da range. Ligand B (347.423 Da) is slightly preferred due to being lower.
2. **TPSA:** Ligand B (105.04) is better than Ligand A (40.85). While both are reasonably low, Ligand B is closer to the ideal <140 for oral absorption.
3. **logP:** Ligand A (3.506) is optimal (1-3), while Ligand B (-0.532) is significantly lower, potentially hindering membrane permeability. This is a major drawback for Ligand B.
4. **H-Bond Donors:** Ligand A (0) is preferred over Ligand B (2). Fewer HBDs generally improve permeability.
5. **H-Bond Acceptors:** Ligand A (5) is better than Ligand B (7).
6. **QED:** Both ligands have similar, acceptable QED values (0.653 and 0.655).
7. **DILI:** Ligand B (36.642) has a much lower DILI risk than Ligand A (57.619), which is a significant advantage.
8. **BBB:** Both have reasonable BBB penetration, but Ligand A (89.531) is slightly better. However, BBB isn't a primary concern for a cardiovascular target.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Both have negative solubility values, also unusual. It suggests poor solubility for both.
11. **hERG:** Ligand A (0.966) is better than Ligand B (0.024). Lower hERG inhibition is crucial for avoiding cardiotoxicity.
12. **Cl_mic:** Ligand B (10.453) has significantly lower microsomal clearance than Ligand A (73.382), indicating better metabolic stability.
13. **t1/2:** Ligand A (17.315) has a longer half-life than Ligand B (6.279).
14. **Pgp:** Ligand A (0.736) is better than Ligand B (0.02). Lower P-gp efflux is desirable.
15. **Affinity:** Ligand A (-6.6 kcal/mol) has a slightly better binding affinity than Ligand B (-6.2 kcal/mol), although the difference is not huge.
**Overall Assessment:**
Ligand A is better overall. While Ligand B has a lower DILI risk and better metabolic stability, Ligand A's superior logP, H-bond characteristics, hERG profile, Pgp efflux, and slightly better affinity are more critical for a GPCR target like ADRB2. The negative Caco-2 and solubility values are concerning for both, but the other properties of Ligand A make it the more promising candidate.
**Output:**
1
2025-04-18 00:11:31,605 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, the priorities are logP, TPSA, Pgp, affinity, and, to a lesser extent, BBB.
Let's break down the comparison:
1. **MW:** Both ligands are within the ideal range (351.491 and 356.413 Da).
2. **TPSA:** Ligand B (62.55) is significantly better than Ligand A (76.8), falling well below the 140 threshold and closer to the 90 ideal for GPCRs.
3. **logP:** Both ligands have good logP values (2.764 and 3.018), within the optimal 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability.
4. **HBD/HBA:** Both have acceptable HBD (1) and HBA (5/3) counts.
5. **QED:** Both have good QED scores (0.788 and 0.852), indicating drug-likeness.
6. **DILI:** Ligand B (38.891) has a much lower DILI risk than Ligand A (4.731), a significant advantage.
7. **BBB:** Both have similar, high BBB penetration (76.347 and 76.541).
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not defined, so it's hard to interpret.
9. **Solubility:** Ligand A (-1.377) has better solubility than Ligand B (-3.095).
10. **hERG:** Ligand A (0.923) has a slightly better hERG profile than Ligand B (0.704).
11. **Cl_mic:** Ligand A (-1.36) has much better metabolic stability (lower clearance) than Ligand B (30.328).
12. **t1/2:** Ligand B (4.314) has a significantly longer half-life than Ligand A (-5.187).
13. **Pgp:** Ligand A (0.101) has lower P-gp efflux than Ligand B (0.262), which is preferable.
14. **Affinity:** Both have excellent binding affinity (-5.2 and -5.0 kcal/mol). The difference is minimal.
**Overall Assessment:**
Ligand B excels in several crucial areas: lower DILI risk, longer half-life, and lower TPSA. While Ligand A has better solubility, metabolic stability, and P-gp efflux, the lower DILI risk and longer half-life of Ligand B are more important for a viable drug candidate, especially considering the similar binding affinities. The lower TPSA of Ligand B is also a significant advantage for a GPCR target.
Output:
0
2025-04-18 00:11:31,605 - INFO - Reasoning:
Let's analyze Ligand A and Ligand B for their potential as ADRB2 ligands, keeping in mind the GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key).
**Molecular Weight:** Both ligands (361.511 and 346.427 Da) fall within the ideal 200-500 Da range.
**TPSA:** Ligand A (81.99) is slightly higher than Ligand B (67.87). Both are below the 140 threshold for oral absorption, but B is better.
**logP:** Ligand A (3.818) is within the optimal 1-3 range, while Ligand B (0.725) is slightly below, potentially hindering permeation. This is a significant advantage for A.
**H-Bond Donors/Acceptors:** Ligand A has 2 HBD and 4 HBA, while Ligand B has 1 HBD and 4 HBA. Both are within acceptable limits.
**QED:** Both ligands have reasonable QED scores (0.723 and 0.602), indicating good drug-like properties.
**DILI:** Both ligands have similar DILI risk (54.323 and 55.138), both being acceptable.
**BBB:** Both ligands have moderate BBB penetration (52.423 and 57.968). Not a primary concern for a cardiovascular target, but higher is generally better.
**Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.807 and -4.6). These values are unusual and suggest poor permeability.
**Aqueous Solubility:** Ligand A (-4.908) and Ligand B (-2.576) both have negative solubility values, indicating poor solubility. B is better here.
**hERG Inhibition:** Ligand A (0.609) has a slightly higher hERG risk than Ligand B (0.274). B is preferable.
**Microsomal Clearance:** Ligand A (69.156) has a significantly higher microsomal clearance than Ligand B (23.851), suggesting lower metabolic stability. This is a major drawback for A.
**In vitro Half-Life:** Ligand A (40.394) has a longer half-life than Ligand B (-5.084). However, the negative value for B is problematic.
**P-gp Efflux:** Ligand A (0.136) has lower P-gp efflux than Ligand B (0.087), which is favorable.
**Binding Affinity:** Ligand A (-5.9 kcal/mol) has a slightly better binding affinity than Ligand B (-6.1 kcal/mol). While the difference is small, it's a positive for A.
**Overall Assessment:**
Ligand A has a better logP and slightly better affinity, but suffers from higher microsomal clearance and a higher hERG risk. Ligand B has better solubility, lower hERG risk, and significantly better metabolic stability (lower Cl_mic). Given the GPCR target class, the balance of properties leans towards Ligand B. Metabolic stability is crucial for *in vivo* efficacy, and the lower hERG risk is a significant safety advantage. The slightly weaker affinity of B is likely surmountable with further optimization.
Output:
0
2025-04-18 00:11:31,605 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (369.893 and 389.279 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (82.53) is slightly higher than Ligand B (75.71). Both are below the 140 threshold for oral absorption, but closer to the 90 threshold for CNS targets. Ligand B is slightly preferred.
3. **logP:** Ligand A (3.833) is at the higher end of the optimal range (1-3), while Ligand B (1.342) is at the lower end. For a GPCR, a slightly higher logP can be beneficial for membrane permeability, but Ligand A is getting close to the upper limit where solubility issues might arise.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable. Lower is generally preferred, so Ligand B has a slight edge.
5. **HBA:** Both ligands have 4 HBA, which is within the acceptable range.
6. **QED:** Ligand A (0.692) has a slightly better QED score than Ligand B (0.582), indicating a more drug-like profile.
7. **DILI:** Ligand B (29.934) has a significantly lower DILI risk than Ligand A (55.913). This is a major advantage for Ligand B.
8. **BBB:** Both ligands have similar BBB penetration (Ligand A: 65.219, Ligand B: 67.546). While not exceptionally high, it's not a primary concern for ADRB2, which isn't a CNS target.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.675 and -4.985), indicating poor permeability. This is a significant drawback for both.
10. **Solubility:** Ligand B (-2.978) has better solubility than Ligand A (-4.021). This is a positive for Ligand B, especially considering Ligand A's higher logP.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.379 and 0.268).
12. **Cl_mic:** Ligand B (17.762) has significantly lower microsomal clearance than Ligand A (84.141), suggesting better metabolic stability. This is a substantial advantage for Ligand B.
13. **t1/2:** Ligand A (64.232) has a longer in vitro half-life than Ligand B (-7.433). This is a positive for Ligand A.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.213 and 0.053).
15. **Binding Affinity:** Ligand B (-5.6) has a slightly better binding affinity than Ligand A (-5.3). While the difference is small, it's still a positive for Ligand B.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity) and the general guidelines, Ligand B emerges as the more promising candidate. While Ligand A has a slightly better QED and in vitro half-life, Ligand B excels in critical areas like DILI risk, metabolic stability (lower Cl_mic), and solubility. The slightly better binding affinity of Ligand B further strengthens its position. The poor Caco-2 values for both are concerning and would need to be addressed in further optimization, but the other advantages of Ligand B outweigh the benefits of Ligand A.
Output:
0
2025-04-18 00:11:31,605 - INFO - Batch 459 complete. Total preferences: 7344
2025-04-18 00:11:31,605 - INFO - Processing batch 460/512...
2025-04-18 00:12:20,967 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (361.869 and 388.823 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (58.56) is significantly better than Ligand B (81.42). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (3.852 and 3.442), falling within the 1-3 range. Ligand A is slightly higher, potentially aiding membrane permeability.
4. **HBD:** Both have 2 HBD, which is within the acceptable limit of 5.
5. **HBA:** Ligand A has 3 HBA, and Ligand B has 4. Both are below the 10 threshold.
6. **QED:** Both ligands have similar, good QED values (0.713 and 0.795), indicating good drug-like properties.
7. **DILI:** Ligand B (64.676) has a higher DILI risk than Ligand A (47.034). This is a significant negative for Ligand B.
8. **BBB:** Ligand B (76.658) has a higher BBB penetration percentile than Ligand A (33.424). However, as ADRB2 is a cardiovascular target, BBB penetration is not a primary concern.
9. **Caco-2:** Both have negative Caco-2 values (-4.799 and -4.858). This is unusual and suggests poor permeability. However, the values are very similar.
10. **Solubility:** Ligand A (-4.488) has slightly better solubility than Ligand B (-5.255).
11. **hERG:** Ligand A (0.783) has a slightly better hERG profile than Ligand B (0.49). Lower is better.
12. **Cl_mic:** Ligand B (50.554) has a lower microsomal clearance than Ligand A (66.733), indicating better metabolic stability. This is a positive for Ligand B.
13. **t1/2:** Ligand A (30.447) has a longer in vitro half-life than Ligand B (20.041). This is a positive for Ligand A.
14. **Pgp:** Ligand A (0.837) has higher P-gp efflux than Ligand B (0.171). Lower is better, so Ligand B is favored.
15. **Binding Affinity:** Ligand B (-6.9 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.3 kcal/mol). This is a 1.5 kcal/mol difference, which is substantial and can outweigh some ADME drawbacks.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B has a better logP and significantly better Pgp efflux. The affinity difference is also substantial. While Ligand A has a better TPSA and lower DILI risk, the affinity advantage of Ligand B is likely to be more impactful for efficacy.
**Overall Assessment:**
Ligand B's superior binding affinity and Pgp profile, coupled with acceptable logP and QED, outweigh its slightly higher DILI risk and lower half-life. The better metabolic stability is also a plus.
Output:
0
2025-04-18 00:12:20,967 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.478 and 361.406 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (40.62) is significantly better than Ligand B (81.21). ADRB2 is a cardiovascular target, not CNS, but lower TPSA generally aids absorption. Ligand A is well below the 140 threshold, while B is approaching it.
3. **logP:** Ligand A (3.344) is optimal, while Ligand B (0.291) is quite low. This is a major concern for B, as it might struggle with membrane permeability.
4. **HBD:** Both have 0 HBD, which is good.
5. **HBA:** Ligand A (2) is better than Ligand B (8). Higher HBA can sometimes hinder permeability.
6. **QED:** Both ligands have similar QED values (0.661 and 0.667), indicating good drug-likeness.
7. **DILI:** Ligand A (19.271) has a much lower DILI risk than Ligand B (57.58). This is a significant advantage for A.
8. **BBB:** Both have high BBB penetration (96.937 and 83.908). While not crucial for a cardiovascular target, it doesn't hurt.
9. **Caco-2:** Ligand A (-4.347) is better than Ligand B (-5.203), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-3.415) is better than Ligand B (-1.678).
11. **hERG:** Both ligands have low hERG inhibition risk (0.783 and 0.323).
12. **Cl_mic:** Ligand A (47.744) has higher clearance than Ligand B (4.689), indicating lower metabolic stability. This is a negative for A.
13. **t1/2:** Ligand B (-24.136) has a much longer half-life than Ligand A (-6.05). This is a significant advantage for B.
14. **Pgp:** Ligand A (0.374) has lower P-gp efflux than Ligand B (0.239). Lower P-gp efflux is generally preferred.
15. **Binding Affinity:** Ligand B (-6.5) has a slightly better binding affinity than Ligand A (-5.5). The difference is 1 kcal/mol, which is significant but not overwhelming.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A excels in logP and TPSA, and has better Pgp. Ligand B has a slightly better affinity and a significantly longer half-life. However, the poor logP of Ligand B is a major drawback, potentially hindering its ability to reach the receptor. The DILI risk is also much higher for Ligand B.
**Overall Assessment:**
While Ligand B has a slight edge in binding affinity and a much longer half-life, the significantly lower logP, higher DILI risk, and higher TPSA of Ligand B are major concerns. Ligand A presents a better balance of properties, particularly concerning permeability and safety. The slightly higher clearance of A can be addressed with formulation strategies.
Output:
1
2025-04-18 00:12:20,967 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (367.877 and 358.479 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (70.67) is better than Ligand B (77.1), being closer to the <140 threshold for good absorption.
3. **logP:** Both are good (2.451 and 1.35), falling within the 1-3 range. Ligand A is slightly higher, potentially aiding membrane permeability.
4. **HBD:** Both are acceptable (2 and 1 respectively), well below the 5 limit.
5. **HBA:** Both are acceptable (4 and 5 respectively), below the 10 limit.
6. **QED:** Both are good (0.784 and 0.673), indicating good drug-like properties.
7. **DILI:** Ligand A (34.277) has a slightly better DILI score than Ligand B (24.777), indicating lower potential for liver injury.
8. **BBB:** Ligand A (76.696) has a significantly better BBB penetration score than Ligand B (68.166). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant for off-target effects or peripheral effects mediated by CNS pathways.
9. **Caco-2:** Both are very poor (-4.766 and -4.782). This is a significant concern for both compounds, indicating poor intestinal absorption.
10. **Solubility:** Ligand A (-2.906) is better than Ligand B (-0.885), indicating better aqueous solubility.
11. **hERG:** Both are very low (0.468 and 0.212), indicating minimal hERG inhibition risk.
12. **Cl_mic:** Ligand A (17.372) has a lower microsomal clearance than Ligand B (34.75), suggesting better metabolic stability.
13. **t1/2:** Both are similar (24.098 and 23.549 hours).
14. **Pgp:** Both are very low (0.034 and 0.027), indicating minimal P-gp efflux.
15. **Binding Affinity:** Ligand B (-6.5 kcal/mol) has a substantially stronger binding affinity than Ligand A (-2.3 kcal/mol). This is a >1.5 kcal/mol difference, which is a major advantage.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. While both ligands have acceptable logP and Pgp values, Ligand B's significantly higher binding affinity is a critical advantage. The poor Caco-2 permeability is a concern for both, but can be addressed with formulation strategies. Ligand A has better TPSA, solubility, and metabolic stability, but these are outweighed by the substantial affinity difference.
**Conclusion:**
Despite the poor Caco-2 permeability, Ligand B's significantly stronger binding affinity to the ADRB2 receptor makes it the more promising drug candidate. The affinity difference is large enough to potentially overcome the absorption challenges.
Output:
0
2025-04-18 00:12:20,967 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (355.523 and 364.274 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (70.67) is slightly higher than Ligand B (61.2). Both are below the 140 threshold for oral absorption, but closer to the 90 threshold for CNS targets, which isn't a primary concern for ADRB2 (cardiovascular). Ligand B is preferable.
3. **logP:** Both ligands have good logP values (1.933 and 2.29) within the optimal 1-3 range. No clear advantage.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1). Both are within the acceptable limit of 5.
5. **HBA:** Ligand A (4) is lower than Ligand B (6). Lower HBA is generally preferred for better permeability. Ligand A is preferable.
6. **QED:** Both ligands have good QED scores (0.628 and 0.797), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (7.794) has a significantly lower DILI risk than Ligand B (73.09). This is a major advantage for Ligand A.
8. **BBB:** Both ligands have reasonable BBB penetration (59.325 and 71.229). While ADRB2 isn't a CNS target, higher BBB is generally favorable. Ligand B is preferable.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.981 and -4.859). These values are difficult to interpret without knowing the scale, but it suggests poor permeability.
10. **Solubility:** Ligand A (-0.733) has better solubility than Ligand B (-3.213). Solubility is important for bioavailability. Ligand A is preferable.
11. **hERG:** Both ligands have low hERG inhibition liability (0.322 and 0.403). No significant difference.
12. **Cl_mic:** Ligand A (6.047) has lower microsomal clearance than Ligand B (6.91), suggesting better metabolic stability. Ligand A is preferable.
13. **t1/2:** Ligand A (0.059) has a very short half-life, while Ligand B (-11.955) has a negative half-life, which is also problematic. Both are poor.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.022 and 0.144). No significant difference.
15. **Binding Affinity:** Ligand A (-7.0) has a slightly better binding affinity than Ligand B (-6.3). While the difference is less than 1.5 kcal/mol, it's still a positive for Ligand A.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand B has a slightly better logP and BBB, but Ligand A excels in DILI risk, solubility, metabolic stability (Cl_mic), and has a slightly better binding affinity. The significantly lower DILI risk and better metabolic stability of Ligand A outweigh the minor advantages of Ligand B.
**Conclusion:**
Considering the balance of properties, particularly the crucial DILI risk and metabolic stability, Ligand A is the more promising drug candidate.
Output:
1
2025-04-18 00:12:20,967 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (346.5) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (49.41) is significantly better than Ligand B (87.74). ADRB2 is a cardiovascular target, not CNS, but lower TPSA is still beneficial for absorption. Ligand B is approaching a level that could hinder oral absorption.
3. **logP:** Ligand A (3.666) is optimal, while Ligand B (1.44) is on the lower side. A logP between 1-3 is preferred, and Ligand A is closer to the upper end of that range, potentially aiding membrane permeability.
4. **HBD:** Both have acceptable HBD counts (Ligand A: 1, Ligand B: 2).
5. **HBA:** Ligand A (2) is better than Ligand B (5). Lower HBA is generally preferred for permeability.
6. **QED:** Ligand B (0.826) has a higher QED score than Ligand A (0.565), suggesting a more generally drug-like profile.
7. **DILI:** Ligand A (23.226) has a much lower DILI risk than Ligand B (69.678). This is a significant advantage for Ligand A.
8. **BBB:** Not a primary concern for a cardiovascular target, but Ligand A (64.676) is better than Ligand B (53.044).
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
10. **Solubility:** Both have negative solubility values, which is also unusual and suggests poor solubility. Again, the scale is not specified.
11. **hERG:** Ligand A (0.549) has a slightly better hERG profile than Ligand B (0.197), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand B (-15.687) has a *much* lower (better) microsomal clearance than Ligand A (66.464), suggesting greater metabolic stability. This is a major advantage for Ligand B.
13. **t1/2:** Ligand B (12.965) has a significantly longer in vitro half-life than Ligand A (2.453). This is another substantial advantage for Ligand B.
14. **Pgp:** Ligand A (0.639) has a slightly better Pgp efflux profile than Ligand B (0.045).
15. **Binding Affinity:** Ligand A (-6.6 kcal/mol) has a slightly better binding affinity than Ligand B (-5.4 kcal/mol). While the difference is not huge, it's a factor.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand A excels in logP and has a slightly better affinity. However, Ligand B's superior metabolic stability (Cl_mic and t1/2) and lower DILI risk are crucial considerations. While TPSA is higher for Ligand B, the substantial improvements in metabolic stability and safety outweigh this drawback.
**Overall Assessment:**
Ligand B, despite its higher TPSA and lower QED, presents a more favorable overall profile due to its significantly improved metabolic stability, longer half-life, and lower DILI risk. These factors are critical for developing a safe and effective drug, even if the binding affinity is slightly lower.
Output:
0
2025-04-18 00:12:20,967 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (338.411 Da) is better than Ligand B (383.832 Da). Both are within the ideal range, but A is closer to the lower, preferred end.
2. **TPSA:** Ligand B (80.32) is slightly better than Ligand A (86.88). Both are well below the 140 threshold for oral absorption, and acceptable for a GPCR.
3. **logP:** Ligand A (2.145) is better than Ligand B (3.718). Ligand B is pushing towards the higher end of the optimal range, increasing the risk of off-target effects and solubility issues.
4. **HBD:** Ligand A (3) is slightly better than Ligand B (2). Both are within the acceptable limit of 5.
5. **HBA:** Ligand B (5) is slightly better than Ligand A (3). Both are within the acceptable limit of 10.
6. **QED:** Ligand A (0.801) is significantly better than Ligand B (0.625). A higher QED suggests a more drug-like profile.
7. **DILI:** Ligand A (59.442) is *much* better than Ligand B (93.757). Ligand B's DILI risk is high, a major concern.
8. **BBB:** Both Ligand A (74.176) and Ligand B (77.123) are good, exceeding the 70 percentile. This isn't a primary concern for ADRB2 (cardiovascular target), but it's not detrimental.
9. **Caco-2:** Ligand A (-5.456) is better than Ligand B (-4.379). Higher (less negative) values indicate better absorption.
10. **Solubility:** Ligand A (-3.088) is better than Ligand B (-5.178). Better solubility is crucial for bioavailability.
11. **hERG:** Both Ligand A (0.52) and Ligand B (0.44) are low, indicating minimal hERG inhibition risk.
12. **Cl_mic:** Ligand A (5.841) is *much* better than Ligand B (81.837). Lower clearance indicates better metabolic stability.
13. **t1/2:** Ligand B (74.999) is significantly better than Ligand A (4.865). A longer half-life is generally desirable.
14. **Pgp:** Ligand A (0.247) is better than Ligand B (0.583). Lower P-gp efflux is preferable.
15. **Binding Affinity:** Ligand A (-7.9) is significantly better than Ligand B (-6.7). A difference of 1.2 kcal/mol is substantial and can outweigh some ADME drawbacks.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A excels in affinity and has a better logP and Pgp profile. While both have acceptable TPSA, Ligand A's significantly better DILI and Cl_mic profiles are critical. The longer half-life of Ligand B is attractive, but the high DILI risk and poor metabolic stability are major drawbacks. The superior binding affinity of Ligand A is also a significant advantage.
**Conclusion:**
Ligand A is the superior candidate due to its significantly better binding affinity, lower DILI risk, better metabolic stability (lower Cl_mic), improved solubility, and more favorable logP. These factors outweigh the slightly shorter half-life of Ligand A.
Output:
1
2025-04-18 00:12:20,968 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
Let's systematically compare Ligand A and Ligand B against the provided guidelines, keeping in mind the GPCR-specific priorities (logP, Pgp, TPSA, and affinity are crucial).
1. **MW:** Both ligands (346.431 and 361.511 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (84.42) is slightly higher than Ligand B (53.51). Both are below 140, but B is better for oral absorption.
3. **logP:** Ligand A (1.642) is within the optimal range (1-3), while Ligand B (3.095) is at the higher end. Both are acceptable, but A is slightly preferred.
4. **HBD:** Ligand A (1) is better than Ligand B (0). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (5) is slightly higher than Ligand B (4). Both are within the acceptable limit of 10.
6. **QED:** Both ligands have good QED scores (0.773 and 0.813), indicating good drug-like properties.
7. **DILI:** Both ligands have low DILI risk (48.779 and 45.56), which is good. No clear advantage.
8. **BBB:** Both ligands have similar BBB penetration (77.898 and 77.743). This is good, but not a major differentiating factor since ADRB2 is primarily a cardiovascular target.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.42 and -4.719). This is unusual and suggests poor permeability.
10. **Solubility:** Both ligands have negative solubility values (-2.899 and -3.086). This is also unusual and suggests poor aqueous solubility.
11. **hERG:** Ligand A (0.236) has a lower hERG risk than Ligand B (0.525), which is a significant advantage for cardiovascular drugs.
12. **Cl_mic:** Ligand A (77.337) has a higher microsomal clearance than Ligand B (66.378), meaning it's metabolized faster. B is preferred here.
13. **t1/2:** Ligand B (-12.121) has a longer in vitro half-life than Ligand A (-34.526). This is a significant advantage.
14. **Pgp:** Ligand A (0.079) has lower P-gp efflux liability than Ligand B (0.308), which is beneficial for bioavailability.
15. **Affinity:** Ligand A (-7.8 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.6 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME drawbacks.
**Overall Assessment:**
While both ligands have issues with Caco-2 and solubility, Ligand A's superior binding affinity (-7.8 vs -6.6 kcal/mol) and lower hERG risk are key advantages for a cardiovascular GPCR target. The lower Pgp efflux is also a positive. Although Ligand B has a better half-life and lower clearance, the potency and safety profile of Ligand A are more compelling.
**Output:**
1
2025-04-18 00:12:20,968 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (361.471 and 348.451 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Both ligands (78.43 and 79.54) are below the 140 A^2 threshold for good oral absorption, and acceptable for a non-CNS GPCR target like ADRB2. Similar values.
3. **logP:** Both ligands (1.149 and 1.106) are within the optimal 1-3 range. No significant difference.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 6 HBA, and Ligand B has 8 HBA. Both are acceptable (<=10), but Ligand A is slightly better.
6. **QED:** Ligand A (0.87) has a better QED score than Ligand B (0.727), indicating a more drug-like profile.
7. **DILI:** Ligand A (52.423) has a slightly lower DILI risk than Ligand B (58.434), both are acceptable (<60).
8. **BBB:** ADRB2 is primarily a cardiovascular target, so BBB penetration is not a high priority. Ligand B (84.141) has a higher BBB value than Ligand A (62.233), but this is less important here.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.983 and -4.718), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Both ligands have negative solubility values (-2.508 and -1.691), indicating poor aqueous solubility. This is a major drawback for both compounds.
11. **hERG:** Ligand A (0.187) has a significantly lower hERG inhibition liability than Ligand B (0.712). This is a crucial advantage, as ADRB2 is a cardiovascular target and hERG inhibition can cause cardiotoxicity.
12. **Cl_mic:** Ligand A (38.015) has a lower microsomal clearance than Ligand B (46.693), suggesting better metabolic stability.
13. **t1/2:** Ligand B (61.075) has a longer in vitro half-life than Ligand A (6.331). This is a positive for Ligand B.
14. **Pgp:** Ligand A (0.064) has a lower P-gp efflux liability than Ligand B (0.241), which is favorable for oral bioavailability.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.3 and -6.2 kcal/mol). The difference is negligible.
**Overall Assessment:**
While both ligands have significant drawbacks (poor Caco-2 and solubility), Ligand A is preferable due to its significantly lower hERG risk, better QED, lower DILI, lower Cl_mic, and lower Pgp efflux. The longer half-life of Ligand B is a benefit, but the increased hERG risk is a major concern for a cardiovascular target. Given the GPCR-specific priorities, and the importance of minimizing cardiotoxicity, Ligand A is the better candidate despite the shared solubility/permeability issues. Further work would be needed to address these ADME properties for either compound.
Output:
1
2025-04-18 00:12:20,968 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (358.276 and 345.443 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (84.64) is significantly better than Ligand A (117.2), being well below the 140 threshold for good absorption. This is a positive for Ligand B, especially for a GPCR.
3. **logP:** Both ligands have similar logP values (1.252 and 1.291), falling within the optimal 1-3 range.
4. **HBD:** Ligand B (1) has fewer HBDs than Ligand A (3), which is generally preferable for permeability.
5. **HBA:** Ligand B (4) has fewer HBAs than Ligand A (5), again favoring permeability.
6. **QED:** Both ligands have similar QED values (0.757 and 0.786), indicating good drug-likeness.
7. **DILI:** Ligand B (13.61) has a *much* lower DILI risk than Ligand A (89.066). This is a major advantage for Ligand B.
8. **BBB:** Both ligands have similar BBB penetration (64.676 and 63.164). While not exceptionally high, it's not a primary concern for ADRB2, which isn't a CNS target.
9. **Caco-2:** Ligand B (-4.725) is slightly better than Ligand A (-5.528), indicating better intestinal absorption.
10. **Solubility:** Ligand B (-1.993) is slightly better than Ligand A (-3.365).
11. **hERG:** Ligand B (0.231) has a lower hERG risk than Ligand A (0.059). This is a positive for Ligand B.
12. **Cl_mic:** Ligand B (-3.267) has a significantly lower microsomal clearance than Ligand A (-13.895), suggesting better metabolic stability.
13. **t1/2:** Ligand B (21.797) has a longer in vitro half-life than Ligand A (-24.555). This is a significant advantage.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.007 and 0.022).
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.6 and -6.5 kcal/mol). The difference is negligible.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand B excels in TPSA, has comparable logP and affinity, and similar Pgp. The *major* advantage of Ligand B is its significantly improved safety profile (DILI) and metabolic stability (Cl_mic, t1/2).
**Conclusion:**
Ligand B is the superior candidate due to its significantly lower DILI risk, better metabolic stability, improved permeability characteristics (lower TPSA, HBD, HBA), and slightly better solubility and Caco-2 permeability. The binding affinity is comparable between the two.
Output:
0
2025-04-18 00:12:20,968 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (361.389 Da and 355.389 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (87.74) is better than Ligand B (110). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (1.426) is better than Ligand A (0.149). A logP between 1-3 is optimal, and Ligand A is quite low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (2) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is preferable to Ligand B (5). Similar to HBD, fewer HBAs are generally better.
6. **QED:** Ligand B (0.715) is significantly better than Ligand A (0.428). A higher QED indicates a more drug-like profile.
7. **DILI:** Ligand A (33.695) is much better than Ligand B (54.44). Lower DILI risk is crucial.
8. **BBB:** Ligand A (87.476) is better than Ligand B (79.294), but this is less important for a cardiovascular target.
9. **Caco-2:** Both are negative, suggesting poor permeability. Ligand A (-5.186) is slightly better than Ligand B (-5.313).
10. **Solubility:** Ligand A (-1.428) is slightly better than Ligand B (-2.682).
11. **hERG:** Both are very low (0.402 and 0.279), indicating minimal hERG inhibition risk, which is excellent.
12. **Cl_mic:** Ligand A (-1.101) is better than Ligand B (3.902). Lower clearance is preferred for improved metabolic stability.
13. **t1/2:** Ligand B (-10.965) is better than Ligand A (-9.479). Longer half-life is generally desirable.
14. **Pgp:** Both are very low (0.025 and 0.011), indicating minimal P-gp efflux.
15. **Binding Affinity:** Ligand B (-6.9) is slightly better than Ligand A (-6.0). While both are good, the difference is significant enough to consider.
**GPCR-Specific Priorities & Overall Assessment:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand B has a better logP and slightly better affinity. However, Ligand A has a significantly better DILI score and better metabolic stability (Cl_mic). The low logP of Ligand A is a concern, but the substantial advantage in DILI risk and Cl_mic, coupled with acceptable TPSA, makes it the more promising candidate. The slightly better affinity of Ligand B isn't enough to overcome these ADME/Tox concerns.
Output:
1
2025-04-18 00:12:20,968 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (345.443 and 351.407 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (87.39) is better than Ligand B (107.77). For a GPCR, keeping TPSA under 140 is good for oral absorption, and lower is generally preferred.
**3. logP:** Ligand A (3.246) is optimal (1-3 range), while Ligand B (-1.576) is significantly lower, potentially hindering membrane permeability. This is a major strike against Ligand B.
**4. H-Bond Donors:** Both ligands are acceptable (3 and 2 respectively), falling within the <5 guideline.
**5. H-Bond Acceptors:** Ligand A (4) is better than Ligand B (7). Keeping HBA under 10 is preferred.
**6. QED:** Both ligands have similar, acceptable QED values (0.685 and 0.614, both > 0.5).
**7. DILI:** Ligand B (30.361) has a much lower DILI risk than Ligand A (47.732), which is a significant advantage.
**8. BBB:** Ligand A (64.831) has a better BBB penetration percentile than Ligand B (21.287). While ADRB2 is a cardiovascular target, some CNS effects are possible with beta-blockers, and moderate CNS penetration isn't necessarily detrimental.
**9. Caco-2 Permeability:** Ligand A (-4.764) is better than Ligand B (-5.347). Higher values are better, indicating better absorption.
**10. Aqueous Solubility:** Ligand A (-3.473) is better than Ligand B (0.048). Higher values are better for formulation and bioavailability.
**11. hERG Inhibition:** Ligand A (0.554) is better than Ligand B (0.073). Lower is better to avoid cardiotoxicity.
**12. Microsomal Clearance:** Ligand B (-27.38) has a significantly lower (better) microsomal clearance than Ligand A (35.609), indicating greater metabolic stability.
**13. In vitro Half-Life:** Ligand A (71.482) has a much longer half-life than Ligand B (6.182). This is a significant advantage for dosing convenience.
**14. P-gp Efflux:** Ligand A (0.458) is better than Ligand B (0.005). Lower efflux is preferred for better bioavailability.
**15. Binding Affinity:** Ligand B (-6.5 kcal/mol) has a significantly stronger binding affinity than Ligand A (-3.5 kcal/mol). This is a substantial advantage, potentially outweighing some ADME concerns.
**Overall Assessment:**
While Ligand B has a superior binding affinity and lower DILI and microsomal clearance, its significantly negative logP is a major concern. Poor logP can lead to poor permeability and bioavailability. Ligand A has a more balanced profile, with acceptable logP, TPSA, and reasonable ADME properties. The stronger binding affinity of Ligand B is attractive, but the permeability issues are a significant hurdle. Given the GPCR-specific priorities (logP, TPSA, Pgp, affinity), and considering the cardiovascular context where systemic exposure is crucial, I favor Ligand A.
Output:
1
2025-04-18 00:12:20,968 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (374.794 Da and 370.837 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (72.94) is significantly better than Ligand B (113.44). For a GPCR, keeping TPSA below 140 is good for oral absorption, and lower is generally preferred. Ligand B is pushing the upper limit and could have absorption issues.
**3. logP:** Ligand A (3.402) is optimal, while Ligand B (0.46) is quite low. A logP below 1 can hinder membrane permeability. This is a substantial advantage for Ligand A.
**4. H-Bond Donors:** Both have acceptable HBD counts (2 and 3 respectively), well within the limit of 5.
**5. H-Bond Acceptors:** Both have acceptable HBA counts (4 and 6 respectively), well within the limit of 10.
**6. QED:** Both are reasonably drug-like (0.842 and 0.642), exceeding the 0.5 threshold.
**7. DILI:** Both have acceptable DILI risk (54.634 and 50.136), below the 60% threshold.
**8. BBB:** Ligand A (80.419) has a much better BBB penetration score than Ligand B (46.064). While ADRB2 is primarily a cardiovascular target, some CNS effects are possible with beta-blockers, and better BBB penetration isn't necessarily a negative.
**9. Caco-2 Permeability:** Ligand A (-4.705) is better than Ligand B (-5.026), indicating better intestinal absorption.
**10. Aqueous Solubility:** Ligand A (-3.468) is better than Ligand B (-2.103), indicating better solubility.
**11. hERG Inhibition:** Ligand A (0.631) has a slightly better hERG profile than Ligand B (0.066), indicating lower cardiotoxicity risk.
**12. Microsomal Clearance:** Ligand B (7.247) has significantly lower microsomal clearance than Ligand A (22.478), suggesting better metabolic stability.
**13. In vitro Half-Life:** Ligand B (25.959) has a much longer in vitro half-life than Ligand A (8.654), which is a significant advantage.
**14. P-gp Efflux:** Ligand A (0.357) has better P-gp efflux liability than Ligand B (0.046), meaning it's less likely to be pumped out of cells, improving bioavailability.
**15. Binding Affinity:** Ligand B (-6.6 kcal/mol) has a significantly stronger binding affinity than Ligand A (-2.6 kcal/mol). This is a substantial advantage, potentially outweighing some ADME concerns.
**Overall Assessment:**
The binding affinity of Ligand B is much stronger. However, Ligand A has superior properties regarding permeability (logP, TPSA, Caco-2), solubility, and P-gp efflux. Ligand B's low logP is a major concern. The longer half-life of Ligand B is attractive, but the weaker ADME profile overall is concerning. Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), and the fact that this is a cardiovascular target where CNS penetration isn't critical, the stronger binding affinity of Ligand B is the deciding factor.
Output:
0
2025-04-18 00:12:20,968 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
Let's systematically compare Ligand A and Ligand B based on the provided parameters and the guidelines, keeping in mind that ADRB2 is a GPCR, so logP, Pgp, TPSA, and affinity are particularly important.
1. **Molecular Weight:** Both ligands (374.5 & 362.6 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (83.99) is higher than Ligand B (33.2). For a GPCR, lower TPSA is generally preferred for better brain penetration and membrane permeability. Ligand B is significantly better here.
3. **logP:** Ligand A (0.543) is quite low, potentially leading to poor membrane permeability. Ligand B (4.729) is high, potentially causing solubility issues and off-target effects, but is within the acceptable range. Given ADRB2 is a cardiovascular target, CNS penetration isn't critical, so a slightly higher logP is less concerning than a very low one.
4. **H-Bond Donors:** Both have 0 HBD, which is good.
5. **H-Bond Acceptors:** Ligand A has 5, Ligand B has 3. Both are within the acceptable limit of 10.
6. **QED:** Both ligands have similar QED values (0.717 and 0.733), indicating good drug-likeness.
7. **DILI:** Ligand A (47.54%) has a higher DILI risk than Ligand B (24.66%). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (64.33%) has lower BBB penetration than Ligand B (78.05%). While not a primary concern for a cardiovascular target, higher BBB is generally favorable.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests a potential issue with the data or the compounds themselves. However, we must proceed with the available information.
10. **Solubility:** Ligand A (-1.308) has better solubility than Ligand B (-4.234). This is a positive for Ligand A, especially considering Ligand B's higher logP.
11. **hERG:** Both ligands have low hERG inhibition risk (0.258 and 0.694).
12. **Cl_mic:** Ligand A (11.999) has lower microsomal clearance than Ligand B (100.136), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (20.448) has a longer in vitro half-life than Ligand B (7.093). This is another advantage for Ligand A.
14. **Pgp:** Ligand A (0.08) has lower P-gp efflux than Ligand B (0.706). This is favorable for bioavailability.
15. **Binding Affinity:** Ligand B (-5.8 kcal/mol) has a slightly better binding affinity than Ligand A (-5.2 kcal/mol), but the difference is not substantial enough to outweigh other factors.
**Overall Assessment:**
Ligand B has a better TPSA and affinity, but suffers from a high logP, higher DILI risk, and significantly worse metabolic stability (high Cl_mic, short t1/2). Ligand A has a lower logP (potentially problematic), but excels in metabolic stability, P-gp efflux, and has a lower DILI risk. The lower TPSA of Ligand B is attractive for a GPCR, but the metabolic liabilities and DILI risk are concerning. Given the cardiovascular target, metabolic stability and safety (DILI) are crucial.
Therefore, I believe Ligand A is the more promising candidate.
**Output:**
1
2025-04-18 00:12:20,968 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [427.32 , 77.85 , 3.557, 0. , 5. , 0.632, 80.031, 63.862, -4.711, -3.82 , 0.463, 58.566, 28.803, 0.355, -6.5 ]
**Ligand B:** [381.977, 45.98 , 4.422, 1. , 6. , 0.851, 53.974, 83.908, -4.941, -4.296, 0.767, 52.497, 66.275, 0.702, -6.6 ]
**Step-by-step comparison:**
1. **MW:** Ligand A (427.32 Da) is within the ideal range, while Ligand B (381.977 Da) is also good. No clear advantage here.
2. **TPSA:** Ligand A (77.85) is slightly higher than Ligand B (45.98). For a cardiovascular GPCR, TPSA isn't *as* critical as for CNS targets, but lower is generally better for permeability. Ligand B has a clear advantage.
3. **logP:** Both ligands have good logP values (A: 3.557, B: 4.422), falling within the optimal 1-3 range. Ligand B is slightly higher, which *could* be a minor concern for solubility, but is still acceptable.
4. **HBD:** Ligand A (0) is preferable to Ligand B (1). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (6). Fewer HBAs generally improve permeability.
6. **QED:** Ligand B (0.851) has a better QED score than Ligand A (0.632), indicating a more drug-like profile.
7. **DILI:** Ligand A (80.031) has a higher DILI risk than Ligand B (53.974), which is a significant negative.
8. **BBB:** Ligand B (83.908) has a higher BBB penetration percentile than Ligand A (63.862). While not a CNS target, some degree of BBB penetration can be indicative of good overall permeability.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the values are close (-4.711 vs -4.941), so no clear advantage.
10. **Solubility:** Both have negative solubility values, which is also unusual. Ligand B (-4.296) is slightly better than Ligand A (-3.82).
11. **hERG:** Both ligands have low hERG inhibition liability (A: 0.463, B: 0.767), which is good.
12. **Cl_mic:** Ligand B (52.497) has a lower microsomal clearance than Ligand A (58.566), suggesting better metabolic stability.
13. **t1/2:** Ligand B (66.275) has a significantly longer in vitro half-life than Ligand A (28.803), which is a major advantage.
14. **Pgp:** Ligand A (0.355) has lower P-gp efflux liability than Ligand B (0.702), which is preferable.
15. **Affinity:** Both ligands have very similar binding affinities (A: -6.5, B: -6.6). The difference is negligible.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand B is the stronger candidate. While Ligand A has lower Pgp efflux, Ligand B compensates with a significantly better DILI profile, longer half-life, better QED, and lower TPSA. The slightly higher logP of Ligand B is a minor concern, but the benefits outweigh this potential drawback. The improved metabolic stability (lower Cl_mic and longer t1/2) is also a crucial advantage.
Output:
0
2025-04-18 00:12:20,968 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (361.47 & 347.46 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (84.23 & 88.91) are below the 140 A^2 threshold for good oral absorption. They are also reasonably low, not raising immediate concerns for CNS penetration if desired (though ADRB2 isn't primarily a CNS target).
3. **logP:** Both ligands have good logP values (2.23 & 1.77), falling within the optimal 1-3 range. Ligand A is slightly higher, which *could* be beneficial for membrane permeability, but isn't a major differentiator.
4. **HBD & HBA:** Both have 2 HBD and 5 HBA, which are acceptable values, balancing solubility and permeability.
5. **QED:** Ligand A (0.755) has a significantly better QED score than Ligand B (0.526), indicating a more drug-like profile. This is a positive for Ligand A.
6. **DILI:** Both ligands have low DILI risk (32.30 & 35.91 percentile), well below the concerning threshold of 60. No significant difference.
7. **BBB:** Ligand A (68.86) has a better BBB penetration score than Ligand B (54.48), but this is less important for a primarily cardiovascular target like ADRB2.
8. **Caco-2:** Both ligands have negative Caco-2 values (-5.39 & -5.25), which is unusual and suggests poor permeability. This is a significant concern for both.
9. **Solubility:** Both ligands have negative solubility values (-1.87 & -1.61), indicating poor aqueous solubility. This is a major drawback for both, potentially hindering bioavailability.
10. **hERG:** Both ligands have very low hERG inhibition liability (0.095 & 0.164), which is excellent and minimizes cardiotoxicity risk.
11. **Cl_mic:** Ligand B has a lower microsomal clearance (28.41 mL/min/kg) than Ligand A (46.53 mL/min/kg), suggesting better metabolic stability. This is a significant advantage for Ligand B.
12. **t1/2:** Ligand A has a longer in vitro half-life (-7.69 hours) than Ligand B (-4.65 hours). This is a positive for Ligand A.
13. **Pgp:** Both ligands have low P-gp efflux liability (0.071 & 0.068).
14. **Binding Affinity:** Ligand A (-7.2 kcal/mol) has a slightly better binding affinity than Ligand B (-6.8 kcal/mol). While the difference is less than the 1.5 kcal/mol threshold to strongly favor one over the other, it's still a positive for Ligand A.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Both ligands perform similarly on logP and Pgp. TPSA is acceptable for both. The affinity difference favors Ligand A, but isn't huge. The biggest differentiator is the metabolic stability (Cl_mic) which favors Ligand B, and the QED score which favors Ligand A. The poor Caco-2 and solubility are concerning for both.
**Overall Assessment:**
While Ligand A has a better QED, affinity, and half-life, the improved metabolic stability of Ligand B is a significant advantage. Given the poor permeability and solubility of both, metabolic stability becomes more crucial for achieving adequate *in vivo* exposure. A longer half-life is less valuable if the compound is rapidly cleared before it can exert its effect.
Output:
0
2025-04-18 00:12:20,968 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (345.443 Da) is better than Ligand B (373.519 Da), falling comfortably within the 200-500 Da range.
2. **TPSA:** Both ligands are good (A: 84.23, B: 81.16), well below the 140 threshold for oral absorption.
3. **logP:** Ligand A (2.437) is optimal, while Ligand B (-0.339) is quite low, potentially hindering membrane permeability. This is a significant strike against Ligand B.
4. **HBD:** Both are acceptable (A: 2, B: 1).
5. **HBA:** Both are acceptable (A: 4, B: 5).
6. **QED:** Both are good (A: 0.709, B: 0.63), indicating good drug-like properties.
7. **DILI:** Ligand A (38.503) is better than Ligand B (4.188), indicating a lower risk of liver injury.
8. **BBB:** Ligand A (70.88) is significantly better than Ligand B (35.246). While ADRB2 isn't exclusively a CNS target, some CNS penetration can be beneficial and reduced penetration isn't necessarily a dealbreaker, but the large difference is notable.
9. **Caco-2:** Ligand A (-4.492) is better than Ligand B (-5.186), suggesting better intestinal absorption.
10. **Solubility:** Ligand A (-3.766) is better than Ligand B (-0.064), which is a significant advantage.
11. **hERG:** Both are low risk (A: 0.3, B: 0.215).
12. **Cl_mic:** Ligand B (-0.955) is much better than Ligand A (56.881), suggesting superior metabolic stability. This is a strong point for Ligand B.
13. **t1/2:** Ligand B (-8.568) is much better than Ligand A (-18.388), indicating a longer half-life. Another strong point for Ligand B.
14. **Pgp:** Both are low risk (A: 0.127, B: 0.008).
15. **Affinity:** Ligand B (-6.3 kcal/mol) is significantly better than Ligand A (-4.1 kcal/mol), a difference of 2.2 kcal/mol. This is a substantial advantage that can outweigh some ADME concerns.
**Overall Assessment:**
Ligand B has a substantially better binding affinity and significantly improved metabolic stability and half-life. However, it suffers from a very low logP, which is a major concern for permeability. Ligand A has a better logP, solubility, and DILI profile, but its affinity is weaker and metabolic clearance is higher.
Given that we are targeting a GPCR, logP and affinity are critical. The 2.2 kcal/mol difference in binding affinity is substantial. While the low logP of Ligand B is a concern, it's not insurmountable; formulation strategies could potentially mitigate this issue. The improved metabolic stability and half-life of Ligand B are also highly desirable.
Therefore, I favor Ligand B.
Output:
0
2025-04-18 00:12:20,969 - INFO - Batch 460 complete. Total preferences: 7360
2025-04-18 00:12:20,969 - INFO - Processing batch 461/512...
2025-04-18 00:13:10,453 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (356.482 and 344.415 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (61.8) is significantly better than Ligand B (91.4). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary goal, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold. Ligand B is approaching the upper limit.
3. **logP:** Both ligands have acceptable logP values (2.865 and 1.693), falling within the 1-3 range. Ligand A is slightly more lipophilic, which could be beneficial for membrane permeability.
4. **HBD:** Both have 2 HBD, which is good.
5. **HBA:** Ligand A has 3 HBA, while Ligand B has 6. Ligand A is preferable here as it's closer to the ideal of 10 or less.
6. **QED:** Both ligands have good QED scores (0.817 and 0.832), indicating good drug-like properties.
7. **DILI:** Ligand A (8.996%) has a much lower DILI risk than Ligand B (43.971%). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (88.29%) has better BBB penetration than Ligand B (72.005%). While not a primary concern for a cardiovascular target, it isn't detrimental.
9. **Caco-2:** Both have negative Caco-2 values (-4.599 and -4.712), indicating poor permeability. This is a concern for both, but similar for both.
10. **Solubility:** Both have negative solubility values (-3.312 and -2.778), indicating poor solubility. This is a concern for both, but similar for both.
11. **hERG:** Both have low hERG inhibition liability (0.405 and 0.31). This is good for both.
12. **Cl_mic:** Both have similar microsomal clearance values (38.324 and 39.178 mL/min/kg).
13. **t1/2:** Ligand A (6.463) has a longer in vitro half-life than Ligand B (-2.855). This is a positive for Ligand A.
14. **Pgp:** Both have very low Pgp efflux liability (0.043 and 0.028). This is good for both.
15. **Binding Affinity:** Ligand B (-4.8 kcal/mol) has a significantly stronger binding affinity than Ligand A (-0.0 kcal/mol). This is a substantial advantage for Ligand B.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, affinity, and Pgp. Ligand B has a better affinity, but Ligand A has better TPSA, logP, DILI risk, and half-life. The affinity difference is substantial (-4.8 vs -0.0). While TPSA and logP are important, a strong binding affinity is crucial for GPCRs.
**Conclusion:**
Despite Ligand A having better ADME properties (lower DILI, better TPSA, logP, and half-life), the significantly stronger binding affinity of Ligand B (-4.8 kcal/mol vs -0.0 kcal/mol) outweighs these advantages. A strong starting point for potency is paramount, and the ADME properties can be optimized later.
Output:
0
2025-04-18 00:13:10,453 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
The target is ADRB2, a GPCR. Therefore, I will prioritize logP, Pgp, TPSA, BBB, and binding affinity, followed by general drug-like properties.
* **Molecular Weight:** Both ligands are within the ideal range (200-500 Da).
* **TPSA:** Ligand B (58.64) is significantly better than Ligand A (108.8), falling well below the 140 threshold for good absorption. This is a substantial advantage for Ligand B.
* **logP:** Ligand B (2.344) is within the optimal range (1-3), while Ligand A (0.656) is slightly low, potentially impacting permeability.
* **H-Bond Donors/Acceptors:** Ligand A has 2 HBD and 6 HBA, while Ligand B has 1 HBD and 3 HBA. Both are acceptable.
* **QED:** Both ligands have similar QED values (0.846 and 0.821), indicating good drug-likeness.
* **DILI:** Ligand B (25.242) has a much lower DILI risk than Ligand A (67.003). This is a significant advantage.
* **BBB:** Ligand B (95.502) shows excellent BBB penetration, while Ligand A (26.483) is poor. While ADRB2 isn't exclusively a CNS target, better BBB penetration is generally favorable for GPCRs and can open up potential therapeutic avenues.
* **Caco-2 Permeability:** Ligand A (-5.326) is better than Ligand B (-4.59), indicating better intestinal absorption.
* **Aqueous Solubility:** Both have poor aqueous solubility (-2.224 and -2.779).
* **hERG:** Ligand B (0.459) has a slightly higher hERG risk than Ligand A (0.106), but both are relatively low.
* **Microsomal Clearance:** Ligand A (-3.996) has significantly better metabolic stability (lower clearance) than Ligand B (0.241).
* **In vitro Half-Life:** Ligand A (-7.37) has a longer half-life than Ligand B (4.375).
* **P-gp Efflux:** Ligand A (0.007) has lower P-gp efflux, which is better. Ligand B (0.046) is slightly higher.
* **Binding Affinity:** Both ligands have the same binding affinity (-6.7 kcal/mol).
**Overall Assessment:**
Ligand B is superior due to its significantly better TPSA, lower DILI risk, and excellent BBB penetration. While Ligand A has better Caco-2 permeability, microsomal clearance, and P-gp efflux, the advantages of Ligand B in TPSA, DILI, and BBB are more critical for a GPCR target like ADRB2. The similar binding affinity removes that as a differentiating factor. The slightly lower metabolic stability and higher P-gp efflux of Ligand B can be addressed through further optimization.
**Output:**
0
2025-04-18 00:13:10,453 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A:** [351.359, 110.97 , 0.023, 1. , 7. , 0.745, 62.195, 60.876, -4.609, -1.993, 0.075, 45.216, -11.28 , 0.027, -5.4 ]
**Ligand B:** [351.422, 93.45 , 1.623, 3. , 4. , 0.621, 44.087, 82.862, -4.834, -3.042, 0.603, 33.007, 0.73 , 0.052, -5.8 ]
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). No significant difference.
**2. TPSA:** Ligand A (110.97) is slightly higher than Ligand B (93.45). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B is better here.
**3. logP:** Ligand A (0.023) is very low, potentially causing permeability issues. Ligand B (1.623) is within the optimal range (1-3). Ligand B is significantly better.
**4. H-Bond Donors:** Ligand A (1) is good. Ligand B (3) is acceptable, but higher HBD can sometimes reduce permeability. Ligand A is slightly better.
**5. H-Bond Acceptors:** Ligand A (7) is good. Ligand B (4) is also good. No significant difference.
**6. QED:** Ligand A (0.745) is better than Ligand B (0.621), indicating a more drug-like profile.
**7. DILI:** Ligand A (62.195) has a higher DILI risk than Ligand B (44.087). Ligand B is preferred.
**8. BBB:** Ligand A (60.876) is lower than Ligand B (82.862). While ADRB2 isn't primarily a CNS target, some CNS penetration might be acceptable or even desirable for certain cardiovascular effects. Ligand B is better.
**9. Caco-2:** Both are negative, indicating poor permeability. However, Ligand A (-4.609) is slightly better than Ligand B (-4.834).
**10. Solubility:** Ligand A (-1.993) is better than Ligand B (-3.042).
**11. hERG:** Ligand A (0.075) is much better than Ligand B (0.603), indicating a lower risk of cardiotoxicity. This is a crucial factor for a cardiovascular target.
**12. Cl_mic:** Ligand B (33.007) has lower microsomal clearance than Ligand A (45.216), suggesting better metabolic stability. Ligand B is preferred.
**13. t1/2:** Ligand B (0.73) has a slightly better in vitro half-life than Ligand A (-11.28).
**14. Pgp:** Ligand A (0.027) has lower P-gp efflux than Ligand B (0.052), which is favorable for bioavailability. Ligand A is slightly better.
**15. Binding Affinity:** Ligand B (-5.8) has a slightly better binding affinity than Ligand A (-5.4).
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand B is the stronger candidate. Its logP is within the optimal range, it has better BBB penetration, lower DILI risk, and better metabolic stability. While Ligand A has a slightly better QED and Pgp profile, the significant advantage of Ligand B in logP, hERG, and DILI outweigh these minor differences. The slightly better affinity of Ligand B also contributes to its preference. The low logP of Ligand A is a major concern for permeability.
Output:
0
2025-04-18 00:13:10,454 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [346.475, 67.23, 2.256, 1, 4, 0.823, 16.014, 71.113, -4.932, -1.825, 0.32, 57.194, -7.706, 0.172, -7.7]
**Ligand B:** [350.459, 71.78, 2.939, 1, 4, 0.782, 35.867, 75.184, -4.329, -3.216, 0.754, 34.701, 12.229, 0.391, -7.2]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). A (346.475) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are reasonably low (A: 67.23, B: 71.78), well under the 140 threshold for oral absorption.
3. **logP:** Both are within the optimal range (1-3), A (2.256) is slightly better.
4. **HBD/HBA:** Both have 1 HBD and 4 HBA, which is acceptable.
5. **QED:** Both have good QED scores (A: 0.823, B: 0.782), indicating good drug-like properties.
6. **DILI:** Ligand A (16.014) has a significantly better DILI score than Ligand B (35.867). This is a major advantage.
7. **BBB:** Both have good BBB penetration (A: 71.113, B: 75.184). B is slightly better, but both are acceptable for a non-CNS target like cardiovascular.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. A (-4.932) is worse than B (-4.329).
9. **Solubility:** Both have negative solubility values, which is also unusual and suggests poor solubility. B (-3.216) is better than A (-1.825).
10. **hERG:** Both have very low hERG risk (A: 0.32, B: 0.754), which is excellent.
11. **Cl_mic:** Ligand B (34.701) has significantly lower microsomal clearance than Ligand A (57.194), indicating better metabolic stability.
12. **t1/2:** Ligand B (12.229) has a longer in vitro half-life than Ligand A (-7.706). This is a significant advantage.
13. **Pgp:** Both have low Pgp efflux liability (A: 0.172, B: 0.391).
14. **Binding Affinity:** Ligand A (-7.7) has a slightly better binding affinity than Ligand B (-7.2), a difference of 0.5 kcal/mol.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Both ligands perform reasonably well on these parameters. However, ADME properties like DILI and metabolic stability are crucial.
**Overall Assessment:**
Ligand A has a superior binding affinity and a much lower DILI risk. However, Ligand B has better metabolic stability (lower Cl_mic and longer t1/2) and slightly better solubility. The DILI risk for Ligand A is a significant advantage, outweighing the slightly better affinity and solubility of Ligand B. The Caco-2 values are concerning for both, but the lower DILI risk is a critical factor for a cardiovascular drug.
Output:
1
2025-04-18 00:13:10,454 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (378.332) is slightly higher than Ligand B (340.427), but both are acceptable.
2. **TPSA:** Ligand A (116.31) is higher than Ligand B (86.09). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B is better here.
3. **logP:** Ligand A (0.738) is a bit low, potentially hindering permeability. Ligand B (1.908) is within the optimal range (1-3). Ligand B is significantly better.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable, well below the limit of 5.
5. **HBA:** Ligand A (6) and Ligand B (4) are both acceptable, below the limit of 10.
6. **QED:** Both ligands have good QED scores (A: 0.769, B: 0.907), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (90.733) has a concerningly high DILI risk. Ligand B (39.085) is excellent, well below the 40% threshold. This is a major advantage for Ligand B.
8. **BBB:** Both ligands have moderate BBB penetration (A: 65.413, B: 78.907). Since ADRB2 isn't primarily a CNS target, this isn't a decisive factor. Ligand B is slightly better.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale isn't specified, so it's hard to interpret.
10. **Solubility:** Both ligands have very poor solubility (-3.268 and -3.107 respectively). This is a significant concern for both.
11. **hERG:** Ligand A (0.153) has a slightly higher hERG risk than Ligand B (0.547), but both are relatively low.
12. **Cl_mic:** Ligand A (2.69) has much lower microsomal clearance than Ligand B (23.258), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (4.377) has a shorter half-life than Ligand B (-15.783). The negative value for Ligand B is concerning and likely an error. Ligand A is better.
14. **Pgp:** Ligand A (0.093) has lower P-gp efflux than Ligand B (0.04), suggesting better bioavailability.
15. **Binding Affinity:** Ligand B (-7.4 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.2 kcal/mol). This is a substantial advantage for Ligand B, potentially outweighing some of the ADME concerns.
**Overall Assessment:**
Ligand B has a substantially better binding affinity and a much lower DILI risk. While its solubility is poor, similar to Ligand A, the strong binding and safety profile are crucial. Ligand A has better metabolic stability and a slightly better half-life, but the high DILI risk is a major red flag. Given the GPCR-specific priorities (logP, Pgp, TPSA, affinity), and the importance of safety, Ligand B is the more promising candidate despite its solubility issues.
Output:
0
2025-04-18 00:13:10,454 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (354.4 and 347.4 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (108.05 and 104.12) are reasonably low, suggesting good potential for absorption. Both are above the ideal <90 for CNS targets, but this is less critical for a cardiovascular target like ADRB2.
3. **logP:** Ligand A (-1.669) is lower than Ligand B (1.617). While Ligand A is still within an acceptable range, Ligand B's logP is closer to the optimal 1-3 range, suggesting better membrane permeability.
4. **HBD:** Both have 2 HBD, which is good.
5. **HBA:** Ligand A has 6 HBA, and Ligand B has 5. Both are acceptable.
6. **QED:** Ligand B (0.755) has a better QED score than Ligand A (0.552), indicating a more drug-like profile.
7. **DILI:** Ligand A (26.755) has a significantly lower DILI risk than Ligand B (45.522). This is a major advantage for Ligand A.
8. **BBB:** Both have low BBB penetration (29.74 and 23.032). This isn't a primary concern for a cardiovascular target.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual. Assuming these are percentile scores, both are very poor.
10. **Solubility:** Ligand A (-0.425) has slightly better solubility than Ligand B (-1.664).
11. **hERG:** Both have very low hERG inhibition liability (0.021 and 0.08). This is excellent for both.
12. **Cl_mic:** Ligand A (3.252) has significantly lower microsomal clearance than Ligand B (15.835), indicating better metabolic stability.
13. **t1/2:** Ligand B (25.042) has a much longer in vitro half-life than Ligand A (-20.296). This is a significant advantage for Ligand B.
14. **Pgp:** Both have very low Pgp efflux liability (0.003 and 0.016).
15. **Binding Affinity:** Ligand B (-7.7 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.9 kcal/mol). This is a substantial advantage, potentially outweighing some ADME concerns.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand B excels in logP and affinity. While TPSA is similar, the superior affinity of Ligand B is a strong driver. The lower DILI and Cl_mic of Ligand A are attractive, but the significantly better binding affinity of Ligand B is more critical for a GPCR target. The longer half-life of Ligand B is also a positive.
**Conclusion:**
Despite the higher DILI risk and higher clearance, Ligand B's substantially stronger binding affinity and better QED and half-life make it the more promising drug candidate for ADRB2.
Output:
0
2025-04-18 00:13:10,454 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Ligand A (350.419 Da) is within the ideal range (200-500), while Ligand B (402.64 Da) is towards the upper limit. Both are acceptable, but A is slightly preferred.
2. **TPSA:** Ligand A (104.39) is better than Ligand B (62.3). Both are below 140, but B is significantly lower, which is good for permeability.
3. **logP:** Ligand A (1.596) is optimal (1-3). Ligand B (4.148) is above the preferred range, potentially leading to solubility issues and off-target effects. This is a significant drawback for B.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable (<=5).
5. **HBA:** Ligand A (5) and Ligand B (3) are both acceptable (<=10).
6. **QED:** Ligand A (0.843) is excellent, indicating high drug-likeness. Ligand B (0.477) is below the desirable threshold of 0.5, raising concerns.
7. **DILI:** Ligand A (59.636) is better than Ligand B (89.686). Both are above 60, indicating higher risk, but A is preferable.
8. **BBB:** Ligand A (55.642) is lower than Ligand B (83.831). While ADRB2 isn't strictly a CNS target, some CNS penetration might be acceptable, and B has a clear advantage here.
9. **Caco-2:** Both ligands have negative values, which is unusual. Assuming these are logP-scale values, lower values indicate poorer permeability. Ligand A (-4.758) is worse than Ligand B (-4.562).
10. **Solubility:** Ligand A (-2.901) is better than Ligand B (-5.65). Solubility is a concern for B due to its high logP.
11. **hERG:** Both ligands have low hERG risk (0.301 and 0.209 respectively).
12. **Cl_mic:** Ligand A (-2.256) has a much lower (better) microsomal clearance than Ligand B (42.182), indicating greater metabolic stability.
13. **t1/2:** Ligand A (-27.428) has a much longer half-life than Ligand B (20.028).
14. **Pgp:** Ligand A (0.038) has lower P-gp efflux than Ligand B (0.105), which is preferable.
15. **Affinity:** Ligand A (-7.0) has a significantly better binding affinity than Ligand B (-21.8). This is a substantial advantage.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A has a better logP, lower Pgp efflux, and *much* better affinity. While Ligand B has a better BBB score, the other drawbacks are too significant to ignore.
**Overall Assessment:**
Ligand A is superior due to its excellent QED, better DILI risk, superior metabolic stability (lower Cl_mic and longer t1/2), lower Pgp efflux, and, most importantly, significantly stronger binding affinity. The slightly higher TPSA and lower Caco-2 are less concerning than the solubility and metabolic issues with Ligand B.
Output:
1
2025-04-18 00:13:10,454 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (370.852 Da) is slightly higher than Ligand B (345.487 Da), but both are acceptable.
2. **TPSA:** Both ligands have TPSA values below 140, indicating good potential for oral absorption. Ligand A (69.64) is slightly higher than Ligand B (64.41), but both are good.
3. **logP:** Both ligands have logP values within the optimal range (1-3). Ligand A (2.607) and Ligand B (2.812) are both very good.
4. **HBD:** Ligand A has 2 HBD, while Ligand B has 0. Both are within the acceptable limit of <=5.
5. **HBA:** Both ligands have 3 HBA, which is well within the acceptable limit of <=10.
6. **QED:** Both ligands have QED values above 0.5 (Ligand A: 0.775, Ligand B: 0.679), indicating good drug-like properties.
7. **DILI:** Ligand A has a DILI risk of 38.775%, while Ligand B has 18.418%. Ligand B is significantly better here, indicating a lower risk of liver injury.
8. **BBB:** Ligand B (78.984%) has a significantly higher BBB penetration percentile than Ligand A (53.781%). This is a crucial advantage for a GPCR target, even a peripheral one like ADRB2, as some CNS off-target effects are always a concern, and better brain penetration can sometimes correlate with better overall distribution.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.783) is slightly worse than Ligand B (-4.591). This is a significant concern for both.
10. **Solubility:** Both ligands have negative solubility values, which is also unusual and indicates poor aqueous solubility. Ligand A (-3.006) is slightly worse than Ligand B (-3.093). This is a significant concern for both.
11. **hERG:** Both ligands have low hERG inhibition liability (Ligand A: 0.625, Ligand B: 0.609), which is good.
12. **Cl_mic:** Ligand A has a lower microsomal clearance (2.441 mL/min/kg) than Ligand B (58.325 mL/min/kg), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A has a longer in vitro half-life (22.917 hours) than Ligand B (-9.981 hours). The negative value for Ligand B is concerning and suggests very rapid metabolism. This is a major advantage for Ligand A.
14. **Pgp:** Both ligands have low P-gp efflux liability (Ligand A: 0.303, Ligand B: 0.384).
15. **Binding Affinity:** Ligand A (-6.2 kcal/mol) has a stronger binding affinity than Ligand B (-2.9 kcal/mol). This is a substantial advantage for Ligand A, potentially outweighing some of its ADME drawbacks.
**Overall Assessment:**
While Ligand B has advantages in DILI risk and BBB penetration, Ligand A is significantly better in terms of metabolic stability (Cl_mic, t1/2) and, crucially, binding affinity. The large difference in binding affinity (-6.2 vs -2.9 kcal/mol) is a major factor. The poor Caco-2 and solubility for both are concerning, but these can potentially be addressed with formulation strategies. The superior affinity and metabolic stability of Ligand A make it the more promising candidate.
Output:
1
2025-04-18 00:13:10,454 - INFO - Here's a step-by-step reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A Analysis:**
* **MW (432.286 Da):** Within the ideal range (200-500 Da).
* **TPSA (46.61):** Good, below the 140 threshold for oral absorption.
* **logP (3.842):** Optimal, within the 1-3 range.
* **HBD (0):** Acceptable, low number of hydrogen bond donors.
* **HBA (4):** Acceptable, within the limit of 10.
* **QED (0.652):** Good, above the 0.5 threshold.
* **DILI (64.831):** Moderate risk, slightly above the preferred <40, but not excessively high.
* **BBB (88.484):** Excellent, high BBB penetration, favorable for a GPCR.
* **Caco-2 (-4.373):** Poor permeability.
* **Solubility (-3.966):** Very poor solubility.
* **hERG (0.659):** Low risk.
* **Cl_mic (120.675):** High, indicating rapid metabolism.
* **t1/2 (66.137):** Good in vitro half-life.
* **Pgp (0.749):** Moderate P-gp efflux.
* **Affinity (-6.8 kcal/mol):** Good binding affinity.
**Ligand B Analysis:**
* **MW (350.419 Da):** Within the ideal range (200-500 Da).
* **TPSA (92.67):** Acceptable, but approaching the upper limit for good absorption.
* **logP (-0.083):** Suboptimal, potentially leading to poor permeation.
* **HBD (2):** Acceptable.
* **HBA (5):** Acceptable.
* **QED (0.702):** Good, above the 0.5 threshold.
* **DILI (34.393):** Excellent, low DILI risk.
* **BBB (42.962):** Low, unfavorable for a GPCR.
* **Caco-2 (-4.821):** Poor permeability.
* **Solubility (-0.956):** Poor solubility.
* **hERG (0.046):** Very low risk.
* **Cl_mic (0.97):** Very low, indicating high metabolic stability.
* **t1/2 (1.046):** Very short in vitro half-life.
* **Pgp (0.012):** Very low P-gp efflux.
* **Affinity (-7.2 kcal/mol):** Excellent, significantly stronger binding affinity.
**Comparison and Decision:**
Given that the target is a GPCR (ADRB2), several factors are crucial: affinity, logP, TPSA, Pgp, and BBB. Ligand B has a significantly better binding affinity (-7.2 vs -6.8 kcal/mol), which is a substantial advantage. However, it suffers from poor BBB penetration and a very short half-life. Ligand A has better BBB penetration but lower affinity, poor Caco-2 permeability and solubility, and high metabolic clearance.
While Ligand B's affinity is compelling, the poor BBB penetration is a major drawback for a GPCR target. The improved metabolic stability is a plus, but a short half-life is concerning. Ligand A's poor permeability and solubility are also significant issues.
Despite the drawbacks of both, Ligand B's superior affinity is a strong driver. The issues with permeability and half-life are more readily addressed through medicinal chemistry optimization than improving binding affinity. The low Pgp efflux is also a significant benefit.
Therefore, I would prioritize Ligand B for further development, with a focus on improving its permeability, solubility, and half-life.
Output:
0
2025-04-18 00:13:10,454 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (355.419 and 343.431 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Both ligands (90.27 and 91.81) are below the 140 A^2 threshold for good oral absorption, but relatively high. This isn't a major concern for a peripherally acting GPCR like ADRB2, but lower is generally better.
3. **logP:** Both ligands have good logP values (1.814 and 1.398), falling within the optimal 1-3 range. Ligand B is slightly lower, which *could* indicate slightly better solubility, but both are acceptable.
4. **HBD:** Ligand A (1 HBD) is preferable to Ligand B (3 HBD). Fewer HBDs generally improve permeability.
5. **HBA:** Both ligands have 4 HBA, which is within the acceptable range.
6. **QED:** Ligand A (0.906) has a significantly higher QED score than Ligand B (0.633), indicating a more drug-like profile. This is a substantial advantage.
7. **DILI:** Ligand B (49.593) has a much lower DILI risk than Ligand A (73.245). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (59.636) has a higher BBB penetration percentile than Ligand B (35.401). While ADRB2 isn't a CNS target, some degree of BBB penetration can sometimes indicate favorable partitioning. However, this is a lower priority.
9. **Caco-2:** Ligand A (-4.774) has a higher Caco-2 permeability than Ligand B (-5.525), suggesting better intestinal absorption.
10. **Solubility:** Ligand B (-2.82) has better aqueous solubility than Ligand A (-4.861).
11. **hERG:** Ligand A (0.59) has a slightly lower hERG inhibition liability than Ligand B (0.272), which is preferable.
12. **Cl_mic:** Ligand B (6.887) has significantly lower microsomal clearance than Ligand A (62.646), indicating better metabolic stability. This is a major advantage.
13. **t1/2:** Ligand B (8.288) has a longer in vitro half-life than Ligand A (-4.899). This is a significant advantage.
14. **Pgp:** Ligand A (0.184) has lower P-gp efflux liability than Ligand B (0.04).
15. **Binding Affinity:** Ligand A (-7.1 kcal/mol) has a slightly better binding affinity than Ligand B (-6.0 kcal/mol). This is a 1.1 kcal/mol difference, which is significant.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Both ligands are acceptable in terms of logP and TPSA. Ligand A has a better Pgp profile and a superior binding affinity. However, Ligand B has a much better safety profile (DILI) and pharmacokinetic properties (Cl_mic, t1/2). The difference in binding affinity, while present, is not large enough to overcome the substantial advantages of Ligand B in terms of safety and PK.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity and Pgp profile, Ligand B's superior DILI, metabolic stability (lower Cl_mic), longer half-life, and better solubility make it the more promising drug candidate. The improved ADME properties outweigh the modest difference in binding affinity.
Output:
0
2025-04-18 00:13:10,454 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (362.47 and 357.495 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (52.57) is significantly better than Ligand B (101.9). ADRB2 is a cardiovascular target, not CNS, but lower TPSA generally improves absorption. Ligand A is well below the 140 threshold, while B is approaching it.
3. **logP:** Ligand A (3.727) is optimal, while Ligand B (0.109) is quite low. Low logP can hinder membrane permeability. This is a significant advantage for A.
4. **HBD:** Ligand A (2) is preferable to Ligand B (4). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (5) for similar reasons as HBD.
6. **QED:** Ligand A (0.871) is substantially better than Ligand B (0.444), indicating a more drug-like profile.
7. **DILI:** Ligand A (30.322) is much better than Ligand B (2.792). Lower DILI risk is crucial.
8. **BBB:** This is less critical for a cardiovascular target. Ligand A (83.249) is better than Ligand B (23.42), but the difference isn't decisive.
9. **Caco-2:** Ligand A (-4.758) is better than Ligand B (-5.609). Higher Caco-2 permeability is desirable.
10. **Solubility:** Ligand A (-3.654) is better than Ligand B (-0.652). Better solubility aids formulation and bioavailability.
11. **hERG:** Ligand A (0.784) is better than Ligand B (0.252). Lower hERG inhibition is crucial for avoiding cardiotoxicity.
12. **Cl_mic:** Ligand A (22.178) is worse than Ligand B (-21.6). Lower clearance is better for metabolic stability. This is a point in favor of B.
13. **t1/2:** Ligand A (5.008) is better than Ligand B (-4.72). Longer half-life is generally desirable.
14. **Pgp:** Ligand A (0.358) is better than Ligand B (0.005). Lower P-gp efflux is better.
15. **Binding Affinity:** Ligand B (-7.3) is significantly better than Ligand A (-5.6). This is a 1.7 kcal/mol advantage, which is substantial.
**Overall Assessment:**
Ligand B has a significantly better binding affinity. However, it suffers from several ADME drawbacks: very low logP, higher HBD/HBA counts, poor QED, and a concerningly low solubility. Ligand A, while having a weaker binding affinity, is much more balanced across all parameters, with good drug-likeness, solubility, permeability, and safety profiles (DILI, hERG). Given the substantial difference in binding affinity, it is still worth considering Ligand B. However, the ADME liabilities are significant and would likely require substantial medicinal chemistry effort to address. For a first-in-class or early-stage lead, a more balanced profile like Ligand A is preferable.
Output:
1
2025-04-18 00:13:10,454 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (345.403 and 352.435 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (101.22) is slightly higher than Ligand B (87.9). Both are below the 140 threshold for good oral absorption, but B is closer to the preferred <90 for GPCRs.
3. **logP:** Ligand A (1.291) is within the optimal 1-3 range. Ligand B (-0.191) is slightly below 1, which *could* indicate permeability issues. This is a point in favor of A.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Both ligands have 6 HBA, which is good.
6. **QED:** Ligand A (0.811) has a slightly better QED score than Ligand B (0.767), indicating better overall drug-likeness.
7. **DILI:** Ligand B (34.277) has a significantly lower DILI risk than Ligand A (54.207). This is a major advantage for B.
8. **BBB:** Ligand A (64.25) has a slightly better BBB penetration than Ligand B (50.523). While ADRB2 isn't necessarily a CNS target, some peripheral ADRB2 activity can be modulated by CNS effects, and better BBB penetration isn't a major negative.
9. **Caco-2:** Ligand A (-5.024) has a worse Caco-2 permeability than Ligand B (-4.859). Both are negative, indicating poor permeability, but B is better.
10. **Solubility:** Ligand A (-0.868) has slightly worse solubility than Ligand B (0.081). Solubility is important for bioavailability.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.124 and 0.186 respectively). No significant difference.
12. **Cl_mic:** Ligand B (4.595) has significantly lower microsomal clearance than Ligand A (41.66), suggesting better metabolic stability. This is a significant advantage for B.
13. **t1/2:** Ligand A (-27.591) has a significantly longer in vitro half-life than Ligand B (5.688). This is a strong advantage for A.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.024 and 0.068 respectively). No significant difference.
15. **Binding Affinity:** Ligand B (-5.3) has a slightly better binding affinity than Ligand A (-4.4). This is a 0.9 kcal/mol difference, which is substantial and can outweigh some ADME drawbacks.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in TPSA and affinity, and has a better logP. Ligand A has a better half-life, but the metabolic stability of B is a major advantage. The lower DILI risk for B is also very important.
**Overall Assessment:**
While Ligand A has a longer half-life, Ligand B's superior binding affinity, lower DILI risk, better metabolic stability (lower Cl_mic), and better TPSA make it the more promising candidate. The slightly lower logP of B is a minor concern, but the affinity difference and improved safety profile outweigh this.
Output:
0
2025-04-18 00:13:10,454 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (a cardiovascular GPCR) drug candidates.
**Ligand A:** [418.169, 92.18, 2.929, 2, 4, 0.779, 93.098, 53.432, -5.22, -3.547, 0.188, 24.075, -14.067, 0.083, -5.8]
**Ligand B:** [345.407, 90.96, 0.458, 0, 8, 0.677, 73.09, 62.97, -5.011, -1.145, 0.062, 19.67, 29.464, 0.018, -6.6]
**Step-by-step comparison:**
1. **MW:** Ligand A (418.169 Da) is within the ideal range. Ligand B (345.407 Da) is also acceptable, but closer to the lower limit.
2. **TPSA:** Both ligands (A: 92.18, B: 90.96) are below 140, which is good for oral absorption.
3. **logP:** Ligand A (2.929) is optimal. Ligand B (0.458) is a bit low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (2) is good. Ligand B (0) is also acceptable.
5. **HBA:** Ligand A (4) is good. Ligand B (8) is acceptable, but higher.
6. **QED:** Both ligands (A: 0.779, B: 0.677) have good drug-likeness scores.
7. **DILI:** Ligand A (93.098) has a significantly higher DILI risk than Ligand B (73.09). This is a major concern.
8. **BBB:** Ligand A (53.432) has a lower BBB penetration percentile than Ligand B (62.97). While not a primary concern for a cardiovascular target, some CNS exposure is possible with ADRB2.
9. **Caco-2:** Both have negative values, indicating poor permeability.
10. **Solubility:** Both have negative values, indicating poor solubility.
11. **hERG:** Both ligands have very low hERG risk (A: 0.188, B: 0.062).
12. **Cl_mic:** Ligand B (19.67) has a lower microsomal clearance, suggesting better metabolic stability than Ligand A (24.075).
13. **t1/2:** Ligand B (29.464) has a longer in vitro half-life than Ligand A (-14.067). This is a significant advantage.
14. **Pgp:** Both have low Pgp efflux liability (A: 0.083, B: 0.018).
15. **Affinity:** Ligand B (-6.6 kcal/mol) has a slightly better binding affinity than Ligand A (-5.8 kcal/mol).
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand B is better in terms of logP, Pgp, and affinity. While BBB isn't critical for a cardiovascular target, Ligand B has a slightly better score. The biggest drawback for Ligand A is its high DILI risk.
**Conclusion:**
Despite the similar TPSA and QED scores, Ligand B is the more promising candidate. Its better logP, metabolic stability (lower Cl_mic, longer t1/2), slightly better affinity, and significantly lower DILI risk outweigh the slightly lower BBB penetration.
Output:
0
2025-04-18 00:13:10,455 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (369.34 and 364.364 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand B (70.08) is significantly better than Ligand A (127.76). ADRB2 is a cardiovascular target, so BBB isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (0.784) is within the optimal range (1-3), while Ligand A (-1.335) is below 1, potentially hindering permeation. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (5) is at the upper limit, while Ligand B (1) is excellent. Lower HBD is generally preferred for better permeability.
5. **HBA:** Ligand A (5) and Ligand B (4) are both acceptable, below the 10 threshold.
6. **QED:** Ligand B (0.786) is better than Ligand A (0.38), indicating a more drug-like profile.
7. **DILI:** Both ligands have low DILI risk (33.346 and 32.028 percentile), which is good. No significant difference.
8. **BBB:** Not a primary concern for a cardiovascular target. Ligand B (77.084) is higher, but this isn't a deciding factor.
9. **Caco-2:** Ligand B (-4.362) is better than Ligand A (-5.495), indicating better intestinal absorption.
10. **Solubility:** Ligand B (-1.871) is slightly better than Ligand A (-1.679), though both are poor. Solubility is a potential concern for both, but can be addressed with formulation strategies.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.075 and 0.461), which is excellent.
12. **Cl_mic:** Ligand A (10.882) has a lower microsomal clearance than Ligand B (26.982), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-33.995) has a longer in vitro half-life than Ligand A (-21.135), which is desirable.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.008 and 0.021).
15. **Binding Affinity:** Ligand B (-7.3) has slightly better binding affinity than Ligand A (-7.0), but the difference is small.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand B excels in logP and TPSA, and has a slightly better affinity. While metabolic stability (Cl_mic) is important, the benefit of Ligand A in this area is outweighed by the advantages of Ligand B in permeability and drug-likeness.
**Conclusion:**
Ligand B demonstrates a superior balance of properties, particularly regarding permeability (logP, TPSA, Caco-2) and drug-likeness (QED). The slightly better affinity and half-life further support its selection.
Output:
0
2025-04-18 00:13:10,455 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (a cardiovascular GPCR) drug candidates.
**Ligand A:** [355.435, 99.18, -0.641, 2, 5, 0.683, 31.291, 29.74, -5.138, -0.27, 0.063, 2.31, 25.235, 0.016, -6.6]
**Ligand B:** [349.431, 89.43, 0.827, 2, 5, 0.763, 25.165, 67.158, -4.59, -1.93, 0.118, 29.46, -2.105, 0.014, -7]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal 200-500 Da range. Ligand B (349.431) is slightly lower, which is generally favorable.
2. **TPSA:** Ligand A (99.18) is slightly above the preferred <90 for CNS targets, but acceptable for a cardiovascular GPCR. Ligand B (89.43) is better, falling comfortably under 90.
3. **logP:** Ligand A (-0.641) is quite low, potentially hindering membrane permeability. Ligand B (0.827) is much better, falling within the optimal 1-3 range. This is a significant advantage for B.
4. **HBD/HBA:** Both have 2 HBD and 5 HBA, which are acceptable.
5. **QED:** Both have good QED scores (A: 0.683, B: 0.763), indicating drug-likeness. B is slightly better.
6. **DILI:** Ligand A (31.291) has a slightly higher DILI risk than Ligand B (25.165), though both are reasonably low.
7. **BBB:** Not a primary concern for a cardiovascular target. Ligand B (67.158) is higher, but this isn't a deciding factor.
8. **Caco-2:** Both have negative values, which is unusual. Assuming these are percentile scores, both are poor.
9. **Solubility:** Both have negative values, which is unusual. Assuming these are percentile scores, both are poor.
10. **hERG:** Both are very low (A: 0.063, B: 0.118), indicating minimal hERG inhibition risk.
11. **Cl_mic:** Ligand A (2.31) has a significantly lower microsomal clearance than Ligand B (29.46), suggesting better metabolic stability. This is a major advantage for A.
12. **t1/2:** Ligand A (25.235) has a longer in vitro half-life than Ligand B (-2.105), which is favorable.
13. **Pgp:** Both have very low Pgp efflux liability (A: 0.016, B: 0.014), which is good.
14. **Affinity:** Ligand B (-7 kcal/mol) has a slightly better binding affinity than Ligand A (-6.6 kcal/mol). While A is good, the 0.4 kcal/mol difference is noticeable.
**Overall Assessment:**
Ligand B has a significantly better logP, making it more likely to have good permeability. It also has a better TPSA and QED. While Ligand A has better metabolic stability (lower Cl_mic and longer t1/2), the poor logP is a major concern for a GPCR target. The slightly better affinity of Ligand B, combined with its superior ADME properties, outweighs the metabolic advantage of Ligand A.
Output:
0
2025-04-18 00:13:10,455 - INFO - Here's my reasoning and final output for the ligand preference:
**Reasoning:**
We are targeting ADRB2, a GPCR, so the priorities are logP, Pgp, TPSA, affinity, and BBB. Let's break down each ligand:
* **Molecular Weight:** Both are within the ideal range (200-500 Da).
* **TPSA:** Ligand A (91.22) is slightly higher than Ligand B (85.43), but both are acceptable for a non-CNS GPCR target.
* **logP:** Ligand A (2.463) is optimal, while Ligand B (1.371) is a bit low, potentially impacting permeability.
* **H-Bond Donors/Acceptors:** Ligand A (2/4) and Ligand B (3/3) are both within acceptable limits.
* **QED:** Both have good QED scores (A: 0.827, B: 0.706), indicating good drug-like properties.
* **DILI:** Ligand B (21.869) has a significantly lower DILI risk than Ligand A (53.781). This is a major advantage for Ligand B.
* **BBB:** Ligand A (72.237) has better BBB penetration than Ligand B (57.387), but BBB isn't a primary concern for ADRB2, which is primarily cardiovascular.
* **Caco-2:** Ligand B (-5.103) has a more negative Caco-2 value, suggesting better permeability. Ligand A (-4.468) is also reasonable.
* **Solubility:** Ligand B (-3.382) has better solubility than Ligand A (-4.076).
* **hERG:** Both ligands have low hERG inhibition risk (A: 0.524, B: 0.23).
* **Microsomal Clearance:** Ligand B (18.35) has significantly lower microsomal clearance than Ligand A (55.153), indicating better metabolic stability.
* **In vitro Half-Life:** Ligand B (-18.249) has a much longer half-life than Ligand A (-0.23), which is a significant advantage.
* **P-gp Efflux:** Ligand B (0.021) has lower P-gp efflux than Ligand A (0.117), which is favorable for bioavailability.
* **Binding Affinity:** Ligand A (-7.6) has a slightly better binding affinity than Ligand B (-7.0), but the difference is not substantial enough to outweigh the ADME advantages of Ligand B.
**Overall:**
Ligand B demonstrates a superior ADME profile with lower DILI risk, better solubility, significantly improved metabolic stability (lower Cl_mic and longer t1/2), and lower P-gp efflux. While Ligand A has slightly better binding affinity and BBB penetration, the ADME advantages of Ligand B are more critical for overall drug development success, especially considering the target is a cardiovascular GPCR.
**Output:**
0
2025-04-18 00:13:10,455 - INFO - Batch 461 complete. Total preferences: 7376
2025-04-18 00:13:10,455 - INFO - Processing batch 462/512...
2025-04-18 00:13:58,592 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (427.682 Da) is within the ideal range, while Ligand B (347.459 Da) is towards the lower end but still acceptable.
2. **TPSA:** Ligand A (72.68) is good, well below 140. Ligand B (82.53) is also acceptable, but slightly higher.
3. **logP:** Ligand A (4.499) is a bit high, potentially leading to solubility issues and off-target effects. Ligand B (1.847) is excellent, falling right within the optimal range.
4. **HBD:** Ligand A (0) is ideal. Ligand B (2) is still reasonable.
5. **HBA:** Ligand A (5) is good. Ligand B (4) is also good.
6. **QED:** Both ligands have good QED scores (A: 0.385, B: 0.714), with Ligand B being significantly better.
7. **DILI:** Ligand A (80.923) has a concerningly high DILI risk. Ligand B (22.8) has a very low DILI risk, a major advantage.
8. **BBB:** Ligand A (77.549) has good BBB penetration, while Ligand B (69.911) is lower. However, for ADRB2, which is not necessarily a CNS target, BBB isn't a primary concern.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. This is a red flag for both.
10. **Solubility:** Ligand A (-6.818) has very poor predicted solubility, likely due to its high logP. Ligand B (-2.562) is also poor, but better than Ligand A.
11. **hERG:** Both ligands have low hERG risk (A: 0.64, B: 0.354).
12. **Cl_mic:** Ligand A (106.323) has a higher microsomal clearance, indicating lower metabolic stability. Ligand B (50.005) has better metabolic stability.
13. **t1/2:** Ligand A (57.632) has a reasonable half-life, while Ligand B (-1.059) has a very short half-life, which is a significant drawback.
14. **Pgp:** Both ligands have low Pgp efflux (A: 0.468, B: 0.13), which is good.
15. **Affinity:** Both ligands have similar and excellent binding affinities (A: -5.9 kcal/mol, B: -6.1 kcal/mol). Ligand B is slightly better.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. While Ligand A has better BBB penetration, this is less critical for a non-CNS target. Ligand B excels in logP, QED, DILI risk, and metabolic stability. The slightly better affinity of Ligand B is a bonus. The biggest concern with Ligand A is its high DILI risk and poor solubility.
**Conclusion:**
Despite Ligand A's better BBB penetration and reasonable half-life, Ligand B is the more promising candidate due to its significantly lower DILI risk, better QED, improved logP, and better metabolic stability. The similar affinities make the ADME properties the deciding factors.
Output:
0
2025-04-18 00:13:58,593 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (354.491 & 368.499 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (98.66) is slightly higher than Ligand B (86.71). Both are below the 140 threshold for good oral absorption, but closer to the 90 threshold for CNS targets, which isn't a primary concern for ADRB2 (cardiovascular). Ligand B is preferable here.
3. **logP:** Ligand A (1.203) is within the optimal range (1-3), while Ligand B (0.575) is slightly below. While still acceptable, lower logP can sometimes indicate permeability issues. Ligand A is preferable.
4. **HBD:** Ligand A (4) is higher than Ligand B (2). Lower is generally better, but both are within the acceptable limit of 5. Ligand B is preferable.
5. **HBA:** Both ligands have 4 HBA, which is well within the acceptable range of 10. No difference.
6. **QED:** Ligand B (0.695) has a slightly better QED score than Ligand A (0.526), indicating a more drug-like profile. Ligand B is preferable.
7. **DILI:** Ligand A (8.298%) has a significantly lower DILI risk than Ligand B (55.952%). This is a major advantage for Ligand A.
8. **BBB:** Both ligands have low BBB penetration, which is not a major concern for a cardiovascular target like ADRB2. Ligand B (45.366%) is slightly higher than Ligand A (40.093%), but the difference is not significant.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. Ligand B (-4.812) is slightly better than Ligand A (-5.08), but both are problematic.
10. **Solubility:** Ligand B (-3.11) has slightly better solubility than Ligand A (-2.561), but both are poor.
11. **hERG:** Ligand A (0.117) has a lower hERG inhibition liability than Ligand B (0.338), which is a significant safety advantage.
12. **Cl_mic:** Ligand A (21.892) has a lower microsomal clearance than Ligand B (35.167), suggesting better metabolic stability. This is a positive for Ligand A.
13. **t1/2:** Ligand B (-43.697) has a much longer in vitro half-life than Ligand A (-3.861). This is a substantial advantage for Ligand B.
14. **Pgp:** Ligand A (0.032) has lower P-gp efflux liability than Ligand B (0.121), which is preferable.
15. **Binding Affinity:** Ligand B (-7.2) has a significantly stronger binding affinity than Ligand A (-2.8). This is a substantial advantage for Ligand B, and can often outweigh minor ADME drawbacks.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand B excels in affinity and has a better TPSA. Ligand A has a better logP and Pgp.
**Overall Assessment:**
While Ligand A has advantages in DILI risk, hERG, Cl_mic, and Pgp, the significantly stronger binding affinity of Ligand B (-7.2 vs -2.8) and its longer half-life are compelling. The DILI and hERG concerns with Ligand B are manageable with further optimization, but a substantial potency difference is harder to overcome. The slightly better QED of Ligand B also contributes to its overall favorability. The poor Caco-2 values for both are a concern that would need to be addressed in further development, but the potency advantage of Ligand B is more critical at this stage.
Output:
0
2025-04-18 00:13:58,593 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (360.401 and 349.435 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (67.87) is better than Ligand B (80.56). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally favors absorption.
3. **logP:** Ligand A (1.153) is slightly better than Ligand B (0.704), both are within the optimal 1-3 range.
4. **HBD:** Ligand A (1) is better than Ligand B (0). While both are acceptable, a single HBD can sometimes improve solubility without drastically impacting permeability.
5. **HBA:** Ligand A (4) is better than Ligand B (6). Lower HBA is preferred for better permeability.
6. **QED:** Both ligands (0.799 and 0.782) have excellent drug-likeness scores. No significant difference.
7. **DILI:** Ligand A (44.707) is slightly better than Ligand B (49.942), both are below the concerning 60 threshold.
8. **BBB:** Ligand A (87.01) is better than Ligand B (72.082). While not critical for a cardiovascular target, higher BBB is generally favorable.
9. **Caco-2:** Ligand A (-4.479) is better than Ligand B (-4.704). Both are negative, indicating poor permeability, but A is slightly better.
10. **Solubility:** Ligand A (-1.994) is better than Ligand B (-1.57). Both are poor, but A is slightly better.
11. **hERG:** Ligand A (0.384) is better than Ligand B (0.25). Lower hERG inhibition is crucial for avoiding cardiotoxicity, making A preferable.
12. **Cl_mic:** Ligand A (15.651) is significantly better than Ligand B (28.05). Lower clearance indicates better metabolic stability, a key factor for drug duration.
13. **t1/2:** Ligand A (-9.489) is significantly better than Ligand B (2.212). A longer half-life is generally desirable.
14. **Pgp:** Ligand A (0.035) is significantly better than Ligand B (0.139). Lower P-gp efflux is beneficial for bioavailability.
15. **Binding Affinity:** Ligand B (-7.2) is significantly better than Ligand A (-6.3). This is a substantial difference (0.9 kcal/mol), and affinity is a primary driver for GPCR drug candidates.
**Overall Assessment:**
While Ligand B has a superior binding affinity, Ligand A demonstrates a much more favorable ADMET profile. Specifically, the lower DILI, better metabolic stability (lower Cl_mic and longer t1/2), lower P-gp efflux, and lower hERG risk are substantial advantages. The affinity difference, while significant, can potentially be addressed through further optimization, while fixing poor ADMET properties is often more challenging. Considering the cardiovascular target, minimizing off-target effects (like hERG inhibition) and ensuring reasonable metabolic stability are crucial.
Output:
1
2025-04-18 00:13:58,593 - INFO - Reasoning:
Let's analyze both ligands against the provided guidelines, prioritizing GPCR-relevant parameters.
**Ligand A:**
* **MW:** 350.419 Da - Good.
* **TPSA:** 94.9 A^2 - Acceptable, though approaching the upper limit for good absorption.
* **logP:** -0.505 - Low. Could hinder permeability.
* **HBD:** 1 - Good.
* **HBA:** 6 - Good.
* **QED:** 0.734 - Excellent.
* **DILI:** 36.681 - Very good, low risk.
* **BBB:** 45.56 - Moderate. Not ideal for a CNS target, but acceptable for a peripheral GPCR like ADRB2.
* **Caco-2:** -4.995 - Poor permeability. A significant concern.
* **Solubility:** -0.716 - Poor solubility.
* **hERG:** 0.163 - Very low risk. Excellent.
* **Cl_mic:** -28.989 - Excellent metabolic stability.
* **t1/2:** 30.318 - Good in vitro half-life.
* **Pgp:** 0.01 - Very low efflux. Good.
* **Affinity:** -6.0 kcal/mol - Good binding affinity.
**Ligand B:**
* **MW:** 337.335 Da - Good.
* **TPSA:** 104.46 A^2 - Slightly higher than ideal, could impact absorption.
* **logP:** 1.196 - Good.
* **HBD:** 3 - Good.
* **HBA:** 5 - Good.
* **QED:** 0.727 - Excellent.
* **DILI:** 64.521 - Moderate risk. Higher than Ligand A.
* **BBB:** 24.855 - Low. Not a concern for ADRB2.
* **Caco-2:** -5.126 - Poor permeability. Similar to Ligand A.
* **Solubility:** -3.958 - Poor solubility.
* **hERG:** 0.144 - Very low risk. Excellent.
* **Cl_mic:** -28.535 - Excellent metabolic stability.
* **t1/2:** 28.545 - Good in vitro half-life.
* **Pgp:** 0.024 - Very low efflux. Good.
* **Affinity:** -7.5 kcal/mol - Excellent binding affinity. Significantly better than Ligand A.
**Comparison & Decision:**
Both ligands suffer from poor Caco-2 permeability and solubility, which are significant drawbacks. However, Ligand B possesses a substantially better binding affinity (-7.5 kcal/mol vs -6.0 kcal/mol). For a GPCR target, affinity is paramount, and a 1.5 kcal/mol difference is substantial enough to potentially overcome the permeability/solubility issues, especially considering the target is ADRB2 (not a CNS target, so BBB is less critical). Ligand A has a slightly better DILI score, but Ligand B's DILI is still within an acceptable range. The metabolic stability and P-gp efflux are comparable between the two.
Therefore, I prioritize Ligand B due to its superior binding affinity.
Output:
0
2025-04-18 00:13:58,593 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (412.324 Da) is within the ideal range, while Ligand B (358.463 Da) is also good. No clear advantage here.
2. **TPSA:** Ligand A (64.63) is better than Ligand B (49.85). Both are well below the 140 threshold for oral absorption, but lower TPSA is generally preferred for GPCRs, aiding in membrane permeability.
3. **logP:** Ligand A (3.628) is optimal, while Ligand B (1.702) is on the lower side, potentially hindering membrane permeability. This is a significant advantage for Ligand A.
4. **HBD:** Ligand A (1) is better than Ligand B (0). Lower is generally preferred.
5. **HBA:** Both Ligand A (4) and Ligand B (4) are acceptable.
6. **QED:** Both Ligand A (0.695) and Ligand B (0.608) are above the 0.5 threshold, indicating good drug-likeness. Ligand A is slightly better.
7. **DILI:** Both Ligand A (37.03) and Ligand B (39.434) have low DILI risk, both under 40. No significant difference.
8. **BBB:** Both Ligand A (73.672) and Ligand B (74.564) have good BBB penetration. No significant difference.
9. **Caco-2:** Both Ligand A (-4.534) and Ligand B (-4.683) have similar Caco-2 permeability.
10. **Solubility:** Ligand A (-4.222) is slightly better than Ligand B (-2.875).
11. **hERG:** Both Ligand A (0.387) and Ligand B (0.58) have low hERG inhibition liability. No significant difference.
12. **Cl_mic:** Ligand A (110.867) has a higher microsomal clearance than Ligand B (45.493), indicating lower metabolic stability. This is a disadvantage for Ligand A.
13. **t1/2:** Ligand A (6.949) has a longer half-life than Ligand B (0.729). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.39) has lower P-gp efflux liability than Ligand B (0.486). This is a slight advantage for Ligand A.
15. **Binding Affinity:** Ligand A (-6.4 kcal/mol) is slightly weaker than Ligand B (-5.7 kcal/mol). However, the difference is not substantial enough to outweigh the other advantages of Ligand A.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand A emerges as the more promising candidate. It has a better logP, lower Pgp efflux, and a lower TPSA. While its metabolic stability (Cl_mic) is a concern, its longer half-life partially mitigates this. The binding affinity difference is not large enough to favor Ligand B, especially given the superior ADME properties of Ligand A.
Output:
1
2025-04-18 00:13:58,593 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
We are targeting ADRB2, a GPCR. Therefore, priorities are logP, Pgp, TPSA, affinity, and BBB. Let's analyze each ligand against these and other important parameters:
1. **Molecular Weight:** Both ligands (360.479 and 359.447 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (62.55) is better than Ligand B (64.63). Both are reasonably low, suggesting good potential for cell permeability, but A is slightly favored.
3. **logP:** Ligand A (3.496) is within the optimal 1-3 range. Ligand B (4.34) is a bit higher, potentially leading to solubility issues and off-target interactions, though not drastically so. A is favored.
4. **H-Bond Donors/Acceptors:** Both have 1 HBD, which is good. Ligand A has 4 HBA, and Ligand B has 5. Both are acceptable, but A is slightly better.
5. **QED:** Ligand A (0.908) has a significantly better QED score than Ligand B (0.588), indicating a more drug-like profile. This is a substantial advantage for A.
6. **DILI:** Ligand A (63.978) has a lower DILI risk than Ligand B (82.125). This is a significant advantage for A, as lower DILI is crucial.
7. **BBB:** Ligand A (70.376) has a better BBB penetration percentile than Ligand B (57.154). While not a primary concern for all GPCRs, it's a positive attribute, especially if some CNS off-target effects are a concern.
8. **Caco-2 Permeability:** Both are negative, indicating poor permeability. Ligand A (-5.026) is slightly better than Ligand B (-4.772), but both are problematic.
9. **Aqueous Solubility:** Ligand A (-4.186) is better than Ligand B (-5.843). Both are poor, but A is less poor.
10. **hERG Inhibition:** Ligand A (0.433) has a lower hERG inhibition liability than Ligand B (0.722). This is a significant safety advantage for A.
11. **Microsomal Clearance:** Ligand A (56.348) has a lower microsomal clearance than Ligand B (114.822), indicating better metabolic stability. This is a substantial advantage for A.
12. **In vitro Half-Life:** Ligand A (31.511) has a significantly longer in vitro half-life than Ligand B (1.045). This is a major advantage for A, suggesting less frequent dosing potential.
13. **P-gp Efflux:** Ligand A (0.569) has lower P-gp efflux liability than Ligand B (0.343). This is a positive attribute for A.
14. **Binding Affinity:** Ligand B (-7.6 kcal/mol) has a slightly better binding affinity than Ligand A (-7.2 kcal/mol). While a 0.4 kcal/mol difference is noticeable, it's unlikely to overcome the numerous advantages of Ligand A, especially given the other ADME properties.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical ADME properties (QED, DILI, BBB, solubility, hERG, clearance, half-life, P-gp efflux). While Ligand B has a slightly better binding affinity, the superior overall profile of Ligand A makes it the more promising drug candidate for ADRB2. The better ADME profile will likely translate to better *in vivo* efficacy and safety.
**Output:**
1
2025-04-18 00:13:58,593 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (385.873) is slightly higher than Ligand B (350.419), but both are acceptable.
2. **TPSA:** Both are reasonably good, but Ligand A (95.58) is better than Ligand B (103.71). For a cardiovascular GPCR, TPSA is not a major concern, but lower is generally preferred.
3. **logP:** Both ligands have good logP values (A: 1.127, B: 0.82), falling within the optimal 1-3 range.
4. **HBD:** Ligand A (2) is slightly better than Ligand B (1). Both are within the acceptable limit of 5.
5. **HBA:** Ligand A (5) is acceptable, while Ligand B (7) is a bit higher. Keeping HBA lower than 10 is good for permeability.
6. **QED:** Both ligands have good QED scores (A: 0.757, B: 0.857), indicating good drug-like properties. Ligand B is slightly better here.
7. **DILI:** Ligand A (67.313) has a higher DILI risk than Ligand B (15.82). This is a significant advantage for Ligand B.
8. **BBB:** Ligand B (74.758) has significantly better BBB penetration potential than Ligand A (60.644). While ADRB2 isn't strictly a CNS target, some CNS exposure can occur, and higher BBB is generally favorable.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-5.024) is slightly better than Ligand B (-5.252), but both are problematic.
10. **Solubility:** Both ligands have poor aqueous solubility (A: -3.726, B: -1.305). Ligand B is better, but both are concerning.
11. **hERG:** Both have very low hERG inhibition risk (A: 0.086, B: 0.171). This is excellent for both.
12. **Cl_mic:** Ligand A (-16.853) has a significantly lower (better) microsomal clearance than Ligand B (-9.016), indicating better metabolic stability.
13. **t1/2:** Ligand B (9.385) has a much longer in vitro half-life than Ligand A (0.135). This is a major advantage for Ligand B.
14. **Pgp:** Both ligands have low P-gp efflux liability (A: 0.082, B: 0.011). Ligand B is slightly better.
15. **Binding Affinity:** Ligand A (-7.0) has slightly better binding affinity than Ligand B (-6.8). However, the difference is small (0.2 kcal/mol).
**Overall Assessment & GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Both ligands perform reasonably well on logP and Pgp. Ligand A has a slightly better TPSA and a marginally better binding affinity. However, Ligand B excels in crucial ADME properties: significantly lower DILI risk, better BBB penetration, and a much longer half-life. The poor Caco-2 and solubility are concerning for both, but the improved metabolic stability and reduced toxicity of Ligand B outweigh the small affinity difference.
**Output:**
0
2025-04-18 00:13:58,593 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.41 and 346.471 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (87.47) is better than Ligand B (49.85). For a cardiovascular GPCR, TPSA is not a major concern, but lower is generally preferred for permeability.
3. **logP:** Ligand B (2.482) is slightly better than Ligand A (0.905). Both are within the optimal 1-3 range, but Ligand B is closer to the upper end, which is generally favorable for GPCRs. Ligand A is a bit low.
4. **HBD:** Ligand A (2) is better than Ligand B (0). Having some HBDs can help with solubility.
5. **HBA:** Ligand A (5) is better than Ligand B (3). Similar to HBD, a moderate number of HBAs is beneficial.
6. **QED:** Both ligands are very similar (0.794 and 0.786), indicating good drug-like properties.
7. **DILI:** Ligand A (36.293) has a significantly higher DILI risk than Ligand B (17.642). This is a major concern, as minimizing liver toxicity is crucial.
8. **BBB:** Both ligands have good BBB penetration (83.288 and 84.141). This isn't a primary concern for a cardiovascular target, but it doesn't hurt.
9. **Caco-2:** Ligand A (-5.187) is worse than Ligand B (-4.605). Lower values are less favorable.
10. **Solubility:** Ligand A (-1.779) is worse than Ligand B (-2.21). Lower values are less favorable.
11. **hERG:** Ligand A (0.5) is better than Ligand B (0.283). Lower hERG inhibition is preferred.
12. **Cl_mic:** Ligand A (12.192) is much better than Ligand B (29.196). Lower clearance indicates better metabolic stability, a key factor for drug duration.
13. **t1/2:** Ligand A (10.781) is similar to Ligand B (11.642).
14. **Pgp:** Ligand A (0.061) is much better than Ligand B (0.11). Lower P-gp efflux is favorable for bioavailability.
15. **Affinity:** Ligand B (-7.4) is 0.5 kcal/mol better than Ligand A (-6.9). This is a substantial difference in binding affinity.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are important. Ligand B has a better logP and affinity. Ligand A has a better TPSA, but the difference is not significant enough to outweigh the other factors.
**Overall Assessment:**
While Ligand A has some advantages in terms of H-bonding and hERG, the significantly higher DILI risk and worse metabolic stability (higher Cl_mic) are major drawbacks. Ligand B's superior binding affinity and lower DILI risk make it the more promising candidate, despite slightly lower TPSA and Pgp. The 0.5 kcal/mol difference in binding affinity is significant and can outweigh the minor ADME drawbacks.
Output:
0
2025-04-18 00:13:58,593 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
The ADRB2 receptor is a GPCR, so the priorities are logP, TPSA, Pgp efflux, BBB penetration, and binding affinity. Metabolic stability (Cl_mic, t1/2) and safety (DILI, hERG) are also important.
Let's compare the ligands property by property:
1. **MW:** Both ligands (376.563 and 368.821 Da) are within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (75.71) is better than Ligand B (93.62). Lower TPSA generally improves oral absorption, and is important for GPCRs.
3. **logP:** Both ligands have good logP values (2.253 and 1.623), falling within the optimal 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability.
4. **HBD/HBA:** Both have 1 HBD, which is good. Ligand A has 4 HBA, and Ligand B has 7. Ligand A is better here.
5. **QED:** Both ligands have similar QED values (0.705 and 0.761), indicating good drug-likeness.
6. **DILI:** Ligand A (23.769) has a significantly lower DILI risk than Ligand B (35.789), which is a major advantage.
7. **BBB:** Ligand A (80.613) has better BBB penetration than Ligand B (70.182), which is beneficial for a GPCR target.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual. However, the magnitude is similar.
9. **Solubility:** Both have negative solubility values, which is also unusual. The magnitude is similar.
10. **hERG:** Ligand A (0.619) has a lower hERG risk than Ligand B (0.345), which is a safety advantage.
11. **Cl_mic:** Ligand A (72.117) has higher microsomal clearance than Ligand B (31.839), indicating lower metabolic stability. This is a drawback for Ligand A.
12. **t1/2:** Ligand B (52.438) has a longer in vitro half-life than Ligand A (-32.559), which is a significant advantage.
13. **Pgp:** Ligand A (0.031) has a lower Pgp efflux liability than Ligand B (0.195), which is favorable.
14. **Binding Affinity:** Both ligands have very similar binding affinities (-6.4 and -6.1 kcal/mol). The difference is not substantial enough to be a deciding factor.
**Overall Assessment:**
Ligand A has advantages in TPSA, DILI, BBB, hERG, and Pgp efflux. Ligand B has a better half-life and lower Cl_mic. The lower DILI and better BBB penetration of Ligand A are particularly important for a GPCR target. While the lower metabolic stability of Ligand A is a concern, the other advantages outweigh this drawback, especially considering the similar binding affinities.
**Output:**
1
2025-04-18 00:13:58,594 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (366.405 and 356.467 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (96.89) is better than Ligand B (133.55). ADRB2 is not a CNS target, but lower TPSA generally improves absorption.
3. **logP:** Ligand A (1.439) is within the optimal range (1-3), while Ligand B (0.387) is slightly below, potentially impacting permeability.
4. **HBD:** Ligand A (3) and Ligand B (5) are both acceptable, but Ligand A is preferable.
5. **HBA:** Ligand A (5) and Ligand B (4) are both acceptable.
6. **QED:** Ligand A (0.604) is significantly better than Ligand B (0.382), indicating a more drug-like profile.
7. **DILI:** Ligand A (17.642) has a much lower DILI risk than Ligand B (10.818). This is a major advantage for Ligand A.
8. **BBB:** Not a primary concern for ADRB2 (cardiovascular target). Ligand A (68.67) is better than Ligand B (58.666), but this is less critical.
9. **Caco-2:** Ligand A (-4.515) is better than Ligand B (-5.497). Higher Caco-2 values indicate better intestinal absorption.
10. **Solubility:** Ligand A (-1.734) is better than Ligand B (-1.573).
11. **hERG:** Ligand A (0.386) is better than Ligand B (0.191), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand A (42.842) is worse than Ligand B (-2.684). Ligand B has a negative value, indicating greater metabolic stability.
13. **t1/2:** Ligand A (-45.151) is worse than Ligand B (-6.087). Ligand B has a longer in vitro half-life.
14. **Pgp:** Ligand A (0.022) is better than Ligand B (0.013), indicating lower P-gp efflux.
15. **Binding Affinity:** Ligand A (-6.4) is slightly better than Ligand B (-5.5).
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A performs better in logP, TPSA, and Pgp. The affinity difference is small.
**Overall Assessment:**
Ligand A has a significantly better safety profile (lower DILI, lower hERG), better drug-likeness (higher QED), and better absorption/permeability characteristics (TPSA, Caco-2, Solubility). While Ligand B has better metabolic stability (Cl_mic, t1/2), the other advantages of Ligand A outweigh this. The slightly better binding affinity of Ligand A is also a plus.
Output:
1
2025-04-18 00:13:58,594 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (366.799 and 373.425 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (72.11) is significantly better than Ligand B (91.32). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (3.21) is slightly higher than Ligand B (1.791), both are within the optimal 1-3 range. Ligand A is preferable.
4. **HBD:** Ligand A (1) is better than Ligand B (3). Lower HBD is generally preferred for better permeability.
5. **HBA:** Ligand A (4) is better than Ligand B (5). Lower HBA is generally preferred for better permeability.
6. **QED:** Ligand A (0.905) is significantly better than Ligand B (0.606), indicating a more drug-like profile.
7. **DILI:** Ligand B (52.656) has a lower DILI risk than Ligand A (61.07), which is a significant advantage.
8. **BBB:** Ligand A (86.545) has better BBB penetration than Ligand B (67.352). While not crucial for a cardiovascular target, it's a slight positive.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. Ligand A (-4.915) is slightly better than Ligand B (-5.027).
10. **Solubility:** Ligand A (-4.155) is slightly better than Ligand B (-2.569), indicating better aqueous solubility.
11. **hERG:** Ligand A (0.567) has a lower hERG risk than Ligand B (0.299), which is a significant advantage.
12. **Cl_mic:** Ligand A (10.418) has a significantly lower microsomal clearance than Ligand B (21.887), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-13.678) has a more negative in vitro half-life than Ligand B (-6.738), indicating a shorter half-life. This is a disadvantage for Ligand A.
14. **Pgp:** Ligand A (0.094) has lower P-gp efflux than Ligand B (0.059), which is a slight advantage.
15. **Binding Affinity:** Ligand B (-7.9) has a significantly stronger binding affinity than Ligand A (-5.8). This is a substantial advantage and can often outweigh other drawbacks.
**Overall Assessment:**
Ligand B has a significantly better binding affinity (-7.9 kcal/mol vs -5.8 kcal/mol), which is a critical factor for GPCR targets. While Ligand A has advantages in several ADME properties (TPSA, logP, QED, DILI, hERG, Cl_mic), the substantial difference in binding affinity is the deciding factor. The lower DILI risk of Ligand B is also a significant positive. Although Ligand A has a slightly better solubility, the difference is not enough to offset the potency advantage of Ligand B.
Output:
0
2025-04-18 00:13:58,594 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (335.451) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (39.08) is significantly better than Ligand B (93.53). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand B's TPSA is quite high.
3. **logP:** Ligand A (4.294) is higher than Ligand B (0.647). While 4.294 is approaching the upper limit, it's still acceptable. Ligand B's logP is quite low, potentially hindering membrane permeability.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A (4) is better than Ligand B (6). Lower HBA is generally preferred for permeability.
6. **QED:** Both ligands have similar QED values (0.7 and 0.76), indicating good drug-likeness.
7. **DILI:** Ligand A (37.611) has a slightly higher DILI risk than Ligand B (31.718), but both are below the 40 threshold and considered good.
8. **BBB:** Both have moderate BBB penetration, but Ligand B (63.358) is slightly higher than Ligand A (55.176). This isn't a major factor for a cardiovascular target.
9. **Caco-2:** Ligand A (-5.135) is better than Ligand B (-4.633) indicating better intestinal absorption.
10. **Solubility:** Ligand A (-4.187) is better than Ligand B (-1.238), suggesting better aqueous solubility.
11. **hERG:** Ligand A (0.929) is better than Ligand B (0.305), indicating lower hERG inhibition liability and reduced cardiotoxicity risk.
12. **Cl_mic:** Ligand B (42.187) has lower microsomal clearance than Ligand A (60.467), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-11.24) has a longer in vitro half-life than Ligand A (-10.368), which is desirable.
14. **Pgp:** Ligand A (0.806) is better than Ligand B (0.034), indicating lower P-gp efflux.
15. **Affinity:** Ligand A (-6.2 kcal/mol) has a slightly better binding affinity than Ligand B (-5.4 kcal/mol).
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A excels in logP, TPSA, and Pgp. While the affinity difference isn't huge, it favors Ligand A. Ligand B has better metabolic stability (Cl_mic) and half-life, but the overall profile of Ligand A is more favorable considering the balance of properties.
**Conclusion:**
Considering the balance of properties, especially the favorable TPSA, logP, Pgp, solubility, and hERG profile, Ligand A appears to be the more promising drug candidate for the ADRB2 receptor.
Output:
1
2025-04-18 00:13:58,594 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (352.431 Da and 365.861 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (92.01) is slightly higher than Ligand B (78.45). For a cardiovascular GPCR, TPSA is moderately important, and lower is generally better for permeability. Ligand B has a clear advantage.
**3. logP:** Both ligands have good logP values (1.413 and 1.759, respectively), falling within the optimal 1-3 range. Ligand B is slightly more lipophilic, which could aid membrane permeability.
**4. H-Bond Donors:** Both ligands have 2 HBD, which is within the acceptable limit of <=5.
**5. H-Bond Acceptors:** Ligand A has 5 HBA, and Ligand B has 4. Both are under the 10 limit.
**6. QED:** Both ligands have acceptable QED values (0.664 and 0.753), indicating good drug-like properties. Ligand B is slightly better.
**7. DILI Risk:** Ligand A (15.083 percentile) has a significantly lower DILI risk than Ligand B (52.889 percentile). This is a major advantage for Ligand A.
**8. BBB Penetration:** Ligand A (62.544 percentile) has better BBB penetration than Ligand B (48.352 percentile). While ADRB2 is primarily a cardiovascular target, some CNS effects are possible with certain ligands, and better BBB penetration isn't necessarily a negative.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.561 and -4.835). These values are unusual and suggest poor permeability. However, the scale is not specified, so it's difficult to interpret the absolute impact.
**10. Aqueous Solubility:** Ligand A (-1.719) has slightly better aqueous solubility than Ligand B (-3.102).
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (0.314 and 0.439).
**12. Microsomal Clearance:** Ligand B (18.244 mL/min/kg) has significantly lower microsomal clearance than Ligand A (31.029 mL/min/kg), indicating better metabolic stability. This is a significant advantage for Ligand B.
**13. In vitro Half-Life:** Ligand A (27.491 hours) has a much longer in vitro half-life than Ligand B (8.77 hours). This is a major advantage for Ligand A.
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (0.091 and 0.268).
**15. Binding Affinity:** Ligand B (-6.3 kcal/mol) has a stronger binding affinity than Ligand A (-5.5 kcal/mol). This is a substantial advantage for Ligand B (a difference of 0.8 kcal/mol).
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand B appears slightly better. It has a lower TPSA, slightly higher logP, and significantly better binding affinity. However, Ligand A has a much lower DILI risk and a significantly longer half-life. The lower DILI risk and longer half-life are crucial factors for drug development. While the affinity difference is notable, it's not so large that it completely outweighs the safety and PK advantages of Ligand A.
Therefore, I prefer Ligand A.
Output:
1
2025-04-18 00:13:58,594 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**1. Molecular Weight:** Both ligands (350.419 and 356.451 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand B (83.98) is significantly better than Ligand A (111.53). For a GPCR, lower TPSA is generally preferred for better permeability.
**3. logP:** Ligand B (2.415) is optimal, while Ligand A (-0.061) is quite low. This is a major concern for Ligand A, as it may struggle with membrane permeability.
**4. H-Bond Donors:** Both ligands have 2 HBD, which is within the acceptable limit of 5.
**5. H-Bond Acceptors:** Both ligands have 5 HBA, which is within the acceptable limit of 10.
**6. QED:** Ligand B (0.862) has a higher QED score than Ligand A (0.668), indicating a more drug-like profile.
**7. DILI:** Ligand A (21.908) has a much lower DILI risk than Ligand B (70.182). This is a significant advantage for Ligand A.
**8. BBB:** Ligand A (58.278) has a slightly better BBB penetration than Ligand B (49.011), but neither are particularly high. For ADRB2, which is not necessarily a CNS target, this is not a primary concern.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, indicating poor permeability. However, Ligand B (-5.367) is slightly better than Ligand A (-4.971).
**10. Aqueous Solubility:** Ligand A (-1.362) has better solubility than Ligand B (-3.192).
**11. hERG Inhibition:** Ligand A (0.073) has a lower hERG risk than Ligand B (0.136).
**12. Microsomal Clearance:** Ligand A (-6.492) has significantly lower (better) microsomal clearance than Ligand B (-0.307), suggesting better metabolic stability.
**13. In vitro Half-Life:** Ligand A (17.3) has a shorter half-life than Ligand B (25.411).
**14. P-gp Efflux:** Ligand A (0.009) has much lower P-gp efflux than Ligand B (0.063), which is favorable for bioavailability.
**15. Binding Affinity:** Ligand A (-7.1) has slightly better binding affinity than Ligand B (-6.5). While both are good, the 1.5 kcal/mol difference is noteworthy.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand A is the better candidate. While Ligand B has a better QED and slightly better Caco-2 permeability, the significantly lower logP of Ligand A is a major drawback. The superior affinity of Ligand A, combined with its lower DILI risk, better metabolic stability (lower Cl_mic), and lower P-gp efflux, outweigh the slightly shorter half-life and lower BBB penetration. The lower TPSA of Ligand B is beneficial, but the logP issue is more critical.
Output:
1
2025-04-18 00:13:58,594 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [346.515, 61.36, 2.926, 3, 3, 0.742, 15.161, 63.94, -4.707, -2.927, 0.59, 57.857, 4.869, 0.25, -7.3]**
**Ligand B: [352.475, 78.87, 2.155, 2, 4, 0.743, 23.497, 40.83, -5.138, -2.344, 0.167, 3.235, -12.194, 0.093, -5.9]**
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). A (346.5) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (61.36) is better than Ligand B (78.87). ADRB2 is not a CNS target, but lower TPSA generally improves absorption.
3. **logP:** Both ligands have good logP values (A: 2.926, B: 2.155), falling within the optimal 1-3 range. A is slightly higher, which could be a minor advantage.
4. **H-Bond Donors:** Ligand A (3) is slightly higher than Ligand B (2), but both are acceptable (<=5).
5. **H-Bond Acceptors:** Ligand B (4) is slightly higher than Ligand A (3), but both are acceptable (<=10).
6. **QED:** Both ligands have similar QED values (A: 0.742, B: 0.743), indicating good drug-like properties.
7. **DILI:** Ligand A (15.161) has a significantly lower DILI risk than Ligand B (23.497). This is a crucial advantage.
8. **BBB:** This is less critical for ADRB2 (a cardiovascular target), but Ligand A (63.94) is better than Ligand B (40.83).
9. **Caco-2:** Ligand A (-4.707) is better than Ligand B (-5.138), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-2.927) is better than Ligand B (-2.344), indicating better solubility.
11. **hERG:** Ligand A (0.59) is better than Ligand B (0.167), indicating a lower risk of cardiotoxicity. This is *very* important for a cardiovascular target.
12. **Cl_mic:** Ligand B (3.235) has significantly lower microsomal clearance than Ligand A (57.857), suggesting better metabolic stability. This is a significant advantage for B.
13. **t1/2:** Ligand B (-12.194) has a much longer in vitro half-life than Ligand A (4.869). This is a major advantage for B, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.25) is better than Ligand B (0.093), indicating lower P-gp efflux.
15. **Binding Affinity:** Ligand A (-7.3) has a significantly stronger binding affinity than Ligand B (-5.9). This is a substantial advantage, potentially outweighing some ADME concerns.
**Overall Assessment:**
Ligand A has a significantly better binding affinity and lower DILI and hERG risk, which are critical for a cardiovascular drug. It also has better solubility, Caco-2 permeability, and Pgp efflux. However, Ligand B has much better metabolic stability (lower Cl_mic and longer t1/2). The difference in binding affinity (-1.4 kcal/mol) is substantial enough to favor Ligand A, especially given the lower safety liabilities.
Output:
1
2025-04-18 00:13:58,594 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [360.483, 78.09, 2.048, 2, 4, 0.828, 44.048, 39.473, -5.628, -2.738, 0.226, 25.87, -6.579, 0.102, -5.7]**
**Ligand B: [371.503, 86.79, -0.025, 1, 4, 0.736, 20.396, 56.456, -5.027, -1.03, 0.048, 21.439, -5.831, 0.014, -6.6]**
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). A (360.483) is slightly preferred.
2. **TPSA:** Both are reasonably low, but A (78.09) is better than B (86.79) for potential oral absorption, aligning with GPCR preferences.
3. **logP:** A (2.048) is optimal. B (-0.025) is quite low, potentially hindering membrane permeability. This is a significant drawback.
4. **H-Bond Donors:** Both have acceptable numbers (A: 2, B: 1). B is slightly better.
5. **H-Bond Acceptors:** Both are equal (4).
6. **QED:** A (0.828) is better than B (0.736), indicating a more drug-like profile.
7. **DILI:** A (44.048) is better than B (20.396), indicating a lower risk of drug-induced liver injury.
8. **BBB:** B (56.456) is better than A (39.473). While ADRB2 isn't exclusively a CNS target, some CNS penetration can be beneficial, and this is a GPCR priority.
9. **Caco-2 Permeability:** A (-5.628) is worse than B (-5.027), indicating lower intestinal absorption.
10. **Aqueous Solubility:** B (-1.03) is better than A (-2.738).
11. **hERG Inhibition:** Both are very low, indicating minimal cardiotoxicity risk. A (0.226) is slightly better than B (0.048).
12. **Microsomal Clearance:** B (21.439) is lower than A (25.87), suggesting better metabolic stability.
13. **In vitro Half-Life:** A (-6.579) is better than B (-5.831), indicating a longer half-life.
14. **P-gp Efflux:** A (0.102) is better than B (0.014), suggesting less P-gp mediated efflux.
15. **Binding Affinity:** B (-6.6) is slightly better than A (-5.7), but the difference is not substantial enough to overcome other significant drawbacks.
**Overall Assessment:**
Ligand A has a better overall profile, despite the slightly worse Caco-2 permeability. Its superior logP, QED, DILI, and P-gp efflux properties are crucial for oral bioavailability and safety. While Ligand B has better BBB penetration and metabolic stability, its very low logP is a major concern for permeability and absorption. The slightly better affinity of B is not enough to offset the significant ADME liabilities.
Output:
1
2025-04-18 00:13:58,594 - INFO - Batch 462 complete. Total preferences: 7392
2025-04-18 00:13:58,594 - INFO - Processing batch 463/512...
2025-04-18 00:14:47,707 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (341.367 and 344.415 Da) fall comfortably within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Both are around 92, which is acceptable, but slightly higher than the ideal <90 for GPCRs. Ligand B is slightly higher.
3. **logP:** Ligand A (3.202) is optimal, while Ligand B (1.986) is a bit low, potentially impacting permeability. This favors A.
4. **HBD:** Ligand A (2) and Ligand B (1) are both good, well within the limit of 5. Slight advantage to B.
5. **HBA:** Ligand A (4) and Ligand B (7) are both acceptable, but B is getting closer to the upper limit of 10. Advantage to A.
6. **QED:** Ligand A (0.891) is excellent, indicating high drug-likeness. Ligand B (0.736) is still good, but not as strong. Advantage to A.
7. **DILI:** Ligand A (75.184) has a higher DILI risk than Ligand B (49.128). This is a significant advantage for B.
8. **BBB:** Ligand A (78.48) is better than Ligand B (63.746), though neither is exceptionally high. For a cardiovascular target, BBB isn't a primary concern, but a higher value is generally preferable. Slight advantage to A.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-4.869) is slightly better than Ligand B (-5.287). Slight advantage to A.
10. **Solubility:** Ligand A (-3.278) is slightly worse than Ligand B (-1.821). Advantage to B.
11. **hERG:** Ligand A (0.031) has a very low hERG risk, while Ligand B (0.186) is higher. Significant advantage to A.
12. **Cl_mic:** Ligand A (-13.22) has much lower (better) microsomal clearance than Ligand B (17.058). This indicates better metabolic stability. Strong advantage to A.
13. **t1/2:** Ligand A (-7.517) has a longer half-life than Ligand B (-8.587). Advantage to A.
14. **Pgp:** Ligand A (0.006) has very low P-gp efflux, while Ligand B (0.354) is higher. Significant advantage to A.
15. **Binding Affinity:** Ligand A (-9.0) has a stronger binding affinity than Ligand B (-6.0). This is a substantial advantage, potentially outweighing some ADME concerns.
**Overall Assessment:**
Ligand A demonstrates a superior profile overall, particularly regarding binding affinity, metabolic stability (Cl_mic), P-gp efflux, hERG risk, and QED. While Ligand B has a lower DILI risk and slightly better solubility, the stronger binding affinity of Ligand A is critical for a GPCR target like ADRB2. The slight permeability issues can be addressed through formulation strategies. The lower DILI risk of B is good, but not enough to overcome the substantial advantages of A.
Output:
1
2025-04-18 00:14:47,708 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (344.46 and 353.43 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (58.44) is significantly better than Ligand B (130.47). For a GPCR, lower TPSA is generally preferred for better permeability. Ligand B is quite high, potentially hindering absorption.
3. **logP:** Ligand A (1.935) is within the optimal range (1-3). Ligand B (-1.031) is below this range, which could lead to poor membrane permeability.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer hydrogen bond donors generally improve permeability.
5. **HBA:** Ligand A (4) is better than Ligand B (8). Lower HBA also contributes to better permeability.
6. **QED:** Both ligands have acceptable QED values (0.741 and 0.668, respectively), indicating good drug-like properties.
7. **DILI:** Ligand A (10.82) has a much lower DILI risk than Ligand B (69.29). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (66.73) has a better BBB penetration percentile than Ligand B (43.82). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant, and higher BBB is generally favorable.
9. **Caco-2:** Ligand A (-4.843) and Ligand B (-5.377) are both negative, indicating poor permeability. However, the scale is not specified, so it is difficult to interpret.
10. **Solubility:** Ligand A (-0.913) is slightly better than Ligand B (-1.608), but both are negative, suggesting poor solubility.
11. **hERG:** Ligand A (0.34) is significantly better than Ligand B (0.157), indicating a lower risk of cardiotoxicity. This is critical for a cardiovascular target.
12. **Cl_mic:** Ligand A (38.152) has a higher microsomal clearance than Ligand B (7.619), suggesting lower metabolic stability. This is a drawback for Ligand A.
13. **t1/2:** Ligand A (-18.013) has a negative half-life, which is concerning. Ligand B (0.099) is also very low.
14. **Pgp:** Ligand A (0.032) is much better than Ligand B (0.042), meaning less P-glycoprotein efflux.
15. **Binding Affinity:** Ligand A (-8.0) has a significantly stronger binding affinity than Ligand B (-6.4). This is a substantial advantage, potentially outweighing some of the ADME concerns.
**Overall Assessment:**
Ligand A is the stronger candidate. While it has a higher Cl_mic and a concerning t1/2, its superior binding affinity (-8.0 vs -6.4 kcal/mol), lower TPSA, better logP, significantly lower DILI risk, and better hERG profile are compelling advantages. The improved BBB penetration is also a plus. The lower solubility and Caco-2 permeability are concerns, but the strong binding affinity suggests that potency might be less dependent on achieving extremely high concentrations.
Output:
1
2025-04-18 00:14:47,708 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (366.542 and 344.499 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (49.41) is significantly better than Ligand A (94.22). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally improves absorption. This favors Ligand B.
3. **logP:** Ligand B (3.417) is closer to the optimal 1-3 range than Ligand A (0.253), which is quite low and could indicate poor membrane permeability. This is a substantial advantage for Ligand B.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1), but both are within the acceptable limit of 5.
5. **HBA:** Ligand A (5) is higher than Ligand B (2), but both are within the acceptable limit of 10.
6. **QED:** Both ligands have good QED scores (0.704 and 0.777), indicating good drug-like properties. No significant difference.
7. **DILI:** Both ligands have low DILI risk (43.622 and 40.054), below the 60% threshold. No clear advantage.
8. **BBB:** Ligand B (66.382) has a higher BBB penetration score than Ligand A (34.161). While not a primary concern for a cardiovascular target, higher BBB is generally favorable.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.479 and -5.023), which is unusual and suggests poor permeability. However, the scale isn't fully defined, so it's hard to interpret.
10. **Solubility:** Ligand A (-2.148) has better solubility than Ligand B (-4.458). Solubility is important for bioavailability.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.097 and 0.23), which is excellent. No difference.
12. **Cl_mic:** Ligand A (24.834) has a significantly lower microsomal clearance than Ligand B (57.423), suggesting better metabolic stability. This is a strong advantage for Ligand A.
13. **t1/2:** Ligand A (-18.667) has a more negative in vitro half-life than Ligand B (-14.188). A more negative value indicates a shorter half-life, which is unfavorable.
14. **Pgp:** Ligand A (0.013) has much lower P-gp efflux liability than Ligand B (0.41). Lower P-gp efflux is desirable for improved bioavailability.
15. **Binding Affinity:** Ligand A (-6.7 kcal/mol) has a slightly better binding affinity than Ligand B (-5.8 kcal/mol). This 0.9 kcal/mol difference is significant, and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand B has advantages in TPSA, logP, and BBB. However, Ligand A has a significant advantage in metabolic stability (Cl_mic), P-gp efflux, and binding affinity, and better solubility. Considering ADRB2 is a cardiovascular target, metabolic stability and affinity are critical. The lower logP of Ligand A is a concern, but the superior binding affinity and metabolic stability are more important. The slightly better solubility of Ligand A is also a plus.
Output:
1
2025-04-18 00:14:47,708 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (346.358 Da) is well within the ideal range (200-500 Da). Ligand B (422.71 Da) is also acceptable, but closer to the upper limit.
2. **TPSA:** Ligand A (88.52) is good, under the 140 threshold for oral absorption. Ligand B (62.3) is excellent, suggesting good permeability.
3. **logP:** Ligand A (2.063) is optimal. Ligand B (3.912) is slightly higher, but still within the acceptable range.
4. **HBD:** Ligand A (2) is good. Ligand B (1) is also good.
5. **HBA:** Ligand A (5) is good. Ligand B (3) is also good.
6. **QED:** Ligand A (0.782) is excellent. Ligand B (0.6) is still reasonable, but slightly lower.
7. **DILI:** Ligand A (49.05) is very good (low risk). Ligand B (63.823) is higher, indicating a moderate risk of liver injury.
8. **BBB:** Ligand A (55.215) is moderate. Ligand B (80.109) is good, suggesting better potential for CNS penetration, though ADRB2 is primarily a cardiovascular target, so this is less critical.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Both ligands have negative solubility values, which is also unusual and suggests poor solubility. Again, the scale is not specified.
11. **hERG:** Ligand A (0.165) is very low risk. Ligand B (0.311) is also low risk, but slightly higher.
12. **Cl_mic:** Ligand A (58.776) is moderate. Ligand B (40.255) is lower, indicating better metabolic stability.
13. **t1/2:** Ligand A (-15.968) is very poor. Ligand B (14.025) is good.
14. **Pgp:** Ligand A (0.033) is very low efflux, which is good. Ligand B (0.427) is also low, but higher than Ligand A.
15. **Affinity:** Ligand B (-7.1) has significantly better binding affinity than Ligand A (-5.9), a difference of 1.2 kcal/mol. This is a substantial advantage.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in affinity and has good logP and TPSA values. While BBB isn't crucial for a cardiovascular target, Ligand B's higher BBB score isn't detrimental. The biggest drawback for Ligand B is the higher DILI risk, but the significantly improved affinity and metabolic stability (lower Cl_mic, better t1/2) outweigh this concern. Ligand A has a better DILI score, but its poor half-life and lower affinity are significant drawbacks.
**Conclusion:**
Despite the slightly higher DILI risk, Ligand B's superior binding affinity and metabolic stability make it the more promising candidate. The 1.2 kcal/mol difference in binding affinity is a substantial advantage that can compensate for the moderate DILI risk.
Output:
0
2025-04-18 00:14:47,708 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [356.463, 95.94, 1.092, 2, 5, 0.571, 13.61, 36.254, -4.71, -1.039, 0.287, 49.558, -16.535, 0.019, -6.6]
**Ligand B:** [361.913, 29.54, 4.531, 0, 2, 0.744, 23.885, 92.672, -5.008, -4.766, 0.824, 76.521, 34.155, 0.734, -6.8]
Here's a breakdown, comparing each parameter and considering GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal 200-500 Da range. A (356.463) is slightly better.
2. **TPSA:** A (95.94) is higher than the ideal <140, but still acceptable. B (29.54) is excellent, well below 140, suggesting better permeability. This is a significant advantage for B.
3. **logP:** A (1.092) is optimal. B (4.531) is pushing the upper limit and could lead to solubility issues and off-target interactions. This favors A.
4. **HBD:** A (2) is good. B (0) is also good, but doesn't contribute to solubility.
5. **HBA:** A (5) is good. B (2) is also good.
6. **QED:** B (0.744) is better than A (0.571), indicating a more drug-like profile.
7. **DILI:** A (13.61) is much better than B (23.885), indicating lower liver injury risk. This is a significant advantage for A.
8. **BBB:** B (92.672) is very high, while A (36.254) is low. While ADRB2 isn't necessarily a CNS target, higher BBB penetration can sometimes correlate with better overall drug distribution.
9. **Caco-2:** A (-4.71) is poor, suggesting limited intestinal absorption. B (-5.008) is also poor.
10. **Solubility:** A (-1.039) is poor. B (-4.766) is even worse. Both have solubility concerns.
11. **hERG:** A (0.287) is very low risk. B (0.824) is slightly higher, but still acceptable. A is preferred.
12. **Cl_mic:** A (49.558) is better than B (76.521), indicating better metabolic stability.
13. **t1/2:** B (34.155) is much better than A (-16.535), suggesting a longer half-life and potentially less frequent dosing. This is a strong advantage for B.
14. **Pgp:** A (0.019) is very low efflux, which is good. B (0.734) is higher, indicating more P-gp efflux, which could limit bioavailability. A is preferred.
15. **Affinity:** B (-6.8) is slightly better than A (-6.6), but the difference is small.
**Overall Assessment:**
Ligand A has advantages in logP, DILI, hERG, Cl_mic, and Pgp efflux. Ligand B excels in QED, BBB, and t1/2. The solubility and Caco-2 permeability are poor for both. However, considering the GPCR-specific priorities, the lower logP and better metabolic stability of Ligand A, along with the significantly lower DILI risk, outweigh the slightly better BBB and half-life of Ligand B. The affinity difference is minimal. The poor Caco-2 values for both are concerning, but can potentially be addressed through formulation strategies.
Therefore, I would choose Ligand A.
Output:
1
2025-04-18 00:14:47,708 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [357.451, 88.18, 0.014, 1, 5, 0.588, 26.444, 55.138, -4.94, -0.213, 0.088, 16.653, -30.305, 0.009, -6.5]
**Ligand B:** [368.409, 76.02, 2.268, 2, 5, 0.821, 57.619, 79.721, -5.166, -3.416, 0.305, 6.775, -3.394, 0.083, -6]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (357.451) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are good, below the 140 A^2 threshold. Ligand B (76.02) is better, being closer to the 90 A^2 ideal for GPCRs.
3. **logP:** Ligand A (0.014) is very low, potentially causing permeability issues. Ligand B (2.268) is within the optimal 1-3 range. This is a significant advantage for B.
4. **HBD:** Ligand A (1) is good. Ligand B (2) is also acceptable.
5. **HBA:** Both have 5 HBA, which is within the acceptable limit.
6. **QED:** Ligand B (0.821) has a significantly better QED score than Ligand A (0.588), indicating a more drug-like profile.
7. **DILI:** Ligand A (26.444) has a much lower DILI risk than Ligand B (57.619). This is a strong point in favor of A.
8. **BBB:** Ligand B (79.721) has a much higher BBB penetration percentile than Ligand A (55.138). This is important for a GPCR target, though not strictly essential for ADRB2.
9. **Caco-2:** Ligand B (-5.166) has a better Caco-2 permeability than Ligand A (-4.94).
10. **Solubility:** Ligand A (-0.213) has better solubility than Ligand B (-3.416).
11. **hERG:** Ligand A (0.088) has a lower hERG risk than Ligand B (0.305).
12. **Cl_mic:** Ligand B (6.775) has a much lower microsomal clearance, indicating better metabolic stability, than Ligand A (16.653).
13. **t1/2:** Ligand B (-3.394) has a longer in vitro half-life than Ligand A (-30.305).
14. **Pgp:** Ligand A (0.009) has lower P-gp efflux liability than Ligand B (0.083).
15. **Affinity:** Both have very similar binding affinities (-6.5 kcal/mol and -6 kcal/mol respectively). The difference is negligible.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP and TPSA, and has a better BBB score. While Ligand A has better solubility and lower DILI, the poor logP is a major concern for permeability and overall drug-like properties. The metabolic stability (Cl_mic and t1/2) of Ligand B is also much better.
**Conclusion:**
Despite the lower DILI risk of Ligand A, the significantly better logP, QED, metabolic stability, and BBB penetration of Ligand B make it the more promising candidate for further development as an ADRB2 ligand. The slightly higher DILI risk can be addressed during optimization.
Output:
0
2025-04-18 00:14:47,709 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (345.374) is slightly lower, which can be beneficial for permeability.
2. **TPSA:** Both ligands are below the 140 A^2 threshold for good oral absorption (A: 82.27, B: 82.53).
3. **logP:** Both ligands have acceptable logP values (A: 0.988, B: 1.957), falling within the 1-3 range. Ligand B is slightly higher, which could potentially improve membrane permeability but also increase off-target binding.
4. **HBD:** Both have 2 HBD, which is within the acceptable limit of <=5.
5. **HBA:** Ligand A has 3 HBA, and Ligand B has 5 HBA. Both are below the 10 threshold.
6. **QED:** Ligand A (0.854) has a significantly better QED score than Ligand B (0.596), indicating a more drug-like profile.
7. **DILI:** Ligand A (37.611) has a lower DILI risk than Ligand B (53.276), which is a significant advantage.
8. **BBB:** Ligand A (69.833) has a better BBB penetration percentile than Ligand B (55.797). While ADRB2 isn't exclusively a CNS target, some cardiovascular effects are mediated through CNS pathways, and better BBB penetration isn't necessarily a negative.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-5.061) is slightly better than Ligand B (-4.714).
10. **Solubility:** Both have negative solubility values, which is also unusual and suggests poor solubility. Ligand A (-2.991) is slightly better than Ligand B (-2.778).
11. **hERG:** Both ligands have low hERG inhibition risk (A: 0.268, B: 0.376).
12. **Cl_mic:** Ligand A (-21.283) has a much lower (better) microsomal clearance than Ligand B (61.315), indicating greater metabolic stability.
13. **t1/2:** Ligand B (36.866) has a significantly longer in vitro half-life than Ligand A (-15.1). This is a substantial advantage.
14. **Pgp:** Both ligands have very low Pgp efflux liability (A: 0.014, B: 0.165).
15. **Binding Affinity:** Ligand B (-6.3 kcal/mol) has a slightly better binding affinity than Ligand A (-5.7 kcal/mol). This is a 0.6 kcal/mol difference, which is notable.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Both ligands perform reasonably well on logP and Pgp. Affinity is slightly better for Ligand B. However, Ligand A has a significantly better QED, lower DILI risk, better BBB penetration, and much better metabolic stability (lower Cl_mic). The poor Caco-2 and solubility values are concerning for both, but the other advantages of Ligand A outweigh the slightly better affinity of Ligand B.
**Conclusion:**
Considering the balance of properties, particularly the superior drug-likeness, safety (DILI), metabolic stability, and acceptable affinity, Ligand A is the more promising drug candidate.
Output:
1
2025-04-18 00:14:47,709 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Step-by-step comparison:**
1. **MW:** Both ligands (352.475 and 347.419 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (78.87) is significantly better than Ligand B (112.91). ADRB2 is a cardiovascular target, not CNS, but lower TPSA generally aids absorption.
3. **logP:** Both ligands (2.155 and 1.851) are within the optimal 1-3 range. Ligand B is slightly lower, which could be a minor drawback.
4. **HBD:** Ligand A (2) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is preferable to Ligand B (5). Fewer HBAs generally improve permeability.
6. **QED:** Ligand A (0.743) is better than Ligand B (0.641), indicating a more drug-like profile.
7. **DILI:** Ligand A (23.497) has a much lower DILI risk than Ligand B (73.09). This is a significant advantage for Ligand A.
8. **BBB:** Not a primary concern for a cardiovascular target like ADRB2, but Ligand A (40.83) is slightly better than Ligand B (36.371).
9. **Caco-2:** Ligand A (-5.138) and Ligand B (-5.664) are both negative, which is unusual. This suggests poor permeability in this assay, but the absolute values are similar.
10. **Solubility:** Ligand A (-2.344) is better than Ligand B (-3.194), indicating better aqueous solubility.
11. **hERG:** Both ligands (0.167 and 0.275) have low hERG inhibition risk, which is good. Ligand A is slightly better.
12. **Cl_mic:** Ligand A (3.235) has a much lower microsomal clearance than Ligand B (54.645), suggesting better metabolic stability. This is a major advantage.
13. **t1/2:** Ligand A (-12.194) has a much longer in vitro half-life than Ligand B (0.18). This is a significant advantage.
14. **Pgp:** Both ligands (0.093 and 0.262) have low P-gp efflux liability. Ligand A is slightly better.
15. **Binding Affinity:** Ligand B (-6.9 kcal/mol) has a slightly better binding affinity than Ligand A (-5.9 kcal/mol). This is a 1.0 kcal/mol difference, which is a noticeable but not overwhelming advantage.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has better TPSA, Pgp, and a more favorable ADME profile (DILI, Cl_mic, t1/2, solubility). While Ligand B has slightly better affinity, the overall balance of properties favors Ligand A. The improved metabolic stability and reduced toxicity risk of Ligand A are particularly important.
**Conclusion:**
Ligand A demonstrates a superior balance of properties, particularly regarding ADME-Tox parameters, making it a more promising drug candidate despite the slightly lower binding affinity.
Output:
1
2025-04-18 00:14:47,709 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (399.347 Da) is slightly higher than Ligand B (349.366 Da), but both are acceptable.
**2. TPSA:** Ligand A (71.25) is significantly better than Ligand B (120). For a GPCR, a lower TPSA is generally preferred for better permeability. Ligand B is above the 90 A^2 threshold.
**3. logP:** Ligand A (3.787) is within the optimal range (1-3), while Ligand B (1.605) is on the lower end. While not terrible, lower logP can sometimes indicate poor membrane permeability.
**4. H-Bond Donors:** Ligand A (2) is preferable to Ligand B (4). Fewer HBDs generally improve permeability.
**5. H-Bond Acceptors:** Both ligands have 5 HBA, which is acceptable.
**6. QED:** Ligand A (0.821) has a higher QED score than Ligand B (0.591), indicating a more drug-like profile.
**7. DILI:** Both ligands have similar DILI risk (Ligand A: 68.592, Ligand B: 67.429), and are within an acceptable range (< 60 is ideal, but both are below 70).
**8. BBB:** Ligand A (65.374) has a significantly higher BBB penetration percentile than Ligand B (30.748). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be beneficial for distribution and off-target effects.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
**10. Aqueous Solubility:** Both ligands have negative solubility values, which is also unusual and suggests poor solubility.
**11. hERG Inhibition:** Ligand A (0.741) is better than Ligand B (0.198), indicating lower risk of cardiotoxicity.
**12. Microsomal Clearance:** Ligand A (23.939) has lower microsomal clearance than Ligand B (33.114), suggesting better metabolic stability.
**13. In vitro Half-Life:** Ligand A (41.43) has a positive half-life, while Ligand B (-47.84) has a negative half-life. This is a significant advantage for Ligand A.
**14. P-gp Efflux:** Ligand A (0.552) has lower P-gp efflux than Ligand B (0.052), which is preferable.
**15. Binding Affinity:** Ligand B (-7.5 kcal/mol) has a slightly better binding affinity than Ligand A (-6.4 kcal/mol). This is a 1.1 kcal/mol difference, which is notable, but not overwhelming given the other ADME properties.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand A is the better candidate. It has a more favorable balance of properties, including better TPSA, logP, QED, BBB penetration, metabolic stability (lower Cl_mic and better t1/2), and lower P-gp efflux. While Ligand B has slightly better binding affinity, the ADME profile of Ligand A is significantly more promising for oral bioavailability and reduced off-target effects.
Output:
1
2025-04-18 00:14:47,709 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (353.463 Da) is within the ideal range (200-500 Da). Ligand B (376.418 Da) is also acceptable. No clear advantage here.
2. **TPSA:** Ligand A (82.11) is better than Ligand B (66.48). Both are below 140, indicating good potential for oral absorption, but lower TPSA is generally preferred for GPCRs.
3. **logP:** Ligand A (-0.026) is slightly low, potentially hindering permeation. Ligand B (3.143) is within the optimal range (1-3). This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (2) is good. Ligand B (1) is also good.
5. **HBA:** Ligand A (5) is good. Ligand B (4) is also good.
6. **QED:** Both ligands have good QED scores (A: 0.701, B: 0.816), indicating drug-likeness. Ligand B is slightly better.
7. **DILI:** Ligand A (5.894) has a very favorable DILI score, significantly lower than Ligand B (60.721), which is considered high risk. This is a major advantage for Ligand A.
8. **BBB:** Ligand A (31.097) is low, while Ligand B (66.227) is moderate. While ADRB2 isn't strictly a CNS target, some CNS penetration can be beneficial for understanding off-target effects.
9. **Caco-2:** Both ligands have similar Caco-2 permeability (-4.994 and -4.9).
10. **Solubility:** Ligand A (-0.303) is better than Ligand B (-3.005). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.159) is very low risk, while Ligand B (0.554) is slightly higher. This favors Ligand A.
12. **Cl_mic:** Ligand A (-12.086) has a lower (better) microsomal clearance than Ligand B (53.856), indicating greater metabolic stability.
13. **t1/2:** Ligand A (19.702) has a shorter half-life than Ligand B (42.464). Longer half-life is generally preferred.
14. **Pgp:** Ligand A (0.004) has very low P-gp efflux, while Ligand B (0.451) has moderate efflux. This is a significant advantage for Ligand A.
15. **Affinity:** Both ligands have good binding affinity (-7.0 and -5.6 kcal/mol), but Ligand A is substantially better.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp efflux, and affinity are key. Ligand B has a better logP. Ligand A has better TPSA, Pgp efflux, and significantly better affinity. The DILI and hERG profiles of Ligand A are also substantially better.
**Overall Assessment:**
While Ligand B has a better logP and half-life, Ligand A's superior affinity, significantly lower DILI and hERG risk, better solubility, and lower Pgp efflux outweigh these drawbacks. The substantial difference in binding affinity (-7.0 vs -5.6 kcal/mol) is a crucial factor. The lower DILI score is also a major advantage for progressing a candidate into development.
Output:
1
2025-04-18 00:14:47,709 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (364.423 and 363.502 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (93.73) is higher than Ligand B (56.92). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is generally preferred for absorption. Ligand B is better here.
3. **logP:** Ligand A (2.22) is within the optimal 1-3 range. Ligand B (4.253) is slightly higher, potentially leading to solubility issues and off-target interactions. Ligand A is better.
4. **HBD:** Ligand A (2) and Ligand B (3) are both acceptable, below the threshold of 5. No significant difference.
5. **HBA:** Ligand A (5) and Ligand B (2) are both acceptable, below the threshold of 10. Ligand B is better.
6. **QED:** Ligand A (0.701) is better than Ligand B (0.509), indicating a more drug-like profile.
7. **DILI:** Ligand A (83.598) has a higher DILI risk than Ligand B (42.962). Ligand B is significantly better here.
8. **BBB:** Ligand A (65.607) has a lower BBB penetration than Ligand B (91.392). While ADRB2 isn't a primary CNS target, some peripheral exposure is still desirable, and lower efflux is generally beneficial. Ligand B is better.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. Ligand A (-4.963) is slightly better (less negative) than Ligand B (-5.071).
10. **Solubility:** Both ligands have negative solubility values, indicating poor solubility. Ligand A (-4.049) is slightly better (less negative) than Ligand B (-4.351).
11. **hERG:** Ligand A (0.556) has a lower hERG inhibition liability than Ligand B (0.921). Ligand A is better.
12. **Cl_mic:** Ligand A (37.616) has a lower microsomal clearance than Ligand B (59.059), indicating better metabolic stability. Ligand A is better.
13. **t1/2:** Ligand A (-12.319) has a negative half-life, indicating very rapid clearance. Ligand B (45.203) has a much more favorable half-life. Ligand B is significantly better.
14. **Pgp:** Ligand A (0.229) has lower P-gp efflux liability than Ligand B (0.757). Ligand A is better.
15. **Affinity:** Ligand A (-7.5) has a slightly better binding affinity than Ligand B (-6.0). This is a significant advantage.
**Overall Assessment:**
Ligand A has a better binding affinity, QED, lower DILI, lower hERG, lower Cl_mic, and lower Pgp efflux. However, Ligand B has a significantly better half-life, BBB penetration, and lower DILI risk. The affinity difference is substantial, and the metabolic stability (lower Cl_mic) of Ligand A is also a strong point. While both have poor Caco-2 and solubility, the affinity advantage of Ligand A outweighs the other drawbacks, especially considering it's a cardiovascular target where CNS penetration isn't paramount.
Output:
1
2025-04-18 00:14:47,709 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (368.865 and 369.506 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (74.77) is higher than Ligand B (64.41). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is still preferred for absorption. Ligand B has a slight advantage.
3. **logP:** Both ligands (2.298 and 2.611) are within the optimal 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability, but not dramatically so.
4. **HBD:** Ligand A (1) is better than Ligand B (0). While both are acceptable, having one HBD can sometimes improve solubility without significantly impacting permeability.
5. **HBA:** Ligand A (5) is slightly higher than Ligand B (4). Both are within the acceptable limit of 10.
6. **QED:** Both ligands (0.78 and 0.722) have good drug-likeness scores, exceeding the 0.5 threshold. Ligand A is slightly better.
7. **DILI:** Ligand B (23.73) has a significantly lower DILI risk than Ligand A (60.682). This is a major advantage for Ligand B. A DILI percentile below 40 is highly desirable.
8. **BBB:** Ligand B (92.672) has a much higher BBB penetration percentile than Ligand A (68.554). While ADRB2 isn't a primary CNS target, some degree of BBB penetration can be useful for understanding off-target effects and potential peripheral distribution.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.57 and -4.692), which is unusual and suggests poor permeability. These values are likely errors or indicate a significant issue with intestinal absorption.
10. **Solubility:** Ligand B (-3.789) has a slightly better (less negative) solubility score than Ligand A (-2.789), indicating slightly better aqueous solubility.
11. **hERG:** Ligand A (0.458) has a lower hERG inhibition liability than Ligand B (0.659), which is favorable.
12. **Cl_mic:** Both ligands have similar microsomal clearance values (52.292 and 52.713 mL/min/kg).
13. **t1/2:** Ligand B (-16.561 hours) has a negative in vitro half-life, which is not possible. This is likely an error. Ligand A (21.413 hours) has a reasonable half-life.
14. **Pgp:** Both ligands have similar Pgp efflux liability (0.073 and 0.091).
15. **Binding Affinity:** Ligand A (-6.8 kcal/mol) has a slightly better binding affinity than Ligand B (-6.4 kcal/mol). This is a 0.4 kcal/mol difference, which is not huge, but noticeable.
**Overall Assessment & GPCR Prioritization:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), and the general drug-like properties, Ligand B emerges as the more promising candidate *despite* the questionable Caco-2 and t1/2 values. The significantly lower DILI risk and higher BBB penetration are major advantages. The slight edge in logP and solubility also contribute. The affinity difference is small enough to be outweighed by the improved safety profile. The negative half-life for Ligand B is a significant concern, but could be an error in the data.
Output:
0
2025-04-18 00:14:47,710 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (351.403 and 342.483 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (107.97) is better than Ligand B (49.41). Both are under 140, but Ligand B is significantly lower, potentially improving absorption.
3. **logP:** Ligand B (3.745) is higher than Ligand A (-1.368). Ligand A's logP is quite low, which could hinder membrane permeability. Ligand B is closer to the optimal 1-3 range.
4. **HBD:** Ligand A (3) is higher than Ligand B (1). Both are acceptable, but lower is generally preferred for permeability.
5. **HBA:** Ligand A (5) is higher than Ligand B (2). Similar to HBD, lower is better.
6. **QED:** Ligand B (0.732) is significantly better than Ligand A (0.369), indicating a more drug-like profile.
7. **DILI:** Ligand A (25.165) has a much lower DILI risk than Ligand B (38.542). This is a significant advantage for Ligand A.
8. **BBB:** Ligand B (79.411) has a much higher BBB penetration percentile than Ligand A (25.863). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant, and higher BBB is generally favorable.
9. **Caco-2:** Ligand A (-5.132) and Ligand B (-4.376) are both negative, indicating poor permeability.
10. **Solubility:** Ligand A (-1.21) is better than Ligand B (-4.104).
11. **hERG:** Both ligands have very low hERG inhibition risk (0.044 and 0.411 respectively). No significant difference.
12. **Cl_mic:** Ligand A (-14.437) has a much lower (better) microsomal clearance than Ligand B (84.3). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (-28.296) has a longer in vitro half-life than Ligand B (1.593). This is a significant advantage.
14. **Pgp:** Ligand A (0.006) has a much lower P-gp efflux liability than Ligand B (0.253). This is a significant advantage for Ligand A.
15. **Binding Affinity:** Ligand B (-6.6) has a slightly better binding affinity than Ligand A (-6.3). However, the difference is less than 1.5 kcal/mol, so it's not decisive.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp efflux, and binding affinity are crucial. Ligand B has a better logP and slightly better affinity. However, Ligand A excels in metabolic stability (Cl_mic, t1/2), DILI risk, and P-gp efflux, which are all important for overall drug development. Ligand B's higher BBB is a plus, but not a deal-breaker for a peripheral target like ADRB2. The poor Caco-2 values for both are concerning, but can be addressed with formulation strategies.
**Overall Assessment:**
While Ligand B has a slightly better binding affinity and logP, Ligand A's superior ADME properties (lower DILI, better metabolic stability, lower P-gp efflux) and solubility make it a more promising drug candidate. The lower DILI risk is particularly important.
Output:
1
2025-04-18 00:14:47,710 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [351.451, 99.49, -0.264, 3, 6, 0.628, 13.92, 31.601, -5.402, -1.188, 0.218, -20.396, 8.749, 0.008, -7.4]
**Ligand B:** [363.487, 88.91, 2.145, 2, 6, 0.823, 49.593, 57.464, -5.234, -2.585, 0.571, 46.608, 21.112, 0.071, -7.8]
Here's a breakdown, prioritizing GPCR-relevant parameters:
1. **Molecular Weight:** Both are within the ideal 200-500 Da range. Ligand A (351.451) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (99.49) is slightly higher than Ligand B (88.91), but both are below the 140 A^2 threshold for oral absorption. Ligand B is better here.
3. **logP:** Ligand A (-0.264) is quite low, potentially hindering membrane permeability. Ligand B (2.145) is within the optimal 1-3 range. This is a significant advantage for Ligand B.
4. **H-Bond Donors/Acceptors:** Both have acceptable numbers (A: 3/6, B: 2/6).
5. **QED:** Both have good QED scores (A: 0.628, B: 0.823), indicating good drug-like properties. Ligand B is better.
6. **DILI Risk:** Ligand A (13.92) has a much lower DILI risk than Ligand B (49.593). This is a major advantage for Ligand A.
7. **BBB Penetration:** Ligand B (57.464) has better BBB penetration than Ligand A (31.601). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be beneficial or at least needs to be considered.
8. **Caco-2 Permeability:** Both have negative values, indicating poor permeability.
9. **Aqueous Solubility:** Both have negative values, indicating poor solubility.
10. **hERG Inhibition:** Ligand A (0.218) has a lower hERG risk than Ligand B (0.571). This is a positive for Ligand A.
11. **Microsomal Clearance:** Ligand A (-20.396) has *much* lower microsomal clearance than Ligand B (46.608), suggesting better metabolic stability. This is a significant advantage for Ligand A.
12. **In vitro Half-Life:** Ligand B (21.112) has a longer half-life than Ligand A (8.749). This is a positive for Ligand B.
13. **P-gp Efflux:** Ligand A (0.008) has very low P-gp efflux, while Ligand B (0.071) has slightly higher efflux. This favors Ligand A.
14. **Binding Affinity:** Ligand B (-7.8) has a slightly better binding affinity than Ligand A (-7.4), but the difference is relatively small (0.4 kcal/mol).
15. **GPCR Focus:** Considering this is a GPCR, logP, TPSA, and Pgp are important. Ligand B has a better logP and TPSA. Ligand A has better Pgp.
**Overall Assessment:**
Ligand A has several key advantages: significantly lower DILI risk, much better metabolic stability (lower Cl_mic), lower P-gp efflux, and lower hERG risk. While Ligand B has a slightly better binding affinity and BBB penetration, the ADME profile of Ligand A is far superior, and the binding affinity difference isn't large enough to overcome these advantages. The low logP of Ligand A is a concern, but the other benefits are more impactful for overall drug development potential.
Output:
1
2025-04-18 00:14:47,710 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (340.39 and 342.45 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand B (70.31) is significantly better than Ligand A (88.55). For a GPCR, lower TPSA is generally preferred for better permeability.
3. **logP:** Both ligands have acceptable logP values (0.938 and 1.73), falling within the 1-3 range. Ligand B is slightly better, being closer to the optimal range.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Both ligands have 7 HBA, which is also good.
6. **QED:** Ligand B (0.892) has a higher QED score than Ligand A (0.747), indicating a more drug-like profile.
7. **DILI:** Ligand B (35.79%) has a much lower DILI risk than Ligand A (73.52%). This is a substantial advantage for Ligand B.
8. **BBB:** Both ligands have relatively low BBB penetration (29.70% and 73.67%). Since ADRB2 is a cardiovascular target, high BBB penetration is *not* a priority. Ligand B is better, but it's not a critical factor here.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.232 and -4.972). This is unusual and suggests poor permeability. However, the values are similar.
10. **Solubility:** Both ligands have negative solubility values (-1.119 and -2.496), indicating poor aqueous solubility. Ligand B is slightly worse.
11. **hERG:** Ligand A (0.194) has a lower hERG inhibition liability than Ligand B (0.689), which is a positive.
12. **Cl_mic:** Ligand A (9.327) has a significantly lower microsomal clearance than Ligand B (58.857), suggesting better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand B (25.017) has a longer in vitro half-life than Ligand A (18.537). This is a positive for Ligand B.
14. **Pgp:** Ligand A (0.054) has lower P-gp efflux liability than Ligand B (0.048), which is slightly better.
15. **Affinity:** Ligand A (-8.0 kcal/mol) has a slightly better binding affinity than Ligand B (-6.0 kcal/mol). This is a 2 kcal/mol difference, which is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand A has a better binding affinity and lower clearance, while Ligand B has a better QED, lower DILI risk, and longer half-life. The lower DILI risk of Ligand B is a significant advantage, as is the better QED score. However, the 2 kcal/mol difference in binding affinity is substantial, and the lower clearance of Ligand A is also important. Considering the GPCR-specific priorities (logP, TPSA, affinity), the affinity advantage of Ligand A is the most important factor. While Ligand B has a better safety profile (DILI), the affinity difference is large enough to prioritize Ligand A.
Output:
1
2025-04-18 00:14:47,710 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (333.391 and 347.419 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (63.25) is significantly better than Ligand B (96.33). ADRB2 is a cardiovascular target, not CNS, but lower TPSA generally improves absorption. Ligand A is well below the 140 threshold. Ligand B is approaching the upper limit.
3. **logP:** Ligand A (4.725) is high, potentially causing solubility issues and off-target effects. Ligand B (-0.041) is very low, which could impede permeation. This is a significant drawback for Ligand B.
4. **HBD:** Both ligands have 2 HBD, which is within the acceptable limit of 5.
5. **HBA:** Ligand A has 3 HBA, while Ligand B has 5. Both are acceptable (<=10), but Ligand A is slightly better.
6. **QED:** Both ligands have good QED values (0.664 and 0.731), indicating generally drug-like properties.
7. **DILI:** Ligand A (86.002) has a higher DILI risk than Ligand B (45.25). This is a significant negative for Ligand A.
8. **BBB:** Not a primary concern for a cardiovascular target like ADRB2, but Ligand A (76.425) is better than Ligand B (59.364).
9. **Caco-2:** Ligand A (-4.849) and Ligand B (-5.167) both have negative Caco-2 values, which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-5.887) has significantly better solubility than Ligand B (-2.232). This is important given Ligand A's higher logP.
11. **hERG:** Ligand A (0.748) has a slightly higher hERG risk than Ligand B (0.067). Ligand B is much better here.
12. **Cl_mic:** Ligand A (93.479) has a higher microsomal clearance than Ligand B (30.826), indicating lower metabolic stability. This is a negative for Ligand A.
13. **t1/2:** Ligand A (58.112) has a much longer in vitro half-life than Ligand B (3.11). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.568) has lower P-gp efflux than Ligand B (0.024), which is favorable.
15. **Binding Affinity:** Ligand A (-6.8 kcal/mol) has a slightly better binding affinity than Ligand B (-6.5 kcal/mol). While the difference is not huge, it's a positive for Ligand A.
**Overall Assessment:**
Ligand B has a much better safety profile (lower DILI, lower hERG). However, its extremely low logP is a major concern, likely leading to poor absorption. Ligand A has a higher logP and DILI risk, but its better solubility, longer half-life, and slightly better affinity make it a more promising starting point. The higher logP can be addressed with further optimization. The poor permeability of both is concerning, but the other issues with Ligand B are more critical.
Output:
1
2025-04-18 00:14:47,710 - INFO - Batch 463 complete. Total preferences: 7408
2025-04-18 00:14:47,710 - INFO - Processing batch 464/512...
2025-04-18 00:15:35,995 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (347.443 and 354.426 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (57.78) is significantly better than Ligand B (86.6). ADRB2 is a cardiovascular target, not CNS, but lower TPSA generally improves permeability. Ligand A is well below the 140 threshold, while B is approaching it.
3. **logP:** Ligand A (4.53) is higher than Ligand B (-0.096). While 4.53 is at the upper end of the optimal range, it's still acceptable. Ligand B's logP is quite low, potentially hindering membrane permeability.
4. **HBD:** Both have acceptable HBD counts (2 and 3 respectively), well below the 5 threshold.
5. **HBA:** Both have acceptable HBA counts (3 and 5 respectively), below the 10 threshold.
6. **QED:** Both ligands have good QED scores (0.57 and 0.638), indicating good drug-like properties.
7. **DILI:** Ligand A (80.923) has a significantly higher DILI risk than Ligand B (16.014). This is a major concern for Ligand A.
8. **BBB:** Not a primary concern for a cardiovascular target, but Ligand A (55.874) is better than Ligand B (36.177).
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. This is concerning for both.
10. **Solubility:** Ligand A (-4.832) has slightly better solubility than Ligand B (-0.468), but both are poor.
11. **hERG:** Ligand A (0.866) has a slightly higher hERG risk than Ligand B (0.143).
12. **Cl_mic:** Ligand B (-9.758) has a much lower (better) microsomal clearance than Ligand A (57.857), suggesting better metabolic stability.
13. **t1/2:** Ligand B (4.744) has a much longer in vitro half-life than Ligand A (-15.672). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.792) has a slightly higher Pgp efflux liability than Ligand B (0.006).
15. **Binding Affinity:** Ligand B (-7.3) has a significantly stronger binding affinity than Ligand A (-3.9). This is a substantial advantage for Ligand B. A difference of 3.4 kcal/mol is very significant.
**Overall Assessment:**
Ligand B is the stronger candidate. While both have permeability issues (negative Caco-2), Ligand B's significantly better binding affinity, metabolic stability (lower Cl_mic, longer t1/2), lower DILI risk, and lower Pgp efflux outweigh Ligand A's slightly better TPSA and solubility. The large difference in binding affinity is the most critical factor. The higher DILI risk for Ligand A is a major red flag.
Output:
0
2025-04-18 00:15:35,996 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (357.4 & 349.5 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (78.51) is slightly higher than Ligand B (64.09). Both are below the 140 threshold for oral absorption, but B is better.
3. **logP:** Both ligands (1.196 & 1.001) are within the optimal 1-3 range. Very similar.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1). Both are acceptable.
5. **HBA:** Ligand A (3) is lower than Ligand B (4). Both are acceptable, but A is slightly better.
6. **QED:** Both ligands (0.75 & 0.769) have excellent drug-likeness scores, well above the 0.5 threshold.
7. **DILI:** Ligand A (27.6) has a significantly lower DILI risk than Ligand B (5.894). This is a major advantage for A.
8. **BBB:** Ligand A (83.366) has a much higher BBB penetration percentile than Ligand B (62.621). While ADRB2 isn't *strictly* a CNS target, some CNS exposure can be relevant for off-target effects and overall safety assessment.
9. **Caco-2:** Both ligands (-4.863 & -4.773) have similar, very negative Caco-2 values. This suggests poor permeability, which is concerning.
10. **Solubility:** Ligand A (-2.23) has slightly worse solubility than Ligand B (-0.496). Solubility is important, so B has a slight edge here.
11. **hERG:** Both ligands (0.154 & 0.125) have very low hERG inhibition liability. No significant difference.
12. **Cl_mic:** Ligand A (1.054) has a much lower microsomal clearance than Ligand B (6.02). This indicates better metabolic stability for A.
13. **t1/2:** Ligand A (-1.634) has a slightly longer in vitro half-life than Ligand B (5.644).
14. **Pgp:** Both ligands (0.01 & 0.022) have very low P-gp efflux liability, which is good.
15. **Binding Affinity:** Ligand A (-7.3) has a significantly stronger binding affinity than Ligand B (-5.1). This is a substantial advantage, potentially outweighing some ADME concerns.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Both ligands are good on logP and Pgp. Ligand B is slightly better on TPSA, but Ligand A is *significantly* better on affinity and has a lower DILI risk and better metabolic stability. The stronger binding affinity of Ligand A is a major driver, and the lower DILI risk is a significant safety advantage.
**Conclusion:**
Ligand A is the more promising candidate due to its superior binding affinity, lower DILI risk, better metabolic stability, and higher BBB penetration. While Ligand B has slightly better solubility and TPSA, the advantages of Ligand A are more impactful for a GPCR target.
Output:
1
2025-04-18 00:15:35,996 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (347.503 and 347.419 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (43.86) is significantly better than Ligand B (93.26). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand B's TPSA is quite high.
3. **logP:** Both ligands have acceptable logP values (2.3 and 1.068), falling within the 1-3 range. Ligand A is slightly better.
4. **HBD:** Ligand A (0) is preferable to Ligand B (1). Fewer HBDs generally improve membrane permeability.
5. **HBA:** Ligand A (3) is better than Ligand B (6). Lower HBA is generally preferred for better permeability.
6. **QED:** Ligand B (0.732) has a slightly higher QED than Ligand A (0.524), suggesting a more drug-like profile. This is a small advantage.
7. **DILI:** Ligand A (14.23) has a significantly lower DILI risk than Ligand B (38.736). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (71.888) has a higher BBB penetration percentile than Ligand B (57.193). While not a primary concern for a cardiovascular target, higher BBB is generally favorable.
9. **Caco-2:** Ligand A (-4.745) and Ligand B (-5.282) are both negative, indicating poor permeability. This is a concern for both, but the values are similar.
10. **Solubility:** Ligand A (-1.51) has slightly better solubility than Ligand B (-0.995).
11. **hERG:** Ligand A (0.542) has a lower hERG inhibition liability than Ligand B (0.093). This is a significant safety advantage for Ligand A.
12. **Cl_mic:** Ligand B (32.172) has a lower microsomal clearance than Ligand A (37.22), suggesting better metabolic stability. This is a slight advantage for Ligand B.
13. **t1/2:** Ligand B (42.746) has a significantly longer in vitro half-life than Ligand A (-10.607). This is a substantial advantage for Ligand B.
14. **Pgp:** Ligand A (0.103) has lower P-gp efflux liability than Ligand B (0.024). This is a slight advantage for Ligand A.
15. **Binding Affinity:** Ligand B (-7.0) has a slightly better binding affinity than Ligand A (-5.9). This is a 1.1 kcal/mol difference, which is significant.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B has better affinity and slightly better metabolic stability (Cl_mic, t1/2), but Ligand A excels in TPSA, DILI, and hERG. The large difference in TPSA and safety profiles (DILI, hERG) are more important than the slight affinity advantage of Ligand B. The negative Caco-2 values are concerning for both, but can be addressed with formulation strategies.
**Conclusion:**
Despite the slightly better affinity of Ligand B, the superior ADME/Tox profile of Ligand A (lower TPSA, DILI, hERG, and better solubility) makes it the more promising drug candidate for ADRB2.
Output:
1
2025-04-18 00:15:35,996 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (358.458 Da) is within the ideal range (200-500 Da). Ligand B (405.973 Da) is also acceptable, but closer to the upper limit.
2. **TPSA:** Ligand A (67.33) is excellent, well below the 140 threshold for good absorption. Ligand B (82.53) is still reasonable, but less favorable.
3. **logP:** Ligand A (-0.599) is a bit low, potentially hindering permeation. Ligand B (2.413) is within the optimal 1-3 range. This is a significant advantage for Ligand B.
4. **HBD:** Both ligands have acceptable HBD counts (1 and 2, respectively), well below the 5 threshold.
5. **HBA:** Both ligands have acceptable HBA counts (5 and 6, respectively), below the 10 threshold.
6. **QED:** Both ligands have similar and good QED values (0.687 and 0.616, respectively), indicating good drug-likeness.
7. **DILI:** Ligand A (6.32) has a much lower DILI risk than Ligand B (63.629). This is a major advantage for Ligand A.
8. **BBB:** Both ligands have low BBB penetration (36.293 and 35.324, respectively). Since ADRB2 is a cardiovascular target, BBB penetration is not a primary concern.
9. **Caco-2:** Both ligands have negative Caco-2 permeability values (-5.024 and -5.289, respectively). This is unusual and suggests poor permeability.
10. **Solubility:** Ligand A (0.656) has better solubility than Ligand B (-3.431).
11. **hERG:** Both ligands have low hERG inhibition risk (0.245 and 0.611, respectively).
12. **Cl_mic:** Ligand A (-19.659) has significantly lower (better) microsomal clearance than Ligand B (39.421), indicating better metabolic stability.
13. **t1/2:** Ligand A (-31.215) has a negative half-life which is not possible. Ligand B (25.457) has a more reasonable half-life.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.004 and 0.512, respectively).
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.6 and -6.7 kcal/mol).
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand B has a better logP, while Ligand A has a better TPSA. The affinities are nearly identical. However, the significantly lower DILI risk and better metabolic stability (Cl_mic) of Ligand A are crucial factors. The negative half-life of Ligand A is concerning, but could be an error in the data.
**Conclusion:**
Despite the slightly lower logP, Ligand A is the preferred candidate due to its significantly lower DILI risk, better metabolic stability, and better solubility. The similar binding affinities make these ADME properties the deciding factors.
Output:
1
2025-04-18 00:15:35,996 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [341.411, 80.32, 3.758, 2, 4, 0.812, 75.611, 60.915, -4.604, -4.567, 0.314, 92.307, 15.295, 0.095, -6.2]
**Ligand B:** [348.403, 98.9, -0.85, 2, 6, 0.741, 39.434, 44.668, -5.015, -1.598, 0.134, 5.538, 0.291, 0.015, -7.4]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity) are paramount:
1. **MW:** Both are within the ideal range (200-500 Da). A is slightly lower, which is generally favorable.
2. **TPSA:** A (80.32) is excellent, well below the 140 threshold. B (98.9) is still acceptable but less ideal.
3. **logP:** A (3.758) is optimal. B (-0.85) is significantly low, potentially hindering membrane permeability and bioavailability. This is a major concern.
4. **HBD/HBA:** Both have reasonable HBD (2) and HBA (A:4, B:6) counts.
5. **QED:** Both are above 0.5, indicating good drug-likeness.
6. **DILI:** A (75.611) is concerningly high, indicating a substantial risk of liver injury. B (39.434) is much better, falling well within the acceptable range.
7. **BBB:** A (60.915) is moderate. B (44.668) is lower. While ADRB2 isn't necessarily a CNS target, some peripheral distribution is still needed.
8. **Caco-2:** Both are negative, indicating poor permeability. This is a significant issue for both.
9. **Solubility:** Both are negative, indicating poor solubility. This is a significant issue for both.
10. **hERG:** A (0.314) is slightly higher, indicating a slightly elevated risk. B (0.134) is better.
11. **Cl_mic:** A (92.307) is high, suggesting rapid metabolism and potentially low bioavailability. B (5.538) is excellent, indicating high metabolic stability.
12. **t1/2:** A (15.295) is decent, but B (0.291) is extremely short.
13. **Pgp:** A (0.095) is very low, suggesting minimal efflux. B (0.015) is even lower, which is favorable.
14. **Affinity:** B (-7.4) has a significantly stronger binding affinity than A (-6.2) - a difference of 1.2 kcal/mol. This is a substantial advantage.
**Overall Assessment:**
Ligand B has a much stronger binding affinity, excellent metabolic stability (low Cl_mic), and a low DILI risk. However, its low logP is a major drawback, potentially leading to poor absorption. Ligand A has a better logP, but suffers from high DILI risk and rapid metabolism. The affinity difference is substantial enough to potentially overcome the logP issue with B through formulation strategies (e.g., salt formation, lipid-based formulations). The DILI risk with A is too high to ignore.
Considering the GPCR-specific priorities and the significant affinity advantage of B, I believe **Ligand B** is the more promising candidate, despite the logP concern.
0
2025-04-18 00:15:35,996 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (363.8) is within the ideal range (200-500), while Ligand B (341.5) is also good. No clear advantage here.
2. **TPSA:** Ligand A (98.14) is acceptable, but approaching the upper limit for good oral absorption. Ligand B (55.63) is excellent, well below the 140 threshold. This favors Ligand B.
3. **logP:** Ligand A (0.704) is a bit low, potentially hindering permeability. Ligand B (3.601) is optimal. This strongly favors Ligand B.
4. **HBD:** Both ligands have acceptable HBD counts (Ligand A: 2, Ligand B: 1).
5. **HBA:** Both ligands have acceptable HBA counts (Ligand A: 6, Ligand B: 5).
6. **QED:** Both ligands have good QED values (Ligand A: 0.833, Ligand B: 0.734), indicating drug-likeness.
7. **DILI:** Ligand A (83.792) has a significantly higher DILI risk than Ligand B (25.204). This is a major concern for Ligand A.
8. **BBB:** Both have reasonable BBB penetration (Ligand A: 39.434, Ligand B: 83.56). Ligand B is better, but BBB isn't a primary concern for a cardiovascular target like ADRB2.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale isn't specified, so it's hard to interpret.
10. **Solubility:** Both have negative solubility values, also unusual. Again, the scale is unknown.
11. **hERG:** Both ligands have low hERG inhibition risk (Ligand A: 0.143, Ligand B: 0.33).
12. **Cl_mic:** Ligand A (-3.687) has a much lower (better) microsomal clearance than Ligand B (36.806), indicating better metabolic stability. This favors Ligand A.
13. **t1/2:** Ligand A (25.44) has a longer half-life than Ligand B (-6.632). This favors Ligand A.
14. **Pgp:** Ligand A (0.07) has lower P-gp efflux liability than Ligand B (0.341). This favors Ligand A.
15. **Binding Affinity:** Ligand A (-7.3) has a slightly better binding affinity than Ligand B (-6.2), but the difference is less than 1.5 kcal/mol.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand B excels in logP and TPSA. Ligand A has a slightly better affinity, but the difference isn't substantial enough to overcome the significant DILI risk and lower logP. Metabolic stability (Cl_mic and t1/2) are also important, and Ligand A is better in these aspects. However, the high DILI risk is a critical drawback.
**Overall Assessment:**
Despite Ligand A's better metabolic stability and slightly better affinity, the significantly higher DILI risk and suboptimal logP make it a less desirable candidate. Ligand B's superior TPSA, optimal logP, and much lower DILI risk outweigh the slightly weaker affinity and poorer metabolic properties.
Output:
0
2025-04-18 00:15:35,996 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (361.419 Da and 353.555 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (81.7) is slightly higher than Ligand B (64.86). Both are below the 140 threshold for good oral absorption, but Ligand B is preferable given the GPCR target class.
3. **logP:** Ligand A (2.069) is within the optimal 1-3 range. Ligand B (4.017) is a bit high, potentially leading to solubility issues and off-target interactions. This favors Ligand A.
4. **HBD:** Both ligands have 1 HBD, which is acceptable.
5. **HBA:** Ligand A has 5 HBA, and Ligand B has 6. Both are within the acceptable limit of 10.
6. **QED:** Ligand A (0.882) has a significantly higher QED score than Ligand B (0.688), indicating better overall drug-likeness. This is a strong advantage for Ligand A.
7. **DILI:** Ligand A (93.292) has a much higher DILI risk than Ligand B (22.8). This is a major concern for Ligand A.
8. **BBB:** Ligand B (71.268) has a better BBB penetration percentile than Ligand A (56.65). While not a primary concern for ADRB2 (a cardiovascular target), it's a slight advantage for Ligand B.
9. **Caco-2:** Both ligands have similar, very negative Caco-2 values, suggesting poor permeability. This is a concern for both.
10. **Solubility:** Both ligands have similar, very negative solubility values, indicating poor aqueous solubility. This is a concern for both.
11. **hERG:** Both ligands have low hERG inhibition liability (0.426 and 0.389), which is good.
12. **Cl_mic:** Ligand A (30.514) and Ligand B (33.838) have similar microsomal clearance values.
13. **t1/2:** Ligand A (13.717) and Ligand B (14.504) have similar in vitro half-lives.
14. **Pgp:** Ligand A (0.545) has slightly higher P-gp efflux liability than Ligand B (0.077). This favors Ligand B.
15. **Binding Affinity:** Ligand B (-6.9) has a slightly better binding affinity than Ligand A (-6.8). While the difference is small, it's a positive for Ligand B.
**Overall Assessment:**
Ligand A has a better QED score and logP, but suffers from a significantly higher DILI risk. Ligand B has a much lower DILI risk, better BBB penetration, lower P-gp efflux, and slightly better binding affinity. Considering the GPCR target class, a balance of properties is crucial. The high DILI risk associated with Ligand A is a major drawback that outweighs its slightly better QED and logP. The slightly better binding affinity of Ligand B, combined with its improved safety profile and ADME properties, makes it the more promising candidate.
Output:
0
2025-04-18 00:15:35,996 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (345.443 Da) is better than Ligand B (384.868 Da). Both are within the ideal range, but A is closer to the lower, preferred end.
2. **TPSA:** Ligand A (66.65) is significantly better than Ligand B (74.25). Both are acceptable, but A is closer to the optimal <90 for GPCRs.
3. **logP:** Ligand A (2.827) is slightly better than Ligand B (1.902). Both are within the optimal 1-3 range, but A is closer to the upper end, which is generally preferred for GPCRs.
4. **HBD:** Ligand A (0) is better than Ligand B (1). Fewer HBDs are generally preferred for better permeability.
5. **HBA:** Ligand A (4) is better than Ligand B (7). Lower HBA is preferable.
6. **QED:** Both Ligand A (0.77) and Ligand B (0.867) are excellent, well above the 0.5 threshold.
7. **DILI:** Ligand A (56.301) is better than Ligand B (76.076). Both are acceptable, but A has a lower risk.
8. **BBB:** Ligand A (85.537) is significantly better than Ligand B (66.499). This is a key factor for GPCRs, even if not CNS-focused, as it suggests better distribution.
9. **Caco-2:** Both are negative values, indicating a similar permeability profile.
10. **Solubility:** Ligand A (-3.316) is slightly better than Ligand B (-2.677). Both are very poor, and this is a concern.
11. **hERG:** Ligand A (0.303) is better than Ligand B (0.569). Lower hERG inhibition is crucial for safety.
12. **Cl_mic:** Ligand A (70.331) is much better than Ligand B (15.821). A higher value indicates faster clearance, meaning lower metabolic stability. Ligand A is preferable here.
13. **t1/2:** Ligand A (-25.206) is much worse than Ligand B (9.888). A positive value is preferable.
14. **Pgp:** Ligand A (0.457) is better than Ligand B (0.147). Lower P-gp efflux is preferred.
15. **Binding Affinity:** Ligand B (-7.2) is significantly better than Ligand A (-5.1). This is a substantial difference in potency (2.1 kcal/mol).
**Overall Assessment:**
Ligand B has a much stronger binding affinity, which is a critical factor for GPCRs. However, Ligand A has superior ADME properties across most parameters (TPSA, logP, DILI, BBB, hERG, Cl_mic, Pgp). The solubility for both is poor. While the affinity difference is significant, the overall balance of properties for Ligand A is more favorable for drug development, particularly considering the metabolic stability and reduced toxicity/off-target effects. The better BBB penetration for Ligand A is also a plus. The half-life is a significant drawback for Ligand A, but the other advantages are strong enough to outweigh this.
Output:
1
2025-04-18 00:15:35,996 - INFO - Here's my reasoning and the final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, the key priorities are logP, TPSA, Pgp efflux, binding affinity, and, to a lesser extent, BBB.
Let's compare the ligands property by property:
1. **MW:** Both ligands (346.4 and 344.5 Da) are within the ideal 200-500 Da range.
2. **TPSA:** Both are good (60.3 and 58.6), well below the 140 threshold for oral absorption.
3. **logP:** Ligand A (3.179) is slightly higher than Ligand B (2.019). Both are within the 1-3 optimal range, but A is closer to the upper limit.
4. **HBD/HBA:** Both have 1 HBD, which is good. Ligand A has 4 HBA, and Ligand B has 3. Both are acceptable.
5. **QED:** Both are good (0.838 and 0.794), indicating good drug-like properties.
6. **DILI:** Ligand B (14.6%) is *significantly* better than Ligand A (55.0%). This is a major advantage for Ligand B.
7. **BBB:** Both have good BBB penetration (75.1% and 78.5%). Not a primary concern for a cardiovascular target, but a positive for both.
8. **Caco-2:** Both are negative, which is unusual and suggests poor permeability. However, the values are close enough that this isn't a major differentiator.
9. **Solubility:** Both are negative, indicating poor solubility.
10. **hERG:** Ligand A (0.66) is slightly higher than Ligand B (0.211), indicating a slightly higher risk of hERG inhibition.
11. **Cl_mic:** Ligand B (21.0) has substantially lower microsomal clearance than Ligand A (43.8), suggesting better metabolic stability.
12. **t1/2:** Both have very short in vitro half-lives (29.4 and 0.25 hours). Ligand A is better here.
13. **Pgp:** Ligand A (0.246) has slightly higher Pgp efflux than Ligand B (0.032). Lower Pgp is preferred.
14. **Binding Affinity:** Ligand B (-6.1 kcal/mol) is slightly better than Ligand A (-6.5 kcal/mol).
**Overall Assessment:**
While Ligand A has a slightly better binding affinity and in vitro half-life, Ligand B is superior in almost all ADME-Tox properties. The significantly lower DILI risk and lower Pgp efflux of Ligand B are compelling advantages. The better metabolic stability (lower Cl_mic) is also a significant plus. Given the GPCR target class, balancing potency with good ADME properties is crucial, and Ligand B strikes a better balance.
**Output:**
0
2025-04-18 00:15:35,996 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (339.443 and 346.387 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (77.04) is significantly better than Ligand B (94.05). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (2.65) is within the optimal 1-3 range. Ligand B (-0.665) is below 1, which could hinder permeation. This is a significant advantage for Ligand A.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Both ligands have 5 HBA, which is good.
6. **QED:** Both ligands have good QED scores (0.671 and 0.717), indicating generally drug-like properties.
7. **DILI:** Ligand A (50.291) has a slightly higher DILI risk than Ligand B (42.458), but both are below the concerning threshold of 60.
8. **BBB:** Ligand A (73.556) has better BBB penetration than Ligand B (32.144). While not critical for a cardiovascular target, it's still a positive attribute.
9. **Caco-2:** Ligand A (-5.095) and Ligand B (-4.594) are both negative, indicating poor permeability.
10. **Solubility:** Ligand A (-2.24) is better than Ligand B (-0.88), but both are poor.
11. **hERG:** Ligand A (0.394) has a lower hERG risk than Ligand B (0.068), which is preferable.
12. **Cl_mic:** Ligand B (-6.581) has a significantly lower (better) microsomal clearance than Ligand A (22.695), suggesting greater metabolic stability. This is a substantial advantage for Ligand B.
13. **t1/2:** Ligand B (17.46) has a better in vitro half-life than Ligand A (-23.981). This is a substantial advantage for Ligand B.
14. **Pgp:** Ligand A (0.257) has lower P-gp efflux than Ligand B (0.016), which is preferable.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-8.3 and -6.8 kcal/mol). Ligand A is significantly better.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand A excels in logP and affinity, while Ligand B has better metabolic stability (Cl_mic) and half-life. The significantly better affinity of Ligand A (-8.3 vs -6.8) is a major advantage that can often outweigh some ADME liabilities. The better logP and TPSA of Ligand A are also beneficial.
**Conclusion:**
Despite Ligand B's better metabolic stability and half-life, the superior binding affinity and logP of Ligand A make it the more promising candidate. The affinity difference is large enough to compensate for the slightly higher DILI risk and poorer metabolic stability.
Output:
1
2025-04-18 00:15:35,996 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [405.278, 66.48, 3.382, 1, 3, 0.83, 84.219, 65.839, -4.502, -5.188, 0.546, 77.361, 50.056, 0.368, -6.7]
**Ligand B:** [344.499, 49.41, 2.824, 1, 2, 0.772, 8.026, 85.964, -4.793, -4.064, 0.717, 42.048, 2.187, 0.085, -6.5]
**Step-by-step comparison:**
1. **MW:** Ligand A (405.278 Da) is within the ideal range, while Ligand B (344.499 Da) is a bit lower but still acceptable.
2. **TPSA:** Ligand A (66.48) is slightly higher than ideal for GPCRs, but still reasonable. Ligand B (49.41) is excellent, well below the 90 threshold.
3. **logP:** Both ligands have good logP values (A: 3.382, B: 2.824), falling within the 1-3 range.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 3 HBA, Ligand B has 2. Both are acceptable.
6. **QED:** Ligand A (0.83) has a better QED score than Ligand B (0.772), indicating better overall drug-likeness.
7. **DILI:** Ligand A (84.219) has a significantly higher DILI risk than Ligand B (8.026). This is a major concern for Ligand A.
8. **BBB:** Ligand B (85.964) has a much higher BBB penetration percentile than Ligand A (65.839). While not strictly *required* for ADRB2 (a cardiovascular target), better BBB penetration can reduce off-target effects.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and likely indicates poor permeability. Ligand A (-4.502) is slightly worse than Ligand B (-4.793).
10. **Solubility:** Both have negative solubility values, indicating poor solubility. Ligand B (-4.064) is slightly better.
11. **hERG:** Ligand A (0.546) has a slightly higher hERG risk than Ligand B (0.717), but both are relatively low.
12. **Cl_mic:** Ligand B (42.048) has significantly lower microsomal clearance than Ligand A (77.361), suggesting better metabolic stability.
13. **t1/2:** Ligand A (50.056) has a much longer in vitro half-life than Ligand B (2.187).
14. **Pgp:** Ligand A (0.368) has lower P-gp efflux than Ligand B (0.085), which is favorable.
15. **Affinity:** Ligand A (-6.7 kcal/mol) has a slightly stronger binding affinity than Ligand B (-6.5 kcal/mol), but the difference is small.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Both ligands are reasonable in logP and affinity. Ligand B has a better TPSA and Pgp profile. The biggest differentiator is the DILI risk. Ligand A's high DILI risk is a major red flag.
**Conclusion:**
Despite Ligand A having slightly better QED, half-life, and affinity, the significantly higher DILI risk and lower BBB penetration make it a less desirable candidate. Ligand B's superior safety profile (low DILI), better BBB penetration, and metabolic stability outweigh the slightly weaker affinity and shorter half-life.
Output:
0
2025-04-18 00:15:35,996 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (358.41 and 357.479 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (84.94) is higher than Ligand B (65.2). Both are below the 140 threshold for oral absorption, but Ligand B is preferable given the GPCR target class and the desire for lower TPSA.
3. **logP:** Ligand A (0.81) is slightly lower than the optimal 1-3 range, potentially impacting permeability. Ligand B (3.161) is within the optimal range. This favors Ligand B.
4. **HBD:** Ligand A (1) is better than Ligand B (2). Lower HBD is generally preferred for permeability.
5. **HBA:** Ligand A (5) is better than Ligand B (3). Lower HBA is generally preferred for permeability.
6. **QED:** Both ligands have good QED scores (0.681 and 0.807), indicating good drug-like properties. No major difference.
7. **DILI:** Ligand A (31.214) has a significantly lower DILI risk than Ligand B (61.07). This is a substantial advantage for Ligand A.
8. **BBB:** Ligand A (83.482) has a higher BBB penetration percentile than Ligand B (73.517). While ADRB2 isn't strictly a CNS target, some CNS exposure is possible, and higher BBB is generally favorable.
9. **Caco-2:** Ligand A (-4.56) is better than Ligand B (-5.344). Higher Caco-2 permeability indicates better intestinal absorption.
10. **Solubility:** Ligand A (-1.318) is better than Ligand B (-4.3). Higher aqueous solubility is generally preferred for formulation and bioavailability.
11. **hERG:** Both ligands have low hERG inhibition liability (0.298 and 0.549), indicating low cardiotoxicity risk. No significant difference.
12. **Cl_mic:** Ligand A (3.553) has a lower microsomal clearance than Ligand B (25.794), suggesting better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (-16.828) has a better in vitro half-life than Ligand B (-16.03).
14. **Pgp:** Ligand A (0.031) has a lower P-gp efflux liability than Ligand B (0.13). Lower P-gp efflux is preferable for bioavailability.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-5.5 and -5.7 kcal/mol). The difference is negligible.
**Overall Assessment:**
Ligand A demonstrates a superior ADME profile, particularly regarding DILI risk, metabolic stability (Cl_mic), solubility, and P-gp efflux. While Ligand B has a slightly better logP, the advantages of Ligand A in safety and pharmacokinetic properties outweigh this minor difference. Both ligands have similar binding affinity. Given the GPCR target class, the balance of properties in Ligand A is more favorable for development.
Output:
1
2025-04-18 00:15:35,997 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [349.435, 98.14, 0.696, 2, 6, 0.684, 43.428, 60.644, -5.697, -0.77, 0.048, 7.55, 44.546, 0.034, -7.7]**
**Ligand B: [374.507, 107.61, -0.436, 3, 5, 0.534, 30.206, 40.403, -5.823, -1.365, 0.127, 6.296, -38.517, 0.007, -6.2]**
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (349.435) is slightly preferred.
2. **TPSA:** Ligand A (98.14) is better than Ligand B (107.61), both are acceptable for a non-CNS GPCR target like ADRB2.
3. **logP:** Ligand A (0.696) is slightly below the optimal range (1-3), but still acceptable. Ligand B (-0.436) is lower and potentially problematic for permeability. Ligand A is preferred.
4. **H-Bond Donors:** Ligand A (2) and Ligand B (3) are both within the acceptable limit of 5.
5. **H-Bond Acceptors:** Ligand A (6) and Ligand B (5) are both within the acceptable limit of 10.
6. **QED:** Ligand A (0.684) is slightly better than Ligand B (0.534), indicating a more drug-like profile.
7. **DILI:** Ligand A (43.428) is slightly higher than Ligand B (30.206), but both are below the concerning threshold of 60. Ligand B is preferred.
8. **BBB:** This is less critical for ADRB2 (a cardiovascular target). Ligand A (60.644) is better than Ligand B (40.403).
9. **Caco-2:** Both ligands have negative Caco-2 values, suggesting poor permeability. Ligand A (-5.697) is slightly better than Ligand B (-5.823).
10. **Solubility:** Both ligands have negative solubility values, which is concerning. Ligand A (-0.77) is slightly better than Ligand B (-1.365).
11. **hERG:** Ligand A (0.048) is significantly better than Ligand B (0.127), indicating a lower risk of cardiotoxicity. This is a crucial factor for a cardiovascular target.
12. **Cl_mic:** Ligand A (7.55) has a higher clearance than Ligand B (6.296), indicating lower metabolic stability. Ligand B is preferred.
13. **t1/2:** Ligand A (44.546) has a significantly longer half-life than Ligand B (-38.517). This is a major advantage for Ligand A.
14. **Pgp:** Ligand A (0.034) is much better than Ligand B (0.007), indicating lower P-gp efflux.
15. **Binding Affinity:** Ligand A (-7.7 kcal/mol) has a stronger binding affinity than Ligand B (-6.2 kcal/mol). This is a significant advantage.
**Overall Assessment:**
Ligand A has a better binding affinity, longer half-life, better Pgp efflux, lower hERG risk, and better QED. While Ligand B has a slightly lower DILI risk and clearance, the advantages of Ligand A in binding affinity, half-life, and safety (hERG) are more important for a viable drug candidate targeting ADRB2. The solubility and Caco-2 values are concerning for both, but can be addressed with formulation strategies.
Output:
1
2025-04-18 00:15:35,997 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (396.219 Da) is slightly higher than Ligand B (342.37 Da), but both are acceptable.
2. **TPSA:** Both are below the 140 A^2 threshold for good oral absorption. Ligand A (54.88) is a bit higher than Ligand B (50.8), but still good.
3. **logP:** Both have good logP values (A: 4.937, B: 3.358) within the optimal 1-3 range, but Ligand A is pushing the upper limit. This could potentially lead to solubility issues or off-target interactions.
4. **HBD:** Both have 1 H-bond donor, which is ideal.
5. **HBA:** Both have 3 H-bond acceptors, which is also ideal.
6. **QED:** Both have good QED scores (A: 0.523, B: 0.819). Ligand B's QED is significantly better, indicating a more drug-like profile.
7. **DILI:** Ligand A (99.147%) has a very high DILI risk, which is a major concern. Ligand B (75.766%) is still above the 60% threshold, but significantly lower and more acceptable.
8. **BBB:** Ligand A (73.168%) shows good BBB penetration, while Ligand B (64.986%) is lower. For a cardiovascular target like ADRB2, BBB penetration isn't *critical* but can be beneficial for potential off-target effects or central nervous system side effects.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual. I will assume these are percentile scores, and thus higher is better. Ligand A (-4.836) is worse than Ligand B (-3.984).
10. **Solubility:** Both have negative solubility values, which is also unusual. Assuming these are percentile scores, higher is better. Ligand A (-5.713) is worse than Ligand B (-4.367).
11. **hERG:** Both have low hERG inhibition liability (A: 0.739, B: 0.723), which is good.
12. **Cl_mic:** Ligand B (62.635 mL/min/kg) has significantly lower microsomal clearance than Ligand A (81.086 mL/min/kg), suggesting better metabolic stability.
13. **t1/2:** Ligand A (124.989 hours) has a much longer in vitro half-life than Ligand B (15.486 hours). This is a significant advantage for dosing convenience.
14. **Pgp:** Both have low P-gp efflux liability (A: 0.555, B: 0.243). Ligand B is better.
15. **Binding Affinity:** Ligand A (-8.0 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.1 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME concerns.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand A has a higher logP, better BBB penetration, and *much* better affinity. However, the extremely high DILI risk for Ligand A is a major red flag. Ligand B has a better overall ADME profile, particularly regarding DILI and metabolic stability, despite its lower affinity.
**Conclusion:**
While Ligand A's affinity is very attractive, the unacceptable DILI risk makes it a poor candidate. The improved ADME properties of Ligand B, particularly the lower DILI risk and better metabolic stability, outweigh the affinity difference. Therefore, I would choose Ligand B.
Output:
0
2025-04-18 00:15:35,997 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (351 & 369 Da). No significant difference.
2. **TPSA:** Both are below the 140 A^2 threshold for good oral absorption (80.12 & 80.76 A^2). Very similar.
3. **logP:** Both are within the optimal range (1.113 & 1.934). Ligand B is slightly higher, which *could* be beneficial for membrane permeability, but isn't a major concern.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 5 HBA, Ligand B has 6. Both are acceptable, below the 10 threshold.
6. **QED:** Both have very similar QED scores (0.798 & 0.794), indicating good drug-likeness.
7. **DILI:** Ligand A (35.673) has a significantly lower DILI risk than Ligand B (53.742). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (71.578) has a much higher BBB penetration percentile than Ligand B (48.585). While ADRB2 isn't strictly a CNS target, some CNS exposure can occur, and higher BBB is generally favorable.
9. **Caco-2:** Both have negative Caco-2 values (-4.978 & -4.821), suggesting poor permeability. This is a concern for both.
10. **Solubility:** Both have negative solubility values (-1.876 & -2.272), indicating poor aqueous solubility. This is a significant drawback for both.
11. **hERG:** Ligand A (0.083) has a much lower hERG inhibition liability than Ligand B (0.298). This is a critical advantage for Ligand A, minimizing cardiotoxicity risk.
12. **Cl_mic:** Ligand A (-6.793) has a much lower (better) microsomal clearance than Ligand B (24.963). This means Ligand A is likely to have better metabolic stability.
13. **t1/2:** Ligand A (-3.589) has a more negative (better) in vitro half-life than Ligand B (17.309).
14. **Pgp:** Ligand A (0.019) has a much lower Pgp efflux liability than Ligand B (0.127). Lower Pgp is beneficial for bioavailability.
15. **Binding Affinity:** Ligand B (-6.4 kcal/mol) has a slightly better binding affinity than Ligand A (-7.0 kcal/mol). While this is a difference, it's not a large enough advantage to overcome the significant ADME benefits of Ligand A.
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. While Ligand B has a slightly better logP and affinity, Ligand A excels in Pgp efflux, and the differences aren't substantial enough to outweigh the superior ADME profile of Ligand A.
**Overall Assessment:**
Ligand A demonstrates a significantly more favorable ADME profile than Ligand B, with lower DILI risk, better BBB penetration, lower hERG inhibition, better metabolic stability (lower Cl_mic, better t1/2), and lower Pgp efflux. While Ligand B has slightly better binding affinity, the ADME advantages of Ligand A are more critical for overall drug development success. The poor Caco-2 and solubility for both are concerns that would need to be addressed through formulation strategies, but are less critical than the safety and pharmacokinetic benefits of Ligand A.
Output:
1
2025-04-18 00:15:35,997 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (359.423 and 348.531 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (131.19) is better than Ligand B (40.62). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally aids absorption. Ligand B is *very* low, which could indicate poor aqueous solubility.
3. **logP:** Ligand B (3.987) is closer to the optimal 1-3 range than Ligand A (-1.371). A logP that is too negative can hinder membrane permeability. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (3) is reasonable. Ligand B (0) is also acceptable.
5. **HBA:** Ligand A (6) is reasonable. Ligand B (2) is also acceptable.
6. **QED:** Ligand B (0.754) is better than Ligand A (0.441), indicating a more drug-like profile.
7. **DILI:** Ligand A (11.283) has a much lower DILI risk than Ligand B (31.563). This is a substantial advantage for Ligand A.
8. **BBB:** Ligand B (90.733) has a higher BBB penetration than Ligand A (45.715). While not a primary concern for a cardiovascular target, higher BBB is rarely detrimental.
9. **Caco-2:** Ligand A (-5.677) and Ligand B (-4.588) are both negative, which is unusual. I'm interpreting these as low permeability.
10. **Solubility:** Ligand A (-1.647) is slightly better than Ligand B (-3.5), indicating better aqueous solubility.
11. **hERG:** Ligand A (0.125) is much lower than Ligand B (0.733), indicating a lower risk of cardiotoxicity. This is a critical advantage for a cardiovascular target.
12. **Cl_mic:** Ligand A (0.513) has a much lower microsomal clearance than Ligand B (89.977), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-19.952) has a much longer in vitro half-life than Ligand A (-4.74). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.006) has lower P-gp efflux than Ligand B (0.554), which is favorable for bioavailability.
15. **Affinity:** Ligand B (-6.4) has a slightly better binding affinity than Ligand A (-6.1). While the difference is small, it's still a positive for Ligand B.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand B excels in logP and affinity, and is better in Pgp. Ligand A has a better TPSA. However, the significantly lower DILI and hERG risks for Ligand A are crucial for a cardiovascular drug. The improved metabolic stability (lower Cl_mic) is also a major plus.
**Overall Assessment:**
While Ligand B has advantages in logP, affinity, and half-life, the superior safety profile (DILI and hERG) and metabolic stability of Ligand A are more important for a cardiovascular drug target. The slightly lower affinity of Ligand A can potentially be optimized in later stages of development.
Output:
1
2025-04-18 00:15:35,997 - INFO - Batch 464 complete. Total preferences: 7424
2025-04-18 00:15:35,997 - INFO - Processing batch 465/512...
2025-04-18 00:16:24,539 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.4 and 344.4 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand B (98.32) is significantly better than Ligand A (126.96). For a GPCR, lower TPSA is generally preferred for better permeability.
3. **logP:** Ligand A (-0.935) is slightly below the optimal 1-3 range, while Ligand B (0.459) is within the range. This favors Ligand B.
4. **HBD:** Both ligands have 3 HBD, which is acceptable.
5. **HBA:** Ligand A has 8 HBA, while Ligand B has 4. Lower HBA is generally preferred for permeability, favoring Ligand B.
6. **QED:** Both ligands have good QED scores (0.565 and 0.694), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand B (35.324) has a lower DILI risk than Ligand A (44.048), which is a significant advantage.
8. **BBB:** Ligand B (39.473) has a higher BBB penetration score than Ligand A (14.153). While ADRB2 isn't exclusively a CNS target, some CNS exposure is not detrimental and may even be beneficial depending on the specific therapeutic goal.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it is difficult to interpret.
10. **Solubility:** Both ligands have negative solubility values, which is also unusual.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.009 and 0.168), which is excellent.
12. **Cl_mic:** Ligand A (-1.952) has a lower (better) microsomal clearance than Ligand B (-19.727), indicating greater metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand B (-37.562) has a much longer in vitro half-life than Ligand A (18.394), which is a substantial benefit.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.004 and 0.024).
15. **Binding Affinity:** Both ligands have similar and strong binding affinities (-6.4 and -6.6 kcal/mol). The difference is negligible.
**Overall Assessment:**
Ligand B consistently outperforms Ligand A in several key ADME properties (TPSA, logP, HBA, DILI, BBB), and has a significantly longer half-life. While Ligand A has better metabolic stability (lower Cl_mic), the other advantages of Ligand B, particularly the lower DILI risk and better predicted permeability, outweigh this single benefit. The similar binding affinities make the ADME profile the deciding factor.
**Output:**
0
2025-04-18 00:16:24,539 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.475 and 362.543 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (67.23) is slightly higher than Ligand B (58.12). Both are below the 140 threshold for oral absorption, but closer to the 90 threshold for CNS targets (though ADRB2 isn't necessarily a CNS target). Ligand B is slightly preferred.
3. **logP:** Both ligands have good logP values (2.764 and 3.573), falling within the optimal 1-3 range. Ligand B is a bit higher, potentially leading to slightly reduced solubility, but still acceptable.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 5. Both are acceptable, under the 10 threshold.
6. **QED:** Both ligands have high QED scores (0.891 and 0.805), indicating good drug-likeness. Ligand A is slightly better.
7. **DILI:** Ligand A (30.322) has a significantly lower DILI risk than Ligand B (50.174). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (83.637) has a higher BBB penetration percentile than Ligand A (70.415). While ADRB2 isn't a primary CNS target, some peripheral ADRB2 activity can influence sympathetic outflow, and better BBB penetration isn't necessarily a negative.
9. **Caco-2:** Both have negative Caco-2 values (-4.424 and -4.761). This is unusual and suggests poor permeability. However, these values are on a scale where negative values are possible and don't necessarily preclude development.
10. **Solubility:** Ligand A (-3.244) has better solubility than Ligand B (-4.841). This is a positive for Ligand A.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.259 and 0.262), which is excellent.
12. **Cl_mic:** Ligand A (37.497) has lower microsomal clearance than Ligand B (76.588), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand B (43.996) has a longer in vitro half-life than Ligand A (23.639). This is a positive for Ligand B.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.028 and 0.4).
15. **Binding Affinity:** Ligand B (-6.8) has a slightly better binding affinity than Ligand A (-6.0). This is a 0.8 kcal/mol difference, which is substantial.
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, TPSA, affinity, and metabolic stability are key. Ligand B has a slightly better logP and significantly better affinity. However, Ligand A has a much better safety profile (DILI) and metabolic stability (Cl_mic). The affinity difference, while notable, is not so large as to completely outweigh the safety and metabolic advantages of Ligand A. The Caco-2 permeability values are concerning for both, but not disqualifying.
**Conclusion:**
Considering the balance of properties, particularly the significantly lower DILI risk and better metabolic stability of Ligand A, I believe it is the more promising drug candidate. The slightly better affinity of Ligand B is not enough to overcome these advantages.
Output:
1
2025-04-18 00:16:24,540 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (342.439 and 340.467 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (53.76) is slightly higher than Ligand B (41.57). Both are below the 140 threshold for good oral absorption, but Ligand B is better positioned, especially considering ADRB2 is a cardiovascular target and CNS penetration isn't a primary goal.
3. **logP:** Both ligands have good logP values (2.932 and 3.201), falling within the optimal 1-3 range. Ligand B is slightly higher, which could be a minor advantage for membrane permeability.
4. **HBD:** Ligand A has 0 HBD, while Ligand B has 1. Both are acceptable, but lower is generally preferred for permeability.
5. **HBA:** Both ligands have 3 HBA, which is well within the acceptable limit of 10.
6. **QED:** Both ligands have good QED scores (0.773 and 0.809), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (22.024) has a significantly higher DILI risk than Ligand B (10.857). This is a major concern, as minimizing liver toxicity is crucial.
8. **BBB:** Both ligands have high BBB penetration (88.833 and 77.2). While not a primary concern for a cardiovascular target, it's not detrimental.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.666 and -4.686). These values are unusual and suggest very poor permeability. This is a significant drawback for both.
10. **Solubility:** Both ligands have poor aqueous solubility (-2.668 and -3.568). This is a concern for bioavailability.
11. **hERG:** Both ligands have low hERG inhibition risk (0.396 and 0.628), which is good.
12. **Cl_mic:** Ligand A (53.657) has a higher microsomal clearance than Ligand B (39.441), indicating lower metabolic stability.
13. **t1/2:** Ligand B (-1.433) has a negative in vitro half-life, which is highly problematic. Ligand A (31.672) has a much more reasonable half-life.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.339 and 0.182), which is favorable.
15. **Binding Affinity:** Both ligands have the same binding affinity (-6.1 kcal/mol).
**Overall Assessment:**
Despite both ligands having issues with Caco-2 permeability and solubility, Ligand B is the better candidate. The most significant factor is the drastically lower DILI risk for Ligand B. The better QED score and lower Cl_mic also contribute. While Ligand B has a concerning negative half-life, this is a parameter that can be improved through structural modifications. The high DILI risk of Ligand A is a more difficult issue to address.
Output:
0
2025-04-18 00:16:24,540 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (338.411 and 357.479 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (91.81) is slightly higher than Ligand B (46.84). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for permeability. Ligand B has a substantial advantage here.
**3. logP:** Both ligands have similar logP values (3.806 and 3.747), both falling within the optimal 1-3 range. No clear advantage.
**4. H-Bond Donors:** Ligand A has 1 HBD, while Ligand B has 0. Both are acceptable, but fewer HBDs often correlate with better membrane permeability. Ligand B is slightly favored.
**5. H-Bond Acceptors:** Both ligands have 5 HBAs, which is within the acceptable range of <=10. No significant difference.
**6. QED:** Ligand A (0.829) has a higher QED score than Ligand B (0.699), indicating a more drug-like profile. This is a positive for Ligand A.
**7. DILI Risk:** Ligand B (60.062) has a higher DILI risk than Ligand A (48.119). This is a significant concern, as a DILI percentile above 60 is considered high risk. Ligand A is favored.
**8. BBB Penetration:** Ligand A (85.459) has better BBB penetration than Ligand B (66.925). While ADRB2 is primarily cardiovascular, some CNS off-target effects are possible, and higher BBB penetration could contribute to those. This favors Ligand A.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.698 and -4.564). These values are unusual and suggest poor permeability in this *in vitro* assay. However, the values are very close, so this isn't a deciding factor.
**10. Aqueous Solubility:** Ligand A (-4.763) has slightly worse solubility than Ligand B (-3.496). Solubility is important, but not a primary concern for this target.
**11. hERG Inhibition:** Ligand A (0.378) has a lower hERG inhibition risk than Ligand B (0.712). Lower hERG inhibition is crucial for avoiding cardiotoxicity, making Ligand A significantly more favorable.
**12. Microsomal Clearance:** Ligand B (79.356) has a higher microsomal clearance than Ligand A (29.477), indicating faster metabolism and lower metabolic stability. This is a major drawback for Ligand B.
**13. In vitro Half-Life:** Ligand A (18.22 hours) has a much longer in vitro half-life than Ligand B (2.72 hours). This is a significant advantage for Ligand A, potentially allowing for less frequent dosing.
**14. P-gp Efflux:** Ligand A (0.197) has lower P-gp efflux than Ligand B (0.83). Lower P-gp efflux is desirable for better bioavailability. Ligand A is favored.
**15. Binding Affinity:** Ligand B (-7.1 kcal/mol) has a slightly stronger binding affinity than Ligand A (-6.6 kcal/mol). While affinity is important, the difference of 0.5 kcal/mol is not substantial enough to outweigh the numerous ADME/Tox advantages of Ligand A.
**Overall Assessment:**
Ligand A demonstrates a significantly better overall profile, particularly regarding safety (DILI, hERG), metabolic stability (Cl_mic, t1/2), and permeability (TPSA, P-gp). While Ligand B has slightly better binding affinity, the other factors strongly favor Ligand A as a more viable drug candidate for the ADRB2 receptor.
Output:
1
2025-04-18 00:16:24,540 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (359.373 Da and 385.921 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (70.16) is significantly better than Ligand B (84.14). For a GPCR, keeping TPSA lower is beneficial for permeability. Ligand A is well below the 140 threshold, while B is approaching it.
**3. logP:** Ligand A (0.932) is slightly lower than Ligand B (2.293). Both are within the optimal 1-3 range, but Ligand B is closer to the upper limit.
**4. H-Bond Donors:** Ligand A (0) is preferable to Ligand B (1). Fewer HBDs generally improve membrane permeability.
**5. H-Bond Acceptors:** Ligand B (7) is higher than Ligand A (4). Again, lower is generally better for permeability.
**6. QED:** Both ligands have similar QED values (0.732 and 0.753), indicating good drug-likeness.
**7. DILI:** Ligand B (40.403) has a slightly lower DILI risk than Ligand A (49.128), which is a minor advantage. Both are below the concerning threshold of 60.
**8. BBB:** Ligand A (89.027) has a significantly higher BBB penetration percentile than Ligand B (46.336). While ADRB2 is a cardiovascular target, some CNS exposure can occur, and higher BBB is generally favorable.
**9. Caco-2 Permeability:** Ligand A (-4.171) is better than Ligand B (-5.093). Higher values indicate better intestinal absorption.
**10. Aqueous Solubility:** Ligand A (-1.977) is better than Ligand B (-3.012). Higher solubility is generally preferred.
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.348 and 0.172), which is excellent.
**12. Microsomal Clearance:** Ligand A (14.566) has a significantly lower microsomal clearance than Ligand B (55.642), indicating better metabolic stability.
**13. In vitro Half-Life:** Ligand A (-27.13) has a much longer in vitro half-life than Ligand B (12.392). This is a significant advantage for dosing frequency.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.063 and 0.156).
**15. Binding Affinity:** Ligand A (-7.3) has a slightly better binding affinity than Ligand B (-6.4). While the difference is not huge, it's enough to be noticeable.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand A is clearly superior. It has better TPSA, solubility, metabolic stability (lower Cl_mic and longer t1/2), and a slightly better binding affinity. While Ligand B has a marginally lower DILI risk, the advantages of Ligand A in permeability, metabolic stability, and binding outweigh this minor difference.
Output:
1
2025-04-18 00:16:24,540 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
Let's systematically compare Ligand A and Ligand B based on the provided parameters, keeping in mind the GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key).
1. **MW:** Both ligands (335.411 and 360.47 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both are good (72.7 and 70.08), well below the 140 threshold for oral absorption.
3. **logP:** Both ligands have good logP values (2.966 and 1.752), falling within the optimal 1-3 range. Ligand A is slightly higher, which *could* be beneficial for membrane permeability, but isn't a major concern for either.
4. **HBD/HBA:** Both have 1 HBD and a reasonable number of HBAs (5 and 4 respectively), satisfying the <5 HBD and <10 HBA guidelines.
5. **QED:** Both ligands have good QED scores (0.532 and 0.603), indicating good drug-like properties.
6. **DILI:** Ligand B has a significantly lower DILI risk (18.883 percentile) compared to Ligand A (69.911 percentile). This is a *major* advantage for Ligand B.
7. **BBB:** Ligand B has a better BBB penetration score (83.366) than Ligand A (65.529). While ADRB2 isn't exclusively a CNS target, some peripheral effects are mediated by CNS pathways, and better BBB penetration can be advantageous.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the values are similar (-5.26 and -4.345).
9. **Solubility:** Ligand B has better aqueous solubility (-1.325) than Ligand A (-3.188).
10. **hERG:** Both have low hERG inhibition liability (0.499 and 0.655), which is good.
11. **Cl_mic:** Ligand B has a lower microsomal clearance (47.442 mL/min/kg) than Ligand A (93.005 mL/min/kg), indicating better metabolic stability.
12. **t1/2:** Ligand B has a slightly better in vitro half-life (-3.143 hours) than Ligand A (-34.681 hours).
13. **Pgp:** Ligand A has lower P-gp efflux (0.427) than Ligand B (0.291), which is preferable.
14. **Binding Affinity:** Ligand B has a slightly better binding affinity (-5.8 kcal/mol) than Ligand A (-4.9 kcal/mol). This is a significant difference.
**Overall Assessment:**
While Ligand A has a slightly better Pgp profile, Ligand B overwhelmingly wins on safety (DILI), metabolic stability (Cl_mic), solubility, and binding affinity. The improved BBB penetration is also a plus. The slightly better affinity of Ligand B, combined with its superior ADME properties, makes it the more promising drug candidate.
**Output:**
0
2025-04-18 00:16:24,541 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 drug candidates. ADRB2 is a GPCR, so we'll prioritize logP, Pgp, TPSA, and affinity, alongside general drug-like properties.
**Ligand A:** [414.3, 84.67, 1.686, 1, 5, 0.517, 44.281, 86.196, -4.863, -2.984, 0.528, 64.451, 67.904, 0.42, -7.4]
**Ligand B:** [429.38, 66.48, 3.181, 1, 4, 0.755, 53.858, 78.751, -4.956, -3.383, 0.641, 41.325, 33.645, 0.528, -6.3]
1. **MW:** Both are within the ideal range (200-500 Da). A is 414.3, B is 429.38. No significant difference.
2. **TPSA:** A (84.67) is higher than B (66.48). B is better, being closer to the <140 threshold for oral absorption.
3. **logP:** A (1.686) is good, within the 1-3 range. B (3.181) is also acceptable but edging towards the higher end. A is slightly preferred here.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** A has 5, B has 4. Both are acceptable.
6. **QED:** A (0.517) is just above the 0.5 threshold, while B (0.755) is significantly better, indicating a more drug-like profile.
7. **DILI:** A (44.281) is better than B (53.858), indicating lower liver injury risk.
8. **BBB:** A (86.196) is significantly better than B (78.751). While not a primary concern for ADRB2 (cardiovascular target), higher BBB is generally a positive.
9. **Caco-2:** Both are negative, indicating poor permeability. A (-4.863) is worse than B (-4.956).
10. **Solubility:** Both are negative, indicating poor solubility. A (-2.984) is worse than B (-3.383).
11. **hERG:** Both are low, indicating low cardiotoxicity risk. A (0.528) is slightly better than B (0.641).
12. **Cl_mic:** A (64.451) is higher than B (41.325), meaning B has better metabolic stability.
13. **t1/2:** A (67.904) is significantly better than B (33.645), indicating a longer half-life.
14. **Pgp:** Both are low (0.42 and 0.528), suggesting limited efflux.
15. **Affinity:** A (-7.4) is significantly better than B (-6.3). This is a 1.1 kcal/mol difference, which is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand A has a significantly better binding affinity, which is paramount for GPCR targets. It also has better DILI and BBB penetration. While Ligand B has a better QED and metabolic stability, the substantial affinity advantage of A, coupled with acceptable ADME properties, makes it the more promising candidate. The poor Caco-2 and solubility of both ligands are concerning, but can be addressed through formulation strategies. The longer half-life of A is also a benefit.
Output:
1
2025-04-18 00:16:24,541 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (355.395 Da) is slightly lower, which is generally favorable for permeability.
**2. TPSA:** Ligand B (67.87) is significantly better than Ligand A (128.87). For a GPCR, lower TPSA is preferred for better membrane permeability. This is a substantial advantage for Ligand B.
**3. logP:** Ligand B (1.538) is within the optimal range (1-3), while Ligand A (-1.09) is below 1, potentially hindering permeation. Ligand B is clearly better here.
**4. H-Bond Donors:** Ligand A (4) is acceptable, while Ligand B (1) is even more favorable. Fewer HBDs generally improve permeability.
**5. H-Bond Acceptors:** Both ligands have 5 HBA, which is within the acceptable limit of 10.
**6. QED:** Ligand B (0.665) has a better QED score than Ligand A (0.461), indicating a more drug-like profile.
**7. DILI Risk:** Ligand B (15.936) has a much lower DILI risk than Ligand A (49.283). This is a critical advantage for Ligand B.
**8. BBB Penetration:** Both ligands have reasonable BBB penetration (Ligand A: 68.67, Ligand B: 61.38). While not a primary concern for a cardiovascular target, it's still a positive attribute.
**9. Caco-2 Permeability:** Ligand A (-5.401) and Ligand B (-4.848) both have negative Caco-2 values, which is unusual and indicates poor permeability. However, the difference is small.
**10. Aqueous Solubility:** Ligand A (-0.97) has slightly better aqueous solubility than Ligand B (-1.92).
**11. hERG Inhibition:** Ligand A (0.04) has a lower hERG risk than Ligand B (0.337), which is desirable.
**12. Microsomal Clearance:** Ligand A (4.84) has significantly lower microsomal clearance than Ligand B (37.693), indicating better metabolic stability.
**13. In vitro Half-Life:** Ligand A (-13.033) has a negative half-life, which is not possible. This is a major red flag. Ligand B (9.455) has a reasonable half-life.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (Ligand A: 0.004, Ligand B: 0.038).
**15. Binding Affinity:** Ligand B (-6.8 kcal/mol) has a significantly stronger binding affinity than Ligand A (-2.5 kcal/mol). This is a substantial advantage that can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand B is the clear winner. While Ligand A has better metabolic stability and slightly better solubility, it suffers from a significantly weaker binding affinity, a negative in vitro half-life, and a higher DILI risk. Ligand B excels in key GPCR properties like TPSA and logP, has a much better QED score, a substantially stronger binding affinity, and a much lower DILI risk. The superior binding affinity of Ligand B is a crucial factor, and the other advantages outweigh the slightly higher hERG risk.
Output:
0
2025-04-18 00:16:24,541 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [345.403, 108.21 , 0.746, 1. , 6. , 0.815, 48.275, 44.668, -4.884, -2.217, 0.114, 11.214, -8.306, 0.01 , -6.3 ]
**Ligand B:** [352.435, 96.69 , -0.082, 2. , 6. , 0.682, 24.234, 23.11 , -5.229, -0.647, 0.132, 6.744, 3.008, 0.02 , -4. ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (345.403) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (108.21) is slightly higher than Ligand B (96.69), but both are below the 140 threshold for oral absorption.
3. **logP:** Ligand A (0.746) is within the optimal range, while Ligand B (-0.082) is slightly below. This is a point in favor of Ligand A, as GPCRs benefit from a reasonable logP for membrane permeability.
4. **HBD:** Ligand A (1) is better than Ligand B (2). Lower HBD is generally preferred for permeability.
5. **HBA:** Both have 6 HBA, which is acceptable.
6. **QED:** Ligand A (0.815) has a better QED score than Ligand B (0.682), indicating a more drug-like profile.
7. **DILI:** Ligand B (24.234) has a significantly lower DILI risk than Ligand A (48.275). This is a major advantage for Ligand B.
8. **BBB:** Ligand A (44.668) has a higher BBB penetration percentile than Ligand B (23.11). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be useful for understanding off-target effects and distribution.
9. **Caco-2:** Ligand B (-5.229) has a better Caco-2 permeability than Ligand A (-4.884), indicating better intestinal absorption.
10. **Solubility:** Ligand B (-0.647) has better aqueous solubility than Ligand A (-2.217).
11. **hERG:** Both have very low hERG risk (0.114 and 0.132).
12. **Cl_mic:** Ligand B (6.744) has lower microsomal clearance than Ligand A (11.214), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-8.306) has a longer in vitro half-life than Ligand B (3.008).
14. **Pgp:** Both have very low Pgp efflux liability (0.01 and 0.02).
15. **Affinity:** Ligand A (-6.3 kcal/mol) has a slightly better binding affinity than Ligand B (-4.0 kcal/mol). This is a significant advantage.
**GPCR-specific considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A has a better logP and affinity. Ligand B excels in DILI and solubility, and has a better Caco-2 permeability and metabolic stability. The affinity difference is substantial (2.3 kcal/mol), which often outweighs minor ADME concerns.
**Conclusion:**
Despite Ligand B's better safety profile (DILI) and solubility, the significantly stronger binding affinity of Ligand A makes it the more promising candidate. The difference in affinity is large enough to compensate for the slightly higher DILI risk, especially in early-stage drug discovery where optimization can address safety concerns.
Output:
1
2025-04-18 00:16:24,541 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (367.471 and 378.845 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (107.53) is better than Ligand B (110.17). Both are reasonably good for oral absorption, but lower is preferable.
3. **logP:** Ligand A (-0.747) is suboptimal, being slightly below the preferred 1-3 range, potentially hindering permeability. Ligand B (2.63) is within the optimal range. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (4) is acceptable, while Ligand B (2) is even better, minimizing potential issues with solubility and permeability.
5. **HBA:** Ligand A (5) is good, while Ligand B (8) is higher, potentially impacting permeability.
6. **QED:** Ligand B (0.72) is significantly better than Ligand A (0.257), indicating a more drug-like profile.
7. **DILI:** Ligand A (18.418) has a much lower DILI risk than Ligand B (93.68). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (68.864) is better than Ligand A (39.046). While ADRB2 isn't exclusively a CNS target, some CNS penetration can be beneficial.
9. **Caco-2:** Both ligands have similar, poor Caco-2 permeability (-5.514 and -5.018).
10. **Solubility:** Ligand A (-1.659) is better than Ligand B (-4.497).
11. **hERG:** Ligand A (0.079) has a lower hERG risk than Ligand B (0.618). This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand A (-2.421) has a much lower (better) microsomal clearance than Ligand B (21.526), indicating better metabolic stability.
13. **t1/2:** Ligand B (16.828) has a longer in vitro half-life than Ligand A (-11.308). This is an advantage for Ligand B.
14. **Pgp:** Ligand B (0.147) has lower P-gp efflux liability than Ligand A (0.006). This is a slight advantage for Ligand B.
15. **Binding Affinity:** Ligand B (-7.4) has a significantly stronger binding affinity than Ligand A (-6.7). This is a substantial advantage for Ligand B, potentially outweighing some ADME concerns.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand B excels in logP and affinity, and is reasonable for Pgp and TPSA. Ligand A has better DILI and hERG, but its logP is a concern. The substantial affinity difference of Ligand B is likely to be the most important factor.
**Overall Assessment:**
While Ligand A has advantages in safety parameters (DILI, hERG) and metabolic stability, Ligand B's significantly stronger binding affinity and better logP outweigh these concerns. The longer half-life of Ligand B is also a positive. The poor Caco-2 permeability is a concern for both, but can be addressed with formulation strategies.
Output:
0
2025-04-18 00:16:24,541 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.5 and 355.5 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (24.94) is excellent, well below the 140 threshold and highly favorable for oral absorption. Ligand B (89.95) is higher, but still potentially acceptable, though less optimal.
3. **logP:** Ligand A (3.538) is within the optimal 1-3 range. Ligand B (0.756) is slightly low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (0) is ideal. Ligand B (2) is acceptable.
5. **HBA:** Both ligands (4) are within the acceptable limit of 10.
6. **QED:** Both ligands (0.754 and 0.705) are good, indicating drug-like properties.
7. **DILI:** Ligand A (3.645) has a very low DILI risk. Ligand B (12.524) is higher, indicating a moderate risk of liver injury. This is a significant concern.
8. **BBB:** Ligand A (83.055) shows good BBB penetration, which could be beneficial. Ligand B (18.457) has poor BBB penetration. While ADRB2 isn't exclusively a CNS target, some peripheral effects are desired, and good BBB penetration isn't detrimental.
9. **Caco-2:** Both ligands have negative Caco-2 permeability values, which is unusual and suggests a potential issue with in vitro permeability assessment. However, the magnitude of the negative value is smaller for Ligand A (-4.738 vs -5.144).
10. **Solubility:** Ligand A (-1.814) has slightly better solubility than Ligand B (-0.811).
11. **hERG:** Ligand A (0.955) has a lower hERG risk than Ligand B (0.114). This is a crucial safety parameter.
12. **Cl_mic:** Ligand A (20.475) has a higher microsomal clearance than Ligand B (12.406), suggesting faster metabolism and potentially lower in vivo exposure.
13. **t1/2:** Ligand B (-9.162) has a longer in vitro half-life than Ligand A (-6.647), which is a positive attribute.
14. **Pgp:** Ligand A (0.219) has lower P-gp efflux than Ligand B (0.021), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand A (-7.9) has a significantly stronger binding affinity than Ligand B (-5.9), a difference of 2 kcal/mol. This is a substantial advantage.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A excels in these areas (good logP, very low TPSA, lower Pgp efflux, and significantly higher affinity). The lower DILI risk and hERG liability of Ligand A are also major advantages. While Ligand B has a longer half-life, the weaker affinity, higher DILI risk, and lower Pgp properties are concerning.
**Conclusion:**
Ligand A clearly outperforms Ligand B across several critical parameters, particularly binding affinity, safety (DILI, hERG), and permeability-related properties (TPSA, Pgp). The stronger binding affinity is likely to outweigh the slightly higher metabolic clearance.
Output:
1
2025-04-18 00:16:24,541 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (396.299) is slightly higher than Ligand B (375.485), but both are acceptable.
2. **TPSA:** Ligand A (75.11) is higher than Ligand B (52.65). While both are reasonably good, Ligand B is preferable as lower TPSA generally correlates with better permeability, important for GPCRs.
3. **logP:** Ligand A (4.375) is higher than Ligand B (1.434). Ligand A is pushing the upper limit, potentially leading to solubility issues and off-target effects. Ligand B is well within the optimal range. This favors Ligand B.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable, well below the threshold of 5.
5. **HBA:** Ligand A (5) and Ligand B (4) are both acceptable, below the threshold of 10.
6. **QED:** Both ligands have similar and good QED values (Ligand A: 0.628, Ligand B: 0.652), indicating good drug-like properties.
7. **DILI:** Ligand A (75.456) has a significantly higher DILI risk than Ligand B (11.788). This is a major concern, making Ligand B much more favorable.
8. **BBB:** Ligand A (47.809) has a lower BBB penetration percentile than Ligand B (96.472). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be beneficial for distribution and off-target effects assessment. Ligand B is significantly better here.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.276 and -5.179). This is unusual and suggests poor permeability. However, the values are very similar.
10. **Solubility:** Ligand A (-4.686) has worse solubility than Ligand B (-2.32). This, combined with its higher logP, is concerning for Ligand A.
11. **hERG:** Ligand A (0.521) has a slightly higher hERG risk than Ligand B (0.79). Lower is better, so Ligand B is preferred.
12. **Cl_mic:** Ligand A (70.079) has a higher microsomal clearance than Ligand B (8.134), indicating lower metabolic stability. Ligand B is significantly better.
13. **t1/2:** Ligand A (16.241) has a shorter in vitro half-life than Ligand B (-11.826). A negative value for t1/2 is unusual, but suggests a very long half-life for Ligand B, which is desirable.
14. **Pgp:** Ligand A (0.616) has a slightly higher P-gp efflux liability than Ligand B (0.04). Lower is better, favoring Ligand B.
15. **Binding Affinity:** Ligand A (-6.6) and Ligand B (-6.4) have very similar binding affinities. The difference (0.2 kcal/mol) is not substantial enough to override the significant ADME advantages of Ligand B.
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP, TPSA, and Pgp, while the affinity difference is minimal. The significantly lower DILI risk and better metabolic stability of Ligand B further solidify its advantage.
**Conclusion:**
Ligand B is the more promising drug candidate due to its superior ADME properties (lower DILI, better solubility, metabolic stability, and Pgp efflux), and acceptable binding affinity. While Ligand A has a slightly higher MW, the benefits of Ligand B's profile outweigh this minor difference.
Output:
0
2025-04-18 00:16:24,542 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (373.356 and 363.439 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (71.62) is significantly better than Ligand B (95.67). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold. Ligand B is approaching it.
3. **logP:** Ligand A (3.233) is within the optimal 1-3 range. Ligand B (0.743) is a bit low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (3) and Ligand B (2) are both acceptable, below the 5 threshold.
5. **HBA:** Ligand A (5) and Ligand B (6) are both acceptable, below the 10 threshold.
6. **QED:** Both ligands have good QED scores (0.72 and 0.819), indicating good drug-like properties.
7. **DILI:** Both ligands have similar DILI risk (82.435 and 80.341), and are relatively high, but not extremely concerning.
8. **BBB:** Ligand A (77.007) has a better BBB percentile than Ligand B (53.548). While not a primary concern for a cardiovascular target, higher BBB is generally favorable.
9. **Caco-2:** Ligand A (-5.014) and Ligand B (-5.522) are both negative, which is unusual and suggests poor permeability. However, the scale isn't specified, so it's difficult to interpret.
10. **Solubility:** Ligand A (-4.497) and Ligand B (-2.56) are both negative, suggesting poor solubility. Ligand B is slightly better.
11. **hERG:** Ligand A (0.723) has a much lower hERG risk than Ligand B (0.127), which is a significant advantage. Avoiding hERG inhibition is crucial for cardiovascular drugs.
12. **Cl_mic:** Ligand A (34.855) has a lower microsomal clearance than Ligand B (57.683), indicating better metabolic stability.
13. **t1/2:** Ligand A (20.494) has a significantly longer in vitro half-life than Ligand B (1.4). This is a major advantage, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.568) has lower P-gp efflux than Ligand B (0.109), indicating better bioavailability.
15. **Binding Affinity:** Ligand B (-11.1) has a substantially stronger binding affinity than Ligand A (-5.3). This is a very large difference, and a >1.5 kcal/mol advantage is often decisive.
**Overall Assessment:**
Ligand B has a significantly better binding affinity. However, it suffers from lower logP, poor solubility, higher Pgp efflux, and a much shorter half-life. Ligand A has better ADME properties (TPSA, logP, hERG, Cl_mic, t1/2, Pgp) and a reasonable binding affinity. Given the importance of ADME properties for *in vivo* efficacy, and the relatively good (though not exceptional) binding affinity of Ligand A, I believe it represents a more viable starting point for drug development. The large affinity difference of Ligand B is tempting, but the poor ADME profile is a substantial hurdle.
Output:
1
2025-04-18 00:16:24,542 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.431 and 350.459 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (110.69) is higher than Ligand B (70.08). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B is significantly better.
3. **logP:** Ligand A (0.486) is quite low, potentially hindering membrane permeability. Ligand B (0.881) is better, though still on the lower side of the optimal 1-3 range. Ligand B is preferable.
4. **HBD:** Ligand A (5) is at the upper limit of the preferred range, while Ligand B (1) is excellent. Ligand B is better.
5. **HBA:** Ligand A (5) is within the acceptable range, and Ligand B (4) is also good. No major difference.
6. **QED:** Ligand B (0.772) has a higher QED score than Ligand A (0.492), indicating a more drug-like profile. Ligand B is better.
7. **DILI:** Ligand A (34.781) has a higher DILI risk than Ligand B (11.361). Lower is better, so Ligand B is significantly better.
8. **BBB:** While ADRB2 isn't a primary CNS target, some peripheral effects can be modulated by CNS penetration. Ligand A (43.311) is low, while Ligand B (61.535) is moderate. Ligand B is better.
9. **Caco-2:** Ligand A (-5.123) is very poor, indicating poor intestinal absorption. Ligand B (-4.466) is also poor, but slightly better.
10. **Solubility:** Ligand A (-2.326) is very poor, while Ligand B (-0.643) is slightly better. Solubility is important for bioavailability. Ligand B is better.
11. **hERG:** Both ligands (0.213 and 0.215) have very low hERG inhibition liability, which is excellent. No significant difference.
12. **Cl_mic:** Ligand A (6.743) has a higher microsomal clearance than Ligand B (4.442), indicating lower metabolic stability. Ligand B is better.
13. **t1/2:** Ligand A (4.75) has a slightly longer in vitro half-life than Ligand B (2.997). This is a minor advantage for Ligand A.
14. **Pgp:** Both ligands (0.009 and 0.072) show very low P-gp efflux liability, which is good. No significant difference.
15. **Binding Affinity:** Ligand B (-9.1 kcal/mol) has a significantly stronger binding affinity than Ligand A (-7.7 kcal/mol). This is a substantial advantage, and a >1.5 kcal/mol difference can often outweigh other ADME concerns.
**Overall Assessment:**
Ligand B consistently outperforms Ligand A across most critical ADME properties (TPSA, logP, HBD, QED, DILI, solubility, Cl_mic) and has a significantly stronger binding affinity. While Ligand A has a slightly longer half-life, the overall profile of Ligand B is far more promising for drug development. The lower TPSA, better logP, and significantly reduced DILI risk are particularly attractive. The substantial improvement in binding affinity seals the deal.
Output:
0
2025-04-18 00:16:24,542 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (351.487) is slightly lower, which is generally favorable for permeability, but both are acceptable.
2. **TPSA:** Ligand A (56.79) is significantly better than Ligand B (84.94). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (3.911) is better than Ligand B (1.14). The optimal range is 1-3, and Ligand A is closer to the upper end, which is preferable for a GPCR. Ligand B's logP is quite low, potentially hindering membrane permeability.
4. **HBD:** Both ligands have 1 HBD, which is within the acceptable limit of 5.
5. **HBA:** Ligand A (4) is better than Ligand B (5). Both are within the acceptable limit of 10.
6. **QED:** Ligand A (0.733) is better than Ligand B (0.578), indicating a more drug-like profile.
7. **DILI:** Ligand B (25.204) is *much* better than Ligand A (49.864). This is a significant advantage for Ligand B.
8. **BBB:** Ligand B (75.611) is better than Ligand A (63.358), but neither is exceptionally high. Since ADRB2 is primarily a cardiovascular target, BBB penetration isn't a critical factor.
9. **Caco-2:** Ligand A (-4.305) is better than Ligand B (-5.059). Higher values are better, indicating better intestinal absorption.
10. **Solubility:** Ligand A (-4.629) is better than Ligand B (-1.802). Higher values are better.
11. **hERG:** Both ligands have similar hERG inhibition liability (0.73 and 0.578), and are within acceptable limits.
12. **Cl_mic:** Ligand B (23.321) is significantly better than Ligand A (90.642). Lower clearance is preferred for metabolic stability.
13. **t1/2:** Ligand B (-26.63) is significantly better than Ligand A (14.609). A longer half-life is generally desirable.
14. **Pgp:** Ligand A (0.498) is better than Ligand B (0.096). Lower efflux is preferred.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-5.6 and -5.0 kcal/mol). This difference is not substantial enough to override other factors.
**Overall Assessment:**
While Ligand B has a significantly better DILI score, lower Cl_mic, and longer t1/2, Ligand A has better TPSA, logP, Caco-2 permeability, solubility, and Pgp efflux. Considering the GPCR-specific priorities (logP, TPSA, Pgp), Ligand A appears to be slightly more favorable. However, the DILI risk for Ligand A is concerning. The difference in binding affinity is minimal.
Given the balance of properties, and the importance of metabolic stability and reduced toxicity, I lean towards Ligand B. The lower DILI risk and improved metabolic profile are significant advantages that outweigh the slightly less optimal TPSA and logP.
Output:
0
2025-04-18 00:16:24,542 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (343.427 Da) is well within the ideal range (200-500 Da). Ligand B (447.34 Da) is at the higher end, but still acceptable.
2. **TPSA:** Ligand A (84.08) is excellent, well below the 140 threshold for good absorption. Ligand B (126.66) is still reasonable, but less optimal.
3. **logP:** Both ligands (A: 3.115, B: 2.663) are within the optimal 1-3 range.
4. **HBD:** Both have 2 HBD, which is good.
5. **HBA:** Ligand A has 5 HBA, which is good. Ligand B has 8 HBA, which is a bit higher but still acceptable.
6. **QED:** Ligand A (0.815) has a better QED score than Ligand B (0.595), indicating better overall drug-likeness.
7. **DILI:** Ligand A (56.572) has a significantly lower DILI risk than Ligand B (96.549). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (51.919) has a moderate BBB penetration, while Ligand B (33.85) is lower. While ADRB2 isn't necessarily a CNS target, some peripheral ADRB2 receptors can be affected by CNS penetration.
9. **Caco-2:** Ligand A (-4.847) and Ligand B (-5.568) both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
10. **Solubility:** Ligand A (-4.727) and Ligand B (-3.653) both have negative solubility values, which is also unusual and suggests poor solubility. Again, the scale is not specified.
11. **hERG:** Both ligands have low hERG risk (A: 0.559, B: 0.479).
12. **Cl_mic:** Ligand A (88.37) has a higher microsomal clearance than Ligand B (30.76), indicating faster metabolism and potentially lower *in vivo* exposure.
13. **t1/2:** Ligand A (4.707) has a shorter half-life than Ligand B (-1.019). Again, the scale is not specified, but a negative value is unusual.
14. **Pgp:** Both ligands have low P-gp efflux (A: 0.103, B: 0.262).
15. **Affinity:** Ligand B (-7.1 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.3 kcal/mol). This is a substantial advantage.
**GPCR-specific considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are particularly important. Both ligands are reasonable in logP and Pgp. Ligand A has a better TPSA. However, the substantial affinity advantage of Ligand B (-7.1 vs -6.3 kcal/mol) is likely to outweigh the slightly less favorable TPSA and solubility/permeability concerns. The DILI risk of Ligand B is a significant concern, but the potency difference is substantial.
**Conclusion:**
Despite the higher DILI risk and slightly less favorable TPSA, the significantly improved binding affinity of Ligand B makes it the more promising candidate. The potency advantage is likely to be crucial for efficacy, and optimization efforts could focus on mitigating the DILI risk.
Output:
0
2025-04-18 00:16:24,543 - INFO - Batch 465 complete. Total preferences: 7440
2025-04-18 00:16:24,543 - INFO - Processing batch 466/512...
2025-04-18 00:17:14,801 - INFO - Here's my reasoning and the final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, key priorities are logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB.
Let's compare the ligands property by property:
1. **MW:** Both ligands (341.415 and 356.419 Da) are within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (85.84) is better than Ligand B (97.33), being closer to the <140 threshold for good absorption.
3. **logP:** Ligand A (2.428) is optimal (1-3), while Ligand B (-0.705) is below 1, potentially hindering permeation. This is a significant advantage for Ligand A.
4. **HBD/HBA:** Both have acceptable HBD (1/2) and HBA (6/6) counts.
5. **QED:** Ligand A (0.863) has a better QED score than Ligand B (0.597), indicating a more drug-like profile.
6. **DILI:** Ligand A (64.521) has a higher DILI risk than Ligand B (16.014), but both are reasonably acceptable.
7. **BBB:** Ligand A (67.623) has a slightly better BBB penetration than Ligand B (33.967), but this is less critical for a cardiovascular target.
8. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. This is a concern for both.
9. **Solubility:** Both have negative solubility values, indicating poor solubility. This is a concern for both.
10. **hERG:** Both ligands have very low hERG inhibition risk (0.051 and 0.127).
11. **Cl_mic:** Ligand B (-4.586) has a negative clearance, which is unusual and likely indicates very high metabolic stability. Ligand A (15.851) is moderate.
12. **t1/2:** Ligand B (22.44) has a longer half-life than Ligand A (16.764).
13. **Pgp:** Ligand A (0.15) has a much lower Pgp efflux liability than Ligand B (0.008), which is favorable for bioavailability.
14. **Binding Affinity:** Ligand A (-7.4) has a slightly better binding affinity than Ligand B (-5.8). This is a substantial difference.
**Overall Assessment:**
Ligand A is superior due to its optimal logP, better TPSA, higher QED, and significantly better binding affinity. While Ligand B has better metabolic stability (negative Cl_mic) and a longer half-life, the poor logP and lower affinity are major drawbacks for a GPCR target. The slightly higher DILI risk for Ligand A is less concerning than the permeability issues associated with Ligand B's low logP. The improved Pgp profile of Ligand A is also a significant advantage. The binding affinity difference is large enough to outweigh the metabolic stability advantage of Ligand B.
**Output:**
1
2025-04-18 00:17:14,801 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (351.447 and 362.417 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (78.87) is significantly better than Ligand A (112.73). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (1.028) is within the optimal range (1-3), while Ligand A (0.322) is quite low, potentially hindering membrane permeability. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (3) and Ligand B (2) are both acceptable, below the threshold of 5.
5. **HBA:** Both ligands have 4 HBA, which is good.
6. **QED:** Both ligands have similar QED values (0.64 and 0.676), indicating good drug-likeness.
7. **DILI:** Ligand B (17.449) has a lower DILI risk than Ligand A (13.687), which is preferable.
8. **BBB:** Ligand B (82.474) has a higher BBB penetration percentile than Ligand A (57.736). While not a primary concern for a cardiovascular target, it doesn't hurt.
9. **Caco-2:** Ligand A (-5.538) has a more negative Caco-2 value, suggesting *lower* permeability than Ligand B (-4.817).
10. **Solubility:** Both ligands have very poor aqueous solubility (-1.882 and -1.714). This is a concern for both, but not a deciding factor between them.
11. **hERG:** Ligand A (0.161) has a slightly lower hERG risk than Ligand B (0.587), which is a minor advantage.
12. **Cl_mic:** Ligand A (-10.679) has a much lower (better) microsomal clearance than Ligand B (0.474), suggesting better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (-20.057) has a more negative in vitro half-life, which translates to a shorter half-life. Ligand B (-11.215) is better in this regard.
14. **Pgp:** Ligand A (0.016) has a much lower P-gp efflux liability than Ligand B (0.047), which is a positive.
15. **Binding Affinity:** Ligand B (-2.2 kcal/mol) has a better binding affinity than Ligand A (-6.2 kcal/mol). This is a substantial advantage for Ligand B, and likely outweighs many of the ADME concerns.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP and affinity. While Ligand A has better Pgp and Cl_mic, the significantly stronger binding affinity of Ligand B is the most important factor. The lower TPSA of Ligand B is also a plus.
**Conclusion:**
Despite some ADME drawbacks, the substantially improved binding affinity of Ligand B makes it the more promising candidate. The difference in affinity (-2.2 vs -6.2 kcal/mol) is large enough to compensate for the slightly higher DILI and Pgp efflux.
Output:
0
2025-04-18 00:17:14,802 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (339.374 and 349.475 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (72.7) is better than Ligand B (83.22). For a cardiovascular GPCR, TPSA under 140 is acceptable, but lower is preferred for better absorption.
**3. logP:** Both ligands have good logP values (2.184 and 2.562), falling within the optimal 1-3 range. Ligand B is slightly higher, which could potentially lead to some off-target interactions, but isn't a major concern.
**4. H-Bond Donors:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
**5. H-Bond Acceptors:** Ligand A (5) is preferable to Ligand B (4). Similar to HBDs, fewer HBAs are generally better.
**6. QED:** Both ligands have similar QED values (0.773 and 0.73), indicating good drug-like properties.
**7. DILI:** Ligand A (63.397) has a higher DILI risk than Ligand B (46.297). This is a significant negative for Ligand A.
**8. BBB:** Ligand A (71.268) has a significantly better BBB penetration score than Ligand B (54.556). While not a CNS target, some degree of BBB penetration can be indicative of favorable permeability characteristics.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-5.009 and -5.104), which is unusual and suggests poor permeability. This is a concern for both.
**10. Aqueous Solubility:** Both ligands have very poor aqueous solubility (-2.81 and -2.407). This is a major drawback for both, potentially hindering bioavailability.
**11. hERG Inhibition:** Ligand A (0.16) has a much lower hERG inhibition risk than Ligand B (0.617). This is a significant advantage for Ligand A, as hERG inhibition can lead to cardiotoxicity.
**12. Microsomal Clearance:** Ligand B (22.973) has a lower microsomal clearance than Ligand A (36.586), suggesting better metabolic stability.
**13. In vitro Half-Life:** Ligand B (13.555) has a longer in vitro half-life than Ligand A (-23.276). This is a positive for Ligand B.
**14. P-gp Efflux:** Ligand A (0.21) has lower P-gp efflux liability than Ligand B (0.061). Lower efflux is generally preferred for better bioavailability.
**15. Binding Affinity:** Ligand B (-7.7) has a significantly stronger binding affinity than Ligand A (-6.4). A 1.3 kcal/mol difference is substantial and can often outweigh minor ADME drawbacks.
**Overall Assessment:**
Ligand B has a superior binding affinity and better metabolic stability (lower Cl_mic, longer t1/2). However, Ligand A has a significantly lower hERG risk and better BBB penetration. The DILI risk is higher for Ligand A, which is a concern. The poor Caco-2 and solubility for both are problematic.
Given the GPCR target class, binding affinity is paramount. The 1.3 kcal/mol difference in binding affinity for Ligand B is a substantial advantage. While the DILI risk for Ligand B is lower, the hERG risk for Ligand A is significantly lower. Considering the cardiovascular context, minimizing hERG risk is crucial. However, the difference in binding affinity is too significant to ignore. The slightly better metabolic stability of Ligand B is also a plus.
Therefore, I favor Ligand B.
Output:
0
2025-04-18 00:17:14,802 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Step-by-step comparison:**
1. **MW:** Ligand A (363.527 Da) and Ligand B (346.515 Da) both fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (54.34) is better than Ligand B (58.2). Both are acceptable for a non-CNS GPCR, but lower is generally preferred for better permeability.
3. **logP:** Ligand B (3.334) is slightly higher than Ligand A (2.351), but both are within the optimal 1-3 range.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is preferable to Ligand B (2). Fewer HBAs generally improve permeability.
6. **QED:** Ligand A (0.844) is significantly better than Ligand B (0.72), indicating a more drug-like profile.
7. **DILI:** Ligand A (21.442) has a much lower DILI risk than Ligand B (26.095), which is a significant advantage.
8. **BBB:** Both are fairly low, which is appropriate for a cardiovascular target. Ligand B (61.923) is slightly higher than Ligand A (58.085), but this isn't a major factor here.
9. **Caco-2:** Ligand A (-5.302) is better than Ligand B (-4.695), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-2.423) is better than Ligand B (-4.021), indicating better aqueous solubility.
11. **hERG:** Ligand A (0.303) is much better than Ligand B (0.747), indicating lower cardiotoxicity risk. This is a critical parameter.
12. **Cl_mic:** Ligand A (30.05) is significantly better than Ligand B (94.332), indicating better metabolic stability.
13. **t1/2:** Ligand B (22.02) is better than Ligand A (18.875).
14. **Pgp:** Ligand A (0.228) is much better than Ligand B (0.299), indicating lower P-gp efflux.
15. **Affinity:** Ligand A (-5.8 kcal/mol) is significantly better than Ligand B (-1.2 kcal/mol). This is a huge difference in potency.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A excels in all these areas. The significantly better affinity of Ligand A (-5.8 vs -1.2 kcal/mol) is a major driver, easily outweighing any minor ADME drawbacks.
**Overall Assessment:**
Ligand A is clearly superior. It has a better drug-like profile (QED), lower DILI risk, lower hERG risk, better metabolic stability (Cl_mic), better solubility, better permeability (Caco-2), lower P-gp efflux, and *much* stronger binding affinity. While Ligand B has a slightly longer half-life, the other advantages of Ligand A are far more important.
Output:
1
2025-04-18 00:17:14,802 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.419 and 346.475 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (78.87) is slightly higher than Ligand B (74.33). Both are below the 140 threshold for good oral absorption, and acceptable for a cardiovascular GPCR.
3. **logP:** Ligand A (0.069) is quite low, potentially hindering membrane permeability. Ligand B (1.08) is better, falling within the optimal 1-3 range. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (6) is preferable to Ligand B (4). Lower HBA is generally better for permeability.
6. **QED:** Both ligands have similar QED values (0.669 and 0.656), indicating good drug-likeness.
7. **DILI:** Ligand A (62.195) has a higher DILI risk than Ligand B (14.23). This is a major advantage for Ligand B.
8. **BBB:** Both ligands have similar BBB penetration (63.784 and 68.36). While not CNS-focused, higher BBB is generally favorable.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.257 and -4.988). This is unusual and suggests poor permeability.
10. **Solubility:** Both ligands have negative solubility values (-1.042 and -0.746). This is also unusual and suggests poor aqueous solubility.
11. **hERG:** Both ligands have low hERG inhibition liability (0.266 and 0.362), which is good.
12. **Cl_mic:** Ligand A (25.04) has a higher microsomal clearance than Ligand B (21.686), suggesting lower metabolic stability. Ligand B is preferable.
13. **t1/2:** Ligand A (-13.511) has a much lower in vitro half-life than Ligand B (-5.817). This is a significant disadvantage for Ligand A.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.018 and 0.058), which is good.
15. **Binding Affinity:** Both ligands have the same binding affinity (-6.0 kcal/mol).
**GPCR-specific priorities:** For ADRB2 (a cardiovascular GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B is superior in logP and DILI risk, and has comparable values for the other parameters. The negative Caco-2 and solubility values are concerning for both, but the other advantages of Ligand B outweigh these.
**Conclusion:**
Ligand B is the more promising candidate due to its better logP, lower DILI risk, and improved metabolic stability (lower Cl_mic and higher t1/2).
Output:
0
2025-04-18 00:17:14,802 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (343.471 and 345.443 Da) are within the ideal range of 200-500 Da. No significant difference here.
2. **TPSA:** Ligand A (61.44) is significantly better than Ligand B (91.32). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is approaching a level that could hinder absorption.
3. **logP:** Both ligands (2.053 and 2.26) are within the optimal 1-3 range. Similar.
4. **HBD:** Ligand A (2) is preferable to Ligand B (3). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (4). Similar to HBD, lower HBA is generally better.
6. **QED:** Ligand A (0.797) is better than Ligand B (0.69). Higher QED indicates better drug-likeness.
7. **DILI:** Ligand A (12.524) is *much* better than Ligand B (42.885). This is a significant advantage for Ligand A. Lower DILI risk is crucial.
8. **BBB:** Ligand A (62.35) is better than Ligand B (57.619), though neither is exceptionally high. For a cardiovascular target like ADRB2, BBB penetration isn't a primary concern, but it's still a slight advantage for A.
9. **Caco-2:** Ligand A (-5.206) is better than Ligand B (-4.96). Higher Caco-2 permeability is desirable.
10. **Solubility:** Ligand A (-2.029) is better than Ligand B (-3.481). Better solubility is generally preferred.
11. **hERG:** Ligand A (0.35) is significantly better than Ligand B (0.09). Lower hERG inhibition is critical for avoiding cardiotoxicity, especially important for a cardiovascular target.
12. **Cl_mic:** Ligand A (-2.435) is *much* better than Ligand B (45.626). A negative value for Ligand A suggests very low clearance and high metabolic stability, a major advantage.
13. **t1/2:** Ligand A (-4.343) is better than Ligand B (-43.288). A more negative value suggests a longer half-life.
14. **Pgp:** Ligand A (0.021) is better than Ligand B (0.041). Lower P-gp efflux is preferable.
15. **Binding Affinity:** Ligand B (-6.5) is slightly better than Ligand A (-6.0). While affinity is important, the difference of 0.5 kcal/mol is not enough to overcome the substantial ADME advantages of Ligand A.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across almost all ADME-Tox parameters. The significant advantages in DILI risk, hERG inhibition, and metabolic stability (Cl_mic) are particularly compelling. While Ligand B has a slightly better binding affinity, the ADME profile of Ligand A is far superior, making it a much more promising drug candidate. The GPCR-specific priorities (logP, TPSA, Pgp) also favor Ligand A.
Output:
1
2025-04-18 00:17:14,802 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.515 and 344.499 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands have a TPSA of 49.41, which is acceptable for a GPCR target, though not exceptionally low.
3. **logP:** Both ligands have logP values within the optimal range (3.666 and 3.444). Ligand B is slightly lower, which could be marginally better for solubility.
4. **HBD & HBA:** Both have 1 HBD and 2 HBA, which are ideal.
5. **QED:** Ligand B (0.777) has a better QED score than Ligand A (0.538), indicating a more drug-like profile.
6. **DILI:** Ligand B (22.722 percentile) has a significantly lower DILI risk than Ligand A (10.198 percentile). This is a major advantage for Ligand B.
7. **BBB:** Ligand A (93.757 percentile) has a better BBB penetration score than Ligand B (73.711 percentile). While ADRB2 isn't strictly a CNS target, some CNS exposure can occur, and higher BBB is generally favorable.
8. **Caco-2:** Both have similar, poor Caco-2 permeability (-4.883 and -4.891). This is a concern for oral bioavailability for both.
9. **Solubility:** Both ligands have similar, poor aqueous solubility (-3.95 and -3.669).
10. **hERG:** Both ligands have low hERG inhibition liability (0.689 and 0.505).
11. **Cl_mic:** Both ligands have similar microsomal clearance (54.556 and 54.931 mL/min/kg). This suggests moderate metabolic stability.
12. **t1/2:** Ligand B (-13.812 hours) has a significantly longer in vitro half-life than Ligand A (-3.649 hours). This is a substantial advantage for Ligand B, potentially allowing for less frequent dosing.
13. **Pgp:** Both ligands have very low P-gp efflux liability (0.173 and 0.351).
14. **Binding Affinity:** Ligand B (-7.8 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.5 kcal/mol). This is a crucial factor, as a 2.3 kcal/mol difference is substantial and can outweigh minor ADME drawbacks.
**GPCR-specific priorities:** For GPCRs, logP, Pgp, TPSA, and affinity are key. Both ligands are good on logP and Pgp. TPSA is similar. However, Ligand B has a much better binding affinity. The lower DILI and longer half-life of Ligand B are also significant benefits.
**Conclusion:**
Despite Ligand A's slightly better BBB penetration, the much stronger binding affinity, significantly lower DILI risk, and longer half-life of Ligand B make it the more promising drug candidate for the ADRB2 receptor. The affinity difference is the most important factor here.
Output:
0
2025-04-18 00:17:14,803 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (364.789 Da and 357.34 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (117.67) is higher than Ligand B (81.73). For a GPCR, lower TPSA is generally preferred for better BBB penetration, giving a slight edge to Ligand B.
3. **logP:** Both ligands have good logP values (1.812 and 1.399), falling within the optimal 1-3 range. Ligand B is slightly lower, which could be beneficial for solubility.
4. **HBD:** Ligand A has 3 HBD, while Ligand B has 0. While not a hard rule, fewer HBDs can sometimes improve membrane permeability, favoring Ligand B.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 7. Ligand A is better here, as lower HBA is preferred.
6. **QED:** Both ligands have good QED scores (0.724 and 0.808), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (73.517) has a slightly higher DILI risk than Ligand B (69.135), but both are acceptable (below 70). This favors Ligand B.
8. **BBB:** Ligand B (72.315) has a better BBB percentile than Ligand A (57.736). This is a significant advantage for a GPCR target, especially if CNS effects are anticipated or need to be modulated.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.307 and -4.869), which is unusual and suggests poor permeability. This is a significant drawback for both, but the values are very close.
10. **Solubility:** Both ligands have poor solubility (-3.367 and -2.301). This is a major concern for both.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.162 and 0.092). This is excellent.
12. **Cl_mic:** Ligand B (15.383) has lower microsomal clearance than Ligand A (18.028), indicating better metabolic stability. This is a positive for Ligand B.
13. **t1/2:** Ligand A (69.821) has a much longer in vitro half-life than Ligand B (-19.199). This is a significant advantage for Ligand A, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.035 and 0.032). This is good.
15. **Binding Affinity:** Ligand B (-5.9 kcal/mol) has a slightly better binding affinity than Ligand A (-6.0 kcal/mol). While the difference is small, it's still a factor.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, BBB, and affinity), Ligand B appears to be the slightly more promising candidate. It has a lower TPSA, better BBB penetration, lower DILI risk, and better metabolic stability. While Ligand A has a longer half-life, the other factors outweigh this advantage, especially the poor Caco-2 values for both. The slight affinity difference is not enough to overcome the other advantages of Ligand B. The solubility issues for both are concerning and would need to be addressed through formulation strategies.
Output:
0
2025-04-18 00:17:14,803 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (342.374 Da) is within the ideal range (200-500), while Ligand B (368.487 Da) is also acceptable. No clear advantage here.
2. **TPSA:** Ligand A (83.98) is better than Ligand B (69.88). Both are below 140, but lower TPSA generally favors permeability, which is important for GPCRs.
3. **logP:** Ligand A (1.544) is optimal (1-3). Ligand B (3.648) is at the higher end of optimal, potentially increasing off-target effects and decreasing solubility. Ligand A is preferred.
4. **HBD:** Ligand A (2) is good. Ligand B (0) is also acceptable, but some H-bond donors can improve solubility.
5. **HBA:** Ligand A (4) is good. Ligand B (6) is also acceptable, but higher HBA can sometimes reduce permeability.
6. **QED:** Ligand A (0.834) is excellent, indicating high drug-likeness. Ligand B (0.689) is still reasonable, but lower. Ligand A is preferred.
7. **DILI:** Ligand A (65.723) is better than Ligand B (81.078). Both are above the 40% threshold, but Ligand A has a lower risk.
8. **BBB:** Ligand A (77.588) is better than Ligand B (46.491). While ADRB2 isn't strictly a CNS target, some CNS penetration can be beneficial for understanding off-target effects and potential side effects.
9. **Caco-2:** Ligand A (-4.777) is better than Ligand B (-5.088). Both are negative, indicating poor permeability.
10. **Solubility:** Ligand A (-2.581) is better than Ligand B (-3.555). Both are poor, but Ligand A is slightly better.
11. **hERG:** Ligand A (0.143) is much better than Ligand B (0.403). Lower hERG inhibition is crucial for avoiding cardiotoxicity, especially for a cardiovascular target like ADRB2.
12. **Cl_mic:** Ligand A (22.746) is much better than Ligand B (63.138). Lower clearance means better metabolic stability, a significant advantage.
13. **t1/2:** Ligand A (-25.58) is much better than Ligand B (8.995). A negative value indicates a very long half-life, which is highly desirable.
14. **Pgp:** Ligand A (0.046) is much better than Ligand B (0.423). Lower P-gp efflux means better bioavailability.
15. **Affinity:** Both Ligand A (-7.5) and Ligand B (-7.5) have the same binding affinity.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most ADME-Tox parameters, particularly in areas critical for a cardiovascular drug candidate: DILI risk, hERG inhibition, metabolic stability (Cl_mic and t1/2), and P-gp efflux. While both have similar binding affinity and poor Caco-2 permeability, the superior ADME profile of Ligand A makes it the more promising candidate.
Output:
1
2025-04-18 00:17:14,803 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Step-by-step comparison:**
1. **MW:** Ligand A (369.531 Da) is within the ideal range (200-500 Da). Ligand B (417.3 Da) is also acceptable, but approaching the upper limit.
2. **TPSA:** Ligand A (61.88) is good, well below the 140 threshold. Ligand B (70.12) is still reasonable, but higher.
3. **logP:** Ligand A (0.958) is slightly low, potentially impacting permeability. Ligand B (2.797) is within the optimal 1-3 range. This is a point in favor of B.
4. **HBD:** Ligand A (1) is good. Ligand B (0) is also good.
5. **HBA:** Ligand A (5) is good. Ligand B (6) is also acceptable.
6. **QED:** Ligand A (0.69) is good, indicating drug-likeness. Ligand B (0.546) is acceptable, but slightly lower.
7. **DILI:** Ligand A (14.23) has a very low DILI risk, excellent. Ligand B (45.677) is higher, but still within an acceptable range.
8. **BBB:** Ligand A (67.119) is moderate. Ligand B (85.111) is good, suggesting better potential for CNS penetration if desired (though ADRB2 is primarily cardiovascular, some CNS effects can be relevant).
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.082 and -4.681), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Both ligands have negative solubility values (-1.781 and -1.796), indicating very poor aqueous solubility. This is a major drawback for both.
11. **hERG:** Ligand A (0.315) has a very low hERG risk, excellent. Ligand B (0.641) is slightly higher, but still acceptable.
12. **Cl_mic:** Ligand A (31.285) has a moderate clearance. Ligand B (26.111) has a lower clearance, indicating better metabolic stability. This favors B.
13. **t1/2:** Ligand B (37.783) has a significantly longer half-life than Ligand A (11.37). This is a substantial advantage for B.
14. **Pgp:** Ligand A (0.018) has very low P-gp efflux, which is good. Ligand B (0.131) is slightly higher, but still acceptable.
15. **Affinity:** Ligand B (-7.2 kcal/mol) has a stronger binding affinity than Ligand A (-6.9 kcal/mol). This 1.5 kcal/mol difference is significant, and can outweigh some of the ADME drawbacks.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand B performs better on logP, Cl_mic, t1/2, and significantly on affinity. While both have poor Caco-2 and solubility, the stronger binding and improved metabolic stability of Ligand B are more critical.
**Conclusion:**
Despite the poor Caco-2 and solubility of both compounds, Ligand B's superior binding affinity, metabolic stability, and longer half-life make it the more promising candidate. The slightly better BBB penetration is a bonus.
Output:
0
2025-04-18 00:17:14,803 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (356.463 and 342.399 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (84.42) is significantly better than Ligand A (106.94). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (1.064) is slightly better than Ligand A (0.622), falling comfortably within the optimal 1-3 range. Ligand A is a bit low, potentially hindering permeation.
4. **HBD:** Ligand B (1) is better than Ligand A (3). Fewer HBDs generally improve permeability.
5. **HBA:** Both ligands have 5 HBA, which is acceptable.
6. **QED:** Ligand B (0.885) has a substantially higher QED score than Ligand A (0.532), indicating a more drug-like profile.
7. **DILI:** Ligand A (14.114) has a significantly lower DILI risk than Ligand B (52.036). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (79.488) has a higher BBB penetration score than Ligand A (19.232). While ADRB2 is not a CNS target, some degree of BBB penetration can sometimes be beneficial for distribution.
9. **Caco-2:** Both ligands have negative Caco-2 values, suggesting poor permeability. However, Ligand B (-4.803) is slightly better than Ligand A (-5.134).
10. **Solubility:** Both ligands have very poor solubility scores (-0.475 and -1.606). This is a significant concern for both.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.1 and 0.12).
12. **Cl_mic:** Ligand A (1.226) has a much lower microsomal clearance than Ligand B (23.191), indicating better metabolic stability.
13. **t1/2:** Ligand B (1.369) has a slightly longer in vitro half-life than Ligand A (-4.668).
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.029 and 0.032).
15. **Binding Affinity:** Ligand B (-7.5 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.4 kcal/mol). This 1.1 kcal/mol difference is substantial and can outweigh some ADME drawbacks.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, and affinity. Ligand B is better on logP, TPSA, and *significantly* better on affinity. While Ligand A has a better DILI score and Cl_mic, the binding affinity difference is critical. The poor solubility of both is a concern, but can potentially be addressed with formulation strategies.
**Conclusion:**
Despite the lower DILI and better metabolic stability of Ligand A, the significantly stronger binding affinity of Ligand B (-7.5 vs -6.4 kcal/mol) is the deciding factor. This difference is large enough to overcome the slightly higher DILI risk and poorer metabolic stability, especially considering the potential for formulation to address solubility.
Output:
0
2025-04-18 00:17:14,803 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, key properties to prioritize are logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB (though less critical for a cardiovascular target than a CNS one).
Let's compare the ligands property by property:
1. **MW:** Both ligands (345.4 & 355.5 Da) fall within the ideal 200-500 Da range.
2. **TPSA:** Both are acceptable (80.8 & 82.1), being below the 140 A^2 threshold for oral absorption.
3. **logP:** Ligand A (1.59) is better than Ligand B (0.22). Ligand B is quite low, potentially hindering membrane permeability.
4. **HBD/HBA:** Both have reasonable HBD/HBA counts (A: 1/5, B: 2/5), unlikely to be problematic.
5. **QED:** Ligand A (0.85) has a significantly better QED score than Ligand B (0.68), indicating better overall drug-likeness.
6. **DILI:** Ligand B (7.45) has a much lower DILI risk than Ligand A (41.4), a significant advantage.
7. **BBB:** Ligand A (77.9) has a higher BBB penetration percentile than Ligand B (29.5), but BBB is less critical for a cardiovascular target.
8. **Caco-2:** Ligand A (-4.65) is better than Ligand B (-5.12), indicating better intestinal absorption.
9. **Solubility:** Ligand A (-3.34) is better than Ligand B (-0.09), which is a good thing.
10. **hERG:** Both ligands have very low hERG inhibition risk (0.24 & 0.23).
11. **Cl_mic:** Ligand B (-2.14) has a *much* lower microsomal clearance than Ligand A (15.38), suggesting better metabolic stability. This is a major advantage.
12. **t1/2:** Ligand B (9.66) has a longer in vitro half-life than Ligand A (-7.56), further supporting better metabolic stability.
13. **Pgp:** Both ligands have very low Pgp efflux liability (0.024 & 0.019).
14. **Binding Affinity:** Both ligands have excellent binding affinity (-6.0 & -5.6 kcal/mol). Ligand A is slightly better, but the difference is not huge.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity and QED, Ligand B has a significantly better safety profile (lower DILI), superior metabolic stability (lower Cl_mic, longer t1/2), and acceptable logP. Given the importance of metabolic stability for *in vivo* efficacy and the relatively small difference in binding affinity, Ligand B is the more promising candidate.
**Output:**
0
2025-04-18 00:17:14,804 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.435 and 349.479 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (100.74) is higher than Ligand B (70.47). For a cardiovascular GPCR, TPSA is moderately important. Ligand B is preferable due to its lower TPSA, suggesting better permeability.
3. **logP:** Ligand A (1.645) and Ligand B (0.971) are both within the optimal 1-3 range. Ligand A is slightly better.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable. Ligand B is slightly preferable.
5. **HBA:** Ligand A (6) and Ligand B (5) are both acceptable. Ligand B is slightly preferable.
6. **QED:** Both ligands have similar QED values (0.785 and 0.759), indicating good drug-likeness. No significant difference.
7. **DILI:** Ligand A (47.266) has a higher DILI risk than Ligand B (13.843). This is a significant advantage for Ligand B.
8. **BBB:** Both ligands have similar BBB penetration (65.18 and 63.474). Since ADRB2 is a cardiovascular target, BBB penetration is not a primary concern.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.091 and -5.045), which is unusual and suggests poor permeability. However, the values are very close.
10. **Solubility:** Both ligands have negative solubility values (-2.111 and -0.196), indicating poor aqueous solubility. Ligand B is slightly better.
11. **hERG:** Both ligands have low hERG inhibition liability (0.322 and 0.136). No significant difference.
12. **Cl_mic:** Ligand B (11.114) has a lower microsomal clearance than Ligand A (27.004), indicating better metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand B (12.125) has a longer in vitro half-life than Ligand A (-12.117). This is a significant advantage for Ligand B.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.051 and 0.012). Ligand B is slightly preferable.
15. **Binding Affinity:** Ligand B (-7.5) has a slightly better binding affinity than Ligand A (-7.4). While the difference is small, it's still a positive for Ligand B.
**Overall Assessment:**
Ligand B consistently demonstrates preferable ADME properties (lower DILI, lower Cl_mic, longer t1/2, slightly better solubility, slightly lower Pgp efflux) and a slightly better binding affinity. While both ligands have issues with Caco-2 and solubility, Ligand B's superior safety profile (DILI) and metabolic stability make it the more promising candidate for further development as a cardiovascular drug targeting ADRB2.
Output:
0
2025-04-18 00:17:14,804 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
Let's analyze each ligand against the provided guidelines, keeping in mind ADRB2 is a GPCR and therefore we prioritize logP, Pgp, TPSA, and affinity, alongside general drug-like properties.
* **Molecular Weight:** Both ligands (344.46 & 349.48 Da) are within the ideal 200-500 Da range.
* **TPSA:** Ligand A (58.64) is slightly higher than Ligand B (53.09), but both are well below the 140 threshold for good absorption.
* **logP:** Ligand A (2.535) is optimal, while Ligand B (0.953) is a bit low, potentially hindering membrane permeability.
* **H-Bond Donors/Acceptors:** Ligand A (1 HBD, 3 HBA) and Ligand B (0 HBD, 4 HBA) are both acceptable.
* **QED:** Ligand A (0.913) has a significantly better QED score than Ligand B (0.761), indicating a more drug-like profile.
* **DILI:** Ligand B (9.035) has a much lower DILI risk than Ligand A (15.122), a significant advantage.
* **BBB:** Ligand B (70.027) shows better BBB penetration than Ligand A (59.829), which is beneficial for a GPCR target, though not strictly necessary for ADRB2.
* **Caco-2 Permeability:** Both are negative, indicating poor permeability. Ligand A (-4.606) is slightly worse than Ligand B (-4.438).
* **Aqueous Solubility:** Both are negative, indicating poor solubility. Ligand B (-0.556) is slightly better than Ligand A (-2.514).
* **hERG:** Both ligands have low hERG inhibition risk (0.351 and 0.425 respectively).
* **Microsomal Clearance:** Ligand B (18.649) has a higher microsomal clearance than Ligand A (16.755), suggesting faster metabolism.
* **In vitro Half-Life:** Ligand A (-6.124) has a longer in vitro half-life than Ligand B (4.518), which is preferable.
* **P-gp Efflux:** Both ligands have low P-gp efflux liability (0.104 and 0.022 respectively).
* **Binding Affinity:** Ligand B (-7.1 kcal/mol) has a slightly better binding affinity than Ligand A (-7.0 kcal/mol), but the difference is small.
**Overall Assessment:**
Ligand B is preferable. While Ligand A has a better QED and half-life, Ligand B exhibits a significantly lower DILI risk, better BBB penetration, and slightly better binding affinity. The lower logP of Ligand B is a concern, but the other advantages, particularly the lower DILI risk, outweigh this drawback. For a GPCR, a balance of properties is key, and Ligand B strikes a better balance.
**Output:**
0
2025-04-18 00:17:14,804 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [349.391, 109.58 , -0.891, 2. , 7. , 0.465, 46.956, 40.364, -5.353, -0.733, 0.067, 12.257, 9.177, 0.059, -6.9 ]
**Ligand B:** [345.447, 71.33 , 1.482, 0. , 5. , 0.775, 33.075, 71.035, -4.674, -1.554, 0.277, 36.838, -7.276, 0.081, -6.8 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (345.447) is slightly lower, which is generally favorable.
2. **TPSA:** Ligand A (109.58) is higher than Ligand B (71.33). For a cardiovascular GPCR, TPSA isn't *as* critical as for CNS targets, but lower is still preferred for better absorption. Ligand B is significantly better here.
3. **logP:** Ligand A (-0.891) is lower than the optimal 1-3 range, potentially hindering permeability. Ligand B (1.482) is within the optimal range. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (2) is acceptable, Ligand B (0) is even better. Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (7) is acceptable, Ligand B (5) is better.
6. **QED:** Ligand B (0.775) has a better QED score than Ligand A (0.465), indicating a more drug-like profile.
7. **DILI:** Ligand B (33.075) has a much lower DILI risk than Ligand A (46.956). This is a crucial advantage, as liver toxicity is a major concern.
8. **BBB:** Ligand B (71.035) has a higher BBB percentile than Ligand A (40.364). While ADRB2 isn't primarily a CNS target, some peripheral exposure is desirable, and higher BBB can indicate better overall distribution.
9. **Caco-2:** Ligand A (-5.353) and Ligand B (-4.674) are both negative, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Ligand A (-0.733) and Ligand B (-1.554) are both negative, suggesting poor solubility.
11. **hERG:** Both ligands have very low hERG risk (0.067 and 0.277 respectively), which is excellent.
12. **Cl_mic:** Ligand A (12.257) has a lower microsomal clearance than Ligand B (36.838), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand B (-7.276) has a longer in vitro half-life than Ligand A (9.177). This is a positive for Ligand B.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.059 and 0.081 respectively).
15. **Affinity:** Both ligands have very similar binding affinities (-6.9 and -6.8 kcal/mol). The difference is negligible.
**GPCR-Specific Considerations:**
For a cardiovascular GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP and TPSA, has a better QED score, and a significantly lower DILI risk. While Ligand A has better metabolic stability (Cl_mic), the other advantages of Ligand B outweigh this. The similar binding affinities mean potency isn't a differentiating factor.
**Conclusion:**
Ligand B is the more promising candidate due to its superior ADME properties (logP, TPSA, DILI, QED, t1/2) and comparable binding affinity.
0
2025-04-18 00:17:14,804 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (373.425) is slightly higher than Ligand B (350.478), but both are acceptable.
2. **TPSA:** Ligand A (91.32) is above the preferred <90 for GPCRs, while Ligand B (40.62) is well within the range. This is a significant advantage for Ligand B.
3. **logP:** Both ligands have acceptable logP values (Ligand A: 1.28, Ligand B: 3.034), falling within the 1-3 range. Ligand B is closer to the optimal end of the range.
4. **HBD:** Ligand A has 3 HBD, which is acceptable. Ligand B has 0 HBD, which is also acceptable.
5. **HBA:** Ligand A has 5 HBA, acceptable. Ligand B has 2 HBA, also acceptable.
6. **QED:** Both ligands have similar QED values (Ligand A: 0.67, Ligand B: 0.631), indicating good drug-likeness.
7. **DILI:** Ligand A (43.117) has a higher DILI risk than Ligand B (18.108). This is a clear advantage for Ligand B.
8. **BBB:** Ligand B (94.416) has significantly better BBB penetration potential than Ligand A (64.676). Given ADRB2's involvement in cardiovascular function, CNS penetration isn't a primary goal, but it's still a positive attribute.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-5.207) is worse than Ligand B (-4.679).
10. **Solubility:** Both ligands have negative solubility values, indicating poor aqueous solubility. Ligand A (-2.45) is slightly better than Ligand B (-3.26).
11. **hERG:** Ligand A (0.178) has a slightly lower hERG risk than Ligand B (0.783), which is favorable.
12. **Cl_mic:** Ligand B (52.073) has significantly lower microsomal clearance than Ligand A (9.838), indicating better metabolic stability.
13. **t1/2:** Ligand B (1.491) has a slightly better in vitro half-life than Ligand A (-11.599).
14. **Pgp:** Ligand A (0.018) has much lower P-gp efflux liability than Ligand B (0.369), which is a positive.
15. **Binding Affinity:** Ligand A (-6.7 kcal/mol) has a slightly better binding affinity than Ligand B (-6.2 kcal/mol). The difference is 0.5 kcal/mol, which is not a huge advantage.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand B emerges as the more promising candidate. While Ligand A has a slightly better affinity and lower Pgp efflux, Ligand B excels in TPSA (critical for permeability), DILI risk, BBB penetration, and metabolic stability (Cl_mic). The lower TPSA and DILI risk are particularly important. The slight difference in affinity can potentially be optimized during lead optimization. The poor Caco-2 and solubility for both are concerning and would require attention, but are less critical than the other factors.
Output:
0
2025-04-18 00:17:14,804 - INFO - Batch 466 complete. Total preferences: 7456
2025-04-18 00:17:14,804 - INFO - Processing batch 467/512...
2025-04-18 00:18:01,912 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (357.4 & 369.8 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (74.58) is significantly better than Ligand B (93.46). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands (2.753 & 2.015) are within the optimal 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability, but both are acceptable.
4. **HBD:** Both ligands have 2 HBD, which is within the acceptable limit of <=5. No clear advantage.
5. **HBA:** Ligand A has 3 HBA, while Ligand B has 5. Ligand A is preferable here, as lower HBA generally improves permeability.
6. **QED:** Both ligands have very similar QED scores (0.769 & 0.766), indicating good drug-likeness.
7. **DILI:** Ligand A (29.43) has a much lower DILI risk than Ligand B (62.544). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (84.064) has a higher BBB penetration percentile than Ligand B (68.903). While not a primary concern for a cardiovascular target, it's a slight positive for Ligand A.
9. **Caco-2:** Ligand A (-4.521) and Ligand B (-5.031) both have negative values, which is unusual and suggests poor permeability. Ligand A is slightly better.
10. **Solubility:** Ligand A (-2.883) is better than Ligand B (-3.6).
11. **hERG:** Both ligands have very low hERG inhibition risk (0.271 & 0.268). No clear advantage.
12. **Cl_mic:** Ligand B (33.648) has slightly lower microsomal clearance than Ligand A (35.651), suggesting slightly better metabolic stability.
13. **t1/2:** Ligand A (38.876) has a longer in vitro half-life than Ligand B (31.798). This is a significant advantage.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.053 & 0.144). No clear advantage.
15. **Binding Affinity:** Ligand B (-6.7) has a slightly better binding affinity than Ligand A (-6.1). This is a 0.6 kcal/mol difference, which is notable, but not overwhelming.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Both ligands are reasonable in logP and Pgp. Ligand A is significantly better in TPSA. The affinity difference is present but not substantial enough to outweigh the other advantages of Ligand A. The significantly lower DILI risk of Ligand A is a major factor.
**Conclusion:**
Ligand A demonstrates a better balance of properties, particularly with respect to safety (DILI), absorption (TPSA, solubility), and metabolic stability (t1/2). While Ligand B has slightly better binding affinity, the other advantages of Ligand A make it the more promising drug candidate.
Output:
1
2025-04-18 00:18:01,912 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
We are targeting ADRB2, a GPCR, so the priorities are logP, TPSA, Pgp, BBB, and affinity. Let's break down each ligand against these and other important parameters:
* **Molecular Weight:** Both ligands (352.291 and 341.411 Da) fall within the ideal 200-500 Da range.
* **TPSA:** Ligand A (77.81) is slightly higher than Ligand B (62.21). Both are acceptable, but Ligand B is preferable for better absorption.
* **logP:** Ligand A (3.994) is at the upper end of the optimal range (1-3), while Ligand B (1.753) is towards the lower end. For a GPCR, a slightly higher logP can be beneficial for membrane interactions, but we need to consider other factors.
* **H-Bond Donors/Acceptors:** Ligand A has 2 HBD and 3 HBA, while Ligand B has 0 HBD and 4 HBA. Both are within acceptable limits.
* **QED:** Both ligands have similar QED values (0.82 and 0.767), indicating good drug-likeness.
* **DILI:** Ligand A (73.323) has a significantly higher DILI risk than Ligand B (35.828). This is a major concern for Ligand A.
* **BBB:** Ligand A (69.678) has a better BBB penetration percentile than Ligand B (53.238). While ADRB2 isn't necessarily a CNS target, some peripheral ADRB2 activity can have CNS effects, so this is a slight advantage for A.
* **Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.631) is worse than Ligand B (-4.234).
* **Aqueous Solubility:** Ligand A (-4.935) has worse solubility than Ligand B (-1.643).
* **hERG:** Ligand A (0.628) has a slightly higher hERG risk than Ligand B (0.178).
* **Microsomal Clearance:** Ligand A (21.995) has a higher microsomal clearance than Ligand B (16.626), indicating faster metabolism.
* **In vitro Half-Life:** Ligand A (53.108) has a better in vitro half-life than Ligand B (-3.614).
* **P-gp Efflux:** Ligand A (0.173) has lower P-gp efflux than Ligand B (0.077), which is favorable.
* **Binding Affinity:** Ligand A (-6.5 kcal/mol) has a slightly better binding affinity than Ligand B (-4.5 kcal/mol). This 1.5 kcal/mol difference is significant.
**Overall Assessment:**
While Ligand A has better binding affinity and BBB penetration, its significantly higher DILI risk, worse solubility, and higher clearance are major drawbacks. Ligand B, despite the weaker binding affinity, presents a much safer ADME profile, particularly the low DILI risk, which is crucial for cardiovascular drugs. The difference in binding affinity, while noticeable, can potentially be optimized in later stages of drug development. The poor Caco-2 values for both are concerning and would need to be addressed, but the overall profile of Ligand B is more promising for progression as a drug candidate.
**Output:**
0
2025-04-18 00:18:01,912 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [366.487, 72.96, 0.927, 1, 4, 0.841, 25.785, 65.491, -4.912, -2.025, 0.497, 9.297, -44.909, 0.011, -5.5]
**Ligand B:** [345.399, 121.52, 0.213, 4, 4, 0.538, 31.718, 32.144, -5.577, -2.538, 0.141, -1.913, 9.303, 0.005, -3.1]
Here's a breakdown, considering the GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the acceptable 200-500 Da range. A (366.49) is slightly higher, but not concerning.
2. **TPSA:** A (72.96) is excellent, well below 140 and good for oral absorption. B (121.52) is higher, but still within a reasonable range.
3. **logP:** A (0.927) is optimal. B (0.213) is quite low, potentially leading to poor membrane permeability. This is a significant drawback.
4. **HBD/HBA:** A (1 HBD, 4 HBA) is better balanced. B (4 HBD, 4 HBA) is acceptable, but the higher HBD count could slightly impact permeability.
5. **QED:** Both are good (A: 0.841, B: 0.538), indicating drug-like properties. A is better.
6. **DILI:** A (25.79) is very favorable, indicating low liver injury risk. B (31.72) is also acceptable, but A is preferable.
7. **BBB:** A (65.49) is decent, but not stellar. B (32.14) is low, suggesting poor brain penetration. While ADRB2 isn't necessarily a CNS target, some peripheral ADRB2 receptors can be relevant to CNS effects.
8. **Caco-2:** A (-4.912) is better than B (-5.577), indicating better intestinal absorption.
9. **Solubility:** Both are poor (-2.025 and -2.538). This is a concern for both, but might be manageable with formulation.
10. **hERG:** Both are low risk (A: 0.497, B: 0.141).
11. **Cl_mic:** A (9.297) is better than B (-1.913), suggesting better metabolic stability.
12. **t1/2:** A (-44.909) is much better than B (9.303), indicating a longer half-life.
13. **Pgp:** A (0.011) is much lower than B (0.005), suggesting less P-gp efflux and better bioavailability.
14. **Affinity:** A (-5.5 kcal/mol) is significantly better than B (-3.1 kcal/mol). This is a substantial difference in binding potency.
**Overall Assessment:**
Ligand A clearly outperforms Ligand B across most critical parameters. The most significant advantages are its superior logP, metabolic stability (Cl_mic and t1/2), Pgp efflux, and, crucially, its much stronger binding affinity. While both have solubility issues, the other benefits of A outweigh this concern. The lower logP of B is a major red flag for a GPCR ligand, as it suggests poor membrane permeability and reduced target engagement.
Output:
1
2025-04-18 00:18:01,912 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (338.411 and 367.515 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (86.09) is better than Ligand B (91.32). Both are below 140, suggesting good oral absorption potential, but lower TPSA is generally preferred for GPCRs to improve brain penetration, even if not a CNS target.
**3. logP:** Both ligands have good logP values (2.03 and 2.512), falling within the optimal 1-3 range. Ligand B is slightly higher, which could potentially lead to some off-target interactions, but it's not a major concern.
**4. H-Bond Donors:** Ligand A (1) is better than Ligand B (3). Fewer HBDs generally improve membrane permeability.
**5. H-Bond Acceptors:** Ligand A (4) is better than Ligand B (5). Similar to HBDs, fewer HBAs are generally preferred.
**6. QED:** Ligand A (0.851) is significantly better than Ligand B (0.583). A higher QED indicates a more drug-like profile.
**7. DILI:** Both ligands have similar DILI risk (53.548 and 56.146), both falling into the acceptable range (<60).
**8. BBB:** Both ligands have similar BBB penetration (64.133 and 65.801). While not a CNS target, some BBB penetration can be beneficial for distribution.
**9. Caco-2 Permeability:** Ligand A (-4.871) is better than Ligand B (-5.188). Higher Caco-2 permeability indicates better intestinal absorption.
**10. Aqueous Solubility:** Ligand A (-3.692) is better than Ligand B (-3.569). Better solubility is important for formulation and bioavailability.
**11. hERG Inhibition:** Both ligands have low hERG inhibition liability (0.571 and 0.601), which is good.
**12. Microsomal Clearance:** Ligand A (15.764) is *much* better than Ligand B (36.611). Lower clearance indicates greater metabolic stability, a crucial factor for drug duration and efficacy.
**13. In vitro Half-Life:** Ligand A (-15.501) is better than Ligand B (-8.263). A more negative value indicates a longer half-life.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.091 and 0.496).
**15. Binding Affinity:** Ligand B (-7.2) is slightly better than Ligand A (-6.7). While a 0.5 kcal/mol difference is good, it's not enough to overcome the significant ADME advantages of Ligand A.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across multiple key ADME properties (QED, TPSA, HBD/HBA, solubility, clearance, half-life, Caco-2). While Ligand B has a slightly better binding affinity, the superior ADME profile of Ligand A suggests it is more likely to be a viable drug candidate. The better metabolic stability (lower Cl_mic and longer t1/2) and drug-likeness (higher QED) are particularly important.
Output:
1
2025-04-18 00:18:01,913 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (334.419 Da and 332.367 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (54.12) is significantly better than Ligand B (77.11). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand A is well below the 90 A^2 threshold, while Ligand B is approaching the upper limit.
**3. logP:** Ligand A (4.923) is higher than Ligand B (1.982). While both are within the acceptable range (1-3), Ligand A is pushing the upper limit. This could potentially lead to solubility issues, but for a GPCR, some lipophilicity is often desirable for membrane interaction. Ligand B's logP is quite low and might hinder permeability.
**4. H-Bond Donors:** Ligand A (2) is slightly higher than Ligand B (1), but both are within the acceptable limit of 5.
**5. H-Bond Acceptors:** Ligand B (6) is higher than Ligand A (2). Both are within the acceptable limit of 10.
**6. QED:** Ligand A (0.711) is better than Ligand B (0.62), indicating a more drug-like profile.
**7. DILI:** Ligand A (83.637) and Ligand B (79.333) are both reasonably good, below the 80 percentile threshold. No major difference here.
**8. BBB:** Ligand A (70.609) is significantly better than Ligand B (39.279). While ADRB2 is primarily a cardiovascular target, some CNS penetration is not necessarily detrimental and could offer additional therapeutic avenues.
**9. Caco-2 Permeability:** Ligand A (-4.74) is better than Ligand B (-5.41), indicating better intestinal absorption.
**10. Aqueous Solubility:** Ligand B (-2.737) is better than Ligand A (-6.754). This is a potential drawback for Ligand A, given its higher logP.
**11. hERG Inhibition:** Ligand A (0.815) is slightly higher than Ligand B (0.199). Lower is better, so Ligand B is preferable here.
**12. Microsomal Clearance:** Ligand B (29.57) is much lower than Ligand A (69.806), indicating better metabolic stability. This is a significant advantage for Ligand B.
**13. In vitro Half-Life:** Ligand A (37.423) is better than Ligand B (31.588).
**14. P-gp Efflux:** Ligand A (0.777) is better than Ligand B (0.091). Lower efflux is desirable.
**15. Binding Affinity:** Ligand A (-7.7) is significantly better than Ligand B (-6.3). A 1.4 kcal/mol difference in binding affinity is substantial and can often outweigh minor ADME concerns.
**Overall Assessment:**
Ligand A has a much stronger binding affinity, better BBB penetration, better Caco-2 permeability, better P-gp efflux, and a higher QED score. Ligand B has better metabolic stability (lower Cl_mic) and lower hERG inhibition, and better solubility. However, the substantial advantage in binding affinity for Ligand A, coupled with acceptable ADME properties, makes it the more promising candidate. The lower solubility of Ligand A could be addressed through formulation strategies. Given the GPCR target class, the balance of properties leans towards Ligand A.
Output:
1
2025-04-18 00:18:01,913 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (365.495 and 364.515 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (63.68) is significantly better than Ligand B (78.09). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary driver, but lower TPSA generally correlates with better permeability.
3. **logP:** Ligand A (2.846) is slightly higher than Ligand B (1.837), both within the optimal 1-3 range. Ligand A is preferable.
4. **HBD:** Ligand A (0) is better than Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Both ligands have 4 HBA, which is acceptable.
6. **QED:** Both ligands have very similar QED scores (0.727 and 0.738), indicating good drug-likeness.
7. **DILI:** Ligand B (26.91) has a much lower DILI risk than Ligand A (39.162). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (79.682) has a higher BBB penetration percentile than Ligand B (50.523). While not critical for a cardiovascular target, it's a slight positive for A.
9. **Caco-2:** Ligand A (-4.519) has a slightly better Caco-2 permeability than Ligand B (-5.32), indicating better intestinal absorption.
10. **Solubility:** Ligand B (-1.626) has better aqueous solubility than Ligand A (-4.34). This is a positive for Ligand B.
11. **hERG:** Ligand A (0.748) has a slightly higher hERG inhibition liability than Ligand B (0.222). Lower hERG is preferred, favoring Ligand B.
12. **Cl_mic:** Ligand B (17.79) has significantly lower microsomal clearance than Ligand A (108.344), indicating better metabolic stability. This is a major advantage for Ligand B.
13. **t1/2:** Ligand B (-17.536) has a longer in vitro half-life than Ligand A (-48.908). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand B (0.036) has much lower P-gp efflux liability than Ligand A (0.312). This is a positive for Ligand B.
15. **Binding Affinity:** Ligand A (-6.6 kcal/mol) has a slightly better binding affinity than Ligand B (-5.9 kcal/mol). While a difference of 0.7 kcal/mol is noticeable, it's not a massive advantage, especially considering the ADME benefits of Ligand B.
**Overall Assessment:**
Ligand B demonstrates a superior ADME profile. Its lower DILI risk, significantly improved metabolic stability (lower Cl_mic, longer t1/2), lower P-gp efflux, and better solubility are substantial advantages. While Ligand A has slightly better affinity and Caco-2 permeability, the ADME profile of Ligand B is more favorable for overall drug development success. The affinity difference is not large enough to overcome the ADME liabilities of Ligand A.
Output:
0
2025-04-18 00:18:01,913 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (339.391 and 348.447 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (59.75) is significantly better than Ligand B (83.56). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (3.16) is optimal, while Ligand B (1.357) is on the lower side. A logP between 1-3 is preferred, and Ligand A is closer to this ideal.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer HBDs generally improve membrane permeability.
5. **HBA:** Ligand A (4) is better than Ligand B (5). Similar to HBDs, lower HBA is generally favored.
6. **QED:** Ligand A (0.843) is significantly better than Ligand B (0.547), indicating a more drug-like profile.
7. **DILI:** Ligand B (35.905) has a much lower DILI risk than Ligand A (60.682). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (78.364) has better BBB penetration than Ligand B (68.748), but this isn't a primary concern for a cardiovascular target.
9. **Caco-2:** Ligand A (-4.207) has a worse Caco-2 permeability than Ligand B (-5.227). Lower values indicate poorer permeability.
10. **Solubility:** Ligand A (-3.73) has better solubility than Ligand B (-1.523). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.551) has a lower hERG risk than Ligand B (0.325). Lower is better.
12. **Cl_mic:** Ligand B (1.962) has significantly lower microsomal clearance than Ligand A (82.191), suggesting better metabolic stability.
13. **t1/2:** Ligand A (22.536) has a longer in vitro half-life than Ligand B (5.277).
14. **Pgp:** Ligand A (0.659) has better Pgp efflux liability than Ligand B (0.025). Lower is better.
15. **Affinity:** Ligand A (-4.7 kcal/mol) has a slightly better binding affinity than Ligand B (-3.5 kcal/mol). The difference is 1.2 kcal/mol, which is substantial.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A excels in logP, TPSA, Pgp and affinity. Ligand B has a much better DILI score and Cl_mic, which are also important.
**Overall Assessment:**
Ligand A has a superior binding affinity, better logP, TPSA, Pgp efflux, QED, solubility and hERG profile. While Ligand B has a significantly better DILI score and metabolic stability, the stronger binding affinity of Ligand A, combined with its more favorable physicochemical properties, outweighs these concerns. The difference in affinity is considerable. The DILI risk of Ligand A is still within an acceptable range.
Output:
1
2025-04-18 00:18:01,913 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (352.316 Da) is slightly higher than Ligand B (342.403 Da), but both are acceptable.
2. **TPSA:** Ligand A (61.94) is significantly better than Ligand B (100.97). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is pushing the upper limit for good oral absorption.
3. **logP:** Ligand A (2.991) is optimal, while Ligand B (1.084) is on the lower side. While not terrible, lower logP can sometimes hinder membrane permeability.
4. **HBD:** Ligand A (0) is preferable to Ligand B (1). Fewer HBDs generally improve permeability.
5. **HBA:** Both ligands have 6 HBA, which is acceptable.
6. **QED:** Both ligands have good QED scores (A: 0.68, B: 0.843), indicating good drug-like properties. Ligand B is slightly better here.
7. **DILI:** Ligand A (60.682) is slightly higher than Ligand B (57.193), but both are within an acceptable range.
8. **BBB:** Ligand A (89.027) is significantly better than Ligand B (64.056). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be useful for understanding off-target effects and distribution.
9. **Caco-2:** Ligand A (-4.476) is better than Ligand B (-5.1), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-3.511) is better than Ligand B (-1.194). Solubility is important for formulation and bioavailability.
11. **hERG:** Ligand A (0.725) is better than Ligand B (0.062). Lower hERG inhibition is crucial for avoiding cardiotoxicity, a significant concern with cardiovascular targets.
12. **Cl_mic:** Ligand A (53.338) is significantly better than Ligand B (13.114). Lower microsomal clearance indicates greater metabolic stability, which is highly desirable.
13. **t1/2:** Ligand A (4.475) is better than Ligand B (27.173). However, this is an *in vitro* half-life and can be misleading. A very long *in vitro* half-life doesn't always translate to a long *in vivo* half-life.
14. **Pgp:** Ligand A (0.529) is better than Ligand B (0.006). Lower P-gp efflux is preferred for better bioavailability.
15. **Binding Affinity:** Ligand A (-8.3 kcal/mol) is *significantly* better than Ligand B (-5.9 kcal/mol). This is a substantial difference in potency (2.4 kcal/mol), and this difference is likely to outweigh any minor ADME drawbacks.
**Overall Assessment:**
Ligand A is the stronger candidate. While Ligand B has a slightly better QED score and lower DILI, Ligand A excels in key areas for a GPCR target: TPSA, logP, BBB, hERG, Cl_mic, Pgp, and, most importantly, *binding affinity*. The substantial difference in binding affinity (-8.3 vs -5.9 kcal/mol) is a major advantage that outweighs the slightly less favorable properties of Ligand A. The better metabolic stability (Cl_mic) and lower hERG risk also contribute to its superior profile.
Output:
1
2025-04-18 00:18:01,913 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (354.447 Da) is slightly higher than Ligand B (342.483 Da), but both are acceptable.
**2. TPSA:** Ligand A (68.31) is higher than Ligand B (49.41). For a GPCR, lower TPSA is generally preferred for better permeability, giving a slight edge to Ligand B.
**3. logP:** Ligand B (3.173) is closer to the optimal range (1-3) than Ligand A (0.524). Ligand A's low logP is a concern as it might hinder membrane permeability. This is a significant advantage for Ligand B.
**4. H-Bond Donors:** Ligand A has 0 HBDs, while Ligand B has 1. Both are within the acceptable limit of 5.
**5. H-Bond Acceptors:** Ligand A has 5 HBAs, and Ligand B has 2. Both are within the acceptable limit of 10.
**6. QED:** Both ligands have good QED values (A: 0.667, B: 0.798), indicating good drug-like properties. Ligand B is slightly better.
**7. DILI Risk:** Ligand B (19.465) has a significantly lower DILI risk than Ligand A (30.322). This is a crucial advantage for Ligand B.
**8. BBB Penetration:** Ligand A (84.102) has better BBB penetration than Ligand B (73.943). While ADRB2 isn't exclusively a CNS target, some cardiovascular effects can be mediated by central pathways, so this is a minor positive for Ligand A.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.146) is slightly better than Ligand B (-4.945), but both are problematic.
**10. Aqueous Solubility:** Ligand B (-4.47) has worse solubility than Ligand A (-1.008). Solubility is important, giving a slight edge to Ligand A.
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (A: 0.232, B: 0.293).
**12. Microsomal Clearance:** Ligand B (47.904) has a higher microsomal clearance than Ligand A (30.231), indicating faster metabolism and potentially lower *in vivo* exposure. This favors Ligand A.
**13. In vitro Half-Life:** Ligand A (-18.076) has a longer half-life than Ligand B (12.177). This is a significant advantage for Ligand A.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (A: 0.075, B: 0.18).
**15. Binding Affinity:** Ligand A (-5.9 kcal/mol) has a significantly stronger binding affinity than Ligand B (-1.2 kcal/mol). This is a major advantage for Ligand A, potentially outweighing some of its ADME drawbacks.
**Overall Assessment:**
While Ligand B has better logP, DILI risk, and QED, Ligand A's significantly stronger binding affinity (-5.9 vs -1.2 kcal/mol) and longer half-life are critical for a GPCR target. The lower logP of Ligand A is a concern, but the substantial affinity difference is likely to be more impactful, especially considering the potential for structural modifications to improve permeability. The better half-life also suggests a more favorable pharmacokinetic profile.
Therefore, I prefer Ligand A.
Output:
1
2025-04-18 00:18:01,914 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (351.403 and 348.334 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Both ligands (110.53 and 108.56) are below the 140 A^2 threshold for good oral absorption, but higher than the 90 A^2 for CNS targets. Since ADRB2 is a cardiovascular target, CNS penetration is not a primary concern. No significant difference.
3. **logP:** Ligand A (0.88) is slightly lower than Ligand B (1.257), both within the optimal 1-3 range. Ligand B is preferable.
4. **HBD:** Both have 2 HBD, which is acceptable. No difference.
5. **HBA:** Both have 6 HBA, which is acceptable. No difference.
6. **QED:** Ligand B (0.842) has a better QED score than Ligand A (0.673), indicating a more drug-like profile. This is a positive for Ligand B.
7. **DILI:** Ligand A (32.61%) has a significantly lower DILI risk than Ligand B (72.276%). This is a major advantage for Ligand A.
8. **BBB:** Both ligands have reasonable BBB penetration (68.476% and 64.482%), but this isn't a high priority for a cardiovascular target.
9. **Caco-2:** Both ligands have negative Caco-2 values, suggesting poor permeability. Ligand A (-4.765) is slightly better than Ligand B (-4.48), but both are concerning.
10. **Solubility:** Ligand A (-1.722) has better solubility than Ligand B (-3.045). This is a positive for Ligand A.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.037 and 0.088). No significant difference.
12. **Cl_mic:** Ligand B (36.742) has significantly lower microsomal clearance than Ligand A (60.506), indicating better metabolic stability. This is a strong advantage for Ligand B.
13. **t1/2:** Ligand A (-4.409) has a slightly longer in vitro half-life than Ligand B (0.114).
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.017 and 0.01). No significant difference.
15. **Binding Affinity:** Ligand B (-5.5 kcal/mol) has a significantly stronger binding affinity than Ligand A (-4.3 kcal/mol). This is a substantial advantage for Ligand B, potentially outweighing some ADME concerns.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are important. Ligand B is better in logP and significantly better in binding affinity. Both are good on Pgp and TPSA is similar. The biggest concern with Ligand B is the higher DILI risk. However, the substantial affinity advantage and better metabolic stability (lower Cl_mic) are compelling. The improved QED also favors Ligand B.
**Conclusion:**
Despite the higher DILI risk, the significantly improved binding affinity and metabolic stability of Ligand B, coupled with its better QED, make it the more promising drug candidate for ADRB2. The affinity difference is large enough to potentially mitigate the DILI risk through careful dose optimization and patient monitoring.
Output:
0
2025-04-18 00:18:01,914 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (340.423 and 362.436 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (49.85) is better than Ligand B (58.2). For a GPCR, keeping TPSA lower is generally favorable for permeability.
**3. logP:** Both ligands have logP values within the optimal range (1-3), with Ligand A (1.547) being slightly preferred over Ligand B (3.414). While 3.414 isn't *bad*, it's closer to the upper limit and could potentially lead to off-target interactions or solubility issues.
**4. H-Bond Donors:** Ligand A (0) is preferable to Ligand B (2). Fewer H-bond donors generally improve membrane permeability.
**5. H-Bond Acceptors:** Ligand A (3) is slightly better than Ligand B (2). Both are acceptable.
**6. QED:** Both ligands have similar QED values (0.73 and 0.682), indicating good drug-like properties.
**7. DILI Risk:** Ligand A (28.189) has a significantly lower DILI risk than Ligand B (40.054). This is a crucial advantage, as liver toxicity is a major concern in drug development.
**8. BBB Penetration:** Ligand A (68.282) shows better BBB penetration than Ligand B (57.852). While ADRB2 is a cardiovascular target, some CNS exposure can occur, and better BBB penetration is rarely a detriment.
**9. Caco-2 Permeability:** Ligand A (-4.353) is better than Ligand B (-4.696). Both are negative values, indicating poor permeability, but Ligand A is slightly better.
**10. Aqueous Solubility:** Ligand A (-2.714) is better than Ligand B (-4.296). Better aqueous solubility is generally desirable.
**11. hERG Inhibition:** Ligand A (0.225) has a much lower hERG inhibition risk than Ligand B (0.461). This is a critical safety parameter, and Ligand A is clearly superior.
**12. Microsomal Clearance:** Ligand A (37.262) has lower microsomal clearance than Ligand B (53.858), indicating better metabolic stability.
**13. In vitro Half-Life:** Ligand A (-8.114) has a better in vitro half-life than Ligand B (3.083).
**14. P-gp Efflux:** Ligand A (0.073) has lower P-gp efflux than Ligand B (0.082).
**15. Binding Affinity:** Ligand B (-6.8 kcal/mol) has a stronger binding affinity than Ligand A (-5.2 kcal/mol). This is a substantial difference (1.6 kcal/mol), and is a significant advantage.
**Overall Assessment:**
While Ligand B has a better binding affinity, Ligand A demonstrates a significantly better safety profile (lower DILI, lower hERG inhibition) and more favorable ADME properties (better BBB, solubility, metabolic stability, and lower P-gp efflux). Given the importance of safety and ADME characteristics in drug development, especially for a cardiovascular target where chronic administration is likely, the benefits of Ligand A outweigh the affinity advantage of Ligand B. The affinity of Ligand A is still quite good (-5.2 kcal/mol).
Output:
1
2025-04-18 00:18:01,914 - INFO - Here's my reasoning and output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands (384.395 and 347.503 Da) fall within the ideal 200-500 Da range. Ligand B is slightly smaller, which *could* be beneficial for permeability, but the difference isn't substantial.
2. **TPSA:** Ligand A (49.85) is better than Ligand B (52.65). Both are reasonably good, under 140, but lower TPSA generally favors better absorption.
3. **logP:** Both ligands have good logP values (2.021 and 2.49), falling within the optimal 1-3 range. Ligand B is slightly higher, which could potentially lead to some off-target interactions, but it's not a major concern.
4. **HBD:** Ligand A has 0 HBD, while Ligand B has 1. Lower is generally preferred for GPCRs to avoid strong interactions that might hinder receptor activation or selectivity. Ligand A is better here.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 3. Both are acceptable (under 10).
6. **QED:** Both ligands have similar QED values (0.696 and 0.72), indicating good drug-likeness.
7. **DILI:** Ligand A (35.983) has a significantly lower DILI risk than Ligand B (13.339). This is a crucial advantage, as liver toxicity is a major concern in drug development.
8. **BBB:** Ligand A (93.912) has a much higher BBB penetration percentile than Ligand B (77.007). While ADRB2 isn't strictly a CNS target, some peripheral ADRB2 receptors can be affected by CNS penetration, and higher BBB is generally a positive attribute.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand B (-4.725) is slightly worse than Ligand A (-4.462).
10. **Solubility:** Ligand A (-3.401) has better solubility than Ligand B (-2.015). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.588) has a slightly higher hERG risk than Ligand B (0.235). This is a negative for Ligand A, but the values are relatively low overall.
12. **Cl_mic:** Ligand B (33.488) has lower microsomal clearance than Ligand A (51.715), indicating better metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand A (-26.136) has a much longer in vitro half-life than Ligand B (-5.377). This is a major positive for Ligand A, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.054) has lower P-gp efflux than Ligand B (0.043). Lower P-gp efflux is generally desirable for improved bioavailability.
15. **Affinity:** Ligand A (-7.7 kcal/mol) has a stronger binding affinity than Ligand B (-5.8 kcal/mol). This is a substantial difference (over 1.9 kcal/mol), and affinity is a primary driver of potency.
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A excels in affinity and has acceptable logP and TPSA. Ligand B has better metabolic stability (Cl_mic) but weaker affinity. The significantly better DILI and BBB scores for Ligand A are also important considerations.
**Overall Assessment:**
While Ligand B has better metabolic stability, Ligand A's significantly stronger binding affinity, lower DILI risk, better solubility, and higher BBB penetration outweigh this advantage. The longer half-life of Ligand A is also a significant benefit. The Caco-2 permeability is poor for both, but the stronger binding of A suggests it may still be able to exert a biological effect.
Output:
1
2025-04-18 00:18:01,914 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's systematically compare Ligand A and Ligand B based on the provided parameters and the guidelines, keeping in mind that ADRB2 is a GPCR, so logP, TPSA, Pgp, BBB, and affinity are particularly important.
1. **Molecular Weight:** Both ligands (344.323 and 347.415 Da) fall comfortably within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (86.88) is significantly better than Ligand A (108.63). A lower TPSA generally favors better cell permeability, which is crucial for GPCR targeting.
3. **logP:** Ligand A (2.696) is slightly better than Ligand B (1.297). Both are within the optimal 1-3 range, but Ligand A is closer to the upper end, which can be beneficial for membrane permeability. Ligand B is a bit low and could suffer from permeability issues.
4. **H-Bond Donors:** Ligand B (1) is preferable to Ligand A (0). While both are low, a single donor can sometimes improve solubility without significantly impacting permeability.
5. **H-Bond Acceptors:** Ligand A (7) is preferable to Ligand B (5). Both are acceptable, but fewer H-bonds are generally better for permeability.
6. **QED:** Ligand B (0.784) is better than Ligand A (0.45). A higher QED suggests a more drug-like profile.
7. **DILI:** Ligand B (36.332) is *much* better than Ligand A (86.157). This is a significant advantage for Ligand B, as lower DILI risk is critical for drug development.
8. **BBB:** Ligand B (74.37) is better than Ligand A (66.344). While ADRB2 isn't necessarily a CNS target, higher BBB penetration is generally favorable, minimizing off-target effects.
9. **Caco-2 Permeability:** Ligand A (-4.429) is better than Ligand B (-5.026). A less negative value indicates better permeability.
10. **Aqueous Solubility:** Ligand A (-5.385) is better than Ligand B (-1.182). Better solubility is generally desirable.
11. **hERG Inhibition:** Ligand B (0.149) is much better than Ligand A (0.397). Lower hERG inhibition is crucial for avoiding cardiotoxicity, a major concern for cardiovascular targets.
12. **Microsomal Clearance:** Ligand B (15.035) is better than Ligand A (121.766). Lower clearance indicates better metabolic stability.
13. **In vitro Half-Life:** Ligand A (15.377) is better than Ligand B (-3.925). A longer half-life is generally preferred.
14. **P-gp Efflux:** Ligand A (0.405) is better than Ligand B (0.089). Lower P-gp efflux is preferable.
15. **Binding Affinity:** Ligand A (-7.0) and Ligand B (-6.7) are both good, but Ligand A is slightly better. The difference is 0.3 kcal/mol, which is not substantial enough to outweigh the other significant advantages of Ligand B.
**Overall Assessment:**
Ligand B has several significant advantages over Ligand A, particularly in terms of safety (DILI, hERG) and ADME properties (BBB, clearance, P-gp efflux). While Ligand A has slightly better affinity, solubility, Caco-2 permeability, and half-life, these differences are not large enough to compensate for the superior safety and ADME profile of Ligand B. The lower TPSA of Ligand B is also a plus for a GPCR target.
**Output:**
0
2025-04-18 00:18:01,914 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.435 and 352.494 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (80.41) is higher than Ligand B (49.41). For a cardiovascular GPCR, TPSA is not a primary concern as BBB penetration isn't crucial, but lower is generally preferable for absorption. Ligand B is better here.
3. **logP:** Ligand A (1.453) is within the optimal 1-3 range. Ligand B (3.757) is at the higher end, potentially leading to solubility issues or off-target interactions. Ligand A is better.
4. **HBD:** Ligand A (0) has no H-bond donors, which is good for permeability. Ligand B (1) has one, which is acceptable. Ligand A is slightly better.
5. **HBA:** Ligand A (8) is higher than Ligand B (2). Lower HBA is generally better for permeability. Ligand B is better.
6. **QED:** Both ligands have similar QED values (0.745 and 0.74), indicating good drug-likeness. No significant difference.
7. **DILI:** Ligand A (63.397) has a higher DILI risk than Ligand B (33.501). This is a significant concern, as we want to minimize liver toxicity. Ligand B is much better.
8. **BBB:** Both ligands have high BBB penetration (92.827 and 93.68), but this is less important for a cardiovascular target. No significant difference.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.824 and -4.675). These values are unusual and suggest poor permeability. However, the values are very close.
10. **Solubility:** Ligand A (-2.394) has slightly better solubility than Ligand B (-4.33). Solubility is important for bioavailability. Ligand A is better.
11. **hERG:** Both ligands have low hERG inhibition liability (0.742 and 0.551), which is good. Ligand B is slightly better.
12. **Cl_mic:** Ligand A (66.517) has higher microsomal clearance than Ligand B (49.627), indicating lower metabolic stability. Ligand B is better.
13. **t1/2:** Ligand A (-5.375) has a more negative in vitro half-life, which is worse than Ligand B (-2.726). This suggests faster metabolism and a shorter duration of action. Ligand B is better.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.143 and 0.315), which is good. Ligand A is slightly better.
15. **Binding Affinity:** Ligand B (-5.8 kcal/mol) has a slightly better binding affinity than Ligand A (-5.3 kcal/mol). While the difference is not huge, it's still a factor.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has a better logP and Pgp, while Ligand B has a better TPSA and affinity. However, the significant advantage of Ligand B in terms of DILI risk and metabolic stability (lower Cl_mic, better t1/2) outweighs the slightly better logP and Pgp of Ligand A.
**Conclusion:**
Considering the balance of properties, particularly the lower DILI risk and improved metabolic stability of Ligand B, it is the more promising drug candidate for the ADRB2 receptor.
Output:
0
2025-04-18 00:18:01,915 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (356.451) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (90.95) is better than Ligand B (66.06). While both are reasonably low, lower TPSA is generally preferred for GPCRs to enhance brain penetration and overall absorption.
3. **logP:** Both ligands have good logP values (A: 3.457, B: 3.644) falling within the optimal 1-3 range.
4. **HBD:** Ligand A (2) has a slightly lower HBD count than Ligand B (1), which is preferable, as fewer HBDs can improve membrane permeability.
5. **HBA:** Both ligands have the same HBA count (5), which is acceptable.
6. **QED:** Ligand A (0.875) has a significantly higher QED score than Ligand B (0.53), indicating a more drug-like profile.
7. **DILI:** Both ligands have acceptable DILI risk (A: 72.354, B: 64.133), with Ligand B being slightly better.
8. **BBB:** Ligand B (74.292) shows better BBB penetration potential than Ligand A (45.909). This is a key consideration for GPCRs, even cardiovascular ones, as some off-target CNS effects are possible.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability in this assay. However, the values are similar (-5.182 for A, -5.415 for B).
10. **Solubility:** Both ligands have negative solubility values, indicating very poor aqueous solubility. This is a significant drawback for both.
11. **hERG:** Ligand A (0.219) has a much lower hERG inhibition liability than Ligand B (0.848), a crucial safety parameter.
12. **Cl_mic:** Ligand B (81.147) has a higher microsomal clearance than Ligand A (64.468), meaning it's metabolized faster and has lower metabolic stability.
13. **t1/2:** Ligand A (29.247) has a longer in vitro half-life than Ligand B (22.895), which is desirable.
14. **Pgp:** Ligand B (0.607) has a higher P-gp efflux liability than Ligand A (0.141), which could reduce oral bioavailability.
15. **Affinity:** Ligand A (-7.7 kcal/mol) has a significantly stronger binding affinity than Ligand B (-5.5 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME drawbacks.
**Overall Assessment:**
Ligand A is the stronger candidate. While Ligand B has better BBB penetration, the superior binding affinity of Ligand A, combined with its better QED score, lower hERG risk, lower Pgp efflux, and longer half-life, make it a more promising starting point for drug development. The poor solubility and Caco-2 values are concerning for both, but these can be addressed through formulation strategies or further chemical modifications. The significantly stronger binding affinity of Ligand A is a major advantage for a GPCR target.
Output:
1
2025-04-18 00:18:01,915 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (a cardiovascular GPCR) drug candidates.
**Ligand A:** [347.415, 98.74, 0.249, 3, 4, 0.658, 34.82, 31.059, -5.085, -1.605, 0.033, 10.979, -15.41, 0.012, -7.6]
**Ligand B:** [356.507, 78.87, 2.094, 2, 4, 0.698, 13.843, 38.891, -4.743, -1.181, 0.235, 26.167, 19.487, 0.035, -7.2]
Here's a breakdown, considering the guidelines and GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal 200-500 Da range. A (347.4) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** A (98.74) is higher than B (78.87). Both are reasonably good, but B is better positioned for potential BBB penetration, even though this isn't a CNS target.
3. **logP:** A (0.249) is quite low, potentially hindering membrane permeability. B (2.094) is much better, falling within the optimal 1-3 range. This is a significant advantage for B.
4. **HBD:** A (3) is slightly higher than B (2), but both are acceptable.
5. **HBA:** Both are equal at 4, which is good.
6. **QED:** Both are good (A: 0.658, B: 0.698), indicating drug-like properties. B is slightly better.
7. **DILI:** A (34.82) has a higher DILI risk than B (13.843). This is a clear advantage for B.
8. **BBB:** Not a primary concern for a cardiovascular target, but B (38.891) is better than A (31.059).
9. **Caco-2:** A (-5.085) is worse than B (-4.743), suggesting lower intestinal absorption for A.
10. **Solubility:** A (-1.605) is worse than B (-1.181). Solubility is important for bioavailability.
11. **hERG:** Both are very low (A: 0.033, B: 0.235), indicating minimal hERG inhibition risk.
12. **Cl_mic:** A (10.979) has a lower clearance than B (26.167), suggesting better metabolic stability. This is a positive for A.
13. **t1/2:** B (19.487) has a longer half-life than A (-15.41), which is a significant advantage.
14. **Pgp:** Both are very low (A: 0.012, B: 0.035), indicating minimal P-gp efflux.
15. **Affinity:** A (-7.6) has a slightly better binding affinity than B (-7.2), but the difference is relatively small (0.4 kcal/mol).
**Overall Assessment:**
While Ligand A has a slightly better binding affinity and lower clearance, Ligand B demonstrates a much more favorable ADME profile. The significantly better logP, lower DILI risk, improved solubility, and longer half-life of Ligand B outweigh the small affinity difference. The low logP of Ligand A is a major concern for permeability and bioavailability. For a cardiovascular GPCR, a balance of potency *and* good pharmacokinetic properties is crucial.
Therefore, I prefer Ligand B.
0
2025-04-18 00:18:01,915 - INFO - Batch 467 complete. Total preferences: 7472
2025-04-18 00:18:01,915 - INFO - Processing batch 468/512...
2025-04-18 00:18:48,012 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (346.471 and 355.485 Da) fall well within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (58.64) is better than Ligand B (66.91). Both are below the 140 A^2 threshold for oral absorption, but lower TPSA is generally preferred for GPCR ligands, aiding in membrane permeability.
**3. logP:** Both ligands have acceptable logP values (2.243 and 3.352), falling within the 1-3 range. Ligand B is slightly higher, which could potentially lead to some solubility issues, but isn't a major concern.
**4. H-Bond Donors:** Ligand A (1) is preferable to Ligand B (2). Fewer H-bond donors generally improve membrane permeability.
**5. H-Bond Acceptors:** Ligand A (3) is preferable to Ligand B (5). Similar reasoning as HBDs - fewer is generally better for permeability.
**6. QED:** Both ligands have good QED scores (0.593 and 0.636), indicating good drug-like properties.
**7. DILI:** Ligand A (11.128) is significantly better than Ligand B (62.582). A lower DILI percentile is crucial, and Ligand B's value is concerningly high.
**8. BBB:** Ligand B (78.519) has a better BBB penetration percentile than Ligand A (64.017). While ADRB2 isn't exclusively a CNS target, some CNS penetration can be beneficial, and is a priority for GPCRs.
**9. Caco-2 Permeability:** Ligand A (-4.77) is better than Ligand B (-5.321). Higher Caco-2 permeability suggests better intestinal absorption.
**10. Aqueous Solubility:** Ligand A (-2.608) is better than Ligand B (-4.272). Better solubility is always desirable for formulation and bioavailability.
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (0.4 and 0.506), which is excellent.
**12. Microsomal Clearance:** Ligand A (-10.711) is significantly better than Ligand B (40.416). Lower clearance indicates greater metabolic stability, a crucial factor for drug duration.
**13. In vitro Half-Life:** Ligand A (10.908) is better than Ligand B (26.795). Longer half-life is generally preferred.
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (0.107 and 0.241), which is good.
**15. Binding Affinity:** Ligand B (-7.7) has a significantly stronger binding affinity than Ligand A (-2.9). This is a substantial advantage, potentially outweighing some of the ADME drawbacks.
**Overall Assessment:**
Ligand B has a much stronger binding affinity, which is a critical factor for GPCRs. However, its significantly higher DILI risk and higher microsomal clearance are major concerns. Ligand A has a more balanced profile with better ADME properties (lower DILI, better clearance, solubility, permeability, and H-bonding) and acceptable affinity. Considering the balance of properties, and the importance of avoiding toxicity (DILI), I favor Ligand A.
Output:
1
2025-04-18 00:18:48,012 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (335.5) is well within the ideal range (200-500). Ligand B (370.4) is also acceptable. No clear advantage here.
2. **TPSA:** Ligand A (27.3) is excellent, well below the 140 threshold and favorable for absorption. Ligand B (121.3) is higher, but still potentially acceptable for a peripherally acting GPCR like ADRB2. Ligand A is better.
3. **logP:** Ligand A (3.8) is optimal. Ligand B (0.6) is low, potentially leading to poor membrane permeability. Ligand A is significantly better.
4. **HBD:** Both ligands have acceptable HBD counts (2 and 3 respectively), within the guideline of <=5.
5. **HBA:** Ligand A (3) is good. Ligand B (6) is higher, but still within the guideline of <=10.
6. **QED:** Ligand A (0.81) is excellent, indicating high drug-likeness. Ligand B (0.41) is below the 0.5 threshold, suggesting a less desirable drug-like profile. Ligand A is better.
7. **DILI:** Ligand A (11.6) has a very low DILI risk. Ligand B (34.2) is higher, indicating a moderate risk. Ligand A is better.
8. **BBB:** Ligand A (97.9) has excellent BBB penetration. Ligand B (16.1) is very low. While ADRB2 isn't primarily a CNS target, good BBB penetration can sometimes correlate with favorable distribution properties.
9. **Caco-2:** Ligand A (-4.9) is a negative value, which is unusual and requires careful interpretation. It suggests very poor permeability. Ligand B (-6.0) is also poor. This is a concern for both, but the negative value for A is more concerning.
10. **Solubility:** Ligand A (-3.0) is very poor. Ligand B (-0.4) is also poor, but slightly better.
11. **hERG:** Ligand A (0.98) is low risk. Ligand B (0.08) is very low risk. No clear advantage.
12. **Cl_mic:** Ligand A (23.8) is moderate. Ligand B (1.9) is very low, indicating good metabolic stability. Ligand B is better.
13. **t1/2:** Ligand A (54.8) is good. Ligand B (-2.5) is very poor. Ligand A is significantly better.
14. **Pgp:** Ligand A (0.22) is low efflux. Ligand B (0.005) is very low efflux. No clear advantage.
15. **Affinity:** Ligand B (-7.1) has a slightly better binding affinity than Ligand A (-6.6), but the difference is less than 1.5 kcal/mol.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A excels in logP and TPSA, and has acceptable Pgp. Ligand B has a poor logP. While Ligand B has slightly better affinity, the significant drawbacks in logP, QED, DILI, solubility, and half-life outweigh this benefit. The poor Caco-2 values for both are concerning, but the other properties of A are more favorable.
**Conclusion:**
Despite the poor Caco-2 and solubility values, Ligand A presents a more balanced profile with better drug-likeness, lower toxicity risk, and better metabolic stability. The superior logP and TPSA are crucial for a GPCR target.
**Output:**
1
2025-04-18 00:18:48,012 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (354.36 and 350.43 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (87.32) is higher than Ligand B (51.66). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B is better here.
3. **logP:** Both ligands have good logP values (1.42 and 2.98), falling within the 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability, but not dramatically so.
4. **HBD:** Ligand A has 2 HBD, while Ligand B has 0. Both are acceptable, but fewer HBDs can sometimes improve permeability. Ligand B is slightly better.
5. **HBA:** Both ligands have 4 HBA, which is well within the acceptable limit of 10. No significant difference.
6. **QED:** Both ligands have similar QED values (0.787 and 0.723), indicating good drug-likeness. No significant difference.
7. **DILI:** Ligand A has a DILI risk of 57.35%, while Ligand B has 12.21%. This is a *major* difference. Ligand B is significantly safer regarding potential liver toxicity.
8. **BBB:** Ligand A has 70.03% BBB penetration, while Ligand B has 91.66%. While ADRB2 is primarily a cardiovascular target, some CNS off-target effects are possible, and higher BBB penetration is generally undesirable. Ligand B is better.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.817 and -4.005), which is unusual and suggests poor permeability. This is a concern for both, but the values are similar.
10. **Solubility:** Both ligands have negative solubility values (-2.575 and -3.112), also unusual and indicating poor aqueous solubility. This is a concern for both, and the values are similar.
11. **hERG:** Both ligands have low hERG inhibition risk (0.608 and 0.643), which is good. No significant difference.
12. **Cl_mic:** Ligand A has a lower microsomal clearance (12.72 mL/min/kg) than Ligand B (66.9 mL/min/kg). Lower clearance indicates better metabolic stability, making Ligand A preferable.
13. **t1/2:** Ligand A has a longer in vitro half-life (39.11 hours) than Ligand B (-17.90 hours). This is a significant advantage for Ligand A, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.09 and 0.113). No significant difference.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-5.5 and -5.8 kcal/mol). The difference is negligible.
**Overall Assessment:**
Ligand B clearly wins on safety (DILI) and has better TPSA and BBB penetration. Ligand A has a better metabolic profile (lower Cl_mic, longer t1/2). The negative Caco-2 and solubility values are concerning for both, and would require further investigation (formulation strategies, prodrug approaches). However, the significantly lower DILI risk for Ligand B is a critical advantage, especially in early-stage drug development. The slightly better metabolic stability of Ligand A is outweighed by the safety concerns.
Output:
0
2025-04-18 00:18:48,013 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (330.395 Da) is slightly lower than Ligand B (348.487 Da), which is marginally preferable.
2. **TPSA:** Ligand A (79.47) is higher than Ligand B (58.64). For a cardiovascular GPCR like ADRB2, TPSA is less critical than for CNS targets, but lower is still preferred for absorption. Ligand B wins here.
3. **logP:** Ligand A (4.559) is higher than Ligand B (2.799). While both are within the acceptable range, Ligand A is pushing the upper limit and could potentially have solubility issues or off-target effects. Ligand B is better.
4. **HBD:** Ligand A (0) has fewer H-bond donors than Ligand B (1). This is generally favorable for permeability. Ligand A wins.
5. **HBA:** Ligand A (4) has more H-bond acceptors than Ligand B (3). This is less ideal, but not a major concern. Ligand B wins.
6. **QED:** Ligand B (0.686) has a better QED score than Ligand A (0.377), indicating a more drug-like profile. Ligand B wins.
7. **DILI:** Ligand B (15.471) has a significantly lower DILI risk than Ligand A (64.133). This is a major advantage for Ligand B.
8. **BBB:** Both ligands have good BBB penetration, but Ligand B (81.815) is slightly higher than Ligand A (78.48). While ADRB2 isn't a primary CNS target, some CNS exposure can occur, making this slightly favorable for Ligand B.
9. **Caco-2:** Both ligands have negative Caco-2 values which is unusual and suggests poor permeability.
10. **Solubility:** Ligand B (-3.083) has better solubility than Ligand A (-5.57). This is important for bioavailability and formulation. Ligand B wins.
11. **hERG:** Ligand A (0.856) has a slightly higher hERG risk than Ligand B (0.444). Lower is better, so Ligand B wins.
12. **Cl_mic:** Ligand A (21.181) has a lower microsomal clearance than Ligand B (61.723), indicating better metabolic stability. Ligand A wins.
13. **t1/2:** Ligand A (-42.743) has a much longer in vitro half-life than Ligand B (11.445). This is a significant advantage for Ligand A, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.565) has lower P-gp efflux than Ligand B (0.141). Lower efflux is generally preferred for bioavailability. Ligand A wins.
15. **Binding Affinity:** Ligand A (-7.7) has a slightly better binding affinity than Ligand B (-7.5). While the difference is small, it's still a positive for Ligand A.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand B emerges as the more promising candidate. While Ligand A has a slightly better affinity and half-life, Ligand B excels in crucial ADME properties like DILI risk, solubility, QED, and logP. The lower DILI risk alone is a significant factor, as liver toxicity is a major concern in drug development. The better solubility and QED also contribute to a more favorable overall profile. The small difference in affinity is outweighed by the substantial improvements in safety and pharmacokinetic properties.
Output:
0
2025-04-18 00:18:48,013 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (347.415) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are below the 140 A^2 threshold for good oral absorption. Ligand B (71.53) is better than Ligand A (82.85), leaning towards better absorption.
3. **logP:** Ligand A (0.363) is quite low, potentially hindering membrane permeability. Ligand B (2.317) is within the optimal range (1-3). This is a significant advantage for Ligand B.
4. **HBD:** Both have 1 HBD, which is acceptable.
5. **HBA:** Both have 5 HBA, which is acceptable.
6. **QED:** Both have high QED scores (A: 0.834, B: 0.805), indicating good drug-like properties.
7. **DILI:** Ligand A (27.608) has a lower DILI risk than Ligand B (35.13), which is preferable.
8. **BBB:** Both have reasonable BBB penetration, but Ligand B (70.531) is slightly better than Ligand A (64.715). For a cardiovascular target, BBB isn't a primary concern, but it's a slight positive for B.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.626) is slightly better than Ligand B (-4.844), but both are concerning.
10. **Solubility:** Ligand A (-0.901) has better solubility than Ligand B (-2.017). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.064) has a much lower hERG risk than Ligand B (0.408). This is a crucial safety parameter, and A is significantly better.
12. **Cl_mic:** Ligand A (-5.179) has a much lower (better) microsomal clearance than Ligand B (24.811), indicating greater metabolic stability.
13. **t1/2:** Ligand A (-0.088) has a negative half-life, which is not possible, and likely an error. Ligand B (5.645) has a reasonable half-life.
14. **Pgp:** Ligand A (0.019) has much lower P-gp efflux liability than Ligand B (0.118), which is beneficial for bioavailability.
15. **Affinity:** Ligand A (-7.6 kcal/mol) has a slightly better binding affinity than Ligand B (-7.3 kcal/mol). While the difference is not huge, it is still a factor.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP and has acceptable TPSA and Pgp. Ligand A has a problematic logP, but better Pgp and affinity. The hERG and Cl_mic are also very important. Ligand A is significantly better in both of these parameters.
**Overall Assessment:**
Despite Ligand B's better logP and half-life, Ligand A is the stronger candidate. The significantly lower hERG risk, lower DILI risk, lower Pgp efflux, and better metabolic stability (Cl_mic) outweigh the slightly lower logP and questionable Caco-2 permeability. The affinity difference is also a small benefit. The negative half-life for Ligand A is a data error that would need to be resolved, but the other factors currently favor it.
Output:
1
2025-04-18 00:18:48,013 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.46 and 349.52 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (72.36) is higher than Ligand B (52.65). For a cardiovascular GPCR like ADRB2, TPSA is less critical than for CNS targets, but lower is generally preferable for absorption. Ligand B has a clear advantage.
3. **logP:** Both ligands (1.765 and 2.119) are within the optimal 1-3 range. Ligand B is slightly higher, which could be marginally better for membrane permeability.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable, being less than 5. Ligand B is slightly better.
5. **HBA:** Ligand A (4) and Ligand B (3) are both acceptable, being less than 10. Ligand B is slightly better.
6. **QED:** Both ligands (0.753 and 0.766) have excellent drug-likeness scores, well above the 0.5 threshold. No significant difference.
7. **DILI:** Ligand A (25.79%) has a significantly lower DILI risk than Ligand B (6.82%). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (77.71%) shows much better BBB penetration than Ligand A (54.79%). While ADRB2 isn't primarily a CNS target, some CNS exposure can occur, and higher BBB is generally a positive.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.67 and -4.871), indicating poor permeability. This is a concern for both compounds.
10. **Solubility:** Both ligands have negative solubility values (-2.585 and -1.655), indicating poor solubility. This is a concern for both compounds.
11. **hERG:** Ligand A (0.13) has a lower hERG inhibition liability than Ligand B (0.536), indicating a lower risk of cardiotoxicity. This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand B (32.84) has a lower microsomal clearance than Ligand A (36.50), suggesting better metabolic stability. This is a slight advantage for Ligand B.
13. **t1/2:** Ligand A (10.88) has a longer in vitro half-life than Ligand B (-0.03). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.125) has lower P-gp efflux liability than Ligand B (0.035), which is a positive.
15. **Binding Affinity:** Ligand B (-7.3 kcal/mol) has a slightly better binding affinity than Ligand A (-7.1 kcal/mol). This is a 0.2 kcal/mol difference, which is noticeable but not overwhelmingly decisive.
**Overall Assessment:**
Ligand B has advantages in BBB penetration, slightly better logP, and slightly better metabolic stability (Cl_mic). However, Ligand A is superior in DILI risk, hERG inhibition, in vitro half-life, and P-gp efflux. The most critical factors for this cardiovascular GPCR target, considering the safety profile, are DILI and hERG. Ligand A demonstrates a significantly better safety profile in these areas. The slightly better affinity of Ligand B is unlikely to outweigh the safety concerns. The poor Caco-2 and solubility for both compounds are concerning, but can be addressed with formulation strategies.
Output:
1
2025-04-18 00:18:48,014 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (384.173) is slightly higher than Ligand B (346.515), but both are acceptable.
2. **TPSA:** Ligand B (49.41) is significantly better than Ligand A (82.7). ADRB2 is a cardiovascular target, so CNS penetration isn't crucial, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (A: 4.701, B: 3.217), falling within the optimal 1-3 range. Ligand B is slightly better, being closer to the ideal range. Ligand A is pushing the upper limit and could present solubility challenges.
4. **HBD:** Ligand A (3) is higher than Ligand B (1). Both are acceptable, but lower is generally preferred.
5. **HBA:** Ligand A (3) is higher than Ligand B (2). Again, both are acceptable, but lower is generally preferred.
6. **QED:** Both ligands have good QED scores (A: 0.573, B: 0.686), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A has a very high DILI risk (99.341), which is a major red flag. Ligand B has a much lower and acceptable DILI risk (18.922). This is a significant advantage for Ligand B.
8. **BBB:** This is less critical for a cardiovascular target. Ligand A (53.974) and Ligand B (64.948) are both moderate.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.751 and -4.387), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand B (-4.091) is better than Ligand A (-6.525), though both are quite poor.
11. **hERG:** Both ligands have low hERG inhibition liability (A: 0.401, B: 0.269). This is good.
12. **Cl_mic:** Ligand A (25.237) has a much lower (better) microsomal clearance than Ligand B (65.344), indicating better metabolic stability.
13. **t1/2:** Ligand A (102.667) has a significantly longer in vitro half-life than Ligand B (10.28). This is a major advantage for Ligand A.
14. **Pgp:** Both ligands have low Pgp efflux liability (A: 0.168, B: 0.172).
15. **Binding Affinity:** Ligand B (-6.7) has a slightly better binding affinity than Ligand A (-6.4), but the difference is relatively small (0.3 kcal/mol).
**Overall Assessment:**
While Ligand A has a longer half-life and better metabolic stability, the extremely high DILI risk is a deal-breaker. The poor Caco-2 and solubility are also concerning. Ligand B, despite having a shorter half-life and higher clearance, presents a much more favorable safety profile (DILI) and slightly better solubility and TPSA. The small difference in binding affinity is outweighed by the significant ADME/Tox advantages of Ligand B. Given the GPCR-specific priorities, a balance of properties is key, and Ligand B achieves this better.
Output:
0
2025-04-18 00:18:48,014 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.447 and 342.399 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (75.51) is better than Ligand B (79.54) as it is closer to the <140 threshold for good oral absorption.
3. **logP:** Both ligands have good logP values (1.605 and 2.063), falling within the optimal 1-3 range. Ligand B is slightly higher, which could potentially lead to slight solubility issues, but is still acceptable.
4. **HBD:** Both ligands have 0 H-bond donors, which is good.
5. **HBA:** Both ligands have 5 H-bond acceptors, which is acceptable.
6. **QED:** Ligand B (0.853) has a significantly better QED score than Ligand A (0.366), indicating a more drug-like profile. This is a substantial advantage for Ligand B.
7. **DILI:** Ligand A (46.297) has a lower DILI risk than Ligand B (64.56), which is a positive for Ligand A.
8. **BBB:** Both ligands have moderate BBB penetration (56.301 and 63.125). Since ADRB2 is a cardiovascular target, BBB penetration is not a primary concern, but higher is generally preferable. Ligand B is slightly better here.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. This is a significant drawback for both.
10. **Solubility:** Both ligands have poor aqueous solubility (-1.627 and -1.838). This is a significant issue that would need to be addressed during formulation.
11. **hERG:** Ligand A (0.089) has a lower hERG inhibition liability than Ligand B (0.249), which is a safety advantage.
12. **Cl_mic:** Ligand B (40.476) has a lower microsomal clearance than Ligand A (60.476), suggesting better metabolic stability. This is a positive for Ligand B.
13. **t1/2:** Ligand A (15.44) has a longer in vitro half-life than Ligand B (5.091). This is a positive for Ligand A.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.099 and 0.109).
15. **Binding Affinity:** Ligand B (-5.1 kcal/mol) has a slightly better binding affinity than Ligand A (-5.7 kcal/mol). While the difference is small, it is still a factor.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand B has a slightly better logP and affinity, and both have acceptable Pgp values. Ligand A has a better TPSA.
**Overall Assessment:**
Ligand B has a significantly better QED score and lower microsomal clearance, indicating a more favorable overall drug-like profile and potentially better metabolic stability. While Ligand A has a lower DILI risk and longer half-life, the QED and Cl_mic advantages of Ligand B are more impactful, especially considering the poor Caco-2 and solubility of both. The slight affinity advantage of Ligand B also contributes to its preference.
Output:
0
2025-04-18 00:18:48,014 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
We are targeting ADRB2, a GPCR. Therefore, the most important parameters are binding affinity, logP, TPSA, Pgp efflux, and BBB penetration. Metabolic stability (Cl_mic, t1/2) and safety (DILI, hERG) are also crucial.
Let's compare the ligands:
1. **Molecular Weight:** Both ligands (346.475 and 345.443 Da) are within the ideal range (200-500 Da).
2. **TPSA:** Ligand A (62.47) is better than Ligand B (71.53). Lower TPSA generally favors better absorption.
3. **logP:** Ligand A (3.364) is slightly higher than Ligand B (2.305), both are within the optimal range (1-3), but A is closer to the upper limit.
4. **H-Bond Donors:** Ligand A (0) is better than Ligand B (1). Fewer HBDs generally improve permeability.
5. **H-Bond Acceptors:** Both ligands have 4 HBA, which is acceptable.
6. **QED:** Ligand A (0.842) is slightly better than Ligand B (0.77), indicating a more drug-like profile.
7. **DILI:** Ligand A (26.057) is significantly better than Ligand B (32.377), indicating a lower risk of drug-induced liver injury.
8. **BBB:** Ligand A (97.053) is much better than Ligand B (68.282). High BBB penetration is a plus for GPCRs, even if not strictly CNS-focused, as it can indicate better distribution.
9. **Caco-2:** Both are negative, indicating poor permeability. However, Ligand A (-4.663) is slightly better than Ligand B (-4.505).
10. **Solubility:** Both are negative, indicating poor solubility. Ligand B (-2.114) is slightly better than Ligand A (-3.199).
11. **hERG:** Ligand A (0.64) is better than Ligand B (0.254), indicating lower hERG inhibition risk.
12. **Cl_mic:** Ligand B (33.834) has lower microsomal clearance than Ligand A (74.674), suggesting better metabolic stability.
13. **t1/2:** Ligand B (14.416) has a much longer in vitro half-life than Ligand A (-2.195), which is a significant advantage.
14. **Pgp:** Ligand A (0.501) is better than Ligand B (0.042), indicating lower P-gp efflux.
15. **Binding Affinity:** Ligand B (-6.4 kcal/mol) has a slightly better binding affinity than Ligand A (-5.7 kcal/mol). This is a 1.5 kcal/mol difference, which is significant.
**Overall Assessment:**
Ligand B has a better binding affinity and a significantly longer half-life and better metabolic stability. However, Ligand A has superior DILI, BBB, Pgp, and hERG profiles, and a slightly better QED and TPSA. Given the importance of metabolic stability and half-life for *in vivo* efficacy, and the relatively small difference in binding affinity, Ligand B is the more promising candidate. The better BBB penetration of Ligand A is attractive, but the improved metabolic properties of Ligand B are more critical for a successful drug.
**Output:**
0
2025-04-18 00:18:48,015 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (341.415 Da) is slightly lower, which is generally favorable for permeability.
**2. TPSA:** Both are below the 140 A^2 threshold for good oral absorption. Ligand A (80.12 A^2) is better than Ligand B (87.11 A^2), aligning with GPCR preference for lower TPSA.
**3. logP:** Ligand A (1.47) is optimal, while Ligand B (3.049) is approaching the upper limit. This favors Ligand A.
**4. H-Bond Donors:** Ligand A (1) is better than Ligand B (3). Fewer HBDs generally improve permeability.
**5. H-Bond Acceptors:** Both ligands have 5 HBA, which is acceptable.
**6. QED:** Ligand A (0.913) has a significantly better QED score than Ligand B (0.451), indicating a more drug-like profile.
**7. DILI:** Ligand A (47.77) has a much lower DILI risk than Ligand B (89.957). This is a critical advantage.
**8. BBB:** Both ligands have reasonable BBB penetration (Ligand A: 67.119, Ligand B: 66.615). While not CNS-focused, moderate penetration is not detrimental for a peripheral GPCR like ADRB2.
**9. Caco-2 Permeability:** Ligand A (-4.823) shows better Caco-2 permeability than Ligand B (-5.681), indicating better absorption.
**10. Aqueous Solubility:** Ligand A (-1.322) is better than Ligand B (-3.439).
**11. hERG Inhibition:** Ligand A (0.253) has a much lower hERG inhibition liability than Ligand B (0.787), a significant safety advantage.
**12. Microsomal Clearance:** Ligand A (-2.953) has a lower (better) microsomal clearance than Ligand B (36.283), indicating greater metabolic stability.
**13. In vitro Half-Life:** Ligand A (-8.5) has a longer in vitro half-life than Ligand B (59.379).
**14. P-gp Efflux:** Ligand A (0.03) has much lower P-gp efflux liability than Ligand B (0.623), improving bioavailability.
**15. Binding Affinity:** Ligand B (-6.4 kcal/mol) has a slightly better binding affinity than Ligand A (-5.4 kcal/mol). However, the difference is not substantial enough to outweigh the numerous advantages of Ligand A.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical ADME-Tox properties. It has a better safety profile (lower DILI, hERG), better permeability, solubility, metabolic stability, and a superior drug-likeness score (QED). While Ligand B has slightly better binding affinity, the comprehensive advantages of Ligand A make it the more promising drug candidate for the ADRB2 receptor.
Output:
1
2025-04-18 00:18:48,015 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (371.415 Da) is slightly higher than Ligand B (346.427 Da), but both are acceptable.
2. **TPSA:** Ligand B (84.5) is significantly better than Ligand A (114.13). For a GPCR, lower TPSA is generally preferred for better permeability.
3. **logP:** Ligand B (1.163) is within the optimal range, while Ligand A (-0.652) is slightly below, potentially hindering permeability.
4. **HBD:** Both ligands have 2 HBD, which is acceptable.
5. **HBA:** Ligand B (4) is better than Ligand A (8), contributing to better permeability.
6. **QED:** Ligand A (0.65) has a better QED score than Ligand B (0.392), suggesting a more drug-like profile overall.
7. **DILI:** Ligand B (32.299) has a significantly lower DILI risk than Ligand A (53.315), a crucial advantage.
8. **BBB:** Ligand B (49.36) has a better BBB penetration score than Ligand A (32.183). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be beneficial for distribution.
9. **Caco-2:** Both ligands have very similar, poor Caco-2 permeability (-5.383 and -5.287).
10. **Solubility:** Both ligands have poor aqueous solubility (-2.36 and -2.206). This is a concern for both, but can be addressed with formulation strategies.
11. **hERG:** Both ligands show very low hERG inhibition liability (0.037 and 0.091). This is excellent.
12. **Cl_mic:** Ligand B (12.706) has a significantly lower microsomal clearance than Ligand A (26.059), indicating better metabolic stability.
13. **t1/2:** Ligand B (-8.87) has a much longer in vitro half-life than Ligand A (2.355), which is a substantial benefit.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.011 and 0.048).
15. **Binding Affinity:** Ligand B (-7.5 kcal/mol) has a significantly stronger binding affinity than Ligand A (-2.8 kcal/mol). This is a major advantage, potentially outweighing some of the ADME drawbacks of Ligand A.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in these areas. While Ligand A has a better QED, the superior affinity, lower TPSA, better logP, lower DILI, and improved metabolic stability/half-life of Ligand B are more critical for a successful GPCR drug candidate. The significantly stronger binding affinity of Ligand B is a decisive factor.
**Output:**
0
2025-04-18 00:18:48,015 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, key priorities are logP, TPSA, Pgp efflux, binding affinity, and, to a lesser extent, BBB (though less critical for a cardiovascular target than a CNS one).
Let's compare the ligands property by property:
1. **MW:** Both ligands (343.43 & 353.46 Da) fall within the ideal 200-500 Da range.
2. **TPSA:** Both ligands (82.27 & 82.11) are below the 140 A^2 threshold for good oral absorption, which is good.
3. **logP:** Ligand A (1.423) is within the optimal 1-3 range. Ligand B (-0.023) is slightly below 1, which *could* indicate permeability issues. This is a slight negative for Ligand B.
4. **HBD/HBA:** Both have acceptable HBD (2) and HBA (3/5) counts.
5. **QED:** Both have good QED scores (0.553 & 0.672), indicating drug-likeness.
6. **DILI:** Ligand A (16.44%) has a significantly higher DILI risk than Ligand B (8.375%). This is a major concern for Ligand A.
7. **BBB:** Both are relatively low, as expected for a cardiovascular target, but Ligand B (49.83%) is higher than Ligand A (42.81%).
8. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability.
9. **Solubility:** Both have negative solubility values, indicating poor solubility.
10. **hERG:** Both have very low hERG inhibition risk (0.206 & 0.221).
11. **Cl_mic:** Ligand A (-21.524) has a much *lower* (better) microsomal clearance than Ligand B (5.669), suggesting better metabolic stability.
12. **t1/2:** Ligand B (5.772) has a longer in vitro half-life than Ligand A (-11.477), which is desirable.
13. **Pgp:** Both have low Pgp efflux liability (0.087 & 0.006).
14. **Binding Affinity:** Ligand B (-6.8 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.8 kcal/mol). This is a 1.0 kcal/mol difference, which is substantial and can outweigh some ADME concerns.
**Overall Assessment:**
Ligand B is the more promising candidate. While both have some ADME liabilities (poor Caco-2 and solubility), Ligand B's significantly stronger binding affinity (-6.8 vs -5.8 kcal/mol) and lower DILI risk are major advantages. The slightly better half-life and logP also contribute to its preference. Ligand A's higher DILI risk is a significant red flag. The better metabolic stability of Ligand A is not enough to overcome the DILI risk and weaker binding.
Output:
0
2025-04-18 00:18:48,015 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [342.359, 103.08 , 1.717, 0. , 8. , 0.695, 68.98 , 78.868, -5.343, -1.709, 0.138, 11.617, 14.355, 0.081, -6.1 ]
**Ligand B:** [339.443, 73.05 , 2.503, 3. , 3. , 0.801, 32.648, 70.105, -5.328, -2.482, 0.769, -18.364, 13.562, 0.071, -6.1 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). A (342.359) and B (339.443) are very similar.
2. **TPSA:** A (103.08) is slightly higher than B (73.05). B is better, being closer to the <140 threshold for oral absorption, and more favorable for GPCRs.
3. **logP:** A (1.717) is within the optimal range, while B (2.503) is slightly higher. Both are acceptable, but A is marginally better.
4. **HBD:** A (0) is excellent, minimizing potential issues. B (3) is acceptable but less ideal.
5. **HBA:** A (8) is good. B (3) is excellent.
6. **QED:** Both are reasonable (A: 0.695, B: 0.801), with B being slightly better, indicating a more drug-like profile.
7. **DILI:** A (68.98) is higher than B (32.648). B is significantly better, indicating a much lower risk of liver injury. This is a critical advantage.
8. **BBB:** A (78.868) is better than B (70.105), but both are acceptable for a cardiovascular target.
9. **Caco-2:** Both are negative, suggesting poor permeability. This is a concern for both.
10. **Solubility:** Both are negative, indicating poor solubility. This is a concern for both.
11. **hERG:** A (0.138) is much better than B (0.769), indicating a lower risk of cardiotoxicity. This is a significant advantage for A.
12. **Cl_mic:** A (11.617) is better than B (-18.364). A has a lower clearance, suggesting better metabolic stability.
13. **t1/2:** Both are similar (A: 14.355, B: 13.562).
14. **Pgp:** Both are very low (A: 0.081, B: 0.071), suggesting minimal P-gp efflux.
15. **Affinity:** Both have the same binding affinity (-6.1 kcal/mol).
**GPCR-Specific Considerations:**
For a cardiovascular GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. While affinity is equal, B has a better TPSA and a significantly lower DILI risk. A has a better hERG profile and Cl_mic. The DILI risk is a major concern, and the better metabolic stability of A is also a plus.
**Overall Assessment:**
The DILI risk associated with Ligand B is concerning. While its TPSA is better, the significantly higher DILI percentile outweighs this benefit. Ligand A, despite the slightly higher TPSA, presents a more favorable safety profile (lower DILI, lower hERG) and better metabolic stability.
**Output:**
1
2025-04-18 00:18:48,016 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (357.4 and 346.5 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (69.72) is slightly higher than Ligand B (58.2). Both are below the 140 A^2 threshold for good oral absorption, but Ligand B is preferable due to the lower TPSA.
**3. logP:** Ligand B (3.402) is higher than Ligand A (1.007). While both are within the acceptable range (1-3), Ligand B is pushing the upper limit. Ligand A is better here.
**4. H-Bond Donors:** Ligand A (1) is better than Ligand B (2). Fewer HBDs generally improve permeability.
**5. H-Bond Acceptors:** Ligand A (3) is slightly higher than Ligand B (2). Both are acceptable.
**6. QED:** Both ligands have similar QED values (0.816 and 0.819), indicating good drug-likeness.
**7. DILI:** Ligand A (30.83) has a slightly lower DILI risk than Ligand B (33.23), both are good.
**8. BBB:** Ligand A (86.04) has a significantly higher BBB penetration percentile than Ligand B (73.87). While ADRB2 is a cardiovascular target and CNS penetration isn't *essential*, some degree of BBB penetration can be beneficial for off-target effects assessment and potential future applications.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand B (-4.68) is slightly worse than Ligand A (-4.577).
**10. Aqueous Solubility:** Ligand A (-2.371) is better than Ligand B (-4.326). Higher solubility is generally desirable.
**11. hERG Inhibition:** Ligand A (0.286) has a significantly lower hERG inhibition liability than Ligand B (0.415). This is a critical advantage, as hERG inhibition can lead to cardiotoxicity.
**12. Microsomal Clearance:** Ligand A (11.953) has a lower microsomal clearance than Ligand B (24.097), indicating better metabolic stability.
**13. In vitro Half-Life:** Ligand A (-21.659) has a much longer in vitro half-life than Ligand B (38.02). This is a significant advantage.
**14. P-gp Efflux:** Ligand A (0.022) has a much lower P-gp efflux liability than Ligand B (0.142). Lower efflux is preferable for better bioavailability.
**15. Binding Affinity:** Ligand B (-8.1) has a significantly stronger binding affinity than Ligand A (-5.1). This is a substantial advantage, potentially outweighing some of the ADME drawbacks.
**Overall Assessment:**
While Ligand B boasts a superior binding affinity, Ligand A demonstrates a much more favorable ADME profile. Specifically, the lower hERG inhibition, better metabolic stability (lower Cl_mic and longer t1/2), lower P-gp efflux, and better solubility are critical advantages. The higher BBB penetration of Ligand A is a bonus. Given the cardiovascular target, minimizing off-target effects and ensuring a reasonable pharmacokinetic profile are paramount. The substantial affinity difference *could* be overcome with further optimization of Ligand A, while mitigating the ADME liabilities of Ligand B would be more challenging.
Therefore, I favor Ligand A.
Output:
1
2025-04-18 00:18:48,016 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (342.439 and 344.459 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (69.64) is better than Ligand B (78.09). Both are below 140, but lower TPSA generally favors absorption.
3. **logP:** Both ligands have good logP values (3.151 and 2.358), falling within the optimal 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability, but not drastically so.
4. **HBD:** Both ligands have 2 H-bond donors, which is within the acceptable limit of 5.
5. **HBA:** Both ligands have 3 H-bond acceptors, also within the acceptable limit of 10.
6. **QED:** Ligand B (0.823) has a better QED score than Ligand A (0.638), indicating a more drug-like profile.
7. **DILI:** Ligand A (20.279) has a significantly lower DILI risk than Ligand B (33.23). This is a crucial advantage, as liver toxicity is a major concern in drug development.
8. **BBB:** Both ligands have reasonable BBB penetration (64.676 and 68.282). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration isn't necessarily detrimental and could allow for off-target effects to be assessed.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.674 and -5.098). This is unusual and suggests poor permeability. However, these values are on a scale where negative values are possible, and the absolute magnitude isn't directly interpretable without knowing the scale's specifics.
10. **Solubility:** Ligand A (-4.168) has slightly worse solubility than Ligand B (-2.739). Solubility is important, but not a primary concern given the logP values.
11. **hERG:** Both ligands have low hERG inhibition liability (0.399 and 0.526), which is good.
12. **Cl_mic:** Ligand B (6.672) has significantly lower microsomal clearance than Ligand A (48.85). This suggests better metabolic stability for Ligand B, which is highly desirable.
13. **t1/2:** Ligand B (-28.865) has a much longer in vitro half-life than Ligand A (-5.095). This is a substantial advantage, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.028 and 0.144).
15. **Binding Affinity:** Both ligands have very similar binding affinities (-4.6 and -4.5 kcal/mol). The difference is negligible.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, and affinity are important. Both ligands perform similarly in these areas. However, ADME properties like DILI and metabolic stability (Cl_mic, t1/2) become critical for overall viability. Ligand B clearly wins on these fronts.
**Conclusion:**
While Ligand A has a slightly better TPSA and comparable logP, the significantly lower DILI risk, improved metabolic stability (lower Cl_mic), and longer half-life of Ligand B make it the more promising drug candidate. The similar binding affinity seals the deal.
Output:
0
2025-04-18 00:18:48,016 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (342.443) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are below 140, good for oral absorption. Ligand A (83.98) is better than Ligand B (88.33).
3. **logP:** Both are within the optimal range (1-3). Ligand A (1.988) is slightly better, being closer to the middle of the range. Ligand B (3.009) is at the upper end, potentially increasing off-target interactions.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1), but both are acceptable.
5. **HBA:** Ligand A (4) is lower than Ligand B (7). Lower HBA is generally preferred for better membrane permeability.
6. **QED:** Both are above 0.5, indicating good drug-likeness, but Ligand A (0.857) is better than Ligand B (0.736).
7. **DILI:** Ligand A (47.77) has a significantly lower DILI risk than Ligand B (87.166). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (54.246) has better BBB penetration than Ligand B (27.259). While ADRB2 isn't strictly a CNS target, some peripheral ADRB2 receptors can be affected by CNS penetration, and it's generally a positive attribute.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-5.012) is slightly better than Ligand B (-5.342) but both are problematic.
10. **Solubility:** Both are negative, indicating poor solubility. Ligand A (-2.975) is slightly better than Ligand B (-4.329).
11. **hERG:** Both have low hERG inhibition liability, which is good. Ligand A (0.178) is slightly better than Ligand B (0.336).
12. **Cl_mic:** Ligand A (16.356) has significantly lower microsomal clearance than Ligand B (54.596), indicating better metabolic stability.
13. **t1/2:** Ligand B (35.448) has a much longer in vitro half-life than Ligand A (-1.639). This is a significant advantage for Ligand B.
14. **Pgp:** Both have low P-gp efflux liability, which is good. Ligand A (0.067) is slightly better than Ligand B (0.149).
15. **Affinity:** Both have very similar and strong binding affinities (-8.3 and -8.1 kcal/mol). The difference is negligible.
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A has better logP and TPSA. Pgp is comparable. Affinity is nearly identical. However, the significantly better DILI score, BBB penetration, and metabolic stability (lower Cl_mic) of Ligand A are crucial advantages. While Ligand B has a longer half-life, the other ADME properties of Ligand A are more favorable overall. The poor Caco-2 and solubility for both are concerning, but can be addressed with formulation strategies.
**Conclusion:**
Considering the balance of properties, Ligand A is the more promising drug candidate. Its superior ADME profile, particularly the lower DILI risk and better metabolic stability, outweighs the slightly longer half-life of Ligand B.
Output:
1
2025-04-18 00:18:48,017 - INFO - Batch 468 complete. Total preferences: 7488
2025-04-18 00:18:48,017 - INFO - Processing batch 469/512...
2025-04-18 00:19:39,549 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.5 and 363.4 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (54.26) is significantly better than Ligand B (87.74). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both are good (2.659 and 1.5), falling within the 1-3 range. Ligand A is slightly better.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Both ligands have 5 HBA, which is acceptable.
6. **QED:** Ligand B (0.83) is better than Ligand A (0.645), suggesting a more drug-like profile overall.
7. **DILI:** Ligand A (13.532) is much better than Ligand B (59.131). This is a significant advantage for Ligand A, as liver toxicity is a major concern.
8. **BBB:** Ligand A (83.831) is better than Ligand B (63.862), though neither is exceptionally high. This isn't a major factor for a cardiovascular target.
9. **Caco-2:** Ligand A (-4.974) is better than Ligand B (-5.145). Both are negative, indicating poor permeability.
10. **Solubility:** Ligand A (-0.914) is better than Ligand B (-2.434). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.414) is better than Ligand B (0.088). Lower hERG inhibition is crucial to avoid cardiotoxicity.
12. **Cl_mic:** Ligand B (-18.577) is *much* better than Ligand A (31.493). Lower clearance indicates greater metabolic stability. This is a substantial advantage for Ligand B.
13. **t1/2:** Ligand B (-17.74) is better than Ligand A (7.66). Longer half-life is generally desirable.
14. **Pgp:** Ligand A (0.318) is better than Ligand B (0.036). Lower P-gp efflux is preferable.
15. **Affinity:** Ligand A (-7.1) is slightly better than Ligand B (-7.0). While the difference is small, it's still a factor.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A is better on logP, TPSA, and Pgp. Affinity is similar.
**Overall Assessment:**
Ligand A has a significant advantage in terms of safety (DILI, hERG) and reasonable ADME properties (Solubility, BBB, Pgp). Ligand B excels in metabolic stability (Cl_mic and t1/2) and has a slightly better QED score. However, the higher DILI and hERG risk associated with Ligand B are concerning. The slight advantage in metabolic stability doesn't outweigh the safety concerns. The small affinity difference is not enough to overcome the other factors.
Therefore, I prefer Ligand A.
Output:
1
2025-04-18 00:19:39,549 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [363.483, 71.53, 1.976, 1, 5, 0.752, 56.262, 44.203, -5.055, -2.134, 0.156, 31.758, 17.342, 0.118, -5.6]
**Ligand B:** [349.435, 122.11, 1.119, 3, 5, 0.546, 39.822, 20.512, -5.286, -1.887, 0.662, 13.962, 8.962, 0.119, -6.7]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (349.435) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (71.53) is much better than Ligand B (122.11). For a GPCR, keeping TPSA low is good, and A is well under the 140 threshold. B is pushing it.
3. **logP:** Both are good (between 1-3), but Ligand A (1.976) is a bit higher, which could be slightly better for membrane permeability.
4. **HBD:** Ligand A (1) is better than Ligand B (3). Lower HBD is generally preferred for permeability.
5. **HBA:** Both have 5 HBA, which is acceptable.
6. **QED:** Ligand A (0.752) is significantly better than Ligand B (0.546), indicating a more drug-like profile.
7. **DILI:** Ligand B (39.822) has a lower DILI risk than Ligand A (56.262), which is a significant advantage.
8. **BBB:** Ligand A (44.203) has better BBB penetration than Ligand B (20.512). While this isn't a CNS target, some peripheral GPCRs benefit from limited BBB penetration to reduce off-target effects.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. This is concerning for both.
10. **Solubility:** Both have negative solubility values, indicating poor solubility. This is concerning for both.
11. **hERG:** Ligand A (0.156) has a lower hERG risk than Ligand B (0.662), which is a crucial safety factor.
12. **Cl_mic:** Ligand B (13.962) has a lower microsomal clearance than Ligand A (31.758), suggesting better metabolic stability.
13. **t1/2:** Ligand A (17.342) has a longer half-life than Ligand B (8.962), which is desirable.
14. **Pgp:** Both have low Pgp efflux liability (0.118 and 0.119).
15. **Affinity:** Ligand B (-6.7 kcal/mol) has a better binding affinity than Ligand A (-5.6 kcal/mol). This is a 1.1 kcal/mol difference, which is substantial and could outweigh some ADME drawbacks.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, and affinity. Ligand A has better logP and TPSA, while Ligand B has better affinity. The difference in affinity is significant.
**Overall Assessment:**
While Ligand A has a better QED, hERG, and half-life, the significantly stronger binding affinity of Ligand B (-6.7 vs -5.6 kcal/mol) is a major advantage. The lower DILI risk of Ligand B is also a plus. The poor Caco-2 and solubility for both are concerning and would need to be addressed through formulation or further chemical modifications, but the affinity difference is the most important factor here.
Therefore, I would choose Ligand B.
Output:
0
2025-04-18 00:19:39,549 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (346.5 and 347.4 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (58.2) is excellent, well below the 140 threshold and favorable for oral absorption. Ligand B (92.77) is higher, but still acceptable, though less optimal.
3. **logP:** Ligand A (3.57) is within the optimal 1-3 range. Ligand B (-0.376) is significantly lower, which is a concern for membrane permeability and bioavailability.
4. **HBD:** Both ligands have 2 HBD, which is within the acceptable limit of 5.
5. **HBA:** Ligand A has 2 HBA, while Ligand B has 5. Both are within the acceptable limit of 10, but Ligand A is more favorable.
6. **QED:** Both ligands have similar QED values (0.799 and 0.728), indicating good drug-likeness.
7. **DILI:** Ligand A (31.563) has a lower DILI risk than Ligand B (37.185), which is preferable.
8. **BBB:** Ligand A (66.499) has a much better BBB penetration score than Ligand B (11.555). While ADRB2 isn't strictly a CNS target, some CNS exposure can occur, and higher BBB is generally favorable.
9. **Caco-2:** Ligand A (-4.616) and Ligand B (-5.263) both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale isn't specified, so the absolute values are less informative.
10. **Solubility:** Ligand A (-4.42) has better solubility than Ligand B (-0.734).
11. **hERG:** Ligand A (0.345) has a lower hERG risk than Ligand B (0.165), which is a significant advantage.
12. **Cl_mic:** Ligand A (60.668) has a higher microsomal clearance than Ligand B (-11.521). This suggests Ligand B is more metabolically stable, which is a positive.
13. **t1/2:** Ligand A (-4.272) has a shorter in vitro half-life than Ligand B (-28.472). This is a significant drawback for Ligand A.
14. **Pgp:** Ligand A (0.294) has lower P-gp efflux than Ligand B (0.033), which is favorable for bioavailability.
15. **Affinity:** Ligand B (-6.6 kcal/mol) has a significantly stronger binding affinity than Ligand A (-4.5 kcal/mol). This is a substantial advantage, potentially outweighing some ADME concerns.
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B excels in affinity, but suffers from a poor logP and lower Pgp. Ligand A has a better logP and Pgp, but weaker affinity. The affinity difference is substantial (2.1 kcal/mol).
**Overall Assessment:**
Despite Ligand A's better ADME profile (logP, solubility, hERG, DILI, BBB, Pgp), the significantly stronger binding affinity of Ligand B is a major advantage. The difference in affinity is large enough to potentially overcome the lower logP and Pgp efflux. The improved metabolic stability (lower Cl_mic and longer t1/2) of Ligand B is also a plus. While the lower logP of Ligand B is a concern, it might be addressable through formulation strategies or minor structural modifications.
Output:
0
2025-04-18 00:19:39,549 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (355.825 and 353.467 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (81.99) is better than Ligand B (91.16). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (3.244) is slightly higher than Ligand B (1.685), placing it more optimally within the 1-3 range. Ligand B is a bit low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1), but both are acceptable (<=5).
5. **HBA:** Ligand B (8) is higher than Ligand A (3). Both are within the acceptable range (<=10), but A is preferable.
6. **QED:** Ligand A (0.863) is significantly better than Ligand B (0.505), indicating a more drug-like profile.
7. **DILI:** Ligand B (42.769) has a much lower DILI risk than Ligand A (63.862). This is a substantial advantage for Ligand B.
8. **BBB:** Ligand B (75.184) shows better BBB penetration than Ligand A (56.844). While ADRB2 is not a CNS target, some degree of BBB penetration can sometimes indicate favorable partitioning properties.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand B (-4.768) is slightly worse than Ligand A (-4.573).
10. **Solubility:** Ligand A (-5.36) is better than Ligand B (-2.347), indicating better aqueous solubility.
11. **hERG:** Ligand A (0.584) has a lower hERG inhibition liability than Ligand B (0.093), which is a significant advantage.
12. **Cl_mic:** Ligand B (67.565) has a higher microsomal clearance than Ligand A (51.763), suggesting faster metabolism and potentially lower *in vivo* exposure.
13. **t1/2:** Ligand A (30.747) has a significantly longer *in vitro* half-life than Ligand B (-20.285). This is a major advantage for Ligand A.
14. **Pgp:** Ligand A (0.092) has lower P-gp efflux liability than Ligand B (0.115).
15. **Binding Affinity:** Ligand A (-8.0) has a stronger binding affinity than Ligand B (-5.0). This is a substantial advantage for Ligand A.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A is better on logP, TPSA, Pgp, and *significantly* better on affinity. While Ligand B has a better DILI score, the superior affinity and drug-like properties of Ligand A outweigh this concern. The longer half-life of Ligand A is also a significant benefit.
**Conclusion:**
Ligand A is the more promising candidate due to its superior binding affinity, drug-likeness (QED), metabolic stability (t1/2, Cl_mic), solubility, and favorable Pgp/hERG profiles. The slightly higher DILI risk is a concern, but can be investigated further in subsequent studies.
Output:
1
2025-04-18 00:19:39,550 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (350.434 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (58.64) is significantly better than Ligand B (94.05). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand B's TPSA is approaching a level that could hinder oral absorption.
3. **logP:** Ligand A (2.249) is optimal, while Ligand B (0.373) is quite low. Low logP can lead to poor membrane permeability. This is a significant drawback for Ligand B.
4. **HBD:** Both have 1 HBD, which is acceptable.
5. **HBA:** Ligand A has 3 HBA, Ligand B has 6. Ligand B is higher, potentially impacting permeability.
6. **QED:** Both are similar and acceptable (A: 0.821, B: 0.76).
7. **DILI:** Ligand A (34.432) has a much lower DILI risk than Ligand B (49.399). This is a crucial advantage for Ligand A.
8. **BBB:** Ligand A (83.055) has better BBB penetration than Ligand B (45.017), though this is less critical for a cardiovascular target.
9. **Caco-2:** Ligand A (-4.316) is better than Ligand B (-5.252), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-2.391) is better than Ligand B (-0.754).
11. **hERG:** Both are very low (A: 0.756, B: 0.057), indicating minimal cardiotoxicity risk.
12. **Cl_mic:** Ligand A (40.886) has a higher (worse) microsomal clearance than Ligand B (-17.706). Ligand B demonstrates significantly better metabolic stability.
13. **t1/2:** Ligand B (9.096) has a longer half-life than Ligand A (3.004). This is a positive attribute for Ligand B.
14. **Pgp:** Ligand A (0.315) has lower P-gp efflux than Ligand B (0.024), which is favorable for bioavailability.
15. **Affinity:** Both have very similar binding affinity (-5.4 kcal/mol). The difference is negligible.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand A excels in logP and TPSA, while affinity is comparable. Ligand B has a better half-life and metabolic stability, but the poor logP and higher TPSA are significant drawbacks. The lower DILI risk for Ligand A is also a major advantage.
**Conclusion:**
While Ligand B has a longer half-life and better metabolic stability, the significantly better physicochemical properties (logP, TPSA, solubility) and lower DILI risk of Ligand A outweigh these benefits. The comparable binding affinity seals the decision.
Output:
1
2025-04-18 00:19:39,550 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, prioritizing logP, TPSA, Pgp, and affinity is crucial.
* **Molecular Weight:** Both ligands are within the acceptable range (354.45 and 352.48 Da).
* **TPSA:** Ligand A (68.31) is significantly better than Ligand B (78.87). Lower TPSA generally favors better absorption and potentially BBB penetration.
* **logP:** Ligand B (2.155) is better than Ligand A (0.524). A logP between 1-3 is optimal, and Ligand B falls within this range, while Ligand A is quite low, potentially hindering membrane permeability.
* **H-Bond Donors/Acceptors:** Ligand A has 0 HBD and 5 HBA, while Ligand B has 2 HBD and 4 HBA. Both are within acceptable limits.
* **QED:** Both have good QED scores (0.667 and 0.743).
* **DILI:** Ligand B (23.50) has a considerably lower DILI risk than Ligand A (30.32). This is a significant advantage.
* **BBB:** Ligand A (84.10) has a much higher BBB percentile than Ligand B (40.83). While ADRB2 is cardiovascular, some CNS off-target effects are possible, and higher BBB penetration could be a concern. However, for a cardiovascular target, this is less critical than other parameters.
* **Caco-2:** Ligand A (-4.146) is better than Ligand B (-5.138), indicating better intestinal absorption.
* **Solubility:** Ligand A (-1.008) is better than Ligand B (-2.344).
* **hERG:** Both have very low hERG inhibition risk (0.232 and 0.167).
* **Cl_mic:** Ligand B (3.235) has significantly lower microsomal clearance than Ligand A (30.231), indicating better metabolic stability.
* **t1/2:** Ligand B (-12.194) has a slightly better in vitro half-life than Ligand A (-18.076).
* **Pgp:** Both have low P-gp efflux liability (0.075 and 0.093).
* **Binding Affinity:** Both ligands have identical binding affinity (-5.9 kcal/mol).
**Overall Assessment:**
Ligand B is preferable. While Ligand A has a better TPSA and Caco-2 permeability, Ligand B excels in crucial areas like logP, DILI risk, and metabolic stability (Cl_mic). The lower logP of Ligand A is a major concern for permeability, and the higher DILI risk is unacceptable. The slightly better BBB penetration of Ligand A is not a significant advantage for a cardiovascular target. The similar binding affinity makes the ADME properties the deciding factor.
**Output:**
0
2025-04-18 00:19:39,550 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands (352.519 and 349.475 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (69.64) is better than Ligand B (78.51). Both are under 140, but lower TPSA generally favors absorption.
3. **logP:** Both ligands have good logP values (2.286 and 1.612), falling within the optimal 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability, but not drastically.
4. **HBD:** Both have 2 HBD, which is within the acceptable limit of 5.
5. **HBA:** Both have 3 HBA, also within the acceptable limit of 10.
6. **QED:** Ligand A (0.704) has a better QED score than Ligand B (0.565), indicating a more drug-like profile.
7. **DILI:** Ligand B (22.063) has a significantly lower DILI risk than Ligand A (6.747), a major advantage. Lower DILI is crucial.
8. **BBB:** Both ligands have good BBB penetration (73.672 and 70.26), which is good for a GPCR, but not a primary concern for ADRB2 (cardiovascular target).
9. **Caco-2:** Ligand A (-4.709) and Ligand B (-5.022) have similar, poor Caco-2 permeability. This is a potential issue for oral bioavailability.
10. **Solubility:** Ligand A (-2.793) and Ligand B (-2.226) have similar, poor aqueous solubility. This could pose formulation challenges.
11. **hERG:** Ligand A (0.597) has a slightly higher hERG inhibition risk than Ligand B (0.199), which is preferable.
12. **Cl_mic:** Ligand B (20.901) has lower microsomal clearance than Ligand A (30.738), suggesting better metabolic stability.
13. **t1/2:** Ligand A (4.685) has a longer in vitro half-life than Ligand B (-2.824). This is a positive attribute.
14. **Pgp:** Ligand A (0.076) has lower P-gp efflux than Ligand B (0.046), which is favorable for bioavailability.
15. **Affinity:** Ligand A (-7.8 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.8 kcal/mol). This 1 kcal/mol difference is substantial and can outweigh some ADME drawbacks.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), affinity, logP, and metabolic stability are key. While BBB is less critical for a cardiovascular target, it's still a positive attribute.
**Overall Assessment:**
Ligand A has a significantly better binding affinity, a better QED score, a longer half-life, and lower P-gp efflux. However, Ligand B has a much lower DILI risk and better metabolic stability. The affinity difference is substantial. While the solubility and Caco-2 values are concerning for both, the superior binding of Ligand A is likely to be more impactful for *in vivo* efficacy, and the DILI risk of Ligand B is a serious concern.
**Output:**
1
2025-04-18 00:19:39,550 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [348.443, 76.66, 2.657, 2, 4, 0.858, 38.116, 76.968, -4.548, -3.434, 0.682, 63.714, -2.081, 0.191, -6.5]**
**Ligand B: [352.381, 58.64, 2.288, 1, 3, 0.849, 47.421, 95.192, -4.426, -3.246, 0.588, 34.726, -15.825, 0.332, -6.8]**
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). A (348.443) and B (352.381) are very close, so this isn't a major differentiator.
2. **TPSA:** Ligand A (76.66) is slightly higher than Ligand B (58.64). Both are acceptable for a non-CNS GPCR, but B is better.
3. **logP:** Both ligands have good logP values (A: 2.657, B: 2.288) within the optimal 1-3 range. B is slightly lower, which could be beneficial for solubility.
4. **H-Bond Donors:** Ligand A (2) and B (1) are both within the acceptable limit of <=5. B is slightly better.
5. **H-Bond Acceptors:** Ligand A (4) and B (3) are both within the acceptable limit of <=10. B is slightly better.
6. **QED:** Both ligands have similar, good QED values (A: 0.858, B: 0.849), indicating good drug-like properties.
7. **DILI:** Ligand A (38.116) has a lower DILI risk than Ligand B (47.421), which is favorable.
8. **BBB:** Ligand B (95.192) has a significantly higher BBB penetration percentile than Ligand A (76.968). While ADRB2 isn't strictly a CNS target, some CNS exposure can occur, and higher BBB is generally preferable.
9. **Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified. Assuming a lower number is worse, A (-4.548) is slightly worse than B (-4.426).
10. **Aqueous Solubility:** Both ligands have negative solubility values, which is also unusual. Assuming a lower number is worse, A (-3.434) is slightly worse than B (-3.246).
11. **hERG Inhibition:** Both ligands have low hERG inhibition risk (A: 0.682, B: 0.588), which is good.
12. **Microsomal Clearance:** Ligand B (34.726) has significantly lower microsomal clearance than Ligand A (63.714), indicating better metabolic stability.
13. **In vitro Half-Life:** Ligand B (-15.825) has a much longer in vitro half-life than Ligand A (-2.081). This is a significant advantage.
14. **P-gp Efflux:** Ligand A (0.191) has lower P-gp efflux than Ligand B (0.332), which is preferable.
15. **Binding Affinity:** Ligand B (-6.8) has a slightly better binding affinity than Ligand A (-6.5), although the difference is small.
**Overall Assessment:**
Ligand B is the stronger candidate. While Ligand A has a slightly lower DILI risk, Ligand B excels in several crucial ADME properties: significantly better metabolic stability (lower Cl_mic), a longer half-life, and higher BBB penetration. The slightly better affinity of Ligand B is also a plus. The TPSA, H-bond donors/acceptors are also slightly better for Ligand B. The negative Caco-2 and solubility values are concerning for both, but the differences are small. Given the GPCR-specific priorities (logP, Pgp, TPSA, affinity), and the importance of metabolic stability for a viable drug, Ligand B is the more promising candidate.
Output:
0
2025-04-18 00:19:39,550 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (369.372 Da) is slightly higher than Ligand B (348.443 Da), but this difference isn't significant.
**2. TPSA:** Both ligands have TPSA values below 140, which is good for oral absorption. Ligand A (63.91) is better than Ligand B (67.87), but both are acceptable.
**3. logP:** Ligand A (3.268) is optimal, while Ligand B (1.949) is a bit low, potentially hindering membrane permeability. This favors Ligand A.
**4. H-Bond Donors:** Both ligands have acceptable HBD counts (Ligand A: 0, Ligand B: 1).
**5. H-Bond Acceptors:** Both ligands have acceptable HBA counts (Ligand A: 6, Ligand B: 4).
**6. QED:** Both ligands have good QED scores (Ligand A: 0.708, Ligand B: 0.789), indicating drug-likeness. Ligand B is slightly better.
**7. DILI Risk:** Ligand B (45.25) has a significantly lower DILI risk than Ligand A (92.633). This is a substantial advantage for Ligand B.
**8. BBB Penetration:** Ligand A (89.104) has better BBB penetration than Ligand B (71.966). While ADRB2 is cardiovascular, some CNS effects are possible with beta-blockers, and better BBB penetration could be beneficial.
**9. Caco-2 Permeability:** Ligand B (-5.076) has better Caco-2 permeability than Ligand A (-4.545).
**10. Aqueous Solubility:** Ligand B (-2.993) has better aqueous solubility than Ligand A (-4.13).
**11. hERG Inhibition:** Ligand A (0.383) has slightly lower hERG inhibition risk than Ligand B (0.246), which is favorable.
**12. Microsomal Clearance:** Ligand B (28.594) has significantly lower microsomal clearance than Ligand A (68.719), indicating better metabolic stability.
**13. In vitro Half-Life:** Both ligands have similar in vitro half-lives (Ligand A: 21.961, Ligand B: 21.492).
**14. P-gp Efflux:** Ligand A (0.607) has higher P-gp efflux than Ligand B (0.057). Lower P-gp efflux is preferred for better bioavailability.
**15. Binding Affinity:** Ligand B (-7.1 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.5 kcal/mol). This is a major advantage, potentially outweighing some ADME drawbacks.
**GPCR-Specific Priorities:** For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are crucial. Ligand B excels in affinity and Pgp efflux, has acceptable logP and TPSA, and is better in solubility and permeability. While Ligand A has better BBB penetration, the substantial difference in binding affinity and the lower DILI risk of Ligand B are more compelling.
**Conclusion:**
Considering the balance of properties, particularly the significantly stronger binding affinity of Ligand B and its lower DILI risk and P-gp efflux, I believe **Ligand B** is the more promising drug candidate.
0
2025-04-18 00:19:39,550 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (370.519 Da and 351.403 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (89.01) is better than Ligand B (106.62). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand A is comfortably below the 140 A^2 threshold, while Ligand B is approaching it.
**3. logP:** Ligand A (3.066) is slightly higher than Ligand B (1.901), placing it more optimally within the 1-3 range. Ligand B is at the lower end, potentially impacting permeability.
**4. H-Bond Donors:** Both ligands have 2 HBD, which is within the acceptable limit of 5.
**5. H-Bond Acceptors:** Both ligands have 6 HBA, also within the acceptable limit of 10.
**6. QED:** Ligand B (0.758) has a slightly better QED score than Ligand A (0.569), indicating a more drug-like profile. However, the difference isn't substantial enough to be decisive.
**7. DILI:** Ligand A (34.471) has a significantly lower DILI risk than Ligand B (64.366). This is a major advantage for Ligand A.
**8. BBB:** Ligand A (75.456) has a better BBB penetration percentile than Ligand B (64.87). While ADRB2 isn't exclusively a CNS target, some peripheral effects are mediated by CNS pathways, and better BBB penetration can be advantageous.
**9. Caco-2 Permeability:** Ligand A (-5.082) has a better Caco-2 permeability than Ligand B (-4.528). This suggests better intestinal absorption for Ligand A.
**10. Aqueous Solubility:** Ligand A (-4.13) has slightly better aqueous solubility than Ligand B (-3.467).
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.342 and 0.29, respectively). This is good for both.
**12. Microsomal Clearance:** Ligand B (81.736) has a slightly lower microsomal clearance than Ligand A (83.653), suggesting better metabolic stability.
**13. In vitro Half-Life:** Ligand A (-29.773) has a much longer in vitro half-life than Ligand B (-17.441). This is a significant advantage for Ligand A, potentially allowing for less frequent dosing.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.294 and 0.036, respectively).
**15. Binding Affinity:** Both ligands have the same binding affinity (-5.8 kcal/mol).
**Overall Assessment:**
Ligand A is the stronger candidate. While Ligand B has a slightly better QED and microsomal clearance, Ligand A excels in crucial areas: lower DILI risk, better BBB penetration, better Caco-2 permeability, better solubility, and a significantly longer half-life. Given the GPCR target class, the balance of TPSA, logP, and permeability is also more favorable for Ligand A. The equal binding affinity removes that as a differentiating factor. The lower DILI risk is a critical factor for clinical development.
Output:
1
2025-04-18 00:19:39,550 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (381.395) is slightly higher than Ligand B (345.447), but both are acceptable.
2. **TPSA:** Ligand A (62.3) is better than Ligand B (72.28). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally favors absorption.
3. **logP:** Both ligands have good logP values (A: 2.187, B: 1.406), falling within the 1-3 range. Ligand A is slightly more lipophilic, which could be beneficial for membrane permeability.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 4 HBA, while Ligand B has 6. Ligand A is preferable here.
6. **QED:** Both ligands have similar, good QED values (A: 0.702, B: 0.744).
7. **DILI:** Both have acceptable DILI risk (A: 38.62, B: 40.403), below the 40 threshold.
8. **BBB:** Ligand A (71.229) has a better BBB percentile than Ligand B (64.482). While not a CNS target, some degree of BBB penetration can sometimes indicate favorable permeability characteristics.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual, and suggests poor permeability. Ligand A (-4.943) is slightly better than Ligand B (-4.896).
10. **Solubility:** Both have negative solubility values, indicating very poor aqueous solubility. Ligand A (-2.526) is slightly better than Ligand B (-2.007).
11. **hERG:** Both ligands have low hERG inhibition liability (A: 0.367, B: 0.407), which is excellent.
12. **Cl_mic:** Ligand A (13.183) has significantly lower microsomal clearance than Ligand B (46.962). This is a major advantage for Ligand A, indicating better metabolic stability.
13. **t1/2:** Ligand A (-4.816) has a much more negative in vitro half-life than Ligand B (0.34). This suggests a significantly shorter half-life for Ligand A, which is a drawback.
14. **Pgp:** Both ligands have low P-gp efflux liability (A: 0.077, B: 0.206), which is good.
15. **Binding Affinity:** Both have excellent binding affinity (A: -5.7 kcal/mol, B: -5.9 kcal/mol). Ligand B is slightly better, but the difference is small.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A has slightly better logP and TPSA, and comparable Pgp. The affinity difference is minimal. However, the significantly lower Cl_mic of Ligand A is a major advantage, indicating better metabolic stability. The shorter half-life of Ligand A is a concern, but can potentially be addressed through structural modifications. The poor Caco-2 and solubility are concerning for both, but can be addressed through formulation strategies.
**Conclusion:**
Considering the balance of properties, particularly the superior metabolic stability (lower Cl_mic) of Ligand A, I believe it is the more promising drug candidate despite the shorter half-life. The half-life can be improved, but metabolic instability is harder to fix.
Output:
1
2025-04-18 00:19:39,550 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
The target is ADRB2, a GPCR. Therefore, I will prioritize logP, TPSA, Pgp efflux, BBB penetration, and binding affinity. Metabolic stability (Cl_mic, t1/2) and safety (DILI, hERG) are also important.
Let's compare the ligands property by property:
1. **MW:** Both ligands (370.471 and 373.387 Da) fall within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (92.78) is significantly better than Ligand B (135.92). ADRB2 is not a CNS target, but lower TPSA generally improves permeability.
3. **logP:** Both ligands have good logP values (1.079 and 1.278), falling within the optimal 1-3 range.
4. **HBD/HBA:** Both have 1 HBD, which is good. Ligand B has 7 HBA vs 5 for Ligand A. This is a slight negative for B.
5. **QED:** Ligand A (0.802) is much better than Ligand B (0.45), indicating a more drug-like profile.
6. **DILI:** Both have the same DILI risk (83.443 percentile), which is relatively high. This is a concern for both, but doesn't differentiate them.
7. **BBB:** Ligand A (83.443) has better BBB penetration than Ligand B (70.415). While not a CNS target, some peripheral exposure can be mitigated with better BBB scores.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and difficult to interpret.
9. **Solubility:** Ligand A (-2.165) has better solubility than Ligand B (-3.549).
10. **hERG:** Ligand A (0.193) has a much lower hERG risk than Ligand B (0.438). This is a significant advantage for A.
11. **Cl_mic:** Ligand A (14.375) has significantly better metabolic stability (lower clearance) than Ligand B (61.675).
12. **t1/2:** Ligand A (16.099) has a shorter half-life than Ligand B (30.486), but still reasonable.
13. **Pgp:** Ligand A (0.021) has much lower P-gp efflux liability than Ligand B (0.157). This is a key advantage for A, improving bioavailability.
14. **Binding Affinity:** Ligand B (-7.0) has a slightly better binding affinity than Ligand A (-6.8), but the difference is small (0.2 kcal/mol).
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most crucial ADME properties (TPSA, QED, solubility, hERG, Cl_mic, Pgp). While Ligand B has a slightly better binding affinity, the advantages of Ligand A in terms of safety, metabolic stability, and bioavailability are more compelling for overall drug development potential. The difference in binding affinity is not large enough to overcome the ADME deficiencies of Ligand B.
**Output:**
1
2025-04-18 00:19:39,551 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (378.529 Da and 348.531 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (49.41) is slightly higher than Ligand B (41.57). Both are below the 140 A^2 threshold for good oral absorption, but closer to the ideal range for GPCRs. Ligand B is slightly favored.
**3. logP:** Both ligands have good logP values (3.554 and 3.373 respectively), falling within the optimal 1-3 range. No significant difference.
**4. H-Bond Donors:** Both have 1 HBD, which is within the acceptable limit of <=5.
**5. H-Bond Acceptors:** Both have 3 HBA, which is within the acceptable limit of <=10.
**6. QED:** Both ligands have very similar QED values (0.719 and 0.717), indicating good drug-likeness.
**7. DILI:** Ligand A (23.653) has a slightly higher DILI risk than Ligand B (16.285), but both are well below the concerning threshold of 60. Ligand B is favored.
**8. BBB:** Both ligands have high BBB penetration (90.306 and 81.815), which is good, but not critical for ADRB2 as it's primarily a cardiovascular target. Ligand A is slightly favored.
**9. Caco-2 Permeability:** Both have negative Caco-2 values (-4.825 and -4.802), which is unusual and suggests poor permeability. This is a concern for both.
**10. Aqueous Solubility:** Both have negative solubility values (-3.8 and -3.171), which is also unusual and suggests poor solubility. This is a concern for both.
**11. hERG Inhibition:** Ligand A (0.883) has a slightly higher hERG inhibition liability than Ligand B (0.518). Ligand B is favored.
**12. Microsomal Clearance:** Ligand A (50.899) has slightly higher microsomal clearance than Ligand B (47.45), suggesting slightly lower metabolic stability. Ligand B is favored.
**13. In vitro Half-Life:** Ligand B (44.612) has a significantly longer in vitro half-life than Ligand A (-12.977). This is a major advantage for Ligand B.
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (0.204 and 0.387), which is good.
**15. Binding Affinity:** Ligand A (-7.1 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.3 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME drawbacks.
**Overall Assessment:**
While Ligand B shows advantages in several ADME properties (lower DILI, better metabolic stability, longer half-life, lower hERG risk), the significantly stronger binding affinity of Ligand A (-7.1 vs -6.3 kcal/mol) is a critical factor, especially for a GPCR target. A 0.8 kcal/mol difference in binding affinity is a substantial benefit. The ADME issues with both ligands are concerning, but could potentially be addressed through further optimization. Given the importance of potency for GPCRs, and the magnitude of the affinity difference, I favor Ligand A.
Output:
1
2025-04-18 00:19:39,551 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (405.227 Da) is within the ideal range, while Ligand B (367.515 Da) is also acceptable. No clear advantage here.
2. **TPSA:** Ligand A (70.47) is better than Ligand B (80.32). Both are below 140, but lower is preferred for absorption.
3. **logP:** Both ligands (A: 2.902, B: 2.676) are within the optimal 1-3 range. Very similar.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is preferable to Ligand B (5). Fewer HBAs generally improve permeability.
6. **QED:** Both ligands have good QED scores (A: 0.713, B: 0.74), indicating good drug-likeness.
7. **DILI:** Ligand A (89.027) has a higher DILI risk than Ligand B (52.966). This is a significant drawback for Ligand A.
8. **BBB:** Ligand A (77.239) has a better BBB penetration score than Ligand B (49.244). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant for off-target effects.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.989 and -4.851). This is unusual and suggests poor permeability. However, the values are very close.
10. **Solubility:** Ligand A (-4.654) has slightly worse solubility than Ligand B (-2.761).
11. **hERG:** Ligand A (0.714) has a slightly higher hERG risk than Ligand B (0.173). This is a concern for Ligand A.
12. **Cl_mic:** Ligand B (30.656) has better metabolic stability (lower clearance) than Ligand A (26.136).
13. **t1/2:** Ligand B (20.222) has a significantly longer half-life than Ligand A (2.045). This is a major advantage for Ligand B.
14. **Pgp:** Ligand A (0.482) has lower P-gp efflux than Ligand B (0.124), which is favorable.
15. **Affinity:** Ligand B (-7.1 kcal/mol) has a slightly better binding affinity than Ligand A (-8.0 kcal/mol).
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Both ligands are good on logP. Ligand A has a better TPSA and Pgp profile. However, the significantly better DILI, metabolic stability (Cl_mic & t1/2), hERG, and binding affinity of Ligand B outweigh the slight advantages of Ligand A.
**Conclusion:**
Ligand B is the more promising candidate due to its superior safety profile (lower DILI and hERG), better metabolic stability (longer half-life and lower clearance), and slightly better binding affinity. While Ligand A has some favorable properties, the safety and pharmacokinetic advantages of Ligand B are more critical for overall drug development success.
Output:
0
2025-04-18 00:19:39,551 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (348.443 and 349.381 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (78.87) is higher than Ligand B (66.64). While both are below the 140 threshold for oral absorption, the lower TPSA of Ligand B is slightly preferable for a GPCR, potentially aiding membrane permeability.
**3. logP:** Ligand A (1.196) is closer to the optimal 1-3 range than Ligand B (1.97). Both are acceptable, but A is slightly better.
**4. H-Bond Donors:** Ligand A (2) is slightly higher than Ligand B (1). Both are within the acceptable limit of <=5.
**5. H-Bond Acceptors:** Ligand A (4) is higher than Ligand B (3). Both are within the acceptable limit of <=10.
**6. QED:** Ligand A (0.748) has a slightly higher QED score than Ligand B (0.67), indicating a more drug-like profile.
**7. DILI:** Ligand B (56.727) has a significantly lower DILI risk than Ligand A (19.93). This is a major advantage for Ligand B.
**8. BBB:** Ligand B (69.988) has a higher BBB penetration percentile than Ligand A (60.411). While ADRB2 is a cardiovascular target, some CNS penetration is not necessarily detrimental and could provide additional pharmacological effects or off-target safety information.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.802 and -4.605). This is unusual and suggests poor permeability. However, the values are very similar.
**10. Aqueous Solubility:** Ligand B (-3.514) has better aqueous solubility than Ligand A (-1.917). This is a positive for formulation and bioavailability.
**11. hERG Inhibition:** Ligand A (0.296) has a lower hERG inhibition liability than Ligand B (0.642). This is a significant safety advantage for Ligand A.
**12. Microsomal Clearance:** Ligand B (4.287) has a much lower microsomal clearance than Ligand A (11.434), indicating better metabolic stability. This is a major advantage for Ligand B.
**13. In vitro Half-Life:** Ligand B (-13.748) has a much longer in vitro half-life than Ligand A (-11.441). This is a significant advantage for Ligand B, potentially enabling less frequent dosing.
**14. P-gp Efflux:** Ligand A (0.048) has lower P-gp efflux liability than Ligand B (0.062). This is a slight advantage for Ligand A.
**15. Binding Affinity:** Ligand B (-7.8) has a significantly stronger binding affinity than Ligand A (-4.2). This is a substantial advantage that can outweigh some of the ADME drawbacks of Ligand B. A difference of 3.6 kcal/mol is considerable.
**Overall Assessment:**
While Ligand A has advantages in hERG inhibition and P-gp efflux, Ligand B demonstrates a superior profile overall, especially considering the GPCR-specific priorities. The significantly improved binding affinity, lower DILI risk, better metabolic stability (lower Cl_mic and longer t1/2), and higher BBB penetration, coupled with better solubility, make Ligand B the more promising candidate. The slightly higher TPSA of Ligand A is less concerning than the other advantages of Ligand B.
Output:
0
2025-04-18 00:19:39,551 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the acceptable range (200-500 Da). Ligand A (343.343 Da) is slightly lower, which is generally favorable for permeability.
**2. TPSA:** Ligand B (85.13) is significantly better than Ligand A (128.28). For a GPCR, lower TPSA is generally preferred as it aids membrane permeability.
**3. logP:** Ligand B (1.428) is within the optimal range (1-3), while Ligand A (-0.012) is slightly below 1. While not drastically outside the range, a slightly higher logP is generally preferred for GPCRs to facilitate membrane interactions.
**4. H-Bond Donors:** Ligand A (3) is slightly higher than Ligand B (2), but both are acceptable (<=5).
**5. H-Bond Acceptors:** Ligand A (6) is slightly higher than Ligand B (5), but both are acceptable (<=10).
**6. QED:** Both ligands have similar QED values (0.716 and 0.708), indicating good drug-like properties.
**7. DILI:** Ligand B (62.35) has a better DILI score than Ligand A (76.425), indicating a lower risk of drug-induced liver injury. This is a significant advantage.
**8. BBB:** Ligand B (67.003) has a significantly higher BBB penetration percentile than Ligand A (28.189). While ADRB2 is a cardiovascular target, some CNS effects are possible with certain ligands, and higher BBB penetration could be beneficial or detrimental depending on the desired profile.
**9. Caco-2 Permeability:** Both ligands have similar, very negative Caco-2 values. This is concerning for both, suggesting poor intestinal absorption.
**10. Aqueous Solubility:** Both ligands have similar, very negative solubility values. This is also concerning for both, suggesting poor aqueous solubility.
**11. hERG Inhibition:** Ligand A (0.122) has a slightly lower hERG inhibition liability than Ligand B (0.619), which is favorable.
**12. Microsomal Clearance:** Ligand A (-10.662) has much lower (better) microsomal clearance than Ligand B (18.184), indicating greater metabolic stability. This is a significant advantage.
**13. In vitro Half-Life:** Ligand B (31.46) has a much longer in vitro half-life than Ligand A (-5.478), which is a significant advantage.
**14. P-gp Efflux:** Ligand A (0.005) has a much lower P-gp efflux liability than Ligand B (0.182), which is a significant advantage.
**15. Binding Affinity:** Ligand B (-7.9) has a slightly better binding affinity than Ligand A (-8.7). While both are excellent, the difference is relatively small.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand B appears to be the better candidate. While Ligand A has advantages in metabolic stability (Cl_mic) and P-gp efflux, Ligand B has a superior TPSA, better logP, lower DILI risk, and a higher BBB penetration. The slightly better binding affinity of Ligand B further supports this choice. The poor Caco-2 and solubility values are concerning for both, but can be addressed with formulation strategies.
Output:
0
2025-04-18 00:19:39,551 - INFO - Batch 469 complete. Total preferences: 7504
2025-04-18 00:19:39,551 - INFO - Processing batch 470/512...
2025-04-18 00:20:24,372 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.463 and 350.459 Da) fall comfortably within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (80.12) is slightly higher than Ligand B (73.99). Both are below the 140 threshold for oral absorption, and acceptable for a peripheral GPCR like ADRB2. Ligand B is slightly preferred.
3. **logP:** Ligand B (2.533) is a bit higher than Ligand A (1.458), but both are within the optimal 1-3 range. Ligand B is slightly preferred.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 5 HBA, and Ligand B has 4. Both are below the 10 threshold.
6. **QED:** Ligand A (0.845) has a better QED score than Ligand B (0.782), indicating a more drug-like profile. This favors Ligand A.
7. **DILI:** Ligand B (20.008) has a significantly lower DILI risk than Ligand A (41.062). This is a major advantage for Ligand B.
8. **BBB:** Ligand A (68.67) has a higher BBB penetration percentile than Ligand B (47.615). While ADRB2 isn't a CNS target, some degree of BBB penetration can sometimes indicate favorable permeability characteristics.
9. **Caco-2:** Ligand A (-5.334) has a more negative Caco-2 value, which is unusual and suggests *poor* permeability. Ligand B (-4.587) is also negative, but less so. This is a significant negative for Ligand A.
10. **Solubility:** Ligand A (-1.984) has slightly worse solubility than Ligand B (-1.569). Both are poor, but Ligand B is slightly better.
11. **hERG:** Ligand A (0.171) has a lower hERG inhibition liability than Ligand B (0.648), which is a positive.
12. **Cl_mic:** Ligand A (16.126) has a much lower microsomal clearance than Ligand B (36.25), indicating better metabolic stability. This is a strong advantage for Ligand A.
13. **t1/2:** Ligand B (40.513) has a significantly longer in vitro half-life than Ligand A (-8.906). This is a major advantage for Ligand B.
14. **Pgp:** Ligand A (0.032) has a much lower P-gp efflux liability than Ligand B (0.359). This is a strong advantage for Ligand A.
15. **Affinity:** Ligand A (-7.9) has a slightly better binding affinity than Ligand B (-5.9). This is a significant advantage for Ligand A.
**Overall Assessment and GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A has a better affinity, lower Pgp efflux, and a slightly better QED. However, Ligand B has a much lower DILI risk, better half-life, and slightly better logP and TPSA. The poor Caco-2 permeability and high clearance of Ligand A are concerning. The affinity difference, while present, isn't large enough to overcome the ADME liabilities of Ligand A. The lower DILI risk and longer half-life of Ligand B are more valuable for overall drug development.
**Output:**
0
2025-04-18 00:20:24,373 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (357.885 and 381.973 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (49.25) is slightly higher than Ligand B (45.23), but both are well below the 140 threshold for good oral absorption, and acceptable for a cardiovascular GPCR.
3. **logP:** Both ligands have good logP values (3.842 and 4.409), falling within the optimal 1-3 range. Ligand B is slightly higher, which *could* present a minor solubility issue, but isn't a major concern.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Both have 4 HBA, which is good.
6. **QED:** Both ligands have high QED scores (0.887 and 0.821), indicating good drug-like properties.
7. **DILI:** Both have acceptable DILI risk (50.795 and 47.964), below the 60 threshold.
8. **BBB:** Ligand A (90.074) has significantly better BBB penetration than Ligand B (74.952). While ADRB2 isn't a CNS target, some off-target CNS effects are always a consideration, and higher BBB penetration can sometimes correlate with better overall distribution.
9. **Caco-2:** Both have negative Caco-2 values (-4.852 and -5.219). This is unusual and suggests poor permeability. However, these values are on a scale where negative values are possible, and the absolute magnitude isn't directly interpretable without knowing the scale's specifics.
10. **Solubility:** Both have negative solubility values (-4.773 and -4.496). Similar to Caco-2, these are on a scale where negative values are possible, and the absolute magnitude isn't directly interpretable.
11. **hERG:** Both ligands have very low hERG risk (0.713 and 0.498). This is excellent.
12. **Cl_mic:** Both have similar microsomal clearance values (52.543 and 50.963 mL/min/kg). These are moderate, suggesting reasonable metabolic stability.
13. **t1/2:** Ligand A (27.909 hours) has a significantly longer in vitro half-life than Ligand B (11.989 hours). This is a major advantage, potentially allowing for less frequent dosing.
14. **Pgp:** Both have low P-gp efflux liability (0.811 and 0.689).
15. **Binding Affinity:** Ligand B (-6.8 kcal/mol) has a slightly better binding affinity than Ligand A (-6.4 kcal/mol). This is a 0.4 kcal/mol difference, which is notable but not overwhelmingly large.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, affinity, and metabolic stability are key. Both ligands perform well on logP and TPSA. Ligand B has a slightly better affinity, but Ligand A has a substantially longer half-life. The better BBB penetration of Ligand A is a bonus, even for a non-CNS target.
**Overall Assessment:**
While Ligand B has a slightly better binding affinity, the significantly longer half-life of Ligand A, combined with its better BBB penetration, makes it the more promising candidate. The longer half-life translates to potentially better *in vivo* exposure and less frequent dosing, which are crucial for patient compliance. The Caco-2 and solubility values are concerning for both, but are difficult to interpret without more information on the scale used.
Output:
1
2025-04-18 00:20:24,373 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (385.335) is slightly higher than Ligand B (362.499), but both are acceptable.
2. **TPSA:** Ligand A (52.57) is significantly better than Ligand B (65.54). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (4.362) is a bit high, potentially leading to solubility issues and off-target effects. Ligand B (2.255) is within the optimal range. This favors Ligand B.
4. **HBD:** Ligand A (2) and Ligand B (1) are both good, well below the threshold of 5.
5. **HBA:** Ligand A (2) and Ligand B (5) are both acceptable, below the threshold of 10.
6. **QED:** Both ligands have good QED scores (A: 0.791, B: 0.892), indicating good drug-like properties.
7. **DILI:** Ligand B (40.83) has a significantly lower DILI risk than Ligand A (18.147). This is a major advantage for Ligand B.
8. **BBB:** Both have reasonable BBB penetration, but Ligand A (90.384) is better than Ligand B (78.402). However, as ADRB2 is a cardiovascular target, BBB penetration is not a critical factor.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Both ligands have negative solubility values, indicating poor aqueous solubility. This is a significant drawback for both.
11. **hERG:** Ligand A (0.844) has a slightly higher hERG risk than Ligand B (0.33), which is preferable.
12. **Cl_mic:** Ligand B (42.139) has a much higher microsomal clearance than Ligand A (12.5). This suggests Ligand A is more metabolically stable.
13. **t1/2:** Ligand A (57.274) has a significantly longer in vitro half-life than Ligand B (-3.334). This is a major advantage for Ligand A.
14. **Pgp:** Ligand A (0.549) has lower P-gp efflux liability than Ligand B (0.309), which is preferable.
15. **Affinity:** Ligand A (-7.2 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.6 kcal/mol). This is a substantial advantage that can outweigh some ADME drawbacks.
**GPCR-specific priorities:** For ADRB2 (a GPCR), we prioritize logP, Pgp, TPSA, and affinity. Ligand B has a better logP, while Ligand A has better TPSA, Pgp, and a significantly better affinity.
**Overall Assessment:**
Ligand A's significantly stronger binding affinity (-7.2 vs -6.6 kcal/mol) and better metabolic stability (lower Cl_mic, longer t1/2) are compelling advantages. While its logP is slightly high, the substantial binding advantage and improved metabolic profile outweigh this concern. The lower DILI risk of Ligand B is attractive, but the superior potency and PK of Ligand A are more critical for a successful drug candidate. The poor Caco-2 and solubility for both are concerning and would require formulation strategies, but are not decision-breaking at this stage.
Output:
1
2025-04-18 00:20:24,373 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (425.999 Da) is within the ideal range, while Ligand B (370.494 Da) is also good. No clear advantage here.
2. **TPSA:** Ligand A (128.27) is approaching the upper limit for good oral absorption but still acceptable. Ligand B (67.23) is excellent, well below the 140 threshold. Advantage: B.
3. **logP:** Ligand A (4.764) is high, potentially leading to solubility issues and off-target effects. Ligand B (1.815) is optimal. Advantage: B.
4. **HBD:** Both ligands have 1 HBD, which is good. No difference.
5. **HBA:** Ligand A has 6 HBA, acceptable. Ligand B has 5 HBA, also acceptable. No significant difference.
6. **QED:** Ligand B (0.795) has a better QED score than Ligand A (0.427), indicating a more drug-like profile. Advantage: B.
7. **DILI:** Ligand A (98.565) has a very high DILI risk, a major concern. Ligand B (39.201) has a low DILI risk. Advantage: B.
8. **BBB:** Ligand A (53.432) has moderate BBB penetration. Ligand B (76.309) has good BBB penetration. Advantage: B. While ADRB2 isn't *strictly* a CNS target, some CNS exposure can be relevant for side effect profiles.
9. **Caco-2:** Ligand A (-4.551) shows poor permeability. Ligand B (-5.086) is also poor, but slightly better. Advantage: B.
10. **Solubility:** Ligand A (-6.072) has very poor solubility, likely due to its high logP. Ligand B (-2.317) has better solubility. Advantage: B.
11. **hERG:** Ligand A (0.398) has a slightly higher hERG risk than Ligand B (0.229). Advantage: B.
12. **Cl_mic:** Ligand A (44.027) has a moderate clearance. Ligand B (34.299) has a lower clearance, suggesting better metabolic stability. Advantage: B.
13. **t1/2:** Ligand A (125.543) has a good in vitro half-life. Ligand B (-1.154) has a very short half-life, a significant drawback. Advantage: A.
14. **Pgp:** Ligand A (0.408) has moderate Pgp efflux. Ligand B (0.065) has very low Pgp efflux, which is favorable. Advantage: B.
15. **Affinity:** Ligand A (-7.5 kcal/mol) has a slightly better binding affinity than Ligand B (-5.9 kcal/mol). Advantage: A. The difference is 1.6 kcal/mol, which is significant.
**Overall Assessment:**
Ligand B overwhelmingly outperforms Ligand A in almost all critical ADME-Tox properties. The high DILI risk and poor solubility of Ligand A are major red flags. While Ligand A has a slightly better binding affinity, the ADME profile of Ligand B is far superior, and the affinity difference is not large enough to overcome the significant liabilities of Ligand A. The better TPSA, logP, QED, DILI, BBB, solubility, hERG, Cl_mic, and Pgp properties of Ligand B make it a much more promising drug candidate. The shorter half-life of Ligand B is a concern, but can potentially be addressed through structural modifications.
Output:
0
2025-04-18 00:20:24,373 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (348.45 & 362.35 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (87.46) is better than Ligand B (96.25). Both are below 140, but lower TPSA generally favors absorption.
3. **logP:** Both ligands have good logP values (1.03 & 0.81), falling within the 1-3 range. No clear advantage.
4. **HBD:** Ligand A (2) is preferable to Ligand B (3). Lower HBD is generally better for permeability.
5. **HBA:** Both ligands have the same HBA count (5), which is within the acceptable range.
6. **QED:** Ligand A (0.804) has a slightly better QED score than Ligand B (0.739), indicating a more drug-like profile.
7. **DILI:** Ligand A (40.40) is significantly better than Ligand B (50.33). Both are below 60, but A has a lower risk.
8. **BBB:** Ligand B (58.86) has a higher BBB penetration percentile than Ligand A (44.59). While ADRB2 isn't *necessarily* a CNS target, some CNS exposure could be beneficial or at least not detrimental, and this is a GPCR.
9. **Caco-2:** Both ligands have similar, very negative Caco-2 values (-4.841 and -4.933). This is unusual and suggests poor permeability.
10. **Solubility:** Both ligands have similar, very negative solubility values (-1.939 and -1.781). This is also concerning and suggests poor aqueous solubility.
11. **hERG:** Both ligands have low hERG inhibition liability (0.23 and 0.29), which is good.
12. **Cl_mic:** Ligand B (-10.696) has a *much* lower (better) microsomal clearance than Ligand A (17.701). This indicates greater metabolic stability.
13. **t1/2:** Ligand B (-26.157) has a substantially longer in vitro half-life than Ligand A (15.877). This is a significant advantage.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.066 and 0.016).
15. **Binding Affinity:** Ligand B (-7.2) has a slightly better binding affinity than Ligand A (-6.5). This is a 0.7 kcal/mol difference, which is significant enough to consider.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Both ligands are reasonable on logP and Pgp. Ligand A has a better TPSA. However, Ligand B has a substantially better binding affinity and significantly improved metabolic stability (Cl_mic and t1/2). The slightly better BBB penetration for Ligand B is also a small bonus. The poor Caco-2 and solubility for both are concerning, but the affinity and metabolic stability of B are more critical at this stage.
**Conclusion:**
Despite the slightly better TPSA and QED of Ligand A, the superior binding affinity, metabolic stability (lower Cl_mic, longer t1/2), and slightly better BBB penetration of Ligand B make it the more promising drug candidate. The solubility and permeability issues are shared by both and would need to be addressed in further optimization, but the core pharmacokinetics and pharmacodynamics of Ligand B are more favorable.
Output:
0
2025-04-18 00:20:24,374 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (344.5) is well within the ideal range (200-500). Ligand B (383.3) is also acceptable. No clear advantage here.
2. **TPSA:** Ligand A (40.62) is excellent, well below the 140 threshold and suitable for oral absorption. Ligand B (58.2) is still reasonable, but higher. Ligand A is better.
3. **logP:** Ligand A (4.104) is slightly high, potentially leading to solubility issues or off-target interactions. Ligand B (3.139) is optimal. Ligand B is better.
4. **HBD:** Ligand A (0) is good, minimizing potential issues with permeability. Ligand B (2) is acceptable. Ligand A is slightly better.
5. **HBA:** Both ligands have 2 HBA, which is good. No difference.
6. **QED:** Both ligands have similar QED scores (0.747 vs 0.768), indicating good drug-likeness. No difference.
7. **DILI:** Ligand A (18.922) has a significantly lower DILI risk than Ligand B (36.448). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (97.829) has excellent BBB penetration, while Ligand B (61.962) is moderate. Given that ADRB2 is a GPCR, BBB penetration is a desirable characteristic, making Ligand A more attractive.
9. **Caco-2:** Ligand A (-4.347) and Ligand B (-5.075) both have negative values, which is unusual and suggests poor permeability. However, the scale isn't specified, so it's hard to interpret.
10. **Solubility:** Both ligands have very poor aqueous solubility (-3.874 and -3.859 respectively). This is a significant concern for both, but the scale is unknown.
11. **hERG:** Ligand A (0.919) has a slightly higher hERG risk than Ligand B (0.434). Ligand B is better.
12. **Cl_mic:** Ligand A (70.301) has a higher microsomal clearance than Ligand B (17.183), indicating lower metabolic stability. Ligand B is better.
13. **t1/2:** Ligand B (20.936) has a significantly longer in vitro half-life than Ligand A (8.894). This is a substantial advantage for Ligand B.
14. **Pgp:** Ligand A (0.611) has lower P-gp efflux liability than Ligand B (0.262). This is better for bioavailability. Ligand A is better.
15. **Affinity:** Ligand B (-7.8 kcal/mol) has a significantly stronger binding affinity than Ligand A (-4.2 kcal/mol). This is a very substantial advantage, potentially outweighing some of the ADME drawbacks.
**Overall Assessment:**
Ligand B has a significantly better binding affinity and a longer half-life, which are crucial for a GPCR target. While Ligand A has better BBB penetration and lower DILI risk, the substantial affinity advantage of Ligand B is hard to ignore. The solubility issues are a concern for both, but can be addressed with formulation strategies. The higher logP of Ligand A is also a concern.
Output:
0
2025-04-18 00:20:24,374 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (343.43 & 352.44 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (66.65) is significantly better than Ligand B (96.69). ADRB2 is not a CNS target, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (2.022) is optimal (1-3), while Ligand B (-0.119) is quite low, potentially hindering membrane permeability. This is a significant advantage for A.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is better than Ligand B (6). Lower HBA also supports permeability.
6. **QED:** Ligand A (0.788) is better than Ligand B (0.572), indicating a more drug-like profile.
7. **DILI:** Ligand A (41.88) is better than Ligand B (16.67). Both are good, but A is slightly preferable.
8. **BBB:** Irrelevant for a non-CNS target like ADRB2.
9. **Caco-2:** Ligand A (-4.556) is better than Ligand B (-5.121), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-2.877) is better than Ligand B (0.16). Better solubility is always a plus.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.214 and 0.211). No significant difference.
12. **Cl_mic:** Both ligands have similar microsomal clearance (15.49 and 15.28). No significant difference.
13. **t1/2:** Ligand A (3.678) is better than Ligand B (-11.323). A positive half-life is preferred.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.233 and 0.023). No significant difference.
15. **Binding Affinity:** Ligand B (-6.7) is slightly better than Ligand A (-5.8), offering a 0.9 kcal/mol advantage.
**Overall Assessment:**
Ligand B has a slightly better binding affinity, which is a key factor. However, Ligand A demonstrates a significantly better ADME profile across multiple parameters crucial for oral bioavailability and drug-likeness: logP, TPSA, HBD, HBA, QED, Solubility, and in vitro half-life. The difference in binding affinity (0.9 kcal/mol) is not substantial enough to outweigh the clear advantages of Ligand A's ADME properties, especially considering the importance of these factors for a GPCR target.
**Output:**
1
2025-04-18 00:20:24,374 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (348.531) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are reasonably low (A: 49.41, B: 40.54), well under the 140 threshold for oral absorption. Ligand B is slightly better.
3. **logP:** Both ligands have logP values in the optimal range (1-3), but Ligand B (4.79) is pushing the upper limit and could potentially lead to solubility issues. Ligand A (3.887) is preferable.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 2 HBA, and Ligand B has 3. Both are acceptable, but lower is generally better.
6. **QED:** Ligand A (0.838) has a significantly better QED score than Ligand B (0.643), indicating a more drug-like profile.
7. **DILI:** Ligand A (14.889) has a much lower DILI risk than Ligand B (18.34). This is a significant advantage for Ligand A.
8. **BBB:** Both have high BBB penetration (A: 93.098, B: 87.01), which is good, but not critically important for ADRB2 (a cardiovascular target).
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Both have negative solubility values, suggesting poor solubility. This is a concern for both.
11. **hERG:** Ligand A (0.533) has a lower hERG inhibition liability than Ligand B (0.854), which is a positive.
12. **Cl_mic:** Ligand A (44.74) has a lower microsomal clearance than Ligand B (71.379), indicating better metabolic stability.
13. **t1/2:** Ligand A (1.161) has a shorter half-life than Ligand B (5.48). This is a negative for Ligand A.
14. **Pgp:** Ligand A (0.233) has lower P-gp efflux liability than Ligand B (0.558), which is favorable.
15. **Affinity:** Ligand A (-6.6 kcal/mol) has a slightly better binding affinity than Ligand B (-6.1 kcal/mol).
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A has a better logP and Pgp profile. The affinity difference is not huge, but favors Ligand A.
**Overall Assessment:**
Ligand A is the stronger candidate. While Ligand B has a better half-life, Ligand A excels in crucial areas like QED, DILI risk, metabolic stability (Cl_mic), Pgp efflux, and hERG inhibition. The slightly better affinity also contributes to its favorability. The poor Caco-2 and solubility are concerns for both, but can be addressed with formulation strategies.
Output:
1
2025-04-18 00:20:24,374 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (349.479) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (80.12) is significantly better than Ligand B (118.87). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (1.782) is optimal, while Ligand B (0.013) is very low. This is a major concern for Ligand B, as it may struggle with membrane permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2).
5. **HBA:** Ligand A (5) is preferable to Ligand B (7).
6. **QED:** Ligand A (0.898) is excellent, indicating high drug-likeness. Ligand B (0.655) is still acceptable, but less optimal.
7. **DILI:** Ligand A (35.789) has a lower DILI risk than Ligand B (44.126), both are acceptable.
8. **BBB:** Both ligands have similar BBB penetration (around 64%). This isn't a critical factor for a cardiovascular target.
9. **Caco-2:** Ligand A (-4.691) is better than Ligand B (-5.679), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-2.512) is better than Ligand B (-0.798). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.264) is much better than Ligand B (0.018). Lower hERG inhibition is crucial for avoiding cardiotoxicity, especially for a cardiovascular target.
12. **Cl_mic:** Ligand A (50.622) has a better (lower) microsomal clearance than Ligand B (12.578), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-7.662) has a much longer in vitro half-life than Ligand B (17.441). This is a significant advantage.
14. **Pgp:** Ligand A (0.138) has lower P-gp efflux than Ligand B (0.033), which is preferable.
15. **Affinity:** Ligand B (-6.6 kcal/mol) has slightly better binding affinity than Ligand A (-6.1 kcal/mol). While affinity is important, the difference of 0.5 kcal/mol is not substantial enough to overcome the significant ADME deficiencies of Ligand B.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A excels in logP and TPSA, and has acceptable Pgp and affinity. Ligand B's very low logP is a major drawback.
**Conclusion:**
Ligand A demonstrates a much more favorable balance of properties, particularly regarding permeability (logP, TPSA, Caco-2), metabolic stability (Cl_mic, t1/2), and safety (hERG, DILI). While Ligand B has slightly better affinity, the ADME profile of Ligand A is far superior, making it the more promising drug candidate.
Output:
1
2025-04-18 00:20:24,374 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (360.435 and 347.459 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (84.5) is slightly higher than Ligand B (78.51), but both are well below the 140 threshold for good oral absorption and acceptable for a cardiovascular GPCR.
3. **logP:** Ligand A (1.835) is within the optimal 1-3 range. Ligand B (0.564) is a bit low, potentially indicating permeability issues. This is a point in favor of Ligand A.
4. **HBD:** Both ligands have 2 H-bond donors, which is good.
5. **HBA:** Ligand A has 5 H-bond acceptors, while Ligand B has 4. Both are within the acceptable limit of 10.
6. **QED:** Ligand A (0.85) has a better QED score than Ligand B (0.706), indicating a more drug-like profile.
7. **DILI:** Ligand A (73.013) has a higher DILI risk than Ligand B (7.91). This is a significant advantage for Ligand B.
8. **BBB:** Both ligands have relatively low BBB penetration (60.411 and 58.821 respectively). Since ADRB2 is a cardiovascular target, BBB penetration is not a primary concern, so this isn't a major differentiator.
9. **Caco-2:** Ligand A (-4.981) and Ligand B (-5.4) both have negative Caco-2 values, which is unusual and suggests very poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand A (-3.797) has slightly better solubility than Ligand B (-0.992), but both are quite poor.
11. **hERG:** Ligand A (0.355) has a lower hERG risk than Ligand B (0.121), which is favorable.
12. **Cl_mic:** Ligand A (9.423) has a significantly higher microsomal clearance than Ligand B (-16.86). This means Ligand B is more metabolically stable.
13. **t1/2:** Ligand A (54.626) has a much longer in vitro half-life than Ligand B (3.754). This is a strong point for Ligand A.
14. **Pgp:** Ligand A (0.082) has lower P-gp efflux liability than Ligand B (0.006), which is favorable.
15. **Affinity:** Ligand A (-6.7 kcal/mol) has a better binding affinity than Ligand B (-4.0 kcal/mol). This is a substantial difference and a major advantage for Ligand A.
**Overall Assessment:**
Ligand A has a significantly better binding affinity and longer half-life, which are crucial for drug efficacy. It also has a better QED score, lower Pgp efflux, and lower hERG risk. However, Ligand B has a much lower DILI risk, which is a significant safety advantage. Both ligands have poor Caco-2 permeability and solubility, which are major drawbacks.
Given the GPCR-specific priorities (logP, Pgp, TPSA, affinity), and the substantial affinity difference, I favor Ligand A despite its higher DILI risk. The improved potency and PK properties (half-life, Pgp) are likely to be more impactful for a cardiovascular target. The solubility and permeability issues would need to be addressed through formulation or further chemical modification, but the core pharmacodynamic and pharmacokinetic properties of Ligand A are more promising.
Output:
1
2025-04-18 00:20:24,375 - INFO - Here's my reasoning and the final output for ligand selection:
**Reasoning:**
We are looking for a ligand for ADRB2, a cardiovascular GPCR. Therefore, we prioritize logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB.
Let's compare Ligand A and Ligand B across the key parameters:
1. **Molecular Weight:** Both are within the ideal range (200-500 Da).
2. **TPSA:** Ligand A (77.29) is significantly better than Ligand B (111.99). Lower TPSA generally favors oral absorption, crucial for a cardiovascular drug.
3. **logP:** Ligand A (4.201) is higher than optimal, but Ligand B (0.155) is *too* low, potentially hindering membrane permeability.
4. **H-Bond Donors/Acceptors:** Ligand B has more HBD/HBA (3/6) than Ligand A (1/5), which could slightly reduce permeability.
5. **QED:** Both are acceptable (>0.5).
6. **DILI:** Ligand A (53.548) has a slightly higher DILI risk than Ligand B (33.346), but both are within an acceptable range.
7. **BBB:** Ligand A (69.794) is better than Ligand B (17.72), but BBB isn't a primary concern for a cardiovascular target.
8. **Caco-2:** Ligand A (-4.658) is better than Ligand B (-5.118), indicating better intestinal absorption.
9. **Solubility:** Ligand A (-4.803) is better than Ligand B (-1.127).
10. **hERG:** Ligand A (0.579) is better than Ligand B (0.187).
11. **Cl_mic:** Ligand B (-13.955) has significantly lower (better) microsomal clearance than Ligand A (35.169), suggesting greater metabolic stability.
12. **t1/2:** Ligand B (-12.02) has a longer in vitro half-life than Ligand A (25.161), which is desirable.
13. **Pgp:** Ligand A (0.412) is better than Ligand B (0.008), indicating lower P-gp efflux and improved bioavailability.
14. **Binding Affinity:** Ligand B (-7.2 kcal/mol) has a slightly better binding affinity than Ligand A (-6.9 kcal/mol), a 0.3 kcal/mol difference.
**Overall Assessment:**
While Ligand B has better metabolic stability (Cl_mic, t1/2) and slightly better affinity, Ligand A is superior in most other critical parameters, particularly TPSA, logP, solubility, and Pgp efflux. The higher logP of Ligand A is a concern, but the extremely low logP of Ligand B is more problematic for permeability. The better TPSA and Pgp values of Ligand A are more important for a GPCR target. The slight difference in binding affinity (0.3 kcal/mol) is unlikely to outweigh the advantages of Ligand A in terms of ADME properties.
**Output:**
1
2025-04-18 00:20:24,375 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (398.26) is slightly higher than Ligand B (364.555), but both are acceptable.
2. **TPSA:** Ligand A (74.48) is higher than Ligand B (40.62). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is generally preferred for absorption. Ligand B has a significantly better TPSA.
3. **logP:** Ligand A (4.069) is slightly higher than the optimal range (1-3), potentially leading to solubility issues. Ligand B (2.729) is within the optimal range. This favors Ligand B.
4. **HBD:** Ligand A (1) and Ligand B (0) are both acceptable.
5. **HBA:** Ligand A (4) and Ligand B (3) are both acceptable.
6. **QED:** Both ligands have similar QED values (A: 0.847, B: 0.728), indicating good drug-likeness.
7. **DILI:** Ligand A (79.411) has a higher DILI risk than Ligand B (19.542). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (59.597) and Ligand B (88.406). While not a CNS target, higher BBB penetration can sometimes correlate with better overall distribution. Ligand B is better here.
9. **Caco-2:** Both have negative values, indicating poor permeability. Ligand A (-4.66) is slightly better than Ligand B (-4.965), but both are concerning.
10. **Solubility:** Ligand A (-5.773) has worse solubility than Ligand B (-3.587). This is a concern given Ligand A's higher logP.
11. **hERG:** Both ligands show low hERG inhibition risk (A: 0.799, B: 0.735).
12. **Cl_mic:** Ligand A (45.203) has a lower microsomal clearance than Ligand B (80.332), suggesting better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (42.651) has a longer in vitro half-life than Ligand B (-6.116). This is a major advantage for Ligand A.
14. **Pgp:** Both ligands have similar Pgp efflux liability (A: 0.676, B: 0.299).
15. **Binding Affinity:** Ligand A (-7.9) has a significantly stronger binding affinity than Ligand B (-5.5). This is a substantial advantage for Ligand A, potentially outweighing some of its ADME drawbacks.
**Overall Assessment:**
Ligand A has a significantly better binding affinity and metabolic stability (lower Cl_mic, longer t1/2). However, Ligand B excels in TPSA, logP, DILI risk, and BBB penetration. The strong binding affinity of Ligand A is a major driver, and the longer half-life is also very desirable. While Ligand A's solubility and Caco-2 permeability are concerns, the potency advantage is substantial. Given the target is a cardiovascular GPCR, the lower TPSA and better logP of Ligand B are less critical than potency and metabolic stability.
Output:
1
2025-04-18 00:20:24,375 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.475 and 371.547 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (70.67) is slightly higher than Ligand B (61.88). Both are below the 140 A^2 threshold for good oral absorption, but B is closer to the 90 A^2 threshold for CNS targets, though this isn't a primary concern for ADRB2.
3. **logP:** Both ligands have good logP values (1.073 and 1.205), falling within the optimal 1-3 range.
4. **HBD:** Ligand A has 2 HBD, while Ligand B has 1. Both are acceptable.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 5. Both are within the acceptable limit of 10.
6. **QED:** Ligand A (0.704) has a slightly better QED score than Ligand B (0.65), indicating a more drug-like profile.
7. **DILI:** Ligand A (15.432%) has a significantly lower DILI risk than Ligand B (20.396%). This is a substantial advantage.
8. **BBB:** Ligand B (60.333%) has a higher BBB penetration score than Ligand A (39.007%). While ADRB2 isn't a primary CNS target, some CNS exposure can be a consequence of systemic administration, and higher BBB is generally preferable.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.232 and -5.175). This is unusual and suggests poor permeability. However, the values are very similar.
10. **Solubility:** Ligand A (-0.97) has slightly better solubility than Ligand B (-1.619).
11. **hERG:** Ligand A (0.108%) has a much lower hERG inhibition liability than Ligand B (0.403%). This is a critical advantage, as hERG inhibition can lead to cardiotoxicity.
12. **Cl_mic:** Ligand A (0.73 mL/min/kg) has significantly lower microsomal clearance than Ligand B (33.011 mL/min/kg), indicating better metabolic stability.
13. **t1/2:** Ligand A (12.534 hours) has a much longer in vitro half-life than Ligand B (3.301 hours). This is a significant advantage, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.024) has much lower P-gp efflux liability than Ligand B (0.056).
15. **Binding Affinity:** Ligand A (-7.2 kcal/mol) has a slightly better binding affinity than Ligand B (-6.5 kcal/mol). This difference of 0.7 kcal/mol is meaningful and can outweigh some ADME drawbacks.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are important. Ligand A is better across most of these.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B in crucial ADME-Tox properties (DILI, hERG, Cl_mic, t1/2, Pgp) and has a slightly better binding affinity and QED score. While Ligand B has better BBB penetration, this is less critical for a non-CNS-focused target like ADRB2. The significant advantages of Ligand A in safety (DILI, hERG) and metabolic stability (Cl_mic, t1/2) make it the more promising drug candidate. The Caco-2 values are concerning for both, but the other benefits of A outweigh this.
Output:
1
2025-04-18 00:20:24,375 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (356.46 & 346.47 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (58.2) is significantly better than Ligand B (69.64). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (3.06 & 2.15), falling within the 1-3 range. Ligand A is slightly higher, which *could* be beneficial for membrane permeability, but isn't a major concern for either.
4. **HBD:** Both ligands have 2 HBD, which is within the acceptable limit of 5.
5. **HBA:** Ligand A has 2 HBA, while Ligand B has 3. Both are acceptable (<=10), but lower is generally preferred.
6. **QED:** Ligand A (0.737) has a better QED score than Ligand B (0.572), indicating a more drug-like profile.
7. **DILI:** Ligand A (14.89%) has a slightly higher DILI risk than Ligand B (13.34%), but both are well below the concerning threshold of 60%.
8. **BBB:** Ligand A (86.35%) has significantly higher BBB penetration potential than Ligand B (61.50%). While not a primary concern for a cardiovascular target, higher BBB is rarely detrimental.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.79 & -4.66), which is unusual and suggests poor permeability. This is a significant drawback for both.
10. **Solubility:** Ligand A (-3.92) has slightly worse solubility than Ligand B (-2.67), but both are poor. Solubility is a concern for both.
11. **hERG:** Ligand A (0.65) has a much lower hERG inhibition liability than Ligand B (0.14). This is a crucial advantage, as hERG inhibition can lead to cardiotoxicity.
12. **Cl_mic:** Ligand A (45.55) has a higher microsomal clearance than Ligand B (33.24), indicating lower metabolic stability. This is a negative for Ligand A.
13. **t1/2:** Ligand B (-15.29) has a negative in vitro half-life, which is highly problematic. Ligand A (19.76) has a reasonable half-life.
14. **Pgp:** Ligand A (0.174) has a lower P-gp efflux liability than Ligand B (0.051), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand B (-7.0) has a slightly better binding affinity than Ligand A (-6.4). However, the difference is only 0.6 kcal/mol, which is not substantial enough to outweigh other significant differences.
**GPCR-specific considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Ligand A performs better on logP, TPSA, and Pgp. The affinity difference is small. The biggest differentiator is the hERG inhibition liability, where Ligand A is significantly safer. The negative half-life of Ligand B is a major red flag.
**Conclusion:**
Despite Ligand B having slightly better binding affinity, Ligand A is the more promising candidate due to its superior drug-like properties (QED), lower hERG risk, better Pgp profile, and a reasonable half-life. The poor Caco-2 and solubility are concerns for both, but can be addressed with formulation strategies. The negative half-life of Ligand B is a dealbreaker.
Output:
1
2025-04-18 00:20:24,375 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (377.457) is slightly higher than Ligand B (346.383), but both are acceptable.
2. **TPSA:** Both are good, below the 140 A^2 threshold for oral absorption. Ligand A (87.3) is slightly better than Ligand B (88.85), but the difference is minor.
3. **logP:** Both ligands have optimal logP values (between 1 and 3). Ligand A (1.078) is slightly lower, which could slightly hinder permeability, while Ligand B (1.711) is better.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (1), but both are within the acceptable limit of 5.
5. **HBA:** Ligand A (4) is lower than Ligand B (5), which is favorable.
6. **QED:** Ligand B (0.792) has a significantly better QED score than Ligand A (0.436), indicating a more drug-like profile.
7. **DILI:** Ligand A (44.281) has a lower DILI risk than Ligand B (59.984), which is a significant advantage.
8. **BBB:** Ligand A (72.664) has a much better BBB penetration percentile than Ligand B (50.523). This is important for GPCR targets.
9. **Caco-2:** Ligand A (-5.262) has a better Caco-2 permeability than Ligand B (-4.384).
10. **Solubility:** Ligand A (-2.824) has better solubility than Ligand B (-2.509).
11. **hERG:** Both ligands have very low hERG inhibition liability (0.271 and 0.032 respectively), indicating low cardiotoxicity risk. Ligand B is slightly better.
12. **Cl_mic:** Ligand A (20.021) has a significantly lower microsomal clearance than Ligand B (62.831), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-11.617) has a more negative in vitro half-life than Ligand B (18.745), which means a longer half-life.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.021 and 0.02 respectively).
15. **Binding Affinity:** Ligand B (-6.7 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.3 kcal/mol). This is a substantial advantage.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, Pgp, TPSA, and affinity. Ligand B has a slightly better logP, similar Pgp, comparable TPSA, but a *much* stronger binding affinity. The stronger affinity is a significant advantage that can outweigh some of the ADME drawbacks.
**Overall Assessment:**
While Ligand A has better DILI, BBB, solubility, and metabolic stability, the significantly stronger binding affinity of Ligand B (-6.7 vs -5.3 kcal/mol) is a decisive factor. The difference in affinity is large enough to overcome the slightly higher DILI risk and lower BBB penetration.
Output:
0
2025-04-18 00:20:24,376 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.431 and 352.519 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (80.76) is higher than Ligand B (49.85). For a cardiovascular GPCR like ADRB2, TPSA is less critical than for CNS targets, but lower is generally preferred for permeability. Ligand B has a substantial advantage here.
3. **logP:** Ligand B (2.589) is slightly higher than Ligand A (1.476), both within the optimal 1-3 range. Ligand B is edging towards the higher end, but still acceptable.
4. **HBD:** Ligand A (1) is slightly higher than Ligand B (0). This isn't a major concern for either.
5. **HBA:** Ligand A (5) is slightly higher than Ligand B (4). Both are within the acceptable limit of 10.
6. **QED:** Ligand A (0.754) has a better QED score than Ligand B (0.606), indicating a more drug-like profile.
7. **DILI:** Ligand B (2.171) has a significantly lower DILI risk than Ligand A (31.524). This is a major advantage for Ligand B.
8. **BBB:** Ligand B (86.468) has a higher BBB penetration percentile than Ligand A (77.472). While ADRB2 isn't a CNS target, some peripheral exposure can be undesirable.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.578 and -4.47), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand A (-1.421) has slightly better solubility than Ligand B (-0.963).
11. **hERG:** Ligand A (0.36) has a lower hERG inhibition liability than Ligand B (0.614). This is a positive for Ligand A.
12. **Cl_mic:** Ligand A (8.876) has a significantly lower microsomal clearance than Ligand B (17.672), suggesting better metabolic stability.
13. **t1/2:** Ligand A (8.888) has a longer in vitro half-life than Ligand B (-9.277). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.03) has a lower P-gp efflux liability than Ligand B (0.041). This is a slight advantage for Ligand A.
15. **Binding Affinity:** Ligand B (-6.8 kcal/mol) has a slightly better binding affinity than Ligand A (-5.5 kcal/mol). This is a 1.3 kcal/mol difference, which is substantial enough to consider.
**Overall Assessment:**
For a cardiovascular GPCR, binding affinity, metabolic stability, and safety are paramount. Ligand B has a better binding affinity and a *much* lower DILI risk. While Ligand A has advantages in QED, t1/2, Cl_mic, and hERG, the DILI risk associated with Ligand A is concerning. The lower TPSA of Ligand B is also a plus. The negative Caco-2 values for both are a red flag, but the affinity advantage of Ligand B, coupled with the significantly improved safety profile, outweighs the other factors.
Output:
0
2025-04-18 00:20:24,376 - INFO - Batch 470 complete. Total preferences: 7520
2025-04-18 00:20:24,376 - INFO - Processing batch 471/512...
2025-04-18 00:21:12,708 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (343.387 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (78.35) is significantly better than Ligand A (105.12). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA is still beneficial for absorption.
3. **logP:** Both ligands have acceptable logP values (A: 1.162, B: 2.463), falling within the 1-3 range. Ligand B is slightly better, being closer to the optimal range.
4. **HBD:** Both are acceptable (A: 3, B: 2).
5. **HBA:** Both are acceptable (A: 5, B: 7).
6. **QED:** Both are good (A: 0.685, B: 0.787), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand B (67.003) is better than Ligand A (77.007), indicating a lower risk of drug-induced liver injury.
8. **BBB:** Not a high priority for a cardiovascular target, but Ligand B (73.517) is better than Ligand A (56.146).
9. **Caco-2:** Both are negative, indicating poor permeability. This is a significant concern for both.
10. **Solubility:** Both are negative, indicating poor solubility. This is also a significant concern for both.
11. **hERG:** Both are very low (A: 0.18, B: 0.495), indicating a very low risk of hERG inhibition.
12. **Cl_mic:** Ligand A (-5.461) has significantly better (lower) microsomal clearance than Ligand B (37.463), suggesting better metabolic stability.
13. **t1/2:** Ligand A (57.486) has a much longer in vitro half-life than Ligand B (33.813). This is a major advantage.
14. **Pgp:** Both are very low (A: 0.075, B: 0.094), indicating minimal P-gp efflux.
15. **Binding Affinity:** Ligand A (-7.3 kcal/mol) has a significantly stronger binding affinity than Ligand B (-3.6 kcal/mol). This is a substantial advantage, potentially outweighing some ADME concerns.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B has better logP and TPSA, while Ligand A has a much better affinity. The large difference in binding affinity (-7.3 vs -3.6) is a critical factor. While both have poor Caco-2 and solubility, the superior affinity of Ligand A, coupled with its better metabolic stability (Cl_mic and t1/2) makes it the more promising candidate.
**Conclusion:**
Despite the poor Caco-2 and solubility of both, the significantly higher binding affinity and improved metabolic stability of Ligand A make it the more viable drug candidate.
Output:
1
2025-04-18 00:21:12,708 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [345.487, 64.41, 2.817, 0, 3, 0.635, 11.361, 72.237, -4.498, -2.636, 0.697, 31.973, -7.335, 0.135, -5.6]
**Ligand B:** [349.475, 70.67, 1.23, 2, 4, 0.536, 18.185, 71.307, -4.793, -1.579, 0.286, 22.042, -4.186, 0.008, -6.2]
Here's a breakdown of the comparison, considering the guidelines and GPCR-specific priorities:
1. **MW:** Both are within the ideal range (200-500 Da). A is 345.487, B is 349.475. Very similar.
2. **TPSA:** A (64.41) is better than B (70.67). Both are acceptable for oral absorption, but A is closer to the preferred <90 for GPCRs.
3. **logP:** A (2.817) is optimal, while B (1.23) is a bit low, potentially hindering permeability.
4. **HBD:** A (0) is preferable to B (2). Fewer HBDs generally improve permeability.
5. **HBA:** A (3) is preferable to B (4). Fewer HBAs generally improve permeability.
6. **QED:** A (0.635) is slightly better than B (0.536), indicating a more drug-like profile.
7. **DILI:** A (11.361) is significantly better than B (18.185), indicating a much lower risk of liver injury. This is a crucial factor.
8. **BBB:** Both are good (A: 72.237, B: 71.307), exceeding the 70% threshold for CNS targets, but less important for a cardiovascular target like ADRB2.
9. **Caco-2:** Both are negative, indicating poor permeability. A (-4.498) is slightly better than B (-4.793).
10. **Solubility:** A (-2.636) is better than B (-1.579). Higher solubility is generally preferred.
11. **hERG:** A (0.697) is better than B (0.286) indicating a lower risk of cardiotoxicity.
12. **Cl_mic:** A (31.973) is higher than B (22.042), indicating faster clearance and lower metabolic stability. B is better here.
13. **t1/2:** A (-7.335) is better than B (-4.186), indicating a longer half-life.
14. **Pgp:** A (0.135) is better than B (0.008), indicating lower P-gp efflux.
15. **Affinity:** B (-6.2) is slightly better than A (-5.6), a 0.6 kcal/mol difference. While affinity is important, the difference isn't huge enough to outweigh other factors.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B in most critical ADME properties (DILI, solubility, hERG, Pgp, t1/2) and has a better QED score. While Ligand B has a slightly better binding affinity, the superior ADME profile of Ligand A, particularly the significantly lower DILI risk and better solubility, makes it the more promising drug candidate. The lower logP of Ligand B is also a concern.
Output:
1
2025-04-18 00:21:12,708 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [382.442, 77.44, 2.518, 0, 9, 0.581, 98.488, 85.421, -4.219, -4.074, 0.467, 109.857, 20.324, 0.623, -7.1]
**Ligand B:** [360.336, 95.42, 1.333, 2, 5, 0.826, 49.593, 76.774, -4.612, -2.525, 0.144, 36.799, -33.941, 0.015, -6.3]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity, and BBB):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (360.336) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (77.44) is better than Ligand B (95.42). Both are acceptable, but lower TPSA generally improves oral absorption.
3. **logP:** Ligand A (2.518) is optimal. Ligand B (1.333) is a bit low, potentially hindering membrane permeability.
4. **HBD/HBA:** Ligand A (0 HBD, 9 HBA) is better than Ligand B (2 HBD, 5 HBA). Fewer H-bonds are generally preferred for better permeability.
5. **QED:** Ligand B (0.826) has a better QED score than Ligand A (0.581), indicating a more drug-like profile.
6. **DILI:** Ligand A (98.488) has a *very* high DILI risk, which is a major concern. Ligand B (49.593) is much better, falling well within the acceptable range.
7. **BBB:** Ligand A (85.421) has a good BBB penetration score. Ligand B (76.774) is also reasonable, but lower.
8. **Caco-2:** Both are negative, suggesting poor permeability.
9. **Solubility:** Both are negative, suggesting poor solubility.
10. **hERG:** Ligand A (0.467) is better than Ligand B (0.144), indicating lower hERG inhibition risk.
11. **Cl_mic:** Ligand B (36.799) has significantly lower microsomal clearance than Ligand A (109.857), suggesting better metabolic stability.
12. **t1/2:** Ligand B (-33.941) has a much longer in vitro half-life than Ligand A (20.324), which is a significant advantage.
13. **Pgp:** Ligand A (0.623) has better Pgp efflux liability than Ligand B (0.015). Lower Pgp is preferred.
14. **Affinity:** Ligand A (-7.1 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.3 kcal/mol). This is a substantial advantage.
**Overall Assessment:**
While Ligand A boasts a superior binding affinity and better Pgp efflux, its extremely high DILI risk is a deal-breaker. The DILI risk outweighs the benefits of stronger binding. Ligand B, despite having a slightly weaker affinity and lower BBB, presents a much more favorable safety profile (DILI) and better metabolic stability (Cl_mic, t1/2). The QED score is also better for Ligand B. Given the importance of safety in drug development, and the fact that the affinity difference isn't *massive*, Ligand B is the more promising candidate.
Output:
0
2025-04-18 00:21:12,708 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.49 & 353.45 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (62.55) is better than Ligand B (71.09). Both are below 140, but lower TPSA generally favors absorption.
3. **logP:** Ligand A (3.83) is slightly higher than Ligand B (2.97). Both are within the optimal 1-3 range, but A is approaching the upper limit.
4. **HBD:** Ligand A (1) is better than Ligand B (2). Lower is generally preferred.
5. **HBA:** Ligand A (3) is better than Ligand B (4). Lower is generally preferred.
6. **QED:** Both ligands have good QED scores (0.726 and 0.83), indicating good drug-like properties.
7. **DILI:** Ligand A (28.89) is significantly better than Ligand B (63.40). This is a major advantage for Ligand A as it indicates a much lower risk of drug-induced liver injury.
8. **BBB:** Ligand A (78.87) is better than Ligand B (61.73). While ADRB2 isn't strictly a CNS target, some peripheral effects can be modulated by CNS penetration, and higher BBB is generally favorable.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.204 and -4.676). These values are unusual and suggest poor permeability. However, since both are similarly poor, this doesn't differentiate them.
10. **Solubility:** Ligand A (-3.525) is better than Ligand B (-4.897). Higher solubility is preferred.
11. **hERG:** Ligand A (0.667) is better than Ligand B (0.26). Lower hERG inhibition is crucial for avoiding cardiotoxicity, and A has a much better profile.
12. **Cl_mic:** Ligand A (77.02) is worse than Ligand B (20.14). Lower clearance is better for metabolic stability, so B is favored here.
13. **t1/2:** Ligand A (74.60) is better than Ligand B (22.66). Longer half-life is generally desirable.
14. **Pgp:** Ligand A (0.588) is better than Ligand B (0.157). Lower P-gp efflux is preferred.
15. **Binding Affinity:** Ligand B (-7.7) is significantly better than Ligand A (-6.2). This is a substantial 1.5 kcal/mol advantage.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B has a better logP and significantly better affinity. However, the DILI and hERG risk associated with Ligand B are concerning. Ligand A has a much better safety profile (DILI and hERG) and acceptable logP and TPSA. The affinity difference, while significant, can potentially be optimized in later stages of drug development. The safety profile is harder to fix.
**Conclusion:**
While Ligand B boasts superior binding affinity, the significantly higher DILI and hERG risk, coupled with lower solubility and Pgp efflux, make it a less attractive candidate. Ligand A, despite slightly lower affinity, presents a much more favorable balance of properties, particularly regarding safety and ADME characteristics. Therefore, I would select Ligand A.
Output:
1
2025-04-18 00:21:12,708 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [345.487, 54.46, 4.319, 1, 3, 0.809, 23.342, 85.033, -4.182, -3.674, 0.459, 88.028, -2.209, 0.066, -6.4]**
**Ligand B: [370.563, 57.17, 1.807, 1, 6, 0.595, 6.282, 71.617, -5.469, -1.734, 0.743, 5.144, 6.825, 0.046, -5.1]**
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (345.487) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are reasonably good (A: 54.46, B: 57.17), and below the 140 threshold for oral absorption.
3. **logP:** Ligand A (4.319) is higher than ideal (1-3), potentially leading to solubility issues. Ligand B (1.807) is within the optimal range. This is a significant advantage for Ligand B.
4. **H-Bond Donors:** Both have 1 HBD, which is good.
5. **H-Bond Acceptors:** Ligand A (3) is better than Ligand B (6). Fewer HBA are generally preferred.
6. **QED:** Ligand A (0.809) has a better QED score than Ligand B (0.595), indicating a more drug-like profile.
7. **DILI:** Ligand A (23.342) has a much lower DILI risk than Ligand B (6.282), a major advantage.
8. **BBB:** Ligand A (85.033) has a higher BBB penetration percentile than Ligand B (71.617). While not a primary concern for ADRB2 (a cardiovascular target), higher BBB is rarely detrimental.
9. **Caco-2 Permeability:** Ligand A (-4.182) has worse Caco-2 permeability than Ligand B (-5.469).
10. **Aqueous Solubility:** Ligand A (-3.674) has worse aqueous solubility than Ligand B (-1.734).
11. **hERG Inhibition:** Ligand A (0.459) has a lower hERG inhibition liability than Ligand B (0.743), which is a significant safety advantage.
12. **Microsomal Clearance:** Ligand A (88.028) has a higher microsomal clearance than Ligand B (5.144), meaning it's less metabolically stable. This is a disadvantage for Ligand A.
13. **In vitro Half-Life:** Ligand B (6.825) has a longer in vitro half-life than Ligand A (-2.209), which is favorable.
14. **P-gp Efflux:** Ligand A (0.066) has lower P-gp efflux than Ligand B (0.046), which is slightly better.
15. **Binding Affinity:** Ligand A (-6.4) has a slightly better binding affinity than Ligand B (-5.1). However, the difference is not substantial enough to overcome the other ADME/Tox issues with Ligand A.
**Overall Assessment:**
Ligand B is the preferred candidate. While Ligand A has a slightly better binding affinity and QED, Ligand B demonstrates a significantly better ADME profile, particularly regarding logP, DILI, solubility, and metabolic stability. The lower DILI risk and more favorable logP of Ligand B are crucial advantages. The better Caco-2 permeability and in vitro half-life also contribute to its overall superiority. For a cardiovascular target like ADRB2, minimizing off-target effects (DILI, hERG) and ensuring reasonable pharmacokinetic properties are paramount.
Output:
0
2025-04-18 00:21:12,708 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (341.459 and 346.431 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (53.4) is significantly better than Ligand B (100.02). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold. Ligand B is approaching the upper limit.
3. **logP:** Both ligands (1.97 and 2.51) are within the optimal 1-3 range. Ligand B is slightly higher, which *could* indicate a slightly better ability to cross membranes, but it's not a huge difference.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (4). Lower HBA is generally better for permeability.
6. **QED:** Ligand A (0.924) is significantly better than Ligand B (0.684). A higher QED suggests a more drug-like profile.
7. **DILI:** Ligand A (50.136) is better than Ligand B (68.437). Lower DILI risk is crucial. Ligand B is creeping into a moderately concerning range.
8. **BBB:** Ligand A (79.992) is better than Ligand B (32.299). While not a CNS target, some peripheral distribution is expected, and higher BBB penetration can indicate better overall permeability.
9. **Caco-2:** Ligand A (-4.826) is better than Ligand B (-5.416). Higher Caco-2 permeability is desired.
10. **Solubility:** Ligand A (-1.649) is better than Ligand B (-3.598). Better solubility is important for formulation and bioavailability.
11. **hERG:** Ligand A (0.843) is better than Ligand B (0.428). Lower hERG inhibition is critical for avoiding cardiotoxicity, a major concern for cardiovascular drugs.
12. **Cl_mic:** Ligand A (18.612) is significantly better than Ligand B (32.843). Lower microsomal clearance indicates greater metabolic stability.
13. **t1/2:** Ligand B (39.525) is better than Ligand A (18.133). A longer half-life is generally desirable.
14. **Pgp:** Ligand A (0.19) is better than Ligand B (0.249). Lower P-gp efflux is preferable.
15. **Binding Affinity:** Ligand B (-5.5) is slightly better than Ligand A (-6.3). This is a difference of 0.8 kcal/mol, which is not substantial enough to outweigh the numerous advantages of Ligand A.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A performs better on logP, TPSA, and Pgp. The affinity difference is small.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical ADME-Tox properties (QED, DILI, solubility, hERG, Cl_mic). While Ligand B has a slightly better half-life and binding affinity, the superior overall profile of Ligand A, particularly its lower toxicity risk and better predicted permeability, makes it the more promising drug candidate.
Output:
1
2025-04-18 00:21:12,709 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.435 & 363.527 Da) fall comfortably within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (45.67) is significantly better than Ligand A (105.48). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally correlates with better permeability. This is a significant advantage for Ligand B.
3. **logP:** Both ligands (2.068 & 2.512) are within the optimal 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Ligand A has 3 HBDs, and Ligand B has 0. While neither is excessive, fewer HBDs (Ligand B) can sometimes improve permeability.
5. **HBA:** Ligand A has 6 HBAs, and Ligand B has 5. Both are acceptable, under the threshold of 10.
6. **QED:** Both ligands have similar QED values (0.752 and 0.71), indicating good drug-likeness.
7. **DILI:** Ligand B (16.014) has a *much* lower DILI risk than Ligand A (48.623). This is a major advantage for Ligand B, as liver toxicity is a common drug development issue.
8. **BBB:** Both ligands have similar BBB penetration (78.558 & 77.627). This isn't a primary concern for a cardiovascular target.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.466 & -4.905). These values are difficult to interpret without knowing the scale, but negative values suggest poor permeability.
10. **Solubility:** Both ligands have negative solubility values (-2.925 & -2.112). Similar to Caco-2, these values are difficult to interpret without knowing the scale, but negative values suggest poor solubility.
11. **hERG:** Ligand A (0.118) has a slightly lower hERG risk than Ligand B (0.725), which is preferable.
12. **Cl_mic:** Ligand A (44.697) has a lower microsomal clearance than Ligand B (70.581), indicating better metabolic stability.
13. **t1/2:** Ligand A (-10.841) has a negative in vitro half-life, which is concerning. Ligand B (3.4) has a positive, though relatively short, half-life. This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.023) has a lower P-gp efflux liability than Ligand B (0.203), which is favorable.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-5.4 & -4.4 kcal/mol). The difference of 1.0 kcal/mol is not substantial enough to outweigh other factors.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, and affinity are key. While both ligands have acceptable logP and similar affinity, Ligand B excels in TPSA and has a much better safety profile (DILI). The improved half-life is also a significant benefit. The slightly higher P-gp efflux is a minor drawback.
**Conclusion:**
Considering the balance of properties, particularly the significantly lower DILI risk, better TPSA, and improved half-life, Ligand B is the more promising drug candidate.
Output:
0
2025-04-18 00:21:12,709 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.427 and 346.431 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (62.99) is significantly better than Ligand B (95.42). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is pushing the upper limit for good oral absorption (<=140), while A is well below.
3. **logP:** Ligand A (2.047) is within the optimal 1-3 range. Ligand B (0.872) is slightly below 1, which *could* indicate potential permeability issues, although not severely.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer hydrogen bond donors generally improve membrane permeability.
5. **HBA:** Ligand A (4) is better than Ligand B (5). Lower HBA counts are generally favored for permeability.
6. **QED:** Both ligands have good QED scores (0.642 and 0.715), indicating generally drug-like properties. No strong preference.
7. **DILI:** Ligand A (14.696) has a notably lower DILI risk than Ligand B (22.063). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (73.672) has a much higher BBB penetration percentile than Ligand B (35.324). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant, and higher BBB is generally desirable.
9. **Caco-2:** Ligand A (-3.942) is better than Ligand B (-5.118). Higher Caco-2 permeability suggests better intestinal absorption.
10. **Solubility:** Ligand A (-2.148) is better than Ligand B (-1.177). Higher aqueous solubility is generally preferred.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.126 and 0.047). No significant difference.
12. **Cl_mic:** Ligand B (7.15) has significantly lower microsomal clearance than Ligand A (50.27). This suggests better metabolic stability for Ligand B.
13. **t1/2:** Ligand A (26.889) has a longer in vitro half-life than Ligand B (-2.444). This is a positive for Ligand A.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.02 and 0.002). No significant difference.
15. **Binding Affinity:** Ligand B (-5.9) has a slightly better binding affinity than Ligand A (-5.3). This is a 0.6 kcal/mol difference, which is noticeable but not overwhelming.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, TPSA, logP, and permeability (Caco-2) are important. Ligand A is significantly better across these parameters. While Ligand B has better metabolic stability (Cl_mic), the advantages of Ligand A in TPSA, logP, solubility, DILI risk, and BBB penetration outweigh this benefit. The affinity difference is relatively small.
**Conclusion:**
Ligand A presents a more balanced profile with better predicted ADME properties and a lower risk profile, despite a slightly weaker binding affinity.
Output:
1
2025-04-18 00:21:12,709 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (368.449 Da and 370.465 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (46.38) is significantly better than Ligand B (58.2). For a GPCR, lower TPSA is generally preferred for better permeability. Ligand A is well below the 140 threshold, while B is approaching it.
**3. logP:** Ligand A (4.59) is slightly higher than Ligand B (3.635). Both are above the optimal 1-3 range, but A is pushing the upper limit. This could potentially lead to solubility issues, but is not a dealbreaker.
**4. H-Bond Donors:** Ligand A (0) is preferable to Ligand B (2). Fewer H-bond donors generally improve membrane permeability.
**5. H-Bond Acceptors:** Ligand A (4) is slightly better than Ligand B (3). Both are within the acceptable range of <=10.
**6. QED:** Ligand B (0.77) has a much better QED score than Ligand A (0.232). This indicates a more drug-like profile for Ligand B.
**7. DILI:** Both ligands have acceptable DILI risk (36.216 and 47.538, both < 40). No significant difference.
**8. BBB:** Both ligands have good BBB penetration (86.196 and 88.29). This is less critical for a cardiovascular target, but still a positive.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests a potential issue with the data or modeling. However, since both are similarly affected, it doesn't differentiate them.
**10. Aqueous Solubility:** Ligand A (-5.26) has better solubility than Ligand B (-4.133).
**11. hERG Inhibition:** Ligand A (0.881) has a slightly better hERG profile than Ligand B (0.599). Lower is better here, indicating less cardiotoxicity risk.
**12. Microsomal Clearance:** Ligand B (43.97) has lower microsomal clearance than Ligand A (49.644), suggesting better metabolic stability.
**13. In vitro Half-Life:** Ligand B (45.389) has a significantly longer half-life than Ligand A (-1.37). This is a major advantage for dosing convenience.
**14. P-gp Efflux:** Ligand A (0.394) has lower P-gp efflux than Ligand B (0.412). Lower efflux is generally preferred.
**15. Binding Affinity:** Both ligands have excellent binding affinity (-6.0 and -4.9 kcal/mol respectively). Ligand A is significantly better, with a 1.1 kcal/mol advantage. This is a substantial difference and outweighs many of the ADME drawbacks of Ligand A.
**Overall Assessment:**
While Ligand B has a better QED and metabolic stability (lower Cl_mic, longer t1/2), the significantly stronger binding affinity of Ligand A (-6.0 vs -4.9 kcal/mol) is the most important factor for a GPCR target. The lower TPSA and HBD of Ligand A are also beneficial. The slightly higher logP of Ligand A is a minor concern, but the strong binding is likely to compensate.
Output:
1
2025-04-18 00:21:12,709 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (385.877 Da) is within the ideal range (200-500 Da). Ligand B (337.463 Da) is also within range, and slightly smaller, which could be beneficial for permeability.
2. **TPSA:** Ligand A (89.35) is excellent, well below the 140 threshold for oral absorption and good for a GPCR. Ligand B (38.33) is even better, suggesting potentially improved permeability.
3. **logP:** Ligand A (1.318) is optimal. Ligand B (4.575) is a bit high, potentially leading to solubility issues and off-target interactions.
4. **HBD:** Both Ligand A (1) and Ligand B (1) are within the acceptable limit of 5.
5. **HBA:** Ligand A (6) is good. Ligand B (2) is excellent.
6. **QED:** Both Ligand A (0.776) and Ligand B (0.803) are above the 0.5 threshold, indicating good drug-likeness.
7. **DILI:** Ligand A (75.184) is higher than Ligand B (39.744), suggesting a greater risk of liver injury. This is a significant drawback for Ligand A.
8. **BBB:** Both Ligand A (68.748) and Ligand B (69.911) have moderate BBB penetration. Since ADRB2 is a cardiovascular target, BBB penetration isn't *critical* but isn't detrimental either.
9. **Caco-2:** Ligand A (-5.397) and Ligand B (-4.666) both have negative values, which is unusual. Assuming these are logP values, they suggest good permeability.
10. **Solubility:** Ligand A (-2.993) is better than Ligand B (-5.402), indicating higher aqueous solubility.
11. **hERG:** Both Ligand A (0.185) and Ligand B (0.573) have low hERG inhibition risk, which is good.
12. **Cl_mic:** Ligand A (23.74) has significantly lower microsomal clearance than Ligand B (111.14), indicating better metabolic stability.
13. **t1/2:** Ligand A (33.501) has a much longer in vitro half-life than Ligand B (-5.948), which is a major advantage.
14. **Pgp:** Ligand A (0.233) has lower P-gp efflux than Ligand B (0.507), suggesting better bioavailability.
15. **Affinity:** Ligand B (-6.2) has a slightly better binding affinity than Ligand A (-4.7), a difference of 1.5 kcal/mol.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B excels in TPSA and has a slightly better affinity. However, Ligand A has a more optimal logP, better solubility, significantly better metabolic stability (lower Cl_mic, longer t1/2), and lower Pgp efflux. The DILI risk for Ligand A is a concern, but the substantial improvements in metabolic stability and half-life are crucial for a viable drug candidate. The affinity difference, while present, isn't large enough to overcome these ADME advantages.
**Conclusion:**
Considering the balance of properties and the specific priorities for a GPCR target, Ligand A is the more promising candidate. Its superior metabolic stability and longer half-life are significant advantages that outweigh the slightly higher DILI risk and slightly weaker affinity.
Output:
1
2025-04-18 00:21:12,709 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
The ADRB2 receptor is a GPCR, so the priorities are logP, TPSA, Pgp, BBB, and binding affinity. Let's break down each ligand against these and other important parameters:
* **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (358.479) is slightly higher than Ligand B (345.487), but both are acceptable.
* **TPSA:** Ligand A (79.31) is better than Ligand B (43.86). Lower TPSA generally favors better cell permeability, which is crucial for GPCR targeting.
* **logP:** Ligand B (1.908) is better than Ligand A (0.752). A logP between 1-3 is optimal, and Ligand B falls squarely within this range, while Ligand A is a bit low, potentially hindering membrane permeability.
* **H-Bond Donors/Acceptors:** Ligand A has 1 HBD and 5 HBA, while Ligand B has 0 HBD and 3 HBA. Both are within acceptable limits.
* **QED:** Both ligands have good QED scores (A: 0.623, B: 0.691), indicating good drug-like properties. Ligand B is slightly better.
* **DILI:** Both ligands have low DILI risk (A: 15.355, B: 13.571), which is positive. Ligand B is slightly better.
* **BBB:** Ligand B (71.229) has a significantly better BBB penetration score than Ligand A (50.446). While not strictly necessary for ADRB2 (a cardiovascular target), higher BBB is rarely detrimental and could offer some off-target safety benefits.
* **Caco-2 Permeability:** Both are negative, indicating poor permeability. Ligand A (-4.319) is slightly worse than Ligand B (-4.69).
* **Aqueous Solubility:** Ligand A (-0.661) is better than Ligand B (-2.127). Solubility is important for formulation and bioavailability.
* **hERG Inhibition:** Both ligands have low hERG inhibition risk (A: 0.252, B: 0.462).
* **Microsomal Clearance:** Both have similar microsomal clearance (A: 53.051, B: 51.776).
* **In vitro Half-Life:** Ligand A (3.78) has a slightly longer half-life than Ligand B (2.08).
* **P-gp Efflux:** Both ligands have low P-gp efflux (A: 0.051, B: 0.096).
* **Binding Affinity:** Both ligands have very similar binding affinities (-6.4 and -6.3 kcal/mol). The difference is negligible.
**Overall Assessment:**
Ligand B is preferable. While Ligand A has slightly better solubility and half-life, Ligand B excels in key GPCR-relevant properties: logP, TPSA, and BBB penetration. The better logP and TPSA of Ligand B suggest it will have better membrane permeability and receptor engagement. The higher BBB score, while not critical for ADRB2, is a bonus. The binding affinities are essentially the same, so the ADME advantages of Ligand B outweigh the minor benefits of Ligand A.
**Output:**
0
2025-04-18 00:21:12,709 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (354.5 & 350.5 Da) fall comfortably within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (49.85) is significantly better than Ligand B (66.92). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (3.32 & 2.28), falling within the 1-3 range. Ligand A is slightly higher, which *could* be a minor advantage for membrane permeability.
4. **HBD:** Both have 0 HBD, which is good.
5. **HBA:** Ligand A has 3 HBA, Ligand B has 4. Both are acceptable (<=10).
6. **QED:** Ligand A (0.761) has a substantially better QED score than Ligand B (0.419), indicating a more drug-like profile.
7. **DILI:** Ligand A (26.1%) has a lower DILI risk than Ligand B (31.7%), both are good.
8. **BBB:** Ligand A (81.8%) has slightly better BBB penetration than Ligand B (77.2%), but this is less critical for a cardiovascular target.
9. **Caco-2:** Ligand A (-4.122) is slightly better than Ligand B (-4.803), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-2.919) is slightly better than Ligand B (-2.654).
11. **hERG:** Both ligands have very low hERG inhibition risk (0.37 & 0.21).
12. **Cl_mic:** Both ligands have similar microsomal clearance (80.4 & 80.7).
13. **t1/2:** Ligand A (11.17 hours) has a significantly longer in vitro half-life than Ligand B (-6.01 hours). This is a major advantage.
14. **Pgp:** Both ligands are very low Pgp efflux substrates (0.093 & 0.106).
15. **Binding Affinity:** Ligand B (-6.8 kcal/mol) has a significantly better binding affinity than Ligand A (-4.4 kcal/mol). This is a 2.4 kcal/mol difference, which is substantial.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), affinity, logP, TPSA, and Pgp are key. Ligand B wins on affinity by a large margin. Ligand A is better on TPSA, logP, QED, solubility and half-life.
**Overall Assessment:**
The significantly stronger binding affinity of Ligand B (-6.8 kcal/mol vs -4.4 kcal/mol) is the most important factor. This advantage is likely to outweigh the slightly less favorable ADME properties of Ligand B compared to Ligand A. While Ligand A has a better overall ADME profile, the potency difference is too significant to ignore.
Output:
0
2025-04-18 00:21:12,709 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, affinity, logP, TPSA, Pgp efflux, and BBB penetration are key considerations.
Let's break down the comparison:
1. **MW:** Both ligands (356.35 and 348.49) fall within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (101.24) is higher than Ligand B (68.3). Ligand B is significantly better, being well below the 140 threshold for good absorption.
3. **logP:** Ligand A (-0.012) is quite low, potentially hindering membrane permeability. Ligand B (3.241) is within the optimal 1-3 range. This is a significant advantage for Ligand B.
4. **HBD/HBA:** Both have 2 HBD and 6 HBA, which are acceptable.
5. **QED:** Both are reasonably good (0.743 and 0.668), indicating drug-likeness.
6. **DILI:** Ligand A (54.091) has a slightly higher DILI risk than Ligand B (34.665), but both are acceptable (<60).
7. **BBB:** Ligand B (90.306) has excellent BBB penetration, while Ligand A (57.736) is moderate. While not critical for a cardiovascular target, higher BBB is generally favorable.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
9. **Solubility:** Ligand A (-1.586) has better solubility than Ligand B (-3.004).
10. **hERG:** Ligand A (0.315) has a lower hERG risk than Ligand B (0.879), which is a positive.
11. **Cl_mic:** Ligand A (-9.983) has significantly lower (better) microsomal clearance than Ligand B (75.675), indicating better metabolic stability.
12. **t1/2:** Ligand B (30.048) has a slightly longer half-life than Ligand A (27.096).
13. **Pgp:** Ligand A (0.02) has much lower P-gp efflux than Ligand B (0.306), which is a significant advantage for bioavailability.
14. **Affinity:** Ligand A (-8.2 kcal/mol) has a slightly better binding affinity than Ligand B (-7.6 kcal/mol). This is a 1.6 kcal/mol difference, which is substantial.
**Overall Assessment:**
Despite Ligand A's slightly better affinity and lower hERG risk, Ligand B is the more promising candidate. The significantly better logP, TPSA, BBB penetration, and P-gp efflux profile of Ligand B outweigh the small advantage in affinity. The poor logP of Ligand A is a major concern for permeability and overall drug-like properties. The lower metabolic clearance of Ligand A is a positive, but can be addressed through structural modifications.
**Output:**
0
2025-04-18 00:21:12,709 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (364.471 and 367.812 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (84.42) is better than Ligand B (90.12). Both are below the 140 threshold for oral absorption, but closer to the 90 threshold for GPCRs.
3. **logP:** Ligand A (1.411) is within the optimal range (1-3), while Ligand B (2.206) is also acceptable, but slightly higher.
4. **HBD:** Ligand A (1) is preferred over Ligand B (3). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (7) is better than Ligand B (4). Both are acceptable, but lower HBA is generally preferred.
6. **QED:** Ligand B (0.699) is better than Ligand A (0.48). A higher QED suggests a more drug-like profile.
7. **DILI:** Ligand A (47.77) is significantly better than Ligand B (68.437). Lower DILI risk is crucial.
8. **BBB:** Ligand A (73.943) is better than Ligand B (63.164). While ADRB2 isn't strictly a CNS target, some CNS penetration can be beneficial or at least avoid off-target effects.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.105 and -5.259), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand A (-2.587) is better than Ligand B (-3.631), indicating slightly better aqueous solubility.
11. **hERG:** Ligand A (0.25) is much better than Ligand B (0.653). Lower hERG inhibition is critical for avoiding cardiotoxicity, especially for a cardiovascular target like ADRB2.
12. **Cl_mic:** Ligand A (81.705) is worse than Ligand B (19.947). Lower clearance is preferred for metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand B (76.874) is much better than Ligand A (-4.26). A longer half-life is desirable.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.038 and 0.041).
15. **Affinity:** Both ligands have similar binding affinities (-6.0 and -5.3 kcal/mol). Ligand A is slightly better.
**Overall Assessment:**
Ligand A has a better profile overall, despite Ligand B's superior metabolic stability and half-life. Ligand A demonstrates better solubility, a significantly lower DILI risk, lower hERG inhibition, and a slightly better binding affinity. The Caco-2 values are concerning for both, but the other advantages of Ligand A outweigh the benefits of Ligand B's improved metabolic properties. For a cardiovascular target, minimizing cardiotoxicity (hERG) and liver toxicity (DILI) are paramount.
Output:
1
2025-04-18 00:21:12,709 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Ligand A (380.5) is within the ideal range (200-500), while Ligand B (411.3) is towards the upper end but still acceptable.
2. **TPSA:** Ligand A (101.8) is borderline for good oral absorption (<=140), but Ligand B (50.8) is excellent. This favors B.
3. **logP:** Ligand A (0.719) is a bit low, potentially hindering permeation. Ligand B (3.302) is optimal. This strongly favors B.
4. **HBD:** Both ligands have acceptable HBD counts (A: 2, B: 1).
5. **HBA:** Both ligands have acceptable HBA counts (A: 8, B: 4).
6. **QED:** Ligand A (0.654) is better than Ligand B (0.501), indicating a slightly more drug-like profile.
7. **DILI:** Ligand A (86.0) has a higher DILI risk than Ligand B (26.2), which is a significant concern. This favors B.
8. **BBB:** Ligand A (33.1) has poor BBB penetration, while Ligand B (79.2) is good. Since ADRB2 is a GPCR, BBB penetration isn't *critical* unless targeting CNS effects, but it's a bonus.
9. **Caco-2:** Ligand A (-5.73) is very poor, indicating poor absorption. Ligand B (-4.85) is also poor, but better than A.
10. **Solubility:** Ligand A (-2.66) is poor, while Ligand B (-3.12) is also poor. Both are problematic.
11. **hERG:** Ligand A (0.147) has a lower hERG risk than Ligand B (0.84), which is preferable.
12. **Cl_mic:** Ligand A (32.3) has a much lower microsomal clearance than Ligand B (77.9), indicating better metabolic stability. This favors A.
13. **t1/2:** Ligand B (46.7) has a longer half-life than Ligand A (12.2), which is desirable. This favors B.
14. **Pgp:** Ligand A (0.029) has very low P-gp efflux, while Ligand B (0.392) has moderate efflux. This favors A.
15. **Affinity:** Both ligands have very similar binding affinities (-6.5 and -6.4 kcal/mol). The difference is negligible.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP and TPSA, and has a better BBB score. Ligand A has better Pgp and Cl_mic. The DILI risk for Ligand A is a major red flag.
**Overall Assessment:**
While Ligand A has advantages in metabolic stability (Cl_mic) and Pgp efflux, the significantly higher DILI risk, poor Caco-2 permeability, and low logP are major drawbacks. Ligand B, despite slightly worse metabolic stability and Pgp efflux, presents a much more favorable overall profile with better absorption characteristics, lower toxicity risk, and good logP. The similar binding affinities make the ADME profile the deciding factor.
Output:
0
2025-04-18 00:21:12,709 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, the key priorities are logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB.
Let's break down the comparison:
1. **MW:** Both ligands (362.455 and 365.455 Da) are within the ideal 200-500 Da range.
2. **TPSA:** Ligand B (97.39) is better than Ligand A (106.32), being closer to the <140 threshold for good absorption.
3. **logP:** Ligand A (1.304) is slightly better than Ligand B (0.775), falling comfortably within the 1-3 range. Ligand B is a little low, potentially impacting permeability.
4. **HBD/HBA:** Both have 2 HBD and are similar in HBA (6 vs 5). This is acceptable for both.
5. **QED:** Ligand A (0.818) has a better QED score than Ligand B (0.664), indicating better overall drug-likeness.
6. **DILI:** Ligand B (47.15) has a significantly lower DILI risk than Ligand A (58.666), which is a substantial advantage.
7. **BBB:** Ligand B (46.413) has a higher BBB penetration than Ligand A (26.871). While not a primary concern for a cardiovascular target, higher BBB is generally favorable.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-5.189) is slightly better than Ligand B (-4.951).
9. **Solubility:** Both have negative solubility values, which is also unusual and suggests poor solubility. Ligand A (-2.861) is slightly better than Ligand B (-2.553).
10. **hERG:** Both ligands have very low hERG risk (0.253 and 0.151).
11. **Cl_mic:** Ligand A (0.456) has much lower microsomal clearance than Ligand B (19.263), indicating better metabolic stability. This is a significant advantage.
12. **t1/2:** Ligand B (-43.522) has a much longer in vitro half-life than Ligand A (16.258), which is a major positive.
13. **Pgp:** Both have very low Pgp efflux liability (0.061 and 0.021).
14. **Binding Affinity:** Ligand B (-5.3) has a slightly better binding affinity than Ligand A (-5.9). While the difference is small, it's still a positive for Ligand B.
**Overall Assessment:**
Ligand B has a better safety profile (lower DILI), better BBB penetration, and a longer half-life. Ligand A has better metabolic stability (lower Cl_mic) and a slightly better QED score. The binding affinity difference is minimal. The poor Caco-2 and solubility values are concerning for both, but the other advantages of Ligand B, particularly the lower DILI and longer half-life, outweigh the benefits of Ligand A's metabolic stability.
**Output:**
0
2025-04-18 00:21:12,710 - INFO - Batch 471 complete. Total preferences: 7536
2025-04-18 00:21:12,710 - INFO - Processing batch 472/512...
2025-04-18 00:22:00,179 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (346.471 Da and 345.447 Da). No significant difference.
2. **TPSA:** Ligand A (62.55) is significantly better than Ligand B (87.22). For a GPCR, lower TPSA is generally preferred for permeability.
3. **logP:** Ligand A (3.748) is optimal, while Ligand B (0.711) is quite low. This is a major advantage for Ligand A, as logP impacts both permeability and off-target interactions.
4. **HBD:** Ligand A (1) is better than Ligand B (2). Lower is generally preferred.
5. **HBA:** Ligand A (3) is better than Ligand B (5). Lower is generally preferred.
6. **QED:** Ligand A (0.883) is significantly better than Ligand B (0.678), indicating a more drug-like profile.
7. **DILI:** Ligand A (40.364) is slightly higher than Ligand B (25.204), but both are within acceptable limits (<60).
8. **BBB:** Ligand A (64.637) is better than Ligand B (55.603), although neither is exceptionally high. For ADRB2, which isn't necessarily a CNS target, this isn't a primary driver.
9. **Caco-2:** Ligand A (-4.807) is better than Ligand B (-5.504). Higher values are better, indicating better absorption.
10. **Solubility:** Ligand A (-3.961) is better than Ligand B (-0.796). Better solubility is always preferred.
11. **hERG:** Ligand A (0.391) is better than Ligand B (0.206). Lower values are better, indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand A (32.598) is worse than Ligand B (-3.913). Lower clearance is better for metabolic stability. This is a point in favor of Ligand B.
13. **t1/2:** Ligand A (29.24) is much better than Ligand B (-0.944). Longer half-life is desirable.
14. **Pgp:** Ligand A (0.359) is better than Ligand B (0.006). Lower efflux is preferred.
15. **Affinity:** Ligand A (-5.3) is better than Ligand B (-7.0). Ligand B has a 1.7 kcal/mol advantage in binding affinity.
**Overall Assessment:**
Ligand B has a significantly better binding affinity (-7.0 kcal/mol vs -5.3 kcal/mol), which is a crucial factor for GPCRs. However, Ligand A demonstrates superior ADME properties across the board, including logP, TPSA, QED, solubility, and half-life. The difference in affinity, while substantial, is potentially outweighed by the superior overall drug-like characteristics of Ligand A. Ligand B's very low logP and negative half-life are significant concerns. While the lower clearance of Ligand B is a positive, it doesn't compensate for the other issues. Considering the balance of properties, and prioritizing a more well-rounded profile for a drug candidate, Ligand A is the more promising option.
Output:
1
2025-04-18 00:22:00,179 - INFO - Here's my reasoning and final output for the ligand preference:
**Reasoning:**
We are targeting ADRB2, a GPCR. Therefore, the priorities are logP, Pgp, TPSA, affinity, and to a lesser extent, BBB. Let's compare Ligand A and Ligand B across these and other relevant parameters.
* **Molecular Weight:** Both ligands are within the ideal range (200-500 Da).
* **TPSA:** Ligand A (87.68) is significantly better than Ligand B (114.57). Lower TPSA generally favors oral absorption, a key consideration for a cardiovascular drug.
* **logP:** Ligand A (1.15) is within the optimal range (1-3), while Ligand B (-0.394) is slightly below, potentially hindering permeability.
* **H-Bond Donors/Acceptors:** Ligand B has more HBDs and HBAs (3/6 vs 2/5), which *could* slightly impact permeability, but isn't a major concern.
* **QED:** Ligand A (0.869) has a better QED score than Ligand B (0.642), indicating a more drug-like profile.
* **DILI:** Both have acceptable DILI risk, but Ligand A (54.827) is slightly better than Ligand B (61.07).
* **BBB:** Both have low BBB penetration, which is acceptable for a cardiovascular target.
* **Caco-2:** Both have negative Caco-2 values, which is unusual and requires further investigation, but doesn't immediately disqualify either.
* **Solubility:** Both have negative solubility values, which is also unusual and requires further investigation, but doesn't immediately disqualify either.
* **hERG:** Both have very low hERG inhibition risk, which is excellent.
* **Cl_mic:** Ligand A (-12.896) has a *much* lower (better) microsomal clearance than Ligand B (-6.979), suggesting better metabolic stability.
* **t1/2:** Ligand B (24.559) has a slightly longer in vitro half-life than Ligand A (19.649), which is a minor advantage.
* **Pgp:** Both have very low Pgp efflux liability, which is good.
* **Binding Affinity:** Ligand A (-7.2 kcal/mol) has a slightly better binding affinity than Ligand B (-6.5 kcal/mol). While the difference is less than the 1.5 kcal/mol threshold, it's still a positive.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across several crucial parameters, especially TPSA, logP, QED, and importantly, metabolic stability (Cl_mic). The slightly better affinity of Ligand A further supports its selection. While Ligand B has a slightly longer half-life, the other advantages of Ligand A are more significant for a GPCR target. The negative Caco-2 and solubility values are concerning for both, but the overall profile of Ligand A is superior.
**Output:**
1
2025-04-18 00:22:00,180 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A Analysis:**
* **MW:** 358.438 Da - Good, within the ideal range.
* **TPSA:** 44.12 - Excellent, well below the 140 threshold, favorable for absorption.
* **logP:** 4.197 - Slightly high, could potentially lead to solubility issues or off-target effects, but still within a manageable range.
* **HBD:** 0 - Low, potentially impacting solubility.
* **HBA:** 5 - Good, within the acceptable range.
* **QED:** 0.659 - Excellent, indicates good drug-likeness.
* **DILI:** 75.766 - Moderate risk, needs consideration.
* **BBB:** 80.807 - Very good, suggesting potential for CNS penetration if desired (though ADRB2 is primarily cardiovascular, some CNS effects are possible).
* **Caco-2:** -4.277 - Poor permeability, a significant concern.
* **Solubility:** -4.734 - Very poor solubility, a major drawback.
* **hERG:** 0.369 - Low risk, good.
* **Cl_mic:** 91.636 - High metabolic clearance, suggesting rapid metabolism and potentially low bioavailability.
* **t1/2:** 22.412 - Moderate half-life.
* **Pgp:** 0.659 - Moderate P-gp efflux, could limit bioavailability.
* **Affinity:** -5.3 kcal/mol - Good binding affinity.
**Ligand B Analysis:**
* **MW:** 376.435 Da - Good, within the ideal range.
* **TPSA:** 131.78 - Approaching the upper limit for good oral absorption, but still acceptable.
* **logP:** -1.673 - Low, potentially hindering membrane permeability.
* **HBD:** 3 - Good, within the acceptable range.
* **HBA:** 8 - Good, within the acceptable range.
* **QED:** 0.469 - Acceptable, but lower than Ligand A, indicating slightly less ideal drug-like properties.
* **DILI:** 77.007 - Moderate risk, similar to Ligand A.
* **BBB:** 21.404 - Low, not a priority for this target, but indicates poor CNS penetration.
* **Caco-2:** -5.655 - Poor permeability, a significant concern.
* **Solubility:** -1.655 - Poor solubility, but better than Ligand A.
* **hERG:** 0.115 - Very low risk, excellent.
* **Cl_mic:** 10.028 - Low metabolic clearance, suggesting good metabolic stability.
* **t1/2:** -1.495 - Very short half-life, a significant drawback.
* **Pgp:** 0.012 - Very low P-gp efflux, favorable for bioavailability.
* **Affinity:** -6.7 kcal/mol - Excellent binding affinity, 1.4 kcal/mol better than Ligand A.
**Comparison and Decision:**
Both ligands have significant drawbacks, primarily poor permeability and solubility. However, Ligand B possesses a substantially better binding affinity (-6.7 vs -5.3 kcal/mol), which is a crucial factor for GPCRs. It also has significantly better metabolic stability (lower Cl_mic) and lower P-gp efflux. While its half-life is very short, the strong binding and improved metabolic profile could potentially be optimized through structural modifications. Ligand A's high metabolic clearance and very poor solubility are more difficult to overcome. The slightly higher logP of Ligand A is less concerning than the other issues.
Given the GPCR-specific priorities (affinity being paramount), and considering the potential to address the short half-life through medicinal chemistry, Ligand B is the more promising candidate.
Output:
0
2025-04-18 00:22:00,180 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (353.463 and 368.459 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (104.2 and 102.44) are reasonably low, suggesting good potential for absorption. They are above the ideal <90 for CNS targets, but ADRB2 isn't necessarily a CNS target.
3. **logP:** Ligand A (2.445) is better than Ligand B (0.632). ADRB2 is a GPCR, and a logP between 1-3 is preferred. Ligand B is a bit low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (2), but both are within the acceptable limit of 5.
5. **HBA:** Ligand B (7) is higher than Ligand A (4). Both are within the acceptable limit of 10.
6. **QED:** Both ligands have similar QED values (0.601 and 0.616), indicating good drug-likeness.
7. **DILI:** Ligand B (80.186) has a significantly higher DILI risk than Ligand A (53.354). This is a major concern, as DILI is a frequent cause of drug attrition.
8. **BBB:** Both ligands have similar BBB penetration (45.832 and 46.879). This isn't a primary concern for ADRB2, but it's good to see they aren't completely blocked.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.028 and -5.445). This is unusual and suggests poor permeability, but the scale is not well-defined in the prompt.
10. **Solubility:** Both ligands have negative solubility values (-3.199 and -3.018). This is also unusual and suggests poor solubility, but the scale is not well-defined in the prompt.
11. **hERG:** Both ligands have low hERG inhibition risk (0.296 and 0.32), which is good.
12. **Cl_mic:** Ligand B (41.575) has a lower microsomal clearance than Ligand A (44.635), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-31.068) has a significantly longer in vitro half-life than Ligand A (-18.195), which is a major advantage.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.108 and 0.033), which is good.
15. **Binding Affinity:** Ligand A (-6.7 kcal/mol) has a slightly better binding affinity than Ligand B (-6.5 kcal/mol), but the difference is small.
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are important. Ligand A is better in logP and has a slightly better affinity. However, Ligand B has a significantly longer half-life and lower DILI risk, which are also crucial factors.
**Overall Assessment:**
While Ligand A has a slightly better logP and affinity, the significantly higher DILI risk associated with Ligand B is a major drawback. The longer half-life of Ligand B is also a significant advantage. Considering the balance of properties, I believe Ligand A is the more promising candidate despite the slightly weaker affinity.
Output:
1
2025-04-18 00:22:00,180 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (356.3 & 340.4 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (58.64) is significantly better than Ligand A (95.99). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (1.767 & 1.702), falling within the optimal 1-3 range. Similar.
4. **HBD:** Ligand B (1) is preferable to Ligand A (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand B (3) is slightly better than Ligand A (4), but both are acceptable.
6. **QED:** Both ligands have good QED scores (0.713 & 0.802), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand B (23.769) has a *much* lower DILI risk than Ligand A (65.568). This is a major advantage for Ligand B.
8. **BBB:** Ligand A (70.143) has a better BBB penetration score than Ligand B (57.115). However, since ADRB2 is primarily a cardiovascular target, BBB penetration is not a high priority.
9. **Caco-2:** Ligand B (-4.686) is better than Ligand A (-5.318), indicating better intestinal absorption.
10. **Solubility:** Ligand B (-2.753) is better than Ligand A (-4.164), indicating better aqueous solubility.
11. **hERG:** Ligand B (0.203) has a much lower hERG inhibition liability than Ligand A (0.576). This is a significant safety advantage.
12. **Cl_mic:** Ligand B (2.188) has a slightly lower microsomal clearance than Ligand A (1.711), suggesting better metabolic stability.
13. **t1/2:** Ligand A (10.743) has a longer in vitro half-life than Ligand B (6.171). This is a slight advantage for Ligand A.
14. **Pgp:** Ligand B (0.077) has significantly lower P-gp efflux liability than Ligand A (0.32). This is a positive for bioavailability.
15. **Binding Affinity:** Ligand B (-7.5) has a significantly stronger binding affinity than Ligand A (-5.6). This is a substantial advantage, potentially outweighing some minor ADME drawbacks.
**Overall Assessment:**
Ligand B consistently outperforms Ligand A in most critical ADME-Tox properties (DILI, hERG, Pgp, Solubility, Caco-2) and has a significantly better binding affinity. While Ligand A has a slightly longer half-life and better BBB penetration (which isn't crucial here), the superior safety profile and potency of Ligand B make it the more promising drug candidate.
Output:
0
2025-04-18 00:22:00,180 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (345.443 and 358.36 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (70.49) is better than Ligand B (78.43), being closer to the <140 threshold for good absorption.
3. **logP:** Both ligands (2.489 and 2.444) are within the optimal 1-3 range. No clear advantage.
4. **HBD:** Ligand A (2) is preferable to Ligand B (3), as lower HBD generally improves permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (3), as lower HBA generally improves permeability.
6. **QED:** Ligand A (0.757) is slightly better than Ligand B (0.701), indicating a more drug-like profile.
7. **DILI:** Ligand A (8.181) is *significantly* better than Ligand B (28.616). This is a major advantage for Ligand A, as lower DILI risk is crucial.
8. **BBB:** Both ligands have good BBB penetration (79.062 and 73.866), but Ligand A is slightly better. This is a positive for both, given ADRB2 is a GPCR.
9. **Caco-2:** Ligand A (-5.345) is slightly better than Ligand B (-4.763), indicating better intestinal absorption.
10. **Solubility:** Both ligands have poor solubility (-3.167 and -3.055). This is a concern for both, but not a deciding factor.
11. **hERG:** Ligand A (0.904) is better than Ligand B (0.518), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand A (7.455) is *much* better than Ligand B (14.635), indicating significantly improved metabolic stability.
13. **t1/2:** Ligand A (-34.235) is significantly better than Ligand B (-1.334), indicating a much longer half-life.
14. **Pgp:** Ligand A (0.079) is better than Ligand B (0.023), indicating lower P-gp efflux.
15. **Affinity:** Ligand A (-6.5) is slightly better than Ligand B (-6.0), but the difference is relatively small.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical ADME-Tox properties. The most significant advantages are in DILI risk, metabolic stability (Cl_mic), and in vitro half-life. While both have acceptable BBB penetration and binding affinity, the superior safety and pharmacokinetic profile of Ligand A make it the more promising drug candidate. The small advantage in binding affinity isn't enough to overcome the substantial benefits of Ligand A in other areas.
Output:
1
2025-04-18 00:22:00,180 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [360.458, 68.49, 3.735, 1, 5, 0.882, 63.862, 66.77, -4.667, -4.731, 0.939, 32.554, 85.146, 0.505, -6.6]
**Ligand B:** [345.403, 100.21, 0.039, 2, 5, 0.802, 41.024, 45.095, -5.192, -2.55, 0.048, 19.178, -1.916, 0.007, -5.8]
Here's a breakdown, considering the GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal 200-500 Da range. A (360.458) is slightly higher, but not concerning.
2. **TPSA:** A (68.49) is excellent, well below the 140 threshold. B (100.21) is still acceptable, but less ideal.
3. **logP:** A (3.735) is optimal. B (0.039) is *very* low, raising concerns about permeability and potentially requiring formulation strategies to enhance absorption.
4. **HBD/HBA:** Both have reasonable HBD/HBA counts (A: 1/5, B: 2/5).
5. **QED:** Both are good (A: 0.882, B: 0.802), indicating drug-like properties.
6. **DILI:** A (63.862) is moderately high, a potential concern. B (41.024) is much better, indicating lower liver injury risk.
7. **BBB:** A (66.77) is acceptable, but not great. B (45.095) is lower, less favorable. However, since this is a cardiovascular target, BBB penetration isn't *critical*.
8. **Caco-2:** Both are negative, suggesting poor permeability. A (-4.667) is worse than B (-5.192).
9. **Solubility:** Both are negative, suggesting poor solubility. A (-4.731) is worse than B (-2.55).
10. **hERG:** A (0.939) is better than B (0.048), indicating lower cardiotoxicity risk.
11. **Cl_mic:** A (32.554) is better than B (19.178), suggesting better metabolic stability.
12. **t1/2:** A (85.146) is significantly better than B (-1.916), indicating a much longer half-life.
13. **Pgp:** A (0.505) is better than B (0.007), suggesting less P-glycoprotein efflux.
14. **Affinity:** A (-6.6) is slightly better than B (-5.8), though the difference is not huge.
**Overall Assessment:**
Ligand A has a significantly better logP, Pgp efflux, metabolic stability (Cl_mic and t1/2), and slightly better affinity. While its DILI score is higher, the poor logP of Ligand B is a major drawback for oral bioavailability. The poor Caco-2 and solubility of both are concerning, but the more favorable ADME profile of Ligand A, particularly the logP and metabolic stability, makes it the more promising candidate, despite the DILI risk. The slightly better affinity reinforces this decision.
Output:
1
2025-04-18 00:22:00,180 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [367.921, 44.81, 3.086, 1, 3, 0.729, 11.594, 91.857, -4.214, -2.413, 0.802, 42.81, 46.846, 0.084, -5.9]
**Ligand B:** [344.375, 123.84, -0.155, 3, 5, 0.644, 61.109, 36.487, -5.38, -2.647, 0.036, -0.702, -24.374, 0.005, -5.2]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, BBB, Affinity):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (344.375) is slightly smaller.
2. **TPSA:** Ligand A (44.81) is significantly better than Ligand B (123.84). A TPSA under 140 is good for oral absorption, but lower is preferable for GPCRs, and A is much closer to the ideal <90 for CNS penetration.
3. **logP:** Ligand A (3.086) is optimal (1-3). Ligand B (-0.155) is quite low, potentially hindering permeability. This is a significant negative for B.
4. **HBD/HBA:** Ligand A (1 HBD, 3 HBA) is better than Ligand B (3 HBD, 5 HBA). Fewer H-bonds are generally preferred for permeability.
5. **QED:** Both are reasonably good (A: 0.729, B: 0.644), indicating drug-like properties.
6. **DILI:** Ligand A (11.594) has a much lower DILI risk than Ligand B (61.109). This is a major advantage for A.
7. **BBB:** Ligand A (91.857) has excellent BBB penetration potential, while Ligand B (36.487) is poor. This is crucial for a GPCR target, even if not strictly CNS-focused, as it indicates better distribution characteristics.
8. **Caco-2:** Ligand A (-4.214) is better than Ligand B (-5.38), suggesting better intestinal absorption.
9. **Solubility:** Both are poor (-2.413 and -2.647). This is a concern for both, but not a deciding factor.
10. **hERG:** Ligand A (0.802) is slightly higher than Ligand B (0.036), indicating a slightly higher hERG risk, but still relatively low.
11. **Cl_mic:** Ligand A (42.81) has a higher clearance than Ligand B (-0.702), meaning it's less metabolically stable. This is a negative for A.
12. **t1/2:** Ligand A (46.846) has a much longer half-life than Ligand B (-24.374). This is a significant advantage for A.
13. **Pgp:** Ligand A (0.084) has lower P-gp efflux than Ligand B (0.005), which is beneficial for bioavailability and distribution.
14. **Affinity:** Both have very similar and excellent binding affinities (-5.9 and -5.2 kcal/mol). The difference is not substantial enough to outweigh other factors.
**Conclusion:**
Despite Ligand A's higher microsomal clearance, its superior TPSA, logP, DILI risk, BBB penetration, Caco-2 permeability, Pgp efflux, and half-life make it the more promising drug candidate. Ligand B's very low logP is a significant drawback, likely impacting its permeability and bioavailability. The higher DILI risk for B is also concerning.
Output:
1
2025-04-18 00:22:00,181 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (389.483 and 375.535 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (81.06) is well below the 140 threshold and reasonably good for a non-CNS GPCR. Ligand B (98.74) is higher, but still acceptable.
3. **logP:** Ligand A (3.267) is optimal. Ligand B (0.443) is quite low, potentially hindering membrane permeability and bioavailability. This is a significant drawback.
4. **HBD:** Ligand A (1) is good. Ligand B (3) is slightly higher, but still within acceptable limits.
5. **HBA:** Ligand A (7) is good. Ligand B (5) is also good.
6. **QED:** Both ligands have good QED scores (0.581 and 0.626), indicating generally drug-like properties.
7. **DILI:** Ligand A (98.759) has a very high DILI risk, which is a major concern. Ligand B (12.796) has a very low DILI risk, a significant advantage.
8. **BBB:** This is less critical for ADRB2 (cardiovascular target), but Ligand A (50.679) is better than Ligand B (24.738).
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale isn't specified, so the absolute values are hard to interpret.
10. **Solubility:** Both have negative solubility values, again making interpretation difficult.
11. **hERG:** Ligand A (0.381) has a very low hERG risk. Ligand B (0.233) also has a low hERG risk.
12. **Cl_mic:** Ligand A (18.97) is moderate. Ligand B (-1.906) is excellent, indicating very high metabolic stability.
13. **t1/2:** Ligand A (100.44) has a very long half-life, which is desirable. Ligand B (-40.183) has a very short half-life, which is a major drawback.
14. **Pgp:** Ligand A (0.434) has moderate Pgp efflux liability. Ligand B (0.008) has very low Pgp efflux, which is favorable.
15. **Binding Affinity:** Ligand A (-7.1) has significantly better binding affinity than Ligand B (-2.7). This is a substantial advantage, potentially outweighing some ADME concerns.
**GPCR-specific priorities:** For ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand A excels in affinity and has acceptable logP and TPSA. Ligand B has poor logP. The DILI risk for Ligand A is concerning, but the superior binding affinity and metabolic stability of Ligand B are also important. The very long half-life of Ligand A is also a strong positive.
**Overall Assessment:**
Despite the high DILI risk, Ligand A's significantly stronger binding affinity (-7.1 vs -2.7) and long half-life are compelling advantages for a GPCR target. The low logP of Ligand B is a substantial drawback that would likely hinder its *in vivo* performance. While the DILI risk for Ligand A is a concern, it might be mitigated through structural modifications in subsequent optimization rounds.
Output:
1
2025-04-18 00:22:00,181 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (358.869) is slightly higher than Ligand B (348.447), but both are acceptable.
2. **TPSA:** Ligand A (41.57) is significantly better than Ligand B (67.67). A TPSA under 140 is good for oral absorption, and lower is better for GPCRs. Ligand B's TPSA is approaching a level that could hinder absorption.
3. **logP:** Ligand A (3.669) is within the optimal range (1-3), while Ligand B (1.3) is on the lower end. Lower logP can lead to permeability issues.
4. **HBD:** Ligand A (1) is preferable to Ligand B (0). While both are low, a single HBD can sometimes improve solubility without significantly impacting permeability.
5. **HBA:** Ligand A (3) is better than Ligand B (5). Lower HBA is generally preferred for better permeability.
6. **QED:** Both ligands have good QED scores (Ligand A: 0.906, Ligand B: 0.826), indicating good drug-like properties.
7. **DILI:** Ligand B (21.908) has a much lower DILI risk than Ligand A (54.711). This is a significant advantage for Ligand B.
8. **BBB:** Ligand B (72.005) has a higher BBB penetration percentile than Ligand A (57.736). While ADRB2 isn't strictly a CNS target, some cardiovascular effects can be mediated by CNS pathways, and higher BBB penetration isn't detrimental.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.885 and -4.461), which is unusual and suggests poor permeability. This is a major concern for both.
10. **Solubility:** Ligand B (-0.977) is better than Ligand A (-3.981), indicating better aqueous solubility.
11. **hERG:** Ligand A (0.914) has a slightly higher hERG risk than Ligand B (0.353), but both are relatively low.
12. **Cl_mic:** Ligand A (17.93) has a lower microsomal clearance than Ligand B (21.775), indicating better metabolic stability.
13. **t1/2:** Ligand B (1.25) has a slightly longer half-life than Ligand A (1.155), but the difference is minimal.
14. **Pgp:** Ligand B (0.047) has significantly lower P-gp efflux liability than Ligand A (0.681). This is a major advantage for Ligand B, improving oral bioavailability.
15. **Binding Affinity:** Ligand B (-7.1) has a slightly better binding affinity than Ligand A (-7.0). While the difference is small, it's enough to potentially outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand B is the stronger candidate. While both have concerning Caco-2 permeability values, Ligand B excels in several key areas: lower DILI risk, higher BBB penetration, better solubility, lower P-gp efflux, and slightly better binding affinity. Ligand A has better metabolic stability (lower Cl_mic), but the other advantages of Ligand B are more critical for a GPCR target like ADRB2. The lower TPSA and logP of Ligand A are less desirable than the better safety profile and bioavailability indicators of Ligand B.
Output:
0
2025-04-18 00:22:00,181 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (363.447 & 348.447 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (69.48) is significantly better than Ligand A (137.08). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (1.699 & 1.446), falling within the 1-3 range. Again, no strong differentiator.
4. **HBD:** Ligand B (0) is preferable to Ligand A (2). Fewer HBDs generally improve membrane permeability.
5. **HBA:** Both have 6 HBA, which is acceptable.
6. **QED:** Ligand B (0.805) has a substantially higher QED score than Ligand A (0.467), indicating a more drug-like profile.
7. **DILI:** Ligand B (32.997) has a much lower DILI risk than Ligand A (68.437). This is a significant advantage.
8. **BBB:** Both have reasonable BBB penetration (67.623 & 64.327), but this is less critical for a cardiovascular target.
9. **Caco-2:** Ligand A (-5.343) and Ligand B (-4.724) are both negative, which is unusual and suggests poor permeability. However, the scale is not specified, so it is hard to interpret.
10. **Solubility:** Ligand B (-1.765) is better than Ligand A (-3.424).
11. **hERG:** Ligand B (0.143) has a lower hERG risk than Ligand A (0.394), which is crucial for avoiding cardiotoxicity, especially for a cardiovascular target.
12. **Cl_mic:** Ligand A (9.975) has significantly lower microsomal clearance than Ligand B (32.685), suggesting better metabolic stability.
13. **t1/2:** Ligand B (14.032) has a much longer in vitro half-life than Ligand A (-8.257). This is a major advantage.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.054 & 0.061).
15. **Affinity:** Ligand A (-7.2) has a slightly better binding affinity than Ligand B (-6.5), a difference of 0.7 kcal/mol. While affinity is important, the other factors are more compelling.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. While Ligand A has slightly better affinity, Ligand B excels in TPSA, has comparable logP and Pgp, and demonstrates significantly better ADME properties (DILI, solubility, hERG, Cl_mic, t1/2, QED). The improved ADME profile outweighs the small difference in affinity.
**Conclusion:**
Ligand B is the more promising drug candidate due to its superior ADME properties and acceptable binding affinity.
Output:
0
2025-04-18 00:22:00,181 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (362.417 Da and 365.543 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (78.87) is higher than Ligand B (54.34). For a cardiovascular GPCR, TPSA is moderately important. Ligand B's lower TPSA is preferable as it suggests better permeability.
**3. logP:** Ligand A (1.028) is slightly lower than Ligand B (2.917). Both are within the optimal 1-3 range, but Ligand B is closer to the upper end, which could potentially lead to off-target effects or solubility issues, but is still acceptable.
**4. H-Bond Donors:** Ligand A (2) is slightly higher than Ligand B (1). Both are within the acceptable limit of <=5.
**5. H-Bond Acceptors:** Both ligands have the same number of H-bond acceptors (4), well within the acceptable limit of <=10.
**6. QED:** Both ligands have similar QED values (0.676 and 0.649), indicating good drug-likeness.
**7. DILI Risk:** Ligand A (17.449) has a significantly lower DILI risk compared to Ligand B (32.183). This is a major advantage for Ligand A.
**8. BBB Penetration:** Ligand A (82.474) has better BBB penetration than Ligand B (65.413). While ADRB2 is a cardiovascular target, some CNS effects are possible with certain ligands, and better BBB penetration isn't necessarily a negative.
**9. Caco-2 Permeability:** Ligand A (-4.817) has worse Caco-2 permeability than Ligand B (-5.426). Both are negative, indicating poor permeability, but B is slightly better.
**10. Aqueous Solubility:** Ligand A (-1.714) has better aqueous solubility than Ligand B (-2.575). This is a slight advantage for Ligand A.
**11. hERG Inhibition:** Ligand A (0.587) has a lower hERG inhibition risk than Ligand B (0.801). This is a significant advantage for Ligand A, as hERG inhibition can lead to cardiotoxicity.
**12. Microsomal Clearance:** Ligand B (74.353) has much higher microsomal clearance than Ligand A (0.474). This suggests Ligand A is more metabolically stable, a crucial factor for drug duration and efficacy.
**13. In vitro Half-Life:** Ligand B (11.008) has a longer in vitro half-life than Ligand A (-11.215). This is a positive for Ligand B, but the negative value for A is concerning.
**14. P-gp Efflux:** Ligand A (0.047) has significantly lower P-gp efflux than Ligand B (0.638). Lower P-gp efflux is desirable for better oral bioavailability.
**15. Binding Affinity:** Ligand B (-6.7) has a significantly stronger binding affinity than Ligand A (-2.2). This is a substantial advantage for Ligand B, and could outweigh some of the ADME drawbacks.
**Overall Assessment:**
Ligand B has a significantly better binding affinity, which is paramount for GPCR targets. However, it suffers from higher DILI risk, higher hERG inhibition, and much higher metabolic clearance. Ligand A has a superior safety profile (lower DILI, hERG), better metabolic stability, and lower P-gp efflux. The slightly lower affinity of Ligand A is a concern, but the substantial improvements in safety and pharmacokinetic properties are more important for a cardiovascular drug.
Given the GPCR-specific priorities (logP, Pgp, TPSA, affinity) and the overall balance of properties, Ligand A is the more viable candidate.
Output:
1
2025-04-18 00:22:00,181 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (356.4 and 362.4 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand B (59.08) is significantly better than Ligand A (107.71). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (1.607 and 1.39), falling within the optimal 1-3 range. Ligand B is slightly lower, which could be marginally better for solubility.
4. **HBD:** Ligand A has 3 HBD, while Ligand B has 0. Lower HBD is generally preferred for permeability, making Ligand B slightly better.
5. **HBA:** Ligand A has 5 HBA, Ligand B has 4. Both are acceptable, under the 10 threshold.
6. **QED:** Both ligands have similar QED values (0.645 and 0.687), indicating good drug-likeness.
7. **DILI:** Ligand A has a significantly higher DILI risk (87.631) than Ligand B (25.436). This is a major concern for Ligand A.
8. **BBB:** Ligand B has a higher BBB penetration (85.498) than Ligand A (21.171). While not critical for a cardiovascular target, higher BBB is rarely detrimental.
9. **Caco-2:** Ligand A (-5.402) and Ligand B (-4.269) both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale isn't specified, so it's hard to interpret.
10. **Solubility:** Ligand A (-3.21) and Ligand B (-1.415) both have negative solubility values. Again, the scale is unknown, but both suggest poor solubility. Ligand B is slightly better.
11. **hERG:** Ligand A (0.13) has a lower hERG risk than Ligand B (0.579), which is favorable.
12. **Cl_mic:** Ligand A (-1.797) has a lower (better) microsomal clearance than Ligand B (24.918). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (-9.643) has a longer in vitro half-life than Ligand B (-0.455). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.127) has lower P-gp efflux than Ligand B (0.04). Lower Pgp is generally better.
15. **Affinity:** Ligand A (-7.6) has a slightly better binding affinity than Ligand B (-7.3). While the difference is small (0.3 kcal/mol), it's within the range where it could outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand A has a better binding affinity, lower Pgp efflux, and better metabolic stability (lower Cl_mic and longer t1/2). However, its major drawback is the significantly higher DILI risk. Ligand B has a much better safety profile (DILI), better TPSA, and slightly better solubility. The affinity difference is small. Considering the importance of safety and the fact that the affinity difference isn't huge, the lower DILI risk of Ligand B makes it the more promising candidate.
Output:
0
2025-04-18 00:22:00,182 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (372.853 and 371.909 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (98.76) is higher than Ligand B (61.88). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for better absorption. Ligand B is significantly better.
3. **logP:** Both ligands (1.679 and 1.761) are within the optimal 1-3 range. Again, no substantial difference.
4. **HBD:** Ligand A has 2 HBD, and Ligand B has 1. Both are acceptable, with Ligand B being slightly better.
5. **HBA:** Ligand A has 5 HBA, and Ligand B has 4. Both are within the acceptable limit of 10. Ligand B is slightly better.
6. **QED:** Ligand A (0.822) has a significantly better QED score than Ligand B (0.627), indicating a more drug-like profile. This is a substantial advantage for Ligand A.
7. **DILI:** Ligand A (70.841) has a higher DILI risk than Ligand B (23.924). This is a major concern for Ligand A. Ligand B is significantly better.
8. **BBB:** Ligand A (19.698) has very low BBB penetration, while Ligand B (66.499) has good BBB penetration. While ADRB2 isn't primarily a CNS target, some off-target CNS effects are possible with GPCR ligands, and higher BBB is generally preferable. Ligand B is better.
9. **Caco-2:** Ligand A (-4.786) and Ligand B (-5.012) both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand B is slightly better.
10. **Solubility:** Ligand A (-2.565) and Ligand B (-1.161) both have poor solubility. Ligand B is slightly better.
11. **hERG:** Ligand A (0.287) has a slightly lower hERG risk than Ligand B (0.41). This is a minor advantage for Ligand A.
12. **Cl_mic:** Both ligands have similar microsomal clearance (34.001 and 33.624 mL/min/kg). No significant difference.
13. **t1/2:** Ligand B (42.771) has a significantly longer in vitro half-life than Ligand A (-17.353). This is a major advantage for Ligand B.
14. **Pgp:** Ligand A (0.156) has lower P-gp efflux than Ligand B (0.019). This is a slight advantage for Ligand A.
15. **Affinity:** Ligand A (-9.0 kcal/mol) has a substantially stronger binding affinity than Ligand B (-5.4 kcal/mol). This is a very significant advantage for Ligand A, potentially outweighing some of its ADME liabilities.
**Overall Assessment & GPCR Prioritization:**
For a cardiovascular GPCR like ADRB2, affinity is paramount. Ligand A's substantially better binding affinity (-9.0 vs -5.4 kcal/mol) is a major advantage. However, the high DILI risk (70.841) for Ligand A is a serious concern. Ligand B has a much better safety profile (DILI 23.924), better BBB penetration, and a longer half-life, but its affinity is significantly weaker. Considering the balance, the substantial affinity difference of Ligand A is likely to be more easily addressed through medicinal chemistry optimization than the high DILI risk. The slightly better Pgp value for Ligand A is also a positive.
Output:
1
2025-04-18 00:22:00,182 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (344.415 Da) is slightly lower, which is generally favorable for permeability.
**2. TPSA:** Both ligands have TPSA values below 140, suggesting reasonable oral absorption potential. Ligand B (79.24) is slightly lower than Ligand A (86.37), which is a minor advantage.
**3. logP:** Ligand A (0.881) is within the optimal range (1-3), while Ligand B (4.493) is higher. A logP of 4.493 is approaching the upper limit and could potentially lead to solubility issues and off-target interactions. This is a significant negative for Ligand B.
**4. H-Bond Donors:** Both ligands have 1 HBD, which is within the acceptable limit of 5.
**5. H-Bond Acceptors:** Ligand A has 4 HBAs and Ligand B has 3. Both are below the limit of 10.
**6. QED:** Ligand A (0.882) has a significantly higher QED score than Ligand B (0.325), indicating a much more drug-like profile.
**7. DILI Risk:** Ligand A (32.028) has a much lower DILI risk than Ligand B (64.754). This is a critical advantage for Ligand A.
**8. BBB Penetration:** Both ligands have similar BBB penetration (Ligand A: 62.156, Ligand B: 64.482). While not a primary concern for a cardiovascular target, it's not a differentiating factor.
**9. Caco-2 Permeability:** Both have negative Caco-2 values, which is unusual. However, the magnitude is similar.
**10. Aqueous Solubility:** Ligand A (-2.176) has better solubility than Ligand B (-5.487).
**11. hERG Inhibition:** Ligand A (0.25) has a much lower hERG inhibition liability than Ligand B (0.822), which is a significant safety advantage.
**12. Microsomal Clearance:** Ligand B (79.374) has a higher microsomal clearance than Ligand A (9.286), indicating faster metabolism and potentially lower bioavailability.
**13. In vitro Half-Life:** Ligand A (-28.391) has a much longer in vitro half-life than Ligand B (11.805).
**14. P-gp Efflux:** Ligand A (0.012) has much lower P-gp efflux liability than Ligand B (0.602), which is favorable for bioavailability.
**15. Binding Affinity:** Ligand A (-6.8 kcal/mol) and Ligand B (-4.8 kcal/mol) have different affinities. Ligand A has a 2 kcal/mol advantage in binding affinity.
**GPCR-Specific Considerations:** For a GPCR like ADRB2, logP, TPSA, Pgp efflux, and affinity are important. Ligand A is superior in all these aspects except for TPSA, where the difference is small. The significantly better ADME profile of Ligand A (QED, DILI, solubility, hERG, clearance, half-life, P-gp) outweighs the slightly lower TPSA.
**Conclusion:**
Ligand A is the more promising drug candidate due to its superior ADME properties, lower toxicity risk, and comparable binding affinity.
1
2025-04-18 00:22:00,182 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (399.263 Da) is slightly higher, but still acceptable.
2. **TPSA:** Ligand A (34.89) is excellent, well below the 140 threshold for oral absorption. Ligand B (93.45) is higher, potentially impacting absorption, though not drastically.
3. **logP:** Ligand A (4.823) is a bit high, potentially leading to solubility issues or off-target effects. Ligand B (1.683) is within the optimal range.
4. **HBD:** Ligand A (0) is ideal. Ligand B (2) is acceptable.
5. **HBA:** Ligand A (3) is good. Ligand B (5) is also acceptable.
6. **QED:** Both ligands have good QED scores (A: 0.59, B: 0.832), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Both ligands have similar, moderately high DILI risk (A: 60.915, B: 63.513). This is a concern for both, but not a deciding factor.
8. **BBB:** Ligand A (82.047) has a better BBB percentile than Ligand B (46.452). While ADRB2 isn't exclusively a CNS target, some CNS exposure could be relevant, and this favors A.
9. **Caco-2:** Ligand A (-4.762) and Ligand B (-5.341) both have negative values, indicating poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand A (-4.242) is better than Ligand B (-2.249), indicating better aqueous solubility.
11. **hERG:** Ligand A (0.814) has a slightly higher hERG risk than Ligand B (0.032). This favors Ligand B.
12. **Cl_mic:** Ligand A (49.193) has a higher microsomal clearance than Ligand B (-4.202), indicating lower metabolic stability. This favors Ligand B.
13. **t1/2:** Ligand A (27.319) has a longer in vitro half-life than Ligand B (-4.606). This favors Ligand A.
14. **Pgp:** Ligand A (0.967) has a higher Pgp efflux liability than Ligand B (0.016). This favors Ligand B.
15. **Affinity:** Ligand B (-8.3 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.2 kcal/mol). This is a substantial advantage, exceeding the 1.5 kcal/mol threshold.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are crucial. Ligand B excels in affinity and Pgp efflux, and has a more favorable logP. While Ligand A has a better BBB score, the substantial affinity difference of Ligand B outweighs this. The TPSA of Ligand B is less ideal, but the strong binding could compensate.
**Conclusion:**
Despite some drawbacks in TPSA and solubility, Ligand B's significantly higher binding affinity and favorable Pgp efflux outweigh the advantages of Ligand A. The stronger binding is likely to translate to greater efficacy and potentially allow for a lower dose, mitigating some of the ADME concerns.
Output:
0
2025-04-18 00:22:00,182 - INFO - Batch 472 complete. Total preferences: 7552
2025-04-18 00:22:00,182 - INFO - Processing batch 473/512...
2025-04-18 00:22:50,310 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [372.893, 67.87, 2.619, 1, 4, 0.551, 31.989, 73.401, -5.056, -2.695, 0.449, 20.413, -4.866, 0.141, -6.4]
**Ligand B:** [372.799, 62.55, 2.947, 1, 3, 0.864, 35.983, 86.778, -4.547, -4.244, 0.506, 10.315, 22.318, 0.087, -6.6]
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (around 373 Da). No significant difference.
2. **TPSA:** Ligand A (67.87) is slightly higher than Ligand B (62.55). Both are acceptable for oral absorption, but Ligand B is preferable.
3. **logP:** Both are within the optimal range (2.6-2.9). Ligand B is slightly higher, which is generally fine for a GPCR target.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 4 HBA, Ligand B has 3. Ligand B is slightly better.
6. **QED:** Ligand B (0.864) has a significantly better QED score than Ligand A (0.551), indicating a more drug-like profile.
7. **DILI:** Both have acceptable DILI risk (Ligand A: 31.989, Ligand B: 35.983). Ligand B is slightly higher, but still within a good range.
8. **BBB:** Ligand B (86.778) has a much higher BBB penetration percentile than Ligand A (73.401). This is a *significant* advantage for a GPCR target, even if not specifically a CNS target, as it suggests better distribution.
9. **Caco-2:** Both have negative values, indicating poor permeability. Ligand A (-5.056) is worse than Ligand B (-4.547).
10. **Solubility:** Both have negative values, indicating poor solubility. Ligand B (-4.244) is slightly better than Ligand A (-2.695).
11. **hERG:** Both have low hERG risk (0.449 and 0.506). No significant difference.
12. **Cl_mic:** Ligand B (10.315) has a significantly lower microsomal clearance than Ligand A (20.413), indicating better metabolic stability.
13. **t1/2:** Ligand B (22.318) has a much longer in vitro half-life than Ligand A (-4.866). This is a significant advantage.
14. **Pgp:** Ligand B (0.087) has a lower P-gp efflux liability than Ligand A (0.141). This is beneficial for bioavailability.
15. **Affinity:** Ligand B (-6.6) has a slightly better binding affinity than Ligand A (-6.4). While the difference is small, it contributes to the overall preference.
**Overall Assessment:**
Ligand B consistently outperforms Ligand A across several crucial parameters, especially those prioritized for GPCRs: BBB penetration, metabolic stability (Cl_mic, t1/2), Pgp efflux, and QED. While both have issues with Caco-2 and solubility, Ligand B is better on both. The slightly better affinity further solidifies its advantage.
Output:
0
2025-04-18 00:22:50,310 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
We are targeting ADRB2, a GPCR, so the priorities are logP, Pgp, TPSA, BBB, and affinity.
* **Molecular Weight:** Both ligands are within the ideal range (344.4 vs 342.5 Da).
* **TPSA:** Ligand B (32.34) is significantly better than Ligand A (107.11). Lower TPSA generally correlates with better cell permeability, crucial for GPCR targeting.
* **logP:** Ligand B (4.089) is slightly higher than Ligand A (2.659), but both are acceptable. Ligand B is approaching the upper limit where solubility could become an issue.
* **H-Bond Donors/Acceptors:** Ligand A has 4 HBD and 4 HBA, while Ligand B has 1 HBD and 2 HBA. Ligand B is preferable here, as fewer hydrogen bonds can improve membrane permeability.
* **QED:** Both ligands have good QED scores (0.579 vs 0.79), indicating good drug-like properties. Ligand B is better.
* **DILI:** Ligand A has a significantly higher DILI risk (63.358) compared to Ligand B (16.053). This is a major concern for Ligand A.
* **BBB:** Ligand B (96.278) has excellent BBB penetration, while Ligand A (35.905) is poor. This is a significant advantage for Ligand B, even though ADRB2 isn't exclusively a CNS target, good CNS penetration can sometimes translate to better overall distribution.
* **Caco-2:** Both are negative, indicating poor permeability. However, the scale is not provided, so it is difficult to compare.
* **Solubility:** Both ligands have negative solubility values, indicating poor solubility.
* **hERG:** Both ligands have similar hERG inhibition liability (0.703 vs 0.787).
* **Cl_mic:** Both ligands have similar microsomal clearance (49.895 vs 51.331).
* **t1/2:** Ligand B has a much better in vitro half-life (6.813) compared to Ligand A (-52.62).
* **Pgp:** Ligand A (0.173) has slightly lower P-gp efflux liability than Ligand B (0.217), which is favorable.
* **Binding Affinity:** Both ligands have the same binding affinity (-5.8 kcal/mol).
**Overall Assessment:**
Ligand B is significantly better due to its superior TPSA, DILI score, BBB penetration, and in vitro half-life. While Ligand A has slightly lower P-gp efflux, the other advantages of Ligand B outweigh this minor benefit. The lower DILI risk and better BBB penetration of Ligand B are particularly important for a potentially chronically administered cardiovascular drug.
**Output:**
0
2025-04-18 00:22:50,310 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (350.5 and 366.5 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (59.39) is better than Ligand B (67.43). Both are below the 140 threshold for oral absorption, but lower TPSA is generally preferred for GPCRs.
3. **logP:** Both ligands have good logP values (3.418 and 3.273), falling within the optimal 1-3 range. No clear advantage.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBDs are generally better for permeability.
5. **HBA:** Both ligands have the same number of HBA (4).
6. **QED:** Ligand A (0.82) is slightly better than Ligand B (0.778), indicating a more drug-like profile.
7. **DILI:** Ligand A (19.465) has a significantly lower DILI risk than Ligand B (31.02). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (90.772) has a much higher BBB penetration percentile than Ligand B (56.301). While ADRB2 isn't strictly a CNS target, some CNS exposure can be relevant for off-target effects, and higher BBB is generally favorable.
9. **Caco-2:** Ligand A (-4.174) is better than Ligand B (-5.023). Higher Caco-2 permeability suggests better absorption.
10. **Solubility:** Both ligands have similar, poor aqueous solubility (-3.167 and -3.053). This is a potential concern for both, but not a deciding factor.
11. **hERG:** Both ligands have low hERG inhibition risk (0.424 and 0.269). No significant difference.
12. **Cl_mic:** Ligand B (54.687) has lower microsomal clearance than Ligand A (75.49), suggesting better metabolic stability. This is a positive for Ligand B.
13. **t1/2:** Ligand B (23.997) has a longer in vitro half-life than Ligand A (19.875). This is a positive for Ligand B.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.146 and 0.078). No significant difference.
15. **Binding Affinity:** Ligand B (-5.9 kcal/mol) has a slightly better binding affinity than Ligand A (-6.5 kcal/mol). This is a positive for Ligand B, but the difference is relatively small.
**Overall Assessment:**
Ligand A has several advantages: significantly lower DILI risk, better BBB penetration, better Caco-2 permeability, slightly better QED, and a slightly better binding affinity. Ligand B has better metabolic stability (lower Cl_mic) and a longer half-life. However, the DILI risk for Ligand B is concerning. Given the GPCR-specific priorities (logP, Pgp, TPSA, affinity), and the importance of minimizing toxicity, the lower DILI risk and favorable ADME properties of Ligand A outweigh the slightly better metabolic stability of Ligand B.
**Output:**
1
2025-04-18 00:22:50,310 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [347.459, 93.43, 1.607, 2, 4, 0.714, 19.193, 61.419, -4.797, -2.485, 0.181, 14.826, -16.933, 0.009, -6.0]
**Ligand B:** [377.941, 41.19, 4.429, 0, 5, 0.649, 19.542, 79.449, -4.943, -5.148, 0.856, 60.938, 45.529, 0.754, -6.4]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (347.459) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (93.43) is better than Ligand B (41.19) as it is closer to the 140 cutoff.
3. **logP:** Ligand A (1.607) is optimal, while Ligand B (4.429) is pushing the upper limit and could lead to solubility issues.
4. **HBD:** Ligand A (2) is better than Ligand B (0).
5. **HBA:** Ligand A (4) is better than Ligand B (5).
6. **QED:** Both are reasonably good (A: 0.714, B: 0.649), indicating drug-like properties.
7. **DILI:** Both have similar, acceptable DILI risk (A: 19.193, B: 19.542).
8. **BBB:** Ligand B (79.449) is significantly better at BBB penetration than Ligand A (61.419), which is a key consideration for GPCRs.
9. **Caco-2:** Both have negative values, which is unusual. Assuming these are logP values, both are similar.
10. **Solubility:** Ligand A (-2.485) is better than Ligand B (-5.148).
11. **hERG:** Both have low hERG risk (A: 0.181, B: 0.856).
12. **Cl_mic:** Ligand A (14.826) has a lower clearance, suggesting better metabolic stability than Ligand B (60.938).
13. **t1/2:** Ligand B (45.529) has a significantly longer half-life than Ligand A (-16.933).
14. **Pgp:** Both have very low Pgp efflux (A: 0.009, B: 0.754).
15. **Affinity:** Both have excellent binding affinity (A: -6.0, B: -6.4). Ligand B is slightly better.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, BBB, and affinity. Ligand B excels in BBB penetration and has slightly better affinity. However, its higher logP is a concern. Ligand A has better TPSA, logP, solubility, and metabolic stability. The affinity difference is small enough that the better ADME properties of Ligand A are more important.
**Conclusion:**
Considering the balance of properties, especially for a GPCR target, and the slightly better ADME profile of Ligand A, I would choose Ligand A as the more promising drug candidate.
**Output:**
1
2025-04-18 00:22:50,311 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (353.555 and 346.479 Da) fall comfortably within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (64.86) is significantly better than Ligand B (76.89). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (4.017 and 3.111), falling within the 1-3 range. Ligand B is slightly better, closer to the optimal range.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD is generally better for permeability.
5. **HBA:** Ligand A (6) is preferable to Ligand B (7). Lower HBA is generally better for permeability.
6. **QED:** Both ligands have good QED scores (0.688 and 0.765), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (22.8) has a much lower DILI risk than Ligand B (42.536). This is a significant advantage for Ligand A.
8. **BBB:** Ligand B (92.051) has a higher BBB penetration than Ligand A (71.268). While not a primary concern for a cardiovascular target, it's a slight positive for Ligand B.
9. **Caco-2:** Both ligands have similar, poor Caco-2 permeability (-4.926 and -4.685). This is a potential issue for both.
10. **Solubility:** Both ligands have similar, poor aqueous solubility (-3.639 and -3.878). This is a potential issue for both.
11. **hERG:** Ligand A (0.389) has a lower hERG inhibition liability than Ligand B (0.869). This is a significant advantage for Ligand A, reducing cardiotoxicity risk.
12. **Cl_mic:** Ligand A (33.838) has a lower microsomal clearance than Ligand B (66.008), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand B (48.304) has a longer in vitro half-life than Ligand A (14.504). This is a positive for Ligand B.
14. **Pgp:** Ligand A (0.077) has lower P-gp efflux liability than Ligand B (0.178). This is a slight advantage for Ligand A.
15. **Affinity:** Ligand A (-6.9) has a slightly better binding affinity than Ligand B (-5.5). While the difference is less than 1.5 kcal/mol, it's still a positive for Ligand A.
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A performs better on TPSA, Pgp, and affinity. Ligand B has a slightly better logP and BBB, but the differences aren't substantial. The significantly lower DILI and hERG risks, combined with better metabolic stability (lower Cl_mic) for Ligand A are crucial advantages.
**Conclusion:**
Considering the balance of properties and the priorities for a GPCR target, Ligand A is the more promising drug candidate. Its lower toxicity risks (DILI, hERG), better metabolic stability, and slightly improved affinity outweigh the minor advantages of Ligand B.
Output:
1
2025-04-18 00:22:50,311 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A: [343.431, 80.12, 1.548, 1, 5, 0.762, 47.538, 74.796, -4.861, -3.184, 0.102, 41.966, -13.388, 0.047, -8]**
**Ligand B: [365.455, 97.39, 0.775, 2, 5, 0.664, 47.15, 46.413, -4.951, -2.553, 0.151, 19.263, -43.522, 0.021, -5.3]**
Here's a breakdown, comparing each parameter and considering GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (343.431) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (80.12) is better than Ligand B (97.39). Both are under 140, but A is closer to the optimal for good absorption.
3. **logP:** Ligand A (1.548) is better than Ligand B (0.775). Both are within the acceptable range, but A is closer to the optimal 1-3. B is a bit low, potentially impacting membrane permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower is generally better for permeability.
5. **HBA:** Both have 5 HBA, which is acceptable.
6. **QED:** Ligand A (0.762) is better than Ligand B (0.664), indicating a more drug-like profile.
7. **DILI:** Both are similar and acceptable (around 47 percentile).
8. **BBB:** Ligand A (74.796) is significantly better than Ligand B (46.413). While not a CNS target, some BBB penetration can be useful for distribution.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-4.861) is slightly better than Ligand B (-4.951), but both are concerning.
10. **Solubility:** Ligand A (-3.184) is better than Ligand B (-2.553). Both are poor, but A is slightly less poor.
11. **hERG:** Both are very low risk (0.102 and 0.151).
12. **Cl_mic:** Ligand B (19.263) has significantly lower clearance than Ligand A (41.966), suggesting better metabolic stability. This is a major advantage for B.
13. **t1/2:** Ligand B (-43.522) has a much longer half-life than Ligand A (-13.388). This is a substantial advantage for B, potentially allowing for less frequent dosing.
14. **Pgp:** Both are very low efflux (0.047 and 0.021).
15. **Affinity:** Ligand A (-8) has a stronger binding affinity than Ligand B (-5.3). This is a 2.7 kcal/mol difference, which is a substantial advantage.
**Overall Assessment:**
Ligand A has a better profile for permeability (TPSA, logP, HBD) and significantly stronger binding affinity. However, Ligand B has superior metabolic stability (Cl_mic) and a much longer half-life. The poor Caco-2 and solubility for both are concerning, but can potentially be addressed with formulation strategies.
Given the GPCR target and the substantial difference in binding affinity (-8 vs -5.3 kcal/mol), I prioritize the stronger binding of Ligand A. While metabolic stability is important, a 2.7 kcal/mol difference in affinity is a significant advantage that can potentially overcome some ADME liabilities. The slightly better TPSA, logP, and QED of A also contribute to its favorability.
Output:
1
2025-04-18 00:22:50,311 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for the ADRB2, a cardiovascular GPCR. Therefore, prioritizing logP, TPSA, Pgp, and binding affinity is crucial.
* **Molecular Weight:** Both ligands (353.275 and 356.507 Da) are within the ideal range (200-500 Da).
* **TPSA:** Ligand A (66.63) is better than Ligand B (76.66). Lower TPSA generally favors oral absorption, important for a cardiovascular target.
* **logP:** Both ligands have good logP values (3.128 and 3.39), falling within the optimal 1-3 range. Ligand B is slightly higher, which could potentially lead to off-target effects, but is still acceptable.
* **H-Bond Donors/Acceptors:** Both have 2 HBD and 4 HBA, which are within acceptable limits.
* **QED:** Both ligands have similar, good QED scores (0.711 and 0.765).
* **DILI:** Ligand A has a significantly higher DILI risk (69.794) than Ligand B (29.042). This is a major concern.
* **BBB:** Ligand B (80.574) has a much higher BBB penetration score than Ligand A (57.619). While not a primary concern for a cardiovascular target, higher BBB is generally favorable.
* **Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.955 and -4.269), indicating poor permeability. This is a significant drawback for both.
* **Aqueous Solubility:** Both have very poor aqueous solubility (-4.09 and -4.1). This is a major issue for both compounds.
* **hERG:** Ligand A (0.772) has a slightly higher hERG risk than Ligand B (0.291), but both are relatively low.
* **Microsomal Clearance:** Ligand B (82.763) has a higher microsomal clearance than Ligand A (57.932), meaning it's less metabolically stable.
* **In vitro Half-Life:** Ligand A (-30.649) has a longer in vitro half-life than Ligand B (-21.31), which is desirable.
* **P-gp Efflux:** Ligand A (0.432) has lower P-gp efflux than Ligand B (0.03), which is preferable.
* **Binding Affinity:** Both ligands have excellent binding affinity (-6.7 and -6.0 kcal/mol). The difference of 0.7 kcal/mol is not large enough to outweigh other factors.
**Overall Assessment:**
Despite the poor Caco-2 and solubility for both, Ligand B is the better candidate. The significantly lower DILI risk and higher BBB penetration are major advantages. While Ligand A has better metabolic stability and P-gp efflux, the high DILI risk is a critical safety concern that outweighs these benefits.
**Output:**
0
2025-04-18 00:22:50,311 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [371.434, 91.76, 1.132, 3, 6, 0.533, 60.915, 52.889, -5.263, -2.161, 0.151, -24.082, 8.705, 0.027, -6.7]
**Ligand B:** [349.475, 65.79, 2.203, 1, 4, 0.855, 21.093, 63.94, -4.866, -1.347, 0.746, 0.305, 27.795, 0.194, -7.1]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, Affinity, and BBB):
1. **MW:** Both are within the ideal 200-500 Da range. Ligand B (349.475) is slightly preferred due to being a bit lower.
2. **TPSA:** Ligand A (91.76) is higher than Ligand B (65.79). Ligand B is significantly better here, being well under the 140 threshold for oral absorption and more favorable for GPCRs.
3. **logP:** Both are within the optimal 1-3 range. Ligand A (1.132) is slightly lower, which isn't a major concern, but Ligand B (2.203) is a little better positioned.
4. **HBD/HBA:** Ligand A has 3 HBD and 6 HBA, while Ligand B has 1 HBD and 4 HBA. Ligand B is preferable as it has fewer H-bond donors/acceptors, potentially improving permeability.
5. **QED:** Ligand B (0.855) has a substantially better QED score than Ligand A (0.533), indicating a more drug-like profile.
6. **DILI:** Ligand A (60.915) has a higher DILI risk than Ligand B (21.093). This is a significant advantage for Ligand B.
7. **BBB:** Ligand B (63.94) has a better BBB percentile than Ligand A (52.889). While not exceptionally high, it's a positive for a GPCR target.
8. **Caco-2:** Ligand A (-5.263) is worse than Ligand B (-4.866). Lower values are less desirable.
9. **Solubility:** Ligand A (-2.161) is worse than Ligand B (-1.347). Both are negative, indicating poor solubility, but Ligand B is slightly better.
10. **hERG:** Ligand A (0.151) has a slightly lower hERG risk than Ligand B (0.746), which is a small advantage.
11. **Cl_mic:** Ligand A (-24.082) has a much lower (better) microsomal clearance than Ligand B (0.305), indicating higher metabolic stability. This is a significant advantage for Ligand A.
12. **t1/2:** Ligand B (27.795) has a significantly longer in vitro half-life than Ligand A (8.705). This is a strong advantage for Ligand B.
13. **Pgp:** Ligand A (0.027) has a much lower Pgp efflux liability than Ligand B (0.194). This is a significant advantage for Ligand A.
14. **Affinity:** Ligand B (-7.1) has a slightly better binding affinity than Ligand A (-6.7). This is a good advantage for Ligand B.
**Overall Assessment:**
Ligand B has a better overall profile. While Ligand A has advantages in metabolic stability (Cl_mic) and Pgp efflux, Ligand B excels in crucial areas for a GPCR drug candidate: TPSA, QED, DILI risk, BBB penetration, and half-life. The slightly better affinity of Ligand B further strengthens its position. The solubility and Caco-2 values are not ideal for either, but Ligand B is slightly better. The lower DILI risk is a major factor in favor of Ligand B.
Therefore, I would choose Ligand B.
0
2025-04-18 00:22:50,311 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands (354.491 and 351.451 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (67.87) is significantly better than Ligand B (99.61). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally correlates with better permeability. Ligand B's TPSA is getting towards the upper limit for good oral absorption.
3. **logP:** Both ligands have good logP values (1.973 and 1.622), falling within the 1-3 optimal range. Ligand B is slightly lower, which could be a minor drawback.
4. **HBD:** Ligand A (1) is preferred over Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is better than Ligand B (7). Similar to HBD, lower HBA is generally preferred.
6. **QED:** Ligand A (0.724) is slightly better than Ligand B (0.612), indicating a more drug-like profile.
7. **DILI:** Ligand A (27.104) has a significantly lower DILI risk than Ligand B (39.473). This is a crucial advantage.
8. **BBB:** Ligand B (72.547) has a slightly higher BBB penetration than Ligand A (65.529). However, as ADRB2 is a cardiovascular target, BBB penetration is not a primary concern.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.713 and -4.982). This is unusual and suggests poor permeability, but the scale is not specified, so it's difficult to interpret.
10. **Solubility:** Ligand A (-1.303) is better than Ligand B (-2.685). Higher solubility is generally preferred.
11. **hERG:** Ligand A (0.339) has a lower hERG risk than Ligand B (0.806). This is a significant advantage for cardiovascular safety.
12. **Cl_mic:** Ligand A (21.937) has a lower microsomal clearance than Ligand B (36.855), indicating better metabolic stability.
13. **t1/2:** Ligand A (0.898) has a shorter in vitro half-life than Ligand B (2.091). This is a drawback for Ligand A, but not overwhelming.
14. **Pgp:** Ligand A (0.043) has a lower Pgp efflux liability than Ligand B (0.069). This is a slight advantage for bioavailability.
15. **Binding Affinity:** Ligand A (-5.7 kcal/mol) has a stronger binding affinity than Ligand B (-4.4 kcal/mol). This is a substantial difference (1.3 kcal/mol) and a major driver for preference.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A performs better on all of these except BBB, which is not critical for a cardiovascular target.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical ADME-Tox properties (DILI, hERG, Cl_mic, solubility) and has a significantly better binding affinity. While Ligand B has slightly better BBB penetration and in vitro half-life, these are less important for a cardiovascular target. The combination of lower risk profiles and stronger binding makes Ligand A the more promising candidate.
Output:
1
2025-04-18 00:22:50,312 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for the ADRB2, a cardiovascular GPCR. Therefore, priorities are logP, TPSA, Pgp efflux, affinity, and to a lesser extent, BBB.
* **Molecular Weight:** Both ligands are within the ideal range (342-350 Da).
* **TPSA:** Ligand A (85.89) is better than Ligand B (95.73). Lower TPSA generally favors better absorption.
* **logP:** Ligand A (1.889) is slightly better than Ligand B (0.874). Both are within the acceptable range, but Ligand A is closer to the optimal 1-3 range. Ligand B is a little low, potentially impacting permeability.
* **H-Bond Donors/Acceptors:** Ligand A (HBD=2, HBA=5) and Ligand B (HBD=3, HBA=5) are both acceptable.
* **QED:** Both ligands have good QED scores (A: 0.664, B: 0.751), indicating good drug-like properties.
* **DILI:** Ligand B (47.421) has a significantly lower DILI risk than Ligand A (61.264). This is a substantial advantage for Ligand B.
* **BBB:** Ligand A (65.839) has a better BBB percentile than Ligand B (41.14). While not a primary concern for a cardiovascular target, it's a slight positive for A.
* **Caco-2 Permeability:** Ligand A (-4.703) has better Caco-2 permeability than Ligand B (-5.23).
* **Aqueous Solubility:** Ligand A (-2.251) has better aqueous solubility than Ligand B (-1.983).
* **hERG:** Both ligands have low hERG risk (A: 0.192, B: 0.314).
* **Microsomal Clearance:** Ligand B (-24.957) has significantly lower microsomal clearance than Ligand A (28.308), suggesting better metabolic stability. This is a major advantage for Ligand B.
* **In vitro Half-Life:** Ligand B (18.153) has a much longer in vitro half-life than Ligand A (2.973). This is a significant advantage for Ligand B.
* **P-gp Efflux:** Both ligands have low P-gp efflux liability (A: 0.084, B: 0.022), with B being slightly better.
* **Binding Affinity:** Ligand B (-8.3 kcal/mol) has a substantially better binding affinity than Ligand A (-5.8 kcal/mol). This difference of 2.5 kcal/mol is a very strong advantage, and often outweighs minor ADME concerns.
**Overall Assessment:**
While Ligand A has slightly better TPSA, logP, Caco-2 permeability, solubility and BBB, Ligand B has a much stronger binding affinity, significantly lower DILI risk, lower microsomal clearance, and a longer half-life. The binding affinity difference is particularly compelling for a GPCR target. The superior ADME properties of Ligand B (lower DILI, better metabolic stability, longer half-life) further solidify its position as the more promising candidate.
**Output:**
0
2025-04-18 00:22:50,312 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (353.463 and 346.431 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (84.32) is slightly higher than Ligand B (67.67). Both are below the 140 A^2 threshold for good oral absorption, but Ligand B is preferable due to the lower TPSA.
**3. logP:** Ligand A (-0.479) is a bit low, potentially hindering membrane permeability. Ligand B (1.283) is within the optimal 1-3 range. This is a clear advantage for Ligand B.
**4. H-Bond Donors:** Ligand A (2) is acceptable, while Ligand B (0) is even better, potentially improving permeability.
**5. H-Bond Acceptors:** Both ligands have 5 HBA, which is within the acceptable range.
**6. QED:** Both ligands have good QED scores (0.674 and 0.806), indicating good drug-like properties. Ligand B is slightly better.
**7. DILI Risk:** Ligand A (8.104) has a very low DILI risk, significantly better than Ligand B (34.82). This is a major advantage for Ligand A.
**8. BBB Penetration:** Ligand B (90.074) shows excellent BBB penetration, while Ligand A (53.432) is moderate. While ADRB2 is a cardiovascular target, some CNS off-target effects are possible, and good CNS penetration could be a concern. However, for a cardiovascular target, this is less critical than other factors.
**9. Caco-2 Permeability:** Both ligands have similar, very negative Caco-2 permeability values (-4.793 and -4.661). This suggests poor permeability, which is concerning.
**10. Aqueous Solubility:** Both ligands have very poor aqueous solubility (-0.634 and -1.61). This is a significant drawback for both.
**11. hERG Inhibition:** Ligand A (0.108) has a very low hERG inhibition risk, much better than Ligand B (0.568). This is a crucial advantage for Ligand A, minimizing cardiotoxicity risk.
**12. Microsomal Clearance:** Ligand A (9.241) has lower microsomal clearance than Ligand B (46.962), suggesting better metabolic stability.
**13. In vitro Half-Life:** Ligand A (16.214) has a longer half-life than Ligand B (-10.366), which is desirable.
**14. P-gp Efflux:** Ligand A (0.004) has very low P-gp efflux, while Ligand B (0.178) has slightly higher efflux.
**15. Binding Affinity:** Ligand B (-6.1) has a slightly better binding affinity than Ligand A (-4.6). This is a 1.5 kcal/mol difference, which is significant.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand B has advantages in logP, affinity, and TPSA. However, Ligand A has significantly better safety profiles (DILI and hERG) and metabolic stability (Cl_mic, t1/2). The poor solubility and Caco-2 permeability are concerning for both, but the safety profile is paramount, especially for a cardiovascular target where off-target effects can be detrimental. The slightly better affinity of Ligand B is outweighed by the superior safety and metabolic properties of Ligand A.
Output:
1
2025-04-18 00:22:50,312 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [336.435, 41.57, 3.705, 1, 3, 0.925, 54.789, 91.586, -4.692, -4.452, 0.919, 92.773, 5.171, 0.715, -6.1]
**Ligand B:** [346.387, 104.54, 0.221, 2, 5, 0.655, 38.969, 48.352, -4.787, -1.699, 0.028, 27.336, -43.042, 0.006, -7.4]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, Affinity, and BBB):
1. **MW:** Both are within the ideal range (200-500 Da). A is 336.435, B is 346.387 - very similar.
2. **TPSA:** A (41.57) is excellent, well below the 140 threshold and favorable for absorption. B (104.54) is higher, but still potentially acceptable.
3. **logP:** A (3.705) is optimal. B (0.221) is *very* low, which is a significant concern for membrane permeability and bioavailability.
4. **HBD/HBA:** A (1 HBD, 3 HBA) is good. B (2 HBD, 5 HBA) is also acceptable, but slightly higher.
5. **QED:** A (0.925) is excellent, indicating high drug-likeness. B (0.655) is still reasonable, but lower.
6. **DILI:** A (54.789) is good, below the 60% threshold. B (38.969) is even better, indicating lower liver injury risk.
7. **BBB:** A (91.586) is excellent, suggesting good potential for CNS penetration (though ADRB2 isn't *primarily* a CNS target, some CNS off-target effects are possible). B (48.352) is much lower.
8. **Caco-2:** Both are negative, indicating good permeability.
9. **Solubility:** Both are negative, indicating good solubility.
10. **hERG:** A (0.919) is good, low risk. B (0.028) is *extremely* low, indicating very low hERG inhibition risk.
11. **Cl_mic:** A (92.773) is high, suggesting rapid metabolism. B (27.336) is much lower, indicating better metabolic stability.
12. **t1/2:** A (5.171) is reasonable. B (-43.042) is very negative, indicating a very short half-life.
13. **Pgp:** A (0.715) is acceptable. B (0.006) is excellent, suggesting minimal P-gp efflux.
14. **Affinity:** B (-7.4) is significantly better than A (-6.1) - a difference of 1.3 kcal/mol.
**Decision:**
While Ligand B has a superior binding affinity and better metabolic stability and lower hERG risk, its extremely low logP is a major drawback. This will severely impact its ability to cross cell membranes and achieve adequate bioavailability. Ligand A, despite having a higher metabolic clearance, has a much more favorable logP, good BBB penetration, and excellent drug-likeness. For a GPCR target, achieving sufficient concentration at the receptor is critical, and logP is a key determinant of that. The 1.3 kcal/mol affinity difference is not enough to overcome the likely bioavailability issues of Ligand B.
Therefore, I prefer Ligand A.
Output:
1
2025-04-18 00:22:50,312 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Step-by-step comparison:**
1. **MW:** Both ligands (348.399 and 357.455 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (93.73 and 94.22) are below the 140 A^2 threshold for good oral absorption, but slightly above the 90 A^2 ideal for CNS targets (less relevant for ADRB2, a cardiovascular target). Very similar.
3. **logP:** Ligand A (2.204) is optimal (1-3). Ligand B (-2.04) is significantly lower, potentially hindering permeability. This is a notable disadvantage for Ligand B.
4. **HBD:** Both ligands have 2 HBD, which is within the acceptable limit of <=5.
5. **HBA:** Both ligands have 6 HBA, also within the acceptable limit of <=10.
6. **QED:** Ligand A (0.605) has a better QED score than Ligand B (0.494), indicating a more drug-like profile.
7. **DILI:** Ligand A (65.723) has a higher DILI risk than Ligand B (8.181). This is a significant concern for Ligand A.
8. **BBB:** Ligand A (77.2) has a higher BBB penetration percentile than Ligand B (32.532). While ADRB2 is not a CNS target, some off-target CNS effects are possible, and higher BBB penetration could contribute to this.
9. **Caco-2:** Ligand A (-4.399) has a lower Caco-2 permeability than Ligand B (-5.474). Both are negative, which is unusual, but Ligand B is slightly worse.
10. **Solubility:** Ligand A (-3.753) has better solubility than Ligand B (-0.137). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.409) has a lower hERG inhibition liability than Ligand B (0.096), which is preferable.
12. **Cl_mic:** Ligand A (64.562) has a higher microsomal clearance than Ligand B (6.274), meaning it's less metabolically stable. This is a disadvantage for Ligand A.
13. **t1/2:** Ligand B (-38.849) has a much longer in vitro half-life than Ligand A (-5.012). This is a major advantage for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.064) has lower P-gp efflux liability than Ligand B (0.0). Lower P-gp is generally better.
15. **Affinity:** Ligand A (-7.4 kcal/mol) has a significantly stronger binding affinity than Ligand B (-5.9 kcal/mol). This is a substantial advantage for Ligand A, potentially outweighing some of its ADME drawbacks.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand A has a better logP and Pgp, while Ligand B has a better TPSA. However, the *significant* difference in binding affinity (1.5 kcal/mol) in favor of Ligand A is the most important factor. The longer half-life of Ligand B is also very attractive.
**Overall Assessment:**
While Ligand A has a higher DILI risk and lower metabolic stability, its substantially stronger binding affinity is a major advantage. The better solubility and lower hERG risk are also positive. Ligand B's lower logP is a significant concern for permeability, despite its better half-life and lower DILI. Given the importance of potency for GPCRs, and the magnitude of the affinity difference, I believe Ligand A is the more promising candidate.
Output:
1
2025-04-18 00:22:50,312 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (378.313 and 363.527 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (60.85) is better than Ligand B (71.09). Both are under the 140 threshold for oral absorption, but lower TPSA is generally preferred for GPCRs, aiding permeability.
3. **logP:** Ligand A (2.092) is within the optimal range (1-3). Ligand B (3.301) is slightly higher, but still acceptable.
4. **HBD:** Ligand A (1) is better than Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (3) is better than Ligand B (4). Similar to HBD, lower HBA is preferred.
6. **QED:** Both ligands (0.763 and 0.696) are above the 0.5 threshold, indicating good drug-likeness. Ligand A is slightly better.
7. **DILI:** Both ligands have low DILI risk (36.526 and 34.393 percentile), which is excellent. No significant difference.
8. **BBB:** Ligand A (73.556) is significantly better than Ligand B (53.897). While ADRB2 isn't exclusively a CNS target, some CNS penetration can be beneficial, and a higher BBB percentile is generally desirable.
9. **Caco-2:** Ligand A (-4.636) is better than Ligand B (-5.093). Lower values are less desirable, but the difference is minimal.
10. **Solubility:** Ligand A (-1.574) is better than Ligand B (-3.392). Better solubility is always preferred for bioavailability.
11. **hERG:** Both ligands have very low hERG risk (0.567 and 0.411), which is excellent. No significant difference.
12. **Cl_mic:** Ligand A (4.322) is significantly better than Ligand B (51.874). Lower clearance indicates better metabolic stability, a crucial factor for drug duration.
13. **t1/2:** Ligand A (5.034) is better than Ligand B (8.105). Longer half-life is generally preferred.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.105 and 0.341). No significant difference.
15. **Binding Affinity:** Ligand B (-7.1) is significantly better than Ligand A (-5.8). This is a 1.3 kcal/mol difference, which is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand B has a significantly stronger binding affinity (-7.1 kcal/mol vs -5.8 kcal/mol). While Ligand A has better ADME properties across several parameters (TPSA, logP, HBD, HBA, BBB, Solubility, Cl_mic, t1/2), the substantial affinity advantage of Ligand B is a major deciding factor, especially for a GPCR target. The difference in affinity is large enough to potentially compensate for slightly less favorable ADME properties.
Output:
0
2025-04-18 00:22:50,313 - INFO - Here's my reasoning and the final output:
**Reasoning:**
We are evaluating two ligands for the ADRB2, a cardiovascular GPCR. Therefore, key properties to prioritize are binding affinity, logP, TPSA, Pgp efflux, and to a lesser extent, BBB (though less critical for a cardiovascular target).
Let's compare the ligands property by property:
1. **MW:** Both ligands (344.411 and 348.403 Da) are within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (73.99) is significantly better than Ligand B (138.22). A TPSA under 140 is good for oral absorption, and A is comfortably within that range, while B is approaching the upper limit.
3. **logP:** Both ligands have acceptable logP values (1.425 and 0.986), falling within the 1-3 range.
4. **HBD/HBA:** Ligand A (1 HBD, 4 HBA) is preferable to Ligand B (3 HBD, 5 HBA) as lower counts generally improve permeability.
5. **QED:** Ligand A (0.839) has a substantially better QED score than Ligand B (0.611), indicating a more drug-like profile.
6. **DILI:** Ligand A (26.173) has a significantly lower DILI risk than Ligand B (44.126). This is a major advantage for A.
7. **BBB:** Both have relatively low BBB penetration (46.336 and 44.668), which is not a major concern for a cardiovascular target.
8. **Caco-2:** Ligand A (-4.634) is slightly better than Ligand B (-5.365), indicating better intestinal absorption.
9. **Solubility:** Ligand A (-1.824) is better than Ligand B (-3.32), indicating better aqueous solubility.
10. **hERG:** Both ligands have low hERG inhibition risk (0.213 and 0.319).
11. **Cl_mic:** Ligand A (-13.67) has much better metabolic stability (lower clearance) than Ligand B (26.991).
12. **t1/2:** Ligand B (37.997) has a longer half-life than Ligand A (3.89), which is a positive.
13. **Pgp:** Both ligands have very low Pgp efflux liability (0.163 and 0.076).
14. **Binding Affinity:** Both ligands have very similar and excellent binding affinities (-6.6 and -6.2 kcal/mol). The difference is not substantial enough to override other factors.
**Overall Assessment:**
Ligand A is significantly better across multiple critical ADME properties (TPSA, QED, DILI, Cl_mic, Solubility) and has comparable affinity to Ligand B. While Ligand B has a longer half-life, the superior overall profile of Ligand A makes it the more promising drug candidate.
**Output:**
1
2025-04-18 00:22:50,313 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [358.454, 98.66, 1.049, 4, 4, 0.547, 18.147, 66.111, -5.027, -2.213, 0.217, 29.697, -24.269, 0.014, -5.8]
**Ligand B:** [340.471, 51.02, 3.735, 0, 4, 0.833, 31.912, 74.564, -4.737, -4.14, 0.358, 77.589, -10.769, 0.331, -8.2]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, Affinity, and BBB):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (340.471) is slightly lower, which is generally favorable.
2. **TPSA:** Ligand A (98.66) is higher than Ligand B (51.02). For a cardiovascular GPCR, TPSA isn't *as* critical as for a CNS target, but lower is still preferred for permeability. Ligand B is significantly better here.
3. **logP:** Ligand A (1.049) is within the optimal range, but on the lower side. Ligand B (3.735) is also acceptable, but approaching the upper limit.
4. **HBD/HBA:** Ligand A has 4 HBD and 4 HBA. Ligand B has 0 HBD and 4 HBA. Ligand B is preferable here as fewer HBDs generally improve permeability.
5. **QED:** Ligand B (0.833) has a better QED score than Ligand A (0.547), indicating a more drug-like profile.
6. **DILI:** Ligand A (18.147) has a much lower DILI risk than Ligand B (31.912), which is a significant advantage.
7. **BBB:** Ligand B (74.564) has a better BBB penetration score than Ligand A (66.111). While not a CNS target, some level of BBB penetration can influence off-target effects.
8. **Caco-2:** Ligand A (-5.027) and Ligand B (-4.737) are both negative, which is unusual and suggests poor permeability.
9. **Solubility:** Ligand A (-2.213) is better than Ligand B (-4.14).
10. **hERG:** Both are very low, indicating minimal hERG inhibition risk.
11. **Cl_mic:** Ligand A (29.697) has a lower microsomal clearance than Ligand B (77.589), suggesting better metabolic stability.
12. **t1/2:** Ligand A (-24.269) has a more negative in vitro half-life, which is better.
13. **Pgp:** Ligand A (0.014) has much lower P-gp efflux liability than Ligand B (0.331), which is beneficial for bioavailability.
14. **Affinity:** Ligand B (-8.2) has a significantly stronger binding affinity than Ligand A (-5.8) - a difference of 2.4 kcal/mol. This is a substantial advantage and can often outweigh other drawbacks.
**Overall Assessment:**
Ligand B has a significantly better binding affinity and a better BBB score. It also has a better QED and TPSA. However, Ligand A has a much lower DILI risk, better metabolic stability (lower Cl_mic), longer half-life, and lower P-gp efflux. The difference in affinity is substantial, and for a GPCR, potency is paramount. While the DILI risk for Ligand A is preferable, this can be addressed through further optimization. The improved ADME properties of Ligand A are valuable, but the large affinity difference of Ligand B is more important.
Therefore, I would choose Ligand B.
0
2025-04-18 00:22:50,313 - INFO - Batch 473 complete. Total preferences: 7568
2025-04-18 00:22:50,313 - INFO - Processing batch 474/512...
2025-04-18 00:23:39,956 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (343.43 and 351.53 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (78.51) is higher than Ligand B (38.77). For a GPCR, lower TPSA is generally preferred for better BBB penetration and overall drug-like properties. Ligand B is significantly better here.
3. **logP:** Ligand A (2.308) is within the optimal 1-3 range. Ligand B (4.397) is higher, potentially leading to solubility issues and off-target interactions. Ligand A is better.
4. **HBD:** Ligand A (2) is reasonable, while Ligand B (0) is also acceptable. No strong preference.
5. **HBA:** Both ligands (3) are within the acceptable limit of 10. No significant difference.
6. **QED:** Ligand A (0.805) has a better QED score than Ligand B (0.682), indicating a more drug-like profile.
7. **DILI:** Ligand B (17.642) has a much lower DILI risk than Ligand A (61.303). This is a significant advantage for Ligand B.
8. **BBB:** Ligand B (91.392) has a significantly higher BBB penetration percentile than Ligand A (68.67). This is a key consideration for a GPCR target, even a cardiovascular one, as some CNS off-target effects are possible.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.416 and -4.23). This is unusual and suggests poor permeability. However, the values are very close.
10. **Solubility:** Ligand A (-4.387) is slightly better than Ligand B (-4.843), but both are poor.
11. **hERG:** Ligand A (0.256) has a lower hERG inhibition liability than Ligand B (0.828), which is preferable.
12. **Cl_mic:** Ligand A (23.304) has a much lower microsomal clearance than Ligand B (128.637), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (23.606) has a longer in vitro half-life than Ligand B (0.154). This is a major advantage for Ligand A.
14. **Pgp:** Ligand B (0.806) has a higher Pgp efflux liability than Ligand A (0.042), which is less desirable.
15. **Binding Affinity:** Ligand B (-6.7) has a slightly stronger binding affinity than Ligand A (-6.5). While a difference of 0.2 kcal/mol isn't huge, it's a positive for Ligand B.
**Overall Assessment:**
Ligand B excels in BBB penetration and DILI risk, and has a slightly better binding affinity. However, it suffers from high Pgp efflux, high microsomal clearance, short half-life, and a higher logP. Ligand A has a better QED, lower DILI, lower Pgp efflux, better metabolic stability (lower Cl_mic and longer t1/2), and a better hERG profile. The slightly weaker binding affinity of Ligand A is likely outweighed by its superior ADME properties, especially the metabolic stability and half-life. For a GPCR like ADRB2, a balance of potency and good pharmacokinetic properties is crucial.
Therefore, I believe Ligand A is the more viable drug candidate.
Output:
1
2025-04-18 00:23:39,957 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (366.53 and 367.47 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (67.43) is significantly better than Ligand B (98.66). For a GPCR, keeping TPSA low is beneficial for permeability, and Ligand A is well below the 140 threshold. Ligand B is approaching a level that could hinder absorption.
3. **logP:** Ligand A (2.754) is slightly higher than Ligand B (1.724), both are within the optimal 1-3 range. Ligand A is preferable, but the difference isn't massive.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable.
5. **HBA:** Ligand A (4) is better than Ligand B (6), keeping within the ideal range.
6. **QED:** Both ligands (0.626 and 0.632) have good drug-likeness scores, exceeding the 0.5 threshold.
7. **DILI:** Ligand A (20.67%) has a much lower DILI risk than Ligand B (37.65%). This is a significant advantage for Ligand A.
8. **BBB:** Ligand B (83.172%) has a better BBB penetration score than Ligand A (68.399%). However, for ADRB2, which is primarily a cardiovascular target, high BBB penetration isn't as crucial as it would be for a CNS target.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. Ligand A (-5.035) is slightly better than Ligand B (-5.216) but both are concerning.
10. **Solubility:** Both ligands have negative solubility values, indicating poor solubility. Ligand B (-2.52) is slightly better than Ligand A (-2.811), but both are concerning.
11. **hERG:** Ligand A (0.472) has a lower hERG inhibition liability than Ligand B (0.165), which is preferable.
12. **Cl_mic:** Ligand B (60.791) has slightly lower microsomal clearance than Ligand A (57.973). Lower is better for metabolic stability, but the difference is small.
13. **t1/2:** Ligand A (21.755 hours) has a much longer in vitro half-life than Ligand B (0.867 hours). This is a major advantage for Ligand A, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.178) has a lower P-gp efflux liability than Ligand B (0.208). Lower is better.
15. **Binding Affinity:** Ligand A (-7.8 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.0 kcal/mol). This is a substantial advantage, as a difference of >1.5 kcal/mol can often outweigh other drawbacks.
**Overall Assessment:**
Ligand A is the superior candidate. While Ligand B has slightly better BBB penetration and microsomal clearance, Ligand A excels in critical areas: significantly stronger binding affinity, lower DILI risk, longer half-life, and a more favorable TPSA. The poor Caco-2 and solubility of both are concerning and would need to be addressed in further optimization, but the potency and safety profile of Ligand A make it a better starting point. The cardiovascular focus of ADRB2 diminishes the importance of BBB penetration.
Output:
1
2025-04-18 00:23:39,957 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (389.279 Da and 378.567 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (67.87) is slightly higher than Ligand B (58.12). Both are below the 140 A^2 threshold for good oral absorption, but Ligand B is preferable due to being closer to the 90 A^2 threshold which is desirable for GPCRs.
**3. logP:** Both ligands have good logP values (3.499 and 3.299) within the optimal 1-3 range. No clear advantage.
**4. H-Bond Donors:** Both have 1 HBD, which is acceptable.
**5. H-Bond Acceptors:** Ligand A has 4 HBAs, while Ligand B has 6. Both are below the 10 threshold, but Ligand A is slightly better.
**6. QED:** Both ligands have similar QED values (0.691 and 0.605), indicating good drug-likeness.
**7. DILI:** Both ligands have similar DILI risk (62.544 and 62.35), both are acceptable but not ideal.
**8. BBB:** Ligand B (79.566) shows better BBB penetration than Ligand A (71.307). While not a primary concern for a cardiovascular target, it's a slight advantage.
**9. Caco-2 Permeability:** Ligand A (-4.778) has worse Caco-2 permeability than Ligand B (-5.212). This suggests Ligand B may have better intestinal absorption.
**10. Aqueous Solubility:** Ligand A (-3.776) has slightly better aqueous solubility than Ligand B (-4.318).
**11. hERG Inhibition:** Both ligands have similar hERG inhibition liability (0.655 and 0.652), indicating a low risk of cardiotoxicity.
**12. Microsomal Clearance:** Ligand B (92.874) has significantly higher microsomal clearance than Ligand A (28.339). This means Ligand A is more metabolically stable.
**13. In vitro Half-Life:** Ligand A (14.755) has a much better in vitro half-life than Ligand B (-1.491). This is a significant advantage.
**14. P-gp Efflux:** Both ligands have similar P-gp efflux liability (0.397 and 0.451).
**15. Binding Affinity:** Ligand A (-7.4) has a stronger binding affinity than Ligand B (-5.7). This is a substantial difference (1.7 kcal/mol), and a key driver in my decision.
**Overall Assessment:**
While Ligand B has slightly better BBB penetration and Caco-2 permeability, Ligand A possesses a significantly stronger binding affinity and superior metabolic stability (lower Cl_mic, longer t1/2). For a GPCR target like ADRB2, strong binding affinity is paramount. The improved metabolic stability of Ligand A is also a critical advantage, potentially leading to a longer duration of action and less frequent dosing. The slight difference in TPSA is also in favor of Ligand B, but is outweighed by the binding affinity and metabolic stability of Ligand A.
Output:
1
2025-04-18 00:23:39,957 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.415 and 351.466 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (79.9) is higher than Ligand B (58.36). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is generally preferred for absorption. Ligand B has a slight edge.
3. **logP:** Both ligands have good logP values (2.394 & 2.945), falling within the optimal 1-3 range. Ligand B is slightly higher, which could potentially lead to slightly better membrane permeability, but also a small increase in off-target interactions.
4. **HBD:** Ligand A (2) and Ligand B (1) both have acceptable HBD counts. Ligand B is slightly better.
5. **HBA:** Ligand A (5) and Ligand B (4) both have acceptable HBA counts. Ligand B is slightly better.
6. **QED:** Both ligands have good QED scores (0.557 and 0.696), indicating good drug-like properties. Ligand B is better.
7. **DILI:** Ligand A (54.285) has a higher DILI risk than Ligand B (19.969). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (89.453) has a higher BBB penetration percentile than Ligand B (78.79). While ADRB2 is not a CNS target, some off-target CNS effects are possible, and higher BBB is generally not detrimental.
9. **Caco-2:** Ligand A (-5.146) has a lower Caco-2 permeability than Ligand B (-4.583). Lower values indicate poorer permeability, so Ligand B is better.
10. **Solubility:** Ligand A (-2.942) has slightly worse solubility than Ligand B (-2.578). Solubility is important for bioavailability, so Ligand B is better.
11. **hERG:** Both ligands have similar, low hERG inhibition liabilities (0.703 and 0.718). No significant difference.
12. **Cl_mic:** Ligand A (26.987) has a lower microsomal clearance than Ligand B (51.681), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (22.463) has a longer in vitro half-life than Ligand B (-6.967). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.131) has a lower P-gp efflux liability than Ligand B (0.344). Lower efflux is better for bioavailability. This is a significant advantage for Ligand A.
15. **Binding Affinity:** Ligand B (-7.3) has a significantly stronger binding affinity than Ligand A (-6.1). This is a 1.2 kcal/mol difference, which is substantial and can outweigh many ADME drawbacks.
**Overall Assessment:**
Ligand B has a superior binding affinity, better ADME properties (lower DILI, better Caco-2, better solubility, better QED, and lower HBD/HBA), making it a more promising candidate. While Ligand A has better metabolic stability (lower Cl_mic, longer t1/2) and lower Pgp efflux, the substantial binding affinity advantage of Ligand B is more critical for a GPCR target like ADRB2.
Output:
0
2025-04-18 00:23:39,958 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (343.431 Da) is within the ideal range (200-500 Da). Ligand B (370.515 Da) is also within range. No clear advantage here.
2. **TPSA:** Ligand A (101.88) is slightly higher than ideal (<140), but still reasonable. Ligand B (74.76) is excellent, well below 140. This favors Ligand B.
3. **logP:** Both Ligand A (1.513) and Ligand B (1.761) are within the optimal 1-3 range. No significant difference.
4. **HBD:** Ligand A (2) is good. Ligand B (0) is also good, potentially improving permeability. Slight edge to Ligand B.
5. **HBA:** Both Ligand A (4) and Ligand B (4) are within the acceptable limit of 10. No difference.
6. **QED:** Ligand A (0.699) is better than Ligand B (0.482), indicating a more drug-like profile. This favors Ligand A.
7. **DILI:** Ligand A (14.502) has a significantly lower DILI risk than Ligand B (35.13). This is a substantial advantage for Ligand A.
8. **BBB:** Ligand B (71.733) shows better BBB penetration than Ligand A (46.064). While ADRB2 isn't exclusively a CNS target, some cardiovascular effects are mediated through CNS pathways. This favors Ligand B.
9. **Caco-2:** Ligand A (-5.572) and Ligand B (-4.825) are both negative, which is unusual and suggests poor permeability. The values are similar, so no clear advantage.
10. **Solubility:** Ligand A (-1.183) and Ligand B (-1.744) are both poor. No clear advantage.
11. **hERG:** Both Ligand A (0.491) and Ligand B (0.311) have low hERG inhibition liability, which is good. Ligand B is slightly better.
12. **Cl_mic:** Ligand A (-23.347) has a much lower (better) microsomal clearance than Ligand B (15.336), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (-17.205) has a longer in vitro half-life than Ligand B (13.969), again favoring metabolic stability. This favors Ligand A.
14. **Pgp:** Both Ligand A (0.035) and Ligand B (0.221) have low P-gp efflux, which is good. Ligand A is slightly better.
15. **Binding Affinity:** Ligand A (-7.4) has a slightly better binding affinity than Ligand B (-5.6). While the difference is not huge, it is enough to consider.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Ligand B has better TPSA and BBB penetration. Ligand A has better affinity, QED, DILI, Cl_mic, t1/2, and Pgp. The superior metabolic stability (Cl_mic and t1/2) and lower DILI risk of Ligand A are crucial for a viable drug candidate. The slightly better affinity also contributes.
**Conclusion:**
Considering the balance of properties, especially the crucial factors of metabolic stability (Cl_mic, t1/2), safety (DILI), and binding affinity, Ligand A is the more promising candidate.
Output:
1
2025-04-18 00:23:39,958 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (343.431 & 346.471 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (69.64) is better than Ligand B (73.58). Both are below the 140 threshold for oral absorption, but lower is generally preferred.
3. **logP:** Ligand A (1.348) is within the optimal 1-3 range. Ligand B (2.419) is also acceptable, but slightly higher, potentially increasing off-target interactions.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Both ligands have 5 HBA, which is acceptable.
6. **QED:** Ligand A (0.828) has a better QED score than Ligand B (0.742), indicating a more drug-like profile.
7. **DILI:** Ligand A (51.26) has a significantly lower DILI risk than Ligand B (7.445). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (87.631) has a much higher BBB penetration percentile than Ligand B (59.519). While ADRB2 isn't *strictly* a CNS target, some CNS exposure can occur, and higher BBB penetration is generally favorable.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.765 and -4.861), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Both ligands have negative solubility values (-2.008 and -2.088), indicating poor aqueous solubility. This is a significant drawback for both.
11. **hERG:** Ligand A (0.278) has a lower hERG inhibition liability than Ligand B (0.68). This is a critical safety advantage for Ligand A.
12. **Cl_mic:** Both ligands have similar microsomal clearance rates (29.376 and 29.161 mL/min/kg).
13. **t1/2:** Ligand A (-6.895) has a much longer in vitro half-life than Ligand B (-12.257). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.166) has lower P-gp efflux liability than Ligand B (0.068). Lower P-gp efflux is generally preferred.
15. **Affinity:** Ligand A (-7.7 kcal/mol) has a slightly better binding affinity than Ligand B (-6.0 kcal/mol). This is a substantial difference, and the affinity difference is likely to outweigh minor ADME drawbacks.
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A performs better in all of these categories. The significantly lower DILI and hERG risks for Ligand A are also crucial for a cardiovascular target.
**Conclusion:**
Ligand A is clearly the superior candidate. It has better QED, DILI, BBB, hERG, t1/2, Pgp, and affinity. While both have poor Caco-2 and solubility, the overall profile of Ligand A is much more favorable for development as a drug candidate.
Output:
1
2025-04-18 00:23:39,958 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [366.458, 49.85, 2.384, 0, 4, 0.745, 46.375, 91.819, -4.418, -2.296, 0.416, 51.438, 28.335, 0.204, -8.9]
**Ligand B:** [344.411, 80.57, 2.031, 2, 4, 0.774, 35.401, 65.219, -5.068, -2.566, 0.221, 19.501, 47.844, 0.036, -6.6]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (344.411) is slightly lower, which *could* be beneficial for permeability, but both are acceptable.
2. **TPSA:** Ligand A (49.85) is significantly better than Ligand B (80.57). GPCRs benefit from lower TPSA for better brain penetration and overall absorption. Ligand B is quite high, potentially hindering oral absorption.
3. **logP:** Both are within the optimal range (1-3). Ligand A (2.384) is slightly higher, which isn't a major concern.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Both have 4 HBA, which is acceptable.
6. **QED:** Both are good (above 0.5), with Ligand B (0.774) being slightly better. This isn't a major differentiating factor.
7. **DILI:** Ligand B (35.401) has a significantly lower DILI risk than Ligand A (46.375), which is a substantial advantage.
8. **BBB:** Ligand A (91.819) has a much higher BBB penetration percentile than Ligand B (65.219). This is *highly* desirable for a GPCR target, even a cardiovascular one, as some CNS off-target effects are possible and good brain penetration can be a biomarker for overall distribution.
9. **Caco-2:** Ligand B (-5.068) is better than Ligand A (-4.418), indicating better intestinal absorption.
10. **Solubility:** Both are poor (-2.296 and -2.566). This is a concern for both, but not a deciding factor between them.
11. **hERG:** Both are very low risk (0.416 and 0.221), which is excellent.
12. **Cl_mic:** Ligand B (19.501) has significantly lower microsomal clearance than Ligand A (51.438), indicating better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand B (47.844) has a longer in vitro half-life than Ligand A (28.335), which is preferable.
14. **Pgp:** Ligand A (0.204) has lower P-gp efflux than Ligand B (0.036), which is preferable.
15. **Affinity:** Ligand A (-8.9 kcal/mol) has a substantially better binding affinity than Ligand B (-6.6 kcal/mol). This is a >1.3 kcal/mol difference, which is a major advantage and can outweigh many ADME concerns.
**Overall Assessment:**
While Ligand B has advantages in DILI, metabolic stability, and Caco-2 permeability, Ligand A's *significantly* stronger binding affinity (-8.9 vs -6.6 kcal/mol) and superior BBB penetration are crucial for a GPCR target like ADRB2. The higher affinity is likely to drive efficacy, and the better BBB suggests better overall distribution and potentially fewer off-target effects. The slightly higher DILI risk and lower metabolic stability of Ligand A are manageable concerns that could be addressed through further optimization. The lower TPSA and HBD also contribute to better drug-like properties.
Therefore, I prefer Ligand A.
Output:
1
2025-04-18 00:23:39,958 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.381 and 341.419 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (69.64 and 70.51) are below the 140 A^2 threshold for good oral absorption, and are reasonably low. No major difference.
3. **logP:** Ligand A (1.847) is slightly higher than Ligand B (0.82). Both are within the optimal 1-3 range, but Ligand A is closer to the ideal.
4. **HBD:** Ligand A (2) is better than Ligand B (0). While both are acceptable, a small number of HBDs can improve solubility without drastically impacting permeability.
5. **HBA:** Ligand A (3) is lower than Ligand B (8). This is a significant difference. Higher HBA can sometimes lead to poorer permeability.
6. **QED:** Both ligands have similar QED scores (0.85 and 0.813), indicating good drug-likeness.
7. **DILI:** Ligand A (40.054) is significantly better than Ligand B (84.102). This is a major advantage for Ligand A, as lower DILI risk is crucial.
8. **BBB:** Both ligands show reasonable BBB penetration (63.862 and 70.841). Ligand B is slightly better, but this isn't a primary concern for a cardiovascular target like ADRB2.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.783 and -4.805), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Both ligands have negative solubility values (-2.693 and -2.193), indicating very poor aqueous solubility. This is a significant drawback for both.
11. **hERG:** Both ligands have low hERG inhibition liability (0.665 and 0.578), which is good.
12. **Cl_mic:** Ligand A (16.033) has significantly lower microsomal clearance than Ligand B (41.032), suggesting better metabolic stability.
13. **t1/2:** Ligand A (36.512) has a much longer in vitro half-life than Ligand B (2.442). This is a major advantage for Ligand A, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.069 and 0.027).
15. **Binding Affinity:** Ligand A (-6.4 kcal/mol) is slightly better than Ligand B (-5.6 kcal/mol), although the difference is less than 1.5 kcal/mol.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A is slightly better on logP and affinity. However, the significant advantages of Ligand A in DILI risk, metabolic stability (Cl_mic), and in vitro half-life outweigh these minor differences. The poor Caco-2 and solubility are concerning for both, but can potentially be addressed with formulation strategies.
**Conclusion:**
Ligand A is the more promising candidate due to its significantly lower DILI risk, better metabolic stability, and longer half-life. These factors are crucial for overall drug development success.
Output:
1
2025-04-18 00:23:39,958 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.322 and 356.463 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand B (95.94) is significantly better than Ligand A (118.73). For a GPCR, lower TPSA is generally preferred for better permeability.
3. **logP:** Ligand B (1.092) is optimal, while Ligand A (-0.355) is slightly low, potentially hindering permeability.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (2), but both are within the acceptable limit of 5.
5. **HBA:** Ligand A (8) is higher than Ligand B (5), but both are within the acceptable limit of 10.
6. **QED:** Both ligands have similar QED values (0.623 and 0.571), indicating good drug-likeness.
7. **DILI:** Ligand B (13.61) has a *much* lower DILI risk than Ligand A (81.078). This is a major advantage for Ligand B.
8. **BBB:** Ligand A (41.838) and Ligand B (36.254) are both low, but this isn't a high priority for ADRB2, a cardiovascular target.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.169 and -4.71), which is unusual and suggests poor permeability. However, the scale isn't specified, so it's hard to interpret.
10. **Solubility:** Ligand A (-2.093) has slightly worse solubility than Ligand B (-1.039).
11. **hERG:** Ligand A (0.085) has a slightly lower hERG risk than Ligand B (0.287), which is good.
12. **Cl_mic:** Ligand A (-6.099) has significantly lower microsomal clearance than Ligand B (49.558), indicating better metabolic stability.
13. **t1/2:** Ligand A (23.503) has a longer half-life than Ligand B (-16.535), which is desirable.
14. **Pgp:** Ligand A (0.02) has a much lower P-gp efflux liability than Ligand B (0.019), suggesting better bioavailability.
15. **Affinity:** Ligand A (-7.4) has a slightly better binding affinity than Ligand B (-6.6). This is a 0.8 kcal/mol difference, which is significant.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity and metabolic stability, Ligand B has a significantly better safety profile (much lower DILI risk), better logP, and lower TPSA. The lower DILI risk is a critical advantage, and the better logP/TPSA profile suggests better permeability. The difference in affinity (0.8 kcal/mol) can potentially be optimized during lead optimization, while mitigating a high DILI risk is much more challenging.
Given the GPCR-specific priorities (logP, TPSA, and affinity) and the overall balance of properties, Ligand B is the more promising candidate.
Output:
0
2025-04-18 00:23:39,959 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Step-by-step comparison:**
1. **MW:** Both ligands (360.483 and 367.471 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (75.19) is better than Ligand B (82.97). Both are below 140, but lower TPSA generally favors better absorption.
3. **logP:** Ligand A (1.188) is slightly better than Ligand B (0.532). Both are within the optimal 1-3 range, but Ligand B is getting closer to the lower limit which could impact permeability.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 5 HBA, and Ligand B has 6. Both are acceptable, below the 10 threshold.
6. **QED:** Ligand A (0.854) is better than Ligand B (0.793), indicating a more drug-like profile.
7. **DILI:** Ligand A (37.185) is slightly higher than Ligand B (33.773), but both are well below the concerning 60 percentile, indicating low liver injury risk.
8. **BBB:** Ligand A (68.748) is significantly better than Ligand B (27.491). While ADRB2 isn't exclusively a CNS target, some cardiovascular effects are mediated by central pathways, and better BBB penetration could be beneficial.
9. **Caco-2:** Ligand A (-5.332) is better than Ligand B (-4.726). Higher (less negative) Caco-2 values indicate better intestinal absorption.
10. **Solubility:** Ligand A (-1.895) is better than Ligand B (-0.445). Higher solubility is generally preferred.
11. **hERG:** Ligand A (0.084) is significantly better than Ligand B (0.202), indicating a lower risk of cardiotoxicity. This is *critical* for a cardiovascular target.
12. **Cl_mic:** Ligand A (18.934) is slightly higher than Ligand B (16.171), indicating slightly lower metabolic stability.
13. **t1/2:** Ligand A (4.379) is slightly better than Ligand B (4.094).
14. **Pgp:** Ligand A (0.02) is significantly better than Ligand B (0.083), indicating lower P-glycoprotein efflux. Lower efflux is desirable for better bioavailability.
15. **Binding Affinity:** Ligand B (-7.0) has a 1 kcal/mol advantage over Ligand A (-3.0). This is a substantial difference in potency.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. While Ligand B has a superior binding affinity, Ligand A performs better across several other critical ADME properties, particularly hERG inhibition and Pgp efflux. The substantial affinity difference is important, but the safety profile and bioavailability advantages of Ligand A are compelling.
**Overall Assessment:**
Ligand B's significantly stronger binding affinity is a major plus. However, Ligand A demonstrates a more balanced profile with better predicted absorption, solubility, safety (hERG), and efflux properties. Given the cardiovascular context, minimizing cardiotoxicity (hERG) and maximizing bioavailability are paramount. The affinity difference, while significant, might be overcome with further optimization of Ligand A.
Output:
1
2025-04-18 00:23:39,959 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (350.373 Da and 342.311 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (75.94) is significantly better than Ligand B (134.33). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is above the preferred 90 A^2 threshold.
**3. logP:** Both ligands have acceptable logP values (2.585 and 3.089, respectively) within the 1-3 range. Ligand B is slightly higher, which *could* indicate potential off-target interactions, but isn't a major concern.
**4. H-Bond Donors:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
**5. H-Bond Acceptors:** Ligand A (5) is preferable to Ligand B (6). Fewer HBAs generally improve permeability.
**6. QED:** Ligand A (0.92) has a much better QED score than Ligand B (0.465), indicating a more drug-like profile. This is a significant advantage for Ligand A.
**7. DILI Risk:** Ligand B (85.731) has a substantially higher DILI risk than Ligand A (52.191). This is a major concern for Ligand B.
**8. BBB Penetration:** Ligand A (83.443) has significantly better BBB penetration potential than Ligand B (34.742). While ADRB2 is a cardiovascular target, some CNS effects are possible with certain ligands, and better BBB penetration isn't necessarily a negative.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual. However, the magnitude is similar (-4.965 vs -5.249).
**10. Aqueous Solubility:** Ligand A (-1.996) is slightly better than Ligand B (-5.32), although both are poor. Solubility is less critical than permeability for this target.
**11. hERG Inhibition:** Ligand A (0.158) has a much lower hERG inhibition liability than Ligand B (0.684), which is a significant safety advantage.
**12. Microsomal Clearance:** Ligand A (-6.991) has a much lower (better) microsomal clearance than Ligand B (25.51). This indicates better metabolic stability.
**13. In vitro Half-Life:** Ligand A (-8.664) has a much longer in vitro half-life than Ligand B (54.686). This is a significant advantage.
**14. P-gp Efflux:** Ligand A (0.016) has a much lower P-gp efflux liability than Ligand B (0.317). This is a positive for bioavailability.
**15. Binding Affinity:** Ligand B (-7.8) has a slightly better binding affinity than Ligand A (-5.8), a difference of 2.0 kcal/mol. While affinity is important, the other ADME properties of Ligand B are significantly worse.
**Overall Assessment:**
Ligand A is overwhelmingly the better candidate. While Ligand B has a slightly better binding affinity, Ligand A excels in nearly all other critical parameters, including drug-likeness (QED), safety (DILI, hERG), metabolic stability (Cl_mic, t1/2), permeability (TPSA, P-gp), and BBB penetration. The substantial advantages in ADME/Tox properties outweigh the minor affinity difference.
Output:
1
2025-04-18 00:23:39,959 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (351.403 and 371.453 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (96.11) is higher than Ligand B (62.3). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for permeability. Ligand B is better here.
3. **logP:** Ligand A (0.656) is quite low, potentially hindering membrane permeability. Ligand B (2.854) is within the optimal 1-3 range. Ligand B is significantly better.
4. **HBD:** Both ligands have 1 HBD, which is good. No difference.
5. **HBA:** Ligand A has 6 HBA, while Ligand B has 4. Both are acceptable (<=10), but Ligand B is slightly better.
6. **QED:** Both ligands have high QED scores (0.809 and 0.885), indicating good drug-like properties. No significant difference.
7. **DILI:** Ligand A (39.434) has a lower DILI risk than Ligand B (49.787), which is desirable. Ligand A is better.
8. **BBB:** Ligand A (64.87) has a lower BBB penetration than Ligand B (90.229). Since ADRB2 is not a CNS target, this is less critical, but higher BBB is generally preferable. Ligand B is better.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Ligand A (-1.216) has worse solubility than Ligand B (-3.612). Lower solubility can hinder bioavailability. Ligand B is better.
11. **hERG:** Ligand A (0.214) has a lower hERG risk than Ligand B (0.421), which is crucial for cardiovascular drugs. Ligand A is better.
12. **Cl_mic:** Ligand A (6.019) has a lower microsomal clearance than Ligand B (31.992), suggesting better metabolic stability. Ligand A is better.
13. **t1/2:** Ligand A (0.433) has a shorter in vitro half-life than Ligand B (-24.354). A longer half-life is generally preferred, making Ligand B better.
14. **Pgp:** Ligand A (0.089) has lower P-gp efflux than Ligand B (0.179), which is good for bioavailability. Ligand A is better.
15. **Binding Affinity:** Ligand B (-7.2 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.9 kcal/mol). This is a substantial advantage, potentially outweighing some ADME drawbacks.
**Overall Assessment:**
Ligand B has a superior binding affinity and better logP, BBB, solubility, and half-life. While Ligand A has better DILI, hERG, Cl_mic, and Pgp properties, the substantial difference in binding affinity (-1.3 kcal/mol) is a critical factor for GPCR targets. The improved logP of Ligand B also addresses a significant concern with Ligand A. The slightly higher DILI and hERG risks of Ligand B can be further investigated and potentially mitigated during optimization.
Output:
0
2025-04-18 00:23:39,959 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Step-by-step comparison:**
1. **MW:** Both ligands (339.395 and 346.387 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (83.38) is better than Ligand B (95.34). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally favors absorption.
3. **logP:** Ligand A (3.385) is better than Ligand B (1.111). A logP between 1-3 is optimal, and Ligand B is on the lower end, potentially hindering permeability.
4. **HBD:** Ligand A (2) is slightly better than Ligand B (1). Both are acceptable.
5. **HBA:** Ligand A (4) is better than Ligand B (8). Lower HBA is preferred for permeability.
6. **QED:** Ligand A (0.845) is significantly better than Ligand B (0.565), indicating a more drug-like profile.
7. **DILI:** Ligand B (51.377) is significantly better than Ligand A (76.076). Lower DILI risk is crucial.
8. **BBB:** Ligand B (69.407) is better than Ligand A (59.364), but this isn't a high priority for a cardiovascular target.
9. **Caco-2:** Ligand A (-4.679) is better than Ligand B (-5.033). Higher Caco-2 permeability is desirable.
10. **Solubility:** Ligand A (-4.427) is better than Ligand B (-1.673). Better solubility is generally preferred.
11. **hERG:** Ligand A (0.815) is better than Ligand B (0.22). Lower hERG inhibition is crucial for avoiding cardiotoxicity.
12. **Cl_mic:** Ligand B (70.118) is slightly better than Ligand A (72.853). Lower clearance is preferred.
13. **t1/2:** Ligand A (17.898) is much better than Ligand B (1.269). A longer half-life is desirable.
14. **Pgp:** Ligand A (0.249) is better than Ligand B (0.158). Lower P-gp efflux is preferred.
15. **Affinity:** Ligand A (-6.8 kcal/mol) is better than Ligand B (-5.5 kcal/mol). This is a substantial difference in binding affinity.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A excels in these areas. While DILI is important, the significantly better affinity and overall drug-like properties of Ligand A outweigh the higher DILI risk, especially given that the DILI risk is still below the concerning threshold of 60. The substantial affinity difference (-6.8 vs -5.5) is a major advantage.
**Conclusion:**
Ligand A is the more promising candidate due to its superior binding affinity, drug-like properties (QED), permeability, solubility, and metabolic stability.
Output:
1
2025-04-18 00:23:39,959 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Ligand A (346.383 Da) is better than Ligand B (401.228 Da). Both are within the ideal range, but A is closer to the lower, preferred end.
2. **TPSA:** Ligand A (97.64) is better than Ligand B (117.17). Both are acceptable for a non-CNS GPCR, but lower is generally preferred for better absorption.
3. **logP:** Ligand B (1.737) is slightly better than Ligand A (1.249). Both are within the optimal range, but B is a bit closer to the center.
4. **HBD:** Ligand A (2) is better than Ligand B (3). Lower HBD is generally preferred for better permeability.
5. **HBA:** Ligand A (5) is better than Ligand B (6). Similar to HBD, lower HBA is preferred.
6. **QED:** Ligand A (0.572) is better than Ligand B (0.471). A higher QED indicates a more drug-like profile.
7. **DILI:** Ligand A (50.291) is significantly better than Ligand B (94.765). This is a major advantage for Ligand A, as lower DILI risk is crucial.
8. **BBB:** Ligand A (40.442) is better than Ligand B (24.079). While ADRB2 isn't necessarily a CNS target, higher BBB penetration isn't detrimental and can offer flexibility.
9. **Caco-2:** Ligand A (-4.649) is better than Ligand B (-5.774). Higher Caco-2 permeability suggests better absorption.
10. **Solubility:** Ligand A (-2.924) is better than Ligand B (-3.676). Higher solubility is generally preferred.
11. **hERG:** Ligand A (0.053) is better than Ligand B (0.499). Lower hERG inhibition is crucial for avoiding cardiotoxicity, a major concern for cardiovascular targets.
12. **Cl_mic:** Ligand A (40.265) is better than Ligand B (13.557). Lower microsomal clearance indicates better metabolic stability.
13. **t1/2:** Ligand A (-9.532) is better than Ligand B (34.38). A negative value suggests a longer half-life.
14. **Pgp:** Ligand A (0.01) is significantly better than Ligand B (0.094). Lower P-gp efflux is desirable for improved bioavailability.
15. **Affinity:** Ligand B (-7.7) is slightly better than Ligand A (-7.6). While a small difference, it's a positive for Ligand B.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical ADME-Tox parameters (DILI, hERG, Cl_mic, Pgp, Solubility, Caco-2). While Ligand B has a slightly better binding affinity, the substantial advantages of Ligand A in safety and pharmacokinetic properties outweigh this minor difference. For a cardiovascular target like ADRB2, minimizing off-target effects (DILI, hERG) and ensuring good bioavailability are paramount.
Output:
1
2025-04-18 00:23:39,960 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [342.418, 62.46, 1.482, 1, 5, 0.806, 44.242, 84.374, -5.006, -2.358, 0.93, 38.188, -34.951, 0.53, -6.4]
**Ligand B:** [393.236, 47.28, 4.81, 2, 3, 0.741, 28.732, 70.415, -4.892, -4.178, 0.964, 28.581, 15.966, 0.681, -6.4]
**Step-by-step comparison:**
1. **MW:** Ligand A (342.418 Da) is better, falling nicely within the 200-500 Da range. Ligand B (393.236 Da) is still acceptable, but closer to the upper limit.
2. **TPSA:** Ligand B (47.28) is better than Ligand A (62.46). Both are reasonably low, but lower TPSA generally favors better permeability.
3. **logP:** Ligand A (1.482) is optimal. Ligand B (4.81) is high, potentially leading to solubility issues and off-target interactions.
4. **HBD:** Ligand A (1) is preferred. Ligand B (2) is still acceptable.
5. **HBA:** Ligand B (3) is better than Ligand A (5).
6. **QED:** Ligand A (0.806) is better than Ligand B (0.741), indicating a more drug-like profile.
7. **DILI:** Ligand B (28.732) is significantly better than Ligand A (44.242), indicating a lower risk of liver injury. This is a substantial advantage.
8. **BBB:** Ligand A (84.374) is better than Ligand B (70.415). While ADRB2 is primarily cardiovascular, some CNS effects are possible with beta-blockers, so higher BBB is a slight benefit.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-5.006) is slightly worse than Ligand B (-4.892).
10. **Solubility:** Ligand B (-4.178) is better than Ligand A (-2.358).
11. **hERG:** Both are very low (0.93 and 0.964), indicating a low risk of cardiotoxicity.
12. **Cl_mic:** Ligand B (28.581) is better than Ligand A (38.188), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-34.951) is much better than Ligand B (15.966), indicating a significantly longer half-life.
14. **Pgp:** Ligand B (0.681) is better than Ligand A (0.53), suggesting lower P-glycoprotein efflux.
15. **Affinity:** Both ligands have the same binding affinity (-6.4 kcal/mol).
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B has a better TPSA, Pgp, and solubility, but a significantly worse logP. Ligand A has a better logP, QED, BBB, and half-life. The DILI score for Ligand B is a significant advantage.
**Overall Assessment:**
While Ligand A has a better overall drug-like profile (QED, BBB, half-life) and a more optimal logP, the substantially lower DILI risk for Ligand B is a major factor. The high logP of Ligand B is concerning, but could potentially be mitigated through formulation strategies. The longer half-life of Ligand A is attractive, but the DILI risk is a serious concern. Considering the cardiovascular target, minimizing potential liver toxicity is crucial.
Therefore, I believe **Ligand B** is the more viable drug candidate.
0
2025-04-18 00:23:39,960 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
The ADRB2 receptor is a GPCR, so the priorities are logP, Pgp, TPSA, affinity, and BBB. Let's break down the comparison:
1. **Molecular Weight:** Both ligands are within the acceptable 200-500 Da range. Ligand A (363.849) is slightly higher than Ligand B (355.523), but this isn't a major concern.
2. **TPSA:** Ligand B (61.88) is significantly better than Ligand A (102.04). Lower TPSA generally improves oral absorption and is highly desirable for GPCRs.
3. **logP:** Ligand A (3.597) is good, falling within the optimal 1-3 range. Ligand B (1.6) is on the lower side, potentially hindering permeability.
4. **H-Bond Donors:** Ligand A (3) is slightly higher than Ligand B (1), but both are acceptable.
5. **H-Bond Acceptors:** Both ligands have 4 HBA, which is within the acceptable range.
6. **QED:** Both ligands have reasonable QED scores (A: 0.773, B: 0.638), indicating good drug-like properties.
7. **DILI:** Ligand B (4.653) has a *much* lower DILI risk than Ligand A (78.247). This is a critical advantage for Ligand B.
8. **BBB:** Ligand B (70.531) has better BBB penetration than Ligand A (64.095), which is a positive for a GPCR target, although not strictly essential for ADRB2.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Ligand B (-0.687) has better solubility than Ligand A (-5.052).
11. **hERG:** Both ligands have low hERG inhibition risk (A: 0.341, B: 0.494).
12. **Cl_mic:** Ligand B (1.857) has significantly lower microsomal clearance than Ligand A (56.676), indicating better metabolic stability.
13. **t1/2:** Ligand B (-6.942) has a significantly longer in vitro half-life than Ligand A (85.904).
14. **Pgp:** Ligand B (0.019) has much lower P-gp efflux liability than Ligand A (0.218). This is a significant advantage for bioavailability and potentially CNS exposure.
15. **Binding Affinity:** Ligand B (-6.6) has slightly better binding affinity than Ligand A (-6.3). While the difference is small, it's still a positive.
**Overall Assessment:**
Ligand B is clearly superior. While Ligand A has a slightly better logP, Ligand B excels in almost every other critical parameter, especially DILI risk, metabolic stability (Cl_mic, t1/2), P-gp efflux, solubility, and TPSA. The lower TPSA and P-gp efflux are particularly beneficial for a GPCR target. The slightly better affinity of Ligand B further solidifies its advantage.
**Output:**
0
2025-04-18 00:23:39,960 - INFO - Batch 474 complete. Total preferences: 7584
2025-04-18 00:23:39,960 - INFO - Processing batch 475/512...
2025-04-18 00:24:29,928 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (353.419 Da and 351.359 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (88.18) is significantly better than Ligand B (121.71). ADRB2 is a cardiovascular target, so BBB isn't a high priority, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands are acceptable (-0.071 and -0.114), falling within the 1-3 range, though on the lower end. This isn't a major concern, but higher logP could improve membrane permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (6). Lower HBA generally improves permeability.
6. **QED:** Both ligands are similar (0.747 and 0.73), indicating good drug-likeness.
7. **DILI:** Ligand A (26.871) is *much* better than Ligand B (69.058). This is a critical advantage for Ligand A, as lower DILI risk is essential.
8. **BBB:** Not a primary concern for a cardiovascular target. Ligand A (54.091) is better than Ligand B (19.814), but this isn't a deciding factor.
9. **Caco-2:** Both are negative (-4.968 and -5.062), indicating poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-1.033) is better than Ligand B (-2.115), though both are quite poor. Solubility is a concern, but can sometimes be addressed with formulation strategies.
11. **hERG:** Both ligands have very low hERG risk (0.12 and 0.046). This is excellent.
12. **Cl_mic:** Ligand A (-0.844) is *much* better than Ligand B (-15.551). This indicates significantly better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (0.032) is significantly better than Ligand B (-34.443). This indicates a much longer in vitro half-life for Ligand A.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.009 and 0.021). This is excellent.
15. **Binding Affinity:** Ligand B (-6.8) is slightly better than Ligand A (-6.2), but the difference is less than 1.5 kcal/mol.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. While Ligand B has slightly better affinity, Ligand A is superior in TPSA, Pgp, and significantly better in crucial ADMET properties like DILI and metabolic stability (Cl_mic and t1/2). The slightly better affinity of Ligand B is unlikely to outweigh the substantial advantages of Ligand A in terms of safety (DILI) and pharmacokinetics (Cl_mic, t1/2).
**Conclusion:**
Ligand A is the more promising drug candidate due to its significantly better DILI profile, metabolic stability, and in vitro half-life, combined with acceptable TPSA, logP, and hERG values. The slight affinity difference is not enough to overcome the substantial advantages of Ligand A.
Output:
1
2025-04-18 00:24:29,928 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (348.491 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (59.39) is significantly better than Ligand B (74.25). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally improves absorption.
3. **logP:** Both ligands have good logP values (A: 2.476, B: 1.902) within the optimal 1-3 range.
4. **HBD:** Both have 1 HBD, which is acceptable.
5. **HBA:** Ligand A (6) is slightly better than Ligand B (7), keeping within the preferred range.
6. **QED:** Both ligands have good QED scores (A: 0.801, B: 0.867), indicating good drug-like properties.
7. **DILI:** Ligand A (9.035) has a much lower DILI risk than Ligand B (76.076). This is a significant advantage.
8. **BBB:** Not a primary concern for a cardiovascular target. Ligand A (74.564) is slightly better than Ligand B (66.499).
9. **Caco-2:** Ligand A (-5.224) and Ligand B (-4.723) are both negative, which is unusual. Higher values are better, so both are not ideal, but they are similar.
10. **Solubility:** Ligand A (-1.038) is better than Ligand B (-2.677). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.849) has a lower hERG risk than Ligand B (0.569), which is preferable.
12. **Cl_mic:** Ligand A (-6.738) has significantly better metabolic stability (lower clearance) than Ligand B (15.821).
13. **t1/2:** Ligand A (5.033) has a shorter half-life than Ligand B (9.888), but it's not a drastic difference.
14. **Pgp:** Ligand A (0.133) has lower P-gp efflux than Ligand B (0.147).
15. **Binding Affinity:** Ligand B (-7.2) has a significantly stronger binding affinity than Ligand A (-4.8). This is a substantial advantage (2.4 kcal/mol difference).
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, and affinity. Ligand B has a slightly lower logP and similar Pgp. Ligand A has a significantly better TPSA. However, the difference in binding affinity is substantial. A 2.4 kcal/mol difference is often enough to overcome minor ADME drawbacks.
**Overall Assessment:**
While Ligand A has better ADME properties (DILI, solubility, metabolic stability, hERG), the significantly stronger binding affinity of Ligand B (-7.2 vs -4.8 kcal/mol) is a major advantage. For a GPCR target, potency is often paramount. The improved ADME profile of Ligand A is valuable, but the stronger binding of Ligand B is likely to translate to greater efficacy *in vivo*, and can potentially be optimized further.
Output:
0
2025-04-18 00:24:29,929 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [365.861, 79.46, 2.768, 3, 3, 0.767, 56.301, 73.362, -4.81, -3.774, 0.163, 28.005, 30.229, 0.132, -6.3]
**Ligand B:** [348.407, 115.63, -0.208, 2, 4, 0.786, 39.744, 64.482, -5.215, -2.13, 0.203, -17.144, -4.781, 0.006, -6.6]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (348.4) is slightly lower, which could be beneficial for permeability, but both are acceptable.
2. **TPSA:** Ligand A (79.46) is better than Ligand B (115.63). GPCRs benefit from lower TPSA for better BBB penetration and oral absorption. Ligand B is a bit high.
3. **logP:** Ligand A (2.768) is optimal, while Ligand B (-0.208) is quite low. Low logP can hinder membrane permeability and reduce binding affinity. This is a significant negative for Ligand B.
4. **HBD:** Both have acceptable HBD counts (3 and 2 respectively).
5. **HBA:** Both are acceptable, but Ligand B (4) is slightly higher than Ligand A (3).
6. **QED:** Both have good QED scores (0.767 and 0.786), indicating drug-likeness.
7. **DILI:** Ligand A (56.3) has a slightly higher DILI risk than Ligand B (39.7), but both are below the concerning threshold of 60.
8. **BBB:** Ligand A (73.362) is significantly better than Ligand B (64.482). This is important for a GPCR target, even if not strictly CNS-focused, as it can influence distribution.
9. **Caco-2:** Ligand A (-4.81) is better than Ligand B (-5.215), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-3.774) is better than Ligand B (-2.13). Solubility is important for bioavailability.
11. **hERG:** Both have very low hERG risk (0.163 and 0.203).
12. **Cl_mic:** Ligand B (-17.144) has significantly lower microsomal clearance than Ligand A (28.005), suggesting better metabolic stability. This is a strong point for Ligand B.
13. **t1/2:** Ligand A (30.229) has a longer in vitro half-life than Ligand B (-4.781). This is a positive for Ligand A.
14. **Pgp:** Ligand A (0.132) has lower P-gp efflux than Ligand B (0.006), which is favorable for bioavailability and potential CNS exposure.
15. **Affinity:** Ligand B (-6.6) has a slightly better binding affinity than Ligand A (-6.3), but the difference is not substantial enough to outweigh other factors.
**Overall Assessment:**
Ligand A has a more balanced profile, particularly excelling in key GPCR properties like logP, TPSA, BBB penetration, solubility, and P-gp efflux. While Ligand B has better metabolic stability (lower Cl_mic) and slightly better affinity, its poor logP and higher TPSA are significant drawbacks. The better ADME properties of Ligand A, combined with its acceptable affinity, make it a more promising drug candidate for the ADRB2 receptor.
Output:
1
2025-04-18 00:24:29,929 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [378.303, 53.16, 4.049, 3, 3, 0.688, 53.083, 74.641, -5.058, -4.372, 0.879, -7.155, 22.404, 0.344, -7.1]
**Ligand B:** [342.443, 79.53, 1.915, 1, 4, 0.91, 45.095, 83.249, -4.995, -2.39, 0.53, 16.824, -27.984, 0.041, -7.2]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal 200-500 Da range. Ligand B (342.443) is slightly preferred due to being a bit lower.
2. **TPSA:** Ligand A (53.16) is better than Ligand B (79.53). We want TPSA < 140 for oral absorption, both are fine, but A is better.
3. **logP:** Ligand A (4.049) is a bit high, potentially leading to solubility issues and off-target effects. Ligand B (1.915) is closer to the optimal 1-3 range. This favors B.
4. **HBD:** Ligand A (3) is acceptable. Ligand B (1) is even better.
5. **HBA:** Ligand A (3) is acceptable. Ligand B (4) is also acceptable.
6. **QED:** Both ligands have reasonable QED scores (A: 0.688, B: 0.91), indicating good drug-like properties. B is slightly better.
7. **DILI:** Ligand A (53.083) has a higher DILI risk than Ligand B (45.095). This favors B.
8. **BBB:** Ligand B (83.249) has better BBB penetration than Ligand A (74.641). This is a positive for a GPCR target, even if not strictly CNS-focused.
9. **Caco-2:** Both have negative values, indicating poor permeability. Ligand A (-5.058) is worse than Ligand B (-4.995).
10. **Solubility:** Both have negative solubility values, indicating poor solubility. Ligand B (-2.39) is better than Ligand A (-4.372).
11. **hERG:** Both have low hERG inhibition risk (A: 0.879, B: 0.53), which is good.
12. **Cl_mic:** Ligand A (-7.155) has a much lower (better) microsomal clearance than Ligand B (16.824), suggesting greater metabolic stability. This is a significant advantage for A.
13. **t1/2:** Ligand A (22.404) has a longer in vitro half-life than Ligand B (-27.984). This is a strong advantage for A.
14. **Pgp:** Ligand A (0.344) has lower P-gp efflux than Ligand B (0.041). This is a positive for A.
15. **Affinity:** Both have very similar binding affinities (A: -7.1 kcal/mol, B: -7.2 kcal/mol). The difference is negligible.
**Overall Assessment:**
Ligand B has advantages in logP, DILI, BBB, solubility, and Pgp. However, Ligand A excels in metabolic stability (Cl_mic and t1/2) and Pgp efflux. Considering the GPCR target class, the improved metabolic stability and longer half-life of Ligand A are crucial. While Ligand B has a slightly better logP, the higher DILI risk and poorer metabolic profile are concerning. The affinity is similar, so the ADME properties become the deciding factor.
Therefore, I prefer Ligand A.
Output:
1
2025-04-18 00:24:29,929 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.435 and 353.463 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand B (87.74) is significantly better than Ligand A (106.14). ADRB2 is not a CNS target, but lower TPSA generally improves absorption.
3. **logP:** Ligand A (1.446) is better than Ligand B (0.683). Both are within the optimal 1-3 range, but A is closer to the sweet spot.
4. **HBD:** Both ligands have 2 HBD, which is acceptable.
5. **HBA:** Ligand A has 5 HBA, and Ligand B has 4. Both are within the acceptable limit of 10.
6. **QED:** Ligand A (0.864) has a much better QED score than Ligand B (0.471), indicating a more drug-like profile.
7. **DILI:** Ligand B (13.532) has a significantly lower DILI risk than Ligand A (43.234). This is a major advantage for Ligand B.
8. **BBB:** Not a primary concern for ADRB2, but Ligand A (73.439) has a slightly higher BBB penetration than Ligand B (65.684).
9. **Caco-2:** Ligand A (-5.143) and Ligand B (-4.881) are both negative, indicating poor permeability. However, the values are very close.
10. **Solubility:** Ligand A (-2.977) has slightly better solubility than Ligand B (-2.25), but both are poor.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.206 and 0.165, respectively).
12. **Cl_mic:** Ligand A (3.295) has a much lower microsomal clearance than Ligand B (54.149), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-24.605) has a much longer in vitro half-life than Ligand A (-2.049). This is a significant advantage.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.018 and 0.039, respectively).
15. **Binding Affinity:** Ligand B (-6.6 kcal/mol) has a slightly better binding affinity than Ligand A (-5.9 kcal/mol). This difference is significant (0.7 kcal/mol).
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has a better logP, while Ligand B has a better TPSA and affinity. The difference in affinity is substantial enough to be a major driver. The lower DILI risk of Ligand B is also very important. While Ligand A has better metabolic stability, the longer half-life of Ligand B may compensate for the higher clearance.
**Overall Assessment:**
Despite Ligand A's better QED and metabolic stability, Ligand B's superior binding affinity, lower DILI risk, and better TPSA make it the more promising candidate. The longer half-life is also a significant benefit.
Output:
0
2025-04-18 00:24:29,929 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.471 and 356.495 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (78.43) is higher than Ligand B (43.18). For a cardiovascular GPCR, TPSA isn't a *major* concern unless it's excessively high, but lower is generally better for permeability. Ligand B is significantly better.
3. **logP:** Both ligands have good logP values (2.945 and 3.52), falling within the 1-3 optimal range. Ligand B is slightly higher, which *could* be a minor advantage, but not decisive.
4. **HBD:** Ligand A has 3 HBD, and Ligand B has 0. Lower HBD is generally preferred for permeability, giving Ligand B an edge.
5. **HBA:** Ligand A has 3 HBA, and Ligand B has 6. Ligand A is better here, as lower HBA is generally preferred.
6. **QED:** Both have reasonable QED values (0.677 and 0.588), indicating good drug-like properties. Ligand A is slightly better.
7. **DILI:** Ligand A (21.326) has a significantly lower DILI risk than Ligand B (38.309). This is a substantial advantage for Ligand A.
8. **BBB:** Both have moderate BBB penetration (51.454 and 59.325). For a cardiovascular target, BBB penetration isn't critical, so the difference isn't major.
9. **Caco-2:** Ligand A (-4.723) has a worse Caco-2 permeability than Ligand B (-5.378). Lower values indicate worse permeability. Ligand B is better.
10. **Solubility:** Ligand A (-3.185) has better aqueous solubility than Ligand B (-2.33). Better solubility is generally preferred.
11. **hERG:** Ligand A (0.335) has a much lower hERG inhibition liability than Ligand B (0.919). This is a significant safety advantage for Ligand A.
12. **Cl_mic:** Ligand A (30.89) has a lower microsomal clearance than Ligand B (58.049), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (5.995) and Ligand B (6.92) have similar in vitro half-lives. No significant difference.
14. **Pgp:** Ligand A (0.071) has a much lower P-gp efflux liability than Ligand B (0.483). This is a significant advantage for Ligand A, improving bioavailability.
15. **Binding Affinity:** Ligand A (-7.0) has slightly better binding affinity than Ligand B (-5.9). This is a significant advantage for Ligand A.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), and the general drug-like properties, Ligand A is the superior candidate. While Ligand B has a slightly better logP and Caco-2 permeability, Ligand A excels in crucial areas like DILI risk, hERG inhibition, metabolic stability (Cl_mic), P-gp efflux, and binding affinity. The lower TPSA of Ligand B is a plus, but the substantial advantages of Ligand A in safety (DILI, hERG) and pharmacokinetics (Cl_mic, Pgp) outweigh this benefit. The affinity difference is also important.
Output:
1
2025-04-18 00:24:29,929 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (365.953 Da) is within the ideal range (200-500), while Ligand B (342.439 Da) is also good. No clear advantage here.
2. **TPSA:** Ligand A (35.5) is excellent, well below the 140 threshold and favorable for absorption. Ligand B (78.43) is higher, but still potentially acceptable, though less ideal.
3. **logP:** Both ligands (A: 3.153, B: 2.358) are within the optimal 1-3 range.
4. **HBD:** Ligand A (0) is preferable to Ligand B (3). Fewer HBDs generally improve membrane permeability.
5. **HBA:** Ligand A (5) is good, while Ligand B (3) is also good.
6. **QED:** Ligand A (0.723) is better than Ligand B (0.603), indicating a more drug-like profile.
7. **DILI:** Ligand A (21.946) has a significantly lower DILI risk than Ligand B (19.969), which is a major advantage.
8. **BBB:** Ligand A (94.727) shows excellent potential for BBB penetration, while Ligand B (42.497) is considerably lower. This is a key consideration for a GPCR target, even a cardiovascular one, as off-target CNS effects are always a concern.
9. **Caco-2:** Ligand A (-4.925) and Ligand B (-5.135) are similar, indicating comparable intestinal absorption.
10. **Solubility:** Ligand A (-2.294) and Ligand B (-2.689) are similar.
11. **hERG:** Ligand A (0.96) is preferable to Ligand B (0.307), indicating lower risk of cardiotoxicity.
12. **Cl_mic:** Ligand A (6.892) has a much lower microsomal clearance than Ligand B (43.417), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-6.674) has a more negative (longer) in vitro half-life than Ligand B (19.728).
14. **Pgp:** Ligand A (0.128) has lower P-gp efflux liability than Ligand B (0.198), which is favorable.
15. **Affinity:** Ligand A (-8.0) has a slightly better binding affinity than Ligand B (-7.7). While the difference is not huge, it's a positive factor.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are particularly important. Ligand A excels in these areas. The high BBB penetration of Ligand A is also a plus, even for a cardiovascular target, as it suggests better overall drug-like properties. The significantly lower DILI risk and better metabolic stability (lower Cl_mic and longer t1/2) of Ligand A are also crucial advantages.
**Conclusion:**
Ligand A consistently outperforms Ligand B across most critical parameters, especially those prioritized for GPCR targets and overall drug safety/pharmacokinetics. The combination of better ADME properties, lower toxicity risk, and slightly improved affinity makes it the more promising candidate.
Output:
1
2025-04-18 00:24:29,930 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (343.36 and 357.52 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (46.17) is significantly better than Ligand A (80.32). ADRB2 is not a CNS target, but lower TPSA generally improves absorption.
3. **logP:** Both ligands have good logP values (3.10 and 4.30), falling within the optimal 1-3 range, though Ligand B is slightly higher. This could potentially lead to some solubility issues, but is not a major concern.
4. **HBD:** Ligand A has 2 HBD, and Ligand B has 1. Both are acceptable.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 3. Both are acceptable.
6. **QED:** Ligand A (0.878) has a better QED score than Ligand B (0.752), indicating a more drug-like profile.
7. **DILI:** Ligand B (41.06) has a much lower DILI risk than Ligand A (88.64). This is a significant advantage for Ligand B.
8. **BBB:** Both ligands have reasonable BBB penetration (64.95 and 68.79), but this is less critical for a non-CNS target like ADRB2.
9. **Caco-2:** Ligand B (-5.05) shows better Caco-2 permeability than Ligand A (-4.44). This suggests better intestinal absorption.
10. **Solubility:** Ligand A (-5.36) has slightly better aqueous solubility than Ligand B (-4.21).
11. **hERG:** Ligand A (0.478) has a lower hERG inhibition liability than Ligand B (0.834). This is a positive for Ligand A.
12. **Cl_mic:** Ligand B (50.98) has a lower microsomal clearance than Ligand A (68.44), suggesting better metabolic stability.
13. **t1/2:** Ligand A (33.42) has a longer in vitro half-life than Ligand B (18.59). This is a positive for Ligand A.
14. **Pgp:** Ligand B (0.758) has lower P-gp efflux liability than Ligand A (0.31). Lower Pgp is generally desirable for bioavailability.
15. **Binding Affinity:** Ligand B (-6.9 kcal/mol) has a slightly better binding affinity than Ligand A (-6.5 kcal/mol). This is a 0.4 kcal/mol difference, which is significant and can outweigh some ADME drawbacks.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand B excels in logP, Pgp, TPSA, and has a slightly better affinity. While Ligand A has better QED, solubility, and half-life, the DILI risk is concerning, and the affinity is weaker. The improved metabolic stability of Ligand B is also a plus.
**Overall Assessment:**
While Ligand A has some favorable properties, the significantly lower DILI risk and better absorption characteristics (Caco-2, Pgp, TPSA) of Ligand B, combined with its slightly improved binding affinity, make it the more promising candidate. The slightly shorter half-life of Ligand B can be addressed through formulation or structural modifications.
Output:
0
2025-04-18 00:24:29,930 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [369.487, 109.57 , 0.356, 2. , 4. , 0.498, 21.908, 58.123, -5.32 , -2.32 , 0.113, -5.083, -24.545, 0.014, -6.8 ]
**Ligand B:** [349.391, 105.56 , -1.106, 2. , 6. , 0.678, 62.233, 27.336, -5.552, -0.572, 0.071, -16.642, 22.785, 0.024, -7.2 ]
Here's a breakdown, prioritizing GPCR-relevant properties (logP, TPSA, Pgp, BBB, Affinity):
1. **Molecular Weight:** Both are within the acceptable range (200-500 Da). Ligand B (349.391) is slightly preferred due to being a bit lower.
2. **TPSA:** Both are reasonably good (109.57 and 105.56). Ideally, we'd like them lower, but they aren't dealbreakers for a peripheral GPCR like ADRB2.
3. **logP:** Ligand A (0.356) is quite low. This is a significant concern, potentially hindering membrane permeability and bioavailability. Ligand B (-1.106) is also low, but less so than A.
4. **H-Bond Donors/Acceptors:** Both have acceptable numbers (2 HBD, 4/6 HBA).
5. **QED:** Ligand B (0.678) has a better QED score than Ligand A (0.498), indicating a more drug-like profile.
6. **DILI Risk:** Ligand A (21.908) has a much lower DILI risk than Ligand B (62.233). This is a substantial advantage for Ligand A.
7. **BBB Penetration:** Ligand A (58.123) has better BBB penetration than Ligand B (27.336). While ADRB2 isn't a primary CNS target, some CNS exposure can sometimes lead to off-target effects, but is not a primary concern here.
8. **Caco-2 Permeability:** Both are poor (-5.32 and -5.552). This is concerning for oral absorption.
9. **Aqueous Solubility:** Both are very poor (-2.32 and -0.572). This will present formulation challenges.
10. **hERG Inhibition:** Both have low hERG risk (0.113 and 0.071).
11. **Microsomal Clearance:** Ligand A (-5.083) has a lower (better) clearance than Ligand B (-16.642), suggesting better metabolic stability.
12. **In vitro Half-Life:** Ligand B (22.785) has a longer half-life than Ligand A (-24.545).
13. **P-gp Efflux:** Both are very low (0.014 and 0.024), which is good.
14. **Binding Affinity:** Ligand B (-7.2) has a slightly better binding affinity than Ligand A (-6.8). This is a 0.4 kcal/mol difference, which is not huge, but noticeable.
**Overall Assessment:**
Ligand A has a significantly better safety profile (DILI) and metabolic stability (Cl_mic), and a better BBB score. However, its logP is very low, which is a major drawback. Ligand B has a better QED, half-life, and binding affinity, but carries a higher DILI risk and poorer metabolic stability.
Considering the importance of a balance between potency, safety, and ADME properties, and given the relatively small affinity difference, the lower DILI risk and better metabolic stability of Ligand A are more compelling. The low logP is a concern, but might be addressable through prodrug strategies or formulation techniques.
Output:
1
2025-04-18 00:24:29,930 - INFO - Here's my reasoning and final output for the ligand preference:
**Reasoning:**
We are targeting ADRB2, a GPCR, so the priorities are logP, TPSA, Pgp, BBB, and affinity. Let's break down each ligand against these and other important parameters:
* **Molecular Weight:** Both ligands are within the ideal range (200-500 Da).
* **TPSA:** Ligand B (87.74) is significantly better than Ligand A (104.65). Lower TPSA generally favors oral absorption and is particularly important for GPCRs.
* **logP:** Ligand A (2.036) is optimal, while Ligand B (0.433) is quite low. A logP below 1 can hinder membrane permeability.
* **H-Bond Donors/Acceptors:** Both are acceptable, within the guidelines.
* **QED:** Both are good, above 0.5, indicating drug-likeness.
* **DILI:** Ligand A has a very high DILI risk (98.41 percentile), which is a major concern. Ligand B has a much lower DILI risk (19.349 percentile).
* **BBB:** Ligand B (52.695) is better than Ligand A (20.318), though neither are exceptionally high. For a cardiovascular target, BBB isn't *critical*, but higher is still preferred.
* **Caco-2:** Both have negative values, which is unusual. I'll interpret these as very low permeability.
* **Solubility:** Both have negative values, which is also unusual. I'll interpret these as very low solubility.
* **hERG:** Both have low hERG risk.
* **Cl_mic:** Ligand B (-10.628) has significantly lower (better) microsomal clearance than Ligand A (6.564), suggesting better metabolic stability.
* **t1/2:** Ligand B (7.134) has a longer half-life than Ligand A (1.054).
* **Pgp:** Both have very low Pgp efflux, which is good.
* **Binding Affinity:** Ligand B (-6.2 kcal/mol) has a slightly better binding affinity than Ligand A (-3.9 kcal/mol). This is a 2.3 kcal/mol difference, which is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Despite Ligand A having a better logP, the significantly higher DILI risk, poorer metabolic stability (higher Cl_mic), shorter half-life, and lower affinity make it a less desirable candidate. Ligand B, while having a lower logP and Caco-2/Solubility, presents a much more favorable safety profile (DILI) and pharmacokinetic profile (Cl_mic, t1/2) and a better binding affinity. The lower logP is a concern, but might be mitigated with formulation strategies. The superior binding affinity and significantly reduced toxicity risk of Ligand B are decisive factors.
**Output:**
0
2025-04-18 00:24:29,930 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (351.491 and 360.845 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (53.09) is significantly better than Ligand B (76.02). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have acceptable logP values (1.226 and 2.17), falling within the 1-3 range. Ligand B is slightly higher, which *could* be a minor benefit, but not a decisive factor.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Both have the same number of HBA (4), which is acceptable.
6. **QED:** Ligand B (0.794) has a slightly better QED score than Ligand A (0.586), indicating a more drug-like profile. This is a positive for Ligand B.
7. **DILI:** Ligand A (12.796) has a much lower DILI risk than Ligand B (59.442). This is a *major* advantage for Ligand A. DILI is a critical safety concern.
8. **BBB:** Ligand A (70.57) has a higher BBB percentile than Ligand B (66.382). While not a primary concern for a cardiovascular target, higher BBB is generally a positive.
9. **Caco-2:** Ligand A (-4.22) is better than Ligand B (-5.194). Higher Caco-2 values indicate better intestinal absorption.
10. **Solubility:** Ligand A (-0.877) is better than Ligand B (-3.199). Solubility is important for formulation and bioavailability.
11. **hERG:** Ligand A (0.301) is significantly better than Ligand B (0.135). Lower hERG inhibition is crucial to avoid cardiotoxicity, especially for a cardiovascular target.
12. **Cl_mic:** Ligand B (22.462) has a significantly lower microsomal clearance than Ligand A (46.957), indicating better metabolic stability. This is a positive for Ligand B.
13. **t1/2:** Ligand B (14.543) has a longer in vitro half-life than Ligand A (5.454). This is a positive for Ligand B.
14. **Pgp:** Ligand A (0.022) has a lower Pgp efflux liability than Ligand B (0.069), which is preferable.
15. **Binding Affinity:** Ligand B (-6.7) has a slightly better binding affinity than Ligand A (-6.4). While a difference of 0.3 kcal/mol is noticeable, it's not a huge advantage, and can be overcome by better ADME properties.
**Overall Assessment:**
Ligand A has a significantly better safety profile (DILI, hERG) and better absorption/solubility properties (Caco-2, Solubility). Ligand B has a better QED, metabolic stability (Cl_mic), and half-life, and slightly better binding affinity. However, the lower DILI and hERG risks of Ligand A are *critical* for a cardiovascular drug. The slightly better affinity of Ligand B doesn't outweigh these safety concerns.
Output:
1
2025-04-18 00:24:29,930 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A: [366.487, 85.51, 0.807, 2, 5, 0.807, 20.047, 46.879, -5.246, -1.853, 0.338, -31.948, -11.058, 0.012, -7.8]**
**Ligand B: [344.415, 84.42, 1.239, 1, 5, 0.834, 65.103, 63.086, -4.795, -1.683, 0.134, 22.08, 0.917, 0.016, -7.2]**
Here's a breakdown, considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity) and general guidelines:
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (344.415) is slightly lower, which is generally favorable.
2. **TPSA:** Both are good, under the 140 A^2 threshold for oral absorption (A: 85.51, B: 84.42).
3. **logP:** Both are within the optimal range (1-3), but Ligand B (1.239) is a bit higher, potentially leading to better membrane permeability. Ligand A (0.807) is on the lower side.
4. **HBD:** Ligand A (2) is slightly better than Ligand B (1). Lower HBD is generally preferred for permeability.
5. **HBA:** Both have 5 HBA, which is acceptable.
6. **QED:** Both are good (A: 0.807, B: 0.834), indicating good drug-like properties.
7. **DILI:** Ligand A (20.047) is significantly better than Ligand B (65.103). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (63.086) has better BBB penetration than Ligand A (46.879). While ADRB2 is a cardiovascular target, some CNS exposure is not necessarily detrimental and could offer additional therapeutic avenues.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-5.246) is worse than Ligand B (-4.795).
10. **Solubility:** Both have negative solubility values, which is also unusual and suggests poor solubility. Ligand A (-1.853) is worse than Ligand B (-1.683).
11. **hERG:** Both have low hERG risk (A: 0.338, B: 0.134). Ligand B is slightly better.
12. **Cl_mic:** Ligand A (-31.948) has a much lower (better) microsomal clearance than Ligand B (22.08). This indicates greater metabolic stability for Ligand A.
13. **t1/2:** Ligand A (-11.058) has a worse in vitro half-life than Ligand B (0.917).
14. **Pgp:** Both have very low Pgp efflux liability (A: 0.012, B: 0.016).
15. **Affinity:** Ligand B (-7.2) has a slightly better binding affinity than Ligand A (-7.8). However, the difference is relatively small (0.6 kcal/mol).
**Overall Assessment:**
Ligand A has a significantly better DILI score and a much better microsomal clearance, which are critical for drug development. While Ligand B has slightly better BBB penetration and affinity, the lower DILI risk and improved metabolic stability of Ligand A outweigh these advantages. The poor Caco-2 and solubility for both ligands are concerning, but can be addressed with formulation strategies. The slightly better affinity of Ligand B is not enough to overcome the significant DILI risk.
Therefore, I prefer Ligand A.
Output:
1
2025-04-18 00:24:29,930 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.46 and 348.41 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (74.43) is significantly better than Ligand B (114.2). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have a logP around 2.1, which is optimal. No clear advantage.
4. **HBD:** Ligand A (2) is preferable to Ligand B (3). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (8). Lower HBA generally improves permeability.
6. **QED:** Ligand A (0.793) is better than Ligand B (0.59), indicating a more drug-like profile.
7. **DILI:** Ligand A (25.67) is *much* better than Ligand B (64.68). This is a critical advantage, as DILI is a major concern in drug development.
8. **BBB:** Both ligands have reasonably good BBB penetration (A: 70.8, B: 73.5). Not a major differentiating factor for a cardiovascular target.
9. **Caco-2:** Ligand A (-4.758) is better than Ligand B (-5.061), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-2.951) is better than Ligand B (-3.277). Better solubility is always preferred.
11. **hERG:** Ligand A (0.393) is better than Ligand B (0.516). Lower hERG inhibition is crucial for avoiding cardiotoxicity.
12. **Cl_mic:** Ligand A (38.189) is better than Ligand B (74.647). Lower clearance indicates better metabolic stability.
13. **t1/2:** Ligand A (-11.978) is better than Ligand B (-1.666). A longer in vitro half-life is generally desirable.
14. **Pgp:** Both ligands have very low Pgp efflux (0.037 and 0.035). This is good.
15. **Binding Affinity:** Ligand A (-6.2) is slightly better than Ligand B (-5.5). While the difference is not huge, it's a positive.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Both ligands perform well on logP and Pgp. Ligand A is significantly better on TPSA, and has a slightly better affinity. The *major* advantage of Ligand A is its significantly lower DILI risk and better metabolic stability (Cl_mic and t1/2). Given the importance of safety and efficacy, these factors outweigh the slightly better BBB penetration of Ligand B.
**Conclusion:**
Ligand A is the superior candidate due to its better overall ADME-Tox profile, particularly the significantly lower DILI risk, improved metabolic stability, and slightly better binding affinity.
Output:
1
2025-04-18 00:24:29,931 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (345.491 and 336.326 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (63.05) is significantly better than Ligand B (76.97). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (3.044 and 3.493), falling within the optimal 1-3 range. Ligand B is slightly higher, which could potentially lead to some off-target interactions, but it's not a major concern.
4. **HBD:** Both ligands have 1 HBD, which is within the acceptable limit of <=5.
5. **HBA:** Ligand A has 4 HBAs, while Ligand B has 6. Both are within the acceptable limit of <=10, but Ligand A is preferable.
6. **QED:** Ligand A (0.892) has a much better QED score than Ligand B (0.617), indicating a more drug-like profile.
7. **DILI:** Ligand A (29.081) has a significantly lower DILI risk than Ligand B (91.857). This is a crucial factor, as liver toxicity is a major concern in drug development.
8. **BBB:** Ligand A (83.87) has a higher BBB penetration score than Ligand B (33.579). While not a primary concern for a cardiovascular target, higher BBB is generally a positive attribute.
9. **Caco-2:** Ligand A (-4.805) and Ligand B (-5.001) have similar Caco-2 permeability, suggesting similar intestinal absorption.
10. **Solubility:** Ligand A (-3.23) has slightly better solubility than Ligand B (-4.089).
11. **hERG:** Ligand A (0.112) has a much lower hERG inhibition liability than Ligand B (0.527). This is a critical safety parameter, and Ligand A is significantly better.
12. **Cl_mic:** Ligand B (77.077) has a higher microsomal clearance than Ligand A (47.745), indicating faster metabolism and potentially lower bioavailability.
13. **t1/2:** Ligand A (21.076) has a significantly longer in vitro half-life than Ligand B (-60.697). This is a major advantage, as it suggests less frequent dosing.
14. **Pgp:** Ligand A (0.144) has lower P-gp efflux liability than Ligand B (0.304), suggesting better bioavailability.
15. **Binding Affinity:** Ligand B (-8.6) has a slightly better binding affinity than Ligand A (-5.6). However, the difference is significant enough to be considered, but not enough to outweigh the other factors.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand B has a slightly better logP and affinity, but Ligand A excels in TPSA and Pgp. The substantial differences in DILI, hERG, Cl_mic, and t1/2 overwhelmingly favor Ligand A.
**Conclusion:**
Considering all factors, especially the significantly improved safety profile (DILI, hERG) and pharmacokinetic properties (Cl_mic, t1/2, Pgp) of Ligand A, it is the more promising drug candidate despite the slightly lower binding affinity.
Output:
1
2025-04-18 00:24:29,931 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [347.419, 101.53 , -0.236, 1. , 5. , 0.794, 28.422, 62.97 ,
-5.558, -1.466, 0.135, -9.082, -1.738, 0.011, -6.8 ]
**Ligand B:** [343.427, 75.44 , 2.325, 1. , 4. , 0.805, 40.403, 70.997,
-4.837, -3.23 , 0.274, 34.784, -3.142, 0.131, -5.4 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B is slightly lower (343.43 vs 347.42 Da), which is marginally better.
2. **TPSA:** Ligand A (101.53) is higher than Ligand B (75.44). Ligand B is much better, being closer to the <140 threshold for oral absorption and more favorable for GPCRs.
3. **logP:** Ligand A (-0.236) is quite low, potentially hindering permeability. Ligand B (2.325) is within the optimal 1-3 range. This is a significant advantage for Ligand B.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 5 HBA, while Ligand B has 4. Both are acceptable, but Ligand B is slightly better.
6. **QED:** Both have good QED scores (0.794 and 0.805), indicating drug-likeness.
7. **DILI:** Ligand A (28.422) has a lower DILI risk than Ligand B (40.403), which is a positive.
8. **BBB:** Ligand B (70.997) has a better BBB penetration score than Ligand A (62.97). This is important for a GPCR target, though not strictly required for ADRB2.
9. **Caco-2:** Ligand A (-5.558) has a very poor Caco-2 permeability, while Ligand B (-4.837) is slightly better, but still not ideal.
10. **Solubility:** Ligand A (-1.466) has better solubility than Ligand B (-3.23).
11. **hERG:** Both have low hERG inhibition risk (0.135 and 0.274).
12. **Cl_mic:** Ligand A (-9.082) has significantly lower microsomal clearance, indicating better metabolic stability than Ligand B (34.784). This is a major advantage for Ligand A.
13. **t1/2:** Ligand A (-1.738) has a shorter in vitro half-life than Ligand B (-3.142).
14. **Pgp:** Both have low P-gp efflux liability (0.011 and 0.131).
15. **Affinity:** Ligand A (-6.8) has a slightly better binding affinity than Ligand B (-5.4).
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, and affinity. Ligand B excels in TPSA and logP, while Ligand A has slightly better affinity and significantly better metabolic stability (Cl_mic). The lower logP of Ligand A is a concern.
**Overall Assessment:**
While Ligand A has better metabolic stability and affinity, the significantly lower logP and poor Caco-2 permeability are major drawbacks. Ligand B, despite slightly higher DILI risk and lower metabolic stability, has a much more favorable balance of properties, particularly regarding permeability and lipophilicity, which are crucial for GPCR targets. The better TPSA also contributes to its favorability. The affinity difference isn't large enough to overcome the ADME deficiencies of Ligand A.
Therefore, I prefer Ligand B.
Output:
0
2025-04-18 00:24:29,931 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.487 Da) are within the ideal range (200-500 Da).
2. **TPSA:** Both ligands (49.85) are well below the 140 A^2 threshold for good oral absorption, and appropriate for a non-CNS GPCR target like ADRB2.
3. **logP:** Both ligands (2.587 and 2.629) are within the optimal range of 1-3.
4. **HBD:** Both ligands have 0 HBD, which is acceptable.
5. **HBA:** Ligand A has 4 HBA, Ligand B has 3. Both are below the 10 threshold.
6. **QED:** Ligand A (0.736) has a slightly better QED score than Ligand B (0.665), indicating a more drug-like profile.
7. **DILI:** Ligand A (19.969) has a significantly lower DILI risk than Ligand B (34.781). This is a substantial advantage.
8. **BBB:** BBB is less critical for ADRB2 (a cardiovascular target), but Ligand B (79.721) has a higher BBB penetration than Ligand A (53.47).
9. **Caco-2:** Ligand A (-4.682) and Ligand B (-4.103) both have negative Caco-2 permeability values, which is unusual and suggests poor absorption. However, the scale is not defined, so it's difficult to interpret.
10. **Solubility:** Both ligands have negative solubility values (-2.181 and -2.809), which is concerning. Again, the scale is undefined, making interpretation difficult.
11. **hERG:** Both ligands have low hERG inhibition liability (0.574 and 0.513).
12. **Cl_mic:** Ligand A (54.743) has a lower microsomal clearance than Ligand B (86.241), suggesting better metabolic stability.
13. **t1/2:** Ligand B (16.065) has a longer in vitro half-life than Ligand A (-13.362). This is a positive attribute.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.258 and 0.285).
15. **Binding Affinity:** Ligand A (-8.2 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.3 kcal/mol). This is a >1.5 kcal/mol advantage, which is a major factor.
**GPCR-specific priorities:** For ADRB2, logP, TPSA, Pgp, and affinity are key. Both ligands are good on logP, TPSA, and Pgp. However, Ligand A has a substantially better binding affinity. The DILI risk is also a major concern, and Ligand A is much better in this regard. While Ligand B has a better half-life and BBB penetration, these are less critical for a cardiovascular target. The solubility and Caco-2 values are problematic for both, but the affinity and safety profile of Ligand A outweigh the slightly better PK properties of Ligand B.
**Output:**
1
2025-04-18 00:24:29,931 - INFO - Batch 475 complete. Total preferences: 7600
2025-04-18 00:24:29,931 - INFO - Processing batch 476/512...
2025-04-18 00:25:14,925 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.43 and 346.52 Da) fall comfortably within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (67.87) is higher than Ligand B (54.19). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferable for absorption. Ligand B has a slight advantage.
3. **logP:** Ligand A (2.393) is within the optimal 1-3 range. Ligand B (3.506) is slightly higher, bordering on potentially causing solubility issues, but still acceptable. Ligand A is slightly preferred.
4. **HBD:** Both ligands have 1 HBD, which is good. No difference.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 5. Both are acceptable (<=10), but Ligand A is slightly better.
6. **QED:** Both ligands have good QED scores (0.831 and 0.884), indicating good drug-like properties. Ligand B is marginally better.
7. **DILI:** Ligand A (59.48%) has a higher DILI risk than Ligand B (9.97%). This is a *significant* advantage for Ligand B. DILI is a major concern in drug development.
8. **BBB:** Both ligands have high BBB penetration (90.62% and 92.01%). Since ADRB2 is a cardiovascular target, BBB penetration is not a primary concern, but higher is not detrimental. Ligand B is slightly better.
9. **Caco-2:** Ligand A (-4.341) and Ligand B (-5.455) both have negative values, which is unusual and suggests poor permeability. Ligand B is slightly worse.
10. **Solubility:** Ligand A (-2.774) and Ligand B (-1.921) both have negative solubility values, suggesting poor aqueous solubility. Ligand B is slightly better.
11. **hERG:** Ligand A (0.306) has a lower hERG risk than Ligand B (0.889). This is a significant advantage for Ligand A, as hERG inhibition can lead to cardiotoxicity.
12. **Cl_mic:** Ligand A (43.265) has a higher microsomal clearance than Ligand B (-2.345). This means Ligand B is likely more metabolically stable, which is desirable.
13. **t1/2:** Ligand A (29.538) has a longer in vitro half-life than Ligand B (23.973). This is a positive for Ligand A.
14. **Pgp:** Ligand A (0.106) has lower P-gp efflux than Ligand B (0.231). Lower P-gp efflux is generally preferred for better bioavailability. Ligand A is better.
15. **Binding Affinity:** Ligand B (-5.9 kcal/mol) has a stronger binding affinity than Ligand A (-4.6 kcal/mol). This is a 1.3 kcal/mol difference, which is a substantial advantage for Ligand B and can outweigh some ADME concerns.
**Overall Assessment:**
While Ligand A has advantages in hERG, P-gp efflux, and half-life, Ligand B's significantly lower DILI risk and stronger binding affinity are more critical. The stronger binding affinity is a substantial advantage for a GPCR target. Although solubility and Caco-2 permeability are poor for both, the DILI risk is a major concern that tips the balance in favor of Ligand B. The metabolic stability (lower Cl_mic) of Ligand B is also a positive.
Output:
0
2025-04-18 00:25:14,925 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (336.395 and 362.455 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (92.24) is slightly higher than Ligand B (87.46), but both are below the 140 threshold for good oral absorption, and acceptable for a cardiovascular GPCR.
3. **logP:** Both ligands have excellent logP values (2.062 and 1.951), falling within the optimal 1-3 range.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2) as lower HBD generally improves permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (6) for similar reasons as HBD.
6. **QED:** Both ligands have high QED scores (0.922 and 0.87), indicating good drug-like properties.
7. **DILI:** Ligand A (58.627) is slightly better than Ligand B (61.613) in terms of DILI risk, both are acceptable.
8. **BBB:** Ligand A (70.88) has a significantly better BBB penetration percentile than Ligand B (43.273). While ADRB2 isn't strictly a CNS target, some brain exposure can be relevant for off-target effects and overall safety.
9. **Caco-2:** Ligand A (-4.954) and Ligand B (-5.298) are both very poor. This is a significant drawback for both, suggesting poor intestinal absorption.
10. **Solubility:** Ligand A (-3.856) is slightly better than Ligand B (-3.128), but both are poor. This is a concern for bioavailability.
11. **hERG:** Ligand A (0.824) is better than Ligand B (0.26), indicating a lower risk of cardiotoxicity. This is crucial for a cardiovascular target.
12. **Cl_mic:** Ligand A (58.29) is better than Ligand B (-0.067). Lower clearance is preferred for metabolic stability.
13. **t1/2:** Ligand A (9.341) has a significantly longer half-life than Ligand B (11.981). This is a major advantage, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.312) is better than Ligand B (0.1), indicating lower P-gp efflux.
15. **Binding Affinity:** Ligand B (-5.9 kcal/mol) has a slightly better binding affinity than Ligand A (-7.0 kcal/mol). However, the difference is not substantial enough to overcome the other advantages of Ligand A.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B in most critical ADME-Tox properties (DILI, hERG, Cl_mic, t1/2, Pgp) and has a better BBB profile. While Ligand B has a slightly better binding affinity, the overall profile of Ligand A is more favorable for development as a drug candidate. The poor Caco-2 and solubility for both are concerning, but can be addressed with formulation strategies.
Output:
1
2025-04-18 00:25:14,926 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (336.4) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (85.2) is better than Ligand B (104.5). Both are below 140, but closer to 90 is better for GPCRs, and A is closer.
3. **logP:** Ligand A (1.96) is within the optimal range (1-3), while Ligand B (-0.83) is below 1, which could indicate poor membrane permeability. This is a significant disadvantage for Ligand B.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 6 HBA, while Ligand B has 7. Both are acceptable, but lower is generally preferred.
6. **QED:** Ligand A (0.92) has a significantly better QED score than Ligand B (0.67), indicating a more drug-like profile.
7. **DILI:** Ligand B (39.3) has a much lower DILI risk than Ligand A (75.3), which is a strong positive for Ligand B.
8. **BBB:** Ligand A (50.7) has a better BBB penetration score than Ligand B (27.6). While ADRB2 isn't strictly a CNS target, some CNS exposure can be relevant, and higher BBB is generally preferable.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Ligand A (-3.21) has better solubility than Ligand B (-0.69). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.58) has a slightly higher hERG risk than Ligand B (0.03), but both are quite low.
12. **Cl_mic:** Ligand B (9.5) has a significantly lower microsomal clearance than Ligand A (20.8), indicating better metabolic stability.
13. **t1/2:** Ligand A (6.0) has a positive in vitro half-life, while Ligand B (-17.1) is negative, which is concerning.
14. **Pgp:** Ligand A (0.05) has lower P-gp efflux liability than Ligand B (0.02), which is favorable.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.3 and -6.4 kcal/mol). The difference is negligible.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, and Pgp are important. Ligand A is significantly better in logP and TPSA. While Pgp is slightly better for A, the difference is minimal. Metabolic stability (Cl_mic) is also important, and Ligand B performs better here. DILI risk is a concern for Ligand A.
**Overall Assessment:**
Ligand A has a better overall drug-like profile (QED, solubility, TPSA, logP) and comparable affinity. Ligand B has a lower DILI risk and better metabolic stability. However, the poor logP and lower QED of Ligand B are significant drawbacks. The negative in vitro half-life of Ligand B is also a major concern. Given the similar binding affinities, the better ADME properties of Ligand A, particularly its logP and QED, make it the more promising candidate.
Output:
1
2025-04-18 00:25:14,926 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**1. Molecular Weight:** Both ligands (349.381 and 348.363 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (62.3) is significantly better than Ligand B (137.24). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is above the 140 threshold for good oral absorption, which is a concern.
**3. logP:** Ligand A (2.247) is within the optimal 1-3 range. Ligand B (-1.178) is below 1, which could hinder membrane permeability.
**4. H-Bond Donors:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
**5. H-Bond Acceptors:** Ligand A (3) is better than Ligand B (7). Similar reasoning as with HBDs.
**6. QED:** Ligand A (0.907) has a much higher QED score than Ligand B (0.597), indicating a more drug-like profile.
**7. DILI:** Ligand B (60.799) has a higher DILI risk than Ligand A (43.738), though both are acceptable.
**8. BBB:** Ligand A (87.553) shows significantly better BBB penetration potential than Ligand B (13.61). While ADRB2 isn't exclusively a CNS target, some CNS exposure may be relevant, and better BBB penetration is generally desirable.
**9. Caco-2 Permeability:** Ligand A (-4.554) is better than Ligand B (-6.187).
**10. Aqueous Solubility:** Ligand A (-2.844) is better than Ligand B (-0.976).
**11. hERG:** Both ligands have very low hERG inhibition risk (0.459 and 0.029 respectively).
**12. Microsomal Clearance:** Ligand B (-22.888) has lower (better) microsomal clearance than Ligand A (26.401), suggesting greater metabolic stability.
**13. In vitro Half-Life:** Ligand B (-1.81) has a longer half-life than Ligand A (-32.13).
**14. P-gp Efflux:** Both ligands show very low P-gp efflux liability (0.105 and 0.006 respectively).
**15. Binding Affinity:** Ligand B (-7.1) has a slightly better binding affinity than Ligand A (-6.0). However, the difference is less than 1.5 kcal/mol, and is outweighed by the other factors.
**Overall Assessment:**
Ligand A is significantly better overall. It excels in key ADME properties (TPSA, logP, QED, solubility, BBB) crucial for oral bioavailability and distribution. While Ligand B has slightly better binding affinity and metabolic stability, the substantial drawbacks in TPSA, logP, and BBB penetration make it a less favorable candidate. The higher QED score of Ligand A also indicates a more promising drug-like profile.
Output:
1
2025-04-18 00:25:14,926 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (348.575 Da and 344.415 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (32.34) is significantly better than Ligand B (86.37). For a GPCR, lower TPSA is generally preferred for better permeability, and Ligand A is well below the 140 threshold. Ligand B is higher, potentially hindering absorption.
**3. logP:** Ligand A (4.9) is higher than Ligand B (1.108). While both are within the acceptable range, Ligand A is approaching the upper limit. This could lead to solubility issues, but for a GPCR, a slightly higher logP can be tolerated if other parameters are favorable.
**4. H-Bond Donors:** Both have 1 HBD, which is good.
**5. H-Bond Acceptors:** Ligand A has 2, Ligand B has 4. Both are acceptable, but Ligand A is preferable.
**6. QED:** Both ligands have good QED values (0.74 and 0.832), indicating generally drug-like properties.
**7. DILI Risk:** Ligand A (13.532) has a much lower DILI risk than Ligand B (51.881). This is a significant advantage for Ligand A.
**8. BBB Penetration:** Ligand A (79.992) has considerably better BBB penetration than Ligand B (49.399). While ADRB2 is primarily a cardiovascular target, some CNS effects are possible with beta-blockers, and higher BBB penetration could be beneficial or detrimental depending on the desired profile.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.883 and -4.862). These values are difficult to interpret without knowing the scale, but the similarity suggests comparable intestinal absorption potential.
**10. Aqueous Solubility:** Ligand A (-4.344) is slightly worse than Ligand B (-2.242), but both are poor. This is a concern for Ligand A, given its higher logP.
**11. hERG Inhibition:** Ligand A (0.895) has a slightly higher hERG risk than Ligand B (0.264). This is a negative for Ligand A, and a significant advantage for Ligand B.
**12. Microsomal Clearance:** Ligand A (62.387) has higher microsomal clearance than Ligand B (30.162), indicating lower metabolic stability. This is a disadvantage for Ligand A.
**13. In vitro Half-Life:** Ligand A (8.915) has a significantly longer half-life than Ligand B (-19.979). This is a major advantage for Ligand A.
**14. P-gp Efflux:** Ligand A (0.433) has lower P-gp efflux than Ligand B (0.088), suggesting better bioavailability.
**15. Binding Affinity:** Ligand A (-6.6 kcal/mol) has a slightly better binding affinity than Ligand B (-6.0 kcal/mol). While the difference is not huge, it's enough to consider.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand A appears to be the better candidate. Its lower TPSA, lower DILI risk, better BBB penetration, longer half-life, and slightly better affinity outweigh its higher logP, lower solubility, and slightly higher hERG risk. The significant advantage in metabolic stability (lower Cl_mic and longer t1/2) is also crucial. While the solubility and hERG are concerns, they can potentially be addressed through formulation strategies or further chemical modifications. Ligand B's lower hERG is attractive, but its higher TPSA, higher DILI risk, and poorer BBB penetration are more significant drawbacks.
Output:
1
2025-04-18 00:25:14,926 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (355.435 and 343.387 Da) are within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (121.96) is slightly higher than Ligand B (114.35). Both are below the 140 threshold for good oral absorption, but closer to the 90 threshold for CNS targets. Ligand B is slightly better.
3. **logP:** Ligand A (-0.466) is a bit low, potentially hindering permeation. Ligand B (1.902) is within the optimal 1-3 range. Ligand B is significantly better.
4. **HBD:** Ligand A (3) is acceptable. Ligand B (2) is also good. No clear advantage.
5. **HBA:** Ligand A (5) is acceptable. Ligand B (6) is also acceptable. No clear advantage.
6. **QED:** Ligand B (0.828) is much better than Ligand A (0.516), indicating a stronger drug-like profile.
7. **DILI:** Ligand A (16.44) has a much lower DILI risk than Ligand B (60.062). This is a significant advantage for Ligand A.
8. **BBB:** Ligand B (70.105) shows good BBB penetration, while Ligand A (40.403) is lower. Given ADRB2's cardiovascular involvement, BBB penetration isn't a primary concern, but it's a slight advantage for B.
9. **Caco-2:** Both ligands have similar, very negative Caco-2 values (-5.4 and -5.102). This indicates poor permeability, which is a concern for both.
10. **Solubility:** Ligand A (-0.823) has slightly better solubility than Ligand B (-2.787).
11. **hERG:** Ligand A (0.037) has a very low hERG risk, while Ligand B (0.186) is slightly higher. This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand A (9.656) has much lower microsomal clearance than Ligand B (32.79), indicating better metabolic stability.
13. **t1/2:** Ligand B (-33.367) has a very negative half-life, indicating very poor stability. Ligand A (1.41) is better, but still not ideal.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.006 and 0.007). No clear advantage.
15. **Binding Affinity:** Ligand B (-8.2) has a significantly stronger binding affinity than Ligand A (-6.4), a difference of 1.8 kcal/mol. This is a substantial advantage.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP and affinity. However, Ligand A has a much better safety profile (DILI, hERG) and metabolic stability (Cl_mic). The strong affinity of Ligand B is tempting, but the high DILI risk and poor metabolic stability are major concerns. The slightly lower affinity of Ligand A is acceptable given its superior safety and pharmacokinetic properties.
**Conclusion:**
Despite the stronger binding affinity of Ligand B, the significantly better safety profile and metabolic stability of Ligand A make it the more promising drug candidate.
Output:
1
2025-04-18 00:25:14,926 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (360.357 and 350.463 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (81.01) is better than Ligand B (84.42). Both are below the 140 threshold for oral absorption, but lower is preferred.
3. **logP:** Both ligands (1.601 and 1.952) are within the optimal 1-3 range. Ligand B is slightly higher, which could be a minor concern for off-target effects, but not a deal-breaker.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 5 HBA, and Ligand B has 6. Both are acceptable (<=10).
6. **QED:** Ligand A (0.712) is slightly better than Ligand B (0.685), indicating a more drug-like profile.
7. **DILI:** Ligand A (31.485) has a significantly lower DILI risk than Ligand B (52.191). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (94.455) has a much higher BBB penetration potential than Ligand B (44.281). While ADRB2 isn't exclusively a CNS target, better BBB penetration can sometimes translate to improved distribution and reduced off-target effects.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-4.676) is slightly better than Ligand B (-4.735), but both are concerning.
10. **Solubility:** Both ligands have poor solubility (-2.39 and -2.047). This is a significant drawback for both.
11. **hERG:** Ligand A (0.689) has a lower hERG inhibition liability than Ligand B (0.104), which is a significant safety advantage.
12. **Cl_mic:** Ligand A (-1.494) has a lower (better) microsomal clearance than Ligand B (77.883), indicating greater metabolic stability.
13. **t1/2:** Ligand A (-9.06) has a longer in vitro half-life than Ligand B (4.482), which is desirable.
14. **Pgp:** Ligand A (0.089) has lower P-gp efflux liability than Ligand B (0.03), which is a positive.
15. **Binding Affinity:** Ligand B (-3.6 kcal/mol) has a slightly better binding affinity than Ligand A (-5.6 kcal/mol). However, the difference is not substantial enough to outweigh the other significant advantages of Ligand A.
**GPCR-specific priorities:** For GPCRs, logP, TPSA, Pgp, and affinity are important. While Ligand B has a slightly better logP and affinity, Ligand A excels in TPSA, Pgp, and crucially, safety parameters (DILI, hERG).
**Overall Assessment:**
Ligand A demonstrates a significantly more favorable ADMET profile, particularly regarding safety (DILI, hERG) and metabolic stability (Cl_mic, t1/2). While both have solubility and Caco-2 permeability issues, the superior safety and pharmacokinetic properties of Ligand A make it the more promising drug candidate, despite the slightly lower binding affinity.
Output:
1
2025-04-18 00:25:14,927 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [354.357, 93.21, 1.902, 2, 5, 0.761, 54.362, 89.725, -4.668, -2.541, 0.104, 21.546, 7.179, 0.037, -6.3]
**Ligand B:** [346.431, 107.01, 1.802, 3, 4, 0.593, 56.689, 38.581, -4.956, -3.862, 0.674, 56.434, 13.154, 0.148, -5.7]
Here's a breakdown, prioritizing GPCR properties (logP, Pgp, TPSA, BBB, Affinity) and general drug-like characteristics:
1. **MW:** Both are within the ideal 200-500 Da range. A (354.357) is slightly higher, but not concerning.
2. **TPSA:** A (93.21) is better than B (107.01), both are acceptable for a non-CNS GPCR target like ADRB2.
3. **logP:** Both are excellent (around 1.8-1.9), falling within the optimal 1-3 range.
4. **HBD/HBA:** A (2/5) is slightly better than B (3/4). Lower counts are generally preferred for permeability.
5. **QED:** A (0.761) is significantly better than B (0.593), indicating a more drug-like profile.
6. **DILI:** Both are reasonably good (A: 54.362, B: 56.689), below the concerning 60 threshold.
7. **BBB:** A (89.725) is *much* better than B (38.581). While ADRB2 isn't primarily a CNS target, some off-target CNS effects are always a consideration, and higher BBB is generally favorable.
8. **Caco-2:** Both are negative, suggesting poor permeability. This is a significant drawback for both.
9. **Solubility:** Both are negative, indicating poor solubility. This is also a significant drawback for both.
10. **hERG:** A (0.104) is significantly better than B (0.674), indicating a lower risk of cardiotoxicity, which is *critical* for an ADRB2 ligand given its cardiovascular implications.
11. **Cl_mic:** A (21.546) is much better than B (56.434), indicating better metabolic stability.
12. **t1/2:** A (7.179) is better than B (13.154) - longer half-life is generally preferred.
13. **Pgp:** A (0.037) is significantly better than B (0.148), indicating lower P-glycoprotein efflux. This improves bioavailability.
14. **Affinity:** A (-6.3 kcal/mol) is slightly better than B (-5.7 kcal/mol), though the difference is not massive.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most key ADME-Tox properties, and has a slightly better binding affinity. The most important differences are the significantly better hERG inhibition profile, lower Pgp efflux, and improved metabolic stability (lower Cl_mic) of Ligand A. While both have poor Caco-2 and solubility, the other advantages of A outweigh this. Given the cardiovascular target, minimizing hERG risk is paramount.
Output:
1
2025-04-18 00:25:14,927 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.46 & 349.39 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (80.32) is significantly better than Ligand B (124.26). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is pushing the upper limit for good oral absorption.
3. **logP:** Ligand A (1.983) is within the optimal 1-3 range. Ligand B (-0.593) is slightly below 1, which *could* indicate permeability issues, though not drastically.
4. **HBD:** Ligand A (2) and Ligand B (3) are both acceptable, being less than 5.
5. **HBA:** Ligand A (4) and Ligand B (5) are both acceptable, being less than 10.
6. **QED:** Both ligands have good QED scores (0.753 and 0.655), indicating generally drug-like properties.
7. **DILI:** Ligand A (27.88) has a much lower DILI risk than Ligand B (51.22). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (51.73) has a better BBB penetration score than Ligand B (33.11). While ADRB2 isn't exclusively a CNS target, some CNS exposure or off-target effects are possible, and higher BBB is generally preferable.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.213 and -5.526). These values are unusual and difficult to interpret without further context. However, a more negative value generally suggests poorer permeability.
10. **Solubility:** Both ligands have negative solubility values (-2.065 and -2.429). These values are also unusual and suggest very poor aqueous solubility.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.123 and 0.067). This is excellent.
12. **Cl_mic:** Ligand A (9.008) has a much lower microsomal clearance than Ligand B (-21.93). This indicates better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (27.755) has a longer in vitro half-life than Ligand B (-17.886). This is a significant advantage for Ligand A.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.019 and 0.005). This is excellent.
15. **Binding Affinity:** Ligand B (-7.5 kcal/mol) has a slightly better binding affinity than Ligand A (-6.3 kcal/mol). This is a 1.2 kcal/mol difference, which is significant, but needs to be weighed against the other factors.
**Overall Assessment:**
Ligand B has a slightly better binding affinity, which is a key factor for GPCRs. However, Ligand A is superior in almost all ADME-Tox properties. Specifically, the lower DILI risk, better BBB penetration, significantly improved metabolic stability (lower Cl_mic and longer t1/2), and better TPSA make Ligand A a much more promising drug candidate. The solubility and Caco-2 values are concerning for both, but the other advantages of Ligand A outweigh the slight affinity benefit of Ligand B. The negative solubility and Caco-2 values would need further investigation.
Output:
1
2025-04-18 00:25:14,927 - INFO - Here's my reasoning and final output:
**Reasoning:**
We're evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, key priorities are logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB.
Let's break down the comparison:
1. **MW:** Both ligands are within the acceptable range (200-500 Da). Ligand A (356.394) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (67.43) has a significantly lower TPSA than Ligand A (92.78). This is a major advantage for Ligand B, suggesting better membrane permeability and oral absorption.
3. **logP:** Ligand B (2.542) is within the optimal range (1-3), while Ligand A (0.753) is slightly below, potentially hindering permeation.
4. **HBD/HBA:** Both have acceptable HBD/HBA counts.
5. **QED:** Both ligands have good QED scores (>0.5), indicating drug-likeness. Ligand B (0.678) is slightly better.
6. **DILI:** Both have acceptable DILI risk (below 50). Ligand B (47.693) is slightly better.
7. **BBB:** Ligand A (77.162) has a better BBB score than Ligand B (68.748), but BBB is less critical for a cardiovascular target.
8. **Caco-2:** Ligand B (-5.546) shows better Caco-2 permeability than Ligand A (-4.495).
9. **Solubility:** Ligand B (-3.009) has slightly better solubility than Ligand A (-2.266).
10. **hERG:** Both ligands have low hERG inhibition risk.
11. **Cl_mic:** Ligand A (44.492) has lower microsomal clearance, indicating better metabolic stability.
12. **t1/2:** Ligand B (14.156) has a significantly longer in vitro half-life than Ligand A (-30.173). This is a significant advantage.
13. **Pgp:** Ligand A (0.059) has lower P-gp efflux liability than Ligand B (0.085), which is favorable.
14. **Binding Affinity:** Ligand B (-7.3) has a slightly stronger binding affinity than Ligand A (-7.0). While the difference is small, it's still a positive.
**Overall Assessment:**
Ligand B demonstrates a superior balance of properties, particularly regarding TPSA, logP, Caco-2 permeability, solubility, and half-life. While Ligand A has slightly better metabolic stability and Pgp efflux, the advantages of Ligand B in permeability and pharmacokinetic properties outweigh these minor drawbacks. The slightly stronger binding affinity of Ligand B further supports its selection.
**Output:**
0
2025-04-18 00:25:14,927 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (350.478 and 346.475 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (49.41) is significantly better than Ligand B (67.23). ADRB2 is not a CNS target, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (3.199 and 2.373), falling within the optimal 1-3 range. Ligand A is slightly higher, which *could* be beneficial for membrane permeability, but isn't a major concern.
4. **HBD:** Both ligands have 1 HBD, which is within the acceptable limit of 5.
5. **HBA:** Ligand A has 2 HBA, while Ligand B has 4. Lower is generally preferred, giving a slight edge to Ligand A.
6. **QED:** Both ligands have similar QED values (0.828 and 0.771), indicating good drug-likeness.
7. **DILI:** Ligand A (17.449%) has a substantially lower DILI risk than Ligand B (21.946%). This is a significant advantage for Ligand A.
8. **BBB:** While not a primary concern for ADRB2, Ligand A (89.104%) has a higher BBB penetration percentile than Ligand B (74.874%).
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.834 and -4.919). These values are difficult to interpret without knowing the scale, but suggest poor permeability.
10. **Solubility:** Ligand A (-4.44) has slightly better solubility than Ligand B (-2.112), although both are poor.
11. **hERG:** Ligand A (0.72) has a slightly better hERG profile than Ligand B (0.284), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand A (21.563) has a significantly lower microsomal clearance than Ligand B (34.988). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (6.323) has a longer in vitro half-life than Ligand B (-1.568). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.158) has lower P-gp efflux liability than Ligand B (0.111).
15. **Binding Affinity:** Ligand B (-7.3 kcal/mol) has a slightly better binding affinity than Ligand A (-8.1 kcal/mol). While a difference of 0.8 kcal/mol is noticeable, it is not a large enough difference to outweigh the other advantages of Ligand A.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A is better on TPSA, Pgp, and has comparable logP. The difference in affinity is small.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B in crucial ADME-Tox properties (DILI, Cl_mic, t1/2, solubility, hERG) and has a more favorable TPSA. While Ligand B has slightly better binding affinity, the other advantages of Ligand A make it the more promising drug candidate.
Output:
1
2025-04-18 00:25:14,927 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for the ADRB2, a cardiovascular GPCR. Therefore, the key properties to prioritize are logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB (though less critical for a cardiovascular target).
Let's compare the ligands property by property:
1. **MW:** Both ligands (350.344 and 352.381 Da) are within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (66.91) is slightly higher than Ligand B (58.64). Both are below the 140 threshold for good absorption, but B is better.
3. **logP:** Ligand A (3.622) is at the upper end of the optimal range (1-3), while Ligand B (2.112) is well within it. This favors B.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1). Both are acceptable.
5. **HBA:** Both ligands have 3 HBA, which is good.
6. **QED:** Both ligands have good QED scores (0.81 and 0.903), indicating drug-likeness.
7. **DILI:** Ligand A (76.076) has a significantly higher DILI risk than Ligand B (35.867). This is a major concern for A.
8. **BBB:** Ligand A (66.731) has lower BBB penetration than Ligand B (86.274). While not critical for a cardiovascular target, higher BBB is generally preferable.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the values are similar (-4.922 vs -4.504).
10. **Solubility:** Both ligands have negative solubility values, which is also unusual. The values are similar (-3.936 vs -2.405).
11. **hERG:** Both ligands have low hERG inhibition risk (0.537 and 0.535).
12. **Cl_mic:** Ligand A (17.811) has a higher microsomal clearance than Ligand B (-16.965). B is favored here as negative values indicate slower clearance.
13. **t1/2:** Ligand B (17.878) has a slightly longer in vitro half-life than Ligand A (12.251).
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.046 and 0.052).
15. **Binding Affinity:** Ligand A (-7.3 kcal/mol) has a significantly stronger binding affinity than Ligand B (-5.8 kcal/mol). This is a substantial advantage for A.
**Overall Assessment:**
Ligand A has a much stronger binding affinity, which is a significant advantage. However, its higher DILI risk and higher microsomal clearance are concerning. Ligand B has a better safety profile (lower DILI), better logP, and better metabolic stability. The difference in binding affinity is substantial (1.5 kcal/mol), but the safety concerns with Ligand A outweigh this benefit. Given the cardiovascular context, minimizing off-target effects and toxicity is paramount.
**Output:**
0
2025-04-18 00:25:14,928 - INFO - Reasoning:
Let's analyze Ligand A and Ligand B for their potential as ADRB2 ligands, keeping in mind GPCR priorities (logP, Pgp, TPSA, affinity).
**Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (352.391 Da) is slightly lower, which is generally favorable for permeability.
**TPSA:** Ligand B (58.64) is significantly better than Ligand A (105.92). A TPSA under 90 is preferred, and Ligand B is comfortably within that range, suggesting better permeability. Ligand A is pushing the upper limit for good oral absorption.
**logP:** Ligand B (2.138) is within the optimal range (1-3), while Ligand A (-0.636) is below 1, potentially hindering permeation. This is a significant advantage for Ligand B.
**H-Bond Donors/Acceptors:** Ligand A has 2 HBD and 7 HBA, while Ligand B has 1 HBD and 4 HBA. Both are within acceptable limits.
**QED:** Both ligands have good QED scores (A: 0.676, B: 0.777), indicating good drug-like properties.
**DILI:** Ligand B (21.598) has a much lower DILI risk than Ligand A (40.597), which is a substantial advantage.
**BBB:** Both ligands have similar BBB penetration (A: 62.854, B: 61.807). Not a major differentiating factor here, as ADRB2 is primarily a cardiovascular target.
**Caco-2 Permeability:** Both are negative, indicating poor permeability. This is concerning, but the TPSA and logP values suggest Ligand B might overcome this better.
**Aqueous Solubility:** Both are negative, indicating poor solubility.
**hERG:** Both ligands show low hERG inhibition risk (A: 0.102, B: 0.194).
**Microsomal Clearance:** Ligand A (-5.545) has a much lower (better) microsomal clearance than Ligand B (29.181), indicating greater metabolic stability.
**In vitro Half-Life:** Ligand A (0.899) has a slightly longer half-life than Ligand B (0.429).
**P-gp Efflux:** Both ligands show very low P-gp efflux (A: 0.008, B: 0.06).
**Binding Affinity:** Ligand B (-5.3) has a slightly better binding affinity than Ligand A (-6.0). While A is better, the difference isn't large enough to outweigh other significant drawbacks.
**Overall Assessment:**
Ligand B is the stronger candidate. While Ligand A has a slightly better binding affinity and metabolic stability, Ligand B excels in crucial areas for a GPCR drug: logP, TPSA, and DILI risk. The better logP and TPSA of Ligand B suggest it will have superior permeability and absorption, despite the negative Caco-2 and solubility values. The lower DILI risk is also a critical advantage. The small difference in binding affinity is not enough to offset the significant ADME advantages of Ligand B.
Output:
0
2025-04-18 00:25:14,928 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (347.361 Da) is slightly lower, which is generally favorable for permeability.
**2. TPSA:** Ligand A (55.4) is significantly better than Ligand B (107.19). For a GPCR, keeping TPSA low is beneficial for permeability and receptor engagement. Ligand B is quite high, potentially hindering oral absorption.
**3. logP:** Ligand A (3.154) is optimal, while Ligand B (0.276) is quite low. Low logP can lead to poor membrane permeability and bioavailability. This is a significant drawback for Ligand B.
**4. H-Bond Donors:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
**5. H-Bond Acceptors:** Ligand A (3) is preferable to Ligand B (5). Fewer HBAs generally improve permeability.
**6. QED:** Ligand A (0.855) has a much better QED score than Ligand B (0.628), indicating a more drug-like profile.
**7. DILI Risk:** Ligand B (63.707) has a higher DILI risk than Ligand A (55.37), although both are moderately risky.
**8. BBB Penetration:** Ligand A (89.492) has significantly better BBB penetration potential than Ligand B (28.422). While ADRB2 is a cardiovascular target, some CNS effects are possible with beta-blockers, and good BBB penetration could be a benefit or a concern depending on the desired selectivity.
**9. Caco-2 Permeability:** Ligand A (-4.322) is better than Ligand B (-5.795). Higher (less negative) values indicate better permeability.
**10. Aqueous Solubility:** Ligand A (-4.365) is better than Ligand B (-2.852). Higher (less negative) values indicate better solubility.
**11. hERG Inhibition:** Ligand A (0.291) has a much lower hERG risk than Ligand B (0.05), which is a critical safety consideration.
**12. Microsomal Clearance:** Ligand B (3.969) has a lower clearance than Ligand A (25.272), suggesting better metabolic stability. However, the difference isn't massive, and other factors are more important.
**13. In vitro Half-Life:** Ligand B (-20.103) has a much longer half-life than Ligand A (-0.91). This is a significant advantage for Ligand B.
**14. P-gp Efflux:** Ligand A (0.329) has lower P-gp efflux than Ligand B (0.018), which is favorable for bioavailability.
**15. Binding Affinity:** Ligand A (-7.6) has a slightly better binding affinity than Ligand B (-2.4). The difference in affinity is substantial (5.2 kcal/mol).
**Overall Assessment:**
Ligand A is the clear winner. While Ligand B has a longer half-life, its significantly lower logP, higher TPSA, higher DILI risk, lower BBB penetration, and higher hERG risk are major drawbacks. Ligand A balances drug-like properties much better, with a good QED score, acceptable safety profiles (DILI and hERG), and favorable ADME properties (logP, TPSA, permeability). The substantial difference in binding affinity further solidifies Ligand A as the preferred candidate.
Output:
1
2025-04-18 00:25:14,928 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (383.8) is within the ideal range (200-500), while Ligand B (331.4) is also good. No clear advantage here.
2. **TPSA:** Ligand A (46.84) is better than Ligand B (38.56), both are well below the 140 threshold for oral absorption, and suitable for a GPCR.
3. **logP:** Both ligands (A: 4.244, B: 4.822) are slightly above the optimal range of 1-3, but still acceptable. Ligand B is a bit higher, potentially leading to off-target effects or solubility issues, but not drastically.
4. **HBD:** Ligand A (0) is preferable to Ligand B (1). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (4). Lower HBA is generally favorable for permeability.
6. **QED:** Ligand A (0.679) is slightly better than Ligand B (0.585), indicating a more drug-like profile.
7. **DILI:** Both ligands have high DILI risk (A: 86.002, B: 84.18), which is concerning. This will be a key area for further optimization regardless of which ligand is chosen.
8. **BBB:** Ligand A (80.264) has significantly better BBB penetration potential than Ligand B (58.085). While ADRB2 isn't exclusively a CNS target, some CNS exposure can occur, and higher BBB is generally a plus.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.302 and -4.736), which is unusual and suggests poor permeability. This is a significant drawback for both.
10. **Solubility:** Both ligands have very poor predicted aqueous solubility (A: -5.705, B: -6.017). This is a major concern for bioavailability.
11. **hERG:** Both ligands have low hERG inhibition risk (A: 0.713, B: 0.954), which is good.
12. **Cl_mic:** Ligand A (52.339) has a lower microsomal clearance than Ligand B (57.217), indicating better metabolic stability.
13. **t1/2:** Ligand A (16.289) has a longer in vitro half-life than Ligand B (11.997), which is desirable.
14. **Pgp:** Both ligands have low P-gp efflux liability (A: 0.769, B: 0.947), which is favorable.
15. **Binding Affinity:** Ligand A (-7.5 kcal/mol) has a slightly better binding affinity than Ligand B (-7.2 kcal/mol). While the difference is not huge, it's enough to potentially outweigh some of the ADME drawbacks.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are particularly important. Both ligands have acceptable logP and Pgp values. Ligand A has a better TPSA and slightly better affinity. The biggest differentiator is the BBB score, where Ligand A is significantly better.
**Overall Assessment:**
Both ligands have significant drawbacks (poor solubility, negative Caco-2, high DILI). However, Ligand A demonstrates a better balance of properties, with a slightly better binding affinity, better BBB penetration, improved metabolic stability, and a more drug-like QED score. The slightly better affinity, coupled with the better BBB and metabolic stability, makes it the more promising starting point for optimization.
Output:
1
2025-04-18 00:25:14,928 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (375.491 and 350.419 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (118.8 and 116.4) are below the 140 A^2 threshold for good oral absorption, which is good.
3. **logP:** Both ligands (-0.575 and -0.665) are slightly below the optimal 1-3 range, but not drastically. This might slightly impact permeability, but isn't a major concern at this stage.
4. **HBD:** Ligand A (2) is preferable to Ligand B (4). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand B (4) is preferable to Ligand A (6). Fewer HBAs generally improve permeability.
6. **QED:** Ligand A (0.637) is slightly better than Ligand B (0.508), indicating a more drug-like profile.
7. **DILI:** Both ligands have acceptable DILI risk (33.307 and 35.867 percentile), below the 40% threshold. No major difference.
8. **BBB:** Ligand A (34.781) is slightly better than Ligand B (29.12), but both are low. Since ADRB2 is a cardiovascular target, BBB penetration is not a high priority.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.634 and -5.696), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand A (-0.746) is slightly better than Ligand B (-1.614), indicating better aqueous solubility.
11. **hERG:** Both ligands have very low hERG risk (0.092 and 0.021 percentile), which is excellent.
12. **Cl_mic:** Ligand A (-16.932) has a lower (better) microsomal clearance than Ligand B (-13.412), suggesting greater metabolic stability.
13. **t1/2:** Ligand A (29.343) has a longer in vitro half-life than Ligand B (25.286), which is desirable.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.019 and 0.004 percentile), which is excellent.
15. **Binding Affinity:** Ligand A (-7.1 kcal/mol) has a slightly better binding affinity than Ligand B (-6.7 kcal/mol). This 0.4 kcal/mol difference is significant.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are key. While both ligands have similar logP and TPSA, Ligand A has a significantly better binding affinity. Metabolic stability (Cl_mic and t1/2) are also important, and Ligand A is better in both categories.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B in most critical parameters, including binding affinity, metabolic stability, half-life, QED, and solubility. While both have poor Caco-2 permeability, the superior binding affinity and ADME properties of Ligand A make it the more promising candidate.
Output:
1
2025-04-18 00:25:14,928 - INFO - Batch 476 complete. Total preferences: 7616
2025-04-18 00:25:14,928 - INFO - Processing batch 477/512...
2025-04-18 00:26:04,506 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [341.43 , 46.09 , 3.857, 0. , 3. , 0.801, 31.369, 89.066, -4.589, -3.401, 0.754, 63.66 , -0.914, 0.218, -7.4 ]
**Ligand B:** [351.535, 43.86 , 2.914, 0. , 3. , 0.474, 10.934, 84.878, -4.406, -1.501, 0.621, 79.046, 4.61 , 0.127, -7.7 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal 200-500 Da range. Ligand A (341.43) is slightly lower than Ligand B (351.535), which is preferable.
2. **TPSA:** Both are acceptable for GPCRs (below 140). Ligand A (46.09) is better than Ligand B (43.86) as lower TPSA generally improves BBB penetration.
3. **logP:** Both are within the optimal 1-3 range. Ligand A (3.857) is slightly higher than Ligand B (2.914). While higher logP can sometimes cause issues, it's not a major concern here.
4. **HBD:** Both have 0 HBD, which is good.
5. **HBA:** Both have 3 HBA, which is good.
6. **QED:** Ligand A (0.801) has a significantly better QED score than Ligand B (0.474), indicating a more drug-like profile.
7. **DILI:** Ligand A (31.369) has a much lower DILI risk than Ligand B (10.934). This is a major advantage.
8. **BBB:** Ligand A (89.066) has a better BBB percentile than Ligand B (84.878). This is important for a GPCR target.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, these values are on a strange scale, so it's hard to interpret.
10. **Solubility:** Both have negative solubility values, which is also unusual. Again, difficult to interpret.
11. **hERG:** Both have low hERG inhibition risk. Ligand A (0.754) is slightly higher than Ligand B (0.621), but both are acceptable.
12. **Cl_mic:** Ligand A (63.66) has lower microsomal clearance than Ligand B (79.046), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-0.914) has a shorter in vitro half-life than Ligand B (4.61). This is a drawback for Ligand A.
14. **Pgp:** Ligand A (0.218) has lower P-gp efflux liability than Ligand B (0.127), which is beneficial.
15. **Affinity:** Ligand B (-7.7) has a slightly better binding affinity than Ligand A (-7.4). This is a 0.3 kcal/mol difference, which is not huge, but noticeable.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity) and the general drug-like properties, Ligand A is the more promising candidate. The significantly better QED, lower DILI risk, and better BBB penetration outweigh the slightly weaker affinity and shorter half-life. The lower TPSA is also a plus. While the Caco-2 and solubility values are strange, the other parameters strongly favor Ligand A.
Output:
1
2025-04-18 00:26:04,506 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (364.364 Da) is slightly higher than Ligand B (337.383 Da), but both are acceptable.
2. **TPSA:** Ligand A (67.87) is significantly better than Ligand B (85.69). ADRB2 is a cardiovascular target, not CNS, but lower TPSA is generally favorable for absorption.
3. **logP:** Both ligands have good logP values (A: 2.081, B: 2.472), falling within the optimal 1-3 range.
4. **HBD:** Both have 1 HBD, which is excellent.
5. **HBA:** Ligand A has 4 HBA, while Ligand B has 6. Both are acceptable, but A is slightly better.
6. **QED:** Both ligands have similar QED values (A: 0.762, B: 0.739), indicating good drug-likeness.
7. **DILI:** Ligand A (40.054) is significantly better than Ligand B (77.549). Lower DILI risk is crucial.
8. **BBB:** This is less critical for a cardiovascular target. Ligand A (91.508) is better than Ligand B (59.403).
9. **Caco-2:** Ligand A (-4.608) is better than Ligand B (-5.125), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-3.042) is better than Ligand B (-3.361).
11. **hERG:** Both ligands have similar hERG risk (A: 0.449, B: 0.465).
12. **Cl_mic:** Ligand A (38.396) has a lower microsomal clearance than Ligand B (59.192), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-2.94) has a better (longer) in vitro half-life than Ligand B (-33.534).
14. **Pgp:** Ligand A (0.083) is better than Ligand B (0.321), indicating lower P-gp efflux.
15. **Binding Affinity:** Ligand B (-0.0) has a significantly better binding affinity than Ligand A (-7.8). This is a major advantage.
**Overall Assessment:**
Ligand B's significantly superior binding affinity (-0.0 kcal/mol vs -7.8 kcal/mol) is a substantial advantage that outweighs most of the other differences. While Ligand A has better ADME properties across the board (lower DILI, better solubility, lower clearance, better half-life, lower Pgp efflux, and lower TPSA), the binding affinity difference is large enough to make Ligand B the more promising candidate. A 1.8 kcal/mol advantage in binding is substantial and can often be optimized further through medicinal chemistry efforts. The ADME properties of Ligand B are still within acceptable ranges, and can be improved upon.
Output:
0
2025-04-18 00:26:04,506 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (360.483 and 349.431 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (65.54) is significantly better than Ligand B (93.46). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have acceptable logP values (1.095 and 1.739), falling within the 1-3 range. Ligand B is slightly higher, which *could* be a minor drawback, but not a dealbreaker.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD can improve permeability.
5. **HBA:** Both ligands have 5 HBA, which is acceptable.
6. **QED:** Both ligands have similar QED values (0.799 and 0.782), indicating good drug-likeness.
7. **DILI:** Ligand A (30.012) has a much lower DILI risk than Ligand B (51.338). This is a significant advantage for Ligand A.
8. **BBB:** Ligand B (70.105) has a higher BBB penetration percentile than Ligand A (50.058). While not critical for a cardiovascular target, it's a slight positive for Ligand B.
9. **Caco-2:** Both ligands have negative Caco-2 values, suggesting poor permeability. Ligand A (-5.064) is slightly better than Ligand B (-4.857).
10. **Solubility:** Ligand A (-1.782) has better solubility than Ligand B (-3.149). This is beneficial for bioavailability.
11. **hERG:** Both ligands have low hERG inhibition liability (0.257 and 0.289), which is good.
12. **Cl_mic:** Ligand A (-4.071) has significantly lower microsomal clearance, indicating better metabolic stability, than Ligand B (42.167). This is a major advantage.
13. **t1/2:** Ligand B (7.814) has a longer in vitro half-life than Ligand A (-2.249). This is a positive for Ligand B.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.031 and 0.051).
15. **Binding Affinity:** Ligand B (-7.6) has a significantly stronger binding affinity than Ligand A (-4.4). This is a substantial advantage, potentially outweighing some of the ADME drawbacks.
**Overall Assessment:**
Ligand B has a much better binding affinity, which is the most important factor for GPCRs. However, Ligand A has significantly better DILI risk, metabolic stability (lower Cl_mic), and solubility. The longer half-life of Ligand B is also a plus. The TPSA and HBD are also better for Ligand A. Considering the balance, the substantial improvement in binding affinity of Ligand B is the deciding factor, despite the higher DILI risk and worse metabolic stability. The difference in binding affinity (-7.6 vs -4.4) is a 3.2 kcal/mol difference, which is a large advantage.
Output:
0
2025-04-18 00:26:04,506 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (356.463) is slightly higher than Ligand B (343.519), but both are acceptable.
2. **TPSA:** Ligand A (99.1) is higher than Ligand B (53.08). For a GPCR, lower TPSA is generally preferred, so Ligand B has an advantage.
3. **logP:** Ligand B (3.469) is better than Ligand A (0.456). A logP between 1-3 is optimal, and Ligand A is significantly below this, which could indicate poor membrane permeability. Ligand B is within the optimal range.
4. **HBD:** Ligand A (3) and Ligand B (2) are both acceptable, being less than 5.
5. **HBA:** Both ligands have 5 HBA, which is acceptable (<=10).
6. **QED:** Ligand B (0.828) has a higher QED score than Ligand A (0.601), indicating a more drug-like profile.
7. **DILI:** Ligand A (19.271) has a much lower DILI risk than Ligand B (30.361). This is a significant advantage for Ligand A.
8. **BBB:** Ligand B (95.657) has a much higher BBB penetration percentile than Ligand A (49.128). While ADRB2 isn't exclusively a CNS target, some cardiovascular effects can be mediated through CNS pathways, and higher BBB penetration could be beneficial or detrimental depending on the desired effect.
9. **Caco-2:** Ligand A (-4.775) and Ligand B (-5.265) both have negative values, which is unusual. This likely indicates poor permeability in this assay.
10. **Solubility:** Ligand A (-1.474) and Ligand B (-3.309) both have negative solubility values, which is unusual and suggests poor aqueous solubility.
11. **hERG:** Ligand A (0.303) has a lower hERG inhibition liability than Ligand B (0.95). This is a significant safety advantage for Ligand A.
12. **Cl_mic:** Ligand B (43.664) has a much higher microsomal clearance than Ligand A (7.205). Lower clearance is preferred for better metabolic stability, giving Ligand A a strong advantage.
13. **t1/2:** Ligand B (33.666) has a much longer in vitro half-life than Ligand A (-14.712). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.023) has a much lower P-gp efflux liability than Ligand B (0.192). Lower efflux is generally preferred.
15. **Binding Affinity:** Ligand A (-6.8) and Ligand B (-6.0) are both strong binders, but Ligand A has a slightly better affinity.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are critical. Ligand B excels in logP and BBB, but struggles with Pgp and has a lower affinity. Ligand A has a lower logP, but excels in DILI, hERG, Cl_mic, and Pgp, and has a slightly better affinity.
**Overall Assessment:**
While Ligand B has a better BBB penetration and in vitro half-life, the significantly better DILI and hERG profiles of Ligand A, coupled with its lower P-gp efflux and better metabolic stability (lower Cl_mic), make it the more promising candidate. The lower logP of Ligand A is a concern, but the other advantages outweigh this drawback. The slightly better binding affinity of Ligand A also contributes to its preference.
Output:
1
2025-04-18 00:26:04,507 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (373.381 and 350.459 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (89.77) is slightly higher than Ligand B (60.03). Both are below the 140 A^2 threshold for good oral absorption, but Ligand B is significantly better, especially considering it's a GPCR target.
3. **logP:** Ligand A (1.853) and Ligand B (2.42) are both within the optimal 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Both ligands have 1 HBD, which is acceptable.
5. **HBA:** Ligand A has 7 HBA, while Ligand B has 4. Both are below the 10 threshold. Ligand B is preferable here.
6. **QED:** Both ligands have similar QED values (0.748 and 0.767), indicating good drug-likeness.
7. **DILI:** Ligand A (81.815) has a significantly higher DILI risk than Ligand B (23.497). This is a major concern for Ligand A.
8. **BBB:** Ligand B (84.141) has a higher BBB penetration percentile than Ligand A (74.06). While ADRB2 isn't strictly a CNS target, better BBB penetration can sometimes translate to improved distribution and reduced off-target effects.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.584 and -4.354), which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Both ligands have negative solubility values (-3.264 and -2.651), which is also unusual and suggests poor solubility. Again, the scale is not specified.
11. **hERG:** Ligand A (0.283) has a slightly lower hERG inhibition liability than Ligand B (0.823), which is preferable.
12. **Cl_mic:** Ligand A (69.554) has a slightly higher microsomal clearance than Ligand B (59.886), suggesting lower metabolic stability.
13. **t1/2:** Ligand A (12.68) has a longer in vitro half-life than Ligand B (1.725). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.173) has lower P-gp efflux liability than Ligand B (0.153). This is a slight advantage for Ligand A.
15. **Binding Affinity:** Ligand A (-6.6 kcal/mol) has a slightly better binding affinity than Ligand B (-6.1 kcal/mol). This difference is within the range where it could outweigh some ADME drawbacks.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand B is the stronger candidate. While Ligand A has a slightly better affinity and half-life, the significantly higher DILI risk and worse TPSA and Pgp values are major drawbacks. The lower DILI risk of Ligand B is a critical advantage for a cardiovascular target. The better TPSA and BBB penetration also contribute to its favorability.
Output:
0
2025-04-18 00:26:04,507 - INFO - Reasoning:
Let's analyze both ligands for their potential as ADRB2 (GPCR) drug candidates, prioritizing logP, Pgp, TPSA, affinity, and then considering other factors.
**Ligand A:**
* **MW:** 352.475 Da - Good.
* **TPSA:** 89.87 - Excellent, well below the 140 threshold.
* **logP:** 1.218 - Good, within the optimal range.
* **HBD:** 3 - Acceptable.
* **HBA:** 4 - Acceptable.
* **QED:** 0.666 - Good, above the 0.5 threshold.
* **DILI:** 19.504 - Excellent, very low risk.
* **BBB:** 42.148 - Moderate, not ideal for a CNS-targeting GPCR, but acceptable for a peripherally acting one like ADRB2.
* **Caco-2:** -4.82 - Very poor permeability. A significant concern.
* **Solubility:** -2.201 - Poor solubility.
* **hERG:** 0.149 - Very low risk.
* **Cl_mic:** 22.778 - Moderate clearance.
* **t1/2:** 2.779 - Short half-life.
* **Pgp:** 0.028 - Very low efflux, excellent.
* **Affinity:** -7.4 kcal/mol - Excellent.
**Ligand B:**
* **MW:** 352.475 Da - Good.
* **TPSA:** 86.71 - Excellent, well below the 140 threshold.
* **logP:** 1.365 - Good, within the optimal range.
* **HBD:** 2 - Acceptable.
* **HBA:** 4 - Acceptable.
* **QED:** 0.656 - Good, above the 0.5 threshold.
* **DILI:** 9.655 - Excellent, very low risk.
* **BBB:** 53.16 - Moderate, similar to Ligand A.
* **Caco-2:** -4.942 - Very poor permeability. A significant concern.
* **Solubility:** -0.991 - Poor solubility.
* **hERG:** 0.181 - Very low risk.
* **Cl_mic:** 10.231 - Low clearance, better metabolic stability.
* **t1/2:** -10.89 - Very long half-life.
* **Pgp:** 0.025 - Very low efflux, excellent.
* **Affinity:** -1.5 kcal/mol - Poor affinity.
**Comparison and Decision:**
Both ligands have significant issues with Caco-2 permeability and solubility. However, the difference in binding affinity is massive. Ligand A has an affinity of -7.4 kcal/mol, while Ligand B only has -1.5 kcal/mol. This 5.9 kcal/mol difference is substantial and likely outweighs the slightly better metabolic stability and half-life of Ligand B. While poor permeability is a major hurdle, it can potentially be addressed through formulation strategies. A compound with very weak binding is unlikely to be a viable drug candidate regardless of its ADME properties. Ligand A also has a slightly better DILI score.
Therefore, I would prioritize Ligand A due to its significantly superior binding affinity.
Output:
1
2025-04-18 00:26:04,507 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A: [331.419, 38.13, 3.892, 0, 3, 0.73, 64.211, 88.329, -4.82, -4.089, 0.835, 54.211, -19.374, 0.711, -7.4]**
**Ligand B: [350.503, 69.64, 2.186, 2, 3, 0.798, 4.692, 71.733, -4.673, -2.752, 0.488, 41.268, -8.622, 0.017, -3.1]**
Here's a breakdown, comparing each parameter and considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (331.419) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (38.13) is significantly better than Ligand B (69.64). ADRB2 is not a CNS target, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (3.892) is optimal, while Ligand B (2.186) is a bit low. A logP closer to 3 is preferred for GPCRs to balance solubility and permeability.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer HBDs generally improve membrane permeability.
5. **HBA:** Both have 3 HBA, which is acceptable.
6. **QED:** Both are good (above 0.5), with Ligand B slightly higher (0.798 vs 0.73). This isn't a major differentiator.
7. **DILI:** Ligand B (4.692) is *much* better than Ligand A (64.211). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (88.329) is better than Ligand B (71.733), but BBB isn't a primary concern for a cardiovascular target.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-4.82) is slightly worse than Ligand B (-4.673).
10. **Solubility:** Ligand B (-2.752) is better than Ligand A (-4.089), although both are quite poor.
11. **hERG:** Ligand A (0.835) is better than Ligand B (0.488), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand B (41.268) has lower clearance than Ligand A (54.211), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-19.374) has a longer half-life than Ligand B (-8.622), which is desirable.
14. **Pgp:** Ligand A (0.711) is better than Ligand B (0.017), indicating lower P-glycoprotein efflux.
15. **Affinity:** Ligand A (-7.4) has a significantly stronger binding affinity than Ligand B (-3.1). This is a substantial advantage.
**Overall Assessment:**
The biggest advantage of Ligand A is its significantly higher binding affinity. This is a critical factor for GPCRs. However, Ligand B has a much lower DILI risk and better metabolic stability (lower Cl_mic). The solubility of both is poor and Caco-2 permeability is also poor. Ligand A has better Pgp efflux, but the affinity difference is so large that it likely outweighs this. The DILI risk for Ligand A is concerning.
Given the importance of potency for GPCRs, and the substantial difference in binding affinity (-7.4 vs -3.1), I believe Ligand A is the more promising candidate *despite* its higher DILI risk. The DILI risk could potentially be mitigated through structural modifications later in the optimization process.
Output:
1
2025-04-18 00:26:04,507 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (335.415 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (62.97) is significantly better than Ligand B (71.78). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (1.375) is within the optimal range, while Ligand B (3.142) is approaching the upper limit. Higher logP can sometimes lead to off-target effects and solubility issues.
4. **HBD:** Ligand A (0) is preferable to Ligand B (1). Fewer HBDs generally improve membrane permeability.
5. **HBA:** Ligand A (7) is better than Ligand B (5). Lower HBA is generally preferred.
6. **QED:** Both ligands have good QED scores (A: 0.702, B: 0.765), indicating good drug-like properties.
7. **DILI:** Ligand A (42.846) has a slightly higher DILI risk than Ligand B (37.069), but both are below the concerning threshold of 60.
8. **BBB:** Both have similar BBB penetration (A: 64.676, B: 67.197). Since this is a cardiovascular target, BBB isn't a major consideration.
9. **Caco-2:** Ligand A (-5.032) is better than Ligand B (-4.234), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-1.25) is better than Ligand B (-3.551), which is important for bioavailability.
11. **hERG:** Ligand A (0.711) is better than Ligand B (0.277). Lower hERG inhibition is crucial for avoiding cardiotoxicity, especially for a cardiovascular target.
12. **Cl_mic:** Ligand A (11.224) has a significantly lower microsomal clearance than Ligand B (92.41), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-39.054) has a much longer in vitro half-life than Ligand B (36.079), which is highly desirable.
14. **Pgp:** Ligand A (0.029) has a much lower Pgp efflux liability than Ligand B (0.137), indicating better oral bioavailability.
15. **Binding Affinity:** Ligand B (-1.3 kcal/mol) has a slightly better binding affinity than Ligand A (-5.8 kcal/mol). However, the difference is not substantial enough to overcome the significant ADME advantages of Ligand A.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A performs better on TPSA, Pgp, and has a reasonable logP. While Ligand B has slightly better affinity, the ADME profile of Ligand A is far superior.
**Conclusion:**
Ligand A exhibits a significantly more favorable ADME profile (better solubility, lower clearance, longer half-life, lower Pgp efflux, and lower hERG risk) despite a slightly weaker binding affinity. Given the importance of a balanced profile for *in vivo* efficacy and safety, Ligand A is the more promising drug candidate.
Output:
1
2025-04-18 00:26:04,507 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands (354.4 & 346.4 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand B (119.57) is significantly better than Ligand A (138.78) as it's closer to the <140 threshold for good absorption. This is a positive for Ligand B.
3. **logP:** Ligand A (-1.421) is lower than optimal (1-3), potentially hindering permeation. Ligand B (0.782) is within the preferred range. Advantage: Ligand B.
4. **HBD:** Ligand A (5) is at the upper limit, while Ligand B (2) is more favorable. Advantage: Ligand B.
5. **HBA:** Ligand A (6) is good, Ligand B (9) is acceptable but higher. Slight advantage: Ligand A.
6. **QED:** Ligand B (0.583) has a better QED score than Ligand A (0.327), indicating better overall drug-likeness. Advantage: Ligand B.
7. **DILI:** Ligand A (15.083) has a much lower DILI risk than Ligand B (63.397). This is a significant advantage for Ligand A.
8. **BBB:** Ligand B (40.558) is substantially lower than Ligand A (11.439). While ADRB2 isn't necessarily a CNS target, some peripheral distribution is still desired, and a lower BBB is less concerning than a high DILI risk.
9. **Caco-2:** Both are very poor (-5.97 and -5.878). This is a concern for both, but doesn't differentiate them.
10. **Solubility:** Ligand A (-0.014) is slightly better than Ligand B (-1.561), but both are poor.
11. **hERG:** Both ligands have very low hERG risk (0.045 and 0.1). No clear advantage.
12. **Cl_mic:** Ligand A (-1.767) has a lower (better) microsomal clearance than Ligand B (-2.369), indicating greater metabolic stability. Advantage: Ligand A.
13. **t1/2:** Ligand B (23.003) has a significantly longer in vitro half-life than Ligand A (-18.103). This is a major advantage for Ligand B.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.007 and 0.042). No clear advantage.
15. **Binding Affinity:** Both ligands have similar binding affinities (-6.3 and -5.4 kcal/mol). Ligand A is slightly better, but the difference isn't substantial enough to outweigh other factors.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are important. Ligand B excels in logP and TPSA. While affinity is slightly better for A, the other ADME properties of B are more favorable. The DILI risk for Ligand B is a significant concern, but the longer half-life and better QED are attractive.
**Overall Assessment:**
Ligand A has a lower DILI risk and slightly better metabolic stability, but suffers from a poor logP and lower QED. Ligand B has better physicochemical properties (logP, TPSA, QED) and a longer half-life, but a higher DILI risk. Considering the balance, the better physicochemical profile and longer half-life of Ligand B outweigh the higher DILI risk, especially given the low hERG risk.
Output:
0
2025-04-18 00:26:04,508 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.312 and 346.471 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (55.61) is significantly better than Ligand B (67.43). ADRB2 is not a CNS target, but lower TPSA generally improves permeability.
3. **logP:** Ligand A (4.226) is higher than Ligand B (2.169). While both are within the acceptable range, Ligand A is approaching the upper limit where solubility issues could arise. Ligand B is closer to the optimal range.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer HBDs generally improve membrane permeability.
5. **HBA:** Ligand A (4) is preferable to Ligand B (3). Lower HBA is generally better for permeability.
6. **QED:** Both ligands have good QED scores (0.61 and 0.724), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (77.394) has a significantly higher DILI risk than Ligand B (15.394). This is a major concern for Ligand A.
8. **BBB:** This is less critical for ADRB2, but Ligand A (82.629) has a higher BBB penetration than Ligand B (69.019).
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.819) is slightly better than Ligand B (-5.042).
10. **Solubility:** Ligand A (-5.73) has worse solubility than Ligand B (-2.911).
11. **hERG:** Ligand A (0.892) has a higher hERG risk than Ligand B (0.221). This is a significant safety concern.
12. **Cl_mic:** Ligand B (34.32) has lower microsomal clearance than Ligand A (44.792), indicating better metabolic stability.
13. **t1/2:** Ligand B (-0.471) has a longer in vitro half-life than Ligand A (-8.567).
14. **Pgp:** Ligand A (0.611) has lower P-gp efflux than Ligand B (0.053), which is favorable.
15. **Affinity:** Ligand A (-7.5 kcal/mol) has a slightly better binding affinity than Ligand B (-6.8 kcal/mol). This is a 0.7 kcal/mol difference, which is not huge, but still noticeable.
**Overall Assessment:**
Ligand A has a better binding affinity and Pgp profile, but it is significantly hampered by its higher DILI risk, hERG inhibition, and lower solubility. Ligand B, while having slightly weaker binding, presents a much more favorable ADMET profile, particularly regarding safety (DILI, hERG) and metabolic stability. For a cardiovascular target like ADRB2, minimizing off-target effects and ensuring metabolic stability are crucial. The modest difference in binding affinity is outweighed by the substantial improvements in safety and ADME properties offered by Ligand B.
Output:
0
2025-04-18 00:26:04,508 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (353.325 and 336.395 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (98.66) is slightly higher than Ligand B (78.09). Both are below 140, which is good for oral absorption, but Ligand B is preferable.
3. **logP:** Both ligands have good logP values (1.755 and 1.556), falling within the optimal 1-3 range. No clear advantage.
4. **HBD:** Ligand A has 1 HBD, while Ligand B has 2. Both are acceptable (<=5).
5. **HBA:** Ligand A has 5 HBA, while Ligand B has 3. Both are acceptable (<=10).
6. **QED:** Both ligands have high QED scores (0.78 and 0.813), indicating good drug-likeness. No significant difference.
7. **DILI:** Ligand A (57.038) has a slightly lower DILI risk than Ligand B (60.915), but both are acceptable (<60 is ideal, both are below 61).
8. **BBB:** Ligand A (84.025) has a significantly higher BBB penetration percentile than Ligand B (31.02). This is a *major* advantage for a GPCR target, even if not specifically a CNS target, as it suggests better distribution.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.769 and -4.731). These values are unusual and suggest very poor permeability. However, the values are very close, so this isn't a deciding factor.
10. **Solubility:** Both ligands have negative solubility values (-2.992 and -3.257). These values suggest poor solubility. Again, the values are very close.
11. **hERG:** Both ligands have low hERG inhibition liability (0.417 and 0.332), which is good.
12. **Cl_mic:** Ligand A (51.612) has a higher microsomal clearance than Ligand B (24.123), indicating faster metabolism and potentially lower *in vivo* exposure. Ligand B is preferable.
13. **t1/2:** Ligand B (8.341) has a significantly longer *in vitro* half-life than Ligand A (-40.403). This is a substantial advantage.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.215 and 0.03).
15. **Binding Affinity:** Both ligands have the same binding affinity (-6.6 kcal/mol).
**GPCR-specific priorities:** For GPCRs like ADRB2, logP, TPSA, Pgp, and affinity are important. BBB penetration is also valuable.
**Overall Assessment:**
Ligand B has better metabolic stability (lower Cl_mic, longer t1/2) and a lower TPSA. However, Ligand A has a significantly higher BBB penetration, which is a key consideration for GPCRs. The negative Caco-2 and solubility values are concerning for both, but the difference in BBB is the most significant factor. Considering the overall balance, the improved BBB penetration of Ligand A outweighs the slightly better metabolic properties of Ligand B.
**Output:**
1
2025-04-18 00:26:04,508 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [379.507, 102.15 , 2.209, 2. , 6. , 0.829, 82.59 , 62.156, -5.209, -2.923, 0.361, 10.697, 8.051, 0.332, -6.4 ]
**Ligand B:** [346.391, 116.12 , 0.478, 2. , 6. , 0.666, 54.168, 32.648, -5.649, -1.883, 0.065, -6.776, 24.236, 0.007, -5.4 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (346.391) is slightly lower, which could be beneficial for permeability, but both are acceptable.
2. **TPSA:** Ligand A (102.15) is better than Ligand B (116.12), being closer to the <140 threshold for good oral absorption.
3. **logP:** Ligand A (2.209) is optimal (1-3), while Ligand B (0.478) is a bit low, potentially hindering permeation. This is a significant advantage for Ligand A.
4. **HBD:** Both have 2 HBD, which is good.
5. **HBA:** Both have 6 HBA, which is also good.
6. **QED:** Ligand A (0.829) has a better QED score than Ligand B (0.666), indicating a more drug-like profile.
7. **DILI:** Ligand B (54.168) has a much lower DILI risk than Ligand A (82.59), which is a substantial advantage for Ligand B.
8. **BBB:** Ligand A (62.156) has a better BBB penetration score than Ligand B (32.648). While ADRB2 isn't exclusively a CNS target, some cardiovascular effects are mediated by central pathways, so some BBB penetration is helpful.
9. **Caco-2:** Both are negative, indicating poor permeability. This is a concern for both.
10. **Solubility:** Both are negative, indicating poor solubility. This is a concern for both.
11. **hERG:** Both have low hERG inhibition liability, which is good. Ligand B (0.065) is slightly better than Ligand A (0.361).
12. **Cl_mic:** Ligand B (-6.776) has a *much* lower (better) microsomal clearance than Ligand A (10.697), suggesting greater metabolic stability.
13. **t1/2:** Ligand B (24.236) has a significantly longer in vitro half-life than Ligand A (8.051), which is highly desirable.
14. **Pgp:** Ligand B (0.007) has very low P-gp efflux liability, while Ligand A (0.332) has moderate efflux. This is a significant advantage for Ligand B.
15. **Binding Affinity:** Ligand A (-6.4) has slightly better binding affinity than Ligand B (-5.4), but the difference is not substantial enough to overcome the other ADME issues.
**GPCR-specific priorities:** For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand A has a better logP and slightly better affinity, but Ligand B excels in Pgp efflux and has a much better metabolic profile (Cl_mic and t1/2). The DILI risk is also considerably lower for Ligand B. While TPSA is better for A, the other factors are more important for a balanced profile.
**Conclusion:**
Considering the overall profile, particularly the superior metabolic stability, lower DILI risk, and better P-gp properties of Ligand B, it is the more promising drug candidate despite the slightly lower affinity and logP. The improvements in ADME properties are likely to translate to better *in vivo* performance.
0
2025-04-18 00:26:04,508 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (340.383 and 354.422 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand B (67.87) is significantly better than Ligand A (117.34). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (1.18) is within the optimal range (1-3), while Ligand A (0.658) is slightly lower, potentially impacting permeability. Ligand B has a slight edge.
4. **HBD:** Ligand A (4) is higher than Ligand B (1). While both are acceptable, lower HBD can improve permeability. Ligand B is preferred.
5. **HBA:** Ligand A (5) is higher than Ligand B (4). Similar to HBD, lower HBA is generally preferred. Ligand B is preferred.
6. **QED:** Both ligands have good QED scores (0.638 and 0.778), indicating drug-likeness. Ligand B is slightly better.
7. **DILI:** Ligand B (29.042) has a much lower DILI risk than Ligand A (61.419). This is a significant advantage for Ligand B.
8. **BBB:** Ligand B (83.831) has a higher BBB penetration score than Ligand A (23.265). While not crucial for a cardiovascular target, it's a positive attribute.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual. I will interpret these as very low permeability.
10. **Solubility:** Both have negative solubility values, which is also unusual. I will interpret these as very low solubility.
11. **hERG:** Both ligands have low hERG inhibition liability (0.328 and 0.374), which is good. No clear advantage.
12. **Cl_mic:** Ligand A (-32.821) has a lower (more negative) microsomal clearance than Ligand B (-5.537), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (26.708) has a longer in vitro half-life than Ligand B (12.451). This is a positive for Ligand A.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.008 and 0.035). No clear advantage.
15. **Binding Affinity:** Ligand B (-5.8) has a slightly better binding affinity than Ligand A (-5.4). This is a small advantage, but potentially important.
**Overall Assessment:**
Ligand B has several advantages: lower DILI risk, better TPSA, logP, HBD, HBA, QED, and BBB penetration, and slightly better binding affinity. Ligand A has better metabolic stability (Cl_mic) and a longer half-life. However, the significantly lower DILI risk of Ligand B is a major factor, as is its better overall ADME profile. The slight advantage in binding affinity of Ligand B also contributes to its preference. The negative Caco-2 and solubility values are concerning for both, but can be addressed with formulation strategies.
Output:
0
2025-04-18 00:26:04,508 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [376.435, 133.91 , -1.899, 3. , 6. , 0.366, 47.926, 44.707, -5.632, -1.896, 0.049, -1.266, -30.289, 0.004, -8. ]
**Ligand B:** [379.873, 80.12 , 1.955, 1. , 6. , 0.883, 68.05 , 55.913, -5.103, -3.402, 0.27 , 13.055, 30.931, 0.094, -5.5 ]
Here's a breakdown of the comparison, considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal 200-500 Da range. (A: 376.4, B: 379.9) - No significant difference.
2. **TPSA:** Ligand B (80.12) is significantly better than Ligand A (133.91). Lower TPSA is preferred for GPCRs, aiding permeability.
3. **logP:** Ligand A (-1.899) is lower than the optimal 1-3 range, potentially hindering permeability. Ligand B (1.955) is within the optimal range. This is a significant advantage for B.
4. **HBD:** Ligand A (3) is higher than Ligand B (1). Lower HBD is generally preferred for better permeability.
5. **HBA:** Both have 6 HBA, which is acceptable.
6. **QED:** Ligand B (0.883) has a much better QED score than Ligand A (0.366), indicating a more drug-like profile.
7. **DILI:** Ligand A (47.9%) has a lower DILI risk than Ligand B (68.1%). This favors A, but both are reasonably acceptable.
8. **BBB:** Ligand B (55.9%) has a slightly higher BBB penetration than Ligand A (44.7%). While not a primary concern for ADRB2 (not a CNS target), it's a minor plus for B.
9. **Caco-2:** Both are negative, indicating poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-1.896) is slightly better than Ligand B (-3.402), but both are quite poor.
11. **hERG:** Both have very low hERG risk (A: 0.049, B: 0.27).
12. **Cl_mic:** Ligand A (-1.266) has a lower (better) microsomal clearance than Ligand B (13.055), indicating better metabolic stability. This is a significant advantage for A.
13. **t1/2:** Ligand B (30.931) has a much longer in vitro half-life than Ligand A (-30.289). This is a major advantage for B.
14. **Pgp:** Ligand A (0.004) has a much lower Pgp efflux liability than Ligand B (0.094). This is a significant advantage for A.
15. **Affinity:** Both have comparable binding affinities (-8.0 and -5.5 kcal/mol).
**Overall Assessment:**
Ligand B has a significantly better logP, QED, and in vitro half-life. The lower TPSA is also a major benefit. While Ligand A has advantages in DILI, Cl_mic, and Pgp, the improvements in ADME properties and drug-likeness of Ligand B outweigh these benefits. The better logP and QED of Ligand B are particularly important for a GPCR target. The longer half-life is also a major advantage.
Therefore, I favor Ligand B.
0
2025-04-18 00:26:04,509 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (344.455 and 358.511 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (59.5 and 59.07) are below the 140 A^2 threshold for good oral absorption, and well below the 90 A^2 threshold for CNS targets (though ADRB2 isn't necessarily a CNS target, lower TPSA is generally favorable for permeability). Again, no major difference.
3. **logP:** Both ligands have logP values (3.154 and 3.791) within the optimal 1-3 range. Ligand B is slightly higher, which could potentially lead to slight solubility issues, but is still acceptable.
4. **HBD:** Ligand A has 0 HBDs, while Ligand B has 2. Lower HBDs are generally preferred for better permeability, giving a slight edge to Ligand A.
5. **HBA:** Ligand A has 4 HBAs, and Ligand B has 6. Similar to HBD, lower HBA is preferred, favoring Ligand A.
6. **QED:** Both ligands have good QED scores (0.79 and 0.823), indicating good drug-like properties. No significant difference.
7. **DILI:** Ligand A (30.826%) has a significantly lower DILI risk than Ligand B (63.125%). This is a *major* advantage for Ligand A. DILI is a critical safety concern.
8. **BBB:** Both ligands have high BBB penetration (91.857% and 88.445%). While ADRB2 isn't a primary CNS target, good BBB penetration isn't detrimental.
9. **Caco-2:** Ligand A (-4.347) has a slightly better Caco-2 permeability than Ligand B (-5.159), suggesting better intestinal absorption.
10. **Solubility:** Ligand A (-3.683) has slightly better aqueous solubility than Ligand B (-4.52).
11. **hERG:** Both ligands have low hERG inhibition liability (0.723% and 0.773%), which is good. No significant difference.
12. **Cl_mic:** Ligand A (83.967) has a lower microsomal clearance than Ligand B (86.287), indicating better metabolic stability.
13. **t1/2:** Ligand A (-7.449) has a significantly longer in vitro half-life than Ligand B (67.572). This is a significant advantage, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.454 and 0.329). No significant difference.
15. **Binding Affinity:** Ligand B (-6.3 kcal/mol) has a slightly better binding affinity than Ligand A (-5.7 kcal/mol). This is a 0.6 kcal/mol difference. While affinity is important, the other ADME/Tox properties are more compelling.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Both ligands perform well on logP and TPSA. Pgp is similar. The affinity difference is not large enough to overcome the substantial advantages of Ligand A in terms of DILI risk, metabolic stability (Cl_mic), and half-life.
**Conclusion:**
Ligand A demonstrates a significantly better safety profile (lower DILI), improved metabolic stability, and a longer half-life, outweighing the slightly weaker binding affinity compared to Ligand B. These factors are crucial for developing a viable drug candidate.
Output:
1
2025-04-18 00:26:04,509 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (362.499 and 365.499 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (70.4) is better than Ligand B (82.53). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (3.323) is slightly higher than Ligand B (1.682). Both are within the optimal 1-3 range, but Ligand A is closer to the upper end, which *could* lead to solubility issues, but also better membrane permeability.
4. **HBD:** Both ligands have 2 HBD, which is good.
5. **HBA:** Both ligands have 5 HBA, which is good.
6. **QED:** Ligand A (0.827) is better than Ligand B (0.732), indicating a more drug-like profile.
7. **DILI:** Ligand A (28.306) has a significantly lower DILI risk than Ligand B (35.673). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (83.249) has a higher BBB penetration percentile than Ligand B (40.558). While not crucial for a cardiovascular target, it doesn't hurt.
9. **Caco-2:** Both are negative, suggesting poor permeability. Ligand A (-5.212) is slightly better than Ligand B (-5.074).
10. **Solubility:** Ligand A (-2.288) is better than Ligand B (-2.64).
11. **hERG:** Ligand A (0.768) has a lower hERG inhibition liability than Ligand B (0.151), which is a significant safety advantage.
12. **Cl_mic:** Ligand A (9.183) has a lower microsomal clearance, indicating better metabolic stability than Ligand B (28.589).
13. **t1/2:** Ligand B (32.385) has a longer in vitro half-life than Ligand A (15.611). This is a positive for Ligand B.
14. **Pgp:** Ligand A (0.196) has lower P-gp efflux liability than Ligand B (0.046), which is favorable.
15. **Binding Affinity:** Ligand B (-7.3) has a significantly stronger binding affinity than Ligand A (-5.9). This is a 1.4 kcal/mol difference, which is substantial and can outweigh some ADME drawbacks.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B has a better logP and significantly better affinity. However, Ligand A excels in safety parameters (DILI, hERG) and metabolic stability (Cl_mic). The affinity difference is substantial, but the safety profile of Ligand A is very attractive. Considering the cardiovascular context, minimizing off-target effects and toxicity is paramount.
**Conclusion:**
While Ligand B boasts superior binding affinity, Ligand A presents a much more favorable safety profile (lower DILI, lower hERG) and better metabolic stability. The affinity difference, while significant, isn't so overwhelming that it completely overshadows the substantial advantages of Ligand A in terms of safety and ADME properties. Therefore, I believe Ligand A is the more viable drug candidate.
Output:
1
2025-04-18 00:26:04,509 - INFO - Batch 477 complete. Total preferences: 7632
2025-04-18 00:26:04,509 - INFO - Processing batch 478/512...
2025-04-18 00:26:51,321 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.45 & 369.85 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (93.09) is slightly higher than Ligand B (76.82). Both are below the 140 threshold for oral absorption, but Ligand B is better positioned, especially considering it's a GPCR target.
3. **logP:** Both ligands have good logP values (1.39 & 0.98), falling within the optimal 1-3 range. Ligand B is slightly lower, which could slightly improve solubility.
4. **HBD:** Ligand A has 2 HBD, and Ligand B has 1. Both are within the acceptable limit of <=5.
5. **HBA:** Ligand A has 5 HBA, and Ligand B has 6. Both are within the acceptable limit of <=10.
6. **QED:** Ligand B (0.809) has a higher QED score than Ligand A (0.625), suggesting a more drug-like profile.
7. **DILI:** Both ligands have low DILI risk (38.74 & 35.98), well below the 40% threshold. No significant difference.
8. **BBB:** Both ligands have good BBB penetration (69.76 & 70.99), but Ligand B is slightly better. While ADRB2 isn't exclusively a CNS target, some peripheral effects are mediated by CNS pathways, so some BBB penetration isn't detrimental.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.862 & -4.778). This is unusual and suggests poor permeability. However, the values are very similar.
10. **Solubility:** Both ligands have negative solubility values (-2.282 & -2.918), indicating poor aqueous solubility. This is a concern for both.
11. **hERG:** Both ligands have very low hERG risk (0.096 & 0.362), which is excellent.
12. **Cl_mic:** Ligand A (41.477) has a lower microsomal clearance than Ligand B (49.325), indicating better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand B (36.566) has a significantly longer in vitro half-life than Ligand A (-12.95). This is a major advantage, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.028 & 0.122), which is good.
15. **Binding Affinity:** Ligand B (-6.6 kcal/mol) has a slightly better binding affinity than Ligand A (-6.2 kcal/mol). While the difference is not huge, it's enough to be considered.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B is better in terms of TPSA and affinity. While both have good logP and Pgp values, Ligand B's slightly lower logP could help with solubility. The longer half-life of Ligand B is also a substantial benefit. The slightly better BBB penetration of Ligand B is also a plus.
**Overall Assessment:**
While Ligand A has better metabolic stability (lower Cl_mic), Ligand B's superior binding affinity, longer half-life, better TPSA, and slightly better BBB penetration outweigh this advantage. The solubility issues are a concern for both, but can be addressed with formulation strategies.
Output:
0
2025-04-18 00:26:51,321 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (342.395 and 346.431 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (79.2) is better than Ligand B (95.16). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (2.258 and 1.713), falling within the optimal 1-3 range. Ligand B is slightly lower, which might slightly improve solubility but could also slightly hinder permeability.
4. **HBD:** Ligand A (1) is better than Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Both ligands have the same number of HBA (4), which is acceptable.
6. **QED:** Ligand A (0.914) is better than Ligand B (0.848), indicating a more drug-like profile.
7. **DILI:** Ligand A (36.177) has a significantly lower DILI risk than Ligand B (51.221). This is a crucial advantage.
8. **BBB:** Both ligands have relatively low BBB penetration (53.587 and 48.779). This isn't a major concern for a cardiovascular target.
9. **Caco-2:** Ligand A (-4.899) is better than Ligand B (-5.139), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-2.013) is better than Ligand B (-2.862), which is important for bioavailability.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.016 and 0.034), which is excellent.
12. **Cl_mic:** Ligand A (-17.481) has a much lower (better) microsomal clearance than Ligand B (10.876), suggesting greater metabolic stability.
13. **t1/2:** Ligand B (-29.724) has a much longer in vitro half-life than Ligand A (4.7). This is a significant advantage.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.019 and 0.035).
15. **Binding Affinity:** Ligand A (-7.7) has a slightly better binding affinity than Ligand B (-6.7). While the difference is less than the 1.5 kcal/mol threshold, it contributes to the overall preference.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Both ligands perform reasonably well in these areas. However, metabolic stability (Cl_mic, t1/2) and safety (DILI, hERG) are also critical. Ligand A excels in DILI and Cl_mic, while Ligand B has a much longer half-life. The longer half-life of Ligand B is attractive, but the lower DILI risk of Ligand A is a more important factor for a cardiovascular drug.
**Overall Assessment:**
Ligand A demonstrates a better overall balance of properties, particularly regarding safety (DILI) and metabolic stability (Cl_mic). While Ligand B has a longer half-life, the superior safety profile and better ADME properties of Ligand A make it the more promising drug candidate.
Output:
1
2025-04-18 00:26:51,322 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.463 and 386.539 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Both ligands (89.27 and 86.71) are below the 140 A^2 threshold for good oral absorption, and are reasonably well-suited for a GPCR. Ligand B is slightly better.
3. **logP:** Both ligands (1.766 and 1.78) are within the optimal 1-3 range, indicating good potential for membrane permeability and avoiding solubility issues. Very similar.
4. **HBD:** Both ligands have 2 HBD, which is within the acceptable limit of <=5. No difference.
5. **HBA:** Ligand A has 6 HBA, and Ligand B has 5. Both are below the 10 threshold. Ligand B is slightly better.
6. **QED:** Ligand A (0.816) has a higher QED score than Ligand B (0.748), suggesting a more drug-like profile. This is a significant advantage for Ligand A.
7. **DILI:** Ligand A (36.293) has a lower DILI risk than Ligand B (46.219), both are below the 60 threshold, but A is preferred.
8. **BBB:** Both ligands have reasonable BBB penetration (64.87% and 67.352%). For a cardiovascular target like ADRB2, BBB penetration isn't *critical* but isn't detrimental. Ligand B is slightly better.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual. It suggests poor permeability. Ligand B (-5.319) is slightly worse than Ligand A (-4.741).
10. **Solubility:** Both ligands have negative solubility values, which is unusual. It suggests poor solubility. Ligand B (-3.014) is slightly worse than Ligand A (-3.307).
11. **hERG:** Both ligands have very low hERG inhibition liability (0.247 and 0.522), which is excellent. No difference.
12. **Cl_mic:** Ligand B (33.834) has a lower microsomal clearance than Ligand A (38.889), indicating better metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand B (-34.812) has a *negative* in vitro half-life, which is highly problematic. Ligand A (25.256) has a reasonable half-life. This is a *major* advantage for Ligand A.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.103 and 0.055), which is good. Ligand B is slightly better.
15. **Binding Affinity:** Ligand A (-7.9 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.7 kcal/mol). This is a substantial advantage for Ligand A, potentially outweighing some ADME drawbacks.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Both ligands perform well on logP and Pgp. Ligand A has a significantly better binding affinity, and a more reasonable half-life. While Ligand B has better metabolic stability, the negative half-life is a major red flag.
**Conclusion:**
Despite Ligand B having slightly better metabolic stability and Pgp efflux, Ligand A's superior binding affinity, better QED, lower DILI risk, and *positive* in vitro half-life make it the more promising drug candidate. The negative half-life for Ligand B is a critical flaw.
Output:
1
2025-04-18 00:26:51,322 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (427.328 Da) is slightly higher than Ligand B (392.424 Da), but both are acceptable.
**2. TPSA:** Ligand A (88.33) is slightly above the preferred <90 for GPCRs, while Ligand B (66.48) is well within the range. This favors Ligand B.
**3. logP:** Both ligands have good logP values (A: 2.556, B: 3.546), falling within the optimal 1-3 range. Ligand B is slightly higher, which could potentially lead to some solubility issues, but is still acceptable.
**4. H-Bond Donors:** Ligand A (2) and Ligand B (1) are both within the acceptable limit of <=5. Ligand B is slightly better.
**5. H-Bond Acceptors:** Ligand A (9) is approaching the upper limit of 10, while Ligand B (4) is well below. This favors Ligand B.
**6. QED:** Both ligands have good QED scores (A: 0.561, B: 0.846), indicating good drug-like properties. Ligand B is significantly better.
**7. DILI Risk:** Ligand A (83.986) has a higher DILI risk than Ligand B (73.401), both are acceptable but B is preferred.
**8. BBB Penetration:** While not a primary concern for a cardiovascular target, Ligand B (74.874) shows better BBB penetration than Ligand A (50.407).
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-5.421) is slightly better than Ligand B (-4.947).
**10. Aqueous Solubility:** Ligand A (-1.858) has slightly better solubility than Ligand B (-4.622).
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (A: 0.636, B: 0.811).
**12. Microsomal Clearance:** Ligand A (17.879) has lower microsomal clearance than Ligand B (58.213), indicating better metabolic stability. This is a significant advantage for Ligand A.
**13. In vitro Half-Life:** Ligand A (90.979) has a much longer in vitro half-life than Ligand B (15.502). This is a major advantage for Ligand A.
**14. P-gp Efflux:** Both ligands have low P-gp efflux (A: 0.134, B: 0.401). Ligand A is better.
**15. Binding Affinity:** Ligand B (-6.6 kcal/mol) has a slightly better binding affinity than Ligand A (-6.3 kcal/mol). While a 0.3 kcal/mol difference is not huge, it's noticeable.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), and the general drug-like properties, Ligand A appears to be the more promising candidate. While Ligand B has better TPSA, QED, and slightly better affinity, Ligand A excels in metabolic stability (lower Cl_mic, longer t1/2) and P-gp efflux. The longer half-life and improved metabolic stability are crucial for *in vivo* efficacy and reducing dosing frequency. The slight difference in affinity is outweighed by the ADME advantages of Ligand A.
Output:
1
2025-04-18 00:26:51,322 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (342.399 and 350.503 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (85.25) is higher than Ligand B (58.64). For a cardiovascular GPCR, TPSA is moderately important, and Ligand B is better positioned for good absorption.
3. **logP:** Ligand B (3.189) is higher than Ligand A (1.516). This is a significant difference. For a GPCR, a logP between 1-3 is optimal, and Ligand B is closer to the upper end of this range, potentially offering better membrane permeability. Ligand A is at the lower end, which could limit permeability.
4. **HBD:** Ligand A (2) has more HBD than Ligand B (1). Lower HBD is generally preferred for permeability, giving a slight edge to Ligand B.
5. **HBA:** Ligand A (5) has more HBA than Ligand B (3). Again, lower HBA is generally preferred, favoring Ligand B.
6. **QED:** Ligand B (0.718) has a significantly higher QED score than Ligand A (0.411), indicating a more drug-like profile.
7. **DILI:** Ligand B (27.918) has a much lower DILI risk than Ligand A (60.915). This is a crucial advantage for Ligand B.
8. **BBB:** Ligand B (71.229) has a higher BBB penetration percentile than Ligand A (63.086). While ADRB2 isn't a primary CNS target, some degree of BBB penetration can be beneficial and doesn't necessarily pose a risk in this context.
9. **Caco-2:** Ligand A (-5.368) and Ligand B (-4.441) are both negative, which is unusual. Negative values suggest very poor permeability. However, the scale is not specified, so it is hard to interpret.
10. **Solubility:** Both have very poor solubility (-2.365 and -2.529). This is a concern for both, but might be addressed through formulation.
11. **hERG:** Both ligands have low hERG inhibition risk (0.342 and 0.199). No significant difference here.
12. **Cl_mic:** Ligand A (25.423) has a significantly lower microsomal clearance than Ligand B (89.461), suggesting better metabolic stability. This is a strong point in favor of Ligand A.
13. **t1/2:** Ligand A (10.628) has a longer in vitro half-life than Ligand B (0.972). This is another advantage for Ligand A.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.125 and 0.249). No significant difference here.
15. **Binding Affinity:** Ligand A (-6.5 kcal/mol) has a slightly better binding affinity than Ligand B (-6.1 kcal/mol). While the difference is not huge, it is a factor.
**Overall Assessment:**
Ligand B has several advantages: better logP, lower TPSA, higher QED, and significantly lower DILI risk. These are all important factors for a viable drug candidate. Ligand A has better metabolic stability (lower Cl_mic) and a longer half-life, and slightly better binding affinity. However, the DILI risk for Ligand A is concerning, and the lower logP and higher TPSA are less desirable for a GPCR target. The slightly better binding affinity of Ligand A is not enough to overcome these drawbacks.
**Output:**
0
2025-04-18 00:26:51,322 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands (357.37 & 366.38 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Both ligands (92.18 & 89.87) are below the 140 A^2 threshold for good oral absorption, but higher than the 90 A^2 for CNS targets. This is acceptable for a cardiovascular target. Ligand B is slightly better.
3. **logP:** Ligand A (2.972) is optimal, while Ligand B (0.529) is a bit low, potentially hindering permeability. Ligand A is better.
4. **HBD:** Ligand A (2) and Ligand B (3) are both within the acceptable limit of 5. No significant difference.
5. **HBA:** Ligand A (5) and Ligand B (4) are both within the acceptable limit of 10. No significant difference.
6. **QED:** Both ligands (0.732 & 0.64) have good drug-likeness scores (>0.5). No clear advantage.
7. **DILI:** Ligand A (98.371) has a very high DILI risk, which is a major concern. Ligand B (17.138) has a much lower, and acceptable, DILI risk. Ligand B is significantly better.
8. **BBB:** Ligand A (23.304) has very low BBB penetration, while Ligand B (65.374) is better, though not exceptionally high. Given this is a cardiovascular target, BBB isn't paramount, but higher is still preferable. Ligand B is better.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.148 & -4.999), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Both ligands have negative solubility values (-3.75 & -1.819), which is also unusual and suggests poor solubility. This is a concern for both.
11. **hERG:** Ligand A (0.115) has a very low hERG risk, which is excellent. Ligand B (0.398) is slightly higher, but still relatively low. Ligand A is better.
12. **Cl_mic:** Ligand A (1.568) has a lower microsomal clearance, indicating better metabolic stability than Ligand B (-10.218). Ligand A is better.
13. **t1/2:** Ligand A (-3.247) has a negative in vitro half-life, which is concerning. Ligand B (-7.115) is even worse. Both are poor.
14. **Pgp:** Ligand A (0.022) has very low P-gp efflux, which is good. Ligand B (0.012) is even lower. Ligand B is slightly better.
15. **Affinity:** Ligand A (-7.1 kcal/mol) has a slightly better binding affinity than Ligand B (-5.3 kcal/mol). This is a significant advantage.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are important. Ligand A has better logP and affinity, while Ligand B has better Pgp and TPSA. However, the *critical* issue is the extremely high DILI risk associated with Ligand A.
**Overall Assessment:**
Despite Ligand A's slightly better affinity and logP, the extremely high DILI risk is a deal-breaker. The DILI risk outweighs the benefits. Ligand B, while having some drawbacks (lower logP, worse half-life), presents a much more favorable safety profile. The negative Caco-2 and solubility values are concerning for both, but these can potentially be addressed with formulation strategies. The lower DILI risk and better Pgp efflux of Ligand B make it the more promising candidate.
Output:
0
2025-04-18 00:26:51,322 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, the key priorities are logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB.
Let's break down the comparison:
1. **MW:** Both ligands (357.332 and 341.455 Da) are within the ideal range (200-500 Da).
2. **TPSA:** Ligand B (45.55) is significantly better than Ligand A (75.44). Lower TPSA is preferred for GPCRs, aiding membrane permeability.
3. **logP:** Both ligands have a logP of 2.741, which is optimal.
4. **HBD/HBA:** Ligand B (0 HBD, 3 HBA) is slightly better than Ligand A (1 HBD, 4 HBA) as lower values are generally preferred.
5. **QED:** Ligand A (0.849) has a slightly better QED score than Ligand B (0.794), indicating a more drug-like profile.
6. **DILI:** Ligand B (43.234) has a significantly lower DILI risk than Ligand A (67.778). This is a major advantage for Ligand B.
7. **BBB:** Ligand A (89.066) has better BBB penetration than Ligand B (71.229), but BBB is less critical for a cardiovascular target.
8. **Caco-2:** Both are negative, suggesting poor permeability.
9. **Solubility:** Both are negative, suggesting poor solubility.
10. **hERG:** Ligand B (0.392) has a lower hERG risk than Ligand A (0.163), which is a significant safety advantage.
11. **Cl_mic:** Ligand A (26.915) has a lower microsomal clearance than Ligand B (71.535), indicating better metabolic stability.
12. **t1/2:** Ligand B (38.533) has a longer in vitro half-life than Ligand A (-25.256). This is a positive attribute.
13. **Pgp:** Ligand A (0.072) has lower P-gp efflux than Ligand B (0.413), which is beneficial for bioavailability.
14. **Binding Affinity:** Ligand A (-8.7 kcal/mol) has a significantly stronger binding affinity than Ligand B (-7.0 kcal/mol). This is a substantial advantage.
**Overall Assessment:**
While Ligand A has a stronger binding affinity and lower P-gp efflux, Ligand B demonstrates a superior safety profile (lower DILI and hERG risk) and better metabolic stability (longer half-life). The significantly better TPSA of Ligand B is also a major plus for GPCR targeting. The binding affinity difference, while notable, is not so large that it completely outweighs the ADME/Tox advantages of Ligand B. Given the cardiovascular context, prioritizing safety and reasonable metabolic properties is crucial.
**Output:**
0
2025-04-18 00:26:51,323 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [345.443, 71.53, 1.782, 1, 4, 0.883, 44.048, 70.609, -4.644, -1.497, 0.249, 21.832, -13.856, 0.043, -8.3]
**Ligand B:** [389.861, 112.65, -0.154, 2, 5, 0.385, 45.715, 75.533, -5.958, -2.504, 0.101, -9.587, -23.677, 0.021, -7.1]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity, and BBB):
1. **MW:** Both are within the acceptable 200-500 Da range. Ligand A (345.443) is slightly preferred.
2. **TPSA:** Ligand A (71.53) is significantly better than Ligand B (112.65). A lower TPSA generally indicates better permeability, crucial for GPCRs.
3. **logP:** Ligand A (1.782) is optimal, while Ligand B (-0.154) is quite low, potentially hindering membrane permeability. This is a significant advantage for A.
4. **HBD/HBA:** Ligand A (1 HBD, 4 HBA) is better than Ligand B (2 HBD, 5 HBA). Lower counts are generally preferred.
5. **QED:** Ligand A (0.883) is much better than Ligand B (0.385), indicating a more drug-like profile.
6. **DILI:** Both are reasonably good (A: 44.048, B: 45.715), below the 60% threshold.
7. **BBB:** Both have good BBB penetration (A: 70.609, B: 75.533), but B is slightly better. However, for a cardiovascular target, BBB isn't *as* critical as for CNS targets.
8. **Caco-2:** Ligand A (-4.644) is much better than Ligand B (-5.958). Higher values indicate better absorption.
9. **Solubility:** Ligand A (-1.497) is better than Ligand B (-2.504).
10. **hERG:** Both are very low (A: 0.249, B: 0.101), indicating low cardiotoxicity risk.
11. **Cl_mic:** Ligand A (21.832) is better than Ligand B (-9.587). Lower clearance is preferred for metabolic stability.
12. **t1/2:** Ligand A (-13.856) is better than Ligand B (-23.677). Longer half-life is preferable.
13. **Pgp:** Both are very low (A: 0.043, B: 0.021), indicating minimal efflux.
14. **Affinity:** Ligand A (-8.3) is slightly better than Ligand B (-7.1). While both are good, the difference is significant.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical parameters, especially logP, TPSA, QED, Caco-2, and metabolic stability (Cl_mic and t1/2). The slightly better affinity of Ligand A further strengthens its position. While Ligand B has a slightly better BBB score, this is less crucial for a cardiovascular target. The significantly better ADME properties of Ligand A make it the more promising drug candidate.
Output:
1
2025-04-18 00:26:51,323 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (344.37 and 346.48 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (90.7 and 87.89) are below the 140 A^2 threshold for good oral absorption, and reasonably close to the 90 A^2 threshold for CNS penetration (though ADRB2 isn't necessarily a CNS target). Ligand B is slightly better.
3. **logP:** Both ligands (3.62 and 3.05) are within the optimal 1-3 range. Ligand B is slightly lower, which could be beneficial for solubility.
4. **HBD:** Ligand A has 1 HBD, while Ligand B has 3. Ligand A is preferable here, as fewer HBDs generally improve membrane permeability.
5. **HBA:** Ligand A has 6 HBA, and Ligand B has 7. Both are acceptable, under the 10 threshold.
6. **QED:** Both ligands have good QED scores (0.489 and 0.647), indicating reasonable drug-likeness. Ligand B is better.
7. **DILI:** Ligand A has a DILI risk of 83.4%, while Ligand B is 60.6%. Ligand B is significantly better, falling well within the 'good' risk category (<40 is ideal, but <60 is good). This is a major advantage for Ligand B.
8. **BBB:** Ligand A has a BBB penetration of 50.4%, while Ligand B is 70.8%. While ADRB2 isn't a primary CNS target, higher BBB penetration is generally favorable, reducing potential off-target effects. Ligand B is better.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.716 and -5.061). This is unusual and suggests poor permeability. However, the values are similar.
10. **Solubility:** Both ligands have negative solubility values (-5.884 and -4.066). This is also unusual and suggests poor solubility. Ligand B is slightly better.
11. **hERG:** Both ligands have low hERG inhibition liability (0.692 and 0.738), which is excellent. No significant difference.
12. **Cl_mic:** Ligand A has a higher microsomal clearance (106.084) than Ligand B (63.606). Lower clearance is preferred for better metabolic stability, so Ligand B is better.
13. **t1/2:** Ligand B has a much longer in vitro half-life (80.34 hours) compared to Ligand A (-18.618 hours). This is a significant advantage for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.361 and 0.253), which is good. Ligand B is slightly better.
15. **Binding Affinity:** Ligand B has a significantly better binding affinity (-7.1 kcal/mol) compared to Ligand A (-8.1 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME drawbacks of Ligand A.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B excels in affinity and has favorable scores for logP, TPSA, and Pgp. The DILI score and longer half-life are also significant advantages.
**Overall Assessment:**
While Ligand A has a slightly better HBD count, Ligand B demonstrates a superior overall profile. The significantly improved binding affinity, lower DILI risk, longer half-life, and better BBB penetration outweigh the minor drawbacks in HBD and solubility. The negative Caco-2 and solubility values are concerning for both, but the overall balance favors Ligand B.
Output:
0
2025-04-18 00:26:51,323 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (345.443 and 353.423 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (73.22) is significantly better than Ligand B (111.39). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is pushing the upper limit for good oral absorption.
3. **logP:** Ligand A (2.319) is optimal, while Ligand B (-0.027) is quite low. A logP near zero can lead to poor membrane permeability. This is a major strike against Ligand B.
4. **HBD:** Ligand A (1) is good, and Ligand B (2) is acceptable.
5. **HBA:** Ligand A (5) is good, while Ligand B (9) is higher, potentially impacting permeability.
6. **QED:** Both ligands (0.85 and 0.658) have acceptable drug-likeness scores, with Ligand A being slightly better.
7. **DILI:** Both ligands have low DILI risk (31.912 and 33.501), which is positive.
8. **BBB:** Ligand A (70.997) has a better BBB penetration score than Ligand B (62.737), though ADRB2 isn't necessarily a CNS target, some peripheral distribution is still desirable.
9. **Caco-2:** Ligand A (-4.567) is better than Ligand B (-5.165), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-3.27) is better than Ligand B (-1.2). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.656) has a lower hERG risk than Ligand B (0.07). This is a significant advantage for Ligand A, as hERG inhibition can lead to cardiotoxicity.
12. **Cl_mic:** Ligand B (38.497) has a lower microsomal clearance than Ligand A (74.957), suggesting better metabolic stability. This is a positive for Ligand B.
13. **t1/2:** Both ligands have similar in vitro half-lives (5.549 and 5.343 hours).
14. **Pgp:** Ligand A (0.31) has a lower P-gp efflux liability than Ligand B (0.031), which is preferable for bioavailability.
15. **Binding Affinity:** Ligand A (-8.4 kcal/mol) has a *much* stronger binding affinity than Ligand B (-1.7 kcal/mol). This is a decisive factor. A difference of 6.7 kcal/mol is substantial and can often overcome minor ADME deficiencies.
**Overall Assessment:**
Ligand A significantly outperforms Ligand B in several crucial areas: logP, TPSA, hERG risk, binding affinity, and solubility. While Ligand B has slightly better metabolic stability, the superior binding affinity and more favorable ADME properties of Ligand A make it a much more promising drug candidate for the ADRB2 receptor. The strong binding affinity of Ligand A is the most important factor, given the GPCR target class.
Output:
1
2025-04-18 00:26:51,323 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (342.359 Da and 346.395 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (102.24) is preferable to Ligand B (121.69). While both are under the 140 A^2 threshold for oral absorption, lower TPSA generally correlates with better membrane permeability, which is important for GPCR ligands.
**3. logP:** Ligand B (-0.238) is slightly lower than Ligand A (0.274). Both are a bit low, potentially hindering membrane permeability. However, the difference is small.
**4. H-Bond Donors:** Ligand A (1) is better than Ligand B (2). Fewer H-bond donors generally improve permeability.
**5. H-Bond Acceptors:** Both ligands have 7 H-bond acceptors, which is acceptable.
**6. QED:** Ligand A (0.859) has a higher QED score than Ligand B (0.771), indicating a more drug-like profile.
**7. DILI:** Ligand B (72.47) has a slightly lower DILI risk than Ligand A (78.325), which is favorable. However, both are reasonably low risk.
**8. BBB:** Ligand A (74.254) has a significantly higher BBB penetration percentile than Ligand B (54.634). While ADRB2 is a cardiovascular target, some CNS penetration can be acceptable or even desirable for off-target effects assessment. More importantly, higher BBB suggests better overall permeability.
**9. Caco-2 Permeability:** Ligand A (-5.172) has a better Caco-2 permeability than Ligand B (-5.632).
**10. Aqueous Solubility:** Ligand B (-2.43) has slightly worse solubility than Ligand A (-2.289).
**11. hERG Inhibition:** Ligand A (0.099) has a slightly lower hERG inhibition liability than Ligand B (0.038), which is preferable.
**12. Microsomal Clearance:** Ligand B (-5.385) has a much lower (better) microsomal clearance than Ligand A (15.342), indicating better metabolic stability. This is a significant advantage for Ligand B.
**13. In vitro Half-Life:** Ligand B (-4.909) has a better in vitro half-life than Ligand A (36.801).
**14. P-gp Efflux:** Ligand A (0.007) has a much lower P-gp efflux liability than Ligand B (0.056), which is a significant advantage.
**15. Binding Affinity:** Ligand B (3.4 kcal/mol) has a significantly better binding affinity than Ligand A (-5.0 kcal/mol). This is the most important factor, and the >1.5 kcal/mol difference outweighs many of the ADME drawbacks of Ligand B.
**Overall Assessment:**
While Ligand A has better TPSA, QED, BBB, Caco-2 permeability, hERG, and P-gp efflux, Ligand B's significantly superior binding affinity and improved metabolic stability (lower Cl_mic and better half-life) are crucial for a GPCR target. The slightly lower logP and solubility of Ligand B are less concerning given the strong affinity. The difference in binding affinity is substantial enough to overcome the other minor drawbacks.
Output:
0
2025-04-18 00:26:51,323 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (a cardiovascular GPCR) drug candidates.
**Ligand A:** [376.737, 75.35, 3.633, 3, 3, 0.713, 41.218, 43.273, -5.182, -3.649, 0.782, 12.761, 12.142, 0.236, -7.4]
**Ligand B:** [349.431, 84.67, 2.146, 1, 5, 0.691, 39.201, 79.682, -4.524, -2.526, 0.387, 69.391, 4.914, 0.156, -6.9]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal 200-500 Da range. Ligand B (349.431) is slightly preferred due to being a bit lower.
2. **TPSA:** Ligand A (75.35) is better than Ligand B (84.67). Both are acceptable, but lower TPSA generally favors permeability.
3. **logP:** Ligand A (3.633) is optimal. Ligand B (2.146) is on the lower side, potentially hindering membrane permeability.
4. **HBD/HBA:** Ligand A (3/3) is better than Ligand B (1/5). Lower counts are generally preferred for permeability.
5. **QED:** Both are similar (0.713 and 0.691), indicating good drug-likeness.
6. **DILI:** Both are good, below the 40% threshold, with Ligand A (41.218) being slightly higher.
7. **BBB:** Ligand B (79.682) is significantly better than Ligand A (43.273). While not a primary concern for a cardiovascular target, higher BBB is never detrimental.
8. **Caco-2:** Ligand A (-5.182) is worse than Ligand B (-4.524), indicating lower intestinal absorption.
9. **Solubility:** Ligand A (-3.649) is worse than Ligand B (-2.526).
10. **hERG:** Ligand A (0.782) is better than Ligand B (0.387), indicating lower cardiotoxicity risk.
11. **Cl_mic:** Ligand A (12.761) is significantly better than Ligand B (69.391), indicating better metabolic stability.
12. **t1/2:** Ligand A (12.142) is much better than Ligand B (4.914), indicating a longer half-life.
13. **Pgp:** Ligand A (0.236) is better than Ligand B (0.156), indicating lower P-gp efflux.
14. **Affinity:** Ligand A (-7.4) is significantly better than Ligand B (-6.9). This 1.5 kcal/mol difference is substantial and can outweigh minor ADME drawbacks.
**Overall Assessment:**
Ligand A has a significantly better binding affinity and much better metabolic stability (Cl_mic and t1/2). It also has better Pgp efflux and hERG inhibition profiles. While Ligand B has better BBB penetration and slightly better solubility, the superior affinity and metabolic properties of Ligand A are crucial for a GPCR target, especially considering the cardiovascular context where sustained target engagement is desirable. The slightly worse Caco-2 and solubility of Ligand A are less concerning than the weaker binding and faster metabolism of Ligand B.
Therefore, I prefer Ligand A.
Output:
1
2025-04-18 00:26:51,324 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (337.339 and 337.467 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (115.98) is higher than Ligand B (28.6). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is generally preferred for absorption. Ligand B is significantly better here.
**3. logP:** Ligand B (3.382) is slightly higher than Ligand A (1.5). Both are within the optimal 1-3 range, but Ligand B is closer to the upper limit.
**4. H-Bond Donors:** Ligand A has 4 HBDs, while Ligand B has 0. Lower is generally better for permeability, so Ligand B has an advantage.
**5. H-Bond Acceptors:** Both ligands have 4 HBAs. No significant difference.
**6. QED:** Ligand B (0.858) has a higher QED score than Ligand A (0.51), indicating a more drug-like profile.
**7. DILI Risk:** Ligand A (85.537) has a significantly higher DILI risk than Ligand B (14.385). This is a major concern for Ligand A.
**8. BBB Penetration:** Ligand B (97.674) has much higher predicted BBB penetration than Ligand A (40.558). While ADRB2 isn't strictly a CNS target, some CNS exposure can occur, and higher BBB penetration can sometimes correlate with better overall distribution.
**9. Caco-2 Permeability:** Ligand A (-5.835) has lower Caco-2 permeability than Ligand B (-4.504). Lower values suggest poorer absorption.
**10. Aqueous Solubility:** Ligand A (-4.693) has lower aqueous solubility than Ligand B (-2.341). Solubility is important for formulation and bioavailability.
**11. hERG Inhibition:** Ligand A (0.483) has a slightly lower hERG inhibition risk than Ligand B (0.949), which is preferable.
**12. Microsomal Clearance:** Ligand A (-4.185) has lower microsomal clearance (better metabolic stability) than Ligand B (47.982). This is a significant advantage for Ligand A.
**13. In vitro Half-Life:** Ligand A (66.321) has a longer in vitro half-life than Ligand B (-26.421). This is a major advantage for Ligand A.
**14. P-gp Efflux:** Ligand A (0.03) has much lower P-gp efflux than Ligand B (0.338). Lower efflux is desirable for better bioavailability.
**15. Binding Affinity:** Ligand A (-7.8 kcal/mol) has slightly better binding affinity than Ligand B (-5.9 kcal/mol). This is a 1.9 kcal/mol difference, which is substantial.
**Overall Assessment:**
Ligand B excels in properties related to absorption and drug-likeness (TPSA, QED, Caco-2, Solubility, BBB). However, its high DILI risk and poor metabolic stability are major drawbacks. Ligand A, despite having a higher TPSA and lower solubility, has a significantly lower DILI risk, better metabolic stability (lower Cl_mic, longer t1/2), lower P-gp efflux, and only slightly weaker binding affinity. The binding affinity difference is outweighed by the ADME/Tox advantages of Ligand A. For a cardiovascular target, minimizing toxicity (DILI) and ensuring reasonable metabolic stability are crucial.
Output:
1
2025-04-18 00:26:51,324 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (349.475) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (67.87) has a lower TPSA than Ligand A (82.53), which is better for oral absorption and potentially better for GPCRs.
3. **logP:** Both ligands have good logP values (A: 2.548, B: 1.249) within the optimal 1-3 range. Ligand B is slightly lower, which could slightly improve solubility but might compromise membrane permeability.
4. **HBD:** Ligand A (2) has a slightly higher HBD count than Ligand B (1), but both are acceptable.
5. **HBA:** Ligand A (4) and Ligand B (5) are both within the acceptable range of <=10.
6. **QED:** Both ligands have similar QED values (A: 0.718, B: 0.685), indicating good drug-likeness.
7. **DILI:** Ligand B (29.159) has a significantly lower DILI risk than Ligand A (35.595), which is a major advantage.
8. **BBB:** Both ligands have similar BBB penetration (A: 54.285, B: 56.146). While not exceptionally high, it's not a primary concern for ADRB2, which is not a CNS target.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual. It's difficult to interpret, but suggests poor permeability.
10. **Solubility:** Ligand B (-3.152) has a better solubility score than Ligand A (-2.346).
11. **hERG:** Both ligands have low hERG inhibition liability (A: 0.435, B: 0.193), which is excellent. Ligand B is slightly better.
12. **Cl_mic:** Ligand B (16.982) has a significantly lower microsomal clearance than Ligand A (57.291), indicating better metabolic stability.
13. **t1/2:** Ligand B (15.179) has a longer in vitro half-life than Ligand A (21.16), which is desirable.
14. **Pgp:** Both ligands have very low Pgp efflux liability (A: 0.08, B: 0.04), which is favorable.
15. **Binding Affinity:** Both ligands have very similar binding affinities (A: -6.5, B: -6.4 kcal/mol). The difference is negligible.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, and metabolic stability are important. Ligand B excels in TPSA, DILI, Cl_mic, solubility, and half-life. While both have acceptable logP values, Ligand B is slightly lower. The binding affinity is nearly identical.
**Conclusion:**
Ligand B demonstrates a superior overall profile, particularly regarding safety (DILI) and metabolic stability (Cl_mic, t1/2). The lower TPSA and better solubility are also beneficial. Although the Caco-2 values are concerning for both, the other advantages of Ligand B outweigh the minor differences.
Output:
0
2025-04-18 00:26:51,324 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [346.387, 95. , 0.709, 2. , 5. , 0.786, 65.607, 49.826, -4.633, -1.842, 0.133, -17.822, -10.037, 0.006, -7.3 ]
**Ligand B:** [367.475, 126.21 , 0.822, 4. , 5. , 0.507, 44.591, 61.225, -5.637, -1.937, 0.059, 12.198, 4.618, 0.02 , -7.3 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (346.387) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (95) is better than Ligand B (126.21). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally aids absorption.
3. **logP:** Both are good (around 0.7-0.8), falling within the optimal 1-3 range.
4. **HBD:** Ligand A (2) is better than Ligand B (4). Fewer HBDs are preferred for better permeability.
5. **HBA:** Both have 5 HBA, which is acceptable.
6. **QED:** Ligand A (0.786) is significantly better than Ligand B (0.507), indicating a more drug-like profile.
7. **DILI:** Ligand B (44.591) is better than Ligand A (65.607). Lower DILI risk is crucial.
8. **BBB:** Ligand B (61.225) is better than Ligand A (49.826), but since this is a cardiovascular target, this isn't a major deciding factor.
9. **Caco-2:** Ligand B (-5.637) is better than Ligand A (-4.633), indicating better intestinal absorption.
10. **Solubility:** Ligand B (-1.937) is slightly better than Ligand A (-1.842).
11. **hERG:** Both are very low risk (0.133 and 0.059).
12. **Cl_mic:** Ligand A (-17.822) is *much* better than Ligand B (12.198). Lower clearance means greater metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand B (4.618) is better than Ligand A (-10.037). Longer half-life is desirable.
14. **Pgp:** Both are very low efflux (0.006 and 0.02).
15. **Affinity:** Both have the same affinity (-7.3 kcal/mol).
**GPCR-Specific Priorities:** For ADRB2 (a cardiovascular GPCR), we prioritize logP, TPSA, Pgp, and affinity. Metabolic stability (Cl_mic, t1/2) is also important.
**Overall Assessment:**
Ligand A has a better QED, TPSA, HBD, and *significantly* better metabolic stability (Cl_mic). Ligand B has a slightly better Caco-2 permeability, solubility, and half-life, and lower DILI risk. However, the superior metabolic stability of Ligand A is a critical advantage for a drug candidate, especially considering the potential for first-pass metabolism. The better QED and TPSA of ligand A also contribute to its overall drug-likeness. While the DILI risk is higher for Ligand A, it is still within an acceptable range.
Therefore, I favor Ligand A.
Output:
1
2025-04-18 00:26:51,324 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.491 and 360.479 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (67.23) is slightly higher than Ligand B (58.64). Both are below the 140 threshold for oral absorption, but closer to the 90 threshold for CNS targets (less relevant for ADRB2, but still a positive). Ligand B is preferable.
3. **logP:** Both ligands (2.49 and 2.962) are within the optimal 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability, but not dramatically.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 5. Both are acceptable (<=10).
6. **QED:** Ligand B (0.852) has a significantly better QED score than Ligand A (0.745), indicating a more drug-like profile. This is a notable advantage for Ligand B.
7. **DILI:** Ligand A (19.155) has a much lower DILI risk than Ligand B (50.64). This is a substantial advantage for Ligand A.
8. **BBB:** Both have good BBB penetration (70.686 and 78.945). While BBB isn't the highest priority for ADRB2 (a cardiovascular target), higher is still preferable. Ligand B is slightly better.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. This is a significant concern for both, but the values are very close.
10. **Solubility:** Ligand A (-1.749) has better solubility than Ligand B (-3.943). Solubility is important for bioavailability, so this favors Ligand A.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.275 and 0.522). No significant difference.
12. **Cl_mic:** Ligand A (57.886) has a lower microsomal clearance than Ligand B (73.764), suggesting better metabolic stability. This is a positive for Ligand A.
13. **t1/2:** Ligand B (29.936) has a much longer in vitro half-life than Ligand A (-4.721). This is a significant advantage for Ligand B.
14. **Pgp:** Both have low Pgp efflux liability (0.158 and 0.26). No significant difference.
15. **Binding Affinity:** Both ligands have the same binding affinity (-5.9 kcal/mol).
**GPCR-Specific Priorities & Overall Assessment:**
For a GPCR like ADRB2, logP, TPSA, and affinity are key. Both ligands perform similarly on logP and affinity. Ligand B has a better TPSA and BBB. However, Ligand A has a much better DILI score, better solubility, and lower Cl_mic. The longer half-life of Ligand B is attractive, but the lower DILI risk and better metabolic stability of Ligand A are more critical. The poor Caco-2 permeability is a concern for both, and would need to be addressed in further optimization.
Considering the balance of these factors, the lower DILI risk and better metabolic stability of Ligand A outweigh the slightly better pharmacokinetic properties of Ligand B.
Output:
1
2025-04-18 00:26:51,324 - INFO - Batch 478 complete. Total preferences: 7648
2025-04-18 00:26:51,324 - INFO - Processing batch 479/512...
2025-04-18 00:27:41,254 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (356.535 Da and 362.459 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (25.24) is significantly lower than Ligand B (93.01). For a GPCR, lower TPSA is generally preferred for better permeability, and Ligand A is well below the 140 cutoff. Ligand B is quite high, potentially hindering absorption.
**3. logP:** Ligand A (4.867) is higher than Ligand B (1.312). While 4.867 is approaching the upper limit, it's still within a reasonable range. Ligand B's logP is quite low, potentially leading to poor membrane permeability.
**4. H-Bond Donors:** Ligand A (0) is better than Ligand B (1). Fewer H-bond donors generally improve permeability.
**5. H-Bond Acceptors:** Ligand A (3) is lower than Ligand B (7). Again, fewer H-bond acceptors are generally preferred for permeability.
**6. QED:** Both ligands have good QED scores (0.77 and 0.885), indicating good overall drug-likeness.
**7. DILI:** Ligand A (41.954) has a lower DILI risk than Ligand B (72.509). Both are acceptable, but Ligand A is preferable.
**8. BBB:** Ligand A (92.051) has a significantly higher BBB penetration percentile than Ligand B (56.65). While ADRB2 is a cardiovascular target, some CNS exposure can occur, and higher BBB is generally not detrimental unless specifically trying to avoid CNS effects.
**9. Caco-2 Permeability:** Ligand A (-4.899) is better than Ligand B (-5.182). Both are negative, indicating poor permeability, but Ligand A is slightly better.
**10. Aqueous Solubility:** Ligand A (-4.756) is better than Ligand B (-2.578). Both are poor, but Ligand A is slightly better.
**11. hERG Inhibition:** Ligand A (0.778) has a lower hERG inhibition liability than Ligand B (0.205). This is a significant advantage for Ligand A, reducing the risk of cardiotoxicity.
**12. Microsomal Clearance:** Ligand A (75.59) has a higher microsomal clearance than Ligand B (55.197). This means Ligand B is more metabolically stable, which is desirable.
**13. In vitro Half-Life:** Ligand A (26.204) has a longer half-life than Ligand B (0.314). This is a significant advantage for Ligand A.
**14. P-gp Efflux:** Ligand A (0.883) has a higher P-gp efflux liability than Ligand B (0.093). Ligand B is much better here, indicating less efflux and potentially better bioavailability.
**15. Binding Affinity:** Ligand B (-6.0) has a slightly better binding affinity than Ligand A (-5.8). However, the difference is only 0.2 kcal/mol, which is not substantial enough to outweigh the numerous advantages of Ligand A.
**Overall Assessment:**
Ligand A demonstrates a better balance of properties, particularly regarding permeability (lower TPSA, fewer H-bonds), safety (lower DILI, lower hERG), and PK (longer half-life). While Ligand B has slightly better affinity and metabolic stability, the significant drawbacks in permeability, TPSA, and hERG risk make it a less attractive candidate. The slightly better affinity of Ligand B does not outweigh the other advantages of Ligand A.
Output:
1
2025-04-18 00:27:41,254 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [351.403, 101.73 , 0.348, 1. , 7. , 0.785, 41.722, 36.836, -4.415, -2.113, 0.177, 44.129, -19.623, 0.049, -6.2 ]
**Ligand B:** [351.353, 73.64 , 1.777, 0. , 4. , 0.81 , 48.275, 85.731, -4.159, -2.409, 0.536, 15.972, -12.621, 0.136, -7.2 ]
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (around 351 Da). No significant difference.
2. **TPSA:** Ligand A (101.73) is higher than Ligand B (73.64). For a cardiovascular GPCR, we don't *need* extremely low TPSA for CNS penetration, but lower is generally preferable for permeability. Ligand B is better here.
3. **logP:** Ligand A (0.348) is quite low, potentially hindering membrane permeability. Ligand B (1.777) is within the optimal range. Ligand B is significantly better.
4. **HBD:** Ligand A (1) is good. Ligand B (0) is also good, and potentially slightly better for permeability.
5. **HBA:** Ligand A (7) is acceptable. Ligand B (4) is better.
6. **QED:** Both are good (A: 0.785, B: 0.81), indicating drug-like properties. No clear winner.
7. **DILI:** Both are reasonably low (A: 41.722, B: 48.275), suggesting acceptable liver safety. No significant difference.
8. **BBB:** Ligand A (36.836) is low, while Ligand B (85.731) is high. While ADRB2 isn't exclusively a CNS target, higher BBB penetration can sometimes be beneficial, and certainly isn't detrimental in this case. Ligand B is much better.
9. **Caco-2:** Both are negative, indicating poor permeability. This is concerning for both, but the lower TPSA and higher logP of Ligand B might mitigate this somewhat.
10. **Solubility:** Both are negative, indicating poor solubility. This is a significant issue for both.
11. **hERG:** Both are very low (A: 0.177, B: 0.536), indicating low cardiotoxicity risk. No significant difference.
12. **Cl_mic:** Ligand A (44.129) has a higher clearance than Ligand B (15.972), meaning it's likely to be metabolized faster. Ligand B is better.
13. **t1/2:** Ligand A (-19.623) has a negative half-life, which is concerning. Ligand B (-12.621) is also negative, but less so.
14. **Pgp:** Ligand A (0.049) has lower P-gp efflux than Ligand B (0.136), which is preferable.
15. **Affinity:** Ligand B (-7.2 kcal/mol) has a 1 kcal/mol stronger binding affinity than Ligand A (-6.2 kcal/mol). This is a substantial difference and a major advantage for Ligand B.
**Overall Assessment:**
Ligand B consistently outperforms Ligand A across most critical parameters, especially logP, TPSA, BBB, Cl_mic, and crucially, binding affinity. While both have solubility and Caco-2 permeability issues, Ligand B's better ADME profile and significantly stronger binding make it the more promising candidate. The higher BBB is a bonus, even for a cardiovascular target.
Output:
0
2025-04-18 00:27:41,254 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (346.39 and 354.49 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand B (89.87) is significantly better than Ligand A (114.62). For a GPCR, lower TPSA is generally preferred for better permeability.
**3. logP:** Ligand B (1.44) is within the optimal range (1-3), while Ligand A (-0.453) is slightly below, potentially hindering permeability.
**4. H-Bond Donors:** Ligand A (2) and Ligand B (3) are both acceptable, falling under the limit of 5.
**5. H-Bond Acceptors:** Ligand A (5) and Ligand B (4) are both acceptable, falling under the limit of 10.
**6. QED:** Both ligands have similar QED values (0.717 and 0.697), indicating good drug-likeness.
**7. DILI:** Ligand B (16.092) has a much lower DILI risk than Ligand A (43.66), which is a significant advantage. Lower DILI is crucial for drug safety.
**8. BBB:** Both ligands have reasonable BBB penetration (Ligand A: 68.2%, Ligand B: 60.8%). While not a CNS target, some level of BBB penetration can influence off-target effects and distribution.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-5.12 and -4.86), which is unusual and suggests poor permeability. However, these values are on a logarithmic scale and may not be directly comparable.
**10. Aqueous Solubility:** Both ligands have negative solubility values (-2.36 and -2.71), indicating poor aqueous solubility. This is a concern for bioavailability.
**11. hERG Inhibition:** Both ligands show very low hERG inhibition risk (0.061 and 0.18), which is excellent.
**12. Microsomal Clearance:** Ligand A (-4.914) has significantly lower (better) microsomal clearance than Ligand B (19.154), suggesting greater metabolic stability.
**13. In vitro Half-Life:** Ligand A (7.32 hours) has a better in vitro half-life than Ligand B (-8.45 hours).
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.019 and 0.05), which is favorable.
**15. Binding Affinity:** Ligand B (-6.7 kcal/mol) has a slightly better binding affinity than Ligand A (-6.1 kcal/mol), but the difference is not substantial enough to outweigh other factors.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity) and the general drug-like properties, **Ligand B** is the more promising candidate. While Ligand A has better metabolic stability and half-life, Ligand B excels in TPSA, logP, and crucially, DILI risk. The lower DILI risk is a major advantage, and the slightly better affinity is a bonus. The solubility and Caco-2 permeability are concerns for both, but the other advantages of Ligand B make it the preferred choice.
Output:
0
2025-04-18 00:27:41,254 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.503 and 349.381 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (58.64 and 58.37) are below the 140 A^2 threshold for good oral absorption, and well below the 90 A^2 threshold for CNS targets (though ADRB2 isn't primarily a CNS target, lower TPSA is generally favorable). Again, no major distinction.
3. **logP:** Both ligands have logP values (3.047 and 3.243) within the optimal 1-3 range. Ligand B is slightly higher, which *could* be a minor negative if it leads to solubility issues, but it's not a major concern.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 3 HBA, Ligand B has 4. Both are acceptable (<=10), but Ligand A is slightly better.
6. **QED:** Ligand B (0.87) has a higher QED than Ligand A (0.65), indicating a more drug-like profile. This is a significant advantage for Ligand B.
7. **DILI:** Ligand A has a DILI risk of 9.19%, while Ligand B has 39.473%. This is a *substantial* difference. Ligand A is clearly preferable regarding liver toxicity risk.
8. **BBB:** Both ligands have good BBB penetration (81.233% and 70.919%). Since ADRB2 isn't a primary CNS target, this isn't a critical factor, but higher is still slightly preferred. Ligand A is better here.
9. **Caco-2:** Both have negative Caco-2 values (-4.359 and -4.959), which is unusual and suggests poor permeability. This is a significant concern for both. Ligand B is slightly worse.
10. **Solubility:** Both have negative solubility values (-2.178 and -2.934), indicating very poor aqueous solubility. This is a major drawback for both, but Ligand A is slightly better.
11. **hERG:** Both ligands have low hERG inhibition risk (0.387% and 0.661%), which is good.
12. **Cl_mic:** Ligand A has a higher microsomal clearance (70.712) than Ligand B (28.19), meaning Ligand B is more metabolically stable. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand B has a much longer in vitro half-life (5.678 hours) compared to Ligand A (-1.548 hours). This is a major advantage for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Both have very low Pgp efflux liability (0.116 and 0.061), which is favorable.
15. **Binding Affinity:** Ligand B (-7.5 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.2 kcal/mol). This is a 1.3 kcal/mol difference, which is substantial and can outweigh some ADME drawbacks.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), we prioritize logP, Pgp, TPSA, and affinity. Ligand B excels in affinity and has acceptable values for the other parameters. While both have poor solubility and Caco-2 permeability, the stronger binding and better metabolic stability/half-life of Ligand B are more critical for a GPCR target. The DILI risk for Ligand A is a serious concern.
**Conclusion:**
Despite the poor solubility and permeability of both, Ligand B's superior binding affinity, metabolic stability (lower Cl_mic, longer t1/2), and better QED outweigh the slightly higher logP and the lower BBB penetration. The significantly lower DILI risk of Ligand A is tempting, but the large difference in binding affinity is a more critical factor for a GPCR target.
Output:
0
2025-04-18 00:27:41,254 - INFO - Here's my reasoning and output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Step-by-step comparison:**
1. **MW:** Both ligands (371.463 and 351.451 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand B (91.56) is significantly better than Ligand A (136.18), being well below the 140 threshold and closer to the 90 desired for GPCRs. This favors Ligand B.
3. **logP:** Ligand B (0.94) is slightly lower than Ligand A (-0.319), but both are within the 1-3 range. Ligand B is preferable.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (1), but both are acceptable (<=5).
5. **HBA:** Both ligands have 6 HBA, which is within the acceptable range.
6. **QED:** Ligand B (0.823) has a substantially higher QED than Ligand A (0.382), indicating a more drug-like profile. This is a significant advantage for Ligand B.
7. **DILI:** Ligand B (55.991) has a slightly lower DILI risk than Ligand A (60.644), both are acceptable but lower is better.
8. **BBB:** Both ligands have similar BBB penetration (Ligand A: 39.667, Ligand B: 41.218). This is not a major differentiating factor for ADRB2, a cardiovascular target.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. Ligand B (-4.715) is slightly better than Ligand A (-5.941).
10. **Solubility:** Both ligands have negative solubility values, indicating poor solubility. Ligand B (-2.171) is slightly better than Ligand A (-1.533).
11. **hERG:** Ligand B (0.273) has a lower hERG risk than Ligand A (0.067), which is preferable.
12. **Cl_mic:** Ligand A (16.583) has a significantly lower microsomal clearance than Ligand B (45.118), suggesting better metabolic stability. This favors Ligand A.
13. **t1/2:** Ligand B (-13.353) has a slightly longer in vitro half-life than Ligand A (-12.893).
14. **Pgp:** Ligand B (0.134) has a lower P-gp efflux liability than Ligand A (0.021), which is preferable.
15. **Binding Affinity:** Ligand A (-6.2 kcal/mol) has a slightly better binding affinity than Ligand B (-4.6 kcal/mol). This is a 1.6 kcal/mol difference, which is significant.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity and metabolic stability, Ligand B demonstrates a superior ADME profile overall. Specifically, its significantly better TPSA, QED, and lower hERG risk are crucial advantages. The slightly better solubility and Caco-2 permeability also contribute. The difference in binding affinity, while noticeable, can potentially be optimized during lead optimization without drastically altering the core structure. Given the GPCR-specific priorities (logP, TPSA, Pgp), Ligand B is the more promising candidate.
Output:
0
2025-04-18 00:27:41,254 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (372.401 and 374.535 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (85.17) is higher than Ligand B (69.02). While both are below 140, the lower TPSA of Ligand B is preferable for better absorption, aligning with GPCR preferences.
3. **logP:** Ligand A (1.718) is within the optimal range (1-3). Ligand B (3.676) is at the higher end, potentially causing solubility issues and off-target effects, but still acceptable.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 7 HBA, Ligand B has 6. Both are acceptable, below the 10 threshold.
6. **QED:** Ligand A (0.864) has a significantly better QED score than Ligand B (0.507), indicating a more drug-like profile.
7. **DILI:** Ligand A (73.943) has a higher DILI risk than Ligand B (57.387). Ligand B is clearly better here.
8. **BBB:** Ligand A (78.247) has a better BBB penetration score than Ligand B (55.874). While ADRB2 isn't strictly a CNS target, some level of BBB penetration can be useful for understanding off-target effects.
9. **Caco-2:** Ligand A (-4.879) and Ligand B (-5.209) both have negative Caco-2 values, indicating poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-2.616) has better solubility than Ligand B (-4.024).
11. **hERG:** Ligand A (0.076) has a much lower hERG risk than Ligand B (0.776). This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand B (92.612) has a much higher microsomal clearance than Ligand A (27.436), indicating lower metabolic stability. This is a major drawback for Ligand B.
13. **t1/2:** Ligand A (26.366) has a significantly longer in vitro half-life than Ligand B (11.259). This is a substantial advantage for Ligand A.
14. **Pgp:** Ligand A (0.084) has lower P-gp efflux liability than Ligand B (0.308), which is preferable.
15. **Binding Affinity:** Ligand A (-6.2 kcal/mol) has a slightly better binding affinity than Ligand B (-5.7 kcal/mol). While the difference isn't huge, it's a positive for Ligand A.
**Overall Assessment:**
Ligand A demonstrates a better overall profile. It has a superior QED score, lower DILI risk, significantly better metabolic stability (lower Cl_mic, longer t1/2), lower Pgp efflux, better hERG profile, and slightly better binding affinity. While Ligand B has a lower TPSA, the benefits of Ligand A in terms of ADME properties and safety outweigh this advantage. The Caco-2 permeability is a concern for both, but can be addressed with formulation strategies.
Output:
1
2025-04-18 00:27:41,254 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**1. Molecular Weight:** Both ligands (341.382 Da and 350.491 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (55.4) is higher than Ligand B (41.05). For a cardiovascular GPCR, TPSA is not a primary concern, but lower is generally preferred for better absorption. Ligand B has an advantage.
**3. logP:** Ligand B (4.808) is higher than Ligand A (3.619). While both are above the optimal 1-3 range, Ligand B is pushing the upper limit and could potentially have solubility issues or off-target effects. Ligand A is more favorable here.
**4. H-Bond Donors:** Both have 1 HBD, which is good.
**5. H-Bond Acceptors:** Ligand A has 3 HBAs, while Ligand B has 5. Lower is generally better for permeability, giving a slight edge to Ligand A.
**6. QED:** Ligand A (0.845) has a better QED score than Ligand B (0.717), indicating a more drug-like profile.
**7. DILI:** Both ligands have relatively high DILI risk (67.429 and 65.995), but are close enough that it doesn't significantly sway the decision.
**8. BBB:** Ligand A (84.141) has a significantly higher BBB penetration percentile than Ligand B (77.239). While ADRB2 is not a CNS target, some degree of BBB penetration can be useful for understanding off-target effects.
**9. Caco-2 Permeability:** Both have negative Caco-2 values, indicating poor permeability. Ligand B (-4.975) is worse than Ligand A (-4.454). Ligand A is slightly better.
**10. Aqueous Solubility:** Ligand A (-5.19) is slightly better than Ligand B (-4.426), both are poor.
**11. hERG Inhibition:** Ligand A (0.577) has a lower hERG inhibition liability than Ligand B (0.872). This is a crucial factor for cardiovascular drugs, making Ligand A more desirable.
**12. Microsomal Clearance:** Both have similar microsomal clearance values (73.849 and 72.234).
**13. In vitro Half-Life:** Ligand A (-10.107) has a significantly longer in vitro half-life than Ligand B (1.919). This is a major advantage for Ligand A, suggesting less frequent dosing.
**14. P-gp Efflux:** Ligand A (0.242) has a lower P-gp efflux liability than Ligand B (0.788), which is beneficial for bioavailability.
**15. Binding Affinity:** Ligand A (-7.6 kcal/mol) has a slightly better binding affinity than Ligand B (-6.0 kcal/mol). This 1.6 kcal/mol difference is substantial and outweighs many of the minor ADME drawbacks of Ligand A.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), and the general drug-like properties, Ligand A is the superior candidate. Its significantly better binding affinity, longer half-life, lower hERG risk, lower P-gp efflux, and better QED score outweigh the slightly higher TPSA and logP. While both have solubility issues, Ligand A is still preferable.
Output:
1
2025-04-18 00:27:41,254 - INFO - Here's my reasoning and final output, considering the provided guidelines and the GPCR-specific priorities for the ADRB2 target:
**Step-by-step comparison:**
1. **MW:** Ligand A (403.28 Da) is within the ideal range. Ligand B (335.371 Da) is also acceptable, slightly lower but still reasonable.
2. **TPSA:** Ligand A (69.04) is excellent, well below the 140 threshold. Ligand B (87.45) is still acceptable, though less optimal.
3. **logP:** Ligand A (3.873) is at the upper end of the optimal range, potentially raising concerns about solubility and off-target effects. Ligand B (2.455) is ideal.
4. **HBD:** Ligand A (1) is good. Ligand B (0) is also good.
5. **HBA:** Ligand A (6) is good. Ligand B (8) is acceptable.
6. **QED:** Both ligands (A: 0.479, B: 0.538) are reasonably drug-like, with Ligand B being slightly better.
7. **DILI:** Both ligands have acceptable DILI risk (A: 79.721, B: 76.037), below the 80 threshold.
8. **BBB:** Ligand A (68.903) is moderate, while Ligand B (43.699) is lower. While ADRB2 isn't necessarily a CNS target, some degree of BBB penetration can be beneficial for distribution.
9. **Caco-2:** Both have negative values which are unusual. Assuming these are logP values, both are poor.
10. **Solubility:** Both have negative solubility values which are unusual.
11. **hERG:** Both ligands show low hERG inhibition liability (A: 0.767, B: 0.816), which is excellent.
12. **Cl_mic:** Ligand A (113.21) has a higher clearance, suggesting lower metabolic stability. Ligand B (19.155) has much lower clearance, indicating better metabolic stability.
13. **t1/2:** Ligand A (77.415) has a reasonable half-life. Ligand B (-30.753) has a negative half-life which is unusual.
14. **Pgp:** Both ligands have low P-gp efflux liability (A: 0.535, B: 0.109), which is good. Ligand B is better.
15. **Affinity:** Ligand A (-6.6 kcal/mol) has a slightly better binding affinity than Ligand B (-5 kcal/mol). This is a significant advantage.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B has a more favorable logP and Pgp profile. However, Ligand A has a better affinity. The difference in affinity (1.6 kcal/mol) is substantial enough to outweigh the slightly less ideal logP.
**Conclusion:**
Despite Ligand B's better metabolic stability and Pgp efflux, Ligand A's significantly stronger binding affinity is the deciding factor. The affinity difference is large enough to compensate for the slightly higher logP and clearance.
Output:
1
2025-04-18 00:27:41,255 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.447 and 351.403 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (82.7) is better than Ligand B (96.97). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally favors absorption.
3. **logP:** Ligand A (0.713) is slightly below the optimal 1-3 range, but still acceptable. Ligand B (-0.307) is quite low, potentially hindering membrane permeability. This is a significant negative for Ligand B.
4. **HBD:** Both ligands have acceptable HBD counts (3 and 2, respectively), well below the threshold of 5.
5. **HBA:** Both ligands have acceptable HBA counts (4 and 5, respectively), well below the threshold of 10.
6. **QED:** Both ligands have identical QED scores (0.614), indicating good drug-likeness.
7. **DILI:** Ligand A (12.02) has a much lower DILI risk than Ligand B (35.789). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (71.733) has better BBB penetration than Ligand B (48.895), but this is less critical for a cardiovascular target.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.185 and -5.323). These values are difficult to interpret without knowing the scale, but the similarity suggests comparable intestinal absorption potential.
10. **Solubility:** Both ligands have negative solubility values (-1 and -1.413). Similar to Caco-2, these values are hard to interpret, but the similarity suggests comparable solubility.
11. **hERG:** Ligand A (0.385) has a lower hERG risk than Ligand B (0.096), which is a positive.
12. **Cl_mic:** Ligand A (-8.816) has a significantly lower (better) microsomal clearance than Ligand B (-5.143), indicating greater metabolic stability.
13. **t1/2:** Ligand A (-1.508) has a longer in vitro half-life than Ligand B (-12.63), indicating greater stability.
14. **Pgp:** Ligand A (0.004) has a lower P-gp efflux liability than Ligand B (0.022), which is favorable.
15. **Binding Affinity:** Both ligands have similar binding affinities (-6.6 and -6.8 kcal/mol). The difference is minimal and doesn't outweigh other factors.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Ligand A performs better on logP, TPSA, and Pgp. Affinity is comparable.
**Overall Assessment:**
Ligand A is clearly superior. It has a significantly lower DILI risk, better metabolic stability (lower Cl_mic and longer t1/2), better logP, lower Pgp efflux, and a lower hERG risk. While both have similar affinities, the ADME properties of Ligand A make it a much more promising drug candidate.
Output:
1
2025-04-18 00:27:41,255 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [346.427, 73.99, 2.027, 1, 4, 0.909, 21.753, 63.901, -4.722, -1.731, 0.362, 7.255, 37.574, 0.125, -7.2]**
**Ligand B: [358.41, 95.94, 0.2, 2, 5, 0.574, 33.075, 54.207, -4.85, -1.539, 0.2, 5.477, -23.368, 0.049, -5.1]**
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). A (346.427) is slightly preferred.
2. **TPSA:** Ligand A (73.99) is well below the 140 threshold and better than Ligand B (95.94). This favors oral absorption.
3. **logP:** Ligand A (2.027) is optimal (1-3), while Ligand B (0.2) is quite low, potentially hindering membrane permeability. A is significantly better.
4. **H-Bond Donors:** Both have 2 HBD, which is acceptable.
5. **H-Bond Acceptors:** Ligand A (4) is better than Ligand B (5), keeping the count lower for better permeability.
6. **QED:** Ligand A (0.909) has a much higher QED score than Ligand B (0.574), indicating a more drug-like profile.
7. **DILI:** Ligand A (21.753) has a lower DILI risk than Ligand B (33.075). Both are acceptable, but A is preferred.
8. **BBB:** Ligand A (63.901) has a better BBB penetration percentile than Ligand B (54.207). While ADRB2 isn't strictly a CNS target, some CNS exposure can occur, making this a slight advantage for A.
9. **Caco-2 Permeability:** Both have negative Caco-2 values, indicating poor permeability. Ligand A (-4.722) is slightly better than Ligand B (-4.85).
10. **Aqueous Solubility:** Both have negative solubility values, indicating poor solubility. Ligand A (-1.731) is slightly better than Ligand B (-1.539).
11. **hERG Inhibition:** Both have very low hERG inhibition risk. Ligand A (0.362) is slightly better than Ligand B (0.2).
12. **Microsomal Clearance:** Ligand A (7.255) has a lower clearance than Ligand B (5.477), suggesting better metabolic stability.
13. **In vitro Half-Life:** Ligand A (37.574) has a significantly longer half-life than Ligand B (-23.368). This is a major advantage for A.
14. **P-gp Efflux:** Ligand A (0.125) has lower P-gp efflux than Ligand B (0.049), which is preferable.
15. **Binding Affinity:** Ligand A (-7.2) has a slightly better binding affinity than Ligand B (-5.1).
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most crucial parameters. The most significant advantages are its superior QED, longer half-life, better logP, and slightly better binding affinity. While both ligands have permeability and solubility issues, Ligand A's profile is more favorable for overall drug development. Given that this is a GPCR target, the balance of properties in Ligand A is better suited for potential clinical translation.
Output:
1
2025-04-18 00:27:41,255 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.43 & 370.88 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand B (62.99) is better than Ligand A (75.71). Lower TPSA generally favors better absorption, and is particularly important for GPCRs.
3. **logP:** Ligand A (1.535) is within the optimal range (1-3), while Ligand B (3.059) is at the higher end. While still acceptable, higher logP can sometimes lead to off-target effects.
4. **HBD:** Ligand A (1) is preferable to Ligand B (0). Having at least one HBD can improve solubility.
5. **HBA:** Both ligands have 4 HBA, which is acceptable.
6. **QED:** Ligand A (0.725) has a slightly better QED score than Ligand B (0.66), indicating a more drug-like profile.
7. **DILI:** Both ligands have very similar, low DILI risk (30.83 & 31.21).
8. **BBB:** Both ligands show good BBB penetration (70.03 & 75.92). This is important for GPCR targets, though less critical for ADRB2 specifically as it's primarily a cardiovascular target.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the values are similar (-4.182 vs -4.378).
10. **Solubility:** Both ligands have negative solubility values, indicating very poor aqueous solubility. This is a significant concern for both.
11. **hERG:** Ligand A (0.129) has a much lower hERG inhibition liability than Ligand B (0.624). This is a crucial advantage, as hERG inhibition can lead to cardiotoxicity.
12. **Cl_mic:** Ligand A (77.21) has a higher microsomal clearance than Ligand B (43.951), indicating faster metabolism and potentially lower *in vivo* exposure.
13. **t1/2:** Ligand B (51.374) has a significantly longer *in vitro* half-life than Ligand A (-16.325). This is a major advantage, suggesting less frequent dosing could be possible.
14. **Pgp:** Ligand A (0.048) has a lower P-gp efflux liability than Ligand B (0.377), which is favorable for bioavailability.
15. **Affinity:** Ligand A (-7.3 kcal/mol) has a significantly stronger binding affinity than Ligand B (-5.4 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME drawbacks.
**Overall Assessment:**
Ligand A has a significantly better binding affinity and lower hERG risk, which are critical for a GPCR drug candidate. While Ligand B has a better half-life and lower clearance, the substantial affinity advantage of Ligand A, coupled with the safety profile (lower hERG), makes it the more promising candidate. The poor solubility and Caco-2 permeability are concerns for both, but these can be addressed through formulation strategies.
Output:
1
2025-04-18 00:27:41,255 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (374.48 & 362.39 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (69.64) is significantly better than Ligand A (92.34). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (1.786 & 1.987), falling within the 1-3 range. Ligand B is slightly better.
4. **HBD:** Both ligands have 2 HBD, which is within the acceptable limit of <=5.
5. **HBA:** Ligand A has 4 HBA, while Ligand B has 3. Both are acceptable (<=10).
6. **QED:** Ligand B (0.786) has a better QED score than Ligand A (0.5), indicating a more drug-like profile.
7. **DILI:** Ligand B (22.102) has a much lower DILI risk than Ligand A (57.348). This is a significant advantage.
8. **BBB:** Both ligands have reasonable BBB penetration (75.805 & 74.176), but this isn't a high priority for a cardiovascular target.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.703 & -4.891). These values are unusual and suggest poor permeability.
10. **Solubility:** Both ligands have negative solubility values (-2.54 & -2.628). These values are also unusual and suggest poor solubility.
11. **hERG:** Ligand A (0.215) has a slightly better hERG profile than Ligand B (0.556), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand B (-5.1) has a lower (better) microsomal clearance than Ligand A (30.955), suggesting greater metabolic stability.
13. **t1/2:** Ligand A (25.44) has a longer in vitro half-life than Ligand B (-3.987). This is a positive for Ligand A.
14. **Pgp:** Ligand A (0.151) has lower Pgp efflux liability than Ligand B (0.055), which is favorable.
15. **Binding Affinity:** Ligand B (-6.9 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.2 kcal/mol). This is a substantial advantage.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, Pgp, TPSA, and affinity. Ligand B excels in logP, TPSA, and *especially* affinity. While Pgp is slightly better for Ligand A, the difference is less impactful than the affinity advantage of Ligand B. The lower DILI risk for Ligand B is also a major benefit.
**Overall Assessment:**
Despite the unusual Caco-2 and solubility values for both compounds, Ligand B's superior binding affinity, lower DILI risk, better QED, and better metabolic stability outweigh the slightly better hERG and Pgp profiles of Ligand A. The strong binding affinity is a critical factor, and the other improvements contribute to a more promising overall profile.
Output:
0
2025-04-18 00:27:41,255 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [336.435, 40.62, 3.185, 0, 2, 0.76, 48.623, 91.353, -4.587, -4.13, 0.894, 105.441, 21.706, 0.808, -6]
**Ligand B:** [342.443, 88.32, 2.275, 2, 4, 0.744, 46.956, 80.264, -5.13, -3.459, 0.511, 48.515, -17.083, 0.09, -6.9]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (336.435) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (40.62) is significantly better than Ligand B (88.32). A TPSA under 140 is good for oral absorption, but for a GPCR, lower is often preferred. Ligand B's TPSA is relatively high.
3. **logP:** Both are within the optimal range (1-3). Ligand A (3.185) is slightly higher, which could potentially lead to off-target effects, but is still acceptable. Ligand B (2.275) is a bit lower, which might impact permeation.
4. **HBD:** Ligand A (0) is better than Ligand B (2). Fewer HBDs generally improve membrane permeability.
5. **HBA:** Ligand A (2) is better than Ligand B (4). Fewer HBAs also generally improve membrane permeability.
6. **QED:** Both are similar and acceptable (A: 0.76, B: 0.744).
7. **DILI:** Both are good, with low risk (A: 48.623, B: 46.956).
8. **BBB:** Ligand A (91.353) is significantly better than Ligand B (80.264). For a GPCR, even if not a CNS target, some BBB penetration can be useful for distribution. This is a major advantage for Ligand A.
9. **Caco-2:** Ligand A (-4.587) is better than Ligand B (-5.13). Higher Caco-2 values indicate better absorption.
10. **Solubility:** Ligand A (-4.13) is better than Ligand B (-3.459). Higher solubility is generally desirable.
11. **hERG:** Both are very low (A: 0.894, B: 0.511), indicating a low risk of cardiotoxicity.
12. **Cl_mic:** Ligand B (48.515) is better than Ligand A (105.441). Lower clearance means greater metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand A (21.706) is better than Ligand B (-17.083). Longer half-life is generally preferred.
14. **Pgp:** Both are very low (A: 0.808, B: 0.09), indicating low P-glycoprotein efflux. Ligand B is slightly better.
15. **Affinity:** Ligand B (-6.9) is slightly better than Ligand A (-6). While both are good, the small advantage in binding affinity for Ligand B is a plus.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, and affinity. Ligand A has a better logP and significantly better TPSA and BBB penetration. Ligand B has a slight edge in affinity and clearance.
**Overall Assessment:**
While Ligand B has a slightly better affinity and metabolic stability, Ligand A's superior TPSA, BBB penetration, solubility, and Caco-2 permeability are more critical for a GPCR target, especially considering the need for good distribution and potential for oral bioavailability. The difference in affinity is small enough to be outweighed by the ADME advantages of Ligand A.
Output:
1
2025-04-18 00:27:41,255 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (399.288 Da) is slightly higher than Ligand B (348.407 Da), but both are acceptable.
**2. TPSA:** Ligand A (38.5) is excellent, well below the 140 threshold for oral absorption and suitable for a GPCR. Ligand B (115.63) is higher, but still within a reasonable range, though less optimal.
**3. logP:** Ligand A (4.505) is a bit high, potentially leading to solubility issues or off-target interactions. Ligand B (-0.208) is too low, suggesting poor membrane permeability. This is a significant drawback.
**4. H-Bond Donors:** Ligand A (0) is ideal. Ligand B (2) is acceptable.
**5. H-Bond Acceptors:** Both ligands have 4 H-bond acceptors, which is within the acceptable range.
**6. QED:** Both ligands have good QED scores (A: 0.612, B: 0.786), indicating generally drug-like properties.
**7. DILI Risk:** Ligand A (58.705) has a moderate DILI risk, while Ligand B (39.744) is better with a lower risk.
**8. BBB Penetration:** Ligand A (81.698) shows good BBB penetration, which isn't critical for a cardiovascular target but isn't detrimental. Ligand B (64.482) is lower, suggesting limited CNS exposure.
**9. Caco-2 Permeability:** Both ligands show negative Caco-2 values, which is unusual and suggests issues with the assay or potential membrane disruption. However, the values are similar.
**10. Aqueous Solubility:** Both ligands have negative solubility values, which is also unusual. This suggests poor aqueous solubility.
**11. hERG Inhibition:** Ligand A (0.922) has a slightly higher hERG risk than Ligand B (0.203), which is preferable.
**12. Microsomal Clearance:** Ligand A (97.189) has high microsomal clearance, indicating rapid metabolism. Ligand B (-17.144) has negative clearance, which is not possible.
**13. In vitro Half-Life:** Ligand A (-32.821) has a negative half-life, which is not possible. Ligand B (-4.781) also has a negative half-life, which is not possible.
**14. P-gp Efflux:** Both ligands show low P-gp efflux liability.
**15. Binding Affinity:** Ligand A (-8.0) has a significantly stronger binding affinity than Ligand B (-6.6). This is a substantial advantage.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand A is the better candidate despite some drawbacks. The significantly stronger binding affinity (-8.0 kcal/mol vs -6.6 kcal/mol) is a major advantage that can outweigh some of the ADME concerns. While Ligand A has a higher logP and DILI risk, Ligand B's extremely low logP is a major concern for permeability and bioavailability. The negative values for clearance and half-life are also concerning for Ligand B.
Therefore, I choose Ligand A.
1
2025-04-18 00:27:41,255 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.39 and 348.403 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (82.43) is significantly better than Ligand B (102.74). For a GPCR, keeping TPSA under 140 is good, but lower is preferred for better permeability. Ligand A is closer to the ideal range.
3. **logP:** Ligand A (1.792) is within the optimal 1-3 range. Ligand B (0.627) is a bit low, potentially hindering membrane permeability. This favors Ligand A.
4. **HBD:** Both ligands have 1 HBD, which is acceptable.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 5. Both are within the acceptable limit of 10.
6. **QED:** Both ligands have relatively high QED scores (0.815 and 0.785), indicating good drug-like properties.
7. **DILI:** Ligand A (48.623) has a slightly higher DILI risk than Ligand B (32.842), but both are below the concerning threshold of 60.
8. **BBB:** Ligand A (85.653) has a significantly higher BBB penetration percentile than Ligand B (71.811). While ADRB2 isn't exclusively a CNS target, some CNS exposure can occur, and higher BBB is generally favorable.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.731 and -4.749). This is unusual and suggests poor permeability in this *in vitro* assay.
10. **Solubility:** Ligand A (-3.064) has slightly better solubility than Ligand B (-1.952).
11. **hERG:** Ligand A (0.615) has a much lower hERG inhibition liability than Ligand B (0.16). This is a critical advantage, as hERG inhibition can cause cardiotoxicity.
12. **Cl_mic:** Ligand A (1.348) has much lower microsomal clearance than Ligand B (-43.109). This indicates better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (24.382) has a significantly longer *in vitro* half-life than Ligand B (-2.376). This is a major advantage, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.101) has a lower P-gp efflux liability than Ligand B (0.007). Lower P-gp efflux is desirable for improved bioavailability.
15. **Binding Affinity:** Ligand A (-7.0) and Ligand B (-5.3) both have good binding affinity. Ligand A is 1.7 kcal/mol more potent, which is a substantial difference and can outweigh some ADME concerns.
**Overall Assessment:**
Ligand A is clearly the superior candidate. It has a better logP, TPSA, solubility, significantly lower hERG risk, better metabolic stability (lower Cl_mic, longer t1/2), lower P-gp efflux, and a substantially higher binding affinity. While Ligand B has a slightly lower DILI risk, the other advantages of Ligand A are far more important for a viable drug candidate, especially considering the GPCR target class. The superior binding affinity of Ligand A is a key driver of this decision.
Output:
1
2025-04-18 00:27:41,256 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.429 and 370.806 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (59.81) is slightly higher than Ligand B (49.84), but both are well below the 140 A^2 threshold for good oral absorption, and acceptable for a non-CNS GPCR target like ADRB2.
3. **logP:** Ligand B (4.781) is higher than Ligand A (3.052). While both are above the optimal 1-3 range, Ligand B is approaching a level where solubility could become an issue.
4. **HBD:** Ligand A (1) has fewer HBD than Ligand B (2). Fewer HBD generally improves permeability, so Ligand A is slightly favored.
5. **HBA:** Both ligands have the same number of HBA (4), which is within the acceptable range of <=10.
6. **QED:** Both ligands have similar QED scores (0.782 and 0.768), indicating good drug-likeness.
7. **DILI:** Ligand A (25.785) has a significantly lower DILI risk than Ligand B (79.682). This is a major advantage for Ligand A.
8. **BBB:** Both ligands have high BBB penetration (90.074 and 90.772). While ADRB2 isn't a primary CNS target, high BBB isn't detrimental.
9. **Caco-2:** Both ligands have similar, very negative Caco-2 values (-4.59 and -4.589), indicating poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-4.382) has better (less negative) solubility than Ligand B (-6.219). This is a significant advantage, especially considering Ligand B's higher logP.
11. **hERG:** Ligand A (0.391) has a lower hERG risk than Ligand B (0.853). Lower hERG is always preferred.
12. **Cl_mic:** Ligand A (39.486) has a lower microsomal clearance than Ligand B (59.592), suggesting better metabolic stability.
13. **t1/2:** Ligand B (82.718) has a significantly longer in vitro half-life than Ligand A (1.847). This is a substantial advantage for Ligand B.
14. **Pgp:** Ligand A (0.048) has lower P-gp efflux than Ligand B (0.376), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand A (-6.9) has a slightly better binding affinity than Ligand B (-5.4). This difference of 1.5 kcal/mol is significant and can outweigh some ADME drawbacks.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand A has better logP, Pgp, and affinity, while TPSA is similar for both.
**Overall Assessment:**
Ligand A is the stronger candidate. While Ligand B has a significantly longer half-life, Ligand A excels in crucial areas like DILI risk, solubility, hERG inhibition, metabolic stability, and binding affinity. The lower DILI risk and better solubility are particularly important for a cardiovascular target. The affinity difference is also substantial. The poor Caco-2 values are a concern for both, but can be addressed through formulation strategies.
Output:
1
2025-04-18 00:27:41,256 - INFO - Batch 479 complete. Total preferences: 7664
2025-04-18 00:27:41,256 - INFO - Processing batch 480/512...
2025-04-18 00:28:32,570 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [338.411, 72.09, 4.627, 2, 4, 0.728, 73.517, 82.358, -4.834, -5.566, 0.427, 64.043, 120.517, 0.217, -5.5]
**Ligand B:** [355.479, 118.36, 1.15, 3, 4, 0.509, 27.104, 50.795, -5.278, -2.856, 0.116, 42.959, -30.48, 0.006, -5.3]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (338.411) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (72.09) is excellent, well below the 140 threshold for oral absorption. Ligand B (118.36) is higher, but still acceptable, though less ideal.
3. **logP:** Ligand A (4.627) is pushing the upper limit and could present solubility issues. Ligand B (1.15) is quite low, potentially hindering membrane permeability.
4. **HBD/HBA:** Both have reasonable HBD (2/3) and HBA (4/4) counts, within acceptable ranges.
5. **QED:** Ligand A (0.728) has a better QED score than Ligand B (0.509), indicating a more drug-like profile.
6. **DILI:** Ligand B (27.104) has a significantly lower DILI risk than Ligand A (73.517), a major advantage.
7. **BBB:** Ligand A (82.358) shows better BBB penetration than Ligand B (50.795). While ADRB2 is cardiovascular, some CNS exposure can occur, and higher BBB is generally favorable.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.834) is slightly better than Ligand B (-5.278).
9. **Solubility:** Ligand B (-2.856) has better solubility than Ligand A (-5.566).
10. **hERG:** Both have very low hERG risk (0.427 and 0.116), which is excellent.
11. **Cl_mic:** Ligand B (42.959) has lower microsomal clearance, suggesting better metabolic stability, which is good. Ligand A (64.043) is higher.
12. **t1/2:** Ligand A (120.517) has a much longer in vitro half-life than Ligand B (-30.48). This is a significant advantage.
13. **Pgp:** Ligand A (0.217) has lower P-gp efflux, which is preferable. Ligand B (0.006) is very low, but extremely low Pgp can sometimes indicate issues with absorption.
14. **Affinity:** Both have excellent binding affinity (-5.5 and -5.3 kcal/mol), with Ligand A being slightly better.
**Overall Assessment:**
Ligand A has a slight edge in affinity and BBB penetration, and a significantly better half-life. However, its higher logP and DILI risk are concerning. Ligand B has a much better safety profile (DILI, solubility, metabolic stability), but suffers from lower logP and BBB penetration.
Given the cardiovascular target and the importance of minimizing off-target effects and toxicity, the lower DILI risk and improved metabolic stability of Ligand B are more compelling. The slightly lower affinity can potentially be optimized in later stages of development. The poor Caco-2 values for both are a concern that would need to be addressed, but the other properties of Ligand B make it the more promising starting point.
Output:
0
2025-04-18 00:28:32,571 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (342.399 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (86.95) is significantly better than Ligand B (43.86), falling well below the 140 threshold for good oral absorption and being more favorable for GPCRs.
3. **logP:** Both ligands have acceptable logP values (A: 1.245, B: 1.672) within the 1-3 range.
4. **HBD:** Ligand A (1) is preferable to Ligand B (0) as it provides some hydrogen bonding capability.
5. **HBA:** Ligand A (6) is slightly higher than Ligand B (4), but both are within the acceptable limit of 10.
6. **QED:** Both ligands have reasonable QED scores (A: 0.806, B: 0.743), indicating good drug-like properties. Ligand A is slightly better.
7. **DILI:** Ligand A (19.698) has a slightly higher DILI risk than Ligand B (13.339), but both are well below the concerning threshold of 60.
8. **BBB:** Ligand B (84.839) has a significantly higher BBB penetration percentile than Ligand A (65.374). While ADRB2 isn't strictly a CNS target, some CNS exposure can be acceptable and even beneficial in certain cardiovascular contexts.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.997 and -4.875), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Both ligands have negative solubility values (-2.322 and -1.923), indicating very poor aqueous solubility. This is a major drawback for both.
11. **hERG:** Both ligands have low hERG inhibition liability (A: 0.556, B: 0.46), which is excellent.
12. **Cl_mic:** Ligand A (19.552) has a much lower microsomal clearance than Ligand B (49.757), indicating better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand A (6.215) has a longer in vitro half-life than Ligand B (-0.55), which is preferable.
14. **Pgp:** Both ligands have very low P-gp efflux liability (A: 0.027, B: 0.115), which is good.
15. **Binding Affinity:** Both ligands have similar and strong binding affinities (A: -5.4 kcal/mol, B: -5.6 kcal/mol). Ligand B is slightly better, but the difference is small.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, TPSA, logP, Pgp, and affinity are key. Ligand A excels in TPSA and has better metabolic stability (Cl_mic and t1/2). Ligand B has better BBB penetration, which could be a minor advantage. The binding affinity difference is negligible. The poor Caco-2 and solubility are concerning for both, but the better ADME profile of Ligand A (lower Cl_mic, longer t1/2, better TPSA) outweighs the slight advantage of Ligand B in BBB penetration and binding affinity.
**Conclusion:**
Considering the balance of properties and the priorities for a GPCR target, Ligand A is the more promising drug candidate.
Output:
1
2025-04-18 00:28:32,571 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's analyze each ligand against the provided guidelines, keeping in mind ADRB2 is a GPCR, so logP, TPSA, Pgp, and affinity are key.
* **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (447.28) is slightly higher, but still acceptable.
* **TPSA:** Both are reasonably good, but slightly above the optimal <140. Ligand A (75.6) is better than Ligand B (79.13).
* **logP:** Both ligands have good logP values (between 1-3). Ligand A (3.775) is a bit higher, potentially leading to slight solubility issues, but still within a reasonable range. Ligand B (2.323) is better.
* **H-Bond Donors/Acceptors:** Ligand A (2 HBD, 4 HBA) is slightly better balanced than Ligand B (0 HBD, 7 HBA).
* **QED:** Both ligands have similar and acceptable QED values (A: 0.601, B: 0.662).
* **DILI:** Ligand B (88.872) has a higher DILI risk than Ligand A (78.441), which is concerning.
* **BBB:** Both have moderate BBB penetration. Ligand B (69.135) is slightly better than Ligand A (62.233), but this isn't a primary concern for a cardiovascular target.
* **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. Ligand A (-5.275) is better than Ligand B (-4.148).
* **Solubility:** Both have negative solubility values, indicating poor solubility. Ligand A (-4.454) is slightly better than Ligand B (-4.19).
* **hERG:** Ligand A (0.926) has a much lower hERG risk than Ligand B (0.218), which is a significant advantage.
* **Cl_mic:** Ligand A (39.987) has a much lower microsomal clearance, indicating better metabolic stability, than Ligand B (109.36).
* **t1/2:** Ligand A (47.487) has a significantly longer in vitro half-life than Ligand B (-35.073).
* **Pgp:** Ligand A (0.843) has a lower P-gp efflux liability than Ligand B (0.195), which is favorable.
* **Binding Affinity:** Ligand B (-7.5 kcal/mol) has a slightly better binding affinity than Ligand A (-7.2 kcal/mol), but the difference is relatively small.
**Overall Assessment:**
While Ligand B has a slightly better binding affinity, Ligand A demonstrates a significantly superior ADME-Tox profile. Specifically, the lower DILI risk, lower hERG inhibition, lower microsomal clearance, longer half-life, and lower P-gp efflux make Ligand A a much more promising drug candidate. The slightly better logP of Ligand B is outweighed by these critical factors. Given the GPCR target class, the improved ADME properties of Ligand A are crucial for potential clinical success.
**Output:**
1
2025-04-18 00:28:32,571 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step Comparison:**
1. **MW:** Both ligands (371.277 and 354.535 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (47.56) is significantly better than Ligand B (58.64). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (4.056 and 3.229), falling within the optimal 1-3 range. Ligand B is slightly better.
4. **HBD:** Both have 1 HBD, which is acceptable.
5. **HBA:** Both have 3 HBA, which is acceptable.
6. **QED:** Ligand A (0.768) has a slightly better QED score than Ligand B (0.691), indicating a more drug-like profile.
7. **DILI:** Ligand A (42.264) has a better DILI score than Ligand B (9.926), indicating lower potential for liver injury. This is a crucial factor.
8. **BBB:** Ligand A (88.135) has a higher BBB penetration percentile than Ligand B (77.821). While not a primary concern for a cardiovascular target, it's a slight advantage.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand B (-4.334) is slightly worse than Ligand A (-4.258).
10. **Solubility:** Ligand A (-5.249) has better solubility than Ligand B (-2.782). Solubility is important for bioavailability.
11. **hERG:** Both ligands have low hERG inhibition risk (0.783 and 0.66). No significant difference.
12. **Cl_mic:** Ligand A (41.762) has a lower microsomal clearance than Ligand B (78.646), suggesting better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand B (5.314) has a longer in vitro half-life than Ligand A (-0.683). This is a positive for Ligand B.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.169 and 0.063). No significant difference.
15. **Binding Affinity:** Ligand B (-6.2 kcal/mol) has a slightly better binding affinity than Ligand A (-5.3 kcal/mol). This is a 0.9 kcal/mol difference, which is substantial.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, and affinity. Ligand B has a slightly better logP and significantly better affinity. However, Ligand A excels in TPSA, DILI, solubility, and metabolic stability (Cl_mic). The better DILI and Cl_mic profiles of Ligand A are very important, and the affinity difference, while notable, isn't large enough to outweigh these advantages. The negative Caco-2 values are concerning for both, but the other ADME properties of Ligand A are more favorable overall.
**Conclusion:**
Considering the balance of properties, particularly the better DILI, solubility, and metabolic stability of Ligand A, I believe it is the more promising drug candidate despite the slightly weaker binding affinity.
Output:
1
2025-04-18 00:28:32,571 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
We are targeting ADRB2, a GPCR. Therefore, priorities are logP, Pgp efflux, TPSA, BBB penetration, and binding affinity. Let's break down each ligand:
* **Molecular Weight:** Both ligands (347.419 and 364.471 Da) fall within the ideal 200-500 Da range.
* **TPSA:** Ligand B (75.51) is significantly better than Ligand A (105.12). Lower TPSA generally improves cell permeability, which is crucial for GPCR targeting.
* **logP:** Ligand B (1.346) is within the optimal 1-3 range, while Ligand A (-0.192) is slightly below 1, potentially hindering permeability.
* **H-Bond Donors/Acceptors:** Ligand A has 3 HBD and 5 HBA, while Ligand B has 0 HBD and 5 HBA. Both are acceptable.
* **QED:** Both have good QED scores (0.567 and 0.725).
* **DILI:** Ligand B (52.772) has a slightly higher DILI risk than Ligand A (40.287), but both are below the concerning threshold of 60.
* **BBB:** Ligand B (82.164) shows significantly better BBB penetration than Ligand A (41.218). While not strictly necessary for ADRB2 (depending on the desired therapeutic effect), it's a bonus.
* **Caco-2 Permeability:** Both have negative values, indicating poor permeability. Ligand B (-4.965) is slightly better than Ligand A (-5.861).
* **Aqueous Solubility:** Both have negative values, suggesting poor solubility.
* **hERG:** Ligand A (0.029) has a slightly lower hERG risk than Ligand B (0.543).
* **Microsomal Clearance:** Ligand A (-14.506) has a much lower (better) microsomal clearance than Ligand B (83.625), indicating greater metabolic stability.
* **In vitro Half-Life:** Ligand A (22.811 hours) has a significantly longer half-life than Ligand B (-26.991 hours).
* **P-gp Efflux:** Ligand A (0.008) has a much lower P-gp efflux liability than Ligand B (0.203), which is beneficial for bioavailability and potentially CNS exposure.
* **Binding Affinity:** Ligand A (-7.9 kcal/mol) has a slightly better binding affinity than Ligand B (-6.7 kcal/mol). This 1.2 kcal/mol difference is significant.
**Overall Assessment:**
Ligand A has a stronger binding affinity, better metabolic stability (lower Cl_mic, longer t1/2), and lower P-gp efflux. However, Ligand B excels in TPSA and BBB penetration, and has a more favorable logP. The binding affinity difference is substantial, and the improved ADME properties of Ligand A (stability, efflux) are critical for a viable drug candidate. While Ligand B's TPSA and logP are better, the affinity advantage of Ligand A outweighs these benefits, especially considering the acceptable (though not ideal) TPSA and logP of Ligand A.
**Output:**
1
2025-04-18 00:28:32,571 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (376.513 and 376.507 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (64.35) is significantly better than Ligand B (75.19). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand A is well below the 90 A^2 threshold, while Ligand B is approaching it.
**3. logP:** Both ligands have good logP values (2.804 and 2.902), falling within the optimal 1-3 range. No clear advantage.
**4. H-Bond Donors:** Ligand A (2) is slightly higher than Ligand B (1), but both are within the acceptable limit of 5.
**5. H-Bond Acceptors:** Ligand B (6) is higher than Ligand A (4), but both are within the acceptable limit of 10.
**6. QED:** Both ligands have acceptable QED values (0.774 and 0.841), indicating good drug-like properties. Ligand B is slightly better.
**7. DILI:** Ligand A (17.449) has a *much* lower DILI risk than Ligand B (72.819). This is a major advantage for Ligand A. A DILI percentile above 60 is concerning.
**8. BBB:** Ligand A (92.904) has a significantly higher BBB penetration percentile than Ligand B (64.095). While ADRB2 isn't strictly a CNS target, some CNS exposure can be relevant for off-target effects and overall safety assessment.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-5.298 and -5.255), which is unusual and suggests poor permeability. However, the values are very similar.
**10. Aqueous Solubility:** Ligand A (-2.627) is better than Ligand B (-4.088), indicating slightly better solubility.
**11. hERG Inhibition:** Ligand A (0.732) has a slightly higher hERG inhibition risk than Ligand B (0.299), but both are relatively low.
**12. Microsomal Clearance:** Ligand B (31.465) has a lower microsomal clearance than Ligand A (17.486), suggesting better metabolic stability. This is a positive for Ligand B.
**13. In vitro Half-Life:** Ligand A (20.262) has a longer in vitro half-life than Ligand B (10.411). This is a significant advantage for Ligand A, potentially allowing for less frequent dosing.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.115 and 0.177). No significant difference.
**15. Binding Affinity:** Ligand A (-7.6) has a stronger binding affinity than Ligand B (-6.6), by a margin of 1.0 kcal/mol. This is a substantial difference and outweighs many of the minor ADME drawbacks of Ligand A.
**Overall Assessment:**
Ligand A is the stronger candidate. The significantly lower DILI risk, higher BBB penetration, longer half-life, and substantially better binding affinity outweigh the slightly less favorable TPSA and solubility compared to Ligand B. The affinity difference is particularly important for a GPCR target. While both have poor Caco-2 permeability, this is a shared issue that would need to be addressed in further optimization regardless of which lead is chosen.
Output:
1
2025-04-18 00:28:32,572 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (345.487 and 350.507 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (63.99) is significantly better than Ligand B (85.23). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (2.97 and 2.202), falling within the optimal 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD can improve permeability.
5. **HBA:** Both ligands have the same number of HBA (4), which is acceptable.
6. **QED:** Ligand A (0.892) has a considerably higher QED score than Ligand B (0.632), indicating a more drug-like profile.
7. **DILI:** Ligand A (35.673) has a much lower DILI risk than Ligand B (9.151). This is a critical advantage.
8. **BBB:** Both ligands have reasonable BBB penetration, but Ligand A (74.447) is better than Ligand B (62.233). While not a primary concern for a cardiovascular target, it's a positive attribute.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not defined, so it's difficult to interpret.
10. **Solubility:** Ligand A (-3.661) has slightly worse solubility than Ligand B (-1.911). Solubility is important, but not as crucial as other factors here.
11. **hERG:** Both ligands have low hERG inhibition risk (0.476 and 0.335). No significant difference.
12. **Cl_mic:** Ligand A (70.664) has a higher microsomal clearance than Ligand B (29.937), indicating faster metabolism and potentially lower *in vivo* exposure. This is a disadvantage for Ligand A.
13. **t1/2:** Ligand B (13.095) has a significantly longer *in vitro* half-life than Ligand A (-12.303). This is a major advantage for Ligand B.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.362 and 0.005). Ligand B is slightly better.
15. **Binding Affinity:** Ligand B (-7.6 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.3 kcal/mol). This is a substantial advantage that can outweigh some of the ADME drawbacks.
**Overall Assessment:**
Ligand B has a significantly stronger binding affinity and a longer half-life, which are crucial for a GPCR target. While Ligand A has better TPSA, QED, and DILI, the superior potency and metabolic stability of Ligand B are more important. The slightly lower solubility of Ligand A is a concern, but potentially manageable. The difference in Cl_mic is also a significant factor favoring Ligand B.
Output:
0
2025-04-18 00:28:32,572 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (346.39 and 359.41 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (106.35) is better than Ligand B (121.18). For a GPCR, keeping TPSA under 140 is good for oral absorption, and lower is generally preferred.
**3. logP:** Ligand A (2.02) is optimal, while Ligand B (0.376) is quite low. GPCRs benefit from a logP between 1-3 for good membrane permeability. Ligand B's low logP is a concern.
**4. H-Bond Donors:** Ligand A (2) and Ligand B (3) are both acceptable, being under the 5 threshold.
**5. H-Bond Acceptors:** Both ligands have 6 HBA, which is within the acceptable range of <=10.
**6. QED:** Ligand A (0.743) is slightly better than Ligand B (0.681), indicating a more drug-like profile.
**7. DILI:** Both ligands have high DILI risk (78.13 and 83.44), which is a concern. However, this is often a prediction and needs further investigation.
**8. BBB:** Ligand A (81.66) has significantly better BBB penetration potential than Ligand B (45.91). While ADRB2 is primarily a cardiovascular target, some CNS effects are possible with certain ligands, and better BBB penetration isn't necessarily a negative.
**9. Caco-2 Permeability:** Ligand A (-4.925) is better than Ligand B (-5.595), indicating better intestinal absorption.
**10. Aqueous Solubility:** Both ligands have similar, very poor aqueous solubility (-3.147 and -3.135). This could pose formulation challenges.
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (0.162 and 0.385), which is good.
**12. Microsomal Clearance:** Ligand A (78.58) has higher clearance than Ligand B (-6.554), meaning Ligand B is more metabolically stable. This is a significant advantage for Ligand B.
**13. In vitro Half-Life:** Ligand B (-26.371) has a much longer half-life than Ligand A (-2.354). This is a major advantage for Ligand B, potentially allowing for less frequent dosing.
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (0.082 and 0.017), which is good.
**15. Binding Affinity:** Both ligands have very similar binding affinities (-6.4 and -6.6 kcal/mol). The difference is negligible.
**Overall Assessment:**
Ligand B has a significant advantage in metabolic stability (lower Cl_mic, longer half-life). However, its low logP is a major concern for permeability and overall drug-like properties. Ligand A has better TPSA, logP, Caco-2 permeability, and BBB penetration. Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), and the fact that the affinities are nearly identical, Ligand A is the more promising candidate due to its more favorable physicochemical properties, despite the similar DILI scores.
Output:
1
2025-04-18 00:28:32,572 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (360.483 and 366.868 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (78.09) is higher than Ligand B (51.02). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferable for absorption. Ligand B is better.
3. **logP:** Ligand B (3.885) is higher than Ligand A (2.624). While both are within the optimal 1-3 range, Ligand B is approaching the upper limit. This *could* lead to solubility issues, but isn't a major concern yet.
4. **HBD:** Ligand A (2) is higher than Ligand B (0). Lower HBD is generally preferred for better permeability. Ligand B is better.
5. **HBA:** Both ligands have the same number of HBA (4). No difference.
6. **QED:** Ligand A (0.86) has a slightly higher QED than Ligand B (0.712), indicating a more drug-like profile. Ligand A is better.
7. **DILI:** Ligand A (36.914) has a lower DILI risk than Ligand B (40.83). Both are acceptable, but Ligand A is better.
8. **BBB:** Ligand B (81.621) has a significantly higher BBB penetration percentile than Ligand A (64.482). While ADRB2 isn't primarily a CNS target, some CNS exposure can contribute to side effects, and better control is preferred. Ligand B is better.
9. **Caco-2:** Ligand A (-5.342) has a more negative Caco-2 value, suggesting *lower* permeability than Ligand B (-4.706). Ligand B is better.
10. **Solubility:** Ligand A (-2.995) has a more negative solubility value, indicating *lower* solubility than Ligand B (-4.018). Ligand B is better.
11. **hERG:** Both ligands have similar hERG inhibition liability (0.768 and 0.791). No significant difference.
12. **Cl_mic:** Ligand B (82.013) has a much higher microsomal clearance than Ligand A (10.07). This indicates Ligand A is significantly more metabolically stable. Ligand A is *much* better.
13. **t1/2:** Ligand B (32.359) has a longer in vitro half-life than Ligand A (-20.889). This is a strong advantage for Ligand B.
14. **Pgp:** Both ligands have similar Pgp efflux liability (0.323 and 0.512). No significant difference.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-5.6 and -5.2 kcal/mol). The difference is not substantial enough to be a deciding factor.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), and the general drug-like properties, Ligand A emerges as the more promising candidate. While Ligand B has better BBB penetration and half-life, the significantly improved metabolic stability (lower Cl_mic) and better DILI profile of Ligand A are crucial advantages for a cardiovascular drug. The slightly lower TPSA and higher QED of Ligand A also contribute positively. The solubility and permeability are not ideal for either, but Ligand A is better in this regard. The affinity is comparable.
Output:
1
2025-04-18 00:28:32,572 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (358.869 and 341.415 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (75.35) is better than Ligand B (91.81). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally improves absorption.
3. **logP:** Both ligands have good logP values (2.102 and 1.426), falling within the 1-3 range. Ligand A is slightly higher, potentially aiding membrane permeability.
4. **HBD:** Both have 3 HBD, which is acceptable.
5. **HBA:** Ligand A has 3 HBA, while Ligand B has 4. Both are within the acceptable range of <=10.
6. **QED:** Ligand A (0.74) has a better QED score than Ligand B (0.501), indicating a more drug-like profile.
7. **DILI:** Ligand A (32.183) has a significantly lower DILI risk than Ligand B (49.632). This is a major advantage for Ligand A.
8. **BBB:** Not a primary concern for a cardiovascular target, but Ligand A (66.344) has a higher BBB percentile than Ligand B (43.699).
9. **Caco-2:** Both have negative Caco-2 values (-5.304 and -5.729), which is unusual and suggests poor permeability. This is a significant drawback for both.
10. **Solubility:** Both have negative solubility values (-2.978 and -2.39). This is a major concern for both compounds.
11. **hERG:** Ligand A (0.819) has a slightly better hERG profile than Ligand B (0.47). Lower is better.
12. **Cl_mic:** Ligand A (15.968) has a lower microsomal clearance than Ligand B (25.589), suggesting better metabolic stability.
13. **t1/2:** Ligand A (15.913) has a longer in vitro half-life than Ligand B (-3.805). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.304) has a lower Pgp efflux liability than Ligand B (0.152), which is beneficial for oral bioavailability.
15. **Binding Affinity:** Ligand A (-6.1 kcal/mol) has a slightly better binding affinity than Ligand B (-4.7 kcal/mol). The difference is 1.4 kcal/mol, which is significant enough to outweigh some of the ADME drawbacks.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B in most crucial ADME properties (DILI, Cl_mic, t1/2, Pgp) and has a slightly better binding affinity. While both compounds have poor Caco-2 and solubility values, the superior ADME profile and binding affinity of Ligand A make it the more promising candidate. The lower DILI risk is particularly important.
Output:
1
2025-04-18 00:28:32,572 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
The ADRB2 receptor is a GPCR, so the priorities are logP, TPSA, Pgp efflux, BBB penetration, and binding affinity. Metabolic stability (Cl_mic, t1/2) and safety (DILI, hERG) are also important.
Let's break down the comparison:
1. **Molecular Weight:** Both ligands (350.423 and 356.423 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands are below the 140 A^2 threshold (112.85 and 116.93 A^2), which is good for oral absorption. Ligand A is slightly better.
3. **logP:** Ligand A (0.345) is a bit low, potentially hindering permeation. Ligand B (0.482) is also low, but slightly better. Ideally, we'd want values between 1-3.
4. **H-Bond Donors/Acceptors:** Ligand A (1 HBD, 5 HBA) is preferable to Ligand B (3 HBD, 7 HBA). Lower counts generally improve permeability.
5. **QED:** Both are similar (0.438 and 0.412), indicating moderate drug-likeness.
6. **DILI:** Ligand A (16.673%) has a significantly lower DILI risk than Ligand B (35.285%). This is a major advantage for Ligand A.
7. **BBB:** Ligand A (27.84%) and Ligand B (24.622%) both have low BBB penetration. This is not critical for ADRB2 (a cardiovascular target), but higher is always preferred.
8. **Caco-2:** Both have negative values (-5.168 and -5.6), which is unusual and suggests poor permeability. It's hard to interpret these values without knowing the scale.
9. **Solubility:** Both have negative solubility values (-0.553 and -1.03), suggesting poor aqueous solubility. This is a concern for bioavailability.
10. **hERG:** Both ligands have very low hERG inhibition risk (0.236 and 0.159).
11. **Cl_mic:** Ligand A (-19.318 mL/min/kg) has a much lower (better) microsomal clearance than Ligand B (-0.652 mL/min/kg). This suggests greater metabolic stability for Ligand A.
12. **t1/2:** Both have similar in vitro half-lives (18.49 and 18.76 hours).
13. **Pgp:** Both have very low Pgp efflux liability (0.008 and 0.019).
14. **Binding Affinity:** Ligand A (-7.2 kcal/mol) has a slightly stronger binding affinity than Ligand B (-6.8 kcal/mol). While the difference is not huge, it's still a positive for Ligand A.
**Overall Assessment:**
Ligand A is the better candidate. It has a significantly lower DILI risk, better metabolic stability (lower Cl_mic), slightly better binding affinity, and a more favorable H-bond profile. While both ligands have issues with logP and solubility, the safety and metabolic advantages of Ligand A outweigh the slightly weaker logP.
**Output:**
1
2025-04-18 00:28:32,572 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [352.503, 23.55, 4.414, 0, 2, 0.719, 37.689, 79.411, -4.717, -4.993, 0.944, 100.737, 28.544, 0.481, -6.1]
**Ligand B:** [359.417, 56.59, 1.944, 0, 5, 0.633, 23.691, 96.084, -4.415, -1.472, 0.732, 44.619, 11.004, 0.259, -5.3]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (352.5) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (23.55) is significantly better than Ligand B (56.59). A TPSA under 140 is good for oral absorption, and lower is better for GPCRs. Ligand B is pushing the upper limit.
3. **logP:** Ligand A (4.414) is higher than Ligand B (1.944). While 4.414 is approaching the upper limit, it's still acceptable. Ligand B's logP is quite low, potentially hindering membrane permeability.
4. **HBD:** Both have 0 HBD, which is good.
5. **HBA:** Ligand A (2) is better than Ligand B (5). Lower HBA is generally preferred for permeability.
6. **QED:** Ligand A (0.719) is better than Ligand B (0.633), indicating a more drug-like profile.
7. **DILI:** Ligand A (37.689) is slightly higher than Ligand B (23.691), but both are below the concerning threshold of 60. Ligand B is preferable here.
8. **BBB:** Ligand A (79.411) is good, but Ligand B (96.084) is excellent. For a GPCR, especially if CNS effects are possible, higher BBB penetration is desirable.
9. **Caco-2:** Both are negative, indicating poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Ligand A (-4.993) is worse than Ligand B (-1.472). Solubility is important, and Ligand B is better in this regard.
11. **hERG:** Ligand A (0.944) is better than Ligand B (0.732), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand A (100.737) has a higher clearance than Ligand B (44.619), meaning it's less metabolically stable. Ligand B is preferable.
13. **t1/2:** Ligand A (28.544) has a significantly longer half-life than Ligand B (11.004). This is a major advantage for dosing frequency.
14. **Pgp:** Ligand A (0.481) is better than Ligand B (0.259), indicating lower P-glycoprotein efflux.
15. **Affinity:** Ligand A (-6.1) has a slightly better binding affinity than Ligand B (-5.3). While the difference is not huge, it's still a positive for Ligand A.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, BBB, and affinity. Ligand A has a better logP, TPSA, and Pgp. Ligand B has a significantly better BBB and solubility. The affinity difference is small. The metabolic stability (Cl_mic) is better for Ligand B. The half-life is much better for Ligand A.
**Overall Assessment:**
Ligand A has a better balance of properties, especially considering the importance of TPSA and logP for GPCR targets. The slightly better affinity and significantly longer half-life are also important advantages. While Ligand B has better BBB penetration and solubility, the lower logP and higher TPSA are concerning. The longer half-life of Ligand A is a significant advantage.
Output:
1
2025-04-18 00:28:32,573 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (357.454 and 345.399 Da) are within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (47.34) is significantly better than Ligand B (91.64). ADRB2 is a cardiovascular target, not CNS, but lower TPSA generally improves absorption. Ligand A is well below the 140 threshold, while B is pushing it.
3. **logP:** Ligand A (3.349) is optimal. Ligand B (-0.02) is quite low, potentially hindering membrane permeability and absorption. This is a significant drawback.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is better than Ligand B (5). Lower HBA is generally preferred.
6. **QED:** Ligand A (0.843) is excellent, indicating high drug-likeness. Ligand B (0.56) is acceptable, but less ideal.
7. **DILI:** Ligand B (35.944) has a much lower DILI risk than Ligand A (66.809). This is a substantial advantage for Ligand B.
8. **BBB:** Ligand A (86.468) has better BBB penetration than Ligand B (30.593). While ADRB2 isn't a CNS target, some off-target CNS effects are always a consideration, and higher BBB penetration can sometimes correlate with better overall distribution.
9. **Caco-2:** Ligand A (-4.741) and Ligand B (-5.177) are both very poor. This is concerning for both, but the values are similar.
10. **Solubility:** Ligand A (-4.274) is slightly better than Ligand B (-0.894), but both are poor. Solubility is a potential formulation challenge for both.
11. **hERG:** Ligand A (0.86) is significantly better than Ligand B (0.157). Lower hERG risk is crucial for cardiovascular drugs.
12. **Cl_mic:** Ligand B (20.539) has much lower microsomal clearance than Ligand A (72.852), suggesting better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand A (-14.022) has a negative half-life, which is not possible. This is a major red flag. Ligand B (-6.954) is also negative, but less so. Both are problematic.
14. **Pgp:** Ligand A (0.753) is better than Ligand B (0.063). Lower P-gp efflux is desirable.
15. **Affinity:** Ligand A (-7.5) has a slightly better binding affinity than Ligand B (-6.3). While a 1.2 kcal/mol difference is good, it's not enough to overcome the significant ADME liabilities of Ligand A.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand A excels in affinity and TPSA, but fails badly on logP. Ligand B has a poor logP, but excels in DILI and Cl_mic, and has acceptable TPSA.
**Overall Assessment:**
Ligand A has a better binding affinity, but its extremely low logP, poor solubility, high DILI risk, and impossible half-life are major concerns. Ligand B, despite its lower affinity, has a much more favorable ADME profile, particularly its low DILI risk and improved metabolic stability. The negative half-life values for both are concerning and would require investigation, but are less immediately disqualifying than the other issues with Ligand A.
Therefore, I would choose Ligand B as the more promising drug candidate.
Output:
0
2025-04-18 00:28:32,573 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (364.833 and 362.901 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (82.61) is higher than Ligand B (49.41). For a cardiovascular GPCR, TPSA is not a major concern unless targeting the CNS, but lower is generally preferred for permeability. Ligand B is better here.
3. **logP:** Ligand A (0.475) is quite low, potentially hindering membrane permeability. Ligand B (3.95) is within the optimal 1-3 range. This is a significant advantage for Ligand B.
4. **HBD:** Both have 1 HBD, which is acceptable.
5. **HBA:** Ligand A has 4 HBAs, and Ligand B has 2. Both are within the acceptable range of <=10. Ligand B is slightly better.
6. **QED:** Both ligands have good QED scores (0.77 and 0.798), indicating good drug-like properties.
7. **DILI:** Ligand A (30.942) has a slightly lower DILI risk than Ligand B (35.673). Both are below the 40 threshold, so the difference is minor.
8. **BBB:** Ligand A (33.346) has a very low BBB penetration, while Ligand B (81.466) has high BBB penetration. Since ADRB2 is not a CNS target, this is a negative for Ligand B.
9. **Caco-2:** Ligand A (-5.122) and Ligand B (-4.784) both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
10. **Solubility:** Ligand A (-2.399) has better solubility than Ligand B (-4.528). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.081) has a lower hERG risk than Ligand B (0.67). This is a significant advantage for Ligand A, given the cardiovascular target.
12. **Cl_mic:** Ligand A (-6.818) has a much lower (better) microsomal clearance than Ligand B (62.087). This indicates better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (7.713) has a longer half-life than Ligand B (-1.365). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.004) has very low P-gp efflux, while Ligand B (0.602) has moderate efflux. Lower Pgp is better for bioavailability.
15. **Binding Affinity:** Ligand B (-8.3) has a significantly stronger binding affinity than Ligand A (-6.2). This is a substantial advantage, potentially outweighing some ADME concerns.
**Overall Assessment:**
Ligand B has a superior binding affinity, which is crucial for GPCR targets. However, it suffers from a higher logP, moderate Pgp efflux, and significantly worse metabolic stability (high Cl_mic and short half-life). Ligand A has a lower logP, better metabolic stability, lower hERG risk, and lower Pgp efflux, but its binding affinity is weaker.
Given the cardiovascular target, metabolic stability and hERG risk are important. The substantial difference in binding affinity (-8.3 vs -6.2) is a 1.5 kcal/mol difference, and is a strong advantage for Ligand B. While Ligand B's ADME profile isn't ideal, the potency advantage is likely to be more impactful in this case.
Output:
0
2025-04-18 00:28:32,573 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (348.399 Da and 362.461 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (92.01) is higher than Ligand B (58.64). For a cardiovascular GPCR, TPSA is moderately important, and lower is generally better for permeability. Ligand B has a clear advantage.
**3. logP:** Ligand A (0.954) is slightly below the optimal 1-3 range, while Ligand B (2.838) is well within it. LogP is crucial for GPCRs, and Ligand B is better positioned for good membrane permeability and receptor engagement.
**4. H-Bond Donors:** Ligand A (2) is slightly higher than Ligand B (1), but both are acceptable (<=5).
**5. H-Bond Acceptors:** Ligand A (5) is higher than Ligand B (3), but both are acceptable (<=10).
**6. QED:** Both ligands have similar QED values (0.716 and 0.722), indicating good drug-like properties.
**7. DILI Risk:** Ligand A (34.471) has a significantly higher DILI risk than Ligand B (18.922). This is a major concern, as liver toxicity is a common reason for drug failure. Ligand B is much preferred.
**8. BBB Penetration:** Ligand A (46.879) has lower BBB penetration than Ligand B (88.6). While ADRB2 is a cardiovascular target, some CNS effects can be relevant or undesirable. Higher BBB penetration isn't *essential* but isn't detrimental.
**9. Caco-2 Permeability:** Ligand A (-4.869) is lower than Ligand B (-4.445). Both are negative, suggesting poor permeability, but Ligand B is slightly better.
**10. Aqueous Solubility:** Ligand A (-1.415) is better than Ligand B (-2.769). Solubility is important for formulation, but less critical than permeability for a GPCR.
**11. hERG Inhibition:** Ligand A (0.144) has a lower hERG risk than Ligand B (0.672). This is a positive for Ligand A.
**12. Microsomal Clearance:** Ligand A (-4.556) has a lower (better) microsomal clearance than Ligand B (16.153), indicating greater metabolic stability.
**13. In vitro Half-Life:** Ligand A (18.549) has a longer half-life than Ligand B (-2.248). This is a significant advantage for Ligand A, potentially allowing for less frequent dosing.
**14. P-gp Efflux:** Ligand A (0.023) has much lower P-gp efflux than Ligand B (0.075), which is beneficial for bioavailability.
**15. Binding Affinity:** Ligand B (-7.5) has a stronger binding affinity than Ligand A (-6.4) by 1.1 kcal/mol. This is a substantial difference and can often outweigh minor ADME concerns.
**Overall Assessment:**
While Ligand A has advantages in hERG, metabolic stability, half-life, and P-gp efflux, the significantly higher DILI risk is a major red flag. Ligand B excels in key GPCR properties like logP, TPSA, and most importantly, binding affinity. The stronger binding affinity of Ligand B (-7.5 kcal/mol) is a substantial advantage that outweighs its slightly higher DILI risk and lower metabolic stability. The better Caco-2 permeability and BBB penetration of Ligand B are also beneficial.
Therefore, I recommend Ligand B.
0
2025-04-18 00:28:32,573 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (387.307 Da) is slightly higher than Ligand B (347.459 Da), but both are acceptable.
**2. TPSA:** Ligand A (50.8) is significantly better than Ligand B (82.53). For a GPCR, a lower TPSA generally favors better permeability and brain penetration, even if this isn't a CNS target.
**3. logP:** Ligand A (3.959) is optimal, while Ligand B (1.629) is on the lower side. A logP between 1-3 is preferred, and Ligand A is closer to this ideal. Lower logP can sometimes indicate poor membrane permeability.
**4. H-Bond Donors:** Ligand A (1) is preferable to Ligand B (2). Fewer H-bond donors generally improve permeability.
**5. H-Bond Acceptors:** Ligand A (3) is preferable to Ligand B (4). Similar to HBD, fewer HBAs are generally better for permeability.
**6. QED:** Both ligands have similar, good QED values (0.851 and 0.848).
**7. DILI:** Ligand A (47.421) has a higher DILI risk than Ligand B (23.032). This is a significant advantage for Ligand B.
**8. BBB:** Ligand A (92.904) has a much higher BBB penetration percentile than Ligand B (50.795). While ADRB2 isn't exclusively a CNS target, some peripheral ADRB2 receptors are relevant in the brain, and higher BBB penetration could be beneficial.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests a potential issue with the data or modeling. However, the values are similar (-4.451 and -4.793) and don't strongly differentiate the ligands.
**10. Aqueous Solubility:** Ligand A (-4.484) is slightly better than Ligand B (-2.224), indicating better solubility.
**11. hERG Inhibition:** Ligand A (0.732) has a lower hERG inhibition liability than Ligand B (0.291), which is a significant safety advantage.
**12. Microsomal Clearance:** Ligand B (17.745) has lower microsomal clearance than Ligand A (49.782), suggesting better metabolic stability.
**13. In vitro Half-Life:** Ligand A (18.471) has a longer half-life than Ligand B (5.444), which is desirable.
**14. P-gp Efflux:** Ligand A (0.412) has lower P-gp efflux liability than Ligand B (0.079), which is preferable for bioavailability.
**15. Binding Affinity:** Ligand B (-6.6) has a slightly better binding affinity than Ligand A (-6.8), but the difference is minimal (0.2 kcal/mol).
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp), Ligand A is more favorable. It has a better logP, significantly lower TPSA, and lower P-gp efflux. While Ligand B has a lower DILI risk and better metabolic stability, the advantages of Ligand A in terms of permeability and potential brain exposure outweigh these concerns. The slightly better binding affinity of Ligand B isn't substantial enough to overcome the ADME deficiencies. The hERG risk is also lower for Ligand A, a crucial safety parameter.
Output:
1
2025-04-18 00:28:32,574 - INFO - Batch 480 complete. Total preferences: 7680
2025-04-18 00:28:32,574 - INFO - Processing batch 481/512...
2025-04-18 00:29:22,630 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (383.5) is slightly higher than Ligand B (350.4), but both are acceptable.
2. **TPSA:** Both ligands are below the 140 A^2 threshold for good oral absorption. Ligand A (107.2) is better than Ligand B (113.4).
3. **logP:** Ligand A (0.188) is quite low, potentially hindering permeability. Ligand B (0.869) is better, falling within the optimal range. This is a significant advantage for Ligand B.
4. **HBD:** Both have 3 HBD, which is acceptable.
5. **HBA:** Both have 6 HBA, which is acceptable.
6. **QED:** Both have good QED scores (A: 0.58, B: 0.609), indicating good drug-like properties.
7. **DILI:** Ligand A (60.9) is at the upper limit of acceptable DILI risk. Ligand B (47.7) is better, indicating lower potential for liver injury.
8. **BBB:** Both have relatively low BBB penetration (A: 41.6, B: 46.8). Since ADRB2 is a cardiovascular target, BBB penetration is not a high priority.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the values are close enough that this isn't a major differentiator.
10. **Solubility:** Both have negative solubility values, which is also unusual. Again, the values are similar and not a major factor.
11. **hERG:** Both have very low hERG inhibition risk (A: 0.068, B: 0.108).
12. **Cl_mic:** Ligand A (11.3) has significantly lower microsomal clearance than Ligand B (32.3), suggesting better metabolic stability. This is a positive for Ligand A.
13. **t1/2:** Ligand A (-14.7) has a more negative in vitro half-life, which is not ideal. Ligand B (-8.7) is better, though still not great.
14. **Pgp:** Both have low Pgp efflux liability (A: 0.019, B: 0.026).
15. **Binding Affinity:** Ligand A (-7.3) has a stronger binding affinity than Ligand B (-6.3) by 1 kcal/mol. This is a significant advantage for Ligand A, potentially outweighing some of its ADME drawbacks.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand A has a lower TPSA, better metabolic stability, and significantly better binding affinity. Ligand B has a better logP and lower DILI risk. The affinity difference is substantial.
**Overall Assessment:**
While Ligand B has a better logP and DILI profile, the significantly stronger binding affinity of Ligand A (-7.3 vs -6.3 kcal/mol) is a major advantage. The lower metabolic clearance of Ligand A is also beneficial. The slightly lower logP of Ligand A is a concern, but the potency advantage is likely to be more impactful for a GPCR target.
Output:
1
2025-04-18 00:29:22,630 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
We are targeting ADRB2, a GPCR. Therefore, the priorities are logP, Pgp, TPSA, affinity, and BBB. Let's compare the ligands across all parameters:
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (338.371) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are reasonably low. Ligand B (82.53) is better than Ligand A (93.96) and closer to the ideal <140 for oral absorption.
3. **logP:** Both are within the optimal range (1-3). Ligand B (2.609) is slightly higher, which could be beneficial for membrane permeability, but not excessively high.
4. **HBD/HBA:** Both have 2 HBD and 5-6 HBA, which are acceptable.
5. **QED:** Both have good QED scores (>0.5), indicating drug-likeness. Ligand B (0.836) is slightly better.
6. **DILI:** Ligand A (82.668) has a higher DILI risk than Ligand B (63.513), which is a significant concern.
7. **BBB:** Ligand A (73.013) has a slightly better BBB penetration than Ligand B (66.033), but both are not exceptionally high. Given ADRB2 is a cardiovascular target, BBB penetration is less critical than for CNS targets.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-5.421) is slightly better than Ligand B (-5.018).
9. **Solubility:** Both have very poor solubility scores. Ligand A (-2.59) is slightly better than Ligand B (-3.841).
10. **hERG:** Ligand A (0.106) has a much lower hERG risk than Ligand B (0.724), which is a major advantage.
11. **Cl_mic:** Ligand A (2.412) has significantly lower microsomal clearance than Ligand B (24.072), indicating better metabolic stability.
12. **t1/2:** Ligand A (56.379) has a much longer in vitro half-life than Ligand B (3.194), which is highly desirable.
13. **Pgp:** Ligand A (0.04) has much lower P-gp efflux liability than Ligand B (0.281), which is favorable for bioavailability.
14. **Affinity:** Ligand A (-7.2 kcal/mol) has a stronger binding affinity than Ligand B (-6.4 kcal/mol). The difference is 0.8 kcal/mol, which is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand A is the better candidate. While both have issues with solubility and Caco-2 permeability, Ligand A demonstrates a significantly superior safety profile (lower DILI, lower hERG), better metabolic stability (lower Cl_mic, longer t1/2), lower P-gp efflux, and, critically, a substantially higher binding affinity. The slightly better BBB penetration of Ligand A is a minor benefit given the cardiovascular target. The stronger affinity of Ligand A is a key driver in this decision.
**Output:**
1
2025-04-18 00:29:22,630 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.41 and 349.406 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (76.46 and 75.44) are below the 140 A^2 threshold for good oral absorption, which is good.
3. **logP:** Ligand A (0.507) is quite low, potentially hindering permeation. Ligand B (2.12) is within the optimal 1-3 range. This is a significant advantage for Ligand B.
4. **HBD:** Both have 1 HBD, which is acceptable.
5. **HBA:** Ligand A has 5 HBA, and Ligand B has 4. Both are below the 10 threshold.
6. **QED:** Both ligands have high QED scores (0.838 and 0.798), indicating good drug-like properties.
7. **DILI:** Both ligands have similar, acceptable DILI risk (42.536 and 43.971 percentile).
8. **BBB:** Both ligands have high BBB penetration (87.631 and 87.941 percentile), which is good, but less crucial for ADRB2 as it's not a CNS target.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the values are similar (-4.915 and -4.618).
10. **Solubility:** Ligand A (-1.228) has better solubility than Ligand B (-3.294). This is a positive for Ligand A.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.143 and 0.353).
12. **Cl_mic:** Ligand A (5.736) has significantly lower microsomal clearance than Ligand B (48.753), indicating better metabolic stability. This is a strong advantage for Ligand A.
13. **t1/2:** Ligand A (5.045) has a positive in vitro half-life, while Ligand B (-4.999) has a negative value, which is concerning. This is a significant advantage for Ligand A.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.015 and 0.255).
15. **Binding Affinity:** Ligand A (-7.7 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.3 kcal/mol). This is a substantial advantage for Ligand A, exceeding the 1.5 kcal/mol difference threshold.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, and affinity are key. Ligand B has a better logP, but Ligand A excels in affinity and metabolic stability (Cl_mic, t1/2). The substantial difference in binding affinity (-7.7 vs -6.3) and the improved metabolic stability of Ligand A outweigh the slightly less optimal logP.
**Conclusion:**
Ligand A is the more promising drug candidate due to its significantly stronger binding affinity, better metabolic stability, and a more favorable in vitro half-life. While Ligand B has a better logP, the advantages of Ligand A are more critical for a successful drug.
Output:
1
2025-04-18 00:29:22,630 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [411.34 , 67.43 , 3.801, 2. , 3. , 0.53 , 33.424, 77.239, -4.765, -4.704, 0.745, 76.043, 33.132, 0.377, -7.5 ]
**Ligand B:** [355.454, 83.71 , 1.643, 1. , 3. , 0.638, 18.651, 85.964, -4.661, -1.91 , 0.457, 23.89 , -10.497, 0.027, -6.4 ]
**Step-by-step comparison:**
1. **MW:** Ligand A (411.34 Da) is within the ideal range, while Ligand B (355.454 Da) is also acceptable. No strong preference here.
2. **TPSA:** Ligand A (67.43) is better than Ligand B (83.71). For a cardiovascular GPCR, we don't *need* extremely low TPSA for CNS penetration, but lower is generally preferable for permeability.
3. **logP:** Ligand A (3.801) is optimal, while Ligand B (1.643) is on the lower side. This is a significant advantage for A, as it suggests better membrane permeability.
4. **HBD:** Ligand A (2) is good, Ligand B (1) is also good.
5. **HBA:** Both ligands have 3 HBA, which is acceptable.
6. **QED:** Both ligands have good QED scores (A: 0.53, B: 0.638), indicating drug-like properties. B is slightly better here.
7. **DILI:** Ligand A (33.424) has a slightly higher DILI risk than Ligand B (18.651). This favors B.
8. **BBB:** Both have acceptable BBB penetration, but Ligand B (85.964) is higher than Ligand A (77.239). Not a huge factor for a cardiovascular target, but a slight edge to B.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not provided, so it is difficult to interpret.
10. **Solubility:** Ligand A (-4.704) has worse solubility than Ligand B (-1.91). This is a significant drawback for A.
11. **hERG:** Ligand A (0.745) has a slightly higher hERG risk than Ligand B (0.457), favoring B.
12. **Cl_mic:** Ligand A (76.043) has higher metabolic clearance than Ligand B (23.89), meaning A will be cleared faster. This favors B.
13. **t1/2:** Ligand A (33.132) has a longer half-life than Ligand B (-10.497). This is a strong advantage for A.
14. **Pgp:** Ligand A (0.377) has lower P-gp efflux than Ligand B (0.027), which is preferable.
15. **Affinity:** Ligand A (-7.5 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.4 kcal/mol). This is a substantial advantage for A, potentially outweighing some of the ADME concerns.
**Overall Assessment:**
Ligand A has a significantly better binding affinity and lower P-gp efflux, which are crucial for GPCR targets. However, it suffers from poorer solubility, higher DILI risk, and higher metabolic clearance. Ligand B has better solubility, lower DILI, and lower clearance, but its binding affinity is considerably weaker.
Considering the importance of potency for GPCRs, and the fact that the difference in affinity is >1.5 kcal/mol, I believe the stronger binding of Ligand A is the most important factor. While the ADME properties of A are not ideal, they can potentially be optimized through further medicinal chemistry efforts. The weaker binding of Ligand B is a more fundamental limitation.
Output:
1
2025-04-18 00:29:22,630 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [398.937, 76.13, 3.407, 1, 5, 0.856, 88.251, 68.748, -4.95, -4.485, 0.547, 15.003, 15.752, 0.462, -6.7]
**Ligand B:** [376.523, 121.6, 0.371, 3, 4, 0.477, 33.695, 43.815, -5.38, -1.785, 0.219, 40.419, -7.543, 0.006, -6.3]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, Affinity, and BBB):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (376.523) is slightly lower, which could be beneficial for permeability.
2. **TPSA:** Ligand A (76.13) is significantly better than Ligand B (121.6), falling well below the 140 threshold for good absorption. Ligand B is higher, potentially hindering absorption.
3. **logP:** Ligand A (3.407) is optimal. Ligand B (0.371) is very low, raising concerns about permeability and potentially off-target interactions due to increased polarity.
4. **HBD/HBA:** Ligand A (1 HBD, 5 HBA) is preferable to Ligand B (3 HBD, 4 HBA).
5. **QED:** Ligand A (0.856) is much better than Ligand B (0.477), indicating a more drug-like profile.
6. **DILI:** Ligand B (33.695) has a significantly lower DILI risk than Ligand A (88.251), a major advantage.
7. **BBB:** Ligand A (68.748) has better BBB penetration than Ligand B (43.815), which is important for a GPCR.
8. **Caco-2:** Ligand A (-4.95) has a better Caco-2 value than Ligand B (-5.38).
9. **Solubility:** Ligand A (-4.485) has better solubility than Ligand B (-1.785).
10. **hERG:** Ligand A (0.547) has a slightly better hERG profile than Ligand B (0.219).
11. **Cl_mic:** Ligand A (15.003) has a lower microsomal clearance, suggesting better metabolic stability, than Ligand B (40.419).
12. **t1/2:** Ligand A (15.752) has a longer in vitro half-life than Ligand B (-7.543).
13. **Pgp:** Ligand A (0.462) has lower P-gp efflux than Ligand B (0.006), which is favorable.
14. **Affinity:** Both have good binding affinities (-6.7 and -6.3 kcal/mol respectively), with Ligand A being slightly better. The difference is not substantial enough to outweigh other factors.
**Overall Assessment:**
While Ligand B has a much lower DILI risk, Ligand A is superior in almost every other critical parameter, especially for a GPCR target. Ligand A has better TPSA, logP, QED, BBB penetration, solubility, metabolic stability, and P-gp efflux. The slightly better affinity of Ligand A further supports its selection. The lower logP of Ligand B is a significant concern, potentially leading to poor absorption and bioavailability.
Therefore, I recommend Ligand A.
Output:
1
2025-04-18 00:29:22,630 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [348.462, 49.41, 3.302, 1, 2, 0.696, 18.185, 90.772, -4.375, -3.472, 0.675, 71.206, 19.952, 0.202, -5.5]
**Ligand B:** [358.423, 79.54, 1.222, 0, 6, 0.768, 74.874, 54.246, -4.659, -2.529, 0.124, 50.852, -46.644, 0.205, -7.1]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (348.462) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (49.41) is significantly better than Ligand B (79.54). ADRB2 is a cardiovascular target, so CNS penetration isn't *essential*, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (3.302) is optimal, while Ligand B (1.222) is a bit low. This could impact membrane permeability for Ligand B.
4. **HBD/HBA:** Ligand A (1 HBD, 2 HBA) is preferable to Ligand B (0 HBD, 6 HBA). Fewer hydrogen bond donors and acceptors are generally better for permeability.
5. **QED:** Both are acceptable (A: 0.696, B: 0.768), indicating reasonable drug-likeness.
6. **DILI:** Ligand A (18.185) has a much lower DILI risk than Ligand B (74.874). This is a critical advantage.
7. **BBB:** Ligand A (90.772) has a higher BBB penetration percentile than Ligand B (54.246). While not a primary concern for a cardiovascular target, it isn't detrimental.
8. **Caco-2:** Both are negative, suggesting poor permeability. This is concerning for both.
9. **Solubility:** Both are negative, suggesting poor solubility. This is concerning for both.
10. **hERG:** Ligand A (0.675) is better than Ligand B (0.124), indicating lower cardiotoxicity risk.
11. **Cl_mic:** Ligand B (50.852) has a lower microsomal clearance than Ligand A (71.206), suggesting better metabolic stability.
12. **t1/2:** Ligand B (-46.644) has a much longer in vitro half-life than Ligand A (19.952), which is a significant advantage.
13. **Pgp:** Both are very low (A: 0.202, B: 0.205), indicating minimal P-gp efflux.
14. **Binding Affinity:** Ligand B (-7.1) has a significantly stronger binding affinity than Ligand A (-5.5). This is a substantial advantage.
**GPCR-Specific Priorities:** For ADRB2 (a GPCR), we prioritize logP, Pgp, TPSA, and affinity. Ligand B excels in affinity, while Ligand A is better in TPSA and logP. However, the *magnitude* of the affinity difference for Ligand B is substantial. The lower DILI and hERG risk for Ligand A are also important, but the strong binding of Ligand B is likely to outweigh these concerns, especially if further optimization can address the DILI and hERG risks. The longer half-life of Ligand B is also a significant positive.
**Conclusion:**
Despite some ADME drawbacks in Ligand B, the significantly stronger binding affinity (-7.1 vs -5.5 kcal/mol) and longer half-life are compelling. The difference in affinity is large enough to potentially overcome the higher DILI risk and lower logP through further medicinal chemistry optimization.
0
2025-04-18 00:29:22,630 - INFO - Here's my reasoning and final output for the ligand preference:
**Reasoning:**
We are looking for a ligand for the ADRB2, a cardiovascular GPCR. Therefore, the priorities are logP, Pgp, TPSA, and affinity, with metabolic stability and solubility also being important.
Let's compare Ligand A and Ligand B across the 15 parameters:
1. **MW:** Both are within the ideal range (354.5 vs 357.5 Da).
2. **TPSA:** Ligand A (42.01) is significantly better than Ligand B (102.34). Lower TPSA is preferred for GPCRs, aiding permeability.
3. **logP:** Ligand A (3.913) is within the optimal range, while Ligand B (-1.198) is too low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (0) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is better than Ligand B (6).
6. **QED:** Ligand A (0.75) is better than Ligand B (0.529), indicating a more drug-like profile.
7. **DILI:** Ligand A (4.343) is significantly better than Ligand B (10.818), indicating a lower risk of liver injury.
8. **BBB:** Ligand A (93.408) is much better than Ligand B (28.306). While not a CNS target, some degree of BBB penetration can be favorable.
9. **Caco-2:** Ligand A (-4.358) is better than Ligand B (-5.109), suggesting better absorption.
10. **Solubility:** Ligand A (-2.542) is better than Ligand B (-0.324).
11. **hERG:** Ligand A (0.91) is better than Ligand B (0.095), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand A (38.65) is much better than Ligand B (-15.042), indicating better metabolic stability.
13. **t1/2:** Ligand A (-7.742) is better than Ligand B (-0.257).
14. **Pgp:** Ligand A (0.279) is better than Ligand B (0.004), suggesting less efflux and better bioavailability.
15. **Affinity:** Ligand A (-6.1 kcal/mol) is slightly weaker than Ligand B (-6.6 kcal/mol). However, the substantial advantages of Ligand A in other key ADME properties outweigh this small difference in binding affinity.
**Conclusion:**
Ligand A demonstrates a significantly more favorable overall profile, particularly regarding TPSA, logP, DILI, metabolic stability, and Pgp efflux. While Ligand B has slightly better binding affinity, the ADME profile of Ligand A is far superior, making it a more promising drug candidate for the ADRB2 receptor.
**Output:**
1
2025-04-18 00:29:22,631 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [352.435, 109.74 , 1.202, 1. , 5. , 0.718, 27.879, 72.896, -5.16 , -1.444, 0.172, 36.075, 8.46 , 0.052, -6.4 ]
**Ligand B:** [349.391, 92.55 , -0.115, 1. , 9. , 0.805, 68.166, 61.225, -5.475, -2.196, 0.077, 1.005, 31.965, 0.033, -6.3 ]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity, and BBB):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (352.435) is slightly higher, but not concerning.
2. **TPSA:** Ligand A (109.74) is a bit higher than Ligand B (92.55). Both are acceptable for a non-CNS GPCR like ADRB2, but B is better.
3. **logP:** Ligand A (1.202) is within the optimal range. Ligand B (-0.115) is a bit low, potentially hindering permeability. This is a significant drawback for GPCRs.
4. **HBD/HBA:** Both have 1 HBD, which is good. Ligand B has 9 HBA, while Ligand A has 5. Both are acceptable, but A is slightly better.
5. **QED:** Both have good QED scores (A: 0.718, B: 0.805). B is slightly better here.
6. **DILI:** Ligand A (27.879) has a much lower DILI risk than Ligand B (68.166). This is a major advantage for A.
7. **BBB:** Ligand A (72.896) has better BBB penetration than Ligand B (61.225), though this isn't a primary concern for ADRB2.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability.
9. **Solubility:** Both have negative solubility values, which is also unusual and suggests poor solubility.
10. **hERG:** Both have very low hERG risk (A: 0.172, B: 0.077), which is excellent.
11. **Cl_mic:** Ligand B (1.005) has significantly lower microsomal clearance than Ligand A (36.075), indicating better metabolic stability. This is a substantial advantage for B.
12. **t1/2:** Ligand B (31.965) has a much longer in vitro half-life than Ligand A (8.46). This is a significant advantage for B.
13. **Pgp:** Both have low P-gp efflux liability (A: 0.052, B: 0.033), which is good.
14. **Affinity:** Both have comparable binding affinities (-6.4 and -6.3 kcal/mol). The difference is negligible.
**Overall Assessment:**
While Ligand B has advantages in metabolic stability (Cl_mic, t1/2) and QED, Ligand A is superior due to its better logP, significantly lower DILI risk, and better BBB penetration. The low logP of Ligand B is a concern for a GPCR target, potentially hindering its ability to reach the receptor. The DILI risk of Ligand B is also a significant concern. The Caco-2 and solubility values for both are concerning, but can be addressed in later optimization stages.
Therefore, I prefer Ligand A.
Output:
1
2025-04-18 00:29:22,631 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (364.5 and 351.4 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand B (78.95) is significantly better than Ligand A (97.11). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (2.566) is optimal, while Ligand B (0.241) is quite low. This is a major concern for Ligand B, as it may struggle with membrane permeability.
4. **HBD:** Ligand A (3) is acceptable, and Ligand B (1) is even better.
5. **HBA:** Ligand A (5) is acceptable, and Ligand B (4) is also good.
6. **QED:** Both ligands have good QED scores (0.66 and 0.787), indicating generally drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand B (29.236) has a much lower DILI risk than Ligand A (56.146). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (75.223) has better BBB penetration than Ligand B (68.748), but this isn't a primary concern for a cardiovascular target.
9. **Caco-2:** Ligand A (-5.291) is better than Ligand B (-4.57), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-3.427) is better than Ligand B (-2.271), which is a positive.
11. **hERG:** Both ligands have low hERG inhibition risk (0.546 and 0.106), which is good. Ligand B is better.
12. **Cl_mic:** Ligand B (17.126) has significantly lower microsomal clearance than Ligand A (31.3), suggesting better metabolic stability.
13. **t1/2:** Ligand B (10.591) has a much longer in vitro half-life than Ligand A (1.031). This is a substantial advantage.
14. **Pgp:** Ligand A (0.225) has lower P-gp efflux than Ligand B (0.021), which is better.
15. **Binding Affinity:** Ligand A (-6.6) has slightly better binding affinity than Ligand B (-6.4), but the difference is small (0.2 kcal/mol).
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has better affinity and Pgp, but Ligand B excels in logP, TPSA, DILI, Cl_mic, and t1/2. The low logP of Ligand B is a significant drawback, but its superior metabolic stability (Cl_mic and t1/2) and lower DILI risk are compelling. The slight affinity difference is unlikely to outweigh these ADME/Tox advantages.
**Conclusion:**
Considering the balance of properties, particularly the improved ADME/Tox profile of Ligand B, I believe it is the more promising drug candidate.
Output:
0
2025-04-18 00:29:22,631 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (341.419 and 370.494 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (78.66) is slightly higher than Ligand B (67.23). Both are below the 140 threshold for oral absorption, but closer to the 90 threshold for CNS targets (less relevant for ADRB2, a cardiovascular target). Ligand B is preferable here.
3. **logP:** Ligand B (1.86) is within the optimal 1-3 range, while Ligand A (0.037) is quite low. Low logP can hinder membrane permeability. Ligand B is significantly better.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 7 HBA, while Ligand B has 5. Both are acceptable (<=10), but Ligand B is slightly better.
6. **QED:** Both ligands have similar QED values (0.774 and 0.72), indicating good drug-likeness.
7. **DILI:** Ligand A (69.756) has a higher DILI risk than Ligand B (54.75). Lower is better, so Ligand B is preferable.
8. **BBB:** This is less critical for a cardiovascular target, but Ligand A (83.87) has a higher BBB penetration than Ligand B (66.537).
9. **Caco-2:** Ligand A (-4.969) and Ligand B (-5.013) have similar, very negative Caco-2 permeability values. This suggests poor intestinal absorption for both, which is concerning.
10. **Solubility:** Ligand A (-2.09) and Ligand B (-3.246) have similar, very negative solubility values. This is a major concern for both compounds.
11. **hERG:** Ligand A (0.581) has a higher hERG inhibition liability than Ligand B (0.291). Lower is better, so Ligand B is preferable.
12. **Cl_mic:** Ligand A (53.762) has a lower microsomal clearance than Ligand B (43.252), indicating better metabolic stability. Ligand A is preferable.
13. **t1/2:** Ligand B (-7.897) has a much longer in vitro half-life than Ligand A (4.097). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.055) has lower P-gp efflux liability than Ligand B (0.119). Lower is better, so Ligand A is preferable.
15. **Binding Affinity:** Ligand B (-5.8 kcal/mol) has a slightly better binding affinity than Ligand A (-6.6 kcal/mol). While Ligand A is better, the difference is not substantial enough to overcome other issues.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand B is the better candidate. While Ligand A has better metabolic stability (Cl_mic) and P-gp efflux, Ligand B has a much more favorable logP, lower DILI risk, and a longer half-life. The solubility and Caco-2 permeability are poor for both, but the other advantages of Ligand B outweigh the slight affinity difference.
Output:
0
2025-04-18 00:29:22,631 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [358.829, 69.04, 3.511, 1, 5, 0.757, 84.18, 49.593, -4.776, -3.63, 0.385, 74.528, 57.225, 0.384, -5.8]
**Ligand B:** [348.447, 78.67, 0.976, 1, 5, 0.745, 19.93, 42.187, -4.59, -0.648, 0.271, 25.779, -20.363, 0.082, -6.1]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (348.447) is slightly lower, which is generally favorable.
2. **TPSA:** Ligand A (69.04) is better than Ligand B (78.67). Both are acceptable for a non-CNS GPCR, but lower is preferred.
3. **logP:** Ligand A (3.511) is optimal, while Ligand B (0.976) is a bit low. A logP below 1 can hinder membrane permeability.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Both have 5 HBA, which is good.
6. **QED:** Both are very similar (0.757 vs 0.745) and above the 0.5 threshold, indicating good drug-likeness.
7. **DILI:** Ligand A (84.18) has a significantly higher DILI risk than Ligand B (19.93). This is a major concern for Ligand A.
8. **BBB:** Both are relatively low, which is fine for a cardiovascular target. Ligand A (49.593) is slightly higher than Ligand B (42.187), but neither is a priority here.
9. **Caco-2:** Both are negative, indicating poor permeability.
10. **Solubility:** Ligand B (-0.648) is better than Ligand A (-3.63).
11. **hERG:** Ligand A (0.385) is better than Ligand B (0.271), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand B (25.779) has significantly lower microsomal clearance than Ligand A (74.528), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-20.363) has a longer in vitro half-life than Ligand A (57.225), which is desirable.
14. **Pgp:** Ligand B (0.082) has lower P-gp efflux than Ligand A (0.384), which is favorable for bioavailability.
15. **Affinity:** Ligand B (-6.1) has a slightly better binding affinity than Ligand A (-5.8), but the difference is not substantial.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are important. Ligand B is better in terms of logP and Pgp. TPSA is only slightly better for Ligand A. Affinity is slightly better for Ligand B. However, the *major* deciding factor is the DILI risk. Ligand A's high DILI risk (84.18) is a significant red flag.
**Conclusion:**
Considering the balance of properties and the critical importance of minimizing toxicity, Ligand B is the more promising candidate. Its lower DILI risk, better metabolic stability (lower Cl_mic, longer t1/2), and improved Pgp profile outweigh the slightly better TPSA and hERG of Ligand A.
Output:
0
2025-04-18 00:29:22,631 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (349.431 & 368.543 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (78.95) is higher than Ligand B (67.43). Both are below 140, but B is better for absorption.
3. **logP:** Ligand A (0.45) is quite low, potentially hindering permeability. Ligand B (2.49) is within the optimal 1-3 range. This is a significant advantage for B.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2), but both are acceptable.
5. **HBA:** Both ligands have 4 HBA, which is good.
6. **QED:** Ligand A (0.748) has a slightly better QED score than Ligand B (0.646), indicating better overall drug-likeness.
7. **DILI:** Ligand A (31.097) has a slightly higher DILI risk than Ligand B (26.25), but both are well below the concerning threshold of 60.
8. **BBB:** Ligand B (74.758) has a higher BBB penetration percentile than Ligand A (66.615). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant for off-target effects, and higher BBB is generally favorable.
9. **Caco-2:** Ligand B (-5.128) has a better Caco-2 permeability than Ligand A (-4.761), suggesting better intestinal absorption.
10. **Solubility:** Ligand B (-3.171) has better aqueous solubility than Ligand A (-2.007).
11. **hERG:** Ligand A (0.124) has a lower hERG inhibition liability than Ligand B (0.463), which is a significant safety advantage.
12. **Cl_mic:** Ligand A (3.491) has a much lower microsomal clearance than Ligand B (67.284), indicating better metabolic stability. This is a major advantage for A.
13. **t1/2:** Ligand B (19.55) has a longer in vitro half-life than Ligand A (-13.744). This is a significant advantage for B.
14. **Pgp:** Ligand A (0.027) has a much lower P-gp efflux liability than Ligand B (0.145), which is favorable.
15. **Affinity:** Both ligands have very similar binding affinities (-6.6 kcal/mol and -6.0 kcal/mol respectively). The difference is not substantial enough to be decisive.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP, Caco-2 permeability, solubility, and BBB penetration. Ligand A has a better hERG profile and lower Pgp efflux. Metabolic stability (Cl_mic) is also important, and Ligand A is significantly better in this regard.
**Overall Assessment:**
While Ligand B has advantages in permeability and half-life, the combination of Ligand A's superior metabolic stability (lower Cl_mic), lower hERG risk, and lower P-gp efflux makes it the more promising candidate. The slightly lower logP of Ligand A is a concern, but the other advantages outweigh this drawback.
Output:
1
2025-04-18 00:29:22,631 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (337.383 Da) is better than Ligand B (388.599 Da). Both are within the ideal range, but A is closer to the lower, preferred end.
2. **TPSA:** Ligand B (58.64) is significantly better than Ligand A (85.84). ADRB2 is not a CNS target, but lower TPSA generally improves absorption.
3. **logP:** Both ligands are excellent (A: 2.504, B: 2.251) and fall within the optimal 1-3 range.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand B (5) is slightly better than Ligand A (6). Both are acceptable, but lower is preferable.
6. **QED:** Ligand A (0.747) is better than Ligand B (0.622), indicating a more drug-like profile.
7. **DILI:** Ligand B (29.469) is *much* better than Ligand A (69.058). This is a significant advantage for B.
8. **BBB:** Both are good (A: 74.641, B: 71.966), but not critical for a non-CNS target like ADRB2.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-5.16) is slightly worse than Ligand B (-4.904).
10. **Solubility:** Both are negative, indicating poor solubility. Ligand A (-3.244) is slightly worse than Ligand B (-3.598).
11. **hERG:** Ligand A (0.116) is better than Ligand B (0.432). Lower hERG inhibition is crucial for cardiovascular safety.
12. **Cl_mic:** Ligand A (19.501) is significantly better than Ligand B (67.354). Lower clearance indicates better metabolic stability.
13. **t1/2:** Ligand B (-5.771) is better than Ligand A (6.018). A negative value suggests a very long half-life, which is desirable.
14. **Pgp:** Ligand A (0.078) is better than Ligand B (0.16). Lower P-gp efflux is preferable.
15. **Binding Affinity:** Ligand A (-6.4) is slightly better than Ligand B (-5.2). A difference of 1.2 kcal/mol is substantial.
**Overall Assessment:**
While Ligand B has a significantly better DILI score and a longer half-life, Ligand A has a better QED, lower Cl_mic, lower Pgp efflux, and a slightly better binding affinity. The lower metabolic clearance and Pgp efflux of Ligand A are important for achieving adequate exposure. The binding affinity difference is also substantial. The DILI risk of Ligand A is concerning, but the better overall ADME profile and affinity outweigh this risk, especially considering that DILI risk can be further mitigated during lead optimization.
Output:
1
2025-04-18 00:29:22,631 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (345.403 and 347.415 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (82.78) is better than Ligand B (99.5). For a GPCR, keeping TPSA under 140 is good, and lower is generally preferred for better permeability. Ligand B is getting closer to the upper limit.
**3. logP:** Ligand B (0.844) is slightly better than Ligand A (-0.14). While both are within the acceptable range (1-3), a slightly positive logP is generally preferred for better membrane permeability. Ligand A's negative logP could indicate potential issues with absorption.
**4. H-Bond Donors:** Ligand A (0) is preferable to Ligand B (1). Fewer H-bond donors generally improve permeability.
**5. H-Bond Acceptors:** Both ligands have a similar number of H-bond acceptors (6 and 5 respectively), and are within the acceptable limit of 10.
**6. QED:** Ligand B (0.718) has a slightly better QED score than Ligand A (0.52), indicating a more drug-like profile.
**7. DILI:** Ligand B (30.71) has a significantly lower DILI risk than Ligand A (38.116). This is a crucial advantage, as minimizing liver toxicity is paramount.
**8. BBB:** Both ligands have similar BBB penetration (59.636 and 59.364). While not exceptionally high, it's not a primary concern for ADRB2, which isn't a CNS target.
**9. Caco-2 Permeability:** Both ligands have similar, poor Caco-2 permeability (-4.541 and -4.696). This is a potential concern for oral bioavailability.
**10. Aqueous Solubility:** Ligand A (-0.681) is better than Ligand B (-2.148). Better solubility is generally preferred for formulation and bioavailability.
**11. hERG Inhibition:** Ligand A (0.025) has a much lower hERG risk than Ligand B (0.364). This is a significant advantage, as hERG inhibition can lead to cardiotoxicity.
**12. Microsomal Clearance:** Ligand A (6.737) has a lower microsomal clearance than Ligand B (29.684), indicating better metabolic stability.
**13. In vitro Half-Life:** Ligand A (-25.846) has a much longer in vitro half-life than Ligand B (2.485). This is a significant advantage, potentially allowing for less frequent dosing.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux (0.02 and 0.05).
**15. Binding Affinity:** Ligand B (-6.8 kcal/mol) has a slightly better binding affinity than Ligand A (-5.7 kcal/mol). This is a 1.1 kcal/mol difference, which is substantial and could outweigh some of the ADME drawbacks.
**Overall Assessment:**
While Ligand B has a better binding affinity and QED, Ligand A demonstrates a significantly better safety profile (lower DILI and hERG risk), better metabolic stability (lower Cl_mic, longer t1/2), and better solubility. Considering ADRB2 is a cardiovascular target, minimizing cardiotoxicity (hERG) and maximizing metabolic stability are crucial. The slightly weaker binding affinity of Ligand A can potentially be optimized in subsequent iterations. The poor Caco-2 permeability is a concern for both, but can be addressed with formulation strategies.
Therefore, I prefer Ligand A.
Output:
1
2025-04-18 00:29:22,631 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (356.438 Da and 353.463 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Both ligands have similar TPSA values (78.87 and 78.95). These are acceptable for a non-CNS GPCR target like ADRB2, being below the 140 A^2 threshold.
**3. logP:** Both ligands have good logP values (1.018 and 0.777), falling within the optimal 1-3 range. Ligand B is slightly lower, which could marginally improve solubility, but both are good.
**4. H-Bond Donors & Acceptors:** Ligand A has 2 HBD and 4 HBA, while Ligand B has 1 HBD and 5 HBA. Both are within acceptable limits (<=5 HBD and <=10 HBA).
**5. QED:** Ligand A (0.771) has a slightly better QED score than Ligand B (0.652), indicating a more drug-like profile.
**6. DILI Risk:** Ligand A (21.598 percentile) has a significantly lower DILI risk than Ligand B (6.049 percentile). This is a major advantage for Ligand A.
**7. BBB Penetration:** Both ligands have relatively low BBB penetration (62.97% and 71.772%). This isn't a major concern for a cardiovascular target like ADRB2. Ligand B is slightly better.
**8. Caco-2 Permeability:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.817) is slightly better than Ligand B (-4.991).
**9. Aqueous Solubility:** Both ligands have negative solubility values, suggesting very poor aqueous solubility. Ligand B (-0.705) is slightly better than Ligand A (-1.239).
**10. hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.28 and 0.234). This is excellent.
**11. Microsomal Clearance:** Ligand A (-15.197) has a much lower (better) microsomal clearance than Ligand B (6.126). This indicates greater metabolic stability for Ligand A.
**12. In vitro Half-Life:** Ligand A (14.875 hours) has a significantly longer half-life than Ligand B (-22.249 hours). This is a substantial advantage for Ligand A, potentially allowing for less frequent dosing.
**13. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.043 and 0.006). This is good.
**14. Binding Affinity:** Ligand B (-7.7 kcal/mol) has a slightly better binding affinity than Ligand A (-6.6 kcal/mol). This is a 1.1 kcal/mol difference, which is significant.
**Overall Assessment:**
While Ligand B has a slightly better binding affinity, Ligand A demonstrates a significantly superior ADME-Tox profile. The lower DILI risk, better metabolic stability (lower Cl_mic), and longer half-life are crucial advantages for a drug candidate. The solubility and permeability are poor for both, but these can be addressed through formulation strategies. Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), the improved safety and pharmacokinetic properties of Ligand A outweigh the slightly better affinity of Ligand B.
Output:
1
2025-04-18 00:29:22,631 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands (349.406 and 347.459 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (80.32) is better than Ligand B (84.23). Both are below 140, but lower TPSA generally favors absorption.
3. **logP:** Both ligands (2.386 and 2.68) are within the optimal 1-3 range. Ligand B is slightly higher, which could be a minor concern for off-target effects, but not a major issue.
4. **HBD:** Both ligands have 2 HBD, which is well within the acceptable limit of 5.
5. **HBA:** Both ligands have 4 HBA, also well within the acceptable limit of 10.
6. **QED:** Both ligands have high QED scores (0.818 and 0.858), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (41.838) has a significantly lower DILI risk than Ligand B (53.47). This is a crucial advantage, as minimizing liver toxicity is paramount.
8. **BBB:** Ligand A (83.288) has a much higher BBB penetration percentile than Ligand B (69.988). For a GPCR, even a non-CNS one like ADRB2, some BBB penetration can be useful for distribution and off-target profiling.
9. **Caco-2:** Ligand A (-4.303) and Ligand B (-4.804) both have negative Caco-2 values, which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand A (-3.264) is slightly better than Ligand B (-3.727), but both are poor. Solubility is a concern for both.
11. **hERG:** Ligand A (0.174) has a lower hERG inhibition liability than Ligand B (0.339), which is a positive.
12. **Cl_mic:** Ligand A (47.906) and Ligand B (46.656) are very similar in terms of microsomal clearance.
13. **t1/2:** Ligand A (-18.334) has a significantly *worse* in vitro half-life than Ligand B (4.674). This is a major drawback for Ligand A.
14. **Pgp:** Ligand A (0.033) has a much lower P-gp efflux liability than Ligand B (0.348). This is a significant advantage for Ligand A, as it suggests better bioavailability.
15. **Binding Affinity:** Ligand B (-6.6 kcal/mol) has a slightly better binding affinity than Ligand A (-7.7 kcal/mol). While Ligand A has a better affinity, the difference is not substantial enough to outweigh other factors.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has better TPSA and Pgp, while Ligand B has slightly better logP and affinity. However, the DILI and BBB scores of Ligand A are significantly better, and the half-life of Ligand B is much better.
**Overall Assessment:**
While Ligand B has a slightly better binding affinity and half-life, Ligand A is the preferable candidate due to its significantly lower DILI risk, better BBB penetration, and lower P-gp efflux. The poor Caco-2 and solubility are concerns for both, but can be addressed with formulation strategies. The lower DILI risk is a critical advantage in early drug development.
Output:
1
2025-04-18 00:29:22,631 - INFO - Batch 481 complete. Total preferences: 7696
2025-04-18 00:29:22,632 - INFO - Processing batch 482/512...
2025-04-18 00:30:10,997 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [342.355, 100.46 , 0.683, 2. , 5. , 0.721, 68.903, 32.61 , -5.152, -3.047, 0.125, -1.077, 2.588, 0.011, -5.9 ]
**Ligand B:** [361.389, 112.73 , 0.177, 3. , 4. , 0.535, 34.82 , 57.076, -5.228, -2.163, 0.31 , 17.033, -17.592, 0.042, -8.3 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (342.355) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (100.46) is better than Ligand B (112.73), being closer to the <140 threshold for good absorption.
3. **logP:** Ligand A (0.683) is closer to the optimal 1-3 range than Ligand B (0.177), which is quite low and could hinder membrane permeability.
4. **HBD:** Ligand A (2) is preferable to Ligand B (3), keeping HBD count lower.
5. **HBA:** Ligand A (5) is preferable to Ligand B (4), keeping HBA count lower.
6. **QED:** Ligand A (0.721) is better than Ligand B (0.535), indicating a more drug-like profile.
7. **DILI:** Ligand B (34.82) has a significantly lower DILI risk than Ligand A (68.903), which is a major advantage.
8. **BBB:** Ligand B (57.076) has a better BBB penetration score than Ligand A (32.61), although neither is particularly high. For a cardiovascular target, BBB isn't *critical*, but some penetration could be beneficial for off-target effects.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. Ligand A (-5.152) is slightly better than Ligand B (-5.228).
10. **Solubility:** Both have negative solubility values, indicating poor solubility. Ligand A (-3.047) is slightly better than Ligand B (-2.163).
11. **hERG:** Ligand A (0.125) has a lower hERG risk than Ligand B (0.31).
12. **Cl_mic:** Ligand A (-1.077) has a lower (better) microsomal clearance than Ligand B (17.033), suggesting better metabolic stability.
13. **t1/2:** Ligand A (2.588) has a better in vitro half-life than Ligand B (-17.592).
14. **Pgp:** Ligand A (0.011) has a lower Pgp efflux liability than Ligand B (0.042).
15. **Affinity:** Ligand B (-8.3) has a significantly stronger binding affinity than Ligand A (-5.9). This is a substantial advantage, exceeding the 1.5 kcal/mol threshold.
**GPCR-specific priorities:** For ADRB2 (a GPCR), we prioritize logP, Pgp, TPSA, and affinity. Ligand B excels in affinity, and while its logP is low, the substantial binding advantage outweighs this drawback. Ligand A has better TPSA and Pgp, but the affinity difference is too large to ignore. The DILI score of Ligand B is also significantly better.
**Conclusion:**
Despite Ligand A having slightly better ADME properties in some areas, the significantly stronger binding affinity of Ligand B (-8.3 vs -5.9 kcal/mol) and lower DILI risk make it the more promising drug candidate.
0
2025-04-18 00:30:10,997 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (363.443 and 348.447 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (67.67) is significantly better than Ligand A (94.64). ADRB2 is not a CNS target, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (1.416) is within the optimal 1-3 range, while Ligand A (0.28) is quite low, potentially hindering membrane permeability. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (0), but both are acceptable.
5. **HBA:** Ligand A (6) is higher than Ligand B (5), but both are within the acceptable range of <=10.
6. **QED:** Ligand A (0.804) has a better QED score than Ligand B (0.526), indicating a more drug-like profile. This is a positive for Ligand A.
7. **DILI:** Ligand B (23.226) has a much lower DILI risk than Ligand A (65.917). This is a substantial advantage for Ligand B.
8. **BBB:** Not a primary concern for ADRB2, but Ligand B (78.519) is higher than Ligand A (54.517).
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-5.018) is slightly worse than Ligand B (-4.712).
10. **Solubility:** Ligand B (-0.933) is better than Ligand A (-3.158).
11. **hERG:** Ligand A (0.145) has a lower hERG risk than Ligand B (0.362), which is favorable.
12. **Cl_mic:** Ligand A (5.593) has a significantly lower microsomal clearance than Ligand B (19.847), indicating better metabolic stability. This is a strong advantage for Ligand A.
13. **t1/2:** Ligand B (7.513) has a longer in vitro half-life than Ligand A (-1.436). This is a positive for Ligand B.
14. **Pgp:** Ligand A (0.031) has lower P-gp efflux than Ligand B (0.096), which is favorable.
15. **Binding Affinity:** Ligand B (-7.6) has a significantly stronger binding affinity than Ligand A (-5.5). This is a major advantage for Ligand B, potentially outweighing some ADME concerns.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP, TPSA, and *significantly* in binding affinity. While Ligand A has better QED, Cl_mic, Pgp, and hERG, the substantial advantage in binding affinity and the better overall ADME profile (lower DILI, better solubility) of Ligand B are more critical. The lower logP of Ligand A is a significant drawback.
**Conclusion:**
Despite Ligand A's advantages in QED, metabolic stability, and safety (hERG, Pgp), Ligand B's superior binding affinity, better logP, lower DILI risk, and acceptable solubility make it the more promising drug candidate for ADRB2.
Output:
0
2025-04-18 00:30:10,997 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Ligand A (341.382 Da) is well within the ideal range (200-500 Da). Ligand B (393.491 Da) is also acceptable, though approaching the upper limit.
2. **TPSA:** Ligand A (47.56) is excellent, well below the 140 threshold for oral absorption. Ligand B (134.93) is still reasonable, but higher and potentially impacting absorption.
3. **logP:** Ligand A (3.332) is optimal. Ligand B (-1.208) is significantly lower, which is a concern for membrane permeability and bioavailability.
4. **HBD:** Ligand A (1) is good. Ligand B (2) is acceptable.
5. **HBA:** Ligand A (3) is good. Ligand B (7) is higher, potentially impacting permeability.
6. **QED:** Ligand A (0.931) is excellent, indicating high drug-likeness. Ligand B (0.479) is below the desirable 0.5 threshold, raising concerns.
7. **DILI:** Both Ligand A (53.276) and Ligand B (52.036) have similar, acceptable DILI risk.
8. **BBB:** Ligand A (78.209) is good, indicating reasonable potential for CNS penetration (though ADRB2 is primarily cardiovascular, some CNS off-target effects are possible). Ligand B (53.044) is lower.
9. **Caco-2:** Ligand A (-4.684) is poor. Ligand B (-5.574) is also poor. Both are negative, indicating very low permeability.
10. **Solubility:** Ligand A (-4.072) is poor. Ligand B (-1.047) is slightly better, but still poor.
11. **hERG:** Ligand A (0.739) is good, low risk. Ligand B (0.185) is very good, even lower risk.
12. **Cl_mic:** Ligand A (65.907) is moderate. Ligand B (32.658) is lower, indicating better metabolic stability.
13. **t1/2:** Ligand A (21.352) is reasonable. Ligand B (-1.968) is very poor, suggesting rapid metabolism.
14. **Pgp:** Ligand A (0.617) is moderate. Ligand B (0.012) is very low, suggesting minimal P-gp efflux.
15. **Affinity:** Ligand A (-7.1) is slightly better than Ligand B (-6.6), but both are strong binders. The 1.5 kcal/mol difference is not overwhelming.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are crucial. Ligand A has a much better logP and TPSA, and a slightly better affinity. Ligand B has a better Pgp profile, but the poor logP and QED are significant drawbacks. The poor Caco-2 and solubility for both are concerning, but the overall profile of Ligand A is more promising.
**Conclusion:**
Despite the poor Caco-2 and solubility for both, Ligand A's superior logP, TPSA, QED, and slightly better affinity make it the more viable candidate. The lower metabolic stability of Ligand B (higher Cl_mic, very short half-life) is also a significant concern.
Output:
1
2025-04-18 00:30:10,998 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (347.459 Da) is within the ideal range, while Ligand B (399.647 Da) is approaching the upper limit. Both are acceptable.
2. **TPSA:** Ligand A (84.66) is good for oral absorption, while Ligand B (29.54) is excellent. This favors Ligand B.
3. **logP:** Ligand A (2.775) is optimal. Ligand B (4.652) is slightly high, potentially leading to solubility issues and off-target effects, but not critically so.
4. **HBD:** Ligand A (2) and Ligand B (0) are both acceptable.
5. **HBA:** Ligand A (5) and Ligand B (5) are both acceptable.
6. **QED:** Ligand A (0.741) is better than Ligand B (0.604), indicating a more drug-like profile.
7. **DILI:** Ligand A (46.413) has a moderate risk, while Ligand B (21.908) has a very low risk. This strongly favors Ligand B.
8. **BBB:** Both Ligand A (81.776) and Ligand B (84.374) have good BBB penetration. This is less critical for ADRB2 (a cardiovascular target) but still a positive.
9. **Caco-2:** Ligand A (-4.523) and Ligand B (-5.116) both suggest poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-3.508) and Ligand B (-4.384) both indicate poor aqueous solubility. This is a significant drawback for both.
11. **hERG:** Both Ligand A (0.7) and Ligand B (0.7) have similar hERG inhibition liability, which is acceptable.
12. **Cl_mic:** Ligand A (80.897) has better metabolic stability (lower clearance) than Ligand B (109.837). This favors Ligand A.
13. **t1/2:** Ligand A (-6.328) has a longer half-life than Ligand B (2.488). This favors Ligand A.
14. **Pgp:** Both Ligand A (0.187) and Ligand B (0.633) have low P-gp efflux, which is good.
15. **Affinity:** Ligand A (-7.0) has a slightly better binding affinity than Ligand B (-6.2). This difference is significant (0.8 kcal/mol).
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B has a better TPSA, while Ligand A has a better logP, Pgp, and significantly better affinity. The DILI score of Ligand B is also much better. The metabolic stability and half-life are better for Ligand A.
**Overall Assessment:**
While Ligand A has a slight edge in binding affinity and metabolic stability, the significantly lower DILI risk for Ligand B is a major advantage. The TPSA of Ligand B is also more favorable. The solubility and Caco-2 permeability are poor for both, which would require formulation strategies. However, the lower toxicity profile of Ligand B makes it the more promising candidate. The 0.8 kcal/mol difference in binding affinity can likely be overcome with further optimization of Ligand B.
Output:
0
2025-04-18 00:30:10,998 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (354.397 Da) is slightly lower, which is generally favorable for permeability.
**2. TPSA:** Ligand A (49.85) is significantly better than Ligand B (114.18). For a GPCR, keeping TPSA low is beneficial for permeability and receptor engagement. Ligand B is quite high, potentially hindering oral absorption.
**3. logP:** Ligand A (2.122) is optimal, while Ligand B (0.469) is a bit low. A logP between 1-3 is preferred for good balance of solubility and permeability. Ligand B's low logP could lead to poor membrane permeability.
**4. H-Bond Donors:** Ligand A (0) is preferable to Ligand B (2). Fewer H-bond donors generally improve membrane permeability.
**5. H-Bond Acceptors:** Ligand A (3) is better than Ligand B (7). Similar to HBDs, fewer HBAs are generally preferred.
**6. QED:** Both ligands have acceptable QED values (A: 0.754, B: 0.644), indicating reasonable drug-likeness.
**7. DILI:** Ligand A (23.536) has a much lower DILI risk than Ligand B (57.58), which is a significant advantage.
**8. BBB:** Ligand A (96.006) shows excellent BBB penetration, while Ligand B (61.535) is lower. While ADRB2 isn't strictly a CNS target, some CNS exposure can occur, and higher BBB penetration is generally not detrimental.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
**10. Aqueous Solubility:** Both ligands have similar, very poor aqueous solubility (-2.091 and -2.074). This is a concern for both, but formulation strategies could potentially address it.
**11. hERG Inhibition:** Ligand A (0.744) has a slightly higher hERG risk than Ligand B (0.072), but both are relatively low.
**12. Microsomal Clearance:** Ligand B (-6.287) has a significantly lower (better) microsomal clearance than Ligand A (7.409), indicating greater metabolic stability.
**13. In vitro Half-Life:** Ligand B (-8.055) has a much longer in vitro half-life than Ligand A (5.936), which is a major advantage.
**14. P-gp Efflux:** Ligand A (0.098) has lower P-gp efflux than Ligand B (0.057), which is preferable.
**15. Binding Affinity:** Both ligands have very similar and strong binding affinities (-5.0 and -6.2 kcal/mol). The difference is not substantial enough to outweigh the other ADME differences.
**Overall Assessment:**
Ligand A is superior due to its significantly better TPSA, logP, DILI risk, and BBB penetration. While Ligand B has better metabolic stability and half-life, the permeability issues indicated by TPSA and logP, combined with the higher DILI risk, make it a less attractive candidate. The slightly higher hERG risk of Ligand A is less concerning given the overall profile.
Output:
1
2025-04-18 00:30:10,998 - INFO - Here's my reasoning and final output for the ligand preference:
**Reasoning:**
We are looking for a viable drug candidate for the ADRB2, a cardiovascular GPCR. Therefore, we prioritize logP, TPSA, Pgp, and binding affinity, alongside general drug-like properties.
Let's break down the comparison:
1. **MW:** Both ligands are within the ideal range (355.395 Da and 357.514 Da).
2. **TPSA:** Ligand B (52.65) is significantly better than Ligand A (124.44). Lower TPSA generally correlates with better cell permeability, crucial for GPCR targeting.
3. **logP:** Ligand B (2.456) is optimal, while Ligand A (0.342) is quite low, potentially hindering membrane permeability.
4. **HBD/HBA:** Ligand B has fewer HBD/HBA (1/3) compared to Ligand A (2/8), which is generally favorable for permeability.
5. **QED:** Both ligands have good QED scores (0.676 and 0.761).
6. **DILI:** Both have low DILI risk (49.011 and 8.492), which is excellent. Ligand B is slightly better.
7. **BBB:** Ligand B (86.08) has a much higher BBB percentile than Ligand A (61.923). While ADRB2 is cardiovascular, some CNS penetration might be acceptable or even desirable for off-target effects monitoring.
8. **Caco-2:** Both are negative, indicating poor permeability.
9. **Solubility:** Both are negative, indicating poor solubility.
10. **hERG:** Ligand A (0.036) has a slightly lower hERG risk than Ligand B (0.721), which is good.
11. **Cl_mic:** Ligand B (-8.146) has much lower (better) microsomal clearance than Ligand A (71.401), indicating better metabolic stability.
12. **t1/2:** Ligand B (-4.699) has a better (more negative) in vitro half-life than Ligand A (-10.267).
13. **Pgp:** Ligand A (0.011) has a much lower Pgp efflux liability than Ligand B (0.124), which is favorable for bioavailability.
14. **Binding Affinity:** Both ligands have the same binding affinity (-5.8 kcal/mol).
**Overall Assessment:**
Despite Ligand A having a slightly better hERG profile and Pgp efflux, Ligand B is significantly superior in terms of TPSA, logP, BBB penetration, metabolic stability (Cl_mic), and in vitro half-life. The lower TPSA and optimal logP of Ligand B are particularly important for a GPCR target, suggesting better cell permeability and receptor engagement. The improved metabolic stability is also a major advantage. The slightly higher Pgp efflux and hERG risk of Ligand B are less concerning given the other benefits.
**Output:**
0
2025-04-18 00:30:10,998 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (347.419) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (95.5) is better than Ligand A (112.04), being closer to the preferred <140 for oral absorption.
3. **logP:** Both are within the optimal 1-3 range. Ligand B (0.967) is slightly lower, while Ligand A (0.735) is a bit lower still.
4. **HBD:** Ligand A (4) is higher than Ligand B (1), but both are acceptable.
5. **HBA:** Both ligands have 5 HBA, which is within the acceptable range.
6. **QED:** Ligand B (0.699) has a slightly better QED score than Ligand A (0.564), indicating a more drug-like profile.
7. **DILI:** Both ligands have DILI risk around the 50-60 percentile, which is acceptable, but Ligand B (56.495) is slightly higher than Ligand A (50.33).
8. **BBB:** Ligand B (49.011) is significantly higher than Ligand A (15.82). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be beneficial for distribution.
9. **Caco-2:** Both have negative values, indicating poor permeability. Ligand A (-5.573) is slightly better than Ligand B (-5.014).
10. **Solubility:** Ligand A (-2.388) is slightly better than Ligand B (-1.276).
11. **hERG:** Both ligands have low hERG risk (0.315 and 0.134, respectively), which is excellent.
12. **Cl_mic:** Ligand A (-3.118) has a significantly lower (better) microsomal clearance than Ligand B (42.183), suggesting better metabolic stability.
13. **t1/2:** Ligand A (35.982) has a longer in vitro half-life than Ligand B (26.895), which is desirable.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.061 and 0.015, respectively), which is good.
15. **Binding Affinity:** Ligand B (-7.1) has a substantially stronger binding affinity than Ligand A (-4.8). This is a significant advantage, potentially outweighing some ADME drawbacks.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, affinity, logP, TPSA, and Pgp are key. Ligand B excels in affinity, and has a better TPSA. While Ligand A has a slightly better logP, the difference isn't substantial. Ligand A has better metabolic stability (Cl_mic and t1/2) and solubility, but the affinity difference is too large to ignore.
**Conclusion:**
Despite Ligand A's advantages in metabolic stability and solubility, the significantly stronger binding affinity of Ligand B (-7.1 vs -4.8 kcal/mol) is the deciding factor. A 2.3 kcal/mol difference in binding affinity is substantial and likely to translate to greater efficacy.
Output:
0
2025-04-18 00:30:10,998 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (389.901 Da and 352.41 Da) fall within the ideal 200-500 Da range. Ligand B is slightly preferred due to its lower MW.
**2. TPSA:** Both ligands have TPSA values (80.75 and 76.46) below the 140 A^2 threshold for good oral absorption, and are acceptable for a cardiovascular target (not requiring significant BBB penetration). Ligand B is slightly better.
**3. logP:** Ligand A (2.936) is within the optimal 1-3 range. Ligand B (0.507) is below 1, which could hinder permeation. This is a significant drawback for Ligand B.
**4. H-Bond Donors:** Both have acceptable HBD counts (0 for A, 1 for B), well below the 5 threshold.
**5. H-Bond Acceptors:** Both have acceptable HBA counts (5 for both), below the 10 threshold.
**6. QED:** Both ligands have good QED scores (0.723 and 0.838), indicating good drug-like properties. Ligand B is slightly better.
**7. DILI Risk:** Ligand A (66.615) has a higher DILI risk than Ligand B (42.536). This favors Ligand B.
**8. BBB Penetration:** While not a primary concern for a cardiovascular target, Ligand B (87.631) shows better BBB penetration than Ligand A (56.34).
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand B (-4.915) is slightly better than Ligand A (-4.376).
**10. Aqueous Solubility:** Both ligands have negative solubility values, indicating poor solubility. Ligand B (-1.228) is slightly better than Ligand A (-2.964).
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.123 and 0.143).
**12. Microsomal Clearance:** Ligand A (67.392) has higher microsomal clearance than Ligand B (5.736), indicating lower metabolic stability. This favors Ligand B.
**13. In vitro Half-Life:** Ligand A (76.498) has a significantly longer half-life than Ligand B (5.045). This is a strong advantage for Ligand A.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.232 and 0.015).
**15. Binding Affinity:** Ligand B (-7.7 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.2 kcal/mol). This is a substantial advantage, potentially outweighing some ADME concerns.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand B is the stronger candidate. While its logP is low, its significantly improved binding affinity (-7.7 vs -5.2 kcal/mol) is a major advantage. It also exhibits lower DILI risk and better metabolic stability (lower Cl_mic). The longer half-life of Ligand A is appealing, but the substantial affinity difference makes Ligand B the more promising starting point for optimization.
Output:
0
2025-04-18 00:30:10,999 - INFO - Reasoning:
Let's analyze Ligand A and Ligand B for their potential as ADRB2 ligands, keeping in mind GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key).
**Molecular Weight:** Both ligands (354.353 and 349.45 Da) fall within the ideal 200-500 Da range.
**TPSA:** Ligand A (76.66) is higher than Ligand B (52.65). While both are reasonably good, Ligand B is preferable as lower TPSA generally correlates with better membrane permeability for GPCRs.
**logP:** Ligand A (2.161) and Ligand B (1.348) are both within the optimal 1-3 range. Ligand A is slightly better.
**H-Bond Donors/Acceptors:** Ligand A has 2 HBD and 4 HBA, while Ligand B has 1 HBD and 3 HBA. Both are within acceptable limits (<=5 HBD and <=10 HBA).
**QED:** Ligand B (0.737) has a higher QED score than Ligand A (0.405), indicating a more drug-like profile.
**DILI:** Ligand B (11.439) has a significantly lower DILI risk than Ligand A (58.046). This is a major advantage for Ligand B.
**BBB:** Ligand B (90.074) shows better BBB penetration potential than Ligand A (82.513), which is important for GPCRs, even if this is a peripheral target.
**Caco-2 Permeability:** Both have negative Caco-2 values, which is unusual and suggests a potential issue with the data or modeling. However, the values are similar (-4.719 vs -4.907).
**Aqueous Solubility:** Ligand B (-1.797) is better than Ligand A (-3.886).
**hERG Inhibition:** Both ligands have similar, low hERG inhibition liabilities (0.56 and 0.59).
**Microsomal Clearance:** Ligand B (3.124) has significantly lower microsomal clearance than Ligand A (67.29), indicating better metabolic stability.
**In vitro Half-Life:** Ligand B (7.181) has a longer in vitro half-life than Ligand A (-9.806).
**P-gp Efflux:** Ligand B (0.054) has much lower P-gp efflux liability than Ligand A (0.25), which is favorable for bioavailability and potentially CNS exposure.
**Binding Affinity:** Ligand B (-7.8 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.7 kcal/mol). This 1.1 kcal/mol difference is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand B consistently outperforms Ligand A in most critical ADME properties (DILI, BBB, solubility, metabolic stability, P-gp efflux) and crucially, has a significantly higher binding affinity. While Ligand A has a slightly better logP, the advantages of Ligand B are far more compelling, especially considering the GPCR target class.
Output:
0
2025-04-18 00:30:10,999 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands (338.37 & 351.40 Da) fall within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (90.45) is slightly higher than Ligand B (70.23). Both are acceptable, but B is better, especially for a GPCR where some CNS penetration might be desirable.
3. **logP:** Both ligands have good logP values (2.07 & 2.77) within the 1-3 range.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3) as lower HBD generally improves permeability.
5. **HBA:** Ligand A (6) is higher than Ligand B (2). Ligand B is better here.
6. **QED:** Both ligands have similar, good QED scores (0.736 & 0.73).
7. **DILI:** Ligand B (60.68) is significantly better than Ligand A (89.10) regarding DILI risk. This is a major advantage for B.
8. **BBB:** Ligand B (81.47) is better than Ligand A (77.98). While ADRB2 isn't exclusively a CNS target, some degree of BBB penetration can be beneficial for distribution.
9. **Caco-2:** Both have negative Caco-2 values (-4.604 & -4.708), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Both have negative solubility values (-3.36 & -4.274), indicating very poor aqueous solubility. This is a major drawback for both.
11. **hERG:** Both ligands have low hERG risk (0.323 & 0.322).
12. **Cl_mic:** Ligand A (81.05) has a higher (worse) microsomal clearance than Ligand B (23.18). B is preferable for metabolic stability.
13. **t1/2:** Ligand A (21 hours) has a much longer in vitro half-life than Ligand B (6.66 hours). This is a significant advantage for A.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.094 & 0.104).
15. **Binding Affinity:** Ligand A (-7.2 kcal/mol) has a stronger binding affinity than Ligand B (-6.4 kcal/mol). This is a substantial advantage for A.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. While both ligands have acceptable logP and Pgp profiles, Ligand A has a significantly better binding affinity. The lower TPSA of Ligand B is favorable, but the substantial difference in affinity outweighs this. The DILI and Cl_mic values of Ligand B are also very attractive. However, the longer half-life of Ligand A is a significant benefit. The solubility and Caco-2 values are problematic for both, and would need to be addressed through formulation or further chemical modification.
**Overall Assessment:**
Despite the poor solubility and permeability indicated by Caco-2 and solubility values, the superior binding affinity of Ligand A, coupled with its longer half-life, makes it the more promising candidate. The lower DILI risk and better metabolic stability of Ligand B are attractive, but the potency advantage of A is more critical for a GPCR target.
Output:
1
2025-04-18 00:30:10,999 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [346.519, 48.47, 3.265, 1, 3, 0.707, 5.777, 84.8, -4.611, -0.872, 0.809, 22.676, 74.493, 0.022, -6.1]
**Ligand B:** [350.459, 59.08, 1.598, 0, 4, 0.707, 15.936, 93.563, -4.179, -1.867, 0.364, 57.078, 25.021, 0.044, -6.2]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity, and BBB):
1. **MW:** Both are within the ideal range (200-500 Da).
2. **TPSA:** Ligand A (48.47) is significantly better than Ligand B (59.08), falling well below the 140 threshold for oral absorption.
3. **logP:** Ligand A (3.265) is optimal, while Ligand B (1.598) is on the lower side, potentially impacting permeability.
4. **HBD/HBA:** Ligand A (1 HBD, 3 HBA) is preferable to Ligand B (0 HBD, 4 HBA).
5. **QED:** Both have the same QED (0.707), indicating good drug-likeness.
6. **DILI:** Ligand A (5.777) has a much lower DILI risk than Ligand B (15.936). This is a significant advantage.
7. **BBB:** Ligand B (93.563) has a higher BBB penetration than Ligand A (84.8), but for a cardiovascular target, high BBB penetration isn't *critical*.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
9. **Solubility:** Both have negative solubility values, which is also unusual.
10. **hERG:** Both have very low hERG inhibition risk.
11. **Cl_mic:** Ligand A (22.676) has significantly lower microsomal clearance than Ligand B (57.078), indicating better metabolic stability.
12. **t1/2:** Ligand A (74.493) has a much longer in vitro half-life than Ligand B (25.021).
13. **Pgp:** Ligand A (0.022) has lower P-gp efflux liability than Ligand B (0.044), which is favorable for bioavailability.
14. **Affinity:** Both have very similar binding affinities (-6.1 and -6.2 kcal/mol). The difference is negligible.
**Overall Assessment:**
Ligand A is clearly superior. It has better TPSA, logP, DILI risk, metabolic stability (lower Cl_mic, longer t1/2), and P-gp efflux. While Ligand B has slightly better BBB penetration, this is less important for a cardiovascular target. The similar binding affinities make the ADME/Tox advantages of Ligand A decisive.
Output:
1
2025-04-18 00:30:10,999 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [348.422, 86.88, 2.393, 3, 3, 0.631, 44.048, 78.441, -4.899, -3.983, 0.417, 22.24, -6.344, 0.068, -5.4]
**Ligand B:** [346.515, 40.62, 3.739, 0, 2, 0.704, 15.083, 91.392, -4.539, -3.901, 0.575, 80.527, 1.205, 0.333, -5.8]
Here's a breakdown, considering the GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal range (200-500 Da). A is 348.422, B is 346.515 - very similar.
2. **TPSA:** A is 86.88, B is 40.62. B is significantly better, falling well below the 140 threshold for oral absorption and closer to the ideal for GPCRs.
3. **logP:** A is 2.393, B is 3.739. Both are within the optimal 1-3 range, but B is slightly higher. This could be a small advantage for membrane permeability, but needs to be balanced against solubility.
4. **HBD:** A is 3, B is 0. B is better. Fewer HBDs generally improve permeability.
5. **HBA:** A is 3, B is 2. B is better. Fewer HBAs generally improve permeability.
6. **QED:** A is 0.631, B is 0.704. B is slightly better, indicating a more drug-like profile.
7. **DILI:** A is 44.048, B is 15.083. B is *much* better, indicating a significantly lower risk of drug-induced liver injury. This is a major advantage.
8. **BBB:** A is 78.441, B is 91.392. B is significantly better, indicating a higher potential for brain penetration (though less critical for a cardiovascular target, it's still a positive).
9. **Caco-2:** Both are negative, indicating poor permeability. However, the scale is not provided, so it's hard to compare.
10. **Solubility:** Both are negative, indicating poor solubility. Again, the scale is unknown.
11. **hERG:** A is 0.417, B is 0.575. B is slightly better, suggesting a lower risk of hERG inhibition and cardiotoxicity.
12. **Cl_mic:** A is 22.24, B is 80.527. A is *much* better, indicating significantly higher metabolic stability. This is a major advantage.
13. **t1/2:** A is -6.344, B is 1.205. B is better, indicating a longer in vitro half-life.
14. **Pgp:** A is 0.068, B is 0.333. A is better, indicating lower P-gp efflux.
15. **Affinity:** A is -5.4, B is -5.8. B has a slightly better binding affinity.
**Overall Assessment:**
Ligand B clearly wins on several crucial ADME-Tox properties: DILI risk, BBB penetration, and in vitro half-life. It also has a slightly better QED, TPSA, logP, hERG, and binding affinity. Ligand A has an advantage in metabolic stability (Cl_mic) and Pgp efflux. However, the lower DILI risk and better BBB penetration of Ligand B are particularly valuable for a GPCR target, and the slight affinity advantage is a bonus. The metabolic stability difference, while important, can often be addressed with structural modifications during lead optimization.
Therefore, I would choose Ligand B.
Output:
0
2025-04-18 00:30:10,999 - INFO - Here's my reasoning and final output for the ligand preference:
**Reasoning:**
We are looking for a ligand for ADRB2, a cardiovascular GPCR. Therefore, we prioritize logP, TPSA, Pgp, and affinity, alongside general drug-like properties.
Let's compare Ligand A and Ligand B across the parameters:
1. **MW:** Both are within the ideal range (348-349 Da).
2. **TPSA:** Ligand A (67.23) is significantly better than Ligand B (101.21). Lower TPSA generally favors oral absorption, crucial for a cardiovascular drug.
3. **logP:** Both are good (1.462 and 1.308), falling within the optimal 1-3 range.
4. **HBD/HBA:** Ligand A (1 HBD, 4 HBA) is slightly better than Ligand B (2 HBD, 5 HBA) in terms of maintaining a balance between solubility and permeability.
5. **QED:** Ligand A (0.91) is better than Ligand B (0.806), indicating a more drug-like profile.
6. **DILI:** Ligand B (49.283) has a slightly better DILI score than Ligand A (41.024), but both are acceptable.
7. **BBB:** Ligand B (90.772) has a better BBB score than Ligand A (81.698), but BBB is less critical for a cardiovascular target.
8. **Caco-2:** Ligand B (-5.172) has a slightly better Caco-2 permeability than Ligand A (-4.532).
9. **Solubility:** Ligand B (-2.912) has slightly better solubility than Ligand A (-2.581).
10. **hERG:** Both are very low (0.449 and 0.377), indicating a low risk of cardiotoxicity.
11. **Cl_mic:** Ligand B (2.823) has much better microsomal clearance than Ligand A (20.359), suggesting better metabolic stability.
12. **t1/2:** Ligand B (-20.936) has a slightly better in vitro half-life than Ligand A (-21.853).
13. **Pgp:** Both are very low (0.066 and 0.023), indicating low P-gp efflux.
14. **Affinity:** Ligand B (-6.6 kcal/mol) has a slightly better binding affinity than Ligand A (-5.5 kcal/mol). This is a significant advantage.
**Overall Assessment:**
While Ligand B has a slightly better affinity and metabolic stability, Ligand A has a significantly lower TPSA and better QED. Given the GPCR nature of the target, the lower TPSA of Ligand A is a significant advantage for permeability and potentially better receptor engagement. The difference in affinity is not large enough to outweigh the TPSA benefit.
**Output:**
1
2025-04-18 00:30:11,000 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Ligand A (371.5) is within the ideal range (200-500). Ligand B (346.5) is also excellent. No clear advantage here.
2. **TPSA:** Ligand A (98.7) is acceptable, but approaching the upper limit for good oral absorption. Ligand B (58.2) is excellent, well below the 140 threshold. This favors Ligand B.
3. **logP:** Ligand A (0.124) is quite low, potentially hindering permeability. Ligand B (3.714) is optimal. This strongly favors Ligand B.
4. **HBD:** Ligand A (3) is good. Ligand B (2) is also good. No significant difference.
5. **HBA:** Ligand A (5) is good. Ligand B (2) is excellent. This favors Ligand B.
6. **QED:** Both ligands have good QED scores (A: 0.591, B: 0.69), indicating drug-likeness. Ligand B is slightly better.
7. **DILI:** Both have low DILI risk (A: 29.8, B: 22.3), well below the 40 threshold. Ligand B is slightly better.
8. **BBB:** Ligand A (20.1) is very low, suggesting poor brain penetration. Ligand B (65.4) is good, indicating reasonable brain penetration. Since ADRB2 is a GPCR, BBB is a relevant consideration, favoring Ligand B.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Both have negative solubility values, also unusual. Again, the scale is not specified.
11. **hERG:** Ligand A (0.104) has a very low hERG risk, which is excellent. Ligand B (0.453) is also acceptable. This favors Ligand A.
12. **Cl_mic:** Ligand A (24.1) is relatively low, indicating better metabolic stability. Ligand B (65.0) is higher, suggesting faster metabolism. This favors Ligand A.
13. **t1/2:** Ligand A (16.5) is reasonable. Ligand B (4.0) is short, suggesting frequent dosing might be needed. This favors Ligand A.
14. **Pgp:** Ligand A (0.012) has very low P-gp efflux, which is excellent. Ligand B (0.435) is moderate. This favors Ligand A.
15. **Affinity:** Ligand B (-7.4) has significantly better binding affinity than Ligand A (-5.0). This is a substantial advantage, potentially outweighing some ADME drawbacks.
**Overall Assessment:**
Ligand B has a superior logP, TPSA, and BBB penetration, all important for GPCR targets. Its binding affinity is also significantly better. However, it has a higher Cl_mic, shorter half-life, and higher Pgp efflux compared to Ligand A. Ligand A excels in metabolic stability, P-gp efflux, and hERG safety.
The difference in binding affinity (-7.4 vs -5.0 kcal/mol) is substantial (2.4 kcal/mol difference). Given the importance of potency for GPCRs, and considering the other parameters, the stronger binding of Ligand B is the deciding factor. While Ligand A has better ADME properties, the improved affinity of Ligand B is likely to be more impactful in driving efficacy.
Output:
0
2025-04-18 00:30:11,000 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [353.409, 46.61, 3.89, 0, 3, 0.755, 35.014, 92.323, -4.372, -4.068, 0.681, 69.01, -25.726, 0.387, -7.8]
**Ligand B:** [355.385, 62.74, 1.731, 0, 4, 0.713, 34.936, 96.355, -4.123, -1.541, 0.253, 20.737, -5.64, 0.039, -6.4]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity, and BBB):
1. **MW:** Both ligands are within the ideal range (200-500 Da).
2. **TPSA:** Ligand A (46.61) is significantly better than Ligand B (62.74). Lower TPSA generally favors better oral absorption and potentially better BBB penetration.
3. **logP:** Ligand A (3.89) is optimal, while Ligand B (1.731) is on the lower side. This could impact membrane permeability for Ligand B.
4. **HBD/HBA:** Both have acceptable HBD (0) and HBA counts (3 & 4 respectively).
5. **QED:** Both are good (0.755 and 0.713), indicating drug-like properties.
6. **DILI:** Both have low DILI risk (35.014 and 34.936 percentile), which is excellent.
7. **BBB:** Both have good BBB penetration (92.323 and 96.355 percentile). Ligand B is slightly better, but this isn't a primary driver here as it's a cardiovascular target.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and indicates poor permeability. This is a significant concern for both.
9. **Solubility:** Ligand A (-4.068) is worse than Ligand B (-1.541). Solubility is a concern for Ligand A.
10. **hERG:** Ligand A (0.681) is better than Ligand B (0.253), indicating lower cardiotoxicity risk.
11. **Cl_mic:** Ligand B (20.737) has significantly lower microsomal clearance than Ligand A (69.01), suggesting better metabolic stability.
12. **t1/2:** Ligand B (-5.64) has a slightly better (less negative) in vitro half-life than Ligand A (-25.726).
13. **Pgp:** Ligand A (0.387) has lower P-gp efflux than Ligand B (0.039), which is favorable for bioavailability.
14. **Affinity:** Ligand A (-7.8 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.4 kcal/mol). This is a substantial advantage.
**Overall Assessment:**
The biggest advantage of Ligand A is its significantly superior binding affinity. While Ligand B has better metabolic stability (lower Cl_mic) and solubility, the affinity difference is substantial (1.4 kcal/mol). For a GPCR, strong affinity is paramount. The TPSA of Ligand A is also better. The poor Caco-2 values are a concern for both, but the strong binding of Ligand A makes it more likely that optimization could overcome this permeability issue. The slightly higher hERG risk for Ligand B is also a negative.
Therefore, I would prioritize Ligand A.
Output:
1
2025-04-18 00:30:11,000 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (368.5 and 352.4 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (87.32) is significantly better than Ligand B (117.67). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (1.463) is within the optimal 1-3 range. Ligand B (-0.731) is slightly below 1, which *could* indicate permeability issues. This is a point in favor of A.
4. **HBD:** Both have 2 HBD, which is good.
5. **HBA:** Ligand A has 5 HBA, while Ligand B has 7. Both are acceptable, but A is slightly preferable.
6. **QED:** Both are very similar (0.725 and 0.697), indicating good drug-likeness.
7. **DILI:** Both are reasonably low (47.421 and 44.591), indicating similar low risk of liver injury.
8. **BBB:** Ligand A (63.358) has a better BBB percentile than Ligand B (25.204). While ADRB2 isn't a CNS target, some off-target CNS effects are always a consideration.
9. **Caco-2:** Both have negative Caco-2 values (-5.322 and -5.258), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand A (-2.685) is slightly better than Ligand B (-1.026), but both are quite poor. Formulation challenges are likely.
11. **hERG:** Both are very low (0.402 and 0.034), indicating minimal hERG inhibition risk.
12. **Cl_mic:** Ligand B (-7.095) has a *much* lower (better) microsomal clearance than Ligand A (11.186). This suggests significantly better metabolic stability for Ligand B.
13. **t1/2:** Ligand B (-5.018) has a longer in vitro half-life than Ligand A (-9.32). This is a strong advantage for B.
14. **Pgp:** Both are very low (0.036 and 0.008), indicating minimal P-gp efflux.
15. **Binding Affinity:** Ligand B (-7.3 kcal/mol) has a slightly better binding affinity than Ligand A (-6.0 kcal/mol). This 1.3 kcal/mol difference is substantial and can often outweigh minor ADME concerns.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A has a better logP and TPSA, but Ligand B has a superior binding affinity and better metabolic stability (Cl_mic and t1/2). The affinity difference is significant.
**Overall Assessment:**
While Ligand A has some advantages in TPSA and logP, the significantly better binding affinity, metabolic stability, and half-life of Ligand B are more critical for a successful drug candidate. The poor Caco-2 and solubility are concerns for both, but can potentially be addressed with formulation strategies. The affinity advantage of B is likely to be more impactful than the slight improvements in A's permeability-related properties.
Output:
0
2025-04-18 00:30:11,000 - INFO - Batch 482 complete. Total preferences: 7712
2025-04-18 00:30:11,000 - INFO - Processing batch 483/512...
2025-04-18 00:31:00,110 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Step-by-step comparison:**
1. **MW:** Both ligands (336.366 and 348.447 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (51.22) is significantly better than Ligand B (78.67). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally improves absorption. Ligand A is well below the 140 threshold, while B is approaching it.
3. **logP:** Ligand A (4.015) is at the upper end of the optimal range (1-3), but still acceptable. Ligand B (0.523) is quite low, potentially hindering membrane permeability and bioavailability. This is a significant negative for Ligand B.
4. **HBD:** Both ligands have 1 HBD, which is within the acceptable limit of 5.
5. **HBA:** Ligand A has 3 HBA, and Ligand B has 5. Both are within the acceptable limit of 10.
6. **QED:** Both ligands have similar QED values (0.769 and 0.779), indicating good drug-like properties.
7. **DILI:** Ligand A (87.01) has a higher DILI risk than Ligand B (15.859). This is a substantial negative for Ligand A.
8. **BBB:** Ligand A (79.721) has better BBB penetration than Ligand B (45.25). While not critical for a cardiovascular target, it's a slight positive for A.
9. **Caco-2:** Ligand A (-4.733) and Ligand B (-5.011) have similar Caco-2 permeability values.
10. **Solubility:** Ligand A (-5.242) has slightly better solubility than Ligand B (-0.252).
11. **hERG:** Ligand A (0.788) has a lower hERG inhibition liability than Ligand B (0.108), which is a positive.
12. **Cl_mic:** Ligand A (87.181) has a higher microsomal clearance than Ligand B (12.521), indicating lower metabolic stability. This is a negative for Ligand A.
13. **t1/2:** Ligand A (18.078) has a longer in vitro half-life than Ligand B (-3.469). This is a positive for Ligand A.
14. **Pgp:** Ligand A (0.782) has a lower Pgp efflux liability than Ligand B (0.07). This is a positive for Ligand A.
15. **Binding Affinity:** Ligand A (-7.3) has a significantly stronger binding affinity than Ligand B (-5.6). This is a major advantage for Ligand A, potentially outweighing some of its ADME drawbacks.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are particularly important. Ligand A excels in affinity and Pgp efflux, and has a better logP and TPSA. Ligand B has a much better DILI score.
**Overall Assessment:**
While Ligand A has a higher DILI risk and higher Cl_mic, its significantly stronger binding affinity (-7.3 vs -5.6 kcal/mol) and better logP and TPSA are highly favorable for a GPCR target. The improved affinity is likely to be crucial for efficacy. The DILI risk, while concerning, could be addressed with further structural modifications. The lower metabolic stability is also a concern, but could be improved with structural modifications.
Output:
1
2025-04-18 00:31:00,110 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's break down the comparison of Ligand A and Ligand B, considering the provided guidelines and the GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key).
1. **Molecular Weight:** Both ligands (348.422 and 348.491 Da) fall comfortably within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (83.12) is slightly higher than Ligand B (47.1). Both are below the 140 threshold for oral absorption, but Ligand B is significantly better, suggesting potentially improved cell permeability.
3. **logP:** Ligand A (1.888) is within the optimal 1-3 range. Ligand B (0.484) is a bit low, potentially hindering membrane permeability.
4. **H-Bond Donors:** Ligand A (3) is acceptable, while Ligand B (0) is also good.
5. **H-Bond Acceptors:** Both ligands have 4 H-bond acceptors, which is well within the acceptable range.
6. **QED:** Both ligands have similar QED values (0.67 and 0.628), indicating good drug-likeness.
7. **DILI:** Ligand A (29.624) has a much lower DILI risk than Ligand B (12.02). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (79.294) has a better BBB penetration percentile than Ligand B (62.699). While ADRB2 isn't exclusively a CNS target, some distribution to the CNS is possible, and higher BBB penetration is generally favorable.
9. **Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual. However, the magnitude is similar, so this isn't a major differentiator.
10. **Aqueous Solubility:** Ligand A (-3.307) has slightly better solubility than Ligand B (-0.994).
11. **hERG Inhibition:** Both ligands have low hERG inhibition risk (0.459 and 0.515).
12. **Microsomal Clearance:** Ligand A (24.844) has lower microsomal clearance than Ligand B (31.387), indicating better metabolic stability.
13. **In vitro Half-Life:** Ligand A (15.982) has a significantly longer in vitro half-life than Ligand B (3.498). This is a major advantage for Ligand A.
14. **P-gp Efflux:** Both ligands have similar P-gp efflux liability (0.013 and 0.014).
15. **Binding Affinity:** Ligand A (-7.1) has a stronger binding affinity than Ligand B (-6.4). This 0.7 kcal/mol difference is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across multiple critical parameters. The most significant advantages of Ligand A are its superior binding affinity, lower DILI risk, better BBB penetration, and longer half-life. While Ligand B has a lower TPSA, the other advantages of Ligand A are more impactful for overall drug development potential, especially considering the GPCR target class.
Output:
1
2025-04-18 00:31:00,111 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [344.455, 78.43, 3.7, 3, 3, 0.262, 39.046, 52.966, -5.159, -4.255, 0.498, 90.827, -18.225, 0.403, -5.1]
**Ligand B:** [370.425, 66.71, 1.209, 1, 5, 0.859, 50.989, 78.558, -5.004, -1.751, 0.602, 16.155, -1.827, 0.039, -8.1]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal 200-500 Da range. Ligand A (344.455) is slightly preferred.
2. **TPSA:** Ligand B (66.71) is better than Ligand A (78.43), being closer to the <90 target for GPCRs.
3. **logP:** Ligand A (3.7) is a bit high, but still acceptable. Ligand B (1.209) is low, potentially hindering membrane permeability. This favors Ligand A.
4. **HBD:** Ligand A (3) is acceptable, Ligand B (1) is also good. No strong preference.
5. **HBA:** Ligand A (3) is good, Ligand B (5) is acceptable, but slightly higher.
6. **QED:** Ligand B (0.859) is significantly better than Ligand A (0.262), indicating a more drug-like profile. This is a strong point for Ligand B.
7. **DILI:** Ligand B (50.989) has a slightly better DILI risk profile than Ligand A (39.046), but both are acceptable.
8. **BBB:** Ligand B (78.558) is better than Ligand A (52.966), which is important for GPCRs.
9. **Caco-2:** Both have negative values, indicating poor permeability. Ligand A (-5.159) is slightly worse than Ligand B (-5.004).
10. **Solubility:** Ligand B (-1.751) is better than Ligand A (-4.255).
11. **hERG:** Both are low, indicating low hERG inhibition risk. No strong preference.
12. **Cl_mic:** Ligand B (16.155) has much lower clearance than Ligand A (90.827), suggesting better metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand B (-1.827) is better than Ligand A (-18.225), indicating a longer half-life.
14. **Pgp:** Ligand A (0.403) is better than Ligand B (0.039), meaning less P-gp efflux.
15. **Binding Affinity:** Ligand B (-8.1) has a significantly stronger binding affinity than Ligand A (-5.1), a difference of 3 kcal/mol. This is a major advantage for Ligand B.
**Overall Assessment:**
While Ligand A has a slightly better MW and Pgp profile, Ligand B excels in several key areas crucial for GPCR drug development: significantly higher binding affinity, better QED, improved metabolic stability (lower Cl_mic), longer half-life, better BBB penetration, and improved solubility. The lower logP of Ligand B is a concern, but the strong binding affinity and other favorable ADME properties likely outweigh this drawback. The substantial difference in binding affinity (-8.1 vs -5.1 kcal/mol) is a decisive factor.
Output:
0
2025-04-18 00:31:00,111 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (342.443) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (78.09) is significantly better than Ligand B (101.81). For a GPCR, keeping TPSA low is beneficial for permeability and receptor engagement.
3. **logP:** Ligand A (2.577) is optimal, while Ligand B (-0.711) is quite low. Low logP can hinder membrane permeability and bioavailability. This is a significant strike against Ligand B.
4. **HBD:** Ligand A (2) and Ligand B (0) are both acceptable.
5. **HBA:** Ligand A (3) is good, while Ligand B (7) is higher, potentially impacting permeability.
6. **QED:** Ligand A (0.876) is excellent, indicating high drug-likeness. Ligand B (0.678) is still acceptable, but lower.
7. **DILI:** Ligand A (49.399) has a better DILI score than Ligand B (63.552), indicating lower liver injury risk.
8. **BBB:** Both ligands have similar BBB penetration (Ligand A: 58.976, Ligand B: 59.829). While not CNS-focused for ADRB2, some level of BBB penetration can be relevant.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability *in vitro*. However, the scale is not specified, so it's difficult to interpret.
10. **Solubility:** Ligand A (-3.25) is better than Ligand B (-1.798), indicating better aqueous solubility.
11. **hERG:** Ligand A (0.569) is much better than Ligand B (0.108), indicating a lower risk of cardiotoxicity. This is crucial for a cardiovascular target.
12. **Cl_mic:** Ligand A (25.781) has a lower microsomal clearance than Ligand B (8.637), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-9.037) has a longer in vitro half-life than Ligand B (-2.947), which is desirable.
14. **Pgp:** Ligand A (0.035) has a lower Pgp efflux liability than Ligand B (0.072), suggesting better bioavailability.
15. **Affinity:** Ligand B (-6.5 kcal/mol) has a slightly better binding affinity than Ligand A (-5.5 kcal/mol). This is a 1 kcal/mol difference, which is noticeable but not overwhelming given the other factors.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A excels in logP and TPSA, and has acceptable Pgp. Ligand B has a poor logP and higher TPSA. While Ligand B has slightly better affinity, the ADME properties of Ligand A are far superior. The hERG risk is also a critical consideration for a cardiovascular target, and Ligand A is significantly better in this regard.
**Conclusion:**
Despite the slightly better binding affinity of Ligand B, the significantly improved ADME properties (logP, TPSA, solubility, metabolic stability, hERG risk, Pgp efflux) of Ligand A make it the more promising drug candidate for the ADRB2 receptor.
Output:
1
2025-04-18 00:31:00,111 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (350.438) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (58.44) is significantly better than Ligand B (91.76). For a GPCR, keeping TPSA low is beneficial for permeability and receptor engagement. Ligand B is approaching a level that could hinder oral absorption.
3. **logP:** Ligand A (1.819) is within the optimal range, while Ligand B (0.672) is a bit low. A lower logP can sometimes indicate poor membrane permeability, though it's not a critical issue here.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer hydrogen bond donors generally improve membrane permeability.
5. **HBA:** Ligand A (4) is better than Ligand B (6). Lower HBA counts are generally preferred for permeability.
6. **QED:** Both ligands have similar QED values (0.786 vs 0.618), indicating reasonable drug-likeness.
7. **DILI:** Ligand A (23.11) has a much lower DILI risk than Ligand B (46.724). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (96.782) has excellent BBB penetration potential, while Ligand B (74.254) is good but not as high. While ADRB2 isn't exclusively a CNS target, good BBB penetration can be beneficial and reduce off-target effects.
9. **Caco-2:** Ligand A (-4.581) and Ligand B (-5.04) both have negative Caco-2 values, which is unusual and suggests very poor permeability. However, the scale used here is unclear, and negative values could represent a different type of measurement. I will assume these are percentile scores and interpret them as very low permeability.
10. **Solubility:** Ligand A (-2.35) and Ligand B (-1.629) both have poor solubility. This is a concern for both compounds.
11. **hERG:** Ligand A (0.741) has a lower hERG risk than Ligand B (0.552), which is a positive.
12. **Cl_mic:** Ligand A (40.243) has a higher microsomal clearance than Ligand B (-2.322), suggesting lower metabolic stability. This is a drawback for Ligand A.
13. **t1/2:** Ligand A (-30.829) has a very short in vitro half-life, while Ligand B (6.062) has a more reasonable half-life. This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.195) has lower P-gp efflux than Ligand B (0.079), which is preferable.
15. **Affinity:** Ligand A (-8.2 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.5 kcal/mol). This is a substantial advantage that can outweigh some of the ADME drawbacks.
**Overall Assessment:**
Ligand A has a much stronger binding affinity, lower DILI risk, better BBB penetration, and lower P-gp efflux. However, it suffers from higher microsomal clearance and a very short half-life. Ligand B has a better half-life and lower clearance, but its TPSA is higher, DILI risk is greater, and its binding affinity is weaker.
Given the GPCR target class, the strong binding affinity of Ligand A is a major advantage. While the metabolic stability is a concern, it might be addressable through structural modifications. The lower DILI risk and better BBB penetration also contribute to its favorability. The poor Caco-2 values for both are concerning, but the affinity difference is large enough to prioritize Ligand A.
Output:
1
2025-04-18 00:31:00,111 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (333.395 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are below the 140 A^2 threshold for good oral absorption. Ligand B (73.66) is slightly lower than Ligand A (77.97), which is a minor advantage.
3. **logP:** Both ligands have logP values within the optimal range (1-3). Ligand A (2.555) is slightly better than Ligand B (3.351) as it is closer to the center of the range.
4. **HBD:** Both are within the acceptable limit of 5. Ligand A has 1 HBD, while Ligand B has 2.
5. **HBA:** Both are within the acceptable limit of 10. Ligand A has 6 HBA, while Ligand B has 5.
6. **QED:** Both have good QED scores (>0.5), indicating drug-likeness. Ligand B (0.857) is slightly higher than Ligand A (0.797).
7. **DILI:** Ligand B (23.846) has a significantly lower DILI risk than Ligand A (64.793), which is a major advantage.
8. **BBB:** Ligand A (50.679) has slightly better BBB penetration than Ligand B (40.946), but both are not particularly high. For a cardiovascular target, BBB penetration is not a primary concern, but it's a slight edge for A.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. Ligand B (-4.938) is slightly better than Ligand A (-5.029).
10. **Solubility:** Both ligands have negative solubility values, indicating poor solubility. Ligand B (-4.265) is slightly better than Ligand A (-3.277).
11. **hERG:** Both ligands have low hERG inhibition risk. Ligand A (0.929) is slightly higher than Ligand B (0.47).
12. **Cl_mic:** Ligand A (51.359) has lower microsomal clearance than Ligand B (80.623), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-33.532) has a much longer in vitro half-life than Ligand A (26.033), which is a significant advantage.
14. **Pgp:** Both ligands have low Pgp efflux liability. Ligand A (0.536) is slightly higher than Ligand B (0.279).
15. **Binding Affinity:** Ligand B (-7.1 kcal/mol) has a significantly stronger binding affinity than Ligand A (-4.2 kcal/mol). This is a crucial factor, as a 1.5 kcal/mol advantage is considered substantial.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B excels in affinity, has a better logP, and lower Pgp efflux. While Ligand A has slightly better BBB penetration, this isn't critical for a cardiovascular target. The significantly lower DILI risk and longer half-life of Ligand B are also very important. The slightly poorer Caco-2 and solubility of B are offset by the strong binding affinity.
**Conclusion:**
Despite some slightly better permeability parameters for Ligand A, the superior binding affinity, lower DILI risk, and longer half-life of Ligand B make it the more promising drug candidate.
Output:
0
2025-04-18 00:31:00,111 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (344.415 and 344.459 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (65.86) is significantly better than Ligand B (78.09). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand A is well below the 140 threshold.
3. **logP:** Ligand B (2.756) is better than Ligand A (0.381). A logP between 1-3 is optimal, and Ligand B falls within this range. Ligand A is quite low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is preferable to Ligand B (3). Fewer HBAs generally improve permeability.
6. **QED:** Both ligands have similar QED values (0.779 and 0.712), both above the desirable threshold of 0.5.
7. **DILI:** Ligand B (38.852) is slightly better than Ligand A (42.575), both being below the 40 threshold, indicating low risk.
8. **BBB:** Both ligands have similar BBB penetration (62.195 and 67.701). While not exceptionally high, they are reasonable for a peripherally-acting GPCR like ADRB2.
9. **Caco-2:** Both ligands have very poor Caco-2 permeability (-4.517 and -4.885). This is a concern for oral bioavailability.
10. **Solubility:** Ligand A (-1.25) is better than Ligand B (-3.45). Higher solubility is generally preferred.
11. **hERG:** Ligand A (0.206) is significantly better than Ligand B (0.417). Lower hERG inhibition is crucial for avoiding cardiotoxicity, a major concern with ADRB2 modulators.
12. **Cl_mic:** Ligand A (30.622) is significantly better than Ligand B (67.23). Lower clearance indicates better metabolic stability.
13. **t1/2:** Ligand A (-1.986) is better than Ligand B (-8.688). Longer half-life is generally desirable.
14. **Pgp:** Ligand A (0.066) is significantly better than Ligand B (0.189). Lower P-gp efflux improves bioavailability.
15. **Binding Affinity:** Ligand A (-7.8) is significantly better than Ligand B (-6.5). A difference of 1.3 kcal/mol is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
While Ligand B has a better logP, Ligand A excels in almost all other critical parameters, particularly binding affinity, metabolic stability (Cl_mic and t1/2), hERG inhibition, and P-gp efflux. The significantly stronger binding affinity of Ligand A is a major advantage for a GPCR target. The lower hERG risk is also a critical factor. The poor Caco-2 permeability is a concern for both, but can potentially be addressed with formulation strategies. Given the GPCR-specific priorities (affinity, logP, TPSA, Pgp), and the substantial advantage in binding affinity and safety (hERG), Ligand A is the more promising candidate.
Output:
1
2025-04-18 00:31:00,112 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step Comparison:**
1. **MW:** Both ligands (344.39 and 346.431 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (78.09) is slightly higher than Ligand B (74.65). Both are below the 140 threshold for good oral absorption, and acceptable for a cardiovascular GPCR target where CNS penetration isn't paramount.
3. **logP:** Ligand A (1.899) is optimal, while Ligand B (0.265) is a bit low. A logP below 1 can sometimes hinder membrane permeability. This is a point in favor of Ligand A.
4. **HBD:** Ligand A (2) and Ligand B (1) are both within the acceptable limit of 5.
5. **HBA:** Ligand A (3) and Ligand B (5) are both within the acceptable limit of 10.
6. **QED:** Ligand A (0.813) has a better QED score than Ligand B (0.613), indicating a more drug-like profile.
7. **DILI:** Ligand B (32.959) has a significantly lower DILI risk than Ligand A (51.725). This is a substantial advantage for Ligand B.
8. **BBB:** Ligand A (77.976) has a better BBB penetration score than Ligand B (58.782). While ADRB2 is a cardiovascular target, some CNS effects are possible with certain ligands, and higher BBB is generally favorable.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.558 and -4.913), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-2.909) has slightly better solubility than Ligand B (-1.01), though both are poor.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.447 and 0.071), which is excellent.
12. **Cl_mic:** Ligand A (4.566) has a lower microsomal clearance, suggesting better metabolic stability than Ligand B (10.736).
13. **t1/2:** Ligand A (-19.292) has a much longer in vitro half-life than Ligand B (-12.362), which is a significant advantage.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.188 and 0.017).
15. **Binding Affinity:** Both ligands have the same binding affinity (-8.0 kcal/mol).
**GPCR-Specific Priorities & Overall Assessment:**
For a cardiovascular GPCR like ADRB2, logP, TPSA, and metabolic stability are important. Ligand A has a better logP and Cl_mic, and a significantly better t1/2. However, Ligand B has a much lower DILI risk, which is critical. The Caco-2 values are concerning for both, but the better metabolic stability and half-life of Ligand A, combined with its slightly better logP and QED, outweigh the DILI risk.
Output:
1
2025-04-18 00:31:00,112 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (366.4) is within the ideal range (200-500), while Ligand B (349.5) is also good. No clear advantage here.
2. **TPSA:** Ligand A (103.6) is slightly higher than ideal for oral absorption (<140), but acceptable. Ligand B (53.5) is excellent, well below the threshold. This favors Ligand B.
3. **logP:** Ligand A (0.586) is a bit low, potentially impacting permeability. Ligand B (2.647) is within the optimal range (1-3). This favors Ligand B.
4. **HBD:** Both ligands have 0 HBD, which is good.
5. **HBA:** Ligand A has 8 HBA, acceptable. Ligand B has 3 HBA, also good.
6. **QED:** Both ligands have similar QED values (0.729 and 0.768), indicating good drug-likeness.
7. **DILI:** Ligand A (87.1%) has a significantly higher DILI risk than Ligand B (17.3%). This is a major concern for Ligand A.
8. **BBB:** Ligand A (62.0%) is moderate, while Ligand B (88.3%) is very good. Since ADRB2 is a GPCR, BBB penetration is a consideration, favoring Ligand B.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Ligand A (-4.375) and Ligand B (-1.972) both have negative solubility values, suggesting poor aqueous solubility.
11. **hERG:** Ligand A (0.116) has a slightly better hERG profile than Ligand B (0.392), but both are relatively low risk.
12. **Cl_mic:** Ligand A (119.6) has a higher microsomal clearance than Ligand B (26.0), indicating lower metabolic stability. This favors Ligand B.
13. **t1/2:** Ligand A (-50.6) has a negative in vitro half-life, which is concerning. Ligand B (-14.3) is also negative, but less so.
14. **Pgp:** Ligand A (0.094) has lower P-gp efflux liability than Ligand B (0.075), which is slightly favorable.
15. **Affinity:** Ligand A (-7.4) has a significantly better binding affinity than Ligand B (-5.9). This is a substantial advantage.
**Overall Assessment:**
Ligand A has a much stronger binding affinity, which is a critical factor for GPCRs. However, it suffers from a high DILI risk, poor metabolic stability (high Cl_mic), and a negative in vitro half-life. Ligand B, while having a weaker affinity, presents a much more favorable ADMET profile: lower DILI risk, better BBB penetration, lower Cl_mic, and a better logP.
Given the balance of properties and prioritizing a safer, more developable molecule, Ligand B is the more promising candidate, despite the lower affinity. The affinity difference, while substantial, might be addressable through further optimization, whereas mitigating a high DILI risk is far more challenging.
Output:
0
2025-04-18 00:31:00,112 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (376.5 & 348.4 Da) fall within the ideal 200-500 Da range.
2. **TPSA:** Ligand B (69.48) is significantly better than Ligand A (112.57). ADRB2 is not a CNS target, but lower TPSA generally improves absorption.
3. **logP:** Ligand B (1.916) is optimal, while Ligand A (0.619) is a bit low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (3) is acceptable, Ligand B (0) is even better, minimizing potential for off-target interactions.
5. **HBA:** Both ligands (A: 5, B: 6) are within the acceptable range of <=10.
6. **QED:** Both ligands have good QED scores (A: 0.564, B: 0.785), indicating drug-likeness. Ligand B is better.
7. **DILI:** Ligand A (31.291) has a much lower DILI risk than Ligand B (47.77). This is a significant advantage for Ligand A.
8. **BBB:** Not a major concern for ADRB2 (cardiovascular target), but Ligand B (75.572) has a higher BBB penetration than Ligand A (39.511).
9. **Caco-2:** Ligand A (-5.214) and Ligand B (-4.584) have negative values, which is unusual and requires further investigation, but are relatively similar.
10. **Solubility:** Ligand A (-1.88) and Ligand B (-2.353) have negative solubility values, which is also unusual and requires further investigation, but are relatively similar.
11. **hERG:** Both ligands have very low hERG risk (A: 0.208, B: 0.115).
12. **Cl_mic:** Ligand A (25.553) has a significantly lower microsomal clearance than Ligand B (49.247), indicating better metabolic stability.
13. **t1/2:** Ligand B (18.623) has a much longer in vitro half-life than Ligand A (1.54). This is a major advantage for Ligand B.
14. **Pgp:** Both ligands have low P-gp efflux liability (A: 0.034, B: 0.054).
15. **Binding Affinity:** Ligand A (-7.4) has a slightly better binding affinity than Ligand B (-6.7), a difference of 0.7 kcal/mol.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand B excels in logP and TPSA. Ligand A has a slightly better affinity, but the difference is not substantial enough to overcome the other advantages of Ligand B. Metabolic stability (Cl_mic) is also important, and Ligand A is better here. However, the longer half-life of Ligand B is a significant benefit. The DILI risk is also a factor, and Ligand A is better.
**Overall Assessment:**
Ligand B has a better balance of properties. While Ligand A has a slightly better affinity and lower DILI risk, Ligand B's superior logP, TPSA, longer half-life, and good QED profile make it the more promising candidate. The lower metabolic stability of Ligand B is a concern, but could potentially be addressed with structural modifications.
Output:
0
2025-04-18 00:31:00,112 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (366.443 and 341.455 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand B (73.2) is significantly better than Ligand A (100.63). For a GPCR, lower TPSA is generally preferred for better permeability.
**3. logP:** Ligand B (2.881) is closer to the optimal 1-3 range than Ligand A (0.641). Ligand A's logP is quite low, potentially hindering membrane permeability.
**4. H-Bond Donors:** Ligand A (2) and Ligand B (1) are both acceptable.
**5. H-Bond Acceptors:** Ligand A (6) and Ligand B (3) are both acceptable.
**6. QED:** Both ligands have very similar and good QED values (0.818 and 0.829).
**7. DILI:** Ligand B (38.077) has a much lower DILI risk than Ligand A (86.817). This is a substantial advantage for Ligand B.
**8. BBB:** Both ligands have good BBB penetration (64.056 and 72.935). While ADRB2 isn't a CNS target, some peripheral exposure is acceptable, and higher BBB is not detrimental.
**9. Caco-2 Permeability:** Both have negative Caco-2 values, indicating poor permeability. This is concerning for both, but less so for a cardiovascular target where IV administration is an option.
**10. Aqueous Solubility:** Both have negative solubility values, which is concerning.
**11. hERG Inhibition:** Ligand A (0.274) has a slightly lower hERG inhibition risk than Ligand B (0.542), but both are relatively low.
**12. Microsomal Clearance:** Ligand B (65.354) has a lower microsomal clearance than Ligand A (12.058), indicating better metabolic stability.
**13. In vitro Half-Life:** Ligand B (26.541) has a longer half-life than Ligand A (19.633).
**14. P-gp Efflux:** Ligand A (0.085) has lower P-gp efflux than Ligand B (0.121), which is favorable.
**15. Binding Affinity:** Both ligands have excellent binding affinities (-6.0 and -5.7 kcal/mol). The difference of 0.3 kcal/mol is not substantial enough to outweigh the other ADME differences.
**Overall Assessment:**
Ligand B is the stronger candidate. While Ligand A has slightly better P-gp efflux, Ligand B excels in critical ADME properties: lower DILI risk, better logP, lower microsomal clearance, and longer half-life. The lower TPSA of Ligand B is also advantageous for a GPCR target. The slight difference in binding affinity is not enough to overcome the significant ADME advantages of Ligand B.
Output:
0
2025-04-18 00:31:00,112 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [349.431, 94.81, 0.877, 3, 5, 0.75, 26.328, 45.25, -5.164, -1.77, 0.426, -21.507, 58.564, 0.05, -10]
**Ligand B:** [344.371, 106.35, 1.468, 2, 6, 0.851, 77.976, 46.219, -4.676, -3.605, 0.123, 30.497, 3.562, 0.063, -6.5]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (349.431 Da) is slightly higher than Ligand B (344.371 Da), but the difference is negligible.
2. **TPSA:** Ligand A (94.81) is better than Ligand B (106.35). Both are below 140, but A is closer to the preferred <90 for potential CNS penetration, though this is less critical for a cardiovascular target.
3. **logP:** Ligand A (0.877) is a bit low, potentially hindering permeability. Ligand B (1.468) is better, falling within the optimal 1-3 range.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (2), but both are acceptable.
5. **HBA:** Ligand A (5) is slightly lower than Ligand B (6), but both are acceptable.
6. **QED:** Both are good (A: 0.75, B: 0.851), indicating drug-like properties. B is slightly better.
7. **DILI:** Ligand A (26.328) has a significantly lower DILI risk than Ligand B (77.976). This is a major advantage for Ligand A.
8. **BBB:** Both are similar (A: 45.25, B: 46.219), and not particularly high, which is fine for a cardiovascular target.
9. **Caco-2:** Ligand A (-5.164) is worse than Ligand B (-4.676). Higher values are better, so B is preferred.
10. **Solubility:** Ligand A (-1.77) is better than Ligand B (-3.605).
11. **hERG:** Ligand A (0.426) is much better than Ligand B (0.123), indicating a lower risk of cardiotoxicity. This is crucial for a cardiovascular drug.
12. **Cl_mic:** Ligand A (-21.507) has a much lower (better) microsomal clearance than Ligand B (30.497), suggesting greater metabolic stability.
13. **t1/2:** Ligand A (58.564) has a significantly longer in vitro half-life than Ligand B (3.562). This is a significant advantage.
14. **Pgp:** Both are very low (A: 0.05, B: 0.063), indicating minimal P-glycoprotein efflux.
15. **Affinity:** Ligand A (-10 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.5 kcal/mol). This is a substantial advantage, potentially outweighing some ADME concerns.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has a slightly lower logP, but its much better TPSA, DILI, hERG, Cl_mic, t1/2, and *significantly* better affinity outweigh this.
**Conclusion:**
Ligand A is the more promising candidate. The substantial advantages in DILI risk, hERG inhibition, metabolic stability (Cl_mic & t1/2), and, most importantly, binding affinity, make it a much better choice despite the slightly lower logP and Caco-2 permeability.
```
1
```
2025-04-18 00:31:00,113 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
The target is ADRB2, a GPCR. Therefore, I will prioritize logP, TPSA, Pgp efflux, BBB penetration, and binding affinity, while also considering ADME-Tox properties.
* **Molecular Weight:** Both ligands (348.363 and 348.378 Da) fall within the ideal 200-500 Da range. No significant difference here.
* **TPSA:** Ligand B (81.69) is significantly better than Ligand A (127.24). Lower TPSA generally correlates with better cell permeability, which is crucial for GPCR targeting. Ligand B is well below the 140 A^2 threshold.
* **logP:** Ligand B (1.063) is within the optimal range (1-3), while Ligand A (-0.897) is slightly below, potentially hindering permeability.
* **H-Bond Donors/Acceptors:** Ligand B has fewer HBDs (2 vs 3) and HBAs (5 vs 7) than Ligand A, which is favorable for permeability.
* **QED:** Both ligands have good QED scores (0.608 and 0.86), indicating good drug-like properties. Ligand B is slightly better.
* **DILI:** Both have acceptable DILI risk (78.48 and 60.217), but Ligand B is noticeably lower, suggesting a reduced risk of liver injury.
* **BBB:** Ligand B (67.623) has better BBB penetration than Ligand A (58.821), which is a plus for a GPCR target, even if not strictly CNS-focused.
* **Caco-2 Permeability:** Both are negative, indicating poor permeability.
* **Aqueous Solubility:** Both are negative, indicating poor solubility.
* **hERG Inhibition:** Ligand A (0.029) has a very low hERG risk, while Ligand B (0.445) is slightly higher. This is a significant advantage for Ligand A.
* **Microsomal Clearance:** Ligand A (-19.11) has a much lower (better) microsomal clearance than Ligand B (14.046), indicating greater metabolic stability.
* **In vitro Half-Life:** Ligand A (31.811) has a longer half-life than Ligand B (-17.387), which is desirable.
* **P-gp Efflux:** Ligand A (0.002) has very low P-gp efflux, while Ligand B (0.009) is slightly higher. Lower efflux is preferred.
* **Binding Affinity:** Ligand A (-7.1) has a significantly stronger binding affinity than Ligand B (-3.9). This is a substantial advantage that can outweigh some of the ADME drawbacks of Ligand B.
**Overall Assessment:**
While Ligand B has better TPSA, logP, and DILI, Ligand A's superior binding affinity, metabolic stability (lower Cl_mic), longer half-life, lower P-gp efflux, and very low hERG risk are more critical for a viable drug candidate, especially considering the GPCR target class. The substantial difference in binding affinity (-7.1 vs -3.9 kcal/mol) is a major deciding factor.
**Output:**
1
2025-04-18 00:31:00,113 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**1. Molecular Weight:** Both ligands (351.328 Da and 360.498 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (84.22) is significantly better than Ligand B (33.2). For a cardiovascular GPCR, a lower TPSA is generally preferred for better permeability, but it shouldn't be *too* low. Ligand B is exceptionally low, which *could* indicate poor interactions, but is generally favorable.
**3. logP:** Ligand A (1.65) is within the optimal 1-3 range. Ligand B (4.539) is higher, potentially leading to solubility issues and off-target effects. This is a negative for Ligand B.
**4. H-Bond Donors:** Ligand A (3) is acceptable, while Ligand B (0) is also acceptable.
**5. H-Bond Acceptors:** Both ligands have 3 H-bond acceptors, which is within the acceptable range.
**6. QED:** Both ligands have good QED scores (0.692 and 0.805), indicating good drug-like properties.
**7. DILI Risk:** Both ligands have similar DILI risk (51.609 and 56.844), both being acceptable.
**8. BBB Penetration:** Ligand B (86.817) has better BBB penetration than Ligand A (74.06). While ADRB2 isn't strictly a CNS target, some CNS exposure can be relevant for side effect profiles.
**9. Caco-2 Permeability:** Ligand A (-5.004) has better Caco-2 permeability than Ligand B (-4.749).
**10. Aqueous Solubility:** Ligand A (-2.884) has better aqueous solubility than Ligand B (-4.642). This is important for formulation and bioavailability, and Ligand B's lower solubility is concerning.
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (0.842 and 0.642).
**12. Microsomal Clearance:** Ligand A (-2.339) has significantly lower microsomal clearance than Ligand B (63.126). This indicates better metabolic stability for Ligand A, a crucial factor for drug duration.
**13. In Vitro Half-Life:** Ligand A (21.382) has a much longer in vitro half-life than Ligand B (4.245). This further supports Ligand A's better metabolic stability.
**14. P-gp Efflux:** Ligand A (0.112) has lower P-gp efflux than Ligand B (0.76). Lower P-gp efflux is desirable for improved bioavailability.
**15. Binding Affinity:** Ligand A (-6.7 kcal/mol) has slightly better binding affinity than Ligand B (-6.2 kcal/mol). While the difference isn't huge, it's enough to be considered.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand A is the stronger candidate. While Ligand B has better BBB penetration, its significantly higher logP, lower solubility, and much higher microsomal clearance/shorter half-life are major drawbacks. Ligand A strikes a better balance between potency, ADME properties, and drug-likeness. The slightly better affinity of Ligand A further reinforces this conclusion.
Output:
1
2025-04-18 00:31:00,113 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [360.351, 49.41, 2.821, 1, 2, 0.821, 35.983, 79.333, -4.408, -3.032, 0.714, 8.716, 5.223, 0.027, -6.6]
**Ligand B:** [374.503, 77.1, 0.523, 1, 6, 0.625, 33.346, 43.583, -5.098, -1.668, 0.317, 10.539, 14.402, 0.029, -5.2]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal 200-500 Da range. Ligand A (360.351) is slightly preferred.
2. **TPSA:** Ligand A (49.41) is excellent, well below the 140 threshold. Ligand B (77.1) is still acceptable, but less ideal.
3. **logP:** Ligand A (2.821) is optimal (1-3). Ligand B (0.523) is quite low, potentially hindering permeability. This is a significant drawback.
4. **HBD/HBA:** Both have 1 HBD, which is good. Ligand A has 2 HBA, and Ligand B has 6. Ligand A is better here.
5. **QED:** Ligand A (0.821) is strong, indicating good drug-likeness. Ligand B (0.625) is acceptable, but lower.
6. **DILI:** Both are good, below 40. Ligand B (33.346) is slightly better.
7. **BBB:** Ligand A (79.333) is good, indicating reasonable potential for some CNS penetration (though not a primary concern for a cardiovascular target). Ligand B (43.583) is lower.
8. **Caco-2:** Ligand A (-4.408) is better than Ligand B (-5.098), indicating better absorption.
9. **Solubility:** Ligand A (-3.032) is better than Ligand B (-1.668).
10. **hERG:** Both are low, indicating low cardiotoxicity risk. Ligand A (0.714) is slightly better.
11. **Cl_mic:** Ligand A (8.716) has lower clearance, suggesting better metabolic stability. Ligand B (10.539) is higher.
12. **t1/2:** Ligand B (14.402) has a longer half-life than Ligand A (5.223). This is a positive for Ligand B.
13. **Pgp:** Both are very low (0.027 and 0.029), indicating minimal P-glycoprotein efflux.
14. **Affinity:** Ligand A (-6.6) is significantly more potent than Ligand B (-5.2) - a difference of 1.4 kcal/mol. This is a substantial advantage.
**Overall Assessment:**
Ligand A is clearly superior. While Ligand B has a longer half-life, the significant drawbacks of its low logP, higher TPSA, and substantially weaker binding affinity outweigh this benefit. The better logP, TPSA, solubility, metabolic stability, and, crucially, the much stronger binding affinity of Ligand A make it the more promising drug candidate. The GPCR-specific priorities strongly favor Ligand A.
Output:
1
2025-04-18 00:31:00,113 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (334.394 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (26.71) is significantly better than Ligand B (124.26). For a GPCR, keeping TPSA low is beneficial for permeability and potential BBB penetration. Ligand B's TPSA is quite high, potentially hindering absorption.
3. **logP:** Ligand A (4.69) is higher than the optimal range (1-3), but still potentially manageable. Ligand B (-0.593) is too low, potentially leading to poor membrane permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (5) for the same reason as HBDs.
6. **QED:** Ligand A (0.753) is better than Ligand B (0.567), indicating a more drug-like profile.
7. **DILI:** Both ligands have acceptable DILI risk (Ligand A: 68.088, Ligand B: 70.26), though ideally, lower is better. The difference is minimal.
8. **BBB:** Ligand A (66.344) is significantly better than Ligand B (38.232). While ADRB2 isn't exclusively a CNS target, some CNS exposure is not necessarily detrimental and higher BBB penetration is generally a positive attribute for a GPCR ligand.
9. **Caco-2:** Ligand A (-4.888) and Ligand B (-5.412) are both negative, indicating poor permeability. This is a concern for both, but Ligand A's value is slightly less negative.
10. **Solubility:** Ligand A (-5.186) is better than Ligand B (-2.774), indicating better aqueous solubility.
11. **hERG:** Ligand A (0.959) is better than Ligand B (0.258), indicating a lower risk of hERG inhibition and cardiotoxicity.
12. **Cl_mic:** Ligand B (13.804) has a much lower microsomal clearance than Ligand A (92.685), suggesting better metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand A (-28.383) has a longer in vitro half-life than Ligand B (-20.434).
14. **Pgp:** Ligand A (0.767) is better than Ligand B (0.029), indicating lower P-gp efflux.
15. **Affinity:** Ligand B (-7.2) has a slightly better binding affinity than Ligand A (-8.9). However, the difference is not substantial enough to outweigh the numerous ADME advantages of Ligand A.
**Overall Assessment:**
Ligand A demonstrates a significantly better balance of properties, particularly regarding TPSA, BBB, solubility, hERG, and Pgp efflux. While Ligand B has better metabolic stability (lower Cl_mic), the other ADME properties are considerably less favorable. For a GPCR like ADRB2, optimizing permeability and minimizing off-target effects (hERG) are crucial. The slightly better affinity of Ligand B doesn't compensate for its poor ADME profile.
Output:
1
2025-04-18 00:31:00,113 - INFO - Batch 483 complete. Total preferences: 7728
2025-04-18 00:31:00,113 - INFO - Processing batch 484/512...
2025-04-18 00:31:50,132 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (360.483 and 371.478 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (69.3) is significantly better than Ligand B (88.16). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally favors absorption.
3. **logP:** Both ligands have good logP values (2.338 and 1.721), falling within the 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Both ligands have the same number of HBA (4), which is acceptable.
6. **QED:** Ligand A (0.91) has a better QED score than Ligand B (0.692), indicating a more drug-like profile.
7. **DILI:** Ligand B (41.838) has a lower DILI risk than Ligand A (56.727), which is a significant advantage.
8. **BBB:** Ligand B (74.292) has a higher BBB penetration percentile than Ligand A (34.122). While not a primary concern for a cardiovascular target, it's still a slight positive for Ligand B.
9. **Caco-2:** Both ligands have similar, poor Caco-2 permeability (-5.254 and -5.283). This is a concern for both.
10. **Solubility:** Both ligands have similar, poor aqueous solubility (-2.441 and -2.132). This is a concern for both.
11. **hERG:** Ligand A (0.585) has a slightly lower hERG risk than Ligand B (0.225), which is preferable.
12. **Cl_mic:** Ligand B (8.631) has significantly lower microsomal clearance than Ligand A (36.709), indicating better metabolic stability. This is a major advantage.
13. **t1/2:** Ligand A (-32.423) has a longer in vitro half-life than Ligand B (-18.905), which is desirable.
14. **Pgp:** Ligand A (0.184) has lower P-gp efflux liability than Ligand B (0.085), which is preferable.
15. **Binding Affinity:** Ligand A (-6.9 kcal/mol) has a slightly better binding affinity than Ligand B (-5.9 kcal/mol). This is a significant advantage, potentially outweighing some ADME drawbacks.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A performs better on logP, TPSA, and Pgp. The affinity difference is also substantial. While Ligand B has better metabolic stability (Cl_mic) and lower DILI risk, the affinity advantage of Ligand A is substantial. The poor Caco-2 and solubility are concerns for both, but can be addressed with formulation strategies.
**Overall Assessment:**
Despite the better metabolic stability and lower DILI risk of Ligand B, the stronger binding affinity of Ligand A, coupled with its better TPSA, logP, and Pgp properties, makes it the more promising candidate. The affinity difference is likely to have a greater impact on efficacy than the metabolic differences, especially considering formulation strategies can be employed to address solubility and permeability.
Output:
1
2025-04-18 00:31:50,132 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (443.084 Da) is slightly above the ideal range, but acceptable. Ligand B (372.853 Da) is well within the ideal range.
2. **TPSA:** Ligand A (83.7) is good, below 140, and acceptable for a non-CNS target. Ligand B (113.18) is still under 140, but higher than A.
3. **logP:** Ligand A (4.032) is at the upper end of the optimal range, potentially leading to solubility issues. Ligand B (1.728) is good, within the optimal range.
4. **HBD:** Ligand A (2) is good. Ligand B (3) is also acceptable.
5. **HBA:** Ligand A (4) is good. Ligand B (5) is acceptable.
6. **QED:** Both Ligand A (0.638) and Ligand B (0.571) are above 0.5, indicating good drug-likeness.
7. **DILI:** Ligand A (90.151) has a high DILI risk. Ligand B (72.121) has a lower, more acceptable DILI risk. This is a significant negative for Ligand A.
8. **BBB:** Both ligands have low BBB penetration, which is fine for a cardiovascular target.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and requires further investigation. However, we'll proceed assuming they represent low permeability.
10. **Solubility:** Ligand A (-4.176) has very poor solubility, a major concern given its high logP. Ligand B (-2.827) has slightly better, but still poor solubility.
11. **hERG:** Ligand A (0.073) has a very low hERG risk, which is excellent. Ligand B (0.181) also has a low hERG risk.
12. **Cl_mic:** Ligand A (7.203) has a lower microsomal clearance, suggesting better metabolic stability. Ligand B (50.039) has a much higher clearance, indicating faster metabolism.
13. **t1/2:** Ligand A (24.192) has a better in vitro half-life. Ligand B (14.931) is shorter.
14. **Pgp:** Both ligands have low Pgp efflux liability.
15. **Affinity:** Ligand A (-7.0) has a slightly better binding affinity than Ligand B (-6.6). However, the difference is less than 1.5 kcal/mol.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. While Ligand A has slightly better affinity, its high logP, very poor solubility, and significantly higher DILI risk are major drawbacks. Ligand B, while having a slightly lower affinity, presents a much more balanced profile with a better logP, lower DILI, and acceptable TPSA. The improved metabolic stability of Ligand A is not enough to overcome these significant liabilities.
**Conclusion:**
Considering the overall profile and GPCR-specific priorities, Ligand B is the more promising drug candidate.
Output:
0
2025-04-18 00:31:50,133 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (345.414 and 343.471 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (46.61) is better than Ligand B (54.34). Both are below 140, but lower TPSA generally favors absorption.
3. **logP:** Ligand A (3.479) is slightly higher than Ligand B (2.823), both within the optimal 1-3 range.
4. **HBD:** Ligand A (0) is preferable to Ligand B (1). Fewer HBDs generally improve permeability.
5. **HBA:** Both ligands have 3 HBA, which is acceptable.
6. **QED:** Ligand A (0.771) has a better QED score than Ligand B (0.611), indicating a more drug-like profile.
7. **DILI:** Ligand B (41.605) has a lower DILI risk than Ligand A (58.123), which is a significant advantage.
8. **BBB:** Ligand A (92.943) has a substantially higher BBB penetration percentile than Ligand B (67.352). While ADRB2 isn't *necessarily* a CNS target, higher BBB is rarely detrimental and can open up possibilities.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.239) is slightly better than Ligand B (-4.886).
10. **Solubility:** Ligand A (-4.7) has a slightly better solubility score than Ligand B (-2.75).
11. **hERG:** Ligand A (0.53) has a lower hERG risk than Ligand B (0.394), which is a positive.
12. **Cl_mic:** Ligand B (45.738) has a slightly lower microsomal clearance than Ligand A (43.866), indicating better metabolic stability.
13. **t1/2:** Ligand B (-5.107) has a longer in vitro half-life than Ligand A (5.65), which is a significant advantage.
14. **Pgp:** Ligand B (0.375) has a lower P-gp efflux liability than Ligand A (0.646), which is beneficial for bioavailability.
15. **Binding Affinity:** Ligand A (-8.9 kcal/mol) has a significantly stronger binding affinity than Ligand B (-5.1 kcal/mol). This is a substantial advantage, potentially outweighing some ADME concerns.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A excels in affinity and has acceptable logP and TPSA. Ligand B has better Pgp efflux and DILI, and a longer half-life. However, the difference in binding affinity is very large (3.8 kcal/mol). A stronger binding affinity is often the most important factor, especially in early-stage drug discovery. The slightly worse DILI of Ligand A can be addressed in later optimization stages.
**Conclusion:**
Despite Ligand B's advantages in DILI, half-life, and Pgp efflux, the significantly stronger binding affinity of Ligand A makes it the more promising candidate. The other parameters are reasonably balanced, and the affinity advantage is substantial.
Output:
1
2025-04-18 00:31:50,133 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.415 and 359.495 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (84.67) is slightly higher than Ligand B (73.2). Both are below the 140 threshold for good oral absorption, and acceptable for a cardiovascular target (not requiring significant BBB penetration). Ligand B is preferable.
3. **logP:** Ligand A (1.588) is within the optimal 1-3 range. Ligand B (3.167) is at the higher end of optimal, but still acceptable. No major concern for either.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 5 HBA, and Ligand B has 4. Both are below the 10 threshold.
6. **QED:** Both ligands have good QED scores (0.733 and 0.775), indicating good drug-like properties.
7. **DILI:** Ligand A (38.309) has a slightly better DILI score than Ligand B (43.117), indicating a lower risk of liver injury.
8. **BBB:** Both ligands have the same BBB penetration (74.254). This is acceptable for a cardiovascular target, where high BBB penetration is not crucial.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.51 and -4.864). These values are unusual and difficult to interpret without more context, but suggest poor permeability.
10. **Solubility:** Ligand A (-2.705) has better aqueous solubility than Ligand B (-4.759). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.177) has a significantly lower hERG inhibition liability than Ligand B (0.693). This is a critical advantage, as hERG inhibition can cause cardiotoxicity.
12. **Cl_mic:** Ligand A (40.371) has lower microsomal clearance than Ligand B (75.365), suggesting better metabolic stability.
13. **t1/2:** Ligand B (23.173) has a significantly longer in vitro half-life than Ligand A (8.494). This is a desirable property for less frequent dosing.
14. **Pgp:** Ligand A (0.057) has lower P-gp efflux liability than Ligand B (0.491), which can improve oral bioavailability.
15. **Binding Affinity:** Ligand B (-6.1) has a slightly better binding affinity than Ligand A (-5.8). This is a 0.3 kcal/mol difference, which is not huge, but still a factor.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are important. Ligand B has a slightly better logP and affinity, but Ligand A has better TPSA, Pgp, and crucially, a much better hERG profile and lower Cl_mic. The hERG risk is a major concern, and the metabolic stability is also important.
**Overall Assessment:**
While Ligand B has a slightly better affinity and half-life, Ligand A is preferable due to its significantly lower hERG inhibition liability, better solubility, lower Pgp efflux, and lower microsomal clearance. The improved safety profile and potentially better bioavailability outweigh the small difference in binding affinity.
Output:
1
2025-04-18 00:31:50,133 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.475 and 343.431 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (83.36) is slightly higher than Ligand B (78.43). Both are below the 140 threshold for good oral absorption, and acceptable for a cardiovascular target (not necessarily CNS).
3. **logP:** Ligand A (1.377) is better than Ligand B (0.538). Both are within the optimal 1-3 range, but Ligand A is closer to the sweet spot. Ligand B is a bit low, potentially impacting permeability.
4. **HBD:** Ligand A (3) is higher than Ligand B (1). Both are within the acceptable limit of 5.
5. **HBA:** Ligand A (4) is lower than Ligand B (5). Both are within the acceptable limit of 10.
6. **QED:** Ligand B (0.863) has a higher QED score than Ligand A (0.63), indicating a more drug-like profile overall. This is a positive for Ligand B.
7. **DILI:** Ligand B (23.11) has a significantly lower DILI risk than Ligand A (12.059). This is a major advantage for Ligand B.
8. **BBB:** Ligand B (79.992) has a much higher BBB penetration percentile than Ligand A (38.891). While ADRB2 isn't exclusively a CNS target, some CNS exposure can occur, and higher BBB is generally favorable.
9. **Caco-2:** Both ligands have very poor Caco-2 permeability (-5.001 and -5.054), suggesting poor intestinal absorption. This is a significant concern for both.
10. **Solubility:** Both ligands have poor aqueous solubility (-1.103 and -1.353). This is a concern for both, potentially hindering bioavailability.
11. **hERG:** Ligand A (0.154) has a slightly lower hERG inhibition liability than Ligand B (0.417), which is preferable.
12. **Cl_mic:** Ligand A (7.837) has a higher microsomal clearance than Ligand B (1.871), indicating lower metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand B (-11.898) has a much longer in vitro half-life than Ligand A (26.095). This is a strong positive for Ligand B, suggesting less frequent dosing potential.
14. **Pgp:** Ligand A (0.081) has lower P-gp efflux liability than Ligand B (0.006). Lower Pgp is better.
15. **Binding Affinity:** Ligand A (-6.7 kcal/mol) has a slightly better binding affinity than Ligand B (-6.1 kcal/mol). This is a 0.6 kcal/mol difference, which is not huge, but is a factor.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand A has a better logP and slightly better affinity, and better Pgp. However, Ligand B excels in DILI risk, BBB penetration, and crucially, metabolic stability (Cl_mic and t1/2). The poor Caco-2 and solubility are concerning for both, but can be addressed with formulation strategies. The lower DILI and better metabolic stability of Ligand B are more critical for overall drug development success, outweighing the slight advantage in affinity for Ligand A.
**Conclusion:**
Considering the balance of properties and the priorities for a GPCR target, Ligand B is the more promising candidate.
Output:
0
2025-04-18 00:31:50,133 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (349.519) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (33.2) is significantly better than Ligand A (52.65). ADRB2 is not a CNS target, but lower TPSA generally improves absorption.
3. **logP:** Ligand A (1.975) is within the optimal range, while Ligand B (4.214) is pushing the upper limit. Higher logP can lead to solubility issues and off-target effects.
4. **HBD:** Ligand A (1) is preferable to Ligand B (0). Having at least one HBD can improve solubility.
5. **HBA:** Both ligands have 3 HBA, which is acceptable.
6. **QED:** Both ligands have similar QED values (0.648 and 0.683), indicating good drug-likeness.
7. **DILI:** Ligand A (6.592) has a much lower DILI risk than Ligand B (27.181). This is a significant advantage for Ligand A.
8. **BBB:** This is less critical for ADRB2, but Ligand B (94.261) has a higher BBB penetration than Ligand A (64.87).
9. **Caco-2:** Both ligands have similar, poor Caco-2 permeability (-4.528 and -4.51).
10. **Solubility:** Ligand A (-1.62) has better aqueous solubility than Ligand B (-4.69).
11. **hERG:** Ligand A (0.46) has a lower hERG inhibition liability than Ligand B (0.665), which is a safety advantage.
12. **Cl_mic:** Ligand B (67.82) has higher microsomal clearance than Ligand A (18.922), suggesting lower metabolic stability.
13. **t1/2:** Ligand A (-1.644) has a slightly better in vitro half-life than Ligand B (-1.562).
14. **Pgp:** Ligand A (0.017) has much lower P-gp efflux liability than Ligand B (0.225), which is favorable for bioavailability.
15. **Affinity:** Ligand A (-6.7) has a slightly better binding affinity than Ligand B (-6.3). While the difference is not huge, it is still a positive.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A has better logP, TPSA, Pgp and affinity.
**Overall Assessment:**
Ligand A demonstrates a more favorable balance of properties. It has a lower DILI risk, better solubility, lower hERG inhibition, lower P-gp efflux, and slightly better affinity. While Ligand B has better BBB penetration, this is less crucial for a non-CNS target like ADRB2. The higher logP and clearance of Ligand B are concerning.
Output:
1
2025-04-18 00:31:50,133 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (408.34 Da) is within the ideal range. Ligand B (346.391 Da) is also within range, but closer to the lower limit.
2. **TPSA:** Ligand A (58.22) is excellent, well below the 140 threshold. Ligand B (132.63) is higher, but still acceptable for a non-CNS target.
3. **logP:** Ligand A (4.125) is slightly high, potentially leading to solubility issues. Ligand B (0.357) is quite low, which could hinder permeability.
4. **HBD:** Both ligands have acceptable HBD counts (1 and 4 respectively), within the guideline of <=5.
5. **HBA:** Both ligands have acceptable HBA counts (4 and 5 respectively), within the guideline of <=10.
6. **QED:** Ligand A (0.777) has a better QED score than Ligand B (0.599), indicating better overall drug-likeness.
7. **DILI:** Ligand A (26.018) has a significantly lower DILI risk than Ligand B (63.513). This is a major advantage.
8. **BBB:** ADRB2 is a cardiovascular target, so BBB penetration is not a priority. Ligand A (74.292) is better, but not crucial. Ligand B (24.351) is low.
9. **Caco-2:** Ligand A (-4.973) and Ligand B (-5.52) both have negative values, indicating poor permeability.
10. **Solubility:** Ligand A (-4.04) has slightly better solubility than Ligand B (-2.783).
11. **hERG:** Ligand A (0.894) has a lower hERG risk than Ligand B (0.315).
12. **Cl_mic:** Ligand A (67.49) has a higher (worse) microsomal clearance than Ligand B (-11.571). This suggests Ligand B is more metabolically stable.
13. **t1/2:** Ligand A (-5.127) has a shorter in vitro half-life than Ligand B (12.231).
14. **Pgp:** Ligand A (0.373) has lower P-gp efflux than Ligand B (0.028), which is favorable.
15. **Affinity:** Both ligands have very similar and excellent binding affinities (-7.0 and -7.1 kcal/mol). The difference is negligible.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. While Ligand A has a slightly higher logP, its significantly better DILI score, lower Pgp efflux, and better QED outweigh this concern. The affinities are almost identical. The higher metabolic stability of Ligand B is a plus, but the DILI risk is a substantial negative.
**Conclusion:**
Ligand A presents a more favorable overall profile, particularly regarding safety (DILI) and drug-likeness, despite a slightly higher logP.
Output:
1
2025-04-18 00:31:50,133 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (347.459 Da and 355.389 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (60.93) is significantly better than Ligand B (99.77). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is approaching a TPSA that could hinder oral absorption.
**3. logP:** Both ligands have similar and good logP values (1.247 and 1.185, respectively), falling within the optimal 1-3 range.
**4. H-Bond Donors:** Ligand A (0) is preferable to Ligand B (3). Fewer H-bond donors generally improve membrane permeability.
**5. H-Bond Acceptors:** Ligand A (3) is preferable to Ligand B (4). Fewer H-bond acceptors also generally improve membrane permeability.
**6. QED:** Ligand A (0.671) has a slightly better QED score than Ligand B (0.579), indicating a more drug-like profile.
**7. DILI Risk:** Ligand B (47.189) has a lower DILI risk than Ligand A (29.546), which is a positive. However, both are below the concerning threshold of 60.
**8. BBB Penetration:** Ligand A (83.443) has better predicted BBB penetration than Ligand B (74.874). While ADRB2 isn't exclusively a CNS target, some CNS exposure may be acceptable or even desirable depending on the specific therapeutic goal.
**9. Caco-2 Permeability:** Ligand A (-4.26) is significantly better than Ligand B (-5.572). Higher Caco-2 values indicate better intestinal absorption.
**10. Aqueous Solubility:** Both ligands have very poor aqueous solubility (-2.722 and -2.584). This is a significant concern for both, and formulation strategies would be crucial.
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.175 and 0.278), which is excellent.
**12. Microsomal Clearance:** Ligand B (-0.731) has a *much* lower (better) microsomal clearance than Ligand A (52.156). This suggests significantly improved metabolic stability for Ligand B.
**13. In vitro Half-Life:** Ligand B (-9.054) has a much longer in vitro half-life than Ligand A (18.18). This is a substantial advantage for Ligand B.
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (0.034 and 0.023).
**15. Binding Affinity:** Both ligands have very similar binding affinities (-6.4 and -6.9 kcal/mol). The difference is less than the 1.5 kcal/mol threshold that would decisively favor one over the other.
**Overall Assessment:**
Ligand A has advantages in TPSA, Caco-2 permeability, and BBB penetration, which are important for a GPCR target. However, Ligand B demonstrates a substantial advantage in metabolic stability (Cl_mic) and in vitro half-life, and a lower DILI risk. Given the poor solubility of both compounds, metabolic stability and longer half-life are crucial to achieving adequate exposure *in vivo*. The slightly better permeability of Ligand A is outweighed by the significant pharmacokinetic advantages of Ligand B.
Output:
0
2025-04-18 00:31:50,133 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (344.405 and 353.427 Da) are within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (33.2) is significantly better than Ligand B (116.48). ADRB2 is a cardiovascular target, not CNS, but lower TPSA generally improves absorption. Ligand A is well below the 140 threshold, while B is approaching it.
3. **logP:** Ligand A (4.431) is higher than Ligand B (-1.741). While >4 can be problematic, 4.431 is acceptable, and -1.741 is quite low, potentially hindering permeability.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (2) is better than Ligand B (8). Lower HBA is generally preferred for permeability.
6. **QED:** Ligand A (0.822) is significantly better than Ligand B (0.57). Higher QED indicates better drug-likeness.
7. **DILI:** Ligand B (20.706) is *much* better than Ligand A (47.693). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (90.927) is better than Ligand B (19.31). While not a CNS target, higher BBB can sometimes correlate with better overall distribution.
9. **Caco-2:** Ligand A (-4.693) is better than Ligand B (-5.581). Higher Caco-2 permeability is desirable.
10. **Solubility:** Ligand A (-4.916) is better than Ligand B (0.22). Better solubility is generally preferred.
11. **hERG:** Ligand A (0.842) is better than Ligand B (0.04). Lower hERG inhibition is crucial for avoiding cardiotoxicity.
12. **Cl_mic:** Ligand B (-9.038) is *much* better than Ligand A (43.468). Lower clearance indicates better metabolic stability.
13. **t1/2:** Ligand B (13.828) is better than Ligand A (1.019). Longer half-life is generally preferred.
14. **Pgp:** Ligand B (0.005) is *much* better than Ligand A (0.623). Lower P-gp efflux is desirable.
15. **Affinity:** Ligand B (-8.0) is significantly better than Ligand A (-5.6). This is a substantial difference in binding affinity.
**Overall Assessment:**
Ligand B has a significantly better binding affinity (-8.0 vs -5.6 kcal/mol). This is a major advantage, potentially outweighing some of its ADME drawbacks. It also has a much lower DILI risk, better metabolic stability (Cl_mic and t1/2), and lower P-gp efflux. While Ligand A has better TPSA, logP, solubility, and hERG, the superior affinity and safety profile of Ligand B are more important for a GPCR target like ADRB2. The lower logP of Ligand B is a concern, but can be addressed with formulation strategies.
Output:
0
2025-04-18 00:31:50,133 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [350.419, 111.12 , -0.831, 2. , 6. , 0.601, 19.698, 72.237, -5.401, -0.689, 0.172, -11.173, -18.414, 0.005, -6.3 ]
**Ligand B:** [366.571, 40.62 , 3.548, 0. , 3. , 0.764, 12.834, 88.561, -4.85 , -3.416, 0.562, 70.999, -25.349, 0.221, -5.7 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (350.419) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (111.12) is higher than Ligand B (40.62). For a cardiovascular GPCR, TPSA isn't *as* critical as for a CNS target, but lower is still preferred for better absorption. Ligand B is significantly better here.
3. **logP:** Ligand A (-0.831) is quite low, potentially hindering membrane permeability. Ligand B (3.548) is within the optimal range (1-3). This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (2) is reasonable. Ligand B (0) is even better, potentially improving permeability.
5. **HBA:** Ligand A (6) is acceptable. Ligand B (3) is better.
6. **QED:** Both ligands have good QED scores (A: 0.601, B: 0.764), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (19.698) has a higher DILI risk than Ligand B (12.834), which is undesirable.
8. **BBB:** Ligand A (72.237) and Ligand B (88.561) both have good BBB penetration, but this is less critical for a cardiovascular target. Ligand B is slightly better.
9. **Caco-2:** Both have negative values, which is unusual. Assuming these are percentile scores, this suggests poor permeability for both. However, the absolute values are similar.
10. **Solubility:** Ligand A (-0.689) has poor solubility, while Ligand B (-3.416) is even worse. This is a concern for both, but more so for Ligand B.
11. **hERG:** Both have low hERG inhibition liability (A: 0.172, B: 0.562), which is good.
12. **Cl_mic:** Ligand A (-11.173) has a significantly lower (better) microsomal clearance than Ligand B (70.999), indicating better metabolic stability.
13. **t1/2:** Ligand A (-18.414) has a longer (better) in vitro half-life than Ligand B (-25.349).
14. **Pgp:** Ligand A (0.005) has very low P-gp efflux, which is excellent. Ligand B (0.221) is also low, but higher than A.
15. **Affinity:** Both have similar binding affinities (-6.3 and -5.7 kcal/mol). The difference is not substantial enough to override other factors.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand B is better. While solubility is a concern for both, Ligand B has a much more favorable logP and TPSA. Ligand A has better metabolic stability and P-gp efflux, but the significant issues with logP and solubility outweigh these benefits. The DILI risk is also lower for Ligand B.
Output:
0
2025-04-18 00:31:50,133 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (355.47 & 368.47 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Both ligands (71.84 & 69.64) are below the 140 A^2 threshold for good oral absorption, and acceptable for a cardiovascular GPCR. No clear advantage.
3. **logP:** Ligand A (4.03) is at the higher end of the optimal range (1-3), while Ligand B (1.82) is closer to the lower end. For a GPCR, a slightly higher logP can be beneficial for membrane permeability, but we need to consider other factors.
4. **HBD:** Both have 2 HBD, which is within the acceptable limit of <=5. No clear advantage.
5. **HBA:** Ligand A has 6 HBA, and Ligand B has 4. Both are within the acceptable limit of <=10. No clear advantage.
6. **QED:** Both ligands have good QED scores (0.741 & 0.805), indicating good drug-like properties. No clear advantage.
7. **DILI:** Ligand A has a DILI risk of 83.25%, which is concerning (high risk). Ligand B has a much lower DILI risk of 22.99%, which is excellent. This is a significant advantage for Ligand B.
8. **BBB:** Both ligands have similar BBB penetration (61.61% & 68.21%). As ADRB2 is a cardiovascular target, BBB penetration is not a primary concern.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.129 & -5.16), which is unusual and suggests poor permeability. This is a significant drawback for both.
10. **Solubility:** Both ligands have negative solubility values (-4.085 & -2.084), indicating very poor aqueous solubility. This is a major concern for both.
11. **hERG:** Ligand A (0.626) has a slightly higher hERG risk than Ligand B (0.442), but both are relatively low.
12. **Cl_mic:** Ligand A (39.77) has a higher microsomal clearance than Ligand B (20.17), indicating lower metabolic stability. Ligand B is preferable here.
13. **t1/2:** Ligand A (80.97) has a significantly longer in vitro half-life than Ligand B (-1.94). This is a strong advantage for Ligand A.
14. **Pgp:** Ligand A (0.689) has a higher P-gp efflux liability than Ligand B (0.337). Lower P-gp is preferred, giving an advantage to Ligand B.
15. **Affinity:** Ligand A (-6.6 kcal/mol) has a slightly better binding affinity than Ligand B (-6.3 kcal/mol). While this is a positive for Ligand A, the difference is relatively small.
**Overall Assessment:**
Despite Ligand A's slightly better affinity and longer half-life, the significantly higher DILI risk and higher P-gp efflux liability are major drawbacks. Ligand B demonstrates a much more favorable safety profile (lower DILI) and better metabolic properties (lower Cl_mic, lower Pgp). Both compounds have poor solubility and permeability, which would require significant formulation work, but the safety profile is paramount. Given the cardiovascular context, minimizing off-target effects and toxicity is critical.
Output:
0
2025-04-18 00:31:50,133 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (353.463 and 358.511 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (96.53) is higher than Ligand B (58.12). For a cardiovascular GPCR (ADRB2), TPSA is less critical than for CNS targets, but lower is still preferred for permeability. Ligand B wins here.
3. **logP:** Ligand A (0.729) is a bit low, potentially impacting permeability. Ligand B (3.65) is within the optimal 1-3 range. Ligand B is better.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (1), but both are acceptable (<=5).
5. **HBA:** Ligand A (4) and Ligand B (5) are both acceptable (<=10).
6. **QED:** Ligand B (0.782) has a better QED score than Ligand A (0.539), indicating a more drug-like profile. Ligand B wins.
7. **DILI:** Ligand A (23.885) has a significantly lower DILI risk than Ligand B (39.124). Ligand A wins.
8. **BBB:** Ligand B (87.437) has a higher BBB penetration percentile than Ligand A (66.227). While ADRB2 isn't a CNS target, some degree of BBB penetration can sometimes be acceptable and might indicate favorable partitioning. Ligand B wins.
9. **Caco-2:** Ligand A (-4.884) and Ligand B (-5.199) are both negative, indicating poor permeability. This is concerning for both, but similar.
10. **Solubility:** Ligand A (-1.644) is better than Ligand B (-2.988). Ligand A wins.
11. **hERG:** Ligand A (0.093) has a lower hERG inhibition liability than Ligand B (0.836). This is a significant advantage for Ligand A, as it reduces the risk of cardiotoxicity. Ligand A wins.
12. **Cl_mic:** Ligand A (29.336) has a lower microsomal clearance than Ligand B (61.035), suggesting better metabolic stability. Ligand A wins.
13. **t1/2:** Ligand B (44.489) has a significantly longer in vitro half-life than Ligand A (12.584). This is a substantial advantage for Ligand B. Ligand B wins.
14. **Pgp:** Ligand A (0.007) has much lower P-gp efflux liability than Ligand B (0.467). This is a significant advantage for Ligand A, improving bioavailability. Ligand A wins.
15. **Affinity:** Ligand A (-7.2) has a slightly better binding affinity than Ligand B (-5.8). This is a significant advantage for Ligand A.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand A and Ligand B are both flawed. Ligand A has a slightly lower logP, but excels in safety parameters (DILI, hERG) and metabolic stability (Cl_mic). Ligand B has better TPSA, BBB, QED, and half-life, but comes with higher DILI, hERG, and Pgp efflux. The affinity difference is also in favor of Ligand A.
Given the cardiovascular context, minimizing cardiotoxicity (hERG) and maximizing metabolic stability are paramount. The superior hERG profile, lower DILI, lower Cl_mic, and better Pgp profile of Ligand A, coupled with its slightly better binding affinity, outweigh the benefits of Ligand B's slightly better TPSA and half-life.
Output:
1
2025-04-18 00:31:50,133 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 drug candidates. ADRB2 is a GPCR, so we'll prioritize logP, Pgp, TPSA, and affinity, alongside general drug-like properties.
**Ligand A:**
* **MW:** 346.475 Da - Good, within the ideal range.
* **TPSA:** 58.44 - Excellent, well below the 140 threshold, suggesting good absorption.
* **logP:** 2.245 - Optimal, within the 1-3 range.
* **HBD:** 0 - Acceptable, low HBD can aid permeability.
* **HBA:** 4 - Acceptable, within the limit.
* **QED:** 0.712 - Excellent, highly drug-like.
* **DILI:** 12.098 - Very good, low risk of liver injury.
* **BBB:** 73.866 - Good, indicating reasonable potential for CNS penetration (though not critical for ADRB2, it's a bonus).
* **Caco-2:** -4.846 - Concerningly low, suggesting poor intestinal absorption.
* **Solubility:** -0.518 - Poor solubility, which could hinder bioavailability.
* **hERG:** 0.269 - Very low risk of hERG inhibition, excellent.
* **Cl_mic:** 21.885 - Moderate clearance, could be better.
* **t1/2:** -5.895 - Very short half-life, potentially requiring frequent dosing.
* **Pgp:** 0.093 - Low P-gp efflux, favorable for bioavailability.
* **Affinity:** -6.5 kcal/mol - Good binding affinity.
**Ligand B:**
* **MW:** 348.334 Da - Good, within the ideal range.
* **TPSA:** 124.18 - Higher than ideal, could impact absorption.
* **logP:** 0.439 - Low, potentially hindering permeation.
* **HBD:** 4 - Acceptable, within the limit.
* **HBA:** 5 - Acceptable, within the limit.
* **QED:** 0.603 - Good, drug-like.
* **DILI:** 64.288 - Moderate-high risk of liver injury.
* **BBB:** 33.036 - Low BBB penetration, not a major concern for ADRB2.
* **Caco-2:** -5.529 - Very low, suggesting poor intestinal absorption.
* **Solubility:** -3.072 - Very poor solubility, a significant issue.
* **hERG:** 0.304 - Very low risk of hERG inhibition, excellent.
* **Cl_mic:** 22.771 - Moderate clearance, similar to Ligand A.
* **t1/2:** -35.578 - Extremely short half-life, even worse than Ligand A.
* **Pgp:** 0.021 - Low P-gp efflux, favorable.
* **Affinity:** -6.9 kcal/mol - Slightly better binding affinity than Ligand A.
**Comparison and Decision:**
Both ligands have significant drawbacks. Both have poor Caco-2 permeability and solubility. However, Ligand A has a much better DILI score and a better BBB score. While Ligand B has slightly better affinity (-6.9 vs -6.5), the difference is not substantial enough to outweigh the significant liabilities of Ligand B (higher DILI, very poor solubility, and extremely short half-life). Ligand A's better ADME profile, particularly the lower DILI risk and better solubility, makes it the more promising candidate despite the Caco-2 issue. The Caco-2 issue could potentially be addressed with formulation strategies.
Therefore, I prefer Ligand A.
Output:
1
2025-04-18 00:31:50,134 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (355.429 and 343.471 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (61.44) is slightly higher than Ligand B (54.46). Both are below the 140 A^2 threshold for good oral absorption, and acceptable for a cardiovascular GPCR. Ligand B is slightly preferred.
3. **logP:** Ligand A (1.693) is within the optimal 1-3 range. Ligand B (3.229) is at the higher end of optimal, potentially increasing off-target effects. Ligand A is preferred.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable (<=5). Ligand B is slightly preferred.
5. **HBA:** Ligand A (3) and Ligand B (4) are both acceptable (<=10). No clear advantage.
6. **QED:** Both ligands have good QED scores (0.713 and 0.806, respectively), indicating good drug-like properties. Ligand B is slightly preferred.
7. **DILI:** Ligand A (26.522) has a significantly lower DILI risk than Ligand B (19.426). This is a major advantage for Ligand A.
8. **BBB:** Both ligands have good BBB penetration (72.78 and 78.519). ADRB2 is a cardiovascular target, so BBB penetration isn't critical, but higher is still preferable. Ligand B is slightly preferred.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.025 and -4.811). This is unusual and suggests poor permeability. No clear advantage.
10. **Solubility:** Both ligands have negative solubility values (-2.544 and -3.42). This is also unusual and suggests poor solubility. No clear advantage.
11. **hERG:** Both ligands have low hERG inhibition liability (0.512 and 0.751). No clear advantage.
12. **Cl_mic:** Ligand A (-13.579) has a *much* lower (better) microsomal clearance than Ligand B (70.604). This indicates significantly better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (-1.503) has a negative half-life, which is unusual. Ligand B (4.046) has a reasonable half-life. Ligand B is preferred.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.025 and 0.218). No clear advantage.
15. **Affinity:** Both ligands have very similar binding affinities (-6.6 and -6.4 kcal/mol). The difference is not substantial enough to be decisive.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. While both ligands perform reasonably well on these metrics, the significant advantages of Ligand A in DILI risk and microsomal clearance are crucial. Metabolic stability (low Cl_mic) is vital for maintaining therapeutic concentrations, and minimizing liver toxicity (low DILI) is paramount.
**Conclusion:**
Despite Ligand B having slightly better BBB penetration and half-life, the superior DILI profile and significantly improved metabolic stability of Ligand A outweigh these minor advantages. The similar binding affinities make the ADME properties the deciding factor.
Output:
1
2025-04-18 00:31:50,134 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [369.447, 105.55 , -2.059, 2. , 7. , 0.558, 41.295, 12.873, -5.603, -1.416, 0.091, -18.925, 23.673, 0.003, -7.4 ]
**Ligand B:** [357.483, 64.34 , 3.876, 1. , 7. , 0.751, 84.335, 69.252, -4.928, -3.806, 0.759, 48.176, 20.024, 0.701, -7.4 ]
Here's a step-by-step comparison, considering the provided guidelines and GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (357.483) is slightly lower, which is generally favorable.
2. **TPSA:** Ligand A (105.55) is higher than Ligand B (64.34). Ligand B is much better, being well below the 140 A^2 threshold for good oral absorption.
3. **logP:** Ligand A (-2.059) is quite low, potentially hindering permeability. Ligand B (3.876) is excellent, falling within the optimal 1-3 range. This is a significant advantage for Ligand B.
4. **HBD:** Both have acceptable HBD counts (2 and 1, respectively), well below the 5 threshold.
5. **HBA:** Both have the same HBA count (7), which is acceptable (<=10).
6. **QED:** Both have reasonable QED scores (0.558 and 0.751), indicating drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (41.295) has a much lower DILI risk than Ligand B (84.335). This is a significant advantage for Ligand A.
8. **BBB:** Ligand B (69.252) has a higher BBB penetration percentile than Ligand A (12.873). While ADRB2 isn't a CNS target, some peripheral exposure can be undesirable.
9. **Caco-2:** Ligand A (-5.603) has a negative Caco-2 value, which is concerning. Ligand B (-4.928) is also low, but less negative.
10. **Solubility:** Ligand A (-1.416) has slightly better solubility than Ligand B (-3.806).
11. **hERG:** Both have very low hERG risk (0.091 and 0.759), which is excellent.
12. **Cl_mic:** Ligand A (-18.925) has a much lower (better) microsomal clearance than Ligand B (48.176), indicating greater metabolic stability.
13. **t1/2:** Ligand A (23.673) has a longer in vitro half-life than Ligand B (20.024).
14. **Pgp:** Ligand A (0.003) has significantly lower P-gp efflux liability than Ligand B (0.701). This is a major advantage for Ligand A, improving bioavailability.
15. **Affinity:** Both ligands have the same binding affinity (-7.4 kcal/mol), so this parameter doesn't differentiate them.
**Overall Assessment:**
Ligand B has a superior logP and BBB penetration, but suffers from a high DILI risk and relatively poor metabolic stability (higher Cl_mic). Ligand A has a lower DILI risk, better metabolic stability, lower P-gp efflux, and a slightly better solubility. The very low logP of Ligand A is a concern, but the other advantages, particularly the significantly lower DILI and P-gp efflux, outweigh this drawback. Given the GPCR-specific priorities, the combination of good metabolic stability, low P-gp efflux, and acceptable TPSA makes Ligand A the more promising candidate.
Output:
1
2025-04-18 00:31:50,134 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (356.47 Da) is better positioned within the ideal range (200-500 Da) than Ligand B (380.94 Da). Both are acceptable.
2. **TPSA:** Ligand B (43.78) is significantly better than Ligand A (133.55). ADRB2 is not a CNS target, but lower TPSA generally improves absorption.
3. **logP:** Ligand B (3.47) is optimal, while Ligand A (0.387) is quite low, potentially hindering membrane permeability. This is a significant drawback for Ligand A.
4. **HBD:** Ligand A (5) is at the upper limit, while Ligand B (1) is excellent.
5. **HBA:** Both ligands have 4 HBA, which is acceptable.
6. **QED:** Ligand B (0.799) is much better than Ligand A (0.382), indicating a more drug-like profile.
7. **DILI:** Ligand A (10.82) is considerably better than Ligand B (22.99), indicating a lower risk of liver injury.
8. **BBB:** Both are not particularly relevant as ADRB2 is not a CNS target, but Ligand B (69.95) is higher.
9. **Caco-2:** Ligand A (-5.497) and Ligand B (-4.708) are both negative, which is unusual and difficult to interpret without knowing the scale. However, a less negative value is generally preferred.
10. **Solubility:** Ligand A (-1.573) is better than Ligand B (-3.72).
11. **hERG:** Ligand A (0.191) has a much lower hERG risk than Ligand B (0.831). This is a critical advantage.
12. **Cl_mic:** Ligand A (-2.684) has a lower (better) microsomal clearance than Ligand B (78.108), suggesting greater metabolic stability.
13. **t1/2:** Ligand B (61.161) has a significantly longer in vitro half-life than Ligand A (-6.087).
14. **Pgp:** Ligand A (0.013) has much lower P-gp efflux liability than Ligand B (0.687), which is favorable for bioavailability.
15. **Affinity:** Ligand B (-8.1 kcal/mol) has a substantially stronger binding affinity than Ligand A (-5.5 kcal/mol). This is a major advantage, exceeding the 1.5 kcal/mol threshold.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP and affinity, while Ligand A has better TPSA and Pgp. However, the significant difference in binding affinity (-8.1 vs -5.5) and the acceptable logP of Ligand B outweigh the advantages of Ligand A. The longer half-life of Ligand B is also a positive. While Ligand A has better DILI and hERG, the affinity difference is too large to ignore.
**Conclusion:**
Despite some drawbacks in DILI and hERG, the significantly stronger binding affinity of Ligand B, coupled with its better logP, QED, and half-life, makes it the more promising drug candidate for ADRB2.
Output:
0
2025-04-18 00:31:50,134 - INFO - Batch 484 complete. Total preferences: 7744
2025-04-18 00:31:50,134 - INFO - Processing batch 485/512...
2025-04-18 00:32:39,257 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (360.204 and 367.515 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (137.46) is slightly higher than Ligand B (80.32). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is generally preferred for permeability. Ligand B has a significant advantage here.
3. **logP:** Both ligands have good logP values (1.689 and 2.148), falling within the optimal 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Ligand A (1) has fewer H-bond donors than Ligand B (2). This favors Ligand A slightly, as fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (8) has more H-bond acceptors than Ligand B (5). This favors Ligand B, as fewer HBAs generally improve permeability.
6. **QED:** Ligand B (0.738) has a significantly better QED score than Ligand A (0.376), indicating a more drug-like profile. This is a substantial advantage for Ligand B.
7. **DILI:** Ligand A (99.147) has a very high DILI risk, while Ligand B (48.391) has a much lower risk. This is a *major* advantage for Ligand B.
8. **BBB:** Ligand A (72.16) has a better BBB penetration percentile than Ligand B (56.999). However, since ADRB2 is primarily a cardiovascular target, BBB penetration is not a high priority.
9. **Caco-2:** Ligand A (-4.785) has a better Caco-2 permeability than Ligand B (-5.301). This is a slight advantage for Ligand A.
10. **Solubility:** Ligand A (-4.709) has better aqueous solubility than Ligand B (-2.305). This is a slight advantage for Ligand A.
11. **hERG:** Both ligands have low hERG inhibition liability (0.378 and 0.252), indicating a low risk of cardiotoxicity. No significant difference here.
12. **Cl_mic:** Ligand B (43.17) has significantly lower microsomal clearance than Ligand A (80.406), indicating better metabolic stability. This is a substantial advantage for Ligand B.
13. **t1/2:** Ligand B (9.568) has a much longer in vitro half-life than Ligand A (0.16). This is a significant advantage for Ligand B.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.198 and 0.165). No significant difference here.
15. **Binding Affinity:** Ligand B (-7.8) has a slightly better binding affinity than Ligand A (-7.7). While the difference is small, it is still a positive for Ligand B.
**Overall Assessment:**
Ligand B clearly outperforms Ligand A across several critical parameters. The lower DILI risk, better QED score, significantly improved metabolic stability (lower Cl_mic and longer t1/2), and slightly better binding affinity outweigh the minor advantages of Ligand A in BBB penetration, Caco-2 permeability, and solubility. Given the GPCR target class, the balance of properties in Ligand B makes it a more promising drug candidate.
Output:
0
2025-04-18 00:32:39,258 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (348.487 Da) is within the ideal range (200-500 Da). Ligand B (396.843 Da) is also acceptable, but closer to the upper limit.
2. **TPSA:** Ligand A (58.64) is excellent, well below the 140 threshold and favorable for absorption. Ligand B (89.87) is still reasonable, but higher and potentially impacting permeability.
3. **logP:** Both ligands have good logP values (A: 2.679, B: 1.357) within the 1-3 range. Ligand B is slightly lower, which *could* indicate a slight permeability issue, but is still acceptable.
4. **HBD:** Ligand A (1) is preferred, as lower HBD generally improves permeability. Ligand B (3) is still within the acceptable limit of 5.
5. **HBA:** Ligand A (3) is good. Ligand B (5) is also acceptable, but higher.
6. **QED:** Both ligands have good QED scores (A: 0.542, B: 0.649), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (21.52) has a significantly lower DILI risk than Ligand B (45.483), which is a major advantage.
8. **BBB:** Ligand A (81.233) shows better BBB penetration than Ligand B (64.482). While ADRB2 isn't exclusively a CNS target, some cardiovascular effects are mediated by central pathways, and better BBB penetration isn't detrimental.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.393 and -4.97), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Both ligands have negative solubility values (-2.391 and -2.186), indicating poor aqueous solubility. This is a significant concern for both.
11. **hERG:** Both ligands have low hERG inhibition risk (A: 0.242, B: 0.31).
12. **Cl_mic:** Ligand A (62.47) has a higher microsomal clearance than Ligand B (6.467), indicating lower metabolic stability. This favors Ligand B.
13. **t1/2:** Ligand A (-8.074) has a longer in vitro half-life than Ligand B (3.945), which is a positive.
14. **Pgp:** Both ligands have very low P-gp efflux liability (A: 0.051, B: 0.065).
15. **Affinity:** Ligand B (-6.9 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.7 kcal/mol) - a difference of 1.2 kcal/mol. This is a substantial advantage.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are crucial. Ligand B excels in affinity. While Ligand A has better TPSA and BBB, the large affinity difference of Ligand B outweighs these factors. The poor Caco-2 and solubility for both are concerning and would require formulation strategies, but the potency advantage of Ligand B is more critical at this stage.
**Conclusion:**
Despite the poor permeability and solubility predictions for both, Ligand B's significantly stronger binding affinity makes it the more promising candidate. The difference in affinity is substantial enough to overcome the other drawbacks, especially considering the potential for formulation work to address solubility and permeability.
Output:
0
2025-04-18 00:32:39,258 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (351.359 Da and 343.479 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (110.11) is higher than Ligand B (70.9). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is generally preferred for absorption. Ligand B is better.
3. **logP:** Ligand A (0.111) is quite low, potentially hindering membrane permeability. Ligand B (2.351) is within the optimal 1-3 range. Ligand B is significantly better.
4. **HBD:** Both ligands have 2 HBD, which is acceptable.
5. **HBA:** Ligand A has 6 HBA, and Ligand B has 7. Both are within the acceptable limit of 10.
6. **QED:** Both ligands have similar QED values (0.779 and 0.717), indicating good drug-likeness.
7. **DILI:** Both ligands have acceptable DILI risk (57.929 and 54.827, respectively), below the 60 threshold.
8. **BBB:** Ligand A (50.679) has a lower BBB penetration percentile than Ligand B (85.072). While ADRB2 isn't a primary CNS target, some distribution to the CNS is possible, and higher BBB is generally favorable. Ligand B is better.
9. **Caco-2:** Ligand A (-4.87) has a worse Caco-2 permeability than Ligand B (-5.295). Both are poor, but Ligand B is slightly better.
10. **Solubility:** Ligand A (-2.308) has worse solubility than Ligand B (-3.198). Solubility is important for bioavailability. Ligand B is better.
11. **hERG:** Ligand A (0.128) has a lower hERG inhibition liability than Ligand B (0.955), which is a significant advantage for cardiac safety. Ligand A is better.
12. **Cl_mic:** Ligand A (-40.235) has a much lower (better) microsomal clearance than Ligand B (60.109), indicating greater metabolic stability. Ligand A is much better.
13. **t1/2:** Ligand B (48.595) has a significantly longer in vitro half-life than Ligand A (8.194). Longer half-life is generally preferred. Ligand B is better.
14. **Pgp:** Ligand A (0.009) has a much lower Pgp efflux liability than Ligand B (0.35), suggesting better oral bioavailability and potentially better CNS exposure. Ligand A is much better.
15. **Binding Affinity:** Ligand A (-7.1) has a slightly better binding affinity than Ligand B (-6.7). This is a 0.4 kcal/mol difference, which is significant.
**Overall Assessment:**
Ligand A has a better binding affinity, significantly better metabolic stability (Cl_mic), lower Pgp efflux, and lower hERG risk. However, Ligand B has better logP, BBB penetration, solubility, and a longer half-life.
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), and the fact that this is a cardiovascular target (where CNS penetration is less critical), the superior binding affinity and metabolic stability of Ligand A, combined with its lower Pgp efflux and hERG risk, outweigh the benefits of Ligand B's slightly better logP and half-life. The low logP of Ligand A is a concern, but the strong binding and improved ADME properties are more critical for a viable drug candidate.
Output:
1
2025-04-18 00:32:39,258 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (362.861 and 363.439 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (67.35) is significantly lower than Ligand B (116.13). This is a major advantage for Ligand A, as lower TPSA generally correlates with better cell permeability, which is crucial for GPCR targeting.
3. **logP:** Ligand A (3.82) is higher than Ligand B (1.368). While both are within the acceptable range (1-3), Ligand A is closer to the upper limit. This could potentially lead to off-target effects, but is less concerning than the high TPSA of Ligand B.
4. **HBD:** Ligand A (1) has fewer HBDs than Ligand B (2). Fewer HBDs are generally preferred for better permeability.
5. **HBA:** Ligand A (4) has fewer HBAs than Ligand B (5). Again, fewer HBAs are generally preferred.
6. **QED:** Ligand A (0.848) has a slightly higher QED than Ligand B (0.792), indicating a more drug-like profile.
7. **DILI:** Ligand B (66.421) has a slightly higher DILI risk than Ligand A (57.348), although both are above the ideal <40.
8. **BBB:** Both ligands have similar BBB penetration (Ligand A: 43.815, Ligand B: 41.373). This isn't a primary concern for ADRB2, which isn't a CNS target.
9. **Caco-2:** Ligand A (-4.717) has a more negative Caco-2 value, suggesting better permeability than Ligand B (-5.032).
10. **Solubility:** Ligand A (-3.676) has slightly better solubility than Ligand B (-3.16), though both are poor.
11. **hERG:** Both ligands have very low hERG inhibition risk (Ligand A: 0.2, Ligand B: 0.086).
12. **Cl_mic:** Ligand B (7.592) has significantly lower microsomal clearance than Ligand A (63.904), indicating better metabolic stability. This is a positive for Ligand B.
13. **t1/2:** Ligand B (30.629) has a longer in vitro half-life than Ligand A (24.048), which is desirable.
14. **Pgp:** Both ligands have low P-gp efflux liability (Ligand A: 0.039, Ligand B: 0.088).
15. **Binding Affinity:** Ligand B (-7.7 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.2 kcal/mol). This is a substantial advantage for Ligand B. A 2.5 kcal/mol difference is significant.
**Overall Assessment:**
Ligand B has a much stronger binding affinity and better metabolic stability (lower Cl_mic, longer t1/2). However, Ligand A has a significantly lower TPSA, which is critical for GPCR targeting and permeability. The higher logP of Ligand A is a potential concern, but the TPSA difference is more impactful. The affinity difference is substantial enough to overcome the TPSA disadvantage.
Considering the GPCR-specific priorities (logP, TPSA, affinity), and the significant advantage in binding affinity for Ligand B, I believe it is the more promising candidate.
Output:
0
2025-04-18 00:32:39,258 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.419 and 384.527 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (87.54) is better than Ligand B (92.26). Both are below 140, but lower is preferred for absorption.
3. **logP:** Ligand A (-0.071) is slightly lower than the optimal 1-3 range, potentially impacting permeability. Ligand B (1.584) is within the optimal range. This favors Ligand B.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 5 HBA, and Ligand B has 6. Both are acceptable, below the 10 threshold.
6. **QED:** Both ligands have very similar QED scores (0.755 and 0.752), indicating good drug-likeness.
7. **DILI:** Ligand A (30.322) has a significantly lower DILI risk than Ligand B (56.883). This is a substantial advantage for Ligand A.
8. **BBB:** Ligand B (73.401) has better BBB penetration than Ligand A (57.813). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant, and this favors Ligand B.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. Ligand A (-4.994) is slightly better than Ligand B (-5.055), but both are concerning.
10. **Solubility:** Ligand A (-1.747) has better solubility than Ligand B (-3.63). This is a positive for Ligand A.
11. **hERG:** Both ligands have low hERG inhibition risk (0.279 and 0.242). No significant difference.
12. **Cl_mic:** Ligand A (21.745) has significantly lower microsomal clearance than Ligand B (66.441), indicating better metabolic stability. This is a major advantage for Ligand A.
13. **t1/2:** Ligand A (-1.528) has a negative half-life, which is concerning. Ligand B (-38.786) is even worse. Both are poor.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.006 and 0.229). No significant difference.
15. **Binding Affinity:** Ligand A (-8.7 kcal/mol) has a slightly better binding affinity than Ligand B (-6.8 kcal/mol). This is a significant advantage for Ligand A.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B has a better logP and BBB penetration. However, Ligand A has a significantly better binding affinity, lower DILI risk, and better metabolic stability (lower Cl_mic). The substantial difference in binding affinity (-8.7 vs -6.8) is a major factor, and the lower DILI risk is crucial. The poor Caco-2 values for both are a concern, but can be addressed with formulation strategies.
**Conclusion:**
Despite Ligand B's slightly better logP and BBB, Ligand A's superior binding affinity, significantly lower DILI risk, better solubility, and improved metabolic stability make it the more promising drug candidate.
Output:
1
2025-04-18 00:32:39,258 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [352.435, 107.69 , 0.002, 3. , 6. , 0.691, 42.807, 21.326, -5.155, -1.473, 0.156, 10.052, -6.567, 0.055, -8.5 ]
**Ligand B:** [350.39 , 78.87 , 2.376, 2. , 4. , 0.855, 36.603, 74.796, -5.106, -3.024, 0.545, 15.357, -11.099, 0.035, -2.5 ]
Here's a breakdown, comparing each parameter and considering GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal range (350-352 Da). No significant difference.
2. **TPSA:** Ligand B (78.87) is significantly better than Ligand A (107.69). Lower TPSA generally favors better permeability, crucial for GPCR ligands.
3. **logP:** Ligand A (0.002) is very low, potentially hindering membrane permeability. Ligand B (2.376) is within the optimal range (1-3). This is a major advantage for Ligand B.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (2), but both are acceptable.
5. **HBA:** Ligand A (6) is higher than Ligand B (4), but both are within acceptable limits.
6. **QED:** Ligand B (0.855) is better than Ligand A (0.691), indicating a more drug-like profile.
7. **DILI:** Ligand B (36.603) has a lower DILI risk than Ligand A (42.807), which is favorable.
8. **BBB:** Ligand B (74.796) has a much higher BBB penetration potential than Ligand A (21.326). While ADRB2 isn't *primarily* a CNS target, some CNS exposure can be relevant, and higher BBB is generally a positive trait.
9. **Caco-2:** Both are negative, indicating poor permeability. This is concerning for both.
10. **Solubility:** Both are negative, indicating poor solubility. This is concerning for both.
11. **hERG:** Ligand A (0.156) has a lower hERG risk than Ligand B (0.545), which is favorable.
12. **Cl_mic:** Ligand A (10.052) has a lower microsomal clearance than Ligand B (15.357), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-11.099) has a longer in vitro half-life than Ligand A (-6.567), which is desirable.
14. **Pgp:** Ligand A (0.055) has lower P-gp efflux than Ligand B (0.035), which is favorable.
15. **Affinity:** Ligand A (-8.5) has a significantly stronger binding affinity than Ligand B (-2.5). This is a substantial advantage, potentially outweighing some ADME concerns.
**Overall Assessment:**
Ligand A has a much stronger binding affinity, which is paramount for GPCR targets. However, its very low logP is a major concern, potentially leading to poor absorption. Ligand B has a better overall ADME profile (better logP, TPSA, QED, DILI, BBB, and t1/2) but significantly weaker binding affinity.
Given the substantial difference in binding affinity (-8.5 vs -2.5 kcal/mol), I believe the stronger binding of Ligand A is likely to be more impactful than its lower logP, *especially* if formulation strategies can be employed to address the solubility and permeability issues. The difference in affinity is greater than 1.5 kcal/mol, which, as per the guidelines, can outweigh minor ADME drawbacks.
Output:
1
2025-04-18 00:32:39,259 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Step-by-step comparison:**
1. **MW:** Both ligands (349.391 and 356.382 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand B (82.51) is significantly better than Ligand A (118.37). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (2.995) is optimal, while Ligand A (0.583) is a bit low, potentially hindering membrane permeability. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (1), but both are within the acceptable limit of 5.
5. **HBA:** Both ligands have 7 HBA, which is acceptable.
6. **QED:** Ligand A (0.687) is slightly better than Ligand B (0.571), indicating a marginally more drug-like profile.
7. **DILI:** Ligand A (65.917) is better than Ligand B (97.131). Lower DILI is crucial, and Ligand B's value is concerningly high.
8. **BBB:** Not a primary concern for a cardiovascular target. Ligand A (63.862) is higher, but the difference isn't critical.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. This is a shared weakness.
10. **Solubility:** Ligand A (-2.789) is better than Ligand B (-4.203), which is a positive for formulation.
11. **hERG:** Ligand A (0.098) is significantly better than Ligand B (0.57). hERG inhibition is a major safety concern, making Ligand A preferable.
12. **Cl_mic:** Ligand B (62.43) is slightly better than Ligand A (42.656), suggesting better metabolic stability.
13. **t1/2:** Ligand A (21.546) is better than Ligand B (-25.239). A longer half-life is generally desirable.
14. **Pgp:** Ligand A (0.033) is much better than Ligand B (0.417), indicating lower efflux and potentially better bioavailability.
15. **Binding Affinity:** Ligand A (-7.8) is significantly better than Ligand B (-5.4). A 2.4 kcal/mol difference is substantial and can often outweigh minor ADME concerns.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand B has a better logP and TPSA, but Ligand A excels in affinity and Pgp efflux. The DILI and hERG liabilities of Ligand B are also significant drawbacks.
**Overall Assessment:**
Despite Ligand B's better logP and TPSA, Ligand A is the stronger candidate. The significantly higher binding affinity (-7.8 vs -5.4 kcal/mol) is a major advantage. Furthermore, Ligand A has a much lower DILI risk, better hERG profile, and lower Pgp efflux, all critical for a safe and effective drug. While both have poor Caco-2 permeability, the superior potency and safety profile of Ligand A make it the more promising candidate.
Output:
1
2025-04-18 00:32:39,259 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.415 and 368.43 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (87.66) is significantly better than Ligand A (102.76). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (-0.219) is quite low, potentially hindering membrane permeability. Ligand B (0.423) is better, falling within the acceptable range. This is a significant advantage for Ligand B.
4. **HBD:** Both have 3 HBD, which is acceptable.
5. **HBA:** Both have 5 HBA, which is acceptable.
6. **QED:** Both are good (0.66 and 0.678), indicating reasonable drug-likeness.
7. **DILI:** Ligand A (21.675) has a much lower DILI risk than Ligand B (55.719). This is a major advantage for Ligand A.
8. **BBB:** Not a primary concern for a cardiovascular target. Ligand B has a higher BBB percentile, but this is less important here.
9. **Caco-2:** Both are similar and quite poor (-5.314 and -5.402). This suggests potential absorption issues for both, but doesn't differentiate them.
10. **Solubility:** Both have poor solubility (-1.464 and -2.884). This is a concern for both, but Ligand B is worse.
11. **hERG:** Ligand A (0.037) has a slightly lower hERG risk than Ligand B (0.39), which is preferable.
12. **Cl_mic:** Ligand A (-8.185) has significantly lower (better) microsomal clearance than Ligand B (7.519), indicating better metabolic stability.
13. **t1/2:** Ligand A (-6.828) has a slightly better in vitro half-life than Ligand B (6.656).
14. **Pgp:** Both have very low Pgp efflux (0.004 and 0.046), which is good.
15. **Binding Affinity:** Both have identical binding affinity (-5 kcal/mol).
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand B has a better logP and TPSA. However, Ligand A has a much better DILI score and better metabolic stability (Cl_mic). The affinity is the same. Given the importance of minimizing toxicity and maximizing metabolic stability, Ligand A is the better choice. The slightly lower logP of Ligand A is a concern, but the other advantages outweigh this.
**Output:**
1
2025-04-18 00:32:39,259 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.455 and 347.415 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (56.79) is significantly lower than Ligand B (93.97). This is a major advantage for Ligand A, as lower TPSA generally correlates with better cell permeability, crucial for GPCR targets.
3. **logP:** Ligand A (3.322) is within the optimal 1-3 range. Ligand B (0.787) is slightly below 1, potentially hindering membrane permeability. This favors Ligand A.
4. **HBD:** Ligand A (1) and Ligand B (2) are both acceptable, below the threshold of 5.
5. **HBA:** Ligand A (4) and Ligand B (5) are both acceptable, below the threshold of 10.
6. **QED:** Both ligands have very similar QED values (0.858 and 0.84), indicating good drug-likeness.
7. **DILI:** Ligand A (54.75) has a higher DILI risk than Ligand B (31.679). This favors Ligand B.
8. **BBB:** Ligand A (44.397) has a higher BBB penetration percentile than Ligand B (29.857). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be beneficial for distribution. This favors Ligand A.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.802 and -4.827), which is unusual and suggests poor permeability in this assay. This is a concern for both.
10. **Solubility:** Ligand A (-3.678) has slightly better solubility than Ligand B (-1.601).
11. **hERG:** Both ligands have low hERG inhibition liability (0.431 and 0.221), which is good.
12. **Cl_mic:** Ligand A (23.902) has a higher microsomal clearance than Ligand B (-0.546). This means Ligand B is likely more metabolically stable, which is a significant advantage.
13. **t1/2:** Ligand A (30.646) has a longer in vitro half-life than Ligand B (-19.05). This favors Ligand A.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.235 and 0.032), which is good.
15. **Binding Affinity:** Ligand B (-7.7) has a slightly better binding affinity than Ligand A (-6.8). This is a 0.9 kcal/mol difference, which is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand A initially looks more promising due to its superior TPSA and logP, and reasonable BBB penetration. However, Ligand B has a significantly better binding affinity and lower DILI risk, and importantly, better metabolic stability (lower Cl_mic). The binding affinity difference is substantial. While the Caco-2 values are concerning for both, the improved metabolic stability and binding of Ligand B are more critical for a GPCR target like ADRB2. The slightly lower logP of Ligand B is a manageable concern.
Output:
0
2025-04-18 00:32:39,259 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [348.403, 105.83 , -0.397, 1. , 5. , 0.533, 34.742, 78.48 ,
-4.881, -0.616, 0.289, 29.238, 1.519, 0.077, -7.5 ]
**Ligand B:** [349.431, 84.67 , 1.945, 1. , 5. , 0.813, 51.648, 78.79 ,
-4.582, -2.242, 0.2 , 48.733, -31.671, 0.067, -5.9 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). A: 348.4, B: 349.4 - very similar.
2. **TPSA:** Ligand A (105.83) is slightly higher than Ligand B (84.67). Both are acceptable for oral absorption, but B is better.
3. **logP:** Ligand A (-0.397) is a bit low, potentially hindering permeability. Ligand B (1.945) is within the optimal range (1-3). This is a significant advantage for B.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Both have 5 HBA, which is good.
6. **QED:** Ligand B (0.813) has a better QED score than Ligand A (0.533), indicating a more drug-like profile.
7. **DILI:** Ligand A (34.742) has a lower DILI risk than Ligand B (51.648), which is preferable.
8. **BBB:** Both have similar BBB penetration (around 78-79%), which is acceptable but not outstanding for a GPCR.
9. **Caco-2:** Ligand A (-4.881) has a negative Caco-2 value, indicating poor permeability. Ligand B (-4.582) is also poor, but slightly better.
10. **Solubility:** Ligand A (-0.616) has slightly better solubility than Ligand B (-2.242).
11. **hERG:** Both have very low hERG risk (0.289 and 0.2, respectively).
12. **Cl_mic:** Ligand A (29.238) has a significantly lower microsomal clearance than Ligand B (48.733), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-31.671) has a negative half-life, which is concerning. Ligand A (1.519) is better, though not ideal.
14. **Pgp:** Both have very low Pgp efflux liability (0.077 and 0.067, respectively).
15. **Affinity:** Ligand A (-7.5) has a significantly stronger binding affinity than Ligand B (-5.9). This is a substantial advantage for A.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are crucial. Ligand B excels in logP and TPSA, but Ligand A has a much better binding affinity. The slightly better solubility of A is also helpful. The negative half-life of B is a major concern. While A's Caco-2 permeability is poor, the strong binding affinity could potentially compensate, especially if formulation strategies can address the permeability issue.
**Conclusion:**
Despite Ligand A's poor Caco-2 permeability, its significantly stronger binding affinity (-7.5 vs -5.9 kcal/mol) and better metabolic stability (lower Cl_mic) outweigh the advantages of Ligand B. The difference in affinity is substantial enough to potentially overcome the permeability issue.
Output:
1
2025-04-18 00:32:39,259 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's analyze each ligand against the provided guidelines, with emphasis on GPCR-relevant parameters (logP, TPSA, Pgp, BBB, and affinity).
* **Molecular Weight:** Both ligands (336.355 Da and 360.527 Da) fall comfortably within the ideal 200-500 Da range.
* **TPSA:** Ligand A (99.83) is higher than Ligand B (61.88). While both are under 140, the lower TPSA of Ligand B is more favorable for permeability, a key consideration for GPCRs.
* **logP:** Ligand A (1.382) is within the optimal range (1-3). Ligand B (3.641) is at the higher end, potentially raising concerns about solubility and off-target effects, but still acceptable.
* **H-Bond Donors/Acceptors:** Both ligands have similar and acceptable HBD (1) and HBA (6 & 4) counts.
* **QED:** Both ligands have similar QED scores (0.762 and 0.741), indicating good drug-likeness.
* **DILI:** Ligand A (92.168) has a significantly higher DILI risk than Ligand B (44.591). This is a major concern for Ligand A.
* **BBB:** Both ligands have similar BBB penetration (52.268 and 52.036). While not exceptionally high, it's not a primary concern for ADRB2, which is not a CNS target.
* **Caco-2 Permeability:** Both have negative Caco-2 values, which is unusual and suggests poor permeability.
* **Aqueous Solubility:** Both have negative solubility values, which is also unusual and suggests poor solubility.
* **hERG Inhibition:** Both ligands show low hERG inhibition liability (0.5 and 0.554), which is good.
* **Microsomal Clearance:** Ligand B (90.288) has a much higher microsomal clearance than Ligand A (-5.598), indicating lower metabolic stability. This is a significant drawback for Ligand B.
* **In vitro Half-Life:** Ligand B (15.8) has a much longer half-life than Ligand A (0.224). This is a substantial advantage for Ligand B.
* **P-gp Efflux:** Both ligands have similar P-gp efflux liability (0.103 and 0.105).
* **Binding Affinity:** Ligand A (-8.3 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.2 kcal/mol). This is a substantial advantage for Ligand A.
**Overall Assessment:**
The key trade-offs are: Ligand A has a much better binding affinity but a significantly higher DILI risk. Ligand B has a better safety profile (lower DILI) and longer half-life, but weaker binding affinity and poorer metabolic stability.
Given the importance of safety in drug development, and the substantial difference in DILI risk, I prioritize Ligand B. While the affinity is lower, it is still in a reasonable range, and optimization could potentially improve it. The longer half-life also contributes to a more favorable pharmacokinetic profile. The poor Caco-2 and solubility values are concerning for both, but these are properties that can be addressed through formulation strategies.
**Output:**
0
2025-04-18 00:32:39,260 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's analyze each ligand against the provided guidelines, keeping in mind ADRB2 is a GPCR, so logP, TPSA, Pgp, and affinity are key.
* **Molecular Weight:** Both ligands (352.479 and 349.439 Da) fall comfortably within the ideal 200-500 Da range.
* **TPSA:** Ligand A (104.53) is slightly higher than Ligand B (96.25). Both are below the 140 threshold for good oral absorption, but closer to the ideal for GPCRs.
* **logP:** Ligand A (0.407) is a bit low, potentially hindering permeation. Ligand B (-0.571) is even lower, raising more concerns about membrane permeability.
* **H-Bond Donors/Acceptors:** Ligand A has 3 HBD and 4 HBA, while Ligand B has 1 HBD and 7 HBA. Both are acceptable, but Ligand A seems slightly better balanced.
* **QED:** Ligand B (0.782) has a significantly better QED score than Ligand A (0.413), indicating a more drug-like profile overall.
* **DILI:** Ligand B (30.942) has a much lower DILI risk than Ligand A (4.459), a substantial advantage.
* **BBB:** Ligand A (56.766) has a better BBB penetration percentile than Ligand B (50.795), but neither are particularly high. Since ADRB2 isn't a CNS target, this isn't a major deciding factor.
* **Caco-2 Permeability:** Both ligands have negative Caco-2 values (-5.8 and -5.376), which is unusual and indicates poor permeability.
* **Aqueous Solubility:** Both ligands have negative solubility values (-1.78 and -0.016), which is also concerning.
* **hERG:** Ligand A (0.15) has a slightly better hERG profile (lower risk) than Ligand B (0.05).
* **Microsomal Clearance:** Ligand B (-3.857) has a significantly lower (better) microsomal clearance than Ligand A (-13.74), suggesting greater metabolic stability.
* **In vitro Half-Life:** Ligand B (13.329) has a much longer in vitro half-life than Ligand A (-22.586), a significant advantage.
* **P-gp Efflux:** Both ligands show very low P-gp efflux liability (0.003 and 0.011).
* **Binding Affinity:** Ligand B (-7.0 kcal/mol) has a slightly better binding affinity than Ligand A (-6.5 kcal/mol). This difference, while not huge, is still meaningful.
**Overall Assessment:**
While Ligand A has a slightly better BBB penetration and hERG profile, Ligand B is superior in almost every other critical parameter. The significantly lower DILI risk, better QED, improved metabolic stability (lower Cl_mic and longer t1/2), and slightly better binding affinity of Ligand B outweigh the minor advantages of Ligand A. The negative Caco-2 and solubility values are concerning for both, but can be addressed with formulation strategies.
**Output:**
0
2025-04-18 00:32:39,260 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (348.45 and 340.43 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (85.25) is slightly higher than Ligand B (69.3). Both are below the 140 threshold for oral absorption, but Ligand B is better positioned, especially considering GPCRs benefit from lower TPSA.
**3. logP:** Both ligands have good logP values (1.425 and 1.232), falling within the optimal 1-3 range. No clear advantage.
**4. H-Bond Donors:** Ligand A has 2 HBD, and Ligand B has 1. Both are acceptable (<=5).
**5. H-Bond Acceptors:** Ligand A has 6 HBA, and Ligand B has 3. Both are acceptable (<=10), but Ligand B is preferable.
**6. QED:** Both ligands have good QED scores (0.76 and 0.838), indicating good drug-like properties.
**7. DILI Risk:** Ligand A (34.63) has a slightly lower DILI risk than Ligand B (38.15), both are good.
**8. BBB Penetration:** Ligand B (71.85) has better BBB penetration than Ligand A (68.79). While ADRB2 is a cardiovascular target, some CNS off-target effects are always a concern, and better BBB penetration could potentially exacerbate those. However, it's not a primary driver for this target.
**9. Caco-2 Permeability:** Ligand A (-4.835) has better Caco-2 permeability than Ligand B (-4.711). This suggests better intestinal absorption for Ligand A.
**10. Aqueous Solubility:** Ligand B (-3.214) has better aqueous solubility than Ligand A (-1.623). This is a significant advantage, as solubility is crucial for formulation and bioavailability.
**11. hERG Inhibition:** Ligand A (0.114) has slightly lower hERG inhibition risk than Ligand B (0.395), which is preferable.
**12. Microsomal Clearance:** Ligand B (45.624) has lower microsomal clearance than Ligand A (65.30), indicating better metabolic stability. This is a significant advantage.
**13. In vitro Half-Life:** Ligand A (11.863) has a longer in vitro half-life than Ligand B (-27.13). This is a major advantage.
**14. P-gp Efflux:** Ligand A (0.031) has much lower P-gp efflux than Ligand B (0.112), which is highly desirable for improved bioavailability.
**15. Binding Affinity:** Ligand A (-7.9) has a significantly stronger binding affinity than Ligand B (-5.4). This is a substantial advantage, potentially outweighing some minor ADME drawbacks.
**Overall Assessment:**
While Ligand B has better solubility and metabolic stability, Ligand A's significantly stronger binding affinity (-7.9 vs -5.4 kcal/mol) and lower P-gp efflux are critical advantages for a GPCR target. The longer half-life also contributes positively. The slightly higher TPSA and lower solubility of Ligand A are acceptable trade-offs for the improved potency and reduced efflux.
Output:
1
2025-04-18 00:32:39,260 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.28 and 363.50 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand B (29.54) is significantly lower than Ligand A (104.31). This is a major advantage for Ligand B, as lower TPSA generally correlates with better cell permeability, crucial for GPCR targets.
3. **logP:** Both ligands have acceptable logP values (2.59 and 3.99), falling within the 1-3 range. Ligand B is slightly higher, which could potentially lead to some off-target effects, but is still within reasonable limits.
4. **HBD:** Ligand A has 3 HBD, while Ligand B has 0. Lower HBD is generally preferred for better permeability, giving Ligand B an edge.
5. **HBA:** Ligand A has 5 HBA, Ligand B has 3. Again, lower is generally better for permeability, favoring Ligand B.
6. **QED:** Both ligands have similar QED values (0.632 and 0.63), indicating comparable drug-likeness.
7. **DILI:** Ligand A has a very high DILI risk (99.11%), which is a major red flag. Ligand B has a much lower, and acceptable, DILI risk (39.55%). This is a critical difference.
8. **BBB:** Ligand B (90.85%) has a significantly higher BBB penetration potential than Ligand A (31.64%). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be beneficial or at least less detrimental than complete exclusion.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not defined, so it's hard to interpret.
10. **Solubility:** Both ligands have very poor aqueous solubility (-4.975 and -4.479). This is a concern for both, but might be mitigated through formulation strategies.
11. **hERG:** Both ligands have similar, low hERG inhibition liability (0.714 and 0.717).
12. **Cl_mic:** Ligand B has a higher microsomal clearance (95.58) than Ligand A (61.20), indicating faster metabolism and potentially lower *in vivo* exposure. This is a negative for Ligand B.
13. **t1/2:** Ligand A has a negative in vitro half-life (-9.025), which is concerning. Ligand B has a positive half-life (10.08), suggesting better metabolic stability.
14. **Pgp:** Both have similar Pgp efflux liability (0.328 and 0.495).
15. **Binding Affinity:** Ligand A (-6.1 kcal/mol) has a slightly better binding affinity than Ligand B (-4.7 kcal/mol). However, the difference is not substantial enough to overcome the significant ADME/Tox liabilities of Ligand A.
**Overall Assessment:**
Ligand B is the far superior candidate. While it has a higher Cl_mic, its significantly lower TPSA, DILI risk, and higher BBB penetration, along with a positive in vitro half-life, outweigh the slight decrease in binding affinity and the poor solubility. Ligand A's extremely high DILI risk is a deal-breaker. The GPCR-specific priorities (logP, TPSA, Pgp, and affinity) all favor Ligand B, even considering the slightly lower affinity.
Output:
0
2025-04-18 00:32:39,260 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [366.38 , 78.87 , 1.941, 2. , 4. , 0.391, 21.869, 77.317, -5.008, -2.003, 0.513, 7.062, -27.609, 0.08 , -6.7 ]**
**Ligand B: [351.487, 48. , 2.193, 0. , 4. , 0.736, 13.532, 83.443, -4.463, -2.461, 0.677, 57.487, 22.115, 0.114, -6.7 ]**
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand B (351.487) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (78.87) is higher than Ligand B (48). Both are below 140, but Ligand B is significantly better, increasing the likelihood of good oral absorption.
3. **logP:** Both ligands have optimal logP values (around 2), falling within the 1-3 range. Ligand B (2.193) is slightly higher.
4. **H-Bond Donors:** Ligand A has 2 HBD, and Ligand B has 0. Both are within the acceptable limit of 5. Ligand B is preferred here.
5. **H-Bond Acceptors:** Both ligands have 4 HBA, which is acceptable (<=10).
6. **QED:** Ligand B (0.736) has a better QED score than Ligand A (0.391), indicating a more drug-like profile.
7. **DILI:** Ligand B (13.532) has a much lower DILI risk than Ligand A (21.869), a significant advantage.
8. **BBB:** Ligand B (83.443) has a higher BBB penetration percentile than Ligand A (77.317). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be beneficial or at least needs to be considered.
9. **Caco-2 Permeability:** Ligand A (-5.008) has worse Caco-2 permeability than Ligand B (-4.463).
10. **Aqueous Solubility:** Ligand A (-2.003) has worse aqueous solubility than Ligand B (-2.461).
11. **hERG Inhibition:** Both ligands have similar hERG inhibition liability (0.513 and 0.677, respectively).
12. **Microsomal Clearance:** Ligand A (7.062) has lower microsomal clearance than Ligand B (57.487), suggesting better metabolic stability. This is a key advantage for Ligand A.
13. **In vitro Half-Life:** Ligand B (22.115) has a longer in vitro half-life than Ligand A (-27.609). This is a significant advantage for Ligand B.
14. **P-gp Efflux:** Both ligands have similar P-gp efflux liability (0.08 and 0.114, respectively).
15. **Binding Affinity:** Both ligands have the same binding affinity (-6.7 kcal/mol).
**GPCR-Specific Priorities:** For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Ligand B excels in TPSA, logP, and has a better QED and DILI profile. While Ligand A has better metabolic stability (lower Cl_mic), the other advantages of Ligand B are more impactful for overall drug development potential. The similar binding affinity means potency isn't a differentiating factor.
**Conclusion:**
Ligand B is the more promising candidate due to its superior ADME properties (lower DILI, better QED, better TPSA, better BBB, and longer half-life) despite slightly worse metabolic stability.
```
0
```
2025-04-18 00:32:39,260 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (381.782) is slightly higher than Ligand B (348.359), but both are acceptable.
**2. TPSA:** Ligand A (79.46) is better than Ligand B (101.93). For a cardiovascular GPCR, TPSA under 140 is good, but lower is generally preferred for better absorption.
**3. logP:** Ligand A (3.471) is within the optimal range (1-3). Ligand B (-0.136) is significantly *below* the optimal range, which could lead to poor membrane permeability and bioavailability. This is a major drawback.
**4. H-Bond Donors:** Ligand A (3) is acceptable. Ligand B (0) is also acceptable, but a lack of HBDs can sometimes hinder solubility.
**5. H-Bond Acceptors:** Ligand A (4) is good. Ligand B (7) is acceptable, but approaching the upper limit.
**6. QED:** Both ligands have similar, good QED values (A: 0.659, B: 0.683), indicating reasonable drug-likeness.
**7. DILI:** Both ligands have similar, acceptable DILI risk (A: 77.433, B: 76.192).
**8. BBB:** Ligand B (70.454) has a better BBB penetration score than Ligand A (58.123). However, since ADRB2 is primarily a cardiovascular target, high BBB penetration isn't a critical priority.
**9. Caco-2 Permeability:** Both have negative Caco-2 values, indicating poor permeability. Ligand A (-4.724) is slightly better than Ligand B (-4.217).
**10. Aqueous Solubility:** Ligand A (-4.556) is slightly better than Ligand B (-1.928).
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (A: 0.536, B: 0.032). Ligand B is slightly better.
**12. Microsomal Clearance:** Ligand B (41.727) has significantly lower microsomal clearance than Ligand A (62.963), suggesting better metabolic stability.
**13. In vitro Half-Life:** Ligand B (-16.639) has a significantly longer in vitro half-life than Ligand A (-3.393). This is a major advantage.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (A: 0.077, B: 0.009). Ligand B is slightly better.
**15. Binding Affinity:** Ligand B (-6.7) has a slightly better binding affinity than Ligand A (-6.5). While the difference is small, it's still a positive.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand B is the more promising candidate. The significantly better logP value is crucial for permeability and bioavailability. While Ligand A has a slightly better TPSA, the poor logP of Ligand B is a major concern. The improved metabolic stability (lower Cl_mic, longer t1/2) and slightly better affinity of Ligand B further strengthen its profile. The slightly better BBB penetration is not a significant factor for a cardiovascular target.
Output:
0
2025-04-18 00:32:39,260 - INFO - Batch 485 complete. Total preferences: 7760
2025-04-18 00:32:39,261 - INFO - Processing batch 486/512...
2025-04-18 00:33:29,682 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (376.312 and 350.459 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (75.8) is significantly better than Ligand A (105.59). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (2.393 and 2.679), falling within the optimal 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Ligand A has 2 HBD, and Ligand B has 1. Both are acceptable.
5. **HBA:** Ligand A has 6 HBA, and Ligand B has 5. Both are acceptable.
6. **QED:** Both ligands have good QED scores (0.794 and 0.818), indicating good drug-like properties.
7. **DILI:** Ligand A has a DILI risk of 84.257, which is concerningly high. Ligand B has a very low DILI risk of 10.508. This is a *major* advantage for Ligand B.
8. **BBB:** Ligand A has a BBB penetration of 24.389, and Ligand B has 62.699. While not a primary concern for a cardiovascular target, higher BBB is generally preferable.
9. **Caco-2:** Ligand A (-5.185) and Ligand B (-4.313) both have negative Caco-2 values, indicating poor permeability. This is a weakness for both.
10. **Solubility:** Ligand A (-4.038) and Ligand B (-1.958) both have negative solubility values, indicating poor solubility. This is a weakness for both.
11. **hERG:** Both ligands have low hERG inhibition liability (0.32 and 0.466), which is good.
12. **Cl_mic:** Ligand A (23.297) has a lower microsomal clearance than Ligand B (69.227), suggesting better metabolic stability.
13. **t1/2:** Ligand B (5.877) has a significantly longer in vitro half-life than Ligand A (-2.834). This is a significant advantage for Ligand B.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.127 and 0.199).
15. **Binding Affinity:** Ligand B (-6.6 kcal/mol) has a significantly stronger binding affinity than Ligand A (-1.1 kcal/mol). This is a *major* advantage for Ligand B. A difference of 5.5 kcal/mol is substantial and can often outweigh minor ADME concerns.
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B excels in affinity and has a better TPSA and logP. The significantly lower DILI risk is also a critical factor. While both have poor Caco-2 and solubility, the superior binding affinity and safety profile of Ligand B make it the more promising candidate.
**Conclusion:**
Ligand B is the preferred candidate due to its significantly better binding affinity, much lower DILI risk, longer half-life, and better TPSA.
Output:
0
2025-04-18 00:33:29,683 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (349.431 and 343.519 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (83.81) is slightly higher than Ligand B (44.29). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B is significantly better here.
**3. logP:** Ligand A (1.312) is within the optimal 1-3 range, while Ligand B (3.096) is at the higher end. Both are acceptable, but Ligand A's lower logP might translate to fewer off-target interactions.
**4. H-Bond Donors:** Ligand A has 2 HBDs, and Ligand B has 1. Both are within the acceptable limit of <=5.
**5. H-Bond Acceptors:** Both ligands have 5 HBAs, which is within the acceptable limit of <=10.
**6. QED:** Ligand B (0.86) has a higher QED score than Ligand A (0.519), indicating a more drug-like profile overall. This is a significant advantage for Ligand B.
**7. DILI Risk:** Ligand A (22.8) has a much lower DILI risk than Ligand B (52.036). This is a crucial factor, as liver toxicity is a major concern in drug development.
**8. BBB Penetration:** Ligand A (61.923) has lower BBB penetration than Ligand B (96.743). While ADRB2 is primarily a cardiovascular target, some CNS side effects are possible with GPCR modulators, and higher BBB penetration could contribute to those. However, for a cardiovascular target, this isn't a primary concern.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-5 and -4.81), which is unusual and suggests poor permeability. This is a significant drawback for both.
**10. Aqueous Solubility:** Ligand A (-1.599) has better solubility than Ligand B (-3.196). Solubility is important for formulation and bioavailability.
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (0.371 and 0.968, respectively).
**12. Microsomal Clearance:** Ligand A (-9.218) has significantly lower microsomal clearance than Ligand B (58.178), suggesting better metabolic stability. This is a major advantage for Ligand A.
**13. In vitro Half-Life:** Ligand B (17.792 hours) has a much longer in vitro half-life than Ligand A (5.711 hours). This is desirable for less frequent dosing.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.029 and 0.248, respectively).
**15. Binding Affinity:** Both ligands have similar strong binding affinities (-6.0 and -5.8 kcal/mol). The difference is minimal.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity) and general drug-like properties, Ligand A emerges as the more promising candidate. While Ligand B has a better QED and longer half-life, Ligand A's significantly lower DILI risk and better metabolic stability (lower Cl_mic) are critical advantages. The lower TPSA of Ligand B is beneficial, but the poor Caco-2 permeability of both is a concern that would need to be addressed regardless. The slightly better solubility of Ligand A is also a plus. The affinity is comparable.
Output:
1
2025-04-18 00:33:29,683 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (369.422 and 360.361 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (98.66) is better than Ligand B (112.81). For a GPCR, keeping TPSA under 140 is good for oral absorption, and lower is generally preferred.
**3. logP:** Ligand B (-0.895) is slightly less lipophilic than Ligand A (-0.299). Both are within the acceptable range of 1-3, but closer to the lower end. This isn't a major concern for a cardiovascular target, but slightly higher logP is generally preferred for membrane permeability.
**4. H-Bond Donors:** Both ligands have 2 HBD, which is within the acceptable limit of 5.
**5. H-Bond Acceptors:** Ligand A has 7 HBA, while Ligand B has 4. Both are within the acceptable limit of 10.
**6. QED:** Ligand A (0.755) has a substantially better QED score than Ligand B (0.472), indicating a more drug-like profile.
**7. DILI Risk:** Ligand B (35.13) has a significantly lower DILI risk than Ligand A (65.995). This is a major advantage for Ligand B.
**8. BBB Penetration:** Ligand B (74.176) has better predicted BBB penetration than Ligand A (45.832). While ADRB2 isn't a CNS target, some peripheral exposure can be beneficial, and avoiding high CNS exposure can reduce off-target effects.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-5.17 and -5.463). These values are unusual and suggest very poor permeability. This is a significant concern for both.
**10. Aqueous Solubility:** Both ligands have negative solubility values (-1.98 and -2.039). These values are also unusual and suggest very poor solubility. This is a significant concern for both.
**11. hERG Inhibition:** Ligand A (0.092) has a slightly lower hERG inhibition risk than Ligand B (0.197), which is preferable.
**12. Microsomal Clearance:** Ligand B (-24.049) has significantly lower (better) microsomal clearance than Ligand A (2.77), indicating better metabolic stability.
**13. In vitro Half-Life:** Ligand B (-27.045) has a dramatically longer in vitro half-life than Ligand A (-12.989). This is a substantial advantage for Ligand B.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.01 and 0.007).
**15. Binding Affinity:** Ligand B (-7.6) has a slightly better binding affinity than Ligand A (-6.9). While the difference is less than 1.5 kcal/mol, it's still a positive for Ligand B.
**Overall Assessment:**
Despite both ligands having poor Caco-2 and solubility predictions, Ligand B presents a more favorable profile overall. Its significantly lower DILI risk, better BBB penetration, substantially improved metabolic stability (lower Cl_mic and longer t1/2), and slightly better binding affinity outweigh the slightly lower logP and slightly higher hERG risk. The QED score is lower, but the other ADME properties are more critical for a GPCR target.
Output:
0
2025-04-18 00:33:29,683 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (354.5 & 343.5 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (32.34) is significantly better than Ligand B (58.36). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (4.747) is higher than Ligand B (2.674). While both are within the acceptable range (1-3 is optimal, up to 4 is tolerable), Ligand A is pushing the upper limit. Ligand B is closer to the sweet spot.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Both have 3 HBA, which is acceptable.
6. **QED:** Ligand B (0.864) is slightly better than Ligand A (0.76), indicating a marginally more drug-like profile.
7. **DILI:** Ligand B (2.21) is *much* better than Ligand A (44.63). This is a significant advantage for Ligand B. A DILI percentile below 40 is desirable, and Ligand B is well within that range, while Ligand A is concerningly high.
8. **BBB:** Not a major priority for a cardiovascular target. Ligand A (93.6) is higher than Ligand B (82.2), but this is less important.
9. **Caco-2:** Ligand A (-4.999) is better than Ligand B (-5.248). Higher (less negative) values indicate better permeability.
10. **Solubility:** Ligand B (-1.271) is better than Ligand A (-4.577). Better solubility is crucial for bioavailability.
11. **hERG:** Both ligands have low hERG risk (0.964 and 0.804 respectively). No significant difference.
12. **Cl_mic:** Ligand B (-32.655) is *much* better than Ligand A (103.529). Lower clearance indicates greater metabolic stability, a critical factor for drug efficacy.
13. **t1/2:** Ligand A (50.768) is better than Ligand B (-9.56). A longer half-life is generally preferred.
14. **Pgp:** Ligand A (0.77) is better than Ligand B (0.044). Lower P-gp efflux is desirable.
15. **Binding Affinity:** Ligand B (-7.7) is significantly better than Ligand A (-6.2). A 1.5 kcal/mol difference in binding affinity is substantial and can outweigh minor ADME drawbacks.
**Overall Assessment:**
Ligand B demonstrates a superior balance of properties. While Ligand A has better Caco-2 permeability, Pgp efflux, and in vitro half-life, Ligand B excels in crucial areas like DILI risk, metabolic stability (Cl_mic), solubility, and, most importantly, binding affinity. The significantly lower DILI risk and improved metabolic stability of Ligand B are particularly compelling. The stronger binding affinity of Ligand B is also a major advantage for a GPCR target.
Output:
0
2025-04-18 00:33:29,683 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (346.515) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (58.2) is significantly better than Ligand B (88.16). ADRB2 is a cardiovascular target, not CNS, but lower TPSA is still generally desirable for absorption. Ligand B's TPSA is approaching a level that could hinder oral absorption.
3. **logP:** Both ligands have acceptable logP values (A: 3.572, B: 2.067), falling within the 1-3 range. Ligand A is slightly higher, which could potentially lead to off-target effects, but is still within a reasonable range.
4. **HBD & HBA:** Both ligands have 2 HBD and acceptable HBA counts (A: 2, B: 4).
5. **QED:** Both ligands have good QED scores (A: 0.66, B: 0.776), indicating drug-like properties. Ligand B is slightly better here.
6. **DILI:** Ligand A (9.771) has a much lower DILI risk than Ligand B (59.519). This is a significant advantage for Ligand A.
7. **BBB:** While not a primary concern for a cardiovascular target, Ligand A (71.035) has a better BBB percentile than Ligand B (59.364).
8. **Caco-2:** Both ligands have negative Caco-2 values (-4.676 and -4.97), which is unusual and suggests poor permeability. This is a concern for both, but slightly worse for Ligand B.
9. **Solubility:** Both ligands have negative solubility values (-4.094 and -3.131), indicating very poor aqueous solubility. This is a major drawback for both.
10. **hERG:** Both ligands have low hERG inhibition risk (A: 0.317, B: 0.154). Ligand B is slightly better here.
11. **Cl_mic:** Ligand B (45.235) has significantly lower microsomal clearance than Ligand A (80.792), suggesting better metabolic stability. This is a significant advantage for Ligand B.
12. **t1/2:** Ligand B (-48.83) has a much longer in vitro half-life than Ligand A (-7.319). This is a major advantage for Ligand B.
13. **Pgp:** Both ligands have low P-gp efflux liability (A: 0.094, B: 0.071).
14. **Binding Affinity:** Ligand A (-6.7 kcal/mol) has a slightly better binding affinity than Ligand B (-5.7 kcal/mol). This is a 1 kcal/mol difference, which is noticeable.
**Overall Assessment:**
Ligand A has a better binding affinity and significantly lower DILI risk. However, Ligand B excels in metabolic stability (lower Cl_mic) and has a much longer half-life. Both have poor solubility and Caco-2 permeability. Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), the better affinity of Ligand A combined with its lower DILI risk and slightly better TPSA outweigh the advantages of Ligand B's metabolic stability and half-life. The solubility and permeability issues are significant for both, but could be addressed with formulation strategies.
Output:
1
2025-04-18 00:33:29,684 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (360.405 and 345.447 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (87.46) is slightly higher than Ligand B (80.12). Both are below the 140 A^2 threshold for good oral absorption, and acceptable for a peripheral GPCR like ADRB2.
3. **logP:** Ligand A (0.991) is a bit lower than Ligand B (1.483), but both are within the optimal 1-3 range.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1). Both are within the acceptable limit of 5.
5. **HBA:** Both ligands have 5 HBA, which is within the acceptable limit of 10.
6. **QED:** Ligand B (0.847) has a higher QED score than Ligand A (0.651), indicating a more drug-like profile.
7. **DILI:** Ligand A (19) has a significantly lower DILI risk than Ligand B (41.411). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (69.756) has a higher BBB penetration than Ligand A (58.24). However, since ADRB2 is primarily a cardiovascular target, high BBB penetration is not a priority.
9. **Caco-2:** Ligand A (-4.896) and Ligand B (-5.026) have similar Caco-2 permeability values, suggesting comparable intestinal absorption.
10. **Solubility:** Ligand A (-0.976) has a slightly better solubility than Ligand B (-2.828).
11. **hERG:** Ligand A (0.56) has a lower hERG inhibition liability than Ligand B (0.179), indicating a lower risk of cardiotoxicity. This is a critical advantage given the cardiovascular target.
12. **Cl_mic:** Ligand A (14.776) has a lower microsomal clearance than Ligand B (46.16), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-22.445) has a longer in vitro half-life than Ligand B (-19.498).
14. **Pgp:** Ligand A (0.051) has a lower P-gp efflux liability than Ligand B (0.1).
15. **Binding Affinity:** Ligand B (-7.9) has a significantly stronger binding affinity than Ligand A (-6.3). This is a 1.6 kcal/mol difference, which is substantial.
**Overall Assessment:**
While Ligand B has a superior binding affinity, Ligand A demonstrates a significantly better safety profile (lower DILI, lower hERG) and improved ADME properties (lower Cl_mic, longer t1/2, lower Pgp efflux). For a cardiovascular target, minimizing off-target effects and ensuring favorable ADME properties are crucial. The 1.6 kcal/mol difference in binding affinity, while notable, can potentially be optimized during lead optimization without sacrificing the favorable safety and ADME profile of Ligand A. The higher QED of Ligand B is a plus, but the safety concerns outweigh this benefit.
Output:
1
2025-04-18 00:33:29,684 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
We are targeting ADRB2, a GPCR, so the priorities are logP, Pgp, TPSA, affinity, and BBB. Let's break down each ligand against these and other important parameters:
* **Molecular Weight:** Both ligands (355.479 and 358.551 Da) are within the ideal 200-500 Da range.
* **TPSA:** Ligand A (71.11) is better than Ligand B (36.36). Lower TPSA generally favors better cell permeability, which is crucial for GPCR targeting.
* **logP:** Ligand B (4.727) is significantly higher than Ligand A (0.344). While a logP between 1-3 is optimal, 4.727 is pushing the limit and could lead to solubility issues and off-target effects. Ligand A's low logP might hinder permeability, but this is less concerning than Ligand B's high value.
* **H-Bond Donors/Acceptors:** Both have 1 HBD and a reasonable number of HBAs (5 and 4 respectively). No major concerns here.
* **QED:** Both ligands have good QED scores (0.68 and 0.777), indicating drug-like properties.
* **DILI:** Ligand A (7.445) has a much lower DILI risk than Ligand B (9.965). This is a significant advantage.
* **BBB:** Ligand B (78.519) has a better BBB penetration percentile than Ligand A (56.146). This is a positive for GPCRs, but less critical for ADRB2 which isn't a primary CNS target.
* **Caco-2 Permeability:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
* **Aqueous Solubility:** Ligand A (-0.282) is better than Ligand B (-4.322), which is a significant concern given Ligand B's high logP.
* **hERG Inhibition:** Both have low hERG inhibition risk (0.309 and 0.827).
* **Microsomal Clearance:** Ligand A (-2.961) has a significantly *lower* (better) microsomal clearance than Ligand B (44.528), indicating better metabolic stability.
* **In vitro Half-Life:** Ligand A (-17.449) has a longer in vitro half-life than Ligand B (-6.574).
* **P-gp Efflux:** Both have very low P-gp efflux liability (0.005 and 0.567).
* **Binding Affinity:** Both have very similar binding affinities (-6.5 and -6.2 kcal/mol). The difference is not substantial enough to outweigh other factors.
**Overall Assessment:**
Ligand B has better BBB penetration, but its high logP, poor solubility, high DILI risk, and high microsomal clearance are significant drawbacks. Ligand A, while having a lower BBB score and slightly worse Caco-2 permeability, presents a much more balanced profile with lower DILI risk, better solubility, and improved metabolic stability. Given the overall profile, Ligand A is the more promising candidate.
**Output:**
1
2025-04-18 00:33:29,684 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's systematically compare Ligand A and Ligand B against the provided guidelines, keeping in mind ADRB2 is a GPCR, so logP, Pgp, TPSA, and affinity are key.
1. **MW:** Both ligands (367.877 and 357.336 Da) fall comfortably within the ideal 200-500 Da range.
2. **TPSA:** Both ligands (82.53 and 81.93) are below the 140 A^2 threshold for good oral absorption.
3. **logP:** Both ligands (2.399 and 2.039) are within the optimal 1-3 range.
4. **HBD/HBA:** Ligand A (2 HBD, 4 HBA) and Ligand B (1 HBD, 6 HBA) both have acceptable numbers of hydrogen bond donors and acceptors.
5. **QED:** Both ligands have good QED scores (0.656 and 0.695), indicating drug-likeness.
6. **DILI:** Ligand A (43.738) has a lower DILI risk than Ligand B (62.66), which is a significant advantage.
7. **BBB:** Ligand B (76.347) has a better BBB penetration score than Ligand A (60.644). While ADRB2 isn't necessarily a CNS target, some peripheral ADRB2 activity can influence CNS pathways, so some BBB penetration isn't detrimental.
8. **Caco-2:** Both ligands have negative Caco-2 values (-4.645 and -4.548), which is unusual and suggests poor permeability. This is a concern for both.
9. **Solubility:** Both ligands have negative solubility values (-2.899 and -2.819), indicating very poor aqueous solubility. This is a major drawback for both.
10. **hERG:** Both ligands have low hERG inhibition liability (0.341 and 0.294).
11. **Cl_mic:** Ligand B (50.998) has a lower microsomal clearance than Ligand A (45.957), suggesting better metabolic stability.
12. **t1/2:** Ligand B (-24.565) has a significantly longer in vitro half-life than Ligand A (57.632). This is a major advantage for Ligand B.
13. **Pgp:** Both ligands have low P-gp efflux liability (0.151 and 0.114).
14. **Affinity:** Ligand A (-7.2 kcal/mol) has a slightly better binding affinity than Ligand B (-6.9 kcal/mol). This is a 0.3 kcal/mol difference, which is not a huge margin.
**Overall Assessment:**
Both ligands have significant drawbacks (poor Caco-2 and solubility). However, Ligand B has a substantially better half-life and lower clearance, which are critical for *in vivo* efficacy. The slightly better affinity of Ligand A is not enough to offset the pharmacokinetic advantages of Ligand B. The DILI score is better for Ligand A, but the difference isn't large enough to outweigh the PK benefits of Ligand B.
Output:
0
2025-04-18 00:33:29,684 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (368.459 Da and 350.419 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (127.32) is slightly higher than Ligand B (104.65). Both are below the 140 threshold for oral absorption, but Ligand B is better positioned, especially considering ADRB2 isn't necessarily a CNS target requiring a very low TPSA.
3. **logP:** Ligand B (0.996) is closer to the optimal 1-3 range than Ligand A (0.286), which is quite low and could indicate poor membrane permeability. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (2), but both are within the acceptable limit of 5.
5. **HBA:** Both ligands have 6 HBA, which is within the acceptable limit of 10.
6. **QED:** Both ligands have good QED scores (0.605 and 0.688 respectively), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand B (37.146) has a lower DILI risk than Ligand A (43.622), which is preferable.
8. **BBB:** Both are relatively low, suggesting limited CNS penetration. This is acceptable for a cardiovascular target like ADRB2. Ligand B (39.473) is slightly better than Ligand A (55.448).
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. This is a concern for both, but the magnitude of the negative value is similar.
10. **Solubility:** Ligand A (-2.752) has a worse solubility than Ligand B (-1.658). Solubility is important for bioavailability, so Ligand B is favored.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.029 and 0.07 respectively), which is excellent.
12. **Cl_mic:** Both ligands have similar microsomal clearance (21.061 and 19.993 mL/min/kg), suggesting comparable metabolic stability.
13. **t1/2:** Ligand A (17.764 hours) has a significantly longer in vitro half-life than Ligand B (0.397 hours). This is a major advantage for Ligand A, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.015 and 0.016 respectively), which is good.
15. **Binding Affinity:** Ligand B (-6.0 kcal/mol) has a slightly better binding affinity than Ligand A (-5.6 kcal/mol). While the difference isn't huge, it's enough to be considered.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand B excels in logP and TPSA, and has a slightly better affinity. While Ligand A has a much better half-life, the ADME properties of Ligand B are superior overall, and the affinity difference is sufficient to outweigh the half-life concern.
Output:
0
2025-04-18 00:33:29,684 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (372.368 and 354.491 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (61.19) is significantly better than Ligand B (76.66). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (3.525) is slightly higher than Ligand B (2.57), both are within the optimal 1-3 range. Ligand A is closer to the upper limit, which *could* be a minor concern for solubility, but is not a dealbreaker.
4. **HBD:** Ligand A (0) is preferred over Ligand B (2). Fewer hydrogen bond donors generally improve membrane permeability.
5. **HBA:** Ligand A (6) is slightly higher than Ligand B (4), but both are acceptable (<=10).
6. **QED:** Ligand A (0.754) is better than Ligand B (0.591), indicating a more drug-like profile.
7. **DILI:** Ligand B (42.458) has a significantly lower DILI risk than Ligand A (68.592). This is a major advantage for Ligand B.
8. **BBB:** Ligand A (93.37) has better BBB penetration than Ligand B (71.811). While ADRB2 is not a CNS target, some off-target CNS effects are possible with GPCR ligands, and higher BBB can sometimes correlate with increased off-target activity.
9. **Caco-2:** Ligand A (-4.263) is better than Ligand B (-5.175). Higher (less negative) Caco-2 values indicate better intestinal absorption.
10. **Solubility:** Ligand B (-2.908) has better aqueous solubility than Ligand A (-4.325). This is a positive for Ligand B.
11. **hERG:** Ligand A (0.137) has a lower hERG risk than Ligand B (0.343). This is a significant advantage for Ligand A, as hERG inhibition can lead to cardiotoxicity.
12. **Cl_mic:** Ligand B (32.382) has lower microsomal clearance than Ligand A (59.861), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-28.28) has a longer in vitro half-life than Ligand B (11.275). This is a positive for Ligand A.
14. **Pgp:** Ligand A (0.312) has lower P-gp efflux than Ligand B (0.061), suggesting better bioavailability.
15. **Affinity:** Ligand A (-7.5 kcal/mol) has a better binding affinity than Ligand B (-5.8 kcal/mol). This is a substantial advantage for Ligand A, exceeding the 1.5 kcal/mol threshold.
**Overall Assessment:**
Ligand A has a significantly better binding affinity and a longer half-life, and better Caco-2 permeability and Pgp efflux. The better affinity is a major driver. While Ligand B has a lower DILI risk and better solubility and metabolic stability, the strong binding affinity of Ligand A, coupled with acceptable ADME properties, makes it the more promising candidate. The hERG risk for Ligand A is also lower.
Output:
1
2025-04-18 00:33:29,684 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A: [351.447, 84.67, 2.186, 1, 5, 0.776, 40.675, 76.541, -4.647, -2.131, 0.247, 41.769, -15.714, 0.045, -6.8]**
**Ligand B: [356.817, 96.45, 3.063, 2, 5, 0.748, 88.639, 62.233, -5.429, -3.851, 0.155, 10.371, 9.826, 0.215, -7.8]**
Here's a breakdown of the comparison, considering the provided guidelines and GPCR-specific priorities:
1. **MW:** Both ligands are within the ideal range (200-500 Da). A is 351.447, B is 356.817 - very similar.
2. **TPSA:** Ligand A (84.67) is better than Ligand B (96.45). Both are acceptable, but A is closer to the <140 threshold for good absorption.
3. **logP:** Ligand A (2.186) is within the optimal range. Ligand B (3.063) is also acceptable, but edging towards the higher end.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Both ligands have 5 HBA, which is acceptable.
6. **QED:** Both ligands are similar (A: 0.776, B: 0.748), and both are above the 0.5 threshold, indicating good drug-likeness.
7. **DILI:** Ligand A (40.675) has a significantly lower DILI risk than Ligand B (88.639). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (76.541) has a better BBB penetration score than Ligand B (62.233). While ADRB2 isn't strictly a CNS target, some CNS penetration can be beneficial, and lower penetration minimizes off-target effects.
9. **Caco-2:** Ligand A (-4.647) appears to have better Caco-2 permeability than Ligand B (-5.429). Lower (more negative) values indicate better permeability.
10. **Solubility:** Ligand A (-2.131) has better aqueous solubility than Ligand B (-3.851).
11. **hERG:** Both ligands have very low hERG risk (A: 0.247, B: 0.155) - excellent.
12. **Cl_mic:** Ligand A (41.769) has a lower microsomal clearance than Ligand B (10.371), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-15.714) has a longer in vitro half-life than Ligand B (9.826).
14. **Pgp:** Ligand A (0.045) has lower P-gp efflux than Ligand B (0.215).
15. **Affinity:** Ligand B (-7.8) has a significantly better binding affinity than Ligand A (-6.8). This is a 1.0 kcal/mol difference, which is substantial.
**Overall Assessment:**
Ligand B has a clear advantage in binding affinity (-7.8 kcal/mol vs -6.8 kcal/mol). However, Ligand A excels in almost all ADME-Tox properties. Specifically, the significantly lower DILI risk, better BBB penetration, improved solubility, lower clearance, longer half-life, and lower P-gp efflux of Ligand A are very compelling. For a GPCR, balancing affinity with good ADME properties is crucial. While the affinity difference is notable, the ADME profile of Ligand A is far superior and mitigates potential risks associated with drug development. The difference in affinity *might* be overcome with further optimization of Ligand A, while fixing the ADME issues of Ligand B would likely be more challenging.
Therefore, I would prioritize Ligand A.
Output:
1
2025-04-18 00:33:29,685 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.419 and 341.455 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (99.68) is higher than Ligand B (62.3). While both are below the 140 threshold for oral absorption, the lower TPSA of Ligand B is preferable for a GPCR, potentially aiding permeability.
3. **logP:** Both ligands (1.523 and 2.252) are within the optimal 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable, being less than 5. Ligand B is slightly better.
5. **HBA:** Ligand A (5) and Ligand B (3) are both acceptable, being less than 10. Ligand B is better.
6. **QED:** Both ligands have very similar QED values (0.843 and 0.855), indicating good drug-likeness.
7. **DILI:** Ligand A (22.683) has a lower DILI risk than Ligand B (25.165), which is a significant advantage. Lower DILI is always preferred.
8. **BBB:** Ligand B (65.956) has a substantially higher BBB penetration percentile than Ligand A (29.003). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant, and higher BBB is generally favorable.
9. **Caco-2:** Ligand A (-5.44) and Ligand B (-4.949) are both negative, which is unusual and suggests poor permeability. This is a concern for both, but the values are close.
10. **Solubility:** Ligand A (-1.74) and Ligand B (-2.143) both have negative solubility values, indicating poor aqueous solubility. This is a significant drawback for both.
11. **hERG:** Ligand A (0.089) has a slightly lower hERG inhibition liability than Ligand B (0.163), which is preferable.
12. **Cl_mic:** Ligand A (-26.937) has a much lower (better) microsomal clearance than Ligand B (41.249), indicating greater metabolic stability. This is a major advantage for Ligand A.
13. **t1/2:** Ligand A (-9.411) has a slightly longer in vitro half-life than Ligand B (-10.618), which is preferable.
14. **Pgp:** Ligand A (0.009) has a much lower P-gp efflux liability than Ligand B (0.08), which is a significant advantage. Lower P-gp efflux improves bioavailability.
15. **Binding Affinity:** Ligand B (-8.0) has a stronger binding affinity than Ligand A (-6.0). This is a 2 kcal/mol difference, which is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand B has a significantly better binding affinity and BBB penetration, which are important for a GPCR target. However, Ligand A demonstrates superior metabolic stability (lower Cl_mic), lower DILI risk, and lower P-gp efflux. The solubility and Caco-2 permeability are poor for both, but the metabolic advantages of Ligand A, combined with acceptable hERG and DILI profiles, make it a more promising starting point for optimization. The affinity difference, while significant, can potentially be addressed through medicinal chemistry efforts, whereas improving metabolic stability and reducing efflux are often more challenging.
Output:
1
2025-04-18 00:33:29,685 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (365.792 and 364.486 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (79.46) is higher than Ligand B (40.62). For a cardiovascular GPCR, TPSA isn't *as* critical as for CNS targets, but lower is generally preferred for absorption. Ligand B is significantly better.
3. **logP:** Both ligands have good logP values (3.465 and 3.308), falling within the optimal 1-3 range. A slight edge to Ligand B being closer to 3.
4. **HBD:** Ligand A has 1 HBD, while Ligand B has 0. Both are acceptable, but fewer HBDs can sometimes improve permeability. Ligand B is slightly better.
5. **HBA:** Ligand A has 5 HBA, and Ligand B has 3. Both are within the acceptable limit of 10, but Ligand B is preferable.
6. **QED:** Ligand A (0.901) has a significantly higher QED than Ligand B (0.752), suggesting a more drug-like profile overall. This is a substantial advantage for Ligand A.
7. **DILI:** Ligand A (75.262) has a higher DILI risk than Ligand B (30.748). This is a major concern, as lower DILI is crucial. Ligand B is significantly better.
8. **BBB:** Ligand A (82.668) has a good BBB penetration percentile, while Ligand B (90.772) is even better. While ADRB2 isn't exclusively a CNS target, some brain exposure can occur, and higher BBB is generally favorable. Ligand B is better.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.844 and -4.443). These values are difficult to interpret without knowing the scale, but negative values suggest poor permeability. No clear advantage.
10. **Solubility:** Both ligands have negative solubility values (-4.31 and -3.825). Similar to Caco-2, these are hard to interpret without knowing the scale, but suggest poor solubility. No clear advantage.
11. **hERG:** Ligand A (0.283) has a slightly lower hERG risk than Ligand B (0.828). Lower is better, so Ligand A is slightly better.
12. **Cl_mic:** Ligand A (47.23) has lower microsomal clearance than Ligand B (50.147), indicating better metabolic stability. Ligand A is better.
13. **t1/2:** Ligand A (-13.694) has a *much* lower in vitro half-life than Ligand B (11.174). This is a significant disadvantage for Ligand A. Ligand B is much better.
14. **Pgp:** Ligand A (0.242) has lower P-gp efflux than Ligand B (0.672), which is favorable for bioavailability. Ligand A is better.
15. **Affinity:** Ligand A (-7.6) has a slightly better binding affinity than Ligand B (-5.4). This is a 2.2 kcal/mol difference, which is substantial and can outweigh some ADME drawbacks. Ligand A is better.
**Overall Assessment:**
Ligand A has a superior QED, affinity, and metabolic stability (lower Cl_mic, better Pgp, and lower hERG). However, it has a significantly higher DILI risk and a much shorter half-life. Ligand B excels in ADME properties: lower DILI, better BBB penetration, and a much longer half-life. The TPSA is also much more favorable.
Given that ADRB2 is a cardiovascular target, metabolic stability and avoiding toxicity (DILI) are paramount. While the affinity difference is notable, the significantly better ADME profile of Ligand B, particularly the lower DILI risk and longer half-life, makes it the more promising candidate. The lower TPSA is also a bonus.
Output:
0
2025-04-18 00:33:29,685 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands are within the acceptable range (200-500 Da). Ligand A (432.384 Da) is slightly higher, but not concerning.
**2. TPSA:** Ligand A (63.69) is well below the 140 threshold and preferable for oral absorption. Ligand B (94.48) is higher, but still within a reasonable range, though less optimal.
**3. logP:** Both ligands have good logP values (A: 3.862, B: 2.665) within the 1-3 range, suggesting good permeability.
**4. H-Bond Donors:** Both are acceptable (A: 1, B: 2), well below the limit of 5.
**5. H-Bond Acceptors:** Both are acceptable (A: 5, B: 6), below the limit of 10.
**6. QED:** Both have good QED scores (A: 0.771, B: 0.874), indicating drug-like properties. Ligand B is slightly better here.
**7. DILI:** Both have similar DILI risk (A: 68.98, B: 68.786), both are acceptable.
**8. BBB:** Ligand A (80.031) has a better BBB penetration percentile than Ligand B (76.154). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant for off-target effects and overall safety assessment.
**9. Caco-2 Permeability:** Both have negative Caco-2 values, which is unusual and indicates poor permeability. However, the values are similar (-4.403 for A, -4.53 for B), so this isn't a major differentiator.
**10. Aqueous Solubility:** Both have negative solubility values, which is also unusual. Again, the values are similar (-4.577 for A, -4.28 for B).
**11. hERG Inhibition:** Ligand A (0.458) has a significantly lower hERG inhibition liability than Ligand B (0.166), which is a crucial safety advantage.
**12. Microsomal Clearance:** Ligand A (81.423) has higher microsomal clearance than Ligand B (45.123). This suggests Ligand B is more metabolically stable, which is desirable.
**13. In vitro Half-Life:** Ligand A (28.297) has a longer half-life than Ligand B (14.341), which is a positive attribute.
**14. P-gp Efflux:** Ligand A (0.522) has lower P-gp efflux than Ligand B (0.047), which is favorable for bioavailability.
**15. Binding Affinity:** Ligand A (-8.5 kcal/mol) has a significantly stronger binding affinity than Ligand B (-7.5 kcal/mol). This 1 kcal/mol difference is substantial and can outweigh minor ADME drawbacks.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand A is the stronger candidate. The significantly improved binding affinity (-8.5 vs -7.5 kcal/mol) and lower hERG risk are major advantages. While Ligand B has a slightly better QED and lower microsomal clearance, the superior potency and safety profile of Ligand A are more critical for a GPCR target. The slightly better BBB penetration of Ligand A is also a bonus. The unusual Caco-2 and solubility values for both compounds would need further investigation, but don't currently sway the decision significantly.
Output:
1
2025-04-18 00:33:29,685 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [356.438, 84.5, 1.664, 2, 4, 0.68, 56.844, 80.574, -4.995, -2.332, 0.194, 20.907, 2.448, 0.052, -5.3]**
**Ligand B: [357.451, 91.34, -0.788, 2, 6, 0.648, 13.416, 27.608, -5.083, 0.295, 0.045, -7.646, -9.996, 0.002, -3.5]**
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). No significant difference.
2. **TPSA:** Ligand A (84.5) is better than Ligand B (91.34). ADRB2 is not a CNS target, but lower TPSA is generally favorable for absorption.
3. **logP:** Ligand A (1.664) is within the optimal range (1-3). Ligand B (-0.788) is slightly below 1, which could potentially hinder permeation. This favors Ligand A.
4. **H-Bond Donors:** Both have 2 HBD, which is acceptable.
5. **H-Bond Acceptors:** Ligand A (4) is better than Ligand B (6). Lower HBA is generally preferred for permeability.
6. **QED:** Both are similar (0.68 and 0.648), indicating reasonable drug-likeness.
7. **DILI:** Ligand A (56.844) has a higher DILI risk than Ligand B (13.416). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (80.574) has much better BBB penetration than Ligand B (27.608). While ADRB2 isn't a primary CNS target, some peripheral distribution is still desirable, and higher BBB penetration can sometimes correlate with better overall distribution.
9. **Caco-2:** Both have negative values, indicating poor permeability. Ligand A (-4.995) is slightly better than Ligand B (-5.083).
10. **Solubility:** Ligand B (0.295) has better solubility than Ligand A (-2.332). This is a positive for Ligand B.
11. **hERG:** Both have very low hERG inhibition risk (0.194 and 0.045). No significant difference.
12. **Cl_mic:** Ligand B (-7.646) has significantly lower microsomal clearance than Ligand A (20.907). This indicates better metabolic stability for Ligand B.
13. **t1/2:** Ligand B (-9.996) has a longer in vitro half-life than Ligand A (2.448). This is a major advantage for Ligand B.
14. **Pgp:** Both have very low Pgp efflux liability (0.052 and 0.002). No significant difference.
15. **Binding Affinity:** Ligand A (-5.3) has a slightly better binding affinity than Ligand B (-3.5). This is a 1.8 kcal/mol difference, which is substantial.
**Overall Assessment:**
Ligand A has a better binding affinity and slightly better Caco-2 permeability, and better BBB penetration. However, Ligand B shines in ADME properties: significantly lower DILI risk, much better metabolic stability (lower Cl_mic), and a longer half-life. The binding affinity difference, while significant, can potentially be optimized in later stages of drug development. The improved ADME profile of Ligand B, particularly the lower DILI and better metabolic stability, makes it a more promising starting point for a drug candidate targeting ADRB2.
Output:
0
2025-04-18 00:33:29,685 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (358.36 & 363.85 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (44.76) is significantly better than Ligand B (69.72). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (3.81) is slightly higher than Ligand B (2.14), both are within the optimal 1-3 range. Ligand A is preferable here.
4. **HBD:** Ligand A (0) is better than Ligand B (1). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is slightly better than Ligand B (3). Both are within the acceptable range.
6. **QED:** Both ligands have good QED scores (0.768 and 0.894), indicating good drug-like properties. No clear advantage.
7. **DILI:** Ligand B (42.46) has a lower DILI risk than Ligand A (48.82), which is a significant advantage.
8. **BBB:** Ligand A (91.70) has higher BBB penetration than Ligand B (82.51). While not a primary concern for a cardiovascular target, it's a slight positive for Ligand A.
9. **Caco-2:** Both ligands have very negative Caco-2 values (-4.752 and -4.786). This is unusual and suggests poor permeability *in vitro*. This is a major concern for both.
10. **Solubility:** Ligand A (-4.553) is slightly better than Ligand B (-3.814), both are poor.
11. **hERG:** Ligand A (0.725) has a lower hERG risk than Ligand B (0.345). This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand B (-17.94) has *much* lower microsomal clearance than Ligand A (50.13). This indicates significantly better metabolic stability for Ligand B.
13. **t1/2:** Ligand B (19.76) has a much longer in vitro half-life than Ligand A (-0.053). This is a major advantage for Ligand B.
14. **Pgp:** Ligand A (0.237) has lower P-gp efflux than Ligand B (0.111), indicating better bioavailability.
15. **Binding Affinity:** Ligand B (-6.2 kcal/mol) has a slightly better binding affinity than Ligand A (-5.0 kcal/mol). This is a 1.2 kcal/mol difference, which is substantial.
**GPCR-Specific Priorities & Overall Assessment:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, and affinity. Ligand A has better logP, TPSA, and Pgp. However, Ligand B has a significantly better binding affinity (-6.2 vs -5.0 kcal/mol) and *much* improved metabolic stability (Cl_mic and t1/2). The poor Caco-2 values for both are concerning, but the superior affinity and metabolic profile of Ligand B are likely to be more impactful in driving forward a lead optimization program. The lower DILI risk for Ligand B is also a positive. While Ligand A has a better hERG profile, this is less critical than the other factors.
**Output:**
0
2025-04-18 00:33:29,686 - INFO - Batch 486 complete. Total preferences: 7776
2025-04-18 00:33:29,686 - INFO - Processing batch 487/512...
2025-04-18 00:34:16,044 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.43 and 356.46 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (75.71) is better than Ligand B (88.1). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (1.923) is better than Ligand B (0.552). Both are within the acceptable range, but Ligand A is closer to the optimal 1-3 range, suggesting better membrane permeability. Ligand B is a bit low, potentially hindering absorption.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (4) is preferable to Ligand B (5). Similar reasoning as HBD.
6. **QED:** Ligand A (0.799) is better than Ligand B (0.651), indicating a more drug-like profile.
7. **DILI:** Ligand A (41.3) is significantly better than Ligand B (8.5). This is a major advantage for Ligand A, as lower DILI risk is crucial.
8. **BBB:** Ligand A (64.0) is better than Ligand B (45.7). While not a primary concern for a cardiovascular target, higher BBB is generally favorable.
9. **Caco-2:** Ligand A (-4.433) is better than Ligand B (-4.782). Higher values are better, indicating better intestinal absorption.
10. **Solubility:** Ligand A (-2.023) is better than Ligand B (-1.187). Higher values are better.
11. **hERG:** Ligand A (0.144) is better than Ligand B (0.277). Lower hERG inhibition is crucial for avoiding cardiotoxicity.
12. **Cl_mic:** Ligand B (5.648) is better than Ligand A (67.137). Lower clearance is better, indicating greater metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand A (3.674) is better than Ligand B (-1.858). Longer half-life is generally desirable.
14. **Pgp:** Ligand A (0.041) is better than Ligand B (0.025). Lower P-gp efflux is better.
15. **Affinity:** Ligand B (-5.8) is significantly better than Ligand A (-4.5). A 1.3 kcal/mol difference in binding affinity is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand B has a significantly better binding affinity, which is a primary driver for GPCR drug candidates. While Ligand A has advantages in several ADME properties (DILI, solubility, hERG, QED, TPSA), the substantial difference in binding affinity of Ligand B is likely to be more impactful. The lower metabolic stability (higher Cl_mic) of Ligand B is a concern, but could potentially be addressed through structural modifications. The DILI risk of Ligand A is also very favorable. However, the binding affinity difference is substantial enough to favor Ligand B.
Output:
0
2025-04-18 00:34:16,045 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (344.342 Da) is better than Ligand B (391.27 Da). Both are within the ideal range, but A is closer to the lower end, potentially aiding permeability.
2. **TPSA:** Ligand B (53.76) is significantly better than Ligand A (73.44). ADRB2 is not a CNS target, but lower TPSA generally improves absorption.
3. **logP:** Both ligands have good logP values (A: 3.084, B: 3.48), falling within the optimal 1-3 range. B is slightly higher, which could be a minor concern for solubility, but not a dealbreaker.
4. **HBD:** Ligand A (1) is preferable to Ligand B (0). While both are low, having one HBD can sometimes improve solubility without significantly impacting permeability.
5. **HBA:** Ligand B (3) is better than Ligand A (5). Lower HBA is generally preferred for permeability.
6. **QED:** Ligand B (0.723) is better than Ligand A (0.527). A higher QED indicates a more drug-like profile.
7. **DILI:** Ligand B (53.276) is *much* better than Ligand A (91.004). This is a significant advantage for Ligand B; a DILI percentile above 90 is concerning.
8. **BBB:** Ligand B (85.964) is better than Ligand A (62.776). While ADRB2 isn't a primary CNS target, higher BBB penetration isn't necessarily detrimental and could provide some flexibility.
9. **Caco-2:** Both are very poor (-4.496 and -4.423). This is a major concern for both compounds, suggesting poor intestinal absorption.
10. **Solubility:** Ligand B (-3.617) is slightly better than Ligand A (-4.933), though both are poor.
11. **hERG:** Both ligands have low hERG risk (A: 0.85, B: 0.669). This is good.
12. **Cl_mic:** Ligand B (56.949) is significantly better than Ligand A (97.215). Lower clearance indicates better metabolic stability.
13. **t1/2:** Ligand B (32.616) is much better than Ligand A (-4.428). A longer half-life is highly desirable.
14. **Pgp:** Both are very low (A: 0.48, B: 0.507). This is good.
15. **Binding Affinity:** Ligand A (-5.7 kcal/mol) is slightly better than Ligand B (-4.4 kcal/mol). This is a 1.3 kcal/mol difference, which is a substantial advantage.
**GPCR-Specific Priorities & Overall Assessment:**
For a GPCR like ADRB2, logP, TPSA, and affinity are important. Ligand A has a slightly better affinity, but Ligand B excels in crucial ADME properties: significantly lower DILI risk, better metabolic stability (lower Cl_mic), longer half-life, and a better QED score. The poor Caco-2 permeability is a concern for both, but the other advantages of Ligand B outweigh the slightly weaker binding. The DILI risk for Ligand A is a major red flag.
**Output:**
0
2025-04-18 00:34:16,045 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (351.397) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (62.3) is significantly better than Ligand B (123.84). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (2.402) is optimal. Ligand B (-0.419) is too low, potentially hindering membrane permeability and bioavailability.
4. **HBD:** Both are acceptable (Ligand A: 1, Ligand B: 3).
5. **HBA:** Both are acceptable (Ligand A: 3, Ligand B: 7).
6. **QED:** Ligand A (0.886) is excellent, indicating high drug-likeness. Ligand B (0.64) is still reasonable, but less optimal.
7. **DILI:** Ligand A (39.667) has a much lower DILI risk than Ligand B (76.464). This is a significant advantage.
8. **BBB:** Not a primary concern for a cardiovascular target, but Ligand A (89.919) is better than Ligand B (45.715).
9. **Caco-2:** Ligand A (-4.578) is better than Ligand B (-5.549), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-2.798) is better than Ligand B (-3.037), although both are quite poor.
11. **hERG:** Both are very low risk (Ligand A: 0.478, Ligand B: 0.225).
12. **Cl_mic:** Ligand A (24.675) has a lower microsomal clearance, suggesting better metabolic stability than Ligand B (6.839).
13. **t1/2:** Ligand A (-31.728) has a much longer in vitro half-life than Ligand B (10.439).
14. **Pgp:** Ligand A (0.081) has lower P-gp efflux liability than Ligand B (0.029).
15. **Affinity:** Ligand B (-6.8) has a slightly better binding affinity than Ligand A (-5.9). However, this 1.5 kcal/mol difference is not substantial enough to outweigh the numerous ADME advantages of Ligand A.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A performs better on logP, TPSA and Pgp. The affinity difference is small.
**Overall Assessment:**
Ligand A demonstrates a significantly more favorable ADME profile, with better solubility, lower DILI risk, better metabolic stability, longer half-life, and lower P-gp efflux. While Ligand B has a slightly better binding affinity, the overall balance of properties strongly favors Ligand A as a more viable drug candidate.
Output:
1
2025-04-18 00:34:16,045 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
Let's break down the comparison of Ligand A and Ligand B, considering the provided guidelines and GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key).
1. **Molecular Weight:** Both ligands (352.475 Da and 346.435 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (76.66) is better than Ligand B (100.74). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (1.795 and 1.645), falling within the optimal 1-3 range. Very similar.
4. **H-Bond Donors:** Both have 2 HBD, which is acceptable.
5. **H-Bond Acceptors:** Ligand A has 4 HBA, while Ligand B has 6. Ligand A is preferable here, as fewer HBA generally improves permeability.
6. **QED:** Both ligands have good QED scores (0.62 and 0.785), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI Risk:** Ligand A (25.669%) has a significantly lower DILI risk than Ligand B (47.266%). This is a major advantage for Ligand A.
8. **BBB Penetration:** Both are similar (66.266% and 65.18%), and BBB isn't critical for a cardiovascular target.
9. **Caco-2 Permeability:** Ligand A (-4.494) is better than Ligand B (-5.091), indicating better intestinal absorption.
10. **Aqueous Solubility:** Ligand A (-2.832) is better than Ligand B (-2.111), which is important for formulation.
11. **hERG Inhibition:** Ligand A (0.151) has a lower hERG risk than Ligand B (0.322). This is a significant safety advantage.
12. **Microsomal Clearance:** Ligand A (75.178) has higher microsomal clearance than Ligand B (27.004), indicating lower metabolic stability. This is a drawback for Ligand A.
13. **In vitro Half-Life:** Ligand B (-12.117) has a longer in vitro half-life than Ligand A (-11.706), which is preferable.
14. **P-gp Efflux:** Ligand A (0.127) has lower P-gp efflux than Ligand B (0.051), which is a slight advantage.
15. **Binding Affinity:** Ligand B (-7.4 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.1 kcal/mol). This is a substantial advantage that can potentially offset some ADME drawbacks.
**Overall Assessment:**
Ligand B has a stronger binding affinity, and a longer half-life. However, Ligand A has a significantly lower DILI risk and hERG inhibition liability, better solubility, and better Caco-2 permeability. While the affinity difference is substantial, the safety profile of Ligand A is much more favorable. Given the cardiovascular target, a slightly lower affinity can be tolerated if it means a safer drug. The lower DILI and hERG risks are critical for a cardiovascular drug.
Output:
1
2025-04-18 00:34:16,045 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (353.423 and 352.395 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (129.37) is slightly higher than Ligand B (119.54). Both are below the 140 A^2 threshold for good oral absorption, but Ligand B is preferable due to being closer to the ideal.
3. **logP:** Ligand A (-0.799) is slightly less lipophilic than Ligand B (-1.295). Both are a bit low, potentially hindering membrane permeability, but not drastically so.
4. **HBD:** Ligand A (4) has one more H-bond donor than Ligand B (3). Ligand B is slightly better here.
5. **HBA:** Ligand A (7) has two more H-bond acceptors than Ligand B (5). Ligand B is preferable.
6. **QED:** Ligand B (0.565) has a slightly higher QED score than Ligand A (0.46), indicating a more favorable drug-like profile.
7. **DILI:** Ligand B (49.321) has a lower DILI risk than Ligand A (54.556), which is preferable.
8. **BBB:** Ligand B (42.032) has a significantly higher BBB penetration percentile than Ligand A (25.902). This is a *major* advantage for a GPCR target, even if it's not a CNS target, as it suggests better distribution.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.912 and -5.216), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Both ligands have negative solubility values (-1.188 and -1.746), which is also concerning.
11. **hERG:** Ligand A (0.057) has a slightly lower hERG inhibition liability than Ligand B (0.19), which is preferable.
12. **Cl_mic:** Ligand A (-17.04) has a lower (better) microsomal clearance than Ligand B (-13.716), indicating better metabolic stability.
13. **t1/2:** Ligand B (3.621) has a slightly longer in vitro half-life than Ligand A (3.183), which is preferable.
14. **Pgp:** Ligand A (0.012) has a lower P-gp efflux liability than Ligand B (0.009), which is preferable.
15. **Binding Affinity:** Ligand B (-8.0) has a significantly stronger binding affinity than Ligand A (-6.1). This is a substantial advantage that can outweigh some of the ADME drawbacks.
**Overall Assessment:**
Given that ADRB2 is a GPCR, the BBB penetration and binding affinity are key. Ligand B excels in both of these areas. While Ligand A has better metabolic stability (Cl_mic) and Pgp efflux, the stronger binding affinity and better BBB penetration of Ligand B are more critical for a GPCR target. The slightly better QED and lower DILI risk of Ligand B are also positive factors. The poor Caco-2 and solubility are concerning for both, but can potentially be addressed with formulation strategies.
Output:
0
2025-04-18 00:34:16,046 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A: [350.463, 96.11, 1.578, 3, 4, 0.663, 38.581, 65.374, -4.792, -3.209, 0.288, 43.973, -1.304, 0.053, -6.8]**
**Ligand B: [370.475, 84.74, 0.601, 0, 6, 0.626, 46.956, 77.162, -4.591, -1.715, 0.684, 59.511, -43.424, 0.317, -6.8]**
Here's a breakdown, prioritizing GPCR-relevant properties:
1. **Molecular Weight:** Both are within the ideal range (200-500 Da). A is 350.463, B is 370.475. No significant difference.
2. **TPSA:** A (96.11) is slightly higher than B (84.74). Both are acceptable for oral absorption, but B is better.
3. **logP:** A (1.578) is optimal, while B (0.601) is a bit low, potentially impacting membrane permeability. This favors A.
4. **H-Bond Donors/Acceptors:** A (3/4) and B (0/6) are both reasonable.
5. **QED:** Both are similar (A: 0.663, B: 0.626), indicating good drug-like properties.
6. **DILI:** A (38.581) is better than B (46.956) indicating lower liver injury risk.
7. **BBB:** B (77.162) has a significantly higher BBB penetration percentile than A (65.374). While ADRB2 isn't *strictly* a CNS target, some CNS exposure is not necessarily detrimental and could provide off-target effects.
8. **Caco-2:** Both are negative, indicating poor permeability.
9. **Solubility:** A (-3.209) is worse than B (-1.715). B has better solubility.
10. **hERG:** Both are very low (A: 0.288, B: 0.684), indicating a low risk of cardiotoxicity.
11. **Cl_mic:** A (43.973) is better than B (59.511), suggesting greater metabolic stability.
12. **t1/2:** A (-1.304) is better than B (-43.424), indicating a longer half-life.
13. **Pgp:** A (0.053) is much lower than B (0.317), indicating less P-gp efflux and potentially better bioavailability.
14. **Binding Affinity:** Both are identical (-6.8 kcal/mol).
15. **Overall Assessment:** Considering the GPCR priorities (logP, Pgp, TPSA, and affinity), Ligand A is more promising. While Ligand B has better BBB penetration and solubility, Ligand A has a better logP, lower Pgp efflux, lower DILI risk, and better metabolic stability. The equal binding affinity removes that as a differentiating factor. The slightly higher TPSA of A is less concerning than the lower logP of B.
Output:
1
2025-04-18 00:34:16,046 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (368.449 and 365.861 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (61.36) is slightly higher than Ligand B (53.09). Both are below the 140 threshold for good absorption, but closer to the ideal <90 for CNS targets (less relevant for ADRB2, a cardiovascular target). Ligand B is preferable here.
3. **logP:** Ligand A (3.949) is at the upper end of the optimal range (1-3), while Ligand B (2.243) is well within it. Ligand B is preferable, as high logP can sometimes lead to off-target effects.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (0). Lower HBD is generally preferred for better permeability. Ligand B is preferable.
5. **HBA:** Ligand A (3) and Ligand B (4) are both acceptable, below the 10 threshold. No strong preference.
6. **QED:** Both ligands (0.765 and 0.751) have excellent QED scores, indicating good drug-like properties. No significant difference.
7. **DILI:** Both ligands have similar DILI risk (46.801 and 47.693 percentile), both are good (below 60). No strong preference.
8. **BBB:** Ligand B (94.261) has a significantly higher BBB penetration percentile than Ligand A (83.637). While ADRB2 isn't a CNS target, higher BBB is rarely detrimental and can indicate better overall permeability. Ligand B is preferable.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.793 and -4.413). These values are unusual and suggest poor permeability. However, the difference is small.
10. **Solubility:** Ligand B (-3.083) has slightly better solubility than Ligand A (-3.776). Better solubility is generally preferred. Ligand B is preferable.
11. **hERG:** Both ligands have low hERG inhibition risk (0.705 and 0.535 percentile). No significant difference.
12. **Cl_mic:** Ligand B (7.086) has a much lower microsomal clearance than Ligand A (46.82). This indicates better metabolic stability for Ligand B, a significant advantage.
13. **t1/2:** Ligand A (30.801 hours) has a much longer in vitro half-life than Ligand B (2.95 hours). This is a strong advantage for Ligand A, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.446) has lower P-gp efflux than Ligand B (0.091). Lower P-gp efflux is preferable. Ligand A is preferable.
15. **Binding Affinity:** Ligand A (-7.3 kcal/mol) has a significantly stronger binding affinity than Ligand B (-4.8 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME drawbacks of Ligand A.
**Overall Assessment:**
Ligand A has a much stronger binding affinity and better P-gp efflux, and a longer half-life. Ligand B has better logP, TPSA, solubility, metabolic stability (lower Cl_mic), and BBB penetration. The difference in binding affinity is substantial (2.5 kcal/mol), and for a GPCR, potency is paramount. While Ligand B has a better ADME profile overall, the superior binding affinity of Ligand A is likely to be more critical for efficacy.
Output:
1
2025-04-18 00:34:16,046 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (361.511) is slightly higher than Ligand B (342.483), but both are acceptable.
2. **TPSA:** Ligand A (65.46) is higher than Ligand B (49.41). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B has a more favorable TPSA.
3. **logP:** Ligand A (4.363) is higher than Ligand B (3.03). Ligand A is pushing the upper limit and could potentially have solubility issues or off-target effects. Ligand B is well within the optimal range.
4. **HBD:** Ligand A (2) and Ligand B (1) are both good, below the threshold of 5.
5. **HBA:** Ligand A (4) and Ligand B (2) are both good, below the threshold of 10.
6. **QED:** Both ligands have similar QED values (0.853 and 0.806), indicating good drug-likeness.
7. **DILI:** Ligand A (64.831) has a significantly higher DILI risk than Ligand B (28.228). This is a major concern for Ligand A.
8. **BBB:** Both have reasonable BBB penetration, but Ligand B (75.107) is slightly better than Ligand A (68.592). While ADRB2 isn't a CNS target, some off-target CNS effects are always a consideration.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Both have negative solubility values, which is also unusual. Again, the scale is not specified, making interpretation difficult.
11. **hERG:** Ligand A (0.597) has a slightly higher hERG risk than Ligand B (0.39). Both are relatively low, but lower is always better.
12. **Cl_mic:** Ligand A (45.383) has lower microsomal clearance than Ligand B (56.859), indicating better metabolic stability.
13. **t1/2:** Ligand A (79.89) has a much longer in vitro half-life than Ligand B (-7.362). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.304) has lower P-gp efflux than Ligand B (0.27), which is slightly favorable.
15. **Binding Affinity:** Ligand A (-7.5 kcal/mol) has a slightly better binding affinity than Ligand B (-6.1 kcal/mol). This is a 1.4 kcal/mol difference, which is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand A has a better binding affinity and longer half-life, which are both desirable. However, it suffers from a significantly higher DILI risk and a higher logP, potentially leading to solubility and off-target issues. Ligand B has a better safety profile (lower DILI) and more favorable physicochemical properties (lower logP and TPSA). The binding affinity difference is significant, but the DILI risk associated with Ligand A is a major red flag. Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), and the overall balance of properties, Ligand B is the more promising candidate.
Output:
0
2025-04-18 00:34:16,046 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (347.39 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (84.23) is better than Ligand B (53.09). Both are below 140, but lower TPSA is generally preferred for GPCRs to facilitate brain penetration if desired.
3. **logP:** Ligand A (1.881) is optimal, while Ligand B (0.379) is a bit low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (2) is good, while Ligand B (0) is also acceptable.
5. **HBA:** Ligand A (4) is good, and Ligand B (5) is also acceptable.
6. **QED:** Both ligands have similar QED values (A: 0.77, B: 0.658), indicating good drug-likeness.
7. **DILI:** Ligand B (29.43) has a significantly lower DILI risk than Ligand A (44.591), which is a major advantage.
8. **BBB:** Ligand A (75.107) has better BBB penetration than Ligand B (58.938), which is a plus for a GPCR.
9. **Caco-2:** Both ligands have similar negative Caco-2 values (-4.544 and -4.502), which is not ideal, but not a dealbreaker.
10. **Solubility:** Ligand A (-3.521) has better solubility than Ligand B (-1.871).
11. **hERG:** Both ligands show low hERG inhibition risk (A: 0.153, B: 0.265).
12. **Cl_mic:** Ligand A (10.077) has a much lower microsomal clearance, indicating better metabolic stability than Ligand B (39.312).
13. **t1/2:** Ligand A (-18.859) has a significantly longer in vitro half-life than Ligand B (1.102).
14. **Pgp:** Both ligands have very low Pgp efflux liability (A: 0.038, B: 0.049).
15. **Affinity:** Ligand B (-6.7) has a slightly better binding affinity than Ligand A (-6.0). The difference is 0.7 kcal/mol, which is a reasonable advantage.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand A appears initially stronger due to its better logP, TPSA, BBB penetration, solubility, metabolic stability (Cl_mic and t1/2). However, Ligand B's significantly lower DILI risk is a crucial factor. While affinity is important, a lower DILI risk often outweighs a small difference in binding. The slightly better affinity of Ligand B is not enough to overcome the higher DILI risk.
Therefore, I favor Ligand A.
Output:
1
2025-04-18 00:34:16,046 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (353.463 and 342.403 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (82.11) is better than Ligand B (103.87). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (-0.023) is slightly lower than the optimal 1-3 range, but still acceptable. Ligand B (1.16) is within the optimal range. Ligand B has an edge here.
4. **HBD:** Both ligands have 2 HBD, which is good.
5. **HBA:** Both ligands have 5 HBA, which is good.
6. **QED:** Ligand B (0.871) has a higher QED score than Ligand A (0.672), indicating better overall drug-likeness.
7. **DILI:** Ligand A (8.375) has a significantly lower DILI risk than Ligand B (60.45). This is a major advantage for Ligand A. A DILI percentile >60 is concerning.
8. **BBB:** This is less critical for a cardiovascular target. Ligand A (49.826) and Ligand B (41.722) are both low, which is fine.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.838) is slightly better than Ligand B (-5.215).
10. **Solubility:** Ligand A (-0.619) is better than Ligand B (-2.85). Solubility is important for bioavailability.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.221 and 0.167), which is excellent.
12. **Cl_mic:** Ligand A (5.669) has a significantly lower microsomal clearance than Ligand B (-15.059). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (5.772) has a better in vitro half-life than Ligand B (-8.732).
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.006 and 0.018).
15. **Binding Affinity:** Ligand A (-6.8 kcal/mol) has a slightly better binding affinity than Ligand B (-6.1 kcal/mol). While the difference is not huge, it's a positive for Ligand A.
**GPCR-Specific Priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand B is better on logP, but Ligand A is better on TPSA, Pgp, and affinity.
**Overall Assessment:**
Ligand A has a clear advantage due to its significantly lower DILI risk and better metabolic stability (lower Cl_mic, longer t1/2). While Ligand B has a slightly better QED and logP, the DILI risk associated with Ligand B is a major concern. The slightly better affinity of Ligand A also contributes to its preference. The solubility is also better for Ligand A.
Output:
1
2025-04-18 00:34:16,047 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (382.913) is slightly higher than Ligand B (346.431), but both are acceptable.
2. **TPSA:** Ligand A (58.64) is significantly better than Ligand B (91.4). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand B is pushing the upper limit for good oral absorption.
3. **logP:** Ligand A (3.082) is optimal, while Ligand B (0.945) is a bit low. A logP below 1 can sometimes hinder membrane permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Both ligands have the same number of HBA (4), which is within the acceptable range.
6. **QED:** Ligand A (0.851) has a higher QED score than Ligand B (0.719), indicating a more drug-like profile.
7. **DILI:** Ligand A (50.601) has a slightly higher DILI risk than Ligand B (41.877), but both are below the concerning threshold of 60.
8. **BBB:** Ligand A (79.488) has a better BBB penetration score than Ligand B (51.997). While not a primary concern for a cardiovascular target, some peripheral ADRB2 receptors may benefit from some level of tissue distribution.
9. **Caco-2:** Ligand A (-4.736) has a better Caco-2 permeability value than Ligand B (-5.166). Higher values are better.
10. **Solubility:** Ligand A (-4.23) has a better solubility value than Ligand B (-1.562).
11. **hERG:** Ligand A (0.432) has a lower hERG inhibition liability than Ligand B (0.226), which is a significant advantage for cardiovascular safety.
12. **Cl_mic:** Ligand A (30.796) has a better (lower) microsomal clearance than Ligand B (15.801), suggesting better metabolic stability.
13. **t1/2:** Ligand A (8.585) has a slightly better in vitro half-life than Ligand B (9.423).
14. **Pgp:** Ligand A (0.57) has a better Pgp efflux liability than Ligand B (0.025). Lower efflux is preferred.
15. **Binding Affinity:** Ligand A (-7.4) has a significantly stronger binding affinity than Ligand B (-6.7). This 1.7 kcal/mol difference is substantial and can outweigh minor ADME drawbacks.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A excels in all these areas.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical parameters. The significantly stronger binding affinity, combined with better TPSA, logP, solubility, hERG, Cl_mic, and Pgp properties, make it a much more promising drug candidate despite a slightly higher DILI risk (which is still acceptable).
Output:
1
2025-04-18 00:34:16,047 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (357.451 and 348.403 Da) are within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (91.34) is slightly higher than Ligand B (84.86). Both are below the 140 threshold for oral absorption, but closer to the 90 threshold for CNS targets, which isn't a primary concern here. Ligand B is slightly better.
3. **logP:** Ligand A (-1.076) is lower than the optimal 1-3 range, potentially hindering permeation. Ligand B (0.669) is closer to the ideal range. Ligand B is significantly better.
4. **HBD:** Ligand A (2) is acceptable, while Ligand B (0) is even better, minimizing potential issues with hydrogen bonding and metabolic lability.
5. **HBA:** Both ligands have 6 HBA, which is within the acceptable limit of 10. No clear advantage.
6. **QED:** Both ligands have good QED scores (0.574 and 0.703), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (4.42%) has a much lower DILI risk than Ligand B (63.629%). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (72.354%) shows better BBB penetration than Ligand A (32.144%), but BBB isn't a high priority for ADRB2.
9. **Caco-2:** Ligand A (-5.214) and Ligand B (-4.344) both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand B is slightly better.
10. **Solubility:** Ligand A (0.28) has very poor solubility, while Ligand B (-0.967) is also poor. This is a significant drawback for both.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.151 and 0.087). No clear advantage.
12. **Cl_mic:** Ligand A (-7.355) has a much lower (better) microsomal clearance than Ligand B (34.664), indicating greater metabolic stability.
13. **t1/2:** Ligand A (-17.34) has a negative in vitro half-life, which is not possible and suggests a very rapid clearance. Ligand B (-26.475) is also negative, but less so. Both are problematic.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.004 and 0.011). No clear advantage.
15. **Binding Affinity:** Ligand A (-6.9 kcal/mol) has a slightly better binding affinity than Ligand B (-5.6 kcal/mol). This is a 1.3 kcal/mol difference, which is significant.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand B has better logP and TPSA, but Ligand A has better affinity and significantly better DILI and Cl_mic. The negative half-life values are concerning for both, but the affinity difference and lower DILI risk of Ligand A are compelling.
**Overall Assessment:**
Despite the solubility issues and negative half-life, Ligand A's superior binding affinity, lower DILI risk, and better metabolic stability outweigh the slightly better logP and TPSA of Ligand B. The negative half-life values are a serious concern and would require further investigation, but the other factors favor Ligand A.
Output:
1
2025-04-18 00:34:16,047 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [354.451, 90.98, 0.037, 2, 5, 0.673, 15.083, 49.515, -5.253, -0.499, 0.144, -57.626, -27.574, 0.002, -6.9]
**Ligand B:** [348.487, 69.64, 2.272, 2, 3, 0.522, 16.867, 70.182, -4.898, -2.537, 0.324, 58.332, -5.753, 0.068, -6.2]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, Affinity, and BBB):
1. **MW:** Both are within the ideal 200-500 Da range. A (354.451) and B (348.487) are very similar.
2. **TPSA:** A (90.98) is slightly higher than B (69.64). B is better, being closer to the optimal <90 for GPCRs.
3. **logP:** A (0.037) is very low, potentially causing permeability issues. B (2.272) is much better, falling within the optimal 1-3 range. This is a significant advantage for B.
4. **HBD/HBA:** Both have 2 HBD and acceptable HBA counts (5 and 3 respectively). No major difference here.
5. **QED:** A (0.673) is better than B (0.522), indicating a slightly more drug-like profile.
6. **DILI:** A (15.083) is better than B (16.867), suggesting a lower risk of liver injury.
7. **BBB:** B (70.182) is significantly better than A (49.515). This is a key advantage for B, as BBB penetration is important for GPCRs.
8. **Caco-2:** A (-5.253) is worse than B (-4.898), indicating lower intestinal absorption.
9. **Solubility:** A (-0.499) is better than B (-2.537).
10. **hERG:** A (0.144) is better than B (0.324), indicating lower cardiotoxicity risk.
11. **Cl_mic:** A (-57.626) is *much* better than B (58.332), suggesting significantly higher metabolic stability.
12. **t1/2:** A (-27.574) is better than B (-5.753), indicating a longer half-life.
13. **Pgp:** A (0.002) is *much* better than B (0.068), suggesting lower P-gp efflux.
14. **Affinity:** A (-6.9) is slightly better than B (-6.2), but the difference is relatively small (0.7 kcal/mol).
**Overall Assessment:**
Ligand B has a much better logP and BBB penetration, which are critical for a GPCR target like ADRB2. While Ligand A has advantages in metabolic stability (Cl_mic, t1/2), Pgp efflux, and a slightly better binding affinity, the poor logP of Ligand A is a major concern for oral bioavailability and target engagement. The slightly better affinity of A is unlikely to overcome the permeability issues. The better TPSA of B is also a positive.
Therefore, I believe **Ligand B** is the more promising drug candidate.
0
2025-04-18 00:34:16,047 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [361.467, 72.88, 1.927, 2, 3, 0.781, 60.062, 20.628, -5.35, -1.676, 0.024, 4.64, 8.013, 0.046, -6.7]
**Ligand B:** [352.379, 109.59, 2.513, 2, 7, 0.571, 95.502, 20.434, -5.689, -3.394, 0.26, 12.415, 0.636, 0.073, -7.6]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). A (361.467) is slightly higher than B (352.379), but this isn't a major concern.
2. **TPSA:** A (72.88) is excellent, well below the 140 threshold for oral absorption and good for a GPCR. B (109.59) is still acceptable, but less ideal.
3. **logP:** Both are within the optimal range (1-3). A (1.927) is slightly better positioned in the middle of the range than B (2.513).
4. **HBD:** Both have 2 HBD, which is good.
5. **HBA:** A (3) is preferable to B (7). Higher HBA can sometimes hinder permeability.
6. **QED:** A (0.781) is significantly better than B (0.571), indicating a more drug-like profile.
7. **DILI:** A (60.062) is acceptable, but B (95.502) is concerningly high. This is a significant negative for B.
8. **BBB:** Both are similar and low (around 20%), which isn't a major factor for a non-CNS target like ADRB2.
9. **Caco-2:** Both are negative, indicating poor permeability. This is a concern for both, but the lower TPSA of A might mitigate this somewhat.
10. **Solubility:** A (-1.676) is better than B (-3.394), though both are poor.
11. **hERG:** A (0.024) is very low risk, while B (0.26) is slightly higher, but still acceptable.
12. **Cl_mic:** A (4.64) is much better than B (12.415), indicating better metabolic stability.
13. **t1/2:** A (8.013) is better than B (0.636), suggesting a longer duration of action.
14. **Pgp:** Both are very low, indicating minimal P-gp efflux.
15. **Binding Affinity:** B (-7.6) has a 0.9 kcal/mol advantage in binding affinity over A (-6.7). This is a substantial difference.
**GPCR-specific priorities:** For ADRB2 (a cardiovascular GPCR), logP, TPSA, and affinity are key. While B has better affinity, A excels in TPSA, logP, QED, DILI risk, metabolic stability (Cl_mic), and half-life. The significantly lower DILI risk for A is a major advantage. The affinity difference, while substantial, can potentially be optimized in later stages of drug development. The poor Caco-2 values are a concern for both, but A's better physicochemical properties overall suggest it might be more amenable to formulation strategies to improve absorption.
**Conclusion:**
Considering the balance of properties and the GPCR-specific priorities, **Ligand A** is the more promising drug candidate. The lower DILI risk and better ADME properties outweigh the affinity difference, especially given the potential for optimization.
Output:
1
2025-04-18 00:34:16,047 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [372.853, 107.55 , 0.819, 3. , 5. , 0.626, 45.095, 39.511, -5.198, -2.867, 0.351, -13.152, 27.575, 0.163, -6. ]
**Ligand B:** [384.889, 91.4 , 1.432, 2. , 5. , 0.821, 58.589, 62.233, -5.259, -2.772, 0.209, -23.986, 2.218, 0.056, -7.4 ]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, Affinity, and BBB):
1. **MW:** Both are within the ideal range (200-500 Da). A is 372.853, B is 384.889 - very similar.
2. **TPSA:** A (107.55) is slightly higher than B (91.4). Both are acceptable for a non-CNS GPCR like ADRB2, but B is better.
3. **logP:** A (0.819) is a bit low, potentially impacting permeability. B (1.432) is better, falling within the optimal 1-3 range.
4. **HBD/HBA:** A has 3 HBD and 5 HBA, B has 2 HBD and 5 HBA. Both are reasonable.
5. **QED:** Both have good QED scores (A: 0.626, B: 0.821), indicating drug-likeness. B is better.
6. **DILI:** A (45.095) has a lower DILI risk than B (58.589). This is a significant advantage for A.
7. **BBB:** Both have low BBB penetration (A: 39.511, B: 62.233). This isn't a major concern for ADRB2, as it's not a CNS target. B is better.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. This is a concern for both.
9. **Solubility:** Both have negative solubility values, which is also unusual and suggests poor solubility. This is a concern for both.
10. **hERG:** Both have low hERG risk (A: 0.351, B: 0.209). B is slightly better.
11. **Cl_mic:** A (-13.152) has a *much* lower (better) microsomal clearance than B (-23.986), indicating better metabolic stability.
12. **t1/2:** A (27.575) has a significantly longer half-life than B (2.218). This is a major advantage for A.
13. **Pgp:** A (0.163) has lower P-gp efflux than B (0.056), suggesting better bioavailability. B is better.
14. **Affinity:** B (-7.4) has a significantly stronger binding affinity than A (-6.0). This is a substantial advantage for B.
**Overall Assessment:**
The biggest differentiator is binding affinity. B has a -7.4 kcal/mol binding affinity, while A is at -6.0 kcal/mol. That 1.4 kcal/mol difference is substantial, and often outweighs other concerns. While A has better DILI, Cl_mic, and t1/2, the potency advantage of B is critical for a GPCR target. Both have issues with Caco-2 and solubility, but these can potentially be addressed with formulation strategies.
Therefore, I would choose Ligand B.
0
2025-04-18 00:34:16,048 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (350.5 and 368.5 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (79.04) is higher than Ligand B (49.85). For a cardiovascular GPCR, TPSA is not as critical as for CNS targets, but lower is generally preferred for permeability. Ligand B has a significant advantage here.
**3. logP:** Ligand A (3.769) is slightly higher than Ligand B (2.394). Both are within the optimal 1-3 range, but Ligand A is closer to the upper limit.
**4. H-Bond Donors:** Ligand A (3) is higher than Ligand B (0). While not a major concern, fewer HBDs often correlate with better permeability. Ligand B is better.
**5. H-Bond Acceptors:** Both ligands have 4 HBA, so no difference here.
**6. QED:** Both ligands have similar QED values (0.654 and 0.692), indicating good drug-likeness.
**7. DILI Risk:** Ligand A (17.72) has a lower DILI risk than Ligand B (20.744). This is a positive for Ligand A.
**8. BBB Penetration:** Ligand B (80.419) has slightly better BBB penetration than Ligand A (76.851). While ADRB2 is a cardiovascular target, some CNS off-target effects are always a consideration, and better BBB penetration could potentially exacerbate those. However, it's not a primary concern here.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-5.089) is slightly worse than Ligand B (-4.898).
**10. Aqueous Solubility:** Both ligands have negative solubility values, indicating poor solubility. Ligand A (-2.697) is slightly worse than Ligand B (-2.424).
**11. hERG Inhibition:** Ligand A (0.835) has a higher hERG inhibition risk than Ligand B (0.365). This is a significant concern, as hERG inhibition can lead to cardiotoxicity. Ligand B is much better.
**12. Microsomal Clearance:** Ligand B (74.032) has significantly higher microsomal clearance than Ligand A (29.2). Lower clearance is preferred for better metabolic stability, giving Ligand A a substantial advantage.
**13. In vitro Half-Life:** Ligand A (-17.9) has a negative half-life, which is problematic. Ligand B (1.947) has a short half-life, but it's at least positive. Ligand B is better.
**14. P-gp Efflux:** Ligand A (0.328) has lower P-gp efflux than Ligand B (0.149), which is favorable for bioavailability.
**15. Binding Affinity:** Ligand B (-7.2) has a significantly stronger binding affinity than Ligand A (-5.6). This is a crucial factor, as a 1.6 kcal/mol difference is substantial and can outweigh many ADME drawbacks.
**Overall Assessment:**
Ligand B has a significantly better binding affinity and a much lower hERG risk, which are the most important factors for this cardiovascular GPCR target. While Ligand A has better metabolic stability (lower Cl_mic) and lower DILI risk, the superior affinity and safety profile of Ligand B outweigh these advantages. The poor Caco-2 and solubility for both are concerning and would require formulation work, but the potency and safety of Ligand B make it the more promising candidate.
Output:
0
2025-04-18 00:34:16,048 - INFO - Batch 487 complete. Total preferences: 7792
2025-04-18 00:34:16,048 - INFO - Processing batch 488/512...
2025-04-18 00:35:04,552 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (338.45 & 346.43 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (35.53) is significantly better than Ligand B (87.32). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold, while Ligand B is approaching it.
3. **logP:** Ligand A (4.373) is higher than Ligand B (1.812). While both are within the acceptable range, Ligand A is pushing the upper limit and could potentially have solubility issues. Ligand B is closer to optimal.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer HBDs generally improve membrane permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (4). Similar to HBD, fewer HBAs are generally better for permeability.
6. **QED:** Both ligands have good QED scores (0.637 and 0.763), indicating good drug-like properties. No significant difference.
7. **DILI:** Ligand A (15.083) has a much lower DILI risk than Ligand B (40.403). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (68.127) shows better BBB penetration than Ligand B (55.021). While ADRB2 is not a CNS target, some degree of BBB penetration can sometimes indicate better overall distribution.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.408 and -4.969), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-5.589) has slightly better solubility than Ligand B (-2.263), but both are very poor. This is a significant drawback for both.
11. **hERG:** Ligand A (0.854) has a lower hERG risk than Ligand B (0.581), which is a positive.
12. **Cl_mic:** Ligand A (110.003) has a higher microsomal clearance than Ligand B (24.236), indicating faster metabolism and potentially lower *in vivo* exposure. This favors Ligand B.
13. **t1/2:** Ligand B (27.57) has a significantly longer *in vitro* half-life than Ligand A (-8.945). This is a major advantage for Ligand B.
14. **Pgp:** Ligand A (0.42) has lower P-gp efflux than Ligand B (0.037), which is preferable.
15. **Binding Affinity:** Ligand A (-8.8 kcal/mol) has a stronger binding affinity than Ligand B (-5.5 kcal/mol). This is a substantial advantage for Ligand A, potentially outweighing some of its ADME drawbacks.
**Overall Assessment:**
Ligand A has a significantly better binding affinity and lower DILI risk, which are crucial. It also has better TPSA, HBD/HBA counts, BBB penetration, and hERG risk. However, its higher logP and poor solubility are concerns. Ligand B has better metabolic stability (lower Cl_mic, longer t1/2) and slightly better solubility, but its weaker binding affinity and higher DILI risk are significant drawbacks.
Given the importance of potency (binding affinity) for GPCRs and the relatively low risk associated with the other drawbacks of Ligand A, I believe it is the more promising candidate. The strong binding affinity could potentially be optimized through further medicinal chemistry efforts to address the solubility and logP issues.
Output:
1
2025-04-18 00:35:04,552 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (339.483) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (48.13) is better than Ligand B (53.09), both are below the 140 threshold for oral absorption, but lower is preferred.
3. **logP:** Ligand B (2.243) is better than Ligand A (4.247). Ligand A is a bit high, potentially leading to solubility issues and off-target interactions.
4. **HBD:** Ligand A (2) is better than Ligand B (0), but both are within the acceptable limit of 5.
5. **HBA:** Ligand A (1) is better than Ligand B (4), both are within the acceptable limit of 10.
6. **QED:** Ligand A (0.812) is better than Ligand B (0.751), indicating a more drug-like profile.
7. **DILI:** Ligand B (47.693) is slightly better than Ligand A (40.054), but both are below the concerning threshold of 60.
8. **BBB:** Both ligands have excellent BBB penetration (Ligand A: 96.084, Ligand B: 94.261). This is less critical for ADRB2 (cardiovascular target) but still a positive.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. Ligand A (-4.928) is slightly worse than Ligand B (-4.413).
10. **Solubility:** Ligand B (-3.083) is better than Ligand A (-4.354). This is important, especially given Ligand A's higher logP.
11. **hERG:** Ligand A (0.9) is better than Ligand B (0.535). Lower hERG inhibition is always preferred.
12. **Cl_mic:** Ligand B (7.086) is significantly better than Ligand A (60.497). Lower clearance indicates better metabolic stability.
13. **t1/2:** Ligand A (4.108) is better than Ligand B (2.95), indicating a longer half-life.
14. **Pgp:** Ligand B (0.091) is better than Ligand A (0.711). Lower P-gp efflux is desirable for improved bioavailability.
15. **Binding Affinity:** Ligand A (-6.7 kcal/mol) is significantly better than Ligand B (-4.8 kcal/mol). This is a substantial difference in potency, and a >1.5 kcal/mol advantage often outweighs other concerns.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand A has a higher logP, but its significantly better affinity (-6.7 vs -4.8) is a major advantage. Ligand B has better Pgp and TPSA, but the affinity difference is too large to ignore.
**Overall Assessment:**
While Ligand B has better metabolic stability (Cl_mic) and solubility, Ligand A's superior binding affinity is the most critical factor, especially for a GPCR target. The slightly higher logP of Ligand A can be addressed through further optimization, but regaining a 1.9 kcal/mol difference in binding affinity is much more challenging.
Output:
1
2025-04-18 00:35:04,552 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [367.442, 55.84, 2.813, 0, 4, 0.64, 48.313, 81.97, -4.301, -4.015, 0.931, 102.928, -64.355, 0.513, -7.3]
**Ligand B:** [345.443, 71.53, 1.782, 1, 4, 0.903, 37.999, 58.627, -4.551, -2.373, 0.267, 31.396, -5.948, 0.053, -7.7]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, Affinity, and BBB):
1. **MW:** Both are within the ideal 200-500 Da range. Ligand B (345.443) is slightly lower, which isn't a major concern.
2. **TPSA:** Ligand A (55.84) is significantly better than Ligand B (71.53). A TPSA under 90 is preferred for GPCRs, and A is comfortably within that range, while B is pushing the limit.
3. **logP:** Ligand A (2.813) is optimal, while Ligand B (1.782) is a bit low. Lower logP can hinder membrane permeability.
4. **HBD/HBA:** Both have acceptable HBD/HBA counts. Ligand B has 1 HBD vs 0 for A, which isn't a major differentiating factor.
5. **QED:** Both have reasonable QED scores (A: 0.64, B: 0.903). Ligand B is better here.
6. **DILI:** Ligand A (48.313) has a slightly higher DILI risk than Ligand B (37.999), but both are below the concerning 60% threshold.
7. **BBB:** Ligand A (81.97) has a significantly higher BBB penetration percentile than Ligand B (58.627). This is a crucial advantage for a GPCR target, even if it's not strictly CNS-focused, as it suggests better distribution.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. This is a red flag for both, but the values are close enough that it doesn't heavily sway the decision.
9. **Solubility:** Both have negative solubility values, also unusual. Again, similar enough to not be decisive.
10. **hERG:** Ligand A (0.931) has a slightly higher hERG risk than Ligand B (0.267). This is a concern, but not overwhelming.
11. **Cl_mic:** Ligand B (31.396) has significantly lower microsomal clearance than Ligand A (102.928), indicating better metabolic stability. This is a significant advantage.
12. **t1/2:** Ligand A (-64.355) has a much longer in vitro half-life than Ligand B (-5.948). This is a major positive for A.
13. **Pgp:** Ligand A (0.513) has lower P-gp efflux than Ligand B (0.053), which is favorable for bioavailability and distribution.
14. **Affinity:** Ligand B (-7.7) has a slightly better binding affinity than Ligand A (-7.3), a 0.4 kcal/mol difference. While affinity is important, the other factors are more critical in this case.
**Overall Assessment:**
Ligand A has several advantages that outweigh the slightly weaker affinity. Its superior TPSA, BBB penetration, and longer half-life are particularly important for a GPCR target. While Ligand B has better metabolic stability and QED, the lower TPSA and BBB penetration are significant drawbacks. The negative Caco-2 and solubility values are concerning for both, but not enough to disqualify either outright.
Therefore, I believe Ligand A is the more promising drug candidate.
1
2025-04-18 00:35:04,552 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (341.419 and 340.383 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (89.14) is better than Ligand B (97.12). Both are below 140, but A is closer to the preferred <90 for potential CNS penetration, even though ADRB2 isn't strictly a CNS target.
3. **logP:** Ligand A (2.781) is optimal, while Ligand B (1.179) is a bit low, potentially hindering membrane permeability.
4. **HBD:** Both ligands have 2 HBD, which is acceptable.
5. **HBA:** Ligand A has 6 HBA, and Ligand B has 5. Both are within the acceptable range.
6. **QED:** Both ligands have good QED scores (0.721 and 0.789), indicating good drug-like properties.
7. **DILI:** Ligand A (66.886) has a slightly higher DILI risk than Ligand B (55.293), but both are reasonably acceptable.
8. **BBB:** Ligand A (61.38) has better BBB penetration than Ligand B (37.96). While ADRB2 isn't primarily a CNS target, some degree of BBB penetration can be beneficial for off-target effects assessment.
9. **Caco-2:** Ligand A (-5.129) has a worse Caco-2 permeability than Ligand B (-5.705).
10. **Solubility:** Ligand A (-3.198) has worse solubility than Ligand B (-1.146).
11. **hERG:** Ligand A (0.421) has a slightly higher hERG risk than Ligand B (0.058), which is preferable.
12. **Cl_mic:** Ligand A (51.048) has a higher microsomal clearance than Ligand B (-16.733), indicating lower metabolic stability. This is a significant drawback for Ligand A.
13. **t1/2:** Ligand A (52.433) has a longer in vitro half-life than Ligand B (23.236).
14. **Pgp:** Ligand A (0.163) has lower P-gp efflux than Ligand B (0.012), which is desirable.
15. **Affinity:** Ligand A (-8.1 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.3 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME concerns.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are particularly important. Ligand A has a better logP and Pgp profile, and a *much* better binding affinity. While Ligand B has better solubility and lower hERG, the difference in affinity is substantial. The lower metabolic stability (higher Cl_mic) of Ligand A is a concern, but can potentially be addressed with structural modifications during lead optimization.
**Conclusion:**
The significantly stronger binding affinity of Ligand A (-8.1 kcal/mol vs -6.3 kcal/mol) is the deciding factor. This advantage, combined with acceptable (though not ideal) ADME properties, makes it the more promising candidate, despite the higher Cl_mic.
Output:
1
2025-04-18 00:35:04,552 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (367.877 Da and 363.523 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (73.83) is higher than Ligand B (38.77). For a cardiovascular GPCR, TPSA is not a primary concern, but lower is generally preferable for absorption. Ligand B is significantly better.
3. **logP:** Both ligands have good logP values (2.851 and 3.974, respectively), falling within the optimal 1-3 range. Ligand B is slightly higher, which *could* be a minor drawback if it leads to solubility issues, but it's still acceptable.
4. **HBD:** Ligand A has 3 HBD, while Ligand B has 0. Lower is generally better for permeability, so Ligand B is favored.
5. **HBA:** Both ligands have 4 HBA, which is within the acceptable range. No significant difference.
6. **QED:** Both ligands have similar QED values (0.748 and 0.701), indicating good drug-likeness.
7. **DILI:** Ligand B (27.181) has a considerably lower DILI risk than Ligand A (41.179). This is a significant advantage for Ligand B.
8. **BBB:** Ligand B (88.29) has a much higher BBB penetration percentile than Ligand A (61.923). While ADRB2 isn't a CNS target, higher BBB is generally a positive indicator of permeability.
9. **Caco-2:** Ligand A (-4.802) and Ligand B (-5.109) both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the values are very close.
10. **Solubility:** Ligand A (-3.306) and Ligand B (-3.769) both have very poor solubility. This is a major concern for both.
11. **hERG:** Both ligands have low hERG inhibition risk (0.656 and 0.687, respectively). No significant difference.
12. **Cl_mic:** Ligand A (5.827) has a lower microsomal clearance than Ligand B (81.616), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (86.649) has a much longer in vitro half-life than Ligand B (30.128). This is a major advantage for Ligand A.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.148 and 0.696, respectively). No significant difference.
15. **Binding Affinity:** Ligand B (-6.1) has a slightly better binding affinity than Ligand A (-6.4). However, the difference is small (0.3 kcal/mol) and may not be enough to overcome other deficiencies.
**Overall Assessment:**
Ligand B has a significantly better safety profile (lower DILI), better permeability characteristics (lower TPSA, no HBD), and better BBB penetration. However, it suffers from significantly worse metabolic stability (higher Cl_mic) and shorter half-life. Ligand A has better metabolic stability and half-life, but has a higher DILI risk and worse permeability.
Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity), and the fact that this is a cardiovascular target (less emphasis on BBB), the improved safety profile and permeability of Ligand B are more compelling. The difference in binding affinity is small, and the metabolic stability issues could potentially be addressed through structural modifications.
Output:
0
2025-04-18 00:35:04,552 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (350.415 and 351.422 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (90.31) is slightly better than Ligand B (93.45), both being under the 140 A^2 threshold for good oral absorption, and acceptable for a cardiovascular target (not CNS).
3. **logP:** Ligand A (-0.31) is a bit low, potentially hindering permeation. Ligand B (1.848) is within the optimal 1-3 range. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (2) and Ligand B (3) are both acceptable, below the 5 threshold.
5. **HBA:** Ligand A (5) and Ligand B (4) are both acceptable, below the 10 threshold.
6. **QED:** Both ligands have good QED scores (0.507 and 0.623), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (25.94) has a much lower DILI risk than Ligand B (47.15). This is a substantial advantage for Ligand A.
8. **BBB:** Ligand B (81.815) has significantly better BBB penetration than Ligand A (47.111). While ADRB2 is not a CNS target, some off-target CNS effects are possible with GPCR ligands, and higher BBB penetration could contribute to this.
9. **Caco-2:** Both ligands have similar, very poor Caco-2 permeability (-4.848 and -4.996). This is a concern for both, suggesting potential absorption issues.
10. **Solubility:** Ligand A (-1.242) has slightly better solubility than Ligand B (-2.896), though both are quite poor.
11. **hERG:** Ligand A (0.255) has a lower hERG risk than Ligand B (0.469), which is a positive.
12. **Cl_mic:** Ligand A (4.273) has a significantly lower microsomal clearance than Ligand B (26.791), indicating better metabolic stability. This is a major advantage for Ligand A.
13. **t1/2:** Ligand A (9.716) has a longer in vitro half-life than Ligand B (5.262), further supporting its better metabolic stability.
14. **Pgp:** Ligand A (0.026) has much lower P-gp efflux liability than Ligand B (0.07), which is beneficial for oral bioavailability.
15. **Binding Affinity:** Ligand B (-6.8 kcal/mol) has a 0.1 kcal/mol stronger binding affinity than Ligand A (-5.7 kcal/mol). While this is a positive for Ligand B, the difference is not substantial enough to outweigh the other factors.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B has a better logP and affinity, but Ligand A excels in TPSA, Pgp, and has a much better safety profile (DILI, hERG) and metabolic stability (Cl_mic, t1/2).
**Overall Assessment:**
While Ligand B has slightly better affinity and BBB penetration, Ligand A is the more promising candidate. The combination of lower DILI risk, lower hERG risk, significantly better metabolic stability (lower Cl_mic and longer t1/2), and lower P-gp efflux outweighs the modest affinity advantage of Ligand B. The poor Caco-2 permeability is a concern for both, but can be addressed with formulation strategies.
Output:
1
2025-04-18 00:35:04,553 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [360.292, 110.25 , 1.099, 2. , 7. , 0.773, 67.39 , 62.97 ,
-4.804, -1.869, 0.076, 41.317, -40.233, 0.083, -6.6 ]
**Ligand B:** [384.487, 110.08 , 0.491, 1. , 8. , 0.776, 77.2 , 52.307,
-5.333, -2.586, 0.112, 18.158, 7.584, 0.148, -6.3 ]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity, and to a lesser extent BBB):
1. **MW:** Both are within the ideal 200-500 Da range. A (360.292) is slightly preferred.
2. **TPSA:** Both are around 110, acceptable for a non-CNS GPCR target like ADRB2, but a bit high.
3. **logP:** A (1.099) is better than B (0.491). ADRB2 is a cardiovascular target, so moderate lipophilicity is good for membrane permeability and receptor engagement. B is a bit too hydrophilic.
4. **HBD/HBA:** A (2/7) is reasonable. B (1/8) is also acceptable, but slightly higher HBA could potentially cause issues.
5. **QED:** Both are good (0.773 and 0.776).
6. **DILI:** A (67.39) is significantly better than B (77.2). Lower DILI risk is crucial.
7. **BBB:** Not a primary concern for ADRB2, but A (62.97) is slightly better than B (52.307).
8. **Caco-2:** A (-4.804) is better than B (-5.333), indicating better absorption.
9. **Solubility:** A (-1.869) is better than B (-2.586).
10. **hERG:** Both are very low risk (0.076 and 0.112).
11. **Cl_mic:** A (41.317) is higher than B (18.158), meaning B has better metabolic stability. This is a significant advantage for B.
12. **t1/2:** A (-40.233) is much better than B (7.584). A has a much longer half-life.
13. **Pgp:** A (0.083) is better than B (0.148), indicating less efflux.
14. **Affinity:** A (-6.6) is slightly better than B (-6.3). While the difference is small, it's still a factor.
**Overall Assessment:**
Ligand A has a better balance of properties. It has a better logP, lower DILI risk, better Caco-2 permeability, better solubility, less Pgp efflux, and slightly better affinity. The biggest advantage for Ligand B is its improved metabolic stability (lower Cl_mic and a positive half-life), but the other factors weigh more heavily in favor of A, especially the lower DILI risk. For a cardiovascular target, a slight edge in metabolic stability is less critical than avoiding liver toxicity and ensuring good absorption and bioavailability.
Output:
1
2025-04-18 00:35:04,553 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for the ADRB2, a cardiovascular GPCR. Therefore, key properties to prioritize are binding affinity, logP, TPSA, Pgp efflux, and to a lesser extent, BBB.
Let's compare the ligands property by property:
1. **MW:** Both ligands (337.423 and 376.909 Da) are within the ideal range (200-500 Da).
2. **TPSA:** Ligand A (54.46) is better than Ligand B (58.2), being closer to the <140 threshold for good absorption.
3. **logP:** Both ligands have good logP values (3.819 and 4.599), falling within the optimal 1-3 range, although Ligand B is a bit higher.
4. **HBD/HBA:** Ligand A (HBD=1, HBA=4) is slightly better than Ligand B (HBD=2, HBA=3) regarding the number of hydrogen bond donors and acceptors.
5. **QED:** Ligand A (0.921) has a significantly better QED score than Ligand B (0.774), indicating a more drug-like profile.
6. **DILI:** Both ligands have similar DILI risk (62.35 and 62.195), which is acceptable but not ideal.
7. **BBB:** Ligand A (77.239) has a better BBB percentile than Ligand B (53.858), which is a positive for GPCRs.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability.
9. **Solubility:** Both have negative solubility values, which is also unusual and suggests poor solubility.
10. **hERG:** Both ligands have low hERG inhibition liability (0.715 and 0.653), which is good.
11. **Cl_mic:** Ligand A (76.928) has a higher microsomal clearance than Ligand B (19.417), indicating lower metabolic stability. This is a significant drawback for Ligand A.
12. **t1/2:** Ligand B (49.459) has a longer in vitro half-life than Ligand A (38.336), which is favorable.
13. **Pgp:** Ligand A (0.431) has lower P-gp efflux liability than Ligand B (0.275), which is a positive.
14. **Binding Affinity:** Ligand B (-7.8 kcal/mol) has a slightly better binding affinity than Ligand A (-7.5 kcal/mol). While the difference is not huge, it is still a factor.
**Overall Assessment:**
Ligand B has a better binding affinity, lower microsomal clearance (better metabolic stability), and a longer half-life. The higher logP is slightly concerning, but not enough to outweigh the benefits. Ligand A has a better QED and BBB, but the significantly higher clearance is a major concern for *in vivo* efficacy. Given the importance of metabolic stability for a viable drug candidate, and the slight edge in binding affinity, Ligand B is the preferable choice.
**Output:**
0
2025-04-18 00:35:04,553 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, priorities are logP, TPSA, Pgp, affinity, and to a lesser extent, BBB.
* **Molecular Weight:** Both ligands (343.43 and 342.40 Da) are within the ideal 200-500 Da range.
* **TPSA:** Ligand A (71.53) is significantly better than Ligand B (84.42). A lower TPSA generally favors oral absorption, which is important for a cardiovascular drug.
* **logP:** Ligand A (1.848) is optimal, while Ligand B (0.172) is quite low, potentially hindering membrane permeability.
* **H-Bond Donors/Acceptors:** Both have acceptable HBD (1) and HBA (4/5) counts.
* **QED:** Both ligands have identical and good QED scores (0.847).
* **DILI:** Ligand A (30.94) has a much lower DILI risk than Ligand B (44.44), a significant advantage.
* **BBB:** Both have reasonable BBB penetration (79.49% and 71.66%), but this is less critical for a cardiovascular target.
* **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
* **Solubility:** Both have negative solubility values, again unusual and suggesting poor solubility.
* **hERG:** Both ligands have very low hERG inhibition risk (0.261 and 0.229).
* **Cl_mic:** Ligand B (-12.005) has a significantly *lower* (better) microsomal clearance than Ligand A (13.831), indicating greater metabolic stability.
* **t1/2:** Ligand B (23.329 hours) has a much longer in vitro half-life than Ligand A (15.517 hours), which is desirable.
* **Pgp:** Both have very low Pgp efflux (0.076 and 0.017).
* **Binding Affinity:** Ligand B (-5.7 kcal/mol) has a slightly better binding affinity than Ligand A (-5.0 kcal/mol), a 0.7 kcal/mol difference.
**Overall Assessment:**
While Ligand B has better metabolic stability (Cl_mic) and half-life, and slightly better affinity, Ligand A is superior due to its much more favorable logP and TPSA values, and significantly lower DILI risk. The low logP of Ligand B is a major concern for permeability and bioavailability. The DILI risk for Ligand B is also concerning. For a GPCR, optimizing permeability and minimizing toxicity are crucial, and Ligand A does this better. The affinity difference is not large enough to overcome these ADME/Tox concerns.
**Output:**
1
2025-04-18 00:35:04,553 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.471 and 349.431 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (58.64) is significantly better than Ligand B (78.95). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (2.243) is within the optimal range (1-3). Ligand B (0.45) is quite low, potentially hindering membrane permeability. This is a significant negative for Ligand B.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 3 HBA, and Ligand B has 4. Both are acceptable, but lower is generally preferred.
6. **QED:** Ligand B (0.748) has a slightly better QED score than Ligand A (0.593), indicating a more drug-like profile.
7. **DILI:** Ligand A (11.128) has a much lower DILI risk than Ligand B (31.097). This is a crucial advantage for Ligand A.
8. **BBB:** Both ligands have reasonable BBB penetration (A: 64.017, B: 66.615). Not a major factor here as ADRB2 is not a CNS target.
9. **Caco-2:** Both ligands have similar, poor Caco-2 permeability (-4.77 and -4.761).
10. **Solubility:** Both ligands have very poor aqueous solubility (-2.608 and -2.007). This is a concern for both, but might be mitigated with formulation strategies.
11. **hERG:** Both ligands show low hERG inhibition risk (0.4 and 0.124).
12. **Cl_mic:** Ligand A (-10.711) has significantly lower (better) microsomal clearance than Ligand B (3.491). This suggests greater metabolic stability for Ligand A.
13. **t1/2:** Ligand A (10.908) has a longer in vitro half-life than Ligand B (-13.744). This is a clear advantage.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.107 and 0.027).
15. **Binding Affinity:** Ligand B (-6.6 kcal/mol) has a significantly stronger binding affinity than Ligand A (-2.9 kcal/mol). This is a substantial advantage for Ligand B.
**GPCR-Specific Priorities & Overall Assessment:**
For a GPCR like ADRB2, logP, TPSA, and affinity are key. Ligand B excels in affinity, but suffers from a very low logP and a higher TPSA. Ligand A has a better logP and TPSA, and significantly better ADME properties (DILI, Cl_mic, t1/2), despite its weaker binding affinity. The affinity difference is substantial (3.7 kcal/mol), but the ADME profile of Ligand B is concerning. While a strong affinity is important, poor permeability (low logP) and rapid metabolism (high Cl_mic, short t1/2) can severely limit *in vivo* efficacy. The lower DILI risk of Ligand A is also a major plus.
Considering the balance, I believe Ligand A is the more promising starting point for optimization. The affinity can be improved through medicinal chemistry efforts, but fixing the poor logP of Ligand B would be more challenging.
Output:
1
2025-04-18 00:35:04,553 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [356.423, 125.71 , 0.572, 4. , 7. , 0.479, 57.697, 15.277, -5.483, -2.343, 0.131, 26.89 , -23.271, 0.05 , -6.6 ]
**Ligand B:** [362.392, 78.43 , 1.915, 3. , 3. , 0.577, 18.651, 79.488, -4.916, -2.527, 0.336, 24.424, -8.933, 0.076, -7.5 ]
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). A is 356.423, B is 362.392. Very similar.
2. **TPSA:** Ligand A (125.71) is slightly above the preferred <140 for oral absorption, but not drastically. Ligand B (78.43) is excellent, well below 140. This favors B.
3. **logP:** Ligand A (0.572) is quite low, potentially hindering membrane permeability. Ligand B (1.915) is much better, falling within the optimal 1-3 range. This strongly favors B.
4. **HBD:** Ligand A (4) is acceptable. Ligand B (3) is also good.
5. **HBA:** Ligand A (7) is acceptable. Ligand B (3) is excellent. This favors B.
6. **QED:** Both are similar and acceptable (A: 0.479, B: 0.577), both above the 0.5 threshold.
7. **DILI:** Ligand A (57.697) is moderately risky. Ligand B (18.651) is very good, indicating a low risk of liver injury. This strongly favors B.
8. **BBB:** Ligand A (15.277) has poor BBB penetration. Ligand B (79.488) is very good, suggesting good CNS penetration. While ADRB2 is primarily cardiovascular, some CNS off-target effects are possible, and better BBB control is generally preferred. This favors B.
9. **Caco-2:** Ligand A (-5.483) is very poor. Ligand B (-4.916) is also poor, but slightly better.
10. **Solubility:** Both ligands have very poor solubility scores (-2.343 and -2.527 respectively). This is a significant concern for both.
11. **hERG:** Ligand A (0.131) is very low risk. Ligand B (0.336) is also low risk.
12. **Cl_mic:** Ligand A (26.89) is moderate. Ligand B (24.424) is slightly better, indicating better metabolic stability.
13. **t1/2:** Ligand A (-23.271) is very poor. Ligand B (-8.933) is poor, but better than A.
14. **Pgp:** Ligand A (0.05) is very low efflux, which is good. Ligand B (0.076) is also low efflux, but slightly higher.
15. **Affinity:** Ligand B (-7.5) is 0.9 kcal/mol stronger than Ligand A (-6.6). This is a substantial difference in binding affinity.
**Overall Assessment:**
Ligand B is significantly better across most critical parameters. It has a much better logP, TPSA, DILI score, and BBB penetration. While both have poor solubility and Caco-2 permeability, the superior binding affinity and better ADME profile of Ligand B outweigh the shared drawbacks. The affinity difference is large enough to potentially overcome the solubility issues with formulation strategies.
Output:
0
2025-04-18 00:35:04,553 - INFO - Here's my reasoning and final output for the ligand preference:
**Reasoning:**
We are targeting ADRB2, a GPCR, so the priorities are logP, Pgp, TPSA, affinity, and BBB. Let's break down the comparison:
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da).
2. **TPSA:** Ligand B (91.34) is better than Ligand A (102.27), being closer to the desirable threshold of <=140 for oral absorption.
3. **logP:** Ligand A (1.576) is better than Ligand B (-0.79). A logP between 1-3 is optimal, and Ligand B is slightly negative, potentially hindering permeation.
4. **H-Bond Donors/Acceptors:** Ligand A has 0 HBD and 5 HBA, while Ligand B has 2 HBD and 6 HBA. Both are acceptable.
5. **QED:** Ligand B (0.621) has a slightly better QED score than Ligand A (0.449), indicating a more drug-like profile.
6. **DILI:** Ligand B (21.171) has a significantly lower DILI risk than Ligand A (57.697), a major advantage.
7. **BBB:** Ligand A (67.468) has a better BBB penetration score than Ligand B (24.506). While not a CNS target, some degree of BBB penetration can be beneficial for distribution.
8. **Caco-2 Permeability:** Ligand B (-5.151) has a slightly better Caco-2 permeability than Ligand A (-4.876).
9. **Aqueous Solubility:** Ligand B (-0.007) has better aqueous solubility than Ligand A (-2.153).
10. **hERG:** Both ligands have very low hERG inhibition risk.
11. **Microsomal Clearance:** Ligand B (-17.901) has significantly lower microsomal clearance than Ligand A (13.047), suggesting better metabolic stability.
12. **In vitro Half-Life:** Ligand B (9.682) has a longer in vitro half-life than Ligand A (-3.618).
13. **P-gp Efflux:** Both ligands have low P-gp efflux liability.
14. **Binding Affinity:** Ligand A (-7.9) has a slightly better binding affinity than Ligand B (-7.0), but the difference is less than 1.5 kcal/mol.
**Overall Assessment:**
Ligand B demonstrates a superior ADME profile, particularly regarding DILI risk, metabolic stability (lower Cl_mic, longer t1/2), and solubility. While Ligand A has a slightly better logP and binding affinity, the ADME advantages of Ligand B are more critical for overall drug development success, especially considering the GPCR target class. The slightly better affinity of Ligand A is not enough to overcome the significant improvements in safety and pharmacokinetic properties offered by Ligand B.
**Output:**
0
2025-04-18 00:35:04,553 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (a cardiovascular GPCR) drug candidates.
**Ligand A: [353.419, 116.76 , -0.092, 4. , 5. , 0.377, 19.969, 60.76 , -4.662, -1.548, 0.126, 18.575, -32.82 , 0.005, -5.6 ]**
**Ligand B: [368.503, 81.75 , 0.156, 2. , 5. , 0.722, 15.626, 55.642, -5.625, -1.595, 0.048, 0.978, -0.783, 0.009, -3.1 ]**
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity) and general drug-like properties:
1. **MW:** Both are within the acceptable 200-500 Da range. Ligand A (353.419) is slightly preferable.
2. **TPSA:** Ligand B (81.75) is significantly better than Ligand A (116.76). Lower TPSA generally means better cell permeability.
3. **logP:** Ligand B (0.156) is better than Ligand A (-0.092), falling within the optimal 1-3 range. Ligand A is slightly negative, which could hinder permeability.
4. **HBD:** Ligand B (2) is better than Ligand A (4). Fewer HBDs generally improve permeability.
5. **HBA:** Both have 5 HBA, which is acceptable.
6. **QED:** Ligand B (0.722) is significantly better than Ligand A (0.377), indicating a more drug-like profile.
7. **DILI:** Ligand B (15.626) is much better than Ligand A (19.969). Lower DILI is crucial.
8. **BBB:** Ligand A (60.76) is slightly better than Ligand B (55.642), but both are not high enough to be considered CNS-penetrant. Since this is a cardiovascular target, BBB isn't a primary concern, but a higher value is still favorable.
9. **Caco-2:** Ligand A (-4.662) is better than Ligand B (-5.625), indicating better intestinal absorption.
10. **Solubility:** Both are very poor (-1.548 and -1.595). This is a significant drawback for both.
11. **hERG:** Both are very low (0.126 and 0.048), indicating low cardiotoxicity risk.
12. **Cl_mic:** Ligand B (0.978) is *much* better than Ligand A (18.575). Lower clearance means greater metabolic stability.
13. **t1/2:** Ligand B (-0.783) is better than Ligand A (-32.82). A less negative value (closer to zero or positive) indicates a longer half-life.
14. **Pgp:** Both are very low (0.005 and 0.009), indicating low P-gp efflux.
15. **Affinity:** Ligand A (-5.6) is significantly better than Ligand B (-3.1). This is a substantial advantage in binding.
**Overall Assessment:**
While Ligand A has a better binding affinity, Ligand B demonstrates a superior ADME profile. Specifically, it has better QED, lower DILI risk, significantly better metabolic stability (Cl_mic), and a better half-life. The TPSA and logP values are also more favorable for Ligand B. The solubility is poor for both, which is a concern, but the other ADME properties of Ligand B are significantly more promising. The large difference in binding affinity is a concern, but the better ADME profile of Ligand B is more important for a cardiovascular target.
Therefore, I would choose Ligand B.
0
2025-04-18 00:35:04,554 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (344.46 and 360.46 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (67.23) is slightly higher than Ligand B (58.98). Both are below the 140 threshold for oral absorption, but closer to the 90 threshold for CNS targets, which isn't a primary concern for ADRB2 (cardiovascular). Ligand B is slightly preferred.
3. **logP:** Ligand A (2.335) is within the optimal 1-3 range. Ligand B (3.517) is slightly higher, pushing the boundary. While still acceptable, Ligand A is slightly preferred.
4. **HBD:** Ligand A (1) is better than Ligand B (0). Lower HBD is generally preferred for permeability.
5. **HBA:** Ligand A (4) is better than Ligand B (5). Lower HBA is generally preferred for permeability.
6. **QED:** Ligand A (0.853) is significantly better than Ligand B (0.758), indicating a more drug-like profile. This is a substantial advantage for Ligand A.
7. **DILI:** Ligand A (22.024) has a much lower DILI risk than Ligand B (49.399). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (91.431) has a higher BBB penetration percentile than Ligand A (72.237). While ADRB2 isn't a CNS target, higher BBB is rarely detrimental.
9. **Caco-2:** Both ligands have similar, poor Caco-2 permeability (-4.924 and -4.744). This is a potential concern for both, suggesting limited intestinal absorption.
10. **Solubility:** Ligand A (-2.031) has better solubility than Ligand B (-4.058). Better solubility is always preferred.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.165 and 0.336). No significant difference.
12. **Cl_mic:** Ligand A (28.146) has significantly lower microsomal clearance than Ligand B (58.919), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (-18.299) has a much longer in vitro half-life than Ligand B (0.719). This is a major advantage for Ligand A.
14. **Pgp:** Ligand A (0.07) has lower P-gp efflux liability than Ligand B (0.187). This is a slight advantage for Ligand A.
15. **Binding Affinity:** Ligand B (-6.1) has slightly better binding affinity than Ligand A (-5.9). While a difference of 0.2 kcal/mol is noticeable, it's not a huge advantage.
**GPCR-specific priorities:** For ADRB2 (a cardiovascular GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B has a slightly better logP and affinity, and a better BBB. However, Ligand A excels in QED, DILI, solubility, metabolic stability (Cl_mic & t1/2), and Pgp efflux. The significantly lower DILI risk, better metabolic stability, and superior QED of Ligand A are more important considerations for overall drug development success. The slight affinity difference is outweighed by these factors.
**Final Decision:**
Ligand A is the more promising drug candidate.
1
2025-04-18 00:35:04,554 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (366.933 Da) is slightly higher than Ligand B (342.443 Da), but both are acceptable.
2. **TPSA:** Ligand A (50.36) is significantly better than Ligand B (83.12). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is approaching a level that could hinder absorption.
3. **logP:** Ligand A (4.727) is higher than Ligand B (2.247). While both are within the acceptable range (1-3 is optimal), Ligand A is pushing the upper limit. This *could* lead to solubility issues, but it's not a deal-breaker.
4. **HBD:** Ligand A (2) is preferable to Ligand B (3). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (2) is preferable to Ligand B (4). Similar to HBD, lower HBA is generally better.
6. **QED:** Both ligands have the same QED (0.664), indicating similar drug-likeness.
7. **DILI:** Ligand A (19.969%) is *much* better than Ligand B (47.421%). This is a significant advantage for Ligand A, as lower DILI risk is crucial.
8. **BBB:** Ligand A (88.329%) is better than Ligand B (65.374%). While ADRB2 isn't exclusively a CNS target, some distribution to the CNS is possible, and higher BBB penetration is generally favorable.
9. **Caco-2:** Ligand A (-4.468) is better than Ligand B (-5.054). Higher (less negative) Caco-2 values indicate better intestinal absorption.
10. **Solubility:** Ligand A (-4.668) is better than Ligand B (-2.919). Higher solubility is important for bioavailability.
11. **hERG:** Ligand A (0.808) is better than Ligand B (0.492). Lower hERG inhibition is critical to avoid cardiotoxicity, a major concern with cardiovascular targets.
12. **Cl_mic:** Ligand A (51.291) is worse than Ligand B (12.01). Ligand B has significantly better metabolic stability.
13. **t1/2:** Ligand A (59.334) is better than Ligand B (8.214). A longer half-life is generally preferred.
14. **Pgp:** Ligand A (0.414) is better than Ligand B (0.038). Lower P-gp efflux is desirable for better bioavailability.
15. **Affinity:** Ligand A (-6.6 kcal/mol) is slightly better than Ligand B (-5.9 kcal/mol). While the difference isn't huge, it's enough to consider, especially given the other favorable properties of Ligand A.
**GPCR-Specific Priorities:**
Considering ADRB2 is a GPCR, logP, TPSA, Pgp, and affinity are key. Ligand A performs better on TPSA, Pgp, and has slightly better affinity. While Ligand A's logP is higher, the benefits in other areas outweigh this potential drawback.
**Overall Assessment:**
Ligand A demonstrates a significantly more favorable profile overall, particularly regarding safety (DILI, hERG) and permeability (TPSA, Caco-2, Pgp). The slightly better affinity and longer half-life further support its selection. While Ligand B has better metabolic stability, the other advantages of Ligand A are more critical for a successful drug candidate.
Output:
1
2025-04-18 00:35:04,554 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's systematically compare Ligand A and Ligand B against the provided guidelines, keeping in mind the GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key).
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (342.37) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (60.33) is higher than Ligand B (29.54). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is still preferred for absorption. Ligand B is significantly better here.
3. **logP:** Ligand A (2.543) is within the optimal range (1-3). Ligand B (4.696) is higher, potentially leading to solubility issues and off-target interactions. This favors Ligand A.
4. **HBD/HBA:** Ligand A has 1 HBD and 4 HBA, while Ligand B has 0 HBD and 2 HBA. Both are acceptable, but Ligand A's slightly higher HBD/HBA count could contribute to better solubility.
5. **QED:** Ligand A (0.929) has a significantly higher QED score than Ligand B (0.67), indicating a more drug-like profile.
6. **DILI:** Ligand B (9.771) has a much lower DILI risk than Ligand A (53.819), which is a significant advantage.
7. **BBB:** Both ligands have good BBB penetration (Ligand A: 81.078, Ligand B: 88.29). This isn't a primary concern for a cardiovascular target, but higher is generally better. Ligand B is slightly better.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and hard to interpret.
9. **Solubility:** Ligand B (-5.205) has a better solubility score than Ligand A (-4.032).
10. **hERG:** Ligand A (0.565) has a lower hERG risk than Ligand B (0.871), which is crucial for avoiding cardiotoxicity.
11. **Cl_mic:** Ligand A (12.589) has a lower microsomal clearance than Ligand B (113.537), indicating better metabolic stability.
12. **t1/2:** Ligand B (31.048) has a much longer in vitro half-life than Ligand A (6.787), which is a significant advantage.
13. **Pgp:** Ligand A (0.18) has lower P-gp efflux liability than Ligand B (0.754), which is favorable for bioavailability.
14. **Affinity:** Ligand B (-7.2 kcal/mol) has a significantly stronger binding affinity than Ligand A (-4.8 kcal/mol). This is a substantial advantage, potentially outweighing some ADME drawbacks.
**Overall Assessment:**
Ligand B has a significantly better binding affinity and a longer half-life, which are critical for a GPCR drug candidate. It also has a lower DILI risk and better solubility. While Ligand A has a better QED, lower logP, and lower Pgp efflux, the substantial affinity advantage of Ligand B, coupled with its acceptable ADME profile, makes it the more promising candidate. The higher logP of Ligand B is a concern, but the strong binding may compensate.
**Output:**
0
2025-04-18 00:35:04,554 - INFO - Batch 488 complete. Total preferences: 7808
2025-04-18 00:35:04,554 - INFO - Processing batch 489/512...
2025-04-18 00:35:53,674 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (339.483 and 348.447 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (47.34) is significantly better than Ligand B (87.46). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold. Ligand B is approaching the upper limit.
3. **logP:** Ligand A (3.582) is good, within the optimal 1-3 range. Ligand B (1.53) is on the lower side, potentially impacting permeability.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (5). Similar reasoning as with HBDs.
6. **QED:** Both ligands have good QED scores (0.796 and 0.867), indicating good drug-like properties.
7. **DILI:** Ligand A (13.3) has a much lower DILI risk than Ligand B (29.818). This is a significant advantage for Ligand A.
8. **BBB:** While not critical for a cardiovascular target, Ligand A (88.639) has better BBB penetration than Ligand B (61.535).
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, Ligand A (-4.508) is slightly better than Ligand B (-4.867).
10. **Solubility:** Ligand A (-3.946) is better than Ligand B (-2.513). Better solubility is always desirable.
11. **hERG:** Ligand A (0.955) is better than Ligand B (0.113). Lower hERG inhibition is crucial for avoiding cardiotoxicity, especially for a cardiovascular target.
12. **Cl_mic:** Ligand A (70.644) has a higher microsomal clearance than Ligand B (30.713), meaning it's metabolized more quickly. This is a drawback for Ligand A.
13. **t1/2:** Ligand A (-22.15) has a negative half-life, which is concerning. Ligand B (-9.311) is also negative but less so. These negative values are likely due to the scale used, and indicate very rapid clearance.
14. **Pgp:** Ligand A (0.276) has lower P-gp efflux than Ligand B (0.027). Lower P-gp efflux is preferable.
15. **Binding Affinity:** Ligand B (-7.8) has a slightly better binding affinity than Ligand A (-5.9). This is a 1.9 kcal/mol difference, which is substantial.
**Overall Assessment:**
Ligand B has a better binding affinity and a slightly better half-life. However, Ligand A excels in nearly all ADME properties: TPSA, logP, HBD/HBA, DILI, solubility, hERG, and Pgp. The significantly lower DILI and hERG risk for Ligand A are particularly important for a cardiovascular drug. While the higher clearance and negative half-life of Ligand A are concerning, these could potentially be addressed through structural modifications during lead optimization. The improved ADME profile and safety parameters of Ligand A outweigh the slightly lower binding affinity.
Output:
1
2025-04-18 00:35:53,675 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [386.495, 108.64 , 2.101, 3. , 6. , 0.579, 75.339, 11.439, -5.749, -2.384, 0.218, 35.353, 60.251, 0.165, -6.3 ]**
**Ligand B: [359.354, 105.25 , -0.47 , 1. , 6. , 0.39 , 61.497, 57.852, -5.029, -0.751, 0.167, 28.567, -25.196, 0.036, -6.9 ]**
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand B (359.354) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are reasonably good (108.64 and 105.25). Both exceed the ideal <90 for CNS targets, but ADRB2 isn't necessarily a CNS target, so this isn't a major concern.
3. **logP:** Ligand A (2.101) is optimal, while Ligand B (-0.47) is quite low. This is a significant drawback for Ligand B, potentially hindering membrane permeability and bioavailability.
4. **H-Bond Donors:** Both are acceptable (3 and 1). Ligand B is better.
5. **H-Bond Acceptors:** Both are similar (6).
6. **QED:** Ligand A (0.579) is better than Ligand B (0.39), indicating a more drug-like profile.
7. **DILI:** Both are acceptable, but Ligand B (61.497) is slightly higher than Ligand A (75.339), indicating a slightly higher risk of liver injury.
8. **BBB:** Ligand A (11.439) is significantly lower than Ligand B (57.852). While ADRB2 isn't necessarily a CNS target, higher BBB is generally preferable.
9. **Caco-2 Permeability:** Both are negative, indicating poor permeability. Ligand B (-5.029) is slightly better than Ligand A (-5.749).
10. **Aqueous Solubility:** Both are negative, indicating poor solubility. Ligand B (-0.751) is slightly better than Ligand A (-2.384).
11. **hERG:** Both are very low (0.218 and 0.167), indicating low cardiotoxicity risk.
12. **Microsomal Clearance:** Ligand B (28.567) has lower clearance than Ligand A (35.353), suggesting better metabolic stability.
13. **In vitro Half-Life:** Ligand B (-25.196) has a negative half-life, which is concerning. Ligand A (60.251) is much better.
14. **P-gp Efflux:** Both are very low (0.165 and 0.036), indicating minimal P-gp efflux.
15. **Binding Affinity:** Ligand B (-6.9) has a slightly better binding affinity than Ligand A (-6.3), a 0.6 kcal/mol advantage.
**Overall Assessment:**
Despite Ligand B having a slightly better binding affinity and lower clearance, Ligand A is the more promising candidate. The significantly lower logP of Ligand B is a major concern, likely leading to poor permeability and bioavailability. Ligand A has a better QED score and a much more reasonable *in vitro* half-life. The difference in binding affinity (0.6 kcal/mol) is not substantial enough to overcome the ADME deficiencies of Ligand B. Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity), Ligand A is the better choice.
Output:
1
2025-04-18 00:35:53,675 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the acceptable range (200-500 Da). Ligand A (359.352 Da) is slightly lower, which is generally favorable for permeability.
**2. TPSA:** Ligand A (97.64) is higher than Ligand B (29.54). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is still preferred for better absorption. Ligand B is significantly better here.
**3. logP:** Ligand A (2.534) is within the optimal range (1-3). Ligand B (4.281) is slightly higher, which could potentially lead to solubility issues or off-target interactions, but is not drastically outside the acceptable range.
**4. H-Bond Donors:** Ligand A has 3 HBDs, which is acceptable. Ligand B has 0, which is also acceptable.
**5. H-Bond Acceptors:** Both ligands have 3 HBAs, which is acceptable.
**6. QED:** Both ligands have similar QED values (0.708 and 0.611), indicating good drug-like properties.
**7. DILI:** Both ligands have low DILI risk (48.468 and 43.583), which is good.
**8. BBB:** Ligand A (53.393) has a lower BBB penetration percentile than Ligand B (93.021). While ADRB2 isn't a CNS target, some degree of BBB penetration can sometimes be beneficial for distribution.
**9. Caco-2 Permeability:** Ligand A (-5.124) has worse Caco-2 permeability than Ligand B (-4.329). This suggests Ligand B will have better intestinal absorption.
**10. Aqueous Solubility:** Ligand A (-2.944) has worse aqueous solubility than Ligand B (-5.617). This is a significant drawback for Ligand A.
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (0.579 and 0.67), which is good.
**12. Microsomal Clearance:** Ligand A (-3.59) has a lower (better) microsomal clearance than Ligand B (96.686), suggesting better metabolic stability.
**13. In vitro Half-Life:** Ligand A (-20.121) has a longer in vitro half-life than Ligand B (0.07), which is a significant advantage.
**14. P-gp Efflux:** Ligand A (0.128) has lower P-gp efflux than Ligand B (0.436), which is favorable for bioavailability.
**15. Binding Affinity:** Ligand A (-7.3 kcal/mol) has a slightly better binding affinity than Ligand B (-6.2 kcal/mol). This is a 1.1 kcal/mol difference, which is substantial.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand A's superior affinity is a major advantage. However, Ligand B has significantly better TPSA, Caco-2 permeability, solubility, and BBB penetration. Ligand A's better metabolic stability and P-gp efflux are also positive. The solubility issue with Ligand A is concerning.
Despite the slightly better affinity of Ligand A, the combination of better physicochemical properties (especially solubility and permeability) and lower TPSA of Ligand B make it a more promising candidate. The 1.1 kcal/mol difference in binding affinity can potentially be optimized in later stages of drug development.
Output:
0
2025-04-18 00:35:53,675 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.415 and 359.495 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand B (66.32) is significantly better than Ligand A (93.71). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (3.958) is closer to the optimal range (1-3) than Ligand A (0.456). Ligand A's logP is quite low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (2) and Ligand B (1) both are within the acceptable limit of <=5. Ligand B is slightly better.
5. **HBA:** Ligand A (4) and Ligand B (5) are both within the acceptable limit of <=10. No clear advantage.
6. **QED:** Both ligands have good QED scores (0.809 and 0.877), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Both ligands have low DILI risk (27.414 and 24.118), which is good. Ligand B is slightly better.
8. **BBB:** Ligand B (58.472) is significantly higher than Ligand A (31.408). While not a CNS target, some level of BBB penetration can sometimes indicate better overall distribution.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.821 and -4.722), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand A (-1.5) is better than Ligand B (-4.334). Solubility is important for bioavailability.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.117 and 0.4), which is excellent. No clear advantage.
12. **Cl_mic:** Ligand A (-15.331) has a much lower (better) microsomal clearance than Ligand B (61.255). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (-21.148) has a longer (better) in vitro half-life than Ligand B (-11.665). This also supports better metabolic stability for Ligand A.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.016 and 0.026), which is good. No clear advantage.
15. **Binding Affinity:** Ligand B (-9.7 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.3 kcal/mol). This is a substantial advantage, potentially outweighing some ADME concerns.
**Overall Assessment:**
Ligand B has a significantly better binding affinity, a more optimal logP, and a better TPSA. While its solubility and metabolic stability are worse than Ligand A, the strong binding affinity is a critical factor for a GPCR target. The Caco-2 values are concerning for both, but the potency advantage of Ligand B is likely to be more impactful in driving forward development, and formulation strategies can be explored to address the permeability issue.
Output:
0
2025-04-18 00:35:53,675 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [384.611, 49.41, 3.159, 1, 4, 0.764, 22.373, 70.027, -5.153, -3.672, 0.4, 59.397, -12.767, 0.16, -5.6]
**Ligand B:** [345.443, 71, 2.147, 1, 4, 0.75, 33.773, 68.67, -4.855, -3.063, 0.142, 26.163, 10.791, 0.122, -6.3]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (345.443) is slightly lower, which could be beneficial for permeability, but both are acceptable.
2. **TPSA:** Ligand A (49.41) is better than Ligand B (71). GPCRs benefit from lower TPSA for better brain penetration and membrane permeability. Ligand B is a bit high.
3. **logP:** Both are within the optimal range (1-3). Ligand A (3.159) is slightly higher, which could lead to some off-target effects, but it's still reasonable. Ligand B (2.147) is good.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Both have 4 HBA, which is good.
6. **QED:** Both are very similar and good (0.764 and 0.75).
7. **DILI:** Ligand A (22.373) has a significantly lower DILI risk than Ligand B (33.773). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (70.027) has a slightly better BBB penetration potential than Ligand B (68.67). While not a primary concern for peripheral ADRB2, it's a positive.
9. **Caco-2:** Ligand A (-5.153) and Ligand B (-4.855) are similar and indicate good permeability.
10. **Solubility:** Ligand A (-3.672) and Ligand B (-3.063) are similar, indicating reasonable solubility.
11. **hERG:** Both are very low (0.4 and 0.142), indicating minimal hERG inhibition risk.
12. **Cl_mic:** Ligand B (26.163) has significantly lower microsomal clearance than Ligand A (59.397), suggesting better metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand B (10.791) has a longer in vitro half-life than Ligand A (-12.767). This is a major advantage for Ligand B.
14. **Pgp:** Both are very low (0.16 and 0.122), indicating minimal P-gp efflux.
15. **Binding Affinity:** Ligand B (-6.3) has a slightly better binding affinity than Ligand A (-5.6). This is a 0.7 kcal/mol difference, which is significant.
**Overall Assessment:**
Ligand B has a clear advantage in metabolic stability (lower Cl_mic, longer t1/2) and binding affinity. Ligand A has a significant advantage in DILI risk. Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), and given the relatively small difference in affinity, the lower DILI risk of Ligand A is a crucial factor. While metabolic stability is important, a lower DILI risk is often prioritized in early drug development. The TPSA of Ligand A is also better.
Therefore, I would select Ligand A.
Output:
1
2025-04-18 00:35:53,676 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [367.318, 84.22, 3.665, 3, 2, 0.671, 56.65, 83.443, -5.068, -4.651, 0.712, 28.226, 30.768, 0.087, -6.2]
**Ligand B:** [352.406, 63.94, 2.58, 1, 4, 0.885, 27.297, 89.686, -4.434, -2.761, 0.492, 18.257, 41.683, 0.063, -4.7]
Here's a breakdown, prioritizing GPCR-relevant properties:
1. **Molecular Weight:** Both are within the ideal range (200-500 Da). Ligand B (352.4) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (84.22) is higher than Ligand B (63.94). Both are acceptable, but Ligand B is better for oral absorption and potentially better for receptor penetration.
3. **logP:** Ligand A (3.665) is slightly higher than Ligand B (2.58). Both are within the optimal range (1-3), but Ligand B is closer to the lower end, which might slightly improve solubility.
4. **H-Bond Donors/Acceptors:** Ligand A (3 HBD, 2 HBA) is slightly better than Ligand B (1 HBD, 4 HBA) in terms of balancing solubility and permeability.
5. **QED:** Ligand B (0.885) has a better QED score than Ligand A (0.671), indicating a more drug-like profile.
6. **DILI Risk:** Ligand B (27.3) has a significantly lower DILI risk than Ligand A (56.65). This is a major advantage for Ligand B.
7. **BBB Penetration:** Both have good BBB penetration, but Ligand B (89.7) is slightly better than Ligand A (83.4). While not *critical* for a cardiovascular target, it's a positive.
8. **Caco-2 Permeability:** Both are negative, indicating poor permeability. Ligand A (-5.068) is worse than Ligand B (-4.434).
9. **Aqueous Solubility:** Ligand B (-2.761) is better than Ligand A (-4.651).
10. **hERG Inhibition:** Ligand B (0.492) has a lower hERG risk than Ligand A (0.712).
11. **Microsomal Clearance:** Ligand B (18.257) has a lower clearance, suggesting better metabolic stability than Ligand A (28.226).
12. **In vitro Half-Life:** Ligand B (41.683) has a longer half-life than Ligand A (30.768).
13. **P-gp Efflux:** Both are very low, indicating minimal P-gp efflux.
14. **Binding Affinity:** Ligand A (-6.2 kcal/mol) has a slightly better binding affinity than Ligand B (-4.7 kcal/mol). This is a 1.5 kcal/mol difference, which is significant.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity, Ligand B demonstrates a significantly better ADMET profile. The lower DILI risk, improved solubility, metabolic stability, and half-life are substantial advantages. The slightly lower affinity is likely surmountable with further optimization, while mitigating the ADMET liabilities of Ligand A would be more challenging. Given the GPCR target class, the balance of properties favors Ligand B.
Output:
0
2025-04-18 00:35:53,676 - INFO - Here's my reasoning and final output for the ligand preference:
**Reasoning:**
We are targeting ADRB2, a GPCR, so the priorities are logP, TPSA, Pgp, BBB, and affinity. Let's break down the comparison:
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da).
2. **TPSA:** Ligand A (101.11) is better than Ligand B (110.6), being closer to the <140 threshold for good absorption.
3. **logP:** Both are good (around 1), within the optimal 1-3 range. Ligand A (1.306) is slightly higher, which could be a minor advantage.
4. **H-Bond Donors/Acceptors:** Both have acceptable HBD/HBA counts.
5. **QED:** Both are above 0.5, indicating good drug-likeness.
6. **DILI:** Both have relatively high DILI risk (77.472 and 72.043), but this isn't a major deciding factor here as both are similar.
7. **BBB:** Ligand B (72.276) has a significantly better BBB penetration score than Ligand A (47.15). While ADRB2 isn't necessarily a CNS target, some peripheral ADRB2 signaling can influence CNS function, and better BBB penetration isn't a negative.
8. **Caco-2:** Ligand A (-5.12) is better than Ligand B (-4.826), indicating better intestinal absorption.
9. **Solubility:** Ligand A (-4.186) is better than Ligand B (-3.103), which is important for bioavailability.
10. **hERG:** Both have low hERG inhibition risk.
11. **Cl_mic:** Ligand B (23.506) has much lower microsomal clearance than Ligand A (59.735), suggesting better metabolic stability. This is a significant advantage.
12. **t1/2:** Ligand B (59.125) has a much longer in vitro half-life than Ligand A (-22.055), further supporting better metabolic stability.
13. **Pgp:** Ligand A (0.186) has lower P-gp efflux liability than Ligand B (0.278), which is favorable.
14. **Binding Affinity:** Ligand A (-7.2 kcal/mol) has a stronger binding affinity than Ligand B (-5.9 kcal/mol). This is a substantial difference (1.3 kcal/mol) and a major driver in the decision.
**Overall Assessment:**
Ligand A has a significantly better binding affinity and better Caco-2 permeability and Pgp efflux. Ligand B has a better BBB score, lower Cl_mic, and longer half-life. Given the GPCR target class, binding affinity is paramount. The 1.3 kcal/mol difference in binding is substantial enough to outweigh the benefits of Ligand B's improved metabolic stability and BBB penetration. The better solubility and absorption of Ligand A are also positive factors.
**Output:**
1
2025-04-18 00:35:53,676 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [340.471, 58.95, 2.805, 2, 4, 0.85, 27.181, 55.293, -5.385, -2.096, 0.684, -30.666, 35.094, 0.173, -6.8]
**Ligand B:** [352.494, 58.2, 3.64, 2, 2, 0.623, 27.608, 83.637, -4.814, -4.739, 0.671, 59.609, 13.125, 0.554, -6.7]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal range (200-500 Da). A is 340.471, B is 352.494 - very similar.
2. **TPSA:** Both are good, under the 140 A^2 threshold for oral absorption (A: 58.95, B: 58.2).
3. **logP:** Both are within the optimal 1-3 range (A: 2.805, B: 3.64). B is slightly higher, potentially increasing off-target effects, but still acceptable.
4. **HBD/HBA:** Both have 2 HBD and reasonable HBA counts (A: 4, B: 2). This is good for balancing solubility and permeability.
5. **QED:** A (0.85) is significantly better than B (0.623), indicating a more drug-like profile.
6. **DILI:** Both are low risk, below 40 (A: 27.181, B: 27.608).
7. **BBB:** B (83.637) is much better than A (55.293). While ADRB2 isn't strictly a CNS target, some CNS penetration can be beneficial, and it's not detrimental here.
8. **Caco-2:** Both are negative, indicating poor permeability. A (-5.385) is slightly worse than B (-4.814).
9. **Solubility:** Both are negative, indicating poor solubility. B (-4.739) is slightly worse than A (-2.096).
10. **hERG:** Both are low risk (A: 0.684, B: 0.671).
11. **Cl_mic:** A (-30.666) is significantly better (lower clearance) than B (59.609), suggesting better metabolic stability.
12. **t1/2:** A (35.094) has a much longer half-life than B (13.125). This is a significant advantage.
13. **Pgp:** B (0.554) is better (lower efflux) than A (0.173). Lower Pgp efflux is desirable for better bioavailability.
14. **Affinity:** Both are excellent, very similar at -6.8 and -6.7 kcal/mol. The difference is negligible.
**Overall Assessment:**
The key differentiators are QED, metabolic stability (Cl_mic & t1/2), BBB, and Pgp. Ligand A has a much better QED and significantly improved metabolic stability (lower Cl_mic, longer t1/2). Ligand B has better BBB penetration and Pgp efflux. Given the GPCR target class, the metabolic stability and drug-likeness of Ligand A are more critical than the slightly improved BBB and Pgp of Ligand B. The similar binding affinities make the ADME properties the deciding factor.
Therefore, I prefer Ligand A.
Output:
1
2025-04-18 00:35:53,676 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (340.47 & 346.43 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (40.62) is significantly better than Ligand B (114.18). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand B's TPSA is quite high, potentially hindering oral bioavailability.
3. **logP:** Ligand A (3.122) is within the optimal 1-3 range. Ligand B (0.924) is a bit low, potentially leading to poor membrane permeability.
4. **HBD:** Ligand A (0) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (2) is better than Ligand B (4). Lower HBA is generally preferred for permeability.
6. **QED:** Ligand A (0.845) is significantly better than Ligand B (0.649), indicating a more drug-like profile.
7. **DILI:** Both ligands have acceptable DILI risk (35.05 & 31.99 percentile), below the 40% threshold. No major difference.
8. **BBB:** Ligand A (94.998) has much higher BBB penetration than Ligand B (62.233). While not critical for a cardiovascular target, higher BBB is rarely detrimental and can indicate better overall permeability.
9. **Caco-2:** Ligand A (-4.496) is better than Ligand B (-5.385), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-3.409) is better than Ligand B (-2.832).
11. **hERG:** Ligand A (0.823) is better than Ligand B (0.062). Lower hERG inhibition is crucial for avoiding cardiotoxicity, a major concern for cardiovascular drugs.
12. **Cl_mic:** Ligand A (56.887) has higher clearance than Ligand B (24.349). This is a negative for Ligand A, indicating faster metabolism.
13. **t1/2:** Ligand A (-7.45) has a much longer half-life than Ligand B (-0.309). This is a significant advantage for Ligand A, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.395) is better than Ligand B (0.014), indicating lower P-gp efflux.
15. **Binding Affinity:** Ligand A (-7.2 kcal/mol) is slightly better than Ligand B (-5.7 kcal/mol). The 1.5 kcal/mol difference is substantial and can outweigh some ADME drawbacks.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A excels in logP, TPSA, Pgp, and has a better affinity. While Ligand B has a better metabolic stability (lower Cl_mic), the superior overall profile of Ligand A, particularly its significantly better TPSA, hERG, and binding affinity, makes it the more promising candidate.
Output:
1
2025-04-18 00:35:53,676 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
We are targeting ADRB2, a GPCR. Therefore, the most important parameters are binding affinity, logP, TPSA, Pgp efflux, and BBB penetration. Metabolic stability (Cl_mic and t1/2) and safety (DILI, hERG) are also important.
Let's compare the ligands:
1. **Molecular Weight:** Both ligands (356.511 and 355.383 Da) are within the ideal range (200-500 Da).
2. **TPSA:** Ligand A (76.12) is significantly better than Ligand B (116.76). A lower TPSA generally favors better cell permeability and oral absorption. Ligand A is well below the 140 threshold, while Ligand B is approaching it.
3. **logP:** Ligand A (-0.148) is slightly lower than the optimal range (1-3), while Ligand B (0.664) is within the range. However, a slightly low logP is less concerning than a high one.
4. **H-Bond Donors:** Both have 2 HBD, which is acceptable.
5. **H-Bond Acceptors:** Ligand A has 5 HBA, and Ligand B has 8. Ligand A is better here, as lower HBA is generally preferred.
6. **QED:** Both ligands have good QED scores (0.569 and 0.66), indicating good drug-like properties.
7. **DILI:** Ligand A (3.063%) has a much lower DILI risk than Ligand B (92.982%). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (31.214%) has lower BBB penetration than Ligand B (45.638%). While BBB isn't a primary concern for ADRB2 (a cardiovascular target), higher is still slightly better.
9. **Caco-2:** Ligand A (-5.205) and Ligand B (-5.63) are both very poor, indicating poor intestinal absorption.
10. **Solubility:** Ligand A (0.117) has slightly better solubility than Ligand B (-4.017).
11. **hERG:** Ligand A (0.237) has a much lower hERG risk than Ligand B (0.464). This is a significant safety advantage.
12. **Cl_mic:** Ligand A (-10.261) has a significantly *lower* (better) microsomal clearance than Ligand B (19.069), indicating greater metabolic stability.
13. **t1/2:** Ligand A (-0.343) has a very short half-life, while Ligand B (7.617) has a longer half-life. This favors Ligand B.
14. **Pgp:** Ligand A (0.005) has a much lower Pgp efflux liability than Ligand B (0.09), suggesting better bioavailability and potentially better CNS exposure if needed.
15. **Binding Affinity:** Ligand B (-6.8 kcal/mol) has a slightly better binding affinity than Ligand A (-5.6 kcal/mol). This is a 1.2 kcal/mol difference, which is substantial, but needs to be weighed against other factors.
**Overall Assessment:**
Ligand A has a significantly better safety profile (lower DILI and hERG), better metabolic stability (lower Cl_mic), lower Pgp efflux, and better TPSA/HBA. While Ligand B has a slightly better binding affinity and half-life, the advantages of Ligand A in terms of safety and ADME properties are more critical for overall drug development success, especially considering the slight affinity difference can potentially be optimized. The poor Caco-2 values for both are a concern, but can be addressed through formulation strategies.
Output:
1
2025-04-18 00:35:53,677 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.459 Da and 341.459 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (78.87) is higher than Ligand B (61.36). While both are below the 140 threshold for oral absorption, the lower TPSA of Ligand B is slightly preferable for a GPCR, potentially aiding permeability.
3. **logP:** Ligand A (1.071) is within the optimal range (1-3), while Ligand B (2.198) is closer to the upper end. Both are acceptable, but Ligand A's lower logP might reduce off-target interactions.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1). Both are within the acceptable limit of 5.
5. **HBA:** Ligand A (4) is lower than Ligand B (5). Both are within the acceptable limit of 10.
6. **QED:** Both ligands have good QED scores (0.798 and 0.89), indicating good drug-like properties.
7. **DILI:** Ligand A (12.214) has a significantly lower DILI risk than Ligand B (44.979). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (81.349) has a higher BBB penetration percentile than Ligand A (56.34). While ADRB2 isn't strictly a CNS target, some CNS exposure can occur, making Ligand B slightly preferable here.
9. **Caco-2:** Ligand A (-4.751) and Ligand B (-4.953) both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand B is slightly worse.
10. **Solubility:** Ligand A (-1.851) has better solubility than Ligand B (-3.001). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.174) has a much lower hERG inhibition liability than Ligand B (0.741). This is a critical advantage for Ligand A, minimizing cardiotoxicity risk.
12. **Cl_mic:** Ligand A (-5.574) has a much lower (better) microsomal clearance than Ligand B (79.029), indicating greater metabolic stability.
13. **t1/2:** Ligand A (20.412) has a longer in vitro half-life than Ligand B (-9.932). This is a significant advantage for Ligand A, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.014) has a significantly lower P-gp efflux liability than Ligand B (0.1). This is favorable for bioavailability.
15. **Binding Affinity:** Ligand A (-7.9) has a slightly better binding affinity than Ligand B (-6.9). While both are good, the difference is significant enough to consider.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity) and general drug-like properties, Ligand A is the stronger candidate. While Ligand B has better BBB penetration, Ligand A excels in crucial areas like DILI risk, hERG inhibition, metabolic stability (Cl_mic and t1/2), P-gp efflux, solubility, and binding affinity. The lower DILI and hERG risks are particularly important for a cardiovascular target. The slightly better affinity further strengthens its position. The Caco-2 values are concerning for both, but the other advantages of A outweigh this.
Output:
1
2025-04-18 00:35:53,677 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (352.5 and 365.5 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Both ligands have TPSA values (58.6 and 56.7) below the 140 A^2 threshold for good oral absorption, which is good.
**3. logP:** Both ligands have logP values (3.13 and 2.99) within the optimal 1-3 range. Again, no major distinction.
**4. H-Bond Donors:** Both have 1 HBD, which is within the acceptable limit of <=5.
**5. H-Bond Acceptors:** Ligand A has 3 HBAs, and Ligand B has 5. Both are below the 10 HBA threshold.
**6. QED:** Both ligands have similar QED scores (0.693 and 0.682), indicating good drug-likeness.
**7. DILI Risk:** Ligand A (8.4%) has a significantly lower DILI risk than Ligand B (13.4%). This is a crucial advantage, as liver toxicity is a major concern in drug development.
**8. BBB Penetration:** Ligand A (74.6%) shows better BBB penetration than Ligand B (65.4%). While ADRB2 is a cardiovascular target, some CNS effects are possible with adrenergic agonists, and better BBB penetration could be beneficial or detrimental depending on the desired profile.
**9. Caco-2 Permeability:** Ligand A (-4.24) shows better Caco-2 permeability than Ligand B (-5.04).
**10. Aqueous Solubility:** Both ligands have similar poor aqueous solubility (-3.02 and -2.91).
**11. hERG Inhibition:** Ligand A (0.464) has a slightly lower hERG inhibition liability than Ligand B (0.664), which is favorable for reducing cardiotoxicity risk.
**12. Microsomal Clearance:** Ligand A (100.4 mL/min/kg) has a higher microsomal clearance than Ligand B (80.8 mL/min/kg), indicating lower metabolic stability. This is a disadvantage for Ligand A.
**13. In vitro Half-Life:** Ligand A (-4.72 hours) has a slightly longer half-life than Ligand B (-4.92 hours).
**14. P-gp Efflux:** Ligand A (0.088) has lower P-gp efflux than Ligand B (0.183), which is preferable for improved bioavailability.
**15. Binding Affinity:** Ligand A (-6.4 kcal/mol) has a slightly better binding affinity than Ligand B (-6.1 kcal/mol). While the difference is not huge, it's a positive aspect for Ligand A.
**GPCR-Specific Considerations:** For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Both ligands perform similarly on logP and TPSA. Ligand A has better Pgp efflux and slightly better affinity.
**Overall Assessment:**
Ligand A is the more promising candidate. While it has slightly higher microsomal clearance, its significantly lower DILI risk, better BBB penetration, better Caco-2 permeability, lower hERG inhibition, lower P-gp efflux, and slightly improved binding affinity outweigh this drawback. The lower DILI risk is a particularly important factor.
Output:
1
2025-04-18 00:35:53,677 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (a cardiovascular GPCR) drug candidates.
**Ligand A:** [350.369, 67.23, 2.28, 1, 4, 0.9, 61.07, 83.482, -4.442, -2.812, 0.587, 40.1, 37.623, 0.149, -7.5]
**Ligand B:** [350.503, 69.64, 2.471, 2, 3, 0.821, 5.584, 46.84, -4.739, -2.534, 0.23, 15.085, 4.374, 0.036, -6.6]
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (around 350 Da). No significant difference.
2. **TPSA:** Ligand A (67.23) is better than Ligand B (69.64), being closer to the <140 threshold for good absorption.
3. **logP:** Both are within the optimal range (1-3), with Ligand A (2.28) slightly preferred.
4. **HBD:** Ligand A (1) is better than Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (4) is better than Ligand B (3).
6. **QED:** Ligand A (0.9) is significantly better than Ligand B (0.821), indicating a more drug-like profile.
7. **DILI:** Ligand B (5.584) is *much* better than Ligand A (61.07). This is a major advantage for Ligand B.
8. **BBB:** Ligand A (83.482) is significantly better than Ligand B (46.84). While ADRB2 is a cardiovascular target, some CNS penetration can be acceptable or even desirable for off-target effects, and this is a strong point for Ligand A.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand B (-4.739) is slightly worse than Ligand A (-4.442).
10. **Solubility:** Both are negative, indicating poor solubility. Ligand B (-2.534) is slightly worse than Ligand A (-2.812).
11. **hERG:** Ligand A (0.587) is better than Ligand B (0.23), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand B (15.085) is *much* better than Ligand A (40.1), meaning it has significantly better metabolic stability.
13. **t1/2:** Ligand A (37.623) is better than Ligand B (4.374).
14. **Pgp:** Ligand B (0.036) is *much* better than Ligand A (0.149), indicating lower efflux and better bioavailability.
15. **Affinity:** Ligand A (-7.5) is 1.5 kcal/mol better than Ligand B (-6.6). This is a substantial difference in potency.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, we prioritize logP, Pgp, TPSA, and affinity. Ligand A has better logP, TPSA, and significantly better affinity. Ligand B has better Pgp and a *much* better DILI score, and better Cl_mic.
**Overall Assessment:**
The affinity difference is substantial. The better affinity of Ligand A is a major advantage, and could potentially outweigh some of the ADME drawbacks. However, the DILI risk of Ligand A is concerning. The metabolic stability of Ligand B is also a strong point. The Pgp efflux for Ligand B is also very favorable.
Considering the balance, the superior binding affinity of Ligand A is a critical factor for a GPCR target. While the DILI risk is a concern, it might be mitigated through further structural modifications. The improved metabolic stability and reduced efflux of Ligand B are valuable, but the weaker binding affinity is a significant drawback.
Therefore, I will choose Ligand A.
1
2025-04-18 00:35:53,677 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (386.514 and 383.857 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (49.85) is significantly better than Ligand B (87.74). For a GPCR, keeping TPSA lower is generally beneficial for permeability. Ligand B is quite high, potentially hindering absorption.
**3. logP:** Both ligands have good logP values (1.886 and 1.477), falling within the optimal 1-3 range. Ligand B is slightly lower, which could slightly reduce permeability, but it's not a major concern.
**4. H-Bond Donors:** Ligand A has 0 HBD, which is excellent. Ligand B has 2, still acceptable but less ideal.
**5. H-Bond Acceptors:** Both have 5 HBA, which is within the acceptable range of <=10.
**6. QED:** Both ligands have good QED scores (0.741 and 0.824), indicating good drug-like properties. Ligand B is slightly better.
**7. DILI Risk:** Ligand A (54.983) is better than Ligand B (75.688). Lower DILI risk is always preferred.
**8. BBB Penetration:** Ligand A (88.29) has significantly better BBB penetration than Ligand B (55.487). While ADRB2 is primarily a cardiovascular target, some CNS off-target effects are always a consideration, and better BBB penetration can sometimes indicate better overall distribution properties.
**9. Caco-2 Permeability:** Both have negative Caco-2 values (-4.3 and -4.951), which is unusual and suggests poor permeability. However, these values are on a log scale, and the absolute difference isn't huge.
**10. Aqueous Solubility:** Both have negative solubility values (-3.044 and -3.625), suggesting poor solubility. This is a concern for both, but slightly worse for Ligand B.
**11. hERG Inhibition:** Ligand A (0.488) has a much lower hERG inhibition risk than Ligand B (0.186). This is a critical advantage, as hERG inhibition can lead to cardiotoxicity.
**12. Microsomal Clearance:** Ligand A (47.896) has a better (lower) microsomal clearance than Ligand B (-17.75). This indicates better metabolic stability for Ligand A.
**13. In vitro Half-Life:** Ligand A (5.456) has a better (longer) in vitro half-life than Ligand B (-16.557).
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.094 and 0.076).
**15. Binding Affinity:** Ligand B (-7.7 kcal/mol) has a significantly better binding affinity than Ligand A (-6.5 kcal/mol). This is a substantial advantage (1.2 kcal/mol difference), and can often outweigh minor ADME concerns.
**Overall Assessment:**
While Ligand B boasts superior binding affinity, Ligand A has a much more favorable ADME profile. Specifically, its lower DILI risk, better BBB penetration, significantly lower hERG inhibition, and improved metabolic stability are crucial advantages. The poor Caco-2 and solubility for both are concerning, but can potentially be addressed with formulation strategies. The affinity difference, while notable, isn't so large that it completely overshadows the significant safety and pharmacokinetic benefits of Ligand A. Given the cardiovascular target, minimizing hERG risk is paramount.
Output:
1
2025-04-18 00:35:53,677 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [340.427, 88.32, 2.075, 2, 4, 0.892, 55.642, 87.864, -5.165, -2.931, 0.61, 30.832, 13.171, 0.058, -6.0]
**Ligand B:** [360.451, 119.33, -0.884, 4, 6, 0.468, 11.128, 38.581, -5.087, -0.68, 0.17, -1.56, -18.784, 0.014, -6.4]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). A (340.427) is slightly preferred.
2. **TPSA:** A (88.32) is excellent, well below the 140 threshold and good for GPCRs. B (119.33) is still acceptable but less ideal.
3. **logP:** A (2.075) is optimal. B (-0.884) is too low, potentially hindering membrane permeability. This is a significant drawback for a GPCR ligand.
4. **HBD:** Both have acceptable HBD counts (A: 2, B: 4).
5. **HBA:** Both have acceptable HBA counts (A: 4, B: 6).
6. **QED:** A (0.892) is very good, indicating high drug-likeness. B (0.468) is below the desirable threshold of 0.5.
7. **DILI:** A (55.642) is acceptable, moderate risk. B (11.128) is excellent, very low risk.
8. **BBB:** A (87.864) is excellent, suggesting good potential for CNS penetration if desired (though not strictly necessary for ADRB2, it's a bonus). B (38.581) is low.
9. **Caco-2:** Both are negative, which is unusual and requires further investigation, but we'll assume similar absorption for now.
10. **Solubility:** Both are negative, indicating poor solubility. A (-2.931) is slightly worse than B (-0.68).
11. **hERG:** Both are very low risk (A: 0.61, B: 0.17).
12. **Cl_mic:** A (30.832) is reasonable. B (-1.56) is *excellent*, indicating very high metabolic stability.
13. **t1/2:** A (13.171) is good. B (-18.784) is exceptionally long, a significant advantage.
14. **Pgp:** Both are very low efflux (A: 0.058, B: 0.014).
15. **Affinity:** Both have excellent binding affinity (A: -6.0, B: -6.4). B is slightly better, but the difference is small.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, and affinity. A excels in logP and TPSA. B has slightly better affinity and metabolic stability. However, the significantly lower logP of B is a major concern, potentially leading to poor membrane permeability and bioavailability.
**Conclusion:**
Despite B's slightly better affinity and metabolic stability, Ligand A is the more promising candidate. Its optimal logP, excellent TPSA, good QED, and acceptable DILI risk outweigh the slightly lower affinity and less impressive metabolic stability compared to Ligand B. The poor logP of Ligand B is a critical flaw that would likely hinder its development.
**Output:**
1
2025-04-18 00:35:53,678 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (340.379 Da) is well within the ideal range (200-500 Da). Ligand B (374.941 Da) is also acceptable. No clear advantage here.
2. **TPSA:** Ligand A (81.86) is good, under the 140 threshold. Ligand B (49.84) is excellent, well under 140. Ligand B has a slight advantage.
3. **logP:** Ligand A (2.259) is optimal (1-3). Ligand B (4.97) is a bit high, potentially leading to solubility issues and off-target effects. Ligand A is preferred.
4. **HBD:** Both ligands have acceptable HBD counts (1 and 2 respectively), well under the 5 threshold.
5. **HBA:** Both ligands have acceptable HBA counts (5), well under the 10 threshold.
6. **QED:** Ligand A (0.682) is better than Ligand B (0.529), indicating a more drug-like profile.
7. **DILI:** Ligand A (77.782) is higher than Ligand B (69.407), indicating a slightly increased risk of liver injury. Ligand B is preferred.
8. **BBB:** Ligand A (78.519) is good, while Ligand B (86.002) is even better. Considering ADRB2 is a GPCR, BBB penetration is a relevant factor, and Ligand B has an advantage.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the magnitude of the negative value is important. Ligand A (-4.732) is slightly less negative than Ligand B (-5.079), suggesting marginally better permeability.
10. **Solubility:** Both ligands have negative solubility values, which is also unusual and indicates poor aqueous solubility. Ligand A (-4.49) is slightly less negative than Ligand B (-4.89), suggesting marginally better solubility.
11. **hERG:** Both ligands have low hERG inhibition liability (0.708 and 0.858 respectively), which is good.
12. **Cl_mic:** Ligand A (48.365) has a lower microsomal clearance than Ligand B (86.457), suggesting better metabolic stability. Ligand A is preferred.
13. **t1/2:** Ligand B (67.813) has a significantly longer in vitro half-life than Ligand A (-16.27). This is a major advantage for Ligand B.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.411 and 0.514 respectively).
15. **Binding Affinity:** Ligand A (-6.6 kcal/mol) has a slightly better binding affinity than Ligand B (-5.0 kcal/mol). This is a significant advantage, as a 1.6 kcal/mol difference is substantial.
**Overall Assessment:**
Ligand A has a better binding affinity, QED, metabolic stability, and slightly better permeability/solubility. However, Ligand B excels in BBB penetration and has a much longer half-life and lower DILI risk. For an ADRB2 target (a GPCR), BBB penetration is important, but not paramount unless targeting the CNS. The longer half-life of Ligand B is a significant advantage, potentially allowing for less frequent dosing. The slightly higher logP of Ligand B is a concern, but the strong binding affinity of Ligand A is a compelling factor. Considering the balance, the superior binding affinity of Ligand A outweighs the benefits of Ligand B.
Output:
1
2025-04-18 00:35:53,678 - INFO - Batch 489 complete. Total preferences: 7824
2025-04-18 00:35:53,678 - INFO - Processing batch 490/512...
2025-04-18 00:36:37,029 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (361.433 and 352.41 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (70.67) is significantly better than Ligand B (96.25). ADRB2 is a cardiovascular target, not CNS, but lower TPSA generally improves absorption.
3. **logP:** Ligand A (0.806) is slightly better than Ligand B (0.393), both are a bit low, but Ligand A is closer to the optimal 1-3 range.
4. **HBD:** Ligand A (2) is preferable to Ligand B (3). Lower is generally better for permeability.
5. **HBA:** Ligand A (4) is preferable to Ligand B (5). Lower is generally better for permeability.
6. **QED:** Both ligands are similar (0.671 vs 0.662), both are above the 0.5 threshold, indicating good drug-likeness.
7. **DILI:** Ligand A (11.632) is significantly better than Ligand B (38.503). Lower DILI risk is crucial.
8. **BBB:** Not a primary concern for a cardiovascular target. Ligand A (81.466) is better than Ligand B (69.833), but this is less important.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-5.022) is slightly better than Ligand B (-5.197).
10. **Solubility:** Both are negative, indicating poor solubility. Ligand A (-1.466) is slightly better than Ligand B (-2.124).
11. **hERG:** Both are very low (0.271 and 0.105), indicating minimal hERG inhibition risk.
12. **Cl_mic:** Ligand A (1.883) is *much* better than Ligand B (-12.193). A positive value for B suggests rapid clearance.
13. **t1/2:** Ligand A (-2.562) is better than Ligand B (1.116). A more negative value indicates a longer half-life.
14. **Pgp:** Both are very low (0.008 and 0.02), indicating minimal P-gp efflux.
15. **Binding Affinity:** Ligand B (-7.0) has a slightly better binding affinity than Ligand A (-5.8), a difference of 1.2 kcal/mol.
**Overall Assessment:**
While Ligand B has a slightly better binding affinity, Ligand A is significantly superior in terms of ADME-Tox properties. The lower DILI risk, better metabolic stability (Cl_mic and t1/2), and more favorable TPSA, HBD, and HBA values make Ligand A a much more promising drug candidate. The 1.2 kcal/mol difference in binding affinity is unlikely to outweigh the substantial improvements in safety and pharmacokinetic properties offered by Ligand A. For a cardiovascular target, metabolic stability and safety are paramount.
Output:
1
2025-04-18 00:36:37,029 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (354.422 and 350.409 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (78.87) is higher than Ligand B (58.2). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is generally preferred for absorption. Ligand B is better.
3. **logP:** Ligand A (0.492) is quite low, potentially hindering membrane permeability. Ligand B (3.253) is within the optimal 1-3 range. This is a significant advantage for Ligand B.
4. **HBD:** Both ligands have 2 HBD, which is acceptable.
5. **HBA:** Ligand A has 4 HBA, while Ligand B has 2. Lower HBA is generally preferred for permeability, giving a slight edge to Ligand B.
6. **QED:** Ligand B (0.774) has a substantially higher QED score than Ligand A (0.467), indicating a more drug-like profile. This is a strong positive for Ligand B.
7. **DILI:** Ligand A (12.524%) has a much lower DILI risk than Ligand B (49.438%). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (68.98%) and Ligand B (80.884%) both have acceptable BBB penetration, but Ligand B is better. Since ADRB2 is not a CNS target, this is less critical.
9. **Caco-2:** Both have negative values, indicating poor permeability. Ligand A (-4.727) is slightly better than Ligand B (-4.276).
10. **Solubility:** Ligand A (-1.573) is better than Ligand B (-3.765). Solubility is important for bioavailability.
11. **hERG:** Both ligands have low hERG inhibition risk (0.347 and 0.493 respectively). No significant difference.
12. **Cl_mic:** Ligand A (-12.853) has a much lower (better) microsomal clearance than Ligand B (34.839), indicating greater metabolic stability. This is a major advantage for Ligand A.
13. **t1/2:** Ligand B (33.776) has a significantly longer in vitro half-life than Ligand A (3.503). This is a strong positive for Ligand B.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.039 and 0.146 respectively). No significant difference.
15. **Binding Affinity:** Ligand B (-7.6) has a slightly better binding affinity than Ligand A (-7.0), but the difference is relatively small.
**GPCR-Specific Priorities:**
For ADRB2 (a cardiovascular GPCR), logP, TPSA, and affinity are key. Ligand B excels in logP and has slightly better affinity. Ligand A has better DILI and Cl_mic.
**Overall Assessment:**
While Ligand A has advantages in DILI and metabolic stability, Ligand B's superior logP, QED, and half-life, combined with acceptable DILI and metabolic stability, make it the more promising candidate. The slightly better affinity of Ligand B also contributes. The low logP of Ligand A is a significant concern for permeability and bioavailability.
Output:
0
2025-04-18 00:36:37,030 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
The target is ADRB2, a GPCR. Therefore, I will prioritize logP, TPSA, Pgp efflux, BBB penetration, and binding affinity, while also considering the general drug-like properties.
* **Molecular Weight:** Both ligands are within the ideal range (200-500 Da).
* **TPSA:** Ligand B (75.62) is significantly better than Ligand A (104.46). Lower TPSA generally correlates with better cell permeability, which is crucial for GPCR targeting.
* **logP:** Ligand B (3.63) is higher than Ligand A (0.775). While slightly above the optimal range, it's not excessively high and could aid membrane permeability. Ligand A's logP is quite low, potentially hindering absorption.
* **H-Bond Donors/Acceptors:** Ligand A has 3 HBD and 5 HBA, while Ligand B has 2 HBD and 7 HBA. Both are acceptable, but Ligand A is slightly more favorable.
* **QED:** Ligand A (0.574) is slightly better than Ligand B (0.499), indicating a more drug-like profile.
* **DILI:** Ligand B (69.639) has a higher DILI risk than Ligand A (39.977). This is a significant drawback for Ligand B.
* **BBB:** Ligand B (74.021) has a much better BBB penetration potential than Ligand A (27.336). For a GPCR, even if not specifically a CNS target, some level of BBB penetration can be beneficial for distribution.
* **Caco-2 Permeability:** Both are negative, suggesting poor permeability. Ligand B (-5.43) is slightly better than Ligand A (-4.962).
* **Aqueous Solubility:** Both have negative solubility values, indicating poor solubility. Ligand B (-3.414) is slightly better than Ligand A (-2.112).
* **hERG Inhibition:** Ligand A (0.132) has a lower hERG inhibition risk than Ligand B (0.627), which is a significant advantage.
* **Microsomal Clearance:** Ligand B (74.782) has a much higher microsomal clearance than Ligand A (15.468), indicating faster metabolism and potentially lower in vivo exposure.
* **In vitro Half-Life:** Ligand B (50.948) has a longer half-life than Ligand A (-14.442).
* **P-gp Efflux:** Ligand A (0.052) has lower P-gp efflux than Ligand B (0.474), which is beneficial for bioavailability.
* **Binding Affinity:** Ligand B (-7.0 kcal/mol) has a slightly better binding affinity than Ligand A (-6.5 kcal/mol). This difference is significant enough to consider.
**Overall Assessment:**
Ligand B has a better binding affinity and BBB penetration, which are important for a GPCR target. However, it suffers from higher DILI risk, higher microsomal clearance, and higher P-gp efflux. Ligand A has a better safety profile (lower DILI and hERG), better metabolic stability, and lower P-gp efflux. The slightly weaker binding affinity of Ligand A is outweighed by its superior ADME-Tox profile.
**Output:**
1
2025-04-18 00:36:37,030 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (349.475) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (87.3) is better than Ligand B (29.54). ADRB2 is a cardiovascular target, so BBB penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (1.825) is optimal. Ligand B (4.153) is pushing the upper limit and could potentially lead to solubility issues or off-target interactions.
4. **HBD:** Ligand A (3) is reasonable. Ligand B (0) is also acceptable, but too few HBDs can sometimes hinder solubility.
5. **HBA:** Ligand A (3) is good. Ligand B (2) is also good.
6. **QED:** Both ligands have good QED scores (A: 0.526, B: 0.633), indicating drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (26.095) has a significantly lower DILI risk than Ligand B (12.175). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (48.662) is lower than Ligand B (97.131). Since this is a cardiovascular target, BBB penetration is not a high priority.
9. **Caco-2:** Ligand A (-5.083) and Ligand B (-4.267) are both negative, indicating poor permeability.
10. **Solubility:** Ligand A (-2.248) is better than Ligand B (-3.632), although both are poor.
11. **hERG:** Ligand A (0.065) has a much lower hERG risk than Ligand B (0.842). This is a critical advantage.
12. **Cl_mic:** Ligand A (30.128) has a lower microsomal clearance than Ligand B (53.016), suggesting better metabolic stability.
13. **t1/2:** Ligand A (11.994) has a longer half-life than Ligand B (6.91).
14. **Pgp:** Ligand A (0.025) has a much lower Pgp efflux liability than Ligand B (0.105), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand B (-7.5) has a stronger binding affinity than Ligand A (-6.4), with a difference of 1.1 kcal/mol.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B has a better logP and affinity. However, Ligand A excels in safety parameters (DILI, hERG) and metabolic stability (Cl_mic, t1/2), and Pgp efflux. The affinity difference of 1.1 kcal/mol, while noticeable, is not substantial enough to overcome the significant advantages of Ligand A in terms of safety and ADME properties. The poor Caco-2 and solubility for both compounds are concerning, but can be addressed with formulation strategies.
**Conclusion:**
Considering the balance of properties, particularly the superior safety profile and metabolic stability of Ligand A, I believe it is the more promising drug candidate.
Output:
1
2025-04-18 00:36:37,030 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (386.361 Da) is slightly higher than Ligand B (345.403 Da), but both are acceptable.
**2. TPSA:** Ligand A (41.13) is significantly better than Ligand B (102.05). For a GPCR, especially one not explicitly targeting the CNS, a lower TPSA is generally preferred for better membrane permeability. Ligand B's TPSA is quite high, potentially hindering absorption.
**3. logP:** Ligand A (4.416) is higher than Ligand B (1.096). While both are within the acceptable range (1-3), Ligand A is pushing the upper limit. However, for a GPCR, some lipophilicity is beneficial for receptor binding. Ligand B's logP is quite low and could indicate poor membrane permeability.
**4. H-Bond Donors:** Both ligands have 2 HBD, which is within the ideal range.
**5. H-Bond Acceptors:** Ligand A has 2 HBA, while Ligand B has 6. Ligand A is preferable here, as excessive HBA can reduce permeability.
**6. QED:** Both ligands have good QED scores (A: 0.753, B: 0.845), indicating generally drug-like properties.
**7. DILI Risk:** Ligand A (53.625) has a lower DILI risk than Ligand B (62.893), making it safer.
**8. BBB Penetration:** Ligand A (80.264) shows better BBB penetration than Ligand B (63.125). While ADRB2 isn't a primary CNS target, some BBB penetration isn't detrimental and could allow for off-target effects to be evaluated.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-5.148 and -5.085). This is unusual and suggests poor permeability *in vitro*. However, the values are very similar.
**10. Aqueous Solubility:** Ligand A (-4.495) is slightly better than Ligand B (-2.092), indicating better solubility.
**11. hERG Inhibition:** Ligand A (0.692) has a lower hERG inhibition risk than Ligand B (0.082), which is a significant advantage for cardiovascular safety.
**12. Microsomal Clearance:** Both ligands have similar microsomal clearance rates (A: 23.535, B: 24.698).
**13. In vitro Half-Life:** Ligand A (2.367) has a slightly longer half-life than Ligand B (-13.31).
**14. P-gp Efflux:** Ligand A (0.229) has a much lower P-gp efflux liability than Ligand B (0.016), which is a significant advantage for bioavailability.
**15. Binding Affinity:** Ligand A (-7.1) has a significantly stronger binding affinity than Ligand B (-4.8). This is a crucial factor, and the 2.3 kcal/mol difference is substantial enough to outweigh some of the ADME concerns with Ligand A.
**Overall Assessment:**
Ligand A is the stronger candidate. While it has a slightly higher logP, its superior TPSA, lower HBA, lower DILI risk, better hERG profile, lower P-gp efflux, and *significantly* better binding affinity outweigh the minor drawbacks. Ligand B's high TPSA and low logP are concerning for permeability, and its higher P-gp efflux and weaker affinity are significant disadvantages.
Output:
1
2025-04-18 00:36:37,030 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (403.32 Da) is within the ideal range. Ligand B (335.367 Da) is also within range, but closer to the lower limit.
2. **TPSA:** Ligand A (41.57) is good, well below the 140 threshold. Ligand B (98.81) is higher, but still potentially acceptable for a peripherally acting GPCR.
3. **logP:** Ligand A (4.628) is slightly high, potentially leading to solubility issues. Ligand B (2.751) is optimal.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 3 HBA, Ligand B has 5. Both are acceptable.
6. **QED:** Both ligands have similar QED values (0.792 and 0.776), indicating good drug-likeness.
7. **DILI:** Ligand A (58.666) has a lower DILI risk than Ligand B (82.513). This is a significant advantage.
8. **BBB:** Ligand A (75.107) has better BBB penetration than Ligand B (64.754). While ADRB2 isn't exclusively a CNS target, some CNS exposure can occur, and higher BBB is generally favorable.
9. **Caco-2:** Ligand A (-4.762) and Ligand B (-5.148) both have negative Caco-2 values, indicating poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-4.497) has slightly better solubility than Ligand B (-3.824), but both are poor.
11. **hERG:** Ligand A (0.873) has a lower hERG risk than Ligand B (0.453). This is a significant advantage.
12. **Cl_mic:** Ligand A (104.797) has higher microsomal clearance than Ligand B (25.01). This means Ligand B is more metabolically stable.
13. **t1/2:** Ligand A (78.603) has a longer in vitro half-life than Ligand B (6.391). This is a significant advantage.
14. **Pgp:** Ligand A (0.846) has lower P-gp efflux than Ligand B (0.189). This is a significant advantage.
15. **Affinity:** Both ligands have very similar binding affinities (-6.0 and -5.8 kcal/mol). The difference is not substantial enough to drive the decision.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B has a better logP, but Ligand A has better TPSA, Pgp, DILI, hERG, t1/2 and BBB. The similar affinities mean these ADME properties become more important. The better metabolic stability of Ligand B is appealing, but the significantly lower DILI, hERG, Pgp efflux, and better BBB penetration of Ligand A outweigh this benefit. The poor Caco-2 values are a concern for both, but can be addressed with formulation strategies.
**Conclusion:**
Considering the balance of properties and the priorities for a GPCR target, Ligand A is the more promising drug candidate.
Output:
1
2025-04-18 00:36:37,031 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.46 and 344.51 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (78.51) is higher than Ligand B (58.87). While both are below 140, the lower TPSA of Ligand B is preferable for oral absorption, a key consideration for a cardiovascular target.
3. **logP:** Ligand A (1.366) is within the optimal 1-3 range. Ligand B (3.838) is at the higher end, potentially leading to solubility issues and off-target interactions. This favors Ligand A.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable.
5. **HBA:** Ligand A (3) and Ligand B (6) are both acceptable, but Ligand B is higher and could impact permeability.
6. **QED:** Both ligands have similar QED values (0.712 and 0.737), indicating good drug-likeness.
7. **DILI:** Ligand A (19.271) has a significantly lower DILI risk than Ligand B (59.131). This is a major advantage for Ligand A, as liver toxicity is a common concern.
8. **BBB:** Ligand B (88.949) has a higher BBB penetration than Ligand A (65.374). While ADRB2 is primarily a cardiovascular target, some CNS effects are possible with beta-blockers, and higher BBB penetration isn't necessarily detrimental.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Ligand A (-2.782) has better solubility than Ligand B (-3.935). This is important for bioavailability.
11. **hERG:** Ligand A (0.215) has a lower hERG inhibition liability than Ligand B (0.964), reducing the risk of cardiotoxicity. This is a critical advantage.
12. **Cl_mic:** Ligand A (53.958) has lower microsomal clearance than Ligand B (95.928), indicating better metabolic stability.
13. **t1/2:** Ligand A (-9.779) has a more negative in vitro half-life than Ligand B (29.127). This is unusual, and suggests a faster metabolism.
14. **Pgp:** Ligand A (0.085) has lower P-gp efflux than Ligand B (0.871), which is favorable for bioavailability.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.9 and -6.8 kcal/mol). The difference is negligible.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Ligand A has a better logP, lower TPSA, lower Pgp efflux, and comparable affinity. The significantly lower DILI and hERG risks for Ligand A are also crucial. While Ligand B has better BBB penetration, this is less critical for a primarily cardiovascular target.
**Conclusion:**
Ligand A is the more promising candidate due to its superior ADME properties (lower DILI, hERG, Cl_mic, Pgp, and better solubility) and acceptable binding affinity. The slightly higher TPSA is outweighed by these advantages.
Output:
1
2025-04-18 00:36:37,031 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's break down the comparison of Ligand A and Ligand B, keeping in mind the GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key) and the general guidelines.
1. **Molecular Weight:** Both ligands (357.439 Da and 356.423 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (92.42) is better than Ligand B (120). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally favors absorption.
3. **logP:** Ligand A (1.477) is within the optimal 1-3 range. Ligand B (-1.331) is below 1, which could hinder permeability. This is a significant advantage for Ligand A.
4. **H-Bond Donors:** Ligand A (1) is preferable to Ligand B (4). Fewer HBDs generally improve permeability.
5. **H-Bond Acceptors:** Ligand A (6) is preferable to Ligand B (5).
6. **QED:** Ligand A (0.895) is significantly better than Ligand B (0.408), indicating a more drug-like profile.
7. **DILI:** Ligand B (15.626) has a much lower DILI risk than Ligand A (75.766). This is a major advantage for Ligand B.
8. **BBB:** Ligand A (75.107) has a slightly better BBB penetration than Ligand B (60.799), but this is less critical for a cardiovascular target.
9. **Caco-2:** Ligand A (-4.865) and Ligand B (-5.094) are similar and both indicate poor permeability.
10. **Solubility:** Ligand A (-2.955) is better than Ligand B (-0.667).
11. **hERG:** Both ligands (0.219 and 0.088) have low hERG inhibition risk, which is good.
12. **Cl_mic:** Ligand B (-4.35) has a lower (better) microsomal clearance than Ligand A (11.673), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-26.729) has a longer in vitro half-life than Ligand B (-6.131).
14. **Pgp:** Both ligands (0.085 and 0.001) have low P-gp efflux liability.
15. **Binding Affinity:** Both ligands have the same binding affinity (-6.0 kcal/mol).
**Overall Assessment:**
Ligand A has advantages in logP, TPSA, QED, solubility, and half-life. However, Ligand B has a significantly lower DILI risk and better metabolic stability (lower Cl_mic). The poor Caco-2 values for both are concerning, but the superior logP and QED of Ligand A, coupled with its longer half-life, make it a more promising starting point for optimization. While DILI is important, it can often be addressed through structural modifications. The permeability issues are more challenging to fix.
Output:
1
2025-04-18 00:36:37,031 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (365.547 and 364.511 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (51.71) is significantly better than Ligand B (78.43). ADRB2 is not a CNS target, but lower TPSA generally aids absorption.
3. **logP:** Both are acceptable (1.724 and 2.943), falling within the 1-3 range. Ligand B is slightly higher, potentially leading to some solubility issues, but still reasonable.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (4). Similar to HBD, fewer HBAs are generally better for permeability.
6. **QED:** Ligand A (0.883) is better than Ligand B (0.696), indicating a more drug-like profile.
7. **DILI:** Ligand A (13.416) is *much* better than Ligand B (31.524). This is a critical advantage, as liver toxicity is a major concern.
8. **BBB:** Both ligands have similar BBB penetration (76.541 and 76.347). This isn't a primary concern for ADRB2.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.801 and -4.803). This is unusual and suggests poor permeability.
10. **Solubility:** Ligand A (-0.457) is better than Ligand B (-3.188), indicating better aqueous solubility.
11. **hERG:** Both ligands have low hERG inhibition risk (0.654 and 0.437). No significant difference.
12. **Cl_mic:** Ligand A (-24.064) is *much* better than Ligand B (68.26). Lower clearance indicates better metabolic stability.
13. **t1/2:** Ligand B (35.607) has a much longer half-life than Ligand A (-4.17). This is a significant advantage.
14. **Pgp:** Ligand A (0.023) is much better than Ligand B (0.297), indicating lower P-gp efflux.
15. **Binding Affinity:** Ligand A (-7.6) is slightly better than Ligand B (-6.9), although the difference is less than 1.5 kcal/mol.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Ligand A performs better on logP, TPSA, and Pgp. The affinity difference is small.
**Overall Assessment:**
Ligand A is significantly better overall. It has a much lower DILI risk, better metabolic stability (lower Cl_mic), better solubility, lower P-gp efflux, and a slightly better binding affinity. While Ligand B has a longer half-life, the other advantages of Ligand A outweigh this benefit. The negative Caco-2 values for both are concerning, but the other ADME properties of Ligand A are more favorable.
Output:
1
2025-04-18 00:36:37,031 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
The ADRB2 receptor is a GPCR, so the priorities are logP, TPSA, Pgp efflux, BBB penetration, and binding affinity. Metabolic stability and solubility are also important.
Let's break down the comparison:
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (380.5) is slightly higher than Ligand B (341.4).
2. **TPSA:** Ligand B (71.53) is significantly better than Ligand A (101.8). Lower TPSA generally improves permeability, which is crucial for GPCR ligands.
3. **logP:** Both ligands have acceptable logP values (Ligand A: 0.719, Ligand B: 1.087), falling within the 1-3 range. Ligand B is slightly better.
4. **H-Bond Donors:** Ligand A (2) is slightly higher than Ligand B (1), but both are within the acceptable limit of 5.
5. **H-Bond Acceptors:** Ligand A (8) is higher than Ligand B (4). This is a slight negative for Ligand A, as higher HBA can sometimes reduce permeability.
6. **QED:** Both ligands have good QED scores (Ligand A: 0.654, Ligand B: 0.786), indicating good drug-like properties. Ligand B is better.
7. **DILI:** Ligand A (86.041) has a significantly higher DILI risk than Ligand B (35.634). This is a major concern for Ligand A.
8. **BBB:** Ligand B (54.091) has a better BBB percentile than Ligand A (33.075). While not a primary concern for peripheral GPCRs like ADRB2, it's a positive attribute.
9. **Caco-2:** Ligand A (-5.727) has a worse Caco-2 permeability than Ligand B (-4.488).
10. **Solubility:** Both ligands have similar, very poor aqueous solubility (-2.664 and -2.629). This is a potential formulation challenge for both.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.147 and 0.178).
12. **Cl_mic:** Ligand B (-6.375) has a much lower (better) microsomal clearance than Ligand A (32.316), indicating greater metabolic stability.
13. **t1/2:** Ligand A (12.245) has a longer in vitro half-life than Ligand B (-0.05).
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.029 and 0.017).
15. **Binding Affinity:** Ligand A (-6.5 kcal/mol) has a slightly better binding affinity than Ligand B (-6.1 kcal/mol). However, the difference is not substantial enough to outweigh the other significant drawbacks of Ligand A.
**Overall Assessment:**
Ligand B is the superior candidate. While both have poor solubility, Ligand B excels in crucial ADME properties (lower DILI, better Caco-2, significantly lower Cl_mic) and TPSA, which are all vital for a GPCR-targeted drug. The slightly better binding affinity of Ligand A is not enough to offset its higher DILI risk and poorer metabolic stability.
**Output:**
0
2025-04-18 00:36:37,031 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Step-by-step comparison:**
1. **MW:** Ligand A (385.555 Da) is within the ideal range (200-500 Da). Ligand B (347.423 Da) is also within the ideal range. No clear advantage here.
2. **TPSA:** Ligand A (82.27) is good, below the 140 threshold for oral absorption. Ligand B (90.96) is still acceptable, but slightly higher. Ligand A is slightly preferred.
3. **logP:** Ligand A (1.713) is optimal (1-3). Ligand B (0.752) is a bit low, potentially hindering permeation. Ligand A is preferred.
4. **HBD:** Ligand A (2) is good. Ligand B (0) is also good, but might indicate lower aqueous solubility. No strong preference.
5. **HBA:** Ligand A (5) is good. Ligand B (8) is acceptable, but higher. Ligand A is slightly preferred.
6. **QED:** Both ligands (A: 0.599, B: 0.687) have good drug-likeness scores (>0.5). Ligand B is slightly better.
7. **DILI:** Ligand A (38.154) has a lower DILI risk than Ligand B (55.448). Ligand A is preferred.
8. **BBB:** Ligand A (26.134) has a lower BBB penetration than Ligand B (65.18). Since ADRB2 is a GPCR, BBB penetration is a consideration, and Ligand B is preferred.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests a potential issue with the data or modeling. However, the values are similar, so this doesn't significantly sway the decision.
10. **Solubility:** Ligand A (-2.407) has better solubility than Ligand B (-1.373). Ligand A is preferred.
11. **hERG:** Both ligands have very low hERG risk (A: 0.204, B: 0.086). No clear advantage.
12. **Cl_mic:** Ligand A (39.118) has a higher microsomal clearance than Ligand B (33.414), indicating lower metabolic stability. Ligand B is preferred.
13. **t1/2:** Ligand A (24.472) has a longer in vitro half-life than Ligand B (-14.106). Ligand A is strongly preferred.
14. **Pgp:** Both ligands have very low P-gp efflux liability (A: 0.083, B: 0.056). No clear advantage.
15. **Affinity:** Both ligands have similar binding affinities (-5.8 kcal/mol). No clear advantage.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A has better logP, TPSA, and solubility. Ligand B has better BBB penetration and lower Cl_mic. However, the difference in BBB is not substantial, and the longer half-life of Ligand A is a significant advantage.
**Overall Assessment:**
Ligand A demonstrates a better balance of properties, particularly with its favorable logP, TPSA, solubility, DILI risk, and significantly longer half-life. While Ligand B has better BBB penetration and lower Cl_mic, the other advantages of Ligand A outweigh these benefits.
Output:
1
2025-04-18 00:36:37,032 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (364.408 Da) is slightly larger than Ligand B (332.367 Da), but this difference isn't significant.
**2. TPSA:** Ligand A (58.64) is well below the 140 threshold for oral absorption and is favorable. Ligand B (70.65) is still acceptable but less optimal.
**3. logP:** Both ligands have logP values around 2.5, which is within the optimal range (1-3).
**4. H-Bond Donors & Acceptors:** Ligand A has 1 HBD and 3 HBA, while Ligand B has 0 HBD and 7 HBA. Both are within acceptable limits, but Ligand A's profile is slightly more balanced.
**5. QED:** Ligand A (0.755) has a better QED score than Ligand B (0.562), indicating a more drug-like profile.
**6. DILI Risk:** Ligand A (19.698) has a significantly lower DILI risk than Ligand B (85.033). This is a major advantage for Ligand A.
**7. BBB Penetration:** Ligand A (92.168) shows excellent BBB penetration, while Ligand B (36.371) has poor penetration. Given that ADRB2 is a GPCR, and potential CNS effects are relevant, this is a critical advantage for Ligand A.
**8. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not defined, so it is hard to interpret.
**9. Aqueous Solubility:** Both ligands have negative solubility values, suggesting poor solubility.
**10. hERG Inhibition:** Both ligands have very low hERG inhibition risk, which is excellent.
**11. Microsomal Clearance:** Ligand A (14.288) has a much lower microsomal clearance than Ligand B (43.027), indicating better metabolic stability.
**12. In vitro Half-Life:** Ligand A (-21.092) has a much longer in vitro half-life than Ligand B (-55.187), suggesting a longer duration of action.
**13. P-gp Efflux:** Ligand A (0.072) has lower P-gp efflux than Ligand B (0.294), which is favorable for bioavailability and CNS exposure.
**14. Binding Affinity:** Ligand B (-0.5 kcal/mol) has a slightly better binding affinity than Ligand A (-5.6 kcal/mol). However, the difference is not substantial enough to outweigh the other significant advantages of Ligand A.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity) and the general drug-like properties, Ligand A is the superior candidate. Its significantly lower DILI risk, excellent BBB penetration, better metabolic stability, longer half-life, and lower P-gp efflux outweigh the slightly weaker binding affinity. Ligand B's high DILI risk and poor BBB penetration are major drawbacks.
Output:
1
2025-04-18 00:36:37,032 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Ligand A (345.4) is within the ideal range (200-500), while Ligand B (384.8) is also acceptable. No clear advantage here.
2. **TPSA:** Ligand A (73.7) is good for oral absorption, well below 140. Ligand B (94.2) is still reasonable but higher. A favors here.
3. **logP:** Both ligands (A: 1.15, B: 1.37) are within the optimal 1-3 range. No significant difference.
4. **HBD:** Ligand A (0) is excellent, minimizing potential issues. Ligand B (2) is acceptable, but A is preferred.
5. **HBA:** Both ligands (A: 6, B: 6) are within the acceptable limit of 10. No difference.
6. **QED:** Both ligands (A: 0.78, B: 0.81) are good, indicating drug-likeness. B is slightly better, but not decisive.
7. **DILI:** Ligand A (51.7) has a slightly higher DILI risk than Ligand B (42.6), but both are below the concerning threshold of 60. B is preferred.
8. **BBB:** Ligand A (91.2) shows excellent BBB penetration, while Ligand B (17.6) is very low. This is a significant advantage for Ligand A, as ADRB2 is a GPCR and CNS effects are possible.
9. **Caco-2:** Ligand A (-4.53) and Ligand B (-5.12) both show poor Caco-2 permeability. This is a concern for both, but slightly worse for B.
10. **Solubility:** Ligand A (-1.68) and Ligand B (-2.18) both show poor solubility. This is a concern for both.
11. **hERG:** Both ligands (A: 0.33, B: 0.21) have low hERG inhibition risk, which is good. B is slightly better.
12. **Cl_mic:** Ligand A (68.9) has a higher microsomal clearance than Ligand B (-11.3). B is preferred.
13. **t1/2:** Ligand A (-3.58) has a negative in vitro half-life, which is concerning. Ligand B (52.5) has a good in vitro half-life. B is strongly preferred.
14. **Pgp:** Both ligands (A: 0.20, B: 0.16) have low P-gp efflux, which is good. No significant difference.
15. **Binding Affinity:** Ligand B (-7.3) has a significantly stronger binding affinity than Ligand A (-5.9) (a 1.4 kcal/mol difference). This is a substantial advantage for Ligand B.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. While both ligands have acceptable logP and Pgp, Ligand B has a significantly better binding affinity. Ligand A has a much better BBB penetration, which could be beneficial if CNS effects are desired, but the poor in vitro half-life and lower affinity are major drawbacks. The higher clearance of Ligand A is also a concern.
**Overall Assessment:**
Despite Ligand A's better BBB penetration and lower HBD, Ligand B's significantly stronger binding affinity and better metabolic stability (lower Cl_mic, better t1/2) outweigh these advantages. The poor Caco-2 and solubility are concerns for both, but can be addressed with formulation strategies.
Output:
0
2025-04-18 00:36:37,032 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (359.26 and 351.403 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (104.41) is better than Ligand B (111.89). Both are under 140, but lower TPSA generally favors absorption.
3. **logP:** Ligand A (2.06) is optimal (1-3), while Ligand B (-0.411) is below 1, which could hinder permeation. This is a significant advantage for Ligand A.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (8) is better than Ligand B (6). Both are under the 10 threshold, but lower is better.
6. **QED:** Both ligands (0.692 and 0.673) have good drug-likeness scores (>0.5). No clear winner.
7. **DILI:** Ligand A (84.684) has a significantly higher DILI risk than Ligand B (28.306). This is a major concern for Ligand A.
8. **BBB:** Ligand A (93.835) has much better BBB penetration than Ligand B (29.391). While ADRB2 isn't strictly a CNS target, some CNS exposure can be beneficial or at least not detrimental in cardiovascular indications, and high BBB penetration suggests good overall permeability.
9. **Caco-2:** Ligand A (-4.391) and Ligand B (-4.867) both have negative Caco-2 values, which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-3.253) is slightly better than Ligand B (-1.781), but both are poor. Solubility is a concern for both.
11. **hERG:** Both ligands (0.302 and 0.179) have low hERG risk, which is good. No significant difference.
12. **Cl_mic:** Ligand B (-7.121) has a much lower (better) microsomal clearance than Ligand A (73.06). This suggests better metabolic stability for Ligand B.
13. **t1/2:** Ligand B (22.357) has a significantly longer in vitro half-life than Ligand A (-31.928). This is a strong advantage for Ligand B.
14. **Pgp:** Ligand A (0.107) has lower P-gp efflux than Ligand B (0.007), which is preferable.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.6 and -6.5 kcal/mol). The difference is negligible.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, and Pgp are important. Ligand A has a better logP and Pgp profile, but Ligand B has a better TPSA. However, the DILI risk for Ligand A is very high, and the metabolic stability (Cl_mic and t1/2) are significantly worse than Ligand B.
**Overall Assessment:**
Despite Ligand A's slightly better logP and Pgp, the significantly higher DILI risk and poorer metabolic stability are major drawbacks. Ligand B, while having a less optimal logP, presents a much safer profile with lower DILI risk, better metabolic stability, and a longer half-life. The similar binding affinities make the ADME/Tox profile the deciding factor.
Output:
0
2025-04-18 00:36:37,032 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (348.49 and 342.44 Da) fall comfortably within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (78.43) is significantly better than Ligand B (97.78). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand A is well below the 140 threshold, while B is approaching it.
3. **logP:** Both ligands have acceptable logP values (1.85 and 2.57), falling within the 1-3 range. Ligand B is slightly higher, which could potentially lead to slight solubility issues but isn't a major concern.
4. **HBD & HBA:** Both ligands have 3 HBD and 3 HBA, which is within acceptable limits.
5. **QED:** Ligand A (0.557) has a slightly better QED score than Ligand B (0.45), indicating a more drug-like profile.
6. **DILI:** Ligand A (7.45) has a much lower DILI risk than Ligand B (42.30). This is a significant advantage for Ligand A.
7. **BBB:** Ligand A (49.98) has a lower BBB penetration than Ligand B (54.13). While ADRB2 isn't necessarily a CNS target, some degree of BBB penetration can be useful for off-target effects assessment. This is a slight advantage for Ligand B.
8. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual. It's difficult to interpret without knowing the scale, but it suggests poor permeability. However, Ligand A (-4.65) is better than Ligand B (-4.88).
9. **Solubility:** Both ligands have negative solubility values, indicating poor aqueous solubility. Ligand A (-3.11) is slightly better than Ligand B (-4.72).
10. **hERG:** Ligand A (0.144) has a significantly lower hERG inhibition liability than Ligand B (0.547). This is a crucial advantage, minimizing the risk of cardiotoxicity.
11. **Cl_mic:** Ligand B (47.56) has slightly lower microsomal clearance than Ligand A (36.45), suggesting better metabolic stability.
12. **t1/2:** Ligand B (-15.36) has a much longer in vitro half-life than Ligand A (-5.10). This is a significant advantage, potentially leading to less frequent dosing.
13. **Pgp:** Ligand A (0.023) has a much lower P-gp efflux liability than Ligand B (0.364), which is beneficial for oral bioavailability and potentially CNS exposure.
14. **Binding Affinity:** Ligand B (-6.6 kcal/mol) has a slightly better binding affinity than Ligand A (-5.8 kcal/mol). This is a 0.8 kcal/mol difference, which is a noticeable advantage.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand A emerges as the more promising candidate. While Ligand B has slightly better affinity and half-life, Ligand A excels in crucial safety parameters (DILI, hERG) and permeability-related properties (TPSA, Pgp). The lower DILI and hERG risks are particularly important for a cardiovascular target like ADRB2. The slightly better TPSA and Pgp values of Ligand A also contribute to a more favorable ADME profile. The solubility and Caco-2 values are poor for both, but Ligand A is slightly better.
Output:
1
2025-04-18 00:36:37,032 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (367.515 and 371.413 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (62.21) is better than Ligand B (71.33). Both are below 140, but lower TPSA generally favors better absorption.
3. **logP:** Ligand A (1.991) is better than Ligand B (0.608). Both are within the optimal range of 1-3, but Ligand B is closer to the lower limit, which could potentially hinder permeation.
4. **HBD:** Both ligands have 0 HBD, which is good.
5. **HBA:** Ligand A (5) is better than Ligand B (6). Both are acceptable, but lower is slightly preferred.
6. **QED:** Both ligands have similar QED values (0.746 and 0.776), indicating good drug-likeness.
7. **DILI:** Ligand A (30.787) is significantly better than Ligand B (62.156). Ligand A is well below the 40% threshold for low risk, while Ligand B is approaching the higher risk zone.
8. **BBB:** Ligand B (71.074) is better than Ligand A (63.358). While ADRB2 isn't exclusively a CNS target, some CNS exposure could be beneficial or at least not detrimental, and higher BBB is generally favorable.
9. **Caco-2:** Ligand A (-4.768) is better than Ligand B (-4.947). Higher values indicate better intestinal absorption.
10. **Solubility:** Ligand A (-2.408) is better than Ligand B (-2.232). Higher solubility is preferred.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.18 and 0.123), which is excellent.
12. **Cl_mic:** Ligand B (18.016) is significantly better than Ligand A (46.523). Lower clearance indicates greater metabolic stability.
13. **t1/2:** Ligand A (-9.014) is better than Ligand B (-3.629). Longer half-life is generally preferred.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.096 and 0.063).
15. **Binding Affinity:** Ligand B (-7.8) is significantly better than Ligand A (-5.6). This is a 2.2 kcal/mol difference, which is a substantial advantage and can outweigh some ADME drawbacks.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B has a better BBB score, which is a plus. However, the significantly stronger binding affinity of Ligand B (-7.8 vs -5.6) is the most important factor. While Ligand A has better DILI and solubility, the improved metabolic stability (lower Cl_mic) of Ligand B is also a significant advantage. The slightly lower logP of Ligand B is a minor concern, but the substantial affinity difference outweighs it.
**Conclusion:**
Despite Ligand A's advantages in DILI and solubility, the significantly stronger binding affinity and improved metabolic stability of Ligand B make it the more promising drug candidate for the ADRB2 receptor.
Output:
0
2025-04-18 00:36:37,033 - INFO - Batch 490 complete. Total preferences: 7840
2025-04-18 00:36:37,033 - INFO - Processing batch 491/512...
2025-04-18 00:37:26,270 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (353.463 Da) is slightly lower, which could be beneficial for permeability.
2. **TPSA:** Both are good, below the 140 A^2 threshold for oral absorption. Ligand B (71.09) is better than Ligand A (89.95) - lower TPSA generally favors better cell penetration.
3. **logP:** Ligand A (0.227) is quite low, potentially leading to poor membrane permeability. Ligand B (4.071) is higher, approaching the upper limit but still acceptable. This is a significant advantage for Ligand B.
4. **HBD/HBA:** Both have 2 HBD and 4 HBA, which are within acceptable limits.
5. **QED:** Both have good QED scores (A: 0.669, B: 0.711), indicating drug-likeness. Ligand B is slightly better.
6. **DILI:** Ligand A (18.185) has a much lower DILI risk than Ligand B (77.782). This is a major advantage for Ligand A.
7. **BBB:** Ligand A (38.465) has a low BBB penetration, while Ligand B (52.656) is also low. Since ADRB2 is a cardiovascular target, BBB penetration is not a primary concern.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability.
9. **Solubility:** Ligand A (-0.953) has slightly better solubility than Ligand B (-5.149).
10. **hERG:** Both have low hERG inhibition risk (A: 0.152, B: 0.719), which is good.
11. **Cl_mic:** Ligand A (4.092) has a much lower microsomal clearance, indicating better metabolic stability than Ligand B (74.676).
12. **t1/2:** Ligand A (-4.348) has a negative in vitro half-life, which is concerning. Ligand B (46.382) has a good half-life.
13. **Pgp:** Both have low P-gp efflux liability (A: 0.022, B: 0.492).
14. **Binding Affinity:** Ligand B (-6.2 kcal/mol) has a slightly better binding affinity than Ligand A (-5.6 kcal/mol). This is a meaningful difference.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, and affinity are particularly important. Ligand B excels in logP and has a slightly better affinity. While TPSA is better for Ligand A, the poor logP of Ligand A is a significant drawback. The DILI score for Ligand A is very attractive, but the poor metabolic stability (high Cl_mic) and negative half-life are concerning. Ligand B's higher DILI risk is a trade-off that I'm willing to accept given its better ADME profile overall.
**Conclusion:**
Considering the balance of properties, particularly for a GPCR target, Ligand B is the more promising candidate. The better logP, affinity, and metabolic stability outweigh the higher DILI risk.
Output:
0
2025-04-18 00:37:26,271 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (354.491 and 348.447 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (76.66) is better than Ligand B (87.46). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (2.57) is better than Ligand B (0.873). Both are within the 1-3 range, but Ligand A is closer to the optimal value. Ligand B is a bit low and might have permeability issues.
4. **HBD:** Both ligands have 2 HBD, which is within the acceptable limit of <=5.
5. **HBA:** Ligand A (4) is better than Ligand B (5). Lower HBA is generally preferred for better permeability.
6. **QED:** Both ligands have good QED scores (0.591 and 0.683), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (42.458) is significantly better than Ligand B (18.728). Lower DILI risk is crucial.
8. **BBB:** Ligand A (71.811) is better than Ligand B (39.705). While not a CNS target, some distribution to the CNS is possible, and higher BBB is generally favorable.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.175 and -5.034), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand A (-2.908) is better than Ligand B (-1.544). Higher solubility is important for bioavailability.
11. **hERG:** Both ligands have low hERG inhibition risk (0.343 and 0.31), which is excellent.
12. **Cl_mic:** Ligand A (32.382) is better than Ligand B (0.589). Lower clearance indicates better metabolic stability.
13. **t1/2:** Ligand A (11.275) is better than Ligand B (-10.032). A longer half-life is generally preferred.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.061 and 0.066).
15. **Binding Affinity:** Ligand A (-5.8) is slightly better than Ligand B (-5.3). While both are good, the 0.5 kcal/mol difference is noticeable.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A performs better in logP, TPSA, and affinity.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical ADME properties (DILI, Cl_mic, t1/2, solubility) and has a slightly better binding affinity. While both have poor Caco-2 permeability, the other advantages of Ligand A make it the more promising candidate. The lower DILI risk is a major factor.
Output:
1
2025-04-18 00:37:26,271 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands are within the acceptable range (200-500 Da). Ligand B (342.439 Da) is significantly smaller than Ligand A (468.372 Da), which is generally favorable for permeability.
**2. TPSA:** Ligand B (69.64) is well below the 140 threshold and preferable for oral absorption. Ligand A (106.61) is still reasonable, but less optimal.
**3. logP:** Both ligands have good logP values (A: 2.643, B: 1.109) falling within the 1-3 range. Ligand A is slightly better.
**4. H-Bond Donors/Acceptors:** Ligand A (HBD=1, HBA=7) and Ligand B (HBD=2, HBA=3) both have acceptable numbers of hydrogen bond donors and acceptors.
**5. QED:** Both ligands have acceptable QED scores (A: 0.654, B: 0.459), but Ligand A is better.
**6. DILI:** Ligand B (33.307) has a much lower DILI risk than Ligand A (98.449). This is a significant advantage for Ligand B.
**7. BBB:** Ligand A (61.923) has a better BBB penetration score than Ligand B (35.052). While ADRB2 isn't exclusively a CNS target, some CNS exposure could be beneficial or at least needs to be considered.
**8. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual. I will interpret this as very poor permeability.
**9. Aqueous Solubility:** Both ligands have negative solubility values, which is also unusual. I will interpret this as very poor solubility.
**10. hERG Inhibition:** Ligand B (0.54) has a slightly higher hERG inhibition risk than Ligand A (0.363).
**11. Microsomal Clearance:** Ligand A (27.231) has a lower microsomal clearance than Ligand B (56.043), indicating better metabolic stability.
**12. In vitro Half-Life:** Ligand A (95.428) has a much longer in vitro half-life than Ligand B (2.97).
**13. P-gp Efflux:** Ligand A (0.531) has a lower P-gp efflux liability than Ligand B (0.267).
**14. Binding Affinity:** Ligand B (-7.0 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.0 kcal/mol). This is a crucial advantage.
**GPCR-Specific Priorities:** For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B excels in affinity and has a better TPSA and Pgp profile. While Ligand A has a slightly better logP and BBB, the substantial difference in binding affinity and the significantly lower DILI risk of Ligand B outweigh these factors. The poor permeability and solubility of both compounds are concerning, but the stronger binding of Ligand B suggests it might be optimized more effectively.
**Conclusion:**
Considering the balance of properties, particularly the significantly stronger binding affinity and lower DILI risk, Ligand B is the more promising drug candidate.
0
2025-04-18 00:37:26,271 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [368.434, 75.63, 1.379, 0, 6, 0.785, 54.634, 75.843, -4.573, -1.702, 0.142, 34.793, -7.806, 0.036, -5.6]
**Ligand B:** [346.427, 78.87, 1.601, 2, 4, 0.786, 36.758, 40.52, -4.572, -2.007, 0.532, 37.604, -22.865, 0.227, -6.3]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (346.43) is slightly lower, which could be advantageous for permeability, but both are acceptable.
2. **TPSA:** Both are reasonably good (75.63 and 78.87), being under 140. This suggests decent oral absorption potential.
3. **logP:** Both are within the optimal range (1-3). Ligand B is slightly higher at 1.601, which might slightly improve membrane permeability.
4. **HBD:** Ligand A has 0 HBD, while Ligand B has 2. Lower HBD is generally preferred for permeability, giving a slight edge to Ligand A.
5. **HBA:** Ligand A has 6 HBA, and Ligand B has 4. Both are under the limit of 10.
6. **QED:** Both have similar QED values (0.785 and 0.786), indicating good drug-like properties.
7. **DILI:** Ligand A (54.634) has a higher DILI risk than Ligand B (36.758). This is a significant concern, as lower DILI is crucial.
8. **BBB:** Ligand A (75.843) has a significantly better BBB penetration potential than Ligand B (40.52). This is a key consideration for a GPCR target.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests a potential issue with permeability prediction. This needs further investigation, but we'll assume they are similarly poor for now.
10. **Solubility:** Both have negative solubility values, also unusual. Again, assuming similar issues.
11. **hERG:** Ligand A (0.142) has a much lower hERG inhibition liability than Ligand B (0.532). This is a major advantage, as hERG inhibition can lead to cardiotoxicity.
12. **Cl_mic:** Ligand A (34.793) has a lower microsomal clearance than Ligand B (37.604), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-22.865) has a significantly longer in vitro half-life than Ligand A (-7.806). This is a positive for dosing frequency.
14. **Pgp:** Ligand A (0.036) has a lower P-gp efflux liability than Ligand B (0.227), which is beneficial for bioavailability and potentially CNS exposure.
15. **Affinity:** Ligand B (-6.3) has a slightly better binding affinity than Ligand A (-5.6). This is a 1.5 kcal/mol difference, which is significant.
**GPCR-Specific Priorities:** For ADRB2 (a GPCR), we prioritize logP, Pgp, TPSA, BBB, and affinity.
**Overall Assessment:**
Ligand B has a better affinity and half-life. However, Ligand A has a much better safety profile (lower DILI, lower hERG), better BBB penetration, and lower P-gp efflux. The affinity difference is significant, but the safety concerns with Ligand B are substantial. Given the cardiovascular implications of ADRB2 modulation, minimizing hERG risk is paramount. The better BBB penetration of Ligand A is also a plus.
Therefore, despite the slightly weaker binding affinity, Ligand A appears to be the more promising candidate due to its superior safety and pharmacokinetic properties.
Output:
1
2025-04-18 00:37:26,272 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.359 and 361.427 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (106.1) is significantly better than Ligand A (126.32). Lower TPSA generally favors oral absorption, a key consideration for a cardiovascular drug.
3. **logP:** Ligand B (1.088) is slightly better than Ligand A (0.78), both are within the optimal 1-3 range.
4. **HBD:** Ligand B (2) has fewer HBD than Ligand A (3), which is slightly preferable.
5. **HBA:** Ligand B (7) has slightly more HBA than Ligand A (6). This is not a major concern as both are under the 10 threshold.
6. **QED:** Ligand B (0.765) is slightly better than Ligand A (0.635), indicating a more drug-like profile.
7. **DILI:** Ligand B (68.903) has a lower DILI risk than Ligand A (72.509), which is a significant advantage.
8. **BBB:** Both ligands have relatively low BBB penetration (Ligand A: 40.597, Ligand B: 38.542). This is not a major concern for a cardiovascular target, as CNS penetration is not desired.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.233 and -5.627), which is unusual and suggests poor permeability. However, these values are on a scale where negative values are possible and don't necessarily preclude development.
10. **Solubility:** Ligand B (-2.088) is better than Ligand A (-3.581), indicating better aqueous solubility.
11. **hERG:** Ligand B (0.047) has a much lower hERG inhibition liability than Ligand A (0.225), a critical advantage for cardiovascular drugs to minimize cardiotoxicity risk.
12. **Cl_mic:** Ligand B (-8.849) has a much lower (better) microsomal clearance than Ligand A (42.436), indicating better metabolic stability.
13. **t1/2:** Ligand A (38.19) has a longer in vitro half-life than Ligand B (17.878). This is a positive for Ligand A, but can be offset by the other advantages of Ligand B.
14. **Pgp:** Ligand B (0.017) has a much lower P-gp efflux liability than Ligand A (0.098), which is beneficial for oral bioavailability.
15. **Binding Affinity:** Ligand A (-6.8 kcal/mol) has a better binding affinity than Ligand B (-4.5 kcal/mol). This is a significant advantage, but the other ADME properties of Ligand B are more favorable overall.
**Overall Assessment:**
While Ligand A has a better binding affinity, Ligand B demonstrates a significantly more favorable ADME profile. Specifically, the lower DILI risk, lower hERG inhibition, lower microsomal clearance, and lower P-gp efflux are crucial advantages for a cardiovascular drug candidate. The slightly better solubility and QED of Ligand B further support its selection. The longer half-life of Ligand A is a positive, but the substantial improvements in safety and pharmacokinetic properties with Ligand B outweigh this benefit. Considering the GPCR-specific priorities, the balance of properties makes Ligand B the more promising candidate.
Output:
0
2025-04-18 00:37:26,272 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (351.359) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (42.43) is significantly better than Ligand A (102.18). For a GPCR, lower TPSA is preferred for better brain penetration and overall permeability.
3. **logP:** Ligand B (3.503) is optimal, while Ligand A (0.208) is very low, potentially hindering membrane permeability and bioavailability. This is a major drawback for Ligand A.
4. **HBD:** Both have 0 HBD, which is acceptable.
5. **HBA:** Ligand A (7) is higher than Ligand B (4), but both are within reasonable limits.
6. **QED:** Both ligands have similar and good QED scores (0.714 and 0.725).
7. **DILI:** Ligand B (49.399) has a lower DILI risk than Ligand A (62.001), which is a positive.
8. **BBB:** Ligand B (87.515) has a much higher BBB penetration percentile than Ligand A (62.195). While ADRB2 isn't exclusively a CNS target, some brain exposure is possible, and higher BBB is generally favorable.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. However, the scale is not specified, so it is difficult to interpret.
10. **Solubility:** Ligand A (-1.644) has better solubility than Ligand B (-4.941).
11. **hERG:** Both have very low hERG inhibition liability (0.031 and 0.55).
12. **Cl_mic:** Ligand A (-7.071) has a much lower (better) microsomal clearance than Ligand B (113.513), indicating better metabolic stability.
13. **t1/2:** Ligand B (-26.949) has a much longer in vitro half-life than Ligand A (-5.54).
14. **Pgp:** Ligand A (0.056) has lower P-gp efflux liability than Ligand B (0.184), which is favorable.
15. **Affinity:** Both ligands have excellent binding affinity (-5.8 and -5.6 kcal/mol), with Ligand A being slightly better. However, the difference is not substantial enough to override the significant ADME deficiencies of Ligand A.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP and TPSA, and has acceptable Pgp. While Ligand A has slightly better affinity and Pgp, its extremely low logP and higher TPSA are significant drawbacks. The longer half-life of ligand B is also a plus.
**Conclusion:**
Despite Ligand A's slightly better affinity and lower Pgp efflux, Ligand B is the more promising candidate due to its superior logP, TPSA, BBB penetration, lower DILI risk, and longer half-life. These factors are crucial for a GPCR target, outweighing the small difference in binding affinity.
Output:
0
2025-04-18 00:37:26,272 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (356.394) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (58.64) is significantly better than Ligand A (92.01). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally aids absorption.
3. **logP:** Ligand B (3.082) is optimal, while Ligand A (0.665) is quite low. Low logP can hinder membrane permeability. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1), but both are within the acceptable limit of 5.
5. **HBA:** Ligand A (5) is slightly higher than Ligand B (4), but both are within the acceptable limit of 10.
6. **QED:** Both ligands have good QED scores (A: 0.749, B: 0.851), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (35.595) has a much lower DILI risk than Ligand B (50.601). This is a significant advantage for Ligand A.
8. **BBB:** Ligand B (79.488) has better BBB penetration than Ligand A (64.831). However, as ADRB2 is a cardiovascular target, BBB penetration is not a high priority.
9. **Caco-2:** Both ligands have similar, poor Caco-2 permeability (-4.895 and -4.736).
10. **Solubility:** Ligand A (-1.384) has better solubility than Ligand B (-4.23).
11. **hERG:** Both ligands have low hERG inhibition risk (A: 0.24, B: 0.432).
12. **Cl_mic:** Ligand A (5.048) has significantly lower microsomal clearance than Ligand B (30.796), suggesting better metabolic stability.
13. **t1/2:** Ligand B (8.585) has a longer in vitro half-life than Ligand A (2.1).
14. **Pgp:** Ligand A (0.027) has much lower P-gp efflux liability than Ligand B (0.57). This suggests better oral bioavailability and potentially better tissue distribution for Ligand A.
15. **Binding Affinity:** Ligand B (-7.4) has a significantly stronger binding affinity than Ligand A (-5.2). This is a substantial advantage, potentially outweighing some ADME concerns.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP and affinity, while Ligand A has better TPSA and Pgp.
**Overall Assessment:**
The significantly stronger binding affinity of Ligand B (-7.4 vs -5.2) is the most important factor. While Ligand A has advantages in DILI, Cl_mic, solubility, and Pgp, the 2.2 kcal/mol difference in binding affinity is substantial and likely to be critical for efficacy. The slightly higher DILI risk and lower metabolic stability of Ligand B can be addressed through further optimization. The poor Caco-2 values for both compounds suggest formulation work would be needed regardless.
Output:
0
2025-04-18 00:37:26,272 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (403.28 Da) is within the ideal range. Ligand B (352.435 Da) is also within the ideal range. No clear advantage here.
2. **TPSA:** Ligand A (59.73) is excellent, well below the 140 threshold. Ligand B (118.55) is still acceptable but higher, potentially impacting absorption.
3. **logP:** Ligand A (3.335) is optimal. Ligand B (0.127) is very low, which is a significant concern for membrane permeability and bioavailability.
4. **HBD:** Ligand A (0) is good. Ligand B (4) is acceptable, but higher HBD can sometimes lead to issues.
5. **HBA:** Ligand A (5) is good. Ligand B (5) is also good.
6. **QED:** Both ligands (A: 0.656, B: 0.6) have good drug-likeness scores.
7. **DILI:** Ligand A (72.043) is acceptable, but higher than ideal. Ligand B (36.603) is very good, indicating low liver injury risk.
8. **BBB:** Both ligands have similar BBB penetration (A: 73.594, B: 36.758). Since ADRB2 is a cardiovascular target, BBB penetration is not a high priority.
9. **Caco-2:** Ligand A (-4.728) is poor. Ligand B (-5.39) is also poor.
10. **Solubility:** Ligand A (-3.656) is poor. Ligand B (-1.875) is also poor.
11. **hERG:** Ligand A (0.755) is acceptable. Ligand B (0.289) is very good, indicating low cardiotoxicity risk.
12. **Cl_mic:** Ligand A (107.195) is moderate. Ligand B (-25.446) is excellent, suggesting high metabolic stability.
13. **t1/2:** Ligand A (37.57) is good. Ligand B (1.365) is very poor, indicating rapid clearance.
14. **Pgp:** Ligand A (0.775) is acceptable. Ligand B (0.045) is very good, suggesting low efflux.
15. **Affinity:** Ligand A (-6.4) is good. Ligand B (-3.0) is moderate, but significantly weaker.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are particularly important. Ligand A has a much better logP and significantly better binding affinity. While Ligand B has better DILI, hERG, and Pgp, the poor logP and much weaker binding affinity are major drawbacks. The affinity difference of 3.4 kcal/mol is substantial and likely outweighs the benefits of slightly better safety parameters.
**Conclusion:**
Despite Ligand B's advantages in safety and metabolic stability, Ligand A's superior binding affinity and more favorable logP make it the more promising candidate for further development as a drug targeting ADRB2.
Output:
1
2025-04-18 00:37:26,272 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (356.394 Da and 349.391 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (92.01) is better than Ligand B (121.23). For a GPCR, keeping TPSA under 140 is good for oral absorption, and lower is generally preferred. Ligand B is getting closer to a concerning range.
**3. logP:** Ligand B (1.641) is better than Ligand A (0.665). The optimal range is 1-3, and Ligand B falls comfortably within it. Ligand A is a bit low, potentially hindering membrane permeability.
**4. H-Bond Donors:** Both ligands have 2 HBD, which is within the acceptable limit of 5.
**5. H-Bond Acceptors:** Both ligands have 5 HBA, within the acceptable limit of 10.
**6. QED:** Ligand A (0.749) has a substantially better QED score than Ligand B (0.459). A higher QED suggests better overall drug-likeness.
**7. DILI Risk:** Ligand A (35.595) has a significantly lower DILI risk than Ligand B (63.94). This is a crucial factor, as liver toxicity is a major concern in drug development.
**8. BBB Penetration:** Ligand B (71.268) shows better BBB penetration than Ligand A (64.831). While ADRB2 is a cardiovascular target, some CNS effects are possible with beta-blockers, and some degree of BBB penetration might be acceptable or even desirable for certain applications. However, this isn't a primary driver for this target.
**9. Caco-2 Permeability:** Ligand A (-4.895) is better than Ligand B (-5.017). Higher values indicate better intestinal absorption.
**10. Aqueous Solubility:** Ligand A (-1.384) is better than Ligand B (-3.423). Better solubility is generally preferred.
**11. hERG Inhibition:** Both ligands have similar, low hERG inhibition risk (0.24 and 0.27). This is good.
**12. Microsomal Clearance:** Ligand A (5.048) has a lower microsomal clearance than Ligand B (8.305), indicating better metabolic stability.
**13. In vitro Half-Life:** Ligand A (2.1) has a shorter half-life than Ligand B (-25.044). A negative value for half-life is unusual and suggests a very long half-life, which could be positive.
**14. P-gp Efflux:** Both ligands have similar P-gp efflux liability (0.027 and 0.118).
**15. Binding Affinity:** Ligand B (-6.4) has a slightly better binding affinity than Ligand A (-5.2). A 1.2 kcal/mol difference is significant, but not overwhelmingly so.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity) alongside general drug-like properties, Ligand A is the more promising candidate. While Ligand B has a slightly better binding affinity and BBB penetration, Ligand A excels in crucial areas like DILI risk, QED, solubility, and metabolic stability. The lower DILI risk and higher QED are particularly important. The slightly lower logP of Ligand A is a minor concern that could potentially be addressed through further optimization, but the overall profile of Ligand A is more favorable for development. The very long half-life of Ligand B is also a bit concerning and requires further investigation.
Output:
1
2025-04-18 00:37:26,272 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (351.447 and 354.491 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (98.74) is higher than Ligand B (67.87). For a cardiovascular GPCR, TPSA is not a primary concern unless CNS penetration is desired, but lower is generally preferred for oral absorption. Ligand B is better.
3. **logP:** Ligand A (0.027) is quite low, potentially hindering membrane permeability. Ligand B (1.827) is within the optimal 1-3 range. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (3) is higher than Ligand B (1). While both are acceptable, lower HBD can improve permeability. Ligand B is slightly better.
5. **HBA:** Both ligands have 4 HBA, which is within the acceptable range. No significant difference.
6. **QED:** Ligand B (0.757) has a better QED score than Ligand A (0.602), indicating a more drug-like profile.
7. **DILI:** Ligand B (20.24) has a significantly lower DILI risk than Ligand A (31.563). This is a crucial advantage for Ligand B.
8. **BBB:** Ligand B (69.252) has a higher BBB percentile than Ligand A (33.734). While ADRB2 isn't exclusively a CNS target, some CNS exposure could be relevant, and higher BBB is generally favorable. Ligand B is better.
9. **Caco-2:** Ligand A (-5.19) is significantly worse than Ligand B (-4.485), indicating lower intestinal absorption. Ligand B is better.
10. **Solubility:** Ligand A (-1.909) is slightly better than Ligand B (-2.356), but both are poor. Solubility is not a major concern if absorption is good.
11. **hERG:** Ligand A (0.104) has a slightly lower hERG risk than Ligand B (0.378), but both are relatively low.
12. **Cl_mic:** Ligand A (14.218) has lower microsomal clearance than Ligand B (33.611), suggesting better metabolic stability. Ligand A is better.
13. **t1/2:** Ligand A (13.818) has a longer in vitro half-life than Ligand B (0.55). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.037) has lower P-gp efflux than Ligand B (0.065), suggesting better bioavailability. Ligand A is better.
15. **Binding Affinity:** Ligand B (-6.1) has a slightly better binding affinity than Ligand A (-5.6). While not a huge difference, it's a positive for Ligand B.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand B is the stronger candidate. It has a much better logP, lower TPSA, significantly lower DILI risk, better Caco-2 permeability, and higher BBB penetration. While Ligand A has better metabolic stability (Cl_mic and t1/2) and Pgp properties, the advantages of Ligand B in absorption, safety (DILI), and binding affinity outweigh these factors. The slightly better affinity of Ligand B is also a plus.
Output:
0
2025-04-18 00:37:26,273 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.463 and 337.343 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (87.46) is better than Ligand B (98.06). Both are below 140, but lower is preferred for oral absorption, and ADRB2 is not a CNS target, so we don't need to be overly strict about the <90 rule.
3. **logP:** Both ligands have acceptable logP values (1.021 and 1.375), falling within the 1-3 range. Ligand B is slightly higher, which *could* be a minor advantage for membrane permeability, but it's not substantial.
4. **HBD:** Ligand A (2) is slightly better than Ligand B (1). Both are within the acceptable limit of 5.
5. **HBA:** Ligand A (5) is better than Ligand B (7). Both are within the acceptable limit of 10, but lower is generally preferred.
6. **QED:** Ligand A (0.83) is significantly better than Ligand B (0.755), indicating a more drug-like profile.
7. **DILI:** Ligand A (39.356) is *much* better than Ligand B (94.765). This is a critical advantage, as lower DILI risk is paramount.
8. **BBB:** This is less critical for ADRB2 (a cardiovascular target), but Ligand B (60.993) is higher than Ligand A (34.238).
9. **Caco-2:** Both ligands have very poor Caco-2 permeability (-4.992 and -4.926). This is a significant concern for both, suggesting poor oral absorption.
10. **Solubility:** Both ligands have very poor aqueous solubility (-2.429 and -2.453). This is a significant concern for both, and would require formulation work.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.115 and 0.182), which is excellent.
12. **Cl_mic:** Ligand A (53.973) is better than Ligand B (15.738), indicating better metabolic stability.
13. **t1/2:** Ligand A (13.838) is better than Ligand B (-0.745). This is a significant advantage for dosing frequency.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.022 and 0.027), which is good.
15. **Binding Affinity:** Ligand B (-7.5 kcal/mol) is 1.1 kcal/mol stronger than Ligand A (-6.4 kcal/mol). This is a substantial difference in potency.
**Overall Assessment:**
While Ligand B has a significantly better binding affinity, the substantial drawbacks in DILI risk (much higher) and metabolic stability (much higher Cl_mic, shorter half-life) are major concerns. Ligand A demonstrates a much more balanced profile, with better QED, significantly lower DILI risk, better metabolic stability, and a reasonable half-life. The poor Caco-2 and solubility are shared concerns, but can be addressed with formulation strategies. The affinity difference, while notable, can potentially be optimized in later stages of drug development. Given the GPCR-specific priorities (logP, Pgp, TPSA, affinity), and the overall balance of properties, Ligand A is the more promising candidate.
Output:
1
2025-04-18 00:37:26,273 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (367.555 Da and 349.431 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (55.4) is significantly better than Ligand B (84.67). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is pushing the upper limit for good oral absorption.
**3. logP:** Ligand A (3.617) is within the optimal range (1-3), while Ligand B (1.767) is at the lower end. While not terrible, lower logP can sometimes indicate poorer membrane permeability.
**4. H-Bond Donors:** Both have 1 HBD, which is good.
**5. H-Bond Acceptors:** Ligand A has 3 HBA, Ligand B has 5. Both are acceptable, but lower is generally preferred.
**6. QED:** Both ligands have good QED scores (0.755 and 0.895), indicating good drug-like properties.
**7. DILI:** Ligand A (35.789) has a slightly better DILI score than Ligand B (40.83), indicating a lower risk of liver injury. Both are acceptable.
**8. BBB:** Ligand B (77.705) has a significantly higher BBB penetration score than Ligand A (57.774). While ADRB2 is a cardiovascular target, some CNS effects are possible with beta-blockers, and higher BBB penetration could be a concern, but not a dealbreaker.
**9. Caco-2 Permeability:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not defined, so it's difficult to interpret.
**10. Aqueous Solubility:** Ligand A (-5.392) has worse solubility than Ligand B (-1.706). Solubility is important, but can often be improved with formulation.
**11. hERG Inhibition:** Ligand A (0.617) has a better hERG score than Ligand B (0.231), meaning lower risk of cardiotoxicity. This is a critical parameter for cardiovascular drugs.
**12. Microsomal Clearance:** Ligand A (53.538) has higher microsomal clearance than Ligand B (46.74), suggesting faster metabolism. Lower clearance is preferred.
**13. In vitro Half-Life:** Ligand B (-25.594) has a better in vitro half-life than Ligand A (-31.774). Longer half-life is generally desirable.
**14. P-gp Efflux:** Ligand A (0.45) has better P-gp efflux liability than Ligand B (0.071). Lower efflux is preferred.
**15. Binding Affinity:** Ligand A (-8.0) has a significantly stronger binding affinity than Ligand B (-6.2). This is a substantial difference (1.8 kcal/mol), and often outweighs minor ADME drawbacks.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand A is the stronger candidate. The significantly better binding affinity (-8.0 vs -6.2) is a major advantage. While Ligand B has better BBB penetration and solubility, the lower TPSA, better hERG, and better P-gp efflux of Ligand A are more important for a cardiovascular GPCR target. The slightly higher clearance of Ligand A can be addressed through structural modifications.
Output:
1
2025-04-18 00:37:26,273 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (351.412 and 351.403 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (21.26) is significantly lower than Ligand B (96.11). For a GPCR, lower TPSA is generally preferred as it correlates with better membrane permeability. Ligand B's TPSA is quite high, potentially hindering absorption.
**3. logP:** Ligand A (4.869) is higher than Ligand B (0.656). While both are within the acceptable range, Ligand A is approaching the upper limit and could potentially have solubility issues. Ligand B is quite low, potentially impacting permeability.
**4. H-Bond Donors:** Both ligands have 1 HBD, which is within the ideal range.
**5. H-Bond Acceptors:** Ligand A has 2 HBA, while Ligand B has 6. Ligand B's higher HBA count contributes to its higher TPSA and could negatively impact permeability.
**6. QED:** Both ligands have good QED scores (0.651 and 0.809), indicating good drug-like properties.
**7. DILI Risk:** Ligand A (19.116) has a much lower DILI risk than Ligand B (39.434). This is a significant advantage for Ligand A.
**8. BBB Penetration:** Ligand A (77.705) has better BBB penetration than Ligand B (64.87). While ADRB2 is primarily a cardiovascular target, some CNS off-target effects are possible with GPCR ligands, making some BBB penetration a consideration.
**9. Caco-2 Permeability:** Ligand A (-4.732) has better Caco-2 permeability than Ligand B (-4.54).
**10. Aqueous Solubility:** Ligand A (-3.888) has slightly better aqueous solubility than Ligand B (-1.216).
**11. hERG Inhibition:** Ligand A (0.993) has a slightly higher hERG inhibition risk than Ligand B (0.214). This is a minor concern for Ligand A, but Ligand B is much better.
**12. Microsomal Clearance:** Ligand A (29.123) has higher microsomal clearance than Ligand B (6.019), meaning it's metabolized faster. This is a disadvantage for Ligand A.
**13. In vitro Half-Life:** Ligand A (-10.146) has a much shorter in vitro half-life than Ligand B (0.433). This is a significant disadvantage for Ligand A.
**14. P-gp Efflux:** Ligand A (0.929) has higher P-gp efflux than Ligand B (0.089). This is a disadvantage for Ligand A.
**15. Binding Affinity:** Both ligands have very similar binding affinities (-5.7 and -5.9 kcal/mol). The difference is negligible.
**Overall Assessment:**
Ligand A has advantages in TPSA, DILI risk, BBB penetration, Caco-2 permeability, and solubility. However, Ligand B excels in metabolic stability (lower Cl_mic, longer t1/2), P-gp efflux, and hERG inhibition.
Given the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), and considering the cardiovascular target, I prioritize metabolic stability and minimizing off-target effects (hERG). While Ligand A has a lower DILI risk, the significantly better metabolic profile and lower P-gp efflux of Ligand B outweigh the slight advantage of Ligand A. The higher TPSA of Ligand B is a concern, but the improved metabolic stability and reduced efflux are more critical for a successful cardiovascular drug.
Output:
0
2025-04-18 00:37:26,273 - INFO - Here's my reasoning and the final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, the key priorities are logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB.
Let's compare the ligands property by property:
1. **MW:** Both ligands (360.38 and 349.39) are within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (70.39) is significantly better than Ligand B (107.84). A TPSA under 90 is preferred, and Ligand A is much closer to that threshold.
3. **logP:** Ligand A (2.166) is within the optimal 1-3 range. Ligand B (0.693) is a bit low, potentially hindering membrane permeability.
4. **HBD/HBA:** Ligand A has 2 HBD and 4 HBA, while Ligand B has 0 HBD and 5 HBA. Both are acceptable, though Ligand A's HBD count might offer a slight advantage for binding.
5. **QED:** Ligand A (0.865) is significantly better than Ligand B (0.423), indicating a more drug-like profile.
6. **DILI:** Ligand A (18.302) has a much lower DILI risk than Ligand B (35.595). This is a significant advantage.
7. **BBB:** Both are reasonably good (77.937 and 70.997), but not exceptionally high. Since this is a cardiovascular target, BBB isn't *critical*, but it's a bonus.
8. **Caco-2:** Both are negative, indicating poor permeability.
9. **Solubility:** Both are negative, indicating poor solubility.
10. **hERG:** Ligand A (0.494) is better than Ligand B (0.15), indicating lower cardiotoxicity risk.
11. **Cl_mic:** Ligand A (-4.19) is better than Ligand B (5.037), indicating better metabolic stability.
12. **t1/2:** Ligand A (-9.943) is significantly better than Ligand B (14.116), suggesting a much longer half-life.
13. **Pgp:** Ligand A (0.024) is much better than Ligand B (0.012), indicating lower P-gp efflux and better bioavailability.
14. **Binding Affinity:** Ligand B (-7.3) has a slightly better binding affinity than Ligand A (-6.7), a difference of 0.6 kcal/mol.
**Overall Assessment:**
While Ligand B has a slightly better binding affinity, Ligand A is superior in almost every other crucial ADME-Tox property. It has a better logP, TPSA, QED, DILI score, hERG risk, metabolic stability, half-life, and Pgp efflux. The difference in binding affinity (0.6 kcal/mol) is unlikely to outweigh the substantial advantages of Ligand A in terms of drug-likeness and safety. For a GPCR, optimizing for ADME properties is crucial, and Ligand A clearly excels in this regard.
**Output:**
1
2025-04-18 00:37:26,273 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (352.406) is slightly higher than Ligand B (344.503), but this difference is not significant.
**2. TPSA:** Ligand A (75.71) is higher than Ligand B (50.28). For a GPCR, lower TPSA is generally preferred for better permeability, and Ligand B is significantly better in this regard.
**3. logP:** Ligand B (3.866) is higher than Ligand A (1.003). While both are within the acceptable range, Ligand B is approaching the upper limit. This could potentially lead to solubility issues, but for a GPCR, a higher logP can be beneficial for membrane interactions.
**4. H-Bond Donors:** Both ligands have 1 HBD, which is within the ideal range.
**5. H-Bond Acceptors:** Ligand A has 4 HBAs, while Ligand B has 5. Both are acceptable, but lower is generally preferred.
**6. QED:** Both ligands have good QED values (A: 0.694, B: 0.794), indicating good drug-like properties.
**7. DILI:** Both ligands have low DILI risk (A: 28.616, B: 24.506), which is excellent.
**8. BBB:** Both ligands have very high BBB penetration (A: 89.027, B: 89.143), which is good, although the ADRB2 is not necessarily a CNS target.
**9. Caco-2 Permeability:** Ligand A (-4.785) has a more favorable Caco-2 permeability than Ligand B (-5.036), suggesting better intestinal absorption.
**10. Aqueous Solubility:** Ligand A (-2.172) has better aqueous solubility than Ligand B (-3.801). This is a significant advantage, especially considering Ligand B's higher logP.
**11. hERG Inhibition:** Ligand A (0.121) has a much lower hERG inhibition risk than Ligand B (0.934). This is a critical factor for cardiovascular targets, as hERG inhibition can lead to cardiotoxicity.
**12. Microsomal Clearance:** Ligand B (76.498) has a much higher microsomal clearance than Ligand A (10.786), indicating faster metabolism and potentially lower bioavailability.
**13. In vitro Half-Life:** Ligand B (26.452) has a longer in vitro half-life than Ligand A (-1.375), which is a positive attribute.
**14. P-gp Efflux:** Ligand A (0.022) has significantly lower P-gp efflux liability than Ligand B (0.464), which is beneficial for bioavailability.
**15. Binding Affinity:** Ligand B (-6.2) has a slightly better binding affinity than Ligand A (-7.0). However, the difference is not substantial enough to outweigh the other significant drawbacks of Ligand B.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity) and the general drug-like properties, **Ligand A** is the more promising candidate. While Ligand B has slightly better affinity and half-life, it suffers from significantly higher logP, P-gp efflux, microsomal clearance, and hERG inhibition risk. Ligand A's better solubility, lower hERG risk, and lower P-gp efflux make it a safer and more likely to be bioavailable drug candidate. The TPSA is also more favorable for Ligand A.
Output:
1
2025-04-18 00:37:26,274 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (351.403 and 341.415 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (101.73) is slightly higher than Ligand B (88.47). Both are below the 140 threshold for good oral absorption, but Ligand B is closer to the preferred <90 for GPCRs.
3. **logP:** Both ligands have similar logP values (0.348 and 0.311). These are a bit low, potentially hindering membrane permeability, but not drastically.
4. **HBD:** Ligand A has 1 HBD, while Ligand B has 2. Both are within the acceptable limit of 5.
5. **HBA:** Ligand A has 7 HBA, and Ligand B has 5. Both are below the acceptable limit of 10.
6. **QED:** Both ligands have good QED scores (0.785 and 0.756), indicating good drug-like properties.
7. **DILI:** Ligand A (41.722) has a slightly higher DILI risk than Ligand B (37.999), but both are below the concerning threshold of 60.
8. **BBB:** Ligand B (54.13) has a significantly higher BBB penetration percentile than Ligand A (36.836). While ADRB2 isn't strictly a CNS target, some CNS exposure can occur, and higher BBB is generally favorable.
9. **Caco-2:** Ligand A (-4.415) has a worse Caco-2 permeability than Ligand B (-5.006). Lower (more negative) values indicate poorer permeability.
10. **Solubility:** Both ligands have very poor aqueous solubility (-2.113 and -2.278). This is a significant concern for both.
11. **hERG:** Ligand A (0.177) has a lower hERG inhibition liability than Ligand B (0.678), which is a positive.
12. **Cl_mic:** Ligand B (-47.418) has a much lower (better) microsomal clearance than Ligand A (44.129), indicating greater metabolic stability.
13. **t1/2:** Ligand B (13.349) has a significantly longer in vitro half-life than Ligand A (-19.623). This is a major advantage.
14. **Pgp:** Ligand A (0.049) has a lower P-gp efflux liability than Ligand B (0.003), which is a positive.
15. **Binding Affinity:** Ligand B (-7.1) has a stronger binding affinity than Ligand A (-6.2). This is a 0.9 kcal/mol difference, which is substantial and can outweigh some ADME concerns.
**Overall Assessment:**
Ligand B is the stronger candidate. While both have solubility issues, Ligand B exhibits superior metabolic stability (lower Cl_mic, longer t1/2), better BBB penetration, and significantly higher binding affinity. The slightly higher hERG risk is a concern, but the substantial affinity advantage and improved metabolic profile are more important for a GPCR target like ADRB2. The lower TPSA is also a plus.
Output:
0
2025-04-18 00:37:26,274 - INFO - Batch 491 complete. Total preferences: 7856
2025-04-18 00:37:26,274 - INFO - Processing batch 492/512...
2025-04-18 00:38:15,787 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (385.555) is slightly higher than Ligand B (356.467), but both are acceptable.
2. **TPSA:** Ligand A (82.53) is better than Ligand B (90.98). Both are below 140, but closer to 90 is preferable for a GPCR.
3. **logP:** Ligand A (2.513) is optimal (1-3), while Ligand B (0.138) is quite low. This is a significant drawback for Ligand B, as low logP can hinder membrane permeability.
4. **HBD:** Both ligands have 2 HBD, which is within the acceptable limit of 5.
5. **HBA:** Ligand A (6) is slightly higher than Ligand B (5), but both are within the acceptable limit of 10.
6. **QED:** Ligand A (0.754) is better than Ligand B (0.429). A higher QED indicates a more drug-like profile.
7. **DILI:** Ligand B (18.651) is significantly better than Ligand A (61.342). Lower DILI is crucial.
8. **BBB:** Ligand B (63.862) is better than Ligand A (39.007). While ADRB2 isn't exclusively a CNS target, some BBB penetration can be beneficial for distribution.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.304 and -5.173), which is unusual and suggests poor permeability. However, the values are similar.
10. **Solubility:** Ligand A (-3.944) is better than Ligand B (-0.851). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.428) is better than Ligand B (0.13). Lower hERG inhibition is crucial for avoiding cardiotoxicity.
12. **Cl_mic:** Ligand B (22.737) is significantly better than Ligand A (53.689). Lower clearance indicates better metabolic stability.
13. **t1/2:** Ligand A (-7.368) is better than Ligand B (-4.905). Longer half-life is generally desirable.
14. **Pgp:** Ligand A (0.281) is better than Ligand B (0.002). Lower P-gp efflux is better for bioavailability.
15. **Affinity:** Ligand A (-7.5) is significantly better than Ligand B (-2.2). A difference of 5.3 kcal/mol is substantial and can outweigh many ADME drawbacks.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A excels in affinity and has a good logP and Pgp. Ligand B has a poor logP, which is a major concern. While Ligand B has better DILI and Cl_mic, the significantly stronger binding affinity of Ligand A is a critical advantage for a GPCR target.
**Conclusion:**
Despite Ligand B's better DILI and metabolic stability, the significantly superior binding affinity of Ligand A, combined with its acceptable logP and TPSA, makes it the more promising drug candidate for the ADRB2 receptor.
Output:
1
2025-04-18 00:38:15,788 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (380.579 and 366.571 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (58.2) is slightly higher than Ligand B (49.41). Both are well below the 140 threshold for oral absorption, and acceptable for a cardiovascular target (not CNS). Ligand B is slightly preferred.
3. **logP:** Both ligands have good logP values (2.776 and 3.621), falling within the optimal 1-3 range. Ligand B is slightly higher, which *could* be a minor concern for solubility, but is still acceptable.
4. **HBD:** Ligand A (2) and Ligand B (1) are both within the acceptable limit of <=5. Ligand B is slightly preferred.
5. **HBA:** Ligand A (4) and Ligand B (3) are both within the acceptable limit of <=10. Ligand B is slightly preferred.
6. **QED:** Ligand A (0.72) has a better QED score than Ligand B (0.501), indicating a more drug-like profile. This is a significant advantage for Ligand A.
7. **DILI:** Ligand A (37.456) has a much lower DILI risk than Ligand B (16.053). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (49.36) has a lower BBB penetration than Ligand B (67.235). Since ADRB2 is a cardiovascular target, BBB penetration is not a high priority. Ligand B is slightly preferred.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.242 and -5.262), which is unusual and suggests poor permeability. This is a significant drawback for both.
10. **Solubility:** Both ligands have negative solubility values (-3.613 and -3.463). This is a significant drawback for both.
11. **hERG:** Ligand A (0.176) has a lower hERG inhibition liability than Ligand B (0.572). This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand A (13.785) has a lower microsomal clearance than Ligand B (83.04). This indicates better metabolic stability for Ligand A, a significant advantage.
13. **t1/2:** Ligand A (-1.421) has a negative half-life, which is unusual. Ligand B (2.807) has a positive half-life. This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.095) has lower P-gp efflux liability than Ligand B (0.218). This is a slight advantage for Ligand A.
15. **Binding Affinity:** Ligand B (-6.2 kcal/mol) has a slightly better binding affinity than Ligand A (-5.4 kcal/mol). This is a 1.5 kcal/mol advantage, which is significant.
**Overall Assessment:**
While Ligand B has a slightly better binding affinity and BBB penetration, Ligand A demonstrates a superior safety profile (lower DILI, lower hERG) and better metabolic stability (lower Cl_mic). The QED score is also significantly better for Ligand A. The negative Caco-2 and solubility values are concerning for both, but can potentially be addressed through formulation strategies. Given the GPCR-specific priorities (logP, Pgp, TPSA, affinity) and the importance of safety and metabolic stability, Ligand A appears to be the more promising candidate.
Output:
1
2025-04-18 00:38:15,788 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR, followed by the final output.
**Ligand A: [345.487, 43.86, 1.742, 0, 3, 0.732, 7.212, 91.043, -4.711, -1.795, 0.518, 28.229, 7.529, 0.096, -7.3]**
**Ligand B: [344.499, 43.78, 3.357, 1, 3, 0.805, 24.544, 91.198, -4.461, -2.884, 0.842, 55.293, 21.055, 0.624, -5.3]**
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). A is 345.487, B is 344.499. No significant difference.
2. **TPSA:** Both are around 43-44, well below the 140 threshold for oral absorption and acceptable for a non-CNS GPCR target like ADRB2. No significant difference.
3. **logP:** Ligand A (1.742) is better than Ligand B (3.357). While both are within the acceptable range (1-3), A is closer to the optimal value. B is getting towards the upper end where solubility issues could arise.
4. **H-Bond Donors:** Ligand A (0) is preferable to Ligand B (1). Fewer HBDs generally improve permeability.
5. **H-Bond Acceptors:** Both have 3 HBA, which is good.
6. **QED:** Ligand B (0.805) is slightly better than Ligand A (0.732), indicating a marginally more drug-like profile.
7. **DILI:** Ligand A (7.212) has a higher DILI risk than Ligand B (24.544). This is a significant advantage for Ligand B.
8. **BBB:** Both ligands have high BBB penetration (A: 91.043, B: 91.198). This isn't a primary concern for ADRB2, but it isn't detrimental.
9. **Caco-2 Permeability:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. A (-4.711) is slightly worse than B (-4.461).
10. **Aqueous Solubility:** Ligand A (-1.795) is better than Ligand B (-2.884). Solubility is important for bioavailability.
11. **hERG Inhibition:** Ligand A (0.518) has a lower hERG risk than Ligand B (0.842). This is a significant advantage for A.
12. **Microsomal Clearance:** Ligand A (28.229) has significantly lower clearance than Ligand B (55.293), indicating better metabolic stability.
13. **In vitro Half-Life:** Ligand B (21.055) has a longer half-life than Ligand A (7.529). This is a positive for B.
14. **P-gp Efflux:** Ligand A (0.096) has lower P-gp efflux than Ligand B (0.624), which is preferable.
15. **Binding Affinity:** Ligand B (-5.3) has a significantly stronger binding affinity than Ligand A (-7.3). This is a substantial advantage for B, potentially outweighing some ADME concerns.
**Overall Assessment:**
Ligand B has a much stronger binding affinity (-5.3 vs -7.3 kcal/mol). This is a critical factor for GPCR targets. It also has a lower DILI risk and a longer half-life. However, it has a higher logP, higher P-gp efflux, and higher microsomal clearance. Ligand A has better solubility, lower hERG risk, and lower P-gp efflux. The difference in binding affinity is substantial enough to overcome the slightly less favorable ADME profile of Ligand B.
Output:
0
2025-04-18 00:38:15,788 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 drug candidates. ADRB2 is a GPCR, so we'll prioritize logP, Pgp, TPSA, and affinity, alongside general drug-like properties.
**Ligand A: [338.411, 78.09, 2.087, 2, 3, 0.82, 63.397, 38.581, -5.045, -3.348, 0.481, 17.522, -11.092, 0.043, -5.4]**
* **MW:** 338.411 Da - Good, within the ideal range.
* **TPSA:** 78.09 - Good, below the 140 threshold for oral absorption.
* **logP:** 2.087 - Excellent, within the optimal 1-3 range.
* **HBD:** 2 - Acceptable.
* **HBA:** 3 - Acceptable.
* **QED:** 0.82 - Excellent, highly drug-like.
* **DILI:** 63.397 - Moderate risk, but acceptable.
* **BBB:** 38.581 - Low, not a priority for a peripheral target like ADRB2.
* **Caco-2:** -5.045 - Poor permeability. A significant negative.
* **Solubility:** -3.348 - Poor solubility. Another significant negative.
* **hERG:** 0.481 - Low risk, good.
* **Cl_mic:** 17.522 - Moderate clearance, could be better.
* **t1/2:** -11.092 - Very short half-life. A major drawback.
* **Pgp:** 0.043 - Low efflux, good.
* **Affinity:** -5.4 kcal/mol - Good binding affinity.
**Ligand B: [417.965, 79.37, 1.985, 1, 6, 0.804, 79.682, 54.634, -5.208, -4.358, 0.568, 43.864, 17.21, 0.125, -6.4]**
* **MW:** 417.965 Da - Good, within the ideal range.
* **TPSA:** 79.37 - Good, below the 140 threshold.
* **logP:** 1.985 - Excellent, within the optimal range.
* **HBD:** 1 - Acceptable.
* **HBA:** 6 - Acceptable.
* **QED:** 0.804 - Excellent, highly drug-like.
* **DILI:** 79.682 - High risk, a concern.
* **BBB:** 54.634 - Low, not a priority.
* **Caco-2:** -5.208 - Poor permeability, similar to Ligand A.
* **Solubility:** -4.358 - Poor solubility, similar to Ligand A.
* **hERG:** 0.568 - Low risk, good.
* **Cl_mic:** 43.864 - High clearance, a concern.
* **t1/2:** 17.21 - Better half-life than Ligand A, but still not ideal.
* **Pgp:** 0.125 - Low efflux, good.
* **Affinity:** -6.4 kcal/mol - Excellent binding affinity, 1 kcal/mol better than Ligand A.
**Comparison and Decision:**
Both ligands suffer from poor Caco-2 permeability and solubility. However, Ligand B has a significantly better binding affinity (-6.4 vs -5.4 kcal/mol). This 1 kcal/mol difference is substantial for a GPCR and can often outweigh other deficiencies. While Ligand B has a higher DILI risk and clearance, the improved affinity is a critical advantage for a target where achieving sufficient receptor occupancy is paramount. The slightly better half-life of Ligand B is also a plus.
Therefore, I would choose Ligand B as the more promising candidate, despite its drawbacks, due to its superior binding affinity.
0
2025-04-18 00:38:15,788 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (340.467 Da and 352.45 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (50.36) is significantly better than Ligand B (67.43). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand A is well below the 90 A^2 threshold.
**3. logP:** Ligand A (4.405) is slightly higher than Ligand B (3.341). While both are within the acceptable 1-3 range, Ligand A is approaching the upper limit. This could potentially lead to solubility issues, but is not a dealbreaker.
**4. H-Bond Donors:** Both ligands have 2 HBD, which is within the ideal limit of 5.
**5. H-Bond Acceptors:** Ligand A has 2 HBA, while Ligand B has 3. Both are acceptable (<=10).
**6. QED:** Ligand A (0.847) has a substantially better QED score than Ligand B (0.67), indicating a more drug-like profile.
**7. DILI:** Both ligands have acceptable DILI risk (47.383 and 42.885, respectively), both below the 60 threshold.
**8. BBB:** Ligand A (89.066) has a significantly higher BBB penetration percentile than Ligand B (73.284). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant and is not detrimental.
**9. Caco-2 Permeability:** Ligand A (-4.692) has a slightly better Caco-2 permeability than Ligand B (-4.814), but both are negative values and therefore difficult to interpret directly.
**10. Aqueous Solubility:** Both ligands have poor aqueous solubility (-4.368 and -4.052, respectively). This is a concern, but can be addressed with formulation strategies.
**11. hERG Inhibition:** Ligand A (0.88) has a slightly higher hERG inhibition risk than Ligand B (0.689), but both are relatively low.
**12. Microsomal Clearance:** Ligand B (41.639) has a lower microsomal clearance than Ligand A (36.339), suggesting better metabolic stability.
**13. In vitro Half-Life:** Ligand B (7.143) has a significantly longer in vitro half-life than Ligand A (47.782). This is a major advantage.
**14. P-gp Efflux:** Ligand A (0.474) has a lower P-gp efflux liability than Ligand B (0.092), which is favorable.
**15. Binding Affinity:** Ligand B (-7.0) has a slightly better binding affinity than Ligand A (-6.3). This is a 0.7 kcal/mol difference, which is significant.
**Overall Assessment:**
Ligand B has a superior binding affinity and a much longer half-life, which are critical for *in vivo* efficacy. While Ligand A has better TPSA, QED, and BBB penetration, the difference in binding affinity and half-life outweigh these advantages. The solubility is poor for both, but formulation can address that. The slightly better metabolic stability of Ligand B is also a plus.
Output:
0
2025-04-18 00:38:15,788 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
Let's break down the comparison, prioritizing GPCR-relevant properties (logP, TPSA, Pgp, BBB, and Affinity).
1. **Molecular Weight:** Both ligands (345.399 and 346.387 Da) fall comfortably within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (100.55) is better than Ligand B (122.55). Both are under the 140 threshold for good absorption, but lower TPSA is generally preferred for GPCRs to facilitate brain penetration if desired.
3. **logP:** Ligand A (0.688) is better than Ligand B (0.454). Both are a bit low, potentially hindering membrane permeability, but Ligand A is closer to the optimal 1-3 range.
4. **H-Bond Donors/Acceptors:** Ligand A has 3 HBD and 5 HBA, while Ligand B has 4 HBD and 5 HBA. Both are within acceptable limits.
5. **QED:** Ligand A (0.631) is slightly better than Ligand B (0.577), indicating a marginally more drug-like profile.
6. **DILI:** Ligand A (43.273) has a significantly lower DILI risk than Ligand B (67.119). This is a major advantage for Ligand A.
7. **BBB:** Ligand A (57.076) is better than Ligand B (62.544), although neither is particularly high. For a cardiovascular target, BBB penetration isn't critical, but it's still a slight benefit for A.
8. **Caco-2 Permeability:** Both ligands have negative Caco-2 values (-5.122 and -5.478), which is unusual and suggests poor permeability. This is a significant concern for both.
9. **Aqueous Solubility:** Ligand A (-1.956) is better than Ligand B (-3.053), indicating better solubility.
10. **hERG Inhibition:** Ligand A (0.07) has a much lower hERG risk than Ligand B (0.197). This is a critical safety parameter, and Ligand A is clearly favored.
11. **Microsomal Clearance:** Ligand A (-15.553) has a much lower (better) microsomal clearance than Ligand B (-4.178), suggesting greater metabolic stability.
12. **In vitro Half-Life:** Ligand A (26.914) has a longer half-life than Ligand B (-15.896).
13. **P-gp Efflux:** Ligand A (0.021) has a lower P-gp efflux liability than Ligand B (0.008), which is favorable.
14. **Binding Affinity:** Ligand A (-7.9 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.8 kcal/mol). This 1.1 kcal/mol difference is substantial and can outweigh some of the ADME drawbacks.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical parameters, especially DILI risk, hERG inhibition, metabolic stability (Cl_mic), in vitro half-life, and, most importantly, binding affinity. While both have poor Caco-2 permeability, the superior binding affinity of Ligand A makes it more likely to be a viable starting point for optimization. The better ADME profile of A also makes it a more promising candidate.
Output:
1
2025-04-18 00:38:15,788 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (354.397 and 368.499 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (58.64) is significantly better than Ligand B (83.55). ADRB2 is not a CNS target, but lower TPSA generally favors absorption.
3. **logP:** Both ligands have good logP values (1.238 and 0.97), falling within the optimal 1-3 range. Ligand B is slightly lower, which could marginally improve solubility.
4. **HBD:** Both ligands have 1 HBD, which is within the acceptable limit of <=5. No difference.
5. **HBA:** Ligand A has 3 HBAs, and Ligand B has 4. Both are acceptable (<=10), but Ligand A is slightly better.
6. **QED:** Ligand A (0.773) has a better QED score than Ligand B (0.536), indicating a more drug-like profile.
7. **DILI:** Ligand A (41.334) has a higher DILI risk than Ligand B (19.426). This is a significant advantage for Ligand B.
8. **BBB:** Not a primary concern for ADRB2, but Ligand A (90.772) has a much higher BBB penetration than Ligand B (57.736).
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability, but Ligand A (-4.647) is slightly better than Ligand B (-4.985).
10. **Solubility:** Both ligands have very poor aqueous solubility (-2.753 and -1.995). This is a concern for both.
11. **hERG:** Both ligands have low hERG inhibition risk (0.38 and 0.239). No significant difference.
12. **Cl_mic:** Ligand B (-13.973) has a much lower (better) microsomal clearance than Ligand A (7.174), indicating greater metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand A (4.955) has a slightly longer in vitro half-life than Ligand B (2.417).
14. **Pgp:** Both ligands have low Pgp efflux liability (0.154 and 0.055). No significant difference.
15. **Binding Affinity:** Ligand A (-7.4 kcal/mol) has a significantly better binding affinity than Ligand B (-6.3 kcal/mol). This is a substantial advantage for Ligand A. The 1.1 kcal/mol difference is significant enough to outweigh some ADME concerns.
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A excels in affinity and has favorable logP and TPSA. While Ligand B has a better DILI and Cl_mic profile, the strong binding affinity of Ligand A is a major driver for success. The poor solubility of both is a concern, but can be addressed through formulation strategies.
**Conclusion:**
Despite the better DILI and metabolic stability of Ligand B, the significantly stronger binding affinity of Ligand A (-7.4 vs -6.3 kcal/mol) makes it the more promising drug candidate. The affinity advantage is substantial enough to outweigh the slightly higher DILI risk and lower metabolic stability.
Output:
1
2025-04-18 00:38:15,788 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (367.5 and 369.8 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (82.53) is higher than Ligand B (37.61). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B is significantly better.
3. **logP:** Ligand A (2.36) is within the optimal 1-3 range. Ligand B (4.239) is slightly above, potentially raising concerns about solubility and off-target effects, but still within a tolerable range. Ligand A is slightly preferred.
4. **HBD:** Ligand A (2) and Ligand B (0) are both acceptable.
5. **HBA:** Ligand A (5) and Ligand B (3) are both acceptable.
6. **QED:** Both ligands have similar QED values (0.775 and 0.714), indicating good drug-like properties.
7. **DILI:** Ligand A (39.3) and Ligand B (31.6) are both low risk, with Ligand B being slightly better.
8. **BBB:** Ligand A (50.5) is lower than Ligand B (96.8). While ADRB2 isn't a primary CNS target, some brain penetration can be relevant for peripheral effects. Ligand B is significantly better.
9. **Caco-2:** Ligand A (-5.065) and Ligand B (-4.44) are both negative, indicating poor permeability. However, Ligand B is better.
10. **Solubility:** Ligand A (-2.295) is better than Ligand B (-4.217).
11. **hERG:** Ligand A (0.47) is better than Ligand B (0.848), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand A (23.287) has a lower clearance than Ligand B (51.714), suggesting better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (-3.728) has a negative half-life, which is concerning. Ligand B (4.421) has a positive half-life, indicating better in vitro stability.
14. **Pgp:** Ligand A (0.302) is better than Ligand B (0.589), suggesting less efflux.
15. **Binding Affinity:** Ligand B (-7.7 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.6 kcal/mol). This 1.1 kcal/mol difference is a substantial advantage and can often outweigh minor ADME concerns.
**GPCR-Specific Priorities:**
For ADRB2 (a cardiovascular GPCR), affinity, logP, TPSA, and Pgp are key. Ligand B excels in affinity and TPSA, while Ligand A has a slightly better logP. Ligand B's higher BBB is a bonus, even for a non-CNS target.
**Overall Assessment:**
While Ligand A has advantages in metabolic stability (Cl_mic) and hERG, the significantly stronger binding affinity of Ligand B (-7.7 vs -6.6 kcal/mol) is the most critical factor. The lower TPSA and better BBB penetration of Ligand B are also favorable. The slight increase in logP is manageable. The better in vitro half-life of Ligand B is also a significant advantage.
Output:
0
2025-04-18 00:38:15,788 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (340.379 and 370.787 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (85.36) is slightly higher than Ligand B (71.25). Both are below the 140 A^2 threshold for good oral absorption, but closer to the 90 A^2 threshold for CNS targets (though ADRB2 isn't necessarily a CNS target). Ligand B is preferable here.
3. **logP:** Both ligands have good logP values (1.788 and 2.278), falling within the optimal 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Both have 1 HBD, which is within the acceptable limit of <=5.
5. **HBA:** Both have 5 HBA, which is within the acceptable limit of <=10.
6. **QED:** Both ligands have high QED scores (0.81 and 0.838), indicating good drug-like properties. No significant difference.
7. **DILI:** Ligand B (54.634) has a significantly lower DILI risk than Ligand A (71.888). This is a major advantage for Ligand B.
8. **BBB:** Ligand A (66.654) has a slightly higher BBB penetration percentile than Ligand B (53.509). While ADRB2 isn't a primary CNS target, some peripheral ADRB2 activity can influence CNS function, so this is a minor positive for Ligand A.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.68 and -4.447). These values are unusual and suggest poor permeability.
10. **Solubility:** Both ligands have negative solubility values (-3.675 and -3.266). These values are also unusual and suggest poor solubility.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.047 and 0.19). This is excellent for both.
12. **Cl_mic:** Ligand A (67.527) has a higher microsomal clearance than Ligand B (14.977). This indicates that Ligand B is more metabolically stable, which is a significant advantage.
13. **t1/2:** Ligand B (-9.445) has a longer in vitro half-life than Ligand A (-12.415). This is a positive for Ligand B.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.037 and 0.109).
15. **Binding Affinity:** Ligand B (-7.1 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.2 kcal/mol). This 0.9 kcal/mol difference is substantial and likely outweighs minor ADME drawbacks.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, affinity, and metabolic stability are key. Ligand B excels in affinity and metabolic stability (lower Cl_mic, longer t1/2). While Ligand A has slightly better BBB, the difference isn't substantial, and the superior affinity and lower DILI risk of Ligand B are more critical. The negative Caco-2 and solubility values are concerning for both, but the strong binding affinity of Ligand B suggests it might overcome these issues with appropriate formulation strategies.
**Conclusion:**
Ligand B is the more promising drug candidate due to its significantly stronger binding affinity, lower DILI risk, improved metabolic stability, and longer half-life.
Output:
0
2025-04-18 00:38:15,788 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [348.447, 89.53, 1.156, 2, 4, 0.835, 33.307, 32.803, -5.134, -1.517, 0.124, 11.715, -18.304, 0.076, -6.9]
**Ligand B:** [354.441, 49.41, 3.418, 1, 2, 0.509, 25.087, 89.725, -4.762, -3.502, 0.63, 24.764, 5.993, 0.218, -5.8]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). A (348.447) is slightly better.
2. **TPSA:** A (89.53) is excellent, well below 140 and good for oral absorption. B (49.41) is also very good.
3. **logP:** A (1.156) is optimal. B (3.418) is at the higher end of optimal but still acceptable.
4. **HBD:** A (2) and B (1) are both good, within the acceptable limit of 5.
5. **HBA:** A (4) and B (2) are both good, within the acceptable limit of 10.
6. **QED:** A (0.835) is excellent, indicating a very drug-like profile. B (0.509) is acceptable but less ideal.
7. **DILI:** A (33.307) is very good, low risk. B (25.087) is also very good, even lower risk.
8. **BBB:** A (32.803) is moderate. B (89.725) is excellent. This is a significant advantage for B, as ADRB2 is a GPCR and CNS penetration can be valuable.
9. **Caco-2:** Both are negative, indicating poor permeability. A (-5.134) is worse than B (-4.762).
10. **Solubility:** Both are negative, indicating poor solubility. A (-1.517) is better than B (-3.502).
11. **hERG:** A (0.124) is very low risk. B (0.63) is slightly higher, but still acceptable.
12. **Cl_mic:** A (11.715) is lower, suggesting better metabolic stability. B (24.764) is higher.
13. **t1/2:** A (-18.304) is much better, indicating a longer half-life. B (5.993) is relatively short.
14. **Pgp:** A (0.076) is very low efflux, which is good. B (0.218) is slightly higher, but still acceptable.
15. **Affinity:** A (-6.9) is slightly better than B (-5.8), a difference of 1.1 kcal/mol.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, Pgp, TPSA, BBB, and affinity.
* **LogP:** A is better.
* **Pgp:** A is better.
* **TPSA:** Both are good, but A is slightly better.
* **BBB:** B is *significantly* better.
* **Affinity:** A is slightly better.
**Overall Assessment:**
While Ligand A has a better QED, metabolic stability, and slightly better affinity, Ligand B's significantly improved BBB penetration is a major advantage for a GPCR target. The slightly higher logP of B is not a major concern. The affinity difference, while present, is not large enough to overcome the BBB advantage of B. Considering the importance of CNS penetration for GPCRs, and the fact that both compounds have acceptable ADME profiles, Ligand B is the more promising candidate.
Output:
0
2025-04-18 00:38:15,789 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Step-by-step comparison:**
1. **MW:** Both ligands (371.463 and 363.389 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (96.77) is higher than Ligand B (67.01). For a GPCR like ADRB2, lower TPSA is generally preferred for better permeability, giving a slight edge to Ligand B.
3. **logP:** Ligand B (4.475) is higher than Ligand A (0.251). Ligand A's logP is quite low, potentially hindering membrane permeability. Ligand B is at the upper end of the optimal range, but still acceptable. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (1) has fewer HBDs than Ligand B (2). This is a minor difference, both are within the acceptable limit of 5.
5. **HBA:** Ligand A (6) has slightly more HBAs than Ligand B (5). Both are within the acceptable limit of 10.
6. **QED:** Ligand A (0.818) has a higher QED score than Ligand B (0.634), indicating a more drug-like profile. This favors Ligand A.
7. **DILI:** Ligand B (88.484) has a significantly higher DILI risk than Ligand A (65.568). This is a major concern for Ligand B.
8. **BBB:** Ligand A (75.921) has a slightly higher BBB penetration percentile than Ligand B (66.499). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be beneficial for distribution.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.74 and -4.992). This is unusual and suggests poor permeability in this *in vitro* assay.
10. **Solubility:** Ligand A (-2.081) has better solubility than Ligand B (-5.573). Solubility is important for bioavailability, favoring Ligand A.
11. **hERG:** Ligand A (0.127) has a much lower hERG inhibition liability than Ligand B (0.766). This is a critical advantage for Ligand A, minimizing cardiotoxicity risk.
12. **Cl_mic:** Ligand B (86.587) has a significantly higher microsomal clearance than Ligand A (10.893). This indicates faster metabolism and lower metabolic stability for Ligand B, a major drawback.
13. **t1/2:** Ligand A (-38.65) has a much longer *in vitro* half-life than Ligand B (-4.878). This further supports better metabolic stability for Ligand A.
14. **Pgp:** Ligand A (0.014) has much lower P-gp efflux liability than Ligand B (0.48). Lower P-gp efflux is generally desirable for improved oral bioavailability.
15. **Binding Affinity:** Ligand B (-5.4) has a stronger binding affinity than Ligand A (-3.4). This is a 2 kcal/mol difference, which is substantial and could potentially outweigh some of the ADME concerns.
**Overall Assessment:**
While Ligand B boasts a superior binding affinity, its significantly worse ADME profile is concerning. The high DILI risk, high microsomal clearance, short half-life, and higher P-gp efflux are major liabilities. Ligand A, despite its weaker binding, presents a much more balanced profile with better solubility, lower toxicity risk (hERG & DILI), better metabolic stability, and lower P-gp efflux. The lower logP of Ligand A is a concern, but the substantial affinity difference might be overcome with further optimization.
Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity), and the overall balance of properties, Ligand A is the more promising candidate.
Output:
1
2025-04-18 00:38:15,789 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
The ADRB2 receptor is a GPCR, so the priorities are logP, TPSA, Pgp efflux, BBB penetration, and binding affinity. Let's break down each ligand against these and other important parameters:
* **Molecular Weight:** Both ligands are within the ideal range (200-500 Da).
* **TPSA:** Ligand A (40.62) is significantly better than Ligand B (118.8). Lower TPSA generally correlates with better cell permeability, which is crucial for GPCR targeting. Ligand B is quite high and could hinder absorption.
* **logP:** Ligand A (2.674) is optimal. Ligand B (0.339) is low, potentially leading to poor membrane permeability and bioavailability.
* **H-Bond Donors/Acceptors:** Ligand A (0/2) is preferable to Ligand B (2/5). Fewer hydrogen bonds are generally better for permeability.
* **QED:** Both ligands have acceptable QED values (0.74 & 0.609), indicating reasonable drug-likeness.
* **DILI:** Ligand A (5.971) has a much lower DILI risk than Ligand B (15.82), a significant advantage.
* **BBB:** Ligand A (76.309) shows good BBB penetration, while Ligand B (67.623) is lower. While not a primary concern for peripheral GPCRs like ADRB2, it's still a positive attribute.
* **Caco-2:** Ligand A (-4.581) is better than Ligand B (-5.403), indicating better intestinal absorption.
* **Solubility:** Ligand A (-3.45) is better than Ligand B (-1.779).
* **hERG:** Both ligands have low hERG inhibition liability (0.349 and 0.102), which is excellent.
* **Cl_mic:** Ligand A (24.944) and Ligand B (21.198) are relatively similar in terms of metabolic clearance.
* **t1/2:** Ligand A (-10.967) has a longer in vitro half-life than Ligand B (-21.876), which is desirable.
* **Pgp:** Both ligands have very low P-gp efflux (0.061 and 0.005), which is favorable.
* **Binding Affinity:** Both ligands have very similar binding affinities (-6.0 and -5.8 kcal/mol). The difference is not substantial enough to override the ADME advantages of Ligand A.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across multiple crucial ADME properties (TPSA, logP, DILI, solubility, half-life, Caco-2). While the binding affinities are comparable, the superior ADME profile of Ligand A makes it a much more promising drug candidate for the ADRB2 receptor. The lower TPSA and optimal logP of Ligand A suggest better permeability and bioavailability, while the lower DILI risk is a critical safety advantage.
**Output:**
1
2025-04-18 00:38:15,789 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (345.359 Da and 347.419 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (122.71) is slightly higher than Ligand B (87.54). For a cardiovascular GPCR, TPSA is not a primary concern, but lower is generally preferable for absorption. Ligand B is better.
3. **logP:** Both ligands have similar logP values (0.282 and 0.246), which are a bit low. Ideally, we want 1-3. This could indicate potential permeability issues, but it's not a dealbreaker.
4. **HBD:** Ligand A has 3 HBD, while Ligand B has 1. Lower HBD is generally preferred for permeability, giving a slight edge to Ligand B.
5. **HBA:** Ligand A has 7 HBA, Ligand B has 5. Again, lower is better for permeability, favoring Ligand B.
6. **QED:** Ligand B (0.827) has a significantly higher QED than Ligand A (0.54), indicating a more drug-like profile. This is a strong point for Ligand B.
7. **DILI:** Ligand A (70.686) has a higher DILI risk than Ligand B (58.085). Lower is better, so Ligand B is preferred.
8. **BBB:** Both ligands have moderate BBB penetration (46.995 and 53.974). Since ADRB2 is a cardiovascular target, BBB penetration isn't a high priority, but Ligand B is slightly better.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand B (-4.937) is slightly less negative than Ligand A (-5.705), suggesting marginally better permeability.
10. **Solubility:** Ligand B (-1.553) has slightly better solubility than Ligand A (-3.232). Solubility is important for bioavailability, favoring Ligand B.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.222 and 0.136). This is excellent for both.
12. **Cl_mic:** Ligand A (-22.151) has significantly lower microsomal clearance than Ligand B (21.205), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (-29.446) has a longer in vitro half-life than Ligand B (19.176), further supporting its better metabolic stability.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.008 and 0.014). This is good for both.
15. **Binding Affinity:** Ligand B (-6.7 kcal/mol) has a significantly stronger binding affinity than Ligand A (-3.0 kcal/mol). This is a substantial advantage for Ligand B, potentially outweighing some of the ADME drawbacks.
**Overall Assessment:**
Ligand B has a better overall profile, particularly regarding drug-likeness (QED), DILI risk, solubility, and, crucially, binding affinity. While Ligand A has better metabolic stability (Cl_mic and t1/2), the significantly stronger binding affinity of Ligand B is a major advantage for a GPCR target like ADRB2. The slightly lower TPSA and HBD/HBA counts also contribute to its favorability. The slightly lower logP is a concern, but the strong binding may compensate.
Output:
0
2025-04-18 00:38:15,789 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Ligand A: [368.396, 67.87, 1.874, 1, 4, 0.745, 35.324, 78.945, -4.569, -1.851, 0.416, 15.39, -16.119, 0.049, -6.5]**
**Ligand B: [377.463, 105.25, -1.209, 1, 6, 0.645, 56.572, 51.609, -5.209, -1.702, 0.124, 23.301, -46.171, 0.011, -7.5]**
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). A (368.396) is slightly preferred.
2. **TPSA:** Ligand A (67.87) is significantly better than Ligand B (105.25). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (1.874) is within the optimal range. Ligand B (-1.209) is below 1, which could hinder permeation. This is a significant advantage for A.
4. **H-Bond Donors:** Both have 1 HBD, which is good.
5. **H-Bond Acceptors:** Ligand A (4) is better than Ligand B (6). Lower is generally preferred.
6. **QED:** Ligand A (0.745) is better than Ligand B (0.645), indicating a more drug-like profile.
7. **DILI:** Ligand A (35.324) has a much lower DILI risk than Ligand B (56.572). This is a crucial advantage for A.
8. **BBB:** Ligand A (78.945) has better BBB penetration than Ligand B (51.609). While not critical for a cardiovascular target, it's a bonus.
9. **Caco-2:** Ligand A (-4.569) and Ligand B (-5.209) are both poor, but similar.
10. **Aqueous Solubility:** Ligand A (-1.851) and Ligand B (-1.702) are similar, and both are poor.
11. **hERG:** Ligand A (0.416) is better than Ligand B (0.124), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand A (15.39) has lower clearance than Ligand B (23.301), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-16.119) has a *much* longer half-life than Ligand B (-46.171). This is a major advantage for A.
14. **Pgp:** Ligand A (0.049) has lower P-gp efflux than Ligand B (0.011), meaning better bioavailability.
15. **Binding Affinity:** Ligand B (-7.5) has a slightly better binding affinity than Ligand A (-6.5), a 1 kcal/mol difference. While affinity is important, the other ADME properties of Ligand A are far superior.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most crucial ADME properties (DILI, metabolic stability, solubility, logP, TPSA, Pgp efflux). The slightly weaker binding affinity of Ligand A is outweighed by its significantly improved drug-like characteristics and safety profile. Given that this is a GPCR target, the balance of properties is more important than maximizing affinity alone.
Output:
1
2025-04-18 00:38:15,789 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (344.375) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (61.44) is significantly better than Ligand A (130.14). For a GPCR, lower TPSA is preferred for better blood-brain barrier penetration and overall permeability.
3. **logP:** Ligand B (2.474) is within the optimal range (1-3), while Ligand A (0.457) is quite low. Low logP can hinder membrane permeation. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (3) and Ligand B (2) are both acceptable.
5. **HBA:** Ligand A (6) and Ligand B (3) are both acceptable.
6. **QED:** Both ligands have good QED scores (A: 0.722, B: 0.662), indicating drug-like properties.
7. **DILI:** Ligand B (11.245) has a much lower DILI risk than Ligand A (58.434). This is a crucial advantage for Ligand B.
8. **BBB:** Ligand B (70.415) has a better BBB penetration potential than Ligand A (61.535), although both are reasonably good.
9. **Caco-2:** Ligand A (-5.532) and Ligand B (-4.835) are both negative, indicating poor permeability. However, the scale is not defined, so it's difficult to interpret the absolute difference.
10. **Solubility:** Ligand A (-2.99) and Ligand B (-2.142) are both negative, indicating poor solubility.
11. **hERG:** Both ligands have low hERG inhibition liability (A: 0.186, B: 0.237).
12. **Cl_mic:** Ligand A (4.713) has a lower microsomal clearance than Ligand B (43.976), suggesting better metabolic stability.
13. **t1/2:** Ligand B (2.693) has a longer in vitro half-life than Ligand A (-46.246).
14. **Pgp:** Ligand A (0.004) has lower P-gp efflux liability than Ligand B (0.1).
15. **Affinity:** Both ligands have similar binding affinities (-6.2 kcal/mol and -6.4 kcal/mol). The difference is minimal.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are particularly important. Ligand B excels in logP and TPSA, and has a slightly better BBB score. While Ligand A has a lower Cl_mic and Pgp efflux, the significant advantages of Ligand B in logP, TPSA, and DILI risk outweigh these factors.
**Conclusion:**
Ligand B presents a more favorable overall profile for a drug candidate targeting ADRB2, primarily due to its better logP, TPSA, DILI risk, and BBB penetration.
Output:
0
2025-04-18 00:38:15,789 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.375 and 345.443 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (118.38) is higher than Ligand B (69.72). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for permeability. Ligand B is significantly better here.
3. **logP:** Both ligands (1.676 and 1.503) are within the optimal 1-3 range. No strong preference.
4. **HBD:** Ligand A (3) is higher than Ligand B (1). Ligand B is better, as fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (6) is higher than Ligand B (3). Again, Ligand B is better for permeability.
6. **QED:** Both ligands have good QED scores (0.701 and 0.814), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (76.464) has a significantly higher DILI risk than Ligand B (31.33). This is a major concern for Ligand A.
8. **BBB:** Both ligands have good BBB penetration (70.376 and 74.796), but this is less critical for a cardiovascular target.
9. **Caco-2:** Ligand A (-5.177) is worse than Ligand B (-4.52). Lower values indicate poorer permeability. Ligand B is better.
10. **Solubility:** Ligand A (-3.268) is worse than Ligand B (-2.05). Lower values indicate poorer solubility. Ligand B is better.
11. **hERG:** Both ligands have low hERG inhibition risk (0.115 and 0.211). No significant difference.
12. **Cl_mic:** Ligand A (17.772) has a lower (better) microsomal clearance than Ligand B (60.726), suggesting better metabolic stability. This is a positive for Ligand A.
13. **t1/2:** Ligand A (32.642) has a longer half-life than Ligand B (-16.086). This is a significant advantage for Ligand A.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.016 and 0.026). No significant difference.
15. **Binding Affinity:** Ligand B (-6.1) has a slightly better binding affinity than Ligand A (-5.7). While the difference is not huge, it's still a factor.
**Overall Assessment:**
Ligand B is clearly superior. While Ligand A has better metabolic stability (lower Cl_mic) and half-life, the significantly higher DILI risk and poorer ADME properties (TPSA, HBD, HBA, Caco-2, Solubility) outweigh those benefits. Ligand B has a better safety profile (lower DILI), better permeability characteristics, and slightly better binding affinity. For a cardiovascular GPCR, a favorable safety profile and good ADME properties are paramount.
Output:
0
2025-04-18 00:38:15,790 - INFO - Batch 492 complete. Total preferences: 7872
2025-04-18 00:38:15,790 - INFO - Processing batch 493/512...
2025-04-18 00:39:02,254 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (364.49 & 368.54 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (49.41) is slightly higher than Ligand B (43.7). Both are well below the 140 threshold for oral absorption, and acceptable for a cardiovascular target.
3. **logP:** Both ligands have good logP values (3.019 & 2.794), falling within the 1-3 optimal range.
4. **HBD:** Ligand A (1) is better than Ligand B (0). Lower HBD generally improves permeability.
5. **HBA:** Ligand B (5) is better than Ligand A (3). Both are within the acceptable range of <=10.
6. **QED:** Ligand A (0.874) is significantly better than Ligand B (0.596), indicating a more drug-like profile.
7. **DILI:** Ligand B (11.361) is *much* better than Ligand A (48.158). This is a major advantage for Ligand B, as lower DILI risk is crucial.
8. **BBB:** Ligand B (84.684) is better than Ligand A (79.139), but both are reasonably good. For a cardiovascular target, BBB penetration isn't a primary concern, but it's still a positive.
9. **Caco-2:** Ligand A (-5.059) is better than Ligand B (-4.458), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-4.628) is better than Ligand B (-2.628), suggesting better aqueous solubility.
11. **hERG:** Both ligands have similar hERG risk (0.569 & 0.607).
12. **Cl_mic:** Ligand B (107.034) is significantly *higher* than Ligand A (25.913), indicating faster metabolic clearance and lower metabolic stability. This is a significant drawback for Ligand B.
13. **t1/2:** Ligand A (-13.187) is better than Ligand B (6.277), indicating a longer in vitro half-life.
14. **Pgp:** Ligand A (0.252) is better than Ligand B (0.376), indicating lower P-gp efflux.
15. **Affinity:** Ligand A (-7.0) and Ligand B (-5.7) are both good, but Ligand A has a 1.3 kcal/mol advantage in binding affinity. This is a substantial difference.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are important. Ligand A excels in affinity and Pgp, while both are good on logP and TPSA. However, the *major* drawback of Ligand B is its high DILI risk and poor metabolic stability (high Cl_mic). Ligand A has a much better safety profile and longer half-life. The affinity difference is significant enough to outweigh the slightly better Caco-2 and BBB of Ligand B.
**Conclusion:**
Considering the balance of properties, particularly the crucial DILI and metabolic stability issues with Ligand B, and the superior affinity and drug-like properties of Ligand A, I favor Ligand A.
Output:
1
2025-04-18 00:39:02,255 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Ligand A (421.259 Da) is within the ideal range, while Ligand B (348.531 Da) is slightly below, but still acceptable.
2. **TPSA:** Ligand A (71.06) is better than Ligand B (58.2), both are well below the 140 threshold for oral absorption.
3. **logP:** Both ligands have good logP values (A: 3.502, B: 3.984), falling within the 1-3 range. Ligand B is slightly higher.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (6) is better than Ligand B (2). Both are within acceptable limits.
6. **QED:** Both ligands have similar QED values (A: 0.473, B: 0.463), indicating reasonable drug-likeness.
7. **DILI:** Ligand A (55.68) has a higher DILI risk than Ligand B (19.659). This is a significant negative for Ligand A.
8. **BBB:** Both ligands have excellent BBB penetration (A: 74.99, B: 75.107). This is good, but less critical for a cardiovascular target like ADRB2.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability.
10. **Solubility:** Both ligands have negative solubility values, indicating poor solubility.
11. **hERG:** Ligand A (0.664) has a slightly higher hERG risk than Ligand B (0.451), but both are acceptable.
12. **Cl_mic:** Ligand A (117.577) has a higher microsomal clearance than Ligand B (75.735), meaning it's less metabolically stable.
13. **t1/2:** Ligand A (14.163) has a longer half-life than Ligand B (4.592). This is a positive for Ligand A.
14. **Pgp:** Ligand A (0.309) has lower P-gp efflux than Ligand B (0.122), which is preferable.
15. **Affinity:** Ligand B (-7.1 kcal/mol) has a significantly stronger binding affinity than Ligand A (-4.5 kcal/mol). This is a crucial advantage, exceeding the 1.5 kcal/mol threshold.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Both ligands have good logP and TPSA values. Ligand A has better Pgp, but Ligand B's significantly superior affinity outweighs this advantage. The DILI risk for Ligand A is also a major concern.
**Overall Assessment:**
While Ligand A has some favorable properties (lower HBD, longer half-life, better Pgp), the significantly stronger binding affinity of Ligand B (-7.1 vs -4.5 kcal/mol) and its much lower DILI risk are decisive factors. The higher affinity is likely to translate to greater efficacy, and the lower DILI risk is critical for safety.
Output:
0
2025-04-18 00:39:02,255 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
The ADRB2 receptor is a GPCR, so the priorities are logP, TPSA, Pgp efflux, BBB penetration, and binding affinity. Let's compare the ligands:
1. **Molecular Weight:** Both ligands (356.463 and 354.382 Da) are within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (96.89) is slightly higher than Ligand B (85.69). Both are below the 140 A^2 threshold for oral absorption, but B is better.
3. **logP:** Ligand A (0.743) is within the optimal range (1-3), but on the lower end. Ligand B (-0.109) is slightly below 1, which could be problematic for permeability.
4. **H-Bond Donors:** Ligand A (3) is higher than Ligand B (1), but both are acceptable (<=5).
5. **H-Bond Acceptors:** Ligand A (5) and Ligand B (6) are both acceptable (<=10).
6. **QED:** Ligand B (0.704) has a better QED score than Ligand A (0.53), indicating better overall drug-likeness.
7. **DILI:** Ligand A (18.573) has a significantly lower DILI risk than Ligand B (48.313). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (83.831) has much better BBB penetration than Ligand A (28.655). While ADRB2 isn't necessarily a CNS target, some peripheral effects can be modulated by CNS penetration.
9. **Caco-2:** Ligand A (-5.201) and Ligand B (-4.493) both have negative Caco-2 values, which is unusual and suggests poor permeability.
10. **Solubility:** Ligand A (-2.007) and Ligand B (-1.76) both have negative solubility values, which is also unusual and suggests poor solubility.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.228 and 0.151).
12. **Cl_mic:** Ligand B (3.259) has significantly lower microsomal clearance than Ligand A (30.694), indicating better metabolic stability.
13. **t1/2:** Ligand B (-19.638) has a negative in vitro half-life, which is unusual and suggests very rapid metabolism. Ligand A (4.433) is better.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.039 and 0.031).
15. **Binding Affinity:** Ligand A (-7.1) has a slightly better binding affinity than Ligand B (-7.0). While the difference is small, it's still a factor.
**Overall Assessment:**
Ligand B has advantages in BBB penetration, QED, and metabolic stability (Cl_mic). However, Ligand A has a much lower DILI risk and a slightly better binding affinity. The negative Caco-2 and solubility values for both are concerning. Given the importance of minimizing toxicity (DILI) and maximizing potency (affinity) for a drug candidate, and considering the GPCR target class, Ligand A is the more promising candidate.
**Output:**
1
2025-04-18 00:39:02,255 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (351.451 and 352.431 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (99.35) is better than Ligand B (107.89). Both are under 140, acceptable for oral absorption, but lower is preferred.
3. **logP:** Both ligands (0.278 and 0.395) are quite low. Ideally, we want 1-3. This is a weakness for both, potentially hindering membrane permeability. Ligand B is slightly better.
4. **HBD:** Ligand A (3) is preferable to Ligand B (4). Lower is better for permeability.
5. **HBA:** Both ligands have 5 HBA, which is acceptable.
6. **QED:** Ligand A (0.684) has a better QED score than Ligand B (0.518), indicating a more drug-like profile.
7. **DILI:** Ligand B (29.934) has a significantly lower DILI risk than Ligand A (44.009). This is a major advantage for Ligand B.
8. **BBB:** Ligand A (35.44) has a slightly better BBB penetration percentile than Ligand B (29.508). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be beneficial for distribution.
9. **Caco-2:** Both ligands have very poor Caco-2 permeability (-5.274 and -5.365). This is a significant concern for oral bioavailability.
10. **Solubility:** Both ligands have poor aqueous solubility (-1.963 and -2.373). This could present formulation challenges.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.191). This is excellent.
12. **Cl_mic:** Ligand B (3.25) has much lower microsomal clearance than Ligand A (14.441), indicating better metabolic stability. This is a substantial advantage for Ligand B.
13. **t1/2:** Ligand B (25.575) has a much longer in vitro half-life than Ligand A (-1.849). This is a significant advantage for Ligand B.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.005 and 0.006).
15. **Binding Affinity:** Ligand B (-6.7 kcal/mol) has a significantly stronger binding affinity than Ligand A (-4.2 kcal/mol). This is a crucial advantage, outweighing some of the ADME drawbacks. The difference of 2.5 kcal/mol is substantial.
**GPCR-specific priorities:** For GPCRs, logP, Pgp, TPSA, and affinity are key. While both ligands struggle with logP, Ligand B excels in affinity and has better metabolic stability (Cl_mic, t1/2) and lower DILI risk. The stronger binding affinity of Ligand B is the most important factor here.
**Conclusion:**
Despite the low logP and Caco-2 values for both, Ligand B is the more promising candidate due to its significantly stronger binding affinity, lower DILI risk, better metabolic stability, and longer half-life. These factors outweigh the slightly lower BBB penetration compared to Ligand A.
Output:
0
2025-04-18 00:39:02,255 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [350.383, 128.85 , 0.305, 2. , 9. , 0.793, 79.837, 60.527, -5.031, -1.989, 0.007, 31.639, 0.631, 0.025, -5.2 ]
**Ligand B:** [366.487, 90.54 , 1.432, 3. , 4. , 0.608, 43.66 , 60.644, -5.615, -1.48 , 0.174, 25.125, 52.669, 0.026, -5.5 ]
Here's a breakdown, considering the GPCR priorities (logP, Pgp, TPSA, affinity) and general drug-like properties:
1. **MW:** Both are within the ideal range (200-500 Da). A is 350.383, B is 366.487. No significant difference.
2. **TPSA:** A is 128.85, B is 90.54. B is significantly better, falling well below the 140 threshold and closer to the ideal for GPCRs.
3. **logP:** A is 0.305, B is 1.432. B is much better, falling within the optimal 1-3 range. A is quite low, potentially hindering permeability.
4. **HBD:** A is 2, B is 3. Both are acceptable (<=5).
5. **HBA:** A is 9, B is 4. B is better, lower HBA generally improves permeability.
6. **QED:** A is 0.793, B is 0.608. A is slightly better, indicating a more drug-like profile.
7. **DILI:** A is 79.837, B is 43.66. B is *much* better, indicating significantly lower liver injury risk. This is a critical advantage.
8. **BBB:** Both are around 60%, similar, and not a major differentiating factor for a non-CNS target like cardiovascular ADRB2.
9. **Caco-2:** Both are negative, indicating poor permeability. This is concerning for both.
10. **Solubility:** A is -1.989, B is -1.48. B is slightly better, but both are poor.
11. **hERG:** A is 0.007, B is 0.174. A is better, indicating lower hERG inhibition risk.
12. **Cl_mic:** A is 31.639, B is 25.125. B is better, indicating better metabolic stability.
13. **t1/2:** A is 0.631, B is 52.669. B is *significantly* better, suggesting a much longer half-life.
14. **Pgp:** A is 0.025, B is 0.026. Similar, and low, indicating minimal P-gp efflux.
15. **Affinity:** A is -5.2, B is -5.5. B has a slightly better affinity, but the difference is small.
**Overall Assessment:**
While Ligand A has a slightly better QED and hERG profile, Ligand B is significantly superior in several crucial areas for a GPCR drug candidate. Specifically, its lower TPSA, better logP, much lower DILI risk, and substantially longer half-life are compelling advantages. The slightly better affinity of B is a bonus. The poor Caco-2 values are a concern for both, but can be addressed with formulation strategies. The lower DILI risk and improved metabolic stability of Ligand B are particularly important for cardiovascular drugs, where long-term safety is paramount.
Therefore, I favor Ligand B.
0
2025-04-18 00:39:02,255 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (348.491 Da) is slightly lower, which is generally favorable for permeability.
**2. TPSA:** Ligand A (65.54) is higher than Ligand B (33.2). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is still preferred for better absorption. Ligand B is significantly better here.
**3. logP:** Ligand A (1.626) is within the optimal range (1-3), while Ligand B (4.93) is high. High logP can lead to poor solubility and off-target effects. Ligand A is preferable.
**4. H-Bond Donors:** Ligand A (1) is good. Ligand B (0) is also acceptable.
**5. H-Bond Acceptors:** Ligand A (4) is good. Ligand B (3) is also acceptable.
**6. QED:** Both ligands have similar and acceptable QED values (0.737 and 0.728).
**7. DILI Risk:** Ligand A (13.028) has a much lower DILI risk than Ligand B (22.722). This is a significant advantage for Ligand A.
**8. BBB Penetration:** Ligand B (87.127) has better BBB penetration than Ligand A (59.248). However, since ADRB2 is primarily a cardiovascular target, high BBB penetration isn't a primary requirement.
**9. Caco-2 Permeability:** Ligand A (-4.827) and Ligand B (-5.185) have similar, poor Caco-2 permeability.
**10. Aqueous Solubility:** Ligand A (-0.833) is better than Ligand B (-4.684). Solubility is important for bioavailability.
**11. hERG Inhibition:** Ligand A (0.195) has a lower hERG risk than Ligand B (0.765). This is a crucial safety parameter.
**12. Microsomal Clearance:** Ligand B (88.877) has a much higher microsomal clearance than Ligand A (45.637), indicating faster metabolism and potentially lower *in vivo* exposure. Ligand A is preferable.
**13. In vitro Half-Life:** Ligand A (21.639) has a much longer half-life than Ligand B (3.088). This is a significant advantage for Ligand A, potentially allowing for less frequent dosing.
**14. P-gp Efflux:** Ligand A (0.011) has significantly lower P-gp efflux than Ligand B (0.497). Lower efflux is generally desirable for improved bioavailability.
**15. Binding Affinity:** Ligand B (-7.5 kcal/mol) has a slightly better binding affinity than Ligand A (-6.7 kcal/mol). While affinity is important, the difference of 0.8 kcal/mol isn't large enough to outweigh the numerous ADME advantages of Ligand A.
**Overall Assessment:**
Ligand A demonstrates a superior balance of properties, particularly regarding safety (DILI, hERG), metabolic stability (Cl_mic, t1/2), solubility, and P-gp efflux. While Ligand B has slightly better affinity and BBB penetration, these are less critical for a cardiovascular GPCR target. The higher logP of Ligand B is also a concern.
Therefore, I recommend Ligand A.
Output:
1
2025-04-18 00:39:02,256 - INFO - Reasoning:
Let's analyze Ligand A and Ligand B for their potential as ADRB2 ligands, keeping in mind GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key).
**Molecular Weight:** Both ligands (343.43 and 349.39 Da) fall comfortably within the ideal 200-500 Da range.
**TPSA:** Ligand A (71.53) is significantly better than Ligand B (92.55). A TPSA under 140 is good for oral absorption, and lower is generally better for GPCRs. Ligand B is pushing the upper limit.
**logP:** Ligand A (1.672) is within the optimal 1-3 range. Ligand B (-0.115) is slightly below 1, which *could* indicate potential permeability issues.
**H-Bond Donors/Acceptors:** Both have 1 HBD, which is good. Ligand A has 4 HBA, while Ligand B has 9. Ligand A is preferable here, as higher HBA can sometimes reduce permeability.
**QED:** Both ligands have good QED scores (0.765 and 0.805), indicating generally drug-like properties.
**DILI:** Ligand A (24.78) has a much lower DILI risk than Ligand B (68.17). This is a significant advantage for Ligand A.
**BBB:** Ligand A (70.997) has a better BBB penetration score than Ligand B (61.225), though both are not exceptionally high. This is relevant, though not critical, for a cardiovascular target.
**Caco-2:** Ligand A (-4.705) and Ligand B (-5.475) both have negative values, which is unusual and suggests poor permeability.
**Solubility:** Both have negative solubility values (-1.881 and -2.196), indicating poor aqueous solubility. This is a concern for both.
**hERG:** Both ligands have very low hERG inhibition risk (0.14 and 0.077).
**Microsomal Clearance:** Ligand A (29.063) has a higher (worse) microsomal clearance than Ligand B (1.005). This suggests Ligand B is more metabolically stable.
**In vitro Half-Life:** Ligand B (31.965) has a significantly longer in vitro half-life than Ligand A (-25.953). This is a major advantage for Ligand B.
**P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.045 and 0.033).
**Binding Affinity:** Ligand B (-6.3 kcal/mol) has a slightly better binding affinity than Ligand A (-5.9 kcal/mol). This 0.4 kcal/mol difference is noticeable but not overwhelming.
**Overall Assessment:**
Ligand A excels in TPSA, DILI risk, and BBB penetration. Ligand B has better metabolic stability (lower Cl_mic, longer t1/2) and slightly better binding affinity. However, the significantly higher DILI risk and higher TPSA of Ligand B are concerning. The slightly better affinity of Ligand B doesn't outweigh the substantial advantage Ligand A has in safety (DILI) and permeability (TPSA). The negative Caco-2 and solubility values are problematic for both, but can potentially be addressed with formulation strategies.
Output:
1
2025-04-18 00:39:02,256 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for the ADRB2, a cardiovascular GPCR. Therefore, key priorities are logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB (though less critical for a cardiovascular target).
Let's break down the comparison:
1. **MW:** Both ligands (346.431 and 347.459 Da) are within the ideal 200-500 Da range.
2. **TPSA:** Ligand B (72.88) is significantly better than Ligand A (83.56), falling comfortably under the 140 threshold for good absorption.
3. **logP:** Ligand B (1.241) is slightly better than Ligand A (0.85) and both are within the optimal 1-3 range.
4. **HBD/HBA:** Both ligands have 2 HBD and 4-5 HBA, which are acceptable.
5. **QED:** Both ligands have similar QED scores (0.773 and 0.705), indicating good drug-likeness.
6. **DILI:** Ligand B (8.026) has a *much* lower DILI risk than Ligand A (49.632). This is a significant advantage.
7. **BBB:** Ligand A (60.682) has a slightly better BBB score than Ligand B (46.413), but this is less important for a cardiovascular target.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and difficult to interpret without knowing the scale. However, they are similar.
9. **Solubility:** Both have negative solubility values, also unusual and hard to interpret. They are similar.
10. **hERG:** Both ligands have low hERG inhibition risk (0.256 and 0.376).
11. **Cl_mic:** Ligand B (-0.643) has a *much* lower (better) microsomal clearance than Ligand A (22.76). This suggests better metabolic stability.
12. **t1/2:** Ligand B (-4.39) has a longer in vitro half-life than Ligand A (32.791), indicating better stability.
13. **Pgp:** Both have very low Pgp efflux liability (0.016 and 0.012).
14. **Binding Affinity:** Ligand B (-6.1 kcal/mol) has slightly better binding affinity than Ligand A (-6.4 kcal/mol). While the difference is small, it's still a positive.
**Overall Assessment:**
Ligand B is clearly the superior candidate. It has a significantly lower DILI risk, better metabolic stability (lower Cl_mic and longer t1/2), a lower TPSA, and slightly better binding affinity. While Ligand A has a slightly better BBB score, this is less critical for a cardiovascular target. The improvements in safety (DILI) and pharmacokinetics (Cl_mic, t1/2) outweigh the minor difference in BBB.
**Output:**
0
2025-04-18 00:39:02,256 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (347.5 and 358.8 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (61.44) is higher than Ligand B (44.1). Both are below 140, but B is better for absorption.
3. **logP:** Ligand A (2.371) is within the optimal 1-3 range. Ligand B (4.797) is high, potentially leading to solubility issues and off-target effects.
4. **HBD:** Ligand A (2) is reasonable. Ligand B (0) is also acceptable.
5. **HBA:** Ligand A (3) is reasonable. Ligand B (2) is also acceptable.
6. **QED:** Both ligands (0.725 and 0.713) have good drug-likeness scores.
7. **DILI:** Ligand A (11.128) has a significantly lower DILI risk than Ligand B (45.173). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (75.921) has a better BBB penetration score than Ligand A (61.535). While ADRB2 isn't strictly a CNS target, some CNS exposure can occur, so this is a slight benefit for B.
9. **Caco-2:** Ligand A (-5.018) is worse than Ligand B (-4.537), indicating lower intestinal absorption.
10. **Solubility:** Ligand A (-2.236) is better than Ligand B (-5.431). This is important, especially given Ligand B's higher logP.
11. **hERG:** Ligand A (0.28) has a much lower hERG risk than Ligand B (0.927). This is a critical safety parameter.
12. **Cl_mic:** Ligand B (69.862) has a higher microsomal clearance than Ligand A (8.591), indicating lower metabolic stability.
13. **t1/2:** Ligand A (11.648) has a longer in vitro half-life than Ligand B (0.892).
14. **Pgp:** Ligand A (0.037) has much lower P-gp efflux liability than Ligand B (0.458).
15. **Affinity:** Ligand A (-7.7) has a slightly better binding affinity than Ligand B (-5.9). While the difference is less than 1.5 kcal/mol, it's still a positive factor.
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A has a better logP, lower Pgp efflux, and slightly better affinity. Ligand B has better TPSA and BBB. However, the significantly lower DILI and hERG risks for Ligand A, coupled with its better metabolic stability (lower Cl_mic and longer t1/2), outweigh the benefits of Ligand B.
**Conclusion:**
Ligand A presents a more favorable overall profile, particularly regarding safety (DILI, hERG) and metabolic stability, which are crucial for drug development.
Output:
1
2025-04-18 00:39:02,256 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (368.499 Da) is within the ideal range (200-500 Da). Ligand B (401.312 Da) is also acceptable, though approaching the upper limit.
2. **TPSA:** Ligand A (84.5) is good, under the 140 threshold. Ligand B (62.15) is excellent, further improving potential for absorption.
3. **logP:** Ligand A (1.421) is optimal. Ligand B (3.382) is slightly higher, but still within the acceptable range (1-3).
4. **HBD:** Ligand A (2) is good. Ligand B (0) is also good.
5. **HBA:** Ligand A (5) is good. Ligand B (6) is also good.
6. **QED:** Both Ligand A (0.71) and Ligand B (0.609) are above the 0.5 threshold, indicating good drug-likeness.
7. **DILI:** Both Ligand A (40.054) and Ligand B (41.915) have low DILI risk, below the 40 percentile threshold.
8. **BBB:** Ligand A (54.44) is moderate. Ligand B (71.268) is significantly better, exceeding the 70 percentile, which is favorable for GPCRs.
9. **Caco-2:** Both Ligand A (-5.453) and Ligand B (-5.279) are negative, indicating poor permeability.
10. **Solubility:** Both Ligand A (-2.617) and Ligand B (-2.685) are poor.
11. **hERG:** Ligand A (0.064) is very low risk. Ligand B (0.882) is slightly higher, but still relatively low.
12. **Cl_mic:** Ligand A (30.239) has lower clearance, suggesting better metabolic stability. Ligand B (55.847) has higher clearance.
13. **t1/2:** Ligand B (50.898) has a much longer half-life than Ligand A (-9.98). This is a significant advantage.
14. **Pgp:** Ligand A (0.103) has lower P-gp efflux, which is favorable. Ligand B (0.42) is higher, indicating more efflux.
15. **Affinity:** Ligand A (-6.9 kcal/mol) and Ligand B (-6.2 kcal/mol) both have good affinity, but Ligand A is slightly better.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), BBB penetration, logP, Pgp efflux, TPSA, and binding affinity are key. Ligand B excels in BBB penetration and has a longer half-life, which is a significant advantage. While Ligand A has slightly better affinity and lower Pgp efflux, the superior BBB penetration and half-life of Ligand B outweigh these minor differences, especially considering the poor Caco-2 and solubility of both.
**Conclusion:**
Ligand B is the more promising candidate due to its better BBB penetration, longer half-life, and acceptable overall profile.
Output:
0
2025-04-18 00:39:02,256 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (358.316 and 364.515 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (88.42) is slightly higher than Ligand B (65.54). Both are below the 140 threshold for oral absorption, but B is better positioned, especially considering it's a GPCR.
3. **logP:** Ligand A (3.137) is within the optimal range (1-3), while Ligand B (1.624) is at the lower end. For a GPCR, a slightly higher logP is generally preferred for membrane permeability, giving A an edge.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Both have 5 HBA, which is good.
6. **QED:** Ligand B (0.862) has a significantly better QED score than Ligand A (0.541), indicating a more drug-like profile overall.
7. **DILI:** Ligand B (47.499) has a lower DILI risk than Ligand A (60.915), which is a substantial advantage.
8. **BBB:** Both ligands have good BBB penetration (A: 74.564, B: 75.107), but are not exceptionally high. This isn't a major deciding factor for ADRB2, which isn't a CNS target.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so these values are difficult to interpret.
10. **Solubility:** Ligand B (-2.162) has better solubility than Ligand A (-4.244).
11. **hERG:** Both ligands have low hERG inhibition liability (A: 0.652, B: 0.474), which is good.
12. **Cl_mic:** Ligand B (63.717) has a slightly higher microsomal clearance than Ligand A (55.595), suggesting faster metabolism. A is slightly better here.
13. **t1/2:** Ligand B (-1.659) has a negative in vitro half-life, which is concerning. Ligand A (2.693) has a reasonable half-life.
14. **Pgp:** Both ligands have low Pgp efflux liability (A: 0.08, B: 0.313).
15. **Binding Affinity:** Ligand A (-7.1 kcal/mol) has a slightly better binding affinity than Ligand B (-6.8 kcal/mol). This 0.3 kcal/mol difference is significant, and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand A has a better binding affinity and a more reasonable half-life. Ligand B has a better QED, lower DILI risk, and better solubility. The slightly better affinity of Ligand A, coupled with the concerning negative half-life of Ligand B, pushes me towards Ligand A. While Ligand B has a better safety profile (lower DILI), the affinity difference is substantial enough to prioritize, assuming further optimization can address the DILI risk.
Output:
1
2025-04-18 00:39:02,256 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
We are targeting ADRB2, a GPCR, so the priorities are logP, Pgp, TPSA, affinity, and BBB. Let's compare the two ligands across all parameters:
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (351.378) is slightly lower than Ligand B (370.515), which is generally favorable for permeability.
2. **TPSA:** Ligand B (84.5) is better than Ligand A (93.89). Both are below 140, but lower is preferred for absorption.
3. **logP:** Ligand B (2.016) is better than Ligand A (0.544). A logP between 1-3 is optimal, and Ligand A is quite low, potentially hindering membrane permeability.
4. **HBD:** Both have 2 HBD, which is acceptable.
5. **HBA:** Both have 5 HBA, which is acceptable.
6. **QED:** Both are good (above 0.5), with Ligand B (0.607) being slightly better than Ligand A (0.597).
7. **DILI:** Ligand B (37.185) is significantly better than Ligand A (63.009). Lower DILI risk is crucial.
8. **BBB:** Ligand A (78.868) is better than Ligand B (45.173). While not a CNS target, some degree of BBB penetration can be helpful for distribution.
9. **Caco-2:** Both have negative values, indicating poor permeability. Ligand A (-5.037) is slightly worse than Ligand B (-5.327).
10. **Solubility:** Both have negative values, indicating poor solubility. Ligand A (-2.269) is slightly better than Ligand B (-2.594).
11. **hERG:** Both are low, indicating low risk of hERG inhibition. Ligand A (0.544) is slightly worse than Ligand B (0.166).
12. **Cl_mic:** Ligand A (2.648) is significantly better than Ligand B (31.872). Lower clearance indicates better metabolic stability.
13. **t1/2:** Ligand B (5.107) is better than Ligand A (-9.277). Longer half-life is generally preferred.
14. **Pgp:** Ligand A (0.021) is significantly better than Ligand B (0.045). Lower P-gp efflux is desirable.
15. **Affinity:** Ligand B (-6.7 kcal/mol) is better than Ligand A (-6.1 kcal/mol). This is a substantial difference in binding affinity.
**Overall Assessment:**
Ligand B has a significantly better binding affinity and a much lower DILI risk. It also has a more favorable logP. While Ligand A has better BBB penetration and metabolic stability, the substantial advantage in affinity and safety profile of Ligand B outweighs these factors. The poor Caco-2 and solubility for both are concerning, but can be addressed through formulation strategies. The improved affinity of Ligand B is a critical factor for a GPCR target.
**Output:**
0
2025-04-18 00:39:02,256 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (344.423) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are reasonably good, below the 140 A^2 threshold. Ligand A (91.21) is better than Ligand B (98.66), suggesting better absorption.
3. **logP:** Ligand A (-0.103) is quite low, potentially hindering membrane permeability. Ligand B (1.461) is within the optimal range (1-3). This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (2) is better than Ligand B (4). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (8) is better than Ligand B (4). Fewer HBAs generally improve permeability.
6. **QED:** Ligand A (0.756) is significantly better than Ligand B (0.37), indicating a more drug-like profile.
7. **DILI:** Ligand A (60.527) is higher than Ligand B (19.387), indicating a higher risk of drug-induced liver injury. This is a major concern for Ligand A.
8. **BBB:** Both ligands have similar BBB penetration (Ligand A: 48.313, Ligand B: 60.566). Since ADRB2 is a cardiovascular target, BBB penetration is not a primary concern, but higher is generally better.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests very poor permeability. Ligand A (-5.291) is slightly better than Ligand B (-4.938), but both are problematic.
10. **Solubility:** Ligand A (-0.892) is better than Ligand B (-2.382), indicating better aqueous solubility.
11. **hERG:** Both ligands have low hERG inhibition risk (Ligand A: 0.281, Ligand B: 0.627), which is good.
12. **Cl_mic:** Ligand A (-51.673) has a much lower (better) microsomal clearance than Ligand B (31.455), suggesting better metabolic stability.
13. **t1/2:** Ligand A (28.521) has a better in vitro half-life than Ligand B (-31.848).
14. **Pgp:** Both ligands have very low Pgp efflux (Ligand A: 0.006, Ligand B: 0.109).
15. **Affinity:** Both ligands have similar binding affinity (-6.7 kcal/mol and -6.6 kcal/mol).
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand B has a much better logP value. While Ligand A has better TPSA, the poor logP and higher DILI risk are significant drawbacks. The similar affinity doesn't resolve the other issues.
**Overall Assessment:**
Ligand A has a better QED, solubility, metabolic stability, and half-life. However, its very low logP and higher DILI risk are major concerns. Ligand B, while having a lower QED, has a much more favorable logP, significantly lower DILI risk, and comparable affinity. Given the importance of logP for GPCRs and the serious concern of DILI, Ligand B is the more promising candidate.
Output:
0
2025-04-18 00:39:02,256 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's systematically compare Ligand A and Ligand B based on the provided parameters and the guidelines, keeping in mind the GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key).
1. **MW:** Both ligands (347.46 and 364.36 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Both are below the 140 A^2 threshold for good oral absorption (78.51 and 75.71). Ligand B is slightly better.
3. **logP:** Both have acceptable logP values (1.05 and 1.78), falling within the 1-3 range. Ligand B is slightly better.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1), but both are within the acceptable limit of 5.
5. **HBA:** Ligand A (3) is lower than Ligand B (4), which is preferable.
6. **QED:** Ligand A (0.798) has a significantly better QED score than Ligand B (0.552), indicating a more drug-like profile.
7. **DILI:** Ligand A (18.22) has a much lower DILI risk than Ligand B (29.08), which is a significant advantage.
8. **BBB:** Ligand B (92.67) has a much higher BBB penetration percentile than Ligand A (49.21). While ADRB2 isn't necessarily a CNS target, higher BBB is generally favorable.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand B (-4.71) is slightly better than Ligand A (-5.12).
10. **Solubility:** Both have negative solubility values, indicating poor solubility. Ligand B (-2.62) is slightly better than Ligand A (-2.07).
11. **hERG:** Both have very low hERG inhibition liability (0.073 and 0.44), which is excellent.
12. **Cl_mic:** Ligand A (3.59) has a significantly lower microsomal clearance than Ligand B (17.34), indicating better metabolic stability.
13. **t1/2:** Ligand A (9.02) has a better in vitro half-life than Ligand B (-19.33).
14. **Pgp:** Ligand A (0.013) has a much lower P-gp efflux liability than Ligand B (0.038), suggesting better oral bioavailability and potentially better CNS exposure.
15. **Affinity:** Ligand A (-6.8 kcal/mol) has a slightly better binding affinity than Ligand B (-5.9 kcal/mol).
**Overall Assessment:**
Ligand A demonstrates a superior balance of properties. It has a better QED score, significantly lower DILI risk, lower microsomal clearance (better metabolic stability), longer half-life, lower P-gp efflux, and slightly better binding affinity. While Ligand B has better BBB penetration and slightly better logP and Caco-2 values, the advantages of Ligand A in terms of safety (DILI), drug-likeness (QED), and pharmacokinetics (Cl_mic, t1/2, Pgp) outweigh these minor differences.
**Output:**
1
2025-04-18 00:39:02,257 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's break down the comparison of Ligand A and Ligand B, considering the provided guidelines and the GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key).
1. **Molecular Weight:** Both ligands (352.45 Da and 353.354 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (61.8) is significantly better than Ligand B (116.42). A TPSA under 140 is good for oral absorption, but lower is generally preferred for GPCRs. Ligand B is pushing the upper limit and could have absorption issues.
3. **logP:** Ligand A (3.049) is optimal, while Ligand B (-0.802) is quite low. Low logP can hinder membrane permeability. This is a substantial advantage for Ligand A.
4. **H-Bond Donors:** Both have acceptable numbers (2 and 3, respectively), within the guideline of <=5.
5. **H-Bond Acceptors:** Both are also acceptable (4 and 5, respectively), within the guideline of <=10.
6. **QED:** Ligand A (0.826) has a much better QED score than Ligand B (0.438), indicating a more drug-like profile.
7. **DILI Risk:** Ligand B (70.919) has a significantly higher DILI risk than Ligand A (13.843). This is a major concern for Ligand B.
8. **BBB Penetration:** Ligand A (68.282) shows better BBB penetration than Ligand B (56.534), though neither are exceptionally high. For a cardiovascular target, BBB penetration isn't *critical*, but it's a bonus.
9. **Caco-2 Permeability:** Ligand A (-4.678) is better than Ligand B (-5.178), indicating better intestinal absorption.
10. **Aqueous Solubility:** Ligand A (-2.731) is better than Ligand B (-1.331), indicating better solubility.
11. **hERG Inhibition:** Both ligands have low hERG inhibition risk (0.807 and 0.178, respectively).
12. **Microsomal Clearance:** Ligand B (-16.442) has a significantly lower (better) microsomal clearance than Ligand A (32.21). This suggests greater metabolic stability for Ligand B.
13. **In vitro Half-Life:** Ligand B (-34.042) has a much longer in vitro half-life than Ligand A (22.616), which is desirable.
14. **P-gp Efflux:** Ligand A (0.142) has lower P-gp efflux than Ligand B (0.012), which is favorable for bioavailability.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.3 and -6.4 kcal/mol). The difference is negligible.
**Overall Assessment:**
Ligand A is clearly the superior candidate. While Ligand B has better metabolic stability and half-life, its significantly lower logP, higher DILI risk, and higher TPSA are major drawbacks. Ligand A balances properties much better, with a good logP, lower DILI risk, better TPSA, and a better QED score. The slight advantage in P-gp efflux is also beneficial. The similar binding affinities make the ADME properties the deciding factor.
**Output:**
1
2025-04-18 00:39:02,257 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands (352.475 and 364.339 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (78.87) is higher than Ligand B (58.64). For a GPCR, lower TPSA is generally preferred for better permeability, giving a slight edge to Ligand B.
3. **logP:** Both ligands have good logP values (1.485 and 1.826), falling within the optimal 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Ligand A (2) has a slightly higher HBD count than Ligand B (1). Both are acceptable (<=5).
5. **HBA:** Ligand A (4) has a slightly higher HBA count than Ligand B (3). Both are acceptable (<=10).
6. **QED:** Both ligands have good QED scores (0.616 and 0.775), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand B (41.179) has a significantly lower DILI risk than Ligand A (5.312). This is a major advantage for Ligand B.
8. **BBB:** Ligand B (87.476) has a much higher BBB penetration percentile than Ligand A (68.864). This is a crucial factor for GPCRs, even those not directly in the CNS, as it can influence off-target effects and distribution.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.746 and -4.649). These values are difficult to interpret without knowing the scale, but the negative values suggest poor permeability.
10. **Solubility:** Ligand A (-1.402) has better solubility than Ligand B (-3.749). Solubility is important for bioavailability.
11. **hERG:** Both ligands have low hERG inhibition liability (0.356 and 0.42). No significant difference here.
12. **Cl_mic:** Ligand A (10.362) has a significantly lower microsomal clearance than Ligand B (35.102), indicating better metabolic stability.
13. **t1/2:** Ligand A (-12.318) has a longer in vitro half-life than Ligand B (-10.01). This is a positive attribute.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.083 and 0.12). No significant difference.
15. **Binding Affinity:** Ligand A (-6.8 kcal/mol) has slightly better binding affinity than Ligand B (-6.5 kcal/mol). This is a 0.3 kcal/mol difference, which is not huge, but still relevant.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity) and the general drug-like properties, Ligand B emerges as the more promising candidate. While Ligand A has slightly better affinity and metabolic stability, Ligand B excels in crucial areas like DILI risk, BBB penetration, and TPSA. The lower DILI risk and higher BBB penetration are particularly important for a GPCR target, potentially mitigating off-target effects and improving overall safety. The slightly better QED score also supports Ligand B.
Output:
0
2025-04-18 00:39:02,257 - INFO - Batch 493 complete. Total preferences: 7888
2025-04-18 00:39:02,257 - INFO - Processing batch 494/512...
2025-04-18 00:39:50,347 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (378.78 and 349.41 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (68.29) is significantly better than Ligand B (92.5). For a GPCR, keeping TPSA under 140 is good for absorption, and lower is generally preferred. Ligand B is pushing the upper limit.
**3. logP:** Ligand A (3.61) is optimal, while Ligand B (1.51) is a bit low. GPCRs benefit from a good logP for membrane permeability. Ligand B's lower logP could hinder its ability to reach the receptor efficiently.
**4. H-Bond Donors:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
**5. H-Bond Acceptors:** Ligand A (4) is preferable to Ligand B (3). Fewer HBAs generally improve permeability.
**6. QED:** Both ligands have good QED scores (0.61 and 0.84), indicating drug-like properties. Ligand B is slightly better here.
**7. DILI Risk:** Ligand A (59.17) has a moderate DILI risk, while Ligand B (39.74) has a lower risk. This favors Ligand B.
**8. BBB Penetration:** Ligand A (88.17) has better BBB penetration than Ligand B (74.80). While ADRB2 is a cardiovascular target and doesn't *require* high BBB penetration, some level is still useful for distribution and potential off-target effects.
**9. Caco-2 Permeability:** Ligand A (-4.58) is significantly worse than Ligand B (-5.02). Lower values indicate lower permeability.
**10. Aqueous Solubility:** Ligand A (-4.48) is slightly worse than Ligand B (-3.07). Higher solubility is generally preferred.
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.37 and 0.24). This is excellent for both.
**12. Microsomal Clearance:** Ligand A (83.77) has a higher clearance than Ligand B (-3.87). Ligand B is much more metabolically stable.
**13. In vitro Half-Life:** Ligand A (12.02) has a shorter half-life than Ligand B (-7.04). Ligand B is much more stable.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.26 and 0.05). This is excellent for both.
**15. Binding Affinity:** Ligand B (-8.9 kcal/mol) has a significantly stronger binding affinity than Ligand A (-4.2 kcal/mol). This is a substantial advantage, potentially outweighing some ADME concerns.
**Overall Assessment:**
Ligand B has a significantly stronger binding affinity, better metabolic stability (lower Cl_mic, longer t1/2), and a lower DILI risk. While its TPSA and logP are less ideal than Ligand A, the dramatic improvement in binding affinity and metabolic properties is compelling. The slightly lower logP and higher TPSA are manageable, and the strong binding should compensate.
Output:
0
2025-04-18 00:39:50,347 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [348.447, 85.67, 0.364, 1, 5, 0.749, 5.545, 63.358, -5.201, -0.96, 0.359, -37.701, 9.775, 0.006, -7]
**Ligand B:** [345.403, 102.05, 1.096, 2, 6, 0.845, 62.893, 63.125, -5.085, -2.092, 0.082, 24.698, -13.31, 0.016, 4.8]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal 200-500 Da range. A (348.447) and B (345.403) are very close, so no significant difference here.
2. **TPSA:** A (85.67) is better than B (102.05). We want <140 for oral absorption, both are good, but A is preferred.
3. **logP:** A (0.364) is lower than B (1.096). Both are a bit low, but B is better, falling closer to the optimal 1-3 range. Low logP can hinder membrane permeability.
4. **HBD:** A (1) is better than B (2). Lower is generally preferred for permeability.
5. **HBA:** A (5) is better than B (6). Lower is generally preferred for permeability.
6. **QED:** B (0.845) is slightly better than A (0.749), indicating a more drug-like profile.
7. **DILI:** Both are acceptable, with A (5.545) being slightly better than B (62.893). Both are below the 60 threshold.
8. **BBB:** Both are similar, around 63%, which isn't *high* but isn't a dealbreaker for a non-CNS target like ADRB2.
9. **Caco-2:** Both are negative, suggesting poor permeability. A (-5.201) is slightly better than B (-5.085) but both are concerning.
10. **Solubility:** A (-0.96) is better than B (-2.092). Higher solubility is preferred.
11. **hERG:** A (0.359) is significantly better than B (0.082). Lower hERG inhibition is crucial for avoiding cardiotoxicity, a major concern with ADRB2 ligands.
12. **Cl_mic:** A (-37.701) is *much* better than B (24.698). A negative value indicates very low clearance and high metabolic stability, a major advantage.
13. **t1/2:** A (9.775) is better than B (-13.31). A longer half-life is generally desirable.
14. **Pgp:** A (0.006) is much better than B (0.016). Lower P-gp efflux is preferred.
15. **Affinity:** A (-7.0) is significantly better than B (-4.8). This is a substantial difference in binding potency.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are particularly important. While both have suboptimal logP and Caco-2 permeability, Ligand A significantly wins on affinity, hERG, metabolic stability (Cl_mic), Pgp efflux, and has better TPSA. The superior binding affinity of Ligand A (-7.0 kcal/mol vs -4.8 kcal/mol) is a major advantage and can compensate for some of the ADME deficiencies.
**Conclusion:**
Ligand A is the more promising candidate despite the low logP and Caco-2 values. The significantly better binding affinity, hERG profile, metabolic stability, and Pgp efflux, combined with acceptable DILI and TPSA, make it the preferred choice.
1
2025-04-18 00:39:50,347 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (333.435 and 350.434 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (47.34) is significantly better than Ligand B (62.55). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (3.446 and 2.806), falling within the optimal 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Ligand A (0) is preferable to Ligand B (1). Fewer HBDs generally improve permeability.
5. **HBA:** Both ligands have the same number of HBA (3), which is acceptable.
6. **QED:** Both ligands have similar QED values (0.846 and 0.803), indicating good drug-likeness.
7. **DILI:** Ligand B (44.009) has a much lower DILI risk than Ligand A (76.58). This is a significant advantage for Ligand B.
8. **BBB:** Both ligands have reasonably high BBB penetration (79.488 and 75.378). While ADRB2 isn't primarily a CNS target, some degree of BBB penetration isn't necessarily detrimental.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.56 and -4.747). These values are difficult to interpret without knowing the scale, but the similarity suggests similar absorption potential.
10. **Solubility:** Ligand B (-2.895) has better solubility than Ligand A (-4.994). This is a positive for Ligand B.
11. **hERG:** Ligand A (0.923) has a slightly higher hERG risk than Ligand B (0.631), although both are relatively low.
12. **Cl_mic:** Ligand B (27.195) has significantly lower microsomal clearance than Ligand A (51.942), indicating better metabolic stability. This is a major advantage for Ligand B.
13. **t1/2:** Ligand A (-8.564) has a longer in vitro half-life than Ligand B (3.297). This is a positive for Ligand A.
14. **Pgp:** Ligand A (0.645) has lower P-gp efflux than Ligand B (0.39). Lower P-gp efflux is generally favorable.
15. **Binding Affinity:** Ligand B (-8.3) has a slightly better binding affinity than Ligand A (-7.2). While the difference is less than the 1.5 kcal/mol threshold, it's still a positive for Ligand B.
**Overall Assessment:**
Ligand B demonstrates a better balance of properties, particularly regarding safety (lower DILI) and pharmacokinetics (lower Cl_mic, better solubility). While Ligand A has a longer half-life and lower P-gp efflux, the superior safety profile and metabolic stability of Ligand B outweigh these advantages. The slightly better affinity of Ligand B also contributes to its preference. Considering ADRB2 is a cardiovascular target, the slightly lower TPSA and better solubility of Ligand B are also beneficial.
Output:
0
2025-04-18 00:39:50,347 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (351.447 and 364.515 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (84.67) is slightly higher than Ligand B (58.44). Both are below the 140 A^2 threshold for oral absorption, but Ligand B is significantly better, which is important for a GPCR.
3. **logP:** Both ligands have good logP values (2.512 and 2.208) within the optimal 1-3 range. Ligand B is slightly lower, which is generally preferable.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 6 HBA, and Ligand B has 5. Both are acceptable, below the 10 threshold.
6. **QED:** Ligand B (0.815) has a higher QED score than Ligand A (0.626), indicating better overall drug-likeness.
7. **DILI:** Both ligands have similar, acceptable DILI risk (41.411 and 42.691 percentile).
8. **BBB:** Both have good BBB penetration (71.229 and 79.566 percentile). Ligand B is better, which is a priority for GPCRs.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. This is a concern for both.
10. **Solubility:** Both have negative solubility values, indicating poor solubility. This is a concern for both.
11. **hERG:** Both have low hERG inhibition liability (0.408 and 0.455), which is excellent.
12. **Cl_mic:** Ligand B (35.217) has significantly lower microsomal clearance than Ligand A (82.125), suggesting better metabolic stability. This is a major advantage.
13. **t1/2:** Ligand B (5.643) has a longer in vitro half-life than Ligand A (-6.876). This is a significant advantage.
14. **Pgp:** Both have low Pgp efflux liability (0.27 and 0.402).
15. **Binding Affinity:** Ligand B (-7.0 kcal/mol) has a stronger binding affinity than Ligand A (-5.6 kcal/mol). This is a substantial advantage, and can often outweigh minor ADME concerns.
**Overall Assessment:**
Ligand B is the stronger candidate. While both have issues with Caco-2 and solubility, Ligand B demonstrates superior drug-like properties (higher QED), better metabolic stability (lower Cl_mic, longer t1/2), better BBB penetration, and significantly stronger binding affinity. The combination of these factors makes Ligand B the more promising starting point for drug development targeting the ADRB2 receptor.
Output:
0
2025-04-18 00:39:50,348 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (416.218 Da) is slightly higher than Ligand B (354.491 Da), but both are acceptable.
**2. TPSA:** Ligand A (68.53) is well below the 140 threshold for oral absorption and is quite favorable. Ligand B (87.66) is still under 140, but less optimal than A.
**3. logP:** Both ligands have good logP values (A: 2.692, B: 1.898), falling within the 1-3 range.
**4. H-Bond Donors:** Ligand A has 1 HBD, and Ligand B has 3. Both are within the acceptable limit of 5.
**5. H-Bond Acceptors:** Ligand A has 5 HBA, and Ligand B has 4. Both are within the acceptable limit of 10.
**6. QED:** Both ligands have similar QED values (A: 0.601, B: 0.59), indicating good drug-likeness.
**7. DILI:** Ligand A has a DILI risk of 55.215, which is acceptable (under 60). Ligand B has a much lower DILI risk of 15.51, which is significantly better.
**8. BBB:** Ligand A shows good BBB penetration (71.656%), while Ligand B is lower (57.968%). While ADRB2 is a cardiovascular target, some CNS off-target effects are always a concern, and higher BBB penetration could be a negative.
**9. Caco-2 Permeability:** Ligand A (-4.507) and Ligand B (-5.107) both have negative Caco-2 values, indicating poor permeability. This is a significant drawback for both.
**10. Aqueous Solubility:** Ligand A (-4.082) and Ligand B (-1.379) both have negative solubility values, indicating poor solubility. This is a significant drawback for both.
**11. hERG Inhibition:** Ligand A (0.688) has a slightly higher hERG risk than Ligand B (0.301), but both are relatively low.
**12. Microsomal Clearance:** Ligand A (77.831) has a higher microsomal clearance than Ligand B (10.294), suggesting faster metabolism and potentially lower *in vivo* exposure.
**13. In vitro Half-Life:** Ligand A (14.068) has a longer half-life than Ligand B (9.658), which is desirable.
**14. P-gp Efflux:** Ligand A (0.627) has lower P-gp efflux than Ligand B (0.052), which is favorable for bioavailability.
**15. Binding Affinity:** Ligand A (-8.0) has a significantly stronger binding affinity than Ligand B (-5.1). This is a substantial advantage.
**Overall Assessment:**
Given the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), the stronger binding affinity of Ligand A (-8.0 kcal/mol vs -5.1 kcal/mol) is a major deciding factor. While Ligand B has a better DILI profile and lower P-gp efflux, the difference in binding affinity is substantial enough to outweigh these advantages. Both compounds have poor Caco-2 and solubility, which would need to be addressed in further optimization, but the potency advantage of A is critical.
Output:
1
2025-04-18 00:39:50,348 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (337.423) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (61.44) is significantly better than Ligand B (76.46). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally aids absorption.
3. **logP:** Ligand A (4.049) is at the upper end of the optimal range, while Ligand B (1.748) is at the low end. For a GPCR, a higher logP can be beneficial for membrane interactions, but needs to be balanced with solubility.
4. **HBD/HBA:** Ligand A has 2 HBD and 2 HBA, while Ligand B has 1 HBD and 5 HBA. Both are acceptable, but Ligand A's profile is slightly more balanced.
5. **QED:** Both ligands have similar QED values (0.827 and 0.726), indicating good drug-likeness.
6. **DILI:** Ligand B (32.299) has a much lower DILI risk than Ligand A (84.025). This is a significant advantage for Ligand B.
7. **BBB:** Ligand A (71.462) has better BBB penetration than Ligand B (61.923), but this is less critical for a cardiovascular target.
8. **Caco-2:** Ligand A (-4.624) has a worse Caco-2 permeability than Ligand B (-5.493).
9. **Solubility:** Ligand B (-1.036) has better aqueous solubility than Ligand A (-5.23). This is important, especially given Ligand A's higher logP.
10. **hERG:** Ligand A (0.724) has a slightly higher hERG risk than Ligand B (0.226). Lower hERG is always preferred.
11. **Cl_mic:** Ligand B (9.589) has significantly lower microsomal clearance than Ligand A (55.008), indicating better metabolic stability.
12. **t1/2:** Ligand A (35.151) has a longer in vitro half-life than Ligand B (7.483). This is desirable.
13. **Pgp:** Ligand A (0.23) has lower P-gp efflux than Ligand B (0.054), which is good.
14. **Binding Affinity:** Ligand A (-8.2 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.8 kcal/mol). This is a substantial advantage.
**Overall Assessment:**
Ligand A has a significantly better binding affinity, a longer half-life, and lower P-gp efflux. However, it suffers from higher DILI risk, poorer solubility, higher hERG risk, and higher metabolic clearance. Ligand B excels in safety (DILI, hERG), solubility, and metabolic stability, but its affinity is considerably weaker.
Given the strong affinity advantage of Ligand A (-8.2 vs -6.8 kcal/mol), and the fact that ADRB2 is a cardiovascular target (less stringent BBB requirements), I believe the benefits of the higher potency outweigh the ADME drawbacks, *provided* that the DILI risk can be mitigated through further optimization. The difference in binding affinity is substantial (>1.5 kcal/mol).
Output:
1
2025-04-18 00:39:50,348 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (352.475 Da and 349.475 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (87.66) is slightly higher than Ligand B (65.79). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is generally preferred for absorption. Ligand B has a clear advantage.
**3. logP:** Both ligands have good logP values (1.386 and 1.826, respectively), falling within the optimal 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability.
**4. H-Bond Donors:** Ligand A has 3 HBD, while Ligand B has 1. Lower HBD is generally preferred for better permeability. Ligand B is better here.
**5. H-Bond Acceptors:** Both ligands have 4 HBA, which is acceptable.
**6. QED:** Both ligands have similar QED values (0.604 and 0.691), indicating good drug-likeness. Ligand B is slightly better.
**7. DILI Risk:** Ligand A (18.922) has a significantly higher DILI risk than Ligand B (9.771). This is a major concern, as liver toxicity is a common reason for drug failure. Ligand B is strongly favored.
**8. BBB Penetration:** Both ligands have relatively low BBB penetration (44.203 and 59.093). Since ADRB2 is primarily a cardiovascular target, BBB penetration isn't a primary concern, but higher is still slightly preferable. Ligand B is better.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-5.11 and -5.024), which is unusual and suggests poor permeability. This is a red flag for both.
**10. Aqueous Solubility:** Ligand A (-2.166) has slightly worse solubility than Ligand B (-0.715). Solubility is important for formulation and bioavailability. Ligand B is better.
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.09 and 0.5). This is excellent.
**12. Microsomal Clearance:** Ligand A (35.882) has higher microsomal clearance than Ligand B (17.796), indicating faster metabolism and potentially lower bioavailability. Ligand B is better.
**13. In vitro Half-Life:** Ligand B (33.333 hours) has a significantly longer in vitro half-life than Ligand A (-6.767 hours). This is a substantial advantage, as it suggests less frequent dosing may be possible.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.007 and 0.029).
**15. Binding Affinity:** Both ligands have the same binding affinity (-6 kcal/mol).
**Overall Assessment:**
Considering all factors, **Ligand B is the more promising candidate.** While both have issues with Caco-2 permeability, Ligand B demonstrates significantly better ADME properties: lower DILI risk, better solubility, lower clearance, and a much longer half-life. These factors outweigh the slightly higher TPSA and logP. The equal binding affinity removes that as a differentiating factor. Given the GPCR target class, the improved ADME profile of Ligand B makes it the preferred choice.
Output:
0
2025-04-18 00:39:50,348 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [376.791, 95.42, 1.028, 2, 5, 0.723, 40.054, 65.801, -4.893, -2.664, 0.217, 1.47, -12.733, 0.012, -7.3]
**Ligand B:** [346.435, 85.05, 0.521, 1, 6, 0.755, 33.812, 37.418, -5.315, -0.715, 0.079, 20.352, 27.748, 0.011, -7.3]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity, and to a lesser extent BBB):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (346.435) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (95.42) is a bit higher than Ligand B (85.05). Both are acceptable, but lower is better for GPCRs. Ligand B is preferable here.
3. **logP:** Ligand A (1.028) is within the optimal range, while Ligand B (0.521) is slightly below. While not terrible, lower logP can sometimes indicate permeability issues. Ligand A is preferable.
4. **HBD/HBA:** Ligand A (2 HBD, 5 HBA) and Ligand B (1 HBD, 6 HBA) are both reasonable.
5. **QED:** Both have good QED scores (A: 0.723, B: 0.755), indicating good drug-like properties.
6. **DILI:** Ligand B (33.812) has a significantly lower DILI risk than Ligand A (40.054). This is a strong advantage for Ligand B.
7. **BBB:** Ligand A (65.801) has a better BBB penetration score than Ligand B (37.418). While ADRB2 is cardiovascular, some CNS exposure is not necessarily detrimental and could potentially offer additional therapeutic avenues.
8. **Caco-2:** Ligand B (-5.315) has a more negative Caco-2 value, suggesting *better* permeability than Ligand A (-4.893).
9. **Solubility:** Ligand B (-0.715) is slightly better in terms of aqueous solubility than Ligand A (-2.664).
10. **hERG:** Both ligands have very low hERG risk (A: 0.217, B: 0.079), which is excellent.
11. **Cl_mic:** Ligand A (1.47) has a much lower microsomal clearance than Ligand B (20.352), indicating better metabolic stability. This is a significant advantage for Ligand A.
12. **t1/2:** Ligand B (27.748) has a longer in vitro half-life than Ligand A (-12.733). This is a strong advantage for Ligand B.
13. **Pgp:** Both have very low Pgp efflux liability (A: 0.012, B: 0.011).
14. **Affinity:** Both have the same binding affinity (-7.3 kcal/mol).
**Overall Assessment:**
This is a close call. Ligand B has advantages in DILI risk, Caco-2 permeability, solubility, and half-life. Ligand A has advantages in logP and, crucially, metabolic stability (Cl_mic). Given the importance of metabolic stability for *in vivo* efficacy, and the fact that both ligands have comparable affinity, I lean towards Ligand A. The slightly better BBB penetration of Ligand A is a bonus, even for a cardiovascular target.
Output:
1
2025-04-18 00:39:50,348 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands (365.543 and 360.527 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Both ligands (61.44 and 61.28) are below the 140 A^2 threshold for good oral absorption, and acceptable for a non-CNS GPCR target like ADRB2. No significant difference.
3. **logP:** Both ligands (3.564 and 3.894) are within the optimal 1-3 range, suggesting good permeability and reasonable solubility. Ligand B is slightly higher, which *could* be a minor concern for off-target effects, but not a major issue.
4. **HBD:** Both ligands have 2 H-bond donors, well within the acceptable limit of 5. No difference.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 6. Both are below the 10 limit, but Ligand A is preferable.
6. **QED:** Ligand A (0.81) has a significantly better QED score than Ligand B (0.497), indicating a more drug-like profile. This is a substantial advantage for Ligand A.
7. **DILI:** Ligand A (37.224) has a much lower DILI risk than Ligand B (68.709). This is a significant advantage for Ligand A, as minimizing liver toxicity is crucial.
8. **BBB:** While not a primary concern for ADRB2 (a cardiovascular target), Ligand A (82.823) has a higher BBB penetration than Ligand B (60.45).
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.65 and -5.128). This is unusual and suggests poor permeability. However, the values are similar.
10. **Solubility:** Both ligands have negative solubility values (-3.173 and -3.573). This is also concerning, and suggests poor aqueous solubility. Again, the values are similar.
11. **hERG:** Both ligands have low hERG inhibition risk (0.694 and 0.9). No significant difference.
12. **Cl_mic:** Ligand A (47.008) has a lower microsomal clearance than Ligand B (92.647), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (87.137) has a longer in vitro half-life than Ligand B (108.878). This is a positive for Ligand A, suggesting less frequent dosing potential.
14. **Pgp:** Ligand A (0.231) has lower P-gp efflux liability than Ligand B (0.643), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand B (-6.6 kcal/mol) has a slightly better binding affinity than Ligand A (-5.3 kcal/mol). This is a 1.3 kcal/mol difference, which is substantial, but must be weighed against the other parameters.
**Overall Assessment:**
Ligand A clearly outperforms Ligand B in several crucial ADME-Tox properties: QED, DILI, Cl_mic, Pgp efflux, and t1/2. While Ligand B has a slightly better binding affinity, the superior ADME profile of Ligand A, particularly the lower DILI risk and better metabolic stability, makes it the more promising drug candidate. The negative Caco-2 and solubility values are concerning for both, and would need to be addressed through formulation or further chemical modifications, but these issues are present in both compounds.
**Output:**
1
2025-04-18 00:39:50,348 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
Let's analyze each ligand against the provided guidelines, with emphasis on GPCR-relevant properties (logP, Pgp, TPSA, and affinity).
* **Molecular Weight:** Both ligands (397.86 and 364.47 Da) fall within the ideal 200-500 Da range.
* **TPSA:** Ligand B (76.46) is significantly better than Ligand A (105.76). Lower TPSA generally improves permeability, crucial for GPCR ligands.
* **logP:** Both ligands have good logP values (2.45 and 2.17), falling within the optimal 1-3 range.
* **H-Bond Donors/Acceptors:** Ligand B (1 HBD, 6 HBA) is slightly better than Ligand A (3 HBD, 5 HBA) in terms of balancing solubility and permeability.
* **QED:** Ligand B (0.817) has a higher QED score than Ligand A (0.415), indicating a more drug-like profile.
* **DILI:** Ligand B (65.413) has a lower DILI risk than Ligand A (84.219), which is a significant advantage.
* **BBB:** Ligand A (60.682) has a slightly better BBB penetration than Ligand B (46.491). However, since ADRB2 isn't exclusively a CNS target, this isn't a decisive factor.
* **Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.991 and -4.77). This is unusual and suggests poor permeability in this *in vitro* assay. However, the TPSA differences suggest Ligand B might overcome this better.
* **Aqueous Solubility:** Ligand B (-2.784) is better than Ligand A (-4.341), which is favorable for formulation.
* **hERG Inhibition:** Ligand B (0.306) has a lower hERG risk than Ligand A (0.556), which is critical for avoiding cardiotoxicity, especially important for a cardiovascular target.
* **Microsomal Clearance:** Ligand A (27.378) has lower microsomal clearance than Ligand B (55.108), suggesting better metabolic stability.
* **In vitro Half-Life:** Ligand B (26.966) has a longer in vitro half-life than Ligand A (-24.302), which is desirable.
* **P-gp Efflux:** Both ligands have low P-gp efflux liability (0.2 and 0.175).
* **Binding Affinity:** Ligand A (-6.7 kcal/mol) has a slightly better binding affinity than Ligand B (-5.8 kcal/mol). While a 0.9 kcal/mol difference is noticeable, the other ADME properties of Ligand B are more compelling.
**Overall Assessment:**
Ligand B demonstrates a superior balance of properties, particularly regarding safety (lower DILI, lower hERG) and drug-likeness (higher QED, better solubility). While Ligand A has slightly better affinity and metabolic stability, the advantages of Ligand B in crucial ADME parameters outweigh this difference, especially considering the potential for optimization of Ligand B's affinity. The lower TPSA of Ligand B is also a significant advantage for a GPCR ligand.
**Output:**
0
2025-04-18 00:39:50,348 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [367.515, 81.06, 2.46, 1, 5, 0.886, 60.45, 72.78, -4.781, -4.025, 0.319, 27.197, 39.196, 0.102, -7.4]
**Ligand B:** [347.419, 104.29, 0.246, 2, 5, 0.701, 35.789, 61.264, -5.313, -1.76, 0.022, 16.534, 2.701, 0.005, -6]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity, and BBB):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (347.419) is slightly lower, which could be a minor advantage for permeability.
2. **TPSA:** Ligand A (81.06) is significantly better than Ligand B (104.29). ADRB2 is not a CNS target, but lower TPSA is generally favorable for absorption.
3. **logP:** Ligand A (2.46) is optimal. Ligand B (0.246) is quite low, potentially hindering membrane permeability and bioavailability. This is a significant drawback.
4. **HBD/HBA:** Both have acceptable numbers of HBD (1/2) and HBA (5/5).
5. **QED:** Ligand A (0.886) is better than Ligand B (0.701), indicating a more drug-like profile.
6. **DILI:** Ligand A (60.45) is higher risk than Ligand B (35.789). This is a concern for Ligand A.
7. **BBB:** Ligand A (72.78) is better than Ligand B (61.264), but BBB isn't a high priority for a cardiovascular target.
8. **Caco-2:** Ligand A (-4.781) is better than Ligand B (-5.313), suggesting better intestinal absorption.
9. **Solubility:** Ligand A (-4.025) is better than Ligand B (-1.76), which is a positive attribute.
10. **hERG:** Ligand A (0.319) is better than Ligand B (0.022), indicating a lower risk of cardiotoxicity.
11. **Cl_mic:** Ligand B (16.534) has significantly lower microsomal clearance than Ligand A (27.197), suggesting better metabolic stability.
12. **t1/2:** Ligand A (39.196) has a much longer in vitro half-life than Ligand B (2.701). This is a strong advantage for Ligand A.
13. **Pgp:** Ligand A (0.102) has lower P-gp efflux than Ligand B (0.005), which is favorable for bioavailability.
14. **Affinity:** Ligand A (-7.4) has a slightly better binding affinity than Ligand B (-6). While the difference isn't huge, it's still a positive.
**Overall Assessment:**
Ligand A has several advantages: better logP, QED, solubility, hERG, Pgp efflux, half-life, and binding affinity. However, its DILI risk is higher. Ligand B has lower DILI and better metabolic stability, but suffers from a very low logP, which is a significant concern for permeability and bioavailability. The slightly better affinity of Ligand A, combined with its better overall ADME profile (despite the DILI risk), outweighs the advantages of Ligand B. The low logP of Ligand B is a major red flag.
Therefore, I would choose Ligand A.
1
2025-04-18 00:39:50,348 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (367.471 and 372.487 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (82.66) is better than Ligand B (95.94). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (2.055) is within the optimal 1-3 range. Ligand B (-0.494) is *below* 1, which is a concern for permeability. This is a significant negative for Ligand B.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (6) is better than Ligand B (5). Both are acceptable, but lower is generally favored.
6. **QED:** Both ligands have similar QED values (0.701 and 0.656), indicating good drug-likeness.
7. **DILI:** Ligand A (63.862) has a higher DILI risk than Ligand B (16.673). This is a substantial advantage for Ligand B.
8. **BBB:** Ligand A (53.703) has better BBB penetration than Ligand B (34.044). While not critical for a cardiovascular target, it's a slight positive for A.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.301 and -4.991), which is unusual and suggests poor permeability. However, these values are on a scale where negative values are possible, and the absolute values are similar.
10. **Solubility:** Ligand A (-3.247) has slightly better solubility than Ligand B (-1.027), but both are quite poor.
11. **hERG:** Ligand A (0.624) has a lower hERG risk than Ligand B (0.087), which is a significant advantage.
12. **Cl_mic:** Ligand A (71.462) has higher metabolic clearance than Ligand B (-0.234). This is a negative for Ligand A, suggesting faster metabolism.
13. **t1/2:** Ligand A (-9.83) has a negative half-life, which is concerning. Ligand B (8.38) has a positive half-life, indicating better *in vitro* stability.
14. **Pgp:** Ligand A (0.544) has lower P-gp efflux than Ligand B (0.019), which is favorable.
15. **Binding Affinity:** Ligand B (-6.3 kcal/mol) has a significantly better binding affinity than Ligand A (-4.9 kcal/mol). This 1.4 kcal/mol difference is substantial and can outweigh some ADME concerns.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A has better TPSA and Pgp, but Ligand B has far superior affinity and a more acceptable logP. The DILI risk is also much lower for Ligand B. While Ligand A has a better hERG profile, the substantial affinity advantage of Ligand B is likely to be more impactful. The metabolic stability (Cl_mic and t1/2) is also better for Ligand B.
**Conclusion:**
Despite the better hERG and Pgp properties of Ligand A, the significantly stronger binding affinity, lower DILI risk, and improved metabolic stability of Ligand B make it the more promising drug candidate. The logP issue with Ligand B is concerning, but may be addressable through further optimization.
Output:
0
2025-04-18 00:39:50,348 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (345.378) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (90.98) is better than Ligand B (33.2). While both are acceptable, lower TPSA generally indicates better membrane permeability.
3. **logP:** Ligand A (1.286) is optimal, while Ligand B (4.893) is high. High logP can lead to poor solubility and off-target effects. This is a significant drawback for Ligand B.
4. **HBD:** Ligand A (2) is good, Ligand B (0) is also acceptable.
5. **HBA:** Ligand A (4) is good, Ligand B (3) is also acceptable.
6. **QED:** Ligand A (0.825) is excellent, indicating high drug-likeness. Ligand B (0.655) is still reasonable, but less optimal.
7. **DILI:** Ligand A (50.446) is better than Ligand B (36.758), indicating a lower risk of drug-induced liver injury.
8. **BBB:** Ligand B (84.529) is significantly better than Ligand A (72.896). For a GPCR, BBB penetration isn't *critical* unless targeting the CNS, but it's a positive attribute.
9. **Caco-2:** Ligand A (-5.024) is better than Ligand B (-4.568), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-2.801) is better than Ligand B (-4.341). Solubility is crucial for bioavailability.
11. **hERG:** Ligand A (0.679) is better than Ligand B (0.841), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand A (-5.994) is *much* better than Ligand B (79.299). Lower clearance means better metabolic stability. This is a major advantage for Ligand A.
13. **t1/2:** Ligand A (-25.231) is better than Ligand B (34.256). Longer half-life is generally desirable.
14. **Pgp:** Ligand A (0.018) is much better than Ligand B (0.773), indicating lower P-gp efflux.
15. **Affinity:** Ligand B (-6.3) is significantly better than Ligand A (-3.9). This is a substantial advantage for Ligand B. A difference of 2.4 kcal/mol is quite large.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), we prioritize logP, Pgp, TPSA, and affinity. Ligand B excels in affinity and BBB penetration, but suffers from a high logP and Pgp efflux. Ligand A has a more balanced profile, with better logP, solubility, metabolic stability (Cl_mic, t1/2), and lower Pgp efflux. The superior affinity of Ligand B is tempting, but the high logP and potential for poor solubility/metabolic issues are concerning. The difference in affinity, while significant, may be overcome with further optimization of Ligand A.
**Conclusion:**
Despite the better binding affinity of Ligand B, the significantly better ADME properties of Ligand A make it the more promising drug candidate. The high logP and Pgp efflux of Ligand B are major liabilities that would likely require extensive modification, while Ligand A's profile is already quite favorable.
Output:
1
2025-04-18 00:39:50,349 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
The ADRB2 receptor is a GPCR, so the priorities are logP, TPSA, Pgp efflux, BBB penetration, and binding affinity. Metabolic stability and solubility are also important, but secondary to the first set.
Let's compare the ligands property by property:
1. **MW:** Both ligands (344.415 and 343.431 Da) fall comfortably within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (76.46) is significantly better than Ligand B (90.98). A TPSA under 140 is good for oral absorption, and lower is preferable for GPCRs. Ligand A is much closer to the ideal range for good permeability.
3. **logP:** Ligand A (0.835) is a bit low, potentially hindering permeation, but Ligand B (2.115) is within the optimal 1-3 range. This favors Ligand B slightly.
4. **HBD/HBA:** Ligand A (1 HBD, 5 HBA) is better than Ligand B (2 HBD, 4 HBA). Lower counts are generally preferred for permeability.
5. **QED:** Ligand B (0.84) has a higher QED score than Ligand A (0.56), suggesting a more drug-like profile overall.
6. **DILI:** Ligand A (39.434) has a significantly lower DILI risk than Ligand B (62.35). This is a major advantage for Ligand A.
7. **BBB:** Ligand A (65.452) has better BBB penetration than Ligand B (55.874), though neither is exceptionally high.
8. **Caco-2:** Ligand A (-4.652) has a better Caco-2 permeability than Ligand B (-5.161).
9. **Solubility:** Ligand B (-3.209) has better solubility than Ligand A (-2.209).
10. **hERG:** Ligand A (0.219) has a much lower hERG inhibition liability than Ligand B (0.677), indicating a lower risk of cardiotoxicity.
11. **Cl_mic:** Ligand A (0.421) has significantly lower microsomal clearance than Ligand B (20.002), suggesting better metabolic stability.
12. **t1/2:** Ligand A (-0.787) has a better in vitro half-life than Ligand B (-7.832).
13. **Pgp:** Ligand A (0.054) has a much lower P-gp efflux liability than Ligand B (0.102), which is favorable for bioavailability and potential CNS exposure.
14. **Binding Affinity:** Both ligands have very similar binding affinities (-6.1 and -6.0 kcal/mol). The difference is negligible.
**Overall Assessment:**
Ligand A excels in key ADME properties (DILI, hERG, Cl_mic, Pgp, TPSA) and has comparable binding affinity. While Ligand B has a better QED and logP, the superior safety profile and permeability characteristics of Ligand A outweigh these benefits, especially considering the target is a GPCR where permeability is critical. The lower metabolic clearance and longer half-life of Ligand A are also significant advantages.
**Output:**
1
2025-04-18 00:39:50,349 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (344.39 Da) is slightly lower, which is generally favorable for permeability.
**2. TPSA:** Ligand A (79.18) is significantly better than Ligand B (107.89). For a GPCR, keeping TPSA under 140 is good, but lower is preferable for better absorption. Ligand B is pushing the upper limit and could have absorption issues.
**3. logP:** Ligand A (2.121) is optimal, while Ligand B (0.024) is very low. Low logP can lead to poor membrane permeability and bioavailability. This is a significant drawback for Ligand B.
**4. H-Bond Donors:** Both are acceptable (Ligand A: 3, Ligand B: 4).
**5. H-Bond Acceptors:** Both are acceptable (Ligand A: 5, Ligand B: 6).
**6. QED:** Ligand A (0.797) has a better QED score than Ligand B (0.54), indicating a more drug-like profile.
**7. DILI:** Ligand A (72.082) is better than Ligand B (56.727) in terms of DILI risk, although both are acceptable.
**8. BBB:** Both ligands have reasonable BBB penetration (Ligand A: 70.648, Ligand B: 57.193). Since ADRB2 is a cardiovascular target, BBB penetration is not a primary concern, but it's still a positive attribute.
**9. Caco-2 Permeability:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
**10. Aqueous Solubility:** Both have negative solubility values, which is also unusual. Again, the scale is unclear.
**11. hERG Inhibition:** Ligand A (0.643) is better than Ligand B (0.261), indicating lower cardiotoxicity risk.
**12. Microsomal Clearance:** Ligand A (5.589) is significantly better than Ligand B (-7.095). Lower clearance means greater metabolic stability, a crucial factor for drug duration and efficacy.
**13. In vitro Half-Life:** Ligand A (-1.889) is better than Ligand B (31.538). A negative value is unusual, but likely indicates a longer half-life compared to the positive value of Ligand B.
**14. P-gp Efflux:** Ligand A (0.151) is better than Ligand B (0.029), indicating lower P-gp efflux and potentially better bioavailability.
**15. Binding Affinity:** Ligand B (-7.6) has a slightly better binding affinity than Ligand A (-4.6). However, the difference is not substantial enough to outweigh the significant ADME deficiencies of Ligand B.
**Overall Assessment:**
Ligand A is clearly the superior candidate. It has better physicochemical properties (logP, TPSA, QED), better ADME properties (DILI, clearance, half-life, P-gp efflux, hERG), and acceptable binding affinity. Ligand B's very low logP and poor metabolic stability are major red flags. While its binding affinity is slightly better, the ADME issues are likely to prevent it from being a viable drug candidate.
Output:
1
2025-04-18 00:39:50,349 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.475 and 347.459 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (59.08) is significantly better than Ligand B (73.74). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands (1.679 and 1.931) are within the optimal 1-3 range. Ligand B is slightly higher, but the difference is minimal.
4. **HBD:** Ligand A (0) is preferable to Ligand B (1). Fewer HBDs generally improve permeability.
5. **HBA:** Both ligands have 4 HBA, which is acceptable.
6. **QED:** Ligand B (0.818) has a slightly better QED score than Ligand A (0.667), indicating a more drug-like profile.
7. **DILI:** Both ligands have low DILI risk (11.749 and 12.951), well below the 40% threshold. No clear advantage.
8. **BBB:** Ligand A (84.8) has a significantly higher BBB penetration percentile than Ligand B (61.225). While not a primary concern for a cardiovascular target, higher BBB is generally a positive attribute.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. Ligand A (-4.539) is slightly better than Ligand B (-4.362), but both are concerning.
10. **Solubility:** Both ligands have negative solubility values, indicating poor solubility. Ligand A (-1.182) is slightly better than Ligand B (-1.33).
11. **hERG:** Both ligands have very low hERG inhibition risk (0.343 and 0.426), which is excellent.
12. **Cl_mic:** Ligand A (44.776) has lower microsomal clearance than Ligand B (52.234), suggesting better metabolic stability.
13. **t1/2:** Ligand A (16.233) has a longer in vitro half-life than Ligand B (-5.086). This is a significant advantage.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.052 and 0.085).
15. **Binding Affinity:** Ligand A (-6.6 kcal/mol) has a slightly better binding affinity than Ligand B (-5.6 kcal/mol). This 1 kcal/mol difference is significant and can outweigh some ADME drawbacks.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Both ligands are good on logP and Pgp. Ligand A is significantly better on TPSA, has a better affinity, and a longer half-life. While Ligand B has a slightly better QED, the other factors favor Ligand A. The poor Caco-2 and solubility for both are concerning, but the better affinity and metabolic stability of Ligand A make it the more promising candidate.
**Output:**
1
2025-04-18 00:39:50,349 - INFO - Batch 494 complete. Total preferences: 7904
2025-04-18 00:39:50,349 - INFO - Processing batch 495/512...
2025-04-18 00:40:40,101 - INFO - Reasoning:
Let's analyze both ligands based on the provided guidelines, prioritizing GPCR-relevant parameters (logP, Pgp, TPSA, and affinity).
**Ligand A:**
* **MW:** 348.487 Da - Good.
* **TPSA:** 49.85 - Excellent, well below the 140 threshold.
* **logP:** 3.938 - Very good, within the optimal range.
* **HBD:** 0 - Acceptable.
* **HBA:** 3 - Acceptable.
* **QED:** 0.773 - Excellent.
* **DILI:** 43.195 - Good, low risk.
* **BBB:** 90.074 - Excellent, suggesting good CNS penetration if desired.
* **Caco-2:** -4.265 - Poor, indicates poor intestinal absorption.
* **Solubility:** -4.443 - Poor, indicates low solubility.
* **hERG:** 0.503 - Good, low risk.
* **Cl_mic:** 73.019 - Moderate, could be better.
* **t1/2:** -5.05 - Very poor, indicating rapid metabolism.
* **Pgp:** 0.307 - Good, low efflux.
* **Affinity:** -7.4 kcal/mol - Excellent.
**Ligand B:**
* **MW:** 354.837 Da - Good.
* **TPSA:** 43.26 - Excellent, well below the 140 threshold.
* **logP:** 4.128 - Good, slightly above the optimal range, but acceptable.
* **HBD:** 1 - Acceptable.
* **HBA:** 3 - Acceptable.
* **QED:** 0.723 - Excellent.
* **DILI:** 62.001 - Moderate, slightly elevated risk.
* **BBB:** 56.34 - Moderate, less desirable for CNS targets.
* **Caco-2:** -4.861 - Poor, indicates poor intestinal absorption.
* **Solubility:** -5.23 - Poor, indicates low solubility.
* **hERG:** 0.746 - Good, low risk.
* **Cl_mic:** 83.119 - Moderate-High, indicating faster metabolism.
* **t1/2:** 14.222 - Good, indicating a reasonable half-life.
* **Pgp:** 0.563 - Moderate, higher efflux than Ligand A.
* **Affinity:** -5.4 kcal/mol - Good.
**Comparison & Decision:**
Both compounds have poor Caco-2 permeability and aqueous solubility, which are significant drawbacks. However, considering the GPCR-specific priorities, Ligand A is preferable. Its significantly stronger binding affinity (-7.4 vs -5.4 kcal/mol) is a major advantage. While Ligand B has a better half-life, the 2 kcal/mol difference in binding is substantial and likely to outweigh that benefit, especially for a GPCR target where potency is crucial. Ligand A also has a lower Pgp efflux liability and better BBB penetration. Although Ligand B has a slightly lower DILI risk, the difference isn't dramatic enough to overcome the other advantages of Ligand A.
Output:
1
2025-04-18 00:40:40,101 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.463 and 369.33 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (88.91) is slightly higher than Ligand B (60.77). Both are below the 140 A^2 threshold for good oral absorption, but Ligand B is preferable due to being closer to the 90 A^2 target for GPCRs.
3. **logP:** Both ligands (2.057 and 2.624) are within the optimal 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability, but not drastically.
4. **HBD:** Both ligands have 2 H-bond donors, which is within the acceptable limit of <=5.
5. **HBA:** Ligand A has 5 H-bond acceptors, while Ligand B has 3. Both are below the 10 limit. Ligand B is slightly better here.
6. **QED:** Both ligands have good QED scores (0.669 and 0.785), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (41.877) has a slightly higher DILI risk than Ligand B (35.285), but both are below the concerning threshold of 60.
8. **BBB:** Both ligands have good BBB penetration (70.609 and 74.06), exceeding the 70% threshold for CNS targets. Ligand B is slightly better.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual. This suggests poor permeability. However, the values are relatively close (-4.94 and -4.408).
10. **Solubility:** Both ligands have negative solubility values, which is also unusual and suggests poor aqueous solubility. The values are close (-3.075 and -2.677).
11. **hERG:** Ligand A (0.122) has a slightly lower hERG inhibition liability than Ligand B (0.881), which is preferable.
12. **Cl_mic:** Both ligands have similar microsomal clearance values (30.543 and 30.449), suggesting similar metabolic stability.
13. **t1/2:** Ligand A (4.783) has a longer in vitro half-life than Ligand B (0.013). This is a significant advantage.
14. **Pgp:** Ligand A (0.076) has much lower P-gp efflux liability than Ligand B (0.133), which is a significant advantage for bioavailability and potential CNS exposure.
15. **Binding Affinity:** Ligand B (-5.6 kcal/mol) has a significantly stronger binding affinity than Ligand A (-0.0 kcal/mol). This is a major advantage, potentially outweighing some ADME drawbacks.
**Overall Assessment:**
Ligand B has a significantly stronger binding affinity, which is the most important factor for GPCRs. It also has a lower TPSA, better QED, and slightly better BBB penetration. While Ligand A has a longer half-life and lower P-gp efflux, the substantial difference in binding affinity makes Ligand B the more promising candidate. The negative Caco-2 and solubility values are concerning for both, but can be addressed through formulation strategies.
Output:
0
2025-04-18 00:40:40,101 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's break down the comparison of Ligand A and Ligand B across the 15 parameters, keeping in mind the GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key).
1. **MW:** Both ligands are within the ideal 200-500 Da range. Ligand A (399.252) is slightly higher than Ligand B (354.441), but both are acceptable.
2. **TPSA:** Ligand A (87.11) is a bit higher than Ligand B (45.47). For a cardiovascular GPCR, TPSA isn't *as* critical as for a CNS target, but lower is generally better for absorption. Ligand B is significantly better here.
3. **logP:** Both ligands have a logP around 3.05, which is optimal. No significant difference.
4. **HBD:** Ligand A has 3 HBD, while Ligand B has 1. Both are acceptable (<=5), but Ligand B is slightly favored.
5. **HBA:** Ligand A has 5 HBA, Ligand B has 3. Both are within the acceptable range (<=10).
6. **QED:** Ligand B (0.818) has a better QED score than Ligand A (0.451), indicating a more drug-like profile.
7. **DILI:** Ligand A (89.957) has a significantly higher DILI risk than Ligand B (15.2). This is a major concern for Ligand A.
8. **BBB:** Ligand B (92.168) shows much better BBB penetration potential than Ligand A (66.615). While ADRB2 isn't strictly a CNS target, some CNS exposure can occur, and higher BBB is generally favorable.
9. **Caco-2:** Ligand A (-5.681) and Ligand B (-4.278) both have negative values, which is unusual. This likely indicates poor permeability. However, the scale isn't specified, so it's hard to interpret.
10. **Solubility:** Ligand A (-3.439) and Ligand B (-3.045) both have negative solubility values, which is concerning. Again, the scale is unknown, but this suggests poor aqueous solubility for both.
11. **hERG:** Both ligands have low hERG inhibition risk (0.787 and 0.826 respectively). No significant difference.
12. **Cl_mic:** Ligand A (36.283) and Ligand B (32.665) have similar microsomal clearance values. Both are reasonable.
13. **t1/2:** Ligand B (19.728) has a longer in vitro half-life than Ligand A (59.379). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.623) has slightly higher P-gp efflux liability than Ligand B (0.49). Lower is better, favoring Ligand B.
15. **Affinity:** Ligand B (-7.4 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.4 kcal/mol). This is a crucial advantage, exceeding the 1.5 kcal/mol threshold.
**Overall Assessment:**
Ligand B is the clear winner. While both compounds have solubility and permeability concerns (indicated by negative Caco-2 and solubility values), Ligand B excels in key areas: significantly lower DILI risk, better QED, longer half-life, better BBB penetration, lower P-gp efflux, and, most importantly, a substantially stronger binding affinity. The affinity difference is large enough to outweigh the minor drawbacks.
**Output:**
0
2025-04-18 00:40:40,102 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (428.264 Da) is within the ideal range, while Ligand B (373.356 Da) is also good. No clear advantage here.
2. **TPSA:** Ligand A (115.32) is slightly above the preferred <140 for oral absorption, but acceptable. Ligand B (71.62) is excellent, well below 140 and favorable for permeability. Ligand B has an advantage.
3. **logP:** Ligand A (2.072) is optimal. Ligand B (3.233) is also within the optimal range, but closer to the upper limit. Ligand A has a slight advantage.
4. **HBD:** Ligand A (1) is good. Ligand B (3) is acceptable, but higher. Ligand A has an advantage.
5. **HBA:** Ligand A (7) is good. Ligand B (5) is also good. No clear advantage.
6. **QED:** Both ligands (A: 0.725, B: 0.72) have very similar, excellent QED scores.
7. **DILI:** Ligand A (97.867) has a high DILI risk, which is concerning. Ligand B (82.435) is better, though still relatively high. Ligand B has a significant advantage.
8. **BBB:** Ligand A (57.968) is not great for BBB penetration. Ligand B (77.007) is better, but still not ideal for a CNS-targeting drug (although ADRB2 isn't strictly a CNS target, some peripheral effects are desired).
9. **Caco-2:** Ligand A (-4.888) is poor. Ligand B (-5.014) is also poor. Both are likely to have limited intestinal absorption.
10. **Solubility:** Ligand A (-3.738) is poor. Ligand B (-4.497) is also poor. Both are likely to have formulation challenges.
11. **hERG:** Ligand A (0.245) is very low risk. Ligand B (0.723) is higher, indicating a greater potential for cardiotoxicity. Ligand A has a significant advantage.
12. **Cl_mic:** Ligand A (45.755) is moderate. Ligand B (34.855) is lower, indicating better metabolic stability. Ligand B has an advantage.
13. **t1/2:** Ligand A (88.756) is excellent. Ligand B (20.494) is poor. Ligand A has a significant advantage.
14. **Pgp:** Ligand A (0.191) is low, indicating low efflux. Ligand B (0.568) is higher, suggesting more P-gp mediated efflux. Ligand A has an advantage.
15. **Affinity:** Ligand B (-5.3 kcal/mol) has a significantly stronger binding affinity than Ligand A (-2.3 kcal/mol). This is a substantial difference and a major factor.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B excels in TPSA and has a much better binding affinity. Ligand A has better hERG and half-life. However, the large difference in binding affinity is the most important factor. The improved metabolic stability of Ligand B is also a plus. The higher DILI risk of Ligand A is a significant concern.
**Conclusion:**
Despite the higher DILI risk and slightly worse hERG profile, the significantly stronger binding affinity of Ligand B outweighs the drawbacks. The better TPSA and metabolic stability also contribute to its favorability.
Output:
0
2025-04-18 00:40:40,102 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (a GPCR) drug candidates.
**Ligand A:** [341.367, 100.55 , 1.869, 3. , 5. , 0.788, 73.827, 60.838, -4.938, -4.156, 0.291, 40.197, -5.078, 0.107, -6.9 ]
**Ligand B:** [346.471, 67.43 , 2.684, 2. , 3. , 0.727, 52.152, 66.421, -4.937, -3.887, 0.236, 81.272, -18.092, 0.568, -7. ]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity, and to a lesser extent BBB):
1. **MW:** Both are within the ideal range (200-500 Da).
2. **TPSA:** Ligand A (100.55) is higher than Ligand B (67.43). Lower TPSA is generally better for GPCRs, so B is favored.
3. **logP:** Both are within the optimal range (1-3), but Ligand B (2.684) is slightly higher, which could be beneficial for membrane permeability.
4. **HBD/HBA:** Ligand A has 3 HBD and 5 HBA, while Ligand B has 2 HBD and 3 HBA. Both are acceptable.
5. **QED:** Both have good QED scores (>0.5).
6. **DILI:** Ligand A (73.827) has a higher DILI risk than Ligand B (52.152). B is favored.
7. **BBB:** Ligand B (66.421) has a slightly better BBB penetration potential than Ligand A (60.838), though both are not exceptionally high.
8. **Caco-2:** Both have similar, poor Caco-2 permeability.
9. **Solubility:** Both have similar, poor aqueous solubility.
10. **hERG:** Both have low hERG inhibition liability.
11. **Cl_mic:** Ligand A (40.197) has a significantly lower microsomal clearance than Ligand B (81.272), indicating better metabolic stability. This is a significant advantage for A.
12. **t1/2:** Ligand A (-5.078) has a much longer *in vitro* half-life than Ligand B (-18.092). This is a major advantage for A.
13. **Pgp:** Ligand A (0.107) has lower P-gp efflux liability than Ligand B (0.568), which is favorable for bioavailability and potentially CNS exposure.
14. **Affinity:** Ligand B (-7.0) has a slightly better binding affinity than Ligand A (-6.9). While the difference is small, it's still a factor.
**Overall Assessment:**
Ligand B has advantages in TPSA, logP, BBB, and binding affinity. However, Ligand A shines in metabolic stability (lower Cl_mic, longer t1/2) and P-gp efflux. The difference in binding affinity is minimal. Considering the importance of metabolic stability and reduced efflux for *in vivo* efficacy, and the relatively small benefit of B's affinity, I believe **Ligand A** is the more promising candidate.
Output:
1
2025-04-18 00:40:40,102 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
Let's analyze each ligand against the provided guidelines, keeping in mind ADRB2 is a GPCR, so logP, Pgp, TPSA, and affinity are key.
* **Molecular Weight:** Both ligands (345.443 and 354.426 Da) fall within the ideal 200-500 Da range.
* **TPSA:** Ligand A (61.88) is significantly better than Ligand B (87.32). A TPSA under 140 is good for oral absorption, but lower is preferable for GPCRs, and A is much closer to the ideal range.
* **logP:** Both ligands have acceptable logP values (1.17 and 1.129), falling within the 1-3 range.
* **H-Bond Donors/Acceptors:** Ligand A (1 HBD, 5 HBA) is slightly better than Ligand B (2 HBD, 4 HBA) in terms of maintaining a balance between solubility and permeability.
* **QED:** Ligand B (0.802) has a higher QED score than Ligand A (0.594), indicating a more drug-like profile overall.
* **DILI:** Ligand A (26.095) has a much lower DILI risk than Ligand B (45.677), which is a significant advantage.
* **BBB:** Ligand A (67.08) has a better BBB penetration score than Ligand B (51.842), which is important for GPCRs.
* **Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.88 and -4.972), which is unusual and suggests poor permeability. However, the values are very similar.
* **Aqueous Solubility:** Ligand A (-0.706) is better than Ligand B (-1.925).
* **hERG Inhibition:** Ligand A (0.521) has a lower hERG inhibition liability than Ligand B (0.292), which is a crucial safety parameter.
* **Microsomal Clearance:** Ligand A (42.169) has a higher (worse) microsomal clearance than Ligand B (2.17). This suggests Ligand B is more metabolically stable.
* **In vitro Half-Life:** Ligand B (-35.655) has a significantly longer in vitro half-life than Ligand A (-25.995).
* **P-gp Efflux:** Ligand A (0.02) has a lower P-gp efflux liability than Ligand B (0.034), which is preferable.
* **Binding Affinity:** Ligand B (-7.0) has a stronger binding affinity than Ligand A (-5.1). This is a substantial difference (over 1.9 kcal/mol) and a major factor.
**Overall Assessment:**
Ligand B has a significantly stronger binding affinity and better metabolic stability (lower Cl_mic, longer t1/2), and a better QED score. However, Ligand A has a much better safety profile (lower DILI, lower hERG) and better BBB penetration. The difference in binding affinity is substantial enough to outweigh the ADME concerns with Ligand B, especially considering the potential for further optimization of Ligand B's ADME properties. The lower DILI and hERG risks of Ligand A are important, but can also be addressed through structural modifications.
**Output:**
0
2025-04-18 00:40:40,102 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (348.422 and 347.419 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (76.44) is significantly better than Ligand B (105.98). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is approaching a level that could hinder oral absorption.
**3. logP:** Both ligands have good logP values (0.974 and 0.85), falling within the 1-3 range. No clear advantage.
**4. H-Bond Donors:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
**5. H-Bond Acceptors:** Ligand B (6) is higher than Ligand A (4). Again, lower is generally better for permeability.
**6. QED:** Ligand A (0.803) has a better QED score than Ligand B (0.678), indicating a more drug-like profile.
**7. DILI:** Ligand A (12.796) has a *much* lower DILI risk than Ligand B (53.432). This is a critical advantage. A DILI percentile above 40 is concerning, and Ligand B is significantly higher.
**8. BBB:** Ligand A (74.292) has a better BBB penetration score than Ligand B (56.883). While ADRB2 is a cardiovascular target and CNS penetration isn't paramount, some level of BBB penetration can be useful for off-target effects assessment.
**9. Caco-2 Permeability:** Both ligands show negative Caco-2 values (-4.971 and -5.056). These values are unusual and suggest poor permeability. However, the values are very similar.
**10. Aqueous Solubility:** Both ligands have very poor aqueous solubility (-2.922 and -2.564). This is a significant drawback for both, and would require formulation strategies.
**11. hERG Inhibition:** Ligand A (0.584) has a lower hERG inhibition liability than Ligand B (0.027). This is a crucial safety parameter, and Ligand A is significantly better.
**12. Microsomal Clearance:** Ligand A (8.496) has a much lower microsomal clearance than Ligand B (29.171), suggesting better metabolic stability.
**13. In vitro Half-Life:** Ligand A (-0.638) has a slightly better in vitro half-life than Ligand B (-7.145).
**14. P-gp Efflux:** Ligand A (0.011) has a lower P-gp efflux liability than Ligand B (0.053), which is favorable for bioavailability.
**15. Binding Affinity:** Ligand B (-7.1 kcal/mol) has a slightly better binding affinity than Ligand A (-7.8 kcal/mol). However, the difference is relatively small (0.7 kcal/mol) and is outweighed by the significant advantages of Ligand A in other critical parameters.
**Overall Assessment:**
Ligand A is the clear preference. It exhibits a significantly better safety profile (lower DILI, lower hERG), better drug-likeness (higher QED), better metabolic stability (lower Cl_mic), and better permeability characteristics (lower TPSA, lower HBD/HBA). While Ligand B has slightly better binding affinity, the other advantages of Ligand A are far more important for overall drug development success. The solubility issues are a concern for both, but can be addressed with formulation work.
Output:
1
2025-04-18 00:40:40,102 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [367.421, 71.09, 3.58, 2, 4, 0.786, 71.617, 63.823, -4.75, -3.481, 0.314, 51.832, 43.286, 0.246, -6.7]**
**Ligand B: [368.474, 67.43, 2.281, 2, 4, 0.691, 60.799, 72.005, -5.142, -3.175, 0.74, 58.312, 11.345, 0.297, -6.9]**
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). A: 367.421, B: 368.474. No significant difference.
2. **TPSA:** Both are reasonably good, but ligand B (67.43) is better than A (71.09). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA is generally favorable for absorption.
3. **logP:** Ligand A (3.58) is slightly higher than ligand B (2.281). While both are within the optimal range, A is approaching the upper limit where solubility issues could arise.
4. **H-Bond Donors:** Both have 2 HBD, which is good.
5. **H-Bond Acceptors:** Both have 4 HBA, which is good.
6. **QED:** Ligand A (0.786) has a better QED score than Ligand B (0.691), indicating a more drug-like profile.
7. **DILI:** Ligand B (60.799) has a lower DILI risk than Ligand A (71.617), which is a significant advantage.
8. **BBB:** Ligand B (72.005) has a higher BBB penetration than Ligand A (63.823). While not critical for a cardiovascular target, it's a slight positive.
9. **Caco-2:** Ligand B (-5.142) has a better Caco-2 permeability than Ligand A (-4.75). This suggests better intestinal absorption.
10. **Solubility:** Ligand B (-3.175) has better aqueous solubility than Ligand A (-3.481). This is a positive, especially given A's higher logP.
11. **hERG:** Ligand B (0.74) has a slightly higher hERG risk than Ligand A (0.314), which is a negative.
12. **Cl_mic:** Ligand B (58.312) has a lower microsomal clearance than Ligand A (51.832), indicating better metabolic stability.
13. **t1/2:** Ligand A (43.286) has a significantly longer in vitro half-life than Ligand B (11.345). This is a major advantage, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand B (0.297) has a lower P-gp efflux liability than Ligand A (0.246). This is a positive for bioavailability.
15. **Binding Affinity:** Ligand B (-6.9) has a slightly better binding affinity than Ligand A (-6.7). While the difference is small, it's still a factor.
**Overall Assessment:**
Ligand B has several advantages: lower DILI risk, better Caco-2 permeability, better solubility, and better metabolic stability. Ligand A has a better QED and a significantly longer half-life. The difference in binding affinity is minimal. Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity) and the importance of minimizing toxicity (DILI), Ligand B appears to be the more promising candidate. The longer half-life of Ligand A is attractive, but the other benefits of Ligand B outweigh this advantage.
Output:
0
2025-04-18 00:40:40,103 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, key priorities are logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB.
Let's compare the ligands property by property:
1. **MW:** Both ligands (352.475 and 346.358 Da) fall within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (59.08) is significantly better than Ligand B (80.57). A TPSA under 140 is good for oral absorption, and lower is better for GPCRs. Ligand A is much closer to the ideal for GPCRs.
3. **logP:** Both ligands have acceptable logP values (1.818 and 2.427), falling within the 1-3 range. Ligand B is slightly higher, which *could* be a minor drawback.
4. **HBD/HBA:** Ligand A has 0 HBD and 4 HBA, while Ligand B has 2 HBD and 4 HBA. Both are acceptable.
5. **QED:** Both ligands have good QED scores (0.774 and 0.871), indicating good drug-like properties.
6. **DILI:** Ligand A (16.208) has a much lower DILI risk than Ligand B (73.013). This is a significant advantage for Ligand A.
7. **BBB:** Ligand A (85.033) has better BBB penetration than Ligand B (68.864), although this is less critical for a cardiovascular target.
8. **Caco-2:** Both have negative Caco-2 values (-4.208 and -4.313) which is unusual and suggests poor permeability.
9. **Solubility:** Both ligands have poor solubility (-2.098 and -3.628).
10. **hERG:** Both ligands have low hERG inhibition risk (0.46 and 0.322).
11. **Cl_mic:** Ligand B (24.472) has a lower microsomal clearance than Ligand A (33.832), suggesting better metabolic stability.
12. **t1/2:** Ligand B (49.542) has a significantly longer in vitro half-life than Ligand A (12.834). This is a major advantage for Ligand B.
13. **Pgp:** Ligand A (0.062) has much lower P-gp efflux liability than Ligand B (0.175). This is a significant advantage for Ligand A, improving bioavailability.
14. **Binding Affinity:** Ligand A (-6.8 kcal/mol) has a slightly better binding affinity than Ligand B (-5.0 kcal/mol). This 1.8 kcal/mol difference is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand A has a superior safety profile (lower DILI), better TPSA, better Pgp efflux, and a significantly stronger binding affinity. While Ligand B has better metabolic stability (lower Cl_mic) and a longer half-life, the advantages of Ligand A in terms of safety, permeability, and potency are more critical for a GPCR target, especially considering the poor Caco-2 and solubility of both compounds. The binding affinity difference is also significant.
Output:
1
2025-04-18 00:40:40,103 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [406.259, 64.22, 3.478, 1, 5, 0.722, 81.892, 81.039, -4.79, -4.312, 0.583, 48.124, 42.905, 0.453, -8]
**Ligand B:** [356.467, 133.55, 0.387, 5, 4, 0.382, 10.818, 58.666, -5.497, -1.573, 0.191, -2.684, -6.087, 0.013, -5.5]
**Step-by-step comparison:**
1. **MW:** Ligand A (406.259 Da) is within the ideal range. Ligand B (356.467 Da) is also acceptable. No clear advantage here.
2. **TPSA:** Ligand A (64.22) is excellent, well below 140 and good for permeability. Ligand B (133.55) is higher, but still within acceptable limits for a peripheral GPCR like ADRB2, though less ideal.
3. **logP:** Ligand A (3.478) is optimal. Ligand B (0.387) is quite low, potentially leading to poor membrane permeability and bioavailability. This is a significant concern.
4. **HBD:** Ligand A (1) is good. Ligand B (5) is at the upper limit of acceptable, potentially impacting permeability.
5. **HBA:** Ligand A (5) is good. Ligand B (4) is also good.
6. **QED:** Ligand A (0.722) is excellent, indicating good drug-like properties. Ligand B (0.382) is poor, suggesting potential issues.
7. **DILI:** Ligand A (81.892) is relatively high, indicating a moderate risk of liver injury. Ligand B (10.818) is very low, indicating minimal risk.
8. **BBB:** Ligand A (81.039) is good, suggesting some potential for CNS penetration, though ADRB2 is primarily a cardiovascular target. Ligand B (58.666) is lower, less likely to cross the BBB.
9. **Caco-2:** Ligand A (-4.79) is poor. Ligand B (-5.497) is also poor. Both have very low Caco-2 permeability.
10. **Solubility:** Ligand A (-4.312) is poor. Ligand B (-1.573) is also poor. Both have low solubility.
11. **hERG:** Ligand A (0.583) is low risk. Ligand B (0.191) is very low risk.
12. **Cl_mic:** Ligand A (48.124) is moderate. Ligand B (-2.684) is excellent, indicating very high metabolic stability.
13. **t1/2:** Ligand A (42.905) is good. Ligand B (-6.087) is very poor, indicating rapid metabolism.
14. **Pgp:** Ligand A (0.453) is low efflux. Ligand B (0.013) is very low efflux.
15. **Affinity:** Both ligands have very good affinity (-8 kcal/mol and -5.5 kcal/mol respectively). Ligand A is significantly more potent.
**GPCR-Specific Considerations:**
For ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A has a much better logP and significantly better affinity. While Ligand B has a better DILI score and metabolic stability, the poor logP and lower affinity are major drawbacks for a GPCR target. The low Caco-2 and solubility are also concerning.
**Overall Assessment:**
Despite the higher DILI risk, Ligand A is the more promising candidate. The significantly better logP, affinity, and QED outweigh the DILI concern, especially considering optimization strategies can be employed to mitigate liver toxicity. Ligand B's poor logP and lower affinity are likely to translate to poor *in vivo* performance.
**Output:**
1
2025-04-18 00:40:40,103 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (351.443 and 346.427 Da) fall comfortably within the ideal range of 200-500 Da. No significant difference here.
**2. TPSA:** Ligand A (87.85) is slightly higher than Ligand B (64.8). Both are below the 140 A^2 threshold for good oral absorption, but Ligand B is preferable given the GPCR target class.
**3. logP:** Both ligands have logP values within the optimal range (3.08 and 3.404). Ligand B is slightly higher, which could potentially lead to off-target effects, but the difference isn't substantial.
**4. H-Bond Donors:** Ligand A has 1 HBD, while Ligand B has 0. Both are acceptable.
**5. H-Bond Acceptors:** Both ligands have 6 HBAs, which is within the acceptable limit of 10.
**6. QED:** Ligand A (0.648) has a slightly higher QED score than Ligand B (0.539), suggesting a more drug-like profile.
**7. DILI Risk:** Ligand B (39.046) has a significantly lower DILI risk than Ligand A (60.915). This is a major advantage for Ligand B.
**8. BBB Penetration:** Ligand A (77.162) has better BBB penetration than Ligand B (68.748). While ADRB2 is a cardiovascular target, some CNS effects are possible with adrenergic agonists, so moderate BBB penetration isn't necessarily detrimental.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.613 and -4.6), indicating poor permeability. This is a concern for both.
**10. Aqueous Solubility:** Both ligands have negative solubility values (-4.539 and -4.319), indicating poor solubility. This is a concern for both.
**11. hERG Inhibition:** Ligand A (0.657) has slightly lower hERG inhibition risk than Ligand B (0.824), which is preferable.
**12. Microsomal Clearance:** Both ligands have similar microsomal clearance values (108.576 and 106.372), suggesting similar metabolic stability.
**13. In vitro Half-Life:** Ligand A (-27.49) has a slightly longer half-life than Ligand B (-20.726), which is a minor advantage.
**14. P-gp Efflux:** Ligand A (0.163) has lower P-gp efflux than Ligand B (0.832). This is a significant advantage for Ligand A.
**15. Binding Affinity:** Ligand A (-6.2 kcal/mol) has a slightly better binding affinity than Ligand B (-5.0 kcal/mol). This is a substantial advantage for Ligand A.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand A is slightly better. The superior binding affinity (-6.2 vs -5.0 kcal/mol) and lower P-gp efflux (0.163 vs 0.832) are significant advantages. While Ligand B has a much lower DILI risk, the affinity difference is substantial enough to outweigh this concern, especially given the cardiovascular context where DILI risk can be monitored. The slightly better QED and half-life of Ligand A also contribute to its preference. The poor Caco-2 and solubility are concerns for both, and would require formulation strategies.
Output:
1
2025-04-18 00:40:40,103 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (346.381 and 348.403 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (42.54) is significantly lower than Ligand B (118.53). For a GPCR, lower TPSA is generally preferred for better permeability. Ligand A is well below the 140 A^2 threshold, while Ligand B is approaching the upper limit.
**3. logP:** Ligand A (3.394) is within the optimal 1-3 range. Ligand B (0.605) is quite low, potentially indicating poor membrane permeability and bioavailability. This is a significant drawback.
**4. H-Bond Donors:** Ligand A (0) is excellent, minimizing potential issues with permeability. Ligand B (2) is acceptable, but not as favorable.
**5. H-Bond Acceptors:** Ligand A (4) is good. Ligand B (5) is also acceptable.
**6. QED:** Both ligands have good QED scores (0.687 and 0.826), indicating generally drug-like properties.
**7. DILI Risk:** Ligand A (55.138) has a slightly higher DILI risk than Ligand B (43.932), but both are below the concerning threshold of 60.
**8. BBB Penetration:** Ligand A (90.617) shows excellent BBB penetration, which, while not *essential* for a cardiovascular target, isn't detrimental. Ligand B (65.529) is lower, but still reasonable.
**9. Caco-2 Permeability:** Ligand A (-4.387) is poor, while Ligand B (-5.33) is worse. Both are negative, indicating low permeability.
**10. Aqueous Solubility:** Ligand A (-3.462) is poor, while Ligand B (-1.918) is slightly better.
**11. hERG Inhibition:** Ligand A (0.87) is a bit higher than Ligand B (0.096), indicating a slightly increased risk of cardiotoxicity. However, both are relatively low.
**12. Microsomal Clearance:** Ligand A (63.982) has higher clearance than Ligand B (2.411), suggesting faster metabolism and potentially lower *in vivo* exposure. This is a negative for Ligand A.
**13. In vitro Half-Life:** Ligand A (21.527) has a longer half-life than Ligand B (-20.871). This is a positive for Ligand A.
**14. P-gp Efflux:** Ligand A (0.878) has higher P-gp efflux than Ligand B (0.017), which is unfavorable.
**15. Binding Affinity:** Ligand B (-6.6) has a slightly better binding affinity than Ligand A (-5.8). This is a 1.5 kcal/mol difference, which is significant.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand B emerges as the more promising candidate. While Ligand A has better BBB penetration and in vitro half-life, Ligand B's significantly better logP, lower P-gp efflux, and slightly improved binding affinity outweigh these advantages. The lower logP of Ligand A is a major concern for permeability and bioavailability. The substantial difference in microsomal clearance also favors Ligand B.
Output:
0
2025-04-18 00:40:40,103 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor (a GPCR).
**Ligand A:** [338.411, 69.04, 3.527, 1, 5, 0.793, 74.409, 52.385, -4.564, -4.494, 0.848, 80.36, 22.613, 0.61, -7.2]
**Ligand B:** [346.431, 91.48, 0.852, 2, 6, 0.847, 44.203, 29.12, -5.13, -1.877, 0.137, 9.557, -3.281, 0.054, -7.3]
Here's a breakdown, prioritizing GPCR properties (logP, TPSA, Pgp, BBB, and Affinity):
1. **Molecular Weight:** Both are within the ideal 200-500 Da range. A (338.411) is slightly preferred.
2. **TPSA:** Ligand A (69.04) is excellent, well below 140 and good for oral absorption. Ligand B (91.48) is higher, but still acceptable.
3. **logP:** Ligand A (3.527) is optimal. Ligand B (0.852) is quite low, potentially leading to poor membrane permeability. This is a significant drawback.
4. **H-Bond Donors/Acceptors:** Both are within reasonable limits (A: 1/5, B: 2/6).
5. **QED:** Both have good QED scores (A: 0.793, B: 0.847), indicating drug-likeness.
6. **DILI:** Ligand A (74.409) has a higher DILI risk than Ligand B (44.203). This favors B.
7. **BBB:** Ligand A (52.385) has a better BBB penetration potential than Ligand B (29.12).
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. A (-4.564) is worse than B (-5.13).
9. **Solubility:** Both have negative solubility values, which is also unusual. B (-1.877) is slightly better than A (-4.494).
10. **hERG:** Ligand A (0.848) has a slightly higher hERG risk than Ligand B (0.137), favoring B.
11. **Cl_mic:** Ligand B (9.557) has significantly lower microsomal clearance, indicating better metabolic stability, which is a major advantage.
12. **t1/2:** Ligand B (-3.281) has a longer in vitro half-life than Ligand A (22.613), favoring B.
13. **Pgp:** Ligand A (0.61) has a lower P-gp efflux liability than Ligand B (0.054), which is beneficial.
14. **Binding Affinity:** Ligand B (-7.3) has a slightly better binding affinity than Ligand A (-7.2), but the difference is minimal.
**Overall Assessment:**
While Ligand A has better logP and Pgp properties, Ligand B demonstrates superior metabolic stability (lower Cl_mic, longer t1/2), lower DILI risk, lower hERG risk, and a slightly better binding affinity. The low logP of Ligand A is a significant concern for permeability. The negative Caco-2 and solubility values for both are concerning, but the other advantages of Ligand B outweigh these issues. Considering the GPCR-specific priorities, the improved metabolic stability and safety profile of Ligand B make it the more promising candidate.
Output:
0
2025-04-18 00:40:40,104 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (353.419 Da and 352.41 Da) are within the ideal range of 200-500 Da. No significant difference here.
2. **TPSA:** Ligand A (109.25) is higher than Ligand B (84.42). For a GPCR, lower TPSA is preferred, giving a slight edge to Ligand B.
3. **logP:** Ligand A (0.094) is quite low, potentially hindering permeability. Ligand B (1.935) is within the optimal range of 1-3. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (1). Both are acceptable, but lower is generally better.
5. **HBA:** Ligand A (6) is slightly higher than Ligand B (5). Both are acceptable.
6. **QED:** Ligand B (0.811) is better than Ligand A (0.627), indicating a more drug-like profile.
7. **DILI:** Ligand A (35.014) has a slightly higher DILI risk than Ligand B (29.779), but both are below the concerning threshold of 60.
8. **BBB:** Ligand B (92.323) shows significantly better BBB penetration potential than Ligand A (52.734). This is a crucial advantage for a GPCR target, even if it's not a CNS target, as it can indicate better distribution properties.
9. **Caco-2:** Ligand A (-5.018) is worse than Ligand B (-4.36). Higher Caco-2 values are better, indicating better absorption.
10. **Solubility:** Ligand A (-1.478) is worse than Ligand B (-2.76). Higher solubility is preferred.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.198 and 0.207, respectively). No significant difference.
12. **Cl_mic:** Ligand A (0.831) has much lower microsomal clearance than Ligand B (63.06), suggesting better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand B (-26.421) has a much longer in vitro half-life than Ligand A (17.766). This is a significant advantage for Ligand B.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.011 and 0.012, respectively). No significant difference.
15. **Binding Affinity:** Ligand B (-6.9 kcal/mol) has a slightly better binding affinity than Ligand A (-6.7 kcal/mol), but the difference is small.
**Overall Assessment:**
Ligand B demonstrates a superior balance of properties for a GPCR target like ADRB2. Its better logP, TPSA, BBB penetration, QED, solubility, and half-life outweigh the slightly higher DILI risk and lower metabolic stability compared to Ligand A. The small difference in binding affinity is not enough to compensate for the ADME advantages of Ligand B.
Output:
0
2025-04-18 00:40:40,104 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (343.471 and 336.435 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Both ligands (48.31 and 49.41) are below the 140 A^2 threshold for good oral absorption, and are quite favorable. No clear advantage.
3. **logP:** Ligand A (4.483) is slightly higher than Ligand B (2.71). While both are within the optimal 1-3 range, Ligand A is pushing the upper limit. Ligand B is more favorably positioned.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 5 HBA, while Ligand B has 2. Both are acceptable, but Ligand B is better.
6. **QED:** Both ligands have good QED scores (0.646 and 0.841), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (35.712) has a lower DILI risk than Ligand B (42.807), which is a significant advantage.
8. **BBB:** Ligand A (82.241) has a higher BBB penetration percentile than Ligand B (62.97). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be beneficial for understanding off-target effects and overall distribution.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. This is a major concern for both.
10. **Solubility:** Both ligands have very poor aqueous solubility (-5.088 and -3.83). This is a significant drawback for both.
11. **hERG:** Ligand A (0.806) has a slightly higher hERG risk than Ligand B (0.313). Ligand B is significantly better.
12. **Cl_mic:** Ligand A (102.51) has a higher microsomal clearance than Ligand B (39.92), indicating lower metabolic stability. Ligand B is significantly better.
13. **t1/2:** Ligand B (-5.185) has a more negative in vitro half-life, indicating a shorter half-life, which is undesirable. Ligand A (1.603) is better.
14. **Pgp:** Ligand A (0.827) has a higher P-gp efflux liability than Ligand B (0.22). Ligand B is significantly better.
15. **Binding Affinity:** Ligand B (-7.1 kcal/mol) has a significantly stronger binding affinity than Ligand A (-4.8 kcal/mol). This is a substantial advantage that can potentially offset some ADME liabilities.
**GPCR-specific priorities:** For GPCRs, logP, Pgp, TPSA, and affinity are key. Ligand B excels in Pgp, has a better logP, and a much better binding affinity. While both have poor Caco-2 and solubility, the significantly improved affinity and ADME properties of Ligand B make it the more promising candidate. The lower DILI risk of Ligand A is a positive, but the affinity difference is substantial.
**Conclusion:**
Ligand B is the more promising candidate despite its slightly higher DILI risk, due to its significantly improved binding affinity, better logP, lower Pgp efflux, and lower microsomal clearance.
Output:
0
2025-04-18 00:40:40,104 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (349.5 and 344.4 Da). No significant difference here.
2. **TPSA:** Ligand A (52.65) is significantly better than Ligand B (98.39). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both are good (2.425 and 1.51), falling within the optimal 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD is generally preferred for better permeability.
5. **HBA:** Ligand A (3) is better than Ligand B (6). Similar reasoning as HBD.
6. **QED:** Both are good (0.718 and 0.828), indicating good drug-like properties. No clear advantage.
7. **DILI:** Ligand A (11.13) is *much* better than Ligand B (71.50). This is a major advantage for Ligand A. DILI risk is a critical factor.
8. **BBB:** Ligand A (78.87) is better than Ligand B (43.20), but BBB isn't a high priority for a cardiovascular target.
9. **Caco-2:** Both are negative (-4.96 and -4.911), indicating poor permeability. This is a concern for both, but not a deciding factor between them.
10. **Solubility:** Ligand A (-2.622) is better than Ligand B (-3.455), although both are poor. Solubility is a concern for both, but slightly less so for A.
11. **hERG:** Ligand A (0.552) is better than Ligand B (0.349), indicating lower cardiotoxicity risk. This is important for a cardiovascular target.
12. **Cl_mic:** Ligand A (37.43) is better than Ligand B (-0.366). Lower clearance is preferred for longer duration of action.
13. **t1/2:** Ligand A (4.425) is better than Ligand B (17.809). Longer half-life is generally desirable.
14. **Pgp:** Ligand A (0.092) is better than Ligand B (0.068). Lower P-gp efflux is preferred for better bioavailability.
15. **Affinity:** Ligand A (-7.3) is *significantly* better than Ligand B (-1.3). This is a substantial difference in potency. A 6 kcal/mol difference can often outweigh minor ADME drawbacks.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A excels in affinity, has a better TPSA, and better Pgp efflux. While both have acceptable logP values, A is slightly better.
**Overall Assessment:**
Ligand A is clearly superior. Its significantly better binding affinity, much lower DILI risk, better metabolic stability (Cl_mic and t1/2), and favorable TPSA and Pgp properties outweigh the slightly poorer solubility and Caco-2 permeability compared to Ligand B. The large difference in binding affinity is the most important factor.
Output:
1
2025-04-18 00:40:40,104 - INFO - Batch 495 complete. Total preferences: 7920
2025-04-18 00:40:40,104 - INFO - Processing batch 496/512...
2025-04-18 00:41:27,591 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (387.571 and 379.488 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (61.88) is higher than Ligand B (37.38). For a cardiovascular GPCR, TPSA is moderately important. Ligand B's lower TPSA is preferable, suggesting better permeability.
**3. logP:** Ligand A (1.729) is within the optimal 1-3 range. Ligand B (4.099) is slightly above, potentially leading to solubility issues or off-target interactions. Ligand A is favored here.
**4. H-Bond Donors:** Ligand A (1) is good. Ligand B (0) is also acceptable. No strong preference.
**5. H-Bond Acceptors:** Ligand A (6) is acceptable. Ligand B (3) is also good. No strong preference.
**6. QED:** Ligand B (0.637) has a better QED score than Ligand A (0.48), indicating a more drug-like profile.
**7. DILI Risk:** Ligand A (21.132) has a significantly lower DILI risk than Ligand B (27.801). This is a crucial advantage for Ligand A.
**8. BBB Penetration:** Ligand B (95.502) shows much better BBB penetration than Ligand A (64.87). While ADRB2 is primarily a cardiovascular target, some CNS effects are possible with beta-blockers, and better CNS penetration could be a benefit or a liability depending on the desired therapeutic profile.
**9. Caco-2 Permeability:** Ligand A (-5.734) has a worse Caco-2 permeability than Ligand B (-4.684).
**10. Aqueous Solubility:** Ligand A (-1.721) has a worse solubility than Ligand B (-4.093).
**11. hERG Inhibition:** Ligand A (0.238) has a lower hERG inhibition liability than Ligand B (0.47). This is a significant safety advantage for Ligand A.
**12. Microsomal Clearance:** Ligand B (66.043) has a much higher microsomal clearance than Ligand A (4.325), indicating faster metabolism and potentially lower bioavailability. Ligand A is strongly favored here.
**13. In vitro Half-Life:** Ligand A (20.203) has a much longer in vitro half-life than Ligand B (-9.041). This is a major advantage for Ligand A, suggesting less frequent dosing.
**14. P-gp Efflux:** Ligand A (0.011) has a very low P-gp efflux liability, while Ligand B (0.375) is higher. This is a benefit for Ligand A, improving bioavailability.
**15. Binding Affinity:** Ligand B (-6.7) has a slightly better binding affinity than Ligand A (-5.9). However, the difference is less than 1.5 kcal/mol, and can be outweighed by other factors.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity) and general drug-like properties, Ligand A appears to be the more promising candidate. While Ligand B has better BBB penetration and slightly better affinity, Ligand A excels in critical areas like DILI risk, hERG inhibition, metabolic stability (lower Cl_mic, longer t1/2), and P-gp efflux. The lower logP of Ligand A is also preferable. The solubility and Caco-2 permeability are worse for Ligand A, but these can potentially be addressed through formulation strategies. The safety profile of Ligand A is significantly better.
Output:
1
2025-04-18 00:41:27,591 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [390.774, 79.9, 4.261, 2, 5, 0.7, 98.643, 52.889, -4.733, -5.447, 0.778, 41.941, 20.047, 0.766, -6.6]
**Ligand B:** [358.463, 75.27, 2.473, 2, 3, 0.747, 60.799, 52.772, -4.747, -3.778, 0.294, 32.648, -20.474, 0.105, -7.7]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (358.463) is slightly preferred due to being a bit lower.
2. **TPSA:** Both are acceptable for oral absorption (<140), but not optimized for CNS penetration. Ligand B (75.27) is slightly better.
3. **logP:** Ligand A (4.261) is a bit high, potentially leading to solubility issues and off-target effects. Ligand B (2.473) is much better, falling squarely within the optimal 1-3 range.
4. **HBD/HBA:** Both have reasonable HBD (2) and HBA (5/3) counts. No significant difference here.
5. **QED:** Both are good (>0.5), indicating drug-likeness.
6. **DILI:** Ligand A (98.643) has a very high DILI risk, which is a major concern. Ligand B (60.799) is still elevated, but significantly lower and more acceptable.
7. **BBB:** Both have similar BBB penetration (around 53%), which isn't a primary concern for a non-CNS target like a cardiovascular ADRB2.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and indicates very poor permeability. This is a significant drawback for both.
9. **Solubility:** Both have negative solubility values, indicating very poor solubility. This is a significant drawback for both.
10. **hERG:** Ligand A (0.778) has a slightly higher hERG risk than Ligand B (0.294).
11. **Cl_mic:** Ligand B (32.648) has lower microsomal clearance, suggesting better metabolic stability than Ligand A (41.941).
12. **t1/2:** Ligand A (20.047) has a positive in vitro half-life, while Ligand B (-20.474) has a negative one. This is unusual, and suggests that Ligand A has a more stable in vitro half-life.
13. **Pgp:** Ligand A (0.766) has a higher Pgp efflux liability than Ligand B (0.105), meaning Ligand B is less likely to be pumped out of cells.
14. **Affinity:** Ligand B (-7.7 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.6 kcal/mol) - a difference of 1.1 kcal/mol. This is a substantial advantage.
**Overall Assessment:**
Despite both ligands having significant drawbacks (poor Caco-2 and solubility), Ligand B is clearly the better candidate. The stronger binding affinity (-7.7 vs -6.6 kcal/mol) is a major advantage, and it's coupled with a significantly lower DILI risk, better logP, and lower Pgp efflux. The slightly better metabolic stability is also a plus. While the negative in vitro half-life is concerning, the other benefits outweigh this issue.
Output:
0
2025-04-18 00:41:27,592 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (341.363 and 351.466 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (86.51) is better than Ligand B (43.86). Both are well below the 140 A^2 threshold for oral absorption, but Ligand B is significantly lower, which could be beneficial for permeability.
3. **logP:** Ligand A (3.816) is within the optimal range (1-3), while Ligand B (1.526) is at the lower end. For a GPCR, a slightly higher logP is generally preferred for membrane permeability and receptor engagement. Ligand A is better here.
4. **HBD:** Both ligands have 0 HBD, which is good.
5. **HBA:** Ligand A has 5 HBA, and Ligand B has 3. Both are acceptable, but lower is generally preferred. Ligand B is slightly better.
6. **QED:** Ligand B (0.729) has a better QED score than Ligand A (0.453), indicating a more drug-like profile.
7. **DILI:** Ligand B (13.571) has a much lower DILI risk than Ligand A (87.786). This is a major advantage for Ligand B.
8. **BBB:** Both ligands have good BBB penetration (Ligand A: 60.799, Ligand B: 87.476). Ligand B is better.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.307 and -4.631). This is unusual and suggests poor permeability *in vitro*. However, these values are relative and may not be directly comparable without knowing the scale.
10. **Solubility:** Ligand A (-5.624) has slightly better solubility than Ligand B (-1.574).
11. **hERG:** Both ligands have low hERG inhibition risk (Ligand A: 0.415, Ligand B: 0.538). No significant difference.
12. **Cl_mic:** Ligand A (100.923) has significantly better metabolic stability (lower clearance) than Ligand B (15.463). This is a substantial advantage for Ligand A.
13. **t1/2:** Ligand A (-13.875) has a much longer *in vitro* half-life than Ligand B (-0.55). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.451) has lower P-gp efflux than Ligand B (0.107), which is better.
15. **Binding Affinity:** Ligand A (-7.4) has a stronger binding affinity than Ligand B (-6.1). This is a 1.3 kcal/mol difference, which is substantial and can outweigh some ADME drawbacks.
**Overall Assessment & GPCR-Specific Priorities:**
For an ADRB2 (GPCR) target, affinity, logP, TPSA, and metabolic stability are key. Ligand A has a significantly better binding affinity and metabolic stability (Cl_mic and t1/2). While Ligand B has better QED, DILI, and BBB, the strong affinity of Ligand A, combined with acceptable ADME properties, makes it the more promising candidate. The lower DILI risk of Ligand B is attractive, but can be addressed with further optimization. The slightly higher logP of Ligand A is also advantageous for GPCR engagement.
Output:
1
2025-04-18 00:41:27,592 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (361.47 & 351.40 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand B (53.51) is significantly better than Ligand A (73.22). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have similar logP values (2.649 & 2.659), falling within the optimal 1-3 range. No clear advantage.
4. **HBD:** Ligand A has 1 HBD, while Ligand B has 0. Both are acceptable, but fewer HBDs can sometimes improve permeability. Ligand B is slightly favored.
5. **HBA:** Ligand A has 6 HBA, Ligand B has 3. Ligand B is favored here, as lower HBA generally improves permeability.
6. **QED:** Ligand B (0.841) has a higher QED score than Ligand A (0.606), indicating a more drug-like profile. This is a significant advantage.
7. **DILI:** Ligand B (37.11%) has a much lower DILI risk than Ligand A (63.86%). This is a major advantage, as minimizing liver toxicity is crucial.
8. **BBB:** Ligand B (96.67%) has significantly higher BBB penetration than Ligand A (59.09%). While not a primary concern for a cardiovascular target, higher BBB is generally not detrimental.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.96 and -4.50), indicating poor permeability. This is a concern for both.
10. **Solubility:** Ligand B (-2.387) has better solubility than Ligand A (-3.583). Better solubility is always desirable.
11. **hERG:** Ligand B (0.507) has a slightly better hERG profile than Ligand A (0.36), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand B (32.78) has significantly lower microsomal clearance than Ligand A (133.73), suggesting better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand B (-19.01) has a better in vitro half-life than Ligand A (-27.47).
14. **Pgp:** Ligand B (0.162) has lower P-gp efflux than Ligand A (0.363), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand A (-6.3 kcal/mol) has a significantly better binding affinity than Ligand B (-1.8 kcal/mol). This is a substantial advantage.
**Overall Assessment:**
Ligand A has a much stronger binding affinity. However, Ligand B excels in nearly all ADME-Tox properties. The lower DILI risk, better metabolic stability (lower Cl_mic, better t1/2), better solubility, lower Pgp efflux, and higher QED score of Ligand B are compelling. While the Caco-2 values are poor for both, the other advantages of Ligand B outweigh the affinity difference, especially considering the GPCR target class. The affinity difference is substantial, but optimization could potentially improve Ligand B's binding without sacrificing its favorable ADME profile.
Output:
0
2025-04-18 00:41:27,592 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (337.339 and 344.415 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (99) is slightly higher than Ligand B (89.53). Both are below the 140 threshold for good oral absorption, but closer to the 90 threshold for CNS targets (less relevant for ADRB2, a cardiovascular target). Ligand B is slightly preferred.
3. **logP:** Ligand A (1.916) is within the optimal 1-3 range. Ligand B (0.72) is a bit low, potentially hindering permeation. Ligand A is preferred.
4. **HBD:** Ligand A (1) is good. Ligand B (2) is acceptable, but slightly less desirable. Ligand A is preferred.
5. **HBA:** Ligand A (7) is good. Ligand B (4) is excellent. Ligand B is preferred.
6. **QED:** Both ligands (0.73 and 0.774) have excellent QED scores, indicating good drug-like properties. No significant difference.
7. **DILI:** Ligand A (94.959) has a significantly higher DILI risk than Ligand B (48.623). This is a major concern for Ligand A. Ligand B is strongly preferred.
8. **BBB:** Both ligands have similar BBB penetration (40.791 and 40.52). Not a major factor for a cardiovascular target like ADRB2.
9. **Caco-2:** Ligand A (-4.685) and Ligand B (-5.044) are both poor. This suggests poor intestinal absorption for both.
10. **Solubility:** Ligand A (-3.382) is slightly better than Ligand B (-2.308), but both are poor.
11. **hERG:** Both ligands have low hERG inhibition risk (0.217 and 0.325). No significant difference.
12. **Cl_mic:** Ligand B (36.251) has lower microsomal clearance than Ligand A (53.141), indicating better metabolic stability. Ligand B is preferred.
13. **t1/2:** Ligand B (-18.746) has a significantly longer in vitro half-life than Ligand A (8.71). This is a major advantage for Ligand B.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.086 and 0.084). No significant difference.
15. **Binding Affinity:** Ligand B (-6.8) has a slightly better binding affinity than Ligand A (-6.4). While the difference is not huge, it's a positive for Ligand B.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity) and the general guidelines, Ligand B is the clear winner. While Ligand A has a slightly better logP, Ligand B excels in crucial areas like DILI risk (significantly lower), metabolic stability (lower Cl_mic, longer t1/2), and binding affinity. The lower DILI risk alone is a decisive factor. The slightly better TPSA of Ligand B is also a plus.
Output:
0
2025-04-18 00:41:27,592 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (369.799 Da) is slightly higher than Ligand B (353.419 Da), but both are acceptable.
2. **TPSA:** Ligand A (46.84) is well below the 140 threshold and good for oral absorption, and even favorable for potential CNS penetration. Ligand B (99.18) is higher, but still under 140, but less ideal.
3. **logP:** Ligand A (3.151) is optimal. Ligand B (0.263) is quite low, potentially hindering membrane permeability and absorption. This is a significant drawback.
4. **HBD:** Ligand A (0) is excellent. Ligand B (2) is acceptable, but more donors can sometimes lead to issues.
5. **HBA:** Ligand A (4) is good. Ligand B (5) is also acceptable.
6. **QED:** Both ligands have similar QED values (A: 0.835, B: 0.707), indicating good drug-likeness.
7. **DILI:** Ligand A (51.183) has a moderate DILI risk, while Ligand B (28.306) has a lower risk. This favors Ligand B, but it's not a decisive factor.
8. **BBB:** Ligand A (96.084) shows excellent potential for BBB penetration, while Ligand B (62.195) is lower. While ADRB2 isn't *strictly* a CNS target, some peripheral ADRB2 activity can be modulated by CNS effects, and better BBB penetration is generally a plus.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.531 and -4.906), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-4.188) has slightly better solubility than Ligand B (-0.965), but both are poor.
11. **hERG:** Both ligands have very low hERG inhibition risk (A: 0.552, B: 0.142). This is excellent.
12. **Cl_mic:** Ligand A (39.042) has a higher microsomal clearance than Ligand B (5.815), indicating lower metabolic stability. This favors Ligand B.
13. **t1/2:** Ligand B (-28.526) has a much longer in vitro half-life than Ligand A (-18.181), which is a significant advantage.
14. **Pgp:** Both ligands have very low Pgp efflux liability (A: 0.189, B: 0.014). This is excellent.
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.5 kcal/mol and -6.4 kcal/mol). The difference is negligible.
**GPCR-specific priorities:** For GPCRs, logP, TPSA, and affinity are crucial. Ligand A excels in logP and TPSA, while both have comparable affinity. Ligand B has better metabolic stability (lower Cl_mic and longer t1/2) and lower DILI risk. The poor Caco-2 values are a concern for both, but the significantly better logP and TPSA of Ligand A, combined with its good BBB potential, outweigh the slightly higher DILI and clearance.
**Final Decision:**
Ligand A is the better candidate.
Output:
1
2025-04-18 00:41:27,592 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (349.5 and 359.5 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (52.65) is significantly better than Ligand B (84.14). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is pushing the upper limit for good oral absorption.
**3. logP:** Both ligands have acceptable logP values (2.118 and 3.305, respectively), falling within the 1-3 range. Ligand B is slightly higher, potentially leading to some solubility concerns, but not drastically.
**4. H-Bond Donors:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
**5. H-Bond Acceptors:** Ligand B (6) has more HBAs than Ligand A (3). This contributes to the higher TPSA and could impact permeability.
**6. QED:** Ligand A (0.846) has a better QED score than Ligand B (0.585), indicating a more drug-like profile.
**7. DILI:** Ligand A (9.616) has a much lower DILI risk than Ligand B (62.66). This is a significant advantage for Ligand A.
**8. BBB:** Both ligands have good BBB penetration (83.56 and 85.459), which isn't a primary concern for a cardiovascular target, but isn't detrimental.
**9. Caco-2 Permeability:** Both have negative Caco-2 values, which is unusual and suggests a potential issue with the data or the model. However, the values are similar.
**10. Aqueous Solubility:** Both have negative solubility values, which is also unusual. Again, the values are similar.
**11. hERG Inhibition:** Ligand A (0.516) shows a lower hERG inhibition risk than Ligand B (0.826), which is a crucial safety parameter.
**12. Microsomal Clearance:** Ligand A (32.588) has a lower microsomal clearance than Ligand B (88.989), indicating better metabolic stability.
**13. In vitro Half-Life:** Ligand A (-10.661) has a longer in vitro half-life than Ligand B (3.479).
**14. P-gp Efflux:** Ligand A (0.057) has lower P-gp efflux liability than Ligand B (0.544), which is beneficial for bioavailability.
**15. Binding Affinity:** Ligand B (-7.8) has a significantly stronger binding affinity than Ligand A (-6.5). This is a 1.3 kcal/mol difference, which is substantial.
**Overall Assessment:**
While Ligand B has a superior binding affinity, Ligand A demonstrates a much more favorable ADMET profile. Specifically, the lower DILI risk, better QED, lower hERG inhibition, improved metabolic stability (lower Cl_mic and longer t1/2), and lower P-gp efflux are compelling advantages. The TPSA and HBD/HBA values also favor Ligand A. The negative solubility and Caco-2 values are concerning for both, but the other advantages of Ligand A outweigh the affinity difference. For a cardiovascular GPCR, a balance of potency and safety/pharmacokinetics is crucial, and Ligand A strikes that balance better.
Output:
1
2025-04-18 00:41:27,592 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [343.391, 105.04 , 0.059, 2. , 7. , 0.761, 64.831, 59.131, -5.474, -1.436, 0.222, -45.013, 24.009, 0.013, -4.7 ]
**Ligand B:** [367.471, 71.97 , 1.32 , 0. , 6. , 0.785, 59.325, 69.368, -4.592, -1.694, 0.292, 27.858, -3.706, 0.103, -5.6 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (343.391) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (105.04) is higher than Ligand B (71.97). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is still preferred. Ligand B is better here.
3. **logP:** Ligand A (0.059) is quite low, potentially hindering membrane permeability. Ligand B (1.32) is within the optimal range (1-3). This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (2) and Ligand B (0) are both acceptable.
5. **HBA:** Ligand A (7) and Ligand B (6) are both acceptable.
6. **QED:** Both ligands have good QED scores (A: 0.761, B: 0.785), indicating good drug-like properties.
7. **DILI:** Both have similar DILI risk (A: 64.831, B: 59.325), and are reasonably low.
8. **BBB:** Ligand A (59.131) and Ligand B (69.368). BBB is less critical for a cardiovascular target, but higher is generally better. Ligand B is better.
9. **Caco-2:** Ligand A (-5.474) is worse than Ligand B (-4.592), indicating lower intestinal absorption.
10. **Solubility:** Ligand A (-1.436) is better than Ligand B (-1.694).
11. **hERG:** Both ligands have very low hERG risk (A: 0.222, B: 0.292).
12. **Cl_mic:** Ligand A (-45.013) has a much lower (better) microsomal clearance than Ligand B (27.858), suggesting greater metabolic stability.
13. **t1/2:** Ligand A (24.009) has a longer in vitro half-life than Ligand B (-3.706).
14. **Pgp:** Both ligands have very low Pgp efflux liability (A: 0.013, B: 0.103).
15. **Affinity:** Ligand B (-5.6) has a slightly better binding affinity than Ligand A (-4.7).
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP and TPSA, and has a slightly better affinity. While Ligand A has better metabolic stability (Cl_mic and t1/2), the poor logP is a significant drawback for a GPCR target, potentially limiting its ability to reach the receptor. The slightly better affinity of Ligand B helps to offset the slightly worse metabolic properties.
**Conclusion:**
Considering the balance of properties and the priorities for a GPCR target, Ligand B is the more promising candidate.
0
2025-04-18 00:41:27,593 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.431 and 367.515 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Both ligands have a TPSA of approximately 87.3, which is acceptable for a non-CNS GPCR target like ADRB2.
3. **logP:** Both ligands have logP values around 0.9-1.0, which is within the optimal 1-3 range. No significant difference.
4. **HBD:** Ligand A (2 HBD) is slightly better than Ligand B (3 HBD), but both are within the acceptable limit of <=5.
5. **HBA:** Both ligands have 4 HBA, which is within the acceptable limit of <=10.
6. **QED:** Ligand A (0.654) has a slightly better QED score than Ligand B (0.501), indicating better overall drug-likeness.
7. **DILI:** Both ligands have low DILI risk (32.028 and 35.285 percentile), which is good. Ligand A is marginally better.
8. **BBB:** This is less critical for ADRB2 (a cardiovascular target), but Ligand A (56.766) has a higher BBB penetration than Ligand B (33.85).
9. **Caco-2:** Both ligands have negative Caco-2 values, suggesting poor permeability. Ligand B (-5.428) is slightly better than Ligand A (-5.001), but both are concerning.
10. **Solubility:** Both ligands have negative solubility values, indicating poor aqueous solubility. Ligand A (-2.013) is slightly better than Ligand B (-2.843).
11. **hERG:** Both ligands have very low hERG inhibition liability (0.146 and 0.109), which is excellent. Ligand B is slightly better.
12. **Cl_mic:** Ligand A (8.25 mL/min/kg) has significantly lower microsomal clearance than Ligand B (21.329 mL/min/kg), suggesting better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand B (14.954 hours) has a much longer in vitro half-life than Ligand A (-0.945 hours). This is a major advantage for Ligand B.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.038 and 0.026), which is good.
15. **Binding Affinity:** Ligand B (-7.7 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.5 kcal/mol). This is a substantial advantage, potentially outweighing some ADME concerns.
**Overall Assessment:**
Ligand B has a significantly better binding affinity (-7.7 vs -6.5 kcal/mol) and a much longer half-life (14.954 vs -0.945 hours). While Ligand A has better metabolic stability (lower Cl_mic) and slightly better QED and DILI scores, the potency and duration of action conferred by Ligand B are more critical for a GPCR target. The Caco-2 and solubility issues are concerning for both, but the strong binding and longer half-life of Ligand B make it the more promising candidate, assuming formulation strategies can be developed to address the solubility/permeability issues.
Output:
0
2025-04-18 00:41:27,593 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (352.475 and 365.499 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (60.03) is significantly better than Ligand B (87.3). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (2.656 and 1.85), falling within the 1-3 range. Ligand B is slightly lower, which could be a minor drawback for permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve membrane permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (4). Fewer HBAs generally improve membrane permeability.
6. **QED:** Both ligands have acceptable QED values (0.828 and 0.719), indicating good drug-like properties. Ligand A is slightly better.
7. **DILI:** Ligand A (20.589) has a much lower DILI risk than Ligand B (45.444). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (91.392) has a much higher BBB penetration than Ligand B (46.064). While not critical for a cardiovascular target, higher BBB is generally favorable.
9. **Caco-2:** Ligand A (-4.671) is better than Ligand B (-5.168). Higher Caco-2 values indicate better intestinal absorption.
10. **Solubility:** Ligand A (-2.495) is better than Ligand B (-2.724). Higher solubility is generally preferred.
11. **hERG:** Both ligands have low hERG inhibition risk (0.532 and 0.172). Ligand B is slightly better.
12. **Cl_mic:** Ligand A (3.398) has significantly lower microsomal clearance than Ligand B (33.443). This indicates better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (19.855) has a longer in vitro half-life than Ligand B (12.712). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.059) has lower P-gp efflux liability than Ligand B (0.095). Lower P-gp efflux is preferable.
15. **Affinity:** Ligand A (-7.1) has a slightly better binding affinity than Ligand B (-6.7). While the difference is not huge, it's still a positive for Ligand A.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most crucial ADME-Tox properties (DILI, Cl_mic, t1/2, Pgp, solubility, Caco-2, TPSA) and has a slightly better binding affinity. While Ligand B has a slightly better hERG profile, the overall balance of properties strongly favors Ligand A. Given that this is a cardiovascular target (ADRB2), the slightly higher BBB penetration of Ligand A is not a major concern, but the superior ADME profile is highly desirable.
Output:
1
2025-04-18 00:41:27,593 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (366.49 and 365.50 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (78.27) is slightly higher than Ligand B (71.53). Both are below the 140 threshold for oral absorption, but closer to the 90 threshold for CNS targets (less relevant for ADRB2, a cardiovascular target). Ligand B is preferable.
3. **logP:** Ligand A (1.231) is within the optimal range (1-3), while Ligand B (2.317) is towards the higher end. Both are acceptable, but Ligand A is slightly better for avoiding potential off-target effects.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 7 HBA, and Ligand B has 5 HBA. Both are below the 10 threshold. Ligand B is preferable.
6. **QED:** Both ligands have good QED scores (0.782 and 0.805), indicating good drug-like properties. No significant difference.
7. **DILI:** Ligand A (48.313) has a slightly higher DILI risk than Ligand B (35.13). Ligand B is preferable.
8. **BBB:** Ligand A (57.193) has a lower BBB penetration than Ligand B (70.531). While BBB isn't a primary concern for ADRB2, higher BBB is generally favorable. Ligand B is preferable.
9. **Caco-2:** Ligand A (-5.552) and Ligand B (-4.844) both have negative Caco-2 values, which is unusual. This suggests poor permeability. However, the values are relatively close.
10. **Solubility:** Ligand A (-2.504) and Ligand B (-2.017) both have negative solubility values, indicating poor solubility. Again, values are close.
11. **hERG:** Ligand A (0.084) has a lower hERG risk than Ligand B (0.408). Ligand A is preferable.
12. **Cl_mic:** Ligand A (22.672) has a slightly lower microsomal clearance than Ligand B (24.811), indicating better metabolic stability. Ligand A is preferable.
13. **t1/2:** Ligand A (10.307) has a longer in vitro half-life than Ligand B (5.645). Ligand A is preferable.
14. **Pgp:** Ligand A (0.063) has lower P-gp efflux liability than Ligand B (0.118). Ligand A is preferable.
15. **Binding Affinity:** Ligand B (-7.3 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.2 kcal/mol) - a difference of 2.1 kcal/mol. This is a substantial advantage that can outweigh some of the ADME drawbacks.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are crucial. Ligand B excels in affinity and has better TPSA and Pgp values. While Ligand A has better hERG, Cl_mic, and t1/2, the substantial affinity difference of Ligand B is the most important factor.
**Conclusion:**
Despite some ADME drawbacks, the significantly stronger binding affinity of Ligand B makes it the more promising drug candidate for ADRB2.
Output:
0
2025-04-18 00:41:27,593 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [348.447, 76.46, 1.056, 1, 5, 0.834, 29.779, 73.362, -5.038, -1.104, 0.102, 7.747, 7.017, 0.034, -5.9]
**Ligand B:** [383.92, 38.25, 4.268, 0, 5, 0.715, 29.159, 81.698, -4.851, -3.811, 0.867, 48.825, 19.532, 0.613, -5.3]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (348.447) is slightly preferred due to being closer to the lower end, potentially aiding permeability.
2. **TPSA:** Ligand A (76.46) is significantly better than Ligand B (38.25). For a GPCR, lower TPSA is generally favorable for brain penetration and overall absorption.
3. **logP:** Ligand A (1.056) is optimal (1-3). Ligand B (4.268) is pushing the upper limit and could lead to solubility issues and off-target interactions.
4. **HBD:** Ligand A (1) is preferable to Ligand B (0). A single HBD can contribute to solubility without significantly hindering permeability.
5. **HBA:** Both have 5 HBA, which is acceptable.
6. **QED:** Ligand A (0.834) is better than Ligand B (0.715), indicating a more drug-like profile.
7. **DILI:** Both have low DILI risk (around 30%), which is good.
8. **BBB:** Ligand A (73.362) is good, while Ligand B (81.698) is even better. This is a positive for Ligand B, but not a decisive factor given the other issues.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual. Assuming these are logP-like scales, lower values suggest poorer permeability. Ligand A (-5.038) is slightly better than Ligand B (-4.851).
10. **Solubility:** Ligand A (-1.104) is better than Ligand B (-3.811). Solubility is a concern for Ligand B given its higher logP.
11. **hERG:** Both have very low hERG risk (0.102 and 0.867), which is excellent.
12. **Cl_mic:** Ligand A (7.747) has significantly lower clearance than Ligand B (48.825), suggesting better metabolic stability.
13. **t1/2:** Ligand A (7.017) has a shorter half-life than Ligand B (19.532), but it's still acceptable. The longer half-life of Ligand B is a plus.
14. **Pgp:** Ligand A (0.034) has much lower P-gp efflux liability than Ligand B (0.613), which is crucial for bioavailability and potential CNS exposure.
15. **Affinity:** Both have excellent binding affinity (-5.9 and -5.3 kcal/mol). The difference (0.6 kcal/mol) isn't large enough to overcome the ADME deficiencies of Ligand B.
**Overall Assessment:**
Ligand A demonstrates a much more balanced profile. While Ligand B has slightly better BBB penetration and a longer half-life, its significantly higher logP, lower solubility, higher clearance, and higher P-gp efflux liability are major drawbacks. Ligand A's lower TPSA, better logP, solubility, metabolic stability, and P-gp efflux profile make it a more promising drug candidate for ADRB2.
Output:
1
2025-04-18 00:41:27,593 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Ligand A (386.279 Da) is within the ideal range (200-500 Da). Ligand B (340.358 Da) is also within the ideal range. No clear advantage here.
2. **TPSA:** Ligand A (81.67) is good, below the 140 threshold for oral absorption. Ligand B (69.9) is even better, further below the threshold. Slight advantage to B.
3. **logP:** Ligand A (1.437) is optimal (1-3). Ligand B (3.262) is also within the optimal range, but closer to the upper limit. No strong advantage.
4. **HBD:** Ligand A (3) is acceptable (<=5). Ligand B (0) is excellent. Advantage to B.
5. **HBA:** Ligand A (4) is acceptable (<=10). Ligand B (6) is also acceptable. No clear advantage.
6. **QED:** Ligand A (0.734) is very good (>0.5). Ligand B (0.644) is also good, but slightly lower. Slight advantage to A.
7. **DILI:** Ligand A (44.281) is good (<40 is preferred, <60 is acceptable). Ligand B (74.99) is higher, indicating a greater risk of liver injury. Significant advantage to A.
8. **BBB:** Ligand A (24.855) is low, suggesting poor BBB penetration. Ligand B (73.827) is high, suggesting good BBB penetration. Considering ADRB2 is a GPCR, and while not exclusively a CNS target, some CNS effects are possible, this is a moderate advantage to B.
9. **Caco-2:** Ligand A (-5.284) is poor. Ligand B (-4.489) is also poor, but slightly better. Slight advantage to B.
10. **Solubility:** Ligand A (-2.723) is poor. Ligand B (-4.405) is even worse. Both are problematic.
11. **hERG:** Ligand A (0.194) is very low risk. Ligand B (0.34) is slightly higher, but still relatively low. Slight advantage to A.
12. **Cl_mic:** Ligand A (-40.083) is excellent (lower is better). Ligand B (73.356) is very high, indicating rapid metabolism. Significant advantage to A.
13. **t1/2:** Ligand A (20.145) is good. Ligand B (-44.401) is very poor. Significant advantage to A.
14. **Pgp:** Ligand A (0.089) is low, indicating minimal efflux. Ligand B (0.668) is higher, suggesting more efflux. Advantage to A.
15. **Affinity:** Ligand A (-5.7) is better than Ligand B (-6.4). A difference of 0.7 kcal/mol is substantial. Significant advantage to A.
**Overall Assessment:**
While Ligand B has better TPSA, HBD, BBB and Caco-2 permeability, Ligand A significantly outperforms in critical areas like DILI risk, metabolic stability (Cl_mic and t1/2), Pgp efflux, and, most importantly, binding affinity. The poor solubility of both is a concern, but can be addressed with formulation strategies. The higher DILI risk and rapid metabolism of Ligand B are major drawbacks that outweigh its advantages. The strong affinity of Ligand A, combined with its better safety and pharmacokinetic profile, makes it the more promising drug candidate.
Output:
1
2025-04-18 00:41:27,594 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's analyze each ligand against the provided guidelines, with emphasis on GPCR-relevant parameters (logP, TPSA, Pgp, BBB, and affinity).
* **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (348.443) is slightly preferred due to being closer to the lower end, potentially aiding permeability.
* **TPSA:** Ligand A (87.66) is better than Ligand B (47.36). Lower TPSA generally favors oral absorption and BBB penetration, which is important for GPCRs.
* **logP:** Both ligands have acceptable logP values (Ligand A: 1.224, Ligand B: 3.512). Ligand B is higher, which could lead to solubility issues, but is still within the acceptable range.
* **H-Bond Donors/Acceptors:** Ligand A (HBD=3, HBA=4) is slightly better balanced than Ligand B (HBD=0, HBA=6).
* **QED:** Both ligands have good QED scores (Ligand A: 0.555, Ligand B: 0.691), indicating good drug-like properties. Ligand B is slightly better.
* **DILI:** Ligand A (13.3) has a significantly lower DILI risk than Ligand B (54.556). This is a major advantage for Ligand A.
* **BBB:** Ligand B (77.627) has a much higher BBB penetration percentile than Ligand A (44.513). While ADRB2 isn't necessarily a CNS target, some peripheral ADRB2 activity can be modulated by CNS effects, and higher BBB penetration can sometimes correlate with better overall distribution.
* **Caco-2 Permeability:** Ligand A (-4.878) is better than Ligand B (-5.324). Higher Caco-2 permeability indicates better intestinal absorption.
* **Aqueous Solubility:** Ligand A (-2.019) is better than Ligand B (-3.562).
* **hERG Inhibition:** Both ligands have low hERG inhibition risk (Ligand A: 0.322, Ligand B: 0.499).
* **Microsomal Clearance:** Ligand A (36.227) has lower microsomal clearance than Ligand B (84.517), suggesting better metabolic stability.
* **In vitro Half-Life:** Ligand A (-4.243) has a longer in vitro half-life than Ligand B (16.729).
* **P-gp Efflux:** Ligand A (0.071) has lower P-gp efflux than Ligand B (0.51), which is favorable for bioavailability.
* **Binding Affinity:** Ligand A (-6.5 kcal/mol) has slightly better binding affinity than Ligand B (-4.9 kcal/mol). This difference is significant enough to outweigh some of the ADME drawbacks of Ligand B.
**Overall Assessment:**
Ligand A presents a more balanced profile. It has a lower DILI risk, better metabolic stability, longer half-life, lower P-gp efflux, and slightly better binding affinity. While Ligand B has a higher BBB penetration, the other advantages of Ligand A make it the more promising candidate for development as a drug targeting ADRB2.
**Output:**
1
2025-04-18 00:41:27,594 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (366.933) is slightly higher, but still acceptable.
2. **TPSA:** Ligand A (50.36) is significantly better than Ligand B (78.87). ADRB2 is a cardiovascular target, not CNS, but lower TPSA generally improves absorption.
3. **logP:** Ligand A (4.727) is higher than ideal, potentially causing solubility issues. Ligand B (1.241) is on the lower side, which could hinder permeability.
4. **HBD:** Both ligands have 2 HBD, which is good.
5. **HBA:** Ligand A has 2 HBA, while Ligand B has 4. Both are acceptable, but A is preferable.
6. **QED:** Ligand A (0.664) is significantly better than Ligand B (0.353), indicating a more drug-like profile.
7. **DILI:** Ligand A (19.969) has a much lower DILI risk than Ligand B (6.669), a critical advantage.
8. **BBB:** Not a primary concern for a cardiovascular target, but Ligand A (88.329) is better than Ligand B (54.478).
9. **Caco-2:** Both have negative values, indicating poor permeability. Ligand A (-4.468) is slightly better than Ligand B (-4.83).
10. **Solubility:** Ligand A (-4.668) is better than Ligand B (-1.235).
11. **hERG:** Ligand A (0.808) has a slightly higher hERG risk than Ligand B (0.248), but both are relatively low.
12. **Cl_mic:** Ligand B (2.501) has significantly lower microsomal clearance than Ligand A (51.291), indicating better metabolic stability. This is a strong point for Ligand B.
13. **t1/2:** Ligand A (59.334) has a much longer in vitro half-life than Ligand B (-13.382). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.414) has lower P-gp efflux than Ligand B (0.052), which is favorable.
15. **Affinity:** Ligand A (-6.6 kcal/mol) has a slightly better binding affinity than Ligand B (-4.8 kcal/mol). This difference is significant (1.8 kcal/mol).
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are important. Ligand A has a higher logP, but better TPSA, Pgp, and significantly better affinity. The substantial difference in binding affinity (-6.6 vs -4.8 kcal/mol) is a major factor. Furthermore, the much lower DILI risk for Ligand A is a significant safety advantage. While Ligand B has better metabolic stability, the longer half-life of Ligand A mitigates this concern.
**Conclusion:**
Considering the balance of properties, particularly the superior binding affinity, lower DILI risk, better QED, and acceptable ADME profile, Ligand A is the more promising drug candidate.
Output:
1
2025-04-18 00:41:27,594 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (367.798 and 348.487 Da) fall comfortably within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (29.1) is significantly better than Ligand B (49.85). ADRB2 is not a CNS target, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (4.987) is higher than Ligand B (2.894). While both are within the acceptable range (1-3 is optimal, up to 4 is tolerable), Ligand A is approaching the upper limit and could potentially have solubility issues. Ligand B is closer to optimal.
4. **HBD:** Ligand A (1) is better than Ligand B (0). Fewer HBDs generally improve membrane permeability.
5. **HBA:** Ligand A (1) is better than Ligand B (3). Similar to HBD, fewer HBAs are generally preferred.
6. **QED:** Ligand A (0.716) is significantly better than Ligand B (0.475), indicating a more drug-like profile.
7. **DILI:** Ligand B (17.798) is *much* better than Ligand A (55.021). This is a significant advantage for Ligand B, as lower DILI risk is crucial.
8. **BBB:** Ligand B (90.655) is better than Ligand A (75.107). While ADRB2 isn't a primary CNS target, higher BBB penetration can sometimes indicate better overall permeability and distribution.
9. **Caco-2:** Both ligands have very similar, and poor, Caco-2 permeability (-4.613 and -4.579). This is a concern for both.
10. **Solubility:** Ligand B (-2.044) is better than Ligand A (-5.458). This is important, especially given Ligand A's higher logP.
11. **hERG:** Ligand A (0.788) is better than Ligand B (0.602). Lower hERG inhibition is always preferred.
12. **Cl_mic:** Ligand A (55.218) is better than Ligand B (67.201). Lower clearance suggests better metabolic stability.
13. **t1/2:** Ligand B (-8.732) is better than Ligand A (18.485). A negative half-life is unusual and indicates very rapid clearance. Ligand B's value is concerning, but A's is not great either.
14. **Pgp:** Ligand A (0.422) is better than Ligand B (0.304). Lower P-gp efflux is favorable.
15. **Affinity:** Ligand A (-7.3) is significantly better than Ligand B (-6.1). This is a 1.2 kcal/mol difference, which is substantial and can outweigh some ADME drawbacks.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A has a higher logP (potentially problematic), lower TPSA (good), better Pgp (good), and *much* better affinity. Ligand B has a better solubility and a significantly better DILI score.
**Overall Assessment:**
The significantly stronger binding affinity of Ligand A (-7.3 kcal/mol vs -6.1 kcal/mol) is the most important factor. While Ligand A has some ADME liabilities (higher logP, worse DILI), the potency advantage is substantial. The better QED score also supports Ligand A. Ligand B's DILI score is attractive, but the weaker binding is a major drawback. The poor Caco-2 values for both are a concern that would need to be addressed in further optimization.
Output:
1
2025-04-18 00:41:27,594 - INFO - Batch 496 complete. Total preferences: 7936
2025-04-18 00:41:27,594 - INFO - Processing batch 497/512...
2025-04-18 00:42:17,464 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (384.8) is within the ideal range (200-500), while Ligand B (353.4) is also good. No clear advantage here.
2. **TPSA:** Ligand A (116.4) is slightly above the optimal <140 for oral absorption, but acceptable. Ligand B (96.97) is excellent, well below 140. Advantage: B.
3. **logP:** Ligand A (2.335) is within the optimal 1-3 range. Ligand B (0.529) is a bit low, potentially hindering permeation. Advantage: A.
4. **HBD:** Both ligands have acceptable HBD counts (A: 1, B: 2). No significant difference.
5. **HBA:** Both ligands have acceptable HBA counts (A: 7, B: 5). No significant difference.
6. **QED:** Both ligands have good QED scores (A: 0.48, B: 0.59). Ligand B is slightly better. Advantage: B.
7. **DILI:** Ligand A (99.15) has a very high DILI risk, which is a major concern. Ligand B (37.15) has a low DILI risk. Significant advantage: B.
8. **BBB:** Ligand A (45.1) is not particularly good for BBB penetration, while Ligand B (54.4) is better. Advantage: B. While ADRB2 isn't necessarily a CNS target, some peripheral distribution is still desirable.
9. **Caco-2:** Ligand A (-4.91) is very poor, indicating poor intestinal absorption. Ligand B (-5.63) is also poor, but slightly better. Advantage: B.
10. **Solubility:** Ligand A (-4.12) is poor, while Ligand B (-1.72) is somewhat better. Advantage: B.
11. **hERG:** Both ligands have very low hERG risk (A: 0.26, B: 0.15). No significant difference.
12. **Cl_mic:** Ligand A (21.6) has a moderate clearance, while Ligand B (-6.32) has a negative clearance, suggesting very high metabolic stability. Significant advantage: B.
13. **t1/2:** Ligand A (29.0) is reasonable, while Ligand B (-3.77) is very poor. Advantage: A.
14. **Pgp:** Both ligands have low Pgp efflux liability (A: 0.26, B: 0.02). Ligand B is slightly better. Advantage: B.
15. **Binding Affinity:** Both ligands have the same binding affinity (-6.3 kcal/mol). No difference.
**Overall Assessment:**
Ligand B consistently outperforms Ligand A in most critical ADME properties, particularly DILI risk, metabolic stability (Cl_mic), and Caco-2 permeability. While Ligand A has a slightly better in vitro half-life, the high DILI risk is a deal-breaker. The slightly lower logP of Ligand B is a minor concern, but can potentially be addressed with further optimization. Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity), Ligand B is the better candidate.
Output:
0
2025-04-18 00:42:17,465 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (357.4 Da) are within the ideal range (200-500 Da). No significant difference.
2. **TPSA:** Ligand A (29.54) is significantly better than Ligand B (43.86). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally aids absorption.
3. **logP:** Ligand A (4.42) is higher than Ligand B (2.155). While both are within the acceptable range (1-3 is optimal), Ligand A is pushing the upper limit. Ligand B is closer to optimal.
4. **HBD:** Both have 0 HBD, which is good.
5. **HBA:** Both have 3 HBA, which is good.
6. **QED:** Ligand A (0.677) is better than Ligand B (0.494), indicating a more drug-like profile.
7. **DILI:** Ligand A (8.298) is *much* better than Ligand B (25.553). This is a critical difference, as liver toxicity is a major concern.
8. **BBB:** Both have high BBB penetration (Ligand A: 95.541, Ligand B: 90.074). While not essential for a cardiovascular target, it doesn't hurt.
9. **Caco-2:** Both have very negative Caco-2 values (-4.546 and -4.557). This is unusual and suggests poor permeability. This is a significant drawback for both.
10. **Solubility:** Ligand A (-4.433) is better than Ligand B (-0.637). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.979) is better than Ligand B (0.73). Lower hERG inhibition is crucial for avoiding cardiotoxicity, particularly important for a cardiovascular target.
12. **Cl_mic:** Ligand A (48.934) is higher than Ligand B (34.766), indicating faster metabolic clearance and potentially lower *in vivo* exposure. This is a negative for Ligand A.
13. **t1/2:** Ligand A (5.876) is significantly better than Ligand B (-0.266). A longer half-life is generally preferred.
14. **Pgp:** Ligand A (0.562) is better than Ligand B (0.084). Lower P-gp efflux is desirable.
15. **Affinity:** Ligand A (-7.0) is slightly better than Ligand B (-6.9). While the difference is small, it's still a positive for Ligand A.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has a slightly better affinity and Pgp profile, and significantly better TPSA. Ligand B has a better logP. However, the *much* lower DILI risk and better hERG profile of Ligand A are decisive. The better solubility and half-life also contribute to its favorability. The Caco-2 values are concerning for both, but the other advantages of Ligand A outweigh this.
**Conclusion:**
Ligand A is the more promising candidate due to its superior safety profile (DILI, hERG), better solubility, longer half-life, and only slightly lower logP compared to Ligand B. The small affinity difference is less important than these factors.
Output:
1
2025-04-18 00:42:17,465 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (377.384 Da) is slightly higher than Ligand B (340.467 Da), but both are acceptable.
2. **TPSA:** Both are below the 140 A^2 threshold for good oral absorption. Ligand A (64.96) and Ligand B (62.22) are both good.
3. **logP:** Both ligands have logP values around 3.6-3.8, falling within the optimal range of 1-3.
4. **HBD:** Ligand A has 0 HBD, while Ligand B has 2. Both are acceptable, but lower is generally preferred for permeability.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 3. Both are below the 10 threshold.
6. **QED:** Both have good QED scores (A: 0.789, B: 0.892), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (65.568) has a higher DILI risk than Ligand B (47.654). This is a significant concern, as we want to minimize liver toxicity.
8. **BBB:** Ligand A (94.455) has a much higher BBB penetration percentile than Ligand B (81.039). While ADRB2 isn't strictly a CNS target, some CNS exposure could be relevant for off-target effects or peripheral effects mediated by sympathetic nervous system.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual. I'll interpret these as very low permeability.
10. **Solubility:** Both have negative solubility values, which is also unusual. I'll interpret these as very low solubility.
11. **hERG:** Both have low hERG inhibition liability (A: 0.611, B: 0.796), which is good.
12. **Cl_mic:** Ligand B (65.797) has a significantly higher microsomal clearance than Ligand A (13.382). This suggests Ligand A is more metabolically stable.
13. **t1/2:** Ligand A (45.675) has a slightly longer in vitro half-life than Ligand B (43.005).
14. **Pgp:** Both have low Pgp efflux liability (A: 0.643, B: 0.566).
15. **Binding Affinity:** Ligand B (-4.9 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.5 kcal/mol). This is a substantial advantage.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Both ligands are good on logP and Pgp. TPSA is acceptable for both. However, the affinity difference is substantial, and Ligand B is significantly better. The higher DILI risk for Ligand A is a major drawback. While Ligand A has better BBB penetration, this isn't a primary concern for ADRB2. The improved metabolic stability of Ligand A is a plus, but the affinity difference outweighs this benefit.
**Conclusion:**
Despite the unusual Caco-2 and solubility values, the significantly stronger binding affinity of Ligand B and its lower DILI risk make it the more promising drug candidate.
Output:
0
2025-04-18 00:42:17,465 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (344.46 and 354.43 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (67.23) is significantly better than Ligand B (86.6). ADRB2 is not a CNS target, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (2.71) is optimal, while Ligand B (-0.096) is quite low. This is a significant drawback for Ligand B, potentially hindering membrane permeability and bioavailability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is better than Ligand B (5). Similar to HBD, lower HBA is generally preferred.
6. **QED:** Both ligands have similar QED values (0.66 and 0.638), indicating good drug-likeness.
7. **DILI:** Ligand A (41.02) has a slightly higher DILI risk than Ligand B (16.01), but both are well below the concerning threshold of 60.
8. **BBB:** This is less critical for ADRB2, but Ligand A (69.79) is better than Ligand B (36.18).
9. **Caco-2:** Ligand A (-4.84) is better than Ligand B (-5.19), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-2.75) is better than Ligand B (-0.47).
11. **hERG:** Both ligands have very low hERG risk (0.26 and 0.14), which is excellent.
12. **Cl_mic:** Ligand B (-9.76) has a significantly *lower* (better) microsomal clearance than Ligand A (39.65), suggesting greater metabolic stability.
13. **t1/2:** Ligand B (4.74) has a significantly longer in vitro half-life than Ligand A (-0.65). This is a major advantage for Ligand B.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.09 and 0.006).
15. **Binding Affinity:** Ligand B (-7.3) has a slightly better binding affinity than Ligand A (-5.8). This 1.5 kcal/mol difference is significant and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand B has a superior binding affinity and metabolic stability (lower Cl_mic, longer t1/2). However, its low logP is a major concern. Ligand A has a much more favorable logP, better TPSA, solubility, and Caco-2 permeability. The slightly better affinity of Ligand B is valuable, but the poor logP is a significant hurdle for oral bioavailability. Given the importance of logP for GPCRs, and the fact that the affinity difference isn't massive, I believe Ligand A is the more promising candidate.
Output:
1
2025-04-18 00:42:17,465 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (347.411 and 346.431 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (76.07) is significantly better than Ligand B (108.02). ADRB2 is not a CNS target, but lower TPSA generally improves absorption. Ligand A is well below the 140 threshold.
3. **logP:** Both ligands have good logP values (2.447 and 1.642), falling within the optimal 1-3 range. Ligand A is slightly higher, which *could* be beneficial for membrane permeability, but not dramatically so.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (4) is preferable to Ligand B (5). Similar to HBD, lower HBA is generally better for permeability.
6. **QED:** Ligand A (0.885) has a better QED score than Ligand B (0.744), indicating a more drug-like profile.
7. **DILI:** Ligand A (41.179) has a slightly higher DILI risk than Ligand B (29.352), but both are below the 40 threshold and considered good.
8. **BBB:** Both ligands have similar BBB penetration (61.535 and 65.568). Since ADRB2 is not a CNS target, this is less critical.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.578 and -4.915). These values are difficult to interpret without knowing the scale, but negative values suggest poor permeability.
10. **Solubility:** Ligand A (-1.993) is slightly better than Ligand B (-2.36), indicating better aqueous solubility.
11. **hERG:** Ligand A (0.012) has a significantly lower hERG inhibition liability than Ligand B (0.142), which is a crucial advantage for cardiovascular targets.
12. **Cl_mic:** Ligand A (13.997) has a much lower microsomal clearance than Ligand B (34.237), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-9.436) has a more negative in vitro half-life than Ligand B (-10.907). Again, these values are difficult to interpret without knowing the scale, but a less negative value suggests a longer half-life.
14. **Pgp:** Ligand A (0.012) has a much lower P-gp efflux liability than Ligand B (0.025).
15. **Binding Affinity:** Ligand B (-6.6) has a slightly better binding affinity than Ligand A (-5.0). This is a 1.6 kcal/mol difference, which is significant.
**GPCR-Specific Priorities & Overall Assessment:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B has a slightly better affinity, but Ligand A excels in several other critical areas: TPSA, HBD, HBA, QED, hERG, Cl_mic, and Pgp. The improved metabolic stability (lower Cl_mic), reduced hERG risk, and lower P-gp efflux of Ligand A are particularly important for a cardiovascular drug. While the affinity difference is notable, the overall balance of properties in Ligand A makes it the more promising candidate. The slightly better solubility is also a plus.
**Output:**
1
2025-04-18 00:42:17,465 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [363.853, 110.75 , 1.575, 3. , 7. , 0.695, 69.678, 64.482, -5.709, -2.625, 0.216, 44.288, 26.35 , 0.05 , -3.3 ]
**Ligand B:** [357.451, 111.13 , -1.15 , 4. , 6. , 0.415, 5.739, 34.897, -5.322, -0.878, 0.076, 4.524, -18.888, 0.003, -6.7 ]
Here's a breakdown of the comparison, considering the provided guidelines and GPCR-specific priorities (logP, Pgp, TPSA, affinity):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (357.451) is slightly lower, which is generally favorable.
2. **TPSA:** Both are above the optimal <140 for good oral absorption, but not drastically so. Ligand A (110.75) is slightly lower than Ligand B (111.13).
3. **logP:** Ligand A (1.575) is within the optimal range (1-3). Ligand B (-1.15) is below 1, which could indicate poor membrane permeability. This is a significant drawback.
4. **HBD:** Both are acceptable (<=5). Ligand A (3) is slightly better than Ligand B (4).
5. **HBA:** Both are acceptable (<=10). Ligand A (7) is slightly better than Ligand B (6).
6. **QED:** Ligand A (0.695) is better than Ligand B (0.415), suggesting a more drug-like profile.
7. **DILI:** Ligand A (69.678) has a higher DILI risk than Ligand B (5.739). This is a major concern for Ligand A.
8. **BBB:** Ligand A (64.482) has better BBB penetration than Ligand B (34.897). While not a primary concern for a cardiovascular target, it's a slight advantage.
9. **Caco-2:** Both have negative values, indicating poor permeability. Ligand B (-5.322) is slightly worse than Ligand A (-5.709).
10. **Solubility:** Both have negative values, indicating poor solubility. Ligand B (-0.878) is slightly better than Ligand A (-2.625).
11. **hERG:** Both have very low hERG risk.
12. **Cl_mic:** Ligand A (44.288) has higher metabolic clearance than Ligand B (4.524), suggesting lower metabolic stability.
13. **t1/2:** Ligand B (-18.888) has a negative half-life, which is concerning. Ligand A (26.35) is much better.
14. **Pgp:** Both have very low Pgp efflux liability.
15. **Affinity:** Ligand B (-6.7 kcal/mol) has significantly stronger binding affinity than Ligand A (-3.3 kcal/mol). This is a substantial advantage.
**Overall Assessment:**
Ligand B has a significantly better binding affinity (-6.7 vs -3.3 kcal/mol). However, it suffers from a very low logP and a negative in vitro half-life. Ligand A has a better QED, BBB, and t1/2, but has a concerningly high DILI risk and higher metabolic clearance.
Despite the superior affinity of Ligand B, the poor logP is a major issue for oral bioavailability and target engagement. The negative half-life is also a critical flaw. The high DILI risk for Ligand A is also a major concern. Considering the balance, the better *drug-like* properties of Ligand A, despite the DILI risk, make it the slightly more promising candidate, as DILI can sometimes be mitigated through structural modifications. The affinity difference is significant, but permeability and metabolic stability are also crucial.
Output:
1
2025-04-18 00:42:17,466 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (425.304 Da) is within the ideal range, while Ligand B (347.379 Da) is also acceptable, though slightly on the lower side.
2. **TPSA:** Ligand A (76.57) is good, well below 140, and acceptable for a non-CNS GPCR. Ligand B (137.82) is approaching the upper limit for good oral absorption, but still within range.
3. **logP:** Ligand A (2.289) is optimal. Ligand B (-0.621) is too low, potentially hindering membrane permeability and bioavailability. This is a significant negative for Ligand B.
4. **HBD:** Ligand A (0) is excellent. Ligand B (4) is acceptable, but higher HBD can sometimes lead to issues.
5. **HBA:** Ligand A (5) is good. Ligand B (7) is also acceptable.
6. **QED:** Ligand A (0.735) is very good, indicating high drug-likeness. Ligand B (0.527) is acceptable, but lower.
7. **DILI:** Ligand A (84.296) is moderately high, a potential concern. Ligand B (60.644) is better, though still warrants attention.
8. **BBB:** Ligand A (67.003) is acceptable, though not particularly high. Ligand B (13.222) is very low, suggesting poor brain penetration. This isn't a major concern for a cardiovascular target like ADRB2, but it doesn't add any benefit.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.011 and -5.844), which is unusual and suggests poor permeability. This is a significant issue for both.
10. **Solubility:** Both ligands have negative solubility values (-2.899 and -1.907), which is also concerning and suggests poor aqueous solubility.
11. **hERG:** Ligand A (0.361) has a low hERG risk. Ligand B (0.031) has a very low hERG risk, which is excellent.
12. **Cl_mic:** Ligand A (7.693) has a relatively low clearance, suggesting better metabolic stability. Ligand B (-29.997) has a *negative* clearance, which is impossible and likely an error in the data. This is a major red flag.
13. **t1/2:** Ligand A (49.97) has a good in vitro half-life. Ligand B (4.362) has a very short half-life, indicating rapid metabolism.
14. **Pgp:** Ligand A (0.285) has low P-gp efflux. Ligand B (0.005) has very low P-gp efflux, which is excellent.
15. **Affinity:** Ligand A (-6.7 kcal/mol) has a very strong binding affinity. Ligand B (-7.0 kcal/mol) has slightly better binding affinity, but the difference is small.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has a better logP and acceptable TPSA. Both have low Pgp efflux. Ligand B has a slightly better affinity, but the negative clearance and low logP are major drawbacks.
**Overall Assessment:**
Despite the concerning Caco-2 and solubility values for both, Ligand A is the more promising candidate. Ligand B's negative clearance is a critical flaw, suggesting a data error or a fundamentally unstable molecule. Ligand A's better logP, metabolic stability (lower Cl_mic), and reasonable half-life outweigh the slightly weaker affinity and higher DILI risk. The DILI risk can be addressed with further optimization.
Output:
1
2025-04-18 00:42:17,466 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (348.491) is slightly lower, which can be advantageous for permeability.
2. **TPSA:** Ligand A (67.23) is significantly better than Ligand B (102.74). For a GPCR, keeping TPSA low is beneficial for permeability and receptor engagement. Ligand B is pushing the upper limit for good oral absorption.
3. **logP:** Ligand A (2.522) is optimal, while Ligand B (0.597) is a bit low. A logP below 1 can sometimes hinder membrane permeability.
4. **HBD:** Both have 1 HBD, which is within the acceptable range.
5. **HBA:** Ligand A (4) is better than Ligand B (6). Lower HBA generally improves permeability.
6. **QED:** Both are very similar (0.859 vs 0.848), indicating good drug-likeness.
7. **DILI:** Ligand A (24.351) has a much lower DILI risk than Ligand B (68.941). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (72.043) has better BBB penetration than Ligand B (49.826), although ADRB2 is not necessarily a CNS target, some peripheral distribution is still desired.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability in this assay. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Both have negative solubility values, which is also unusual. Again, the scale is not specified, making interpretation difficult.
11. **hERG:** Ligand A (0.637) has a lower hERG risk than Ligand B (0.219). Lower is better.
12. **Cl_mic:** Ligand A (42.371) has a better (lower) microsomal clearance than Ligand B (-14.978). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (-0.545) has a longer in vitro half-life than Ligand B (-7.634).
14. **Pgp:** Ligand A (0.218) has lower P-gp efflux liability than Ligand B (0.048). Lower efflux is generally preferred.
15. **Affinity:** Both ligands have the same binding affinity (-6.3 kcal/mol), so this parameter doesn't differentiate them.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, TPSA, logP, Pgp, and affinity are key. Ligand A excels in TPSA and logP, and has better Pgp efflux. The similar affinity removes that as a differentiating factor. The significantly lower DILI risk and improved metabolic stability (Cl_mic and t1/2) of Ligand A further solidify its advantage.
**Conclusion:**
Ligand A demonstrates a superior balance of properties, particularly regarding ADME characteristics and safety (DILI, hERG), while maintaining comparable binding affinity.
Output:
1
2025-04-18 00:42:17,466 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
The target is ADRB2, a GPCR. Therefore, the priorities are logP, Pgp, TPSA, affinity, and BBB. Let's break down the comparison:
1. **Molecular Weight:** Both ligands are within the ideal range (354.451 and 355.341 Da). No significant difference.
2. **TPSA:** Both are good, below the 140 A^2 threshold for oral absorption (90.98 and 87.74 A^2). Ligand B is slightly better.
3. **logP:** Ligand A (0.733) is better than Ligand B (0.061). Ligand B is quite low, which could hinder membrane permeability.
4. **H-Bond Donors/Acceptors:** Both have 2 HBDs and 4 HBAs, which is acceptable.
5. **QED:** Ligand B (0.724) is slightly better than Ligand A (0.521), indicating a more drug-like profile.
6. **DILI:** Both are acceptable, with Ligand A at 41.411% and Ligand B at 46.452%.
7. **BBB:** Ligand B (63.358%) has a better BBB penetration score than Ligand A (55.254%), which is a plus for a GPCR.
8. **Caco-2 Permeability:** Both are negative, indicating poor permeability. Ligand A (-5.032) is slightly worse than Ligand B (-4.922).
9. **Aqueous Solubility:** Both are negative, indicating poor solubility. Ligand A (-1.759) is slightly worse than Ligand B (-2.643).
10. **hERG Inhibition:** Both are low, indicating low cardiotoxicity risk (0.311 and 0.202).
11. **Microsomal Clearance:** Ligand B (-7.354) has significantly lower (better) microsomal clearance than Ligand A (-5.427), suggesting better metabolic stability.
12. **In vitro Half-Life:** Ligand B (-35.316) has a much longer in vitro half-life than Ligand A (9.787), which is a major advantage.
13. **P-gp Efflux:** Both are very low (0.023 and 0.01), suggesting minimal P-gp efflux.
14. **Binding Affinity:** Ligand A (-6.8 kcal/mol) has a slightly better binding affinity than Ligand B (-5.6 kcal/mol), a 1.2 kcal/mol difference.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity, Ligand B demonstrates a superior ADME profile. The significantly improved metabolic stability (lower Cl_mic), longer half-life, and better BBB penetration outweigh the small difference in binding affinity. The lower logP of Ligand B is a concern, but the other advantages are more critical for a GPCR target.
**Output:**
0
2025-04-18 00:42:17,466 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.454 Da and 349.391 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (76.02) is significantly better than Ligand B (113.46). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold. Ligand B is approaching the upper limit.
3. **logP:** Ligand A (2.577) is within the optimal 1-3 range. Ligand B (0.619) is a bit low, potentially hindering membrane permeability.
4. **HBD:** Both ligands have 2 HBD, which is acceptable.
5. **HBA:** Ligand A has 4 HBA, while Ligand B has 7. Ligand A is preferable, as higher HBA can sometimes reduce permeability.
6. **QED:** Both ligands have similar QED values (0.717 and 0.638), indicating good drug-like properties.
7. **DILI:** Ligand A (35.789%) has a much lower DILI risk than Ligand B (68.244%). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (80.07%) has better BBB penetration than Ligand B (32.92%). While not critical for a cardiovascular target, it's a positive attribute.
9. **Caco-2:** Ligand A (-4.706) is better than Ligand B (-4.979). Both are negative, which is not ideal, but A is slightly better.
10. **Solubility:** Ligand A (-2.675) is better than Ligand B (-1.862). Higher solubility is always preferred.
11. **hERG:** Ligand A (0.707) has a lower hERG risk than Ligand B (0.17). This is a crucial advantage, as hERG inhibition can lead to cardiotoxicity.
12. **Cl_mic:** Ligand B (22.01) has slightly better metabolic stability (lower clearance) than Ligand A (20.485). This is a minor difference.
13. **t1/2:** Ligand B (-21.553) has a longer in vitro half-life than Ligand A (-9.857). This is a positive for Ligand B.
14. **Pgp:** Ligand A (0.178) has better Pgp efflux profile than Ligand B (0.1). Lower efflux is better.
15. **Binding Affinity:** Both ligands have very similar and excellent binding affinities (-6.0 kcal/mol and -5.9 kcal/mol). The difference is negligible.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A is superior in logP, TPSA, and Pgp. Affinity is comparable.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B in several critical ADME properties (DILI, hERG, solubility, TPSA, logP, Pgp) and has comparable affinity. The longer half-life of Ligand B is a benefit, but the significantly lower risk profile of Ligand A, particularly regarding DILI and hERG, makes it the more promising drug candidate.
Output:
1
2025-04-18 00:42:17,466 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (340.295 and 350.409 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (120.39) is slightly higher than Ligand B (50.36). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for permeability. Ligand B is significantly better.
3. **logP:** Ligand A (2.906) is within the optimal 1-3 range. Ligand B (4.412) is above this range, potentially leading to solubility issues and off-target interactions. Ligand A is better.
4. **HBD:** Ligand A (1) and Ligand B (2) are both acceptable, well below the limit of 5. No major difference.
5. **HBA:** Ligand A (7) is higher than Ligand B (2). Lower is better for permeability, so Ligand B is preferable.
6. **QED:** Ligand B (0.845) has a better QED score than Ligand A (0.56), indicating a more drug-like profile. This is a significant advantage for Ligand B.
7. **DILI:** Ligand A (99.147) has a very high DILI risk, which is a major concern. Ligand B (43.738) has a much lower, acceptable DILI risk. This is a critical advantage for Ligand B.
8. **BBB:** Ligand A (50.679) has a moderate BBB penetration, while Ligand B (92.168) has a high BBB penetration. While ADRB2 isn't primarily a CNS target, some level of BBB penetration can be useful. Ligand B is better.
9. **Caco-2:** Both ligands have similar negative Caco-2 values (-4.72 and -4.637), indicating poor permeability. This is a shared weakness.
10. **Solubility:** Both ligands have similar negative solubility values (-4.879 and -4.937), indicating poor solubility. This is a shared weakness.
11. **hERG:** Ligand A (0.514) has a slightly lower hERG risk than Ligand B (0.7), which is preferable.
12. **Cl_mic:** Ligand B (33.787) has a lower microsomal clearance than Ligand A (42.646), suggesting better metabolic stability. This is a benefit for Ligand B.
13. **t1/2:** Ligand B (43.058) has a significantly longer in vitro half-life than Ligand A (-8.887). This is a major advantage for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.184) has lower P-gp efflux liability than Ligand B (0.151), which is slightly better.
15. **Binding Affinity:** Ligand B (-9.0) has a significantly stronger binding affinity than Ligand A (-6.2). This is a substantial advantage, and can often outweigh minor ADME concerns.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand B excels in affinity and has a better TPSA. While its logP is higher, the significantly better affinity, lower DILI, and longer half-life outweigh this concern. The high DILI risk of Ligand A is a dealbreaker.
**Conclusion:**
Ligand B is the more promising candidate due to its superior binding affinity, lower DILI risk, better metabolic stability (lower Cl_mic, longer t1/2), and better QED score. While both have solubility and permeability issues, the benefits of Ligand B outweigh its drawbacks.
Output:
0
2025-04-18 00:42:17,467 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (359.495 and 349.431 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (58.22) is significantly better than Ligand B (112.73). ADRB2 is not a CNS target, but lower TPSA generally improves absorption. Ligand A is well below the 140 threshold, while Ligand B is approaching it.
3. **logP:** Ligand A (3.247) is within the optimal 1-3 range. Ligand B (0.766) is a bit low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Both ligands have 4 HBA, which is acceptable.
6. **QED:** Ligand A (0.89) has a higher QED score than Ligand B (0.602), indicating a more drug-like profile.
7. **DILI:** Ligand A (54.323) has a higher DILI risk than Ligand B (14.889). This is a significant drawback for Ligand A.
8. **BBB:** Both ligands have similar BBB penetration (Ligand A: 49.477, Ligand B: 53.625). Since ADRB2 is not a CNS target, this is less critical.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Ligand A (-4.389) has slightly better solubility than Ligand B (-1.807), though both are poor.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.536 and 0.343 respectively).
12. **Cl_mic:** Ligand A (59.898) has a higher microsomal clearance than Ligand B (19.387), indicating lower metabolic stability.
13. **t1/2:** Ligand A (-20.799) has a much more negative in vitro half-life than Ligand B (-12.889), indicating a shorter half-life and faster metabolism.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.162 and 0.037 respectively).
15. **Binding Affinity:** Both ligands have the same binding affinity (-6.2 kcal/mol).
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, and affinity are important. Ligand A is better in terms of logP and TPSA. However, Ligand B has a significantly lower DILI risk and better metabolic stability (lower Cl_mic, longer t1/2). The DILI risk for Ligand A is concerning. While affinity is the same, the ADME profile of Ligand B is more favorable overall.
**Conclusion:**
Despite Ligand A's slightly better TPSA and logP, the significantly lower DILI risk and improved metabolic stability of Ligand B make it the more promising drug candidate. The DILI risk associated with Ligand A is a major concern that would likely necessitate further structural modifications.
Output:
0
2025-04-18 00:42:17,467 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (345.403 and 350.394 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand B (68.96) is significantly better than Ligand A (107.19). For a GPCR, lower TPSA generally improves permeability. Ligand B is well below the 140 A^2 threshold.
**3. logP:** Ligand B (1.469) is better than Ligand A (0.308). Both are within the acceptable range (1-3), but Ligand A is quite low, potentially hindering membrane permeability.
**4. H-Bond Donors:** Ligand A (3) is slightly higher than Ligand B (0). Lower HBDs are generally preferred for better permeability.
**5. H-Bond Acceptors:** Ligand A (5) and Ligand B (6) are comparable and both within the acceptable limit of 10.
**6. QED:** Both ligands have similar QED values (0.712 and 0.721), indicating good drug-likeness.
**7. DILI:** Both ligands have similar DILI risk (51.609 and 51.842), indicating a moderate risk.
**8. BBB:** Ligand B (89.919) is significantly better than Ligand A (25.94). While ADRB2 is primarily a cardiovascular target, some CNS side effects are possible with GPCR modulators, and higher BBB penetration could be a concern, but it's not a primary driver here.
**9. Caco-2 Permeability:** Ligand A (-5.668) is worse than Ligand B (-4.632). Both are negative, but Ligand B is closer to 0, suggesting slightly better permeability.
**10. Aqueous Solubility:** Both ligands have very poor aqueous solubility (-2.023 and -2.24). This is a significant concern for both, and formulation strategies would be needed.
**11. hERG Inhibition:** Ligand A (0.069) is better than Ligand B (0.509). Lower hERG inhibition is crucial to avoid cardiotoxicity, a major concern for cardiovascular drugs.
**12. Microsomal Clearance:** Ligand A (-12.383) is much better than Ligand B (59.162). Lower clearance means greater metabolic stability, a significant advantage.
**13. In vitro Half-Life:** Ligand A (-31.369) is much better than Ligand B (12.739). A longer half-life is generally desirable.
**14. P-gp Efflux:** Ligand A (0.01) is much better than Ligand B (0.111). Lower P-gp efflux improves bioavailability.
**15. Binding Affinity:** Both ligands have similar binding affinities (-5.8 and -5.5 kcal/mol), which are both good. The difference isn't substantial enough to override other factors.
**Overall Assessment:**
Ligand B has better TPSA, logP, and BBB penetration, which are important for GPCRs. However, Ligand A significantly outperforms Ligand B in hERG inhibition, microsomal clearance, in vitro half-life, and P-gp efflux. The poor solubility is a concern for both, but the superior ADME properties of Ligand A, particularly the lower hERG risk and better metabolic stability, are critical for a cardiovascular drug. The slightly better affinity of Ligand A also contributes.
Output:
1
2025-04-18 00:42:17,467 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (379.833 and 370.435 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (106.73) is better than Ligand B (126.29). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (0.909) is slightly lower than the optimal 1-3 range, but acceptable. Ligand B (-1.248) is below 1, which is less desirable for permeability. This is a point in favor of Ligand A.
4. **HBD:** Both ligands have 2 HBD, which is within the acceptable limit of 5.
5. **HBA:** Ligand A has 8 HBA, and Ligand B has 7. Both are within the acceptable limit of 10.
6. **QED:** Ligand B (0.667) has a slightly better QED score than Ligand A (0.515), suggesting a more drug-like profile.
7. **DILI:** Ligand A (98.604) has a significantly higher DILI risk than Ligand B (71.694). This is a major concern for Ligand A.
8. **BBB:** Both are relatively low, which is fine for a cardiovascular target. Ligand A (53.47) is slightly higher, but not a deciding factor.
9. **Caco-2:** Both have negative values, which is unusual. Assuming these are logP-scale values, lower values indicate poorer permeability. Ligand B (-5.745) is worse than Ligand A (-3.135).
10. **Solubility:** Ligand A (-3.135) has better solubility than Ligand B (-1.918).
11. **hERG:** Both ligands have very low hERG inhibition risk (0.058 and 0.024), which is excellent.
12. **Cl_mic:** Ligand B (-4.209) has a *much* lower (better) microsomal clearance than Ligand A (44.483). This suggests significantly improved metabolic stability for Ligand B.
13. **t1/2:** Ligand A (31.486) has a longer in vitro half-life than Ligand B (10.54). This is a positive for Ligand A.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.124 and 0.026).
15. **Binding Affinity:** Ligand A (-7.6) has a slightly better binding affinity than Ligand B (-7.4). While a 0.2 kcal/mol difference isn't huge, it's a positive for Ligand A.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are important. Ligand A has a slightly better logP and affinity, but Ligand B has a much better TPSA. The significant difference in DILI risk and Cl_mic heavily favors Ligand B. Metabolic stability (Cl_mic) is crucial for *in vivo* efficacy, and a high DILI risk is a major red flag. The slightly better affinity of Ligand A is unlikely to overcome these substantial ADME/Tox liabilities.
**Conclusion:**
Despite the slightly better affinity of Ligand A, the significantly lower DILI risk and improved metabolic stability (lower Cl_mic) of Ligand B make it the more promising drug candidate.
Output:
0
2025-04-18 00:42:17,467 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (349.435) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are acceptable, but Ligand B (88.16) is better than Ligand A (96.33), being closer to the <140 threshold for good oral absorption.
3. **logP:** Ligand B (2.313) is optimal (1-3), while Ligand A (0.534) is a bit low, potentially hindering permeation.
4. **HBD:** Both have 2 HBD, which is within the acceptable limit.
5. **HBA:** Both have 5 HBA, also within the acceptable limit.
6. **QED:** Both have similar QED values (0.716 and 0.714), indicating good drug-likeness.
7. **DILI:** Ligand A (33.734) has a significantly lower DILI risk than Ligand B (69.639), which is a major advantage.
8. **BBB:** Ligand B (78.364) has a better BBB penetration score than Ligand A (68.67), but ADRB2 is a cardiovascular target, so BBB penetration is not a high priority.
9. **Caco-2:** Ligand A (-5.183) has a worse Caco-2 permeability than Ligand B (-4.796).
10. **Solubility:** Ligand A (-1.634) has better solubility than Ligand B (-3.418).
11. **hERG:** Ligand A (0.416) has a lower hERG inhibition liability than Ligand B (0.217), which is a positive.
12. **Cl_mic:** Ligand B (15.391) has significantly lower microsomal clearance than Ligand A (32.628), indicating better metabolic stability.
13. **t1/2:** Ligand A (4.597) has a longer in vitro half-life than Ligand B (-14.752).
14. **Pgp:** Ligand A (0.028) has lower P-gp efflux liability than Ligand B (0.13), which is favorable for bioavailability.
15. **Affinity:** Ligand A (-7.3) has a stronger binding affinity than Ligand B (-6.7), a difference of 0.6 kcal/mol.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B performs better on logP and TPSA, while Ligand A has a better Pgp profile and significantly better affinity. The affinity difference is substantial (0.6 kcal/mol). However, the DILI risk for Ligand B is concerningly high.
**Overall Assessment:**
While Ligand B has some favorable ADME properties (logP, TPSA, Cl_mic), the significantly higher DILI risk and weaker binding affinity compared to Ligand A are major drawbacks. Ligand A's superior affinity and lower DILI risk outweigh its slightly lower logP and Caco-2 permeability. The cardiovascular context also reduces the importance of BBB penetration.
Output:
1
2025-04-18 00:42:17,467 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (353.413 and 349.475 Da) fall within the ideal range of 200-500 Da. No significant difference here.
2. **TPSA:** Ligand A (56.41) is significantly better than Ligand B (101.29). ADRB2 is not a CNS target, but lower TPSA generally improves absorption. Ligand A is well below the 140 threshold. Ligand B is approaching the upper limit.
3. **logP:** Both ligands have acceptable logP values (2.394 and 1.478), falling within the 1-3 range. Ligand A is slightly more lipophilic, which could be beneficial for membrane permeability.
4. **HBD:** Ligand A (1) has fewer HBDs than Ligand B (3). Fewer HBDs are generally preferred for better permeability.
5. **HBA:** Ligand A (2) has fewer HBAs than Ligand B (3). Similar to HBDs, lower is generally better.
6. **QED:** Ligand A (0.904) has a significantly higher QED score than Ligand B (0.677), indicating a more drug-like profile.
7. **DILI:** Ligand A (33.773) has a much lower DILI risk than Ligand B (19.038). This is a critical advantage.
8. **BBB:** Not a primary concern for ADRB2 (cardiovascular target), but Ligand A (85.459) has a higher BBB penetration score than Ligand B (62.427).
9. **Caco-2:** Ligand A (-4.713) and Ligand B (-5.296) both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Ligand A (-2.394) and Ligand B (-3.226) both have negative solubility values, which is also unusual and suggests poor solubility.
11. **hERG:** Ligand A (0.738) has a lower hERG risk than Ligand B (0.13). This is a significant advantage, as hERG inhibition can lead to cardiotoxicity.
12. **Cl_mic:** Both ligands have similar microsomal clearance values (16.874 and 17.222).
13. **t1/2:** Ligand A (-18.573) has a much longer in vitro half-life than Ligand B (4.188). This is a significant advantage, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.229) has lower P-gp efflux liability than Ligand B (0.029). Lower Pgp is generally preferred for better bioavailability.
15. **Binding Affinity:** Ligand B (-7.4) has a significantly stronger binding affinity than Ligand A (-3.1). This is a substantial advantage, and could potentially outweigh some of the ADME drawbacks of Ligand B. However, the difference is 4.3 kcal/mol, which is large enough to consider.
**Overall Assessment:**
While Ligand B has a superior binding affinity, Ligand A demonstrates a significantly better overall ADME profile. It has a higher QED, lower DILI risk, lower hERG risk, longer half-life, and lower P-gp efflux. The TPSA and H-bond counts are also more favorable for Ligand A. The negative Caco-2 and solubility values are concerning for both, but the other advantages of Ligand A, particularly the safety profile (DILI, hERG), are compelling. Given the cardiovascular target, minimizing off-target effects and ensuring a reasonable safety profile are paramount. The affinity difference, while substantial, may be overcome with further optimization of Ligand A.
Output:
1
2025-04-18 00:42:17,468 - INFO - Batch 497 complete. Total preferences: 7952
2025-04-18 00:42:17,468 - INFO - Processing batch 498/512...
2025-04-18 00:43:07,020 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (371.5 and 350.5 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Both ligands (81.7 and 78.4) are well below the 140 A^2 threshold for good oral absorption, and appropriate for a non-CNS GPCR target like ADRB2. No clear advantage.
3. **logP:** Ligand A (1.535) is slightly lower than Ligand B (2.661), but both are within the optimal 1-3 range. Ligand B is slightly better here.
4. **HBD:** Both ligands have 3 H-bond donors, which is acceptable. No clear advantage.
5. **HBA:** Ligand A has 5 H-bond acceptors, while Ligand B has 3. Both are below the 10 threshold. Ligand B is slightly better.
6. **QED:** Both ligands have similar QED scores (0.632 and 0.667), indicating good drug-likeness. No clear advantage.
7. **DILI:** Ligand B (30.4) has a significantly lower DILI risk than Ligand A (52.4). This is a substantial advantage for Ligand B.
8. **BBB:** BBB is less critical for ADRB2 (a cardiovascular target). Ligand B (30.7) is better than Ligand A (17.4), but this is not a major factor.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. This is a significant concern for both.
10. **Solubility:** Both ligands have negative solubility values, indicating poor solubility. This is a significant concern for both.
11. **hERG:** Both ligands have low hERG inhibition risk (0.273 and 0.328). No clear advantage.
12. **Cl_mic:** Ligand B (13.1) has significantly lower microsomal clearance than Ligand A (25.9), suggesting better metabolic stability. This is a major advantage for Ligand B.
13. **t1/2:** Ligand B (8.8) has a longer in vitro half-life than Ligand A (2.2). This is a significant advantage for Ligand B.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.036 and 0.392). No clear advantage.
15. **Binding Affinity:** Ligand B (-6.6 kcal/mol) has a slightly better binding affinity than Ligand A (-6.1 kcal/mol). While the difference is not huge, it is still a positive for Ligand B.
**Overall Assessment:**
Ligand B consistently outperforms Ligand A in several critical ADME-Tox properties: DILI risk, microsomal clearance, and in vitro half-life. It also has slightly better logP and binding affinity. While both compounds have issues with Caco-2 permeability and solubility, the superior safety and pharmacokinetic profile of Ligand B make it the more promising candidate.
Output:
0
2025-04-18 00:43:07,020 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [344.342, 73.44, 3.084, 1, 5, 0.527, 91.004, 62.776, -4.496, -4.933, 0.85, 97.215, -4.428, 0.48, -5.7]
**Ligand B:** [349.435, 77.81, 0.337, 0, 6, 0.717, 16.906, 77.084, -4.716, -1.322, 0.152, -5.428, -10.089, 0.007, -4.7]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (344.342) is slightly lower, which is generally favorable.
2. **TPSA:** Both are reasonably good (A: 73.44, B: 77.81), below the 140 threshold for oral absorption.
3. **logP:** Ligand A (3.084) is optimal, while Ligand B (0.337) is quite low. This is a significant drawback for B, potentially hindering membrane permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (0). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (5) and B (6) are both acceptable, below the 10 threshold.
6. **QED:** Both have good QED scores (A: 0.527, B: 0.717), indicating drug-likeness. B is slightly better here.
7. **DILI:** Ligand A (91.004) has a concerningly high DILI risk. Ligand B (16.906) is excellent in this regard. This is a major negative for A.
8. **BBB:** Ligand B (77.084) has better BBB penetration than Ligand A (62.776), but neither are exceptionally high. For a cardiovascular target, BBB isn't *critical*, but still a consideration.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability.
10. **Solubility:** Both have negative solubility values, which is also unusual and suggests poor solubility.
11. **hERG:** Both have low hERG inhibition liability (A: 0.85, B: 0.152), which is good. B is better.
12. **Cl_mic:** Ligand A (97.215) has a high microsomal clearance, suggesting rapid metabolism. Ligand B (-5.428) has a negative value, which is also unusual, but suggests very low clearance. This is a significant advantage for B.
13. **t1/2:** Ligand A (-4.428) has a negative half-life, which is unusual. Ligand B (-10.089) is also negative.
14. **Pgp:** Ligand A (0.48) has lower P-gp efflux than Ligand B (0.007), which is preferable.
15. **Affinity:** Both have very similar and excellent binding affinities (A: -5.7, B: -4.7 kcal/mol). The 1 kcal/mol difference is not enough to outweigh other factors.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand A has a good logP, but its high DILI risk and high clearance are major concerns. Ligand B has a poor logP, but its excellent DILI profile and low clearance are very attractive.
**Conclusion:**
Despite Ligand B's low logP, the significantly lower DILI risk and improved metabolic stability (lower Cl_mic) make it the more promising candidate. The negative values for Caco-2, solubility and half-life are concerning for both, and would need further investigation. However, the DILI risk for Ligand A is a showstopper.
Output:
0
2025-04-18 00:43:07,020 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (354.422 and 364.511 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (71.78) is higher than Ligand B (51.66). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B has a slight edge.
3. **logP:** Both ligands (2.39 and 2.947) are within the optimal 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability, but not drastically.
4. **HBD:** Ligand A (1) is better than Ligand B (0). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is better than Ligand B (5). Lower HBA is generally preferred for permeability.
6. **QED:** Ligand A (0.851) is significantly better than Ligand B (0.746), indicating a more drug-like profile.
7. **DILI:** Ligand A (29.236) has a lower DILI risk than Ligand B (38.62), which is a significant advantage.
8. **BBB:** Both ligands have high BBB penetration (89.027 and 82.319), but Ligand A is slightly better. This is less critical for a cardiovascular target like ADRB2, but still a positive.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand B (-4.953) is slightly worse than Ligand A (-4.291).
10. **Solubility:** Both ligands have negative solubility values, which is also unusual and suggests poor solubility. Ligand B (-3.341) is slightly worse than Ligand A (-2.959).
11. **hERG:** Both ligands have low hERG inhibition risk (0.538 and 0.465), which is good. No clear advantage.
12. **Cl_mic:** Ligand A (24.328) has significantly lower microsomal clearance than Ligand B (86.221), indicating better metabolic stability. This is a major advantage.
13. **t1/2:** Ligand A (14.087) has a longer in vitro half-life than Ligand B (7.131), further supporting its better metabolic stability.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.077 and 0.499), which is good. Ligand A is better.
15. **Binding Affinity:** Ligand B (-7.2) has a significantly stronger binding affinity than Ligand A (-5.4). This is a substantial advantage, potentially outweighing some ADME drawbacks.
**Overall Assessment:**
Ligand B has a significantly better binding affinity (-7.2 vs -5.4 kcal/mol). However, Ligand A demonstrates a superior ADME profile with a better QED score, lower DILI risk, lower microsomal clearance, longer half-life, and better P-gp efflux liability. The poor Caco-2 and solubility values are concerning for both, but the difference in binding affinity is substantial. For a GPCR, affinity is paramount, and a 1.8 kcal/mol difference is very significant. The improved ADME properties of Ligand A are valuable, but the binding affinity difference is likely to have a greater impact on *in vivo* efficacy.
Output:
0
2025-04-18 00:43:07,021 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (347.459) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (45.67) is significantly better than Ligand A (63.57), falling well below the 140 threshold for oral absorption and closer to the 90 threshold for CNS penetration (though CNS targeting isn't explicitly stated, it's good to have).
3. **logP:** Both ligands have acceptable logP values (1.725 and 3.045), within the 1-3 range. Ligand B is a bit higher, which could potentially lead to solubility issues, but is still within a reasonable range.
4. **HBD:** Ligand A has 1 HBD, while Ligand B has 0. Both are acceptable.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 5. Both are acceptable, below the 10 threshold.
6. **QED:** Ligand A (0.852) has a better QED score than Ligand B (0.638), indicating a more drug-like profile.
7. **DILI:** Ligand B (18.728) has a significantly lower DILI risk than Ligand A (28.926), which is a major advantage.
8. **BBB:** Ligand A (81.388) has slightly better BBB penetration than Ligand B (77.821), but both are reasonably good.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.662 and -4.423). This is unusual and suggests poor permeability. However, the values are similar, so it doesn't strongly favor either.
10. **Solubility:** Both ligands have negative solubility values (-2.296 and -2.784), indicating poor aqueous solubility. Again, similar and doesn't strongly favor either.
11. **hERG:** Both ligands have low hERG inhibition liability (0.6 and 0.531), which is good.
12. **Cl_mic:** Ligand A (14.094) has significantly lower microsomal clearance than Ligand B (81.533), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand B (21.203) has a longer in vitro half-life than Ligand A (18.25), which is generally desirable.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.082 and 0.453).
15. **Binding Affinity:** Ligand B (-7.3 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.6 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME drawbacks.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B excels in affinity and has acceptable logP and Pgp. Ligand A has a better QED and Cl_mic, but the affinity difference is substantial. The lower DILI risk of Ligand B is also a significant positive. While TPSA is better for Ligand B, the poor Caco-2 and solubility for both are concerning. However, the strong binding affinity of Ligand B is a major driver.
**Conclusion:**
Despite the slightly better QED and metabolic stability of Ligand A, the significantly stronger binding affinity and lower DILI risk of Ligand B make it the more promising drug candidate for ADRB2. The affinity difference is large enough to potentially overcome the slightly less favorable TPSA and solubility profiles.
Output:
0
2025-04-18 00:43:07,021 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (369.372 and 349.431 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (72.18) is better than Ligand B (78.95). Both are below 140, but lower TPSA generally favors absorption.
3. **logP:** Ligand A (3.394) is optimal, while Ligand B (0.836) is slightly low. A logP between 1-3 is preferred, and Ligand B is bordering on potentially having permeability issues.
4. **HBD:** Both ligands have 1 HBD, which is excellent.
5. **HBA:** Ligand A has 6 HBA, while Ligand B has 4. Both are within the acceptable range of <=10.
6. **QED:** Both ligands have similar QED values (0.765 and 0.721), indicating good drug-likeness.
7. **DILI:** Ligand A (91.082) has a significantly higher DILI risk than Ligand B (32.183). This is a major concern for Ligand A.
8. **BBB:** Ligand A (72.741) has a better BBB penetration potential than Ligand B (68.437). While ADRB2 isn't exclusively a CNS target, some peripheral ADRB2 activity can be modulated by CNS effects, and higher BBB penetration isn't necessarily a negative.
9. **Caco-2:** Ligand A (-4.836) and Ligand B (-5.022) both have negative Caco-2 values, indicating very poor permeability. This is a significant drawback for both.
10. **Solubility:** Ligand A (-4.117) is slightly better than Ligand B (-2.177), but both are poor.
11. **hERG:** Ligand A (0.383) has a slightly higher hERG risk than Ligand B (0.131). Lower is better, so Ligand B is preferable.
12. **Cl_mic:** Ligand B (9.283) has significantly lower microsomal clearance than Ligand A (34.889), indicating better metabolic stability. This is a major advantage for Ligand B.
13. **t1/2:** Ligand A (20.74) has a longer in vitro half-life than Ligand B (9.589), which is desirable.
14. **Pgp:** Ligand A (0.444) has lower P-gp efflux than Ligand B (0.01), which is preferable.
15. **Binding Affinity:** Ligand A (-6.1 kcal/mol) has a stronger binding affinity than Ligand B (-4.3 kcal/mol). This is a substantial difference (1.8 kcal/mol) and a significant advantage for Ligand A.
**Overall Assessment & GPCR Prioritization:**
For a GPCR like ADRB2, logP, TPSA, Pgp efflux, and binding affinity are key. Ligand A has a better logP and Pgp profile and significantly better binding affinity. However, the extremely high DILI risk associated with Ligand A is a major red flag. Ligand B, while having a lower logP and poorer Caco-2 permeability, exhibits a much more favorable safety profile (DILI) and better metabolic stability (Cl_mic). The binding affinity difference is substantial, but a high DILI risk often translates to clinical failures. Given the balance, the improved safety and metabolic stability of Ligand B outweigh the affinity advantage of Ligand A.
Output:
0
2025-04-18 00:43:07,021 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 drug candidates. ADRB2 is a GPCR, so we'll prioritize logP, Pgp, TPSA, BBB, and affinity.
**Ligand A:**
* **MW:** 356.511 Da - Good, within the ideal range.
* **TPSA:** 90.54 - Acceptable, slightly above the optimal <90 for CNS, but still reasonable for a peripheral GPCR like ADRB2.
* **logP:** 1.589 - Good, within the optimal range.
* **HBD:** 3 - Good, within the acceptable limit.
* **HBA:** 3 - Good, within the acceptable limit.
* **QED:** 0.519 - Good, above the 0.5 threshold.
* **DILI:** 18.108 - Excellent, very low risk.
* **BBB:** 73.827 - Good, indicating some potential for CNS penetration, but not a primary concern for ADRB2.
* **Caco-2:** -4.892 - Concerningly low, suggesting poor intestinal absorption.
* **Solubility:** -2.103 - Concerningly low, potentially leading to formulation issues.
* **hERG:** 0.634 - Good, low risk of cardiotoxicity.
* **Cl_mic:** 35.123 - Moderate, could be better for metabolic stability.
* **t1/2:** 0.024 - Very poor, extremely short half-life.
* **Pgp:** 0.013 - Excellent, low efflux liability.
* **Affinity:** -7.3 kcal/mol - Excellent, strong binding.
**Ligand B:**
* **MW:** 361.433 Da - Good, within the ideal range.
* **TPSA:** 70.67 - Excellent, well below the 90 threshold.
* **logP:** 1.155 - Good, within the optimal range.
* **HBD:** 2 - Good, within the acceptable limit.
* **HBA:** 4 - Good, within the acceptable limit.
* **QED:** 0.714 - Excellent, strong drug-like profile.
* **DILI:** 19.038 - Excellent, very low risk.
* **BBB:** 83.482 - Very good, indicating good potential for CNS penetration (less relevant here, but not detrimental).
* **Caco-2:** -4.84 - Concerningly low, similar to Ligand A, suggesting poor intestinal absorption.
* **Solubility:** -1.486 - Concerningly low, potentially leading to formulation issues.
* **hERG:** 0.4 - Good, low risk of cardiotoxicity.
* **Cl_mic:** 3.07 - Excellent, very low clearance, indicating high metabolic stability.
* **t1/2:** -9.035 - Very poor, extremely short half-life.
* **Pgp:** 0.014 - Excellent, low efflux liability.
* **Affinity:** -5.6 kcal/mol - Good, but significantly weaker than Ligand A.
**Comparison and Decision:**
Both ligands have significant issues with Caco-2 permeability and aqueous solubility, which are major drawbacks. Both also have very poor in vitro half-lives. However, Ligand A has a substantially better binding affinity (-7.3 kcal/mol vs -5.6 kcal/mol). For a GPCR, affinity is paramount, and a 1.7 kcal/mol difference is substantial. Ligand B has slightly better metabolic stability (Cl_mic) and QED, but the affinity difference outweighs these benefits. The slightly better TPSA and BBB of Ligand B are not critical for an ADRB2 target.
Therefore, despite the ADME concerns, Ligand A's superior binding affinity makes it the more promising starting point for optimization.
Output:
1
2025-04-18 00:43:07,021 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (340.379 Da and 345.399 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (75.69) is better than Ligand B (84.67). For a cardiovascular GPCR, TPSA should be kept low to facilitate good absorption, and Ligand A is closer to the <140 threshold.
**3. logP:** Ligand A (2.749) is better than Ligand B (1.142). Both are within the optimal 1-3 range, but Ligand A is closer to the upper end, which can be beneficial for membrane permeability. Ligand B is a bit low, potentially hindering permeation.
**4. H-Bond Donors:** Both ligands have 1 HBD, which is acceptable.
**5. H-Bond Acceptors:** Ligand A has 4 HBAs, and Ligand B has 5. Both are within the acceptable limit of 10.
**6. QED:** Ligand A (0.671) is better than Ligand B (0.564). A higher QED suggests a more drug-like profile.
**7. DILI Risk:** Ligand B (49.128) is significantly better than Ligand A (64.521). Lower DILI risk is crucial, and Ligand B is well below the concerning threshold of 60. Ligand A is approaching the high-risk zone.
**8. BBB Penetration:** Ligand B (63.358) is better than Ligand A (45.715). While ADRB2 is a cardiovascular target, some CNS effects are possible with certain ligands, and higher BBB penetration could be a benefit or a concern depending on the desired profile.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.955 and -4.815). These values are unusual and suggest poor permeability. However, the values are very close and don't significantly differentiate the two.
**10. Aqueous Solubility:** Ligand A (-3.221) is better than Ligand B (-1.817). Higher solubility is generally desirable, though both are quite poor.
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.236 and 0.119). This is excellent.
**12. Microsomal Clearance:** Ligand A (42.281) is better than Ligand B (13.095). Lower clearance indicates better metabolic stability, a significant advantage.
**13. In vitro Half-Life:** Ligand A (27.368) is significantly better than Ligand B (-0.342). A longer half-life is generally preferred.
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (0.131 and 0.093).
**15. Binding Affinity:** Ligand A (-6.3 kcal/mol) is slightly better than Ligand B (-5.7 kcal/mol). This 0.6 kcal/mol difference is meaningful, although not enormous.
**Overall Assessment:**
Ligand B has a much better DILI profile, which is a major advantage. It also has better BBB penetration. However, Ligand A excels in metabolic stability (lower Cl_mic, longer t1/2), QED, solubility, and has a slightly better binding affinity. Considering the GPCR-specific priorities, the balance of properties leans towards Ligand A, especially the more favorable metabolic profile and slightly better binding. The DILI risk of Ligand A is a concern, but it's not dramatically high and could be addressed with further optimization.
Output:
1
2025-04-18 00:43:07,021 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, the most important parameters are binding affinity, logP, TPSA, Pgp efflux, and to a lesser extent, BBB.
Let's compare the ligands property by property:
1. **MW:** Both ligands (367.391 and 346.431 Da) are within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (127.36) is slightly higher than Ligand B (114.18). Both are acceptable, being under 140, but B is preferable.
3. **logP:** Ligand B (0.924) is better than Ligand A (-0.243). A logP closer to 1-3 is desired, and A is a bit too hydrophilic.
4. **HBD:** Ligand A (0) is better than Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (9) is better than Ligand B (4). Lower HBA is preferable.
6. **QED:** Both ligands have good QED scores (0.523 and 0.649).
7. **DILI:** Ligand B (31.989) is significantly better than Ligand A (87.204). Lower DILI risk is crucial.
8. **BBB:** Ligand B (62.233) is better than Ligand A (54.634), although neither is exceptionally high. For a cardiovascular target, BBB isn't paramount, but it's a slight advantage for B.
9. **Caco-2:** Both are negative, indicating poor permeability.
10. **Solubility:** Both are negative, indicating poor solubility.
11. **hERG:** Both ligands have very low hERG risk (0.24 and 0.062).
12. **Cl_mic:** Ligand A (2.509) has significantly lower microsomal clearance than Ligand B (24.349), indicating better metabolic stability.
13. **t1/2:** Ligand B (-0.309) has a slightly better in vitro half-life than Ligand A (-23.299).
14. **Pgp:** Ligand A (0.036) is better than Ligand B (0.014) - lower Pgp efflux is preferred.
15. **Binding Affinity:** Ligand A (-6.9 kcal/mol) is slightly better than Ligand B (-5.7 kcal/mol). This is a 1.2 kcal/mol difference, which is significant.
**Overall Assessment:**
Ligand A has a better binding affinity and lower Pgp efflux, and better metabolic stability. However, Ligand B has a more favorable logP, significantly lower DILI risk, and a slightly better half-life. The DILI risk for Ligand A is concerningly high. The binding affinity difference, while notable, is not large enough to overcome the substantial safety concerns associated with Ligand A's DILI risk. Considering the GPCR-specific priorities and the importance of safety, Ligand B is the more promising candidate.
**Output:**
0
2025-04-18 00:43:07,022 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (a cardiovascular GPCR) drug candidates.
**Ligand A:** [348.487, 78.43, 1.846, 3, 3, 0.557, 7.445, 49.981, -4.648, -3.111, 0.144, 36.446, -5.097, 0.023, -5.8]
**Ligand B:** [368.474, 58.64, 2.578, 1, 4, 0.767, 50.174, 94.029, -4.818, -3.078, 0.522, 34.907, 48.989, 0.333, -6.3]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal 200-500 Da range. Ligand A (348.487) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (78.43) is higher than Ligand B (58.64). Both are acceptable, but Ligand B is better, being closer to the <90 ideal for potential CNS penetration (though not a primary concern for a cardiovascular target, lower TPSA is still generally preferred).
3. **logP:** Ligand A (1.846) is within the optimal range, while Ligand B (2.578) is also good. Both are acceptable.
4. **HBD/HBA:** Ligand A has 3 HBD and 3 HBA, while Ligand B has 1 HBD and 4 HBA. Ligand A is slightly better here, as fewer donors can improve membrane permeability.
5. **QED:** Ligand B (0.767) has a better QED score than Ligand A (0.557), indicating a more drug-like profile.
6. **DILI:** Both have low DILI risk (Ligand A: 7.445, Ligand B: 50.174), with Ligand A being slightly better.
7. **BBB:** Ligand B (94.029) has significantly better BBB penetration potential than Ligand A (49.981). While not crucial for a cardiovascular target, it doesn't hurt.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests a potential issue with permeability prediction. This is a flag for both, but doesn't immediately disqualify either.
9. **Solubility:** Both have negative solubility values, again suggesting issues with prediction.
10. **hERG:** Ligand A (0.144) has a lower hERG risk than Ligand B (0.522), which is a significant advantage.
11. **Cl_mic:** Ligand B (34.907) has a slightly lower microsomal clearance than Ligand A (36.446), suggesting better metabolic stability.
12. **t1/2:** Ligand B (48.989) has a much longer in vitro half-life than Ligand A (-5.097), which is a major advantage.
13. **Pgp:** Ligand A (0.023) has significantly lower P-gp efflux liability than Ligand B (0.333), which is beneficial for bioavailability.
14. **Affinity:** Ligand B (-6.3 kcal/mol) has a stronger binding affinity than Ligand A (-5.8 kcal/mol). This is a 0.5 kcal/mol difference, which is significant enough to potentially outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand B has a better QED, BBB, and significantly longer half-life, and stronger binding affinity. However, Ligand A has better hERG risk and Pgp efflux. The affinity difference is substantial, and the longer half-life of Ligand B is highly desirable. The slightly better metabolic stability of Ligand B is also a plus. While Ligand A has advantages in hERG and Pgp, the stronger binding and longer half-life of Ligand B are more critical for a GPCR target, especially considering the cardiovascular context where sustained receptor engagement can be beneficial.
Therefore, I prefer Ligand B.
Output:
0
2025-04-18 00:43:07,022 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [366.805, 108.47 , 2.006, 2. , 7. , 0.757, 87.243, 57.968, -5.084, -4.028, 0.228, 47.009, -5.925, 0.177, -6.3 ]
**Ligand B:** [383.583, 62.3 , 2.962, 1. , 5. , 0.701, 33.424, 61.729, -5.37 , -2.418, 0.578, 51.729, -0.673, 0.169, -5.2 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (366.8) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (108.47) is higher than Ligand B (62.3). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is still preferred. Ligand B is significantly better here.
3. **logP:** Both are within the optimal range (1-3). Ligand B (2.962) is slightly higher, potentially leading to some off-target interactions, but still acceptable.
4. **HBD:** Ligand A (2) and Ligand B (1) are both good.
5. **HBA:** Ligand A (7) and Ligand B (5) are both reasonable.
6. **QED:** Both are above 0.5 (Ligand A: 0.757, Ligand B: 0.701), indicating good drug-like properties.
7. **DILI:** Ligand A (87.243) has a significantly higher DILI risk than Ligand B (33.424). This is a major concern.
8. **BBB:** Both are relatively low, as expected for a cardiovascular target. Ligand B (61.729) is slightly better.
9. **Caco-2:** Both are negative, indicating poor permeability.
10. **Solubility:** Both are negative, indicating poor solubility.
11. **hERG:** Ligand A (0.228) is better than Ligand B (0.578) in terms of hERG inhibition liability.
12. **Cl_mic:** Ligand A (47.009) has a lower clearance than Ligand B (51.729), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-5.925) has a longer in vitro half-life than Ligand B (-0.673).
14. **Pgp:** Both are very low (0.177 and 0.169) indicating minimal P-gp efflux.
15. **Affinity:** Ligand A (-6.3) has a slightly better binding affinity than Ligand B (-5.2). This is a 1.1 kcal/mol difference, which is significant.
**GPCR-Specific Considerations:**
For ADRB2 (a cardiovascular GPCR), we prioritize logP, Pgp, TPSA, and affinity. Ligand B excels in TPSA, and has acceptable logP and Pgp. Ligand A has a slightly better affinity, better metabolic stability, and a longer half-life. However, the significantly higher DILI risk for Ligand A is a major red flag.
**Conclusion:**
Despite the slightly better affinity of Ligand A, the substantially higher DILI risk makes it a less desirable candidate. The lower DILI risk of Ligand B, combined with its better TPSA, makes it the more promising starting point for further optimization.
Output:
0
2025-04-18 00:43:07,022 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (349.431 and 355.463 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (94.8) is slightly higher than Ligand B (72.36). Both are acceptable for a non-CNS GPCR target like ADRB2, but B is preferable.
3. **logP:** Ligand A (0.116) is quite low, potentially hindering permeability. Ligand B (3.82) is within the optimal 1-3 range. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (3) is higher than Ligand B (1). While both are within the acceptable limit of 5, lower HBD is generally preferred for better permeability. Ligand B is better.
5. **HBA:** Both ligands have 5 HBA, which is acceptable.
6. **QED:** Both ligands have similar QED values (0.68 and 0.682), indicating good drug-likeness.
7. **DILI:** Ligand A (20.783) has a much lower DILI risk than Ligand B (65.762). This is a major advantage for Ligand A.
8. **BBB:** ADRB2 is primarily a cardiovascular target, so BBB penetration is not a high priority. Ligand B (76.696) has higher BBB penetration than Ligand A (42.109), but this isn't critical.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.242 and -5.252), which is unusual and suggests poor permeability. However, the values are very similar.
10. **Solubility:** Ligand A (-1.707) has slightly better solubility than Ligand B (-3.712).
11. **hERG:** Both ligands have very low hERG inhibition risk (0.095 and 0.769). No significant difference.
12. **Cl_mic:** Ligand A (-18.054) has a much lower (better) microsomal clearance than Ligand B (86.074), indicating greater metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (2.986) has a shorter in vitro half-life than Ligand B (-24.899). This is a disadvantage for Ligand A.
14. **Pgp:** Both ligands have similar Pgp efflux liability (0.008 and 0.495).
15. **Binding Affinity:** Ligand B (-5.5 kcal/mol) has a slightly better binding affinity than Ligand A (-6.0 kcal/mol). While A has a better affinity, the difference is not substantial enough to outweigh other factors.
**Overall Assessment:**
Ligand A has advantages in DILI risk, metabolic stability (Cl_mic), and solubility. However, Ligand B excels in logP, which is crucial for permeability, and has a slightly better binding affinity. The low logP of Ligand A is a significant concern, potentially leading to poor oral absorption. While the DILI risk of Ligand A is favorable, the overall balance of properties favors Ligand B.
Output:
0
2025-04-18 00:43:07,022 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (351.451 and 346.471 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (98.61) is higher than Ligand B (58.64). For a cardiovascular GPCR, TPSA is moderately important. Ligand B is significantly better here, suggesting improved permeability.
3. **logP:** Both ligands have similar logP values (2.34 and 2.431), falling within the optimal 1-3 range. No clear advantage.
4. **HBD:** Ligand A has 0 HBD, while Ligand B has 1. Both are acceptable, but lower is generally preferred for permeability.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 3. Both are within the acceptable limit of 10.
6. **QED:** Ligand B (0.687) has a better QED score than Ligand A (0.417), indicating a more drug-like profile.
7. **DILI:** Ligand A (26.561) has a significantly higher DILI risk than Ligand B (9.926). This is a major concern, as liver toxicity is a frequent cause of drug failure.
8. **BBB:** Ligand B (82.396) has a higher BBB penetration percentile than Ligand A (71.733). While ADRB2 isn't a CNS target, some off-target CNS effects are possible with GPCR ligands, and higher BBB is generally preferable.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.642 and -4.818). This is unusual and suggests poor permeability. However, the values are very similar.
10. **Solubility:** Both ligands have negative solubility values (-2.313 and -2.545). This is also concerning, and indicates poor aqueous solubility. Again, the values are similar.
11. **hERG:** Both ligands have low hERG inhibition risk (0.292 and 0.312). No significant difference.
12. **Cl_mic:** Ligand A (39.62) has a higher microsomal clearance than Ligand B (26.772), indicating lower metabolic stability.
13. **t1/2:** Ligand B (-0.524) has a slightly longer in vitro half-life than Ligand A (-15.788).
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.064 and 0.058). No significant difference.
15. **Binding Affinity:** Ligand A (-7.6 kcal/mol) has a significantly better binding affinity than Ligand B (-5.8 kcal/mol). This is a substantial difference (1.8 kcal/mol), and is a strong point in favor of Ligand A.
**Overall Assessment:**
Ligand A has a significantly better binding affinity, which is crucial for a GPCR ligand. However, it suffers from a much higher DILI risk and lower metabolic stability. Ligand B has a better safety profile (lower DILI), better QED, better TPSA, and slightly better metabolic stability and half-life.
Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity), and the overall balance of properties, the improved safety profile and drug-likeness of Ligand B outweigh the affinity advantage of Ligand A. While the Caco-2 and solubility values are poor for both, the DILI risk for Ligand A is a major red flag.
Output:
0
2025-04-18 00:43:07,022 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (343.471) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are reasonably low (A: 75.43, B: 78.51), well below the 140 threshold for oral absorption.
3. **logP:** Both have good logP values (A: 2.37, B: 1.238), falling within the optimal 1-3 range. Ligand A is slightly higher, potentially offering better membrane permeability.
4. **HBD:** Both have 2 H-bond donors, which is acceptable.
5. **HBA:** Ligand A has 3 HBA, and Ligand B has 4. Both are within the acceptable range of <=10.
6. **QED:** Ligand A (0.885) has a substantially better QED score than Ligand B (0.666), indicating better overall drug-likeness.
7. **DILI:** Both have acceptable DILI risk (A: 38.93, B: 41.024), below the 40% threshold.
8. **BBB:** Ligand A (85.343) has a significantly higher BBB penetration score than Ligand B (50.679). While ADRB2 isn't strictly a CNS target, some CNS exposure can be beneficial or at least needs to be understood.
9. **Caco-2:** Both show negative values, indicating permeability. Ligand A (-4.987) has a more negative value, suggesting better permeability.
10. **Solubility:** Both have negative solubility values, indicating good solubility. Ligand A (-3.1) is slightly better than Ligand B (-2.718).
11. **hERG:** Both have very low hERG inhibition liability (A: 0.471, B: 0.106), which is excellent.
12. **Cl_mic:** Ligand B (35.19) has lower microsomal clearance than Ligand A (42.756), suggesting better metabolic stability.
13. **t1/2:** Both have similar in vitro half-lives (A: 1.45, B: 1.35).
14. **Pgp:** Both have very low P-gp efflux liability (A: 0.066, B: 0.051), which is favorable.
15. **Binding Affinity:** Ligand A (-8.7 kcal/mol) has a significantly stronger binding affinity than Ligand B (-5.5 kcal/mol) - a difference of 3.2 kcal/mol. This is a substantial advantage.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A performs better on logP, TPSA, Pgp, and *significantly* better on affinity. The higher BBB score for Ligand A is a bonus. While Ligand B has better metabolic stability (lower Cl_mic), the difference in binding affinity is so large that it outweighs this advantage.
**Conclusion:**
The substantially stronger binding affinity of Ligand A, combined with its better QED, BBB, and Caco-2 permeability, makes it the more promising drug candidate despite the slightly higher microsomal clearance.
Output:
1
2025-04-18 00:43:07,023 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (353.463 and 351.506 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (29.54) is significantly better than Ligand A (98.74). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. This is a strong advantage for B.
3. **logP:** Ligand B (4.659) is higher than Ligand A (0.561). While 4.659 is approaching the upper limit, it's still within a reasonable range. Ligand A's logP is quite low, potentially hindering membrane permeability. Advantage B.
4. **HBD:** Ligand A (3) is higher than Ligand B (0). This isn't a major concern for either, but fewer HBDs can sometimes improve permeability. Slight advantage B.
5. **HBA:** Ligand A (4) is higher than Ligand B (2). Similar to HBD, lower is slightly preferred. Advantage B.
6. **QED:** Ligand A (0.623) is slightly better than Ligand B (0.47). A higher QED is desirable, but the difference isn't huge. Slight advantage A.
7. **DILI:** Both ligands have similar, low DILI risk (10.508 and 10.275 percentile). No significant difference.
8. **BBB:** Ligand B (95.967) is much higher than Ligand A (38.387). While not a primary concern for a cardiovascular target, higher BBB is generally a positive attribute. Advantage B.
9. **Caco-2:** Ligand A (-5.171) is significantly better than Ligand B (-4.412). Higher Caco-2 permeability is desirable. Advantage A.
10. **Solubility:** Ligand A (-1.411) is better than Ligand B (-4.143). Better solubility is always a plus. Advantage A.
11. **hERG:** Ligand A (0.097) is better than Ligand B (0.842). Lower hERG inhibition is crucial for avoiding cardiotoxicity. Significant advantage A.
12. **Cl_mic:** Ligand A (-15.822) is much better than Ligand B (88.415). Lower microsomal clearance indicates better metabolic stability. This is a major advantage for A.
13. **t1/2:** Ligand B (14.77) is much better than Ligand A (0.885). Longer half-life is generally preferred. Significant advantage B.
14. **Pgp:** Ligand A (0.008) is much better than Ligand B (0.742). Lower P-gp efflux is desirable for bioavailability. Significant advantage A.
15. **Binding Affinity:** Ligand A (-6.8) is better than Ligand B (-3.7). A 3.1 kcal/mol difference in binding affinity is substantial and can often outweigh minor ADME drawbacks. Major advantage A.
**Overall Assessment:**
Ligand A has a significantly stronger binding affinity, better metabolic stability (lower Cl_mic), lower P-gp efflux, and better hERG safety. Ligand B excels in TPSA, logP, BBB, and in vitro half-life. For a cardiovascular GPCR target like ADRB2, potency (affinity) and safety (hERG, metabolic stability) are paramount. The substantial advantage in binding affinity and the favorable safety profile of Ligand A outweigh the benefits of Ligand B's slightly improved permeability characteristics.
Output:
1
2025-04-18 00:43:07,023 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (359.451 and 350.459 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (93.43) is slightly higher than Ligand B (78.87). Both are below the 140 threshold for good oral absorption, but B is better.
3. **logP:** Both ligands have good logP values (1.065 and 0.927), falling within the 1-3 range. No clear advantage.
4. **HBD:** Both have 2 HBD, which is acceptable.
5. **HBA:** Ligand A has 5 HBA, Ligand B has 4. Both are within the acceptable range of <=10.
6. **QED:** Ligand A (0.842) has a slightly better QED score than Ligand B (0.773), indicating a more drug-like profile.
7. **DILI:** Ligand B (10.508) has a significantly lower DILI risk than Ligand A (57.697). This is a major advantage for Ligand B.
8. **BBB:** Ligand B (38.232) has a higher BBB penetration percentile than Ligand A (30.399). While not a primary concern for ADRB2 (a cardiovascular target), it's a slight positive.
9. **Caco-2:** Ligand B (-4.779) has a better Caco-2 permeability than Ligand A (-5.006).
10. **Solubility:** Ligand B (-1.216) has better aqueous solubility than Ligand A (-3.203).
11. **hERG:** Ligand B (0.228) has a much lower hERG inhibition liability than Ligand A (0.451), a critical safety parameter.
12. **Cl_mic:** Ligand B (-0.658) has a negative clearance, suggesting potentially *lower* metabolic clearance (more stable) than Ligand A (2.168). This is a significant advantage.
13. **t1/2:** Ligand B (23.573) has a longer in vitro half-life than Ligand A (15.766).
14. **Pgp:** Ligand B (0.027) has lower P-gp efflux liability than Ligand A (0.051).
15. **Binding Affinity:** Ligand A (-6.9) has a slightly better binding affinity than Ligand B (-6.0). However, the difference is less than 1.5 kcal/mol.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity, Ligand B demonstrates a significantly superior ADMET profile. The lower DILI risk, improved solubility, lower hERG inhibition, negative (better) microsomal clearance, longer half-life, and lower P-gp efflux make Ligand B a much more promising drug candidate. The slight difference in binding affinity is outweighed by these substantial improvements in safety and pharmacokinetic properties. Considering ADRB2 is a cardiovascular target, minimizing off-target effects (like hERG inhibition) and ensuring reasonable metabolic stability are crucial.
Output:
0
2025-04-18 00:43:07,023 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.459 and 373.837 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Both ligands (91.32 and 93.9) are reasonably low, suggesting good potential for absorption. They are both below the 140 A^2 threshold.
3. **logP:** Both ligands (1.434 and 1.614) are within the optimal 1-3 range. Again, no significant difference.
4. **HBD:** Ligand A (3) has more HBD than Ligand B (1). While not drastically different, fewer HBDs are generally preferred for better permeability.
5. **HBA:** Ligand B (6) has more HBA than Ligand A (4). Similar to HBD, fewer HBA are generally preferred.
6. **QED:** Both ligands have good QED scores (0.63 and 0.73), indicating good drug-like properties.
7. **DILI:** Ligand A (18.883) has a significantly lower DILI risk than Ligand B (50.136). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (81.039) has a higher BBB penetration percentile than Ligand A (45.25). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be beneficial for distribution.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.996 and -4.678). These values are difficult to interpret without knowing the scale, but negative values are not ideal.
10. **Solubility:** Ligand A (-1.783) has slightly better solubility than Ligand B (-2.63), but both are poor.
11. **hERG:** Both ligands have low hERG inhibition risk (0.184 and 0.263).
12. **Cl_mic:** Ligand A (18.856) has significantly lower microsomal clearance than Ligand B (25.418), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-5.144) has a negative in vitro half-life, which is concerning. Ligand A (2.845) has a positive half-life, indicating better stability.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.016 and 0.168).
15. **Binding Affinity:** Ligand A (-7.1 kcal/mol) has a slightly better binding affinity than Ligand B (-6.0 kcal/mol). This 1.1 kcal/mol difference is significant and can outweigh some ADME drawbacks.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Both ligands perform similarly on logP and TPSA. Pgp is low for both. However, Ligand A has a significantly better binding affinity and a much better safety profile (lower DILI). The improved metabolic stability (lower Cl_mic and positive t1/2) is also a significant advantage. While Ligand B has better BBB penetration, this is less critical for a non-CNS target like ADRB2.
**Conclusion:**
Ligand A is the more promising candidate due to its superior binding affinity, significantly lower DILI risk, improved metabolic stability, and acceptable physicochemical properties.
Output:
1
2025-04-18 00:43:07,023 - INFO - Batch 498 complete. Total preferences: 7968
2025-04-18 00:43:07,023 - INFO - Processing batch 499/512...
2025-04-18 00:43:55,685 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (356.423 and 363.483 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand B (83.71) is significantly better than Ligand A (125.71). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (1.344) is within the optimal 1-3 range, while Ligand A (0.572) is slightly below 1. This suggests Ligand B will have better membrane permeability.
4. **HBD:** Ligand B (1) has fewer HBD than Ligand A (4). Fewer HBDs are generally preferred for better permeability.
5. **HBA:** Ligand B (4) has fewer HBA than Ligand A (7). This also favors Ligand B.
6. **QED:** Ligand B (0.773) has a higher QED score than Ligand A (0.479), indicating a more drug-like profile.
7. **DILI:** Ligand B (33.695) has a much lower DILI risk than Ligand A (57.697). This is a significant advantage for Ligand B.
8. **BBB:** Ligand B (77.123) has a higher BBB penetration than Ligand A (15.277). While not critical for a cardiovascular target, it doesn't hurt.
9. **Caco-2:** Ligand A (-5.483) and Ligand B (-4.82) are both negative, which is unusual and suggests poor permeability. However, the values are close.
10. **Solubility:** Ligand A (-2.343) and Ligand B (-2.555) are both very poor. This is a concern for both, but not a deciding factor.
11. **hERG:** Both ligands have low hERG inhibition risk (0.131 and 0.097 respectively). No significant difference.
12. **Cl_mic:** Ligand B (47.522) has a lower microsomal clearance than Ligand A (26.89), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-14.179) has a longer in vitro half-life than Ligand A (-23.271). This is a positive for Ligand B.
14. **Pgp:** Ligand A (0.05) and Ligand B (0.032) have low P-gp efflux liability. No significant difference.
15. **Binding Affinity:** Ligand B (-7.3 kcal/mol) has a slightly better binding affinity than Ligand A (-6.6 kcal/mol). This 0.7 kcal/mol difference is substantial enough to be a key factor.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP, TPSA, and has a better affinity. While BBB isn't crucial here, it's still a benefit.
**Overall Assessment:**
Ligand B consistently outperforms Ligand A across most crucial parameters. It has a better drug-like profile (QED), lower DILI risk, better metabolic stability (Cl_mic, t1/2), improved permeability characteristics (logP, TPSA, HBD/HBA), and a slightly stronger binding affinity. While both have poor solubility and Caco-2 permeability, Ligand B's other advantages outweigh these drawbacks.
Output:
0
2025-04-18 00:43:55,686 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
Let's analyze each ligand against the provided guidelines, keeping in mind ADRB2 is a GPCR, so logP, Pgp, TPSA, and affinity are key.
* **Molecular Weight:** Both ligands (354.422 and 369.893 Da) fall comfortably within the ideal 200-500 Da range.
* **TPSA:** Ligand A (70.08) is better than Ligand B (78.45). Both are below 140, but lower TPSA generally favors absorption.
* **logP:** Ligand A (1.239) is good, while Ligand B (2.82) is also within the optimal 1-3 range, but closer to the upper limit.
* **H-Bond Donors/Acceptors:** Ligand A has 1 HBD and 4 HBA, while Ligand B has 2 HBD and 4 HBA. Both are acceptable.
* **QED:** Both ligands have good QED scores (0.699 and 0.738), indicating good drug-like properties.
* **DILI:** Both ligands have low DILI risk (32.028 and 35.673), which is positive.
* **BBB:** Ligand A (86.739) has significantly better BBB penetration potential than Ligand B (62.699). While ADRB2 isn't *necessarily* a CNS target, some peripheral ADRB2 activity can be modulated by CNS effects, and higher BBB penetration isn't a major negative.
* **Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.156 and -4.757), which is unusual and suggests poor permeability. However, the values are close, so this isn't a major differentiator.
* **Aqueous Solubility:** Ligand A (-1.233) is better than Ligand B (-3.23), indicating better solubility.
* **hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.381 and 0.494).
* **Microsomal Clearance:** Ligand A (19.922) has lower microsomal clearance than Ligand B (22.738), suggesting better metabolic stability.
* **In vitro Half-Life:** Ligand A (-10.831) has a substantially longer in vitro half-life than Ligand B (43.742). This is a significant advantage.
* **P-gp Efflux:** Both ligands have low P-gp efflux liability (0.097 and 0.596).
* **Binding Affinity:** Ligand B (-6.4 kcal/mol) has a slightly better binding affinity than Ligand A (-5.6 kcal/mol). This is a 0.8 kcal/mol difference, which is meaningful but not overwhelming.
**Overall Assessment:**
Ligand A demonstrates a better balance of properties. While Ligand B has slightly better binding affinity, Ligand A excels in crucial ADME properties like BBB penetration, solubility, metabolic stability (lower Cl_mic and longer t1/2), and has a lower TPSA. The better ADME profile of Ligand A, particularly the improved half-life and BBB, outweighs the modest affinity difference.
**Output:**
1
2025-04-18 00:43:55,686 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [376.389, 109.22 , -1.243, 2. , 7. , 0.601, 75.882, 54.634, -5.421, -1.744, 0.049, 14.619, -10.634, 0.016, -6.1 ]
**Ligand B:** [346.515, 49.41 , 3.641, 1. , 2. , 0.845, 26.095, 88.174, -4.985, -4.499, 0.475, 41.577, 5.88 , 0.232, -6.3 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (346.515) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (109.22) is higher than the preferred <140, but still acceptable. Ligand B (49.41) is excellent, well below 140, suggesting good absorption.
3. **logP:** Ligand A (-1.243) is a bit low, potentially hindering membrane permeability. Ligand B (3.641) is within the optimal range (1-3).
4. **HBD:** Both have acceptable HBD counts (2 and 1 respectively), below the threshold of 5.
5. **HBA:** Both have acceptable HBA counts (7 and 2 respectively), below the threshold of 10.
6. **QED:** Both have good QED scores (>0.5), indicating drug-like properties. Ligand B (0.845) is slightly better.
7. **DILI:** Ligand A (75.882) has a significantly higher DILI risk than Ligand B (26.095). This is a major concern.
8. **BBB:** Ligand B (88.174) has a much higher BBB penetration score than Ligand A (54.634). While ADRB2 isn't a primary CNS target, some CNS exposure can contribute to side effects, and better control is preferable.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and indicates poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Both have negative solubility values, which is also unusual.
11. **hERG:** Both have low hERG inhibition liability, which is good.
12. **Cl_mic:** Ligand A (14.619) has a lower microsomal clearance, indicating better metabolic stability than Ligand B (41.577).
13. **t1/2:** Ligand A (-10.634) has a negative in vitro half-life, which is concerning. Ligand B (5.88) is positive and more reasonable.
14. **Pgp:** Ligand A (0.016) has very low P-gp efflux, which is favorable. Ligand B (0.232) is slightly higher, but still relatively low.
15. **Affinity:** Both have comparable binding affinities (-6.1 and -6.3 kcal/mol), which is excellent.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP and TPSA, and has a good BBB score. While Ligand A has better metabolic stability (Cl_mic) and P-gp efflux, its significantly higher DILI risk and lower logP are major drawbacks. The negative values for Caco-2 and Solubility are concerning for both, but the other parameters weigh more heavily.
**Conclusion:**
Considering the balance of properties, particularly the significantly lower DILI risk and better logP/TPSA profile of Ligand B, it is the more promising drug candidate. The slightly worse metabolic stability of Ligand B can be addressed through further optimization.
Output:
0
2025-04-18 00:43:55,686 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.431 and 350.463 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (79.31) is better than Ligand B (87.46). Both are below 140, but lower TPSA generally favors absorption.
3. **logP:** Ligand B (0.643) is slightly better than Ligand A (0.034). Both are relatively low, which could be a concern for permeability. Ligand A is *very* close to being potentially problematic.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD is generally preferred for permeability.
5. **HBA:** Both ligands have 5 HBA, which is acceptable.
6. **QED:** Ligand A (0.707) is slightly better than Ligand B (0.674), indicating a marginally more drug-like profile.
7. **DILI:** Ligand B (18.224) is significantly better than Ligand A (28.655). Lower DILI risk is a major advantage.
8. **BBB:** Ligand B (49.826) is much better than Ligand A (30.206). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be useful for understanding off-target effects and distribution.
9. **Caco-2:** Ligand B (-5.02) is better than Ligand A (-4.639). Higher Caco-2 permeability is desirable.
10. **Solubility:** Ligand B (-0.978) is slightly better than Ligand A (-0.939). Both are poor.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.111 and 0.167), which is excellent.
12. **Cl_mic:** Ligand A (14.249) has a lower microsomal clearance than Ligand B (21.582), suggesting better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand A (23.013) has a much longer in vitro half-life than Ligand B (5.169). This is a substantial benefit.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.022 and 0.029).
15. **Binding Affinity:** Ligand B (-5.8) has a slightly better binding affinity than Ligand A (-5.5). This is a 0.3 kcal/mol difference, which is not huge, but still noticeable.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, and affinity are key. While Ligand B has a slightly better logP and affinity, Ligand A has a significantly better TPSA, and a much better metabolic profile (Cl_mic and t1/2). The DILI and BBB scores for Ligand B are also favorable. The solubility of both is poor, which is a concern.
**Overall Assessment:**
Ligand B is slightly better overall, despite the lower metabolic stability. The improved DILI, BBB, Caco-2, and affinity outweigh the slightly worse TPSA and metabolic parameters. The binding affinity difference is small enough that the other ADME properties of Ligand B make it the more promising candidate.
Output:
0
2025-04-18 00:43:55,686 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (426.3 Da) is within the ideal range, while Ligand B (365.413 Da) is also good. No clear advantage here.
2. **TPSA:** Ligand A (110.76) is slightly higher than ideal for good oral absorption (<=140), but acceptable. Ligand B (71.76) is excellent. Ligand B is better.
3. **logP:** Both ligands (A: 2.78, B: 2.629) are within the optimal 1-3 range. No clear advantage.
4. **HBD:** Ligand A (2) and Ligand B (1) are both good, below the threshold of 5. Ligand B is slightly better.
5. **HBA:** Both ligands (A: 8, B: 8) are within the acceptable range of <=10. No clear advantage.
6. **QED:** Both ligands have good QED scores (A: 0.649, B: 0.749), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (83.288) has a lower DILI risk than Ligand B (91.47), which is preferable. Ligand A is better.
8. **BBB:** Ligand A (62.35) and Ligand B (59.946) are both relatively low, which is not ideal for a GPCR, but not a major concern for ADRB2 (a cardiovascular target). No clear advantage.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. This is a concern for both.
10. **Solubility:** Both ligands have negative solubility values, indicating poor solubility. This is a concern for both.
11. **hERG:** Both ligands have low hERG inhibition liability (A: 0.108, B: 0.876). Ligand A is better.
12. **Cl_mic:** Ligand B (33.222) has a lower microsomal clearance than Ligand A (44.343), suggesting better metabolic stability. Ligand B is better.
13. **t1/2:** Ligand A (38.93) has a longer in vitro half-life than Ligand B (12.334). Ligand A is better.
14. **Pgp:** Both ligands have low Pgp efflux liability (A: 0.242, B: 0.225). No clear advantage.
15. **Binding Affinity:** Ligand B (-5.7 kcal/mol) has a slightly better binding affinity than Ligand A (-6.4 kcal/mol). Ligand B is better.
**GPCR-Specific Considerations:**
For ADRB2 (a cardiovascular GPCR), logP, TPSA, Pgp, and affinity are important. Both ligands are good in logP and Pgp. Ligand B is better in TPSA. The affinity difference is small, but Ligand B is slightly better. Metabolic stability (Cl_mic and t1/2) are also important, and Ligand A has a better half-life, while Ligand B has better clearance. DILI risk is also a consideration, and Ligand A is better.
**Overall Assessment:**
While Ligand A has advantages in DILI risk and half-life, Ligand B has a better TPSA, slightly better affinity, and better metabolic stability. Given the importance of TPSA and affinity for GPCRs, and the relatively small differences in the other parameters, I favor Ligand B.
Output:
0
2025-04-18 00:43:55,686 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (370.47 & 346.44 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (89.9) is better than Ligand B (107.72). ADRB2 is a cardiovascular target, so CNS penetration isn't the *highest* priority, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands (2.473 & 2.175) are within the optimal 1-3 range. Ligand B is slightly lower, but still acceptable.
4. **HBD:** Ligand A (1) is better than Ligand B (4). Fewer HBDs generally improve permeability.
5. **HBA:** Both ligands have 6 HBA, which is acceptable (<=10).
6. **QED:** Ligand A (0.742) is significantly better than Ligand B (0.518), indicating a more drug-like profile.
7. **DILI:** Ligand A (45.522) is slightly higher than Ligand B (37.456), but both are well below the concerning threshold of 60.
8. **BBB:** Ligand A (71.578) is significantly better than Ligand B (56.34). While ADRB2 isn't a CNS target, some off-target CNS effects are always a consideration, and higher BBB is generally preferable.
9. **Caco-2:** Ligand A (-4.508) is better than Ligand B (-5.269), indicating better intestinal absorption.
10. **Solubility:** Both ligands (-3.175 & -3.123) have similar, poor solubility. This is a potential issue for both.
11. **hERG:** Ligand A (0.261) is significantly better than Ligand B (0.649), indicating a lower risk of cardiotoxicity, which is *critical* for a cardiovascular target.
12. **Cl_mic:** Ligand A (45.656) is higher than Ligand B (25.53), meaning Ligand B has better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand A (5.107) is better than Ligand B (-3.435), indicating a longer in vitro half-life.
14. **Pgp:** Ligand A (0.561) is better than Ligand B (0.101), indicating lower P-gp efflux.
15. **Binding Affinity:** Ligand A (-6.2 kcal/mol) is significantly better than Ligand B (-2.2 kcal/mol). This is a substantial difference in potency. A >1.5 kcal/mol advantage in binding affinity often outweighs minor ADME drawbacks.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A excels in affinity, has better logP and TPSA, and lower Pgp efflux compared to Ligand B. The hERG risk is also significantly lower for Ligand A, which is paramount for a cardiovascular drug. While Ligand B has better metabolic stability, the substantial improvement in binding affinity and safety profile of Ligand A outweighs this benefit.
**Conclusion:**
Ligand A is the more promising drug candidate due to its superior binding affinity, lower hERG risk, better drug-likeness (QED), and more favorable BBB and permeability characteristics.
Output:
1
2025-04-18 00:43:55,686 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (344.411 and 346.383 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (71.77) is better than Ligand B (87.15). ADRB2 is a cardiovascular target, so CNS penetration isn't critical, but lower TPSA generally favors absorption.
3. **logP:** Both ligands have good logP values (2.512 and 1.514), falling within the 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability, but both are acceptable.
4. **HBD:** Both ligands have 1 HBD, which is within the acceptable limit of <=5.
5. **HBA:** Both ligands have 4 HBA, which is within the acceptable limit of <=10.
6. **QED:** Both ligands have high QED scores (0.905 and 0.873), indicating good drug-like properties.
7. **DILI:** Ligand A (62.699) has a higher DILI risk than Ligand B (50.523). This is a significant negative for Ligand A.
8. **BBB:** Ligand B (76.037) has a higher BBB penetration percentile than Ligand A (62.233). While not a primary concern for a cardiovascular target, higher BBB is generally favorable.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.924 and -4.472). These values are unusual and suggest poor permeability. However, the values are similar.
10. **Solubility:** Ligand A (-1.746) has slightly better solubility than Ligand B (-2.241).
11. **hERG:** Both ligands have very low hERG inhibition risk (0.042 and 0.02). This is excellent.
12. **Cl_mic:** Ligand A (17.95) has significantly lower microsomal clearance than Ligand B (22.417), indicating better metabolic stability.
13. **t1/2:** Ligand B (-18.46) has a much longer in vitro half-life than Ligand A (8.119). This is a major advantage for Ligand B.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.061 and 0.006). This is excellent.
15. **Binding Affinity:** Ligand A (-7.4) has a stronger binding affinity than Ligand B (-6.6), by 0.8 kcal/mol. This is a substantial difference.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, Pgp, TPSA, and affinity. Ligand A has a slightly better logP and significantly better affinity. Ligand B has better TPSA and Pgp, but the affinity difference is more important. The DILI risk for Ligand A is concerning.
**Overall Assessment:**
While Ligand A has a better binding affinity and slightly better logP and solubility, the higher DILI risk and shorter half-life are significant drawbacks. Ligand B, despite the slightly weaker binding, presents a more favorable ADMET profile with lower DILI risk and a much longer half-life. The 0.8 kcal/mol difference in binding affinity can often be overcome with further optimization, while mitigating DILI risk is much more challenging.
Output:
0
2025-04-18 00:43:55,687 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [348.399, 103.01 , 0.572, 3. , 5. , 0.722, 27.142, 38.852, -5.145, -1.553, 0.267, -23.636, 46.368, 0.013, -9.5 ]
**Ligand B:** [373.475, 107.78 , 0.455, 0. , 6. , 0.515, 39.162, 74.952, -4.31 , -2.093, 0.34 , 93.548, -59.916, 0.033, -5.9 ]
Here's a breakdown, prioritizing GPCR properties (logP, Pgp, TPSA, Affinity, and BBB):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (348.399) is slightly preferred due to being lower.
2. **TPSA:** Both are reasonably good (A: 103.01, B: 107.78), being under 140.
3. **logP:** Both are acceptable (A: 0.572, B: 0.455), though ideally closer to 1-3. Ligand A is slightly better.
4. **HBD/HBA:** A has 3/5, B has 0/6. A is better, as 0 HBDs can sometimes indicate poor interactions.
5. **QED:** Both are decent (A: 0.722, B: 0.515), above the 0.5 threshold. A is better.
6. **DILI:** Both are good (A: 27.142, B: 39.162), well below the 60 threshold. A is slightly better.
7. **BBB:** Ligand B (74.952) is significantly better than A (38.852) in terms of predicted BBB penetration. This is a key advantage for a GPCR, even if not a CNS target.
8. **Caco-2:** Both are negative, indicating poor permeability. Ligand B (-4.31) is slightly better than A (-5.145).
9. **Solubility:** Both are negative, indicating poor solubility. Ligand B (-2.093) is slightly better than A (-1.553).
10. **hERG:** Both are very low (A: 0.267, B: 0.34), indicating low cardiotoxicity risk.
11. **Cl_mic:** Ligand A (-23.636) has a much lower (better) microsomal clearance than Ligand B (93.548), suggesting better metabolic stability.
12. **t1/2:** Ligand A (46.368) has a better in vitro half-life than Ligand B (-59.916).
13. **Pgp:** Both are very low (A: 0.013, B: 0.033), indicating minimal P-gp efflux.
14. **Binding Affinity:** Ligand A (-9.5 kcal/mol) has a significantly stronger binding affinity than Ligand B (-5.9 kcal/mol). This is a substantial advantage.
**Overall Assessment:**
Ligand A has a clear advantage in terms of binding affinity, metabolic stability (Cl_mic), in vitro half-life, QED, and DILI risk. While Ligand B has better BBB penetration and slightly better Caco-2 and solubility, the superior affinity and ADME properties of Ligand A outweigh these benefits. The large difference in binding affinity (-9.5 vs -5.9) is a major factor.
Output:
1
2025-04-18 00:43:55,687 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (345.407) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (97.94) is better than Ligand B (123.66). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (0.089) is slightly lower than Ligand B (-0.116), but both are a bit low. A logP between 1-3 is optimal, and these are both below 1, potentially hindering permeation.
4. **HBD:** Ligand A (1) is better than Ligand B (4). Fewer HBDs are generally preferred for better permeability.
5. **HBA:** Both ligands have the same number of HBA (7), which is acceptable.
6. **QED:** Ligand A (0.767) has a significantly better QED score than Ligand B (0.425), indicating a more drug-like profile.
7. **DILI:** Both ligands have similar and acceptable DILI risk (Ligand A: 53.47, Ligand B: 44.63).
8. **BBB:** Ligand A (43.583) has a higher BBB percentile than Ligand B (27.646), but since ADRB2 is not a CNS target, this is less critical.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-5.485) is slightly better than Ligand B (-5.813).
10. **Solubility:** Both ligands have very poor aqueous solubility (-1.006 and -1.206 respectively). This is a significant drawback.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.03 and 0.162 respectively), which is excellent.
12. **Cl_mic:** Ligand A (-11.556) has a much lower (better) microsomal clearance than Ligand B (10.756), indicating better metabolic stability.
13. **t1/2:** Ligand A (26.275) has a longer in vitro half-life than Ligand B (13.653), which is desirable.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.007 and 0.015 respectively), which is good.
15. **Binding Affinity:** Ligand B (-7.2) has a slightly better binding affinity than Ligand A (-8.1). However, the difference is not substantial enough to outweigh the other factors.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A is better in terms of TPSA, Pgp, and metabolic stability (Cl_mic, t1/2), and has a better QED score. While Ligand B has a slightly better affinity, the other ADME properties of Ligand A are more favorable. The poor solubility and low logP are concerning for both, but Ligand A's superior overall profile makes it the better candidate.
**Output:**
1
2025-04-18 00:43:55,687 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
The ADRB2 receptor is a GPCR, so the priorities are logP, TPSA, Pgp efflux, BBB penetration, and binding affinity. Let's compare the two ligands across these and other important parameters:
1. **Molecular Weight:** Both ligands (348.443 and 390.615 Da) fall within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (70.08) is significantly higher than Ligand B (49.85). While both are under 140, Ligand B is better positioned for oral absorption and potentially better CNS penetration (though BBB is also a direct measure).
3. **logP:** Ligand A (1.084) is slightly lower than the optimal range of 1-3, but acceptable. Ligand B (2.939) is well within the optimal range.
4. **H-Bond Donors/Acceptors:** Ligand A has 1 HBD and 4 HBA, while Ligand B has 0 HBD and 5 HBA. Both are reasonable.
5. **QED:** Ligand A (0.775) has a better QED score than Ligand B (0.597), indicating a more drug-like profile.
6. **DILI:** Ligand B (49.283) has a much lower DILI risk than Ligand A (17.72). This is a significant advantage for Ligand B.
7. **BBB:** Ligand A (71.035) has a better BBB percentile than Ligand B (57.542). This is a positive for Ligand A, but not overwhelmingly so.
8. **Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.592 and -4.644), which is unusual and suggests poor permeability. This is a concern for both.
9. **Aqueous Solubility:** Both ligands have negative solubility values (-2.327 and -3.313), indicating poor solubility. This is a concern for both.
10. **hERG:** Both ligands have low hERG inhibition liability (0.315 and 0.341).
11. **Microsomal Clearance:** Ligand B (63.966) has a significantly higher microsomal clearance than Ligand A (12.539), suggesting lower metabolic stability.
12. **In vitro Half-Life:** Both ligands have similar in vitro half-lives (18.806 and 18.492 hours).
13. **P-gp Efflux:** Both ligands have low P-gp efflux liability (0.074 and 0.311).
14. **Binding Affinity:** Ligand B (-7.1 kcal/mol) has a slightly better binding affinity than Ligand A (-7.7 kcal/mol). While the difference is small, it's still a positive for Ligand B.
**Overall Assessment:**
Ligand B is preferable. While Ligand A has a better QED and BBB, Ligand B has a significantly lower DILI risk, a better logP, and slightly better binding affinity. The poor Caco-2 and solubility values are concerning for both, but the lower DILI risk of Ligand B is a critical advantage. The higher clearance of Ligand B is a drawback, but could potentially be addressed through structural modifications. Given the GPCR target class, the balance of properties favors Ligand B.
**Output:**
0
2025-04-18 00:43:55,687 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, priorities are affinity, logP, TPSA, Pgp, and BBB.
**Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (370.361 Da) is slightly higher than Ligand B (340.446 Da), but both are acceptable.
**TPSA:** Ligand A (84.5) is better than Ligand B (49.84). Both are below 140, indicating good oral absorption potential, but Ligand B is closer to the ideal for CNS penetration (though not a primary concern here).
**logP:** Ligand A (2.848) is optimal, while Ligand B (4.432) is pushing the upper limit. Higher logP can lead to solubility issues and off-target effects.
**H-Bond Donors/Acceptors:** Both ligands have 2 HBD and 4 HBA, which are within acceptable limits.
**QED:** Ligand B (0.783) has a slightly better QED score than Ligand A (0.517), suggesting a more drug-like profile.
**DILI:** Both ligands have relatively low DILI risk (Ligand A: 46.84, Ligand B: 40.093), with Ligand B being slightly better.
**BBB:** Both ligands have good BBB penetration (Ligand A: 79.992, Ligand B: 80.07). This isn't a primary concern for a cardiovascular target, but it doesn't hurt.
**Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. This is a significant concern for both.
**Aqueous Solubility:** Both ligands have negative solubility values, indicating very poor aqueous solubility. This is a major drawback for both compounds.
**hERG Inhibition:** Ligand A (0.398) has a lower hERG inhibition liability than Ligand B (0.904), which is a significant advantage.
**Microsomal Clearance:** Ligand B (55.466) has a higher microsomal clearance than Ligand A (50.368), indicating faster metabolism and potentially lower exposure.
**In vitro Half-Life:** Ligand B (60.161) has a significantly longer in vitro half-life than Ligand A (-11.986). This is a major advantage for Ligand B.
**P-gp Efflux:** Ligand A (0.179) has lower P-gp efflux liability than Ligand B (0.593), which is favorable.
**Binding Affinity:** Ligand B (-8.0 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.9 kcal/mol). This is a crucial advantage, potentially outweighing some of the ADME concerns.
**Overall Assessment:**
Ligand B has a substantially better binding affinity, a longer half-life, and a slightly better QED and DILI profile. However, it has a higher logP, higher P-gp efflux, and worse hERG inhibition. Ligand A has better logP, hERG, and P-gp, but significantly weaker binding affinity and a much shorter half-life.
Given the importance of binding affinity for GPCR targets, and the substantial difference (-8.0 vs -5.9 kcal/mol), I believe Ligand B is the more promising candidate *despite* its ADME liabilities. These liabilities can potentially be addressed through further optimization, but a weak binder is unlikely to become a viable drug.
**Output:**
0
2025-04-18 00:43:55,687 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (368.405 and 362.377 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (61.19) is well below the 140 threshold and very good for oral absorption. Ligand B (99.77) is higher, but still within a reasonable range, though less optimal.
3. **logP:** Ligand A (3.097) is optimal (1-3). Ligand B (-0.45) is significantly lower, which could hinder membrane permeability and bioavailability. This is a major drawback for a GPCR target.
4. **HBD:** Ligand A (0) is excellent. Ligand B (3) is acceptable, but more donors can sometimes lead to issues with permeability.
5. **HBA:** Ligand A (6) is good. Ligand B (4) is also good.
6. **QED:** Both ligands have good QED scores (0.427 and 0.571 respectively), indicating reasonable drug-likeness. Ligand B is slightly better.
7. **DILI:** Ligand A (70.143) is moderately high, but acceptable. Ligand B (25.048) is excellent, indicating a very low risk of liver injury.
8. **BBB:** Ligand A (98.333) is excellent, suggesting good potential for CNS penetration. Ligand B (81.698) is good, but less favorable. While ADRB2 isn't *necessarily* a CNS target, some peripheral effects are mediated by CNS pathways, and higher BBB penetration can sometimes be beneficial.
9. **Caco-2:** Ligand A (-4.211) is a negative value, which is unusual and suggests very poor permeability. Ligand B (-5.118) is also poor, but similar to A.
10. **Solubility:** Ligand A (-5.167) is very poor. Ligand B (-1.547) is also poor, but slightly better.
11. **hERG:** Both ligands show low hERG inhibition risk (0.533 and 0.143 respectively).
12. **Cl_mic:** Ligand A (95.374) is high, indicating rapid metabolism and potentially low bioavailability. Ligand B (2.555) is very low, suggesting excellent metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand A (-2.163) is very short, indicating rapid clearance. Ligand B (-28.887) is extremely short, and problematic.
14. **Pgp:** Both ligands show low P-gp efflux (0.457 and 0.003 respectively).
15. **Binding Affinity:** Ligand A (-6.0) is slightly better than Ligand B (-6.8), but the difference is not substantial enough to overcome other significant drawbacks.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, and metabolic stability (Cl_mic) are particularly important. Ligand A has a good logP and TPSA, but its poor solubility, high Cl_mic, and short half-life are major concerns. Ligand B has a poor logP and solubility, but a *very* favorable Cl_mic and Pgp profile.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity and BBB penetration, the significantly better metabolic stability (lower Cl_mic) of Ligand B is a crucial advantage for a GPCR target. The poor logP and solubility of Ligand B are concerning, but these could potentially be addressed through formulation strategies or further chemical modifications. The poor Caco-2 and t1/2 values for both are concerning, but the metabolic stability of Ligand B is more readily addressable than the permeability issues of Ligand A.
Output:
0
2025-04-18 00:43:55,688 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (329.359 Da) is better than Ligand B (372.334 Da). Both are within the ideal range, but A is closer to the lower end, potentially aiding permeability.
2. **TPSA:** Ligand B (58.64) is significantly better than Ligand A (71.09). Lower TPSA is highly desirable for GPCRs, promoting better brain penetration and membrane permeability.
3. **logP:** Ligand A (3.244) is slightly higher than Ligand B (1.964). Both are within the optimal range, but B is closer to the lower limit.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1). Both are acceptable.
5. **HBA:** Ligand A (4) is slightly higher than Ligand B (3). Both are acceptable.
6. **QED:** Ligand A (0.721) is slightly better than Ligand B (0.663), indicating a more drug-like profile.
7. **DILI:** Ligand B (37.146) is *much* better than Ligand A (94.804). This is a critical advantage for B. High DILI risk is a major red flag.
8. **BBB:** Ligand B (89.531) is significantly better than Ligand A (62.97). While ADRB2 isn't exclusively a CNS target, some CNS penetration can be beneficial and is not detrimental.
9. **Caco-2:** Both are very poor (-4.8 and -4.918). This is a concern for both, indicating poor intestinal absorption.
10. **Solubility:** Ligand A (-6.193) is better than Ligand B (-2.11), indicating better aqueous solubility.
11. **hERG:** Ligand A (0.61) is slightly better than Ligand B (0.533). Both are relatively low risk.
12. **Cl_mic:** Ligand B (3.195) is *much* better than Ligand A (16.637). Lower clearance is highly desirable for improved metabolic stability.
13. **t1/2:** Ligand A (72.604) is significantly better than Ligand B (-12.81). This is a major advantage for A, indicating a much longer half-life.
14. **Pgp:** Ligand A (0.383) is better than Ligand B (0.05). Lower P-gp efflux is preferred for better bioavailability.
15. **Binding Affinity:** Ligand B (-6.7) is slightly better than Ligand A (-5.8). While both are good, B has a 0.9 kcal/mol advantage.
**Overall Assessment & GPCR Prioritization:**
For a GPCR like ADRB2, TPSA, logP, Pgp, and affinity are key. Ligand B excels in TPSA and has a slightly better affinity. Critically, it has a *much* lower DILI risk and significantly better metabolic stability (Cl_mic). While Ligand A has a longer half-life and better solubility, the DILI and Cl_mic issues with A are too significant to ignore. The slightly lower logP of B is not a major concern. The poor Caco-2 values for both are a concern that would need to be addressed in further optimization, but are less critical than safety and metabolic stability at this stage.
**Output:**
0
2025-04-18 00:43:55,688 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (340.39 and 348.49 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (98.02) is higher than Ligand B (58.64). For a cardiovascular GPCR like ADRB2, TPSA isn't a *critical* factor like it would be for a CNS target, but lower is generally preferred for better absorption. Ligand B is better.
3. **logP:** Ligand A (0.896) is slightly below the optimal 1-3 range, while Ligand B (2.655) is well within it. logP is important for GPCRs, and Ligand B's value is more favorable for membrane permeability and receptor engagement.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 5 HBA, while Ligand B has 3. Lower HBA generally improves permeability. Ligand B is better.
6. **QED:** Ligand A (0.894) has a superior QED score compared to Ligand B (0.542), indicating a more drug-like profile overall. This is a significant advantage for Ligand A.
7. **DILI:** Ligand A (58.67%) has a higher DILI risk than Ligand B (8.57%). This is a major concern, as liver toxicity is a common reason for drug failure. Ligand B is significantly better.
8. **BBB:** Ligand A (32.14%) has a low BBB penetration, which is acceptable for a cardiovascular target. Ligand B (95.19%) has very high BBB penetration. While not a primary concern for ADRB2, it's not necessarily detrimental, but could suggest off-target effects.
9. **Caco-2:** Ligand A (-5.261) and Ligand B (-4.581) both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
10. **Solubility:** Ligand A (-2.547) and Ligand B (-3.015) both have negative solubility values, also making interpretation difficult.
11. **hERG:** Ligand A (0.374) has a lower hERG risk than Ligand B (0.561), which is a positive attribute.
12. **Cl_mic:** Ligand A (30.36 mL/min/kg) has a lower microsomal clearance than Ligand B (55.74 mL/min/kg), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-2.679 hours) has a shorter half-life than Ligand B (-4.457 hours). This is a drawback for Ligand A.
14. **Pgp:** Ligand A (0.047) has a lower P-gp efflux liability than Ligand B (0.151), which is favorable for bioavailability.
15. **Affinity:** Ligand A (-8.2 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.9 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME drawbacks.
**Overall Assessment:**
Ligand A has a superior binding affinity and QED, lower Pgp efflux, and better metabolic stability. However, it has a concerningly higher DILI risk and shorter half-life. Ligand B has a better logP, TPSA, lower DILI risk, and longer half-life. The difference in binding affinity is significant (1.3 kcal/mol), and for a GPCR, potency is often a key driver. The DILI risk for Ligand A is a significant concern, but could potentially be mitigated with further structural modifications.
Given the importance of potency for GPCR targets and the potential to address the DILI risk through further optimization, I believe Ligand A is the more promising starting point.
Output:
1
2025-04-18 00:43:55,688 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (351.535 and 363.361 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (52.65) is significantly better than Ligand B (120.25). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold. Ligand B is approaching the upper limit.
3. **logP:** Ligand A (2.65) is within the optimal 1-3 range. Ligand B (-0.461) is below 1, which could hinder permeation. This is a significant negative for Ligand B.
4. **HBD:** Ligand A (1) is preferable to Ligand B (4). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (6). Similar reasoning as HBD.
6. **QED:** Ligand A (0.731) is better than Ligand B (0.488), indicating a more drug-like profile.
7. **DILI:** Ligand A (6.049%) is *much* better than Ligand B (36.681%). This is a major advantage for Ligand A.
8. **BBB:** Not a primary concern for a cardiovascular target, but Ligand A (87.553%) is better than Ligand B (48.74%).
9. **Caco-2:** Ligand A (-4.743) is better than Ligand B (-5.26), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-2.066) is better than Ligand B (-1.251).
11. **hERG:** Ligand A (0.583) is better than Ligand B (0.204), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand A (36.804) is better than Ligand B (2.815), indicating greater metabolic stability.
13. **t1/2:** Ligand A (-5.622) is better than Ligand B (-29.345).
14. **Pgp:** Ligand A (0.074) is better than Ligand B (0.01).
15. **Affinity:** Ligand B (-6.7 kcal/mol) is slightly better than Ligand A (-6.1 kcal/mol). While a difference of 0.6 kcal/mol is noticeable, it's not a massive advantage, and can be overcome by better ADME properties.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand A is better on logP and TPSA. Affinity is slightly better for Ligand B, but the other ADME properties of Ligand A are significantly superior.
**Overall Assessment:**
Ligand A demonstrates a significantly more favorable ADME profile across almost all parameters. The superior TPSA, logP, QED, DILI, solubility, hERG, metabolic stability, and half-life outweigh the slightly weaker binding affinity of Ligand A. Ligand B has a concerningly low logP and a higher DILI risk.
Output:
1
2025-04-18 00:43:55,688 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [349.431, 78.95, 0.45, 1.0, 4.0, 0.748, 31.097, 66.615, -4.761, -2.007, 0.124, 3.491, -13.744, 0.027, -6.6]
**Ligand B:** [392.543, 92.78, 0.848, 1.0, 6.0, 0.554, 53.548, 60.721, -5.199, -3.21, 0.282, 85.832, -62.401, 0.041, -6.8]
**Step-by-step comparison:**
1. **MW:** Ligand A (349.431 Da) is better, falling nicely within the 200-500 Da range. Ligand B (392.543 Da) is still acceptable, but closer to the upper limit.
2. **TPSA:** Ligand A (78.95) is significantly better, well below the 140 threshold for good absorption. Ligand B (92.78) is higher, potentially indicating lower permeability.
3. **logP:** Both are reasonable, but Ligand B (0.848) is slightly better than Ligand A (0.45). A logP around 1 is good for balancing solubility and permeability. Ligand A is a bit low, potentially leading to permeability issues.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A (4) is better than Ligand B (6). Lower HBA generally improves permeability.
6. **QED:** Ligand A (0.748) is better, indicating a more drug-like profile than Ligand B (0.554).
7. **DILI:** Ligand A (31.097) has a much lower DILI risk than Ligand B (53.548). This is a significant advantage.
8. **BBB:** Both are reasonably good, but Ligand A (66.615) is slightly better than Ligand B (60.721). While not a CNS target, some BBB penetration can be beneficial for distribution.
9. **Caco-2:** Ligand A (-4.761) is better, suggesting better intestinal absorption.
10. **Solubility:** Ligand A (-2.007) is better than Ligand B (-3.21), indicating better aqueous solubility.
11. **hERG:** Both are very low (0.124 and 0.282), indicating a low risk of cardiotoxicity.
12. **Cl_mic:** Ligand A (3.491) has significantly lower microsomal clearance than Ligand B (85.832), indicating better metabolic stability.
13. **t1/2:** Ligand A (-13.744) has a much longer in vitro half-life than Ligand B (-62.401). This is a major advantage.
14. **Pgp:** Both are very low (0.027 and 0.041), indicating minimal P-gp efflux.
15. **Affinity:** Both have comparable binding affinity (-6.6 and -6.8 kcal/mol). The difference is negligible.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A performs better on TPSA, logP, and has a significantly better ADME profile (DILI, Cl_mic, t1/2, solubility). While both have similar affinity, the improved ADME properties of Ligand A outweigh the slight difference in logP.
**Conclusion:**
Ligand A is the more promising candidate due to its superior drug-like properties, lower toxicity risk, and better predicted pharmacokinetic profile.
**Output:**
1
2025-04-18 00:43:55,688 - INFO - Batch 499 complete. Total preferences: 7984
2025-04-18 00:43:55,688 - INFO - Processing batch 500/512...
2025-04-18 00:44:43,904 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (345.403 and 355.391 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (81.39) is significantly better than Ligand B (125.13). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (1.525) is within the optimal 1-3 range. Ligand B (-0.501) is slightly below 1, which could potentially hinder permeation. This favors Ligand A.
4. **HBD:** Ligand A (1) is better than Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (6) is better than Ligand B (7). Fewer HBAs generally improve permeability.
6. **QED:** Ligand A (0.852) is significantly better than Ligand B (0.602), indicating a more drug-like profile.
7. **DILI:** Both ligands have acceptable DILI risk (37.03 and 39.24), below the 40% threshold. No significant difference.
8. **BBB:** Ligand A (71.888) has a better BBB percentile than Ligand B (30.477), but this is less critical for a cardiovascular target.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.694 and -4.933), which is unusual and suggests poor permeability. However, the values are similar.
10. **Solubility:** Both ligands have negative solubility values (-1.782 and -1.605), which is also unusual and suggests poor solubility. The values are similar.
11. **hERG:** Both ligands have low hERG inhibition risk (0.386 and 0.16). No significant difference.
12. **Cl_mic:** Ligand A (65.016) has a lower microsomal clearance than Ligand B (7.098), suggesting better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand A (-7.986) has a much longer in vitro half-life than Ligand B (22.297). This is a major advantage, potentially leading to less frequent dosing.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.065 and 0.09). No significant difference.
15. **Binding Affinity:** Ligand B (-6.3) has a slightly better binding affinity than Ligand A (-5.2), a difference of 1.1 kcal/mol. While affinity is important, the other ADME properties of Ligand A are significantly better.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand A has a better logP and TPSA. While Ligand B has slightly better affinity, the overall profile of Ligand A is superior due to its better drug-likeness (QED), metabolic stability (Cl_mic), and half-life.
**Conclusion:**
Considering all factors, Ligand A is the more promising drug candidate due to its superior ADME properties and drug-likeness, despite the slightly lower binding affinity.
Output:
1
2025-04-18 00:44:43,904 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (359.828 Da and 356.438 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (29.54) is significantly better than Ligand B (59.08). For a GPCR, lower TPSA is generally preferred for better permeability. Ligand B is quite high, potentially hindering absorption.
**3. logP:** Ligand A (4.482) is a bit high, potentially leading to solubility issues or off-target interactions, but still within a tolerable range. Ligand B (1.379) is on the lower side, which could limit permeability. The optimal range is 1-3, and A is closer to the upper limit, while B is closer to the lower limit.
**4. H-Bond Donors:** Both ligands have 0 HBD, which is good.
**5. H-Bond Acceptors:** Ligand A has 2 HBA, while Ligand B has 4. Both are acceptable, but lower is generally better.
**6. QED:** Both ligands have similar QED values (0.805 and 0.767), indicating good drug-like properties.
**7. DILI Risk:** Ligand A (67.429) has a higher DILI risk than Ligand B (30.748). This is a significant concern for Ligand A.
**8. BBB Penetration:** Both ligands show good BBB penetration (88.988 and 89.531). This isn't a primary concern for a cardiovascular target, but it's not detrimental.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.57 and -4.348). This is unusual and suggests poor permeability. However, these values are on a log scale and are likely indicating very low permeability.
**10. Aqueous Solubility:** Ligand A (-5.243) has significantly worse solubility than Ligand B (-1.162). This is a major drawback for Ligand A, especially given its already high logP.
**11. hERG Inhibition:** Ligand A (0.796) has a slightly higher hERG risk than Ligand B (0.314). Lower is better here.
**12. Microsomal Clearance:** Ligand A (93.202) has much higher microsomal clearance than Ligand B (14.747), indicating faster metabolism and potentially lower bioavailability.
**13. In vitro Half-Life:** Ligand A (13.766) has a longer half-life than Ligand B (2.38), which is a positive.
**14. P-gp Efflux:** Ligand A (0.847) has higher P-gp efflux than Ligand B (0.043), meaning it is more likely to be pumped out of cells, reducing bioavailability.
**15. Binding Affinity:** Ligand B (-5.4) has a slightly better binding affinity than Ligand A (-7.0). While A has better affinity, the difference isn't substantial enough to outweigh the other significant drawbacks.
**Overall Assessment:**
Ligand B is the better candidate. While its logP is a bit low, it is significantly better than Ligand A in terms of DILI risk, solubility, microsomal clearance, and P-gp efflux. Ligand A's high logP, poor solubility, high DILI risk, high clearance, and high P-gp efflux are major liabilities. The slightly better binding affinity of Ligand A is not enough to compensate for these issues. The negative Caco-2 values for both are concerning, but the other ADME properties of Ligand B are more favorable.
Output:
0
2025-04-18 00:44:43,904 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (344.46 & 341.42 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (49.85) is significantly better than Ligand B (80.12). ADRB2 is not a CNS target, but lower TPSA generally improves absorption.
3. **logP:** Both ligands have acceptable logP values (1.69 & 2.24), falling within the 1-3 range. Ligand B is slightly higher, which *could* be a minor negative.
4. **HBD:** Ligand A (0) is preferable to Ligand B (1). Fewer HBDs generally improve membrane permeability.
5. **HBA:** Ligand A (3) is better than Ligand B (5). Lower HBA contributes to better permeability.
6. **QED:** Ligand B (0.904) has a significantly higher QED score than Ligand A (0.563), indicating a more drug-like profile overall. This is a substantial advantage for Ligand B.
7. **DILI:** Ligand A (11.44) has a much lower DILI risk than Ligand B (64.79). This is a major advantage for Ligand A.
8. **BBB:** Not a primary concern for ADRB2 (cardiovascular target), but Ligand A (86.82) is better than Ligand B (62.16).
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.442) is slightly better than Ligand B (-4.86).
10. **Solubility:** Both ligands have negative solubility values, which is also unusual and suggests poor solubility. Ligand A (-2.569) is slightly better than Ligand B (-3.516).
11. **hERG:** Both ligands have very low hERG inhibition risk (0.387 & 0.185).
12. **Cl_mic:** Ligand B (25.83) has a significantly lower microsomal clearance than Ligand A (38.35), indicating better metabolic stability.
13. **t1/2:** Ligand B (6.42) has a much longer in vitro half-life than Ligand A (-1.50). This is a significant advantage for Ligand B.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.138 & 0.03).
15. **Binding Affinity:** Ligand A (-7.0) has a slightly better binding affinity than Ligand B (-5.7). This is a 1.3 kcal/mol difference, which is significant.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A excels in TPSA, Pgp, and affinity. Ligand B excels in QED and metabolic stability (Cl_mic, t1/2). The DILI risk for Ligand A is a major positive.
**Overall Assessment:**
While Ligand B has a superior QED and metabolic stability profile, the significantly lower DILI risk of Ligand A, combined with its better affinity and TPSA, makes it the more promising candidate. The slight advantage in binding affinity is also important. The negative Caco-2 and solubility values are concerning for both, but can be addressed with formulation strategies. The lower DILI risk is a critical safety factor.
Output:
1
2025-04-18 00:44:43,905 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [348.447, 95.42, 1.045, 2, 5, 0.801, 38.969, 30.593, -5.28, -1.334, 0.043, 12.679, -9.848, 0.016, -7.9]
**Ligand B:** [369.853, 116.19, 2.391, 2, 4, 0.246, 41.411, 55.138, -5.025, -2.298, 0.32, 23.198, 22.807, 0.048, -5.7]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (348.447) is slightly preferred due to being a bit lower.
2. **TPSA:** Ligand A (95.42) is better than Ligand B (116.19). Both are acceptable for a non-CNS GPCR, but lower is generally better for permeability.
3. **logP:** Ligand A (1.045) is slightly lower, but still within the optimal range. Ligand B (2.391) is also acceptable.
4. **HBD:** Both have 2 HBD, which is good.
5. **HBA:** Ligand A has 5 HBA, Ligand B has 4. Both are acceptable.
6. **QED:** Ligand A (0.801) is significantly better than Ligand B (0.246), indicating a much more drug-like profile. This is a major advantage for Ligand A.
7. **DILI:** Ligand A (38.969) is better than Ligand B (41.411), both are acceptable.
8. **BBB:** Ligand B (55.138) is better than Ligand A (30.593). However, since ADRB2 is primarily a cardiovascular target, BBB penetration is not a high priority.
9. **Caco-2:** Both are negative, indicating poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-1.334) is better than Ligand B (-2.298). Better solubility is always preferred.
11. **hERG:** Ligand A (0.043) is much better than Ligand B (0.32), indicating a lower risk of cardiotoxicity. This is crucial for a cardiovascular target.
12. **Cl_mic:** Ligand A (12.679) is better than Ligand B (23.198), indicating better metabolic stability.
13. **t1/2:** Ligand A (-9.848) is better than Ligand B (22.807), indicating a longer half-life.
14. **Pgp:** Ligand A (0.016) is much better than Ligand B (0.048), indicating lower P-gp efflux.
15. **Affinity:** Ligand A (-7.9) is significantly better than Ligand B (-5.7). A 2.2 kcal/mol difference is substantial and can outweigh some ADME concerns.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, affinity, logP, TPSA, Pgp, and metabolic stability are key. Ligand A excels in affinity, has a better TPSA, Pgp, Cl_mic and t1/2. While Ligand B has better BBB penetration, this is less important for a cardiovascular target. The significantly better QED and hERG profile of Ligand A are also very important.
**Conclusion:**
Ligand A is the superior candidate due to its significantly better binding affinity, QED, hERG risk, metabolic stability, and Pgp efflux. The slightly better solubility also contributes to its preference. While both have poor Caco-2 permeability, the other advantages of Ligand A outweigh this concern.
Output:
1
2025-04-18 00:44:43,905 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 drug candidates. ADRB2 is a GPCR, so we'll prioritize logP, Pgp, TPSA, and affinity, alongside general drug-like properties.
**Ligand A:** [343.471, 62.3, 2.584, 1, 3, 0.863, 20.706, 74.176, -4.94, -1.723, 0.39, 18.796, -16.736, 0.093, -6.6]
**Ligand B:** [348.491, 76.02, 2.858, 2, 4, 0.674, 25.281, 74.176, -4.853, -2.655, 0.716, 44.952, -2.78, 0.398, -5.6]
**1. Molecular Weight:** Both are within the ideal range (200-500 Da). A is 343.471, B is 348.491 - very similar.
**2. TPSA:** A (62.3) is excellent, well below the 140 threshold and good for oral absorption. B (76.02) is still acceptable, but less optimal.
**3. logP:** Both are within the optimal 1-3 range. A (2.584) is slightly better than B (2.858).
**4. H-Bond Donors:** A (1) is preferred over B (2). Fewer donors generally improve permeability.
**5. H-Bond Acceptors:** A (3) is preferred over B (4).
**6. QED:** A (0.863) is significantly better than B (0.674), indicating a more drug-like profile.
**7. DILI Risk:** A (20.706) is significantly better than B (25.281), indicating a lower risk of liver injury.
**8. BBB Penetration:** Both are identical at 74.176, which is good, but not exceptional. For a non-CNS target like ADRB2, this isn't a major differentiating factor.
**9. Caco-2 Permeability:** Both are negative, indicating poor permeability. A (-4.94) is slightly better than B (-4.853).
**10. Aqueous Solubility:** Both are negative, indicating poor solubility. B (-2.655) is worse than A (-1.723).
**11. hERG Inhibition:** A (0.39) is better than B (0.716), indicating lower cardiotoxicity risk.
**12. Microsomal Clearance:** A (18.796) is much better than B (44.952), indicating better metabolic stability.
**13. In vitro Half-Life:** A (-16.736) is much better than B (-2.78), indicating a longer half-life.
**14. P-gp Efflux:** A (0.093) is significantly better than B (0.398), indicating less efflux and potentially better bioavailability.
**15. Binding Affinity:** A (-6.6) is slightly better than B (-5.6). While both are good, the 1 kcal/mol difference is notable.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical ADME-Tox properties. It has a better QED score, lower DILI risk, better metabolic stability (lower Cl_mic, longer t1/2), lower P-gp efflux, better hERG profile, and slightly better affinity. While both have poor Caco-2 and solubility, A is still better in these areas. The combination of these factors makes Ligand A a much more promising drug candidate for ADRB2.
Output:
1
2025-04-18 00:44:43,905 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (387.391 and 368.499 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (78.87) is significantly better than Ligand A (139.83). ADRB2 is not a CNS target, but lower TPSA generally favors absorption.
3. **logP:** Both ligands have good logP values (1.306 and 0.941), falling within the optimal 1-3 range. Ligand B is slightly lower, which could be beneficial for solubility.
4. **HBD:** Both ligands have 2 H-bond donors, which is within the acceptable limit of 5.
5. **HBA:** Ligand A has 8 H-bond acceptors, while Ligand B has 5. Both are under the 10 limit, but Ligand B is preferable.
6. **QED:** Ligand B (0.722) has a slightly better QED score than Ligand A (0.578), indicating a more drug-like profile.
7. **DILI:** Ligand A has a very high DILI risk (98.643%), which is a major concern. Ligand B has a much lower DILI risk (36.293%), which is a significant advantage.
8. **BBB:** This is less critical for ADRB2 (a cardiovascular target), but Ligand B (17.914%) is lower than Ligand A (9.81%).
9. **Caco-2:** Ligand A (-5.386) and Ligand B (-4.965) are both negative, which is unusual. However, these values are close, and the negative values suggest poor permeability.
10. **Solubility:** Ligand A (-3.012) and Ligand B (-2.559) both have poor solubility.
11. **hERG:** Ligand A (0.025) has a very low hERG risk, while Ligand B (0.162) is slightly higher.
12. **Cl_mic:** Ligand A (-12.973) has a much lower (better) microsomal clearance than Ligand B (31.599), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-2.148) has a negative in vitro half-life, which is concerning. Ligand A (45.447) has a good half-life.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.076 and 0.142).
15. **Binding Affinity:** Ligand A (-7.2) has a slightly better binding affinity than Ligand B (-7.0). However, the difference is relatively small (0.2 kcal/mol).
**Overall Assessment:**
Despite Ligand A having a slightly better binding affinity and metabolic stability, the extremely high DILI risk is a deal-breaker. Ligand B, while having a slightly weaker affinity and poorer metabolic stability, presents a much more favorable safety profile (DILI) and a better QED score. The TPSA is also significantly better for Ligand B. Given the importance of safety in drug development, especially for a cardiovascular target, Ligand B is the more viable candidate.
Output:
0
2025-04-18 00:44:43,905 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (346.431 and 350.394 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (87.32) is slightly higher than Ligand B (75.93). Both are below the 140 threshold for good oral absorption, but B is better positioned.
3. **logP:** Ligand A (1.887) is within the optimal 1-3 range. Ligand B (0.956) is a bit low, potentially impacting permeability.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable, below the 5 limit.
5. **HBA:** Ligand A (4) and Ligand B (5) are both acceptable, below the 10 limit.
6. **QED:** Both ligands have good QED scores (A: 0.738, B: 0.83), indicating good drug-like properties. B is slightly better.
7. **DILI:** Ligand A (46.064) has a slightly higher DILI risk than Ligand B (37.185), but both are well below the concerning 60 threshold.
8. **BBB:** Ligand B (70.648) demonstrates better BBB penetration than Ligand A (57.774). While ADRB2 isn't exclusively a CNS target, some CNS exposure is not necessarily detrimental and could offer additional therapeutic avenues.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.482 and -4.764), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Both ligands have negative solubility values (-3.283 and -2.141), indicating very poor aqueous solubility. This is a major drawback for both.
11. **hERG:** Both ligands have low hERG inhibition liability (A: 0.242, B: 0.344), which is positive.
12. **Cl_mic:** Ligand B (7.172) has a much lower microsomal clearance than Ligand A (64.248), suggesting better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand B (-2.719) has a slightly better (less negative) in vitro half-life than Ligand A (-44.409), indicating better stability.
14. **Pgp:** Both ligands have low P-gp efflux liability (A: 0.09, B: 0.098), which is good.
15. **Binding Affinity:** Ligand A (-5.9 kcal/mol) has a significantly stronger binding affinity than Ligand B (-3.6 kcal/mol). This is a substantial advantage, exceeding the 1.5 kcal/mol threshold.
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. While Ligand B has better TPSA and a slightly better BBB score, Ligand A's significantly stronger binding affinity (-5.9 vs -3.6 kcal/mol) is a major driver. The poor Caco-2 and solubility are concerning for both, but a higher affinity can sometimes compensate for these issues, especially with formulation strategies. The improved metabolic stability (lower Cl_mic and better t1/2) of Ligand B is also a strong point.
**Overall Assessment:**
Despite the poor permeability and solubility profiles of both compounds, the substantial difference in binding affinity favors Ligand A. The stronger binding is likely to translate to greater efficacy *in vivo*, and formulation strategies can be explored to address the solubility and permeability issues. Ligand B's better metabolic stability is attractive, but the affinity difference is too significant to ignore.
Output:
1
2025-04-18 00:44:43,906 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [346.391, 132.63 , 0.357, 4. , 5. , 0.599, 63.513, 24.351, -5.52 , -2.783, 0.315, -11.571, 12.231, 0.028, -7.1 ]
**Ligand B:** [345.334, 108.05 , 0.196, 2. , 5. , 0.823, 69.756, 55.603, -4.913, -2.983, 0.29 , -15.203, -21.238, 0.008, -7.1 ]
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (346.391 and 345.334 Da). No significant difference.
2. **TPSA:** Ligand A (132.63) is slightly above the preferred <140 for good absorption, while Ligand B (108.05) is well within the range. This favors Ligand B.
3. **logP:** Ligand A (0.357) is quite low, potentially hindering membrane permeability. Ligand B (0.196) is also low, but slightly better. Both are suboptimal.
4. **HBD:** Ligand A (4) is acceptable, Ligand B (2) is even better, reducing potential for off-target interactions and improving permeability. Favors Ligand B.
5. **HBA:** Both ligands have 5 HBA, which is acceptable.
6. **QED:** Ligand B (0.823) has a significantly higher QED score than Ligand A (0.599), indicating a more drug-like profile. This is a strong advantage for Ligand B.
7. **DILI:** Both ligands have DILI risk above 60, indicating a higher risk. Ligand A (63.513) is slightly better than Ligand B (69.756).
8. **BBB:** Ligand B (55.603) has a much higher BBB penetration percentile than Ligand A (24.351). This is a crucial advantage for a GPCR target, even if not specifically a CNS target, as it suggests better distribution.
9. **Caco-2:** Ligand B (-4.913) shows better Caco-2 permeability than Ligand A (-5.52).
10. **Solubility:** Ligand B (-2.983) is slightly better than Ligand A (-2.783).
11. **hERG:** Both ligands have low hERG inhibition liability (0.315 and 0.29), which is good.
12. **Cl_mic:** Ligand B (-15.203) has a significantly lower (better) microsomal clearance than Ligand A (-11.571), suggesting greater metabolic stability.
13. **t1/2:** Ligand B (-21.238) has a much longer in vitro half-life than Ligand A (12.231), which is highly desirable.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.028 and 0.008).
15. **Affinity:** Both ligands have identical binding affinity (-7.1 kcal/mol).
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, BBB, and affinity are key. Ligand B excels in TPSA, BBB, and metabolic stability (Cl_mic and t1/2) while being comparable in affinity and Pgp. Although both have low logP, Ligand B is slightly better. Ligand A is only better in DILI, but the difference is small.
**Conclusion:**
Ligand B is the superior candidate due to its better QED, TPSA, BBB penetration, metabolic stability, and half-life. These factors outweigh the slightly higher DILI risk.
0
2025-04-18 00:44:43,906 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for the ADRB2, a cardiovascular GPCR. Therefore, priorities are logP, TPSA, Pgp, affinity, and to a lesser extent, BBB.
**Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (348.491) is slightly higher than Ligand B (345.399), but this difference is negligible.
**TPSA:** Ligand A (67.65) is significantly better than Ligand B (114.43). A TPSA under 140 is good for oral absorption, and lower is generally preferred for GPCRs. Ligand B's TPSA is approaching a level that could hinder absorption.
**logP:** Both ligands have acceptable logP values (A: 1.717, B: 1.192), falling within the 1-3 range. Ligand A is slightly more lipophilic, which could be beneficial for membrane permeability.
**H-Bond Donors/Acceptors:** Ligand A (0 HBD, 4 HBA) has a more favorable profile than Ligand B (3 HBD, 4 HBA). Fewer H-bond donors generally improve permeability.
**QED:** Both ligands have similar and good QED scores (A: 0.733, B: 0.743).
**DILI:** Ligand A (13.532) has a much lower DILI risk than Ligand B (56.301). This is a significant advantage for Ligand A.
**BBB:** Ligand A (65.529) has a better BBB penetration score than Ligand B (41.528). While not a primary concern for a cardiovascular target, better BBB penetration is generally desirable.
**Caco-2 Permeability:** Ligand A (-4.825) is better than Ligand B (-5.4). Both are negative, indicating low permeability.
**Aqueous Solubility:** Ligand B (-3.901) has better aqueous solubility than Ligand A (-0.792). Solubility is important, but can be addressed with formulation.
**hERG Inhibition:** Both ligands show very low hERG inhibition risk (A: 0.644, B: 0.212).
**Microsomal Clearance:** Ligand B (-0.665) has a negative clearance, which is excellent, indicating high metabolic stability. Ligand A (5.462) has a positive clearance, indicating faster metabolism.
**In vitro Half-Life:** Ligand B (25.717) has a substantially longer half-life than Ligand A (10.457). This is a significant advantage for Ligand B.
**P-gp Efflux:** Both ligands have very low P-gp efflux liability (A: 0.038, B: 0.044).
**Binding Affinity:** Ligand B (-5.9) has a slightly better binding affinity than Ligand A (-5.0). This is a 0.9 kcal/mol difference, which is significant but not overwhelming.
**Overall Assessment:**
Ligand A has a clear advantage in terms of DILI risk, TPSA, and BBB penetration. Ligand B has a better half-life and slightly better affinity. However, the lower TPSA and significantly lower DILI risk of Ligand A, coupled with acceptable affinity, make it the more promising candidate. The metabolic stability of Ligand B is attractive, but can potentially be improved through structural modifications. The high TPSA of Ligand B is a more difficult property to address.
**Output:**
1
2025-04-18 00:44:43,906 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A Analysis:**
* **MW:** 352.406 Da - Good, within the ideal range.
* **TPSA:** 67.87 - Good, below the 140 threshold for oral absorption.
* **logP:** 2.039 - Excellent, within the optimal 1-3 range.
* **HBD:** 1 - Good, well below the 5 threshold.
* **HBA:** 4 - Good, well below the 10 threshold.
* **QED:** 0.842 - Excellent, very drug-like.
* **DILI:** 60.217 - Moderate risk, slightly above the preferred <40, but not alarming.
* **BBB:** 67.507 - Moderate, not ideal for a CNS target, but ADRB2 isn't necessarily a CNS target.
* **Caco-2:** -4.349 - Poor permeability. This is a significant concern.
* **Solubility:** -2.063 - Poor solubility. Another significant concern.
* **hERG:** 0.217 - Low risk, favorable.
* **Cl_mic:** 43.937 - Moderate clearance, could be better.
* **t1/2:** 1.464 - Short half-life, potentially requiring frequent dosing.
* **Pgp:** 0.063 - Low efflux, favorable.
* **Affinity:** -5.6 kcal/mol - Good binding affinity.
**Ligand B Analysis:**
* **MW:** 349.435 Da - Good, within the ideal range.
* **TPSA:** 100.35 - Acceptable, but approaching the upper limit for good absorption.
* **logP:** 0.192 - Low, potentially hindering permeation.
* **HBD:** 2 - Good, well below the 5 threshold.
* **HBA:** 6 - Good, below the 10 threshold.
* **QED:** 0.764 - Good, drug-like.
* **DILI:** 30.787 - Excellent, low risk.
* **BBB:** 59.868 - Low, not favorable.
* **Caco-2:** -5.064 - Very poor permeability. A major drawback.
* **Solubility:** -1.394 - Poor solubility.
* **hERG:** 0.24 - Low risk, favorable.
* **Cl_mic:** 9.086 - Low clearance, excellent metabolic stability.
* **t1/2:** -8.664 - Very long half-life, excellent.
* **Pgp:** 0.038 - Low efflux, favorable.
* **Affinity:** -8.1 kcal/mol - Excellent binding affinity, significantly better than Ligand A.
**Comparison and Decision:**
Both ligands have significant issues with Caco-2 permeability and aqueous solubility. However, Ligand B has a *much* stronger binding affinity (-8.1 vs -5.6 kcal/mol). This 2.5 kcal/mol difference is substantial and can often outweigh ADME concerns, especially for a GPCR target where potency is critical. Ligand B also exhibits superior metabolic stability (lower Cl_mic) and a much longer half-life. While Ligand B's logP is low, the strong affinity and metabolic properties are more important in this case. Ligand A's DILI risk is slightly higher.
Given the GPCR-specific priorities (affinity being paramount), and the substantial difference in binding affinity, Ligand B is the more promising candidate despite its permeability and solubility issues. These issues could potentially be addressed through formulation strategies.
Output:
0
2025-04-18 00:44:43,907 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (351.403 and 354.491 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (96.11) is higher than Ligand B (78.87). For a cardiovascular GPCR, TPSA is moderately important, and Ligand B is preferable due to its lower value, suggesting better potential for membrane permeability.
3. **logP:** Ligand B (1.563) is slightly better than Ligand A (0.656). Both are within the optimal 1-3 range, but Ligand B is closer to the sweet spot. A slightly higher logP can improve membrane permeability.
4. **HBD:** Ligand A (1) has fewer HBD than Ligand B (2). Fewer HBDs generally improve permeability, so Ligand A is slightly favored.
5. **HBA:** Ligand A (6) has more HBA than Ligand B (4). Fewer HBA are generally preferred for permeability. Ligand B is favored here.
6. **QED:** Ligand A (0.809) has a higher QED than Ligand B (0.727), indicating a more drug-like profile. This is a significant advantage for Ligand A.
7. **DILI:** Ligand B (13.959) has a *much* lower DILI risk than Ligand A (39.434). This is a critical advantage for Ligand B, as liver toxicity is a major concern in drug development.
8. **BBB:** Both ligands have similar BBB penetration (64.87% and 69.019%). Since ADRB2 is a cardiovascular target, BBB penetration is not a primary concern.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.54 and -4.41). These values are difficult to interpret without knowing the scale, but the similarity suggests comparable intestinal absorption potential.
10. **Solubility:** Ligand A (-1.216) has slightly better solubility than Ligand B (-2.224). Solubility is important for bioavailability, but not a deciding factor here.
11. **hERG:** Ligand A (0.214) has a lower hERG inhibition liability than Ligand B (0.398), indicating a lower risk of cardiotoxicity. This is a slight advantage for Ligand A.
12. **Cl_mic:** Ligand B (46.248) has significantly lower microsomal clearance than Ligand A (6.019). Lower clearance means greater metabolic stability, which is a major advantage for Ligand B.
13. **t1/2:** Ligand B (5.752) has a longer in vitro half-life than Ligand A (0.433). This is a significant advantage for Ligand B, potentially leading to less frequent dosing.
14. **Pgp:** Ligand A (0.089) has lower P-gp efflux liability than Ligand B (0.026). Lower P-gp efflux is favorable for bioavailability, giving a slight edge to Ligand A.
15. **Binding Affinity:** Ligand B (-7.1 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.9 kcal/mol). This is a substantial advantage for Ligand B, potentially outweighing some of the ADME drawbacks. A 1.2 kcal/mol difference is meaningful.
**Overall Assessment:**
While Ligand A has a better QED and slightly better solubility and Pgp efflux, Ligand B excels in critical areas for drug development: significantly lower DILI risk, much better metabolic stability (lower Cl_mic, longer t1/2), and substantially stronger binding affinity. The lower TPSA of Ligand B is also favorable. The improved binding affinity is the most important factor for a GPCR target. The DILI risk of Ligand A is concerning.
Output:
0
2025-04-18 00:44:43,907 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.435 and 342.443 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (104.97) is slightly higher than Ligand B (83.98). Both are below the 140 A^2 threshold for good oral absorption, but Ligand B is better, closer to the 90 A^2 target for GPCRs.
3. **logP:** Ligand B (2.012) is within the optimal 1-3 range, while Ligand A (0.063) is quite low. This is a significant drawback for Ligand A, potentially impacting permeability.
4. **HBD:** Both ligands have 2 H-bond donors, which is acceptable.
5. **HBA:** Ligand A has 5 H-bond acceptors, and Ligand B has 4. Both are within the acceptable limit of 10.
6. **QED:** Both ligands have good QED scores (0.601 and 0.743), indicating drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand B (53.121) has a much lower DILI risk than Ligand A (7.057). This is a major advantage for Ligand B.
8. **BBB:** Ligand A (93.292) has significantly better BBB penetration than Ligand B (63.746). While ADRB2 isn't exclusively a CNS target, some CNS exposure might be beneficial or at least not detrimental, and this is a point in favor of Ligand A.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual. This suggests poor permeability.
10. **Solubility:** Both have negative solubility values, indicating poor aqueous solubility.
11. **hERG:** Ligand A (0.388) has a slightly lower hERG risk than Ligand B (0.255), but both are relatively low.
12. **Cl_mic:** Ligand A (1.06) has much lower microsomal clearance than Ligand B (30.961), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (-25.447) has a very negative in vitro half-life, which is concerning. Ligand B (-12.129) is also negative, but less so.
14. **Pgp:** Ligand A (0.003) has very low P-gp efflux liability, while Ligand B (0.126) is slightly higher. This favors Ligand A.
15. **Binding Affinity:** Ligand B (-6.2 kcal/mol) has a slightly better binding affinity than Ligand A (-5.9 kcal/mol). While the difference is not huge, it is still a factor.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are crucial. Ligand B excels in TPSA and has a good logP. Ligand A has better Pgp and Cl_mic, but suffers from a very poor logP. The binding affinity difference is small. The DILI risk for Ligand B is significantly lower.
**Overall Assessment:**
Despite Ligand A's better metabolic stability and Pgp profile, its extremely low logP is a major concern, likely hindering permeability and bioavailability. Ligand B, while having a higher DILI risk than ideal, presents a more balanced profile with better predicted absorption characteristics (TPSA, logP) and acceptable affinity. The lower DILI risk is also a significant advantage.
Output:
0
2025-04-18 00:44:43,907 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (350.39 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (78.87) is significantly better than Ligand B (100.09). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (1.459) is within the optimal range. Ligand B (0.121) is quite low, potentially hindering membrane permeability and absorption.
4. **HBD:** Both ligands have 2 HBD, which is acceptable.
5. **HBA:** Ligand A has 4 HBA, while Ligand B has 7. Ligand A is preferable here.
6. **QED:** Both ligands have good QED scores (A: 0.601, B: 0.747), indicating drug-likeness. Ligand B is slightly better.
7. **DILI:** Ligand A (35.285) has a considerably lower DILI risk than Ligand B (62.621). This is a significant advantage for Ligand A.
8. **BBB:** Not a primary concern for a cardiovascular target, but Ligand A (76.619) has a higher BBB percentile than Ligand B (28.383).
9. **Caco-2:** Ligand A (-4.715) is better than Ligand B (-5.704), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-1.591) is better than Ligand B (-2.791), indicating better aqueous solubility.
11. **hERG:** Both ligands have very low hERG inhibition risk (A: 0.358, B: 0.035). Ligand B is slightly better.
12. **Cl_mic:** Ligand B (-3.409) has a *negative* clearance, which is unusual and suggests very high metabolic stability. Ligand A (3.163) is positive, indicating faster clearance. This is a major advantage for Ligand B.
13. **t1/2:** Ligand B (-22.985) has a longer half-life than Ligand A (-17.768). This is a positive for Ligand B.
14. **Pgp:** Both ligands have very low Pgp efflux liability (A: 0.058, B: 0.022). Ligand B is slightly better.
15. **Binding Affinity:** Ligand A (-7.1) has a slightly better binding affinity than Ligand B (-6.9). While the difference is small, it's still a factor.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A performs better on logP, TPSA, and affinity. Ligand B has a significant advantage in metabolic stability (Cl_mic) and half-life, and slightly better Pgp.
**Overall Assessment:**
Ligand A has a more balanced profile with better physicochemical properties (logP, TPSA, solubility) and a lower DILI risk. The slightly better binding affinity is a bonus. While Ligand B has superior metabolic stability and half-life, the low logP is a significant concern for absorption. The DILI risk is also higher. Given the importance of absorption for oral bioavailability, and the relatively small advantage in metabolic stability, I favor Ligand A.
Output:
1
2025-04-18 00:44:43,907 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (342.447 Da and 361.515 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (74.25) is higher than Ligand B (56.07). For a peripheral GPCR like ADRB2, TPSA is less critical than for a CNS target, but lower is generally preferred for absorption. Ligand B has a clear advantage.
**3. logP:** Both ligands have good logP values (2.753 and 3.278, respectively), falling within the optimal 1-3 range. Ligand B is slightly higher, which could potentially lead to slightly better membrane permeability.
**4. H-Bond Donors:** Ligand A has 1 HBD, and Ligand B has 0. Both are acceptable, staying within the recommended limit of 5.
**5. H-Bond Acceptors:** Ligand A has 5 HBA, and Ligand B has 7. Both are within the acceptable range of 10, but Ligand A is slightly better.
**6. QED:** Both ligands have good QED scores (0.904 and 0.836), indicating good drug-like properties. Ligand A is slightly better.
**7. DILI Risk:** Ligand A (55.68) has a slightly higher DILI risk than Ligand B (49.128). Both are below the 60 threshold, but lower is better. Ligand B is preferred.
**8. BBB Penetration:** Both ligands exhibit high BBB penetration (90.655 and 88.329). While ADRB2 is not primarily a CNS target, some degree of BBB penetration isn't necessarily detrimental.
**9. Caco-2 Permeability:** Ligand A (-4.543) has a worse Caco-2 permeability than Ligand B (-5.087). Lower values are worse. Ligand B is preferred.
**10. Aqueous Solubility:** Ligand A (-2.799) has worse solubility than Ligand B (-3.48). Lower values are worse. Ligand B is preferred.
**11. hERG Inhibition:** Ligand A (0.677) has a slightly higher hERG inhibition risk than Ligand B (0.283). Lower is better, so Ligand B is preferred.
**12. Microsomal Clearance:** Ligand A (38) has lower microsomal clearance than Ligand B (55.591), indicating better metabolic stability. Ligand A is preferred.
**13. In vitro Half-Life:** Ligand A (62.84) has a significantly longer in vitro half-life than Ligand B (-13.582). This is a major advantage for Ligand A.
**14. P-gp Efflux:** Ligand A (0.115) has lower P-gp efflux than Ligand B (0.539), indicating better bioavailability. Ligand A is preferred.
**15. Binding Affinity:** Ligand A (-7.8) has a significantly stronger binding affinity than Ligand B (-5.6). This is a substantial advantage, potentially outweighing some of the ADME drawbacks.
**Overall Assessment:**
Ligand A has a significantly stronger binding affinity and better metabolic stability (lower Cl_mic, longer t1/2) and P-gp efflux. Ligand B has better TPSA, solubility, DILI risk, Caco-2 permeability, and hERG inhibition. However, the substantial difference in binding affinity (-7.8 vs -5.6 kcal/mol) and half-life is a critical advantage for Ligand A. For a GPCR target, strong binding is paramount. The slightly higher DILI risk and lower solubility of Ligand A are manageable and can be addressed through further optimization.
Output:
1
2025-04-18 00:44:43,908 - INFO - Reasoning:
Let's analyze both ligands for their potential as ADRB2 drug candidates, keeping in mind the GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key).
**Ligand A:**
* **MW:** 343.39 Da - Good, within the ideal range.
* **TPSA:** 89.35 - Excellent, well below the 140 threshold.
* **logP:** 1.403 - Good, within the optimal range.
* **HBD:** 1 - Good, low.
* **HBA:** 6 - Good, within the acceptable range.
* **QED:** 0.906 - Excellent, highly drug-like.
* **DILI:** 83.99 - Concerning, relatively high DILI risk.
* **BBB:** 57.93 - Moderate, not ideal for a GPCR but not a complete dealbreaker for a peripherally acting one like ADRB2.
* **Caco-2:** -4.967 - Very poor, suggests very low intestinal absorption.
* **Solubility:** -2.888 - Very poor, a significant concern.
* **hERG:** 0.232 - Low risk, favorable.
* **Cl_mic:** 38.57 - Moderate, could be better.
* **t1/2:** -13.04 - Very short, a major drawback.
* **Pgp:** 0.099 - Low efflux, good.
* **Affinity:** -0.1 kcal/mol - Very weak binding, a critical flaw.
**Ligand B:**
* **MW:** 340.43 Da - Good, within the ideal range.
* **TPSA:** 77.49 - Excellent, well below the 140 threshold.
* **logP:** 2.212 - Good, within the optimal range.
* **HBD:** 3 - Good, low.
* **HBA:** 4 - Good, within the acceptable range.
* **QED:** 0.78 - Good, reasonably drug-like.
* **DILI:** 52.23 - Acceptable, lower DILI risk than Ligand A.
* **BBB:** 60.41 - Moderate, similar to Ligand A.
* **Caco-2:** -5.23 - Very poor, similar to Ligand A.
* **Solubility:** -3.138 - Very poor, similar to Ligand A.
* **hERG:** 0.663 - Moderate risk, higher than Ligand A.
* **Cl_mic:** 66.06 - High, suggesting poor metabolic stability.
* **t1/2:** 12.16 - Moderate, better than Ligand A.
* **Pgp:** 0.146 - Low efflux, good.
* **Affinity:** -6.1 kcal/mol - Significantly stronger binding than Ligand A.
**Comparison and Decision:**
Both ligands have significant issues with Caco-2 permeability and solubility. However, the binding affinity is the most crucial factor for a starting point in drug discovery. Ligand B has a much stronger binding affinity (-6.1 kcal/mol vs -0.1 kcal/mol). While Ligand B has a higher hERG risk and worse metabolic stability, the substantial improvement in binding affinity outweighs these drawbacks, especially at this early stage. The poor ADME properties can be addressed through subsequent optimization. Ligand A's extremely weak binding makes it unlikely to be a viable starting point.
Output:
0
2025-04-18 00:44:43,908 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.431 and 361.471 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (86.02) is slightly higher than Ligand B (69.95). Both are below the 140 threshold for oral absorption, and acceptable for a cardiovascular target (not CNS focused). Ligand B is better.
3. **logP:** Ligand B (1.068) is slightly better than Ligand A (0.651), both are within the optimal 1-3 range. Ligand B is better.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1). Both are within the acceptable limit of 5. No significant difference.
5. **HBA:** Ligand A (5) is lower than Ligand B (6). Both are within the acceptable limit of 10. Ligand A is better.
6. **QED:** Ligand B (0.888) has a better QED score than Ligand A (0.737), indicating a more drug-like profile. Ligand B is better.
7. **DILI:** Ligand A (40.132) has a slightly lower DILI risk than Ligand B (47.926), both are below the 60 threshold and considered good. Ligand A is better.
8. **BBB:** Ligand B (43.273) has a higher BBB penetration percentile than Ligand A (32.144). While ADRB2 isn't strictly a CNS target, some CNS exposure can be a concern for off-target effects. Ligand B is better.
9. **Caco-2:** Both ligands have very negative Caco-2 values (-5.108 and -5.139). This is unusual and suggests very poor permeability. This is a major concern for both.
10. **Solubility:** Ligand A (-0.671) has better solubility than Ligand B (-1.542). Solubility is important for bioavailability. Ligand A is better.
11. **hERG:** Ligand A (0.281) has a significantly lower hERG inhibition liability than Ligand B (0.588). This is a crucial advantage, as hERG inhibition can lead to cardiotoxicity. Ligand A is better.
12. **Cl_mic:** Ligand A (7.05) has a much lower microsomal clearance than Ligand B (-16.049). This indicates better metabolic stability for Ligand A. Ligand A is better.
13. **t1/2:** Ligand A (21.713) has a significantly longer in vitro half-life than Ligand B (1.758). This is a substantial advantage, potentially allowing for less frequent dosing. Ligand A is better.
14. **Pgp:** Ligand A (0.164) has a lower P-gp efflux liability than Ligand B (0.048). Lower efflux is better for bioavailability. Ligand A is better.
15. **Binding Affinity:** Ligand A (-7.3) has slightly better binding affinity than Ligand B (-7.2). While the difference is small, it's still a positive for Ligand A.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Ligand B is better on logP and BBB, but Ligand A excels in most other critical ADME properties (Cl_mic, t1/2, Pgp, hERG, solubility) and has comparable affinity. The poor Caco-2 values are concerning for both, but the superior ADME profile of Ligand A outweighs the slight advantage of Ligand B in BBB penetration.
**Conclusion:**
Ligand A demonstrates a significantly more favorable balance of properties, particularly regarding metabolic stability, safety (hERG, DILI), and pharmacokinetic parameters (t1/2, Pgp, solubility). The slight advantage in binding affinity further supports its selection.
Output:
1
2025-04-18 00:44:43,908 - INFO - Batch 500 complete. Total preferences: 8000
2025-04-18 00:44:43,908 - INFO - Processing batch 501/512...
2025-04-18 00:45:34,240 - INFO - Here's my reasoning and the final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, priorities are logP, TPSA, Pgp, affinity, and to a lesser extent, BBB. Let's break down the comparison:
1. **MW:** Both ligands (355.379 and 383.832 Da) fall within the ideal 200-500 Da range.
2. **TPSA:** Ligand B (80.32) is significantly better than Ligand A (103.29). Lower TPSA generally favors oral absorption and is particularly important for GPCRs.
3. **logP:** Both are good (2.929 and 3.718), falling within the optimal 1-3 range. Ligand B is slightly higher, which could be a minor concern for solubility, but not a dealbreaker.
4. **HBD/HBA:** Ligand A (0 HBD, 8 HBA) is slightly better in terms of HBD, but both are acceptable.
5. **QED:** Both have good QED scores (0.525 and 0.625), indicating drug-likeness.
6. **DILI:** Both have very high DILI risk (93.176 and 93.757), which is a significant concern. This will need to be addressed in further optimization regardless of which ligand is chosen.
7. **BBB:** Ligand A (82.435) has a slightly better BBB penetration score than Ligand B (77.123), but for a cardiovascular target, this is not a primary concern.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. This is a major red flag for both.
9. **Solubility:** Ligand A (-3.7) is better than Ligand B (-5.178), which is important.
10. **hERG:** Both have very low hERG inhibition risk (0.119 and 0.44), which is excellent.
11. **Cl_mic:** Ligand A (41.26) has significantly lower microsomal clearance than Ligand B (81.837), indicating better metabolic stability.
12. **t1/2:** Ligand B (74.999) has a much longer in vitro half-life than Ligand A (8.13). This is a significant advantage.
13. **Pgp:** Both have low Pgp efflux liability (0.561 and 0.583), which is good.
14. **Affinity:** Ligand A (-6.9 kcal/mol) is slightly better than Ligand B (-6.7 kcal/mol), but the difference is small.
**Overall Assessment:**
Ligand B has a more favorable TPSA and a significantly longer half-life, which are important for a GPCR target. While Ligand A has better solubility and metabolic stability, the benefits of better TPSA and half-life outweigh these advantages for Ligand B. Both ligands have very high DILI risk and poor Caco-2 permeability, which are major liabilities that need to be addressed. However, considering the balance of properties, Ligand B appears to be the slightly more promising starting point.
**Output:**
0
2025-04-18 00:45:34,241 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.5 & 368.5 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (49.85) is significantly better than Ligand B (81.75). ADRB2 is not a CNS target, but lower TPSA generally improves absorption.
3. **logP:** Ligand A (2.974) is optimal, while Ligand B (-0.621) is quite low. This is a major concern for B, as it could hinder membrane permeability.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (3) is better than Ligand B (5). Lower HBA is generally preferred.
6. **QED:** Both ligands (0.676 & 0.626) have good drug-likeness scores, above the 0.5 threshold.
7. **DILI:** Ligand A (35.673) has a much lower DILI risk than Ligand B (12.641). This is a significant advantage for A.
8. **BBB:** Not a primary concern for ADRB2, but Ligand A (86.468) is better than Ligand B (58.821).
9. **Caco-2:** Ligand A (-4.39) is better than Ligand B (-5.624), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-3.121) is better than Ligand B (-1.856), indicating better aqueous solubility.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.46 & 0.071).
12. **Cl_mic:** Ligand B (-13.614) has a much lower (better) microsomal clearance than Ligand A (75.457), suggesting better metabolic stability.
13. **t1/2:** Ligand B (3.142) has a slightly better in vitro half-life than Ligand A (-9.289).
14. **Pgp:** Ligand A (0.429) is better than Ligand B (0.005). Lower P-gp efflux is preferred.
15. **Binding Affinity:** Both ligands have similar binding affinities (-5.4 & -6.1 kcal/mol).
**Overall Assessment:**
Ligand A is significantly better overall. While Ligand B has a better metabolic stability (lower Cl_mic) and slightly better half-life, Ligand A excels in crucial areas like logP, TPSA, DILI risk, solubility, and Caco-2 permeability. The low logP of Ligand B is a major red flag, likely to severely impact its absorption. The better DILI score for Ligand A is also a significant advantage. The similar binding affinities mean that the superior ADME properties of Ligand A outweigh the slight advantage in metabolic stability offered by Ligand B.
Output:
1
2025-04-18 00:45:34,241 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands (351.411 and 368.459 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand B (92.58) is significantly better than Ligand A (128.26). Lower TPSA generally favors better permeability, crucial for GPCR ligands.
3. **logP:** Ligand A (-0.822) is slightly below the optimal 1-3 range, potentially hindering permeation. Ligand B (0.151) is closer to optimal.
4. **HBD:** Ligand A (2) is preferable to Ligand B (0). A small number of HBDs are generally desired.
5. **HBA:** Ligand A (8) is preferable to Ligand B (6).
6. **QED:** Both ligands have good QED scores (0.685 and 0.713), indicating good drug-like properties.
7. **DILI:** Ligand A (49.632) has a lower DILI risk than Ligand B (69.097), which is a significant advantage.
8. **BBB:** Both ligands have good BBB penetration (74.719 and 81.194). Ligand B is slightly better.
9. **Caco-2:** Ligand B (-4.634) is slightly better than Ligand A (-5.471).
10. **Solubility:** Both ligands have poor aqueous solubility (-2.267 and -2.956).
11. **hERG:** Ligand A (0.075) has a much lower hERG inhibition liability than Ligand B (0.388), a critical safety parameter.
12. **Cl_mic:** Ligand A (1.749) has significantly lower microsomal clearance than Ligand B (63.328), indicating better metabolic stability.
13. **t1/2:** Ligand B (-48.648) has a negative in vitro half-life, which is not possible. This is a major red flag. Ligand A (1.445) is reasonable.
14. **Pgp:** Ligand A (0.018) has much lower P-gp efflux liability than Ligand B (0.149).
15. **Affinity:** Both ligands have comparable binding affinities (-6.7 and -6.0 kcal/mol). The difference is less than the 1.5 kcal/mol threshold.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B has better TPSA and BBB, and a slightly better logP. However, Ligand A has significantly better DILI, hERG, Cl_mic, and Pgp values. The negative half-life of Ligand B is a dealbreaker.
**Conclusion:**
Considering the balance of properties, especially the critical safety parameters (DILI, hERG) and metabolic stability (Cl_mic), Ligand A is the more promising drug candidate. The slightly better TPSA and BBB of Ligand B are outweighed by its significant liabilities.
Output:
1
2025-04-18 00:45:34,241 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [349.387, 115.9 , -0.156, 3. , 6. , 0.68 , 39.201, 60.644, -5.187, -1.188, 0.092, 3.378, -4.219, 0.007, -7.9 ]
**Ligand B:** [360.426, 90.31 , -0.055, 2. , 5. , 0.592, 12.524, 73.943, -4.711, -0.016, 0.348, 3.812, 4.007, 0.039, -7.5 ]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity, and BBB):
1. **MW:** Both are within the ideal 200-500 Da range. Ligand A (349.387) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (90.31) is significantly better than Ligand A (115.9), falling well below the 140 threshold and closer to the 90 ideal for CNS penetration (though ADRB2 isn't strictly a CNS target, lower TPSA is still beneficial).
3. **logP:** Both are acceptable, around 0. Ligand B (-0.055) is slightly better, being closer to the optimal 1-3 range.
4. **HBD/HBA:** Ligand B (2 HBD, 5 HBA) is slightly better than Ligand A (3 HBD, 6 HBA) in terms of balancing solubility and permeability.
5. **QED:** Both are good (above 0.5), indicating drug-like properties. Ligand A (0.68) is slightly better.
6. **DILI:** Ligand B (12.524) has a much lower DILI risk than Ligand A (39.201), a significant advantage.
7. **BBB:** Ligand B (73.943) has a considerably higher BBB penetration score than Ligand A (60.644). While not a primary concern for ADRB2, it's a positive attribute.
8. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-5.187) is worse than Ligand B (-4.711).
9. **Solubility:** Ligand B (-0.016) is better than Ligand A (-1.188).
10. **hERG:** Ligand B (0.348) has a lower hERG risk than Ligand A (0.092), which is a crucial safety parameter.
11. **Cl_mic:** Ligand B (3.812) has a slightly higher clearance than Ligand A (3.378), meaning Ligand A is more metabolically stable.
12. **t1/2:** Ligand B (4.007) has a longer half-life than Ligand A (-4.219).
13. **Pgp:** Ligand B (0.039) has lower P-gp efflux than Ligand A (0.007), which is favorable for bioavailability.
14. **Affinity:** Ligand A (-7.9) has a slightly better binding affinity than Ligand B (-7.5). This is a 1.5 kcal/mol difference, which is significant.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity, Ligand B demonstrates a significantly superior ADMET profile. Specifically, the lower DILI risk, better BBB penetration, lower hERG risk, and improved solubility and Pgp efflux make it a much more promising candidate. The TPSA is also much more favorable for Ligand B. The slightly longer half-life is also a plus. The small difference in affinity can likely be optimized in subsequent iterations of drug design.
Therefore, I would choose Ligand B.
0
2025-04-18 00:45:34,241 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [365.415, 117.43 , 0.541, 2. , 7. , 0.767, 85.576, 62.854, -5.306, -3.376, 0.315, 41.777, 29.625, 0.05 , -5.6 ]
**Ligand B:** [353.507, 72.88 , 1.399, 2. , 4. , 0.615, 4.382, 54.013, -4.939, -1.23 , 0.298, 11.272, 11.969, 0.037, -6. ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (353.5) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (117.43) is higher than Ligand B (72.88). Ligand B is much better, being well below the 140 threshold for oral absorption and closer to the ideal for GPCRs.
3. **logP:** Ligand A (0.541) is quite low, potentially hindering membrane permeability. Ligand B (1.399) is better, falling within the optimal 1-3 range.
4. **HBD:** Both have 2 HBD, which is acceptable.
5. **HBA:** Ligand A (7) is higher than Ligand B (4). Ligand B is preferred.
6. **QED:** Both are reasonably good (A: 0.767, B: 0.615), indicating drug-like properties. Ligand A is slightly better.
7. **DILI:** Ligand A (85.576) has a significantly higher DILI risk than Ligand B (4.382). This is a major concern for Ligand A.
8. **BBB:** Ligand A (62.854) has a moderate BBB penetration, while Ligand B (54.013) is lower. While not a primary concern for a cardiovascular target, some CNS exposure is not necessarily detrimental.
9. **Caco-2:** Ligand A (-5.306) and Ligand B (-4.939) are both negative, indicating poor permeability.
10. **Solubility:** Ligand A (-3.376) and Ligand B (-1.23) are both negative, indicating poor solubility. Ligand B is better.
11. **hERG:** Both are very low (A: 0.315, B: 0.298), indicating low cardiotoxicity risk.
12. **Cl_mic:** Ligand A (41.777) has a higher microsomal clearance than Ligand B (11.272), suggesting lower metabolic stability. Ligand B is preferred.
13. **t1/2:** Ligand A (29.625) has a longer half-life than Ligand B (11.969). This is a positive for Ligand A.
14. **Pgp:** Both have very low P-gp efflux (A: 0.05, B: 0.037), which is good.
15. **Affinity:** Ligand B (-6.0) has a slightly better binding affinity than Ligand A (-5.6).
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand B excels in TPSA and logP, and has a slightly better affinity. The significantly lower DILI risk for Ligand B is a critical advantage. While Ligand A has a longer half-life, the higher DILI risk and poorer physicochemical properties outweigh this benefit.
**Conclusion:**
Ligand B is the more promising candidate due to its superior ADME profile (especially lower DILI risk and better TPSA and logP) and comparable binding affinity.
0
2025-04-18 00:45:34,242 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (a cardiovascular GPCR) drug candidates.
**Ligand A:** [351.403, 104.9 , 0.488, 2. , 6. , 0.773, 47.034, 62.621, -4.842, -1.55 , 0.198, 4.847, -7.632, 0.045, -5.7 ]
**Ligand B:** [385.647, 55.63 , 4.097, 1. , 7. , 0.612, 54.323, 74.564, -5.656, -4.151, 0.617, 83.091, 15.976, 0.636, -5.6 ]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity) and general drug-like properties:
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (351.4) is slightly preferred.
2. **TPSA:** Ligand B (55.63) is significantly better than Ligand A (104.9), falling well below the 140 threshold for oral absorption and being more favorable for potential CNS penetration (though not a CNS target here, lower TPSA is generally good).
3. **logP:** Ligand B (4.097) is higher than ideal (1-3), but still potentially manageable. Ligand A (0.488) is *too* low, potentially leading to poor membrane permeability. This is a significant negative for Ligand A.
4. **HBD/HBA:** Ligand A (2 HBD, 6 HBA) is slightly better balanced than Ligand B (1 HBD, 7 HBA), but both are acceptable.
5. **QED:** Ligand A (0.773) has a better QED score than Ligand B (0.612), indicating a more drug-like profile.
6. **DILI:** Both are reasonably good, with Ligand A (47.034) being slightly better than Ligand B (54.323).
7. **BBB:** Ligand B (74.564) has a better BBB score than Ligand A (62.621), but this isn't a primary concern for a cardiovascular target.
8. **Caco-2:** Ligand A (-4.842) is much better than Ligand B (-5.656), suggesting better intestinal absorption.
9. **Solubility:** Ligand A (-1.55) is better than Ligand B (-4.151).
10. **hERG:** Both are very low (0.198 and 0.617), indicating low cardiotoxicity risk.
11. **Cl_mic:** Ligand A (4.847) has a much lower (better) microsomal clearance than Ligand B (83.091), suggesting greater metabolic stability.
12. **t1/2:** Ligand B (15.976) has a significantly longer in vitro half-life than Ligand A (-7.632). This is a major advantage for Ligand B.
13. **Pgp:** Both are very low (0.045 and 0.636), indicating low P-gp efflux.
14. **Affinity:** Ligand A (-5.7) has a slightly better binding affinity than Ligand B (-5.6). However, the difference is small.
**Overall Assessment:**
Ligand A has a better QED, solubility, Caco-2 permeability, and metabolic stability. However, its very low logP is a major concern, likely hindering its ability to cross cell membranes effectively. Ligand B, while having a slightly lower QED and solubility, has a much more favorable logP, a longer half-life, and a better BBB score. For a GPCR, logP and metabolic stability are key. The slight advantage in affinity for Ligand A is unlikely to overcome the significant permeability issues.
Therefore, I believe Ligand B is the more promising candidate.
0
2025-04-18 00:45:34,242 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (359.421 and 348.447 Da). No clear advantage.
2. **TPSA:** Ligand A (72.28) is significantly better than Ligand B (86.6). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally favors absorption.
3. **logP:** Ligand A (2.422) is optimal. Ligand B (0.025) is very low, potentially hindering membrane permeability and bioavailability. This is a significant negative for Ligand B.
4. **HBD:** Ligand A (1) is good. Ligand B (3) is acceptable, but higher.
5. **HBA:** Ligand A (6) is good. Ligand B (5) is also good.
6. **QED:** Ligand A (0.874) is excellent. Ligand B (0.7) is still reasonable, but lower.
7. **DILI:** Ligand A (39.473) is very good (low risk). Ligand B (19.426) is also excellent, and slightly better.
8. **BBB:** Ligand A (77.937) is good. Ligand B (38.736) is low. Not a major concern for a cardiovascular target, but a point for Ligand A.
9. **Caco-2:** Ligand A (-4.473) is better than Ligand B (-5.228), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-2.625) is better than Ligand B (-0.327). Solubility is important for bioavailability.
11. **hERG:** Both ligands (0.334 and 0.186) have very low hERG risk, which is excellent.
12. **Cl_mic:** Ligand A (33.818) is higher than Ligand B (-25.604), indicating faster clearance and lower metabolic stability. This is a negative for Ligand A.
13. **t1/2:** Ligand A (-6.132) is worse than Ligand B (9.154), indicating a shorter half-life. This is a significant negative for Ligand A.
14. **Pgp:** Both ligands (0.061 and 0.013) have low P-gp efflux, which is good.
15. **Affinity:** Both ligands (-5.2 and -5.4 kcal/mol) have comparable binding affinities. The difference is not substantial enough to outweigh other factors.
**GPCR-specific considerations:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand A excels in logP and TPSA, while the affinities are similar. However, Ligand A has significantly worse metabolic stability and shorter half-life.
**Overall Assessment:**
While Ligand A has advantages in TPSA, logP, solubility, and DILI, Ligand B's superior metabolic stability (lower Cl_mic) and longer half-life are crucial for a viable drug candidate. The low logP of Ligand B is a concern, but the other favorable properties, combined with the importance of metabolic stability for a chronic cardiovascular condition, tip the balance in its favor.
Output:
0
2025-04-18 00:45:34,242 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (353.5 & 348.5 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (61.88) is better than Ligand B (79.54). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally favors absorption.
3. **logP:** Both ligands have good logP values (2.767 and 1.806), falling within the 1-3 optimal range. Ligand A is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (0) as it provides some hydrogen bonding potential, which can aid solubility.
5. **HBA:** Ligand A (4) and Ligand B (5) are both acceptable, below the 10 threshold.
6. **QED:** Both ligands have similar, good QED values (0.847 and 0.811), indicating good drug-like properties.
7. **DILI:** Ligand A (16.712) is significantly better than Ligand B (31.485) in terms of DILI risk. This is a crucial factor, as liver toxicity is a major concern in drug development.
8. **BBB:** Both ligands show reasonable BBB penetration (71.384 and 77.86). Since ADRB2 is a cardiovascular target, BBB penetration is not a primary concern.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual. Assuming these are logP values, they are both good.
10. **Solubility:** Both ligands have negative solubility values, which is unusual. Assuming these are logS values, they are both good.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.492 and 0.045). This is excellent.
12. **Cl_mic:** Ligand B (24.209) has a lower microsomal clearance than Ligand A (34.454), suggesting better metabolic stability. This is a positive for Ligand B.
13. **t1/2:** Ligand A (8.535) has a slightly longer in vitro half-life than Ligand B (7.591), which is desirable.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.086 and 0.058), which is good for bioavailability.
15. **Binding Affinity:** Ligand B (-7.4) has a slightly better binding affinity than Ligand A (-7.0), a 0.4 kcal/mol difference. While affinity is important, the other factors play a role.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Both ligands perform well in these areas. However, DILI risk is a significant concern, and Ligand A has a much lower DILI risk.
**Overall Assessment:**
While Ligand B has a slightly better binding affinity and lower Cl_mic, Ligand A's significantly lower DILI risk and better TPSA make it the more promising candidate. The small difference in affinity is likely outweighed by the reduced toxicity potential.
Output:
1
2025-04-18 00:45:34,242 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [353.419, 107.11 , -0.036, 2. , 6. , 0.743, 22.955, 31.214, -5.125, -0.467, 0.132, -1.761, -2.918, 0.041, -7.2 ]
**Ligand B:** [354.405, 61. , 1.848, 0. , 7. , 0.652, 33.773, 91.508, -4.671, -2.204, 0.573, 13.646, 9.709, 0.145, -5.5 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal 200-500 Da range. A: 353.4, B: 354.4 - very similar.
2. **TPSA:** A: 107.11, B: 61.0. Ligand B is significantly better, falling well below the 140 threshold for oral absorption and closer to the 90 threshold for CNS penetration.
3. **logP:** A: -0.036, B: 1.848. Ligand B is much better here, falling within the optimal 1-3 range. Ligand A is slightly hydrophilic and could have permeability issues.
4. **HBD:** A: 2, B: 0. Both are good, under the 5 limit.
5. **HBA:** A: 6, B: 7. Both are acceptable, under the 10 limit.
6. **QED:** A: 0.743, B: 0.652. Both are good, above 0.5. A is slightly better.
7. **DILI:** A: 22.955, B: 33.773. Ligand A has a lower DILI risk, which is a significant advantage.
8. **BBB:** A: 31.214, B: 91.508. Ligand B is *much* better regarding BBB penetration. This is a key factor for a GPCR, even if not specifically a CNS target, as it suggests better distribution.
9. **Caco-2:** A: -5.125, B: -4.671. Both are negative, indicating poor permeability. B is slightly better.
10. **Solubility:** A: -0.467, B: -2.204. Ligand A has better aqueous solubility.
11. **hERG:** A: 0.132, B: 0.573. Ligand A has a lower hERG risk, which is crucial for cardiovascular safety.
12. **Cl_mic:** A: -1.761, B: 13.646. Ligand A has much lower microsomal clearance, indicating better metabolic stability.
13. **t1/2:** A: -2.918, B: 9.709. Ligand B has a significantly longer in vitro half-life.
14. **Pgp:** A: 0.041, B: 0.145. Ligand A has lower P-gp efflux, which is favorable.
15. **Affinity:** A: -7.2, B: -5.5. Ligand A has a substantially stronger binding affinity (1.7 kcal/mol difference). This is a very important advantage.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, BBB, and affinity. Ligand B excels in TPSA and BBB, and has a reasonable logP. However, Ligand A's *significantly* stronger affinity (-7.2 vs -5.5) and lower DILI/hERG risks, coupled with better metabolic stability and Pgp profile, outweigh the slightly less favorable logP and TPSA. The 1.7 kcal/mol difference in binding is substantial. While ligand B has better BBB penetration, the overall balance favors ligand A.
**Conclusion:**
Given the priorities for a GPCR target and the substantial advantage in binding affinity, lower toxicity risks, and metabolic stability, I believe Ligand A is the more promising drug candidate.
0
2025-04-18 00:45:34,243 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (387.439 Da) is within the ideal range, while Ligand B (350.459 Da) is also acceptable. No clear advantage here.
2. **TPSA:** Ligand A (129.72) is slightly above the optimal <140 for oral absorption, but still reasonable. Ligand B (87.66) is excellent, well below 140 and favorable for permeability. Advantage: B.
3. **logP:** Ligand A (-0.727) is a bit low, potentially hindering permeation. Ligand B (1.141) is within the optimal 1-3 range. Advantage: B.
4. **HBD:** Ligand A (2) is good. Ligand B (3) is also acceptable. No significant difference.
5. **HBA:** Ligand A (6) is good. Ligand B (4) is also good. No significant difference.
6. **QED:** Ligand A (0.703) is excellent, indicating good drug-likeness. Ligand B (0.582) is still acceptable, but lower. Advantage: A.
7. **DILI:** Ligand A (72.547) is moderately high, suggesting potential liver toxicity concerns. Ligand B (14.424) is very low, indicating a much lower risk of DILI. Advantage: B.
8. **BBB:** Ligand A (25.397) has poor BBB penetration. Ligand B (55.176) is better, but still not high. Since ADRB2 is a cardiovascular target, BBB penetration isn't *critical*, but it's a bonus. Slight advantage: B.
9. **Caco-2:** Ligand A (-5.502) is very poor, indicating poor intestinal absorption. Ligand B (-4.806) is also poor, but slightly better. Advantage: B.
10. **Solubility:** Ligand A (-2.775) is poor. Ligand B (-1.772) is also poor, but slightly better. Advantage: B.
11. **hERG:** Ligand A (0.045) has a very low hERG risk. Ligand B (0.183) is slightly higher, but still acceptable. Advantage: A.
12. **Cl_mic:** Ligand A (-17.764) has very low microsomal clearance, indicating good metabolic stability. Ligand B (19.05) has moderate clearance. Advantage: A.
13. **t1/2:** Ligand A (68.248) has a good in vitro half-life. Ligand B (0.399) has a very short half-life. Advantage: A.
14. **Pgp:** Ligand A (0.016) has very low P-gp efflux, which is good. Ligand B (0.123) has moderate P-gp efflux. Advantage: A.
15. **Affinity:** Ligand B (-7.6 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.5 kcal/mol) - a difference of 1.1 kcal/mol. This is a substantial advantage.
**Overall Assessment:**
Ligand B has a clear advantage in terms of ADME properties (TPSA, logP, DILI, Caco-2, Solubility) and, crucially, a significantly higher binding affinity. While Ligand A has better QED, hERG, metabolic stability, and half-life, the strong binding affinity of Ligand B outweighs these benefits, especially for a GPCR target where potency is paramount. The lower DILI risk for Ligand B is also a significant factor. The slightly lower BBB penetration of Ligand B is not a major concern for a cardiovascular target.
Output:
0
2025-04-18 00:45:34,243 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (356.413 and 350.503 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Both ligands have a TPSA of 67.43, which is acceptable for a non-CNS GPCR target like ADRB2.
**3. logP:** Ligand A (2.31) is slightly lower than Ligand B (2.949), both are within the optimal 1-3 range.
**4. H-Bond Donors:** Both ligands have 2 HBD, which is good.
**5. H-Bond Acceptors:** Both ligands have 3 HBA, which is good.
**6. QED:** Ligand A (0.718) has a significantly better QED score than Ligand B (0.496), indicating a more drug-like profile.
**7. DILI:** Ligand A (35.789) has a much lower DILI risk than Ligand B (13.843), which is a crucial advantage.
**8. BBB:** BBB is less critical for a cardiovascular target. Ligand A (89.492) has a higher BBB penetration than Ligand B (69.058), but this is not a major deciding factor.
**9. Caco-2 Permeability:** Ligand A (-4.974) has slightly better Caco-2 permeability than Ligand B (-4.522).
**10. Aqueous Solubility:** Ligand B (-3.073) has slightly better aqueous solubility than Ligand A (-2.599).
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (0.248 and 0.421 respectively).
**12. Microsomal Clearance:** Ligand A (33.53) has significantly lower microsomal clearance than Ligand B (66.755), suggesting better metabolic stability.
**13. In vitro Half-Life:** Ligand B (-7.171) has a longer in vitro half-life than Ligand A (6.107).
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.034 and 0.295 respectively).
**15. Binding Affinity:** Ligand B (-6.2 kcal/mol) has a slightly better binding affinity than Ligand A (-5.6 kcal/mol). The difference is 0.6 kcal/mol, which is not substantial enough to outweigh other factors.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity) and general drug-like properties, Ligand A is the more promising candidate. While Ligand B has a slightly better binding affinity and half-life, Ligand A excels in critical areas like QED, DILI risk, and metabolic stability (lower Cl_mic). The lower DILI risk is particularly important for a cardiovascular drug. The difference in binding affinity is not large enough to overcome these advantages.
Output:
1
2025-04-18 00:45:34,243 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (369.447 Da) is well within the ideal range (200-500 Da). Ligand B (462.46 Da) is at the upper limit, but still acceptable.
2. **TPSA:** Ligand A (111.71) is borderline for good oral absorption (<=140), but acceptable. Ligand B (62.3) is excellent, well below the threshold.
3. **logP:** Ligand A (0.1) is quite low, potentially hindering membrane permeability. Ligand B (3.887) is optimal. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (2) is good. Ligand B (1) is also good.
5. **HBA:** Ligand A (5) is good. Ligand B (6) is also acceptable.
6. **QED:** Both ligands (A: 0.734, B: 0.706) have excellent drug-likeness scores.
7. **DILI:** Both ligands have similar and acceptable DILI risk (A: 84.141, B: 82.823).
8. **BBB:** Ligand A (48.779) has poor BBB penetration. Ligand B (68.282) is better, but still not ideal. Since ADRB2 is a cardiovascular target, BBB penetration is not a primary concern, but it's a slight advantage for B.
9. **Caco-2:** Ligand A (-4.755) has poor Caco-2 permeability. Ligand B (-5.355) is also poor, but slightly better.
10. **Solubility:** Ligand A (-3.137) has poor solubility. Ligand B (-4.854) is also poor.
11. **hERG:** Ligand A (0.234) has very low hERG risk, which is excellent. Ligand B (0.795) has a slightly higher, but still acceptable, hERG risk.
12. **Cl_mic:** Ligand A (15.131) has a lower microsomal clearance, indicating better metabolic stability. Ligand B (61.913) has significantly higher clearance. This is a major advantage for Ligand A.
13. **t1/2:** Ligand A (-42.707) has a very negative in vitro half-life, suggesting rapid metabolism. Ligand B (31.928) has a better, but still not ideal, half-life.
14. **Pgp:** Ligand A (0.009) has very low P-gp efflux, which is excellent. Ligand B (0.567) has moderate P-gp efflux.
15. **Affinity:** Ligand A (-7.4 kcal/mol) has a slightly better binding affinity than Ligand B (-6.4 kcal/mol). This 1 kcal/mol difference is significant.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp efflux, and binding affinity are key. Ligand B excels in logP and has a better TPSA. Ligand A has much better Pgp efflux and a slightly better binding affinity. The metabolic stability (Cl_mic) is a significant concern for Ligand B.
**Overall Assessment:**
While Ligand B has a better logP and TPSA, the significantly higher metabolic clearance, coupled with the slightly worse binding affinity, makes it less attractive. Ligand A's superior metabolic stability, excellent P-gp properties, and slightly better affinity outweigh its lower logP and TPSA. The poor solubility and permeability of both are concerns, but can potentially be addressed with formulation strategies.
Output:
1
2025-04-18 00:45:34,243 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (338.415 and 388.917 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Both ligands (76.77 and 78.87) are below the 140 A^2 threshold for good oral absorption. They are also reasonably low for a GPCR. No clear advantage.
3. **logP:** Both ligands (2.86 and 2.012) are within the optimal 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability, but both are acceptable.
4. **HBD:** Both have 2 H-bond donors, which is good.
5. **HBA:** Both have 5 H-bond acceptors, which is good.
6. **QED:** Both ligands have good QED scores (0.695 and 0.748), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Both ligands have similar DILI risk (61.691 and 60.644), placing them in a moderate risk category. Not a major differentiating factor.
8. **BBB:** Ligand A (62.466) has a significantly better BBB penetration percentile than Ligand B (38.813). While ADRB2 isn't exclusively a CNS target, some CNS exposure could be beneficial or at least not detrimental.
9. **Caco-2:** Both have negative Caco-2 values (-5.07 and -4.816), which is unusual and indicates poor permeability. This is a significant concern for both.
10. **Solubility:** Both have negative solubility values (-3.963 and -2.783), indicating very poor aqueous solubility. This is a major drawback for both compounds.
11. **hERG:** Both have low hERG inhibition liability (0.555 and 0.382), which is excellent.
12. **Cl_mic:** Ligand B (31.821) has a much lower microsomal clearance than Ligand A (71.686), suggesting better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand B (36.872) has a longer in vitro half-life than Ligand A (14.238), further supporting its better metabolic stability.
14. **Pgp:** Both have low P-gp efflux liability (0.164 and 0.361).
15. **Binding Affinity:** Ligand A (-5.6 kcal/mol) has a slightly better binding affinity than Ligand B (-3.5 kcal/mol). This is a 2.1 kcal/mol difference, which is substantial and could outweigh some of the ADME drawbacks.
**Overall Assessment & GPCR-Specific Priorities:**
For a GPCR like ADRB2, affinity, logP, and metabolic stability are crucial. Ligand A has a significantly better binding affinity. However, Ligand B has much better metabolic stability (lower Cl_mic, longer t1/2) and a slightly better QED. The poor Caco-2 and solubility for both are concerning, but can potentially be addressed with formulation strategies. The better BBB for Ligand A is a minor plus. The substantial difference in binding affinity is the deciding factor.
Output:
1
2025-04-18 00:45:34,243 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (367.515 Da) is slightly higher than Ligand B (347.419 Da), but both are acceptable.
2. **TPSA:** Ligand A (80.32) is better than Ligand B (91.46). Both are below 140, but lower TPSA generally favors absorption.
3. **logP:** Ligand A (2.753) is optimal, while Ligand B (0.781) is a bit low. A logP below 1 can sometimes hinder permeability.
4. **HBD:** Ligand A (2) is reasonable, Ligand B (0) is also good.
5. **HBA:** Ligand A (5) is good, Ligand B (6) is also acceptable.
6. **QED:** Both ligands have good QED scores (A: 0.658, B: 0.785), indicating good drug-likeness.
7. **DILI:** Both ligands have acceptable DILI risk (A: 40.83, B: 46.917), below the 60 threshold.
8. **BBB:** Both ligands have moderate BBB penetration (A: 61.38, B: 66.305). While not exceptionally high, this isn't a primary concern for ADRB2, which isn't a CNS target.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. Ligand A (-4.966) is slightly better than Ligand B (-4.461).
10. **Solubility:** Ligand A (-2.864) is better than Ligand B (-1.658). Solubility is important for bioavailability.
11. **hERG:** Both ligands have very low hERG inhibition risk (A: 0.436, B: 0.637).
12. **Cl_mic:** Ligand B (21.731) has significantly lower microsomal clearance than Ligand A (52.962), suggesting better metabolic stability.
13. **t1/2:** Both ligands have similar in vitro half-lives (A: 8.429, B: 8.251).
14. **Pgp:** Both ligands have low P-gp efflux (A: 0.276, B: 0.209), which is good.
15. **Binding Affinity:** Ligand A (-7.3 kcal/mol) has a significantly stronger binding affinity than Ligand B (-5.4 kcal/mol). This is a substantial difference (1.9 kcal/mol), and often outweighs minor ADME concerns.
**GPCR-specific priorities:** For GPCRs, logP, TPSA, and affinity are key. Ligand A excels in logP and significantly in affinity. While TPSA is slightly better for Ligand A, the difference isn't huge. The superior binding affinity of Ligand A is the most important factor. Although Ligand B has better metabolic stability, the strong binding of Ligand A is more likely to translate to efficacy.
**Conclusion:**
Ligand A is the better candidate due to its significantly stronger binding affinity and acceptable ADME properties.
Output:
1
2025-04-18 00:45:34,243 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (367.5 and 350.4 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (98.17) is higher than Ligand B (76.02). While both are reasonably good, Ligand B is preferable as it's closer to the <140 threshold for good oral absorption, and GPCRs benefit from lower TPSA.
3. **logP:** Both ligands have good logP values (2.96 and 1.84), falling within the optimal 1-3 range. Ligand B is slightly lower, which could be beneficial for solubility.
4. **HBD:** Ligand A (1) and Ligand B (2) are both acceptable.
5. **HBA:** Both ligands have 4 HBA, which is within the acceptable range.
6. **QED:** Ligand B (0.703) has a significantly better QED score than Ligand A (0.405), indicating a more drug-like profile.
7. **DILI:** Both ligands have low DILI risk (37.185 and 32.687), which is good. Ligand B is slightly better.
8. **BBB:** Ligand B (76.696) has a significantly higher BBB penetration score than Ligand A (59.674). This is a key advantage for a GPCR target, even if it's not strictly a CNS target, as it suggests better distribution.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. Ligand A (-5.216) is worse than Ligand B (-4.951).
10. **Solubility:** Both ligands have negative solubility values, indicating poor solubility. Ligand B (-1.986) is slightly better than Ligand A (-2.951).
11. **hERG:** Both ligands have very low hERG inhibition risk (0.312 and 0.229), which is excellent.
12. **Cl_mic:** Ligand B (20.768) has a significantly lower microsomal clearance than Ligand A (46.856), indicating better metabolic stability.
13. **t1/2:** Ligand B (-11.339) has a longer in vitro half-life than Ligand A (-9.345), which is desirable.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.058 and 0.086), which is good.
15. **Binding Affinity:** Both ligands have similar binding affinities (-5.9 and -4.9 kcal/mol). Ligand A is slightly better, but the difference is not substantial enough to overcome its other weaknesses.
**Overall Assessment:**
Ligand B consistently outperforms Ligand A in several critical ADME properties (QED, BBB, Cl_mic, t1/2, solubility, Caco-2) and has a slightly better DILI score. While Ligand A has a marginally better binding affinity, the improvements in ADME properties, especially BBB penetration and metabolic stability, make Ligand B the more promising drug candidate for the ADRB2 receptor. The GPCR-specific priorities of logP, Pgp, TPSA, and affinity are all reasonably addressed by Ligand B.
Output:
0
2025-04-18 00:45:34,244 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (433.37 & 402.65 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand B (50.27) is significantly better than Ligand A (75.71). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (1.84) is better than Ligand B (3.646). While both are within the acceptable range, Ligand A is closer to the optimal 1-3 range. Ligand B is approaching a logP where solubility issues could arise.
4. **HBD:** Ligand A (1) is better than Ligand B (0). While both are low, having at least one HBD can improve solubility.
5. **HBA:** Ligand B (6) is slightly better than Ligand A (5). Both are within the acceptable range.
6. **QED:** Both ligands are similar (0.665 and 0.631), indicating good drug-likeness.
7. **DILI:** Ligand A (28.31) is significantly better than Ligand B (50.14). Lower DILI risk is crucial.
8. **BBB:** Ligand B (71.97) is better than Ligand A (57.93), but as ADRB2 is a cardiovascular target, BBB penetration is not a major priority.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-5.011) is slightly better than Ligand B (-5.489).
10. **Solubility:** Ligand A (-2.742) is better than Ligand B (-3.785). Solubility is important for bioavailability.
11. **hERG:** Both ligands have very low hERG risk (0.671 and 0.66).
12. **Cl_mic:** Ligand A (17.81) is significantly better than Ligand B (35.32). Lower clearance indicates better metabolic stability.
13. **t1/2:** Ligand A (7.78) is slightly better than Ligand B (7.25).
14. **Pgp:** Both ligands have low Pgp efflux (0.136 and 0.399).
15. **Binding Affinity:** Ligand B (-6.1) is slightly better than Ligand A (-5.6). This is a 0.5 kcal/mol difference, which is significant enough to consider.
**Overall Assessment:**
While Ligand B has a slightly better binding affinity, Ligand A demonstrates a significantly more favorable ADMET profile. Specifically, the lower DILI risk, better metabolic stability (lower Cl_mic), and improved solubility are critical advantages. The slightly lower affinity of Ligand A can potentially be optimized in subsequent iterations of drug design. For a cardiovascular target like ADRB2, metabolic stability and safety (DILI) are paramount.
Output:
1
2025-04-18 00:45:34,244 - INFO - Batch 501 complete. Total preferences: 8016
2025-04-18 00:45:34,244 - INFO - Processing batch 502/512...
2025-04-18 00:46:20,318 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (342.443 and 335.415 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (58.44) is significantly better than Ligand B (78.86). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have acceptable logP values (1.459 and 2.557, respectively), falling within the 1-3 range. Ligand B is slightly higher, which *could* be beneficial for membrane permeability, but isn't a major concern.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is better than Ligand B (7). Similar to HBDs, fewer HBAs are generally preferred.
6. **QED:** Both ligands have similar QED values (0.736 and 0.687), indicating good drug-likeness.
7. **DILI:** Ligand A (29.391) has a much lower DILI risk than Ligand B (63.086). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (82.668) has a higher BBB penetration percentile than Ligand B (40.675). While not crucial for a cardiovascular target, higher BBB is generally a positive attribute.
9. **Caco-2:** Ligand A (-4.545) and Ligand B (-5.358) both have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it is difficult to interpret.
10. **Solubility:** Both ligands have similar, very poor aqueous solubility (-3.01 and -3.062). This is a significant drawback for both.
11. **hERG:** Ligand A (0.268) has a much lower hERG inhibition liability than Ligand B (0.729). This is a crucial advantage, as hERG inhibition can lead to cardiotoxicity.
12. **Cl_mic:** Ligand A (29.911) has lower microsomal clearance than Ligand B (67.547), indicating better metabolic stability.
13. **t1/2:** Ligand B (45.932) has a significantly longer in vitro half-life than Ligand A (-9.933). This is a major advantage for Ligand B.
14. **Pgp:** Ligand A (0.145) has lower P-gp efflux liability than Ligand B (0.014). Lower P-gp is generally preferred.
15. **Affinity:** Both ligands have very similar and excellent binding affinities (-6.0 and -5.7 kcal/mol). The difference is not substantial enough to be a deciding factor.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A is better on TPSA, Pgp, and DILI/hERG safety. Ligand B has a longer half-life, but the other safety and absorption parameters are more concerning.
**Overall Assessment:**
Ligand A is the better candidate. While both have poor solubility, Ligand A has a significantly better safety profile (lower DILI and hERG), better permeability characteristics (lower TPSA, fewer HBD/HBA), and comparable affinity. The longer half-life of Ligand B is appealing, but the safety concerns are too significant to ignore.
Output:
1
2025-04-18 00:46:20,318 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's systematically compare Ligand A and Ligand B based on the provided parameters and the guidelines, keeping in mind ADRB2 is a GPCR and thus we prioritize logP, Pgp, TPSA, and affinity.
1. **Molecular Weight:** Both ligands (345.447 and 349.475 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (80.12) is slightly higher than Ligand B (65.79). Both are below the 140 A^2 threshold for good oral absorption, but Ligand B is better in this regard.
3. **logP:** Ligand A (1.38) is within the optimal range (1-3), while Ligand B (2.203) is also acceptable. Ligand B is slightly better.
4. **H-Bond Donors:** Both ligands have 1 HBD, which is good.
5. **H-Bond Acceptors:** Ligand A has 5 HBA, and Ligand B has 4. Both are below the 10 threshold.
6. **QED:** Both ligands have good QED scores (0.757 and 0.855), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (37.069) has a slightly higher DILI risk than Ligand B (21.093). This favors Ligand B.
8. **BBB:** Ligand A (53.974) has a lower BBB penetration percentile than Ligand B (63.94). While ADRB2 isn't necessarily a CNS target, some peripheral ADRB2 activity can influence CNS function, and higher BBB penetration isn't a major negative. Ligand B is better.
9. **Caco-2 Permeability:** Ligand A (-5.141) has worse Caco-2 permeability than Ligand B (-4.866).
10. **Aqueous Solubility:** Both ligands have poor aqueous solubility (-1.563 and -1.347). This is a concern for both, but not a deciding factor.
11. **hERG Inhibition:** Ligand A (0.057) has a lower hERG inhibition risk than Ligand B (0.746). This is a significant advantage for Ligand A.
12. **Microsomal Clearance:** Ligand A (33.555) has significantly higher microsomal clearance than Ligand B (0.305). This means Ligand B is much more metabolically stable.
13. **In vitro Half-Life:** Ligand A (3.656) has a shorter half-life than Ligand B (27.795). This favors Ligand B.
14. **P-gp Efflux:** Ligand A (0.021) has much lower P-gp efflux than Ligand B (0.194). This is a significant advantage for Ligand A.
15. **Binding Affinity:** Ligand B (-7.1 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.1 kcal/mol). This is a substantial advantage that can outweigh some ADME drawbacks. The 1.0 kcal/mol difference is significant.
**Overall Assessment:**
Ligand B has a superior binding affinity, better metabolic stability, longer half-life, and lower DILI risk. While Ligand A has better hERG and P-gp profiles, the substantial affinity advantage of Ligand B, coupled with its better metabolic properties, makes it the more promising candidate. The slightly worse hERG and P-gp profiles of Ligand B can be addressed through further optimization, but improving a 1.0 kcal/mol affinity difference is often much more challenging.
**Output:**
0
2025-04-18 00:46:20,318 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Both ligands have identical binding affinities (-7.5 kcal/mol), which is excellent and removes that as a differentiating factor. Given that ADRB2 is a GPCR, I will prioritize logP, TPSA, Pgp efflux, BBB penetration, and metabolic stability.
1. **Molecular Weight:** Both ligands (346.43 and 359.37 Da) fall comfortably within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (59.08) is better than Ligand B (39.5). Both are well below the 140 A^2 threshold for good oral absorption, but lower TPSA generally correlates with better membrane permeability.
3. **logP:** Both ligands have good logP values (2.37 and 2.89), falling within the optimal 1-3 range. Ligand B is slightly higher, which could be marginally beneficial for membrane permeability, but also slightly increases the risk of off-target interactions.
4. **H-Bond Donors/Acceptors:** Both ligands have 0 HBD and 4 HBA, which is favorable.
5. **QED:** Both ligands have similar QED scores (0.733 and 0.702), indicating good drug-like properties.
6. **DILI Risk:** Ligand A (53.86%) has a significantly higher DILI risk than Ligand B (15.90%). This is a major concern, as liver toxicity is a common cause of drug failure.
7. **BBB Penetration:** Ligand B (93.29%) shows better BBB penetration than Ligand A (87.13%). While ADRB2 isn't exclusively a CNS target, some cardiovascular effects are mediated by central pathways, and better BBB penetration could be advantageous.
8. **Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. This is a red flag for both compounds.
9. **Aqueous Solubility:** Both ligands have negative solubility values, which is also unusual and suggests poor solubility. This is a red flag for both compounds.
10. **hERG Inhibition:** Ligand A (0.418) has a lower hERG inhibition risk than Ligand B (0.981). This is a positive for Ligand A.
11. **Microsomal Clearance:** Ligand A (88.43) has a higher microsomal clearance than Ligand B (12.76). This suggests Ligand A will be metabolized more quickly, potentially leading to a shorter duration of action and requiring higher doses.
12. **In vitro Half-Life:** Ligand B (-10.696) has a longer in vitro half-life than Ligand A (-9.014). This is a positive for Ligand B.
13. **P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.153 and 0.247).
**Overall Assessment:**
Despite the similar binding affinities, Ligand B is the more promising candidate. Its significantly lower DILI risk is a major advantage, outweighing the slightly better hERG profile of Ligand A. The better BBB penetration and longer half-life of Ligand B are also favorable. While both compounds exhibit poor Caco-2 permeability and solubility, the DILI risk is the most critical factor in this comparison.
**Output:**
0
2025-04-18 00:46:20,319 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (363.5 and 358.5 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (52.65) is significantly better than Ligand B (75.5). ADRB2 is not a CNS target, but lower TPSA generally improves permeability.
3. **logP:** Both ligands have good logP values (3.21 and 2.17), falling within the 1-3 range. Ligand A is slightly higher, potentially offering better membrane permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is preferable to Ligand B (5). Fewer HBAs generally improve permeability.
6. **QED:** Both ligands have acceptable QED values (0.835 and 0.56), indicating reasonable drug-likeness. Ligand A is significantly better.
7. **DILI:** Both ligands have similar DILI risk (66.6 and 59.9), which is acceptable (below 60 is good).
8. **BBB:** This is less critical for ADRB2, but Ligand A (67.6) is better than Ligand B (53.6).
9. **Caco-2:** Both have negative Caco-2 values which is unusual. However, the absolute value for Ligand A (-4.83) is less negative than Ligand B (-5.17), suggesting slightly better absorption.
10. **Solubility:** Both ligands have negative solubility values, which is also unusual. Ligand A (-3.91) is slightly better than Ligand B (-2.99).
11. **hERG:** Both ligands show low hERG inhibition liability (0.537 and 0.582), which is good.
12. **Cl_mic:** Ligand B (39.7) has significantly lower microsomal clearance than Ligand A (58.7), indicating better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand A (54.8) has a much longer in vitro half-life than Ligand B (20.1). This is a significant advantage.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.188 and 0.13).
15. **Binding Affinity:** Ligand B (-7.8 kcal/mol) has a substantially stronger binding affinity than Ligand A (-5.8 kcal/mol). This is a 2 kcal/mol difference, which is a major advantage and can outweigh some ADME concerns.
**Overall Assessment:**
Ligand B has a significantly better binding affinity, which is the most important factor for GPCRs. While Ligand A has better TPSA, QED, and half-life, the substantial difference in binding affinity of Ligand B is a key advantage. The slightly higher metabolic stability of Ligand B is also beneficial. The unusual negative values for Caco-2 and solubility are concerning for both, but the affinity difference is the deciding factor.
Output:
0
2025-04-18 00:46:20,319 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.459 and 356.413 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (82.53) is higher than Ligand B (66.48). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B has an advantage.
3. **logP:** Both ligands have good logP values (1.772 and 2.31), falling within the optimal 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable, being less than 5. Ligand B is slightly better.
5. **HBA:** Ligand A (4) and Ligand B (3) are both acceptable, being less than 10. Ligand B is slightly better.
6. **QED:** Ligand A (0.822) has a significantly higher QED score than Ligand B (0.679), indicating a more drug-like profile overall. This is a significant advantage for Ligand A.
7. **DILI:** Ligand A (33.734) has a lower DILI risk than Ligand B (41.838), both are acceptable, but A is better.
8. **BBB:** Ligand B (87.631) has a much higher BBB penetration percentile than Ligand A (32.726). While ADRB2 isn't a primary CNS target, some brain exposure is possible, and higher BBB is generally favorable.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.838 and -4.487). This is unusual and suggests poor permeability. However, these values are on the same scale, so the difference is not significant.
10. **Solubility:** Ligand A (-1.588) has slightly better solubility than Ligand B (-2.687).
11. **hERG:** Both ligands have very low hERG inhibition risk (0.289 and 0.212). No significant difference.
12. **Cl_mic:** Both ligands have similar microsomal clearance (15.188 and 15.255 mL/min/kg). No significant difference.
13. **t1/2:** Ligand A (2.957) has a shorter half-life than Ligand B (-14.994). The negative value for Ligand B is unusual and likely represents a very long half-life or an error in the data. This is a significant advantage for Ligand B.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.069 and 0.094). No significant difference.
15. **Binding Affinity:** Ligand B (-6.0) has a slightly better binding affinity than Ligand A (-5.3). This is a 0.7 kcal/mol difference, which is significant enough to consider.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand B has advantages in logP, TPSA, and affinity. Ligand A has a better QED and lower DILI risk. The half-life of Ligand B is a significant positive, assuming the negative value is accurate.
**Overall Assessment:**
While Ligand A has a better QED and DILI profile, Ligand B demonstrates superior binding affinity, better TPSA, and a potentially much longer half-life. The slightly better logP of Ligand B is also beneficial. Considering the importance of affinity for GPCRs and the potential for improved pharmacokinetics with the longer half-life, Ligand B appears to be the more promising candidate.
Output:
0
2025-04-18 00:46:20,319 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.413 and 349.362 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (58.95) is significantly better than Ligand B (99.5). ADRB2 is a cardiovascular target, not CNS, but lower TPSA generally improves absorption. Ligand A is well below the 140 threshold. Ligand B is approaching a level that could hinder oral absorption.
3. **logP:** Ligand A (3.85) is optimal, while Ligand B (0.092) is very low. This is a major concern for Ligand B, as it may struggle with membrane permeability.
4. **HBD:** Ligand A (2) and Ligand B (1) are both acceptable.
5. **HBA:** Ligand A (3) and Ligand B (5) are both acceptable, though Ligand A is slightly better.
6. **QED:** Both ligands (0.88 and 0.758) have good drug-likeness scores, exceeding the 0.5 threshold.
7. **DILI:** Both ligands have similar, acceptable DILI risk (40.287 and 41.062, both < 40).
8. **BBB:** Both ligands have high BBB penetration (88.639 and 83.637). While not a primary concern for a cardiovascular target, it doesn't hurt.
9. **Caco-2:** Both ligands have negative Caco-2 values which is unusual, but the values are similar.
10. **Solubility:** Both ligands have negative solubility values which is unusual, but the values are similar.
11. **hERG:** Both ligands have low hERG inhibition risk (0.674 and 0.172).
12. **Cl_mic:** Ligand A (28.2) has a much more favorable (lower) microsomal clearance than Ligand B (6.853), indicating better metabolic stability.
13. **t1/2:** Ligand A (19.728) has a longer in vitro half-life than Ligand B (-6.446), which is a significant advantage.
14. **Pgp:** Ligand A (0.266) has lower P-gp efflux liability than Ligand B (0.068).
15. **Binding Affinity:** Ligand A (-5.9 kcal/mol) and Ligand B (-5.0 kcal/mol) have good binding affinities, but Ligand A is 0.9 kcal/mol stronger. This difference is substantial enough to be a key deciding factor.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most crucial ADME properties and has a significantly better binding affinity. The lower logP of Ligand B is a major red flag, suggesting poor permeability. While both have acceptable safety profiles, the superior metabolic stability (Cl_mic and t1/2) and binding affinity of Ligand A make it the more promising drug candidate. Given the GPCR target class, the balance of logP, TPSA, Pgp, and affinity heavily favors Ligand A.
Output:
1
2025-04-18 00:46:20,319 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (370.833 and 356.463 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (99.88) is better than Ligand B (107.89), both being under the 140 threshold for oral absorption.
3. **logP:** Ligand A (1.615) is optimal, while Ligand B (0.501) is slightly low, potentially hindering permeability. This favors Ligand A.
4. **HBD:** Ligand A (2) is preferable to Ligand B (4). Fewer HBDs generally improve permeability.
5. **HBA:** Both ligands have 5 HBA, which is acceptable.
6. **QED:** Ligand A (0.688) is better than Ligand B (0.45), indicating a more drug-like profile.
7. **DILI:** Ligand A (51.221) is significantly better than Ligand B (11.128) with respect to DILI risk. Lower is better, and Ligand B is approaching a concerning percentile.
8. **BBB:** Ligand A (81.388) is much better than Ligand B (34.858). While ADRB2 isn't necessarily a CNS target, higher BBB penetration can sometimes correlate with better overall drug distribution.
9. **Caco-2:** Ligand A (-4.884) is better than Ligand B (-5.013). Both are negative values, indicating permeability, but A is slightly less negative.
10. **Solubility:** Ligand A (-3.463) is better than Ligand B (-1.866). Higher solubility is generally preferred.
11. **hERG:** Both ligands (0.153 and 0.062) show very low hERG inhibition liability, which is excellent. No clear advantage.
12. **Cl_mic:** Ligand A (31.896) is slightly higher than Ligand B (28.4), meaning Ligand B has better metabolic stability.
13. **t1/2:** Ligand A (-17.797) is better than Ligand B (-13.369). A more negative value indicates a longer half-life.
14. **Pgp:** Both ligands (0.139 and 0.016) have low P-gp efflux liability, which is good. Ligand B is slightly better.
15. **Binding Affinity:** Both ligands have the same binding affinity (-5.8 kcal/mol), which is excellent.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Ligand A excels in logP, TPSA, and Pgp. While affinity is the same, the superior ADME properties of Ligand A, especially the significantly lower DILI risk and better BBB penetration, make it a more promising candidate.
**Conclusion:**
Ligand A demonstrates a superior balance of properties, particularly in ADME characteristics and safety (DILI), while maintaining excellent binding affinity. Ligand B's lower logP and higher DILI risk are concerning.
Output:
1
2025-04-18 00:46:20,319 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (356.379 and 351.491 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (87.3) is significantly better than Ligand A (129.56). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (1.738) is within the optimal range (1-3), while Ligand A (-2.151) is quite low, potentially hindering permeability. This is a significant advantage for Ligand B.
4. **HBD:** Both ligands have 3 HBD, which is acceptable.
5. **HBA:** Ligand B (3) is better than Ligand A (7). Lower HBA is generally preferred for better permeability.
6. **QED:** Ligand B (0.622) has a slightly better QED than Ligand A (0.455), indicating a more drug-like profile.
7. **DILI:** Ligand B (27.608) has a much lower DILI risk than Ligand A (60.217). This is a major advantage for Ligand B.
8. **BBB:** Ligand B (67.623) has a higher BBB penetration than Ligand A (14.23). While not critical for a cardiovascular target, it's still a positive.
9. **Caco-2:** Both have negative values, indicating poor permeability. No clear advantage.
10. **Solubility:** Ligand B (-2.35) is worse than Ligand A (-1.211), but both are poor.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.133 and 0.114).
12. **Cl_mic:** Ligand A (1.517) has a much lower microsomal clearance than Ligand B (34.367), suggesting better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand B (-3.211) has a longer in vitro half-life than Ligand A (-2.308).
14. **Pgp:** Both ligands have low P-gp efflux liability (0.008 and 0.021).
15. **Binding Affinity:** Ligand A (-6.4) has a slightly better binding affinity than Ligand B (-5.7), but the difference is less than 1.5 kcal/mol.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand B excels in logP and TPSA, while Ligand A has a slightly better affinity. However, the significantly lower DILI risk and better QED of Ligand B, combined with its acceptable affinity, outweigh the minor affinity advantage of Ligand A. The improved metabolic stability of Ligand A is a benefit, but the other factors favor Ligand B.
**Conclusion:**
Considering the balance of properties and the priorities for a GPCR target, Ligand B is the more promising drug candidate.
Output:
0
2025-04-18 00:46:20,319 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (350.419 and 349.391 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (102.32) is better than Ligand B (111.27). While both are under the 140 A^2 threshold for oral absorption, lower TPSA is generally preferred for GPCR ligands as it can improve brain penetration and receptor binding.
**3. logP:** Ligand A (0.834) is slightly outside the optimal 1-3 range, but still acceptable. Ligand B (0.103) is quite low, potentially hindering membrane permeability and reducing binding affinity. This is a significant drawback for a GPCR ligand.
**4. H-Bond Donors:** Both have 2 HBD, which is within the acceptable limit of <=5.
**5. H-Bond Acceptors:** Ligand A has 6 HBA, while Ligand B has 8. Both are within the acceptable limit of <=10, but Ligand A is slightly better.
**6. QED:** Ligand A (0.723) has a better QED score than Ligand B (0.654), indicating a more drug-like profile.
**7. DILI Risk:** Ligand B (63.242) has a slightly higher DILI risk than Ligand A (59.131), but both are within an acceptable range (<60 is good).
**8. BBB Penetration:** Ligand A (77.433) has significantly better predicted BBB penetration than Ligand B (41.566). While ADRB2 is a cardiovascular target, some CNS effects are possible with beta-adrenergic agonists, and better BBB penetration could be beneficial or detrimental depending on the desired profile.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests a potential issue with the prediction method. However, the magnitude of the negative value is larger for Ligand B (-5.001) than for Ligand A (-4.838), suggesting potentially lower permeability for Ligand B.
**10. Aqueous Solubility:** Ligand A (-3.348) has slightly better predicted solubility than Ligand B (-1.929).
**11. hERG Inhibition:** Both ligands have very low predicted hERG inhibition risk (0.062 and 0.044), which is excellent.
**12. Microsomal Clearance:** Ligand A (41.196) has a higher microsomal clearance than Ligand B (17.034), meaning it will be metabolized faster. This is a drawback for Ligand A.
**13. In vitro Half-Life:** Ligand B (24.738 hours) has a much longer predicted half-life than Ligand A (6.34 hours). This is a significant advantage for Ligand B.
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (0.083 and 0.193).
**15. Binding Affinity:** Ligand B (-6.5 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.4 kcal/mol). This is a substantial advantage, potentially outweighing some of the ADME drawbacks.
**Overall Assessment:**
Ligand B has a significantly stronger binding affinity, a longer half-life, and a lower microsomal clearance. However, it has a lower logP and poorer BBB penetration. Ligand A has better TPSA, QED, solubility, and BBB penetration, but a weaker binding affinity and shorter half-life.
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), the superior binding affinity of Ligand B is the most critical factor. The lower logP is a concern, but the stronger binding could compensate for reduced permeability. The longer half-life is also a significant benefit.
Output:
0
2025-04-18 00:46:20,320 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (353.482 and 348.531 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (52.65) is slightly higher than Ligand B (49.41). Both are below the 140 threshold for good oral absorption, and acceptable for a cardiovascular GPCR.
3. **logP:** Ligand B (3.748) is higher than Ligand A (2.272). While both are within the optimal 1-3 range, Ligand B is approaching the upper limit. This could potentially lead to solubility issues, but is not a major concern at this level.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 3 HBA, and Ligand B has 2. Both are within the acceptable range of <=10.
6. **QED:** Ligand B (0.795) has a slightly better QED score than Ligand A (0.681), indicating a more drug-like profile.
7. **DILI:** Ligand A (15.355) has a significantly higher DILI risk than Ligand B (8.104). This is a major concern, as liver toxicity is a common reason for drug failure.
8. **BBB:** Ligand A (89.957) has a higher BBB penetration than Ligand B (79.488). While ADRB2 is not a CNS target, some off-target CNS effects are always a consideration.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.745 and -4.52), which is unusual and suggests poor permeability. This is a significant drawback for both.
10. **Solubility:** Ligand B (-3.715) has slightly worse solubility than Ligand A (-2.517), both are very poor.
11. **hERG:** Both ligands have low hERG inhibition risk (0.864 and 0.657).
12. **Cl_mic:** Ligand B (82.534) has a significantly higher microsomal clearance than Ligand A (26.529), suggesting faster metabolism and potentially lower bioavailability.
13. **t1/2:** Both have similar in vitro half-lives (0.717 and 0.78 hours) which are quite short.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.201 and 0.138).
15. **Affinity:** Both ligands have the same binding affinity (-6.2 kcal/mol), so this parameter does not differentiate them.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. While both ligands are similar in affinity, Ligand A has a better logP and TPSA, and a much better metabolic stability (lower Cl_mic). The biggest differentiating factor is the DILI score. Ligand A's significantly higher DILI risk is a major red flag.
**Conclusion:**
Despite the slightly better QED and BBB of Ligand A, the significantly lower DILI risk and better metabolic stability of Ligand B make it the more promising candidate. The poor Caco-2 and solubility are concerning for both, but these can potentially be addressed through formulation strategies. The liver toxicity risk associated with Ligand A is harder to mitigate.
Output:
0
2025-04-18 00:46:20,320 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (366.809 Da and 349.41 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand B (80.12) is significantly better than Ligand A (124.79). ADRB2 is not a CNS target, but lower TPSA generally improves absorption.
3. **logP:** Both ligands have similar logP values (0.757 and 0.773), both within the optimal 1-3 range.
4. **HBD:** Ligand B (1) has fewer HBD than Ligand A (4). Fewer HBD generally improves permeability.
5. **HBA:** Both ligands have the same number of HBA (5), which is acceptable.
6. **QED:** Both ligands have similar QED scores (0.549 and 0.555), indicating good drug-likeness.
7. **DILI:** Ligand B (39.046) has a much lower DILI risk than Ligand A (73.245). This is a significant advantage for Ligand B.
8. **BBB:** This is less critical for ADRB2, but Ligand B (63.125) has a higher BBB percentile than Ligand A (43.815).
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. Ligand B (-5.011) is slightly better than Ligand A (-5.452) but both are problematic.
10. **Solubility:** Both ligands have negative solubility values, indicating poor solubility. Ligand B (-2.126) is slightly better than Ligand A (-3.156).
11. **hERG:** Ligand B (0.214) has a much lower hERG inhibition liability than Ligand A (0.02). This is a major advantage for Ligand B.
12. **Cl_mic:** Ligand B (2.928) has a much lower microsomal clearance than Ligand A (-14.689). This indicates better metabolic stability for Ligand B.
13. **t1/2:** Ligand A (12.812) has a longer in vitro half-life than Ligand B (-10.919). This is a slight advantage for Ligand A.
14. **Pgp:** Ligand B (0.034) has a lower Pgp efflux liability than Ligand A (0.032).
15. **Binding Affinity:** Ligand A (-5.5 kcal/mol) has a slightly better binding affinity than Ligand B (-1.4 kcal/mol). This is a substantial difference, but can be overcome by other factors.
**Overall Assessment:**
While Ligand A has a better binding affinity, Ligand B is superior in almost all ADME-Tox properties. Specifically, the significantly lower DILI risk, hERG inhibition, and microsomal clearance of Ligand B are crucial advantages. The slightly better half-life of Ligand A is not enough to compensate for these significant safety and pharmacokinetic liabilities. Both ligands have poor Caco-2 and solubility, which would require formulation work, but the other issues with Ligand A are more concerning. Given the GPCR target class, balancing potency with ADME properties is key, and Ligand B strikes a better balance.
Output:
0
2025-04-18 00:46:20,320 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (372.55 and 343.43 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (49.41) is significantly better than Ligand B (91.32). ADRB2 is not a CNS target, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold, while Ligand B is approaching it.
3. **logP:** Ligand A (3.403) is optimal, while Ligand B (1.567) is on the lower side. For a GPCR, a logP between 1-3 is preferred, and A is closer to the upper end of that range, suggesting better membrane permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (4). Similar reasoning as HBDs.
6. **QED:** Both ligands (0.697 and 0.708) have excellent QED scores, indicating good drug-likeness.
7. **DILI:** Ligand A (7.29%) has a much lower DILI risk than Ligand B (35.75%). This is a significant advantage for Ligand A.
8. **BBB:** This is less critical for ADRB2, but Ligand A (94.998%) is higher than Ligand B (53.315%).
9. **Caco-2:** Both are negative, indicating poor permeability. This is a concern for both, but the negative values are on a similar scale.
10. **Solubility:** Ligand A (-3.803) is better than Ligand B (-2.301), indicating better aqueous solubility.
11. **hERG:** Ligand A (0.844) is slightly higher than Ligand B (0.059), indicating a slightly higher risk of hERG inhibition. However, both are relatively low.
12. **Cl_mic:** Ligand B (7.74) has a significantly lower microsomal clearance than Ligand A (61.194), suggesting better metabolic stability. This is a strong point for Ligand B.
13. **t1/2:** Ligand B (-7.752) has a longer in vitro half-life than Ligand A (-12.931). This is another advantage for Ligand B.
14. **Pgp:** Ligand A (0.172) has lower P-gp efflux than Ligand B (0.014), which is favorable for bioavailability.
15. **Binding Affinity:** Both ligands have the same binding affinity (-7.6 kcal/mol). This eliminates affinity as a differentiating factor.
**Overall Assessment:**
Ligand A has advantages in TPSA, logP, HBD, HBA, DILI, Solubility, and Pgp efflux. Ligand B excels in metabolic stability (Cl_mic) and half-life. The lower DILI risk and better physicochemical properties (TPSA, logP) of Ligand A are more critical for initial drug development, especially considering the equal binding affinity. While metabolic stability is important, it can be addressed through structural modifications later in the optimization process. The poor Caco-2 values for both are a concern that would need to be addressed regardless of which ligand is chosen.
**Output:**
1
2025-04-18 00:46:20,320 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (354.491 and 349.41 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (76.66) is better than Ligand B (88.91). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands (1.875 and 1.777) are within the optimal 1-3 range. Very similar.
4. **HBD:** Both ligands have 2 HBD, which is acceptable.
5. **HBA:** Ligand A has 4 HBA, while Ligand B has 5. Ligand A is slightly preferable.
6. **QED:** Both ligands have good QED scores (0.698 and 0.793), indicating good drug-likeness. Ligand B is slightly better.
7. **DILI:** Ligand A (17.953) has a significantly lower DILI risk than Ligand B (72.819). This is a major advantage for Ligand A.
8. **BBB:** Both are moderate, but Ligand B (72.896) is slightly higher than Ligand A (64.482). Given ADRB2 is a cardiovascular target, BBB isn't a critical factor.
9. **Caco-2:** Both are negative, suggesting poor permeability. This is a concern for both.
10. **Solubility:** Both ligands have poor aqueous solubility (-2.117 and -2.634). This is a significant drawback for both, potentially impacting bioavailability.
11. **hERG:** Ligand A (0.3) has a lower hERG inhibition liability than Ligand B (0.069), indicating a lower risk of cardiotoxicity. This is a significant advantage for Ligand A.
12. **Cl_mic:** Ligand B (29.962) has a lower microsomal clearance than Ligand A (42.445), suggesting better metabolic stability. This is a benefit for Ligand B.
13. **t1/2:** Both have similar in vitro half-lives (6.148 and 6.803 hours).
14. **Pgp:** Both have low Pgp efflux liability (0.041 and 0.08).
15. **Binding Affinity:** Ligand B (-7.3 kcal/mol) has a slightly better binding affinity than Ligand A (-6.4 kcal/mol). This is a 0.9 kcal/mol difference, which is substantial.
**Overall Assessment:**
While Ligand B has a slightly better binding affinity and metabolic stability, Ligand A is significantly better in terms of safety (DILI and hERG) and has a slightly better TPSA and HBA count. The DILI risk for Ligand B is concerningly high. The affinity difference, while notable, can potentially be optimized during lead optimization. Given the importance of safety for a cardiovascular drug, and the relatively small difference in affinity, I would prioritize Ligand A.
Output:
1
2025-04-18 00:46:20,320 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (360.42 and 358.511 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (49.41) is better than Ligand B (51.02). Both are reasonably good, but lower TPSA generally favors absorption.
3. **logP:** Both ligands have good logP values (3.117 and 3.821), falling within the optimal 1-3 range. Ligand B is slightly higher, which *could* be a minor concern for solubility, but not a dealbreaker.
4. **HBD:** Ligand A (1) is preferable to Ligand B (0). While both are low, having one HBD can sometimes improve solubility without significantly impacting permeability.
5. **HBA:** Ligand A (2) is preferable to Ligand B (5). Lower HBA is generally favored for better permeability.
6. **QED:** Ligand A (0.841) is significantly better than Ligand B (0.756), indicating a more drug-like profile.
7. **DILI:** Ligand A (25.4%) is *much* better than Ligand B (55.5%). This is a major advantage for Ligand A. A DILI percentile below 40 is highly desirable.
8. **BBB:** Ligand A (93.5%) is significantly better than Ligand B (78.6%). While ADRB2 isn't exclusively a CNS target, some CNS penetration can be beneficial, and higher BBB is generally a positive attribute.
9. **Caco-2:** Ligand A (-4.552) is better than Ligand B (-5.318). Higher Caco-2 values indicate better intestinal absorption.
10. **Solubility:** Ligand A (-4.304) is better than Ligand B (-3.497). Higher aqueous solubility is always a plus.
11. **hERG:** Both ligands have low hERG inhibition liability (0.605 and 0.44), which is excellent. No significant difference.
12. **Cl_mic:** Ligand B (96.015) has a much lower microsomal clearance than Ligand A (19.768). This suggests better metabolic stability for Ligand B.
13. **t1/2:** Ligand B (3.127) has a longer in vitro half-life than Ligand A (-12.69). This is a significant advantage for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.101) is better than Ligand B (0.664). Lower P-gp efflux is desirable for improved bioavailability.
15. **Binding Affinity:** Ligand B (-7.1) has a *significantly* stronger binding affinity than Ligand A (-5.7). A 1.4 kcal/mol difference is substantial and can often outweigh minor ADME drawbacks.
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B excels in affinity and has acceptable logP and TPSA. The lower Pgp efflux is also a plus. While Ligand A has better TPSA, solubility, and BBB, the substantial difference in binding affinity and the concerning DILI risk for Ligand A outweigh these benefits. The longer half-life of Ligand B is also a considerable advantage.
**Conclusion:**
Despite Ligand A's better scores in several ADME properties, the significantly stronger binding affinity of Ligand B, coupled with its better metabolic stability (lower Cl_mic, longer t1/2) and acceptable ADME profile, makes it the more promising drug candidate. The lower DILI risk for Ligand A is attractive, but the affinity difference is too large to ignore.
Output:
0
2025-04-18 00:46:20,321 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's break down the comparison of Ligand A and Ligand B based on the provided parameters and the guidelines, keeping in mind ADRB2 is a GPCR.
1. **Molecular Weight:** Both ligands (357.3 and 370.3 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (56.15) is significantly better than Ligand B (91.49). For a GPCR, lower TPSA is generally preferred for better permeability. Ligand B is pushing the upper limit for good oral absorption.
3. **logP:** Both ligands have acceptable logP values (2.755 and 1.992, respectively), falling within the 1-3 range. Ligand B is slightly lower, which could potentially impact permeability, but isn't a major concern.
4. **H-Bond Donors:** Ligand A (1) is better than Ligand B (4). Fewer HBDs generally improve permeability.
5. **H-Bond Acceptors:** Ligand A (4) is slightly higher than Ligand B (3), but both are within the acceptable limit of 10.
6. **QED:** Ligand A (0.838) has a considerably higher QED score than Ligand B (0.472), indicating a more drug-like profile.
7. **DILI:** Both ligands have similar DILI risk (64.444 and 65.529), placing them in a moderate risk category. This isn't a deciding factor.
8. **BBB:** Ligand A (80.225) has a better BBB penetration score than Ligand B (66.576). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be beneficial for distribution and off-target effects.
9. **Caco-2 Permeability:** Ligand A (-4.546) is better than Ligand B (-5.031). Higher values indicate better absorption.
10. **Aqueous Solubility:** Ligand A (-3.288) is better than Ligand B (-2.873). Better solubility is always a plus.
11. **hERG Inhibition:** Ligand A (0.786) has a slightly better hERG profile than Ligand B (0.46). Lower is better.
12. **Microsomal Clearance:** Ligand B (13.278) has slightly better microsomal clearance than Ligand A (13.799), suggesting better metabolic stability. However, the difference is small.
13. **In vitro Half-Life:** Ligand B (-28.554) has a much better in vitro half-life than Ligand A (20.066). This is a significant advantage.
14. **P-gp Efflux:** Ligand A (0.279) has a better P-gp efflux profile than Ligand B (0.044). Lower efflux is preferred.
15. **Binding Affinity:** Ligand A (-9.0) has a significantly stronger binding affinity than Ligand B (-6.1). This is a crucial factor. A 2.9 kcal/mol difference is substantial and can outweigh many ADME concerns.
**Overall Assessment:**
Ligand A is the stronger candidate. Its superior binding affinity, TPSA, QED, BBB penetration, solubility, and P-gp efflux profile outweigh the slightly worse microsomal clearance and half-life compared to Ligand B. The strong binding affinity is particularly important for a GPCR target, and the better ADME properties of Ligand A suggest a higher probability of success.
Output:
1
2025-04-18 00:46:20,321 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (a cardiovascular GPCR) drug candidates.
**Ligand A:** [349.475, 74.57, 1.936, 2, 4, 0.634, 16.053, 55.021, -4.888, -2.1, 0.757, 45.354, 8.333, 0.218, -6.1]
**Ligand B:** [357.479, 47.36, 3.307, 0, 5, 0.797, 48.662, 86.468, -5.152, -3.171, 0.589, 70.662, -1.285, 0.504, -5.2]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). A is 349.475, B is 357.479. Very similar.
2. **TPSA:** A (74.57) is higher than B (47.36). B is significantly better, falling well below the 140 threshold for oral absorption and closer to the ideal for GPCRs.
3. **logP:** A (1.936) is good, within the 1-3 range. B (3.307) is a bit higher, but still acceptable.
4. **HBD:** A (2) is good. B (0) is excellent. Fewer HBDs generally improve permeability.
5. **HBA:** A (4) is good. B (5) is also acceptable.
6. **QED:** Both are good (A: 0.634, B: 0.797), indicating drug-like properties. B is slightly better.
7. **DILI:** A (16.053) is excellent, very low risk. B (48.662) is higher, but still reasonably low.
8. **BBB:** A (55.021) is moderate. B (86.468) is very good, significantly higher. This is a key advantage for a GPCR.
9. **Caco-2:** A (-4.888) is poor. B (-5.152) is also poor, but slightly better. Both suggest limited intestinal absorption.
10. **Solubility:** A (-2.1) is poor. B (-3.171) is worse. Solubility is a concern for both.
11. **hERG:** A (0.757) is good. B (0.589) is even better, lower risk of cardiotoxicity.
12. **Cl_mic:** A (45.354) is moderate. B (70.662) is higher, suggesting faster metabolism and potentially lower exposure.
13. **t1/2:** A (8.333) is okay. B (-1.285) is very poor, indicating rapid elimination.
14. **Pgp:** A (0.218) is good, suggesting low efflux. B (0.504) is moderate, suggesting some efflux.
15. **Affinity:** A (-6.1) is slightly better than B (-5.2), a 0.9 kcal/mol difference.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, BBB, and affinity. Ligand B excels in TPSA and BBB, which are crucial for GPCRs. While A has a slightly better affinity, the substantial advantage of B in TPSA and BBB, combined with its better hERG profile, outweighs the small difference in binding. The poor half-life of B is a concern, but can potentially be addressed through structural modifications.
**Conclusion:**
Considering the balance of properties and the specific requirements for a GPCR target, **Ligand B** is the more promising candidate.
0
2025-04-18 00:46:20,321 - INFO - Batch 502 complete. Total preferences: 8032
2025-04-18 00:46:20,321 - INFO - Processing batch 503/512...
2025-04-18 00:47:08,255 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (370.503 Da and 364.467 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (66.91) is well below the 140 threshold for oral absorption and is more favorable than Ligand B (87.66). For a cardiovascular target, CNS penetration isn't a primary concern, but lower TPSA generally aids absorption.
**3. logP:** Ligand A (4.44) is slightly high, potentially leading to solubility issues or off-target interactions, but still within a manageable range. Ligand B (0.529) is quite low, which could hinder membrane permeability and bioavailability. This is a significant drawback for a GPCR ligand.
**4. H-Bond Donors:** Ligand A (2) and Ligand B (3) are both acceptable, being less than 5.
**5. H-Bond Acceptors:** Ligand A (6) and Ligand B (5) are both acceptable, being less than 10.
**6. QED:** Ligand A (0.644) has a better QED score than Ligand B (0.527), indicating a more drug-like profile.
**7. DILI Risk:** Ligand B (37.107) has a much lower DILI risk than Ligand A (86.894). This is a very important factor.
**8. BBB Penetration:** Ligand A (70.415) has better BBB penetration than Ligand B (16.247), but this isn't a high priority for a cardiovascular target.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
**10. Aqueous Solubility:** Ligand A (-5.376) and Ligand B (-3.204) both have poor solubility, but Ligand B is slightly better.
**11. hERG Inhibition:** Ligand A (0.606) has a slightly higher hERG risk than Ligand B (0.193), which is preferable.
**12. Microsomal Clearance:** Ligand A (80.217) has higher clearance than Ligand B (25.598), meaning Ligand B is more metabolically stable.
**13. In vitro Half-Life:** Ligand A (72.594) has a longer half-life than Ligand B (12.034).
**14. P-gp Efflux:** Ligand A (0.739) has higher P-gp efflux than Ligand B (0.091), meaning Ligand B is less prone to efflux.
**15. Binding Affinity:** Ligand B (-7.0) has a slightly better binding affinity than Ligand A (-6.7). While a 1.5 kcal/mol difference is significant, the other ADME properties are more concerning.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand A has a better logP and TPSA. However, Ligand B demonstrates a significantly lower DILI risk, better metabolic stability (lower Cl_mic, longer t1/2), and lower P-gp efflux. The slightly better binding affinity of Ligand B is a bonus. The poor solubility of both is a concern, but can potentially be addressed through formulation. The low logP of Ligand B is a major drawback, potentially leading to poor absorption.
Despite the slightly better affinity of Ligand B, the combination of a higher logP, better metabolic stability, and lower DILI risk makes Ligand A the more promising candidate.
Output:
1
2025-04-18 00:47:08,256 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (350.463) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (40.62) is significantly better than Ligand A (104.53). For a GPCR, lower TPSA is preferred for better blood-brain barrier penetration and overall permeability.
3. **logP:** Both ligands have acceptable logP values (Ligand A: 1.144, Ligand B: 2.918), falling within the 1-3 range. Ligand B is closer to the optimal value.
4. **HBD/HBA:** Ligand A has 3 HBD and 3 HBA, while Ligand B has 0 HBD and 2 HBA. Both are within acceptable limits, but lower counts are generally preferred for permeability.
5. **QED:** Both ligands have good QED scores (Ligand A: 0.6, Ligand B: 0.72), indicating good drug-like properties.
6. **DILI:** Ligand A (22.567) has a significantly lower DILI risk than Ligand B (31.679), which is a major advantage.
7. **BBB:** Ligand B (94.61) has a much higher BBB penetration score than Ligand A (80.031). While ADRB2 isn't strictly a CNS target, some CNS exposure can be acceptable and even beneficial for certain cardiovascular indications.
8. **Caco-2:** Ligand A (-5.165) shows better Caco-2 permeability than Ligand B (-4.468).
9. **Solubility:** Both ligands have poor aqueous solubility (-2.769 and -3.926 respectively). This is a potential issue for both, but could be addressed with formulation strategies.
10. **hERG:** Ligand A (0.146) has a lower hERG inhibition liability than Ligand B (0.626), which is a critical safety advantage.
11. **Cl_mic:** Ligand A (25.535) has a significantly lower microsomal clearance than Ligand B (58.211), indicating better metabolic stability.
12. **t1/2:** Ligand A (-17.974) has a shorter in vitro half-life than Ligand B (-24.003), but both are negative values indicating rapid degradation.
13. **Pgp:** Ligand A (0.018) has a much lower P-gp efflux liability than Ligand B (0.156), which is favorable for both bioavailability and potential CNS exposure.
14. **Binding Affinity:** Ligand B (-7.5) has a slightly better binding affinity than Ligand A (-6.7). This is a 0.8 kcal/mol difference, which is significant.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. While Ligand B excels in affinity and BBB, Ligand A is better in terms of TPSA, Pgp efflux, and crucially, safety (DILI and hERG). The lower metabolic clearance of Ligand A is also a significant benefit.
**Overall Assessment:**
Despite Ligand B's slightly better binding affinity, the superior safety profile (lower DILI and hERG), better metabolic stability, and lower P-gp efflux of Ligand A make it the more promising drug candidate. The TPSA difference is also substantial. While solubility is a concern for both, it's a more tractable problem than significant safety liabilities.
Output:
1
2025-04-18 00:47:08,256 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (345.443 and 341.371 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (61.88) is significantly better than Ligand B (93.26). ADRB2 is a cardiovascular target, not CNS, but lower TPSA generally improves absorption. Ligand A is well below the 140 threshold, while B is approaching it.
3. **logP:** Both ligands have good logP values (1.65 and 1.303), falling within the optimal 1-3 range. Ligand B is slightly lower, which *could* be a minor drawback, but both are acceptable.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 3 HBA, while Ligand B has 6. Ligand A is preferable here, as higher HBA can sometimes hinder permeability.
6. **QED:** Ligand A (0.906) has a much better QED score than Ligand B (0.699), indicating a more drug-like profile. This is a significant advantage for Ligand A.
7. **DILI:** Ligand B (73.982) has a substantially higher DILI risk than Ligand A (34.393). This is a major concern, as we want to minimize liver toxicity.
8. **BBB:** Not a primary concern for a cardiovascular target like ADRB2, but Ligand A (76.735) is better than Ligand B (52.268).
9. **Caco-2:** Ligand A (-4.466) is better than Ligand B (-5.345). Higher Caco-2 permeability suggests better absorption.
10. **Solubility:** Both ligands have very poor aqueous solubility (-1.508 and -1.577). This is a significant issue for both, and will require formulation work.
11. **hERG:** Both ligands have very low hERG risk (0.247 and 0.221). This is good.
12. **Cl_mic:** Ligand A (-2.32) has a much lower (better) microsomal clearance than Ligand B (47.415). This indicates better metabolic stability for Ligand A.
13. **t1/2:** Ligand B (71.765) has a significantly longer in vitro half-life than Ligand A (-4.835). This is a positive for Ligand B.
14. **Pgp:** Ligand A (0.041) has lower P-gp efflux than Ligand B (0.078), which is preferable.
15. **Binding Affinity:** Ligand B (0.1) has a *much* better binding affinity than Ligand A (3.7). This is a very substantial advantage for Ligand B. A difference of 3.6 kcal/mol is substantial and can often outweigh other drawbacks.
**Overall Assessment:**
Ligand B has a significantly better binding affinity, and a longer half-life. However, it has a much higher DILI risk and higher microsomal clearance. Ligand A has a better overall ADME profile (QED, TPSA, solubility, Cl_mic, Pgp), but significantly weaker binding affinity.
Given the importance of potency for GPCR targets, and the substantial difference in binding affinity (3.6 kcal/mol), I believe Ligand B is the more promising candidate *despite* its ADME liabilities. The DILI risk is concerning, but could potentially be mitigated through structural modifications during lead optimization. The weaker binding of Ligand A would likely require a much higher dose to achieve therapeutic effect, potentially exacerbating other issues.
Output:
0
2025-04-18 00:47:08,256 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (354.29 & 346.43 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Both ligands (94.05 & 95.5) are reasonably low, suggesting good potential for absorption. They are below the 140 threshold, and acceptable for a peripheral GPCR like ADRB2.
3. **logP:** Ligand A (3.283) is slightly higher than Ligand B (2.028), placing it closer to the optimal 1-3 range. Ligand B is a bit low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (1) has fewer H-bond donors than Ligand B (3). Fewer donors are generally preferred for better permeability.
5. **HBA:** Ligand A (6) has more H-bond acceptors than Ligand B (3). While both are within the acceptable range, fewer is generally better.
6. **QED:** Ligand A (0.773) has a better QED score than Ligand B (0.637), indicating a more drug-like profile.
7. **DILI:** Ligand A (92.012) has a significantly higher DILI risk than Ligand B (41.14). This is a major concern for Ligand A.
8. **BBB:** Both are low, which is fine for a cardiovascular target like ADRB2.
9. **Caco-2:** Ligand A (-4.725) is better than Ligand B (-5.95).
10. **Solubility:** Ligand A (-4.166) is better than Ligand B (-1.177).
11. **hERG:** Both ligands show very low hERG inhibition risk (0.263 and 0.03).
12. **Cl_mic:** Ligand B (-7.896) has a negative clearance, which is highly unusual and suggests *very* high metabolic stability. Ligand A (67.584) is moderate.
13. **t1/2:** Ligand B (15.782) has a much longer half-life than Ligand A (-5.345).
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.156 and 0.012).
15. **Binding Affinity:** Both ligands have the same binding affinity (-6.3 kcal/mol).
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, and metabolic stability are important. While both have acceptable TPSA, Ligand A has a better logP. However, the *extremely* high DILI risk for Ligand A and the superior metabolic stability (Cl_mic and t1/2) of Ligand B are decisive. The longer half-life of Ligand B is also a significant advantage.
**Conclusion:**
Despite Ligand A having a slightly better logP and solubility, the significantly higher DILI risk and poorer metabolic stability outweigh these benefits. Ligand B's exceptional metabolic stability and lower DILI risk make it the more promising drug candidate.
Output:
0
2025-04-18 00:47:08,256 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**1. Molecular Weight:** Both ligands (341.426 and 354.401 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (38.33) is significantly better than Ligand B (74.33). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is quite high, potentially hindering absorption.
**3. logP:** Ligand A (4.713) is higher than Ligand B (1.137). While a logP of 4.713 is approaching the upper limit, it's still acceptable. Ligand B's logP is quite low, potentially causing permeability issues.
**4. H-Bond Donors:** Both have acceptable HBD counts (1 and 2 respectively), well below the threshold of 5.
**5. H-Bond Acceptors:** Both have acceptable HBA counts (2 and 4 respectively), well below the threshold of 10.
**6. QED:** Both ligands have similar and good QED values (0.826 and 0.803), indicating good drug-like properties.
**7. DILI:** Ligand A (42.42) has a higher DILI risk than Ligand B (14.036). This is a significant drawback for Ligand A.
**8. BBB:** Both ligands have good BBB penetration (78.17 and 70.88). Since ADRB2 is a cardiovascular target, BBB penetration is less critical, but still a positive.
**9. Caco-2 Permeability:** Ligand A (-4.367) has a worse Caco-2 permeability than Ligand B (-5.045). Both are negative, indicating poor permeability.
**10. Aqueous Solubility:** Ligand A (-5.681) has worse aqueous solubility than Ligand B (-1.481). Solubility is important for formulation.
**11. hERG Inhibition:** Ligand A (0.742) has a slightly higher hERG risk than Ligand B (0.425), but both are reasonably low.
**12. Microsomal Clearance:** Ligand B (-43.588) has significantly better metabolic stability (lower clearance) than Ligand A (63.566). This is a major advantage for Ligand B.
**13. In vitro Half-Life:** Ligand B (-10.318) has a much longer half-life than Ligand A (2.597). This is a significant advantage for Ligand B.
**14. P-gp Efflux:** Ligand A (0.211) has lower P-gp efflux than Ligand B (0.007). This is a slight advantage for Ligand A.
**15. Binding Affinity:** Ligand B (-7.2 kcal/mol) has a slightly better binding affinity than Ligand A (-6.6 kcal/mol). While the difference is not huge, it is still a factor.
**Overall Assessment:**
Ligand B is the better candidate. While Ligand A has slightly better P-gp efflux, Ligand B excels in several crucial areas: significantly lower DILI risk, much better metabolic stability (lower Cl_mic and longer half-life), better solubility, and slightly better binding affinity. The lower TPSA and logP of Ligand A are positives, but are outweighed by the significant safety and pharmacokinetic advantages of Ligand B. The higher TPSA of Ligand B is a concern, but the other benefits are more impactful for overall drug development potential.
Output:
0
2025-04-18 00:47:08,256 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [404.637, 95.52, 2.9, 2, 4, 0.799, 86.545, 18.069, -5.143, -3.749, 0.038, -17.471, -22.405, 0.034, -4.6]
**Ligand B:** [347.459, 69.72, 1.149, 1, 3, 0.811, 17.759, 71.539, -4.896, -2.635, 0.134, 10.657, 3.792, 0.053, -6.7]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, Affinity, and BBB):
1. **MW:** Both are within the acceptable range (200-500 Da). Ligand B (347.459) is slightly preferred due to being closer to the optimal lower end.
2. **TPSA:** Ligand A (95.52) is higher than Ligand B (69.72). Ligand B is significantly better here, being well under the 140 A^2 threshold for oral absorption and more favorable for GPCRs.
3. **logP:** Both are within the optimal 1-3 range. Ligand A (2.9) is slightly higher, which could potentially lead to off-target effects, while Ligand B (1.149) is on the lower side but still acceptable.
4. **HBD/HBA:** Ligand A (2/4) and Ligand B (1/3) both have reasonable H-bond donor/acceptor counts.
5. **QED:** Both have good QED scores (A: 0.799, B: 0.811), indicating good drug-like properties.
6. **DILI:** Ligand A (86.545) has a concerningly high DILI risk, while Ligand B (17.759) is excellent. This is a major drawback for Ligand A.
7. **BBB:** Ligand B (71.539) has a much better BBB penetration prediction than Ligand A (18.069). This is a significant advantage for a GPCR target.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests potential issues with permeability predictions. However, the magnitude is smaller for Ligand B (-4.896 vs -5.143).
9. **Solubility:** Both have negative solubility values, which is also unusual. Ligand B (-2.635) is slightly better than Ligand A (-3.749).
10. **hERG:** Both have very low hERG inhibition risk (A: 0.038, B: 0.134).
11. **Cl_mic:** Ligand A (-17.471) has a much lower (better) microsomal clearance than Ligand B (10.657), suggesting better metabolic stability.
12. **t1/2:** Ligand A (-22.405) has a very long in vitro half-life, while Ligand B (3.792) is shorter. This is a positive for Ligand A.
13. **Pgp:** Both have low Pgp efflux liability (A: 0.034, B: 0.053).
14. **Affinity:** Ligand B (-6.7 kcal/mol) has a significantly stronger binding affinity than Ligand A (-4.6 kcal/mol). This is a substantial advantage.
**Overall Assessment:**
While Ligand A has better metabolic stability (lower Cl_mic and longer t1/2), the significantly higher DILI risk, lower BBB penetration, and weaker binding affinity are major concerns. Ligand B excels in key GPCR properties (TPSA, BBB, Affinity) and has a much more favorable safety profile (DILI). The slight disadvantage in metabolic stability is likely outweighed by these benefits.
Therefore, I prefer Ligand B.
0
2025-04-18 00:47:08,257 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (351.403 and 350.463 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (116.76) is higher than Ligand B (85.25). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B has a clear advantage here.
3. **logP:** Ligand A (-1.32) is lower than the optimal 1-3 range, potentially hindering permeability. Ligand B (1.446) is within the optimal range. Ligand B is better.
4. **HBD:** Ligand A (4) is at the upper end of the preferred range (<=5), while Ligand B (2) is excellent. Ligand B is better.
5. **HBA:** Both ligands have 5 HBA, which is acceptable. No significant difference.
6. **QED:** Ligand B (0.669) has a better QED score than Ligand A (0.425), indicating a more drug-like profile. Ligand B is better.
7. **DILI:** Ligand A (33.695) has a slightly higher DILI risk than Ligand B (22.8), but both are below the 40% threshold considered good. A minor advantage to Ligand B.
8. **BBB:** Ligand A (29.003) has a low BBB penetration, as expected for a non-CNS target. Ligand B (65.839) has a significantly higher BBB penetration. While ADRB2 isn't primarily a CNS target, some off-target CNS effects are possible with GPCRs, and lower BBB penetration is generally preferred to minimize these. Ligand A is better.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual. Assuming these are percentile scores, Ligand B (-4.853) is slightly worse than Ligand A (-5.204). Ligand A is slightly better.
10. **Solubility:** Both ligands have poor solubility (-1.354 and -1.565). This is a concern for both. No significant difference.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.101 and 0.153). No significant difference.
12. **Cl_mic:** Ligand A (4.168) has significantly lower microsomal clearance than Ligand B (31.068), indicating better metabolic stability. Ligand A is better.
13. **t1/2:** Ligand B (18.346) has a much longer in vitro half-life than Ligand A (-10.535). This is a significant advantage for Ligand B.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.007 and 0.017). No significant difference.
15. **Binding Affinity:** Ligand B (-7.4 kcal/mol) has a 0.6 kcal/mol stronger binding affinity than Ligand A (-6.8 kcal/mol). This is a substantial difference and a major advantage for Ligand B.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand B excels in logP, TPSA, and significantly in affinity. While BBB is less critical, the lower value for Ligand A is preferable. Metabolic stability (Cl_mic) is also important, and Ligand A has a clear advantage there. However, the superior binding affinity and overall drug-like properties of Ligand B outweigh the metabolic stability advantage of Ligand A.
**Conclusion:**
Ligand B demonstrates a superior balance of properties, particularly its optimal logP, lower TPSA, better QED, and significantly stronger binding affinity. While Ligand A has better metabolic stability, the potency advantage of Ligand B is more critical for a GPCR target.
Output:
0
2025-04-18 00:47:08,257 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, key priorities are logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB.
Let's compare the ligands property by property:
1. **MW:** Both ligands (348.45 & 348.38 Da) are within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (85.77) is slightly higher than Ligand B (76.46). Both are below the 140 threshold for oral absorption, but B is preferable.
3. **logP:** Both ligands (0.952 & 0.923) are within the optimal 1-3 range. Very similar.
4. **HBD:** Ligand A (2) has one more HBD than Ligand B (1). B is preferable.
5. **HBA:** Both ligands have 5 HBA, which is acceptable.
6. **QED:** Ligand B (0.803) has a slightly better QED score than Ligand A (0.766), indicating better overall drug-likeness.
7. **DILI:** Ligand A (18.651) has a significantly lower DILI risk than Ligand B (60.682). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (72.664) has a higher BBB penetration than Ligand A (36.371). While not a primary concern for a cardiovascular target, it's a slight positive for B.
9. **Caco-2:** Ligand A (-5.2) has a worse Caco-2 permeability than Ligand B (-4.47). B is preferable.
10. **Solubility:** Ligand A (-1.348) has better solubility than Ligand B (-3.134). A is preferable.
11. **hERG:** Both ligands have low hERG inhibition risk (0.245 & 0.333).
12. **Cl_mic:** Ligand A (-23.136) has a much lower (better) microsomal clearance than Ligand B (25.904), indicating greater metabolic stability. This is a significant advantage for A.
13. **t1/2:** Ligand B (-24.082) has a longer in vitro half-life than Ligand A (-12.494). B is preferable.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.009 & 0.052).
15. **Binding Affinity:** Ligand B (-6.4) has a slightly better binding affinity than Ligand A (-6.1). This is a small advantage for B.
**Overall Assessment:**
Ligand A has a substantial advantage in DILI risk and metabolic stability (Cl_mic). Ligand B has a slightly better QED, Caco-2 permeability, half-life, and binding affinity. Considering the GPCR target class, a balance of properties is crucial. The significantly lower DILI risk and improved metabolic stability of Ligand A are more important for long-term viability and safety than the minor improvements in permeability and binding seen in Ligand B.
**Output:**
1
2025-04-18 00:47:08,257 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Step-by-step comparison:**
1. **MW:** Ligand A (361.438 Da) is within the ideal range, while Ligand B (346.431 Da) is also acceptable. No clear advantage here.
2. **TPSA:** Ligand A (55.4) is excellent, well below the 140 threshold for oral absorption. Ligand B (96.11) is higher, but still within a reasonable range for a non-CNS target.
3. **logP:** Ligand A (4.927) is slightly high, potentially leading to solubility issues or off-target interactions. Ligand B (1.882) is optimal. This favors Ligand B.
4. **HBD:** Ligand A (1) is good. Ligand B (3) is acceptable, but slightly higher.
5. **HBA:** Both ligands have 4 HBA, which is good.
6. **QED:** Both ligands have similar QED scores (0.769 and 0.758), indicating good drug-likeness.
7. **DILI:** Ligand A (80.186) has a significantly higher DILI risk than Ligand B (54.362). This is a major concern for Ligand A.
8. **BBB:** ADRB2 is a cardiovascular target, so BBB penetration is not a primary concern. Ligand A (77.627) is higher than Ligand B (34.626), but this is less important.
9. **Caco-2:** Ligand A (-4.28) is better than Ligand B (-5.331), suggesting better intestinal absorption.
10. **Solubility:** Ligand A (-6.116) is worse than Ligand B (-2.841). This is concerning given Ligand A's higher logP.
11. **hERG:** Both ligands have low hERG inhibition risk (0.346 and 0.207).
12. **Cl_mic:** Ligand A (118.638) has a higher microsomal clearance than Ligand B (37.768), indicating lower metabolic stability. This favors Ligand B.
13. **t1/2:** Ligand A (50.789) has a longer in vitro half-life than Ligand B (-12.578). This is a positive for Ligand A.
14. **Pgp:** Ligand A (0.334) has lower P-gp efflux liability than Ligand B (0.112), which is good.
15. **Affinity:** Ligand B (-7.3 kcal/mol) has a significantly stronger binding affinity than Ligand A (-4.3 kcal/mol). This is a substantial advantage for Ligand B.
**GPCR-specific priorities:** For GPCRs, logP, Pgp, TPSA, and affinity are key. Ligand B excels in logP and affinity, and has acceptable TPSA and Pgp.
**Overall Assessment:**
Ligand B is the better candidate. While Ligand A has a longer half-life and slightly better Caco-2 permeability, its high DILI risk, higher logP, lower solubility, and significantly weaker binding affinity are major drawbacks. Ligand B's superior affinity and lower toxicity profile outweigh the slightly shorter half-life.
Output:
0
2025-04-18 00:47:08,257 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (358.435 and 344.375 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (113.96) is better than Ligand B (125.02), being closer to the <140 threshold for good oral absorption. This is a slight advantage for A.
3. **logP:** Ligand A (-0.16) is a bit low, potentially hindering permeation. Ligand B (0.505) is better, falling within the optimal 1-3 range. Advantage B.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (2), but both are within the acceptable limit of <=5. No significant difference.
5. **HBA:** Ligand A (6) is lower than Ligand B (7), which is preferable.
6. **QED:** Ligand B (0.753) has a significantly better QED score than Ligand A (0.494), indicating a more drug-like profile. Advantage B.
7. **DILI:** Ligand A (25.708) has a much lower DILI risk than Ligand B (56.572). This is a substantial advantage for A.
8. **BBB:** Ligand B (71.733) has a better BBB penetration score than Ligand A (53.121). Given ADRB2 is a GPCR, and potential CNS effects are relevant, this is an advantage for B.
9. **Caco-2:** Both ligands have negative Caco-2 values, suggesting poor permeability. Ligand A (-4.942) is slightly better than Ligand B (-5.453), but both are concerning.
10. **Solubility:** Both ligands have negative solubility values, indicating poor aqueous solubility. Ligand A (-1.564) is slightly better than Ligand B (-1.069), but both are concerning.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.118 and 0.04), which is excellent. No difference.
12. **Cl_mic:** Ligand B (15.839) has a much lower microsomal clearance than Ligand A (54.352), indicating better metabolic stability. Advantage B.
13. **t1/2:** Ligand A (-50.805) has a more negative in vitro half-life, which means a shorter half-life. Ligand B (-10.586) is better. Advantage B.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.041 and 0.037), which is excellent. No difference.
15. **Binding Affinity:** Ligand A (-6.1) has a slightly better binding affinity than Ligand B (-6.0). However, the difference is small (0.1 kcal/mol) and may not be enough to overcome other deficiencies.
**Overall Assessment:**
While Ligand A has a lower DILI risk and slightly better affinity, Ligand B demonstrates a superior overall profile for a GPCR target like ADRB2. Ligand B has a better logP, QED, BBB penetration, metabolic stability (lower Cl_mic), and longer half-life. The slightly lower DILI risk of A is outweighed by the other advantages of B. The poor Caco-2 and solubility of both are concerning and would require formulation work, but the other ADME properties of B are more favorable.
Output:
0
2025-04-18 00:47:08,257 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (378.519) is slightly higher than Ligand B (356.482), but both are acceptable.
2. **TPSA:** Both are reasonably low, but Ligand A (66.48) is better than Ligand B (69.64). For a GPCR, lower TPSA is generally preferred for better permeability.
3. **logP:** Both ligands have good logP values (A: 3.241, B: 2.419), falling within the optimal 1-3 range. Ligand A is slightly higher, which *could* be a minor concern for solubility, but is still acceptable.
4. **HBD:** Ligand A (1) is better than Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is better than Ligand B (3). Fewer HBAs generally improve permeability.
6. **QED:** Both have reasonable QED scores (A: 0.888, B: 0.736), indicating good drug-like properties. Ligand A is superior.
7. **DILI:** Ligand A (60.062) has a higher DILI risk than Ligand B (13.3). This is a significant drawback for Ligand A.
8. **BBB:** Ligand A (89.531) has better BBB penetration than Ligand B (76.735). While ADRB2 isn't exclusively a CNS target, some CNS exposure or off-target effects are possible, so higher BBB is a plus.
9. **Caco-2:** Ligand A (-5.032) has worse Caco-2 permeability than Ligand B (-4.669). Lower (more negative) values indicate lower permeability.
10. **Solubility:** Ligand A (-3.826) has worse solubility than Ligand B (-2.228). Solubility is important for bioavailability.
11. **hERG:** Both ligands have low hERG inhibition risk (A: 0.635, B: 0.416), which is good. Ligand B is slightly better.
12. **Cl_mic:** Ligand B (21.807) has lower microsomal clearance than Ligand A (26.241), indicating better metabolic stability.
13. **t1/2:** Ligand B (-10.409) has a longer in vitro half-life than Ligand A (32.716). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.513) has slightly lower P-gp efflux than Ligand B (0.058), which is favorable.
15. **Affinity:** Ligand A (-8.2 kcal/mol) has significantly better binding affinity than Ligand B (-6.9 kcal/mol). This is a substantial advantage, exceeding the 1.5 kcal/mol threshold.
**Overall Assessment:**
Ligand A has a significantly better binding affinity, which is the most important factor for a GPCR target. It also has better BBB penetration, QED, Pgp efflux, and slightly better TPSA. However, it suffers from a higher DILI risk, worse solubility, worse Caco-2 permeability, and a shorter half-life. Ligand B has a much better safety profile (DILI, hERG), better metabolic stability (Cl_mic, t1/2), and solubility.
The difference in binding affinity (-8.2 vs -6.9) is substantial. While the ADME properties of Ligand A are less ideal, the potency advantage is likely to outweigh these concerns, *especially* if further optimization can address the DILI and solubility issues.
Output:
1
2025-04-18 00:47:08,258 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.475 and 362.455 Da) are within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (98.66) is slightly higher than Ligand B (87.46). Both are below the 140 threshold for oral absorption, but B is better positioned for potential CNS penetration if desired.
3. **logP:** Ligand A (0.955) is a bit low, potentially hindering permeability. Ligand B (2.05) is closer to the optimal 1-3 range. This favors Ligand B.
4. **HBD:** Ligand A (4) is acceptable, while Ligand B (2) is even better, reducing potential for off-target interactions and improving permeability.
5. **HBA:** Ligand A (4) and Ligand B (6) are both reasonable, below the 10 threshold.
6. **QED:** Ligand B (0.823) has a significantly better QED score than Ligand A (0.572), indicating a more drug-like profile.
7. **DILI:** Ligand A (14.424) has a much lower DILI risk than Ligand B (64.25). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (24.738) has a lower BBB penetration percentile than Ligand B (33.385). For a cardiovascular target like ADRB2, BBB penetration is not a primary concern, so this difference is less critical.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.172 and -5.383), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Both ligands have negative solubility values (-2.354 and -2.427), which is also concerning. Poor solubility can hinder bioavailability.
11. **hERG:** Ligand A (0.185) has a much lower hERG inhibition liability than Ligand B (0.516), indicating a lower risk of cardiotoxicity. This is a crucial advantage for Ligand A, given the cardiovascular target.
12. **Cl_mic:** Ligand A (-6.533) has a much lower (better) microsomal clearance than Ligand B (37.844), suggesting better metabolic stability.
13. **t1/2:** Ligand A (20.392) has a significantly longer in vitro half-life than Ligand B (-0.153). This is a major advantage for Ligand A, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.038) has much lower P-gp efflux liability than Ligand B (0.299), which is favorable for oral bioavailability.
15. **Affinity:** Both ligands have very similar binding affinities (-7.0 and -6.4 kcal/mol). The difference of 0.6 kcal/mol is not substantial enough to outweigh other factors.
**Overall Assessment:**
While Ligand B has a better QED and logP, Ligand A demonstrates significantly better safety profiles (DILI, hERG) and pharmacokinetic properties (Cl_mic, t1/2, Pgp). The negative Caco-2 and solubility values are concerning for both, but the superior ADME-Tox profile of Ligand A, particularly the lower DILI and hERG risk, makes it the more promising candidate for development as a cardiovascular drug targeting ADRB2. The slightly better affinity of Ligand A is a bonus.
Output:
1
2025-04-18 00:47:08,258 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (384.479 Da) and Ligand B (360.447 Da) both fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (100.62) is better than Ligand B (118.61). Both are under the 140 A^2 threshold for good oral absorption, but lower TPSA is generally preferred for GPCRs.
3. **logP:** Ligand B (0.947) is slightly better than Ligand A (0.314). Both are within the 1-3 range, but A is a bit low, potentially impacting permeability.
4. **HBD:** Ligand A (1) is better than Ligand B (2). Lower HBD is preferred for better permeability.
5. **HBA:** Ligand A (5) is better than Ligand B (8). Lower HBA is preferred for better permeability.
6. **QED:** Ligand A (0.791) is significantly better than Ligand B (0.617), indicating a more drug-like profile.
7. **DILI:** Ligand B (56.262) is significantly better than Ligand A (78.325), indicating a lower risk of drug-induced liver injury. This is a crucial factor.
8. **BBB:** Ligand A (53.936) is better than Ligand B (35.13). While ADRB2 isn't strictly a CNS target, some CNS penetration can be beneficial for understanding off-target effects and potential side effects.
9. **Caco-2:** Ligand A (-5.291) is better than Ligand B (-6.183). Higher Caco-2 permeability is preferred, suggesting better absorption.
10. **Solubility:** Ligand A (-3.509) is better than Ligand B (-1.375). Higher solubility is generally preferred.
11. **hERG:** Ligand A (0.165) is significantly better than Ligand B (0.523), indicating a lower risk of cardiotoxicity. This is a critical consideration for a cardiovascular target.
12. **Cl_mic:** Ligand B (-2.444) is significantly better than Ligand A (16.792), suggesting better metabolic stability.
13. **t1/2:** Ligand A (56.417) is significantly better than Ligand B (-18.053), indicating a longer half-life.
14. **Pgp:** Ligand A (0.084) is significantly better than Ligand B (0.024), indicating lower P-gp efflux.
15. **Affinity:** Ligand A (-8.0) is better than Ligand B (-5.2). This is a substantial difference in binding affinity.
**Overall Assessment:**
Ligand A has a significantly better binding affinity (-8.0 kcal/mol vs -5.2 kcal/mol). This is a major advantage. It also has better QED, TPSA, Caco-2 permeability, solubility, hERG inhibition profile, Pgp efflux, and in vitro half-life. While Ligand B has a better DILI score and microsomal clearance, the substantial advantage in binding affinity and the better overall ADME profile of Ligand A make it the more promising candidate. The hERG risk is also substantially lower for Ligand A, which is crucial for a cardiovascular target.
Output:
1
2025-04-18 00:47:08,258 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**1. Molecular Weight:** Both ligands (366.38 Da and 346.406 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (75.71) is slightly higher than Ligand B (67.23). Both are below the 140 A^2 threshold for good oral absorption, but closer to the 90 A^2 threshold for CNS targets. This is acceptable for a cardiovascular target, but lower is generally preferred.
**3. logP:** Both ligands have good logP values (1.675 and 2.317, respectively), falling within the optimal 1-3 range. Ligand B is slightly higher, which could potentially improve membrane permeability.
**4. H-Bond Donors:** Both ligands have 1 HBD, which is within the acceptable limit of <=5.
**5. H-Bond Acceptors:** Both ligands have 4 HBA, which is within the acceptable limit of <=10.
**6. QED:** Ligand A (0.751) has a slightly better QED score than Ligand B (0.657), indicating a more drug-like profile.
**7. DILI Risk:** Ligand B (58.55) has a lower DILI risk than Ligand A (40.558), which is a significant advantage. Lower DILI risk is crucial for drug development.
**8. BBB Penetration:** Both ligands have good BBB penetration (73.401 and 76.231). This isn't a primary concern for a cardiovascular target, but it's not detrimental.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.549 and -4.619). These values are unusual and suggest poor permeability. It's difficult to interpret these values without further context, but they are a concern for both compounds.
**10. Aqueous Solubility:** Both ligands have negative solubility values (-2.694 and -2.285). These values are also unusual and suggest very poor solubility. This is a significant drawback for both compounds.
**11. hERG Inhibition:** Ligand A (0.387) has a lower hERG inhibition liability than Ligand B (0.604), which is a positive.
**12. Microsomal Clearance:** Ligand B (35.187) has slightly higher microsomal clearance than Ligand A (32.988), indicating faster metabolism.
**13. In vitro Half-Life:** Ligand A (-25.373) has a significantly longer in vitro half-life than Ligand B (2.115), which is a major advantage.
**14. P-gp Efflux:** Ligand A (0.053) has lower P-gp efflux liability than Ligand B (0.278), which is a positive.
**15. Binding Affinity:** Ligand A (-6.7 kcal/mol) has a slightly better binding affinity than Ligand B (-5.8 kcal/mol). This 0.9 kcal/mol difference is substantial and could outweigh some of the ADME drawbacks.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand A appears to be a better candidate. While Ligand B has a lower DILI risk, Ligand A has a significantly better binding affinity, longer half-life, lower P-gp efflux, and lower hERG inhibition. The slightly better QED score also favors Ligand A. The poor solubility and permeability are concerns for both, but the superior potency and pharmacokinetic properties of Ligand A make it the more promising candidate.
Output:
1
2025-04-18 00:47:08,258 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (346.435 and 345.443 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (107.83) is higher than Ligand B (75.44). For a cardiovascular GPCR, TPSA is moderately important. Ligand B's lower TPSA is preferable, suggesting better potential for membrane permeability.
**3. logP:** Both ligands have acceptable logP values (1.794 and 2.54), falling within the 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability, but not dramatically so.
**4. H-Bond Donors:** Ligand A has 2 HBDs, and Ligand B has 1. Both are within the acceptable limit of <=5.
**5. H-Bond Acceptors:** Ligand A has 6 HBAs, and Ligand B has 4. Both are within the acceptable limit of <=10.
**6. QED:** Both ligands have similar QED values (0.71 and 0.609), indicating good drug-likeness.
**7. DILI Risk:** Ligand A (52.346) has a higher DILI risk than Ligand B (32.842). This is a significant advantage for Ligand B.
**8. BBB Penetration:** Both ligands have reasonable BBB penetration (68.554 and 70.997). While not CNS targets, some degree of BBB penetration can influence off-target effects. Ligand B is slightly better.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-5.195 and -4.877). This is unusual and suggests poor permeability *in vitro*. However, these values are on a similar scale, so the difference isn't decisive.
**10. Aqueous Solubility:** Both ligands have very poor aqueous solubility (-2.34 and -2.115). This is a significant drawback for both, and formulation challenges are expected.
**11. hERG Inhibition:** Ligand A (0.06) has a slightly lower hERG inhibition risk than Ligand B (0.331). This is a positive for Ligand A, as cardiotoxicity is a concern with GPCR ligands.
**12. Microsomal Clearance:** Ligand A (21.329) has a higher microsomal clearance than Ligand B (11.719), indicating faster metabolism and potentially lower *in vivo* exposure. Ligand B is preferable here.
**13. In vitro Half-Life:** Ligand A (-1.237) has a very short half-life, while Ligand B (-21.692) is also short, but less so. This is a significant negative for both, but more so for Ligand A.
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (0.214 and 0.225).
**15. Binding Affinity:** Ligand B (-6.1 kcal/mol) has a significantly stronger binding affinity than Ligand A (-3.6 kcal/mol). This is a crucial advantage, as a 2.5 kcal/mol difference is substantial and can outweigh many ADME concerns.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand B is the stronger candidate. Its superior binding affinity is the most important factor. It also has a lower DILI risk, lower microsomal clearance, and better TPSA. While both have poor solubility and permeability, the affinity advantage of Ligand B is compelling.
Output:
0
2025-04-18 00:47:08,258 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.5 and 349.4 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (52.65) is significantly better than Ligand B (71.53). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is getting towards the upper limit for good oral absorption.
3. **logP:** Both ligands have good logP values (2.375 and 1.807), falling within the optimal 1-3 range. Ligand B is slightly lower, which *could* indicate slightly better solubility, but the difference isn't huge.
4. **HBD:** Both have 1 HBD, which is ideal.
5. **HBA:** Ligand A has 3 HBA, and Ligand B has 4. Both are acceptable, but lower is generally preferred.
6. **QED:** Both ligands have good QED scores (0.746 and 0.85), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (7.057) has a considerably lower DILI risk than Ligand B (38.387). This is a significant advantage for Ligand A.
8. **BBB:** Ligand B (88.561) has a much higher BBB penetration percentile than Ligand A (63.823). While ADRB2 isn't strictly a CNS target, some CNS exposure can be acceptable or even desirable for peripheral effects. However, this is less critical than other factors.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. Ligand A (-4.714) is slightly better than Ligand B (-4.366), but both are concerning.
10. **Solubility:** Ligand A (-1.342) has a slightly better solubility score than Ligand B (-2.814), but both are poor.
11. **hERG:** Ligand A (0.773) shows a lower hERG inhibition liability than Ligand B (0.544), which is a positive.
12. **Cl_mic:** Ligand B (24.619) has significantly lower microsomal clearance than Ligand A (41.721), indicating better metabolic stability. This is a substantial advantage for Ligand B.
13. **t1/2:** Ligand B (-39.122) has a much longer in vitro half-life than Ligand A (6.279). This is a major advantage for Ligand B.
14. **Pgp:** Ligand A (0.017) has a much lower P-gp efflux liability than Ligand B (0.05). This is a positive for Ligand A.
15. **Affinity:** Ligand B (-6.9 kcal/mol) has a slightly better binding affinity than Ligand A (-6.6 kcal/mol), but the difference is small.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), and the general drug-like properties, Ligand B emerges as the more promising candidate. The significantly improved metabolic stability (lower Cl_mic) and longer half-life are crucial advantages. While Ligand A has better DILI and Pgp scores, the metabolic profile of Ligand B is more favorable. The slightly better BBB penetration of Ligand B is a minor bonus. The small difference in affinity is outweighed by the ADME benefits of Ligand B. The poor Caco-2 and solubility of both are concerns, but can potentially be addressed with formulation strategies.
Output:
0
2025-04-18 00:47:08,258 - INFO - Batch 503 complete. Total preferences: 8048
2025-04-18 00:47:08,259 - INFO - Processing batch 504/512...
2025-04-18 00:47:58,561 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (a cardiovascular GPCR) drug candidates.
**Ligand A:** [346.387, 128.16 , -0.459, 3. , 5. , 0.575, 37.456, 35.44 ,
-5.668, -2.107, 0.051, -16.242, 10.779, 0.003, -8.5 ]
**Ligand B:** [356.463, 95.94 , 1.09 , 2. , 5. , 0.666, 21.598, 40.171,
-4.699, -2.304, 0.196, 60.656, -19.393, 0.044, -5.7 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). A (346.39) is slightly preferred.
2. **TPSA:** A (128.16) is a bit higher than ideal for GPCRs, but still acceptable. B (95.94) is excellent, well below the 140 threshold and very favorable for permeability.
3. **logP:** A (-0.459) is a little low, potentially hindering membrane permeability. B (1.09) is much better, falling within the optimal 1-3 range.
4. **HBD:** A (3) is acceptable. B (2) is slightly better.
5. **HBA:** Both have 5 HBA, which is acceptable.
6. **QED:** Both are good (A: 0.575, B: 0.666), indicating drug-like properties. B is slightly better.
7. **DILI:** A (37.46) is better than B (21.60), indicating lower liver injury risk.
8. **BBB:** B (40.17) is better than A (35.44), but neither is particularly high. For a cardiovascular target, BBB penetration isn't a major priority, but it's a slight edge for B.
9. **Caco-2:** A (-5.668) is a negative value, which is unusual and suggests very poor permeability. B (-4.699) is also poor, but less so.
10. **Solubility:** Both are very poor (-2.107 and -2.304). This is a significant concern for both.
11. **hERG:** Both are very low (A: 0.051, B: 0.196), indicating minimal hERG inhibition risk.
12. **Cl_mic:** A (-16.242) is much better (lower is preferred) than B (60.656), suggesting significantly better metabolic stability.
13. **t1/2:** A (10.779) is better than B (-19.393), indicating a longer half-life.
14. **Pgp:** Both are very low (A: 0.003, B: 0.044), suggesting minimal P-gp efflux.
15. **Affinity:** A (-8.5) is significantly better than B (-5.7), representing a substantial difference in binding potency.
**GPCR-specific priorities:** For ADRB2 (a cardiovascular GPCR), we prioritize logP, TPSA, affinity, and metabolic stability.
**Overall Assessment:**
Ligand A has a much stronger binding affinity, significantly better metabolic stability (Cl_mic and t1/2), and a lower DILI risk. However, it suffers from a low logP and poor Caco-2 permeability. Ligand B has a better logP and TPSA, but significantly weaker binding affinity and poorer metabolic stability. The large difference in binding affinity (-8.5 vs -5.7 kcal/mol) is a major advantage for Ligand A. While the solubility and permeability are concerns for both, the potency advantage of A is likely to outweigh these issues, especially given the cardiovascular target (where CNS penetration is less critical).
Therefore, I would choose Ligand A.
Output:
1
2025-04-18 00:47:58,562 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.415 and 356.256 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (87.74) is better than Ligand B (98.61). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (2.473) is better than Ligand A (0.355). A logP between 1-3 is optimal, and Ligand B is within this range. Ligand A is quite low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1), but both are acceptable (<=5).
5. **HBA:** Ligand B (6) is higher than Ligand A (4), but both are within the acceptable range (<=10).
6. **QED:** Both ligands have good QED scores (0.703 and 0.794, respectively), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (36.914) is *significantly* better than Ligand B (95.347). This is a major advantage for Ligand A. A DILI percentile above 60 is concerning.
8. **BBB:** Ligand B (64.211) is better than Ligand A (48.275), but as ADRB2 is a cardiovascular target, BBB penetration is not a high priority.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.729 and -4.591). These values are difficult to interpret without knowing the scale, but negative values suggest poor permeability.
10. **Solubility:** Ligand A (-2.289) is slightly better than Ligand B (-3.498), but both are poor. Solubility is a concern for both.
11. **hERG:** Both ligands have very low hERG risk (0.099 and 0.087). This is excellent.
12. **Cl_mic:** Ligand A (-22.21) has a much lower (better) microsomal clearance than Ligand B (47.919). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (-18.401) has a slightly better in vitro half-life than Ligand B (-17.659).
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.019 and 0.129). This is good.
15. **Binding Affinity:** Ligand B (-7.8 kcal/mol) has a significantly better binding affinity than Ligand A (-3.6 kcal/mol). This is a substantial advantage, exceeding the 1.5 kcal/mol threshold.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand B excels in logP and affinity, while Ligand A has a better TPSA. However, the *magnitude* of the affinity difference for Ligand B is very significant. The DILI risk for Ligand B is also a major concern.
**Overall Assessment:**
While Ligand A has advantages in DILI risk and metabolic stability, the significantly stronger binding affinity of Ligand B (-7.8 vs -3.6 kcal/mol) is a decisive factor. The improved logP of Ligand B is also beneficial. The high DILI risk of Ligand B is a concern, but could potentially be mitigated through structural modifications in later stages of optimization.
Output:
0
2025-04-18 00:47:58,562 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [349.387, 109.78 , 0.816, 3. , 6. , 0.629, 49.709, 63.203, -5.186, -2.571, 0.217, 15.318, -7.021, 0.008, -6.5 ]
**Ligand B:** [342.443, 57.92 , 2.385, 0. , 4. , 0.726, 41.877, 70.997, -4.566, -1.522, 0.755, 69.972, 25.402, 0.248, -4.6 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (342.443) is slightly lower, which is generally favorable.
2. **TPSA:** Ligand A (109.78) is higher than Ligand B (57.92). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is still preferred for permeability. Ligand B is significantly better here.
3. **logP:** Ligand A (0.816) is a bit low, potentially hindering membrane permeability. Ligand B (2.385) is within the optimal range (1-3). Ligand B is better.
4. **HBD:** Ligand A (3) is acceptable, Ligand B (0) is even better. Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (6) is acceptable, Ligand B (4) is better.
6. **QED:** Both are good (A: 0.629, B: 0.726), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (49.709) is slightly higher than Ligand B (41.877), indicating a marginally higher risk of liver injury. Ligand B is preferred.
8. **BBB:** Ligand B (70.997) has a significantly higher BBB penetration percentile than Ligand A (63.203). While ADRB2 isn't *primarily* a CNS target, some degree of BBB penetration can be helpful for off-target effects and overall distribution.
9. **Caco-2:** Ligand A (-5.186) is worse than Ligand B (-4.566), indicating lower intestinal absorption.
10. **Solubility:** Ligand A (-2.571) is worse than Ligand B (-1.522). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.217) is better than Ligand B (0.755), indicating lower cardiotoxicity risk. This is a crucial factor for a cardiovascular target.
12. **Cl_mic:** Ligand A (15.318) has a much lower microsomal clearance than Ligand B (69.972), suggesting better metabolic stability.
13. **t1/2:** Ligand B (25.402) has a longer half-life than Ligand A (-7.021), which is desirable for less frequent dosing.
14. **Pgp:** Ligand A (0.008) has much lower P-gp efflux than Ligand B (0.248), which is good for bioavailability.
15. **Affinity:** Ligand A (-6.5) is slightly better than Ligand B (-4.6). A difference of 1.9 kcal/mol is substantial and can often outweigh minor ADME drawbacks.
**Overall Assessment:**
Ligand A has a better binding affinity and lower Pgp efflux, but Ligand B excels in almost every other ADME property: TPSA, logP, DILI, BBB, Caco-2, solubility, and metabolic stability (Cl_mic and t1/2). The hERG risk is a concern for Ligand B, but the affinity difference is not large enough to overcome the significant ADME advantages of Ligand B. For a cardiovascular GPCR, a balance of potency and good ADME properties is crucial.
Therefore, I prefer Ligand B.
0
2025-04-18 00:47:58,562 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (371.5 and 344.5 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (89.35) is better than Ligand B (48.47), being closer to the upper limit for good oral absorption but still acceptable. Lower TPSA is generally preferred for GPCRs. Ligand B is excellent.
3. **logP:** Ligand B (2.757) is optimal, while Ligand A (0.857) is a bit low, potentially hindering membrane permeability. This favors Ligand B.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 7 HBA, acceptable. Ligand B has 4 HBA, also acceptable.
6. **QED:** Both ligands have similar QED values (0.765 and 0.773), indicating good drug-likeness.
7. **DILI:** Ligand B (25.359) has a significantly lower DILI risk than Ligand A (47.15). This is a major advantage for Ligand B.
8. **BBB:** Ligand B (89.957) has a much higher BBB penetration potential than Ligand A (67.08). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant for side effect profiles, and higher BBB is generally favorable.
9. **Caco-2:** Ligand A (-5.403) has a more negative Caco-2 value, indicating *better* permeability than Ligand B (-4.722).
10. **Solubility:** Ligand A (-1.539) has better solubility than Ligand B (-2.322).
11. **hERG:** Ligand A (0.48) has a lower hERG risk than Ligand B (0.779). This is a slight advantage for Ligand A.
12. **Cl_mic:** Ligand A (-6.955) has significantly lower microsomal clearance, indicating better metabolic stability, than Ligand B (91.428). This is a significant advantage for Ligand A.
13. **t1/2:** Ligand B (80.359) has a much longer in vitro half-life than Ligand A (5.257). This is a major advantage for Ligand B.
14. **Pgp:** Ligand A (0.257) has lower P-gp efflux liability than Ligand B (0.221), which is slightly better.
15. **Affinity:** Ligand A (-6.9 kcal/mol) has a slightly better binding affinity than Ligand B (-4.7 kcal/mol). This is a substantial advantage for Ligand A.
**Overall Assessment:**
Ligand A has a better binding affinity and metabolic stability (lower Cl_mic), and a slightly better Pgp profile. However, Ligand B excels in several critical ADME properties: significantly lower DILI risk, much better BBB penetration, and a substantially longer half-life. While Ligand A's logP is a bit low, Ligand B's is ideal. The affinity difference is significant, but not insurmountable, and can potentially be optimized further. Given the GPCR target class, the balance of properties leans towards Ligand B due to the favorable ADME profile, particularly the lower DILI and better BBB penetration. The longer half-life also reduces dosing frequency.
Output:
0
2025-04-18 00:47:58,562 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.5 & 347.5 Da) fall comfortably within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (49.85) is significantly better than Ligand B (71). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (3.55) is good, within the optimal 1-3 range. Ligand B (1.941) is on the lower side, potentially impacting permeability.
4. **HBD:** Ligand A (0) is preferable to Ligand B (1). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (3) is better than Ligand B (4). Lower HBA is favorable for permeability.
6. **QED:** Both ligands have good QED scores (0.688 and 0.826), indicating drug-likeness. Ligand B is slightly better.
7. **DILI:** Ligand A (43.66) is slightly higher than Ligand B (33.773), but both are well below the concerning 60 percentile. Ligand B is preferable.
8. **BBB:** Ligand A (84.917) has significantly better BBB penetration than Ligand B (63.784). While not critical for a cardiovascular target, it's a bonus.
9. **Caco-2:** Both ligands have similar, poor Caco-2 permeability (-4.848 and -4.723). This is a concern for both.
10. **Solubility:** Both ligands have similar, poor aqueous solubility (-3.287 and -3.166). This is a concern for both.
11. **hERG:** Ligand A (0.684) is better than Ligand B (0.188) indicating a lower risk of cardiotoxicity. This is *very* important for a cardiovascular target.
12. **Cl_mic:** Ligand A (54.121) has a higher microsomal clearance than Ligand B (19.494), suggesting lower metabolic stability. Ligand B is significantly better.
13. **t1/2:** Ligand A (-15.815) has a very poor in vitro half-life, while Ligand B (0.126) is also poor, but less so. Ligand B is preferable.
14. **Pgp:** Ligand A (0.383) is better than Ligand B (0.158), indicating lower P-gp efflux.
15. **Affinity:** Ligand A (-7.5 kcal/mol) has a stronger binding affinity than Ligand B (-6.8 kcal/mol). This is a significant advantage (0.7 kcal/mol difference).
**GPCR-Specific Priorities & Overall Assessment:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A excels in affinity and has a better logP and Pgp profile. While Ligand B has better DILI and Cl_mic, the stronger binding affinity of Ligand A, coupled with its better hERG profile, outweighs these drawbacks. The poor Caco-2 and solubility are concerns for both, but can be addressed through formulation strategies. The slightly better BBB for Ligand A is a minor bonus. The significant affinity advantage of Ligand A is the deciding factor.
Output:
1
2025-04-18 00:47:58,562 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (342.374 and 345.305 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (74.33) is better than Ligand B (77.29), both are below the 140 threshold for good oral absorption, but closer to the 90 threshold for CNS targets.
3. **logP:** Ligand A (3.3) is optimal, while Ligand B (4.453) is pushing the upper limit and could potentially lead to solubility issues or off-target interactions.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1), but both are within the acceptable limit of 5.
5. **HBA:** Ligand A (3) is lower than Ligand B (5), which is preferable.
6. **QED:** Ligand A (0.899) is significantly better than Ligand B (0.546), indicating a more drug-like profile.
7. **DILI:** Ligand A (70.686) is much better than Ligand B (98.953), indicating a lower risk of drug-induced liver injury. This is a crucial factor.
8. **BBB:** Ligand A (70.88) is slightly better than Ligand B (68.941), but both are reasonably good.
9. **Caco-2:** Both ligands have similar negative Caco-2 values (-4.776 and -4.701), suggesting poor permeability.
10. **Solubility:** Ligand A (-4.496) is better than Ligand B (-6.795), indicating better aqueous solubility.
11. **hERG:** Ligand A (0.627) is better than Ligand B (0.733), indicating a lower risk of hERG inhibition and cardiotoxicity.
12. **Cl_mic:** Ligand A (-33.824) is significantly better than Ligand B (61.8), indicating much better metabolic stability.
13. **t1/2:** Ligand A (41.623) is slightly better than Ligand B (50.408).
14. **Pgp:** Ligand A (0.062) is substantially better than Ligand B (0.293), indicating lower P-gp efflux and potentially better bioavailability.
15. **Binding Affinity:** Ligand B (-6.9) is slightly better than Ligand A (-6.3), but the difference is not large enough to outweigh the significant advantages of Ligand A in other critical parameters.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Ligand A is better in logP, TPSA, and Pgp. While Ligand B has slightly better affinity, the other ADME properties of Ligand A are far superior, especially the DILI and metabolic stability.
**Conclusion:**
Ligand A demonstrates a significantly more favorable overall profile, particularly regarding safety (DILI, hERG), metabolic stability (Cl_mic), and drug-likeness (QED). The slightly better affinity of Ligand B is not enough to compensate for these critical drawbacks.
Output:
1
2025-04-18 00:47:58,562 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [377.422, 76.34, 4.099, 0, 6, 0.38, 98.178, 83.055, -4.734, -4.903, 0.517, 122.009, 43.567, 0.668, -6.1]
**Ligand B:** [356.419, 102.96, 1.355, 2, 6, 0.452, 59.403, 49.515, -5.222, -1.826, 0.212, 56.375, -8.747, 0.129, -7.3]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (356.419) is slightly lower, which could be beneficial for permeability.
2. **TPSA:** Ligand A (76.34) is better than Ligand B (102.96), falling well under the 140 threshold for oral absorption.
3. **logP:** Ligand A (4.099) is a bit high, potentially leading to solubility issues. Ligand B (1.355) is closer to the optimal range (1-3).
4. **HBD:** Ligand A (0) is preferable. Ligand B has 2 HBD, which is still acceptable.
5. **HBA:** Both have 6 HBA, which is within the acceptable range.
6. **QED:** Both are reasonably good (A: 0.38, B: 0.452), but neither is exceptionally high.
7. **DILI:** Ligand A (98.178) has a very high DILI risk, which is a major concern. Ligand B (59.403) is much better, though still above the ideal <40.
8. **BBB:** Ligand A (83.055) has good BBB penetration, while Ligand B (49.515) is lower. For a cardiovascular target, BBB isn't *as* critical as for CNS targets, but it's still a positive.
9. **Caco-2:** Both have negative values, indicating poor permeability. Ligand B (-5.222) is slightly worse than Ligand A (-4.734).
10. **Solubility:** Ligand B (-1.826) is better than Ligand A (-4.903).
11. **hERG:** Ligand A (0.517) is better than Ligand B (0.212), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand B (56.375) has significantly lower microsomal clearance than Ligand A (122.009), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-8.747) has a negative half-life, which is concerning. Ligand A (43.567) is much more reasonable.
14. **Pgp:** Ligand A (0.668) is better than Ligand B (0.129), indicating lower P-gp efflux.
15. **Affinity:** Ligand B (-7.3) has a slightly better binding affinity than Ligand A (-6.1).
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, Pgp, TPSA, and affinity. Ligand B excels in logP and affinity, while Ligand A is better in TPSA and Pgp. However, the *extremely* high DILI risk associated with Ligand A is a dealbreaker. While affinity is important, a high risk of liver injury is unacceptable.
**Conclusion:**
Despite Ligand B's slightly worse Caco-2 permeability and negative half-life, its significantly lower DILI risk and better metabolic stability make it the more promising candidate. The affinity difference is not large enough to overcome the safety concerns with Ligand A.
Output:
0
2025-04-18 00:47:58,562 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [353.459, 77.77, 3.362, 1, 5, 0.794, 44.824, 56.146, -4.246, -4.014, 0.413, 100.99, 63.154, 0.112, -7.0]
**Ligand B:** [366.443, 104.54, 0.561, 2, 6, 0.683, 58.705, 36.332, -5.596, -2.441, 0.089, 28.583, -0.283, 0.048, -6.6]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, Affinity, and to a lesser extent BBB):
1. **MW:** Both are within the acceptable 200-500 Da range. Ligand A (353.459) is slightly preferred.
2. **TPSA:** Ligand A (77.77) is significantly better than Ligand B (104.54). Below 140 is good for oral absorption, and both are, but lower is better, especially for potential CNS effects.
3. **logP:** Ligand A (3.362) is optimal (1-3). Ligand B (0.561) is quite low, potentially hindering membrane permeability and bioavailability. This is a significant drawback for Ligand B.
4. **HBD/HBA:** Ligand A (1 HBD, 5 HBA) is preferable to Ligand B (2 HBD, 6 HBA). Both are within acceptable limits, but lower counts generally improve permeability.
5. **QED:** Both are reasonable (A: 0.794, B: 0.683), indicating good drug-like properties.
6. **DILI:** Ligand A (44.824) has a lower DILI risk than Ligand B (58.705), which is preferable.
7. **BBB:** Ligand A (56.146) has a better BBB penetration score than Ligand B (36.332). While ADRB2 isn't necessarily a CNS target, some peripheral distribution is still desirable.
8. **Caco-2:** Ligand A (-4.246) is better than Ligand B (-5.596). Higher is better, indicating better intestinal absorption.
9. **Solubility:** Ligand A (-4.014) is better than Ligand B (-2.441). Higher is better.
10. **hERG:** Ligand A (0.413) is better than Ligand B (0.089). Lower is better.
11. **Cl_mic:** Ligand B (28.583) has significantly lower microsomal clearance than Ligand A (100.99), suggesting better metabolic stability. This is a strong point for Ligand B.
12. **t1/2:** Ligand A (63.154) has a longer in vitro half-life than Ligand B (-0.283). This is a significant advantage for Ligand A.
13. **Pgp:** Ligand A (0.112) has lower P-gp efflux than Ligand B (0.048). Lower is better.
14. **Affinity:** Ligand A (-7.0) has a slightly better binding affinity than Ligand B (-6.6). While the difference is not huge, it is still a factor.
**Overall Assessment:**
Ligand A is clearly the stronger candidate. Its superior logP, TPSA, solubility, hERG, BBB, Caco-2, and affinity outweigh the benefit of Ligand B's lower microsomal clearance. The lower logP of Ligand B is a major concern for oral bioavailability and target engagement. The better half-life and affinity of Ligand A are also important advantages.
Output:
1
2025-04-18 00:47:58,562 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
Let's break down the comparison of Ligand A and Ligand B based on the provided parameters, keeping in mind the GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key).
1. **Molecular Weight:** Both ligands (347.46 and 366.45 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (82.53) is significantly better than Ligand B (122.9). A TPSA under 140 is good for oral absorption, but lower is generally preferred for GPCRs, and A is much closer to the ideal range.
3. **logP:** Both ligands have acceptable logP values (1.63 and 1.2), falling within the 1-3 range. Ligand A is slightly higher, which could be a minor advantage for membrane permeability.
4. **H-Bond Donors:** Both have 2 HBD, which is within the acceptable limit of 5.
5. **H-Bond Acceptors:** Ligand A has 4 HBA, while Ligand B has 9. This is a notable difference. Higher HBA can sometimes hinder permeability.
6. **QED:** Ligand A (0.848) has a better QED score than Ligand B (0.744), indicating a more drug-like profile.
7. **DILI Risk:** Ligand A (23.03) has a much lower DILI risk than Ligand B (79.45). This is a critical advantage.
8. **BBB Penetration:** Ligand B (65.41) shows slightly better BBB penetration than Ligand A (50.80). While ADRB2 isn't exclusively a CNS target, some distribution to the CNS can be relevant, and this is a slight win for B.
9. **Caco-2 Permeability:** Ligand A (-4.793) has better Caco-2 permeability than Ligand B (-5.417). This suggests better intestinal absorption for A.
10. **Aqueous Solubility:** Both ligands have similar, poor aqueous solubility (-2.22 and -2.46). This could be a formulation challenge for both.
11. **hERG Inhibition:** Both ligands show very low hERG inhibition risk (0.291 and 0.231). No significant difference.
12. **Microsomal Clearance:** Ligand A (17.75) has lower microsomal clearance than Ligand B (26.54), suggesting better metabolic stability.
13. **In vitro Half-Life:** Ligand B (10.99) has a longer in vitro half-life than Ligand A (5.44). This is a positive for B, potentially allowing for less frequent dosing.
14. **P-gp Efflux:** Both ligands have similar P-gp efflux liability (0.079 and 0.023).
15. **Binding Affinity:** Ligand B (-8.4 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.6 kcal/mol). This is a substantial advantage, exceeding the 1.5 kcal/mol threshold where it can outweigh other drawbacks.
**Overall Assessment:**
While Ligand B has a superior binding affinity and slightly better half-life, Ligand A demonstrates a much more favorable safety profile (significantly lower DILI risk) and better ADME properties (lower TPSA, better QED, better Caco-2 permeability, and lower clearance). The difference in binding affinity is significant, but the substantial improvement in safety and ADME for Ligand A, especially the DILI risk, makes it the more promising candidate. For a cardiovascular target, minimizing off-target effects and ensuring good ADME properties are crucial.
**Output:**
1
2025-04-18 00:47:58,563 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, key priorities are logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB.
Let's break down the comparison:
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (348.487) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (58.64) is significantly better than Ligand B (67.23). Lower TPSA is preferred for oral absorption and GPCR targets.
3. **logP:** Both ligands have good logP values (A: 2.346, B: 2.001), falling within the optimal 1-3 range.
4. **HBD/HBA:** Both have acceptable HBD (1) and HBA (A:3, B:5) counts.
5. **QED:** Both are reasonably good (A: 0.83, B: 0.783), indicating drug-like properties.
6. **DILI:** Ligand A (6.049) has a much lower DILI risk than Ligand B (39.434). This is a significant advantage.
7. **BBB:** Ligand A (87.864) has a better BBB penetration score than Ligand B (71.733), though this isn't a primary concern for a cardiovascular target.
8. **Caco-2:** Ligand A (-4.563) is better than Ligand B (-5.074), indicating better intestinal absorption.
9. **Solubility:** Ligand A (-2.753) is better than Ligand B (-2.486).
10. **hERG:** Both ligands have low hERG inhibition liability (A: 0.487, B: 0.311).
11. **Cl_mic:** Ligand A (38.614) has lower microsomal clearance, suggesting better metabolic stability than Ligand B (51.943).
12. **t1/2:** Ligand A (11.499) has a shorter half-life than Ligand B (15.076), but the difference isn't huge.
13. **Pgp:** Ligand A (0.032) has significantly lower P-gp efflux liability than Ligand B (0.127). This is a crucial advantage for bioavailability and potentially tissue distribution.
14. **Binding Affinity:** Ligand B (-8.1) has a slightly better binding affinity than Ligand A (-7.0), a difference of 1.1 kcal/mol. While affinity is important, the other ADME properties of Ligand A are significantly better.
**Overall Assessment:**
Ligand A demonstrates a superior balance of properties, particularly in terms of ADME characteristics (DILI, Pgp, Cl_mic, solubility, Caco-2, TPSA). The slightly weaker binding affinity of Ligand A is outweighed by its significantly improved drug-like properties. Ligand B's better affinity isn't enough to overcome its higher DILI risk and Pgp efflux.
**Output:**
1
2025-04-18 00:47:58,563 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (344.46 and 362.51 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (58.64) is significantly higher than Ligand B (33.2). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for better permeability. Ligand B is much better here.
**3. logP:** Both ligands have good logP values (3.785 and 4.066), falling within the optimal 1-3 range. Ligand B is slightly higher, which *could* be a minor concern for solubility, but not a dealbreaker.
**4. H-Bond Donors:** Ligand A has 1 HBD, while Ligand B has 0. Both are acceptable, within the guideline of <=5.
**5. H-Bond Acceptors:** Both ligands have 3 HBAs, well within the acceptable limit of <=10.
**6. QED:** Ligand A (0.908) has a significantly higher QED score than Ligand B (0.764), indicating a more drug-like profile. This is a substantial advantage for Ligand A.
**7. DILI Risk:** Ligand A (35.09%) has a higher DILI risk than Ligand B (16.91%). This is a significant advantage for Ligand B.
**8. BBB Penetration:** Both have good BBB penetration, but Ligand B (94.92%) is better than Ligand A (87.40%). While ADRB2 is a cardiovascular target, some CNS off-target effects are possible with GPCRs, so higher BBB is slightly preferred.
**9. Caco-2 Permeability:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.336) is slightly better than Ligand B (-4.723), but both are concerning.
**10. Aqueous Solubility:** Both have negative solubility values, indicating very poor solubility. Ligand A (-4.587) is slightly better than Ligand B (-4.761), but both are a major issue.
**11. hERG Inhibition:** Ligand A (0.519) has a slightly lower hERG risk than Ligand B (0.793), which is preferable.
**12. Microsomal Clearance:** Ligand B (56.068) has significantly lower microsomal clearance than Ligand A (81.756), indicating better metabolic stability. This is a significant advantage for Ligand B.
**13. In Vitro Half-Life:** Ligand B (18.004 hours) has a much longer in vitro half-life than Ligand A (-8.947 hours). This is a major advantage for Ligand B.
**14. P-gp Efflux:** Ligand A (0.159) has lower P-gp efflux than Ligand B (0.672), which is preferable.
**15. Binding Affinity:** Ligand A (-6.6 kcal/mol) has a slightly better binding affinity than Ligand B (-5.8 kcal/mol). This is a 1.5kcal/mol difference, which is significant.
**Overall Assessment:**
Despite Ligand A's better QED and binding affinity, Ligand B is the more promising candidate. The significant advantages of Ligand B in terms of DILI risk, metabolic stability (lower Cl_mic, longer t1/2), and BBB penetration outweigh the slightly better QED and affinity of Ligand A. The poor solubility and permeability of both are concerning, but can potentially be addressed with formulation strategies. The lower DILI risk and improved metabolic profile of Ligand B make it a safer and more likely candidate to progress.
Output:
0
2025-04-18 00:47:58,563 - INFO - Reasoning:
Let's analyze Ligand A and Ligand B for their potential as ADRB2 ligands, keeping in mind the GPCR-specific priorities (logP, Pgp, TPSA, and affinity) alongside general drug-like properties.
**Molecular Weight:** Both ligands (348.38 and 357.84 Da) fall within the ideal 200-500 Da range.
**TPSA:** Ligand A (76.46) is higher than Ligand B (59.23). Both are acceptable, but B is preferable as it's closer to the <90 target for potential CNS penetration, even though this is a cardiovascular target.
**logP:** Ligand A (0.923) is slightly lower than the optimal 1-3 range, potentially hindering permeability. Ligand B (3.783) is within the optimal range. This favors B.
**H-Bond Donors/Acceptors:** Ligand A has 1 HBD and 5 HBA, while Ligand B has 0 HBD and 4 HBA. Both are within acceptable limits.
**QED:** Ligand A (0.803) has a slightly better QED score than Ligand B (0.764), indicating a more drug-like profile.
**DILI:** Ligand A (60.682) has a higher DILI risk than Ligand B (26.871). This is a significant advantage for B.
**BBB:** Both ligands have reasonable BBB penetration (A: 72.664, B: 76.658).
**Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not defined, so this is difficult to interpret.
**Aqueous Solubility:** Both ligands have negative solubility values, which is also unusual and suggests poor solubility. Again, the scale is undefined.
**hERG:** Ligand A (0.333) has a lower hERG risk than Ligand B (0.524), which is preferable.
**Microsomal Clearance:** Ligand A (25.904) has a significantly lower microsomal clearance than Ligand B (44.394), indicating better metabolic stability.
**In vitro Half-Life:** Ligand A (-24.082) has a much longer in vitro half-life than Ligand B (13.256). This is a strong advantage for A.
**P-gp Efflux:** Ligand A (0.052) has a lower P-gp efflux liability than Ligand B (0.222), which is favorable.
**Binding Affinity:** Ligand A (-6.4 kcal/mol) has a slightly better binding affinity than Ligand B (-4.5 kcal/mol). This 1.9 kcal/mol difference is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand A has a better binding affinity, metabolic stability, half-life, and P-gp efflux profile. However, Ligand B has a significantly lower DILI risk and a more optimal logP. Considering the GPCR-specific priorities, the binding affinity difference is the most crucial factor. The lower DILI risk of B is attractive, but the stronger binding of A is likely to translate to greater efficacy and potentially allow for lower dosing, mitigating some toxicity concerns. The slightly lower logP of A is a minor concern.
Output:
1
2025-04-18 00:47:58,563 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor (a GPCR).
**Ligand A:** [338.411, 66.71, 2.165, 1, 4, 0.869, 64.831, 60.838, -5.025, -3.418, 0.323, 55.044, -5.922, 0.084, -6.4]
**Ligand B:** [343.471, 52.65, 1.712, 1, 3, 0.773, 18.108, 75.921, -4.726, -1.925, 0.397, 44.802, 6.813, 0.145, 0.8]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity, and BBB):
1. **MW:** Both are within the ideal range (200-500 Da). A is 338.411, B is 343.471 - very similar.
2. **TPSA:** A (66.71) is a bit higher than ideal (<140), but acceptable. B (52.65) is excellent, well below 60, suggesting good permeability. B is better here.
3. **logP:** A (2.165) and B (1.712) are both within the optimal 1-3 range. A is slightly better.
4. **HBD/HBA:** Both have 1 HBD, which is good. A has 4 HBA, B has 3. Both are acceptable.
5. **QED:** A (0.869) is better than B (0.773), indicating a more drug-like profile.
6. **DILI:** A (64.831) is concerningly high, indicating a significant risk of liver injury. B (18.108) is excellent, very low risk. B is *much* better here.
7. **BBB:** A (60.838) is moderate. B (75.921) is good, suggesting better potential for CNS penetration if needed (though ADRB2 isn't strictly a CNS target, some peripheral effects may benefit from some CNS penetration). B is better.
8. **Caco-2:** Both are negative, indicating poor permeability. A (-5.025) is worse than B (-4.726).
9. **Solubility:** Both are negative, indicating poor solubility. B (-1.925) is better than A (-3.418).
10. **hERG:** Both are low risk (0.323 and 0.397). Similar.
11. **Cl_mic:** A (55.044) is higher than B (44.802), suggesting faster metabolism and lower stability. B is better.
12. **t1/2:** A (-5.922) is a negative half-life, which is concerning. B (6.813) is positive, indicating a reasonable in vitro half-life. B is *much* better.
13. **Pgp:** A (0.084) is very low, suggesting minimal P-gp efflux. B (0.145) is also low, but slightly higher. A is better.
14. **Affinity:** A (-6.4) is significantly better than B (-0.8). This is a substantial difference in binding strength.
**Overall Assessment:**
While Ligand A has a better binding affinity and lower Pgp efflux, the significant concerns with its DILI risk, metabolic stability (higher Cl_mic), and negative half-life are major drawbacks. Ligand B, despite a weaker binding affinity, presents a much more favorable ADMET profile: lower DILI risk, better BBB penetration, better metabolic stability, and a positive half-life. The difference in binding affinity, while substantial, might be overcome with further optimization of Ligand B. The safety profile and pharmacokinetic properties of Ligand B are far superior, making it a more promising starting point for drug development.
Output:
0
2025-04-18 00:47:58,563 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [353.333, 106.73 , 0.786, 2. , 7. , 0.765, 80.07 , 74.06 , -5.003, -3.363, 0.154, 5.782, 14.498, 0.024, -7.5 ]**
**Ligand B: [367.534, 38.13 , 3.761, 0. , 4. , 0.736, 28.499, 92.323, -5.017, -3.808, 0.696, 86.683, -13.48 , 0.606, -6. ]**
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). A (353.333) is slightly better.
2. **TPSA:** Ligand A (106.73) is higher than the preferred <140, but still reasonable. Ligand B (38.13) is excellent, well below 140 and favorable for permeability.
3. **logP:** Ligand A (0.786) is a bit low, potentially impacting permeability. Ligand B (3.761) is within the optimal 1-3 range.
4. **H-Bond Donors:** Ligand A (2) is good. Ligand B (0) is also good, but potentially could reduce aqueous solubility.
5. **H-Bond Acceptors:** Ligand A (7) is good. Ligand B (4) is also good.
6. **QED:** Both ligands are similar (A: 0.765, B: 0.736) and above the 0.5 threshold, indicating good drug-likeness.
7. **DILI:** Ligand A (80.07) has a higher DILI risk than Ligand B (28.499). This is a significant concern.
8. **BBB:** Ligand A (74.06) is acceptable, but Ligand B (92.323) is much better, indicating higher potential for CNS penetration (though ADRB2 isn't strictly a CNS target, some CNS exposure can be relevant for off-target effects).
9. **Caco-2:** Both are negative, indicating poor permeability.
10. **Aqueous Solubility:** Both are negative, indicating poor solubility.
11. **hERG:** Both are very low, indicating minimal hERG inhibition risk.
12. **Microsomal Clearance:** Ligand A (5.782) has a lower clearance, suggesting better metabolic stability than Ligand B (86.683).
13. **In vitro Half-Life:** Ligand A (14.498) has a longer half-life than Ligand B (-13.48), which is a positive.
14. **P-gp Efflux:** Ligand A (0.024) has very low P-gp efflux, which is favorable. Ligand B (0.606) is higher, suggesting more efflux.
15. **Binding Affinity:** Ligand A (-7.5) has a slightly better binding affinity than Ligand B (-6).
**GPCR-Specific Considerations:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand B excels in TPSA and BBB penetration, and has a good logP. Ligand A has a slightly better affinity and P-gp profile, but suffers from a significantly higher DILI risk. The better metabolic stability and half-life of Ligand A are also positives. However, the DILI risk is a major drawback.
**Overall Assessment:**
While Ligand A has slightly better affinity and metabolic stability, the significantly higher DILI risk and lower BBB penetration compared to Ligand B make it a less desirable candidate. Ligand B's lower DILI, better BBB, and acceptable logP outweigh the slightly weaker affinity.
Output:
0
2025-04-18 00:47:58,563 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (341.455 and 353.507 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Both ligands (62.3 and 61.88) are below the 140 A^2 threshold for good oral absorption. Very similar.
3. **logP:** Ligand A (3.348) is optimal, while Ligand B (1.498) is on the lower side. For a GPCR, a slightly higher logP is generally preferred for membrane permeability, giving a slight edge to Ligand A.
4. **HBD:** Both have 1 HBD, which is acceptable.
5. **HBA:** Ligand A has 3 HBA, and Ligand B has 4. Both are within the acceptable limit of 10.
6. **QED:** Both ligands have similar QED scores (0.774 and 0.753), indicating good drug-likeness.
7. **DILI:** Ligand A (21.753) has a significantly lower DILI risk than Ligand B (3.102). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (83.831) has a higher BBB penetration percentile than Ligand B (68.941). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant for off-target effects and overall safety assessment.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.799 and -4.878). This is unusual and suggests poor permeability.
10. **Solubility:** Ligand A (-3.233) has slightly better solubility than Ligand B (-0.684).
11. **hERG:** Both ligands have low hERG inhibition liability (0.415 and 0.422).
12. **Cl_mic:** Ligand B (-19.57) has a significantly lower (better) microsomal clearance than Ligand A (41.972). This suggests better metabolic stability for Ligand B.
13. **t1/2:** Ligand B (-3.966) has a slightly longer in vitro half-life than Ligand A (-10.023).
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.093 and 0.01).
15. **Binding Affinity:** Ligand B (-6.6 kcal/mol) has a slightly better binding affinity than Ligand A (-5.8 kcal/mol). This is a 0.8 kcal/mol difference, which is significant.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand A has a better logP, and similar TPSA and Pgp. Ligand B has a better binding affinity and metabolic stability. The lower DILI risk and better BBB penetration of Ligand A are also important positives.
**Overall Assessment:**
The binding affinity difference of 0.8 kcal/mol is substantial, and Ligand B's improved metabolic stability (lower Cl_mic and longer t1/2) are valuable. While Ligand A has advantages in DILI risk and BBB, the binding affinity and metabolic properties of Ligand B are more critical for a GPCR target. The negative Caco-2 values are concerning for both, but can be addressed with formulation strategies.
Output:
0
2025-04-18 00:47:58,563 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.471 and 352.475 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (58.64) is significantly better than Ligand B (87.66). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold. Ligand B is approaching the upper limit.
3. **logP:** Ligand A (3.403) is slightly higher than Ligand B (1.506), placing it within the optimal 1-3 range, while Ligand B is at the lower end. For a GPCR, a slightly higher logP is often beneficial for membrane interactions.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (4). Fewer HBAs generally improve permeability.
6. **QED:** Ligand A (0.734) is better than Ligand B (0.648), indicating a more drug-like profile.
7. **DILI:** Ligand A (43.932) is significantly better than Ligand B (16.44). Lower DILI risk is crucial. Ligand B is quite low, but A is better.
8. **BBB:** Ligand A (75.107) is better than Ligand B (25.94). While not a CNS target, some level of BBB penetration can sometimes indicate favorable permeability characteristics.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-4.382) is slightly better than Ligand B (-4.901).
10. **Solubility:** Ligand A (-3.841) is better than Ligand B (-1.702). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.786) is better than Ligand B (0.151). Lower hERG risk is critical for cardiovascular drugs.
12. **Cl_mic:** Ligand A (86.399) is worse than Ligand B (10.518). Lower clearance is preferred for metabolic stability. This is a significant advantage for Ligand B.
13. **t1/2:** Ligand B (11.617) is better than Ligand A (6.849). Longer half-life is generally desirable.
14. **Pgp:** Ligand A (0.228) is better than Ligand B (0.024). Lower P-gp efflux is preferred.
15. **Binding Affinity:** Ligand A (-6.3) is slightly better than Ligand B (-5.9). While both are good, the difference is not huge.
**Overall Assessment:**
Ligand A has a significantly better profile across most key ADME properties (TPSA, logP, HBD, HBA, QED, DILI, BBB, Solubility, hERG, Pgp) and a slightly better binding affinity. While Ligand B has better metabolic stability (Cl_mic) and half-life, the other advantages of Ligand A outweigh this. The lower DILI and hERG risk for Ligand A are particularly important for a cardiovascular target.
Output:
1
2025-04-18 00:47:58,563 - INFO - Batch 504 complete. Total preferences: 8064
2025-04-18 00:47:58,563 - INFO - Processing batch 505/512...
2025-04-18 00:48:41,221 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (376.356) is slightly higher than Ligand B (347.423), but both are acceptable.
2. **TPSA:** Ligand A (94.56) is better than Ligand B (124.01). For a GPCR, keeping TPSA lower is generally preferred for better permeability, although both are reasonably within acceptable limits.
3. **logP:** Ligand A (3.041) is slightly higher than Ligand B (1.986), and both are within the optimal 1-3 range. Ligand B is on the lower side, which *could* indicate potential permeability issues.
4. **HBD:** Ligand A (2) is better than Ligand B (3). Fewer HBDs are generally preferred for better membrane permeability.
5. **HBA:** Ligand A (5) is better than Ligand B (9). Similar to HBD, lower HBA is favored.
6. **QED:** Ligand A (0.808) is significantly better than Ligand B (0.657). A higher QED suggests a more drug-like profile.
7. **DILI:** Ligand A (72.276) is slightly higher than Ligand B (63.862), but both are within an acceptable range (< 40 is good, >60 is high risk).
8. **BBB:** Both ligands have similar BBB penetration (Ligand A: 66.344, Ligand B: 64.482). Since ADRB2 is a cardiovascular target, BBB penetration isn't a primary concern, but it's not detrimental to have some.
9. **Caco-2:** Ligand A (-4.806) is better than Ligand B (-5.29). Higher Caco-2 permeability is desirable.
10. **Solubility:** Ligand A (-3.782) is better than Ligand B (-3.499). Better solubility is always a plus.
11. **hERG:** Both ligands have very low hERG inhibition risk (Ligand A: 0.476, Ligand B: 0.427). This is excellent.
12. **Cl_mic:** Ligand A (16.214) is significantly better than Ligand B (38.255). Lower microsomal clearance indicates better metabolic stability.
13. **t1/2:** Ligand A (-14.245) is better than Ligand B (29.021). A negative value for t1/2 is unusual and likely indicates a very long half-life, which is desirable.
14. **Pgp:** Both ligands have very low P-gp efflux liability (Ligand A: 0.236, Ligand B: 0.014).
15. **Binding Affinity:** Ligand A (-8.5) is significantly better than Ligand B (-5.7). A 2.8 kcal/mol difference in binding affinity is substantial and can often outweigh minor ADME drawbacks.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, and affinity. Ligand A performs better on all these counts, and also has a significantly better QED and metabolic stability (Cl_mic). The better binding affinity of Ligand A is a major advantage.
**Conclusion:**
Ligand A is the superior candidate due to its better overall profile, particularly its significantly higher binding affinity, better QED, lower microsomal clearance, and more favorable TPSA and logP values.
Output:
1
2025-04-18 00:48:41,222 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands (344.455 and 374.35 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (50.8) is better than Ligand B (58.64), both are below the 140 threshold for oral absorption, but closer to the ideal for GPCRs.
3. **logP:** Both ligands have excellent logP values (2.453 and 2.352), falling within the optimal 1-3 range. No significant difference.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 3. Both are acceptable.
6. **QED:** Ligand A (0.787) is slightly better than Ligand B (0.696), indicating a more drug-like profile.
7. **DILI:** Ligand A (14.192) has a significantly lower DILI risk than Ligand B (31.02). This is a major advantage for Ligand A.
8. **BBB:** Both ligands have good BBB penetration (79.721 and 76.774). No significant difference.
9. **Caco-2:** Both have negative values, indicating poor permeability. Ligand A (-4.695) is slightly worse than Ligand B (-4.528).
10. **Solubility:** Both have negative solubility values, indicating poor solubility. Ligand A (-2.176) is slightly worse than Ligand B (-2.104).
11. **hERG:** Both ligands have low hERG inhibition liability (0.702 and 0.488). No significant difference.
12. **Cl_mic:** Ligand A (51.493) has a higher microsomal clearance than Ligand B (23.818), suggesting lower metabolic stability. This favors Ligand B.
13. **t1/2:** Ligand B (-22.934) has a much longer in vitro half-life than Ligand A (18.507). This is a significant advantage for Ligand B.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.247 and 0.035). Ligand B is slightly better.
15. **Binding Affinity:** Ligand B (-6.5 kcal/mol) has a slightly better binding affinity than Ligand A (-6.1 kcal/mol). This is a positive for Ligand B, but the difference is not huge.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, Pgp, TPSA, and affinity. Both ligands perform well on logP and Pgp. Ligand A has a slightly better TPSA. Ligand B has a slightly better affinity. However, the significant advantage of Ligand A in DILI risk and its slightly better QED outweigh the minor benefits of Ligand B. The longer half-life of Ligand B is also a positive, but the DILI risk is a major concern.
**Conclusion:**
Considering the balance of properties, particularly the significantly lower DILI risk of Ligand A, I believe it is the more promising drug candidate.
Output:
1
2025-04-18 00:48:41,222 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Ligand A (365.352 Da) is within the ideal range (200-500 Da). Ligand B (344.375 Da) is also within the ideal range. No clear advantage here.
2. **TPSA:** Ligand A (102.66) is good for oral absorption, being under 140. Ligand B (121.89) is still acceptable but closer to the upper limit. Ligand A is slightly preferred.
3. **logP:** Ligand A (0.585) is a bit low, potentially hindering permeation. Ligand B (0.18) is even lower, raising more concerns about permeability. Both are suboptimal, but Ligand A is better.
4. **HBD:** Ligand A (2) is good. Ligand B (3) is acceptable, but slightly less favorable.
5. **HBA:** Ligand A (5) is good. Ligand B (6) is acceptable, but slightly less favorable.
6. **QED:** Both Ligand A (0.655) and Ligand B (0.616) are above 0.5, indicating good drug-likeness. No significant difference.
7. **DILI:** Ligand A (25.048) has a much lower DILI risk than Ligand B (84.18). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (61.535) has better BBB penetration than Ligand B (57.929), although neither is exceptionally high. Given this is a GPCR, some BBB penetration is desirable.
9. **Caco-2:** Ligand A (-4.801) and Ligand B (-5.314) are both negative, indicating poor permeability. Ligand B is slightly worse.
10. **Solubility:** Ligand A (-1.856) is better than Ligand B (-3.34). Solubility is important for bioavailability.
11. **hERG:** Both Ligand A (0.427) and Ligand B (0.458) have low hERG inhibition risk, which is good. No significant difference.
12. **Cl_mic:** Ligand A (-6.778) has much lower microsomal clearance, indicating better metabolic stability, than Ligand B (24.043). This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (9.8) has a much longer in vitro half-life than Ligand B (0.157). This is a major advantage for Ligand A.
14. **Pgp:** Both Ligand A (0.021) and Ligand B (0.013) have low P-gp efflux liability, which is good. No significant difference.
15. **Affinity:** Ligand A (-7.3 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.1 kcal/mol). This is a substantial advantage, exceeding the 1.5 kcal/mol threshold.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. While both ligands have suboptimal logP, Ligand A is better. Ligand A also has better TPSA. Affinity is significantly better for Ligand A.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical parameters, most notably in DILI risk, metabolic stability (Cl_mic and t1/2), and binding affinity. While both have permeability issues, Ligand A's superior affinity and safety profile make it the more promising candidate.
Output:
1
2025-04-18 00:48:41,222 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (343.427 and 348.447 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (70.67) is better than Ligand B (87.46). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (1.927 and 1.53), falling within the 1-3 range. Ligand B is slightly lower, which could marginally improve solubility, but both are acceptable.
4. **HBD:** Both have 2 H-bond donors, which is within the acceptable limit of <=5.
5. **HBA:** Ligand A has 3 H-bond acceptors, while Ligand B has 5. Ligand A is preferable here, as fewer HBA generally improves permeability.
6. **QED:** Both ligands have good QED scores (0.776 and 0.867), indicating good drug-like properties.
7. **DILI:** Ligand A (43.622) has a slightly higher DILI risk than Ligand B (29.818), but both are below the concerning threshold of 60. Ligand B is preferable here.
8. **BBB:** Both have moderate BBB penetration (67.507 and 61.535). Since ADRB2 is not a CNS target, this isn't a major differentiating factor.
9. **Caco-2:** Both have negative Caco-2 values (-4.557 and -4.867), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand A (-1.882) has slightly better solubility than Ligand B (-2.513), but both are poor.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.332 and 0.113). This is excellent.
12. **Cl_mic:** Ligand A (-3.327) has significantly *lower* (better) microsomal clearance than Ligand B (30.713). This suggests better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (9.38) has a significantly longer in vitro half-life than Ligand B (-9.311). This is a strong advantage for Ligand A.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.072 and 0.027). This is good.
15. **Binding Affinity:** Ligand B (-7.8) has a significantly stronger binding affinity than Ligand A (-6.3). This is a substantial advantage, potentially outweighing some ADME concerns.
**Overall Assessment & GPCR-Specific Priorities:**
For a GPCR like ADRB2, affinity is paramount. Ligand B's -7.8 kcal/mol binding affinity is a significant advantage over Ligand A's -6.3 kcal/mol. While Ligand A has better metabolic stability (lower Cl_mic, longer t1/2) and slightly better TPSA/HBA, the difference in affinity is substantial enough to favor Ligand B. The poor Caco-2 values for both are concerning, but can potentially be addressed through formulation strategies. The DILI risk for Ligand B is also lower.
Output:
0
2025-04-18 00:48:41,222 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.45 & 371.522 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (69.64) is better than Ligand B (54.46). Both are below the 140 A^2 threshold for good oral absorption, but lower TPSA is generally preferred for GPCRs, aiding permeability.
3. **logP:** Ligand A (1.783) is within the optimal 1-3 range. Ligand B (3.427) is slightly higher, potentially increasing off-target effects and decreasing solubility, but still acceptable.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1), but both are within the acceptable limit of 5.
5. **HBA:** Ligand A (3) is lower than Ligand B (5). Lower HBA is generally favorable for permeability.
6. **QED:** Ligand A (0.81) has a significantly better QED score than Ligand B (0.676), indicating a more drug-like profile.
7. **DILI:** Ligand A (11.361) has a much lower DILI risk than Ligand B (26.444). This is a significant advantage for Ligand A.
8. **BBB:** Ligand B (91.431) shows much better BBB penetration than Ligand A (51.881). While ADRB2 isn't necessarily a CNS target, some peripheral ADRB2 activity can influence CNS function, and better BBB penetration isn't necessarily a negative.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.884 and -4.743). These values are unusual and suggest poor permeability.
10. **Solubility:** Ligand A (-2.538) is slightly better than Ligand B (-3.875), but both are poor.
11. **hERG:** Ligand A (0.362) has a lower hERG risk than Ligand B (0.873). This is a crucial advantage, minimizing cardiotoxicity concerns.
12. **Cl_mic:** Ligand A (5.726) has a much lower microsomal clearance than Ligand B (61.148), indicating better metabolic stability.
13. **t1/2:** Ligand A (11.174) has a longer in vitro half-life than Ligand B (-8.516). This is a significant advantage, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.053) has a much lower Pgp efflux liability than Ligand B (0.678), indicating better oral bioavailability and potentially better CNS exposure.
15. **Binding Affinity:** Ligand A (-6.6) is slightly better than Ligand B (-6.3) in binding affinity. While the difference is small, it's still a positive for Ligand A.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity) and the general drug-like properties, Ligand A is the superior candidate. It exhibits a significantly better safety profile (lower DILI, lower hERG), improved metabolic stability (lower Cl_mic, longer t1/2), better QED, and lower Pgp efflux. While Ligand B has better BBB penetration, the other advantages of Ligand A outweigh this benefit for a peripheral target like ADRB2. The Caco-2 values are concerning for both, but Ligand A's other properties are more favorable.
Output:
1
2025-04-18 00:48:41,222 - INFO - Here's my reasoning and the final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, the key priorities are logP, TPSA, Pgp efflux, binding affinity, and to a lesser extent, BBB.
Let's compare the ligands property by property:
1. **MW:** Both ligands (371.453 and 362.836 Da) are within the ideal 200-500 Da range.
2. **TPSA:** Ligand B (50.28) is significantly better than Ligand A (75.43). Lower TPSA is preferred for GPCRs, aiding permeability.
3. **logP:** Both are good (2.411 and 3.525), falling within the optimal 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability, but not drastically.
4. **HBD/HBA:** Ligand A has 2 HBD and 4 HBA, while Ligand B has 1 HBD and 5 HBA. Both are acceptable.
5. **QED:** Ligand B (0.901) has a substantially better QED score than Ligand A (0.57), indicating a more drug-like profile.
6. **DILI:** Both have concerning DILI risk (61.691 and 68.515), but Ligand B is slightly worse. This is a significant drawback for both.
7. **BBB:** Both have reasonable BBB penetration (76.774 and 81.039). Not a primary concern for a cardiovascular target, but higher is better.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability.
9. **Solubility:** Both have negative solubility values, which is also unusual and suggests poor solubility.
10. **hERG:** Both have low hERG inhibition risk (0.817 and 0.893), which is good.
11. **Cl_mic:** Ligand A (32.916) has a much lower microsomal clearance than Ligand B (69.802), suggesting better metabolic stability.
12. **t1/2:** Ligand B (39.774) has a significantly longer in vitro half-life than Ligand A (8.141). This is a major advantage.
13. **Pgp:** Ligand A (0.078) has a much lower Pgp efflux liability than Ligand B (0.27), which is highly desirable.
14. **Binding Affinity:** Ligand B (-7.4 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.2 kcal/mol). This is a crucial advantage, potentially outweighing some ADME concerns.
**Overall Assessment:**
Ligand B has a superior binding affinity and a better QED score, along with a longer half-life. The lower TPSA is also a benefit. While its DILI risk and Pgp efflux are slightly higher, the substantially improved binding affinity is the most critical factor for a GPCR target. Ligand A has better metabolic stability and lower Pgp efflux, but the weaker binding affinity is a major drawback.
Output:
0
2025-04-18 00:48:41,222 - INFO - Here's my reasoning and final output:
**Reasoning:**
Both ligands are reasonably drug-like, falling within acceptable ranges for MW and possessing good QED scores. The target is ADRB2, a cardiovascular GPCR, so we prioritize logP, TPSA, Pgp, BBB, and affinity.
* **Molecular Weight:** Both are within the ideal range (363.89 vs 360.42 Da).
* **TPSA:** Ligand B (49.41) is better than Ligand A (62.3), being closer to the optimal value for GPCRs.
* **logP:** Both are good (3.03 and 3.25), within the 1-3 range.
* **H-Bond Donors/Acceptors:** Similar for both, within acceptable limits.
* **QED:** Ligand A (0.874) is slightly better than Ligand B (0.507).
* **DILI:** Both have low DILI risk (23.19 vs 26.48).
* **BBB:** Ligand B (87.75) has a significantly higher BBB penetration percentile than Ligand A (74.80). While not a CNS target, some peripheral exposure is still desirable.
* **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-4.87) is slightly better than Ligand B (-4.34).
* **Solubility:** Both are negative, indicating poor solubility. Ligand A (-3.31) is slightly better than Ligand B (-3.73).
* **hERG:** Both are low risk (0.40 and 0.75).
* **Cl_mic:** Ligand A (46.03) has lower microsomal clearance, indicating better metabolic stability than Ligand B (65.40).
* **t1/2:** Ligand A (-8.097) has a slightly longer in vitro half-life than Ligand B (-7.776).
* **Pgp:** Ligand A (0.057) has lower P-gp efflux, which is favorable for bioavailability. Ligand B (0.165) is higher.
* **Binding Affinity:** Ligand B (-6.8 kcal/mol) has a slightly better binding affinity than Ligand A (-5.8 kcal/mol). This is a 1 kcal/mol difference, which is significant.
**Overall Assessment:**
Ligand B has a substantially higher BBB value and a better binding affinity. The slightly worse metabolic stability and Pgp efflux are acceptable trade-offs for the improved affinity and potential for better distribution. While Ligand A has slightly better metabolic stability and Pgp efflux, the affinity difference is more crucial for a GPCR target.
**Output:**
0
2025-04-18 00:48:41,222 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (367.5 & 348.5 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (58.64) is significantly better than Ligand A (98.17). ADRB2 is not a CNS target, but lower TPSA generally correlates with better absorption. This favors Ligand B.
3. **logP:** Both ligands have good logP values (2.96 & 2.511), falling within the 1-3 range. Ligand B is slightly lower, which could be beneficial for solubility.
4. **HBD:** Both ligands have 1 HBD, which is within the acceptable limit of <=5.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 3. Both are within the acceptable limit of <=10.
6. **QED:** Ligand B (0.777) has a substantially better QED score than Ligand A (0.405), indicating a more drug-like profile. This is a significant advantage for Ligand B.
7. **DILI:** Ligand B (11.13) has a much lower DILI risk than Ligand A (37.19). This is a major advantage for Ligand B.
8. **BBB:** While not a primary concern for ADRB2, Ligand B (79.53) has a higher BBB penetration percentile than Ligand A (59.67).
9. **Caco-2:** Ligand A (-5.216) and Ligand B (-4.553) have negative values, suggesting poor permeability.
10. **Solubility:** Ligand A (-2.951) and Ligand B (-2.448) have negative values, suggesting poor solubility.
11. **hERG:** Both ligands have low hERG inhibition liability (0.312 & 0.282), which is good.
12. **Cl_mic:** Ligand B (33.95) has a lower microsomal clearance than Ligand A (46.86), suggesting better metabolic stability. This favors Ligand B.
13. **t1/2:** Ligand B (-3.278) has a slightly better in vitro half-life than Ligand A (-9.345).
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.058 & 0.062).
15. **Binding Affinity:** Ligand B (-6.8 kcal/mol) has a slightly better binding affinity than Ligand A (-5.9 kcal/mol). While the difference is not huge, it's a positive for Ligand B.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Ligand B excels in most of these areas. While BBB isn't crucial here, the higher value for Ligand B is a bonus.
**Overall Assessment:**
Ligand B consistently outperforms Ligand A across multiple critical parameters, including QED, DILI risk, metabolic stability (Cl_mic), and binding affinity. While both have issues with Caco-2 and solubility, Ligand B's superior profile makes it the more promising drug candidate.
Output:
0
2025-04-18 00:48:41,222 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (361.36 and 346.519 Da). No significant difference here.
2. **TPSA:** Both ligands are reasonably low (56.79 and 57.26), suggesting good potential for absorption.
3. **logP:** Both have acceptable logP values (2.321 and 3.23), falling within the 1-3 range. Ligand B is slightly higher, potentially improving membrane permeability but also increasing the risk of off-target interactions.
4. **HBD:** Both have acceptable HBD counts (1 and 2).
5. **HBA:** Both have acceptable HBA counts (5 and 3).
6. **QED:** Both have good QED scores (0.569 and 0.831), indicating drug-likeness. Ligand B is significantly better here.
7. **DILI:** Ligand A has a DILI risk of 39.977, which is good (low risk). Ligand B has a DILI risk of 8.104, which is excellent.
8. **BBB:** Both ligands have high BBB penetration (89.066 and 82.668), which isn't a primary concern for ADRB2 (a cardiovascular target), but isn't detrimental.
9. **Caco-2:** Both have negative Caco-2 values (-4.452 and -4.631). This is unusual and suggests poor permeability. However, these values are on a scale where negative values are possible and don't necessarily preclude development.
10. **Solubility:** Both have negative solubility values (-2.669 and -1.745). Similar to Caco-2, this suggests poor aqueous solubility, which could be a formulation challenge.
11. **hERG:** Both ligands show low hERG inhibition liability (0.679 and 0.512), which is excellent.
12. **Cl_mic:** Ligand A has a higher microsomal clearance (51.646) than Ligand B (16.199), indicating faster metabolism and potentially lower exposure. This is a significant drawback for Ligand A.
13. **t1/2:** Ligand B has a significantly longer in vitro half-life (50.895 hours) than Ligand A (29.669 hours). This is a major advantage for Ligand B.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.136 and 0.036).
15. **Binding Affinity:** Ligand B has a substantially better binding affinity (-6.5 kcal/mol) than Ligand A (-5.1 kcal/mol). This 1.4 kcal/mol difference is significant and can outweigh some of the ADME drawbacks.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, affinity, logP, and metabolic stability are crucial. Ligand B excels in affinity and has significantly better metabolic stability (lower Cl_mic and longer t1/2). While both have acceptable logP values, Ligand B's slightly higher value isn't a major concern.
**Overall Assessment:**
Ligand B is the superior candidate. Its significantly higher binding affinity, better QED, lower DILI risk, and improved metabolic stability (lower Cl_mic, longer t1/2) outweigh the slightly higher logP. The negative Caco-2 and solubility values are concerning for both, but can potentially be addressed through formulation strategies.
Output:
0
2025-04-18 00:48:41,223 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (360.498 and 366.443 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (23.55) is excellent, well below the 140 threshold and very favorable for oral absorption. Ligand B (94.05) is higher, but still within a reasonable range, though less optimal.
3. **logP:** Ligand A (4.454) is slightly high, potentially leading to solubility issues or off-target interactions. Ligand B (0.373) is quite low, which could hinder membrane permeability.
4. **HBD:** Ligand A (0) is ideal. Ligand B (1) is acceptable.
5. **HBA:** Ligand A (3) is good. Ligand B (6) is higher, potentially impacting permeability.
6. **QED:** Both ligands (0.786 and 0.76) have good drug-likeness scores, exceeding the 0.5 threshold.
7. **DILI:** Ligand A (26.018) has a very favorable DILI risk profile. Ligand B (49.399) is higher, indicating a moderate risk.
8. **BBB:** Ligand A (97.325) shows excellent BBB penetration, which is a plus for GPCRs, even if ADRB2 isn't a CNS target, it's not detrimental. Ligand B (45.017) is low, suggesting poor brain penetration.
9. **Caco-2:** Ligand A (-4.85) is very poor. Ligand B (-5.252) is also poor. Both ligands are likely to have poor intestinal absorption.
10. **Solubility:** Ligand A (-3.466) is poor. Ligand B (-0.754) is also poor.
11. **hERG:** Both ligands (0.983 and 0.057) have low hERG inhibition liability, which is good.
12. **Cl_mic:** Ligand A (51.789) has a moderate clearance. Ligand B (-17.706) has a *negative* clearance, which is impossible and likely an error in the data. This is a major red flag.
13. **t1/2:** Ligand A (16.706) has a reasonable half-life. Ligand B (9.096) has a shorter half-life.
14. **Pgp:** Ligand A (0.859) has moderate P-gp efflux. Ligand B (0.024) has very low P-gp efflux, which is favorable.
15. **Affinity:** Both ligands (-5.3 and -5.5 kcal/mol) have comparable and good binding affinity.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has a better TPSA and Pgp profile. Ligand B has a better logP profile, but the negative Cl_mic is a dealbreaker.
**Overall Assessment:**
While Ligand A has a slightly higher logP and poor Caco-2/Solubility, the extremely problematic negative microsomal clearance of Ligand B makes it an unsuitable candidate. The excellent DILI and BBB scores of Ligand A, combined with its acceptable ADME properties, make it the more promising option. The negative clearance is likely a data error, but it's a critical one.
Output:
1
2025-04-18 00:48:41,223 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (367.327 and 367.515 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (57.94) is significantly better than Ligand B (80.32). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold. Ligand B is approaching it.
3. **logP:** Ligand A (4.992) is higher than Ligand B (2.67). While both are within the acceptable range, Ligand A is pushing the upper limit and could present solubility challenges. Ligand B is closer to optimal.
4. **HBD:** Ligand A (1) is better than Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Both ligands have 5 HBA, which is acceptable.
6. **QED:** Ligand B (0.838) is slightly better than Ligand A (0.66), indicating a more drug-like profile.
7. **DILI:** Ligand B (57.076) has a much lower DILI risk than Ligand A (97.674). This is a *major* advantage for Ligand B. A DILI percentile >60 is concerning.
8. **BBB:** Both ligands have reasonable BBB penetration (Ligand A: 68.748, Ligand B: 62.311), but this isn't a high priority for a cardiovascular target.
9. **Caco-2:** Ligand A (-4.573) is worse than Ligand B (-5.169). Lower values indicate poorer permeability.
10. **Solubility:** Ligand B (-3.051) is significantly better than Ligand A (-6.371). This is crucial, especially given Ligand A's higher logP.
11. **hERG:** Ligand A (0.823) is slightly higher than Ligand B (0.324), indicating a slightly higher risk of hERG inhibition.
12. **Cl_mic:** Ligand B (36.573) has a significantly lower microsomal clearance than Ligand A (54.035), suggesting better metabolic stability.
13. **t1/2:** Ligand A (72.14) has a much longer in vitro half-life than Ligand B (14.442). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.72) is slightly higher than Ligand B (0.107), indicating greater P-gp efflux.
15. **Affinity:** Ligand B (-7.0) has a slightly better binding affinity than Ligand A (-6.6). While the difference is not huge, it's enough to be considered.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP, TPSA, and Pgp, and has a slightly better affinity. Ligand A has a better half-life, but this is outweighed by its poor DILI score, solubility, and higher Pgp efflux.
**Overall Assessment:**
Ligand B presents a much more favorable safety profile (lower DILI) and better ADME properties (solubility, metabolic stability, permeability, Pgp efflux) despite a slightly shorter half-life. The affinity difference is not substantial enough to overcome the significant ADME/Tox advantages of Ligand B.
Output:
0
2025-04-18 00:48:41,223 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (348.531 and 384.464 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (49.41) is significantly better than Ligand B (66.48). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (3.626 and 2.533), falling within the 1-3 range. Ligand A is slightly higher, which *could* be a minor drawback, but not a dealbreaker.
4. **HBD:** Both have 1 HBD, which is acceptable.
5. **HBA:** Ligand A has 2 HBA, Ligand B has 3. Both are within the acceptable limit of 10.
6. **QED:** Both ligands have similar QED values (0.745 and 0.664), indicating good drug-likeness.
7. **DILI:** Ligand A (14.424) has a much lower DILI risk than Ligand B (22.993). This is a significant advantage.
8. **BBB:** Both have high BBB penetration (85.537 and 91.586), but this is less critical for a cardiovascular target.
9. **Caco-2:** Both have negative Caco-2 values (-4.54 and -4.681). These values are unusual and suggest poor permeability. However, the values are very similar.
10. **Solubility:** Both have negative solubility values (-4.1 and -3.801). These values are also unusual and suggest poor solubility. Again, the values are very similar.
11. **hERG:** Ligand A (0.638) has a slightly better hERG profile than Ligand B (0.813), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand A (97.263) has a higher microsomal clearance than Ligand B (60.936), meaning it's metabolized faster. This is a disadvantage for A.
13. **t1/2:** Ligand B (-46.574) has a much longer in vitro half-life than Ligand A (-13.379). This is a substantial advantage for B.
14. **Pgp:** Ligand A (0.314) has lower P-gp efflux than Ligand B (0.082), which is favorable.
15. **Binding Affinity:** Ligand B (-6.9 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.3 kcal/mol). This is a major advantage, exceeding the 1.5 kcal/mol threshold.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, affinity is crucial. The 1.6 kcal/mol difference in binding affinity between Ligand B and Ligand A is substantial. While Ligand A has advantages in DILI and Pgp, the superior affinity of Ligand B, combined with its significantly better half-life, outweighs these benefits. The similar Caco-2 and solubility values are concerning for both, but can be addressed with formulation strategies.
**Conclusion:**
Ligand B's significantly stronger binding affinity and longer half-life make it the more promising drug candidate, despite its slightly higher DILI risk and Pgp efflux.
Output:
0
2025-04-18 00:48:41,223 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's break down the comparison of Ligand A and Ligand B, considering the provided guidelines and GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key).
1. **Molecular Weight:** Both ligands (353.463 and 346.439 Da) fall comfortably within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (78.95) is significantly better than Ligand B (97.79). A TPSA under 140 is good for oral absorption, and lower is generally preferred for GPCRs. Ligand A is much closer to the ideal range for good permeability.
3. **logP:** Both ligands have acceptable logP values (0.776 and 0.874), falling within the 1-3 range.
4. **H-Bond Donors:** Both have 1 HBD, which is good.
5. **H-Bond Acceptors:** Ligand A has 4 HBAs, while Ligand B has 9. Ligand A is preferable here, as fewer HBAs generally correlate with better membrane permeability.
6. **QED:** Ligand B (0.823) has a slightly better QED score than Ligand A (0.699), indicating a slightly more drug-like profile overall.
7. **DILI:** Both have relatively low DILI risk (24.195 and 29.818), both being well below the 40% threshold.
8. **BBB:** Ligand B (86.39) has a significantly higher BBB penetration percentile than Ligand A (56.417). While ADRB2 isn't *necessarily* a CNS target, some peripheral ADRB2 activity can influence CNS function, and higher BBB penetration isn't a major negative.
9. **Caco-2:** Ligand A (-4.773) is better than Ligand B (-5.659). Higher Caco-2 values indicate better absorption.
10. **Solubility:** Both ligands have poor aqueous solubility (-1.107 and -1.193). This is a concern for both, but not a deciding factor between the two.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.112 and 0.136).
12. **Cl_mic:** Ligand B (-4.598) has a *much* lower microsomal clearance than Ligand A (13.76). This indicates significantly better metabolic stability for Ligand B.
13. **t1/2:** Ligand B (-6.789) has a longer in vitro half-life than Ligand A (3.741). This is a significant advantage for Ligand B.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.029 and 0.025).
15. **Binding Affinity:** Ligand B (-6.9 kcal/mol) has a slightly better binding affinity than Ligand A (-6.7 kcal/mol). While the difference is small, it's still a positive for Ligand B.
**Overall Assessment:**
Ligand B has several key advantages: significantly better metabolic stability (Cl_mic, t1/2), slightly better binding affinity, and higher BBB penetration. Ligand A has a better TPSA and Caco-2 permeability, but the improvements in metabolic stability and affinity for Ligand B outweigh these benefits, especially for a GPCR target where metabolic issues are common. The solubility is a concern for both, but can be addressed with formulation strategies.
Output:
0
2025-04-18 00:48:41,223 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (344.415 and 351.466 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (87.32) is slightly higher than Ligand B (69.22). Both are below the 140 A^2 threshold for good oral absorption, but Ligand B is better positioned, especially considering it's a GPCR.
3. **logP:** Ligand A (1.566) is within the optimal range, while Ligand B (2.99) is approaching the upper limit. Both are acceptable, but Ligand A is slightly preferred.
4. **HBD:** Both ligands have 2 H-bond donors, which is good.
5. **HBA:** Ligand A has 4 H-bond acceptors, and Ligand B has 3. Both are within the acceptable limit of 10.
6. **QED:** Both ligands have similar QED values (0.862 and 0.828), indicating good drug-likeness.
7. **DILI:** Ligand A (52.695) has a higher DILI risk than Ligand B (21.481). This is a significant advantage for Ligand B.
8. **BBB:** Ligand B (63.746) has a better BBB penetration percentile than Ligand A (52.889). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be relevant for off-target effects and overall safety.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
10. **Solubility:** Both ligands have similar, very poor solubility scores (-2.675 and -2.729). This is a concern for both compounds and would require formulation strategies.
11. **hERG:** Both ligands have low hERG inhibition liability (0.512 and 0.621), which is good.
12. **Cl_mic:** Ligand A (7.541) has a significantly lower microsomal clearance than Ligand B (16.066), indicating better metabolic stability. This is a substantial advantage for Ligand A.
13. **t1/2:** Ligand A (10.442) has a longer in vitro half-life than Ligand B (4.53), further supporting its better metabolic stability.
14. **Pgp:** Ligand A (0.036) has much lower P-gp efflux liability than Ligand B (0.294). This is a significant advantage for Ligand A, improving bioavailability.
15. **Binding Affinity:** Ligand B (-7.6 kcal/mol) has a 1 kcal/mol stronger binding affinity than Ligand A (-6.6 kcal/mol). This is a major advantage for Ligand B and could potentially outweigh some of the ADME drawbacks.
**Overall Assessment:**
Ligand B has a significantly better binding affinity and lower DILI risk, and better BBB penetration. However, Ligand A demonstrates superior ADME properties: lower Cl_mic, longer t1/2, and significantly lower P-gp efflux. The solubility is poor for both. The affinity difference is substantial (1 kcal/mol), and for a GPCR, strong binding is crucial. While Ligand A's ADME profile is better, the improved potency of Ligand B is a more critical factor for a GPCR target.
Output:
0
2025-04-18 00:48:41,223 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (338.411 and 345.443 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (69.3) is significantly better than Ligand B (82.27). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (2.346 and 1.554), falling within the 1-3 range. Ligand A is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Both ligands have the same number of HBA (3).
6. **QED:** Both ligands have similar QED values (0.855 and 0.821), indicating good drug-likeness.
7. **DILI:** Ligand B (24.04) has a much lower DILI risk than Ligand A (59.636). This is a significant advantage for Ligand B.
8. **BBB:** Ligand B (77.549) has a higher BBB penetration percentile than Ligand A (48.662). While not crucial for a cardiovascular target, it's not a detriment.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.058 and -5.1), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Both ligands have negative solubility values (-3.497 and -3.116), also concerning.
11. **hERG:** Both ligands have low hERG risk (0.493 and 0.598).
12. **Cl_mic:** Ligand B (8.722) has a much lower microsomal clearance than Ligand A (29.601), indicating better metabolic stability.
13. **t1/2:** Ligand B (-22.592) has a more negative in vitro half-life, indicating a longer half-life than Ligand A (-12.613).
14. **Pgp:** Both ligands have low Pgp efflux liability (0.094 and 0.106).
15. **Binding Affinity:** Ligand A (-6.6) has a slightly better binding affinity than Ligand B (-5.7), a difference of 0.9 kcal/mol.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Ligand A has a better logP and affinity, while Ligand B has better TPSA and Pgp. However, the significant advantages of Ligand B in terms of DILI risk and metabolic stability (Cl_mic and t1/2) outweigh the slight affinity advantage of Ligand A. The poor Caco-2 and solubility for both are concerning, but can be addressed through formulation strategies.
**Conclusion:**
Considering the balance of properties, particularly the lower DILI risk and improved metabolic stability of Ligand B, it is the more promising drug candidate.
Output:
0
2025-04-18 00:48:41,223 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (365.455 and 372.446 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (75.71) is better than Ligand A (87.74). Lower TPSA generally favors oral absorption, which is important for a cardiovascular target.
3. **logP:** Ligand B (2.169) is within the optimal 1-3 range, while Ligand A (0.042) is quite low. This is a significant advantage for Ligand B, as low logP can hinder membrane permeability.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1), but both are acceptable (<=5).
5. **HBA:** Ligand A (5) is slightly higher than Ligand B (4), but both are acceptable (<=10).
6. **QED:** Ligand B (0.725) is better than Ligand A (0.526), indicating a more drug-like profile.
7. **DILI:** Ligand B (12.641) is *much* better than Ligand A (62.737). This is a critical advantage, as DILI is a major concern in drug development.
8. **BBB:** Both ligands have similar BBB penetration (around 57%). Not a major differentiating factor for a cardiovascular target.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, Ligand B (-4.817) is slightly less negative than Ligand A (-5.165).
10. **Solubility:** Ligand B (-1.369) is better than Ligand A (-2.584), indicating better aqueous solubility.
11. **hERG:** Ligand B (0.227) is better than Ligand A (0.104), suggesting a lower risk of cardiotoxicity.
12. **Cl_mic:** Ligand B (0.853) is *much* better than Ligand A (24.21). Lower clearance indicates better metabolic stability, a crucial factor for drug efficacy.
13. **t1/2:** Ligand B (-3.307) is better than Ligand A (-11.637), indicating a longer in vitro half-life.
14. **Pgp:** Ligand B (0.041) is better than Ligand A (0.035), suggesting lower P-gp efflux.
15. **Binding Affinity:** Ligand B (-8.1) has a significantly stronger binding affinity than Ligand A (-6.0). This is a substantial advantage, potentially outweighing minor ADME drawbacks.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP, has a better TPSA, slightly better Pgp, and *significantly* better affinity. The lower DILI and improved metabolic stability (Cl_mic, t1/2) are also very important.
**Conclusion:**
Ligand B consistently outperforms Ligand A across multiple critical parameters, including DILI risk, metabolic stability, solubility, and, most importantly, binding affinity. While both have issues with Caco-2 permeability, Ligand B's overall profile is far more promising for development as a drug candidate targeting ADRB2.
Output:
0
2025-04-18 00:48:41,223 - INFO - Batch 505 complete. Total preferences: 8080
2025-04-18 00:48:41,223 - INFO - Processing batch 506/512...
2025-04-18 00:49:32,766 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Reasoning:**
Let's systematically compare the two ligands based on the provided parameters and the guidelines, keeping in mind the GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key).
1. **Molecular Weight:** Both ligands (350.419 and 347.419 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (94.48) is slightly higher than Ligand B (86.71). Both are below the 140 threshold for oral absorption, but B is preferable.
3. **logP:** Both ligands have a logP around 0.11-0.118, which is quite low. While not ideal, it's not a deal-breaker, especially given the other parameters.
4. **H-Bond Donors:** Ligand A has 2 HBD, while Ligand B has 0. Lower HBD is generally better for permeability, so Ligand B is slightly favored.
5. **H-Bond Acceptors:** Ligand A has 6 HBA, and Ligand B has 5. Both are within the acceptable range (<=10).
6. **QED:** Ligand B (0.709) has a better QED score than Ligand A (0.617), indicating a more drug-like profile.
7. **DILI:** Ligand B (55.758) has a lower DILI risk than Ligand A (41.218). Both are below the threshold of 60, but lower is better.
8. **BBB:** Both ligands have similar BBB penetration (43.583 and 49.244). Since ADRB2 is a cardiovascular target, BBB penetration isn't a primary concern, but a slightly higher value is still preferable.
9. **Caco-2 Permeability:** Ligand B (-4.762) has better Caco-2 permeability than Ligand A (-5.33). This suggests better intestinal absorption for Ligand B.
10. **Aqueous Solubility:** Ligand B (0.095) has better aqueous solubility than Ligand A (-1.137). This is a positive attribute for formulation and bioavailability.
11. **hERG Inhibition:** Ligand B (0.032) has a significantly lower hERG inhibition liability than Ligand A (0.279). This is a crucial advantage, as hERG inhibition can lead to cardiotoxicity.
12. **Microsomal Clearance:** Ligand A (0.613) has significantly lower microsomal clearance than Ligand B (20.241). This indicates better metabolic stability for Ligand A.
13. **In vitro Half-Life:** Ligand A (10.378) has a longer in vitro half-life than Ligand B (-0.547). This is a positive attribute, suggesting less frequent dosing.
14. **P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.019 and 0.004).
15. **Binding Affinity:** Both ligands have the same binding affinity (-6.2 kcal/mol).
**Overall Assessment:**
Ligand B demonstrates a more favorable profile overall. While Ligand A has better metabolic stability and half-life, Ligand B excels in crucial areas like QED, DILI risk, Caco-2 permeability, aqueous solubility, and *significantly* lower hERG inhibition liability. The lower hERG risk is a major advantage for a cardiovascular target. The slightly better TPSA and solubility also contribute to its favorability.
Output:
0
2025-04-18 00:49:32,766 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
The ADRB2 receptor is a GPCR, so the priorities are logP, Pgp, TPSA, affinity, and BBB. Let's compare the ligands step-by-step:
1. **MW:** Both ligands (374.853 and 343.427 Da) fall within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (70.25) is slightly higher than Ligand B (65.78), but both are below the 140 threshold for good absorption.
3. **logP:** Ligand A (2.927) is optimal, while Ligand B (0.883) is a bit low, potentially hindering permeation.
4. **HBD/HBA:** Both have acceptable HBD (2/1 for A and 1/4 for B) and HBA (4/4) counts.
5. **QED:** Both have good QED scores (0.622 and 0.78), indicating drug-likeness.
6. **DILI:** Ligand A (91.082) has a significantly higher DILI risk than Ligand B (10.857). This is a major concern.
7. **BBB:** Ligand B (58.86) has a better BBB penetration percentile than Ligand A (35.169), though neither are exceptionally high. For a cardiovascular target, BBB isn't *critical*, but it's a bonus.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and requires further investigation. However, the magnitude of negativity is similar.
9. **Solubility:** Both have negative solubility values, also unusual. Ligand B (-2.078) is slightly better than Ligand A (-4.509).
10. **hERG:** Both have very low hERG inhibition risk (0.285 and 0.133).
11. **Cl_mic:** Ligand B (0.749) has much lower microsomal clearance than Ligand A (17.369), indicating better metabolic stability.
12. **t1/2:** Ligand B (-1.057) has a negative in vitro half-life, which is concerning. Ligand A (31.972) is much better.
13. **Pgp:** Ligand A (0.252) has lower P-gp efflux than Ligand B (0.035), which is favorable.
14. **Affinity:** Ligand A (-6.2 kcal/mol) has a slightly better binding affinity than Ligand B (-5.7 kcal/mol), but the difference is not huge.
**Overall Assessment:**
Ligand A has a better binding affinity and Pgp profile, but its high DILI risk and higher clearance are significant drawbacks. Ligand B has a much better safety profile (DILI) and metabolic stability (Cl_mic), and acceptable logP and TPSA. While its affinity is slightly lower, the improved safety and pharmacokinetic properties outweigh this difference. The negative solubility and Caco-2 values are concerning for both and would require further investigation, but the overall profile of Ligand B is more promising.
**Output:**
0
2025-04-18 00:49:32,766 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (372.774) is slightly higher than Ligand B (349.431), but both are acceptable.
2. **TPSA:** Ligand A (42.43) is well below the 140 threshold and good for oral absorption. Ligand B (82.97) is also below 140, but higher, potentially impacting absorption slightly.
3. **logP:** Ligand A (4.18) is at the upper end of the optimal range (1-3) and could present solubility challenges. Ligand B (1.523) is well within the optimal range. This favors Ligand B.
4. **HBD:** Both ligands have acceptable HBD counts (Ligand A: 0, Ligand B: 1), well below the 5 threshold.
5. **HBA:** Both ligands have acceptable HBA counts (Ligand A: 3, Ligand B: 5), below the 10 threshold.
6. **QED:** Both ligands have good QED scores (Ligand A: 0.79, Ligand B: 0.842), indicating good drug-like properties.
7. **DILI:** Ligand A (56.146) has a moderate DILI risk, while Ligand B (21.869) has a very low DILI risk. This strongly favors Ligand B.
8. **BBB:** Ligand A (79.488) shows good BBB penetration. Ligand B (58.123) is lower, but still not terrible. Given ADRB2 is a cardiovascular target, BBB penetration isn't *critical*, but is a bonus.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.512 and -4.568), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand A (-3.98) has slightly better solubility than Ligand B (-1.307), but both are quite poor.
11. **hERG:** Ligand A (0.719) has a slightly better hERG profile than Ligand B (0.268), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand A (50.423) has a higher microsomal clearance than Ligand B (-3.641), suggesting lower metabolic stability. This favors Ligand B.
13. **t1/2:** Ligand A (7.099) has a longer half-life than Ligand B (-0.627), which is desirable.
14. **Pgp:** Ligand A (0.559) has lower P-gp efflux than Ligand B (0.022), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand A (-7.0) has slightly better binding affinity than Ligand B (-4.6). This is a significant advantage.
**Overall Assessment & GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, Pgp, TPSA, and affinity are key. Ligand A has a higher logP which is a concern, but its significantly better binding affinity (-7.0 vs -4.6) is a substantial advantage that can often outweigh minor ADME drawbacks. The better Pgp profile and longer half-life of Ligand A are also positives. While Ligand B has a much better DILI score and lower Cl_mic, the binding affinity difference is too large to ignore. The Caco-2 values are concerning for both, and would need to be addressed through formulation or structural modification.
Considering the balance of properties, the superior binding affinity of Ligand A makes it the more promising candidate, despite its slightly less favorable ADME profile.
Output:
1
2025-04-18 00:49:32,766 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands (365.5 & 368.5 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (61.88) is significantly better than Ligand B (113.44). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (1.466) is better than Ligand B (0.542). Both are within the acceptable range (1-3), but Ligand A is closer to the optimal range. Ligand B is a bit low, potentially impacting permeability.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (7). Similar to HBD, lower HBA is generally better.
6. **QED:** Ligand A (0.795) is slightly better than Ligand B (0.675), indicating a more drug-like profile.
7. **DILI:** Ligand A (19.43) is *much* better than Ligand B (47.93). This is a major advantage for Ligand A. Lower DILI risk is crucial.
8. **BBB:** Ligand A (78.52) is better than Ligand B (43.89). While not a CNS target, some degree of BBB penetration can sometimes indicate favorable permeability characteristics.
9. **Caco-2:** Both are negative, indicating poor permeability. However, the scale is not provided, so it is hard to compare.
10. **Solubility:** Both are negative, indicating poor solubility. However, the scale is not provided, so it is hard to compare.
11. **hERG:** Ligand A (0.292) is significantly better than Ligand B (0.075). Lower hERG inhibition is critical for avoiding cardiotoxicity, especially important for a cardiovascular target.
12. **Cl_mic:** Ligand A (21.29) is worse than Ligand B (-13.812). Ligand B has a negative value, suggesting very high metabolic stability.
13. **t1/2:** Ligand B (21.786) is better than Ligand A (8.95). Longer half-life is generally desirable.
14. **Pgp:** Ligand A (0.034) is better than Ligand B (0.018). Lower P-gp efflux is preferred.
15. **Affinity:** Ligand A (-7.5 kcal/mol) is 1.2 kcal/mol better than Ligand B (-5.3 kcal/mol). This is a substantial difference in binding affinity.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A performs better on logP, TPSA, and Pgp. The affinity difference is substantial.
**Overall Assessment:**
Ligand A is significantly better overall. While Ligand B has superior metabolic stability and half-life, Ligand A's superior DILI profile, hERG inhibition, affinity, logP, and TPSA outweigh these advantages. The substantial affinity difference is a key factor. The lower DILI and hERG risks are also critical for a cardiovascular drug candidate.
Output:
1
2025-04-18 00:49:32,766 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [353.463, 87.74, 0.681, 2, 4, 0.705, 14.967, 57.929, -5.166, -0.977, 0.155, 11.193, -5.528, 0.011, -6.4]
**Ligand B:** [366.447, 104.05, 0.777, 1, 9, 0.772, 77.2, 57.425, -5.199, -2.166, 0.128, 40.462, 11.835, 0.051, -6.1]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity) and general guidelines:
1. **MW:** Both are within the ideal 200-500 Da range. Ligand A (353.463) is slightly preferred.
2. **TPSA:** Ligand A (87.74) is better than Ligand B (104.05), both are below the 140 threshold, but closer to 90 is better for GPCRs.
3. **logP:** Both are acceptable (around 0.7), falling within the 1-3 range. Ligand B (0.777) is slightly higher.
4. **HBD:** Ligand A (2) is slightly better than Ligand B (1).
5. **HBA:** Ligand A (4) is better than Ligand B (9).
6. **QED:** Both are good (above 0.5). Ligand A (0.705) is slightly better.
7. **DILI:** Ligand A (14.967) is *significantly* better than Ligand B (77.2). This is a major advantage for Ligand A.
8. **BBB:** Both are similar (around 57-58%). Not a primary concern for ADRB2, which is not a CNS target.
9. **Caco-2:** Both are negative, suggesting poor permeability.
10. **Solubility:** Both are negative, suggesting poor solubility.
11. **hERG:** Both are very low risk (0.155 and 0.128).
12. **Cl_mic:** Ligand A (11.193) has much lower clearance than Ligand B (40.462), indicating better metabolic stability.
13. **t1/2:** Ligand B (11.835) has a longer half-life than Ligand A (-5.528).
14. **Pgp:** Both are very low efflux (0.011 and 0.051).
15. **Affinity:** Ligand A (-6.4) has a slightly better binding affinity than Ligand B (-6.1).
**Overall Assessment:**
Ligand A is the stronger candidate. While Ligand B has a slightly better half-life, Ligand A excels in critical areas: significantly lower DILI risk, better metabolic stability (lower Cl_mic), better TPSA and HBA/HBD, and slightly better binding affinity. The DILI risk for Ligand B is concerning. The small advantage in half-life for Ligand B is not enough to overcome the other significant drawbacks.
Output:
1
2025-04-18 00:49:32,766 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A: [384.929, 50.8, 3.334, 1, 4, 0.868, 60.644, 75.533, -4.817, -4.213, 0.466, 51.744, 38.195, 0.178, -8.6]**
**Ligand B: [364.515, 78.09, 1.983, 2, 4, 0.739, 23.342, 63.474, -5.643, -2.388, 0.218, 13.912, -18.953, 0.045, -6.4]**
Here's a breakdown, comparing each parameter and considering GPCR priorities (logP, Pgp, TPSA, affinity):
1. **MW:** Both are within the ideal 200-500 Da range. Ligand B (364.515) is slightly lower, which is generally favorable.
2. **TPSA:** Ligand A (50.8) is better than Ligand B (78.09). ADRB2 is not a CNS target, but lower TPSA generally aids absorption.
3. **logP:** Ligand A (3.334) is optimal, while Ligand B (1.983) is on the lower side. This is a significant advantage for Ligand A, as good lipophilicity is important for GPCR binding and membrane permeability.
4. **HBD:** Ligand A (1) is better than Ligand B (2). Fewer HBDs are generally preferred for permeability.
5. **HBA:** Both have 4 HBA, which is acceptable.
6. **QED:** Ligand A (0.868) is better than Ligand B (0.739), indicating a more drug-like profile.
7. **DILI:** Ligand A (60.644) is higher risk than Ligand B (23.342). This is a major concern for Ligand A.
8. **BBB:** Not a primary concern for a cardiovascular target, but Ligand A (75.533) is better than Ligand B (63.474).
9. **Caco-2:** Ligand B (-5.643) is better than Ligand A (-4.817), indicating better intestinal absorption.
10. **Solubility:** Ligand B (-2.388) is better than Ligand A (-4.213).
11. **hERG:** Both are low risk (0.466 and 0.218 respectively).
12. **Cl_mic:** Ligand B (13.912) has significantly lower clearance than Ligand A (51.744), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-18.953) has a longer half-life than Ligand A (38.195), which is desirable.
14. **Pgp:** Ligand A (0.178) has lower P-gp efflux than Ligand B (0.045), which is favorable for bioavailability.
15. **Affinity:** Ligand A (-8.6) has a significantly stronger binding affinity than Ligand B (-6.4). This is a substantial advantage.
**Overall Assessment:**
Ligand A has a much stronger binding affinity and better logP, QED, BBB, and Pgp properties. However, it has a significantly higher DILI risk and poorer metabolic stability (higher Cl_mic, shorter t1/2). Ligand B has a better safety profile (lower DILI), better solubility, absorption (Caco-2), and metabolic stability, but its affinity is weaker and logP is less optimal.
The affinity difference is substantial (2.2 kcal/mol). For a GPCR, strong binding is crucial. While the DILI risk for Ligand A is concerning, it's often possible to mitigate this through structural modifications during lead optimization. The weaker affinity of Ligand B is harder to overcome.
Therefore, despite the DILI risk, I believe Ligand A is the more promising starting point for drug development.
Output:
1
2025-04-18 00:49:32,766 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [342.399, 90.54, 1.175, 3, 3, 0.754, 39.977, 65.529, -5.281, -2.886, 0.148, -36.237, 21.422, 0.008, -7]
**Ligand B:** [364.515, 56.75, 1.619, 0, 5, 0.77, 16.479, 55.293, -5.001, -0.233, 0.221, 7.686, 17.406, 0.051, -6.7]
Here's a breakdown of each parameter, comparing A and B, and considering GPCR priorities (logP, Pgp, TPSA, affinity):
1. **MW:** Both are within the ideal range (200-500 Da). A (342.399) is slightly preferred.
2. **TPSA:** A (90.54) is better than B (56.75). Lower TPSA generally improves permeability, and while both are reasonable, A is closer to the upper limit for good absorption.
3. **logP:** Both are good (between 1-3). B (1.619) is slightly higher, which *could* be better for membrane permeability, but not significantly.
4. **HBD:** A (3) is reasonable, B (0) is excellent. Fewer HBDs generally improve permeability.
5. **HBA:** A (3) is good, B (5) is acceptable.
6. **QED:** Both are similar and acceptable (A: 0.754, B: 0.77).
7. **DILI:** A (39.977) is significantly better than B (16.479). Lower DILI risk is crucial.
8. **BBB:** A (65.529) is better than B (55.293). While not a primary concern for a cardiovascular target, some CNS exposure is possible, and higher BBB is preferable.
9. **Caco-2:** Both are negative, indicating poor permeability. A (-5.281) is slightly worse than B (-5.001).
10. **Solubility:** A (-2.886) is worse than B (-0.233). Solubility is important for bioavailability.
11. **hERG:** Both are very low (A: 0.148, B: 0.221), indicating minimal cardiotoxicity risk.
12. **Cl_mic:** A (-36.237) is *much* better than B (7.686). Lower clearance means greater metabolic stability, a significant advantage.
13. **t1/2:** A (21.422) is better than B (17.406). Longer half-life is generally desirable.
14. **Pgp:** Both are very low (A: 0.008, B: 0.051), indicating minimal efflux.
15. **Affinity:** A (-7.0) is slightly better than B (-6.7), but the difference is small.
**Overall Assessment:**
Ligand A clearly outperforms Ligand B in several critical areas: DILI risk, metabolic stability (Cl_mic), and in vitro half-life. While Ligand B has slightly better solubility and fewer HBDs, the superior safety profile and pharmacokinetic properties of Ligand A are more important for a viable drug candidate, especially given the relatively small difference in binding affinity. The TPSA is also better for Ligand A.
Therefore, I prefer Ligand A.
Output:
1
2025-04-18 00:49:32,767 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Ligand A: [354.447, 79.31, 0.26, 1, 5, 0.783, 20.706, 40.907, -4.419, -0.601, 0.197, 8.876, -0.015, 0.016, -7.4]**
**Ligand B: [360.483, 75.02, 3.368, 1, 5, 0.781, 52.191, 72.431, -5.225, -4.033, 0.35, 65.236, 1.575, 0.385, -6.1]**
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da).
**2. TPSA:** Both are acceptable for a non-CNS GPCR target (<140 A^2). Ligand B (75.02) is slightly better than Ligand A (79.31).
**3. logP:** Ligand A (0.26) is quite low, potentially hindering permeability. Ligand B (3.368) is within the optimal range (1-3). This is a significant advantage for Ligand B.
**4. H-Bond Donors:** Both have 1 HBD, which is good.
**5. H-Bond Acceptors:** Both have 5 HBA, which is good.
**6. QED:** Both have similar, good QED values (0.783 and 0.781).
**7. DILI:** Ligand A (20.706) has a much lower DILI risk than Ligand B (52.191). This is a substantial advantage for Ligand A.
**8. BBB:** BBB is less critical for ADRB2 (a cardiovascular target). Ligand B (72.431) has a higher BBB penetration than Ligand A (40.907), but this is not a major deciding factor.
**9. Caco-2:** Ligand B (-5.225) has a better Caco-2 permeability than Ligand A (-4.419).
**10. Solubility:** Ligand A (-0.601) has better solubility than Ligand B (-4.033).
**11. hERG:** Ligand A (0.197) has a lower hERG inhibition liability than Ligand B (0.35).
**12. Cl_mic:** Ligand A (8.876) has a lower microsomal clearance, indicating better metabolic stability, compared to Ligand B (65.236).
**13. t1/2:** Ligand B (1.575) has a longer in vitro half-life than Ligand A (-0.015).
**14. Pgp:** Ligand A (0.016) has lower P-gp efflux liability than Ligand B (0.385).
**15. Binding Affinity:** Ligand A (-7.4) has a slightly better binding affinity than Ligand B (-6.1). While the difference is not huge, it's a factor.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand B has a better logP and Caco-2 permeability. However, Ligand A excels in crucial safety parameters (DILI, hERG) and metabolic stability (Cl_mic). The slightly better affinity of Ligand A, combined with the significantly lower DILI and hERG risk, and better metabolic stability, makes it the more promising candidate. The low logP of Ligand A is a concern, but could potentially be addressed with further optimization.
Output:
1
2025-04-18 00:49:32,767 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (359.495 and 365.861 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (54.46) is significantly better than Ligand B (82.53). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold. Ligand B is approaching the upper limit.
3. **logP:** Both ligands have good logP values (2.825 and 2.008), falling within the optimal 1-3 range. Ligand A is slightly higher, which *could* be beneficial for membrane permeability, but both are acceptable.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (4). Lower HBA generally improves permeability.
6. **QED:** Ligand A (0.862) is slightly better than Ligand B (0.774), indicating a more drug-like profile.
7. **DILI:** Ligand A (68.05) has a higher DILI risk than Ligand B (34.703). This is a significant drawback for Ligand A.
8. **BBB:** Both have similar BBB penetration (67.003 and 66.615). Not a major differentiating factor for a cardiovascular target.
9. **Caco-2:** Both have negative Caco-2 values (-4.986 and -4.916). These values are unusual and suggest poor permeability. However, the values are very close.
10. **Solubility:** Both have negative solubility values (-2.971 and -2.916). These values are unusual and suggest poor solubility. However, the values are very close.
11. **hERG:** Ligand A (0.865) is slightly higher than Ligand B (0.369), indicating a potentially higher risk of hERG inhibition. This is a negative for Ligand A.
12. **Cl_mic:** Ligand A (54.586) has significantly better metabolic stability (lower clearance) than Ligand B (14.471). This is a major advantage for Ligand A.
13. **t1/2:** Ligand A (54.609) has a much longer in vitro half-life than Ligand B (-13.478). This is a substantial advantage for Ligand A, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.653) has lower P-gp efflux liability than Ligand B (0.18). Lower P-gp is generally preferred.
15. **Binding Affinity:** Ligand A (-7.7 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.7 kcal/mol). This 1.0 kcal/mol difference is substantial and can often outweigh minor ADME drawbacks.
**Overall Assessment:**
Ligand A has a substantially better binding affinity and metabolic stability (Cl_mic and t1/2), and lower Pgp efflux. These are critical factors for a viable drug candidate. While Ligand A has higher DILI and hERG risk, the strong binding affinity and improved PK properties are likely to be more impactful. The Caco-2 and solubility values are concerning for both, but the strong affinity of Ligand A suggests it may overcome these issues. Ligand B's lower DILI and hERG are attractive, but its weaker binding and poorer PK profile are less desirable.
Output:
1
2025-04-18 00:49:32,767 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.415 and 344.499 Da) fall comfortably within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (67.77) is higher than Ligand B (40.62). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B has a clear advantage here.
3. **logP:** Ligand A (4.314) is slightly higher than Ligand B (3.372). While both are within the acceptable range (1-3 is optimal, and these are both above 3), Ligand A is pushing the upper limit and could potentially have solubility issues. Ligand B is better.
4. **HBD:** Ligand A (1) is slightly higher than Ligand B (0). This isn't a major concern for either, but fewer HBDs generally correlate with better permeability. Ligand B is slightly better.
5. **HBA:** Ligand A (5) is higher than Ligand B (2). Similar to HBD, lower HBA is generally preferred for permeability. Ligand B is better.
6. **QED:** Both ligands have good QED scores (0.6 and 0.734), indicating generally drug-like properties. No significant difference.
7. **DILI:** Ligand A (92.865) has a significantly higher DILI risk than Ligand B (25.281). This is a major red flag for Ligand A. A lower DILI score is crucial for drug development.
8. **BBB:** Both ligands have reasonable BBB penetration (67.158 and 78.945). Since ADRB2 is not a CNS target, this is less critical, but Ligand B is slightly better.
9. **Caco-2:** Ligand A (-5.213) and Ligand B (-4.81) are both negative, indicating poor permeability. However, Ligand B is slightly less negative, suggesting marginally better permeability.
10. **Solubility:** Ligand A (-5.107) has worse solubility than Ligand B (-3.531). This, combined with its higher logP, raises concerns about formulation.
11. **hERG:** Both ligands have low hERG inhibition risk (0.679 and 0.513), which is good. No significant difference.
12. **Cl_mic:** Ligand A (72.849) has a higher microsomal clearance than Ligand B (66.288), suggesting faster metabolism and potentially lower bioavailability. Ligand B is better.
13. **t1/2:** Ligand A (94.695) has a much longer in vitro half-life than Ligand B (-5.114). This is a significant advantage for Ligand A, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.626) has slightly higher P-gp efflux liability than Ligand B (0.585). Lower P-gp efflux is generally preferred. Ligand B is slightly better.
15. **Binding Affinity:** Ligand B (-6.8 kcal/mol) has a significantly stronger binding affinity than Ligand A (-4.3 kcal/mol). This is a substantial difference (2.5 kcal/mol), and a stronger affinity can often outweigh minor ADME drawbacks.
**Overall Assessment:**
Ligand B is clearly the more promising candidate. While Ligand A has a longer half-life, its significantly higher DILI risk, higher logP, lower solubility, and weaker binding affinity are major concerns. Ligand B excels in key ADME properties (lower DILI, better solubility, lower logP, better Caco-2) and, crucially, has a much stronger binding affinity. The affinity difference is large enough to overcome the slightly shorter half-life.
Output:
0
2025-04-18 00:49:32,767 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [347.419, 97.8, -0.626, 3, 6, 0.634, 37.224, 7.135, -5.395, -0.845, 0.296, -33.919, 25.699, 0.005, -7]
**Ligand B:** [340.427, 75.19, 1.698, 1, 4, 0.85, 65.297, 67.197, -4.688, -3.559, 0.116, 29.144, -18.207, 0.259, -1.1]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (340.427) is slightly lower, which is generally favorable.
2. **TPSA:** Ligand A (97.8) is higher than Ligand B (75.19). Both are acceptable for a cardiovascular target, but Ligand B is better, being closer to the <140 threshold for good absorption.
3. **logP:** Ligand A (-0.626) is a bit low, potentially hindering membrane permeability. Ligand B (1.698) is within the optimal 1-3 range. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (3) is higher than Ligand B (1). Both are acceptable, but lower is generally preferred.
5. **HBA:** Ligand A (6) is higher than Ligand B (4). Again, lower is generally preferred.
6. **QED:** Both ligands have good QED scores (A: 0.634, B: 0.85), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (37.224) has a much lower DILI risk than Ligand B (65.297). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (7.135) has very low BBB penetration, while Ligand B (67.197) has a much better score. While not a primary concern for a cardiovascular target, higher BBB is still generally favorable.
9. **Caco-2:** Ligand A (-5.395) is very poor, indicating poor intestinal absorption. Ligand B (-4.688) is also poor, but slightly better.
10. **Solubility:** Ligand A (-0.845) is poor, while Ligand B (-3.559) is even worse. Both are problematic.
11. **hERG:** Both have low hERG risk (A: 0.296, B: 0.116). Ligand B is slightly better.
12. **Cl_mic:** Ligand A (-33.919) has a much lower (better) microsomal clearance than Ligand B (29.144), indicating greater metabolic stability.
13. **t1/2:** Ligand A (25.699) has a longer half-life than Ligand B (-18.207). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.005) has very low P-gp efflux, while Ligand B (0.259) has a slightly higher efflux. This is a benefit for Ligand A.
15. **Affinity:** Ligand A (-7.0) has a significantly better binding affinity than Ligand B (-1.1). This is a major advantage for Ligand A.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B has a better logP and TPSA, but Ligand A *significantly* outperforms in affinity and has better Pgp efflux. The DILI risk is also much lower for Ligand A. While solubility and Caco-2 are poor for both, the superior affinity and metabolic stability of Ligand A are likely to outweigh these drawbacks, especially given the potential for formulation strategies to address solubility.
**Conclusion:**
Despite the solubility and Caco-2 issues, the much stronger binding affinity, lower DILI, better metabolic stability, and lower P-gp efflux of Ligand A make it the more promising drug candidate.
**Output:**
1
2025-04-18 00:49:32,767 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.431 and 367.368 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (86.02) is better than Ligand B (93.11), both are below the 140 threshold for oral absorption.
3. **logP:** Ligand A (0.651) is slightly lower than optimal (1-3), but still acceptable. Ligand B (-0.528) is a bit low, potentially hindering permeation. Ligand A is preferred.
4. **HBD:** Ligand A (2) is better than Ligand B (3), both are within the acceptable limit of 5.
5. **HBA:** Both ligands have 5 HBA, which is within the acceptable limit of 10.
6. **QED:** Ligand A (0.737) is better than Ligand B (0.563), indicating a more drug-like profile.
7. **DILI:** Ligand A (40.132) is slightly higher than Ligand B (18.573), but both are below the concerning threshold of 60. Ligand B is preferred.
8. **BBB:** Ligand B (39.899) is better than Ligand A (32.144), but for a cardiovascular target, BBB penetration is not a high priority.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.108 and -5.186), indicating poor permeability. This is a significant concern for both.
10. **Solubility:** Both ligands have negative solubility values (-0.671 and -0.673), indicating poor solubility. This is a significant concern for both.
11. **hERG:** Ligand A (0.281) is much better than Ligand B (0.473), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand A (7.05) is much better than Ligand B (-17.624), indicating better metabolic stability.
13. **t1/2:** Ligand A (21.713) is much better than Ligand B (-9.449), indicating a longer half-life.
14. **Pgp:** Ligand A (0.164) is much better than Ligand B (0.008), indicating lower P-gp efflux.
15. **Binding Affinity:** Ligand A (-7.3) is better than Ligand B (-6.5), indicating stronger binding.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand A is better in terms of logP, Pgp, and significantly better in affinity. While TPSA is acceptable for both, the substantial difference in affinity and the better overall ADME profile of Ligand A make it more promising.
**Overall Assessment:**
Ligand A has a superior binding affinity, better metabolic stability (Cl_mic and t1/2), lower P-gp efflux, and a better QED score. While Ligand B has a slightly lower DILI risk, the other advantages of Ligand A outweigh this. The poor Caco-2 and solubility for both are concerning and would require formulation strategies, but the stronger binding and better ADME properties of Ligand A make it the more viable candidate.
Output:
1
2025-04-18 00:49:32,767 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 drug candidates. ADRB2 is a GPCR, so we'll prioritize logP, Pgp, TPSA, and affinity, alongside general drug-like properties.
**Ligand A:** [360.479, 78.43, 2.844, 3, 4, 0.677, 33.307, 28.189, -5.436, -2.976, 0.339, 47.544, -5.437, 0.101, -6.7]
**Ligand B:** [352.475, 89.87, 1.363, 3, 4, 0.652, 10.896, 52.036, -4.85, -1.887, 0.162, 7.827, -12.432, 0.024, -7.1]
1. **MW:** Both are within the ideal range (200-500 Da). A is 360.479, B is 352.475. No significant difference.
2. **TPSA:** A (78.43) is better than B (89.87). We want <140 for oral absorption, both are fine, but A is preferable.
3. **logP:** A (2.844) is optimal, B (1.363) is a bit low, potentially impacting permeability. A is better.
4. **HBD:** Both have 3 HBD, which is acceptable.
5. **HBA:** Both have 4 HBA, which is acceptable.
6. **QED:** Both are similar (A: 0.677, B: 0.652) and above the 0.5 threshold, indicating good drug-likeness.
7. **DILI:** A (33.307) is significantly better than B (10.896). Lower DILI risk is crucial. A is much better.
8. **BBB:** B (52.036) is better than A (28.189), but for a cardiovascular target, BBB penetration isn't a high priority.
9. **Caco-2:** A (-5.436) is worse than B (-4.85). Higher is better, so B is slightly better here.
10. **Solubility:** A (-2.976) is worse than B (-1.887). Higher is better, so B is slightly better here.
11. **hERG:** A (0.339) is better than B (0.162). Lower hERG risk is critical for cardiovascular drugs. A is better.
12. **Cl_mic:** A (47.544) is better than B (7.827). Lower clearance indicates better metabolic stability. A is much better.
13. **t1/2:** B (-12.432) is significantly better than A (-5.437). Longer half-life is desirable. B is better.
14. **Pgp:** A (0.101) is better than B (0.024). Lower Pgp efflux is preferable. A is better.
15. **Affinity:** B (-7.1) is slightly better than A (-6.7), a 0.4 kcal/mol difference. This is a reasonable advantage, but not overwhelming.
**Overall Assessment:**
Ligand A has a significantly better safety profile (DILI, hERG) and metabolic stability (Cl_mic). Its logP is optimal, and it has better Pgp properties. While Ligand B has a slightly better affinity and half-life, the advantages of A in safety and metabolic stability are more important for a cardiovascular drug candidate. The slight advantage in affinity of B is not enough to overcome the substantial benefits of A.
Output:
1
2025-04-18 00:49:32,767 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [362.901, 49.41, 3.95, 1, 2, 0.798, 35.673, 81.466, -4.784, -4.528, 0.67, 62.087, -1.365, 0.602, -8.3]**
**Ligand B: [350.463, 87.47, 1.491, 2, 5, 0.704, 9.965, 64.986, -5.223, -0.864, 0.085, 17.549, 11.267, 0.005, -6.2]**
1. **Molecular Weight:** Both are within the ideal range (200-500 Da). Ligand B (350.463) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (49.41) is significantly better than Ligand B (87.47). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (3.95) is optimal, while Ligand B (1.491) is on the lower side. A logP between 1-3 is preferred, and Ligand A is closer to this ideal.
4. **H-Bond Donors:** Both have 2 HBD, which is within the acceptable limit of <=5.
5. **H-Bond Acceptors:** Ligand A (2) is better than Ligand B (5). Lower HBA is generally preferred for better permeability.
6. **QED:** Both are good (>=0.5), with Ligand A (0.798) slightly better than Ligand B (0.704).
7. **DILI:** Ligand A (35.673) has a much lower DILI risk than Ligand B (9.965), which is a significant advantage.
8. **BBB:** Ligand A (81.466) has higher BBB penetration than Ligand B (64.986), but this is less critical for a cardiovascular target.
9. **Caco-2:** Ligand A (-4.784) is better than Ligand B (-5.223), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-4.528) is better than Ligand B (-0.864).
11. **hERG:** Ligand A (0.67) has a lower hERG risk than Ligand B (0.085), which is a critical safety parameter.
12. **Cl_mic:** Ligand A (62.087) has a higher (worse) microsomal clearance than Ligand B (17.549), indicating faster metabolism.
13. **t1/2:** Ligand B (11.267) has a significantly longer in vitro half-life than Ligand A (-1.365). This is a major advantage for dosing frequency.
14. **Pgp:** Ligand A (0.602) has lower P-gp efflux than Ligand B (0.005), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand A (-8.3) has a significantly stronger binding affinity than Ligand B (-6.2). A difference of >1.5 kcal/mol is substantial and can outweigh other drawbacks.
**Overall Assessment:**
Ligand A has a significantly better binding affinity, lower DILI risk, lower hERG risk, better solubility, better Caco-2 permeability, and lower Pgp efflux. While Ligand B has a longer half-life and lower clearance, the substantial advantage in binding affinity and safety profile of Ligand A are more important for a GPCR target like ADRB2. The longer half-life of Ligand B is valuable, but can be addressed through formulation strategies or prodrug approaches. The strong binding affinity of Ligand A suggests a potentially lower dose requirement, which could mitigate some of the clearance concerns.
Output:
1
2025-04-18 00:49:32,767 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (353.394 and 346.387 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (110.52 and 110.28) are below the 140 A^2 threshold for good oral absorption, but higher than the <90 A^2 for CNS targets (not a primary concern for ADRB2, a cardiovascular target). Again, no major difference.
3. **logP:** Ligand A (1.348) is slightly higher than Ligand B (0.73). Both are within the optimal 1-3 range, but A is closer to the sweet spot.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (2), both are acceptable.
5. **HBA:** Ligand A (4) is lower than Ligand B (6). Lower HBA is generally preferred for better permeability.
6. **QED:** Both ligands have similar QED scores (0.613 and 0.601), indicating good drug-likeness.
7. **DILI:** Ligand A (43.66) has a significantly lower DILI risk than Ligand B (65.684). This is a substantial advantage for Ligand A.
8. **BBB:** Ligand A (75.572) has a higher BBB penetration percentile than Ligand B (56.378). While ADRB2 isn't a CNS target, some peripheral exposure can be beneficial.
9. **Caco-2:** Ligand A (-5.091) and Ligand B (-4.855) are both negative, indicating poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-2.629) and Ligand B (-2.412) are both negative, indicating poor solubility. This is a concern for both.
11. **hERG:** Ligand A (0.662) has a higher hERG inhibition liability than Ligand B (0.058). This is a significant advantage for Ligand B.
12. **Cl_mic:** Ligand B (39.612) has a lower microsomal clearance than Ligand A (51.216), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-24.258) has a longer in vitro half-life than Ligand B (0.811). This is a major advantage for Ligand A.
14. **Pgp:** Ligand A (0.114) has a lower P-gp efflux liability than Ligand B (0.012). Lower efflux is generally preferred.
15. **Affinity:** Ligand A (-7.4 kcal/mol) has a stronger binding affinity than Ligand B (-6.0 kcal/mol). This is a 1.4 kcal/mol difference, which is substantial and can outweigh some ADME drawbacks.
**GPCR-specific priorities:** For ADRB2 (a cardiovascular GPCR), logP, Pgp, TPSA, and affinity are key. Ligand A has a slightly better logP, lower Pgp efflux, comparable TPSA, and significantly better affinity. The lower DILI risk and longer half-life of Ligand A are also highly desirable. While Ligand B has a better hERG profile and lower clearance, the superior affinity and safety profile of Ligand A are more important.
**Conclusion:**
Considering the balance of properties, especially the significantly better binding affinity, lower DILI risk, and longer half-life of Ligand A, it is the more promising drug candidate.
Output:
1
2025-04-18 00:49:32,768 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (341.382 Da) is slightly lower than Ligand B (350.503 Da), which isn't a significant difference.
**2. TPSA:** Ligand A (55.4) is slightly higher than Ligand B (49.85). Both are well below the 140 Angstrom threshold for good oral absorption.
**3. logP:** Ligand A (3.619) is slightly higher than Ligand B (2.687), both within the optimal 1-3 range. Ligand B is closer to the lower end, which could potentially impact permeability.
**4. H-Bond Donors:** Ligand A (1) is better than Ligand B (0). Having some H-bond donors can aid solubility.
**5. H-Bond Acceptors:** Both ligands have 3 H-bond acceptors, which is acceptable.
**6. QED:** Ligand A (0.845) has a better QED score than Ligand B (0.74), indicating a more drug-like profile.
**7. DILI Risk:** Ligand B (6.282) has a *much* lower DILI risk than Ligand A (67.429). This is a significant advantage for Ligand B.
**8. BBB Penetration:** Both ligands have high BBB penetration (Ligand A: 84.141, Ligand B: 83.443). This is less crucial for a cardiovascular target like ADRB2, but not detrimental.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the values are similar (-4.454 for A, -4.22 for B).
**10. Aqueous Solubility:** Ligand A (-5.19) has worse solubility than Ligand B (-2.011).
**11. hERG Inhibition:** Ligand A (0.577) has a slightly higher hERG inhibition risk than Ligand B (0.479), but both are relatively low.
**12. Microsomal Clearance:** Ligand A (73.849) has higher clearance than Ligand B (63.63), indicating lower metabolic stability.
**13. In vitro Half-Life:** Both ligands have negative half-life values (-10.107 for A, -10.012 for B), which is also unusual. The values are similar.
**14. P-gp Efflux:** Both ligands have low P-gp efflux liability (0.242 for A, 0.106 for B).
**15. Binding Affinity:** Ligand A (-7.6 kcal/mol) has a significantly stronger binding affinity than Ligand B (-5.1 kcal/mol). This is a substantial difference (>1.5 kcal/mol advantage).
**Overall Assessment:**
The primary trade-off is between binding affinity (strongly favors Ligand A) and safety/ADME properties (strongly favor Ligand B). The DILI risk for Ligand A is very concerning. While the affinity of Ligand A is excellent, the high DILI risk and poorer solubility/metabolic stability are major drawbacks. Ligand B, despite its weaker affinity, presents a much more favorable safety profile and better ADME properties. For a cardiovascular target where chronic administration is likely, minimizing toxicity is paramount. The difference in affinity, while significant, might be overcome with further optimization of Ligand B.
Output:
0
2025-04-18 00:49:32,768 - INFO - Batch 506 complete. Total preferences: 8096
2025-04-18 00:49:32,768 - INFO - Processing batch 507/512...
2025-04-18 00:50:23,293 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (346.343 Da) is slightly lower, which is generally favorable for permeability.
**2. TPSA:** Ligand A (121.72) is better than Ligand B (49.41). For a cardiovascular GPCR, TPSA is important, and lower is generally better for absorption.
**3. logP:** Ligand B (2.816) is within the optimal range (1-3), while Ligand A (-0.958) is below 1, potentially hindering permeation. This is a significant advantage for Ligand B.
**4. H-Bond Donors:** Ligand A (2) is slightly higher than Ligand B (1), but both are acceptable.
**5. H-Bond Acceptors:** Ligand A (7) is higher than Ligand B (3), but both are within the acceptable limit of 10.
**6. QED:** Both ligands have good QED scores (A: 0.674, B: 0.813), indicating drug-like properties. Ligand B is slightly better.
**7. DILI:** Ligand A (74.409) has a higher DILI risk than Ligand B (13.61). This is a significant concern, as lower DILI is highly desirable.
**8. BBB:** Ligand B (77.2) has a higher BBB percentile than Ligand A (48.779). While not a primary concern for a cardiovascular target, higher BBB is generally favorable.
**9. Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
**10. Solubility:** Ligand A (-1.673) has better solubility than Ligand B (-3.252). Solubility is important for bioavailability.
**11. hERG:** Ligand A (0.087) has a lower hERG inhibition liability than Ligand B (0.561), which is a positive attribute.
**12. Cl_mic:** Ligand A (19.04) has significantly lower microsomal clearance than Ligand B (67.033), indicating better metabolic stability.
**13. t1/2:** Ligand A (-10.383) has a negative in vitro half-life, which is concerning. Ligand B (-7.406) is also negative but less so.
**14. Pgp:** Ligand A (0.031) has lower P-gp efflux liability than Ligand B (0.07), which is favorable.
**15. Binding Affinity:** Ligand A (-7.1) has a slightly better binding affinity than Ligand B (-5). However, the difference is not substantial enough to outweigh other significant drawbacks.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand B appears more promising despite its slightly lower affinity. The significantly better logP, lower DILI risk, and higher BBB penetration are crucial advantages. While Ligand A has better metabolic stability and lower Pgp efflux, its poor logP and higher DILI risk are major concerns. The negative half-life for both is concerning and would require further investigation, but the other properties of Ligand B make it the more viable candidate.
Output:
0
2025-04-18 00:50:23,293 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (345.359 Da and 348.418 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (110.45) is higher than Ligand B (58.64). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for permeability. Ligand B is significantly better here.
3. **logP:** Both ligands have good logP values (1.472 and 2.379), falling within the optimal 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability.
4. **HBD:** Both have 1 HBD, which is within the acceptable limit of 5.
5. **HBA:** Ligand A has 7 HBA, while Ligand B has 3. Both are below the 10 threshold, but Ligand B is better.
6. **QED:** Both ligands have good QED scores (0.789 and 0.853), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (75.107) has a higher DILI risk than Ligand B (43.738). This is a significant advantage for Ligand B.
8. **BBB:** Ligand A (75.572) has a moderate BBB penetration, while Ligand B (88.135) is better. While ADRB2 isn't a CNS target, some peripheral exposure is still desirable, and higher BBB penetration *can* correlate with better overall distribution.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.484 and -4.514), indicating poor permeability. This is a concern for both, but similar for both.
10. **Solubility:** Both ligands have negative solubility values (-2.627 and -3.551), indicating poor solubility. This is a concern for both, but Ligand B is slightly worse.
11. **hERG:** Ligand A (0.116) has a slightly lower hERG risk than Ligand B (0.56). This is a slight advantage for Ligand A.
12. **Cl_mic:** Ligand A (68.322) has a lower microsomal clearance than Ligand B (46.901), suggesting better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand B (17.422) has a significantly longer in vitro half-life than Ligand A (-13.837). This is a major advantage for Ligand B.
14. **Pgp:** Ligand A (0.004) has much lower P-gp efflux than Ligand B (0.293). This is a significant advantage for Ligand A.
15. **Binding Affinity:** Ligand B (-6.9 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.3 kcal/mol). This is a substantial advantage for Ligand B, potentially outweighing some ADME concerns.
**Overall Assessment:**
Ligand B has a significantly better binding affinity, a longer half-life, lower DILI risk, and lower TPSA. While it has slightly worse solubility and higher Pgp efflux, the strong affinity and improved safety profile are compelling. Ligand A has better metabolic stability and Pgp efflux, but its weaker binding affinity and higher DILI risk are concerning. Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity), the strong affinity of Ligand B is the most important factor.
Output:
0
2025-04-18 00:50:23,293 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 drug candidates. ADRB2 is a GPCR, so we'll prioritize logP, Pgp, TPSA, and affinity, alongside general drug-like properties.
**Ligand A: [348.418, 75.27, 3.117, 2, 3, 0.829, 40.442, 82.823, -4.576, -3.013, 0.164, 32.942, 9.685, 0.13, -8.1]**
* **MW:** 348.418 Da - Good, within the ideal range.
* **TPSA:** 75.27 - Good, below the 140 threshold for oral absorption.
* **logP:** 3.117 - Excellent, within the optimal 1-3 range.
* **HBD:** 2 - Good, well within the acceptable limit.
* **HBA:** 3 - Good, well within the acceptable limit.
* **QED:** 0.829 - Excellent, very drug-like.
* **DILI:** 40.442 - Good, low risk.
* **BBB:** 82.823 - Very good, suggesting reasonable CNS penetration if desired (though not critical for ADRB2 which is primarily cardiovascular).
* **Caco-2:** -4.576 - Poor, indicates poor permeability.
* **Solubility:** -3.013 - Poor, indicates poor solubility.
* **hERG:** 0.164 - Very good, low risk of cardiotoxicity.
* **Cl_mic:** 32.942 - Moderate, not ideal, but not terrible.
* **t1/2:** 9.685 - Moderate, could be better.
* **Pgp:** 0.13 - Excellent, low efflux.
* **Affinity:** -8.1 kcal/mol - Excellent, very strong binding.
**Ligand B: [371.503, 100.55, 1.668, 3, 6, 0.578, 55.758, 41.218, -5.128, -2.739, 0.462, 36.002, 23.465, 0.107, -7.1]**
* **MW:** 371.503 Da - Good, within the ideal range.
* **TPSA:** 100.55 - Acceptable, but approaching the upper limit for good absorption.
* **logP:** 1.668 - Acceptable, but on the lower end of the optimal range.
* **HBD:** 3 - Good, within the acceptable limit.
* **HBA:** 6 - Good, within the acceptable limit.
* **QED:** 0.578 - Acceptable, but not as strong as Ligand A.
* **DILI:** 55.758 - Moderate, slightly elevated risk.
* **BBB:** 41.218 - Poor, low CNS penetration.
* **Caco-2:** -5.128 - Poor, indicates poor permeability.
* **Solubility:** -2.739 - Poor, indicates poor solubility.
* **hERG:** 0.462 - Moderate, slightly elevated risk.
* **Cl_mic:** 36.002 - Moderate, similar to Ligand A.
* **t1/2:** 23.465 - Good, better than Ligand A.
* **Pgp:** 0.107 - Excellent, low efflux.
* **Affinity:** -7.1 kcal/mol - Very good, strong binding, but not as strong as Ligand A.
**Comparison and Decision:**
Ligand A has a significantly better binding affinity (-8.1 vs -7.1 kcal/mol). While Ligand B has a slightly longer half-life, the poor Caco-2 and solubility of both ligands are concerning. However, the superior affinity of Ligand A, combined with its better QED, lower DILI risk, and excellent Pgp profile, outweigh the slightly shorter half-life. The BBB value of Ligand A is also a bonus, even though not crucial for this target. The logP of Ligand A is also more favorable.
Therefore, I would choose Ligand A.
1
2025-04-18 00:50:23,293 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [363.443, 96.67, 1.693, 1, 6, 0.876, 80.225, 83.249, -4.951, -3.976, 0.203, -4.707, 45.781, 0.073, -6.2]
**Ligand B:** [348.407, 99.69, 0.388, 2, 7, 0.717, 61.225, 66.382, -4.868, -2.147, 0.222, 44.782, -18.078, 0.007, -4.5]
Here's a step-by-step comparison, keeping GPCR priorities (logP, Pgp, TPSA, affinity) in mind:
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (348.4) is slightly lower, which *could* be a minor advantage for permeability, but both are acceptable.
2. **TPSA:** Both are reasonably good (96.67 and 99.69), being under 140, suggesting reasonable oral absorption potential.
3. **logP:** Ligand A (1.693) is better than Ligand B (0.388). The ideal range is 1-3, and Ligand B is quite low, potentially hindering membrane permeability. This is a significant drawback for a GPCR target.
4. **HBD/HBA:** Ligand A (1 HBD, 6 HBA) is slightly better than Ligand B (2 HBD, 7 HBA). Both are within acceptable limits, but fewer H-bonds generally improve permeability.
5. **QED:** Ligand A (0.876) has a better QED score than Ligand B (0.717), indicating a more drug-like profile.
6. **DILI:** Ligand B (61.225) has a lower DILI risk than Ligand A (80.225), which is a positive.
7. **BBB:** Ligand A (83.249) has a better BBB penetration score than Ligand B (66.382). While not a primary concern for a cardiovascular target, it's a slight advantage.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. This is a concern for both.
9. **Solubility:** Ligand A (-3.976) has better solubility than Ligand B (-2.147). Solubility is important for bioavailability.
10. **hERG:** Both have very low hERG inhibition risk (0.203 and 0.222), which is excellent.
11. **Cl_mic:** Ligand A (-4.707) has a lower (better) microsomal clearance than Ligand B (44.782), indicating better metabolic stability. This is a significant advantage.
12. **t1/2:** Ligand A (45.781) has a much longer in vitro half-life than Ligand B (-18.078). This is a major advantage, potentially leading to less frequent dosing.
13. **Pgp:** Both have very low Pgp efflux liability (0.073 and 0.007).
14. **Affinity:** Ligand A (-6.2 kcal/mol) has a stronger binding affinity than Ligand B (-4.5 kcal/mol). This is a substantial difference, and a >1.5 kcal/mol advantage often outweighs other concerns.
**Overall Assessment:**
Ligand A is the stronger candidate. While Ligand B has a slightly lower DILI risk, Ligand A excels in key areas: logP, QED, metabolic stability (Cl_mic), half-life, and, most importantly, binding affinity. The significantly better affinity of Ligand A (-6.2 vs -4.5) is a major driver for this decision. The lower logP of Ligand B is a significant concern for a GPCR target, potentially hindering its ability to reach the receptor. The longer half-life and better metabolic stability of Ligand A also contribute to its superior profile.
Output:
1
2025-04-18 00:50:23,293 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
We are targeting ADRB2, a GPCR, so the priorities are logP, Pgp, TPSA, and affinity, with metabolic stability also being important.
* **Molecular Weight:** Both ligands are within the ideal range (200-500 Da).
* **TPSA:** Ligand B (52.65) is significantly better than Ligand A (114.35). Lower TPSA generally improves oral absorption and is particularly important for GPCRs.
* **logP:** Ligand B (1.583) is within the optimal range (1-3), while Ligand A (-0.955) is slightly below, which could hinder permeability.
* **H-Bond Donors/Acceptors:** Ligand A has 3 HBD and 6 HBA, while Ligand B has 1 HBD and 3 HBA. Both are acceptable, but Ligand B is slightly more favorable.
* **QED:** Both ligands have good QED scores (A: 0.558, B: 0.785), indicating good drug-like properties. Ligand B is better.
* **DILI:** Ligand B (8.841) has a much lower DILI risk than Ligand A (44.552). This is a significant advantage.
* **BBB:** Ligand B (91.082) has excellent BBB penetration, while Ligand A (33.424) is moderate. While ADRB2 isn't exclusively a CNS target, good BBB penetration can be beneficial for overall distribution and reducing off-target effects.
* **Caco-2 Permeability:** Both are negative, but Ligand B (-4.499) is less negative than Ligand A (-5.554), suggesting slightly better permeability.
* **Aqueous Solubility:** Both are negative, indicating poor solubility. Ligand A (-1.08) is slightly better than Ligand B (-2.245).
* **hERG Inhibition:** Both have low hERG risk (A: 0.109, B: 0.573).
* **Microsomal Clearance:** Ligand B (-18.275) has significantly lower (better) microsomal clearance than Ligand A (-8.125), indicating better metabolic stability.
* **In vitro Half-Life:** Ligand B (7.26) has a much longer half-life than Ligand A (-6.016).
* **P-gp Efflux:** Both have very low P-gp efflux (A: 0.006, B: 0.039).
* **Binding Affinity:** Ligand A (-5.8 kcal/mol) and Ligand B (-6.1 kcal/mol) have similar binding affinities, with Ligand B being slightly better.
**Overall Assessment:**
Ligand B consistently outperforms Ligand A across most critical ADME properties, particularly TPSA, logP, DILI, BBB, microsomal clearance, and half-life. While Ligand A has slightly better solubility, the other advantages of Ligand B are far more important for a GPCR target like ADRB2. The small difference in binding affinity is not enough to overcome the superior ADME profile of Ligand B.
**Output:**
0
2025-04-18 00:50:23,294 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (a cardiovascular GPCR) drug candidates.
**Ligand A:** [354.837, 43.26, 4.128, 1, 3, 0.723, 62.001, 56.34, -4.861, -5.23, 0.746, 83.119, 14.222, 0.563, -5.4]
**Ligand B:** [346.515, 40.62, 3.332, 0, 2, 0.717, 13.339, 82.164, -4.556, -3.277, 0.544, 60.133, -1.014, 0.204, -6.8]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity) and general drug-like properties:
1. **MW:** Both are within the ideal 200-500 Da range. Ligand B (346.5) is slightly smaller, which is generally favorable.
2. **TPSA:** Both are reasonably good, under 140. Ligand B (40.62) is better than Ligand A (43.26), increasing the chance of good oral absorption.
3. **logP:** Ligand A (4.128) is a bit high, potentially leading to off-target effects or solubility issues. Ligand B (3.332) is much better, falling within the optimal 1-3 range.
4. **HBD/HBA:** Ligand A has 1 HBD and 3 HBA, while Ligand B has 0 HBD and 2 HBA. Both are acceptable.
5. **QED:** Both are similar and above the 0.5 threshold, indicating good drug-likeness.
6. **DILI:** Ligand A (62.001) has a moderate DILI risk, while Ligand B (13.339) has a very low risk. This is a significant advantage for Ligand B.
7. **BBB:** Ligand B (82.164) has a much higher BBB penetration score than Ligand A (56.34). While ADRB2 isn't necessarily a CNS target, some peripheral distribution can be influenced by BBB transporters, and higher BBB is generally a positive sign of good permeability.
8. **Caco-2:** Both have negative values, indicating good permeability. Ligand A (-4.861) is slightly better than Ligand B (-4.556).
9. **Solubility:** Both have negative values, indicating good solubility. Ligand B (-3.277) is better than Ligand A (-5.23).
10. **hERG:** Both have low hERG risk. Ligand B (0.544) is slightly better.
11. **Cl_mic:** Ligand B (60.133) has lower microsomal clearance, suggesting better metabolic stability than Ligand A (83.119).
12. **t1/2:** Ligand B (-1.014) has a slightly longer in vitro half-life than Ligand A (14.222).
13. **Pgp:** Ligand A (0.563) has higher P-gp efflux, which is undesirable. Ligand B (0.204) has much lower efflux, improving bioavailability.
14. **Affinity:** Ligand B (-6.8 kcal/mol) has significantly stronger binding affinity than Ligand A (-5.4 kcal/mol). This is a >1.5 kcal/mol advantage and is a major deciding factor.
**Overall Assessment:**
Ligand B is clearly superior. It has a better logP, significantly lower DILI risk, better BBB penetration, lower P-gp efflux, better metabolic stability, and, most importantly, a substantially stronger binding affinity. While Ligand A has slightly better Caco-2 permeability, the other advantages of Ligand B outweigh this minor difference.
Output:
0
2025-04-18 00:50:23,294 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.475 and 344.415 Da) fall comfortably within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (81.08) is significantly better than Ligand B (108.29). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (1.173 and 1.023), falling within the optimal 1-3 range. Similar.
4. **HBD:** Ligand A (2) is preferable to Ligand B (3). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (4) is preferable to Ligand B (3). Lower HBA generally improves permeability.
6. **QED:** Both ligands have similar, good QED scores (0.728 and 0.759), indicating good drug-like properties.
7. **DILI:** Ligand A (17.449) has a much lower DILI risk than Ligand B (40.83). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (43.738) has a lower BBB penetration than Ligand B (51.066). Since ADRB2 is a cardiovascular target, BBB penetration is not a high priority.
9. **Caco-2:** Ligand A (-4.755) is better than Ligand B (-5.436). Higher Caco-2 permeability indicates better intestinal absorption.
10. **Solubility:** Ligand A (-0.935) is better than Ligand B (-3.996). Better solubility is generally preferred.
11. **hERG:** Ligand A (0.221) has a lower hERG risk than Ligand B (0.139). Lower hERG risk is crucial for avoiding cardiotoxicity.
12. **Cl_mic:** Ligand A (0.564) has a much lower microsomal clearance than Ligand B (2.474), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-0.472) has a better in vitro half-life than Ligand B (-16.079).
14. **Pgp:** Ligand A (0.059) has a lower Pgp efflux liability than Ligand B (0.01). Lower Pgp efflux is generally preferred.
15. **Affinity:** Both ligands have the same binding affinity (-7.0 kcal/mol).
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most ADME-Tox properties. The most significant advantages for Ligand A are its lower DILI risk, lower microsomal clearance, better solubility, and better in vitro half-life. While Ligand B has slightly better BBB penetration, this is not a major concern for a cardiovascular target. The equal binding affinity removes that as a differentiating factor.
Output:
1
2025-04-18 00:50:23,294 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (341.386 and 367.471 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (62.3) is significantly better than Ligand B (88.6). ADRB2 is a cardiovascular target, not CNS, but lower TPSA generally aids absorption.
3. **logP:** Both ligands have good logP values (2.559 and 1.906), falling within the 1-3 range. Ligand B is slightly lower, which could be a minor drawback.
4. **HBD:** Both have 1 HBD, which is acceptable.
5. **HBA:** Ligand A has 3 HBA, while Ligand B has 6. Ligand A is preferable here, keeping within the desired range.
6. **QED:** Ligand A (0.93) has a much better QED score than Ligand B (0.744), indicating a more drug-like profile.
7. **DILI:** Both ligands have acceptable DILI risk (52.772 and 49.128), below the 60 threshold. Ligand B is slightly better.
8. **BBB:** Ligand A (80.109) has a higher BBB penetration percentile than Ligand B (68.786). While not a primary concern for a cardiovascular target, higher BBB is generally favorable.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-4.764) is slightly better than Ligand B (-5.066).
10. **Solubility:** Both have negative solubility values, indicating poor solubility. Ligand A (-3.082) is slightly better than Ligand B (-2.63).
11. **hERG:** Both ligands have low hERG inhibition liability (0.43 and 0.302), which is excellent.
12. **Cl_mic:** Ligand A (13.405) has a significantly lower microsomal clearance than Ligand B (60.667), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-1.417) has a slightly better in vitro half-life than Ligand B (-17.024).
14. **Pgp:** Both ligands have low P-gp efflux liability (0.198 and 0.067).
15. **Binding Affinity:** Ligand A (-7.0) and Ligand B (-6.7) have very similar binding affinities. The 0.3 kcal/mol difference is not substantial enough to override other ADME considerations.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A is better in TPSA, Pgp, and has a slightly better logP. The affinity difference is minimal. Ligand A also has a significantly better QED and Cl_mic.
**Conclusion:**
Ligand A demonstrates a superior overall profile, particularly regarding drug-likeness (QED), metabolic stability (Cl_mic), and TPSA. While both ligands have acceptable DILI and hERG, the combined advantages of Ligand A make it the more promising candidate.
Output:
1
2025-04-18 00:50:23,294 - INFO - Here's a step-by-step reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 GPCR, followed by the final output.
**Ligand A: [383.319, 61.36, 4.234, 3, 2, 0.729, 18.379, 74.176, -4.596, -4.327, 0.669, -3.012, 30.796, 0.272, -7.2]**
**Ligand B: [348.487, 58.64, 2.346, 1, 3, 0.83, 6.049, 87.864, -4.563, -2.753, 0.487, 38.614, 11.499, 0.032, -7.0]**
1. **Molecular Weight:** Both ligands are within the ideal 200-500 Da range. Ligand B (348.487 Da) is slightly lower, which is generally favorable for permeability, but both are acceptable.
2. **TPSA:** Both are below the 140 A^2 threshold for oral absorption (A: 61.36, B: 58.64). This is good.
3. **logP:** Ligand A (4.234) is a bit high, potentially leading to solubility issues and off-target effects. Ligand B (2.346) is within the optimal 1-3 range. This favors Ligand B.
4. **H-Bond Donors:** Ligand A has 3 HBD, which is acceptable. Ligand B has 1 HBD, which is also good.
5. **H-Bond Acceptors:** Both have acceptable HBA counts (A: 2, B: 3).
6. **QED:** Both have good QED values (A: 0.729, B: 0.83), indicating drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A has a DILI risk of 18.379%, which is good (below 40%). Ligand B has a very low DILI risk of 6.049%, which is excellent. This strongly favors Ligand B.
8. **BBB:** Both have reasonable BBB penetration (A: 74.176%, B: 87.864%). Ligand B is better, which is important for a GPCR.
9. **Caco-2 Permeability:** Both have negative Caco-2 values, which is unusual and potentially problematic. However, the values are similar (-4.596 and -4.563) and don't strongly differentiate the ligands.
10. **Aqueous Solubility:** Both have negative solubility values, which is also unusual. Ligand B (-2.753) is slightly better than Ligand A (-4.327).
11. **hERG Inhibition:** Both have low hERG inhibition risk (A: 0.669, B: 0.487). Ligand B is slightly better.
12. **Microsomal Clearance:** Ligand A has a negative clearance (-3.012), indicating good metabolic stability. Ligand B has a higher clearance (38.614), suggesting faster metabolism. This favors Ligand A.
13. **In vitro Half-Life:** Ligand A has a longer half-life (30.796 hours) than Ligand B (11.499 hours). This is a significant advantage for dosing convenience and favors Ligand A.
14. **P-gp Efflux:** Both have low P-gp efflux liability (A: 0.272, B: 0.032). Ligand B is better.
15. **Binding Affinity:** Ligand A (-7.2 kcal/mol) has a slightly better binding affinity than Ligand B (-7.0 kcal/mol). While the difference is small, it's still a factor.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand B appears to be the better candidate. It has a more optimal logP, lower DILI risk, better BBB penetration, and lower P-gp efflux. While Ligand A has better metabolic stability and slightly better affinity, the ADME properties of Ligand B are more favorable overall for a GPCR target. The slight affinity difference is likely surmountable with further optimization.
Output:
0
2025-04-18 00:50:23,294 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (344.419 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (88.21) is better than Ligand B (46.09), falling well below the 140 A^2 threshold for oral absorption.
3. **logP:** Ligand A (1.589) is optimal, while Ligand B (4.642) is pushing the upper limit and could present solubility issues.
4. **HBD:** Ligand A (2) is reasonable, and Ligand B (0) is also acceptable.
5. **HBA:** Ligand A (6) is good, while Ligand B (3) is also good.
6. **QED:** Ligand A (0.885) is excellent, indicating a highly drug-like profile. Ligand B (0.645) is still acceptable but less favorable.
7. **DILI:** Ligand A (49.632) has a slightly higher DILI risk than Ligand B (37.069), but both are below the concerning threshold of 60.
8. **BBB:** Ligand B (92.943) has significantly better BBB penetration than Ligand A (71.966). While ADRB2 isn't strictly a CNS target, some CNS exposure can occur, and higher BBB penetration is generally a plus.
9. **Caco-2:** Both ligands have negative Caco-2 values, indicating poor permeability. Ligand A (-4.854) is slightly better than Ligand B (-4.575).
10. **Solubility:** Ligand A (-2.434) has better solubility than Ligand B (-4.6). This is important given Ligand B's higher logP.
11. **hERG:** Ligand A (0.422) has a lower hERG risk than Ligand B (0.843). This is a significant advantage.
12. **Cl_mic:** Ligand A (11.523) has a lower microsomal clearance, suggesting better metabolic stability than Ligand B (56.211).
13. **t1/2:** Ligand A (29.337) has a longer in vitro half-life than Ligand B (23.51), which is desirable.
14. **Pgp:** Ligand A (0.012) has significantly lower P-gp efflux liability than Ligand B (0.681).
15. **Binding Affinity:** Ligand A (-6.1) has a slightly better binding affinity than Ligand B (-5.0).
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A excels in logP, TPSA, and Pgp. Ligand B has better BBB penetration, but the other factors favor Ligand A. The affinity difference, while not huge, combined with the better ADME properties, tips the balance.
**Conclusion:**
Ligand A presents a more balanced profile with better predicted ADME properties (solubility, metabolic stability, P-gp efflux, hERG risk) and comparable binding affinity. While Ligand B has better BBB penetration, the other advantages of Ligand A are more critical for overall drug development success.
Output:
1
2025-04-18 00:50:23,294 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (344.455 Da) is slightly lower, which can be advantageous for permeability.
2. **TPSA:** Ligand A (52.61) is better than Ligand B (58.2). Both are acceptable, but lower TPSA generally favors oral absorption, a key consideration for a cardiovascular drug.
3. **logP:** Both ligands have good logP values (A: 4.299, B: 3.676), falling within the optimal 1-3 range. Ligand A is a bit higher, which *could* lead to slight solubility issues, but isn't a major concern.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs generally improve membrane permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (4). Similar to HBD, lower HBA is generally better for permeability.
6. **QED:** Both ligands have similar and acceptable QED values (A: 0.735, B: 0.721).
7. **DILI:** Both ligands have acceptable DILI risk (A: 41.838, B: 49.283), below the 60% threshold. Ligand A is slightly better.
8. **BBB:** Both ligands have moderate BBB penetration (A: 52.889, B: 56.766). While ADRB2 isn't a CNS target, some degree of BBB penetration isn't necessarily detrimental and could provide some off-target safety information.
9. **Caco-2:** Ligand A (-4.779) is significantly better than Ligand B (-5.61). This suggests better intestinal absorption for Ligand A.
10. **Solubility:** Ligand A (-4.127) is slightly better than Ligand B (-3.813), indicating better aqueous solubility.
11. **hERG:** Both ligands have low hERG inhibition liability (A: 0.7, B: 0.395), which is excellent. Ligand B is slightly better.
12. **Cl_mic:** Ligand B (69.414) has a lower microsomal clearance than Ligand A (79.922), suggesting better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand B (17.243) has a much longer in vitro half-life than Ligand A (0.466). This is a major advantage, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have low P-gp efflux (A: 0.252, B: 0.458).
15. **Binding Affinity:** Both ligands have excellent binding affinity (A: -5.9 kcal/mol, B: -5.2 kcal/mol). Ligand A is slightly better, but the difference is not huge.
**GPCR-specific considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A has a better logP, TPSA, Pgp, and affinity. However, Ligand B has a significantly better half-life and metabolic stability (Cl_mic).
**Overall Assessment:**
While Ligand A has a slight edge in several key properties (TPSA, Caco-2, solubility, affinity), the substantially improved metabolic stability (lower Cl_mic) and significantly longer half-life of Ligand B are compelling advantages. A longer half-life translates to less frequent dosing and potentially better patient compliance. The slightly lower affinity of Ligand B is less concerning given its improved pharmacokinetic profile.
Output:
0
2025-04-18 00:50:23,294 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the ideal 200-500 Da range (A: 363.443, B: 347.459). No significant difference here.
**2. TPSA:** Ligand B (53.09) is significantly better than Ligand A (111.21). For a GPCR, lower TPSA is generally preferred for better permeability.
**3. logP:** Both are reasonably within the optimal range (A: 0.659, B: 0.877), but both are on the lower end, which *could* be a slight concern for permeability.
**4. H-Bond Donors:** Ligand A has 3 HBDs, Ligand B has 0. Lower is generally better for permeability, favoring Ligand B.
**5. H-Bond Acceptors:** Ligand A has 6 HBAs, Ligand B has 4. Again, Ligand B is preferable.
**6. QED:** Both are similar and acceptable (A: 0.723, B: 0.711).
**7. DILI:** Ligand B (6.863) is *much* better than Ligand A (66.848). This is a major advantage for Ligand B.
**8. BBB:** Ligand B (74.874) is significantly better than Ligand A (7.6). While ADRB2 is primarily cardiovascular, some CNS side effects are possible with GPCR modulators, so higher BBB is a bonus.
**9. Caco-2 Permeability:** Ligand A (-5.531) is better than Ligand B (-4.607).
**10. Aqueous Solubility:** Ligand A (-2.329) is better than Ligand B (-0.995).
**11. hERG Inhibition:** Ligand A (0.118) is better than Ligand B (0.333). Lower is better to avoid cardiotoxicity.
**12. Microsomal Clearance:** Ligand A (-7.828) is *much* better than Ligand B (8.702). Lower clearance indicates better metabolic stability.
**13. In vitro Half-Life:** Ligand A (-8.373) is significantly better than Ligand B (-19.555).
**14. P-gp Efflux:** Ligand A (0.017) is significantly better than Ligand B (0.041). Lower efflux is preferred.
**15. Binding Affinity:** Ligand A (-7.5) is slightly better than Ligand B (-7.0). While a difference of 0.5 kcal/mol is not huge, it is noticeable.
**Overall Assessment:**
Ligand B excels in several critical ADME properties: DILI risk, BBB penetration, TPSA, and H-bonding. These are particularly important for a GPCR target. While Ligand A has better affinity, permeability, metabolic stability, and lower hERG risk, the significantly higher DILI risk and lower BBB penetration of Ligand A are concerning. The benefits of Ligand A's better affinity are outweighed by the liabilities.
Therefore, I favor Ligand B.
0
2025-04-18 00:50:23,294 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (354.451 and 358.467 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand B (83.98) is significantly better than Ligand A (105.48). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary concern, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (2.37) is optimal, while Ligand A (0.236) is quite low. This is a major concern for Ligand A, as low logP can severely hinder membrane permeability and bioavailability.
4. **HBD:** Ligand A (3) and Ligand B (2) are both acceptable.
5. **HBA:** Ligand A (6) and Ligand B (5) are both acceptable.
6. **QED:** Ligand B (0.859) is substantially better than Ligand A (0.589), indicating a more drug-like profile.
7. **DILI:** Ligand A (27.026) is much better than Ligand B (60.14). This is a significant advantage for Ligand A.
8. **BBB:** Not a primary concern for a cardiovascular target. Ligand B (61.691) is higher, but this isn't a deciding factor.
9. **Caco-2:** Both are negative, indicating poor permeability. However, the scale is not provided, so it's difficult to interpret the absolute values.
10. **Solubility:** Both are negative, indicating poor solubility. Again, the scale is not provided.
11. **hERG:** Ligand A (0.082) is better than Ligand B (0.144), indicating lower cardiotoxicity risk.
12. **Cl_mic:** Ligand B (18.191) has significantly lower microsomal clearance than Ligand A (36.056), suggesting better metabolic stability.
13. **t1/2:** Ligand B (14.066) has a much longer in vitro half-life than Ligand A (7.181). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.029) is better than Ligand B (0.075), indicating lower P-gp efflux.
15. **Binding Affinity:** Ligand A (-5.8 kcal/mol) is significantly better than Ligand B (-2.5 kcal/mol). This is a substantial advantage for Ligand A.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, TPSA, Pgp, and affinity. Ligand B excels in TPSA and Cl_mic/t1/2, while Ligand A has a superior binding affinity and Pgp profile. The low logP of Ligand A is a major drawback.
**Overall Assessment:**
The significantly stronger binding affinity of Ligand A (-5.8 vs -2.5 kcal/mol) is a compelling advantage. While its logP is low, the difference in affinity is substantial (over 3 kcal/mol), potentially outweighing the permeability concerns. The lower DILI risk and Pgp efflux also favor Ligand A. Ligand B has better metabolic stability and QED, but the weaker binding makes it less likely to be effective at a reasonable dose.
Output:
1
2025-04-18 00:50:23,294 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's break down the comparison of Ligand A and Ligand B, considering the provided guidelines and GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key).
1. **Molecular Weight:** Both ligands (349.431 and 351.491 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand B (78.51) is significantly better than Ligand A (91.5). Lower TPSA generally improves permeability, which is important for GPCRs.
3. **logP:** Both ligands have acceptable logP values (1.077 and 1.838, respectively), falling within the 1-3 range. Ligand B is slightly better.
4. **H-Bond Donors:** Both have 2 HBD, which is good.
5. **H-Bond Acceptors:** Ligand A has 4 HBA, and Ligand B has 3. Both are acceptable.
6. **QED:** Ligand A (0.804) has a slightly better QED score than Ligand B (0.7), suggesting a more drug-like profile.
7. **DILI:** Ligand B (14.424) has a much lower DILI risk than Ligand A (30.787). This is a significant advantage for Ligand B.
8. **BBB:** Ligand B (65.452) has a better BBB penetration percentile than Ligand A (53.083), although neither is exceptionally high. For a cardiovascular target, BBB isn't *critical*, but it's a bonus.
9. **Caco-2 Permeability:** Ligand A (-4.781) and Ligand B (-5.017) are both poor, indicating low intestinal absorption.
10. **Aqueous Solubility:** Ligand A (-2.268) and Ligand B (-1.84) are both poor.
11. **hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.237 and 0.282, respectively).
12. **Microsomal Clearance:** Ligand A (-5.109) has significantly better metabolic stability (lower clearance) than Ligand B (17.558). This is a major advantage for Ligand A.
13. **In vitro Half-Life:** Ligand A (-13.4) has a better in vitro half-life than Ligand B (-9.81).
14. **P-gp Efflux:** Both ligands have low P-gp efflux liability (0.031 and 0.058, respectively).
15. **Binding Affinity:** Ligand A (-7.1) has a slightly better binding affinity than Ligand B (-5.4). This is a 1.7 kcal/mol difference, which is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand A has a better binding affinity and metabolic stability, and a longer half-life. However, Ligand B has a significantly lower DILI risk and a better TPSA. The difference in affinity is substantial, and the metabolic stability of Ligand A is a significant plus. While both have poor Caco-2 permeability and solubility, the better affinity of Ligand A, coupled with its improved metabolic profile, makes it the more promising candidate.
**Output:**
1
2025-04-18 00:50:23,294 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**1. Molecular Weight:** Both ligands (343.431 and 348.393 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (80.12) is significantly better than Ligand B (49.41). For a GPCR, lower TPSA is generally preferred for better permeability, and both are well below the 140 A^2 threshold.
**3. logP:** Ligand B (3.34) is higher than Ligand A (0.774). While 0.774 is a bit low, 3.34 is approaching the upper limit of the optimal range. This could lead to solubility issues for Ligand B.
**4. H-Bond Donors:** Both have 1 HBD, which is good.
**5. H-Bond Acceptors:** Ligand A has 5, and Ligand B has 2. Both are within the acceptable range.
**6. QED:** Ligand B (0.802) has a slightly better QED score than Ligand A (0.611), indicating a more drug-like profile.
**7. DILI:** Ligand A (37.418) has a much lower DILI risk than Ligand B (51.958). This is a significant advantage for Ligand A.
**8. BBB:** Ligand B (78.79) has a better BBB penetration percentile than Ligand A (47.073). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be beneficial or at least needs to be considered.
**9. Caco-2 Permeability:** Ligand A (-5.323) has a worse Caco-2 permeability than Ligand B (-4.234).
**10. Aqueous Solubility:** Ligand A (-0.927) has a better aqueous solubility than Ligand B (-5.37). This is important given Ligand B's higher logP.
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.036 and 0.39 respectively).
**12. Microsomal Clearance:** Ligand A (11.537) has a much lower microsomal clearance than Ligand B (58.767), suggesting better metabolic stability.
**13. In vitro Half-Life:** Ligand A (8.428) has a better in vitro half-life than Ligand B (-2.303).
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.025 and 0.064 respectively).
**15. Binding Affinity:** Ligand B (-5.7) has a slightly stronger binding affinity than Ligand A (-5.3). However, the difference is only 0.4 kcal/mol, which isn't a huge advantage.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), and the general drug-like properties, Ligand A is the more promising candidate. While Ligand B has a slightly better QED and affinity, Ligand A excels in crucial areas like DILI risk, metabolic stability (lower Cl_mic and better t1/2), aqueous solubility, and TPSA. The lower logP of Ligand A is also less likely to cause formulation or off-target issues. The difference in affinity is not substantial enough to outweigh the significant advantages of Ligand A in ADME-Tox properties.
Output:
1
2025-04-18 00:50:23,295 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (341.415 and 349.475 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (76.71) is better than Ligand B (85.43). Both are below 140, but lower TPSA generally favors permeability, a key consideration for GPCRs.
3. **logP:** Both ligands (2.16 and 2.095) are within the optimal 1-3 range. Very similar.
4. **HBD:** Both ligands have 3 H-bond donors, which is within the acceptable limit of 5.
5. **HBA:** Both ligands have 3 H-bond acceptors, well below the 10 limit.
6. **QED:** Ligand B (0.705) has a slightly better QED score than Ligand A (0.582), indicating a more drug-like profile.
7. **DILI:** Ligand B (29.081) has a significantly lower DILI risk than Ligand A (52.074). This is a crucial advantage, as liver toxicity is a major concern in drug development.
8. **BBB:** Ligand A (68.592) has a better BBB penetration score than Ligand B (36.06). While ADRB2 isn't exclusively a CNS target, some cardiovascular effects are mediated by central pathways, so moderate BBB penetration can be beneficial.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.748 and -4.993). These values are unusual and suggest poor permeability. However, negative values are often artifacts of the prediction method and don't necessarily preclude further investigation.
10. **Solubility:** Ligand A (-3.335) has slightly better aqueous solubility than Ligand B (-2.25).
11. **hERG:** Both ligands have very low hERG inhibition risk (0.368 and 0.307). Excellent.
12. **Cl_mic:** Ligand A (-39.89) has significantly lower microsomal clearance than Ligand B (9.604). This indicates better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (20.573) has a longer in vitro half-life than Ligand B (9.163). This is a positive attribute, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.008 and 0.145).
15. **Binding Affinity:** Both ligands have identical binding affinities (-5.8 kcal/mol).
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Both ligands are comparable in logP, Pgp, and affinity. Ligand A has a better TPSA. The biggest difference is the DILI risk, where Ligand B is significantly better, and the metabolic stability, where Ligand A is better.
**Overall Assessment:**
While Ligand A has advantages in metabolic stability (Cl_mic, t1/2) and TPSA, the significantly lower DILI risk associated with Ligand B is a major factor. DILI is a common reason for drug development failure. The slightly better QED score of Ligand B also contributes to its overall drug-likeness. The Caco-2 values are concerning for both, but not decisive at this stage.
Therefore, I favor Ligand B.
Output:
0
2025-04-18 00:50:23,295 - INFO - Batch 507 complete. Total preferences: 8112
2025-04-18 00:50:23,295 - INFO - Processing batch 508/512...
2025-04-18 00:51:11,395 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.475 and 361.511 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Both are below the 140 A^2 threshold for good oral absorption (78.87 and 73.2 A^2). Ligand B is slightly better, closer to the ideal for GPCRs.
3. **logP:** Both are within the optimal 1-3 range (1.173 and 2.653). Ligand B is higher, potentially improving membrane permeability, but still within acceptable limits for both.
4. **HBD:** Ligand A has 2 HBD, and Ligand B has 1. Both are acceptable (<=5).
5. **HBA:** Both have 4 HBA, well within the acceptable range (<=10).
6. **QED:** Both have similar QED values (0.752 and 0.738), indicating good drug-likeness.
7. **DILI:** Ligand A (12.059%) has a significantly lower DILI risk than Ligand B (30.593%). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (62.117%) has a higher BBB penetration percentile than Ligand A (55.215%). While ADRB2 isn't necessarily a CNS target, some distribution to the CNS is possible, making this a slight advantage for Ligand B.
9. **Caco-2:** Both have negative Caco-2 values, indicating poor permeability. Ligand A (-4.927) is slightly better than Ligand B (-5.013).
10. **Solubility:** Ligand A (-1.663) has better aqueous solubility than Ligand B (-3.328). This is a positive for formulation and bioavailability.
11. **hERG:** Both have low hERG inhibition liability (0.253 and 0.478), which is good.
12. **Cl_mic:** Ligand A (36.691 mL/min/kg) has a lower microsomal clearance than Ligand B (55.838 mL/min/kg), suggesting better metabolic stability.
13. **t1/2:** Ligand A (14.577 hours) has a significantly longer in vitro half-life than Ligand B (2.327 hours). This is a substantial advantage, potentially allowing for less frequent dosing.
14. **Pgp:** Both have very low Pgp efflux liability (0.034 and 0.063).
15. **Binding Affinity:** Ligand A (-7.9 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.2 kcal/mol). This is a substantial advantage that can outweigh minor ADME drawbacks.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, affinity, and metabolic stability are key. Ligand A excels in affinity and metabolic stability (lower Cl_mic, longer t1/2). While Ligand B has slightly better BBB penetration, the difference isn't substantial. The significantly lower DILI risk and superior binding affinity of Ligand A are compelling advantages. The slightly better solubility of Ligand A is also a plus.
**Conclusion:**
Ligand A is the more promising drug candidate due to its significantly better binding affinity, lower DILI risk, improved metabolic stability (longer half-life, lower clearance), and better solubility. These factors outweigh the slightly better BBB penetration of Ligand B.
Output:
1
2025-04-18 00:51:11,395 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Step-by-step comparison:**
1. **MW:** Both ligands (369.535 Da and 355.41 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (69.73) is better than Ligand B (75.88). Both are below 140, but lower is preferable for absorption.
3. **logP:** Both ligands have good logP values (1.205 and 2.13), falling within the optimal 1-3 range. Ligand B is slightly higher, which *could* be beneficial for membrane permeability, but not dramatically.
4. **HBD:** Ligand A has 2 HBD, while Ligand B has 0. Both are acceptable, but having some HBD can aid solubility.
5. **HBA:** Ligand A has 7 HBA, and Ligand B has 5. Both are within the acceptable range of <=10.
6. **QED:** Both ligands have good QED scores (0.604 and 0.781), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (35.169) has a lower DILI risk than Ligand B (41.915). This is a significant advantage for Ligand A.
8. **BBB:** Ligand B (92.71) has a significantly higher BBB penetration percentile than Ligand A (78.209). This is a key consideration for GPCRs, even cardiovascular ones, as some off-target CNS effects are possible.
9. **Caco-2:** Ligand A (-4.956) has a more negative Caco-2 value, indicating *better* permeability than Ligand B (-4.041). Note that lower values are better in this scale.
10. **Solubility:** Ligand A (-1.502) has better solubility than Ligand B (-2.473).
11. **hERG:** Both ligands have very low hERG inhibition liability (0.913 and 0.365), which is excellent.
12. **Cl_mic:** Ligand A (14.96) has significantly lower microsomal clearance than Ligand B (39.027), suggesting better metabolic stability.
13. **t1/2:** Ligand A (29.019) has a longer in vitro half-life than Ligand B (-28.382). This is a major advantage.
14. **Pgp:** Ligand A (0.058) has lower P-gp efflux liability than Ligand B (0.145).
15. **Binding Affinity:** Both ligands have very similar binding affinities (-6.1 and -6.2 kcal/mol). The difference is negligible.
**GPCR-Specific Priorities & Overall Assessment:**
For an ADRB2 (GPCR) target, we prioritize logP, TPSA, Pgp, and affinity. While Ligand B has a better BBB score, the significant advantages of Ligand A in terms of DILI risk, metabolic stability (Cl_mic and t1/2), Caco-2 permeability, solubility, and Pgp efflux outweigh this benefit. The binding affinity is essentially the same. The slightly lower TPSA of Ligand A is also beneficial. The lower DILI is a critical factor for clinical development.
**Output:**
1
2025-04-18 00:51:11,395 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [376.429, 114.18 , 1.221, 3. , 5. , 0.601, 57.038, 64.327, -5.669, -2.683, 0.301, 31.148, 3.415, 0.09 , -7.9 ]
**Ligand B:** [354.403, 117.87 , 1.128, 3. , 6. , 0.572, 47.421, 24.195, -5.168, -1.978, 0.136, 38.452, 24.133, 0.072, -5.7 ]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, Affinity, and BBB):
1. **MW:** Both are within the ideal 200-500 Da range. Ligand B (354.403) is slightly preferred due to being a bit lower.
2. **TPSA:** Both are reasonably good (114.18 and 117.87), but ideally below 140 for oral absorption. No major difference.
3. **logP:** Both are excellent (1.221 and 1.128), falling within the optimal 1-3 range.
4. **HBD/HBA:** Both have 3 HBD and acceptable HBA counts (5 and 6 respectively).
5. **QED:** Both are above 0.5 (0.601 and 0.572), indicating good drug-likeness.
6. **DILI:** Ligand A (57.038) has a higher DILI risk than Ligand B (47.421), which is a negative.
7. **BBB:** Ligand A (64.327) has a significantly better BBB penetration percentile than Ligand B (24.195). This is a *major* advantage for a GPCR target, even if not directly CNS-focused, as it suggests better distribution.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability.
9. **Solubility:** Both have negative solubility values, which is also unusual and suggests poor solubility.
10. **hERG:** Both have very low hERG inhibition risk (0.301 and 0.136).
11. **Cl_mic:** Ligand A (31.148) has a lower microsomal clearance than Ligand B (38.452), indicating better metabolic stability.
12. **t1/2:** Ligand B (24.133) has a longer in vitro half-life than Ligand A (3.415).
13. **Pgp:** Ligand A (0.09) has a slightly lower P-gp efflux liability than Ligand B (0.072).
14. **Affinity:** Ligand A (-7.9 kcal/mol) has a significantly stronger binding affinity than Ligand B (-5.7 kcal/mol). This is a substantial advantage, exceeding the 1.5 kcal/mol threshold.
**Overall Assessment:**
Despite the unusual negative Caco-2 and solubility values for both compounds, the superior binding affinity of Ligand A (-7.9 vs -5.7) and better BBB penetration (64.327 vs 24.195) are compelling. The lower DILI risk of Ligand B is a plus, but the affinity difference is substantial enough to outweigh this concern, especially considering the metabolic stability of Ligand A is also better. The longer half-life of Ligand B is a benefit, but not enough to overcome the affinity gap.
Therefore, I prefer Ligand A.
Output:
1
2025-04-18 00:51:11,395 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (351.447 and 368.374 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (78.95) is significantly better than Ligand B (109.42). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally aids absorption. Ligand A is well below the 140 threshold.
3. **logP:** Ligand B (0.855) is slightly better than Ligand A (0.387), falling closer to the optimal 1-3 range. Ligand A is a bit low, potentially hindering permeation.
4. **HBD:** Ligand A (1) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (6). Similar to HBD, lower HBA is generally better.
6. **QED:** Ligand A (0.671) is slightly better than Ligand B (0.529), indicating a more drug-like profile.
7. **DILI:** Ligand A (16.557%) has a much lower DILI risk than Ligand B (30.516%). This is a significant advantage for Ligand A.
8. **BBB:** Both ligands have similar BBB penetration (62.97% and 60.45%). Not a major factor for a cardiovascular target.
9. **Caco-2:** Ligand A (-4.76) has a better Caco-2 permeability than Ligand B (-5.485).
10. **Solubility:** Ligand A (-0.443) has better solubility than Ligand B (-1.414).
11. **hERG:** Both ligands have very low hERG inhibition liability (0.116 and 0.053). No significant difference.
12. **Cl_mic:** Ligand A (3.737) has a lower microsomal clearance than Ligand B (1.137), suggesting better metabolic stability.
13. **t1/2:** Ligand B (15.227) has a significantly longer in vitro half-life than Ligand A (0.551). This is a major advantage for Ligand B.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.016 and 0.004). No significant difference.
15. **Binding Affinity:** Ligand B (-6.6) has a slightly better binding affinity than Ligand A (-6.0). While a 1.5 kcal/mol difference is generally significant, the other factors weigh more heavily in this case.
**Overall Assessment:**
Considering the priorities for a GPCR (logP, TPSA, Pgp, and affinity) and the general drug-like properties, Ligand A emerges as the more promising candidate. While Ligand B has a better half-life and slightly better affinity, Ligand A excels in crucial areas like TPSA, DILI risk, solubility, and metabolic stability (Cl_mic). The lower TPSA and DILI risk are particularly important for a cardiovascular drug. The slightly lower logP of Ligand A is a minor drawback that could potentially be addressed through further optimization.
Output:
1
2025-04-18 00:51:11,396 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (350.419 Da and 363.437 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (114.53) is better than Ligand B (45.46), being below the 140 A^2 threshold for good oral absorption. Ligand B is excellent and well within the range for good absorption.
**3. logP:** Ligand A (-0.264) is suboptimal, being below the preferred 1-3 range. Ligand B (4.043) is slightly high, but still within an acceptable range. This favors Ligand B slightly.
**4. H-Bond Donors:** Ligand A (4) is acceptable, while Ligand B (1) is excellent.
**5. H-Bond Acceptors:** Ligand A (4) is acceptable, while Ligand B (6) is also acceptable.
**6. QED:** Ligand B (0.743) is significantly better than Ligand A (0.459), indicating a more drug-like profile. This is a strong advantage for Ligand B.
**7. DILI Risk:** Ligand A (18.108) has a much lower DILI risk than Ligand B (85.072). This is a major advantage for Ligand A.
**8. BBB Penetration:** Ligand A (21.171) has poor BBB penetration, while Ligand B (68.631) is better. For a cardiovascular target, BBB penetration is less critical, but still a consideration.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-5.814) is slightly better than Ligand B (-4.696).
**10. Aqueous Solubility:** Both ligands have negative solubility values, which is also unusual. Ligand A (-1.219) is slightly better than Ligand B (-4.466).
**11. hERG Inhibition:** Ligand A (0.041) has a very low hERG risk, while Ligand B (0.855) has a moderate risk. This is a significant advantage for Ligand A.
**12. Microsomal Clearance:** Ligand A (-3.256) has a lower (better) microsomal clearance than Ligand B (44.814), suggesting better metabolic stability.
**13. In vitro Half-Life:** Ligand A (-3.394) has a slightly better in vitro half-life than Ligand B (-3.919).
**14. P-gp Efflux:** Ligand A (0.008) has very low P-gp efflux, while Ligand B (0.672) has moderate efflux. This favors Ligand A.
**15. Binding Affinity:** Ligand B (-6.7 kcal/mol) has a stronger binding affinity than Ligand A (-5.3 kcal/mol). This is a substantial advantage for Ligand B, potentially outweighing some ADME drawbacks.
**Overall Assessment:**
Given the GPCR target, affinity is paramount. Ligand B has a significantly better binding affinity (-6.7 vs -5.3 kcal/mol). While Ligand A has better safety profiles (DILI, hERG) and metabolic stability, the substantial affinity difference of Ligand B is crucial. The slightly higher logP of Ligand B is manageable, and the moderate P-gp efflux can be addressed with formulation strategies. The QED score of Ligand B is also a positive factor.
Therefore, I favor Ligand B.
0
2025-04-18 00:51:11,396 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (366.527) is slightly higher than Ligand B (345.422), but both are acceptable.
2. **TPSA:** Ligand A (58.64) is better than Ligand B (64.86). Both are below the 140 threshold for good oral absorption, but lower TPSA is generally preferred for GPCRs.
3. **logP:** Ligand A (4.812) is higher than Ligand B (2.335). While 4.812 is approaching the upper limit, it's still within a reasonable range. Ligand B is excellent. This is a point in favor of B.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 6. Both are acceptable, but A is slightly better.
6. **QED:** Both ligands have good QED scores (A: 0.832, B: 0.901), indicating good drug-like properties. B is slightly better.
7. **DILI:** Both ligands have similar, acceptable DILI risk (A: 41.256, B: 42.148).
8. **BBB:** Ligand B (91.508) has a significantly higher BBB penetration percentile than Ligand A (82.513). This is a key advantage for a GPCR target, even if it's not a CNS target, as it suggests better distribution.
9. **Caco-2:** Ligand A (-4.583) and Ligand B (-5.041) both have negative Caco-2 values, which is unusual and suggests very poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand A (-4.463) is slightly better than Ligand B (-3.061), but both are very poor. This is a major drawback for both.
11. **hERG:** Both ligands have low hERG inhibition risk (A: 0.636, B: 0.32). B is better.
12. **Cl_mic:** Ligand B (21.901) has a much lower microsomal clearance than Ligand A (79). This indicates better metabolic stability, a significant advantage.
13. **t1/2:** Ligand A (14.758) has a longer in vitro half-life than Ligand B (8.651). This is a positive for A.
14. **Pgp:** Ligand A (0.313) has lower P-gp efflux than Ligand B (0.405), which is preferred.
15. **Binding Affinity:** Ligand B (-5.8 kcal/mol) has a stronger binding affinity than Ligand A (-5.3 kcal/mol). This is a substantial advantage (0.5 kcal/mol difference).
**Overall Assessment:**
Ligand B is the stronger candidate. While both have poor solubility and Caco-2 permeability, Ligand B excels in several critical areas: significantly better BBB penetration, much lower microsomal clearance (better metabolic stability), and a stronger binding affinity. The better logP and hERG profile of Ligand B also contribute to its favorability. The longer half-life of Ligand A is a benefit, but is outweighed by the other advantages of Ligand B.
Output:
0
2025-04-18 00:51:11,396 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [363.805, 109.14 , 1.711, 3. , 6. , 0.723, 76.386, 36.371, -5.347, -3.86 , 0.158, 12.93 , 23.097, 0.029, -9.2 ]
**Ligand B:** [345.359, 120.32 , -0.294, 3. , 6. , 0.703, 56.146, 19.349, -5.408, -2.832, 0.202, -18.016, -35.024, 0.013, -6.3 ]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity):
1. **MW:** Both are within the acceptable 200-500 Da range. Ligand B (345.359) is slightly preferred due to being lower.
2. **TPSA:** Ligand A (109.14) is better than Ligand B (120.32), being closer to the <140 threshold for oral absorption.
3. **logP:** Ligand A (1.711) is within the optimal 1-3 range. Ligand B (-0.294) is *below* 1, which is a concern for permeability. This is a significant drawback for Ligand B.
4. **HBD/HBA:** Both have 3 HBD and 6 HBA, which are acceptable.
5. **QED:** Both are good (above 0.5).
6. **DILI:** Ligand A (76.386) has a higher DILI risk than Ligand B (56.146), which is unfavorable.
7. **BBB:** Ligand A (36.371) has a very low BBB penetration, while Ligand B (19.349) is also low, but comparatively better. This isn't a primary concern for a non-CNS target like ADRB2, but it's still a consideration.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability.
9. **Solubility:** Both have negative solubility values, which is also unusual and suggests poor solubility.
10. **hERG:** Both have very low hERG inhibition risk, which is excellent.
11. **Cl_mic:** Ligand A (12.93) has a lower (better) microsomal clearance than Ligand B (-18.016), indicating better metabolic stability.
12. **t1/2:** Ligand A (23.097) has a better in vitro half-life than Ligand B (-35.024).
13. **Pgp:** Ligand A (0.029) has lower P-gp efflux than Ligand B (0.013), which is favorable.
14. **Affinity:** Ligand A (-9.2 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.3 kcal/mol). This is a substantial advantage (2.9 kcal/mol difference).
**Overall Assessment:**
Despite Ligand A's higher DILI risk, its substantially better binding affinity (-9.2 vs -6.3 kcal/mol) and more favorable logP (1.711 vs -0.294) outweigh the concerns. The logP value for Ligand B is a major red flag, suggesting poor permeability. While both have concerning Caco-2 and solubility values, the strong affinity of Ligand A makes it more likely to be optimized to overcome these issues. The better metabolic stability (lower Cl_mic and longer t1/2) of Ligand A further supports its selection.
Output:
1
2025-04-18 00:51:11,396 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (374.497 and 342.443 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (58.2) is better than Ligand B (66.4). Both are below the 140 threshold for good oral absorption, but lower TPSA is generally preferred for GPCRs.
3. **logP:** Both ligands have good logP values (2.965 and 2.181), falling within the optimal 1-3 range. Ligand A is slightly higher, which could be advantageous for membrane permeability.
4. **HBD:** Ligand A (2) is slightly better than Ligand B (0). A small number of HBDs is generally preferred.
5. **HBA:** Ligand A (3) is slightly better than Ligand B (4). Lower HBA is generally preferred.
6. **QED:** Both ligands have good QED scores (0.752 and 0.844), indicating good drug-like properties. No significant difference.
7. **DILI:** Both ligands have similar, acceptable DILI risk (37.03 and 38.542 percentile).
8. **BBB:** Both ligands have high BBB penetration (85.033 and 86.933 percentile). This is a positive for a GPCR target, although ADRB2 isn't strictly a CNS target, some peripheral exposure is desirable.
9. **Caco-2:** Ligand A (-5.322) is better than Ligand B (-4.891). Higher Caco-2 permeability suggests better absorption.
10. **Solubility:** Ligand A (-3.575) is better than Ligand B (-2.633). Higher solubility is generally preferred.
11. **hERG:** Both ligands have low hERG inhibition liability (0.51 and 0.257 percentile), which is excellent.
12. **Cl_mic:** Ligand A (8.016) is significantly better than Ligand B (44.163). Lower microsomal clearance indicates better metabolic stability.
13. **t1/2:** Ligand A (15.433) is significantly better than Ligand B (-19.249). A longer half-life is generally preferred.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.15 and 0.264 percentile).
15. **Binding Affinity:** Ligand B (-7.8 kcal/mol) has a slightly better binding affinity than Ligand A (-7.2 kcal/mol). This is a 0.6 kcal/mol difference, which is significant.
**Overall Assessment:**
While Ligand B has a slightly better binding affinity, Ligand A demonstrates a superior ADME profile. Specifically, the significantly lower microsomal clearance and longer half-life of Ligand A are crucial advantages. The better Caco-2 permeability and solubility also contribute to improved potential bioavailability. For a GPCR target like ADRB2, a balance between potency and ADME properties is essential. The 0.6 kcal/mol difference in binding affinity is not enough to outweigh the substantial improvements in metabolic stability and pharmacokinetic properties offered by Ligand A.
**Output:**
1
2025-04-18 00:51:11,396 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (407.312 Da) is within the ideal range, while Ligand B (362.455 Da) is also acceptable. No clear advantage here.
2. **TPSA:** Both ligands (A: 79.9, B: 76.46) are below the 140 threshold for good oral absorption, and reasonably aligned for a GPCR target.
3. **logP:** Ligand A (3.346) is optimal, while Ligand B (0.61) is quite low, potentially hindering membrane permeability. This is a significant drawback for Ligand B.
4. **HBD:** Both ligands are acceptable (A: 2, B: 1), well below the 5 limit.
5. **HBA:** Both ligands are acceptable (A: 4, B: 6), below the 10 limit.
6. **QED:** Both ligands have good QED scores (A: 0.77, B: 0.817), indicating drug-likeness.
7. **DILI:** Both ligands have acceptable DILI risk (A: 53.432, B: 60.217), below the concerning 60 threshold.
8. **BBB:** Ligand A (74.952) has a better BBB percentile than Ligand B (68.399), which is relevant for a GPCR.
9. **Caco-2:** Both have negative values, indicating permeability issues, but Ligand A (-4.936) is better than Ligand B (-5.355).
10. **Solubility:** Ligand A (-5.187) has better solubility than Ligand B (-2.058).
11. **hERG:** Both ligands have low hERG inhibition liability (A: 0.541, B: 0.156).
12. **Cl_mic:** Ligand B (9.726) has significantly lower microsomal clearance than Ligand A (61.149), suggesting better metabolic stability. This is a positive for Ligand B.
13. **t1/2:** Ligand A (22.184) has a longer in vitro half-life than Ligand B (15.237).
14. **Pgp:** Both ligands have low Pgp efflux liability (A: 0.559, B: 0.065).
15. **Binding Affinity:** Ligand B (-5.8 kcal/mol) has a slightly better binding affinity than Ligand A (-5.0 kcal/mol). This is a 0.8 kcal/mol difference, which is notable.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand A appears to be the more promising candidate. While Ligand B has better metabolic stability (lower Cl_mic) and slightly better affinity, its significantly lower logP is a major concern. A low logP can severely hinder membrane permeability and oral bioavailability. Ligand A balances these properties better, with an optimal logP, acceptable permeability, and good BBB penetration. The affinity difference, while present, isn't large enough to overcome the permeability concerns with Ligand B.
Output:
1
2025-04-18 00:51:11,396 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (350.5 & 362.4 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (58.64) is significantly better than Ligand B (95.86). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold, while B is approaching it.
3. **logP:** Ligand A (2.591) is optimal, while Ligand B (0.506) is a bit low. A logP below 1 can hinder membrane permeability. This is a clear advantage for A.
4. **HBD:** Both have 1 HBD, which is acceptable.
5. **HBA:** Ligand A (3) is preferable to Ligand B (7). Higher HBA can sometimes reduce permeability.
6. **QED:** Both ligands have similar, good QED scores (0.801 and 0.832).
7. **DILI:** Ligand A (18.379) has a much lower DILI risk than Ligand B (53.315). This is a major advantage for A, as liver toxicity is a significant concern.
8. **BBB:** Ligand A (77.782) has better BBB penetration than Ligand B (31.756), but this isn't a primary concern for a cardiovascular target.
9. **Caco-2:** Both ligands have negative Caco-2 values, suggesting poor permeability. However, Ligand A (-4.533) is slightly better than Ligand B (-4.767).
10. **Solubility:** Ligand A (-3.079) is slightly better than Ligand B (-2.57), but both are poor.
11. **hERG:** Ligand A (0.541) has a lower hERG risk than Ligand B (0.18), which is a positive.
12. **Cl_mic:** Ligand A (31.433) has a higher (worse) microsomal clearance than Ligand B (6.356), indicating faster metabolism. This favors B.
13. **t1/2:** Ligand B (-4.779) has a longer in vitro half-life than Ligand A (2.557), which is desirable.
14. **Pgp:** Ligand A (0.095) has lower P-gp efflux than Ligand B (0.087), which is favorable.
15. **Binding Affinity:** Both ligands have very similar, strong binding affinities (-6.3 and -6.1 kcal/mol). The difference is negligible.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand A excels in logP and TPSA, while affinity is comparable. The significantly lower DILI risk for Ligand A is also a critical factor. While Ligand B has better metabolic stability (lower Cl_mic and longer t1/2), the other advantages of Ligand A outweigh this.
**Conclusion:**
Considering the balance of properties, particularly the favorable logP, TPSA, DILI risk, and comparable affinity, Ligand A is the more promising drug candidate.
Output:
1
2025-04-18 00:51:11,396 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.431 and 350.459 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (91.65) is slightly higher than Ligand B (76.66). Both are acceptable for a non-CNS GPCR target like ADRB2, but Ligand B is preferable.
3. **logP:** Ligand A (1.154) and Ligand B (1.668) are both within the optimal 1-3 range. Ligand B is slightly better.
4. **HBD:** Both ligands have 2 HBD, which is good.
5. **HBA:** Both ligands have 4 HBA, which is good.
6. **QED:** Ligand A (0.772) is slightly better than Ligand B (0.732), indicating a marginally more drug-like profile.
7. **DILI:** Ligand A (22.334) has a significantly lower DILI risk than Ligand B (31.679). This is a major advantage for Ligand A.
8. **BBB:** Both are low, as expected for a non-CNS target. Ligand A (48.352) is slightly better than Ligand B (40.558), but this is not a critical factor here.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand A (-5.269) is slightly better than Ligand B (-5.096).
10. **Solubility:** Ligand A (-1.34) is better than Ligand B (-2.196).
11. **hERG:** Both ligands have very low hERG inhibition risk (0.172 and 0.226), which is excellent.
12. **Cl_mic:** Ligand A (2.263) has a lower microsomal clearance than Ligand B (3.692), suggesting better metabolic stability.
13. **t1/2:** Ligand A (17.025) has a slightly shorter half-life than Ligand B (19.562), but both are acceptable.
14. **Pgp:** Both ligands have very low P-gp efflux liability (0.034 and 0.033).
15. **Binding Affinity:** Ligand B (-6.6) has a slightly better binding affinity than Ligand A (-6.0). This is a 0.6 kcal/mol difference, which is significant.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand B has a slightly better logP and significantly better affinity. However, Ligand A has a much lower DILI risk and better solubility and metabolic stability.
**Overall Assessment:**
The improved binding affinity of Ligand B is a strong positive. However, the significantly lower DILI risk and better solubility/metabolic stability of Ligand A are crucial for overall drug development success. The difference in affinity (0.6 kcal/mol) is not large enough to overcome the safety and ADME advantages of Ligand A.
Output:
1
2025-04-18 00:51:11,396 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [347.463, 90.12, 1.595, 3, 4, 0.443, 32.183, 43.815, -5.366, -2.021, 0.369, 1.859, -0.271, 0.038, -6.4]
**Ligand B:** [344.459, 58.44, 1.797, 0, 4, 0.758, 17.1, 77.007, -4.927, -1.529, 0.32, 37.753, -13.417, 0.106, -7.3]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity) and general drug-like properties:
1. **MW:** Both are within the ideal range (200-500 Da). A is 347.463, B is 344.459 - very similar.
2. **TPSA:** Ligand A (90.12) is slightly higher than Ligand B (58.44). Both are acceptable, but B is significantly better, being well below the 140 threshold and more favorable for permeability.
3. **logP:** Both are in the optimal range (1-3). A is 1.595, B is 1.797 - again, very similar.
4. **HBD:** Ligand A has 3 HBD, Ligand B has 0. Lower is generally better for permeability, so B is favored.
5. **HBA:** Both have 4 HBA, which is within the acceptable range.
6. **QED:** Ligand B (0.758) has a significantly better QED score than Ligand A (0.443), indicating a more drug-like profile.
7. **DILI:** Ligand B (17.1) has a much lower DILI risk than Ligand A (32.183). This is a substantial advantage for B.
8. **BBB:** Ligand B (77.007) has a considerably higher BBB penetration potential than Ligand A (43.815). While ADRB2 is cardiovascular, some CNS off-target effects are always a consideration, and higher BBB is generally less likely to cause these.
9. **Caco-2:** Ligand A (-5.366) and B (-4.927) are both negative, which is unusual and suggests poor permeability. However, the values are close.
10. **Solubility:** Ligand A (-2.021) and B (-1.529) are both poor.
11. **hERG:** Both have low hERG risk (0.369 and 0.32).
12. **Cl_mic:** Ligand A (1.859) has a significantly lower (better) microsomal clearance than Ligand B (37.753), indicating better metabolic stability.
13. **t1/2:** Ligand B (-13.417) has a much longer in vitro half-life than Ligand A (-0.271), which is a major advantage.
14. **Pgp:** Ligand A (0.038) has lower P-gp efflux than Ligand B (0.106), which is favorable.
15. **Affinity:** Ligand B (-7.3) has a slightly better binding affinity than Ligand A (-6.4). While the difference is less than 1.5 kcal/mol, it still contributes to the overall preference.
**Overall Assessment:**
Ligand B is clearly the more promising candidate. It excels in several key areas: QED, DILI risk, BBB penetration, and in vitro half-life. While Ligand A has better metabolic stability (lower Cl_mic) and Pgp efflux, the advantages of Ligand B in the other critical parameters outweigh these benefits. The lower TPSA of Ligand B is also a significant plus for permeability. The slightly better affinity of Ligand B further supports its selection.
Output:
0
2025-04-18 00:51:11,396 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a drug candidate targeting the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands (344.415 and 344.455 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (84.42) is higher than Ligand B (58.64). For a GPCR, lower TPSA is generally preferred for better brain penetration, even though ADRB2 isn't exclusively a CNS target. Ligand B is significantly better.
3. **logP:** Both ligands (2.601 and 2.428) are within the optimal 1-3 range. Ligand B is slightly lower, which could be beneficial for solubility.
4. **HBD:** Both ligands have 1 HBD, which is acceptable.
5. **HBA:** Ligand A has 5 HBA, while Ligand B has 3. Lower HBA is generally preferred for permeability, giving a slight edge to Ligand B.
6. **QED:** Both ligands have similar QED values (0.673 and 0.629), indicating good drug-likeness.
7. **DILI:** Ligand B (23.846) has a *much* lower DILI risk than Ligand A (47.421). This is a critical advantage, as liver toxicity is a major concern in drug development.
8. **BBB:** Both ligands have high BBB penetration (85.343 and 82.047), which isn't a primary concern for ADRB2, but isn't detrimental.
9. **Caco-2:** Ligand B (-5.199) has a more negative Caco-2 value, indicating better permeability than Ligand A (-4.572).
10. **Solubility:** Ligand B (-3.338) has better aqueous solubility than Ligand A (-2.824).
11. **hERG:** Both ligands have low hERG inhibition risk (0.122 and 0.298).
12. **Cl_mic:** Ligand B (24.399) has significantly lower microsomal clearance than Ligand A (54.131), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-3.219) has a slightly longer in vitro half-life than Ligand A (-4.254).
14. **Pgp:** Both ligands have low Pgp efflux liability (0.029 and 0.09).
15. **Binding Affinity:** Ligand B (-7.7 kcal/mol) has a slightly stronger binding affinity than Ligand A (-7.1 kcal/mol). While the difference is not huge, it's a meaningful advantage.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B excels in TPSA, solubility, metabolic stability (Cl_mic and t1/2) and has a slightly better affinity. The *significant* reduction in DILI risk for Ligand B is a major factor.
**Conclusion:**
Ligand B consistently outperforms Ligand A across multiple crucial ADME-Tox parameters, and has a slightly better binding affinity. The lower DILI risk and improved metabolic stability are particularly compelling.
Output:
0
2025-04-18 00:51:11,396 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (356.463 Da) is better, falling comfortably within the 200-500 Da range. Ligand B (420.292 Da) is still acceptable, but closer to the upper limit.
2. **TPSA:** Ligand A (88.1) is preferable, being below the 140 threshold and closer to the 90 threshold for potential CNS penetration (though not a primary concern for ADRB2). Ligand B (100.03) is higher, potentially hindering absorption.
3. **logP:** Both ligands have acceptable logP values (A: 1.822, B: 2.91), falling within the 1-3 range. Ligand B is slightly higher, which could be a minor concern for off-target effects, but not a dealbreaker.
4. **HBD:** Ligand A (2) is better. Fewer HBDs generally improve permeability. Ligand B has 3.
5. **HBA:** Ligand A (5) is better. Ligand B has 7, increasing the risk of reduced permeability.
6. **QED:** Ligand A (0.788) is significantly better than Ligand B (0.531), indicating a more drug-like profile.
7. **DILI:** Ligand A (39.744) is *much* better than Ligand B (88.639). This is a critical advantage, as lower DILI risk is essential.
8. **BBB:** Both are relatively low, indicating limited CNS penetration (A: 39.085, B: 32.765). This isn't a major concern for ADRB2, which is primarily a cardiovascular target.
9. **Caco-2:** Ligand A (-4.636) is better, suggesting better intestinal absorption. Ligand B (-5.443) is worse.
10. **Solubility:** Ligand A (-2.173) is better than Ligand B (-3.704), though both are poor. Solubility is a concern for both, but less so for Ligand A.
11. **hERG:** Ligand A (0.21) is significantly better than Ligand B (0.692), indicating a lower risk of cardiotoxicity. This is a crucial advantage for a cardiovascular target.
12. **Cl_mic:** Both have similar microsomal clearance (A: 42.52, B: 43.434), indicating similar metabolic stability.
13. **t1/2:** Ligand B (-6.247) has a better in vitro half-life than Ligand A (1.194). This is a positive for Ligand B.
14. **Pgp:** Ligand A (0.067) is better, indicating lower P-gp efflux and potentially better bioavailability. Ligand B (0.197) is worse.
15. **Affinity:** Ligand B (-6.6 kcal/mol) has a slightly better binding affinity than Ligand A (-5.1 kcal/mol). This is a 1.5 kcal/mol difference, which is significant.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B has a slightly better logP and significantly better affinity. However, the substantial advantages of Ligand A in terms of DILI, hERG, QED, TPSA, Caco-2, and Pgp outweigh the affinity difference. The lower DILI and hERG risks are particularly important for a cardiovascular drug.
**Conclusion:**
Ligand A is the more promising candidate due to its superior safety profile (DILI, hERG), better drug-like properties (QED), and improved absorption/permeability characteristics (TPSA, Caco-2, Pgp). While Ligand B has slightly better affinity and half-life, the overall balance of properties favors Ligand A.
Output:
1
2025-04-18 00:51:11,397 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (342.33 Da) is within the ideal range (200-500 Da). Ligand B (377.378 Da) is also acceptable. No clear advantage here.
2. **TPSA:** Ligand A (91.4) is good, below the 140 threshold, but higher than the 90 threshold for CNS targets. Ligand B (21.26) is excellent, well below both thresholds. This favors Ligand B.
3. **logP:** Ligand A (2.228) is optimal (1-3). Ligand B (4.788) is slightly high, potentially leading to solubility issues and off-target effects. This favors Ligand A.
4. **HBD:** Ligand A (2) is good. Ligand B (1) is also good. No significant difference.
5. **HBA:** Ligand A (4) is good. Ligand B (3) is also good. No significant difference.
6. **QED:** Ligand A (0.837) is excellent, indicating high drug-likeness. Ligand B (0.406) is below the 0.5 threshold, suggesting a less favorable drug-like profile. This strongly favors Ligand A.
7. **DILI:** Ligand A (98.565) has a very high DILI risk. Ligand B (51.028) has a moderate DILI risk. This strongly favors Ligand B.
8. **BBB:** Ligand A (68.748) is acceptable, but not ideal. Ligand B (73.672) is better. While ADRB2 isn't strictly a CNS target, some peripheral distribution is still desired, and better BBB penetration can indicate better overall permeability. This favors Ligand B.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.748 and -4.829), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Both ligands have negative solubility values (-4.414 and -4.951), indicating very poor aqueous solubility. This is a major concern for both.
11. **hERG:** Ligand A (0.161) has a very low hERG risk. Ligand B (0.961) has a moderate hERG risk. This favors Ligand A.
12. **Cl_mic:** Ligand A (-6.473) has a very low (and likely good) microsomal clearance, indicating high metabolic stability. Ligand B (49.99) has a high clearance, suggesting rapid metabolism. This strongly favors Ligand A.
13. **t1/2:** Ligand A (33.881) has a good in vitro half-life. Ligand B (28.232) is acceptable, but shorter. This favors Ligand A.
14. **Pgp:** Ligand A (0.016) has very low P-gp efflux liability. Ligand B (0.738) has moderate P-gp efflux. This favors Ligand A.
15. **Affinity:** Both ligands have very similar binding affinities (-7.4 and -7.3 kcal/mol). The difference is negligible.
**Overall Assessment:**
Despite the similar binding affinities, Ligand A demonstrates a significantly better overall profile. While it has a high DILI risk, it excels in QED, metabolic stability (Cl_mic, t1/2), hERG risk, and P-gp efflux. Ligand B, while having a lower DILI risk and better TPSA, suffers from a lower QED score, higher logP, and poorer metabolic stability. The poor Caco-2 and solubility for both are concerning, but can potentially be addressed with formulation strategies. Given the GPCR-specific priorities (logP, Pgp, TPSA, affinity), and the overall balance of properties, Ligand A is the more promising candidate.
Output:
1
2025-04-18 00:51:11,397 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Step-by-step comparison:**
1. **MW:** Both ligands (347.331 and 386.543 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (101.05) is better than Ligand A (127.49). Both are below 140, but lower TPSA generally favors permeability, especially for GPCRs.
3. **logP:** Ligand B (1.482) is better than Ligand A (0.353). Ligand A is quite low, potentially hindering membrane permeability. Ligand B is within the optimal 1-3 range.
4. **HBD:** Ligand B (2) is slightly better than Ligand A (3). Lower is generally preferred.
5. **HBA:** Both ligands have 7 HBA, which is acceptable.
6. **QED:** Ligand B (0.795) is significantly better than Ligand A (0.541), indicating a more drug-like profile.
7. **DILI:** Ligand B (66.382) is better than Ligand A (85.576), indicating a lower risk of drug-induced liver injury. Both are acceptable, but lower is always preferred.
8. **BBB:** Both ligands have similar BBB penetration (Ligand A: 65.374, Ligand B: 70.803). Since ADRB2 is a cardiovascular target, BBB penetration is not a primary concern, but slightly higher is still preferable.
9. **Caco-2:** Both ligands have negative Caco-2 values, suggesting poor permeability. Ligand B (-5.635) is slightly better than Ligand A (-5.191).
10. **Solubility:** Both ligands have poor solubility (-2.914 and -2.769). This is a concern for both, but not a deciding factor.
11. **hERG:** Ligand B (0.256) is better than Ligand A (0.051). Lower hERG inhibition is crucial for avoiding cardiotoxicity, a critical consideration for a cardiovascular target.
12. **Cl_mic:** Ligand B (3.16) is significantly better than Ligand A (28.872), indicating much better metabolic stability.
13. **t1/2:** Ligand A (70.138) is better than Ligand B (25.948). Longer half-life is generally desirable.
14. **Pgp:** Ligand B (0.118) is better than Ligand A (0.044). Lower P-gp efflux is preferred for better bioavailability.
15. **Binding Affinity:** Ligand A (-7.1) is significantly better than Ligand B (-6.5). A 0.6 kcal/mol difference in binding affinity is substantial and can often outweigh minor ADME drawbacks.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B excels in logP, TPSA, and Pgp, while Ligand A has a significantly better binding affinity. The improved metabolic stability of Ligand B (lower Cl_mic) is also a significant benefit.
**Overall Assessment:**
While Ligand A has a superior binding affinity, the substantial improvements in ADME properties with Ligand B (logP, TPSA, Cl_mic, Pgp, DILI, hERG) are compelling. The slightly longer half-life of Ligand A is a positive, but the other ADME issues are more concerning. The improved ADME profile of Ligand B suggests a higher probability of *in vivo* efficacy and a safer profile.
Output:
0
2025-04-18 00:51:11,397 - INFO - Batch 508 complete. Total preferences: 8128
2025-04-18 00:51:11,397 - INFO - Processing batch 509/512...
2025-04-18 00:51:59,446 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (363.483 Da) is slightly higher than Ligand B (337.379 Da), but both are acceptable.
2. **TPSA:** Ligand A (95.08) is slightly higher than Ligand B (78.11). Both are below 140, which is good for oral absorption, but Ligand B is preferable here.
3. **logP:** Ligand A (2.222) is within the optimal range (1-3). Ligand B (3.92) is pushing the upper limit, potentially raising concerns about solubility and off-target effects. Ligand A is preferred.
4. **HBD:** Ligand A (3) is acceptable. Ligand B (0) is also acceptable, but having some HBD can aid solubility.
5. **HBA:** Ligand A (5) is acceptable. Ligand B (6) is also acceptable.
6. **QED:** Both ligands have similar QED values (A: 0.703, B: 0.657) and are above the 0.5 threshold, indicating good drug-likeness.
7. **DILI:** Ligand A (54.207) has a significantly lower DILI risk than Ligand B (77.007). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (70.143) has a better BBB penetration score than Ligand A (52.889). While ADRB2 isn't strictly a CNS target, some CNS exposure can occur, making this a slight advantage for Ligand B.
9. **Caco-2:** Ligand A (-5.573) and Ligand B (-4.649) both have negative values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's difficult to interpret.
10. **Solubility:** Ligand A (-2.882) has better solubility than Ligand B (-4.465). This is an important consideration, especially given Ligand B's higher logP.
11. **hERG:** Ligand A (0.557) has a slightly higher hERG risk than Ligand B (0.367). This is a minor concern, but Ligand B is preferable.
12. **Cl_mic:** Ligand A (21.727) has a significantly lower microsomal clearance than Ligand B (126.817), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (26.179) has a longer in vitro half-life than Ligand B (-39.811). This is a major advantage for Ligand A.
14. **Pgp:** Ligand A (0.402) has lower P-gp efflux liability than Ligand B (0.314). Lower is better, so Ligand B is slightly preferred.
15. **Binding Affinity:** Ligand B (-8.0) has a slightly better binding affinity than Ligand A (-7.6). While a 0.4 kcal/mol difference is noticeable, it's not a huge advantage, and can be overcome by other factors.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B has a better logP and Pgp, and slightly better affinity. However, Ligand A has a significantly better DILI score, better solubility, and much better metabolic stability (Cl_mic and t1/2). The improved ADME profile of Ligand A outweighs the slight advantage in binding affinity of Ligand B.
**Conclusion:**
Considering the balance of properties, particularly the significantly improved ADME profile (DILI, Cl_mic, t1/2, solubility) of Ligand A, it is the more promising drug candidate.
Output:
1
2025-04-18 00:51:59,446 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (344.375 Da) is better, falling squarely within the ideal 200-500 Da range. Ligand B (380.945 Da) is still acceptable but less optimal.
2. **TPSA:** Ligand B (59.81) is significantly better than Ligand A (122.03). For a GPCR, lower TPSA is generally preferred for better permeability.
3. **logP:** Ligand B (3.669) is better, being within the optimal 1-3 range. Ligand A (0.289) is quite low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (1), but both are within the acceptable limit of 5.
5. **HBA:** Ligand A (7) is higher than Ligand B (5), but both are within the acceptable limit of 10.
6. **QED:** Both ligands have good QED scores (A: 0.621, B: 0.674), indicating good drug-like properties.
7. **DILI:** Ligand B (48.313) has a much lower DILI risk than Ligand A (74.68). This is a significant advantage for Ligand B.
8. **BBB:** Ligand B (51.066) is better than Ligand A (29.275). While ADRB2 isn't strictly a CNS target, some degree of BBB penetration can be beneficial for distribution.
9. **Caco-2:** Both have negative Caco-2 values which is unusual. I will assume these are percentile scores and therefore higher is better. Ligand A (-5.548) is better.
10. **Solubility:** Ligand A (-2.037) is better than Ligand B (-3.808). Higher solubility is generally preferred.
11. **hERG:** Both ligands have low hERG inhibition liability (A: 0.216, B: 0.39), which is good.
12. **Cl_mic:** Ligand A (17.878) has a much lower microsomal clearance than Ligand B (82.748), indicating better metabolic stability.
13. **t1/2:** Ligand B (51.454) has a significantly longer in vitro half-life than Ligand A (29.307). This is a major advantage.
14. **Pgp:** Ligand A (0.006) has lower P-gp efflux liability than Ligand B (0.406), which is favorable.
15. **Affinity:** Ligand A (-7.2 kcal/mol) has a slightly better binding affinity than Ligand B (-6.8 kcal/mol). This is a significant advantage.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are crucial. Ligand B excels in logP and has a reasonable TPSA. Ligand A has a better affinity and lower Pgp efflux. The DILI risk is a significant concern for Ligand A.
**Overall Assessment:**
While Ligand A has a slightly better binding affinity and lower Pgp efflux, Ligand B's superior logP, significantly lower DILI risk, and longer half-life outweigh these advantages. The low logP of Ligand A is a major concern for permeability. The DILI risk for Ligand A is also concerning.
**Output:**
0
2025-04-18 00:51:59,446 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (339.4 & 342.4 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (111.48) is higher than Ligand B (78.43). For a cardiovascular GPCR, TPSA isn't a *major* concern unless extremely high, but lower is generally preferred for better permeability. Ligand B is better.
3. **logP:** Both ligands have good logP values (1.338 & 2.087), falling within the optimal 1-3 range. Ligand B is slightly better, being closer to the middle of the range.
4. **HBD:** Ligand A (4) is slightly higher than Ligand B (3). Both are acceptable, but lower is preferable. Ligand B is better.
5. **HBA:** Ligand A (5) is higher than Ligand B (3). Similar to HBD, lower is preferable. Ligand B is better.
6. **QED:** Both ligands have good QED scores (0.563 & 0.664), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (63.862) has a significantly higher DILI risk than Ligand B (23.769). This is a *major* concern. Lower DILI is crucial. Ligand B is significantly better.
8. **BBB:** Ligand A (57.968) has a higher BBB penetration percentile than Ligand B (45.095). While ADRB2 isn't a CNS target, some degree of BBB penetration can sometimes indicate favorable permeability characteristics. However, this is less important than other factors.
9. **Caco-2:** Ligand A (-6.015) has a worse Caco-2 permeability than Ligand B (-4.868). Higher is better, so Ligand B is better.
10. **Solubility:** Ligand A (-2.369) has a worse solubility than Ligand B (-2.727). Higher is better, so Ligand B is better.
11. **hERG:** Ligand A (0.364) has a slightly higher hERG inhibition liability than Ligand B (0.104). Lower is better. Ligand B is better.
12. **Cl_mic:** Ligand A (-7.993) has a much lower (better) microsomal clearance than Ligand B (29.891). This suggests better metabolic stability for Ligand A. Ligand A is better.
13. **t1/2:** Ligand A (73.845) has a significantly longer in vitro half-life than Ligand B (7.556). This is a significant advantage for Ligand A. Ligand A is better.
14. **Pgp:** Ligand A (0.039) has a much lower P-gp efflux liability than Ligand B (0.094). Lower is better. Ligand A is better.
15. **Affinity:** Ligand B (-7.6) has a slightly better (more negative) binding affinity than Ligand A (-5.3). This is a 0.3 kcal/mol difference, which is not substantial enough to outweigh other significant differences.
**Overall Assessment:**
Ligand B excels in many key ADME properties (DILI, TPSA, logP, HBD, HBA, solubility, hERG), making it a more promising starting point despite its slightly weaker binding affinity. Ligand A has a better metabolic profile (Cl_mic, t1/2, Pgp) and slightly better BBB, but the significantly higher DILI risk is a major red flag. For a cardiovascular target, minimizing toxicity is paramount. The affinity difference is not large enough to overcome the DILI concerns with Ligand A.
Output:
0
2025-04-18 00:51:59,446 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (352.475 and 345.487 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (78.87) is higher than Ligand B (63.13). Both are below the 140 threshold for oral absorption, but B is better, especially considering ADRB2 is a GPCR and lower TPSA is generally preferred.
3. **logP:** Ligand A (2.155) is within the optimal 1-3 range. Ligand B (3.114) is at the higher end of optimal. This favors A slightly, as excessively high logP can cause issues.
4. **HBD:** Both ligands have 2 H-bond donors, which is acceptable.
5. **HBA:** Ligand A has 4 H-bond acceptors, and Ligand B has 3. Both are within the acceptable range of <=10.
6. **QED:** Ligand A (0.743) has a slightly better QED score than Ligand B (0.64), indicating a more drug-like profile.
7. **DILI:** Ligand A (23.497) has a significantly lower DILI risk than Ligand B (33.424). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (56.417) has a higher BBB penetration percentile than Ligand A (40.83). While ADRB2 isn't a CNS target, some peripheral distribution is still important, and higher BBB can sometimes correlate with better overall distribution.
9. **Caco-2:** Ligand A (-5.138) has a worse Caco-2 permeability than Ligand B (-4.85). This suggests B might have better intestinal absorption.
10. **Solubility:** Ligand A (-2.344) has better aqueous solubility than Ligand B (-3.06). Better solubility is generally preferred.
11. **hERG:** Ligand A (0.167) has a lower hERG inhibition liability than Ligand B (0.478), which is a significant safety advantage.
12. **Cl_mic:** Ligand A (3.235) has a much lower microsomal clearance than Ligand B (49.508), indicating better metabolic stability. This is a crucial advantage.
13. **t1/2:** Ligand B (48.791) has a significantly longer in vitro half-life than Ligand A (-12.194). This is a strong point in favor of Ligand B.
14. **Pgp:** Ligand A (0.093) has lower P-gp efflux liability than Ligand B (0.285). Lower P-gp efflux is generally desirable.
15. **Binding Affinity:** Ligand B (-7.3) has a significantly stronger binding affinity than Ligand A (-5.9). This is a substantial advantage, potentially outweighing some ADME concerns.
**Overall Assessment:**
Ligand B has a significantly better binding affinity and a longer half-life. However, Ligand A demonstrates a much more favorable safety profile with lower DILI and hERG risk, and better metabolic stability (lower Cl_mic). The better solubility and Pgp profile of Ligand A are also beneficial. Given the importance of safety and metabolic stability in drug development, and the substantial difference in DILI and Cl_mic, I believe Ligand A is the more viable candidate despite the weaker binding affinity. The 1.4 kcal/mol difference in binding affinity can potentially be addressed with further optimization, while mitigating the safety concerns of Ligand B would be far more challenging.
Output:
1
2025-04-18 00:51:59,446 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (343.431 and 344.411 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (86.36) is slightly higher than Ligand B (67.87). Both are below the 140 A^2 threshold for good oral absorption, but Ligand B is preferable due to the lower TPSA, which generally correlates with better membrane permeability.
**3. logP:** Ligand B (1.578) is within the optimal 1-3 range, while Ligand A (0.209) is quite low. A low logP can hinder membrane permeability. This is a significant advantage for Ligand B.
**4. H-Bond Donors:** Ligand A has 3 HBDs, and Ligand B has 1. Both are within the acceptable limit of 5.
**5. H-Bond Acceptors:** Ligand A has 5 HBAs, and Ligand B has 4. Both are within the acceptable limit of 10.
**6. QED:** Both ligands have similar QED values (0.73 and 0.763), indicating good drug-likeness.
**7. DILI:** Ligand B (35.285) has a lower DILI risk than Ligand A (27.142). While both are below the 40% threshold, lower is always better.
**8. BBB:** Ligand B (87.515) has a significantly higher BBB penetration percentile than Ligand A (49.826). While ADRB2 is a cardiovascular target, some CNS exposure can occur, and better BBB penetration is generally favorable.
**9. Caco-2 Permeability:** Ligand A (-5.546) has a more negative Caco-2 value, suggesting *better* permeability than Ligand B (-4.722). This is a point in favor of Ligand A.
**10. Aqueous Solubility:** Ligand A (-1.611) has slightly better aqueous solubility than Ligand B (-2.333).
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.388 and 0.379).
**12. Microsomal Clearance:** Ligand A (-37.208) has a much lower (better) microsomal clearance than Ligand B (24.156), indicating greater metabolic stability. This is a significant advantage for Ligand A.
**13. In vitro Half-Life:** Ligand A (19.551 hours) has a longer half-life than Ligand B (15.983 hours). This is a positive for Ligand A, potentially allowing for less frequent dosing.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.003 and 0.059).
**15. Binding Affinity:** Ligand B (-5.7 kcal/mol) has a slightly better binding affinity than Ligand A (-4.7 kcal/mol). This is a 1.0 kcal/mol difference, which is substantial and a key factor.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), Ligand B is the stronger candidate. The significantly better logP and BBB penetration outweigh the advantages of Ligand A in terms of Caco-2 permeability, solubility, metabolic stability, and half-life. The affinity difference is also crucial. While Ligand A has better metabolic stability, the binding affinity is paramount for GPCRs, and Ligand B has a noticeable advantage.
Output:
0
2025-04-18 00:51:59,446 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands (372.877 and 365.43 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (50.27) is significantly better than Ligand B (82.53). ADRB2 is a cardiovascular target, so CNS penetration isn't a primary goal, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold. Ligand B is approaching the upper limit.
3. **logP:** Ligand A (3.944) is slightly higher than Ligand B (2.577), both are within the optimal 1-3 range. Ligand A is closer to the upper limit, which could potentially lead to off-target effects, but is still acceptable.
4. **HBD:** Ligand A (0) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (5). Lower HBA counts also favor permeability.
6. **QED:** Ligand B (0.824) is slightly better than Ligand A (0.64), indicating a more drug-like profile.
7. **DILI:** Ligand B (64.831) has a lower DILI risk than Ligand A (78.054), which is a significant advantage.
8. **BBB:** Ligand A (65.568) has a higher BBB penetration percentile than Ligand B (46.646). While not crucial for a cardiovascular target, some degree of CNS penetration can sometimes be beneficial or at least not detrimental.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5 and -4.73), which is unusual and suggests poor permeability. This is a major concern for both.
10. **Solubility:** Ligand A (-5.787) has slightly better (less negative) solubility than Ligand B (-3.286).
11. **hERG:** Ligand A (0.629) has a lower hERG risk than Ligand B (0.321), which is a critical safety advantage.
12. **Cl_mic:** Ligand B (67.671) has lower microsomal clearance than Ligand A (86.587), indicating better metabolic stability.
13. **t1/2:** Ligand B (13.703 hours) has a significantly longer half-life than Ligand A (7.431 hours). This is a major advantage for dosing convenience.
14. **Pgp:** Ligand A (0.421) has lower P-gp efflux liability than Ligand B (0.115), which is favorable for bioavailability.
15. **Affinity:** Ligand A (-6.9 kcal/mol) has a significantly stronger binding affinity than Ligand B (-4.8 kcal/mol). This 1.5+ kcal/mol difference is substantial and can outweigh many ADME drawbacks.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, affinity, logP, TPSA, and Pgp efflux are key. Ligand A excels in affinity and has better TPSA and Pgp. Ligand B has better metabolic stability (Cl_mic and t1/2) and lower DILI risk. The strong affinity of Ligand A is the most important factor, and the lower TPSA is also beneficial. The slightly higher logP of Ligand A is acceptable given the potency. The hERG risk for Ligand A is also much better.
**Conclusion:**
Despite Ligand B's better metabolic stability and lower DILI, the substantially stronger binding affinity of Ligand A (-6.9 vs -4.8 kcal/mol) and better hERG profile make it the more promising drug candidate. The Caco-2 permeability is a concern for both, but the potency advantage of Ligand A is likely to be more impactful in driving overall efficacy.
Output:
1
2025-04-18 00:51:59,446 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.447 and 350.459 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (67.67) is significantly better than Ligand B (95.5). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption. Ligand A is well below the 140 threshold. Ligand B is approaching it, but less favorably.
3. **logP:** Both ligands have similar and good logP values (1.361 and 1.33), falling within the optimal 1-3 range.
4. **HBD:** Ligand A (0) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (4). Both are within the acceptable limit of 10.
6. **QED:** Ligand A (0.824) is significantly better than Ligand B (0.455). A higher QED indicates a more drug-like profile.
7. **DILI:** Both ligands have low DILI risk (35.75 and 33.307), both well below the concerning threshold of 60. No significant difference.
8. **BBB:** Ligand A (85.459) is much better than Ligand B (43.699). While not a CNS target, some level of BBB penetration can sometimes indicate favorable permeability characteristics.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.477 and -4.937). This is unusual and suggests poor permeability *in vitro*. However, the values are similar.
10. **Solubility:** Both ligands have negative solubility values (-1.6 and -1.89), indicating poor aqueous solubility. This is a concern for both.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.209 and 0.082). This is excellent.
12. **Cl_mic:** Ligand A (28.31) is slightly higher than Ligand B (25.825), indicating slightly faster metabolic clearance.
13. **t1/2:** Ligand B (-26.642) has a *much* longer in vitro half-life than Ligand A (1.571). This is a significant advantage for Ligand B.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.079 and 0.047), which is good.
15. **Binding Affinity:** Ligand B (-7.0) has a slightly better binding affinity than Ligand A (-6.8). While the difference is small, it's within the range where it could outweigh some ADME drawbacks.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Both ligands have good logP and Pgp profiles. Ligand A has a significantly better TPSA. The affinity difference is small, but favors Ligand B. The biggest difference is the half-life, which strongly favors Ligand B. The QED and BBB also favor Ligand A.
**Overall Assessment:**
While Ligand A has better drug-like properties (QED, TPSA, BBB), Ligand B's significantly longer half-life and slightly better binding affinity are crucial for a GPCR target. The poor solubility and Caco-2 values are concerns for both, but can be addressed through formulation strategies. The longer half-life of Ligand B suggests better *in vivo* exposure and potentially less frequent dosing.
Output:
0
2025-04-18 00:51:59,447 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.475 and 348.531 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (72.88) is higher than Ligand B (49.41). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for permeability. Ligand B is better.
3. **logP:** Ligand B (3.75) is higher than Ligand A (0.6). While 0.6 is quite low and may hinder permeability, 3.75 is approaching the upper limit and could cause solubility issues. However, for a GPCR, a higher logP is often tolerated and can improve binding. Ligand B is better.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (1). Both are within the acceptable limit of 5. No major difference.
5. **HBA:** Ligand A (4) is higher than Ligand B (2). Both are within the acceptable limit of 10. Ligand B is better.
6. **QED:** Ligand A (0.689) is better than Ligand B (0.536), indicating a more drug-like profile. Ligand A is better.
7. **DILI:** Ligand A (4.692) has a significantly lower DILI risk than Ligand B (14.075). This is a crucial advantage for Ligand A.
8. **BBB:** Ligand B (58.162) has a higher BBB penetration percentile than Ligand A (29.275). While ADRB2 isn't primarily a CNS target, some degree of BBB penetration can be beneficial. Ligand B is better.
9. **Caco-2:** Ligand A (-5.056) has a lower Caco-2 permeability than Ligand B (-4.72). Both are negative, which is unusual and suggests poor permeability. Ligand B is slightly better.
10. **Solubility:** Ligand A (-0.408) has better aqueous solubility than Ligand B (-3.733). Solubility is important for bioavailability. Ligand A is better.
11. **hERG:** Ligand A (0.365) has a lower hERG inhibition liability than Ligand B (0.615). This is a significant safety advantage for Ligand A.
12. **Cl_mic:** Ligand A (-25.518) has much lower microsomal clearance than Ligand B (45.309), indicating better metabolic stability. This is a major advantage for Ligand A.
13. **t1/2:** Ligand A (-9.877) has a longer in vitro half-life than Ligand B (-1.085). This is a strong advantage for Ligand A.
14. **Pgp:** Ligand A (0.033) has lower P-gp efflux liability than Ligand B (0.463). This is a benefit for bioavailability. Ligand A is better.
15. **Binding Affinity:** Ligand A (-6.3) has a slightly better binding affinity than Ligand B (-5.9). While the difference is not huge, it's still a positive for Ligand A.
**Overall Assessment:**
Ligand A demonstrates a significantly more favorable ADMET profile. It has lower DILI risk, lower hERG inhibition, better metabolic stability (lower Cl_mic and longer t1/2), lower P-gp efflux, and better solubility. While Ligand B has a slightly better logP and BBB penetration, the safety and pharmacokinetic advantages of Ligand A are more compelling for a cardiovascular drug candidate. The slightly better affinity of Ligand A further supports its selection.
Output:
1
2025-04-18 00:51:59,447 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (346.471 and 354.491 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (62.55) is significantly better than Ligand B (78.87). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (3.461) is good, while Ligand B (1.419) is on the lower side of optimal. For a GPCR, a slightly higher logP is generally preferred for membrane permeability and receptor engagement.
4. **HBD:** Ligand A (1) is preferable to Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (3) is preferable to Ligand B (4). Similar reasoning as HBD.
6. **QED:** Ligand A (0.908) is significantly better than Ligand B (0.756), indicating a more drug-like profile.
7. **DILI:** Ligand A (36.603) is considerably better than Ligand B (15.781). Lower DILI risk is crucial.
8. **BBB:** Both ligands have good BBB penetration (Ligand A: 80.962, Ligand B: 77.588), but this isn't a primary concern for a cardiovascular target.
9. **Caco-2:** Both have negative values, which is unusual. Assuming these are logP values, they are similar and suggest reasonable permeability.
10. **Solubility:** Ligand A (-4.092) is better than Ligand B (-2.384). Higher solubility is generally desirable.
11. **hERG:** Both ligands show very low hERG inhibition risk (Ligand A: 0.327, Ligand B: 0.273). This is excellent.
12. **Cl_mic:** Ligand A (49.216) and Ligand B (47.337) are comparable.
13. **t1/2:** Ligand A (6.324) is better than Ligand B (-7.772). A positive half-life is preferable.
14. **Pgp:** Both ligands have low Pgp efflux liability (Ligand A: 0.269, Ligand B: 0.173).
15. **Binding Affinity:** Ligand A (-6.3 kcal/mol) is slightly better than Ligand B (-5.8 kcal/mol), although the difference is not huge.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, and binding affinity are key. Ligand A has a better logP and TPSA. The affinity difference is small, but combined with the superior ADME properties, it tips the balance.
**Overall Assessment:**
Ligand A consistently outperforms Ligand B across most critical ADME properties (QED, DILI, Solubility, t1/2, TPSA) and has a slightly better binding affinity. While both have acceptable profiles, Ligand A presents a more favorable risk-benefit profile.
Output:
1
2025-04-18 00:51:59,447 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (400.28 and 395.561 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (63.91) is better than Ligand B (91.83). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally aids absorption.
3. **logP:** Ligand A (3.146) is optimal, while Ligand B (0.471) is quite low. This is a significant drawback for Ligand B, potentially hindering membrane permeability and bioavailability.
4. **HBD:** Both ligands have 0 HBD, which is acceptable.
5. **HBA:** Both ligands have 5 HBA, which is acceptable.
6. **QED:** Both ligands have similar QED values (0.663 and 0.675), indicating good drug-likeness.
7. **DILI:** Ligand A (76.386) has a higher DILI risk than Ligand B (47.615). This favors Ligand B.
8. **BBB:** Ligand A (92.323) has better BBB penetration than Ligand B (78.209), but this is less critical for a cardiovascular target.
9. **Caco-2:** Ligand A (-5.326) and Ligand B (-4.826) have similar Caco-2 permeability values.
10. **Solubility:** Ligand A (-2.621) has slightly better solubility than Ligand B (-3.35), but both are poor.
11. **hERG:** Both ligands have low hERG inhibition risk (0.69 and 0.5), which is good.
12. **Cl_mic:** Ligand A (27.945) has lower microsomal clearance than Ligand B (39.271), indicating better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (20.969) has a much longer in vitro half-life than Ligand B (-11.551). This is a substantial advantage for Ligand A, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.663 and 0.061). Ligand B is slightly better.
15. **Binding Affinity:** Ligand A (-7.2 kcal/mol) has a significantly stronger binding affinity than Ligand B (-3.8 kcal/mol). This is a crucial advantage, as a 3.4 kcal/mol difference is substantial and can outweigh minor ADME drawbacks.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand A excels in logP and significantly outperforms Ligand B in binding affinity. While Ligand B has a lower DILI risk, the superior potency and metabolic stability of Ligand A are more important for overall drug development success.
**Conclusion:**
Despite the slightly higher DILI risk, Ligand A's superior binding affinity, logP, metabolic stability, and half-life make it the more promising drug candidate. The strong binding affinity is a major driver in this decision.
Output:
1
2025-04-18 00:51:59,447 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands (348.45 & 344.42 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (85.25) is better than Ligand B (97.43). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally favors absorption.
3. **logP:** Ligand A (1.405) is better than Ligand B (0.174). Ligand B is quite low, potentially hindering membrane permeability. GPCRs benefit from a logP between 1-3.
4. **HBD:** Both have 2 HBD, which is good.
5. **HBA:** Ligand A has 5 HBA, Ligand B has 4. Both are acceptable.
6. **QED:** Ligand B (0.797) is better than Ligand A (0.522), indicating a more drug-like profile.
7. **DILI:** Ligand B (29.24) is significantly better than Ligand A (38.15). Lower DILI is a major advantage.
8. **BBB:** Both have good BBB penetration (73.40 & 77.08), but this is less critical for a cardiovascular target.
9. **Caco-2:** Both are negative, indicating poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-1.555) is better than Ligand B (-3.019), though both are quite poor.
11. **hERG:** Both are very low risk (0.175 & 0.096).
12. **Cl_mic:** Ligand B (9.64) is much better than Ligand A (37.59). Lower clearance is preferred for metabolic stability.
13. **t1/2:** Ligand A (20.43) is better than Ligand B (-9.67). A negative half-life is concerning.
14. **Pgp:** Both are low risk (0.105 & 0.026).
15. **Binding Affinity:** Ligand A (-6.9) is significantly better than Ligand B (-2.6). A 4.3 kcal/mol difference is substantial and can often outweigh other ADME concerns.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has a better logP and TPSA, and a *much* better binding affinity. While Ligand B has a better QED and DILI, the significantly weaker binding affinity is a major drawback. The poor Caco-2 values for both are concerning, but can potentially be addressed with formulation strategies.
**Overall Assessment:**
The substantial difference in binding affinity (-6.9 vs -2.6 kcal/mol) is the deciding factor. While Ligand B has some advantages in QED, DILI, and Cl_mic, the potency of Ligand A is far superior. A strong binding affinity is crucial for a GPCR ligand, and the other issues with Ligand A are more readily addressable through further optimization than improving a weak binder.
**Output:**
1
2025-04-18 00:51:59,447 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
The target is ADRB2, a GPCR. Therefore, I will prioritize logP, TPSA, Pgp efflux, BBB penetration, and binding affinity. Metabolic stability (Cl_mic, t1/2) and safety (DILI, hERG) are also important, but less so than the first five.
Let's compare the ligands property by property:
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (351.403) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (93.9) is significantly better than Ligand B (121.28). Lower TPSA is crucial for good oral absorption and GPCR engagement.
3. **logP:** Both are within the optimal range (1-3), but Ligand A (0.704) is on the lower side, while Ligand B (0.576) is even lower. This could potentially affect membrane permeability.
4. **HBD/HBA:** Ligand A has 1 HBD and 6 HBA, while Ligand B has 3 HBD and 6 HBA. Both are acceptable, but Ligand A is slightly more favorable.
5. **QED:** Ligand A (0.806) has a much better QED score than Ligand B (0.409), indicating a more drug-like profile.
6. **DILI:** Ligand A (55.991) has a higher DILI risk than Ligand B (34.161), but both are below the concerning threshold of 60.
7. **BBB:** Ligand A (65.801) has better BBB penetration than Ligand B (16.13). While not a primary concern for peripheral GPCRs like ADRB2, it's still a positive attribute.
8. **Caco-2:** Ligand A (-4.792) has a much better Caco-2 permeability than Ligand B (-6.014), indicating better intestinal absorption.
9. **Solubility:** Ligand A (-0.982) has better solubility than Ligand B (-0.401).
10. **hERG:** Both ligands have very low hERG risk (0.039 and 0.079 respectively).
11. **Cl_mic:** Ligand B (1.947) has significantly lower microsomal clearance than Ligand A (17.362), suggesting better metabolic stability.
12. **t1/2:** Ligand A (27.595) has a longer in vitro half-life than Ligand B (-2.497).
13. **Pgp:** Both ligands have very low Pgp efflux liability (0.03 and 0.005 respectively).
14. **Binding Affinity:** Ligand B (-7.1) has a slightly better binding affinity than Ligand A (-6.5). The difference is 0.6 kcal/mol, which is a notable advantage.
**Overall Assessment:**
Ligand B has a better binding affinity and metabolic stability. However, Ligand A excels in most other crucial parameters for a GPCR drug candidate, including TPSA, QED, Caco-2 permeability, solubility, and BBB penetration. The 0.6 kcal/mol difference in binding affinity is not enough to outweigh the superior ADME properties of Ligand A, especially given that the affinity of Ligand A is already quite good.
**Output:**
1
2025-04-18 00:51:59,447 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (360.42 and 363.487 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand A (58.2) is significantly better than Ligand B (80.24). For a GPCR, keeping TPSA low is beneficial for permeability. Ligand B is pushing the upper limit for good oral absorption (<=140), while A is well within.
**3. logP:** Both ligands have excellent logP values (2.815 and 2.741), falling within the optimal 1-3 range.
**4. H-Bond Donors:** Ligand A has 2 HBD, and Ligand B has 1. Both are acceptable, well below the limit of 5.
**5. H-Bond Acceptors:** Ligand A has 2 HBA, while Ligand B has 7. Ligand B is higher, but still within the acceptable range of <=10.
**6. QED:** Ligand A (0.81) has a better QED score than Ligand B (0.69), indicating a more drug-like profile.
**7. DILI Risk:** Ligand A (30.83) has a much lower DILI risk than Ligand B (63.98). This is a major advantage for Ligand A.
**8. BBB Penetration:** Ligand A (91.90) has significantly better BBB penetration than Ligand B (68.94). While ADRB2 is a cardiovascular target, some CNS effects are possible with certain ligands, and higher BBB penetration can be useful for understanding off-target effects.
**9. Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.585 and -4.969). This is unusual and suggests poor permeability *in vitro*. However, the values are similar.
**10. Aqueous Solubility:** Ligand A (-4.424) has slightly better aqueous solubility than Ligand B (-2.332), but both are poor.
**11. hERG Inhibition:** Both ligands have low hERG inhibition risk (0.547 and 0.676).
**12. Microsomal Clearance:** Ligand B (73.273) has a significantly higher microsomal clearance than Ligand A (26.426), indicating faster metabolism and potentially lower *in vivo* exposure.
**13. In vitro Half-Life:** Ligand A (5.504 hours) has a shorter half-life than Ligand B (18.81 hours). This is a drawback for Ligand A.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.041 and 0.097).
**15. Binding Affinity:** Ligand A (-7.2 kcal/mol) has a slightly better binding affinity than Ligand B (-6.5 kcal/mol). This 0.7 kcal/mol difference is significant and can outweigh some ADME drawbacks.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity), Ligand A is the stronger candidate. It has a better TPSA, lower DILI risk, better BBB penetration, better QED, and a slightly better binding affinity. While Ligand B has a longer half-life, the superior ADME profile and safety profile of Ligand A, combined with its slightly improved potency, make it the more promising drug candidate. The poor Caco-2 values for both are concerning and would require further investigation, but the other advantages of A are substantial.
Output:
1
2025-04-18 00:51:59,447 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [352.475, 75.71, 1.627, 1, 4, 0.606, 21.753, 75.805, -4.387, -1.953, 0.123, 56.49, -1.864, 0.075, -4.6]
**Ligand B:** [348.487, 69.64, 2.247, 2, 3, 0.749, 20.9, 65.297, -5.074, -2.543, 0.361, 37.22, 3.573, 0.204, -6]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal range (200-500 Da). Ligand A (352.475) is slightly higher than Ligand B (348.487), but the difference is negligible.
2. **TPSA:** Ligand A (75.71) is slightly higher than Ligand B (69.64), both are acceptable for a non-CNS GPCR target like ADRB2, but lower is generally preferred.
3. **logP:** Ligand A (1.627) and Ligand B (2.247) are both within the optimal range (1-3). Ligand B is slightly better here.
4. **HBD:** Ligand A (1) is better than Ligand B (2). Fewer HBDs are generally preferred for better permeability.
5. **HBA:** Ligand A (4) is better than Ligand B (3). Fewer HBAs are generally preferred for better permeability.
6. **QED:** Ligand B (0.749) has a better QED score than Ligand A (0.606), indicating a more drug-like profile.
7. **DILI:** Both have low DILI risk (Ligand A: 21.753, Ligand B: 20.9), which is excellent. Ligand B is marginally better.
8. **BBB:** Ligand A (75.805) has a significantly higher BBB penetration score than Ligand B (65.297). While ADRB2 isn't primarily a CNS target, some degree of BBB penetration can be beneficial for off-target effects.
9. **Caco-2:** Ligand B (-5.074) shows better Caco-2 permeability than Ligand A (-4.387), suggesting better intestinal absorption.
10. **Solubility:** Ligand B (-2.543) has better aqueous solubility than Ligand A (-1.953).
11. **hERG:** Ligand A (0.123) has a lower hERG inhibition liability than Ligand B (0.361), which is a significant advantage for cardiovascular safety.
12. **Cl_mic:** Ligand B (37.22) has a lower microsomal clearance than Ligand A (56.49), indicating better metabolic stability.
13. **t1/2:** Ligand B (3.573) has a longer in vitro half-life than Ligand A (-1.864), which is desirable.
14. **Pgp:** Ligand B (0.204) has lower P-gp efflux liability than Ligand A (0.075), suggesting better bioavailability.
15. **Affinity:** Ligand B (-6 kcal/mol) has a stronger binding affinity than Ligand A (-4.6 kcal/mol). This is a substantial difference (1.4 kcal/mol), and a key driver in this decision.
**Overall Assessment:**
Ligand B is superior in several key ADME properties (Caco-2, solubility, Cl_mic, t1/2, Pgp) and, most importantly, has a significantly stronger binding affinity. While Ligand A has a better hERG profile and BBB penetration, the affinity difference is substantial enough to outweigh these benefits, especially considering ADRB2 is not a CNS target. The better QED score for Ligand B also contributes to its favorability.
Output:
0
2025-04-18 00:51:59,447 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands (364.43 and 350.46 Da) fall within the ideal 200-500 Da range. No significant difference here.
**2. TPSA:** Ligand B (84.42) is significantly better than Ligand A (117.09). For a GPCR, lower TPSA is generally preferred for better permeability.
**3. logP:** Both ligands have acceptable logP values (0.839 and 1.606, respectively), falling within the 1-3 range. Ligand B is slightly better.
**4. H-Bond Donors:** Ligand A has 3 HBD, and Ligand B has 1. Both are within the acceptable limit of 5. Ligand B is preferable.
**5. H-Bond Acceptors:** Ligand A has 6 HBA, and Ligand B has 5. Both are within the acceptable limit of 10.
**6. QED:** Both ligands have similar QED values (0.639 and 0.648), indicating good drug-likeness.
**7. DILI Risk:** Ligand B (25.44%) has a much lower DILI risk than Ligand A (72.08%). This is a significant advantage for Ligand B.
**8. BBB Penetration:** Ligand B (59.05%) shows better BBB penetration than Ligand A (25.79%). While ADRB2 is primarily a cardiovascular target, some CNS effects can be relevant, and better BBB penetration isn't necessarily a negative.
**9. Caco-2 Permeability:** Ligand A (-5.788) has better Caco-2 permeability than Ligand B (-4.896).
**10. Aqueous Solubility:** Ligand A (-2.864) has better aqueous solubility than Ligand B (-0.571).
**11. hERG Inhibition:** Both ligands have very low hERG inhibition risk (0.125 and 0.192, respectively).
**12. Microsomal Clearance:** Both ligands have similar microsomal clearance values (37.79 and 39.68 mL/min/kg).
**13. In vitro Half-Life:** Ligand B (18.96 hours) has a considerably longer half-life than Ligand A (-23.16 hours). This is a significant advantage.
**14. P-gp Efflux:** Both ligands have very low P-gp efflux liability (0.035 and 0.016).
**15. Binding Affinity:** Both ligands have very similar binding affinities (-6.6 and -5.7 kcal/mol). The difference of 0.9 kcal/mol is not substantial enough to outweigh other factors.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, TPSA, Pgp, and affinity) and the general drug-like properties, Ligand B is the more promising candidate. It has a significantly lower DILI risk, better TPSA, better BBB penetration, and a longer half-life. While Ligand A has slightly better Caco-2 permeability and aqueous solubility, the advantages of Ligand B in safety (DILI) and pharmacokinetics (half-life) are more critical for overall drug development success. The binding affinity difference is not significant enough to favor Ligand A.
Output:
0
2025-04-18 00:51:59,447 - INFO - Here's my reasoning and the final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, key properties are affinity, logP, TPSA, Pgp efflux, and to a lesser extent, BBB.
Let's break down the comparison:
1. **MW:** Both ligands (348.4 and 339.4 Da) are within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (82.81) is higher than Ligand B (54.34). Ligand B is significantly better, being well below the 140 threshold for good absorption.
3. **logP:** Ligand A (1.711) is optimal. Ligand B (4.423) is high, potentially leading to solubility issues and off-target effects.
4. **HBD/HBA:** Both have acceptable HBD (1) and HBA counts (7 for A, 3 for B).
5. **QED:** Both have good QED scores (0.658 and 0.842), indicating drug-likeness.
6. **DILI:** Ligand A (26.483) has a much lower DILI risk than Ligand B (63.125). This is a significant advantage.
7. **BBB:** Ligand B (87.864) has a higher BBB penetration than Ligand A (38.232). While ADRB2 is cardiovascular, some CNS effects are possible with beta-blockers, so this isn't a major negative for B.
8. **Caco-2:** Both are negative, indicating poor permeability.
9. **Solubility:** Ligand A (-1.879) is better than Ligand B (-5.145). Ligand B's high logP likely contributes to this.
10. **hERG:** Both have low hERG inhibition risk (0.569 and 0.608).
11. **Cl_mic:** Ligand A (56.17) has lower microsomal clearance than Ligand B (69.531), suggesting better metabolic stability.
12. **t1/2:** Ligand B (48.422) has a longer half-life than Ligand A (-24.762). This is a positive for B.
13. **Pgp:** Ligand A (0.304) has lower P-gp efflux than Ligand B (0.757), which is favorable for bioavailability.
14. **Affinity:** Ligand B (-7.1) has a significantly stronger binding affinity than Ligand A (-2.9). This is a substantial advantage, potentially outweighing some of the ADME drawbacks.
**Overall Assessment:**
Ligand B has a much better binding affinity, a longer half-life, and better BBB penetration. However, it suffers from a high logP, increased DILI risk, and higher P-gp efflux. Ligand A has better solubility, lower DILI risk, lower P-gp efflux, and better metabolic stability.
The difference in binding affinity (-7.1 vs -2.9 kcal/mol) is substantial (a 4.2 kcal/mol difference). For a GPCR, strong binding is paramount. While the ADME properties of Ligand B are not ideal, the potency advantage is likely to be critical for efficacy, and optimization could address the ADME concerns.
Output:
0
2025-04-18 00:51:59,448 - INFO - Batch 509 complete. Total preferences: 8144
2025-04-18 00:51:59,448 - INFO - Processing batch 510/512...
2025-04-18 00:52:49,757 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (347.327 and 353.442 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (70.47) is significantly better than Ligand A (97.41). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand B (1.275) is better than Ligand A (0.325). Ligand A is quite low, potentially hindering membrane permeability. 1-3 is optimal, and B is within this range.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Ligand B (5) is slightly better than Ligand A (6). Both are acceptable.
6. **QED:** Ligand B (0.866) is better than Ligand A (0.735), indicating a more drug-like profile.
7. **DILI:** Ligand B (30.748) is *much* better than Ligand A (80.225). This is a significant advantage for Ligand B. A DILI percentile under 40 is highly desirable.
8. **BBB:** Ligand B (88.988) is better than Ligand A (57.231). While not a primary concern for a cardiovascular target, higher BBB is generally favorable.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand B (-4.763) is slightly better than Ligand A (-4.478), but both are concerning.
10. **Solubility:** Both are negative, indicating poor solubility. Ligand B (-2.262) is slightly better than Ligand A (-3.023).
11. **hERG:** Both are very low (0.185 and 0.247), suggesting minimal hERG inhibition risk, which is excellent.
12. **Cl_mic:** Ligand A (3.7) is *much* better than Ligand B (17.03). Lower clearance indicates better metabolic stability.
13. **t1/2:** Ligand B (-13.393) is better than Ligand A (-12.02), indicating a longer half-life.
14. **Pgp:** Both are very low (0.03 and 0.018), suggesting minimal P-gp efflux.
15. **Binding Affinity:** Both ligands have the same binding affinity (-6.1 kcal/mol).
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand B excels in logP and TPSA, while affinity is equal. The DILI score is a major factor, and Ligand B is significantly better. While Ligand A has better metabolic stability (Cl_mic), the overall profile of Ligand B is more favorable, especially considering the lower DILI risk. The poor Caco-2 and solubility of both are concerning, but can be addressed with formulation strategies.
**Conclusion:**
Ligand B is the more promising candidate due to its superior DILI profile, better logP and TPSA, and a more drug-like QED score. The slightly longer half-life is also a benefit. While Ligand A has better metabolic stability, the other advantages of Ligand B outweigh this concern.
Output:
0
2025-04-18 00:52:49,757 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (a cardiovascular GPCR) drug candidates.
**Ligand A: [354.447, 99.1, -0.097, 3, 5, 0.502, 27.336, 29.779, -4.852, -1.241, 0.209, 21.483, -14.512, 0.017, -5.6]**
**Ligand B: [408.888, 84.5, 3.22, 2, 5, 0.613, 46.724, 68.748, -5.03, -3.785, 0.517, 50.834, 21.165, 0.099, -5.1]**
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity) and general drug-like properties:
1. **MW:** Ligand A (354.447 Da) is better, falling nicely within the 200-500 range. Ligand B (408.888 Da) is still acceptable, but approaching the upper limit.
2. **TPSA:** Ligand B (84.5) is superior, being lower than Ligand A (99.1). Both are under the 140 threshold for oral absorption, but lower TPSA is generally preferred for GPCRs.
3. **logP:** Ligand A (-0.097) is suboptimal, being slightly below the ideal 1-3 range. Ligand B (3.22) is excellent, right in the sweet spot. This is a significant advantage for Ligand B.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (2), but both are within the acceptable limit of 5.
5. **HBA:** Both ligands have 5 HBA, which is acceptable.
6. **QED:** Ligand B (0.613) is slightly better than Ligand A (0.502), indicating a more drug-like profile.
7. **DILI:** Ligand A (27.336) has a much lower DILI risk than Ligand B (46.724). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (68.748) has a better BBB penetration score than Ligand A (29.779). While not a primary concern for a cardiovascular target, it's a slight positive for B.
9. **Caco-2:** Both are negative, indicating poor permeability. Ligand B (-5.03) is slightly worse than Ligand A (-4.852).
10. **Solubility:** Ligand A (-1.241) is slightly better than Ligand B (-3.785).
11. **hERG:** Ligand A (0.209) has a much lower hERG risk than Ligand B (0.517). This is a significant safety advantage for Ligand A.
12. **Cl_mic:** Ligand A (21.483) has a lower microsomal clearance than Ligand B (50.834), suggesting better metabolic stability.
13. **t1/2:** Ligand B (21.165) has a longer in vitro half-life than Ligand A (-14.512). This is a positive for Ligand B.
14. **Pgp:** Ligand A (0.017) has a much lower P-gp efflux liability than Ligand B (0.099), which is preferable for bioavailability.
15. **Affinity:** Both ligands have very similar binding affinities (-5.6 and -5.1 kcal/mol, respectively). The difference is not substantial enough to be a deciding factor.
**Overall Assessment:**
Ligand B has advantages in logP, QED, BBB, and t1/2. However, Ligand A is significantly better in terms of safety (DILI, hERG) and metabolic stability (Cl_mic), and Pgp efflux. The slightly better solubility of Ligand A is also a plus. Considering the cardiovascular target and the importance of minimizing off-target effects and toxicity, the safety profile and metabolic stability of Ligand A are more crucial. While Ligand B's logP is ideal, the risks associated with Ligand B outweigh this benefit.
Therefore, I prefer Ligand A.
Output:
1
2025-04-18 00:52:49,757 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor (a GPCR).
**Ligand A:** [382.869, 95.5, 2.073, 3, 4, 0.609, 52.385, 12.602, -5.687, -2.802, 0.454, 30.482, -13.197, 0.13, -7.7]
**Ligand B:** [369.981, 30.29, 4.905, 0, 4, 0.587, 5.777, 89.725, -4.793, -4.149, 0.919, 52.444, 42.691, 0.583, -6.4]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, affinity, and BBB):
1. **MW:** Both are within the ideal 200-500 Da range. Ligand B (369.981) is slightly lower, which is generally favorable.
2. **TPSA:** Ligand A (95.5) is higher than the preferred <140 for good absorption, but not drastically so. Ligand B (30.29) is excellent, well below 140. This is a significant advantage for Ligand B.
3. **logP:** Ligand A (2.073) is within the optimal 1-3 range. Ligand B (4.905) is a bit high, potentially leading to solubility issues and off-target interactions.
4. **HBD:** Ligand A (3) is acceptable. Ligand B (0) is also good.
5. **HBA:** Both ligands have 4 HBA, which is within the acceptable range.
6. **QED:** Both are around 0.6, indicating good drug-likeness.
7. **DILI:** Ligand A (52.385) is better than Ligand B (5.777) in terms of DILI risk.
8. **BBB:** Ligand B (89.725) has a much higher BBB penetration percentile than Ligand A (12.602). This is a major advantage for Ligand B, given it's a GPCR target.
9. **Caco-2:** Ligand A (-5.687) and Ligand B (-4.793) are both negative, which is unusual and suggests poor permeability.
10. **Solubility:** Ligand A (-2.802) is better than Ligand B (-4.149).
11. **hERG:** Ligand A (0.454) is better than Ligand B (0.919).
12. **Cl_mic:** Ligand B (52.444) has a slightly higher clearance than Ligand A (30.482), indicating potentially lower metabolic stability.
13. **t1/2:** Ligand B (42.691) has a significantly longer half-life than Ligand A (-13.197).
14. **Pgp:** Ligand A (0.13) has lower P-gp efflux than Ligand B (0.583).
15. **Affinity:** Ligand A (-7.7) has a slightly better binding affinity than Ligand B (-6.4). However, the difference is less than 1.5 kcal/mol.
**Overall Assessment:**
Ligand B has several advantages: excellent TPSA, very high BBB penetration, and a longer half-life. While its logP is slightly high, the strong BBB penetration is a significant benefit for a GPCR target. Ligand A has better DILI and hERG profiles, but the lower BBB penetration and shorter half-life are concerning. The affinity difference is not large enough to overcome the other ADME advantages of Ligand B.
Therefore, I favor Ligand B.
Output:
0
2025-04-18 00:52:49,757 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (a cardiovascular GPCR) drug candidates.
**Ligand A:** [367.559, 61.44, 1.728, 2, 4, 0.686, 15.083, 78.558, -5.496, -3.105, 0.466, 45.397, 3.14, 0.058, -5.4]
**Ligand B:** [368.459, 121.02, 0.491, 3, 5, 0.617, 63.552, 52.966, -5.566, -2.818, 0.126, -2.143, 12.772, 0.049, -6.7]
Here's a breakdown, comparing each parameter and considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal 200-500 Da range. A is 367.559, B is 368.459 - very similar.
2. **TPSA:** Ligand A (61.44) is significantly better than Ligand B (121.02). GPCRs benefit from lower TPSA for permeability. Ligand B is quite high, potentially hindering oral absorption.
3. **logP:** Ligand A (1.728) is within the optimal range. Ligand B (0.491) is a bit low, potentially impacting permeability.
4. **HBD:** Ligand A (2) is good. Ligand B (3) is acceptable, but slightly less desirable.
5. **HBA:** Ligand A (4) is good. Ligand B (5) is acceptable, but slightly less desirable.
6. **QED:** Both are similar and acceptable (A: 0.686, B: 0.617).
7. **DILI:** Ligand A (15.083) is *much* better than Ligand B (63.552). This is a significant advantage for A.
8. **BBB:** Ligand A (78.558) is good, indicating reasonable potential for some CNS penetration (though not a primary concern for a cardiovascular target). Ligand B (52.966) is lower.
9. **Caco-2:** Both are negative, which is unusual. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Both are negative, again, scale unspecified.
11. **hERG:** Ligand A (0.466) is preferable to Ligand B (0.126) - lower risk of cardiotoxicity.
12. **Cl_mic:** Ligand B (-2.143) has a *negative* clearance, which is not physically possible. This is a major red flag and suggests a data error or a very unusual metabolic profile. Ligand A (45.397) is reasonable.
13. **t1/2:** Ligand B (12.772) has a longer half-life than Ligand A (3.14), which is a positive.
14. **Pgp:** Both are very low (A: 0.058, B: 0.049), indicating minimal P-gp efflux.
15. **Affinity:** Ligand B (-6.7) has a significantly stronger binding affinity than Ligand A (-5.4) - a difference of 1.3 kcal/mol. This is a substantial advantage.
**Overall Assessment:**
Ligand B has a significantly better binding affinity, and a longer half-life. However, it suffers from a very high DILI risk, a problematic TPSA, a low logP, and a nonsensical negative microsomal clearance. Ligand A has a more balanced profile, with acceptable values across most parameters, a much lower DILI risk, and a plausible clearance value. The affinity difference is significant, but the ADME/Tox profile of Ligand B is severely compromised.
Given the importance of a balanced profile for drug development, and the serious concerns with Ligand B's DILI and clearance, I would prioritize Ligand A.
Output:
1
2025-04-18 00:52:49,757 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (361.511 and 365.499 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (71.09) is significantly better than Ligand B (95.66). ADRB2 is a cardiovascular target, not CNS, but lower TPSA generally improves absorption.
3. **logP:** Ligand A (2.96) is optimal, while Ligand B (1.549) is a bit low. A logP between 1-3 is preferred, and Ligand A is closer to this ideal. Lower logP can sometimes indicate poor membrane permeability.
4. **HBD:** Ligand A (2) is preferable to Ligand B (3). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (4) is preferable to Ligand B (5). Fewer HBAs generally improve permeability.
6. **QED:** Both ligands have reasonable QED scores (0.847 and 0.738), indicating good drug-like properties. Ligand A is slightly better.
7. **DILI:** Ligand A (43.66) has a slightly higher DILI risk than Ligand B (23.187), but both are below the concerning threshold of 60.
8. **BBB:** Ligand A (46.336) has a lower BBB penetration than Ligand B (62.699). However, since ADRB2 is a cardiovascular target, BBB penetration is not a high priority.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the magnitude is similar (-5.077 vs -5.789).
10. **Solubility:** Both ligands have very poor solubility scores (-2.755 and -2.938). This is a significant concern for both.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.112 and 0.241), which is excellent.
12. **Cl_mic:** Ligand A (20.789) has a higher microsomal clearance than Ligand B (8.338), indicating faster metabolism. This is a negative for Ligand A.
13. **t1/2:** Ligand A (9.213) has a longer in vitro half-life than Ligand B (4.563), which is positive.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.164 and 0.071).
15. **Binding Affinity:** Ligand B (-6.3 kcal/mol) has a significantly stronger binding affinity than Ligand A (-4.1 kcal/mol). This is a substantial advantage (2.2 kcal/mol difference) and can outweigh some of the ADME drawbacks.
**Overall Assessment:**
Ligand B has a significantly better binding affinity, which is the most important factor for GPCRs. While Ligand A has better TPSA, logP, and half-life, the substantial difference in affinity makes Ligand B the more promising candidate. The solubility issues are concerning for both, but can potentially be addressed through formulation strategies. The lower clearance of Ligand B is also a benefit.
Output:
0
2025-04-18 00:52:49,757 - INFO - Here's my reasoning and final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, prioritizing logP, TPSA, Pgp, and binding affinity is crucial, alongside general drug-like properties.
* **Molecular Weight:** Ligand A (464.225 Da) is slightly above the ideal range, but acceptable. Ligand B (339.399 Da) is well within the ideal range.
* **TPSA:** Ligand A (50.36) is good, under the 140 threshold. Ligand B (80.12) is also acceptable, though higher.
* **logP:** Ligand A (3.759) is optimal. Ligand B (1.255) is a bit low, potentially impacting permeability.
* **H-Bond Donors/Acceptors:** Both ligands are within acceptable ranges.
* **QED:** Both ligands have good QED scores (A: 0.506, B: 0.832), indicating good drug-likeness.
* **DILI:** Both have similar, moderate DILI risk (A: 67.739, B: 64.288).
* **BBB:** Ligand A (71.229) has better BBB penetration than Ligand B (61.38). While not a primary concern for a cardiovascular target, it's a slight advantage.
* **Caco-2:** Ligand A (-4.765) is significantly better than Ligand B (-5.27), indicating superior intestinal absorption.
* **Solubility:** Ligand A (-4.731) is better than Ligand B (-2.518).
* **hERG:** Ligand A (0.799) has a slightly higher hERG risk than Ligand B (0.153), which is a concern.
* **Cl_mic:** Ligand B (-0.902) has significantly better metabolic stability (lower clearance) than Ligand A (70.815).
* **t1/2:** Ligand B (-0.131) has a much longer half-life than Ligand A (41.938).
* **Pgp:** Ligand A (0.518) has better Pgp efflux properties than Ligand B (0.03).
* **Binding Affinity:** Ligand A (-7.6 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.2 kcal/mol). This is a substantial advantage, potentially outweighing some ADME drawbacks.
**Overall Assessment:**
Ligand A has a superior binding affinity and better Caco-2 permeability and solubility, which are important for oral bioavailability. Its BBB penetration is also slightly better. However, it has a higher hERG risk and poorer metabolic stability. Ligand B has better metabolic stability, a longer half-life, and lower hERG risk, but its binding affinity is considerably weaker, and its logP is on the lower side.
Given the importance of potency for GPCRs, and the substantial difference in binding affinity (-7.6 vs -6.2 kcal/mol), I believe Ligand A is the more promising candidate, despite its drawbacks. The hERG risk can be addressed through further structural modifications, and metabolic stability can be improved. The strong binding affinity provides a solid foundation for optimization.
**Output:**
1
2025-04-18 00:52:49,758 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.43 & 362.42 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (55.14) is significantly better than Ligand B (87.66). ADRB2 is a cardiovascular target, not CNS, but lower TPSA generally improves absorption. Ligand A is well below the 140 threshold, while Ligand B is approaching it.
3. **logP:** Ligand A (4.89) is higher than Ligand B (1.22). While both are within the acceptable range, Ligand A is pushing the upper limit and could potentially have solubility issues. Ligand B is closer to the optimal range.
4. **HBD:** Ligand A (0) is preferable to Ligand B (3). Fewer HBDs generally improve membrane permeability.
5. **HBA:** Ligand A (5) is preferable to Ligand B (4). Lower HBA is generally better for permeability.
6. **QED:** Both ligands have similar QED values (0.636 and 0.635), indicating comparable drug-likeness.
7. **DILI:** Ligand A (89.84) has a considerably higher DILI risk than Ligand B (32.80). This is a major concern for Ligand A.
8. **BBB:** Both ligands have reasonably high BBB penetration (45.68 and 82.01). Since ADRB2 is not a CNS target, this isn't a primary driver, but higher is still slightly favorable.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.86 and -4.904). These values are unusual and suggest poor permeability.
10. **Solubility:** Ligand A (-6.452) has worse solubility than Ligand B (-1.658). This, combined with its higher logP, is a potential formulation challenge.
11. **hERG:** Ligand A (0.744) has a slightly higher hERG risk than Ligand B (0.347), but both are relatively low.
12. **Cl_mic:** Ligand B (8.37) has significantly lower microsomal clearance than Ligand A (84.61), indicating better metabolic stability.
13. **t1/2:** Ligand B (-6.05) has a longer in vitro half-life than Ligand A (-12.88), suggesting slower metabolism and potentially less frequent dosing.
14. **Pgp:** Ligand A (0.825) has higher P-gp efflux than Ligand B (0.011). Lower P-gp efflux is preferable for better bioavailability.
15. **Binding Affinity:** Ligand A (-5.8) has slightly better binding affinity than Ligand B (-4.6), a difference of 1.2 kcal/mol. While a difference of >1.5 kcal/mol would be very significant, this is a moderate advantage.
**Overall Assessment:**
Ligand A has a better binding affinity, but it is significantly hampered by its high DILI risk, poor solubility, high metabolic clearance, and high P-gp efflux. Ligand B, while having slightly weaker binding, presents a much more favorable ADME-Tox profile, particularly regarding liver toxicity and metabolic stability. Given the cardiovascular target, minimizing toxicity is paramount. The moderate affinity difference can likely be overcome with further optimization of Ligand B.
Output:
0
2025-04-18 00:52:49,758 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
The ADRB2 receptor is a GPCR, so the priorities are logP, TPSA, Pgp, BBB, and affinity. Let's break down the comparison:
1. **Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (342.439 Da) is slightly higher than Ligand B (337.387 Da), but this difference isn't significant.
2. **TPSA:** Ligand A (67.43) is significantly better than Ligand B (101.38). A TPSA under 140 is good for oral absorption, but lower is preferable for GPCRs. Ligand A is much closer to the ideal range for good permeability.
3. **logP:** Both ligands have acceptable logP values (A: 1.087, B: 1.432), falling within the 1-3 range. Ligand B is slightly higher, which could potentially lead to off-target effects, but it's not a major concern.
4. **H-Bond Donors:** Both have 2 HBD, which is good.
5. **H-Bond Acceptors:** Ligand A has 3 HBA, while Ligand B has 6. Ligand A is preferable here, as fewer HBA generally improves permeability.
6. **QED:** Both ligands have similar QED values (A: 0.752, B: 0.708), indicating good drug-likeness.
7. **DILI:** Ligand A (40.752) has a much lower DILI risk than Ligand B (75.766). This is a significant advantage for Ligand A.
8. **BBB:** Both ligands have similar BBB penetration (A: 54.75, B: 57.193). While neither is exceptionally high, it's not a primary concern for ADRB2, which isn't necessarily a CNS target.
9. **Caco-2:** Ligand A (-4.766) has a more negative Caco-2 value, suggesting *lower* permeability. Ligand B (-5.637) is even lower. This is a potential issue for both, but less critical than other factors.
10. **Solubility:** Both have very poor aqueous solubility (A: -3.164, B: -2.765). This is a significant drawback for both compounds and would require formulation strategies.
11. **hERG:** Both ligands have low hERG inhibition risk (A: 0.22, B: 0.081). Ligand B is slightly better, but both are acceptable.
12. **Cl_mic:** Ligand A (7.636) has a significantly lower microsomal clearance than Ligand B (27.188). This suggests better metabolic stability for Ligand A, which is highly desirable.
13. **t1/2:** Ligand A (7.449) has a positive in vitro half-life, while Ligand B (-27.131) has a negative half-life. This is a major advantage for Ligand A.
14. **Pgp:** Both ligands have low P-gp efflux liability (A: 0.049, B: 0.095).
15. **Binding Affinity:** Ligand B (-7.4 kcal/mol) has a slightly stronger binding affinity than Ligand A (-6.4 kcal/mol). This is a 1.0 kcal/mol difference, which is significant.
**Overall Assessment:**
While Ligand B has a slightly better binding affinity, Ligand A demonstrates a superior overall profile. Its lower DILI risk, significantly better metabolic stability (lower Cl_mic, positive t1/2), lower TPSA, and fewer HBA outweigh the slightly weaker binding. The solubility is a concern for both, but formulation strategies can be explored. Given the GPCR target class, the balance of properties in Ligand A makes it the more promising candidate.
**Output:**
1
2025-04-18 00:52:49,758 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (342.443 and 348.487 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (59.39 and 58.64) are below the 140 A^2 threshold for good oral absorption, and suitable for a peripherally acting GPCR like ADRB2. Again, no major difference.
3. **logP:** Both ligands (2.997 and 2.513) are within the optimal 1-3 range, suggesting good permeability and reasonable solubility. Ligand A is slightly higher, potentially offering a small advantage in membrane permeability.
4. **HBD:** Both have 1 HBD, which is acceptable.
5. **HBA:** Ligand A has 4 HBA, Ligand B has 3. Both are below the 10 threshold.
6. **QED:** Ligand A (0.929) has a significantly better QED score than Ligand B (0.769), indicating a more drug-like profile overall. This is a positive for Ligand A.
7. **DILI:** Ligand A (36.603) has a slightly higher DILI risk than Ligand B (25.436), but both are below the concerning 60 percentile threshold. Ligand B is preferable here.
8. **BBB:** Both ligands have high BBB penetration (79.682 and 79.992), but this is less crucial for ADRB2, a cardiovascular target.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and likely indicates a problem with the data or the model. This is a flag for both compounds, but doesn't allow for a clear differentiation.
10. **Solubility:** Both ligands have very poor aqueous solubility (-2.45 and -2.403). This is a significant concern for both, and would require formulation strategies.
11. **hERG:** Both ligands have low hERG inhibition liability (0.437 and 0.416), which is good.
12. **Cl_mic:** Ligand B (75.839) has a significantly higher microsomal clearance than Ligand A (26.465), indicating faster metabolism and potentially lower *in vivo* exposure. This is a major advantage for Ligand A.
13. **t1/2:** Ligand B has a negative in vitro half-life (-8.757), which is highly problematic and suggests very rapid degradation. Ligand A (2.459) is much better, although still not ideal.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.18 and 0.26), which is favorable.
15. **Binding Affinity:** Ligand A (-6.2 kcal/mol) has a slightly better binding affinity than Ligand B (-5.8 kcal/mol). While the difference is less than the 1.5 kcal/mol threshold for outweighing other issues, it contributes to the overall preference.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, affinity) and the general guidelines, Ligand A is the more promising candidate. Its superior QED score, significantly lower microsomal clearance, and more reasonable *in vitro* half-life outweigh the slightly higher DILI risk. The solubility issues are a concern for both, but can be addressed with formulation. Ligand B's extremely rapid metabolism (negative half-life) is a deal-breaker.
Output:
1
2025-04-18 00:52:49,758 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (348.487 Da) is slightly preferred due to being closer to the lower end, potentially aiding permeability.
**2. TPSA:** Ligand A (49.85) is better than Ligand B (42.43). Both are below the 140 A^2 threshold for good oral absorption, but lower TPSA is generally preferred for GPCR ligands, potentially improving brain penetration even if not a CNS target.
**3. logP:** Ligand A (2.468) is within the optimal range (1-3), while Ligand B (4.733) is higher. The higher logP of Ligand B could lead to solubility issues and off-target interactions.
**4. H-Bond Donors:** Both ligands have 0 HBD, which is acceptable.
**5. H-Bond Acceptors:** Ligand A has 3 HBA, and Ligand B has 4. Both are within the acceptable range (<=10).
**6. QED:** Both ligands have acceptable QED values (A: 0.475, B: 0.609), indicating reasonable drug-likeness. Ligand B is slightly better here.
**7. DILI:** Ligand A (17.255) has a significantly lower DILI risk than Ligand B (49.089). This is a major advantage for Ligand A.
**8. BBB:** Both have good BBB penetration (A: 73.75, B: 80.031). While not a primary concern for a cardiovascular target, higher BBB is generally favorable.
**9. Caco-2 Permeability:** Both have negative Caco-2 values which is unusual. However, the absolute value is closer to 0 for Ligand A (-4.248) than Ligand B (-4.782), suggesting slightly better permeability.
**10. Aqueous Solubility:** Both ligands have negative solubility values, which is also unusual. The absolute value is closer to 0 for Ligand A (-2.548) than Ligand B (-4.239), suggesting slightly better solubility.
**11. hERG Inhibition:** Both ligands show low hERG inhibition risk (A: 0.545, B: 0.742).
**12. Microsomal Clearance:** Ligand A (70.259) has lower microsomal clearance than Ligand B (101.115), indicating better metabolic stability.
**13. In vitro Half-Life:** Ligand B (53.157) has a significantly longer half-life than Ligand A (6.305). This is a significant advantage for Ligand B.
**14. P-gp Efflux:** Both ligands show low P-gp efflux liability (A: 0.154, B: 0.778). Ligand A is preferred here.
**15. Binding Affinity:** Ligand B (-6.4 kcal/mol) has a slightly better binding affinity than Ligand A (-5.5 kcal/mol). This is a 0.9 kcal/mol difference, which is substantial.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), and the general drug-like properties, Ligand B's superior binding affinity and longer half-life are compelling. However, Ligand B's higher logP and significantly higher DILI risk are concerning. Ligand A has a more balanced profile with lower DILI, better logP, and acceptable metabolic stability. The difference in binding affinity (0.9 kcal/mol) is significant, but not insurmountable, especially given the safety and ADME advantages of Ligand A.
Therefore, I believe Ligand A is the more viable drug candidate.
Output:
1
2025-04-18 00:52:49,758 - INFO - Here's a step-by-step reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by the final output.
**Ligand A: [355.341, 91.76, 1.744, 2, 5, 0.8, 80.109, 48.042, -4.976, -2.451, 0.056, -21.566, -30.524, 0.002, -7.2]**
**Ligand B: [383.254, 47.09, 4.539, 0, 5, 0.601, 47.421, 70.57, -5.01, -3.844, 0.919, 70.495, 9.672, 0.751, -6.6]**
1. **Molecular Weight:** Both are within the ideal range (200-500 Da). Ligand A (355.341) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (91.76) is higher than Ligand B (47.09). For a cardiovascular GPCR like ADRB2, TPSA is less critical than for CNS targets, but lower is still preferred. Ligand B is significantly better here.
3. **logP:** Ligand A (1.744) is within the optimal range (1-3). Ligand B (4.539) is higher, potentially leading to solubility issues and off-target interactions. Ligand A is better.
4. **H-Bond Donors:** Ligand A (2) is good. Ligand B (0) is also acceptable, but having some H-bond donors can aid solubility.
5. **H-Bond Acceptors:** Both ligands have 5 H-bond acceptors, which is within the acceptable range.
6. **QED:** Ligand A (0.8) is better than Ligand B (0.601), indicating a more drug-like profile.
7. **DILI:** Ligand A (80.109) has a higher DILI risk than Ligand B (47.421). This is a significant drawback for Ligand A.
8. **BBB:** Ligand B (70.57) has a higher BBB penetration percentile than Ligand A (48.042). While ADRB2 isn't strictly a CNS target, some CNS exposure can occur, and higher BBB is generally preferable.
9. **Caco-2 Permeability:** Ligand A (-4.976) is better than Ligand B (-5.01). Both are negative, which is unusual. This suggests poor permeability. Ligand A is slightly better.
10. **Aqueous Solubility:** Ligand A (-2.451) is better than Ligand B (-3.844). Both are poor, but A is less poor.
11. **hERG Inhibition:** Ligand A (0.056) has a much lower hERG inhibition risk than Ligand B (0.919). This is a critical advantage for Ligand A, as hERG inhibition can cause cardiotoxicity.
12. **Microsomal Clearance:** Ligand A (-21.566) has a much lower (better) microsomal clearance than Ligand B (70.495), indicating better metabolic stability.
13. **In vitro Half-Life:** Ligand A (-30.524) has a much longer in vitro half-life than Ligand B (9.672), which is desirable.
14. **P-gp Efflux:** Ligand A (0.002) has a much lower P-gp efflux liability than Ligand B (0.751), indicating better oral bioavailability.
15. **Binding Affinity:** Ligand A (-7.2) has a slightly better binding affinity than Ligand B (-6.6). While the difference isn't huge, it's still a positive for Ligand A.
**Overall Assessment:**
Ligand A has a clear advantage in several key ADME properties (microsomal clearance, half-life, P-gp efflux, hERG inhibition) and binding affinity. While its DILI risk is higher, the significant improvements in metabolic stability and safety (hERG) outweigh this concern. Ligand B has a better TPSA and BBB, but its higher logP, poorer ADME profile, and lower affinity make it a less attractive candidate.
Output:
1
2025-04-18 00:52:49,758 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (365.396 and 352.431 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (72.88) is better than Ligand B (85.89). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (0.749) is slightly higher than Ligand B (0.369), placing it closer to the optimal 1-3 range. Ligand B is a bit low, potentially hindering membrane permeability.
4. **HBD:** Both have 2 HBD, which is within the acceptable limit of 5.
5. **HBA:** Ligand A has 4 HBA, while Ligand B has 5. Both are acceptable, being under the limit of 10.
6. **QED:** Both ligands have similar QED values (0.729 and 0.721), indicating good drug-likeness.
7. **DILI:** Ligand A (21.946) has a significantly lower DILI risk than Ligand B (46.258). This is a crucial advantage.
8. **BBB:** Both have moderate BBB penetration (64.831 and 62.466). Not a major factor for a cardiovascular target.
9. **Caco-2:** Ligand A (-4.859) is better than Ligand B (-5.163), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-1.259) is better than Ligand B (-1.977), suggesting better aqueous solubility.
11. **hERG:** Ligand A (0.655) has a lower hERG risk than Ligand B (0.16). This is a significant safety advantage.
12. **Cl_mic:** Ligand A (-9.151) has a much lower (better) microsomal clearance than Ligand B (-1.423), implying greater metabolic stability.
13. **t1/2:** Ligand A (-9.644) has a significantly longer in vitro half-life than Ligand B (38.476). This is a major advantage for dosing convenience.
14. **Pgp:** Ligand A (0.023) has lower P-gp efflux liability than Ligand B (0.03).
15. **Binding Affinity:** Ligand B (-7.7) has a slightly better binding affinity than Ligand A (-6.3). This is a 1.4 kcal/mol difference, which is significant, but needs to be weighed against other factors.
**Overall Assessment:**
While Ligand B has a slightly better binding affinity, Ligand A demonstrates a superior ADMET profile. Specifically, Ligand A has significantly lower DILI and hERG risks, better solubility, and much improved metabolic stability (lower Cl_mic and longer t1/2). These factors are critical for developing a safe and effective drug. The modest difference in binding affinity is outweighed by the substantial improvements in ADMET properties. Given that we're dealing with a GPCR (ADRB2) and prioritizing safety and drug-like properties, Ligand A is the more promising candidate.
Output:
1
2025-04-18 00:52:49,758 - INFO - Here's my reasoning and the final output:
**Reasoning:**
We are evaluating two ligands for ADRB2, a cardiovascular GPCR. Therefore, priorities are logP, TPSA, Pgp, affinity, and, to a lesser extent, BBB.
* **Molecular Weight:** Both ligands are within the acceptable range (200-500 Da). Ligand A (342.4) is slightly preferred due to being lower.
* **TPSA:** Both are reasonably low (A: 104.45, B: 106.34), under the 140 threshold for oral absorption.
* **logP:** Ligand A (0.627) is a bit low, potentially hindering permeation. Ligand B (1.014) is better, falling within the optimal 1-3 range. This is a significant advantage for B.
* **H-Bond Donors/Acceptors:** Both have acceptable HBD (A: 2, B: 3) and HBA (both 6) counts.
* **QED:** Both have good QED scores (A: 0.798, B: 0.626), indicating drug-likeness.
* **DILI:** Ligand A (75.107) has a higher DILI risk than Ligand B (44.281). This is a substantial negative for A.
* **BBB:** Both have moderate BBB penetration (A: 64.211, B: 70.531). Since this is a cardiovascular target, BBB isn't a primary concern, but B is slightly better.
* **Caco-2 Permeability:** Both are negative, indicating poor permeability. This is concerning for both, but the values are similar.
* **Aqueous Solubility:** Both are negative, indicating poor solubility. This is concerning for both, but the values are similar.
* **hERG Inhibition:** Both have low hERG inhibition risk (A: 0.376, B: 0.122), which is good. B is slightly better.
* **Microsomal Clearance:** Ligand A (17.625) has lower clearance than Ligand B (7.706), suggesting better metabolic stability. This is a positive for A.
* **In vitro Half-Life:** Ligand A (-1.545) has a shorter half-life than Ligand B (-3.704). This is a negative for A.
* **P-gp Efflux:** Both have very low P-gp efflux liability (A: 0.035, B: 0.063), which is excellent.
* **Binding Affinity:** Both have excellent binding affinity (A: -7.4, B: -7.5). The difference is negligible.
**Overall Assessment:**
Ligand B is preferred. While Ligand A has better metabolic stability, Ligand B has a more favorable logP, lower DILI risk, and slightly better BBB penetration. The logP and DILI differences are significant enough to outweigh the slightly better clearance of Ligand A. Considering the GPCR target class, the balance of properties in Ligand B makes it a more promising drug candidate.
**Output:**
0
2025-04-18 00:52:49,758 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [366.483, 83.55, 1.17, 1, 4, 0.757, 46.84, 62.233, -5.073, -3.03, 0.107, 7.318, 44.504, 0.049, -6.9]
**Ligand B:** [353.463, 89.95, 1.549, 2, 4, 0.512, 25.94, 67.041, -5.055, -1.713, 0.206, 18.445, -3.712, 0.02, -6.3]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, Affinity, and BBB):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (353.463) is slightly lower, which is generally favorable.
2. **TPSA:** Both are reasonably good (A: 83.55, B: 89.95), under the 140 threshold for oral absorption.
3. **logP:** Both are within the optimal range (1-3). Ligand A (1.17) is slightly better.
4. **HBD/HBA:** Both have acceptable numbers of HBD/HBA. Ligand A (1 HBD, 4 HBA) is slightly preferable to Ligand B (2 HBD, 4 HBA).
5. **QED:** Ligand A (0.757) has a significantly better QED score than Ligand B (0.512), indicating a more drug-like profile.
6. **DILI:** Ligand B (25.94) has a much lower DILI risk than Ligand A (46.84), a significant advantage.
7. **BBB:** Both have reasonable BBB penetration (A: 62.233, B: 67.041). Ligand B is slightly better.
8. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. This is a concern for both.
9. **Solubility:** Both have negative solubility values, which is also concerning. Ligand B is slightly better (-1.713 vs -3.03).
10. **hERG:** Both show very low hERG inhibition risk.
11. **Cl_mic:** Ligand A (7.318) has a much lower microsomal clearance than Ligand B (18.445), indicating better metabolic stability.
12. **t1/2:** Ligand A (44.504) has a significantly longer in vitro half-life than Ligand B (-3.712), which is a major advantage.
13. **Pgp:** Both have very low P-gp efflux liability.
14. **Affinity:** Ligand A (-6.9 kcal/mol) has a slightly better binding affinity than Ligand B (-6.3 kcal/mol). While the difference is not huge, it's still a factor.
**Overall Assessment:**
Ligand A has a better QED score, better metabolic stability (lower Cl_mic, longer t1/2), and slightly better affinity. However, Ligand B has a significantly lower DILI risk and slightly better BBB penetration. The negative Caco-2 and solubility values are concerning for both, but the improved metabolic stability and half-life of Ligand A are crucial for a GPCR target, where sustained signaling is often important. The slightly better affinity of Ligand A also tips the balance.
Therefore, I would choose Ligand A.
1
2025-04-18 00:52:49,758 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, a cardiovascular GPCR:
**1. Molecular Weight:** Both ligands are within the ideal range (200-500 Da). Ligand A (410.268 Da) is slightly higher than Ligand B (361.555 Da), but both are acceptable.
**2. TPSA:** Ligand A (99.5) is higher than Ligand B (46.09). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for permeability. Ligand B has a significantly better TPSA.
**3. logP:** Ligand A (2.717) is within the optimal range (1-3), while Ligand B (4.536) is slightly above. While not drastically high, the higher logP of Ligand B could potentially lead to solubility issues or off-target interactions.
**4. H-Bond Donors:** Ligand A (1) is preferable to Ligand B (0). Having at least one HBD can improve solubility.
**5. H-Bond Acceptors:** Ligand A (5) and Ligand B (4) are both acceptable.
**6. QED:** Both ligands have good QED values (Ligand A: 0.551, Ligand B: 0.638), indicating good drug-like properties. Ligand B is slightly better.
**7. DILI Risk:** Ligand A (71.384) has a higher DILI risk than Ligand B (41.877). This is a significant concern, and Ligand B is considerably safer in this regard.
**8. BBB Penetration:** BBB is less critical for a cardiovascular target. Ligand A (62.97) and Ligand B (78.015) are both relatively low, which is fine for this indication.
**9. Caco-2 Permeability:** Ligand A (-4.442) has better Caco-2 permeability than Ligand B (-5.102).
**10. Aqueous Solubility:** Ligand A (-4.396) has better aqueous solubility than Ligand B (-4.082).
**11. hERG Inhibition:** Ligand A (0.572) has a slightly higher hERG risk than Ligand B (0.474), but both are relatively low.
**12. Microsomal Clearance:** Ligand A (109.574) has higher microsomal clearance than Ligand B (122.139), indicating lower metabolic stability. This is a disadvantage for Ligand A.
**13. In vitro Half-Life:** Ligand A (37.431) has a longer half-life than Ligand B (-1.291). This is a significant advantage for Ligand A.
**14. P-gp Efflux:** Ligand A (0.13) has lower P-gp efflux than Ligand B (0.539), which is favorable for bioavailability.
**15. Binding Affinity:** Ligand B (-6.2 kcal/mol) has a slightly better binding affinity than Ligand A (-5.5 kcal/mol). This 0.7 kcal/mol difference is significant and can outweigh some ADME drawbacks.
**Overall Assessment:**
Considering the GPCR-specific priorities (logP, Pgp, TPSA, and affinity), and the overall balance of properties, **Ligand B is the more promising candidate.** While Ligand A has a longer half-life and better Caco-2 permeability, Ligand B demonstrates a significantly lower DILI risk, better TPSA, and a slightly stronger binding affinity. The higher logP of Ligand B is a minor concern, but the lower DILI risk is a major advantage, especially in a cardiovascular context where safety is paramount.
Output:
0
2025-04-18 00:52:49,759 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
The target is ADRB2, a GPCR. Therefore, the priorities are logP, TPSA, Pgp efflux, BBB penetration, and binding affinity. Metabolic stability and solubility are also important, but slightly lower priority.
Let's compare the ligands property by property:
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (349.391) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand B (91.76) is significantly better than Ligand A (120.18). Lower TPSA is preferred for GPCRs to enhance brain penetration and membrane permeability.
3. **logP:** Ligand B (0.735) is within the optimal range (1-3), while Ligand A (-0.366) is below 1, potentially hindering permeation. This is a significant advantage for Ligand B.
4. **HBD/HBA:** Both have similar numbers of H-bond donors (3) and acceptors (Ligand A: 5, Ligand B: 6), both within acceptable limits.
5. **QED:** Both have similar QED values (A: 0.685, B: 0.645), indicating good drug-likeness.
6. **DILI:** Ligand B (72.199) has a slightly higher DILI risk than Ligand A (68.592), but both are still within a moderate range.
7. **BBB:** Ligand A (37.379) has better BBB penetration than Ligand B (18.961). However, for a cardiovascular target like ADRB2, BBB penetration isn't as critical as for CNS targets.
8. **Caco-2:** Both have very poor Caco-2 permeability (-5.158 and -5.102). This is a concern for both, suggesting potential absorption issues.
9. **Solubility:** Both have very poor aqueous solubility (-2.863 and -1.694). This is a significant drawback for both compounds.
10. **hERG:** Both have low hERG inhibition risk (0.15 and 0.155).
11. **Cl_mic:** Ligand B (0.102) has significantly lower microsomal clearance than Ligand A (1.813), indicating better metabolic stability.
12. **t1/2:** Ligand B (4.656) has a slightly longer in vitro half-life than Ligand A (5.095).
13. **Pgp:** Both have very low Pgp efflux liability (0.012 and 0.034).
14. **Binding Affinity:** Ligand A (-9.2 kcal/mol) has a significantly stronger binding affinity than Ligand B (-6.9 kcal/mol). This is a substantial advantage for Ligand A.
**Overall Assessment:**
The biggest differentiating factor is the binding affinity. Ligand A has a much stronger affinity (-9.2 vs -6.9 kcal/mol). While Ligand B has better logP and metabolic stability, the substantial difference in binding affinity outweighs these advantages, especially given the similar issues with solubility and Caco-2 permeability. The lower TPSA of Ligand B is beneficial, but not enough to overcome the affinity difference.
**Output:**
1
2025-04-18 00:52:49,759 - INFO - Batch 510 complete. Total preferences: 8160
2025-04-18 00:52:49,759 - INFO - Processing batch 511/512...
2025-04-18 00:53:39,536 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [343.304, 39.19, 4.523, 0, 3, 0.654, 88.329, 65.452, -4.206, -5.819, 0.396, 99.837, -24.006, 0.229, -6.2]
**Ligand B:** [348.535, 59.81, 4.282, 1, 4, 0.781, 24.661, 74.952, -4.702, -4.998, 0.162, 71.116, 0.388, 0.242, -6.7]
Here's a breakdown, considering GPCR priorities (logP, Pgp, TPSA, Affinity, and BBB):
1. **MW:** Both are within the ideal range (200-500 Da). A is 343.3, B is 348.5. Very similar.
2. **TPSA:** A (39.19) is excellent, well below 140 and good for oral absorption. B (59.81) is still reasonable but less optimal.
3. **logP:** Both are good (around 4.3-4.5), within the 1-3 range, but slightly high. This could potentially lead to off-target effects, but is acceptable.
4. **HBD/HBA:** A (0/3) is better than B (1/4). Lower HBD/HBA generally improves permeability.
5. **QED:** Both are acceptable (A: 0.654, B: 0.781), indicating reasonable drug-likeness. B is slightly better.
6. **DILI:** A (88.329) is concerningly high, indicating a significant risk of liver injury. B (24.661) is very good, a low risk. This is a major difference.
7. **BBB:** A (65.452) is moderate. B (74.952) is better, indicating a higher likelihood of CNS penetration, though not crucial for ADRB2 which is primarily a cardiovascular target.
8. **Caco-2:** Both are negative, which is unusual and suggests poor permeability. This is a significant drawback for both.
9. **Solubility:** Both are very poor (negative values). This is a major concern for both compounds.
10. **hERG:** A (0.396) is better than B (0.162), indicating lower cardiotoxicity risk.
11. **Cl_mic:** A (99.837) is very high, suggesting rapid metabolism and low metabolic stability. B (71.116) is better, but still relatively high.
12. **t1/2:** A (-24.006) is terrible, indicating extremely short half-life. B (0.388) is also poor, but better than A.
13. **Pgp:** A (0.229) is better than B (0.242), indicating lower P-gp efflux.
14. **Affinity:** B (-6.7 kcal/mol) is significantly better than A (-6.2 kcal/mol). This 1.5 kcal/mol difference is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
Ligand B is the stronger candidate despite some ADME concerns. The significantly better binding affinity (-6.7 vs -6.2 kcal/mol) is a major advantage for a GPCR target. Critically, the DILI risk is much lower for B (24.661 vs 88.329), which is a deal-breaker for A. While both have poor solubility and Caco-2 permeability, the superior affinity and safety profile of B make it the more promising starting point for optimization. The slightly better BBB for B is a bonus.
Output:
0
2025-04-18 00:53:39,537 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (358.368 and 339.439 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (86.89) is better than Ligand B (65.2). Both are below the 140 threshold for oral absorption, and reasonably good for a GPCR.
3. **logP:** Both ligands have good logP values (3.68 and 3.079), falling within the optimal 1-3 range. Ligand B is slightly better.
4. **HBD:** Ligand A has 0 HBD, which is excellent. Ligand B has 2, which is still acceptable but less ideal.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 2. Both are below the 10 threshold. Ligand B is better.
6. **QED:** Ligand B (0.899) has a significantly better QED score than Ligand A (0.467), indicating a more drug-like profile.
7. **DILI:** Ligand A (32.067) has a much lower DILI risk than Ligand B (47.421). This is a significant advantage for Ligand A.
8. **BBB:** Ligand A (93.641) has a much higher BBB penetration percentile than Ligand B (78.945). This is a critical advantage for a GPCR target, even a cardiovascular one, as some CNS off-target effects are always a concern.
9. **Caco-2:** Ligand A (-4.698) and Ligand B (-5.016) both have negative values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
10. **Solubility:** Ligand A (-3.073) and Ligand B (-4.421) both have negative solubility values, indicating poor aqueous solubility. This is a concern for both.
11. **hERG:** Ligand A (0.417) has a lower hERG inhibition liability than Ligand B (0.737). This is a safety advantage for Ligand A.
12. **Cl_mic:** Ligand A (18.005) has a much lower microsomal clearance than Ligand B (44.578), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-23.711) has a much longer in vitro half-life than Ligand B (-2.784). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.229) has a lower P-gp efflux liability than Ligand B (0.138).
15. **Binding Affinity:** Ligand B (-6.3 kcal/mol) has a significantly stronger binding affinity than Ligand A (-3.6 kcal/mol). This is a substantial advantage for Ligand B.
**Overall Assessment:**
Ligand B has a superior binding affinity, and a better QED score. However, Ligand A excels in safety parameters (DILI, hERG), metabolic stability (Cl_mic, t1/2), and BBB penetration. The difference in binding affinity is significant (~2.7 kcal/mol), but the combination of better ADME/Tox properties and BBB penetration for Ligand A makes it a more promising starting point for drug development, especially considering the potential for off-target effects with GPCRs. The poor solubility of both is a concern that would need to be addressed through formulation strategies.
Output:
1
2025-04-18 00:53:39,537 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (349.435 and 348.447 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (120.0) is slightly higher than Ligand B (103.95). Both are below the 140 threshold for good oral absorption, but B is better.
3. **logP:** Ligand A (0.829) is a bit low, potentially hindering permeation. Ligand B (1.385) is better, falling within the optimal 1-3 range.
4. **HBD:** Ligand A (4) and Ligand B (3) are both acceptable, below the 5 threshold.
5. **HBA:** Ligand A (5) and Ligand B (4) are both acceptable, below the 10 threshold.
6. **QED:** Both ligands have good QED scores (0.587 and 0.692, respectively), indicating good drug-like properties. Ligand B is slightly better.
7. **DILI:** Ligand A (60.799) is at the upper limit of acceptable DILI risk. Ligand B (48.507) has a significantly lower and more favorable DILI risk.
8. **BBB:** Ligand A (27.142) has very low BBB penetration. Ligand B (55.215) is better, but still not ideal. Considering ADRB2 is a cardiovascular target, BBB isn't *critical*, but some penetration could be beneficial for off-target effects.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.467 and -5.074), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Both ligands have negative solubility values (-2.737 and -3.385), indicating poor aqueous solubility. This is a major drawback for both.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.05 and 0.119, respectively). This is excellent.
12. **Cl_mic:** Ligand A (14.217) has a lower microsomal clearance than Ligand B (29.5), suggesting better metabolic stability.
13. **t1/2:** Ligand B (-24.933) has a much longer in vitro half-life than Ligand A (-4.477). This is a substantial advantage.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.099 and 0.038, respectively).
15. **Binding Affinity:** Ligand B (-7.1 kcal/mol) has a significantly stronger binding affinity than Ligand A (-6.7 kcal/mol). This 0.4 kcal/mol difference is substantial and can outweigh some ADME concerns.
**GPCR-specific priorities:**
For ADRB2 (a GPCR), logP, Pgp, TPSA, and affinity are key. Ligand B excels in affinity and has better logP and TPSA. While BBB isn't crucial for a cardiovascular target, Ligand B is better.
**Overall Assessment:**
While both ligands have significant drawbacks (poor Caco-2 and solubility), Ligand B is the stronger candidate. Its superior binding affinity, lower DILI risk, and longer half-life outweigh the slightly higher TPSA and lower metabolic stability compared to Ligand A. The improved logP is also a benefit. The negative Caco-2 and solubility values are concerning for both, and would require significant formulation work.
Output:
0
2025-04-18 00:53:39,537 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 GPCR:
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (349.431) is slightly higher than Ligand B (338.371), but both are acceptable.
2. **TPSA:** Ligand A (71.44) is better than Ligand B (84.53). For a GPCR, keeping TPSA lower is generally preferred for better permeability.
3. **logP:** Both ligands have good logP values (A: 0.887, B: 0.712), falling within the optimal 1-3 range. Ligand A is slightly more lipophilic.
4. **HBD:** Ligand A (0) is preferable to Ligand B (1). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (5) is better than Ligand B (6). Lower HBA is generally preferred for permeability.
6. **QED:** Both ligands have good QED scores (A: 0.61, B: 0.762), indicating good drug-like properties. Ligand B is slightly better here.
7. **DILI:** Ligand A (35.712) has a significantly lower DILI risk than Ligand B (64.754). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (73.866) has a much better BBB penetration score than Ligand B (32.144). This is a key consideration for GPCRs, even if not CNS-focused, as it can influence off-target effects.
9. **Caco-2:** Ligand A (-4.492) is better than Ligand B (-5.14). Higher Caco-2 permeability suggests better absorption.
10. **Solubility:** Ligand A (-2.258) is better than Ligand B (-2.086). Higher solubility is generally preferred.
11. **hERG:** Both ligands have very low hERG risk (A: 0.363, B: 0.379), which is excellent.
12. **Cl_mic:** Ligand A (40.201) has a lower microsomal clearance than Ligand B (8.201), suggesting better metabolic stability.
13. **t1/2:** Ligand B (11.417) has a significantly longer in vitro half-life than Ligand A (-4.036). This is a positive for Ligand B.
14. **Pgp:** Both ligands have low P-gp efflux (A: 0.163, B: 0.023), with Ligand B being slightly better.
15. **Binding Affinity:** Ligand B (-7.4) has a significantly stronger binding affinity than Ligand A (-5.8). This is a substantial advantage for Ligand B.
**Overall Assessment:**
While Ligand B boasts a superior binding affinity and longer half-life, Ligand A demonstrates a significantly better safety profile (lower DILI) and better predicted permeability (lower TPSA, fewer HBD/HBA, better Caco-2, better solubility) and BBB penetration. The substantial difference in DILI risk and the good BBB score for Ligand A are particularly important. The 1.6 kcal/mol difference in binding affinity, while significant, can potentially be optimized in later stages of drug development. Given the GPCR target class, balancing permeability, safety, and affinity is crucial, and Ligand A strikes a better balance.
Output:
1
2025-04-18 00:53:39,537 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A:** [356.375, 111.24 , -0.743, 1. , 7. , 0.363, 52.191, 43.117, -5.018, -1.24 , 0.055, 34.827, -20.851, 0.014, -6. ]
**Ligand B:** [343.427, 82.27 , 1.423, 2. , 3. , 0.553, 16.44 , 42.807, -5.199, -1.685, 0.206, -21.524, -11.477, 0.087, -5.8 ]
Here's a step-by-step comparison, considering GPCR priorities (logP, Pgp, TPSA, affinity):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (343.427) is slightly lower, which is generally favorable.
2. **TPSA:** Ligand A (111.24) is higher than Ligand B (82.27). Both are below 140, but B is better for absorption.
3. **logP:** Ligand A (-0.743) is quite low, potentially hindering permeability. Ligand B (1.423) is within the optimal range (1-3). This is a significant advantage for B.
4. **HBD:** Ligand A (1) is good. Ligand B (2) is acceptable.
5. **HBA:** Ligand A (7) is acceptable. Ligand B (3) is excellent.
6. **QED:** Ligand B (0.553) is better than Ligand A (0.363), indicating a more drug-like profile.
7. **DILI:** Ligand A (52.191) has a higher DILI risk than Ligand B (16.44). B is much preferred here.
8. **BBB:** Both are similar (A: 43.117, B: 42.807). Not a primary concern for a cardiovascular target, but lower is fine.
9. **Caco-2:** Both are negative, indicating poor permeability.
10. **Solubility:** Both are negative, indicating poor solubility.
11. **hERG:** Ligand A (0.055) is slightly better than Ligand B (0.206), but both are low risk.
12. **Cl_mic:** Ligand B (-21.524) has a lower (better) clearance than Ligand A (34.827), suggesting greater metabolic stability.
13. **t1/2:** Ligand B (-11.477) has a longer half-life than Ligand A (-20.851).
14. **Pgp:** Both are very low (A: 0.014, B: 0.087), indicating minimal P-gp efflux.
15. **Affinity:** Both have similar binding affinities (-6.0 and -5.8 kcal/mol). The difference is not substantial enough to outweigh other factors.
**Overall Assessment:**
Ligand B is significantly better. It has a more favorable logP, better QED, a much lower DILI risk, better metabolic stability (lower Cl_mic), and a longer half-life. While both have poor Caco-2 and solubility, the other advantages of Ligand B outweigh this. The slightly better TPSA and HBA count also contribute to its improved profile. The affinity difference is negligible.
Output:
0
2025-04-18 00:53:39,537 - INFO - Here's my reasoning for selecting between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (352.45 and 366.424 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (66.48) is slightly higher than Ligand B (58.64). Both are below the 140 A^2 threshold for good oral absorption, and acceptable for a cardiovascular GPCR. Ligand B is slightly preferred.
3. **logP:** Both ligands have excellent logP values (2.405 and 2.602), falling within the optimal 1-3 range. No clear preference.
4. **HBD:** Both ligands have 1 HBD, which is within the acceptable limit of <=5. No preference.
5. **HBA:** Both ligands have 3 HBA, also within the acceptable limit of <=10. No preference.
6. **QED:** Ligand B (0.754) has a slightly higher QED score than Ligand A (0.682), indicating a more drug-like profile. This is a minor advantage for Ligand B.
7. **DILI:** Ligand B (27.685) has a higher DILI risk than Ligand A (17.72). This is a significant negative for Ligand B.
8. **BBB:** Both ligands have high BBB penetration (89.531 and 86.39). Since ADRB2 is a cardiovascular target, BBB penetration isn't a primary concern, but it doesn't hurt.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.572 and -4.548). This is unusual and suggests poor permeability. It's difficult to interpret without further context, but it's a potential concern for both.
10. **Solubility:** Both ligands have negative solubility values (-2.615 and -2.676). This is also unusual and suggests poor aqueous solubility. This is a significant drawback for both.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.157 and 0.577). This is excellent and a strong positive for both.
12. **Cl_mic:** Ligand A (23.317) has a significantly lower microsomal clearance than Ligand B (44.885), indicating better metabolic stability. This is a major advantage for Ligand A.
13. **t1/2:** Ligand A (-20.759) has a much more negative in vitro half-life than Ligand B (-0.156). A more negative value indicates a shorter half-life, which is a disadvantage. Ligand B is preferred here.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.048 and 0.05). This is positive for both.
15. **Binding Affinity:** Both ligands have very similar and strong binding affinities (-5.8 and -5.9 kcal/mol). The difference is negligible.
**Overall Assessment & GPCR-Specific Priorities:**
For a cardiovascular GPCR like ADRB2, potency (affinity) is crucial, but metabolic stability and safety are also paramount. While both ligands have excellent affinity and hERG profiles, Ligand A demonstrates a clear advantage in metabolic stability (lower Cl_mic). The lower DILI risk for Ligand A is also a significant benefit. The slightly higher QED of Ligand B is not enough to outweigh these factors. The negative Caco-2 and solubility values are concerning for both, but can potentially be addressed with formulation strategies.
**Output:**
1
2025-04-18 00:53:39,537 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (351.535 and 358.507 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Both ligands (52.65 and 53.33) are below the 140 A^2 threshold for good oral absorption, and are acceptable for a peripheral GPCR like ADRB2. Very similar.
3. **logP:** Ligand A (2.22) is within the optimal 1-3 range. Ligand B (3.952) is pushing the upper limit, potentially leading to solubility issues or off-target interactions. This favors Ligand A.
4. **HBD:** Ligand A (1) is good. Ligand B (0) is also acceptable, but having one HBD can sometimes improve solubility.
5. **HBA:** Ligand A (3) and Ligand B (4) are both within the acceptable range of <=10.
6. **QED:** Both ligands (0.693 and 0.774) have good drug-likeness scores, exceeding the 0.5 threshold.
7. **DILI:** Ligand A (5.428%) has a significantly lower DILI risk than Ligand B (38.813%). This is a substantial advantage for Ligand A.
8. **BBB:** Both ligands have high BBB penetration (85.033% and 80.264%), but this is less critical for ADRB2 as it's not a CNS target.
9. **Caco-2:** Ligand A (-4.794) and Ligand B (-5.117) both have negative values, which is unusual and suggests poor permeability. However, the difference is small.
10. **Solubility:** Ligand A (-2.11) is better than Ligand B (-4.781), which is expected given its lower logP.
11. **hERG:** Ligand A (0.719) has a lower hERG risk than Ligand B (0.604). This is a positive for Ligand A.
12. **Cl_mic:** Ligand A (31.9) has significantly lower microsomal clearance than Ligand B (75.502), indicating better metabolic stability. This is a major advantage for Ligand A.
13. **t1/2:** Ligand A (0.377) has a shorter half-life than Ligand B (24.417). This is a drawback for Ligand A, but can potentially be addressed with formulation strategies.
14. **Pgp:** Ligand A (0.076) has lower P-gp efflux liability than Ligand B (0.677), which is favorable for oral bioavailability.
15. **Binding Affinity:** Ligand A (-8.0) has a stronger binding affinity than Ligand B (-6.5). This is a significant advantage, potentially outweighing some of the ADME drawbacks of Ligand A.
**Overall Assessment:**
Ligand A demonstrates a superior balance of properties, particularly regarding safety (DILI, hERG) and metabolic stability (Cl_mic). While Ligand B has a longer half-life, the stronger binding affinity of Ligand A, combined with its better predicted ADME profile, makes it the more promising candidate. The higher affinity is a substantial advantage for a GPCR target.
Output:
1
2025-04-18 00:53:39,537 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.49 & 362.46 Da) fall within the ideal 200-500 Da range. No clear advantage.
2. **TPSA:** Ligand A (58.64) is significantly better than Ligand B (80.82). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Both ligands have good logP values (3.35 & 3.09), falling within the 1-3 range. Ligand B is slightly lower, which is acceptable.
4. **HBD:** Ligand A (1) is better than Ligand B (0). While both are good, having one HBD can sometimes improve solubility.
5. **HBA:** Ligand A (3) is better than Ligand B (7). Lower HBA is generally preferred for better permeability.
6. **QED:** Ligand B (0.756) has a slightly better QED score than Ligand A (0.567), indicating a more drug-like profile.
7. **DILI:** Ligand A (21.09) has a significantly lower DILI risk than Ligand B (66.58). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (70.61) has a higher BBB penetration percentile than Ligand B (61.73). While not critical for a cardiovascular target, it's a positive attribute.
9. **Caco-2:** Both ligands have negative Caco-2 values (-5.121 and -5.054), which is unusual and suggests poor permeability. This is a concern for both.
10. **Solubility:** Ligand A (-3.141) has slightly better solubility than Ligand B (-2.458).
11. **hERG:** Both ligands have very low hERG inhibition risk (0.309 and 0.127). No significant difference.
12. **Cl_mic:** Ligand A (40.72) has lower microsomal clearance than Ligand B (51.40), suggesting better metabolic stability.
13. **t1/2:** Ligand A (-15.79) has a more negative in vitro half-life than Ligand B (-8.915), which is not ideal.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.131 and 0.26).
15. **Affinity:** Ligand B (-7.6) has a significantly stronger binding affinity than Ligand A (-6.1). This is a substantial advantage, exceeding the 1.5 kcal/mol threshold.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand B has a slightly better logP, comparable Pgp, and *much* better affinity. However, Ligand A excels in TPSA and has a much better safety profile (DILI).
**Overall Assessment:**
The significantly stronger binding affinity of Ligand B (-7.6 kcal/mol vs -6.1 kcal/mol) is a major driver. While Ligand A has advantages in DILI risk, TPSA, and metabolic stability, the potency difference is substantial enough to outweigh these concerns, especially given the cardiovascular target. The negative Caco-2 values for both are concerning and would require further investigation, but the binding affinity difference is the most critical factor here.
Output:
0
2025-04-18 00:53:39,537 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (354.435 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Ligand A (62.51) is significantly better than Ligand B (76.8). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (3.92) is at the upper end of optimal, while Ligand B (2.793) is well within the ideal range. Both are acceptable, but Ligand A's higher logP *could* lead to off-target interactions or solubility issues.
4. **HBD:** Both have 0 HBD, which is good.
5. **HBA:** Ligand A (6) is better than Ligand B (7). Lower HBA is generally preferred for permeability.
6. **QED:** Ligand B (0.834) has a better QED score than Ligand A (0.527), indicating a more drug-like profile overall.
7. **DILI:** Ligand B (73.09) has a significantly lower DILI risk than Ligand A (85.266). This is a major advantage for Ligand B.
8. **BBB:** Both have high BBB penetration (Ligand A: 82.125, Ligand B: 87.941). This isn't a primary concern for a cardiovascular target.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and suggests poor permeability. Ligand A (-4.843) is slightly better than Ligand B (-5.062), but both are problematic.
10. **Solubility:** Ligand B (-3.093) has better solubility than Ligand A (-5.107). Solubility is crucial for bioavailability.
11. **hERG:** Ligand A (0.806) has a slightly higher hERG risk than Ligand B (0.067). Lower hERG is always preferred.
12. **Cl_mic:** Ligand B (34.739) has *much* lower microsomal clearance than Ligand A (78.613), indicating better metabolic stability. This is a significant advantage.
13. **t1/2:** Ligand A (-7.037) has a significantly longer in vitro half-life than Ligand B (-0.476). This is a major advantage for Ligand A.
14. **Pgp:** Ligand A (0.582) has lower P-gp efflux than Ligand B (0.241). Lower P-gp efflux is generally better.
15. **Affinity:** Ligand A (-6.5 kcal/mol) has a slightly better binding affinity than Ligand B (-5.3 kcal/mol). This is a 1.2 kcal/mol difference, which is notable but not overwhelming.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has a slightly better affinity and Pgp profile, but Ligand B excels in TPSA, DILI, solubility, and, crucially, metabolic stability (Cl_mic). The lower DILI risk and improved metabolic stability of Ligand B are particularly important for a cardiovascular drug, where long-term safety and consistent exposure are critical. While the longer half-life of Ligand A is attractive, the other ADME properties of Ligand B are more favorable overall.
**Conclusion:**
Despite Ligand A's slightly better affinity and half-life, Ligand B's superior DILI profile, solubility, metabolic stability, and TPSA make it the more promising drug candidate for ADRB2.
Output:
0
2025-04-18 00:53:39,538 - INFO - Okay, let's analyze these two ligands for their potential as drug candidates targeting the ADRB2 receptor, a cardiovascular GPCR.
**Ligand A: [373.471, 74.3, 1.792, 0, 6, 0.647, 65.374, 65.374, -4.345, -3.153, 0.476, 85.432, -41.326, 0.261, -6.0]**
**Ligand B: [348.443, 98.66, 1.873, 4, 4, 0.631, 37.03, 51.493, -4.707, -2.767, 0.359, 26.019, 15.379, 0.096, -7.8]**
Here's a breakdown of the comparison, considering the provided guidelines and GPCR-specific priorities (logP, Pgp, TPSA, and affinity are key):
1. **MW:** Both are within the ideal range (200-500 Da). Ligand B (348.443) is slightly lower, which could be beneficial for permeability, but both are acceptable.
2. **TPSA:** Ligand A (74.3) is significantly better than Ligand B (98.66). A TPSA under 140 is good for oral absorption, and A is closer to the ideal <90 for CNS targets (though this isn't a CNS target, lower TPSA is generally favorable).
3. **logP:** Both are within the optimal 1-3 range. Ligand A (1.792) and Ligand B (1.873) are very similar here.
4. **HBD:** Ligand A (0) is preferable to Ligand B (4). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (6) is better than Ligand B (4). Lower HBA is preferable.
6. **QED:** Both are similar (A: 0.647, B: 0.631) and above the 0.5 threshold, indicating good drug-like properties.
7. **DILI:** Ligand B (37.03) is significantly better than Ligand A (65.374). Lower DILI risk is crucial.
8. **BBB:** Both have moderate BBB penetration, but Ligand A (65.374) is slightly better than Ligand B (51.493). Not a primary concern for a cardiovascular target.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual. Assuming these are logP-like scales, lower values indicate poorer permeability. Ligand B (-4.707) is worse than Ligand A (-4.345).
10. **Solubility:** Both have negative solubility values, indicating poor solubility. Ligand B (-2.767) is slightly worse than Ligand A (-3.153).
11. **hERG:** Both have low hERG inhibition risk (A: 0.476, B: 0.359).
12. **Cl_mic:** Ligand B (26.019) has significantly lower microsomal clearance than Ligand A (85.432), indicating better metabolic stability.
13. **t1/2:** Ligand B (15.379) has a longer in vitro half-life than Ligand A (-41.326). This is a significant advantage.
14. **Pgp:** Ligand A (0.261) has lower P-gp efflux than Ligand B (0.096), which is preferable.
15. **Affinity:** Ligand B (-7.8) has a substantially stronger binding affinity than Ligand A (-6.0). A 1.8 kcal/mol difference is very significant and can outweigh many ADME drawbacks.
**Overall Assessment:**
While Ligand A has better TPSA, HBD, HBA, and Pgp properties, Ligand B's significantly stronger binding affinity (-7.8 vs -6.0 kcal/mol), lower DILI risk, and longer half-life are compelling advantages. The lower metabolic clearance is also a positive. The slightly worse TPSA and Caco-2 permeability are less concerning given the strong binding and improved safety profile.
Therefore, I favor Ligand B.
Output:
0
2025-04-18 00:53:39,538 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (351.491 and 359.579 Da) are within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand A (81.67) is better than Ligand B (20.31). For a cardiovascular GPCR, TPSA is less critical than for CNS targets, but lower is generally preferred for absorption. Ligand B is exceptionally low, which could be a concern.
3. **logP:** Ligand A (1.199) is optimal, while Ligand B (4.895) is high. High logP can lead to poor solubility and off-target effects. This is a significant negative for Ligand B.
4. **HBD:** Ligand A (3) is reasonable, Ligand B (0) is also acceptable.
5. **HBA:** Ligand A (4) is reasonable, Ligand B (2) is also acceptable.
6. **QED:** Both ligands have good QED scores (0.517 and 0.629), indicating good drug-like properties.
7. **DILI:** Ligand A (5.312) has a much lower DILI risk than Ligand B (35.052). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (78.868) has a significantly higher BBB penetration than Ligand A (34.199). While ADRB2 isn't a CNS target, some peripheral exposure can be beneficial.
9. **Caco-2:** Ligand A (-5.285) and Ligand B (-5.33) are comparable and both are poor.
10. **Solubility:** Ligand A (-1.013) is better than Ligand B (-5.475). Solubility is important for bioavailability.
11. **hERG:** Ligand A (0.211) has a lower hERG risk than Ligand B (0.694). This is a positive for Ligand A.
12. **Cl_mic:** Ligand A (-3.693) has a much lower (better) microsomal clearance than Ligand B (104.185). This indicates better metabolic stability for Ligand A.
13. **t1/2:** Ligand A (-17.421) has a longer in vitro half-life than Ligand B (12.865). This is a positive for Ligand A.
14. **Pgp:** Ligand A (0.021) has a lower P-gp efflux liability than Ligand B (0.755). This is a positive for Ligand A.
15. **Binding Affinity:** Ligand B (-7.1) has a slightly better binding affinity than Ligand A (-5.5). However, the difference is not substantial enough to outweigh the significant ADME deficiencies of Ligand B.
**Overall Assessment:**
Ligand B has a slightly better binding affinity and BBB penetration, but it suffers from a high logP, high DILI risk, poor solubility, high P-gp efflux, and very high microsomal clearance. Ligand A, while having a slightly lower affinity, presents a much more balanced profile with acceptable ADME properties, lower toxicity risk, and better metabolic stability. For a cardiovascular target, prioritizing metabolic stability, minimizing toxicity, and ensuring reasonable solubility are crucial.
Output:
1
2025-04-18 00:53:39,538 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (383.941 Da) is within the ideal range (200-500 Da). Ligand B (349.406 Da) is also within range, slightly lower. No clear advantage here.
2. **TPSA:** Ligand A (46.61) is excellent, well below the 140 threshold for oral absorption. Ligand B (91.32) is higher but still acceptable, though less optimal. Ligand A is better.
3. **logP:** Ligand A (4.543) is a bit high, potentially leading to solubility issues and off-target effects. Ligand B (1.511) is good, within the optimal 1-3 range. Ligand B is better.
4. **HBD:** Ligand A (0) is ideal. Ligand B (3) is acceptable, but more donors can sometimes hinder permeability. Ligand A is better.
5. **HBA:** Both Ligand A (4) and Ligand B (4) are within the acceptable limit of 10. No clear difference.
6. **QED:** Ligand A (0.553) is good, indicating a drug-like profile. Ligand B (0.377) is lower, suggesting a less favorable drug-like profile. Ligand A is better.
7. **DILI:** Ligand A (44.397) has a slightly higher DILI risk than Ligand B (35.595), but both are below the concerning threshold of 60. Ligand B is slightly better.
8. **BBB:** Ligand A (50.058) is moderate. Ligand B (70.531) is better, suggesting better potential for CNS penetration, though this is less critical for a cardiovascular target like ADRB2.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.711 and -4.881), which is unusual and suggests poor permeability. This is a significant concern for both.
10. **Solubility:** Ligand A (-5.183) has worse solubility than Ligand B (-2.016). Ligand B is better.
11. **hERG:** Both ligands have low hERG inhibition risk (0.347 and 0.195). No clear difference.
12. **Cl_mic:** Ligand A (100.03) has higher metabolic clearance than Ligand B (28.754), indicating lower metabolic stability. Ligand B is better.
13. **t1/2:** Ligand A (19.801) has a longer half-life than Ligand B (-7.037). This is a significant advantage for Ligand A.
14. **Pgp:** Ligand A (0.337) has lower P-gp efflux than Ligand B (0.036), suggesting better bioavailability. Ligand A is better.
15. **Binding Affinity:** Ligand A (-6.5 kcal/mol) has slightly weaker binding affinity than Ligand B (-6.2 kcal/mol). However, the difference is small.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B has a better logP and Pgp profile, while Ligand A has a better TPSA. The affinity difference is small. The longer half-life of Ligand A is a significant advantage.
**Overall Assessment:**
While Ligand B has some advantages in terms of logP, DILI, solubility and metabolic stability, Ligand A's superior TPSA, QED, Pgp profile, and significantly longer half-life outweigh these benefits. The negative Caco-2 values are concerning for both, but the longer half-life of Ligand A could compensate for potential absorption issues.
Output:
1
2025-04-18 00:53:39,538 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (363.435 and 355.435 Da) are within the ideal range (200-500 Da). No significant difference here.
2. **TPSA:** Ligand A (76.82) is better than Ligand B (88.18). Both are under 140, but A is closer to the preferred value for good absorption.
3. **logP:** Ligand A (2.896) is optimal (1-3). Ligand B (0.176) is quite low, potentially leading to poor membrane permeability. This is a significant drawback.
4. **HBD:** Ligand A (0) is preferable to Ligand B (1). Lower HBD generally improves permeability.
5. **HBA:** Ligand A (6) is preferable to Ligand B (5). Both are within the acceptable range (<=10).
6. **QED:** Both ligands have similar and acceptable QED values (0.556 and 0.596).
7. **DILI:** Ligand A (88.949) has a higher DILI risk than Ligand B (37.999). This is a negative for Ligand A.
8. **BBB:** Both ligands have reasonably good BBB penetration (69.756 and 62.97). Since ADRB2 is a cardiovascular target, BBB penetration is not a primary concern, but it's still a positive attribute.
9. **Caco-2:** Ligand A (-4.687) is better than Ligand B (-5.076). Higher values indicate better absorption.
10. **Solubility:** Ligand A (-3.897) is better than Ligand B (-0.962). Better solubility is generally desirable.
11. **hERG:** Both ligands have very low hERG inhibition liability (0.563 and 0.177). This is excellent.
12. **Cl_mic:** Ligand A (76.23) has significantly higher metabolic clearance than Ligand B (13.76). This is a major negative for Ligand A, suggesting rapid metabolism and potentially lower *in vivo* exposure.
13. **t1/2:** Ligand A (83.628) has a longer half-life than Ligand B (-4.05). This is a positive for Ligand A.
14. **Pgp:** Ligand A (0.47) has lower P-gp efflux than Ligand B (0.006). Lower efflux is generally better.
15. **Binding Affinity:** Both ligands have identical binding affinities (-5.9 kcal/mol).
**GPCR-Specific Priorities and Overall Assessment:**
For a GPCR like ADRB2, logP, TPSA, and affinity are key. Ligand A has a much better logP and TPSA. While Ligand B has a lower DILI risk, the significantly lower logP and higher Cl_mic of Ligand B are major concerns. The higher clearance of Ligand A is a drawback, but the longer half-life partially mitigates this. Given the equal binding affinity, the better predicted absorption and permeability of Ligand A outweigh the higher DILI risk.
**Output:**
1
2025-04-18 00:53:39,538 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (365.25 & 362.42 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (29.1) is significantly better than Ligand B (134.19). For a GPCR, lower TPSA is generally preferred, facilitating membrane permeability. Ligand B's TPSA is quite high, potentially hindering absorption.
3. **logP:** Ligand A (4.75) is higher than Ligand B (-1.05). While both are within acceptable ranges, Ligand A is closer to the upper limit. Ligand B is quite low, potentially causing issues with membrane permeability.
4. **HBD:** Ligand A (1) is better than Ligand B (4). Fewer HBDs are generally preferred for better permeability.
5. **HBA:** Ligand A (1) is better than Ligand B (7). Similar to HBD, lower HBA is favored.
6. **QED:** Ligand A (0.78) is significantly better than Ligand B (0.36). A higher QED indicates a more drug-like profile.
7. **DILI:** Ligand B (32.2) is much better than Ligand A (68.5). Lower DILI risk is crucial.
8. **BBB:** Ligand A (79.95) is better than Ligand B (23.42). While ADRB2 isn't exclusively a CNS target, some CNS penetration can be beneficial and is not detrimental.
9. **Caco-2:** Ligand A (-4.47) is better than Ligand B (-5.53). Higher Caco-2 permeability is better.
10. **Solubility:** Ligand A (-5.82) is better than Ligand B (-1.36). Higher aqueous solubility is preferred.
11. **hERG:** Ligand A (0.82) is better than Ligand B (0.15). Lower hERG inhibition is critical for avoiding cardiotoxicity, especially for a cardiovascular target.
12. **Cl_mic:** Ligand A (42.47) is better than Ligand B (67.62). Lower microsomal clearance indicates greater metabolic stability.
13. **t1/2:** Ligand A (36.24) is better than Ligand B (-19.32). Longer in vitro half-life is desirable.
14. **Pgp:** Ligand A (0.36) is better than Ligand B (0.04). Lower P-gp efflux is preferred.
15. **Affinity:** Ligand B (-7.8) is significantly better than Ligand A (-6.2). A 1.6 kcal/mol difference in binding affinity is substantial and can often outweigh minor ADME concerns.
**Overall Assessment:**
Ligand B has a substantially better binding affinity, which is the most important factor. While Ligand B has some ADME liabilities (high TPSA, low QED, low BBB), the significant potency advantage is likely to be decisive. The DILI risk is also much lower for Ligand B. Ligand A has a better ADME profile overall, but the affinity difference is too large to ignore.
**Output:**
0
2025-04-18 00:53:39,538 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.403 and 352.479 Da) are within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (85.69) is better than Ligand B (95.74). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (-0.012) is slightly lower than Ligand B (1.034). Both are within the acceptable range (1-3), but Ligand B is closer to optimal.
4. **HBD:** Ligand A (1) is better than Ligand B (2). Fewer HBDs generally improve permeability.
5. **HBA:** Ligand A (6) is better than Ligand B (3). Lower HBA is favorable for permeability.
6. **QED:** Both ligands are similar (0.76 and 0.716), indicating good drug-likeness.
7. **DILI:** Ligand A (63.086) has a significantly higher DILI risk than Ligand B (18.612). This is a major concern.
8. **BBB:** Both ligands have reasonable BBB penetration (71.578 and 75.107). Not a primary concern for a cardiovascular target.
9. **Caco-2:** Ligand A (-4.779) and Ligand B (-5.08) are both poor.
10. **Solubility:** Ligand A (-1.83) is slightly better than Ligand B (-2.076), but both are poor.
11. **hERG:** Ligand A (0.043) is better than Ligand B (0.349). Lower hERG risk is crucial for cardiovascular drugs.
12. **Cl_mic:** Ligand B (19.613) has lower microsomal clearance than Ligand A (30.019), suggesting better metabolic stability.
13. **t1/2:** Ligand A (23.747) has a longer in vitro half-life than Ligand B (-15.33). This is a positive for Ligand A.
14. **Pgp:** Both ligands have very low Pgp efflux (0.021 and 0.02).
15. **Binding Affinity:** Ligand A (-8.1 kcal/mol) has a significantly stronger binding affinity than Ligand B (-1.6 kcal/mol). This is a substantial advantage.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Ligand A has a better TPSA, lower HBD/HBA, and *much* better affinity. However, the DILI risk for Ligand A is concerning. Ligand B has better logP and Cl_mic. The difference in affinity is so large (-8.1 vs -1.6) that it likely outweighs the other factors, *except* the DILI risk. The high DILI risk of Ligand A is a major red flag.
**Conclusion:**
Despite the significantly better binding affinity of Ligand A, the high DILI risk is a critical drawback. The lower DILI risk and acceptable properties of Ligand B make it the more promising candidate, even with its weaker binding.
Output:
0
2025-04-18 00:53:39,538 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Ligand A (451.308 Da) is within the ideal range. Ligand B (374.459 Da) is also within the ideal range. No clear advantage here.
2. **TPSA:** Ligand A (54.46) is excellent, well below the 140 threshold. Ligand B (102.01) is still reasonable, but higher. A favors permeability.
3. **logP:** Ligand A (3.748) is optimal. Ligand B (-0.463) is significantly lower, potentially causing permeability issues. A is better.
4. **HBD:** Both ligands have 1 HBD, which is good.
5. **HBA:** Ligand A has 3 HBA, Ligand B has 6 HBA. A is better.
6. **QED:** Both ligands have similar QED values (0.721 and 0.671), indicating good drug-likeness.
7. **DILI:** Both ligands have low DILI risk (44.164 and 41.76), which is good.
8. **BBB:** Ligand A (84.917) has better BBB penetration than Ligand B (70.454). While ADRB2 isn't exclusively a CNS target, some CNS exposure is not necessarily detrimental and could offer additional therapeutic avenues.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.914 and -4.865), which is unusual and indicates poor permeability. This is a concern for both, but the values are very similar.
10. **Solubility:** Ligand A (-4.359) has slightly better solubility than Ligand B (-1.153).
11. **hERG:** Ligand A (0.773) has a slightly higher hERG risk than Ligand B (0.082). B is better.
12. **Cl_mic:** Ligand A (68.839) has higher metabolic clearance than Ligand B (-0.569). B is better.
13. **t1/2:** Ligand A (-5.586) has a negative half-life, which is concerning. Ligand B (31.195) has a reasonable half-life. B is better.
14. **Pgp:** Ligand A (0.446) has lower P-gp efflux than Ligand B (0.017). A is better.
15. **Affinity:** Ligand A (-6.6 kcal/mol) has a stronger binding affinity than Ligand B (-5.0 kcal/mol). This is a significant advantage (1.6 kcal/mol difference).
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand A excels in logP, TPSA, and affinity. While Ligand B has a better hERG and Cl_mic profile, the superior affinity and permeability characteristics of Ligand A, combined with acceptable safety parameters, make it the more promising candidate. The strong binding affinity of Ligand A can potentially offset some of the ADME liabilities.
**Conclusion:**
Ligand A is the better candidate due to its superior binding affinity, logP, TPSA, and Pgp profile, which are critical for GPCR targets.
Output:
1
2025-04-18 00:53:39,538 - INFO - Batch 511 complete. Total preferences: 8176
2025-04-18 00:53:39,538 - INFO - Processing batch 512/512...
2025-04-18 00:54:26,974 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 (GPCR) drug candidates.
**Ligand A:** [355.439, 133.63 , -0.687, 4. , 4. , 0.407, 19.969, 70.105, -5.504, -2.205, 0.11 , 20.215, -16.295, 0.004, -6.4 ]
**Ligand B:** [353.463, 87.74 , 0.823, 2. , 4. , 0.766, 22.334, 63.94 , -5.046, -1.049, 0.128, -0.183, -2.078, 0.014, -6.2 ]
**Step-by-step comparison:**
1. **MW:** Both are within the ideal 200-500 Da range. A (355.439) and B (353.463) are very close, so no significant difference here.
2. **TPSA:** A (133.63) is slightly above the preferred <140 for good oral absorption, but acceptable. B (87.74) is excellent, well below 90, which is beneficial for GPCRs.
3. **logP:** A (-0.687) is a bit low, potentially hindering permeation. B (0.823) is better, falling within the optimal 1-3 range.
4. **HBD:** A (4) is acceptable, within the <5 guideline. B (2) is even better, reducing potential for off-target interactions.
5. **HBA:** Both A (4) and B (4) are good, well below the 10 limit.
6. **QED:** B (0.766) has a significantly higher QED score than A (0.407), indicating a more drug-like profile.
7. **DILI:** A (19.969) has a lower DILI risk than B (22.334), which is good. Both are below the 40 threshold.
8. **BBB:** A (70.105) has a better BBB penetration score than B (63.94). This is a GPCR-specific priority and is a significant advantage for A.
9. **Caco-2:** Both are negative, indicating poor permeability. A (-5.504) is slightly worse than B (-5.046).
10. **Solubility:** Both are negative, indicating poor solubility. B (-1.049) is slightly better than A (-2.205).
11. **hERG:** Both are very low (0.11 and 0.128), indicating minimal hERG inhibition risk.
12. **Cl_mic:** A (20.215) has a higher microsomal clearance than B (-0.183), meaning it's metabolized faster. B is much more metabolically stable.
13. **t1/2:** A (-16.295) has a negative in vitro half-life, which is concerning. B (-2.078) is also negative, but less so.
14. **Pgp:** Both are very low (0.004 and 0.014), indicating minimal P-gp efflux.
15. **Affinity:** Both have similar binding affinities (-6.4 and -6.2 kcal/mol). The difference is not substantial enough to override other factors.
**Overall Assessment:**
While Ligand A has a better BBB score, Ligand B is superior in almost every other key parameter. Specifically, the higher QED, better logP, lower HBD, and significantly improved metabolic stability (lower Cl_mic, less negative t1/2) make it a more promising candidate. The slightly lower BBB score of B is a trade-off that is acceptable given the other advantages. The poor Caco-2 and solubility for both are concerning, but can be addressed with formulation strategies.
Therefore, I prefer Ligand B.
0
2025-04-18 00:54:26,974 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
The target is ADRB2, a GPCR. Therefore, I will prioritize logP, TPSA, Pgp efflux, BBB penetration, and binding affinity, while also considering ADME-Tox properties.
* **Molecular Weight:** Both ligands are within the ideal range (359.455 and 361.417 Da).
* **TPSA:** Ligand B (37.61) is significantly better than Ligand A (91.97). Lower TPSA generally improves oral absorption and is particularly important for GPCRs. Ligand A's TPSA is relatively high.
* **logP:** Both ligands have acceptable logP values (1.704 and 3.549), falling within the 1-3 range. Ligand B is slightly higher, which could be beneficial for membrane permeability.
* **H-Bond Donors/Acceptors:** Ligand A has 3 HBD and 6 HBA, while Ligand B has 0 HBD and 5 HBA. Both are within acceptable limits.
* **QED:** Ligand B (0.716) has a better QED score than Ligand A (0.494), indicating a more drug-like profile.
* **DILI:** Ligand A (68.98) has a lower DILI risk than Ligand B (78.247), which is preferable.
* **BBB:** Ligand B (89.415) has significantly better BBB penetration potential than Ligand A (63.009). While not strictly necessary for ADRB2 (depending on the desired therapeutic effect), better BBB penetration is generally a plus for GPCRs, allowing for potential off-target effects to be assessed.
* **Caco-2 Permeability:** Both ligands have negative Caco-2 values, which is unusual and suggests poor permeability. However, the scale is not specified, so it's hard to interpret.
* **Aqueous Solubility:** Both ligands have negative solubility values, indicating poor solubility.
* **hERG:** Both ligands have low hERG inhibition liability (0.619 and 0.56), which is good.
* **Microsomal Clearance:** Ligand A (27.366) has lower microsomal clearance than Ligand B (50.187), suggesting better metabolic stability.
* **In vitro Half-Life:** Ligand A (52.262) has a longer in vitro half-life than Ligand B (42.411).
* **P-gp Efflux:** Ligand A (0.093) has lower P-gp efflux liability than Ligand B (0.727), which is favorable for bioavailability and CNS exposure.
* **Binding Affinity:** Ligand B (-6.6 kcal/mol) has a slightly better binding affinity than Ligand A (-6.8 kcal/mol). While the difference is small, it's still a factor.
**Overall Assessment:**
Ligand B has a significantly better TPSA and QED score, and better BBB penetration. These are crucial for a GPCR target. While Ligand A has better DILI, metabolic stability, and P-gp efflux, the advantages of Ligand B in TPSA and QED outweigh these factors. The slightly better binding affinity of Ligand B also contributes to its preference. The poor solubility and Caco-2 permeability are concerning for both, but can be addressed through formulation strategies.
**Output:**
0
2025-04-18 00:54:26,975 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (350.39 and 348.49 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (87.66) is higher than Ligand B (58.64). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is generally preferred for absorption. Ligand B is better.
3. **logP:** Both ligands have good logP values (1.99 and 2.66), falling within the optimal 1-3 range. Ligand B is slightly higher, which *could* be beneficial for membrane permeability, but isn't a major concern for either.
4. **HBD:** Ligand A has 3 HBD, while Ligand B has 1. Lower is generally preferred, so Ligand B is slightly better.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 3. Similar to HBD, Ligand B is slightly better.
6. **QED:** Both ligands have very similar QED values (0.685 and 0.686), indicating good drug-likeness. No difference.
7. **DILI:** Ligand A has a DILI risk of 47.9%, while Ligand B has a much lower risk of 10.4%. This is a significant advantage for Ligand B. DILI is a critical factor.
8. **BBB:** Both ligands have good BBB penetration (71.5% and 74.3%). Since ADRB2 is not a primary CNS target, this is less important, but Ligand B is slightly better.
9. **Caco-2:** Ligand A (-5.39) has a worse Caco-2 permeability score than Ligand B (-4.36). This suggests Ligand B will have better intestinal absorption.
10. **Solubility:** Ligand A (-3.343) has worse solubility than Ligand B (-2.479). Solubility is important for bioavailability, so Ligand B is better.
11. **hERG:** Both ligands have low hERG inhibition risk (0.419 and 0.278), which is good. Ligand B is slightly better.
12. **Cl_mic:** Ligand A has a lower (better) microsomal clearance (-6.053) than Ligand B (73.557). This suggests greater metabolic stability for Ligand A. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand B has a much longer in vitro half-life (12.972 hours) than Ligand A (-1.997 hours). This is a major advantage for Ligand B, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have very low Pgp efflux liability (0.081 and 0.083). No significant difference.
15. **Binding Affinity:** Ligand A (-6.4 kcal/mol) has slightly better binding affinity than Ligand B (-6.1 kcal/mol). While the difference is not huge, it's a positive for Ligand A.
**Overall Assessment:**
Ligand B has a clear advantage in several key ADME properties: DILI risk, Caco-2 permeability, solubility, and in vitro half-life. While Ligand A has better metabolic stability and a slightly better binding affinity, the lower DILI risk and improved pharmacokinetic profile of Ligand B are more critical for overall drug development success, especially considering the cardiovascular target. The small difference in binding affinity is unlikely to outweigh the ADME benefits of Ligand B.
Output:
0
2025-04-18 00:54:26,975 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (349.435 Da) is slightly lower, which is generally favorable for permeability.
2. **TPSA:** Both are acceptable, but Ligand B (95.94) is better than Ligand A (107.45). Lower TPSA is preferred for GPCRs.
3. **logP:** Ligand A (-0.134) is a bit low, potentially hindering membrane permeability. Ligand B (0.112) is better, falling within the optimal range.
4. **HBD:** Ligand A (3) is slightly higher than Ligand B (2), but both are acceptable.
5. **HBA:** Both ligands have the same number of HBA (6), which is within the acceptable range.
6. **QED:** Ligand A (0.603) has a slightly better QED score than Ligand B (0.555), indicating a more drug-like profile.
7. **DILI:** Both ligands have low DILI risk (Ligand A: 25.087, Ligand B: 23.885), which is good.
8. **BBB:** Ligand B (43.505) has a significantly higher BBB penetration percentile than Ligand A (11.749). While ADRB2 isn't strictly a CNS target, some CNS exposure can occur, and better BBB penetration is generally a plus.
9. **Caco-2:** Both have negative Caco-2 values, which is unusual and indicates very poor permeability. This is a significant concern for both.
10. **Solubility:** Both have negative solubility values, which is also a significant concern.
11. **hERG:** Both ligands have very low hERG inhibition risk (Ligand A: 0.189, Ligand B: 0.114).
12. **Cl_mic:** Ligand A (-12.097) has a lower (better) microsomal clearance than Ligand B (-9.275), indicating greater metabolic stability.
13. **t1/2:** Ligand A (11.404 hours) has a much longer in vitro half-life than Ligand B (1.218 hours). This is a significant advantage.
14. **Pgp:** Both ligands have very low P-gp efflux liability (Ligand A: 0.01, Ligand B: 0.024).
15. **Affinity:** Ligand A (-7.6 kcal/mol) has a stronger binding affinity than Ligand B (-6.3 kcal/mol). This is a substantial difference and a major factor.
**GPCR-specific priorities:** For GPCRs, logP, TPSA, Pgp, and affinity are crucial. Ligand B has better logP and TPSA, and a significantly better BBB score. However, Ligand A has a substantially stronger binding affinity and a longer half-life, and a better QED score. The poor Caco-2 and solubility for both are concerning, but the affinity difference is large enough to potentially overcome these issues with formulation strategies.
**Overall Assessment:**
Despite the poor Caco-2 and solubility, Ligand A's significantly stronger binding affinity (-7.6 vs -6.3 kcal/mol) and longer half-life are compelling advantages, especially for a GPCR target. The difference in affinity is likely to have a greater impact on efficacy than the slight improvements in logP and BBB seen in Ligand B.
Output:
1
2025-04-18 00:54:26,975 - INFO - Here's my reasoning and final output for selecting the better drug candidate between Ligand A and Ligand B for the ADRB2 receptor:
**Reasoning:**
We are targeting ADRB2, a GPCR, so the priorities are logP, TPSA, Pgp, BBB, and affinity. Let's compare the ligands property by property:
1. **MW:** Both ligands (346.431 and 341.371 Da) are within the ideal 200-500 Da range.
2. **TPSA:** Ligand A (87.46) is slightly higher than Ligand B (79.51), but both are well below the 140 threshold for oral absorption.
3. **logP:** Both ligands have acceptable logP values (0.692 and 0.783), falling within the 1-3 range.
4. **HBD:** Ligand A has 2 HBD, while Ligand B has 0. This is a slight advantage for A, as some hydrogen bonding can aid solubility.
5. **HBA:** Ligand A has 5 HBA, and Ligand B has 6. Both are within the acceptable range.
6. **QED:** Ligand A (0.843) has a better QED score than Ligand B (0.61), indicating a more drug-like profile.
7. **DILI:** Ligand A (37.069) has a significantly lower DILI risk than Ligand B (62.737). This is a major advantage for Ligand A.
8. **BBB:** Ligand B (63.552) has a higher BBB penetration percentile than Ligand A (27.879). While ADRB2 isn't necessarily a CNS target, some degree of BBB penetration can be beneficial for distribution.
9. **Caco-2:** Both ligands have very poor Caco-2 permeability (-4.972 and -4.843). This is a significant drawback for both.
10. **Solubility:** Both ligands have poor aqueous solubility (-1.34 and -1.574).
11. **hERG:** Both ligands have low hERG inhibition risk (0.316 and 0.351).
12. **Cl_mic:** Ligand A (-0.249) has a *much* lower (better) microsomal clearance than Ligand B (26.659), indicating greater metabolic stability.
13. **t1/2:** Ligand A (2.641) has a better in vitro half-life than Ligand B (-13.104).
14. **Pgp:** Both ligands have low P-gp efflux liability (0.025 and 0.06).
15. **Affinity:** Ligand B (-6.7 kcal/mol) has a slightly better binding affinity than Ligand A (-5.6 kcal/mol). This is a 1.1 kcal/mol difference, which is notable but not overwhelming.
**Overall Assessment:**
Despite Ligand B's slightly better affinity, Ligand A is the superior candidate. The significantly lower DILI risk, much better metabolic stability (lower Cl_mic and better t1/2), and higher QED score outweigh the small affinity difference. Both ligands have poor Caco-2 and solubility, which would need to be addressed in further optimization, but these are less critical than safety and metabolic properties at this stage.
**Output:**
1
2025-04-18 00:54:26,975 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (362.348 and 352.366 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (76.66) is significantly better than Ligand B (104.39). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (3.566) is optimal, while Ligand B (0.34) is quite low. This is a major concern for Ligand B, as it may struggle with membrane permeability.
4. **HBD:** Both ligands have 2 HBD, well within the acceptable limit of 5.
5. **HBA:** Ligand A has 4 HBA, and Ligand B has 5, both acceptable (<=10).
6. **QED:** Both ligands have reasonable QED scores (0.803 and 0.744), indicating good drug-like properties.
7. **DILI:** Both ligands have similar DILI risk (62.001 and 63.862), placing them in a moderate risk category. This isn't a deciding factor.
8. **BBB:** Ligand A (70.027) has slightly better BBB penetration than Ligand B (68.282), but this isn't critical for a cardiovascular target.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.596 and -4.911), which is unusual and suggests poor permeability. However, the values are very similar.
10. **Solubility:** Ligand A (-4.287) has slightly better solubility than Ligand B (-2.566).
11. **hERG:** Ligand A (0.641) has a slightly higher hERG risk than Ligand B (0.215), but both are relatively low.
12. **Cl_mic:** Ligand A (70.267) has a significantly higher microsomal clearance than Ligand B (16.78). This indicates Ligand B is more metabolically stable.
13. **t1/2:** Ligand B (-27.417) has a much longer in vitro half-life than Ligand A (2.392). This is a significant advantage for Ligand B.
14. **Pgp:** Ligand A (0.141) has lower P-gp efflux than Ligand B (0.016), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand A (-3.7 kcal/mol) has slightly better binding affinity than Ligand B (-3.3 kcal/mol), but the difference is relatively small.
**GPCR-specific priorities:** For ADRB2 (a GPCR), logP, TPSA, and affinity are key. Ligand A excels in logP and has a slightly better affinity. Ligand B has a better metabolic profile (lower Cl_mic, longer t1/2) and lower P-gp efflux, but its very low logP is a major drawback. The TPSA of Ligand A is also better.
**Conclusion:**
Despite Ligand B's better metabolic stability and half-life, the significantly lower logP is a critical issue that will likely hinder its absorption and bioavailability. Ligand A, while having a slightly higher Cl_mic, presents a more balanced profile with an optimal logP and acceptable TPSA, making it more likely to be a viable drug candidate.
Output:
1
2025-04-18 00:54:26,975 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output:
**Step-by-step comparison:**
1. **MW:** Both ligands (363.443 and 355.463 Da) fall within the ideal 200-500 Da range. No clear advantage here.
2. **TPSA:** Ligand B (62.17) is significantly better than Ligand A (95.81). ADRB2 is a cardiovascular target, so CNS penetration isn't *required*, but lower TPSA generally improves absorption.
3. **logP:** Ligand B (3.975) is higher than Ligand A (0.497). While 3.975 is approaching the upper limit of optimal, it's still acceptable. Ligand A's logP is quite low, potentially hindering membrane permeability.
4. **HBD:** Ligand A (2) is slightly higher than Ligand B (0). This is not a major concern for either.
5. **HBA:** Ligand A (6) is slightly higher than Ligand B (5). Again, both are within acceptable limits.
6. **QED:** Ligand A (0.827) has a better QED score than Ligand B (0.557), indicating a more drug-like profile overall.
7. **DILI:** Ligand B (53.044) has a lower DILI risk than Ligand A (62.35). Lower is better, so Ligand B is preferred.
8. **BBB:** Ligand B (45.095) has a higher BBB penetration percentile than Ligand A (26.638). While not critical for a cardiovascular target, higher BBB is rarely detrimental.
9. **Caco-2:** Both ligands have very poor Caco-2 permeability (-5.057 and -5.307). This is a significant concern for both.
10. **Solubility:** Ligand A (-2.11) has slightly better solubility than Ligand B (-4.987).
11. **hERG:** Ligand B (0.612) has a lower hERG risk than Ligand A (0.193). Lower is better, so Ligand B is preferred.
12. **Cl_mic:** Ligand B (80.472) has a much *higher* microsomal clearance than Ligand A (-2.222). This indicates significantly lower metabolic stability for Ligand B, a major drawback.
13. **t1/2:** Ligand B (68.288) has a much longer in vitro half-life than Ligand A (-1.32). This is a strong advantage for Ligand B, potentially offsetting the higher Cl_mic.
14. **Pgp:** Ligand B (0.731) has a higher P-gp efflux liability than Ligand A (0.046). This is a negative for Ligand B.
15. **Binding Affinity:** Both ligands have comparable binding affinities (-6.1 and -5.3 kcal/mol). Ligand A is slightly better, but the difference is not substantial enough to override other factors.
**GPCR-Specific Considerations:**
For a GPCR like ADRB2, logP, TPSA, and affinity are key. Ligand B has a better logP and TPSA. While affinity is slightly better for Ligand A, the metabolic instability (high Cl_mic) of Ligand B is a major concern. However, the significantly longer half-life of Ligand B mitigates this concern somewhat. The lower DILI and hERG risks for Ligand B are also favorable.
**Overall Assessment:**
Despite the poor Caco-2 permeability for both, Ligand B's better logP, TPSA, lower DILI/hERG, and longer half-life outweigh the slightly better affinity and QED of Ligand A. The high Cl_mic is concerning, but the long half-life suggests it might be manageable.
Output:
0
2025-04-18 00:54:26,975 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.491 and 344.459 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (58.44) is better than Ligand B (66.4), both are below the 140 threshold for good absorption.
3. **logP:** Both ligands (2.36 and 2.14) are within the optimal 1-3 range. Again, a minor difference.
4. **HBD:** Both have 0 HBD, which is good.
5. **HBA:** Both have 4 HBA, which is good.
6. **QED:** Ligand B (0.842) has a slightly better QED score than Ligand A (0.76), indicating a more drug-like profile.
7. **DILI:** Ligand A (25.669) has a significantly lower DILI risk than Ligand B (46.297). This is a major advantage for Ligand A.
8. **BBB:** Ligand A (79.139) has a slightly better BBB penetration score than Ligand B (73.827). While ADRB2 isn't strictly a CNS target, some CNS exposure can be relevant for off-target effects, and higher BBB is generally favorable.
9. **Caco-2:** Both ligands have very similar and poor Caco-2 permeability (-4.682 and -4.697). This is a potential concern for both.
10. **Solubility:** Ligand A (-1.6) has slightly better solubility than Ligand B (-2.06).
11. **hERG:** Both ligands have very low hERG inhibition liability (0.268 and 0.451). This is excellent.
12. **Cl_mic:** Both ligands have similar microsomal clearance (48.252 and 46.793).
13. **t1/2:** Ligand A (8.329) has a significantly longer in vitro half-life than Ligand B (0.401). This is a substantial advantage for Ligand A, potentially allowing for less frequent dosing.
14. **Pgp:** Both ligands have low P-gp efflux liability (0.149 and 0.181).
15. **Binding Affinity:** Ligand A (-6.8 kcal/mol) has a slightly better binding affinity than Ligand B (-6.5 kcal/mol). While the difference is not huge, it's enough to be considered.
**GPCR-Specific Priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are important. Both ligands perform similarly on logP and Pgp. Ligand A is better on TPSA and Affinity.
**Overall Assessment:**
Ligand A demonstrates a better overall profile. The significantly lower DILI risk, longer half-life, and slightly better binding affinity outweigh the slightly better QED score of Ligand B. The similar Caco-2 permeability is a concern for both, but can be addressed in formulation.
Output:
1
2025-04-18 00:54:26,975 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (367.33 and 360.48 Da) fall within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (57.94) is significantly better than Ligand B (79.53). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (4.992) is a bit high, potentially causing solubility issues, while Ligand B (2.29) is within the optimal range. This favors Ligand B.
4. **HBD:** Both have 1 HBD, which is good.
5. **HBA:** Both have 5 HBA, which is good.
6. **QED:** Both have good QED scores (0.66 and 0.821), indicating drug-likeness.
7. **DILI:** Ligand A (97.674) has a very high DILI risk, which is a major concern. Ligand B (43.389) has a much lower, acceptable DILI risk. This is a significant advantage for Ligand B.
8. **BBB:** Both have reasonable BBB penetration, but Ligand B (78.519) is better than Ligand A (68.748). While not critical for a cardiovascular target, it's a slight positive for Ligand B.
9. **Caco-2:** Ligand A (-4.573) is better than Ligand B (-5.077).
10. **Solubility:** Ligand A (-6.371) is better than Ligand B (-2.315).
11. **hERG:** Ligand A (0.823) has a slightly higher hERG risk than Ligand B (0.491), but both are reasonably low.
12. **Cl_mic:** Ligand A (54.035) has a much better (lower) microsomal clearance than Ligand B (14.405), suggesting better metabolic stability. This is a significant advantage for Ligand A.
13. **t1/2:** Ligand A (72.14) has a much longer in vitro half-life than Ligand B (-16.319), which is a major advantage.
14. **Pgp:** Ligand A (0.72) has a better Pgp efflux profile than Ligand B (0.112).
15. **Affinity:** Ligand B (-6.9 kcal/mol) has slightly better binding affinity than Ligand A (-6.6 kcal/mol). While the difference is not huge, it's a positive for Ligand B.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand B has better logP and affinity, while Ligand A has better TPSA and Pgp. However, the *extremely* high DILI risk associated with Ligand A is a deal-breaker. Metabolic stability (Cl_mic and t1/2) are also important, and Ligand A is significantly better in these parameters.
**Overall Assessment:**
Despite Ligand A's advantages in metabolic stability and half-life, the extremely high DILI risk outweighs these benefits. Ligand B, while having a slightly less optimal logP, presents a much safer profile with a significantly lower DILI risk, and only marginally weaker binding affinity. The better solubility of Ligand A is also a plus.
Output:
0
2025-04-18 00:54:26,975 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (362.417 and 363.571 Da) are within the ideal 200-500 Da range. No significant difference.
2. **TPSA:** Ligand A (59.08) is better than Ligand B (38.13). Both are well below the 140 A^2 threshold for oral absorption, and suitable for a GPCR target.
3. **logP:** Ligand A (1.39) is optimal, while Ligand B (3.964) is approaching the upper limit. This favors Ligand A.
4. **HBD:** Both ligands have 0 HBD, which is good.
5. **HBA:** Both ligands have 4 HBA, which is good.
6. **QED:** Both ligands have good QED scores (0.687 and 0.701), indicating drug-likeness. No significant difference.
7. **DILI:** Ligand A (25.436) has a significantly lower DILI risk than Ligand B (13.804). This is a major advantage for Ligand A.
8. **BBB:** Both ligands have high BBB penetration (85.498 and 82.862), which is good, but not critical for ADRB2 (a cardiovascular target).
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual. However, the magnitude of the negative value for Ligand A (-4.269) is less than that of Ligand B (-4.819), suggesting slightly better permeability for Ligand A.
10. **Solubility:** Ligand A (-1.415) has better solubility than Ligand B (-3.968). This is a positive for Ligand A.
11. **hERG:** Both ligands have low hERG inhibition risk (0.579 and 0.636). No significant difference.
12. **Cl_mic:** Ligand A (24.918) has significantly lower microsomal clearance than Ligand B (97.021), indicating better metabolic stability. This is a major advantage for Ligand A.
13. **t1/2:** Ligand A (-0.455) has a negative half-life, which is unusual. Ligand B (25.234) has a positive half-life. This favors Ligand B.
14. **Pgp:** Both ligands have low Pgp efflux liability (0.04 and 0.505). No significant difference.
15. **Binding Affinity:** Ligand A (-7.3) has a slightly better binding affinity than Ligand B (-6.8). While the difference is less than the 1.5 kcal/mol threshold, it still contributes to the overall preference.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are important. Ligand A is better in logP and TPSA, and has a slightly better affinity. The lower DILI and Cl_mic are also significant advantages.
**Overall Assessment:**
Ligand A demonstrates a superior balance of properties, particularly in terms of safety (DILI), metabolic stability (Cl_mic), solubility, and logP. While Ligand B has a better in vitro half-life, the other advantages of Ligand A outweigh this single benefit.
Output:
1
2025-04-18 00:54:26,975 - INFO - Here's my reasoning and final output for selecting between Ligand A and Ligand B as a potential drug candidate for the ADRB2 receptor:
**Reasoning:**
Let's break down the comparison of Ligand A and Ligand B based on the provided parameters and the guidelines, keeping in mind ADRB2 is a GPCR.
1. **Molecular Weight:** Both ligands (361.873 and 361.511 Da) fall comfortably within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (65.2) is higher than Ligand B (43.43). For a GPCR, lower TPSA is generally preferred for better BBB penetration. Ligand B is significantly better here.
3. **logP:** Both ligands have similar logP values (3.651 and 3.712), falling within the optimal 1-3 range.
4. **H-Bond Donors:** Ligand A has 2 HBD, while Ligand B has 0. Both are acceptable, but lower is often preferred for permeability. Ligand B is slightly better.
5. **H-Bond Acceptors:** Ligand A has 2 HBA, and Ligand B has 6. Ligand A is better here, as higher HBA can sometimes hinder permeability.
6. **QED:** Both ligands have similar QED values (0.872 and 0.717), both above the 0.5 threshold, indicating good drug-likeness.
7. **DILI Risk:** Ligand A (64.288) has a higher DILI risk than Ligand B (20.9). This is a significant advantage for Ligand B.
8. **BBB Penetration:** Ligand B (84.529) shows significantly better BBB penetration than Ligand A (70.764). This is a crucial factor for GPCRs, even non-CNS ones, as it can influence off-target effects and overall distribution.
9. **Caco-2 Permeability:** Both ligands have negative Caco-2 values (-4.916 and -5.047), which is unusual and suggests poor permeability. However, the values are very close.
10. **Aqueous Solubility:** Both ligands have negative solubility values (-4.789 and -3.836), which is also unusual. Ligand B is slightly better.
11. **hERG Inhibition:** Both ligands have low hERG inhibition risk (0.729 and 0.839).
12. **Microsomal Clearance:** Ligand A (33.599) has lower microsomal clearance than Ligand B (94.551), indicating better metabolic stability. This is a benefit for Ligand A.
13. **In vitro Half-Life:** Ligand A (32.597) has a slightly longer in vitro half-life than Ligand B (30.15).
14. **P-gp Efflux:** Both ligands have low P-gp efflux liability (0.415 and 0.386).
15. **Binding Affinity:** Ligand B (-6.3 kcal/mol) has a slightly better binding affinity than Ligand A (-7.0 kcal/mol). While A is better, the difference is not substantial enough to outweigh other factors.
**Overall Assessment:**
Ligand B demonstrates a superior profile for a GPCR target like ADRB2. Its lower TPSA, significantly lower DILI risk, and substantially better BBB penetration are key advantages. While Ligand A has better metabolic stability and a slightly longer half-life, the benefits of Ligand B in terms of safety (DILI) and potential for better distribution (BBB) outweigh these considerations. The slightly better binding affinity of Ligand B is also a plus. The unusual negative Caco-2 and solubility values for both compounds are concerning and would require further investigation, but the relative ranking remains the same.
**Output:**
0
2025-04-18 00:54:26,976 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (348.487 and 357.445 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (59.59) is slightly higher than Ligand B (52.65). Both are well below the 140 A^2 threshold for good oral absorption, and suitable for a GPCR target.
3. **logP:** Ligand A (3.582) is slightly higher than Ligand B (2.037), both are within the optimal 1-3 range. Ligand B is closer to the lower bound, which might slightly hinder permeation.
4. **HBD:** Ligand A (2) is higher than Ligand B (1). Both are acceptable, well below the 5 limit.
5. **HBA:** Ligand A (4) is higher than Ligand B (3). Both are below the 10 limit.
6. **QED:** Ligand A (0.825) is better than Ligand B (0.71), indicating a more drug-like profile.
7. **DILI:** Both ligands have similar, low DILI risk (21.714 and 22.257 percentile).
8. **BBB:** Both ligands have high BBB penetration (87.398 and 84.451 percentile). This is good, but less critical for ADRB2 as it's not a CNS target.
9. **Caco-2:** Both have negative Caco-2 values which is unusual and likely indicates a problem with the data. I will assume these are permeability values and higher is better. Ligand A (-4.535) is slightly better than Ligand B (-4.759).
10. **Solubility:** Ligand A (-3.587) is slightly worse than Ligand B (-2.13). Solubility is important, and Ligand B has a better value.
11. **hERG:** Both ligands show very low hERG inhibition risk (0.851 and 0.619 percentile).
12. **Cl_mic:** Ligand A (54.9) has a higher microsomal clearance than Ligand B (3.823), suggesting faster metabolism and potentially lower *in vivo* exposure. This is a significant drawback for Ligand A.
13. **t1/2:** Ligand A (19.702) has a longer half-life than Ligand B (-17.489). The negative value for Ligand B is problematic.
14. **Pgp:** Ligand A (0.161) has lower P-gp efflux than Ligand B (0.081), which is favorable.
15. **Binding Affinity:** Ligand B (-6.3 kcal/mol) has a slightly better binding affinity than Ligand A (-5.5 kcal/mol). This is a 0.8 kcal/mol difference, which is significant, but not overwhelming.
**GPCR-Specific Considerations:**
For ADRB2 (a GPCR), logP, TPSA, Pgp, and affinity are key. Both ligands perform well on logP and TPSA. Ligand B has slightly better Pgp efflux and a better binding affinity. The biggest difference is in metabolic stability (Cl_mic), where Ligand B is significantly better.
**Overall Assessment:**
While Ligand A has a slightly better QED and half-life, the significantly lower microsomal clearance and better binding affinity of Ligand B outweigh these advantages. The problematic negative half-life for Ligand B is concerning, but the superior metabolic stability is crucial for *in vivo* efficacy.
Output:
0
2025-04-18 00:54:26,976 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (362.861 Da and 348.462 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (94.88) is higher than Ligand B (58.2). For a cardiovascular GPCR, TPSA is less critical than for a CNS target, but lower is generally preferred for absorption. Ligand B is better here.
3. **logP:** Both ligands have excellent logP values (3.208 and 3.191), falling within the optimal 1-3 range. No significant difference.
4. **HBD:** Both ligands have 2 H-bond donors, which is within the acceptable limit of <=5. No difference.
5. **HBA:** Ligand A has 4 H-bond acceptors, while Ligand B has 2. Lower HBA is generally preferred for permeability, giving a slight edge to Ligand B.
6. **QED:** Both ligands have good QED scores (0.728 and 0.75), indicating good drug-like properties. No significant difference.
7. **DILI:** Ligand A (38.658) has a slightly higher DILI risk than Ligand B (31.059), but both are below the 40% threshold considered good. Ligand B is better.
8. **BBB:** Both ligands have good BBB penetration (74.176 and 74.835). Since ADRB2 is not a CNS target, this is less important, but similar values.
9. **Caco-2:** Both ligands have negative Caco-2 values (-4.829 and -4.844). These values are unusual and likely represent a scaling issue or error in the data. It's difficult to interpret them directly, but they suggest poor permeability.
10. **Solubility:** Both ligands have poor aqueous solubility (-3.987 and -3.9). This is a significant concern for both, potentially impacting bioavailability.
11. **hERG:** Both ligands have very low hERG inhibition risk (0.466 and 0.273). This is excellent and minimizes cardiotoxicity concerns. Ligand B is slightly better.
12. **Cl_mic:** Ligand A (35.856) has a higher microsomal clearance than Ligand B (23.334). Lower clearance is preferred for metabolic stability, giving an advantage to Ligand B.
13. **t1/2:** Ligand A (27.131) has a longer in vitro half-life than Ligand B (3.823). This is a significant advantage for Ligand A, potentially allowing for less frequent dosing.
14. **Pgp:** Ligand A (0.032) has much lower P-gp efflux liability than Ligand B (0.207). Lower P-gp efflux is desirable for improved bioavailability. Ligand A is better.
15. **Binding Affinity:** Ligand B (-6.5 kcal/mol) has a significantly stronger binding affinity than Ligand A (-5.5 kcal/mol). This 1.0 kcal/mol difference is substantial and can outweigh some ADME drawbacks.
**Overall Assessment:**
The key trade-offs are between Ligand A's better half-life and P-gp properties versus Ligand B's better TPSA, DILI, hERG, and *significantly* stronger binding affinity. For a GPCR, binding affinity is paramount. The 1.0 kcal/mol difference is a substantial advantage that outweighs the slightly poorer metabolic stability and P-gp efflux of Ligand B. The solubility issues are a concern for both, but can be addressed through formulation strategies.
Output:
0
2025-04-18 00:54:26,976 - INFO - Okay, let's analyze these two ligands for their potential as ADRB2 drug candidates. ADRB2 is a GPCR, so we'll prioritize logP, Pgp, TPSA, and affinity, alongside general drug-like properties.
**Ligand A:**
* **MW:** 348.4 Da - Good. Within the ideal range.
* **TPSA:** 92.78 - Acceptable, but pushing the upper limit for good oral absorption.
* **logP:** 0.582 - Low. Could lead to poor membrane permeability.
* **HBD:** 1 - Good.
* **HBA:** 5 - Good.
* **QED:** 0.56 - Good, drug-like.
* **DILI:** 41.722 - Good, low risk.
* **BBB:** 66.499 - Moderate. Not ideal, but not terrible for a peripherally acting GPCR.
* **Caco-2:** -4.731 - Very poor permeability. A significant concern.
* **Solubility:** -2.004 - Very poor solubility. A significant concern.
* **hERG:** 0.055 - Excellent, very low risk.
* **Cl_mic:** 33.276 - Moderate. Acceptable, but could be better.
* **t1/2:** -15.795 - Very short half-life. A major drawback.
* **Pgp:** 0.029 - Low efflux. Good.
* **Affinity:** -6.7 kcal/mol - Good binding affinity.
**Ligand B:**
* **MW:** 342.483 Da - Good. Within the ideal range.
* **TPSA:** 49.41 - Excellent. Well below the threshold for good absorption.
* **logP:** 2.891 - Excellent. Within the optimal range.
* **HBD:** 1 - Good.
* **HBA:** 2 - Good.
* **QED:** 0.633 - Good, very drug-like.
* **DILI:** 36.603 - Good, low risk.
* **BBB:** 71.035 - Good. A reasonable value.
* **Caco-2:** -4.612 - Poor permeability, but slightly better than Ligand A.
* **Solubility:** -3.807 - Poor solubility, but slightly better than Ligand A.
* **hERG:** 0.468 - Acceptable, low risk.
* **Cl_mic:** 74.402 - High. Suggests rapid metabolism and potential for low bioavailability.
* **t1/2:** -15.085 - Very short half-life. A major drawback, similar to Ligand A.
* **Pgp:** 0.326 - Moderate efflux.
* **Affinity:** -8.5 kcal/mol - Excellent. Significantly stronger binding than Ligand A.
**Comparison & Decision:**
Both ligands have significant drawbacks regarding solubility, permeability, and half-life. However, Ligand B has a substantially better binding affinity (-8.5 vs -6.7 kcal/mol), a much better logP, and a lower TPSA. The improved affinity is a significant advantage for a GPCR target, and the logP/TPSA values suggest better membrane permeability *potential* despite the Caco-2 values. While Ligand B has a higher Cl_mic, the superior binding affinity is likely to outweigh this concern, especially in early-stage optimization where modifications can address metabolic stability. Ligand A's very low logP and poor Caco-2/solubility are more difficult to overcome.
Therefore, I would prioritize Ligand B for further development.
0
2025-04-18 00:54:26,976 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands are within the ideal range (200-500 Da). Ligand A (341.371) is slightly lower, which could be beneficial for permeability.
2. **TPSA:** Ligand B (74.86) is significantly better than Ligand A (109.04). ADRB2 is a cardiovascular target, so CNS penetration isn't paramount, but lower TPSA generally correlates with better absorption.
3. **logP:** Ligand A (1.253) is optimal, while Ligand B (4.085) is pushing the upper limit. High logP can lead to poor solubility and off-target effects.
4. **HBD:** Both ligands have acceptable HBD counts (2 and 3, respectively).
5. **HBA:** Both ligands have acceptable HBA counts (6).
6. **QED:** Ligand A (0.788) has a better QED score than Ligand B (0.565), indicating a more drug-like profile.
7. **DILI:** Both ligands have relatively high DILI risk (70.725 and 77.084). This is a concern for both, but not a deciding factor at this stage.
8. **BBB:** Not a primary concern for a cardiovascular target, but Ligand B (64.25) shows slightly higher potential for BBB penetration than Ligand A (55.913).
9. **Caco-2:** Ligand A (-4.889) is better than Ligand B (-5.548), indicating better intestinal absorption.
10. **Solubility:** Ligand A (-3.411) is better than Ligand B (-3.72), indicating better aqueous solubility.
11. **hERG:** Both ligands have low hERG inhibition risk (0.283 and 0.882).
12. **Cl_mic:** Ligand A (37.204) has significantly lower microsomal clearance than Ligand B (88.956), suggesting better metabolic stability.
13. **t1/2:** Ligand B (119.391) has a much longer in vitro half-life than Ligand A (9.403). This is a significant advantage.
14. **Pgp:** Ligand A (0.057) has much lower P-gp efflux liability than Ligand B (0.646), which is favorable for bioavailability.
15. **Affinity:** Ligand B (-6.8 kcal/mol) has a stronger binding affinity than Ligand A (-5.7 kcal/mol). This is a 1.1 kcal/mol difference, which is substantial and can outweigh some ADME concerns.
**GPCR-Specific Priorities:**
For ADRB2 (a GPCR), we prioritize logP, Pgp, TPSA, and affinity. Ligand B has a higher logP and better affinity, while Ligand A has better TPSA and Pgp. The affinity difference is significant.
**Overall Assessment:**
While Ligand A has a better overall drug-like profile (QED, solubility, metabolic stability, Pgp efflux), the significantly stronger binding affinity of Ligand B (-6.8 vs -5.7 kcal/mol) is a major advantage. The longer half-life of Ligand B is also a positive. The higher logP of Ligand B is a concern, but the strong binding may compensate for potential solubility issues.
Therefore, I favor Ligand B.
Output:
0
2025-04-18 00:54:26,976 - INFO - Here's my reasoning for choosing between Ligand A and Ligand B as a drug candidate for the ADRB2 receptor, followed by my final output.
**Step-by-step comparison:**
1. **MW:** Both ligands (370.519 Da and 365.539 Da) fall within the ideal 200-500 Da range. No significant difference here.
2. **TPSA:** Ligand A (85.51) is slightly higher than Ligand B (38.77). Ligand B is much better, falling well below the 140 threshold for oral absorption and is very favorable for a GPCR.
3. **logP:** Ligand A (1.383) is within the optimal range (1-3). Ligand B (4.373) is a bit high, potentially leading to solubility issues and off-target interactions.
4. **HBD:** Ligand A (2) is acceptable, while Ligand B (0) is also good.
5. **HBA:** Ligand A (5) is acceptable, while Ligand B (4) is also good.
6. **QED:** Both ligands have similar QED values (0.652 and 0.618), indicating good drug-likeness.
7. **DILI:** Ligand A (29.43) has a slightly higher DILI risk than Ligand B (22.451), but both are comfortably below the 40 threshold.
8. **BBB:** Ligand B (89.492) shows significantly better BBB penetration than Ligand A (35.673). While ADRB2 isn't exclusively a CNS target, some CNS exposure can be beneficial for understanding off-target effects and potential side effects.
9. **Caco-2:** Both ligands have negative Caco-2 values, which is unusual. However, the magnitude of the negative value for Ligand A (-5.202) is larger than Ligand B (-4.752), suggesting potentially worse intestinal absorption for Ligand A.
10. **Solubility:** Ligand A (-1.706) has better solubility than Ligand B (-4.587). This is a positive for Ligand A, mitigating some of the concerns about Ligand B's higher logP.
11. **hERG:** Ligand A (0.479) has a lower hERG risk than Ligand B (0.748), which is a significant advantage.
12. **Cl_mic:** Ligand B (94.802) has a much higher microsomal clearance than Ligand A (23.705), indicating lower metabolic stability. This is a major drawback for Ligand B.
13. **t1/2:** Ligand A (43.269) has a longer in vitro half-life than Ligand B (30.425), further supporting its better metabolic stability.
14. **Pgp:** Ligand A (0.02) has a much lower P-gp efflux liability than Ligand B (0.788), which is favorable for bioavailability.
15. **Binding Affinity:** Ligand B (-6.5 kcal/mol) has a stronger binding affinity than Ligand A (-4.8 kcal/mol). This is a substantial difference (1.7 kcal/mol), and is a major point in Ligand B's favor.
**GPCR-specific priorities:**
For a GPCR like ADRB2, logP, TPSA, Pgp, and affinity are key. Ligand B excels in affinity and TPSA, and has a good BBB score. However, its high logP, high Pgp efflux, and especially its poor metabolic stability (high Cl_mic, short t1/2) are significant concerns. Ligand A, while having a weaker affinity, presents a much more balanced profile with better solubility, lower hERG risk, better metabolic stability, and lower Pgp efflux.
**Conclusion:**
Despite the stronger binding affinity of Ligand B, the significant concerns regarding its metabolic stability and efflux liability outweigh this benefit. Ligand A, with its more balanced ADME profile and lower toxicity risk, is the more promising drug candidate.
Output:
1
2025-04-18 00:54:26,976 - INFO - Batch 512 complete. Total preferences: 8192
2025-04-18 00:54:26,976 - INFO - LLM processing complete.
2025-04-18 00:54:27,146 - INFO - Saved final results to llm_preferecence_ADRB2_4ldo.npz
2025-04-18 00:54:27,146 - INFO - --- Script finished in 7:06:06.927840 ---